{"meta":{"query_hash":"11ee7dc1d95b","filters":{"venue":"Journal of Clinical Oncology"},"cohort_total":9514,"direct_labels_cover":106,"predictions_cover":9514,"exported":9514,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/11ee7dc1d95b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Clinical+Oncology"},"results":[{"id":"W103407665","doi":"10.1200/jco.2014.32.4_suppl.79","title":"The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Prostate cancer; Abiraterone acetate; Medicine; Comparative genomic hybridization; Prostate; Biopsy; Cancer research; Cancer; Liquid biopsy; Oncology; PTEN; Pathology; Androgen receptor; Internal medicine; Androgen deprivation therapy; Biology; Gene; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.054671961056361164,"score_gpt":0.3879471556691834,"score_spread":0.33327519461282223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W103407665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98611313,0.000922833,0.000037482056,0.010582619,0.00024474016,0.0016644442,0.0003884558,0.000008900388,0.000037367805],"genre_scores_gemma":[0.98986006,0.007905047,0.00042905041,0.00090521015,0.0002381238,0.00012643378,0.00009831577,0.000044618326,0.0003931703],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958792,0.00094059797,0.0016925689,0.0003636492,0.0007548742,0.00036911023],"domain_scores_gemma":[0.99438477,0.0016280904,0.0020933384,0.000353369,0.001226564,0.0003138616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022735011,0.00027055005,0.001013363,0.00006602272,0.00018164475,0.00005088302,0.0002001297,0.00012747766,0.000016348347],"category_scores_gemma":[0.0006690047,0.000106707834,0.00009336036,0.00025406055,0.0005089422,0.00022181039,0.000055616736,0.000658316,0.000001336004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5627944,0.0018378653,0.11454758,0.00010242855,0.0017103404,0.0003036452,0.0038750826,0.00018366148,0.03231373,0.000011331789,0.0005588797,0.28176108],"study_design_scores_gemma":[0.029682266,0.06384249,0.87779075,0.0007213276,0.00047769875,0.00002113067,0.000489905,0.00007085493,0.005640879,0.000035030796,0.021038732,0.00018893272],"about_ca_topic_score_codex":0.00032923228,"about_ca_topic_score_gemma":0.0014575736,"teacher_disagreement_score":0.7632432,"about_ca_system_score_codex":0.0001994187,"about_ca_system_score_gemma":0.0022008002,"threshold_uncertainty_score":0.4351419},"labels":[],"label_agreement":null},{"id":"W106475423","doi":"10.1200/jco.2005.23.16_suppl.710","title":"The prognostic effect of lipids on early-stage breast cancer (BC) outcome","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dyslipidemia; Internal medicine; Body mass index; Hazard ratio; Breast cancer; Insulin resistance; Stage (stratigraphy); Proportional hazards model; Univariate analysis; Cohort; Obesity; Diabetes mellitus; Cancer; Oncology; Endocrinology; Confidence interval; Multivariate analysis","score_opus":0.040153434202434314,"score_gpt":0.4235928328138736,"score_spread":0.3834393986114393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W106475423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806337,0.0014059201,0.000035149144,0.0034341763,0.013238788,0.00017553485,0.000021748727,0.0000030371048,0.001051949],"genre_scores_gemma":[0.9555666,0.0032405332,0.00012745956,0.0009348758,0.03862227,0.00001076833,0.000001508814,0.000018969082,0.0014770355],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971839,0.00056079385,0.0015618344,0.00018446853,0.00025070074,0.0002583082],"domain_scores_gemma":[0.9969111,0.0010983986,0.0012725624,0.000266531,0.00025233382,0.00019906355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029927716,0.00015496019,0.00083270174,0.000039048748,0.000059312217,0.0000109747125,0.0003573556,0.00035435034,0.000049401482],"category_scores_gemma":[0.0019460638,0.00008737349,0.0005860268,0.00006368467,0.00027830052,0.0000065989693,0.00007222968,0.00053845166,0.000010422856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009109692,0.0006638095,0.505943,0.000042780342,0.0005489885,0.0000024738358,0.000038378705,0.00031639668,0.0056643123,0.00017602967,0.04068644,0.4368077],"study_design_scores_gemma":[0.0024848324,0.0052597667,0.31611046,0.000021454616,0.00012331006,0.000029670087,0.000008120869,0.0000096669155,0.0010569869,0.000007669421,0.6748106,0.00007743595],"about_ca_topic_score_codex":0.000055403023,"about_ca_topic_score_gemma":0.0002513294,"teacher_disagreement_score":0.63412416,"about_ca_system_score_codex":0.000037157944,"about_ca_system_score_gemma":0.00055418786,"threshold_uncertainty_score":0.35629874},"labels":[],"label_agreement":null},{"id":"W107421448","doi":"10.1200/jco.2006.24.18_suppl.3064","title":"A phase I study of reolysin given intravenously to patients with advanced malignancies","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Chills; Viral shedding; Antibody; Toxicity; Gastroenterology; Immune system; Internal medicine; Immunology; Virology; Pharmacology","score_opus":0.04143602565583635,"score_gpt":0.43043790314076574,"score_spread":0.38900187748492937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W107421448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986857,0.00012733904,0.00016240492,0.0003172007,0.00014950777,0.0003504155,0.000007894386,0.0000019191054,0.00019760765],"genre_scores_gemma":[0.9979929,0.000038801376,0.001239912,0.00025971822,0.00034459023,0.0000068039503,0.0000062773993,0.0000177846,0.00009326596],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.997423,0.00045509558,0.0013278667,0.00021013925,0.00036160345,0.00022230417],"domain_scores_gemma":[0.9977152,0.00015433456,0.000918266,0.00026306693,0.00078280026,0.00016637422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001353839,0.00012137116,0.0006966947,0.00009388179,0.000031698983,0.000005659167,0.0003103648,0.00016037532,0.000020851352],"category_scores_gemma":[0.00056094845,0.000086684,0.00014961476,0.0001477543,0.00012178719,0.000006060638,0.0000735567,0.00026289796,0.000003269584],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20674501,0.069252655,0.14737417,0.000026192074,0.0009887731,0.00024793885,0.00033791357,0.002166982,0.24937412,0.000011082961,0.004016614,0.31945854],"study_design_scores_gemma":[0.04204293,0.78654903,0.10917043,0.000036968402,0.00011916758,0.000016548187,0.00028355911,0.0000053188423,0.044941936,0.00007095147,0.01654205,0.00022114],"about_ca_topic_score_codex":0.000027348684,"about_ca_topic_score_gemma":0.0005855917,"teacher_disagreement_score":0.71729636,"about_ca_system_score_codex":0.000030109604,"about_ca_system_score_gemma":0.0005715366,"threshold_uncertainty_score":0.35348707},"labels":[],"label_agreement":null},{"id":"W129944274","doi":"10.1200/jco.2007.25.18_suppl.7627","title":"Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Febrile neutropenia; Performance status; Adverse effect; Progressive disease; Nausea; Oncology; Neutropenia; Lung cancer; Carboplatin; Sunitinib; Surgery; Cancer; Chemotherapy","score_opus":0.05390957801326977,"score_gpt":0.43178274645929626,"score_spread":0.3778731684460265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W129944274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961967,0.00077085185,0.0000044374556,0.0014252394,0.00017040301,0.0010786754,0.000011912919,0.0000016546503,0.00034014453],"genre_scores_gemma":[0.9993706,0.0002138775,0.00012682374,0.00010492657,0.00012814542,0.0000022384907,3.1634565e-7,0.000013391433,0.0000397134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955526,0.00067771564,0.0025121698,0.00019970161,0.0008003181,0.0002574692],"domain_scores_gemma":[0.9936022,0.0032985667,0.002123981,0.00029847247,0.0005113011,0.00016543671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043809703,0.00015033515,0.0015381915,0.00013944149,0.00008180087,0.0000024114677,0.0002557302,0.00016752808,0.000010872331],"category_scores_gemma":[0.0030516782,0.00007328335,0.00015434388,0.00029572882,0.0009000172,0.000055263783,0.00024465704,0.00103334,4.9954096e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08134987,0.013965804,0.87045217,0.00017730227,0.00080294244,0.00008394774,0.005834037,0.000009338568,0.00029004493,0.000012634088,0.0002588997,0.026763005],"study_design_scores_gemma":[0.05595072,0.092208706,0.84879386,0.0004883771,0.00040834583,0.000026871963,0.0017364346,0.000011722539,0.00010152253,0.000019737086,0.00019992597,0.000053790154],"about_ca_topic_score_codex":0.00008526882,"about_ca_topic_score_gemma":0.0005379378,"teacher_disagreement_score":0.078242905,"about_ca_system_score_codex":0.00014045298,"about_ca_system_score_gemma":0.00081045413,"threshold_uncertainty_score":0.44894058},"labels":[],"label_agreement":null},{"id":"W130495402","doi":"10.1200/jco.2005.23.16_suppl.6595","title":"Evaluation of three prognostic indexes in follicular lymphoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; International Prognostic Index; Internal medicine; Follicular lymphoma; Erythrocyte sedimentation rate; Concordance; Stage (stratigraphy); Lymphoma; Gastroenterology; Oncology; Surgery; Rituximab","score_opus":0.1932692705109697,"score_gpt":0.48550509627348576,"score_spread":0.29223582576251605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W130495402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902868,0.0020506755,0.000017318935,0.0049981903,0.0003039178,0.0003074467,7.7055097e-7,0.0000027104213,0.00203213],"genre_scores_gemma":[0.99645406,0.00031703128,0.0021328044,0.0005121587,0.00055289007,0.000011692302,0.0000011319543,0.0000068999084,0.000011346221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653745,0.00041287657,0.0020072137,0.00011650222,0.0007890267,0.00013691078],"domain_scores_gemma":[0.99633473,0.0014002726,0.0011871228,0.00013591457,0.00078368984,0.00015824698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073349746,0.0000878475,0.0010165875,0.00014157091,0.000010400431,0.0000028061713,0.000080298756,0.00025139525,0.00012023532],"category_scores_gemma":[0.006150623,0.000057566725,0.00034986122,0.00013042035,0.00008653655,0.00007966669,0.000022194014,0.00015687007,0.000015360718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004155864,0.003978859,0.5046979,0.0000061714363,0.00021467375,0.00011965631,0.00002975606,0.00008277819,0.00001623117,0.00006869619,0.00024073856,0.49012893],"study_design_scores_gemma":[0.023739992,0.0062114117,0.9600922,0.00015792313,0.0012761042,0.00020416612,0.000022790373,0.0010800145,0.00024039371,0.000858129,0.0060717133,0.000045146073],"about_ca_topic_score_codex":0.00002590968,"about_ca_topic_score_gemma":0.00029251646,"teacher_disagreement_score":0.49008378,"about_ca_system_score_codex":0.0004838627,"about_ca_system_score_gemma":0.0026769745,"threshold_uncertainty_score":0.73633146},"labels":[],"label_agreement":null},{"id":"W132642020","doi":"10.1200/jco.2006.24.18_suppl.13555","title":"First-line bolus IFL and second-line FOLFOX: A retrospective review of two hundred thirty patients","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Irinotecan; FOLFOX; Regimen; Oxaliplatin; FOLFIRI; Bolus (digestion); Colorectal cancer; Neutropenia; Tolerability; Population; Performance status; Surgery; Fluorouracil; Internal medicine; Chemotherapy; Cancer; Adverse effect","score_opus":0.1477996421375486,"score_gpt":0.5062496609053662,"score_spread":0.35845001876781757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W132642020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084989687,0.99166584,0.0000052511573,0.00088592735,0.001296216,0.0011149831,0.00011704779,0.0000074621184,0.004057361],"genre_scores_gemma":[0.0004180926,0.99576604,0.0006162529,0.0010646931,0.0013660478,0.000025658353,0.000041366493,0.0000395957,0.00066227757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923257,0.0005519027,0.0058870986,0.00040490055,0.0005394945,0.0002908919],"domain_scores_gemma":[0.9886198,0.002218296,0.007263328,0.00031856663,0.0012757494,0.00030427118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023888755,0.00044174903,0.011535412,0.00017793191,0.00006409081,0.000005938414,0.00019677324,0.00057888863,0.00023305714],"category_scores_gemma":[0.004222024,0.00027518443,0.0021360503,0.0002942296,0.0003324728,0.00006800258,0.00018454688,0.0015789361,0.000006529114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006872884,0.0021553822,0.003389728,0.031083208,0.0022461321,0.00027430497,0.000016358974,7.9183984e-8,1.1696646e-8,0.000019793988,0.010550974,0.94957674],"study_design_scores_gemma":[0.0074281064,0.023571882,0.016790468,0.05861801,0.00877021,0.00025918198,0.000002995954,9.70596e-7,1.0080073e-7,0.00017182642,0.8842018,0.00018440328],"about_ca_topic_score_codex":0.000039968705,"about_ca_topic_score_gemma":0.0003045842,"teacher_disagreement_score":0.9493923,"about_ca_system_score_codex":0.00060070603,"about_ca_system_score_gemma":0.0018144364,"threshold_uncertainty_score":0.99997},"labels":[],"label_agreement":null},{"id":"W14257684","doi":"10.1200/jco.2009.27.15_suppl.9623","title":"The McGill Cancer Nutrition and Rehabilitation Program","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Cancer; Rehabilitation; Physical therapy; Breast cancer; Nausea; Anorexia; Depression (economics); Colorectal cancer; Lung cancer; Psychological intervention; Internal medicine; Nursing","score_opus":0.0868758995317074,"score_gpt":0.5096447215957558,"score_spread":0.4227688220640484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W14257684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8174438,0.0030401484,0.000008134564,0.17561455,0.0015276124,0.0003232158,0.000003661129,0.000011928407,0.0020269516],"genre_scores_gemma":[0.9887628,0.005270041,0.001190971,0.0035385664,0.0010921904,0.000011018909,4.0206166e-7,0.0000036525312,0.00013033194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986703,0.0001837368,0.0008148436,0.00007381257,0.00016261057,0.00009468716],"domain_scores_gemma":[0.99726117,0.0016944845,0.0004704268,0.000072891184,0.0003592448,0.00014176387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016637518,0.000046772086,0.0003932007,0.000028962928,0.000055534158,0.0000046256546,0.000043440985,0.00014424545,0.000013117722],"category_scores_gemma":[0.0017201548,0.000026390762,0.00018059871,0.00007294545,0.00013290567,0.000052413532,0.0000063920534,0.00040924893,0.0000010248827],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016191684,0.0006418062,0.0077413684,0.000016312579,0.000034175075,0.000021715961,0.00006661839,3.3326614e-7,0.000020362275,0.00033768226,0.010116503,0.97938395],"study_design_scores_gemma":[0.0022140008,0.013971334,0.30210605,0.00008038135,0.000090831665,0.000065368746,0.00020269895,0.000015859476,0.000006162033,0.0020324562,0.6791898,0.000025088319],"about_ca_topic_score_codex":0.000025956437,"about_ca_topic_score_gemma":0.0003475499,"teacher_disagreement_score":0.97935885,"about_ca_system_score_codex":0.000075154196,"about_ca_system_score_gemma":0.000244124,"threshold_uncertainty_score":0.20593102},"labels":[],"label_agreement":null},{"id":"W144180828","doi":"10.1200/jco.2009.27.15_suppl.5163","title":"Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Medicine; Agonist; Internal medicine; Receptor; Prostate; Endocrinology; Cancer; Oncology; Urology","score_opus":0.050099633772841747,"score_gpt":0.4177052210699097,"score_spread":0.36760558729706794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W144180828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631524,0.0013897321,0.00012683758,0.0008116406,0.00089506374,0.00027036626,0.000002210698,0.0000021690742,0.00018671431],"genre_scores_gemma":[0.9893925,0.0029580088,0.0059489976,0.0006475966,0.00045561092,0.000009880291,0.000003279136,0.000013922246,0.0005701617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979657,0.00020992204,0.0011919423,0.00022365546,0.00018556102,0.00022322274],"domain_scores_gemma":[0.99870354,0.00009494586,0.0007352869,0.00016144538,0.000117840464,0.00018692644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000801075,0.00015924951,0.0007862826,0.00006474207,0.000028868182,0.000008429149,0.0001495912,0.00021644865,0.000029660709],"category_scores_gemma":[0.00015762167,0.00009341145,0.00033708455,0.00011248178,0.000034753266,0.000013627903,0.00002060227,0.00017528958,7.5754696e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074146213,0.0011272004,0.014036154,0.0000053771,0.00020069694,0.00022037582,0.0005135042,0.0005190833,0.63326764,0.0000033705817,0.0010328073,0.34165913],"study_design_scores_gemma":[0.013517809,0.04230224,0.034750085,0.00021689608,0.00014785475,0.00003864548,0.00039095784,0.000007060793,0.68439144,0.000025649559,0.22391604,0.00029533266],"about_ca_topic_score_codex":0.00003610372,"about_ca_topic_score_gemma":0.0002016817,"teacher_disagreement_score":0.34136382,"about_ca_system_score_codex":0.00005425142,"about_ca_system_score_gemma":0.0010292357,"threshold_uncertainty_score":0.38092083},"labels":[],"label_agreement":null},{"id":"W145828222","doi":"10.1200/jco.2014.32.26_suppl.92","title":"Diagnostic delay in young women with breast cancer: A population-based analysis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Stage (stratigraphy); Cancer; Population; Surgery; Radiology; Breast-conserving surgery; Mastectomy; Internal medicine","score_opus":0.019534751868466458,"score_gpt":0.374461507497865,"score_spread":0.3549267556293985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W145828222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963133,0.00018903233,0.0007088605,0.0022917099,0.00023585673,0.000061659855,0.000013130428,0.0000024291771,0.0001840721],"genre_scores_gemma":[0.99761134,0.00019850512,0.00067363406,0.00085609057,0.0006019956,0.000023282437,0.000010155651,0.000010956506,0.000014020597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812955,0.00034065504,0.0009422847,0.00020403917,0.00016509852,0.00021840446],"domain_scores_gemma":[0.99780864,0.0008088527,0.00084517966,0.00016311312,0.000221516,0.00015271064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001106605,0.00012609757,0.0008532089,0.00011758944,0.000030923806,0.000006679283,0.00014563552,0.00018859572,0.000036382295],"category_scores_gemma":[0.0009872642,0.0000863528,0.00018911397,0.00023724775,0.0000886245,0.0000056034332,0.000030055699,0.00021846467,0.0000014270954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018612568,0.00042665962,0.9743279,0.0000045859183,0.0009478445,0.000027481243,0.000026071837,0.005089243,0.000021742146,0.000007690845,0.00013677662,0.017122751],"study_design_scores_gemma":[0.003723069,0.001860315,0.9921602,0.000021288333,0.00043231912,0.00004752421,0.000031808777,0.00014427531,0.00001326643,0.0000393101,0.0014278478,0.000098800454],"about_ca_topic_score_codex":0.0005553542,"about_ca_topic_score_gemma":0.009936896,"teacher_disagreement_score":0.01783228,"about_ca_system_score_codex":0.00015350695,"about_ca_system_score_gemma":0.0004808374,"threshold_uncertainty_score":0.5545021},"labels":[],"label_agreement":null},{"id":"W145933131","doi":"10.1200/jco.2006.24.18_suppl.10021","title":"Telomere dysfunction in prostatic carcinogenesis","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Ontario Institute for Cancer Research","funders":"","keywords":"Telomere; Prostate cancer; Prostate; Intraepithelial neoplasia; Telomerase; Chromosome instability; Medicine; Carcinogenesis; Pathology; Chromosome; Fluorescence in situ hybridization; Biology; Cancer; Cancer research; Internal medicine; Genetics; DNA; Gene","score_opus":0.09290498661668292,"score_gpt":0.42901880620570876,"score_spread":0.33611381958902586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W145933131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949885,0.00085277384,0.00010670293,0.0040709437,0.0012214324,0.00018984979,0.0000014816837,0.000012376937,0.0040455842],"genre_scores_gemma":[0.99404263,0.0003200373,0.002227272,0.001361759,0.001410856,0.0000033916256,0.0000028139423,0.00001678987,0.00061445223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962592,0.00032337,0.002568647,0.00019349298,0.00038189153,0.00027339047],"domain_scores_gemma":[0.9970429,0.0011067034,0.0010949944,0.00017325103,0.00034840356,0.00023373315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002254555,0.00013563412,0.0012924171,0.0002797453,0.00002967124,0.000007218735,0.00011199979,0.00034022913,0.00013583897],"category_scores_gemma":[0.0019498387,0.00009885109,0.00034012218,0.00032575126,0.00016729403,0.00011751601,0.000022581135,0.0007829555,0.00003785322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023242359,0.0017122357,0.8623581,0.00006114745,0.00005811319,0.0015688495,0.000053160118,0.00003331078,0.0016075763,0.00018781431,0.0045114215,0.12552406],"study_design_scores_gemma":[0.006289895,0.0044798474,0.9556349,0.000101382815,0.00015412708,0.0006327729,0.00014981859,0.00007911544,0.00041318743,0.0006910263,0.031274617,0.00009932892],"about_ca_topic_score_codex":0.00018602479,"about_ca_topic_score_gemma":0.00036279412,"teacher_disagreement_score":0.12542474,"about_ca_system_score_codex":0.00018650731,"about_ca_system_score_gemma":0.0012776685,"threshold_uncertainty_score":0.40310302},"labels":[],"label_agreement":null},{"id":"W146673348","doi":"10.1200/jco.2012.30.15_suppl.6018","title":"Use of palliative chemotherapy and targeted agents in elderly patients with metastatic colorectal cancer (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Capecitabine; FOLFOX; FOLFIRI; Internal medicine; Colorectal cancer; Chemotherapy; Adverse effect; Cancer; Oncology; Proportional hazards model; Irinotecan; Oxaliplatin","score_opus":0.15946722296810914,"score_gpt":0.46344601312853684,"score_spread":0.3039787901604277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W146673348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972436,0.0011811558,0.000006565869,0.00082868116,0.0003141662,0.0002854228,0.000011971652,0.0000020119912,0.00012645169],"genre_scores_gemma":[0.9955262,0.0018643253,0.0018641002,0.0005668096,0.00011257282,0.000010002415,0.000001920226,0.0000107099595,0.000043362423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826026,0.0001683764,0.0010297588,0.00010254981,0.00024510358,0.00019394189],"domain_scores_gemma":[0.9975082,0.0009134975,0.0010032142,0.000051857834,0.0003305611,0.00019261948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050132687,0.00012031262,0.0012071196,0.00008599973,0.000018423374,0.0000029973291,0.000037576152,0.00009297874,0.00009669102],"category_scores_gemma":[0.00057919644,0.00006923699,0.00012244219,0.00012927361,0.00018322495,0.00014260724,0.000020154195,0.00030441914,5.588843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010403743,0.0024639005,0.9050235,0.000021524866,0.0009678812,0.000031969248,0.0006919254,0.0000029720825,0.000021449074,0.0000051116917,0.0003388535,0.08002714],"study_design_scores_gemma":[0.012640254,0.018176068,0.9640469,0.000098045144,0.0003594339,0.0000055944492,0.00011124287,0.000012235609,0.00009017,0.000016528727,0.004382127,0.00006140451],"about_ca_topic_score_codex":0.00012986634,"about_ca_topic_score_gemma":0.00035159325,"teacher_disagreement_score":0.07996574,"about_ca_system_score_codex":0.00016197242,"about_ca_system_score_gemma":0.00036743758,"threshold_uncertainty_score":0.28234026},"labels":[],"label_agreement":null},{"id":"W147364354","doi":"10.1200/jco.2009.27.15_suppl.6531","title":"The effect of a cancer diagnosis on disability status","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Marital status; Breast cancer; Cancer; Epidemiology; Logistic regression; Colorectal cancer; Cohort; Prostate cancer; Stage (stratigraphy); Retrospective cohort study; Pediatrics; Internal medicine; Population","score_opus":0.08197772579326319,"score_gpt":0.5138553629723824,"score_spread":0.43187763717911926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W147364354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744357,0.001467584,0.0000026284104,0.019308172,0.0011046946,0.00019159412,0.0000066020893,0.0000033945205,0.0034796149],"genre_scores_gemma":[0.9900826,0.0054515167,0.0000929704,0.003443886,0.0008440061,0.00000895997,6.3448846e-7,0.000005015717,0.000070401664],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99724483,0.0005840441,0.0015664725,0.00011492357,0.0002896873,0.00020005008],"domain_scores_gemma":[0.98804957,0.010279347,0.0010540909,0.00020853245,0.0001389441,0.00026950243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031216252,0.0000944763,0.0011494225,0.000024073724,0.000040364623,0.0000036237038,0.00012813105,0.00017923057,0.0002836156],"category_scores_gemma":[0.0055442452,0.00004530085,0.0005563377,0.000078389996,0.0003330927,0.000044218792,0.000013545473,0.00080331945,0.0000032890628],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009588322,0.00033949994,0.4171598,0.000013053961,0.00012528029,0.000030522362,0.000019823623,0.000011284216,0.000026399599,0.000015939613,0.0059482916,0.5667218],"study_design_scores_gemma":[0.00594855,0.04536068,0.74527335,0.000058355035,0.00021664852,0.000010304818,0.000013996763,0.000019992573,0.0005505123,0.000080342266,0.20243208,0.00003517505],"about_ca_topic_score_codex":0.000049371145,"about_ca_topic_score_gemma":0.000085463376,"teacher_disagreement_score":0.56668663,"about_ca_system_score_codex":0.00027206482,"about_ca_system_score_gemma":0.0008638546,"threshold_uncertainty_score":0.66373795},"labels":[],"label_agreement":null},{"id":"W1484884408","doi":"10.1200/jco.2012.30.15_suppl.6505","title":"Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Discontinuation; Internal medicine; Imatinib mesylate; Myeloid leukemia; Clinical endpoint; Oncology; Gastroenterology; Clinical trial","score_opus":0.05594910151100691,"score_gpt":0.3982784705581594,"score_spread":0.3423293690471525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484884408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518836,0.00046068837,0.000028830573,0.00045830966,0.0012562558,0.0017111611,0.000021125621,0.00003427874,0.0008410031],"genre_scores_gemma":[0.99350864,0.00015820109,0.0032696316,0.0009093167,0.0012652857,0.00017116865,0.0000240341,0.00013722094,0.0005565291],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99283254,0.00056129403,0.0033659053,0.000675727,0.001148125,0.0014164108],"domain_scores_gemma":[0.9935903,0.0022489517,0.002010221,0.0006667162,0.00037045954,0.0011133405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024898709,0.0006511961,0.003054674,0.0005609224,0.00005599488,0.000029302182,0.000429074,0.00069345493,0.00053693843],"category_scores_gemma":[0.002328415,0.00043091242,0.00037889977,0.00070043025,0.00027690083,0.0004754381,0.00013769347,0.0021503635,0.00015032559],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.38338798,0.007965658,0.32804444,0.00024372515,0.0011204208,0.0032488897,0.001627584,0.00072163355,0.00035301826,0.000009254829,0.0015550992,0.2717223],"study_design_scores_gemma":[0.28308886,0.13447192,0.56054235,0.001757433,0.000680405,0.00019463534,0.00023383551,0.000331627,0.00051151944,0.00000548038,0.01761974,0.00056219776],"about_ca_topic_score_codex":0.00034737718,"about_ca_topic_score_gemma":0.004922728,"teacher_disagreement_score":0.27116007,"about_ca_system_score_codex":0.01654366,"about_ca_system_score_gemma":0.011688766,"threshold_uncertainty_score":0.9998143},"labels":[],"label_agreement":null},{"id":"W149133153","doi":"10.1200/jco.2004.22.90140.6123","title":"Parental perceptions of the informed consent process in pediatric bone marrow transplantation (BMT)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Informed consent; Medicine; Anxiety; Feeling; Family medicine; Phone; Pediatrics; Psychiatry; Psychology; Alternative medicine; Social psychology","score_opus":0.13594947439309543,"score_gpt":0.5221321534493605,"score_spread":0.386182679056265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W149133153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806249,0.00037096013,0.000029167826,0.016284728,0.00089081435,0.00020961669,0.0000056206045,0.0000032331734,0.001580968],"genre_scores_gemma":[0.98850405,0.008556065,0.0006632702,0.0012867757,0.0009429429,0.0000029010312,0.0000028873342,0.0000068051845,0.000034324818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675906,0.00023084562,0.0023410935,0.0000933387,0.00041551393,0.00016014991],"domain_scores_gemma":[0.9961899,0.0019150528,0.001171261,0.000111092486,0.00041378426,0.0001989401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021463041,0.00008125608,0.0007108987,0.00014022915,0.000034287994,0.0000029195762,0.00012573999,0.00040001638,0.000049203896],"category_scores_gemma":[0.004553919,0.00005019389,0.00028579537,0.00028483683,0.00019648566,0.00007848808,0.00001410606,0.0015312642,0.0000041854914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012738549,0.0011874107,0.9887364,0.0007631897,0.000028057853,0.00025919924,0.0036137074,0.00021714137,0.00002265412,0.0002866043,0.00022584797,0.0033859669],"study_design_scores_gemma":[0.0072010043,0.0032305203,0.9850732,0.00022564395,0.00027427537,0.0005548356,0.0012999893,0.000008642569,0.000023147257,0.0011584952,0.00089078455,0.00005944851],"about_ca_topic_score_codex":0.00007970635,"about_ca_topic_score_gemma":0.0009783357,"teacher_disagreement_score":0.014997954,"about_ca_system_score_codex":0.0001655106,"about_ca_system_score_gemma":0.008464757,"threshold_uncertainty_score":0.9971563},"labels":[],"label_agreement":null},{"id":"W1495769661","doi":"10.1200/jco.2012.30.5_suppl.7","title":"Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Antioxidant Activity and Oxidative Stress","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Vitamin E; Cancer; Hazard ratio; Internal medicine; Vitamin; Rectal examination; Selenium; Placebo; Randomized controlled trial; Confidence interval; Gynecology; Oncology; Urology; Pathology; Antioxidant","score_opus":0.05786038145646651,"score_gpt":0.4309512289106883,"score_spread":0.37309084745422183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1495769661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917899,0.0013615631,0.000023161003,0.0052314005,0.00081104855,0.0005074727,0.000045025346,0.0000020130517,0.00022844161],"genre_scores_gemma":[0.9880531,0.010500756,0.00016109225,0.00013388095,0.0007265338,0.0000067973792,0.0000012102245,0.00000713613,0.00040948312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634194,0.0015551397,0.0015631968,0.00011124268,0.0002625526,0.00016593676],"domain_scores_gemma":[0.99357677,0.0024241768,0.0033953406,0.00012894509,0.00035748573,0.00011726487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055719274,0.000102219616,0.0010643866,0.000048377402,0.000056751207,0.0000034645686,0.000098224125,0.00021252657,0.000022552287],"category_scores_gemma":[0.0034400967,0.000047684785,0.000253645,0.00014939184,0.0008259615,0.00014535896,0.00006430227,0.00077619066,2.0806898e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40102983,0.0021044153,0.44522735,0.00011270078,0.0014044957,0.0000048402085,0.0015037616,0.000008880316,0.0033916894,0.000190506,0.0038766211,0.14114489],"study_design_scores_gemma":[0.13047668,0.005650355,0.84677887,0.00027462252,0.0016189282,0.000044490745,0.00028799134,0.000069371,0.006941244,0.00017731097,0.00760961,0.00007055292],"about_ca_topic_score_codex":0.0002476148,"about_ca_topic_score_gemma":0.0003361228,"teacher_disagreement_score":0.40155149,"about_ca_system_score_codex":0.000037375543,"about_ca_system_score_gemma":0.0006408643,"threshold_uncertainty_score":0.41183656},"labels":[],"label_agreement":null},{"id":"W150572272","doi":"10.1200/jco.2009.27.15_suppl.8524","title":"Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Calgary; University of Alberta; Saint John Regional Hospital; University of Ottawa; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Anaplastic large-cell lymphoma; Clinical endpoint; Peripheral T-cell lymphoma; Gastroenterology; Interim analysis; Phases of clinical research; Surgery; Progressive disease; Mycosis fungoides; Lymphoma; Oncology; Chemotherapy; Clinical trial; Multiple myeloma; T cell; Immunology; Immune system","score_opus":0.20177150045491404,"score_gpt":0.4937980521055584,"score_spread":0.29202655165064434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W150572272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627057,0.00014644802,0.000008405219,0.034117434,0.0008616456,0.00063973357,0.000005517482,0.0000030332715,0.0015121257],"genre_scores_gemma":[0.99585754,0.00021984016,0.00028024026,0.0024946947,0.0009633374,0.000019178577,0.0000013611227,0.000006883101,0.00015692973],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99702895,0.00020395106,0.0021467563,0.00016984822,0.00027280636,0.00017770349],"domain_scores_gemma":[0.9890846,0.008108763,0.0022112934,0.00024094895,0.00019728337,0.00015709297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034157038,0.00012597244,0.0014812934,0.00009270179,0.000053540753,0.000004185326,0.000104696286,0.00023866078,0.000030211344],"category_scores_gemma":[0.008020493,0.00006624627,0.00077775837,0.0000962963,0.000099898105,0.000049034526,0.000019287228,0.00022210783,0.0000018289686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.545044,0.16203322,0.0077611217,0.00002694286,0.00035584622,0.012752068,0.00009760612,0.000006905759,0.00014901716,0.0002338989,0.026697265,0.2448421],"study_design_scores_gemma":[0.5983787,0.24127963,0.057550985,0.00017636034,0.0006304291,0.0017615188,0.000038638937,0.000035674766,0.0042553716,0.0004367657,0.09536657,0.00008933113],"about_ca_topic_score_codex":0.00003898152,"about_ca_topic_score_gemma":0.000057541398,"teacher_disagreement_score":0.24475276,"about_ca_system_score_codex":0.00026301816,"about_ca_system_score_gemma":0.0014764213,"threshold_uncertainty_score":0.9601859},"labels":[],"label_agreement":null},{"id":"W1519992109","doi":"10.1200/jco.2007.25.18_suppl.14117","title":"A phase 1 study of the selective cyclin dependent kinase inhibitor P276–00 in patients with advanced refractory neoplasms","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cohort; Pharmacokinetics; Cyclin-dependent kinase; Refractory (planetary science); Pharmacology; Internal medicine; Toxicity; Pharmacodynamics; Cyclin D1; CDK inhibitor; Oncology; Cancer; Gastroenterology; Cell cycle; Biology","score_opus":0.03457207641801923,"score_gpt":0.4150979245156015,"score_spread":0.3805258480975823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1519992109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970319,0.00011437964,0.00009196144,0.00023141653,0.0011792639,0.0008782452,0.0000036157023,0.0000055862547,0.00046358953],"genre_scores_gemma":[0.99865925,0.000025290674,0.00053957605,0.00044798988,0.00027485527,0.000004592143,0.0000010921475,0.000024299536,0.000023057308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563134,0.0005260097,0.002565967,0.00024292992,0.0007574183,0.00027636375],"domain_scores_gemma":[0.9950177,0.0012254621,0.0024446214,0.00030259174,0.0007319597,0.00027763695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028888725,0.0001670612,0.0012406576,0.00021221988,0.000031905278,0.000002806906,0.00018938442,0.0003366218,0.000022755206],"category_scores_gemma":[0.0035089927,0.000100217774,0.0002528805,0.0004058853,0.00015659716,0.00008841608,0.00006929404,0.0019784837,0.0000025318554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10923226,0.08907388,0.6306172,0.000027753124,0.0007249327,0.0017346505,0.0012447588,0.00030397793,0.0028967715,0.0000057260495,0.00037560982,0.1637625],"study_design_scores_gemma":[0.11632823,0.14023428,0.73712444,0.00024472192,0.00038358202,0.00006727267,0.0006313192,0.000011037719,0.0025579527,0.000020093976,0.0022778804,0.00011915746],"about_ca_topic_score_codex":0.000036355385,"about_ca_topic_score_gemma":0.0007417614,"teacher_disagreement_score":0.16364333,"about_ca_system_score_codex":0.0005290013,"about_ca_system_score_gemma":0.0015507112,"threshold_uncertainty_score":0.85956377},"labels":[],"label_agreement":null},{"id":"W1556680452","doi":"10.1200/jco.2007.25.18_suppl.7506","title":"Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Neutropenia; Paclitaxel; Lung cancer; Oncology; Gastroenterology; Discontinuation; Performance status; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Chemotherapy; Progressive disease; Clinical trial","score_opus":0.041269961632896285,"score_gpt":0.393867574699987,"score_spread":0.3525976130670907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556680452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275315,0.0013134329,0.0005399183,0.0026495825,0.0009756389,0.0013876517,0.00002449467,0.000009199929,0.0003469085],"genre_scores_gemma":[0.99285454,0.0034427952,0.0025560758,0.00053027633,0.00041062068,0.000014687672,0.000012266279,0.00004064441,0.00013812089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610424,0.00019475174,0.0025611306,0.00034053833,0.00037980662,0.00041952773],"domain_scores_gemma":[0.9928489,0.003669654,0.0021959937,0.00024712217,0.0006746208,0.00036374063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016283635,0.00031244563,0.0017703901,0.00024060113,0.000079871184,0.0000091282545,0.00019275984,0.0004832058,0.000024556277],"category_scores_gemma":[0.0016533594,0.00018250091,0.00042106822,0.00035105483,0.00022873403,0.00014052956,0.000047576745,0.0007517314,0.0000014004768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018149251,0.0059201373,0.92624104,0.00024571695,0.000435731,0.00009600212,0.0012535807,0.00004289465,0.013506769,0.000040194947,0.0002296642,0.033839032],"study_design_scores_gemma":[0.050348055,0.028950075,0.9020161,0.00048389964,0.0005165926,0.00003482006,0.00023232255,0.00017489865,0.014149819,0.000039977607,0.0028488794,0.00020456697],"about_ca_topic_score_codex":0.00024347592,"about_ca_topic_score_gemma":0.0003271128,"teacher_disagreement_score":0.033634465,"about_ca_system_score_codex":0.00037768402,"about_ca_system_score_gemma":0.0014685122,"threshold_uncertainty_score":0.7442171},"labels":[],"label_agreement":null},{"id":"W161061911","doi":"10.1200/jco.2006.24.18_suppl.6601","title":"Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Fluorescence in situ hybridization; Internal medicine; Alemtuzumab; Chromosome instability; Gastroenterology; Cytogenetics; Chromosome; Trisomy 8; Trisomy; Progressive disease; Oncology; Pathology; Chemotherapy; Biology; Genetics; Gene","score_opus":0.044682266617835774,"score_gpt":0.39532079396820063,"score_spread":0.3506385273503649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W161061911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287134,0.0012186839,0.0007526898,0.0005572817,0.000560315,0.0024091145,0.000011147516,0.00003695882,0.001582464],"genre_scores_gemma":[0.9916673,0.00040014263,0.002997501,0.00095243193,0.0023435487,0.000071550545,0.00007773104,0.00011256118,0.0013772872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99416757,0.00035702263,0.002599683,0.0006130138,0.0014695764,0.0007931134],"domain_scores_gemma":[0.9906747,0.003800255,0.0027157995,0.0005739674,0.001665966,0.000569338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016505261,0.0004547757,0.0020183483,0.00027415785,0.00013997084,0.000039663595,0.0003921459,0.00069287885,0.00019850969],"category_scores_gemma":[0.0013151913,0.00027449176,0.000512575,0.0002870241,0.000610339,0.00015955455,0.000055451892,0.0011297734,0.00011066437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.62615037,0.017473063,0.05293554,0.00059976854,0.0025212083,0.0027944339,0.00030423058,0.055034656,0.0002560747,0.00020059291,0.0134385135,0.22829156],"study_design_scores_gemma":[0.51585305,0.36326656,0.062331747,0.0010217747,0.0009791467,0.0009402242,0.000050339277,0.025936322,0.0015851546,0.00021750944,0.027245592,0.0005726286],"about_ca_topic_score_codex":0.0002099866,"about_ca_topic_score_gemma":0.000087570384,"teacher_disagreement_score":0.3457935,"about_ca_system_score_codex":0.052340597,"about_ca_system_score_gemma":0.09858229,"threshold_uncertainty_score":0.99997073},"labels":[],"label_agreement":null},{"id":"W1748137726","doi":"10.1200/jco.2014.32.18_suppl.lba4","title":"First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Hazard ratio; Regimen; Clinical endpoint; Oncology; Anthracycline; Gastroenterology; Breast cancer; Cancer; Confidence interval; Clinical trial","score_opus":0.27672095696187204,"score_gpt":0.4792496435740614,"score_spread":0.20252868661218937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1748137726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810945,0.00069066376,0.00010523335,0.015359561,0.00042784668,0.0017083749,0.00031891323,0.000009027753,0.00028590474],"genre_scores_gemma":[0.9906993,0.0067951456,0.000369745,0.0005518329,0.0014042106,0.00006368158,0.000033562854,0.000040040413,0.000042495616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9926824,0.002188846,0.0031955033,0.00043216444,0.0010473597,0.000453732],"domain_scores_gemma":[0.9853062,0.010041793,0.0028800038,0.0006511282,0.0008785874,0.00024227916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057642963,0.00034156034,0.002863874,0.000112601934,0.00011044671,0.00002532268,0.00066528906,0.0003357883,0.000093934774],"category_scores_gemma":[0.0009352971,0.00015300924,0.000416298,0.00047971675,0.0009274644,0.00012824476,0.000051060673,0.0011744893,0.0000040005684],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61690706,0.02544352,0.048386835,0.000051064602,0.0018980918,0.00020563403,0.014038696,0.00023316176,0.0016683851,0.0000519421,0.00061798556,0.29049766],"study_design_scores_gemma":[0.35768485,0.09250093,0.5382621,0.0014134846,0.0003366209,0.00010186728,0.0017225777,0.0008287623,0.0023653095,0.00016076553,0.0044063884,0.00021628197],"about_ca_topic_score_codex":0.0062468983,"about_ca_topic_score_gemma":0.006474436,"teacher_disagreement_score":0.48987532,"about_ca_system_score_codex":0.00052548526,"about_ca_system_score_gemma":0.0023841355,"threshold_uncertainty_score":0.94434834},"labels":[],"label_agreement":null},{"id":"W1748212683","doi":"10.1200/jco.2006.24.18_suppl.18626","title":"Competency building for self-management and self-care: evidence informed development of an empowerment course for breast cancer survivors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Survivorship curve; Medicine; Empowerment; Psychosocial; Nursing; Psychological intervention; Focus group; Breast cancer; Health care; Medical education; Family medicine; Cancer; Psychiatry","score_opus":0.055832099676404824,"score_gpt":0.44624492604039834,"score_spread":0.3904128263639935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1748212683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915265,0.0020954155,0.0011761488,0.0021849163,0.0018899251,0.0008230969,0.000032462678,0.000015328362,0.00025620495],"genre_scores_gemma":[0.9293405,0.0009988209,0.06815213,0.0006650963,0.0007175424,0.000058026475,0.000005560248,0.000018011238,0.00004432261],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969375,0.000089156965,0.0020945766,0.0002049904,0.0004061279,0.00026765701],"domain_scores_gemma":[0.99580663,0.0014441498,0.0013793245,0.00014552702,0.0009720804,0.00025229834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018490988,0.00015973403,0.0010770442,0.000082831204,0.0000716053,0.000009740929,0.00016406487,0.00017344253,0.000017472945],"category_scores_gemma":[0.00015084392,0.0001238096,0.00023672247,0.000099863806,0.00006852404,0.00014632804,0.00005307318,0.00022303661,1.6035791e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012310861,0.004401186,0.3206316,0.003773161,0.001960862,0.00009747025,0.0032217207,0.00010117942,0.00011325836,0.0010621834,0.0036263317,0.6487002],"study_design_scores_gemma":[0.009152523,0.005272494,0.7629684,0.00076871685,0.0011532786,0.000102425125,0.0020925207,0.00016932891,0.00022210616,0.00015371699,0.21772859,0.00021588575],"about_ca_topic_score_codex":0.0020203341,"about_ca_topic_score_gemma":0.09228834,"teacher_disagreement_score":0.6484843,"about_ca_system_score_codex":0.0005226631,"about_ca_system_score_gemma":0.0057132845,"threshold_uncertainty_score":0.9999234},"labels":[],"label_agreement":null},{"id":"W1750189415","doi":"10.1200/jco.2005.23.16_suppl.756","title":"Subgroup analysis of a phase III trial of doxorubicin vs doxorubicin plus tesmilifene in advanced breast cancer (ABC): Tesmilifene survival benefit focused on patients with more aggressive disease","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Doxorubicin; Internal medicine; Chemotherapy; Subgroup analysis; Oncology; Breast cancer; Proportional hazards model; Survival analysis; Cancer; Gastroenterology; Confidence interval","score_opus":0.05199588958467272,"score_gpt":0.45966956780422985,"score_spread":0.40767367821955713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1750189415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916154,0.0007209105,0.000015547916,0.005422864,0.0008046847,0.00095116126,0.00032493743,0.000008715886,0.00013575797],"genre_scores_gemma":[0.9957547,0.0013477855,0.0003690191,0.0012894953,0.0009843183,0.000044139237,0.000061828294,0.000034176905,0.00011449953],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99396294,0.00045794155,0.0037909667,0.00045737004,0.0008828912,0.00044786982],"domain_scores_gemma":[0.99019176,0.002528139,0.005194977,0.00038629165,0.0009883284,0.0007104992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013329883,0.00037701536,0.00437275,0.00088591856,0.000040422725,0.000003807668,0.00027290772,0.00034962766,0.00056683214],"category_scores_gemma":[0.0008066065,0.0002550817,0.0009968808,0.0011157463,0.00045825908,0.00016414335,0.00005735181,0.0008607984,0.0000016443872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5966579,0.021635214,0.29629132,0.000036802023,0.0036406487,0.00033930477,0.0001909678,0.0045529883,0.00023198756,0.000012874621,0.00019762033,0.0762124],"study_design_scores_gemma":[0.40980622,0.034629155,0.5452151,0.0003289339,0.0080378065,0.000006933722,0.000053752876,0.00081718306,0.00031571864,0.000013551571,0.0006008327,0.00017483362],"about_ca_topic_score_codex":0.00036114256,"about_ca_topic_score_gemma":0.00193808,"teacher_disagreement_score":0.24892375,"about_ca_system_score_codex":0.000699086,"about_ca_system_score_gemma":0.0021905007,"threshold_uncertainty_score":0.99999017},"labels":[],"label_agreement":null},{"id":"W1750557753","doi":"10.1200/jco.2015.33.3_suppl.417","title":"FOLFIRINOX for advanced pancreatic cancer: The Princess Margaret experience.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"FOLFIRINOX; Medicine; Irinotecan; Oxaliplatin; Pancreatic cancer; Internal medicine; Gemcitabine; Regimen; Oncology; Gastroenterology; Cancer; Surgery; Colorectal cancer","score_opus":0.17762392773686533,"score_gpt":0.5321233904144728,"score_spread":0.35449946267760746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1750557753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004996,0.0035151236,0.0006769426,0.0034448584,0.0010200607,0.00028965372,0.0000115529,0.0000022935872,0.0009895433],"genre_scores_gemma":[0.993592,0.0023139901,0.0014298162,0.000838477,0.0012094672,0.00008883649,0.0000052538353,0.000011785063,0.0005103341],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984357,0.0001980688,0.0007521821,0.00016285824,0.00021889538,0.00023233925],"domain_scores_gemma":[0.9981603,0.0003052191,0.0006056366,0.00019970925,0.0004266149,0.0003024942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012416603,0.00009351934,0.00043518,0.0000202467,0.000050278915,0.000012482075,0.00035011387,0.0001530395,0.000017167256],"category_scores_gemma":[0.0020927107,0.00005361319,0.00025789626,0.000053184638,0.00019292936,0.000008313361,0.000083532526,0.00019554551,0.0000025450054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022303041,0.001493753,0.19843775,0.00003474943,0.0013417469,0.00012894908,0.00040661072,0.0003096135,0.0047768042,0.00025616644,0.06275078,0.70776004],"study_design_scores_gemma":[0.008721407,0.012275899,0.016378375,0.000024404888,0.0000972165,0.00006719002,0.00036324465,0.000031611286,0.0056377854,0.0007804879,0.95550734,0.00011501742],"about_ca_topic_score_codex":0.000066470115,"about_ca_topic_score_gemma":0.00040452243,"teacher_disagreement_score":0.8927566,"about_ca_system_score_codex":0.00006986558,"about_ca_system_score_gemma":0.0016932742,"threshold_uncertainty_score":0.30037957},"labels":[],"label_agreement":null},{"id":"W1755097868","doi":"10.1200/jco.2013.31.6_suppl.1","title":"Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Biopsy; Watchful waiting; Prostate; Cancer; Internal medicine; Prostate-specific antigen; Prostate biopsy; Pathological; Urology; Surgery","score_opus":0.04349498938675373,"score_gpt":0.39905427752625144,"score_spread":0.3555592881394977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1755097868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204344,0.00045162297,0.000049478538,0.004892763,0.0002618709,0.0005661989,0.000004466488,0.00000821003,0.0017219275],"genre_scores_gemma":[0.9964973,0.0009540605,0.00074085046,0.0010088389,0.00033258554,0.000039260216,0.000006514444,0.000021481654,0.00039914335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786437,0.00022522984,0.0010509257,0.00022797055,0.00031592458,0.00031556195],"domain_scores_gemma":[0.99688315,0.0011546973,0.0010232523,0.00016938242,0.00041692363,0.00035258348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011433596,0.00016275766,0.0014889676,0.00009705002,0.000026827038,0.000013080595,0.00009581193,0.00018685237,0.00032699382],"category_scores_gemma":[0.0004666292,0.00009050626,0.00018448874,0.00017570345,0.00012104298,0.000172282,0.000024542715,0.0006682799,0.00004802885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005395595,0.0015737502,0.94814485,0.000017415592,0.0007177476,0.0015577064,0.00006741132,0.000004183182,0.00001538658,0.000008208911,0.0015839499,0.040913776],"study_design_scores_gemma":[0.018641641,0.018310068,0.95995986,0.00037884086,0.00021565106,0.00041416803,0.000038370436,0.00003264671,0.00006643416,0.000026940004,0.0018139108,0.00010145966],"about_ca_topic_score_codex":0.000058729194,"about_ca_topic_score_gemma":0.00047137105,"teacher_disagreement_score":0.040812317,"about_ca_system_score_codex":0.0003807709,"about_ca_system_score_gemma":0.0010287467,"threshold_uncertainty_score":0.36907384},"labels":[],"label_agreement":null},{"id":"W175900201","doi":"10.1200/jco.2006.24.18_suppl.lba525","title":"Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Letrozole; Toremifene; Clinical endpoint; Internal medicine; Hazard ratio; Breast cancer; Hormonal therapy; Metastatic breast cancer; Population; Oncology; Interim analysis; Adjuvant therapy; Tamoxifen; Randomization; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.024596754428208044,"score_gpt":0.4299108434528482,"score_spread":0.40531408902464017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W175900201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692756,0.0014830972,0.00001686229,0.00047753524,0.00054767024,0.00014994669,0.000008433116,0.0000018828007,0.00038700458],"genre_scores_gemma":[0.998061,0.00074969576,0.00025257046,0.00013148946,0.00067018846,0.000004122987,0.0000051035713,0.000012917948,0.000112916896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975734,0.00033831014,0.0015510884,0.00017764141,0.00017256298,0.000186992],"domain_scores_gemma":[0.99827653,0.00012859158,0.0011018905,0.00016439609,0.00021722661,0.00011136334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010788157,0.00011769899,0.00075562403,0.00006844187,0.000016920818,0.000002991353,0.00019716627,0.0003498285,0.000020567168],"category_scores_gemma":[0.00022726758,0.00008833525,0.00021403564,0.00011726516,0.000100316196,0.0000073653437,0.000055922454,0.00045826923,0.000001331287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031323407,0.047317713,0.40027222,0.00003889765,0.00066487066,0.001029106,0.00009136422,0.0029039718,0.30531293,0.000037664584,0.0066105565,0.2043973],"study_design_scores_gemma":[0.12638487,0.17262523,0.61113495,0.0002032484,0.0005511004,0.0008938653,0.0006973154,0.00023798463,0.041420266,0.0001768771,0.045035705,0.0006386245],"about_ca_topic_score_codex":0.00010366117,"about_ca_topic_score_gemma":0.00016493845,"teacher_disagreement_score":0.26389265,"about_ca_system_score_codex":0.000039180766,"about_ca_system_score_gemma":0.00045855035,"threshold_uncertainty_score":0.3602207},"labels":[],"label_agreement":null},{"id":"W1760304583","doi":"10.1200/jco.2013.31.26_suppl.52","title":"Sentinel node biopsy after neoadjuvant therapy: Relevance of sentinel node micrometastases, isolated tumor cells, and value of immunohistochemistry.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; Hôpital du Saint-Sacrement; Ottawa Hospital; University Health Network; London Health Sciences Centre; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; McGill University Health Centre; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Sentinel node; Immunohistochemistry; Breast cancer; Biopsy; Axillary Dissection; Neoadjuvant therapy; Oncology; Metastasis; Cancer; Sentinel lymph node; Internal medicine; Pathology","score_opus":0.021075401171763646,"score_gpt":0.34077084133966723,"score_spread":0.3196954401679036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1760304583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933,0.008654586,0.00009777383,0.0012570904,0.00032509194,0.00012013603,0.000052624295,0.0000030586905,0.00015966831],"genre_scores_gemma":[0.99071133,0.004123786,0.003994784,0.00075822277,0.00027745604,0.000010477035,0.000012044705,0.00002481218,0.00008710863],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972351,0.00020838773,0.0018402855,0.0002874593,0.0001805186,0.00024824808],"domain_scores_gemma":[0.99657786,0.00028583713,0.002089505,0.0003179623,0.0005881846,0.00014063584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006058581,0.00023111067,0.0011194003,0.000055324617,0.00003066424,0.0000068818704,0.00022550338,0.00025944234,0.00006513349],"category_scores_gemma":[0.00041273632,0.00017558529,0.00040711288,0.0000937457,0.0004892904,0.000011752407,0.00016068145,0.0003056154,0.000003996331],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027525371,0.0011579655,0.048044704,0.00006560581,0.00090608903,0.000056459176,0.000040086055,0.0000134358415,0.93972814,0.0000022152421,0.002989783,0.0042430074],"study_design_scores_gemma":[0.017056294,0.002795125,0.5964965,0.0002856661,0.00066037534,0.0009029046,0.00020119947,0.00012469463,0.351424,0.00014787425,0.029328508,0.0005768019],"about_ca_topic_score_codex":0.000091866525,"about_ca_topic_score_gemma":0.0000010438182,"teacher_disagreement_score":0.5883041,"about_ca_system_score_codex":0.000028500053,"about_ca_system_score_gemma":0.00033957284,"threshold_uncertainty_score":0.71601605},"labels":[],"label_agreement":null},{"id":"W1761630621","doi":"10.1200/jco.2014.32.3_suppl.45","title":"Discovery of prognostic and predictive tissue biomarkers in patients with resectable esophageal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Oxaliplatin; Cisplatin; Oncology; Internal medicine; Chemotherapy; Esophageal cancer; Fluorouracil; Adenocarcinoma; Cancer; Gastroenterology; Colorectal cancer","score_opus":0.017417578558657453,"score_gpt":0.3519290472748519,"score_spread":0.33451146871619447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1761630621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979008,0.0007097483,0.00042473545,0.0001965982,0.0003211454,0.00013154138,0.000027417067,5.0800014e-7,0.00028753644],"genre_scores_gemma":[0.9981027,0.0006834167,0.0006963809,0.00015950084,0.00031207106,0.0000038048738,0.000008028735,0.000009272335,0.000024795356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986752,0.00015523042,0.0007675534,0.00015089572,0.00011980868,0.00013128071],"domain_scores_gemma":[0.9983873,0.00048511542,0.00071969006,0.00010558156,0.00021175291,0.000090559035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008191692,0.00008113377,0.0004643088,0.000047765825,0.000013534195,0.000006912474,0.00010942872,0.0001786359,0.000003157377],"category_scores_gemma":[0.0019137347,0.00005966537,0.00005585832,0.00005955852,0.0001931373,0.0000090628355,0.0000672493,0.00017314304,1.667847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049268794,0.0005038819,0.96990556,0.000021227992,0.00019516391,0.000008673038,0.000019987496,0.00020145284,0.0008840935,0.000024414381,0.000664348,0.022644311],"study_design_scores_gemma":[0.0052784183,0.021298625,0.96605283,0.00006143593,0.00008704661,0.00000485748,0.000018826619,0.000054610307,0.0020100288,0.00011464728,0.0049396716,0.00007901279],"about_ca_topic_score_codex":0.000048425183,"about_ca_topic_score_gemma":0.00023178534,"teacher_disagreement_score":0.022565298,"about_ca_system_score_codex":0.00002552956,"about_ca_system_score_gemma":0.00050202955,"threshold_uncertainty_score":0.2433083},"labels":[],"label_agreement":null},{"id":"W1763748567","doi":"10.1200/jco.2012.30.15_suppl.5504","title":"Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Panitumumab; Response Evaluation Criteria in Solid Tumors; Larynx; Head and neck squamous-cell carcinoma; Chemotherapy; Head and neck cancer; Phases of clinical research; Cetuximab; Cancer; Surgery","score_opus":0.057174723813613576,"score_gpt":0.46188841779417833,"score_spread":0.4047136939805648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1763748567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397385,0.0024337987,0.000026528247,0.0013715242,0.000383382,0.0005869149,0.00009650486,9.628476e-7,0.0011265196],"genre_scores_gemma":[0.99894726,0.0004158075,0.0003412426,0.00014914795,0.000113455884,0.0000024155288,0.0000024948747,0.0000057877296,0.000022392152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969312,0.00070051244,0.0017875363,0.00013415517,0.00025865593,0.00018792748],"domain_scores_gemma":[0.9947667,0.0026413484,0.002049022,0.00017089989,0.00017415758,0.00019788682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013575024,0.00013406384,0.0015549529,0.00011770414,0.000048332888,0.0000032876314,0.00008905502,0.00011232526,0.000030237628],"category_scores_gemma":[0.001456262,0.000070335314,0.0003603039,0.0005049244,0.0005468327,0.000090483016,0.00007557937,0.00035459743,1.0655977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085991286,0.0135856075,0.8255345,0.00010588496,0.0028185043,0.00002503278,0.003968649,0.000023992669,0.000058933187,0.0004681832,0.00007127617,0.067348115],"study_design_scores_gemma":[0.11491016,0.009411926,0.86695945,0.000074439275,0.0073123993,0.000043053173,0.00064331345,0.00009209266,0.00025437173,0.00010918491,0.00013789024,0.000051735256],"about_ca_topic_score_codex":0.00028502394,"about_ca_topic_score_gemma":0.00029412584,"teacher_disagreement_score":0.06729638,"about_ca_system_score_codex":0.00017282067,"about_ca_system_score_gemma":0.00064330956,"threshold_uncertainty_score":0.28681907},"labels":[],"label_agreement":null},{"id":"W1769572924","doi":"10.1200/jco.2014.32.4_suppl.106","title":"One-step ultrasound-based high dose rate (HDR) prostate brachytherapy with dose escalation to the dominant intra-prostatic lesion.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Brachytherapy; Nuclear medicine; Prostate; Prostate cancer; Ultrasound; Prostate brachytherapy; Lesion; Radiology; Urology; Radiation therapy; Cancer; Surgery; Internal medicine","score_opus":0.06410035498426628,"score_gpt":0.4014892183562366,"score_spread":0.33738886337197027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1769572924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93156505,0.00024643072,0.0036510904,0.06237584,0.0007998711,0.0011640004,0.000009527148,0.000014424661,0.0001737924],"genre_scores_gemma":[0.9724879,0.00089359924,0.010600315,0.0148306405,0.00094085216,0.00007467679,0.000013606509,0.000036933787,0.000121440455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959753,0.0008999634,0.00195673,0.0003212367,0.00048102342,0.00036570974],"domain_scores_gemma":[0.99156857,0.005267907,0.0016293674,0.00039590066,0.0006086501,0.00052963063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045555364,0.0002391039,0.0013860447,0.000117018244,0.00012055956,0.000038210113,0.00017933268,0.00020452334,0.00008506222],"category_scores_gemma":[0.0021070163,0.00012233276,0.0002914786,0.00025509766,0.00023321454,0.0001255963,0.000022659291,0.00074310455,0.000049743277],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054956693,0.0075251763,0.11783431,0.00013440891,0.0010387871,0.00057331147,0.00065837125,0.0022721298,0.0024069138,0.00063464564,0.008060006,0.80390525],"study_design_scores_gemma":[0.036018033,0.06964441,0.8082043,0.00063531415,0.0008637267,0.00018500608,0.000098564946,0.0005892158,0.0027257071,0.00079419866,0.07999786,0.00024364487],"about_ca_topic_score_codex":0.000056714453,"about_ca_topic_score_gemma":0.00017489374,"teacher_disagreement_score":0.8036616,"about_ca_system_score_codex":0.00029836487,"about_ca_system_score_gemma":0.0013835512,"threshold_uncertainty_score":0.49885848},"labels":[],"label_agreement":null},{"id":"W1773789492","doi":"10.1200/jco.2001.19.12.3111","title":"Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Osteoporosis Canada","funders":"","keywords":"Raloxifene; Medicine; Breast cancer; Estrogen; Selective estrogen receptor modulator; Osteoporosis; Internal medicine; Oncology; Hormone replacement therapy (female-to-male); Gynecology; Placebo; Risk factors for breast cancer; Hormone therapy; Menopause; Cancer; Tamoxifen; Pathology","score_opus":0.05578704183471094,"score_gpt":0.44957323875016947,"score_spread":0.3937861969154585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1773789492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815,0.00079167174,0.0000052426753,0.00038299875,0.0001821574,0.00046331182,0.0000022727997,0.0000010944784,0.00002125783],"genre_scores_gemma":[0.9986028,0.0010346181,0.00004499478,0.00015906889,0.00012215428,0.000022431845,0.000001984533,0.000008932038,0.0000029910966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966819,0.0016471371,0.0010236478,0.00016385752,0.0003372562,0.00014614737],"domain_scores_gemma":[0.997386,0.0009456731,0.001249644,0.00017255111,0.00016340191,0.0000827422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00463632,0.0001268083,0.00064692704,0.000095863325,0.000023737133,0.0000046151154,0.00017201644,0.00022105912,0.00000816066],"category_scores_gemma":[0.0009197411,0.00006531891,0.00013548248,0.00015101004,0.00014367707,0.000012733338,0.00002780174,0.00037078935,3.9967418e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008738156,0.0015064869,0.90233076,0.0000045404418,0.00040708538,0.00002595213,0.0001925034,0.00034003635,0.009663692,9.435372e-7,0.000016354477,0.07677348],"study_design_scores_gemma":[0.00840783,0.036430992,0.9458209,0.000046175464,0.00018645466,0.00007873285,0.0002015404,0.00007383704,0.008624383,0.00000561094,0.000058241392,0.000065265995],"about_ca_topic_score_codex":0.00006247245,"about_ca_topic_score_gemma":0.00008650548,"teacher_disagreement_score":0.07670821,"about_ca_system_score_codex":0.00002465197,"about_ca_system_score_gemma":0.00029655604,"threshold_uncertainty_score":0.2663628},"labels":[],"label_agreement":null},{"id":"W1776948253","doi":"10.1200/jco.2001.19.15.3524","title":"Comparison of Breast Magnetic Resonance Imaging, Mammography, and Ultrasound for Surveillance of Women at High Risk for Hereditary Breast Cancer","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":460,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Mammography; Breast cancer; Breast MRI; Radiology; Magnetic resonance imaging; Physical examination; Breast ultrasound; Malignancy; Cancer; Family history; Oncology; Gynecology; Internal medicine","score_opus":0.028055447146298665,"score_gpt":0.39625886711510244,"score_spread":0.3682034199688038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1776948253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98319405,0.013340311,0.0006642116,0.00094906084,0.0007945214,0.00022942435,0.0007906796,0.0000018715642,0.00003587002],"genre_scores_gemma":[0.9895674,0.0047872504,0.004408591,0.00017574594,0.0009121374,0.00003619066,0.000015613366,0.00002068545,0.00007635796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976533,0.00019654883,0.0014801555,0.000248694,0.00014883328,0.00027244244],"domain_scores_gemma":[0.9961937,0.0010067925,0.0017025963,0.00020295412,0.0007403304,0.00015360117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001768562,0.00013488825,0.00087783055,0.000060641385,0.000050232677,0.0000044409885,0.00022421218,0.00023007751,0.000047951784],"category_scores_gemma":[0.0006265913,0.00011730198,0.0002487908,0.00009675386,0.00047329624,0.000007911468,0.000057933095,0.00017571743,1.5654122e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059866332,0.00037364502,0.8390786,0.00005076852,0.00015220327,0.000002593754,0.000065097774,0.000110659596,0.0057175853,0.000010249828,0.008524729,0.13992724],"study_design_scores_gemma":[0.0051013585,0.0042833183,0.9186535,0.000030207844,0.00011995005,0.00038932162,0.00014649883,0.000105357074,0.0010363465,0.00037306856,0.06962897,0.0001320876],"about_ca_topic_score_codex":0.000097092816,"about_ca_topic_score_gemma":0.0005084709,"teacher_disagreement_score":0.13979515,"about_ca_system_score_codex":0.00012272564,"about_ca_system_score_gemma":0.00058200787,"threshold_uncertainty_score":0.4783436},"labels":[],"label_agreement":null},{"id":"W1778464498","doi":"10.1200/jco.2006.24.18_suppl.9560","title":"Malignant hemangiopericytoma: A study of long-term outcomes","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Medicine; Surgery; Hemangiopericytoma; Radiation therapy; Adjuvant therapy; Pelvis; Chemotherapy; Radiology","score_opus":0.17668907938340236,"score_gpt":0.505009783266687,"score_spread":0.3283207038832846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1778464498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937409,0.00084013754,0.000023387991,0.0022061248,0.0009526123,0.0003201237,0.0000012108309,0.000013613874,0.0019018907],"genre_scores_gemma":[0.99694836,0.00006529277,0.0007946692,0.00039811857,0.0009941396,0.0000043675373,5.6448073e-7,0.000018742418,0.0007757384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995533,0.00029143548,0.003270036,0.000176142,0.0005075638,0.00022181084],"domain_scores_gemma":[0.9950277,0.0019520244,0.0020369827,0.00025581196,0.0005522653,0.00017521984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020271312,0.00016019082,0.002592352,0.0001638498,0.000032531894,0.0000035933065,0.0001595897,0.00016071578,0.000099635385],"category_scores_gemma":[0.0025868507,0.000099950994,0.00061112695,0.00017334342,0.00022707872,0.000057819747,0.00009838912,0.00051199895,0.000018954765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014022094,0.00926874,0.96479255,0.00003820044,0.00066948077,0.012034151,0.00017801861,0.0000029137589,0.000103779465,0.000027097081,0.0022963432,0.0091865435],"study_design_scores_gemma":[0.011685217,0.02481946,0.9592532,0.0000717724,0.00089545344,0.0015023646,0.0005210744,0.0000017045344,0.00008106144,0.00004894705,0.0010379889,0.000081768216],"about_ca_topic_score_codex":0.000065810265,"about_ca_topic_score_gemma":0.00014473277,"teacher_disagreement_score":0.01555072,"about_ca_system_score_codex":0.00008668352,"about_ca_system_score_gemma":0.00044478677,"threshold_uncertainty_score":0.40758833},"labels":[],"label_agreement":null},{"id":"W1779133220","doi":"10.1200/jco.2000.18.5.1036","title":"Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Odds ratio; Confidence interval; Prostate-specific antigen; Urology; Prostate biopsy; Cancer; Prostate; Internal medicine; Rectal examination; Quartile; Gynecology; Biopsy; Oncology; Gastroenterology","score_opus":0.10882255173298519,"score_gpt":0.4401482671797492,"score_spread":0.33132571544676404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1779133220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887267,0.0015492544,0.0000045625784,0.0052860696,0.00012756862,0.0019854943,0.00005561265,0.000017087365,0.002247665],"genre_scores_gemma":[0.98777324,0.0051818956,0.0002215692,0.0001739357,0.00055260636,0.00007726321,0.000009894577,0.000035241523,0.0059743486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956356,0.00065490825,0.0019846924,0.00032132657,0.0009015104,0.0005019469],"domain_scores_gemma":[0.99637926,0.000551644,0.00131996,0.00039073714,0.00089935114,0.00045905396],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029797293,0.00023678584,0.001307546,0.00011122433,0.00014609142,0.000023575025,0.00036219455,0.00026748024,0.0009848245],"category_scores_gemma":[0.00027194578,0.000113301656,0.00028203728,0.00035887703,0.0010886134,0.00022231802,0.000053870506,0.0012952054,0.00000849241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025603043,0.001721516,0.9044787,0.00012771615,0.0012429836,0.001545978,0.001199203,0.0001762728,0.0032568278,0.000020662974,0.0035149609,0.0571121],"study_design_scores_gemma":[0.015617699,0.018543113,0.9204205,0.00061028457,0.00027451193,0.00010339761,0.00019710122,0.00012012984,0.0049184165,0.0001580446,0.03889205,0.00014471468],"about_ca_topic_score_codex":0.00021813375,"about_ca_topic_score_gemma":0.00006984153,"teacher_disagreement_score":0.05696739,"about_ca_system_score_codex":0.00017146199,"about_ca_system_score_gemma":0.0023489434,"threshold_uncertainty_score":0.9999284},"labels":[],"label_agreement":null},{"id":"W1782284105","doi":"10.1200/jco.2015.33.7_suppl.228","title":"Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Enzalutamide; Medicine; Cabazitaxel; Docetaxel; Abiraterone acetate; Prostate cancer; Abiraterone; Internal medicine; Oncology; Medical prescription; Cancer; Pharmacology; Androgen receptor; Androgen deprivation therapy","score_opus":0.4458819072764866,"score_gpt":0.5576866826355011,"score_spread":0.11180477535901456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1782284105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759795,0.0077089146,0.00008021289,0.014310142,0.00068522,0.0005644846,0.00043625006,0.0000072768958,0.00022801755],"genre_scores_gemma":[0.96734405,0.024666939,0.004400295,0.00033044085,0.0010535339,0.000026135676,0.000102532955,0.000026173477,0.0020498896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642575,0.00036094926,0.0020371713,0.0002489302,0.00065420975,0.0002730166],"domain_scores_gemma":[0.99504954,0.0018048374,0.0015486969,0.00034285104,0.0005208715,0.00073322374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014608436,0.00019194778,0.0014973136,0.00014063322,0.000029829986,0.000016221205,0.00019887133,0.00010815931,0.00039308312],"category_scores_gemma":[0.0008377629,0.00010899572,0.00031988183,0.00017506907,0.00017166536,0.00023149031,0.00004360575,0.0004153074,0.000012445941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02893374,0.0020674684,0.7211069,0.000069408816,0.0029252244,0.002060871,0.0017391217,0.000047145866,0.00089657906,0.000033644716,0.010775683,0.22934422],"study_design_scores_gemma":[0.03408932,0.04296263,0.8519541,0.0011156275,0.002453331,0.00006909057,0.001060704,0.0001240627,0.0018466924,0.0017501521,0.062355567,0.00021872052],"about_ca_topic_score_codex":0.015494291,"about_ca_topic_score_gemma":0.020838765,"teacher_disagreement_score":0.22912548,"about_ca_system_score_codex":0.0006662252,"about_ca_system_score_gemma":0.009240433,"threshold_uncertainty_score":0.99702835},"labels":[],"label_agreement":null},{"id":"W1783107099","doi":"10.1200/jco.2011.29.18_suppl.lba1003","title":"NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":241,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Radiation therapy; Internal medicine; Oncology; Adjuvant; Population; Interim analysis; Cancer; Surgery; Randomized controlled trial; Gynecology","score_opus":0.12501629163712794,"score_gpt":0.4324982227718473,"score_spread":0.30748193113471933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1783107099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996391,0.00028520555,0.00004345609,0.0013307547,0.0012080643,0.00011295932,0.000026336098,0.0000020434484,0.0006001879],"genre_scores_gemma":[0.99626786,0.00066030095,0.0008471146,0.000401723,0.0017550127,0.0000104418405,0.000008505738,0.000012710903,0.00003633016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762285,0.00036173026,0.0014514283,0.00020817574,0.00017871142,0.00017713352],"domain_scores_gemma":[0.99794674,0.00013276345,0.0013313203,0.00017110573,0.00027881222,0.0001392675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010624074,0.00012824185,0.0007027361,0.000078836034,0.000020006726,0.0000031346242,0.00023814499,0.000340887,0.00005102398],"category_scores_gemma":[0.00025125087,0.000101952806,0.00028996414,0.0000762971,0.00021757951,0.000017764909,0.00006385706,0.00029359973,0.0000020692953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28695855,0.006144497,0.56914264,0.000018114108,0.0008979768,0.00010388027,0.00078655273,0.000023967936,0.0029888349,0.00020625154,0.0022608172,0.13046794],"study_design_scores_gemma":[0.036759242,0.011332342,0.94711846,0.000034560813,0.00010487426,0.00010550597,0.00011028654,0.000006852116,0.00024862462,0.00027640283,0.003794005,0.00010881696],"about_ca_topic_score_codex":0.0004275457,"about_ca_topic_score_gemma":0.0012914783,"teacher_disagreement_score":0.37797585,"about_ca_system_score_codex":0.000081055776,"about_ca_system_score_gemma":0.0007046439,"threshold_uncertainty_score":0.4157515},"labels":[],"label_agreement":null},{"id":"W1783154753","doi":"10.1200/jco.2000.18.12.2385","title":"Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Vinorelbine; Metastatic breast cancer; Anthracycline; Chemotherapy; Neutropenia; Internal medicine; Doxorubicin; Surgery; Breast cancer; Toxicity; Vinca alkaloid; Cancer; Febrile neutropenia; Gastroenterology; Phases of clinical research; Cyclophosphamide; Vincristine; Cisplatin","score_opus":0.310743133948084,"score_gpt":0.5937902368847396,"score_spread":0.28304710293665564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1783154753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915551,0.0006803738,0.0000028941809,0.0021836737,0.0028121474,0.002159539,0.00021009822,0.000005777463,0.00039041648],"genre_scores_gemma":[0.9977808,0.00089096127,0.000114553804,0.0002618817,0.0006392873,0.0000994739,0.00002875002,0.000019150375,0.00016515913],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.987626,0.0030835017,0.007438636,0.00042266733,0.0010636295,0.0003655777],"domain_scores_gemma":[0.9873012,0.006321248,0.004504314,0.0002075095,0.0011787816,0.00048697682],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008246344,0.00035944663,0.0061772023,0.00027908947,0.000054427182,0.0000055748937,0.00027654986,0.00018103546,0.0015656512],"category_scores_gemma":[0.00077315106,0.00023578045,0.0003794419,0.00065036665,0.00044377174,0.00016310018,0.000046306435,0.0012249958,9.3524517e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.598758,0.16110893,0.15226984,0.0000529152,0.009406178,0.0013867632,0.0014966656,0.00084202253,0.00019841648,0.000018773448,0.0077357823,0.066725746],"study_design_scores_gemma":[0.4148371,0.23557626,0.33825746,0.00027635804,0.0052687307,0.00007683507,0.0022698427,0.0003599221,0.00012100643,0.000016596214,0.0027128975,0.0002270148],"about_ca_topic_score_codex":0.089422986,"about_ca_topic_score_gemma":0.68382764,"teacher_disagreement_score":0.59440464,"about_ca_system_score_codex":0.0008820232,"about_ca_system_score_gemma":0.00886884,"threshold_uncertainty_score":0.99934703},"labels":[],"label_agreement":null},{"id":"W1788564901","doi":"10.1200/jco.2015.33.7_suppl.151","title":"Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Urology; Proportional hazards model; Confidence interval; Internal medicine; Cancer","score_opus":0.08898261223170705,"score_gpt":0.43744846036789686,"score_spread":0.3484658481361898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1788564901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97537386,0.021559514,0.00005565926,0.00041644266,0.00055375084,0.0018326294,0.00002722111,0.0000034095106,0.00017749725],"genre_scores_gemma":[0.9831432,0.015583591,0.00067943777,0.000029101733,0.00024866735,0.00019044554,0.0000055878636,0.000017025057,0.00010296028],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99205196,0.0023754088,0.0039586257,0.00022259165,0.001159483,0.00023194651],"domain_scores_gemma":[0.9887692,0.0038710262,0.00406086,0.0003654244,0.0024946555,0.00043886303],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013643902,0.00018609007,0.009297477,0.00047379246,0.000012304451,0.0000021990277,0.0001589224,0.00031372524,0.000039701732],"category_scores_gemma":[0.010425055,0.000096652286,0.004146575,0.00057722314,0.00068396155,0.000078357596,0.000051536175,0.0006522669,7.7160547e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87775904,0.0017630233,0.0264418,0.000055493598,0.09079067,0.00018203797,0.00031670407,0.0004360531,0.000033561064,0.0000018727249,0.00020382491,0.0020159145],"study_design_scores_gemma":[0.916296,0.01756075,0.0019117156,0.00018727033,0.06233177,0.0000059183785,0.00022635238,0.00015842877,0.0007405699,0.000045032448,0.00045899674,0.000077220335],"about_ca_topic_score_codex":0.00015779622,"about_ca_topic_score_gemma":0.000028639732,"teacher_disagreement_score":0.038536932,"about_ca_system_score_codex":0.00021444436,"about_ca_system_score_gemma":0.0042819628,"threshold_uncertainty_score":0.99791056},"labels":[],"label_agreement":null},{"id":"W1796791327","doi":"10.1200/jco.2001.19.10.2731","title":"Functional Evaluation of Plasmin Formation in Primary Breast Cancer","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Plasmin; Breast cancer; Internal medicine; Cancer; Confidence interval; Oncology; Univariate analysis; Population; Metastatic breast cancer; Quartile; Pathology; Metastasis; Urokinase; Gastroenterology; Multivariate analysis; Enzyme; Biology","score_opus":0.10511175932976563,"score_gpt":0.42267164951664776,"score_spread":0.31755989018688213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1796791327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564743,0.00041626184,0.00082696445,0.0008913594,0.0006783363,0.00009834519,0.0000055470714,7.6867593e-7,0.0014349816],"genre_scores_gemma":[0.99760497,0.00059024873,0.00034008917,0.00049625605,0.0009025863,0.000006791947,0.000011431932,0.000004490611,0.0000431629],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813014,0.00032456138,0.0010760686,0.00008603717,0.0002930162,0.00009019965],"domain_scores_gemma":[0.9983953,0.00006458378,0.0008901203,0.00007534874,0.00051283365,0.00006180282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003206208,0.000056254925,0.0002987722,0.000059713777,0.000011774051,0.000002055413,0.00007827326,0.00024434153,0.00012208315],"category_scores_gemma":[0.00045028146,0.000045466262,0.00014475115,0.000061327504,0.00003910047,0.000016349744,0.000027583075,0.00018894036,0.0000024790302],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067782337,0.0014963257,0.025110453,0.000026277947,0.00015357119,0.000027286771,0.0000341285,0.0015754583,0.54287964,0.00011067367,0.009048236,0.41275972],"study_design_scores_gemma":[0.02350129,0.009696994,0.7028375,0.00021491136,0.00037993098,0.0015035938,0.00016326227,0.0027412353,0.21759011,0.0031865435,0.037848733,0.0003358676],"about_ca_topic_score_codex":0.0000066610196,"about_ca_topic_score_gemma":0.000046188747,"teacher_disagreement_score":0.67772704,"about_ca_system_score_codex":0.00007760203,"about_ca_system_score_gemma":0.0008754691,"threshold_uncertainty_score":0.18845856},"labels":[],"label_agreement":null},{"id":"W1797421894","doi":"10.1200/jco.2006.24.18_suppl.7008","title":"Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Internal medicine; Hazard ratio; Etoposide; Chemotherapy; Vinca; Cisplatin; Oncology; Lung cancer; Confidence interval; Stage (stratigraphy); Clinical trial; Randomized controlled trial; Pharmacology","score_opus":0.18839369014743626,"score_gpt":0.5980156452928224,"score_spread":0.40962195514538613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1797421894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98704106,0.0010405186,0.0026045984,0.0022507778,0.001627638,0.0013219482,0.000024959176,0.000007745372,0.004080783],"genre_scores_gemma":[0.9930432,0.00033272765,0.004861996,0.00048099994,0.00094598666,0.000023231652,0.00009322279,0.000013638774,0.00020499177],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9808538,0.007829917,0.009983098,0.00025578137,0.00088197103,0.00019543798],"domain_scores_gemma":[0.9596471,0.02770618,0.009863629,0.00023286465,0.0022854519,0.00026475565],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05594835,0.00017112363,0.0066505424,0.0004914447,0.000054419084,0.000009548607,0.00011813791,0.00043015776,0.00040235536],"category_scores_gemma":[0.06566642,0.00010546792,0.003256561,0.0005270112,0.00023245497,0.00011669727,0.000042183554,0.000572177,0.0000035506746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21947473,0.009548011,0.40304485,0.000046446967,0.048372094,0.00009885514,0.0003183748,0.01138909,0.000030319341,0.00019189034,0.0057861763,0.30169916],"study_design_scores_gemma":[0.42267323,0.0036654905,0.3558921,0.00013687783,0.14873901,0.000007046321,0.000094660456,0.067362964,0.000012798695,0.0004630037,0.0008456316,0.00010721651],"about_ca_topic_score_codex":0.0001248028,"about_ca_topic_score_gemma":0.000068788024,"teacher_disagreement_score":0.30159193,"about_ca_system_score_codex":0.00036124166,"about_ca_system_score_gemma":0.0022723305,"threshold_uncertainty_score":0.97209984},"labels":[],"label_agreement":null},{"id":"W1797772724","doi":"10.1200/jco.2006.24.18_suppl.514","title":"ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Breast cancer; Gefitinib; Tissue microarray; Cancer; Internal medicine; Oncology; Estrogen receptor; Microarray; Cancer research; Immunohistochemistry; Epidermal growth factor receptor; Fulvestrant; Pathology; Gene expression; Biology; Gene","score_opus":0.11404282470768969,"score_gpt":0.4747955722268884,"score_spread":0.3607527475191987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1797772724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8223865,0.0021255512,0.000090607384,0.17390734,0.00036561614,0.00042511252,0.0005841689,0.000012338033,0.00010276089],"genre_scores_gemma":[0.9823811,0.0020617482,0.0024370593,0.011098275,0.0012009782,0.000034884983,0.000004511903,0.000058565005,0.00072289637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596244,0.0005457503,0.0017355051,0.0003914075,0.0008503074,0.0005145618],"domain_scores_gemma":[0.99491763,0.0016268367,0.0009960032,0.00024410877,0.0014653297,0.00075009075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001707064,0.0002721317,0.0017191551,0.00033005583,0.00006300765,0.000025267147,0.00033902502,0.00047315983,0.0011796664],"category_scores_gemma":[0.0006543325,0.00019460566,0.00029692618,0.00047242935,0.0003539124,0.00013681207,0.00012711815,0.0010663086,0.000004652347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014086675,0.0007598442,0.8330783,0.0001664917,0.00062051264,0.00021393102,0.0010181832,0.000034094734,0.042756468,0.000050208153,0.069442935,0.037772324],"study_design_scores_gemma":[0.0038857255,0.0041118856,0.9381608,0.0006329656,0.00022263848,0.00034348672,0.00025482877,0.000021639562,0.008047585,0.0001772957,0.043903835,0.00023734345],"about_ca_topic_score_codex":0.0038648322,"about_ca_topic_score_gemma":0.0013284246,"teacher_disagreement_score":0.16280906,"about_ca_system_score_codex":0.00047766982,"about_ca_system_score_gemma":0.0030965968,"threshold_uncertainty_score":0.9997334},"labels":[],"label_agreement":null},{"id":"W1798388355","doi":"10.1200/jco.2007.25.18_suppl.18500","title":"Retrospective review of DPACE therapy for aggressive, refractory multiple myeloma (MM)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Thalidomide; Neutropenia; Regimen; Salvage therapy; Surgery; Internal medicine; Etoposide; Refractory (planetary science); Febrile neutropenia; Lenalidomide; Multiple myeloma; Bortezomib; Gastroenterology; Cyclophosphamide; Progressive disease; Chemotherapy","score_opus":0.1624343293685952,"score_gpt":0.5268634708977441,"score_spread":0.3644291415291489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1798388355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9188943,0.063899375,0.00096364535,0.007217986,0.0013133262,0.0017823017,0.0000310218,0.000015294683,0.0058827675],"genre_scores_gemma":[0.88769174,0.09650819,0.011764686,0.002357391,0.001182019,0.000010165519,0.000008145569,0.000025541474,0.0004521345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99609226,0.00031089148,0.0024649533,0.00020515425,0.00058236567,0.00034434785],"domain_scores_gemma":[0.9885976,0.005016855,0.0037434315,0.00027930143,0.0018171915,0.000545651],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006553267,0.00015271088,0.00195817,0.00015024719,0.00004061407,0.0000027657568,0.00018113444,0.00031776345,0.0001844564],"category_scores_gemma":[0.03062604,0.000096153926,0.0009000284,0.00017431933,0.0002556019,0.00008865267,0.000033305154,0.0007940971,0.000009673516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027189853,0.0041192006,0.26242864,0.0006987282,0.001201077,0.0012511894,0.000053348424,1.5745263e-7,0.0010702213,0.000053818992,0.013004093,0.6889297],"study_design_scores_gemma":[0.023263466,0.033033866,0.7738837,0.0029253913,0.000205379,0.00027681876,0.000046405912,0.0000136644,0.0013910711,0.00017824963,0.16469231,0.0000896481],"about_ca_topic_score_codex":0.000011131962,"about_ca_topic_score_gemma":0.000020020565,"teacher_disagreement_score":0.68884003,"about_ca_system_score_codex":0.0002611408,"about_ca_system_score_gemma":0.0012920828,"threshold_uncertainty_score":0.9775394},"labels":[],"label_agreement":null},{"id":"W1801481254","doi":"10.1200/jco.2009.27.15_suppl.8092","title":"Anatomic response correlation with biological response","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Chemotherapy; C-reactive protein; Stage (stratigraphy); Surgery; Inflammation","score_opus":0.10775424800469743,"score_gpt":0.4641151207687246,"score_spread":0.35636087276402717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1801481254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795535,0.00023071842,0.00030755674,0.018351933,0.0004855362,0.00020825214,0.0000016004244,0.000025481337,0.0008353784],"genre_scores_gemma":[0.9866844,0.00009294071,0.007845491,0.0047922116,0.00044529903,0.0000018646797,0.0000013512117,0.000009956084,0.00012650808],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9947877,0.0024905263,0.0019296906,0.00019748324,0.00036569615,0.00022889192],"domain_scores_gemma":[0.991863,0.0054388545,0.0014660445,0.00022971061,0.00051943836,0.0004829685],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012184864,0.00014253023,0.0010446047,0.00022507219,0.000048711045,0.000008437768,0.00015917757,0.00054772565,0.00014719536],"category_scores_gemma":[0.01719469,0.00008657135,0.00040009627,0.00021263542,0.00033164612,0.00010671586,0.000021871092,0.0008805267,0.000040399966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68255866,0.0013946183,0.23723808,0.0000045549637,0.00022766447,0.00424759,0.000052097468,0.000009662861,0.0020494875,0.00007496787,0.0047088014,0.06743386],"study_design_scores_gemma":[0.008206799,0.038697943,0.9180675,0.000094700285,0.00023910926,0.0013524453,0.00006900627,0.00012954496,0.00014492338,0.000289359,0.032611106,0.00009753648],"about_ca_topic_score_codex":3.3804986e-7,"about_ca_topic_score_gemma":4.884487e-7,"teacher_disagreement_score":0.68082947,"about_ca_system_score_codex":0.00022424951,"about_ca_system_score_gemma":0.0023421452,"threshold_uncertainty_score":0.9910839},"labels":[],"label_agreement":null},{"id":"W1806756686","doi":"10.1200/jco.2010.28.15_suppl.5018","title":"Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Topotecan; Carboplatin; Internal medicine; Oncology; Ovarian cancer; Paclitaxel; Breast cancer; Immunohistochemistry; Tissue microarray; Debulking; Cisplatin; Progression-free survival; Cancer; Chemotherapy","score_opus":0.062083655998273916,"score_gpt":0.45545814546020036,"score_spread":0.39337448946192644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1806756686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833037,0.00032106874,0.0000122220235,0.010792455,0.0028342393,0.0016428434,0.000037624814,0.000014425566,0.0010414184],"genre_scores_gemma":[0.99449164,0.0002717663,0.00076501316,0.00071149203,0.0028485404,0.00029861418,0.0000039242855,0.000042664553,0.00056636427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954435,0.0007823125,0.002281462,0.0004789702,0.00059842225,0.00041532496],"domain_scores_gemma":[0.9956258,0.00096488814,0.0018141231,0.00035293648,0.00051434035,0.00072794664],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029565925,0.00029529087,0.0017577447,0.00022867147,0.000070821676,0.000022154267,0.00023294217,0.0005564633,0.0037685235],"category_scores_gemma":[0.0011226031,0.0001946126,0.00035125043,0.00028186146,0.00023480676,0.0002630043,0.000068886555,0.002328361,0.000027948734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0112312725,0.012406257,0.8188377,0.000024913084,0.00040864144,0.0017703685,0.00051231694,0.000011054345,0.00068656163,0.000051317264,0.00079504144,0.15326454],"study_design_scores_gemma":[0.020676317,0.012230452,0.95681876,0.00073063176,0.0006458698,0.0005715338,0.00032725645,0.00005422329,0.00015293446,0.00035494356,0.0072485507,0.00018852191],"about_ca_topic_score_codex":0.0023731159,"about_ca_topic_score_gemma":0.0064353966,"teacher_disagreement_score":0.15307602,"about_ca_system_score_codex":0.00058434554,"about_ca_system_score_gemma":0.004858306,"threshold_uncertainty_score":0.9999733},"labels":[],"label_agreement":null},{"id":"W1810994930","doi":"10.1200/jco.2006.24.18_suppl.11503","title":"Combination procarbazine and temozolomide for temozolomide-resistant adult gliomas","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Temozolomide; Medicine; Procarbazine; Regimen; Dacarbazine; Oncology; Concomitant; Progression-free survival; Internal medicine; Oligodendroglioma; Radiation therapy; Glioma; Chemotherapy; Chemoradiotherapy; Surgery; Vincristine; Cyclophosphamide; Astrocytoma; Cancer research","score_opus":0.05838298242811408,"score_gpt":0.41917751228527744,"score_spread":0.36079452985716337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1810994930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755498,0.00096618396,0.00011428247,0.020734778,0.0005390538,0.0005081807,0.0000067761607,0.00001213833,0.00156878],"genre_scores_gemma":[0.9929396,0.00019864214,0.0048132646,0.0010473747,0.0008046747,0.000024397352,0.000009453402,0.00001751314,0.00014508107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723643,0.00013368069,0.0019789273,0.00019260652,0.00024908024,0.0002092501],"domain_scores_gemma":[0.9953996,0.0020869882,0.0013441908,0.00012705462,0.000810478,0.00023170734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015171994,0.00014194402,0.0012019367,0.00015796853,0.000056486388,0.000013460138,0.000069683854,0.00029971093,0.0000143601565],"category_scores_gemma":[0.0028285168,0.0000949595,0.00037382086,0.000116783856,0.00015205341,0.00008212229,0.000023966455,0.00028327983,0.0000044816334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02327348,0.022624608,0.59556204,0.00033519295,0.0015765708,0.0024636153,0.000075441734,0.000017557599,0.017256925,0.027113462,0.09662534,0.21307574],"study_design_scores_gemma":[0.046144724,0.035100687,0.8301512,0.00019482113,0.001290922,0.0006933996,0.00007760147,0.00031016197,0.0036096638,0.009630342,0.07261945,0.00017700608],"about_ca_topic_score_codex":0.0000310894,"about_ca_topic_score_gemma":0.00008999753,"teacher_disagreement_score":0.23458916,"about_ca_system_score_codex":0.00013096092,"about_ca_system_score_gemma":0.00043336226,"threshold_uncertainty_score":0.3872336},"labels":[],"label_agreement":null},{"id":"W1814462863","doi":"10.1200/jco.2009.27.15_suppl.5148","title":"Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomization; Placebo; Docetaxel; Clinical endpoint; Prostate cancer; Analgesic; Internal medicine; Prednisone; Randomized controlled trial; Chemotherapy; Cancer; Anesthesia","score_opus":0.1391352726429714,"score_gpt":0.45676784729240283,"score_spread":0.3176325746494314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1814462863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878838,0.00025709407,0.000027989023,0.0098302495,0.00041852132,0.0013792242,0.00016376222,0.0000059469176,0.00003337976],"genre_scores_gemma":[0.99475414,0.00071097544,0.0015276447,0.0022427852,0.00051484274,0.000021018954,0.00007769393,0.000013062015,0.00013784794],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99383146,0.0030853148,0.00212692,0.00027207233,0.00045218974,0.00023202423],"domain_scores_gemma":[0.98911464,0.008363024,0.0016625647,0.00016789715,0.00039451808,0.00029738163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064762845,0.00018938821,0.0012109389,0.00009859152,0.00003831742,0.000010534718,0.000090029425,0.0001624264,0.00008929506],"category_scores_gemma":[0.0055790055,0.00010021131,0.00013965394,0.00016626382,0.00014095087,0.00013954203,0.000028203902,0.0005536908,7.7716084e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47750312,0.00505394,0.33215466,0.000013716896,0.00039286312,0.00019398033,0.00042166896,0.0001187076,0.00021194555,9.980093e-7,0.0078013614,0.17613305],"study_design_scores_gemma":[0.17956795,0.09493979,0.7124257,0.00038526274,0.00073247385,0.000007590392,0.000033582528,0.0005028303,0.0000813864,0.000028087768,0.0111878365,0.00010748863],"about_ca_topic_score_codex":0.00046924961,"about_ca_topic_score_gemma":0.002094227,"teacher_disagreement_score":0.38027108,"about_ca_system_score_codex":0.00025331264,"about_ca_system_score_gemma":0.00096954964,"threshold_uncertainty_score":0.66789937},"labels":[],"label_agreement":null},{"id":"W181489850","doi":"10.1200/jco.2012.30.27_suppl.65","title":"Acute care utilization (ACU) among women receiving adjuvant chemotherapy for early breast cancer (EBC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Health Sciences Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Breast cancer; Population; Taxane; Cancer; Anthracycline; Logistic regression; Cancer registry; Toxicity; Oncology; Environmental health","score_opus":0.12673114578102893,"score_gpt":0.5171077527380621,"score_spread":0.39037660695703313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W181489850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886234,0.001929009,0.00014140346,0.004815982,0.0032649653,0.00037649705,0.00003115366,0.000013727902,0.0008038717],"genre_scores_gemma":[0.9870584,0.0035342465,0.0007585817,0.002926951,0.004874647,0.000051752973,0.000007729478,0.000029955934,0.0007577453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787855,0.00016446403,0.0012116821,0.00014533289,0.00018955788,0.00041040577],"domain_scores_gemma":[0.9970321,0.0007033225,0.0011256025,0.000108888846,0.0005203249,0.0005097696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011503376,0.00014888454,0.0011671832,0.00009687309,0.000054293727,0.0000069614703,0.00010643336,0.00034587167,0.000844376],"category_scores_gemma":[0.00016468027,0.00010664009,0.00038643455,0.00011373762,0.0001294354,0.00021944629,0.000020958274,0.00047016778,0.0000060754387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008720386,0.0010944997,0.64069736,0.00003996359,0.0010724161,0.00003101665,0.0028864543,0.0000023683021,0.00036483372,0.0000076237648,0.0064852997,0.3385978],"study_design_scores_gemma":[0.014759521,0.0066688573,0.8773878,0.000072487135,0.0008805425,0.00016373653,0.00033339518,0.000023405968,0.00024742348,0.000028460146,0.09933512,0.00009920506],"about_ca_topic_score_codex":0.00003791983,"about_ca_topic_score_gemma":0.00003976458,"teacher_disagreement_score":0.3384986,"about_ca_system_score_codex":0.00064917566,"about_ca_system_score_gemma":0.0008795168,"threshold_uncertainty_score":0.92453253},"labels":[],"label_agreement":null},{"id":"W1819148429","doi":"10.1200/jco.2012.30.15_suppl.lba7500","title":"LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Pemetrexed; Medicine; Afatinib; Oncology; Internal medicine; Cisplatin; Adenocarcinoma; Lung cancer; Erlotinib; Chemotherapy; Epidermal growth factor receptor; Cancer","score_opus":0.1257192747879889,"score_gpt":0.5202801478412544,"score_spread":0.39456087305326554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819148429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417585,0.00077979325,0.00019478747,0.00045672586,0.0006232182,0.0034133017,0.00001744707,0.0000034982438,0.00033536422],"genre_scores_gemma":[0.99313563,0.00010779759,0.0062758066,0.00005503248,0.00017911958,0.0001560842,0.000009672982,0.000020640357,0.000060211296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971076,0.00029280307,0.0019289535,0.00017004556,0.00030283365,0.0001977235],"domain_scores_gemma":[0.9906925,0.0053310604,0.0029815405,0.00019772584,0.00059974415,0.00019743173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011709051,0.0001744088,0.0017281846,0.000098231365,0.00012962666,0.00000888671,0.00012357793,0.00009591366,0.000026518495],"category_scores_gemma":[0.0030843585,0.000092744616,0.00017985904,0.00018030233,0.00015221674,0.0002549251,0.000059281574,0.0002087004,1.5373313e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.510997,0.035624932,0.36433238,0.00009671506,0.00503364,0.000014275526,0.0048185177,0.00011415192,0.000042158,0.00009333482,0.000055284145,0.07877762],"study_design_scores_gemma":[0.844467,0.055713058,0.09202893,0.00023962828,0.0050472803,0.000010683287,0.0015600086,0.00046698368,0.00012465932,0.000016522199,0.00023687685,0.00008836195],"about_ca_topic_score_codex":0.000094164665,"about_ca_topic_score_gemma":0.000037038888,"teacher_disagreement_score":0.33347002,"about_ca_system_score_codex":0.00026201925,"about_ca_system_score_gemma":0.0006641988,"threshold_uncertainty_score":0.37820157},"labels":[],"label_agreement":null},{"id":"W1819484237","doi":"10.1200/jco.2009.27.15_suppl.lba4505","title":"ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Folinic acid; Gemcitabine; Fluorouracil; Oncology; Internal medicine; Pancreatic ductal adenocarcinoma; Adjuvant; Clinical trial; Adenocarcinoma; Adjuvant chemotherapy; Chemotherapy; Pancreatic cancer; Cancer; Breast cancer","score_opus":0.12236937871655054,"score_gpt":0.49387600900732787,"score_spread":0.37150663029077735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819484237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845624,0.0010593596,0.00016745001,0.00430805,0.0016320656,0.005344283,0.000013963505,0.000012193679,0.0029002456],"genre_scores_gemma":[0.99130005,0.0017937187,0.005073917,0.00053672417,0.0007830956,0.000092698516,0.00003879122,0.000027486725,0.00035355095],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98737293,0.0032006516,0.0070584463,0.00046440092,0.001322108,0.00058144546],"domain_scores_gemma":[0.97922176,0.012475983,0.005151393,0.00048424437,0.002020265,0.0006463709],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012725375,0.0003870838,0.0102354875,0.00061583705,0.00006355954,0.00003242171,0.0008031017,0.00061514904,0.00047292854],"category_scores_gemma":[0.039781373,0.00023623931,0.00074275024,0.000386185,0.00070895744,0.0003627962,0.00017432497,0.0017419843,0.000011602181],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91020274,0.030189319,0.0430431,0.000023971284,0.0035748763,0.0012174513,0.00018587895,0.0000023235289,0.0001317163,0.00006500777,0.00050534407,0.010858249],"study_design_scores_gemma":[0.8023811,0.1273568,0.06416634,0.0003405287,0.0029234376,0.000063818276,0.00011085513,0.0022244083,0.000014725245,0.00008491702,0.00017015658,0.00016290318],"about_ca_topic_score_codex":0.00007099946,"about_ca_topic_score_gemma":0.0000673563,"teacher_disagreement_score":0.10782164,"about_ca_system_score_codex":0.00041773095,"about_ca_system_score_gemma":0.003206178,"threshold_uncertainty_score":0.96830696},"labels":[],"label_agreement":null},{"id":"W1821546071","doi":"10.1200/jco.2014.32.18_suppl.lba6008","title":"A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup>I-refractory differentiated thyroid cancer (SELECT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenvatinib; Medicine; Internal medicine; Hazard ratio; Thyroid cancer; Clinical endpoint; Gastroenterology; Refractory (planetary science); Placebo; Progression-free survival; Confidence interval; Oncology; Cancer; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.06840121577109488,"score_gpt":0.42627886317781005,"score_spread":0.3578776474067152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821546071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944903,0.00055069674,0.00003069534,0.001361048,0.0008385463,0.0023419778,0.000011633101,0.000010660209,0.0003644019],"genre_scores_gemma":[0.9967859,0.001036721,0.0002720835,0.0006452702,0.0009525764,0.00017229105,0.00001678807,0.000037155463,0.000081240774],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99409777,0.0007771436,0.0036805104,0.00034455582,0.00069989375,0.00040012348],"domain_scores_gemma":[0.9921935,0.0028016786,0.0035239325,0.00030792542,0.0007421698,0.00043074496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019229188,0.0003169328,0.0034329668,0.00029692383,0.00003658831,0.00001123831,0.00021085817,0.00042574637,0.00021693743],"category_scores_gemma":[0.0014420897,0.0001910573,0.00064570416,0.00021789198,0.0001838181,0.00014041165,0.000040738818,0.0010580126,0.000006496316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80253845,0.04692876,0.11578602,0.00003246601,0.0013757737,0.00004732028,0.000152573,0.000069919864,0.00003165539,0.00001093829,0.00053496,0.03249115],"study_design_scores_gemma":[0.83644605,0.10093967,0.057023358,0.0002830821,0.0013209811,0.000004282281,0.00003183152,0.0003125869,0.00009951158,0.000010184723,0.0033866216,0.00014183632],"about_ca_topic_score_codex":0.00013231479,"about_ca_topic_score_gemma":0.00021960394,"teacher_disagreement_score":0.058762666,"about_ca_system_score_codex":0.00035657117,"about_ca_system_score_gemma":0.0013327603,"threshold_uncertainty_score":0.77910906},"labels":[],"label_agreement":null},{"id":"W1824988371","doi":"10.1200/jco.2015.64.0888","title":"Limited-Stage Small-Cell Lung Cancer: An Age Limit for Combined Modality Therapy?","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Radiology","score_opus":0.3601170311879099,"score_gpt":0.5497337496686522,"score_spread":0.1896167184807423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1824988371","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054645088,0.009399097,0.00012555359,0.9237748,0.005230745,0.0022676855,0.00020354266,0.00004888681,0.004304594],"genre_scores_gemma":[0.006801546,0.026372071,0.0041209366,0.8848051,0.04993912,0.00025890087,0.00019508392,0.00023850733,0.027268758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99195176,0.0015627326,0.0037370203,0.00061685266,0.001246788,0.0008848378],"domain_scores_gemma":[0.9853779,0.0062125446,0.00382359,0.00075860624,0.0029712268,0.0008561001],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0085365595,0.00051924225,0.004888955,0.00031290026,0.00010551104,0.000043328568,0.00086337293,0.0025272742,0.00018180997],"category_scores_gemma":[0.0052367016,0.00035707155,0.0015175614,0.00019698219,0.0004965388,0.00014681401,0.00020309047,0.008177607,0.000007195985],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011595182,0.0017040645,0.0074755955,0.000811945,0.00242495,0.004689662,0.00019355798,0.0000118193875,0.000032460586,0.000007509072,0.95075285,0.020300424],"study_design_scores_gemma":[0.022745304,0.035303105,0.0042718635,0.0002989977,0.0012353456,0.000056477344,0.00006276952,0.00022020625,0.000024318486,0.0003694821,0.93509686,0.00031527266],"about_ca_topic_score_codex":0.000212132,"about_ca_topic_score_gemma":0.00021229354,"teacher_disagreement_score":0.047843542,"about_ca_system_score_codex":0.0013772884,"about_ca_system_score_gemma":0.0106935175,"threshold_uncertainty_score":0.9998881},"labels":[],"label_agreement":null},{"id":"W1828494712","doi":"10.1200/jco.2000.18.19.3360","title":"Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Radiation therapy; Internal medicine; Cohort; Estrogen receptor; Germline mutation; Cancer; Mutation","score_opus":0.01434391743818245,"score_gpt":0.3846752919627554,"score_spread":0.37033137452457293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1828494712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995871,0.0017116123,0.000029368352,0.0019926247,0.000119376484,0.00014120562,0.000035993664,0.0000014368759,0.000097361335],"genre_scores_gemma":[0.9949863,0.0029400575,0.0009594606,0.00048455116,0.00041553585,0.00004899933,0.0000021209005,0.000015449676,0.00014752938],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99840754,0.0003400357,0.0008184255,0.00017369227,0.00009835053,0.0001619766],"domain_scores_gemma":[0.99888396,0.0003108633,0.00042563753,0.00013930144,0.00012124895,0.00011899267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008859539,0.00012310751,0.00059497944,0.00006265524,0.000017593553,0.000005837692,0.000093097886,0.00019427818,0.00030898815],"category_scores_gemma":[0.000049877763,0.000081953454,0.00009642676,0.0000936399,0.00021144183,0.000008714397,0.000012519313,0.00015770737,6.6458534e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017664908,0.00041110849,0.11807591,0.00001987382,0.00043477534,0.000058342663,0.00024033542,0.0009255775,0.0029370508,6.111649e-7,0.00010172694,0.8591298],"study_design_scores_gemma":[0.012875416,0.018102175,0.9511581,0.00008308561,0.00014367148,0.0012485902,0.000060090053,0.00010057856,0.0016501027,0.000022765698,0.014400006,0.00015542442],"about_ca_topic_score_codex":0.000073731775,"about_ca_topic_score_gemma":0.0002794558,"teacher_disagreement_score":0.85897434,"about_ca_system_score_codex":0.00020516214,"about_ca_system_score_gemma":0.0009385261,"threshold_uncertainty_score":0.33832037},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W1830813972","doi":"10.1200/jco.2000.18.12.2395","title":"Palliative Effect of Chemotherapy: Objective Tumor Response Is Associated With Symptom Improvement in Patients With Metastatic Breast Cancer","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Quality of life (healthcare); Nausea; Cancer; Performance status; Lethargy; Mood; Anorexia; Metastatic breast cancer; Chemotherapy; Palliative care; Constipation; Disease; Oncology; Physical therapy","score_opus":0.02691237818351398,"score_gpt":0.4283669197826241,"score_spread":0.4014545415991101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1830813972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633497,0.00009255611,0.0000015561859,0.002538814,0.0001381621,0.0006411124,0.000053901324,0.000004270111,0.00019464937],"genre_scores_gemma":[0.996863,0.00014712325,0.000105403255,0.0024693587,0.00009490238,0.000027396753,0.0000035781873,0.000020575219,0.0002686735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971059,0.00089879555,0.0012033866,0.00019373547,0.0003666625,0.00023150192],"domain_scores_gemma":[0.9948461,0.0029619841,0.0014803142,0.00010120268,0.00042671536,0.00018366621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018145564,0.00018971428,0.0017730326,0.00012722154,0.000019078203,0.0000027608985,0.000083652434,0.000113670234,0.0013510007],"category_scores_gemma":[0.0002444389,0.00010369955,0.000208384,0.00026796234,0.00020639841,0.000071868664,0.000009094269,0.00055742677,0.0000026774655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28648296,0.0043241167,0.6578732,0.00002054082,0.0024747541,0.00022058042,0.00040766413,0.000019342846,0.00007407003,2.725106e-7,0.00032672373,0.047775775],"study_design_scores_gemma":[0.069312364,0.11858697,0.80972886,0.00027882427,0.0011056752,0.000019372128,0.000027721027,0.000017649701,0.0004976329,0.0000075238986,0.0003365333,0.00008084659],"about_ca_topic_score_codex":0.0001163827,"about_ca_topic_score_gemma":0.00014278459,"teacher_disagreement_score":0.21717058,"about_ca_system_score_codex":0.000699872,"about_ca_system_score_gemma":0.0015128738,"threshold_uncertainty_score":0.9995619},"labels":[],"label_agreement":null},{"id":"W1831246453","doi":"10.1200/jco.2000.18.4.780","title":"Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Chemotherapy; Randomized controlled trial; Oncology; Cytarabine; Granulocyte colony-stimulating factor; Leukemia; Myeloid; Internal medicine; Immunology; Cancer research","score_opus":0.05203594964406163,"score_gpt":0.4147628829395778,"score_spread":0.3627269332955162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1831246453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172384,0.000114432914,0.000035900684,0.0048343223,0.00090928766,0.0009684126,0.000018340448,0.000007489752,0.0013879664],"genre_scores_gemma":[0.99479824,0.0023702015,0.0004654305,0.0013967127,0.00062475906,0.000027268341,0.0000025659806,0.000015270065,0.00029956008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942429,0.0011199034,0.0039291154,0.00018129773,0.00034699554,0.00017978338],"domain_scores_gemma":[0.99136615,0.0047048596,0.0026069623,0.00021393572,0.0009965659,0.00011155561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026705498,0.00016798753,0.0027583728,0.00014466453,0.00003193915,0.0000073629376,0.00015458935,0.0003671161,0.0001834071],"category_scores_gemma":[0.0057144193,0.00009871152,0.0009057138,0.00022477933,0.0007092948,0.00013930596,0.000028837301,0.0009338499,0.0000028986499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97139066,0.0005396041,0.0065038786,0.000023924376,0.0005475118,0.00005333874,0.0007989423,0.00011457937,0.0011848237,0.000019339519,0.00034360518,0.018479778],"study_design_scores_gemma":[0.8556913,0.011627726,0.12418577,0.0004886018,0.0007858768,0.00013512677,0.00014015373,0.00016572226,0.0032715623,0.00032224442,0.0030752325,0.00011067346],"about_ca_topic_score_codex":0.00016356482,"about_ca_topic_score_gemma":0.00021079912,"teacher_disagreement_score":0.11768189,"about_ca_system_score_codex":0.00021832627,"about_ca_system_score_gemma":0.0013745334,"threshold_uncertainty_score":0.68411064},"labels":[],"label_agreement":null},{"id":"W1831778925","doi":"10.1200/jco.2000.18.15.2902","title":"Communication Between Primary Care Physicians and Radiation Oncologists Regarding Patients With Cancer Treated With Palliative Radiotherapy","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital","funders":"","keywords":"Medicine; Palliative care; Primary care; Family medicine; Cancer; Radiation therapy; Internal medicine; Nursing","score_opus":0.04256696034428153,"score_gpt":0.45315342578186907,"score_spread":0.41058646543758753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1831778925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878944,0.005505827,0.0004127032,0.0024220939,0.00012849888,0.00040566968,0.000011923875,0.000016583426,0.0023072336],"genre_scores_gemma":[0.947562,0.03064133,0.016724475,0.003570471,0.0011341937,0.000014662961,0.00004956025,0.0000324447,0.00027088713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978926,0.00051874336,0.0009519657,0.00019970184,0.00025039574,0.00018659959],"domain_scores_gemma":[0.996163,0.0016765216,0.0013671021,0.0001982352,0.00043935367,0.00015578866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005530737,0.00016774138,0.0013462662,0.00007378625,0.00011732672,0.0000068921904,0.00012987087,0.0003557466,0.00008262192],"category_scores_gemma":[0.00009893288,0.0001006809,0.000116875526,0.00015953225,0.00062819745,0.00020983194,0.000008418082,0.0008196565,9.4529224e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064703235,0.00034866345,0.5071745,0.00001551043,0.00044501148,0.000023873292,0.00035963202,0.000068563495,0.0000035523285,0.0000037895015,0.0002150125,0.48487157],"study_design_scores_gemma":[0.019302156,0.019727629,0.8905069,0.00028751002,0.00044133764,0.000020515197,0.00011503143,0.000016256501,0.000015148045,0.000021723168,0.06942909,0.00011667854],"about_ca_topic_score_codex":0.000021321717,"about_ca_topic_score_gemma":0.000047297217,"teacher_disagreement_score":0.4847549,"about_ca_system_score_codex":0.0007641262,"about_ca_system_score_gemma":0.00076938054,"threshold_uncertainty_score":0.4105648},"labels":[],"label_agreement":null},{"id":"W1834243275","doi":"10.1200/jco.2010.28.15_suppl.e21092","title":"Estrogen receptor-beta (ER-beta) expression and non-small cell lung cancer (NSCLC) outcome.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Estrogen receptor; Cohort; Stage (stratigraphy); Cancer; Univariate analysis; Multivariate analysis; Breast cancer; Biology","score_opus":0.0652614506696828,"score_gpt":0.4781060407951108,"score_spread":0.412844590125428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834243275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789909,0.0012262616,0.00012891123,0.008134482,0.003182141,0.00026755058,0.00000931203,0.000009733039,0.008050694],"genre_scores_gemma":[0.9812064,0.0011228798,0.012413212,0.0016321217,0.0020035268,0.0000141134915,0.0000044746116,0.000024770734,0.0015784863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776405,0.000108220396,0.0014696345,0.000208229,0.00022558603,0.00022427955],"domain_scores_gemma":[0.9971368,0.000709565,0.0011201589,0.00020041999,0.00030695403,0.00052614044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009650493,0.00015074147,0.0010058413,0.000086352615,0.00006998933,0.000013695125,0.00012511415,0.00039808848,0.000443874],"category_scores_gemma":[0.0002878843,0.00009708031,0.0003230425,0.0000717117,0.00013075647,0.000102616745,0.000054896238,0.001141615,0.000013449915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000778384,0.0010874907,0.9214801,0.00006391869,0.00031508564,0.00013185026,0.00024090499,0.000005603369,0.013080258,0.00006191851,0.010574494,0.052179955],"study_design_scores_gemma":[0.022428911,0.0056977477,0.67980415,0.0002747381,0.0027650883,0.0002339417,0.0002370305,0.000069509966,0.006254903,0.00006549098,0.28191796,0.0002505738],"about_ca_topic_score_codex":0.000048473496,"about_ca_topic_score_gemma":0.000048896865,"teacher_disagreement_score":0.27134344,"about_ca_system_score_codex":0.000099806726,"about_ca_system_score_gemma":0.0015501241,"threshold_uncertainty_score":0.49598122},"labels":[],"label_agreement":null},{"id":"W1839064654","doi":"10.1200/jco.2000.18.13.2515","title":"Use of Complementary/Alternative Medicine by Breast Cancer Survivors in Ontario: Prevalence and Perceptions","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Family medicine; Alternative medicine; Breast cancer; Attendance; Logistic regression; Naturopathy; Cancer; Integrative medicine; Complementary medicine; Traditional medicine; Internal medicine; Pathology","score_opus":0.21567948859224748,"score_gpt":0.49750112696989957,"score_spread":0.28182163837765206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1839064654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878503,0.00049791293,0.00001909161,0.01022864,0.0004585503,0.00020248102,0.00006368343,0.0000023643854,0.00067699223],"genre_scores_gemma":[0.9887492,0.0078957835,0.00042381504,0.0012860587,0.000493213,0.0000040065756,0.000006790494,0.0000072286507,0.0011339152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694216,0.0003315693,0.0020068039,0.00018396026,0.00035669206,0.00017878473],"domain_scores_gemma":[0.99685985,0.001785556,0.00077041826,0.000104688195,0.00026919463,0.00021027622],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013187137,0.00013957817,0.0013193026,0.00012298195,0.000035099867,0.0000019944055,0.000114211245,0.00003584081,0.0126514],"category_scores_gemma":[0.00032584296,0.0000926322,0.00012660385,0.0001035746,0.00069503224,0.00015147215,0.000048449998,0.0007013001,0.0000015185647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017501849,0.00070135435,0.8894885,0.000034984543,0.00030290333,0.00008810213,0.0012890201,0.000005188129,0.000087510816,0.000019138995,0.002888612,0.103344485],"study_design_scores_gemma":[0.005910771,0.0069741616,0.92131525,0.0005138916,0.00030318514,0.00018173743,0.0006614965,0.000029614532,0.000005740353,0.00010700069,0.06393106,0.00006608078],"about_ca_topic_score_codex":0.10529128,"about_ca_topic_score_gemma":0.22389127,"teacher_disagreement_score":0.118599996,"about_ca_system_score_codex":0.00019294284,"about_ca_system_score_gemma":0.00031785024,"threshold_uncertainty_score":0.98825115},"labels":[],"label_agreement":null},{"id":"W1844424555","doi":"10.1200/jco.2015.33.7_suppl.25","title":"Using radiogenomics to characterize MRI-guided prostate cancer biopsy heterogenity.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Radiogenomics; Prostate cancer; Medicine; Prostate; Biopsy; Cancer; Radiology; Pathology; Internal medicine; Radiomics","score_opus":0.26198606516777245,"score_gpt":0.5140470768292913,"score_spread":0.25206101166151884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1844424555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96473306,0.00035774717,0.0020937847,0.02882809,0.003286764,0.00022675822,0.0000045847405,0.000013660653,0.00045557317],"genre_scores_gemma":[0.89668316,0.0006249229,0.08041368,0.016694868,0.0051369146,0.000004667297,0.000003918868,0.000053408126,0.0003844849],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654067,0.00035349236,0.0021603554,0.00021207315,0.0004039963,0.00032939354],"domain_scores_gemma":[0.9960233,0.00039266108,0.0013240922,0.00019518504,0.0006131569,0.0014515996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049393564,0.00015611926,0.0014278365,0.00018035676,0.000044462988,0.00002169779,0.00021196168,0.00024397105,0.00005616837],"category_scores_gemma":[0.0054813884,0.00011457791,0.00037809458,0.00018428377,0.00016640386,0.000103705286,0.00008760655,0.0012114807,0.000019831352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009580058,0.0019433788,0.46101034,0.000099511126,0.0013755759,0.005441947,0.0014824508,0.002648749,0.034539077,0.00008423118,0.029877609,0.45191708],"study_design_scores_gemma":[0.022338077,0.009339853,0.13994373,0.00044327482,0.0010918115,0.012251801,0.00021635278,0.01711199,0.00048278514,0.00037398582,0.79595464,0.00045169564],"about_ca_topic_score_codex":0.000101289064,"about_ca_topic_score_gemma":0.000003822408,"teacher_disagreement_score":0.76607704,"about_ca_system_score_codex":0.0003695124,"about_ca_system_score_gemma":0.0022830511,"threshold_uncertainty_score":0.656213},"labels":[],"label_agreement":null},{"id":"W1847026520","doi":"10.1200/jco.2009.27.15_suppl.e20514","title":"A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada); Montreal General Hospital","funders":"","keywords":"Medicine; Apixaban; Internal medicine; Cancer; Population; Adverse effect; Surgery; Randomized controlled trial; Vitamin K antagonist; Warfarin; Oncology; Rivaroxaban","score_opus":0.29037449288737294,"score_gpt":0.6024170944603658,"score_spread":0.3120426015729929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1847026520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725571,0.002222225,0.00007513307,0.021580461,0.0016330285,0.0007659912,0.000003194596,0.0000043138275,0.0011585042],"genre_scores_gemma":[0.9885394,0.0042467653,0.0016148782,0.0030765447,0.0016604894,0.000007932925,0.0000019398467,0.000007826491,0.00084424927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954803,0.0007364187,0.0031891877,0.00013797035,0.00025260734,0.0002035401],"domain_scores_gemma":[0.9948968,0.0024534154,0.002053657,0.00010633115,0.00017697137,0.00031276626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037260633,0.00013352734,0.003799896,0.00022621766,0.000015258737,0.0000022711545,0.00010686421,0.00018141075,0.00063236617],"category_scores_gemma":[0.0023824917,0.00008559763,0.00086848513,0.00019483973,0.00016622571,0.00006563796,0.000016259211,0.00061538996,0.000002433545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8190559,0.014561575,0.00032826772,0.000012246805,0.0007622903,0.0006222417,0.00023559335,0.0000089713085,0.00051743916,0.00006284509,0.0073428876,0.1564897],"study_design_scores_gemma":[0.9028471,0.07637496,0.0011554732,0.00009324671,0.0023435187,0.00013439235,0.000019727542,0.0001211601,0.00022267297,0.0010967471,0.015529424,0.00006154096],"about_ca_topic_score_codex":0.00015609233,"about_ca_topic_score_gemma":0.00008552272,"teacher_disagreement_score":0.15642816,"about_ca_system_score_codex":0.00010940017,"about_ca_system_score_gemma":0.003307383,"threshold_uncertainty_score":0.6923966},"labels":[],"label_agreement":null},{"id":"W1847137107","doi":"10.1200/jco.2000.18.14.2695","title":"Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":559,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Chemotherapy; Mood; Cognition; Adjuvant chemotherapy; Cancer; Oncology; Psychosocial; Psychiatry","score_opus":0.05671204534862369,"score_gpt":0.43629221609781116,"score_spread":0.3795801707491875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1847137107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813018,0.0004885008,0.000013689171,0.010259886,0.0012504068,0.00027229657,0.0000105631225,0.000009457147,0.0063934014],"genre_scores_gemma":[0.98374104,0.0065025385,0.000052253512,0.00794494,0.0012296513,0.000010152118,0.0000026120008,0.000018122122,0.0004986823],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973319,0.00026196853,0.0016659761,0.00018397206,0.0003188885,0.00023724814],"domain_scores_gemma":[0.9971512,0.0010223658,0.0008622282,0.00005859815,0.0007132324,0.00019237048],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011821056,0.00013633103,0.001120692,0.00013484302,0.000035168156,0.000004313856,0.000055823122,0.00026208966,0.0025264737],"category_scores_gemma":[0.0008054685,0.000101960955,0.00028001124,0.00022203983,0.00016697437,0.00013641619,0.000015103545,0.000994309,0.00004249612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0135307,0.0015256985,0.44456038,0.000007845138,0.00031736822,0.000047199126,0.00010354415,0.000003982711,0.0000070724063,4.119833e-7,0.0026761065,0.5372197],"study_design_scores_gemma":[0.023639046,0.0077009234,0.9549168,0.00065500167,0.00042155222,0.00008426507,0.00013924252,0.000024801317,0.00000966196,0.000060781316,0.012256157,0.00009179476],"about_ca_topic_score_codex":0.000051126135,"about_ca_topic_score_gemma":0.0000968996,"teacher_disagreement_score":0.5371279,"about_ca_system_score_codex":0.00033064696,"about_ca_system_score_gemma":0.00069380587,"threshold_uncertainty_score":0.99838537},"labels":[],"label_agreement":null},{"id":"W1848225071","doi":"10.1200/jco.2015.33.7_suppl.7","title":"Investigating the long noncoding RNA SChLAP1 as a prognostic tissue and urine biomarker in prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Biomarker; Confidence interval; Cancer; Metastasis; Prostate; PCA3; Odds ratio; Biology; Genetics","score_opus":0.11032679631222005,"score_gpt":0.4706411634270213,"score_spread":0.36031436711480125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848225071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695153,0.0048454874,0.00037308008,0.0062405355,0.0005161083,0.0003335991,0.0000023016596,0.0000031939105,0.0007341549],"genre_scores_gemma":[0.9955845,0.0017362704,0.0009975645,0.00093661813,0.00046285006,0.000020740592,0.0000029305152,0.000022510194,0.00023601906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973593,0.00064307067,0.0011244391,0.000249472,0.0003199805,0.00030378153],"domain_scores_gemma":[0.99800867,0.00032316142,0.00072032766,0.0001791508,0.0003912711,0.00037742523],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004466953,0.00013383375,0.00047410344,0.00008802196,0.000048773305,0.00002833157,0.00027110844,0.00028993963,0.000012637893],"category_scores_gemma":[0.008561404,0.00009273285,0.00009841787,0.00020002076,0.0003103167,0.000011937463,0.00026033347,0.0007915776,0.000004370864],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028690905,0.0006402482,0.05890812,0.0000881625,0.00057000143,0.0013421408,0.00051232404,0.0010017845,0.38131166,0.00015045525,0.004898868,0.54770714],"study_design_scores_gemma":[0.047222823,0.057593223,0.21751179,0.0016831938,0.000701233,0.005670803,0.0021826047,0.005204295,0.29734683,0.0065288558,0.35668728,0.0016670784],"about_ca_topic_score_codex":0.00014630069,"about_ca_topic_score_gemma":0.00046192628,"teacher_disagreement_score":0.54604006,"about_ca_system_score_codex":0.00008522969,"about_ca_system_score_gemma":0.0024062102,"threshold_uncertainty_score":0.9997899},"labels":[],"label_agreement":null},{"id":"W1848577014","doi":"10.1200/jco.2000.18.21.3677","title":"Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Carboplatin; Medicine; Paclitaxel; Pharmacokinetics; Urology; Neutropenia; Chemotherapy; Area under the curve; Pharmacology; Internal medicine; Gastroenterology; Cisplatin","score_opus":0.048894745014274356,"score_gpt":0.43657007901309336,"score_spread":0.387675333998819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848577014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988786,0.00014095043,0.000009983449,0.0001736119,0.00008512803,0.0004245086,0.0000029695134,0.0000037542,0.00028046936],"genre_scores_gemma":[0.9979451,0.0001582913,0.0016287756,0.00013371801,0.00006328456,0.000002691461,0.0000014003845,0.000015429228,0.000051321018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976975,0.00015493414,0.0014497895,0.00018248342,0.00032848096,0.0001868601],"domain_scores_gemma":[0.9984917,0.0002731597,0.0007511284,0.00009116303,0.00014861474,0.00024422863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009981731,0.00014084062,0.0013952048,0.0001225512,0.000024495659,0.0000033752012,0.000058344624,0.00009703833,0.00005720549],"category_scores_gemma":[0.00007846796,0.0000824582,0.000054804204,0.00014978703,0.00016669533,0.00009143218,0.000007834464,0.0005311793,2.747972e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053000912,0.0121248085,0.7166135,0.00006681848,0.00025540055,0.0010815364,0.0008756836,0.000076818935,0.0002680421,0.0000039248043,0.00000734347,0.21562523],"study_design_scores_gemma":[0.10452947,0.08604884,0.80746835,0.00029375823,0.00044014823,0.000050176935,0.0006958661,0.000044766675,0.00009478957,0.00002458686,0.00021105114,0.000098193465],"about_ca_topic_score_codex":0.000009871179,"about_ca_topic_score_gemma":0.000086351996,"teacher_disagreement_score":0.21552703,"about_ca_system_score_codex":0.000028106006,"about_ca_system_score_gemma":0.0002531108,"threshold_uncertainty_score":0.3362548},"labels":[],"label_agreement":null},{"id":"W1857442781","doi":"10.1200/jco.2000.18.6.1220","title":"Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis","year":2000,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":511,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Randomized controlled trial; Radiation therapy; Odds ratio; Breast cancer; Mastectomy; Confidence interval; Internal medicine; Meta-analysis; Cancer; Clinical trial; Oncology; Systemic therapy; Surgery","score_opus":0.18539374679667336,"score_gpt":0.4936439274428207,"score_spread":0.30825018064614734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1857442781","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019185741,0.9957163,0.000012186769,0.0019928012,0.0013528756,0.0002809057,0.00031538002,0.000002674061,0.00013504678],"genre_scores_gemma":[0.00063575007,0.9954772,0.00011322901,0.00047494136,0.0029151968,0.00009824266,0.000079018384,0.000034066867,0.00017234255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941088,0.001477748,0.0032744154,0.0005195964,0.00032740278,0.0002920316],"domain_scores_gemma":[0.9946649,0.00080313475,0.0037446606,0.00035146452,0.00025787507,0.00017796876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020597705,0.00044840405,0.008151812,0.00027305985,0.00003669115,0.0000146887505,0.00043630486,0.0009899791,0.0003551856],"category_scores_gemma":[0.00016423698,0.00021530988,0.007143084,0.0003915548,0.00020351502,0.00000849675,0.0000723071,0.00075006456,0.000005513861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006770419,0.0005864197,0.0011315144,0.00009071441,0.16278017,0.000047965408,0.0000075766975,0.000017801172,3.3589478e-7,0.0000036664037,0.000538387,0.8341184],"study_design_scores_gemma":[0.0016439166,0.0006129045,0.0036008211,0.000054840984,0.12376271,0.000039716688,0.0000064138208,8.8831075e-7,7.9952105e-7,0.00002961352,0.8700274,0.0002199428],"about_ca_topic_score_codex":0.00017797895,"about_ca_topic_score_gemma":0.00059674884,"teacher_disagreement_score":0.869489,"about_ca_system_score_codex":0.00018750239,"about_ca_system_score_gemma":0.0026878598,"threshold_uncertainty_score":0.8780082},"labels":[],"label_agreement":null},{"id":"W1859196561","doi":"10.1200/jco.2015.33.7_suppl.374","title":"Frailty as a marker of adverse outcomes during cystectomy for urothelial cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Logistic regression; Frailty Index; Adverse effect; Lung cancer; Univariate analysis; Population; Internal medicine; Quality of life (healthcare); Surgery; Cancer; Multivariate analysis","score_opus":0.20843508561351248,"score_gpt":0.5160904572270377,"score_spread":0.30765537161352524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1859196561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707676,0.0003800483,0.00007337052,0.0039917547,0.0018826782,0.00041381558,0.000028324876,0.000008628036,0.006144647],"genre_scores_gemma":[0.99244726,0.00017101744,0.0023727692,0.0014688023,0.001314835,0.000021702732,0.0000010371199,0.000022724822,0.0021798357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738,0.00016121537,0.0017372663,0.00015001213,0.00036374616,0.00020775205],"domain_scores_gemma":[0.99665207,0.00079196057,0.001267596,0.0001674973,0.00066047854,0.0004603888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013267803,0.00013688757,0.0015378336,0.000091335016,0.000022913397,0.0000017451159,0.00013421618,0.00027688296,0.00021989048],"category_scores_gemma":[0.002952823,0.00008918772,0.00070384995,0.000076726814,0.00013428045,0.00008295027,0.000034968147,0.00038727585,0.000012751331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045605514,0.0022831797,0.9110131,0.00014863827,0.0021577857,0.00048158952,0.00032006632,0.000023732902,0.000562145,0.0000822527,0.0042176573,0.033104334],"study_design_scores_gemma":[0.073432416,0.023007832,0.7919584,0.00020857266,0.0014847594,0.00039758126,0.00030515197,0.000021819276,0.0013844229,0.0009720141,0.10667303,0.00015401818],"about_ca_topic_score_codex":0.0001382859,"about_ca_topic_score_gemma":0.000050026974,"teacher_disagreement_score":0.11905473,"about_ca_system_score_codex":0.00020785477,"about_ca_system_score_gemma":0.003457437,"threshold_uncertainty_score":0.6133345},"labels":[],"label_agreement":null},{"id":"W18653149","doi":"10.1200/jco.2009.27.15_suppl.7548","title":"Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Toronto; University of Ottawa; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Stage (stratigraphy); Positron emission tomography; Lung cancer; Nuclear medicine; Radiology; Hazard ratio; Clinical endpoint; PET-CT; Radiation therapy; Target lesion; Randomized controlled trial; Oncology; Surgery; Confidence interval; Internal medicine","score_opus":0.03083908665868453,"score_gpt":0.44610825922349023,"score_spread":0.4152691725648057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W18653149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133295,0.0017647791,0.000041855143,0.0018533496,0.0007069422,0.0020139304,0.0000133807325,0.000006691037,0.0022661143],"genre_scores_gemma":[0.99431264,0.0033014452,0.0008896515,0.0003992654,0.00082219613,0.000045272125,0.0000035043738,0.000016055279,0.00020995198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99527174,0.00063131907,0.0030792067,0.0002836092,0.00040270056,0.00033144635],"domain_scores_gemma":[0.9942022,0.0021100547,0.0026118022,0.00022072786,0.00042682327,0.00042840355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003455057,0.0002460172,0.003586309,0.00030643019,0.00002797274,0.000010418654,0.00015208096,0.00021490797,0.00021226192],"category_scores_gemma":[0.0007395378,0.00014467414,0.0019885711,0.0002834116,0.00013436274,0.0001057406,0.000027807058,0.0009152915,8.4246346e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7551249,0.00785919,0.22799028,0.00004124598,0.0009648101,0.0008780981,0.00026378856,0.000054255328,0.00026386973,0.00000935676,0.0018684578,0.004681743],"study_design_scores_gemma":[0.7170155,0.03421279,0.24611771,0.0005187802,0.0011778872,0.000036849655,0.000034829736,0.00016441014,0.00038578498,0.000103284416,0.00012963823,0.00010252875],"about_ca_topic_score_codex":0.00053298904,"about_ca_topic_score_gemma":0.0001302824,"teacher_disagreement_score":0.038109392,"about_ca_system_score_codex":0.0011059805,"about_ca_system_score_gemma":0.0034748593,"threshold_uncertainty_score":0.6164251},"labels":[],"label_agreement":null},{"id":"W1867192432","doi":"10.1200/jco.2013.31.15_suppl.lba509","title":"Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Everolimus; Oncology; Internal medicine; Breast cancer; Clinical Oncology; Hormone receptor; Gynecology; Cancer","score_opus":0.05320648071431263,"score_gpt":0.37501452567669796,"score_spread":0.32180804496238535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1867192432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936886,0.0007225881,0.00033298336,0.0036544949,0.00022067534,0.00043092004,0.00007384699,0.000003435759,0.00087244593],"genre_scores_gemma":[0.9916771,0.00047952702,0.007310627,0.0002633551,0.0001704086,0.000010993332,0.000012920885,0.0000143411935,0.000060705457],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962909,0.0006435142,0.002392764,0.00018837585,0.00033878122,0.00014567039],"domain_scores_gemma":[0.99299604,0.0034338562,0.0022988163,0.00018458976,0.00092886493,0.00015780718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086336693,0.00014108673,0.0013395956,0.000116876894,0.000022088434,0.0000046780974,0.00012381621,0.00020330878,0.00013268155],"category_scores_gemma":[0.002136014,0.00009153184,0.00023604877,0.00015901422,0.00026377564,0.00020184791,0.000034377324,0.0005542947,0.000006644361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35992476,0.0093684625,0.04502768,0.00010294354,0.0024445534,0.00017595076,0.0052166847,0.01637578,0.18654515,0.0001491251,0.0024467933,0.37222213],"study_design_scores_gemma":[0.013274855,0.021798447,0.95148015,0.00085911195,0.00032894505,0.00004595868,0.00033981053,0.0014021125,0.009972067,0.0001870781,0.00020212935,0.00010930979],"about_ca_topic_score_codex":0.0009857824,"about_ca_topic_score_gemma":0.00008370289,"teacher_disagreement_score":0.9064525,"about_ca_system_score_codex":0.00008998706,"about_ca_system_score_gemma":0.0006445174,"threshold_uncertainty_score":0.37325603},"labels":[],"label_agreement":null},{"id":"W1867789233","doi":"10.1200/jco.2012.30.15_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lapatinib; Capecitabine; Medicine; Trastuzumab emtansine; Trastuzumab; Oncology; Internal medicine; Metastatic breast cancer; Breast cancer; Cancer; Gynecology; Colorectal cancer","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1867789233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942012,0.0019666222,0.000042958327,0.0013223616,0.00023029612,0.0017039474,0.0002467417,0.000010570448,0.00027530038],"genre_scores_gemma":[0.99424976,0.002383856,0.0024667967,0.00026524335,0.00040675362,0.000061287734,0.000021477239,0.000048426336,0.00009642373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9934989,0.0011873767,0.0033739232,0.00048868824,0.00085595855,0.0005951606],"domain_scores_gemma":[0.99086356,0.0053097066,0.0019090315,0.00031622365,0.0007603456,0.0008411157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032309147,0.00035688566,0.0031006548,0.00027361466,0.000050072318,0.000012633763,0.00018367368,0.00025049088,0.00014467101],"category_scores_gemma":[0.0024290823,0.00022776477,0.00013483106,0.00049582607,0.0005594547,0.00029397378,0.00008639996,0.0013843793,0.000001080625],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5207486,0.02438756,0.05873552,0.00018235228,0.0018934886,0.0029618798,0.0060076504,0.000033075852,0.000839036,0.0000013177698,0.00028505063,0.38392445],"study_design_scores_gemma":[0.29844466,0.15140864,0.5389225,0.0014589467,0.0018579497,0.0009180638,0.005868028,0.00014962952,0.00013057211,0.000004965116,0.0005585541,0.00027752077],"about_ca_topic_score_codex":0.0023609905,"about_ca_topic_score_gemma":0.008142427,"teacher_disagreement_score":0.48018694,"about_ca_system_score_codex":0.00081570173,"about_ca_system_score_gemma":0.003592645,"threshold_uncertainty_score":0.9287978},"labels":[],"label_agreement":null},{"id":"W1868723162","doi":"10.1200/jco.2009.27.15_suppl.e11637","title":"Acute interstitial pneumonitis following adjuvant tamoxifen therapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Diffuse alveolar damage; Surgery; Internal medicine; Cancer; Gastroenterology; Lung","score_opus":0.10781864155486769,"score_gpt":0.48949711419765063,"score_spread":0.38167847264278293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1868723162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96518075,0.00081957865,0.00054590456,0.024878215,0.002480985,0.00019243777,0.000001947777,0.000030464305,0.0058697397],"genre_scores_gemma":[0.9750076,0.0024669112,0.0043966775,0.015662001,0.0020929154,8.473195e-7,0.0000019297743,0.000023230961,0.00034790204],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962513,0.00032343302,0.002417003,0.00022084638,0.0004669899,0.00032044633],"domain_scores_gemma":[0.9965835,0.0010403933,0.0014048604,0.00024451682,0.00024857232,0.00047816552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022079726,0.0001959437,0.0018607579,0.00015036047,0.000047680296,0.000013830793,0.00026193954,0.00062789075,0.00028457996],"category_scores_gemma":[0.001422573,0.00014008323,0.0013606057,0.00016857186,0.00011473196,0.00016151981,0.000024462135,0.0018026041,0.000035860303],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077020405,0.0027835523,0.00793049,0.000004119355,0.0018041889,0.009574706,0.00033633594,0.0000050686,0.019824835,0.00004958866,0.010161381,0.9398237],"study_design_scores_gemma":[0.076100335,0.122252874,0.48605064,0.00073671876,0.0019034941,0.009464472,0.0001857623,0.00023561901,0.013136868,0.005731041,0.28353363,0.00066852977],"about_ca_topic_score_codex":0.000004589556,"about_ca_topic_score_gemma":0.000003201664,"teacher_disagreement_score":0.93915516,"about_ca_system_score_codex":0.00020395352,"about_ca_system_score_gemma":0.00095046667,"threshold_uncertainty_score":0.7831518},"labels":[],"label_agreement":null},{"id":"W1868820390","doi":"10.1200/jco.2015.33.7_suppl.5","title":"Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Radiation therapy; Bicalutamide; Urology; Randomized controlled trial; Prostate; Log-rank test; Proportional hazards model; Surgery; Internal medicine; Cancer; Androgen receptor","score_opus":0.15267072776502538,"score_gpt":0.5027679033095561,"score_spread":0.35009717554453074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1868820390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385965,0.0034202111,0.00003225365,0.0012433737,0.00028884894,0.0009977425,0.000010456622,0.000006908739,0.00014055739],"genre_scores_gemma":[0.97532046,0.023388203,0.0003494285,0.00016714713,0.0004932528,0.000041361334,0.000009725544,0.00002100864,0.00020942985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968305,0.00051935826,0.0018294532,0.00018241712,0.00040754533,0.00023069311],"domain_scores_gemma":[0.99698126,0.0007237337,0.0012337829,0.00016011175,0.00054930034,0.0003517981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030669142,0.00014543635,0.0014033783,0.00022893913,0.00001611247,0.0000070733604,0.00012459549,0.00023080086,0.000056436595],"category_scores_gemma":[0.0006171734,0.00008004884,0.0001916413,0.00026872777,0.0002607075,0.00012670382,0.000016093118,0.0006615392,7.5369735e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42618623,0.0028494478,0.36506042,0.000010026297,0.000540899,0.0003861207,0.0006143797,0.000019689765,0.00031725856,8.678417e-7,0.00037764004,0.20363702],"study_design_scores_gemma":[0.7618601,0.14760862,0.07890836,0.00028882164,0.00029395366,0.00010024372,0.00029708404,0.00031844174,0.0026833203,0.000051527684,0.0074512525,0.00013828841],"about_ca_topic_score_codex":0.00013368853,"about_ca_topic_score_gemma":0.00015672603,"teacher_disagreement_score":0.33567384,"about_ca_system_score_codex":0.00040328488,"about_ca_system_score_gemma":0.0033565087,"threshold_uncertainty_score":0.59543025},"labels":[],"label_agreement":null},{"id":"W1870066362","doi":"10.1200/jco.2004.03.104","title":"Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Folinic acid; Fluorouracil; Internal medicine; Colorectal cancer; Meta-analysis; Randomized controlled trial; Odds ratio; Oncology; Hazard ratio; Gastroenterology; Confidence interval; Cancer","score_opus":0.17483757848867537,"score_gpt":0.49784366704264554,"score_spread":0.32300608855397017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1870066362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066939846,0.9314294,0.000012330089,0.00017325082,0.0002832873,0.00084132375,0.00015679655,0.000006294638,0.00015746766],"genre_scores_gemma":[0.07876161,0.9197164,0.00093521737,0.0000648815,0.00011427539,0.0000562872,0.0002422147,0.000032443237,0.00007664239],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99394035,0.0006526402,0.004163913,0.00038807094,0.0006083275,0.0002467173],"domain_scores_gemma":[0.992458,0.0005959907,0.005601622,0.00022744661,0.0008647904,0.00025218815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012120871,0.00040214753,0.013511359,0.0004262701,0.000030010373,0.000005717781,0.00018519573,0.00055151817,0.00026432937],"category_scores_gemma":[0.00031996303,0.0002181424,0.0030164355,0.0007449639,0.0001670367,0.00015744971,0.000044145305,0.00095286977,0.0000012738441],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045821993,0.0037408804,0.013760502,0.00052861415,0.16950469,0.0000861505,0.00005301481,0.00021049069,2.0352945e-7,0.0000027020142,0.00009928028,0.8074313],"study_design_scores_gemma":[0.01234068,0.04249369,0.09654461,0.00078717206,0.6473466,0.000018219143,0.000028603494,0.000013488182,0.0000014189649,0.00001785415,0.20007877,0.00032890367],"about_ca_topic_score_codex":0.0001979514,"about_ca_topic_score_gemma":0.0009183317,"teacher_disagreement_score":0.8071024,"about_ca_system_score_codex":0.0010209419,"about_ca_system_score_gemma":0.0027783436,"threshold_uncertainty_score":0.92360944},"labels":[],"label_agreement":null},{"id":"W1871373392","doi":"10.1200/jco.2006.24.18_suppl.10780","title":"Changing demographics of locally advanced breast cancer: Data from a regional cancer centre","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Mammography; Cancer; Demographics; Retrospective cohort study; Population; Stage (stratigraphy); Internal medicine; Cancer registry; Gynecology; Oncology; Demography","score_opus":0.07173389354841089,"score_gpt":0.420097517738306,"score_spread":0.3483636241898951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1871373392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700444,0.013214629,0.0005135567,0.013733313,0.0012848588,0.000115347124,0.0008718114,0.000005398036,0.00021672339],"genre_scores_gemma":[0.9833052,0.009767677,0.0024217898,0.0010692714,0.0032139674,0.000005191535,0.00011432949,0.00002156345,0.000081008104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768883,0.000179396,0.0012860062,0.0003251742,0.0002544416,0.00026614167],"domain_scores_gemma":[0.99710095,0.00030271296,0.0016177141,0.00036312055,0.00049475534,0.00012077263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006049521,0.00016658402,0.0008125181,0.00007114743,0.00004955281,0.0000046841365,0.00048406204,0.00029482078,0.00006246872],"category_scores_gemma":[0.00017457991,0.00013136904,0.000284278,0.00014943122,0.00029428198,0.000014074415,0.00026571398,0.00027975047,0.000001092208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006315568,0.0016539862,0.7373446,0.0000291179,0.002015792,0.00008505228,0.000051813582,0.00067104236,0.005105216,0.000077919736,0.031282265,0.21536759],"study_design_scores_gemma":[0.00991607,0.0009988672,0.83687073,0.0003118159,0.0007491162,0.000115831346,0.00031696106,0.00012619385,0.001168199,0.000390135,0.14871903,0.00031704534],"about_ca_topic_score_codex":0.0006900157,"about_ca_topic_score_gemma":0.004289521,"teacher_disagreement_score":0.21505053,"about_ca_system_score_codex":0.000053570515,"about_ca_system_score_gemma":0.0010866988,"threshold_uncertainty_score":0.5357075},"labels":[],"label_agreement":null},{"id":"W1873924279","doi":"10.1200/jco.2001.19.20.4048","title":"Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II Study","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Regimen; Internal medicine; Chemotherapy; Surgery; Gastroenterology; Serous fluid; Survival rate; Endometrial cancer; Cancer; Cisplatin","score_opus":0.17266811327372392,"score_gpt":0.5203369402089048,"score_spread":0.34766882693518086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1873924279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918201,0.0019739312,0.0000133210115,0.004000472,0.0010338308,0.0008128446,0.000009007433,0.000008098668,0.00032838335],"genre_scores_gemma":[0.9902278,0.0060177436,0.001130174,0.0008227385,0.0014038332,0.000043843687,0.0000023830385,0.000016056618,0.00033539205],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961903,0.0004390193,0.00233325,0.0002747666,0.0004930315,0.0002696046],"domain_scores_gemma":[0.9941305,0.0035386444,0.0013602037,0.00014770069,0.00033194057,0.0004910395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021002085,0.00018466321,0.0020085147,0.00036480822,0.000055467546,0.000008346859,0.00009706798,0.00018374543,0.00042680823],"category_scores_gemma":[0.008016783,0.00009358102,0.00015029823,0.0010201101,0.000105705236,0.0001379029,0.000043720647,0.0007157091,0.0000016875508],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23736098,0.012292579,0.1699243,0.000014965968,0.00045591648,0.002650719,0.00025892432,0.000008025916,0.00001733161,0.0000025570102,0.00017318636,0.5768405],"study_design_scores_gemma":[0.29014722,0.37014472,0.31065336,0.00019041935,0.0008316985,0.00051184924,0.0006791645,0.000030975134,0.000010573817,0.00004995704,0.026605932,0.00014414816],"about_ca_topic_score_codex":0.00019683986,"about_ca_topic_score_gemma":0.0029740673,"teacher_disagreement_score":0.57669634,"about_ca_system_score_codex":0.00033659427,"about_ca_system_score_gemma":0.0017019256,"threshold_uncertainty_score":0.9597417},"labels":[],"label_agreement":null},{"id":"W1877063338","doi":"10.1200/jco.2001.19.14.3323","title":"Variation in Delivery of Palliative Radiotherapy to Persons Dying of Cancer in Nova Scotia, 1994 to 1998","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Nova scotia; Palliative care; Cancer; Odds ratio; Confidence interval; Radiation therapy; Demography; Multivariate analysis; Cancer registry; Family medicine; Internal medicine","score_opus":0.13788928855650812,"score_gpt":0.4983880190058196,"score_spread":0.36049873044931147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1877063338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792154,0.0003370979,0.001980128,0.008434692,0.00045628447,0.0003772079,0.000005543165,0.0000017216277,0.00048579008],"genre_scores_gemma":[0.9796224,0.00045870396,0.015657578,0.003967105,0.00019741477,0.0000032658,6.611858e-7,0.000010507278,0.00008234285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968904,0.00032753762,0.0020956022,0.00014803103,0.00036775746,0.00017061667],"domain_scores_gemma":[0.99748516,0.0011309256,0.0008743819,0.0001317869,0.00014971792,0.00022802291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002837836,0.00009328004,0.0011893769,0.00047711385,0.000005270134,0.0000021230876,0.00013310341,0.00011495314,0.00035732274],"category_scores_gemma":[0.0016233542,0.00007802046,0.00018803868,0.00045789883,0.00004960115,0.00006680706,0.0000305248,0.00035493117,0.0000041870035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0111741945,0.0028984498,0.8934977,0.00010458563,0.00040906228,0.00044403295,0.0027129152,0.0023800172,0.0028079986,0.000057479912,0.0010921262,0.08242145],"study_design_scores_gemma":[0.008316908,0.0042988765,0.98253703,0.00045195248,0.00018351947,0.0000039765628,0.00049154396,0.0008631339,0.000032449367,0.000052749507,0.002701967,0.00006589418],"about_ca_topic_score_codex":0.0013919768,"about_ca_topic_score_gemma":0.0029905029,"teacher_disagreement_score":0.08903934,"about_ca_system_score_codex":0.00027831527,"about_ca_system_score_gemma":0.0007459843,"threshold_uncertainty_score":0.39124334},"labels":[],"label_agreement":null},{"id":"W1882099583","doi":"10.1200/jco.2001.19.5.1266","title":"Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Palliative chemotherapy; Palliative care; Chemotherapy; Cancer; Minimal clinically important difference; Ovarian cancer; Internal medicine; Oncology; Physical therapy; Randomized controlled trial; Nursing","score_opus":0.2659272261845475,"score_gpt":0.5812635838279501,"score_spread":0.31533635764340257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1882099583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862177,0.0022184213,0.0003416072,0.009998909,0.0004718125,0.00049311237,0.000007264715,0.000003730893,0.000247449],"genre_scores_gemma":[0.959258,0.027545957,0.011264681,0.001484629,0.00028437452,0.000056104655,0.0000027509614,0.000017284417,0.00008619073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971174,0.00032732013,0.0018142073,0.0001717343,0.00037822165,0.00019112938],"domain_scores_gemma":[0.99375814,0.0030640478,0.0018194932,0.00011540804,0.0011031937,0.00013969172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003549016,0.00013024439,0.001411952,0.00015035667,0.000018727735,0.0000031996337,0.0000896505,0.00022391797,0.00012974236],"category_scores_gemma":[0.004931863,0.00007932813,0.00019531406,0.00017254951,0.00012397952,0.0001099435,0.0000099332,0.0002811253,2.824032e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052268263,0.00049317675,0.6030137,0.0000344506,0.00032745252,0.0000057009324,0.0033317534,0.000024900159,0.00048411096,0.000021449538,0.00009456402,0.3869419],"study_design_scores_gemma":[0.033976875,0.00352362,0.9438479,0.00092362217,0.00016674817,0.0000027686685,0.0045834775,0.0003853291,0.00088804745,0.0013377012,0.010255345,0.00010860087],"about_ca_topic_score_codex":0.000049280883,"about_ca_topic_score_gemma":0.0002313264,"teacher_disagreement_score":0.3868333,"about_ca_system_score_codex":0.0004688775,"about_ca_system_score_gemma":0.0008981229,"threshold_uncertainty_score":0.59042567},"labels":[],"label_agreement":null},{"id":"W1886678647","doi":"10.1200/jco.2005.23.16_suppl.1543","title":"Fractionated stereotactic radiotherapy (SRT) for pituitary adenomas","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pituitary Gland Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Hypopituitarism; Pituitary adenoma; Radiosurgery; Radiation therapy; Radiological weapon; Visual acuity; Pituitary tumors; Discontinuation; Surgery; Adenoma; Internal medicine","score_opus":0.10971110844146592,"score_gpt":0.4775798366912681,"score_spread":0.36786872824980216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1886678647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9499572,0.0046943114,0.0012724971,0.038208485,0.0013846143,0.00036487635,0.000006660402,0.00001628613,0.004095064],"genre_scores_gemma":[0.9715769,0.0018757564,0.01588768,0.0071247444,0.002534859,0.0000058145893,0.000008364688,0.000018341327,0.000967532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979903,0.00011482833,0.001373648,0.0001383823,0.0001945867,0.00018825455],"domain_scores_gemma":[0.99707085,0.0014143818,0.0008307543,0.00012845502,0.00025418997,0.0003013731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090336305,0.00011379302,0.0009694338,0.0001015226,0.00004593352,0.000005261075,0.00008472679,0.0002608603,0.00034739997],"category_scores_gemma":[0.0008137916,0.00007584183,0.00052076095,0.00006357184,0.00006623272,0.00017197781,0.000008625554,0.00042924238,0.000022135648],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016766133,0.008074684,0.16240728,0.000030365904,0.0025062163,0.0006050334,0.00011585517,0.00004083746,0.00013745493,0.00015890287,0.04388795,0.7652693],"study_design_scores_gemma":[0.027654037,0.016994413,0.23997447,0.000032298412,0.0005292116,0.0007303469,0.000055063472,0.00033770848,0.000028813152,0.00084596983,0.7127258,0.00009186416],"about_ca_topic_score_codex":0.00000819956,"about_ca_topic_score_gemma":0.000017287548,"teacher_disagreement_score":0.7651774,"about_ca_system_score_codex":0.00015800238,"about_ca_system_score_gemma":0.0008176117,"threshold_uncertainty_score":0.3803786},"labels":[],"label_agreement":null},{"id":"W1888844917","doi":"10.1200/jco.2001.19.21.4126","title":"Epoetin Alfa Therapy Increases Hemoglobin Levels and Improves Quality of Life in Patients With Cancer-Related Anemia Who Are Not Receiving Chemotherapy and Patients With Anemia Who Are Receiving Chemotherapy","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epoetin alfa; Anemia; Chemotherapy; Internal medicine; Quality of life (healthcare); Cancer; Cohort; Hemoglobin; Surgery","score_opus":0.05407053482158148,"score_gpt":0.37753576375921055,"score_spread":0.3234652289376291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1888844917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206245,0.001257795,0.000004107424,0.0057252734,0.00012743345,0.0006634918,0.000024251714,0.000018591763,0.00011662669],"genre_scores_gemma":[0.98610234,0.008954841,0.0011444833,0.0034366301,0.0001896965,0.000009262919,0.0000088736615,0.000055887172,0.00009800033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99532956,0.0006329979,0.0025308637,0.00049129594,0.00060852163,0.00040673872],"domain_scores_gemma":[0.9923543,0.0021299133,0.0040062317,0.0002937289,0.0007217763,0.0004940787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018804091,0.00040840986,0.002804777,0.00017045453,0.00008187854,0.000020594805,0.00015423882,0.0005359496,0.00012724406],"category_scores_gemma":[0.0016064917,0.0002595915,0.00017202043,0.00030586644,0.0005160344,0.00019923579,0.000038952872,0.0009271982,3.6792267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017092185,0.003687349,0.8829361,0.00011428403,0.00040573577,0.000054012555,0.000497103,0.0000036992515,0.00009113584,0.000001413351,0.00028333173,0.09483361],"study_design_scores_gemma":[0.056866534,0.01082936,0.9284852,0.0024882697,0.00012020986,0.000023310684,0.00028600267,0.000011429373,0.00016056493,0.000022489578,0.00044211873,0.0002645062],"about_ca_topic_score_codex":0.0002531067,"about_ca_topic_score_gemma":0.0003360642,"teacher_disagreement_score":0.09456911,"about_ca_system_score_codex":0.00028405603,"about_ca_system_score_gemma":0.00072395493,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W1898026383","doi":"10.1200/jco.2014.32.4_suppl.86","title":"Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Goserelin; Testosterone (patch); Antiandrogen; Urology; Hazard ratio; Agonist; Internal medicine; Proportional hazards model; Prostate-specific antigen; Androgen deprivation therapy; Luteinizing hormone; Gynecology; Cancer; Oncology; Hormone; Confidence interval; Receptor","score_opus":0.10982308765571903,"score_gpt":0.4488715295684615,"score_spread":0.33904844191274247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1898026383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812527,0.010961996,0.00010493751,0.005637587,0.00021978206,0.0010732508,0.0000044090916,0.000008749093,0.0007365965],"genre_scores_gemma":[0.95785403,0.040406518,0.0009506157,0.00011054589,0.00045314847,0.00007426131,0.0000046584864,0.000024501802,0.00012170343],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972809,0.00049886224,0.0012214483,0.00022203183,0.00045815937,0.00031858002],"domain_scores_gemma":[0.9975083,0.0006746401,0.0010781274,0.00021602094,0.0003484392,0.00017446205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011453836,0.00018702203,0.0011635727,0.00014306675,0.00008232403,0.000014593845,0.0001414037,0.00020530343,0.000007277085],"category_scores_gemma":[0.00023588931,0.00009463187,0.00024860053,0.00027350354,0.0002251744,0.00012413082,0.00001225519,0.0005165287,0.0000016606464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18204486,0.0023502724,0.007358373,0.00004881209,0.0010244923,0.00049586524,0.0030031248,0.0004380643,0.00525976,0.000018443174,0.00022619855,0.79773176],"study_design_scores_gemma":[0.23953712,0.38794884,0.2807492,0.00066623115,0.0011145069,0.0003746437,0.0031275104,0.0025260488,0.0061398605,0.00020599987,0.07720492,0.00040512992],"about_ca_topic_score_codex":0.00024398924,"about_ca_topic_score_gemma":0.0001705951,"teacher_disagreement_score":0.7973266,"about_ca_system_score_codex":0.0006657564,"about_ca_system_score_gemma":0.0014763344,"threshold_uncertainty_score":0.38589755},"labels":[],"label_agreement":null},{"id":"W1899192341","doi":"10.1200/jco.2001.19.21.4107","title":"Does Histologic Grade Have a Role in the Management of Head and Neck Cancers?","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Stage (stratigraphy); Head and neck cancer; Head and neck; Radiation therapy; Proportional hazards model; Internal medicine; Chemotherapy; Retrospective cohort study; Overall survival; Surgery; Oncology","score_opus":0.1388098399005458,"score_gpt":0.4808633536526869,"score_spread":0.3420535137521411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1899192341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516112,0.0031202582,0.0000050258705,0.029195845,0.00043375712,0.00013138977,6.0156304e-7,0.0000019333756,0.015499966],"genre_scores_gemma":[0.97926897,0.016101182,0.0011432192,0.0028981282,0.00029360398,0.0000043764394,1.284228e-7,0.0000036184672,0.00028674773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827385,0.00018495267,0.0011055119,0.00010062043,0.00018876325,0.000146288],"domain_scores_gemma":[0.9984904,0.0007075411,0.00053915207,0.000103777966,0.0000736853,0.000085449086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016175978,0.00007130684,0.0009597082,0.00005616154,0.000023059825,0.0000019106303,0.000100828765,0.00011347462,0.000031023028],"category_scores_gemma":[0.00027263482,0.00003007055,0.00014567722,0.00008261662,0.00020737683,0.000030263434,0.00003554837,0.00045135955,9.397912e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036674256,0.0014000809,0.65850997,0.000112048445,0.0004304877,0.002668464,0.0013504168,0.000005343892,0.000025635318,0.0003725098,0.003760085,0.32769758],"study_design_scores_gemma":[0.0046221707,0.0070855636,0.740436,0.00024676562,0.00018763408,0.0002214468,0.0022430741,0.000018947294,0.0000048662646,0.0008784932,0.24401554,0.000039497536],"about_ca_topic_score_codex":0.00012169342,"about_ca_topic_score_gemma":0.00083788706,"teacher_disagreement_score":0.32765806,"about_ca_system_score_codex":0.000116733325,"about_ca_system_score_gemma":0.00022008424,"threshold_uncertainty_score":0.19609578},"labels":[],"label_agreement":null},{"id":"W1899330773","doi":"10.1200/jco.2000.18.9.1960","title":"Dexamethasone for the Prophylaxis of Radiation-Induced Emesis: A National Cancer Institute of Canada Clinical Trials Group Phase III Study","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Antiemetic; Dexamethasone; Nausea; Vomiting; Placebo; Population; Clinical endpoint; Randomized controlled trial; Quality of life (healthcare); Anesthesia; Clinical trial; Surgery; Internal medicine","score_opus":0.3967720623634717,"score_gpt":0.5860232199434188,"score_spread":0.1892511575799471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1899330773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98834187,0.00038824242,0.00026969207,0.006504589,0.0024940353,0.0015213242,0.00002105014,0.0000032250189,0.00045598473],"genre_scores_gemma":[0.99434435,0.00046045086,0.00090872496,0.0012766712,0.0026277828,0.00004551178,0.000002378398,0.000010965975,0.0003231308],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99112743,0.0014366055,0.0062615615,0.00019381604,0.0007938778,0.00018671837],"domain_scores_gemma":[0.97895163,0.015452574,0.004259975,0.00020375178,0.0009046165,0.00022744623],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0331154,0.00012403916,0.002332992,0.000100327976,0.000064435575,0.000004845559,0.0002485019,0.00020626391,0.00033917016],"category_scores_gemma":[0.03165644,0.00007244246,0.00066559983,0.00021540016,0.00016363342,0.00007786399,0.000026041336,0.0006052647,5.615197e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021976264,0.007883204,0.01806603,0.00005587527,0.0030359752,0.000049743885,0.000111981964,0.00009034439,0.00009044555,0.000121388526,0.015351872,0.93316686],"study_design_scores_gemma":[0.20183063,0.08995673,0.38630927,0.00026889355,0.00533843,0.00003722754,0.00087095576,0.0009896328,0.00036673914,0.00044435367,0.31332868,0.0002584591],"about_ca_topic_score_codex":0.008748744,"about_ca_topic_score_gemma":0.0246536,"teacher_disagreement_score":0.9329084,"about_ca_system_score_codex":0.00019964023,"about_ca_system_score_gemma":0.0081057465,"threshold_uncertainty_score":0.9978521},"labels":[],"label_agreement":null},{"id":"W1900875154","doi":"10.1200/jco.2014.59.0273","title":"Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Children's Hospital of Eastern Ontario; Seagen (Canada); University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute","keywords":"Medicine; Oxidative stress; Lymphoblastic Leukemia; Cognition; Leukemia; Gene; Oncology; Cancer research; Internal medicine; Genetics; Psychiatry; Biology","score_opus":0.06025451552736993,"score_gpt":0.39881384166594663,"score_spread":0.3385593261385767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1900875154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938235,0.00036993413,0.0013680091,0.0024668141,0.0006107743,0.0010582149,0.000058905298,0.000019948935,0.00022386949],"genre_scores_gemma":[0.9949982,0.00015804592,0.0009016328,0.0030335714,0.000468892,0.000093681825,0.00002680041,0.000048315833,0.00027082764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957428,0.00064211857,0.0020058258,0.00036858013,0.00073656585,0.0005041067],"domain_scores_gemma":[0.990493,0.0047561163,0.0015814465,0.00017600789,0.002133548,0.00085985486],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027230692,0.00027536505,0.001772715,0.00041430222,0.000039553175,0.000019840058,0.0001884044,0.00069996226,0.000064572974],"category_scores_gemma":[0.011476646,0.00018195645,0.0003029376,0.00057096337,0.00027242614,0.00021162872,0.00007347131,0.00094818504,0.000027513315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20842761,0.00532033,0.67550623,0.000019544561,0.005998945,0.004052588,0.001845706,0.00029408437,0.0003649694,0.000019132078,0.0023120518,0.095838785],"study_design_scores_gemma":[0.064298086,0.051444255,0.879823,0.00079125015,0.0008177034,0.0003431175,0.0007301017,0.00035904135,0.00035196161,0.00020408547,0.00062985334,0.0002075073],"about_ca_topic_score_codex":0.000028662524,"about_ca_topic_score_gemma":0.00015880655,"teacher_disagreement_score":0.20431678,"about_ca_system_score_codex":0.0023652506,"about_ca_system_score_gemma":0.01091567,"threshold_uncertainty_score":0.99685013},"labels":[],"label_agreement":null},{"id":"W1901693378","doi":"10.1200/jco.2001.19.23.4291","title":"Impact of the Media and the Internet on Oncology: Survey of Cancer Patients and Oncologists in Canada","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":264,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; The Internet; Family medicine; Medical information; Affect (linguistics); Relevance (law); Psychology; World Wide Web","score_opus":0.23895799575025353,"score_gpt":0.6081252877488674,"score_spread":0.36916729199861387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1901693378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280286,0.00014837112,0.0000023261402,0.0036184713,0.0016494002,0.00035634774,0.000042686414,7.7368105e-7,0.0013787427],"genre_scores_gemma":[0.99370843,0.0010627958,0.00003228898,0.0050673294,0.00009481184,0.000006496122,0.0000016776241,0.000003451508,0.000022704047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98859745,0.006113549,0.004718202,0.00009301426,0.00025841888,0.00021937375],"domain_scores_gemma":[0.9668252,0.02645621,0.0055696764,0.00014822453,0.00081228267,0.00018842876],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0154354265,0.00008904999,0.0011181561,0.00005672815,0.00006371938,0.0000017726153,0.0002746005,0.0002947865,0.00017226007],"category_scores_gemma":[0.022708535,0.000037672136,0.000098305514,0.00018438381,0.00042772602,0.00014290946,0.00012988025,0.0015694442,6.4911393e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049386425,0.0002551114,0.9270889,0.000031186188,0.000035615627,0.0000019188628,0.0012125701,0.000010451381,1.2113487e-7,0.000033546512,0.0033315255,0.0630604],"study_design_scores_gemma":[0.007128759,0.0016021914,0.9849436,0.00012888297,0.000016537082,0.0000017638209,0.00019666836,0.00026966044,4.644931e-7,0.00014221693,0.0055367043,0.000032500844],"about_ca_topic_score_codex":0.7362365,"about_ca_topic_score_gemma":0.93621296,"teacher_disagreement_score":0.19997649,"about_ca_system_score_codex":0.0009924195,"about_ca_system_score_gemma":0.015110089,"threshold_uncertainty_score":0.99047333},"labels":[],"label_agreement":null},{"id":"W1909262779","doi":"10.1200/jco.2000.18.18.3280","title":"Health-Related Quality of Life in Survivors of Wilms’ Tumor and Advanced Neuroblastoma: A Cross-Sectional Study","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Neuroblastoma; Quality of life (healthcare); Wilms' tumor; Pediatrics; Pediatric oncology; Ototoxicity; Health related quality of life; Health Utilities Index; Family medicine; Cancer; Internal medicine; Cisplatin; Disease; Chemotherapy","score_opus":0.1342079267205625,"score_gpt":0.5006428924964068,"score_spread":0.36643496577584433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1909262779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936532,0.0006872542,0.000005262755,0.0040800925,0.0007634975,0.00044351546,0.000011696184,0.000009729454,0.00034578636],"genre_scores_gemma":[0.99699664,0.00025790892,0.0005103425,0.0018816954,0.00025257908,0.0000028293216,0.0000013880596,0.000019102627,0.000077525474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9859765,0.00284322,0.009771133,0.00032417782,0.00081270013,0.0002722795],"domain_scores_gemma":[0.988454,0.005267361,0.004992086,0.00028193687,0.00047150618,0.00053310895],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016280403,0.00017930016,0.0035258012,0.00021635933,0.0000356025,0.0000050891476,0.00019485525,0.0002514869,0.00025858727],"category_scores_gemma":[0.009773425,0.00015252305,0.0004257275,0.0003669156,0.0005216387,0.00014994353,0.000055887842,0.001337687,0.0000034455736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016529514,0.0063653956,0.9663235,0.00019579644,0.00024194155,0.00007344845,0.0008512155,0.00017914287,0.000037598384,0.000020427233,0.00008527294,0.009096744],"study_design_scores_gemma":[0.020089168,0.021345159,0.9569901,0.00013367375,0.000040528892,0.00015024397,0.00047534518,0.000024799328,0.0000064691444,0.00017168844,0.00047789147,0.00009492655],"about_ca_topic_score_codex":0.0028819446,"about_ca_topic_score_gemma":0.00410221,"teacher_disagreement_score":0.014979764,"about_ca_system_score_codex":0.00011065632,"about_ca_system_score_gemma":0.00255402,"threshold_uncertainty_score":0.9985677},"labels":[],"label_agreement":null},{"id":"W1910063761","doi":"10.1200/jco.2000.18.15.2828","title":"Relationship Between Tumor Location and Relapse in 6,781 Women With Early Invasive Breast Cancer","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Internal medicine; Oncology; Occult; Cancer; Adjuvant therapy; Disease; Proportional hazards model; Relative risk; Surgery; Pathology; Confidence interval","score_opus":0.05161378538367365,"score_gpt":0.3850992451810786,"score_spread":0.3334854597974049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1910063761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959626,0.0004529195,0.0000126209825,0.0030925267,0.00007594789,0.00007880538,0.000011564546,0.0000018885582,0.00031110615],"genre_scores_gemma":[0.99800897,0.00050351257,0.00028051066,0.00046297247,0.00059546443,0.000016034777,0.0000027722574,0.000010733671,0.00011900664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986011,0.00022190271,0.0007295934,0.00017420296,0.00010976134,0.00016343748],"domain_scores_gemma":[0.9986284,0.00048156024,0.00048030633,0.000102759295,0.00017016385,0.00013683108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066998973,0.00010205108,0.00045813646,0.000046161025,0.00003777646,0.000006707799,0.00008821843,0.00016894887,0.000036273013],"category_scores_gemma":[0.00038375208,0.00007433816,0.00004443856,0.0001108071,0.00019001274,0.000013670991,0.000025634257,0.00029917283,0.000004207631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025372019,0.000152919,0.9654701,0.000008268325,0.00012491699,0.000034333818,0.00017843836,0.0000395694,0.000026071872,0.000009489721,0.00020273768,0.031215977],"study_design_scores_gemma":[0.0034713994,0.002347829,0.991959,0.00004948145,0.0000666237,0.00013012676,0.00010810893,5.0719007e-7,0.000035108988,0.00019193947,0.0015585931,0.000081332066],"about_ca_topic_score_codex":0.000111038185,"about_ca_topic_score_gemma":0.0004818653,"teacher_disagreement_score":0.031134645,"about_ca_system_score_codex":0.00010603666,"about_ca_system_score_gemma":0.0007252098,"threshold_uncertainty_score":0.30314222},"labels":[],"label_agreement":null},{"id":"W1917082840","doi":"10.1200/jco.2009.27.15_suppl.10064","title":"Endocrine complications in children treated for medulloblastoma or ependymoma using radiation therapy. Outcomes in the CT-planning era","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Medulloblastoma; Ependymoma; Radiation therapy; Diabetes insipidus; Precocious puberty; Pediatrics; Surgery; Internal medicine; Hormone; Pathology","score_opus":0.1680418983207571,"score_gpt":0.5061768560947706,"score_spread":0.3381349577740135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1917082840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804128,0.00041741403,0.00003508268,0.018230908,0.00010921372,0.0006469204,0.000004616449,0.0000048951124,0.00013816087],"genre_scores_gemma":[0.99476457,0.00017050178,0.0014650272,0.0032857365,0.00027095378,0.000018194938,0.000010063117,0.000007603194,0.0000073685824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977728,0.00027293884,0.0014590962,0.0001338459,0.00017241234,0.00018891631],"domain_scores_gemma":[0.9963976,0.0025041988,0.0007546044,0.00014431402,0.00010451356,0.000094774994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011143532,0.000116450436,0.0008956406,0.00021872832,0.00004261923,0.000010733373,0.00012736613,0.000081397564,0.000020304344],"category_scores_gemma":[0.00089862937,0.000059675658,0.00026466008,0.00020610738,0.000039885876,0.0000725357,0.000006556259,0.00038394233,0.0000014952395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010919346,0.0037658766,0.85559237,0.0000014111756,0.00016012754,0.00038147144,0.000073710675,0.00011568996,0.0000753159,0.00006195988,0.00032609902,0.138354],"study_design_scores_gemma":[0.017695092,0.006461913,0.97161585,0.000049228336,0.00013091842,0.001426111,0.000052325624,0.00040217582,0.00009477329,0.00021297141,0.001805035,0.00005358173],"about_ca_topic_score_codex":0.000039932012,"about_ca_topic_score_gemma":0.000037267146,"teacher_disagreement_score":0.13830042,"about_ca_system_score_codex":0.00013702735,"about_ca_system_score_gemma":0.00030704256,"threshold_uncertainty_score":0.24335028},"labels":[],"label_agreement":null},{"id":"W1918528668","doi":"10.1200/jco.2000.18.5.1012","title":"“Low-Risk” Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Neutropenia; Bacteremia; Internal medicine; Leukopenia; Confidence interval; Febrile neutropenia; Population; Absolute neutrophil count; Gastroenterology; Surgery; Chemotherapy; Antibiotics","score_opus":0.049370461354705436,"score_gpt":0.410179160385271,"score_spread":0.36080869903056556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1918528668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926477,0.00010149253,0.00009348704,0.0012944852,0.0008891668,0.00044402713,0.000013113609,0.000013585198,0.0045029367],"genre_scores_gemma":[0.9905803,0.0019795357,0.0024275538,0.00094870484,0.0030523252,0.000022795564,0.0000054740017,0.000023727212,0.00095957296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976315,0.0002653377,0.0014418358,0.00020939604,0.0002176238,0.00023430656],"domain_scores_gemma":[0.99679023,0.0011316868,0.0011418934,0.00012259398,0.00048364076,0.00032993205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011960829,0.00012204502,0.0009162256,0.00010440739,0.00011997671,0.000012187633,0.00008107557,0.00029316713,0.0002803594],"category_scores_gemma":[0.00063807116,0.000081826794,0.0002284262,0.00013629647,0.000125941,0.00018825136,0.000022891049,0.0008033827,0.000012610832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048524346,0.0015723503,0.85488164,0.000036253692,0.00017731547,0.000049672926,0.000059077094,0.000046594803,0.000014445352,0.000008725577,0.0067283222,0.13157316],"study_design_scores_gemma":[0.0144029,0.018546902,0.7968992,0.000017898672,0.0010242768,0.00023783515,0.000020864238,0.000053482883,0.000024085955,0.00008789757,0.16861461,0.000070070506],"about_ca_topic_score_codex":0.000014853872,"about_ca_topic_score_gemma":0.000028034618,"teacher_disagreement_score":0.16188629,"about_ca_system_score_codex":0.00011911029,"about_ca_system_score_gemma":0.000929057,"threshold_uncertainty_score":0.34903428},"labels":[],"label_agreement":null},{"id":"W1918853968","doi":"10.1200/jco.2001.19.2.597","title":"Bleomycin-Induced Lung Toxicity and Pentoxifylline","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Bleomycin; Citation; Pentoxifylline; Oncology; Library science; Internal medicine; Chemotherapy","score_opus":0.11237570906052013,"score_gpt":0.4764555924609486,"score_spread":0.36407988340042846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1918853968","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1863096,0.0011617017,0.0000785543,0.8053444,0.0029704424,0.00036051637,0.0000050818508,0.000018940715,0.0037507808],"genre_scores_gemma":[0.039267212,0.0022306626,0.0026500525,0.9068241,0.045508303,0.0000036488414,0.00002457858,0.0000695454,0.0034218752],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99396676,0.00096838805,0.0035301824,0.00036200744,0.000772834,0.00039981585],"domain_scores_gemma":[0.9881034,0.005905429,0.004110039,0.00036632814,0.0010002768,0.00051453465],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0045557832,0.000336537,0.0034253104,0.00033544388,0.000045838573,0.000020614541,0.00026810291,0.003447092,0.00038763846],"category_scores_gemma":[0.011359389,0.00024869957,0.00082727295,0.00015929142,0.00019454017,0.00013521302,0.00007426605,0.00902783,0.000032368804],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080305105,0.00057045766,0.012865333,0.00019326367,0.0006960204,0.012111912,0.000023277502,0.0000012819229,0.00013854311,0.000004588623,0.9398674,0.032724924],"study_design_scores_gemma":[0.008791061,0.013799631,0.027163146,0.000268779,0.0013447539,0.004472684,0.000010164533,0.00008894052,0.000042731484,0.000107266445,0.9436976,0.00021327083],"about_ca_topic_score_codex":0.000010976104,"about_ca_topic_score_gemma":0.0000104197625,"teacher_disagreement_score":0.1470424,"about_ca_system_score_codex":0.00026506782,"about_ca_system_score_gemma":0.0020708248,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W1922842186","doi":"10.1200/jco.2001.19.1.205","title":"Attitudes and Practices Among Pediatric Oncologists Regarding End-of-Life Care: Results of the 1998 American Society of Clinical Oncology Survey","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Palliative care; Specialty; Family medicine; End-of-life care; Pediatric oncology; Nursing; Cancer; Internal medicine; Psychiatry","score_opus":0.29956016406432967,"score_gpt":0.5538173332881565,"score_spread":0.25425716922382685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1922842186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800055,0.0016754066,0.000031753305,0.014048039,0.002148725,0.0003835837,0.000041939857,0.000011090256,0.0016539319],"genre_scores_gemma":[0.9759119,0.012886623,0.0056256875,0.002547565,0.0029276595,0.000002799777,0.0000060048174,0.00002759219,0.00006414785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9808564,0.007087723,0.010012275,0.0005053838,0.0011337942,0.00040441836],"domain_scores_gemma":[0.9080465,0.055475235,0.033540267,0.000677146,0.0015951677,0.00066568993],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.038642533,0.00028139306,0.005207698,0.00014470704,0.00008033136,0.000008228708,0.0006453897,0.000915307,0.000018994018],"category_scores_gemma":[0.11058381,0.00018723834,0.0016093511,0.00068990805,0.003569744,0.00020766942,0.00037980554,0.0026320969,0.0000016163452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013184954,0.0027349617,0.9309248,0.0002860788,0.00091420946,0.000053112617,0.00092287385,0.000019922323,0.000018763669,0.000010960496,0.009328201,0.041601162],"study_design_scores_gemma":[0.012711751,0.019253563,0.9261835,0.000190221,0.000910643,0.00009679059,0.0018739484,0.000023796554,0.000019574472,0.000024285304,0.038566645,0.00014525333],"about_ca_topic_score_codex":0.003918679,"about_ca_topic_score_gemma":0.009210113,"teacher_disagreement_score":0.07280991,"about_ca_system_score_codex":0.00022990073,"about_ca_system_score_gemma":0.009827754,"threshold_uncertainty_score":0.9996689},"labels":[],"label_agreement":null},{"id":"W1926992252","doi":"10.1200/jco.2012.30.15_suppl.4519","title":"Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Interim analysis; Docetaxel; Adverse effect; Randomized controlled trial; Oncology; Chemotherapy","score_opus":0.28065086882574053,"score_gpt":0.5250663325708724,"score_spread":0.2444154637451319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1926992252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927232,0.0031677468,0.000011238548,0.0022888456,0.0007030644,0.00047583913,0.00008131104,0.000004724293,0.00054401305],"genre_scores_gemma":[0.99591666,0.000829624,0.0007925029,0.00043530104,0.0019111157,0.0000037748393,0.00002902187,0.00001422241,0.00006775038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994279,0.0014735898,0.0032299247,0.00019298974,0.0005682621,0.00025623615],"domain_scores_gemma":[0.99110603,0.0053599137,0.0022426748,0.0002818551,0.0004258668,0.000583653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009903721,0.00014006594,0.0016428402,0.00008070381,0.00006283229,0.0000075085877,0.00017766001,0.00023373804,0.00014566955],"category_scores_gemma":[0.0029175386,0.00007662743,0.00024090918,0.00011882594,0.00035705365,0.00018834045,0.00010852772,0.000923461,0.0000020371099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24147734,0.044767912,0.36611882,0.0001456522,0.0035204063,0.00013458697,0.016915021,0.0000045033644,0.025361976,0.000047134246,0.006418107,0.29508853],"study_design_scores_gemma":[0.2904408,0.11555362,0.51240474,0.00035342964,0.0014261024,0.000051564857,0.017991966,0.000018734749,0.012871128,0.0001773322,0.048391953,0.00031866785],"about_ca_topic_score_codex":0.00021795814,"about_ca_topic_score_gemma":0.00006277941,"teacher_disagreement_score":0.29476985,"about_ca_system_score_codex":0.0000956922,"about_ca_system_score_gemma":0.001493353,"threshold_uncertainty_score":0.40120298},"labels":[],"label_agreement":null},{"id":"W1929450387","doi":"10.1200/jco.2000.18.24.4098","title":"Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Toxicity; Volume of distribution; Taxane; Diarrhea; Renal cell carcinoma; Urology; Gastroenterology; Internal medicine; Pharmacology; Cancer","score_opus":0.11412075096877355,"score_gpt":0.5012709397139472,"score_spread":0.38715018874517365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1929450387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962576,0.0000933088,0.00000638584,0.0012559713,0.00033036366,0.0008961011,0.0000058601795,0.0000083048435,0.0011460929],"genre_scores_gemma":[0.99613285,0.00025629273,0.0012302403,0.00143315,0.00047600296,0.000008689064,0.0000040496693,0.000021742484,0.00043697903],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9969196,0.00024482305,0.001939648,0.00025589284,0.0003725495,0.00026748748],"domain_scores_gemma":[0.9968647,0.0006367454,0.0013380673,0.00016571261,0.00024781236,0.00074695854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066159794,0.0001917279,0.0017752022,0.00018380636,0.00005205514,0.0000072632415,0.00012729382,0.00017527584,0.0008168919],"category_scores_gemma":[0.00046675262,0.00013602375,0.00014066503,0.00020420202,0.000094008574,0.000099752855,0.000044985787,0.00056908256,0.000012351093],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09644947,0.040124368,0.08610721,0.000026912485,0.0006590733,0.00092065893,0.002767265,0.00002604968,0.0005958192,0.000002128258,0.0007220589,0.771599],"study_design_scores_gemma":[0.1197014,0.45665872,0.41059405,0.00024071969,0.0011026401,0.00022694257,0.0005064839,0.000009351156,0.00018462895,0.000034286626,0.010590808,0.00014996421],"about_ca_topic_score_codex":0.00011580183,"about_ca_topic_score_gemma":0.00021549549,"teacher_disagreement_score":0.771449,"about_ca_system_score_codex":0.000128013,"about_ca_system_score_gemma":0.0012893018,"threshold_uncertainty_score":0.89443934},"labels":[],"label_agreement":null},{"id":"W1930759119","doi":"10.1200/jco.2001.19.22.4252","title":"Activity of Oral Fludarabine Phosphate in Previously Treated Chronic Lymphocytic Leukemia","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Fludarabine; Leukemia; Cancer research; Internal medicine; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.12239556206196289,"score_gpt":0.47236688523374076,"score_spread":0.34997132317177787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1930759119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219966,0.0019239229,0.00006122605,0.0007307582,0.0004906692,0.00046123686,0.0000016039838,0.000016383832,0.0041145636],"genre_scores_gemma":[0.9911031,0.00590983,0.00060679327,0.00034211553,0.0005887699,0.0000071641603,0.000002313523,0.000034527417,0.0014053689],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99420047,0.0007215387,0.0033016524,0.000329385,0.0007876682,0.00065930205],"domain_scores_gemma":[0.9941296,0.0023237972,0.0018905968,0.00046026203,0.00058896537,0.0006067735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057479204,0.00024391315,0.0028471688,0.00035097136,0.000026235986,0.0000079179,0.0003773211,0.0006745569,0.0005594036],"category_scores_gemma":[0.0053614415,0.00017892045,0.0006742091,0.0006981167,0.000544258,0.00021047617,0.00012773559,0.001336971,0.000049415827],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06511167,0.0035790082,0.09764985,0.00060527615,0.0013988962,0.022093331,0.00023281387,0.0028068826,0.006239198,0.000115085524,0.006123088,0.7940449],"study_design_scores_gemma":[0.41789415,0.0803647,0.29816192,0.0019920738,0.0014684311,0.014058713,0.00009861565,0.089202635,0.012202425,0.0005942009,0.08328988,0.0006722516],"about_ca_topic_score_codex":0.001742382,"about_ca_topic_score_gemma":0.00052077323,"teacher_disagreement_score":0.79337263,"about_ca_system_score_codex":0.083957806,"about_ca_system_score_gemma":0.12847205,"threshold_uncertainty_score":0.9195587},"labels":[],"label_agreement":null},{"id":"W193386846","doi":"10.1200/jco.2009.27.15_suppl.598","title":"Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel and capecitabine for HER2-negative locally advanced breast cancer (LABC): A multicenter study from British Columbia","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Taxane; Breast cancer; Internal medicine; Capecitabine; Febrile neutropenia; Epirubicin; Population; Regimen; Oncology; Cyclophosphamide; Breast-conserving surgery; Hazard ratio; Neutropenia; Anthracycline; Surgery; Chemotherapy; Cancer; Mastectomy; Confidence interval","score_opus":0.05665022831420631,"score_gpt":0.4761407311572904,"score_spread":0.4194905028430841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W193386846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888457,0.0008745235,0.00007093925,0.0054071485,0.0021140417,0.0020543074,0.0005284651,0.000009560842,0.00009530983],"genre_scores_gemma":[0.99294585,0.0010653387,0.0013415415,0.0019921772,0.0018360056,0.000056227465,0.00002170024,0.000020987784,0.0007201588],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962142,0.00038584418,0.0024114451,0.00035620606,0.00032560958,0.00030671374],"domain_scores_gemma":[0.9955147,0.0014018477,0.0018485694,0.00013479228,0.00067438284,0.00042573296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010252501,0.00018939364,0.0023002704,0.000051369592,0.00009231997,0.000024046032,0.000140642,0.00029413286,0.0006831142],"category_scores_gemma":[0.0006198275,0.00019138279,0.0005193583,0.00010834609,0.00023988384,0.00015010562,0.00004433807,0.0005748584,6.508314e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43125448,0.07649977,0.010929194,0.00001968288,0.0020828508,0.0006243904,0.00038833465,0.00000389642,0.004498764,5.169062e-7,0.04205755,0.43164057],"study_design_scores_gemma":[0.70294064,0.2268764,0.05027998,0.00014769523,0.0028566627,0.00010344559,0.00021180874,0.000106387335,0.00015421945,0.00009559083,0.016060527,0.0001666652],"about_ca_topic_score_codex":0.0047296067,"about_ca_topic_score_gemma":0.01661633,"teacher_disagreement_score":0.4314739,"about_ca_system_score_codex":0.00022816549,"about_ca_system_score_gemma":0.0011006899,"threshold_uncertainty_score":0.9272302},"labels":[],"label_agreement":null},{"id":"W1934417358","doi":"10.1200/jco.2013.31.15_suppl.lba4510","title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Oncology; Clinical Oncology; Clinical trial; Internal medicine; Gynecology; Family medicine; Cancer","score_opus":0.09654002515118829,"score_gpt":0.4726979184230209,"score_spread":0.3761578932718326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934417358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727816,0.0017991879,0.000032017342,0.008372516,0.0004933221,0.0018244642,0.0000024254123,0.0000034853288,0.00019442113],"genre_scores_gemma":[0.9518407,0.046308674,0.00082219025,0.00024512922,0.00043182497,0.000105172134,0.000004609582,0.000008653508,0.00023301953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995767,0.0010175736,0.0026594838,0.00011311242,0.0002945098,0.00014833345],"domain_scores_gemma":[0.9943393,0.0025492967,0.0022474884,0.00010601373,0.0006198347,0.00013806684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005327292,0.00008466813,0.0015953392,0.0001681845,0.000017965669,0.0000066236507,0.00007476556,0.00020688606,0.00019558845],"category_scores_gemma":[0.0042950986,0.00004702208,0.0003237522,0.0001715695,0.00018846556,0.00014463,0.0000145443255,0.00050307147,0.0000055383443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66689736,0.0009833762,0.07490205,0.000012021188,0.00033487173,0.00002827133,0.00016116054,0.000010686,0.00024484977,0.000020705273,0.00048204508,0.25592262],"study_design_scores_gemma":[0.9113613,0.011507853,0.07173991,0.00007710363,0.00013654017,0.000010058809,0.000045319684,0.00017984545,0.0011305242,0.0023650203,0.0014026756,0.000043859567],"about_ca_topic_score_codex":0.0006907461,"about_ca_topic_score_gemma":0.00004796891,"teacher_disagreement_score":0.25587875,"about_ca_system_score_codex":0.00013628785,"about_ca_system_score_gemma":0.0016989468,"threshold_uncertainty_score":0.5141944},"labels":[],"label_agreement":null},{"id":"W1938050263","doi":"10.1200/jco.2014.32.4_suppl.lba1","title":"Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Interim analysis; Placebo; Clinical endpoint; Hazard ratio; Internal medicine; Prostate cancer; Population; Docetaxel; Asymptomatic; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Urology; Confidence interval; Androgen receptor; Pathology","score_opus":0.11634759506263968,"score_gpt":0.5176789045011821,"score_spread":0.40133130943854245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1938050263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878753,0.000730821,0.000023765186,0.0063064587,0.00015128346,0.0010257188,0.000012647586,0.000005434481,0.0029563608],"genre_scores_gemma":[0.9943349,0.0021328188,0.0009278979,0.00046095406,0.00028979612,0.000032957912,0.000003514532,0.000021960992,0.0017952253],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99561906,0.0007861598,0.0024595924,0.0002500508,0.000579494,0.00030566097],"domain_scores_gemma":[0.995404,0.0016847447,0.0017854266,0.00023605886,0.0005813568,0.0003084357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005729652,0.0001673666,0.0018783065,0.00021330039,0.000024554272,0.0000064711858,0.00016937684,0.00011929521,0.00008555015],"category_scores_gemma":[0.0012530101,0.00009291288,0.00019855269,0.00028389663,0.00030819772,0.00011086831,0.000035995134,0.0008135616,0.0000030250192],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31977826,0.023286803,0.18569653,0.00018367087,0.0028683492,0.0015911153,0.004939748,0.000108661414,0.0009906774,0.000019126343,0.004423451,0.4561136],"study_design_scores_gemma":[0.5226707,0.19079949,0.24737768,0.0008586909,0.0014437864,0.00015227808,0.0027524068,0.0006940779,0.0027615172,0.0003929652,0.029837517,0.00025891923],"about_ca_topic_score_codex":0.00024633875,"about_ca_topic_score_gemma":0.00028361243,"teacher_disagreement_score":0.45585468,"about_ca_system_score_codex":0.00023015405,"about_ca_system_score_gemma":0.002150732,"threshold_uncertainty_score":0.38153064},"labels":[],"label_agreement":null},{"id":"W1942558153","doi":"10.1200/jco.2000.18.6.1193","title":"Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; World Health Organization","keywords":"Medicine; Oxaliplatin; Carboplatin; Ovarian cancer; Paclitaxel; Internal medicine; Neutropenia; Population; Cisplatin; Chemotherapy; Progression-free survival; Gynecologic oncology; Febrile neutropenia; Oncology; Cancer; Surgery; Colorectal cancer","score_opus":0.10580411642949675,"score_gpt":0.4781313047964457,"score_spread":0.372327188366949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1942558153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950384,0.00027146627,0.0000045655875,0.0015977544,0.00018658534,0.002664213,0.00003652006,0.0000031168206,0.00019739299],"genre_scores_gemma":[0.99732226,0.0016976442,0.0005096157,0.00007435174,0.00013449471,0.00008113348,0.000008115061,0.000026829177,0.00014554612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578977,0.0015292757,0.0019341893,0.00024005501,0.00030316907,0.00020355583],"domain_scores_gemma":[0.9938448,0.0036860162,0.0013474042,0.00020845723,0.0007760664,0.00013722556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021277654,0.00015145626,0.0019039558,0.00013191719,0.00008690757,0.0000043263462,0.00010450319,0.00012959643,0.00038770546],"category_scores_gemma":[0.0015708694,0.00007198748,0.0001327291,0.00041937616,0.0002842644,0.000058347403,0.000030805375,0.00023969961,2.500195e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22754717,0.02525916,0.40326473,0.000018432027,0.0009480933,0.000035340363,0.0010851054,0.00006589813,0.000010269025,0.000011950218,0.000043991065,0.34170985],"study_design_scores_gemma":[0.42378664,0.098621294,0.47600693,0.00014135586,0.0006055902,0.0000037472246,0.00016000113,0.000021262484,0.00003639781,0.000024362707,0.00055145967,0.00004094821],"about_ca_topic_score_codex":0.00055514084,"about_ca_topic_score_gemma":0.0024603852,"teacher_disagreement_score":0.3416689,"about_ca_system_score_codex":0.0003619153,"about_ca_system_score_gemma":0.00069035625,"threshold_uncertainty_score":0.42451027},"labels":[],"label_agreement":null},{"id":"W1943333141","doi":"10.1200/jco.2000.18.14.2755","title":"Cost of Outpatient Blood Transfusion in Cancer Patients","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Blood transfusion and management","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Medicine; Blood transfusion; Cancer; Intensive care medicine; Emergency medicine; Surgery; Internal medicine","score_opus":0.11867684406706581,"score_gpt":0.4598344266746117,"score_spread":0.3411575826075459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1943333141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885794,0.0001759441,0.000018679375,0.0034951179,0.0006761326,0.00037468504,0.000003295037,0.0000031416716,0.0066736354],"genre_scores_gemma":[0.9890239,0.007751862,0.0004627367,0.002219989,0.00016769448,0.000005331495,0.0000014946393,0.000008483868,0.00035851245],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970202,0.00024954448,0.0021279843,0.00011778954,0.0003404569,0.00014404682],"domain_scores_gemma":[0.99862367,0.00035006416,0.0005048824,0.00010174397,0.00021811988,0.0002015085],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001475181,0.00008354343,0.00096285733,0.00012366289,0.0000114438735,0.0000013749676,0.0000941308,0.00021729521,0.0018689038],"category_scores_gemma":[0.00028813773,0.000058804697,0.00030441672,0.00014253269,0.00008017674,0.000047665417,0.000010183509,0.00057652994,0.0000075357098],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00584745,0.015894517,0.3040355,0.000050537405,0.0001726714,0.0001244637,0.00032327976,0.00005688648,0.00006240338,0.000019412686,0.0010761037,0.67233676],"study_design_scores_gemma":[0.027975647,0.01888622,0.8513284,0.00024082925,0.00052856375,0.000012847256,0.000062137304,0.000030477575,0.00021959736,0.00003322287,0.10061749,0.000064574095],"about_ca_topic_score_codex":0.00012227673,"about_ca_topic_score_gemma":0.0002950154,"teacher_disagreement_score":0.6722722,"about_ca_system_score_codex":0.00004717969,"about_ca_system_score_gemma":0.00035580716,"threshold_uncertainty_score":0.9990435},"labels":[],"label_agreement":null},{"id":"W1945259850","doi":"10.1200/jco.2006.24.18_suppl.588","title":"Autoimmune hypothyroidism protects against breast cancer development in the elderly","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Cohort; Internal medicine; Cancer registry; Propensity score matching; Population; Cancer; Epidemiology; Incidence (geometry); Proportional hazards model; Cohort study; Confidence interval; Oncology; Gynecology","score_opus":0.06843077951072332,"score_gpt":0.4091462693613125,"score_spread":0.3407154898505892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1945259850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573111,0.0036408443,0.000015937378,0.035056878,0.0010353721,0.00036976542,0.0000027657302,0.0000072921252,0.0025600416],"genre_scores_gemma":[0.9938686,0.0012043854,0.0012119949,0.002298851,0.0011818515,0.000069908994,0.000002037155,0.000013428352,0.00014898233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969125,0.00029826458,0.0019710474,0.00016054444,0.0003923028,0.00026535458],"domain_scores_gemma":[0.99751824,0.00095641986,0.0010277493,0.00017271902,0.00020616155,0.00011872677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021999772,0.00014314237,0.0009611093,0.00009360347,0.000050220868,0.000012372248,0.0001865655,0.00022106274,0.00005660714],"category_scores_gemma":[0.0002800132,0.00007714376,0.000290882,0.00017128554,0.00010439909,0.00006515156,0.00002607447,0.0008059532,0.000015521555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018004638,0.0067654666,0.10388061,0.000029999013,0.0003180727,0.0020525416,0.00025846972,0.00009874316,0.0003886177,0.00018285043,0.020390961,0.8638332],"study_design_scores_gemma":[0.007288257,0.0028507658,0.8163344,0.00015241858,0.00008287432,0.0002751291,0.000064689346,0.000006362449,0.00013418673,0.00013002248,0.17260982,0.00007102649],"about_ca_topic_score_codex":0.00018553915,"about_ca_topic_score_gemma":0.00046376037,"teacher_disagreement_score":0.8637622,"about_ca_system_score_codex":0.00042083705,"about_ca_system_score_gemma":0.0023650005,"threshold_uncertainty_score":0.41954094},"labels":[],"label_agreement":null},{"id":"W1945826548","doi":"10.1200/jco.2014.59.4747","title":"Volunteering in Honduras: Results and Reflections","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Volunteers Overseas","keywords":"Medicine; Cancer; Family medicine; Population; Cervix; Breast cancer; Cervical cancer; Environmental health; Internal medicine","score_opus":0.349936773152367,"score_gpt":0.5717843468754239,"score_spread":0.2218475737230569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1945826548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612171,0.0006367664,0.000032807802,0.019030826,0.0019761685,0.00005907805,9.920755e-7,0.000005203564,0.017041069],"genre_scores_gemma":[0.99257183,0.0005686201,0.0025963928,0.0031174181,0.000843591,5.8887935e-7,4.9374665e-7,0.000004145327,0.00029690642],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766916,0.00019970641,0.0017115852,0.00008538556,0.00015831254,0.0001758494],"domain_scores_gemma":[0.99734795,0.0011333575,0.00051177584,0.000073817384,0.00026224623,0.00067087484],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005397561,0.00004929139,0.00070916134,0.000120686294,0.000012586681,0.0000026864552,0.000034417095,0.00022035222,0.000004993807],"category_scores_gemma":[0.015080487,0.000035458434,0.00009572361,0.00013421223,0.00006831133,0.00006300081,0.00001884907,0.00072620995,0.00000810727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027584374,0.0017864963,0.58699834,0.00005998532,0.00010005091,0.003842969,0.00061042403,0.000032395088,0.00007892837,0.00026124623,0.13504885,0.24359591],"study_design_scores_gemma":[0.009060824,0.0067252116,0.48508835,0.000111016685,0.000037679773,0.0014911292,0.00035786198,0.000092047834,0.000004339783,0.0005935184,0.49639457,0.00004343364],"about_ca_topic_score_codex":0.00006973846,"about_ca_topic_score_gemma":0.00023441056,"teacher_disagreement_score":0.36134574,"about_ca_system_score_codex":0.00012989173,"about_ca_system_score_gemma":0.0016077386,"threshold_uncertainty_score":0.9932159},"labels":[],"label_agreement":null},{"id":"W1949811104","doi":"10.1200/jco.2001.19.2.314","title":"Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Metastatic breast cancer; Neutropenia; Cyclophosphamide; Febrile neutropenia; Internal medicine; Chemotherapy; Doxorubicin; Regimen; Breast cancer; Surgery; Phases of clinical research; Gastroenterology; Adverse effect; Cancer; Oncology","score_opus":0.1341035759241524,"score_gpt":0.5424805441816323,"score_spread":0.4083769682574799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1949811104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738836,0.0021827442,0.000052049312,0.021960964,0.00087341556,0.00076683075,0.000022546315,0.000006385672,0.00025143902],"genre_scores_gemma":[0.98311406,0.010691467,0.0006366586,0.0036672864,0.0011053585,0.000033779022,0.0000025689271,0.00002119593,0.0007276441],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972617,0.00014600769,0.0019309392,0.00020693152,0.0002253716,0.00022902808],"domain_scores_gemma":[0.9959768,0.0015532564,0.0015315858,0.00013102486,0.0004786811,0.0003286214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013382088,0.00017460065,0.0018566757,0.000118996024,0.000069136426,0.0000036210188,0.00010535037,0.00014662725,0.0008294496],"category_scores_gemma":[0.00032673613,0.00011857911,0.00031772553,0.00015791504,0.00017414965,0.00007991251,0.00003165809,0.00039337183,0.0000014984482],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12532137,0.11347961,0.106308624,0.00012942485,0.0052676387,0.0010722543,0.0012423923,0.0000573147,0.0013993691,0.000029894012,0.012842275,0.6328498],"study_design_scores_gemma":[0.312093,0.40478864,0.091823414,0.00013457538,0.005389199,0.002310494,0.00052916975,0.00019530009,0.0005757895,0.0006836724,0.18126795,0.00020879002],"about_ca_topic_score_codex":0.00023567467,"about_ca_topic_score_gemma":0.00040529436,"teacher_disagreement_score":0.632641,"about_ca_system_score_codex":0.000108714376,"about_ca_system_score_gemma":0.00077384064,"threshold_uncertainty_score":0.9081892},"labels":[],"label_agreement":null},{"id":"W1951094693","doi":"10.1200/jco.2007.25.18_suppl.21060","title":"Interval and non-compliant breast cancers diagnosed in women aged 50–69 in a Canadian breast cancer screening program: Clinical-pathologic correlations","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Mammography; Confidence interval; Breast cancer screening; Cancer; Incidence (geometry); Odds ratio; Medical diagnosis; Internal medicine; Gynecology; Radiology","score_opus":0.18598027645065732,"score_gpt":0.504501682189248,"score_spread":0.31852140573859067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1951094693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901873,0.00053807814,0.00018432112,0.00680549,0.0009757779,0.0004727479,0.00002709056,0.0000115288685,0.0007976581],"genre_scores_gemma":[0.9887415,0.00071246614,0.0041444437,0.005399068,0.0009024806,0.000028670547,0.0000031928969,0.000018172255,0.000049999875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945074,0.00041370362,0.0034684623,0.0003660208,0.00035069895,0.0008937651],"domain_scores_gemma":[0.9949753,0.0017922703,0.0012476692,0.00018418107,0.0003212839,0.0014792559],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0115947835,0.00021365948,0.0017515123,0.0004833338,0.00006960571,0.000022320883,0.00023951104,0.00059361296,0.00015606823],"category_scores_gemma":[0.001972571,0.00017298151,0.0002885373,0.00053338055,0.0004265932,0.00020866748,0.00006849877,0.0024068214,0.000004970093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027092325,0.00031397858,0.68633467,0.000011827335,0.00007042882,0.0050580655,0.00027929182,0.000072986186,0.0000046350783,0.0000041077915,0.00058094156,0.30455986],"study_design_scores_gemma":[0.008484578,0.0036878765,0.9780991,0.00087387284,0.000088872344,0.0016562539,0.0013116862,0.00042029264,2.9659762e-7,0.0000592835,0.0051569194,0.0001609771],"about_ca_topic_score_codex":0.20434155,"about_ca_topic_score_gemma":0.70178145,"teacher_disagreement_score":0.4974399,"about_ca_system_score_codex":0.0018733455,"about_ca_system_score_gemma":0.0048583113,"threshold_uncertainty_score":0.9998947},"labels":[],"label_agreement":null},{"id":"W1952021403","doi":"10.1200/jco.2006.24.18_suppl.10106","title":"Regulation of IKKe expression by androgen receptor and NF-kB transcriptional factor in prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"LNCaP; DU145; Androgen receptor; Tumor necrosis factor alpha; Transcription factor; Biology; Androgen; Cancer research; Signal transduction; Kinase; Transfection; Cell culture; Prostate cancer; Molecular biology; Endocrinology; Internal medicine; Cell biology; Medicine; Cancer; Gene; Hormone; Biochemistry","score_opus":0.04569172435458461,"score_gpt":0.37938823905378277,"score_spread":0.33369651469919814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1952021403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639636,0.0022691714,0.00020674361,0.0005514159,0.00031858077,0.00009362978,0.00005728794,0.0000014913165,0.00010529267],"genre_scores_gemma":[0.99707043,0.0007012335,0.0014547426,0.000116969706,0.00040646046,0.000003567433,0.000027332186,0.000010040789,0.00020920509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815196,0.00023873603,0.0011706022,0.00015996389,0.00015770731,0.00012102691],"domain_scores_gemma":[0.9987441,0.00011551265,0.00081836164,0.0000773725,0.0001668835,0.000077785335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007888026,0.00008775665,0.00041657535,0.000045506593,0.000016856493,0.0000041797666,0.00008838464,0.0002756928,0.000057242316],"category_scores_gemma":[0.00021435403,0.00007043354,0.00012543051,0.000044950804,0.00012077592,0.000009595646,0.000021359381,0.00021349806,5.1022005e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010434737,0.00027501248,0.06476484,0.000012528999,0.000023965926,0.0000033413871,0.00002693971,0.00008998476,0.92183113,0.000015711792,0.0042690043,0.0076440773],"study_design_scores_gemma":[0.0052195694,0.0033438364,0.18299763,0.000101690865,0.000034652952,0.000027939763,0.000030573818,0.000039617113,0.69088614,0.00051467074,0.11664604,0.0001576476],"about_ca_topic_score_codex":0.000030226354,"about_ca_topic_score_gemma":0.000062768966,"teacher_disagreement_score":0.23094498,"about_ca_system_score_codex":0.000025309873,"about_ca_system_score_gemma":0.0003269512,"threshold_uncertainty_score":0.28721964},"labels":[],"label_agreement":null},{"id":"W1955391915","doi":"10.1200/jco.2000.18.12.2435","title":"Second Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":340,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Thyroid; Population; Confidence interval; Internal medicine; Relative risk; Cancer; Esophagus; Breast cancer; Absolute risk reduction; Pediatrics; Gastroenterology","score_opus":0.0386597129460435,"score_gpt":0.3908485813166965,"score_spread":0.352188868370653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1955391915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960138,0.0015818205,9.3869136e-7,0.0011284185,0.00027901575,0.00021427406,0.000008401245,0.0000032453192,0.0007700805],"genre_scores_gemma":[0.99306774,0.0055890344,0.00011297258,0.0008507246,0.00026476427,0.0000061760984,0.0000020716257,0.000009928826,0.00009659819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759144,0.0002453885,0.0015599283,0.00018551748,0.0002268246,0.00019093289],"domain_scores_gemma":[0.99725014,0.0012128826,0.00074002397,0.00015804553,0.00009689059,0.00054202345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008982786,0.00012776183,0.0011672303,0.00009587113,0.000016938722,0.000005129411,0.00009549626,0.00017843359,0.00071541546],"category_scores_gemma":[0.00069505995,0.000090386675,0.00027549636,0.00010487659,0.0002834343,0.00009723153,0.000021252876,0.0003550101,0.000004504942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001418482,0.00267836,0.81931293,0.000041375257,0.00013048702,0.0024776065,0.00010850105,0.00001075888,0.0000022567326,0.0000050205003,0.00019086158,0.17362335],"study_design_scores_gemma":[0.0122421635,0.003476274,0.98278904,0.0004895075,0.00025527875,0.00007311541,0.000025447516,0.000012284698,0.000026002836,0.000039727667,0.00049690716,0.00007423408],"about_ca_topic_score_codex":0.00021794955,"about_ca_topic_score_gemma":0.0023430123,"teacher_disagreement_score":0.17354912,"about_ca_system_score_codex":0.00020232245,"about_ca_system_score_gemma":0.0012654396,"threshold_uncertainty_score":0.7833297},"labels":[],"label_agreement":null},{"id":"W1955610473","doi":"10.1200/jco.2000.18.17.3078","title":"Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":753,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Malignancy; Incidence (geometry); Surgery; Retrospective cohort study; Vitamin K antagonist; Anticoagulant; Low molecular weight heparin; Internal medicine; Heparin; Gastroenterology; Warfarin; Atrial fibrillation","score_opus":0.031509115595474646,"score_gpt":0.373406615148737,"score_spread":0.3418974995532624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1955610473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954012,0.00009907778,0.00025457243,0.0015301311,0.00015934347,0.0004990679,0.000007909973,0.0000062075405,0.002042512],"genre_scores_gemma":[0.9952187,0.0012165966,0.0029250311,0.00048746445,0.00010039493,0.000013890707,0.000011125786,0.000011430315,0.000015371385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972554,0.00018687462,0.0016898374,0.00027435823,0.0004178189,0.00017575524],"domain_scores_gemma":[0.9976679,0.00037369988,0.0011338559,0.00016762188,0.00043323293,0.00022369836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012813683,0.00014376068,0.0018059516,0.00042718445,0.000054691536,0.000017227525,0.00012951768,0.00015066595,0.00010490048],"category_scores_gemma":[0.00054523797,0.00011176951,0.00014940741,0.0005265316,0.00019134382,0.0002594058,0.00006340279,0.00040681433,0.0000017624053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006540902,0.0026442213,0.96859974,0.000020073383,0.0011382841,0.000017231512,0.0009514835,0.00023830529,0.00004571252,0.0006696231,0.00009678502,0.024924451],"study_design_scores_gemma":[0.004149947,0.00504001,0.9879813,0.00027330613,0.0012385102,0.0000101014275,0.000103456936,0.0005176607,0.000008781517,0.00027310709,0.00030323048,0.00010054305],"about_ca_topic_score_codex":0.00015689818,"about_ca_topic_score_gemma":0.0003770937,"teacher_disagreement_score":0.02482391,"about_ca_system_score_codex":0.00015921087,"about_ca_system_score_gemma":0.00017259782,"threshold_uncertainty_score":0.45578283},"labels":[],"label_agreement":null},{"id":"W1956657204","doi":"10.1200/jco.2013.31.6_suppl.6","title":"Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Adverse effect; Concomitant; Abiraterone acetate; Oncology; Urology; Cancer; Randomized controlled trial; Androgen receptor; Androgen deprivation therapy","score_opus":0.1868019128820495,"score_gpt":0.5268007643341991,"score_spread":0.3399988514521496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1956657204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711144,0.000113157475,5.370606e-7,0.00068108155,0.00017023776,0.0018298024,0.0000085201145,0.0000028892075,0.00008234234],"genre_scores_gemma":[0.9991295,0.00032549404,0.00003678562,0.00018653808,0.0002667449,0.000012933059,0.0000029654489,0.000013464323,0.00002559002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547315,0.0013408265,0.0021825864,0.0002152952,0.00055571523,0.00023241773],"domain_scores_gemma":[0.99400836,0.0038700039,0.0011217969,0.00032781827,0.00035861015,0.00031341266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00300991,0.00016280172,0.0014279893,0.00016566053,0.000038431812,0.00001358211,0.00018200112,0.00016495507,0.000101145444],"category_scores_gemma":[0.0017511266,0.00007908779,0.00021420768,0.00020418073,0.0002168959,0.00015564053,0.000050124738,0.0009633648,0.0000043885098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08369541,0.104732335,0.70382124,0.0000135207165,0.00084473763,0.0003870742,0.004042289,0.000028440218,0.0011465065,0.0000023522537,0.0006214564,0.100664616],"study_design_scores_gemma":[0.07181422,0.2730022,0.6519741,0.00008082708,0.00017856526,0.0000308928,0.0025792818,0.000018436283,0.000116613584,0.0000063621615,0.00014968544,0.000048795613],"about_ca_topic_score_codex":0.00029218555,"about_ca_topic_score_gemma":0.00010186625,"teacher_disagreement_score":0.16826987,"about_ca_system_score_codex":0.00016839335,"about_ca_system_score_gemma":0.00058308383,"threshold_uncertainty_score":0.4185394},"labels":[],"label_agreement":null},{"id":"W1957860648","doi":"10.1200/jco.2001.19.1.137","title":"Factors Affecting the Use of Palliative Radiotherapy in Ontario","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer registry; Cancer; Socioeconomic status; Demography; Population; Radiation therapy; Odds ratio; Prostate cancer; Gerontology; Surgery; Internal medicine; Environmental health","score_opus":0.44003362890412834,"score_gpt":0.5066678055075816,"score_spread":0.06663417660345328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1957860648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374753,0.0001092778,0.000563187,0.004102006,0.00049731246,0.00023387696,4.7039958e-7,0.000002593773,0.0007437302],"genre_scores_gemma":[0.9922064,0.0002806271,0.004283531,0.0023647766,0.00016362575,8.0980544e-7,7.458536e-7,0.000009523481,0.00068994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704313,0.0005923863,0.001777746,0.00010126639,0.00033483616,0.00015064604],"domain_scores_gemma":[0.99217504,0.005685759,0.0016492065,0.00016835818,0.00016258635,0.00015902621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029982482,0.00009695199,0.0010874047,0.00012007623,0.000015828418,0.000005885869,0.00012769521,0.00011298829,0.00050137105],"category_scores_gemma":[0.0055226493,0.00005150807,0.00039671455,0.000137926,0.00013929102,0.00009721288,0.000025239377,0.000854219,0.0000014667503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024870543,0.0013567548,0.97089547,0.000012744147,0.00038572328,0.00038468052,0.0009836828,0.00009752952,0.000018849514,0.00004308704,0.0014896597,0.021844791],"study_design_scores_gemma":[0.005116056,0.0034610142,0.9248706,0.00007842898,0.000227108,0.000011145093,0.00049311976,0.00011676192,0.000006324389,0.00008721993,0.06549186,0.000040324976],"about_ca_topic_score_codex":0.0016490119,"about_ca_topic_score_gemma":0.01064045,"teacher_disagreement_score":0.06400221,"about_ca_system_score_codex":0.00022494035,"about_ca_system_score_gemma":0.0009084339,"threshold_uncertainty_score":0.6611526},"labels":[],"label_agreement":null},{"id":"W1958614591","doi":"10.1200/jco.2014.59.7245","title":"Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bevacizumab; Temozolomide; Oncology; Cost–utility analysis; Internal medicine; Glioblastoma; Quality-adjusted life year; Radiation therapy; Cost effectiveness; Chemotherapy; Cancer research","score_opus":0.35013653094247377,"score_gpt":0.5499633049095461,"score_spread":0.19982677396707238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958614591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0121771535,0.9817022,0.000013776346,0.001382295,0.0015379341,0.0029387989,0.00011895095,0.0000035560913,0.00012531965],"genre_scores_gemma":[0.008356187,0.9892287,0.0005112629,0.000053241693,0.0015121303,0.00025053436,0.000028212567,0.000038642716,0.000021069432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931335,0.00050165557,0.0053648213,0.00025286755,0.00052797934,0.0002191962],"domain_scores_gemma":[0.97791064,0.011888279,0.008133316,0.00045887515,0.0013396502,0.00026925938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005703421,0.0003506026,0.006750711,0.00025083192,0.0000354847,0.0000054663665,0.00024174966,0.00069546374,0.000110189314],"category_scores_gemma":[0.003254455,0.00017052583,0.0032153844,0.00010868498,0.00019518558,0.0000521373,0.000036296813,0.00029987778,0.000015580239],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001579871,0.0050784787,0.00030140503,0.0009155812,0.0037868,0.000049620845,0.000051672687,0.00016560873,7.8380886e-8,0.00001986312,0.0020162205,0.9860348],"study_design_scores_gemma":[0.031811967,0.050630912,0.00080392906,0.002380499,0.030472126,0.00018787116,0.000030766612,0.0005349538,0.0000072934577,0.000096209995,0.8829375,0.000105964915],"about_ca_topic_score_codex":0.000039827304,"about_ca_topic_score_gemma":0.00038116588,"teacher_disagreement_score":0.98592883,"about_ca_system_score_codex":0.0015505467,"about_ca_system_score_gemma":0.0072656833,"threshold_uncertainty_score":0.9983622},"labels":[],"label_agreement":null},{"id":"W1963213007","doi":"10.1200/jco.2014.58.0423","title":"Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":344,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"Ministry of Science and Technology of the People's Republic of China","keywords":"Medicine; Incidence (geometry); Cumulative incidence; Internal medicine; Population; Cancer; Esophageal cancer; Dysplasia; Surgery; Cohort; Environmental health","score_opus":0.25389329575029557,"score_gpt":0.5215153736155658,"score_spread":0.2676220778652702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963213007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959329,0.0019056849,0.000046180387,0.000760795,0.0003201405,0.0005088977,0.000008552529,0.0000040572754,0.00051281304],"genre_scores_gemma":[0.99873555,0.0002256667,0.00042952516,0.00012184537,0.00026203349,0.000013319599,0.000002542568,0.000014948438,0.00019457896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946106,0.0019077463,0.0022871734,0.00012365365,0.00079353276,0.00027731122],"domain_scores_gemma":[0.995731,0.0013687449,0.0016198753,0.0003100174,0.00042581145,0.0005445749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005168822,0.00014516935,0.002016105,0.00023115953,0.00003206044,0.0000042879556,0.00029713172,0.00019376593,0.000216601],"category_scores_gemma":[0.0020561428,0.000106674626,0.0002877311,0.00023168938,0.00020933723,0.00010861957,0.00015347797,0.0015772219,0.0000036909828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009410469,0.012895638,0.9262045,0.00007026249,0.00093410775,0.0009546694,0.0012942514,0.000040864936,0.000111887,0.0000038938606,0.00019485384,0.04788459],"study_design_scores_gemma":[0.043457106,0.056211684,0.89872426,0.00026873228,0.00036613373,0.000029700994,0.00040268683,0.000018288292,0.0003896919,0.00007197902,0.000014272335,0.00004544161],"about_ca_topic_score_codex":0.0015234592,"about_ca_topic_score_gemma":0.0014959787,"teacher_disagreement_score":0.04783915,"about_ca_system_score_codex":0.0003692683,"about_ca_system_score_gemma":0.002072042,"threshold_uncertainty_score":0.68523324},"labels":[],"label_agreement":null},{"id":"W1964744337","doi":"10.1200/jco.2008.16.0283","title":"Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Terry Fox Foundation; Genome Canada","keywords":"Medicine; Lymphoma; Follicular lymphoma; Hodgkin lymphoma; Internal medicine; Population; Incidence (geometry); Stage (stratigraphy); Multivariate analysis; Biopsy; Cancer; Survival analysis; Oncology","score_opus":0.11739105286033585,"score_gpt":0.46615780440928595,"score_spread":0.3487667515489501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964744337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758,0.00021819955,0.00018066418,0.0014422187,0.00015929832,0.00011047309,0.000006836597,0.0000022947602,0.00030002758],"genre_scores_gemma":[0.99561137,0.00046841605,0.0032036286,0.00060350285,0.000081110345,0.000002047357,0.0000051139023,0.000005825368,0.000018985596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965712,0.00014116715,0.0026887655,0.00012375636,0.0003589287,0.000116213036],"domain_scores_gemma":[0.9948675,0.0026496188,0.0017468433,0.00015368128,0.00035806,0.00022431664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001168141,0.00010241277,0.0022382198,0.0003284356,0.000024595058,0.0000012703448,0.00007875487,0.00022115097,0.00006633888],"category_scores_gemma":[0.0013226258,0.00006740551,0.00081139145,0.0003518992,0.00019267526,0.00005977182,0.00001093359,0.00011390527,8.5517934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014234364,0.002103592,0.95778877,0.000030817027,0.0015032344,0.00029242842,0.00007585186,0.00009864779,0.000037757898,0.00002521946,0.00005406484,0.036566194],"study_design_scores_gemma":[0.010053408,0.0056129512,0.979196,0.000053259486,0.0036429171,0.00010327673,0.00002468542,0.0006843554,0.0002651537,0.000028321676,0.00028581102,0.000049833707],"about_ca_topic_score_codex":0.00031894055,"about_ca_topic_score_gemma":0.00014146804,"teacher_disagreement_score":0.03651636,"about_ca_system_score_codex":0.00012253047,"about_ca_system_score_gemma":0.0008185685,"threshold_uncertainty_score":0.27487168},"labels":[],"label_agreement":null},{"id":"W1966064734","doi":"10.1200/jco.2014.55.7827","title":"Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":842,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Sentinel node; Breast cancer; Biopsy; Axillary Dissection; Chemotherapy; Cancer; Immunohistochemistry; Prospective cohort study; Internal medicine; Oncology; Surgery; Sentinel lymph node","score_opus":0.026075124420645097,"score_gpt":0.38669578218924505,"score_spread":0.3606206577686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966064734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737259,0.00074233353,0.000097490185,0.023828775,0.0008490854,0.00023202522,0.000031833966,0.0000043814275,0.000488167],"genre_scores_gemma":[0.9922174,0.00075291045,0.0003267955,0.0045901043,0.0019720278,0.000044359105,0.0000039686797,0.00002861978,0.00006378317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703985,0.00066273106,0.0013520916,0.00036647255,0.00024083348,0.00033799515],"domain_scores_gemma":[0.9978159,0.00036126707,0.0010149467,0.00034772948,0.0003185331,0.00014162186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017230925,0.0002518938,0.0009443325,0.00006204182,0.00006744316,0.000016924798,0.0003756714,0.00029260226,0.00004407598],"category_scores_gemma":[0.0002876218,0.00015339088,0.0003753552,0.00013417228,0.00029997143,0.000010017632,0.00016948636,0.0004995882,0.000008869683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006256575,0.0028078584,0.92813706,0.000007404828,0.00091839477,0.00013213526,0.00029477023,0.00003987978,0.0021139781,0.000008033493,0.0015057288,0.057778202],"study_design_scores_gemma":[0.008081328,0.0013249583,0.9816352,0.000044550103,0.00018022697,0.00030402173,0.00029659382,0.000034783858,0.0002778396,0.000053950072,0.0075943987,0.00017212368],"about_ca_topic_score_codex":0.0002534178,"about_ca_topic_score_gemma":0.0002459287,"teacher_disagreement_score":0.05760608,"about_ca_system_score_codex":0.00009688384,"about_ca_system_score_gemma":0.0004000957,"threshold_uncertainty_score":0.62550986},"labels":[],"label_agreement":null},{"id":"W1968538911","doi":"10.1200/jco.2011.38.5732","title":"Design Issues in Randomized Phase II/III Trials","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Randomized controlled trial; Medicine; Phase (matter); Selection (genetic algorithm); N of 1 trial; Clinical trial; Accrual; Internal medicine; Computer science; Artificial intelligence","score_opus":0.8981866011790793,"score_gpt":0.7525624720174812,"score_spread":0.14562412916159817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968538911","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0856123,0.002551155,0.87233764,0.013144577,0.018056575,0.0027447206,0.000012166026,0.0000510681,0.0054898006],"genre_scores_gemma":[0.08085352,0.0013693753,0.91020066,0.0010787349,0.0060533797,0.000028696766,2.1533725e-7,0.00003284949,0.0003825647],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8999875,0.07475863,0.023342686,0.0003046023,0.0008723922,0.0007341841],"domain_scores_gemma":[0.15606825,0.83105755,0.011161552,0.00040360817,0.00049612566,0.0008129062],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.41896912,0.00027063105,0.013024384,0.00023936214,0.000053374726,0.000017250031,0.0005221357,0.0010158577,0.00180352],"category_scores_gemma":[0.9077305,0.00016601395,0.0019425263,0.00024787287,0.0006316023,0.00024025461,0.00014399068,0.0018682869,0.000031069623],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50710607,0.017944168,0.00018963669,0.000039863877,0.0012792937,0.00021700384,0.00062306714,0.000007835183,0.00012008195,0.053046834,0.042405307,0.37702084],"study_design_scores_gemma":[0.37378347,0.0054213814,0.000043741988,0.00010080187,0.0008629192,0.000036711688,0.00005316635,0.00012406678,0.0002057337,0.6082229,0.010995887,0.00014920566],"about_ca_topic_score_codex":0.0000073659958,"about_ca_topic_score_gemma":0.0000020036039,"teacher_disagreement_score":0.75629896,"about_ca_system_score_codex":0.0001126217,"about_ca_system_score_gemma":0.0007701681,"threshold_uncertainty_score":0.99910897},"labels":[],"label_agreement":null},{"id":"W1969333161","doi":"10.1200/jco.2002.07.112","title":"Prognostic Significance of the Number of Axillary Lymph Nodes Removed in Patients With Node-Negative Breast Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Lymph node; Systemic therapy; Axilla; Axillary Lymph Node Dissection; Internal medicine; Lymphatic system; Lymph; Dissection (medical); Axillary lymph nodes; Surgery; Lymphovascular invasion; Cancer; Oncology; Metastasis; Pathology; Sentinel lymph node","score_opus":0.03144399454661245,"score_gpt":0.35049234404770774,"score_spread":0.3190483495010953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969333161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740654,0.00028269918,0.000011258616,0.0012401737,0.00026424715,0.00014249793,0.00004933594,9.3032895e-7,0.0006023374],"genre_scores_gemma":[0.9982626,0.00042176386,0.00077793456,0.00031442932,0.00016058268,0.000008426348,0.0000011577142,0.0000121293,0.000040981253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980906,0.00029155848,0.001060051,0.00016899993,0.00023222207,0.00015651499],"domain_scores_gemma":[0.99722594,0.00037851464,0.0015851569,0.00018551703,0.0005643588,0.000060524802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034746833,0.00012883505,0.0006828288,0.000023835311,0.000022832186,0.0000018445581,0.00022306286,0.00018167812,0.00005113108],"category_scores_gemma":[0.00067836844,0.00007368071,0.00019436867,0.00013869499,0.0004544562,0.0000076283904,0.00008104489,0.00019034412,9.905175e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019965358,0.001330715,0.98397523,0.000019115743,0.000354009,0.000006027531,0.00006546376,0.00007831104,0.00019540712,0.000004681866,0.00016397741,0.011810498],"study_design_scores_gemma":[0.0054847775,0.0004819462,0.9927374,0.00013084059,0.00012542603,0.000022932658,0.000051086816,0.000008174741,0.00068725337,0.000039774288,0.00015358126,0.000076813245],"about_ca_topic_score_codex":0.0001104705,"about_ca_topic_score_gemma":0.00006635308,"teacher_disagreement_score":0.011733685,"about_ca_system_score_codex":0.00006514773,"about_ca_system_score_gemma":0.00035174226,"threshold_uncertainty_score":0.3004612},"labels":[],"label_agreement":null},{"id":"W1971245874","doi":"10.1200/jco.2010.29.1625","title":"Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Genentech; Sanofi; American Society of Clinical Oncology; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cost sharing; Family medicine; Health care; Government (linguistics); Environmental health; Nursing; Economic growth","score_opus":0.14827511893952497,"score_gpt":0.42152505254962636,"score_spread":0.2732499336101014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971245874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9467709,0.0016932206,0.000011267624,0.047243223,0.0008386182,0.0003061614,0.000080988226,0.0000023502396,0.0030532563],"genre_scores_gemma":[0.9900425,0.0023079307,0.000027598362,0.0071010073,0.00041977162,0.0000075719654,7.851326e-7,0.000011248917,0.0000815713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823076,0.00011466038,0.0011784954,0.00016006843,0.000047007565,0.00026902687],"domain_scores_gemma":[0.9944694,0.0026238894,0.00232366,0.00013755834,0.000106993815,0.00033847796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053265635,0.00012474835,0.0010640951,0.00008729296,0.00014105924,0.000036647074,0.00023008356,0.00021897355,0.000065270106],"category_scores_gemma":[0.0021882304,0.00007326302,0.00011396786,0.00008603187,0.00064084877,0.00012467662,0.000038585957,0.00081073836,0.0000028381046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023237379,0.00012705958,0.92586976,0.0000058097294,0.00019645812,0.0000032506334,0.00016522116,0.000010349823,0.0000019271283,0.027092414,0.004376995,0.04191838],"study_design_scores_gemma":[0.0017652179,0.001812106,0.9242846,0.000059222315,0.000018590137,0.000010729395,0.0000424919,0.000012965453,0.00000501791,0.0019746074,0.06993536,0.0000791252],"about_ca_topic_score_codex":0.14756432,"about_ca_topic_score_gemma":0.45835203,"teacher_disagreement_score":0.3107877,"about_ca_system_score_codex":0.0003881635,"about_ca_system_score_gemma":0.001908331,"threshold_uncertainty_score":0.8581121},"labels":[],"label_agreement":null},{"id":"W1971365970","doi":"10.1200/jco.2003.12.044","title":"Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical trial; Cancer; Population; Internal medicine","score_opus":0.6696214308388551,"score_gpt":0.6668644700075376,"score_spread":0.00275696083131749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971365970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432297,0.00050897605,0.0000068184554,0.0111125475,0.0012240564,0.0005304664,0.000018104503,9.612492e-7,0.0022750823],"genre_scores_gemma":[0.9850562,0.006907677,0.00071322615,0.0067089987,0.00021713109,0.000019052606,9.665971e-7,0.000014525988,0.00036218466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98739594,0.0032672638,0.007485206,0.00026400542,0.0012100049,0.00037756245],"domain_scores_gemma":[0.92972606,0.06528377,0.0030085105,0.00034426592,0.0009456572,0.0006917295],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029296895,0.00015033259,0.0035719636,0.0002265625,0.00001348363,0.0000034832055,0.00019643438,0.0006291046,0.00090756424],"category_scores_gemma":[0.13973792,0.00009839197,0.0005573543,0.00026041947,0.00019370273,0.000042698626,0.000040849314,0.0023021407,0.0000022960373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003403303,0.0041779997,0.94810545,0.000059858066,0.0003070467,0.001005389,0.00026842664,0.000025085883,0.000027276132,0.00017835184,0.003413175,0.03902861],"study_design_scores_gemma":[0.038878158,0.014522082,0.89378804,0.00061820104,0.00019554586,0.000010316372,0.00026753554,0.000016288759,0.00058264425,0.002781744,0.048229817,0.000109627785],"about_ca_topic_score_codex":0.28899553,"about_ca_topic_score_gemma":0.892655,"teacher_disagreement_score":0.6036595,"about_ca_system_score_codex":0.0030053167,"about_ca_system_score_gemma":0.03375842,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W1973650196","doi":"10.1200/jco.2012.42.1644","title":"Comparative Effectiveness Research Paradigm: Implications for Systematic Reviews and Clinical Practice Guidelines","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Systematic review; Medicine; Comparative effectiveness research; Context (archaeology); Observational study; Paradigm shift; Guideline; Best practice; Management science; Medical education; Alternative medicine; Engineering ethics; MEDLINE; Epistemology; Pathology","score_opus":0.9761960996014803,"score_gpt":0.8000392173933968,"score_spread":0.17615688220808357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973650196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012040357,0.96236485,0.0036975865,0.020966146,0.003226088,0.00869894,0.0001444264,0.0000090191115,0.00088091666],"genre_scores_gemma":[0.000020852693,0.9649877,0.02428055,0.003678046,0.0057802494,0.0010670698,0.00001952258,0.00005398132,0.00011201767],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.89615,0.040444218,0.061659984,0.0008430294,0.00022531851,0.00067745586],"domain_scores_gemma":[0.5195927,0.4059988,0.06943864,0.0010542333,0.0029340072,0.0009816203],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.56662804,0.00044277546,0.025497021,0.0006137592,0.00026357395,0.000088664565,0.00088289374,0.0015276147,0.000028954304],"category_scores_gemma":[0.5170882,0.00035647946,0.0023934476,0.00038111882,0.00046626403,0.00070326094,0.00016779942,0.0024051254,0.0007486769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027440337,0.002522958,0.0009413981,0.4136527,0.0042290506,0.0000059261392,0.00030285987,0.0000020650707,5.319987e-9,0.12156723,0.15129502,0.30520642],"study_design_scores_gemma":[0.0011194034,0.0017601165,0.000697922,0.031102804,0.0012263983,0.00022132408,0.00012428265,0.000027085667,1.6224725e-9,0.0072093294,0.9562248,0.00028655335],"about_ca_topic_score_codex":0.000032794855,"about_ca_topic_score_gemma":0.000026658412,"teacher_disagreement_score":0.80492973,"about_ca_system_score_codex":0.001002706,"about_ca_system_score_gemma":0.003497513,"threshold_uncertainty_score":0.99989635},"labels":[],"label_agreement":null},{"id":"W1974820090","doi":"10.1200/jco.2011.38.0527","title":"Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1420,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Karnofsky Performance Status; Lung cancer; Recursive partitioning; Oncology; Internal medicine; Multivariate analysis; Performance status; Brain metastasis; Univariate analysis; Cancer; Univariate; Melanoma; Proportional hazards model; Retrospective cohort study; Metastasis; Multivariate statistics","score_opus":0.21877765872960883,"score_gpt":0.47484731789356155,"score_spread":0.25606965916395275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974820090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901366,0.000066056135,0.00071415363,0.0069503947,0.0005110639,0.0013057786,0.0000790526,0.000010610298,0.00022627685],"genre_scores_gemma":[0.9702652,0.000069245616,0.02720707,0.0019113863,0.00026128688,0.00013041585,0.000060460203,0.000027010648,0.000067941386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969087,0.0006205023,0.0015098484,0.00030457546,0.00039282275,0.00026350823],"domain_scores_gemma":[0.99104565,0.0066439584,0.0011618646,0.0003111533,0.00043106975,0.00040632318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004342676,0.00020101218,0.0011044606,0.00008120877,0.00009845596,0.00002434173,0.00013140081,0.00011592685,0.00008026797],"category_scores_gemma":[0.004518317,0.00009797964,0.00023473828,0.00010464093,0.00015376374,0.00013536822,0.00004322263,0.00041389425,0.0000037723744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009225066,0.01335563,0.84141165,0.00004031493,0.0012388364,0.0026721647,0.00013698805,0.000014132126,0.0000058617125,0.0015786969,0.011428787,0.11889188],"study_design_scores_gemma":[0.007703402,0.06365807,0.8672654,0.00011441359,0.000685588,0.00019073107,0.00008825415,0.000015266032,0.00002664541,0.0005020695,0.059624955,0.00012521097],"about_ca_topic_score_codex":0.000008562928,"about_ca_topic_score_gemma":0.000026597372,"teacher_disagreement_score":0.118766665,"about_ca_system_score_codex":0.000062540785,"about_ca_system_score_gemma":0.00045355363,"threshold_uncertainty_score":0.5409174},"labels":[],"label_agreement":null},{"id":"W1974895424","doi":"10.1200/jco.2003.07.056","title":"Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institute of General Medical Sciences; McGill University","keywords":"Medicine; Methylenetetrahydrofolate reductase; Methotrexate; Homocysteine; Hyperhomocysteinemia; Gastroenterology; Internal medicine; Toxicity; Neurotoxicity; Pharmacology; Genotype","score_opus":0.06536491631372009,"score_gpt":0.43582407413286917,"score_spread":0.37045915781914907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974895424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995337,0.00034537158,0.00018688431,0.001031368,0.00016428818,0.00030515433,0.0000012778684,0.0000048435227,0.002623817],"genre_scores_gemma":[0.99169487,0.0007710345,0.005260967,0.0017176927,0.00037840713,0.0000030252806,5.1892164e-7,0.000018899182,0.00015458938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971389,0.0005671098,0.0014069172,0.00019813995,0.00040711797,0.00028181425],"domain_scores_gemma":[0.9973002,0.0011755716,0.00060968066,0.0001493051,0.0002599604,0.00050526817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025983737,0.00012807029,0.0010447135,0.00016813031,0.000022033457,0.000007676411,0.00012419793,0.0002568696,0.00007171433],"category_scores_gemma":[0.003645338,0.0000829073,0.00012151752,0.00020248468,0.00034681475,0.000067481225,0.000040845676,0.0012356521,0.000007772683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028540832,0.0006702477,0.9665485,0.000018424613,0.00028077807,0.00154944,0.000028690523,0.00004828728,0.00052868825,0.0000832883,0.0014060829,0.025983503],"study_design_scores_gemma":[0.032523468,0.012935248,0.93113023,0.0000695826,0.00023344444,0.010630501,0.000028524608,0.00030638173,0.00090087147,0.000100829464,0.011031478,0.00010942924],"about_ca_topic_score_codex":0.000022422939,"about_ca_topic_score_gemma":0.00001740182,"teacher_disagreement_score":0.035418246,"about_ca_system_score_codex":0.00042660383,"about_ca_system_score_gemma":0.005161442,"threshold_uncertainty_score":0.91561764},"labels":[],"label_agreement":null},{"id":"W1976067359","doi":"10.1200/jco.2004.03.087","title":"Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Internal medicine; Folinic acid; Adjuvant therapy; Colorectal cancer; Cancer; Oncology; Randomized controlled trial; Meta-analysis; Clinical trial; Radiation therapy; Stage (stratigraphy); Disease; Surgery","score_opus":0.2786671240307788,"score_gpt":0.5453717605522372,"score_spread":0.2667046365214584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976067359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035882147,0.9749454,0.00000695573,0.002662356,0.00155841,0.016506061,0.00068948476,0.00002787031,0.000015223501],"genre_scores_gemma":[0.0007498905,0.98222053,0.0008272924,0.0027427152,0.0013083438,0.0117873745,0.00013569999,0.000101638616,0.00012653932],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.98898387,0.0020131315,0.0063569495,0.0008926912,0.0010423351,0.0007110015],"domain_scores_gemma":[0.9815648,0.008138706,0.007298786,0.00076311437,0.001329042,0.00090552884],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024330118,0.0008809872,0.012508401,0.0001573109,0.00014016464,0.00003813242,0.0008325924,0.00053085544,0.00049320544],"category_scores_gemma":[0.0041307462,0.00046015633,0.004079262,0.0005003513,0.00031109434,0.00014020732,0.00014153634,0.002704772,0.00000486988],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076714926,0.0016086556,0.019954203,0.42402688,0.0012251466,0.0015741094,0.000282373,0.00002625852,7.142093e-8,0.000001733767,0.00029204463,0.54333705],"study_design_scores_gemma":[0.007725522,0.013946115,0.0053588483,0.64511234,0.014136426,0.000041297437,0.00004019208,0.0000045939355,7.1200795e-8,0.000004240806,0.3133608,0.00026956294],"about_ca_topic_score_codex":0.032761205,"about_ca_topic_score_gemma":0.1906241,"teacher_disagreement_score":0.54306746,"about_ca_system_score_codex":0.014714188,"about_ca_system_score_gemma":0.0512404,"threshold_uncertainty_score":0.999785},"labels":[],"label_agreement":null},{"id":"W1976558206","doi":"10.1200/jco.2003.03.057","title":"Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Rash; Premedication; Nausea; Surgery; Internal medicine; Cancer; Renal cell carcinoma; Gastroenterology","score_opus":0.20779063918195953,"score_gpt":0.48354613626140286,"score_spread":0.27575549707944336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976558206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962584,0.00020307423,0.00001096646,0.00038304433,0.0011431602,0.0017107615,0.00003946673,9.921865e-7,0.00025017603],"genre_scores_gemma":[0.998184,0.00005882086,0.0012853756,0.00015754093,0.00019077428,0.00002499092,0.0000027235612,0.000013943104,0.000081816324],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888869,0.00282994,0.006613928,0.00026157274,0.0011909525,0.00021672479],"domain_scores_gemma":[0.98776317,0.004555367,0.0061463937,0.00021850255,0.0010343089,0.000282288],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009449479,0.00020988923,0.0035765176,0.00016848398,0.000037671933,0.0000018249292,0.00017746199,0.00015242236,0.00006144257],"category_scores_gemma":[0.01515494,0.00010492249,0.00041171678,0.000328259,0.00035299576,0.00009703711,0.000051512303,0.00068944274,5.880986e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.571874,0.086767316,0.32001773,0.0001392876,0.0013690129,0.00025008095,0.00029738495,0.00024087551,0.00024830864,0.000046096724,0.00052060455,0.018229295],"study_design_scores_gemma":[0.45410514,0.19963287,0.34326616,0.00011953824,0.001427433,0.000018759869,0.00017121878,0.000016218866,0.00034190374,0.00003262584,0.0007865866,0.00008152667],"about_ca_topic_score_codex":0.0027574424,"about_ca_topic_score_gemma":0.029981008,"teacher_disagreement_score":0.11776886,"about_ca_system_score_codex":0.00032665743,"about_ca_system_score_gemma":0.009369384,"threshold_uncertainty_score":0.9962466},"labels":[],"label_agreement":null},{"id":"W1977618336","doi":"10.1200/jco.2011.39.7372","title":"Evidence-Based Treatment of Depression in Patients With Cancer","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Depression (economics); Cancer; Cancer treatment; Oncology; Internal medicine; Psychiatry","score_opus":0.39843986357922473,"score_gpt":0.5498381340189935,"score_spread":0.15139827043976878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977618336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00879844,0.98872143,0.0000051722577,0.00015963332,0.0016752989,0.00046634112,0.000011161472,0.0000021278174,0.00016042156],"genre_scores_gemma":[0.013720394,0.984868,0.00013864592,0.00014863722,0.0010033062,0.00002608913,0.000007415261,0.000024409497,0.000063111576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576455,0.0006855089,0.0027452132,0.00017554159,0.00043263924,0.00019654089],"domain_scores_gemma":[0.9927128,0.0025344302,0.0037957244,0.0002423139,0.0004158949,0.0002988395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011539162,0.00022810449,0.0051319897,0.00021136003,0.000008762337,0.0000021120127,0.00012889871,0.0006494394,0.00024102558],"category_scores_gemma":[0.00046565963,0.0001129784,0.0009982036,0.00019923542,0.0001064488,0.00007296051,0.000017264854,0.00065426866,0.000003401746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025414224,0.0018139298,0.2652361,0.001792665,0.0002448214,0.000048997194,0.000024031246,8.902964e-7,1.0430169e-8,3.3684861e-7,0.000063026775,0.72823375],"study_design_scores_gemma":[0.005665307,0.01685144,0.098702826,0.04175956,0.0045345747,0.000012605304,0.0000065427066,3.752478e-7,5.8660515e-7,8.8718167e-7,0.832367,0.00009827423],"about_ca_topic_score_codex":0.0002036252,"about_ca_topic_score_gemma":0.0005567881,"teacher_disagreement_score":0.832304,"about_ca_system_score_codex":0.0007442138,"about_ca_system_score_gemma":0.0055724606,"threshold_uncertainty_score":0.9885306},"labels":[],"label_agreement":null},{"id":"W1978580856","doi":"10.1200/jco.2006.10.2871","title":"Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Nasopharyngeal carcinoma; Oncology; Head and neck squamous-cell carcinoma; Carcinoma; Adverse effect; Chemotherapy; Progressive disease; Head and neck cancer; Response Evaluation Criteria in Solid Tumors; Radiation therapy; Stage (stratigraphy); Gastroenterology; Hepatocellular carcinoma","score_opus":0.12490601408766001,"score_gpt":0.4508927971275671,"score_spread":0.3259867830399071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978580856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965938,0.0005824327,0.0000048144857,0.00086094416,0.000947885,0.0006090617,0.000011314956,0.0000015371572,0.00038821838],"genre_scores_gemma":[0.998472,0.00008189354,0.00068792125,0.00034872568,0.0003099936,0.000002907707,9.618162e-7,0.000012192771,0.00008345653],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961919,0.00031931626,0.0026215778,0.0001663879,0.00045054342,0.00025023526],"domain_scores_gemma":[0.99532497,0.0020716349,0.0017927485,0.00017533053,0.0004012551,0.00023407768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022880877,0.00015273498,0.0020351657,0.00013078112,0.000045339897,0.0000016176937,0.0001333559,0.0001394468,0.000040140574],"category_scores_gemma":[0.0019688727,0.00006935936,0.00023635759,0.00024434493,0.00035377993,0.00005583305,0.00008117316,0.0006657048,2.9559314e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60551953,0.02016822,0.3081369,0.0001791015,0.00010131224,0.00035819077,0.0007021836,7.358377e-7,0.00003507043,0.000004864243,0.0005978827,0.06419603],"study_design_scores_gemma":[0.28029928,0.24673957,0.47087148,0.00011573709,0.00034071895,0.000032186985,0.0001559391,0.0000071844893,0.00021869487,0.000008282682,0.0011565001,0.000054437874],"about_ca_topic_score_codex":0.00004812491,"about_ca_topic_score_gemma":0.0005350548,"teacher_disagreement_score":0.32522026,"about_ca_system_score_codex":0.000098698765,"about_ca_system_score_gemma":0.0017339251,"threshold_uncertainty_score":0.30759087},"labels":[],"label_agreement":null},{"id":"W1978631002","doi":"10.1200/jco.2009.22.6662","title":"Validation of a Web-Based Predictive Nomogram for Ipsilateral Breast Tumor Recurrence After Breast Conserving Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Nomogram; Medicine; Proportional hazards model; Hazard ratio; Breast cancer; Population; Internal medicine; Cohort; Oncology; Confidence interval; Cancer","score_opus":0.03709226604628955,"score_gpt":0.3921205814745454,"score_spread":0.35502831542825586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978631002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559325,0.00019083072,0.0005137534,0.002020715,0.0011775757,0.00021818953,0.00019903477,0.0000040322084,0.00008259566],"genre_scores_gemma":[0.9942713,0.00009061695,0.003917642,0.0006258756,0.0010104115,0.00004131971,0.000018233028,0.000015045702,0.0000095713485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817216,0.00019427975,0.001082196,0.00021774131,0.00014623269,0.0001874158],"domain_scores_gemma":[0.9971675,0.00046214196,0.0012575034,0.00018974226,0.00079560257,0.00012749711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010987588,0.00015047166,0.00061902497,0.00005329864,0.000038022703,0.000008506648,0.00019939026,0.00025153128,0.000039010753],"category_scores_gemma":[0.0004764752,0.00011181192,0.00041332818,0.000059275742,0.0002675549,0.000011286817,0.00004660335,0.0003132585,0.0000010212493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03891537,0.0029191417,0.7812262,0.000046080608,0.00095811964,0.000035317284,0.00008664935,0.000046529392,0.04631051,0.000016077847,0.001814902,0.12762508],"study_design_scores_gemma":[0.0138701,0.008435354,0.94775987,0.00008991725,0.00022525807,0.00069674075,0.00004690039,0.00018612988,0.01623133,0.00020484586,0.012043433,0.00021011209],"about_ca_topic_score_codex":0.000012167352,"about_ca_topic_score_gemma":0.00005020207,"teacher_disagreement_score":0.16653366,"about_ca_system_score_codex":0.000022106722,"about_ca_system_score_gemma":0.0009705954,"threshold_uncertainty_score":0.45595577},"labels":[],"label_agreement":null},{"id":"W1979155042","doi":"10.1200/jco.2011.36.8779","title":"Edmonton Symptom Assessment System Screening and Depression at the End of Life","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Depression (economics); Gerontology; Psychiatry","score_opus":0.37752091435770807,"score_gpt":0.5472954769770033,"score_spread":0.16977456261929524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979155042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51044184,0.039863497,0.0015961268,0.401743,0.007027249,0.00091057224,0.000058514004,0.000025386527,0.03833384],"genre_scores_gemma":[0.59653395,0.020990755,0.02113061,0.3235745,0.03482489,0.000017653701,0.00005976922,0.00013774773,0.002730079],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948528,0.0009946108,0.0030602352,0.000220129,0.0006548413,0.00021739531],"domain_scores_gemma":[0.9861525,0.007328006,0.005294403,0.00031171448,0.000690319,0.00022303428],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003307462,0.00021807842,0.00283465,0.00013234842,0.00004149298,0.000004434112,0.00025420744,0.0013295014,0.00012595687],"category_scores_gemma":[0.0030480523,0.00011629198,0.00066008535,0.00006289637,0.00046648865,0.00005323571,0.00018048652,0.00276965,0.0000027532683],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020641477,0.00024292272,0.32140842,0.00092974957,0.0017764091,0.0012094121,0.00030080177,0.000002375951,0.00007545915,0.000020538311,0.6321218,0.039847974],"study_design_scores_gemma":[0.0043206145,0.004437165,0.12381575,0.0052184965,0.0015951578,0.00026274027,0.00037373544,0.00003584755,0.000098571065,0.000021693182,0.8596973,0.00012293669],"about_ca_topic_score_codex":0.000093060145,"about_ca_topic_score_gemma":0.000019917927,"teacher_disagreement_score":0.22757551,"about_ca_system_score_codex":0.0001551611,"about_ca_system_score_gemma":0.0010840042,"threshold_uncertainty_score":0.999967},"labels":[],"label_agreement":null},{"id":"W1979543333","doi":"10.1200/jco.2007.12.1905","title":"Incidence of Neuroblastoma After a Screening Program","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Hospital for Sick Children; SickKids Foundation; Jewish Rehabilitation Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Neuroblastoma; Incidence (geometry); Oncology; Internal medicine; Genetics","score_opus":0.12673023887844503,"score_gpt":0.5315207376162954,"score_spread":0.40479049873785033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979543333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958259,0.00012159947,0.0005110755,0.0012285542,0.00028489492,0.00023789436,8.783121e-7,0.000010888498,0.0017783192],"genre_scores_gemma":[0.977028,0.00008527448,0.021506099,0.00077251776,0.00044506116,0.0000030787742,3.0129925e-7,0.00001308178,0.00014656346],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99684674,0.00021373162,0.0019339898,0.00014196723,0.0005567256,0.00030682076],"domain_scores_gemma":[0.9956406,0.0019590291,0.0010884615,0.00016552587,0.0005504052,0.0005959858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002979351,0.00010077915,0.00094139617,0.00019935908,0.000017231223,0.0000044954386,0.0001360483,0.00018728606,0.00009167145],"category_scores_gemma":[0.0040676887,0.000067983085,0.00045301742,0.00021475542,0.00028045473,0.00010218566,0.00007328037,0.0008934234,0.000016449601],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023081647,0.0039780103,0.23194057,0.000039350096,0.00027442814,0.01494695,0.000032468186,0.0000018938691,0.0009886039,0.000013573141,0.0004970378,0.7242055],"study_design_scores_gemma":[0.005887934,0.051148076,0.92514247,0.00015523675,0.00014596201,0.0016407435,0.000024219484,0.000034039607,0.0013927262,0.00006130747,0.014320229,0.000047035574],"about_ca_topic_score_codex":0.0000072877656,"about_ca_topic_score_gemma":0.000033183165,"teacher_disagreement_score":0.72415847,"about_ca_system_score_codex":0.00004197064,"about_ca_system_score_gemma":0.00070688425,"threshold_uncertainty_score":0.48696974},"labels":[],"label_agreement":null},{"id":"W1979666460","doi":"10.1200/jco.2003.01.101","title":"Effect of Fish Oil on Appetite and Other Symptoms in Patients With Advanced Cancer and Anorexia/Cachexia: A Double-Blind, Placebo-Controlled Study","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":284,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital","funders":"","keywords":"Appetite; Fish oil; Medicine; Anorexia; Nausea; Cachexia; Placebo; Eicosapentaenoic acid; Internal medicine; Gastroenterology; Cancer; Docosahexaenoic acid; Weight loss; Obesity; Polyunsaturated fatty acid; Fatty acid; Fish <Actinopterygii>; Pathology; Biology","score_opus":0.06016806048737953,"score_gpt":0.4422962401578623,"score_spread":0.38212817967048274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979666460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956481,0.0003272288,7.483062e-7,0.0022606698,0.0003601903,0.00079611497,0.000004041906,0.0000044112176,0.0005985062],"genre_scores_gemma":[0.99839807,0.00027149534,0.00007565478,0.00096927595,0.00018869354,0.000032592212,3.333824e-7,0.000019324101,0.000044562377],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963346,0.0012207815,0.0014317137,0.00023705042,0.0004480435,0.00032778844],"domain_scores_gemma":[0.99466026,0.0036273582,0.0010981284,0.00013837198,0.00016844264,0.00030744687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035962174,0.00016908707,0.0016834922,0.00022590416,0.000051929634,0.00001392619,0.00013312289,0.00022931102,0.00005416625],"category_scores_gemma":[0.0009575279,0.00010084076,0.00011091549,0.00015701423,0.00022992663,0.0001154001,0.00003457004,0.0010536768,0.0000019757267],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40360263,0.00196818,0.4565044,0.00006429644,0.00014154232,0.000022872306,0.00020231454,0.000033152035,0.00000950946,0.0000016792787,0.00013666852,0.13731274],"study_design_scores_gemma":[0.5497597,0.16439453,0.28378946,0.00046711866,0.00016059319,0.0000075706557,0.00007144403,0.00015950836,0.000063844185,0.000006696209,0.0009935861,0.00012599831],"about_ca_topic_score_codex":0.00006752425,"about_ca_topic_score_gemma":0.0007271554,"teacher_disagreement_score":0.17271496,"about_ca_system_score_codex":0.00011790861,"about_ca_system_score_gemma":0.00010743132,"threshold_uncertainty_score":0.45777598},"labels":[],"label_agreement":null},{"id":"W1983188030","doi":"10.1200/jco.2008.17.1785","title":"Stopping Trials for Benefit Can (Sometimes) Benefit Patients","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.8032437598853653,"score_gpt":0.5879681210106045,"score_spread":0.21527563887476087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983188030","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016094303,0.003007458,0.00087665196,0.9590485,0.015258646,0.0016349629,0.0016495655,0.000020430238,0.0024094735],"genre_scores_gemma":[0.0014732649,0.0024542902,0.009434879,0.9454949,0.03687575,0.00009307,0.00025090578,0.00013547871,0.0037874808],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95439327,0.0018709536,0.041758098,0.0008050346,0.00035027514,0.0008223837],"domain_scores_gemma":[0.8828599,0.05028412,0.06459038,0.00067725545,0.001087077,0.0005012726],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.105750486,0.0005014966,0.013007089,0.001009681,0.00022334339,0.00006619824,0.0010549829,0.0034157932,0.00067993556],"category_scores_gemma":[0.13017553,0.00052146154,0.0029223126,0.00018030069,0.0002068127,0.00035758057,0.000104387684,0.0033811918,0.00040153434],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020937777,0.00037001044,0.009168953,0.0002644679,0.0008625949,0.000036671627,0.00016102794,0.00006512176,2.8801153e-8,0.0014555267,0.98161423,0.00579197],"study_design_scores_gemma":[0.0064504044,0.0032584171,0.009955248,0.00019370436,0.00014999887,0.000033198052,0.00003686076,0.000107805296,2.5401408e-7,0.0182259,0.9611238,0.0004643722],"about_ca_topic_score_codex":0.00019575616,"about_ca_topic_score_gemma":0.00009681547,"teacher_disagreement_score":0.07153336,"about_ca_system_score_codex":0.0016743591,"about_ca_system_score_gemma":0.0022955919,"threshold_uncertainty_score":0.9997237},"labels":[],"label_agreement":null},{"id":"W1983718773","doi":"10.1200/jco.2013.52.3290","title":"Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medulloblastoma; Medicine; Hydrocephalus; Neuropsychology; Cerebrospinal fluid; Radiation therapy; Pediatrics; Surgery; Internal medicine; Cognition; Psychiatry; Pathology","score_opus":0.07796224528143117,"score_gpt":0.435449394474195,"score_spread":0.3574871491927638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983718773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667686,0.000020656009,0.00002500367,0.0023856242,0.00011394092,0.00018438968,0.000003695381,0.0000030697172,0.00058678194],"genre_scores_gemma":[0.9986061,0.000020581054,0.00039930863,0.00088113867,0.00007310961,0.0000029157986,0.000002231096,0.000008578554,0.000006046762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790645,0.0002457789,0.0013399028,0.00014488975,0.00021616128,0.00014684658],"domain_scores_gemma":[0.99632645,0.0021134256,0.0008988954,0.00015053625,0.00027529735,0.00023538149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007127803,0.00011659494,0.0010390726,0.00017577884,0.00002021711,0.0000039234333,0.00008184779,0.00014952073,0.00006416946],"category_scores_gemma":[0.0032044707,0.000064595515,0.00021784895,0.00012588047,0.00019344233,0.000037781403,0.000026530292,0.00042064575,0.000007421207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049186028,0.0054950286,0.96663696,0.0000072430303,0.00013371416,0.000035873665,0.000027424916,0.000042434185,0.000009064281,0.00003973642,0.00045239265,0.02220152],"study_design_scores_gemma":[0.012312269,0.09970429,0.886849,0.000039973987,0.00013640277,0.000046216534,0.000006252488,0.000120917306,0.0000029800865,0.00004554471,0.0006917122,0.000044473665],"about_ca_topic_score_codex":0.000015246738,"about_ca_topic_score_gemma":0.00003095092,"teacher_disagreement_score":0.09420926,"about_ca_system_score_codex":0.00007524669,"about_ca_system_score_gemma":0.00020046344,"threshold_uncertainty_score":0.38362822},"labels":[],"label_agreement":null},{"id":"W1984353922","doi":"10.1200/jco.2007.11.3902","title":"Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Carcinogenesis; Ovarian cancer; Genome instability; Cancer research; DNA repair; DNA damage; Medicine; Cancer; Synthetic lethality; Somatic cell; Disease; Mutation; Mechanism (biology); Bioinformatics; Biology; Genetics; Gene; Pathology; Internal medicine; DNA","score_opus":0.11743347313249355,"score_gpt":0.4664257642856814,"score_spread":0.34899229115318786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984353922","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02865826,0.967689,0.000045241806,0.00072479615,0.0019154792,0.00043402085,0.00008395431,0.0000037958443,0.00044546064],"genre_scores_gemma":[0.0030749645,0.9912213,0.001424781,0.00069859385,0.003393589,0.000025408,0.000030494808,0.000035726203,0.00009511365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99106985,0.0027173888,0.0051872134,0.00046603513,0.0003128024,0.00024668517],"domain_scores_gemma":[0.99202156,0.001997087,0.0049990816,0.0005168846,0.00031362564,0.0001517572],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006669829,0.0002891043,0.0028545307,0.00013307702,0.000049035305,0.000007950916,0.00040352464,0.0015054694,0.00002419484],"category_scores_gemma":[0.0044871047,0.00019231484,0.0014013851,0.00024363642,0.0008154792,0.000010740402,0.00014075727,0.0016804746,0.0000027483409],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048753622,0.0006299284,0.00043956068,0.0006591509,0.00042444878,0.00030076894,0.000056019304,0.000009606859,0.000026456823,0.00006841312,0.010500502,0.9863976],"study_design_scores_gemma":[0.0018723258,0.002958777,0.002327074,0.0013074154,0.0003631554,0.00082270155,0.000028813687,0.000004562756,0.000020085537,0.00010392252,0.9900079,0.0001832922],"about_ca_topic_score_codex":0.000022529735,"about_ca_topic_score_gemma":0.00016692589,"teacher_disagreement_score":0.98621434,"about_ca_system_score_codex":0.00013444951,"about_ca_system_score_gemma":0.006780395,"threshold_uncertainty_score":0.9997908},"labels":[],"label_agreement":null},{"id":"W1985328983","doi":"10.1200/jco.2007.12.8033","title":"Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; American Society of Clinical Oncology","keywords":"Medicine; Tissue microarray; Oncology; Internal medicine; Human Epidermal Growth Factor Receptor 2; Biomarker; Clinical Oncology; Trastuzumab; Epidermal growth factor receptor; Estrogen receptor; Immunohistochemistry; Pathology; Cancer; Breast cancer; Biology","score_opus":0.6171535550304519,"score_gpt":0.662183900523995,"score_spread":0.04503034549354312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985328983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562887,0.00012058134,0.0016672508,0.038513336,0.00023532192,0.0017590241,0.0014034497,0.0000023590546,0.0000099925865],"genre_scores_gemma":[0.9534707,0.00023839547,0.043558564,0.002148185,0.00039658675,0.00015511768,0.000008642542,0.000019280033,0.0000045297065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922943,0.001091524,0.0055632433,0.00034606794,0.00038721817,0.0003176273],"domain_scores_gemma":[0.9796314,0.011696144,0.006004799,0.00033739136,0.002138332,0.00019190476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0134263765,0.0001690615,0.002454156,0.00017569361,0.000045360404,0.0000022433533,0.0004889064,0.00020178882,0.000020989737],"category_scores_gemma":[0.007849749,0.000107237574,0.0005607657,0.00053415087,0.0011416489,0.000055987828,0.00009331077,0.00070849323,1.8957378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032393436,0.0019124974,0.9130435,0.00024614035,0.00015136284,0.0000037946568,0.0003330205,0.00001681072,0.037523836,0.00012499097,0.0007110463,0.04269364],"study_design_scores_gemma":[0.00397934,0.00966637,0.98045963,0.00021876098,0.00015389286,0.000007825081,0.0011549186,0.00024059451,0.002933277,0.000054265845,0.0010472118,0.00008393278],"about_ca_topic_score_codex":0.0015588894,"about_ca_topic_score_gemma":0.0023143755,"teacher_disagreement_score":0.067416094,"about_ca_system_score_codex":0.00039209743,"about_ca_system_score_gemma":0.0019386114,"threshold_uncertainty_score":0.93974495},"labels":[],"label_agreement":null},{"id":"W1986337659","doi":"10.1200/jco.2013.52.0288","title":"Wither the Cooperative Groups?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.17177293971052338,"score_gpt":0.5331492846017156,"score_spread":0.36137634489119225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986337659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90580964,0.0005914827,0.000041400257,0.06720249,0.0016114189,0.0002631585,5.1343534e-7,0.0000051237207,0.024474777],"genre_scores_gemma":[0.9765913,0.00045169852,0.00046368624,0.016317414,0.0022459312,0.0000101747855,5.478646e-7,0.0000082387205,0.003911042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983482,0.0003301164,0.0009696867,0.00007894726,0.00014186914,0.00013117469],"domain_scores_gemma":[0.9970006,0.0016824834,0.000631405,0.00009680073,0.00039679086,0.00019195971],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010688124,0.000076120086,0.00070742203,0.0000316711,0.000036774978,0.000006607734,0.00010409932,0.00016157777,0.0038408462],"category_scores_gemma":[0.00056581217,0.000034097837,0.00026429835,0.00007599565,0.00024824063,0.000076838514,0.000023133274,0.00068527757,0.00023021322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004675586,0.004882295,0.10566771,0.000011697645,0.0019941735,0.00055061124,0.000711301,0.000012877067,0.0012557061,0.0008389414,0.5760085,0.30339062],"study_design_scores_gemma":[0.011270978,0.026094807,0.3797876,0.000023531387,0.00062045903,0.00071436237,0.00029974058,0.000065884946,0.00014392397,0.0007979138,0.5801129,0.000067928006],"about_ca_topic_score_codex":0.000030900836,"about_ca_topic_score_gemma":0.000024001318,"teacher_disagreement_score":0.30332267,"about_ca_system_score_codex":0.00006866681,"about_ca_system_score_gemma":0.000735323,"threshold_uncertainty_score":0.9970698},"labels":[],"label_agreement":null},{"id":"W1986821945","doi":"10.1200/jco.2008.17.9341","title":"Flawed Inferences About Screening Mammography's Benefit Based on Observational Data","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Observational study; Mammography; Medical physics; Breast cancer; Family medicine; Gynecology; Cancer; Internal medicine","score_opus":0.669949649069125,"score_gpt":0.5416955548358684,"score_spread":0.12825409423325662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986821945","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01452941,0.0014163159,0.0020797811,0.9688051,0.0037330643,0.00036625378,0.00019012351,0.000036419875,0.008843532],"genre_scores_gemma":[0.010729905,0.0012944266,0.043978788,0.91874266,0.02394221,0.000005001198,0.0007413883,0.000046018176,0.00051959313],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924017,0.0004766811,0.0039933417,0.0005961024,0.0020261907,0.0005059713],"domain_scores_gemma":[0.98693097,0.006128688,0.004341254,0.00094266015,0.0012469175,0.00040949197],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004030947,0.00039682584,0.002922798,0.00043510145,0.00012121689,0.000035205652,0.0013031503,0.00224855,0.00047837634],"category_scores_gemma":[0.006646806,0.00029448164,0.0010786462,0.0003632081,0.00044944856,0.0003011332,0.00017847326,0.0076610358,0.000028180168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002117723,0.00021565169,0.097152114,0.000047129746,0.00043821317,0.0060346317,0.0000071714035,0.00014696574,8.0563757e-7,0.000020410216,0.8273139,0.06650527],"study_design_scores_gemma":[0.0033758862,0.00682052,0.20833655,0.001090473,0.00055731065,0.00047278873,0.00001182217,0.0013646893,9.024105e-7,0.00017188332,0.77757996,0.00021718934],"about_ca_topic_score_codex":0.00011544913,"about_ca_topic_score_gemma":0.000056599463,"teacher_disagreement_score":0.111184426,"about_ca_system_score_codex":0.0001452744,"about_ca_system_score_gemma":0.004819994,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W1987734785","doi":"10.1200/jco.2009.25.4300","title":"Reply to J.B. Aragon-Ching","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Medicine","score_opus":0.1676483901266678,"score_gpt":0.5174934126130348,"score_spread":0.34984502248636706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987734785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75267416,0.00066958496,0.00018413173,0.21980707,0.0011930078,0.00010073188,2.9391296e-7,0.000008664679,0.025362365],"genre_scores_gemma":[0.9488308,0.00027918132,0.005975965,0.039586868,0.004245474,4.1016455e-7,1.3944677e-7,0.0000048564402,0.001076335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782413,0.00013574577,0.0014695708,0.00016259111,0.0002486786,0.0001593022],"domain_scores_gemma":[0.9978871,0.00056613405,0.00060201593,0.00014713439,0.00046161123,0.0003360258],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030043107,0.00008057174,0.0011343419,0.00008722518,0.0000394459,0.0000032355888,0.00008966046,0.00011009532,0.000027071876],"category_scores_gemma":[0.009305269,0.00004662796,0.00037369182,0.000119237135,0.00007634356,0.00006127719,0.000029345763,0.0007105224,0.000045918794],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005776445,0.0019976308,0.024533516,0.000009914089,0.0003791601,0.001676242,0.0003909896,0.000015512562,0.0020244305,0.0006027111,0.06048611,0.90210736],"study_design_scores_gemma":[0.0013364468,0.016619029,0.54652834,0.000042469062,0.00010008141,0.00039469052,0.00012029226,0.0000016550472,0.00013289292,0.0010796083,0.43360028,0.000044220298],"about_ca_topic_score_codex":0.0000038938065,"about_ca_topic_score_gemma":0.0000012380011,"teacher_disagreement_score":0.90206313,"about_ca_system_score_codex":0.000054387903,"about_ca_system_score_gemma":0.00043409888,"threshold_uncertainty_score":0.99903977},"labels":[],"label_agreement":null},{"id":"W1988166197","doi":"10.1200/jco.2011.37.4587","title":"Reply to M.J. Rother","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier; Sanofi; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Internal medicine","score_opus":0.455165440486149,"score_gpt":0.4575689510546844,"score_spread":0.0024035105685354385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988166197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9316673,0.00029022156,0.00027988426,0.012701565,0.00086553657,0.00020512243,6.981939e-7,0.00001063536,0.053978983],"genre_scores_gemma":[0.96320724,0.00006299815,0.018413506,0.016010992,0.0009129113,0.00000275479,3.9972994e-7,0.000013210527,0.0013760063],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980902,0.00019066193,0.0012877932,0.00011107207,0.00017501254,0.0001452479],"domain_scores_gemma":[0.99822634,0.0003730685,0.00051351497,0.00016315894,0.00024151565,0.00048237966],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017472317,0.000077949466,0.0008257218,0.00009146856,0.000014912308,0.0000024076376,0.00009463761,0.00017849567,0.0011560145],"category_scores_gemma":[0.0014361717,0.0000498082,0.00045102395,0.00009396799,0.000053274784,0.000043874694,0.000024086557,0.00036810077,0.00019420548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002484561,0.0013538535,0.7836843,0.0000049164023,0.0002844024,0.0021994615,0.00033751145,4.673114e-8,0.000050522187,0.00010949398,0.025549103,0.18394184],"study_design_scores_gemma":[0.003529765,0.023276446,0.42521247,0.000040566672,0.00037392444,0.00042286664,0.000044924327,0.000009842872,0.00096752186,0.00033220576,0.5457243,0.000065157044],"about_ca_topic_score_codex":0.000034435514,"about_ca_topic_score_gemma":0.0000039241663,"teacher_disagreement_score":0.5201752,"about_ca_system_score_codex":0.000046204084,"about_ca_system_score_gemma":0.00051236537,"threshold_uncertainty_score":0.99975705},"labels":[],"label_agreement":null},{"id":"W1988228415","doi":"10.1200/jco.2008.21.1425","title":"Late Mortality Among 5-Year Survivors of Childhood Cancer: A Summary From the Childhood Cancer Survivor Study","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":781,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Relative risk; Cause of death; National Death Index; Standardized mortality ratio; Mortality rate; Cancer; Cohort; Cohort study; Internal medicine; Relative survival; Pediatrics; Hazard ratio; Disease; Confidence interval; Cancer registry","score_opus":0.17798293909912097,"score_gpt":0.5072822490157154,"score_spread":0.3292993099165944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988228415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1717212,0.81623113,0.0000037261307,0.0023595728,0.005520842,0.0028115024,0.00059213856,0.000043511365,0.00071635214],"genre_scores_gemma":[0.011923422,0.9746226,0.00016207373,0.0022761826,0.010493944,0.00008724993,0.00006660428,0.00017588364,0.00019201235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9732722,0.008474207,0.013700501,0.0011776924,0.0024884471,0.00088696793],"domain_scores_gemma":[0.96622604,0.0123772165,0.017320072,0.0018631701,0.0011190851,0.0010944399],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.017710723,0.0012173273,0.017866673,0.0003613638,0.00017234989,0.000047897778,0.002060013,0.0019969465,0.0005750584],"category_scores_gemma":[0.0065584937,0.00075421226,0.005511816,0.0010395234,0.00086929154,0.000261145,0.00044162915,0.007196982,0.000022371465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006116162,0.0106047485,0.25037348,0.0013360189,0.012476636,0.00034499695,0.0015937678,0.0000092966675,6.1724904e-8,0.000008746548,0.0055503985,0.71709025],"study_design_scores_gemma":[0.0058662253,0.0056996234,0.60118496,0.016869316,0.015418433,0.000041710613,0.00049316615,0.0000012012948,3.0223117e-7,0.000119729215,0.35378498,0.000520368],"about_ca_topic_score_codex":0.032247346,"about_ca_topic_score_gemma":0.061008252,"teacher_disagreement_score":0.71656984,"about_ca_system_score_codex":0.00064971135,"about_ca_system_score_gemma":0.01563917,"threshold_uncertainty_score":0.9994909},"labels":[],"label_agreement":null},{"id":"W1989000254","doi":"10.1200/jco.2002.08.017","title":"Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review","year":2002,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Carcinoembryonic antigen; Epitope; Medicine; Immunology; Vaccination; Immunogenicity; Major histocompatibility complex; Antigen; Immunotherapy; MHC class I; Cytotoxic T cell; CD8; Antibody; Cancer; Immune system; Virology; Biology; Internal medicine; In vitro","score_opus":0.42543386558996743,"score_gpt":0.6138707632001857,"score_spread":0.1884368976102183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989000254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014640341,0.98772794,0.00013537545,0.0068133012,0.0005963046,0.0016171287,0.000021778435,0.000014560353,0.003058999],"genre_scores_gemma":[0.00003482144,0.9869239,0.0016860107,0.006189347,0.0036067066,0.00012964089,0.000021152957,0.000060167837,0.00134828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99334186,0.000411925,0.0051000644,0.00039810603,0.0003582619,0.000389779],"domain_scores_gemma":[0.9902154,0.0042691766,0.003762029,0.00048143335,0.0005854878,0.00068645907],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003024451,0.0004005968,0.008116459,0.0000910594,0.000057768622,0.000009368267,0.00047341504,0.00095086294,0.0012286052],"category_scores_gemma":[0.0031906725,0.00025193818,0.0036867736,0.0003556797,0.00016845031,0.000051780076,0.000042579093,0.0021934402,0.00011570304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017183497,0.0009397901,0.000031866293,0.036610827,0.0012676638,0.00015247529,0.0000028668567,9.328694e-8,0.0000016027055,0.00008342372,0.0270392,0.93369836],"study_design_scores_gemma":[0.0021439642,0.0027790773,0.000029992521,0.024933813,0.010447819,0.0022295706,0.0000027393517,0.000010492665,0.0000023638902,0.00021077562,0.95699835,0.00021104685],"about_ca_topic_score_codex":8.111347e-7,"about_ca_topic_score_gemma":1.5912094e-7,"teacher_disagreement_score":0.9334873,"about_ca_system_score_codex":0.0002196576,"about_ca_system_score_gemma":0.0040781815,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W1989169445","doi":"10.1200/jco.2009.24.0333","title":"Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Vinorelbine; Medicine; Hazard ratio; Internal medicine; Lung cancer; Stage (stratigraphy); Cisplatin; Oncology; Chemotherapy; Cancer; Adjuvant; Surgery; Gastroenterology; Confidence interval","score_opus":0.12710109933766883,"score_gpt":0.46776768107565503,"score_spread":0.3406665817379862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989169445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954096,0.00043024015,0.00017773078,0.0022227862,0.00023226286,0.0011400013,0.000038768067,0.0000048484726,0.00034375643],"genre_scores_gemma":[0.99683183,0.0011816524,0.0013289757,0.00023081574,0.00017978015,0.000016245158,0.000086219756,0.000010134451,0.00013433376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944546,0.0008157975,0.003820914,0.00024658407,0.00045821076,0.00020388022],"domain_scores_gemma":[0.99194777,0.0029266675,0.0038888059,0.00022009973,0.00079023186,0.00022640645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036681409,0.0001950581,0.0052852114,0.00042946983,0.000033516837,0.0000058069018,0.00012227145,0.00023457065,0.00024100981],"category_scores_gemma":[0.00075458456,0.00012571458,0.00053272425,0.0007979629,0.0002094615,0.000072702846,0.000030273244,0.00046805234,1.2498461e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9337209,0.0071023377,0.048979115,0.000057821297,0.0044328813,0.00016659251,0.0002984958,0.0014900477,0.0003991421,0.000025094101,0.00041015874,0.002917403],"study_design_scores_gemma":[0.8085525,0.023698224,0.13673112,0.00020099472,0.009111434,0.0000037529824,0.00006622093,0.021085288,0.00023618012,0.000008323877,0.00021477173,0.0000911594],"about_ca_topic_score_codex":0.00094144425,"about_ca_topic_score_gemma":0.002326548,"teacher_disagreement_score":0.12516838,"about_ca_system_score_codex":0.00033604153,"about_ca_system_score_gemma":0.0014185392,"threshold_uncertainty_score":0.5126492},"labels":[],"label_agreement":null},{"id":"W1989412643","doi":"10.1200/jco.2012.41.8681","title":"Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer; Epidemiology; Oncology; Host factors; Family history; Internal medicine; Bioinformatics; Immunology; Biology","score_opus":0.3038633936729731,"score_gpt":0.5563747030338985,"score_spread":0.25251130936092536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989412643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009818523,0.98989564,0.000272381,0.00024342783,0.0042848005,0.0007210982,0.000058151556,0.00000665413,0.0035359913],"genre_scores_gemma":[0.00023473038,0.9853175,0.0090687005,0.00025470075,0.004554982,0.000025356028,0.000024992085,0.000034782315,0.00048425604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949752,0.00066977734,0.0036007673,0.00025711648,0.0002193442,0.00027777272],"domain_scores_gemma":[0.991175,0.0027627798,0.0051178057,0.00020618268,0.00027850864,0.00045973776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051381118,0.00027757662,0.005044173,0.00017858764,0.000058866113,0.00002259778,0.0001276379,0.0009685587,0.00048725706],"category_scores_gemma":[0.0004105768,0.00017570263,0.0013466851,0.00006872534,0.00019978019,0.00023295013,0.000041470586,0.0019350922,0.0000049941195],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047666035,0.00030500008,0.00010322689,0.005232361,0.0011424836,0.000050931096,0.00003321903,3.6876446e-7,7.6622825e-7,0.00015061142,0.004935592,0.9875688],"study_design_scores_gemma":[0.003213606,0.007406436,0.00072358205,0.0017132296,0.0070842495,0.002225083,0.00016934525,0.0000066309335,2.018353e-7,0.00022333981,0.9770795,0.00015476363],"about_ca_topic_score_codex":0.000004715134,"about_ca_topic_score_gemma":0.000014468351,"teacher_disagreement_score":0.987414,"about_ca_system_score_codex":0.00039169664,"about_ca_system_score_gemma":0.011330644,"threshold_uncertainty_score":0.9942742},"labels":[],"label_agreement":null},{"id":"W1990009253","doi":"10.1200/jco.2005.05.023","title":"Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fluorescence in situ hybridization; Gene expression profiling; Multiple myeloma; Cytogenetics; Pharmacogenomics; Chromosomal translocation; Computational biology; Bioinformatics; Gene; Gene expression; Genetics; Chromosome; Internal medicine; Biology; Pharmacology","score_opus":0.28515556573907846,"score_gpt":0.5364317676440781,"score_spread":0.2512762019049996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990009253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012401067,0.9861003,0.000041388827,0.00013679419,0.00017873677,0.00095691567,0.000010617494,0.000003931743,0.00017021596],"genre_scores_gemma":[0.006841295,0.9761422,0.015990758,0.00006204139,0.00082157645,0.000018478928,0.000006287255,0.000030547828,0.000086793734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956297,0.0007453402,0.0026956168,0.00027384298,0.00040153472,0.0002539399],"domain_scores_gemma":[0.9926341,0.0038662693,0.0024733923,0.0002031578,0.00031971105,0.0005033802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018111548,0.00024983275,0.003821683,0.00018021233,0.000032215616,0.000008429218,0.00013645914,0.0006368458,0.000027545295],"category_scores_gemma":[0.0021434608,0.0001459174,0.00046513614,0.00010469818,0.00034817794,0.000031155636,0.000092345035,0.0010961671,0.000003544253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005717462,0.0006842145,0.007274753,0.0032156492,0.000638967,0.000410168,0.0000135482705,2.0198345e-7,0.00005733699,0.000005232693,0.00003039295,0.9870978],"study_design_scores_gemma":[0.007467487,0.01751072,0.021671228,0.011361019,0.0051667956,0.002400338,0.000024762716,0.00006259966,0.00013089938,0.00008095506,0.93387586,0.00024731024],"about_ca_topic_score_codex":0.0000012544997,"about_ca_topic_score_gemma":0.0000013895958,"teacher_disagreement_score":0.9868505,"about_ca_system_score_codex":0.00007800068,"about_ca_system_score_gemma":0.0021872176,"threshold_uncertainty_score":0.5950339},"labels":[],"label_agreement":null},{"id":"W1990811913","doi":"10.1200/jco.2007.15.3312","title":"Palliative Thoracic Radiotherapy for Lung Cancer: A Systematic Review","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Lung cancer; Randomized controlled trial; Palliative care; Performance status; Dysphagia; Dose fractionation; Internal medicine; Surgery; Cancer","score_opus":0.2644821838927352,"score_gpt":0.6246579621624808,"score_spread":0.3601757782697456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990811913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001080714,0.9888663,0.00013010688,0.003107371,0.0017275993,0.0059709563,0.000037247126,0.000009376121,0.00014994938],"genre_scores_gemma":[6.13675e-7,0.9893023,0.002585403,0.003942879,0.0025527307,0.0011636126,0.000013870037,0.00006808337,0.00037055038],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908184,0.0012478795,0.0068605496,0.00033733866,0.00044686534,0.00028897688],"domain_scores_gemma":[0.97966015,0.008565126,0.010236251,0.00039948113,0.0007095374,0.00042947664],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0029000747,0.00044126442,0.019392485,0.00014745754,0.000048904316,0.000007785624,0.00029367674,0.00074478815,0.000104819905],"category_scores_gemma":[0.0035750698,0.00023049241,0.0055115223,0.00022302922,0.00011219069,0.000050597144,0.000022869574,0.0011061904,0.0000062493905],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014963375,0.0006760522,0.00006209041,0.57791746,0.0069561107,0.0003173721,0.000013469417,1.2926793e-7,1.304858e-9,0.000009131414,0.033104666,0.38079387],"study_design_scores_gemma":[0.0014218637,0.003264024,0.000008591978,0.467283,0.028514909,0.00054369407,0.000001510464,0.00000430289,2.0462496e-8,0.0000029396472,0.498856,0.00009910469],"about_ca_topic_score_codex":0.0000065178997,"about_ca_topic_score_gemma":0.000007825934,"teacher_disagreement_score":0.46575135,"about_ca_system_score_codex":0.002469464,"about_ca_system_score_gemma":0.008676907,"threshold_uncertainty_score":0.996943},"labels":[],"label_agreement":null},{"id":"W1991292584","doi":"10.1200/jco.2009.26.4549","title":"Associations Among Cancer Survivorship Discussions, Patient and Physician Expectations, and Receipt of Follow-Up Care","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Survivorship curve; Concordance; Family medicine; Receipt; Cancer; Cancer survivorship; Primary care; Internal medicine","score_opus":0.051103109828822546,"score_gpt":0.4152388822490513,"score_spread":0.36413577242022876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991292584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905787,0.0014810595,0.0000082306615,0.003626947,0.003056122,0.00014090775,0.00003807322,0.000005492361,0.0010644505],"genre_scores_gemma":[0.9978894,0.0005417833,0.0002846449,0.0004956294,0.0006509805,0.0000074846116,0.000007276952,0.000012479357,0.00011031699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979256,0.00028173797,0.0012249453,0.0001468007,0.00028062903,0.00014030191],"domain_scores_gemma":[0.9964121,0.0012093405,0.0013122844,0.00013221006,0.0006423311,0.00029172192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007269184,0.000102722675,0.0009097592,0.00009190677,0.00006683051,0.000008468289,0.00006497542,0.00029263814,0.000039053168],"category_scores_gemma":[0.0018790181,0.000070281945,0.00023833677,0.00012892344,0.00023044898,0.000104498904,0.000039624185,0.00083120813,5.7117137e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046105278,0.00024600094,0.74673194,0.000036281588,0.00017708071,0.000017175464,0.006556888,4.8727713e-7,0.0003171288,0.0001498062,0.0010892719,0.24421689],"study_design_scores_gemma":[0.0028158154,0.0022125682,0.97136164,0.00013865289,0.00041955218,0.000012470912,0.01478754,0.000009352065,0.00022917762,0.00023186998,0.0076826373,0.00009871297],"about_ca_topic_score_codex":0.00088325795,"about_ca_topic_score_gemma":0.03099506,"teacher_disagreement_score":0.24411818,"about_ca_system_score_codex":0.00006231089,"about_ca_system_score_gemma":0.0006009672,"threshold_uncertainty_score":0.98668677},"labels":[],"label_agreement":null},{"id":"W1992514016","doi":"10.1200/jco.2012.47.5210","title":"Randomized Controlled Trial of Mindfulness-Based Cancer Recovery Versus Supportive Expressive Group Therapy for Distressed Survivors of Breast Cancer (MINDSET)","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; BC Cancer Agency; Alberta Health Services","funders":"Canadian Breast Cancer Research Alliance; Alberta Cancer Foundation","keywords":"Medicine; Randomized controlled trial; Breast cancer; Mindfulness; Cancer; Psychotherapist; Mindset; Oncology; Internal medicine; Clinical psychology; Psychology","score_opus":0.06526885736229851,"score_gpt":0.43198656185800555,"score_spread":0.36671770449570706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992514016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979878,0.0009820664,0.00084315636,0.004529352,0.009010475,0.0041755484,0.00024880463,0.0000060122443,0.00032657705],"genre_scores_gemma":[0.9949223,0.0006327672,0.00014357394,0.000541957,0.0020817101,0.0014532611,0.000016676368,0.000031822798,0.00017593987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928669,0.0013833898,0.0045662588,0.00027095876,0.0005967212,0.00031579923],"domain_scores_gemma":[0.9699342,0.019878294,0.0073093707,0.0002605748,0.0022920638,0.00032549436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045126616,0.00027268424,0.006756919,0.00018627029,0.000032055108,0.000009137924,0.00025108166,0.00053600664,0.0018131218],"category_scores_gemma":[0.0043599424,0.00016719745,0.0030605656,0.00016402233,0.00058870274,0.00014213391,0.000022988996,0.00055144535,9.525896e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91482687,0.0023102448,0.0012300322,0.00009748681,0.0028479788,0.00001695579,0.00013385118,0.00003788604,0.0002581148,0.000028924433,0.0016298483,0.07658179],"study_design_scores_gemma":[0.9740624,0.016062528,0.003230657,0.0003134963,0.00170109,0.0000052148685,0.00040570053,0.00013324345,0.0027376404,0.0002632175,0.0009304363,0.0001543624],"about_ca_topic_score_codex":0.0028209214,"about_ca_topic_score_gemma":0.0018322378,"teacher_disagreement_score":0.07642743,"about_ca_system_score_codex":0.00017923054,"about_ca_system_score_gemma":0.0036457235,"threshold_uncertainty_score":0.9990994},"labels":[],"label_agreement":null},{"id":"W1992538168","doi":"10.1200/jco.2002.20.4.966","title":"Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cervical cancer; Cervix; Chemotherapy; Cisplatin; Radiation therapy; Hazard ratio; Stage (stratigraphy); Oncology; Brachytherapy; Lymph node; Internal medicine; Cancer; Urology; Surgery; Confidence interval","score_opus":0.07049396249064543,"score_gpt":0.42111947435511166,"score_spread":0.3506255118644662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992538168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953993,0.0011255229,0.000025280044,0.001647673,0.00038118646,0.00069382775,0.000003190653,0.0000039222887,0.0007201106],"genre_scores_gemma":[0.9967369,0.0006940847,0.0011969439,0.00092373183,0.0003139479,0.000010272669,8.187384e-7,0.00002064368,0.00010264754],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972855,0.00025458122,0.0015682334,0.0001957688,0.00048584602,0.00021007648],"domain_scores_gemma":[0.99721307,0.00070045853,0.0015079468,0.0001702932,0.00016535199,0.00024287999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006253574,0.00017006704,0.0017263166,0.00009964741,0.000031902462,0.0000049694763,0.00014149584,0.00018346179,0.00025407382],"category_scores_gemma":[0.00020142499,0.00008097579,0.00019033623,0.00031351837,0.00032944765,0.00007664252,0.00001779325,0.0006557991,3.6603473e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32294923,0.008829208,0.52961826,0.000026096099,0.00021152152,0.00002043404,0.00019042108,0.000035453708,0.000036682894,0.0000041540347,0.00006550569,0.13801302],"study_design_scores_gemma":[0.6968502,0.05929415,0.2408604,0.00013663735,0.00025058133,0.000019416118,0.000026783444,0.00017021896,0.000116977644,0.000014342597,0.0021700233,0.000090260786],"about_ca_topic_score_codex":0.000045331428,"about_ca_topic_score_gemma":0.00006732376,"teacher_disagreement_score":0.37390098,"about_ca_system_score_codex":0.00016276177,"about_ca_system_score_gemma":0.00030088355,"threshold_uncertainty_score":0.33020967},"labels":[],"label_agreement":null},{"id":"W1992678256","doi":"10.1200/jco.2010.33.2247","title":"Natural Course of Insomnia Comorbid With Cancer: An 18-Month Longitudinal Study","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sleep and related disorders","field":"Psychology","cited_by":387,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Insomnia; Incidence (geometry); Longitudinal study; Cancer; Breast cancer; Internal medicine; Perioperative; Prostate cancer; Pediatrics; Surgery; Psychiatry; Pathology","score_opus":0.21830815898577116,"score_gpt":0.5137084252299491,"score_spread":0.2954002662441779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992678256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800862,0.0019668252,0.000028219449,0.00035824344,0.0047959154,0.00022744697,0.0000040997243,0.0000124754515,0.012520563],"genre_scores_gemma":[0.9982412,0.00025080147,0.00046097435,0.000348872,0.00046199677,0.0000060311945,0.0000010551314,0.00002323792,0.00020581606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962265,0.00091774185,0.0020033154,0.00025929807,0.00029325526,0.00029990295],"domain_scores_gemma":[0.99591,0.0006649889,0.002287844,0.00032473987,0.0005043853,0.00030806882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020151336,0.00018727362,0.0013229685,0.00013043999,0.000049063412,0.0000043961445,0.0004840373,0.00043412147,0.0019791045],"category_scores_gemma":[0.00018745879,0.0001144751,0.00027952407,0.0002063361,0.0005208195,0.0001542797,0.000042210493,0.0015511055,0.000019078787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01170192,0.020830695,0.880109,0.000004118716,0.0034524284,0.0010419305,0.0032820068,0.000011698309,0.00000567084,0.00020347044,0.0036826187,0.07567444],"study_design_scores_gemma":[0.014729725,0.040205333,0.9344973,0.000030395475,0.0010717551,0.00022644999,0.0058940165,0.000011721412,0.000006529842,0.00016172836,0.003014754,0.00015031821],"about_ca_topic_score_codex":0.00075954426,"about_ca_topic_score_gemma":0.0020862527,"teacher_disagreement_score":0.07552412,"about_ca_system_score_codex":0.0000416055,"about_ca_system_score_gemma":0.0006855172,"threshold_uncertainty_score":0.9989332},"labels":[],"label_agreement":null},{"id":"W1993332165","doi":"10.1200/jco.2009.25.2874","title":"Physicians' Awareness and Attitudes Toward Decision Aids for Patients With Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Decision aids; Specialty; Family medicine; Psychological intervention; Decision analysis; Population; Multivariate analysis; Clinical Practice; MEDLINE; Alternative medicine; Nursing; Internal medicine; Environmental health; Pathology","score_opus":0.38755427486702776,"score_gpt":0.6018456512576631,"score_spread":0.21429137639063534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993332165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876462,0.0003484192,0.00079824467,0.0051228586,0.0052133915,0.0007003638,0.000028809081,0.000011714328,0.00012999181],"genre_scores_gemma":[0.9652028,0.00026411944,0.030758021,0.0026466437,0.00097526005,0.00009697073,0.000005085648,0.000022208415,0.00002888528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639046,0.00062619575,0.002187297,0.00019314335,0.0003074541,0.00029545827],"domain_scores_gemma":[0.98177254,0.012818865,0.002652593,0.00033475694,0.002140227,0.00028102542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015090749,0.00012451818,0.0009253209,0.0000867992,0.0003761042,0.0000057876987,0.0003868505,0.00049093866,0.00007520313],"category_scores_gemma":[0.0055470327,0.00008310257,0.00013462195,0.00010633969,0.00021448552,0.00020939737,0.0001437037,0.0019082192,0.0000060002376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017780894,0.00040722734,0.7715633,0.00008789411,0.000050017527,0.0000010220957,0.0005102702,0.0000031848044,0.0000061491346,0.00021237567,0.0012870537,0.22409345],"study_design_scores_gemma":[0.0064177704,0.0045127776,0.9091287,0.000350014,0.0000713858,0.0000010087922,0.000363548,0.0000543672,0.0000019121946,0.001354255,0.07765039,0.00009384775],"about_ca_topic_score_codex":0.00018305112,"about_ca_topic_score_gemma":0.0027433906,"teacher_disagreement_score":0.2239996,"about_ca_system_score_codex":0.00010625711,"about_ca_system_score_gemma":0.0024726074,"threshold_uncertainty_score":0.8290369},"labels":[],"label_agreement":null},{"id":"W1993487250","doi":"10.1200/jco.2005.05.3025","title":"Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Mucoepidermoid carcinoma; Adenoid cystic carcinoma; Systemic therapy; Salivary gland; Radiation therapy; Chemotherapy; Cancer; Oncology; Adenocarcinoma; Internal medicine; Palliative care; Salivary gland cancer; Disease; Carcinoma; Pathology","score_opus":0.2294520520969557,"score_gpt":0.5319119729803317,"score_spread":0.3024599208833759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993487250","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008900584,0.985243,0.0000021994226,0.00035840948,0.0008411335,0.001099821,0.000014560098,0.0000030181393,0.00353724],"genre_scores_gemma":[0.013444757,0.9849698,0.00047279723,0.00032478178,0.000598255,0.00007108152,0.000019610323,0.000022950586,0.00007599902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99408025,0.0010904889,0.0039584036,0.00022256502,0.00043928178,0.00020904359],"domain_scores_gemma":[0.99162805,0.0035817001,0.0042300094,0.00030160524,0.00015186517,0.000106781314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026809208,0.0002846436,0.005062252,0.00016871012,0.000018253355,0.000004875005,0.0003096367,0.0003834226,0.000031589927],"category_scores_gemma":[0.00013188341,0.000129509,0.0013642354,0.0002674304,0.00011449419,0.000032369844,0.00003014128,0.00093085703,0.0000056336626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008727528,0.0019901867,0.011602499,0.0039082267,0.0020521414,0.00400609,0.000055331366,0.00000822247,1.0542097e-8,0.00013906862,0.0016994476,0.973666],"study_design_scores_gemma":[0.010433596,0.01201584,0.05369089,0.029571401,0.0033301315,0.0007174703,0.0001819932,7.6174473e-7,1.6488323e-7,0.00009838164,0.88981754,0.000141826],"about_ca_topic_score_codex":0.00006713879,"about_ca_topic_score_gemma":0.000027458069,"teacher_disagreement_score":0.9735242,"about_ca_system_score_codex":0.00047126441,"about_ca_system_score_gemma":0.0013927417,"threshold_uncertainty_score":0.5281224},"labels":[],"label_agreement":null},{"id":"W199368778","doi":"10.1200/jco.2013.31.4_suppl.576","title":"Population-based patterns of systemic therapy use in liver-limited metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; BC Cancer Agency","funders":"","keywords":"Medicine; Systemic therapy; Colorectal cancer; Regimen; Internal medicine; Population; Surgery; Gastroenterology; Cancer; Oncology","score_opus":0.15784407855823962,"score_gpt":0.4499079660380158,"score_spread":0.2920638874797762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W199368778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959036,0.0016801503,0.000022376316,0.0012586988,0.0005689187,0.0004766628,0.0000124540575,0.000005220559,0.00007192446],"genre_scores_gemma":[0.99559045,0.002872851,0.00048326852,0.00076275726,0.00017848145,0.00003940336,0.0000042332185,0.000012720369,0.000055808814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708664,0.00038491847,0.0019333807,0.0001414188,0.00027885297,0.00017476855],"domain_scores_gemma":[0.9952594,0.002556163,0.0014032135,0.00009871087,0.00053406117,0.00014847101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071987516,0.00013462795,0.0016006775,0.00017215047,0.00002070789,0.000007001516,0.000082213126,0.00014144958,0.00041870834],"category_scores_gemma":[0.001001168,0.000084518695,0.0003544336,0.00014992642,0.00006412415,0.00011610572,0.000017622451,0.00037812628,0.0000045829297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029404676,0.0012669731,0.9188298,0.00005065379,0.0005172948,0.00018275676,0.00014591515,0.00009459115,0.00026977007,0.000006493656,0.00019524373,0.07550003],"study_design_scores_gemma":[0.0092959525,0.008529307,0.9804312,0.00033362262,0.00023069115,0.000057447163,0.00016617152,0.00044225118,0.00010250845,0.000023413328,0.00031852035,0.00006888752],"about_ca_topic_score_codex":0.005348655,"about_ca_topic_score_gemma":0.0025394058,"teacher_disagreement_score":0.07543114,"about_ca_system_score_codex":0.00031468627,"about_ca_system_score_gemma":0.000774859,"threshold_uncertainty_score":0.80856025},"labels":[],"label_agreement":null},{"id":"W1995312316","doi":"10.1200/jco.2003.04.080","title":"Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Randomization; Randomized controlled trial; Breast cancer; Physical therapy; Metastatic breast cancer; Cancer; Intervention (counseling); Internal medicine; Psychiatry; Nursing","score_opus":0.2396199564415271,"score_gpt":0.5385992403159954,"score_spread":0.29897928387446826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995312316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631333,0.00042917245,0.0005577749,0.0010244704,0.0011107784,0.00048803692,0.000018372304,6.093226e-7,0.000057461937],"genre_scores_gemma":[0.9988881,0.0005037408,0.00032158382,0.00012106401,0.00014808476,0.000005221544,0.000004367203,0.0000050075423,0.0000028701002],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912209,0.0046044155,0.00366318,0.00011813696,0.0003134584,0.00007993871],"domain_scores_gemma":[0.9926341,0.003065835,0.0038141776,0.00019812082,0.00020834246,0.00007940988],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014511921,0.00007173551,0.0023579192,0.00010405529,0.000005916685,0.0000017832976,0.00012784697,0.0001304338,0.000028818527],"category_scores_gemma":[0.008881134,0.00004682415,0.00036737294,0.0001434727,0.00023465806,0.00023729981,0.000030045861,0.0003219476,1.7919305e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88097847,0.0041133827,0.054283116,0.00084065704,0.00032562506,0.000009094736,0.0014280671,0.0000052293976,0.0005553381,0.0003715293,0.000058084344,0.05703139],"study_design_scores_gemma":[0.83790386,0.0054198243,0.15151969,0.00079351524,0.00048994506,0.000010265126,0.0005902688,0.000064378524,0.00013251958,0.002957471,0.00006615223,0.000052092306],"about_ca_topic_score_codex":0.001678156,"about_ca_topic_score_gemma":0.006592022,"teacher_disagreement_score":0.09723657,"about_ca_system_score_codex":0.00004718063,"about_ca_system_score_gemma":0.00088474405,"threshold_uncertainty_score":0.9994675},"labels":[],"label_agreement":null},{"id":"W1996047491","doi":"10.1200/jco.2008.18.8771","title":"Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Presentation (obstetrics); Randomized controlled trial; Oncology; Internal medicine; Medical physics; General surgery; Surgery","score_opus":0.8299503658255415,"score_gpt":0.6809284870618475,"score_spread":0.149021878763694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996047491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84554446,0.003536299,0.00676297,0.038934432,0.0037124567,0.0042514415,0.00002613186,0.0000030346082,0.097228795],"genre_scores_gemma":[0.9729675,0.0005974458,0.019122163,0.00087674474,0.0008043843,0.00001272244,0.0000021700157,0.000006256459,0.0056106066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.41480067,0.33124277,0.24250323,0.0009784539,0.010005643,0.00046923326],"domain_scores_gemma":[0.23341897,0.51061124,0.24564698,0.001408286,0.008516882,0.00039761563],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.802447,0.0002584558,0.06177938,0.0006579922,0.000047420595,0.0000494564,0.0014472493,0.0005383097,0.0032650684],"category_scores_gemma":[0.875994,0.00009904173,0.020171415,0.00057957956,0.00040725205,0.00016981477,0.000082978484,0.00050674856,0.000100236226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7146954,0.0017781929,0.0012537389,0.0000254511,0.004622534,0.00006448787,0.0005029725,0.00021296389,0.0011727365,0.0015369429,0.12114169,0.15299292],"study_design_scores_gemma":[0.8202019,0.01088036,0.008691543,0.00013956775,0.010544726,0.00012093624,0.00043205448,0.00233836,0.00032130952,0.021018112,0.12513943,0.00017171609],"about_ca_topic_score_codex":0.000013298561,"about_ca_topic_score_gemma":0.00003207672,"teacher_disagreement_score":0.18138169,"about_ca_system_score_codex":0.000078431236,"about_ca_system_score_gemma":0.0012062475,"threshold_uncertainty_score":0.9976461},"labels":[],"label_agreement":null},{"id":"W1996242680","doi":"10.1200/jco.2014.60.1153","title":"Localized and Systemic Approaches to Treating Hepatocellular Carcinoma","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Citation; Medicine; Hepatocellular carcinoma; Clinical Oncology; Library science; Oncology; Cancer; Internal medicine","score_opus":0.6570235856718833,"score_gpt":0.4627744044378184,"score_spread":0.19424918123406493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996242680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018976761,0.9768268,0.00007254351,0.00041447286,0.0006669245,0.0014438798,0.000009385591,0.000017015633,0.0015722385],"genre_scores_gemma":[0.027319146,0.96576977,0.0041202726,0.00018314284,0.0020002865,0.00005449528,0.000026958136,0.00008294077,0.00044298603],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918686,0.0017496604,0.004980025,0.00047705948,0.00053794275,0.00038670967],"domain_scores_gemma":[0.9924751,0.002035603,0.0032557978,0.0003929776,0.00035512485,0.0014853977],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006639224,0.0005279988,0.010217268,0.00041860604,0.000047632406,0.000026834352,0.00025032499,0.0014350747,0.00003268191],"category_scores_gemma":[0.002111235,0.00032895934,0.0019406882,0.00032739234,0.00015793758,0.00006750155,0.00014293175,0.0014864601,0.00006956023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044383894,0.00049503613,0.07866441,0.005867405,0.0010404066,0.0040887482,0.00008979448,7.6077846e-8,1.3767765e-7,0.000030398454,0.0009352756,0.90834445],"study_design_scores_gemma":[0.003973578,0.009610024,0.00014700534,0.008037807,0.010631565,0.007791066,0.00007714697,0.00017937305,7.4298777e-7,0.000025423331,0.95925426,0.00027202128],"about_ca_topic_score_codex":0.000019774297,"about_ca_topic_score_gemma":0.000002076261,"teacher_disagreement_score":0.95831895,"about_ca_system_score_codex":0.00048629974,"about_ca_system_score_gemma":0.004788029,"threshold_uncertainty_score":0.99991626},"labels":[],"label_agreement":null},{"id":"W1996331760","doi":"10.1200/jco.2009.27.15_suppl.5123","title":"Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group (RTOG) prostate clinical trials","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Western University","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Proportional hazards model; Internal medicine; Population; Prostate-specific antigen; Oncology; Urology; Radiation therapy; Hazard ratio; Cancer; Gynecology; Confidence interval","score_opus":0.34318990405283833,"score_gpt":0.6349536797485381,"score_spread":0.2917637756956998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996331760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98434764,0.001316225,0.00004156029,0.011784376,0.0010552619,0.0010861973,0.00003508639,0.000012302477,0.00032134753],"genre_scores_gemma":[0.97202975,0.02207505,0.0013347258,0.002466323,0.0019272421,0.000007741624,0.000021967891,0.000022981074,0.00011419907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9813111,0.007387561,0.009681604,0.0005057174,0.00061202666,0.00050202233],"domain_scores_gemma":[0.9612951,0.032916784,0.004008522,0.00033593006,0.0005375054,0.000906108],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.039524987,0.00032777584,0.0056768367,0.00038939348,0.0000351813,0.0000133994245,0.00024218306,0.0009912543,0.00015793035],"category_scores_gemma":[0.036471374,0.00018313146,0.002139948,0.00028988233,0.0007126533,0.00014559895,0.00003185122,0.0027534645,0.000008397356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041080404,0.009586732,0.51590127,0.000007662711,0.0008150057,0.00033634572,0.00003729632,0.0000035839107,0.0006806538,0.000023475961,0.0024290716,0.4290985],"study_design_scores_gemma":[0.068074286,0.107660964,0.8201554,0.00010576397,0.00030080168,0.0000988299,0.000030504865,0.00008413077,0.0001973096,0.00068358716,0.002473976,0.00013447131],"about_ca_topic_score_codex":0.00005077128,"about_ca_topic_score_gemma":0.00002341303,"teacher_disagreement_score":0.42896402,"about_ca_system_score_codex":0.00034962862,"about_ca_system_score_gemma":0.0033167042,"threshold_uncertainty_score":0.99954724},"labels":[],"label_agreement":null},{"id":"W1996867876","doi":"10.1200/jco.2007.11.3670","title":"Statistical Power of Negative Randomized Controlled Trials Presented at American Society for Clinical Oncology Annual Meetings","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sample size determination; Medicine; Post-hoc analysis; Randomized controlled trial; Hazard ratio; Odds ratio; Logistic regression; Internal medicine; Post hoc; Clinical endpoint; Statistical power; Confidence interval; Clinical trial; Clinical Oncology; Statistics; Cancer","score_opus":0.41193859149800466,"score_gpt":0.6415961380156108,"score_spread":0.22965754651760611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996867876","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3247707,0.00028456803,0.6540225,0.0072156847,0.0024680728,0.005714006,0.00019019454,0.00010431578,0.005229941],"genre_scores_gemma":[0.3267157,0.0010186079,0.6684257,0.0018612724,0.00137995,0.000086523505,0.0000049726304,0.000051314863,0.00045598717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9607486,0.012079502,0.02494841,0.00049327104,0.0009939434,0.00073624955],"domain_scores_gemma":[0.37820008,0.58727014,0.029926647,0.00033814003,0.0036505715,0.00061438454],"candidate_categories":["metaresearch","metaepi_broad","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.19649172,0.0003927796,0.02173187,0.00017586467,0.00008022659,0.0000097540915,0.00053413666,0.0011967107,0.000210735],"category_scores_gemma":[0.60230196,0.00024006706,0.0073424634,0.00021360682,0.0037945523,0.00017432585,0.00021451258,0.0018741168,0.0000036325205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8341862,0.004156451,0.0008530651,0.000044521785,0.005822788,0.000096993645,0.0007555648,0.0000026492874,0.00021000567,0.03098384,0.0797488,0.04313911],"study_design_scores_gemma":[0.66543,0.039135475,0.0013878279,0.0001400925,0.0046467637,0.00008291541,0.0026793557,0.00026327572,0.000605275,0.24630246,0.03891649,0.00041005845],"about_ca_topic_score_codex":0.000022934337,"about_ca_topic_score_gemma":0.000071081195,"teacher_disagreement_score":0.58254856,"about_ca_system_score_codex":0.00040011047,"about_ca_system_score_gemma":0.0020743394,"threshold_uncertainty_score":0.99891657},"labels":[],"label_agreement":null},{"id":"W1997043452","doi":"10.1200/jco.2014.59.7559","title":"Reply to E.A. Rakha et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine","score_opus":0.4547363669323985,"score_gpt":0.6349800255671316,"score_spread":0.18024365863473313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997043452","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003414262,0.0048089195,0.00027278098,0.90793395,0.039072685,0.0007144833,0.000043201235,0.000016381447,0.043723345],"genre_scores_gemma":[0.00069157087,0.0049186773,0.008552977,0.8932666,0.062014814,0.000017812647,0.000017358328,0.00014525057,0.030374944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9771824,0.007375939,0.009348145,0.00087969523,0.0036084692,0.001605349],"domain_scores_gemma":[0.96626556,0.019282414,0.0048464937,0.0012227645,0.004589847,0.0037929353],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.0557453,0.0006029106,0.006506801,0.0006726534,0.0000642287,0.00005939585,0.0015688228,0.0032553608,0.0049719913],"category_scores_gemma":[0.09269742,0.0004671006,0.00187229,0.00056406675,0.0010282518,0.00018867395,0.0006247858,0.024011377,0.004673751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004832674,0.0011440545,0.004736393,0.00015989278,0.0008920166,0.02780129,0.00019929565,0.000026017035,0.000026381127,0.00005677613,0.78913623,0.17098896],"study_design_scores_gemma":[0.008494383,0.051511586,0.0055598556,0.0017943423,0.0006564015,0.0033396257,0.00010436287,0.000031082374,0.000011097386,0.0004488102,0.92768246,0.00036597738],"about_ca_topic_score_codex":0.00029896587,"about_ca_topic_score_gemma":0.000086046675,"teacher_disagreement_score":0.17062297,"about_ca_system_score_codex":0.003024483,"about_ca_system_score_gemma":0.0422316,"threshold_uncertainty_score":0.9997781},"labels":[],"label_agreement":null},{"id":"W1997074080","doi":"10.1200/jco.2014.58.8335","title":"Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; International Association for the Study of Lung Cancer","keywords":"Medicine; Adenocarcinoma; Internal medicine; Hazard ratio; Oncology; Clinical endpoint; Lung cancer; Proportional hazards model; Chemotherapy; Adjuvant chemotherapy; Lung; Clinical trial; Cancer; Breast cancer; Confidence interval","score_opus":0.15985273851805837,"score_gpt":0.4324383947818941,"score_spread":0.27258565626383574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997074080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370044,0.00080807414,0.000033694687,0.0035620213,0.0009861432,0.00022483912,0.0000075435078,0.000004242595,0.00067298114],"genre_scores_gemma":[0.99759364,0.00065294583,0.00072970794,0.0004456112,0.00052040763,0.0000038890407,0.000018966297,0.000012350879,0.000022502078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750155,0.00018372906,0.0016439304,0.00016155325,0.00038033735,0.00012889695],"domain_scores_gemma":[0.996598,0.0009857196,0.0014851424,0.00016781261,0.00053003774,0.00023329712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010808276,0.000092886614,0.00091986434,0.000116407435,0.000012702854,0.000003856048,0.000086590146,0.00023230798,0.000037378722],"category_scores_gemma":[0.0010117665,0.000068318404,0.00017978625,0.00012184393,0.00006634052,0.000090124515,0.000019852972,0.0003677011,0.0000045570287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068900944,0.0021983634,0.96853137,0.000022927637,0.0002450482,0.000028627677,0.00017512914,0.000022321776,0.000019733134,0.000046512912,0.0023342397,0.019485654],"study_design_scores_gemma":[0.024143437,0.015328248,0.95758,0.0002957355,0.00022141308,0.0000070032493,0.00007836577,0.00040278392,0.00006123792,0.00046591848,0.0013682257,0.00004767109],"about_ca_topic_score_codex":0.00014179794,"about_ca_topic_score_gemma":0.00041259822,"teacher_disagreement_score":0.019437984,"about_ca_system_score_codex":0.0008090372,"about_ca_system_score_gemma":0.0009961398,"threshold_uncertainty_score":0.27859434},"labels":[],"label_agreement":null},{"id":"W1998611946","doi":"10.1200/jco.2003.03.047","title":"SarCNU, a Nitrosourea Analog on a Day 1, 5, and 9 Oral Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Tumors","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Medicine; Bioavailability; Toxicity; Pharmacology; Neutropenia; Phases of clinical research; Volume of distribution; Glioma; Gastroenterology; Internal medicine","score_opus":0.0597557422925331,"score_gpt":0.46661213404709767,"score_spread":0.40685639175456456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998611946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983086,0.00022859746,0.000004154473,0.00059819105,0.0001335648,0.00053387857,0.0000034313418,0.0000033053868,0.00018628406],"genre_scores_gemma":[0.99820185,0.00009362644,0.00077739224,0.0008372517,0.000058064772,0.0000113095675,0.0000016127394,0.0000131038405,0.000005802453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765867,0.00047740503,0.0011662187,0.00021807314,0.0002732964,0.00020635438],"domain_scores_gemma":[0.997852,0.000812735,0.0006726747,0.00010754728,0.00017620914,0.00037882623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013037488,0.00015948982,0.0012686873,0.0001961856,0.000028221908,0.0000088636525,0.000043606386,0.000093819624,0.00003513752],"category_scores_gemma":[0.0013657124,0.00009598156,0.000081295395,0.00016280921,0.0001291647,0.000068645306,0.000018457582,0.00053674914,0.0000014882758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070331907,0.027122289,0.8960578,0.00000854294,0.0003009608,0.0016101534,0.000119273085,0.00001360618,0.000041134652,0.000012521751,0.000079449674,0.06760111],"study_design_scores_gemma":[0.1075366,0.08887081,0.8018226,0.000109989494,0.00042914017,0.00008832604,0.00014038649,0.000027115546,0.000067209265,0.00004826403,0.00078083633,0.00007872789],"about_ca_topic_score_codex":0.000003972033,"about_ca_topic_score_gemma":0.000028437744,"teacher_disagreement_score":0.10050341,"about_ca_system_score_codex":0.00006883005,"about_ca_system_score_gemma":0.00027605332,"threshold_uncertainty_score":0.39140144},"labels":[],"label_agreement":null},{"id":"W2000202356","doi":"10.1200/jco.2006.09.4342","title":"Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre; London Health Sciences Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Vinorelbine; Clinical trial; Population; Randomized controlled trial; Lung cancer; Internal medicine; Medical record; Oncology; Chemotherapy; Cisplatin; Surgery","score_opus":0.09299786751520156,"score_gpt":0.4426158025879275,"score_spread":0.3496179350727259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000202356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434215,0.001015948,0.00026797832,0.0012961412,0.0011008288,0.0017327771,0.0001359757,0.000001748654,0.000106451516],"genre_scores_gemma":[0.9969277,0.001803895,0.00031809387,0.00025425624,0.00051504606,0.000069760725,0.00004988558,0.000014322781,0.000047065932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9878084,0.0017645352,0.009167564,0.0003945774,0.0006270134,0.00023787776],"domain_scores_gemma":[0.97038007,0.014581035,0.01401252,0.00038745315,0.00037861697,0.00026027946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026650542,0.00025421314,0.0068038264,0.00047159585,0.000047847872,0.000009059625,0.00024243844,0.00021644628,0.00009118283],"category_scores_gemma":[0.0028322928,0.00013730297,0.0018577235,0.00059100176,0.0005852959,0.00009541324,0.000064623324,0.00053005083,5.5399703e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4194182,0.00074884406,0.5403208,0.000062970306,0.010879226,0.00005896096,0.00008942426,0.027527189,0.0000047887756,0.000098964156,0.00009263171,0.0006979648],"study_design_scores_gemma":[0.33732712,0.0009260994,0.6078429,0.00029306646,0.022067022,0.000002013859,0.00002799689,0.0313158,0.0000128767515,0.000012383291,0.00009330879,0.00007935149],"about_ca_topic_score_codex":0.15973407,"about_ca_topic_score_gemma":0.6778926,"teacher_disagreement_score":0.51815856,"about_ca_system_score_codex":0.0018637135,"about_ca_system_score_gemma":0.006988409,"threshold_uncertainty_score":0.9986411},"labels":[],"label_agreement":null},{"id":"W2000525505","doi":"10.1200/jco.2011.37.9792","title":"Reduced-Calorie Dietary Weight Loss, Exercise, and Sex Hormones in Postmenopausal Women: Randomized Controlled Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Environment and Climate Change Canada","funders":"National Center for Research Resources; National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; American Society of Clinical Oncology","keywords":"Medicine; Internal medicine; Estrone; Endocrinology; Weight loss; Sex hormone-binding globulin; Overweight; Body mass index; Testosterone (patch); Aerobic exercise; Obesity; Androstenedione; Very low calorie diet; Estrogen; Hormone; Androgen","score_opus":0.06296552211671606,"score_gpt":0.42413682181540063,"score_spread":0.36117129969868456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000525505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980192,0.0084986845,0.000006344805,0.004094106,0.0043634893,0.0013796539,0.0000020291243,0.0000075365247,0.0014561594],"genre_scores_gemma":[0.9771619,0.016332427,0.00033188285,0.0010249964,0.0046851262,0.0000650052,0.0000017423627,0.000018440673,0.000378516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944397,0.00088702753,0.0037049209,0.00017081248,0.00036698687,0.0004305323],"domain_scores_gemma":[0.99177974,0.005390424,0.001788254,0.00014949472,0.00014887213,0.0007431946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01063666,0.00020394576,0.006216098,0.00019635788,0.000032088374,0.000009191124,0.000096880736,0.00046606522,0.0002221434],"category_scores_gemma":[0.004512823,0.00011788508,0.00064048596,0.00011178425,0.00040222492,0.00019979407,0.000046886693,0.0011151265,0.000006443926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9403917,0.0024562427,0.016024617,0.000014735893,0.0005496675,0.00025794047,0.00044552522,4.1302206e-7,0.00008062837,0.00003584607,0.0013557938,0.038386848],"study_design_scores_gemma":[0.94012237,0.010656992,0.033584025,0.00007262738,0.0008456308,0.00014320533,0.00016932574,0.000014007191,0.000012395962,0.0004409406,0.01381938,0.000119129356],"about_ca_topic_score_codex":0.000031846364,"about_ca_topic_score_gemma":0.0000055467563,"teacher_disagreement_score":0.03826772,"about_ca_system_score_codex":0.00018402655,"about_ca_system_score_gemma":0.0008921293,"threshold_uncertainty_score":0.5402597},"labels":[],"label_agreement":null},{"id":"W2000585758","doi":"10.1200/jco.2012.47.0583","title":"Reply to V. Lorusso et al","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Alberta Cancer Foundation","funders":"","keywords":"Medicine","score_opus":0.13822695942533522,"score_gpt":0.550176613336425,"score_spread":0.41194965391108973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000585758","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012684711,0.0006079691,0.0001039913,0.96928924,0.005896237,0.00025502508,0.000015956566,0.000010163727,0.022552948],"genre_scores_gemma":[0.0011955581,0.0004222064,0.005638256,0.97027934,0.014665601,0.000008138097,0.000033246448,0.000039778293,0.0077178925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963942,0.00036404608,0.0022377248,0.00021136105,0.00047726877,0.00031537877],"domain_scores_gemma":[0.9951852,0.0017235758,0.0018324367,0.00030539502,0.0004858914,0.0004675248],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021123714,0.0001915629,0.0018690398,0.00018111676,0.000026732674,0.000010045144,0.00016222037,0.0008161625,0.00052090816],"category_scores_gemma":[0.0022288219,0.00012293438,0.0007878382,0.000093965886,0.00008360844,0.000080449536,0.000050915816,0.0038197068,0.00026436622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005310942,0.00053764565,0.002800408,0.000019722174,0.00103247,0.003113934,0.00008561416,8.9149665e-7,0.0000021791502,0.000014901259,0.9538853,0.037975796],"study_design_scores_gemma":[0.0033890675,0.008433052,0.013996677,0.00015459949,0.0016703551,0.0010273446,0.00001345371,4.1020385e-7,0.0000019645342,0.000070855705,0.97113717,0.000105030624],"about_ca_topic_score_codex":0.000040502313,"about_ca_topic_score_gemma":0.0000048467964,"teacher_disagreement_score":0.037870765,"about_ca_system_score_codex":0.0003606804,"about_ca_system_score_gemma":0.003511317,"threshold_uncertainty_score":0.99847853},"labels":[],"label_agreement":null},{"id":"W2001182126","doi":"10.1200/jco.2007.11.2839","title":"Docetaxel Plus Cyclophosphamide in Adjuvant Breast Cancer","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Docetaxel; Cyclophosphamide; Oncology; Adjuvant; Breast cancer; Internal medicine; Cancer; Chemotherapy","score_opus":0.14729863909111626,"score_gpt":0.5105592915120212,"score_spread":0.3632606524209049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001182126","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019973895,0.005803116,0.00009068273,0.956895,0.009700906,0.00039220884,0.00007629995,0.000019504316,0.007048371],"genre_scores_gemma":[0.00767823,0.012054038,0.0012516957,0.9338215,0.042473234,0.000018221383,0.00001884593,0.00008842388,0.002595806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914503,0.000596376,0.005790947,0.00043548195,0.0010654455,0.0006614341],"domain_scores_gemma":[0.99043375,0.0029962035,0.0048573255,0.00040669186,0.00087799045,0.00042801883],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0049499855,0.00040382394,0.004463485,0.0005769181,0.000028214487,0.000011559627,0.00041278746,0.0034435827,0.001980738],"category_scores_gemma":[0.0009448439,0.00030504283,0.0012099954,0.00035094816,0.00048326116,0.00011941724,0.00006128722,0.0122195175,0.00007642494],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006307227,0.00046000257,0.0202581,0.00012814385,0.0004940088,0.024751019,0.000050369443,0.000027416852,0.000014566908,0.0000043920086,0.8766594,0.070845366],"study_design_scores_gemma":[0.01702731,0.0025089886,0.09588387,0.0012620847,0.00039040647,0.004561514,0.000018384448,0.00001027377,0.00001857451,0.00025316825,0.8778175,0.0002479379],"about_ca_topic_score_codex":0.00018669135,"about_ca_topic_score_gemma":0.00012272823,"teacher_disagreement_score":0.07562577,"about_ca_system_score_codex":0.0022406569,"about_ca_system_score_gemma":0.009089485,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W2001572319","doi":"10.1200/jco.2013.51.2483","title":"Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Sanofi; Pfizer Pharmaceuticals; Avon Foundation for Women; Pfizer; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Medicine; Exemestane; Placebo; Quality of life (healthcare); Menopause; Vasomotor; Breast cancer; Internal medicine; Gynecology; Randomized controlled trial; Cancer; Physical therapy; Aromatase; Alternative medicine","score_opus":0.239460833733164,"score_gpt":0.5742326152683944,"score_spread":0.3347717815352304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001572319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860721,0.0006382247,0.0027965666,0.004170318,0.001271711,0.0047172424,0.0000071223035,0.0000035790522,0.00032310133],"genre_scores_gemma":[0.99144375,0.00040855372,0.0065363995,0.00031018653,0.0007619052,0.00018012131,0.0000050774847,0.000012759333,0.00034124684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98750085,0.0045330725,0.007080194,0.00016735509,0.00049507123,0.00022345009],"domain_scores_gemma":[0.9795373,0.010608268,0.008590537,0.00018143174,0.000765898,0.00031654435],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037335556,0.00013593641,0.00470289,0.00016794087,0.000022358374,0.0000032795208,0.00009684209,0.0003201858,0.00014514478],"category_scores_gemma":[0.028291006,0.00008675927,0.00045973208,0.0000893404,0.00010049363,0.000116054165,0.00002139019,0.0003703188,7.1455304e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88928264,0.0036249035,0.002183805,0.00043632407,0.0008235267,0.0000037677016,0.000048517322,0.000022534037,0.0002217138,0.00018104727,0.0001464633,0.10302473],"study_design_scores_gemma":[0.92171013,0.05471788,0.018361345,0.00052178354,0.0011081358,0.000013369048,0.000020316173,0.0010794663,0.000009367258,0.002299301,0.000103922335,0.00005498841],"about_ca_topic_score_codex":0.00013942247,"about_ca_topic_score_gemma":0.00015189187,"teacher_disagreement_score":0.102969736,"about_ca_system_score_codex":0.00017861954,"about_ca_system_score_gemma":0.0033361232,"threshold_uncertainty_score":0.99126565},"labels":[],"label_agreement":null},{"id":"W2001697180","doi":"10.1200/jco.2012.42.9530","title":"Reduced Risk of Colorectal Cancer With Use of Oral Bisphosphonates: A Systematic Review and Meta-Analysis","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"","keywords":"Medicine; Meta-analysis; Odds ratio; Internal medicine; Colorectal cancer; Relative risk; Confidence interval; Number needed to harm; Randomized controlled trial; Cohort study; Cancer; Number needed to treat","score_opus":0.46371208564038446,"score_gpt":0.563649460734137,"score_spread":0.09993737509375256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001697180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052441703,0.9969287,0.00000388589,0.00032426318,0.00014412648,0.0019240612,0.00012423052,0.00000283336,0.000023484105],"genre_scores_gemma":[0.00076372497,0.99574375,0.0026896875,0.0003927824,0.00002812763,0.00009921919,0.00000984196,0.000029952595,0.00024289798],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98856467,0.0025136182,0.007913728,0.00025170326,0.0004945381,0.0002617374],"domain_scores_gemma":[0.97342896,0.0050207432,0.01963832,0.00036784518,0.00092009874,0.00062404986],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005556493,0.00038704343,0.036475226,0.00030381235,0.00002194621,0.000003565456,0.00013594097,0.0006448274,0.00024703197],"category_scores_gemma":[0.0037840272,0.00017059947,0.0052794,0.00071179477,0.00026646137,0.00008758775,0.000042932836,0.001169175,0.000003296453],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056075724,0.0011141513,0.0012497875,0.51053274,0.45568812,0.00009578083,0.000015308833,3.2148674e-7,1.540432e-8,0.0000033593826,0.00014163938,0.030598054],"study_design_scores_gemma":[0.0013221656,0.004903434,0.00064123905,0.036084328,0.91829455,0.00047431898,0.000003791174,0.0000010250594,2.672511e-7,0.0000020059988,0.038168408,0.000104492414],"about_ca_topic_score_codex":0.00055015157,"about_ca_topic_score_gemma":0.000308478,"teacher_disagreement_score":0.47444838,"about_ca_system_score_codex":0.00015712614,"about_ca_system_score_gemma":0.003484606,"threshold_uncertainty_score":0.9778293},"labels":[],"label_agreement":null},{"id":"W2002682545","doi":"10.1200/jco.2003.01.501","title":"Small-Cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination Chemotherapy","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Regimen; Chemotherapy; Radiation therapy; Cervix; Cisplatin; Surgery; Internal medicine; Oncology; Cancer","score_opus":0.14573672249233632,"score_gpt":0.4208430608762069,"score_spread":0.27510633838387055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002682545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760526,0.000116728006,0.0001576755,0.0012919452,0.00019505466,0.00028707497,0.0000014864936,0.0000019543386,0.00034280552],"genre_scores_gemma":[0.9969223,0.00004675313,0.0026779843,0.00028958582,0.000036201407,0.0000015972441,5.172173e-7,0.000007478348,0.000017566155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759144,0.0004987985,0.0012916382,0.00012236873,0.0003685489,0.00012719331],"domain_scores_gemma":[0.99595344,0.0013668983,0.0019853888,0.00019331036,0.00039380134,0.00010717196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001039519,0.00007871144,0.00068018626,0.00010058555,0.000027551645,0.0000023905998,0.00012403977,0.000058138754,0.000017182958],"category_scores_gemma":[0.0035520694,0.000059938167,0.00016835146,0.0001901565,0.00035981453,0.000088676854,0.000036745358,0.0003158576,1.1595815e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044897087,0.0028261773,0.9010947,0.00024374093,0.000054510994,0.00009468207,0.00040871528,0.00016771744,0.083912514,0.0004878284,0.000051083807,0.0061686435],"study_design_scores_gemma":[0.01859134,0.017531894,0.6731267,0.00019368091,0.0001232628,0.00014738567,0.00038063244,0.0014046739,0.28683272,0.0011011707,0.00047746827,0.00008906458],"about_ca_topic_score_codex":0.00007837317,"about_ca_topic_score_gemma":0.00004924911,"teacher_disagreement_score":0.22796796,"about_ca_system_score_codex":0.00012779474,"about_ca_system_score_gemma":0.00079938094,"threshold_uncertainty_score":0.42524153},"labels":[],"label_agreement":null},{"id":"W2002832192","doi":"10.1200/jco.2003.11.054","title":"Asian Ethnicity–Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Cancer; Proportional hazards model; Confidence interval; Ethnic group; Survival analysis; Stage (stratigraphy); Disease; Survival rate; Oncology","score_opus":0.10720480142119264,"score_gpt":0.43624752828291097,"score_spread":0.3290427268617183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002832192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143696,0.0002649652,0.0000023026632,0.0037025372,0.0010169727,0.0002982669,0.000007633727,0.0000045563083,0.0032657792],"genre_scores_gemma":[0.995975,0.0011765969,0.00007081181,0.0010346517,0.000108197506,0.000010731414,0.00000441662,0.0000113746255,0.0016082037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732983,0.0003254258,0.0015904579,0.00018819328,0.00025761433,0.00030848407],"domain_scores_gemma":[0.99806046,0.00028092155,0.0009112579,0.000087183806,0.00017651243,0.00048368896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071264285,0.00014008515,0.0009734923,0.00038113433,0.000040444273,0.000010108512,0.00008256771,0.00024791644,0.0005367191],"category_scores_gemma":[0.00087415596,0.0001000713,0.0001687172,0.0003158195,0.00012658592,0.00011538176,0.000025296904,0.0005745556,0.000003083854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036089137,0.00027319803,0.96754706,0.000018307448,0.0001804169,0.00017656632,0.0001542185,0.0000045209126,0.0000010666912,0.000009862012,0.001267452,0.030006446],"study_design_scores_gemma":[0.00985129,0.0011935576,0.98350763,0.00007707351,0.0002508172,0.000019354648,0.00009129467,0.000044166038,0.0000017599383,0.000024717541,0.0048594787,0.000078847086],"about_ca_topic_score_codex":0.03034157,"about_ca_topic_score_gemma":0.2495243,"teacher_disagreement_score":0.21918273,"about_ca_system_score_codex":0.00074558036,"about_ca_system_score_gemma":0.00060003815,"threshold_uncertainty_score":0.97611547},"labels":[],"label_agreement":null},{"id":"W2003045129","doi":"10.1200/jco.2007.12.2481","title":"Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; National Institutes of Health; Enzon Pharmaceuticals; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Lymphoblastic Leukemia; Dexrazoxane; Oncology; Internal medicine; Cancer research; Leukemia; Cancer; Anthracycline; Breast cancer","score_opus":0.02569838649803667,"score_gpt":0.3232095574555233,"score_spread":0.29751117095748664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003045129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863344,0.000087183,0.00024958738,0.00028460743,0.000096332726,0.00024126006,0.000009675738,0.000009306125,0.00038862316],"genre_scores_gemma":[0.9944676,0.0013321534,0.0032831412,0.0005056254,0.0002850194,0.0000028725055,0.00000710416,0.000021428888,0.000095027426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974535,0.00023234767,0.0015097972,0.00020996321,0.00037346335,0.00022090686],"domain_scores_gemma":[0.99691683,0.00072252913,0.0016152133,0.00019934496,0.0002984979,0.0002476093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091232435,0.00017067492,0.0015422656,0.0001734204,0.00003584413,0.0000028663142,0.00012353605,0.00036234962,0.000050921448],"category_scores_gemma":[0.0003194578,0.00010510317,0.0002237997,0.00028575485,0.00041435077,0.00012007759,0.000016000906,0.0009036243,0.000004028689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011985788,0.00084939564,0.94438833,0.000019832547,0.0016075384,0.0019916603,0.00019031198,0.00040495888,0.010429481,0.000017356431,0.00020535004,0.027910002],"study_design_scores_gemma":[0.021444492,0.019238893,0.91626465,0.0002535542,0.00051333086,0.011642282,0.000046912144,0.000047727364,0.030260103,0.000039330742,0.00013065703,0.00011806859],"about_ca_topic_score_codex":0.00022844582,"about_ca_topic_score_gemma":0.00012218705,"teacher_disagreement_score":0.028123675,"about_ca_system_score_codex":0.0003008829,"about_ca_system_score_gemma":0.0034496847,"threshold_uncertainty_score":0.6119593},"labels":[],"label_agreement":null},{"id":"W2003433778","doi":"10.1200/jco.2002.99.002","title":"HER-2/<i>neu</i> Serum Levels Vis-à-Vis Hormonal Response in Metastatic Breast Cancer","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Internal medicine; Citation; Clinical Oncology; Multivariate analysis; Oncology; Hormone; Cancer; Gastroenterology; Library science","score_opus":0.33728410643388906,"score_gpt":0.5535752643029328,"score_spread":0.21629115786904374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003433778","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058124676,0.0027487024,0.000023231518,0.93306273,0.0032932695,0.0006352478,0.00049031747,0.000019171119,0.0016026411],"genre_scores_gemma":[0.09140145,0.005755288,0.0020403569,0.86667466,0.025019689,0.0000693218,0.0000128705815,0.00025294977,0.008773433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9835009,0.0057835598,0.00622607,0.000728877,0.002494955,0.0012656366],"domain_scores_gemma":[0.9815683,0.012274405,0.0033049108,0.00069998484,0.0012950784,0.00085732946],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.015398525,0.000592001,0.005229778,0.0009954463,0.00005936103,0.000042283402,0.000938627,0.0026328433,0.008779211],"category_scores_gemma":[0.007214082,0.00044909044,0.0014765554,0.0006838656,0.000753474,0.00018656331,0.00022484761,0.018800836,0.00026037922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014417851,0.0010470202,0.011211985,0.00029748946,0.0009187169,0.049294315,0.00007449542,0.000015021943,0.000047890524,0.0000014412187,0.8071956,0.11547819],"study_design_scores_gemma":[0.00780815,0.010015825,0.25220323,0.0009894887,0.0005689669,0.0055843038,0.000026956262,0.000073484145,0.000006672838,0.00008006455,0.722339,0.00030386765],"about_ca_topic_score_codex":0.00020437523,"about_ca_topic_score_gemma":0.00013713916,"teacher_disagreement_score":0.24099123,"about_ca_system_score_codex":0.00231389,"about_ca_system_score_gemma":0.01413652,"threshold_uncertainty_score":0.9997961},"labels":[],"label_agreement":null},{"id":"W2005056331","doi":"10.1200/jco.2008.21.1839","title":"Ovarian Failure and Reproductive Outcomes After Childhood Cancer Treatment: Results From the Childhood Cancer Survivor Study","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":509,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Offspring; Premature Menopause; Premature ovarian failure; Obstetrics; Cancer; Pregnancy; Odds ratio; Gynecology; Menopause; Internal medicine","score_opus":0.14327162643317584,"score_gpt":0.5011949336526774,"score_spread":0.3579233072195016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005056331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031876598,0.9474767,5.8536875e-7,0.014985698,0.0027745566,0.0020040749,0.0007170688,0.00001450381,0.00015023987],"genre_scores_gemma":[0.014226376,0.9742616,0.00011889484,0.0013211451,0.009494905,0.0001090854,0.000024782616,0.00006294928,0.00038025383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921926,0.0013931739,0.0045786714,0.00091452646,0.0005323233,0.0003886877],"domain_scores_gemma":[0.98963076,0.0039328965,0.0047579156,0.000877397,0.00033449588,0.00046655795],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024838042,0.00066930155,0.008173723,0.00014747311,0.0001046956,0.00004029198,0.00034458248,0.00089504884,0.00021292828],"category_scores_gemma":[0.0025992896,0.00030530084,0.0018668142,0.00026625607,0.00023216661,0.00010902507,0.00010113035,0.002539071,0.000008399939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015600523,0.0038317817,0.049018547,0.00006412547,0.006017577,0.00050886953,0.0016307326,5.651195e-7,8.656833e-9,0.00000111087,0.0020495974,0.93531704],"study_design_scores_gemma":[0.0068682,0.0048206216,0.4456927,0.0017680044,0.008554153,0.000093411894,0.0001721758,6.824277e-8,3.127742e-8,0.000021639593,0.5318438,0.00016523874],"about_ca_topic_score_codex":0.0055303457,"about_ca_topic_score_gemma":0.014154672,"teacher_disagreement_score":0.9351518,"about_ca_system_score_codex":0.0006452329,"about_ca_system_score_gemma":0.0052867522,"threshold_uncertainty_score":0.9999399},"labels":[],"label_agreement":null},{"id":"W2005550267","doi":"10.1200/jco.2011.34.7658","title":"Neonatal Squamous Cell Carcinoma of the Lip: Case Report and Review of the Literature","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Tumors and Oncological Cases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Basal cell; Dermatology; Pathology; Oncology","score_opus":0.17172192490653845,"score_gpt":0.4682505105917032,"score_spread":0.2965285856851647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005550267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006931567,0.98791736,5.9896513e-7,0.00079081365,0.0015973166,0.0007347419,0.00003564185,0.0000021523485,0.001989775],"genre_scores_gemma":[0.0106611345,0.9858471,0.00023465508,0.0013692455,0.0011154944,0.000005325739,0.0000028318495,0.000022111099,0.0007421084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99171793,0.0016075826,0.005826594,0.00026515036,0.0003865193,0.00019621616],"domain_scores_gemma":[0.9838053,0.0037865916,0.01064384,0.0007033097,0.0007726161,0.00028836154],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0046375883,0.0003051615,0.006332958,0.000068975016,0.000045425626,0.0000043339182,0.00044320486,0.0009779368,0.0001425439],"category_scores_gemma":[0.013110139,0.00011288169,0.0031708498,0.00034333311,0.00064432854,0.000039566617,0.0003310698,0.0029104892,0.0000013045784],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025952928,0.00079438277,0.0025178932,0.07591815,0.000086186395,0.14943425,0.000055216566,1.3641512e-8,1.4842735e-7,0.000050562292,0.010259275,0.7606244],"study_design_scores_gemma":[0.0007279981,0.0035068742,0.0025068114,0.03157332,0.0034067275,0.33337343,0.000011623981,6.0249135e-8,9.93222e-7,0.000027396442,0.624796,0.00006879676],"about_ca_topic_score_codex":0.000019298875,"about_ca_topic_score_gemma":0.000013120097,"teacher_disagreement_score":0.76055557,"about_ca_system_score_codex":0.00008685217,"about_ca_system_score_gemma":0.0036260178,"threshold_uncertainty_score":0.9993898},"labels":[],"label_agreement":null},{"id":"W2009819980","doi":"10.1200/jco.2003.10.044","title":"Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents","year":2003,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; Medicine; Cell cycle; Angiogenesis; Cell cycle checkpoint; DNA damage; Radiation therapy; Pharmacology; Cancer; Biology; Internal medicine","score_opus":0.1326386556859008,"score_gpt":0.4888824301520045,"score_spread":0.35624377446610367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009819980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019167652,0.977351,0.00029094095,0.00003987403,0.0026516079,0.00035911181,0.000049140366,0.0000017308612,0.000088903624],"genre_scores_gemma":[0.00036709732,0.99482423,0.0025492702,0.00026512906,0.0018126764,0.0000057963057,0.00002275494,0.000045911755,0.00010711288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949269,0.0012055223,0.00302885,0.00035726384,0.00021050955,0.00027093603],"domain_scores_gemma":[0.99511564,0.00017827858,0.0037951234,0.00035118108,0.00024479165,0.000314967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001365324,0.00037269792,0.0046657613,0.000112404065,0.000032594155,0.000007339007,0.00023559848,0.00096739293,0.00002745666],"category_scores_gemma":[0.00039707113,0.0002718402,0.0016270269,0.00010574083,0.00028182805,0.0000046977807,0.00004312396,0.0003580514,5.6982503e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048080707,0.0013346423,0.000084695595,0.00066617393,0.002312604,0.00007254574,0.00001855213,0.000014190853,0.0011877905,0.000024384668,0.0009181482,0.9928855],"study_design_scores_gemma":[0.0034187054,0.0066199135,0.00008533332,0.00039235578,0.0014867655,0.00030421445,0.0000068076724,0.000006418379,0.00020657878,0.00004517376,0.9872044,0.00022334831],"about_ca_topic_score_codex":0.00001533292,"about_ca_topic_score_gemma":0.0000047747494,"teacher_disagreement_score":0.99266213,"about_ca_system_score_codex":0.0001183522,"about_ca_system_score_gemma":0.0026184234,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W2010183271","doi":"10.1200/jco.2003.09.111","title":"Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Kallikrein; Ovarian cancer; Medicine; Cancer; Oncology; Internal medicine; Population; Survival analysis; Real-time polymerase chain reaction; Cancer research; Gene; Biology; Enzyme","score_opus":0.10731187233669746,"score_gpt":0.4517095027887338,"score_spread":0.3443976304520363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010183271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217105,0.0016646987,0.0000995781,0.0029469146,0.0011592145,0.00022156886,0.0000013794856,0.0000034878592,0.0017320968],"genre_scores_gemma":[0.99580693,0.00023655305,0.0018730595,0.0010224801,0.00061342656,0.000004079899,7.304837e-7,0.000013210144,0.00042954396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674636,0.00058282225,0.002017943,0.00013934923,0.00032558126,0.00018795308],"domain_scores_gemma":[0.9969257,0.001031687,0.0014383495,0.0001942632,0.00023552518,0.00017449152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023875465,0.00010571941,0.0009188867,0.00008561368,0.00004413428,0.0000037497116,0.00016019022,0.0002926852,0.00028716397],"category_scores_gemma":[0.0035440635,0.000062906736,0.00037340017,0.00018329316,0.0001718692,0.00006120542,0.000033411554,0.0005862145,0.000002367668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037872556,0.0011088896,0.9772383,0.000029653593,0.00008827882,0.0000923294,0.00020976273,0.00015552105,0.010811237,0.0013366184,0.0013071926,0.007243513],"study_design_scores_gemma":[0.005134198,0.0016275493,0.9685375,0.00038409085,0.00018838867,0.00009776835,0.000049687762,0.000054797474,0.008467764,0.0019982206,0.013392391,0.00006760585],"about_ca_topic_score_codex":0.000062755615,"about_ca_topic_score_gemma":0.000099836434,"teacher_disagreement_score":0.012085198,"about_ca_system_score_codex":0.000085763044,"about_ca_system_score_gemma":0.001338008,"threshold_uncertainty_score":0.42428312},"labels":[],"label_agreement":null},{"id":"W2010262144","doi":"10.1200/jco.2008.18.5223","title":"Providing Research Results to Participants: Attitudes and Needs of Adolescents and Parents of Children With Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Medicine; Phone; Family medicine; Quality of life (healthcare); Cancer; Nursing","score_opus":0.29621130237953985,"score_gpt":0.5635283305230323,"score_spread":0.26731702814349245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010262144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98618203,0.00083675823,0.000013000559,0.01233939,0.00013742085,0.00033226926,0.00001314505,0.0000035114635,0.0001424528],"genre_scores_gemma":[0.99635214,0.0009227516,0.00094128837,0.0012755126,0.00046867505,0.0000019743172,7.9054644e-7,0.000009374127,0.000027480404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606895,0.00057724444,0.0021886283,0.00017635648,0.00069252704,0.00029627254],"domain_scores_gemma":[0.9963559,0.0009589238,0.0012248417,0.00019095046,0.00071331323,0.0005560501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070247822,0.00011085634,0.0013541018,0.00024095958,0.000034911216,0.0000069277703,0.0001455648,0.0001776698,0.0000053441972],"category_scores_gemma":[0.0052306885,0.00007628057,0.00009269987,0.00029448592,0.00036163468,0.00009220661,0.00007420721,0.0007273472,4.962949e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013593733,0.0014281104,0.93915945,0.00013453681,0.00028589586,0.000017766783,0.0016711352,0.000006985193,0.00026960555,0.000021546106,0.0008394908,0.042571746],"study_design_scores_gemma":[0.008876877,0.022265637,0.964763,0.0022830316,0.00018271904,0.000054263943,0.0005273899,0.000003923756,0.00054370664,0.000052047617,0.00037910973,0.00006833144],"about_ca_topic_score_codex":0.00028542345,"about_ca_topic_score_gemma":0.00027525792,"teacher_disagreement_score":0.042503417,"about_ca_system_score_codex":0.00006386453,"about_ca_system_score_gemma":0.0010567864,"threshold_uncertainty_score":0.6262},"labels":[],"label_agreement":null},{"id":"W2010546902","doi":"10.1200/jco.2007.15.9772","title":"Preface to Second Review Issue on Breast Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Compendium; Cancer; Gerontology; Internal medicine","score_opus":0.22135672072834317,"score_gpt":0.574805088771253,"score_spread":0.35344836804290986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010546902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7097249,0.01778388,0.000004845315,0.23853517,0.004356915,0.00060622196,0.000027716427,0.000014606341,0.028945744],"genre_scores_gemma":[0.4776953,0.16334487,0.0012185933,0.30807802,0.014600085,0.000039186347,0.0000037287098,0.000042734795,0.0349775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777526,0.00023763825,0.0013992318,0.00016247058,0.00023184597,0.0001935586],"domain_scores_gemma":[0.9974872,0.0007634186,0.00074207707,0.00014273224,0.0003258568,0.0005387323],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000978295,0.00012216385,0.0014626139,0.00007365041,0.00003447736,0.0000013326672,0.00011807971,0.00018712501,0.011930549],"category_scores_gemma":[0.0004069554,0.00008032727,0.00039127728,0.00013742692,0.00009622437,0.00004606635,0.000026548809,0.00071387575,0.0002799934],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050689676,0.0021269717,0.019131213,0.000149547,0.00041940896,0.0012511188,0.00006786913,0.0000051502407,0.00013252352,0.000005868863,0.80643404,0.16520734],"study_design_scores_gemma":[0.004354101,0.012405162,0.1788497,0.00052391324,0.00040098594,0.0021578697,0.0000044911476,0.0000011329381,0.00009695886,0.000008136701,0.80113673,0.000060809936],"about_ca_topic_score_codex":0.00001541765,"about_ca_topic_score_gemma":0.000047096437,"teacher_disagreement_score":0.23202962,"about_ca_system_score_codex":0.00022168683,"about_ca_system_score_gemma":0.0015738049,"threshold_uncertainty_score":0.98897266},"labels":[],"label_agreement":null},{"id":"W2011111385","doi":"10.1200/jco.2007.11.2482","title":"Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Medicine; Conflict of interest; Family medicine; Internal medicine; Oncology; Clinical Oncology; Clinical research; Alternative medicine; Cancer; Finance; Business; Pathology","score_opus":0.9274683866087684,"score_gpt":0.7784366597831833,"score_spread":0.14903172682558508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011111385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96401453,0.001966621,0.00007154326,0.0073941033,0.023776032,0.00047588928,0.0001304499,0.000006205486,0.0021646325],"genre_scores_gemma":[0.9868704,0.003965209,0.00048246572,0.0016015013,0.0069361674,0.0000032573644,0.0000054784477,0.000019063702,0.00011643705],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9577791,0.02024103,0.020443138,0.0004244715,0.00042894483,0.0006832833],"domain_scores_gemma":[0.89974165,0.08459714,0.012903527,0.00023878615,0.0010713949,0.0014474863],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.14801101,0.00027612213,0.006171197,0.00029860198,0.000043061813,0.000003245479,0.0005734378,0.0049259136,0.00057317544],"category_scores_gemma":[0.06475683,0.00021212896,0.0008582694,0.0003193828,0.0020755322,0.00015209378,0.00018598432,0.007222793,0.0000037175878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051265538,0.011484779,0.4446943,0.0004734556,0.0016980694,0.000471082,0.00090901495,0.000025321266,0.0207509,0.0036146971,0.051742673,0.41287014],"study_design_scores_gemma":[0.025738074,0.020692637,0.080182746,0.00026228777,0.0011187113,0.000101544436,0.0008397247,0.00009325833,0.023728585,0.00237027,0.8445948,0.00027740834],"about_ca_topic_score_codex":0.00005006319,"about_ca_topic_score_gemma":0.00015475662,"teacher_disagreement_score":0.7928521,"about_ca_system_score_codex":0.00009947694,"about_ca_system_score_gemma":0.00204077,"threshold_uncertainty_score":0.9963659},"labels":[],"label_agreement":null},{"id":"W2011407375","doi":"10.1200/jco.2014.56.2975","title":"How Well Does Supplemental Screening Magnetic Resonance Imaging Work in High-Risk Women?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Magnetic resonance imaging; Oncology; Radiology","score_opus":0.027552730602386857,"score_gpt":0.355970327573732,"score_spread":0.32841759697134515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011407375","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21671915,0.0081283245,0.0016702045,0.7655874,0.0069044377,0.00040503067,0.0001069666,0.0000101472415,0.00046836422],"genre_scores_gemma":[0.3212071,0.0045646266,0.039150685,0.5821381,0.046717484,0.00008200597,0.00025512665,0.00020265144,0.0056821797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99478775,0.0013588435,0.0022155168,0.00057965814,0.00043267582,0.0006255322],"domain_scores_gemma":[0.99555093,0.000837044,0.002678029,0.00049180834,0.00028165663,0.00016052766],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0035139008,0.00035004644,0.0013649077,0.00020644453,0.000060871924,0.000062155195,0.0007667846,0.0013932647,0.00024742377],"category_scores_gemma":[0.0016121533,0.00027268621,0.00047246926,0.00016477714,0.00038988498,0.000012235311,0.000238923,0.0035801162,0.000010015681],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007253703,0.000109738925,0.06070936,0.000020291147,0.000097113014,0.0005040277,0.000030212768,0.00003594514,0.000078845864,0.0000013700048,0.79012406,0.14756365],"study_design_scores_gemma":[0.003742876,0.002380018,0.01881074,0.000092911585,0.00010249162,0.00010542172,0.00011810865,0.0000135804285,0.00014453841,0.00022635107,0.9739496,0.0003133715],"about_ca_topic_score_codex":0.000031396274,"about_ca_topic_score_gemma":0.0000995825,"teacher_disagreement_score":0.18382552,"about_ca_system_score_codex":0.00033713348,"about_ca_system_score_gemma":0.0010633488,"threshold_uncertainty_score":0.9999725},"labels":[],"label_agreement":null},{"id":"W2011561948","doi":"10.1200/jco.2007.15.8865","title":"Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Cord blood; Lymphoma; Transplantation; Oncology; Immunology; Internal medicine","score_opus":0.04348109056205094,"score_gpt":0.3327086999476953,"score_spread":0.28922760938564435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011561948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968116,0.00017035476,0.001569776,0.00012155139,0.00010372551,0.0010808662,0.000108675784,0.0000044195276,0.000029006134],"genre_scores_gemma":[0.99739176,0.0016444748,0.0007783329,0.0000824242,0.000028732395,0.000021735903,0.000024702502,0.00002057075,0.000007285359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964555,0.0008605144,0.0019863541,0.00022573979,0.00030607352,0.00016582802],"domain_scores_gemma":[0.9923309,0.0056101885,0.0016275994,0.00013825033,0.00020001069,0.00009304519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022359493,0.00017652783,0.0011976038,0.00017770067,0.00006700876,0.0000048402194,0.00011526935,0.00013871262,0.0000035570777],"category_scores_gemma":[0.0003296421,0.000091489586,0.0003151199,0.0003655235,0.00024142124,0.000070388436,0.0000062291865,0.0001894229,3.7099475e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017096119,0.0015133678,0.9679882,0.00021898364,0.001808986,0.00011486268,0.007987826,0.000029652156,0.00037698325,0.0000034000989,0.0000029455905,0.0028586779],"study_design_scores_gemma":[0.030243158,0.0067599835,0.9450116,0.00033626467,0.015248337,0.00037801283,0.0014070036,0.000114547845,0.00039162335,0.000010668871,0.000010685682,0.00008809376],"about_ca_topic_score_codex":0.000092899485,"about_ca_topic_score_gemma":0.0007393891,"teacher_disagreement_score":0.022976575,"about_ca_system_score_codex":0.000017607626,"about_ca_system_score_gemma":0.00014722368,"threshold_uncertainty_score":0.37308368},"labels":[],"label_agreement":null},{"id":"W2011644923","doi":"10.1200/jco.2005.17.129","title":"Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Multiple Myeloma Research Foundation","keywords":"Medicine; Dexamethasone; Vincristine; Internal medicine; Thalidomide; Chemotherapy; Oncology; Multiple myeloma; Salvage therapy; Prednisone; Melphalan; Gastroenterology; Cyclophosphamide","score_opus":0.08755274972010224,"score_gpt":0.45320424101853135,"score_spread":0.3656514912984291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011644923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060465,0.0011420456,0.000071977345,0.01678578,0.00031530092,0.0006073801,0.000024927433,0.000013530746,0.0004344046],"genre_scores_gemma":[0.98110163,0.004584203,0.008185509,0.0038677962,0.00086312415,0.00001615749,0.000012597165,0.000029503753,0.0013394569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432284,0.0011225272,0.0032216494,0.00038775644,0.0005101163,0.00043512866],"domain_scores_gemma":[0.9904358,0.0063274256,0.0014545075,0.00025773433,0.00030852633,0.0012160315],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004497835,0.000234309,0.0021319059,0.0001511603,0.00006047119,0.000016696627,0.00012807116,0.00035210463,0.00008889731],"category_scores_gemma":[0.011344735,0.0001638673,0.00060707936,0.00012006702,0.00035615586,0.0001881823,0.00007204322,0.0013564747,0.000018958946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026024029,0.0032172066,0.67907053,0.000027824495,0.00045399126,0.0017495363,0.00007291088,3.5578643e-7,0.00018862466,0.0000034555762,0.0011436138,0.2880479],"study_design_scores_gemma":[0.039606903,0.0027549218,0.8851249,0.000146665,0.000137365,0.00005109925,0.000051127423,0.00022881039,0.00003209643,0.00002821489,0.07171437,0.00012351692],"about_ca_topic_score_codex":0.000009958716,"about_ca_topic_score_gemma":0.000104977255,"teacher_disagreement_score":0.2879244,"about_ca_system_score_codex":0.00022308774,"about_ca_system_score_gemma":0.00077649334,"threshold_uncertainty_score":0.9969831},"labels":[],"label_agreement":null},{"id":"W2012793842","doi":"10.1200/jco.2005.04.912","title":"Dignity Therapy: Advancing the Science of Spiritual Care in Terminal Illness","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dignity; Medicine; Palliative care; Intervention (counseling); Psychosocial; Distress; End-of-life care; Anxiety; Psychotherapist; Nursing; Meaning (existential); Disease; Psychiatry; Psychology; Clinical psychology","score_opus":0.1683239074630772,"score_gpt":0.4868528052979047,"score_spread":0.3185288978348275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012793842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6739547,0.001334151,0.0000110743285,0.31815,0.0020140193,0.00030952986,0.000009156927,0.000004325616,0.004213016],"genre_scores_gemma":[0.67210436,0.0012970669,0.00090570684,0.3156685,0.009878164,0.000003432491,0.0000066102357,0.00002242123,0.00011372066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947625,0.0007561405,0.0028626977,0.00025206368,0.000951548,0.00041508852],"domain_scores_gemma":[0.99155253,0.0040186523,0.0029320864,0.00039701158,0.00092333916,0.00017637241],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005729307,0.00021068461,0.0020070919,0.00035922814,0.00008630752,0.0000110988585,0.00082148914,0.0009791381,0.000094074734],"category_scores_gemma":[0.0073549347,0.00012106872,0.0005982178,0.00035115107,0.0014925209,0.00020521952,0.00014250848,0.006348788,0.0000063871958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041870703,0.0013667716,0.02334306,0.00025392772,0.00018694287,0.0047530043,0.0026738471,0.000021447539,0.0001779688,0.000010180928,0.11419378,0.848832],"study_design_scores_gemma":[0.005395193,0.010451448,0.04419462,0.0005916123,0.00018905476,0.0006009022,0.0005431666,0.000009255692,0.00021862311,0.0001939317,0.937446,0.00016619168],"about_ca_topic_score_codex":0.000026062644,"about_ca_topic_score_gemma":0.000035210596,"teacher_disagreement_score":0.84866583,"about_ca_system_score_codex":0.00032556124,"about_ca_system_score_gemma":0.0068854117,"threshold_uncertainty_score":0.9987446},"labels":[],"label_agreement":null},{"id":"W2013029269","doi":"10.1200/jco.2009.22.6126","title":"Catheter-Associated Thrombosis in Patients With Malignancy","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Capital District Health Authority","funders":"","keywords":"Medicine; Malignancy; Thrombosis; Catheter; Venous thrombosis; Cancer; Incidence (geometry); Surgery; Intensive care medicine; Internal medicine","score_opus":0.15625057391779792,"score_gpt":0.4808210464594817,"score_spread":0.3245704725416838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013029269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007925732,0.9847951,0.000003662935,0.0006725005,0.0011349644,0.0012387624,0.000009267107,0.000013427387,0.0042066006],"genre_scores_gemma":[0.0015829842,0.99606395,0.00044054323,0.0012660234,0.00046433145,0.000012123464,0.000025244564,0.000046743775,0.000098065604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99339503,0.0007725908,0.004567711,0.00031631507,0.00056700455,0.00038136975],"domain_scores_gemma":[0.99250317,0.0011027645,0.0053530145,0.00031765632,0.0003955624,0.00032785255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027927053,0.00036848322,0.010289424,0.000387678,0.00002540547,0.0000120585055,0.00030680187,0.0009835457,0.00011993944],"category_scores_gemma":[0.0015183426,0.00021568467,0.0014757749,0.00035580673,0.00010121969,0.00008137495,0.000066533146,0.0017354322,0.000036305675],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015227636,0.024626095,0.008841084,0.0010856686,0.0014938659,0.0003581604,0.00002635224,4.873312e-7,1.728019e-9,0.000032920463,0.0060088923,0.9573742],"study_design_scores_gemma":[0.005208736,0.03440506,0.19073305,0.017777657,0.0051577003,0.000015723017,0.000006157102,1.8959251e-7,1.037524e-8,0.000038156362,0.746479,0.00017859001],"about_ca_topic_score_codex":0.00001592482,"about_ca_topic_score_gemma":0.000043552565,"teacher_disagreement_score":0.9571956,"about_ca_system_score_codex":0.0005668718,"about_ca_system_score_gemma":0.0019499708,"threshold_uncertainty_score":0.87953657},"labels":[],"label_agreement":null},{"id":"W2014179352","doi":"10.1200/jco.2014.56.3296","title":"SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Loyola University Chicago Stritch School of Medicine; U.S. Public Health Service; Louisiana State University; Genentech; Barbara Ann Karmanos Cancer Institute; Georgetown University; University of Arizona Cancer Center; National Cancer Institute; Cleveland Clinic; Canadian Cancer Society Research Institute; U.S. Department of Health and Human Services; Wayne State University; Loyola University Chicago","keywords":"Medicine; Taxane; Breast cancer; Anthracycline; Internal medicine; Cyclophosphamide; Oncology; Hazard ratio; Randomization; Paclitaxel; Interim analysis; Chemotherapy; Cancer; Stage (stratigraphy); Gynecology; Randomized controlled trial; Confidence interval","score_opus":0.05815462024215362,"score_gpt":0.43554072943563316,"score_spread":0.37738610919347954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014179352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512213,0.0004373486,0.00047794654,0.002157177,0.0013369758,0.0001757806,0.000023686458,0.0000052522655,0.00026370157],"genre_scores_gemma":[0.99216807,0.002446947,0.0010939265,0.000769521,0.0034166642,0.000018873987,0.0000053361064,0.000023312112,0.000057333247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704844,0.0005490155,0.0015981739,0.0003006092,0.00020377281,0.0002999667],"domain_scores_gemma":[0.99743813,0.0003545069,0.0015843554,0.00023479252,0.00019693768,0.00019126672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019250063,0.00020484798,0.0012667743,0.000077782555,0.000060550054,0.000014021936,0.0002795685,0.00036979918,0.000064815984],"category_scores_gemma":[0.00051209074,0.00015801947,0.00037382808,0.00009349626,0.00022770617,0.000011536871,0.000094136776,0.0005668917,0.000004721888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2171887,0.0042778035,0.5608624,0.000013788091,0.0011920553,0.00004676315,0.00011780594,0.0002619467,0.00077224826,0.00017597439,0.0011582337,0.21393228],"study_design_scores_gemma":[0.3434862,0.008949546,0.61797786,0.00005853481,0.000212833,0.00003884096,0.00007522199,0.00011687443,0.000804539,0.0002328442,0.027790297,0.00025640134],"about_ca_topic_score_codex":0.0008541658,"about_ca_topic_score_gemma":0.0012590038,"teacher_disagreement_score":0.21367589,"about_ca_system_score_codex":0.000092642425,"about_ca_system_score_gemma":0.0004902227,"threshold_uncertainty_score":0.6443847},"labels":[],"label_agreement":null},{"id":"W2015405631","doi":"10.1200/jco.2014.56.2447","title":"Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Raising (metalworking); Conflict of interest; Clinical Oncology; Oncology; Internal medicine; Law; Political science; Cancer","score_opus":0.9220277047279211,"score_gpt":0.7379440141524083,"score_spread":0.18408369057551277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015405631","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11081599,0.0014535328,0.00015206898,0.8714317,0.009159643,0.00070650975,0.00018460778,0.000025290856,0.006070672],"genre_scores_gemma":[0.27957818,0.010826355,0.00042705992,0.67737836,0.03101847,0.000013580195,0.00002549487,0.00006692731,0.0006655997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96428156,0.019403016,0.013646097,0.00071050756,0.00072129513,0.0012375307],"domain_scores_gemma":[0.9213938,0.049422964,0.025465107,0.00069771364,0.0018020263,0.001218366],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.031202,0.0007201087,0.008266253,0.0002585773,0.00023047629,0.000017564475,0.0022235045,0.008334861,0.00097263925],"category_scores_gemma":[0.008414156,0.0004924801,0.0039193444,0.00048950635,0.009619644,0.00012346957,0.0005279176,0.039560977,0.00005252505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004446974,0.0016398234,0.008739197,0.00036400717,0.0032153649,0.00043174086,0.00034670296,0.000036419773,0.00021912061,0.00043366855,0.73836654,0.24176043],"study_design_scores_gemma":[0.00735194,0.014181594,0.0038723955,0.0002602657,0.0017810629,0.0003382131,0.0002681298,0.00025801425,0.00038862752,0.0007035453,0.97020984,0.00038635984],"about_ca_topic_score_codex":0.00026022072,"about_ca_topic_score_gemma":0.00004732847,"teacher_disagreement_score":0.24137408,"about_ca_system_score_codex":0.0005537261,"about_ca_system_score_gemma":0.01084407,"threshold_uncertainty_score":0.99994063},"labels":[{"model":"gpt","categories":["research_integrity","metaresearch"],"domain":"evaluation","study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"opus","categories":["metaresearch","research_integrity"],"domain":"methods","study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2016056732","doi":"10.1200/jco.2008.21.6606","title":"Relationships Between Authorship Contributions and Authors' Industry Financial Ties Among Oncology Clinical Trials","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Clinical trial; Test (biology); Odds ratio; Odds; Family medicine; Internal medicine; Oncology; Logistic regression","score_opus":0.8928417148709451,"score_gpt":0.7447858718868725,"score_spread":0.1480558429840726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016056732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93138415,0.00041143195,0.00019909303,0.047301143,0.015996145,0.0005814406,0.00021694165,0.000053032523,0.003856657],"genre_scores_gemma":[0.9774585,0.0006341194,0.00087832886,0.004336885,0.015854675,0.000019703391,0.00002126771,0.00002917249,0.00076737226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9254272,0.06240931,0.010216081,0.00056373357,0.00042529375,0.00095836894],"domain_scores_gemma":[0.8619454,0.1160998,0.0092976745,0.00043494668,0.001871697,0.010350473],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.22463939,0.00039287645,0.0039530634,0.00028587208,0.0007386959,0.00004023221,0.00062037597,0.028895274,0.0015298553],"category_scores_gemma":[0.28014845,0.0003182123,0.0010062482,0.0003711063,0.002996243,0.00041126844,0.00023521697,0.0965219,0.00008197885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025296267,0.0013610994,0.78381747,0.00002501885,0.000562059,0.00033673155,0.00025961862,0.000006985997,0.00015667456,0.008841304,0.030483833,0.17161956],"study_design_scores_gemma":[0.006317563,0.002834391,0.52318555,0.00003078534,0.0011779217,0.000166254,0.00016338231,0.00015687781,0.00016223358,0.011350556,0.45421314,0.00024132936],"about_ca_topic_score_codex":0.000023947621,"about_ca_topic_score_gemma":0.00020293078,"teacher_disagreement_score":0.4237293,"about_ca_system_score_codex":0.00017540996,"about_ca_system_score_gemma":0.005874461,"threshold_uncertainty_score":0.999927},"labels":[{"model":"gemma","categories":["metaresearch","research_integrity"],"domain":"incentives","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["metaresearch","research_integrity"],"domain":"methods","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2016099956","doi":"10.1200/jco.2005.03.3571","title":"Paraneoplastic Erythropoietin-Induced Polycythemia Associated With Small Lymphocytic Lymphoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Erythropoietin; Lymphoma; Chronic lymphocytic leukemia; Polycythemia vera; Internal medicine; Cancer research; Oncology; Leukemia","score_opus":0.09455510757676037,"score_gpt":0.3866879914780393,"score_spread":0.2921328839012789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016099956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876542,0.0002584086,0.00011074851,0.004990024,0.0007400647,0.00027723386,0.000004417167,0.000024988214,0.0059398967],"genre_scores_gemma":[0.9938308,0.00012531441,0.0023862512,0.0015109638,0.0014663567,0.000012708915,0.000011173707,0.000037210426,0.0006191986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959854,0.00043737743,0.002352362,0.0002961807,0.00051499606,0.0004136736],"domain_scores_gemma":[0.9916721,0.004904585,0.0021137279,0.00022208176,0.0006430642,0.00044442917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014761533,0.00028681615,0.0020957727,0.00014044992,0.000085570624,0.000019120804,0.00013668482,0.00050524547,0.00018499244],"category_scores_gemma":[0.0029267564,0.00017518054,0.0005250388,0.00022827504,0.00023234011,0.00006531699,0.0000310529,0.00047599073,0.000058287365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02089496,0.020588415,0.8183289,0.00007005977,0.004089056,0.01851846,0.0001540448,0.00018885432,0.0006964811,0.0008387858,0.013100932,0.10253104],"study_design_scores_gemma":[0.046622135,0.035886895,0.8941295,0.00048307664,0.0018195139,0.0032927196,0.00007522952,0.00018284339,0.0016338009,0.00035908446,0.015245297,0.00026988052],"about_ca_topic_score_codex":0.00010703126,"about_ca_topic_score_gemma":0.00029480868,"teacher_disagreement_score":0.102261156,"about_ca_system_score_codex":0.0010849141,"about_ca_system_score_gemma":0.0047678095,"threshold_uncertainty_score":0.84578896},"labels":[],"label_agreement":null},{"id":"W2017702479","doi":"10.1200/jco.2005.05.322","title":"Pattern of Care at the End of Life: Does Age Make a Difference?","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; End-of-life care; Gerontology; Demography; Palliative care; Nursing","score_opus":0.2826665578288465,"score_gpt":0.5263861995052802,"score_spread":0.24371964167643373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017702479","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51874053,0.010550278,0.000040426647,0.46203184,0.00279069,0.00030818832,0.00020045089,0.000005524488,0.00533204],"genre_scores_gemma":[0.46886063,0.019738559,0.0012669878,0.4751811,0.02737199,0.000007979855,0.000081231396,0.000078627294,0.0074128928],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99416405,0.00074616465,0.0038258908,0.00021775343,0.00078158895,0.0002645464],"domain_scores_gemma":[0.98532486,0.007738729,0.0054405867,0.00042571628,0.00089136366,0.00017876686],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011534323,0.00026547437,0.0038969114,0.00015530284,0.00002071249,0.000002984037,0.00046454155,0.0014951311,0.00078220456],"category_scores_gemma":[0.0039569666,0.00012671448,0.0013916472,0.00008812076,0.0009820699,0.000020791811,0.0001508246,0.0030771934,0.0000062264944],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022945262,0.00060589914,0.2264163,0.001421305,0.0021341238,0.0025587687,0.0025194965,0.0000021313767,0.00020187853,0.000004209776,0.5733062,0.18853515],"study_design_scores_gemma":[0.003511327,0.006020712,0.04938487,0.001744695,0.0011368619,0.0000628131,0.00051053095,0.0000015171587,0.00032352886,0.000056240762,0.93712944,0.00011744477],"about_ca_topic_score_codex":0.000095889525,"about_ca_topic_score_gemma":0.00052538665,"teacher_disagreement_score":0.36382326,"about_ca_system_score_codex":0.00015380153,"about_ca_system_score_gemma":0.0013325254,"threshold_uncertainty_score":0.99980116},"labels":[],"label_agreement":null},{"id":"W2018038855","doi":"10.1200/jco.2006.09.5281","title":"Palliative Radiotherapy Trials for Bone Metastases: A Systematic Review","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Radiation therapy; Odds ratio; Internal medicine; Palliative care; Forest plot; Pathological; Surgery","score_opus":0.6544507210468016,"score_gpt":0.6580509111508396,"score_spread":0.0036001901040380035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018038855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.6263932e-7,0.9756763,0.007892134,0.001780462,0.0016439758,0.0125169065,0.00009587224,0.000014353373,0.00037981116],"genre_scores_gemma":[8.8413096e-8,0.95441675,0.032214273,0.010091986,0.0018120173,0.00030781148,0.000059880043,0.00009013075,0.0010070824],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9637218,0.009441192,0.024827546,0.00045280592,0.0011119329,0.00044468214],"domain_scores_gemma":[0.8949015,0.06130409,0.040504236,0.00089477526,0.0013448766,0.001050532],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.11767633,0.00064466865,0.04740421,0.00059146516,0.000036785637,0.000020573227,0.0005135049,0.00073386723,0.00049701205],"category_scores_gemma":[0.16842015,0.00035174322,0.012819232,0.00043151964,0.00017978449,0.000088436704,0.000055291133,0.0015288464,0.000041464453],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007183108,0.0010569796,3.8232562e-7,0.554716,0.009146311,0.0007372105,0.000005682569,2.8327952e-8,8.40389e-9,0.00011285707,0.029232075,0.40427417],"study_design_scores_gemma":[0.004318795,0.004195886,7.839786e-7,0.3646241,0.101990305,0.00022804896,0.000014952578,0.0000018264452,1.0905794e-8,0.000051877014,0.5244325,0.00014093713],"about_ca_topic_score_codex":8.6341356e-7,"about_ca_topic_score_gemma":8.782041e-7,"teacher_disagreement_score":0.4952004,"about_ca_system_score_codex":0.0004669106,"about_ca_system_score_gemma":0.0051102727,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W2018698872","doi":"10.1200/jco.2006.10.0651","title":"Trastuzumab-Associated Peripheral Vascular Toxicity","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Toxicity; Peripheral; Cardiotoxicity; Oncology; Internal medicine; Breast cancer; Pharmacology; Cancer","score_opus":0.22312135106304717,"score_gpt":0.5646926958525449,"score_spread":0.3415713447894977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018698872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750635,0.00053306774,0.0010782408,0.0056378325,0.0017009302,0.00019278604,0.0000017518067,0.00001763415,0.015774254],"genre_scores_gemma":[0.9897507,0.000528723,0.0027287793,0.0036772825,0.0024878087,0.0000012738201,0.0000014388349,0.000024860909,0.0007991658],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949766,0.0005994737,0.0027193085,0.00019746232,0.0009958466,0.0005113532],"domain_scores_gemma":[0.9944218,0.0024819414,0.001079606,0.00023351333,0.00091507105,0.00086810306],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018966641,0.00013392724,0.0015723961,0.00015026653,0.000051977288,0.0000102974445,0.00025945017,0.00066031946,0.0010346047],"category_scores_gemma":[0.013948715,0.00009840496,0.00087457465,0.0002817922,0.0003107345,0.00008150453,0.00005635103,0.0023148758,0.00004136602],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068618506,0.0072709885,0.3587375,0.000064335385,0.0016272214,0.0062007704,0.00038767685,0.000021235466,0.002497554,0.00017476449,0.042222034,0.5739341],"study_design_scores_gemma":[0.008740809,0.01910623,0.68943805,0.00010721402,0.00022253659,0.0003694844,0.0001825484,0.00007751687,0.00035940332,0.00024998724,0.28103474,0.00011151927],"about_ca_topic_score_codex":0.000036101945,"about_ca_topic_score_gemma":0.00017023031,"teacher_disagreement_score":0.57382256,"about_ca_system_score_codex":0.0010047193,"about_ca_system_score_gemma":0.0032401737,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W2018888053","doi":"10.1200/jco.2005.04.1376","title":"Bone Loss With Exemestane: Is the Jury Still Out?","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Exemestane; Jury; Internal medicine; Oncology; Intensive care medicine; Gynecology; Breast cancer; Cancer; Aromatase; Law","score_opus":0.12679744801234147,"score_gpt":0.4805428226590737,"score_spread":0.3537453746467323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018888053","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00943254,0.0021169276,0.000019428482,0.97722673,0.0023526447,0.0004456688,0.000017359653,0.000012553319,0.008376154],"genre_scores_gemma":[0.006529906,0.003086657,0.0024484613,0.95246285,0.016085694,0.000008788952,0.000017607237,0.00006189911,0.01929816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99447465,0.0005475771,0.0032388982,0.0003139558,0.0008775722,0.0005473637],"domain_scores_gemma":[0.99138224,0.003215176,0.0037793897,0.0005202129,0.00059092697,0.0005120486],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002170896,0.00034261373,0.0030364797,0.0001337605,0.000062347666,0.000012455423,0.00026517088,0.002059065,0.0004564999],"category_scores_gemma":[0.0009858428,0.0001589188,0.00079226174,0.00010514735,0.00049560994,0.00006859409,0.00004702994,0.008330141,0.00022637023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034069715,0.00076085876,0.004804998,0.000081378734,0.00083380524,0.020687034,0.00008189721,2.275755e-7,1.3296412e-7,0.000003281205,0.8728824,0.096456975],"study_design_scores_gemma":[0.00862833,0.014909323,0.017015763,0.00029747467,0.0017963038,0.0065114475,0.000013203881,0.000001893153,0.0000012342423,0.00008189484,0.95061046,0.00013265091],"about_ca_topic_score_codex":0.000026984953,"about_ca_topic_score_gemma":0.000070692455,"teacher_disagreement_score":0.096324325,"about_ca_system_score_codex":0.00030733956,"about_ca_system_score_gemma":0.00524728,"threshold_uncertainty_score":0.99923646},"labels":[],"label_agreement":null},{"id":"W2018929154","doi":"10.1200/jco.2007.12.1939","title":"Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":549,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Cyclophosphamide; Vascular endothelial growth factor; Regimen; Adverse effect; Ovarian cancer; Clinical endpoint; Oncology; Chemotherapy; Gastroenterology; Phases of clinical research; Cancer; Surgery; Clinical trial","score_opus":0.08053328566653827,"score_gpt":0.47261857151957426,"score_spread":0.392085285853036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018929154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984698,0.0015152101,0.000020012982,0.0076500806,0.004261062,0.0016373788,0.0000937994,0.0000042726883,0.00012021173],"genre_scores_gemma":[0.99264264,0.004770748,0.0007760521,0.00034741595,0.0013924788,0.00002536072,0.0000048826755,0.000020773858,0.000019658317],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921169,0.000712449,0.005915262,0.00042732464,0.00045510943,0.0003729317],"domain_scores_gemma":[0.99178517,0.0028208331,0.0042265314,0.00035157322,0.0002732395,0.00054262695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008533396,0.0002713726,0.003002232,0.00017403475,0.0000835547,0.0000085730335,0.00023700998,0.00052300264,0.00011181227],"category_scores_gemma":[0.0038283283,0.00017309409,0.00073255267,0.00023536051,0.00087532826,0.000091508475,0.0002281943,0.0012319012,5.7981856e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51248485,0.0433751,0.04882451,0.0000395832,0.00072252215,0.00018261177,0.0001412791,0.0000016140395,0.000011626919,0.00008232317,0.0003375409,0.39379644],"study_design_scores_gemma":[0.7095241,0.17561595,0.101542704,0.00030457805,0.0012011895,0.000042907755,0.00007159534,0.00005120429,0.00013817775,0.00015545763,0.011219053,0.00013309406],"about_ca_topic_score_codex":0.00022459222,"about_ca_topic_score_gemma":0.00054161745,"teacher_disagreement_score":0.39366335,"about_ca_system_score_codex":0.00030062866,"about_ca_system_score_gemma":0.0029045902,"threshold_uncertainty_score":0.70585716},"labels":[],"label_agreement":null},{"id":"W2019983958","doi":"10.1200/jco.2004.05.055","title":"Cancer Risks for Male Carriers of Germline Mutations in <i>BRCA1</i> or <i>BRCA2</i>: A Review of the Literature","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":407,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer; Breast cancer; Germline mutation; Oncology; Ovarian cancer; Internal medicine; Prostate cancer; Colorectal cancer; Prostate; BRCA mutation; Mutation; BRCA2 Protein; Genetics; Gene; Biology","score_opus":0.14707110631152173,"score_gpt":0.5251539864488639,"score_spread":0.37808288013734215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019983958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016879375,0.995375,0.00009787511,0.001037461,0.0016999962,0.0009760707,0.0005010382,9.725544e-7,0.00014282005],"genre_scores_gemma":[0.00016110948,0.9940998,0.0031736377,0.0009939724,0.00092604564,0.00013439619,0.00006477489,0.000039930226,0.00040632178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939513,0.00076802395,0.004498734,0.00030941883,0.00025593658,0.00021653948],"domain_scores_gemma":[0.9910909,0.0008886511,0.0063790553,0.00048667335,0.0010409092,0.00011382484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027118388,0.0002796142,0.0032065443,0.00011794296,0.000030558323,0.000005230133,0.0007363862,0.0010632058,0.000073583906],"category_scores_gemma":[0.005523716,0.00016200014,0.0020526398,0.00053537363,0.00037203258,0.0000072038742,0.00012091159,0.0009684947,4.8229094e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046441317,0.00054743927,0.00011206031,0.069045104,0.0012621,0.00002903796,0.00007178498,0.0001838595,0.000034818353,0.000033113152,0.01763197,0.91058433],"study_design_scores_gemma":[0.0015621805,0.0013215581,0.00004064673,0.07080515,0.0015843315,0.00022201946,0.000016309428,7.008922e-7,0.000061032642,0.00007371257,0.9241645,0.00014788886],"about_ca_topic_score_codex":0.000014523415,"about_ca_topic_score_gemma":0.00020003374,"teacher_disagreement_score":0.9104364,"about_ca_system_score_codex":0.00021441685,"about_ca_system_score_gemma":0.016464043,"threshold_uncertainty_score":0.9891117},"labels":[],"label_agreement":null},{"id":"W2020355527","doi":"10.1200/jco.2010.33.4383","title":"Reply to A.A. Brandes et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Medical physics; Overall survival; Neurooncology; End point; Oncology; Surgery; Internal medicine; Computer science","score_opus":0.24356945481004072,"score_gpt":0.507618088322239,"score_spread":0.26404863351219826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020355527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48476142,0.01219241,0.00016622448,0.45466337,0.01757329,0.0002810914,0.00000837648,0.0000088210845,0.030344982],"genre_scores_gemma":[0.69983304,0.006724041,0.011426148,0.2779448,0.0027214186,0.0000062562985,0.0000011460379,0.000031199364,0.0013119768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99477327,0.0009752445,0.003179638,0.00025951004,0.0003830801,0.00042924852],"domain_scores_gemma":[0.99269664,0.0036088226,0.0015906824,0.0002961831,0.0005377674,0.0012698835],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00659234,0.0001983415,0.0019443526,0.00016934903,0.000034544908,0.000010601203,0.00021534866,0.0003826835,0.0025356498],"category_scores_gemma":[0.0075457515,0.00014075654,0.000887436,0.00017272354,0.00024645997,0.00013823916,0.000088472014,0.0010858242,0.00064833055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035066365,0.010619512,0.12779473,0.000019510922,0.0011410944,0.0077996477,0.00055510004,0.0000045728993,0.000055115517,0.0023516987,0.4919538,0.3541986],"study_design_scores_gemma":[0.0075519118,0.028516835,0.28228503,0.00033982124,0.0007126899,0.0007743109,0.0001251943,0.0000062178683,0.0002277247,0.00064561004,0.67872816,0.00008649812],"about_ca_topic_score_codex":0.00019271387,"about_ca_topic_score_gemma":0.000079443955,"teacher_disagreement_score":0.3541121,"about_ca_system_score_codex":0.00020596753,"about_ca_system_score_gemma":0.0017812073,"threshold_uncertainty_score":0.9983762},"labels":[],"label_agreement":null},{"id":"W2020600748","doi":"10.1200/jco.2012.43.4522","title":"Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Epidermal growth factor receptor; Medicine; Epidermal growth factor; Growth factor receptor inhibitor; Cancer research; TGF alpha; Lung cancer; Receptor; Oncology; Internal medicine","score_opus":0.0918863305507524,"score_gpt":0.46809057986487623,"score_spread":0.37620424931412383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020600748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03745329,0.9509221,0.000013246533,0.0016237433,0.0060200514,0.0022842165,0.00022609744,0.00002113621,0.0014361533],"genre_scores_gemma":[0.0053624623,0.9858893,0.0027282757,0.00053956563,0.0040971534,0.000115972674,0.00008327663,0.00013972551,0.001044278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891431,0.0012510753,0.0075453557,0.00066009024,0.0006649664,0.0007354111],"domain_scores_gemma":[0.9857402,0.0037650778,0.0076766848,0.00041066797,0.0014482904,0.0009590739],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001365192,0.0007919932,0.008659048,0.00068449765,0.0000671419,0.000023193224,0.00052983954,0.0019260758,0.0020549083],"category_scores_gemma":[0.0032398407,0.0005307514,0.0023517276,0.00063850003,0.00028530692,0.00031845956,0.00015833486,0.0030743496,0.00011124392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072871835,0.003391323,0.041123703,0.008195232,0.00338405,0.0001889756,0.0004753939,0.0000025121071,0.00009682715,0.000021620614,0.02266726,0.9197244],"study_design_scores_gemma":[0.007825201,0.006388009,0.007677129,0.012234307,0.0062785638,0.00013111101,0.00014036977,0.000012448577,0.0001229612,0.000031771884,0.9585543,0.0006038063],"about_ca_topic_score_codex":0.0006709826,"about_ca_topic_score_gemma":0.00009259001,"teacher_disagreement_score":0.93588704,"about_ca_system_score_codex":0.0015557874,"about_ca_system_score_gemma":0.011749771,"threshold_uncertainty_score":0.9997144},"labels":[],"label_agreement":null},{"id":"W2020681158","doi":"10.1200/jco.2009.24.5217","title":"Reply to S.G. Williams et al","year":2009,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.10431215521935314,"score_gpt":0.5630857426648429,"score_spread":0.4587735874454898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020681158","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048000507,0.010426935,0.0008434286,0.8842186,0.014613663,0.00025432892,0.000010295549,0.000008878021,0.041623395],"genre_scores_gemma":[0.177807,0.0074037174,0.017899405,0.76820916,0.005248752,0.0000023972373,0.0000039276915,0.00002057678,0.02340508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959741,0.00049156253,0.0025860032,0.00021836977,0.00037057308,0.00035937535],"domain_scores_gemma":[0.99532866,0.0016083249,0.0012814495,0.00023527881,0.000534858,0.0010113961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035479346,0.00015910287,0.0013898752,0.000114484814,0.000043562577,0.000015447371,0.00015959976,0.00028591126,0.00055441546],"category_scores_gemma":[0.004650985,0.00011667694,0.00059477123,0.00019716345,0.00012844526,0.00017596703,0.00002498889,0.0010931917,0.00030778407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001131545,0.0025102426,0.00383192,0.0000058587298,0.00044508404,0.0015586566,0.00025181097,0.00006780705,0.00002575167,0.0014120105,0.46814197,0.5206173],"study_design_scores_gemma":[0.005948355,0.03968973,0.11981111,0.0003420317,0.0009750429,0.00061840186,0.00013213186,0.000019577063,0.000012986631,0.0009323921,0.83143187,0.000086385975],"about_ca_topic_score_codex":0.00006113961,"about_ca_topic_score_gemma":0.000018660241,"teacher_disagreement_score":0.52053094,"about_ca_system_score_codex":0.00048564686,"about_ca_system_score_gemma":0.004243673,"threshold_uncertainty_score":0.7528093},"labels":[],"label_agreement":null},{"id":"W2020727031","doi":"10.1200/jco.2014.55.3925","title":"Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":474,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Cisplatin; Head and neck; Randomized controlled trial; Oncology; Head and neck cancer; Internal medicine; Dose fractionation; Chemotherapy; Surgery","score_opus":0.19860946934145188,"score_gpt":0.5206941533948487,"score_spread":0.32208468405339685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020727031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988032,0.00026899364,0.0007425439,0.0066915425,0.0010362213,0.0030922983,0.0000030079304,0.0000033670347,0.00013003759],"genre_scores_gemma":[0.9978435,0.00085167936,0.00030475692,0.00036304395,0.0005212442,0.000090860565,0.0000136181325,0.000007509773,0.0000038060375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960926,0.001036507,0.0022714566,0.00018506391,0.00028134158,0.00013301443],"domain_scores_gemma":[0.9797369,0.017845744,0.0018237749,0.000090327485,0.00039546413,0.00010776282],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010095069,0.00011845811,0.002015175,0.00017601265,0.000044718385,0.000009742487,0.000053296088,0.00021234558,0.0000071530158],"category_scores_gemma":[0.013399921,0.00007006018,0.0001181584,0.0001661098,0.00015418582,0.000098217126,0.000011971776,0.00041133884,6.9662775e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8117976,0.00367923,0.004997822,0.000014661204,0.000104271494,0.000036663605,0.0004938945,0.0000037209547,0.00007345975,0.00005232645,0.00011150683,0.17863484],"study_design_scores_gemma":[0.7507732,0.15977651,0.087097876,0.00006856711,0.00014970453,0.000041400413,0.000049863607,0.00019537883,0.00004977862,0.00003478828,0.0017121243,0.00005081588],"about_ca_topic_score_codex":0.000033702334,"about_ca_topic_score_gemma":0.0005029404,"teacher_disagreement_score":0.17858402,"about_ca_system_score_codex":0.0001760592,"about_ca_system_score_gemma":0.0006592169,"threshold_uncertainty_score":0.99491066},"labels":[],"label_agreement":null},{"id":"W2022598730","doi":"10.1200/jco.2005.05.109","title":"The Metrics of Clinical Trials","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Lakeridge Health; Regional Municipality of Durham; Hamilton Health Sciences; University Health Network; McMaster University; Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"McMaster University; Hamilton Health Sciences","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.9805469177061555,"score_gpt":0.7800014009415808,"score_spread":0.20054551676457477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022598730","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":"methods","domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001239679,0.008908993,0.0031010003,0.9433662,0.021661347,0.00078461133,0.000029849922,0.0000017504838,0.02090654],"genre_scores_gemma":[0.003122006,0.013888622,0.022352628,0.791333,0.10537169,0.000012586967,0.000006892575,0.000064268366,0.06384829],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.10546999,0.5188494,0.35127178,0.0015387177,0.022113398,0.0007567419],"domain_scores_gemma":[0.035431143,0.6760356,0.27469945,0.004332089,0.009025994,0.00047573683],"candidate_categories":["metaresearch","metaepi_broad","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity","insufficient_payload"],"category_scores_codex":[0.93091595,0.000523952,0.053568438,0.00091091834,0.00012413644,0.00040498647,0.008703936,0.0042125117,0.007901698],"category_scores_gemma":[0.9543732,0.0001675007,0.042900365,0.0016697374,0.00082861714,0.00018854463,0.000374445,0.010086415,0.001588515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113075526,0.00016089737,0.0022566651,0.000012334384,0.0016982518,0.0001269882,0.000007817726,0.0000045060497,8.3213905e-8,0.000072131086,0.61265355,0.38289368],"study_design_scores_gemma":[0.0013687197,0.0020228922,0.003127194,0.000055556713,0.0034088343,0.00009246476,0.000055017532,0.00021188037,3.8274237e-7,0.0049383705,0.98456943,0.00014927184],"about_ca_topic_score_codex":0.000003505145,"about_ca_topic_score_gemma":0.00001997166,"teacher_disagreement_score":0.3827444,"about_ca_system_score_codex":0.00007530407,"about_ca_system_score_gemma":0.0042327866,"threshold_uncertainty_score":0.99918884},"labels":[],"label_agreement":null},{"id":"W2023915585","doi":"10.1200/jco.2010.33.5232","title":"Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; St. Michael's Hospital","funders":"","keywords":"Medicine; Biopsy; Metastatic breast cancer; Breast cancer; Prospective cohort study; Primary tumor; Cancer; Metastasis; Progesterone receptor; Oncology; Internal medicine; Estrogen receptor","score_opus":0.0861491838148797,"score_gpt":0.48033749217934274,"score_spread":0.39418830836446306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023915585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904348,0.0003497965,0.000007184168,0.007941658,0.00024142732,0.00077775517,0.00019986015,7.785128e-7,0.000046715017],"genre_scores_gemma":[0.99691474,0.000059691545,0.00010808203,0.0021717874,0.0006393362,0.000040457508,0.000026473019,0.000021034404,0.000018365674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966239,0.0009782503,0.0016302182,0.00021726947,0.00038202087,0.00016836179],"domain_scores_gemma":[0.99424905,0.00038773404,0.003882005,0.00025499237,0.0011647632,0.00006145361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001142092,0.00021814869,0.0012501442,0.000075453245,0.000022864484,0.0000033698025,0.0002520624,0.0001897585,0.000048511814],"category_scores_gemma":[0.00058791187,0.000110782894,0.00029784435,0.00009429549,0.0002803774,0.000008640812,0.00007958796,0.00070407626,5.1651705e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009387151,0.002423684,0.9724615,0.000044707733,0.0029088892,0.000034123743,0.0002398686,0.0001832164,0.000010935967,3.573013e-7,0.0061577554,0.006147783],"study_design_scores_gemma":[0.006786458,0.022298336,0.969298,0.00010981011,0.0011137059,0.0000067277065,0.00006183988,0.0000043820323,0.000015626672,0.000037299284,0.00016811767,0.000099682315],"about_ca_topic_score_codex":0.0006482265,"about_ca_topic_score_gemma":0.00014057064,"teacher_disagreement_score":0.019874653,"about_ca_system_score_codex":0.0001308343,"about_ca_system_score_gemma":0.0017337553,"threshold_uncertainty_score":0.45175952},"labels":[],"label_agreement":null},{"id":"W2026638264","doi":"10.1200/jco.2003.12.066","title":"Exercise and Cancer: No Pain, Some Gain?","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia","funders":"","keywords":"Medicine; Citation; Clinical Oncology; Cancer; Oncology; Internal medicine; Alternative medicine; Gerontology; Family medicine; Library science; Pathology","score_opus":0.09033072698320341,"score_gpt":0.43582885595377385,"score_spread":0.3454981289705704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026638264","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003533768,0.035006363,0.000020691608,0.941239,0.015115603,0.00030583594,0.000021507745,0.000014343138,0.0047429036],"genre_scores_gemma":[0.00061744114,0.060735073,0.0002670954,0.90189403,0.029033845,0.000012164873,0.000010663091,0.000054208333,0.007375489],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521625,0.000976129,0.002525834,0.0003237661,0.0005732686,0.00038476728],"domain_scores_gemma":[0.9933718,0.002731581,0.0022865247,0.00029845376,0.000876833,0.00043483052],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0047543286,0.00029195403,0.0032510012,0.00017906385,0.00003671278,0.000015893005,0.00020113832,0.0024694602,0.0007184906],"category_scores_gemma":[0.0029183335,0.00021222155,0.00087785476,0.00009628699,0.00030232148,0.0000824733,0.000048276568,0.0062820422,0.000032457803],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008662768,0.00013975125,0.0021397674,0.00026456782,0.00028762245,0.003810295,0.000042000716,2.6197714e-7,0.0000018633352,0.000002977914,0.7955263,0.19691826],"study_design_scores_gemma":[0.003327086,0.0054931594,0.0008182511,0.00093492557,0.0011496701,0.0003472179,0.000050441064,0.000004416376,0.0000034206062,0.00025677518,0.9874161,0.00019857232],"about_ca_topic_score_codex":0.00017519134,"about_ca_topic_score_gemma":0.00009916792,"teacher_disagreement_score":0.19671969,"about_ca_system_score_codex":0.0002517999,"about_ca_system_score_gemma":0.0032421257,"threshold_uncertainty_score":0.99882555},"labels":[],"label_agreement":null},{"id":"W2027165472","doi":"10.1200/jco.2009.24.3246","title":"Reply to C. Parker et al","year":2009,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.14655474810116428,"score_gpt":0.5243762752201361,"score_spread":0.37782152711897177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027165472","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09857974,0.023739558,0.00015944935,0.8520795,0.012321871,0.00027683834,0.000011181349,0.0000068863865,0.012824992],"genre_scores_gemma":[0.2554246,0.032455966,0.0066576474,0.6982746,0.0040491396,0.0000042986317,0.000002216101,0.000017345426,0.003114195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949142,0.00076272537,0.0031582238,0.00028072702,0.0004176654,0.00046647745],"domain_scores_gemma":[0.9934773,0.0028835887,0.0015325322,0.000284851,0.00052542426,0.0012963081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006314493,0.00019941463,0.0019074983,0.00010341875,0.000032234144,0.000017002987,0.00017264848,0.000318513,0.00075001473],"category_scores_gemma":[0.005610884,0.00014539609,0.0007549619,0.00016957795,0.00014387065,0.00014642792,0.000041057363,0.0012772832,0.0003319053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002204603,0.0036587268,0.016882472,0.0000069280973,0.00033139548,0.0032251547,0.00009339446,0.000026729458,0.000012506221,0.0007904951,0.5004191,0.47234848],"study_design_scores_gemma":[0.0055753803,0.0525739,0.26463348,0.0004855813,0.0004486857,0.00045448492,0.000047145215,0.000012257744,0.000047816604,0.0008712708,0.6747644,0.000085589825],"about_ca_topic_score_codex":0.00004036367,"about_ca_topic_score_gemma":0.000015829266,"teacher_disagreement_score":0.4722629,"about_ca_system_score_codex":0.0005556817,"about_ca_system_score_gemma":0.0030523734,"threshold_uncertainty_score":0.82121354},"labels":[],"label_agreement":null},{"id":"W2027754619","doi":"10.1200/jco.2005.01.6550","title":"Fatigue, Menopausal Symptoms, and Cognitive Function in Women After Adjuvant Chemotherapy for Breast Cancer: 1- and 2-Year Follow-Up of a Prospective Controlled Study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Tamoxifen; Chemotherapy; Quality of life (healthcare); Cancer; Prospective cohort study; Oncology","score_opus":0.032793146827532184,"score_gpt":0.40631798681814735,"score_spread":0.37352483999061514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027754619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920027,0.001664646,0.000060387385,0.0036177402,0.0003700845,0.0020921633,0.00003923408,0.000005482787,0.00014755887],"genre_scores_gemma":[0.99625516,0.0013096065,0.00009348778,0.001254171,0.00062784454,0.00030269029,4.971231e-7,0.000018274497,0.00013827338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975234,0.00020432411,0.0015601938,0.00023774187,0.00023996097,0.00023436411],"domain_scores_gemma":[0.9961018,0.0017314968,0.0010937287,0.000054945875,0.00083870796,0.00017932011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019380955,0.00017029514,0.002042519,0.00017273343,0.000031369967,0.000005636526,0.000034067554,0.00018051338,0.00008637067],"category_scores_gemma":[0.0010210553,0.00012055655,0.00012426163,0.00012018256,0.00026304208,0.000118814285,0.000031775126,0.00047431074,4.7358057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3085348,0.0023610657,0.4728631,0.000033041644,0.002976275,0.00002387566,0.0019822759,9.973421e-7,0.00005724822,0.0000042622537,0.00013167612,0.21103136],"study_design_scores_gemma":[0.1921268,0.04327248,0.7596812,0.00027441775,0.0012702508,0.000046488796,0.0028528597,0.000031453495,0.0000115348375,0.00010088926,0.00024852107,0.000083092295],"about_ca_topic_score_codex":0.000019416835,"about_ca_topic_score_gemma":0.00026039593,"teacher_disagreement_score":0.28681812,"about_ca_system_score_codex":0.00027436542,"about_ca_system_score_gemma":0.00051132025,"threshold_uncertainty_score":0.49161536},"labels":[],"label_agreement":null},{"id":"W2027807378","doi":"10.1200/jco.2003.04.093","title":"Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":756,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Confidence interval; Randomized controlled trial; VO2 max; Internal medicine; Physical therapy; Cancer; Heart rate; Blood pressure","score_opus":0.1211583229837176,"score_gpt":0.45558913060352874,"score_spread":0.33443080761981114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027807378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872995,0.003789951,0.000014639198,0.0018344049,0.0026181657,0.0011148255,0.00001711242,0.0000033997692,0.0018775375],"genre_scores_gemma":[0.9959812,0.0030430406,0.0001252964,0.00036608885,0.00034348137,0.000036151076,8.1982e-7,0.000013750059,0.00009017434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9897306,0.0035918313,0.0057700505,0.00017930176,0.0005208649,0.00020732955],"domain_scores_gemma":[0.98541635,0.010006849,0.0035198724,0.00017372573,0.0005541712,0.00032904025],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021031445,0.00017637144,0.009950241,0.00019469981,0.000014069323,0.0000032242497,0.000099445584,0.00037692345,0.00010360955],"category_scores_gemma":[0.012344735,0.000111078654,0.0012960556,0.00015056248,0.00040844572,0.00007151644,0.000022929144,0.00065468694,2.2598019e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.845827,0.0008577857,0.14120926,0.00009892643,0.0008514946,0.000048425554,0.00069320196,0.000007702102,0.00003097966,0.00018767292,0.000014678742,0.010172877],"study_design_scores_gemma":[0.8999626,0.0026563907,0.09418274,0.00022902987,0.0009268719,0.00004099724,0.0014691245,0.00000742631,0.0000063043944,0.00023888392,0.00018904581,0.000090556416],"about_ca_topic_score_codex":0.0021038887,"about_ca_topic_score_gemma":0.0017460878,"teacher_disagreement_score":0.05413563,"about_ca_system_score_codex":0.00006593931,"about_ca_system_score_gemma":0.0030241683,"threshold_uncertainty_score":0.9959747},"labels":[],"label_agreement":null},{"id":"W2029461564","doi":"10.1200/jco.2013.53.8272","title":"Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Exemestane; Medicine; Tamoxifen; Internal medicine; Oncology; Breast cancer; Context (archaeology); Mutation; Cancer research; Cancer; Gene; Genetics; Biology","score_opus":0.060028742616158766,"score_gpt":0.4335396661659726,"score_spread":0.37351092354981386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029461564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351794,0.0002971442,0.00463483,0.00030310746,0.00070820714,0.00016389687,0.000020514808,0.0000035254877,0.00035083774],"genre_scores_gemma":[0.9939231,0.000028604867,0.004605411,0.00055528537,0.000747384,0.000010696556,0.000040970503,0.000019769896,0.000068768415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942041,0.0015409063,0.003068558,0.0003990965,0.0005116208,0.00027569395],"domain_scores_gemma":[0.9944708,0.0016555917,0.0025001355,0.00028312163,0.0009132335,0.00017713704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007517168,0.00019620219,0.0014832199,0.00042175516,0.00003768435,0.000008227925,0.00044321007,0.0004766673,0.00012443258],"category_scores_gemma":[0.0058550574,0.00016909487,0.00060438615,0.0004437488,0.0002510737,0.000013223371,0.000120338475,0.0005675665,0.0000030970589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004452717,0.007879464,0.68133163,0.000034299916,0.0040035513,0.0006327885,0.00076677947,0.047320094,0.16243006,0.00038285268,0.0004974027,0.09026833],"study_design_scores_gemma":[0.01757313,0.033875167,0.90225846,0.00007600789,0.0017516697,0.00019690025,0.0007835388,0.005368074,0.020801423,0.0012579885,0.0154018765,0.00065578567],"about_ca_topic_score_codex":0.000020331167,"about_ca_topic_score_gemma":0.00022557582,"teacher_disagreement_score":0.22092678,"about_ca_system_score_codex":0.00007796276,"about_ca_system_score_gemma":0.0010216879,"threshold_uncertainty_score":0.70094734},"labels":[],"label_agreement":null},{"id":"W2029520841","doi":"10.1200/jco.2014.57.2552","title":"Reply to C.G. Azzoli et al and C. Chouaid et al","year":2014,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine","score_opus":0.144624744578,"score_gpt":0.4205264612002924,"score_spread":0.2759017166222924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029520841","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033806253,0.0051865242,0.002325603,0.9115468,0.0156683,0.00029869314,0.00017230118,0.000010301211,0.030985197],"genre_scores_gemma":[0.012853991,0.020002253,0.006260413,0.94957316,0.0060441755,0.000009373224,0.000014641644,0.000107135646,0.005134862],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.988949,0.0006222986,0.008372948,0.0009900894,0.00015322202,0.000912432],"domain_scores_gemma":[0.98365456,0.004451226,0.009977717,0.0006407355,0.00038986572,0.0008858716],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.016509732,0.0005957382,0.0056461394,0.00057175505,0.00010720376,0.00018173426,0.00087200856,0.0017271102,0.00093282125],"category_scores_gemma":[0.010280916,0.0006375169,0.0013119064,0.00017399981,0.0006136354,0.0006984786,0.00032505213,0.006160139,0.0009105465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007182342,0.00034145158,0.025232513,0.00004301939,0.00040632303,0.00031048426,0.00015828341,0.00008016939,7.2824787e-7,0.008382083,0.91694677,0.04737997],"study_design_scores_gemma":[0.0035838226,0.008057103,0.07155454,0.00018282335,0.0000947487,0.00038744416,0.000016158527,0.000110115325,9.63936e-7,0.005619719,0.90978175,0.0006107875],"about_ca_topic_score_codex":0.0004041088,"about_ca_topic_score_gemma":0.00013121661,"teacher_disagreement_score":0.046769183,"about_ca_system_score_codex":0.0005460436,"about_ca_system_score_gemma":0.0014765533,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W2029676595","doi":"10.1200/jco.2012.41.7667","title":"Cancer Survivorship Care: Don't Let the Perfect Be the Enemy of the Good","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Survivorship curve; Cancer survivorship; Medicine; Cancer; Family medicine; Gerontology; Internal medicine","score_opus":0.3509365220914713,"score_gpt":0.546135191554911,"score_spread":0.19519866946343967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029676595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000612184,0.9185728,0.000003047543,0.0676435,0.008679464,0.0012288372,0.00006073982,0.000009012727,0.0031904317],"genre_scores_gemma":[0.0025757116,0.96871656,0.00004368035,0.017186886,0.010796699,0.000046620757,0.0000062030003,0.000077765486,0.000549858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9815067,0.009597803,0.006376982,0.00035462526,0.0016049464,0.0005589491],"domain_scores_gemma":[0.9631261,0.023820873,0.010371103,0.0014285556,0.0008251357,0.00042818472],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02238229,0.00054602436,0.0074493242,0.000093065784,0.00017994746,0.000015698537,0.0020030737,0.0012102606,0.00052443903],"category_scores_gemma":[0.008543223,0.00020269513,0.0052786684,0.00052885886,0.0012023603,0.000079757476,0.0004068795,0.006188039,0.000015679168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032967897,0.0007411541,0.0037498537,0.014350154,0.0030021872,0.000029160345,0.0011148843,0.00000102751,1.8100735e-7,0.00019315144,0.029731374,0.9467572],"study_design_scores_gemma":[0.0013921463,0.0016545894,0.004586288,0.01684245,0.0131556075,0.0005816987,0.00037112008,2.0192873e-7,0.0000011233216,0.000027987895,0.9611891,0.00019772479],"about_ca_topic_score_codex":0.0013726974,"about_ca_topic_score_gemma":0.004428746,"teacher_disagreement_score":0.9465595,"about_ca_system_score_codex":0.0004908189,"about_ca_system_score_gemma":0.011144325,"threshold_uncertainty_score":0.99980825},"labels":[],"label_agreement":null},{"id":"W2029801315","doi":"10.1200/jco.2007.15.2777","title":"Invasive Pulmonary Aspergillosis Associated With Marijuana Use in a Man With Colorectal Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Colorectal cancer; Aspergillosis; Oncology; Lung cancer; Internal medicine; Cancer; Intensive care medicine; Pathology; Immunology","score_opus":0.14672705767809083,"score_gpt":0.416259373939547,"score_spread":0.26953231626145613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029801315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952982,0.00018765492,0.000009937164,0.0021893259,0.00015014593,0.000213756,0.000005830866,0.000008385629,0.0019367334],"genre_scores_gemma":[0.99554825,0.0012105535,0.0006446632,0.0017588076,0.00021853767,0.0000062730523,0.0000036144875,0.00001910853,0.00059019687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971778,0.0004087219,0.001401427,0.00024268865,0.00047843493,0.00029094508],"domain_scores_gemma":[0.9950229,0.0027490573,0.0011119469,0.00014276708,0.0006403131,0.00033304925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013194828,0.0001592858,0.0015184169,0.000118579504,0.00005388966,0.000005270986,0.00011807211,0.00036584123,0.00017250305],"category_scores_gemma":[0.0044403705,0.0000944926,0.00024498353,0.00030388462,0.0005435984,0.0002140531,0.000028181827,0.0012290378,0.000005149527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0211795,0.0021354908,0.95901155,0.0000151168615,0.0004111085,0.01303017,0.00010349773,0.000018275028,0.00022937097,0.000007792429,0.0008968983,0.0029612165],"study_design_scores_gemma":[0.005649791,0.012402105,0.9795208,0.000378209,0.00024573138,0.0006650195,0.0001633445,0.0000334097,0.000090079986,0.000021920392,0.00071546773,0.000114116156],"about_ca_topic_score_codex":0.00028760053,"about_ca_topic_score_gemma":0.011432387,"teacher_disagreement_score":0.020509243,"about_ca_system_score_codex":0.0004413301,"about_ca_system_score_gemma":0.0037635805,"threshold_uncertainty_score":0.667643},"labels":[],"label_agreement":null},{"id":"W2030196700","doi":"10.1200/jco.2005.03.2557","title":"Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Context (archaeology); Prostate cancer; Disease; Androgen deprivation therapy; Intensive care medicine; Quality of life (healthcare); Androgen suppression; Prostate-specific antigen; Oncology; Cancer; Internal medicine","score_opus":0.6002203921010725,"score_gpt":0.658352061162411,"score_spread":0.05813166906133849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030196700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012684521,0.977103,0.00002349227,0.016525887,0.0018096612,0.0010031435,0.000008272596,0.0000110377,0.002247081],"genre_scores_gemma":[0.0003615396,0.9890169,0.0026593693,0.00229013,0.004849601,0.000021789483,0.000044861587,0.00005096183,0.000704845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98674047,0.002743799,0.008795745,0.00044451747,0.0008467344,0.00042871357],"domain_scores_gemma":[0.981343,0.011399328,0.0055385893,0.000405545,0.0006630978,0.00065049715],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01654809,0.0003581142,0.007105548,0.00045974285,0.000029007862,0.00002063026,0.00038643152,0.0018783868,0.00019933615],"category_scores_gemma":[0.021924606,0.00021477147,0.0023433845,0.0003738455,0.00029556276,0.00021920682,0.00017939559,0.005455555,0.00006070516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023295928,0.0038155108,0.0077186655,0.0007195412,0.0012689586,0.00361585,0.000028126642,3.3582657e-7,4.6513094e-8,0.000023504557,0.004897642,0.97558224],"study_design_scores_gemma":[0.010366219,0.008980678,0.003409205,0.0048610615,0.003114885,0.0016009514,0.000042414693,0.000009331905,2.3358358e-7,0.000024365385,0.967429,0.000161692],"about_ca_topic_score_codex":0.000010357264,"about_ca_topic_score_gemma":0.000034982204,"teacher_disagreement_score":0.97542053,"about_ca_system_score_codex":0.000959449,"about_ca_system_score_gemma":0.008325896,"threshold_uncertainty_score":0.99941736},"labels":[],"label_agreement":null},{"id":"W2030535188","doi":"10.1200/jco.2008.19.7343","title":"Quality of Reporting Primary Outcomes in Phase II Cancer Trials","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Clinical trial; Oncology; Internal medicine; Family medicine; Intensive care medicine","score_opus":0.5730829836328443,"score_gpt":0.6293857797842242,"score_spread":0.0563027961513799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030535188","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67004573,0.0017879517,0.00001165481,0.31979316,0.0061391336,0.00046590526,0.000029569113,0.000006441731,0.0017204282],"genre_scores_gemma":[0.19857128,0.008651186,0.0078009707,0.7597943,0.022243964,0.000043312644,0.00003547311,0.00011159457,0.0027479236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9655892,0.0032780415,0.028985253,0.0004108866,0.0013157555,0.00042082753],"domain_scores_gemma":[0.9262828,0.017198905,0.05473107,0.00048782726,0.0010553855,0.00024401199],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.032099403,0.00035359888,0.013506229,0.00039695812,0.000031614447,0.0000034772243,0.000353427,0.0029484432,0.00055097695],"category_scores_gemma":[0.13726364,0.00023779365,0.0026768488,0.00020725174,0.000463227,0.00005594312,0.00015292346,0.0073642093,0.0000021487601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071483953,0.0026309958,0.25297785,0.00051205297,0.0013135732,0.0058406675,0.00013594334,0.000006361418,0.00068711065,5.2903937e-7,0.647501,0.081245534],"study_design_scores_gemma":[0.024553481,0.020302577,0.27253982,0.00069166906,0.0008301525,0.00057341804,0.000019882398,0.0000020088569,0.00023849613,0.00013166436,0.6798537,0.0002631398],"about_ca_topic_score_codex":0.00018605938,"about_ca_topic_score_gemma":0.00010470636,"teacher_disagreement_score":0.47147447,"about_ca_system_score_codex":0.0009255116,"about_ca_system_score_gemma":0.011954939,"threshold_uncertainty_score":0.9983459},"labels":[],"label_agreement":null},{"id":"W2030638302","doi":"10.1200/jco.2014.56.5853","title":"Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; American Society of Hematology","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Clinical endpoint; Oncology; Clinical trial; Surgery; Lymphoma","score_opus":0.13237633855893713,"score_gpt":0.48663721217821676,"score_spread":0.3542608736192796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030638302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88168526,0.00020180842,0.0011735066,0.015117564,0.0035023696,0.09401982,0.00002414969,0.00006492639,0.004210573],"genre_scores_gemma":[0.88070846,0.00016382763,0.03096908,0.0056869546,0.01330647,0.067025855,0.000026329986,0.00011702016,0.0019960192],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933183,0.0012585077,0.0037479103,0.00057684944,0.00051724294,0.00058115355],"domain_scores_gemma":[0.98977566,0.005293443,0.002754607,0.0004672229,0.0008880318,0.0008210508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003335176,0.00045280467,0.004116193,0.00017097266,0.0001508464,0.000037340218,0.0002771767,0.0006981745,0.00029067785],"category_scores_gemma":[0.005226147,0.0002526791,0.0014506062,0.000163401,0.00031343737,0.0001634391,0.00008607254,0.00033771916,0.00010332868],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4336282,0.059049677,0.0016388134,0.00009276584,0.0023394441,0.0030011665,0.0001734766,0.00001610575,0.000049834638,0.00051328575,0.004180598,0.49531662],"study_design_scores_gemma":[0.4022153,0.20692235,0.0015585761,0.00014499758,0.0009629446,0.0005592345,0.00014738743,0.0005621138,0.00026442987,0.00017108792,0.3863359,0.00015566063],"about_ca_topic_score_codex":0.000043727105,"about_ca_topic_score_gemma":0.00015074915,"teacher_disagreement_score":0.49516097,"about_ca_system_score_codex":0.0015591482,"about_ca_system_score_gemma":0.0055615343,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W2030689193","doi":"10.1200/jco.2009.22.9377","title":"Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Alberta","keywords":"Medicine; Hormone receptor; Paclitaxel; Breast cancer; Hormone; Internal medicine; Oncology; Receptor; Cancer","score_opus":0.025570312140239738,"score_gpt":0.3721324102055763,"score_spread":0.34656209806533655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030689193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6580641,0.022701666,0.000036831276,0.31563225,0.0011493424,0.0007052872,0.0010939819,0.0000051658494,0.000611358],"genre_scores_gemma":[0.78065455,0.048087496,0.0048004454,0.15220627,0.013460846,0.00011863851,0.00017685261,0.00013211752,0.0003627624],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99534875,0.0011350157,0.0021505046,0.00062158395,0.00030644215,0.00043771794],"domain_scores_gemma":[0.994287,0.0013354111,0.003253595,0.00028384113,0.00067409605,0.00016606586],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013718184,0.0004902731,0.0026712203,0.00021824766,0.000048885693,0.000011136865,0.00031951442,0.0019220752,0.000044374065],"category_scores_gemma":[0.00076259545,0.00039780381,0.00065668614,0.00016780094,0.0007121247,0.00001968571,0.00019089213,0.002224319,0.000006397768],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012236351,0.001335339,0.014789854,0.000057620044,0.0052765133,0.00013521092,0.00034263398,0.000008279968,0.0057492247,0.0000050566805,0.8264497,0.13361424],"study_design_scores_gemma":[0.018682022,0.021713097,0.7222132,0.0004831923,0.0012581787,0.00020991504,0.0002726876,0.00000373479,0.0055375043,0.00027187954,0.22853014,0.0008244399],"about_ca_topic_score_codex":0.0003255715,"about_ca_topic_score_gemma":0.00011477885,"teacher_disagreement_score":0.7074234,"about_ca_system_score_codex":0.0004716645,"about_ca_system_score_gemma":0.0010050122,"threshold_uncertainty_score":0.9998474},"labels":[],"label_agreement":null},{"id":"W2031250836","doi":"10.1200/jco.2007.13.3082","title":"Involvement of Family Physicians in the Care of Cancer Patients Seen in the Palliative Rapid Response Radiotherapy Program","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Cancer; Palliative care; Family medicine; Radiation therapy; Radiation oncologist; Multivariate analysis; Internal medicine; Nursing","score_opus":0.30480993642849863,"score_gpt":0.5866830140562734,"score_spread":0.2818730776277748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031250836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905777,0.005725458,0.000024156658,0.00241452,0.0002572102,0.00052543316,0.000010198066,0.0000014124787,0.0004639179],"genre_scores_gemma":[0.9896661,0.0054884856,0.0014034518,0.0031504298,0.00026331376,0.000011062036,0.0000026222262,0.000007726618,0.0000068130134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958937,0.0012835155,0.0020206806,0.00010554966,0.00051537395,0.00018114841],"domain_scores_gemma":[0.9917624,0.0056332573,0.0017761174,0.00016528321,0.0006150655,0.00004787476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056220805,0.00010600689,0.0010839717,0.00013858207,0.000011590897,0.00000164214,0.00027866213,0.00017623806,0.000009416735],"category_scores_gemma":[0.0016007718,0.000054571272,0.00031822207,0.00033977866,0.0002969008,0.00003818238,0.000016500051,0.00061273394,2.1888661e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012307583,0.00298853,0.73292685,0.000054521068,0.00020129826,0.000060591068,0.02929112,0.000014395479,0.00038884988,0.000015997968,0.00050024985,0.22125],"study_design_scores_gemma":[0.007315103,0.018161556,0.9160662,0.00064901484,0.00009930179,6.3035463e-7,0.01872192,0.000007889766,0.00041487804,0.000036859747,0.038481057,0.00004558695],"about_ca_topic_score_codex":0.00023157401,"about_ca_topic_score_gemma":0.000645559,"teacher_disagreement_score":0.22120441,"about_ca_system_score_codex":0.00017811016,"about_ca_system_score_gemma":0.00062493444,"threshold_uncertainty_score":0.26620582},"labels":[],"label_agreement":null},{"id":"W2031762038","doi":"10.1200/jco.2008.18.4184","title":"Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"Sanofi","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Breast cancer; Osteoporosis; Osteopenia; Oncology; Cancer; Internal medicine; Prostate; Gynecology; Aromatase; Bone mineral","score_opus":0.2596811351065969,"score_gpt":0.5732909309074599,"score_spread":0.31360979580086296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031762038","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024061184,0.9694919,6.130224e-8,0.0040435595,0.001221431,0.0008404906,0.00006024676,0.000005892343,0.00027521688],"genre_scores_gemma":[0.0010902408,0.9960619,0.00012087296,0.00069999835,0.0010120783,0.000104428975,0.000010099522,0.00004492099,0.0008554478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945359,0.0005444776,0.0038952006,0.0003406743,0.00026103767,0.00042271297],"domain_scores_gemma":[0.99441314,0.001091798,0.003269211,0.00019067986,0.00020751992,0.00082768145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069213123,0.0003877212,0.0073446785,0.00027635074,0.000041354342,0.00000495243,0.00007779229,0.00100856,0.00009418494],"category_scores_gemma":[0.00025946437,0.00022417458,0.0008438894,0.00022746692,0.00017635907,0.00006921007,0.000031783395,0.0014700688,0.000014689588],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013003835,0.0017602084,0.043439504,0.001362106,0.0008512826,0.005492739,0.00004769004,9.285571e-8,4.501594e-8,0.0000015876827,0.000751119,0.94499326],"study_design_scores_gemma":[0.011739978,0.006488155,0.035723735,0.008856018,0.0022260973,0.012390378,0.000004960279,8.4409004e-7,8.234472e-8,0.000009879147,0.9224139,0.0001460144],"about_ca_topic_score_codex":0.0013997405,"about_ca_topic_score_gemma":0.0010027837,"teacher_disagreement_score":0.9448472,"about_ca_system_score_codex":0.0012347894,"about_ca_system_score_gemma":0.01379666,"threshold_uncertainty_score":0.99179417},"labels":[],"label_agreement":null},{"id":"W2033870096","doi":"10.1200/jco.2010.30.8353","title":"Reply to U. Dührsen et al","year":2010,"lang":"de","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.1106455328833646,"score_gpt":0.5054863553609301,"score_spread":0.3948408224775655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033870096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52373105,0.0021510832,0.000013083142,0.44366804,0.02250297,0.00026209722,0.000010078839,0.000008422791,0.0076531665],"genre_scores_gemma":[0.60381365,0.0050881957,0.00719315,0.37525627,0.007834399,0.0000067601936,0.0000039497318,0.0000333001,0.0007703082],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938769,0.00068608276,0.0040055225,0.0003613379,0.00063241547,0.00043778602],"domain_scores_gemma":[0.9884594,0.0062486064,0.0023970052,0.0005224246,0.0007230064,0.0016495397],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008156539,0.0002567591,0.002409557,0.0001737472,0.000054263965,0.000029812929,0.0003179362,0.0005954862,0.0009945927],"category_scores_gemma":[0.01587406,0.00017237764,0.0010819031,0.00016631032,0.0002313982,0.0001076464,0.00014426082,0.0022487524,0.0018051274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030499657,0.0070825256,0.14408061,0.000009544661,0.0014937685,0.0049774614,0.00016740005,0.0000028628094,0.00013707388,0.00070880976,0.5860318,0.2522582],"study_design_scores_gemma":[0.009206194,0.020372458,0.28354248,0.000111657966,0.0011027423,0.00030533937,0.000042449225,0.000009570666,0.00009744472,0.00014864211,0.68495435,0.00010667959],"about_ca_topic_score_codex":0.000102840524,"about_ca_topic_score_gemma":0.000095542535,"teacher_disagreement_score":0.25215152,"about_ca_system_score_codex":0.00020842254,"about_ca_system_score_gemma":0.004630847,"threshold_uncertainty_score":0.99991864},"labels":[],"label_agreement":null},{"id":"W2037339308","doi":"10.1200/jco.2007.11.2144","title":"Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Irinotecan; Fluorouracil; Bolus (digestion); Regimen; Colorectal cancer; Adjuvant; Internal medicine; Oncology; Toxicity; Adjuvant therapy; Surgery; Gastroenterology; Chemotherapy; Cancer","score_opus":0.17808540787193905,"score_gpt":0.49032424084716175,"score_spread":0.3122388329752227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037339308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746517,0.0025014216,0.0002270223,0.015986035,0.0022792525,0.0016313863,0.00037440757,0.00002673537,0.0023220424],"genre_scores_gemma":[0.97928053,0.004079297,0.0031906143,0.0026547054,0.0017841735,0.00011208818,0.000015195492,0.000053015006,0.008830367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929101,0.00021294833,0.004565418,0.0006344694,0.00084356946,0.0008335047],"domain_scores_gemma":[0.9917238,0.0032905287,0.0021952265,0.0004649732,0.0013298575,0.0009956198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033265161,0.000512081,0.0043200194,0.00028723344,0.00018208807,0.000017029877,0.00029606995,0.0005687972,0.00019033605],"category_scores_gemma":[0.0025133388,0.00035777112,0.0011982257,0.00032653802,0.00030263982,0.00013555812,0.00014802451,0.00069279014,0.00001976172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.2781291,0.0037789175,0.0061737522,0.0001376499,0.0028672745,0.0024094826,0.0045278617,0.00021169854,0.0027574855,0.000072836534,0.0071419273,0.691792],"study_design_scores_gemma":[0.111693524,0.19209096,0.082821324,0.0004303801,0.0023921716,0.00039052195,0.0024095117,0.00015758172,0.026831511,0.000053059448,0.5801757,0.00055375585],"about_ca_topic_score_codex":0.006036966,"about_ca_topic_score_gemma":0.010641046,"teacher_disagreement_score":0.6912382,"about_ca_system_score_codex":0.0043962565,"about_ca_system_score_gemma":0.005637401,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W2037624670","doi":"10.1200/jco.2008.16.5456","title":"Evolution of the Randomized Controlled Trial in Oncology Over Three Decades","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Odds ratio; Lung cancer; Likert scale; Colorectal cancer; Cancer","score_opus":0.643067522966339,"score_gpt":0.6586426137141504,"score_spread":0.015575090747811493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037624670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649345,0.0020233197,0.000073509684,0.011886375,0.010524894,0.0022794895,0.0000068265576,0.000010070643,0.008260987],"genre_scores_gemma":[0.9910767,0.0018423684,0.00016992592,0.004188025,0.0023333407,0.000068510235,5.803435e-7,0.00001443935,0.00030609252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9769587,0.015091616,0.006718886,0.00025043762,0.00045647245,0.0005239001],"domain_scores_gemma":[0.9625655,0.031163527,0.004935702,0.00021986834,0.00055766996,0.0005577311],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.027460085,0.00024690788,0.0050173625,0.00022180952,0.00017463577,0.0000031352472,0.0006928397,0.0026647837,0.0010393517],"category_scores_gemma":[0.021907656,0.00014234142,0.0018616568,0.00037503833,0.0021622656,0.00015556694,0.00013655906,0.007101776,0.000016448104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9385771,0.0035385075,0.04092865,0.000019905849,0.0006627152,0.00024586538,0.00020868928,0.00031219784,0.00023393497,0.0034937921,0.0029410704,0.008837581],"study_design_scores_gemma":[0.91648394,0.003514475,0.021553753,0.000038283953,0.00070783333,0.00020453877,0.00006819854,0.0015293636,0.00016806327,0.005079317,0.050521266,0.00013094202],"about_ca_topic_score_codex":0.000057433073,"about_ca_topic_score_gemma":0.00020871185,"teacher_disagreement_score":0.047580194,"about_ca_system_score_codex":0.0004926842,"about_ca_system_score_gemma":0.0055312505,"threshold_uncertainty_score":0.9998738},"labels":[],"label_agreement":null},{"id":"W2041365664","doi":"10.1200/jco.2005.03.3134","title":"Active Surveillance for Prostate Cancer: For Whom?","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Watchful waiting; Prostate cancer; Prostate-specific antigen; Prostate; Cancer; Oncology; Internal medicine; Prostatectomy; Disease; Gynecology","score_opus":0.27595949715843193,"score_gpt":0.5825686908229413,"score_spread":0.30660919366450934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041365664","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006215384,0.98775476,0.000048754842,0.005010255,0.0028286048,0.0034119575,0.00067631545,0.00000874421,0.00019847642],"genre_scores_gemma":[0.000031317595,0.98724943,0.003052993,0.00091902836,0.006822455,0.0010397121,0.00007480644,0.00006932303,0.0007409301],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949183,0.00027428553,0.0038056513,0.00037438588,0.00023089357,0.00039650008],"domain_scores_gemma":[0.98474765,0.007926314,0.005653591,0.00022843659,0.0010106182,0.00043337324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002484717,0.0003623574,0.0076826545,0.00013335061,0.000063992185,0.000016272805,0.00019761371,0.00077606377,0.000051026032],"category_scores_gemma":[0.0022386094,0.00022123607,0.0030916797,0.00011429222,0.00017119138,0.000071237606,0.000034413286,0.00087869744,0.000006531325],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026158614,0.001147955,0.00030723438,0.0044203675,0.0024067922,0.00006916852,0.000024962923,0.000001146108,2.8259292e-8,0.000025067577,0.02517023,0.96381116],"study_design_scores_gemma":[0.008655207,0.017250119,0.0004709672,0.0065883603,0.0043358,0.00014150467,0.000010174978,0.00000397932,9.728751e-7,0.00008824951,0.96227324,0.00018140157],"about_ca_topic_score_codex":0.000009285766,"about_ca_topic_score_gemma":0.00008694825,"teacher_disagreement_score":0.9636298,"about_ca_system_score_codex":0.001096606,"about_ca_system_score_gemma":0.011431668,"threshold_uncertainty_score":0.9941726},"labels":[],"label_agreement":null},{"id":"W2041486920","doi":"10.1200/jco.2009.22.1614","title":"Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Health care; Christian ministry; Positron emission tomography; Promotion (chess); Health technology; Medical physics; Family medicine; Nuclear medicine; Economic growth; Political science","score_opus":0.7168968670768356,"score_gpt":0.5568748666409229,"score_spread":0.16002200043591275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041486920","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005817753,0.94936746,0.000670956,0.04448423,0.0028847405,0.0009621316,0.00002451901,0.000002923459,0.0010212612],"genre_scores_gemma":[0.00090903795,0.97851163,0.0064208847,0.010140623,0.0036705018,0.00003806673,0.000022415805,0.000031848584,0.00025500046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97620386,0.0028607328,0.019909265,0.00047105778,0.00023585458,0.00031924536],"domain_scores_gemma":[0.9710861,0.0076232627,0.020199914,0.000538459,0.00021887569,0.00033342876],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.069202654,0.00026225953,0.007203797,0.00066449615,0.000055727283,0.000019555808,0.0007850455,0.00066190585,0.00013213672],"category_scores_gemma":[0.02163921,0.0002053291,0.0009952055,0.00045730162,0.00007273991,0.00020387504,0.00004585364,0.0017886414,0.000021275528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032339894,0.0012959186,0.008588245,0.0041608317,0.00041896288,0.000011347704,0.00028057682,0.00094892306,2.9004346e-8,0.0022642966,0.36424714,0.6174603],"study_design_scores_gemma":[0.00049631565,0.0011264721,0.008343052,0.0030442164,0.00011009974,0.000022970975,0.000044908753,0.00004785182,4.0603766e-8,0.00039943945,0.98619276,0.00017189884],"about_ca_topic_score_codex":0.41864386,"about_ca_topic_score_gemma":0.63058,"teacher_disagreement_score":0.6219456,"about_ca_system_score_codex":0.0035622895,"about_ca_system_score_gemma":0.016867567,"threshold_uncertainty_score":0.9887059},"labels":[],"label_agreement":null},{"id":"W2041694428","doi":"10.1200/jco.2004.99.130","title":"Dose Density by Any Other Name","year":2004,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Resverlogix (Canada); McGill University","funders":"","keywords":"Medicine","score_opus":0.10623164104860147,"score_gpt":0.4671288951371966,"score_spread":0.3608972540885951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041694428","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023744043,0.0011606265,0.00015351913,0.963828,0.00314888,0.00015133891,0.000008052891,0.000014359417,0.007791168],"genre_scores_gemma":[0.012142013,0.0006527217,0.0011315771,0.9574585,0.023106406,0.0000010696867,0.000014818873,0.00004636488,0.005446519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958046,0.0004278474,0.0026755629,0.00023589829,0.00054613093,0.00030996374],"domain_scores_gemma":[0.9946997,0.0014267152,0.0029516013,0.0002733238,0.00034905502,0.00029958747],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0022478274,0.0002146491,0.0022421605,0.00016118385,0.00003287357,0.00001678634,0.00023515706,0.0018199153,0.0008214802],"category_scores_gemma":[0.0029452194,0.00015455738,0.0009090794,0.00008538185,0.00022611408,0.00011398885,0.00003486266,0.0064103873,0.00021717689],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038144484,0.00035673892,0.0066538295,0.000036465277,0.00045054176,0.0040758885,0.000023725479,0.0000012580292,0.000026760614,0.0000041220537,0.9499572,0.03803205],"study_design_scores_gemma":[0.005534043,0.0031537756,0.0132154,0.00018319584,0.0005627066,0.0013377538,0.000007093387,0.000008593182,0.000029350247,0.00031750073,0.97551566,0.00013491337],"about_ca_topic_score_codex":0.000029559234,"about_ca_topic_score_gemma":0.0000026654375,"teacher_disagreement_score":0.037897136,"about_ca_system_score_codex":0.00035070465,"about_ca_system_score_gemma":0.003110069,"threshold_uncertainty_score":0.99947596},"labels":[],"label_agreement":null},{"id":"W2041901579","doi":"10.1200/jco.2003.12.093","title":"Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Medicine; Topotecan; Internal medicine; Carcinoma; Performance status; Oncology; Toxicity; Phases of clinical research; Radiation therapy; Gastroenterology; Endometrial cancer; Gynecologic oncology; Chemotherapy; Surgery; Cancer","score_opus":0.33240418975099334,"score_gpt":0.5117889101158795,"score_spread":0.17938472036488612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041901579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923604,0.00084947224,0.000052108873,0.002347767,0.0015824253,0.0016213682,0.00002024669,0.0000038814715,0.0011622941],"genre_scores_gemma":[0.9961194,0.0010865359,0.0006772208,0.0011512187,0.0007604191,0.000072014074,0.0000055797436,0.000017098104,0.000110559085],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9924207,0.0031500005,0.0031009775,0.0003603077,0.0006315245,0.0003365382],"domain_scores_gemma":[0.9901851,0.0068379873,0.001821434,0.00032950487,0.00044840047,0.00037760023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033432697,0.0002878982,0.0029719328,0.00038514446,0.00006232151,0.000010049776,0.00024564826,0.00022863982,0.00051293155],"category_scores_gemma":[0.0042536026,0.00013943133,0.00059406424,0.00085399236,0.00020948831,0.000114983355,0.000032059957,0.00067627744,0.0000090721505],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105922595,0.11820064,0.09237353,0.000033620472,0.002697692,0.005089273,0.009473337,0.000021814096,0.000018875158,0.00007497753,0.00016684954,0.6659268],"study_design_scores_gemma":[0.13641153,0.6988519,0.10811718,0.000052191222,0.0026769813,0.00043252474,0.009441207,0.00003281853,0.0003008218,0.00024505917,0.04326526,0.00017251514],"about_ca_topic_score_codex":0.00024271554,"about_ca_topic_score_gemma":0.0025749311,"teacher_disagreement_score":0.66575426,"about_ca_system_score_codex":0.0009686759,"about_ca_system_score_gemma":0.0019982378,"threshold_uncertainty_score":0.56858444},"labels":[],"label_agreement":null},{"id":"W2043769110","doi":"10.1200/jco.2007.15.4864","title":"Predictors of Referral for Specialized Psychosocial Oncology Care in Patients With Metastatic Cancer: The Contributions of Age, Distress, and Marital Status","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; York University","keywords":"Referral; Medicine; Psychosocial; Marital status; Distress; Depression (economics); Cancer; Anxiety; Univariate analysis; Psycho-oncology; Multivariate analysis; Psychiatry; Family medicine; Internal medicine; Clinical psychology; Population","score_opus":0.0728120988796992,"score_gpt":0.4480857615085619,"score_spread":0.3752736626288627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043769110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944825,0.0011039595,0.000022455763,0.0015195718,0.001299927,0.00048543376,0.0005057275,0.0000020467137,0.0005783738],"genre_scores_gemma":[0.9976103,0.0012760436,0.00031109044,0.00021469254,0.0004996519,0.000016796459,0.00003520526,0.000009570009,0.00002670694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748665,0.00036439046,0.0015297934,0.00012247918,0.0002948107,0.00020187283],"domain_scores_gemma":[0.9959085,0.0014903542,0.001413919,0.00010770392,0.0009073022,0.00017224165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068391085,0.00010216514,0.0014144208,0.000072994786,0.000042552438,0.000001802324,0.00009450467,0.0001885924,0.000037933372],"category_scores_gemma":[0.0012638642,0.000060478345,0.00024797596,0.00014002675,0.00070236286,0.00004794558,0.000024858113,0.00048476146,7.393988e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028841889,0.0011931623,0.9376113,0.0000839032,0.0005051668,0.000065553024,0.0020202254,0.000004986758,0.000006944639,0.00012617005,0.0019903232,0.027550397],"study_design_scores_gemma":[0.026087875,0.017927257,0.9026935,0.00009717483,0.00060246396,0.000015808926,0.0011392045,0.0000018378354,0.000015435178,0.00011090203,0.05125239,0.00005612353],"about_ca_topic_score_codex":0.00049278035,"about_ca_topic_score_gemma":0.008625601,"teacher_disagreement_score":0.049262065,"about_ca_system_score_codex":0.00026636012,"about_ca_system_score_gemma":0.0021472774,"threshold_uncertainty_score":0.4813288},"labels":[],"label_agreement":null},{"id":"W2044016668","doi":"10.1200/jco.2014.57.9235","title":"Reply to P. Niravath et al","year":2014,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.24465761939170472,"score_gpt":0.5869392432318591,"score_spread":0.34228162384015437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044016668","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002465773,0.0051858,0.00056587375,0.943619,0.02110915,0.0005930195,0.00001728726,0.00001499589,0.026429089],"genre_scores_gemma":[0.0015205286,0.009945345,0.0051683066,0.9120736,0.052912783,0.000016461021,0.000008278936,0.00009157717,0.018263109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98393613,0.004689706,0.0071693314,0.00073665724,0.0021618316,0.0013063716],"domain_scores_gemma":[0.9663125,0.02380052,0.0048774057,0.0008675633,0.0024522168,0.0016897741],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.028275907,0.00055377977,0.0065038525,0.0004759184,0.00009940023,0.000039012462,0.0010330693,0.0016491391,0.0013569501],"category_scores_gemma":[0.07307661,0.0003924057,0.0019045058,0.00032387726,0.0010530701,0.00014253758,0.00058432715,0.015242163,0.0015805756],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003856055,0.00078619894,0.008999998,0.0002436764,0.0023609486,0.011130746,0.00018986814,0.00001481224,0.000024997855,0.000116589785,0.88859975,0.083676375],"study_design_scores_gemma":[0.0070540477,0.048880864,0.020958291,0.0018047772,0.0009740059,0.0015130449,0.000059819675,0.000017540026,0.0000077386985,0.00025842118,0.91816586,0.00030558053],"about_ca_topic_score_codex":0.00021393826,"about_ca_topic_score_gemma":0.00006425432,"teacher_disagreement_score":0.0833708,"about_ca_system_score_codex":0.0015362828,"about_ca_system_score_gemma":0.010122517,"threshold_uncertainty_score":0.9998528},"labels":[],"label_agreement":null},{"id":"W2044227111","doi":"10.1200/jco.2006.10.3051","title":"Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Bevacizumab; Pharmacodynamics; Vascular endothelial growth factor; Cancer; Surrogate endpoint; Pharmacology; Internal medicine; Cancer research; Oncology; VEGF receptors; Pharmacokinetics; Chemotherapy","score_opus":0.06697504993204398,"score_gpt":0.42807800777594884,"score_spread":0.3611029578439049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044227111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484707,0.001250388,0.00027620865,0.009355667,0.0028339084,0.0004899404,0.0007538433,0.0000028113911,0.0001901576],"genre_scores_gemma":[0.9161211,0.0047105486,0.00071833964,0.07067126,0.006809926,0.000052516963,0.00011684345,0.00012309974,0.00067635905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957059,0.0005195966,0.0023664453,0.00045295758,0.0004593324,0.00049574213],"domain_scores_gemma":[0.9945459,0.0009171822,0.003205274,0.00026366272,0.00094008417,0.00012790895],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014876386,0.00037061088,0.0017733155,0.00021887885,0.00003798868,0.000009911266,0.0005625841,0.002313093,0.00016358793],"category_scores_gemma":[0.0013850619,0.00030401652,0.0016204155,0.000114815666,0.00021124192,0.0000134764805,0.00012862284,0.0014461414,0.0000024341475],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038385767,0.0052250484,0.20816793,0.0010546021,0.010673696,0.00049080985,0.00010984142,0.00009154955,0.10368326,0.000006629873,0.33459306,0.2975178],"study_design_scores_gemma":[0.017098375,0.00784674,0.14598565,0.00019065535,0.0005790309,0.000023880522,0.0000073001615,0.00007709999,0.022577252,0.000049255377,0.8050223,0.0005424551],"about_ca_topic_score_codex":0.00021738089,"about_ca_topic_score_gemma":0.000121341436,"teacher_disagreement_score":0.47042927,"about_ca_system_score_codex":0.00023166009,"about_ca_system_score_gemma":0.0022884298,"threshold_uncertainty_score":0.9999412},"labels":[],"label_agreement":null},{"id":"W2045110923","doi":"10.1200/jco.2007.13.8412","title":"Is There a Role for Positron Emission Tomography in Breast Cancer Staging?","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Positron emission tomography; Breast cancer; Sentinel lymph node; Axilla; Radiology; Lymph node; Sentinel node; Cancer; Biopsy; Primary tumor; Nuclear medicine; Metastasis; Internal medicine","score_opus":0.1547806040897714,"score_gpt":0.5571243346419672,"score_spread":0.4023437305521958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045110923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016342575,0.98066956,0.00029255962,0.01710216,0.00028550666,0.0007868077,0.000057202175,0.0000175946,0.00062521157],"genre_scores_gemma":[0.00007015506,0.9857958,0.010122307,0.0022078021,0.0014315046,0.0001004167,0.000010559577,0.000037638223,0.0002238291],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99593836,0.00023998131,0.0030089547,0.00026472023,0.00029248104,0.0002555148],"domain_scores_gemma":[0.99523264,0.001375234,0.0023699177,0.0002611038,0.0003083168,0.00045278962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014545328,0.00023032789,0.00381275,0.0002638932,0.00003478061,0.000005964842,0.0002961585,0.00083752035,0.00019539047],"category_scores_gemma":[0.00044412352,0.00014049321,0.0018068461,0.00028437053,0.00016687585,0.000040026025,0.000053129796,0.0019133668,0.0000031026013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018687831,0.0008177131,0.0020308162,0.0011824152,0.00019773158,0.000084195606,0.000013421931,1.9787754e-8,0.0000014750242,0.000021399923,0.09523148,0.90023243],"study_design_scores_gemma":[0.0015046572,0.0010605883,0.0010470004,0.011827063,0.00092919974,0.0009140054,0.0000074519794,0.000026103784,0.0000010477644,0.0003027966,0.9822614,0.0001186403],"about_ca_topic_score_codex":0.000034614797,"about_ca_topic_score_gemma":0.000001913938,"teacher_disagreement_score":0.9001138,"about_ca_system_score_codex":0.00020179509,"about_ca_system_score_gemma":0.0031122211,"threshold_uncertainty_score":0.8312733},"labels":[],"label_agreement":null},{"id":"W2045410673","doi":"10.1200/jco.2003.10.089","title":"Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Lung cancer; Toxicity; Etoposide; Chemotherapy; Cyclophosphamide; Vincristine; Chemoradiotherapy; Radiation therapy; Stage (stratigraphy); Surgery; Gastroenterology","score_opus":0.10128393816825154,"score_gpt":0.4610338190641434,"score_spread":0.3597498808958919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045410673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883922,0.0037013162,0.00052721397,0.0032322565,0.0015335046,0.00089557096,0.00007419566,0.000018315548,0.0016254534],"genre_scores_gemma":[0.99047333,0.002645269,0.00050988694,0.0041563855,0.0005235873,0.0000552625,0.000018268913,0.000063773165,0.0015542277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600637,0.0006684084,0.0017405638,0.0003245445,0.00070962176,0.00055047683],"domain_scores_gemma":[0.99028385,0.004929038,0.0022843343,0.00018197054,0.0018018387,0.00051897665],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040897313,0.00024677458,0.0020766582,0.00010063353,0.00010737867,0.00002319798,0.00019289124,0.00034838094,0.00015454015],"category_scores_gemma":[0.010297829,0.00017328325,0.00043208752,0.00022100781,0.00022663016,0.00008530592,0.000027157044,0.0011251016,3.7355798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003435765,0.001954574,0.91396487,0.00011861768,0.0032548758,0.0000794204,0.0002811224,0.0000043915566,0.00015738694,0.0000072001703,0.055276763,0.021465005],"study_design_scores_gemma":[0.14307211,0.025984885,0.48287886,0.0017220123,0.0032409136,0.00001887611,0.00034662202,0.00054446247,0.0033664762,0.000021027083,0.33814797,0.00065580197],"about_ca_topic_score_codex":0.000038319595,"about_ca_topic_score_gemma":0.00012631419,"teacher_disagreement_score":0.43108603,"about_ca_system_score_codex":0.0009896177,"about_ca_system_score_gemma":0.0023614503,"threshold_uncertainty_score":0.9980388},"labels":[],"label_agreement":null},{"id":"W2046899064","doi":"10.1200/jco.2009.21.8438","title":"Prognostic Tools for Cancer Survival: A Secondary Role for Quality-of-Life Measurement","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Quality of life (healthcare); Overall survival; Oncology; Cancer survival; Internal medicine","score_opus":0.5468398928340481,"score_gpt":0.557244149288901,"score_spread":0.010404256454852878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046899064","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065224883,0.013373065,0.0006465177,0.9685929,0.006242201,0.002049562,0.0002452115,0.000014391549,0.0023137075],"genre_scores_gemma":[0.011965779,0.0041843597,0.0065725637,0.93326557,0.042668737,0.0003244624,0.000056179204,0.00009802764,0.00086434925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99238116,0.00060178235,0.005253198,0.00034062297,0.0009428626,0.00048034915],"domain_scores_gemma":[0.97817135,0.013489155,0.0046655047,0.0002523009,0.0031246888,0.0002970096],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010085995,0.00031283393,0.0059223836,0.00014867348,0.000059333368,0.000012243383,0.00026952478,0.0014498652,0.00009850663],"category_scores_gemma":[0.03639247,0.00022124665,0.001891127,0.00008506113,0.00019297989,0.00008421384,0.00003737697,0.0027031794,0.0000019174975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057812,0.0006248202,0.0024973154,0.0012790841,0.0018745107,0.000056385656,0.00006422005,0.00000112097,0.00004085971,0.000017890823,0.7445932,0.24316941],"study_design_scores_gemma":[0.011968975,0.02125895,0.025788805,0.0009266379,0.0015193889,0.000016374835,0.00007061616,0.000005183808,0.000017070972,0.0005881209,0.9376408,0.00019908792],"about_ca_topic_score_codex":0.000041529092,"about_ca_topic_score_gemma":0.00025733982,"teacher_disagreement_score":0.24297032,"about_ca_system_score_codex":0.0004015312,"about_ca_system_score_gemma":0.012146678,"threshold_uncertainty_score":0.99984646},"labels":[],"label_agreement":null},{"id":"W2048474282","doi":"10.1200/jco.2003.06.093","title":"Assessment of Quality of Life in Outpatients With Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being—A Hoosier Oncology Group Study","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Religion, Spirituality, and Psychology","field":"Social Sciences","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Marital status; Cancer; Physical therapy; Clinical psychology; Gerontology; Internal medicine; Population","score_opus":0.13227360440149086,"score_gpt":0.5550003109092564,"score_spread":0.42272670650776556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048474282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98155653,0.0006359902,0.00022248623,0.0076121558,0.0010139401,0.00071222987,0.0000055661208,0.0000021573792,0.008238961],"genre_scores_gemma":[0.99378765,0.0028773046,0.002218645,0.000943339,0.00013084097,0.000016744842,3.8016108e-7,0.000007704487,0.000017407609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9846044,0.009013944,0.0052079316,0.00023551863,0.000686059,0.0002521314],"domain_scores_gemma":[0.96571004,0.024744432,0.008186212,0.00033212226,0.0008839236,0.00014325888],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.024068845,0.00013782858,0.0021237724,0.00010742806,0.00011023581,0.00000513472,0.00054856023,0.0003118289,0.000036371937],"category_scores_gemma":[0.0211972,0.000077899334,0.00027800744,0.00042611183,0.0031217327,0.00015429023,0.000056857385,0.00080663484,2.9142387e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003164513,0.0046633673,0.9352284,0.00004156395,0.00027325482,0.0000040495943,0.011929319,0.0002871967,0.00001267402,0.026131397,0.0001934831,0.01807077],"study_design_scores_gemma":[0.013581556,0.010192126,0.9475587,0.00009760018,0.0001797848,0.000002477529,0.016620813,0.000018618657,0.0000050983413,0.0076187835,0.004034153,0.00009028938],"about_ca_topic_score_codex":0.004745365,"about_ca_topic_score_gemma":0.028542396,"teacher_disagreement_score":0.023797031,"about_ca_system_score_codex":0.000095672054,"about_ca_system_score_gemma":0.002670126,"threshold_uncertainty_score":0.9995912},"labels":[],"label_agreement":null},{"id":"W2048686497","doi":"10.1200/jco.2003.12.109","title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Pharmacokinetics; Internal medicine; Adverse effect; Oncology; Metastatic breast cancer; Pharmacology; Breast cancer; Cancer","score_opus":0.17231465087547926,"score_gpt":0.5133159105305432,"score_spread":0.3410012596550639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048686497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850538,0.00072789256,0.00037996055,0.0064355186,0.00043525972,0.00037411603,0.000003208208,0.0000037985121,0.0065864963],"genre_scores_gemma":[0.9953814,0.0012870209,0.002532978,0.00045343465,0.00017994997,0.000002092042,0.0000011107978,0.000017015662,0.00014496688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631506,0.00064575515,0.002104535,0.00017523032,0.0005280122,0.00023137603],"domain_scores_gemma":[0.9947877,0.0033063758,0.00096408016,0.00016325123,0.00045010756,0.0003284669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049344073,0.00011459052,0.0012457985,0.00019851445,0.000018281817,0.000005268186,0.00012260964,0.0002488541,0.00017701766],"category_scores_gemma":[0.004898801,0.00008153623,0.00014298373,0.00021123627,0.0003986943,0.00006745432,0.00003018094,0.001140609,0.0000030115743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036104307,0.00805772,0.53279865,0.00024052283,0.00046357146,0.0012439834,0.00030255443,0.00002954982,0.00055622065,0.00082424685,0.0018427864,0.4175359],"study_design_scores_gemma":[0.04647345,0.04615868,0.8598821,0.00036753848,0.00021879208,0.00058708957,0.00014420085,0.00011375595,0.0003577825,0.00063765777,0.044954672,0.00010428928],"about_ca_topic_score_codex":0.000015397889,"about_ca_topic_score_gemma":0.00009280396,"teacher_disagreement_score":0.41743162,"about_ca_system_score_codex":0.00020143893,"about_ca_system_score_gemma":0.0022709386,"threshold_uncertainty_score":0.5864676},"labels":[],"label_agreement":null},{"id":"W2049028448","doi":"10.1200/jco.2014.57.5332","title":"Effects of Single-Agent and Combination Chemotherapy for Gestational Trophoblastic Tumors on Risks of Second Malignancy and Early Menopause","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Menopause; Population; Chemotherapy; Internal medicine; Incidence (geometry); Methotrexate; Cancer registry; Malignancy; Cancer; Obstetrics; Gynecology; Surgery","score_opus":0.07349062360245602,"score_gpt":0.4075924648849208,"score_spread":0.3341018412824648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049028448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720854,0.0002445995,0.00097099075,0.0008687501,0.00023609519,0.00029952155,0.0000080838345,0.000002359131,0.0001610833],"genre_scores_gemma":[0.99457407,0.00014853546,0.004752106,0.00031981,0.0001395224,0.0000068017043,0.000001353465,0.000012052336,0.000045720837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981037,0.00017762794,0.0012141711,0.00012900327,0.00027245894,0.000103071245],"domain_scores_gemma":[0.9898443,0.008014526,0.0013642028,0.000055945013,0.0005626063,0.0001583698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008255395,0.00010337449,0.00091932184,0.0001218469,0.000024280578,0.0000032500438,0.000041129955,0.00009505936,0.0000141355395],"category_scores_gemma":[0.005385459,0.00007812346,0.00011572583,0.000049345734,0.00027956846,0.000042576637,0.000014272338,0.00015926568,5.2506647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104900636,0.037287418,0.34193277,0.0098940125,0.0058830935,0.00039294036,0.0032141274,0.000271534,0.19321032,0.040814355,0.004898649,0.25730014],"study_design_scores_gemma":[0.015400822,0.045598652,0.93184185,0.00033629467,0.00034942495,0.000026647842,0.00003681467,0.0001054145,0.0016938153,0.0041416306,0.00041191673,0.000056703142],"about_ca_topic_score_codex":0.0000023517584,"about_ca_topic_score_gemma":0.000001691818,"teacher_disagreement_score":0.5899091,"about_ca_system_score_codex":0.000035001078,"about_ca_system_score_gemma":0.00021839258,"threshold_uncertainty_score":0.64472866},"labels":[],"label_agreement":null},{"id":"W2049479627","doi":"10.1200/jco.2003.11.038","title":"<i>neu</i>/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Citation; Breast cancer; Oncology; Hormonal therapy; Clinical Oncology; Internal medicine; Cancer; Adjuvant; Clinical trial; Adjuvant therapy; Gynecology; Library science","score_opus":0.12406823849787108,"score_gpt":0.49276206234913544,"score_spread":0.36869382385126437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049479627","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5040693,0.000718512,3.8005004e-7,0.4935661,0.0006327364,0.00062824413,0.000038940965,0.0000026944558,0.000343096],"genre_scores_gemma":[0.15726672,0.007763148,0.00024136766,0.8242906,0.0088084275,0.00022027531,0.000010145421,0.00009914855,0.001300225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9860812,0.006723175,0.0037744085,0.00063246844,0.0016138513,0.0011748896],"domain_scores_gemma":[0.9889757,0.008399026,0.0013339885,0.00047972868,0.0003201019,0.0004914674],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.02790052,0.0004159489,0.0026598733,0.0006846309,0.000059380054,0.000033068958,0.000648839,0.0017573192,0.0006937293],"category_scores_gemma":[0.005221363,0.00025808063,0.0002114447,0.00053361215,0.00030689765,0.00015756128,0.00020160392,0.010794389,0.0000062025388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05061081,0.0011823245,0.043977916,0.000084845706,0.00012378917,0.007813501,0.0033198574,0.000020200076,0.00073665753,0.0000013363754,0.85764587,0.03448291],"study_design_scores_gemma":[0.010518135,0.014138358,0.20844242,0.001531718,0.000026259224,0.00079031184,0.0003421874,0.0000067271544,0.000010005807,0.00012268953,0.7638647,0.0002065065],"about_ca_topic_score_codex":0.0002087055,"about_ca_topic_score_gemma":0.000376642,"teacher_disagreement_score":0.3468026,"about_ca_system_score_codex":0.0021096962,"about_ca_system_score_gemma":0.007927944,"threshold_uncertainty_score":0.9999871},"labels":[],"label_agreement":null},{"id":"W2050076975","doi":"10.1200/jco.2007.14.4311","title":"Small Intestinal B-Cell Lymphoma in a Patient With Lymphangiectasia Secondary to Abdominal Lymphangioma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vascular Malformations and Hemangiomas","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Lymphangioma; Lymphangiectasia; Lymphoma; Radiology; Chylothorax; Chyle; Lymphatic system; Pathology; Internal medicine; Complication","score_opus":0.08346070737082423,"score_gpt":0.36366897588185215,"score_spread":0.2802082685110279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050076975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98599356,0.0004468914,0.0012219552,0.0020313498,0.00029206098,0.0002776168,0.0000016448121,0.0000117262525,0.009723166],"genre_scores_gemma":[0.95363134,0.00008275528,0.042876534,0.0028045839,0.00041518096,0.000010860841,0.0000028617335,0.000022881331,0.00015297925],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967021,0.0002242876,0.0021392195,0.00020545372,0.0003833947,0.0003455432],"domain_scores_gemma":[0.99717116,0.00058466353,0.00093240815,0.00022889243,0.0005014094,0.00058145734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014164273,0.00018610901,0.0012795738,0.0004980931,0.000057629277,0.0000072510975,0.00017107601,0.00024350392,0.00012364154],"category_scores_gemma":[0.00084555475,0.00012929853,0.0005030498,0.00042523103,0.00014735675,0.00012673283,0.00006957796,0.00027154607,0.00006752478],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01824206,0.013184876,0.12686434,0.00014732742,0.00049139524,0.064587936,0.002679903,0.000103337836,0.0004632096,0.00010180528,0.006267368,0.76686645],"study_design_scores_gemma":[0.04850673,0.04504266,0.7073984,0.00055325386,0.00042763495,0.12693861,0.00089682883,0.00033760603,0.0009916169,0.00007848816,0.068459645,0.000368502],"about_ca_topic_score_codex":0.000038542355,"about_ca_topic_score_gemma":0.000086437656,"teacher_disagreement_score":0.76649797,"about_ca_system_score_codex":0.00032660217,"about_ca_system_score_gemma":0.0032194038,"threshold_uncertainty_score":0.5711084},"labels":[],"label_agreement":null},{"id":"W2050298407","doi":"10.1200/jco.2008.21.1920","title":"Second Neoplasms in Survivors of Childhood Cancer: Findings From the Childhood Cancer Survivor Study Cohort","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":518,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital","keywords":"Medicine; Cohort; Skin cancer; Cumulative incidence; Cancer; Radiation therapy; Incidence (geometry); Internal medicine; Oncology; Disease; Cohort study; Pediatrics","score_opus":0.13370460960554356,"score_gpt":0.4938509694046368,"score_spread":0.36014635979909326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050298407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26617113,0.7224521,0.0000019775132,0.0028596683,0.004889097,0.0027655046,0.00035241153,0.000020959882,0.0004871495],"genre_scores_gemma":[0.017467061,0.97307724,0.00017284474,0.0032340263,0.005545758,0.0001095768,0.000046891968,0.0001511127,0.00019548008],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.97600317,0.0058737216,0.014103212,0.0011370037,0.002005416,0.00087749766],"domain_scores_gemma":[0.9677173,0.017820358,0.011617821,0.0013000165,0.0007373777,0.0008071302],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.017896777,0.0011086853,0.018058224,0.0005771075,0.00011431311,0.00004052637,0.0018365034,0.0019814405,0.0013818289],"category_scores_gemma":[0.007043556,0.00070866226,0.0036603594,0.0012277206,0.00050665875,0.00021546028,0.0003214121,0.00759134,0.00002551064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068650616,0.009842117,0.28214553,0.0011619135,0.006225722,0.00036287127,0.0024549789,0.0000068749137,1.3502947e-7,0.000007683516,0.005565972,0.6915397],"study_design_scores_gemma":[0.00649541,0.0055585713,0.5151177,0.011919395,0.005807952,0.0001379362,0.00048187768,7.4131424e-7,6.292549e-7,0.00006112568,0.4539981,0.00042053344],"about_ca_topic_score_codex":0.012440721,"about_ca_topic_score_gemma":0.11161318,"teacher_disagreement_score":0.69111913,"about_ca_system_score_codex":0.00093225203,"about_ca_system_score_gemma":0.016993811,"threshold_uncertainty_score":0.99953645},"labels":[],"label_agreement":null},{"id":"W2050555037","doi":"10.1200/jco.2014.58.6537","title":"Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"American Society of Clinical Oncology","keywords":"Medicine; Chemotherapy; Germ cell tumors; Venous thromboembolism; Germ cell; Radiology; Surgery; Oncology; Internal medicine; Pathology; Thrombosis","score_opus":0.028759593720286466,"score_gpt":0.35384643856561226,"score_spread":0.3250868448453258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050555037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947016,0.000190875,0.000012775404,0.00070531317,0.00024521694,0.000606923,0.000009372,0.000015287837,0.0035126184],"genre_scores_gemma":[0.99778646,0.0002184033,0.000595764,0.0009347077,0.00027742615,0.00000906094,0.00001396841,0.000049268296,0.0001149355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962336,0.00031328437,0.0020103457,0.0002784899,0.00076417276,0.00040013736],"domain_scores_gemma":[0.9960249,0.00028374835,0.0020325915,0.00029421324,0.00082310877,0.000541409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018008745,0.0002511685,0.0029212616,0.00023043258,0.000025910149,0.000009211099,0.00022647697,0.00030328805,0.000079493206],"category_scores_gemma":[0.0005514387,0.00015039749,0.00019377671,0.0003496849,0.00023020203,0.00013696191,0.000050285205,0.0005550792,0.000008232126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017855974,0.03732827,0.9320934,0.00010224376,0.0006285047,0.0013773151,0.0016924595,0.000022771434,0.00005857491,0.000059993858,0.002536739,0.006243749],"study_design_scores_gemma":[0.035867903,0.080166444,0.87873006,0.00040286215,0.00048359213,0.00006362375,0.00061507267,0.000021801212,0.00029846118,0.000035085137,0.003166942,0.00014816885],"about_ca_topic_score_codex":0.000101965714,"about_ca_topic_score_gemma":0.000033779572,"teacher_disagreement_score":0.053363364,"about_ca_system_score_codex":0.000286687,"about_ca_system_score_gemma":0.0015264533,"threshold_uncertainty_score":0.6133032},"labels":[],"label_agreement":null},{"id":"W2050608886","doi":"10.1200/jco.2003.10.092","title":"Dispositional Optimism Predicts Survival Status 1 Year After Diagnosis in Head and Neck Cancer Patients","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Optimism, Hope, and Well-being","field":"Psychology","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Confidence interval; Head and neck cancer; Logistic regression; Odds ratio; Optimism; Observational study; Internal medicine; Multivariate analysis; Prospective cohort study; Cohort study; Cancer; Demography; Surgery","score_opus":0.0593620995319706,"score_gpt":0.43925902576526965,"score_spread":0.37989692623329907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050608886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772652,0.0007380942,0.000023613919,0.0008521859,0.0041818405,0.00014382986,0.000024614825,0.00000541965,0.016765215],"genre_scores_gemma":[0.99435705,0.001948364,0.0014747501,0.0013221222,0.00058481545,0.00003136484,0.0000033343613,0.0000218607,0.0002563269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965771,0.00088153774,0.0015891828,0.00026176826,0.00027994145,0.00041050903],"domain_scores_gemma":[0.99686235,0.00173578,0.00067272683,0.00012838692,0.0001992115,0.0004015221],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014665723,0.0001542443,0.0008201348,0.00012593323,0.00003495853,0.000016313394,0.00012198345,0.00042140626,0.0016271087],"category_scores_gemma":[0.000841438,0.0001278862,0.00019365965,0.000120026976,0.00017322398,0.00015651577,0.000038004826,0.0008512617,0.00003146802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016668714,0.0020796992,0.97196156,0.0000066118632,0.00015925014,0.0002029993,0.0004915637,0.00006352413,4.5834759e-7,0.00056776137,0.0030781652,0.019721566],"study_design_scores_gemma":[0.008090596,0.0031453413,0.94989204,0.00007325626,0.00008742441,0.000012195404,0.00010485247,0.000010428119,0.0000021000276,0.0005918532,0.03786125,0.00012866153],"about_ca_topic_score_codex":0.00010030189,"about_ca_topic_score_gemma":0.00020010505,"teacher_disagreement_score":0.034783084,"about_ca_system_score_codex":0.0001199715,"about_ca_system_score_gemma":0.0003981482,"threshold_uncertainty_score":0.9992855},"labels":[],"label_agreement":null},{"id":"W2050871856","doi":"10.1200/jco.2006.08.6801","title":"Suffering With Advanced Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital","funders":"","keywords":"Existentialism; Malaise; Distress; Medicine; Weakness; Depression (economics); Palliative care; Clinical psychology; Cancer; Psychotherapist; Psychiatry; Psychology; Nursing; Surgery","score_opus":0.10937731600696828,"score_gpt":0.5122138322050873,"score_spread":0.40283651619811905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050871856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97943354,0.0010952704,0.0011623928,0.003952451,0.0022742392,0.000073074385,6.851556e-7,0.00000877501,0.011999579],"genre_scores_gemma":[0.992069,0.0006530931,0.001855789,0.0031423485,0.0018449535,0.0000012069769,3.0465725e-7,0.000012603479,0.00042067227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982464,0.000058665308,0.0011204013,0.000102624756,0.0002769494,0.00019500847],"domain_scores_gemma":[0.9975477,0.0008411079,0.000747732,0.00010948053,0.00040854982,0.00034546357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022603075,0.0000784552,0.0008318241,0.000070520255,0.000018707997,0.0000029286505,0.00008008726,0.00018087182,0.00018861172],"category_scores_gemma":[0.00052889675,0.000048736867,0.0002239607,0.00012845796,0.00010284754,0.00006579881,0.000016280685,0.00074869435,0.000004473239],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011758949,0.00035261535,0.24232894,0.00002838885,0.00020513052,0.0013281214,0.00019319436,0.000019459416,0.00032143292,0.00007856567,0.0007759897,0.7426092],"study_design_scores_gemma":[0.0069517307,0.014458693,0.5569189,0.00021064914,0.00026201745,0.00054613064,0.00056499685,0.0000067698506,0.0005380156,0.000055193897,0.4193924,0.00009450311],"about_ca_topic_score_codex":0.000067690424,"about_ca_topic_score_gemma":0.0021648316,"teacher_disagreement_score":0.7425147,"about_ca_system_score_codex":0.00014309854,"about_ca_system_score_gemma":0.0010752673,"threshold_uncertainty_score":0.32527462},"labels":[],"label_agreement":null},{"id":"W2051886314","doi":"10.1200/jco.2008.18.7294","title":"Progress in Quality-of-Care Research and Hope for Supportive Cancer Care","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palliative care; Medicine; Psychosocial; Psychological intervention; Context (archaeology); Quality of life (healthcare); Cancer; Nursing; Family medicine; Intensive care medicine; Psychiatry","score_opus":0.748278313626225,"score_gpt":0.7199506816855153,"score_spread":0.02832763194070964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051886314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681778,0.027616058,0.000010928217,0.0027315912,0.00029556395,0.00027938158,0.000020479676,0.0000017250748,0.0008664709],"genre_scores_gemma":[0.98572373,0.009827797,0.003605896,0.00018921384,0.00053790427,0.000014074442,0.000003967771,0.000009144339,0.000088259156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970293,0.0004439548,0.0018141088,0.0001400881,0.00036989883,0.00020261796],"domain_scores_gemma":[0.99164796,0.0043352842,0.0009662125,0.000103864346,0.00276231,0.00018439257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025263722,0.00007590612,0.0014010224,0.00017302735,0.000027412874,0.0000013735455,0.0001044589,0.00027274957,0.00002554497],"category_scores_gemma":[0.005424691,0.000053664702,0.00022024942,0.00016202593,0.00075320166,0.00005481984,0.000044441727,0.00066851964,5.4561457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061010914,0.00041061235,0.9125839,0.0004218466,0.000120877994,0.00018977262,0.0073746024,7.8202095e-7,0.000031018924,0.000081930135,0.0012503106,0.071433276],"study_design_scores_gemma":[0.009804614,0.022471711,0.8760225,0.0011159751,0.00008397287,0.000029985087,0.01642313,0.0000036728793,0.0009801441,0.00020273992,0.07278634,0.00007517107],"about_ca_topic_score_codex":0.0000888855,"about_ca_topic_score_gemma":0.0003312706,"teacher_disagreement_score":0.07153603,"about_ca_system_score_codex":0.00013392566,"about_ca_system_score_gemma":0.002040148,"threshold_uncertainty_score":0.6494253},"labels":[],"label_agreement":null},{"id":"W2052270022","doi":"10.1200/jco.2012.44.8225","title":"Special Series on Comparative Effectiveness Research: Challenges to Real-World Solutions to Quality Improvement in Personalized Medicine","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; University of British Columbia","funders":"","keywords":"Medicine; Comparative effectiveness research; Personalized medicine; Series (stratigraphy); Quality (philosophy); Medical physics; Intensive care medicine; Alternative medicine; Bioinformatics; Pathology","score_opus":0.9129403212416236,"score_gpt":0.6742510622906759,"score_spread":0.23868925895094772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052270022","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020928238,0.0009869375,0.000065139284,0.9322698,0.008851204,0.0015734549,0.00015097005,0.000009751706,0.035164475],"genre_scores_gemma":[0.022983054,0.0031041603,0.0016419145,0.8107802,0.15669768,0.0003801285,0.000042804702,0.00009440577,0.0042756526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.967952,0.013385413,0.016123794,0.00084637856,0.0006269579,0.0010654284],"domain_scores_gemma":[0.945234,0.044132873,0.0086400965,0.00062206143,0.00065209524,0.0007188723],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2252375,0.00038677582,0.0075023673,0.0020633582,0.0001883065,0.000029932817,0.0007840168,0.0011555312,0.0008107771],"category_scores_gemma":[0.039396998,0.00037733983,0.00052023487,0.0004884506,0.00052784133,0.00031126832,0.00021039587,0.004831358,0.0013024509],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016085499,0.0006455624,0.0020630483,0.00040963735,0.00030697187,0.000043683976,0.0052768607,0.00004744141,8.9894513e-7,0.039992668,0.9478128,0.0017918589],"study_design_scores_gemma":[0.0026021036,0.0076689143,0.10274244,0.00061642,0.000021161031,0.0000059950853,0.0018104245,0.000004249183,4.976804e-7,0.010000394,0.8742286,0.0002988234],"about_ca_topic_score_codex":0.0017411658,"about_ca_topic_score_gemma":0.0076940157,"teacher_disagreement_score":0.18584052,"about_ca_system_score_codex":0.004387687,"about_ca_system_score_gemma":0.0015870938,"threshold_uncertainty_score":0.99986786},"labels":[],"label_agreement":null},{"id":"W2052361246","doi":"10.1200/jco.2003.06.142","title":"Barriers to Hospice Care Among Older Patients Dying With Lung and Colorectal Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Saskatchewan","keywords":"Medicine; Colorectal cancer; Lung cancer; Cancer; Proportional hazards model; Epidemiology; Hospice care; End-of-life care; Logistic regression; Internal medicine; Retrospective cohort study; Palliative care; Family medicine; Emergency medicine; Nursing","score_opus":0.10916587274861882,"score_gpt":0.5053132706730995,"score_spread":0.39614739792448067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052361246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948045,0.0015004408,0.00006696875,0.0005012356,0.00060297817,0.00018151508,0.000002578681,0.0000034111392,0.0023363428],"genre_scores_gemma":[0.9950051,0.00063418667,0.0028374554,0.0012535454,0.00020587955,0.0000043680748,7.0053e-7,0.000011803389,0.000047017667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983989,0.00018630744,0.0008608414,0.00013650343,0.00024998133,0.00016746655],"domain_scores_gemma":[0.99716014,0.00076116895,0.0006518963,0.00006635996,0.00076022005,0.00060021156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547232,0.000102187514,0.00089094497,0.00007401658,0.00003435319,0.0000040327895,0.00005954162,0.00018601729,0.00008992599],"category_scores_gemma":[0.0041761613,0.00006746454,0.0001150841,0.00011650902,0.0001608473,0.00007365457,0.000018413752,0.00043065625,8.052675e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010435277,0.00009375164,0.98458207,0.00004176541,0.00021804617,0.00009513862,0.0022609762,0.000015094132,0.000023520686,0.000007381796,0.0008681967,0.010750533],"study_design_scores_gemma":[0.0060661878,0.008092645,0.9619031,0.00070375623,0.00034153461,0.000013931721,0.0024850266,0.000007557878,0.00049470895,0.0000046957725,0.019798271,0.000088560715],"about_ca_topic_score_codex":0.000041799216,"about_ca_topic_score_gemma":0.00014026728,"teacher_disagreement_score":0.022678943,"about_ca_system_score_codex":0.00013435828,"about_ca_system_score_gemma":0.000950626,"threshold_uncertainty_score":0.49995568},"labels":[],"label_agreement":null},{"id":"W2053890186","doi":"10.1200/jco.2013.53.5096","title":"Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Logistic regression; Confounding; Genitourinary system; Randomized controlled trial; Blood transfusion; Cancer; Surgery; Internal medicine","score_opus":0.12827545554895056,"score_gpt":0.5128770635360715,"score_spread":0.38460160798712095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053890186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926377,0.00036519158,0.000091992115,0.0041023092,0.0001625094,0.00063708087,0.0000018073456,0.0000012983411,0.0020000988],"genre_scores_gemma":[0.9979606,0.00028109996,0.0011867498,0.00044545255,0.00008884858,0.000022941718,0.000003738836,0.0000041696153,0.000006401235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970635,0.0015060138,0.0010344567,0.000118392745,0.00018043125,0.00009719132],"domain_scores_gemma":[0.9919681,0.0068036024,0.00079699315,0.000099967314,0.0002271777,0.00010415072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060769417,0.00007888385,0.0012262292,0.00006154881,0.000021346503,0.000011244282,0.00013740627,0.00012058022,0.000010279864],"category_scores_gemma":[0.0013740553,0.00004147895,0.00010990292,0.0001160077,0.00021326973,0.00008778662,0.000044711596,0.00043699262,9.261592e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020633278,0.009229171,0.58079046,0.00025380417,0.0006013181,0.00035885413,0.0011503069,0.000031391162,0.0014917635,0.0025934114,0.0008329082,0.38203332],"study_design_scores_gemma":[0.011705698,0.016244635,0.96686107,0.00040931176,0.00016668526,0.00017065075,0.00013833687,0.000067668014,0.00095954695,0.0007359821,0.0025024351,0.000037978614],"about_ca_topic_score_codex":0.00002628955,"about_ca_topic_score_gemma":0.000022953649,"teacher_disagreement_score":0.3860706,"about_ca_system_score_codex":0.00009232978,"about_ca_system_score_gemma":0.00045966913,"threshold_uncertainty_score":0.21061587},"labels":[],"label_agreement":null},{"id":"W2054250491","doi":"10.1200/jco.2008.21.2175","title":"Underestimation of Risk by Gail Model Extends Beyond Women With Atypical Hyperplasia","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gynecology","score_opus":0.042654327908067266,"score_gpt":0.3915940868158465,"score_spread":0.34893975890777923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054250491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6424261,0.0029215002,0.039783813,0.30698135,0.001981572,0.00044529897,0.00038139313,0.000014843359,0.0050641247],"genre_scores_gemma":[0.47704497,0.0040625497,0.07349282,0.4310075,0.01164475,0.00003070714,0.0004019836,0.00016087983,0.002153838],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622214,0.0005239347,0.002108628,0.00036881206,0.00045189672,0.00032457113],"domain_scores_gemma":[0.9947396,0.0005390264,0.003538514,0.0004031827,0.00061768445,0.00016198317],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0015101262,0.0002706819,0.0012852155,0.000107982734,0.000041479023,0.000012475936,0.00047734057,0.0022020366,0.000050123374],"category_scores_gemma":[0.0012777696,0.00020765833,0.00032844782,0.00009632171,0.00040677487,0.000009413338,0.00006626641,0.0023328606,0.0000043471473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026932175,0.00034145635,0.0004716675,0.000024716464,0.0005166887,0.00006964788,0.00004269263,0.003431084,0.000631154,0.0000072019366,0.9465076,0.045262888],"study_design_scores_gemma":[0.0045468425,0.015241912,0.0032578262,0.00006974098,0.00056686986,0.00039430382,0.00005607061,0.0009673596,0.000657099,0.003425331,0.9703993,0.00041731505],"about_ca_topic_score_codex":0.0000032221765,"about_ca_topic_score_gemma":0.000010057886,"teacher_disagreement_score":0.16538113,"about_ca_system_score_codex":0.00024717723,"about_ca_system_score_gemma":0.003189221,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W2054513029","doi":"10.1200/jco.2003.10.174","title":"Unusual Abdominal and Pelvic Tumors","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Urologic and reproductive health conditions","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Citation; Oncology; Gynecologic oncology; Internal medicine; General surgery; Gynecology; Library science","score_opus":0.17391533351843902,"score_gpt":0.5163744400982457,"score_spread":0.3424591065798067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054513029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94746405,0.0010454238,0.00025235146,0.016625738,0.0011799781,0.00011918786,8.186989e-7,0.000005981584,0.03330649],"genre_scores_gemma":[0.9887394,0.0003621151,0.004667703,0.004510496,0.0009876558,0.0000012063753,3.733175e-7,0.0000061773603,0.0007249246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976931,0.00045470832,0.0013768262,0.00014680908,0.00016424284,0.00016430915],"domain_scores_gemma":[0.99714136,0.0012259005,0.0008141225,0.00010494327,0.00031674965,0.00039694252],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003686974,0.000072671224,0.000875451,0.00008539126,0.00005292639,0.0000025139675,0.000041564068,0.00022087662,0.00021445191],"category_scores_gemma":[0.008618475,0.000045954497,0.00018188104,0.000082532846,0.00037059636,0.000049510305,0.000013088321,0.00090646936,0.000020751762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068948236,0.0059113093,0.56219363,0.00012259792,0.00067237124,0.0052424446,0.00033670838,0.0000075720186,0.00048743153,0.018075336,0.035822377,0.36423337],"study_design_scores_gemma":[0.004904479,0.015067176,0.7526337,0.000026790936,0.00024565702,0.007051739,0.00021953245,0.000008559032,0.000036868034,0.003638949,0.216109,0.0000575611],"about_ca_topic_score_codex":0.0000021444882,"about_ca_topic_score_gemma":0.0000018761293,"teacher_disagreement_score":0.3641758,"about_ca_system_score_codex":0.000040000534,"about_ca_system_score_gemma":0.0015673523,"threshold_uncertainty_score":0.9997324},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2054565675","doi":"10.1200/jco.2005.03.1435","title":"Management of Advanced Prostate Cancer After First-Line Chemotherapy","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Vinorelbine; Chemotherapy; Capecitabine; Prostate cancer; Oncology; Internal medicine; Prostate; Cancer; Ketoconazole; Radiation therapy; Hormonal therapy; Palliative care; Colorectal cancer","score_opus":0.18161181108515118,"score_gpt":0.5740732991290675,"score_spread":0.3924614880439163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054565675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006581736,0.9922622,0.0000051074367,0.0035637266,0.0009400636,0.0012005902,0.000030359559,0.000006691893,0.0013331252],"genre_scores_gemma":[0.00013261255,0.98813426,0.0022747354,0.00036278073,0.0015946972,0.00012748317,0.000011694427,0.00005629597,0.0073054372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946706,0.00024573214,0.0038749604,0.00029799613,0.00055364874,0.0003570399],"domain_scores_gemma":[0.9948614,0.0006838632,0.0032864227,0.00031851575,0.0004731278,0.00037662982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017608455,0.00033092208,0.00541554,0.00022952716,0.000022144492,0.0000055667415,0.00026267464,0.00059466966,0.00073755794],"category_scores_gemma":[0.00012582075,0.00018771319,0.0017250018,0.00027061146,0.00026035277,0.000073709656,0.00008568622,0.0013785219,0.000023490073],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058952896,0.0015000504,0.0003274778,0.009611825,0.0025319112,0.0016465841,0.00003238691,0.0000034574216,5.7928386e-8,0.0000053765716,0.001348912,0.9770967],"study_design_scores_gemma":[0.009599979,0.006105852,0.0012487398,0.020456638,0.002999981,0.00011855285,0.000014327557,0.000001328264,0.000001396143,0.000030558887,0.9592828,0.00013983126],"about_ca_topic_score_codex":0.0000034921234,"about_ca_topic_score_gemma":0.000014297475,"teacher_disagreement_score":0.97695684,"about_ca_system_score_codex":0.00055918645,"about_ca_system_score_gemma":0.0025560213,"threshold_uncertainty_score":0.8075742},"labels":[],"label_agreement":null},{"id":"W2056553154","doi":"10.1200/jco.2003.09.034","title":"Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Watchful waiting; Prostatectomy; Comorbidity; Cohort; Life expectancy; Radiation therapy; Cancer registry; Cancer; Internal medicine; Quality of life (healthcare); Surgery; Oncology; Population","score_opus":0.11356996123271561,"score_gpt":0.47805929052964413,"score_spread":0.3644893292969285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056553154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711346,0.015640887,0.000040285475,0.007959328,0.00085932366,0.00043549793,0.000036014866,0.000005091508,0.0038889474],"genre_scores_gemma":[0.9400764,0.05548974,0.0019610545,0.0019168734,0.00032772383,0.000027573982,0.0000037869984,0.000017463255,0.00017939374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971049,0.00029294332,0.0019075176,0.00019350275,0.00030828002,0.00019285416],"domain_scores_gemma":[0.9956897,0.0013810267,0.0018496114,0.00017894158,0.0006048414,0.00029587562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010951221,0.00014901736,0.0016164856,0.00005978334,0.000023648725,0.0000059429094,0.00009156627,0.00021935029,0.00085009384],"category_scores_gemma":[0.00057730475,0.00009023289,0.00042687694,0.00011539696,0.00017852377,0.000082162,0.000014768516,0.00045219774,0.0000059563317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008648732,0.004450201,0.489516,0.000017527336,0.0023415796,0.000429977,0.0010506135,0.000044768636,0.0003009405,0.00061738136,0.0086385235,0.48394376],"study_design_scores_gemma":[0.058366977,0.030639868,0.50123703,0.00063162553,0.00066423457,0.00006835714,0.00070647744,0.000029219394,0.012856247,0.0070308303,0.3875573,0.00021182174],"about_ca_topic_score_codex":0.00013536592,"about_ca_topic_score_gemma":0.000029628041,"teacher_disagreement_score":0.48373196,"about_ca_system_score_codex":0.00021227729,"about_ca_system_score_gemma":0.0015842465,"threshold_uncertainty_score":0.93079317},"labels":[],"label_agreement":null},{"id":"W2056593463","doi":"10.1200/jco.2011.36.4281","title":"Tamoxifen Chemoprevention and Cardiac Disease","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Tamoxifen; Disease; Internal medicine; Oncology; Breast cancer; Cancer","score_opus":0.188548134404008,"score_gpt":0.5086288547590361,"score_spread":0.3200807203550281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056593463","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06820332,0.011903008,0.000010427391,0.9043574,0.008670815,0.0004516658,0.00002888551,0.000014076854,0.0063604023],"genre_scores_gemma":[0.021643987,0.018141046,0.0011861157,0.8531069,0.066165335,0.000023067609,0.00011402564,0.00008256,0.039536934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970636,0.0005097682,0.0017036471,0.00023315872,0.00026311039,0.00022671542],"domain_scores_gemma":[0.99615943,0.0010621265,0.0018885473,0.00017717217,0.00026635395,0.0004463369],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00132634,0.00020614525,0.0021799204,0.00013681022,0.000024500234,0.0000055091714,0.00011169057,0.0012246076,0.0008080597],"category_scores_gemma":[0.0006195988,0.00014760053,0.0010400877,0.000051948115,0.00025168585,0.00006099809,0.00005520216,0.0030862552,0.000032208933],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028252744,0.0007000224,0.018996214,0.00013658991,0.0012589343,0.004856515,0.000027735501,2.978022e-8,0.000009845473,0.000008877496,0.92502004,0.046159953],"study_design_scores_gemma":[0.0044441246,0.006696311,0.08528478,0.000115268434,0.004724642,0.00015535724,0.0000030313447,9.766582e-7,0.0000046314462,0.0007063696,0.8977582,0.00010632398],"about_ca_topic_score_codex":0.00001457466,"about_ca_topic_score_gemma":0.0000015731381,"teacher_disagreement_score":0.06628857,"about_ca_system_score_codex":0.00014474976,"about_ca_system_score_gemma":0.0018444988,"threshold_uncertainty_score":0.99921364},"labels":[],"label_agreement":null},{"id":"W2056621958","doi":"10.1200/jco.2013.51.2038","title":"Ototoxicity in Children With High-Risk Neuroblastoma: Prevalence, Risk Factors, and Concordance of Grading Scales—A Report From the Children's Oncology Group","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Children's Hospital of Pittsburgh; National Cancer Institute; University of Texas Health Science Center at San Antonio; University of California, Los Angeles; York University; City of Hope; Cedars-Sinai Medical Center; Children's Hospitals and Clinics of Minnesota; Seattle Children's Research Institute; Cincinnati Children's Hospital Medical Center; Tulane University; Virginia Commonwealth University; McGill University Health Centre; College of Engineering, Michigan State University; Children's National Hospital; Children's Mercy Hospital; University of South Carolina; Loma Linda University; McGill University; Dartmouth College; BC Children's Hospital; Children's Hospital Los Angeles; Louisiana State University; Children's Hospital of Philadelphia; Hospital for Sick Children; Georgetown University; West Virginia University; Kaiser Permanente; University of Illinois at Urbana-Champaign; Michigan State University; Cleveland Clinic; University of Minnesota; Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago","keywords":"Medicine; Ototoxicity; Common Terminology Criteria for Adverse Events; Concordance; Hearing loss; Carboplatin; Neuroblastoma; Grading (engineering); Population; Internal medicine; Cisplatin; Pediatrics; Audiology; Adverse effect; Chemotherapy","score_opus":0.02927050104966246,"score_gpt":0.36576159247394957,"score_spread":0.3364910914242871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056621958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979218,0.0001826979,0.00013727156,0.0006947295,0.00024407735,0.00061512925,0.000047300837,0.000010997731,0.00014597441],"genre_scores_gemma":[0.9955367,0.0018762294,0.001746624,0.00025091588,0.0005318686,0.0000069682537,0.000008681008,0.00002573794,0.000016262515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994188,0.0022237024,0.0022018908,0.0004408212,0.00057029055,0.00037526194],"domain_scores_gemma":[0.9880024,0.007329684,0.0035472705,0.0004205849,0.00022347568,0.00047656437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033833603,0.00025538518,0.0018588908,0.00014572254,0.000093503746,0.0000114476425,0.00030262023,0.00031327768,0.000021766795],"category_scores_gemma":[0.007313537,0.00013513,0.0002854195,0.00023095722,0.0009071773,0.00014347896,0.00013407186,0.0021905457,0.0000026525029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034135522,0.0017108464,0.96874416,0.000010064575,0.00063970155,0.00047397506,0.000037773385,0.000012165658,0.00009517778,0.000020170613,0.00019567514,0.024646765],"study_design_scores_gemma":[0.012201202,0.02931622,0.954837,0.00012942104,0.0005500643,0.0018630772,0.000015861284,0.00004409687,0.000237494,0.00036034925,0.00034451525,0.00010068744],"about_ca_topic_score_codex":0.0012453179,"about_ca_topic_score_gemma":0.00082446996,"teacher_disagreement_score":0.027605373,"about_ca_system_score_codex":0.000114880946,"about_ca_system_score_gemma":0.0005507505,"threshold_uncertainty_score":0.95169526},"labels":[],"label_agreement":null},{"id":"W2058217833","doi":"10.1200/jco.2008.21.1813","title":"Pediatric Cancer Survivorship Research: Experience of the Childhood Cancer Survivor Study","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Survivorship curve; Medicine; Cancer survivorship; Cancer; Pediatric cancer; Childhood cancer; Cohort study; Cohort; MEDLINE; Family medicine; Gerontology","score_opus":0.5724809120383988,"score_gpt":0.6353690353786398,"score_spread":0.06288812334024096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058217833","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07178315,0.91461664,0.00000166849,0.0032466133,0.00726356,0.0023989351,0.000051993098,0.00001741075,0.0006200197],"genre_scores_gemma":[0.013301101,0.97300833,0.00010277799,0.0010227849,0.011874813,0.0001195695,0.0000024155972,0.0001013698,0.0004668382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9692337,0.0143171735,0.011057425,0.00087186147,0.0036010402,0.00091879524],"domain_scores_gemma":[0.96829945,0.0154857095,0.011464523,0.0014874797,0.0023334185,0.0009294196],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.03240176,0.0007039969,0.011775865,0.0007269877,0.00019476378,0.000030364374,0.002318888,0.0015362814,0.0004074338],"category_scores_gemma":[0.021038493,0.00040714518,0.0037253804,0.002358533,0.0008373964,0.00016466361,0.0005212937,0.008408931,0.000018899002],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006209948,0.009837115,0.07706329,0.0046147415,0.0016249082,0.00023311652,0.0035116763,0.0000027204455,9.549971e-8,0.000022324934,0.0067778258,0.8956912],"study_design_scores_gemma":[0.0041304543,0.009785008,0.18257175,0.011290327,0.0056656497,0.00020088174,0.0011701555,4.431195e-7,6.895374e-7,0.00008642018,0.78468287,0.00041533407],"about_ca_topic_score_codex":0.0048371432,"about_ca_topic_score_gemma":0.009437307,"teacher_disagreement_score":0.89527583,"about_ca_system_score_codex":0.00081424735,"about_ca_system_score_gemma":0.026459735,"threshold_uncertainty_score":0.99983805},"labels":[],"label_agreement":null},{"id":"W2058570358","doi":"10.1200/jco.2009.22.3685","title":"Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Concomitant; Radiation therapy; End point; Clinical endpoint; Head and neck cancer; Randomized controlled trial; Surgery","score_opus":0.27790897889696164,"score_gpt":0.576020580268576,"score_spread":0.2981116013716144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058570358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047347557,0.947065,0.00033712556,0.0017433915,0.0002414032,0.0031760081,0.000027511685,0.0000029266641,0.000059096958],"genre_scores_gemma":[0.007307463,0.97382236,0.017970206,0.00038568093,0.0003594196,0.00006119329,0.0000012984938,0.00003395938,0.000058437086],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9814196,0.0014276347,0.016157424,0.00033511617,0.0003896211,0.00027059126],"domain_scores_gemma":[0.9594398,0.0136648165,0.0258112,0.00017815258,0.00067925296,0.00022676597],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.023762478,0.00034456822,0.029147651,0.00028774427,0.000020041389,0.0000042572115,0.00011167273,0.00039639295,0.000055507855],"category_scores_gemma":[0.029815307,0.00017638436,0.0012718319,0.0002010118,0.0004862735,0.000054746513,0.000028722192,0.0005814723,5.807379e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18398477,0.00042924585,0.0009145907,0.005342418,0.0020236587,0.00009323742,0.00019855489,0.0000072023026,0.000046573157,0.00000410098,0.000119283286,0.80683637],"study_design_scores_gemma":[0.4220332,0.05191058,0.0030522253,0.15805183,0.008967977,0.0005631682,0.00012859642,0.00007815348,0.000096588235,0.000049059086,0.3546711,0.0003975421],"about_ca_topic_score_codex":0.00005828324,"about_ca_topic_score_gemma":0.0002477821,"teacher_disagreement_score":0.8064388,"about_ca_system_score_codex":0.00018454564,"about_ca_system_score_gemma":0.0045717726,"threshold_uncertainty_score":0.9852657},"labels":[],"label_agreement":null},{"id":"W2059557295","doi":"10.1200/jco.2009.25.2221","title":"Reply to K. Lin et al","year":2009,"lang":"eo","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.23384896435461994,"score_gpt":0.5941704826705838,"score_spread":0.3603215183159639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059557295","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20002055,0.004613534,0.00009248859,0.77192086,0.0037380701,0.00035395805,0.000007320913,0.000010108905,0.01924308],"genre_scores_gemma":[0.4856478,0.0150323445,0.0035889465,0.48129985,0.004211915,0.0000023045138,0.0000042199035,0.000024966206,0.010187677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942354,0.0009825195,0.0031869204,0.00031032256,0.0007617678,0.0005230517],"domain_scores_gemma":[0.9934142,0.0026729272,0.0013623792,0.00032964337,0.00083081436,0.0013900361],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009494215,0.00020130552,0.0020061892,0.00024132969,0.00005171245,0.000024558169,0.00032334612,0.0004094405,0.0005291831],"category_scores_gemma":[0.0086526135,0.00013094036,0.00075056875,0.00028965378,0.00017450929,0.00013012295,0.00007441508,0.0025004488,0.00039330497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014613151,0.0030908724,0.0065718843,0.000011041082,0.00039879308,0.004299141,0.00022743973,0.000008800269,0.00018265266,0.00016630533,0.60974437,0.36068556],"study_design_scores_gemma":[0.010923078,0.07130316,0.10861789,0.00029112914,0.0002590747,0.00026784668,0.00011027664,0.000020152549,0.00012108145,0.00060282554,0.80737996,0.00010355007],"about_ca_topic_score_codex":0.000025619373,"about_ca_topic_score_gemma":0.000010366744,"teacher_disagreement_score":0.36058202,"about_ca_system_score_codex":0.00040128487,"about_ca_system_score_gemma":0.0056411666,"threshold_uncertainty_score":0.99999595},"labels":[],"label_agreement":null},{"id":"W2059854615","doi":"10.1200/jco.2011.37.2326","title":"Reply to C. McCowan et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.3615371352753022,"score_gpt":0.5805508081408391,"score_spread":0.21901367286553697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059854615","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21027578,0.012806483,0.00024122356,0.5981917,0.055053413,0.0004016845,0.000016438908,0.00001532362,0.12299798],"genre_scores_gemma":[0.26953056,0.012029465,0.015051795,0.668926,0.01002906,0.000008517846,0.0000028079012,0.00005117666,0.024370635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994333,0.0012959301,0.0032380617,0.00028758124,0.00032492363,0.0005204886],"domain_scores_gemma":[0.99333245,0.0027248014,0.0017780493,0.0002528582,0.00053208467,0.0013797333],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006840139,0.00022196172,0.002031811,0.00018226482,0.000037513077,0.0000064667456,0.0002778677,0.0004701605,0.009227332],"category_scores_gemma":[0.0030696187,0.00017482776,0.0008346026,0.0002055985,0.00036802082,0.00015638875,0.00010629555,0.001847349,0.0008810236],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010451161,0.006822437,0.027682181,0.000019481855,0.001059545,0.004660201,0.00094795093,0.0000027054973,0.00010047376,0.0009085401,0.6805051,0.26684025],"study_design_scores_gemma":[0.009280711,0.06387091,0.100379474,0.00017127926,0.0012256481,0.0012058081,0.00014820215,0.000007912561,0.00013881456,0.0005773921,0.82287204,0.000121817524],"about_ca_topic_score_codex":0.00037496065,"about_ca_topic_score_gemma":0.00013781036,"teacher_disagreement_score":0.26671842,"about_ca_system_score_codex":0.00039079267,"about_ca_system_score_gemma":0.0041279644,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W2060211329","doi":"10.1200/jco.2008.17.6792","title":"Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Cancer stem cell; Stem cell; Neuroscience; Medicine; Brain cancer; Brain tumor; Cancer; Cancer research; In vivo; Biology; Bioinformatics; Pathology; Cell biology; Internal medicine; Genetics","score_opus":0.14979854420470537,"score_gpt":0.48952719637559927,"score_spread":0.3397286521708939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060211329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027163832,0.99176526,0.0006818326,0.0021012472,0.0020249025,0.00036054384,0.00002506307,0.000001891742,0.00032286937],"genre_scores_gemma":[0.0004077201,0.99367523,0.000806256,0.0013631491,0.0027931232,0.000013987701,0.0000062308363,0.000043199383,0.0008910741],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950677,0.0011128365,0.00297424,0.00030551662,0.000280833,0.00025886676],"domain_scores_gemma":[0.993923,0.0013510518,0.003535459,0.00037488752,0.0005927106,0.00022288813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030751084,0.00026155595,0.0022866756,0.000109255634,0.00005301833,0.000009505016,0.00060635316,0.00064468704,0.00002909159],"category_scores_gemma":[0.0021652982,0.00016306379,0.0009778066,0.00026100545,0.00016129327,0.0000030515846,0.00019730025,0.0007620091,0.000008701731],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008521459,0.00014701324,0.000036024383,0.00037806248,0.0003536133,0.000032380667,0.000026538042,0.00010532269,0.00038274654,0.0000070097462,0.017173361,0.9812727],"study_design_scores_gemma":[0.0005023549,0.002113862,0.000047180558,0.00083104696,0.00022159588,0.00006449743,0.000012789835,0.0000078045905,0.0005177779,0.000008362383,0.99550474,0.0001679924],"about_ca_topic_score_codex":0.000018955272,"about_ca_topic_score_gemma":0.000074007774,"teacher_disagreement_score":0.98110473,"about_ca_system_score_codex":0.000054372445,"about_ca_system_score_gemma":0.0030006832,"threshold_uncertainty_score":0.6649548},"labels":[],"label_agreement":null},{"id":"W2060258978","doi":"10.1200/jco.2002.01.153","title":"Symptom Experiences: Perceptual Accuracy Between Advanced-Stage Cancer Patients and Family Caregivers in the Home Care Setting","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Distress; Likert scale; Family caregivers; Psychological distress; Perception; Clinical psychology; Proxy (statistics); Cancer stage; Cancer; Physical therapy; Psychiatry; Psychology; Anxiety; Internal medicine","score_opus":0.08955650659065555,"score_gpt":0.43026150423453813,"score_spread":0.34070499764388257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060258978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99153227,0.0035232187,0.0000037569082,0.0019514544,0.0012428912,0.00019355155,0.000016526586,0.0000057386014,0.0015305822],"genre_scores_gemma":[0.99430436,0.0021146433,0.00006873133,0.0025669665,0.000848473,0.0000142708495,0.000003255277,0.000011672443,0.00006764943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974937,0.00039267566,0.0011987152,0.0002085668,0.00045146685,0.00025488308],"domain_scores_gemma":[0.9963928,0.0021628994,0.00076086906,0.00014239617,0.00032036845,0.00022069081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879985,0.00014017781,0.00085391395,0.000091342685,0.00006640184,0.000015619264,0.00022735387,0.00024479744,0.00017365259],"category_scores_gemma":[0.0010474637,0.00008832633,0.00023051727,0.00016202044,0.00025295914,0.00018974526,0.000052402585,0.0009459243,0.0000029389241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024040844,0.00013022767,0.6495589,0.000030819265,0.000040736624,0.00010878558,0.08082439,0.000004571649,0.0000043398745,0.000002857653,0.00081739353,0.26823658],"study_design_scores_gemma":[0.004721784,0.0037476816,0.7273206,0.00014608666,0.00012436774,0.000013460273,0.20301269,0.000010465847,0.0000033248132,0.0000050986378,0.060784645,0.000109773704],"about_ca_topic_score_codex":0.00028813878,"about_ca_topic_score_gemma":0.00066540984,"teacher_disagreement_score":0.26812682,"about_ca_system_score_codex":0.00022784536,"about_ca_system_score_gemma":0.0003313121,"threshold_uncertainty_score":0.4109623},"labels":[],"label_agreement":null},{"id":"W2061337936","doi":"10.1200/jco.2013.54.2456","title":"Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30<sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Takeda Oncology","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Neutropenia; Vincristine; CHOP; Anaplastic large-cell lymphoma; Febrile neutropenia; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cyclophosphamide; Lymphoma; Chemotherapy; CD30","score_opus":0.060078820617117196,"score_gpt":0.4065655712450807,"score_spread":0.3464867506279635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061337936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964136,0.0002364648,0.000012341109,0.0012164522,0.0001750409,0.0007673593,0.000027997905,0.0000032808846,0.0011474842],"genre_scores_gemma":[0.99828076,0.00017891472,0.000798608,0.00031135514,0.00031168532,0.000019672347,0.000016145466,0.000015327414,0.00006754078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949279,0.000991939,0.0030031046,0.00024706783,0.0005937149,0.00023629495],"domain_scores_gemma":[0.99443686,0.0023545867,0.0021920172,0.00039740436,0.00042063525,0.00019850578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019864736,0.00022472348,0.002051708,0.00012574709,0.000027299795,0.000005683609,0.00019184907,0.0001753654,0.000047229958],"category_scores_gemma":[0.0008500417,0.00010626571,0.00043323755,0.0001382,0.0001869626,0.000060913895,0.000026794165,0.000195407,0.0000039368297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035321098,0.1891557,0.64633083,0.000020992962,0.00056072185,0.0003062407,0.0026872223,0.00012722365,0.000005263117,0.000006719026,0.0003775522,0.12510042],"study_design_scores_gemma":[0.23514998,0.23048395,0.52565926,0.000086589396,0.00090150686,0.000027872436,0.0010134168,0.00038236452,0.00008326435,0.000015641013,0.006122345,0.000073832896],"about_ca_topic_score_codex":0.00020662302,"about_ca_topic_score_gemma":0.0001336435,"teacher_disagreement_score":0.19982888,"about_ca_system_score_codex":0.00034258876,"about_ca_system_score_gemma":0.0008326747,"threshold_uncertainty_score":0.433339},"labels":[],"label_agreement":null},{"id":"W2061476279","doi":"10.1200/jco.2006.10.3036","title":"Ethics in Oncology: Consulting for the Investment Industry","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Investment (military); Clinical Oncology; Oncology; Internal medicine; Family medicine; Cancer","score_opus":0.4177980805286127,"score_gpt":0.5996534473641874,"score_spread":0.18185536683557463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061476279","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35173756,0.0010895838,0.0052808076,0.63060504,0.004202168,0.0005705062,0.0000015631528,0.000008244705,0.0065045496],"genre_scores_gemma":[0.93511486,0.00050618075,0.010405533,0.051382195,0.0023589032,0.0000030259055,0.0000014077344,0.0000099344625,0.00021795921],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965931,0.00036258335,0.0023437864,0.00010913923,0.00037125018,0.00022009814],"domain_scores_gemma":[0.9656356,0.031706862,0.0015418621,0.0001254751,0.00063704833,0.0003531684],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.03890203,0.00007506485,0.00074830675,0.00010451948,0.00006446693,0.0000039500064,0.00012451225,0.0028386537,0.00003067465],"category_scores_gemma":[0.022506911,0.000039539158,0.00024673235,0.00017075131,0.0011376755,0.00003118452,0.00003808956,0.0068102027,0.0000020942114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004752728,0.0020341978,0.02447461,0.00007041325,0.0003210472,0.00047703754,0.0012333281,0.000030229663,0.0003232584,0.016456481,0.005277111,0.94454956],"study_design_scores_gemma":[0.010106217,0.0074931174,0.2404201,0.00017322706,0.00020523643,0.00030266715,0.0012290662,0.00064516114,0.00006662757,0.007315539,0.7319815,0.0000615079],"about_ca_topic_score_codex":0.00001683279,"about_ca_topic_score_gemma":0.00016923076,"teacher_disagreement_score":0.94448805,"about_ca_system_score_codex":0.00022993617,"about_ca_system_score_gemma":0.0043505286,"threshold_uncertainty_score":0.9984559},"labels":[],"label_agreement":null},{"id":"W2062867383","doi":"10.1200/jco.2009.22.0392","title":"Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chromosomal translocation; Multiple myeloma; Complete remission; Internal medicine; Oncology; Chemotherapy; Genetics; Gene","score_opus":0.17420673631041428,"score_gpt":0.5012384800363613,"score_spread":0.327031743725947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062867383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005804544,0.99052185,0.00003242473,0.0006452399,0.0003194331,0.0012484716,0.0000069880266,0.000010460026,0.0014105701],"genre_scores_gemma":[0.0069350344,0.98824394,0.0038751382,0.0001858887,0.0004947781,0.000017804285,0.000034704884,0.000037247504,0.00017547724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99335974,0.0011292561,0.0040432885,0.00034360428,0.0007370141,0.00038711404],"domain_scores_gemma":[0.9928292,0.0031273991,0.0025690615,0.00031252834,0.00040740825,0.00075442385],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019999838,0.00034729156,0.0053569833,0.00045033568,0.00003140615,0.000009805579,0.000199393,0.00096332096,0.000073870404],"category_scores_gemma":[0.0041209944,0.00018968793,0.0010144595,0.00033003118,0.00011127592,0.00007108994,0.000023319837,0.0023377358,0.000030862895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005781228,0.0026766334,0.00024113896,0.0009965932,0.00038632326,0.094057895,0.000037175923,0.0000016836005,4.9504416e-7,0.0000015954256,0.00028686668,0.89553237],"study_design_scores_gemma":[0.009313491,0.027615817,0.0018244815,0.017890578,0.0008902821,0.044775274,0.0000185565,0.000026760054,0.0000011184703,0.000013855753,0.89747113,0.0001586262],"about_ca_topic_score_codex":0.000020562513,"about_ca_topic_score_gemma":0.00014866638,"teacher_disagreement_score":0.8971843,"about_ca_system_score_codex":0.00069519505,"about_ca_system_score_gemma":0.005536844,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2064362771","doi":"10.1200/jco.2010.28.8589","title":"Reply to T. Valerius","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine","score_opus":0.12831847706407487,"score_gpt":0.5084899197499724,"score_spread":0.38017144268589753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064362771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9122202,0.00012824713,0.000020104831,0.049729988,0.0034606862,0.00010669286,9.0852376e-7,0.0000066589355,0.03432652],"genre_scores_gemma":[0.96971494,0.00015624525,0.0065625007,0.0198603,0.002227292,0.0000030514177,2.097322e-7,0.000007616593,0.0014678625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984056,0.000056394114,0.0011082587,0.00010799967,0.00019042975,0.00013132502],"domain_scores_gemma":[0.9978985,0.0007509172,0.00048184776,0.00013497255,0.00036418444,0.00036954682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013234286,0.00007102639,0.0009043003,0.000059697308,0.000029035113,0.0000038569756,0.000077074124,0.00013219175,0.00031944553],"category_scores_gemma":[0.0044594733,0.000042998225,0.00032691655,0.000083018684,0.00008808428,0.00003119589,0.000041455336,0.0007174918,0.000047712172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070760995,0.0017512107,0.17209782,0.000009989892,0.00058328937,0.0014243695,0.00019477942,0.0000010078403,0.0009759215,0.00017918293,0.11398708,0.7017192],"study_design_scores_gemma":[0.0020616094,0.012451922,0.3988699,0.0000107204805,0.00012701593,0.00031450653,0.00003051168,0.0000013330144,0.000058312264,0.00012456937,0.5859211,0.000028500566],"about_ca_topic_score_codex":0.000021248823,"about_ca_topic_score_gemma":0.00008183669,"teacher_disagreement_score":0.70169073,"about_ca_system_score_codex":0.000050050978,"about_ca_system_score_gemma":0.0006907401,"threshold_uncertainty_score":0.5338728},"labels":[],"label_agreement":null},{"id":"W2064902793","doi":"10.1200/jco.2004.07.111","title":"Phase I Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Sanofi","keywords":"Tirapazamine; Medicine; Cyclophosphamide; Mesna; Pharmacokinetics; Rhabdomyosarcoma; Urology; Nitrogen mustard; Chemotherapy; Leukopenia; Neuroblastoma; Ifosfamide; Surgery; Internal medicine; Anesthesia; Cisplatin; Pathology; Sarcoma; Chemistry","score_opus":0.07095676193213869,"score_gpt":0.4826067440666012,"score_spread":0.4116499821344625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064902793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975503,0.00027195437,0.000008830893,0.0006473261,0.00020191807,0.001038416,0.000003576863,0.0000059292024,0.00027174526],"genre_scores_gemma":[0.9971101,0.0009916798,0.0008122063,0.00020285163,0.00082603307,0.000013284704,0.0000022628394,0.000019350198,0.00002222312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600625,0.0005783547,0.0023496593,0.00026389334,0.0004941623,0.00030767388],"domain_scores_gemma":[0.9962146,0.0012644054,0.0016079806,0.0001935788,0.00020994921,0.00050942804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023822717,0.0001723496,0.001974973,0.0003845878,0.000025211462,0.000004590386,0.00013928472,0.00022434093,0.000020823387],"category_scores_gemma":[0.0021449663,0.000110126944,0.00019316122,0.00030685918,0.0002661054,0.00011895945,0.000065576474,0.0012109145,0.000003991191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34970096,0.11900673,0.45708933,0.000023154971,0.0007143121,0.008444926,0.0001967685,0.0000064969054,0.00014762126,0.000009641506,0.00006438749,0.06459566],"study_design_scores_gemma":[0.30648652,0.31266406,0.37951714,0.00002818978,0.00028463197,0.0006934448,0.00008240804,9.1026095e-7,0.000027774113,0.000050368944,0.00011831794,0.00004624372],"about_ca_topic_score_codex":0.00006153243,"about_ca_topic_score_gemma":0.00012727777,"teacher_disagreement_score":0.19365731,"about_ca_system_score_codex":0.00021416703,"about_ca_system_score_gemma":0.002391236,"threshold_uncertainty_score":0.5260888},"labels":[],"label_agreement":null},{"id":"W2065582284","doi":"10.1200/jco.2006.06.6159","title":"New Technologies and Directed Agents for Applications of Cancer Imaging","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Molecular imaging; Magnetic resonance imaging; Medicine; Positron emission tomography; Functional imaging; Preclinical imaging; Modality (human–computer interaction); Medical imaging; Radiology; In vivo; Computer science","score_opus":0.09089741032772808,"score_gpt":0.49468970415645475,"score_spread":0.40379229382872667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065582284","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040902745,0.9954626,0.0021929261,0.0002018285,0.0013880421,0.00044647703,0.00006638988,0.0000080316895,0.00019281884],"genre_scores_gemma":[0.000021226726,0.98908865,0.0062068948,0.0000689661,0.003771113,0.000067199406,0.000027657245,0.000025037149,0.0007232566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974818,0.00011342568,0.0018834767,0.00024961776,0.00010118038,0.00017045446],"domain_scores_gemma":[0.99625826,0.00031635785,0.002817428,0.00021995638,0.000290523,0.00009744742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071305543,0.00018839526,0.0021251992,0.00011447164,0.000027820868,0.0000068364648,0.00031866634,0.0006825946,0.0000063813727],"category_scores_gemma":[0.00073212537,0.00014037336,0.00077242806,0.0001113641,0.00017856136,0.0000035927287,0.00010968362,0.00037070966,3.7547522e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055825116,0.00008814096,0.00006951612,0.0006108382,0.00027806376,8.1648176e-7,0.0000013254903,6.0526304e-7,0.000035572008,0.000029276582,0.04087897,0.95795107],"study_design_scores_gemma":[0.0009818011,0.0003581059,0.00010508287,0.00042476566,0.0012493695,0.000038981194,0.000009891707,0.0000011323376,0.000031819967,0.00019024516,0.996482,0.00012681237],"about_ca_topic_score_codex":0.00004371283,"about_ca_topic_score_gemma":0.00009538161,"teacher_disagreement_score":0.95782423,"about_ca_system_score_codex":0.00002702182,"about_ca_system_score_gemma":0.0021258441,"threshold_uncertainty_score":0.57242596},"labels":[],"label_agreement":null},{"id":"W2065712433","doi":"10.1200/jco.2011.36.3879","title":"Reply to J.-J. de Arriba, et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; McMaster University; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine","score_opus":0.20948039005319644,"score_gpt":0.5228774359885989,"score_spread":0.3133970459354025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065712433","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2686704,0.01332239,0.000509386,0.647479,0.021413423,0.00032708194,0.000012061207,0.000010887126,0.048255347],"genre_scores_gemma":[0.4622241,0.01733518,0.026596267,0.48504236,0.0048311343,0.000011741892,0.0000010427221,0.00003784412,0.003920331],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99528,0.00092701765,0.0026955588,0.00026060242,0.00033930392,0.0004974695],"domain_scores_gemma":[0.99363256,0.00269672,0.00146634,0.00030953457,0.00044124594,0.0014536213],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0075007407,0.00018517664,0.0016552142,0.00010520134,0.000031195956,0.000009025055,0.00022261328,0.0003764561,0.0021815726],"category_scores_gemma":[0.0053127757,0.00013731225,0.00077552686,0.0001312778,0.00020853455,0.00011581507,0.0000781422,0.0012655193,0.0004443125],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031052586,0.005808956,0.20011714,0.000029984565,0.0010521641,0.005216893,0.00083915907,0.0000073404462,0.000007680573,0.001473122,0.5684305,0.21391183],"study_design_scores_gemma":[0.004742754,0.029627925,0.30250397,0.0005265875,0.0008152289,0.0007572615,0.00012116326,0.0000079897245,0.000088570436,0.0006810199,0.66004515,0.000082361155],"about_ca_topic_score_codex":0.00053279055,"about_ca_topic_score_gemma":0.00017170364,"teacher_disagreement_score":0.21382947,"about_ca_system_score_codex":0.0010922248,"about_ca_system_score_gemma":0.0047830297,"threshold_uncertainty_score":0.99873054},"labels":[],"label_agreement":null},{"id":"W206579035","doi":"10.1200/jco.2006.24.18_suppl.13000","title":"EGFR expression using immunohistochemistry (IHC) testing as a tool for selecting patients (pts) for treatment with cetuximab","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cetuximab; Medicine; Immunohistochemistry; Oncology; Colorectal cancer; Internal medicine; EGFR inhibitors; Panitumumab; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.12154894995398602,"score_gpt":0.4679790595453479,"score_spread":0.3464301095913619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W206579035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962833,0.00038844705,0.0006911536,0.00035257815,0.00032148248,0.0006589145,0.000008246439,0.000010489039,0.0012854085],"genre_scores_gemma":[0.9384427,0.000025881453,0.059757836,0.00017074063,0.0010964413,0.000058100784,0.000007820928,0.000023479302,0.00041696776],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99803394,0.000046377583,0.0012738552,0.00020344151,0.00018871673,0.00025367932],"domain_scores_gemma":[0.9953034,0.0022729826,0.0013639823,0.00009617746,0.000869212,0.00009424993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050618674,0.0001707218,0.0011339518,0.000045348534,0.00017696159,0.000010238645,0.00005444989,0.00017004718,0.0000086389255],"category_scores_gemma":[0.0017961975,0.00009349962,0.00035291832,0.00008179368,0.00007284443,0.00006275422,0.000020261687,0.0001573296,4.2494864e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049975302,0.0110435495,0.42117092,0.00020777326,0.0012967034,0.00015260628,0.00024758241,0.000113811126,0.028187634,0.000010220305,0.0014889135,0.48610497],"study_design_scores_gemma":[0.214509,0.4564375,0.18569766,0.0020513295,0.0065971003,0.0012089601,0.00073666486,0.0015867801,0.02487178,0.001021147,0.10440217,0.00087991345],"about_ca_topic_score_codex":0.00007328928,"about_ca_topic_score_gemma":0.00001249144,"teacher_disagreement_score":0.48522505,"about_ca_system_score_codex":0.0009176189,"about_ca_system_score_gemma":0.0011267432,"threshold_uncertainty_score":0.3812804},"labels":[],"label_agreement":null},{"id":"W2066143146","doi":"10.1200/jco.2012.43.2518","title":"Reply to M.A. Hoffman et al","year":2012,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine","score_opus":0.527573879963259,"score_gpt":0.639454164836844,"score_spread":0.11188028487358503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066143146","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38651073,0.0757075,0.0010728727,0.4687503,0.032328583,0.00020778553,0.000015233095,0.000009076112,0.035397924],"genre_scores_gemma":[0.45766518,0.040545326,0.04473777,0.4255652,0.021870112,0.0000032161536,0.000004098322,0.000056080597,0.009552993],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99388975,0.0013066618,0.0035434768,0.00017297869,0.00051477965,0.0005723618],"domain_scores_gemma":[0.98703456,0.008214239,0.0022323814,0.00027998275,0.0007850469,0.0014538129],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011928172,0.00019011284,0.0022580563,0.00016019639,0.000023979766,0.000005404704,0.00025248196,0.00046295213,0.00082436897],"category_scores_gemma":[0.029237477,0.00014706589,0.00079768675,0.00021247662,0.00034364066,0.0002561121,0.00011077623,0.0016179582,0.00042375227],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019448528,0.0022406187,0.23003292,0.000051486186,0.00055763486,0.00038213472,0.0014606612,0.000007966148,0.00011307769,0.0015052349,0.58994627,0.17175716],"study_design_scores_gemma":[0.0033818288,0.013394754,0.10948814,0.0013131077,0.0005029233,0.0002494009,0.0006848844,0.000007758326,0.000218934,0.00018098654,0.87046236,0.00011493063],"about_ca_topic_score_codex":0.0000979251,"about_ca_topic_score_gemma":0.00001935638,"teacher_disagreement_score":0.28051612,"about_ca_system_score_codex":0.00022794497,"about_ca_system_score_gemma":0.0016677772,"threshold_uncertainty_score":0.97893965},"labels":[],"label_agreement":null},{"id":"W2066873416","doi":"10.1200/jco.2004.06.057","title":"Evaluation of Diagnostic Assessment Units in Oncology: A Systematic Review","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Breast cancer; Randomized controlled trial; Systematic review; Medical physics; MEDLINE; Colorectal cancer; Lung cancer; Cancer; Intensive care medicine; Oncology; Surgery; Internal medicine; Pathology","score_opus":0.6942139686689651,"score_gpt":0.6760016709222801,"score_spread":0.01821229774668498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066873416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004437423,0.99280053,0.000027642194,0.0007477836,0.0009707948,0.0029387625,0.0000050313515,0.0000036505478,0.0024614444],"genre_scores_gemma":[0.00044863575,0.9970136,0.000962377,0.000997972,0.00041665306,0.00011051511,0.000010888216,0.000021771695,0.000017570545],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.97795707,0.0079592215,0.011522136,0.00027106682,0.0020211092,0.00026938628],"domain_scores_gemma":[0.9602906,0.020029241,0.014823537,0.00045455535,0.00403465,0.00036741988],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.064012595,0.00030266767,0.014632679,0.00034131441,0.000016045762,0.0000046191008,0.00039976425,0.0010177814,0.0001274515],"category_scores_gemma":[0.17040448,0.00019012662,0.0014267165,0.0008133388,0.00014827403,0.00009632898,0.0000756569,0.002449944,0.000018924025],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000037170536,0.000553378,0.000055492856,0.46579152,0.0006453581,0.00066790334,0.000011735139,0.000008060721,1.2465124e-8,0.0000371047,0.00043625012,0.53175604],"study_design_scores_gemma":[0.002796177,0.0074795405,0.00023167484,0.8041289,0.046748567,0.001572111,0.000043643693,0.000009943386,2.271256e-8,0.00015098635,0.13672353,0.00011494851],"about_ca_topic_score_codex":0.000024419625,"about_ca_topic_score_gemma":0.00006608849,"teacher_disagreement_score":0.53164107,"about_ca_system_score_codex":0.0039168904,"about_ca_system_score_gemma":0.06011903,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W2066937933","doi":"10.1200/jco.2014.58.0662","title":"Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Comprehensive Cancer Network","keywords":"Medicine; Prostate cancer; Hazard ratio; Radiation therapy; Androgen suppression; Internal medicine; Randomized controlled trial; Urology; Cancer; Prostate; Surgery; Confidence interval","score_opus":0.08610409569762555,"score_gpt":0.48557413046787257,"score_spread":0.399470034770247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066937933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95763904,0.0070804395,0.005740361,0.017703122,0.0068107233,0.0048163026,0.000028189073,0.000018736508,0.00016310212],"genre_scores_gemma":[0.8737926,0.10342373,0.012145628,0.0034941584,0.006407516,0.0005057928,0.000076948905,0.00005498984,0.00009865263],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9900339,0.0030931283,0.0058753905,0.0003332881,0.00037793283,0.0002863439],"domain_scores_gemma":[0.9822568,0.010418655,0.005988554,0.0002503498,0.0007038847,0.0003817336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015955562,0.00023462548,0.0044486066,0.00014423698,0.000061251856,0.000011231322,0.00015727733,0.0007278367,0.00011598367],"category_scores_gemma":[0.005614117,0.00014126225,0.0016793802,0.00012053345,0.00045350462,0.00014658728,0.000018946057,0.0005672292,0.000001231269],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48990744,0.0027425056,0.010172989,0.000025720887,0.0009431689,0.000012263618,0.00015149017,0.000012404695,0.00006363072,0.00012425645,0.0027592923,0.49308482],"study_design_scores_gemma":[0.6441368,0.0849892,0.0038241975,0.00010351958,0.0006748039,0.000025772004,0.000019957877,0.0011816099,0.00042509192,0.0009058517,0.263627,0.00008621148],"about_ca_topic_score_codex":0.00003818473,"about_ca_topic_score_gemma":0.00003059241,"teacher_disagreement_score":0.49299863,"about_ca_system_score_codex":0.00030857595,"about_ca_system_score_gemma":0.00221631,"threshold_uncertainty_score":0.6721028},"labels":[],"label_agreement":null},{"id":"W2067494708","doi":"10.1200/jco.2007.11.3324","title":"Issues and Challenges With Integrating Patient-Reported Outcomes in Clinical Trials Supported by the National Cancer Institute–Sponsored Clinical Trials Networks","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Mentorship; Clinical trial; Medicine; Respondent; Cancer; Family medicine; Multidisciplinary approach; Medical education; Internal medicine","score_opus":0.650590760351629,"score_gpt":0.6428020467872093,"score_spread":0.00778871356441968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067494708","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003689294,0.9740009,0.000083993444,0.00942173,0.010241549,0.0020097406,0.000058074755,0.000021186948,0.00047358574],"genre_scores_gemma":[0.0016106062,0.986666,0.00038098285,0.002779504,0.00811129,0.00008976452,0.000057141246,0.000070300935,0.00023436772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9262574,0.033359326,0.037289884,0.0009526138,0.0015142744,0.000626503],"domain_scores_gemma":[0.8193877,0.14580105,0.031450745,0.0005349901,0.0018418907,0.0009836616],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.22894132,0.00073317793,0.023687638,0.0004119594,0.00008462064,0.000050028088,0.00047981943,0.0032886053,0.00014758429],"category_scores_gemma":[0.2028398,0.0003401673,0.0044974787,0.0004656083,0.0012195479,0.00018494035,0.00014485097,0.0073455973,0.0000027609096],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060283416,0.0014869826,0.017190035,0.0006098116,0.004714863,0.00058843044,0.00009817332,0.0000018413987,2.606936e-8,0.000052566334,0.0068249614,0.96240395],"study_design_scores_gemma":[0.010378886,0.0072493446,0.0080367895,0.007084124,0.006539135,0.00064055464,0.00035203857,0.0000210667,8.0246245e-8,0.00004315778,0.9593157,0.0003391253],"about_ca_topic_score_codex":0.00027985862,"about_ca_topic_score_gemma":0.004100373,"teacher_disagreement_score":0.96206486,"about_ca_system_score_codex":0.00036509923,"about_ca_system_score_gemma":0.009466182,"threshold_uncertainty_score":0.99990505},"labels":[],"label_agreement":null},{"id":"W2068638421","doi":"10.1200/jco.20.6.1570","title":"Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Cedars-Sinai Medical Center","keywords":"Ovarian cancer; Medicine; Breast cancer; Incidence (geometry); Oncology; Gynecology; Cancer; Cohort; Population; Internal medicine; Cumulative incidence; BRCA mutation","score_opus":0.06350951092679771,"score_gpt":0.42544422377638613,"score_spread":0.36193471284958845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068638421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946068,0.003457932,0.000055149514,0.0007084145,0.0007411581,0.000082403974,0.000025799332,9.119391e-7,0.00032144372],"genre_scores_gemma":[0.9907669,0.0071368474,0.0010948132,0.00028125086,0.00048874726,0.000014918363,0.0000018726349,0.000010540194,0.00020413953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997416,0.0003637324,0.0016990945,0.00016529366,0.000193831,0.0001620399],"domain_scores_gemma":[0.9968263,0.0002381005,0.002325166,0.00018278003,0.0003331361,0.00009450375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016055737,0.00008681953,0.00062376045,0.00008433297,0.000018256991,0.0000019091387,0.00021858851,0.00033974322,0.00038170262],"category_scores_gemma":[0.0015909818,0.000075603784,0.00017985381,0.00015709898,0.0001494265,0.000008850989,0.0000841482,0.00029059936,0.0000012133684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075207674,0.00033003042,0.87648207,0.000020869084,0.00021413974,0.000008481124,0.00025637497,0.0027681675,0.008649945,0.000010836538,0.0020673366,0.108439684],"study_design_scores_gemma":[0.00306533,0.0021701066,0.97172576,0.00006594353,0.000088300534,0.00001963501,0.00005303062,0.0003537058,0.0044849436,0.0004488225,0.01741241,0.00011202498],"about_ca_topic_score_codex":0.0004177133,"about_ca_topic_score_gemma":0.002611086,"teacher_disagreement_score":0.108327664,"about_ca_system_score_codex":0.00037007852,"about_ca_system_score_gemma":0.00055141666,"threshold_uncertainty_score":0.4179376},"labels":[],"label_agreement":null},{"id":"W2068795211","doi":"10.1200/jco.2005.06.679","title":"Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Phase (matter); Internal medicine; Chemistry","score_opus":0.8477716970268385,"score_gpt":0.7455523759788565,"score_spread":0.10221932104798204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068795211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95579904,0.0071303966,0.029106509,0.005728034,0.0014963577,0.0006488895,0.000010251061,0.000010074858,0.00007047225],"genre_scores_gemma":[0.6207306,0.0012507405,0.37718794,0.0004019333,0.00038482854,0.00000361729,3.487245e-8,0.000015553862,0.000024753232],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9810069,0.005584952,0.012208411,0.00025187802,0.0006612052,0.00028665518],"domain_scores_gemma":[0.6288532,0.35912997,0.009968068,0.00030019286,0.001503538,0.0002450319],"candidate_categories":["metaresearch","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037418168,0.0002630651,0.011792016,0.00013844702,0.00006417705,0.0000057322472,0.00027231858,0.00038481454,0.000044338376],"category_scores_gemma":[0.4272853,0.00016087176,0.0011344971,0.000118161304,0.002860699,0.00009262351,0.00016192146,0.00078636885,8.435096e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44637084,0.04034541,0.028426478,0.0020475914,0.074875645,0.00015517695,0.0070985723,0.00014108764,0.003310831,0.12949038,0.0027060567,0.26503193],"study_design_scores_gemma":[0.4378372,0.010996971,0.00060777215,0.00047986943,0.00846293,0.00004113546,0.0013011787,0.0021172757,0.0012724595,0.5363933,0.00026649874,0.00022342],"about_ca_topic_score_codex":0.0000017256691,"about_ca_topic_score_gemma":0.000005016121,"teacher_disagreement_score":0.40690288,"about_ca_system_score_codex":0.000114495575,"about_ca_system_score_gemma":0.0003155994,"threshold_uncertainty_score":0.99985296},"labels":[],"label_agreement":null},{"id":"W2069548171","doi":"10.1200/jco.2010.30.1986","title":"The Curse of Dimensionality: A Blessing to Personalized Medicine","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Blessing; Medicine; Curse; Personalized medicine; Curse of dimensionality; Traditional medicine; Family medicine; Bioinformatics; Artificial intelligence; Computer science; Biology","score_opus":0.10810630315931737,"score_gpt":0.48308619108071454,"score_spread":0.3749798879213972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069548171","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04803263,0.0028684377,0.0002927764,0.94070023,0.0067264833,0.00017246229,0.000015902753,0.0000020348468,0.0011890294],"genre_scores_gemma":[0.011853998,0.00191695,0.010077065,0.93124443,0.04011449,0.000014948137,0.00005068867,0.00007362894,0.004653776],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956607,0.00077353476,0.0024789972,0.00028301982,0.00053986226,0.00026389197],"domain_scores_gemma":[0.9932385,0.0019325286,0.0030344308,0.00047916122,0.0011611156,0.000154242],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0050366456,0.00020176134,0.0012127291,0.00008393838,0.00009381921,0.000008988866,0.0006705099,0.002390672,0.00009410004],"category_scores_gemma":[0.0073676747,0.00011957257,0.000564002,0.00010371555,0.0012155256,0.0000028391994,0.00016928877,0.0037201024,0.0000056898907],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062468933,0.00007436384,0.00013836824,0.00001970988,0.00043175952,0.00008753253,0.000050132094,0.000009502948,0.009237912,0.000026105468,0.9525136,0.036786366],"study_design_scores_gemma":[0.0015558491,0.0029303418,0.00043938734,0.000097367614,0.00026933476,0.00018977364,0.000056792996,0.0000041134153,0.0006884096,0.00046137438,0.9931852,0.00012200401],"about_ca_topic_score_codex":0.000012707413,"about_ca_topic_score_gemma":0.000045012097,"teacher_disagreement_score":0.04067169,"about_ca_system_score_codex":0.00007300242,"about_ca_system_score_gemma":0.003580241,"threshold_uncertainty_score":0.9989044},"labels":[],"label_agreement":null},{"id":"W2070337339","doi":"10.1200/jco.2008.19.6162","title":"High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Medicine; vitamin D deficiency; Breast cancer; Vitamin D and neurology; Internal medicine; Cholecalciferol; Chemotherapy; Cancer; Gastroenterology; Vitamin","score_opus":0.05383098029968381,"score_gpt":0.4507251281791733,"score_spread":0.3968941478794895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070337339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723453,0.00040941927,0.00014803081,0.0115996925,0.0001384059,0.00029147408,0.000009925229,0.000004433894,0.00016409771],"genre_scores_gemma":[0.9894528,0.006259948,0.00312609,0.00076797174,0.00025156687,0.000010015189,6.504321e-7,0.000009817526,0.000121156016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969138,0.00028223265,0.0016728139,0.00018449957,0.00059986766,0.0003468193],"domain_scores_gemma":[0.9969809,0.0010130849,0.001169314,0.00013445385,0.00050656847,0.00019564468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029033148,0.00012663964,0.0010535949,0.00018799024,0.000028292188,0.000004805809,0.000162236,0.00012265709,0.0002527769],"category_scores_gemma":[0.0008474762,0.000080899285,0.00007435781,0.00026452215,0.00023643038,0.00016139775,0.000028174145,0.0005635099,0.0000012456272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011916179,0.0037036308,0.70114136,0.00040267388,0.00026154373,0.0003347264,0.0011963084,0.00015212946,0.0059065493,0.00006321697,0.00086212176,0.27405953],"study_design_scores_gemma":[0.012749757,0.031912588,0.9533113,0.0005235604,0.00009212429,0.00014945277,0.00049165264,0.00002140383,0.0003521032,0.00019245282,0.00013005389,0.00007353491],"about_ca_topic_score_codex":0.000033669574,"about_ca_topic_score_gemma":0.00013242647,"teacher_disagreement_score":0.273986,"about_ca_system_score_codex":0.0005169506,"about_ca_system_score_gemma":0.0017754837,"threshold_uncertainty_score":0.32989773},"labels":[],"label_agreement":null},{"id":"W2072784982","doi":"10.1200/jco.2013.50.7442","title":"Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":370,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Colorectal cancer; Colonoscopy; Physical examination; Protocol (science); Clinical trial; Clinical Oncology; Cancer; Intensive care medicine; General surgery; Internal medicine; Alternative medicine","score_opus":0.1322861554739556,"score_gpt":0.5196073827623042,"score_spread":0.3873212272883486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072784982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645003,0.00075417326,0.003663375,0.007635085,0.003943294,0.017755985,0.00004034396,0.000029121093,0.0016783064],"genre_scores_gemma":[0.8868913,0.0024826375,0.10128942,0.0024716463,0.0030262433,0.0036051683,0.000014573705,0.00005256356,0.0001664468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862217,0.002685524,0.009471038,0.00052395737,0.0007236681,0.0003741176],"domain_scores_gemma":[0.97090393,0.011898634,0.0112047745,0.00027599768,0.0051534404,0.000563235],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02102433,0.00027736722,0.004059024,0.000120174846,0.00007588952,0.000011274913,0.0002394057,0.0008270434,0.000098613156],"category_scores_gemma":[0.02050742,0.00021393494,0.0019042268,0.00029362817,0.0011103007,0.00024766082,0.00013599478,0.0017200897,0.000001506263],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060292494,0.0020575037,0.14207715,0.00022615184,0.001290493,0.00001035895,0.00016638215,0.000014883334,0.00024470908,0.000008465133,0.019961609,0.7736498],"study_design_scores_gemma":[0.03036918,0.17364167,0.32118574,0.00018493013,0.0008166959,0.00014511132,0.001844121,0.000729616,0.0004025706,0.000115507246,0.47034988,0.00021496988],"about_ca_topic_score_codex":0.0020268632,"about_ca_topic_score_gemma":0.0028467563,"teacher_disagreement_score":0.7734348,"about_ca_system_score_codex":0.00027135754,"about_ca_system_score_gemma":0.0067299134,"threshold_uncertainty_score":0.998901},"labels":[],"label_agreement":null},{"id":"W2073700732","doi":"10.1200/jco.2009.23.1407","title":"Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Sanofi; American Society of Clinical Oncology; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Colorectal cancer; Internal medicine; Adjuvant therapy; Adjuvant; Stage (stratigraphy); Cancer; Distributed File System; Oncology; Clinical trial; Survival analysis; Surgery","score_opus":0.16906694899315625,"score_gpt":0.4445056267128781,"score_spread":0.27543867771972186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073700732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96614844,0.0002450189,0.000022406708,0.029570624,0.0012034606,0.0016100832,0.0010842192,0.000010220551,0.00010553657],"genre_scores_gemma":[0.9961077,0.00047125295,0.00024553013,0.0023449715,0.0005848213,0.000050401442,0.0001416037,0.00002127259,0.000032419863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949814,0.001358715,0.0017992498,0.00048051306,0.0009804518,0.00039968142],"domain_scores_gemma":[0.98727995,0.00960046,0.0016110786,0.00056561764,0.0005561551,0.000386726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034939987,0.0002610741,0.0013688239,0.00011691768,0.000091748465,0.0000333501,0.00040212067,0.00030883477,0.00012772936],"category_scores_gemma":[0.007702114,0.0001707996,0.00026956204,0.00017990207,0.000076867924,0.00020988513,0.00012449946,0.00081324094,0.0000014072158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028732976,0.0018972887,0.89692545,0.000012968975,0.00027300048,0.00002746915,0.00013683722,0.000068373294,0.0000026207813,0.0000028275642,0.0015190848,0.07040109],"study_design_scores_gemma":[0.01747299,0.01477387,0.9566268,0.00021635294,0.0003327146,3.5029132e-7,0.000011070283,0.0025681993,0.0000057738143,0.0006383897,0.007197669,0.00015582072],"about_ca_topic_score_codex":0.000045177814,"about_ca_topic_score_gemma":0.00050494814,"teacher_disagreement_score":0.070245266,"about_ca_system_score_codex":0.0009384901,"about_ca_system_score_gemma":0.0010699469,"threshold_uncertainty_score":0.9220706},"labels":[],"label_agreement":null},{"id":"W2075141373","doi":"10.1200/jco.2008.17.1561","title":"Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Follicular lymphoma; Vincristine; Rituximab; Internal medicine; Hazard ratio; Prednisone; Lymphoma; Cyclophosphamide; International Prognostic Index; Gastroenterology; Chemotherapy; Surgery; Oncology; Confidence interval","score_opus":0.029554109536050983,"score_gpt":0.41137157549942155,"score_spread":0.3818174659633706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075141373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854863,0.0020053268,0.0000097930115,0.009085357,0.0006833783,0.0021711036,0.000014900897,0.00000783067,0.000535995],"genre_scores_gemma":[0.996227,0.0011559008,0.0015534492,0.00067022734,0.00022025214,0.00008305166,0.0000016797441,0.000012556697,0.00007583008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993223,0.0013518631,0.0041232402,0.0003527523,0.00063272734,0.00031643143],"domain_scores_gemma":[0.9928412,0.0031062164,0.0028557428,0.0004812429,0.00044128657,0.00027433076],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007480532,0.00025154397,0.00330803,0.00011086033,0.000042122603,0.000010133099,0.00027077648,0.00025522537,0.0000109629245],"category_scores_gemma":[0.010928425,0.00012670553,0.00053835916,0.00021988936,0.00039648102,0.000110004505,0.0001441849,0.0004126062,0.0000011489254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58080494,0.04590476,0.09241938,0.000021251766,0.00033180756,0.001613904,0.00046217168,0.0000033039653,0.000012804668,0.000021280674,0.00036885255,0.27803555],"study_design_scores_gemma":[0.5212825,0.013617939,0.4631668,0.000349992,0.00039526555,0.000117926575,0.00012983344,0.000034427456,0.00007257643,0.00023853044,0.0005266153,0.00006762038],"about_ca_topic_score_codex":0.000049915714,"about_ca_topic_score_gemma":0.00012391685,"teacher_disagreement_score":0.37074742,"about_ca_system_score_codex":0.00022384923,"about_ca_system_score_gemma":0.0009507101,"threshold_uncertainty_score":0.99740297},"labels":[],"label_agreement":null},{"id":"W2075650831","doi":"10.1200/jco.2003.99.201","title":"Hereditary Breast Cancer: Shared Communication and Care","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Istituto Ortopedico Rizzoli di Bologna","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine","score_opus":0.05955317759933865,"score_gpt":0.41782336332033576,"score_spread":0.3582701857209971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075650831","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028597185,0.055801004,0.000069513924,0.90653336,0.0051653692,0.00027809033,0.0004426033,0.000006428168,0.003106425],"genre_scores_gemma":[0.032830212,0.037020706,0.008826909,0.89339477,0.02582776,0.000042632022,0.000601644,0.00012043422,0.0013349116],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969688,0.00079506927,0.0015087501,0.00029028382,0.00023047805,0.00020661156],"domain_scores_gemma":[0.99636936,0.000305698,0.0018876474,0.00046111943,0.0008585897,0.00011759692],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008795731,0.00020813833,0.00087491266,0.000071153,0.00006476605,0.000020054968,0.00047757634,0.0020620206,0.00014996371],"category_scores_gemma":[0.0004671013,0.00018158625,0.00029390623,0.0000598422,0.00033073398,0.000007850247,0.00014620018,0.0022196409,0.0000038513185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001865742,0.000048992682,0.0015890063,0.00004898268,0.00037238197,0.00011413688,0.000047358353,0.00001569314,0.000071721326,0.0000010916848,0.9486476,0.048856467],"study_design_scores_gemma":[0.0015153495,0.0011649193,0.0039699245,0.000070619964,0.00026157236,0.0008741387,0.00014223515,0.0000025255854,0.000053585103,0.000077444405,0.9916821,0.00018554881],"about_ca_topic_score_codex":0.000046298414,"about_ca_topic_score_gemma":0.00015437423,"teacher_disagreement_score":0.04867092,"about_ca_system_score_codex":0.00020081422,"about_ca_system_score_gemma":0.0031301714,"threshold_uncertainty_score":0.9992335},"labels":[],"label_agreement":null},{"id":"W2075878983","doi":"10.1200/jco.2011.38.1434","title":"Chemoresponsive Liver Hemangioma in a Patient With a Metastatic Germ Cell Tumor","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic and Kidney Cyst Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Hemangioma; Metastasis; Pathology; Oncology; Cancer research; Internal medicine; Cancer; Chemotherapy","score_opus":0.06275413407899957,"score_gpt":0.35433651173795677,"score_spread":0.2915823776589572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075878983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532825,0.001157755,0.00015665535,0.00010623318,0.00017829773,0.00012737862,0.00000490377,0.0000016080652,0.0029389218],"genre_scores_gemma":[0.9886959,0.0001629919,0.009258639,0.0016106282,0.00014702772,0.000006774409,0.0000025079862,0.000014203762,0.000101289865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979954,0.00037923292,0.001062796,0.00019124821,0.00016613603,0.00020523532],"domain_scores_gemma":[0.9980887,0.00016847796,0.0010152655,0.00017540742,0.0002444467,0.0003076869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007386393,0.00013057252,0.00057315535,0.00007285003,0.000015631915,0.000003969996,0.0001838754,0.00011833304,0.00009463127],"category_scores_gemma":[0.0010550523,0.00008852634,0.00026222062,0.00007755348,0.00016037725,0.0000046985256,0.00006731806,0.00022045165,0.000012104728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17136343,0.053153865,0.28614476,0.0005336292,0.003737533,0.10288184,0.005934428,0.00023970417,0.12846957,0.00022789578,0.049751163,0.19756216],"study_design_scores_gemma":[0.028333522,0.12200326,0.5307833,0.00020034959,0.0011359853,0.006155655,0.0029618773,0.00010090233,0.18271147,0.0009010516,0.12363909,0.0010735162],"about_ca_topic_score_codex":0.000017862527,"about_ca_topic_score_gemma":0.00004868126,"teacher_disagreement_score":0.24463856,"about_ca_system_score_codex":0.000018234763,"about_ca_system_score_gemma":0.001335898,"threshold_uncertainty_score":0.36099994},"labels":[],"label_agreement":null},{"id":"W2076240151","doi":"10.1200/jco.2012.42.3582","title":"Tale of Two Lymphomas: Peripheral T-Cell Lymphoma After Allogeneic Stem-Cell Transplantation for Marginal Zone Lymphoma","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Niagara Health System","funders":"","keywords":"Medicine; Lymphoma; Transplantation; Marginal zone; Stem cell; Peripheral T-cell lymphoma; Pathology; Cancer research; B cell; T cell; Immunology; Immune system; Internal medicine; Biology; Antibody","score_opus":0.05298566938386337,"score_gpt":0.3877025316011677,"score_spread":0.33471686221730435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076240151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894787,0.005005243,0.0008314427,0.0007276824,0.0016163969,0.0005018363,0.000047013637,0.000011652973,0.0023108441],"genre_scores_gemma":[0.9850381,0.0017824896,0.009495021,0.0012156211,0.0015556783,0.000064485364,0.00001963353,0.000043090575,0.00078585563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956354,0.00035485218,0.0027166307,0.0002643545,0.0004930048,0.00053577224],"domain_scores_gemma":[0.9951908,0.0015517807,0.0018751748,0.00026745468,0.00045670848,0.00065807253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019601495,0.00030174872,0.0018497539,0.0001649,0.000053180614,0.000011363166,0.00018184156,0.0004434479,0.00022252424],"category_scores_gemma":[0.00008664311,0.00021944878,0.001181331,0.00013355291,0.00021787336,0.00025174726,0.00003019309,0.00012182582,0.000025727995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024812331,0.02946136,0.55001616,0.00047889122,0.0008013741,0.00090687594,0.0006846349,0.000019031406,0.0022258032,0.00014548576,0.0016174659,0.38883057],"study_design_scores_gemma":[0.10954743,0.017077398,0.7984562,0.0002012113,0.0029437938,0.0022340338,0.00028618154,0.00007833772,0.014389616,0.000072454546,0.05440518,0.0003081686],"about_ca_topic_score_codex":0.000038601695,"about_ca_topic_score_gemma":0.000022785129,"teacher_disagreement_score":0.3885224,"about_ca_system_score_codex":0.0005516308,"about_ca_system_score_gemma":0.0016137736,"threshold_uncertainty_score":0.89488614},"labels":[],"label_agreement":null},{"id":"W2076304345","doi":"10.1200/jco.2012.45.3050","title":"MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Terry Fox Foundation; Princess Margaret Hospital Foundation; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; European Hematology Association; University of Toronto; University Health Network; Wallace H. Coulter Foundation","keywords":"Mantle cell lymphoma; Medicine; Lymphoma; Hodgkin lymphoma; Aggressive lymphoma; microRNA; Value (mathematics); Signature (topology); Oncology; Pathology; Cancer research; Internal medicine; Rituximab; Gene; Biology; Statistics","score_opus":0.03552455754692488,"score_gpt":0.3681375681061373,"score_spread":0.33261301055921244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076304345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936653,0.0028653357,0.00005786627,0.0056896317,0.0006211819,0.00081700936,0.000010701827,0.000006047887,0.0005656899],"genre_scores_gemma":[0.994242,0.00044826145,0.003182762,0.0013859593,0.00063901616,0.000026291249,0.000012501129,0.00002540597,0.0000377868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560034,0.0005992242,0.0025905361,0.00029312202,0.0005764637,0.0003403024],"domain_scores_gemma":[0.98996127,0.00399095,0.0048591197,0.0003176279,0.0005510591,0.00031996655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009126217,0.00027132314,0.0020413434,0.0001191877,0.000047648835,0.000020635704,0.000336096,0.0005231467,0.00014257917],"category_scores_gemma":[0.0012465599,0.00013702165,0.00048384565,0.00020885191,0.00032192084,0.00010521372,0.00009306861,0.0005597088,0.000033881428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005488811,0.016255634,0.88476574,0.000041631425,0.00084836554,0.0024069876,0.00072328583,0.00019409542,0.0011266808,0.000020753405,0.006055421,0.08207257],"study_design_scores_gemma":[0.040482447,0.013248451,0.9383126,0.0008167256,0.0009048341,0.00030470363,0.0008323773,0.0008347423,0.0028424386,0.00017979507,0.0011005714,0.0001403482],"about_ca_topic_score_codex":0.0005780887,"about_ca_topic_score_gemma":0.00007681641,"teacher_disagreement_score":0.081932224,"about_ca_system_score_codex":0.0003296201,"about_ca_system_score_gemma":0.0019000483,"threshold_uncertainty_score":0.5587581},"labels":[],"label_agreement":null},{"id":"W2076379009","doi":"10.1200/jco.2006.08.1836","title":"Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Incidence (geometry); Germ cell tumors; Chemotherapy; Testicular cancer; Biopsy; Germinoma; Referral; Cancer; Surgery; Oncology; Internal medicine","score_opus":0.1408728241556192,"score_gpt":0.4837464499618206,"score_spread":0.3428736258062014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076379009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036286225,0.9921357,0.000008244601,0.0000813987,0.00040069807,0.00054887205,0.000015488935,0.000006731361,0.003174264],"genre_scores_gemma":[0.0015911122,0.9928661,0.0036031916,0.0001184773,0.00034796487,0.000013238126,0.0000108641425,0.000028663053,0.0014203897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99540675,0.00035275225,0.0034599723,0.00024201402,0.00034183683,0.00019665062],"domain_scores_gemma":[0.9917554,0.0015598929,0.005914513,0.00021411211,0.00024215254,0.0003139317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011326815,0.00026049148,0.004405907,0.00021691248,0.000022652974,0.000007783886,0.00015421785,0.00052319485,0.000034335986],"category_scores_gemma":[0.0008531787,0.0001583391,0.0014190779,0.00018283702,0.00021741721,0.000052915675,0.000105211904,0.0005896828,0.000012655847],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016052957,0.0024448833,0.02202717,0.015057583,0.001328066,0.0040056272,0.0000039524525,2.9606514e-7,5.2902312e-8,0.00004091063,0.0029285238,0.9520024],"study_design_scores_gemma":[0.0029078308,0.004854297,0.030093344,0.013334261,0.01820596,0.00050919404,0.000006981562,9.888588e-7,3.0075608e-7,0.00014416741,0.92982066,0.00012200647],"about_ca_topic_score_codex":0.000011196398,"about_ca_topic_score_gemma":0.0000029228077,"teacher_disagreement_score":0.9518804,"about_ca_system_score_codex":0.000088149754,"about_ca_system_score_gemma":0.0012805767,"threshold_uncertainty_score":0.64568806},"labels":[],"label_agreement":null},{"id":"W2076688605","doi":"10.1200/jco.2013.50.1593","title":"Reply to P. Tralongo et al","year":2013,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.15917284034584886,"score_gpt":0.41399190587441514,"score_spread":0.25481906552856626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076688605","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03983674,0.0058097104,0.0015262219,0.87364846,0.029944958,0.00042336324,0.00019597565,0.000010091473,0.048604492],"genre_scores_gemma":[0.005615022,0.01104139,0.009226947,0.9314031,0.013775413,0.000017407494,0.000013405908,0.000112504495,0.028794806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856863,0.00046424597,0.011781085,0.00087002385,0.0001545159,0.0010438556],"domain_scores_gemma":[0.9806328,0.003621288,0.013430589,0.00074296934,0.00061887054,0.0009534893],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.010916055,0.0005907289,0.0065023405,0.00063402066,0.00009108793,0.00016992215,0.0013633701,0.0024369527,0.005413869],"category_scores_gemma":[0.0110588875,0.00062718295,0.0024326693,0.0002513761,0.0004850351,0.0009440287,0.00023186125,0.0068551647,0.006673199],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040347397,0.0005059533,0.013859788,0.000034432214,0.0005833947,0.00043696436,0.00016630719,0.000096398064,6.950635e-7,0.0060393587,0.87396896,0.1039043],"study_design_scores_gemma":[0.002692271,0.007959895,0.08190968,0.00018911326,0.00009769532,0.00020574365,0.000024404178,0.00006046388,0.0000014892748,0.0071866782,0.899073,0.0005995586],"about_ca_topic_score_codex":0.00085585477,"about_ca_topic_score_gemma":0.00012879417,"teacher_disagreement_score":0.103304744,"about_ca_system_score_codex":0.0009548804,"about_ca_system_score_gemma":0.0021122755,"threshold_uncertainty_score":0.99961793},"labels":[],"label_agreement":null},{"id":"W2076746778","doi":"10.1200/jco.2009.23.8022","title":"Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Docetaxel; Trastuzumab; Cyclophosphamide; Doxorubicin; Breast cancer; Chemotherapy; Internal medicine; Immunohistochemistry; Oncology; Cancer; Fluorouracil; Group A; Human Epidermal Growth Factor Receptor 2; Group B","score_opus":0.07052517594692452,"score_gpt":0.409836656703913,"score_spread":0.33931148075698847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076746778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76428866,0.0009815443,0.000002129419,0.2332417,0.00049502857,0.0003338069,0.0006186551,0.0000016451327,0.00003684378],"genre_scores_gemma":[0.8012822,0.0061227386,0.0006242694,0.18506898,0.0065373266,0.00010969987,0.00015411666,0.000051165993,0.000049468337],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99515706,0.001839671,0.0018681237,0.00044845828,0.00033878672,0.0003478828],"domain_scores_gemma":[0.99633664,0.0013773909,0.001463445,0.0003175718,0.0003969947,0.00010794898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018921546,0.00032608391,0.0014873612,0.00019113152,0.000039671948,0.00002008969,0.00037779572,0.0012619129,0.000020510553],"category_scores_gemma":[0.0005035233,0.00023113601,0.00031686836,0.00016789528,0.00036179865,0.000022666256,0.00008512995,0.0016273179,9.249497e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74394643,0.0040890933,0.017772818,0.00005867614,0.0010717821,0.0014624725,0.00054065156,0.00005945085,0.0045832247,0.0000056419976,0.1550144,0.07139538],"study_design_scores_gemma":[0.05861374,0.00878344,0.8557636,0.0005239911,0.0006577035,0.001971802,0.00010303388,0.0000037547006,0.00020712627,0.00011418952,0.0727449,0.00051273266],"about_ca_topic_score_codex":0.0016615272,"about_ca_topic_score_gemma":0.0012764215,"teacher_disagreement_score":0.83799076,"about_ca_system_score_codex":0.00033614505,"about_ca_system_score_gemma":0.0015741235,"threshold_uncertainty_score":0.9733028},"labels":[],"label_agreement":null},{"id":"W2078102851","doi":"10.1200/jco.2005.03.3068","title":"High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Docetaxel; Prostatectomy; Oncology; Natural history; Hormonal therapy; Chemotherapy; Hormone therapy; Internal medicine; Cancer; Systemic therapy; Disease; Neoadjuvant therapy; Localized disease; Surgery; Breast cancer","score_opus":0.21958434602035504,"score_gpt":0.573140924655637,"score_spread":0.353556578635282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078102851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021904514,0.9906816,0.000040910287,0.0028343077,0.0016069579,0.0023466263,0.00017386375,0.000015329935,0.00010993805],"genre_scores_gemma":[0.00007178183,0.9854846,0.0041781147,0.00054251414,0.006030047,0.00020884714,0.00002314712,0.00009588355,0.0033650552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99354696,0.00076758256,0.0043301284,0.000396023,0.00043158274,0.00052773673],"domain_scores_gemma":[0.98957384,0.0036383143,0.004901915,0.00032164186,0.00081936363,0.0007449192],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004151201,0.00042217155,0.00768722,0.0002860556,0.00009240295,0.000023389612,0.00025466506,0.0012024374,0.00025842208],"category_scores_gemma":[0.0014140919,0.00023677539,0.0028127688,0.00025587578,0.00032362164,0.00008730509,0.000047555164,0.002494085,0.000024967536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006858099,0.0010995014,0.00023124462,0.002839765,0.0032069024,0.0069240825,0.000060478662,7.5096295e-7,4.1084846e-8,0.000009411301,0.007768684,0.971001],"study_design_scores_gemma":[0.022526048,0.017102625,0.00007872867,0.00452564,0.00614214,0.0043660314,0.000015478223,0.000005820554,7.0945964e-7,0.000091889626,0.9449494,0.00019548247],"about_ca_topic_score_codex":0.00018712277,"about_ca_topic_score_gemma":0.00007672208,"teacher_disagreement_score":0.9708056,"about_ca_system_score_codex":0.0008645132,"about_ca_system_score_gemma":0.011009449,"threshold_uncertainty_score":0.9998072},"labels":[],"label_agreement":null},{"id":"W2078386677","doi":"10.1200/jco.2008.15.0243","title":"Locally Advanced and Inflammatory Breast Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Citation; Breast cancer; Clinical Oncology; Inflammatory breast cancer; Cancer; Library science; Family medicine; Oncology; Internal medicine","score_opus":0.07381863549873788,"score_gpt":0.4651542729626489,"score_spread":0.391335637463911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078386677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055546046,0.99726653,0.000012627364,0.00033413293,0.0012305086,0.00018203471,0.00005448747,0.0000036023946,0.00036061916],"genre_scores_gemma":[0.00019692707,0.9960104,0.00041485683,0.00038040773,0.002801813,0.000026329386,0.0000103555285,0.00004127797,0.00011762483],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99652594,0.00042847023,0.0022737882,0.0003431169,0.00018731678,0.00024135737],"domain_scores_gemma":[0.9958647,0.00041623748,0.0028790575,0.00023375332,0.00034412384,0.00026211154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053302734,0.00034882873,0.0031598068,0.00007498099,0.000056863904,0.0000061788064,0.0002770456,0.00092895975,0.000020527386],"category_scores_gemma":[0.00046263018,0.0002372403,0.0009495448,0.000069048714,0.00042616745,0.000006421372,0.00020698483,0.0007195442,0.000006627358],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041128215,0.0001942129,0.00082714827,0.00046392353,0.0013158338,0.00017169859,0.0000067096526,0.0000017249096,0.0000011184829,0.000006137385,0.0037894687,0.9928107],"study_design_scores_gemma":[0.0018807157,0.0011248924,0.0044841273,0.0016821709,0.00074628176,0.003123511,0.000008585525,1.4835025e-7,7.4561495e-7,0.000009706063,0.98672765,0.00021147315],"about_ca_topic_score_codex":0.000006080346,"about_ca_topic_score_gemma":0.000044921013,"teacher_disagreement_score":0.99259925,"about_ca_system_score_codex":0.00010585007,"about_ca_system_score_gemma":0.0036136978,"threshold_uncertainty_score":0.96743786},"labels":[],"label_agreement":null},{"id":"W2079270178","doi":"10.1200/jco.2002.12.047","title":"Phase I and Pharmacokinetic Study of Novel <scp>l</scp>-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Rash; Toxicity; Nausea; Pharmacokinetics; Dysgeusia; Gastroenterology; Pharmacology; Adverse effect; Nucleoside analogue; Internal medicine; Nucleoside","score_opus":0.15747020853399482,"score_gpt":0.47566146979791435,"score_spread":0.3181912612639195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079270178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930019,0.0011055882,0.000084515996,0.0013869853,0.0005219168,0.00061573414,0.000008357023,0.000012804255,0.0032622167],"genre_scores_gemma":[0.99400824,0.0019581497,0.0008557701,0.0010240772,0.0010536447,0.0000070189412,0.000002118118,0.00003480579,0.0010561855],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943647,0.0005427072,0.0032052766,0.0003717059,0.0010430027,0.00047259947],"domain_scores_gemma":[0.9897392,0.0065252804,0.0017955933,0.00037671195,0.0007209633,0.0008422879],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035292744,0.0002503924,0.0021378943,0.0003901749,0.000061707986,0.000014508048,0.00033526827,0.00039198913,0.00049820764],"category_scores_gemma":[0.01201669,0.00018629582,0.0003818036,0.00038846774,0.00046102345,0.00017423411,0.00026012052,0.0014263457,0.00003783466],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0152996,0.1820384,0.024328176,0.0007027107,0.0055071497,0.021589266,0.0076176357,0.00028097414,0.06837221,0.000070751084,0.111668296,0.56252486],"study_design_scores_gemma":[0.60143006,0.2210995,0.03206804,0.00046739288,0.0027674325,0.0065397792,0.002725889,0.040837675,0.0010419183,0.00013549722,0.09066302,0.0002237773],"about_ca_topic_score_codex":0.00012196412,"about_ca_topic_score_gemma":0.000025092828,"teacher_disagreement_score":0.5861305,"about_ca_system_score_codex":0.0014986132,"about_ca_system_score_gemma":0.0034955645,"threshold_uncertainty_score":0.9963055},"labels":[],"label_agreement":null},{"id":"W2080147366","doi":"10.1200/jco.2009.23.5481","title":"Prevention of Thrombosis in Ambulatory Patients With Cancer","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ambulatory; Antithrombotic; Intensive care medicine; Venous thromboembolism; Cancer; Thrombosis; Anticoagulant; Clinical trial; Population; Surgery; Internal medicine","score_opus":0.20316536882761224,"score_gpt":0.5351031510939465,"score_spread":0.3319377822663342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080147366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008714248,0.9879707,0.000009404462,0.00027027895,0.0008341541,0.00090312026,0.0000051517286,0.0000037491727,0.0012892087],"genre_scores_gemma":[0.0012155004,0.99689496,0.00086167286,0.00041573908,0.00049171364,0.000015026879,0.000008550616,0.00002504158,0.00007180757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480075,0.00042329915,0.003923641,0.00021035415,0.0004480473,0.0001939191],"domain_scores_gemma":[0.9932865,0.0005789644,0.0053784065,0.00022291185,0.00035717658,0.00017605825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019633574,0.00022502389,0.007386431,0.0002683482,0.0000113737915,0.0000032854339,0.00018316832,0.00058376516,0.00016018364],"category_scores_gemma":[0.00039437925,0.00013489186,0.0013110089,0.00024092958,0.00010743835,0.000071714654,0.00004465445,0.0010154991,0.0000044192434],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001644164,0.0065678153,0.0066743167,0.0033130464,0.0012517109,0.00003760125,0.000020994215,0.0000031076036,1.5158914e-8,0.000030375824,0.0042686085,0.977668],"study_design_scores_gemma":[0.0032750587,0.012292302,0.21575971,0.022171866,0.005261567,0.000006060228,0.000007808518,4.9994696e-7,6.940939e-8,0.00003637439,0.7410888,0.00009988859],"about_ca_topic_score_codex":0.000029281013,"about_ca_topic_score_gemma":0.00007361012,"teacher_disagreement_score":0.9775681,"about_ca_system_score_codex":0.00031396523,"about_ca_system_score_gemma":0.0024531377,"threshold_uncertainty_score":0.550073},"labels":[],"label_agreement":null},{"id":"W2081498515","doi":"10.1200/jco.2005.03.9297","title":"Quality of Life Among Long-Term Adolescent and Adult Survivors of Childhood Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Optimism; Population; Logistic regression; Odds ratio; Cancer; Pediatrics; Gerontology; Demography; Internal medicine; Psychiatry","score_opus":0.09403853873387616,"score_gpt":0.45986420328103605,"score_spread":0.3658256645471599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081498515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878821,0.0024719895,0.00014862411,0.007496417,0.0010601368,0.00027819586,0.000024197758,0.0000102488475,0.00062813476],"genre_scores_gemma":[0.99298775,0.002032927,0.0006159931,0.0023016816,0.001958158,0.0000025246197,0.0000044558287,0.000025466245,0.00007102202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911916,0.0011439584,0.0062219943,0.00028402597,0.0008704043,0.0002879812],"domain_scores_gemma":[0.98948765,0.002276919,0.0061800745,0.00034562583,0.0011623324,0.00054741255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00600428,0.0002214591,0.0032392826,0.00016405554,0.00003029698,0.000005515618,0.00023877356,0.0004939958,0.00012223591],"category_scores_gemma":[0.005831,0.00017489195,0.0007559783,0.00019734538,0.0007796745,0.0001262817,0.00009697358,0.0010533956,0.0000015210201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026199354,0.0038932061,0.97262836,0.00052560493,0.00045343474,0.00003542882,0.00027150035,0.000012885963,0.00011293791,0.00016216452,0.0012684659,0.018016104],"study_design_scores_gemma":[0.009569589,0.0033988033,0.9848247,0.0006742028,0.00032011187,0.00003705884,0.00017744665,0.000005614183,0.00023360449,0.00015572926,0.00045602227,0.00014708992],"about_ca_topic_score_codex":0.0040438278,"about_ca_topic_score_gemma":0.010417369,"teacher_disagreement_score":0.017869012,"about_ca_system_score_codex":0.0001008014,"about_ca_system_score_gemma":0.0020397608,"threshold_uncertainty_score":0.71318865},"labels":[],"label_agreement":null},{"id":"W2081846694","doi":"10.1200/jco.2011.39.6051","title":"Evolution of Clinical Trials Registries","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.9031209674504469,"score_gpt":0.6598667124981321,"score_spread":0.24325425495231479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081846694","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006623096,0.007570238,0.003807528,0.93885183,0.026141623,0.000785533,0.00041358793,0.000018863662,0.01578772],"genre_scores_gemma":[0.0120394435,0.005213107,0.012343193,0.88368016,0.0816189,0.000027773494,0.000056123354,0.000121778,0.0048995465],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8733193,0.02036459,0.104431465,0.00084552605,0.00040681142,0.000632272],"domain_scores_gemma":[0.7312337,0.093243755,0.17279977,0.0011277922,0.0010756537,0.0005193026],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.43471602,0.00038991313,0.018345252,0.00073940755,0.00007544792,0.000028850503,0.0011782777,0.0053613842,0.0013996724],"category_scores_gemma":[0.4252126,0.00037857512,0.0038786987,0.00019454819,0.0008109693,0.00043503122,0.00012851591,0.0060369065,0.00093940005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046669337,0.00044983107,0.027115313,0.000326691,0.00087574497,0.00006252432,0.0000980524,0.0000045258853,5.0582845e-8,0.00807633,0.9596071,0.0029171223],"study_design_scores_gemma":[0.003505108,0.0033638515,0.021806924,0.00025552127,0.00021182412,0.00005229021,0.000113788745,0.000056435856,2.9066234e-7,0.04325403,0.9270874,0.00029253607],"about_ca_topic_score_codex":0.00048337862,"about_ca_topic_score_gemma":0.000064177635,"teacher_disagreement_score":0.1420856,"about_ca_system_score_codex":0.00080875383,"about_ca_system_score_gemma":0.0067558354,"threshold_uncertainty_score":0.9998666},"labels":[],"label_agreement":null},{"id":"W2082128377","doi":"10.1200/jco.2002.02.130","title":"Nonovarian Pelvic Cancers in <i>BRCA1/2</i> Mutation Carriers and the BRCAPRO Statistical Model","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Citation; Penetrance; Cancer; Oncology; Library science; Family medicine; Internal medicine; Genetics","score_opus":0.05835747440138657,"score_gpt":0.3953351184475681,"score_spread":0.3369776440461815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082128377","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044009894,0.006748223,0.016741687,0.9177604,0.0063040955,0.001024683,0.00025135544,0.000009143549,0.007150537],"genre_scores_gemma":[0.28096777,0.005602521,0.015934024,0.68146485,0.013953793,0.00007255142,0.00016453631,0.00012085592,0.0017191146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995795,0.0009669517,0.0021463775,0.00040817788,0.00035625632,0.00032721023],"domain_scores_gemma":[0.996283,0.0012282919,0.0017022823,0.00031935962,0.00033891585,0.00012817564],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0027774686,0.00025598588,0.0011555934,0.00011804259,0.000058120884,0.000028502225,0.00040991572,0.0016730806,0.000055371587],"category_scores_gemma":[0.0027127156,0.00018309495,0.00030104254,0.000109558,0.0010295548,0.000008612522,0.000099807905,0.0028750517,0.0000033310787],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013550953,0.00007516666,0.0003115064,0.00004583912,0.00051273033,0.0005841532,0.00022922504,0.0059279148,0.000038587612,0.00012056975,0.957361,0.03343824],"study_design_scores_gemma":[0.01365075,0.0023035307,0.0010579788,0.00006488282,0.00051346683,0.00064658746,0.0001396106,0.013271884,0.000038388873,0.0033749945,0.96452,0.00041792827],"about_ca_topic_score_codex":0.00008524289,"about_ca_topic_score_gemma":0.00031007806,"teacher_disagreement_score":0.23695786,"about_ca_system_score_codex":0.0004134003,"about_ca_system_score_gemma":0.0042321035,"threshold_uncertainty_score":0.99962294},"labels":[],"label_agreement":null},{"id":"W2083899124","doi":"10.1200/jco.2003.10.106","title":"Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surveillance, Epidemiology, and End Results; Epidemiology; Stage (stratigraphy); Cancer registry; Cancer; Relative survival; Laryngectomy; Internal medicine; Surgery; Demography; Larynx","score_opus":0.1722519396745949,"score_gpt":0.445150010791655,"score_spread":0.2728980711170601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083899124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96929127,0.0022349427,0.0000017220688,0.027194578,0.00030768325,0.00016581475,0.000012906424,8.515089e-7,0.0007902203],"genre_scores_gemma":[0.989458,0.008003781,0.00009536203,0.002070334,0.000063189764,0.000003327448,8.8679445e-7,0.0000034381064,0.0003016763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663067,0.0011861825,0.0017208849,0.00013639858,0.00014520466,0.0001806504],"domain_scores_gemma":[0.9880859,0.010702989,0.00086368853,0.00010874069,0.00010427609,0.00013435907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058960444,0.00010023168,0.0016050473,0.000055070515,0.00004991091,0.0000023210612,0.00007575204,0.000100616926,0.00001122647],"category_scores_gemma":[0.004291128,0.000044137243,0.000064285385,0.00010935484,0.0007783302,0.000016675702,0.00006364887,0.00055692514,2.8488454e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010897632,0.000043123444,0.99176055,0.000033354958,0.00026861383,0.00003004703,0.00026675782,0.0000026981575,8.566469e-8,0.00022654526,0.0010465148,0.0052319462],"study_design_scores_gemma":[0.007972654,0.00076726265,0.9633143,0.000105241365,0.00016260873,0.000027307344,0.00032103452,0.000010977166,6.3684246e-7,0.0006856533,0.026589587,0.00004274401],"about_ca_topic_score_codex":0.531018,"about_ca_topic_score_gemma":0.9370609,"teacher_disagreement_score":0.40604287,"about_ca_system_score_codex":0.00012117628,"about_ca_system_score_gemma":0.0007233625,"threshold_uncertainty_score":0.5137191},"labels":[],"label_agreement":null},{"id":"W2084446054","doi":"10.1200/jco.2011.41.0910","title":"International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; ABVD; Dacarbazine; Hodgkin's lymphoma; Internal medicine; Vinblastine; Stage (stratigraphy); Regimen; Surgery; Population; Oncology; Hodgkin lymphoma; Lymphoma; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.1556374997009582,"score_gpt":0.46611874311032825,"score_spread":0.31048124340937006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084446054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830583,0.0007563795,0.000033391483,0.008982114,0.0015390471,0.00030916714,0.0000046705964,0.0000041280755,0.005312854],"genre_scores_gemma":[0.9948867,0.0005340343,0.0012639954,0.0022210807,0.0010018286,0.000022642487,0.0000047428002,0.000008515581,0.00005643767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970056,0.00047291818,0.0016905755,0.00015224685,0.00039302482,0.0002856729],"domain_scores_gemma":[0.99636626,0.0023192838,0.0007757711,0.00019151943,0.00014358154,0.00020358548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034888524,0.00012715712,0.00083675963,0.00012574402,0.000018084207,0.000009375085,0.0002245724,0.00020892723,0.00010089224],"category_scores_gemma":[0.002555742,0.000072308874,0.00029093365,0.00012557652,0.00009863232,0.00020596197,0.000053352676,0.00045657536,0.000014674035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013469286,0.0071418444,0.70006716,0.000008918457,0.00007783377,0.0005030863,0.0003344962,0.000010266265,0.000005645074,0.000112215756,0.00042423946,0.2899674],"study_design_scores_gemma":[0.013690826,0.0020960665,0.9516404,0.00010502894,0.00008794381,0.00033233906,0.00019779641,0.00032557035,0.000013490138,0.0004144552,0.031037979,0.000058087593],"about_ca_topic_score_codex":0.000041367435,"about_ca_topic_score_gemma":0.000097703654,"teacher_disagreement_score":0.2899093,"about_ca_system_score_codex":0.00036180275,"about_ca_system_score_gemma":0.0007139167,"threshold_uncertainty_score":0.30596465},"labels":[],"label_agreement":null},{"id":"W2085822159","doi":"10.1200/jco.2007.11.4645","title":"Lessons Learned in the Assessment of Health-Related Quality of Life: Selected Examples From the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Quality of life (healthcare); Quality (philosophy); Alternative medicine; Clinical Practice; Data quality; Family medicine; Gerontology; Medical education; Nursing; Pathology","score_opus":0.8013547844276759,"score_gpt":0.6858960550509003,"score_spread":0.11545872937677559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085822159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014669692,0.9593221,0.00008011285,0.018248744,0.0055535026,0.0010983268,0.000496472,0.0000033020467,0.0005277599],"genre_scores_gemma":[0.043740436,0.9520451,0.00025889245,0.0021981108,0.0016023837,0.000018549732,0.000085744905,0.000020528556,0.000030244324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.93996364,0.029904848,0.027276888,0.00040063405,0.0020846713,0.00036933768],"domain_scores_gemma":[0.8876365,0.082851194,0.027123483,0.00038596548,0.0017130467,0.00028981615],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11896086,0.00028307093,0.012315504,0.00016004399,0.000047617996,0.000004812323,0.00069749804,0.0010530031,0.00019157187],"category_scores_gemma":[0.062029336,0.00014256939,0.0019565797,0.0008257548,0.00057517464,0.000047036956,0.00007564013,0.0037257185,2.1942046e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014914046,0.0015327787,0.018742558,0.0020630087,0.0029451041,0.000025601772,0.00016795544,0.000012014655,6.978508e-7,0.00082033745,0.009731777,0.9624668],"study_design_scores_gemma":[0.004330683,0.0017277055,0.22980732,0.004452892,0.0012404217,0.000015169778,0.00022572075,0.000004212775,1.0573105e-7,0.00017017665,0.7579224,0.00010320674],"about_ca_topic_score_codex":0.3571306,"about_ca_topic_score_gemma":0.7917356,"teacher_disagreement_score":0.96236354,"about_ca_system_score_codex":0.00082693575,"about_ca_system_score_gemma":0.09847688,"threshold_uncertainty_score":0.9985727},"labels":[],"label_agreement":null},{"id":"W2087686137","doi":"10.1200/jco.2009.23.0607","title":"Reply to R.S. Mehta et al","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine","score_opus":0.21334361164083018,"score_gpt":0.5974558753435592,"score_spread":0.384112263702729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087686137","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39239573,0.00029858135,0.0000663313,0.58210474,0.0016526391,0.00013373274,0.0000011487202,0.000009817074,0.02333729],"genre_scores_gemma":[0.47996795,0.00053008215,0.0038583635,0.5134197,0.0009890101,0.0000010548196,0.0000010654992,0.0000058901496,0.0012268893],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978196,0.00024577757,0.0014041238,0.00014156729,0.00021114474,0.00017779443],"domain_scores_gemma":[0.9975552,0.000931682,0.00062865193,0.00013280392,0.0002460056,0.0005056749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00232142,0.00009114598,0.0010274632,0.000102230566,0.000018267088,0.0000042295583,0.00010595829,0.00013917974,0.0004933667],"category_scores_gemma":[0.001401569,0.00006264632,0.00038530605,0.00011457867,0.00004997494,0.000057879966,0.000019657056,0.00070298417,0.00007488143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068163443,0.0024745096,0.007281212,0.0000018578711,0.00019962357,0.0011891405,0.000079492645,0.000005878121,0.0007537298,0.00017023901,0.7854878,0.19554019],"study_design_scores_gemma":[0.0061587603,0.04074043,0.14698714,0.000020636047,0.00022221412,0.0005643636,0.000012970177,0.000004832279,0.00012206514,0.00034058726,0.8047801,0.000045873894],"about_ca_topic_score_codex":0.000012204532,"about_ca_topic_score_gemma":0.000009578684,"teacher_disagreement_score":0.19549432,"about_ca_system_score_codex":0.00011787594,"about_ca_system_score_gemma":0.0011502015,"threshold_uncertainty_score":0.5402019},"labels":[],"label_agreement":null},{"id":"W2088004131","doi":"10.1200/jco.2003.03.133","title":"Trends in Survival Rates After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute and Chronic Leukemia by Ethnicity in the United States and Canada","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Transplantation; Ethnic group; Hematopoietic cell; Stem cell; Haematopoiesis; Acute leukemia; Chronic leukemia; Leukemia; Immunology; Oncology; Internal medicine; Genetics; Biology","score_opus":0.04698949211837073,"score_gpt":0.38844923849652224,"score_spread":0.3414597463781515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088004131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959234,0.000954598,0.0004597072,0.0020860555,0.00019115838,0.00023427632,0.000025519324,0.0000019523206,0.00012330337],"genre_scores_gemma":[0.99273086,0.0057326513,0.00027759132,0.0010830052,0.00004461734,0.000015011511,0.000035806574,0.000012126702,0.000068341375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723524,0.00075788714,0.0013868872,0.00016932233,0.00022815468,0.00022250491],"domain_scores_gemma":[0.99585944,0.0034206638,0.00040518458,0.000084116815,0.000087855406,0.00014274193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002734845,0.00013547626,0.0007919406,0.00016108884,0.000022873366,0.000008677374,0.0000695736,0.0002275218,0.000020602647],"category_scores_gemma":[0.00007537294,0.00008996258,0.000079294754,0.00019332304,0.00010844467,0.000054763037,0.0000035602948,0.0005033106,2.0198205e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01541097,0.0017143716,0.9289188,0.0019890384,0.00074369664,0.00486232,0.0094151,0.0005579909,0.0048675016,0.0002607577,0.003572491,0.027686995],"study_design_scores_gemma":[0.043426573,0.00957823,0.9191201,0.0005260594,0.001884891,0.0027728947,0.0034385084,0.0010661313,0.005903097,0.00038923466,0.011460551,0.00043378567],"about_ca_topic_score_codex":0.008354241,"about_ca_topic_score_gemma":0.19520418,"teacher_disagreement_score":0.18684995,"about_ca_system_score_codex":0.00024375234,"about_ca_system_score_gemma":0.0012804534,"threshold_uncertainty_score":0.99824923},"labels":[],"label_agreement":null},{"id":"W2088148097","doi":"10.1200/jco.2009.23.8691","title":"Reply to L.C. Panasci","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Lesions and Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Alberta Cancer Foundation; University of Alberta","funders":"University of Alberta","keywords":"Medicine; Internal medicine","score_opus":0.15592609959128761,"score_gpt":0.49386708510312305,"score_spread":0.33794098551183543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088148097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8010765,0.00018753223,0.00027134418,0.17711626,0.0008201387,0.00008581262,4.4377023e-7,0.000008386683,0.020433614],"genre_scores_gemma":[0.90408105,0.0000642146,0.0070559825,0.08595346,0.0018558309,3.2743856e-7,2.6302712e-7,0.0000051126076,0.0009837816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782586,0.00014373934,0.0015090816,0.000115794486,0.00024352166,0.00016200735],"domain_scores_gemma":[0.99782926,0.00044600296,0.0005524615,0.00019598863,0.00034833685,0.0006279509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002404452,0.00006971737,0.0009107875,0.000100469086,0.000022039752,0.000004323411,0.00011604971,0.00018093866,0.00019674099],"category_scores_gemma":[0.0026607316,0.000045229277,0.00040723343,0.00014022994,0.000044342818,0.000043390624,0.000019130523,0.0006248372,0.00008172243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027275516,0.0013022769,0.016691903,0.0000036593296,0.00006989656,0.0014567281,0.00004765406,0.0000030096978,0.0005285008,0.000518322,0.13470444,0.84194607],"study_design_scores_gemma":[0.00170613,0.012424366,0.5727734,0.000028502836,0.00008276698,0.0009605668,0.000030814736,0.0000050054055,0.000024402345,0.00037832186,0.41155496,0.000030770316],"about_ca_topic_score_codex":0.0000061418436,"about_ca_topic_score_gemma":0.0000020501006,"teacher_disagreement_score":0.8419153,"about_ca_system_score_codex":0.00006124228,"about_ca_system_score_gemma":0.0008891118,"threshold_uncertainty_score":0.31853363},"labels":[],"label_agreement":null},{"id":"W2088251555","doi":"10.1200/jco.2004.06.157","title":"International Assessment of the Quality of Clinical Practice Guidelines in Oncology Using the Appraisal of Guidelines and Research and Evaluation Instrument","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; CLARITY; Scope (computer science); Quality (philosophy); Rigour; Oncology; Presentation (obstetrics); Stakeholder; Medical physics; Internal medicine; Medical education","score_opus":0.8952957001720149,"score_gpt":0.8055278966843465,"score_spread":0.08976780348766833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088251555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84368753,0.00026315157,0.0006920548,0.15213723,0.0018581873,0.0005657134,0.000006390766,0.0000014220979,0.000788325],"genre_scores_gemma":[0.87601453,0.0021842574,0.11856412,0.0021732338,0.0010396745,0.0000049874625,0.0000026324128,0.000010381729,0.0000061693763],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9678641,0.007815156,0.02092737,0.00037696032,0.002765566,0.00025084804],"domain_scores_gemma":[0.87835234,0.078323446,0.017934298,0.0006041155,0.02453253,0.0002532956],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.16007367,0.0001325902,0.0016607126,0.0002058975,0.00005073748,0.000009080894,0.0003517536,0.00042149387,0.00004202192],"category_scores_gemma":[0.46823093,0.000076103446,0.0003242124,0.00035674096,0.0012525528,0.00031599766,0.0004149454,0.0017233202,2.2184304e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007459803,0.0046287603,0.41142985,0.00009221485,0.0006960404,0.00002111795,0.00030178716,0.001759645,0.001728886,0.0023527904,0.0011479661,0.56838113],"study_design_scores_gemma":[0.0249082,0.0111054005,0.89978117,0.00045162314,0.0008159655,0.00038077377,0.0056277355,0.00995811,0.00014980377,0.0037487391,0.042973705,0.000098797434],"about_ca_topic_score_codex":0.0011952339,"about_ca_topic_score_gemma":0.0004952612,"teacher_disagreement_score":0.56828237,"about_ca_system_score_codex":0.00029465152,"about_ca_system_score_gemma":0.008992684,"threshold_uncertainty_score":0.9966254},"labels":[],"label_agreement":null},{"id":"W2090257361","doi":"10.1200/jco.2009.26.3343","title":"Randomized Phase II Trials: Inevitable or Inadvisable?","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Citation; Medicine; Clinical Oncology; Randomized controlled trial; Clinical trial; Library science; Oncology; Internal medicine; Cancer; Computer science","score_opus":0.8457395369729281,"score_gpt":0.7345951961345429,"score_spread":0.1111443408383852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090257361","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56031954,0.0003533071,0.26691845,0.040501326,0.081910215,0.0047065914,0.000118673976,0.00019157513,0.044980325],"genre_scores_gemma":[0.041433524,0.00042687356,0.94563335,0.001961472,0.008635338,0.0000290849,5.165236e-7,0.000051653846,0.0018282109],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.95317334,0.023933973,0.020933324,0.00043216383,0.0009417368,0.0005854763],"domain_scores_gemma":[0.12201391,0.86005884,0.014798642,0.00072046113,0.0013678618,0.0010402867],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.2703559,0.00031849378,0.0122762425,0.00018711107,0.00012993276,0.000039622177,0.00084268,0.0013369983,0.006280933],"category_scores_gemma":[0.9639343,0.00017061643,0.002490527,0.0003105254,0.0011851566,0.0002143743,0.0002474537,0.003996822,0.000048763217],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5091994,0.008544073,0.000034320416,0.00006174507,0.0011268675,0.00038209712,0.00006697545,7.677347e-7,0.00027178897,0.0830688,0.053801876,0.3434413],"study_design_scores_gemma":[0.35701296,0.008091565,0.000009579047,0.000056455432,0.0011127287,0.00011065884,0.000025246301,0.00012648935,0.0001188348,0.5504248,0.082767636,0.00014300503],"about_ca_topic_score_codex":0.00000719749,"about_ca_topic_score_gemma":0.00002763737,"teacher_disagreement_score":0.83612484,"about_ca_system_score_codex":0.000054626125,"about_ca_system_score_gemma":0.0023766432,"threshold_uncertainty_score":0.99995947},"labels":[],"label_agreement":null},{"id":"W2091059351","doi":"10.1200/jco.2013.49.9061","title":"Reply to Y. Yamamoto et al","year":2013,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.08039891371581853,"score_gpt":0.44870800437819836,"score_spread":0.3683090906623798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091059351","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031316,0.004287586,0.00028123407,0.94706905,0.0104852365,0.00037797497,0.000064873544,0.000005415057,0.0061126254],"genre_scores_gemma":[0.010438331,0.0061821365,0.0077287885,0.9548526,0.015174144,0.000036333033,0.00005624413,0.0000836304,0.005447795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99220073,0.0017227163,0.004080327,0.0007647369,0.0005340332,0.0006974617],"domain_scores_gemma":[0.99189675,0.0017243032,0.0037805228,0.0006844921,0.0012853995,0.0006285293],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0031200824,0.0005882833,0.0029115295,0.00014239889,0.000083382496,0.000040929357,0.0008029354,0.0019661363,0.000499114],"category_scores_gemma":[0.0050495947,0.00046478066,0.0016244377,0.00012926383,0.0005353658,0.000015510172,0.00056909263,0.0031451175,0.00052869087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013382626,0.0008564372,0.0058986275,0.000029987381,0.0022173151,0.0008638658,0.000060049817,0.00002017675,0.00027589785,0.000030082876,0.9151541,0.07325518],"study_design_scores_gemma":[0.0036696033,0.012723027,0.03199003,0.0001786274,0.0005482765,0.00080009166,0.000044855344,0.000001652415,0.00016519293,0.00012488762,0.9493555,0.00039827664],"about_ca_topic_score_codex":0.00022814769,"about_ca_topic_score_gemma":0.000098679964,"teacher_disagreement_score":0.0728569,"about_ca_system_score_codex":0.00027471682,"about_ca_system_score_gemma":0.0028697532,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2091873290","doi":"10.1200/jco.2005.03.4496","title":"Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anxiety; Biopsy; Institutional review board; Clinical trial; Genetic testing; Internal medicine; Oncology; Family medicine; Surgery; Psychiatry","score_opus":0.2863009348367548,"score_gpt":0.5840750352398163,"score_spread":0.2977741004030615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091873290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952845,0.0025616805,0.0007451186,0.0001639948,0.00081407285,0.00019266203,0.00016488422,5.0887235e-7,0.00007256896],"genre_scores_gemma":[0.9895785,0.005906571,0.0034752688,0.00016406484,0.0008277929,0.0000043276405,0.000007771549,0.000008655513,0.000027071908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577117,0.00035885564,0.0034955875,0.00015592905,0.000093158655,0.00012529781],"domain_scores_gemma":[0.9923553,0.0042938055,0.0026767629,0.0001111542,0.00048198405,0.000081023325],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00689865,0.000100817655,0.0015133747,0.000074539894,0.000017329068,0.0000028186234,0.00010488351,0.00023297677,0.000010223642],"category_scores_gemma":[0.015301573,0.00007332203,0.00060624536,0.000050440653,0.0006103536,0.000005378706,0.000070290356,0.00019892126,1.6424326e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076782443,0.0039142673,0.92738086,0.000094743315,0.0012353691,0.00001761778,0.00017809983,0.00067426893,0.02190275,0.0002770348,0.015306097,0.02134065],"study_design_scores_gemma":[0.012043609,0.012805839,0.9645052,0.00010389001,0.00035790695,0.000032060783,0.0005836822,0.00017565828,0.00079586473,0.00064755685,0.007821586,0.0001271263],"about_ca_topic_score_codex":0.000021699005,"about_ca_topic_score_gemma":0.00011165993,"teacher_disagreement_score":0.03712436,"about_ca_system_score_codex":0.000032259733,"about_ca_system_score_gemma":0.0007412507,"threshold_uncertainty_score":0.99299294},"labels":[],"label_agreement":null},{"id":"W2093070825","doi":"10.1200/jco.2006.09.6925","title":"Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; QT interval; Pharmacology; Context (archaeology); Drug development; Long QT syndrome; Oncology; Drug; Internal medicine","score_opus":0.19574457203053525,"score_gpt":0.5282033048717207,"score_spread":0.3324587328411855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093070825","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076622684,0.9875051,0.0000956474,0.0014151151,0.0019480691,0.00054682884,0.000004231599,0.000005005907,0.00081775896],"genre_scores_gemma":[0.0042458456,0.9913806,0.00089500815,0.001745866,0.0015826116,0.000004719001,0.0000051422107,0.000027458194,0.000112805705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993886,0.0019521184,0.0034506426,0.00021302243,0.00026168878,0.00023651298],"domain_scores_gemma":[0.9910239,0.003263807,0.0047954335,0.00027475943,0.00047940866,0.00016271698],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0040347497,0.00024128208,0.0050800582,0.00016746791,0.00003857702,0.0000032848325,0.00021330314,0.0017399411,0.000021111755],"category_scores_gemma":[0.001995561,0.00012743933,0.0020903656,0.00022896349,0.00067266397,0.000038033428,0.000107219625,0.0032394738,0.000004379858],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001064377,0.0004233794,0.00008250562,0.00091123057,0.0016154625,0.0006582558,0.000041740288,4.3566826e-7,0.000033069216,0.00010068936,0.0002654547,0.9948034],"study_design_scores_gemma":[0.0018509367,0.012861152,0.0018074292,0.0018567841,0.005128855,0.00566238,0.00001425173,0.0000046147657,0.00001583747,0.0002449909,0.97044945,0.00010329176],"about_ca_topic_score_codex":0.0000019857766,"about_ca_topic_score_gemma":0.0000042794163,"teacher_disagreement_score":0.99470013,"about_ca_system_score_codex":0.00017252035,"about_ca_system_score_gemma":0.0039560157,"threshold_uncertainty_score":0.999556},"labels":[],"label_agreement":null},{"id":"W2095155610","doi":"10.1200/jco.2006.09.7840","title":"Organ Preservation for Rectal Cancer","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Surgery; Colorectal cancer; Anastomosis; Cancer; Population; Sphincter; Resection; Radical surgery; Internal medicine","score_opus":0.6572578497953064,"score_gpt":0.6752848331087435,"score_spread":0.018026983313437106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095155610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032580394,0.9897915,0.00009888681,0.0008514316,0.0042752577,0.001219884,0.000026055752,0.000013289553,0.0033978568],"genre_scores_gemma":[0.000033507884,0.9888272,0.0026486493,0.00056271645,0.0059842067,0.000071776034,0.000024022022,0.000058480073,0.0017893848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99399424,0.00039618477,0.0045437915,0.0003020215,0.0004462919,0.0003174665],"domain_scores_gemma":[0.9860625,0.0077353143,0.0045921337,0.00022134442,0.0008853584,0.0005033076],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003994455,0.00030220693,0.006530128,0.00023251145,0.000033346132,0.00000834864,0.00023994007,0.0014182129,0.00038188853],"category_scores_gemma":[0.0071478714,0.00018690259,0.002699346,0.00033216862,0.00012635575,0.0001030472,0.000062724794,0.0015557667,0.000019776655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026341544,0.000835041,0.0005320114,0.0027509998,0.0014966062,0.00038245643,0.000008448101,1.8383247e-7,8.731278e-8,0.000021807788,0.006043295,0.98529494],"study_design_scores_gemma":[0.004457739,0.012885551,0.0009212845,0.005599406,0.0053040897,0.0004948111,0.0000034030998,0.0000026531366,7.0558866e-7,0.00008945805,0.9701006,0.00014032109],"about_ca_topic_score_codex":0.000016802438,"about_ca_topic_score_gemma":0.000051012237,"teacher_disagreement_score":0.98515457,"about_ca_system_score_codex":0.0010597473,"about_ca_system_score_gemma":0.007141628,"threshold_uncertainty_score":0.99987817},"labels":[],"label_agreement":null},{"id":"W2095599995","doi":"10.1200/jco.2014.60.0734","title":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":421,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Children's Hospital of Pittsburgh; University College London; National Cancer Institute; University of Nottingham; Hospital for Sick Children; Deutsche Krebshilfe; Universitair Medisch Centrum Groningen; Connecticut Children's Medical Center; Medical Research Council; Children’s Oncology Group; Leids Universitair Medisch Centrum; Dalhousie University; Cliniques Universitaires Saint-Luc; Children's Hospitals and Clinics of Minnesota; Bundesministerium für Bildung und Forschung; Radboud Universiteit; Children's Hospital Colorado; Cleveland Clinic; Universiteit Leiden; Universität Wien; Deutsche Forschungsgemeinschaft; European Science Foundation; University of Leeds; Cancer Research UK; Cedars-Sinai Medical Center; Universitätsspital Basel; Memorial Sloan-Kettering Cancer Center; Ochsner Health; Saint Luke's Health System; European Commission; Nationwide Children's Hospital; Helsingin Yliopisto; Children's Healthcare of Atlanta; Vlaamse regering; National Institute for Health and Care Research; BC Children's Hospital; Arcadia Fund; Medizinische Universität Wien; Carilion Clinic; Norges Forskningsråd; Pennsylvania State University; Sundhed og Sygdom, Det Frie Forskningsråd; Cleveland Clinic Foundation; Cincinnati Children's Hospital Medical Center; Children's National Hospital; University of Pennsylvania; Children's Hospital of Philadelphia","keywords":"Medicine; Chemotherapy; Surgery; Methotrexate; Toxicity; Cisplatin; Osteosarcoma; Doxorubicin; Internal medicine; Gastroenterology; Urology; Pathology","score_opus":0.06444841696875124,"score_gpt":0.37702022538011154,"score_spread":0.3125718084113603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095599995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96171564,0.0011499681,0.000009997973,0.031302735,0.0013119784,0.004372307,0.000033421256,0.000008789535,0.000095161406],"genre_scores_gemma":[0.99591863,0.00011158034,0.0027803532,0.00040340898,0.000119954246,0.00012767341,0.0000070599303,0.00002615222,0.00050519034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9851743,0.009623326,0.0037007974,0.0004685951,0.00063637545,0.00039661542],"domain_scores_gemma":[0.959535,0.035898305,0.0027589693,0.00042251122,0.0008805937,0.0005046445],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017698076,0.00035779257,0.00491273,0.00029018233,0.000074885465,0.00002240561,0.00023349427,0.00041573826,0.000015177542],"category_scores_gemma":[0.044601448,0.0001755219,0.0003909904,0.00027491528,0.0005795754,0.00012031324,0.00018336572,0.0009204748,0.000003487567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97795117,0.003335481,0.013585409,0.000017637161,0.0009955398,0.0006126759,0.0009684686,0.000056617482,0.000051880234,0.000022337748,0.0016087615,0.0007940478],"study_design_scores_gemma":[0.80370855,0.08117872,0.11077756,0.00045191412,0.00090755353,0.000048592687,0.0002625378,0.00008222796,0.00012603056,0.00006429432,0.0022524593,0.0001395441],"about_ca_topic_score_codex":0.0002397462,"about_ca_topic_score_gemma":0.0006696674,"teacher_disagreement_score":0.17424257,"about_ca_system_score_codex":0.00063622417,"about_ca_system_score_gemma":0.0012352989,"threshold_uncertainty_score":0.96344626},"labels":[],"label_agreement":null},{"id":"W2095646262","doi":"10.1200/jco.2012.45.2086","title":"Recommendations for the Return of Research Results to Study Participants and Guardians: A Report From the Children's Oncology Group","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Policy Implementation Science","field":"Health Professions","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Vetting; Medicine; Cog; Scope (computer science); Medical education; Multidisciplinary approach; Family medicine","score_opus":0.9314050232928157,"score_gpt":0.8153585811075182,"score_spread":0.11604644218529747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095646262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64821285,0.00007593409,0.0003887616,0.34641898,0.0023063344,0.0020948986,0.00009897956,0.0000044635935,0.0003987906],"genre_scores_gemma":[0.96927905,0.00022032573,0.00525481,0.021635817,0.0032547032,0.00022786955,0.000003915329,0.0000118097805,0.00011170451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9765406,0.015096259,0.006504707,0.00025841524,0.00068040326,0.00091956713],"domain_scores_gemma":[0.81713915,0.17703037,0.0035271246,0.0004971602,0.001179189,0.00062702893],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14491582,0.00009656126,0.00087220204,0.00012123652,0.00095237605,0.00000848476,0.0005830972,0.00027036382,0.00013171959],"category_scores_gemma":[0.15842666,0.000049656646,0.00013394849,0.00044646958,0.00040643095,0.00018788176,0.0003184483,0.0019228896,0.000021976663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020008846,0.000930814,0.59048784,0.0000075319404,0.0002220996,0.000010017773,0.03808479,8.324148e-7,0.0000125890465,0.00024979585,0.2769709,0.09102191],"study_design_scores_gemma":[0.0029607713,0.0036316272,0.5679799,0.00003082959,0.00007814536,0.000015141892,0.017772444,0.0000047113986,0.0000016643306,0.00051500695,0.40697777,0.000032009],"about_ca_topic_score_codex":0.0011874042,"about_ca_topic_score_gemma":0.0025077993,"teacher_disagreement_score":0.32478315,"about_ca_system_score_codex":0.00022442175,"about_ca_system_score_gemma":0.0030408748,"threshold_uncertainty_score":0.8804891},"labels":[],"label_agreement":null},{"id":"W2095719154","doi":"10.1200/jco.2013.50.1411","title":"Vertebral Compression Fracture After Spine Stereotactic Body Radiotherapy: A Multi-Institutional Analysis With a Focus on Radiation Dose and the Spinal Instability Neoplastic Score","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vertebral compression fracture; Radiosurgery; Radiation therapy; Surgery; Radiology; Vertebral body","score_opus":0.04529786370339408,"score_gpt":0.3947117818135537,"score_spread":0.34941391811015965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095719154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96921176,0.00076178863,0.010876386,0.018075788,0.00024193554,0.0007180868,0.0000026687776,0.0000083970435,0.00010317123],"genre_scores_gemma":[0.98969156,0.00015209065,0.0038291952,0.0059295767,0.0003199605,0.000026270362,0.000004282628,0.000010710407,0.000036340167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683976,0.0007653876,0.0013671578,0.0002554867,0.00058079197,0.00019140888],"domain_scores_gemma":[0.9969867,0.0008732904,0.0011872073,0.0002821276,0.00028660483,0.0003840691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018251512,0.0002016447,0.0013671536,0.00022821076,0.00007468948,0.000037395734,0.00012158621,0.0001531184,0.00048456257],"category_scores_gemma":[0.0018899776,0.00009256024,0.0004305919,0.00025359634,0.0005457122,0.00023735204,0.00003541764,0.000827955,0.000008380182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.110447176,0.006930554,0.72243094,0.0002032059,0.007454126,0.0010171706,0.00030806658,0.0007860458,0.000030121892,0.00032641037,0.00070246955,0.14936371],"study_design_scores_gemma":[0.03269617,0.007035313,0.9366415,0.00014148948,0.0034679119,0.000091150934,0.00004207292,0.018349437,0.0000016060312,0.00015054706,0.0012910842,0.00009171941],"about_ca_topic_score_codex":0.000054245924,"about_ca_topic_score_gemma":0.000036804817,"teacher_disagreement_score":0.21421055,"about_ca_system_score_codex":0.0001333644,"about_ca_system_score_gemma":0.00057287904,"threshold_uncertainty_score":0.53056204},"labels":[],"label_agreement":null},{"id":"W2095720296","doi":"10.1200/jco.2008.16.3972","title":"Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Receptor; Cancer research; Pharmacology; Internal medicine","score_opus":0.20157290432113878,"score_gpt":0.49655173568329786,"score_spread":0.2949788313621591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095720296","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1546556,0.003229857,0.0002920454,0.8353546,0.003865026,0.0007139567,0.000011602664,0.000023974955,0.0018532837],"genre_scores_gemma":[0.10628515,0.017089617,0.040565,0.7810305,0.051232222,0.000037232516,0.000024601752,0.0005457564,0.0031899556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904274,0.002013036,0.004139289,0.000422358,0.0023614778,0.0006364724],"domain_scores_gemma":[0.9889444,0.0037695302,0.0046829986,0.0006496224,0.0015947579,0.0003586563],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005859896,0.0003499911,0.0032745297,0.00027393393,0.00008715048,0.00001128709,0.0006542569,0.0015133771,0.00042190723],"category_scores_gemma":[0.005425009,0.00020192182,0.0011797567,0.00037786693,0.0010593538,0.000056767516,0.00022204687,0.01143881,0.000043818083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023428546,0.00096721627,0.01681352,0.00047938552,0.0018452414,0.010395827,0.00018620223,0.0001383214,0.0018681651,0.000008280151,0.9477478,0.017207177],"study_design_scores_gemma":[0.0050295065,0.008883334,0.0024558296,0.0018706141,0.00068211835,0.0015308679,0.000056028875,0.000024249406,0.0008899606,0.000056864556,0.9783002,0.00022039747],"about_ca_topic_score_codex":0.000107942345,"about_ca_topic_score_gemma":0.00001703618,"teacher_disagreement_score":0.054324184,"about_ca_system_score_codex":0.00054083753,"about_ca_system_score_gemma":0.0068535237,"threshold_uncertainty_score":0.99978286},"labels":[],"label_agreement":null},{"id":"W2095738781","doi":"10.1200/jco.2011.35.1007","title":"Out-of-Pocket Costs for Accessing Adjuvant Radiotherapy Among Canadian Women With Breast Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Canadian Association of Psychosocial Oncology; Natural Sciences and Engineering Research Council of Canada","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Medicine; Breast cancer; Radiation therapy; Quartile; Adjuvant radiotherapy; Cancer; Demography; Family medicine; Surgery; Internal medicine; Confidence interval","score_opus":0.10470402273101975,"score_gpt":0.49543356613978545,"score_spread":0.3907295434087657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095738781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825182,0.0018556842,0.0036273235,0.0043828324,0.0042900746,0.00046004236,0.00003478428,0.000009841253,0.0028212476],"genre_scores_gemma":[0.9477106,0.003009973,0.037187956,0.008611603,0.0029641476,0.000030415189,0.000001447653,0.0000471631,0.00043671316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99746406,0.00022116517,0.0015215182,0.00019141859,0.00018529918,0.0004165574],"domain_scores_gemma":[0.9956195,0.0010981268,0.0017940109,0.0001856542,0.0005664407,0.000736283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021376866,0.00016355979,0.0016969095,0.00018160333,0.000072950446,0.000003972025,0.00024644376,0.00048151612,0.0008898399],"category_scores_gemma":[0.00037342284,0.00010156677,0.00022836753,0.000115497285,0.0007320146,0.00021778789,0.000009487812,0.0007239546,9.43632e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021301942,0.0007612573,0.4377845,0.00003551936,0.0010651406,0.00038287038,0.0013878746,0.000010631067,0.00010086995,0.000053084877,0.0027555577,0.53436077],"study_design_scores_gemma":[0.01629501,0.023593225,0.8507379,0.0003220316,0.00031437736,0.0006978836,0.000637836,0.00008635944,0.00008017204,0.0003141312,0.106724545,0.00019651496],"about_ca_topic_score_codex":0.0013691029,"about_ca_topic_score_gemma":0.01568537,"teacher_disagreement_score":0.53416425,"about_ca_system_score_codex":0.0009805827,"about_ca_system_score_gemma":0.0051653353,"threshold_uncertainty_score":0.9743123},"labels":[],"label_agreement":null},{"id":"W2095988745","doi":"10.1200/jco.2008.16.1562","title":"Availability and Use of Palliative Care and End-of-Life Services for Pediatric Oncology Patients","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Children's Hospital of Eastern Ontario","funders":"","keywords":"Palliative care; Medicine; Psychosocial; Family medicine; Cog; Service (business); Nursing; Psychiatry","score_opus":0.19966114037890756,"score_gpt":0.47617577573392256,"score_spread":0.27651463535501497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095988745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948815,0.0017861921,0.000035938036,0.002026207,0.0006643515,0.00041426296,0.000059411625,0.00000438713,0.0001277641],"genre_scores_gemma":[0.9836083,0.0043723728,0.009333161,0.001921041,0.0007280299,0.0000036861493,0.000006897782,0.000013378993,0.000013107892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545795,0.00060362415,0.0031401482,0.00024004832,0.0003735413,0.00018471846],"domain_scores_gemma":[0.9843043,0.010041401,0.0035029533,0.00018388969,0.0015262782,0.00044114018],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019659568,0.00014715524,0.0021835193,0.00012610531,0.000044846245,0.0000025566064,0.000115151,0.00044174906,0.000030468926],"category_scores_gemma":[0.008572523,0.000114393275,0.0003243117,0.00011298509,0.00054688647,0.00013741227,0.00009281925,0.00052539917,6.941341e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053151743,0.0014424896,0.97036046,0.00087320444,0.0001952947,0.000015045489,0.003441586,0.0000018874963,0.000005990435,0.00001523865,0.00075946,0.017574163],"study_design_scores_gemma":[0.011777997,0.025472678,0.9405368,0.0000767103,0.00046179563,0.000016045553,0.00078678475,0.0000146282955,0.000023713475,0.00010386897,0.020643663,0.00008532536],"about_ca_topic_score_codex":0.0001714339,"about_ca_topic_score_gemma":0.00035571112,"teacher_disagreement_score":0.029823676,"about_ca_system_score_codex":0.000100866564,"about_ca_system_score_gemma":0.002276793,"threshold_uncertainty_score":0.9997787},"labels":[],"label_agreement":null},{"id":"W2096025553","doi":"10.1200/jco.2009.23.1670","title":"Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":319,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Medicine; In situ hybridization; Oncology; Messenger RNA; In situ; Internal medicine; Cancer research; Pathology; Gene; Biology; Genetics","score_opus":0.1539893027342152,"score_gpt":0.4781248716377354,"score_spread":0.32413556890352024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096025553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934045,0.00060529215,0.00026910502,0.002651681,0.00022258444,0.000488323,0.0000034828984,0.0000057256048,0.002349294],"genre_scores_gemma":[0.9961687,0.00004568769,0.0024715208,0.0007578905,0.0005003071,0.000005998388,0.00000537778,0.000008027973,0.000036544843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972695,0.00023774688,0.0018770266,0.00015774718,0.00025328083,0.00020468925],"domain_scores_gemma":[0.99625254,0.0016147443,0.0012236173,0.000100923375,0.00063087064,0.00017731557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011162114,0.00012864279,0.0022664713,0.00012993549,0.000047734415,0.000003179696,0.00009779599,0.00012932328,0.000009911809],"category_scores_gemma":[0.00092910446,0.0000863879,0.00020242043,0.00015721709,0.00018364463,0.00007022151,0.0000137900015,0.00044933875,0.0000010188321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032927092,0.009895087,0.9093844,0.00027287332,0.00050598645,0.0010417645,0.0031531719,0.0003498836,0.007909981,0.0008644437,0.00689894,0.026796356],"study_design_scores_gemma":[0.016910974,0.06109428,0.91809016,0.0002128075,0.00032450343,0.00011769609,0.0002647895,0.00026160662,0.0011253455,0.00025198175,0.0012589385,0.00008689639],"about_ca_topic_score_codex":0.000019754136,"about_ca_topic_score_gemma":0.00020779906,"teacher_disagreement_score":0.051199194,"about_ca_system_score_codex":0.00013440067,"about_ca_system_score_gemma":0.0009787477,"threshold_uncertainty_score":0.35227966},"labels":[],"label_agreement":null},{"id":"W2096028378","doi":"10.1200/jco.2009.22.3958","title":"Anticoagulation in the Treatment of Established Venous Thromboembolism in Patients With Cancer","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Medicine; Thrombosis; Intensive care medicine; Cancer; Low molecular weight heparin; Heparin; Complication; Anticoagulant; Venous thrombosis; Population; Surgery; Internal medicine","score_opus":0.14171884167482843,"score_gpt":0.4841720444544698,"score_spread":0.3424532027796414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096028378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.090808205,0.90494555,0.000002439529,0.0007139059,0.00076870195,0.0018620323,0.000007545975,0.000003097353,0.00088851637],"genre_scores_gemma":[0.014026937,0.984766,0.00021255045,0.00038861096,0.00052428537,0.000028690176,0.000017529816,0.000022257786,0.000013117019],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947704,0.0007536152,0.0034906657,0.00022985172,0.0005001389,0.00025531588],"domain_scores_gemma":[0.99471104,0.00122536,0.0034114576,0.00031151553,0.00023442146,0.000106220774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017747685,0.00027780925,0.007807674,0.0003965185,0.00001704366,0.0000095045425,0.00023623153,0.00048006093,0.000046735728],"category_scores_gemma":[0.00032624623,0.00013273898,0.00068916316,0.000417644,0.000109551474,0.0000808349,0.000015781621,0.000667367,0.000002422643],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034341746,0.025702318,0.011550069,0.00084299495,0.00053868466,0.00021669072,0.00028478014,0.00001777154,8.2312885e-9,0.000044548768,0.000457388,0.96000135],"study_design_scores_gemma":[0.0050725522,0.02562655,0.4828834,0.0048543285,0.0028489004,0.000011512233,0.000026731715,0.0000013692782,3.6842486e-8,0.000035834524,0.47855452,0.000084278756],"about_ca_topic_score_codex":0.00018331023,"about_ca_topic_score_gemma":0.00029928875,"teacher_disagreement_score":0.95991707,"about_ca_system_score_codex":0.0005081724,"about_ca_system_score_gemma":0.001679854,"threshold_uncertainty_score":0.54129386},"labels":[],"label_agreement":null},{"id":"W2096336184","doi":"10.1200/jco.2008.21.2514","title":"Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":709,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib; Lymphoblastic Leukemia; Oncology; Internal medicine; Philadelphia chromosome; Leukemia; Chromosomal translocation; Genetics; Gene; Myeloid leukemia","score_opus":0.03415208848965093,"score_gpt":0.38776667454777614,"score_spread":0.35361458605812524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096336184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903781,0.00019794167,0.00019308679,0.0058478047,0.0008625995,0.0014871889,0.000020443993,0.000033562672,0.000979301],"genre_scores_gemma":[0.9934244,0.00024092352,0.0032032786,0.0015301293,0.0014200538,0.000024726169,0.000017100892,0.000051401483,0.00008797319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923785,0.0012759609,0.004056774,0.00065569713,0.0008608755,0.00077219674],"domain_scores_gemma":[0.99217045,0.0028563195,0.0029954326,0.000713003,0.00049548165,0.00076933746],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0034062022,0.0005126811,0.003816995,0.00039815524,0.00008110122,0.000022556604,0.00064792193,0.0008566923,0.000110005596],"category_scores_gemma":[0.0023560526,0.00035670813,0.0005993894,0.0005428406,0.00035263022,0.0003122435,0.00016945666,0.0025381458,0.00002510504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11348025,0.065311454,0.5642493,0.000053013704,0.012133434,0.050792262,0.0028803176,0.00020290233,0.0023864752,0.00018743657,0.0021470443,0.18617614],"study_design_scores_gemma":[0.09075719,0.17574832,0.72728795,0.00019907106,0.0018179151,0.0030929893,0.00027284105,0.00020985169,0.000036577538,0.00017538326,0.00015697657,0.00024495603],"about_ca_topic_score_codex":0.00023867754,"about_ca_topic_score_gemma":0.00062487996,"teacher_disagreement_score":0.18593118,"about_ca_system_score_codex":0.0059208316,"about_ca_system_score_gemma":0.009032023,"threshold_uncertainty_score":0.9998885},"labels":[],"label_agreement":null},{"id":"W2096672426","doi":"10.1200/jco.2014.57.9961","title":"Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Takeda Oncology; National Institutes of Health; National University Health System; Gachon University; Tel Aviv University; Ostravská Univerzita v Ostravě; Universidad de Salamanca; Eli Lilly and Company; National Taiwan University Hospital; Keio University; Northwestern University; York University; Nagoya City University; Cedars-Sinai Medical Center; University of Arkansas for Medical Sciences; Ankara Universitesi; National Taiwan University; National and Kapodistrian University of Athens; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; University of Alberta; Queen Mary University of London; Universität Wien; Emory University; Gil Medical Center, Gachon University; Universität Heidelberg; Celgene","keywords":"Medicine; Multiple myeloma; Magnetic resonance imaging; Radiology; Plasmacytoma; Bone marrow; Asymptomatic; Pathology; Internal medicine","score_opus":0.0815232574213156,"score_gpt":0.42783843505911334,"score_spread":0.34631517763779773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096672426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459183,0.0017066676,0.000008764554,0.0012095214,0.000078499324,0.00047826947,0.000010039562,0.0000015468628,0.0019148416],"genre_scores_gemma":[0.9923275,0.00015756582,0.007270427,0.0001410728,0.00004106545,0.0000073997826,0.000003041,0.0000075708904,0.000044338056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969376,0.0004201473,0.001611971,0.00011778211,0.00070570124,0.00020681633],"domain_scores_gemma":[0.99714446,0.00094926526,0.0009328279,0.00020092842,0.0005712749,0.00020126524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002551737,0.000092129,0.0007145176,0.00010512844,0.000011526569,0.0000027085005,0.00015927247,0.00005400964,0.00001984398],"category_scores_gemma":[0.0007493055,0.000048532776,0.00011693656,0.00014867606,0.00023727055,0.000033299104,0.000054031876,0.00031126608,0.0000030369856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010670006,0.0030339253,0.75148576,0.000034520148,0.00009981681,0.0006256988,0.00020168978,0.000008172702,0.00000976989,0.000026608399,0.0003537882,0.23345023],"study_design_scores_gemma":[0.03137743,0.010450162,0.9464243,0.00017649143,0.00013342987,0.00002907048,0.0012292161,0.0002095938,0.000030471281,0.0001333724,0.009768306,0.000038126615],"about_ca_topic_score_codex":0.0000587847,"about_ca_topic_score_gemma":0.0000556512,"teacher_disagreement_score":0.2334121,"about_ca_system_score_codex":0.000103389626,"about_ca_system_score_gemma":0.0005079899,"threshold_uncertainty_score":0.19791092},"labels":[],"label_agreement":null},{"id":"W2096721483","doi":"10.1200/jco.2012.44.0248","title":"Referral Practices of Oncologists to Specialized Palliative Care","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Referral; Specialty; Palliative care; Family medicine; Disease; Chemotherapy; Internal medicine; Nursing","score_opus":0.7116477649748835,"score_gpt":0.6753164018865185,"score_spread":0.03633136308836493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096721483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568225,0.0044232565,0.00013082473,0.0053019654,0.0023527201,0.0002209238,0.000008968034,0.0000060302946,0.03073278],"genre_scores_gemma":[0.96336675,0.002475567,0.028905556,0.0016277469,0.0033662694,0.0000025693794,0.0000031296584,0.000012457442,0.00023998368],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606097,0.0006372501,0.0024531547,0.00012879098,0.00045820622,0.00026165767],"domain_scores_gemma":[0.9868848,0.005304007,0.005663614,0.00018701842,0.0014533983,0.0005071719],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028524469,0.00013407088,0.0020338646,0.00014512401,0.00001886429,0.0000024953672,0.0001942983,0.0003972304,0.0002430952],"category_scores_gemma":[0.03510174,0.000091359194,0.00051372964,0.00019576158,0.00023795979,0.00016499996,0.00007184064,0.0007128702,0.000024588733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011035187,0.002033846,0.9080571,0.00012512405,0.00067829055,0.00015507595,0.0063718744,0.000006058903,0.0007767423,0.00046100424,0.013193975,0.057105705],"study_design_scores_gemma":[0.0043491484,0.0126789035,0.4159192,0.00037562748,0.00046974682,0.000021108688,0.0041273623,0.0000012292451,0.0014884659,0.00007158657,0.5604199,0.00007765949],"about_ca_topic_score_codex":0.0000599369,"about_ca_topic_score_gemma":0.000075134325,"teacher_disagreement_score":0.54722595,"about_ca_system_score_codex":0.00022081885,"about_ca_system_score_gemma":0.0012855805,"threshold_uncertainty_score":0.973026},"labels":[],"label_agreement":null},{"id":"W2096864872","doi":"10.1200/jco.2006.10.3523","title":"Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":885,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre","funders":"","keywords":"Breast cancer; Medicine; Clinical trial; Clinical endpoint; Cancer; Medical physics; End point; Oncology; Internal medicine; Computer science","score_opus":0.793096103122032,"score_gpt":0.685672168665247,"score_spread":0.107423934456785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096864872","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03328101,0.00035638394,0.91414577,0.027116496,0.01611434,0.005947098,0.0019428162,0.000049963663,0.0010461406],"genre_scores_gemma":[0.09209808,0.00016100066,0.9014199,0.0007232642,0.0053373324,0.00015885576,0.0000014935271,0.00005647431,0.000043601973],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97900265,0.0070642256,0.012286796,0.00036113124,0.0006702846,0.0006149138],"domain_scores_gemma":[0.45708913,0.5358066,0.005389487,0.00028916393,0.0011133138,0.00031234516],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18637656,0.00024499217,0.0046601705,0.0001509721,0.00012937497,0.000032664753,0.00054902973,0.00069474435,0.00013141744],"category_scores_gemma":[0.5577547,0.00013526333,0.0016477932,0.00022056446,0.0004618925,0.000080342994,0.00006938103,0.0011549369,0.000003706827],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060212694,0.003299183,0.0009177499,0.00043117552,0.001136401,0.000121807716,0.0001961527,0.0000126927425,0.000059270384,0.3919279,0.014579742,0.5271052],"study_design_scores_gemma":[0.047256675,0.005812701,0.0077931806,0.0007232937,0.0017882155,0.00018065202,0.0006692672,0.00018254168,0.00014136302,0.9221726,0.013019864,0.00025966033],"about_ca_topic_score_codex":0.000007576065,"about_ca_topic_score_gemma":0.00017054573,"teacher_disagreement_score":0.5302447,"about_ca_system_score_codex":0.00043907145,"about_ca_system_score_gemma":0.0030421598,"threshold_uncertainty_score":0.83779657},"labels":[],"label_agreement":null},{"id":"W2097271805","doi":"10.1200/jco.2010.32.0994","title":"Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Selenium in Biological Systems","field":"Nursing","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Prostate cancer; Intraepithelial neoplasia; Vitamin E; Internal medicine; Urology; Clinical endpoint; Prostate; Hazard ratio; Randomized controlled trial; Cancer; Gastroenterology; Prostate-specific antigen; Gynecology; Oncology; Confidence interval; Antioxidant","score_opus":0.09162547321242116,"score_gpt":0.42988360171037876,"score_spread":0.3382581284979576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097271805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98533666,0.00022119017,0.00024273033,0.0038649705,0.008569055,0.001612759,0.0000139325975,0.000018105307,0.00012056676],"genre_scores_gemma":[0.98669904,0.00017131948,0.011063317,0.00045341987,0.0015211052,0.000059473638,0.0000032766272,0.000018077482,0.000010963002],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99200034,0.0032077336,0.003788109,0.0002857801,0.00044650782,0.00027150995],"domain_scores_gemma":[0.9876054,0.007707525,0.0037700306,0.0001577018,0.00042885324,0.00033047158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006321433,0.00019902729,0.0027448267,0.00013545457,0.00004948899,0.00001487239,0.00028802713,0.0006244015,0.00007846417],"category_scores_gemma":[0.008304626,0.00012304226,0.0003761318,0.0001659562,0.00042251393,0.00012921498,0.0000717554,0.000706718,0.000006413448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9022814,0.0022491256,0.008312998,0.000030083136,0.00022965533,0.000013384445,0.000901461,0.0000013788721,0.0053990595,0.00015305923,0.00065966236,0.07976871],"study_design_scores_gemma":[0.8964787,0.033247568,0.05163941,0.0003141839,0.000606645,0.000032087002,0.00014659968,0.0001547173,0.009101802,0.0069421767,0.0011218837,0.000214212],"about_ca_topic_score_codex":0.00056743185,"about_ca_topic_score_gemma":0.000083983956,"teacher_disagreement_score":0.0795545,"about_ca_system_score_codex":0.00012051176,"about_ca_system_score_gemma":0.00026669996,"threshold_uncertainty_score":0.9942012},"labels":[],"label_agreement":null},{"id":"W2097312865","doi":"10.1200/jco.2006.06.1663","title":"Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Canadian Child Health Clinician Scientist Program","keywords":"Medicine; Granulocyte colony-stimulating factor; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Randomized controlled trial; Placebo; Relative risk; Risk factor; Stem cell; Surgery; Immunology; Gastroenterology; Confidence interval; Chemotherapy; Pathology","score_opus":0.2792651494151842,"score_gpt":0.4930717815711139,"score_spread":0.2138066321559297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097312865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1320794,0.86051416,0.00072648696,0.00009754049,0.0005946528,0.0054096403,0.00041559924,0.000015031645,0.00014749717],"genre_scores_gemma":[0.43966013,0.55850977,0.0010531143,0.000070911214,0.00023776063,0.00020007492,0.000028796696,0.000047639413,0.00019184189],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96970797,0.011066122,0.017482787,0.00059646147,0.0007715386,0.000375101],"domain_scores_gemma":[0.9248488,0.050618246,0.022897907,0.00032726896,0.00094446115,0.00036330556],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.015464443,0.00076288846,0.06376142,0.0011760188,0.00009270812,0.00003432757,0.00019227732,0.0013130486,0.00030614276],"category_scores_gemma":[0.004297332,0.00042400951,0.017268198,0.00061672373,0.00064269657,0.00013084953,0.00004841892,0.0015273131,0.0000011933046],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30424815,0.0018255165,0.0038945875,0.019643355,0.4515612,0.0010019465,0.00032461053,0.0008267961,0.00026707,0.000014801232,0.000017495242,0.21637447],"study_design_scores_gemma":[0.16185088,0.0047800615,0.002482633,0.00064471824,0.8259736,0.00023982702,0.0000114274735,0.00025478975,0.000028380882,0.000013347151,0.0034124174,0.0003079498],"about_ca_topic_score_codex":0.00009559771,"about_ca_topic_score_gemma":0.000087552056,"teacher_disagreement_score":0.37441236,"about_ca_system_score_codex":0.00017551552,"about_ca_system_score_gemma":0.0017649207,"threshold_uncertainty_score":0.99998343},"labels":[],"label_agreement":null},{"id":"W2097336603","doi":"10.1200/jco.2009.22.7041","title":"Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Mammography; Cancer; Oncology; Randomized controlled trial; Mammography screening; Internal medicine; Gynecology","score_opus":0.35408553172010115,"score_gpt":0.5888175636146504,"score_spread":0.23473203189454928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097336603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027191695,0.9877259,0.000033605484,0.0041041113,0.0015696452,0.002915066,0.00015332602,0.0000141272285,0.00076503126],"genre_scores_gemma":[0.0022980985,0.9904134,0.00066840206,0.002864284,0.0034278196,0.00020190346,0.0000075890143,0.000040413604,0.00007808065],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9766522,0.006986741,0.014167097,0.00060413184,0.0010249589,0.00056485395],"domain_scores_gemma":[0.9633985,0.019740328,0.0150261335,0.00033300536,0.00075375405,0.0007482448],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.045672547,0.0007106774,0.04966252,0.0007743268,0.000058974005,0.00003711069,0.0003403404,0.0013792955,0.00029779944],"category_scores_gemma":[0.012918897,0.00038448744,0.008886385,0.00055281265,0.00045071967,0.00019007965,0.00005908788,0.0033549,0.0000023581374],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26177466,0.00033332015,0.002316055,0.0006186475,0.003575153,0.0005805358,0.000008519523,0.000017764321,1.3067809e-7,0.000029453198,0.00042557457,0.7303202],"study_design_scores_gemma":[0.632122,0.0025974263,0.029691746,0.07073485,0.029968379,0.0021726445,0.0000434233,0.000035604786,7.6188186e-8,0.00018254128,0.23193857,0.00051275594],"about_ca_topic_score_codex":0.00046718918,"about_ca_topic_score_gemma":0.00036360428,"teacher_disagreement_score":0.72980744,"about_ca_system_score_codex":0.00043712705,"about_ca_system_score_gemma":0.0047787447,"threshold_uncertainty_score":0.99991715},"labels":[],"label_agreement":null},{"id":"W2097354398","doi":"10.1200/jco.2009.25.4342","title":"Reply to D.L. Raunig","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine","score_opus":0.20649044368908437,"score_gpt":0.5798411927725939,"score_spread":0.37335074908350957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097354398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7278074,0.00042611946,0.00009239814,0.2290552,0.0023216107,0.00017937263,8.2797914e-7,0.000012359618,0.040104724],"genre_scores_gemma":[0.83999616,0.00038567808,0.0044733486,0.1488275,0.0032487346,0.0000011074159,7.605629e-7,0.00000630049,0.0030604128],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979684,0.00017072038,0.0013972768,0.000117900745,0.0001775594,0.00016813968],"domain_scores_gemma":[0.9977146,0.00075635104,0.0006053147,0.00012684066,0.0002713786,0.0005255178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016121902,0.00008054445,0.0010220902,0.000108688444,0.000019717323,0.0000031770471,0.00010006057,0.00017051001,0.00051212474],"category_scores_gemma":[0.0014026572,0.000055163266,0.00038130628,0.0001275581,0.000047970123,0.00004424035,0.000014436332,0.0005624615,0.00008697239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009970475,0.003350826,0.014009235,0.0000041134094,0.0002490239,0.0017772589,0.00010585986,0.000006979742,0.000891291,0.00016992613,0.4424896,0.5269754],"study_design_scores_gemma":[0.0062397933,0.04572538,0.19351318,0.000019743748,0.00027239576,0.00051323243,0.00001653754,0.0000041756502,0.00016670987,0.00043610463,0.75305057,0.00004219316],"about_ca_topic_score_codex":0.0000073806236,"about_ca_topic_score_gemma":0.0000044846397,"teacher_disagreement_score":0.5269332,"about_ca_system_score_codex":0.00012484955,"about_ca_system_score_gemma":0.00097233144,"threshold_uncertainty_score":0.56074065},"labels":[],"label_agreement":null},{"id":"W2097603292","doi":"10.1200/jco.2011.35.9182","title":"Reply to S.M. Sorscher et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.36529295829556274,"score_gpt":0.5584976683180847,"score_spread":0.19320471002252193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097603292","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3911512,0.008397292,0.0007021139,0.47377753,0.016619623,0.00060612377,0.00001855518,0.00001550575,0.10871206],"genre_scores_gemma":[0.58706063,0.009508582,0.064804874,0.3010094,0.005690534,0.000011713207,0.000003757665,0.00007699761,0.031833503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936008,0.0017688845,0.0030038543,0.00029436804,0.0006490906,0.00068300485],"domain_scores_gemma":[0.9920019,0.0032392761,0.0012599275,0.00036465633,0.000782606,0.0023516356],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00984821,0.00020724471,0.0017585924,0.00019632156,0.00004054219,0.000011207011,0.00031357876,0.00044584234,0.005260723],"category_scores_gemma":[0.01986739,0.00014908427,0.00079234614,0.0001984006,0.00034875635,0.00019102648,0.0001521675,0.002116069,0.0021157488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01149037,0.006281934,0.13089328,0.000025345766,0.0013028848,0.011451906,0.000461579,0.0000015565012,0.000043494118,0.0006142109,0.40070486,0.4367286],"study_design_scores_gemma":[0.007842997,0.029129947,0.31366768,0.00021622804,0.00024850428,0.00064641464,0.00012057618,0.000027105505,0.00008067989,0.00035500046,0.64758337,0.000081494814],"about_ca_topic_score_codex":0.00042079427,"about_ca_topic_score_gemma":0.00007852031,"teacher_disagreement_score":0.4366471,"about_ca_system_score_codex":0.00029745468,"about_ca_system_score_gemma":0.0038812626,"threshold_uncertainty_score":0.9986612},"labels":[],"label_agreement":null},{"id":"W2097881410","doi":"10.1200/jco.2012.45.5766","title":"Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":242,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Placebo; Chemotherapy; Oncology; Internal medicine; Randomized controlled trial; Pathology","score_opus":0.029024308932659764,"score_gpt":0.38276766231945614,"score_spread":0.35374335338679636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097881410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536556,0.000090097645,0.00014124151,0.0007482659,0.0023398444,0.0010398867,0.00017748207,0.0000010003054,0.00009662202],"genre_scores_gemma":[0.9955968,0.00004374304,0.0031180347,0.00047514032,0.00066861237,0.00003615683,0.000018572297,0.000016039394,0.000026859092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995073,0.0008849365,0.003244217,0.00022467406,0.00040234713,0.00017080968],"domain_scores_gemma":[0.99456257,0.001384422,0.0029747558,0.00031230642,0.0006194808,0.00014649442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029501617,0.00015776178,0.0014769777,0.00009581048,0.00001072132,0.00000601849,0.0005042777,0.0002633027,0.00011489279],"category_scores_gemma":[0.004178813,0.000105073734,0.0005837237,0.00007855272,0.00024851333,0.000020194278,0.000070392125,0.00028150808,8.874605e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96741533,0.0024248248,0.0015919289,0.000005684392,0.00068158837,0.000003302027,0.00012394926,0.00022358718,0.014647323,0.0000033339359,0.00028065307,0.012598495],"study_design_scores_gemma":[0.93459606,0.015540165,0.009557782,0.00005157393,0.0001504874,8.481341e-7,0.000027359436,0.0001429755,0.03788608,0.00016309675,0.0017811153,0.00010244738],"about_ca_topic_score_codex":0.00011617327,"about_ca_topic_score_gemma":0.00007727466,"teacher_disagreement_score":0.03281926,"about_ca_system_score_codex":0.000052356947,"about_ca_system_score_gemma":0.00045994204,"threshold_uncertainty_score":0.50027317},"labels":[],"label_agreement":null},{"id":"W2097977223","doi":"10.1200/jco.2005.06.178","title":"Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":572,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Michael Smith Health Research BC; Canadian Breast Cancer Research Alliance","keywords":"Medicine; Breast cancer; Internal medicine; Adjuvant; Oncology; Lymphovascular invasion; Population; Adjuvant therapy; Cancer; Gynecology; Metastasis","score_opus":0.06635707897107647,"score_gpt":0.4282446016400686,"score_spread":0.36188752266899216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097977223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894126,0.00027358157,0.001647612,0.007917738,0.00044669455,0.00017232883,0.00006507743,0.000001618222,0.00006271983],"genre_scores_gemma":[0.9956011,0.000067922505,0.0027242037,0.00056799635,0.0009557137,0.000017851255,0.000007099067,0.000010090543,0.00004799998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986635,0.00011521139,0.0008562156,0.000116081326,0.00013825111,0.0001107289],"domain_scores_gemma":[0.99802387,0.00028522083,0.0010811489,0.00012660299,0.0004287087,0.000054440537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053369114,0.0000828529,0.00040899962,0.000020844554,0.000042040418,0.0000031101583,0.0001527931,0.00016932764,0.000008240915],"category_scores_gemma":[0.00061710045,0.000051742532,0.00032487052,0.000042587224,0.00007791176,0.0000061479004,0.00003042402,0.00011431052,4.2894158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017244562,0.0005624452,0.9274242,0.000014679417,0.00025779993,4.2767633e-7,0.00002262078,0.022416273,0.00092680147,0.000037858183,0.00097164814,0.045640785],"study_design_scores_gemma":[0.0035942497,0.0008203983,0.9897778,0.00003663442,0.00027094473,0.000008444319,0.000008518141,0.0014178114,0.0022597883,0.00019242454,0.001546107,0.00006690131],"about_ca_topic_score_codex":0.000030624975,"about_ca_topic_score_gemma":0.00011962971,"teacher_disagreement_score":0.062353574,"about_ca_system_score_codex":0.00005187963,"about_ca_system_score_gemma":0.00070367,"threshold_uncertainty_score":0.21099992},"labels":[],"label_agreement":null},{"id":"W2098010907","doi":"10.1200/jco.2009.22.8361","title":"Are <i>HER2</i> and <i>TOP2A</i> Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Cancer; Trastuzumab; Predictive value","score_opus":0.16127825424187406,"score_gpt":0.5170535328735052,"score_spread":0.35577527863163116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098010907","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0102144275,0.0024404423,0.0011268064,0.97763675,0.0026257667,0.004390529,0.0013389057,0.000040490086,0.00018586442],"genre_scores_gemma":[0.0073329736,0.0060757254,0.007963047,0.9445143,0.032102484,0.0004698231,0.00009003169,0.00024660668,0.0012050172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99273324,0.0006349563,0.0037465333,0.00084089185,0.0010656908,0.0009786682],"domain_scores_gemma":[0.97630095,0.014808189,0.005332921,0.00047016368,0.0023421382,0.00074561115],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004579144,0.0006084795,0.004594249,0.00039131037,0.00012191786,0.000048639795,0.00054830016,0.00288305,0.00026239152],"category_scores_gemma":[0.009049217,0.00041016805,0.0013440518,0.0002718797,0.00087359495,0.00012015251,0.00005011955,0.004386732,0.0000044673443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050847918,0.0010816036,0.018467924,0.0011579917,0.0014496843,0.0021830138,0.000022838032,0.0000046210653,0.000028896755,4.6039284e-7,0.75593036,0.1688247],"study_design_scores_gemma":[0.02900098,0.040780127,0.04924831,0.0029110215,0.0018056743,0.0013825451,0.0000511149,0.00035922084,0.00009375252,0.00023483958,0.8737466,0.00038582415],"about_ca_topic_score_codex":0.000043091975,"about_ca_topic_score_gemma":0.0000950752,"teacher_disagreement_score":0.16843888,"about_ca_system_score_codex":0.00075617206,"about_ca_system_score_gemma":0.011752545,"threshold_uncertainty_score":0.999835},"labels":[],"label_agreement":null},{"id":"W2098088878","doi":"10.1200/jco.2015.63.0756","title":"Reply to L. Wiener et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Guelph","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.23763856508164666,"score_gpt":0.5320776409967505,"score_spread":0.2944390759151038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098088878","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013160416,0.004448144,0.00046590992,0.90473706,0.058470406,0.0005376049,0.00005184131,0.00002543269,0.01810319],"genre_scores_gemma":[0.001226565,0.0018177336,0.010505841,0.8961885,0.0787555,0.00000844284,0.000027860717,0.00013988142,0.011329651],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97447145,0.007835999,0.012468514,0.0009622597,0.003033113,0.0012286765],"domain_scores_gemma":[0.96495605,0.01790651,0.009466557,0.0012668889,0.0031835334,0.003220443],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.050692838,0.00075695687,0.008178234,0.0005153774,0.00006760649,0.0000502905,0.0012644078,0.0029669288,0.0017070696],"category_scores_gemma":[0.071241945,0.0006162481,0.0025201254,0.00044351513,0.0008202254,0.00031010737,0.0004837258,0.015145175,0.001881352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00460515,0.0018943738,0.004564428,0.00015963778,0.0016531578,0.008549352,0.0009833665,0.000044797933,0.000008537545,0.00013189991,0.9253031,0.052102175],"study_design_scores_gemma":[0.010237746,0.035519358,0.0142953405,0.0021005112,0.0013901535,0.0025084228,0.00028530176,0.00001189761,0.000005294821,0.00069762004,0.93240803,0.00054029917],"about_ca_topic_score_codex":0.000640837,"about_ca_topic_score_gemma":0.0003129636,"teacher_disagreement_score":0.051561877,"about_ca_system_score_codex":0.0014848927,"about_ca_system_score_gemma":0.022082599,"threshold_uncertainty_score":0.9996289},"labels":[],"label_agreement":null},{"id":"W2098099565","doi":"10.1200/jco.2005.02.028","title":"Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Ovarian cancer; Clinical trial; Randomized controlled trial; Epithelial ovarian cancer; Cancer; Oncology; Internal medicine; Gynecology","score_opus":0.09511183689925354,"score_gpt":0.44645178394527024,"score_spread":0.3513399470460167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098099565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683469,0.00039020582,0.000010965153,0.022028184,0.006530418,0.0023565441,0.00013569892,0.0000019170095,0.00019918926],"genre_scores_gemma":[0.99161136,0.0013358431,0.0009827134,0.0008618142,0.004999808,0.00014757652,0.000001292548,0.000018771821,0.000040808973],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9847327,0.0042985454,0.009091266,0.00028136445,0.0012890279,0.00030708683],"domain_scores_gemma":[0.97946924,0.009046,0.0100126825,0.00032618837,0.0008749012,0.00027097878],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020415192,0.0002466246,0.0055717183,0.00015110166,0.000046243345,0.000004686945,0.0003996005,0.00039264682,0.00015729229],"category_scores_gemma":[0.017070932,0.00011937697,0.0012146733,0.0003927593,0.0011186864,0.00009954643,0.00008017086,0.001079094,1.2639734e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.937385,0.0068219574,0.004100505,0.000055229073,0.0024498445,0.000022881426,0.00020698464,0.0006260816,0.0001673723,0.00084207504,0.0002995582,0.047022466],"study_design_scores_gemma":[0.95974493,0.0138695305,0.017795876,0.0007456915,0.0013678658,0.000018055673,0.00006339891,0.000059766102,0.0011669458,0.00036012658,0.004702288,0.000105524465],"about_ca_topic_score_codex":0.034757797,"about_ca_topic_score_gemma":0.16201998,"teacher_disagreement_score":0.12726219,"about_ca_system_score_codex":0.00097514485,"about_ca_system_score_gemma":0.027955823,"threshold_uncertainty_score":0.9912087},"labels":[],"label_agreement":null},{"id":"W2098179714","doi":"10.1200/jco.2002.09.038","title":"Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 Years","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Population; Relative risk; Cancer; Confidence interval; Internal medicine; Breast cancer; Thyroid; Esophagus; Gastroenterology","score_opus":0.10419795874937252,"score_gpt":0.44187201657280184,"score_spread":0.3376740578234293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098179714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959225,0.0006059741,0.00005397876,0.0007040252,0.0013138703,0.00031003729,0.000017099126,0.000006690946,0.0010658277],"genre_scores_gemma":[0.9969702,0.00017067206,0.00041262808,0.0014689864,0.0005562493,0.000004844732,0.000026446856,0.000018577683,0.00037144503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615026,0.00055830047,0.0021900188,0.00020479214,0.00069632375,0.0002002891],"domain_scores_gemma":[0.99553806,0.0014180548,0.0019291872,0.00025701293,0.00040467226,0.00045303407],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027930713,0.00013524141,0.0011133412,0.00019771843,0.000026591619,0.000007684517,0.00013938708,0.00027636203,0.010294772],"category_scores_gemma":[0.0018344274,0.0001093052,0.00057482044,0.00013842132,0.00015089348,0.00017004069,0.000021486741,0.0005464093,0.000012018027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015019622,0.0007052633,0.9199517,0.00007803504,0.00019886081,0.00029088452,0.00005762375,0.00024278685,0.000059601545,0.000008614366,0.001662795,0.07524191],"study_design_scores_gemma":[0.008544686,0.002319414,0.9799295,0.00014830762,0.00048764324,0.000023945859,0.000011538315,0.0058798916,0.00002095774,0.000040567673,0.002491769,0.00010179286],"about_ca_topic_score_codex":0.00006301063,"about_ca_topic_score_gemma":0.00047881005,"teacher_disagreement_score":0.07514012,"about_ca_system_score_codex":0.00028253417,"about_ca_system_score_gemma":0.0012284431,"threshold_uncertainty_score":0.99060994},"labels":[],"label_agreement":null},{"id":"W2098251455","doi":"10.1200/jco.2008.16.8310","title":"Performance of<i>BRCA1/2</i>Mutation Prediction Models in Asian Americans","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institutes of Health; Breast Cancer Research Foundation","keywords":"Mutation; Medicine; Genetics; Breast cancer; Cancer; Oncology; White (mutation); Internal medicine; Biology; Gene","score_opus":0.08448750865067332,"score_gpt":0.4060021244815839,"score_spread":0.32151461583091057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098251455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918992,0.00024184465,0.002566898,0.0005156158,0.0006742324,0.00007173116,0.0000052757255,0.00000195962,0.0040232255],"genre_scores_gemma":[0.99046654,0.0018471156,0.0067662033,0.000287307,0.0005322412,0.00000438979,0.0000071903974,0.000009886222,0.000079156925],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99793565,0.00020815004,0.0014180895,0.00014020919,0.00017657471,0.00012131722],"domain_scores_gemma":[0.9983416,0.00009679516,0.0010429495,0.00014301251,0.0002986362,0.000076979755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010264531,0.00007596305,0.00042316387,0.00009157662,0.000025704308,0.0000014524339,0.00015995282,0.00025615256,0.000011108214],"category_scores_gemma":[0.00049151573,0.00006784462,0.00016657205,0.00014209008,0.00023931405,0.000016140495,0.00003024587,0.00029479672,0.0000018641834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051946486,0.002267539,0.35548523,0.000057035046,0.0005054441,0.00017555813,0.0012033512,0.14448634,0.030553501,0.0001064065,0.010385783,0.44957915],"study_design_scores_gemma":[0.008703214,0.024569029,0.89121836,0.00008240654,0.00013479515,0.0013239004,0.00050246215,0.021253843,0.016522592,0.0006265127,0.034755778,0.00030713013],"about_ca_topic_score_codex":0.000009261626,"about_ca_topic_score_gemma":0.000024291214,"teacher_disagreement_score":0.5357331,"about_ca_system_score_codex":0.00008248921,"about_ca_system_score_gemma":0.0014532511,"threshold_uncertainty_score":0.27666232},"labels":[],"label_agreement":null},{"id":"W2098291266","doi":"10.1200/jco.2014.55.7454","title":"Systemic Treatment of Endometrial Cancer: What Is Doxorubicin's Role?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University","keywords":"Medicine; Endometrial cancer; Doxorubicin; Oncology; Cancer; Internal medicine; Systemic therapy; Gynecology; Chemotherapy; Breast cancer","score_opus":0.14492943697943503,"score_gpt":0.4666326936679015,"score_spread":0.32170325668846644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098291266","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042737085,0.08124576,0.000031854484,0.8484596,0.022607362,0.0014458224,0.000103767095,0.000025986945,0.0033427812],"genre_scores_gemma":[0.11490796,0.1849677,0.00066312065,0.6008076,0.09490452,0.000067788234,0.00006444866,0.00013248854,0.0034843632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99074584,0.001094537,0.005876919,0.00049755466,0.0012578773,0.00052725425],"domain_scores_gemma":[0.981809,0.008570615,0.007528229,0.00055668346,0.0010230358,0.00051242084],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018699018,0.00054187106,0.0082022175,0.0007702933,0.00003693382,0.000027587177,0.00039229746,0.002801286,0.0011519885],"category_scores_gemma":[0.0017018002,0.0003257971,0.0032653844,0.0005066142,0.00028642625,0.0001552419,0.000051151746,0.0023456477,0.00005989392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013998271,0.0023067065,0.0071237413,0.0004686493,0.006841926,0.0032917412,0.00011954195,0.00000304249,0.00009389081,0.0000040814425,0.28176847,0.6839799],"study_design_scores_gemma":[0.04153241,0.059131056,0.00081285194,0.0013583369,0.0059086345,0.0010175416,0.00006540957,0.000004866042,0.00040108972,0.00013810978,0.8894145,0.00021522799],"about_ca_topic_score_codex":0.00037575865,"about_ca_topic_score_gemma":0.0000144655105,"teacher_disagreement_score":0.6837647,"about_ca_system_score_codex":0.0013536798,"about_ca_system_score_gemma":0.0034149573,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W2098447106","doi":"10.1200/jco.2004.06.111","title":"Pattern of Care at the End of Life: Does Age Make a Difference in What Happens to Women With Breast Cancer?","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Palliative care; Breast cancer; Odds ratio; End-of-life care; Odds; Cancer; Family medicine; Health care; Ordered logit; Logistic regression; Population; Demography; Gerontology; Nursing; Internal medicine; Environmental health","score_opus":0.1598639317049944,"score_gpt":0.49596455989168886,"score_spread":0.33610062818669445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098447106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98685294,0.0014453161,0.000033504937,0.010940228,0.00030790945,0.00014686232,0.000031926356,0.0000015708715,0.00023974586],"genre_scores_gemma":[0.9937134,0.0037400373,0.00027619794,0.0018977695,0.00027146377,0.000005836772,8.6746473e-7,0.000008956941,0.00008549175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977848,0.0001733243,0.0013932643,0.0001262622,0.00033326884,0.00018908206],"domain_scores_gemma":[0.99688715,0.0011374346,0.0011376939,0.00017672818,0.0004250205,0.00023597783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006807586,0.00010994815,0.0014229008,0.00008313377,0.000012113817,0.0000033357694,0.00018554935,0.00015400194,0.0001365747],"category_scores_gemma":[0.00063459785,0.000051242263,0.00015231608,0.00013659496,0.00036916512,0.000047478417,0.0000710762,0.00041746296,0.0000012266868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074166264,0.0005451681,0.81928724,0.00018826562,0.00028079195,0.0003317843,0.01232167,0.00009230484,0.000854055,0.000011177781,0.00007286883,0.15859802],"study_design_scores_gemma":[0.006854767,0.009424895,0.9604993,0.0030596154,0.0001303775,0.000053095988,0.013010384,0.0000012956464,0.0010768826,0.000076051125,0.0057390956,0.00007423947],"about_ca_topic_score_codex":0.0005642655,"about_ca_topic_score_gemma":0.010767301,"teacher_disagreement_score":0.15852378,"about_ca_system_score_codex":0.0002843476,"about_ca_system_score_gemma":0.0010683229,"threshold_uncertainty_score":0.6008406},"labels":[],"label_agreement":null},{"id":"W2098523473","doi":"10.1200/jco.2007.11.8612","title":"Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Lapatinib; Adenoid cystic carcinoma; Internal medicine; Epidermal growth factor receptor; Rash; Gastroenterology; Carcinoma; Oncology; Progressive disease; Pathology; Cancer; Chemotherapy; Breast cancer; Trastuzumab","score_opus":0.11172778718905706,"score_gpt":0.42763774448452185,"score_spread":0.3159099572954648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098523473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637383,0.0013437524,0.000024261055,0.0006073963,0.00067108154,0.0008886198,0.000042928707,0.0000048146276,0.000043287182],"genre_scores_gemma":[0.9980111,0.00021403296,0.00116457,0.00020149827,0.0003298213,0.000016299075,0.000004813265,0.00002934308,0.000028539143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936981,0.0010189196,0.003937583,0.00036783773,0.00057106465,0.0004064727],"domain_scores_gemma":[0.9897168,0.006657556,0.0025687132,0.00029314187,0.00030780412,0.00045593482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031537325,0.0003245052,0.0025766888,0.00030308595,0.000095168885,0.000009749461,0.00021401253,0.00018160915,0.00009066787],"category_scores_gemma":[0.00431053,0.00016357974,0.00029034648,0.0003100999,0.0003166335,0.000118759664,0.0001847498,0.00076654553,7.0882413e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026136639,0.021665862,0.9324224,0.00032621532,0.00037241256,0.0042066816,0.002815391,0.0000023528721,0.0004965338,0.0000096210915,0.00014389309,0.01140198],"study_design_scores_gemma":[0.039293103,0.1018798,0.8520952,0.00074930897,0.0010759175,0.0012431556,0.002081676,0.00007671697,0.0012820611,0.00003291075,0.000042386102,0.00014779688],"about_ca_topic_score_codex":0.00022542874,"about_ca_topic_score_gemma":0.00020281122,"teacher_disagreement_score":0.08032725,"about_ca_system_score_codex":0.0001321674,"about_ca_system_score_gemma":0.00091663544,"threshold_uncertainty_score":0.6670588},"labels":[],"label_agreement":null},{"id":"W2098564635","doi":"10.1200/jco.2014.59.2360","title":"Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Guideline; Medicine; Radiation therapy; Chemoradiotherapy; Clinical Oncology; Oncology; Lung cancer; Intensive care medicine; Internal medicine; Family medicine; Cancer; Pathology","score_opus":0.1794983877534998,"score_gpt":0.5643380757702662,"score_spread":0.3848396880167664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098564635","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6253934,0.018426256,0.018817889,0.32575694,0.0059335986,0.0047617857,0.00009799719,0.000029359013,0.00078278926],"genre_scores_gemma":[0.18376139,0.1613055,0.5331704,0.117580295,0.0038621167,0.00018120855,0.000021042768,0.0000807821,0.000037241818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9724493,0.0064901286,0.018099772,0.001065511,0.0011775516,0.00071773276],"domain_scores_gemma":[0.8801535,0.08195501,0.02937655,0.0008036252,0.006530216,0.0011811161],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.055120863,0.0005511507,0.0074689602,0.00013493655,0.000091527334,0.000015017477,0.0006200007,0.001060222,0.000026684333],"category_scores_gemma":[0.0599922,0.0003750043,0.003747815,0.00071025564,0.0029573848,0.0003955346,0.00023613538,0.0030343952,0.0000014323267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040301003,0.015296801,0.2545335,0.000108845365,0.0028898348,0.00011357223,0.0003403997,0.00079366093,0.000043741897,0.000024508488,0.104350455,0.58120364],"study_design_scores_gemma":[0.06981087,0.11576468,0.09626482,0.0007503494,0.0061438563,0.00013070002,0.0038721813,0.015587184,0.00009204262,0.000041099658,0.6911904,0.00035182326],"about_ca_topic_score_codex":0.0012059587,"about_ca_topic_score_gemma":0.00062495394,"teacher_disagreement_score":0.5868399,"about_ca_system_score_codex":0.0024767758,"about_ca_system_score_gemma":0.033233844,"threshold_uncertainty_score":0.9998702},"labels":[],"label_agreement":null},{"id":"W2098604043","doi":"10.1200/jco.2008.18.5066","title":"Treatment Considerations for Gallbladder Cancer Should Include Extent of Surgery","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gallbladder cancer; General surgery; Cancer surgery; Gallbladder; Cancer; Surgery; Oncology; Internal medicine","score_opus":0.4387718535589511,"score_gpt":0.49732835013770693,"score_spread":0.058556496578755834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098604043","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020491654,0.012695453,0.000050145798,0.95959175,0.00499907,0.00069848064,0.00013191676,0.00001198237,0.0013295544],"genre_scores_gemma":[0.09821303,0.048259776,0.0038417992,0.8034493,0.042207737,0.000206999,0.00006718946,0.00011967403,0.0036345227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99451905,0.0003136484,0.0039350344,0.00032343512,0.0005409665,0.00036786028],"domain_scores_gemma":[0.98100764,0.013603223,0.0034433824,0.00031444215,0.0014186522,0.00021267222],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009110873,0.0003473972,0.004615579,0.0002993427,0.00009042819,0.000007003752,0.000109475455,0.001359275,0.00028099213],"category_scores_gemma":[0.003533246,0.00023249806,0.0026657865,0.000089363675,0.00043341753,0.00005665563,0.000049638682,0.0017525408,0.0000034220252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012101977,0.0009377796,0.029427497,0.0001737004,0.003617289,0.0029949006,0.00017845783,0.000004289984,0.000014974751,0.0000050657345,0.9476299,0.013805917],"study_design_scores_gemma":[0.005386555,0.006669784,0.052551106,0.00025947054,0.0028658868,0.0013470172,0.000037854443,0.0000064258606,0.00006513505,0.00018288044,0.9304387,0.00018917021],"about_ca_topic_score_codex":0.00014328184,"about_ca_topic_score_gemma":0.00014962022,"teacher_disagreement_score":0.15614247,"about_ca_system_score_codex":0.0005219474,"about_ca_system_score_gemma":0.008080544,"threshold_uncertainty_score":0.9999372},"labels":[],"label_agreement":null},{"id":"W2098651514","doi":"10.1200/jco.2008.20.3034","title":"Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; Neuroendocrine tumors; Internal medicine; Oncology; Cancer research; Cancer","score_opus":0.08749128159331225,"score_gpt":0.44348474358130463,"score_spread":0.35599346198799237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098651514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8117446,0.00007986147,0.00000202466,0.18573466,0.0006149478,0.0005623268,0.000018745262,0.00000922828,0.001233662],"genre_scores_gemma":[0.8152844,0.0016617527,0.0019134408,0.17629494,0.0036474215,0.000015015069,0.000033239812,0.00014832547,0.0010014955],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99266917,0.0012235838,0.003474418,0.00042482407,0.0015212841,0.00068674685],"domain_scores_gemma":[0.98852074,0.004548697,0.0048748613,0.00049126055,0.001188739,0.0003757061],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006068624,0.00038366436,0.0044041807,0.00069911993,0.00002462057,0.00000440446,0.00047310742,0.00012668883,0.00010326283],"category_scores_gemma":[0.009013385,0.00026322412,0.0006145246,0.00040893277,0.0007563056,0.00024710418,0.00014476047,0.009981688,0.000007750727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036422703,0.005694769,0.3161275,0.00053327973,0.00037471126,0.32435474,0.000012193768,0.000029625433,0.00003607562,0.0000016968933,0.2593119,0.0571008],"study_design_scores_gemma":[0.022125997,0.059171207,0.42206454,0.0005609554,0.0001559035,0.004808012,0.0000070149786,0.000002499886,0.00021124148,0.000026820453,0.4906643,0.00020149972],"about_ca_topic_score_codex":0.000022370716,"about_ca_topic_score_gemma":0.000024140576,"teacher_disagreement_score":0.31954673,"about_ca_system_score_codex":0.00019712835,"about_ca_system_score_gemma":0.0029086845,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W2098753081","doi":"10.1200/jco.2005.03.2235","title":"Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":543,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Survivorship curve; Quality of life (healthcare); Cancer; Clinical trial; Stage (stratigraphy); Internal medicine; Hormonal therapy; Pediatrics","score_opus":0.09056362573536841,"score_gpt":0.4567536643190786,"score_spread":0.3661900385837102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098753081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918098,0.0020936476,0.00022381323,0.00038734725,0.0035585053,0.0005486934,0.00023831084,0.0000024368308,0.0011374357],"genre_scores_gemma":[0.9948588,0.00053018675,0.00038362437,0.000100329096,0.003953002,0.000033886387,0.000036042806,0.00001938075,0.00008473626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967277,0.00036410708,0.0022327723,0.00021908528,0.00024445957,0.00021189128],"domain_scores_gemma":[0.9949995,0.00090369536,0.0030562605,0.00019650947,0.0007610219,0.0000829803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077359396,0.00018919406,0.002379026,0.000052364874,0.000044178414,0.0000057210373,0.00024083145,0.00031298312,0.0000072960925],"category_scores_gemma":[0.00037259213,0.0001450741,0.0013596596,0.00006743315,0.0004725525,0.0000073103784,0.00006747342,0.00018987509,4.658413e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94063824,0.0012469456,0.023683092,0.000051433606,0.0013383557,0.000007476472,0.000089613706,0.000039393046,0.0009613514,0.000058260117,0.0012869244,0.030598909],"study_design_scores_gemma":[0.8924003,0.0072591677,0.09263878,0.000057007615,0.0010503812,0.0000026047696,0.00019207619,0.0000036732117,0.0028815393,0.00003181287,0.0033459582,0.00013669436],"about_ca_topic_score_codex":0.00034071985,"about_ca_topic_score_gemma":0.0006898838,"teacher_disagreement_score":0.0689557,"about_ca_system_score_codex":0.00008014643,"about_ca_system_score_gemma":0.0007341913,"threshold_uncertainty_score":0.591595},"labels":[],"label_agreement":null},{"id":"W2098794292","doi":"10.1200/jco.2006.06.0137","title":"Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Institute of Health Economics; Health Sciences Centre; Hospital for Sick Children; Juravinski Cancer Centre; University of Alberta; McMaster Children's Hospital","funders":"Natural Sciences and Engineering Research Council of Canada; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Medicine; Hazard ratio; Quality of life (healthcare); Internal medicine; Population; Physical therapy; Gerontology; Confidence interval","score_opus":0.07743669874333582,"score_gpt":0.4191428658932841,"score_spread":0.3417061671499483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098794292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98641324,0.00073555874,0.000022491946,0.0064976867,0.0017601638,0.00028019134,0.000016571383,0.000011770427,0.0042623216],"genre_scores_gemma":[0.9963149,0.0003977471,0.00018493882,0.0014624511,0.0011923201,0.0000079169995,0.00001110071,0.000026042106,0.00040261436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493456,0.000714165,0.0026840328,0.00022760754,0.0010423816,0.0003972435],"domain_scores_gemma":[0.993813,0.0017453963,0.002852852,0.00021879625,0.00071495725,0.0006549994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003656522,0.00017371133,0.0019928536,0.00013929616,0.000045498822,0.000004734831,0.00014334358,0.00024380288,0.00018110045],"category_scores_gemma":[0.0019732856,0.00011920434,0.0004264217,0.00022309336,0.00033460403,0.0000876484,0.000046967856,0.0006765395,0.000005341432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00821585,0.0012029969,0.96085036,0.00010578799,0.00026295902,0.00017870868,0.00032854782,0.000022215569,0.000008266008,0.000014337556,0.012785525,0.016024457],"study_design_scores_gemma":[0.009457329,0.023426766,0.9360418,0.0005887764,0.00018220773,0.00007660788,0.00041037175,0.0000036879303,0.00012439693,0.000034880082,0.029556306,0.00009689972],"about_ca_topic_score_codex":0.005551508,"about_ca_topic_score_gemma":0.035716165,"teacher_disagreement_score":0.030164657,"about_ca_system_score_codex":0.0005193078,"about_ca_system_score_gemma":0.002874241,"threshold_uncertainty_score":0.9818795},"labels":[],"label_agreement":null},{"id":"W2098838369","doi":"10.1200/jco.2014.56.2116","title":"Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Seminoma; Medicine; Lymphovascular invasion; Orchiectomy; Internal medicine; Stage (stratigraphy); Oncology; Cancer; Chemotherapy; Metastasis","score_opus":0.047324014141105646,"score_gpt":0.4218944034028319,"score_spread":0.37457038926172626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098838369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983211,0.00010943453,0.00024597562,0.0005600989,0.00025205174,0.00028174516,0.000021181357,0.0000054106936,0.00020300857],"genre_scores_gemma":[0.997489,0.00014817307,0.0015643084,0.0005067396,0.00019342107,0.0000049358973,0.000007004823,0.00002050822,0.00006592038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679667,0.00063215033,0.0017074673,0.00023050037,0.0004315134,0.00020171724],"domain_scores_gemma":[0.99451387,0.0021452634,0.002166346,0.00025405188,0.000555133,0.0003653605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013880902,0.00015250054,0.001548781,0.00008615777,0.000016065454,0.0000034774428,0.000113273134,0.00020077852,0.000061380815],"category_scores_gemma":[0.0029139046,0.00008557836,0.0002472663,0.00012838792,0.00015900971,0.00007257512,0.000031911077,0.0006808513,0.00000284848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011873184,0.0048808074,0.9229392,0.00005474296,0.0006212663,0.0005326427,0.000015986774,0.00008013733,4.8528136e-7,0.000017765447,0.000036116086,0.05894768],"study_design_scores_gemma":[0.028501743,0.02387309,0.9455064,0.0003849276,0.00048142928,0.0000141850805,0.000028823237,0.000057700097,0.0000031646332,0.000016991866,0.0010440749,0.00008747199],"about_ca_topic_score_codex":0.00010687468,"about_ca_topic_score_gemma":0.00035100206,"teacher_disagreement_score":0.05886021,"about_ca_system_score_codex":0.00010019831,"about_ca_system_score_gemma":0.00075034465,"threshold_uncertainty_score":0.34897843},"labels":[],"label_agreement":null},{"id":"W2098876365","doi":"10.1200/jco.2010.28.1717","title":"Reply to C.D. Atkins","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Industries (Canada); Queen's University; McMaster University","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.9099255798320264,"score_gpt":0.7133705965776655,"score_spread":0.19655498325436083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098876365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8363412,0.00008826363,0.006872606,0.07712234,0.0092803985,0.00025462706,0.0000021947494,0.000001980385,0.070036374],"genre_scores_gemma":[0.8837217,0.000025394329,0.06559101,0.033725534,0.0029111179,0.0000026487548,1.7242532e-7,0.000009568594,0.014012823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.93856394,0.014019119,0.041614316,0.00057877175,0.004967728,0.0002561433],"domain_scores_gemma":[0.87796646,0.068031475,0.041859705,0.0042169755,0.006450869,0.0014745258],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.43121767,0.00014244119,0.0069271373,0.000329765,0.00005240926,0.0001837825,0.0024688186,0.00026200712,0.016734703],"category_scores_gemma":[0.5551718,0.000057654088,0.004167224,0.00070873456,0.000101633195,0.00017238072,0.00015312254,0.0011748226,0.0066067358],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006432153,0.00023252063,0.045232058,0.0000018211101,0.00015120534,0.00007207225,0.000071798866,0.000011255997,0.000101996004,0.0016712126,0.6500813,0.30230847],"study_design_scores_gemma":[0.00034731417,0.0010906368,0.09893955,0.0000054663496,0.00012608306,0.00012504225,0.000069370086,0.00009170237,0.000007016245,0.0065589165,0.8925826,0.00005630286],"about_ca_topic_score_codex":0.000005878549,"about_ca_topic_score_gemma":0.00007958484,"teacher_disagreement_score":0.30225217,"about_ca_system_score_codex":0.000018696126,"about_ca_system_score_gemma":0.0007320168,"threshold_uncertainty_score":0.99416673},"labels":[],"label_agreement":null},{"id":"W2099000973","doi":"10.1200/jco.2013.53.2820","title":"Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":655,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Ontario Ministry of Research and Innovation; National Institutes of Health; Canadian Breast Cancer Research Alliance","keywords":"Medicine; Ovarian cancer; Oophorectomy; Fallopian tube cancer; Fallopian tube; Hazard ratio; Gynecology; Incidence (geometry); Cancer; Cancer registry; Breast cancer; Obstetrics; Internal medicine; Hysterectomy; Surgery; Confidence interval","score_opus":0.0489739280017047,"score_gpt":0.4498662731099562,"score_spread":0.4008923451082515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099000973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985824,0.00020816308,0.00024207271,0.0003097583,0.00022267041,0.00010010128,0.0000068810314,0.0000013422022,0.0003265984],"genre_scores_gemma":[0.99715036,0.0006744201,0.0009900909,0.00077318115,0.00035563394,0.000015384085,0.0000013591747,0.000011766632,0.000027786093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980672,0.00035790587,0.0010198222,0.00020185806,0.0001842505,0.00016895271],"domain_scores_gemma":[0.9978792,0.00043245504,0.0010885777,0.00017428989,0.00028667657,0.00013878601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020043766,0.00011390297,0.0006033838,0.000069508926,0.000016845761,0.000005972938,0.00015108132,0.00023695691,0.000032332602],"category_scores_gemma":[0.0013542813,0.00007213266,0.00009708375,0.00014350482,0.00023170626,0.000010004315,0.00003898688,0.00030420208,5.886516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02139317,0.000983385,0.75571436,0.000044529264,0.00070110895,0.00007689205,0.00041594027,0.0060414607,0.01478426,0.000022575563,0.0017266697,0.19809563],"study_design_scores_gemma":[0.0045902636,0.023359418,0.96474135,0.000071581104,0.00005303288,0.00009488363,0.00007281532,0.00010877719,0.002536712,0.00022936278,0.004020551,0.000121267156],"about_ca_topic_score_codex":0.00009923504,"about_ca_topic_score_gemma":0.0007510552,"teacher_disagreement_score":0.20902696,"about_ca_system_score_codex":0.00019366477,"about_ca_system_score_gemma":0.0020896846,"threshold_uncertainty_score":0.37070107},"labels":[],"label_agreement":null},{"id":"W2099088585","doi":"10.1200/jco.2008.20.1293","title":"Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2189,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Canada; Genentech; GlaxoSmithKline; American Society of Clinical Oncology; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Hazard ratio; Discontinuation; Alpha interferon; Adverse effect; Clinical endpoint; Gastroenterology; Log-rank test; Progression-free survival; Oncology; Urology; Proportional hazards model; Randomized controlled trial; Confidence interval; Interferon; Overall survival; Immunology","score_opus":0.10192842348918427,"score_gpt":0.387397130270231,"score_spread":0.28546870678104674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099088585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478686,0.00009036394,0.000087343615,0.0022219243,0.00014221757,0.0005943442,0.000023705035,0.000005436068,0.0020478256],"genre_scores_gemma":[0.99158734,0.000017291608,0.0074549695,0.0005529053,0.00014251041,0.0000034243574,0.00007915462,0.000017163953,0.00014524852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671507,0.00041149466,0.0019332273,0.00026922132,0.00037679635,0.00029416202],"domain_scores_gemma":[0.99624157,0.001256617,0.0013502339,0.00019196208,0.00057950825,0.0003801118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015287428,0.00021561373,0.0016420396,0.00018082921,0.0000273663,0.000012202513,0.00010695068,0.00013940304,0.000013939042],"category_scores_gemma":[0.00036791043,0.00012557046,0.00015326426,0.0001267949,0.00014086333,0.00011175522,0.000020543968,0.00061563606,0.000001386394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45899075,0.009434829,0.5069016,0.00007919635,0.0005341464,0.0023194288,0.00035916857,0.00011402666,0.00016084572,0.00006274344,0.0030816137,0.017961647],"study_design_scores_gemma":[0.07816819,0.12153137,0.79708445,0.00010586823,0.0005100859,0.000100508965,0.00009108274,0.00007528416,0.00019587428,0.00006147391,0.001961788,0.000114035254],"about_ca_topic_score_codex":0.000035090696,"about_ca_topic_score_gemma":0.00013249354,"teacher_disagreement_score":0.38082257,"about_ca_system_score_codex":0.0001880098,"about_ca_system_score_gemma":0.00062781706,"threshold_uncertainty_score":0.5120615},"labels":[],"label_agreement":null},{"id":"W2099192919","doi":"10.1200/jco.2010.31.9897","title":"Trends in the Aggressiveness of End-of-Life Cancer Care in the Universal Health Care System of Ontario, Canada","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":419,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Emergency department; Cancer; Retrospective cohort study; Intensive care unit; Emergency medicine; Health care; Comorbidity; Population; Cancer registry; End-of-life care; Odds ratio; Cohort; Palliative care; Internal medicine; Environmental health; Nursing","score_opus":0.3003416377299417,"score_gpt":0.515043720142865,"score_spread":0.21470208241292332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099192919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822942,0.01080821,0.0000034031464,0.0014955474,0.0006580623,0.00012789897,0.000040069805,8.4219346e-7,0.0045717508],"genre_scores_gemma":[0.998174,0.0008009011,0.0002150272,0.0006144453,0.00016398191,0.0000023174655,0.0000046455216,0.000006142544,0.000018524792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961805,0.0009719182,0.0020981058,0.000107012216,0.00046488416,0.0001776017],"domain_scores_gemma":[0.9947001,0.0016226394,0.0027677608,0.00021140168,0.00058256707,0.00011553556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016048547,0.00010899208,0.001624876,0.00016415896,0.000015423893,7.0138213e-7,0.00036901387,0.00017629753,0.00007700672],"category_scores_gemma":[0.0005748094,0.00005922807,0.0002642207,0.00026611506,0.00022335368,0.000035140656,0.00002872139,0.0006729831,7.348639e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030259402,0.00033700024,0.8792395,0.000511975,0.00020435781,0.00042487413,0.07814586,0.000044455064,0.0000053054014,0.00021333325,0.0012922598,0.03655516],"study_design_scores_gemma":[0.005562362,0.005824428,0.8162889,0.00283366,0.0002177672,0.000029272805,0.1327926,0.0000039978813,0.00013032673,0.0000064029928,0.03624356,0.000066730994],"about_ca_topic_score_codex":0.8624344,"about_ca_topic_score_gemma":0.97632325,"teacher_disagreement_score":0.113888875,"about_ca_system_score_codex":0.0010558527,"about_ca_system_score_gemma":0.019474749,"threshold_uncertainty_score":0.9860839},"labels":[],"label_agreement":null},{"id":"W2099244512","doi":"10.1200/jco.2012.45.0544","title":"Policy Directives in Cancer, Organizational Responses, and the Need for Evaluation","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Veterans Affairs; Colonoscopy; Psychological intervention; Colorectal cancer; Family medicine; Directive; Cancer; Nursing; Internal medicine","score_opus":0.15958158591452337,"score_gpt":0.5147413609373219,"score_spread":0.35515977502279855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099244512","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04952244,0.003945285,0.00015143075,0.9425725,0.0022847746,0.0007076311,0.000011101871,0.0000065932263,0.0007982777],"genre_scores_gemma":[0.35991976,0.0031860038,0.001187688,0.56886566,0.06493644,0.00014306016,0.000028562486,0.000058020953,0.0016748233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964883,0.0014004797,0.001355305,0.00014971962,0.00042831508,0.00017791675],"domain_scores_gemma":[0.9884255,0.008881808,0.0015501326,0.00010390787,0.00095079176,0.00008786439],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008597544,0.00012441409,0.001150391,0.0003074044,0.000046686622,0.000009872415,0.00008562419,0.00086333137,0.000053062275],"category_scores_gemma":[0.025221823,0.0000746245,0.00026015477,0.00024784094,0.0002472903,0.00006193347,0.000028767501,0.0020051764,8.546239e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15935718,0.0003496635,0.024480008,0.0001310117,0.0007817981,0.00005672607,0.0004920088,0.000019249419,0.000019063777,0.00014190539,0.41258195,0.40158942],"study_design_scores_gemma":[0.032176375,0.009752526,0.19641386,0.00022772659,0.00132548,0.0005093009,0.000061910534,0.00060570275,0.000015597285,0.003453848,0.7553186,0.00013910967],"about_ca_topic_score_codex":0.00022284022,"about_ca_topic_score_gemma":0.00014931087,"teacher_disagreement_score":0.40145034,"about_ca_system_score_codex":0.0005085818,"about_ca_system_score_gemma":0.005316694,"threshold_uncertainty_score":0.98298913},"labels":[],"label_agreement":null},{"id":"W2099306472","doi":"10.1200/jco.2003.03.031","title":"Maternal Preoccupation and Parenting as Predictors of Emotional and Behavioral Problems in Children of Women With Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Breast cancer; Medicine; Illness behavior; Disease; Mood; Clinical psychology; Sick child; Cancer; Psychiatry; Pediatrics","score_opus":0.05393827876254349,"score_gpt":0.42060511565413927,"score_spread":0.3666668368915958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099306472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99901885,0.000053274292,0.0000071149716,0.00016902675,0.0002762755,0.00012825154,0.000011132862,0.0000017988532,0.000334254],"genre_scores_gemma":[0.9993308,0.00020784649,0.00028066948,0.000029130413,0.00012290609,0.0000039278507,4.2123852e-7,0.000004672769,0.000019619518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790317,0.00042806912,0.0010577147,0.00010245479,0.000333192,0.00017539397],"domain_scores_gemma":[0.99794066,0.00029697292,0.0013404577,0.00003912884,0.000230716,0.00015209259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003285853,0.00006142182,0.0004916746,0.00008071344,0.000037056732,0.000008021315,0.00008679253,0.00015700565,0.00010134776],"category_scores_gemma":[0.00040933694,0.000046133006,0.000035617228,0.00011046855,0.00049989583,0.00020975122,0.000020183217,0.0002397525,1.2176199e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024895568,0.0003279373,0.9886582,0.000011353018,0.000046371108,0.0000037097088,0.0019366962,0.000034210963,0.000013302639,0.00017887297,0.000012866612,0.008527561],"study_design_scores_gemma":[0.0013978834,0.0012396553,0.995591,0.00009934698,0.000035652727,0.00006087656,0.0009789158,0.000002777294,0.0000106570815,0.0003882435,0.00014958283,0.00004541064],"about_ca_topic_score_codex":0.0019662797,"about_ca_topic_score_gemma":0.001167708,"teacher_disagreement_score":0.008482151,"about_ca_system_score_codex":0.00011684998,"about_ca_system_score_gemma":0.0011994952,"threshold_uncertainty_score":0.29724398},"labels":[],"label_agreement":null},{"id":"W2099309136","doi":"10.1200/jco.2005.04.018","title":"What Health Care Providers Learn As Caregivers","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Daughter; Palliative care; Perspective (graphical); Family member; Nursing; Geriatrics; Independence (probability theory); Family caregivers; Face (sociological concept); Terminally ill; Family medicine; Gerontology; Psychiatry","score_opus":0.12110109305658795,"score_gpt":0.5126315163560258,"score_spread":0.3915304232994378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099309136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50171846,0.01042617,0.000043499407,0.47695535,0.0047170804,0.0003507535,0.0000018574439,0.000029699579,0.0057571228],"genre_scores_gemma":[0.8822118,0.0063492516,0.004885442,0.09796337,0.0071830237,0.0000024138976,0.000004833359,0.000036813602,0.0013630191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99488187,0.0008728881,0.002886662,0.00025989342,0.000738351,0.00036035167],"domain_scores_gemma":[0.99407166,0.0016472362,0.002431065,0.000294434,0.00060381176,0.0009517793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040764054,0.00016681443,0.0018804077,0.00014002356,0.00007140405,0.00002935983,0.00023560502,0.00037609023,0.00027955073],"category_scores_gemma":[0.0042089154,0.00013379577,0.0007448153,0.00013208241,0.00026669278,0.0004979744,0.000058127014,0.0016171319,0.00012479897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003629362,0.001027803,0.01001928,0.0001726049,0.00046887505,0.000359675,0.015831053,0.00005332428,0.000005324746,0.00012231366,0.110907696,0.8574027],"study_design_scores_gemma":[0.008539512,0.017800191,0.01925844,0.00039012992,0.00017156478,0.0005673254,0.03445753,0.00000682561,0.000022039512,0.00007766716,0.9185812,0.00012759576],"about_ca_topic_score_codex":0.00027386652,"about_ca_topic_score_gemma":0.0012751758,"teacher_disagreement_score":0.85727507,"about_ca_system_score_codex":0.0007476833,"about_ca_system_score_gemma":0.00877473,"threshold_uncertainty_score":0.9968446},"labels":[],"label_agreement":null},{"id":"W2099328146","doi":"10.1200/jco.2010.33.7741","title":"Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Oncology; Internal medicine; Cohort; Proportional hazards model; Logistic regression; Radiation therapy","score_opus":0.28991366021873255,"score_gpt":0.45414773177995893,"score_spread":0.16423407156122638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099328146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621666,0.001648298,0.00036719075,0.002863476,0.0060701533,0.0002939954,0.000044187185,0.000008545396,0.026537556],"genre_scores_gemma":[0.9923819,0.00044877338,0.0036880928,0.0006986761,0.0023578512,0.0000048709053,0.0000031809348,0.000012734159,0.00040393925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975044,0.00016736721,0.0017676826,0.00013422586,0.0002482563,0.00017806464],"domain_scores_gemma":[0.99671793,0.0011216003,0.0010797782,0.00012290117,0.0007242032,0.00023358979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020720027,0.00010134199,0.0015393348,0.00008482537,0.000032043212,0.0000011204177,0.00010431872,0.00042962574,0.00012591328],"category_scores_gemma":[0.0016473754,0.000066568544,0.0005447989,0.00007989284,0.00018814004,0.00007073255,0.00002724332,0.0006726069,0.0000023268753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03469123,0.0040384503,0.7337674,0.00030326174,0.0015283717,0.00042652097,0.0012495314,5.592099e-7,0.002068978,0.0013739489,0.085722916,0.13482887],"study_design_scores_gemma":[0.009875486,0.030930115,0.88378364,0.00008547251,0.0005256793,0.000097266595,0.0001828923,0.000038375907,0.0007497458,0.00049503025,0.0731813,0.00005499214],"about_ca_topic_score_codex":0.000008589991,"about_ca_topic_score_gemma":0.000017603592,"teacher_disagreement_score":0.15001628,"about_ca_system_score_codex":0.00006574969,"about_ca_system_score_gemma":0.0010505747,"threshold_uncertainty_score":0.33136672},"labels":[],"label_agreement":null},{"id":"W2099562503","doi":"10.1200/jco.2009.22.1077","title":"Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Saskatchewan Cancer Agency; McMaster University; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Amgen; Queen's University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Epirubicin; Cyclophosphamide; Breast cancer; Internal medicine; Febrile neutropenia; Hazard ratio; Fluorouracil; Chemotherapy; Doxorubicin; Gastroenterology; Oncology; Cancer; Neutropenia; Confidence interval","score_opus":0.04116585421662357,"score_gpt":0.40403025614598265,"score_spread":0.3628644019293591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099562503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517917,0.018566633,0.00002369134,0.023750503,0.003150884,0.0012313403,0.0006531342,0.00005463468,0.0007774568],"genre_scores_gemma":[0.9307961,0.060084343,0.0017292189,0.0055813226,0.0008333225,0.000057359244,0.000046537127,0.00009557536,0.00077622675],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99133694,0.0013179595,0.0039434237,0.0012976759,0.000828895,0.0012751329],"domain_scores_gemma":[0.98267424,0.01163754,0.0029808392,0.00044923605,0.00064471853,0.0016134079],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0030756097,0.0010517198,0.0044862777,0.000366934,0.00030176807,0.00006977545,0.00032146898,0.0012966227,0.00032484965],"category_scores_gemma":[0.003136309,0.0008105802,0.000570207,0.00071458827,0.0011303745,0.00058973813,0.00019141425,0.0027134477,0.000013260852],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41556364,0.0061129835,0.31567124,0.0001251674,0.0038058122,0.0046473984,0.0017160798,0.00004019644,0.008063934,0.000083405204,0.07731989,0.16685025],"study_design_scores_gemma":[0.17710459,0.042269774,0.75966364,0.00055816985,0.0041647563,0.0006625016,0.0010143971,0.00011829836,0.0026008764,0.0005256223,0.010263982,0.0010533895],"about_ca_topic_score_codex":0.00518928,"about_ca_topic_score_gemma":0.0025584593,"teacher_disagreement_score":0.4439924,"about_ca_system_score_codex":0.0011665208,"about_ca_system_score_gemma":0.0016031102,"threshold_uncertainty_score":0.9999999},"labels":[],"label_agreement":null},{"id":"W2099565861","doi":"10.1200/jco.2009.24.9060","title":"Panhypopituitarism Secondary to Hypothalamic Involvement in a Woman With Diffuse Large B-Cell Lymphoma","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Pathology; Oncology; Internal medicine","score_opus":0.04202048376874501,"score_gpt":0.3584886170432175,"score_spread":0.3164681332744725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099565861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988351,0.00013983314,0.000067297064,0.004925045,0.0013346102,0.00034084916,0.000005051889,0.000014505055,0.004821824],"genre_scores_gemma":[0.983546,0.00012893051,0.004043339,0.01100494,0.00086185936,0.000009166555,0.0000040661957,0.000034778684,0.00036692552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960341,0.00020776568,0.0024642965,0.00030384987,0.00047859762,0.0005113835],"domain_scores_gemma":[0.99663794,0.0008271542,0.0010065619,0.00035931557,0.00031012786,0.00085888506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026643467,0.00023873626,0.001609492,0.000394578,0.000044093635,0.000013990076,0.0002898819,0.00058207463,0.00014012094],"category_scores_gemma":[0.0011628296,0.00016070528,0.00034561398,0.00029121508,0.00014032966,0.00017758954,0.00010710291,0.0020006027,0.00007086969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009317297,0.046815827,0.82421786,0.000118240394,0.00041056523,0.0060517774,0.0016420297,0.0000015628391,0.011240254,0.0002924156,0.016688144,0.08320406],"study_design_scores_gemma":[0.049772426,0.017072625,0.7959216,0.00007287861,0.00016405767,0.00036359983,0.00041935142,0.000019927846,0.000943544,0.00023168845,0.13482186,0.00019643165],"about_ca_topic_score_codex":0.00006149482,"about_ca_topic_score_gemma":0.0006989058,"teacher_disagreement_score":0.118133724,"about_ca_system_score_codex":0.00016254402,"about_ca_system_score_gemma":0.0022453426,"threshold_uncertainty_score":0.86917347},"labels":[],"label_agreement":null},{"id":"W2099700317","doi":"10.1200/jco.2013.52.4280","title":"Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated?","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Adjuvant; Internal medicine; Endocrine system; Hormone","score_opus":0.047870577627921164,"score_gpt":0.4115723396403423,"score_spread":0.3637017620124211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099700317","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62195987,0.020737642,0.0000069455227,0.3536998,0.00266273,0.00056104903,0.00028237465,0.000005232395,0.00008434992],"genre_scores_gemma":[0.2638156,0.12134168,0.00017750997,0.59491,0.017571626,0.00020356316,0.00012030318,0.0001544503,0.0017052448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964911,0.0005811811,0.0018694616,0.0003826177,0.00021697365,0.00045869217],"domain_scores_gemma":[0.99588233,0.0006680859,0.0026657793,0.00020175651,0.0004088689,0.00017320362],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011429681,0.00033614144,0.0018247993,0.00010710101,0.000041490486,0.000021024725,0.0003490015,0.002475205,0.000049062997],"category_scores_gemma":[0.00052165764,0.00022553405,0.0006546063,0.000050385697,0.00015992268,0.000008602887,0.00008630322,0.0026029903,0.0000019548836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013478273,0.0004162636,0.2044092,0.00006549082,0.0016511388,0.0004012667,0.000015724794,0.000024649396,0.0008443789,0.000001789101,0.6575829,0.13323939],"study_design_scores_gemma":[0.009398267,0.00540803,0.0998114,0.00025314305,0.0003077698,0.00029065323,0.000011288979,0.00002397182,0.00016391987,0.0001170964,0.88382816,0.00038632538],"about_ca_topic_score_codex":0.00032215958,"about_ca_topic_score_gemma":0.0002226959,"teacher_disagreement_score":0.35814425,"about_ca_system_score_codex":0.00012172016,"about_ca_system_score_gemma":0.0007573198,"threshold_uncertainty_score":0.99969804},"labels":[],"label_agreement":null},{"id":"W2099752220","doi":"10.1200/jco.2008.21.4809","title":"Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2130,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Bevacizumab; Sorafenib; Proportional hazards model; Cohort; Adverse effect; Oncology; Vascular endothelial growth factor; Cancer; Gastroenterology; Hepatocellular carcinoma; Chemotherapy; VEGF receptors","score_opus":0.07369899872305304,"score_gpt":0.3582692181119489,"score_spread":0.2845702193888959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099752220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637306,0.000058373775,0.00011026461,0.00018266383,0.00024627356,0.002631238,0.00027997766,0.000015223856,0.000102902646],"genre_scores_gemma":[0.9968079,0.000012542322,0.00240161,0.00025228196,0.0002252831,0.000017904369,0.000186377,0.000047082947,0.000049033606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99409544,0.0010218208,0.0027867956,0.0005687625,0.0009617065,0.0005654492],"domain_scores_gemma":[0.99255526,0.0036719097,0.0019482488,0.00035121804,0.00091768027,0.00055569457],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011849839,0.00045598304,0.0024326663,0.00027943673,0.00005441655,0.000022173408,0.00021992726,0.0002224574,0.000043610828],"category_scores_gemma":[0.0027379391,0.00025334078,0.0005212167,0.00020939899,0.000079429636,0.00019044963,0.000030880914,0.00082084874,0.000003573975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068777435,0.024179872,0.90303606,0.000019768928,0.0010702563,0.0014990382,0.00074395834,0.000025779236,0.000049848288,9.524935e-7,0.00006768166,0.00052932766],"study_design_scores_gemma":[0.13299467,0.0960781,0.7680778,0.00008645887,0.001839409,0.000004182816,0.000276701,0.00006554793,0.00024790794,0.0000108301865,0.00012787744,0.00019052096],"about_ca_topic_score_codex":0.00027085064,"about_ca_topic_score_gemma":0.00022179197,"teacher_disagreement_score":0.1349583,"about_ca_system_score_codex":0.00042965123,"about_ca_system_score_gemma":0.0007268643,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W2099786312","doi":"10.1200/jco.2013.53.1517","title":"Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Weight loss; Breast cancer; Randomized controlled trial; Letrozole; Body mass index; Quality of life (healthcare); Telephone counseling; Obesity; Internal medicine; Overweight; Cancer; Gynecology; Physical therapy; Tamoxifen","score_opus":0.04770179124738998,"score_gpt":0.42953149077006797,"score_spread":0.381829699522678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099786312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869055,0.00013701005,0.000283172,0.0091671,0.0023124304,0.0008936689,0.000006323121,0.000004633633,0.0002901393],"genre_scores_gemma":[0.99538994,0.0003683852,0.00015795809,0.00086763245,0.0030627572,0.000057083864,0.0000012650847,0.000016487353,0.000078473895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99429506,0.0018430325,0.0030004496,0.00016566619,0.0004492532,0.00024652138],"domain_scores_gemma":[0.99166685,0.0046644234,0.0029598966,0.00019053239,0.00031782832,0.00020045547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012297569,0.00014969922,0.0025556989,0.00016587552,0.000025870524,0.000009618086,0.0001760405,0.00025983035,0.00047927236],"category_scores_gemma":[0.0030482674,0.00007292667,0.0005106262,0.00020417594,0.00041903177,0.00008375856,0.000026766853,0.0009907694,0.0000014041162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89398754,0.0022222542,0.00616744,0.000025346624,0.0003734398,0.00003969925,0.0001505403,0.000028687558,0.000041212126,0.000013950005,0.00033034486,0.09661954],"study_design_scores_gemma":[0.9278801,0.03489025,0.030374933,0.0003122566,0.00040271968,0.00006390675,0.0000693319,0.00012967567,0.000027842727,0.00006938463,0.0057044346,0.00007515911],"about_ca_topic_score_codex":0.00047391877,"about_ca_topic_score_gemma":0.00039097553,"teacher_disagreement_score":0.096544385,"about_ca_system_score_codex":0.0003385901,"about_ca_system_score_gemma":0.0014918288,"threshold_uncertainty_score":0.52476966},"labels":[],"label_agreement":null},{"id":"W2099920119","doi":"10.1200/jco.2013.50.9539","title":"Cytogenetic Prognostication Within Medulloblastoma Subgroups","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary; McMaster University; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Canadian Institutes of Health Research; Brain Tumour Charity; Cancer Research UK","keywords":"Medulloblastoma; Medicine; Oncology; Internal medicine; Context (archaeology); Fluorescence in situ hybridization; Proportional hazards model; Biomarker; Bioinformatics; Pathology; Biology; Chromosome; Genetics; Gene","score_opus":0.0929370066469264,"score_gpt":0.43973104025051984,"score_spread":0.34679403360359345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099920119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859089,0.00022210536,0.0003505351,0.010070757,0.0009724399,0.00017179624,5.411204e-7,0.000009861175,0.0022930554],"genre_scores_gemma":[0.9899804,0.00010498842,0.0070235482,0.0017235331,0.0011095431,0.0000069178827,0.0000018818885,0.000012520259,0.000036664467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730694,0.00033488576,0.0017552184,0.0001429788,0.00030672047,0.0001532652],"domain_scores_gemma":[0.99567807,0.0020159103,0.0013339582,0.00017930834,0.00040053314,0.00039222406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002549066,0.000100949626,0.00092303427,0.00009715989,0.000027668879,0.000007279524,0.00009949799,0.00024104152,0.00008391083],"category_scores_gemma":[0.006436654,0.000064843174,0.00033220177,0.00010479166,0.0001284602,0.0000435049,0.000023780596,0.00038883818,0.000069639056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015048377,0.005517642,0.6838687,0.000029281435,0.0005095662,0.0004198955,0.00009452434,0.000036741614,0.001316138,0.0021038922,0.0036845084,0.30091426],"study_design_scores_gemma":[0.009441636,0.024825124,0.9121964,0.00011814435,0.0008364818,0.0007708638,0.0000410392,0.00046794902,0.002310656,0.0012284027,0.0476756,0.00008773139],"about_ca_topic_score_codex":0.0000033893775,"about_ca_topic_score_gemma":0.000016583077,"teacher_disagreement_score":0.30082652,"about_ca_system_score_codex":0.000074240495,"about_ca_system_score_gemma":0.00050126016,"threshold_uncertainty_score":0.7705741},"labels":[],"label_agreement":null},{"id":"W2100048800","doi":"10.1200/jco.2003.02.022","title":"Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; Biomarker; Gastroenterology; Stage (stratigraphy); Ovarian carcinoma; Univariate analysis; Disease; Serous fluid; Cancer; Population; Pathology; Oncology; Multivariate analysis","score_opus":0.15378426548702984,"score_gpt":0.44418990291878757,"score_spread":0.29040563743175773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100048800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883791,0.0018473924,0.00048418486,0.0073700654,0.000825661,0.00043973117,0.000007269934,0.000008541896,0.00063804636],"genre_scores_gemma":[0.98989636,0.000263188,0.0075531867,0.00085842976,0.0008464532,0.000009589831,0.0000029288303,0.00002322465,0.00054664264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996806,0.0002505917,0.0022019811,0.00021915683,0.00026096555,0.00026126063],"domain_scores_gemma":[0.9964512,0.0010412665,0.0014704188,0.0001525044,0.00039623323,0.00048840523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021514578,0.00015907298,0.0013090821,0.00015801548,0.00007033366,0.000011792373,0.00010553353,0.00040171464,0.00026301277],"category_scores_gemma":[0.002346653,0.00012370707,0.00063399243,0.00013505691,0.00020513008,0.000105754785,0.000029218345,0.00028902522,0.0000016468771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001105092,0.0012174497,0.8879639,0.00008193478,0.0004474181,0.000112336704,0.00011135474,0.0000023273676,0.00034020114,0.0013834207,0.010361892,0.09687266],"study_design_scores_gemma":[0.011243561,0.008409876,0.9313191,0.00011688857,0.000878616,0.00027747,0.00007407613,0.0000810355,0.00088067236,0.0022595767,0.04434098,0.000118102216],"about_ca_topic_score_codex":0.00006897543,"about_ca_topic_score_gemma":0.000051062078,"teacher_disagreement_score":0.09675455,"about_ca_system_score_codex":0.00004364211,"about_ca_system_score_gemma":0.0010815763,"threshold_uncertainty_score":0.5044628},"labels":[],"label_agreement":null},{"id":"W2100291515","doi":"10.1200/jco.2005.05.4882","title":"Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Letrozole; Bone mineral; Bone resorption; Osteoporosis; N-terminal telopeptide; Bone remodeling; Breast cancer; Urology; Placebo; Internal medicine; Aromatase inhibitor; Tamoxifen; Cancer; Osteocalcin; Alkaline phosphatase","score_opus":0.06697956733410208,"score_gpt":0.466207152004377,"score_spread":0.3992275846702749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100291515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963669,0.000075710086,0.0000024527637,0.0022695935,0.00025970838,0.00083332893,0.000012375467,0.000004390968,0.0001755132],"genre_scores_gemma":[0.9983433,0.000029088907,0.00034576282,0.00075409975,0.0004111221,0.000015533762,0.0000024130572,0.000017209648,0.000081479266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560875,0.0010042867,0.0019855122,0.00021450716,0.000776895,0.00041004125],"domain_scores_gemma":[0.9942916,0.0036196485,0.0011203568,0.00019318219,0.000361428,0.00041375635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057994993,0.00014798268,0.0022545366,0.00026761313,0.000025409709,0.0000034972154,0.00013360365,0.00015673805,0.00006703402],"category_scores_gemma":[0.001022122,0.000095823896,0.00013092758,0.00031981338,0.00018460614,0.000040952636,0.00007634092,0.0010186055,0.0000030125043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46894023,0.00467698,0.47487316,0.00027630592,0.00012262464,0.0012180859,0.00034422782,0.00025821407,0.00096459675,0.000001005004,0.0022383605,0.046086214],"study_design_scores_gemma":[0.04107048,0.08858935,0.86871225,0.0003907,0.00009303424,0.00016934723,0.0003522895,0.000054165997,0.00005532482,7.119587e-7,0.00044270037,0.00006967691],"about_ca_topic_score_codex":0.0008875837,"about_ca_topic_score_gemma":0.0015270524,"teacher_disagreement_score":0.42786974,"about_ca_system_score_codex":0.0006097253,"about_ca_system_score_gemma":0.001564387,"threshold_uncertainty_score":0.44253907},"labels":[],"label_agreement":null},{"id":"W2100367991","doi":"10.1200/jco.2003.11.141","title":"Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; International Prognostic Index; Radiation therapy; Chemotherapy; Anthracycline; Stage (stratigraphy); Lymphoma; Internal medicine; Surgery; Retrospective cohort study; Diffuse large B-cell lymphoma; Cancer; Breast cancer","score_opus":0.10533880825817948,"score_gpt":0.3874672162959088,"score_spread":0.2821284080377293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100367991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970652,0.00047344118,0.000003477628,0.0012804432,0.00045150297,0.0004558104,0.000044192726,0.0000017726844,0.0002241651],"genre_scores_gemma":[0.99908227,0.0002802383,0.00004111783,0.00045405075,0.000059663416,0.000009130527,0.000004100519,0.000010442045,0.000058971946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960257,0.0008116939,0.0023389668,0.00017268897,0.0004725219,0.00017845858],"domain_scores_gemma":[0.992127,0.0061294455,0.0013049067,0.00018730715,0.00014733459,0.000103975486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029178231,0.00014398804,0.0011250084,0.000107164626,0.000019574814,0.0000067582996,0.00028422425,0.00016469129,0.00005383792],"category_scores_gemma":[0.002575416,0.000070786606,0.00023477098,0.00015850352,0.00011842406,0.00006306038,0.00011721272,0.00020882842,9.0051066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051034364,0.0322343,0.9465383,0.000022639422,0.00016499255,0.00018968117,0.00036555086,9.1574077e-7,0.000022699744,0.0000047034355,0.00024781545,0.019698007],"study_design_scores_gemma":[0.030577708,0.0049198004,0.96337354,0.0000948428,0.00015096816,0.00008925051,0.00029230694,0.000046148176,0.000030380557,0.000009193139,0.00036091727,0.000054955868],"about_ca_topic_score_codex":0.0006761654,"about_ca_topic_score_gemma":0.0017912801,"teacher_disagreement_score":0.030067364,"about_ca_system_score_codex":0.0002657151,"about_ca_system_score_gemma":0.00023014423,"threshold_uncertainty_score":0.30831993},"labels":[],"label_agreement":null},{"id":"W2100442263","doi":"10.1200/jco.2010.33.7964","title":"Mammographic Density, Response to Hormones, and Breast Cancer Risk","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Hormone; Oncology; Cancer; Internal medicine; MAMMOGRAPHIC DENSITY; Mammography","score_opus":0.081656805638529,"score_gpt":0.41261505337620374,"score_spread":0.33095824773767474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100442263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945975,0.00051513064,0.00010392559,0.00716317,0.00055070483,0.00009943591,0.000011506344,0.000010876152,0.0020854813],"genre_scores_gemma":[0.9931321,0.0010145417,0.0027129895,0.0025568628,0.0004869892,0.0000016871655,1.8567337e-7,0.000012166914,0.000082463586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.00034589015,0.0011227878,0.0001638934,0.00022929169,0.00021352296],"domain_scores_gemma":[0.9972053,0.0008416566,0.0007136857,0.00014390599,0.0003617151,0.0007337079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003531218,0.000114346585,0.00087944366,0.0003464598,0.00003854348,0.000011351035,0.00011283242,0.0001797334,0.000061521605],"category_scores_gemma":[0.0011750932,0.00007938287,0.00039670532,0.0003046694,0.0002682768,0.00015679389,0.00006253007,0.00068670243,0.000007962915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025029818,0.00055614684,0.62637925,0.0000065668814,0.0002474874,0.00069334026,0.00010210584,1.859372e-7,0.000119250486,0.000026299456,0.001483197,0.34535635],"study_design_scores_gemma":[0.0029090003,0.005942586,0.975107,0.00009206099,0.0004251145,0.005436616,0.00008103997,0.0000041395538,0.000028343404,0.00066003855,0.009230648,0.00008340762],"about_ca_topic_score_codex":0.00010790081,"about_ca_topic_score_gemma":0.000044677556,"teacher_disagreement_score":0.34872773,"about_ca_system_score_codex":0.000030033652,"about_ca_system_score_gemma":0.00048803145,"threshold_uncertainty_score":0.32371396},"labels":[],"label_agreement":null},{"id":"W2100593186","doi":"10.1200/jco.2007.14.4105","title":"Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Urology; Radiation therapy; Prostate; Paclitaxel; Stage (stratigraphy); Nuclear medicine; Cancer; Pelvis; Internal medicine; Surgery","score_opus":0.09147938103282988,"score_gpt":0.47687681399470155,"score_spread":0.3853974329618717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100593186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990851,0.0052909506,0.0000039305196,0.0027624816,0.0003466275,0.0006497711,0.00000958533,0.000004295879,0.00008140167],"genre_scores_gemma":[0.9766646,0.022398401,0.00027164142,0.00042230412,0.00014449732,0.00002683055,0.0000025136053,0.00001132946,0.000057904228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972001,0.00022207006,0.0019777108,0.0001845038,0.00024349253,0.0001721704],"domain_scores_gemma":[0.9974691,0.00050764036,0.0013250924,0.00011668544,0.00033652934,0.00024494852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000993813,0.000120410354,0.0012552582,0.00014541538,0.000038818984,0.000002029315,0.00005149788,0.0001474217,0.000028865694],"category_scores_gemma":[0.0006186795,0.00008465985,0.00012156354,0.0001991874,0.00015080291,0.000120547345,0.000030105368,0.0004005195,6.606613e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009961345,0.02264045,0.51533246,0.000027601252,0.00030231185,0.0013413598,0.0013803522,0.000100781624,0.00020054265,0.0000037290433,0.0004451733,0.44826388],"study_design_scores_gemma":[0.11795538,0.22899516,0.64416146,0.00022412043,0.00037781725,0.00022390489,0.00065374054,0.00013337916,0.00053233845,0.00007188333,0.0065642204,0.000106613275],"about_ca_topic_score_codex":0.00010009403,"about_ca_topic_score_gemma":0.0001467373,"teacher_disagreement_score":0.44815725,"about_ca_system_score_codex":0.00018718431,"about_ca_system_score_gemma":0.0011871592,"threshold_uncertainty_score":0.34523284},"labels":[],"label_agreement":null},{"id":"W2100618270","doi":"10.1200/jco.2011.40.4772","title":"Association Between Colonoscopy and Colorectal Cancer Mortality in a US Cohort According to Site of Cancer and Colonoscopist Specialty","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":346,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Colonoscopy; Cohort; Internal medicine; Cancer; Oncology; Specialty; General surgery; Family medicine","score_opus":0.09175242750999035,"score_gpt":0.4817706951419515,"score_spread":0.3900182676319611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100618270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956697,0.00090428704,0.000018748126,0.0015059492,0.0012379872,0.00033465453,0.000019987581,0.0000061119345,0.000302546],"genre_scores_gemma":[0.99621457,0.0010399753,0.0004344822,0.00038003962,0.0018587654,0.000019716077,0.0000013252372,0.000010138707,0.00004100794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760807,0.0002563142,0.0014080468,0.00016701288,0.00030265297,0.00025792656],"domain_scores_gemma":[0.9965998,0.0012675729,0.0013766178,0.00006400694,0.00029535842,0.0003966632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037975977,0.00011434101,0.0013702065,0.00015143225,0.000037204547,0.000008310804,0.000045788973,0.00036030952,0.000031587184],"category_scores_gemma":[0.002377667,0.00009870449,0.000118417556,0.00022369799,0.00009580618,0.0001405484,0.000060770915,0.00064270105,9.203243e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008142873,0.00018444445,0.9752839,0.000037559064,0.00037025244,0.000009398628,0.00021142747,0.0000070514784,0.00039395576,0.0000027865638,0.00023405503,0.015122268],"study_design_scores_gemma":[0.0028234392,0.009004143,0.98394895,0.00014654853,0.00063480216,0.000013916057,0.000058203772,0.000036897774,0.00087492075,0.000016709366,0.002358515,0.00008295257],"about_ca_topic_score_codex":0.0034855665,"about_ca_topic_score_gemma":0.0101202745,"teacher_disagreement_score":0.015039316,"about_ca_system_score_codex":0.00076687976,"about_ca_system_score_gemma":0.0007215442,"threshold_uncertainty_score":0.5647351},"labels":[],"label_agreement":null},{"id":"W2100630326","doi":"10.1200/jco.2012.45.3639","title":"Designing Transformative Clinical Trials in the Cancer Genome Era","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Clinical trial; Genotyping; Precision medicine; Personalized medicine; Breast cancer; Computational biology; Cancer; Bioinformatics; Colorectal cancer; Internal medicine; Biology; Gene; Pathology; Genetics","score_opus":0.4432667977184366,"score_gpt":0.591966524882437,"score_spread":0.14869972716400037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100630326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004981273,0.99352896,0.0010197365,0.0007483418,0.0025007478,0.00091307407,0.00005964636,0.0000014094965,0.00072996086],"genre_scores_gemma":[0.00016774761,0.98889244,0.0019753354,0.0019506373,0.0068104356,0.000086435,0.000030186024,0.000036222897,0.000050574203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97773814,0.010623149,0.010659266,0.00037430608,0.0002588429,0.00034631082],"domain_scores_gemma":[0.975615,0.01600327,0.0074322466,0.0003904719,0.00030652035,0.00025246554],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.051612604,0.00034902513,0.006586966,0.00012366372,0.000045292203,0.000046687135,0.0010776336,0.0016727204,0.00008612476],"category_scores_gemma":[0.021674162,0.00019234471,0.0034395528,0.00015112016,0.00025909874,0.00000840773,0.00010527906,0.002460186,0.000021656911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021123054,0.00037659597,0.000048705755,0.0003256159,0.00069929654,0.00005517006,0.0000511094,0.000014565049,0.000008640693,0.000022492955,0.0088039,0.9893827],"study_design_scores_gemma":[0.0018250908,0.0035352649,0.00017436956,0.0007741924,0.0012768981,0.00010579377,0.00006639358,0.000002121545,0.0000028201903,0.00010644747,0.9919133,0.00021731395],"about_ca_topic_score_codex":0.000026376008,"about_ca_topic_score_gemma":0.00010019388,"teacher_disagreement_score":0.98916537,"about_ca_system_score_codex":0.00010311139,"about_ca_system_score_gemma":0.006313171,"threshold_uncertainty_score":0.99984115},"labels":[],"label_agreement":null},{"id":"W2100738529","doi":"10.1200/jco.2012.47.7901","title":"International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Cilag; Celgene; Takeda Oncology; Onyx Pharmaceuticals; Pfizer; Amgen","keywords":"Medicine; Multiple myeloma; Zoledronic acid; Spinal cord compression; Bone disease; Magnetic resonance imaging; Disease; Radiography; Radiology; Bisphosphonate; Surgery; Internal medicine; Osteoporosis; Spinal cord","score_opus":0.18317516296498768,"score_gpt":0.4766221856333922,"score_spread":0.2934470226684045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100738529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9073236,0.0013624647,0.0010812248,0.083815314,0.0028613044,0.0018476227,0.000041929292,0.00001796423,0.0016485933],"genre_scores_gemma":[0.9853856,0.003091155,0.009316773,0.00035964657,0.00086148066,0.000101653255,0.00004644638,0.000017668333,0.00081959064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971485,0.00022989837,0.001873693,0.00016769202,0.00033732777,0.00024286605],"domain_scores_gemma":[0.9906099,0.0069181104,0.0011997032,0.00022434877,0.0005617934,0.0004861518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009679433,0.00013597579,0.00081457355,0.00014336403,0.000088912915,0.00001587423,0.00018094748,0.00015895873,0.0006945811],"category_scores_gemma":[0.0034115643,0.00007414536,0.00075010565,0.00011309849,0.00019393036,0.00011397317,0.00003411855,0.0002962735,0.000029307217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046264455,0.005088266,0.16227292,0.000010493972,0.0017432132,0.00014152218,0.000108080196,0.00000967774,0.0001376213,0.0001227091,0.003970309,0.82176876],"study_design_scores_gemma":[0.0201649,0.009205356,0.65198636,0.000086279186,0.00048445264,0.000093583665,0.00015216733,0.0043711653,0.00004570383,0.00048177448,0.31286,0.00006826099],"about_ca_topic_score_codex":0.000042492287,"about_ca_topic_score_gemma":0.00002418003,"teacher_disagreement_score":0.8217005,"about_ca_system_score_codex":0.00023899015,"about_ca_system_score_gemma":0.00045414266,"threshold_uncertainty_score":0.76051754},"labels":[],"label_agreement":null},{"id":"W2100754752","doi":"10.1200/jco.2011.35.3979","title":"Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With<i>EGFR</i>-Activating Mutations","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"Academia Sinica; National Science Council","keywords":"Epidermal growth factor receptor; Cancer research; Mutation; Adenocarcinoma; Medicine; Chromosome; Targeted therapy; Comparative genomic hybridization; Lung cancer; Biology; Oncology; Cancer; Gene; Internal medicine; Genetics","score_opus":0.1195927804389629,"score_gpt":0.45732585793151553,"score_spread":0.33773307749255266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100754752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588454,0.0006098582,0.00013299068,0.0018823086,0.00018493999,0.00035712344,0.00001831977,0.0000063791776,0.0009235403],"genre_scores_gemma":[0.98864967,0.00021886283,0.010442167,0.00029901948,0.00009191586,0.000020217967,0.000008540686,0.000015327123,0.00025426436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977576,0.0002566836,0.0015357775,0.00015626659,0.00013865712,0.00015502378],"domain_scores_gemma":[0.9971716,0.0012019255,0.001087892,0.0001359127,0.00021667234,0.00018603541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004589994,0.00013372004,0.0009851252,0.00022207788,0.00005491136,0.0000059238096,0.0000542601,0.00011586565,0.00007064396],"category_scores_gemma":[0.0005442885,0.00008405752,0.00016177038,0.00013109439,0.00017569282,0.00014703027,0.000018228142,0.00023601617,0.0000012559038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004068826,0.0018206245,0.9763078,0.000024735653,0.0010799275,0.00047443586,0.004512169,0.000030484929,0.00073690974,0.00007144888,0.000029061275,0.010843548],"study_design_scores_gemma":[0.012033721,0.010720738,0.97448367,0.00009586121,0.00073703233,0.00024601005,0.00070040463,0.00014543047,0.00035003154,0.00010501541,0.00031061383,0.000071455324],"about_ca_topic_score_codex":0.00020959372,"about_ca_topic_score_gemma":0.00020651009,"teacher_disagreement_score":0.010772092,"about_ca_system_score_codex":0.00030103856,"about_ca_system_score_gemma":0.0014336018,"threshold_uncertainty_score":0.34277663},"labels":[],"label_agreement":null},{"id":"W2100860810","doi":"10.1200/jco.2012.47.8313","title":"Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Ste. Anne's Hospital","funders":"National Cancer Institute; European Regional Development Fund; Instituto de Salud Carlos III; Canadian Institutes of Health Research; National Institutes of Health; Medical Research Council; Ministero dello Sviluppo Economico; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Fondation de France; Ministère du Développement Économique, de l’Innovation et de l’Exportation; National Institute for Health and Care Research; Cancer Australia; National Health and Medical Research Council; Georgetown University; Cancer Research UK; University of Melbourne; Canadian Breast Cancer Research Alliance; Cancer Care Ontario; Royal Marsden NHS Foundation Trust; Huntsman Cancer Institute; National Breast Cancer Foundation","keywords":"Medicine; Oncology; Breast cancer; Tamoxifen; Internal medicine; Cancer; Gynecology; BRCA mutation; Mutation; Genetics; Gene","score_opus":0.02632369664065591,"score_gpt":0.38233300404565584,"score_spread":0.3560093074049999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100860810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449664,0.001656479,0.0007271297,0.0020910809,0.0006104789,0.00022068922,0.00008839941,0.0000014987236,0.00010762959],"genre_scores_gemma":[0.991066,0.003385656,0.0040345215,0.00073538534,0.00067349063,0.000023397874,0.000005494903,0.000013162994,0.000062898274],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843526,0.00017970534,0.0009789722,0.00017111635,0.00009260416,0.0001423507],"domain_scores_gemma":[0.99772704,0.00032332493,0.0011399995,0.000101493046,0.0005479604,0.00016017731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094880466,0.000097513606,0.00048408052,0.000035052526,0.00003886626,0.00001148224,0.00009672264,0.00028658443,0.000024949151],"category_scores_gemma":[0.0005997115,0.00007716841,0.00014879282,0.00003640011,0.00030248892,0.000015346743,0.000038274196,0.00019146288,3.738548e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029459787,0.00032722973,0.392867,0.00009075966,0.002002557,0.0000094012275,0.00041588498,0.00046195768,0.073612146,0.00006618013,0.028433107,0.4987678],"study_design_scores_gemma":[0.016340474,0.008318133,0.8955054,0.00006652413,0.00094710576,0.00060160586,0.00035688537,0.00076722074,0.020858373,0.0032938435,0.05256597,0.00037841158],"about_ca_topic_score_codex":0.000103829494,"about_ca_topic_score_gemma":0.000069432666,"teacher_disagreement_score":0.50263846,"about_ca_system_score_codex":0.00003346657,"about_ca_system_score_gemma":0.000599987,"threshold_uncertainty_score":0.31468368},"labels":[],"label_agreement":null},{"id":"W2100942077","doi":"10.1200/jco.2013.52.4611","title":"Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":734,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Guideline; Medicine; Psychosocial; Anxiety; Depression (economics); Context (archaeology); Quality of life (healthcare); Distress; Clinical Oncology; Family medicine; Cancer; Psychiatry; Clinical psychology; Nursing; Internal medicine; Pathology","score_opus":0.15495990892903538,"score_gpt":0.5482691347036187,"score_spread":0.3933092257745833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100942077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06484896,0.93134856,0.00094598247,0.0006525345,0.00087017886,0.00084201247,0.00009562938,0.000008601762,0.00038756506],"genre_scores_gemma":[0.03456518,0.95255774,0.010737107,0.00062828563,0.0013723334,0.000023206707,0.000058357447,0.00004446713,0.000013342602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891866,0.002149994,0.0073261983,0.00054241985,0.00051841507,0.0002763977],"domain_scores_gemma":[0.98127955,0.0034566622,0.012934443,0.00033958585,0.0014462717,0.000543511],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0050847433,0.0003740619,0.009622889,0.0001779969,0.000028084876,0.0000060272705,0.000244985,0.0011939894,0.000024487412],"category_scores_gemma":[0.0008475662,0.0002493105,0.0011056372,0.0003061459,0.0011812546,0.00011072137,0.00011918909,0.0024422887,9.643464e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021673169,0.00047846214,0.099122696,0.0036426103,0.0008879534,0.00004148102,0.00050517905,0.000011485462,1.5844797e-7,0.000008991693,0.00043755586,0.89269614],"study_design_scores_gemma":[0.012459472,0.040078335,0.06208056,0.015328455,0.0049066567,0.00032173638,0.0031623396,0.00044716365,3.1085628e-7,0.000007120276,0.8609164,0.000291502],"about_ca_topic_score_codex":0.0020926944,"about_ca_topic_score_gemma":0.009539649,"teacher_disagreement_score":0.8924046,"about_ca_system_score_codex":0.0002554316,"about_ca_system_score_gemma":0.008370513,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W2101042741","doi":"10.1200/jco.2005.05.571","title":"Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Cutoff; Neuroblastoma; Stage (stratigraphy); Internal medicine; Pediatric oncology; Risk stratification; Cancer; Oncology; Pediatrics","score_opus":0.2710879266510203,"score_gpt":0.512960278752268,"score_spread":0.24187235210124775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101042741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860043,0.0001220576,0.001168695,0.010304554,0.00038877374,0.0016952651,0.000021684196,0.000013129784,0.00028152732],"genre_scores_gemma":[0.9865012,0.0005723559,0.00843457,0.0022163335,0.0020303614,0.00012272049,0.000022030757,0.000028662736,0.000071769224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952312,0.0015269802,0.0019610124,0.0003938891,0.00041465828,0.0004722422],"domain_scores_gemma":[0.98973703,0.00784553,0.0013520262,0.00038826052,0.0002761446,0.00040099738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056601907,0.00020463631,0.0010691693,0.00020371206,0.00011923323,0.000032991822,0.00044697308,0.0003610106,0.000025143207],"category_scores_gemma":[0.005210136,0.00012226387,0.0005482553,0.00016575234,0.00026521945,0.00039080775,0.00003874181,0.0011298166,0.000013432565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046258606,0.013758098,0.15245931,0.00006576139,0.0005818277,0.0009595686,0.000606426,0.000058027363,0.002463565,0.0006454189,0.0073899725,0.77475345],"study_design_scores_gemma":[0.014355494,0.11280502,0.8539441,0.0000886462,0.00043323459,0.0008493941,0.00008506046,0.0005047241,0.00013776202,0.0009272398,0.015759101,0.00011021797],"about_ca_topic_score_codex":0.000032927786,"about_ca_topic_score_gemma":0.0010965562,"teacher_disagreement_score":0.7746432,"about_ca_system_score_codex":0.0002100669,"about_ca_system_score_gemma":0.0006359004,"threshold_uncertainty_score":0.6237396},"labels":[],"label_agreement":null},{"id":"W2101046684","doi":"10.1200/jco.2011.39.9014","title":"Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":437,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Canada Research Chairs","keywords":"Medicine; Breast cancer; Internal medicine; Hazard ratio; VO2 max; Proportional hazards model; Oncology; Cancer; Confidence interval; Blood pressure; Heart rate","score_opus":0.08881448654940576,"score_gpt":0.4403380973924004,"score_spread":0.3515236108429946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101046684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770677,0.0021884714,0.00008603467,0.016527029,0.002866638,0.00016076362,0.0000068368063,0.000011432007,0.0010850923],"genre_scores_gemma":[0.9899165,0.0012342854,0.00007351006,0.0041985763,0.004195467,0.0000036241406,0.0000030297833,0.000015297368,0.00035969602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975935,0.0005189045,0.0012396654,0.00011345522,0.00027598525,0.00025848692],"domain_scores_gemma":[0.99724543,0.0011514735,0.00086100394,0.000143163,0.00028280617,0.0003161147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006305162,0.00011397991,0.00095091754,0.000032708056,0.000082881685,0.000011158845,0.00007849561,0.00046101425,0.00006807539],"category_scores_gemma":[0.00065139803,0.00006787332,0.00042761292,0.00012087934,0.0003186849,0.00016221197,0.000043168664,0.0010556476,0.00000593356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004337823,0.00059832464,0.67292774,0.000027036125,0.0009815319,0.000097323486,0.00048089633,0.000004562161,0.0082668485,0.000085558306,0.002520401,0.30967194],"study_design_scores_gemma":[0.004235829,0.0010059761,0.96118486,0.00006507527,0.00045712368,0.002234694,0.00027611898,0.000009957912,0.0003529154,0.0004304347,0.029674344,0.00007265972],"about_ca_topic_score_codex":0.00010163408,"about_ca_topic_score_gemma":0.00018049806,"teacher_disagreement_score":0.30959928,"about_ca_system_score_codex":0.00008791359,"about_ca_system_score_gemma":0.00026690582,"threshold_uncertainty_score":0.45863226},"labels":[],"label_agreement":null},{"id":"W2101265600","doi":"10.1200/jco.2013.54.8404","title":"Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Montréal; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Bayer HealthCare; Sanofi; Exelixis; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Cancer Care Ontario; Amgen; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Cabazitaxel; Docetaxel; Enzalutamide; Prostate cancer; Internal medicine; Oncology; Abiraterone acetate; Prednisone; Mitoxantrone; Androgen deprivation therapy; Cancer; Chemotherapy; Androgen receptor","score_opus":0.30336439310637164,"score_gpt":0.6127817755872027,"score_spread":0.30941738248083106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101265600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01110313,0.9786163,0.000017714676,0.00565887,0.0010014668,0.0026751189,0.0000868462,0.000010592857,0.0008299642],"genre_scores_gemma":[0.0012809014,0.98257625,0.011841981,0.0016049728,0.0017911078,0.00018981527,0.000055741704,0.000083118095,0.0005761013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.976689,0.0058198883,0.014952592,0.0008613724,0.0010509508,0.00062622223],"domain_scores_gemma":[0.9642786,0.014104721,0.01716841,0.00052033534,0.0030380248,0.00088990876],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01917472,0.0006424025,0.015142472,0.00024948976,0.000071876646,0.000024427001,0.00041864885,0.0011020541,0.00008581605],"category_scores_gemma":[0.0032405674,0.00035820896,0.0021237624,0.0005051367,0.0017856124,0.00018470375,0.00012683222,0.0053314464,0.0000032099424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01881503,0.0021526555,0.023281557,0.004008163,0.0063201915,0.0010803721,0.0006323889,0.000009378834,7.824501e-7,0.000006012369,0.007187504,0.936506],"study_design_scores_gemma":[0.021153504,0.049892984,0.0046783285,0.008966575,0.006515374,0.0006839507,0.0015785645,0.000023305569,3.8520844e-7,0.000007048652,0.90620816,0.0002918142],"about_ca_topic_score_codex":0.015409323,"about_ca_topic_score_gemma":0.027181758,"teacher_disagreement_score":0.93621415,"about_ca_system_score_codex":0.002299147,"about_ca_system_score_gemma":0.06945899,"threshold_uncertainty_score":0.999887},"labels":[],"label_agreement":null},{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","score_opus":0.11767038809995356,"score_gpt":0.4940915774878471,"score_spread":0.37642118938789354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101299592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943802,0.0001513959,0.0000057437333,0.0030078746,0.00065406127,0.0016188542,0.000103742765,0.000009105857,0.000069074464],"genre_scores_gemma":[0.99752045,0.00038485762,0.001035235,0.00017488778,0.0007341576,0.000052552878,0.0000072528546,0.00005035172,0.000040228268],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99484026,0.00079705316,0.0024155667,0.0003954509,0.0010440657,0.0005075799],"domain_scores_gemma":[0.9949994,0.0013586063,0.0018869031,0.00023811475,0.00093776104,0.0005792216],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002145088,0.00029863825,0.002299356,0.00033962989,0.00011960561,0.000018832507,0.0002688412,0.00034302523,0.0006943983],"category_scores_gemma":[0.001115085,0.00019125934,0.00032560882,0.0002493767,0.00065487437,0.00027816737,0.00007010836,0.0023388048,0.000001079243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38938922,0.03580938,0.25648358,0.00017304243,0.0010685539,0.0002874907,0.001490457,6.2773694e-7,0.003964001,0.000012826969,0.00012807448,0.31119275],"study_design_scores_gemma":[0.2802149,0.096727155,0.62020695,0.0002387832,0.00016344155,0.00011410259,0.000111460125,0.0000086574955,0.0018008122,0.00001776745,0.00024566206,0.00015027935],"about_ca_topic_score_codex":0.00012408086,"about_ca_topic_score_gemma":0.00019682074,"teacher_disagreement_score":0.3637234,"about_ca_system_score_codex":0.00043818323,"about_ca_system_score_gemma":0.0029863843,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W2101364791","doi":"10.1200/jco.2004.12.027","title":"Weekly Epoetin Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Epoetin alfa; Medicine; Anemia; Hemoglobin; Internal medicine; Chemotherapy; Erythropoietin; Breast cancer; Cancer; Quality of life (healthcare); Gastroenterology; Oncology; Surgery","score_opus":0.054986702340926556,"score_gpt":0.4312752769045835,"score_spread":0.37628857456365694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101364791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.937582,0.00047863746,0.000009463754,0.0609867,0.00037345258,0.00018755667,0.0000066574694,0.0000042092433,0.0003713208],"genre_scores_gemma":[0.9848026,0.010985904,0.0020511043,0.0017493162,0.0003456161,0.00000263389,0.0000016109253,0.000012540315,0.000048698937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969097,0.00026217697,0.00218726,0.00018608781,0.00026817285,0.00018663904],"domain_scores_gemma":[0.9975539,0.0005742008,0.001226967,0.00009769786,0.00026622802,0.0002810425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018870753,0.00013183203,0.0012752339,0.00008475756,0.000025420633,0.000003947004,0.0000772303,0.00028807257,0.00007387361],"category_scores_gemma":[0.0007641445,0.000090198075,0.00025409964,0.000112121896,0.00025399277,0.00006933752,0.000019407285,0.000540137,8.0854545e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070388084,0.0057735816,0.72860974,0.00009911162,0.00018989212,0.00005376554,0.0005576778,0.00000720569,0.008127935,0.000031873064,0.0003338903,0.24917653],"study_design_scores_gemma":[0.024561737,0.005623056,0.9669876,0.00039436758,0.00006828548,0.00006047151,0.00043741864,0.0000026024038,0.00095374224,0.00033259921,0.00049684313,0.00008126534],"about_ca_topic_score_codex":0.00047079942,"about_ca_topic_score_gemma":0.00022961218,"teacher_disagreement_score":0.24909528,"about_ca_system_score_codex":0.00023991683,"about_ca_system_score_gemma":0.0011106237,"threshold_uncertainty_score":0.36781707},"labels":[],"label_agreement":null},{"id":"W2101431106","doi":"10.1200/jco.2008.19.4233","title":"Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; BC Cancer Agency","funders":"National Heart, Lung, and Blood Institute; BC Cancer Agency; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Vancouver Coastal Health Research Institute","keywords":"Medicine; Lung cancer; Biomarker; Connective tissue; Cancer; Pathology; Lung; Internal medicine; Cancer research; Oncology; Biology; Biochemistry","score_opus":0.08709562873869169,"score_gpt":0.4787482458669456,"score_spread":0.3916526171282539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101431106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7457919,0.0001436197,0.24990927,0.0014688506,0.00015441526,0.00022066038,0.000013993151,0.00003242564,0.0022648696],"genre_scores_gemma":[0.92048156,0.00013867838,0.07781557,0.00037261238,0.0008690805,0.000062716645,0.0000011714826,0.000015657184,0.0002429471],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812216,0.000027213753,0.0013308638,0.00019818833,0.000120597666,0.00020099168],"domain_scores_gemma":[0.99611443,0.0012847553,0.001900986,0.00013922554,0.00041916524,0.00014140907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007703631,0.00012186818,0.00060679455,0.00004629974,0.00010340329,0.000013438438,0.00018426291,0.0003645476,0.00006973681],"category_scores_gemma":[0.0011638182,0.00010543781,0.0002663945,0.00009389688,0.00006448859,0.0001426772,0.000023023327,0.00061187946,5.1355323e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011777033,0.00075135706,0.001089134,0.0000177132,0.00020936178,0.000008214077,0.000067060035,0.000036462323,0.6487571,0.00039893968,0.00024369267,0.34724328],"study_design_scores_gemma":[0.012105444,0.0049595824,0.014601727,0.00025660306,0.000577954,0.00021072834,0.00014963828,0.0025388086,0.8631599,0.012223523,0.08873028,0.000485819],"about_ca_topic_score_codex":0.00003456953,"about_ca_topic_score_gemma":0.000018871478,"teacher_disagreement_score":0.34675744,"about_ca_system_score_codex":0.00014309143,"about_ca_system_score_gemma":0.00028161446,"threshold_uncertainty_score":0.4299629},"labels":[],"label_agreement":null},{"id":"W2101444561","doi":"10.1200/jco.2013.51.3671","title":"Impact of Wait Times on Survival for Women With Uterine Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Ontario Ministry of Health and Long-Term Care; Canadian Cancer Society Research Institute; Government of Ontario; Institute for Clinical Evaluative Sciences; Cancer Care Ontario","keywords":"Medicine; Proportional hazards model; Uterine cancer; Hysterectomy; Cancer; Survival analysis; Cancer registry; Cohort; Gynecology; Population; Endometrial cancer; Relative survival; Surgery; Internal medicine","score_opus":0.134577394802654,"score_gpt":0.516770161987942,"score_spread":0.38219276718528805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101444561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244636,0.000107835695,0.000031128515,0.0027868173,0.0005356618,0.0002941657,0.000016014694,0.00000383777,0.0037781685],"genre_scores_gemma":[0.99574226,0.00030975873,0.0006789618,0.0006042394,0.0011532835,0.00003302178,0.0000012297976,0.000013711512,0.0014635071],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99816734,0.00010230516,0.001137464,0.00011457625,0.00025989962,0.0002183985],"domain_scores_gemma":[0.99607116,0.0019091568,0.0009843003,0.00011561447,0.000536037,0.00038374745],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007892313,0.00011318234,0.0014346289,0.00009305673,0.000013602194,0.0000038587004,0.00009462062,0.00015371262,0.00285599],"category_scores_gemma":[0.00092362496,0.000054714797,0.0003897266,0.00013313383,0.00009873995,0.00006298528,0.000016630844,0.0002941094,0.000012259568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0818435,0.00644539,0.29692695,0.00012074477,0.004129593,0.00011100305,0.00009823262,0.000063068546,0.00047259242,0.000092158254,0.0063862693,0.60331047],"study_design_scores_gemma":[0.022643652,0.13543639,0.8283753,0.000077905876,0.00019214797,0.00003280638,0.00003439411,0.00001967826,0.0001006619,0.00047617155,0.01254806,0.00006285084],"about_ca_topic_score_codex":0.00019054966,"about_ca_topic_score_gemma":0.000018823845,"teacher_disagreement_score":0.60324764,"about_ca_system_score_codex":0.0003018506,"about_ca_system_score_gemma":0.001031108,"threshold_uncertainty_score":0.9980555},"labels":[],"label_agreement":null},{"id":"W2101580858","doi":"10.1200/jco.2007.12.6334","title":"Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"American Society of Clinical Oncology; Sanofi; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Breast cancer; Hazard ratio; Tamoxifen; Placebo; Quality of life (healthcare); Internal medicine; Adverse effect; Cancer; Gynecology; Oncology; Confidence interval","score_opus":0.05876974179343134,"score_gpt":0.38991834211529347,"score_spread":0.3311486003218621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101580858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988742,0.00027718814,0.0000201697,0.0003457118,0.00009922902,0.00025161676,0.00005820914,0.00000229996,0.000071415976],"genre_scores_gemma":[0.998322,0.0006230247,0.00023910847,0.00027566377,0.00029221099,0.00003247092,0.0000022723389,0.00001813786,0.00019507433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974624,0.00039717348,0.0014047911,0.00025579747,0.0002412423,0.00023861713],"domain_scores_gemma":[0.9976818,0.00039757774,0.0013308414,0.00019022095,0.00021242986,0.00018716147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008291492,0.00017906945,0.001306235,0.000079023994,0.000018958071,0.000003695795,0.00014942292,0.0002641046,0.0000740121],"category_scores_gemma":[0.0002916465,0.0001140109,0.00013068155,0.00012693343,0.0006091233,0.000013119603,0.000098688375,0.0002840526,3.756636e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44659504,0.0019043398,0.5469876,0.000027517806,0.0006904125,0.00010907102,0.00033095526,0.000022923954,0.00050595973,8.512036e-7,0.00014831637,0.0026770057],"study_design_scores_gemma":[0.092186235,0.011947277,0.89455205,0.000083304934,0.000077535144,0.00007571233,0.00014954702,9.0939847e-7,0.00041076523,0.0000011080735,0.00039472163,0.00012085596],"about_ca_topic_score_codex":0.00042021964,"about_ca_topic_score_gemma":0.0018785491,"teacher_disagreement_score":0.3544088,"about_ca_system_score_codex":0.000088000306,"about_ca_system_score_gemma":0.00086038775,"threshold_uncertainty_score":0.46492296},"labels":[],"label_agreement":null},{"id":"W2101660253","doi":"10.1200/jco.2007.11.4686","title":"Significance of Multifocality in Ductal Carcinoma In Situ: Outcomes of Women Treated With Breast-Conserving Therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast-conserving surgery; Mastectomy; Hazard ratio; Breast cancer; Radiation therapy; Ductal carcinoma; Internal medicine; Breast surgery; Oncology; Urology; Confidence interval; Cancer","score_opus":0.04907290255327886,"score_gpt":0.3932421400707141,"score_spread":0.3441692375174353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101660253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99864614,0.0003694498,0.00002976852,0.000499657,0.00009722044,0.00012752989,0.000008037764,0.0000012011599,0.00022100423],"genre_scores_gemma":[0.9988483,0.00019464084,0.0006440263,0.00018921461,0.00009669995,0.0000047049302,0.0000019121394,0.000010128163,0.000010360057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746,0.00028641842,0.0016332727,0.00019006657,0.00015893695,0.00027129837],"domain_scores_gemma":[0.997643,0.0006139676,0.0012030888,0.00017588105,0.0002565713,0.00010752698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023755932,0.00014097433,0.0011380268,0.00010026754,0.0000104064675,0.00000140209,0.00017884174,0.00023061679,0.000007835523],"category_scores_gemma":[0.0004326725,0.00009507188,0.00017230217,0.00015218493,0.00026686082,0.0000073778797,0.000046824112,0.00024157595,2.1840738e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009475127,0.001574293,0.9551388,0.000012385557,0.00028679398,0.0001328279,0.0002454449,0.000030560346,0.015924647,0.0000052427968,0.000010174753,0.017163688],"study_design_scores_gemma":[0.008419461,0.0032940046,0.97417253,0.000025212525,0.000022208838,0.00007149283,0.0005112608,0.0000022975062,0.013233871,0.00002786825,0.00013695897,0.00008285483],"about_ca_topic_score_codex":0.0005473736,"about_ca_topic_score_gemma":0.0020728474,"teacher_disagreement_score":0.019033695,"about_ca_system_score_codex":0.00014995148,"about_ca_system_score_gemma":0.00053379586,"threshold_uncertainty_score":0.3876919},"labels":[],"label_agreement":null},{"id":"W2101819710","doi":"10.1200/jco.2013.50.7715","title":"The Time Is Ripe for a Randomized Trial of Metformin in Clinically Localized Prostate Cancer","year":2013,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Metformin; Randomized controlled trial; Prostate; Oncology; Cancer; Internal medicine; Gynecology; Insulin","score_opus":0.027979775119917075,"score_gpt":0.4291908997814129,"score_spread":0.40121112466149583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101819710","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049570943,0.008772742,0.00013486645,0.0017466377,0.98114073,0.0026866137,0.00018297762,0.000002831614,0.00037548205],"genre_scores_gemma":[0.00008069921,0.0882828,0.0012544327,0.0005501937,0.9035354,0.00039261888,0.000050673945,0.000054628144,0.005798542],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884815,0.001920064,0.008017337,0.00046148364,0.00064881996,0.00047075638],"domain_scores_gemma":[0.97449416,0.014251996,0.008570368,0.0004762123,0.0019433001,0.00026394922],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022487633,0.00036772052,0.005149358,0.000106772924,0.000054934004,0.00002881513,0.0008613023,0.0028345217,0.00006757833],"category_scores_gemma":[0.05284739,0.00021711808,0.0027447846,0.00010261279,0.00087058166,0.00001086392,0.0001632274,0.0015606754,0.0000054017155],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45478478,0.00031050673,0.0000033407343,0.000026996557,0.0005853076,3.8843e-7,0.000022680766,0.0000037605812,0.0000949809,0.0000052751516,0.50696826,0.037193727],"study_design_scores_gemma":[0.41870883,0.0055109533,0.000002098167,0.000061771076,0.00047127722,0.0000018242367,0.000010836769,0.000026478483,0.00003909443,0.00038597363,0.57464635,0.00013448409],"about_ca_topic_score_codex":0.0001512776,"about_ca_topic_score_gemma":0.00020146868,"teacher_disagreement_score":0.079510055,"about_ca_system_score_codex":0.00007290846,"about_ca_system_score_gemma":0.0093777245,"threshold_uncertainty_score":0.99846},"labels":[],"label_agreement":null},{"id":"W2101913110","doi":"10.1200/jco.2005.01.158","title":"Serial Evaluation of Academic and Behavioral Outcome After Treatment With Cranial Radiation in Childhood","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Medulloblastoma; Radiation therapy; Pediatrics; Spelling; Distress; Ependymoma; Posterior cranial fossa; Surgery; Clinical psychology","score_opus":0.14918622918529453,"score_gpt":0.5117061204050959,"score_spread":0.3625198912198013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101913110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949491,0.0007498166,0.0000017334787,0.0036750284,0.00022401691,0.00032112678,0.0000029024513,0.0000017563242,0.00007449556],"genre_scores_gemma":[0.9978781,0.00036455624,0.00075497926,0.00020682899,0.00076564006,0.000017250364,0.0000024925023,0.000006962928,0.0000031985671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977779,0.00025232066,0.0014211457,0.00010990777,0.00033549365,0.00010326983],"domain_scores_gemma":[0.9985775,0.00027383293,0.0007953372,0.00007208801,0.00014047389,0.00014079166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014704146,0.000091336304,0.00080676185,0.00012508307,0.000008895703,0.0000025315883,0.000025572235,0.0002397487,0.000074738404],"category_scores_gemma":[0.00024341966,0.00005465453,0.0001367473,0.00006306884,0.00006612894,0.00009660772,0.00000816146,0.00027649268,0.0000017285714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022215834,0.0028802052,0.63256896,0.0000022110073,0.00006695768,0.00005672346,0.00017577666,0.000035315705,0.00009470291,0.000002989558,0.000007711201,0.36188686],"study_design_scores_gemma":[0.03722101,0.019611005,0.9406482,0.000039400322,0.0013383888,0.00011510594,0.000040319228,0.00010826335,0.00025938317,0.000026079222,0.00055095315,0.00004188139],"about_ca_topic_score_codex":0.000020150832,"about_ca_topic_score_gemma":0.0001556369,"teacher_disagreement_score":0.36184496,"about_ca_system_score_codex":0.00024636294,"about_ca_system_score_gemma":0.0006280561,"threshold_uncertainty_score":0.2228747},"labels":[],"label_agreement":null},{"id":"W2102184347","doi":"10.1200/jco.2008.16.4061","title":"Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Genentech; National Comprehensive Cancer Network; Biogen; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; American Society of Hematology","keywords":"Medicine; Concordance; Lymphoma; Medical diagnosis; Cancer; Follicular lymphoma; Etiology; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Internal medicine; Pathology","score_opus":0.2634506086962319,"score_gpt":0.5057099807041731,"score_spread":0.24225937200794118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102184347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703693,0.00051073625,0.000020233818,0.0016216158,0.00023999742,0.00026546296,0.0000042594265,0.0000016783805,0.00029905874],"genre_scores_gemma":[0.9944272,0.0003729331,0.0030142798,0.0017398355,0.00040440253,0.000020773117,0.0000031155616,0.000009874429,0.0000075714993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819714,0.00016987069,0.0011172998,0.00011427228,0.00025946856,0.00014195168],"domain_scores_gemma":[0.99549115,0.0028022334,0.0010023223,0.000059436363,0.00056816544,0.00007669329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060435745,0.00008796079,0.0009919483,0.00005195401,0.00003966697,0.0000018350901,0.000069630485,0.00014623112,0.000009380313],"category_scores_gemma":[0.00032643156,0.000046901554,0.00013013673,0.00007657403,0.00020828343,0.000036491387,0.000018523511,0.00016083832,6.49405e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043019215,0.0031090917,0.96590143,0.000016417007,0.00016573732,0.000109087516,0.00023538299,0.00017922194,0.0000016773998,0.000063178435,0.0070664356,0.01885042],"study_design_scores_gemma":[0.020639021,0.013701369,0.9519121,0.000099367244,0.00015558384,0.00019406601,0.00006484497,0.00014517864,0.000006793966,0.00007554933,0.012964343,0.00004179987],"about_ca_topic_score_codex":0.00001820447,"about_ca_topic_score_gemma":0.000047669724,"teacher_disagreement_score":0.01880862,"about_ca_system_score_codex":0.00011753006,"about_ca_system_score_gemma":0.00060682197,"threshold_uncertainty_score":0.19125898},"labels":[],"label_agreement":null},{"id":"W2102297522","doi":"10.1200/jco.2005.04.044","title":"Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Internal medicine; Rash; Neutropenia; Interim analysis; Clinical endpoint; Toxicity; Febrile neutropenia; Chemotherapy; Paclitaxel; Surgery; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Cisplatin","score_opus":0.06504719039632889,"score_gpt":0.45168323201611205,"score_spread":0.38663604161978316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102297522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943183,0.0016225385,0.00017272816,0.0003332977,0.00070706266,0.0027459287,0.0000244267,0.000001525634,0.0000741621],"genre_scores_gemma":[0.9972064,0.0006684517,0.001127501,0.00014348248,0.0005795757,0.00019610261,0.0000074714267,0.000017080978,0.000053927524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9906716,0.0027503888,0.0054183747,0.00038469746,0.00053939526,0.00023556032],"domain_scores_gemma":[0.9938608,0.0010684907,0.004084576,0.0001762234,0.00061081094,0.00019910968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017598147,0.0002334114,0.0028932423,0.00018324493,0.00003394587,0.0000070713504,0.00021571241,0.00032835332,0.000021047908],"category_scores_gemma":[0.0040749507,0.00017342236,0.00026243497,0.00019527873,0.00015758339,0.000038389146,0.00009577575,0.00060280284,5.2684687e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69279855,0.061940122,0.06603688,0.00022819605,0.0030238875,0.00033975526,0.00103858,0.0043469183,0.13613486,0.00008842452,0.0008843893,0.03313945],"study_design_scores_gemma":[0.9373431,0.027689487,0.006087844,0.0002434495,0.00071192003,0.000011350074,0.0010608213,0.0014138483,0.024385624,0.000076704135,0.000647725,0.00032810177],"about_ca_topic_score_codex":0.016382346,"about_ca_topic_score_gemma":0.27057943,"teacher_disagreement_score":0.25419706,"about_ca_system_score_codex":0.00017031837,"about_ca_system_score_gemma":0.004373703,"threshold_uncertainty_score":0.9901677},"labels":[],"label_agreement":null},{"id":"W2102345320","doi":"10.1200/jco.2014.57.8724","title":"Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Medical Research Council; Canadian Cancer Society Research Institute","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Radiation therapy; Internal medicine; Randomized controlled trial; Cancer; Oncology","score_opus":0.22302550542301536,"score_gpt":0.5354375963752577,"score_spread":0.3124120909522423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102345320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705899,0.0068715373,0.0011707719,0.01503877,0.0012629334,0.004930172,0.00011062339,0.000008381966,0.000016932756],"genre_scores_gemma":[0.97833735,0.011814468,0.0050492804,0.003208442,0.0010998119,0.0003830226,0.00002603939,0.000036740148,0.000044864508],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937501,0.0011958355,0.0039881626,0.00026051924,0.0005439921,0.0002613982],"domain_scores_gemma":[0.98377615,0.009871563,0.0042801257,0.00035388095,0.0012219013,0.0004963994],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006687906,0.0002467481,0.004023706,0.0000901463,0.000031967127,0.0000119699735,0.0002505911,0.00024332521,0.00009794228],"category_scores_gemma":[0.008484687,0.000120499164,0.0015691626,0.00012326243,0.00024127474,0.0001240019,0.000026998643,0.00033228908,9.161024e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5816983,0.0018194894,0.2911376,0.000014456076,0.0027873036,0.0000070443884,0.0007036727,0.00010128321,0.00012675794,0.000011678674,0.0011186977,0.12047368],"study_design_scores_gemma":[0.6954699,0.030508101,0.2713916,0.00015609637,0.0003839111,0.0000029634698,0.000044805012,0.000025791682,0.00029812363,0.0004782471,0.0011430691,0.00009738111],"about_ca_topic_score_codex":0.00033291455,"about_ca_topic_score_gemma":0.00012034452,"teacher_disagreement_score":0.120376304,"about_ca_system_score_codex":0.00046010385,"about_ca_system_score_gemma":0.0052757636,"threshold_uncertainty_score":0.99986726},"labels":[],"label_agreement":null},{"id":"W2102468400","doi":"10.1200/jco.2011.40.0895","title":"Reach Out to Enhance Wellness Home-Based Diet-Exercise Intervention Promotes Reproducible and Sustainable Long-Term Improvements in Health Behaviors, Body Weight, and Physical Functioning in Older, Overweight/Obese Cancer Survivors","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; National Institute on Aging","keywords":"Medicine; Overweight; Gerontology; Intervention (counseling); Cancer; Physical therapy; Weight loss; Obesity; Internal medicine; Nursing","score_opus":0.038966328039292716,"score_gpt":0.4418511984518319,"score_spread":0.4028848704125392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102468400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040264,0.004414383,0.00044531145,0.002395327,0.0015929264,0.000696938,0.0000030351011,0.000009613884,0.00003979703],"genre_scores_gemma":[0.9966782,0.0013405178,0.000105682695,0.00040058282,0.00070244353,0.00006859487,0.000006670336,0.000025728605,0.0006716262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637055,0.0005342168,0.0016994909,0.00043928996,0.00033075755,0.000625714],"domain_scores_gemma":[0.9975618,0.00044165173,0.0009493776,0.00025840045,0.0002558132,0.00053295534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006818606,0.0002014321,0.0013871031,0.0003066217,0.00006702361,0.000021970915,0.00009714776,0.0002172577,0.000043444048],"category_scores_gemma":[0.00055943016,0.000165146,0.0001829729,0.00030074996,0.00012391023,0.00035910966,0.00012249517,0.0008681979,0.0000014013699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004579345,0.0035712284,0.81999147,0.0007921492,0.000036605114,0.00010436287,0.0017715952,0.0000029735825,0.00015521512,0.000013228049,0.00010664185,0.16887517],"study_design_scores_gemma":[0.0049394732,0.00805991,0.981735,0.0017276176,0.00013841172,0.000014699622,0.0012323636,0.000047288373,0.0010203624,0.00007161461,0.00083556055,0.00017769734],"about_ca_topic_score_codex":0.005211278,"about_ca_topic_score_gemma":0.014743528,"teacher_disagreement_score":0.16869748,"about_ca_system_score_codex":0.0005927213,"about_ca_system_score_gemma":0.0007340915,"threshold_uncertainty_score":0.82272345},"labels":[],"label_agreement":null},{"id":"W2102471696","doi":"10.1200/jco.2010.34.4440","title":"Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: Findings From the Breast Cancer Family Registry","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Institutes of Health; University of Melbourne; National Cancer Institute; Cancer Care Ontario","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Cancer; Population; Germline mutation; Ovarian cancer; Family history; Mutation; Genetics; Biology; Gene","score_opus":0.07266624491473543,"score_gpt":0.38268956176179175,"score_spread":0.3100233168470563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102471696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98177177,0.0094138365,0.0012104443,0.0023075258,0.0020590576,0.00027164086,0.0025991744,0.0000043420005,0.00036221766],"genre_scores_gemma":[0.9724277,0.017857654,0.0055512115,0.002024536,0.0019352437,0.000062788444,0.000028541304,0.000038657032,0.00007364829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972824,0.00029009365,0.0015680201,0.00036921984,0.00023242943,0.00025783453],"domain_scores_gemma":[0.9959672,0.00068010367,0.0019655817,0.00037147384,0.00082255685,0.00019306008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014958387,0.00020213658,0.00070404494,0.000045185916,0.00013185378,0.000016386637,0.00049985433,0.00049221475,0.000055976812],"category_scores_gemma":[0.0003638811,0.00014604401,0.00040128082,0.00013399398,0.00078290317,0.000020124939,0.000104322695,0.00052462675,0.0000012630658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009770141,0.000784795,0.43105477,0.000049742554,0.002792024,0.00002711977,0.0014452382,0.00029842494,0.043146655,0.00013325832,0.20637378,0.30412406],"study_design_scores_gemma":[0.0056979586,0.0012960995,0.8695566,0.00011113088,0.0006484038,0.0002191118,0.001675171,0.00003736736,0.0030536994,0.0013077011,0.11610201,0.00029474517],"about_ca_topic_score_codex":0.00055270165,"about_ca_topic_score_gemma":0.0002843871,"teacher_disagreement_score":0.43850183,"about_ca_system_score_codex":0.0001200948,"about_ca_system_score_gemma":0.0019852838,"threshold_uncertainty_score":0.5955502},"labels":[],"label_agreement":null},{"id":"W2102524820","doi":"10.1200/jco.2013.54.6002","title":"Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Lymphoma; Cancer research; Anaplastic large-cell lymphoma; Internal medicine","score_opus":0.076843681284141,"score_gpt":0.47441961923952775,"score_spread":0.39757593795538676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102524820","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18341762,0.0033258884,0.013443631,0.7715974,0.010573186,0.009693329,0.0009733418,0.00002269853,0.0069529177],"genre_scores_gemma":[0.09476267,0.0016672184,0.0026760867,0.8735749,0.017273696,0.00086133165,0.00024221856,0.0002333776,0.008708488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955356,0.0007950853,0.002298541,0.00044065982,0.00045975068,0.00047034616],"domain_scores_gemma":[0.97650474,0.018623317,0.0028381024,0.00037900393,0.0013196858,0.0003351759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023971633,0.00037690715,0.0029126701,0.00022217003,0.00014428057,0.000020421527,0.00035236226,0.0010866739,0.00011354096],"category_scores_gemma":[0.0016511211,0.00023277465,0.0011303576,0.00020071292,0.00023901399,0.000052446612,0.00010548378,0.0012479101,0.000020161557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009470657,0.00078949885,0.011252665,0.0015581949,0.002947057,0.0006564335,0.00024959905,0.00016003725,0.000098203804,0.0000060941466,0.9086634,0.06414818],"study_design_scores_gemma":[0.02190727,0.01579066,0.029605284,0.0031547297,0.008610655,0.000204187,0.00002703592,0.00030546566,0.0007459354,0.000025867239,0.9193712,0.00025171097],"about_ca_topic_score_codex":0.00009531212,"about_ca_topic_score_gemma":0.000109017274,"teacher_disagreement_score":0.10197752,"about_ca_system_score_codex":0.0015100088,"about_ca_system_score_gemma":0.0040512127,"threshold_uncertainty_score":0.9492275},"labels":[],"label_agreement":null},{"id":"W2102563614","doi":"10.1200/jco.2002.03.137","title":"<i>PAX3-FKHR</i> and <i>PAX7-FKHR</i> Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children’s Oncology Group","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Alveolar rhabdomyosarcoma; Medicine; Rhabdomyosarcoma; Fusion gene; PAX3; Oncology; Cohort; Malignancy; Internal medicine; Disease; Sarcoma; Cancer research; Pathology; Gene; Biology; Transcription factor; Genetics","score_opus":0.07580600184024636,"score_gpt":0.38786957149188106,"score_spread":0.31206356965163473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102563614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9442684,0.014226769,0.000016272668,0.038827773,0.00089713273,0.00071064295,0.00002291473,0.000019570287,0.0010105023],"genre_scores_gemma":[0.9767355,0.009421065,0.0029289047,0.009274856,0.0015008734,0.000038864007,0.000020380827,0.000037058955,0.00004251662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938516,0.0010643234,0.003504225,0.00052283256,0.00057038805,0.00048660504],"domain_scores_gemma":[0.9868124,0.008823345,0.0029859578,0.00052039226,0.00018735428,0.00067052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003110487,0.00032572853,0.0023055968,0.0003054357,0.00014259695,0.000022899205,0.00032829147,0.0007449703,0.00027422482],"category_scores_gemma":[0.0062425598,0.00019600899,0.0006426117,0.00049156544,0.0005515617,0.0001225079,0.00021111088,0.0019683018,0.00003530821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005092884,0.007835106,0.85802597,0.000005219722,0.00057577435,0.014920934,0.00020430946,0.0000012336618,0.00003844014,0.000033630586,0.011820132,0.10602999],"study_design_scores_gemma":[0.010863287,0.0050342875,0.87858224,0.00017004434,0.00086083775,0.008057022,0.00017761208,0.000024264828,0.00003107613,0.0002559846,0.0957858,0.00015757006],"about_ca_topic_score_codex":0.00017821432,"about_ca_topic_score_gemma":0.0004224796,"teacher_disagreement_score":0.105872415,"about_ca_system_score_codex":0.00029670473,"about_ca_system_score_gemma":0.000560653,"threshold_uncertainty_score":0.85514015},"labels":[],"label_agreement":null},{"id":"W2102574286","doi":"10.1200/jco.2003.12.155","title":"Impact of Providing Audiotapes of Primary Adjuvant Treatment Consultations to Women With Breast Cancer: A Multisite, Randomized, Controlled Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Randomized controlled trial; Mood; Breast cancer; Quality of life (healthcare); Patient satisfaction; Cancer; Intervention (counseling); Family medicine; Internal medicine; Clinical psychology; Psychiatry; Nursing","score_opus":0.2218615940306643,"score_gpt":0.5435728584505045,"score_spread":0.3217112644198402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102574286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856562,0.0013953067,0.00009694123,0.002897411,0.0010365852,0.0074937125,0.000094633506,0.000010839945,0.0013183923],"genre_scores_gemma":[0.9910578,0.0009195116,0.005747165,0.00049618044,0.00026334316,0.0013346026,0.0000024228407,0.00002363008,0.00015535054],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9807417,0.010862464,0.0072906814,0.00021061955,0.00045024249,0.00044431828],"domain_scores_gemma":[0.9480496,0.03799322,0.0101401,0.00041464073,0.0028324744,0.00056996994],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0059513724,0.00023198045,0.0061360025,0.00028877897,0.0001919526,0.00000335041,0.0003058296,0.00037099418,0.00027336547],"category_scores_gemma":[0.01795541,0.00012739317,0.00078986277,0.00032085783,0.0003240745,0.00011098963,0.000055540382,0.00087708683,0.0000049454907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9082407,0.002207543,0.06855805,0.00009590725,0.0016814691,0.00000809769,0.00612575,0.00033904935,0.000059872305,0.000112119786,0.00020886053,0.012362632],"study_design_scores_gemma":[0.9229719,0.019304935,0.05332211,0.0004704078,0.00047824602,0.00001895522,0.002524509,0.00006223403,0.0000046001605,0.000108183696,0.00062118465,0.0001127123],"about_ca_topic_score_codex":0.0009215178,"about_ca_topic_score_gemma":0.00037377316,"teacher_disagreement_score":0.032692075,"about_ca_system_score_codex":0.0019051401,"about_ca_system_score_gemma":0.017087562,"threshold_uncertainty_score":0.99031675},"labels":[],"label_agreement":null},{"id":"W2102620699","doi":"10.1200/jco.2007.13.5822","title":"Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":533,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Exemestane; Medicine; Fulvestrant; Internal medicine; Aromatase inhibitor; Oncology; Placebo; Breast cancer; Adverse effect; Hazard ratio; Clinical endpoint; Cancer; Clinical trial; Aromatase; Tamoxifen; Confidence interval","score_opus":0.020642901754743894,"score_gpt":0.32928256788148175,"score_spread":0.3086396661267379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102620699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941174,0.0019813564,0.000027122542,0.00045254536,0.00042085437,0.0027441268,0.00016575286,0.0000059988024,0.00008483625],"genre_scores_gemma":[0.9920984,0.005533777,0.0012083331,0.00015325338,0.0006188222,0.00023110126,0.000085922344,0.000034467073,0.00003592045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945498,0.0014682611,0.0027547055,0.0004280225,0.00040434094,0.00039487108],"domain_scores_gemma":[0.99501425,0.0013791127,0.0025931143,0.00028389477,0.00038420633,0.0003454098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024182573,0.00035888646,0.0030720306,0.00012185782,0.00005017461,0.000010898843,0.00023688737,0.000585548,0.000014484671],"category_scores_gemma":[0.0002627044,0.00020636903,0.0003519308,0.00015424204,0.00070547406,0.000026982112,0.0000413993,0.0007869276,0.0000017845039],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9443905,0.0029243038,0.0003866263,0.0000048444713,0.0019846726,0.0006434857,0.00024976768,0.00021548814,0.04554939,7.339459e-7,0.00008515651,0.0035650635],"study_design_scores_gemma":[0.93165845,0.058504935,0.0037854202,0.00013187407,0.00022502369,0.0003401758,0.000074269214,0.000020234991,0.0048327423,0.0000039024617,0.00017570415,0.00024728107],"about_ca_topic_score_codex":0.000069543115,"about_ca_topic_score_gemma":0.000053372503,"teacher_disagreement_score":0.05558063,"about_ca_system_score_codex":0.00007908862,"about_ca_system_score_gemma":0.0016424892,"threshold_uncertainty_score":0.8415485},"labels":[],"label_agreement":null},{"id":"W2102625113","doi":"10.1200/jco.2013.51.1816","title":"Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; EMD Serono; Varian Medical Systems; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Quest Diagnostics","keywords":"Medicine; Gefitinib; Internal medicine; Hazard ratio; Placebo; Lung cancer; Chemotherapy; Oncology; Cancer; Gastroenterology; Surgery; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.1397857239891092,"score_gpt":0.5090334062363405,"score_spread":0.3692476822472313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102625113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98095375,0.00032245816,0.00000526888,0.0068275835,0.0017298767,0.0011915666,0.000014463539,0.0000046253854,0.008950402],"genre_scores_gemma":[0.9975169,0.00020118267,0.00046830793,0.000519191,0.00046813412,0.000035889454,0.000002447949,0.000013802022,0.0007741644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645114,0.0005117533,0.0022845888,0.00018338456,0.00034305686,0.00022606262],"domain_scores_gemma":[0.9943362,0.0028795602,0.0017042189,0.00027996599,0.0006007387,0.00019931412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014960807,0.0001262325,0.0010622226,0.00010969678,0.000045836183,0.0000075217818,0.00023791124,0.00019325873,0.0001434554],"category_scores_gemma":[0.0019482198,0.00007270769,0.00028154344,0.0002680788,0.00013193513,0.00006717138,0.000072561816,0.0008490974,0.0000089543655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054783624,0.014333377,0.83345914,0.00012935264,0.0023225788,0.0005423058,0.0040790057,0.00047853394,0.00081257307,0.000026228989,0.03550726,0.053526007],"study_design_scores_gemma":[0.08298543,0.013248016,0.8957963,0.00017815706,0.0009809091,0.00002326939,0.0012855395,0.00029747875,0.00008288669,0.00002727567,0.0050206757,0.0000740454],"about_ca_topic_score_codex":0.0019677004,"about_ca_topic_score_gemma":0.0025764757,"teacher_disagreement_score":0.06233716,"about_ca_system_score_codex":0.00035269637,"about_ca_system_score_gemma":0.0025041676,"threshold_uncertainty_score":0.44422856},"labels":[],"label_agreement":null},{"id":"W2102818606","doi":"10.1200/jco.2010.29.8091","title":"Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Grip strength; Quality of life (healthcare); Prospective cohort study; Cohort; Internal medicine; Physical therapy; Cancer","score_opus":0.11232970211998645,"score_gpt":0.4866826939303071,"score_spread":0.37435299181032067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102818606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985122,0.0001259785,0.000022394388,0.0007547617,0.00019290905,0.00016127668,0.0000061493865,0.0000015792178,0.00022274369],"genre_scores_gemma":[0.9989966,0.00041124778,0.000079557794,0.00022943369,0.00025711837,0.000003652522,0.0000012201282,0.00000726113,0.000013921259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828047,0.00024188627,0.0010442114,0.00009924571,0.0002471048,0.00008709138],"domain_scores_gemma":[0.9973447,0.0008508104,0.0012755056,0.00010498585,0.0002852416,0.00013881135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016673377,0.00007693636,0.0009821287,0.00007996084,0.0000073947376,0.0000019273193,0.00003912536,0.00010965016,0.000038288097],"category_scores_gemma":[0.0006127945,0.00004393409,0.00017524938,0.00012313036,0.00015280773,0.00006294289,0.000007954374,0.00056674593,2.5931058e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030224778,0.0012688388,0.8821673,0.00003801609,0.00025704794,0.000004680001,0.00056628755,0.000029353938,0.0051930426,0.000055242614,0.000051391427,0.08014404],"study_design_scores_gemma":[0.0092624305,0.020369418,0.9693279,0.000056325403,0.0000729703,0.0000059656372,0.00011552532,0.000058284448,0.00027032784,0.00023900598,0.00018084543,0.000040986874],"about_ca_topic_score_codex":0.00087610976,"about_ca_topic_score_gemma":0.0012669412,"teacher_disagreement_score":0.08716063,"about_ca_system_score_codex":0.000043163163,"about_ca_system_score_gemma":0.0011385652,"threshold_uncertainty_score":0.24622606},"labels":[],"label_agreement":null},{"id":"W2102852047","doi":"10.1200/jco.2012.47.2365","title":"Outcomes of Critically Ill Patients With Hematologic Malignancies: Prospective Multicenter Data From France and Belgium—A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Intensive care unit; Internal medicine; Organ dysfunction; Population; Comorbidity; Prospective cohort study; Sepsis","score_opus":0.20255962477735842,"score_gpt":0.4897952056117011,"score_spread":0.28723558083434264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102852047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931287,0.00010208522,0.00089753343,0.0043751867,0.00023040482,0.0009149026,0.000018982464,0.000012567145,0.00031960127],"genre_scores_gemma":[0.9745892,0.000097741635,0.02105694,0.0040531927,0.00011725453,0.000030912277,0.000004253293,0.000014710242,0.0000357779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610794,0.00145226,0.0016671824,0.00029028486,0.0002875319,0.00019481289],"domain_scores_gemma":[0.99083585,0.005247866,0.0010600121,0.00038389087,0.0022560866,0.00021632685],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025629937,0.00015544286,0.0014133481,0.00006974267,0.000045727636,0.000013694764,0.00025930913,0.0004186083,0.00012032366],"category_scores_gemma":[0.018203031,0.00009303646,0.00010558897,0.000121496225,0.00025956766,0.00033019323,0.00013562226,0.0011328384,0.000010140646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013282192,0.0040719877,0.9894213,0.000034279743,0.0003911135,0.00007202679,0.00035442074,9.76658e-7,0.00017479545,0.00005015674,0.00041065435,0.0036900665],"study_design_scores_gemma":[0.009082675,0.012359265,0.9756137,0.00013013495,0.00042467847,0.000047478297,0.00092767837,0.00003964994,0.00007907873,0.00066674035,0.0005379744,0.000090925176],"about_ca_topic_score_codex":0.00016932868,"about_ca_topic_score_gemma":0.00018873219,"teacher_disagreement_score":0.020159408,"about_ca_system_score_codex":0.0001736897,"about_ca_system_score_gemma":0.00068386865,"threshold_uncertainty_score":0.99006706},"labels":[],"label_agreement":null},{"id":"W2102879385","doi":"10.1200/jco.2009.26.1917","title":"Translating Gene Expression Into Clinical Care: Sarcomas As a Paradigm","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Carcinogenesis; Gene expression profiling; Cancer research; Epigenetics; Sarcoma; Dermatofibrosarcoma protuberans; Bioinformatics; Computational biology; Gene; Biology; Cancer; Gene expression; Pathology; Genetics; Internal medicine","score_opus":0.12252887199393254,"score_gpt":0.5020317538732869,"score_spread":0.3795028818793544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102879385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739899,0.0022216614,0.000083777166,0.016322875,0.003134943,0.000238957,0.0000013456067,0.000017091088,0.003989427],"genre_scores_gemma":[0.94617325,0.00080003747,0.046605937,0.0027680616,0.0035682921,0.000007546155,0.000003831014,0.000025214362,0.000047819554],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948801,0.00055579154,0.003543085,0.000295523,0.00044995142,0.00027559107],"domain_scores_gemma":[0.99279445,0.0041515767,0.0015774227,0.00035719175,0.00030785557,0.00081149687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034106409,0.00018886848,0.0018380135,0.00010287276,0.000077312456,0.000013474837,0.00020947924,0.0007736464,0.00029394098],"category_scores_gemma":[0.0044487994,0.00012215458,0.0011935957,0.00010265647,0.0002801375,0.00009973897,0.00004991417,0.002248281,0.000076379845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017093838,0.0033242619,0.46242332,0.000015897484,0.00023721615,0.0021473481,0.00028813962,9.834381e-7,0.0017755086,0.00023828702,0.0010473746,0.5267923],"study_design_scores_gemma":[0.022726525,0.019381296,0.63860476,0.00019154575,0.0009891122,0.0021358915,0.00025097217,0.000034390065,0.0028938416,0.002616289,0.3099653,0.00021007797],"about_ca_topic_score_codex":0.00003433272,"about_ca_topic_score_gemma":0.00007626263,"teacher_disagreement_score":0.5265822,"about_ca_system_score_codex":0.000075072436,"about_ca_system_score_gemma":0.0016672682,"threshold_uncertainty_score":0.9767787},"labels":[],"label_agreement":null},{"id":"W2103043365","doi":"10.1200/jco.2010.29.1609","title":"Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prophylactic cranial irradiation; Conventional PCI; Internal medicine; Radiation therapy; Lung cancer; Clinical endpoint; Hazard ratio; Surgery; Cumulative incidence; Oncology; Gastroenterology; Confidence interval; Randomized controlled trial; Cohort; Myocardial infarction","score_opus":0.0690466779464682,"score_gpt":0.45353329635248596,"score_spread":0.3844866184060178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103043365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967998,0.00019972754,0.00039208104,0.0003346989,0.00090632925,0.0012921502,0.000009741687,0.0000035509627,0.000061892126],"genre_scores_gemma":[0.9952959,0.00018446,0.0040591834,0.00016423278,0.00018884844,0.000026153994,0.00006204232,0.000014639923,0.0000045757515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957655,0.0005868742,0.0027481792,0.00023770383,0.00048489776,0.00017686424],"domain_scores_gemma":[0.99295247,0.0015549152,0.004421428,0.00022583787,0.00067959,0.00016576178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020294522,0.00017081264,0.0022734294,0.0003955279,0.00003026478,0.0000041646153,0.00012581074,0.00027881924,0.00006027473],"category_scores_gemma":[0.00044047082,0.000119472024,0.0003164433,0.00064359535,0.00010497696,0.0001537335,0.000017958404,0.0007608399,2.9401957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06341632,0.035768993,0.59434134,0.000030737567,0.0016875266,0.000024242576,0.00044386834,0.0010381944,0.0005120914,0.0000028184277,0.0000123775435,0.30272147],"study_design_scores_gemma":[0.14129499,0.099929415,0.75172406,0.000019725712,0.0037875976,7.446934e-7,0.00018794065,0.0027428868,0.0000698428,0.000002222467,0.00016884795,0.000071725444],"about_ca_topic_score_codex":0.0002155412,"about_ca_topic_score_gemma":0.0013965798,"teacher_disagreement_score":0.30264977,"about_ca_system_score_codex":0.00034443542,"about_ca_system_score_gemma":0.0015312004,"threshold_uncertainty_score":0.48719278},"labels":[],"label_agreement":null},{"id":"W2103059478","doi":"10.1200/jco.2009.26.8771","title":"Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clusterin; Docetaxel; Clinical endpoint; Prednisone; Prostate cancer; Internal medicine; Urology; Prostate; Adverse effect; Cancer; Surgery; Oncology; Randomized controlled trial","score_opus":0.08797018575555066,"score_gpt":0.4825405741041998,"score_spread":0.39457038834864916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103059478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968367,0.00007154747,0.000020120637,0.00069891976,0.00027929607,0.0020001098,0.00001740745,0.0000047184935,0.000071173534],"genre_scores_gemma":[0.9948586,0.000050652758,0.0045934515,0.00020056749,0.0001011643,0.00006568247,0.000002740999,0.00002165674,0.00010544914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958277,0.00074939424,0.0025209272,0.0002511699,0.0004418331,0.00020900893],"domain_scores_gemma":[0.99476844,0.0015429525,0.00243833,0.00022799562,0.00070664746,0.00031561093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00288433,0.00018874458,0.0028355422,0.00018475227,0.000037887472,0.000006920484,0.000103744285,0.00012594566,0.00012862176],"category_scores_gemma":[0.0026476542,0.000095723386,0.00010769344,0.0001687971,0.0006337493,0.000119779244,0.000054287615,0.000833661,3.905002e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6687026,0.015755385,0.3066033,0.000069666,0.0006203522,0.0005808868,0.0011722428,0.000017087983,0.00017813931,0.0000036028182,0.000026385174,0.006270341],"study_design_scores_gemma":[0.64462984,0.09171035,0.2608324,0.00014889355,0.0017166032,0.00014094298,0.000506488,0.00010096702,0.000018767929,0.00002214597,0.000081664846,0.000090959635],"about_ca_topic_score_codex":0.000106834756,"about_ca_topic_score_gemma":0.003469108,"teacher_disagreement_score":0.075954966,"about_ca_system_score_codex":0.000043118413,"about_ca_system_score_gemma":0.0016400944,"threshold_uncertainty_score":0.39034864},"labels":[],"label_agreement":null},{"id":"W2103134643","doi":"10.1200/jco.2004.06.075","title":"Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":808,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Rash; Internal medicine; Tolerability; Epidermal growth factor receptor; Mucositis; Oncology; Head and neck cancer; EGFR inhibitors; Population; Erlotinib Hydrochloride; Phases of clinical research; Gastroenterology; Cancer; Adverse effect; Toxicity","score_opus":0.11746944661713041,"score_gpt":0.4563328035458323,"score_spread":0.33886335692870184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103134643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973692,0.00040179215,0.000001809649,0.00057397847,0.00086090504,0.0007259286,0.000027555294,0.0000021945907,0.000036615686],"genre_scores_gemma":[0.99846166,0.00015577752,0.0008541793,0.0003632166,0.00010661287,0.000009372234,9.823101e-7,0.000015841788,0.000032376527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615353,0.0008746942,0.0021431253,0.0002048567,0.00039824194,0.00022557768],"domain_scores_gemma":[0.9967098,0.00078061054,0.0015147186,0.0001612099,0.0005873284,0.00024633523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010558649,0.00017621249,0.0017662145,0.00009770079,0.00005127725,0.0000027055867,0.00010182477,0.00009598512,0.00011266937],"category_scores_gemma":[0.0021706796,0.00008651295,0.00013273628,0.00020677516,0.00023419001,0.0001112629,0.000054187178,0.0006114028,2.6447051e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038023196,0.053047974,0.87480754,0.00014298895,0.00017554538,0.00004903256,0.0019527187,0.0000035765433,0.00016803527,0.0000021490723,0.0003703084,0.031256933],"study_design_scores_gemma":[0.088506095,0.22888412,0.67904675,0.00030685888,0.00039979361,0.0000059127083,0.0007461074,0.000012601666,0.0006730058,0.0000023684402,0.0013217736,0.000094637486],"about_ca_topic_score_codex":0.0001372212,"about_ca_topic_score_gemma":0.0013062814,"teacher_disagreement_score":0.19576082,"about_ca_system_score_codex":0.00009597719,"about_ca_system_score_gemma":0.00084044604,"threshold_uncertainty_score":0.35278958},"labels":[],"label_agreement":null},{"id":"W2103257412","doi":"10.1200/jco.2005.07.757","title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Gemcitabine; Internal medicine; Transitional cell carcinoma; Hazard ratio; Cisplatin; Bladder cancer; Urology; Oncology; Methotrexate; Chemotherapy; Doxorubicin; Antimetabolite; Progression-free survival; Gastroenterology; Cancer; Confidence interval","score_opus":0.08192046514609955,"score_gpt":0.42374901589519676,"score_spread":0.34182855074909724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103257412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221325,0.0002857507,0.00033865494,0.001348793,0.000882586,0.0017065809,0.00002692611,0.000013231966,0.0031842005],"genre_scores_gemma":[0.99256927,0.0002221709,0.004952338,0.00037490204,0.0013121039,0.000041748248,0.000021109407,0.000048792113,0.00045759632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99209386,0.0011275965,0.0048945877,0.00042066586,0.0010066273,0.00045666486],"domain_scores_gemma":[0.9899384,0.004171566,0.00410124,0.00032191607,0.001041457,0.00042545848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043168864,0.00038907927,0.00563351,0.00032069779,0.000042502183,0.000013570358,0.00023136627,0.00037564125,0.00021057784],"category_scores_gemma":[0.0024303054,0.00022224546,0.00053737714,0.00038568536,0.0004534547,0.00020926578,0.00006353101,0.0011885146,0.0000045269003],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79479307,0.0023568282,0.18737827,0.0000416278,0.0017540449,0.0001856618,0.00023032358,0.0012621686,0.0000116546835,0.000006929673,0.00020104193,0.011778356],"study_design_scores_gemma":[0.6875517,0.017183756,0.29235923,0.00049349555,0.0016220221,0.000030624295,0.000023445253,0.0003322453,0.000066282366,0.000006639565,0.0001698765,0.00016071105],"about_ca_topic_score_codex":0.0003635754,"about_ca_topic_score_gemma":0.0025375083,"teacher_disagreement_score":0.10724141,"about_ca_system_score_codex":0.00050338346,"about_ca_system_score_gemma":0.0029567776,"threshold_uncertainty_score":0.9062907},"labels":[],"label_agreement":null},{"id":"W2103273190","doi":"10.1200/jco.2013.50.3557","title":"Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Cardiomyopathy; Anthracycline; Medicine; Single-nucleotide polymorphism; Trimetazidine; Internal medicine; Cardiotoxicity; Genotype; Pathogenesis; Oncology; Cancer; Heart failure; Genetics; Biology; Chemotherapy; Gene; Breast cancer","score_opus":0.034568330972309984,"score_gpt":0.3930925797206757,"score_spread":0.3585242487483657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103273190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567843,0.0016945882,0.0025273776,0.00617741,0.0015794571,0.00026997202,0.000026632972,0.0000064106885,0.002039738],"genre_scores_gemma":[0.9922303,0.0012045874,0.002313149,0.0013189609,0.0026331467,0.000009766784,0.000052713298,0.00002669302,0.00021069273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949037,0.0017943024,0.0021209258,0.0004643448,0.00034817032,0.0003685434],"domain_scores_gemma":[0.9955935,0.0015797013,0.0015448782,0.00056428235,0.00031543564,0.00040220388],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007845737,0.00021171583,0.0010706492,0.00005820646,0.00013808238,0.000029547144,0.00054348656,0.0007660365,0.000046977486],"category_scores_gemma":[0.008745586,0.00013322425,0.00045085978,0.000108274806,0.000674756,0.0000126009945,0.00031915895,0.0011143438,0.000007662849],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036246837,0.0014723166,0.1034205,0.000009281116,0.0015255222,0.0028373438,0.00008145009,0.00004528741,0.01564726,0.0003896615,0.013905361,0.8570413],"study_design_scores_gemma":[0.006797445,0.017121954,0.310889,0.000037312733,0.00030808308,0.006099406,0.00007136629,0.00023728801,0.0007381554,0.0012138305,0.65620536,0.0002807915],"about_ca_topic_score_codex":0.00031004904,"about_ca_topic_score_gemma":0.00020363044,"teacher_disagreement_score":0.85676056,"about_ca_system_score_codex":0.000040628427,"about_ca_system_score_gemma":0.0010220112,"threshold_uncertainty_score":0.99960417},"labels":[],"label_agreement":null},{"id":"W2103672421","doi":"10.1200/jco.2005.04.3414","title":"Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":725,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Procarbazine; Lomustine; Radiation therapy; Internal medicine; Chemotherapy; Vincristine; Oligodendroglioma; Hazard ratio; Oncology; Oligodendroglial Tumor; Progression-free survival; Surgery; Gastroenterology; Glioma; Confidence interval; Astrocytoma; Cyclophosphamide; Cancer research","score_opus":0.05896249243758883,"score_gpt":0.4160309246196261,"score_spread":0.35706843218203727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103672421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805217,0.0050877472,0.0041239928,0.004929695,0.0021473235,0.0030663533,0.000019369734,0.000021412225,0.00008245454],"genre_scores_gemma":[0.9795484,0.0062816427,0.008568935,0.00095206435,0.004367274,0.00014361234,0.000043341413,0.00006845974,0.000026263699],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944479,0.00066892547,0.0035365536,0.00043628123,0.000495664,0.00041470124],"domain_scores_gemma":[0.9909771,0.0042533833,0.0036777488,0.00030425607,0.0004172125,0.00037029476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024643359,0.00040624474,0.004190665,0.00043064926,0.0000831975,0.000025745572,0.00021042096,0.00067547115,0.0000945692],"category_scores_gemma":[0.0002914648,0.000268048,0.0008514106,0.00029525426,0.00047465853,0.00015653395,0.000012630432,0.0005324386,4.888906e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7199082,0.024458673,0.00058848195,0.000023447135,0.0021683292,0.00023693113,0.00016728247,0.00004157457,0.0026216265,0.00015640653,0.003796994,0.24583207],"study_design_scores_gemma":[0.7029583,0.25845602,0.002389794,0.00006323422,0.0005189893,0.000340876,0.00006107897,0.00091392896,0.0010799821,0.00014914267,0.032897457,0.0001712333],"about_ca_topic_score_codex":0.00005372865,"about_ca_topic_score_gemma":0.00015632182,"teacher_disagreement_score":0.24566083,"about_ca_system_score_codex":0.00047371958,"about_ca_system_score_gemma":0.0011447093,"threshold_uncertainty_score":0.9999772},"labels":[],"label_agreement":null},{"id":"W2103689930","doi":"10.1200/jco.2007.13.9451","title":"Letting Go of the Hope That Psychotherapy Prolongs Cancer Survival","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Psychotherapist; Cancer survival; Oncology; Internal medicine; Psychology","score_opus":0.21420238248057655,"score_gpt":0.5012624062803178,"score_spread":0.28706002379974127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103689930","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05919289,0.0038971724,0.00007903648,0.90549165,0.022945981,0.00040360662,0.000020826652,0.000010182924,0.007958649],"genre_scores_gemma":[0.018516205,0.00541023,0.0002543285,0.9331524,0.037480623,0.000009173246,0.000005043465,0.00008446182,0.0050875447],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99423724,0.0009230851,0.0029318158,0.00030425,0.0011714868,0.00043212334],"domain_scores_gemma":[0.99026924,0.002865421,0.0053692595,0.00050557306,0.0008046446,0.00018585158],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005415517,0.00029967408,0.002847267,0.00016578149,0.00004464554,0.000010391446,0.0006234543,0.0022768613,0.00053175195],"category_scores_gemma":[0.00069502665,0.00017049488,0.0018477294,0.0002505948,0.00050465675,0.000057055742,0.000045434062,0.0076847346,0.0000064963738],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026227157,0.0002622745,0.06984839,0.00020578578,0.0008548187,0.0007093791,0.00024765002,0.0000012494386,0.000030261961,0.000007487465,0.8209402,0.104269765],"study_design_scores_gemma":[0.0036017774,0.002678109,0.034320425,0.00065877533,0.0006494352,0.00023202079,0.00007153224,0.000001288823,0.000057988884,0.00013421517,0.9574423,0.0001521179],"about_ca_topic_score_codex":0.00031188963,"about_ca_topic_score_gemma":0.0012378957,"teacher_disagreement_score":0.13650209,"about_ca_system_score_codex":0.00022792107,"about_ca_system_score_gemma":0.0033403388,"threshold_uncertainty_score":0.9990184},"labels":[],"label_agreement":null},{"id":"W2103690933","doi":"10.1200/jco.2005.05.3801","title":"Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":392,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Rhabdomyosarcoma; Medicine; Stage (stratigraphy); Internal medicine; Sarcoma; Survival rate; Surgery; Localized disease; Gastroenterology; Embryonal rhabdomyosarcoma; Cancer; Pathology","score_opus":0.05119035631378852,"score_gpt":0.3925034858214832,"score_spread":0.34131312950769466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103690933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963811,0.0009251942,0.000012146339,0.0016817629,0.00016740894,0.0006626532,0.0000139671665,0.000006923441,0.00014886592],"genre_scores_gemma":[0.9984503,0.00033149164,0.00059427705,0.00043618266,0.00010389225,0.000020250345,0.0000318634,0.0000197614,0.00001198285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99530846,0.00086421566,0.0026994844,0.00032421894,0.0004909929,0.00031261845],"domain_scores_gemma":[0.9878521,0.009098068,0.0022165806,0.00027609704,0.00037557722,0.00018156094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015005413,0.0003011304,0.00320519,0.0006578291,0.000059022103,0.000008983029,0.00017367609,0.0002326868,0.000027511762],"category_scores_gemma":[0.0013263287,0.00014457288,0.00057143305,0.00073773606,0.0006396684,0.000083411076,0.000074256415,0.000689475,0.0000013532191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049376627,0.01336173,0.93838584,0.000014725721,0.007402339,0.00032571345,0.00020541932,0.000039490682,0.0000027936599,0.000103927494,0.0001494146,0.035070922],"study_design_scores_gemma":[0.018228186,0.036150366,0.9368784,0.00016422,0.007718455,0.00004011916,0.00033289578,0.00004354154,0.000014176861,0.000081192215,0.00023353602,0.00011491189],"about_ca_topic_score_codex":0.00023093283,"about_ca_topic_score_gemma":0.00092695444,"teacher_disagreement_score":0.03495601,"about_ca_system_score_codex":0.0002870804,"about_ca_system_score_gemma":0.00021761637,"threshold_uncertainty_score":0.5895511},"labels":[],"label_agreement":null},{"id":"W2103768560","doi":"10.1200/jco.2004.02.060","title":"Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute of Mental Health","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Proportional hazards model; Epirubicin; Hazard ratio; Multivariate analysis; Population; Cancer; Quality of life (healthcare); Confidence interval","score_opus":0.12593044767154538,"score_gpt":0.49192113056688586,"score_spread":0.3659906828953405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103768560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953136,0.00019097752,0.000025883397,0.003316791,0.0008291799,0.00027103425,0.000030968076,0.000002470678,0.000019101919],"genre_scores_gemma":[0.99837655,0.00017369621,0.000792679,0.00046681805,0.00014224701,0.000010746905,0.000021035732,0.000011331813,0.000004873442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616367,0.0007144707,0.002457906,0.00023026529,0.00026493688,0.00016877694],"domain_scores_gemma":[0.99703467,0.00030327463,0.0020705399,0.00015037249,0.00024649734,0.00019464306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014530966,0.0001388955,0.00095919316,0.000082337305,0.00002664441,0.0000059387144,0.00020194164,0.00014351013,0.000023347506],"category_scores_gemma":[0.0017257849,0.00010528906,0.00021472131,0.00008994811,0.000115167415,0.000020716681,0.00006244026,0.00026772553,0.0000010596885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026135044,0.0047405213,0.9836784,0.000011254574,0.0007300557,0.000016579874,0.00046582762,0.0012947731,0.0000427923,0.000013168876,0.000009448099,0.0063836817],"study_design_scores_gemma":[0.009060216,0.0038472684,0.9859453,0.00004344706,0.00006994573,0.000017711343,0.0007790635,0.000007009404,0.000018908973,0.00009513266,0.00003201771,0.000083984145],"about_ca_topic_score_codex":0.004279852,"about_ca_topic_score_gemma":0.0048501655,"teacher_disagreement_score":0.006446712,"about_ca_system_score_codex":0.00017594208,"about_ca_system_score_gemma":0.0008463353,"threshold_uncertainty_score":0.64698845},"labels":[],"label_agreement":null},{"id":"W2103820559","doi":"10.1200/jco.2013.51.2400","title":"Challenge and Opportunity of Targeted Lung Cancer Chemoprevention","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Selenium in Biological Systems","field":"Nursing","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Army Medical Research Acquisition Activity; National Institutes of Health; University of California, Los Angeles; National Cancer Institute; National Center for Advancing Translational Sciences; U.S. Department of Veterans Affairs","keywords":"Medicine; Lung cancer; Cancer; Oncology; Intensive care medicine; Internal medicine; Cancer research","score_opus":0.2063247216389292,"score_gpt":0.47384274694083894,"score_spread":0.2675180253019097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103820559","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19891825,0.008321145,0.000022511393,0.77502817,0.015065749,0.0005621373,0.0000268553,0.00001991717,0.002035254],"genre_scores_gemma":[0.5208847,0.007228292,0.0016120956,0.42495257,0.043926977,0.000039977283,0.000050733634,0.000104037346,0.0012006408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922978,0.0021642111,0.004373897,0.00032655045,0.00047456566,0.00036293291],"domain_scores_gemma":[0.98664933,0.0038849278,0.008149541,0.00025741625,0.000759955,0.00029884954],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004071197,0.00029022133,0.0030216335,0.0001479453,0.00003980592,0.00001317313,0.0004524279,0.0039274585,0.001041412],"category_scores_gemma":[0.0044236006,0.00019942899,0.0007414318,0.00009361935,0.00039403862,0.00013075545,0.00010434126,0.004919857,0.0000072125695],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052327634,0.0003723547,0.005757958,0.0004323154,0.00047604585,0.00011109194,0.00004814866,8.7166444e-7,0.00039930997,0.0000055509727,0.9346717,0.057201393],"study_design_scores_gemma":[0.0022797526,0.005224329,0.0294387,0.000511431,0.00065914594,0.00013380128,0.000027554092,0.00007991696,0.000089211,0.0008336123,0.9604468,0.0002757608],"about_ca_topic_score_codex":0.00018097319,"about_ca_topic_score_gemma":0.000018267188,"teacher_disagreement_score":0.35007563,"about_ca_system_score_codex":0.00024193921,"about_ca_system_score_gemma":0.00047460187,"threshold_uncertainty_score":0.9998718},"labels":[],"label_agreement":null},{"id":"W2103845135","doi":"10.1200/jco.2012.30.15_suppl.8502","title":"Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF<sup>V600E</sup></i>-mutated melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Vemurafenib; Dacarbazine; Hazard ratio; Internal medicine; Interim analysis; Temozolomide; Metastatic melanoma; Gastroenterology; Oncology; Surgery; Randomized controlled trial; Confidence interval; Chemotherapy; Cancer","score_opus":0.07959961057608907,"score_gpt":0.3936601599823536,"score_spread":0.31406054940626454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103845135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936966,0.0002200617,0.0004225175,0.00032082995,0.0009605181,0.0034373133,0.00008958283,0.000013063314,0.00083951314],"genre_scores_gemma":[0.99403834,0.00011713891,0.002605995,0.00057632127,0.0014569894,0.00008943947,0.0008610373,0.000064257896,0.0001904604],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99263436,0.0016972501,0.0038405673,0.0005898764,0.0004241267,0.0008138216],"domain_scores_gemma":[0.99396014,0.0012658086,0.0029206462,0.00043882985,0.0007790429,0.0006355163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005730469,0.00048015485,0.003068575,0.00014640151,0.00009661718,0.00006822674,0.0006197964,0.00065342983,0.000020498359],"category_scores_gemma":[0.0026007628,0.00031507388,0.00032032898,0.0001911736,0.00030840086,0.00008963889,0.00026017608,0.0007347792,0.0000056789045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96728814,0.010855598,0.013597354,0.000027317552,0.001113146,0.00009604257,0.00019699242,0.00016071646,0.0011417705,0.000027210936,0.0030960115,0.0023997081],"study_design_scores_gemma":[0.94078845,0.034773353,0.0016607754,0.00015309906,0.00064396486,0.000049742313,0.00005275258,0.0009996195,0.0012094303,0.000010395903,0.019231915,0.00042648558],"about_ca_topic_score_codex":0.00009847146,"about_ca_topic_score_gemma":0.00028142857,"teacher_disagreement_score":0.026499664,"about_ca_system_score_codex":0.00010226967,"about_ca_system_score_gemma":0.0008952728,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W2103938143","doi":"10.1200/jco.2008.20.5815","title":"Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Clinical trial; Lung cancer; Cancer; Oncology; Internal medicine; Quality of life (healthcare); Toxicity; Chemotherapy; Surgery; Cisplatin","score_opus":0.17421797725299568,"score_gpt":0.5393429777387311,"score_spread":0.3651250004857354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103938143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99255747,0.0004429322,0.00003309036,0.004588577,0.0010378045,0.00089925533,0.00017081163,0.0000030787896,0.00026700078],"genre_scores_gemma":[0.9942592,0.0017787281,0.0004106519,0.0024029678,0.00083512225,0.000026838683,0.000020410524,0.000012146133,0.00025394303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9867321,0.0025663625,0.008860645,0.00039307977,0.0011701332,0.000277671],"domain_scores_gemma":[0.9836085,0.005269243,0.009127827,0.0003971268,0.0012338386,0.00036348766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015947737,0.00025752911,0.00752037,0.0005572535,0.000036467118,0.000005670322,0.00041739034,0.0004916447,0.0008835795],"category_scores_gemma":[0.004775198,0.00014495711,0.0024913943,0.0019581923,0.00027263895,0.000103842554,0.000035991325,0.00066474744,1.4821318e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14226486,0.0116121415,0.78037626,0.00006472439,0.030417016,0.000032981767,0.00016907755,0.0054782247,0.00022818433,0.000028246619,0.0016864764,0.027641805],"study_design_scores_gemma":[0.1023504,0.0074344845,0.8533804,0.00018514377,0.028255643,0.0000018141578,0.000036446105,0.0071127973,0.00024901828,0.0000124023945,0.0008516022,0.00012988114],"about_ca_topic_score_codex":0.049719375,"about_ca_topic_score_gemma":0.48882657,"teacher_disagreement_score":0.43910718,"about_ca_system_score_codex":0.001384711,"about_ca_system_score_gemma":0.012568345,"threshold_uncertainty_score":0.9930295},"labels":[],"label_agreement":null},{"id":"W2103988492","doi":"10.1200/jco.2009.23.5952","title":"Universal Poor Survival in Children With Medulloblastoma Harboring Somatic <i>TP53</i> Mutations","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medulloblastoma; Medicine; Oncology; Internal medicine; Hazard ratio; Radiation therapy; Mutation; Pathology; Confidence interval; Biology; Genetics; Gene","score_opus":0.03987580452525163,"score_gpt":0.3895007123319772,"score_spread":0.34962490780672556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103988492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917601,0.00003788375,0.000023142535,0.006163328,0.0006569754,0.00017819669,0.0000022462548,0.000008576959,0.0011696022],"genre_scores_gemma":[0.995377,0.000036950958,0.0036612928,0.0003745221,0.00050904416,0.0000035619291,0.0000025020233,0.000014051378,0.00002104629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810374,0.00015332343,0.001126805,0.00013761403,0.00028684255,0.00019170572],"domain_scores_gemma":[0.99747175,0.0011298733,0.0007419653,0.00013670496,0.00019923993,0.00032044962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001119178,0.0001136101,0.0009038585,0.00017813487,0.000030921834,0.000008482486,0.00010923435,0.00020800876,0.00010269552],"category_scores_gemma":[0.0010255061,0.000073581476,0.00021477608,0.00017885004,0.00015563084,0.000106442865,0.000024035524,0.0009275493,0.000016083852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045470995,0.0026382252,0.978381,0.000004788899,0.00040613016,0.0008558308,0.00005265114,0.000026684547,0.0006332119,0.0002886956,0.00014844471,0.016109673],"study_design_scores_gemma":[0.013328951,0.0050944877,0.97793096,0.000070759976,0.0004712551,0.0007901365,0.000112989066,0.00006746746,0.0003401692,0.00011308525,0.0016130066,0.00006675154],"about_ca_topic_score_codex":0.000044873726,"about_ca_topic_score_gemma":0.0005637086,"teacher_disagreement_score":0.016042922,"about_ca_system_score_codex":0.000078477446,"about_ca_system_score_gemma":0.0009780201,"threshold_uncertainty_score":0.40297917},"labels":[],"label_agreement":null},{"id":"W2104011278","doi":"10.1200/jco.2001.19.1.279","title":"Adjuvant Chemotherapy For Women With Young Children: Our Patients as Parents","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Citation; Feeling; Population; Adjuvant chemotherapy; Breast cancer; Family medicine; Disease; Cancer; Isolation (microbiology); Oncology; Internal medicine; Library science; Psychology; Bioinformatics","score_opus":0.0677570143166536,"score_gpt":0.4485080153167142,"score_spread":0.3807510010000606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104011278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98193944,0.00003254986,0.00008102421,0.0046966607,0.0025998948,0.00035516542,0.00000536875,0.000013361099,0.010276565],"genre_scores_gemma":[0.99261695,0.00048808343,0.00078847876,0.0031017477,0.001778851,0.000014827312,0.0000022442657,0.00002062848,0.0011881992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967952,0.0004354403,0.0014460451,0.00019755278,0.00063416857,0.0004916001],"domain_scores_gemma":[0.99626666,0.00075037626,0.0017131162,0.00014026953,0.0006473995,0.00048217052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004315616,0.00013177098,0.0009169041,0.0000745228,0.00019202963,0.000028460672,0.00049010455,0.00035107107,0.00013121258],"category_scores_gemma":[0.0027004608,0.00009336472,0.00021977248,0.00017993784,0.00021554065,0.0002592136,0.00002763622,0.00045556313,0.000024395755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028144892,0.0012054231,0.8502021,0.0000022061122,0.00016336386,0.000034473727,0.0017437193,0.0000046765663,8.5138043e-7,0.000101755475,0.006388699,0.13733825],"study_design_scores_gemma":[0.007938033,0.008525325,0.7722117,0.000024007364,0.000040269202,0.000026074798,0.0050736656,0.0000025070524,0.0000021049607,0.0015044042,0.20450234,0.00014962137],"about_ca_topic_score_codex":0.00017115235,"about_ca_topic_score_gemma":0.00039868767,"teacher_disagreement_score":0.19811364,"about_ca_system_score_codex":0.0003104335,"about_ca_system_score_gemma":0.0017109922,"threshold_uncertainty_score":0.38073027},"labels":[],"label_agreement":null},{"id":"W2104141617","doi":"10.1200/jco.2002.09.018","title":"Chronic Arm Morbidity After Curative Breast Cancer Treatment: Prevalence and Impact on Quality of Life","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":356,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphedema; Quality of life (healthcare); Breast cancer; Asymptomatic; Odds ratio; Cancer; Physical therapy; Radiation therapy; Internal medicine; Surgery","score_opus":0.1964276727885044,"score_gpt":0.5155238768665957,"score_spread":0.31909620407809136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104141617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98647547,0.008554125,0.0000048019415,0.0033655304,0.00033673728,0.00017950188,0.000073467876,0.0000037258558,0.0010066252],"genre_scores_gemma":[0.99270016,0.0051110312,0.000031760756,0.0005968362,0.0013082301,0.000007754405,3.8985365e-7,0.000006886221,0.00023693194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725085,0.00055755296,0.0016182106,0.00014725323,0.0002784753,0.00014767492],"domain_scores_gemma":[0.9956176,0.0019754954,0.0014616534,0.00016036718,0.00026660247,0.0005182464],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008711298,0.0001315794,0.001366769,0.00005367404,0.00001748513,0.0000042223146,0.00005955614,0.00016607191,0.0019312941],"category_scores_gemma":[0.0013829012,0.000070248476,0.0004526571,0.00006219865,0.000232921,0.00009172156,0.000015594796,0.0000862524,0.00001126961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006153107,0.0030388515,0.9468024,0.00019740946,0.0005518835,0.00010875924,0.00017086997,0.0000074902287,0.000023771781,0.000012765054,0.0011342457,0.04179846],"study_design_scores_gemma":[0.00845415,0.0151747465,0.97475743,0.0003201368,0.00041835563,0.00014861426,0.000036638085,0.00007118851,0.000017980115,0.0000378608,0.0005021047,0.000060789076],"about_ca_topic_score_codex":0.00015447018,"about_ca_topic_score_gemma":0.000041855914,"teacher_disagreement_score":0.041737672,"about_ca_system_score_codex":0.00041543756,"about_ca_system_score_gemma":0.0014183004,"threshold_uncertainty_score":0.99898106},"labels":[],"label_agreement":null},{"id":"W2104504726","doi":"10.1200/jco.2007.13.9030","title":"Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2670,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Les Laboratories Pierre Fabre; Sanofi; GlaxoSmithKline; Eli Lilly and Company","keywords":"Medicine; Vinorelbine; Internal medicine; Vinca; Chemotherapy; Etoposide; Hazard ratio; Vinca alkaloid; Cisplatin; Lung cancer; Oncology; Stage (stratigraphy); Vindesine; Clinical trial; Confidence interval; Pharmacology; Cyclophosphamide; Vincristine","score_opus":0.09634526887575641,"score_gpt":0.4933364237251135,"score_spread":0.3969911548493571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104504726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94100076,0.008737335,0.00024729918,0.044155393,0.00072581525,0.0005190164,0.000012991393,0.0000070115275,0.0045943945],"genre_scores_gemma":[0.9920347,0.0025478073,0.0009404092,0.00339382,0.0006803533,0.000027482387,0.000011929615,0.000008739306,0.00035476265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996356,0.0009337307,0.001653245,0.00018391456,0.00071040576,0.00016270335],"domain_scores_gemma":[0.99401885,0.0029166432,0.001550671,0.00022709959,0.0010384427,0.00024831563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040439363,0.00012391653,0.0014036656,0.000094570896,0.00010406673,0.000007706309,0.0001253517,0.00019703768,0.00057915197],"category_scores_gemma":[0.0019809701,0.000064216416,0.00063788326,0.00064436835,0.00019955268,0.000073746945,0.000027133254,0.0005243658,0.0000133928515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038546068,0.0045031738,0.58792436,0.000014566507,0.01826908,0.001029279,0.0007403329,0.0002725642,0.000036228474,0.00012782431,0.30197704,0.081250936],"study_design_scores_gemma":[0.017960796,0.010890061,0.8608953,0.00006571517,0.03005998,0.00034489456,0.00038559732,0.0030873718,0.00005778959,0.00011000505,0.07602202,0.000120499986],"about_ca_topic_score_codex":0.00003052996,"about_ca_topic_score_gemma":0.00013666114,"teacher_disagreement_score":0.2729709,"about_ca_system_score_codex":0.0005461228,"about_ca_system_score_gemma":0.0019546698,"threshold_uncertainty_score":0.63413084},"labels":[],"label_agreement":null},{"id":"W2104523965","doi":"10.1200/jco.2011.39.3330","title":"Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Adjuvant; Chemotherapy; Oncology; Adjuvant chemotherapy; Cancer; Lung cancer; Population; Internal medicine; Environmental health; Breast cancer","score_opus":0.07325339644843908,"score_gpt":0.4445664619504895,"score_spread":0.3713130655020504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104523965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98658866,0.00053390185,0.0000118563685,0.01069,0.00095202145,0.0010258952,0.0000026744003,0.0000011176097,0.00019386101],"genre_scores_gemma":[0.99385744,0.00006214398,0.00037535827,0.0049892706,0.0005124596,0.00011705096,0.0000024553428,0.000010985189,0.00007281031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793506,0.00019691042,0.0012667745,0.00011629145,0.00023976866,0.00024520716],"domain_scores_gemma":[0.9970915,0.001874562,0.0006378817,0.00013967931,0.000104215265,0.00015217987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021057292,0.000108782726,0.00088480086,0.00006340012,0.000023044018,0.0000046058544,0.00011122025,0.00012030849,0.0001533507],"category_scores_gemma":[0.0001804832,0.00006202566,0.00017752293,0.000088722714,0.00001177745,0.000038934428,0.000006810745,0.00052755856,2.6195488e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012708798,0.0055069113,0.97200215,0.000022466571,0.00013217324,0.000100521844,0.0006171396,0.00011131362,0.0000010367621,0.000002229202,0.0028366712,0.017396532],"study_design_scores_gemma":[0.020047104,0.0060659507,0.9651488,0.0000990951,0.0003173842,0.0000061909222,0.00030310027,0.00011137648,0.0000067124465,0.0000084453895,0.007826433,0.00005940906],"about_ca_topic_score_codex":0.8354801,"about_ca_topic_score_gemma":0.9963649,"teacher_disagreement_score":0.16088478,"about_ca_system_score_codex":0.0025154075,"about_ca_system_score_gemma":0.007101996,"threshold_uncertainty_score":0.9985268},"labels":[],"label_agreement":null},{"id":"W2104748005","doi":"10.1200/jco.2009.24.3030","title":"Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Biomarker; Hazard ratio; Epidermal growth factor receptor; KRAS; Cancer; Confidence interval; Biology; Colorectal cancer","score_opus":0.12122439436534593,"score_gpt":0.490069456183446,"score_spread":0.36884506181810006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104748005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81279683,0.005029476,0.00011056207,0.17714004,0.0010080634,0.0030650578,0.000292911,0.000007282604,0.0005498023],"genre_scores_gemma":[0.6755992,0.014041041,0.0021429576,0.2910148,0.014183404,0.00021293339,0.0015624062,0.00014645128,0.0010967684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99362993,0.0010904528,0.0041783825,0.0004306356,0.00038528323,0.00028528637],"domain_scores_gemma":[0.9891506,0.0052449717,0.0044774604,0.0006299021,0.00029973814,0.00019734915],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024969308,0.00035221598,0.004883724,0.00016136357,0.00002962682,0.000020101652,0.0005057906,0.0008673124,0.00008355481],"category_scores_gemma":[0.0015459047,0.0001725228,0.00054125057,0.00014022653,0.0004005752,0.0000910666,0.00009693721,0.0027376944,6.2514374e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8106689,0.0031454663,0.019508561,0.00015206989,0.0071682786,0.0055068927,0.00038561376,0.0000120139275,0.000011817388,0.0000014233051,0.14404379,0.009395188],"study_design_scores_gemma":[0.91934365,0.010500534,0.0017220643,0.0010022788,0.020149916,0.00008685639,0.000045277775,0.00019603879,0.000010080022,0.000019256966,0.0467663,0.00015776789],"about_ca_topic_score_codex":0.0010429894,"about_ca_topic_score_gemma":0.00051152374,"teacher_disagreement_score":0.13719755,"about_ca_system_score_codex":0.00020052852,"about_ca_system_score_gemma":0.0025259387,"threshold_uncertainty_score":0.99956304},"labels":[],"label_agreement":null},{"id":"W2105026490","doi":"10.1200/jco.2007.14.8924","title":"Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":665,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Erlotinib; KRAS; Medicine; Epidermal growth factor receptor; Hazard ratio; Fluorescence in situ hybridization; EGFR inhibitors; Internal medicine; Oncology; Erlotinib Hydrochloride; Cancer research; Cancer; Biology; Gene; Colorectal cancer; Genetics; Confidence interval","score_opus":0.1692448192514435,"score_gpt":0.5560504929225468,"score_spread":0.3868056736711033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105026490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919086,0.000641709,0.0000055974456,0.004614903,0.001031743,0.0006178043,0.000053431377,0.00000164819,0.0011245639],"genre_scores_gemma":[0.9965467,0.00058845023,0.0010721035,0.0013167827,0.00030123498,0.000012963007,0.0000022979618,0.000009676074,0.00014978797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923346,0.001571964,0.0050948523,0.00019845704,0.0006419923,0.00015812744],"domain_scores_gemma":[0.9893016,0.0066954037,0.0027122828,0.00013787576,0.00080314314,0.00034968258],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012268959,0.000121128614,0.0022598053,0.00020821992,0.000028778271,0.0000014692143,0.00012576177,0.00019340047,0.000054287848],"category_scores_gemma":[0.019187357,0.0000869868,0.00029688797,0.0002891482,0.00031346182,0.000083289524,0.00004473938,0.00036684232,4.0137502e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06258963,0.006076464,0.89022267,0.000038271053,0.0023679321,0.00034293983,0.0008674911,0.00008974974,0.0024017163,0.00006733015,0.009072067,0.025863726],"study_design_scores_gemma":[0.023683967,0.016456995,0.9189883,0.00016765705,0.0006069365,0.00009771717,0.0007349998,0.000009943181,0.00019982592,0.0000938048,0.038885757,0.000074114505],"about_ca_topic_score_codex":0.035384122,"about_ca_topic_score_gemma":0.097252354,"teacher_disagreement_score":0.061868228,"about_ca_system_score_codex":0.0002974233,"about_ca_system_score_gemma":0.016725805,"threshold_uncertainty_score":0.98907447},"labels":[],"label_agreement":null},{"id":"W2105469253","doi":"10.1200/jco.2010.31.5192","title":"WT1 Mutation and 11P15 Loss of Heterozygosity Predict Relapse in Very Low-Risk Wilms Tumors Treated With Surgery Alone: A Children's Oncology Group Study","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Children’s Oncology Group; National Cancer Institute; National Institutes of Health; CureSearch for Children's Cancer; National Childhood Cancer Foundation","keywords":"Medicine; Loss of heterozygosity; Wilms' tumor; Oncology; Internal medicine; Mutation; Pediatric oncology; Surgery; Cancer; Allele; Genetics; Gene","score_opus":0.013288757654635266,"score_gpt":0.3238003874179928,"score_spread":0.3105116297633575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105469253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873114,0.00023331003,0.00002229028,0.00017399344,0.0004969386,0.00025133634,0.00000939762,0.0000039132688,0.000077688266],"genre_scores_gemma":[0.9979306,0.0013086594,0.00021745026,0.00012938432,0.0003574794,0.0000061706573,0.000016329948,0.000017180668,0.00001677175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673957,0.0007964313,0.0017128634,0.00030984328,0.00021264545,0.00022864822],"domain_scores_gemma":[0.99681795,0.000623837,0.0019255327,0.00019748748,0.00021128361,0.00022389548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002641641,0.00018165993,0.0011377466,0.00014455957,0.000042237803,0.000006829134,0.00016813754,0.0006941311,0.00000978212],"category_scores_gemma":[0.0010043118,0.00012300166,0.00024253072,0.00015935881,0.00050293904,0.000017965685,0.00006701017,0.0012320369,8.172974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006167596,0.002322381,0.9597938,0.000013652908,0.00052944955,0.00079806405,0.000076211916,0.0001486945,0.003646071,0.0000015535569,0.00023170518,0.026270796],"study_design_scores_gemma":[0.007814076,0.024799485,0.96324426,0.000069555055,0.0002613477,0.00121544,0.00015083177,0.000035610385,0.0017490042,0.00003343364,0.00046532723,0.00016162342],"about_ca_topic_score_codex":0.00024891476,"about_ca_topic_score_gemma":0.0010987683,"teacher_disagreement_score":0.026109172,"about_ca_system_score_codex":0.000039391332,"about_ca_system_score_gemma":0.00072876055,"threshold_uncertainty_score":0.53537744},"labels":[],"label_agreement":null},{"id":"W2105473363","doi":"10.1200/jco.2005.03.209","title":"Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Pediatric Oncology Group","funders":"","keywords":"Medicine; Ifosfamide; Vincristine; Doxorubicin; Oncology; Granulocyte colony-stimulating factor; Chemotherapy; Stage (stratigraphy); Internal medicine; Pediatric oncology; Clinical trial; Cyclophosphamide; Cancer; Etoposide","score_opus":0.03969412717600098,"score_gpt":0.4176416777798495,"score_spread":0.37794755060384855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105473363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562263,0.0010558402,0.00005692892,0.00070290145,0.00014733648,0.0023125694,0.000021088294,0.000015083434,0.000065602886],"genre_scores_gemma":[0.992629,0.00085826934,0.005399445,0.0003646171,0.00064480555,0.000034665412,0.0000082015995,0.000042348798,0.000018667393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947106,0.00061784504,0.0031117934,0.00051402266,0.0005882802,0.00045740698],"domain_scores_gemma":[0.99472225,0.0016414924,0.0025225854,0.00027881967,0.00027953179,0.0005553424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019189236,0.00039207557,0.0031306965,0.00038652978,0.00009334526,0.000012659992,0.00016188029,0.00033605014,0.000037952883],"category_scores_gemma":[0.0008532032,0.00025206068,0.00016618668,0.00028161198,0.00031114498,0.00019766508,0.0001362628,0.0010250537,0.0000018723697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09406111,0.039623704,0.64804214,0.000040349725,0.00025185512,0.0019557618,0.00027370453,0.000026634281,0.00004816139,0.0000030143894,0.000031964664,0.21564157],"study_design_scores_gemma":[0.25377548,0.21262687,0.5309464,0.00012890097,0.00075237325,0.00088370155,0.00014896787,0.00005786209,0.000022823238,0.0000045578586,0.00050881604,0.00014329086],"about_ca_topic_score_codex":0.00010998843,"about_ca_topic_score_gemma":0.00058456656,"teacher_disagreement_score":0.21549828,"about_ca_system_score_codex":0.00024303213,"about_ca_system_score_gemma":0.0009435415,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W2105641380","doi":"10.1200/jco.2010.34.4309","title":"Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Internal medicine; Heart failure; Incidence (geometry); Tyrosine-kinase inhibitor; Placebo; Relative risk; Oncology; Adverse effect; Gastroenterology; Cancer; Confidence interval; Pathology","score_opus":0.09344358486587996,"score_gpt":0.38725832035002,"score_spread":0.29381473548414005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105641380","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68566245,0.31332985,0.000002123364,0.000032938788,0.000040138326,0.0006377356,0.000025865276,0.0000024123256,0.00026646373],"genre_scores_gemma":[0.33045536,0.66653097,0.0027117752,0.000039930394,0.00014152686,0.000011087103,0.000018700077,0.000042835065,0.00004782831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948045,0.0013457112,0.0027691596,0.00041158704,0.00038452845,0.0002845176],"domain_scores_gemma":[0.99100035,0.0029064177,0.0045243516,0.0002666671,0.0007626515,0.0005395722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016863577,0.000454609,0.005920262,0.00036240174,0.000027940521,0.0000074142617,0.00013238477,0.0007093624,0.00003440392],"category_scores_gemma":[0.0006725266,0.00023783608,0.00035766358,0.00024272525,0.0007264791,0.00009941409,0.00007725716,0.0019708206,0.000002225942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068309754,0.0013442327,0.84721,0.0015235601,0.00065694103,0.0011050873,0.00007001702,2.7811532e-7,2.0186867e-7,0.0000032628557,0.00010041668,0.14115502],"study_design_scores_gemma":[0.015487269,0.07373837,0.8534077,0.007908697,0.007947365,0.0013796963,0.00004187448,9.860162e-7,0.000006944727,0.00000607066,0.039838195,0.0002368364],"about_ca_topic_score_codex":0.00020686466,"about_ca_topic_score_gemma":0.00027739178,"teacher_disagreement_score":0.35520712,"about_ca_system_score_codex":0.0001828966,"about_ca_system_score_gemma":0.0023609765,"threshold_uncertainty_score":0.96986735},"labels":[],"label_agreement":null},{"id":"W2105723991","doi":"10.1200/jco.2015.62.1888","title":"Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":391,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority","funders":"National Cancer Institute; Cancer Research UK; Children’s Oncology Group","keywords":"Medicine; Clinical trial; Oncology; Wilms' tumor; Pediatric oncology; Stage (stratigraphy); Internal medicine; Disease; Intensive care medicine; Cancer","score_opus":0.15074486243898555,"score_gpt":0.5547440587690533,"score_spread":0.40399919633006776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105723991","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006999337,0.99505335,0.000016547276,0.00037740744,0.0021982593,0.0002257138,0.000015155164,0.0000016727628,0.0014119832],"genre_scores_gemma":[0.000297471,0.9972194,0.0008288061,0.00011678793,0.001352445,0.0000203072,0.00005683404,0.000014011389,0.00009395419],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973333,0.0005008749,0.0016978271,0.00025288732,0.000075010976,0.00014013147],"domain_scores_gemma":[0.9973118,0.0001422261,0.0020563733,0.00010570505,0.00026442859,0.00011951708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094285555,0.00020103823,0.0017147419,0.00007442541,0.000015635278,0.000011611179,0.0002090366,0.00073643966,0.000005088819],"category_scores_gemma":[0.00041801078,0.000118118645,0.0003287435,0.00010430612,0.0002747113,0.000014819487,0.00006022395,0.0004044963,0.000002624483],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029323917,0.00024571727,0.00031185118,0.00013264317,0.00027716704,0.00003971074,0.000014359797,0.0000040514974,0.0000020299933,0.00004160129,0.00046297288,0.99817467],"study_design_scores_gemma":[0.0016787782,0.0059890915,0.0000113094975,0.00069213565,0.00023678287,0.00024269764,0.000030021973,0.0000020810135,0.0000033484444,0.00023446817,0.99075985,0.000119465185],"about_ca_topic_score_codex":0.0000031170237,"about_ca_topic_score_gemma":0.000030557512,"teacher_disagreement_score":0.9980552,"about_ca_system_score_codex":0.00016425173,"about_ca_system_score_gemma":0.002536547,"threshold_uncertainty_score":0.56800973},"labels":[],"label_agreement":null},{"id":"W2105804758","doi":"10.1200/jco.2008.17.5588","title":"The Physician: A Secure Base","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Base (topology); Family medicine","score_opus":0.46494033592097117,"score_gpt":0.5873250731636364,"score_spread":0.12238473724266519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105804758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95649356,0.0047712605,0.00013946318,0.018496146,0.0012993314,0.0000818279,0.0000018921297,0.000005530755,0.018710999],"genre_scores_gemma":[0.9721643,0.01349912,0.0035419678,0.006735827,0.0031839425,0.000001140524,7.6189446e-7,0.000010654067,0.0008623422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793553,0.00025869318,0.0013182687,0.00007460834,0.00027561703,0.00013726592],"domain_scores_gemma":[0.9938301,0.004223407,0.0011107309,0.0001432432,0.0005083048,0.0001842591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014807425,0.00007216971,0.00090166007,0.000033838518,0.000053074804,0.0000015820898,0.00013354048,0.00017139177,0.000032552452],"category_scores_gemma":[0.0054300884,0.000037551632,0.00049016805,0.00009925455,0.00036518998,0.00004568542,0.00002496095,0.0006860863,0.000020962949],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008917369,0.003157224,0.28598782,0.00006369875,0.0014287595,0.0047830567,0.0019752232,0.000015286265,0.00066274864,0.0014639781,0.30355522,0.3879896],"study_design_scores_gemma":[0.0036708966,0.006215708,0.061077304,0.00017829755,0.00016822534,0.00026126768,0.0004103951,0.000037277427,0.00038275265,0.0004894898,0.92706174,0.00004667372],"about_ca_topic_score_codex":0.0000054196153,"about_ca_topic_score_gemma":0.000007638131,"teacher_disagreement_score":0.6235065,"about_ca_system_score_codex":0.00003959303,"about_ca_system_score_gemma":0.000977758,"threshold_uncertainty_score":0.65007156},"labels":[],"label_agreement":null},{"id":"W2105864650","doi":"10.1200/jco.2010.32.4079","title":"Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Fondation contre le Cancer; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Cohort; Hodgkin lymphoma; Breast cancer; Lymphoma; Oncology; Internal medicine; Radiation therapy; Cancer","score_opus":0.08516803699037885,"score_gpt":0.4012294280667831,"score_spread":0.31606139107640424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105864650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985701,0.00035669582,0.000029870962,0.00027777962,0.00022116027,0.00048134706,0.000024214478,0.0000016235936,0.000037235004],"genre_scores_gemma":[0.9973184,0.00084325566,0.0015051768,0.00018496042,0.000056144298,0.000054011503,8.5148866e-7,0.00000670235,0.000030524086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844563,0.0000904723,0.0011041794,0.000118136006,0.00014492344,0.0000966679],"domain_scores_gemma":[0.99797934,0.00038454932,0.001196186,0.00007710839,0.000230272,0.00013251427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010487151,0.00009568965,0.0013683712,0.00009583082,0.00000955826,0.00000110065,0.000035156907,0.00010544764,0.000019720113],"category_scores_gemma":[0.00031415568,0.000056325232,0.00006440844,0.00003257957,0.00022056242,0.00005874703,0.000015614078,0.00007158679,9.526357e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008104614,0.0071505923,0.90911496,0.00004765316,0.00076045096,0.000054537526,0.0012865424,3.6494194e-7,0.000012667032,0.000014474065,0.000025787389,0.07342735],"study_design_scores_gemma":[0.030255416,0.007389418,0.96092886,0.00007978704,0.0005713035,0.000115315925,0.00022937593,0.00003372748,0.0000072814537,0.000008730722,0.00033326473,0.00004754594],"about_ca_topic_score_codex":0.0002449563,"about_ca_topic_score_gemma":0.00012736041,"teacher_disagreement_score":0.07337981,"about_ca_system_score_codex":0.0005921381,"about_ca_system_score_gemma":0.0014523631,"threshold_uncertainty_score":0.25764298},"labels":[],"label_agreement":null},{"id":"W2105895314","doi":"10.1200/jco.2005.01.9497","title":"Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Ifosfamide; Medicine; Rhabdomyosarcoma; Etoposide; Soft tissue sarcoma; Oncology; Internal medicine; Clinical trial; Sarcoma; Surgery; Chemotherapy; Soft tissue; Pathology","score_opus":0.07534337732692417,"score_gpt":0.42659328670341123,"score_spread":0.35124990937648704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105895314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98024124,0.009728101,0.000060006492,0.008612971,0.0002720853,0.0008555443,0.000115810144,0.0000069713797,0.00010727535],"genre_scores_gemma":[0.9955093,0.0005458984,0.0025999227,0.0008372263,0.0003747207,0.000024491084,0.00006484652,0.000023240278,0.000020317673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918255,0.002202675,0.0046423003,0.000361079,0.00068771327,0.00028068386],"domain_scores_gemma":[0.9823341,0.009234356,0.0070596132,0.000724139,0.00050028996,0.00014753762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041467515,0.00031130502,0.0045122053,0.00030500325,0.00011697046,0.0000056506715,0.00044379506,0.00025454804,0.000046444624],"category_scores_gemma":[0.0025350181,0.00014371851,0.0010689521,0.000880831,0.0012267194,0.00009039483,0.00020008416,0.0010948514,0.0000010009799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031353047,0.020128548,0.9107513,0.000006809852,0.030565232,0.0014373126,0.00021873626,0.00008115057,0.00005199888,0.00006451626,0.0023331258,0.031226011],"study_design_scores_gemma":[0.030651849,0.017582214,0.9236025,0.00014043222,0.02496995,0.00084743486,0.00030889348,0.000020957288,0.00018677049,0.0006270396,0.00094608875,0.00011583607],"about_ca_topic_score_codex":0.0051750024,"about_ca_topic_score_gemma":0.0032786047,"teacher_disagreement_score":0.031110175,"about_ca_system_score_codex":0.00020063775,"about_ca_system_score_gemma":0.0010918356,"threshold_uncertainty_score":0.782309},"labels":[],"label_agreement":null},{"id":"W2106155834","doi":"10.1200/jco.2004.01.106","title":"Determining the Relationship Between Toxicity and Quality of Life in an Ovarian Cancer Chemotherapy Clinical Trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lethargy; Quality of life (healthcare); Nausea; Internal medicine; Randomized controlled trial; Clinical trial; Cancer; Ovarian cancer; Vomiting; Chemotherapy; Gynecologic oncology; Oncology","score_opus":0.6171955787318496,"score_gpt":0.6388170291255502,"score_spread":0.02162145039370056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106155834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836473,0.0001841391,0.000033350632,0.014763233,0.0008761556,0.00031732046,0.000004294738,0.0000036184363,0.00017062317],"genre_scores_gemma":[0.9925566,0.00040012816,0.00080689264,0.0032609822,0.002937594,0.0000052976225,0.0000016855304,0.000009017469,0.000021855662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947517,0.0013093464,0.0034229676,0.0001635088,0.00020253775,0.00014995373],"domain_scores_gemma":[0.9870635,0.010259568,0.0020421746,0.0001455231,0.00017946745,0.0003097177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008119476,0.00010125752,0.0015753361,0.00007325159,0.000036942427,0.000004807346,0.00012753138,0.0004291062,0.00006047097],"category_scores_gemma":[0.0063823285,0.00006275247,0.00031635936,0.00012257333,0.0003700163,0.0000948186,0.000024763558,0.0011010332,7.8602704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047882974,0.002746653,0.91349816,0.00001173774,0.0001704686,0.000011692925,0.00019332644,0.0000048407564,0.000012463546,0.00011562931,0.000070181275,0.03528184],"study_design_scores_gemma":[0.169712,0.015592588,0.8127689,0.000033774104,0.00021510928,0.0000039757683,0.000034936595,0.0000028559202,0.000010843595,0.00075779797,0.000821036,0.00004621708],"about_ca_topic_score_codex":0.00015041308,"about_ca_topic_score_gemma":0.0008005662,"teacher_disagreement_score":0.12182903,"about_ca_system_score_codex":0.00012658145,"about_ca_system_score_gemma":0.0022106033,"threshold_uncertainty_score":0.76407045},"labels":[],"label_agreement":null},{"id":"W2106169155","doi":"10.1200/jco.2003.07.113","title":"Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients","year":2003,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cumulative incidence; Total body irradiation; Internal medicine; Incidence (geometry); Lymphoma; Leukemia; Oncology; Transplantation; Chemotherapy; Cyclophosphamide","score_opus":0.10202499788244729,"score_gpt":0.4875894393266744,"score_spread":0.38556444144422714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106169155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03043088,0.9589946,0.0000036968995,0.00037546805,0.0019032421,0.0016091713,0.000026698024,0.000012906307,0.006643306],"genre_scores_gemma":[0.0003981118,0.9950952,0.0011822012,0.00034886526,0.00054228515,0.000030076233,0.00004750645,0.00010046043,0.002255297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98963916,0.0017520908,0.006713573,0.0005878842,0.000632466,0.00067480205],"domain_scores_gemma":[0.98967737,0.0041320226,0.0042513637,0.00047089692,0.00047807855,0.0009902692],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0030855082,0.0006440547,0.010015264,0.00086524937,0.00005011928,0.000021610193,0.00038158632,0.0029151,0.00013678939],"category_scores_gemma":[0.0027745522,0.00040697877,0.0016907845,0.0006064977,0.0004368633,0.00014631663,0.00014581754,0.0027492,0.00013759844],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010031748,0.0011765657,0.0024350018,0.0009245486,0.0025367006,0.0065153195,0.000046184497,2.738675e-7,1.7085563e-7,0.0000128192305,0.0030253239,0.98232394],"study_design_scores_gemma":[0.02762321,0.01959477,0.008031252,0.003684698,0.0048688925,0.0045307092,0.000015463716,0.00002350756,2.4530024e-7,0.00003636251,0.9313166,0.0002742453],"about_ca_topic_score_codex":0.000039585408,"about_ca_topic_score_gemma":0.00001683529,"teacher_disagreement_score":0.98204964,"about_ca_system_score_codex":0.009162851,"about_ca_system_score_gemma":0.024499506,"threshold_uncertainty_score":0.99983823},"labels":[],"label_agreement":null},{"id":"W2106198994","doi":"10.1200/jco.2004.09.128","title":"The Combination of <i>p53</i> Mutation and <i>neu/erb</i>B-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; North York General Hospital; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Mutation; Disease; Cancer; Cancer research; Gene; Biology; Genetics","score_opus":0.13034729828871386,"score_gpt":0.4943392522767907,"score_spread":0.3639919539880768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106198994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705966,0.00025806093,0.000148325,0.025991173,0.000358814,0.00034696452,0.000013392824,0.0000039208144,0.002282762],"genre_scores_gemma":[0.9974398,0.0011394299,0.00024829703,0.0009199802,0.000098757235,0.000011362351,0.000002005459,0.000013408842,0.00012693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964928,0.0011451306,0.0014271047,0.00015294511,0.0005889852,0.00019301004],"domain_scores_gemma":[0.9919287,0.004908873,0.0015205834,0.00011922273,0.0013680008,0.00015459814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066203275,0.00009339448,0.0007415534,0.000099155775,0.00005276736,0.000011714702,0.00010066516,0.00022547551,0.00004781905],"category_scores_gemma":[0.006147475,0.00005751034,0.00009086115,0.00035694943,0.00039437713,0.00010307668,0.000014913639,0.00082489225,0.0000014965768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079999985,0.0027560405,0.85300565,0.00007956824,0.00061190047,0.00019235187,0.0010336429,0.00007666786,0.0006747078,0.0014836971,0.0038852075,0.12820056],"study_design_scores_gemma":[0.010983234,0.0042348546,0.9783172,0.0002766186,0.00014444783,0.00018121733,0.00059315015,0.00034575598,0.0007425043,0.0012707043,0.002833412,0.00007690729],"about_ca_topic_score_codex":0.00021766376,"about_ca_topic_score_gemma":0.0008757693,"teacher_disagreement_score":0.12812366,"about_ca_system_score_codex":0.00034566838,"about_ca_system_score_gemma":0.002013841,"threshold_uncertainty_score":0.7359546},"labels":[],"label_agreement":null},{"id":"W2106275780","doi":"10.1200/jco.2009.22.3370","title":"Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gefitinib; KRAS; Epidermal growth factor receptor; Internal medicine; Oncology; Lung cancer; Rash; Response Evaluation Criteria in Solid Tumors; Regimen; Stage (stratigraphy); Progressive disease; Cancer; Clinical trial; Phases of clinical research; Chemotherapy; Colorectal cancer","score_opus":0.11865377465017504,"score_gpt":0.572227637953893,"score_spread":0.45357386330371796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106275780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896127,0.000592726,0.000049548526,0.0028993515,0.0008200534,0.0008407116,0.000012488242,0.000004852669,0.0051675895],"genre_scores_gemma":[0.99418014,0.00072133564,0.0011652807,0.0017823608,0.0007577107,0.0000137238,0.0000026333512,0.000011375877,0.001365411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950146,0.0004827532,0.003767366,0.00023780017,0.00028322884,0.00021426036],"domain_scores_gemma":[0.99598235,0.0010650856,0.0019071589,0.00020404933,0.0005197617,0.00032160294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024200606,0.00015092494,0.0017997735,0.00014251668,0.000045984234,0.0000050477015,0.0001461963,0.00027379324,0.00021432039],"category_scores_gemma":[0.0008595006,0.000101759084,0.0003791685,0.00019123612,0.00009868479,0.00010171051,0.000037267906,0.0010284997,0.0000021299525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009752083,0.14669526,0.6223377,0.00004788273,0.001191096,0.0016741968,0.0047869068,0.00021548569,0.00016034207,0.000035654863,0.0029762553,0.21012713],"study_design_scores_gemma":[0.109049916,0.23641284,0.6434891,0.00020033821,0.0019203603,0.00002846646,0.002257097,0.00039253788,0.00008591738,0.000025975703,0.006014386,0.0001230152],"about_ca_topic_score_codex":0.00010799614,"about_ca_topic_score_gemma":0.00031401863,"teacher_disagreement_score":0.21000412,"about_ca_system_score_codex":0.00020405973,"about_ca_system_score_gemma":0.0030897772,"threshold_uncertainty_score":0.5481132},"labels":[],"label_agreement":null},{"id":"W2106286200","doi":"10.1200/jco.2009.26.3756","title":"American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":798,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Tamoxifen; Breast cancer; Oncology; Adverse effect; Internal medicine; Adjuvant therapy; Guideline; Cancer; Hormone therapy; Clinical trial; Gynecology; Pathology","score_opus":0.10339424191195061,"score_gpt":0.5353548132279201,"score_spread":0.4319605713159695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106286200","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004361953,0.96507657,0.00032883385,0.020978821,0.0050018365,0.0019483966,0.0015649238,0.00001792985,0.00072075764],"genre_scores_gemma":[0.0003847126,0.94786555,0.030501109,0.0092590675,0.011301465,0.00025883282,0.0001619101,0.00013769513,0.00012963882],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9835103,0.003279822,0.010642486,0.0011754374,0.00059869944,0.0007932499],"domain_scores_gemma":[0.965619,0.009288607,0.020449184,0.00079250353,0.0031035526,0.0007471363],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.011568228,0.0008797977,0.011002913,0.00010194219,0.00011514543,0.000016156431,0.0009402934,0.0021484673,0.000058156373],"category_scores_gemma":[0.004818075,0.00054553495,0.0038236158,0.00027381908,0.002265074,0.000026041424,0.00031268445,0.003701881,0.000010556059],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036084995,0.005459837,0.0005167733,0.0001684813,0.01002266,0.000057246623,0.000026024692,0.0000023121008,0.000009333709,0.000011340108,0.07530333,0.87233764],"study_design_scores_gemma":[0.012387759,0.06049409,0.003781042,0.00059964164,0.002495129,0.00057418237,0.00016408016,0.0000016277329,0.000006102505,0.000013918378,0.91900027,0.0004821369],"about_ca_topic_score_codex":0.00008498683,"about_ca_topic_score_gemma":0.00008910544,"teacher_disagreement_score":0.8718555,"about_ca_system_score_codex":0.00039572435,"about_ca_system_score_gemma":0.0119221145,"threshold_uncertainty_score":0.9996996},"labels":[],"label_agreement":null},{"id":"W2106869018","doi":"10.1200/jco.2014.55.1192","title":"Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Watchful waiting; Cancer; Cohort; Hazard ratio; Prostate; Internal medicine; Prostate-specific antigen; Prospective cohort study; Oncology; Cohort study; Gynecology; Confidence interval","score_opus":0.03777705958447385,"score_gpt":0.41546686237161967,"score_spread":0.3776898027871458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106869018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970842,0.00032325246,0.00003686072,0.00097470824,0.00069784716,0.00042421013,0.00007737482,0.0000029727894,0.0003786028],"genre_scores_gemma":[0.9974155,0.0015949418,0.0002268259,0.00042856895,0.0002045382,0.000017283308,0.000012835478,0.000015292053,0.000084223015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974545,0.00024354113,0.0015399002,0.00016848744,0.00038873628,0.00020482921],"domain_scores_gemma":[0.994825,0.00095727405,0.0026282233,0.00018157311,0.0011839257,0.000223996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012964748,0.00012874884,0.0016804998,0.00006576098,0.000016955064,0.0000019867277,0.00009434321,0.00015025464,0.000097706754],"category_scores_gemma":[0.00080945616,0.0000764696,0.00028861503,0.00010813457,0.00017733342,0.00007090628,0.00003313005,0.00033749128,0.000001499593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015455274,0.0027896578,0.9091917,0.000084842046,0.0010466664,0.00003948723,0.000106227424,0.000004154483,0.000010120643,0.000014677758,0.00042938747,0.07082779],"study_design_scores_gemma":[0.02438234,0.021235269,0.95037186,0.0003006886,0.00043991845,0.0000064531096,0.000013220579,0.000005051994,0.0004417986,0.000023872399,0.002713857,0.00006567385],"about_ca_topic_score_codex":0.00003312229,"about_ca_topic_score_gemma":0.00025381288,"teacher_disagreement_score":0.07076211,"about_ca_system_score_codex":0.0001562226,"about_ca_system_score_gemma":0.00096110825,"threshold_uncertainty_score":0.31183398},"labels":[],"label_agreement":null},{"id":"W2107283868","doi":"10.1200/jco.2013.50.3870","title":"Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1290,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Incidence (geometry); Medicine; Demography; Lung cancer; Cancer; Internal medicine","score_opus":0.14880951449770635,"score_gpt":0.5240838037066335,"score_spread":0.3752742892089272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107283868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97367823,0.0009808069,0.000011676717,0.022481194,0.0007122427,0.00013641545,0.0000015982655,0.0000030572223,0.0019947786],"genre_scores_gemma":[0.9909785,0.0010724757,0.0030234216,0.003505845,0.0006119857,0.0000153232,6.2422936e-7,0.000007660598,0.00078416395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99814403,0.00013914572,0.0012367154,0.00013682613,0.0001303499,0.00021293353],"domain_scores_gemma":[0.9968919,0.0020076134,0.0005081766,0.00007169723,0.00025605736,0.00026455638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001554917,0.000091787435,0.0013799606,0.00013052221,0.000029743524,0.00000599182,0.000069719936,0.00015523667,0.00014628415],"category_scores_gemma":[0.0021838767,0.00006134074,0.00016787178,0.00014024637,0.00020149766,0.00013476072,0.00003539207,0.00050529017,0.0000036663375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020515209,0.00024658884,0.33121815,0.000028651833,0.00010433896,0.000117231146,0.00018573302,0.0000027487968,0.00015192862,0.0000327451,0.0257756,0.64008474],"study_design_scores_gemma":[0.0071281735,0.00889934,0.93204856,0.0000997336,0.00009883407,0.00008663229,0.000120968776,0.0002048231,0.000031982472,0.00033065543,0.050881516,0.000068798254],"about_ca_topic_score_codex":0.0012315344,"about_ca_topic_score_gemma":0.005668264,"teacher_disagreement_score":0.64001596,"about_ca_system_score_codex":0.00020798862,"about_ca_system_score_gemma":0.00085432833,"threshold_uncertainty_score":0.31630242},"labels":[],"label_agreement":null},{"id":"W2107434300","doi":"10.1200/jco.2005.09.548","title":"Randomized Study on the Efficacy of Cognitive-Behavioral Therapy for Insomnia Secondary to Breast Cancer, Part I: Sleep and Psychological Effects","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Insomnia; Medicine; Randomized controlled trial; Cognitive behavioral therapy for insomnia; Breast cancer; Anxiety; Sleep hygiene; Cognitive behavioral therapy; Physical therapy; Sleep onset; Sleep diary; Quality of life (healthcare); Sleep disorder; Actigraphy; Psychiatry; Internal medicine; Cancer; Sleep quality","score_opus":0.17359648018181192,"score_gpt":0.5183963287239589,"score_spread":0.34479984854214696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107434300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98303753,0.0006699786,0.00004474347,0.012477045,0.001377963,0.002054287,0.000020742491,0.000006426009,0.00031129632],"genre_scores_gemma":[0.9895526,0.0005485184,0.00007089922,0.007860428,0.0017918089,0.000115078976,0.0000011275628,0.0000149265,0.000044624012],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99659646,0.0011875626,0.0015165864,0.00022234746,0.00028548218,0.00019154542],"domain_scores_gemma":[0.9833409,0.014982824,0.00083101704,0.00015142086,0.00041362195,0.00028017387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043453877,0.0001587565,0.0019935481,0.00008061476,0.000046188667,0.000007999942,0.00013891852,0.00022405757,0.00018858715],"category_scores_gemma":[0.0021235473,0.000079965714,0.0005785683,0.0001082612,0.00028797804,0.00003864478,0.000028874238,0.0007645481,0.0000029228072],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46496293,0.009136319,0.015364372,0.000011045689,0.00039269926,0.000037543683,0.00085172284,0.0000013039345,0.00003956633,0.000021317157,0.0013958554,0.5077853],"study_design_scores_gemma":[0.43932557,0.0546659,0.49535564,0.00020292483,0.00071674684,0.00009532705,0.0005918936,0.000005906571,0.00008452921,0.000044144406,0.008811767,0.000099647346],"about_ca_topic_score_codex":0.000031665735,"about_ca_topic_score_gemma":0.00017272089,"teacher_disagreement_score":0.50768566,"about_ca_system_score_codex":0.000049031012,"about_ca_system_score_gemma":0.00027953525,"threshold_uncertainty_score":0.33216235},"labels":[],"label_agreement":null},{"id":"W2107561358","doi":"10.1200/jco.2011.39.7356","title":"Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":231,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; PI3K/AKT/mTOR pathway; Adverse effect; Clinical trial; Discontinuation; Hyperlipidemia; Pharmacology; Intensive care medicine; Bioinformatics; Internal medicine; Signal transduction; Diabetes mellitus; Endocrinology","score_opus":0.05326523387326427,"score_gpt":0.4033217874128861,"score_spread":0.35005655353962184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107561358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893922,0.00605574,0.000601898,0.00036928908,0.0019443836,0.0001972307,0.000006102715,0.0000038109195,0.0014293074],"genre_scores_gemma":[0.9946623,0.0010047548,0.0016570587,0.00093350996,0.0014763771,0.000009686105,0.0000050363274,0.000024633819,0.0002266381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970397,0.0007555473,0.0012584619,0.00018055449,0.00038982768,0.0003759197],"domain_scores_gemma":[0.9966058,0.0006483305,0.001973563,0.00025172488,0.0003187107,0.00020182884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044694934,0.00016788872,0.0007847225,0.0000363023,0.000057158606,0.000007771949,0.00040663526,0.00030670798,0.00004818123],"category_scores_gemma":[0.001415656,0.00009936437,0.0003508336,0.00013386499,0.00025130305,0.00001221986,0.00013262918,0.00044603428,0.00000541551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008866802,0.007824578,0.5631254,0.0003532143,0.01829878,0.0004646559,0.0005794844,0.0008204897,0.12067231,0.0016653145,0.03730023,0.24002878],"study_design_scores_gemma":[0.008325292,0.008907884,0.4930025,0.00034340066,0.0014355748,0.000049749695,0.00020049856,0.000043020056,0.085916415,0.00010855107,0.40124723,0.0004199012],"about_ca_topic_score_codex":0.000004544037,"about_ca_topic_score_gemma":0.0000045881825,"teacher_disagreement_score":0.363947,"about_ca_system_score_codex":0.000039827883,"about_ca_system_score_gemma":0.00034454948,"threshold_uncertainty_score":0.40519613},"labels":[],"label_agreement":null},{"id":"W2107677500","doi":"10.1200/jco.2006.09.5455","title":"Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Letrozole; Toremifene; Hazard ratio; Breast cancer; Internal medicine; Population; Gynecology; Tamoxifen; Adverse effect; Estrogen receptor; Cancer; Gastroenterology; Surgery; Confidence interval","score_opus":0.027483208752830484,"score_gpt":0.40284834115180324,"score_spread":0.37536513239897273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107677500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965626,0.0006904494,0.00014783205,0.00046986976,0.0005247272,0.0009720113,0.000017886021,0.0000036697224,0.0006109421],"genre_scores_gemma":[0.9974825,0.0006200098,0.00077980413,0.0002143534,0.0007321979,0.00003240071,0.000020572468,0.00002468113,0.00009348316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967424,0.00031611015,0.0019242287,0.00027830023,0.0003226959,0.00041623166],"domain_scores_gemma":[0.996427,0.0003863708,0.0021006805,0.00019049554,0.00054192304,0.00035351305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002497361,0.00023372553,0.0017633324,0.00011764701,0.000034221073,0.000006872883,0.00022910442,0.00050478685,0.00003152459],"category_scores_gemma":[0.00012545586,0.00014597418,0.00017259759,0.00019826808,0.0003301126,0.000017334465,0.000044943346,0.00072198326,9.2998846e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92959315,0.0038756307,0.00060194544,0.000008245032,0.0010064207,0.00028828488,0.00010086722,0.00043974482,0.052459035,0.000013191761,0.000114856644,0.0114986515],"study_design_scores_gemma":[0.87137234,0.11595957,0.0009071183,0.0001012192,0.00019156572,0.00027446492,0.00029441327,0.00002034713,0.009572882,0.000003862282,0.0011097986,0.00019242552],"about_ca_topic_score_codex":0.000033812663,"about_ca_topic_score_gemma":0.00009464496,"teacher_disagreement_score":0.112083934,"about_ca_system_score_codex":0.00020861148,"about_ca_system_score_gemma":0.0017448203,"threshold_uncertainty_score":0.59526545},"labels":[],"label_agreement":null},{"id":"W2107785731","doi":"10.1200/jco.2005.01.6089","title":"Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":369,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Chemotherapy; Hazard ratio; Stage (stratigraphy); Proportional hazards model; Internal medicine; Retrospective cohort study; Surgery; Cancer; Univariate analysis; Lymphovascular invasion; Oncology; Multivariate analysis; Metastasis; Confidence interval","score_opus":0.060962952404603525,"score_gpt":0.42434717779524067,"score_spread":0.36338422539063714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107785731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649495,0.00023442236,0.00024763864,0.0012425304,0.00040175862,0.00013209197,0.0009916791,0.0000016504188,0.00025329486],"genre_scores_gemma":[0.9976082,0.0004050644,0.00046584572,0.00035812033,0.001059941,0.000009285036,0.00004247088,0.000017620632,0.000033490476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809426,0.00018630522,0.0012194604,0.00017207013,0.00016735113,0.00016056404],"domain_scores_gemma":[0.99622047,0.0014765435,0.0014867488,0.00012851124,0.0006014639,0.00008625581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074581,0.00014006264,0.0010454861,0.0000654977,0.000018783709,0.000002682252,0.00010580586,0.0002238768,0.00006853795],"category_scores_gemma":[0.00043218478,0.00010158314,0.0005782051,0.00006612657,0.00010685684,0.000006203672,0.000027111391,0.00011206278,0.0000020964121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025485385,0.0020200715,0.9121408,0.000015401702,0.0014349583,0.000011308319,0.00006604928,0.00033124455,0.013572151,0.000023561655,0.0061420174,0.03875707],"study_design_scores_gemma":[0.0031713953,0.003542396,0.98251337,0.000053527787,0.00011525465,0.0000046400073,0.00001896336,0.000004458542,0.009230816,0.00012961011,0.0011243903,0.000091180365],"about_ca_topic_score_codex":0.00066016463,"about_ca_topic_score_gemma":0.00018160386,"teacher_disagreement_score":0.07037259,"about_ca_system_score_codex":0.00006854988,"about_ca_system_score_gemma":0.0006542648,"threshold_uncertainty_score":0.414244},"labels":[],"label_agreement":null},{"id":"W2107792561","doi":"10.1200/jco.2006.08.2933","title":"Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; Centers for Medicare and Medicaid Services; National Science Foundation","keywords":"Medicine; Chemotherapy; Internal medicine; Specialty; Ovarian cancer; Adverse effect; Epidemiology; Oncology; Epithelial ovarian cancer; Propensity score matching; Gynecologic oncology; Surgery; Cancer; Pathology","score_opus":0.09024954363195509,"score_gpt":0.4601325704176186,"score_spread":0.36988302678566354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107792561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89721286,0.0013998357,0.00009785528,0.096306905,0.00249907,0.00032266023,0.000008921491,0.0000063685548,0.0021455477],"genre_scores_gemma":[0.98186845,0.008378312,0.0005389988,0.0035706914,0.0044694715,0.000008980065,0.0000012214776,0.00001738878,0.0011464637],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980552,0.00016337159,0.0011586135,0.00017939715,0.00021666726,0.00022672805],"domain_scores_gemma":[0.9967567,0.0019005884,0.0007606258,0.00014944754,0.0001295954,0.00030305798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021651115,0.00014362688,0.0009808512,0.000037669008,0.00006942281,0.000015016842,0.00007515918,0.00019790619,0.00027229008],"category_scores_gemma":[0.00025502435,0.000053654378,0.00028288466,0.00006843158,0.00017285217,0.000046538127,0.000018091587,0.0003461352,0.0000023732487],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023003875,0.0017640897,0.43829697,0.000007987651,0.0008285353,0.0001771163,0.00019875138,3.2395837e-7,0.000090697045,0.00014190414,0.0045191227,0.55167407],"study_design_scores_gemma":[0.009790817,0.005230199,0.5847188,0.00004153137,0.0004280031,0.0000633489,0.000116553725,0.0000036737517,0.0006573975,0.00014449366,0.39874768,0.000057485515],"about_ca_topic_score_codex":0.00019071219,"about_ca_topic_score_gemma":0.0007004581,"teacher_disagreement_score":0.5516166,"about_ca_system_score_codex":0.00041074574,"about_ca_system_score_gemma":0.0006456739,"threshold_uncertainty_score":0.29813853},"labels":[],"label_agreement":null},{"id":"W2107985230","doi":"10.1200/jco.2005.09.050","title":"Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":465,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Medicine; Tolerability; Nausea; Vomiting; Chemotherapy; Palonosetron; Breast cancer; Oncology; Internal medicine; Chemotherapy-induced nausea and vomiting; Cancer; Antiemetic; Adverse effect","score_opus":0.06944337990183506,"score_gpt":0.42660401991157515,"score_spread":0.35716064000974007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107985230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938427,0.00022833746,0.0001746855,0.0050141714,0.00006159613,0.0006510495,0.0000037963355,0.0000019536378,0.000021682234],"genre_scores_gemma":[0.9970802,0.00029200962,0.0017828804,0.00059904874,0.00020640019,0.000011152164,3.9357482e-7,0.000011501178,0.000016381637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805427,0.00013181457,0.0013546256,0.00014628348,0.00018459946,0.00012842608],"domain_scores_gemma":[0.9974493,0.00091936433,0.0011142248,0.00012157084,0.00031911454,0.00007641986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021554357,0.0000955616,0.0008270802,0.00006097554,0.000018680279,0.000004463829,0.00006032459,0.00011708357,0.000025648887],"category_scores_gemma":[0.00030438954,0.000054390322,0.00012499274,0.00007230882,0.00011873179,0.00007348601,0.000020651576,0.0002463801,5.309052e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033561774,0.0017828655,0.56197435,0.00009800516,0.00038585602,0.0000015690324,0.00021824431,0.000025210935,0.00023545594,0.000008186385,0.00002267785,0.4016858],"study_design_scores_gemma":[0.02550681,0.004998121,0.96778196,0.00020989218,0.00022383037,0.0000075087833,0.000038055627,0.00043314198,0.00048505972,0.00006401627,0.00020074118,0.000050838604],"about_ca_topic_score_codex":0.000014732437,"about_ca_topic_score_gemma":0.000057438072,"teacher_disagreement_score":0.40580764,"about_ca_system_score_codex":0.000059841215,"about_ca_system_score_gemma":0.00021269421,"threshold_uncertainty_score":0.2217973},"labels":[],"label_agreement":null},{"id":"W2108000477","doi":"10.1200/jco.2010.29.9230","title":"Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"National Cancer Institute","keywords":"Medicine; Gabapentin; Venlafaxine; Hot flash; Randomized controlled trial; Nausea; Anesthesia; Breast cancer; Internal medicine; Cancer; Antidepressant","score_opus":0.197700321716199,"score_gpt":0.5624851224113852,"score_spread":0.36478480069518615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108000477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822201,0.00033096893,0.000029914916,0.00403391,0.01118275,0.001784196,0.000031946125,0.0000026558732,0.00038357507],"genre_scores_gemma":[0.9918617,0.0045866817,0.0016314919,0.00041295393,0.0012455463,0.00004179473,0.0000027015735,0.000019044277,0.00019809896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932038,0.0006201011,0.005234531,0.00020161664,0.00043272346,0.00030722216],"domain_scores_gemma":[0.9809054,0.0141597055,0.003820287,0.0003134276,0.00046436748,0.00033680533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014649335,0.00016395852,0.0027502119,0.00009923425,0.000034599103,0.0000072089197,0.00024176434,0.00035663915,0.00049326796],"category_scores_gemma":[0.0037876002,0.00008686121,0.00045048445,0.00011348034,0.00059093646,0.00007669686,0.00006468533,0.0009252843,0.0000035700557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88039374,0.0050129388,0.049688883,0.00018847956,0.0019688515,0.00007710136,0.000032805965,0.000006936738,0.000038010923,0.00009242339,0.00038130992,0.062118527],"study_design_scores_gemma":[0.6870675,0.012542575,0.29161352,0.00015406602,0.0014267011,0.000014230585,0.00002745591,0.00012111917,0.000013898559,0.00003110034,0.0069397767,0.000048063568],"about_ca_topic_score_codex":0.00047726597,"about_ca_topic_score_gemma":0.0009928296,"teacher_disagreement_score":0.24192464,"about_ca_system_score_codex":0.000074315496,"about_ca_system_score_gemma":0.0008208222,"threshold_uncertainty_score":0.5400938},"labels":[],"label_agreement":null},{"id":"W2108067871","doi":"10.1200/jco.2005.06.179","title":"Practitioners As Experts: The Influence of Practicing Oncologists “in-the-Field” on Evidence-Based Guideline Development","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Family medicine; Medical education; Expert opinion; MEDLINE; Evidence-based practice; Evidence-based medicine; Alternative medicine; Pathology; Intensive care medicine","score_opus":0.48751372075295,"score_gpt":0.6355009412122297,"score_spread":0.14798722045927964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108067871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6989896,0.0001042835,0.0012356583,0.2982345,0.00047415888,0.00042415728,3.111188e-7,0.0000054625134,0.0005318213],"genre_scores_gemma":[0.84848386,0.00043449935,0.020278666,0.13015231,0.00060878403,0.000014288681,0.000002087818,0.000010934067,0.000014598032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989705,0.0014794136,0.007220066,0.00023839586,0.0011029659,0.0002541094],"domain_scores_gemma":[0.87324923,0.116250314,0.008089058,0.0005028525,0.0016803966,0.00022817228],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026881399,0.00016809598,0.0009900177,0.00017091792,0.000082088416,0.00001662484,0.0004114073,0.00031809602,0.00012247931],"category_scores_gemma":[0.3767965,0.000089992864,0.0003280829,0.00035607335,0.00025406203,0.00048853393,0.000052087413,0.0016259161,0.00003015037],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06918641,0.022366242,0.0683672,0.00019352982,0.0009985338,0.0050920816,0.0038924674,0.11167689,0.0040932456,0.0019434607,0.053177048,0.6590129],"study_design_scores_gemma":[0.02963047,0.084912665,0.2941564,0.003006065,0.0010982893,0.0014447405,0.0092791915,0.00019142052,0.0032562206,0.0022429926,0.5703892,0.00039234245],"about_ca_topic_score_codex":0.00033151664,"about_ca_topic_score_gemma":0.00028963896,"teacher_disagreement_score":0.65862054,"about_ca_system_score_codex":0.00050634274,"about_ca_system_score_gemma":0.010198652,"threshold_uncertainty_score":0.9954126},"labels":[],"label_agreement":null},{"id":"W2108165913","doi":"10.1200/jco.2002.07.132","title":"Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control—Final Report of Intergroup 0114","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adjuvant; Colorectal cancer; Stage (stratigraphy); Adjuvant therapy; Cancer; Oncology; Internal medicine; Surgery","score_opus":0.15815957837757175,"score_gpt":0.47484566645886284,"score_spread":0.31668608808129106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108165913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923885,0.0033369171,0.00016370449,0.0016598866,0.0003605696,0.00017738578,0.000013581893,0.0000035327002,0.0018959609],"genre_scores_gemma":[0.99328613,0.0054915994,0.00031462385,0.00040292006,0.00014830372,0.000005991894,0.0000016651748,0.00001018879,0.00033855773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954364,0.00042904523,0.0032897212,0.00023104963,0.00041881192,0.00019499281],"domain_scores_gemma":[0.9946552,0.002091206,0.0024641051,0.00018744511,0.00034538744,0.0002566727],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023652157,0.00014763954,0.003158883,0.00037859046,0.0000105691015,0.0000024088936,0.0001073246,0.00028542432,0.0009334527],"category_scores_gemma":[0.0011411351,0.000100772966,0.0007171714,0.00052460755,0.0004231842,0.000065172215,0.000035805875,0.0006363837,6.244997e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009764215,0.0019874761,0.67001104,0.000017293327,0.0030463238,0.0032903107,0.00014631281,0.00011325672,0.00011215793,0.000007328891,0.00015046136,0.31135383],"study_design_scores_gemma":[0.019471196,0.023259286,0.94585407,0.000121360266,0.0017145313,0.00037731562,0.00014704578,0.0028887212,0.00018990527,0.000033262353,0.005853474,0.00008984018],"about_ca_topic_score_codex":0.0003448899,"about_ca_topic_score_gemma":0.00084261765,"teacher_disagreement_score":0.311264,"about_ca_system_score_codex":0.00023082503,"about_ca_system_score_gemma":0.00039066593,"threshold_uncertainty_score":0.99997985},"labels":[],"label_agreement":null},{"id":"W2108362303","doi":"10.1200/jco.2008.18.5868","title":"Perioperative or Adjuvant Therapy for Resectable Colorectal Hepatic Metastases","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Perioperative; Adjuvant; Adjuvant therapy; Surgery; Oncology; Internal medicine; General surgery; Cancer; Chemotherapy","score_opus":0.36931718433075256,"score_gpt":0.46041636783596485,"score_spread":0.09109918350521229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108362303","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4375434,0.008902003,0.00009905254,0.5457362,0.0030645812,0.00266315,0.0001519802,0.000028743423,0.0018109173],"genre_scores_gemma":[0.13330688,0.030973678,0.020516094,0.7645228,0.035186637,0.00036731854,0.0005111054,0.00024650924,0.014369],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99399453,0.0012833204,0.0031851386,0.0004058958,0.00061786594,0.0005132486],"domain_scores_gemma":[0.9874483,0.0083745,0.0023988718,0.00027365546,0.0011713369,0.0003333705],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0024102498,0.00044092635,0.004597448,0.00026841438,0.00012867451,0.00002283936,0.00027019964,0.0018326713,0.0008207582],"category_scores_gemma":[0.004506162,0.00024379557,0.0021230415,0.0001755807,0.0003748497,0.00011587396,0.00004100885,0.0032955061,0.000030891533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022492012,0.0015218268,0.03454434,0.00012725605,0.003286471,0.027078316,0.00018901027,2.9783035e-7,0.00004691903,0.000002388575,0.8714351,0.039276056],"study_design_scores_gemma":[0.015659178,0.08053333,0.0024553859,0.00017869702,0.0016010284,0.0025931143,0.000039233593,0.000104965045,0.00042318777,0.000024974432,0.8961588,0.00022807585],"about_ca_topic_score_codex":0.000031670967,"about_ca_topic_score_gemma":0.000026284255,"teacher_disagreement_score":0.30423653,"about_ca_system_score_codex":0.0002844605,"about_ca_system_score_gemma":0.0066945115,"threshold_uncertainty_score":0.99946314},"labels":[],"label_agreement":null},{"id":"W2108456088","doi":"10.1200/jco.2012.42.8896","title":"Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Exemestane; Internal medicine; Oncology; Tamoxifen; Breast cancer; Cohort; Tissue microarray; Chemotherapy; Cancer","score_opus":0.09018751833828421,"score_gpt":0.443970462360324,"score_spread":0.3537829440220398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108456088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953288,0.0007409809,0.00015915949,0.00019796347,0.0026224826,0.0008006588,0.000056662826,0.0000027300878,0.00009058639],"genre_scores_gemma":[0.9963789,0.0003015526,0.0016159553,0.000105934276,0.0014654926,0.00007424012,0.00002648681,0.000017024357,0.000014405992],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958558,0.0016132661,0.0017574589,0.00024086295,0.0002350929,0.00029751938],"domain_scores_gemma":[0.9964517,0.0013140934,0.0014910212,0.0003279032,0.00028413243,0.0001311522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053398293,0.00017477856,0.00081586116,0.000052060066,0.00005728382,0.000005199,0.00031138858,0.00042920758,0.00000835981],"category_scores_gemma":[0.004051946,0.00011473719,0.0003640617,0.000062612504,0.00023984884,0.000020961063,0.00007611737,0.00048651808,0.0000017700819],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47605342,0.02089849,0.44706085,0.000011898606,0.0011749682,0.000078883844,0.0025519633,0.000014803769,0.013876168,0.000019142748,0.0006049263,0.037654497],"study_design_scores_gemma":[0.15151434,0.06968685,0.77229047,0.000012809472,0.0006979865,0.00006094093,0.0015865039,0.000010990946,0.0011140697,0.00005582323,0.002839599,0.00012962992],"about_ca_topic_score_codex":0.00007019242,"about_ca_topic_score_gemma":0.00012290514,"teacher_disagreement_score":0.32522961,"about_ca_system_score_codex":0.000075166136,"about_ca_system_score_gemma":0.00029548857,"threshold_uncertainty_score":0.48508504},"labels":[],"label_agreement":null},{"id":"W2108565008","doi":"10.1200/jco.2010.33.0068","title":"Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Cancer Care Ontario; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Hazard ratio; Cancer; Population; Cohort; Cause of death; Prospective cohort study; Disease; Confidence interval","score_opus":0.04766505056858668,"score_gpt":0.4034093685408118,"score_spread":0.3557443179722251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108565008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963192,0.0002769856,0.00008811505,0.00085533573,0.0013981805,0.00052762445,0.00014054803,0.00000679285,0.00038721424],"genre_scores_gemma":[0.99646896,0.0003528407,0.0011934724,0.00071232725,0.0010283005,0.00016364527,0.000026005942,0.000028301385,0.000026120013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717206,0.00041313973,0.0014033496,0.0004724426,0.00033084536,0.00020815109],"domain_scores_gemma":[0.99737227,0.00009490998,0.0012815873,0.00022396405,0.0008261419,0.00020110118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015541816,0.00019046503,0.0005807879,0.0001240321,0.000058825586,0.000025321751,0.00032247606,0.00035648514,0.00006646699],"category_scores_gemma":[0.00023595002,0.00016956842,0.00014263295,0.00016592465,0.00018267472,0.00005424809,0.0000631345,0.0004559231,6.9280446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020659561,0.0013576602,0.9677527,0.000007938664,0.00042872367,0.00005631751,0.00026249856,0.00040929788,0.00040632774,0.000008389241,0.00031623582,0.026927985],"study_design_scores_gemma":[0.0038593255,0.0016630809,0.9925265,0.00003982249,0.00017035955,0.00020125887,0.00059247814,0.00014784091,0.00022471466,0.00009617134,0.00029459357,0.00018390924],"about_ca_topic_score_codex":0.0016879716,"about_ca_topic_score_gemma":0.0035429257,"teacher_disagreement_score":0.026744077,"about_ca_system_score_codex":0.000432489,"about_ca_system_score_gemma":0.0019359257,"threshold_uncertainty_score":0.69148},"labels":[],"label_agreement":null},{"id":"W2108582771","doi":"10.1200/jco.2010.34.4341","title":"Induction Chemotherapy and Conformal Radiation Therapy for Very Young Children With Nonmetastatic Medulloblastoma: Children's Oncology Group Study P9934","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Medicine; Medulloblastoma; Chemotherapy; Induction chemotherapy; Radiation therapy; Internal medicine; Oncology; Surgery; Pathology","score_opus":0.051765343500392816,"score_gpt":0.40847871576742156,"score_spread":0.35671337226702876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108582771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994446,0.00090632937,0.00013325989,0.0021767535,0.0007959519,0.0014491072,0.0000052295513,0.000010747798,0.00007661316],"genre_scores_gemma":[0.9939206,0.0011138165,0.0020415972,0.001104314,0.0017114802,0.000055086224,0.000017556582,0.000026727676,0.000008792089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754715,0.00031323772,0.0013403251,0.00018888501,0.00029550007,0.00031490327],"domain_scores_gemma":[0.99701273,0.0007857309,0.001474625,0.00014474841,0.00019934634,0.00038283883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026131407,0.00020337883,0.0013070708,0.00017646265,0.000084743726,0.000013749463,0.000078070414,0.0002747543,0.000038600636],"category_scores_gemma":[0.00030551088,0.00012519391,0.0002411047,0.000117443495,0.00016112895,0.0003122325,0.00001652387,0.00047319062,0.0000030566084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004847765,0.009042443,0.68953246,0.0000034508898,0.0018134073,0.000014212891,0.00040202995,0.0000020295572,0.00004601136,0.000026856367,0.00047882515,0.29379052],"study_design_scores_gemma":[0.044475596,0.07258055,0.87729365,0.000016241009,0.00080843514,0.0012602352,0.00028041436,0.000010676419,0.00011634355,0.000020446781,0.0030335053,0.000103889986],"about_ca_topic_score_codex":0.00003099644,"about_ca_topic_score_gemma":0.000031288197,"teacher_disagreement_score":0.29368663,"about_ca_system_score_codex":0.00017843518,"about_ca_system_score_gemma":0.00039312636,"threshold_uncertainty_score":0.51052594},"labels":[],"label_agreement":null},{"id":"W2108585052","doi":"10.1200/jco.2006.06.1440","title":"Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Oxaliplatin; Medicine; Fluorouracil; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; Cancer","score_opus":0.2516237123749373,"score_gpt":0.5059338816823887,"score_spread":0.25431016930745143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108585052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891604,0.0076086805,0.00007512115,0.0013821122,0.0004581997,0.0011313637,0.00003535559,0.0000034708237,0.00014527758],"genre_scores_gemma":[0.97596663,0.022878243,0.00026897783,0.000030779942,0.00072752975,0.000049046917,0.000012520655,0.000019068075,0.000047186648],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971554,0.0005260746,0.001638445,0.00019424869,0.0003086606,0.00017712619],"domain_scores_gemma":[0.99455416,0.0032468762,0.0014661547,0.00009606364,0.0005553843,0.00008136354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002511861,0.00016368198,0.0013928413,0.000103812104,0.00010907859,0.0000068996005,0.00007734802,0.0000853267,0.000106903404],"category_scores_gemma":[0.0001307212,0.000097642245,0.00025710146,0.00011521278,0.00059324893,0.00005913612,0.000020583555,0.00017368194,1.6504028e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4183602,0.008713089,0.019584244,0.000055062985,0.004081517,0.00001716658,0.001121304,0.00008892828,0.006994679,0.00012113762,0.00019036549,0.5406723],"study_design_scores_gemma":[0.60707307,0.20238104,0.16774228,0.00014032953,0.00082754996,0.00001571661,0.00038072732,0.0009335744,0.010136627,0.00030290923,0.009931711,0.00013446706],"about_ca_topic_score_codex":0.0018602184,"about_ca_topic_score_gemma":0.002015055,"teacher_disagreement_score":0.54053783,"about_ca_system_score_codex":0.00032556485,"about_ca_system_score_gemma":0.0006825096,"threshold_uncertainty_score":0.3981735},"labels":[],"label_agreement":null},{"id":"W2108597878","doi":"10.1200/jco.2005.01.9083","title":"High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Transplantation; Incidence (geometry); Hematopoietic stem cell transplantation; Lymphoma; Radiation therapy; Surgery; Risk factor; Oncology; Gastroenterology","score_opus":0.035314203487995625,"score_gpt":0.3382631690742938,"score_spread":0.3029489655862982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108597878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930573,0.0029505873,0.00030120558,0.0012132757,0.0005891512,0.0014065561,0.00041836663,0.0000144931955,0.000049076],"genre_scores_gemma":[0.9885502,0.009049725,0.0015827105,0.0003568338,0.00012492639,0.000084975996,0.00014028621,0.000035103265,0.00007527877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951595,0.0008102997,0.0026652706,0.00037529785,0.00068595965,0.0003036474],"domain_scores_gemma":[0.9895565,0.0058986964,0.0035061184,0.00023715157,0.0005579642,0.00024357378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013960171,0.00036984542,0.0020057252,0.000140883,0.00014051642,0.00001803556,0.00020083397,0.00041522708,0.00012222164],"category_scores_gemma":[0.00003187018,0.00020173953,0.0006665924,0.0001128783,0.00048842555,0.00016481197,0.000010056547,0.00029550283,0.0000024381416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29800323,0.04947589,0.46856952,0.0006441952,0.004824236,0.00015475607,0.0034341002,0.00014668271,0.002169265,0.0004025047,0.0014225189,0.1707531],"study_design_scores_gemma":[0.2810098,0.0503134,0.6282729,0.00021326635,0.0020372234,0.0002497609,0.0005161575,0.0002069682,0.034544285,0.00015032054,0.0021531412,0.00033279636],"about_ca_topic_score_codex":0.00007762897,"about_ca_topic_score_gemma":0.00009417055,"teacher_disagreement_score":0.1704203,"about_ca_system_score_codex":0.00012949685,"about_ca_system_score_gemma":0.0007806439,"threshold_uncertainty_score":0.8226699},"labels":[],"label_agreement":null},{"id":"W2108848521","doi":"10.1200/jco.2011.35.8838","title":"Is Breast Conservation Therapy Superior to Mastectomy for Women With Triple-Negative Breast Cancers?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Triple-negative breast cancer; Mastectomy; Breast cancer; Triple negative; Oncology; Internal medicine; Cancer","score_opus":0.08198014326064935,"score_gpt":0.3891428949576072,"score_spread":0.30716275169695784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108848521","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22137061,0.0006670273,0.0005021104,0.7710909,0.0025265883,0.0015267028,0.0014165384,0.0000134935635,0.00088600273],"genre_scores_gemma":[0.057316963,0.0015805103,0.0070760394,0.9115879,0.019030787,0.0005313685,0.00010723246,0.00016797782,0.0026012454],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967706,0.00034966518,0.0015229576,0.00053818926,0.00030123317,0.0005173221],"domain_scores_gemma":[0.9955569,0.0005587888,0.001945505,0.00035007816,0.0013483226,0.00024044159],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008960408,0.0004392066,0.0017648108,0.00012053741,0.00008572344,0.000020250614,0.00042801758,0.0012367261,0.00016985124],"category_scores_gemma":[0.00029472628,0.00029897928,0.00047154992,0.00012263405,0.00034004071,0.00001346379,0.00008324909,0.000990392,0.000008152603],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036644567,0.000357985,0.008064108,0.000053546686,0.0041352953,0.00014061887,0.00055925554,0.0000014890461,0.0001655715,0.0000020714006,0.8968873,0.05298817],"study_design_scores_gemma":[0.012498406,0.016643897,0.05975777,0.00010465663,0.00024085773,0.0010420411,0.0002254795,6.306437e-7,0.00031375914,0.00012335602,0.90866876,0.00038039518],"about_ca_topic_score_codex":0.0002236328,"about_ca_topic_score_gemma":0.00026069285,"teacher_disagreement_score":0.16405365,"about_ca_system_score_codex":0.00040880268,"about_ca_system_score_gemma":0.0030744344,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W2108969677","doi":"10.1200/jco.2010.32.0101","title":"Reply to S. Boeck et al","year":2010,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine","score_opus":0.1950563272181935,"score_gpt":0.5810501186673378,"score_spread":0.3859937914491443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108969677","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40998924,0.0018171913,0.00038250096,0.51787025,0.022613315,0.0002695908,0.000006480862,0.000007340131,0.047044102],"genre_scores_gemma":[0.22510402,0.009585707,0.07451369,0.61133623,0.018174574,0.0000125618935,0.0000035009436,0.00007344077,0.061196253],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915802,0.001885673,0.0045121904,0.00036420618,0.00083182007,0.00082589977],"domain_scores_gemma":[0.9801155,0.013645941,0.001867796,0.00054209714,0.0013442907,0.0024843884],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.028885193,0.00023564504,0.0033081737,0.00026156593,0.00007312623,0.000020723452,0.00052020577,0.0011004817,0.0052525084],"category_scores_gemma":[0.060298555,0.00017907834,0.0008145523,0.00028470525,0.0010097403,0.00017705013,0.00021335384,0.0072443094,0.0017059582],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003643449,0.0028363264,0.15857375,0.0000311512,0.00061057165,0.00340994,0.0002043951,0.0000022824756,0.0005559243,0.0022990804,0.6401339,0.18769921],"study_design_scores_gemma":[0.0057615666,0.024517883,0.23901352,0.00019427932,0.0005764088,0.0022067952,0.00012920874,0.000120510005,0.000022829574,0.0007664152,0.72657716,0.000113413436],"about_ca_topic_score_codex":0.00020015903,"about_ca_topic_score_gemma":0.00022340988,"teacher_disagreement_score":0.1875858,"about_ca_system_score_codex":0.00022794273,"about_ca_system_score_gemma":0.012437057,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W2108995265","doi":"10.1200/jco.2014.57.9029","title":"RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":395,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Ductal carcinoma; Radiation therapy; Breast cancer; Hazard ratio; Tamoxifen; Cumulative incidence; Randomized controlled trial; Surgery; Breast-conserving surgery; Prospective cohort study; Internal medicine; Mastectomy; Cancer; Urology; Confidence interval; Cohort","score_opus":0.10859456473376032,"score_gpt":0.41991842277807956,"score_spread":0.3113238580443192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108995265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939268,0.0009953092,0.0018940358,0.0011408781,0.00077777274,0.0008408967,0.0000037447824,0.0000029403302,0.00041762824],"genre_scores_gemma":[0.9905973,0.00026984728,0.0068950457,0.00022182458,0.001872982,0.00008156519,0.00000780718,0.000015544394,0.000038082148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99768007,0.0005793976,0.0012041342,0.0002201351,0.00014011559,0.00017616243],"domain_scores_gemma":[0.9972268,0.00074850145,0.0013619106,0.00012285411,0.0004156117,0.00012434286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030208111,0.00014345122,0.0014068396,0.00004867201,0.000032037013,0.000008842787,0.0001271758,0.00022006956,0.0000014240712],"category_scores_gemma":[0.0023538657,0.00009460629,0.00033698766,0.00007018415,0.00020468704,0.000011167092,0.000029717694,0.00026035684,4.1817262e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7527337,0.00065152475,0.24275388,0.0000035823994,0.0005921746,0.000018100978,0.00019505051,0.00013222177,0.00012453513,0.000070236674,0.0003709547,0.0023540608],"study_design_scores_gemma":[0.86939335,0.012079917,0.11473143,0.000014692714,0.0002305981,0.000055638768,0.00014913612,0.000119030774,0.00035208848,0.00040847313,0.0023571383,0.00010848244],"about_ca_topic_score_codex":0.00007895067,"about_ca_topic_score_gemma":0.0006095961,"teacher_disagreement_score":0.12802245,"about_ca_system_score_codex":0.00015536789,"about_ca_system_score_gemma":0.0009137235,"threshold_uncertainty_score":0.38579324},"labels":[],"label_agreement":null},{"id":"W2109133025","doi":"10.1200/jco.2004.11.020","title":"Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institute of General Medical Sciences; McGill University; American Society of Clinical Oncology","keywords":"Medicine; Pharmacogenetics; Leukemia; Oncology; Internal medicine; Gene; Genotype; Genetics","score_opus":0.07460962482152407,"score_gpt":0.417696029908034,"score_spread":0.34308640508650995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109133025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974574,0.00020906249,0.0001195967,0.0013603474,0.0003541704,0.0003514241,0.0000183816,0.0000045142924,0.00012511537],"genre_scores_gemma":[0.9972963,0.00031622298,0.001208496,0.0008360902,0.00028091363,0.0000030748338,0.0000015683047,0.00001500762,0.000042375446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980223,0.00015491758,0.0012895227,0.0001160865,0.0002546529,0.00016248785],"domain_scores_gemma":[0.99651563,0.0009905827,0.0017857053,0.00016052922,0.0002785753,0.00026900411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008358364,0.00010843005,0.00092276226,0.000051056522,0.0000477557,0.0000034455638,0.0001445133,0.00018241424,0.000039237537],"category_scores_gemma":[0.0019017991,0.000052658612,0.00069529936,0.000104301784,0.0003542174,0.000051713036,0.000028153761,0.0005465579,0.0000014180933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022950424,0.00065856165,0.98060596,0.000017152286,0.00063564547,0.000014042314,0.000074088544,0.00024036762,0.000308223,0.000006260939,0.0009962755,0.014148393],"study_design_scores_gemma":[0.012860689,0.008058771,0.9709308,0.000111084475,0.0020488093,0.000075307005,0.00007740401,0.0000071798104,0.0044161347,0.0002463614,0.0011063735,0.0000610463],"about_ca_topic_score_codex":0.0001389184,"about_ca_topic_score_gemma":0.00006474689,"teacher_disagreement_score":0.014087346,"about_ca_system_score_codex":0.000109099536,"about_ca_system_score_gemma":0.0020887132,"threshold_uncertainty_score":0.37052876},"labels":[],"label_agreement":null},{"id":"W2109240520","doi":"10.1200/jco.2009.22.9427","title":"Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Queen's University","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Placebo; Clinical trial; Lung cancer; Randomized controlled trial; Oncology; Internal medicine; Clinical endpoint; Double blind; Cancer; Chemotherapy; Cisplatin; Pathology","score_opus":0.20092922610680142,"score_gpt":0.563303123281749,"score_spread":0.3623738971749476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109240520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877349,0.0013326264,0.00015602836,0.0019478195,0.0013477039,0.006096399,0.000008835885,0.00000887192,0.001366812],"genre_scores_gemma":[0.99187875,0.001854395,0.0036764836,0.000676999,0.0012537419,0.000119619,0.0000040795157,0.000028387412,0.00050754653],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.988547,0.0031372078,0.007060495,0.00041954505,0.00051053724,0.00032521124],"domain_scores_gemma":[0.9847415,0.0094756475,0.004628488,0.0002792859,0.00041446797,0.00046062606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023106284,0.0003049809,0.006421109,0.0002481029,0.000044984445,0.000017377795,0.00016639323,0.00047201372,0.00009549483],"category_scores_gemma":[0.004644452,0.00016243942,0.00072090665,0.00029504922,0.00027706253,0.00015385232,0.000031448362,0.0011694635,9.837158e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8863081,0.009931212,0.036069352,0.000040862404,0.0013757406,0.0005214801,0.0006799328,0.000059142414,0.000025148038,0.000013187483,0.00020388268,0.064771995],"study_design_scores_gemma":[0.8935656,0.066981405,0.031385235,0.00027497002,0.0059857867,0.000054100256,0.00085453567,0.0001489636,0.000009559163,0.000044654535,0.0005429805,0.00015218939],"about_ca_topic_score_codex":0.00024577053,"about_ca_topic_score_gemma":0.0013180905,"teacher_disagreement_score":0.06461981,"about_ca_system_score_codex":0.00019408109,"about_ca_system_score_gemma":0.003427204,"threshold_uncertainty_score":0.8008223},"labels":[],"label_agreement":null},{"id":"W2109288884","doi":"10.1200/jco.2008.18.7435","title":"Biologic Cost of Caring for a Cancer Patient: Dysregulation of Pro- and Anti-Inflammatory Signaling Pathways","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Inflammation; Internal medicine; Systemic inflammation; Circadian rhythm; Endocrinology; Immunology; Oncology","score_opus":0.1323130167714102,"score_gpt":0.43124323109753554,"score_spread":0.2989302143261253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109288884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965767,0.0014234183,0.00024979113,0.00072990835,0.0005534492,0.00028995183,0.000009319013,0.000003553741,0.00016385435],"genre_scores_gemma":[0.9980227,0.00041241723,0.00076556264,0.00037268,0.00040903964,0.000004142979,0.000001829395,0.0000054304724,0.0000062466984],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979921,0.00011325519,0.0015187347,0.00010486188,0.00015497807,0.00011610076],"domain_scores_gemma":[0.99684,0.00073197717,0.0016797717,0.000078801975,0.00055596785,0.00011349069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012382936,0.000075689844,0.0009500973,0.000082806735,0.000018307437,0.0000019162705,0.000052288276,0.00022861762,0.000013192771],"category_scores_gemma":[0.00080586283,0.000054057855,0.00024486578,0.00007082318,0.00010815161,0.000050167015,0.000013851497,0.00023772183,8.1154724e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044600787,0.0005500981,0.25057456,0.0002624004,0.00021077725,0.00003802374,0.0011160354,0.00020427466,0.042166054,0.00038140206,0.00011855866,0.69991773],"study_design_scores_gemma":[0.009939292,0.02765053,0.9244624,0.0011112131,0.000715858,0.00009137846,0.0011129075,0.00070505694,0.02081195,0.0015546613,0.011659704,0.0001850806],"about_ca_topic_score_codex":0.00002439994,"about_ca_topic_score_gemma":0.000068694986,"teacher_disagreement_score":0.69973266,"about_ca_system_score_codex":0.000057793437,"about_ca_system_score_gemma":0.00058536784,"threshold_uncertainty_score":0.22044154},"labels":[],"label_agreement":null},{"id":"W2109361172","doi":"10.1200/jco.2009.26.5264","title":"Impact of Short-Course Preoperative Radiotherapy for Rectal Cancer on Patients' Quality of Life: Data From the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 Randomized Clinical Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Hotel Dieu Hospital; Medical Council of Canada","funders":"","keywords":"Medicine; Quality of life (healthcare); Sexual function; Colorectal cancer; Radiation therapy; Clinical trial; Cancer; Randomized controlled trial; Chemoradiotherapy; Surgery; Internal medicine","score_opus":0.7352409241861854,"score_gpt":0.6833024811672459,"score_spread":0.05193844301893946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109361172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743489,0.0011122231,0.00012539091,0.0067388066,0.012085719,0.003383482,0.0018312341,0.0000045310244,0.00036970634],"genre_scores_gemma":[0.98354423,0.004718356,0.00081456284,0.0011160416,0.0094851805,0.00015687212,0.00008356514,0.000033300046,0.000047869275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9524061,0.02199678,0.017341007,0.00079245394,0.0069318847,0.00053178886],"domain_scores_gemma":[0.53623724,0.42698893,0.014274555,0.0016254858,0.018739024,0.0021347697],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23063079,0.00034128182,0.008995271,0.000087857174,0.000097585165,0.000011963129,0.0012274295,0.001255032,0.0018307497],"category_scores_gemma":[0.56387836,0.00017351823,0.0028828494,0.00032986494,0.0032288819,0.00019691388,0.00021750135,0.0037494511,6.110461e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7190817,0.009151393,0.17554581,0.000022859707,0.007519671,0.000017746328,0.000067995774,0.000019368897,0.000018487015,0.00007203262,0.028155528,0.06032739],"study_design_scores_gemma":[0.56598115,0.023964975,0.3937619,0.00022510863,0.0010238363,0.0000035771893,0.000028152781,0.0010223968,0.000009635363,0.00018400764,0.013654277,0.00014098467],"about_ca_topic_score_codex":0.095315024,"about_ca_topic_score_gemma":0.3634803,"teacher_disagreement_score":0.41616884,"about_ca_system_score_codex":0.0015160255,"about_ca_system_score_gemma":0.13552968,"threshold_uncertainty_score":0.99948376},"labels":[],"label_agreement":null},{"id":"W2109398899","doi":"10.1200/jco.2012.46.6946","title":"Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"National Cancer Institute; National Institutes of Health; Caring for Carcinoid Foundation","keywords":"PI3K/AKT/mTOR pathway; Neuroendocrine tumors; PTEN; Medicine; Protein kinase B; RPTOR; Cancer research; Everolimus; Immunohistochemistry; Mechanistic target of rapamycin; TSC2; P70-S6 Kinase 1; Internal medicine; Oncology; Biology; Signal transduction; Cell biology","score_opus":0.09507841783384745,"score_gpt":0.4413521650224179,"score_spread":0.34627374718857046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109398899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100393,0.00026852987,0.000027274567,0.0066134627,0.0005147329,0.00071666937,0.0000019960182,0.0000095977775,0.000843788],"genre_scores_gemma":[0.9943355,0.00029730302,0.00409195,0.00057878933,0.00043259354,0.000026068594,0.0000010626928,0.000021540049,0.00021519688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99476665,0.0008215286,0.0031258215,0.00023695934,0.00064413215,0.00040492695],"domain_scores_gemma":[0.99287075,0.0040279957,0.0017715408,0.0002535376,0.0005433046,0.00053287816],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00094083464,0.00015498398,0.0016781442,0.000260709,0.00001706874,0.0000064527335,0.00029426036,0.00002490242,0.0002884694],"category_scores_gemma":[0.012647985,0.0001052784,0.0003134369,0.00023274157,0.0003373558,0.00021272174,0.000120703146,0.0013847897,0.000034279503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006279146,0.008844578,0.6708842,0.00038521073,0.00008751744,0.043252647,0.000049151207,0.00015476026,0.18528318,0.000066011125,0.0069751646,0.07773841],"study_design_scores_gemma":[0.01034131,0.026905611,0.89520335,0.00064128614,0.000049351827,0.0039610816,0.00016377795,0.00023513338,0.038075913,0.0006975244,0.023579726,0.00014590635],"about_ca_topic_score_codex":0.00003475935,"about_ca_topic_score_gemma":0.0000119104325,"teacher_disagreement_score":0.22431917,"about_ca_system_score_codex":0.000077452394,"about_ca_system_score_gemma":0.0009986743,"threshold_uncertainty_score":0.9956689},"labels":[],"label_agreement":null},{"id":"W2109401203","doi":"10.1200/jco.2005.02.7771","title":"Conservation Surgery for Breast Cancer As the Preferred Choice: A Prospective Analysis","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Logistic regression; Breast cancer; Prospective cohort study; Family medicine; Mastectomy; Cancer; Surgery; General surgery; Internal medicine","score_opus":0.06612327579696962,"score_gpt":0.4369308128034184,"score_spread":0.37080753700644875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109401203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722575,0.0011759184,0.0005015184,0.024599731,0.0006877504,0.00023312899,0.000082602644,0.0000038209755,0.00045806114],"genre_scores_gemma":[0.9950046,0.00038997352,0.00023860681,0.0016594077,0.002358825,0.00005781957,0.000017366,0.000009825806,0.0002635606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983193,0.00020086051,0.0009957834,0.00018519221,0.00013910433,0.0001597031],"domain_scores_gemma":[0.9965866,0.0013267322,0.0012119527,0.00014607851,0.0006725396,0.00005605851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011259152,0.0001103899,0.00070330454,0.000054598215,0.0000833654,0.000010550202,0.00012767974,0.00019950715,0.000028135702],"category_scores_gemma":[0.0009944416,0.000066578825,0.0007177514,0.0001809764,0.00017900394,0.0000066807743,0.00003622144,0.00015174097,0.0000012028443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024291063,0.0005017861,0.9535816,0.0000057276034,0.0033561282,0.000004893142,0.000015826987,0.00015548331,0.00025232634,0.000067364424,0.023270296,0.01635952],"study_design_scores_gemma":[0.0016361554,0.0004969288,0.9507094,0.00000780532,0.0013201975,0.000036991052,0.000030366511,0.000024980658,0.0002677226,0.00042462803,0.04497238,0.0000724458],"about_ca_topic_score_codex":0.00052525254,"about_ca_topic_score_gemma":0.0025675686,"teacher_disagreement_score":0.022940323,"about_ca_system_score_codex":0.00007447955,"about_ca_system_score_gemma":0.0008793957,"threshold_uncertainty_score":0.2715006},"labels":[],"label_agreement":null},{"id":"W2109458824","doi":"10.1200/jco.2007.15.4963","title":"Randomized Controlled Trial of Resistance or Aerobic Exercise in Men Receiving Radiation Therapy for Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":553,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Calgary; University of Alberta; University of Ottawa","funders":"","keywords":"Medicine; Aerobic exercise; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Quality of life (healthcare); Adverse effect; Clinical endpoint; Radiation therapy; Internal medicine; Physical therapy; Cancer; Nursing","score_opus":0.08794232037035374,"score_gpt":0.4478021506734625,"score_spread":0.35985983030310875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109458824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805613,0.0068785828,0.000059697897,0.0050777458,0.0023933765,0.0042718635,0.0000031895595,0.000005114511,0.000749105],"genre_scores_gemma":[0.918436,0.07680653,0.00038627363,0.0004260587,0.0010017895,0.00037255939,0.0000015324445,0.0000157386,0.0025535012],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950506,0.0009016688,0.0034406085,0.00014173317,0.00029480088,0.00017057403],"domain_scores_gemma":[0.9886113,0.007691913,0.0029029835,0.000121000216,0.00054234214,0.00013045354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008487676,0.00011530962,0.004365046,0.0001452472,0.000026801661,0.0000029658877,0.00009644102,0.00025462458,0.00008824154],"category_scores_gemma":[0.007090862,0.00006616587,0.0009584325,0.00015770315,0.00017475431,0.00007562331,0.000007491037,0.00040023986,3.5731662e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94780916,0.00071994885,0.0015346719,0.000042957457,0.00029637886,0.000053701842,0.00094789534,0.0000121535095,0.000049423412,0.000008113102,0.002200011,0.04632561],"study_design_scores_gemma":[0.98133886,0.0051694503,0.003712219,0.00035063806,0.00030937855,0.0000107706865,0.00012277467,0.00005987068,0.00009247439,0.00014167323,0.008625627,0.00006624345],"about_ca_topic_score_codex":0.00010726471,"about_ca_topic_score_gemma":0.0008122243,"teacher_disagreement_score":0.069927946,"about_ca_system_score_codex":0.0001550031,"about_ca_system_score_gemma":0.0028354237,"threshold_uncertainty_score":0.84889364},"labels":[],"label_agreement":null},{"id":"W2109606613","doi":"10.1200/jco.2006.05.9188","title":"Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091—A Report From the Children's Oncology Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute; National Institutes of Health; American Society of Clinical Oncology","keywords":"Medicine; Sarcoma; Ifosfamide; Etoposide; Cyclophosphamide; Chemotherapy; Vincristine; Ewing's sarcoma; Doxorubicin; Surgery; Incidence (geometry); Population; Internal medicine; Oncology; Pathology","score_opus":0.04799851228871429,"score_gpt":0.40413740265058945,"score_spread":0.3561388903618752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109606613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96738166,0.0051824916,0.0018438926,0.023328315,0.0008428059,0.0003058758,0.000025152049,0.000013004528,0.0010768144],"genre_scores_gemma":[0.9891254,0.0005333536,0.0019715137,0.0057132537,0.0025078708,0.000013993241,0.00009096443,0.000020792113,0.000022898248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99313605,0.001301674,0.004212681,0.00043346404,0.00053874543,0.00037739516],"domain_scores_gemma":[0.983302,0.013081058,0.0025957446,0.00048789408,0.00024073115,0.00029258372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037587741,0.00025109618,0.0031380423,0.00024865853,0.00006516233,0.000018897572,0.00029835515,0.0006560067,0.00035418072],"category_scores_gemma":[0.0020385638,0.00014783676,0.0014732899,0.00047276323,0.00035946153,0.00009388253,0.00007698124,0.0015714309,0.000029957519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001741453,0.0058175586,0.8631811,9.833655e-7,0.0034613227,0.012401539,0.000043601143,0.00009950582,0.000018784052,0.000049474496,0.004747722,0.108436964],"study_design_scores_gemma":[0.018509207,0.003015316,0.9438967,0.000048746737,0.006338856,0.00063085475,0.00014271516,0.00036339974,0.000011553352,0.001236952,0.025685333,0.00012036591],"about_ca_topic_score_codex":0.0081205545,"about_ca_topic_score_gemma":0.0070785647,"teacher_disagreement_score":0.1083166,"about_ca_system_score_codex":0.00060027343,"about_ca_system_score_gemma":0.00090618595,"threshold_uncertainty_score":0.99848443},"labels":[],"label_agreement":null},{"id":"W2109791945","doi":"10.1200/jco.2008.17.1660","title":"Is Pain Intensity a Predictor of the Complexity of Cancer Pain Management?","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer pain; Analgesic; Opioid; Pain assessment; Univariate analysis; Neuropathic pain; Multivariate analysis; Internal medicine; Anesthesia; Cancer; Pain management","score_opus":0.22582864005319392,"score_gpt":0.4510203441161288,"score_spread":0.22519170406293487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109791945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97434354,0.00029427162,0.0009090182,0.020479385,0.0008388694,0.00029617266,0.000005753986,0.0000060673383,0.0028269447],"genre_scores_gemma":[0.983658,0.0013191125,0.0026553771,0.010848585,0.0004562117,0.0000020544387,6.6580156e-7,0.000008188238,0.0010518194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964131,0.0009904581,0.0018763756,0.00012124334,0.00043964916,0.00015915658],"domain_scores_gemma":[0.9959973,0.0012378301,0.0019022892,0.000280777,0.00044246338,0.00013933786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008831312,0.00009885592,0.0011726731,0.00009040475,0.000037417973,0.0000011818508,0.00029558633,0.00016365922,0.00023698497],"category_scores_gemma":[0.0035224794,0.000058591482,0.00060800393,0.00019232478,0.0009845544,0.000037475005,0.00013809839,0.00054670876,0.0000019788167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017405098,0.00097645924,0.8761551,0.00016599975,0.00074147736,0.00012994661,0.00019608531,0.0000043718533,0.000039993534,0.00023882638,0.099397525,0.020213718],"study_design_scores_gemma":[0.0033875802,0.0023446616,0.9310483,0.00023077842,0.00038903335,0.0000067681103,0.00016396571,0.00060847827,0.000060635954,0.001124229,0.060588915,0.00004668002],"about_ca_topic_score_codex":0.000060896688,"about_ca_topic_score_gemma":0.00004257479,"teacher_disagreement_score":0.054893184,"about_ca_system_score_codex":0.00006822681,"about_ca_system_score_gemma":0.0003448787,"threshold_uncertainty_score":0.42169914},"labels":[],"label_agreement":null},{"id":"W2109809243","doi":"10.1200/jco.2008.16.2727","title":"Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cisplatin; Chemotherapy; Adjuvant chemotherapy; Oncology; Adjuvant; Lung cancer; Internal medicine; Pooled analysis; Cancer; Meta-analysis; Breast cancer","score_opus":0.07958636197760126,"score_gpt":0.4553103020410604,"score_spread":0.3757239400634591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109809243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943,0.00046163963,0.00011685407,0.0035449583,0.00043782042,0.00071606477,0.000030677304,0.0000031525087,0.0003888304],"genre_scores_gemma":[0.996865,0.00043691078,0.0006950375,0.0015852695,0.0002686658,0.00003270535,0.000006029756,0.0000171762,0.00009323753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970771,0.00039749645,0.0017956973,0.00018113629,0.000368078,0.00018050702],"domain_scores_gemma":[0.9902668,0.0065720687,0.002304067,0.00030173192,0.00040076615,0.0001545892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014217105,0.00015650777,0.0024878224,0.00018913596,0.000044140572,0.0000017617479,0.00018741914,0.00022354003,0.000120611185],"category_scores_gemma":[0.00080420927,0.000080513215,0.0016597322,0.00040925515,0.00019013976,0.0000135893315,0.000016259948,0.00039340855,4.1630662e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022531936,0.0030002035,0.93648934,0.00027831245,0.010194728,0.0001700506,0.00013770684,0.0022642824,0.0022477002,0.0000051122092,0.0057521495,0.01692849],"study_design_scores_gemma":[0.03203517,0.0331604,0.8936974,0.00035745822,0.014518088,0.000007969624,0.000006662185,0.0043110526,0.02051207,0.000004237314,0.0013151942,0.00007432361],"about_ca_topic_score_codex":0.0001266114,"about_ca_topic_score_gemma":0.00022012246,"teacher_disagreement_score":0.04279195,"about_ca_system_score_codex":0.00028993687,"about_ca_system_score_gemma":0.0010219773,"threshold_uncertainty_score":0.32832336},"labels":[],"label_agreement":null},{"id":"W2109870736","doi":"10.1200/jco.2012.48.2596","title":"Type I and II Endometrial Cancers: Have They Different Risk Factors?","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":833,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; U.S. Public Health Service; National Institutes of Health; University of Southern California","keywords":"Medicine; Endometrial cancer; Serous fluid; Odds ratio; Internal medicine; Oncology; Clear cell; Risk factor; Cancer; Gynecology; Carcinoma; Gastroenterology","score_opus":0.3214988399669412,"score_gpt":0.5259912797235524,"score_spread":0.20449243975661124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109870736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011739558,0.98026997,0.000003402975,0.00017154566,0.0055734087,0.00080563,0.000042803764,0.000009867289,0.0013837962],"genre_scores_gemma":[0.0027994453,0.99022436,0.00023527394,0.00015682443,0.0057811798,0.000014531837,0.000019545307,0.00004481054,0.00072402053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99349904,0.001153979,0.0040619066,0.00037084817,0.00056257145,0.00035163906],"domain_scores_gemma":[0.9827549,0.010148404,0.0053306157,0.00029551904,0.00053879304,0.00093180354],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016995774,0.00048407938,0.009238332,0.00045598816,0.000083569794,0.000021241392,0.0002592091,0.0012676698,0.0008651539],"category_scores_gemma":[0.016351935,0.00023262101,0.0018894627,0.0003274512,0.00018530198,0.00007840057,0.00019067638,0.0026304808,0.00003250479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013949126,0.00090073346,0.0028835016,0.000817833,0.003110458,0.00013873565,0.00003129872,9.879447e-8,1.03091246e-7,0.000009554948,0.0013508211,0.98936194],"study_design_scores_gemma":[0.010606972,0.030641556,0.0022402,0.0022058114,0.010222712,0.00018297476,0.000026466525,7.7002676e-7,5.358533e-7,0.00016270693,0.94352067,0.00018864036],"about_ca_topic_score_codex":0.00037319688,"about_ca_topic_score_gemma":0.000072074494,"teacher_disagreement_score":0.9891733,"about_ca_system_score_codex":0.00078691816,"about_ca_system_score_gemma":0.0029070543,"threshold_uncertainty_score":0.9996705},"labels":[],"label_agreement":null},{"id":"W2109883040","doi":"10.1200/jco.2003.99.170","title":"CNS and Cutaneous Involvement in Patients With Chronic Myeloid Leukemia Treated With Imatinib in Hematologic Complete Remission: Two Case Reports","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Imatinib; Myeloid leukemia; Complete remission; Leukemia; Internal medicine; Oncology; Hematologic malignancy; Chemotherapy","score_opus":0.05894890658755725,"score_gpt":0.36419404399967265,"score_spread":0.3052451374121154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109883040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674194,0.0006409126,0.000004947766,0.029334093,0.00037644894,0.001413387,0.000013667181,0.000017997245,0.0007791825],"genre_scores_gemma":[0.8484768,0.0009014892,0.0073043187,0.14006333,0.001813915,0.00007524572,0.000318614,0.00022088083,0.00082540856],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9911527,0.0009973006,0.0052756825,0.0008699177,0.0009264926,0.0007779051],"domain_scores_gemma":[0.9908307,0.0019794407,0.005529716,0.00070366485,0.00047381045,0.00048263493],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0016564159,0.0007209663,0.0048239427,0.0005299716,0.00005968515,0.000020836143,0.0001495062,0.0016276768,0.00021686878],"category_scores_gemma":[0.0010547667,0.00043830727,0.000295827,0.00039058147,0.00049970543,0.00011708622,0.00009322783,0.00607158,0.000006132659],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032055,0.0009144809,0.3448156,0.00029246235,0.0005134269,0.61551607,0.000057046607,0.000043658492,0.0000024454969,6.8154645e-7,0.030594544,0.0040440992],"study_design_scores_gemma":[0.09437128,0.0588658,0.065056965,0.0048474465,0.0019539522,0.5852222,0.000097207645,0.00014243036,0.000016619308,0.000089010595,0.1884516,0.00088549795],"about_ca_topic_score_codex":0.00056147366,"about_ca_topic_score_gemma":0.0013840852,"teacher_disagreement_score":0.27975863,"about_ca_system_score_codex":0.008970159,"about_ca_system_score_gemma":0.009483546,"threshold_uncertainty_score":0.9998069},"labels":[],"label_agreement":null},{"id":"W2110046944","doi":"10.1200/jco.2008.21.0534","title":"Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer drugs; Drug; Drug pricing; Cancer; Intensive care medicine; Oncology; Pharmacology; Internal medicine; Actuarial science","score_opus":0.15994885631993133,"score_gpt":0.5037386611490396,"score_spread":0.3437898048291083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110046944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5566326,0.001803891,0.000001110801,0.43776062,0.0013186831,0.002117322,0.000013649684,0.000010905789,0.00034128042],"genre_scores_gemma":[0.71079534,0.004169255,0.000031704752,0.27976608,0.0049520857,0.00012925001,0.0000074285254,0.000045957153,0.000102902806],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99114716,0.0048319134,0.0022346335,0.0005227319,0.000706075,0.0005574893],"domain_scores_gemma":[0.9814682,0.015699623,0.0018902507,0.00029233444,0.000412275,0.00023732122],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0065199076,0.00048047857,0.0035424803,0.00036924798,0.0000850558,0.000023020464,0.00037803772,0.0010255249,0.000056180525],"category_scores_gemma":[0.00081228977,0.0002322457,0.0005674299,0.0003560844,0.00015459022,0.00008051368,0.00003152819,0.006389129,0.000003766433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034489185,0.024945235,0.032755792,0.00027989602,0.0072376365,0.42873937,0.0136223985,0.00015277554,0.000022868802,0.0000024365231,0.069555506,0.38819692],"study_design_scores_gemma":[0.083627984,0.07356099,0.3525417,0.0021468461,0.010390068,0.0060345833,0.0034412455,0.000009192813,0.000016326836,0.000027146809,0.46759775,0.00060619146],"about_ca_topic_score_codex":0.0006332582,"about_ca_topic_score_gemma":0.008631624,"teacher_disagreement_score":0.4227048,"about_ca_system_score_codex":0.00079173193,"about_ca_system_score_gemma":0.0021377283,"threshold_uncertainty_score":0.9959032},"labels":[],"label_agreement":null},{"id":"W2110092116","doi":"10.1200/jco.2011.40.0655","title":"Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Rash; Internal medicine; Nausea; Adverse effect; Surgery; Gastroenterology","score_opus":0.12199987148998305,"score_gpt":0.4138951775415325,"score_spread":0.29189530605154945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110092116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964232,0.00045943834,0.000029556708,0.00033027542,0.002181583,0.0003291665,0.0000113977385,0.00000739167,0.00022799242],"genre_scores_gemma":[0.9991813,0.000018617311,0.0002801503,0.00011378587,0.00017509011,0.00001110391,0.0000070775977,0.000013670718,0.00019921522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608475,0.0018753186,0.0013913023,0.00017939278,0.00008733353,0.0003818771],"domain_scores_gemma":[0.9966928,0.0014685537,0.0013780121,0.0001943045,0.00015854418,0.000107819316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028429406,0.00019790161,0.0014107443,0.00018954033,0.00010001259,0.000006437067,0.0002243827,0.00026516756,0.0002754516],"category_scores_gemma":[0.0006836668,0.00012292081,0.00024937038,0.00015269623,0.00020306741,0.0002885807,0.0000893156,0.00072109717,0.00007094092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015928872,0.042353302,0.66288877,0.0000037232514,0.001461063,0.000090603215,0.0009120134,7.9227664e-7,0.00016835141,0.000009010825,0.00041727914,0.27576622],"study_design_scores_gemma":[0.056424752,0.0728998,0.85597765,0.000021219508,0.00081877806,0.00005085778,0.0003125768,4.1601146e-7,0.00027990388,0.000018700732,0.013056857,0.00013849273],"about_ca_topic_score_codex":0.00003148557,"about_ca_topic_score_gemma":0.00014431297,"teacher_disagreement_score":0.27562773,"about_ca_system_score_codex":0.00012389028,"about_ca_system_score_gemma":0.00039905906,"threshold_uncertainty_score":0.5012565},"labels":[],"label_agreement":null},{"id":"W2110107827","doi":"10.1200/jco.2013.49.8311","title":"Frequency of Non–Cancer-Related Pain in Patients With Cancer","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer pain; Cancer; Oncology; Internal medicine","score_opus":0.05000847068786195,"score_gpt":0.4065391087696425,"score_spread":0.35653063808178054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110107827","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59291756,0.000610718,0.000023730496,0.40125972,0.0022641404,0.00075853604,0.000009616638,0.000009366889,0.002146592],"genre_scores_gemma":[0.09774269,0.0044223634,0.005622854,0.8778336,0.009306334,0.000065436296,0.000069652895,0.00013237073,0.004804687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946501,0.0007742456,0.0033478083,0.0002495305,0.000639747,0.00033852566],"domain_scores_gemma":[0.9927552,0.0016964859,0.004386902,0.00027430188,0.00072960963,0.00015755574],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003322904,0.00025468488,0.002650518,0.00037847908,0.000013086079,0.000005230093,0.00032496642,0.0015445929,0.001042144],"category_scores_gemma":[0.0014155345,0.00016181766,0.000433099,0.00024698785,0.00019163248,0.00009672601,0.000046533918,0.0044304673,0.00001531916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000328102,0.0005992299,0.52125704,0.00017790805,0.0006448515,0.00042276108,0.000031434494,0.000004419275,0.0000010831396,0.0000012685435,0.44605508,0.030476823],"study_design_scores_gemma":[0.009554088,0.0076694814,0.7057451,0.0011512667,0.0006888301,0.0000011403793,0.0000072512134,0.000043738437,7.1512363e-7,0.000110400106,0.27489024,0.00013771596],"about_ca_topic_score_codex":0.0002959024,"about_ca_topic_score_gemma":0.000073545176,"teacher_disagreement_score":0.49517488,"about_ca_system_score_codex":0.0003318987,"about_ca_system_score_gemma":0.0017597113,"threshold_uncertainty_score":0.999871},"labels":[],"label_agreement":null},{"id":"W2110108978","doi":"10.1200/jco.2008.19.6048","title":"Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and <i>KRAS</i>-Specific Results of the NCIC CTG and AGITG CO.17 Trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Cetuximab; Medicine; KRAS; Colorectal cancer; Internal medicine; Oncology; Quality of life (healthcare); Cancer","score_opus":0.07931927460651662,"score_gpt":0.43152633201800994,"score_spread":0.35220705741149333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110108978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917388,0.0021144678,4.128049e-7,0.004567871,0.00016231785,0.0007413778,0.000041838855,0.0000037000418,0.00062922656],"genre_scores_gemma":[0.9970742,0.0021008544,0.00014710576,0.0005427032,0.00007635039,0.0000054041066,0.000003831048,0.000008060761,0.000041474283],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961647,0.00046906294,0.0025644647,0.00022267814,0.00038315653,0.00019598482],"domain_scores_gemma":[0.9952541,0.0010109964,0.0029888079,0.00012826796,0.00041562808,0.00020219093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012630582,0.00016687719,0.0022605888,0.000074362884,0.000047505026,0.0000036048334,0.000070523536,0.00016591437,0.000008562578],"category_scores_gemma":[0.00080158515,0.00008195408,0.00013442425,0.0001994812,0.00043178757,0.000071501396,0.000022930191,0.00049742736,6.465376e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48852506,0.0023108006,0.47729802,0.000022278535,0.0003092725,0.000014592932,0.00032318739,0.000011673633,0.000022148684,0.000008246933,0.00048272475,0.030671977],"study_design_scores_gemma":[0.18887608,0.06556065,0.7445497,0.00021750527,0.00010024276,0.0000074421173,0.00006240888,0.0000023406533,0.00002286199,0.000023086595,0.00051864015,0.00005906394],"about_ca_topic_score_codex":0.0003693265,"about_ca_topic_score_gemma":0.0011563827,"teacher_disagreement_score":0.299649,"about_ca_system_score_codex":0.00019544455,"about_ca_system_score_gemma":0.00097581814,"threshold_uncertainty_score":0.33419904},"labels":[],"label_agreement":null},{"id":"W2110156824","doi":"10.1200/jco.2013.49.6158","title":"Is Tremelimumab Beneficial in Advanced Melanoma?","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Jonsson Comprehensive Cancer Center; University of California, Los Angeles","keywords":"Tremelimumab; Medicine; Melanoma; Oncology; Ipilimumab; Internal medicine; Cancer; Immunotherapy; Cancer research","score_opus":0.1169966416220452,"score_gpt":0.4530544913705417,"score_spread":0.3360578497484965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110156824","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15278658,0.0031401035,0.0000068014133,0.83323836,0.0050683254,0.00034392602,0.000010477945,0.0000085871725,0.005396851],"genre_scores_gemma":[0.01450276,0.004824244,0.0013280847,0.9583754,0.017558381,0.000009348274,0.000017429338,0.00005755452,0.0033268207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938666,0.0004146037,0.0044301827,0.00030679497,0.00058080174,0.00040097823],"domain_scores_gemma":[0.99406385,0.0017523243,0.0032936672,0.00032450745,0.0004001847,0.00016546225],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021234683,0.0002888357,0.0030826111,0.00036875956,0.000021970976,0.000012159418,0.00033272008,0.0027609193,0.002081218],"category_scores_gemma":[0.0009928402,0.00020470795,0.0014477713,0.00018726168,0.0002140045,0.000102874415,0.000042216627,0.005744162,0.000080776306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008179566,0.0003913452,0.0025718359,0.00006422961,0.00048025354,0.0025867647,0.00004890694,5.332674e-7,0.00006497517,0.0000010707452,0.7094096,0.27620092],"study_design_scores_gemma":[0.015392856,0.012215603,0.038802143,0.00039131005,0.0003051723,0.0005285512,0.00003127697,0.000008198828,0.000026738557,0.00016606526,0.9319482,0.00018391752],"about_ca_topic_score_codex":0.00009790147,"about_ca_topic_score_gemma":0.00005511272,"teacher_disagreement_score":0.276017,"about_ca_system_score_codex":0.00045386158,"about_ca_system_score_gemma":0.0027723215,"threshold_uncertainty_score":0.99883103},"labels":[],"label_agreement":null},{"id":"W2110184691","doi":"10.1200/jco.2008.20.6458","title":"Costs and Cost Effectiveness of a Health Care Provider–Directed Intervention to Promote Colorectal Cancer Screening","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; U.S. Department of Veterans Affairs; American Cancer Society","keywords":"Medicine; Academic detailing; Cost effectiveness; Randomized controlled trial; Psychological intervention; Intervention (counseling); Colorectal cancer; Colonoscopy; Colorectal cancer screening; Family medicine; Cost-effectiveness analysis; Cancer screening; Cancer; Internal medicine; Nursing","score_opus":0.08040539863273533,"score_gpt":0.4832884563202415,"score_spread":0.40288305768750615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110184691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093306,0.0022600933,0.00252858,0.0025636398,0.0006392807,0.00081708527,0.000004832324,0.000025698097,0.00022771892],"genre_scores_gemma":[0.99520564,0.00013761876,0.0037712606,0.00054118445,0.00030527246,0.000014983504,0.000002794297,0.000010229525,0.000011011261],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996868,0.00091239053,0.0015453111,0.0002076351,0.00027360674,0.00019306914],"domain_scores_gemma":[0.99677074,0.0007169871,0.0013402062,0.00008089661,0.0007597904,0.0003313826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003823047,0.000121404555,0.001346392,0.00018618086,0.000051160878,0.000008366115,0.00006761149,0.00021129078,0.000010894624],"category_scores_gemma":[0.0025104694,0.00009617895,0.0002874337,0.00027199867,0.00006226334,0.00008606776,0.000030782834,0.00059397606,5.53461e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044756155,0.0003961701,0.017735647,0.00015364148,0.00013582579,0.000034022192,0.00029973531,0.00002721157,0.0011492916,0.0000048626075,0.00016311932,0.9351443],"study_design_scores_gemma":[0.008513921,0.114238456,0.8684307,0.0017876332,0.00016298245,0.0002491058,0.00025739247,0.00023511496,0.002736338,0.000023634479,0.003273818,0.000090948175],"about_ca_topic_score_codex":0.0004536063,"about_ca_topic_score_gemma":0.00055147853,"teacher_disagreement_score":0.93505335,"about_ca_system_score_codex":0.00049094885,"about_ca_system_score_gemma":0.000953939,"threshold_uncertainty_score":0.39220637},"labels":[],"label_agreement":null},{"id":"W2110439344","doi":"10.1200/jco.2005.10.035","title":"Prevention and Management of Hereditary Breast Cancer","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Breast cancer; Medicine; BRCA mutation; Ovarian cancer; Cancer; Genetic testing; Oncology; Genetic counseling; BRCA2 Protein; Mutation; Cancer prevention; Internal medicine; Germline mutation; Gene; Genetics; Biology","score_opus":0.12171889750696623,"score_gpt":0.5167424518299449,"score_spread":0.3950235543229787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110439344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035748878,0.99703014,0.00008726574,0.00030274878,0.0013420583,0.0002055147,0.000041394454,0.0000010980251,0.0006322928],"genre_scores_gemma":[0.00015767245,0.99263537,0.0037934473,0.00009625319,0.0026847802,0.000017221251,0.000015240912,0.000022178318,0.0005778612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99696624,0.00036028717,0.00217417,0.00021800333,0.00016002088,0.000121261946],"domain_scores_gemma":[0.99662566,0.00011560285,0.0027426989,0.00019789432,0.00021170061,0.000106431355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001353731,0.00016503716,0.0015760628,0.00006883225,0.000016294116,0.0000039130164,0.0002486229,0.0006469164,0.00006467738],"category_scores_gemma":[0.00006916663,0.00012577142,0.0005759216,0.00007473751,0.00015991014,0.0000046067585,0.00014148951,0.00039095245,0.000002054612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011047707,0.00021883124,0.00003436129,0.0016201044,0.0012941639,0.00002667889,0.0000024888004,0.0000075111925,0.0000013243971,0.0000142952385,0.008538869,0.98813087],"study_design_scores_gemma":[0.0008200443,0.0012606293,0.00053435494,0.0023139324,0.0016576925,0.0005113252,0.000012169562,9.3431055e-7,0.0000018183355,0.000035244342,0.9927437,0.00010815597],"about_ca_topic_score_codex":0.00000329722,"about_ca_topic_score_gemma":0.000022822736,"teacher_disagreement_score":0.98802274,"about_ca_system_score_codex":0.00010442064,"about_ca_system_score_gemma":0.0017785013,"threshold_uncertainty_score":0.512881},"labels":[],"label_agreement":null},{"id":"W2110573577","doi":"10.1200/jco.2005.02.054","title":"Dietary Counseling Improves Patient Outcomes: A Prospective, Randomized, Controlled Trial in Colorectal Cancer Patients Undergoing Radiotherapy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Liga Portuguesa Contra o Cancro; Terry Fox Foundation","keywords":"Medicine; Radiation therapy; Nausea; Quality of life (healthcare); Anorexia; Internal medicine; Cancer; Vomiting; Randomized controlled trial; Colorectal cancer; Weight loss; Gastroenterology; Obesity","score_opus":0.05604640140435209,"score_gpt":0.459019293098617,"score_spread":0.4029728916942649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110573577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97572535,0.001985966,0.000037590296,0.014829436,0.0032788569,0.0035377908,0.0000017081644,0.000012917009,0.00059035496],"genre_scores_gemma":[0.97678053,0.006237484,0.004199061,0.010904063,0.0016305429,0.00016651282,0.0000013412151,0.00002119597,0.000059267993],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99288386,0.0010622445,0.0050449874,0.00020941404,0.00048683013,0.00031269097],"domain_scores_gemma":[0.98808515,0.008121698,0.0028637866,0.00007965331,0.0005271856,0.00032251197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00556119,0.00018638434,0.0048667155,0.00024813125,0.000056726225,0.000011685346,0.00009148741,0.0003215833,0.00012072774],"category_scores_gemma":[0.0066482127,0.00011570095,0.0010748619,0.00012108622,0.00017330203,0.00013746259,0.0000151053555,0.0011674141,0.0000031398026],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8703408,0.00448971,0.07955343,0.000031271265,0.0005709532,0.00004726816,0.0004579388,0.000031549433,0.000040207742,0.000018455607,0.00043719367,0.043981224],"study_design_scores_gemma":[0.94913596,0.013911202,0.03224892,0.00025009827,0.0002579293,0.000017891167,0.000098725395,0.0008971278,0.000012509579,0.00018321174,0.0028830555,0.000103339946],"about_ca_topic_score_codex":0.000025315938,"about_ca_topic_score_gemma":0.00019242633,"teacher_disagreement_score":0.07879519,"about_ca_system_score_codex":0.00073052663,"about_ca_system_score_gemma":0.002088557,"threshold_uncertainty_score":0.7959012},"labels":[],"label_agreement":null},{"id":"W2110956488","doi":"10.1200/jco.2011.40.1646","title":"Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia, Canada, With Evidence for a Survival Benefit As a Result of Irradiation","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Stage (stratigraphy); Population; Internal medicine; Oncology; Paclitaxel; Clear cell carcinoma; Ovarian carcinoma; Carcinoma; Surgery; Gynecology; Ovarian cancer; Cancer; Chemotherapy; Cisplatin; Biology","score_opus":0.09942625205044944,"score_gpt":0.40801463886365813,"score_spread":0.30858838681320866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110956488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943453,0.00029558165,0.000021697806,0.0039811623,0.000693579,0.00043961426,0.000044948993,0.0000023140456,0.00017581868],"genre_scores_gemma":[0.9959906,0.000049759183,0.0022334515,0.0009962585,0.00036427344,0.000017353337,0.000010486158,0.000016469618,0.00032140312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734986,0.00017715215,0.001673526,0.00015866528,0.00039335404,0.00024744243],"domain_scores_gemma":[0.9939523,0.003789246,0.0014086213,0.00016189799,0.00037231838,0.00031561282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018703989,0.00008878118,0.0011720092,0.000056625406,0.000033474993,0.000014435209,0.000086889086,0.00018821108,0.00011410901],"category_scores_gemma":[0.002170534,0.00009097761,0.00021831706,0.00012403875,0.000041925454,0.00012731693,0.000010773828,0.00029751047,8.016285e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022165983,0.0019879336,0.98828214,0.00008817933,0.000096818636,0.00017635041,0.00003255841,0.00011965673,0.0000028276634,0.000023276947,0.00052298926,0.0064506466],"study_design_scores_gemma":[0.013986115,0.007440497,0.97610646,0.00024875233,0.00030077266,0.000023708679,0.00007981712,0.00006620063,0.0000127882695,0.000020662272,0.0016333875,0.000080830534],"about_ca_topic_score_codex":0.74525857,"about_ca_topic_score_gemma":0.9509222,"teacher_disagreement_score":0.20566365,"about_ca_system_score_codex":0.00068921474,"about_ca_system_score_gemma":0.004424778,"threshold_uncertainty_score":0.78493655},"labels":[],"label_agreement":null},{"id":"W2111077571","doi":"10.1200/jco.2006.08.4046","title":"Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Internal medicine; Randomization; Hepatocellular carcinoma; Gastroenterology; Hazard ratio; Clinical endpoint; Doxorubicin; Liver function; Vomiting; Surgery; Chemotherapy; Randomized controlled trial; Confidence interval","score_opus":0.13469891141558474,"score_gpt":0.3873968513785683,"score_spread":0.2526979399629835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111077571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915098,0.000388793,0.00043850974,0.00037581843,0.0004748535,0.0049565732,0.0000033138426,0.000014078372,0.0018382624],"genre_scores_gemma":[0.998161,0.00007199718,0.000604259,0.00014239427,0.00060656195,0.00004528919,0.000016868727,0.00003651029,0.00031511518],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919184,0.0017957683,0.004586811,0.00027233968,0.00097125163,0.00045541977],"domain_scores_gemma":[0.98270214,0.011251637,0.0040660906,0.00034401807,0.0011832874,0.00045284277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011170188,0.00035230204,0.007586196,0.00024710054,0.000100535406,0.000017304885,0.00025577116,0.00035980972,0.00016782661],"category_scores_gemma":[0.0019248455,0.00013630438,0.0012415033,0.00040781195,0.0005840215,0.000109261004,0.000040732768,0.0008928346,0.000002881464],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54273224,0.0054234955,0.44751313,0.00001660646,0.0020383385,0.00085406675,0.00006897151,0.0000012125754,0.000035209752,0.000013728296,0.000043973585,0.0012589992],"study_design_scores_gemma":[0.9045653,0.0625477,0.024536729,0.000107119165,0.0054964717,0.00005826553,0.00012927377,0.0012012625,0.0005831224,0.0000068889426,0.0006238187,0.00014406185],"about_ca_topic_score_codex":0.00016302757,"about_ca_topic_score_gemma":0.00013400904,"teacher_disagreement_score":0.4229764,"about_ca_system_score_codex":0.00012703419,"about_ca_system_score_gemma":0.001451704,"threshold_uncertainty_score":0.55583316},"labels":[],"label_agreement":null},{"id":"W2111128280","doi":"10.1200/jco.2009.25.2205","title":"Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research","year":2010,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Comparative effectiveness research; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.9570904995417888,"score_gpt":0.7893693240462735,"score_spread":0.16772117549551535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111128280","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01614786,0.00030832496,0.012581496,0.0010333997,0.9637981,0.0033631723,0.000674795,0.000022998513,0.002069867],"genre_scores_gemma":[0.0030999703,0.00052288314,0.4567589,0.000042984753,0.5392692,0.000098999444,0.000011951039,0.00008613665,0.00010899962],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.85620195,0.12434375,0.011964243,0.000942414,0.005304801,0.0012428365],"domain_scores_gemma":[0.043641698,0.9217019,0.007993064,0.0012677768,0.024307419,0.0010881625],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.4497329,0.0004239009,0.007403866,0.000552063,0.0004348901,0.00007236395,0.0030780435,0.005642987,0.00019613399],"category_scores_gemma":[0.9129448,0.00025891844,0.0015521429,0.00061804,0.0051471707,0.00019087619,0.0007205862,0.02573238,0.000007636831],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02200484,0.0041216873,0.000014886395,0.00064166967,0.0012121608,0.000117210155,0.00041647567,0.000008047392,0.00020385502,0.007446836,0.9361819,0.027630422],"study_design_scores_gemma":[0.005033406,0.024451785,0.000109754685,0.00057099684,0.0004242024,0.0000065509603,0.0005378445,0.000117236494,0.000277471,0.59013534,0.3781203,0.00021510985],"about_ca_topic_score_codex":0.00005826093,"about_ca_topic_score_gemma":0.00012895293,"teacher_disagreement_score":0.81256026,"about_ca_system_score_codex":0.0003724943,"about_ca_system_score_gemma":0.017093645,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W2111347432","doi":"10.1200/jco.2009.23.1910","title":"Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"GlaxoSmithKline","keywords":"Trastuzumab; Medicine; Regimen; Loading dose; Cardiotoxicity; Metastatic breast cancer; Internal medicine; Pharmacokinetics; Chemotherapy; Adverse effect; Breast cancer; Phases of clinical research; Oncology; Cancer; Pharmacology; Gastroenterology","score_opus":0.17936158971020888,"score_gpt":0.5111639668432632,"score_spread":0.33180237713305427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111347432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482951,0.0008163252,0.00007545816,0.045470547,0.0007212446,0.00024453228,0.000012272621,0.000009352378,0.00435513],"genre_scores_gemma":[0.9890291,0.0016185397,0.0011626056,0.0064658816,0.0005445302,0.0000011517138,0.0000016533257,0.000013326157,0.0011631784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963504,0.00045340994,0.0022172416,0.0002110415,0.00044344514,0.00032444444],"domain_scores_gemma":[0.99513984,0.0015367972,0.001126449,0.00017986586,0.0015016132,0.00051542383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019923965,0.00014557103,0.0014249603,0.0001429984,0.000048467293,0.00001538873,0.00015929903,0.000308735,0.0004415334],"category_scores_gemma":[0.0020519942,0.000108346925,0.0002637381,0.00022812015,0.00041871262,0.00013035299,0.000036879657,0.0013582021,0.000021720669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027352976,0.006154386,0.20529673,0.00032926895,0.0021804122,0.004765701,0.0061841058,0.00009753335,0.046527527,0.000996375,0.1131494,0.5869656],"study_design_scores_gemma":[0.018141938,0.052147254,0.80486137,0.00073416246,0.00050092064,0.0009524326,0.001409414,0.0005642239,0.007979327,0.0014930895,0.11096104,0.00025481157],"about_ca_topic_score_codex":0.000019961872,"about_ca_topic_score_gemma":0.000019182746,"teacher_disagreement_score":0.5995647,"about_ca_system_score_codex":0.00018559473,"about_ca_system_score_gemma":0.0019225455,"threshold_uncertainty_score":0.5900788},"labels":[],"label_agreement":null},{"id":"W2111373111","doi":"10.1200/jco.2008.16.3527","title":"Longitudinal Changes in Obesity and Body Mass Index Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"American Lebanese Syrian Associated Charities; National Cancer Institute; Children's Cancer Research Fund; University of Minnesota; U.S. Department of Health and Human Services","keywords":"Medicine; Body mass index; Cancer; Pediatrics; Cohort; Obesity; Late effect; Cohort study; Childhood cancer; Longitudinal study; Internal medicine","score_opus":0.05991972117451719,"score_gpt":0.3940113766670141,"score_spread":0.33409165549249686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111373111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902433,0.00094701455,0.00006529085,0.0058463407,0.001768957,0.00090838183,0.00004124138,0.000021204381,0.0001582666],"genre_scores_gemma":[0.9929847,0.0030471657,0.00023405063,0.0014635253,0.002130332,0.0000255327,0.00000763499,0.0000484323,0.000058627076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99103314,0.0017467947,0.0046765357,0.00067632523,0.0013457597,0.00052144506],"domain_scores_gemma":[0.9875891,0.005721807,0.00456038,0.0007036636,0.0008488845,0.00057612295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006665272,0.00043192462,0.0036403562,0.00025519895,0.0001429425,0.000015606372,0.0005275471,0.00064296834,0.00009026692],"category_scores_gemma":[0.007390886,0.00029660464,0.0005340663,0.0005276767,0.0008859806,0.00021303276,0.0002430643,0.0022022522,0.000002839068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00211503,0.004914503,0.98039216,0.000031001917,0.0019137524,0.004300325,0.003644308,0.000026067692,0.000017747583,0.000004397556,0.0005353036,0.0021054063],"study_design_scores_gemma":[0.014202707,0.006483969,0.97366107,0.00041871084,0.0011137663,0.001464541,0.001982368,0.000051475232,0.000039478877,0.00014132273,0.00018373436,0.00025689005],"about_ca_topic_score_codex":0.025616957,"about_ca_topic_score_gemma":0.10801509,"teacher_disagreement_score":0.08239813,"about_ca_system_score_codex":0.00045251523,"about_ca_system_score_gemma":0.004404899,"threshold_uncertainty_score":0.9999486},"labels":[],"label_agreement":null},{"id":"W2111456931","doi":"10.1200/jco.2011.38.2697","title":"Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":643,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cirrhosis; Internal medicine; Hepatitis B virus; microRNA; Receiver operating characteristic; Oncology; Cohort; Liver cancer; Gastroenterology; Liver disease; Logistic regression; Hepatitis B; Cancer; Area under the curve; Virus; Immunology; Gene","score_opus":0.092397048890682,"score_gpt":0.35440491406830077,"score_spread":0.26200786517761876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111456931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611455,0.00051187334,0.00037233162,0.0003902576,0.0012053936,0.00020296712,0.000015915948,0.000006621971,0.0011801065],"genre_scores_gemma":[0.99373347,0.00056583213,0.0037976347,0.0009475581,0.0006941184,0.0000067321716,0.000016477035,0.000031533982,0.0002066434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682486,0.00046891207,0.001918851,0.00030423008,0.0001994303,0.00028374043],"domain_scores_gemma":[0.9973364,0.00018027925,0.0012140449,0.00033768016,0.00039936,0.0005322589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014189256,0.00018592659,0.00069518527,0.000098807024,0.000045540222,0.000009223713,0.0004015156,0.00062264304,0.00018770083],"category_scores_gemma":[0.0018445532,0.00016372679,0.00050902483,0.00011847659,0.00015225951,0.000010607826,0.00015708689,0.00038498058,0.00007552705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019713172,0.001337752,0.68680036,0.00001577129,0.00039715855,0.00073472277,0.00017606893,0.000019851508,0.2682534,0.00007607755,0.015351227,0.02486631],"study_design_scores_gemma":[0.003510415,0.007357659,0.71430457,0.00003661555,0.00021989722,0.0003647631,0.00003003554,0.00014421764,0.14729261,0.00034726263,0.12607026,0.00032167602],"about_ca_topic_score_codex":0.00014635114,"about_ca_topic_score_gemma":0.00018077657,"teacher_disagreement_score":0.12096078,"about_ca_system_score_codex":0.00005765763,"about_ca_system_score_gemma":0.0006470802,"threshold_uncertainty_score":0.66765845},"labels":[],"label_agreement":null},{"id":"W2111479968","doi":"10.1200/jco.2006.06.7835","title":"Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Docetaxel; Pemetrexed; Medicine; Tolerability; Internal medicine; Neutropenia; Chemotherapy; Lung cancer; Oncology; Febrile neutropenia; Population; Toxicity; Surgery; Adverse effect; Cisplatin","score_opus":0.02282379912447964,"score_gpt":0.3976881623197988,"score_spread":0.3748643631953192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111479968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616426,0.00035444184,0.00016192003,0.00015276395,0.00014344431,0.002585906,0.00022621473,0.0000058784944,0.00020516902],"genre_scores_gemma":[0.9967644,0.00018113175,0.0021783393,0.00016473362,0.00011299072,0.000084946194,0.0003509684,0.000027675176,0.00013481874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948571,0.00030925806,0.0037606747,0.00030901047,0.0005084256,0.0002555523],"domain_scores_gemma":[0.99190867,0.0012534916,0.0051780907,0.00026555167,0.0011927212,0.00020148598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008026998,0.0002771832,0.0052162507,0.000520002,0.000025534058,0.000006584008,0.00014304095,0.00021808204,0.00029372805],"category_scores_gemma":[0.00018783445,0.0001641064,0.00077725935,0.0008398654,0.00018071289,0.00011142829,0.000013500156,0.00036041415,2.2462116e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61613554,0.01597285,0.35380986,0.00003440249,0.0074693775,0.000022999628,0.00027135797,0.0008314141,0.00005889134,6.3487965e-7,0.00004512113,0.0053475373],"study_design_scores_gemma":[0.7034489,0.023169447,0.25612038,0.00022533625,0.015870728,4.8809335e-7,0.000035658562,0.00073377887,0.00023198604,0.00000747131,0.000044887103,0.00011095526],"about_ca_topic_score_codex":0.001526933,"about_ca_topic_score_gemma":0.004590672,"teacher_disagreement_score":0.097689465,"about_ca_system_score_codex":0.00029588628,"about_ca_system_score_gemma":0.0010966753,"threshold_uncertainty_score":0.6692065},"labels":[],"label_agreement":null},{"id":"W2111603192","doi":"10.1200/jco.2008.17.4052","title":"Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Hormonal therapy; Radiation therapy; Prostate cancer; Proportional hazards model; Internal medicine; Hormone therapy; Oncology; Prostatectomy; Androgen deprivation therapy; Adjuvant; Cancer; Breast cancer","score_opus":0.025303431166483602,"score_gpt":0.3977312005250005,"score_spread":0.3724277693585169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111603192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966078,0.0015084726,0.000015720461,0.0011321502,0.00004138714,0.00057393766,0.000054612614,0.0000017822438,0.00006414173],"genre_scores_gemma":[0.9950958,0.004048821,0.00047131022,0.0003068481,0.000033348824,0.000009528251,0.000011438329,0.000009830659,0.000013079931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729425,0.00019637347,0.0018190861,0.00015460384,0.00037925382,0.00015643974],"domain_scores_gemma":[0.995623,0.00029511307,0.002977043,0.0001958106,0.00079200533,0.000117006886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005314021,0.00015636181,0.0018211373,0.00021741525,0.000013270652,0.000002200514,0.00010084392,0.0001211554,0.00006073964],"category_scores_gemma":[0.000086432265,0.00006846072,0.0004926463,0.00066139555,0.00023088107,0.00010334578,0.000006360926,0.00032711038,4.188756e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041944996,0.003646814,0.74819547,0.00000973869,0.0035666828,0.000021716856,0.00021187554,0.0019715342,0.00040814633,0.000002048667,0.000046674773,0.19997433],"study_design_scores_gemma":[0.028450282,0.082820065,0.8864845,0.00024678494,0.0010322974,0.0000045052907,0.000022058657,0.000119358316,0.00068436173,0.000013782525,0.00006314669,0.000058859987],"about_ca_topic_score_codex":0.00017112274,"about_ca_topic_score_gemma":0.00022360703,"teacher_disagreement_score":0.19991547,"about_ca_system_score_codex":0.00035290036,"about_ca_system_score_gemma":0.0023745513,"threshold_uncertainty_score":0.4212352},"labels":[],"label_agreement":null},{"id":"W2111631254","doi":"10.1200/jco.2005.03.5600","title":"Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":287,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"Hamilton Health Sciences","keywords":"Medicine; Incidence (geometry); Thrombosis; Cancer; Catheter; Cancer incidence; Internal medicine; Oncology; Intensive care medicine; Surgery","score_opus":0.06622639369514366,"score_gpt":0.4579972671688234,"score_spread":0.3917708734736797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111631254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979387,0.00007831609,0.000010863374,0.00077364984,0.0005940542,0.00021059938,0.00003424803,0.0000038367248,0.00035572273],"genre_scores_gemma":[0.99839425,0.0008177318,0.0003231318,0.00029069564,0.00010104261,0.0000038072185,0.0000029834316,0.0000116252495,0.00005471331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99589473,0.0007881437,0.0026392448,0.0001448174,0.0002599058,0.00027313866],"domain_scores_gemma":[0.99263674,0.0033641178,0.0033157195,0.00011855385,0.00042366335,0.00014122736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001356596,0.00012652692,0.0014971255,0.00013643045,0.00009091546,0.0000021631097,0.00013093806,0.00040651517,0.0001568304],"category_scores_gemma":[0.0011431343,0.00007043021,0.00023971236,0.00015238985,0.00016386787,0.00010611976,0.000047426915,0.0011075271,0.000002342688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031622426,0.0013965899,0.99364156,0.000016764332,0.00016746741,0.0000045460197,0.0008516584,0.000028453875,0.0000027592641,0.00004757434,0.0004010062,0.003125379],"study_design_scores_gemma":[0.00425747,0.0022540742,0.9918695,0.00013456869,0.00025550224,3.2858716e-7,0.00023491902,0.000020898166,0.0000025295521,0.00034209187,0.0005515196,0.00007656027],"about_ca_topic_score_codex":0.006787691,"about_ca_topic_score_gemma":0.009960381,"teacher_disagreement_score":0.0039412454,"about_ca_system_score_codex":0.00015572215,"about_ca_system_score_gemma":0.0006012787,"threshold_uncertainty_score":0.9998262},"labels":[],"label_agreement":null},{"id":"W2111941108","doi":"10.1200/jco.2007.14.0673","title":"Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Nomogram; Adverse effect; Internal medicine; Clinical trial; Body surface area; Oncology; Surgery; Emergency medicine","score_opus":0.7789254010076008,"score_gpt":0.6974319729904782,"score_spread":0.08149342801712256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111941108","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.941763,0.000066451816,0.04872434,0.0014646058,0.005979171,0.0013762481,0.00008186075,0.00002423218,0.0005200783],"genre_scores_gemma":[0.4804759,0.00039043222,0.5161308,0.0013367789,0.0014795869,0.000018129715,0.0000017552229,0.000048099286,0.0001184773],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9394383,0.02714639,0.030726112,0.0006446765,0.0013768781,0.0006676404],"domain_scores_gemma":[0.7493227,0.23274179,0.014408328,0.000828459,0.001160574,0.0015381605],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.12769815,0.00037524686,0.009008789,0.00037074648,0.000073812225,0.000003118799,0.0010253971,0.0013924215,0.0005415703],"category_scores_gemma":[0.7790145,0.00028402678,0.0027951421,0.00063191616,0.0006098085,0.0001528489,0.00037593208,0.0024141574,0.00003160085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0681473,0.09374308,0.13140178,0.000253035,0.004216101,0.0072134123,0.00090094947,0.00014049864,0.00077136705,0.002663318,0.031083582,0.65946555],"study_design_scores_gemma":[0.18193102,0.17989874,0.20512667,0.0011886306,0.0027633465,0.0005090395,0.00022504345,0.0010803273,0.0006090884,0.39205033,0.033447582,0.0011701902],"about_ca_topic_score_codex":0.000016088343,"about_ca_topic_score_gemma":0.000015947104,"teacher_disagreement_score":0.6582954,"about_ca_system_score_codex":0.00015035743,"about_ca_system_score_gemma":0.001871422,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W2111951140","doi":"10.1200/jco.2006.07.0953","title":"Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; American Society of Clinical Oncology; National Center for Research Resources; Amgen","keywords":"Medicine; Alemtuzumab; Fludarabine; Transplantation; Regimen; Internal medicine; Donor lymphocyte infusion; Cyclophosphamide; Surgery; Graft-versus-host disease; Gastroenterology; Chemotherapy","score_opus":0.13396661551039304,"score_gpt":0.474297250354385,"score_spread":0.34033063484399195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111951140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96431875,0.0003072306,0.022252249,0.0041291965,0.002060888,0.00029005166,0.000004167895,0.000017071216,0.006620412],"genre_scores_gemma":[0.9760936,0.00281465,0.0188058,0.001388305,0.0007242861,0.0000016178672,0.000007697929,0.000013939056,0.00015012898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99393576,0.00046462554,0.004756302,0.00022739572,0.00036187825,0.00025403814],"domain_scores_gemma":[0.9912994,0.006008393,0.0016839645,0.0001528143,0.00038742143,0.00046801424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011878922,0.00016237044,0.0017031021,0.0001367769,0.000053116575,0.000008651205,0.000099298864,0.00060597755,0.000110594],"category_scores_gemma":[0.0017149163,0.00011814479,0.000538767,0.00011721527,0.00046754774,0.00015183422,0.000011570649,0.0008958535,0.00003251289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007088058,0.0010215214,0.8746056,0.000108336084,0.0006988186,0.001965824,0.00040987853,0.000005911149,0.0006986662,0.0008448744,0.00008789101,0.11246462],"study_design_scores_gemma":[0.010615544,0.0040808725,0.97645897,0.0001662281,0.00093264115,0.0025940672,0.00021383897,0.000019196283,0.0006150767,0.00040891333,0.0037781368,0.00011652524],"about_ca_topic_score_codex":0.000010513943,"about_ca_topic_score_gemma":0.00007786131,"teacher_disagreement_score":0.112348095,"about_ca_system_score_codex":0.00006197798,"about_ca_system_score_gemma":0.0010306501,"threshold_uncertainty_score":0.48178047},"labels":[],"label_agreement":null},{"id":"W2112036679","doi":"10.1200/jco.2005.03.3027","title":"Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Raltitrexed; Medicine; Cisplatin; Internal medicine; Lung cancer; Clinical endpoint; Mesothelioma; Quality of life (healthcare); Chemotherapy; Oncology; Surgery; Randomized controlled trial; Fluorouracil; Pathology; Thymidylate synthase","score_opus":0.053232513522232475,"score_gpt":0.43457967065182695,"score_spread":0.3813471571295945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112036679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811864,0.00009694365,0.0000044224785,0.00010927247,0.00021594318,0.0010694655,0.000351116,0.0000033347515,0.000030858817],"genre_scores_gemma":[0.9993516,0.000055751505,0.00013322257,0.00007538167,0.00013032049,0.000038316397,0.00016865597,0.000013092845,0.00003363241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958005,0.0005463175,0.002495609,0.0003046882,0.00073231495,0.00012055742],"domain_scores_gemma":[0.99707603,0.0007237719,0.0016105806,0.0001183774,0.00023977912,0.0002314846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090299983,0.00019813122,0.0016789545,0.00013937704,0.00003195515,0.000007672616,0.000099997786,0.0000904368,0.000056926467],"category_scores_gemma":[0.00023703443,0.000108223154,0.00006511255,0.00010245932,0.00031205904,0.000321886,0.00003307121,0.00019183254,2.6383061e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37435806,0.016332535,0.60579866,0.000007834538,0.0011002085,0.00004518325,0.00027673674,0.00013449734,0.000015431784,0.000005617358,0.00000607942,0.0019191401],"study_design_scores_gemma":[0.34018838,0.014510027,0.6438613,0.00010080751,0.00058185146,0.0000030418869,0.00024696084,0.00041915127,0.0000023821062,0.0000049529444,0.000003423801,0.00007769263],"about_ca_topic_score_codex":0.1219539,"about_ca_topic_score_gemma":0.47027647,"teacher_disagreement_score":0.34832257,"about_ca_system_score_codex":0.00031295148,"about_ca_system_score_gemma":0.0009985822,"threshold_uncertainty_score":0.8838931},"labels":[],"label_agreement":null},{"id":"W2112062992","doi":"10.1200/jco.2006.10.4760","title":"Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":541,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Surgery; Chemotherapy; Perioperative; Esophageal cancer; Radiation therapy; Chemoradiotherapy; Cancer; Internal medicine","score_opus":0.17200500507310923,"score_gpt":0.5067784858282472,"score_spread":0.334773480755138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112062992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881403,0.0035686616,0.0016068589,0.0021018197,0.0022428678,0.0021669362,0.00007946055,0.000008117644,0.000084967985],"genre_scores_gemma":[0.99565184,0.0009582578,0.00066523184,0.00029815306,0.0020719778,0.00006763635,0.000055978162,0.00003674671,0.00019416596],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908582,0.00070701184,0.006354512,0.00036025775,0.0011494451,0.0005705566],"domain_scores_gemma":[0.9714942,0.0213356,0.0054045757,0.0003136151,0.000777285,0.000674755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011961166,0.0003035405,0.005688797,0.00032462375,0.000048427024,0.00001031676,0.00021329767,0.00040953542,0.0002114206],"category_scores_gemma":[0.003097434,0.00019807393,0.0016877527,0.00026330212,0.0004490545,0.00010281039,0.000033841992,0.00076218136,0.0000012939204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7489096,0.009970577,0.16385262,0.00011988134,0.0021525053,0.00046559755,0.00010309701,0.0000054797533,0.00013187513,0.0000014433101,0.025410274,0.04887708],"study_design_scores_gemma":[0.83706516,0.07210993,0.07943296,0.0005249285,0.00088803476,0.00004633917,0.000049853046,0.00002858274,0.008136754,0.000012911195,0.0015440803,0.00016048795],"about_ca_topic_score_codex":0.00020090758,"about_ca_topic_score_gemma":0.00059379294,"teacher_disagreement_score":0.08815557,"about_ca_system_score_codex":0.00046304738,"about_ca_system_score_gemma":0.003311119,"threshold_uncertainty_score":0.80772203},"labels":[],"label_agreement":null},{"id":"W2112063281","doi":"10.1200/jco.2007.12.3224","title":"Just Say Die","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine","score_opus":0.803076386307885,"score_gpt":0.7090058020122115,"score_spread":0.0940705842956735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112063281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054854085,0.9726077,0.000089950845,0.0005975639,0.0030759664,0.00019867098,0.0000073078645,0.0000061998658,0.023361841],"genre_scores_gemma":[0.0000069208986,0.98680234,0.004814619,0.0011499773,0.0058574127,0.0000016312811,0.000008960157,0.0000327999,0.0013253314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924569,0.00062538066,0.0059729395,0.00020271608,0.00047146517,0.0002705882],"domain_scores_gemma":[0.98164934,0.0108749755,0.005992403,0.00027359143,0.0007087639,0.00050092995],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0057066414,0.00027594226,0.009016956,0.0003062681,0.000016774511,0.0000032836267,0.0003023154,0.0014967995,0.00023509018],"category_scores_gemma":[0.0136627015,0.00016498515,0.003021976,0.00019103603,0.00030154974,0.000044915716,0.00006958888,0.0025650333,0.00009396096],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000319792,0.00060351763,0.000417789,0.0039302516,0.0010651205,0.0020790803,0.000036723442,5.8526727e-8,6.740908e-8,0.000049852315,0.014868917,0.97662884],"study_design_scores_gemma":[0.0017090301,0.0058186413,0.00020108843,0.026091048,0.0045271725,0.00046355667,0.000050275376,2.5975544e-7,6.668598e-7,0.000043675987,0.96097225,0.00012235067],"about_ca_topic_score_codex":0.0000064506453,"about_ca_topic_score_gemma":0.0000098555,"teacher_disagreement_score":0.9765065,"about_ca_system_score_codex":0.00022043666,"about_ca_system_score_gemma":0.0039759795,"threshold_uncertainty_score":0.9997995},"labels":[],"label_agreement":null},{"id":"W2112237372","doi":"10.1200/jco.2010.32.9979","title":"Testing Women With Endometrial Cancer to Detect Lynch Syndrome","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Endometrial cancer; Lynch syndrome; Cancer; Gynecology; Oncology; Internal medicine; Colorectal cancer; DNA mismatch repair","score_opus":0.25657877345807495,"score_gpt":0.46006436383797766,"score_spread":0.20348559037990271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112237372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99113184,0.00018413112,0.00018601655,0.0006709375,0.00241517,0.00029004435,0.0000022076613,0.000014444651,0.005105188],"genre_scores_gemma":[0.9495431,0.000047473044,0.04718145,0.0018571096,0.0011752043,0.000026515021,7.89265e-8,0.000026835558,0.00014219614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99693197,0.00023782047,0.0017192169,0.00022643237,0.00048505288,0.00039953072],"domain_scores_gemma":[0.9944345,0.0027174787,0.0011285665,0.00020253414,0.00069499115,0.0008219485],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029387437,0.00015768984,0.0015159205,0.00025721823,0.000031696953,0.000005936542,0.00023507971,0.00029518822,0.0011487307],"category_scores_gemma":[0.012676837,0.00010104375,0.000168734,0.0005621439,0.00016316812,0.000055203483,0.0000719295,0.000928663,0.000031565734],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03851292,0.00079521677,0.33174127,0.000048030597,0.0009396965,0.0033716883,0.0007322541,0.000036710946,0.0028848054,0.0000046674204,0.0017706113,0.61916214],"study_design_scores_gemma":[0.00927379,0.112505995,0.8572681,0.00017178075,0.0002910628,0.002709618,0.0001123247,0.000006333151,0.0008413155,0.00019071056,0.016475143,0.0001538544],"about_ca_topic_score_codex":0.00008212052,"about_ca_topic_score_gemma":0.0000583361,"teacher_disagreement_score":0.6190083,"about_ca_system_score_codex":0.00055418635,"about_ca_system_score_gemma":0.0029710366,"threshold_uncertainty_score":0.9997644},"labels":[],"label_agreement":null},{"id":"W2112262310","doi":"10.1200/jco.2010.29.5618","title":"Integrating Supportive and Palliative Care in the Trajectory of Cancer: Establishing Goals and Models of Care","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Palliative care; Gemcitabine; Weakness; Constipation; Oxaliplatin; Pancreatic cancer; Anorexia; Performance status; Vomiting; Physical therapy; Internal medicine; Cancer; Surgery; Colorectal cancer; Nursing","score_opus":0.2706265112097484,"score_gpt":0.5608397782159017,"score_spread":0.2902132670061533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112262310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867443,0.010439258,0.000041684638,0.00069940643,0.00026057626,0.00014066181,0.000028189394,0.0000012118543,0.0016447305],"genre_scores_gemma":[0.99079716,0.0050238795,0.0037016885,0.00023453134,0.000226774,0.0000025569723,0.000001922889,0.000006553444,0.0000049290666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766976,0.0003087745,0.0015501662,0.00011635118,0.00023793869,0.000117035444],"domain_scores_gemma":[0.9927564,0.0044508902,0.0016716912,0.00009918061,0.00092278805,0.0000990186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015438942,0.00009821654,0.0012594399,0.000102611135,0.000015772426,0.0000035976097,0.00012145166,0.00024834654,0.000012150923],"category_scores_gemma":[0.0047306926,0.00005766677,0.00016662125,0.00010782579,0.00039251757,0.0001255064,0.000034547047,0.0010362866,3.3992414e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011728992,0.00016022944,0.8489845,0.00029517864,0.00015381849,0.000061951185,0.061451476,0.000027952148,0.0012719085,0.00028383225,0.000081291284,0.08605496],"study_design_scores_gemma":[0.0077240635,0.012824536,0.7492915,0.002792582,0.0006603386,0.000024611747,0.21710917,0.00030655193,0.004279753,0.0010204287,0.003819584,0.00014690866],"about_ca_topic_score_codex":0.00048828317,"about_ca_topic_score_gemma":0.004079122,"teacher_disagreement_score":0.1556577,"about_ca_system_score_codex":0.000041359974,"about_ca_system_score_gemma":0.00089450734,"threshold_uncertainty_score":0.56634223},"labels":[],"label_agreement":null},{"id":"W2112325336","doi":"10.1200/jco.2005.12.513","title":"Randomized Study on the Efficacy of Cognitive-Behavioral Therapy for Insomnia Secondary to Breast Cancer, Part II: Immunologic Effects","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Immune system; Breast cancer; Internal medicine; Insomnia; Randomized controlled trial; CD8; Cognitive behavioral therapy; Cancer; Oncology; Immunology; Psychiatry","score_opus":0.15819506505990197,"score_gpt":0.47448948161590876,"score_spread":0.31629441655600676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112325336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867146,0.00022752637,0.000021808657,0.00925831,0.0013069992,0.0021747139,0.000023109249,0.000011865312,0.00026108007],"genre_scores_gemma":[0.9899835,0.0004046035,0.000051226198,0.00876261,0.0005830084,0.000108972185,2.6188678e-7,0.000016156131,0.000089659734],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99485654,0.0025428433,0.0017512628,0.00027167017,0.00030397222,0.00027372933],"domain_scores_gemma":[0.9629153,0.03513957,0.0014245065,0.00017678308,0.00020572032,0.00013809551],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038015672,0.00018482663,0.0015812389,0.00010959817,0.00014535311,0.000014664881,0.0005131547,0.0001862751,0.00020189113],"category_scores_gemma":[0.010675917,0.00009745252,0.0007061819,0.0001896315,0.0004905473,0.00009351838,0.00007845717,0.0007716989,0.000011826345],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43248552,0.02160626,0.0009701249,0.000005695148,0.0002046637,0.00003329221,0.0011193412,0.00003125663,0.0039028125,0.00016967008,0.0022195235,0.53725183],"study_design_scores_gemma":[0.71825486,0.061652105,0.1929901,0.00015504875,0.00021981483,0.000049524147,0.0006515031,0.00001994425,0.0113967415,0.00032522428,0.014022014,0.00026310986],"about_ca_topic_score_codex":0.000008870835,"about_ca_topic_score_gemma":0.000018585164,"teacher_disagreement_score":0.53698874,"about_ca_system_score_codex":0.000047907542,"about_ca_system_score_gemma":0.0005661161,"threshold_uncertainty_score":0.9976576},"labels":[],"label_agreement":null},{"id":"W2112387181","doi":"10.1200/jco.2003.06.085","title":"Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; MALT lymphoma; Lymphoma; Mucosa-associated lymphoid tissue; Gastroenterology; Stage (stratigraphy); Internal medicine; Radiation therapy; Thyroid; Lymphatic system; Stomach; Thyroid lymphoma; Chemotherapy; Surgery; Pathology; Thyroiditis","score_opus":0.1762809649238636,"score_gpt":0.462614739162051,"score_spread":0.2863337742381874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112387181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98803526,0.0019857648,0.00010037858,0.005216419,0.0012851135,0.00057260186,0.0000055602204,0.000038231727,0.0027606813],"genre_scores_gemma":[0.98728704,0.0054436126,0.0014889431,0.00450947,0.00062419963,0.000019602183,0.000017634644,0.0000464233,0.0005630723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99159676,0.002089568,0.0047524287,0.0004205386,0.0006873538,0.00045332927],"domain_scores_gemma":[0.9904928,0.0042418274,0.0033260083,0.0003922879,0.00068954204,0.00085748837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005549156,0.00035910803,0.0031620765,0.00017167188,0.00011523837,0.000034471534,0.00017942683,0.00094686454,0.00048171417],"category_scores_gemma":[0.004852239,0.0002129069,0.0009689184,0.00031331135,0.00039675483,0.00012508155,0.000020946914,0.00046621848,0.00010854577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056286636,0.013419276,0.72158426,0.0000063101993,0.0015791513,0.0017858449,0.000053902375,0.0000063970156,0.000015086366,0.0000703303,0.00299014,0.25286064],"study_design_scores_gemma":[0.08074074,0.029000146,0.58059037,0.000062942694,0.00079755724,0.0008199306,0.000046283938,0.000034398166,0.00041076582,0.00006256311,0.30726314,0.00017116741],"about_ca_topic_score_codex":0.00007902507,"about_ca_topic_score_gemma":0.00003834432,"teacher_disagreement_score":0.304273,"about_ca_system_score_codex":0.00091923715,"about_ca_system_score_gemma":0.003427018,"threshold_uncertainty_score":0.8682092},"labels":[],"label_agreement":null},{"id":"W2112417555","doi":"10.1200/jco.2005.00.612","title":"Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Dosing; Toxicity; Internal medicine; Gastroenterology; Area under the curve; Pharmacology","score_opus":0.042561223261090984,"score_gpt":0.4344963087278571,"score_spread":0.39193508546676614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112417555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801105,0.00072676706,0.00032067203,0.00019424273,0.0002477286,0.00028357227,0.000007333713,0.0000016486804,0.0002069803],"genre_scores_gemma":[0.9960915,0.0007452057,0.002072051,0.000713475,0.0002377521,0.0000058200744,0.0000038360085,0.000015963826,0.00011443933],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99788463,0.00024217261,0.0012716455,0.00021537376,0.000197281,0.00018887744],"domain_scores_gemma":[0.9983811,0.00011658566,0.00097103853,0.00013821268,0.00025530314,0.00013778107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010838441,0.00014502711,0.0006756759,0.000091264985,0.000019440122,0.0000041257595,0.00017825534,0.00014418244,0.00002798201],"category_scores_gemma":[0.000099967874,0.00011026107,0.000100957936,0.00008821425,0.00009152243,0.000011295234,0.000065271815,0.0003000361,2.9577507e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014660619,0.015777051,0.029607983,0.000020612904,0.0005186547,0.00004155335,0.00024136055,0.00094126293,0.13640502,0.000012388656,0.00035111996,0.80142236],"study_design_scores_gemma":[0.27343222,0.28331894,0.24949677,0.00015283538,0.0011212073,0.00007189135,0.0010332895,0.0009892902,0.042547185,0.0001350526,0.14685318,0.0008481291],"about_ca_topic_score_codex":0.000005181526,"about_ca_topic_score_gemma":0.00013896356,"teacher_disagreement_score":0.80057424,"about_ca_system_score_codex":0.000029128369,"about_ca_system_score_gemma":0.00023852316,"threshold_uncertainty_score":0.4496316},"labels":[],"label_agreement":null},{"id":"W2112474467","doi":"10.1200/jco.2007.15.9319","title":"Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Pharmacokinetics; Tolerability; Pharmacodynamics; Dexamethasone; Internal medicine; Pharmacology; Endocrinology; Adverse effect","score_opus":0.08983225290521596,"score_gpt":0.4622123649232952,"score_spread":0.37238011201807925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112474467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790245,0.00014937235,0.0000054240363,0.00036388513,0.0005247623,0.000948081,0.000029470768,0.0000059252047,0.000070645176],"genre_scores_gemma":[0.99838614,0.0006321025,0.0005142218,0.00017371261,0.00020501198,0.0000045791817,0.000010612393,0.00002385754,0.00004975059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964421,0.00064164103,0.0016794839,0.00026523983,0.0006544133,0.00031714287],"domain_scores_gemma":[0.9964187,0.0011387113,0.0010985001,0.00019135256,0.0007332165,0.00041947956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063783367,0.00021203043,0.0012953312,0.00020883598,0.00007397179,0.000004539398,0.00022554479,0.0001553625,0.0000951882],"category_scores_gemma":[0.0016262236,0.000116182404,0.00017746349,0.00036384093,0.0003421781,0.00013070811,0.00009979128,0.0009954037,0.0000057508933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023182573,0.028307706,0.92252344,0.000030824813,0.00065098325,0.00049885176,0.00025418476,0.000007858701,0.002166103,4.6329762e-7,0.00014332178,0.022233661],"study_design_scores_gemma":[0.10574392,0.034168564,0.858384,0.00006656277,0.00019103532,0.00007661793,0.00006508034,0.0004369483,0.00040545294,0.0000024412868,0.0003701621,0.000089178015],"about_ca_topic_score_codex":0.000063740954,"about_ca_topic_score_gemma":0.000030577135,"teacher_disagreement_score":0.08256135,"about_ca_system_score_codex":0.00010833128,"about_ca_system_score_gemma":0.00079262623,"threshold_uncertainty_score":0.4737781},"labels":[],"label_agreement":null},{"id":"W2112502628","doi":"10.1200/jco.2001.19.3.895","title":"Insomnia in the Context of Cancer: A Review of a Neglected Problem","year":2001,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Sleep and related disorders","field":"Psychology","cited_by":870,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Insomnia; Medicine; Context (archaeology); Cognitive behavioral therapy for insomnia; Etiology; Intensive care medicine; Psychological intervention; Cancer; Psychiatry; Cognitive behavioral therapy; Cognition; Internal medicine","score_opus":0.1956386416242174,"score_gpt":0.5553692556563371,"score_spread":0.3597306140321197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112502628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006265274,0.9802398,0.0000028186869,0.0017714378,0.0018129244,0.0010068669,0.000013487677,0.0000034171394,0.015086572],"genre_scores_gemma":[0.000040294253,0.9967578,0.00009165996,0.0024615417,0.00039804116,0.000054112446,0.000005476372,0.000029949551,0.00016111047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98459435,0.0053138,0.009141645,0.0002597734,0.00038116303,0.00030928687],"domain_scores_gemma":[0.9797815,0.0067889593,0.012370301,0.00043423031,0.0005007726,0.00012421636],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005030654,0.00030927514,0.007723323,0.00032560108,0.000016186872,0.0000027896358,0.001065775,0.0016456303,0.0011323752],"category_scores_gemma":[0.0026323341,0.0001607128,0.002225882,0.0011678763,0.0004194656,0.0000374222,0.000053551626,0.0033612736,0.000028280461],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002493345,0.002296261,0.00015156703,0.012148029,0.0022348685,0.00022435715,0.00024405716,2.0664127e-7,3.210797e-8,0.0002513836,0.028187057,0.9540129],"study_design_scores_gemma":[0.0030864007,0.0029477726,0.00016414635,0.08054793,0.004420175,0.0003552855,0.00017283543,1.6548066e-7,1.1602358e-8,0.000106265696,0.90807414,0.0001248904],"about_ca_topic_score_codex":0.00027289058,"about_ca_topic_score_gemma":0.00021495072,"teacher_disagreement_score":0.95388794,"about_ca_system_score_codex":0.00010161411,"about_ca_system_score_gemma":0.0029407411,"threshold_uncertainty_score":0.9997807},"labels":[],"label_agreement":null},{"id":"W2112524831","doi":"10.1200/jco.2011.39.2993","title":"Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Erlotinib; Medicine; Sunitinib; Internal medicine; Lung cancer; Rash; Oncology; Erlotinib Hydrochloride; Hazard ratio; Clinical endpoint; Epidermal growth factor receptor; Phases of clinical research; Gastroenterology; Cancer; Chemotherapy; Clinical trial; Confidence interval","score_opus":0.07140800855381599,"score_gpt":0.47321302083902184,"score_spread":0.4018050122852058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112524831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869837,0.000827484,0.000053823765,0.00063045055,0.0031315314,0.0036555745,0.000027880444,0.000023552298,0.004665958],"genre_scores_gemma":[0.9945612,0.00045651878,0.0016944627,0.0005437299,0.0015985644,0.00019373612,0.000057224093,0.00005664497,0.0008379395],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954207,0.00042338733,0.0026578212,0.00031573515,0.0004943082,0.00068805745],"domain_scores_gemma":[0.9940659,0.0017976075,0.002389334,0.00028771738,0.0005985912,0.00086085347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001479458,0.00034056389,0.0022137545,0.00024739627,0.000084991094,0.000014899673,0.00019833681,0.00041380676,0.00026588602],"category_scores_gemma":[0.00092208566,0.00023168331,0.00040718957,0.00034920668,0.0001542648,0.00030669867,0.000046240642,0.0010817259,0.000010821277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8080894,0.012425644,0.12155983,0.000078818484,0.0012573416,0.00026196404,0.0016631957,0.00022499081,0.00000933465,0.000011315884,0.0012023927,0.053215828],"study_design_scores_gemma":[0.88469106,0.051063705,0.047557294,0.00035859097,0.0034351465,0.00002423629,0.00043531726,0.00015543612,0.00003851036,0.0000019884762,0.011987436,0.00025126903],"about_ca_topic_score_codex":0.00019629742,"about_ca_topic_score_gemma":0.00033730746,"teacher_disagreement_score":0.07660172,"about_ca_system_score_codex":0.0014381612,"about_ca_system_score_gemma":0.0055029187,"threshold_uncertainty_score":0.97619414},"labels":[],"label_agreement":null},{"id":"W2112870137","doi":"10.1200/jco.2005.03.171","title":"Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Toxicity; Leukopenia; Gastroenterology; Vomiting; Vincristine; Etoposide; Chemotherapy; Stomatitis; Cyclophosphamide; Lung cancer; Surgery","score_opus":0.16985025298338588,"score_gpt":0.5546774789976718,"score_spread":0.384827226014286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112870137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98437184,0.0014556409,0.0000019529236,0.012450376,0.00009459187,0.00020872743,0.0000026802434,0.0000024848844,0.001411721],"genre_scores_gemma":[0.9911696,0.005768641,0.0005537426,0.0015809288,0.0004461383,0.0000073381752,1.0538898e-7,0.0000065078507,0.0004670178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777097,0.00020377352,0.001486713,0.00013337641,0.0002172108,0.00018795997],"domain_scores_gemma":[0.9971185,0.001713624,0.00065765786,0.00011527678,0.00018458485,0.00021036826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015200495,0.000097780656,0.0012029618,0.000117050804,0.000015615675,0.000002113451,0.00008236818,0.0001502983,0.000030114656],"category_scores_gemma":[0.0014374866,0.00006044688,0.00015523516,0.00008541668,0.00018147976,0.000047416677,0.00004715859,0.0005542374,0.0000018639769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020010634,0.0018418917,0.9231246,0.000059815753,0.00018994413,0.00017319623,0.00030235347,0.0006866275,0.00033689803,0.000010124487,0.00031124617,0.07096223],"study_design_scores_gemma":[0.012061206,0.013867093,0.9616976,0.00016482966,0.0001629355,0.000027241438,0.00007441679,0.00017235885,0.0011106023,0.000019584224,0.010584681,0.000057485806],"about_ca_topic_score_codex":0.00017848455,"about_ca_topic_score_gemma":0.0008234879,"teacher_disagreement_score":0.07090475,"about_ca_system_score_codex":0.0006442981,"about_ca_system_score_gemma":0.0009463385,"threshold_uncertainty_score":0.24649522},"labels":[],"label_agreement":null},{"id":"W2112881933","doi":"10.1200/jco.2005.08.011","title":"Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Radiation therapy; Internal medicine; Pneumonitis; Chemoradiotherapy; Chemotherapy; Paclitaxel; Phases of clinical research; Induction chemotherapy; Clinical endpoint; Oncology; Gastroenterology; Randomized controlled trial; Lung; Cisplatin","score_opus":0.03690897394678632,"score_gpt":0.4640595912714231,"score_spread":0.42715061732463677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112881933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924169,0.0019552123,0.00046023334,0.0024419911,0.00063134846,0.0020574518,0.000014749571,0.000004985842,0.000017134094],"genre_scores_gemma":[0.9926717,0.0020477863,0.003573923,0.0009786125,0.00048645,0.000104714505,0.000005747742,0.000027968497,0.00010306805],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99780244,0.00011526047,0.0013663484,0.0002510572,0.0002661036,0.00019878014],"domain_scores_gemma":[0.99732655,0.00032025203,0.0014954285,0.00013254267,0.0004933111,0.00023193841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054575305,0.0001875845,0.0012197897,0.00006829542,0.000051511422,0.000005820541,0.000078926445,0.00016314899,0.000038061473],"category_scores_gemma":[0.00006600546,0.00011720902,0.00019876233,0.00007292354,0.00008480526,0.00011345507,0.000014442415,0.0003202432,1.3963518e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026239417,0.0613786,0.39617354,0.00008616815,0.0012486702,0.000008922641,0.00080555916,0.000029490457,0.00036613544,4.6455332e-7,0.0028601058,0.5108029],"study_design_scores_gemma":[0.45452663,0.36647716,0.1406824,0.0005414203,0.002564406,0.000008214073,0.00036850545,0.0010898202,0.0025991725,0.0000020059138,0.03086758,0.00027270522],"about_ca_topic_score_codex":0.00001728857,"about_ca_topic_score_gemma":0.00007181884,"teacher_disagreement_score":0.51053023,"about_ca_system_score_codex":0.00038869883,"about_ca_system_score_gemma":0.0004600955,"threshold_uncertainty_score":0.47796452},"labels":[],"label_agreement":null},{"id":"W2112901840","doi":"10.1200/jco.2006.09.7535","title":"Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Ixabepilone; Medicine; Anthracycline; Metastatic breast cancer; Clinical endpoint; Internal medicine; Chemotherapy; Regimen; Adverse effect; Surgery; Breast cancer; Oncology; Cancer; Clinical trial","score_opus":0.13257564656467236,"score_gpt":0.5297732023901652,"score_spread":0.3971975558254929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112901840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915479,0.0004847257,0.00007856211,0.0053086737,0.00063915603,0.0017292709,0.000038587084,0.000016950464,0.00015620836],"genre_scores_gemma":[0.9873452,0.00641745,0.0015246841,0.0028502173,0.0015921405,0.000022495924,0.000046658064,0.000060551843,0.00014056254],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924439,0.0007888508,0.00506198,0.00048885273,0.0006745994,0.0005417925],"domain_scores_gemma":[0.9913543,0.0023050986,0.0041694697,0.00037737776,0.0010281053,0.000765643],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0057181064,0.00041246234,0.0038565225,0.00037395963,0.00007070278,0.0000070794867,0.0002580623,0.00044552374,0.00094500784],"category_scores_gemma":[0.00035050153,0.00024136555,0.00052098336,0.00050984876,0.0007265422,0.00023697452,0.000028725326,0.0013179117,0.0000028851355],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4847801,0.0824802,0.24890007,0.000018550243,0.0018936024,0.0005370602,0.0001591448,0.000016463742,0.000030776733,0.0000022812053,0.00018554652,0.1809962],"study_design_scores_gemma":[0.39703542,0.32492995,0.27453515,0.000133957,0.001037921,0.00012307342,0.00002461442,0.000028140352,0.00011691514,0.000021527208,0.0018752441,0.00013809156],"about_ca_topic_score_codex":0.00038003703,"about_ca_topic_score_gemma":0.001560265,"teacher_disagreement_score":0.24244975,"about_ca_system_score_codex":0.00026666428,"about_ca_system_score_gemma":0.0020645915,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W2112998032","doi":"10.1200/jco.2008.20.0634","title":"Randomized Controlled Trial of the Effects of Aerobic Exercise on Physical Functioning and Quality of Life in Lymphoma Patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Alberta Cancer Foundation","funders":"National Cancer Institute; Fondation pour la Recherche Médicale; Canada Research Chairs; Armstrong Foundation; Lance Armstrong Foundation","keywords":"Medicine; Quality of life (healthcare); Aerobic exercise; Physical therapy; Randomized controlled trial; Psychosocial; Depression (economics); Body mass index; Clinical endpoint; Internal medicine; Physical fitness; Psychiatry","score_opus":0.04859318205145031,"score_gpt":0.4124254843038994,"score_spread":0.3638323022524491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112998032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959799,0.00028542156,0.000007240718,0.0005196276,0.0017264709,0.0010480881,6.327459e-7,0.0000013099105,0.00043130346],"genre_scores_gemma":[0.9989505,0.00024041726,0.000016957794,0.00042277772,0.0003312093,0.000007760105,3.105978e-7,0.0000040749296,0.000025992289],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99448454,0.002003889,0.0029096617,0.00009728328,0.00041115528,0.00009347051],"domain_scores_gemma":[0.9832108,0.012907637,0.0032839163,0.00014149307,0.0003430201,0.00011313064],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004939443,0.00009401346,0.004622629,0.000083074556,0.000011128962,0.0000013812639,0.00008154331,0.00018875614,0.0000058078635],"category_scores_gemma":[0.023091055,0.000049096074,0.0010914095,0.00011802823,0.00023612998,0.000029807472,0.000017993789,0.00031355605,1.5666296e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9472387,0.0042687426,0.0161284,0.00008447296,0.00018130003,0.0000027343447,0.0002724732,0.0000053964814,0.00014390306,0.00009488713,0.000040402752,0.031538617],"study_design_scores_gemma":[0.7719032,0.0134102255,0.21337408,0.0003808868,0.00043552916,6.325905e-7,0.00004209796,0.000018070967,0.00018064694,0.0002064431,0.0000185399,0.000029641824],"about_ca_topic_score_codex":0.00006582975,"about_ca_topic_score_gemma":0.000039207378,"teacher_disagreement_score":0.19724567,"about_ca_system_score_codex":0.00004375688,"about_ca_system_score_gemma":0.000565522,"threshold_uncertainty_score":0.9851379},"labels":[],"label_agreement":null},{"id":"W2113248775","doi":"10.1200/jco.2008.20.0600","title":"Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":477,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Radiosurgery; Radiology; Oncology","score_opus":0.27590122527561073,"score_gpt":0.48971825749469333,"score_spread":0.2138170322190826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113248775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959257,0.002156872,0.000044631535,0.00080215966,0.00021195643,0.00043762915,0.000005778631,0.00000459205,0.00041066617],"genre_scores_gemma":[0.9953993,0.0008266,0.002934802,0.00047612807,0.00029765288,0.0000018488844,0.000002859423,0.000009849982,0.000050962622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957279,0.0009712505,0.0025853203,0.0001359982,0.0004296685,0.00014987268],"domain_scores_gemma":[0.9952061,0.0015872427,0.0023764975,0.00021277569,0.00037449566,0.00024290016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027379412,0.0001371269,0.0021605964,0.0002147179,0.000017345517,0.000003639826,0.00013968562,0.00018600807,0.0003254737],"category_scores_gemma":[0.0009964339,0.00009016401,0.0006139547,0.00017514672,0.00010206562,0.000092617796,0.00001426685,0.00041591123,0.0000021903782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015910355,0.07744146,0.6163545,0.000037543887,0.0032327576,0.0027161972,0.0009737557,4.1273347e-7,0.0018552573,0.000031889413,0.0008744042,0.28057146],"study_design_scores_gemma":[0.11557377,0.41750363,0.44545403,0.000109579836,0.0052253674,0.00043435444,0.00039728807,0.00014175463,0.0025980768,0.00009382486,0.012333735,0.00013460171],"about_ca_topic_score_codex":0.000023424038,"about_ca_topic_score_gemma":0.0000043122964,"teacher_disagreement_score":0.34006214,"about_ca_system_score_codex":0.000047319067,"about_ca_system_score_gemma":0.00055990036,"threshold_uncertainty_score":0.36767817},"labels":[],"label_agreement":null},{"id":"W2113257557","doi":"10.1200/jco.2013.49.1894","title":"Reply to D. Milne et al","year":2013,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.453359698123235,"score_gpt":0.6065341077036822,"score_spread":0.1531744095804472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113257557","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03132171,0.011810116,0.00047562202,0.9179293,0.020937555,0.00036427964,0.000030112336,0.000008504577,0.01712283],"genre_scores_gemma":[0.0011146272,0.021554284,0.02268529,0.91711843,0.025409719,0.0000073980345,0.000019620913,0.00006341235,0.012027235],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879922,0.002391521,0.00737965,0.0004824296,0.0010352868,0.0007188569],"domain_scores_gemma":[0.97011036,0.01995196,0.0060346625,0.000580293,0.0022225955,0.0011001332],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.008345507,0.00046942825,0.0058382987,0.00037498167,0.00003414908,0.000015764477,0.000680974,0.00200978,0.0029821952],"category_scores_gemma":[0.0383508,0.00034496476,0.0019145895,0.00025583775,0.0006248701,0.00016733352,0.0002077519,0.007493673,0.0013343766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016047843,0.0008823113,0.018293126,0.00016284554,0.0014004306,0.004681773,0.00047410882,0.000010598045,0.00008229814,0.00009011135,0.8867554,0.08556218],"study_design_scores_gemma":[0.0051928284,0.02495424,0.01593184,0.004517917,0.0010526357,0.0004270564,0.00023973137,0.000013858806,0.0000722811,0.00025589272,0.94706434,0.0002773836],"about_ca_topic_score_codex":0.00029802165,"about_ca_topic_score_gemma":0.000027720096,"teacher_disagreement_score":0.08528479,"about_ca_system_score_codex":0.00041891384,"about_ca_system_score_gemma":0.003984365,"threshold_uncertainty_score":0.9999002},"labels":[],"label_agreement":null},{"id":"W2113382133","doi":"10.1200/jco.2008.20.7019","title":"Pathologic Complete Response Rates in Young Women With <i>BRCA1</i>-Positive Breast Cancers After Neoadjuvant Chemotherapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":507,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Cyclophosphamide; Chemotherapy; Docetaxel; Oncology; Breast cancer; Regimen; Fluorouracil; Internal medicine; Doxorubicin; Neoadjuvant therapy; Cisplatin; Cancer","score_opus":0.027009090004137294,"score_gpt":0.3800088697682325,"score_spread":0.3529997797640952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113382133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919505,0.00053255697,0.0003681752,0.006095107,0.0003631971,0.00014361725,0.000025946001,0.0000030176695,0.00051785866],"genre_scores_gemma":[0.9891511,0.00046816224,0.002888209,0.0067563723,0.00058194454,0.000015390053,0.000004142618,0.000016068743,0.00011860865],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969144,0.0009312205,0.001292454,0.00031071063,0.00022628467,0.00032491822],"domain_scores_gemma":[0.9978477,0.00036338915,0.00095591415,0.0002544796,0.0003957407,0.00018280171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034363708,0.00017537277,0.0007479347,0.00010285711,0.000031652307,0.000017976216,0.0002905221,0.00034987944,0.00005777572],"category_scores_gemma":[0.00056279055,0.00012607657,0.00015640754,0.00017619763,0.00027033797,0.000012539611,0.000035348763,0.0005100238,0.0000043092687],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35661063,0.0022048517,0.18123306,0.000011640153,0.00078950997,0.0032468121,0.0029013692,0.0033625066,0.13847607,0.000021757485,0.007139163,0.30400264],"study_design_scores_gemma":[0.006314125,0.01780407,0.95968205,0.000037411424,0.000026755773,0.0013605993,0.0004393359,0.000025784111,0.0013278386,0.00035624744,0.012425028,0.00020075422],"about_ca_topic_score_codex":0.000010875494,"about_ca_topic_score_gemma":0.0001522763,"teacher_disagreement_score":0.778449,"about_ca_system_score_codex":0.00050382846,"about_ca_system_score_gemma":0.0020227951,"threshold_uncertainty_score":0.51412535},"labels":[],"label_agreement":null},{"id":"W2113384029","doi":"10.1200/jco.2014.55.4980","title":"Evidence-Based Medicine for Thromboprophylaxis in Hospitalized Patients With Cancer: Why Aren't We There Yet?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health; University of British Columbia","funders":"","keywords":"Medicine; Medical prescription; Cancer; Intensive care medicine; Disease; Emergency medicine; Venous thromboembolism; Thrombosis; Internal medicine","score_opus":0.16089009824165632,"score_gpt":0.4375362327449514,"score_spread":0.2766461345032951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113384029","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046975873,0.0038291698,0.00028383202,0.94253147,0.0038974753,0.0018785861,0.000020347585,0.000015735981,0.00056754285],"genre_scores_gemma":[0.06118673,0.013583476,0.0018875473,0.91077733,0.0119072925,0.00018275004,0.00007052163,0.00012552572,0.00027884237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99337447,0.00069552934,0.0036824304,0.00054770726,0.0011345816,0.0005653079],"domain_scores_gemma":[0.98707217,0.006063151,0.0047112545,0.0005261309,0.0013345621,0.00029271375],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0033909383,0.00048615498,0.005967135,0.00044227618,0.000049505215,0.000015959957,0.000517725,0.00150884,0.00073111325],"category_scores_gemma":[0.0043953536,0.0002791286,0.0007840651,0.00024757872,0.0004911928,0.00012918968,0.00005781666,0.0030416,0.000008783287],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029193002,0.0016836056,0.053796023,0.000933876,0.00094249815,0.0006115459,0.00005613657,0.00001834952,8.957836e-7,0.000012804893,0.89945596,0.039569],"study_design_scores_gemma":[0.018165778,0.052598752,0.1821172,0.009550985,0.0017731544,0.0000067935107,0.000018315312,0.00002059524,0.0000019166362,0.0003263925,0.7351731,0.00024700936],"about_ca_topic_score_codex":0.00035764,"about_ca_topic_score_gemma":0.00020341322,"teacher_disagreement_score":0.16428286,"about_ca_system_score_codex":0.00051527075,"about_ca_system_score_gemma":0.0020199032,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W2113425478","doi":"10.1200/jco.2007.13.5566","title":"Physician-Identified Factors Affecting Patient Participation in Reaching Treatment Decisions","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Family medicine","score_opus":0.7066466686351298,"score_gpt":0.623253533572528,"score_spread":0.08339313506260182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113425478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195313,0.00043665993,0.000091857684,0.0017727485,0.003125166,0.00060151814,0.000004131976,0.000021736016,0.0019930734],"genre_scores_gemma":[0.9957889,0.0006467487,0.0018635374,0.0011409924,0.00043976936,0.000035126366,0.000007683363,0.000020766915,0.000056497982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877992,0.0062268423,0.0049053105,0.00022302671,0.00040380697,0.00044180214],"domain_scores_gemma":[0.9679623,0.026353436,0.004334507,0.0004528807,0.0005474078,0.0003494718],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001978834,0.00016643057,0.0012059484,0.00025138445,0.0006150361,0.0000038456474,0.00028958687,0.0004441558,0.00004561733],"category_scores_gemma":[0.01744009,0.00012234855,0.0003437845,0.00028033037,0.00011131976,0.00028259956,0.00012837748,0.0018827051,0.00005695391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005958274,0.0019300798,0.856767,0.00001576555,0.00006924561,0.000076360535,0.032832526,0.00022358575,0.000048852893,0.000065588414,0.0009114847,0.1064637],"study_design_scores_gemma":[0.0038871076,0.004265805,0.966211,0.00036505517,0.000052570336,0.000007930347,0.012875176,0.00024046515,0.000045936464,0.00047452963,0.01144644,0.00012794796],"about_ca_topic_score_codex":0.0005587209,"about_ca_topic_score_gemma":0.0009828897,"teacher_disagreement_score":0.10944405,"about_ca_system_score_codex":0.0012497279,"about_ca_system_score_gemma":0.002130268,"threshold_uncertainty_score":0.99083644},"labels":[],"label_agreement":null},{"id":"W2113477288","doi":"10.1200/jco.2014.55.5763","title":"Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Oklahoma Health Sciences Center; York University; Connecticut Children's Medical Center; Children's Hospitals and Clinics of Minnesota; Children's National Hospital; Seattle Children's Research Institute; University of Minnesota; Medical Center, University of Pittsburgh; University of Pittsburgh; Johns Hopkins University; Children's Hospital of Pittsburgh; Children's Hospital Colorado; Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago; Wayne State University; Cincinnati Children's Hospital Medical Center; Vanderbilt University; University of Oklahoma; Children's Hospital of Philadelphia","keywords":"Medicine; Asparaginase; Pharmacokinetics; Pharmacodynamics; PEG ratio; Pharmacology; Lymphoblastic Leukemia; Gastroenterology; Internal medicine; Leukemia","score_opus":0.03771024350579944,"score_gpt":0.3682355882289499,"score_spread":0.3305253447231505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113477288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965291,0.00023629173,0.00008241023,0.0010470424,0.00029552853,0.0015478729,0.000066207795,0.0000074920563,0.0001880338],"genre_scores_gemma":[0.997192,0.0009660741,0.0007773898,0.0005532438,0.00039022873,0.000037930637,0.000022041222,0.00003524406,0.000025833564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99285495,0.0021530797,0.003205202,0.00044396508,0.0009113601,0.0004314329],"domain_scores_gemma":[0.9912769,0.004986436,0.0023515448,0.000404783,0.00057800143,0.00040233557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021286043,0.0003506828,0.002488354,0.0002442647,0.00004971647,0.000009503715,0.00041740938,0.00031644775,0.00001826741],"category_scores_gemma":[0.0014184134,0.00018334895,0.00024312202,0.00034939562,0.0008649284,0.000117491334,0.00009018862,0.0008328782,0.0000034896548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25276062,0.07129541,0.55490994,0.00013700784,0.006063542,0.0035847314,0.0062859203,0.00054229825,0.007283388,0.000013309551,0.000843271,0.096280575],"study_design_scores_gemma":[0.15929656,0.13516738,0.69526523,0.0001792351,0.003394262,0.00023891457,0.00044810813,0.0038843418,0.0005794204,0.000017937115,0.0013371787,0.00019142384],"about_ca_topic_score_codex":0.0006563175,"about_ca_topic_score_gemma":0.00020803226,"teacher_disagreement_score":0.14035532,"about_ca_system_score_codex":0.0011678726,"about_ca_system_score_gemma":0.0031897915,"threshold_uncertainty_score":0.74767536},"labels":[],"label_agreement":null},{"id":"W2113953300","doi":"10.1200/jco.2010.33.4714","title":"Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":346,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources","keywords":"Medicine; Oncology; Breast cancer; Internal medicine; Lymphovascular invasion; Triple-negative breast cancer; Lumpectomy; Proportional hazards model; Hazard ratio; Population; Adjuvant therapy; Radiation therapy; Mastectomy; Cancer; Metastasis; Confidence interval","score_opus":0.07281762479871287,"score_gpt":0.3636776205036056,"score_spread":0.29085999570489274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113953300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638206,0.00066490355,0.0012098062,0.00047976148,0.0001173229,0.00075098756,0.0002596804,0.000009620696,0.00012583644],"genre_scores_gemma":[0.99327594,0.002371494,0.0033618768,0.00030108937,0.0003933502,0.00021134899,0.00002117244,0.000042780935,0.00002095581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970341,0.00065732806,0.0011409224,0.00044170552,0.00033856544,0.00038742914],"domain_scores_gemma":[0.9950151,0.0005782433,0.0027237781,0.00027831877,0.0011118178,0.00029278363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097287685,0.00036770498,0.0014831381,0.00010362727,0.00010734923,0.000009626918,0.0003034075,0.0002768768,0.000050370872],"category_scores_gemma":[0.00014165268,0.00020350242,0.00020599128,0.0002088524,0.0007433475,0.000030234123,0.000030402378,0.0003835768,3.9182507e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26546168,0.0018854159,0.6491415,0.000018123548,0.0039308025,0.000026385229,0.00054747,0.00010251125,0.00052074215,0.00000811299,0.00017087752,0.07818639],"study_design_scores_gemma":[0.04950919,0.019839438,0.92564243,0.00015347521,0.00030835415,0.0005571419,0.00033498692,0.000119334065,0.0026754325,0.00008125858,0.00048827918,0.000290668],"about_ca_topic_score_codex":0.0008203826,"about_ca_topic_score_gemma":0.0005673181,"teacher_disagreement_score":0.27650094,"about_ca_system_score_codex":0.00015434662,"about_ca_system_score_gemma":0.0018761391,"threshold_uncertainty_score":0.8298588},"labels":[],"label_agreement":null},{"id":"W2114201736","doi":"10.1200/jco.2005.09.500","title":"Not Working 3 Years After Breast Cancer: Predictors in a Population-Based Study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Medicine; Breast cancer; Population; Cohort; Relative risk; Cancer; Relative survival; Cancer registry; Demography; Cohort study; Internal medicine; Confidence interval; Environmental health","score_opus":0.07602601953675565,"score_gpt":0.4426988357432987,"score_spread":0.3666728162065431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114201736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989018,0.00023477235,0.000007794966,0.008814382,0.0015406312,0.00017186013,0.0000045832803,0.000007653389,0.00020029102],"genre_scores_gemma":[0.99310166,0.000048542595,0.00015600234,0.0038487618,0.002729351,0.000011967265,9.675961e-7,0.0000139408185,0.00008880422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745303,0.0002907856,0.0015629779,0.00014812074,0.00036954504,0.00017554825],"domain_scores_gemma":[0.9982211,0.0006423322,0.00063310954,0.00013397986,0.00014307417,0.00022641635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018174757,0.00009203655,0.0008618684,0.00016949423,0.000011809178,0.000006965767,0.000098217,0.00021065655,0.000415465],"category_scores_gemma":[0.0003276837,0.00007284429,0.00027208088,0.00019016961,0.000033633583,0.00006332291,0.000020550335,0.00080149807,0.000006280759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047873794,0.0011026985,0.82640296,0.0000058010596,0.00006821033,0.00033380717,0.0002838541,0.00013557017,0.0000014861871,0.0000011986118,0.00017055066,0.1667065],"study_design_scores_gemma":[0.005945559,0.001953616,0.97540987,0.00015029215,0.00016505299,0.000036097732,0.0001772265,0.00009923564,9.807648e-7,0.0000054931147,0.015992466,0.00006408553],"about_ca_topic_score_codex":0.00059654715,"about_ca_topic_score_gemma":0.02086556,"teacher_disagreement_score":0.16664241,"about_ca_system_score_codex":0.00039183302,"about_ca_system_score_gemma":0.0010181242,"threshold_uncertainty_score":0.9970011},"labels":[],"label_agreement":null},{"id":"W2114300639","doi":"10.1200/jco.2005.13.011","title":"Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":421,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"University of Washington","keywords":"Medicine; Hazard ratio; Lung cancer; Internal medicine; Toxicity; Cyclophosphamide; Performance status; Stage (stratigraphy); Randomized controlled trial; Chemotherapy; Surgery; Gastroenterology; Confidence interval","score_opus":0.05074711381612095,"score_gpt":0.43071040946688965,"score_spread":0.3799632956507687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114300639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629112,0.031222815,0.00010394361,0.0023491192,0.0022626447,0.0006890835,0.000011007955,0.000006020308,0.00044415443],"genre_scores_gemma":[0.9715778,0.023083476,0.00034406706,0.00074966904,0.00044768065,0.00002248594,0.0000036718711,0.000020102161,0.0037510036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99245924,0.0028411488,0.004064919,0.00021612873,0.00006894455,0.00034963596],"domain_scores_gemma":[0.9899589,0.0067253974,0.002821314,0.00021883842,0.00021558508,0.00005997106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008072216,0.00022310979,0.0031449867,0.0003031449,0.00005569764,0.0000073122947,0.00032642996,0.0007790358,0.00089190935],"category_scores_gemma":[0.0021710058,0.00015810374,0.00064261997,0.00014169367,0.0003787761,0.00016085805,0.0000799883,0.0013073814,0.000009655413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87423676,0.003770659,0.0007026247,0.000028362312,0.0008414722,0.000037057096,0.00044417506,0.00002328654,0.042414375,0.00003541315,0.00076479703,0.076700985],"study_design_scores_gemma":[0.9206285,0.008909231,0.0013036465,0.00010072576,0.00038112613,0.00006301734,0.00013917488,0.00006666389,0.010337854,0.000026155742,0.057886824,0.00015709971],"about_ca_topic_score_codex":0.000110783956,"about_ca_topic_score_gemma":0.000096351454,"teacher_disagreement_score":0.07654388,"about_ca_system_score_codex":0.00007869663,"about_ca_system_score_gemma":0.0011638703,"threshold_uncertainty_score":0.97657824},"labels":[],"label_agreement":null},{"id":"W2114446999","doi":"10.1200/jco.2012.48.1390","title":"Pooled Analysis of the Prognostic and Predictive Effects of <i>KRAS</i> Mutation Status and <i>KRAS</i> Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Institut National Du Cancer; National Cancer Institute; Ligue Contre le Cancer; Sanofi","keywords":"KRAS; Medicine; Hazard ratio; Internal medicine; Mutation; Oncology; Proportional hazards model; Cancer; Lung cancer; Stage (stratigraphy); Gastroenterology; Genetics; Colorectal cancer; Gene; Biology; Confidence interval","score_opus":0.032671352513065584,"score_gpt":0.42311563614531184,"score_spread":0.39044428363224626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114446999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958665,0.0016760958,0.0001307923,0.0006228924,0.00018460628,0.0014041887,0.00003591963,0.0000017957406,0.00007725392],"genre_scores_gemma":[0.9974291,0.0018481147,0.00041421695,0.00015315755,0.00005249162,0.0000435758,0.000007013716,0.000010966895,0.00004141293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963161,0.00080763025,0.002296756,0.00016560151,0.0002583298,0.00015562525],"domain_scores_gemma":[0.991764,0.004480101,0.002936597,0.00011927867,0.00058210065,0.00011791952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017743506,0.000121414145,0.001778747,0.00035408823,0.000015481903,0.000005124569,0.000063294196,0.0002050935,0.000026417605],"category_scores_gemma":[0.0033226546,0.00007405725,0.0002421637,0.0006462637,0.00016230746,0.000109977715,0.00002101182,0.00032497628,8.244468e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024829477,0.00096173584,0.97005093,0.00030761198,0.002443863,0.00004163783,0.002505168,0.0008150961,0.006454626,0.0000038671715,0.00003181598,0.013900722],"study_design_scores_gemma":[0.01676302,0.004291983,0.96537095,0.0004018675,0.0064448966,0.0000045528195,0.00027276305,0.0031129003,0.0032019096,0.00007050286,0.000012791168,0.000051879084],"about_ca_topic_score_codex":0.0015697984,"about_ca_topic_score_gemma":0.001048824,"teacher_disagreement_score":0.014280072,"about_ca_system_score_codex":0.00013986573,"about_ca_system_score_gemma":0.0010428361,"threshold_uncertainty_score":0.39777678},"labels":[],"label_agreement":null},{"id":"W2114480871","doi":"10.1200/jco.2007.10.6450","title":"Assessing Individual Risk for Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Nomogram; Medicine; Prostate cancer; Rectal examination; Prostate-specific antigen; Urology; Internal medicine; Receiver operating characteristic; Prostate biopsy; Gynecology; Cancer; Area under the curve; Oncology","score_opus":0.21683268874431907,"score_gpt":0.5575776122050368,"score_spread":0.3407449234607177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114480871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858009,0.0025688466,0.0009055971,0.0073692724,0.0020508813,0.00038673618,0.000023410308,0.000007666935,0.0008866559],"genre_scores_gemma":[0.9777481,0.0041076723,0.013098717,0.0025843065,0.002310007,0.000016871742,0.0000043969817,0.000017098908,0.00011283973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99740845,0.000107969965,0.001804021,0.00014763848,0.0002622761,0.00026963677],"domain_scores_gemma":[0.9940762,0.0029601592,0.0019903805,0.000098133205,0.00050767284,0.00036745908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062229754,0.00010342113,0.0009789446,0.00008868031,0.000055351466,0.000018791317,0.00007892813,0.00022095288,0.00005336147],"category_scores_gemma":[0.0022226914,0.00006686363,0.0004314692,0.00008751774,0.000109997876,0.00014748731,0.000023341756,0.0005864328,0.0000030731364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001778855,0.00084967306,0.41794634,0.000018346102,0.00044605625,0.00021577298,0.00008801421,0.00000622058,0.000017870716,0.000024177856,0.0040134583,0.5745952],"study_design_scores_gemma":[0.010785041,0.01175202,0.7890497,0.00014093601,0.0010485604,0.00008757711,0.00019215369,0.000014945817,0.00049103645,0.00051929825,0.18585214,0.00006658117],"about_ca_topic_score_codex":0.0000304506,"about_ca_topic_score_gemma":0.000070252885,"teacher_disagreement_score":0.57452863,"about_ca_system_score_codex":0.00024492378,"about_ca_system_score_gemma":0.0018348838,"threshold_uncertainty_score":0.32550052},"labels":[],"label_agreement":null},{"id":"W2114610794","doi":"10.1200/jco.2013.54.7869","title":"Predicting Anthracycline Benefit: <i>TOP2A</i> and CEP17—Not Only but Also","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Anthracycline; Medicine; Internal medicine; Oncology; Hazard ratio; Fluorescence in situ hybridization; Chemotherapy; Cyclophosphamide; Breast cancer; Cancer; Biology; Genetics; Chromosome; Confidence interval","score_opus":0.15502847809360815,"score_gpt":0.4933821748297538,"score_spread":0.3383536967361456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114610794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038892885,0.99209696,0.000017695274,0.00072561996,0.001941216,0.00023914568,0.000095432886,0.0000070882043,0.0009875258],"genre_scores_gemma":[0.00079895684,0.99106526,0.001246693,0.0006422716,0.0057914746,0.000010292831,0.00005182629,0.000055874152,0.00033736366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949053,0.0005521739,0.003371988,0.00049939833,0.0003239293,0.0003472301],"domain_scores_gemma":[0.9935107,0.000963472,0.0042204293,0.0003486641,0.00052681443,0.00042988986],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0029046359,0.00045666032,0.0044150897,0.00009523561,0.00007748755,0.000018510756,0.00040411245,0.0013225966,0.000012473445],"category_scores_gemma":[0.0024927524,0.0003164426,0.0010398031,0.00009081619,0.0003887795,0.0000094652505,0.00042033082,0.0010531456,0.0000097978755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036178844,0.0004290636,0.0018638375,0.00052888604,0.0013730542,0.00012754508,0.000011978985,7.3373775e-7,0.0000027161034,0.000012886854,0.004348057,0.99093944],"study_design_scores_gemma":[0.0023920324,0.0035675166,0.0010838655,0.0012876168,0.0023252615,0.0016399091,0.000031182903,9.907826e-7,0.000005321615,0.00005276076,0.9873536,0.00025990582],"about_ca_topic_score_codex":0.000022737177,"about_ca_topic_score_gemma":0.00007143654,"teacher_disagreement_score":0.99067956,"about_ca_system_score_codex":0.00010411148,"about_ca_system_score_gemma":0.002626177,"threshold_uncertainty_score":0.9999739},"labels":[],"label_agreement":null},{"id":"W2114612266","doi":"10.1200/jco.2006.07.6547","title":"Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Internal medicine; Head and neck squamous-cell carcinoma; Phases of clinical research; Toxicity; Erlotinib Hydrochloride; Oncology; Cisplatin; Head and neck cancer; Gastroenterology; Progressive disease; Chemotherapy; Clinical endpoint; Cancer; Epidermal growth factor receptor; Surgery; Clinical trial","score_opus":0.1661829989492623,"score_gpt":0.5044481561739024,"score_spread":0.33826515722464007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114612266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554265,0.0005304395,0.000005314938,0.00080551725,0.0014416806,0.0015201791,0.00008570365,9.596898e-7,0.000067585344],"genre_scores_gemma":[0.99904567,0.00016996035,0.00033187217,0.00016948671,0.000246737,0.000010085756,0.000001990165,0.000008441891,0.000015773248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932039,0.00083530706,0.004841328,0.00023640943,0.0006809264,0.00020215704],"domain_scores_gemma":[0.9906122,0.0045958445,0.0037730532,0.00011556747,0.00063893525,0.0002643967],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009825644,0.00016878326,0.0028639522,0.000107560474,0.00007262538,0.000002552026,0.000100326215,0.0001223073,0.000015004863],"category_scores_gemma":[0.009364425,0.00009005749,0.00014322728,0.00018143252,0.0006443024,0.00008004443,0.00011694521,0.0005780809,7.619774e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27412564,0.03626877,0.63354146,0.00014001397,0.00034900085,0.00009192909,0.0007339202,0.0000014626344,0.0000093462395,0.00001267221,0.00036898983,0.054356806],"study_design_scores_gemma":[0.29675782,0.19750673,0.5040784,0.00015094304,0.00046453835,0.0000073673823,0.00028799917,0.000014877848,0.000019952422,0.000008116203,0.0006414121,0.00006185339],"about_ca_topic_score_codex":0.003690191,"about_ca_topic_score_gemma":0.10227216,"teacher_disagreement_score":0.16123796,"about_ca_system_score_codex":0.00010455645,"about_ca_system_score_gemma":0.004809974,"threshold_uncertainty_score":0.9989801},"labels":[],"label_agreement":null},{"id":"W2114738305","doi":"10.1200/jco.2013.49.3205","title":"Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":735,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities","keywords":"Medicine; Internal medicine; Heart failure; Cardiology; Coronary artery disease; Relative risk; Dyslipidemia; valvular heart disease; Diabetes mellitus; Cumulative incidence; Incidence (geometry); Disease; Cohort; Confidence interval; Endocrinology","score_opus":0.03868804789570195,"score_gpt":0.3763067019286814,"score_spread":0.3376186540329794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114738305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968895,0.00031587027,0.000035813006,0.00080607686,0.00094255456,0.0002980211,0.000012752908,0.0000056965323,0.00069374306],"genre_scores_gemma":[0.9955324,0.002985423,0.0004091492,0.0002708047,0.0006492982,0.0000055501387,0.0000021355163,0.000014983578,0.0001302425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976886,0.0003410132,0.001358381,0.00014425261,0.0002966042,0.00017113787],"domain_scores_gemma":[0.99664646,0.0008770204,0.0014870662,0.00013815609,0.0005298383,0.00032143036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012225453,0.00012370815,0.0013698989,0.00008405252,0.00003444259,0.000004700516,0.0000799219,0.00040065922,0.0001257681],"category_scores_gemma":[0.0015727953,0.000084540916,0.000514542,0.00009701667,0.00016122026,0.00016194953,0.000023958777,0.0007500502,0.0000030828419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000218882,0.00046336796,0.964531,0.00002829251,0.00083058386,0.000005014033,0.0003116892,0.00003336969,0.0028627734,0.000010894973,0.00068166765,0.030022448],"study_design_scores_gemma":[0.003711416,0.0020603384,0.9825208,0.00011824956,0.00044565907,0.000012746656,0.00031468988,0.00006296702,0.009610765,0.00037437445,0.00068966823,0.00007830028],"about_ca_topic_score_codex":0.0041311807,"about_ca_topic_score_gemma":0.00009744833,"teacher_disagreement_score":0.029944146,"about_ca_system_score_codex":0.000075546704,"about_ca_system_score_gemma":0.0004589299,"threshold_uncertainty_score":0.62451375},"labels":[],"label_agreement":null},{"id":"W2115078134","doi":"10.1200/jco.2014.58.3922","title":"<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Pediatric Oncology Group; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; Hospital for Sick Children; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"CDKN2A; Medicine; Glioma; V600E; Oncology; Cancer research; Exome sequencing; Internal medicine; Mutation; Biology; Gene; Genetics; Cancer","score_opus":0.06472120420027387,"score_gpt":0.39510222639215886,"score_spread":0.330381022191885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115078134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883081,0.0012693125,0.00012664261,0.008403177,0.0008441695,0.00024434677,0.000014926433,0.000012110746,0.0007772527],"genre_scores_gemma":[0.9917082,0.0003529884,0.0056227036,0.0014424609,0.0008139721,0.0000061439764,0.00002355431,0.000020676727,0.000009289309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529624,0.00045749912,0.0033167931,0.00024604573,0.00046852772,0.00021486465],"domain_scores_gemma":[0.9934096,0.0024848662,0.0025735185,0.00020619926,0.0006532873,0.00067253876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003571786,0.00018247514,0.0017150538,0.00016735811,0.00003217598,0.000010949686,0.000111384514,0.0004050415,0.00004340207],"category_scores_gemma":[0.0048157074,0.00012791762,0.00043691316,0.00019956908,0.00028182918,0.00013514145,0.000061862454,0.0006939482,0.000010315603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008243833,0.022982957,0.5171748,0.00011706441,0.0014623335,0.0060609723,0.00040951459,0.000025422905,0.0010884543,0.0007997365,0.01216929,0.42946565],"study_design_scores_gemma":[0.03859646,0.0396074,0.9041063,0.00017745058,0.0012301177,0.0035117702,0.0001337312,0.000043065207,0.00072992995,0.002779275,0.008937063,0.00014741624],"about_ca_topic_score_codex":0.000051222672,"about_ca_topic_score_gemma":0.000055383338,"teacher_disagreement_score":0.42931825,"about_ca_system_score_codex":0.000093782975,"about_ca_system_score_gemma":0.0012249693,"threshold_uncertainty_score":0.5765199},"labels":[],"label_agreement":null},{"id":"W2115157373","doi":"10.1200/jco.2009.26.4325","title":"Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; American Society of Clinical Oncology; GlaxoSmithKline; Ontario Ministry of Health and Long-Term Care; AstraZeneca","keywords":"Medicine; Vinorelbine; Oncology; Internal medicine; Gene signature; Hazard ratio; Cisplatin; Lung cancer; Stage (stratigraphy); Microarray; Gene expression profiling; Chemotherapy; Adjuvant chemotherapy; Gene expression; Breast cancer; Confidence interval; Cancer; Gene; Biology","score_opus":0.03988199868462287,"score_gpt":0.4382248684288923,"score_spread":0.3983428697442694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115157373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838156,0.002994853,0.00009739544,0.010740229,0.0011476276,0.0009350908,0.000020166453,0.0000044854655,0.00024454208],"genre_scores_gemma":[0.9889108,0.003615872,0.0039242613,0.00182592,0.0014387185,0.000100235186,0.0000054790053,0.00002075574,0.00015794452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.000079974445,0.0010262596,0.00021458363,0.00015827367,0.0002092864],"domain_scores_gemma":[0.9966383,0.0018732406,0.00070254307,0.00011931845,0.0003949695,0.00027165774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010990927,0.00012730932,0.0010047478,0.00008923448,0.000024122282,0.0000067072797,0.00007752334,0.00045365357,0.000080731385],"category_scores_gemma":[0.0009713725,0.00008230728,0.00020716988,0.000093399125,0.00010325598,0.000045178353,0.000020553078,0.0010624921,5.2042327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081798155,0.0031628117,0.9083759,0.00014929207,0.0005502849,0.00034072014,0.00026481942,0.000020905169,0.0037235506,0.0000069428866,0.008066803,0.06715811],"study_design_scores_gemma":[0.027108535,0.013813277,0.9447441,0.00027024624,0.00081207603,0.00008387535,0.000037895636,0.000981377,0.0025379865,0.00010751132,0.009410283,0.00009280494],"about_ca_topic_score_codex":0.000033328794,"about_ca_topic_score_gemma":0.00055779377,"teacher_disagreement_score":0.067065306,"about_ca_system_score_codex":0.00018345028,"about_ca_system_score_gemma":0.0015431149,"threshold_uncertainty_score":0.46160585},"labels":[],"label_agreement":null},{"id":"W2115179154","doi":"10.1200/jco.2012.42.1958","title":"Role of Comparative Effectiveness Research in Cancer Funding Decisions in Ontario, Canada","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Comparative effectiveness research; Medicine; Observational study; Health care; Healthcare system; Public administration; Public relations; Economic growth; Political science; Law","score_opus":0.9372753199001308,"score_gpt":0.7136541903122616,"score_spread":0.22362112958786917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115179154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02592633,0.9666753,0.000012939188,0.0008238934,0.0024557698,0.000857061,0.000080044265,0.0000011156635,0.0031675522],"genre_scores_gemma":[0.043860942,0.95442504,0.00046929118,0.00028917988,0.00073669804,0.000100233156,0.000007255051,0.000027636554,0.000083754705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9686749,0.008751736,0.021275304,0.000413285,0.00027624928,0.00060854957],"domain_scores_gemma":[0.90997046,0.074348554,0.014656726,0.00032870975,0.00030246907,0.00039310596],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15650424,0.00023801248,0.011483309,0.0012478976,0.000053218155,0.0000129590935,0.0006694496,0.0008225317,0.00037788454],"category_scores_gemma":[0.012832595,0.00023298318,0.00056460366,0.00055063993,0.00016801416,0.00025431544,0.00013410827,0.0034469208,0.000065031134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00045336084,0.0024705224,0.41881245,0.0061353985,0.0010417479,0.000067249326,0.0020604676,0.00038038898,6.3521476e-8,0.015308315,0.00582813,0.5474419],"study_design_scores_gemma":[0.0010213569,0.00041824798,0.107938126,0.0070990003,0.00004469318,0.000012815,0.00032323925,0.000020728916,3.1854523e-8,0.0030725803,0.8798825,0.00016665226],"about_ca_topic_score_codex":0.89593005,"about_ca_topic_score_gemma":0.9921607,"teacher_disagreement_score":0.8740544,"about_ca_system_score_codex":0.012672091,"about_ca_system_score_gemma":0.031944875,"threshold_uncertainty_score":0.9988522},"labels":[],"label_agreement":null},{"id":"W2115445516","doi":"10.1200/jco.2005.03.9644","title":"Radiotherapy and Hodgkin's Lymphoma","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Hodgkin lymphoma; Lymphoma; Oncology; Internal medicine","score_opus":0.10138300798777258,"score_gpt":0.45435868406205865,"score_spread":0.35297567607428604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115445516","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041069422,0.009522276,0.000012036836,0.9432829,0.001963745,0.00021289139,0.000006624157,0.000010552844,0.0039195763],"genre_scores_gemma":[0.006959075,0.024735773,0.0069348314,0.9210724,0.038099762,0.0000065654417,0.0000117375475,0.00004834429,0.0021315175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99601483,0.000418491,0.0025022805,0.00028493762,0.0004783402,0.00030111836],"domain_scores_gemma":[0.99351615,0.0031899572,0.0024021936,0.0002734782,0.00027517026,0.00034303038],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014302311,0.00028851203,0.0031074288,0.0001893971,0.000032390995,0.000018576104,0.00015608728,0.0021585284,0.00034196425],"category_scores_gemma":[0.00078581105,0.00018202423,0.0009635797,0.000064373715,0.00027435325,0.000064517655,0.00003555754,0.0014924142,0.000027770348],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005931802,0.0008342427,0.008908344,0.000025802667,0.0010140724,0.009928978,0.000015677557,1.5045765e-7,0.0000011583882,0.0000082668,0.5700928,0.40857735],"study_design_scores_gemma":[0.016354695,0.012086867,0.0930255,0.00016727622,0.0010567943,0.0055800946,0.0000052254827,0.0000063817633,0.000005590997,0.0000894504,0.871491,0.00013111807],"about_ca_topic_score_codex":0.000014634959,"about_ca_topic_score_gemma":0.000004582989,"teacher_disagreement_score":0.40844622,"about_ca_system_score_codex":0.0005920657,"about_ca_system_score_gemma":0.0022813266,"threshold_uncertainty_score":0.99913687},"labels":[],"label_agreement":null},{"id":"W2115582804","doi":"10.1200/jco.2013.53.7878","title":"Dexamethasone for Cancer-Related Fatigue","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Dexamethasone; Cancer-related fatigue; Cancer; Internal medicine; Oncology","score_opus":0.25446992047853795,"score_gpt":0.5142387331842156,"score_spread":0.2597688127056777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115582804","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039074323,0.0023848303,0.0009512012,0.97120094,0.016678192,0.00047338154,0.00002599092,0.000027240572,0.0043508066],"genre_scores_gemma":[0.007551161,0.0018834014,0.0026436583,0.93823624,0.044752154,0.000037757436,0.000048749007,0.00009134366,0.0047555254],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944333,0.00066968944,0.0036159023,0.0003254009,0.0005525126,0.0004031912],"domain_scores_gemma":[0.98620945,0.007621,0.004260112,0.00034293364,0.0012364483,0.00033003223],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004122055,0.000289677,0.0037995991,0.00020726534,0.000036640147,0.000011383304,0.00033482426,0.0036966042,0.00048148105],"category_scores_gemma":[0.0039117173,0.00020982885,0.0019381952,0.00013887286,0.0001941984,0.0000463243,0.000036740672,0.006267204,0.000016130247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011029168,0.00020980915,0.0014054596,0.00030840264,0.001217671,0.00079183263,0.00008364679,0.0000027081987,0.0000038324984,0.000015056942,0.887675,0.107183695],"study_design_scores_gemma":[0.00683619,0.010067791,0.0010822592,0.00045882488,0.0023942387,0.00044513785,0.000021403848,0.00004087465,0.000010679383,0.00048197154,0.977962,0.00019861753],"about_ca_topic_score_codex":0.00014589196,"about_ca_topic_score_gemma":0.0002466877,"teacher_disagreement_score":0.10698508,"about_ca_system_score_codex":0.00038498724,"about_ca_system_score_gemma":0.0041470234,"threshold_uncertainty_score":0.9975968},"labels":[],"label_agreement":null},{"id":"W2115675646","doi":"10.1200/jco.2005.06.153","title":"Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Queen's University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Toxicity; Radiation therapy; Regimen; Dose fractionation; Urology; Biopsy; Prostate; Randomized controlled trial; Nuclear medicine; Surgery; Internal medicine; Cancer","score_opus":0.10675177165764538,"score_gpt":0.485499582758439,"score_spread":0.37874781110079364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115675646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98426276,0.00059931714,0.0008578175,0.010916322,0.0011104345,0.001957973,0.0000073882543,0.000008198148,0.00027979971],"genre_scores_gemma":[0.97859776,0.0012424749,0.016673962,0.0012908155,0.001856809,0.0002324757,0.00001652406,0.000015138274,0.0000740299],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974,0.00024232996,0.0017558557,0.0001462534,0.00029764837,0.00015793533],"domain_scores_gemma":[0.9944439,0.002522606,0.0018926195,0.00008096437,0.00085933995,0.00020058712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020141355,0.000114759736,0.0017537801,0.00007605258,0.00004479759,0.000010805656,0.000049985912,0.000112849346,0.00006890048],"category_scores_gemma":[0.00172947,0.00006515269,0.000418565,0.000059086782,0.00013498493,0.00015181841,0.0000110006695,0.00034891543,0.00000333341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7976127,0.0029779423,0.08204279,0.000014235587,0.00074543717,0.0000067375177,0.000030923104,0.00032519118,5.784219e-7,0.0001736617,0.00054910977,0.11552067],"study_design_scores_gemma":[0.9088442,0.011319277,0.014956818,0.00013494465,0.00097310403,0.0000046403507,0.0000120440045,0.00087756163,0.00003801943,0.00026152673,0.06251221,0.000065692424],"about_ca_topic_score_codex":0.000023035847,"about_ca_topic_score_gemma":0.00006518218,"teacher_disagreement_score":0.11545498,"about_ca_system_score_codex":0.00034330832,"about_ca_system_score_gemma":0.0011586469,"threshold_uncertainty_score":0.26568496},"labels":[],"label_agreement":null},{"id":"W2115698139","doi":"10.1200/jco.2003.01.191","title":"Not Just Tired","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"","field":"","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.3955923842322312,"score_gpt":0.5599140768572747,"score_spread":0.16432169262504348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115698139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8829719,0.00022524381,0.00015238697,0.0045441184,0.0059504956,0.000112119655,0.0000057772495,0.00002758488,0.10601036],"genre_scores_gemma":[0.9846295,0.000108900895,0.008890649,0.0036685825,0.0014442231,0.000001060793,4.1527488e-7,0.000046378955,0.0012103068],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928935,0.0021426366,0.0038916608,0.00018701555,0.0005245026,0.0003606832],"domain_scores_gemma":[0.9901399,0.004758358,0.0035943475,0.00026187778,0.00064798025,0.00059755193],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.014031631,0.00014815707,0.0015868912,0.00015756857,0.000050143033,0.000014283411,0.00038702396,0.00054921565,0.0011523851],"category_scores_gemma":[0.031755686,0.00011013727,0.000747912,0.00024297026,0.00032662123,0.00019924871,0.00003795142,0.0015401358,0.0032119246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010068175,0.010392828,0.09475433,0.000026594902,0.001370793,0.0048848614,0.00032748267,0.0002154212,0.0055792956,0.024787448,0.6317605,0.21583228],"study_design_scores_gemma":[0.006712459,0.0056377472,0.06663147,0.000018157258,0.0002173118,0.0007702381,0.00010367532,0.00002918068,0.00039550403,0.0012674402,0.9180792,0.00013762848],"about_ca_topic_score_codex":0.0000035566895,"about_ca_topic_score_gemma":0.000023567147,"teacher_disagreement_score":0.2863187,"about_ca_system_score_codex":0.00020402312,"about_ca_system_score_gemma":0.0023853295,"threshold_uncertainty_score":0.9997607},"labels":[],"label_agreement":null},{"id":"W2115706603","doi":"10.1200/jco.2012.45.3696","title":"Methylphenidate and/or a Nursing Telephone Intervention for Fatigue in Patients With Advanced Cancer: A Randomized, Placebo-Controlled, Phase II Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute","keywords":"Medicine; Placebo; Methylphenidate; Randomized controlled trial; Cancer; Intervention (counseling); Physical therapy; Internal medicine; Nursing; Psychiatry; Alternative medicine","score_opus":0.0696912928475752,"score_gpt":0.475955355865066,"score_spread":0.4062640630174908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115706603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876959,0.00074315956,0.0023240345,0.003170222,0.0020384854,0.003890315,0.0000065126806,0.000006438307,0.00012497624],"genre_scores_gemma":[0.995273,0.00036925744,0.0024458186,0.0005341706,0.00070637086,0.0004537837,0.000005527613,0.000018775661,0.00019328369],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961206,0.00067456346,0.0025144676,0.0001987378,0.00026372663,0.00022793043],"domain_scores_gemma":[0.9936315,0.0034467909,0.0019625402,0.00010839679,0.0005938969,0.00025687277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003624851,0.00015896471,0.003018397,0.00017248151,0.000041447864,0.00001260755,0.00008234828,0.00022857606,0.00018119566],"category_scores_gemma":[0.0044251503,0.00008865077,0.0006154038,0.00012309672,0.00019434433,0.0002048394,0.000018785615,0.0005362273,6.637901e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59906083,0.0030506146,0.0004959827,0.000025595962,0.0002837282,0.000008539756,0.00027234523,0.000005347307,0.000006470784,0.000006362527,0.00021284677,0.3965713],"study_design_scores_gemma":[0.9253795,0.069645435,0.001162214,0.0006889864,0.0007977145,0.000009592062,0.0003091373,0.0003317267,0.000017389128,0.00023565862,0.00132656,0.00009610339],"about_ca_topic_score_codex":0.00017024763,"about_ca_topic_score_gemma":0.0006534012,"teacher_disagreement_score":0.3964752,"about_ca_system_score_codex":0.00019095249,"about_ca_system_score_gemma":0.00065947947,"threshold_uncertainty_score":0.52976376},"labels":[],"label_agreement":null},{"id":"W2115718839","doi":"10.1200/jco.2005.05.119","title":"The Ethics of Early Stopping Rules","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.08672460503754481,"score_gpt":0.4439634421656473,"score_spread":0.3572388371281025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115718839","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22651754,0.015177372,0.0001101204,0.7499306,0.00421071,0.0001918634,0.000012437116,0.0000043157497,0.003845045],"genre_scores_gemma":[0.08035014,0.06655752,0.005771719,0.75650346,0.0828554,0.000009308566,0.000085051186,0.00018078632,0.0076866015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953202,0.0015818538,0.002216339,0.00020046048,0.0003934082,0.00028771674],"domain_scores_gemma":[0.9927969,0.002902841,0.0033167768,0.00033370682,0.0005401206,0.00010963752],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0051700147,0.00019968933,0.0010214489,0.00005428032,0.00009206105,0.000014735386,0.0006505804,0.0049734404,0.000008392648],"category_scores_gemma":[0.004259445,0.000117731026,0.0009936845,0.00004515052,0.0005490773,0.0000035086657,0.00013498923,0.007988418,0.000012874848],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009348768,0.00017286747,0.00042524413,0.000044836837,0.0013192833,0.00037424846,0.000045379387,0.000015977954,0.001972726,0.00005167786,0.91988564,0.074757256],"study_design_scores_gemma":[0.000954197,0.0062753847,0.0007491752,0.000078925164,0.00022980724,0.00018730921,0.0000113742635,0.0000031704474,0.000617898,0.00016186107,0.990605,0.00012592573],"about_ca_topic_score_codex":0.000005895734,"about_ca_topic_score_gemma":0.000005128764,"teacher_disagreement_score":0.14616741,"about_ca_system_score_codex":0.000027452967,"about_ca_system_score_gemma":0.0020217157,"threshold_uncertainty_score":0.99631834},"labels":[],"label_agreement":null},{"id":"W2115718867","doi":"10.1200/jco.2013.50.5511","title":"Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":380,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Breast Cancer Research Alliance","keywords":"Cosmesis; Medicine; Adverse effect; Interim analysis; Breast cancer; Radiation therapy; Breast-conserving surgery; Randomized controlled trial; External beam radiotherapy; Nuclear medicine; Urology; Internal medicine; Surgery; Cancer; Brachytherapy; Mastectomy","score_opus":0.09359448802071771,"score_gpt":0.40098118101360736,"score_spread":0.3073866929928897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115718867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644375,0.0008521583,0.0005326737,0.0006543179,0.0009828444,0.00045646273,0.00004165333,0.0000027063159,0.000033423014],"genre_scores_gemma":[0.9960627,0.00080187747,0.0012868557,0.00035295708,0.0014349257,0.000011606105,0.000035305384,0.000010086643,0.0000036873505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967343,0.0005921149,0.0020911098,0.00020668205,0.00021668783,0.00015909466],"domain_scores_gemma":[0.9960106,0.0009869349,0.0023208437,0.00012998114,0.00041519667,0.00013643823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017768289,0.00015994361,0.0011437852,0.00005691731,0.00004914468,0.00001828081,0.00011514962,0.00030908777,0.00006055715],"category_scores_gemma":[0.0011762822,0.000112848655,0.00033275515,0.00004832951,0.00028693225,0.000031046915,0.0000628677,0.00022174335,0.0000014287655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8552741,0.00080227456,0.002196344,0.000002339574,0.0008683754,0.000004811876,0.000064903,0.0001385893,0.034019884,0.000003565365,0.00024068922,0.106384136],"study_design_scores_gemma":[0.8711216,0.005575469,0.10892526,0.000038315207,0.0002504266,0.00008570213,0.000021613261,0.0028793328,0.010475181,0.00021976254,0.00025875407,0.00014856752],"about_ca_topic_score_codex":0.00039913843,"about_ca_topic_score_gemma":0.00002192396,"teacher_disagreement_score":0.10672892,"about_ca_system_score_codex":0.000040463612,"about_ca_system_score_gemma":0.00048270135,"threshold_uncertainty_score":0.46018347},"labels":[],"label_agreement":null},{"id":"W2115832986","doi":"10.1200/jco.2012.42.7161","title":"Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":352,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Guideline; Intensive care medicine; Neutropenia; Pediatric cancer; Context (archaeology); Hematopoietic cell; Cancer; Pediatrics; Internal medicine; Pathology; Chemotherapy","score_opus":0.07893215920934604,"score_gpt":0.4331626774659091,"score_spread":0.35423051825656304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115832986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916745,0.0016794268,0.0012312274,0.004527241,0.00020609405,0.00039717174,0.000002870681,0.0000017575039,0.00027975347],"genre_scores_gemma":[0.9855716,0.010630681,0.0023265441,0.0010375888,0.00023275848,0.000015172862,6.3212036e-7,0.000008241076,0.0001767822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987955,0.000055969987,0.00086745457,0.00007066333,0.00009939102,0.00011103028],"domain_scores_gemma":[0.99872124,0.00055778713,0.00048795264,0.00006134625,0.00008079952,0.00009086438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009975812,0.000062825246,0.00043999337,0.00004075301,0.000027521644,0.0000033807971,0.000041296797,0.000064168235,0.000027645],"category_scores_gemma":[0.0000104010405,0.00003125187,0.000061434104,0.00006536064,0.00007815484,0.000079905316,0.000011744916,0.00019993841,2.5359222e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006989175,0.00086861505,0.89229757,0.00041764017,0.0008084275,0.00003247845,0.00037495588,0.00014309719,0.00012914823,0.0004994653,0.0012443911,0.09619506],"study_design_scores_gemma":[0.015186285,0.0035854299,0.96817124,0.00029209288,0.0018036277,0.00079115416,0.00042873915,0.000026706872,0.0001875654,0.000037459467,0.009424828,0.00006488197],"about_ca_topic_score_codex":0.000029690393,"about_ca_topic_score_gemma":0.0001517101,"teacher_disagreement_score":0.09613018,"about_ca_system_score_codex":0.000032923028,"about_ca_system_score_gemma":0.00021970621,"threshold_uncertainty_score":0.12744142},"labels":[],"label_agreement":null},{"id":"W2116385092","doi":"10.1200/jco.2007.13.0856","title":"Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"Eli Lilly Canada; American Society of Clinical Oncology; Merck KGaA; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Carboplatin; Cetuximab; Lung cancer; Internal medicine; Chemotherapy; Clinical endpoint; Cisplatin; Pleural effusion; Phases of clinical research; Progression-free survival; Surgery; Gastroenterology; Oncology; Urology; Randomized controlled trial; Cancer; Colorectal cancer","score_opus":0.07258268299772243,"score_gpt":0.5066041090782099,"score_spread":0.43402142608048744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116385092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798585,0.00037152076,0.0038419822,0.00055974553,0.00043677268,0.0065050316,0.00003268299,0.0000117169275,0.00025471728],"genre_scores_gemma":[0.9720887,0.0005449428,0.024384249,0.00070772425,0.00030788008,0.0002831998,0.000017153408,0.000060813756,0.0016053373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955436,0.00022169344,0.002972486,0.0003384809,0.0005554313,0.00036832588],"domain_scores_gemma":[0.98902947,0.0052775485,0.0035031834,0.0002683764,0.0015302267,0.00039120746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002096075,0.00033934953,0.0036912116,0.00019873968,0.00013135627,0.00000860997,0.00015608632,0.00014800286,0.00027604267],"category_scores_gemma":[0.0015075947,0.00014141838,0.0003016736,0.00033778636,0.00019454953,0.00014109642,0.000027959391,0.00045409973,5.0887866e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8915915,0.027364135,0.023377378,0.00014630874,0.004556477,0.00042850967,0.002175474,0.00044098124,0.000014545564,0.000001807692,0.0001189083,0.04978398],"study_design_scores_gemma":[0.7251917,0.26132658,0.0037365085,0.0003069936,0.006316616,0.000052745225,0.00092698593,0.00087145856,0.00007250049,0.00000620202,0.0010366045,0.00015506556],"about_ca_topic_score_codex":0.00019984024,"about_ca_topic_score_gemma":0.003724732,"teacher_disagreement_score":0.23396246,"about_ca_system_score_codex":0.00030774597,"about_ca_system_score_gemma":0.004353341,"threshold_uncertainty_score":0.77226406},"labels":[],"label_agreement":null},{"id":"W2116506335","doi":"10.1200/jco.2009.27.7491","title":"Quality of Care for Breast Cancer for Uninsured Women in California Under the Breast and Cervical Cancer Prevention Treatment Act","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; California Breast Cancer Research Program; American Cancer Society","keywords":"Medicine; Breast cancer; Cohort; Cancer; Stage (stratigraphy); Family medicine; Cervical cancer; Health care; Cohort study; Gynecology; Obstetrics; Internal medicine","score_opus":0.20745984673717702,"score_gpt":0.5433610703184973,"score_spread":0.33590122358132035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116506335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438275,0.0005776786,0.00011629393,0.013530405,0.0005092737,0.00049573765,0.00031458904,0.0000025805232,0.00007068667],"genre_scores_gemma":[0.99707276,0.00046378092,0.0006773833,0.00073979254,0.0008817173,0.000087461405,0.0000039277243,0.000009774889,0.00006340751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978025,0.00020126029,0.0013779032,0.00015553103,0.00020869295,0.00025411003],"domain_scores_gemma":[0.9967156,0.0013089724,0.0009989897,0.00012660769,0.00061466236,0.00023516039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026407626,0.000110805195,0.0010970215,0.00004762077,0.000046005745,0.0000060827742,0.00010560647,0.00028366284,0.000102546495],"category_scores_gemma":[0.00041073645,0.00006252043,0.00032835518,0.00008244792,0.00017430318,0.0000635487,0.000021632113,0.00039682467,2.2469212e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019126385,0.00055300427,0.59183466,0.00013312747,0.00032319626,0.0000060821285,0.00048436126,0.00005025492,0.0005567385,0.00014818757,0.000215959,0.38656804],"study_design_scores_gemma":[0.010517807,0.004748831,0.97192365,0.00013574025,0.00023685844,0.00013623998,0.0016549506,0.00008526161,0.00004208331,0.0007573694,0.009693745,0.00006745142],"about_ca_topic_score_codex":0.0010384446,"about_ca_topic_score_gemma":0.019830376,"teacher_disagreement_score":0.3865006,"about_ca_system_score_codex":0.0004831675,"about_ca_system_score_gemma":0.002320536,"threshold_uncertainty_score":0.99805516},"labels":[],"label_agreement":null},{"id":"W2116542269","doi":"10.1200/jco.2007.10.7128","title":"Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Oxaliplatin; Medicine; Irinotecan; Colorectal cancer; Chemotherapy; Internal medicine; Fluorouracil; Oncology; Cancer; Metastasis; Surgery; Gastroenterology","score_opus":0.10306209718364907,"score_gpt":0.4993748026018864,"score_spread":0.3963127054182373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116542269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916707,0.00021724375,0.000025248759,0.0049805716,0.0011428049,0.0002886805,0.00009296175,0.000005909238,0.0015758574],"genre_scores_gemma":[0.9968116,0.0006009513,0.0008964922,0.0010467231,0.00053773314,0.0000038214916,0.0000037188552,0.000016512522,0.000082392435],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99629295,0.0003546308,0.002421198,0.00024894284,0.00036162196,0.00032066347],"domain_scores_gemma":[0.9911861,0.0067696855,0.0012269565,0.00015773061,0.0003366177,0.00032295342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037907655,0.00018664019,0.0019249709,0.00021989092,0.000023567605,0.0000035281987,0.0001443086,0.00021358901,0.0000953467],"category_scores_gemma":[0.0038278713,0.00012281102,0.0005761128,0.00020584401,0.00012716057,0.000049075716,0.00005076461,0.00062775286,0.0000042834113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62404895,0.0020624558,0.2376799,0.0000036086255,0.00072390214,0.00052312796,0.00074043544,0.000099341334,0.0070841387,0.000006245144,0.0007564488,0.12627146],"study_design_scores_gemma":[0.029741136,0.071150444,0.8928627,0.00020253735,0.000068700894,0.0000144743935,0.0001263075,0.000013387614,0.0003639309,0.000074046526,0.0052925097,0.000089852496],"about_ca_topic_score_codex":0.0010502804,"about_ca_topic_score_gemma":0.003072565,"teacher_disagreement_score":0.6551828,"about_ca_system_score_codex":0.0010743638,"about_ca_system_score_gemma":0.0009497852,"threshold_uncertainty_score":0.5008088},"labels":[],"label_agreement":null},{"id":"W2116554987","doi":"10.1200/jco.2004.04.033","title":"Contralateral Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":619,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Mutation; Gynecology; Internal medicine; Cancer research; Genetics; Gene","score_opus":0.028810250053983,"score_gpt":0.3986959023180364,"score_spread":0.3698856522640534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116554987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995835,0.0014582884,0.00028665544,0.006723592,0.0011420501,0.0000912504,0.000022275604,0.000002213522,0.00031535624],"genre_scores_gemma":[0.99394006,0.001414986,0.001340397,0.0023689596,0.00087456993,0.000006634165,0.0000037869333,0.00001314593,0.000037444235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982485,0.00016382166,0.0010836737,0.00019358825,0.00012943023,0.0001809747],"domain_scores_gemma":[0.9987914,0.000088346074,0.0006264335,0.000108942084,0.000223587,0.0001613233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010478534,0.000104502105,0.00044480705,0.00006006368,0.000027479182,0.000011241646,0.00013254129,0.00033278225,0.00002410556],"category_scores_gemma":[0.0003237143,0.00008915423,0.00013743216,0.000085927124,0.0002156566,0.000013504066,0.000039161972,0.0003566799,0.0000014102618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007336028,0.0014019887,0.3429661,0.000059792572,0.0012082643,0.00082232663,0.0011427669,0.027492385,0.07689823,0.0005317431,0.0067580934,0.53338224],"study_design_scores_gemma":[0.025486112,0.004984159,0.8946688,0.00011721354,0.00019729818,0.0022469498,0.00045207402,0.000074750686,0.00925613,0.0030209098,0.059064247,0.00043132136],"about_ca_topic_score_codex":0.00007065966,"about_ca_topic_score_gemma":0.00056243426,"teacher_disagreement_score":0.55170274,"about_ca_system_score_codex":0.00017738416,"about_ca_system_score_gemma":0.001819516,"threshold_uncertainty_score":0.3635604},"labels":[],"label_agreement":null},{"id":"W2116651864","doi":"10.1200/jco.2013.51.8241","title":"Reply to C.M. Booth et al","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; McMaster University; University of Toronto; Mount Sinai Hospital","funders":"University of Toronto","keywords":"Medicine","score_opus":0.18698776778512705,"score_gpt":0.5078073025736666,"score_spread":0.32081953478853953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116651864","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028408987,0.00053622585,0.000039784296,0.969523,0.0052016657,0.0003855281,0.000011184771,0.000013974317,0.021447731],"genre_scores_gemma":[0.00050335407,0.00093374844,0.0039053282,0.967961,0.015773084,0.000013801435,0.000019393397,0.000048299822,0.010841986],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99430376,0.00068263034,0.003397733,0.00035879135,0.00086571596,0.00039138985],"domain_scores_gemma":[0.991326,0.004508577,0.0023583216,0.0003933006,0.0007218397,0.0006919927],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026533771,0.00028421447,0.0033700352,0.00032157314,0.000023038172,0.000018883313,0.00031495653,0.001228711,0.002013025],"category_scores_gemma":[0.0077941273,0.00017459526,0.0013258264,0.00024210685,0.00011369063,0.00007939464,0.00010481255,0.005843231,0.0006831059],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019303209,0.0005505317,0.0010437442,0.00003118164,0.0007790301,0.005367944,0.000012955747,4.2697823e-7,0.000004308129,0.000006160619,0.92125076,0.069022655],"study_design_scores_gemma":[0.008006148,0.025750382,0.010063047,0.00020399278,0.0006742961,0.00064597675,0.0000057240754,6.231417e-7,0.000006036382,0.00025529406,0.95424414,0.00014437294],"about_ca_topic_score_codex":0.00012360894,"about_ca_topic_score_gemma":0.000005604645,"teacher_disagreement_score":0.068878286,"about_ca_system_score_codex":0.00034136613,"about_ca_system_score_gemma":0.0023461448,"threshold_uncertainty_score":0.9988993},"labels":[],"label_agreement":null},{"id":"W2116760308","doi":"10.1200/jco.2009.25.9820","title":"Metastatic Behavior of Breast Cancer Subtypes","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2284,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Basal (medicine); Internal medicine; Oncology; Cancer; Pathology; Lung cancer; Lung; Metastasis; Stage (stratigraphy); Biology","score_opus":0.06226160108180336,"score_gpt":0.4550223279959653,"score_spread":0.392760726914162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116760308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954417,0.0005512856,0.00002931031,0.0018565255,0.0016367744,0.00006286184,0.00004472859,0.000001607164,0.00037523094],"genre_scores_gemma":[0.99557376,0.0006812164,0.0023155634,0.00032967646,0.0010001616,0.000008648593,0.0000027303047,0.00001126041,0.000077001816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984061,0.0001274716,0.0010479125,0.00013465268,0.00014681114,0.0001370424],"domain_scores_gemma":[0.99790883,0.00020807525,0.0011431278,0.000164125,0.00045034892,0.00012548617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080493774,0.000102471044,0.0006628333,0.000037061785,0.000023019125,0.000002771382,0.0001905643,0.00018718472,0.00014399769],"category_scores_gemma":[0.00049668003,0.00007188594,0.0003271255,0.00005083711,0.00028454507,0.000004941282,0.00006601686,0.0003434005,0.0000031260088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021171358,0.002232484,0.7144217,0.00001829679,0.0010623795,0.000080131016,0.00004218363,0.0000086309565,0.081053026,0.000107965076,0.004149503,0.19470659],"study_design_scores_gemma":[0.002728862,0.0015831038,0.95949167,0.000012702152,0.00054532464,0.00038712076,0.000048990478,0.0000012468631,0.0071803536,0.00007966954,0.027851362,0.00008958641],"about_ca_topic_score_codex":0.00006575212,"about_ca_topic_score_gemma":0.00047555595,"teacher_disagreement_score":0.24507,"about_ca_system_score_codex":0.000013656546,"about_ca_system_score_gemma":0.0007401727,"threshold_uncertainty_score":0.29314235},"labels":[],"label_agreement":null},{"id":"W2116841457","doi":"10.1200/jco.2003.07.007","title":"Application of Breast Cancer Risk Prediction Models in Clinical Practice","year":2003,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Raloxifene; Tamoxifen; Context (archaeology); Risk assessment; Oncology; Risk analysis (engineering); Cancer; Gynecology; Internal medicine; Computer science","score_opus":0.12273205392261761,"score_gpt":0.5292503310996379,"score_spread":0.4065182771770203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116841457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027129287,0.9883638,0.0068241074,0.00024488728,0.0025064184,0.00047232618,0.00020772869,0.000002528692,0.0011068855],"genre_scores_gemma":[0.000733344,0.98958695,0.00681279,0.00028022256,0.0023978476,0.000059070804,0.000032958087,0.0000408713,0.000055974226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893019,0.002912974,0.006821818,0.00044807367,0.00031382096,0.00020137642],"domain_scores_gemma":[0.98601574,0.0015651897,0.010800918,0.0004649308,0.0009804256,0.0001728083],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009598089,0.00024985804,0.0027183543,0.00015379506,0.000024631168,0.000006423291,0.00044184132,0.0019459203,0.000018485802],"category_scores_gemma":[0.0040500434,0.00020131998,0.001215686,0.00026771682,0.000262267,0.000020245965,0.00009109289,0.0017394547,0.0000046921346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004027782,0.00093531085,0.0009823586,0.0003661577,0.0007017161,0.000008835072,0.000007535984,0.00074914296,0.0000017239557,0.000039874118,0.003596862,0.9922077],"study_design_scores_gemma":[0.0014046299,0.0014781953,0.0011435564,0.00061933923,0.0017359785,0.00036276155,0.000020584452,0.00014864777,0.0000012464637,0.00019931949,0.99273306,0.0001526633],"about_ca_topic_score_codex":0.00004242132,"about_ca_topic_score_gemma":0.000064207976,"teacher_disagreement_score":0.99205506,"about_ca_system_score_codex":0.0002887599,"about_ca_system_score_gemma":0.0076573375,"threshold_uncertainty_score":0.9993498},"labels":[],"label_agreement":null},{"id":"W2117050193","doi":"10.1200/jco.2005.51.008","title":"Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"American Society of Clinical Oncology","keywords":"Medicine; Capecitabine; Gemcitabine; Internal medicine; Gallbladder cancer; Regimen; Gastroenterology; Chemotherapy; Neutropenia; Cancer; Oncology; Surgery; Colorectal cancer","score_opus":0.060958821568796916,"score_gpt":0.4316245179837428,"score_spread":0.3706656964149459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117050193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856067,0.002406573,0.0000058075225,0.010330966,0.0006733117,0.0003704207,0.000004192735,0.0000065685485,0.00059550395],"genre_scores_gemma":[0.9944141,0.0009322679,0.0016197462,0.0017059381,0.0012086492,0.000011886175,0.0000024487529,0.000014516385,0.00009046791],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975701,0.000121491656,0.0015908357,0.00019841737,0.00029135315,0.00022782796],"domain_scores_gemma":[0.9978811,0.00058576424,0.00084729824,0.000120988814,0.00030888116,0.0002559746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094992854,0.00014539844,0.0014485717,0.0001444278,0.00005058504,0.0000044148383,0.00007628546,0.00015192849,0.000060989016],"category_scores_gemma":[0.0008579733,0.000094352436,0.00015598164,0.00015563249,0.00018047779,0.0001619622,0.00006359763,0.0007323355,0.0000010373194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18214703,0.0060780095,0.37420732,0.000016160413,0.00024315737,0.00011653817,0.0003270507,0.000010409907,0.000020952717,0.000007752067,0.0010765964,0.43574902],"study_design_scores_gemma":[0.39086008,0.08124239,0.5022733,0.00013109035,0.00024347303,0.00002489842,0.00008584393,0.000031008018,0.000007895758,0.00001382328,0.024995692,0.000090504225],"about_ca_topic_score_codex":0.000020629917,"about_ca_topic_score_gemma":0.00026291562,"teacher_disagreement_score":0.43565854,"about_ca_system_score_codex":0.00016040845,"about_ca_system_score_gemma":0.0006642468,"threshold_uncertainty_score":0.38475809},"labels":[],"label_agreement":null},{"id":"W2117087331","doi":"10.1200/jco.2007.13.5947","title":"<i>VEGF</i> Polymorphisms and Survival in Early-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Lung cancer; VEGF receptors; Oncology; Stage (stratigraphy); Internal medicine; Cancer research; Biology","score_opus":0.06207252919606663,"score_gpt":0.39043651205970575,"score_spread":0.3283639828636391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117087331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991907,0.0063491347,0.00024762066,0.00065214385,0.0009823387,0.000083244086,0.0000073712963,0.0000016344277,0.0017574246],"genre_scores_gemma":[0.979466,0.01553888,0.0007166054,0.00143047,0.0013769239,0.0000054321877,0.0000017563365,0.000018908402,0.0014450075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980654,0.0002084534,0.0011109335,0.00023011188,0.00014403994,0.00024107427],"domain_scores_gemma":[0.9986269,0.00015719772,0.000707121,0.00014950572,0.00014614382,0.00021316964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001140217,0.00013607474,0.00066261727,0.000054919423,0.000043923523,0.0000057823704,0.00020102381,0.00043107537,0.00004551073],"category_scores_gemma":[0.00016847679,0.00010955671,0.000278241,0.00007486296,0.00019306128,0.0000068689733,0.00010071335,0.00034799086,0.0000020401121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083061494,0.0003787321,0.97132546,0.000015363259,0.000114426315,0.00025949994,0.00008293291,0.000061615494,0.01625038,0.0000116348765,0.0041455785,0.0065237638],"study_design_scores_gemma":[0.0060505834,0.0035411501,0.83619875,0.0000398806,0.000095929434,0.00012412996,0.0000691072,0.00008265775,0.008335714,0.000014163178,0.1451715,0.0002764617],"about_ca_topic_score_codex":0.00021639682,"about_ca_topic_score_gemma":0.00028264654,"teacher_disagreement_score":0.14102592,"about_ca_system_score_codex":0.000033242195,"about_ca_system_score_gemma":0.00093814166,"threshold_uncertainty_score":0.4467593},"labels":[],"label_agreement":null},{"id":"W2117496562","doi":"10.1200/jco.2007.14.6795","title":"Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Clinical Oncology; Clinical trial; Consistency (knowledge bases); Oncology; Internal medicine; Family medicine; Medical physics; Cancer","score_opus":0.8705649187613345,"score_gpt":0.6578354220733239,"score_spread":0.21272949668801056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117496562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746264,0.00023281232,0.0006397793,0.006566887,0.0013481228,0.0010323781,0.000070369315,0.000003764677,0.0026432653],"genre_scores_gemma":[0.98567694,0.0005646341,0.011586624,0.0007789246,0.00086455006,0.000011332249,0.000006068492,0.000017250004,0.0004936492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8647,0.05274626,0.0763636,0.001011925,0.0047165416,0.00046166423],"domain_scores_gemma":[0.65838027,0.13656637,0.18584754,0.0042672,0.013720839,0.0012177564],"candidate_categories":["metaresearch","metaepi_broad","sts"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.26199532,0.00037564492,0.017528266,0.0002442397,0.00021162373,0.000032327487,0.0033160604,0.000616962,0.0007650171],"category_scores_gemma":[0.15354583,0.00015650372,0.010033292,0.0015080639,0.005556243,0.00032574608,0.00041443505,0.0016709077,0.00001805463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090588994,0.041614432,0.5438664,0.0000787447,0.008398807,0.00006419273,0.0021692878,0.0007149486,0.00037996678,0.00039232196,0.17399822,0.13773368],"study_design_scores_gemma":[0.09199129,0.051845808,0.60149294,0.00014991427,0.0026666203,0.0004965201,0.006685278,0.0044838823,0.00006665897,0.00044502396,0.23932065,0.0003554188],"about_ca_topic_score_codex":0.00007140215,"about_ca_topic_score_gemma":0.00047319403,"teacher_disagreement_score":0.20631972,"about_ca_system_score_codex":0.00009372207,"about_ca_system_score_gemma":0.0062459423,"threshold_uncertainty_score":0.99988097},"labels":[],"label_agreement":null},{"id":"W2117606080","doi":"10.1200/jco.2004.08.094","title":"Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":456,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cognition; Breast cancer; Neuroimaging; Cancer; Clinical psychology; Oncology; Psychiatry; Internal medicine","score_opus":0.19599095201380948,"score_gpt":0.5439593580105666,"score_spread":0.34796840599675716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117606080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072883157,0.9909724,0.00027831248,0.002441821,0.0015175266,0.0031489288,0.00010810673,0.000017931081,0.00078617106],"genre_scores_gemma":[0.00058178673,0.99537575,0.00066283863,0.0007103399,0.0014771923,0.000207942,0.000046543584,0.00009083076,0.00084679667],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920933,0.0004219107,0.0059857266,0.00042201034,0.00065382215,0.00042323253],"domain_scores_gemma":[0.9722609,0.009037573,0.015121759,0.00020296492,0.0030198384,0.00035698563],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004352931,0.0004955604,0.01015541,0.00030070255,0.00005105393,0.000006075732,0.00017865846,0.0011986737,0.000117547825],"category_scores_gemma":[0.010777515,0.00030573522,0.0027485436,0.00045813117,0.00058959285,0.000061297986,0.000051622716,0.0019664632,0.0000022279671],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078454735,0.005509669,0.0006721831,0.00511101,0.021134967,0.0019350318,0.000094186034,0.0000020070709,5.840624e-8,0.0000062268377,0.0037046417,0.95398456],"study_design_scores_gemma":[0.026743434,0.045313157,0.0014900287,0.14409515,0.026228683,0.002527845,0.00017321525,0.000001108598,0.0000017453425,0.000090317015,0.75300974,0.00032560516],"about_ca_topic_score_codex":0.00001643934,"about_ca_topic_score_gemma":0.000067163906,"teacher_disagreement_score":0.95365894,"about_ca_system_score_codex":0.0016986547,"about_ca_system_score_gemma":0.017259208,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W2117652002","doi":"10.1200/jco.2003.06.121","title":"Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Proportional hazards model; Body mass index; Hazard ratio; Internal medicine; Calorie; Cancer; Bayesian multivariate linear regression; Saturated fat; Multivariate analysis; Oncology; Linear regression; Confidence interval; Cholesterol; Statistics","score_opus":0.22880399638535837,"score_gpt":0.4708514696532185,"score_spread":0.24204747326786014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117652002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985379,0.0025253561,0.000014636671,0.010740847,0.0007652635,0.00011573301,0.000011463441,0.0000053474464,0.00044236332],"genre_scores_gemma":[0.99092954,0.00736958,0.00009937062,0.0011408991,0.00030815316,0.000002778476,4.7703253e-7,0.000013039165,0.00013616912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978122,0.000433862,0.0010126737,0.00017721651,0.00033564272,0.00022842277],"domain_scores_gemma":[0.9954893,0.0022639702,0.0015790049,0.00009890365,0.00026154134,0.00030725572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002536351,0.00012685632,0.0013209449,0.000080404316,0.000027256045,0.000010052697,0.00007734318,0.00025663374,0.00016853641],"category_scores_gemma":[0.0038330618,0.00007888133,0.00015923072,0.00015621397,0.00020700728,0.00013808919,0.00002026417,0.0008598202,0.0000010400069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009617671,0.00050780014,0.97237855,0.000016175767,0.000178787,0.0005228467,0.0000633921,0.000005447055,0.0000123320415,0.000014509253,0.0011493975,0.0155331055],"study_design_scores_gemma":[0.0054908264,0.007995504,0.97682834,0.0008440676,0.00021958412,0.00017064769,0.0003044298,0.000013668528,0.000006968534,0.00005627556,0.007979651,0.000090065434],"about_ca_topic_score_codex":0.0002824883,"about_ca_topic_score_gemma":0.0051440415,"teacher_disagreement_score":0.01544304,"about_ca_system_score_codex":0.00023529724,"about_ca_system_score_gemma":0.0011607639,"threshold_uncertainty_score":0.458881},"labels":[],"label_agreement":null},{"id":"W2117734248","doi":"10.1200/jco.2014.55.9344","title":"Twenty-Twenty Hindsight: An Adjuvant Breast Cancer Trial Through the Retrospectoscope","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; McMaster University; Juravinski Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Cyclophosphamide; Cancer; Sample size determination; Adjuvant; Clinical trial; Chemotherapy; Adjuvant chemotherapy; Surgery; Confidence interval; Statistics","score_opus":0.6772385168178936,"score_gpt":0.6476783877179321,"score_spread":0.02956012909996153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117734248","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018323531,0.00031885895,0.0125575755,0.9256951,0.05267995,0.0016829935,0.0004131003,0.00006978326,0.004750288],"genre_scores_gemma":[0.0007033681,0.0012627057,0.21320792,0.6142003,0.16891247,0.00006833225,0.0000091227075,0.00023255922,0.0014032371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.957928,0.02270368,0.014709904,0.001054271,0.0024916083,0.0011125315],"domain_scores_gemma":[0.75087464,0.2287201,0.016901994,0.0016129857,0.0013666103,0.0005236457],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.04013226,0.00087882293,0.009568088,0.00014239548,0.00022728975,0.0001389245,0.0031510503,0.0057431874,0.0041767578],"category_scores_gemma":[0.21194603,0.00047683672,0.0030349179,0.00032128402,0.0016733997,0.00028252642,0.0004059304,0.018509079,0.0001009677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024025414,0.0014074683,0.00016802219,0.00012480297,0.001222883,0.0009992616,0.00007269995,0.000002237788,0.0000014260878,0.0029925387,0.93735456,0.03162867],"study_design_scores_gemma":[0.030608378,0.008594978,0.00046254805,0.00029749508,0.002017244,0.00023494058,0.000017618391,0.000021327127,0.00000255834,0.38007534,0.5772805,0.00038703755],"about_ca_topic_score_codex":0.0000754062,"about_ca_topic_score_gemma":0.000050672694,"teacher_disagreement_score":0.3770828,"about_ca_system_score_codex":0.00052565336,"about_ca_system_score_gemma":0.0031754936,"threshold_uncertainty_score":0.9997683},"labels":[],"label_agreement":null},{"id":"W2118008308","doi":"10.1200/jco.2006.24.18_suppl.6099","title":"Dose banding of chemotherapy doses at the Juravinski Cancer Centre","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Interim; Chemotherapy; Interim analysis; Pharmacy; Cancer chemotherapy; Surgery; Internal medicine; Clinical trial; Nursing","score_opus":0.15126788787058243,"score_gpt":0.5531755325072808,"score_spread":0.40190764463669837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118008308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95715076,0.0006454076,0.000060123486,0.027599692,0.0048516835,0.00019038141,0.000009080144,0.000009644529,0.009483221],"genre_scores_gemma":[0.984749,0.0010799913,0.000711552,0.0032755597,0.0040131,0.0000030180688,0.0000013768561,0.000022801813,0.0061435546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951122,0.0009601716,0.0030757852,0.00014161889,0.00035581744,0.00035442982],"domain_scores_gemma":[0.98091686,0.014407894,0.003845187,0.00019070412,0.00050502154,0.00013431793],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043697795,0.00012702239,0.0010708014,0.000070228496,0.00023813854,0.0000029851076,0.00031269874,0.0004029808,0.0017648038],"category_scores_gemma":[0.0026395551,0.000070109425,0.00037073946,0.00014261145,0.00028622037,0.00006333441,0.000094083174,0.001205128,0.000059559527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033227229,0.00070221187,0.80089337,0.00007123839,0.0002132147,0.00005653739,0.000759061,0.00012730515,0.0006523882,0.00069985626,0.153031,0.03947107],"study_design_scores_gemma":[0.006878454,0.0006589671,0.584648,0.00033506195,0.00014126855,0.000016737966,0.000547988,0.00004831282,0.00019475995,0.0007319764,0.40570927,0.00008915349],"about_ca_topic_score_codex":0.00037441732,"about_ca_topic_score_gemma":0.0014471177,"teacher_disagreement_score":0.25267828,"about_ca_system_score_codex":0.00019589222,"about_ca_system_score_gemma":0.0026950864,"threshold_uncertainty_score":0.9991477},"labels":[],"label_agreement":null},{"id":"W2118083687","doi":"10.1200/jco.2013.52.7515","title":"An Individual Person Data Meta-Analysis of Preoperative Magnetic Resonance Imaging and Breast Cancer Recurrence","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Magnetic resonance imaging; Hazard ratio; Proportional hazards model; Breast cancer; Breast MRI; Nuclear medicine; Survival analysis; Radiation therapy; Cancer; Confidence interval; Internal medicine; Radiology; Oncology; Mammography","score_opus":0.30721610711359215,"score_gpt":0.5221553341754901,"score_spread":0.21493922706189794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118083687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022657834,0.99678624,0.00003427391,0.00048189095,0.00029182824,0.00018190934,0.0019253871,0.000001687846,0.00007022507],"genre_scores_gemma":[0.0033434292,0.9941708,0.0012054752,0.00025311293,0.00073815393,0.000023418233,0.00021078704,0.000024542636,0.000030323134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948484,0.0017144602,0.002210259,0.0006948851,0.0003054624,0.00022658527],"domain_scores_gemma":[0.9942982,0.0007862352,0.0034465133,0.00079004164,0.00048017962,0.00019878184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029524942,0.00037915824,0.0067005227,0.00018045786,0.000051810966,0.000020734426,0.00096579513,0.00042539244,0.000083562416],"category_scores_gemma":[0.00069265155,0.00024120515,0.0015979864,0.00026876494,0.00051303004,0.00002079709,0.00036989307,0.0005791753,7.543155e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015254311,0.00030010357,0.003041681,0.00025426064,0.0623347,0.000015215169,0.000044067354,0.0000027953658,5.5229395e-7,0.000004415599,0.0013657985,0.93248385],"study_design_scores_gemma":[0.00068334216,0.0013310199,0.024091894,0.0002628246,0.4591846,0.00020190404,0.000054456163,0.00002479305,5.833502e-7,0.000003420998,0.51392514,0.00023603885],"about_ca_topic_score_codex":0.00009547752,"about_ca_topic_score_gemma":0.00043635466,"teacher_disagreement_score":0.9322478,"about_ca_system_score_codex":0.000035733432,"about_ca_system_score_gemma":0.0013810092,"threshold_uncertainty_score":0.9836061},"labels":[],"label_agreement":null},{"id":"W2118094790","doi":"10.1200/jco.2011.41.1165","title":"Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Medicine; Stage (stratigraphy); Wilms' tumor; Histology; Internal medicine; Multivariate analysis; Gastroenterology; Disease; Pathology; Oncology","score_opus":0.022380277808261885,"score_gpt":0.34331411552618507,"score_spread":0.32093383771792316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118094790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959647,0.0010410562,0.00017738734,0.00045056728,0.00046247168,0.00025824655,0.00000702173,0.0000034214677,0.0016351476],"genre_scores_gemma":[0.99606895,0.0012006365,0.0011041199,0.0008458272,0.0002845604,0.000009921494,0.000007433832,0.000016428998,0.00046212436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669635,0.0004779222,0.0020539877,0.0002968746,0.00018879096,0.00028607826],"domain_scores_gemma":[0.9971451,0.0002447292,0.0018683742,0.00021821432,0.00032589576,0.00019765826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017430448,0.0001724891,0.0010928776,0.00011896814,0.000028964914,0.0000049315004,0.0003537186,0.00065099396,0.0000819129],"category_scores_gemma":[0.0009631313,0.00011023127,0.0003011573,0.0001485828,0.00062362774,0.000016528158,0.00009020174,0.0010049846,0.000010302885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059788018,0.001317771,0.96661216,0.000020309328,0.0006582344,0.00026329455,0.00008938412,0.0011423718,0.010431949,0.000057620757,0.004709717,0.008718407],"study_design_scores_gemma":[0.014426487,0.04847565,0.92171973,0.00013407199,0.0002233411,0.0014005805,0.00032918973,0.00007973147,0.004395999,0.00039297534,0.008098966,0.00032326594],"about_ca_topic_score_codex":0.00008381972,"about_ca_topic_score_gemma":0.00003076395,"teacher_disagreement_score":0.04715788,"about_ca_system_score_codex":0.000052424042,"about_ca_system_score_gemma":0.0010169821,"threshold_uncertainty_score":0.50210613},"labels":[],"label_agreement":null},{"id":"W2118138829","doi":"10.1200/jco.2009.24.8542","title":"Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; CLARITY; Oncology; Internal medicine","score_opus":0.21652348365409424,"score_gpt":0.41527792113484757,"score_spread":0.19875443748075333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118138829","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18895702,0.0046794754,0.0008994159,0.78799146,0.0021873114,0.000664346,0.0002107958,0.0000071050977,0.01440307],"genre_scores_gemma":[0.4493101,0.0024046123,0.003268345,0.53695375,0.0072288993,0.000018918685,0.000024576688,0.000060190938,0.0007306511],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98977596,0.00011140221,0.009355841,0.0002865963,0.000093041854,0.00037717543],"domain_scores_gemma":[0.96251893,0.0034137452,0.033381946,0.00028524673,0.00034421275,0.000055943485],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01358719,0.00021875373,0.003609664,0.0002095783,0.000040990104,0.00002872222,0.0005738967,0.0015111818,0.000042426476],"category_scores_gemma":[0.012628626,0.00015258258,0.0007987517,0.00014318079,0.00024785733,0.00018036386,0.000021457317,0.0028569032,0.0000026348891],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015562939,0.0012197907,0.26301578,0.00012717402,0.0014914669,0.0006336833,0.00075731135,0.00010943572,6.362943e-7,0.019597318,0.6556062,0.05588489],"study_design_scores_gemma":[0.002100988,0.0035460063,0.31267726,0.00013801918,0.000073595875,0.000024889649,0.00002563548,0.000026650256,6.659015e-7,0.066276684,0.61493176,0.00017783768],"about_ca_topic_score_codex":0.00015273549,"about_ca_topic_score_gemma":0.0003972441,"teacher_disagreement_score":0.26035306,"about_ca_system_score_codex":0.00026496916,"about_ca_system_score_gemma":0.0007353635,"threshold_uncertainty_score":0.99978507},"labels":[],"label_agreement":null},{"id":"W2118170001","doi":"10.1200/jco.2009.21.7943","title":"Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Medicine; FOLFOX; Pharmacogenetics; Internal medicine; Oxaliplatin; Oncology; Adverse effect; Colorectal cancer; Irinotecan; Neutropenia; Chemotherapy; Genotype; Cancer; Genetics","score_opus":0.030776679461150744,"score_gpt":0.39223981580148803,"score_spread":0.3614631363403373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118170001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733394,0.000050439867,0.00012111547,0.001180235,0.00091168715,0.00024312767,0.00015036113,0.0000018710726,0.0000072088515],"genre_scores_gemma":[0.9937824,0.0003141726,0.004739971,0.00052307756,0.00059459417,0.000007764572,0.000010796371,0.000015179281,0.000012018616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971214,0.00058454263,0.0016644252,0.0002516328,0.00017720177,0.00020080275],"domain_scores_gemma":[0.99774027,0.00077793736,0.00089783274,0.00013040015,0.00014256292,0.0003109738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016243381,0.00015036421,0.0007517395,0.00009787583,0.00001645585,0.0000019397733,0.0002235011,0.0000844961,0.000021455287],"category_scores_gemma":[0.0017181309,0.00012263772,0.00022981151,0.00012722229,0.00024297113,0.0000063197617,0.000046663215,0.00049499713,9.3182865e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4459366,0.00072525156,0.19736794,0.0000029278349,0.00016685842,0.00006844266,0.0001377139,0.000091665446,0.34294975,2.1354288e-7,0.0001410804,0.012411566],"study_design_scores_gemma":[0.068495214,0.035222836,0.88189036,0.000039119772,0.00013725497,0.00009492034,0.00007810756,0.000054567518,0.010830322,0.000009957166,0.003001065,0.00014630763],"about_ca_topic_score_codex":0.0002380794,"about_ca_topic_score_gemma":0.0029443824,"teacher_disagreement_score":0.6845224,"about_ca_system_score_codex":0.000021069807,"about_ca_system_score_gemma":0.0007672969,"threshold_uncertainty_score":0.5001021},"labels":[],"label_agreement":null},{"id":"W2118312468","doi":"10.1200/jco.2007.10.7540","title":"Communicating With Patients About Chemotherapy Costs","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Internal medicine; Intensive care medicine","score_opus":0.593552459994211,"score_gpt":0.5744192701468516,"score_spread":0.019133189847359455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118312468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0327418,0.0018300331,0.00067340577,0.94209135,0.003133495,0.00057561905,0.00009796453,0.000017307157,0.018839028],"genre_scores_gemma":[0.0051911185,0.0011690117,0.013816833,0.96887517,0.01014429,0.000011160489,0.00005952412,0.00009617583,0.0006367007],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9754163,0.0018791998,0.0213126,0.0004762965,0.00031719057,0.000598419],"domain_scores_gemma":[0.9400635,0.017438632,0.040639058,0.0008584368,0.0006693409,0.00033103462],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.06673233,0.0003594652,0.0056256005,0.00051120826,0.0001342745,0.00005624858,0.0012080604,0.0023212275,0.0005538015],"category_scores_gemma":[0.017247487,0.00034147676,0.00069873856,0.00017691166,0.00036680425,0.00032975373,0.000092236485,0.0056658452,0.0006289926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019593241,0.00041536114,0.09043484,0.00012924844,0.00045435966,0.00004939456,0.00020886838,0.0000043308637,1.0772284e-8,0.00036372987,0.8986042,0.009139718],"study_design_scores_gemma":[0.0045520198,0.0027378818,0.056115955,0.00032344746,0.00003708234,0.00003203891,0.00006810665,0.000057266763,1.3292953e-7,0.00093867176,0.9348103,0.00032713945],"about_ca_topic_score_codex":0.00022403273,"about_ca_topic_score_gemma":0.00011027334,"teacher_disagreement_score":0.049484845,"about_ca_system_score_codex":0.0015631644,"about_ca_system_score_gemma":0.001494062,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W2118342755","doi":"10.1200/jco.2013.51.3002","title":"Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Medicine; Melanoma; Tumor-infiltrating lymphocytes; Breslow Thickness; Hazard ratio; Population; Oncology; Cancer; Internal medicine; Stage (stratigraphy); Relative survival; Cancer registry; Confidence interval; Cancer research; Immunotherapy; Breast cancer; Biology","score_opus":0.0648592495248592,"score_gpt":0.3470578250292431,"score_spread":0.2821985755043839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118342755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942601,0.0012477015,0.000010721731,0.0033174157,0.00022194666,0.00070546387,0.0000028689706,0.0000047212966,0.00022909875],"genre_scores_gemma":[0.99692816,0.00034226498,0.00031432085,0.0021532131,0.00018320548,0.000022072092,0.000008201995,0.000017893695,0.000030676892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955494,0.0012176567,0.002099469,0.00025218964,0.00062348915,0.00025781378],"domain_scores_gemma":[0.9959898,0.0022721523,0.0013348752,0.0002149607,0.000064871645,0.00012331767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048216553,0.0001891168,0.0011215294,0.0001768315,0.00005383915,0.000028955597,0.00019084226,0.00021813017,0.00014482629],"category_scores_gemma":[0.00021430757,0.0001127434,0.00016631,0.00020895425,0.00013132542,0.00011999337,0.000026444066,0.00071835757,0.0000033432605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033903548,0.002148439,0.96332383,0.000008117655,0.00022638465,0.00053996185,0.0003364077,0.00002423866,0.0001599799,0.0000031516872,0.00007915378,0.029759996],"study_design_scores_gemma":[0.021761172,0.008673109,0.9670386,0.000085947366,0.00009702563,0.00014395741,0.0008895912,0.00009828319,0.000018188479,0.000032454354,0.0010385256,0.00012316706],"about_ca_topic_score_codex":0.0006226451,"about_ca_topic_score_gemma":0.00069405034,"teacher_disagreement_score":0.029636828,"about_ca_system_score_codex":0.00065689103,"about_ca_system_score_gemma":0.0006950839,"threshold_uncertainty_score":0.45975426},"labels":[],"label_agreement":null},{"id":"W2118531668","doi":"10.1200/jco.2013.52.4645","title":"Effectiveness of the Quadrivalent Human Papillomavirus Vaccine Against Cervical Dysplasia in Manitoba, Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Ascus (bryozoa); Dysplasia; Cervical cancer; Gynecology; Vaccination; Population; Hazard ratio; Proportional hazards model; Cytology; Bethesda system; Obstetrics; Internal medicine; Cancer; Immunology; Pathology; Confidence interval; Environmental health","score_opus":0.09263158353434406,"score_gpt":0.4445426248266213,"score_spread":0.35191104129227724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118531668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98527753,0.00019077829,0.000018199873,0.0033685497,0.0009174257,0.00025923486,0.000002283984,0.000002458972,0.009963535],"genre_scores_gemma":[0.997767,0.00013896944,0.000052234296,0.0012851434,0.0006988255,0.00000414447,0.0000011940353,0.000013680606,0.00003884865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508226,0.001750154,0.0019815576,0.00017682537,0.000727477,0.00028170942],"domain_scores_gemma":[0.9939737,0.0041108294,0.0007484362,0.00030041233,0.0005073792,0.00035927637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058743884,0.00012552795,0.0015307802,0.00008799711,0.00004291908,0.000004081394,0.00037332016,0.0002649511,0.0002988122],"category_scores_gemma":[0.003493546,0.00007262548,0.0003697067,0.00023244915,0.00013774175,0.00003519976,0.00013409437,0.0015392456,0.0000032041771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006003802,0.0013449978,0.8659124,0.00044251286,0.00017886344,0.00028052705,0.000021647145,0.00005342452,0.0011521032,0.00048708246,0.0014551431,0.122667514],"study_design_scores_gemma":[0.009369947,0.0039578024,0.9689993,0.00017026879,0.000088981804,0.000052773885,0.00004281882,0.00006605351,0.00063526706,0.00045397878,0.016097201,0.000065563734],"about_ca_topic_score_codex":0.04177849,"about_ca_topic_score_gemma":0.44429076,"teacher_disagreement_score":0.40251225,"about_ca_system_score_codex":0.00057199,"about_ca_system_score_gemma":0.0026588235,"threshold_uncertainty_score":0.9646024},"labels":[],"label_agreement":null},{"id":"W2118558111","doi":"10.1200/jco.2012.45.2722","title":"Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":2658,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of New Brunswick","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Underweight; Body mass index; Overweight; Obesity paradox; Cachexia; Weight loss; Internal medicine; Cancer; Obesity; Skeletal muscle; Lung cancer; Univariate analysis; Multivariate analysis","score_opus":0.11790128158935613,"score_gpt":0.46822706231165284,"score_spread":0.3503257807222967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118558111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840681,0.00034950636,0.0002180802,0.01385085,0.0005289787,0.00044336964,0.000004604434,0.0000030698484,0.00053346006],"genre_scores_gemma":[0.9946709,0.00057410734,0.0006008357,0.0037195855,0.0003724066,0.00000817971,0.0000017329277,0.000008939653,0.00004328051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964675,0.00048430637,0.0022202672,0.00012256432,0.0004987443,0.0002066529],"domain_scores_gemma":[0.9964609,0.0012633315,0.0015064942,0.0001500617,0.00045414874,0.00016502016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022414352,0.0000965382,0.001018171,0.00017374854,0.000018591107,0.000005067797,0.00017069533,0.00032869456,0.0006789042],"category_scores_gemma":[0.0013490344,0.0000614906,0.00027149936,0.00016779448,0.0001643343,0.00008491043,0.000027713135,0.0011678663,0.000009264399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029140714,0.0018525008,0.97907984,0.00019216603,0.000075242686,0.00015709884,0.00040013203,0.0000023112639,0.001378742,0.000036696296,0.0014703092,0.01506353],"study_design_scores_gemma":[0.004569856,0.0031891416,0.9818613,0.00028948576,0.00008986391,0.000060507147,0.0002940175,0.0000970927,0.00008350281,0.00072095776,0.0086944215,0.000049886625],"about_ca_topic_score_codex":0.0003754417,"about_ca_topic_score_gemma":0.00014728864,"teacher_disagreement_score":0.015013644,"about_ca_system_score_codex":0.0001247629,"about_ca_system_score_gemma":0.00088877586,"threshold_uncertainty_score":0.7433525},"labels":[],"label_agreement":null},{"id":"W2118690190","doi":"10.1200/jco.2014.57.8898","title":"Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Guideline; Medicine; Clinical Practice; Alternative medicine; Odds; Family medicine; Conflict of interest; MEDLINE; Odds ratio; Internal medicine; Political science; Business; Finance; Law; Pathology","score_opus":0.9016899158285367,"score_gpt":0.7554714578609464,"score_spread":0.14621845796759037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118690190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7930188,0.0011239758,0.0009770659,0.18796043,0.012268968,0.00054552854,0.000059065645,0.000023012068,0.0040231375],"genre_scores_gemma":[0.8988721,0.0013054317,0.010975376,0.078450814,0.00954798,0.000011013592,0.000003461524,0.000029457058,0.000804414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891895,0.003600594,0.0059966804,0.00037271672,0.00027595594,0.0005645584],"domain_scores_gemma":[0.9567653,0.032536812,0.0047576097,0.00022751131,0.0040733926,0.0016393659],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.038311724,0.00025744303,0.0019509022,0.00012841127,0.0001562006,0.000014272417,0.00047180947,0.0042829015,0.00032133816],"category_scores_gemma":[0.15445109,0.00020699433,0.00055370014,0.00016687835,0.0011174676,0.0002781658,0.00016997498,0.00837109,0.000010628674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014931331,0.0028975178,0.044304505,0.00024004262,0.000901603,0.00009840519,0.00030534985,0.000027722028,0.0002696267,0.024883246,0.20390196,0.7072387],"study_design_scores_gemma":[0.0081528,0.0073555633,0.015044489,0.000114128874,0.000982055,0.00014642232,0.0002831975,0.0017123464,0.00042121965,0.0026478448,0.96293825,0.00020166983],"about_ca_topic_score_codex":0.00001318624,"about_ca_topic_score_gemma":0.000018011355,"teacher_disagreement_score":0.7590363,"about_ca_system_score_codex":0.000071866365,"about_ca_system_score_gemma":0.0018928722,"threshold_uncertainty_score":0.99700975},"labels":[],"label_agreement":null},{"id":"W2118742901","doi":"10.1200/jco.2014.58.8525","title":"Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Prostatectomy; Medicine; Guideline; Radiation therapy; Prostate cancer; Brachytherapy; Salvage therapy; Oncology; Adjuvant radiotherapy; Internal medicine; Cancer; Pathology; Chemotherapy","score_opus":0.19299422697715204,"score_gpt":0.5886874266163074,"score_spread":0.3956931996391553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118742901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011994381,0.9752598,0.0003723331,0.016072912,0.0042259344,0.002132791,0.00008084083,0.000022694934,0.0006332579],"genre_scores_gemma":[0.00020366859,0.8864201,0.08673686,0.018685417,0.007544658,0.00012218772,0.000039882627,0.000116644376,0.00013061202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96625924,0.006882111,0.024134258,0.0010822492,0.00095581415,0.00068632135],"domain_scores_gemma":[0.9383516,0.030067151,0.027403994,0.00087244,0.0017588217,0.0015460232],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.035367798,0.000841879,0.022886591,0.00021271582,0.00005640862,0.00002263448,0.00045394583,0.0021322805,0.00019251468],"category_scores_gemma":[0.013991149,0.00052100356,0.0069464557,0.00034895982,0.002241964,0.00016878374,0.0002829546,0.0051414995,0.000020328456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061520007,0.008609566,0.0062957364,0.0022445335,0.008066808,0.0013866755,0.00006234951,4.767302e-7,2.1055735e-7,0.00001393608,0.066563845,0.9006039],"study_design_scores_gemma":[0.015810324,0.08109443,0.0042123175,0.0044438853,0.011899172,0.0011235533,0.00009266505,0.00002325227,4.8643267e-7,0.000019903522,0.8809252,0.00035482275],"about_ca_topic_score_codex":0.00006503451,"about_ca_topic_score_gemma":0.000027032069,"teacher_disagreement_score":0.90024906,"about_ca_system_score_codex":0.00085714983,"about_ca_system_score_gemma":0.013631604,"threshold_uncertainty_score":0.99972415},"labels":[],"label_agreement":null},{"id":"W2118821887","doi":"10.1200/jco.2010.32.5332","title":"Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Enucleation; Medicine; Retinoblastoma; Surgery; Metastasis; Chemotherapy; Primary tumor; Internal medicine; Cancer","score_opus":0.07959039444362713,"score_gpt":0.4105581937680145,"score_spread":0.33096779932438736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118821887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972994,0.0009115831,0.0005394243,0.00035646305,0.00020906114,0.00043319576,0.000051257688,0.000009611189,0.00019003394],"genre_scores_gemma":[0.9654945,0.0010347713,0.032580424,0.00062657456,0.00018052557,0.0000068960503,0.000012398802,0.000018840166,0.00004507461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768734,0.0005714204,0.0012324755,0.00020452576,0.00016204597,0.00014217736],"domain_scores_gemma":[0.99504614,0.002261352,0.0019660871,0.00015777705,0.0003529761,0.0002156541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014955701,0.00014003474,0.0012952111,0.0000774707,0.00004565883,0.0000025189913,0.000073736745,0.00033072595,0.00013836326],"category_scores_gemma":[0.0031407382,0.00009528182,0.00034688454,0.00005585974,0.00018259486,0.00009096155,0.000025242583,0.00036395126,0.0000025494803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059155468,0.007657247,0.788822,0.00004737548,0.0040182597,0.00026955147,0.00025212424,6.0768065e-7,0.0025686244,0.00003497553,0.00300172,0.13417207],"study_design_scores_gemma":[0.015701342,0.027425973,0.94611806,0.000094462586,0.0029308568,0.00015589937,0.000047350786,0.000085762505,0.0038833723,0.0011348644,0.002348751,0.00007329558],"about_ca_topic_score_codex":0.00018995802,"about_ca_topic_score_gemma":0.000028606302,"teacher_disagreement_score":0.15729609,"about_ca_system_score_codex":0.00004944203,"about_ca_system_score_gemma":0.0002918601,"threshold_uncertainty_score":0.388548},"labels":[],"label_agreement":null},{"id":"W2118875599","doi":"10.1200/jco.2007.15.1001","title":"Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Radiation therapy; Dacarbazine; Stage (stratigraphy); ABVD; Vinblastine; Vincristine; Chemotherapy; Bleomycin; Hodgkin's lymphoma; Surgery; Nuclear medicine; Cyclophosphamide","score_opus":0.11147853037135746,"score_gpt":0.43829897388396843,"score_spread":0.32682044351261097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118875599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902348,0.0014243526,0.0001681319,0.0066641145,0.000605189,0.0005496535,0.0000060392545,0.000007283393,0.0003404315],"genre_scores_gemma":[0.9811456,0.014722399,0.0017561507,0.0019139849,0.00032667065,0.000019747558,0.000010704627,0.000012605119,0.000092122325],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971284,0.000346893,0.0018905341,0.00014219192,0.0003559232,0.00013605267],"domain_scores_gemma":[0.9914532,0.005201575,0.00233534,0.00016205256,0.00069785677,0.00014999922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015250702,0.00013107603,0.0012088593,0.000121178295,0.000040059964,0.00000291843,0.00009700111,0.0003392786,0.000049666585],"category_scores_gemma":[0.0024027615,0.000091157744,0.00060061016,0.000110493565,0.00011756652,0.00009341348,0.000012312348,0.000118300566,0.0000017938507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026269637,0.022856247,0.42878744,0.00005132705,0.0009808354,0.00016647791,0.00043937485,0.000015056396,0.002278092,0.0018475202,0.003181302,0.5131267],"study_design_scores_gemma":[0.053526968,0.06189958,0.846203,0.0001045165,0.00014667884,0.00012316968,0.00007123249,0.00018725632,0.01576325,0.0006433227,0.021248976,0.00008204371],"about_ca_topic_score_codex":0.00012165618,"about_ca_topic_score_gemma":0.0000072742923,"teacher_disagreement_score":0.51304466,"about_ca_system_score_codex":0.000182971,"about_ca_system_score_gemma":0.0011117805,"threshold_uncertainty_score":0.3717305},"labels":[],"label_agreement":null},{"id":"W2118961573","doi":"10.1200/jco.2010.31.3049","title":"Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic Review","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Comorbidity; Tolerability; Internal medicine; Chemotherapy; MEDLINE; Retrospective cohort study; Intensive care medicine; Oncology; Adverse effect","score_opus":0.45642341852989826,"score_gpt":0.6181094415015292,"score_spread":0.16168602297163098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118961573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010349533,0.9876502,0.0000022268277,0.0003978542,0.0003181083,0.0011591141,0.000010676692,0.000003252188,0.00010901601],"genre_scores_gemma":[0.001178577,0.99641657,0.00033026646,0.0017269808,0.00027867302,0.000010317237,0.0000023471957,0.000022174516,0.000034086435],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9913281,0.0010948665,0.0066823345,0.0002088209,0.00046619534,0.0002196375],"domain_scores_gemma":[0.9850541,0.0059127975,0.007871564,0.0004060784,0.0004065638,0.00034893944],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0073719835,0.00031937228,0.016536294,0.00021631048,0.000011915738,0.000009845905,0.00027001588,0.0007439373,0.00005425182],"category_scores_gemma":[0.021843335,0.0001631016,0.002529619,0.00019524807,0.00017042796,0.0001046317,0.000042128526,0.0026520493,0.000006441455],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006059654,0.0013112077,0.018236978,0.5723298,0.0014844057,0.0011938851,0.000025554677,2.4783827e-7,2.850768e-7,0.00001532072,0.0014728412,0.40332347],"study_design_scores_gemma":[0.0023390816,0.012557706,0.022255277,0.90696406,0.0043917387,0.0021055446,0.000006665525,0.0000017970925,7.831126e-8,0.000023193785,0.049189996,0.00016484223],"about_ca_topic_score_codex":0.000064695094,"about_ca_topic_score_gemma":0.000034098543,"teacher_disagreement_score":0.40315863,"about_ca_system_score_codex":0.000283465,"about_ca_system_score_gemma":0.0029563203,"threshold_uncertainty_score":0.99964887},"labels":[],"label_agreement":null},{"id":"W2119056140","doi":"10.1200/jco.2011.35.1924","title":"Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Confidence interval; Internal medicine; Hazard ratio; Prostate; Incidence (geometry); Concordance; Cancer; Oncology; Gynecology; Urology","score_opus":0.12765460556626645,"score_gpt":0.4901168317255905,"score_spread":0.36246222615932405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119056140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9084436,0.0018095596,0.0014029904,0.08594509,0.0016740091,0.00066100305,0.000021017573,0.0000030867288,0.000039640934],"genre_scores_gemma":[0.9939434,0.0004700041,0.00210868,0.001587396,0.001715185,0.00007460248,0.0000026584094,0.000010795395,0.00008729374],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976494,0.00014767374,0.0016830215,0.00009863021,0.00022998903,0.00019133049],"domain_scores_gemma":[0.9957102,0.0020138123,0.001432783,0.00016628185,0.0005060691,0.00017086526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038181334,0.000083191866,0.0005542853,0.00003133208,0.000050566112,0.000009856116,0.00016649449,0.00011366362,0.000036568086],"category_scores_gemma":[0.002444696,0.000037715763,0.00038844097,0.00008626106,0.00013453807,0.00007137821,0.000051713218,0.00033494213,0.000003411976],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071819015,0.0034331966,0.1979501,0.00016372948,0.0023045097,0.000023912682,0.002389834,0.0001398907,0.03611946,0.00052693696,0.067541346,0.68222517],"study_design_scores_gemma":[0.011448178,0.013702485,0.5558125,0.00054863415,0.0037545215,0.00029469637,0.001876451,0.00021892287,0.09771045,0.00045327446,0.31396878,0.00021115018],"about_ca_topic_score_codex":0.00002146786,"about_ca_topic_score_gemma":0.000012727582,"teacher_disagreement_score":0.68201405,"about_ca_system_score_codex":0.00012500679,"about_ca_system_score_gemma":0.0004885212,"threshold_uncertainty_score":0.2926706},"labels":[],"label_agreement":null},{"id":"W2119100187","doi":"10.1200/jco.2005.03.6491","title":"Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Topotecan; Medicine; Neutropenia; Internal medicine; Lung cancer; Regimen; Chemotherapy; Febrile neutropenia; Gastroenterology; Phases of clinical research; Oncology; Surgery","score_opus":0.04141248829153858,"score_gpt":0.4636003644563013,"score_spread":0.4221878761647627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119100187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953216,0.00015520182,0.00020491975,0.0004930455,0.00043877497,0.0012524843,0.0000058835594,0.000009276892,0.002118836],"genre_scores_gemma":[0.9966058,0.000019226229,0.0023134102,0.00040769254,0.0002537168,0.000034042252,0.000008547829,0.000020227713,0.00033734617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975107,0.00013193667,0.0015599955,0.00022855643,0.00027552195,0.00029330776],"domain_scores_gemma":[0.99808955,0.00019133875,0.0008290035,0.00015832196,0.0004304691,0.00030132133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005233244,0.00016376715,0.0013068077,0.0001744675,0.000046239566,0.00001077788,0.00011086599,0.00012057582,0.000049362247],"category_scores_gemma":[0.00010694729,0.00011056151,0.00011782534,0.00027093175,0.00004576035,0.000088425055,0.0000298725,0.00052455463,0.0000024461842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010662884,0.026910942,0.8984251,0.000019682087,0.00039141055,0.00043492607,0.0005590374,0.0015540584,0.000025020645,0.0000021486449,0.00032082957,0.060693942],"study_design_scores_gemma":[0.12427209,0.040808175,0.83209896,0.00015252517,0.001116403,0.000010019998,0.00023706829,0.00019005369,0.000041217394,0.000007805129,0.00095319847,0.0001124999],"about_ca_topic_score_codex":0.00090160494,"about_ca_topic_score_gemma":0.0032533316,"teacher_disagreement_score":0.11360921,"about_ca_system_score_codex":0.00067289395,"about_ca_system_score_gemma":0.0014307735,"threshold_uncertainty_score":0.45085675},"labels":[],"label_agreement":null},{"id":"W2119131749","doi":"10.1200/jco.2005.11.043","title":"Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Toronto Western Hospital; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Placebo; Internal medicine; Sarcoma; Gastroenterology; Phases of clinical research; Surgery; Chemotherapy; Pathology","score_opus":0.032378292553931244,"score_gpt":0.39159471021931586,"score_spread":0.3592164176653846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119131749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916892,0.003534904,0.0000213943,0.0016205511,0.0006091519,0.0022834549,0.000054694832,0.000013112483,0.00017352347],"genre_scores_gemma":[0.9958834,0.0019987526,0.00009916598,0.0012821575,0.00064080884,0.000041216183,0.000006736077,0.00003378427,0.000013996772],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99397635,0.0019344994,0.0027032623,0.00042102515,0.000538415,0.00042644274],"domain_scores_gemma":[0.99254745,0.004082336,0.0023874221,0.00027365476,0.0004180186,0.00029114203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037987297,0.00037519776,0.0029577685,0.0002560695,0.00010372596,0.000022091981,0.00023672241,0.0005273878,0.000015910608],"category_scores_gemma":[0.0025989064,0.00022296321,0.0008588806,0.0004792708,0.000533148,0.00019809724,0.00008072509,0.0010518497,0.0000013745355],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30971712,0.010730644,0.43637156,0.000022896716,0.0025696026,0.00069099903,0.0014282399,0.000013738262,0.007333988,0.000015240546,0.00026557315,0.2308404],"study_design_scores_gemma":[0.5549683,0.28736869,0.13568869,0.00029183636,0.0013430865,0.00003352656,0.008319808,0.000013687117,0.011326004,0.0003081047,0.00009339666,0.0002448979],"about_ca_topic_score_codex":0.0010979674,"about_ca_topic_score_gemma":0.00015128466,"teacher_disagreement_score":0.30068287,"about_ca_system_score_codex":0.00043619671,"about_ca_system_score_gemma":0.0018157699,"threshold_uncertainty_score":0.90921754},"labels":[],"label_agreement":null},{"id":"W2119331159","doi":"10.1200/jco.2010.29.6053","title":"Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; Bristol-Myers Squibb","keywords":"Medicine; Conventional PCI; Prophylactic cranial irradiation; Neurocognitive; Quality of life (healthcare); Lung cancer; Internal medicine; Radiation therapy; Oncology; Cognition; Myocardial infarction; Psychiatry","score_opus":0.08907000623929474,"score_gpt":0.44547313461021576,"score_spread":0.35640312837092103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119331159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757665,0.00003462092,0.00076770846,0.00041136675,0.00021038228,0.0009489381,0.000015341502,0.0000017855817,0.00003317398],"genre_scores_gemma":[0.994,0.000044463868,0.0055267154,0.00024048987,0.00014115572,0.000013661858,0.000018723957,0.000008983416,0.0000057638413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969371,0.00041384876,0.0020010066,0.00017537833,0.00035336733,0.00011931175],"domain_scores_gemma":[0.9942649,0.0012923691,0.0032760056,0.00012139546,0.0008454614,0.00019989398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014344461,0.00012220215,0.0017152013,0.00018602773,0.000020042247,0.0000039640263,0.000054966727,0.00013369077,0.00002005781],"category_scores_gemma":[0.0010385066,0.00007613062,0.00017657268,0.00035219875,0.00014192394,0.00010619268,0.00001181565,0.0005197063,9.577521e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35554802,0.009358003,0.610828,0.00007760821,0.0009162825,0.000023939087,0.00013480727,0.0002547657,0.00016428226,0.000005211714,0.0000022445922,0.022686848],"study_design_scores_gemma":[0.31625277,0.035437707,0.64492565,0.000042556483,0.0023908229,0.0000011573126,0.00005681088,0.0007844771,0.000034733148,0.0000040415553,0.000017908163,0.00005135947],"about_ca_topic_score_codex":0.00018027742,"about_ca_topic_score_gemma":0.0010024855,"teacher_disagreement_score":0.039295267,"about_ca_system_score_codex":0.00004862,"about_ca_system_score_gemma":0.0013091833,"threshold_uncertainty_score":0.31045166},"labels":[],"label_agreement":null},{"id":"W2119391913","doi":"10.1200/jco.2011.37.8349","title":"Maintenance Therapy Comes of Age for Non–Small-Cell Lung Cancer, but at What Cost?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.13290531571665418,"score_gpt":0.4857187324848399,"score_spread":0.3528134167681857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119391913","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081991956,0.032353424,0.0006815865,0.854436,0.018265879,0.0041936296,0.00027357065,0.000020545052,0.0077834073],"genre_scores_gemma":[0.0072712423,0.13255805,0.0063780276,0.79433537,0.013695879,0.00025655323,0.00013761046,0.00014121099,0.045226045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623686,0.00019496327,0.0025605983,0.0002960242,0.00032412063,0.00038745263],"domain_scores_gemma":[0.99168146,0.0025857857,0.0041937125,0.00033188664,0.00097530487,0.00023182938],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010003458,0.0002960322,0.0028207628,0.00015478101,0.000052371794,0.00001559266,0.00031394407,0.0013156177,0.00034270118],"category_scores_gemma":[0.00036154359,0.00018802259,0.0012758425,0.00007514357,0.00027991927,0.00013001668,0.000050205377,0.001802418,0.000005657943],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003394239,0.00095252023,0.00687637,0.00039773932,0.002522434,0.0017882953,0.00029259373,0.000002399246,0.00005259499,0.000005820097,0.9100674,0.07364764],"study_design_scores_gemma":[0.018880513,0.008397811,0.005834085,0.0009722009,0.0026855087,0.00015057203,0.000087785535,0.000013655371,0.00017768465,0.00013209325,0.96250015,0.00016796334],"about_ca_topic_score_codex":0.00010274555,"about_ca_topic_score_gemma":0.00007788009,"teacher_disagreement_score":0.10020463,"about_ca_system_score_codex":0.00066552573,"about_ca_system_score_gemma":0.003428981,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W2119416636","doi":"10.1200/jco.2007.15.4716","title":"HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Chemotherapy; Topoisomerase; Oncology; Internal medicine; Pharmacology; Genetics; DNA; Biology","score_opus":0.2872185641950503,"score_gpt":0.6115991896106241,"score_spread":0.3243806254155738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119416636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027361475,0.96217746,0.000004667658,0.007012128,0.0012957184,0.0008548792,0.000014906865,0.0000084422345,0.0012703057],"genre_scores_gemma":[0.00019633908,0.9922131,0.0011735465,0.001858022,0.002349861,0.000014457862,0.0000019023324,0.000063614076,0.0021291869],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99138445,0.0021027536,0.00487929,0.00035301162,0.0009145346,0.0003659672],"domain_scores_gemma":[0.98681134,0.008165242,0.0026856842,0.0004735358,0.000657748,0.0012064653],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007600624,0.00031869783,0.007037538,0.0005473605,0.000049394115,0.000005769776,0.00041426474,0.0012432329,0.00045315753],"category_scores_gemma":[0.01857802,0.00021104785,0.0013628915,0.00043000217,0.00053084065,0.000049047354,0.00018191746,0.0027047915,0.00003673993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009253846,0.00099226,0.000519273,0.0017204592,0.00079340825,0.0015175737,0.00014084943,1.4891562e-7,0.000004398506,0.000004679884,0.032935675,0.95211744],"study_design_scores_gemma":[0.003622006,0.040877845,0.0015290811,0.0066852486,0.0005264243,0.0037596554,0.000020471569,3.5982663e-7,0.0000037482193,0.000018242792,0.94282144,0.00013547628],"about_ca_topic_score_codex":0.000020277817,"about_ca_topic_score_gemma":0.000005334232,"teacher_disagreement_score":0.95198196,"about_ca_system_score_codex":0.00044111998,"about_ca_system_score_gemma":0.013925866,"threshold_uncertainty_score":0.999596},"labels":[],"label_agreement":null},{"id":"W2119437277","doi":"10.1200/jco.2005.04.3042","title":"Physical and Emotional Health Effects and Social Consequences After Participation in a Low-Fat, High-Carbohydrate Dietary Trial for More Than 5 Years","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Intervention (counseling); Randomized controlled trial; Psychological intervention; Gerontology; Social support; Breast cancer; Physical therapy; Cancer; Internal medicine; Psychiatry; Psychology","score_opus":0.08391449719980393,"score_gpt":0.4835380197661667,"score_spread":0.3996235225663628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119437277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885229,0.0001893743,0.000025372738,0.010386344,0.000535202,0.00032209992,0.000008960926,0.0000028517836,0.0000068814825],"genre_scores_gemma":[0.99591696,0.00008498681,0.00024238843,0.0010093729,0.0027101964,0.000016340984,0.0000051169177,0.0000064311253,0.0000081908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985438,0.00020526847,0.000822501,0.00012455806,0.00015120296,0.00015268549],"domain_scores_gemma":[0.99824053,0.0010443071,0.0005103646,0.00003225137,0.00005761733,0.00011495122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008068095,0.0000744357,0.0008157934,0.00006248791,0.000025906606,0.0000069636244,0.000022808306,0.00013790932,0.0000039435345],"category_scores_gemma":[0.00026373836,0.00005526585,0.00015218652,0.00004600197,0.0003178601,0.000060403174,0.000012684136,0.00030535596,3.1890562e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30591056,0.0074543934,0.48229975,0.0006489866,0.0004393329,0.00077841396,0.0024951128,0.000051231124,0.0008759582,0.00095684826,0.0030284403,0.195061],"study_design_scores_gemma":[0.040489692,0.009757658,0.9469633,0.000089337314,0.00009250919,0.000011173772,0.000027259302,0.00017053339,0.000012317061,0.0020335244,0.00030332973,0.0000493797],"about_ca_topic_score_codex":0.00022752999,"about_ca_topic_score_gemma":0.00036682197,"teacher_disagreement_score":0.46466357,"about_ca_system_score_codex":0.000070683396,"about_ca_system_score_gemma":0.00047652773,"threshold_uncertainty_score":0.22536759},"labels":[],"label_agreement":null},{"id":"W2119442895","doi":"10.1200/jco.2007.14.3529","title":"Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":597,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Toxicity; Gastroenterology; Intrahepatic Cholangiocarcinoma; Radiation therapy; Internal medicine; Liver function","score_opus":0.15494337915495754,"score_gpt":0.449868472637682,"score_spread":0.29492509348272444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119442895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921336,0.0050205695,0.00013240901,0.00096502464,0.0006129851,0.0009663204,0.0000076829165,0.00000873129,0.00015265364],"genre_scores_gemma":[0.99571425,0.0009483402,0.0016973707,0.00062817975,0.0008891748,0.000022807944,0.0000028527072,0.000029636896,0.000067395864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621177,0.0003803747,0.0024680789,0.0002682139,0.0004080397,0.00026355244],"domain_scores_gemma":[0.99542767,0.0017542505,0.0017013939,0.00026935947,0.0005067625,0.0003405816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017624788,0.00021640689,0.0024366912,0.00024028249,0.000091199065,0.0000067371025,0.000163884,0.00022579782,0.000030058924],"category_scores_gemma":[0.0011841288,0.00015905019,0.00051154563,0.00016148677,0.00029444604,0.00011729052,0.000050127008,0.00055173086,7.0235615e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009506521,0.008965455,0.95620656,0.00009605116,0.0017262448,0.001119686,0.0038339845,2.060221e-7,0.00043941,0.0000095702,0.001317387,0.016778905],"study_design_scores_gemma":[0.078441694,0.092117466,0.8204665,0.000044044307,0.0012905585,0.0013733367,0.0009812173,0.00022068546,0.00014809579,0.000035899044,0.0047452366,0.00013523358],"about_ca_topic_score_codex":0.00005922061,"about_ca_topic_score_gemma":0.000011049086,"teacher_disagreement_score":0.13574004,"about_ca_system_score_codex":0.00009656495,"about_ca_system_score_gemma":0.0007688653,"threshold_uncertainty_score":0.6485879},"labels":[],"label_agreement":null},{"id":"W2119478924","doi":"10.1200/jco.2007.14.5730","title":"Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Tolerability; Pharmacokinetics; Nausea; Pharmacodynamics; Vomiting; Dosing; Pharmacology; Gastroenterology; Internal medicine; Surrogate endpoint; Anorexia; Bioavailability; Adverse effect","score_opus":0.06328768577893447,"score_gpt":0.45033348611699864,"score_spread":0.3870458003380642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119478924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99848205,0.000107118685,0.00002447344,0.00015737381,0.00022914661,0.0004168579,0.000006429894,0.0000025090276,0.0005740216],"genre_scores_gemma":[0.99860126,0.00005864128,0.00083276926,0.00012882534,0.00021271389,0.000008729619,0.000008751399,0.000025549161,0.00012276319],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961729,0.0006263613,0.002029028,0.0003091009,0.0005409621,0.00032162358],"domain_scores_gemma":[0.9972192,0.0002430631,0.0012668363,0.00031631818,0.0006656481,0.00028890104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014566296,0.00017978837,0.0011987089,0.00016468152,0.00005078015,0.0000037146353,0.00036971385,0.00028514845,0.00007200427],"category_scores_gemma":[0.0018422604,0.00013446296,0.00022881886,0.0001806332,0.00038681724,0.000016592128,0.00012879867,0.0007483795,0.000012285845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1061537,0.16154851,0.56904495,0.00004497709,0.001065652,0.003248101,0.0010916218,0.0010152305,0.023508165,0.000007087603,0.0057254424,0.1275466],"study_design_scores_gemma":[0.12227876,0.5224824,0.33122507,0.00009827252,0.000114473216,0.0002327351,0.00053088844,0.000052287007,0.010161728,0.00005361871,0.012323589,0.00044616623],"about_ca_topic_score_codex":0.000049105638,"about_ca_topic_score_gemma":0.00027130052,"teacher_disagreement_score":0.3609339,"about_ca_system_score_codex":0.000075893746,"about_ca_system_score_gemma":0.001524843,"threshold_uncertainty_score":0.54832405},"labels":[],"label_agreement":null},{"id":"W2119607431","doi":"10.1200/jco.2010.34.1578","title":"Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":338,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Temsirolimus; PTEN; Medicine; Internal medicine; Endometrial cancer; Chemotherapy; Progressive disease; Oncology; PI3K/AKT/mTOR pathway; Tensin; Cancer; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Cancer research; Biology; Signal transduction; Discovery and development of mTOR inhibitors","score_opus":0.39245370379939326,"score_gpt":0.5550164775171609,"score_spread":0.16256277371776762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119607431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934293,0.000565952,0.00006122137,0.000121367775,0.004491978,0.0012104023,0.00002861915,0.0000019264482,0.00008922456],"genre_scores_gemma":[0.9959275,0.0010233449,0.00073284376,0.00019704783,0.0019773634,0.00008030499,9.561498e-7,0.000023229553,0.000037413403],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.98389614,0.0071712327,0.0076443264,0.00037749455,0.00057520164,0.0003356009],"domain_scores_gemma":[0.98676336,0.0039698877,0.008111633,0.00048076056,0.00042887303,0.0002454832],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03098215,0.00022833921,0.0032137963,0.00017613985,0.0000372972,0.000004596837,0.00075490214,0.00039156587,0.00013332444],"category_scores_gemma":[0.0256511,0.00011950485,0.0006899582,0.00041661866,0.00044974874,0.000011281181,0.00021032957,0.0008899557,3.8168392e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7786902,0.038263883,0.004945151,0.00002576919,0.0018656519,0.000063621075,0.00054772454,0.000022165183,0.003106995,0.0000065120093,0.0005227706,0.17193957],"study_design_scores_gemma":[0.42967084,0.55209935,0.005648987,0.00012115333,0.0008719961,0.000030046687,0.0006427934,0.000012205153,0.0016075677,0.00010874464,0.009004135,0.00018216451],"about_ca_topic_score_codex":0.0000963312,"about_ca_topic_score_gemma":0.00048573923,"teacher_disagreement_score":0.5138355,"about_ca_system_score_codex":0.0001015729,"about_ca_system_score_gemma":0.0029527922,"threshold_uncertainty_score":0.9978078},"labels":[],"label_agreement":null},{"id":"W2119607854","doi":"10.1200/jco.2011.35.4449","title":"Meta-Analysis of the Association Between Cigarette Smoking and Incidence of Hodgkin's Lymphoma","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Odds ratio; Incidence (geometry); Observational study; Meta-analysis; Hodgkin lymphoma; Publication bias; Confidence interval; Lymphoma; Gastroenterology","score_opus":0.41229916660991,"score_gpt":0.5045479278318453,"score_spread":0.09224876122193532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119607854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012262853,0.9859432,0.0000045143306,0.00053380994,0.0003468932,0.0002956884,0.00004788661,0.0000020099485,0.00056313525],"genre_scores_gemma":[0.052363142,0.9467552,0.00022174299,0.0002436088,0.00028984854,0.00000839176,0.0000058577166,0.00001463664,0.00009762001],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9922673,0.0015657281,0.0051249755,0.00022803484,0.0006482699,0.00016567927],"domain_scores_gemma":[0.9717254,0.010744024,0.016336406,0.00038318115,0.00063041743,0.00018058183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071482365,0.00024950405,0.013525327,0.0003284374,0.000028276654,0.000005325127,0.0003014874,0.0009771525,0.00010556738],"category_scores_gemma":[0.0044741887,0.00011770725,0.008573688,0.0005495668,0.00017349873,0.000053952852,0.00014462465,0.0005080058,9.2845045e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033715645,0.00044564466,0.12620732,0.0003899789,0.3660826,0.00003273806,0.000028411901,1.4850339e-7,1.5625687e-8,0.000040712228,0.0001569927,0.5065817],"study_design_scores_gemma":[0.00087285496,0.0010513561,0.22241777,0.0004960784,0.572962,0.000030088493,0.0000037935126,3.680149e-7,0.0000014541364,0.000034702465,0.20207858,0.00005095388],"about_ca_topic_score_codex":0.00007453633,"about_ca_topic_score_gemma":0.000029225592,"teacher_disagreement_score":0.50653076,"about_ca_system_score_codex":0.00047435827,"about_ca_system_score_gemma":0.0019828137,"threshold_uncertainty_score":0.9245643},"labels":[],"label_agreement":null},{"id":"W2119909547","doi":"10.1200/jco.2006.05.6879","title":"Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto; SickKids Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Procarbazine; Vinblastine; Vincristine; Bleomycin; Internal medicine; Radiation therapy; Lymphoma; Prednisone; Cumulative incidence; Chemotherapy; ABVD; Oncology; Surgery; Gastroenterology; Cyclophosphamide; Cohort","score_opus":0.018974925201696698,"score_gpt":0.3447616431269368,"score_spread":0.3257867179252401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119909547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635214,0.0006383408,0.000012804273,0.0016203204,0.00008589055,0.00030923882,0.0000014492553,0.000008298483,0.0009715095],"genre_scores_gemma":[0.99780226,0.00053382263,0.0007791544,0.00050090457,0.00029662665,0.000008073335,0.0000052794994,0.0000148114705,0.00005904548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983083,0.00023452446,0.00081951683,0.00021530686,0.00022519269,0.00019718226],"domain_scores_gemma":[0.9974624,0.0014825757,0.00061645015,0.000110107365,0.00010671055,0.00022175442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006673879,0.00016571075,0.0010468498,0.00012831078,0.000030902524,0.00001537278,0.000041366773,0.00024647682,0.0000073696606],"category_scores_gemma":[0.00025005557,0.00009426402,0.0000808689,0.00012811125,0.0001238856,0.00010093003,0.00001774581,0.00020671565,0.0000016207312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037081896,0.0020117408,0.87192005,0.0000156107,0.00031355178,0.0014846013,0.000014420555,0.000011364127,0.000014425832,0.00009042003,0.00008477834,0.12033084],"study_design_scores_gemma":[0.036471725,0.02112338,0.9398717,0.00017220632,0.00046649892,0.0013059662,0.000012368284,0.0000728962,0.000097715565,0.0001231363,0.00018619461,0.000096193995],"about_ca_topic_score_codex":0.00039553115,"about_ca_topic_score_gemma":0.00036617156,"teacher_disagreement_score":0.120234646,"about_ca_system_score_codex":0.000119133554,"about_ca_system_score_gemma":0.00039211655,"threshold_uncertainty_score":0.3843975},"labels":[],"label_agreement":null},{"id":"W2120028628","doi":"10.1200/jco.2006.08.2883","title":"Impact of Psychotherapeutic Support for Patients With Gastrointestinal Cancer Undergoing Surgery: 10-Year Survival Results of a Randomized Trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Randomized controlled trial; Surgery; Gastrointestinal cancer; Cancer surgery; Cancer; General surgery; Internal medicine; Colorectal cancer","score_opus":0.10923349328583819,"score_gpt":0.4796940923518055,"score_spread":0.3704605990659673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120028628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946582,0.00007146205,0.0014197809,0.00041992663,0.0016122303,0.00073958404,0.000051562834,0.000004676893,0.00102259],"genre_scores_gemma":[0.9970127,0.00017514458,0.0014414004,0.0001231247,0.0010317415,0.000006782363,0.000011663104,0.000024315192,0.00017317472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99451876,0.00047891636,0.003977156,0.0001773324,0.0005506741,0.000297161],"domain_scores_gemma":[0.9687955,0.024218602,0.0047577494,0.00018540214,0.0017360554,0.0003067095],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012308223,0.00016208868,0.0033660503,0.00020955042,0.000017148577,0.0000035871972,0.00011220434,0.00018033502,0.00022236815],"category_scores_gemma":[0.009678372,0.00009772416,0.0018238607,0.00019083609,0.00030666273,0.000060312188,0.000010819082,0.00038783957,6.2861363e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7892328,0.0017186962,0.19858529,0.00006232644,0.0008209976,0.000020189558,0.00007054531,0.0000063149955,0.000012806268,0.000009306743,0.0010485619,0.008412166],"study_design_scores_gemma":[0.7855207,0.051652074,0.16042808,0.00045053606,0.00082352903,0.000033932683,0.00007381402,0.0000060498687,0.000015199823,0.000064891196,0.00084800547,0.00008321755],"about_ca_topic_score_codex":0.0002247356,"about_ca_topic_score_gemma":0.0013580754,"teacher_disagreement_score":0.049933378,"about_ca_system_score_codex":0.00016256573,"about_ca_system_score_gemma":0.0053130826,"threshold_uncertainty_score":0.99866354},"labels":[],"label_agreement":null},{"id":"W2120050593","doi":"10.1200/jco.2005.04.2127","title":"Human Telomere Reverse Transcriptase Expression Predicts Progression and Survival in Pediatric Intracranial Ependymoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; Cancer Care Ontario; Eli Lilly and Company","keywords":"Telomerase reverse transcriptase; Telomerase; Medicine; Telomere; Immunohistochemistry; Oncology; Hazard ratio; Internal medicine; Reverse transcriptase; Multivariate analysis; Clinical significance; Pathology; Polymerase chain reaction; Biology; Gene","score_opus":0.06534907096962901,"score_gpt":0.4207864605762153,"score_spread":0.35543738960658633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120050593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392164,0.0011584789,0.000037957307,0.0018662149,0.001323584,0.00029010748,0.0000057734756,0.000020609556,0.0013756545],"genre_scores_gemma":[0.9925819,0.0007450048,0.0028462464,0.0003429524,0.0032934146,0.0000038015257,0.0000059708154,0.000023462339,0.00015725663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533,0.000621482,0.002765642,0.00032404865,0.00059228885,0.00036657296],"domain_scores_gemma":[0.9972286,0.00066487043,0.0012127176,0.0001953136,0.00023630829,0.000462151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030789846,0.0002168033,0.0014766143,0.00032766676,0.00007824713,0.000014447626,0.00017039255,0.00060272444,0.00010950555],"category_scores_gemma":[0.0011860329,0.00015558673,0.00028381005,0.00026645695,0.00024327775,0.00023211223,0.00004631537,0.0014439794,0.000005947653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048392145,0.0040691816,0.88917714,0.00020346297,0.000036141857,0.011489566,0.00014650403,0.000005060547,0.0071098916,0.00010913738,0.0069747,0.07584002],"study_design_scores_gemma":[0.013668738,0.0063912384,0.9693133,0.00026629894,0.00023383496,0.0011036559,0.0001149436,0.00003520326,0.00032604972,0.00037274082,0.008005346,0.0001686361],"about_ca_topic_score_codex":0.000053842818,"about_ca_topic_score_gemma":0.00013022218,"teacher_disagreement_score":0.08013619,"about_ca_system_score_codex":0.00008161964,"about_ca_system_score_gemma":0.0006551378,"threshold_uncertainty_score":0.6344643},"labels":[],"label_agreement":null},{"id":"W2120092553","doi":"10.1200/jco.2005.12.901","title":"Catheter-Associated Thrombosis: Thromboprophylaxis or Not?","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Thrombosis; Catheter; Surgery","score_opus":0.1962278270908793,"score_gpt":0.4680130366158854,"score_spread":0.27178520952500607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120092553","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043253597,0.00061666546,0.000022640146,0.93828934,0.007382768,0.00079642085,0.00003196575,0.00005904484,0.009547546],"genre_scores_gemma":[0.03850107,0.008099434,0.0018920928,0.9132352,0.032835547,0.000022044438,0.00004806162,0.00014639841,0.005220142],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99049354,0.00095972326,0.005753662,0.00058997335,0.001404162,0.0007989461],"domain_scores_gemma":[0.9880457,0.0031504359,0.006612705,0.0007108756,0.0010218145,0.00045845637],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004499275,0.000589193,0.007696524,0.00042698454,0.00009516695,0.000043560343,0.00071202393,0.0039171204,0.0023658238],"category_scores_gemma":[0.0055655977,0.00037482876,0.0025580218,0.00028451098,0.00041315838,0.00016394941,0.00022104927,0.008109426,0.00031020862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000814379,0.008514241,0.00044844765,0.00018013643,0.004277604,0.005397724,0.000108247375,0.0000024196208,0.000008963083,0.000010432763,0.9447248,0.035512626],"study_design_scores_gemma":[0.0054437015,0.043575633,0.048606034,0.00066648715,0.0038897735,0.00028436503,0.000044529672,0.000008261042,0.000014284859,0.00008303765,0.8970318,0.00035209683],"about_ca_topic_score_codex":0.00006897851,"about_ca_topic_score_gemma":0.00008907661,"teacher_disagreement_score":0.048157588,"about_ca_system_score_codex":0.0008027163,"about_ca_system_score_gemma":0.0034757415,"threshold_uncertainty_score":0.99987036},"labels":[],"label_agreement":null},{"id":"W2120380557","doi":"10.1200/jco.2007.15.2835","title":"Impact of Caring for a Child With Cancer on Parents’ Health-Related Quality of Life","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Hospital for Sick Children; Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Psychological intervention; Population; Pediatric cancer; Gerontology; Cancer; Pediatrics; Psychiatry; Environmental health; Internal medicine","score_opus":0.29279984806123704,"score_gpt":0.5472415087618822,"score_spread":0.2544416607006451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120380557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98536426,0.0013636672,0.00012723847,0.0115188705,0.0006267785,0.00040746274,0.000034461496,0.000008230164,0.0005490563],"genre_scores_gemma":[0.9948141,0.0009902258,0.0010400172,0.0023516163,0.000740959,0.0000054862267,0.000004123771,0.000024448615,0.000029012146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99259645,0.0007783084,0.0054639555,0.00021671868,0.0006539504,0.00029059523],"domain_scores_gemma":[0.9875482,0.0035102577,0.007234948,0.0002960487,0.0007730153,0.0006375809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054051136,0.00017763017,0.003597512,0.00014717148,0.000055691264,0.0000014699831,0.00018436456,0.00030835887,0.00008077499],"category_scores_gemma":[0.006888246,0.00011670753,0.0010855002,0.00020095482,0.00035391733,0.0000667049,0.000028299251,0.0009895193,9.983173e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03536889,0.003967185,0.940775,0.0003494181,0.0024715078,0.000034458928,0.0017199431,0.00069175684,0.000019535597,0.000073026684,0.002345121,0.01218418],"study_design_scores_gemma":[0.017719507,0.041204844,0.93896765,0.00077797286,0.00017204272,0.00015970282,0.00019667936,0.000038664166,0.00002476309,0.00005539458,0.000582946,0.00009982188],"about_ca_topic_score_codex":0.004089587,"about_ca_topic_score_gemma":0.00088712195,"teacher_disagreement_score":0.03723766,"about_ca_system_score_codex":0.00031621923,"about_ca_system_score_gemma":0.0067840577,"threshold_uncertainty_score":0.99884653},"labels":[],"label_agreement":null},{"id":"W2120452752","doi":"10.1200/jco.2005.04.4974","title":"Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":671,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Biology; Genetics; Gene; Wnt signaling pathway; Medulloblastoma; Gene expression profiling; Gene expression; Computational biology; Cancer research","score_opus":0.09624444758099715,"score_gpt":0.3896221595268317,"score_spread":0.29337771194583456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120452752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97529954,0.0031478333,0.017975897,0.0011529517,0.0019001241,0.00019815908,0.000019374,0.0000061470305,0.0002999788],"genre_scores_gemma":[0.9833378,0.0008987666,0.010383143,0.00048251793,0.0043681613,0.000013821108,0.000017230313,0.000028028973,0.0004705068],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740374,0.00024813434,0.001626557,0.0002720132,0.0001795742,0.00026999463],"domain_scores_gemma":[0.99705595,0.00057902926,0.0014973107,0.0002302461,0.00050890865,0.00012858283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014479603,0.00016883836,0.0007486402,0.00007666214,0.00012774106,0.000031403728,0.00029856505,0.00037378233,0.000014232768],"category_scores_gemma":[0.0009943999,0.00014335915,0.0005457995,0.00006165047,0.00022505395,0.0000074243085,0.000084225416,0.00025811253,0.000009727564],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002411579,0.0019121536,0.062114123,0.00006656865,0.0009959209,0.00021975604,0.00015786734,0.0021516683,0.7705072,0.00038481678,0.14188749,0.017190814],"study_design_scores_gemma":[0.0050645936,0.0053495597,0.28758532,0.000029524555,0.00023613339,0.00021843857,0.00041577095,0.000091081616,0.0439549,0.0027274175,0.65392977,0.00039749296],"about_ca_topic_score_codex":0.0000047763033,"about_ca_topic_score_gemma":0.00019129028,"teacher_disagreement_score":0.7265523,"about_ca_system_score_codex":0.000052164185,"about_ca_system_score_gemma":0.00040552698,"threshold_uncertainty_score":0.58460164},"labels":[],"label_agreement":null},{"id":"W2120480669","doi":"10.1200/jco.2005.11.910","title":"Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Epoetin alfa; Clinical trial; Intensive care medicine; Randomized controlled trial; Dosing; Anemia; Erythropoietin; Cancer; Internal medicine","score_opus":0.1051306805890304,"score_gpt":0.5235894771697811,"score_spread":0.4184587965807507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120480669","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09608454,0.031221043,0.001512401,0.8229276,0.0037270577,0.0048170886,0.011040273,0.000021299265,0.02864869],"genre_scores_gemma":[0.6662006,0.04670319,0.12388173,0.12156392,0.035368875,0.00008202218,0.00023277967,0.00055800145,0.0054089227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9806508,0.0028662481,0.01147432,0.00042955467,0.0041615134,0.0004175637],"domain_scores_gemma":[0.956933,0.010728488,0.021690462,0.00054575724,0.009793145,0.0003091107],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.037200246,0.00046736925,0.010033692,0.0004474781,0.000029104282,0.000007385218,0.00030165698,0.0018165204,0.00068274396],"category_scores_gemma":[0.054128855,0.0003059622,0.0017524476,0.00024240262,0.0017042591,0.00015871333,0.0001307257,0.0032401162,2.4217016e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034751013,0.006042207,0.0018544912,0.0039560464,0.0059589697,0.0018586972,0.00057244155,0.000016539178,0.00043622975,0.000049302336,0.79813665,0.1463674],"study_design_scores_gemma":[0.03228412,0.0574244,0.0002489533,0.0035477474,0.0058557517,0.00083898037,0.0002936716,0.000004967805,0.008045458,0.00032555612,0.8909218,0.00020861147],"about_ca_topic_score_codex":0.000042186894,"about_ca_topic_score_gemma":0.000033193213,"teacher_disagreement_score":0.7013637,"about_ca_system_score_codex":0.0007379104,"about_ca_system_score_gemma":0.021182157,"threshold_uncertainty_score":0.99993926},"labels":[],"label_agreement":null},{"id":"W2120570504","doi":"10.1200/jco.2011.41.4912","title":"Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Carboplatin; Oncology; Clinical trial; Internal medicine; Chemotherapy; Regimen; Chemotherapy regimen; Immunotherapy; Cancer; Cisplatin","score_opus":0.5324042848346785,"score_gpt":0.6436033727356764,"score_spread":0.11119908790099786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120570504","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009707223,0.0014444393,0.020520646,0.94338477,0.022297611,0.0018505523,0.00001659133,0.000019151665,0.0007590232],"genre_scores_gemma":[0.00033662538,0.00067066844,0.47102657,0.4968832,0.02694867,0.00006593138,0.000011008192,0.000099867095,0.0039574536],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9624094,0.025672799,0.009193615,0.0007513887,0.0008126152,0.0011601968],"domain_scores_gemma":[0.97516596,0.0179027,0.005148838,0.0006834364,0.00052566716,0.00057338056],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.0770725,0.000646494,0.008639244,0.0016396111,0.0000311326,0.000022890368,0.0009158681,0.005902021,0.0004178535],"category_scores_gemma":[0.01645374,0.00043316273,0.0018833727,0.0009345482,0.000099923185,0.00016572043,0.00021195602,0.011020065,0.000055573186],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33177385,0.0012635307,0.0008399187,0.00016090913,0.00080961036,0.005919257,0.00020202692,0.000002852582,0.00027125597,0.000004334436,0.3764628,0.28228968],"study_design_scores_gemma":[0.11003929,0.017466517,0.00972675,0.00051855046,0.00079205394,0.0019743666,0.0005565945,0.0000044431295,0.000102436476,0.00030431926,0.8580743,0.00044036002],"about_ca_topic_score_codex":0.00033677978,"about_ca_topic_score_gemma":0.0002722299,"teacher_disagreement_score":0.48161152,"about_ca_system_score_codex":0.0010814817,"about_ca_system_score_gemma":0.00585778,"threshold_uncertainty_score":0.999812},"labels":[],"label_agreement":null},{"id":"W2120629110","doi":"10.1200/jco.2004.06.024","title":"An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Megestrol acetate; Eicosapentaenoic acid; Cancer; Wasting; Internal medicine; Megestrol; Oncology; Fatty acid","score_opus":0.10014297653784564,"score_gpt":0.45862296779596184,"score_spread":0.3584799912581162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120629110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869289,0.00033426352,0.000018260018,0.0076880013,0.0036121316,0.0007400684,0.0006398182,0.0000049503806,0.000033618162],"genre_scores_gemma":[0.99429256,0.0014936731,0.0025523745,0.00079059834,0.00064346386,0.00009556703,0.000104866405,0.000015310128,0.0000115685025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975785,0.00008330144,0.0012404652,0.00020555106,0.0005270682,0.00036513704],"domain_scores_gemma":[0.99652237,0.00036368,0.0015090908,0.00006546059,0.0010078104,0.00053160527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041885654,0.00016973235,0.0009837362,0.00007502842,0.00012228523,0.0000070253977,0.000076929544,0.000111723304,0.00004888032],"category_scores_gemma":[0.00027707225,0.00012257391,0.00009452245,0.00016497412,0.00014268223,0.00014113897,0.000012149679,0.0002799495,4.6832834e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.063542776,0.0040247533,0.91375804,0.00013142276,0.0019591057,0.00006307704,0.00036777265,0.0017404893,0.000026990789,0.00018798021,0.0015146844,0.0126829175],"study_design_scores_gemma":[0.1640757,0.0404175,0.7516266,0.00034024613,0.0008483465,0.0000040027435,0.00018447793,0.00012460358,0.00011338803,0.00001887584,0.042089112,0.00015714199],"about_ca_topic_score_codex":0.031106189,"about_ca_topic_score_gemma":0.7615606,"teacher_disagreement_score":0.73045444,"about_ca_system_score_codex":0.0040083434,"about_ca_system_score_gemma":0.018237557,"threshold_uncertainty_score":0.9998151},"labels":[],"label_agreement":null},{"id":"W2120713475","doi":"10.1200/jco.2006.08.6652","title":"Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC; Ministerul Cercetării, Inovării şi Digitalizării; U.S. Department of Health and Human Services","keywords":"Oxaliplatin; Medicine; Neurotoxicity; Bolus (digestion); Adverse effect; Chemotherapy; Gastroenterology; Internal medicine; Surgery; Fluorouracil; Colorectal cancer; Toxicity; Anesthesia; Cancer","score_opus":0.07383472491052075,"score_gpt":0.44024600971462335,"score_spread":0.3664112848041026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120713475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984424,0.001962587,0.000064325985,0.01147011,0.00045268325,0.00066632015,0.000028343513,0.000012144886,0.0009194728],"genre_scores_gemma":[0.99096733,0.0038475685,0.0013558025,0.0020015053,0.00076650927,0.000020959373,0.0000031524348,0.00002102401,0.0010161684],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99769044,0.00011201887,0.0013146896,0.00029010003,0.00029473403,0.000298007],"domain_scores_gemma":[0.9954452,0.0027810216,0.0009525439,0.00010830125,0.00029822838,0.0004146842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014926812,0.0002127639,0.0018174938,0.000058430825,0.00015998996,0.000012056646,0.00007115192,0.000263631,0.00012997935],"category_scores_gemma":[0.00041043037,0.00013319483,0.00019281702,0.00007812229,0.00031794037,0.00007645,0.000062300314,0.00056040863,7.041653e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2524867,0.0026628172,0.27353942,0.000058122238,0.0016626145,0.0023668397,0.00077671814,0.0000040372033,0.0004956779,0.00019263312,0.0024787989,0.4632756],"study_design_scores_gemma":[0.066480085,0.09962529,0.6591524,0.00012393045,0.00059714913,0.00034105437,0.00040490375,0.00009584963,0.0005664319,0.00020984815,0.17221306,0.00019003049],"about_ca_topic_score_codex":0.00049705856,"about_ca_topic_score_gemma":0.001436553,"teacher_disagreement_score":0.4630856,"about_ca_system_score_codex":0.00017535225,"about_ca_system_score_gemma":0.00065954326,"threshold_uncertainty_score":0.54315275},"labels":[],"label_agreement":null},{"id":"W2120757327","doi":"10.1200/jco.2005.06.742","title":"Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Clinical trial; Cancer registry; Population; Colorectal cancer; Multivariate analysis; Comorbidity; Lung cancer; Breast cancer; Gerontology; Internal medicine; Demography","score_opus":0.14071159194020721,"score_gpt":0.4910309336649357,"score_spread":0.3503193417247285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120757327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987418,0.00013599938,0.000008964044,0.01076359,0.00058677397,0.00021714084,0.000014620373,0.0000011022071,0.0008538327],"genre_scores_gemma":[0.9944564,0.00024528202,0.002506338,0.0012034505,0.00029875236,0.000009084773,0.000008247062,0.00000657036,0.0012658417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719036,0.00012961931,0.0021258602,0.00012942121,0.0002596277,0.00016512307],"domain_scores_gemma":[0.99284744,0.0028084675,0.0034629998,0.00012352692,0.0005574442,0.00020008926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008324805,0.00009242929,0.00149672,0.00018466153,0.000011446812,0.0000022292973,0.000094565294,0.00017224038,0.00036153643],"category_scores_gemma":[0.0034827439,0.000064147374,0.0003982364,0.0001832369,0.000045545876,0.00009016403,0.000010300899,0.0003597779,4.6760192e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001983159,0.0019390301,0.78272253,0.000008005089,0.0020840282,0.00003217599,0.0002005563,0.00050285633,0.000004978557,0.0000018640008,0.0036719893,0.2068488],"study_design_scores_gemma":[0.0077434573,0.013286345,0.71963483,0.000035012996,0.0026722297,0.000004627589,0.000048116508,0.00026864352,0.000023169585,0.0000046569567,0.2562381,0.000040829596],"about_ca_topic_score_codex":0.93761647,"about_ca_topic_score_gemma":0.99960643,"teacher_disagreement_score":0.2525661,"about_ca_system_score_codex":0.0026828828,"about_ca_system_score_gemma":0.0120073985,"threshold_uncertainty_score":0.9935936},"labels":[],"label_agreement":null},{"id":"W2120866780","doi":"10.1200/jco.2006.24.18_suppl.4546","title":"Stage one seminoma: Evidence based guidelines for follow up","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Radiation therapy; Hazard ratio; Carboplatin; Prospective cohort study; Oncology; Internal medicine; Chemotherapy; Confidence interval; Cisplatin","score_opus":0.48933473988036413,"score_gpt":0.5637963916512998,"score_spread":0.07446165177093567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120866780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93705565,0.012490555,0.00884185,0.038498405,0.0019687882,0.00058378984,0.000023633045,0.00002470567,0.0005126389],"genre_scores_gemma":[0.93204063,0.00020049479,0.05882778,0.0046012565,0.0022060713,0.0000095480445,0.000007787801,0.000017492754,0.0020889167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718434,0.00012465352,0.0020194275,0.00016452571,0.0003164051,0.00019066279],"domain_scores_gemma":[0.9933107,0.0033801678,0.0014024328,0.00018494955,0.0014136045,0.00030813838],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017168401,0.00011597321,0.0010338491,0.00005352701,0.000034699333,0.000008328225,0.000105691295,0.00020885175,0.00011874421],"category_scores_gemma":[0.018483048,0.00007916437,0.0008197768,0.00007513251,0.00008190049,0.00009541959,0.000018498451,0.00023102957,0.000012376422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014055472,0.008154919,0.6702047,0.00024625854,0.00085251627,0.002017518,0.0000068555446,0.00018669125,0.0006066381,0.00040776224,0.09469449,0.20856617],"study_design_scores_gemma":[0.028371768,0.019299997,0.82255054,0.00079216977,0.00255404,0.00012896908,0.000022439848,0.0014022576,0.00025480604,0.0008809151,0.12359752,0.0001445792],"about_ca_topic_score_codex":0.00004421236,"about_ca_topic_score_gemma":0.000026628546,"teacher_disagreement_score":0.20842159,"about_ca_system_score_codex":0.00010462408,"about_ca_system_score_gemma":0.0019148681,"threshold_uncertainty_score":0.98978466},"labels":[],"label_agreement":null},{"id":"W2121015279","doi":"10.1200/jco.2010.31.5069","title":"Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Bone remodeling; Internal medicine; Cancer; Bone metastasis; Oncology; Postmenopausal women; Metastasis","score_opus":0.15434048097468273,"score_gpt":0.45973207693120066,"score_spread":0.30539159595651794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121015279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98803157,0.0013416167,0.00002211702,0.0072867246,0.0012202922,0.00062541553,0.00030539415,0.000010103604,0.0011567586],"genre_scores_gemma":[0.99220634,0.0010263339,0.0044738413,0.0015267935,0.00037879412,0.000018735655,0.000016095159,0.00002562158,0.00032743733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945082,0.00032132101,0.0041019586,0.0002530135,0.0003805514,0.00043496984],"domain_scores_gemma":[0.9942344,0.0012814146,0.0028255233,0.00023822223,0.0007926281,0.0006278213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036357683,0.00018992015,0.0022122704,0.00025915517,0.00002639975,0.0000021994144,0.00011596242,0.00047907754,0.00014028736],"category_scores_gemma":[0.0024698623,0.00013179357,0.00035778282,0.00024956232,0.0001751786,0.000118880824,0.000037038255,0.00078014476,0.000007794876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33068082,0.020085916,0.36207056,0.0004162828,0.002338604,0.0035540564,0.0005861346,0.000005990131,0.00097594294,0.00017884318,0.01692396,0.26218286],"study_design_scores_gemma":[0.05474822,0.029268336,0.9009587,0.00031451974,0.0011445356,0.0012374321,0.00004643364,0.00002879415,0.00039611183,0.000479957,0.011267569,0.00010938317],"about_ca_topic_score_codex":0.0006450617,"about_ca_topic_score_gemma":0.0007536148,"teacher_disagreement_score":0.53888816,"about_ca_system_score_codex":0.00024921808,"about_ca_system_score_gemma":0.0026146572,"threshold_uncertainty_score":0.5374386},"labels":[],"label_agreement":null},{"id":"W2121029321","doi":"10.1200/jco.2001.19.3.785","title":"Application of a New Multinomial Phase II Stopping Rule Using Response and Early Progression","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Multinomial distribution; Medicine; Early stopping; Clinical trial; Statistics; Internal medicine; Artificial intelligence; Computer science; Mathematics","score_opus":0.7528928351643551,"score_gpt":0.711611258546088,"score_spread":0.041281576618267146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121029321","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8059501,0.00007621749,0.19193432,0.001101289,0.00057988643,0.00027274626,0.0000030418903,0.000009413089,0.00007296171],"genre_scores_gemma":[0.3653945,0.000054704822,0.63342375,0.00009656443,0.0009730441,0.0000017956559,6.1145656e-8,0.00001473594,0.000040850835],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9915284,0.002883554,0.004735449,0.000235576,0.0003944083,0.00022262028],"domain_scores_gemma":[0.91066,0.08334935,0.0049032415,0.00025079833,0.0004045319,0.00043202142],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021908727,0.00014130138,0.0017998165,0.00012261276,0.00007399777,0.000010745647,0.00023862126,0.0005104237,0.000046989055],"category_scores_gemma":[0.2403882,0.00010578828,0.00032090893,0.00017095776,0.0003312894,0.00011360124,0.000151327,0.0007853756,0.0000016765567],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033842053,0.0029304777,0.00818358,0.000034607765,0.00013177651,0.0001003619,0.00023312004,0.000005502174,0.007553675,0.0013155667,0.00032010663,0.94534916],"study_design_scores_gemma":[0.0627458,0.059163973,0.07009294,0.00082153926,0.0013220401,0.0006001463,0.00020527138,0.0072171288,0.0017652876,0.7692914,0.026253182,0.00052125665],"about_ca_topic_score_codex":0.000013569006,"about_ca_topic_score_gemma":0.0000016305522,"teacher_disagreement_score":0.9448279,"about_ca_system_score_codex":0.00007095722,"about_ca_system_score_gemma":0.00078716164,"threshold_uncertainty_score":0.76601034},"labels":[],"label_agreement":null},{"id":"W2121110745","doi":"10.1200/jco.2007.12.6953","title":"Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Queen's University; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Foundation; GlaxoSmithKline","keywords":"Medicine; Vinorelbine; ERCC1; Cisplatin; Chemotherapy; Oncology; Lung cancer; Internal medicine; Predictive marker; Cancer research; Adjuvant; Gene; Cancer; Biology; DNA repair; Genetics","score_opus":0.043245589385202635,"score_gpt":0.42744431765898633,"score_spread":0.3841987282737837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121110745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862341,0.0073218904,0.0033361737,0.0015821642,0.0004131874,0.00074315415,0.000008349311,0.000003007165,0.00035795363],"genre_scores_gemma":[0.99107796,0.0031206438,0.004228584,0.0010841988,0.00041423296,0.000011501184,0.0000012597576,0.000020123223,0.00004150675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977102,0.00006286313,0.0016655601,0.00018483095,0.00016085278,0.0002156927],"domain_scores_gemma":[0.9965249,0.0015388324,0.0012831506,0.000098224584,0.00031260584,0.0002423338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002687672,0.000113512804,0.0010974489,0.00012242878,0.0000136016915,0.0000022982483,0.00006249625,0.00035135564,0.000015198599],"category_scores_gemma":[0.0013811195,0.00008846632,0.00015797418,0.00011041034,0.00018976926,0.00003964792,0.000022852206,0.00062128296,1.041522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012085435,0.0009826905,0.90940714,0.0002620803,0.0003126338,0.0004902927,0.00045509217,0.000029255478,0.0050490154,0.00001460852,0.00082086236,0.07009087],"study_design_scores_gemma":[0.023849908,0.012029209,0.9562473,0.00049280084,0.00055902917,0.00026729036,0.00014985136,0.0014424939,0.00211527,0.00014536407,0.0026017793,0.000099659526],"about_ca_topic_score_codex":0.000017538618,"about_ca_topic_score_gemma":0.00023566795,"teacher_disagreement_score":0.06999121,"about_ca_system_score_codex":0.00013463301,"about_ca_system_score_gemma":0.0010033022,"threshold_uncertainty_score":0.36075518},"labels":[],"label_agreement":null},{"id":"W2121120744","doi":"10.1200/jco.2003.02.098","title":"Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Interim analysis; Pancreatic cancer; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Cancer; Bay; Adenocarcinoma","score_opus":0.29717185771441457,"score_gpt":0.5606920091573374,"score_spread":0.26352015144292285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121120744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933055,0.00046529833,0.000033279415,0.0016891673,0.002011044,0.0021395078,0.000063025866,0.000001087749,0.0002920738],"genre_scores_gemma":[0.997533,0.00015223424,0.0016764547,0.0001731716,0.000293126,0.000042005922,0.0000026709863,0.000012992546,0.00011429703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9849805,0.005515111,0.0073583345,0.0002185511,0.0016424903,0.00028499492],"domain_scores_gemma":[0.97356087,0.016032916,0.008332438,0.00038334288,0.0014663588,0.00022408462],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019134842,0.00019657554,0.004494951,0.00011863354,0.000059963953,0.0000023485195,0.00047705483,0.00025463372,0.00018301149],"category_scores_gemma":[0.06446907,0.000079334706,0.0006949276,0.0004888657,0.0013122512,0.00009395834,0.00009167496,0.0011920058,1.7808648e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5170864,0.009158072,0.46513838,0.00012915276,0.0022422944,0.000022902275,0.00014002761,0.0001018753,0.00012412765,0.0003469427,0.00087918865,0.0046306713],"study_design_scores_gemma":[0.48082465,0.045339506,0.46480808,0.00048806632,0.0031658395,0.000015852187,0.00045709425,0.00017690606,0.00045397482,0.00011741619,0.0040404657,0.00011214582],"about_ca_topic_score_codex":0.003788475,"about_ca_topic_score_gemma":0.04646735,"teacher_disagreement_score":0.045334224,"about_ca_system_score_codex":0.0003092858,"about_ca_system_score_gemma":0.018685238,"threshold_uncertainty_score":0.9868779},"labels":[],"label_agreement":null},{"id":"W2121304497","doi":"10.1200/jco.2013.49.9202","title":"Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Princess Margaret Cancer Foundation","keywords":"Medicine; Nausea; Hepatocellular carcinoma; Quality of life (healthcare); Internal medicine; Radiation therapy; Refractory (planetary science); Palliative care; Brief Pain Inventory; Cancer; Carcinoma; Liver cancer; Abdominal pain; Performance status; Gastroenterology; Surgery; Physical therapy; Chronic pain","score_opus":0.25207967621690947,"score_gpt":0.44189034673089056,"score_spread":0.1898106705139811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121304497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032253,0.0044331364,0.0006363589,0.0026637872,0.00042652164,0.0013777432,0.000014323853,0.000004691086,0.000120896046],"genre_scores_gemma":[0.98217136,0.0017861566,0.01437363,0.00050347595,0.0009380532,0.00004208652,0.0000079005595,0.00001806301,0.00015928422],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99712116,0.0003798521,0.0018943842,0.00017514653,0.00023450777,0.00019493474],"domain_scores_gemma":[0.9950904,0.0023984755,0.0014462225,0.00014760565,0.00056095055,0.00035634998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018718479,0.00015868504,0.0017756548,0.00012543474,0.0000493961,0.0000070484725,0.000091054266,0.00028116177,0.00028302878],"category_scores_gemma":[0.0012880173,0.000104409264,0.00076516764,0.000083192914,0.00022734857,0.00011168854,0.00002682309,0.00030896685,0.0000026658188],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13523383,0.01840639,0.4762352,0.00013450968,0.0023981342,0.00057923817,0.0004983979,1.5877585e-7,0.002655676,0.00020192163,0.005758225,0.35789832],"study_design_scores_gemma":[0.5160141,0.37625986,0.027620122,0.00008389019,0.0026168786,0.00011494547,0.00014236794,0.0051033353,0.0054228683,0.0005102813,0.065914996,0.00019631944],"about_ca_topic_score_codex":0.000045991877,"about_ca_topic_score_gemma":0.0000022889785,"teacher_disagreement_score":0.44861507,"about_ca_system_score_codex":0.00005737215,"about_ca_system_score_gemma":0.00062939216,"threshold_uncertainty_score":0.4257686},"labels":[],"label_agreement":null},{"id":"W2121313610","doi":"10.1200/jco.2007.15.2090","title":"Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Tolerability; Medicine; Oncology; Pharmacology; Internal medicine; Adverse effect","score_opus":0.25207811009186776,"score_gpt":0.4719691598207691,"score_spread":0.21989104972890133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121313610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779587,0.0019166353,0.00014986446,0.018382648,0.000859711,0.00025828808,0.0000050869785,0.0000031000434,0.00046599287],"genre_scores_gemma":[0.99425066,0.0023103212,0.0016233659,0.00046026337,0.0011290546,0.000012272017,6.862642e-7,0.0000042566785,0.00020909648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981813,0.00010830641,0.0012619589,0.00010011905,0.00023847424,0.000109872475],"domain_scores_gemma":[0.9953505,0.0026665656,0.0011835683,0.0000988881,0.0006156732,0.00008483696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008586531,0.00008060227,0.0010346441,0.000028401373,0.00009321902,0.0000015487414,0.00010273936,0.00011436302,0.00007091071],"category_scores_gemma":[0.002085312,0.000036193378,0.0005705791,0.000049812938,0.00057412207,0.00003236922,0.000028706752,0.00023311384,5.840757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022242246,0.0034573341,0.7815592,0.000074796575,0.0016310711,0.00015606395,0.0004132859,0.0000098542105,0.00024301905,0.00024990665,0.019328378,0.17063484],"study_design_scores_gemma":[0.0034820407,0.013944544,0.9682643,0.000027010601,0.00040304702,0.0003251119,0.00018798154,0.000077513265,0.00010428972,0.00048726672,0.0126610305,0.000035870053],"about_ca_topic_score_codex":0.000024313058,"about_ca_topic_score_gemma":0.000020911024,"teacher_disagreement_score":0.1867051,"about_ca_system_score_codex":0.00004476888,"about_ca_system_score_gemma":0.00083635934,"threshold_uncertainty_score":0.24964641},"labels":[],"label_agreement":null},{"id":"W2121380279","doi":"10.1200/jco.2014.56.5119","title":"Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Takeda Oncology","keywords":"Prednisone; Medicine; Placebo; Clinical endpoint; Adverse effect; Nausea; Internal medicine; Prostate cancer; Gastroenterology; Urology; Clinical trial; Cancer; Pathology","score_opus":0.2686344685691638,"score_gpt":0.4731839606446225,"score_spread":0.2045494920754587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121380279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675954,0.0011183625,0.00013688237,0.0017558411,0.00052477134,0.009596733,0.000026585127,0.000024053466,0.00005720594],"genre_scores_gemma":[0.99546885,0.000247313,0.001900725,0.00020413016,0.00038292905,0.0012649277,0.000048006004,0.00006721184,0.0004159025],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99346143,0.0010151871,0.0028977639,0.000529767,0.00137975,0.00071611325],"domain_scores_gemma":[0.9942464,0.0010565068,0.002460378,0.0003394825,0.0010854881,0.0008116996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034484232,0.0004791725,0.003697604,0.00036403947,0.00010886477,0.00012092435,0.00023480556,0.00024305898,0.00011831353],"category_scores_gemma":[0.0003595906,0.00024028259,0.0003378041,0.00033990238,0.00081311923,0.00045526502,0.000052945463,0.0011670963,0.0000033397166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93394345,0.012310278,0.044589665,0.00016947587,0.0022495403,0.0020615614,0.0015050368,0.0010185882,0.000019424806,5.1815346e-7,0.00007272186,0.0020597642],"study_design_scores_gemma":[0.94224346,0.044748202,0.007705941,0.0009159527,0.0012124212,0.000034266755,0.00035657024,0.0018865678,0.00035378776,0.0000037569052,0.00026689892,0.00027218217],"about_ca_topic_score_codex":0.0001944869,"about_ca_topic_score_gemma":0.0011444988,"teacher_disagreement_score":0.036883723,"about_ca_system_score_codex":0.0011572653,"about_ca_system_score_gemma":0.009056306,"threshold_uncertainty_score":0.9965614},"labels":[],"label_agreement":null},{"id":"W2121381269","doi":"10.1200/jco.2009.26.8797","title":"Energetics in Colorectal and Prostate Cancer","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canada Research Chairs","keywords":"Medicine; Prostate cancer; Colorectal cancer; Oncology; Prostate; Cancer; Internal medicine; Disease; Obesity","score_opus":0.15776965240626467,"score_gpt":0.5395849213723142,"score_spread":0.3818152689660495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121381269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015476746,0.9812266,8.2637044e-8,0.0011388331,0.0013266637,0.00039891535,0.000019108262,0.0000024711835,0.00041058005],"genre_scores_gemma":[0.00055841333,0.99754673,0.00032300764,0.00036747407,0.0010413093,0.000038002123,0.0000068809495,0.000021655584,0.00009654172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967536,0.00029670238,0.0023949672,0.00018857053,0.00019338945,0.0001727875],"domain_scores_gemma":[0.99555224,0.0018332476,0.0019038381,0.00009787517,0.00017903742,0.00043377027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011460402,0.0001985023,0.004186916,0.00014966192,0.000012941784,0.000007216407,0.00008509327,0.0007815212,0.0000814336],"category_scores_gemma":[0.0010255444,0.00011435783,0.00075523776,0.00009675669,0.00016295764,0.000033883018,0.000050515908,0.0016000745,0.0000066658176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031574885,0.0016530809,0.017050799,0.0012443459,0.0005011293,0.0018823099,0.000029513156,9.356913e-8,8.9415465e-8,0.000020458245,0.00067081046,0.97663164],"study_design_scores_gemma":[0.0031461394,0.004220174,0.020030763,0.0051855347,0.004052893,0.00033041617,0.000005794466,0.0000011121449,3.9667688e-7,0.000025917028,0.9629099,0.00009096441],"about_ca_topic_score_codex":0.000019968698,"about_ca_topic_score_gemma":0.000075758784,"teacher_disagreement_score":0.9765407,"about_ca_system_score_codex":0.00017533833,"about_ca_system_score_gemma":0.004411953,"threshold_uncertainty_score":0.78266156},"labels":[],"label_agreement":null},{"id":"W2121394047","doi":"10.1200/jco.2009.26.9944","title":"Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of Ottawa; Princess Margaret Cancer Centre; University Health Network","funders":"Fujirebio US; Princess Margaret Hospital Foundation; American Society of Clinical Oncology","keywords":"Mesothelin; Osteopontin; Mesothelioma; Medicine; Oncology; Peptide; Cancer research; Pathology; Internal medicine; Biology; Biochemistry","score_opus":0.03306109072823992,"score_gpt":0.39797110046021805,"score_spread":0.3649100097319781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121394047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913695,0.00028158593,0.0000012250109,0.005171617,0.0005137081,0.000119776276,0.0000035904898,0.0000033729445,0.0025356156],"genre_scores_gemma":[0.99576545,0.0002731693,0.0015547471,0.00074092374,0.000104827486,0.0000014145326,0.0000015539699,0.000011693984,0.0015462266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739605,0.00036471785,0.0016884501,0.00013367597,0.0002725082,0.00014461225],"domain_scores_gemma":[0.99651897,0.002116972,0.0008674599,0.0001255364,0.00007870785,0.0002923587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003813025,0.00009626031,0.0007868982,0.000164662,0.000016922195,0.0000029697064,0.000089483074,0.00027466478,0.00063467986],"category_scores_gemma":[0.003997648,0.00006774664,0.00023803177,0.000092792856,0.00034196122,0.00007211689,0.000048101538,0.000609048,0.000025117231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.094924316,0.0021000989,0.8399486,0.00003260604,0.00021419136,0.000863152,0.00009476136,0.000008760794,0.040448107,0.00024545993,0.0018866308,0.01923333],"study_design_scores_gemma":[0.0064547583,0.009275416,0.965463,0.000104185914,0.0001567274,0.0004521115,0.00014236792,0.00005343706,0.00045896985,0.0009797795,0.01639437,0.000064911124],"about_ca_topic_score_codex":0.00003503172,"about_ca_topic_score_gemma":0.000032585594,"teacher_disagreement_score":0.12551437,"about_ca_system_score_codex":0.000037204936,"about_ca_system_score_gemma":0.00060778373,"threshold_uncertainty_score":0.69492996},"labels":[],"label_agreement":null},{"id":"W2121434969","doi":"10.1200/jco.2008.17.9945","title":"Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Colorectal cancer; Insulin; Internal medicine; Insulin-like growth factor; Oncology; Cancer; Growth factor; Endocrinology; Cancer research; Receptor","score_opus":0.07164483247721544,"score_gpt":0.37682903184162925,"score_spread":0.3051841993644138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121434969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958448,0.00085329,0.000020478252,0.0016078907,0.00087450875,0.00045177163,0.00002102771,0.0000097959655,0.000316468],"genre_scores_gemma":[0.99317855,0.0032862395,0.0005076797,0.0025668787,0.00039214458,0.000009980146,0.000005704664,0.000027068498,0.000025749812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957417,0.00050829333,0.002401725,0.00029110356,0.00068317883,0.00037397668],"domain_scores_gemma":[0.9956598,0.0014918377,0.0014898704,0.00019665703,0.0006844573,0.00047732738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013885867,0.00026201343,0.0016954917,0.00018242373,0.000100707875,0.000009984941,0.00021885637,0.00035663185,0.0000725319],"category_scores_gemma":[0.0021170727,0.00014042674,0.0002552406,0.00037771155,0.00071011874,0.00025338173,0.00007760799,0.0016663226,0.000007495891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005073976,0.001779018,0.9818076,0.000028395814,0.00040135285,0.00033981947,0.0005158678,0.0000026356645,0.000019855006,0.000016528318,0.0007210882,0.009293887],"study_design_scores_gemma":[0.014189143,0.0118597355,0.9708495,0.00006312491,0.00027181883,0.00012741622,0.0000814515,0.000027418047,0.000044261098,0.00008507922,0.0022458695,0.00015517241],"about_ca_topic_score_codex":0.00021937673,"about_ca_topic_score_gemma":0.00018503451,"teacher_disagreement_score":0.010958066,"about_ca_system_score_codex":0.00017525438,"about_ca_system_score_gemma":0.0016000025,"threshold_uncertainty_score":0.7239435},"labels":[],"label_agreement":null},{"id":"W2121555447","doi":"10.1200/jco.2004.09.070","title":"Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion–Negative Early Breast Cancers Without Adjuvant Systemic Therapies","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine; Systemic therapy; Vascular invasion; Cohort; Population; Adjuvant; Breast cancer; Lymphatic system; Lymphovascular invasion; Cancer; Pathology; Metastasis","score_opus":0.026620606416973985,"score_gpt":0.3520101388439822,"score_spread":0.3253895324270082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121555447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977117,0.0007333654,0.00017815565,0.0008098022,0.00022732369,0.00025362294,0.000028408238,0.0000031392653,0.00005445785],"genre_scores_gemma":[0.995217,0.0008986398,0.003395472,0.00031214018,0.00013084435,0.000017525874,0.0000048738293,0.0000175446,0.0000059535664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761677,0.000349148,0.0013442117,0.00025147593,0.00025566228,0.00018272216],"domain_scores_gemma":[0.997572,0.00050181686,0.001292117,0.00018250156,0.00033508855,0.00011646338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009004437,0.00019082525,0.0012832811,0.00009792232,0.000041280746,0.000006789344,0.00014840797,0.00025195745,0.0000066106195],"category_scores_gemma":[0.00091355137,0.00013410661,0.00027771184,0.0000983277,0.0002867622,0.000017039323,0.000052479427,0.00018318587,9.4068514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009783155,0.00034179742,0.9947295,0.000026414624,0.0009316145,0.000014252097,0.00025663208,0.00058360357,0.0002870176,0.000052294978,0.0000054563857,0.0017930814],"study_design_scores_gemma":[0.010768894,0.0013899964,0.9860634,0.00020407481,0.00019743126,0.000038968043,0.00047223963,0.000007924388,0.0003481131,0.00036515898,0.00001698833,0.00012676766],"about_ca_topic_score_codex":0.0017755956,"about_ca_topic_score_gemma":0.0011788948,"teacher_disagreement_score":0.009790579,"about_ca_system_score_codex":0.00025139385,"about_ca_system_score_gemma":0.0011109824,"threshold_uncertainty_score":0.5468709},"labels":[],"label_agreement":null},{"id":"W2121601348","doi":"10.1200/jco.2011.36.6385","title":"Testing for Discordance at Metastatic Relapse: Does It Matter?","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.379901934180019,"score_gpt":0.5724041181961178,"score_spread":0.1925021840160988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121601348","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008415815,0.0012704182,0.00030343822,0.9768909,0.007657237,0.00086145865,0.00006221053,0.000013831491,0.0045246957],"genre_scores_gemma":[0.0021515896,0.00038133728,0.058751814,0.8606025,0.0493299,0.000085799904,0.000038252743,0.00017755665,0.028481245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99180156,0.0010774365,0.004633018,0.0004325543,0.0011269522,0.0009285079],"domain_scores_gemma":[0.9672566,0.026199412,0.0043154364,0.0005575166,0.0010957714,0.00057524804],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0089098,0.00036523514,0.003702276,0.0002527072,0.000090676236,0.000024062683,0.00060021126,0.0013172631,0.00168611],"category_scores_gemma":[0.021812467,0.0002147712,0.0011812751,0.00018732222,0.00052313396,0.0001383677,0.00023244823,0.007853501,0.00034768367],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013133168,0.00035443,0.030101957,0.0010806207,0.0006408284,0.0029074112,0.000042997686,0.0000012542239,0.000067305155,0.0000027560864,0.93264014,0.030846983],"study_design_scores_gemma":[0.0040983954,0.008406089,0.011781555,0.0010491044,0.0013259045,0.0021705078,0.000027541477,0.000016677484,0.000019815707,0.00043951249,0.9704445,0.00022038727],"about_ca_topic_score_codex":0.000022009615,"about_ca_topic_score_gemma":0.000032544867,"teacher_disagreement_score":0.11628839,"about_ca_system_score_codex":0.0009672064,"about_ca_system_score_gemma":0.0036383031,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W2121664617","doi":"10.1200/jco.2009.27.15_suppl.e16058","title":"A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Tolerability; Internal medicine; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Progressive disease; Nausea; Adverse effect; Phases of clinical research; Oncology; Cancer; Paclitaxel; Urology; Gastroenterology; Surgery; Bladder cancer; Urothelial carcinoma","score_opus":0.08418983834576428,"score_gpt":0.4412281365829351,"score_spread":0.3570382982371708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121664617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966698,0.00021123906,0.000006124332,0.00080810353,0.00040318706,0.0007836445,0.000007413274,0.000005428957,0.0011050266],"genre_scores_gemma":[0.99708146,0.00007039201,0.00038440496,0.0019407173,0.0003489328,0.000004945793,0.0000030534463,0.000016456255,0.00014961536],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99696094,0.0002589427,0.0019082087,0.00021129008,0.00044524428,0.00021536698],"domain_scores_gemma":[0.9976435,0.0002491621,0.0012383217,0.00021766136,0.00039202438,0.00025936402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006437561,0.00017689851,0.0014885595,0.00015662197,0.000029785278,0.00000326787,0.0001338391,0.00016465997,0.00029317563],"category_scores_gemma":[0.00029067774,0.00011052054,0.00021135581,0.00017446055,0.000076784745,0.00010085743,0.000018510094,0.00051261345,0.0000029507446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1120475,0.16119191,0.22468469,0.000008712746,0.00038847205,0.00070937094,0.0010547331,0.000013266882,0.00084445946,0.0000035654145,0.00014418355,0.49890915],"study_design_scores_gemma":[0.12722214,0.4634945,0.40653142,0.000039347728,0.00013127316,0.000024837389,0.00012909342,0.0000019089123,0.00046621857,0.000046461082,0.0018522075,0.000060568756],"about_ca_topic_score_codex":0.00002529331,"about_ca_topic_score_gemma":0.000060532762,"teacher_disagreement_score":0.49884856,"about_ca_system_score_codex":0.0001430488,"about_ca_system_score_gemma":0.0008871959,"threshold_uncertainty_score":0.45068967},"labels":[],"label_agreement":null},{"id":"W2121667178","doi":"10.1200/jco.2013.49.2173","title":"Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Selenium in Biological Systems","field":"Nursing","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Placebo; Lung cancer; Interim analysis; Internal medicine; Gastroenterology; Surgery; Randomized controlled trial; Pathology","score_opus":0.07085758795798644,"score_gpt":0.43254760242794477,"score_spread":0.3616900144699583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121667178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584664,0.00010635025,0.00022513243,0.0008387465,0.00349377,0.008727852,0.000012969926,0.0000126907,0.0007358678],"genre_scores_gemma":[0.9969577,0.00009848553,0.000932003,0.00016855022,0.0010862221,0.0004427269,0.000041298532,0.000028098391,0.000244877],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9887961,0.003215978,0.0065340823,0.0003675484,0.0006317839,0.000454491],"domain_scores_gemma":[0.98528713,0.0055122287,0.007611547,0.00023237715,0.0010931112,0.00026358152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009323788,0.0002961703,0.00387915,0.00030186062,0.000057805766,0.00003437677,0.00039048053,0.00070109183,0.00086194894],"category_scores_gemma":[0.0016372517,0.00018701349,0.00074785145,0.00032474307,0.00021075745,0.00033510206,0.000055550576,0.0010984327,0.000008233398],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9688339,0.005944022,0.018574923,0.0000741916,0.00045593662,0.000004006067,0.0001735046,0.00014800865,0.0009448248,0.000005043016,0.0011332942,0.0037082934],"study_design_scores_gemma":[0.9759531,0.01722812,0.002572668,0.00013692565,0.00066690624,0.000002333743,0.00014403628,0.0011269661,0.0016352308,0.000040252344,0.00029377127,0.00019968668],"about_ca_topic_score_codex":0.0010084228,"about_ca_topic_score_gemma":0.00046627966,"teacher_disagreement_score":0.016002256,"about_ca_system_score_codex":0.00044911273,"about_ca_system_score_gemma":0.00048524857,"threshold_uncertainty_score":0.9437736},"labels":[],"label_agreement":null},{"id":"W2121708973","doi":"10.1200/jco.2004.09.059","title":"Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1015,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Stage (stratigraphy); Adjuvant therapy; Internal medicine; Proportional hazards model; Colorectal cancer; Levamisole; Multivariate analysis; Oncology; Adjuvant; Survival analysis; Cancer; Radiation therapy; Surgery","score_opus":0.09422666171105251,"score_gpt":0.4446239429035839,"score_spread":0.35039728119253144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121708973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733699,0.010470644,0.00010971759,0.015197536,0.00021321428,0.00043979622,0.000118689364,0.00000640936,0.00007410366],"genre_scores_gemma":[0.98745805,0.009480352,0.0011190557,0.0015600154,0.00015631285,0.000023218527,0.000010944685,0.000014889135,0.0001771399],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977448,0.00015152796,0.0012975772,0.00026030437,0.00031796098,0.00022785194],"domain_scores_gemma":[0.99563926,0.0018423394,0.0014769073,0.00014184954,0.00049292046,0.0004067124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012855083,0.00017743683,0.0025158178,0.00020544669,0.00006608431,0.0000088321385,0.000090329166,0.00032319495,0.00007404591],"category_scores_gemma":[0.000763545,0.00012109586,0.0005514693,0.00031492586,0.00024028949,0.00008001426,0.0000363855,0.00035559258,1.0929266e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053708386,0.0042190277,0.21136595,0.00007960123,0.011510259,0.00021096226,0.00031361842,0.00043995917,0.002270369,0.00013052173,0.001107149,0.7146442],"study_design_scores_gemma":[0.12079066,0.116699375,0.6901672,0.00034395175,0.012814505,0.000053672968,0.0002131395,0.0014290771,0.0059977975,0.0002236535,0.05092428,0.00034271393],"about_ca_topic_score_codex":0.00014408286,"about_ca_topic_score_gemma":0.0004185015,"teacher_disagreement_score":0.71430147,"about_ca_system_score_codex":0.0002379243,"about_ca_system_score_gemma":0.0009418098,"threshold_uncertainty_score":0.4938146},"labels":[],"label_agreement":null},{"id":"W2121862214","doi":"10.1200/jco.2008.18.4127","title":"Effectiveness of a Letter Notification Program for Women With Early-Stage Breast Cancer Eligible for Extended Adjuvant Letrozole","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Letrozole; Medicine; Tamoxifen; Breast cancer; Medical prescription; Internal medicine; Population; Oncology; Adjuvant therapy; Gynecology; Cancer; Cohort; Hormone therapy","score_opus":0.03640479592426852,"score_gpt":0.42992095533196656,"score_spread":0.393516159407698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121862214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927699,0.0003096524,0.0030914762,0.0026364936,0.00028373906,0.00073346606,0.000086568674,0.000004973892,0.00008371791],"genre_scores_gemma":[0.99407107,0.00016327377,0.004265374,0.00042996404,0.0006801558,0.00027893978,0.000010718872,0.000014824478,0.00008570645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99850357,0.0001503315,0.0007585878,0.0002238807,0.00012148769,0.00024214166],"domain_scores_gemma":[0.9978074,0.00034506005,0.0009659516,0.00015411335,0.00062605337,0.000101444435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011597989,0.00013537375,0.0007461968,0.00004116036,0.000039737228,0.00000672114,0.00014404922,0.00019334261,0.0000037525454],"category_scores_gemma":[0.00019182534,0.00009181387,0.00023189212,0.00006015491,0.00013371334,0.000009728242,0.000018446928,0.00012258984,2.9436862e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12141574,0.0067441855,0.061075397,0.00038762199,0.00245587,0.000017024566,0.0001635503,0.00028035234,0.07929794,0.00019277884,0.0032487693,0.7247208],"study_design_scores_gemma":[0.010838509,0.026483549,0.9132558,0.00008793465,0.00019523788,0.000030994834,0.00004833289,0.000013980147,0.01552469,0.00017500886,0.033204805,0.00014116633],"about_ca_topic_score_codex":0.000013788596,"about_ca_topic_score_gemma":0.000019499128,"teacher_disagreement_score":0.8521804,"about_ca_system_score_codex":0.00009163873,"about_ca_system_score_gemma":0.00046993452,"threshold_uncertainty_score":0.3744061},"labels":[],"label_agreement":null},{"id":"W2121911732","doi":"10.1200/jco.2014.56.1894","title":"Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":788,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Body mass index; Obesity; Internal medicine; Weight loss; Cancer; Population; Proportional hazards model; Survival analysis; Gastroenterology","score_opus":0.1828963210853511,"score_gpt":0.5328451820138901,"score_spread":0.349948860928539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121911732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649704,0.0007085267,0.0014267816,0.029197736,0.0030343328,0.00022627912,0.000014043479,0.000004270752,0.0004176389],"genre_scores_gemma":[0.99386376,0.0025889538,0.00024153764,0.0011367117,0.0020392165,0.000010893137,0.0000021739409,0.000009707223,0.00010703028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794424,0.00020180372,0.0014593411,0.00008753054,0.00018288137,0.00012418594],"domain_scores_gemma":[0.9843138,0.013031108,0.0018158531,0.00013430767,0.00057516084,0.00012976766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027460176,0.00006756565,0.0008287744,0.00003955067,0.000033206077,0.000003640085,0.00012880359,0.0002222994,0.0001428651],"category_scores_gemma":[0.0156024005,0.000036882426,0.00037829514,0.00007672526,0.00018421435,0.000035325313,0.000013816334,0.00037043123,0.000001871748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029312398,0.0012475039,0.5548039,0.000054006727,0.0005963808,0.000011667105,0.00012886977,0.000011676269,0.0008802181,0.0006922314,0.038950846,0.39969146],"study_design_scores_gemma":[0.0037786458,0.003964258,0.7708985,0.00007881171,0.00052959425,0.000009506819,0.000023569908,0.0006438935,0.00009566204,0.00043007015,0.21951428,0.0000332017],"about_ca_topic_score_codex":0.00008972496,"about_ca_topic_score_gemma":0.00022530039,"teacher_disagreement_score":0.39965826,"about_ca_system_score_codex":0.0001083136,"about_ca_system_score_gemma":0.00066412735,"threshold_uncertainty_score":0.9926896},"labels":[],"label_agreement":null},{"id":"W2121917721","doi":"10.1200/jco.2008.21.3033","title":"Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":261,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Interior Health","funders":"","keywords":"Medicine; Internal medicine; Pneumonitis; Oncology; Everolimus; Metastatic breast cancer; Breast cancer; Regimen; Hormonal therapy; Radiation therapy; Cancer; Lung","score_opus":0.1722342794960939,"score_gpt":0.5339236751883928,"score_spread":0.36168939569229885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121917721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953842,0.0010601414,0.00044146812,0.000352896,0.0017421683,0.0009293451,0.00003004103,0.0000043922355,0.000055345834],"genre_scores_gemma":[0.99610376,0.00055698596,0.0017778118,0.00046387958,0.0010345062,0.000018720055,0.000014719935,0.000021812504,0.000007824603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9842339,0.0071808333,0.0072284774,0.00045366483,0.0005437274,0.000359387],"domain_scores_gemma":[0.98979205,0.0026277981,0.0062308954,0.00034763076,0.0006849639,0.0003166793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027207715,0.00029406376,0.004662006,0.00017452195,0.000051809027,0.000013587145,0.0005097371,0.0003263329,0.00004557197],"category_scores_gemma":[0.008295591,0.00020120191,0.00088223134,0.00020969278,0.00040325074,0.000022832437,0.00011540677,0.0010461265,0.0000011465522],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52753776,0.022972636,0.29154384,0.000016784259,0.0014826139,0.000042601278,0.000074119474,0.00037356635,0.000303686,0.000021904032,0.00029639236,0.15533412],"study_design_scores_gemma":[0.74231666,0.0728327,0.18198012,0.0002462214,0.0011189084,0.000019943755,0.00008512257,0.00020771674,0.000114270624,0.00022341331,0.00057114894,0.0002837892],"about_ca_topic_score_codex":0.000041198116,"about_ca_topic_score_gemma":0.00020037027,"teacher_disagreement_score":0.2147789,"about_ca_system_score_codex":0.00009133355,"about_ca_system_score_gemma":0.0011906689,"threshold_uncertainty_score":0.99311966},"labels":[],"label_agreement":null},{"id":"W2122002540","doi":"10.1200/jco.2010.32.5936","title":"High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Breast cancer; Randomized controlled trial; Internal medicine; Metastatic breast cancer; Hematopoietic stem cell transplantation; Transplantation; Cancer; Surgery","score_opus":0.12877287299218423,"score_gpt":0.4248921680176607,"score_spread":0.2961192950254765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122002540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913897,0.005770879,0.0005277265,0.0012188194,0.00042462966,0.00043830485,0.000040682862,0.0000032334322,0.00018601259],"genre_scores_gemma":[0.9716634,0.024292951,0.0033814833,0.0004158892,0.00016351421,0.00003680266,0.000005219505,0.0000186409,0.000022095133],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946927,0.001941739,0.002766082,0.00021653264,0.00019467008,0.00018831533],"domain_scores_gemma":[0.9950541,0.0013741961,0.0030431866,0.00016552371,0.00025815956,0.000104816325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048120525,0.00019964318,0.0032169314,0.000083092076,0.000018310971,0.0000037016036,0.00018608777,0.00021299209,0.00009365494],"category_scores_gemma":[0.00021109114,0.00012148453,0.000580025,0.000108519576,0.0003175345,0.000012470789,0.000018328066,0.00022878582,0.0000012800512],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79805285,0.0059797033,0.027293323,0.0005200124,0.005279887,0.0004074504,0.0017512282,0.00016136235,0.0033932065,0.00030374207,0.00040195667,0.15645525],"study_design_scores_gemma":[0.7058532,0.009003133,0.24994272,0.00054060435,0.004443738,0.0012000231,0.00058790506,0.000013730219,0.026363509,0.0010072092,0.0005850251,0.0004591814],"about_ca_topic_score_codex":0.00029032514,"about_ca_topic_score_gemma":0.00033931748,"teacher_disagreement_score":0.2226494,"about_ca_system_score_codex":0.000042506515,"about_ca_system_score_gemma":0.000777486,"threshold_uncertainty_score":0.49539953},"labels":[],"label_agreement":null},{"id":"W2122003737","doi":"10.1200/jco.2008.18.0406","title":"Circulating 25-Hydroxyvitamin D, <i>VDR</i> Polymorphisms, and Survival in Advanced Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"FokI; Calcitriol receptor; Medicine; Internal medicine; Hazard ratio; Vitamin D and neurology; Gastroenterology; Haplotype; Lung cancer; Oncology; Proportional hazards model; Survival analysis; Genotype; Polymorphism (computer science); Biology; Confidence interval; Genetics","score_opus":0.09419965999098208,"score_gpt":0.4478745595091091,"score_spread":0.35367489951812703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122003737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98476595,0.0052488702,0.00007247037,0.005052639,0.00090508716,0.00028779986,0.0000027328963,0.000008250005,0.0036561775],"genre_scores_gemma":[0.98565984,0.009130051,0.0024422568,0.0009932434,0.0009786905,0.00001134637,8.37172e-7,0.000025396877,0.0007583663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961532,0.00043910983,0.002139475,0.00028571446,0.00051268487,0.00046981516],"domain_scores_gemma":[0.994989,0.0029268821,0.0010470193,0.00018508485,0.00038440636,0.00046760787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003233529,0.00019072204,0.001851628,0.0002243394,0.000095875956,0.000005509558,0.00017048795,0.0003311549,0.0000521745],"category_scores_gemma":[0.0043190364,0.00014334654,0.0002827607,0.00026232158,0.00042011065,0.00012748103,0.00016821672,0.0016523865,0.000004047463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037378556,0.0008848704,0.95880413,0.00011089764,0.00020827317,0.006227792,0.00045407875,0.00006650432,0.0039255284,0.000005794312,0.0014301079,0.027508244],"study_design_scores_gemma":[0.013446002,0.0032610495,0.97753346,0.00028890758,0.00015392754,0.00088624755,0.00033361735,0.0007173583,0.00017961707,0.000024321384,0.0030334513,0.00014201169],"about_ca_topic_score_codex":0.00011741867,"about_ca_topic_score_gemma":0.00020103448,"teacher_disagreement_score":0.027366232,"about_ca_system_score_codex":0.0002576861,"about_ca_system_score_gemma":0.0017342033,"threshold_uncertainty_score":0.7178889},"labels":[],"label_agreement":null},{"id":"W2122073186","doi":"10.1200/jco.2002.20.6.1449","title":"Effect of Soy Phytoestrogens on Hot Flashes in Postmenopausal Women With Breast Cancer: A Randomized, Controlled Clinical Trial","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phytoestrogen effects and research","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Hot flash; Placebo; Breast cancer; Menopause; Tamoxifen; Discontinuation; Randomized controlled trial; Vasomotor; Internal medicine; Phytoestrogens; Hormone replacement therapy (female-to-male); Cancer; Estrogen","score_opus":0.07177225374043522,"score_gpt":0.4766275680015032,"score_spread":0.40485531426106797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122073186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016917,0.0007047637,0.000004343482,0.0038088795,0.0012045761,0.0026978715,0.000010646142,0.000008506299,0.0013912733],"genre_scores_gemma":[0.9940251,0.0020332187,0.00013246485,0.0006451642,0.002805795,0.00014902375,7.4317074e-7,0.000031861695,0.00017662406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9853942,0.0075605367,0.0051787123,0.00034450003,0.0009254293,0.0005966357],"domain_scores_gemma":[0.96288717,0.032698512,0.002933331,0.00028944825,0.00045473498,0.00073677907],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029101279,0.00030935797,0.009887219,0.00032409516,0.00003550536,0.000011558216,0.0002614602,0.00058765995,0.00043112156],"category_scores_gemma":[0.0123444805,0.00014491698,0.0014155406,0.0002730849,0.0009648478,0.000082426915,0.00004732037,0.0023173753,0.000018925659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8860147,0.0069264653,0.015448127,0.000072115006,0.0024162966,0.0013728224,0.000049582,0.000028808208,0.00012003374,0.000015597814,0.00049368554,0.08704175],"study_design_scores_gemma":[0.76033676,0.22653604,0.010593341,0.00031542592,0.0008453123,0.00041315344,0.000020268064,0.00033647436,0.00006946869,0.00002137326,0.0004116519,0.000100747355],"about_ca_topic_score_codex":0.00002435641,"about_ca_topic_score_gemma":0.000016581525,"teacher_disagreement_score":0.21960957,"about_ca_system_score_codex":0.0002448995,"about_ca_system_score_gemma":0.001406065,"threshold_uncertainty_score":0.9999843},"labels":[],"label_agreement":null},{"id":"W2122074260","doi":"10.1200/jco.2010.31.0805","title":"Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Amphiregulin; Medicine; Internal medicine; Oncology; Transforming growth factor; Clinical trial; Growth factor; Cancer research; Endocrinology; Receptor","score_opus":0.18212409289285192,"score_gpt":0.4839667431214772,"score_spread":0.3018426502286253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122074260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615395,0.00037715916,0.0006560751,0.00090400793,0.0013592517,0.0003822286,0.000020726093,0.0000069166276,0.00013970367],"genre_scores_gemma":[0.99132884,0.00017879013,0.005267154,0.0004654713,0.0026350608,0.000012014352,0.0000060787734,0.000029501713,0.00007707201],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99191093,0.0020508051,0.0049840864,0.00042132425,0.00028468034,0.0003481575],"domain_scores_gemma":[0.99412775,0.0027716379,0.0020778957,0.00024177703,0.0002510629,0.0005298505],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015118807,0.00023602511,0.001752591,0.00011725805,0.000051804607,0.00002715937,0.00041569615,0.0012454176,0.00008264672],"category_scores_gemma":[0.031274684,0.000181495,0.0007346958,0.00008831647,0.000461298,0.0000218457,0.00009221461,0.001497707,0.0000060247216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007594636,0.002918718,0.1387486,0.00007260995,0.0005835245,0.00025703287,0.00009721876,0.000005625469,0.4497866,0.00032094505,0.00059220457,0.39902228],"study_design_scores_gemma":[0.034972824,0.02043423,0.71036685,0.00027818084,0.00046292,0.0004325318,0.00014917216,0.00011871486,0.09000501,0.0026114488,0.1392029,0.0009652028],"about_ca_topic_score_codex":0.000008555778,"about_ca_topic_score_gemma":0.0002696428,"teacher_disagreement_score":0.57161826,"about_ca_system_score_codex":0.00002011701,"about_ca_system_score_gemma":0.0012727594,"threshold_uncertainty_score":0.9768853},"labels":[],"label_agreement":null},{"id":"W2122122462","doi":"10.1200/jco.2012.48.1275","title":"Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Eli Lilly and Company; Université de Montréal; Amgen","keywords":"Medicine; Breast cancer; Internal medicine; Taxane; Anthracycline; Chemotherapy; Cyclophosphamide; Docetaxel; Oncology; Gemcitabine; Paclitaxel; Cancer; Gastroenterology","score_opus":0.06138173237493252,"score_gpt":0.4004361819848379,"score_spread":0.3390544496099054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122122462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996973,0.00042616008,0.000057320136,0.007074598,0.000537506,0.00081075664,0.0000613603,0.000002623374,0.0010599743],"genre_scores_gemma":[0.9960646,0.00119501,0.0003251358,0.00096768065,0.0012601481,0.00013131766,0.000005442059,0.00001945715,0.00003117796],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99674,0.0004850088,0.0018726108,0.00030491347,0.00025470153,0.00034275342],"domain_scores_gemma":[0.9964187,0.0007468009,0.0018941308,0.0002607156,0.00052937964,0.00015028483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001687867,0.0002236526,0.0014523284,0.000057152298,0.00006768847,0.0000135941755,0.0003149411,0.00026152146,0.000037887658],"category_scores_gemma":[0.00036077385,0.00012715565,0.00023547796,0.0001358743,0.00048712618,0.000017713406,0.000093140494,0.0004990997,0.0000018911084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93691844,0.003248382,0.0031078444,0.0000046281616,0.0013406302,0.000031243293,0.00058858684,0.00007675883,0.00047999166,0.000010661351,0.0013485193,0.052844297],"study_design_scores_gemma":[0.85744184,0.029568216,0.10911886,0.00013284376,0.00017514313,0.0000946222,0.00083773275,0.000034044067,0.0006362419,0.00009536611,0.0016767794,0.00018830517],"about_ca_topic_score_codex":0.0007110633,"about_ca_topic_score_gemma":0.0007993439,"teacher_disagreement_score":0.10601101,"about_ca_system_score_codex":0.00017047737,"about_ca_system_score_gemma":0.0011809571,"threshold_uncertainty_score":0.5185257},"labels":[],"label_agreement":null},{"id":"W2122250312","doi":"10.1200/jco.2011.37.9990","title":"Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Medicine; Asymptomatic; Chemotherapy; Neuroblastoma; Stage (stratigraphy); Surgery; Disease; Internal medicine; Oncology","score_opus":0.08496636381527489,"score_gpt":0.41899630753716,"score_spread":0.3340299437218851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122250312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974502,0.000024196619,0.000037572885,0.00052772835,0.00032280985,0.0015209726,0.000089790454,0.000009926048,0.000016820384],"genre_scores_gemma":[0.9952076,0.00013318117,0.00370579,0.00044339264,0.00034016804,0.00003097045,0.00001406564,0.000053561824,0.00007127261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936907,0.0011153773,0.0035349466,0.0003097394,0.0008083815,0.00054083817],"domain_scores_gemma":[0.9822797,0.011468534,0.0040627816,0.0004184253,0.0010993934,0.00067117385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021416417,0.0002813135,0.0028063785,0.00039069468,0.000039334114,0.0000062980344,0.00016418162,0.00029425498,0.000040045248],"category_scores_gemma":[0.007533378,0.00014758276,0.00044428432,0.0004084737,0.00038610093,0.00028334136,0.000060064358,0.0008792611,0.0000026453838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2721508,0.03302577,0.67906547,0.000036521844,0.001151877,0.00035607113,0.00007547257,0.000002447664,0.000017921095,3.5790293e-7,0.0006812754,0.013435975],"study_design_scores_gemma":[0.056268267,0.16702436,0.7747311,0.00008702167,0.0007041712,0.00013511775,0.000027559156,0.0000032074306,0.00010153901,0.0000015733494,0.00081958587,0.00009647107],"about_ca_topic_score_codex":0.00006346592,"about_ca_topic_score_gemma":0.00014122532,"teacher_disagreement_score":0.21588255,"about_ca_system_score_codex":0.00013060648,"about_ca_system_score_gemma":0.0010819983,"threshold_uncertainty_score":0.90187013},"labels":[],"label_agreement":null},{"id":"W2122438981","doi":"10.1200/jco.2010.28.5064","title":"Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institute of General Medical Sciences; Breast Cancer Research Foundation; Pfizer; RIKEN; National Cancer Institute; National Institutes of Health; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Single-nucleotide polymorphism; Genome-wide association study; Medicine; Exemestane; Breast cancer; Oncology; Genotyping; Internal medicine; SNP; Case-control study; Genotype; Bioinformatics; Genetics; Cancer; Tamoxifen; Biology; Gene","score_opus":0.028621922924231272,"score_gpt":0.3728309143251146,"score_spread":0.34420899140088335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122438981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976638,0.00089788507,0.0000067296496,0.00030809152,0.00093797914,0.00008281182,0.0000059984404,0.0000014502955,0.00009524566],"genre_scores_gemma":[0.9972691,0.0015420645,0.0005077808,0.00012283506,0.00049623626,0.0000035373046,0.000008849065,0.000008798129,0.00004080798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981576,0.00028240154,0.0011293434,0.00014392067,0.00012191345,0.00016478042],"domain_scores_gemma":[0.9980665,0.0005666997,0.0009717895,0.000097712014,0.00015629666,0.00014101622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025828744,0.00009496356,0.0005283708,0.00008530543,0.00003652909,0.0000011110573,0.00008519927,0.00039981955,0.000009206736],"category_scores_gemma":[0.0038119438,0.00007592559,0.00020034202,0.00006567464,0.00016681278,0.000009665476,0.000096158255,0.0006172785,0.0000023452653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011920517,0.0009204029,0.6040241,0.000034211884,0.0010415904,0.000046621797,0.00023666612,0.0001594201,0.37971818,0.000015917862,0.00049998617,0.012110826],"study_design_scores_gemma":[0.0027171765,0.0025788648,0.9886967,0.000018029163,0.000064541455,0.000041015584,0.00022770547,0.000005133937,0.0009870204,0.00024721492,0.0043262076,0.00009041823],"about_ca_topic_score_codex":0.0000028836541,"about_ca_topic_score_gemma":0.000024187464,"teacher_disagreement_score":0.38467255,"about_ca_system_score_codex":0.000051145278,"about_ca_system_score_gemma":0.0003841346,"threshold_uncertainty_score":0.4563528},"labels":[],"label_agreement":null},{"id":"W2122566405","doi":"10.1200/jco.2013.53.3448","title":"Reality Check for Pemetrexed and Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Pemetrexed; Medicine; Lung cancer; Maintenance therapy; Oncology; Cancer; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.10795916909754573,"score_gpt":0.5124767683272579,"score_spread":0.40451759922971214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122566405","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0974703,0.004396404,0.00071469054,0.8903273,0.0024255512,0.0015393054,0.000047144276,0.00000898889,0.0030703184],"genre_scores_gemma":[0.05214809,0.023170296,0.010257844,0.89539874,0.011361383,0.0002506525,0.000070146285,0.00009872176,0.0072441576],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967919,0.00023368471,0.0020612665,0.0003414657,0.00022472847,0.000346983],"domain_scores_gemma":[0.99466807,0.0020719187,0.0022799722,0.0002349967,0.00055825175,0.00018678966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016658991,0.00025007047,0.0022397127,0.00016024186,0.000035372883,0.00001014436,0.00015274165,0.0010444763,0.00005305683],"category_scores_gemma":[0.0008040796,0.0001649909,0.0005080113,0.000101372556,0.0001307483,0.000056203033,0.000023153974,0.0020777138,0.000001092331],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031963997,0.0006710521,0.036367867,0.0004500084,0.0008227143,0.0006710909,0.00015715533,0.000014162239,0.000035999383,0.0000053975227,0.8232513,0.13435686],"study_design_scores_gemma":[0.02599844,0.007315753,0.049817313,0.0005138649,0.00094419805,0.00008141991,0.000033485994,0.00014097209,0.00001712237,0.00017903802,0.9147978,0.00016058036],"about_ca_topic_score_codex":0.00014352643,"about_ca_topic_score_gemma":0.00015222224,"teacher_disagreement_score":0.13419627,"about_ca_system_score_codex":0.00047311262,"about_ca_system_score_gemma":0.0026648343,"threshold_uncertainty_score":0.9026748},"labels":[],"label_agreement":null},{"id":"W2122813583","doi":"10.1200/jco.2007.14.1044","title":"Phase II Stopping Rules That Employ Response Rates and Early Progression","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Queen's University","funders":"Amgen","keywords":"Medicine; Clinical endpoint; Phases of clinical research; Type I and type II errors; Stage (stratigraphy); Statistics; End point; Clinical trial; Mathematics; Internal medicine","score_opus":0.8084065580692215,"score_gpt":0.704092019154906,"score_spread":0.10431453891431541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122813583","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98604035,0.00031430158,0.0075554713,0.0039079715,0.0015657664,0.0002630747,0.000008897248,0.000028528093,0.00031565357],"genre_scores_gemma":[0.4178419,0.00052129105,0.5800037,0.0004365255,0.0009801214,0.0000050102553,1.08202514e-7,0.000026835454,0.00018452843],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98755246,0.0068354825,0.004370837,0.00030754894,0.0005940904,0.00033955224],"domain_scores_gemma":[0.79223293,0.20337401,0.003227482,0.00026377407,0.00039237677,0.0005094273],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031167619,0.00021011116,0.0024225714,0.0001386439,0.00022287856,0.000019635412,0.00033972142,0.00064113666,0.00012366765],"category_scores_gemma":[0.4045291,0.00014033372,0.00046461532,0.00011764972,0.00092834403,0.0001808218,0.0002294343,0.0014088379,0.000011036371],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07251133,0.0149836205,0.038479194,0.00010539209,0.0006902796,0.0038905144,0.0011201955,6.2944827e-7,0.0011369896,0.008429011,0.015607906,0.84304494],"study_design_scores_gemma":[0.034579508,0.09376125,0.11111592,0.0005958753,0.00052379473,0.0011442658,0.0001447499,0.000070854905,0.0008872018,0.72182167,0.034911785,0.00044310678],"about_ca_topic_score_codex":0.0000018321986,"about_ca_topic_score_gemma":8.657828e-7,"teacher_disagreement_score":0.84260184,"about_ca_system_score_codex":0.000057741847,"about_ca_system_score_gemma":0.0007333238,"threshold_uncertainty_score":0.9976168},"labels":[],"label_agreement":null},{"id":"W2123027910","doi":"10.1200/jco.2012.43.8820","title":"Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":391,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"Science and Technology Commission of Shanghai Municipality; National Natural Science Foundation of China; Sanofi","keywords":"Medicine; Docetaxel; Induction chemotherapy; Chemotherapy; Surgery; Radiation therapy; Fluorouracil; Perioperative; Cisplatin; Radical surgery; Clinical endpoint; Urology; Internal medicine; Randomized controlled trial; Cancer","score_opus":0.11379933407924268,"score_gpt":0.42908215101970876,"score_spread":0.31528281694046606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123027910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892803,0.0043272157,0.00007222555,0.0017779445,0.003124657,0.000614705,0.0000030890117,0.000006767083,0.00079310033],"genre_scores_gemma":[0.9956951,0.0023502766,0.0005634793,0.00029232577,0.0008042075,0.000023029219,0.0000046163286,0.000023332075,0.00024361096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99482775,0.0009874589,0.0031080311,0.00020918992,0.00045072054,0.0004168493],"domain_scores_gemma":[0.9857952,0.011043183,0.0022416061,0.00016611516,0.0003786429,0.00037523694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010028582,0.00021821962,0.004776565,0.00021816586,0.000043611934,0.000005513504,0.000064493186,0.00035610466,0.00008026329],"category_scores_gemma":[0.005556929,0.00014292038,0.000539948,0.00019441184,0.0003424603,0.00027234008,0.000024724624,0.0007750468,0.000001035116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91447514,0.0030208055,0.011080266,0.00006152297,0.00021737041,0.00008482365,0.0003231467,0.0000018423053,0.0006338483,0.0000013675134,0.013403482,0.05669637],"study_design_scores_gemma":[0.97099763,0.01644454,0.003040292,0.0001122634,0.00044795446,0.00007211471,0.00036598428,0.000026276177,0.0014981552,0.0000065600775,0.006835433,0.000152822],"about_ca_topic_score_codex":0.00011538746,"about_ca_topic_score_gemma":0.00009251352,"teacher_disagreement_score":0.056543548,"about_ca_system_score_codex":0.00016208456,"about_ca_system_score_gemma":0.0016141267,"threshold_uncertainty_score":0.66525644},"labels":[],"label_agreement":null},{"id":"W2123133140","doi":"10.1200/jco.2003.11.126","title":"Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Sanofi","keywords":"Medicine; Oxaliplatin; Irinotecan; Fluorouracil; Internal medicine; Colorectal cancer; Gastroenterology; Interim analysis; Bolus (digestion); Oncology; Chemotherapy; Surgery; Cancer; Clinical trial","score_opus":0.06821672524614635,"score_gpt":0.421301268873285,"score_spread":0.35308454362713865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123133140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962791,0.0016406821,0.0000038571907,0.0003733655,0.00025907936,0.0011120093,0.000054454867,0.00000447434,0.0002729291],"genre_scores_gemma":[0.9979439,0.00068402744,0.0010378056,0.00008493537,0.00013834873,0.000062232284,0.0000037812902,0.000019165338,0.000025839447],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99652815,0.00043073288,0.0020351906,0.0003145482,0.0004288731,0.00026249242],"domain_scores_gemma":[0.9965268,0.0007253302,0.001707419,0.00014595987,0.00066379947,0.00023070576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053713,0.0002714481,0.0023834936,0.00013782202,0.000037383554,0.0000090608655,0.0000739983,0.00021081611,0.000057460093],"category_scores_gemma":[0.00048659067,0.00015538596,0.00014617681,0.00019838371,0.0006522878,0.00013240543,0.000043724227,0.000544913,1.3382287e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51669705,0.004949277,0.4402175,0.000031340078,0.00072353217,0.00018355432,0.0012209776,0.0000015975929,0.00007299802,0.0000027413869,0.000017447845,0.03588197],"study_design_scores_gemma":[0.3187706,0.1123901,0.56640965,0.0003029619,0.00027605068,0.000053097225,0.0003777724,0.000008446112,0.0006109278,0.000009441926,0.0006679326,0.00012306804],"about_ca_topic_score_codex":0.0002878081,"about_ca_topic_score_gemma":0.0012382807,"teacher_disagreement_score":0.19792649,"about_ca_system_score_codex":0.00016782967,"about_ca_system_score_gemma":0.0008639966,"threshold_uncertainty_score":0.63364553},"labels":[],"label_agreement":null},{"id":"W2123142347","doi":"10.1200/jco.2010.32.2750","title":"Randomized, Double-Blind, Controlled Trial of Early Endoscopic Ultrasound–Guided Celiac Plexus Neurolysis to Prevent Pain Progression in Patients With Newly Diagnosed, Painful, Inoperable Pancreatic Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Neurolysis; Morphine; Endoscopic ultrasound; Pancreatic cancer; Quality of life (healthcare); Randomized controlled trial; Brief Pain Inventory; Surgery; Cancer; Internal medicine; Gastroenterology; Chronic pain; Physical therapy","score_opus":0.07854023640213316,"score_gpt":0.4049433325750424,"score_spread":0.32640309617290925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123142347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055237,0.0002257072,0.00016666399,0.0007830296,0.0007935824,0.0068728663,0.000001486481,0.000010520645,0.0005937922],"genre_scores_gemma":[0.9940886,0.0006659773,0.0025894048,0.001370288,0.0004765338,0.00047696708,0.000003844355,0.000028024246,0.0003003496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991245,0.003276948,0.004051377,0.0003077181,0.0007342758,0.0003847378],"domain_scores_gemma":[0.9887788,0.0071414383,0.0027759485,0.0003221662,0.0005665394,0.00041510563],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013404735,0.00026726697,0.004173768,0.0003943951,0.000036480156,0.000014320676,0.00028225846,0.00029158426,0.00021760902],"category_scores_gemma":[0.010655259,0.00015576699,0.0006578367,0.00035730342,0.00018378987,0.00015132387,0.00005550384,0.0007289185,0.0000052649452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6219727,0.0051083276,0.3662214,0.00004162233,0.0006594083,0.000098057215,0.00025943987,0.000034786128,0.00000815113,0.000011750274,0.000439878,0.005144491],"study_design_scores_gemma":[0.8109537,0.029860198,0.15672731,0.000422202,0.0013450186,9.5295974e-7,0.000040533618,0.000042995667,0.000031787284,0.000045279616,0.00041773476,0.0001123062],"about_ca_topic_score_codex":0.00034328207,"about_ca_topic_score_gemma":0.00018418655,"teacher_disagreement_score":0.20949408,"about_ca_system_score_codex":0.00012346405,"about_ca_system_score_gemma":0.0008860625,"threshold_uncertainty_score":0.9976784},"labels":[],"label_agreement":null},{"id":"W2123235255","doi":"10.1200/jco.2010.33.6594","title":"Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Bortezomib; Follicular lymphoma; Internal medicine; Rituximab; Vincristine; Surgery; Prednisone; Gastroenterology; Cyclophosphamide; Lymphoma; Chemotherapy; Multiple myeloma","score_opus":0.21672619874835625,"score_gpt":0.5308915157766564,"score_spread":0.31416531702830014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123235255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899135,0.0013262887,0.00007087968,0.003609055,0.0012784676,0.003247917,0.00022728923,0.0000045405977,0.00032201805],"genre_scores_gemma":[0.9920358,0.0007034161,0.0012834514,0.0047747097,0.0006030459,0.0003334466,0.000008618435,0.000017230639,0.00024024902],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99390525,0.0011639445,0.0037914407,0.0003468582,0.00052042585,0.00027207087],"domain_scores_gemma":[0.9888744,0.006880722,0.0026202584,0.00018795293,0.0008866674,0.00055004086],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009952803,0.00022767346,0.0027514761,0.00007191095,0.00012584738,0.0000063411217,0.00017534682,0.00024161699,0.00010484066],"category_scores_gemma":[0.012457592,0.0001249287,0.0006170977,0.00015556498,0.00019458521,0.00010051157,0.000074444884,0.00022769152,6.9205527e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057566267,0.03978397,0.10935776,0.000057071633,0.008231993,0.0004822526,0.000996581,0.000009053361,0.00010076388,0.0001775068,0.083633244,0.69960356],"study_design_scores_gemma":[0.20193596,0.1452504,0.32487065,0.00023880492,0.0044310065,0.00010646868,0.00041004116,0.00008100716,0.0006255951,0.00014268045,0.3216707,0.00023666245],"about_ca_topic_score_codex":0.014562649,"about_ca_topic_score_gemma":0.037755232,"teacher_disagreement_score":0.69936687,"about_ca_system_score_codex":0.00061571825,"about_ca_system_score_gemma":0.004919022,"threshold_uncertainty_score":0.9958609},"labels":[],"label_agreement":null},{"id":"W2123296725","doi":"10.1200/jco.2003.11.007","title":"Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Prostate cancer; Medicine; Genotype; Odds ratio; Internal medicine; Single-nucleotide polymorphism; Kallikrein; Cancer; Confidence interval; Allele; Prostate-specific antigen; Prostate biopsy; Oncology; Gastroenterology; Gene; Biology; Genetics; Enzyme","score_opus":0.06490098750895404,"score_gpt":0.3748319168342408,"score_spread":0.30993092932528676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123296725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520177,0.0013120396,0.000039798862,0.001967759,0.0007579076,0.00030075246,0.0000031113436,0.000009264481,0.0004076071],"genre_scores_gemma":[0.99821925,0.00024443056,0.00027212308,0.00042978532,0.00024269253,0.000004962763,0.0000012097984,0.000022279748,0.00056324364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971219,0.00037787593,0.0017288642,0.00020862704,0.00033740752,0.0002253542],"domain_scores_gemma":[0.9969478,0.00050084945,0.0018962562,0.00015525632,0.00035114284,0.00014868675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001494438,0.00016594195,0.00091695774,0.00014562803,0.00012684753,0.000013402896,0.000109252906,0.00025043063,0.000060227427],"category_scores_gemma":[0.00042167975,0.000107466694,0.00018153485,0.00023715704,0.00039001624,0.00017591758,0.000026488511,0.00055023254,9.682058e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008840891,0.001468522,0.84055156,0.000062379564,0.00025429658,0.00007026269,0.000622812,0.00008548674,0.12794726,0.00066166307,0.00007641434,0.027315272],"study_design_scores_gemma":[0.0071647707,0.0055065085,0.9036396,0.00032578138,0.0002589719,0.00014022479,0.000114865186,0.00005229332,0.0788163,0.0018541222,0.0020004788,0.00012606237],"about_ca_topic_score_codex":0.00016248284,"about_ca_topic_score_gemma":0.0014102226,"teacher_disagreement_score":0.063088074,"about_ca_system_score_codex":0.00014434195,"about_ca_system_score_gemma":0.00046173364,"threshold_uncertainty_score":0.43823647},"labels":[],"label_agreement":null},{"id":"W2123346471","doi":"10.1200/jco.2008.20.4818","title":"Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; GiST; Internal medicine; Quartile; Imatinib; Gastroenterology; Trough Concentration; Pharmacokinetics; Population; Stromal cell; Confidence interval","score_opus":0.10979779294004183,"score_gpt":0.43447968040108365,"score_spread":0.3246818874610418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123346471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577796,0.000025516321,0.00022177897,0.0024771015,0.000112150854,0.0005862587,0.000017252616,0.000018542803,0.00076344755],"genre_scores_gemma":[0.9497619,0.00000755427,0.049364425,0.00048083172,0.00021343998,0.00000440386,0.000013123526,0.000029087403,0.00012518674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934005,0.00060982467,0.0036548898,0.00042191704,0.0011495616,0.0007632759],"domain_scores_gemma":[0.9915406,0.0028455881,0.0028069874,0.0003038379,0.0012890181,0.0012139423],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003137064,0.00035009964,0.0025721625,0.00031680835,0.000057535868,0.00002750404,0.00028652122,0.00011974609,0.0001564704],"category_scores_gemma":[0.0068961387,0.00020468609,0.0003675923,0.0004248611,0.00041328126,0.00020935587,0.000049905077,0.0027307975,0.000030627372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045688517,0.009572193,0.9093593,0.000024743442,0.0002127462,0.015829133,0.00001296959,0.00017907862,0.000004608469,0.000035284185,0.0002266737,0.01885478],"study_design_scores_gemma":[0.037886605,0.18488294,0.76897997,0.0015102044,0.0002469562,0.005783318,0.00010122385,0.00031803377,0.0000049138034,0.0001096106,0.00005200686,0.00012423006],"about_ca_topic_score_codex":0.000019029334,"about_ca_topic_score_gemma":0.00009952901,"teacher_disagreement_score":0.17531075,"about_ca_system_score_codex":0.00028610654,"about_ca_system_score_gemma":0.0021896653,"threshold_uncertainty_score":0.99956995},"labels":[],"label_agreement":null},{"id":"W2123526038","doi":"10.1200/jco.2010.29.2904","title":"Prognostic Significance of p16 <sup>INK4A</sup> and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; National Cancer Institute; Medical Research Council; National Institutes of Health","keywords":"Medicine; Internal medicine; Hazard ratio; Human papillomavirus; Oncology; Chemoradiotherapy; Cancer; Stage (stratigraphy); Radiation therapy; Head and neck cancer; Phases of clinical research; Chemotherapy; Cisplatin; Gastroenterology; Confidence interval","score_opus":0.08031107520891108,"score_gpt":0.45388413839355296,"score_spread":0.3735730631846419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123526038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659926,0.00018761161,0.0000014849111,0.0010760116,0.00050669874,0.000813729,0.000016741767,0.0000070077076,0.0007914785],"genre_scores_gemma":[0.9978021,0.0002899104,0.00018666947,0.0005510047,0.0010146338,0.000032285156,0.0000036877382,0.000021365893,0.00009834692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965826,0.00028958975,0.0021310926,0.00027686008,0.00042206844,0.00029777485],"domain_scores_gemma":[0.9963175,0.0014213994,0.0013151959,0.00017257813,0.00042451086,0.00034879014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012120473,0.00020897527,0.0024107965,0.00015907869,0.000057437675,0.000005391427,0.00011943631,0.00032546642,0.00013606294],"category_scores_gemma":[0.0013684006,0.00012896431,0.00019303901,0.00017847729,0.00047226396,0.000084995074,0.000030148864,0.0013324524,0.0000018585179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28568467,0.010676663,0.6038182,0.00006048408,0.0004359347,0.00035824373,0.00033460752,0.0000059897616,0.0007943868,0.000034045523,0.0009200642,0.096876726],"study_design_scores_gemma":[0.30277175,0.119215935,0.574191,0.00029105038,0.00045120198,0.000010821676,0.000055741264,0.000019229672,0.00024967486,0.000027914166,0.0025904851,0.00012523061],"about_ca_topic_score_codex":0.00017845676,"about_ca_topic_score_gemma":0.0004859,"teacher_disagreement_score":0.108539276,"about_ca_system_score_codex":0.00010281007,"about_ca_system_score_gemma":0.00092050096,"threshold_uncertainty_score":0.5788917},"labels":[],"label_agreement":null},{"id":"W2123532766","doi":"10.1200/jco.2007.13.5913","title":"Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Queen's University","funders":"National Cancer Institute; American Association for Cancer Research","keywords":"Medicine; Phase (matter); Oncology; Internal medicine","score_opus":0.8553149010815388,"score_gpt":0.7327753985139422,"score_spread":0.1225395025675966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123532766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015237933,0.9787604,0.0009232025,0.00014815615,0.001997105,0.002733004,0.0001522316,0.0000049525015,0.00004299076],"genre_scores_gemma":[0.00023045679,0.9239231,0.07532203,0.00015248226,0.0002721131,0.00004165358,0.0000029684059,0.000046681027,0.000008515395],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9528969,0.0155442385,0.029799405,0.00047375457,0.00091881515,0.0003669042],"domain_scores_gemma":[0.7612075,0.21372554,0.023415497,0.0005270762,0.0008391063,0.00028524097],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.035919085,0.00055501173,0.029057339,0.0005973131,0.000020898668,0.0000026863293,0.00082083413,0.0012780561,0.00010098101],"category_scores_gemma":[0.56651634,0.00036448592,0.0026763268,0.00074056577,0.0013051484,0.00009093404,0.0003351262,0.0020139003,3.919216e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019312112,0.030244147,0.00028075153,0.10249549,0.00524201,0.0008842291,0.00017491794,6.597249e-7,0.0000038780245,0.00064482435,0.0023534952,0.83836347],"study_design_scores_gemma":[0.46347043,0.08953789,0.00007045653,0.2943499,0.016053166,0.000112491376,0.00008967265,0.000009110455,0.000032012424,0.047932208,0.087489225,0.0008534061],"about_ca_topic_score_codex":0.0000074507284,"about_ca_topic_score_gemma":0.0000071372265,"teacher_disagreement_score":0.83751005,"about_ca_system_score_codex":0.00016457199,"about_ca_system_score_gemma":0.00236996,"threshold_uncertainty_score":0.99988073},"labels":[],"label_agreement":null},{"id":"W2123747786","doi":"10.1200/jco.2004.09.122","title":"Acetaminophen (Paracetamol) Improves Pain and Well-Being in People With Advanced Cancer Already Receiving a Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Acetaminophen; Placebo; Regimen; Opioid; Randomized controlled trial; Cancer pain; Anesthesia; Cancer; Internal medicine; Alternative medicine","score_opus":0.03814570226977681,"score_gpt":0.4066347349781842,"score_spread":0.3684890327084074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123747786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871195,0.000953863,0.00085966836,0.0040410804,0.0009017396,0.0036040246,5.272511e-7,0.000019759462,0.0024998698],"genre_scores_gemma":[0.98933595,0.0020122672,0.0042567668,0.0015509719,0.0014284588,0.0002362813,0.0000028493191,0.000039998304,0.0011364556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939995,0.0012231631,0.0032745036,0.00043823314,0.0005437384,0.0005208961],"domain_scores_gemma":[0.9896326,0.006715736,0.0027342802,0.00027166138,0.0002599228,0.00038581135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01797183,0.00033779268,0.0043094316,0.00032786193,0.00008664268,0.00006608706,0.00022553488,0.0004251127,0.00008001346],"category_scores_gemma":[0.0054691187,0.00021826272,0.0005813043,0.00026321583,0.00036338303,0.00039788886,0.000089018555,0.0013884435,0.0000035338703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9471726,0.0009546054,0.03560258,0.00008210199,0.0010544322,0.0003298673,0.0006454319,0.00072951743,0.000059148948,0.00021074744,0.00009110022,0.013067855],"study_design_scores_gemma":[0.963811,0.009747415,0.021487625,0.00050073676,0.0010784242,0.000023149434,0.000282455,0.0009653193,0.00001760211,0.0004829116,0.001375718,0.00022766963],"about_ca_topic_score_codex":0.00020546842,"about_ca_topic_score_gemma":0.00096020114,"teacher_disagreement_score":0.016638365,"about_ca_system_score_codex":0.0003571538,"about_ca_system_score_gemma":0.0015116881,"threshold_uncertainty_score":0.8900496},"labels":[],"label_agreement":null},{"id":"W2123808042","doi":"10.1200/jco.2009.23.2595","title":"Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":514,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Celgene; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Lomustine; Medicine; Internal medicine; Hazard ratio; Phases of clinical research; Adverse effect; Surgery; Progression-free survival; Gastroenterology; Toxicity; Chemotherapy; Confidence interval; Vincristine","score_opus":0.0935028942315687,"score_gpt":0.4665395752541077,"score_spread":0.373036681022539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123808042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971694,0.00013692018,0.000004707913,0.0013610551,0.000508784,0.0006690472,0.0000051177462,0.0000022764182,0.00014273451],"genre_scores_gemma":[0.99881953,0.00013248276,0.00051079085,0.000070711445,0.00043743802,0.000016007856,0.0000013376502,0.000008417704,0.0000032816681],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9966312,0.00035862564,0.0022999912,0.00014663074,0.0004052606,0.00015829579],"domain_scores_gemma":[0.9956399,0.0018408648,0.0017567812,0.00026132795,0.00033403354,0.00016704801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013552074,0.00014878582,0.001715106,0.00016815055,0.000018932844,0.0000034362465,0.00014566426,0.00013331693,0.00008291722],"category_scores_gemma":[0.0003755529,0.00006939466,0.00026228972,0.00020759022,0.00018907155,0.000034271146,0.000013830966,0.0004983855,0.0000012471091],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068490185,0.42890343,0.19306996,0.000023670123,0.0010951933,0.004063599,0.0032388486,0.000028424289,0.0011028223,0.00004108944,0.00032748777,0.2996153],"study_design_scores_gemma":[0.19583656,0.47235322,0.32141465,0.00009809196,0.0012941668,0.00054750947,0.0024271382,0.00010899044,0.0009067525,0.000023287635,0.004915641,0.00007399305],"about_ca_topic_score_codex":0.00007735405,"about_ca_topic_score_gemma":0.0022289713,"teacher_disagreement_score":0.2995413,"about_ca_system_score_codex":0.00006344011,"about_ca_system_score_gemma":0.00045427217,"threshold_uncertainty_score":0.28298318},"labels":[],"label_agreement":null},{"id":"W2123913599","doi":"10.1200/jco.2015.61.3745","title":"Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; HBsAg; Hepatitis B virus; Context (archaeology); Hepatitis B; Internal medicine; Cancer; Immunology; Oncology; Virus","score_opus":0.26140303622353483,"score_gpt":0.5382603169796878,"score_spread":0.27685728075615296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123913599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778396,0.0005812297,0.0017818898,0.014354733,0.0039942474,0.0010370187,0.00014113597,0.00002366713,0.00024649547],"genre_scores_gemma":[0.8198011,0.027085297,0.12966508,0.015552166,0.007557128,0.000067213405,0.000060082693,0.000094376366,0.00011758774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9885282,0.0015165249,0.007767654,0.00055605656,0.0010814936,0.0005500581],"domain_scores_gemma":[0.9796314,0.006432936,0.008367728,0.00036867644,0.0041049384,0.0010942878],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011350208,0.00034919058,0.005164134,0.00009630374,0.00010224489,0.000009880415,0.00038660804,0.00083715393,0.00007487423],"category_scores_gemma":[0.010606439,0.00022418422,0.0017948986,0.0002848485,0.0020645517,0.00022765632,0.00019852626,0.0020199872,0.0000089432715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013988417,0.0034176575,0.5382359,0.000021998198,0.0012700568,0.000020938378,0.000110030815,0.000006127086,0.0000011963772,0.000018807066,0.034454074,0.4084548],"study_design_scores_gemma":[0.020560278,0.08194712,0.5871658,0.00016242266,0.0002922871,0.000015990217,0.00006187859,0.0002696822,0.0000041306766,0.00010387125,0.3092815,0.00013505427],"about_ca_topic_score_codex":0.001607283,"about_ca_topic_score_gemma":0.003401356,"teacher_disagreement_score":0.40831974,"about_ca_system_score_codex":0.0002902342,"about_ca_system_score_gemma":0.006945711,"threshold_uncertainty_score":0.998684},"labels":[],"label_agreement":null},{"id":"W2123941186","doi":"10.1200/jco.2007.15.3726","title":"Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Clinical trial; Breast cancer; Cancer; Protocol (science); Poisson regression; Internal medicine; Confidence interval; Relative risk; Placebo; Multivariate analysis; Alternative medicine; Pathology; Population","score_opus":0.8357822805807328,"score_gpt":0.7434277142463088,"score_spread":0.09235456633442396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123941186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702294,0.0002058681,0.000019782627,0.011083492,0.0006560412,0.01753901,0.000064975095,0.0000060170664,0.00019543982],"genre_scores_gemma":[0.9820372,0.010168651,0.0004532321,0.0009948732,0.0012549273,0.0047877864,0.0000037473148,0.000026277377,0.00027331538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98452014,0.0039014153,0.009869503,0.00033834155,0.0011001761,0.0002704427],"domain_scores_gemma":[0.94170153,0.045831308,0.007955074,0.00028899737,0.0037133242,0.0005097883],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05530498,0.00015184384,0.0032551037,0.00016272055,0.000044648958,0.000007986516,0.00022441997,0.0012206219,0.00015187498],"category_scores_gemma":[0.12870035,0.00009648747,0.00043223565,0.00026289732,0.0010809466,0.0000873163,0.00008381288,0.0040947287,0.0000018703734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013350947,0.0021763558,0.8453777,0.00019560078,0.0004620152,0.0002990555,0.00019732951,0.0000030873534,0.00014552382,0.000040853847,0.00035811204,0.13739346],"study_design_scores_gemma":[0.016044907,0.008132425,0.9705709,0.0013476596,0.0003406312,0.00008169238,0.00013277674,0.00005598797,0.00007956809,0.00022090948,0.0029032696,0.00008925605],"about_ca_topic_score_codex":0.000100557096,"about_ca_topic_score_gemma":0.000730383,"teacher_disagreement_score":0.1373042,"about_ca_system_score_codex":0.00041205622,"about_ca_system_score_gemma":0.009148472,"threshold_uncertainty_score":0.99820286},"labels":[],"label_agreement":null},{"id":"W2123957608","doi":"10.1200/jco.2012.43.4589","title":"Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Michael Smith Health Research BC; Terry Fox Foundation; Canadian Institutes of Health Research; Cancer Research Society; American Society of Hematology; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Oncology; Dacarbazine; Hazard ratio; Proportional hazards model; Population; Bleomycin; Cohort; ABVD; Vinblastine; Chemotherapy; Confidence interval; Vincristine","score_opus":0.16696197063148124,"score_gpt":0.4494040615140494,"score_spread":0.2824420908825681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123957608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297684,0.0008237717,0.0016610989,0.002065068,0.0015280432,0.00031599577,0.000018161305,0.000021923095,0.0005891094],"genre_scores_gemma":[0.93911695,0.00030500634,0.057478875,0.0019052648,0.0010300282,0.000015067491,0.00001032979,0.000033139295,0.00010531534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950206,0.00055494194,0.0028091713,0.00028345597,0.0006660293,0.00066578],"domain_scores_gemma":[0.9946907,0.002185993,0.0016609062,0.000329165,0.00025752635,0.0008757118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002670078,0.00030599211,0.0020463057,0.00023025699,0.00006464393,0.000014923244,0.00019687976,0.0006447927,0.00006932218],"category_scores_gemma":[0.0018002011,0.00021015486,0.00069038157,0.00015841624,0.00020137081,0.0004209487,0.000103427614,0.0004934327,0.0000114328495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024571072,0.03274012,0.8247592,0.00012929727,0.00064630416,0.0025461775,0.00042847876,0.034521244,0.012331564,0.0007563044,0.0018005854,0.06476964],"study_design_scores_gemma":[0.09858061,0.010263338,0.7433166,0.00072069635,0.0009219882,0.0005097599,0.00022340976,0.10782713,0.024636596,0.00038905276,0.012032417,0.0005784439],"about_ca_topic_score_codex":0.000012508137,"about_ca_topic_score_gemma":0.00002092854,"teacher_disagreement_score":0.08144265,"about_ca_system_score_codex":0.00071622984,"about_ca_system_score_gemma":0.0023662443,"threshold_uncertainty_score":0.85698664},"labels":[],"label_agreement":null},{"id":"W2124050495","doi":"10.1200/jco.2011.37.8133","title":"Breast and Ovarian Cancer Risk and Risk Reduction in Jewish <i>BRCA1/2</i> Mutation Carriers","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institute for Health and Care Research; National Institute of General Medical Sciences; Cancer Research UK","keywords":"Medicine; Ovarian cancer; Breast cancer; Gynecology; Hazard ratio; Relative risk; Oncology; Population; Internal medicine; Cohort; Odds ratio; Cancer; Risk factor; Prospective cohort study; Cohort study; Obstetrics; Confidence interval; Environmental health","score_opus":0.0315842676298503,"score_gpt":0.38980872857195986,"score_spread":0.3582244609421096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124050495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911855,0.0058757914,0.00039024436,0.0007403109,0.0014820243,0.00008411551,0.00002606527,0.000001838971,0.0002140954],"genre_scores_gemma":[0.98378724,0.011703295,0.0024825654,0.00015083358,0.0018160818,0.0000069055245,0.0000040401083,0.000011893651,0.0000371637],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99820983,0.0005097036,0.00083424756,0.00016645607,0.000104375606,0.00017537679],"domain_scores_gemma":[0.99838895,0.00014887642,0.0009986082,0.00010367711,0.00016251662,0.00019738715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024934777,0.000093142524,0.00034320596,0.00006594684,0.00005231328,0.000009953498,0.00006874452,0.00034829235,0.000015116832],"category_scores_gemma":[0.0007863957,0.00008169886,0.00008220875,0.00008317893,0.00021176391,0.00002250255,0.000044179014,0.00046371264,7.3903266e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005573372,0.00013614971,0.48978996,0.0000061528094,0.00016592526,0.000005334224,0.00024785663,0.00019159251,0.0015588765,0.000015109885,0.0013659255,0.50595975],"study_design_scores_gemma":[0.004009058,0.0011913563,0.9566203,0.00002148483,0.0002773979,0.001223158,0.0004610906,0.00007779594,0.0013403842,0.0005383345,0.034083113,0.00015655738],"about_ca_topic_score_codex":0.0001738607,"about_ca_topic_score_gemma":0.00032618493,"teacher_disagreement_score":0.5058032,"about_ca_system_score_codex":0.00009297736,"about_ca_system_score_gemma":0.00054096,"threshold_uncertainty_score":0.33315828},"labels":[],"label_agreement":null},{"id":"W2124101267","doi":"10.1200/jco.2005.10.192","title":"Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":331,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Medicine; Warfarin; Placebo; Thrombosis; Venous thrombosis; Hazard ratio; Surgery; Randomized controlled trial; Incidence (geometry); Cancer; Confidence interval; Central venous catheter; Internal medicine; Anesthesia; Catheter; Atrial fibrillation","score_opus":0.11183986246240459,"score_gpt":0.4839757568944656,"score_spread":0.372135894432061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124101267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378055,0.0001375183,0.00008607155,0.00094783795,0.0007333582,0.0042336257,0.000015839962,0.0000034452205,0.00006177428],"genre_scores_gemma":[0.9987105,0.0003553342,0.00016053201,0.00021754655,0.00028802434,0.00016507498,0.0000031558347,0.000017223327,0.000082590625],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916505,0.003120024,0.0042912704,0.00015856088,0.000379643,0.00039997455],"domain_scores_gemma":[0.982405,0.010531462,0.0060699545,0.0001781029,0.0006959313,0.00011955985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008220418,0.00014838706,0.0034764989,0.00011762232,0.00012604057,0.000002646604,0.0002598509,0.00030823745,0.00012025419],"category_scores_gemma":[0.002933315,0.00007733509,0.00085903227,0.00015106253,0.00013651027,0.00008232791,0.000042147858,0.00077693677,9.11604e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68372166,0.041895807,0.24484189,0.000054593263,0.0027615023,0.0000015309311,0.009126343,0.0013457302,0.0000060992475,0.000014371099,0.00019832424,0.016032148],"study_design_scores_gemma":[0.6592538,0.013444458,0.3234895,0.00020192885,0.0016262205,1.2175248e-7,0.0010468302,0.00068051193,0.0000031031816,0.000068535934,0.00011360957,0.00007139349],"about_ca_topic_score_codex":0.00043163492,"about_ca_topic_score_gemma":0.005160591,"teacher_disagreement_score":0.078647606,"about_ca_system_score_codex":0.00035750854,"about_ca_system_score_gemma":0.0012712954,"threshold_uncertainty_score":0.3511664},"labels":[],"label_agreement":null},{"id":"W2124155904","doi":"10.1200/jco.2009.22.6951","title":"Reply to M.M. Mohiuddin et al","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine","score_opus":0.07425164528193878,"score_gpt":0.47832099015626317,"score_spread":0.4040693448743244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124155904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6135495,0.0007339046,0.0007134682,0.375406,0.0012319458,0.00010330753,0.000006047482,0.0000062123463,0.008249681],"genre_scores_gemma":[0.74204063,0.00054884364,0.005706807,0.25073916,0.00075293356,0.0000016338653,0.0000025637166,0.000007372567,0.00020006063],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830395,0.00021460124,0.00097141386,0.00019042859,0.00015062923,0.00016897365],"domain_scores_gemma":[0.9986405,0.00018126216,0.00054691004,0.00018649918,0.00023150322,0.0002133666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014070603,0.00010501567,0.0005438461,0.000039201823,0.00002722586,0.0000062328036,0.00018562157,0.00013853212,0.00001955713],"category_scores_gemma":[0.0018301373,0.00007836658,0.00028963605,0.00006007488,0.0000569796,0.000004234979,0.000060196,0.0002548678,0.000018240758],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002912602,0.0009827149,0.009321587,0.0000011013851,0.00028073307,0.00012478388,0.0000528107,0.000056872865,0.0042365394,0.00015598409,0.7941786,0.18769564],"study_design_scores_gemma":[0.0017754191,0.0077499556,0.16823374,0.000009593262,0.000031191576,0.00012436163,0.000023968698,8.652118e-7,0.0008978352,0.00022870542,0.820851,0.00007331931],"about_ca_topic_score_codex":0.000008544682,"about_ca_topic_score_gemma":0.000019145044,"teacher_disagreement_score":0.18762232,"about_ca_system_score_codex":0.00003259382,"about_ca_system_score_gemma":0.00042638308,"threshold_uncertainty_score":0.31956965},"labels":[],"label_agreement":null},{"id":"W2124891284","doi":"10.1200/jco.2012.44.0164","title":"Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Internal medicine; Hazard ratio; Human papillomavirus; Multivariate analysis; Gastroenterology; Oncology; Chemoradiotherapy; Univariate analysis; Proportional hazards model; Radiation therapy; Confidence interval","score_opus":0.10753892482797123,"score_gpt":0.468738519599136,"score_spread":0.36119959477116476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124891284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126714,0.0010019687,0.00003355203,0.0058463262,0.00075763976,0.0002963221,0.000011785436,0.0000054736497,0.00077977387],"genre_scores_gemma":[0.9954521,0.002273072,0.001007206,0.0008387859,0.0003112858,0.000019224215,0.000002088459,0.000016590458,0.00007966581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958777,0.00040724318,0.0029270086,0.00021528779,0.0002953212,0.00027748215],"domain_scores_gemma":[0.99621934,0.0008824078,0.0016691053,0.00017624858,0.0007036235,0.00034930604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023897912,0.00014652719,0.0021657448,0.0002122211,0.0000499011,0.000005994539,0.00014413455,0.00021048026,0.00025539414],"category_scores_gemma":[0.0024314476,0.00010083663,0.00034113164,0.00029819313,0.00016586932,0.00012913968,0.00006355461,0.0008007606,0.000015376678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003382467,0.0011334078,0.7885773,0.000062291496,0.0009463611,0.00024491452,0.0009085227,0.000021201166,0.028493624,0.000089146284,0.0044292193,0.17171155],"study_design_scores_gemma":[0.005715804,0.008053713,0.97786975,0.00026992444,0.0005926156,0.00003882937,0.0012799912,0.00007533458,0.0014885174,0.00020884129,0.0042904257,0.00011627413],"about_ca_topic_score_codex":0.002589269,"about_ca_topic_score_gemma":0.0012453495,"teacher_disagreement_score":0.18929243,"about_ca_system_score_codex":0.00026649717,"about_ca_system_score_gemma":0.00059413596,"threshold_uncertainty_score":0.41119984},"labels":[],"label_agreement":null},{"id":"W2125024490","doi":"10.1200/jco.2009.24.7346","title":"New Antithrombotic Drugs: Potential for Use in Oncology","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Antithrombotic; Thrombosis; Low molecular weight heparin; Anticoagulant; Intensive care medicine; Heparin; Cancer; Discovery and development of direct thrombin inhibitors; Population; Clinical trial; Internal medicine; Surgery; Thrombin; Platelet","score_opus":0.24156475173770633,"score_gpt":0.5364034308713267,"score_spread":0.2948386791336204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125024490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015042805,0.9867124,0.0009887599,0.0030691454,0.0052691996,0.0019492835,0.000007364261,0.000015286012,0.0018381522],"genre_scores_gemma":[0.000046241905,0.96542805,0.025969604,0.0029181747,0.0048641823,0.000017500572,0.000019369132,0.000060587263,0.0006762926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99085647,0.0009092778,0.006777499,0.0004692073,0.00043359908,0.00055395794],"domain_scores_gemma":[0.9886478,0.004579155,0.0053199856,0.00040333008,0.0003546776,0.00069505844],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0052396525,0.00044470085,0.01382848,0.00066039833,0.000036486254,0.000029051484,0.00044774712,0.0018244786,0.000192092],"category_scores_gemma":[0.003784588,0.00031326403,0.003314121,0.00030076044,0.00012843373,0.00016487348,0.00011344826,0.002206028,0.000053187916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041667226,0.0037166118,0.000022545797,0.0018831984,0.001038652,0.001469928,0.000026703021,0.0000067842043,6.825869e-8,0.00027083134,0.08833578,0.90281224],"study_design_scores_gemma":[0.0071770586,0.021313284,0.001567979,0.0072547286,0.008758783,0.00056592317,0.000031075928,0.000012569572,5.6176074e-8,0.00038409917,0.95269585,0.00023861123],"about_ca_topic_score_codex":0.00006100006,"about_ca_topic_score_gemma":0.000096041644,"teacher_disagreement_score":0.9025736,"about_ca_system_score_codex":0.00075455446,"about_ca_system_score_gemma":0.009697362,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W2125242066","doi":"10.1200/jco.2012.43.5891","title":"Cancer Survivorship: Why Labels Matter","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer; Cancer survivorship; Survivorship curve; Medicine; Disease; Meaning (existential); Confusion; Gerontology; Psychotherapist; Psychology; Pathology; Psychoanalysis; Internal medicine","score_opus":0.5038651825284446,"score_gpt":0.6107279431648726,"score_spread":0.10686276063642797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125242066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959924,0.0076506697,0.00013617208,0.016476762,0.0032237545,0.00006690732,0.000004219843,0.000004531625,0.012513027],"genre_scores_gemma":[0.9710527,0.0038747778,0.003708009,0.015721789,0.004359213,0.000002103839,0.0000011487107,0.000015383695,0.0012648774],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975497,0.0003477146,0.0015256236,0.0000769592,0.00026454634,0.00023545737],"domain_scores_gemma":[0.99554545,0.0023666061,0.0011480247,0.00012483048,0.00043687265,0.0003782477],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026353237,0.00009218437,0.0012056074,0.00007511019,0.000013140727,0.0000021080832,0.0001111791,0.00029046077,0.0015901666],"category_scores_gemma":[0.0023178505,0.00006033927,0.00036691557,0.00009513036,0.00015330537,0.00012517719,0.000031240143,0.0006297075,0.000091839305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007413198,0.0006299997,0.91621333,0.00003655845,0.00028563765,0.0000462586,0.00030070613,8.7735907e-7,0.00015865578,0.000064241656,0.06560915,0.015913272],"study_design_scores_gemma":[0.0020373648,0.0013965829,0.41199845,0.0002448902,0.00025136513,0.000046722278,0.00012277704,0.0000017164953,0.00040806894,0.00009948126,0.5833405,0.000052056766],"about_ca_topic_score_codex":0.00015384013,"about_ca_topic_score_gemma":0.000078627374,"teacher_disagreement_score":0.51773137,"about_ca_system_score_codex":0.00007285217,"about_ca_system_score_gemma":0.0004316739,"threshold_uncertainty_score":0.99932253},"labels":[],"label_agreement":null},{"id":"W2125252914","doi":"10.1200/jco.2007.14.1978","title":"Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Depression (economics); Evening; Internal medicine; Ovarian cancer; Cancer; Endocrinology; Gastroenterology; Oncology; Interleukin 6; Cytokine","score_opus":0.07244892359697049,"score_gpt":0.4323841844744475,"score_spread":0.359935260877477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125252914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364763,0.0010007945,0.0000258537,0.0016694018,0.0020319496,0.000101794016,0.0000030717524,0.0000031263714,0.0015163489],"genre_scores_gemma":[0.99441427,0.0021324866,0.00006389681,0.0024936786,0.00071464095,0.0000042561746,0.0000011219378,0.000009872866,0.00016579787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979526,0.00018008839,0.001353637,0.00013799098,0.00021774421,0.00015796573],"domain_scores_gemma":[0.9979572,0.0005753717,0.00080188405,0.00009052046,0.00030695117,0.0002680508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043735045,0.0000889956,0.0009171799,0.00010312635,0.000021754668,0.0000030361114,0.000082062,0.0002521275,0.00012259507],"category_scores_gemma":[0.00090222276,0.00006510806,0.00017304948,0.00009801163,0.00018388574,0.00008382242,0.000044513992,0.0007445981,0.0000027452284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017490939,0.0005296862,0.91549224,0.000012011182,0.00010393157,0.00067916716,0.00046008627,0.0000017025297,0.000027054804,0.000013185678,0.0014035094,0.07952831],"study_design_scores_gemma":[0.008649712,0.0071965014,0.9675814,0.00014643905,0.000104371946,0.0002717517,0.00005239539,0.000014224559,0.00003185628,0.000055258766,0.015831586,0.00006452103],"about_ca_topic_score_codex":0.0003759256,"about_ca_topic_score_gemma":0.0017232563,"teacher_disagreement_score":0.07946379,"about_ca_system_score_codex":0.00014124785,"about_ca_system_score_gemma":0.00083689624,"threshold_uncertainty_score":0.32349494},"labels":[],"label_agreement":null},{"id":"W2125430981","doi":"10.1200/jco.2005.05.3181","title":"Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Etoposide; Radiation therapy; Chemotherapy; Vincristine; Lung cancer; Hazard ratio; Prophylactic cranial irradiation; Internal medicine; Cyclophosphamide; Surgery; Oncology; Confidence interval","score_opus":0.30821068473514257,"score_gpt":0.571832692282891,"score_spread":0.26362200754774845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125430981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018337902,0.96371114,0.0005565095,0.0036688535,0.0006781653,0.012724538,0.00028826733,0.000016568742,0.00001803779],"genre_scores_gemma":[0.0016960398,0.99029505,0.002133314,0.000507145,0.0014867001,0.0030259038,0.00007938927,0.00008946298,0.0006869843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.979696,0.008721171,0.009151192,0.00097315904,0.00076313503,0.0006953898],"domain_scores_gemma":[0.96484315,0.025519444,0.0072621573,0.0005788337,0.0007827793,0.0010136588],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.012802963,0.00087377825,0.035091307,0.00068126275,0.0000897203,0.00005583249,0.00037224285,0.0007951484,0.00010706867],"category_scores_gemma":[0.0023458293,0.00044546786,0.012503983,0.00063138996,0.0008073544,0.00010388035,0.000088864756,0.0018686774,3.217651e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63973534,0.0050616385,0.009834375,0.0032076256,0.3008286,0.00039780236,0.00004883595,0.00006789031,3.710756e-8,0.000002257618,0.0005225494,0.040293053],"study_design_scores_gemma":[0.47650412,0.005889667,0.0014165613,0.00055377465,0.46969342,0.0000029857408,0.0000023673144,0.0032966926,2.3626953e-8,0.0000040390796,0.042401273,0.0002350799],"about_ca_topic_score_codex":0.0022507308,"about_ca_topic_score_gemma":0.003167203,"teacher_disagreement_score":0.1688648,"about_ca_system_score_codex":0.0018927875,"about_ca_system_score_gemma":0.0053390875,"threshold_uncertainty_score":0.9997997},"labels":[],"label_agreement":null},{"id":"W2125529669","doi":"10.1200/jco.2005.07.109","title":"Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Univariate analysis; Internal medicine; Hazard ratio; Methotrexate; Lymphoma; Gastroenterology; Retrospective cohort study; Multivariate analysis; Oncology; Confidence interval","score_opus":0.06097333208030361,"score_gpt":0.38297155011941714,"score_spread":0.32199821803911355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125529669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96940964,0.002003584,0.00020865425,0.015504458,0.0011134513,0.00032003707,0.00013376819,0.000011976757,0.011294432],"genre_scores_gemma":[0.9742163,0.0032008858,0.013363186,0.0067199995,0.0020573046,0.000019499876,0.00008767095,0.000025397232,0.00030978516],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949545,0.000560554,0.002944542,0.00036810752,0.00088923424,0.00028303245],"domain_scores_gemma":[0.99008656,0.005102877,0.0029606891,0.00040284733,0.0010766312,0.00037039618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019685952,0.0002788417,0.0023290268,0.00027280013,0.00007560083,0.000027905864,0.00048590632,0.00038599077,0.00041163038],"category_scores_gemma":[0.0009833729,0.00016964636,0.0013789504,0.0006930877,0.00041346205,0.0002198959,0.00015957555,0.00029899928,0.000037091686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009417559,0.020734,0.46166414,0.000016930975,0.01470366,0.0009535299,0.0012513866,0.000061271334,0.0009797933,0.00032843556,0.027401254,0.46248803],"study_design_scores_gemma":[0.018024482,0.003944577,0.79603523,0.000072132774,0.0047822483,0.00009733508,0.0006164353,0.00013487124,0.0004062815,0.00012758127,0.17563102,0.00012783804],"about_ca_topic_score_codex":0.00022412848,"about_ca_topic_score_gemma":0.00034806668,"teacher_disagreement_score":0.4623602,"about_ca_system_score_codex":0.0018800843,"about_ca_system_score_gemma":0.0039253044,"threshold_uncertainty_score":0.69633216},"labels":[],"label_agreement":null},{"id":"W2125665528","doi":"10.1200/jco.2015.62.1342","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":851,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Pemetrexed; Oncology; Gefitinib; Erlotinib; Internal medicine; Crizotinib; Docetaxel; Lung cancer; Carboplatin; Afatinib; Chemotherapy; Bevacizumab; Cancer; Epidermal growth factor receptor; Malignant pleural effusion; Cisplatin","score_opus":0.19771397044676403,"score_gpt":0.6016853804165807,"score_spread":0.4039714099698167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125665528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8612616,0.008705594,0.015797526,0.093678646,0.011019387,0.0028364349,0.00015594838,0.00004611282,0.006498754],"genre_scores_gemma":[0.49780864,0.067894705,0.34764895,0.06964326,0.014050971,0.00014209638,0.00006962448,0.00014005552,0.002601716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98576486,0.0017264127,0.010863142,0.00053971977,0.00061979296,0.0004860496],"domain_scores_gemma":[0.96962273,0.01120643,0.0127598625,0.0005171089,0.004650167,0.0012436867],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022424819,0.0003216325,0.00475002,0.00008456826,0.000072049406,0.000013439947,0.0004190161,0.0009345522,0.000076491226],"category_scores_gemma":[0.009520001,0.00021982896,0.0022808968,0.00027973286,0.0007520261,0.0002129917,0.00010190406,0.0018667615,0.000011571618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023709623,0.010999243,0.16160806,0.00014928517,0.005429714,0.00028174557,0.00046545436,0.00018553714,0.000055849818,0.000060664635,0.3294579,0.46759692],"study_design_scores_gemma":[0.049319033,0.045946084,0.01439176,0.00015141824,0.0039245775,0.00022778111,0.002395834,0.0024352307,0.00002214343,0.00004171534,0.8809467,0.00019775484],"about_ca_topic_score_codex":0.0003609189,"about_ca_topic_score_gemma":0.00008066391,"teacher_disagreement_score":0.55148876,"about_ca_system_score_codex":0.0006707331,"about_ca_system_score_gemma":0.02385866,"threshold_uncertainty_score":0.9988232},"labels":[],"label_agreement":null},{"id":"W2125804100","doi":"10.1200/jco.2010.29.0759","title":"Accrual Strategies for Cancer Genetics Research: Blurred Boundaries","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Genetic testing; Medicine; Population; Judaism; Destiny (ISS module); Headline; Newspaper; Genealogy; Genetics; Family medicine; History; Law; Political science; Internal medicine; Biology; Advertising","score_opus":0.3023318599009956,"score_gpt":0.5572070381111532,"score_spread":0.25487517821015765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125804100","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063411616,0.009906274,0.0019742597,0.8956092,0.025654987,0.00082966895,0.0003944936,0.0000103049715,0.0022092033],"genre_scores_gemma":[0.039490677,0.013549704,0.03887242,0.68456525,0.21481045,0.0003484812,0.000455097,0.00032854898,0.007579357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995093,0.00084318017,0.002341036,0.00049599895,0.00062824396,0.0005985321],"domain_scores_gemma":[0.99258786,0.0015101067,0.0021542213,0.00054327917,0.0030288445,0.00017571164],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004943407,0.00029305083,0.0012482,0.00019431941,0.000238687,0.0002006599,0.001049541,0.0061675264,0.00012677092],"category_scores_gemma":[0.0039007252,0.00024672694,0.000776569,0.000120642224,0.0020089203,0.000011412243,0.00023220242,0.00818788,0.000007683556],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005031983,0.0001195343,0.000184395,0.0000643482,0.0006253527,0.00006830725,0.00006443045,0.0000439096,0.0018444313,0.0000396062,0.9574523,0.038990185],"study_design_scores_gemma":[0.0016949369,0.004951105,0.00035788384,0.00003632693,0.00021775524,0.00008737704,0.00014895728,0.000012079601,0.0010322651,0.0035360043,0.98767054,0.00025474452],"about_ca_topic_score_codex":0.000031495932,"about_ca_topic_score_gemma":0.0008307699,"teacher_disagreement_score":0.21104392,"about_ca_system_score_codex":0.00019089041,"about_ca_system_score_gemma":0.033181183,"threshold_uncertainty_score":0.9999985},"labels":[],"label_agreement":null},{"id":"W2125865802","doi":"10.1200/jco.2010.29.0247","title":"Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803—A Report From the Children's Oncology Group","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Rhabdomyosarcoma; Internal medicine; Oncology; Pediatric oncology; Clinical Oncology; Cancer; Pathology; Sarcoma","score_opus":0.04763602729865502,"score_gpt":0.39462550492385723,"score_spread":0.3469894776252022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125865802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713953,0.00070343906,0.00000619339,0.024901293,0.0019188864,0.00047291297,0.0001122819,0.000013525292,0.00047614396],"genre_scores_gemma":[0.9884752,0.0023309758,0.004737544,0.0011587467,0.0031408647,0.000023623741,0.00007444748,0.000026545005,0.000032034055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99441963,0.0008691275,0.0034814358,0.00052277837,0.00035838535,0.00034861555],"domain_scores_gemma":[0.9804243,0.015469854,0.0028246439,0.0006002882,0.00018087037,0.0005000483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029300523,0.00030257276,0.002130225,0.00012235848,0.00007852623,0.000027195014,0.00026033027,0.00083654764,0.000110957706],"category_scores_gemma":[0.0073073343,0.00016272295,0.0005890533,0.00012462494,0.0004929835,0.000117347416,0.00012415202,0.0022306852,0.000027042635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040905196,0.004337063,0.7364724,7.6181277e-7,0.00076587225,0.007721694,0.0004525517,4.2134496e-7,0.00005822864,0.000017505645,0.0026163931,0.24346659],"study_design_scores_gemma":[0.028935265,0.011937396,0.8901937,0.000067052424,0.00097191863,0.0012702323,0.00019192618,0.000011310288,0.000028440692,0.00083160494,0.06544,0.00012116301],"about_ca_topic_score_codex":0.004223536,"about_ca_topic_score_gemma":0.014816374,"teacher_disagreement_score":0.24334542,"about_ca_system_score_codex":0.00029477724,"about_ca_system_score_gemma":0.0009903988,"threshold_uncertainty_score":0.9691341},"labels":[],"label_agreement":null},{"id":"W2125885282","doi":"10.1200/jco.2014.58.1967","title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1023,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Oncology; Human Epidermal Growth Factor Receptor 2; Triple-negative breast cancer; Internal medicine; Triple negative; Breast cancer; Cancer research; Epidermal growth factor receptor; Receptor; Pathology; Cancer; Cisplatin","score_opus":0.038043498804686264,"score_gpt":0.38585307086776915,"score_spread":0.3478095720630829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125885282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929476,0.00017166442,0.000056565095,0.005848472,0.0001869841,0.00043615844,0.000014538836,0.000008487396,0.0003295739],"genre_scores_gemma":[0.986546,0.00023056501,0.0058333636,0.006814192,0.00043151737,0.000008821954,0.0000013622642,0.000026785345,0.00010740596],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967146,0.0009280184,0.0015297362,0.00028640847,0.0002701657,0.00027110506],"domain_scores_gemma":[0.9943917,0.003742065,0.0011318447,0.00011418516,0.0002523782,0.00036784803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031092798,0.0002198564,0.0015784353,0.00018871427,0.00007208447,0.00001958715,0.00008915266,0.00019196363,0.000079823534],"category_scores_gemma":[0.0015920874,0.00013638876,0.000121333054,0.0002020757,0.00040970178,0.00014174976,0.00002665201,0.0005538995,4.977374e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49122003,0.0003557883,0.21504247,0.00006094875,0.00049598614,0.0002568779,0.0031368716,0.00000294172,0.045746796,0.000008006648,0.00027334577,0.24339993],"study_design_scores_gemma":[0.03981677,0.028893119,0.9237468,0.00057769305,0.0000833264,0.0015986795,0.0007623758,0.00007340961,0.0030592699,0.000017001677,0.001169731,0.00020180558],"about_ca_topic_score_codex":0.000512038,"about_ca_topic_score_gemma":0.00055129617,"teacher_disagreement_score":0.70870435,"about_ca_system_score_codex":0.0006870827,"about_ca_system_score_gemma":0.0021998468,"threshold_uncertainty_score":0.55617726},"labels":[],"label_agreement":null},{"id":"W2125942853","doi":"10.1200/jco.2007.11.4769","title":"Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mitoxantrone; Prostate cancer; Docetaxel; Prostate-specific antigen; Oncology; Internal medicine; Hazard ratio; Proportional hazards model; Prostate; Chemotherapy; Urology; Cancer","score_opus":0.13679853117234395,"score_gpt":0.49702988955167593,"score_spread":0.36023135837933196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125942853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97141224,0.023056928,0.000111923386,0.0043092626,0.00026068123,0.00043688016,0.000009808654,0.000007705954,0.0003945699],"genre_scores_gemma":[0.9436057,0.053563416,0.0014354622,0.000557485,0.00031084838,0.000008458383,0.000009544606,0.000018514504,0.0004905745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956803,0.0007096432,0.0023311423,0.0002856449,0.0005094566,0.00048386914],"domain_scores_gemma":[0.9949564,0.0027667016,0.0010647606,0.0001785795,0.00047673378,0.000556857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015057503,0.0001775219,0.0017254611,0.0007281167,0.000046188452,0.000018862045,0.00011581342,0.00020188978,0.00010858951],"category_scores_gemma":[0.0013033228,0.00011536648,0.00040524526,0.00087931193,0.00035298406,0.00018361269,0.000047642206,0.0010917936,0.000005040362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014538449,0.0013705543,0.65341604,0.000036735655,0.001577413,0.0032924016,0.00054191967,0.00001686468,0.00075124606,0.000011922526,0.0012860072,0.32316047],"study_design_scores_gemma":[0.011006687,0.009311323,0.9031235,0.00006807909,0.00065922743,0.000042155014,0.000626923,0.00009878092,0.00008451175,0.00015494737,0.07470747,0.000116401556],"about_ca_topic_score_codex":0.00015671257,"about_ca_topic_score_gemma":0.0005126803,"teacher_disagreement_score":0.32304406,"about_ca_system_score_codex":0.00035048882,"about_ca_system_score_gemma":0.0014096578,"threshold_uncertainty_score":0.521866},"labels":[],"label_agreement":null},{"id":"W2126048792","doi":"10.1200/jco.2003.03.042","title":"Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre","funders":"","keywords":"Medicine; Mitoxantrone; Placebo; Prednisone; Clinical endpoint; Prostate cancer; Internal medicine; Palliative care; Analgesic; Bone pain; Quality of life (healthcare); Randomized controlled trial; Oncology; Surgery; Cancer; Chemotherapy; Anesthesia; Pathology","score_opus":0.06038478894362557,"score_gpt":0.4112908432084104,"score_spread":0.35090605426478483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126048792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541915,0.0074262237,0.000007682056,0.0019278807,0.0007731108,0.004202159,0.000015837566,0.000005723428,0.0002222469],"genre_scores_gemma":[0.98547405,0.012928083,0.00088193297,0.0002948847,0.00016188716,0.00011854394,0.00000583721,0.000027459006,0.00010733128],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99419475,0.0015890809,0.0030120015,0.0003415439,0.0004423228,0.00042028984],"domain_scores_gemma":[0.99042183,0.0059159654,0.0025423837,0.00016415509,0.00033282113,0.00062282605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006551161,0.00029742075,0.004096896,0.00022411863,0.000059370574,0.000012548345,0.000059672882,0.00045741105,0.0000144676005],"category_scores_gemma":[0.0029451395,0.00018634328,0.00022818272,0.000117312564,0.00062058424,0.00016257685,0.00003030966,0.0008699955,0.0000010348341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9051866,0.0031597803,0.066627085,0.00006150618,0.0011776477,0.00009114652,0.0001584123,0.000003481244,0.000009951195,0.000031138137,0.00011919987,0.023374053],"study_design_scores_gemma":[0.92673844,0.036506746,0.032772936,0.00014486162,0.0013533578,0.000028108981,0.00008841688,0.000064170126,0.000005791806,0.00005184497,0.0021044514,0.00014086686],"about_ca_topic_score_codex":0.00014768538,"about_ca_topic_score_gemma":0.00022272622,"teacher_disagreement_score":0.033854146,"about_ca_system_score_codex":0.00014506368,"about_ca_system_score_gemma":0.0015722121,"threshold_uncertainty_score":0.75988585},"labels":[],"label_agreement":null},{"id":"W2126234152","doi":"10.1200/jco.2011.40.7510","title":"Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Hepatitis B virus; HBsAg; Rituximab; Internal medicine; CHOP; Vincristine; Hepatitis B; Lymphoma; Chemotherapy; Prednisone; Population; Cyclophosphamide; Oncology; Immunology; Virus","score_opus":0.15313548527051243,"score_gpt":0.4922027324099327,"score_spread":0.33906724713942027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126234152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647981,0.00093086145,0.029400142,0.0024675457,0.0011342908,0.0006406876,0.000021404798,0.000017948727,0.00058901194],"genre_scores_gemma":[0.97551477,0.0016311735,0.01728679,0.0028319797,0.002543442,0.000048974747,0.0000067891156,0.000030222214,0.00010585912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650764,0.0005304955,0.001970856,0.00018161813,0.00036314392,0.0004462222],"domain_scores_gemma":[0.99285805,0.0041546747,0.0015019104,0.00020342859,0.00077423436,0.00050769193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064339535,0.00018531265,0.0026660946,0.00027994614,0.00009597342,0.000008297374,0.00013659333,0.0003919595,0.0001196148],"category_scores_gemma":[0.005779626,0.00013545352,0.0014661232,0.00041741584,0.00021087182,0.00019424788,0.00004673408,0.00037309586,0.000012550688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023842694,0.0011800448,0.6944134,0.0000279767,0.0040037516,0.00004762051,0.00016202578,0.0000067419933,0.000048466176,0.00007240433,0.0008853201,0.29676795],"study_design_scores_gemma":[0.009271345,0.005990346,0.88684,0.00006267145,0.0030500873,0.000100540106,0.00002059807,0.0002721667,0.00020009538,0.00012678588,0.09396136,0.000104003375],"about_ca_topic_score_codex":0.00069017214,"about_ca_topic_score_gemma":0.0020437376,"teacher_disagreement_score":0.29666394,"about_ca_system_score_codex":0.0003037082,"about_ca_system_score_gemma":0.00052552274,"threshold_uncertainty_score":0.69191694},"labels":[],"label_agreement":null},{"id":"W2126251787","doi":"10.1200/jco.2011.38.7571","title":"Progression-Free Survival: Meaningful or Simply Measurable?","year":2012,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Progression-free survival; Oncology; Randomized controlled trial; Internal medicine; Clinical endpoint; Standard of care; Overall survival; Tumor progression; Intensive care medicine; Cancer","score_opus":0.18336127878651248,"score_gpt":0.5217916929448325,"score_spread":0.33843041415832004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126251787","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011092871,0.005711638,0.000014196992,0.0056860745,0.96254057,0.0004262368,0.000048490587,0.000030453162,0.024433065],"genre_scores_gemma":[0.0033073882,0.0100827105,0.0024203819,0.00047675535,0.9808048,0.000024018877,0.000022186001,0.00008396426,0.0027777806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99204075,0.00076792884,0.003913119,0.0003718089,0.0023300818,0.000576303],"domain_scores_gemma":[0.97456396,0.01638949,0.0049495744,0.0005520552,0.002672383,0.00087256555],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008012476,0.0004625916,0.0051415646,0.00019362652,0.00011173682,0.000022008951,0.00052982307,0.0022907981,0.0005888345],"category_scores_gemma":[0.06972166,0.00024469369,0.0012886135,0.00021404822,0.00034703466,0.00013625369,0.00030302737,0.003919831,0.00003785829],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01991699,0.0020525686,0.004031083,0.0001255817,0.0023434155,0.0013490451,0.00007977214,1.76203e-7,0.0000013740906,0.000008017683,0.81032026,0.15977171],"study_design_scores_gemma":[0.012603948,0.031803414,0.006858095,0.00062125275,0.0029378023,0.00014976434,0.00010645814,9.075651e-7,0.0000035155247,0.00018298691,0.94450814,0.00022369085],"about_ca_topic_score_codex":0.000047773738,"about_ca_topic_score_gemma":0.000442916,"teacher_disagreement_score":0.15954801,"about_ca_system_score_codex":0.0007244423,"about_ca_system_score_gemma":0.008939453,"threshold_uncertainty_score":0.9990044},"labels":[],"label_agreement":null},{"id":"W2126531809","doi":"10.1200/jco.2015.62.5632","title":"Reply to G. Bogani et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.0688039396841855,"score_gpt":0.44099162837697664,"score_spread":0.3721876886927912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126531809","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07733071,0.009279178,0.0002555719,0.88765645,0.013558921,0.00031829436,0.000028972025,0.0000064670844,0.01156545],"genre_scores_gemma":[0.006746671,0.0060618776,0.005960687,0.9594702,0.0135635985,0.0000054312554,0.00007983328,0.00009478933,0.008016901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99114025,0.0029494704,0.0039192797,0.00064908055,0.00064811984,0.0006937833],"domain_scores_gemma":[0.9922044,0.0011882882,0.0034624364,0.00062193954,0.0013169578,0.001205963],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009619963,0.0005050639,0.0024945661,0.00016226403,0.000058200952,0.00003731213,0.00086834247,0.004091466,0.0001105281],"category_scores_gemma":[0.009147054,0.00039789974,0.0015816363,0.00016893886,0.00039816898,0.0000125137785,0.0004229739,0.0063854447,0.0004317533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025728184,0.0007284282,0.00060658756,0.00002642553,0.0012930663,0.0035125369,0.000046802757,0.00007196981,0.0025347024,0.000034701327,0.9566515,0.03192043],"study_design_scores_gemma":[0.0036360573,0.036465764,0.0004650533,0.0001606758,0.00048838794,0.002107559,0.000026716441,0.000009247226,0.0006799484,0.000121843994,0.9554344,0.0004043524],"about_ca_topic_score_codex":0.00003120113,"about_ca_topic_score_gemma":0.0000119891765,"teacher_disagreement_score":0.07181378,"about_ca_system_score_codex":0.000144935,"about_ca_system_score_gemma":0.006272062,"threshold_uncertainty_score":0.9998473},"labels":[],"label_agreement":null},{"id":"W2126715987","doi":"10.1200/jco.2006.07.1514","title":"Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McGill University; Nova Scotia Cancer Centre; Ontario Clinical Oncology Group; McMaster University; Humber River Regional Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Epoetin alfa; Placebo; Anemia; Internal medicine; Erythropoietin; Lung cancer; Randomized controlled trial; Clinical trial; Quality of life (healthcare); Hazard ratio; Performance status; Cancer; Surgery; Confidence interval; Pathology","score_opus":0.05174034177883087,"score_gpt":0.4196665273344285,"score_spread":0.36792618555559764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126715987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757862,0.0017589465,0.00012302016,0.0074833753,0.001497423,0.004041798,0.0000018574614,0.000011010282,0.009296342],"genre_scores_gemma":[0.99211955,0.0024864224,0.0021300914,0.00045251392,0.0011008232,0.000080245605,0.000004701289,0.000036518566,0.0015891291],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925666,0.00070657075,0.0053773667,0.00030954025,0.0005986441,0.00044126532],"domain_scores_gemma":[0.98874027,0.005902911,0.0038655435,0.00027051708,0.00052198744,0.00069876603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011154352,0.00030489248,0.004855068,0.0003203185,0.000038107504,0.0000072453317,0.00018575392,0.0006096523,0.0004437279],"category_scores_gemma":[0.0014607207,0.00017578235,0.0012731458,0.00030053116,0.00060555444,0.000066057284,0.00004032563,0.0014748697,0.0000067422293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9686817,0.006835223,0.01669606,0.00013577832,0.0010557715,0.002544287,0.00021224773,0.00014481506,0.00004604203,0.000043665572,0.0007261912,0.0028782466],"study_design_scores_gemma":[0.9819208,0.010110982,0.002292889,0.0005551453,0.0038140502,0.00011355847,0.0002214177,0.00018828598,0.00012933601,0.00004341976,0.0004453831,0.00016475703],"about_ca_topic_score_codex":0.00012246575,"about_ca_topic_score_gemma":0.00022660563,"teacher_disagreement_score":0.016333327,"about_ca_system_score_codex":0.0003207889,"about_ca_system_score_gemma":0.0032139218,"threshold_uncertainty_score":0.7168196},"labels":[],"label_agreement":null},{"id":"W2126731819","doi":"10.1200/jco.2013.52.8331","title":"Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cargill (Canada)","funders":"","keywords":"Medicine; Breast cancer; Mammography; Magnetic resonance imaging; Family history; Breast MRI; Breast cancer screening; Cancer; Oncology; Internal medicine; Gynecology; Obstetrics; Radiology","score_opus":0.0552042675515845,"score_gpt":0.3958897783272649,"score_spread":0.34068551077568043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126731819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462354,0.0013167684,0.0013622463,0.0014426316,0.00023551431,0.00043693196,0.000100885125,0.0000092750615,0.0004721976],"genre_scores_gemma":[0.9762123,0.00007414721,0.022767318,0.00035563743,0.0005551012,0.000004659856,0.000004602592,0.000016472872,0.000009748529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511373,0.001715431,0.0018455645,0.0002961798,0.00073693105,0.0002921699],"domain_scores_gemma":[0.9902412,0.0058353287,0.002472735,0.00038365345,0.00085399195,0.00021308701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007543616,0.00020140878,0.0013334011,0.000076468736,0.00012375864,0.000016480519,0.00040175952,0.00019808767,0.000012904922],"category_scores_gemma":[0.0024629468,0.00010319557,0.00038213163,0.00030864018,0.0011102778,0.00018280502,0.000166493,0.001470422,2.5693438e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020392437,0.00014846282,0.58378935,0.000013162825,0.00011625435,0.00004169198,0.0001632761,0.000046315516,0.000018223338,0.000022447985,0.00009582331,0.39515254],"study_design_scores_gemma":[0.012093027,0.010567231,0.96846884,0.0019954422,0.0007523924,0.00042607787,0.0003748429,0.00020156955,0.00008554271,0.0002442404,0.0046851276,0.00010564906],"about_ca_topic_score_codex":0.041160163,"about_ca_topic_score_gemma":0.011542996,"teacher_disagreement_score":0.3950469,"about_ca_system_score_codex":0.000049823295,"about_ca_system_score_gemma":0.00066390756,"threshold_uncertainty_score":0.96522486},"labels":[],"label_agreement":null},{"id":"W2126956588","doi":"10.1200/jco.2011.39.1011","title":"Reply to C.B. Simone II","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital; University of Toronto; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.596048569023168,"score_gpt":0.599950795939286,"score_spread":0.003902226916117968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126956588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9345226,0.0007980788,0.00036917243,0.01161134,0.0013499584,0.00009744206,0.0000015418304,0.0000078239445,0.051242035],"genre_scores_gemma":[0.92857593,0.0012273622,0.046496306,0.0206594,0.0016338397,0.0000012584057,5.864457e-7,0.000013279198,0.0013920198],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974607,0.0001638816,0.0018769916,0.0001132086,0.00023501062,0.00015015512],"domain_scores_gemma":[0.9966103,0.0011450732,0.001044204,0.00018119671,0.00059919804,0.00042004517],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021681837,0.00008052496,0.0012342205,0.000105502106,0.000018700006,9.401478e-7,0.0001429307,0.0001963048,0.00037232027],"category_scores_gemma":[0.010271184,0.000054646458,0.00038702853,0.00012235444,0.00012100088,0.000052422114,0.00006409354,0.00050960795,0.00004610481],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013921094,0.004439587,0.48475477,0.000058575264,0.0009606331,0.0021006633,0.004368644,0.0000030862657,0.0009109014,0.000682896,0.19313091,0.29466826],"study_design_scores_gemma":[0.002949712,0.025448266,0.14229982,0.00025126318,0.00021687894,0.0000825222,0.00031527344,0.0000035206454,0.001361718,0.00051552267,0.82649654,0.000058944064],"about_ca_topic_score_codex":0.000045187822,"about_ca_topic_score_gemma":0.000010042466,"teacher_disagreement_score":0.63336563,"about_ca_system_score_codex":0.00004693446,"about_ca_system_score_gemma":0.0005923374,"threshold_uncertainty_score":0.9980657},"labels":[],"label_agreement":null},{"id":"W2127038160","doi":"10.1200/jco.2008.21.1458","title":"Social Outcomes in the Childhood Cancer Survivor Study Cohort","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":469,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Psychosocial; Psychological intervention; Cohort; Survivorship curve; Educational attainment; Cancer survivor; Social skills; Cancer; Psychiatry; Gerontology; Clinical psychology","score_opus":0.30791464842945654,"score_gpt":0.5981866042667011,"score_spread":0.2902719558372446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127038160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01052683,0.96311575,0.0000018817742,0.018682428,0.0030974757,0.0027472845,0.000019982326,0.000017814218,0.0017905342],"genre_scores_gemma":[0.0031263628,0.9796506,0.00008647132,0.008642046,0.008151234,0.000064814885,0.000008262632,0.000060937175,0.0002092565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9799453,0.00764107,0.009698862,0.0005291715,0.0016661728,0.00051940914],"domain_scores_gemma":[0.981228,0.009955921,0.0075004864,0.0005875237,0.00038429804,0.0003437847],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.026030086,0.0006033689,0.014802083,0.00037757494,0.00009844918,0.00003207429,0.0011250888,0.0013282538,0.00013360496],"category_scores_gemma":[0.007216154,0.00032557308,0.003724544,0.00057728816,0.0002486274,0.00009881264,0.00011627344,0.006175585,0.000033556837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024741987,0.012085795,0.089499325,0.00075841375,0.002774468,0.0008770017,0.0013001419,2.0056333e-7,1.5096469e-9,0.00002229054,0.008440436,0.8839945],"study_design_scores_gemma":[0.0038287013,0.0054341964,0.39463878,0.0018659056,0.004830436,0.00023968615,0.00038286814,7.351645e-8,2.3141602e-9,0.00005753272,0.58853185,0.00018995466],"about_ca_topic_score_codex":0.00043487025,"about_ca_topic_score_gemma":0.0027077359,"teacher_disagreement_score":0.88380456,"about_ca_system_score_codex":0.0005456214,"about_ca_system_score_gemma":0.009141993,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W2127140131","doi":"10.1200/jco.2009.26.8425","title":"Hope and Noncurative Chemotherapies: Which Affects the Other?","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Université de Sherbrooke; Hôpital Maisonneuve-Rosemont; Université du Québec à Montréal","funders":"Canadian Institutes of Health Research","keywords":"Medicine","score_opus":0.26395091718040953,"score_gpt":0.563264510009144,"score_spread":0.2993135928287345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127140131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582584,0.0012723444,0.00012501633,0.02722779,0.000981153,0.00012245603,0.0000017814405,0.0000043517925,0.012006689],"genre_scores_gemma":[0.9878188,0.00199174,0.0044014193,0.0039121,0.0016465483,0.000001338152,2.677787e-7,0.000011023791,0.00021679113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985217,0.00024313285,0.00081949815,0.000097529766,0.0001976398,0.000120541205],"domain_scores_gemma":[0.99312997,0.0050837877,0.000987729,0.00014421232,0.0004845723,0.00016974655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023970578,0.00009192648,0.00090441405,0.00004377892,0.000028568542,0.0000052403875,0.00012374033,0.00027014888,0.00017390348],"category_scores_gemma":[0.0068206396,0.000046192243,0.00019063597,0.00010850835,0.0003795087,0.00006220362,0.000027254402,0.0010819356,0.0000050414633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006254235,0.001826002,0.41859034,0.00012398881,0.0019214238,0.0002605932,0.008441531,0.0000029700304,0.014320862,0.0033018345,0.02281041,0.5221458],"study_design_scores_gemma":[0.0067865937,0.009603978,0.13614593,0.0002869722,0.0002783057,0.00022896186,0.0012142468,0.00008063955,0.002622314,0.0007280634,0.841929,0.00009498103],"about_ca_topic_score_codex":0.000016418582,"about_ca_topic_score_gemma":0.00016819128,"teacher_disagreement_score":0.8191186,"about_ca_system_score_codex":0.000015151805,"about_ca_system_score_gemma":0.000550323,"threshold_uncertainty_score":0.8165435},"labels":[],"label_agreement":null},{"id":"W2127333657","doi":"10.1200/jco.2014.58.5828","title":"Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Connective Tissue Oncology Society","keywords":"Medicine; Cohort; Radiation therapy; Image-guided radiation therapy; Sarcoma; Soft tissue sarcoma; Surgery; Randomized controlled trial; Cohort study; Cancer; Soft tissue; Radiology; Internal medicine; Pathology","score_opus":0.10737166096283264,"score_gpt":0.4053801225383275,"score_spread":0.2980084615754949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127333657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416786,0.0003224522,0.00002575947,0.0030776197,0.0005044586,0.0015319005,0.00002127491,0.000010857652,0.00033783272],"genre_scores_gemma":[0.99485415,0.00085112813,0.003427361,0.00023742366,0.00046626208,0.00004127733,0.00005753655,0.00002728485,0.000037603666],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943764,0.0012920006,0.0031220883,0.00032079723,0.0006269678,0.0002616959],"domain_scores_gemma":[0.9938146,0.0010055812,0.003464529,0.00028722125,0.0010778889,0.0003502152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032671196,0.00023962304,0.001985443,0.00040221526,0.000026894564,0.000008037552,0.00013577922,0.00037591474,0.00002800006],"category_scores_gemma":[0.0015874521,0.00014802712,0.00025347414,0.00044066986,0.00023836906,0.00020377368,0.000015628739,0.00044583352,0.000002016371],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45895454,0.013985054,0.31783473,0.000007981863,0.0005259705,0.000094884024,0.00082929607,0.0001178183,0.0011314951,0.000006576077,0.0023340809,0.20417756],"study_design_scores_gemma":[0.25167328,0.11478401,0.6266179,0.000084005405,0.00015903669,0.0000268004,0.00019624502,0.000040747793,0.00406837,0.000053829805,0.0021810909,0.000114669616],"about_ca_topic_score_codex":0.0003376621,"about_ca_topic_score_gemma":0.000032325133,"teacher_disagreement_score":0.30878317,"about_ca_system_score_codex":0.00056654034,"about_ca_system_score_gemma":0.0016052544,"threshold_uncertainty_score":0.60363704},"labels":[],"label_agreement":null},{"id":"W2127650989","doi":"10.1200/jco.2010.34.3996","title":"Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Docetaxel; Cabazitaxel; Medicine; Mitoxantrone; Prostate cancer; Taxane; Oncology; Internal medicine; Abiraterone acetate; Chemotherapy; Bevacizumab; Cancer; Clinical trial; Androgen deprivation therapy; Breast cancer","score_opus":0.46970167107768035,"score_gpt":0.6066352992605301,"score_spread":0.1369336281828497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127650989","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012894123,0.9940793,0.00001761881,0.0017499265,0.0010670229,0.0021853517,0.00011779517,0.000009192982,0.00064484816],"genre_scores_gemma":[0.00003658711,0.991376,0.0021924085,0.00033875112,0.0018685712,0.00032865754,0.000054488624,0.00006212322,0.0037424332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995671,0.0003411288,0.0030540356,0.0003051785,0.00026497233,0.00036371787],"domain_scores_gemma":[0.99384254,0.0017530711,0.00299894,0.0002543728,0.00067124714,0.00047983645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016138384,0.00035727935,0.005058742,0.00021733314,0.000055182547,0.000013303128,0.00017146744,0.0007251257,0.00029420198],"category_scores_gemma":[0.00040083585,0.00018559108,0.0024405736,0.00014733979,0.00020996739,0.00004651692,0.000012256659,0.0007057242,0.000012953941],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008627165,0.0019611055,0.00009923245,0.003247904,0.002275242,0.00032945973,0.000041084106,3.8540935e-7,0.0000011770003,0.000020762827,0.0029470194,0.98044944],"study_design_scores_gemma":[0.013772772,0.03228965,0.000113779606,0.004640927,0.004240916,0.000073897965,0.000010300168,0.0000034662423,0.000010066111,0.000053985856,0.94464815,0.00014209378],"about_ca_topic_score_codex":0.00004289188,"about_ca_topic_score_gemma":0.000058375565,"teacher_disagreement_score":0.98030734,"about_ca_system_score_codex":0.0011465405,"about_ca_system_score_gemma":0.022716356,"threshold_uncertainty_score":0.9828239},"labels":[],"label_agreement":null},{"id":"W2127667466","doi":"10.1200/jco.2004.01.006","title":"Treatment of Children and Adolescents With Stage II Testicular and Stages I and II Ovarian Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9048 and Children's Cancer Group 8891","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Etoposide; Germ cell tumors; Bleomycin; Stage (stratigraphy); Internal medicine; Chemotherapy; Oncology; Gastroenterology; Gynecology","score_opus":0.022404187490171472,"score_gpt":0.3530413730186723,"score_spread":0.3306371855285008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127667466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827044,0.015430685,0.000028218632,0.0004917345,0.0001385513,0.0011233626,0.00005913602,0.000013907504,0.000009983055],"genre_scores_gemma":[0.9826382,0.014962685,0.0015099259,0.00015787373,0.0006397358,0.000021339236,0.000009289947,0.00003725115,0.000023694498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968084,0.00031040018,0.0015913028,0.00055694085,0.00036076328,0.00037218508],"domain_scores_gemma":[0.9965669,0.0003641198,0.0018444887,0.0002239189,0.00016579256,0.00083480804],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058194256,0.00040564765,0.0019525766,0.00027453643,0.00016231938,0.000020344298,0.00009350063,0.0002786593,0.000009991535],"category_scores_gemma":[0.00027575163,0.00025391736,0.00017794957,0.00019608572,0.0003327552,0.0001379213,0.00019685765,0.00042112975,4.089568e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028045098,0.01825079,0.95954067,0.00013404245,0.00071886124,0.0020361603,0.00040014787,0.000006338465,0.000023834606,0.000015657353,0.000009855099,0.016059129],"study_design_scores_gemma":[0.042482574,0.11164066,0.83907014,0.00015259968,0.005007235,0.0012539369,0.00012228977,0.0000050786443,0.000006424195,0.0000375186,0.00003497405,0.00018657517],"about_ca_topic_score_codex":0.00057776354,"about_ca_topic_score_gemma":0.00017955786,"teacher_disagreement_score":0.12047054,"about_ca_system_score_codex":0.00022129278,"about_ca_system_score_gemma":0.00078194065,"threshold_uncertainty_score":0.9999913},"labels":[],"label_agreement":null},{"id":"W2127685474","doi":"10.1200/jco.2007.15.2280","title":"Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"American Society of Clinical Oncology; AstraZeneca","keywords":"Medicine; Erlotinib; Lung cancer; Internal medicine; Placebo; Hazard ratio; Cancer; Clinical trial; Chemotherapy; Quality of life (healthcare); Surgery; Gastroenterology; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.22132737951902,"score_gpt":0.5780171170297974,"score_spread":0.35668973751077737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127685474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093944,0.0005188325,0.00011431837,0.004548507,0.0020439394,0.001348279,0.000118496784,0.0000015641826,0.00036662017],"genre_scores_gemma":[0.9958321,0.00066548,0.00071008655,0.0016500935,0.00079874555,0.000104453735,0.0000071552067,0.000010553221,0.00022132986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336493,0.0012628249,0.004306651,0.00022463966,0.0006468765,0.00019410088],"domain_scores_gemma":[0.9894953,0.0054014022,0.0036848707,0.00022619778,0.0010251665,0.00016709065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008849779,0.00014056478,0.0023028515,0.00015481118,0.00009366184,0.0000035727298,0.00033726165,0.00018357277,0.00007382779],"category_scores_gemma":[0.0046785795,0.000071400056,0.000896175,0.00056530454,0.00020963716,0.00010050549,0.000027981936,0.000562319,5.7111386e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036425106,0.006827572,0.9471015,0.000040162828,0.0059373914,0.000055696662,0.0011194169,0.0073094866,0.00006371794,0.000043140855,0.0030341712,0.024825243],"study_design_scores_gemma":[0.01953246,0.0069418293,0.9536471,0.000072150266,0.009021735,0.000011276996,0.0009083639,0.0011479515,0.00001970044,0.00002742875,0.008593212,0.000076823206],"about_ca_topic_score_codex":0.03208002,"about_ca_topic_score_gemma":0.5316696,"teacher_disagreement_score":0.4995896,"about_ca_system_score_codex":0.00043977392,"about_ca_system_score_gemma":0.015517228,"threshold_uncertainty_score":0.9900639},"labels":[],"label_agreement":null},{"id":"W2127735232","doi":"10.1200/jco.2013.49.4757","title":"Use of Statins and the Risk of Death in Patients With Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":660,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Prostate cancer; Hazard ratio; Proportional hazards model; Internal medicine; Cancer; Cohort; Population; Cohort study; Confidence interval; Oncology","score_opus":0.035762110068693044,"score_gpt":0.36562801515454474,"score_spread":0.3298659050858517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127735232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977955,0.0006935312,0.00002527464,0.00028828063,0.00093555154,0.00018754246,0.000021835547,3.0898045e-7,0.000052161067],"genre_scores_gemma":[0.99088675,0.0069123623,0.0010050406,0.00027394845,0.00083012955,0.000006310847,0.0000016764908,0.0000065260283,0.00007724506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984356,0.0003322492,0.00092722266,0.00009049143,0.00011526993,0.00009914888],"domain_scores_gemma":[0.9977477,0.00032505393,0.0013540771,0.00011103767,0.00039358047,0.00006851762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084976346,0.00006596878,0.00054787914,0.00002809656,0.000010952359,0.0000036919027,0.00008661554,0.0001160558,0.000012535655],"category_scores_gemma":[0.0009666439,0.000033852717,0.00010137136,0.00003925319,0.0002982632,0.000009166456,0.000040482224,0.0002147841,1.7144765e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054709804,0.0003061082,0.9502492,0.000010686632,0.00017495961,1.10972486e-7,0.00011471952,0.000097969896,0.0003187866,0.000029417779,0.0023401077,0.040886942],"study_design_scores_gemma":[0.0078061516,0.0026040955,0.9370321,0.000021143873,0.00009255703,0.0000014044136,0.000035411467,0.000014441774,0.0001811554,0.000104406834,0.052065354,0.0000418008],"about_ca_topic_score_codex":0.0006757103,"about_ca_topic_score_gemma":0.0004985546,"teacher_disagreement_score":0.04972525,"about_ca_system_score_codex":0.00000771944,"about_ca_system_score_gemma":0.00039697922,"threshold_uncertainty_score":0.13804737},"labels":[],"label_agreement":null},{"id":"W2127896588","doi":"10.1200/jco.2009.26.9712","title":"Longitudinal Study of Depressive Symptoms in Patients With Metastatic Gastrointestinal and Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Psychosocial; Depression (economics); Distress; Population; Anxiety; Psychiatry; Social support; Cancer; Clinical psychology; Internal medicine; Psychology","score_opus":0.05514210097744585,"score_gpt":0.44034314537114466,"score_spread":0.3852010443936988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127896588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986991,0.00014589429,0.000039472605,0.0002573129,0.00050593825,0.00023994205,0.000003022599,0.0000018772364,0.000107393476],"genre_scores_gemma":[0.9990941,0.000015058573,0.00055334263,0.00011609929,0.00019237638,0.000005379529,5.3845565e-7,0.000008975178,0.000014092633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805343,0.0001745873,0.0011652493,0.00014185318,0.00032367423,0.00014119386],"domain_scores_gemma":[0.99722636,0.0008087901,0.0010892319,0.00011561097,0.0005513622,0.00020865192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085550675,0.000097198914,0.0010089055,0.00011060671,0.000013683109,0.000003879633,0.000081595994,0.00006180699,0.00007754548],"category_scores_gemma":[0.0008626017,0.000061102226,0.00008636197,0.00011373727,0.00015635579,0.00007294442,0.000035293342,0.0009692541,1.909467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005481001,0.0026079966,0.9761631,0.00003531708,0.00024213843,0.00029304545,0.00026238716,0.00000908393,0.000013437571,0.000008517245,0.00004508132,0.014838883],"study_design_scores_gemma":[0.015489392,0.023766873,0.9593344,0.00019597753,0.0006366289,0.00016100288,0.00025915544,0.00003151975,0.0000045622905,0.000012293296,0.00005782518,0.000050392908],"about_ca_topic_score_codex":0.00038708525,"about_ca_topic_score_gemma":0.0087080235,"teacher_disagreement_score":0.021158876,"about_ca_system_score_codex":0.00004243248,"about_ca_system_score_gemma":0.00063900853,"threshold_uncertainty_score":0.48592818},"labels":[],"label_agreement":null},{"id":"W2128100826","doi":"10.1200/jco.2001.19.3.881","title":"Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer","year":2001,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":302,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Exemestane; Aromatase; Medicine; Letrozole; Anastrozole; Breast cancer; Tamoxifen; Oncology; Internal medicine; Adjuvant; Aromatase inhibitor; Clinical trial; Cancer; Hormonal therapy; Metastatic breast cancer","score_opus":0.08670870874939896,"score_gpt":0.48631868286475793,"score_spread":0.399609974115359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128100826","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033740394,0.96530646,0.0000017406072,0.00015223115,0.0003809684,0.00026115467,0.000020209642,5.240487e-7,0.00013633158],"genre_scores_gemma":[0.0013273895,0.9976065,0.00006298679,0.000041844858,0.0008523369,0.000012535806,0.00002035995,0.000011161509,0.00006487474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970271,0.0009907992,0.0016208851,0.00015131645,0.00009200663,0.000117871714],"domain_scores_gemma":[0.9975435,0.0003286745,0.0018437018,0.00014780254,0.000055123477,0.00008119469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014597693,0.00016300964,0.0014992808,0.00006647684,0.000014620303,0.0000043189343,0.00016027992,0.00079728116,0.000007047062],"category_scores_gemma":[0.00014126988,0.00008104197,0.00071521715,0.000098342265,0.00012706654,0.0000028213133,0.000028661343,0.00045419525,0.0000010108656],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019946448,0.000722355,0.00021751676,0.00024505553,0.000387416,0.00007929672,0.000011529098,0.0000012622271,0.0000131447005,0.0000035370615,0.0008840109,0.9972354],"study_design_scores_gemma":[0.0013565116,0.0075240824,0.00041842056,0.0014461934,0.000974533,0.0010550378,0.000017041846,4.2735022e-7,0.000010566859,0.000024529485,0.9870906,0.00008204749],"about_ca_topic_score_codex":0.000016796768,"about_ca_topic_score_gemma":0.000027788616,"teacher_disagreement_score":0.99715334,"about_ca_system_score_codex":0.000041687512,"about_ca_system_score_gemma":0.0009044033,"threshold_uncertainty_score":0.61493623},"labels":[],"label_agreement":null},{"id":"W2128177739","doi":"10.1200/jco.2011.41.2767","title":"Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Prostate; Oncology; Cancer; Internal medicine; Disease; Colorectal cancer; Lung; Prostate cancer; Gynecology","score_opus":0.09346562231185869,"score_gpt":0.4217044518014467,"score_spread":0.32823882948958805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128177739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564245,0.033494063,0.000023160988,0.0063938443,0.0019357526,0.0015802443,0.000030431269,0.000007763272,0.000110290406],"genre_scores_gemma":[0.9617146,0.034250148,0.000116599724,0.0010926021,0.0023201157,0.00039331464,0.0000065715235,0.000025353715,0.00008064434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677235,0.0005614986,0.0015530455,0.00028062047,0.0003689438,0.0004635339],"domain_scores_gemma":[0.99614173,0.0016555316,0.0012430267,0.00014679652,0.00023356832,0.00057936675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032006633,0.00022815038,0.0012085981,0.0001152139,0.0001236342,0.000054966,0.00009228122,0.00019679456,0.00010903283],"category_scores_gemma":[0.00044102114,0.00013618231,0.00020791254,0.00018260351,0.00040299344,0.0003674254,0.00005008838,0.00084179075,7.186269e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05938706,0.00088676834,0.85061234,0.000052294763,0.0003713685,0.00024909416,0.00074868865,0.000022332357,0.000010150015,0.000020722682,0.00067998265,0.0869592],"study_design_scores_gemma":[0.061849814,0.0037567217,0.92475617,0.00044188768,0.00060991885,0.00004844092,0.00020366177,0.00005954937,0.000007691082,0.00001845478,0.008116388,0.00013130139],"about_ca_topic_score_codex":0.0004953153,"about_ca_topic_score_gemma":0.0016129379,"teacher_disagreement_score":0.0868279,"about_ca_system_score_codex":0.00029636527,"about_ca_system_score_gemma":0.00080907287,"threshold_uncertainty_score":0.55533534},"labels":[],"label_agreement":null},{"id":"W2128499793","doi":"10.1200/jco.2013.51.8373","title":"Mounting Evidence Against Complex Decongestive Therapy As a First-Line Treatment for Early Lymphedema","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lymphedema; Breast cancer; Surgery; Axillary Lymph Node Dissection; Sentinel lymph node; Cancer; Internal medicine","score_opus":0.4433989593471903,"score_gpt":0.5218491694486296,"score_spread":0.07845021010143927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128499793","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34785813,0.005829532,0.00014428842,0.6393323,0.0026406057,0.002035425,0.000028032411,0.000028670598,0.0021030188],"genre_scores_gemma":[0.1419571,0.008889813,0.003719859,0.80172575,0.03940076,0.00019625221,0.00005948921,0.000113132104,0.003937871],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937343,0.0006317526,0.004068995,0.00044855272,0.00061895757,0.00049742614],"domain_scores_gemma":[0.97027814,0.02214908,0.005122713,0.0004209839,0.0015067607,0.0005222905],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018628789,0.0004647912,0.0039986838,0.0002028222,0.00010175649,0.000051371902,0.0003487444,0.0015607307,0.00043966214],"category_scores_gemma":[0.0103148725,0.00028347975,0.0019405758,0.00009628758,0.00027323794,0.00020548662,0.000042428663,0.0002588594,0.00015849638],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053385287,0.0016374543,0.026888056,0.00032222024,0.0026137386,0.003118552,0.00015869318,0.000005554373,0.00001486733,0.000005024346,0.7198101,0.24008717],"study_design_scores_gemma":[0.021953829,0.0430343,0.04639753,0.0021199484,0.0015906008,0.0007647083,0.000061825165,0.00013738243,0.000015231391,0.0003219207,0.8833002,0.00030256866],"about_ca_topic_score_codex":0.00015862343,"about_ca_topic_score_gemma":0.00001480974,"teacher_disagreement_score":0.2397846,"about_ca_system_score_codex":0.0008495686,"about_ca_system_score_gemma":0.005038116,"threshold_uncertainty_score":0.99996173},"labels":[],"label_agreement":null},{"id":"W2128779173","doi":"10.1200/jco.2012.41.9317","title":"Are Medicare-Based Findings Applicable to All Prostatectomy Patients?","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Massachusetts General Hospital","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Oncology; General surgery; Internal medicine; Cancer","score_opus":0.11240819200488464,"score_gpt":0.43371300764677045,"score_spread":0.32130481564188584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128779173","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12698558,0.000324873,0.0007171487,0.86205786,0.0062557133,0.0010351612,0.00002835465,0.000057413778,0.002537873],"genre_scores_gemma":[0.07866191,0.000035243746,0.0025129397,0.9001273,0.017686373,0.000049924085,0.00004291867,0.000070270864,0.0008131415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949941,0.0004069718,0.002624583,0.00036305634,0.001058645,0.00055266474],"domain_scores_gemma":[0.9923767,0.0020973305,0.003442099,0.00032277833,0.0010135362,0.0007475557],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0028481535,0.0003107786,0.0025592933,0.00038185465,0.00004748354,0.000017166301,0.00028387926,0.0022415759,0.0003176237],"category_scores_gemma":[0.0054841484,0.00022712945,0.0008792556,0.00025872016,0.00013595104,0.000073985764,0.000079752,0.006281298,0.00011481332],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009566187,0.0005174339,0.031996153,0.00014649233,0.0002896297,0.00067594287,0.000029625588,0.0000035061867,0.000004535305,2.1311382e-7,0.9145604,0.04220992],"study_design_scores_gemma":[0.005852341,0.027203148,0.05351745,0.0003813894,0.0007259706,0.00012278436,0.0000115046705,0.000009966974,0.00004753573,0.000017643326,0.911912,0.00019824566],"about_ca_topic_score_codex":0.00003211002,"about_ca_topic_score_gemma":0.000020486794,"teacher_disagreement_score":0.048323665,"about_ca_system_score_codex":0.00056853663,"about_ca_system_score_gemma":0.0014509162,"threshold_uncertainty_score":0.9990537},"labels":[],"label_agreement":null},{"id":"W2128936398","doi":"10.1200/jco.2007.12.5070","title":"Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Bendamustine; Internal medicine; Rituximab; Neutropenia; Nausea; Gastroenterology; Phases of clinical research; Adverse effect; Refractory (planetary science); Surgery; Vomiting; Lymphoma; Chemotherapy","score_opus":0.08933246323390666,"score_gpt":0.40151559454303215,"score_spread":0.3121831313091255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128936398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706805,0.00026044893,0.0000098118935,0.0010567326,0.0005204145,0.00084759993,0.000055943245,0.000007811705,0.00017321562],"genre_scores_gemma":[0.99730617,0.00044700064,0.0011989543,0.0006405076,0.0003212836,0.000013483832,0.000031101677,0.000020880645,0.000020620146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957442,0.000298401,0.0027216778,0.000368088,0.0005704901,0.0002970867],"domain_scores_gemma":[0.9961628,0.0014507902,0.001314537,0.0002304178,0.0003245826,0.00051690417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009393158,0.00025570276,0.0018244988,0.00018983036,0.00008660833,0.000007298855,0.00011050559,0.0002451236,0.000029766617],"category_scores_gemma":[0.00097156706,0.00015931985,0.00022750978,0.00013048976,0.00020471434,0.0001541031,0.000054313576,0.00039761982,0.0000046492455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055523623,0.20823726,0.54527706,0.000007578504,0.00052193546,0.0032774683,0.0019217194,0.0000021680924,0.000010939331,1.7152246e-7,0.00028277285,0.1849373],"study_design_scores_gemma":[0.29662055,0.09871376,0.60058933,0.000146516,0.0004154307,0.000046506062,0.0002105079,0.000023522696,0.000037140155,0.0000014811995,0.0031062327,0.00008903116],"about_ca_topic_score_codex":0.00022346567,"about_ca_topic_score_gemma":0.000265283,"teacher_disagreement_score":0.24109693,"about_ca_system_score_codex":0.00047420457,"about_ca_system_score_gemma":0.0008107997,"threshold_uncertainty_score":0.64968747},"labels":[],"label_agreement":null},{"id":"W2128941584","doi":"10.1200/jco.2005.02.027","title":"Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Docetaxel; Medicine; Paclitaxel; Metastatic breast cancer; Internal medicine; Regimen; Chemotherapy; Oncology; Taxane; Hazard ratio; Breast cancer; Population; Cancer; Confidence interval","score_opus":0.17264541902181682,"score_gpt":0.5539230823189485,"score_spread":0.38127766329713164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128941584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886082,0.0009994874,0.000029872215,0.008198516,0.00041278903,0.0009389241,0.00001126278,0.0000048819575,0.0007961062],"genre_scores_gemma":[0.996273,0.00071550114,0.0009762416,0.0010963628,0.00065243663,0.000040262516,0.0000019265035,0.00001361215,0.00023065983],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99494827,0.0011316627,0.0031815849,0.00017702603,0.00033994167,0.00022149089],"domain_scores_gemma":[0.99397993,0.0028934446,0.0022996897,0.0001396288,0.00040706474,0.00028023153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035883945,0.00016930138,0.004075596,0.00022429039,0.00001866977,0.0000032633475,0.00012382683,0.00010845973,0.0008830586],"category_scores_gemma":[0.00031476066,0.00009794416,0.00039384287,0.00022460918,0.00030771925,0.00010456447,0.000023504004,0.000700034,0.0000035260307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85301995,0.05439378,0.03909006,0.000030459225,0.0034238147,0.0008386304,0.0012038194,0.00028805083,0.0000964395,0.000014950009,0.0017614071,0.04583862],"study_design_scores_gemma":[0.93303305,0.023768783,0.03432594,0.00009943697,0.0039626197,0.00048584427,0.0007663087,0.0004372266,0.0000295818,0.000034021767,0.002967361,0.00008984094],"about_ca_topic_score_codex":0.00039917947,"about_ca_topic_score_gemma":0.0018376373,"teacher_disagreement_score":0.08001307,"about_ca_system_score_codex":0.00020679152,"about_ca_system_score_gemma":0.0014746763,"threshold_uncertainty_score":0.9668872},"labels":[],"label_agreement":null},{"id":"W2129057429","doi":"10.1200/jco.2011.34.6379","title":"Association of Diagnostic Radiation Exposure and Second Abdominal-Pelvic Malignancies After Testicular Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Interquartile range; Malignancy; Hazard ratio; Cancer; Testicular cancer; Radiology; Cancer registry; Confidence interval; Surgery; Internal medicine","score_opus":0.05333568842113223,"score_gpt":0.3882795679941915,"score_spread":0.33494387957305927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129057429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98870325,0.00980555,0.000044578843,0.0006805044,0.00043152308,0.00013621779,0.000011479953,0.0000034041282,0.00018347219],"genre_scores_gemma":[0.996305,0.0015115621,0.0012430077,0.00048491335,0.00029341376,0.000009282639,0.0000013408309,0.00000846016,0.00014303718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835664,0.000170943,0.0010430403,0.000102256585,0.00020858675,0.00011853215],"domain_scores_gemma":[0.99534875,0.0024363578,0.0015381705,0.00008547534,0.00037619376,0.0002150269],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0007676082,0.000085957414,0.0007067241,0.000059312744,0.000014354796,0.0000032370933,0.00003698071,0.00020203381,0.00044335614],"category_scores_gemma":[0.009692078,0.000060483908,0.00022159347,0.000058776626,0.00006942925,0.00007984212,0.000016136262,0.00020385467,0.000004775967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009295175,0.00096340803,0.9376403,0.000064681706,0.00054113107,0.0005450334,0.00012696125,0.0000010693135,0.000054446256,0.000010597179,0.00044235188,0.05868049],"study_design_scores_gemma":[0.0050293594,0.0049392916,0.9855631,0.00016249383,0.0019251908,0.00009137271,0.000036995087,0.000017068163,0.00011730124,0.0003569028,0.0017103355,0.000050569146],"about_ca_topic_score_codex":0.000026863556,"about_ca_topic_score_gemma":0.00004317334,"teacher_disagreement_score":0.058629923,"about_ca_system_score_codex":0.00010944577,"about_ca_system_score_gemma":0.0005245635,"threshold_uncertainty_score":0.9986497},"labels":[],"label_agreement":null},{"id":"W2129115519","doi":"10.1200/jco.2004.01.187","title":"Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Women's College Hospital; Hamilton Health Sciences; University of Toronto; SickKids Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Psychological intervention; Logistic regression; Randomized controlled trial; Clinical trial; Decision aids; Odds ratio; Odds; Accrual; Family medicine; Univariate; Multivariate statistics; Internal medicine; Alternative medicine; Nursing; Pathology","score_opus":0.8383024724611503,"score_gpt":0.7025962569994029,"score_spread":0.13570621546174744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129115519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595209,0.00056012557,0.0010951688,0.02991645,0.007601802,0.00093514065,0.000006651612,0.000015291898,0.0003484702],"genre_scores_gemma":[0.9607144,0.022144644,0.0012744678,0.013987433,0.0017255237,0.00004003546,0.0000016494106,0.00003611159,0.0000757592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9725831,0.011772141,0.012263212,0.00051065517,0.002321171,0.00054969627],"domain_scores_gemma":[0.20243953,0.78343654,0.007962511,0.00092302717,0.0038299058,0.001408519],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18499188,0.00029468827,0.0057984083,0.00018685995,0.00014416462,0.000048740596,0.0009660596,0.0012741302,0.00025531146],"category_scores_gemma":[0.7265143,0.00012733207,0.003710967,0.00025726162,0.0019273581,0.00035155477,0.00036525502,0.009610119,0.00003060731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23262922,0.0038890815,0.5464797,0.000041183055,0.0015327404,0.00014280765,0.00050728343,0.00007614629,0.000012251736,0.00044755093,0.0016754866,0.21256655],"study_design_scores_gemma":[0.37111166,0.010154625,0.52996445,0.0015843967,0.0010146118,0.00002698198,0.000647199,0.000027887929,0.00018287708,0.039850798,0.04521064,0.00022384973],"about_ca_topic_score_codex":0.000186628,"about_ca_topic_score_gemma":0.00037336504,"teacher_disagreement_score":0.7716644,"about_ca_system_score_codex":0.00032709472,"about_ca_system_score_gemma":0.004359173,"threshold_uncertainty_score":0.99267477},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"methods","study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2129174532","doi":"10.1200/jco.2008.17.1249","title":"Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Irinotecan; Medicine; Oxaliplatin; Internal medicine; Colorectal cancer; Capecitabine; Oncology; Hazard ratio; Gastroenterology; Progression-free survival; FOLFIRINOX; Chemotherapy; Cancer; Confidence interval","score_opus":0.19102390280021747,"score_gpt":0.4228029072623538,"score_spread":0.23177900446213634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129174532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070203,0.0026763899,0.00012645293,0.00340822,0.0006676829,0.0012485844,0.000047264468,0.000023097591,0.0011002796],"genre_scores_gemma":[0.9897492,0.0009147486,0.006003217,0.0012769348,0.0009073439,0.00015913224,0.000019972582,0.000048720416,0.0009207132],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9963338,0.00025762344,0.0021038176,0.00039678207,0.00044575086,0.0004622281],"domain_scores_gemma":[0.9957114,0.001539049,0.0013259283,0.00024155906,0.00065809453,0.00052398856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006070733,0.00041510037,0.0029710317,0.0001678118,0.00015703616,0.000011855711,0.0001297706,0.0001933459,0.00044904693],"category_scores_gemma":[0.00031848278,0.00024090163,0.0007849646,0.00017221266,0.00046875342,0.00009038366,0.00004024578,0.00042981206,0.00001045872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52089196,0.038904365,0.15551181,0.00015698269,0.013131158,0.019028677,0.004878785,0.00026352608,0.002292307,0.00003239945,0.0042729406,0.24063511],"study_design_scores_gemma":[0.08131931,0.43460706,0.40256268,0.00009728053,0.0018105871,0.004473067,0.0004600646,0.00029920475,0.005544217,0.00006919139,0.068369195,0.00038817406],"about_ca_topic_score_codex":0.00016129366,"about_ca_topic_score_gemma":0.0011716429,"teacher_disagreement_score":0.43957263,"about_ca_system_score_codex":0.0011306655,"about_ca_system_score_gemma":0.002356858,"threshold_uncertainty_score":0.98236835},"labels":[],"label_agreement":null},{"id":"W2129233769","doi":"10.1200/jco.2015.62.9899","title":"Sex: Taboos, Assumptions, and Evidence","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Taboo; Medicine; Survivorship curve; Reproductive health; Health care; Population; Family medicine; Gerontology; Environmental health","score_opus":0.48925170215220937,"score_gpt":0.547231402203237,"score_spread":0.057979700051027594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129233769","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032541244,0.018412918,0.00016025278,0.9620496,0.0096468665,0.00017875926,0.0000034806394,0.000024254488,0.006269712],"genre_scores_gemma":[0.0010256636,0.009030936,0.0013724151,0.921585,0.03145285,0.0000043436385,0.0000064973933,0.000028167384,0.03549412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99566144,0.00064784277,0.0024906541,0.00026665285,0.000721351,0.00021204154],"domain_scores_gemma":[0.99013937,0.0056501147,0.002249796,0.00023310125,0.0013666804,0.00036096724],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0048997034,0.00021238682,0.0024328085,0.00022645011,0.00005326574,0.00001622172,0.00010725617,0.0015808726,0.00033786343],"category_scores_gemma":[0.017082138,0.00014181346,0.00039946247,0.00010849277,0.00033955282,0.00012660041,0.00008469041,0.0048823403,0.00014371754],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092124176,0.00015262085,0.010777966,0.000087689055,0.00059237337,0.0014658927,0.000042479893,3.375922e-7,0.0000027156693,0.0000061970695,0.9505497,0.035400752],"study_design_scores_gemma":[0.002836778,0.0083506545,0.012383928,0.0003011999,0.0012027123,0.002289678,0.00014527663,0.000004533233,6.5296445e-7,0.00013980604,0.9722268,0.000117996344],"about_ca_topic_score_codex":0.000011674825,"about_ca_topic_score_gemma":0.0000036506808,"teacher_disagreement_score":0.040464625,"about_ca_system_score_codex":0.00014323484,"about_ca_system_score_gemma":0.002321106,"threshold_uncertainty_score":0.99971527},"labels":[],"label_agreement":null},{"id":"W2129247180","doi":"10.1200/jco.2015.61.4115","title":"Survivorship and Quality of Life in Head and Neck Cancer","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck cancer; Survivorship curve; Quality of life (healthcare); Head and neck; Cancer; Disease; Intensive care medicine; Incidence (geometry); Radiation therapy; Human papillomavirus; Oncology; Internal medicine; Surgery; Nursing","score_opus":0.6494552911413024,"score_gpt":0.6409589376341076,"score_spread":0.008496353507194798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129247180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049213972,0.9468773,4.9152044e-7,0.0015857896,0.0008460158,0.0002138132,0.000011254575,0.0000019359559,0.0012494539],"genre_scores_gemma":[0.0017030023,0.996366,0.00021937107,0.0005643199,0.0010083184,0.0000060372795,9.5069964e-7,0.000014819839,0.00011717581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99347216,0.0013014413,0.004556865,0.00019817623,0.0002890721,0.00018225783],"domain_scores_gemma":[0.99178624,0.004122666,0.00307125,0.00013599549,0.00037393425,0.000509921],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009274121,0.00019418508,0.010084918,0.00014705966,0.000012141688,0.0000028503475,0.000092034476,0.0006988928,0.000023841285],"category_scores_gemma":[0.008531276,0.000119206525,0.00043016297,0.00015031244,0.00032883583,0.000039458213,0.0000875802,0.0014176473,0.0000011199168],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008856009,0.0003494156,0.07618311,0.0079324525,0.00038090642,0.000057559922,0.00008146566,3.536931e-8,5.5267886e-8,0.000030870022,0.0014109286,0.9126876],"study_design_scores_gemma":[0.0043269936,0.00487319,0.07613478,0.010158325,0.00067492377,0.000058473775,0.000039043425,3.6713735e-7,1.9457532e-8,0.000051939634,0.90358603,0.00009592974],"about_ca_topic_score_codex":0.00071138644,"about_ca_topic_score_gemma":0.0036386182,"teacher_disagreement_score":0.9125917,"about_ca_system_score_codex":0.00014244198,"about_ca_system_score_gemma":0.005741123,"threshold_uncertainty_score":0.9998954},"labels":[],"label_agreement":null},{"id":"W2129277265","doi":"10.1200/jco.2012.42.2444","title":"Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Genentech; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; IC Design Education Center; Biogen","keywords":"Medicine; Vincristine; Mantle cell lymphoma; Rituximab; Cyclophosphamide; Ibritumomab tiuxetan; Radioimmunotherapy; Internal medicine; Oncology; Phases of clinical research; Doxorubicin; Prednisone; Lymphoma; Chemotherapy; Monoclonal antibody; Immunology; Antibody","score_opus":0.05367725134889992,"score_gpt":0.41884830891929253,"score_spread":0.3651710575703926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129277265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880233,0.007312927,0.000015128021,0.0007731248,0.00081481284,0.0021393655,0.000023178498,0.000019365672,0.00087883737],"genre_scores_gemma":[0.99648476,0.0016064567,0.0005210638,0.00054888695,0.00036795813,0.00007108664,0.000019415076,0.000054833443,0.00032552643],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921996,0.0015762756,0.0044183303,0.0005339434,0.00062933785,0.000642539],"domain_scores_gemma":[0.99334586,0.0023351794,0.0026900207,0.0004442684,0.00052753737,0.00065716077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030443124,0.0005219617,0.004632468,0.00030638845,0.00012967021,0.000018082952,0.00028385554,0.00054425414,0.000100458405],"category_scores_gemma":[0.00073190854,0.00037751562,0.00037810527,0.000436511,0.00032055058,0.00026979623,0.00020428082,0.00060715835,0.000012491744],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034680184,0.43846577,0.4600355,0.00003329797,0.0017329701,0.0022270493,0.0038800086,0.0000021691415,0.0012144226,0.000007755325,0.0022146462,0.055506222],"study_design_scores_gemma":[0.44707233,0.30000418,0.23725517,0.00011790822,0.0017583442,0.00051427307,0.006223032,0.00009031249,0.0009096486,0.000009079518,0.0057591777,0.00028656697],"about_ca_topic_score_codex":0.00082761334,"about_ca_topic_score_gemma":0.00036389494,"teacher_disagreement_score":0.41239214,"about_ca_system_score_codex":0.0009789569,"about_ca_system_score_gemma":0.0013123372,"threshold_uncertainty_score":0.9998677},"labels":[],"label_agreement":null},{"id":"W2129318139","doi":"10.1200/jco.2005.07.168","title":"Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":312,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health","funders":"","keywords":"Melanoma; Medicine; Protein kinase B; Tissue microarray; Immunohistochemistry; Pathology; Metastasis; Proportional hazards model; Oncology; Internal medicine; Cancer; Cancer research; Apoptosis; Biology","score_opus":0.11109159700651668,"score_gpt":0.4550711240125238,"score_spread":0.34397952700600715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129318139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978039,0.0008983559,0.000091133734,0.00018704336,0.00048979814,0.0003291263,0.000007137018,0.000003212991,0.00019029569],"genre_scores_gemma":[0.9962879,0.00024683395,0.0025841936,0.00016288985,0.0006487629,0.0000139417425,0.000002555016,0.000017099323,0.000035819172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950366,0.001150852,0.0029888628,0.00031087903,0.00028464617,0.0002281755],"domain_scores_gemma":[0.9943356,0.0016764079,0.0031148419,0.00030982436,0.00043200355,0.00013131634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031637927,0.00016748448,0.0011901754,0.00011437047,0.000019639352,0.0000034304094,0.00041714963,0.00051185297,0.000037821672],"category_scores_gemma":[0.007453127,0.00012835204,0.00027908484,0.00016446307,0.00023934833,0.000012458823,0.00012812675,0.00058581604,0.0000017497925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054097716,0.009644215,0.29635447,0.00003139282,0.00015072922,0.00029996593,0.00017155605,0.0009558803,0.66335016,0.0000021055462,0.00070295396,0.022926766],"study_design_scores_gemma":[0.01919088,0.10377929,0.302519,0.00031108918,0.0003120176,0.00030357533,0.0010748858,0.000052371157,0.5624661,0.000108981905,0.009476657,0.00040518734],"about_ca_topic_score_codex":0.000016293237,"about_ca_topic_score_gemma":0.00011186529,"teacher_disagreement_score":0.10088411,"about_ca_system_score_codex":0.00005010758,"about_ca_system_score_gemma":0.0008783959,"threshold_uncertainty_score":0.89226276},"labels":[],"label_agreement":null},{"id":"W2129331946","doi":"10.1200/jco.2012.48.5052","title":"Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":488,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"University of California, Los Angeles; Hospices Civils de Lyon; Masarykova Univerzita; Erasmus Medisch Centrum; University of Ulsan; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Seoul National University; Brain Tumour Charity; Chonnam National University; Université de Lyon; Semmelweis Egyetem; Newcastle University; Debreceni Egyetem; Cancer Research UK; Action Medical Research; Children's Cancer and Leukaemia Group; Deutsche Krebshilfe; University of Cincinnati; University of Pittsburgh; Chonnam National University Hwasun Hospital; Johns Hopkins University; National Cancer Institute; Emory University","keywords":"Medulloblastoma; Sonic hedgehog; Wnt signaling pathway; Medicine; Mutation; Oncology; Cohort; Cancer research; PTCH1; Germline; Internal medicine; Mutant; Biology; Genetics; Gene","score_opus":0.09211854731170643,"score_gpt":0.43136135795658187,"score_spread":0.33924281064487544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129331946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98173094,0.0004892573,0.000059672442,0.01531953,0.00031266492,0.0003881804,0.0000017209593,0.0000045579955,0.0016934894],"genre_scores_gemma":[0.99630857,0.00035547884,0.002496742,0.00054341584,0.00023673387,0.000032973734,0.0000035236594,0.000009449161,0.000013142656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722487,0.00018352555,0.0021128238,0.00012469868,0.00020262695,0.00015146591],"domain_scores_gemma":[0.9955776,0.002291889,0.0012578954,0.00015618645,0.00049525464,0.00022121561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000928121,0.00008735739,0.0008988932,0.00018103319,0.0000143494235,0.0000052340383,0.000093720184,0.000198636,0.0002147592],"category_scores_gemma":[0.0015284114,0.000060450333,0.00028241068,0.00022291536,0.00012263673,0.000086316744,0.000019804813,0.00034914957,0.000047511556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002935633,0.005648835,0.79633147,0.000020072945,0.00014527282,0.0002190351,0.0000796689,0.000017357279,0.0020970863,0.00083333196,0.0054048053,0.1889095],"study_design_scores_gemma":[0.005459559,0.0061157104,0.97846836,0.00009220265,0.0001426175,0.00028992703,0.00008455346,0.000030730538,0.00048095177,0.0016029854,0.0071877167,0.000044716446],"about_ca_topic_score_codex":0.000025870842,"about_ca_topic_score_gemma":0.00004671019,"teacher_disagreement_score":0.1888648,"about_ca_system_score_codex":0.000105127576,"about_ca_system_score_gemma":0.00040967262,"threshold_uncertainty_score":0.24650931},"labels":[],"label_agreement":null},{"id":"W2129455737","doi":"10.1200/jco.2015.63.5979","title":"Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Penn State Hershey Cancer Institute; National Cancer Institute; Walter Reed National Military Medical Center; University of Texas MD Anderson Cancer Center; West Virginia University; University of South Florida; University of South Carolina; University of California, Irvine; University of Ottawa; Pennsylvania State University; University of Pittsburgh; University of Cincinnati; Ochsner Health; University of Louisville; Wake Forest University; University of Pennsylvania; Moffitt Cancer Center; Vanderbilt University; Yale University","keywords":"Medicine; Workforce; Reimbursement; Cancer prevention; Oncology; Focus group; Internal medicine; Medical education; Career development; Family medicine; Clinical Oncology; Cancer; Health care","score_opus":0.2421789295470344,"score_gpt":0.5889012365373968,"score_spread":0.3467223069903624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129455737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8294579,0.004305415,0.012813155,0.14604037,0.0059306114,0.0007520947,0.000023487695,0.000013571952,0.0006634191],"genre_scores_gemma":[0.82767063,0.026096687,0.09940335,0.030909017,0.014335545,0.00016212887,0.000024317085,0.000057548554,0.0013407634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928406,0.0018685369,0.0042872704,0.0003655079,0.00035380534,0.00028429882],"domain_scores_gemma":[0.988486,0.005482446,0.0043862015,0.00028834637,0.00061557954,0.00074145367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009571182,0.0001845747,0.0023266128,0.00007707025,0.00007123198,0.0000057451084,0.00024342541,0.000579193,0.00024494965],"category_scores_gemma":[0.007176172,0.0001229997,0.0006317005,0.00047643925,0.001025385,0.000142757,0.00009873803,0.0017917838,0.0000014180948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008689592,0.00082163326,0.3641962,0.000004842157,0.00046429274,0.00019627032,0.0006200008,0.00008216617,0.000008153166,0.000017606837,0.04514797,0.57975125],"study_design_scores_gemma":[0.014493418,0.017163692,0.2913638,0.00048746163,0.0007273859,0.00037529838,0.0022121011,0.0001368441,0.0000059158137,0.0021620982,0.6706984,0.00017356846],"about_ca_topic_score_codex":0.00044996507,"about_ca_topic_score_gemma":0.0038669931,"teacher_disagreement_score":0.62555045,"about_ca_system_score_codex":0.00053499825,"about_ca_system_score_gemma":0.006595571,"threshold_uncertainty_score":0.99903613},"labels":[],"label_agreement":null},{"id":"W2129554678","doi":"10.1200/jco.2008.17.1363","title":"Predictive Model for Survival in Patients With Advanced Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":203,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer; Prognostic variable; Radiation therapy; Internal medicine; Palliative care; Survival analysis; Oncology; Proportional hazards model","score_opus":0.14664893419694497,"score_gpt":0.4731475998314987,"score_spread":0.3264986656345537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129554678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862779,0.00007573002,0.00926434,0.0022392143,0.00048553414,0.0005557938,0.000017042197,0.000004953333,0.0010795346],"genre_scores_gemma":[0.9807056,0.00018481108,0.01685677,0.0016213986,0.00018766428,0.000021104122,0.000004440614,0.00001508226,0.00040313607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978361,0.00012548044,0.0013114095,0.00014478057,0.00040471653,0.00017752015],"domain_scores_gemma":[0.9973773,0.00073701533,0.00095600385,0.000117009324,0.0005554625,0.00025725825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011870757,0.0000952627,0.0010195555,0.00010207019,0.000019746012,0.0000013019896,0.00009221542,0.0000987597,0.000039947656],"category_scores_gemma":[0.0020898676,0.000063175874,0.00019489681,0.0000859915,0.00012586276,0.0001136392,0.00002189273,0.00037107893,0.0000012699937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053707626,0.0044712494,0.8912456,0.00005509741,0.00038794221,0.00018643077,0.00014966675,0.004915697,0.0000011136275,0.000057359648,0.0031831623,0.04163907],"study_design_scores_gemma":[0.03815853,0.013777303,0.9277257,0.00008563223,0.0003634938,0.0000040432456,0.000053224045,0.017122097,0.0000010016763,0.00020491866,0.0024354341,0.000068650515],"about_ca_topic_score_codex":0.0000035623955,"about_ca_topic_score_gemma":0.000021305335,"teacher_disagreement_score":0.041570418,"about_ca_system_score_codex":0.0001198161,"about_ca_system_score_gemma":0.0013616743,"threshold_uncertainty_score":0.25762373},"labels":[],"label_agreement":null},{"id":"W2129638180","doi":"10.1200/jco.2007.12.3083","title":"Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Internal medicine; Placebo; Gastroenterology; Oncology; Cancer; Phases of clinical research; Chemotherapy; Surgery; Pathology; Sorafenib","score_opus":0.2888795793822542,"score_gpt":0.5751775702922032,"score_spread":0.28629799090994895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129638180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916983,0.00019286993,0.00006169825,0.0021736003,0.0017370756,0.0040662424,0.00004566471,0.0000049902246,0.000019551244],"genre_scores_gemma":[0.9961205,0.0004947144,0.00033229537,0.0012335115,0.0013109974,0.00019119219,0.0000025693942,0.000029365967,0.00028481253],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9893242,0.0030901686,0.0053922096,0.00039862233,0.001411468,0.0003833211],"domain_scores_gemma":[0.988769,0.0057030264,0.0032400722,0.00021217066,0.0016422048,0.00043351497],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02533067,0.00025731712,0.002976155,0.00035772385,0.00008141948,0.000007648467,0.0002267897,0.0002252886,0.0002631452],"category_scores_gemma":[0.010044691,0.00013846277,0.00018561613,0.00061725016,0.00020896502,0.0001645301,0.000071790164,0.0009513591,1.9612688e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50277686,0.02059345,0.44300854,0.000030835214,0.0012282392,0.00017746871,0.0017128503,0.0000714317,0.00013955327,1.4249586e-7,0.0012085704,0.029052082],"study_design_scores_gemma":[0.18923001,0.18104297,0.6173336,0.0001913615,0.00039398923,0.000007609947,0.0011875748,0.00008715585,0.000100430356,0.0000011030448,0.010277772,0.00014643448],"about_ca_topic_score_codex":0.0197544,"about_ca_topic_score_gemma":0.6925155,"teacher_disagreement_score":0.6727611,"about_ca_system_score_codex":0.0014118936,"about_ca_system_score_gemma":0.016168335,"threshold_uncertainty_score":0.9982941},"labels":[],"label_agreement":null},{"id":"W2129660553","doi":"10.1200/jco.2010.34.2766","title":"Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"GlaxoSmithKline; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Tamoxifen; Breast cancer; Hazard ratio; Cancer; Cause of death; Randomized controlled trial; Adjuvant therapy; Internal medicine; Disease; Confidence interval","score_opus":0.09580322712969981,"score_gpt":0.43579809778631096,"score_spread":0.33999487065661116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129660553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472486,0.009536673,0.000020012669,0.03932019,0.002749752,0.00062903966,0.0003953221,0.0000015822341,0.000098824006],"genre_scores_gemma":[0.6846921,0.14094262,0.0006258736,0.15698375,0.01434127,0.00012224833,0.00018412701,0.00018285941,0.0019251365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99217355,0.0010686868,0.0056151384,0.000348173,0.000271433,0.00052299624],"domain_scores_gemma":[0.989122,0.0012306441,0.008534276,0.00034098187,0.000563469,0.00020862887],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008737988,0.00032159683,0.0040872246,0.00017632611,0.000013622368,0.000004366577,0.00054929004,0.003266992,0.00022388487],"category_scores_gemma":[0.0016626435,0.00021778555,0.0018935051,0.00008523283,0.00027158685,0.0000065020986,0.0000737698,0.0015633173,9.844912e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047280923,0.0019541942,0.08606748,0.00050355616,0.007785252,0.00071013824,0.0005146781,0.0000040179275,0.026303528,0.0000041656076,0.67762643,0.15124565],"study_design_scores_gemma":[0.060091715,0.06163117,0.07252465,0.0011435621,0.0016056472,0.00061699,0.00008800461,0.000007182965,0.028532801,0.00046894353,0.77232516,0.00096419087],"about_ca_topic_score_codex":0.000039931474,"about_ca_topic_score_gemma":0.000022793376,"teacher_disagreement_score":0.2625565,"about_ca_system_score_codex":0.00010543031,"about_ca_system_score_gemma":0.002738844,"threshold_uncertainty_score":0.99802697},"labels":[],"label_agreement":null},{"id":"W2129805561","doi":"10.1200/jco.2013.49.3007","title":"Do<i>BRCA1</i>and<i>BRCA2</i>Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital","funders":"","keywords":"Medicine; Ovarian cancer; BRCA mutation; Breast cancer; Proportional hazards model; Hazard ratio; Oophorectomy; Internal medicine; Germline mutation; Mutation; Gynecology; Cohort; Cancer; Oncology; Obstetrics; Genetics; Surgery; Hysterectomy; Confidence interval; Biology; Gene","score_opus":0.08474180481747456,"score_gpt":0.44651590242212136,"score_spread":0.3617740976046468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129805561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979754,0.0014513623,0.0005003293,0.015037099,0.0020734917,0.0006653828,0.00017884494,0.000005542026,0.00033399306],"genre_scores_gemma":[0.99136657,0.0008513548,0.0028807707,0.001040909,0.0032191116,0.00010376065,0.000096912685,0.00003540448,0.00040521318],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99588674,0.0012236784,0.0016265488,0.00049006427,0.00040573717,0.00036720344],"domain_scores_gemma":[0.9930131,0.0029664298,0.001306696,0.00039296172,0.0020818457,0.00023895837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047425306,0.00020861303,0.00055572926,0.00008208057,0.00032685057,0.00009366005,0.00045168263,0.000538804,0.000045203557],"category_scores_gemma":[0.00526617,0.00013816314,0.00023809669,0.00014047914,0.0009615455,0.000060641403,0.00017964485,0.0010722778,0.0000075628564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023578672,0.0006397762,0.058801383,0.000042485866,0.004184421,0.000034155764,0.01848202,0.0010140247,0.14392145,0.00039988806,0.110463984,0.63843775],"study_design_scores_gemma":[0.022419391,0.008259724,0.61684555,0.00020907335,0.0005361533,0.00018565274,0.01366003,0.002054704,0.00917366,0.0127380695,0.31311944,0.00079853315],"about_ca_topic_score_codex":0.0008860295,"about_ca_topic_score_gemma":0.0010880774,"teacher_disagreement_score":0.6376392,"about_ca_system_score_codex":0.00029266806,"about_ca_system_score_gemma":0.002220685,"threshold_uncertainty_score":0.63044775},"labels":[],"label_agreement":null},{"id":"W2129931005","doi":"10.1200/jco.2007.13.4452","title":"Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1077,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Imatinib mesylate; Imatinib; GiST; Regimen; Internal medicine; Surgery; Oncology; Phases of clinical research; Clinical trial; Gastroenterology; Tyrosine-kinase inhibitor; Progression-free survival; Chemotherapy; Stromal cell; Cancer","score_opus":0.16920565310826752,"score_gpt":0.4733452979920085,"score_spread":0.30413964488374096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129931005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947917,0.000121659024,0.001120298,0.0016164196,0.0003168733,0.0017233397,0.000014656627,0.000016607524,0.00027848876],"genre_scores_gemma":[0.951799,0.00002061041,0.046923578,0.00027362962,0.0005245562,0.000049331018,0.000019416217,0.00004469743,0.00034519908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99080926,0.0026804158,0.0040527303,0.00041050138,0.0012496614,0.00079745747],"domain_scores_gemma":[0.9865208,0.008448825,0.0031246159,0.00034244158,0.00079286564,0.00077040115],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007107732,0.00040743803,0.003439924,0.00029027782,0.0002380097,0.00006532886,0.00035840584,0.00006944214,0.00058424636],"category_scores_gemma":[0.01667129,0.00019440727,0.0006333539,0.00037931008,0.0010883595,0.0004234565,0.00019162659,0.0018180149,0.000016480482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9376905,0.011159046,0.033732478,0.00003843485,0.00036914437,0.009041002,0.00011006052,0.000045185603,0.00038885375,0.000009832721,0.0006098198,0.006805665],"study_design_scores_gemma":[0.87539554,0.08784369,0.028323581,0.0015310084,0.00046894167,0.0052105444,0.00016327186,0.00054664497,0.00016846124,0.0000374449,0.0001534578,0.00015740584],"about_ca_topic_score_codex":0.00007514468,"about_ca_topic_score_gemma":0.000046916884,"teacher_disagreement_score":0.07668464,"about_ca_system_score_codex":0.00059721613,"about_ca_system_score_gemma":0.0026980676,"threshold_uncertainty_score":0.9916117},"labels":[],"label_agreement":null},{"id":"W2129949052","doi":"10.1200/jco.2005.17.624","title":"Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Florida","keywords":"Pathology; Lymphoma; Medicine; Follicular lymphoma; Meningioma; Trisomy; CD20; Biology","score_opus":0.06687284808909537,"score_gpt":0.3863512028436509,"score_spread":0.3194783547545555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129949052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98814416,0.0034938592,0.00012639814,0.0061988006,0.0007311913,0.00039540094,0.000016279017,0.000017148506,0.00087673677],"genre_scores_gemma":[0.9442575,0.0044499813,0.047677357,0.0019188904,0.0015386852,0.000014703065,0.000007412607,0.000029715795,0.000105770945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950077,0.00044918843,0.003187393,0.0003883951,0.0005529012,0.00041441395],"domain_scores_gemma":[0.9939955,0.0022622016,0.0025478431,0.00031979263,0.00031780318,0.00055689155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018822835,0.00030399574,0.002475924,0.0002236221,0.000062640276,0.0000152310195,0.00021622077,0.0006308197,0.00013238324],"category_scores_gemma":[0.00093751505,0.00021762129,0.0007472026,0.00016990361,0.00056255277,0.00012964787,0.0001342524,0.0003131985,0.000023642824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004765914,0.010482676,0.22380981,0.00008813088,0.00041957732,0.0051796455,0.00010787545,0.000006530492,0.0005351926,0.00004126673,0.0014059017,0.7531575],"study_design_scores_gemma":[0.029756956,0.014646785,0.9253414,0.00021511498,0.0010796421,0.0128958365,0.00007939206,0.0002591043,0.00061733514,0.00010057724,0.014830238,0.00017758866],"about_ca_topic_score_codex":0.000016187569,"about_ca_topic_score_gemma":0.000020039362,"teacher_disagreement_score":0.7529799,"about_ca_system_score_codex":0.0004252928,"about_ca_system_score_gemma":0.0018889778,"threshold_uncertainty_score":0.8874339},"labels":[],"label_agreement":null},{"id":"W2129967236","doi":"10.1200/jco.20005.14.589","title":"Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":621,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; AstraZeneca","keywords":"Raltitrexed; Medicine; Internal medicine; Lung cancer; Neutropenia; Cisplatin; Gastroenterology; Mesothelioma; Chemotherapy; Cancer; Surgery; Oncology; Thymidylate synthase; Pathology; Fluorouracil","score_opus":0.10968481404991379,"score_gpt":0.47846716869778916,"score_spread":0.36878235464787534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129967236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997334,0.00018756496,0.0000027354147,0.0004271583,0.00007553971,0.0019044015,0.000048198966,5.5308925e-7,0.000019840014],"genre_scores_gemma":[0.99949753,0.0001376275,0.000089540365,0.000058310176,0.000097398195,0.00006817432,0.0000031192321,0.000009628419,0.00003865689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997226,0.00074539037,0.0012050184,0.00013192056,0.0005952176,0.0000964685],"domain_scores_gemma":[0.9974756,0.0008599238,0.0011928449,0.000082067054,0.00030981237,0.0000797301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016644488,0.00009897817,0.0010006706,0.000076186996,0.00004549472,0.000002295971,0.000083360705,0.000029169607,0.00002814908],"category_scores_gemma":[0.00019291394,0.00003905518,0.000045772078,0.00010710816,0.00047587353,0.00008261838,0.000030652685,0.0001189566,5.8496794e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34602675,0.0079110535,0.63987464,0.000025260246,0.00061017746,0.0000031173504,0.0016538906,0.0003027345,0.000037643884,0.000006110459,0.000017470016,0.0035311917],"study_design_scores_gemma":[0.35547614,0.015509077,0.6269971,0.000117070354,0.0005049193,0.0000016891287,0.0009377255,0.0003714583,0.000034202243,0.000004252102,0.000016726011,0.00002966325],"about_ca_topic_score_codex":0.044718422,"about_ca_topic_score_gemma":0.4645396,"teacher_disagreement_score":0.41982117,"about_ca_system_score_codex":0.00028093177,"about_ca_system_score_gemma":0.001067938,"threshold_uncertainty_score":0.96164286},"labels":[],"label_agreement":null},{"id":"W2130090226","doi":"10.1200/jco.2008.18.1891","title":"Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Medicine; Hazard ratio; Breast cancer; Proportional hazards model; Radiation therapy; Confidence interval; Chemotherapy; Breast-conserving surgery; Internal medicine; Confounding; Stage (stratigraphy); Surgery; Cancer; Gynecology; Oncology; Mastectomy","score_opus":0.07716643206880092,"score_gpt":0.3776667982616139,"score_spread":0.300500366192813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130090226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875779,0.00033564022,0.00020464067,0.010678133,0.00039968302,0.0003099192,0.00046307375,0.000012100501,0.000018880877],"genre_scores_gemma":[0.99180084,0.0013774051,0.0003196581,0.00487377,0.0011593943,0.00009820912,0.000019597586,0.0000611989,0.00028992145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727786,0.00033614997,0.0012729841,0.00041007725,0.00027543976,0.00042749452],"domain_scores_gemma":[0.9951746,0.0011073172,0.0024640313,0.00025994144,0.0007100024,0.00028411715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011151241,0.00031237092,0.0016184191,0.00009197143,0.0001289007,0.000025058318,0.00024060193,0.00037046004,0.000066212066],"category_scores_gemma":[0.00052396196,0.00021351983,0.0003205792,0.0001454285,0.00016944719,0.000031217878,0.000054810276,0.00032842063,0.0000015076121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017456545,0.0005338502,0.9510916,0.000009699916,0.0020047836,0.00005895074,0.0004740901,0.000047801717,0.00054691953,1.5031944e-7,0.0013139892,0.026461639],"study_design_scores_gemma":[0.0067637158,0.0022945344,0.9859971,0.00025421733,0.00007938174,0.00009511097,0.00023302955,0.0000052008727,0.00045127474,0.0000046321566,0.0035530636,0.00026877638],"about_ca_topic_score_codex":0.00027395427,"about_ca_topic_score_gemma":0.0020505236,"teacher_disagreement_score":0.03490548,"about_ca_system_score_codex":0.00030893798,"about_ca_system_score_gemma":0.0007568964,"threshold_uncertainty_score":0.8707086},"labels":[],"label_agreement":null},{"id":"W2130244150","doi":"10.1200/jco.2005.08.391","title":"Dignity Therapy: A Novel Psychotherapeutic Intervention for Patients Near the End of Life","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":1020,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; St. Boniface Hospital","funders":"","keywords":"Dignity; Medicine; Intervention (counseling); Psychosocial; Feeling; Distress; Palliative care; Meaning (existential); Psychotherapist; Depression (economics); Psychiatry; Nursing; Clinical psychology; Psychology; Social psychology","score_opus":0.3032002047393502,"score_gpt":0.5107964315329052,"score_spread":0.207596226793555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130244150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871226,0.00038633528,0.0016525037,0.009026664,0.0007739645,0.00037274614,0.000008405326,0.0000038136184,0.00065295014],"genre_scores_gemma":[0.9895477,0.00031724115,0.0034027656,0.005911405,0.0007401493,0.0000043774917,0.0000030318702,0.000009994083,0.00006328727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974587,0.00025182322,0.0018204034,0.00009163435,0.00024558138,0.00013186007],"domain_scores_gemma":[0.99518317,0.0022318247,0.0017722001,0.00016311729,0.00049144594,0.00015824303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025016833,0.0000846,0.00072543445,0.000047676935,0.000054577962,0.000007910858,0.00018844848,0.00020116674,0.00013972221],"category_scores_gemma":[0.0029063807,0.000048013437,0.0006932884,0.00007606104,0.00028794887,0.0001006307,0.000017870227,0.00047976006,0.000006032033],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016011173,0.013388175,0.09516155,0.000039193827,0.00064055424,0.0000011721596,0.00062499254,0.000007996568,0.00014220944,0.0001260503,0.0023139168,0.871543],"study_design_scores_gemma":[0.030953478,0.031069392,0.46684453,0.00010306784,0.00022825424,0.0000117536665,0.0000650449,0.00026096095,0.00009810448,0.00097498926,0.469321,0.00006939619],"about_ca_topic_score_codex":0.0000061649334,"about_ca_topic_score_gemma":0.000011252831,"teacher_disagreement_score":0.8714736,"about_ca_system_score_codex":0.00003910031,"about_ca_system_score_gemma":0.0005788638,"threshold_uncertainty_score":0.3479419},"labels":[],"label_agreement":null},{"id":"W2130421964","doi":"10.1200/jco.2013.31.31_suppl.248","title":"The Ontario oncology electronic medical record (EMR): The integration of end user and provincial needs.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Focus group; Blueprint; Health care; Information system; Data collection; Medical education","score_opus":0.24168618807998107,"score_gpt":0.5449903661789212,"score_spread":0.30330417809894006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130421964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8354671,0.00018653173,0.00061603216,0.16001439,0.001549154,0.0005368309,6.2997475e-7,0.000005055219,0.0016242499],"genre_scores_gemma":[0.9832121,0.0018971342,0.0021245647,0.009836189,0.0020483946,0.000017801065,0.0000035231799,0.000015868158,0.00084440893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922823,0.0014208427,0.00511437,0.00015870857,0.0007098773,0.000313935],"domain_scores_gemma":[0.96256196,0.031248312,0.0041788192,0.00028703207,0.0013427123,0.0003811682],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016604742,0.00013823951,0.0010695052,0.000084839136,0.000104934705,0.000020744723,0.00030580175,0.0005500136,0.0011468998],"category_scores_gemma":[0.06342275,0.00006526808,0.000336781,0.00015469079,0.0007199759,0.00024393084,0.00011937722,0.0029246542,0.000022193026],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003086399,0.00070707826,0.035878915,0.000006866861,0.00028485575,0.000029866851,0.0003946137,4.900737e-7,0.00018482332,0.0012482927,0.02064772,0.9375301],"study_design_scores_gemma":[0.006032086,0.020137003,0.24410677,0.000044524608,0.0005269098,0.00065545697,0.0014160688,0.00023694703,0.000040498082,0.0034981351,0.72323096,0.000074662516],"about_ca_topic_score_codex":0.008352137,"about_ca_topic_score_gemma":0.14088027,"teacher_disagreement_score":0.9374554,"about_ca_system_score_codex":0.00047850297,"about_ca_system_score_gemma":0.011036808,"threshold_uncertainty_score":0.9997662},"labels":[],"label_agreement":null},{"id":"W2130500372","doi":"10.1200/jco.2012.44.0891","title":"Running on Empty: Cardiovascular Reserve Capacity and Late Effects of Therapy in Cancer Survivorship","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Survivorship curve; Cancer survivorship; Cancer therapy; Cancer; Oncology; Internal medicine; Gerontology","score_opus":0.4039983713532273,"score_gpt":0.5129550905837975,"score_spread":0.10895671923057021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130500372","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32542956,0.6728781,0.0000038854787,0.000103654675,0.0009182408,0.00047246373,0.0000022992292,0.000003323157,0.00018846744],"genre_scores_gemma":[0.05911795,0.9386494,0.000116278665,0.00030424833,0.001725026,0.000016560234,0.0000026376642,0.000036614154,0.000031256754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471647,0.0018318532,0.0024560757,0.0002464364,0.00048683325,0.00026232345],"domain_scores_gemma":[0.9930746,0.0039021722,0.002189051,0.00032159418,0.00023138602,0.00028121],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00877178,0.0002831886,0.00681097,0.00027086562,0.000021308988,0.000005312861,0.00014835245,0.0013509421,0.000011480244],"category_scores_gemma":[0.0015695989,0.00018899988,0.0024072656,0.00023227581,0.00019140226,0.00007742295,0.000030261324,0.002442451,0.0000017445024],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000525783,0.00048192102,0.0029029134,0.0057485164,0.002851007,0.00016028986,0.0001476919,0.000003005436,0.00003062087,0.000019112678,0.00002046124,0.98710865],"study_design_scores_gemma":[0.008767886,0.0075589763,0.026263012,0.027394371,0.0042537604,0.00026928092,0.000014547776,0.000002983932,0.00030538306,0.00011168557,0.9247811,0.0002770062],"about_ca_topic_score_codex":0.0003354825,"about_ca_topic_score_gemma":0.00010781901,"teacher_disagreement_score":0.98683167,"about_ca_system_score_codex":0.00027911304,"about_ca_system_score_gemma":0.001138312,"threshold_uncertainty_score":0.9999455},"labels":[],"label_agreement":null},{"id":"W2130588419","doi":"10.1200/jco.2006.05.6564","title":"Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Proportional hazards model; Oncology; Breast cancer; Internal medicine; Hazard ratio; Cohort; Biomarker; Cancer; Estrogen receptor; Confidence interval","score_opus":0.07107749962900999,"score_gpt":0.41324720208829896,"score_spread":0.34216970245928896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130588419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98302156,0.0037193624,0.0026865501,0.0074055027,0.0017676832,0.00039620115,0.00043585664,0.000008616728,0.0005586836],"genre_scores_gemma":[0.9878763,0.00034988957,0.007821726,0.00062564714,0.0029785722,0.00006797097,0.000075593984,0.000032064825,0.0001722316],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997869,0.00010646671,0.0012785638,0.00028608023,0.00016488573,0.00029496767],"domain_scores_gemma":[0.9974453,0.0005217439,0.0010863565,0.00015586874,0.0006583727,0.0001323563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000668815,0.00019648044,0.00073999376,0.000039406696,0.0000706552,0.000009174617,0.00022225062,0.00040669137,0.00002807836],"category_scores_gemma":[0.0005802327,0.00015206024,0.00055896,0.00006874189,0.00030958588,0.000007667711,0.00008585122,0.00023078441,0.0000039397555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018317632,0.0053635025,0.19223595,0.000042532924,0.0031313624,0.00003814283,0.00003986482,0.000052826577,0.57684135,0.0002610016,0.06681724,0.1368586],"study_design_scores_gemma":[0.013570269,0.004049688,0.8781106,0.00011104635,0.00087022886,0.00085604395,0.00006894514,0.000026448773,0.013998284,0.00025679762,0.08765533,0.00042635217],"about_ca_topic_score_codex":0.000116915624,"about_ca_topic_score_gemma":0.00003131624,"teacher_disagreement_score":0.68587464,"about_ca_system_score_codex":0.0001432909,"about_ca_system_score_gemma":0.00084467744,"threshold_uncertainty_score":0.62008363},"labels":[],"label_agreement":null},{"id":"W2130603905","doi":"10.1200/jco.2014.56.2157","title":"Targeted Therapies in Non–Small-Cell Lung Cancer Management: No Cost-Effective Strategies?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.05229756594478189,"score_gpt":0.47000264755812027,"score_spread":0.41770508161333836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130603905","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028138753,0.008797962,0.0010010101,0.7902801,0.011495626,0.007816302,0.000055411387,0.000039063747,0.1523758],"genre_scores_gemma":[0.052788004,0.01006263,0.0040657525,0.8992564,0.02005828,0.0008791864,0.00012158403,0.00014416942,0.012623975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622995,0.0005717176,0.0020767078,0.00034571998,0.0003722152,0.00040371958],"domain_scores_gemma":[0.99512917,0.0015872563,0.00228312,0.00026879882,0.00055185327,0.00017977705],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012448969,0.00033247075,0.0022590465,0.00032566648,0.000041376432,0.000028393675,0.00024997987,0.0012768578,0.0004485107],"category_scores_gemma":[0.00016901363,0.00022750981,0.00064258615,0.00016791528,0.00014948868,0.00010817782,0.00004518465,0.003648844,0.00004150413],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014218568,0.0011148852,0.011873719,0.0007962982,0.0046075163,0.007888245,0.00034654516,0.000075076685,0.000010916687,0.000021225906,0.8953525,0.076491244],"study_design_scores_gemma":[0.013759449,0.004436771,0.036913272,0.00069557526,0.003269052,0.00006647198,0.00014064414,0.00009573141,0.0000040153327,0.00013798618,0.9402812,0.00019979487],"about_ca_topic_score_codex":0.0001357939,"about_ca_topic_score_gemma":0.0000900281,"teacher_disagreement_score":0.13975182,"about_ca_system_score_codex":0.0008096364,"about_ca_system_score_gemma":0.0020382535,"threshold_uncertainty_score":0.9986498},"labels":[],"label_agreement":null},{"id":"W2130888802","doi":"10.1200/jco.2012.45.5733","title":"Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":361,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Clinical Oncology; Guideline; Clinical Practice; Cancer; Central venous catheter; Intensive care medicine; Patient care; Internal medicine; Oncology; Catheter; Family medicine; Surgery; Nursing; Pathology","score_opus":0.18802318823459033,"score_gpt":0.568407217957096,"score_spread":0.38038402972250573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130888802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.831571,0.0027491974,0.0053715385,0.1416919,0.012320229,0.0036005338,0.00013478455,0.00003378397,0.0025270812],"genre_scores_gemma":[0.7934612,0.019852752,0.09542702,0.078176506,0.01250338,0.0002235631,0.000022717277,0.00009844093,0.00023441392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9818655,0.004420712,0.011609766,0.00048175562,0.00064033107,0.0009818926],"domain_scores_gemma":[0.9363621,0.0423698,0.015247358,0.000580397,0.0045665936,0.00087374036],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0124681685,0.000303419,0.004122656,0.000055611436,0.00045703174,0.000011329382,0.00069479516,0.0010722829,0.00039582563],"category_scores_gemma":[0.009575515,0.00016370375,0.0027493057,0.00023108847,0.0012955978,0.00020744442,0.00020431132,0.0039959326,0.000024151304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005844189,0.005744631,0.07019275,0.00006704543,0.001806164,0.00003206274,0.004182694,0.0001415865,0.000003961614,0.00004059758,0.16548367,0.7464607],"study_design_scores_gemma":[0.0069513978,0.046284553,0.05134543,0.00009759846,0.0017378286,0.000033812394,0.016961133,0.0006862162,0.0000020827213,0.000066484215,0.8756472,0.00018625746],"about_ca_topic_score_codex":0.0026736087,"about_ca_topic_score_gemma":0.0014688622,"teacher_disagreement_score":0.7462744,"about_ca_system_score_codex":0.000526135,"about_ca_system_score_gemma":0.0107417395,"threshold_uncertainty_score":0.99876726},"labels":[],"label_agreement":null},{"id":"W2130925341","doi":"10.1200/jco.2012.44.8936","title":"Moving Toward Quality Palliative Cancer Care: Parent and Clinician Perspectives on Gaps Between What Matters and What Is Accessible","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Palliative care; Pediatric oncology; Family medicine; Childhood cancer; Sibling; Cancer; Nursing; Psychology; Internal medicine","score_opus":0.2780482237289408,"score_gpt":0.5585018613591504,"score_spread":0.2804536376302096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130925341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83222073,0.050261017,0.000034523764,0.11493111,0.002149256,0.0002349032,0.000010238,0.000011585607,0.0001466111],"genre_scores_gemma":[0.8777656,0.08587168,0.0007581821,0.031512868,0.004026947,0.0000063463285,0.0000022905706,0.000025473239,0.00003062152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99459624,0.001257054,0.002670285,0.00039674086,0.00065004034,0.0004296643],"domain_scores_gemma":[0.9903412,0.0055473694,0.002473167,0.00025777068,0.00045945312,0.00092103827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00587494,0.0002634599,0.0022221857,0.00014025091,0.00009403276,0.00014601715,0.00018159283,0.00044430012,0.00012718327],"category_scores_gemma":[0.0018609202,0.00020066657,0.00039777337,0.0001250651,0.00046331447,0.0017176861,0.00014905394,0.0014201184,0.00000678944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001388799,0.0005036668,0.72828704,0.00020371072,0.00060449925,0.000016611919,0.044034418,6.9790923e-7,0.00000613962,0.0000527502,0.0010086366,0.223893],"study_design_scores_gemma":[0.004369123,0.0032799179,0.83090246,0.0012427628,0.00047157414,0.000013933087,0.13884205,0.0000014740804,0.00006019112,0.00014077284,0.020484416,0.00019132464],"about_ca_topic_score_codex":0.0003157961,"about_ca_topic_score_gemma":0.0001555926,"teacher_disagreement_score":0.22370169,"about_ca_system_score_codex":0.00039234612,"about_ca_system_score_gemma":0.0008025801,"threshold_uncertainty_score":0.8182945},"labels":[],"label_agreement":null},{"id":"W2130986759","doi":"10.1200/jco.2011.41.5851","title":"Ocular Toxicity of Targeted Therapies","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Targeted therapy; Clinical trial; Toxicity; Pharmacology; Intensive care medicine; Oncology; Internal medicine; Cancer","score_opus":0.2882437561746445,"score_gpt":0.5463924532056644,"score_spread":0.25814869703101995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130986759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001198039,0.99425775,0.000040160667,0.00037864983,0.002160126,0.0003912612,0.000009838398,0.0000069047996,0.0015572719],"genre_scores_gemma":[0.0013681413,0.99095404,0.0053486624,0.00033570582,0.0016788392,0.0000054688953,0.000014120116,0.000035026307,0.00026001176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99302286,0.0016088169,0.0045345845,0.00019104138,0.00035794644,0.0002847293],"domain_scores_gemma":[0.9893279,0.0028453018,0.0066562695,0.0003414593,0.0004108856,0.00041815557],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004219182,0.00031415728,0.008863462,0.00022492673,0.00002846278,0.000002252684,0.0002579313,0.0020129438,0.00048820477],"category_scores_gemma":[0.0021655525,0.0001807776,0.0033357039,0.00018133108,0.0003904612,0.000074330834,0.00006811308,0.0019348373,0.000073590156],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046346214,0.0037553753,0.0023457643,0.0020958555,0.0061064754,0.0008273615,0.000025621528,3.7259518e-8,8.188755e-7,0.00015395637,0.00045996672,0.9837653],"study_design_scores_gemma":[0.0031489271,0.009725966,0.0018404725,0.0023981873,0.014054016,0.0012132244,0.000012628378,1.6846802e-7,0.0000047765543,0.00020898136,0.9672766,0.00011607621],"about_ca_topic_score_codex":0.0000023388836,"about_ca_topic_score_gemma":0.0000029088103,"teacher_disagreement_score":0.98364925,"about_ca_system_score_codex":0.0001920563,"about_ca_system_score_gemma":0.0034644476,"threshold_uncertainty_score":0.99928266},"labels":[],"label_agreement":null},{"id":"W2131164186","doi":"10.1200/jco.2008.21.2951","title":"Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lapatinib; Medicine; Metastatic breast cancer; Paclitaxel; Human Epidermal Growth Factor Receptor 2; Oncology; Cancer; Internal medicine; Breast cancer; Epidermal growth factor receptor; Trastuzumab","score_opus":0.49592093157260586,"score_gpt":0.6018659244381601,"score_spread":0.10594499286555425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131164186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58732086,0.0005160906,0.00003726028,0.39632332,0.0036666584,0.0035792997,0.008353854,0.000044843448,0.00015781498],"genre_scores_gemma":[0.5221087,0.0016932919,0.0006285289,0.46252924,0.011435551,0.00025053765,0.0008627263,0.0001302245,0.00036125525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9824681,0.009186706,0.0052301134,0.00096098357,0.0008934076,0.0012606678],"domain_scores_gemma":[0.96904594,0.020098206,0.006295148,0.00038883396,0.0028168352,0.00135505],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004013363,0.0010123304,0.0050968877,0.000296535,0.00086960354,0.000050404633,0.001192844,0.0041050254,0.0039371043],"category_scores_gemma":[0.0019483026,0.000719506,0.0010840921,0.00030947247,0.0008949152,0.00031011098,0.00019103082,0.018235328,0.000045168847],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11248269,0.028087243,0.11848758,0.00030155142,0.014521125,0.0028744827,0.002742849,0.00011114958,0.000050420076,0.00007549172,0.5991059,0.1211595],"study_design_scores_gemma":[0.074704856,0.060109485,0.18601507,0.0003777226,0.0040534087,0.00009080714,0.00031833228,0.00016568236,0.00007840906,0.0014963597,0.6713668,0.0012230447],"about_ca_topic_score_codex":0.00039766586,"about_ca_topic_score_gemma":0.00016705893,"teacher_disagreement_score":0.11993646,"about_ca_system_score_codex":0.00086302904,"about_ca_system_score_gemma":0.0038106819,"threshold_uncertainty_score":0.9995256},"labels":[],"label_agreement":null},{"id":"W2131206723","doi":"10.1200/jco.2013.48.9377","title":"Risk-Directed Treatment Intensification Significantly Reduces the Risk of Relapse Among Children and Adolescents With Acute Lymphoblastic Leukemia and Intrachromosomal Amplification of Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 Trials","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children; Leukemia and Lymphoma Research","keywords":"Medicine; Lymphoblastic Leukemia; Oncology; Internal medicine; Chromosome; Pediatrics; Leukemia; Genetics; Gene","score_opus":0.05022134207939971,"score_gpt":0.38013799819351857,"score_spread":0.32991665611411886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131206723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969672,0.00060386356,0.00014865269,0.0007779539,0.00013843876,0.0013005557,0.000038078142,0.0000073672654,0.000017869683],"genre_scores_gemma":[0.9938488,0.004588362,0.0012828212,0.000037458787,0.00018051601,0.000018184901,0.000005358264,0.000021560227,0.000016938411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99337655,0.0023039712,0.0031992926,0.0003163258,0.0005733091,0.00023057702],"domain_scores_gemma":[0.98616034,0.005103692,0.0069888225,0.00039594856,0.0010632892,0.000287931],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003596689,0.00023698002,0.0022387076,0.00014558643,0.00009416263,0.00001787552,0.00024305999,0.00037334565,0.0000129377495],"category_scores_gemma":[0.009747949,0.000109670844,0.00023171716,0.0002744708,0.0020077268,0.00013774303,0.00009223654,0.00070974336,9.2046037e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009575378,0.001676207,0.9067162,0.0000856782,0.00284951,0.000014582594,0.0011364509,0.000047270238,0.029139647,0.000018547025,0.0005263823,0.048214108],"study_design_scores_gemma":[0.01266999,0.009746638,0.9612613,0.00049827166,0.0032368978,0.00038431145,0.00048418413,0.0040317294,0.007498801,0.000081983955,0.00001375264,0.000092170856],"about_ca_topic_score_codex":0.0006767005,"about_ca_topic_score_gemma":0.000078693585,"teacher_disagreement_score":0.05454503,"about_ca_system_score_codex":0.00039017797,"about_ca_system_score_gemma":0.0019219684,"threshold_uncertainty_score":0.9985934},"labels":[],"label_agreement":null},{"id":"W2131352716","doi":"10.1200/jco.2004.08.174","title":"Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Topotecan; Medicine; Cyclophosphamide; Internal medicine; Chemotherapy; Neuroblastoma; Transplantation; Paclitaxel; Surgery; Oncology; Gastroenterology","score_opus":0.04608675601567265,"score_gpt":0.43348587867623634,"score_spread":0.3873991226605637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131352716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278575,0.000095380565,0.000007697092,0.005370595,0.00009614414,0.0015628457,0.0000156931,0.000024406423,0.00004146421],"genre_scores_gemma":[0.99765086,0.000102942504,0.0010208356,0.00089075894,0.0001802314,0.000047829544,0.000015187239,0.000039926974,0.00005142525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940836,0.0018853836,0.0022492367,0.0006036751,0.0005923134,0.0005858067],"domain_scores_gemma":[0.9957454,0.00141899,0.0007944712,0.00030063104,0.000337133,0.0014033363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002828776,0.00033597677,0.0017294366,0.0010070701,0.00009284177,0.000020251651,0.0002285962,0.00036728074,0.00003398995],"category_scores_gemma":[0.003543226,0.0002495745,0.00012893179,0.0011236776,0.0002914617,0.0002697009,0.00012794649,0.0014439209,0.000006772855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11088779,0.032358084,0.82033354,0.0000075281555,0.00023737473,0.0149983335,0.00060608983,0.00016459612,0.0017025608,0.0000075025505,0.000055810957,0.018640798],"study_design_scores_gemma":[0.060781147,0.25105268,0.68614656,0.000061118626,0.00018927775,0.0011013543,0.00017082262,0.000013711939,0.00016563991,0.00008340971,0.00009880855,0.00013546305],"about_ca_topic_score_codex":0.00048317172,"about_ca_topic_score_gemma":0.003693607,"teacher_disagreement_score":0.21869458,"about_ca_system_score_codex":0.0008105722,"about_ca_system_score_gemma":0.0024263412,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2131398863","doi":"10.1200/jco.2007.14.0228","title":"Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":340,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Exemestane; Medicine; Breast cancer; Tamoxifen; Adjuvant therapy; Internal medicine; Placebo; Oncology; Adjuvant; Letrozole; Aromatase inhibitor; Surgery; Cancer; Pathology","score_opus":0.060607640100994085,"score_gpt":0.4051019761763338,"score_spread":0.34449433607533975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131398863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959408,0.0018307146,0.000013922121,0.00093715056,0.000511827,0.0002814545,0.00029390142,0.0000024100405,0.00018784327],"genre_scores_gemma":[0.9948795,0.0036094533,0.00042092212,0.00039241582,0.0004878383,0.000020988819,0.000027558239,0.00001521472,0.000146103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968269,0.00037169625,0.0017229343,0.00034218482,0.00053774874,0.00019856216],"domain_scores_gemma":[0.9970038,0.0005316697,0.0013491635,0.0002417525,0.00072815316,0.00014546148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008624319,0.00020078618,0.0013915971,0.00016629799,0.000048275433,0.0000052963114,0.00026872294,0.00030405607,0.00007274652],"category_scores_gemma":[0.00060620223,0.00012837817,0.00096179,0.00029504122,0.00048573673,0.000012089765,0.00017253066,0.00025958047,0.0000014111835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3609268,0.008563158,0.43808177,0.000022076001,0.014980984,0.0005356705,0.0010409079,0.00013918563,0.0065465965,0.00008041196,0.002683772,0.16639866],"study_design_scores_gemma":[0.027076542,0.004437177,0.9606051,0.000039279326,0.0009602036,0.00027378154,0.00008767105,0.000015931262,0.0006564749,0.00014043179,0.005571432,0.00013598223],"about_ca_topic_score_codex":0.00026384133,"about_ca_topic_score_gemma":0.00023157286,"teacher_disagreement_score":0.52252334,"about_ca_system_score_codex":0.000059561997,"about_ca_system_score_gemma":0.00077782245,"threshold_uncertainty_score":0.523511},"labels":[],"label_agreement":null},{"id":"W2131571854","doi":"10.1200/jco.2014.55.0616","title":"Nutritional Status As a Prognostic Indicator for Pediatric Malignancies","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Intensive care medicine; Gerontology","score_opus":0.12868426166086264,"score_gpt":0.46553060837307636,"score_spread":0.3368463467122137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131571854","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10909125,0.0030853234,0.00036412134,0.878748,0.006291264,0.0011542373,0.00017421464,0.000023287419,0.0010682964],"genre_scores_gemma":[0.027510017,0.0045749084,0.003914298,0.86103266,0.101560794,0.00006613449,0.00017225038,0.000085880114,0.0010830573],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99504244,0.0002810257,0.003135975,0.00030951935,0.00071539177,0.00051565474],"domain_scores_gemma":[0.98674434,0.0077431295,0.0040811077,0.00020625185,0.00074872345,0.00047646032],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019614717,0.00027134962,0.002688977,0.00038668947,0.00004911029,0.000017861004,0.00023067748,0.002193695,0.00041599767],"category_scores_gemma":[0.008088903,0.00019371099,0.001476662,0.00011747837,0.00022971413,0.000055905333,0.000039083912,0.004048808,0.000067611],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015976311,0.00055445515,0.088948086,0.00044166387,0.0003418503,0.0011860661,0.000018443014,2.839117e-7,0.0000014919424,0.000026979522,0.901515,0.00536801],"study_design_scores_gemma":[0.0068399515,0.017940802,0.07194317,0.00015770088,0.0018919838,0.0008079932,0.000010263737,0.0000029312312,0.0000015783161,0.00093564903,0.89929724,0.00017074723],"about_ca_topic_score_codex":0.00001601429,"about_ca_topic_score_gemma":0.000004022653,"teacher_disagreement_score":0.09526953,"about_ca_system_score_codex":0.0002760127,"about_ca_system_score_gemma":0.0076999473,"threshold_uncertainty_score":0.99910164},"labels":[],"label_agreement":null},{"id":"W2131639313","doi":"10.1200/jco.2011.41.1975","title":"Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Adverse effect; Hazard ratio; Clinical trial; Adjuvant therapy; Cancer; Colorectal cancer; Nausea; Clinical endpoint; Surgery; Confidence interval","score_opus":0.20893334700636526,"score_gpt":0.4811881307217808,"score_spread":0.27225478371541556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131639313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98333204,0.0053154626,0.0000033714705,0.0051040063,0.0047950028,0.0009787544,0.00038022152,0.00000801163,0.000083152045],"genre_scores_gemma":[0.9865901,0.00898809,0.00048469353,0.0024311098,0.0012598719,0.00007962704,0.000074393654,0.000037679656,0.00005446844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657065,0.00035170265,0.0016692509,0.00040055657,0.0004904175,0.000517447],"domain_scores_gemma":[0.9927611,0.0049034166,0.0012265737,0.00036548267,0.00029515955,0.00044829046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023579325,0.00026096328,0.0015333206,0.00007829997,0.00007969339,0.000005310395,0.00037529218,0.00041713705,0.00027678968],"category_scores_gemma":[0.0024804974,0.00016785596,0.0002487717,0.00017945126,0.00014669355,0.0004161792,0.00021888786,0.0007783606,0.000005515615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025877224,0.0012265141,0.7862599,0.000017844837,0.00054935867,0.000016600023,0.0004347667,0.000007356142,0.000019883564,0.0000029094717,0.0027190098,0.18286864],"study_design_scores_gemma":[0.04149716,0.0040914887,0.92608446,0.00049409794,0.0006304552,0.000010835423,0.00011293428,0.0000871143,0.000057746754,0.000022894423,0.026759319,0.00015148689],"about_ca_topic_score_codex":0.0005977571,"about_ca_topic_score_gemma":0.0021259338,"teacher_disagreement_score":0.18271716,"about_ca_system_score_codex":0.0008240127,"about_ca_system_score_gemma":0.00078116666,"threshold_uncertainty_score":0.68449676},"labels":[],"label_agreement":null},{"id":"W2131692225","doi":"10.1200/jco.2007.14.2018","title":"Adjuvant Radiotherapy After Surgery for Pathologically Advanced Prostate Cancer","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Adjuvant; Cancer; Prostate; Adjuvant radiotherapy; Oncology; Surgery; Internal medicine","score_opus":0.11697877079212395,"score_gpt":0.47569068396395,"score_spread":0.35871191317182605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131692225","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.055997916,0.03708816,0.0002522184,0.89742213,0.0072488426,0.001581684,0.00019857519,0.000023597539,0.00018686675],"genre_scores_gemma":[0.0037755994,0.08214342,0.009579273,0.8835111,0.018845525,0.00044331126,0.00007200382,0.00010480423,0.0015249306],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99372524,0.0003622554,0.0041468376,0.0005145187,0.00056517636,0.00068596215],"domain_scores_gemma":[0.9866646,0.007433751,0.0040593455,0.00033887508,0.0011076326,0.0003958006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0036831743,0.00044599493,0.0047319694,0.00026812457,0.00003865154,0.000016530139,0.000180138,0.0020220673,0.0003722488],"category_scores_gemma":[0.001666965,0.00027496048,0.0023282464,0.0001268437,0.00031290797,0.000093543254,0.000032318796,0.003188443,0.000007069848],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01178731,0.0007511678,0.027571775,0.00020622106,0.00088563876,0.015785756,0.00003242735,0.0000030163844,0.000007387556,6.5913986e-7,0.56941617,0.37355247],"study_design_scores_gemma":[0.008439951,0.016407222,0.05740495,0.0008704704,0.0010173722,0.00046084382,0.00000814367,0.0000034917407,0.000031381198,0.00012595508,0.9149761,0.0002540923],"about_ca_topic_score_codex":0.000007454172,"about_ca_topic_score_gemma":0.000012839451,"teacher_disagreement_score":0.37329838,"about_ca_system_score_codex":0.00082350365,"about_ca_system_score_gemma":0.0040184953,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W2131838911","doi":"10.1200/jco.2008.18.0950","title":"Prevention, Screening, and Surveillance Care for Breast Cancer Survivors Compared With Controls: Changes from 1998 to 2002","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"National Cancer Institute; American Cancer Society","keywords":"Medicine; Comorbidity; Survivorship curve; Breast cancer; Cohort; Epidemiology; Internal medicine; Cancer; Mammography; Breast cancer screening","score_opus":0.07542361519554991,"score_gpt":0.4297634887299893,"score_spread":0.3543398735344394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131838911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558785,0.0062649036,0.0026046883,0.03275381,0.0011218061,0.0006321618,0.0002956019,0.000017787177,0.00043077313],"genre_scores_gemma":[0.98959696,0.00070001726,0.002111007,0.0051424396,0.0021438028,0.000015540974,0.000011511918,0.000015663774,0.00026305456],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812686,0.00021735096,0.00091258396,0.00023595251,0.0002744493,0.00023282711],"domain_scores_gemma":[0.996865,0.0009957043,0.0007920282,0.00015225085,0.00075048144,0.00044453196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009778418,0.00015184184,0.0014545674,0.000078555895,0.000051632735,0.00001506722,0.0001156944,0.00020683541,0.000098893615],"category_scores_gemma":[0.00029280884,0.000105103485,0.00021515574,0.000117674834,0.000086070904,0.000056462366,0.000016796672,0.00035876056,0.0000015817426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023905303,0.00038169898,0.35884896,0.000051084255,0.0004705662,0.00007897465,0.0009404734,0.000038341554,0.00007344363,0.000013553451,0.0056988136,0.6094988],"study_design_scores_gemma":[0.009618188,0.010888508,0.7959042,0.00027737126,0.00024981014,0.000091190814,0.0010623693,0.000045991972,0.000012419036,0.000046701654,0.18167385,0.00012936135],"about_ca_topic_score_codex":0.0010662584,"about_ca_topic_score_gemma":0.1046253,"teacher_disagreement_score":0.60936946,"about_ca_system_score_codex":0.00008347373,"about_ca_system_score_gemma":0.0005088501,"threshold_uncertainty_score":0.91171294},"labels":[],"label_agreement":null},{"id":"W2131905261","doi":"10.1200/jco.2002.20.4.987","title":"Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre","funders":"","keywords":"Medicine; Taxane; Internal medicine; Nausea; Anthracycline; Mucositis; Gastroenterology; Adverse effect; Fluorouracil; Regimen; Vomiting; Breast cancer; Diarrhea; Surgery; Cancer; Chemotherapy","score_opus":0.07787047245788842,"score_gpt":0.4332763708389843,"score_spread":0.3554058983810959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131905261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952824,0.0018844522,5.848763e-7,0.0018573105,0.00009444753,0.0007062886,0.000066058565,0.0000013404592,0.00010712728],"genre_scores_gemma":[0.99594694,0.0035667766,0.0002534632,0.000084118066,0.000057287525,0.000020998123,0.0000012777427,0.000008273665,0.000060837465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973779,0.00029641046,0.0016725125,0.00017937958,0.00033051614,0.00014333596],"domain_scores_gemma":[0.99654025,0.00091399177,0.0018456021,0.00016087695,0.00042917416,0.00011011741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004998409,0.0001651419,0.0015654769,0.00008343284,0.000039802082,0.000002589698,0.00007189539,0.00008132037,0.000047612328],"category_scores_gemma":[0.00023961821,0.00007981023,0.00012366372,0.00011291704,0.00028578914,0.00007271871,0.00003160317,0.00016574752,6.717181e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07040321,0.05328146,0.46424752,0.000054708253,0.0009958197,0.00021313653,0.0077523147,0.0000028142008,0.00011102751,0.0000010101586,0.000060177877,0.4028768],"study_design_scores_gemma":[0.06671639,0.242784,0.68521357,0.0001567253,0.00079335825,0.000023140477,0.0029317536,0.000026187696,0.000039681123,0.00000211608,0.0012545623,0.000058496815],"about_ca_topic_score_codex":0.00013695839,"about_ca_topic_score_gemma":0.0011538613,"teacher_disagreement_score":0.4028183,"about_ca_system_score_codex":0.000097897195,"about_ca_system_score_gemma":0.00014577595,"threshold_uncertainty_score":0.32545668},"labels":[],"label_agreement":null},{"id":"W2131998753","doi":"10.1200/jco.2006.06.9427","title":"Fluorodeoxyglucose Positron Emission Tomography for the Preoperative Staging of Oral Cavity Cancers: Only One Piece of the Puzzle","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Positron emission tomography; Magnetic resonance imaging; Fluorodeoxyglucose; Radiology; Cancer; Presentation (obstetrics); Disease; Nuclear medicine; Pathology; Internal medicine","score_opus":0.11454260340739665,"score_gpt":0.4463007192964313,"score_spread":0.33175811588903464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131998753","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24195194,0.0069367704,0.00024191177,0.7445206,0.003354947,0.0013322934,0.00015143064,0.000007845617,0.0015022615],"genre_scores_gemma":[0.6319436,0.0047728512,0.005717977,0.33861202,0.014531599,0.000063333115,0.00003365184,0.00012545078,0.004199517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952815,0.00068005937,0.0027568634,0.0002579137,0.0006829925,0.00034066333],"domain_scores_gemma":[0.9901863,0.00453132,0.003553219,0.00039939303,0.0012251154,0.00010470227],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028412645,0.00026381246,0.0029816497,0.000116305404,0.00014272022,0.0000065510476,0.00044529053,0.0008492294,0.00003399167],"category_scores_gemma":[0.0016121443,0.00012777929,0.0014306296,0.00022534566,0.0006989431,0.000066329194,0.00012646463,0.0032471474,3.5448267e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031154864,0.000872844,0.03393161,0.0004969017,0.0019247304,0.00006087224,0.0003708066,0.000021886597,0.0005716481,0.000010165371,0.9168619,0.04176116],"study_design_scores_gemma":[0.00785415,0.01517238,0.16021556,0.0020450572,0.00346797,0.000058960533,0.0001718917,0.000056145982,0.0018597225,0.00020357674,0.80868465,0.00020994364],"about_ca_topic_score_codex":0.0005479359,"about_ca_topic_score_gemma":0.0005076831,"teacher_disagreement_score":0.40590855,"about_ca_system_score_codex":0.00032115213,"about_ca_system_score_gemma":0.0038991822,"threshold_uncertainty_score":0.9990524},"labels":[],"label_agreement":null},{"id":"W2132125467","doi":"10.1200/jco.2012.47.6481","title":"Risk of Colorectal Cancer After Diagnosis of Endometrial Cancer: A Population-Based Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Colorectal cancer; Endometrial cancer; Hazard ratio; Cancer; Cancer registry; Internal medicine; Population; Family history; Gynecology; Incidence (geometry); Cohort; Oncology; Confidence interval; Environmental health","score_opus":0.08279932031482591,"score_gpt":0.461081315364959,"score_spread":0.3782819950501331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132125467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944003,0.0016441756,0.000007779065,0.0011663515,0.0017949076,0.00079437677,0.000058367023,0.0000046924924,0.0001290128],"genre_scores_gemma":[0.9963257,0.001296392,0.0006838849,0.0003420593,0.0010885817,0.00021769588,0.0000021022638,0.0000157143,0.000027921544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995294,0.0006621372,0.0030241606,0.00018894036,0.00062957336,0.00020122273],"domain_scores_gemma":[0.9886382,0.0067288396,0.0032041431,0.00015293642,0.0009402184,0.00033566446],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015942308,0.000157259,0.002308664,0.00034525173,0.00002194266,0.000004354497,0.00014945173,0.00026768155,0.0033905576],"category_scores_gemma":[0.0073235203,0.000099572295,0.0008017388,0.0006079903,0.00010987588,0.000088347115,0.00003771104,0.00055454305,0.000005943681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015421472,0.005770632,0.86471826,0.000036209607,0.0013162794,0.000045181532,0.000053228752,0.00006379655,0.000031291096,0.0000013078289,0.00022649734,0.11231583],"study_design_scores_gemma":[0.03152672,0.02718567,0.93806344,0.00011283702,0.001966967,0.0000030831904,0.00006449866,0.000029680261,0.00041888945,0.0000829324,0.00047159113,0.00007371284],"about_ca_topic_score_codex":0.009499431,"about_ca_topic_score_gemma":0.0012298347,"teacher_disagreement_score":0.112242125,"about_ca_system_score_codex":0.0002789753,"about_ca_system_score_gemma":0.0012258999,"threshold_uncertainty_score":0.9975205},"labels":[],"label_agreement":null},{"id":"W2132278342","doi":"10.1200/jco.2007.14.6373","title":"A for Effort: Learning From the Application of the GRADE Approach to Cancer Guideline Development","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Rubric; Grading (engineering); Guideline; Confusion; Clinical Practice; Breast cancer; Quality of evidence; Health care; Medical physics; Cancer; Family medicine; Randomized controlled trial; Pathology; Mathematics education; Internal medicine; Psychology","score_opus":0.5005251985294076,"score_gpt":0.5837039913770481,"score_spread":0.08317879284764051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132278342","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012472917,0.0003329486,0.048317406,0.93503934,0.0017202453,0.0018537816,0.000024633824,0.000008881264,0.0002298577],"genre_scores_gemma":[0.008655608,0.0005406754,0.101242505,0.8661982,0.022354763,0.00017363444,0.0001943006,0.000066659355,0.0005736923],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.989105,0.0007307122,0.008576374,0.00036012862,0.00094132527,0.00028644947],"domain_scores_gemma":[0.97362405,0.015242964,0.00905388,0.00039940642,0.0015204593,0.00015922086],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0077119977,0.0002488733,0.0019124907,0.000080817284,0.00012902857,0.000008594367,0.00065223454,0.0010444453,0.000038544113],"category_scores_gemma":[0.026947087,0.00012858582,0.00093841454,0.00022142848,0.00020086828,0.000060061062,0.00017232973,0.0044796993,0.000007162905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010442847,0.00040773043,0.009608345,0.000044771266,0.00062872085,0.0000114533,0.00017949915,0.00036482853,0.000035958357,0.000004316979,0.85546684,0.13220322],"study_design_scores_gemma":[0.004183881,0.0013070559,0.027377998,0.00012856151,0.0011541842,0.00008525559,0.00012032267,0.00066996686,0.000031008512,0.00011089956,0.9647088,0.0001220375],"about_ca_topic_score_codex":0.00034357322,"about_ca_topic_score_gemma":0.00012980733,"teacher_disagreement_score":0.1320812,"about_ca_system_score_codex":0.0003420322,"about_ca_system_score_gemma":0.0048849983,"threshold_uncertainty_score":0.997817},"labels":[],"label_agreement":null},{"id":"W2132364830","doi":"10.1200/jco.2014.57.6926","title":"Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Anastrozole; Exemestane; Vasomotor; Aromatase inhibitor; Breast cancer; Internal medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tamoxifen; Cancer; Surgery","score_opus":0.02097737467456347,"score_gpt":0.3624859293299106,"score_spread":0.34150855465534713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132364830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940072,0.0016708861,0.0000041669687,0.0024405112,0.0013418533,0.00027748098,0.000038041067,0.0000035137664,0.00021639382],"genre_scores_gemma":[0.99499005,0.0028729807,0.0000637466,0.00027328776,0.0016796223,0.000011259458,0.000016756063,0.000016825508,0.0000754456],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968475,0.0014138296,0.0010290428,0.00025434783,0.00019991137,0.00025536396],"domain_scores_gemma":[0.9978813,0.00084256247,0.0007433776,0.00023284015,0.00008410647,0.00021582232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025143698,0.00019069246,0.00078422704,0.000051598512,0.000059563357,0.000019785584,0.00021795531,0.0006554128,0.0000074278055],"category_scores_gemma":[0.0015369706,0.00010967727,0.00028998937,0.00007406431,0.00025077653,0.000011041846,0.00009299785,0.0005225508,0.0000019406812],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17154598,0.011773095,0.24337174,0.000094844116,0.0040152106,0.0010829038,0.0005014335,0.00003628768,0.031227762,0.00045352385,0.014535652,0.5213616],"study_design_scores_gemma":[0.31808537,0.10964848,0.5050241,0.00017340563,0.0015385781,0.0015483384,0.00026912955,0.0002726894,0.0007573773,0.0005244144,0.06143266,0.0007254881],"about_ca_topic_score_codex":0.0000559796,"about_ca_topic_score_gemma":0.0001567235,"teacher_disagreement_score":0.5206361,"about_ca_system_score_codex":0.000049791055,"about_ca_system_score_gemma":0.00034065932,"threshold_uncertainty_score":0.5055143},"labels":[],"label_agreement":null},{"id":"W2132432813","doi":"10.1200/jco.2005.06.233","title":"Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Anthracycline; Multivariate analysis; Chemotherapy; Cancer; Radiation therapy; Retrospective cohort study; Oncology; Population; Mastectomy; Gynecology","score_opus":0.05732890414022893,"score_gpt":0.4341003369506959,"score_spread":0.37677143281046693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132432813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030024,0.0014044188,0.0020870063,0.005112716,0.00061401003,0.00016214016,0.00010125943,0.0000071394884,0.00021108548],"genre_scores_gemma":[0.9936711,0.00041736162,0.0028748435,0.0003805203,0.0025241002,0.000031963566,0.000033999644,0.000014389308,0.000051725365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804544,0.0001940133,0.0011807879,0.00022070334,0.00015301388,0.00020602935],"domain_scores_gemma":[0.9976852,0.0004764355,0.0010825915,0.00017201898,0.00044242194,0.00014134114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007102835,0.00016673494,0.0009154236,0.000102698454,0.00007700488,0.00001727945,0.00013783433,0.00023861193,0.00005365199],"category_scores_gemma":[0.00021343844,0.0001227093,0.000843098,0.00011161054,0.00007813889,0.000014445032,0.000023006427,0.00010809751,0.0000013070648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023389244,0.00084148784,0.88018054,0.000010287961,0.0049134823,0.0000091354905,0.000040340918,0.015017845,0.00030153157,0.000065790766,0.00060017046,0.09568046],"study_design_scores_gemma":[0.005225636,0.0018800168,0.96651775,0.000012692837,0.0019186995,0.000012670331,0.0001413744,0.00074336276,0.00013596783,0.00006574843,0.02319805,0.00014802245],"about_ca_topic_score_codex":0.0001795759,"about_ca_topic_score_gemma":0.004582977,"teacher_disagreement_score":0.09553244,"about_ca_system_score_codex":0.0002521483,"about_ca_system_score_gemma":0.0015870263,"threshold_uncertainty_score":0.500394},"labels":[],"label_agreement":null},{"id":"W2132435203","doi":"10.1200/jco.2005.02.6005","title":"The Importance of Reporting Patient Recruitment Details in Phase III Trials","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Biostatistics; Medicine; Biomedical sciences; Family medicine; Cancer genetics; Research centre; Alternative medicine; Cancer; Gerontology; Epidemiology; Library science; Internal medicine; Pathology","score_opus":0.8490387405144592,"score_gpt":0.6497597711003957,"score_spread":0.19927896941406342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132435203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95712113,0.0048243003,0.00047277773,0.0314537,0.0021384123,0.0007318913,0.000016776914,0.0000038423814,0.003237196],"genre_scores_gemma":[0.9908127,0.0007949207,0.0033583858,0.0037545494,0.001099279,0.000039111314,0.0000025622403,0.000013614192,0.00012483672],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9224448,0.0027465909,0.07399619,0.0002905879,0.00017761727,0.00034419633],"domain_scores_gemma":[0.8659402,0.020675544,0.11264084,0.00034823452,0.0002356429,0.00015950752],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2695063,0.000120359386,0.004252427,0.00018944606,0.000076249016,0.00001954808,0.00026919763,0.00027705805,0.00011707158],"category_scores_gemma":[0.15219972,0.00009555103,0.0006372769,0.00015055297,0.00014021108,0.00020423913,0.000041792337,0.00052661495,0.000029301016],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016936684,0.0031015,0.8515245,0.00010051343,0.00035131304,0.000101220896,0.0006384677,0.00049334386,0.000014982421,0.04442569,0.04467015,0.05288467],"study_design_scores_gemma":[0.022041231,0.006095697,0.2547719,0.0002436408,0.000066680484,0.00008306937,0.0016720569,0.0012093622,0.000048246613,0.092644945,0.6207933,0.00032988525],"about_ca_topic_score_codex":0.00025837272,"about_ca_topic_score_gemma":0.0008993456,"teacher_disagreement_score":0.5967526,"about_ca_system_score_codex":0.0005084311,"about_ca_system_score_gemma":0.0010497262,"threshold_uncertainty_score":0.85494167},"labels":[],"label_agreement":null},{"id":"W2132545630","doi":"10.1200/jco.2007.11.3357","title":"Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":857,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"FOLFIRI; Medicine; Irinotecan; Bevacizumab; Internal medicine; Clinical endpoint; Colorectal cancer; Gastroenterology; Fluorouracil; Capecitabine; Surgery; Oncology; Randomized controlled trial; Chemotherapy; Cancer","score_opus":0.17411976480386157,"score_gpt":0.48761399367652064,"score_spread":0.3134942288726591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132545630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865525,0.0027623763,0.000013103079,0.0040178276,0.001665405,0.004580766,0.0000603052,0.0000049624336,0.00034276524],"genre_scores_gemma":[0.9905751,0.0075618383,0.0004647114,0.00017134775,0.00088879024,0.00013761176,0.00000548934,0.000014604306,0.00018053011],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910022,0.0012659978,0.006568719,0.0002567101,0.0006391401,0.00026723402],"domain_scores_gemma":[0.96143955,0.033452254,0.004109135,0.00020272785,0.00061961927,0.00017673134],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007878307,0.00028026328,0.007764979,0.0001904893,0.000062178624,0.0000049894693,0.0001751395,0.00017409396,0.0001441318],"category_scores_gemma":[0.012271207,0.00011619135,0.001270829,0.0002928716,0.0005033391,0.00004799999,0.000066682514,0.00037222155,7.705389e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9073694,0.01735956,0.012406583,0.000009628816,0.0054811616,0.0006294564,0.0016877863,0.000111230795,0.000014884747,0.000006684456,0.00019515086,0.054728474],"study_design_scores_gemma":[0.8338621,0.098500855,0.060968753,0.000104842315,0.0039375895,0.000020570591,0.0010131698,0.0001720225,0.00007049687,0.000059849335,0.0012098849,0.00007985874],"about_ca_topic_score_codex":0.005765606,"about_ca_topic_score_gemma":0.040262055,"teacher_disagreement_score":0.0811413,"about_ca_system_score_codex":0.0005090489,"about_ca_system_score_gemma":0.0024317838,"threshold_uncertainty_score":0.99604887},"labels":[],"label_agreement":null},{"id":"W2132610466","doi":"10.1200/jco.2013.52.4546","title":"Reply to J. Zhu et al","year":2013,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine","score_opus":0.22589682097931352,"score_gpt":0.5549399594787293,"score_spread":0.3290431384994158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132610466","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013706975,0.0069013676,0.00009240758,0.93983936,0.019611118,0.0007655571,0.000024816956,0.000010315029,0.019048106],"genre_scores_gemma":[0.00096117205,0.01468553,0.0037696278,0.8861927,0.02590011,0.000023970277,0.00002837939,0.00007359566,0.068364955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891908,0.0025142017,0.005327972,0.00056819513,0.0013215133,0.0010772826],"domain_scores_gemma":[0.98324376,0.009672153,0.0030511955,0.00058810663,0.0017297373,0.0017150322],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.009961567,0.00045673095,0.0042142835,0.00042654903,0.00007203737,0.0000493511,0.0006740362,0.0018532341,0.0054631643],"category_scores_gemma":[0.010902871,0.0002951207,0.001605535,0.00028159807,0.0006599638,0.00020572364,0.0002828971,0.010808169,0.0038605132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038233215,0.0012758633,0.005043394,0.0001013777,0.0015327788,0.014844732,0.000110079505,0.0000052105866,0.000039720977,0.00005312512,0.8148394,0.15833099],"study_design_scores_gemma":[0.009702012,0.03938178,0.020981327,0.0010738255,0.0007345852,0.0011111927,0.000066254535,0.000016136133,0.00002643452,0.000313027,0.92635214,0.00024129626],"about_ca_topic_score_codex":0.0001655837,"about_ca_topic_score_gemma":0.000013979125,"teacher_disagreement_score":0.1580897,"about_ca_system_score_codex":0.001130787,"about_ca_system_score_gemma":0.010171634,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W2132645593","doi":"10.1200/jco.2006.10.0909","title":"Hidden Morbidity in Cancer: Spouse Caregivers","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":527,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Hospital Foundation","keywords":"Spouse; Caregiver burden; Depression (economics); Medicine; Multilevel model; Distress; Family caregivers; Beck Depression Inventory; Clinical psychology; Grief; Population; Psychiatry; Gerontology; Anxiety; Disease","score_opus":0.1543823405513725,"score_gpt":0.49705944712505945,"score_spread":0.34267710657368694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132645593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97991914,0.0011458928,0.00006856143,0.0075947205,0.004010699,0.0000826361,0.000002313195,0.00000688859,0.007169125],"genre_scores_gemma":[0.99248326,0.0016134637,0.00028827335,0.0029531715,0.0022566991,8.9788733e-7,6.4362894e-7,0.000010475945,0.00039312293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764514,0.0001543386,0.0015206723,0.00012965345,0.00031571274,0.00023447453],"domain_scores_gemma":[0.9972589,0.0011417862,0.0007750791,0.00013973843,0.00031018836,0.0003743356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040045306,0.00008763002,0.0010026956,0.00015640934,0.000014300192,0.0000030955719,0.00013428756,0.00034227772,0.0002939337],"category_scores_gemma":[0.0009943522,0.00006742015,0.00036403048,0.00019014336,0.00012905351,0.00006808883,0.000030099864,0.0010927877,0.000010145295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055524157,0.0007202896,0.62498474,0.000026051674,0.00012466515,0.0033341292,0.00060908566,0.000011690633,0.00009699888,0.00010344098,0.008057636,0.35637885],"study_design_scores_gemma":[0.0051778387,0.0031126596,0.7812865,0.000090831076,0.00013157586,0.00019518808,0.0013853796,0.0000048664247,0.00011310717,0.00013762695,0.20829219,0.00007227305],"about_ca_topic_score_codex":0.0022726394,"about_ca_topic_score_gemma":0.026560787,"teacher_disagreement_score":0.35630658,"about_ca_system_score_codex":0.00043635652,"about_ca_system_score_gemma":0.0016723041,"threshold_uncertainty_score":0.99120194},"labels":[],"label_agreement":null},{"id":"W2132696402","doi":"10.1200/jco.2009.23.3239","title":"Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; ABVD; Lymphoma; Cancer; Randomized controlled trial; Internal medicine; Regimen; Hodgkin lymphoma; Vinblastine; Oncology; Family medicine; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.2911474729327905,"score_gpt":0.5579397610728143,"score_spread":0.2667922881400238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132696402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987472,0.0015360874,0.000004740444,0.008382525,0.00042207938,0.001512356,0.0000072255507,0.0000029577523,0.00066004257],"genre_scores_gemma":[0.9962768,0.0022875722,0.0004171206,0.0006540352,0.00025252084,0.000060407903,0.0000035664184,0.000007846698,0.000040115345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99344546,0.002304877,0.0026451717,0.00022387622,0.0011316724,0.00024891773],"domain_scores_gemma":[0.9886627,0.008276565,0.001821838,0.00028305582,0.00082604116,0.00012978552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006606835,0.00018375566,0.0022870451,0.0003237605,0.00009405941,0.000013761505,0.00026639333,0.00020178975,0.0000090218],"category_scores_gemma":[0.0024611435,0.00008342241,0.0004467072,0.00059970294,0.00067027204,0.00013029059,0.00003916311,0.00021936612,4.7292264e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23895417,0.07247418,0.28948477,0.000028644386,0.0017346082,0.0003384695,0.004238902,0.00018293504,0.000066456705,0.0038071107,0.0009405924,0.38774917],"study_design_scores_gemma":[0.36333048,0.02043949,0.5966539,0.00015894738,0.0004713873,0.000044703873,0.001072779,0.000113867776,0.00009614197,0.00047986666,0.017082071,0.000056364646],"about_ca_topic_score_codex":0.0007629968,"about_ca_topic_score_gemma":0.00069217966,"teacher_disagreement_score":0.38769278,"about_ca_system_score_codex":0.0008239669,"about_ca_system_score_gemma":0.0017132265,"threshold_uncertainty_score":0.34018672},"labels":[],"label_agreement":null},{"id":"W2132912081","doi":"10.1200/jco.2004.12.091","title":"Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Psychosocial; Breast cancer; Quality of life (healthcare); Oncology; Internal medicine; Health related quality of life; Cancer; Gerontology; Family medicine; Gynecology; Disease; Psychiatry","score_opus":0.11732354653470395,"score_gpt":0.48808492978275997,"score_spread":0.370761383248056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132912081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798062,0.0026533213,0.000041088795,0.01658142,0.0005730313,0.00013476341,0.0000699734,0.0000031222817,0.00013712367],"genre_scores_gemma":[0.99510634,0.003266379,0.0004016726,0.001009848,0.00019390964,0.0000038788016,0.0000037241039,0.0000071138534,0.0000071071695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99502426,0.0005936459,0.0037034294,0.0001534277,0.00032416682,0.00020106958],"domain_scores_gemma":[0.9948113,0.0011880095,0.0030409337,0.000109340275,0.00048336238,0.00036703577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039247726,0.0000924477,0.0026294286,0.00033883587,0.000015611931,0.0000022084876,0.000074829426,0.0003068803,0.00008720351],"category_scores_gemma":[0.0016627788,0.00007147218,0.00045256215,0.0008636893,0.00022291005,0.000054822503,0.000022606,0.0005704123,1.8016348e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061235977,0.0016535141,0.9598712,0.00012922668,0.0018000845,0.000011413728,0.0011309633,0.00021375653,0.000045815876,0.00013056876,0.00011546208,0.028774435],"study_design_scores_gemma":[0.010092629,0.0018070826,0.9856536,0.00018643058,0.0006740716,0.0000088150055,0.000729377,0.000039265673,0.000005443264,0.00021979354,0.00052845693,0.00005503066],"about_ca_topic_score_codex":0.01988151,"about_ca_topic_score_gemma":0.0376637,"teacher_disagreement_score":0.028719403,"about_ca_system_score_codex":0.00021283704,"about_ca_system_score_gemma":0.003696166,"threshold_uncertainty_score":0.98664516},"labels":[],"label_agreement":null},{"id":"W2133000379","doi":"10.1200/jco.2012.47.6952","title":"Evaluation of Treatment Benefit in <i>Journal of Clinical Oncology</i>","year":2013,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Clinical Oncology; Oncology; Internal medicine; Medical physics; Cancer","score_opus":0.7478075336161993,"score_gpt":0.6442118186150595,"score_spread":0.10359571500113984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133000379","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1450574,0.0089385025,0.00011881811,0.014241086,0.82423985,0.0010835715,0.00025181653,0.000005402793,0.0060635325],"genre_scores_gemma":[0.03483797,0.021317026,0.00784454,0.0026675395,0.9324062,0.00005656238,0.00004889669,0.00011197275,0.00070928386],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9033694,0.011471051,0.08222487,0.00079722365,0.0014557599,0.00068169204],"domain_scores_gemma":[0.7399282,0.090154156,0.16000879,0.0009989446,0.007837854,0.0010720585],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.38548282,0.0004679907,0.014339495,0.0011586259,0.000055051096,0.00003460436,0.0011340437,0.0048219343,0.0009384619],"category_scores_gemma":[0.2660035,0.00043664637,0.002421981,0.00027007403,0.00043709422,0.0006392755,0.000114415445,0.0037508146,0.0003140181],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009701267,0.0039696875,0.01711098,0.00015534673,0.0016334053,0.00003030842,0.00042959934,0.00078018085,2.9431024e-7,0.00065313256,0.89880747,0.0754595],"study_design_scores_gemma":[0.018935133,0.023351237,0.016560102,0.000435513,0.0006874922,0.000032007356,0.00035948673,0.0010640331,6.052336e-7,0.013564812,0.92469704,0.00031253867],"about_ca_topic_score_codex":0.0008429474,"about_ca_topic_score_gemma":0.0011438782,"teacher_disagreement_score":0.1634412,"about_ca_system_score_codex":0.0061772545,"about_ca_system_score_gemma":0.033392206,"threshold_uncertainty_score":0.9999748},"labels":[],"label_agreement":null},{"id":"W2133082414","doi":"10.1200/jco.2009.22.5060","title":"Late-Occurring Neurologic Sequelae in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Swim Across America; American Lebanese Syrian Associated Charities; National Cancer Institute; Frank A. Campini Foundation","keywords":"Medicine; Pediatrics; Headaches; Cohort; Incidence (geometry); Cohort study; Relative risk; Retrospective cohort study; Cumulative incidence; Adverse effect; Surgery; Internal medicine; Confidence interval","score_opus":0.04966151127471731,"score_gpt":0.40995889054411255,"score_spread":0.36029737926939526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133082414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905103,0.00034664833,0.00007438921,0.0062041944,0.0013661663,0.00086744543,0.000023504612,0.000023201446,0.00058418146],"genre_scores_gemma":[0.99206287,0.0006851145,0.00036294913,0.005357256,0.0014144267,0.000015139545,0.0000057492575,0.00003723409,0.00005928836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904758,0.0016982653,0.0052441885,0.0005932225,0.0013182816,0.00067026383],"domain_scores_gemma":[0.9861826,0.008228319,0.0033425668,0.0007456724,0.0009885718,0.0005122937],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0063300645,0.00037486793,0.002939959,0.0002785581,0.00007845651,0.000020480837,0.00084214075,0.000699413,0.00011279836],"category_scores_gemma":[0.016336972,0.00022437419,0.0006762374,0.0007429301,0.00036816113,0.00018055501,0.00023054694,0.0028964242,0.0000135953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060665836,0.0078658275,0.92819035,0.000015599013,0.0014011199,0.020234307,0.0015602732,0.0007542846,0.00021292845,0.000015539224,0.001113699,0.03256947],"study_design_scores_gemma":[0.0199592,0.01564284,0.9594224,0.00017356775,0.0009920591,0.0017337906,0.00045876252,0.00059306296,0.000044072283,0.0003748254,0.000427624,0.00017780959],"about_ca_topic_score_codex":0.0030087773,"about_ca_topic_score_gemma":0.0026578177,"teacher_disagreement_score":0.032391664,"about_ca_system_score_codex":0.0012119071,"about_ca_system_score_gemma":0.010884678,"threshold_uncertainty_score":0.99940395},"labels":[],"label_agreement":null},{"id":"W2133106296","doi":"10.1200/jco.2004.11.125","title":"Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Irinotecan; Medicine; Diarrhea; Loperamide; Gastroenterology; Toxicity; Colorectal cancer; Internal medicine; Laxative; SN-38; Cancer","score_opus":0.11278261336461685,"score_gpt":0.47802513886449416,"score_spread":0.3652425254998773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133106296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996722,0.00008316002,0.0005156706,0.0012229296,0.0010176256,0.00029802718,0.0000049679675,0.0000024691233,0.00013316136],"genre_scores_gemma":[0.9975942,0.00012591992,0.00053421763,0.00087922544,0.00077686395,0.000007210033,0.0000019693482,0.000016335604,0.00006410171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782676,0.00019453479,0.0013530403,0.00020938872,0.00022072741,0.00019552404],"domain_scores_gemma":[0.99818456,0.00006163014,0.0009434659,0.0002451166,0.0002876525,0.00027759612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012866847,0.00012735138,0.0006946188,0.00007049611,0.000043579712,0.000004073321,0.00028779934,0.00027475468,0.00002096226],"category_scores_gemma":[0.00037639256,0.00010269229,0.00026864748,0.00009651254,0.00003645505,0.000004427835,0.00014362314,0.0003411076,0.0000020310033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003089396,0.02193125,0.000034573648,0.0000044750905,0.00035352664,0.000035114423,0.00023926458,0.00011501976,0.8700238,0.00004361587,0.00010545364,0.1040245],"study_design_scores_gemma":[0.016839324,0.2507689,0.0005356221,0.000025618216,0.00012812788,0.00003917341,0.00024250867,0.0000019925305,0.69825333,0.00025879627,0.03277024,0.0001363804],"about_ca_topic_score_codex":0.000034269106,"about_ca_topic_score_gemma":0.000113289854,"teacher_disagreement_score":0.22883764,"about_ca_system_score_codex":0.00005526668,"about_ca_system_score_gemma":0.00092756713,"threshold_uncertainty_score":0.418767},"labels":[],"label_agreement":null},{"id":"W2133201432","doi":"10.1200/jco.2006.09.2403","title":"Revised Response Criteria for Malignant Lymphoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4448,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Medical physics; Harmonization; Lymphoma; Positron emission tomography; Clinical trial; Oncology; Internal medicine; Nuclear medicine","score_opus":0.18308287476718046,"score_gpt":0.5290861835862772,"score_spread":0.3460033088190968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133201432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98074424,0.00070967025,0.0005589846,0.014046807,0.0016625896,0.00033789387,0.0000048138054,0.000009040019,0.0019259634],"genre_scores_gemma":[0.9757976,0.0003553906,0.01582222,0.0057994677,0.0017052786,0.00000663612,0.0000019762283,0.000015900674,0.00049551367],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964332,0.0004222936,0.0024627782,0.00016236477,0.00024638505,0.00027296314],"domain_scores_gemma":[0.9879258,0.009604478,0.0012486276,0.00019474776,0.00053566013,0.000490648],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0142215565,0.00012113604,0.0013223087,0.00012398041,0.00004633707,0.0000083711175,0.0001044544,0.00032457913,0.00012492384],"category_scores_gemma":[0.010908005,0.00007619528,0.0007779118,0.00008556961,0.00011523405,0.000056240016,0.000024255929,0.00015787159,0.000024365807],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15471116,0.007330968,0.062456753,0.000053865988,0.00070268154,0.0057048164,0.00010105541,3.56788e-7,0.0017998168,0.00058298575,0.047714245,0.7188413],"study_design_scores_gemma":[0.020865763,0.019820334,0.54039854,0.00012002501,0.00038981508,0.000917596,0.000055563192,0.000009048169,0.0010533353,0.0002555153,0.41605607,0.000058419402],"about_ca_topic_score_codex":0.0000042664738,"about_ca_topic_score_gemma":0.000004433834,"teacher_disagreement_score":0.7187829,"about_ca_system_score_codex":0.00032093455,"about_ca_system_score_gemma":0.0015219192,"threshold_uncertainty_score":0.9974235},"labels":[],"label_agreement":null},{"id":"W2133345449","doi":"10.1200/jco.2013.53.9593","title":"Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Eli Lilly Canada; Eli Lilly and Company","keywords":"Medicine; Gemcitabine; DHAP; Autologous stem-cell transplantation; Internal medicine; Oncology; Cytarabine; Transplantation; Aggressive lymphoma; Population; Chemotherapy; Gastroenterology; Rituximab; Urology; Surgery; Lymphoma","score_opus":0.0665883136468229,"score_gpt":0.4124516741035159,"score_spread":0.345863360456693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133345449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990829,0.0042232256,0.0012368333,0.0014958765,0.0005928399,0.0010448919,0.00002066789,0.000014788418,0.0005418573],"genre_scores_gemma":[0.9718104,0.0059422385,0.021403724,0.0003993904,0.00027977134,0.000041695985,0.00001786586,0.000036391717,0.000068550384],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949983,0.0009838927,0.002916151,0.00041723717,0.0003727284,0.0003117217],"domain_scores_gemma":[0.9735608,0.021079415,0.004323524,0.00021791113,0.0003922624,0.00042607987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004153774,0.0003474593,0.0038399273,0.00021204283,0.00009229172,0.00001933519,0.00010606711,0.0006836354,0.000018845041],"category_scores_gemma":[0.0028971296,0.00023983137,0.00045573726,0.00010102121,0.00065327383,0.00015318212,0.000027643056,0.00042501063,8.927599e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3628067,0.0021950174,0.1089663,0.00039567304,0.0011189705,0.00011578966,0.0013883263,0.000011332941,0.00039779628,0.0003423328,0.00038023025,0.5218815],"study_design_scores_gemma":[0.6267493,0.029969309,0.33197138,0.0004195906,0.0031441476,0.00043088454,0.00033572217,0.0033258542,0.0010450553,0.0004729854,0.0018992415,0.00023656366],"about_ca_topic_score_codex":0.000047254067,"about_ca_topic_score_gemma":0.000085580614,"teacher_disagreement_score":0.52164495,"about_ca_system_score_codex":0.00013145922,"about_ca_system_score_gemma":0.0005035444,"threshold_uncertainty_score":0.9780039},"labels":[],"label_agreement":null},{"id":"W2133354033","doi":"10.1200/jco.2011.36.4950","title":"American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Guideline; Systemic therapy; Tamoxifen; Oncology; Breast cancer; Internal medicine; Cancer; Hormonal therapy; Adjuvant therapy; Gynecology; Clinical trial; Intensive care medicine; Hormone therapy; Stage (stratigraphy); Pathology","score_opus":0.21755191730877613,"score_gpt":0.5159748102747106,"score_spread":0.2984228929659345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133354033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13890564,0.8237088,0.000019873867,0.019660825,0.003868917,0.008619952,0.0010108014,0.000010717697,0.0041945125],"genre_scores_gemma":[0.030748198,0.9637299,0.0022536744,0.0016344475,0.0010992984,0.00035643709,0.000016473008,0.000047093366,0.0001144875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872733,0.0028293214,0.008080486,0.00054934376,0.0008560187,0.0004115762],"domain_scores_gemma":[0.9717965,0.0064452644,0.01919875,0.0007863189,0.0014899527,0.00028320443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048791366,0.0005225502,0.007963447,0.00013885467,0.000046961115,0.0000061039586,0.00053600234,0.00067609455,0.00041475697],"category_scores_gemma":[0.000634535,0.00023251247,0.001603018,0.00042200516,0.0008065284,0.00008935427,0.0000845286,0.0016260598,0.0000014730738],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009480983,0.013552754,0.056845833,0.0010069129,0.0073537542,0.0001734717,0.0060594007,0.000045980498,5.2092264e-7,0.000043810298,0.0010516832,0.9043849],"study_design_scores_gemma":[0.010102889,0.0763298,0.16080284,0.0046333745,0.008449429,0.00009818425,0.0017901869,0.0000010665262,0.0000039942165,0.00000516254,0.7376355,0.00014760702],"about_ca_topic_score_codex":0.056439977,"about_ca_topic_score_gemma":0.07469551,"teacher_disagreement_score":0.9042373,"about_ca_system_score_codex":0.005194443,"about_ca_system_score_gemma":0.030721534,"threshold_uncertainty_score":0.99862444},"labels":[],"label_agreement":null},{"id":"W2133389067","doi":"10.1200/jco.2007.14.2372","title":"Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Prednisone; Regimen; Cyclophosphamide; Refractory (planetary science); Internal medicine; Multiple myeloma; Gastroenterology; Surgery; Urology; Chemotherapy","score_opus":0.15452083648870732,"score_gpt":0.4762083366351059,"score_spread":0.3216875001463986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133389067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963984,0.001168649,0.000011329732,0.0010864127,0.00036776892,0.00051418424,0.00000867876,0.000005662475,0.0004389101],"genre_scores_gemma":[0.9916919,0.004195606,0.0032981262,0.00017368853,0.00035080904,0.0000069193625,0.000004139568,0.000014997036,0.00026384703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963727,0.00045362933,0.0022521724,0.00022428541,0.000416071,0.00028111285],"domain_scores_gemma":[0.9953342,0.0025561054,0.001102184,0.00018003955,0.00023803148,0.00058945344],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021593592,0.00015155584,0.0017915152,0.00020731505,0.000061198916,0.0000030603107,0.000089743684,0.00037989035,0.00003960343],"category_scores_gemma":[0.008755589,0.00010753356,0.00022330866,0.00013408184,0.0005337418,0.00010659929,0.00008956161,0.0008893945,0.000001916042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52721673,0.016407639,0.21589847,0.000047898506,0.00046149563,0.005963204,0.0003683095,0.0000023766395,0.0008127522,0.000008803468,0.00084509014,0.23196723],"study_design_scores_gemma":[0.49876675,0.09237756,0.4007994,0.00008444028,0.00012104113,0.00063517527,0.00006147782,0.0003969882,0.00016052817,0.00005365581,0.0064698784,0.00007311055],"about_ca_topic_score_codex":0.00010935748,"about_ca_topic_score_gemma":0.00010254839,"teacher_disagreement_score":0.2318941,"about_ca_system_score_codex":0.00013642335,"about_ca_system_score_gemma":0.0015446411,"threshold_uncertainty_score":0.9995941},"labels":[],"label_agreement":null},{"id":"W2133441044","doi":"10.1200/jco.2012.47.6010","title":"Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Stage (stratigraphy); Cancer; Testicular cancer; Oncology; Gynecology; Internal medicine","score_opus":0.20228146020208565,"score_gpt":0.5090877160212609,"score_spread":0.30680625581917526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133441044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739429,0.0012134868,0.0003323726,0.019074274,0.001161861,0.0008609182,0.00002315421,0.00001475855,0.0033763114],"genre_scores_gemma":[0.98313636,0.00047150438,0.004085508,0.0099826325,0.0013852498,0.00004376137,0.0000029151265,0.000020825113,0.0008712543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964592,0.00063038594,0.0019262015,0.00028012015,0.00042756126,0.00027652268],"domain_scores_gemma":[0.9937172,0.0029952347,0.001325832,0.00037363553,0.0007641271,0.000823965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016861693,0.00016725964,0.0013239793,0.000046946538,0.000054839777,0.0000189492,0.00024565088,0.00028476896,0.00037649221],"category_scores_gemma":[0.007182114,0.00008504891,0.0007347512,0.00016423868,0.00022457833,0.0000868697,0.00008439301,0.00085124857,0.00012213094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017232858,0.0049515534,0.74505264,0.00002763857,0.001452773,0.00018746902,0.00009050836,0.000047897887,0.000011862841,0.000039321843,0.022957629,0.22345746],"study_design_scores_gemma":[0.0049514193,0.004958359,0.93866134,0.000050028222,0.0004619549,0.000084059655,0.000109573084,0.00032486772,0.000007654013,0.00011577969,0.050187953,0.000086988206],"about_ca_topic_score_codex":0.00015664959,"about_ca_topic_score_gemma":0.000014720019,"teacher_disagreement_score":0.22337046,"about_ca_system_score_codex":0.00012287532,"about_ca_system_score_gemma":0.001497048,"threshold_uncertainty_score":0.85981804},"labels":[],"label_agreement":null},{"id":"W2133539678","doi":"10.1200/jco.2014.55.1937","title":"Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":546,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Human papillomavirus; Basal cell; Oncology; Internal medicine; Cancer research","score_opus":0.08223994791545691,"score_gpt":0.44832521480592985,"score_spread":0.36608526689047294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133539678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880333,0.0018514913,0.000008033178,0.0014665722,0.0007597626,0.00010570253,0.0000016462515,0.0000046055843,0.007768921],"genre_scores_gemma":[0.99670273,0.00022638035,0.0007551727,0.0008695696,0.0011902488,0.0000025223178,4.459321e-7,0.000012946759,0.0002399572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974311,0.0003714779,0.0015513125,0.00015353198,0.00030236738,0.00019022007],"domain_scores_gemma":[0.9975282,0.00082453905,0.0009397406,0.00013370824,0.00027338744,0.0003004525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019179522,0.00011941561,0.0016822628,0.00006545649,0.000037651946,0.0000033379617,0.000076654775,0.00024518996,0.00008474384],"category_scores_gemma":[0.00070202263,0.00007630074,0.00026061456,0.000042170373,0.00026377587,0.00005394119,0.000075233664,0.0005750337,0.000003357584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006483922,0.0019210201,0.8646211,0.00026197484,0.00008317187,0.00062354916,0.0002766539,4.8994656e-7,0.0034595164,0.00008592761,0.002751119,0.11943156],"study_design_scores_gemma":[0.010589122,0.03564945,0.9259719,0.00008570564,0.00023471452,0.00007661138,0.000035639627,0.000011738873,0.0004498741,0.00015005236,0.026667317,0.000077864024],"about_ca_topic_score_codex":0.000023264021,"about_ca_topic_score_gemma":0.000030379866,"teacher_disagreement_score":0.1193537,"about_ca_system_score_codex":0.000041029652,"about_ca_system_score_gemma":0.00031103668,"threshold_uncertainty_score":0.3111454},"labels":[],"label_agreement":null},{"id":"W2133619234","doi":"10.1200/jco.2011.40.2503","title":"Classical Clinical Trial Design in Testicular Cancer: Time to Move On","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Testicular cancer; Cancer; Clinical trial; Oncology; Internal medicine; Gynecology","score_opus":0.2699669059110745,"score_gpt":0.5248767183265719,"score_spread":0.2549098124154974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133619234","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03928476,0.0022949115,0.00020816321,0.9458791,0.008349201,0.0024558627,0.000043578948,0.000032913667,0.0014514859],"genre_scores_gemma":[0.013346957,0.00055445824,0.008399928,0.9056178,0.06793206,0.000081667196,0.00003947039,0.00014197388,0.0038857185],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893899,0.0029570393,0.0054241847,0.0005546106,0.000995822,0.00067842175],"domain_scores_gemma":[0.9776486,0.016967347,0.0031418472,0.00052522117,0.00041744023,0.0012995551],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0053309007,0.00046576664,0.0047428343,0.00033361517,0.000028232924,0.00001793611,0.00036471934,0.003142339,0.0010106926],"category_scores_gemma":[0.02624058,0.00031142595,0.0020161653,0.00021885711,0.00028332532,0.00006362531,0.00009619639,0.0069187703,0.001221218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08977856,0.0075268988,0.006835771,0.000036259233,0.0010955994,0.02022521,0.000005382573,0.00002744562,9.263303e-7,0.0000028195707,0.7405994,0.13386573],"study_design_scores_gemma":[0.09155667,0.05736475,0.072157755,0.00068891584,0.003220842,0.00026868482,0.0000015581838,0.00007251586,0.0000011010778,0.00012368817,0.7742801,0.00026344674],"about_ca_topic_score_codex":0.000020349244,"about_ca_topic_score_gemma":0.0000024548972,"teacher_disagreement_score":0.13360229,"about_ca_system_score_codex":0.00078053435,"about_ca_system_score_gemma":0.0062539345,"threshold_uncertainty_score":0.9999338},"labels":[],"label_agreement":null},{"id":"W2133643739","doi":"10.1200/jco.2011.37.8661","title":"Molecular Genetic Approaches and Potential New Therapeutic Strategies for Pediatric Diffuse Intrinsic Pontine Glioma","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Clinical trial; Anaplastic astrocytoma; Pediatric cancer; Glioma; Disease; Oncology; Astrocytoma; Cancer; Internal medicine; Pediatrics; Cancer research","score_opus":0.13343426519000462,"score_gpt":0.38010523446320466,"score_spread":0.24667096927320004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133643739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.668906,0.015160966,0.0012314302,0.31167427,0.0018452987,0.00087786635,0.00001107716,0.000016494305,0.00027665],"genre_scores_gemma":[0.7662455,0.0047709504,0.010989921,0.18626167,0.031328302,0.000048575064,0.000041203122,0.0001509269,0.00016295974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620354,0.00031991734,0.0022902105,0.00039488907,0.00038918277,0.0004022778],"domain_scores_gemma":[0.99561155,0.0011553263,0.0022638547,0.0002982299,0.00029188502,0.00037913723],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007233154,0.0003840816,0.00240641,0.0003910886,0.000040073475,0.00004507706,0.00022540914,0.0016072828,0.000053050506],"category_scores_gemma":[0.00041193317,0.00025724331,0.0010465345,0.00012530478,0.00017457079,0.000072485534,0.00006907798,0.0018335641,0.0000059912763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050702076,0.0073107863,0.017384965,0.00076923234,0.0068941982,0.04460637,0.00017081486,0.000016336613,0.0002092276,0.00035625292,0.5687945,0.3484171],"study_design_scores_gemma":[0.08215985,0.082653984,0.23025666,0.00028692378,0.038091883,0.010567304,0.00016578434,0.00010386689,0.0001784456,0.022512339,0.5318745,0.0011484704],"about_ca_topic_score_codex":0.00002337007,"about_ca_topic_score_gemma":0.000004683442,"teacher_disagreement_score":0.34726864,"about_ca_system_score_codex":0.000068836875,"about_ca_system_score_gemma":0.00211295,"threshold_uncertainty_score":0.99998796},"labels":[],"label_agreement":null},{"id":"W2133685049","doi":"10.1200/jco.2012.44.1659","title":"Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":834,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hepatocellular carcinoma; Oncology; Radiation therapy; Internal medicine; Radiology","score_opus":0.25901016925198844,"score_gpt":0.46460969214301634,"score_spread":0.2055995228910279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133685049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858446,0.0038217606,0.0016037066,0.0036307445,0.0006992682,0.0015093061,0.000013668723,0.0000074054383,0.0001297003],"genre_scores_gemma":[0.9861757,0.0009982394,0.010963747,0.00061946805,0.0009585477,0.000040651164,0.000010534139,0.000027834443,0.0002052859],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99466735,0.0007583927,0.0038107797,0.00022311891,0.00027991427,0.00026045094],"domain_scores_gemma":[0.9925717,0.0032549717,0.0028150324,0.00020483685,0.00068312394,0.00047031534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050558434,0.00020020842,0.003018637,0.0001624211,0.00005636759,0.0000117746695,0.000118539225,0.0003891603,0.0004298179],"category_scores_gemma":[0.0031550524,0.00013523581,0.0010677165,0.00009074989,0.00021008021,0.00018218042,0.000031673484,0.00039792928,0.000002812158],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01807198,0.004722318,0.59014964,0.0001778835,0.0019974047,0.0005382804,0.00021859077,4.671035e-7,0.038000792,0.00009416041,0.0018363089,0.34419215],"study_design_scores_gemma":[0.29978782,0.34840518,0.100267395,0.0005318482,0.007864609,0.0017963803,0.00028950154,0.019624326,0.038335677,0.0017237155,0.18067901,0.0006945568],"about_ca_topic_score_codex":0.000027315788,"about_ca_topic_score_gemma":0.0000016646205,"teacher_disagreement_score":0.48988226,"about_ca_system_score_codex":0.00009051935,"about_ca_system_score_gemma":0.0010886928,"threshold_uncertainty_score":0.5514756},"labels":[],"label_agreement":null},{"id":"W2133707964","doi":"10.1200/jco.2009.21.9022","title":"Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Clinical trial; Pancreatic cancer; Cancer; Clinical endpoint; Oncology; Pancreatic ductal adenocarcinoma; Clinical study design; Disease; Internal medicine","score_opus":0.7756416888283236,"score_gpt":0.7102944836768414,"score_spread":0.06534720515148218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133707964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0078814,0.96395105,0.0000047487165,0.0065795663,0.005713736,0.0015392251,0.000066242486,0.000009583903,0.014254473],"genre_scores_gemma":[0.000509767,0.9854418,0.0009972211,0.0012695845,0.009641848,0.00006786759,0.000010467099,0.000031783922,0.0020296634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9746185,0.008261539,0.014922751,0.0004866394,0.0012967285,0.00041386476],"domain_scores_gemma":[0.93324983,0.043555383,0.020572819,0.00043328077,0.0015889169,0.00059974764],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.045227673,0.00043732033,0.016203484,0.00027734265,0.00010868506,0.000009146592,0.00041646423,0.0018427239,0.00017865808],"category_scores_gemma":[0.10574605,0.00020800698,0.0046290522,0.0003098713,0.00096391735,0.000034223995,0.00008231861,0.0031033999,0.000009210278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026585257,0.00205092,0.026927916,0.00074096164,0.006109135,0.0024174128,0.000023532748,0.000019792466,4.2949333e-7,0.000063982385,0.016649636,0.94233775],"study_design_scores_gemma":[0.006430354,0.007844187,0.012527097,0.020212239,0.012200719,0.0026037735,0.000013148445,0.000018146055,7.055756e-7,0.00009774042,0.9379005,0.00015140722],"about_ca_topic_score_codex":0.00019036981,"about_ca_topic_score_gemma":0.000075002616,"teacher_disagreement_score":0.94218636,"about_ca_system_score_codex":0.0014101999,"about_ca_system_score_gemma":0.048947435,"threshold_uncertainty_score":0.99945307},"labels":[],"label_agreement":null},{"id":"W2133910360","doi":"10.1200/jco.2013.53.4495","title":"Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":678,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Guideline; Psychological intervention; Cancer-related fatigue; Quality of life (healthcare); Cancer; Physical therapy; Disease; MEDLINE; Intensive care medicine; Internal medicine; Psychiatry; Nursing; Pathology","score_opus":0.24263067647348097,"score_gpt":0.5867453241569545,"score_spread":0.3441146476834735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133910360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96469766,0.00039102725,0.016754689,0.012642984,0.0019521242,0.0004137687,0.000017840395,0.000008691833,0.0031212105],"genre_scores_gemma":[0.8237773,0.018124804,0.15261142,0.0044134147,0.0009939288,0.0000074460186,0.000011114683,0.000024103641,0.000036447585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98398966,0.003803993,0.010698973,0.00043067083,0.0007915253,0.00028515363],"domain_scores_gemma":[0.975269,0.009344112,0.012145377,0.0004097962,0.0023304708,0.00050121325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027799057,0.00021475337,0.0039252867,0.0001508398,0.000023924975,0.0000042664497,0.00030235574,0.00064987317,0.000050462226],"category_scores_gemma":[0.005187849,0.0001742877,0.0009312883,0.00039542405,0.0011901833,0.00021680335,0.00013975028,0.0016759912,3.169438e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053149983,0.0028236166,0.39766732,0.00016240777,0.0007678295,0.000035234607,0.00023879048,0.00013729837,0.000011665866,0.00035530436,0.0016023231,0.5908832],"study_design_scores_gemma":[0.014313694,0.037970584,0.82018876,0.00048264055,0.0014297016,0.000033297092,0.008237484,0.0077928747,0.0000147133605,0.00009771097,0.10927593,0.00016260763],"about_ca_topic_score_codex":0.0067319633,"about_ca_topic_score_gemma":0.013759592,"teacher_disagreement_score":0.5907206,"about_ca_system_score_codex":0.00012944346,"about_ca_system_score_gemma":0.0022202977,"threshold_uncertainty_score":0.9998823},"labels":[],"label_agreement":null},{"id":"W2133959685","doi":"10.1200/jco.2007.12.6078","title":"Predictors of Contralateral Prophylactic Mastectomy in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation: The Hereditary Breast Cancer Clinical Study Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Prophylactic Mastectomy; Prophylactic Surgery; Breast cancer; Mastectomy; Oophorectomy; Tamoxifen; Cancer; Surgery; Gynecology; Cohort; Hysterectomy; Internal medicine","score_opus":0.046615911233690084,"score_gpt":0.38528227885668687,"score_spread":0.3386663676229968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133959685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549955,0.00042178994,0.00006743444,0.0018177925,0.0015334613,0.0005203745,0.00002223242,0.000004137331,0.0001132438],"genre_scores_gemma":[0.9953823,0.0004632207,0.00050555693,0.0012595685,0.002167268,0.00007826504,0.0000026811656,0.000027550752,0.00011360556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951123,0.001180422,0.0026597402,0.0003378845,0.0003988042,0.00031083237],"domain_scores_gemma":[0.99638623,0.0006997303,0.0018303208,0.0003358798,0.00054728007,0.0002005294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030703193,0.00019880179,0.0010199274,0.0000699056,0.00006551497,0.000008203459,0.00045389094,0.00035311515,0.000080309175],"category_scores_gemma":[0.000644564,0.000109232205,0.00017133859,0.0002918686,0.00076194823,0.000024586727,0.00009428741,0.0008402142,0.0000014104488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044381484,0.0049172486,0.91367835,0.000033306507,0.0016076305,0.0014086729,0.0011687948,0.00088266225,0.00045105067,0.0000019716972,0.0044021867,0.027066668],"study_design_scores_gemma":[0.015875464,0.033815008,0.93742096,0.000041049105,0.00019012742,0.002229631,0.0014097458,0.00002758898,0.00009404776,0.000021827946,0.0086968895,0.00017764397],"about_ca_topic_score_codex":0.000060205486,"about_ca_topic_score_gemma":0.00064230035,"teacher_disagreement_score":0.028897759,"about_ca_system_score_codex":0.00016755509,"about_ca_system_score_gemma":0.0039060432,"threshold_uncertainty_score":0.6929153},"labels":[],"label_agreement":null},{"id":"W2134103116","doi":"10.1200/jco.2010.29.8133","title":"Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Institute on Aging; Celgene; Genentech; Amgen","keywords":"Lenalidomide; Medicine; Neutropenia; Chronic lymphocytic leukemia; Regimen; Internal medicine; Multiple myeloma; Tumor lysis syndrome; Oncology; Rituximab; Gastroenterology; Chemotherapy; Leukemia; Lymphoma","score_opus":0.13373254987909994,"score_gpt":0.4623345683900938,"score_spread":0.32860201851099385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134103116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926021,0.0014922585,0.000013752037,0.0015151107,0.00091418106,0.0005879108,0.0000018237087,0.000008479626,0.0028643522],"genre_scores_gemma":[0.9936705,0.0030497413,0.0006794076,0.000508329,0.0016264736,0.000013616517,0.000003228319,0.00002480934,0.00042386536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945126,0.0007745187,0.0032003983,0.00025782434,0.0007516859,0.0005029295],"domain_scores_gemma":[0.9916365,0.005438142,0.0015331943,0.00059428095,0.00042278023,0.00037511712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045711696,0.00021988993,0.0019054085,0.00023521326,0.00003431514,0.0000130997005,0.00043847377,0.00054853596,0.00027564255],"category_scores_gemma":[0.0038098472,0.00011769413,0.0007571998,0.00035729245,0.000612765,0.00007908607,0.0000422497,0.0010009778,0.000041643827],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03167019,0.013706716,0.020422857,0.00048343986,0.0024227654,0.018996065,0.0038747317,0.0012653037,0.026205294,0.0005624973,0.0074284696,0.87296164],"study_design_scores_gemma":[0.3493485,0.19178708,0.039154433,0.00071528915,0.0021428803,0.0149018,0.00061262166,0.013407159,0.012065407,0.0006816466,0.37474298,0.0004402114],"about_ca_topic_score_codex":0.00082271826,"about_ca_topic_score_gemma":0.0012783926,"teacher_disagreement_score":0.87252146,"about_ca_system_score_codex":0.06082598,"about_ca_system_score_gemma":0.09971304,"threshold_uncertainty_score":0.94277936},"labels":[],"label_agreement":null},{"id":"W2134148147","doi":"10.1200/jco.2007.12.4669","title":"External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nomogram; Medicine; Prostatectomy; Biomarker; Urology; Prostate cancer; Stage (stratigraphy); Lymphadenectomy; Biochemical recurrence; Prostate-specific antigen; Oncology; Internal medicine; Cancer","score_opus":0.10540458247217942,"score_gpt":0.4340280477409639,"score_spread":0.32862346526878444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134148147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447244,0.001411272,0.00072823954,0.002068023,0.000556835,0.00050106744,0.00002318871,0.000009217835,0.00022973698],"genre_scores_gemma":[0.9890824,0.0010840246,0.008787994,0.00055389403,0.00039409188,0.000050265568,0.0000103924995,0.000013420502,0.000023506282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996533,0.00036394832,0.00214239,0.00024386392,0.00049188436,0.00022493217],"domain_scores_gemma":[0.996265,0.0011145783,0.0013232207,0.00018457822,0.00066903356,0.00044358915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012290828,0.00016676099,0.0011975494,0.00012869509,0.000030183053,0.000005343323,0.00011933147,0.00030395182,0.00017461195],"category_scores_gemma":[0.0018647511,0.00011117573,0.00048909616,0.0001865782,0.00067631487,0.000108928034,0.0000345928,0.00059006666,0.000008110915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022966592,0.010053018,0.9017097,0.00014089822,0.00056072057,0.0026389223,0.00023785412,0.00001561623,0.001883359,0.000013165881,0.0036443397,0.056135815],"study_design_scores_gemma":[0.019493168,0.030454999,0.8843338,0.0009889064,0.00053360447,0.00087118795,0.000020179808,0.0002607613,0.056924477,0.00012409745,0.005841922,0.00015289617],"about_ca_topic_score_codex":0.0000068947684,"about_ca_topic_score_gemma":8.8623136e-7,"teacher_disagreement_score":0.055982918,"about_ca_system_score_codex":0.00019382256,"about_ca_system_score_gemma":0.0025150315,"threshold_uncertainty_score":0.45336148},"labels":[],"label_agreement":null},{"id":"W2134169247","doi":"10.1200/jco.2005.03.0981","title":"Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid Tumors","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Pharmacokinetics; Urology; Taxane; Dosing; Internal medicine; Surgery; Cancer; Breast cancer","score_opus":0.15033976515414665,"score_gpt":0.517848584346359,"score_spread":0.3675088191922124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134169247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966574,0.0001388282,0.000007258217,0.0013939874,0.0005929175,0.00054696,0.0000029188466,0.0000055663177,0.00065416464],"genre_scores_gemma":[0.9976148,0.000065942055,0.0010374852,0.000625131,0.0005265203,0.000006823268,0.000003305311,0.00001716128,0.00010281146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964015,0.00031292997,0.0024776638,0.00019118926,0.00036537732,0.0002513777],"domain_scores_gemma":[0.9965741,0.000733371,0.0019671463,0.00013954188,0.00031300922,0.00027283077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010744676,0.00015549007,0.001733896,0.00022984802,0.000023498864,0.0000027817837,0.0001164302,0.00014854675,0.00018288793],"category_scores_gemma":[0.00039246972,0.000105398714,0.00018517389,0.00020799992,0.00010895858,0.00012401209,0.00003452991,0.00070023816,0.0000055745354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04677338,0.13712135,0.5381626,0.000018259052,0.0005155784,0.0005858002,0.00070067233,0.00019231884,0.00052743487,0.0000020134642,0.0005298037,0.27487078],"study_design_scores_gemma":[0.15442361,0.2744938,0.5651033,0.00011807558,0.00054203917,0.000035123903,0.000369298,0.00002895666,0.00026289278,0.00000774652,0.004520589,0.00009457183],"about_ca_topic_score_codex":0.0000120787345,"about_ca_topic_score_gemma":0.00013127076,"teacher_disagreement_score":0.27477622,"about_ca_system_score_codex":0.00034758318,"about_ca_system_score_gemma":0.0005933878,"threshold_uncertainty_score":0.4298035},"labels":[],"label_agreement":null},{"id":"W2134235269","doi":"10.1200/jco.2013.52.7804","title":"Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Interpretation (philosophy); Internal medicine; Clinical trial; Cancer; Pathology","score_opus":0.5294642514651834,"score_gpt":0.6664420095163952,"score_spread":0.13697775805121182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134235269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90173423,0.000054197895,0.08741729,0.0052638818,0.003934674,0.0010064298,0.0000122650445,0.0000061327137,0.0005708747],"genre_scores_gemma":[0.9110779,0.00038000906,0.08355193,0.003444786,0.0014559344,0.000039493254,3.261454e-7,0.00002742848,0.000022166078],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.972396,0.013221253,0.012901004,0.00039466366,0.000666941,0.00042012462],"domain_scores_gemma":[0.62972534,0.36188212,0.0073499554,0.0005435845,0.000326614,0.00017241194],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07849623,0.00025585448,0.0036691604,0.00014028998,0.000053802538,0.000026619733,0.001170233,0.00063218153,0.00013989193],"category_scores_gemma":[0.29376674,0.00013743376,0.0010779549,0.00025981717,0.00035191653,0.00011915148,0.00017792995,0.0029170972,0.0000029656414],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059389398,0.009527541,0.22727107,0.00025356928,0.0004795381,0.00010276911,0.00330637,0.00014689198,0.000032355678,0.0028054358,0.00074549817,0.6959396],"study_design_scores_gemma":[0.5246569,0.03254096,0.1109986,0.0020787378,0.0020903717,0.000022445782,0.0032455549,0.06640035,0.00010957579,0.25567856,0.0014544699,0.00072351185],"about_ca_topic_score_codex":0.000053326603,"about_ca_topic_score_gemma":0.00020710017,"teacher_disagreement_score":0.69521606,"about_ca_system_score_codex":0.0001105633,"about_ca_system_score_gemma":0.00066340185,"threshold_uncertainty_score":0.9993832},"labels":[],"label_agreement":null},{"id":"W2134392974","doi":"10.1200/jco.2012.48.3552","title":"Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":494,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"West China Hospital, Sichuan University; BC Cancer Agency; Novartis Pharma; Chugai Pharmaceutical; Ruijin Hospital; Hebei Medical University; Nanfang Hospital; Institut Gustave-Roussy; School of Medicine, Shanghai Jiao Tong University; Peking University; KU Leuven; Sichuan University; Universitair Ziekenhuis Gent; Sun Yat-sen University; China Medical University; Fudan University; McGill University; Sir Run Run Shaw Hospital; Shanghai Jiao Tong University; Harbin Medical University; Sanofi; Soochow University; GlaxoSmithKline","keywords":"Everolimus; Medicine; Ramucirumab; Internal medicine; Hazard ratio; Clinical endpoint; Adverse effect; Cancer; Placebo; Phases of clinical research; Gastroenterology; Chemotherapy; Surgery; Oncology; Clinical trial; Confidence interval; Pathology","score_opus":0.12856657992921147,"score_gpt":0.4762735821499621,"score_spread":0.3477070022207507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134392974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842721,0.0005698305,0.0002017474,0.0067859483,0.0015897235,0.0056934445,0.0000075743446,0.000010902214,0.0008686997],"genre_scores_gemma":[0.9945421,0.0011326475,0.0005319418,0.00085884705,0.000796572,0.00020192047,0.0000031699967,0.000018887242,0.0019138679],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945682,0.0004983761,0.0039480324,0.00022802473,0.00045321274,0.00030411532],"domain_scores_gemma":[0.99099416,0.0034891095,0.0039852806,0.00033666432,0.0009486906,0.00024610487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045635435,0.00019431156,0.0029043797,0.00019643529,0.00005820922,0.000011408916,0.000339661,0.0001756544,0.000106186315],"category_scores_gemma":[0.0032261652,0.000101934165,0.0011936299,0.0003968542,0.00022348545,0.00013613525,0.000075327545,0.0005690604,0.0000035965638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82758224,0.00364056,0.017417867,0.000042761505,0.0013532956,0.000027906312,0.00020936974,0.00006706538,0.000029606585,0.000015556716,0.007079181,0.1425346],"study_design_scores_gemma":[0.94667083,0.016451076,0.023929253,0.000104887695,0.0032325955,0.00002878294,0.00031568803,0.00013403679,0.0000340763,0.00012069224,0.008894481,0.00008361538],"about_ca_topic_score_codex":0.00035548865,"about_ca_topic_score_gemma":0.00017605428,"teacher_disagreement_score":0.14245099,"about_ca_system_score_codex":0.0001448901,"about_ca_system_score_gemma":0.0007232709,"threshold_uncertainty_score":0.41567546},"labels":[],"label_agreement":null},{"id":"W2134637758","doi":"10.1200/jco.2007.10.9231","title":"Donepezil for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Donepezil; Medicine; Placebo; Internal medicine; Clinical endpoint; Randomized controlled trial; Cancer-related fatigue; Clinical trial; Physical therapy; Cancer; Dementia; Disease","score_opus":0.2101748905513043,"score_gpt":0.5233416413377198,"score_spread":0.3131667507864154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134637758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92542744,0.0028784492,0.010740015,0.017041432,0.023260219,0.0071980935,0.000006056713,0.000025270681,0.013423012],"genre_scores_gemma":[0.973616,0.0011531736,0.0016239502,0.0046546645,0.015971553,0.0003532902,0.0000038375138,0.000036528247,0.0025870225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937451,0.0005026386,0.004598392,0.0002323644,0.0005326598,0.0003888589],"domain_scores_gemma":[0.9804266,0.014738889,0.0029931706,0.0001994774,0.0010683582,0.0005734732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0238206,0.00020213396,0.0048134956,0.00021561813,0.000056315675,0.0000144661835,0.00019473753,0.000682124,0.00033423214],"category_scores_gemma":[0.006717307,0.0001262366,0.0027382744,0.00016120479,0.00026721176,0.00008926471,0.000027521895,0.0010680205,0.000005556321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92124116,0.0010065401,0.00023298421,0.000034488523,0.0013461134,0.00014211684,0.00019196511,0.000009273346,0.000012749715,0.00033395164,0.0037547627,0.07169391],"study_design_scores_gemma":[0.88256925,0.008406211,0.000078370205,0.00007907567,0.0019980266,0.00007016742,0.00017039952,0.000048210117,0.000051527986,0.00031631129,0.106098086,0.00011436358],"about_ca_topic_score_codex":0.00016835232,"about_ca_topic_score_gemma":0.0020299798,"teacher_disagreement_score":0.10234333,"about_ca_system_score_codex":0.00022451753,"about_ca_system_score_gemma":0.002898424,"threshold_uncertainty_score":0.82557917},"labels":[],"label_agreement":null},{"id":"W2134653630","doi":"10.1200/jco.2012.43.8259","title":"Reply to R. de Wit et al","year":2012,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Humanities","score_opus":0.16794835680587594,"score_gpt":0.5465062618033805,"score_spread":0.3785579049975045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134653630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49144757,0.06101099,0.0011120562,0.42621312,0.014443585,0.00023008513,0.0000120101495,0.000010143183,0.0055204546],"genre_scores_gemma":[0.7408721,0.0022647653,0.01641357,0.2332151,0.005192961,0.0000025743664,0.0000015851774,0.00002448409,0.0020129045],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996155,0.00090059236,0.001884988,0.00014430491,0.0003366967,0.000578415],"domain_scores_gemma":[0.9928587,0.002836559,0.0012399687,0.00022969295,0.00028361543,0.0025514823],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005466069,0.00015333689,0.0011972426,0.00007408678,0.000029761004,0.00000919718,0.00013467015,0.00028128445,0.0007654625],"category_scores_gemma":[0.015116315,0.000114455885,0.000693537,0.00011556245,0.00014983662,0.00016488727,0.00007063733,0.00091815135,0.0006043009],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017155394,0.0069310414,0.4933724,0.000023774905,0.0007784315,0.0022144928,0.00013389098,0.000012396304,0.000014773688,0.00062826916,0.24247032,0.25170466],"study_design_scores_gemma":[0.0034392793,0.008549383,0.44641775,0.00021869376,0.0010240641,0.0012344597,0.000056945428,0.000013086717,0.00000510222,0.00019130744,0.5387943,0.00005567447],"about_ca_topic_score_codex":0.000094660514,"about_ca_topic_score_gemma":0.000008710169,"teacher_disagreement_score":0.29632393,"about_ca_system_score_codex":0.00038671686,"about_ca_system_score_gemma":0.002996199,"threshold_uncertainty_score":0.9931798},"labels":[],"label_agreement":null},{"id":"W2134667653","doi":"10.1200/jco.2004.08.163","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2433,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Lung cancer; Febrile neutropenia; Chemotherapy; Regimen; Dexamethasone; Chemotherapy regimen; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cisplatin","score_opus":0.04615425508884495,"score_gpt":0.4591494644487017,"score_spread":0.41299520935985673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134667653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441224,0.00032962157,0.00016438459,0.0012749071,0.00040331783,0.0020576632,0.0000055493642,0.000005462451,0.0013468437],"genre_scores_gemma":[0.9959084,0.00078666775,0.0023927519,0.0003744359,0.00028272456,0.000056517347,0.00001018772,0.000023232025,0.00016512744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971646,0.00020848235,0.0018921841,0.00018511592,0.0003387604,0.00021084558],"domain_scores_gemma":[0.99612427,0.00084663375,0.0021092144,0.00015926769,0.0005312697,0.00022931822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010514946,0.00017942865,0.0024215388,0.00016968531,0.000022848244,0.0000051589236,0.00009388992,0.00018971063,0.0000915265],"category_scores_gemma":[0.00034268646,0.00009518034,0.0003518582,0.00025829606,0.00019095783,0.00008287624,0.000008470229,0.00041339535,6.777243e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94633883,0.012823638,0.025257964,0.00003585609,0.0021707984,0.000119915276,0.00039568037,0.00014738104,0.000008424442,0.0000051693232,0.00008796329,0.012608364],"study_design_scores_gemma":[0.9316074,0.053101726,0.010592678,0.00029246448,0.003769055,0.0000057012776,0.000053058397,0.000027603512,0.000118354685,0.0000075799767,0.00033418243,0.00009020005],"about_ca_topic_score_codex":0.00038064,"about_ca_topic_score_gemma":0.0002439179,"teacher_disagreement_score":0.04027809,"about_ca_system_score_codex":0.0004222906,"about_ca_system_score_gemma":0.003233135,"threshold_uncertainty_score":0.57354426},"labels":[],"label_agreement":null},{"id":"W2134749269","doi":"10.1200/jco.2006.07.8626","title":"Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Children's Hospital; Montreal Neurological Institute and Hospital","funders":"Hungarian Scientific Research Fund","keywords":"Gene expression profiling; Carcinogenesis; Cancer research; Protein kinase B; Phenotype; Gene expression; Gene; Medicine; Immunohistochemistry; Biology; Signal transduction; Pathology; Genetics","score_opus":0.04393065785903776,"score_gpt":0.3982926014638596,"score_spread":0.3543619436048218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134749269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725276,0.0016801693,0.000054539734,0.00031467556,0.000249549,0.0002981394,0.0000019424194,0.0000051408756,0.00014305532],"genre_scores_gemma":[0.99754965,0.00024548924,0.0017384513,0.00014720164,0.00030001235,0.0000047126914,0.0000015623797,0.000010347634,0.0000025423838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967448,0.00023882723,0.0022759466,0.00017430568,0.0003473436,0.00021876191],"domain_scores_gemma":[0.99538726,0.0025640447,0.0013503343,0.000121868936,0.00026977382,0.00030673598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034828212,0.0001253845,0.0011338574,0.00039040676,0.000018352532,0.000005945437,0.00008122204,0.00024566374,0.000019939958],"category_scores_gemma":[0.004800307,0.00008745148,0.0002387891,0.00023449295,0.00011492017,0.000079624406,0.000054353,0.00047315683,0.0000018252389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023635188,0.0027346693,0.96140856,0.000089282,0.00007582948,0.0048075435,0.000058397352,0.000008607452,0.022345316,0.000030498062,0.00009827073,0.0059795096],"study_design_scores_gemma":[0.008396083,0.007980257,0.91824543,0.00022774035,0.0004189556,0.0003077821,0.00018811726,0.00003401562,0.06388159,0.00018368074,0.00005811986,0.000078230514],"about_ca_topic_score_codex":0.000012180732,"about_ca_topic_score_gemma":0.00004069707,"teacher_disagreement_score":0.043163132,"about_ca_system_score_codex":0.00006194171,"about_ca_system_score_gemma":0.00038964185,"threshold_uncertainty_score":0.5746763},"labels":[],"label_agreement":null},{"id":"W2134780987","doi":"10.1200/jco.2013.53.2960","title":"Patient Navigation Improves the Care Experience for Patients With Newly Diagnosed Cancer","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Agency for Healthcare Research and Quality","keywords":"Medicine; Cancer; Breast cancer; Disease; Family medicine; Internal medicine","score_opus":0.11821797114463228,"score_gpt":0.4626835359873241,"score_spread":0.3444655648426918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134780987","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73167586,0.0013457341,0.00008619285,0.2620574,0.003221059,0.0013156567,0.00003315042,0.000008094067,0.00025686697],"genre_scores_gemma":[0.2885792,0.0003956955,0.0033038252,0.6955903,0.01152891,0.00028961396,0.00008718088,0.00004861423,0.0001766409],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650747,0.00021099538,0.001884402,0.00027249794,0.0007887931,0.0003358602],"domain_scores_gemma":[0.99182373,0.0020569633,0.0032125541,0.00026967935,0.0024548084,0.00018228249],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00043208798,0.00023561646,0.0013368926,0.000053785097,0.00009152177,0.000027435488,0.00028847624,0.0008892536,0.00006704725],"category_scores_gemma":[0.0015882532,0.0001164881,0.00049948273,0.00009445439,0.00027861938,0.00017243423,0.000046369423,0.0024173162,0.000004679702],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019410166,0.00014948809,0.04118428,0.000101970625,0.00024688744,0.0002867992,0.0010497582,0.000012011131,0.0000029517473,0.0000015484749,0.6569034,0.2981199],"study_design_scores_gemma":[0.005625629,0.023543373,0.06778804,0.0008368928,0.0005868948,0.00003751261,0.00092626817,0.000015008841,0.00000978331,0.000032584685,0.90043527,0.00016273883],"about_ca_topic_score_codex":0.0002809902,"about_ca_topic_score_gemma":0.000045196604,"teacher_disagreement_score":0.44309667,"about_ca_system_score_codex":0.0003896435,"about_ca_system_score_gemma":0.001974052,"threshold_uncertainty_score":0.9998841},"labels":[],"label_agreement":null},{"id":"W2134788484","doi":"10.1200/jco.2007.13.4536","title":"American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Docetaxel; Prostate cancer; Oncology; Cancer; Internal medicine; Context (archaeology); Intensive care medicine; Gynecology; Pathology","score_opus":0.3416810237339488,"score_gpt":0.6018721482134523,"score_spread":0.26019112447950343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134788484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035393306,0.9817139,0.00004842355,0.0069862395,0.00095924863,0.0045685107,0.00038824533,0.000006952224,0.0017891618],"genre_scores_gemma":[0.0009070346,0.9824075,0.011886538,0.0020435068,0.0014366664,0.00028880168,0.00007028664,0.00007615482,0.0008835085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868379,0.0017367827,0.00881607,0.0005977787,0.0014455881,0.00056585635],"domain_scores_gemma":[0.9675831,0.010631403,0.016807396,0.00054461195,0.003953473,0.000479968],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009811341,0.00055878743,0.007849891,0.00018077096,0.000105731604,0.000011315086,0.0005766128,0.0006622852,0.00012786579],"category_scores_gemma":[0.0016002813,0.00026596338,0.0031951172,0.00043541356,0.001422679,0.00012608552,0.0000983282,0.003267483,0.0000011170405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049284875,0.0042092726,0.00084888114,0.0015126523,0.009757383,0.00012718952,0.00058869855,0.000016035303,0.0000151747845,0.000010197112,0.026603593,0.90702605],"study_design_scores_gemma":[0.016920066,0.07287797,0.0029113805,0.0027689198,0.007021358,0.000059555903,0.0010833845,0.000007632799,0.000015988111,0.000008596384,0.8961179,0.00020719608],"about_ca_topic_score_codex":0.0054756277,"about_ca_topic_score_gemma":0.00916622,"teacher_disagreement_score":0.90681887,"about_ca_system_score_codex":0.002886591,"about_ca_system_score_gemma":0.06493657,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W2134897113","doi":"10.1200/jco.2010.33.3757","title":"Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Internal medicine; Oncology; Mutation; Cancer research; Wild type; Cancer; Biology; Gene; Genetics; Mutant","score_opus":0.10864596059875335,"score_gpt":0.4753398324394152,"score_spread":0.3666938718406618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134897113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785003,0.0027562068,0.0031018467,0.0015915872,0.0013861912,0.0010217153,0.0003088244,0.000011490383,0.011321814],"genre_scores_gemma":[0.94029856,0.001912939,0.05436187,0.00065312744,0.00065742957,0.00014757947,0.00003895329,0.000029739951,0.0018998068],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975006,0.00006795668,0.0018150271,0.00022659778,0.00017815278,0.00021168444],"domain_scores_gemma":[0.99497634,0.0016805531,0.0020955736,0.00018838831,0.00076292915,0.00029621954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034067116,0.00017027363,0.0012262434,0.00008384183,0.000062535604,0.0000032383728,0.00011006349,0.00024483458,0.00019332305],"category_scores_gemma":[0.00037801312,0.00011848777,0.0005521575,0.000106213265,0.00014097113,0.00015287563,0.000016877035,0.0002742895,0.0000034000616],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024060812,0.02036679,0.43012112,0.00029043993,0.011989856,0.00050193834,0.017902367,0.00094448705,0.0021541873,0.001263487,0.0037449955,0.48665953],"study_design_scores_gemma":[0.1254218,0.07953912,0.6848562,0.0014596697,0.022743542,0.00008518334,0.0020005256,0.0011466857,0.011972159,0.007093317,0.063169435,0.0005123948],"about_ca_topic_score_codex":0.0002874319,"about_ca_topic_score_gemma":0.00028605296,"teacher_disagreement_score":0.4861471,"about_ca_system_score_codex":0.00042477163,"about_ca_system_score_gemma":0.0023031444,"threshold_uncertainty_score":0.4831791},"labels":[],"label_agreement":null},{"id":"W2134955678","doi":"10.1200/jco.2007.11.6814","title":"Truth Telling: Yes, but How?","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Deutsche Krebshilfe","keywords":"Medicine","score_opus":0.7167884433344921,"score_gpt":0.620585558686035,"score_spread":0.09620288464845705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134955678","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011929993,0.0051978417,0.00027035762,0.94021684,0.036103114,0.00082961144,0.000044963366,0.000054037457,0.016090255],"genre_scores_gemma":[0.0038895456,0.004221418,0.009780312,0.9227669,0.05148644,0.00003463293,0.00007666674,0.00012598083,0.0076180524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9755755,0.0116567165,0.009895681,0.00048243368,0.001235086,0.0011545975],"domain_scores_gemma":[0.91202396,0.06527992,0.01768965,0.0013903419,0.002954178,0.0006619316],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009492357,0.0004545507,0.003851538,0.0005561935,0.0004894184,0.00001475875,0.0020912988,0.008743053,0.0006186362],"category_scores_gemma":[0.031089786,0.0003544714,0.0011909357,0.0002975236,0.0004956985,0.00020558102,0.0004543099,0.038825072,0.00051507755],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048897427,0.00021953169,0.0053521874,0.0004523293,0.00022893636,0.0009030582,0.00048483384,0.0000010281418,6.899881e-7,0.000090928435,0.9690755,0.02270198],"study_design_scores_gemma":[0.002840745,0.0029791787,0.0019320451,0.00080640486,0.00023972141,0.00005709934,0.0013024999,0.000014381448,0.0000010351164,0.001324242,0.9882115,0.0002911321],"about_ca_topic_score_codex":0.00010165117,"about_ca_topic_score_gemma":0.000062608306,"teacher_disagreement_score":0.063551515,"about_ca_system_score_codex":0.0010904891,"about_ca_system_score_gemma":0.012323864,"threshold_uncertainty_score":0.99989074},"labels":[],"label_agreement":null},{"id":"W2134967339","doi":"10.1200/jco.2002.20.4.1036","title":"Assessment of Coronary Heart Disease Morbidity and Mortality After Radiation Therapy for Early Breast Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"World Health Organization","keywords":"Medicine; Breast cancer; Cohort; Population; Incidence (geometry); Myocardial infarction; Cancer; Retrospective cohort study; Radiation therapy; Cohort study; Internal medicine; Surgery","score_opus":0.1274513846161727,"score_gpt":0.4797739968221271,"score_spread":0.3523226122059544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134967339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906097,0.0009080847,0.00016227672,0.007473651,0.00039894853,0.00031412736,0.00003907667,0.0000036150957,0.00009053223],"genre_scores_gemma":[0.9926092,0.0029451856,0.0005292452,0.0028755835,0.00097501394,0.0000167933,0.0000020505095,0.000008689379,0.000038233662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984919,0.00017497336,0.00089148176,0.000117978016,0.00022363396,0.00010002516],"domain_scores_gemma":[0.99829805,0.0004646418,0.00061343156,0.000107741296,0.00026731833,0.0002488057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011503954,0.0000768493,0.0006970719,0.00004092013,0.000020482172,0.000004277055,0.000035784895,0.00016561647,0.00017078749],"category_scores_gemma":[0.00016650243,0.00005807843,0.00032087867,0.000044455453,0.00012281265,0.00010903271,0.000007704718,0.00028337166,3.426263e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024131087,0.000902908,0.900287,0.00003594848,0.0002487902,0.000024726118,0.00004567871,0.000004878326,0.0021909394,0.000014604507,0.00073312165,0.09309834],"study_design_scores_gemma":[0.006373517,0.0028448866,0.98744637,0.000048324608,0.0002142941,0.000060451664,0.000008650772,0.0002587133,0.000283102,0.00023909294,0.0021711881,0.000051415198],"about_ca_topic_score_codex":0.00002504075,"about_ca_topic_score_gemma":0.000006684711,"teacher_disagreement_score":0.093046926,"about_ca_system_score_codex":0.00009073385,"about_ca_system_score_gemma":0.00040658197,"threshold_uncertainty_score":0.23683695},"labels":[],"label_agreement":null},{"id":"W2135104074","doi":"10.1200/jco.2012.45.6954","title":"Barriers to Breast and Colorectal Cancer Survivorship Care: Perceptions of Primary Care Physicians and Medical Oncologists in the United States","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"U.S. Public Health Service","keywords":"Medicine; Family medicine; Survivorship curve; Breast cancer; Reimbursement; Odds ratio; Health care; Primary care physician; Logistic regression; Colorectal cancer; Cancer; Primary care; Internal medicine","score_opus":0.03909200500992915,"score_gpt":0.40037856109146475,"score_spread":0.3612865560815356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135104074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794116,0.0010257236,0.000011818169,0.017940236,0.00057661626,0.0003275419,0.000036752404,0.0000050646563,0.00066463655],"genre_scores_gemma":[0.9884031,0.0020645228,0.000085121275,0.008894824,0.00048553207,0.000025762987,0.000015482863,0.000011807601,0.000013888582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972091,0.00079903926,0.0011110937,0.00017919434,0.00047653215,0.00022507057],"domain_scores_gemma":[0.99594444,0.0022154977,0.000446857,0.000119752614,0.000696261,0.00057717215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014931428,0.00013329338,0.0010487391,0.00016237867,0.000051179468,0.000011903568,0.0001842431,0.00035069435,0.0002081907],"category_scores_gemma":[0.0012255956,0.00008383325,0.00016252193,0.0003180567,0.00062019663,0.00007163445,0.00007227017,0.0009410046,0.00000155531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012608218,0.0001884,0.81706434,0.00014837533,0.000094697316,0.000109664026,0.020257939,0.000015561001,0.00007270736,0.000020437032,0.0013670062,0.15940006],"study_design_scores_gemma":[0.002479032,0.0043139965,0.9298103,0.00025362824,0.0001583242,0.00022304997,0.058158364,0.00003103853,0.000005635805,0.000038933566,0.0044424944,0.0000852319],"about_ca_topic_score_codex":0.011872577,"about_ca_topic_score_gemma":0.04886441,"teacher_disagreement_score":0.15931483,"about_ca_system_score_codex":0.000270964,"about_ca_system_score_gemma":0.0019312799,"threshold_uncertainty_score":0.99470747},"labels":[],"label_agreement":null},{"id":"W2135121296","doi":"10.1200/jco.2004.00.1768","title":"Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Clinical endpoint; Breast cancer; Radiation therapy; Lung cancer; Internal medicine; Hazard ratio; Brain metastasis; Proportional hazards model; Adverse effect; Oncology; Cancer; Surgery; Confidence interval; Metastasis; Randomized controlled trial","score_opus":0.0759687803889326,"score_gpt":0.47654857778052123,"score_spread":0.40057979739158867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135121296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886196,0.0014835275,0.001198456,0.006512232,0.0014583489,0.0006225776,0.000031621777,0.0000029004214,0.00007070326],"genre_scores_gemma":[0.9808639,0.00033353752,0.0023590254,0.0077226935,0.00816557,0.000026633954,0.000028252141,0.000022328519,0.00047802753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970349,0.0006299657,0.0016295017,0.00026859978,0.00021608188,0.00022094243],"domain_scores_gemma":[0.997478,0.00044294758,0.0011417085,0.00026250095,0.0003684981,0.00030636182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038049635,0.00015366112,0.0009315513,0.000101759266,0.00004456501,0.000010786035,0.00028488925,0.00025589886,0.00003442436],"category_scores_gemma":[0.002274042,0.00012014573,0.00040410724,0.000091011156,0.00007310503,0.000019553883,0.000039201164,0.00021939,0.0000026231776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014645727,0.009113805,0.00022169031,0.000004250475,0.00040424953,0.000004024982,0.00033059457,0.00014915827,0.14735408,0.00004445438,0.053258825,0.77446914],"study_design_scores_gemma":[0.04039184,0.080679655,0.0019573707,0.0000046323426,0.00012260006,0.000024124223,0.00033580398,0.000027958793,0.015048457,0.00007897004,0.86120176,0.00012680703],"about_ca_topic_score_codex":0.000023114684,"about_ca_topic_score_gemma":0.00022620207,"teacher_disagreement_score":0.8079429,"about_ca_system_score_codex":0.000023146305,"about_ca_system_score_gemma":0.0007725062,"threshold_uncertainty_score":0.48994005},"labels":[],"label_agreement":null},{"id":"W2135321054","doi":"10.1200/jco.2007.13.5376","title":"Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":592,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine; International Prognostic Index; Follicular lymphoma; Prednisone; Vincristine; Internal medicine; Subgroup analysis; Rituximab; Cyclophosphamide; Gastroenterology; Univariate analysis; Lymphoma; Surgery; Oncology; Confidence interval; Chemotherapy; Multivariate analysis","score_opus":0.037635128536769286,"score_gpt":0.3714512317465326,"score_spread":0.3338161032097633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135321054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790674,0.00053018547,0.000009524658,0.00016286141,0.000089829795,0.0011316204,0.0000054146726,0.000009216287,0.00015463123],"genre_scores_gemma":[0.9975442,0.0003846545,0.0017524115,0.00017510273,0.000056270605,0.000023207142,0.0000107793,0.000021952597,0.000031403193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963441,0.00039140732,0.0022326638,0.00026905938,0.0005065888,0.00025619668],"domain_scores_gemma":[0.9960768,0.0008469189,0.0018537015,0.00026016237,0.00058838393,0.00037399592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069293706,0.00024155296,0.0025068359,0.00014449039,0.00006249376,0.000003924237,0.00010139198,0.00015894232,0.000013805086],"category_scores_gemma":[0.0004454304,0.00013973686,0.0001286611,0.000281021,0.00025753718,0.00011364966,0.00003915035,0.00026498846,0.0000010784693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0676992,0.08403176,0.8187889,0.000026284577,0.00091754925,0.0028850257,0.00062396924,0.000044429107,0.0000070446463,0.0000018156667,0.000106417654,0.02486763],"study_design_scores_gemma":[0.26901844,0.111968294,0.6173728,0.00019574974,0.00061115186,0.00024282452,0.00023152826,0.00001926232,0.000046318924,0.0000029659568,0.00020757415,0.00008306626],"about_ca_topic_score_codex":0.00032572565,"about_ca_topic_score_gemma":0.00028200593,"teacher_disagreement_score":0.20141606,"about_ca_system_score_codex":0.00023335303,"about_ca_system_score_gemma":0.0008077032,"threshold_uncertainty_score":0.56983036},"labels":[],"label_agreement":null},{"id":"W2135469527","doi":"10.1200/jco.2009.25.0720","title":"Is Seeing Believing?","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.6229299339797766,"score_gpt":0.6274863464467391,"score_spread":0.004556412466962478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135469527","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002480463,0.00263643,0.000028539698,0.95031613,0.02709176,0.00064143556,0.000034991725,0.00003841003,0.016731858],"genre_scores_gemma":[0.0036843775,0.0014822399,0.007891701,0.9455754,0.036944315,0.00003857258,0.000029033947,0.000096797376,0.0042575365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97857815,0.008814786,0.0103701865,0.00040971156,0.0009621593,0.0008650248],"domain_scores_gemma":[0.9432046,0.034608483,0.017324679,0.0014712105,0.002896988,0.0004940301],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0063872603,0.00036779308,0.0032997709,0.00036669231,0.00058652146,0.0000105443,0.0020436987,0.014204686,0.0022756963],"category_scores_gemma":[0.023236249,0.0002902536,0.0010966536,0.00020663088,0.00037541887,0.0002014241,0.0006577739,0.08281207,0.00089958473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016135175,0.00012232126,0.029452847,0.00037985138,0.00017607327,0.00030989628,0.0012545817,2.2495854e-7,0.0000021280707,0.00002510502,0.9495377,0.018577954],"study_design_scores_gemma":[0.0021082372,0.0017101134,0.006731645,0.00088075513,0.00020000403,0.0000548444,0.00045599893,0.000014786012,7.208597e-7,0.0014296281,0.9861787,0.00023455994],"about_ca_topic_score_codex":0.0001617786,"about_ca_topic_score_gemma":0.00013467883,"teacher_disagreement_score":0.06860738,"about_ca_system_score_codex":0.0005715364,"about_ca_system_score_gemma":0.01308796,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W2135530224","doi":"10.1200/jco.2014.57.1513","title":"Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; Taxane; Breast cancer; Placebo; Chemotherapy; Progression-free survival; Cancer; Randomized controlled trial; Pathology; Confidence interval","score_opus":0.1991386133547665,"score_gpt":0.5626661216359241,"score_spread":0.3635275082811576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135530224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504351,0.0004403009,0.00078652863,0.040949814,0.0010457942,0.005105356,0.000084203224,0.0000072184016,0.0011456574],"genre_scores_gemma":[0.9909129,0.0010933442,0.002710428,0.0027740446,0.0019776134,0.0002523033,0.000009661021,0.00003282902,0.00023686833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9849678,0.005427701,0.00752074,0.00030600335,0.0013916522,0.00038605218],"domain_scores_gemma":[0.95537364,0.03720142,0.005337568,0.0004337223,0.0012980845,0.0003555851],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.060486425,0.00022026755,0.005796141,0.00035196054,0.00004490346,0.000010307088,0.00038229357,0.00028009995,0.0006346181],"category_scores_gemma":[0.0560234,0.00012369204,0.0011073354,0.00038790662,0.0004563042,0.00008785962,0.00006305752,0.0013517357,0.0000035634948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7939595,0.0032441316,0.000051365638,0.00008870941,0.0007396224,0.00002647677,0.00033288685,0.00041333292,0.00060543395,0.000011204743,0.003051179,0.19747615],"study_design_scores_gemma":[0.9504265,0.03569443,0.00092225964,0.0006341785,0.0008725091,0.00007492074,0.00005789293,0.007953767,0.00016397693,0.0003044512,0.002799246,0.000095847994],"about_ca_topic_score_codex":0.00025345176,"about_ca_topic_score_gemma":0.00036307596,"teacher_disagreement_score":0.1973803,"about_ca_system_score_codex":0.00043742725,"about_ca_system_score_gemma":0.004580464,"threshold_uncertainty_score":0.96742696},"labels":[],"label_agreement":null},{"id":"W2135545421","doi":"10.1200/jco.2007.15.4872","title":"Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-Stimulating Agent Guidelines","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clinical Oncology; Hematology; Erythropoiesis; Internal medicine; Oncology; Intensive care medicine; Anemia; Cancer","score_opus":0.334552262891635,"score_gpt":0.5305250784811254,"score_spread":0.19597281558949042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135545421","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21180622,0.0013322191,0.0005178662,0.7821698,0.0024721008,0.0006194664,0.00005643029,0.000027023034,0.0009988676],"genre_scores_gemma":[0.07017885,0.044537924,0.43386242,0.43608204,0.014066005,0.000015552434,0.00012951133,0.00015855764,0.00096914667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9771849,0.0023084218,0.017950812,0.00074649265,0.0011738677,0.0006354967],"domain_scores_gemma":[0.9474843,0.016434632,0.031107467,0.0007417239,0.003810738,0.00042113021],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007269278,0.0006591226,0.0128502315,0.00020407054,0.000102156344,0.0000050522426,0.00044539888,0.0029461896,0.00023572786],"category_scores_gemma":[0.008576771,0.0004909223,0.007079327,0.00044058048,0.0074794204,0.00008970211,0.000220901,0.0057500578,0.000007922602],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013332177,0.0030197878,0.047855914,0.0005518757,0.0039490312,0.000623335,0.0003043727,0.00004567507,0.00014638185,0.0000072804746,0.83363193,0.1085312],"study_design_scores_gemma":[0.0148652755,0.06729258,0.018026628,0.0015296999,0.003882342,0.0029701174,0.002546252,0.00082456344,0.00039777913,0.00014937573,0.8869681,0.00054731267],"about_ca_topic_score_codex":0.00040070634,"about_ca_topic_score_gemma":0.00004598973,"teacher_disagreement_score":0.43334454,"about_ca_system_score_codex":0.00045795008,"about_ca_system_score_gemma":0.009121975,"threshold_uncertainty_score":0.9997744},"labels":[],"label_agreement":null},{"id":"W2135680696","doi":"10.1200/jco.2010.32.0093","title":"Reply to C.D. Atkins","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine","score_opus":0.13861954052961445,"score_gpt":0.5134301666929931,"score_spread":0.3748106261633787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135680696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92796546,0.00004027357,0.00010530259,0.04414454,0.008045706,0.00013561585,8.858421e-7,0.000009023836,0.019553192],"genre_scores_gemma":[0.9314327,0.00004603579,0.029469315,0.03480173,0.0033960314,0.0000021342762,2.3740766e-7,0.000014760784,0.00083700864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974811,0.00011764828,0.0017079522,0.0001550982,0.00034535164,0.00019284783],"domain_scores_gemma":[0.9962956,0.0014225676,0.00076207943,0.0002712595,0.0005593397,0.0006891904],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002921547,0.000090289635,0.0009589457,0.00010530801,0.000020222615,0.0000052302807,0.00019631237,0.00033470563,0.0009640993],"category_scores_gemma":[0.015105213,0.00006265293,0.00037575117,0.00013591403,0.00013978509,0.0000327036,0.0000630467,0.0016626447,0.00012985498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006303372,0.0015762942,0.2183303,0.000020520914,0.00028211885,0.000932955,0.00018633048,0.000010868391,0.02269829,0.00023694467,0.2666624,0.48275962],"study_design_scores_gemma":[0.0018012614,0.011821088,0.28842708,0.000016735481,0.00008538636,0.0006046119,0.000017376167,0.0000056696103,0.0009550754,0.00025792577,0.69595885,0.000048902126],"about_ca_topic_score_codex":0.000014393593,"about_ca_topic_score_gemma":0.00006148284,"teacher_disagreement_score":0.48271072,"about_ca_system_score_codex":0.00007671363,"about_ca_system_score_gemma":0.0018932434,"threshold_uncertainty_score":0.99994916},"labels":[],"label_agreement":null},{"id":"W2135906122","doi":"10.1200/jco.2013.49.1845","title":"Cancer Drugs in the United States: <i>Justum Pretium</i>—The Just Price","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":284,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Formulary; Health care; Bevacizumab; Gross domestic product; Sofosbuvir; Debt; Family medicine; Economic growth; Finance; Business; Surgery","score_opus":0.13220225340663308,"score_gpt":0.39830942494819777,"score_spread":0.2661071715415647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135906122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9177349,0.0025042167,0.00023129207,0.05336272,0.0023417247,0.0003118869,0.000018865014,0.0000050822678,0.023489311],"genre_scores_gemma":[0.9635627,0.008610472,0.0002490286,0.025497582,0.0014265773,0.000035760735,0.0000021886183,0.000018849361,0.0005968189],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961312,0.00018054963,0.0030473776,0.00020057928,0.00007048441,0.00036984382],"domain_scores_gemma":[0.99425274,0.0021227843,0.0029721684,0.0002899041,0.00020781702,0.00015456784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006253088,0.00014708776,0.0010318267,0.0001784045,0.00007913761,0.00007138971,0.0008275398,0.0002901672,0.0008166659],"category_scores_gemma":[0.0016360023,0.000090690635,0.00032376059,0.0003459672,0.00028949714,0.00039543762,0.00006188204,0.0012092697,0.00030245853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000737062,0.0017539995,0.3670637,0.00005417042,0.00048831827,0.000050617695,0.010316574,0.0031140344,0.000002246766,0.06855698,0.45310855,0.09475375],"study_design_scores_gemma":[0.0016217772,0.00075113727,0.28867346,0.000021769247,0.000020854271,0.0000128620695,0.00116913,0.0009375138,9.0797613e-7,0.025821626,0.68084157,0.00012741353],"about_ca_topic_score_codex":0.0025315073,"about_ca_topic_score_gemma":0.00025644503,"teacher_disagreement_score":0.22773302,"about_ca_system_score_codex":0.00024339152,"about_ca_system_score_gemma":0.0004148746,"threshold_uncertainty_score":0.8941919},"labels":[],"label_agreement":null},{"id":"W2135939943","doi":"10.1200/jco.2007.15.8808","title":"Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; EGFR inhibitors; Endometrial cancer; Erlotinib Hydrochloride; Cancer; Chemotherapy; Progressive disease; Gastroenterology","score_opus":0.38246967619841105,"score_gpt":0.5661995313252967,"score_spread":0.1837298551268856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135939943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932984,0.001635696,0.000010359684,0.0010529284,0.002716822,0.0008033956,0.000013808162,0.0000060158854,0.00046256435],"genre_scores_gemma":[0.9940725,0.0032392743,0.0007336837,0.00043635757,0.0012645492,0.00002799877,0.000002149073,0.000016380154,0.0002071305],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9934573,0.00088124233,0.004335452,0.00025096268,0.00078106066,0.0002939411],"domain_scores_gemma":[0.9915667,0.004849471,0.0024771115,0.00020266269,0.0004433065,0.00046075787],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003090328,0.00019453015,0.0031529672,0.0006550117,0.00005117104,0.0000024326043,0.0002182968,0.00019184902,0.0008247095],"category_scores_gemma":[0.0116514815,0.000115108356,0.00052391115,0.0012605822,0.00017615057,0.00009811373,0.00008328272,0.0010564261,0.0000059208446],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16368888,0.12928446,0.098504156,0.000066245324,0.0017257538,0.0052163787,0.0010341107,0.000016528036,0.000071783346,0.000010770026,0.0010827415,0.5992982],"study_design_scores_gemma":[0.35835272,0.52716774,0.09575962,0.00020003326,0.0016144238,0.00046835397,0.00065572053,0.00001798336,0.00017329998,0.000102050064,0.015333509,0.00015455608],"about_ca_topic_score_codex":0.00027371917,"about_ca_topic_score_gemma":0.0005291393,"teacher_disagreement_score":0.5991436,"about_ca_system_score_codex":0.000326199,"about_ca_system_score_gemma":0.0027593696,"threshold_uncertainty_score":0.9966738},"labels":[],"label_agreement":null},{"id":"W2136007869","doi":"10.1200/jco.2005.04.5823","title":"Hodgkin's Lymphoma in Adolescents","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Young adult; Hodgkin lymphoma; Cancer; Pediatrics; Malignancy; Internal medicine; Population; Disease; Stage (stratigraphy); Lymphoma; Hazard ratio; Confidence interval","score_opus":0.07967849297874934,"score_gpt":0.44699982434358665,"score_spread":0.3673213313648373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136007869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541415,0.0007121647,0.0000105944055,0.004470989,0.0008523855,0.000107701766,7.081874e-7,0.0000051668476,0.008426158],"genre_scores_gemma":[0.9954016,0.00027007752,0.001006919,0.001978557,0.001167694,0.000002415854,0.0000010365477,0.000008716174,0.000162992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973507,0.0001933707,0.0018792122,0.000126008,0.00026030256,0.00019041965],"domain_scores_gemma":[0.9982438,0.00043382795,0.00084640965,0.00012482035,0.00015519808,0.00019596203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012484333,0.00009753507,0.0010712519,0.00012484894,0.000013406442,0.000005160005,0.0000849569,0.00026840193,0.000049265524],"category_scores_gemma":[0.00068038097,0.000064656735,0.00040230682,0.00011304778,0.00008333606,0.000056702058,0.000025147567,0.000214974,0.00004891379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001211933,0.007488244,0.7857616,0.000011179506,0.000055246488,0.0032656344,0.0000070102665,0.000004823559,0.000015309608,0.00014496177,0.004557796,0.19747627],"study_design_scores_gemma":[0.021034377,0.0046407315,0.92017174,0.0002149682,0.0001311297,0.0005052438,0.000015728294,0.000015945017,0.000076130884,0.00043146472,0.052712183,0.00005034904],"about_ca_topic_score_codex":0.00012852166,"about_ca_topic_score_gemma":0.00012077617,"teacher_disagreement_score":0.19742592,"about_ca_system_score_codex":0.00033666653,"about_ca_system_score_gemma":0.0009856842,"threshold_uncertainty_score":0.26366252},"labels":[],"label_agreement":null},{"id":"W2136105871","doi":"10.1200/jco.2010.32.6371","title":"Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Nomogram; Cancer; Oncology; Internal medicine; Prospective cohort study; Area under the curve; Prostate; Risk assessment; Gynecology","score_opus":0.22910703701414104,"score_gpt":0.5124133112724907,"score_spread":0.28330627425834964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136105871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965214,0.0010067256,0.000010262282,0.00036476576,0.00090657163,0.00088026177,0.00001011076,0.0000044535136,0.0002954345],"genre_scores_gemma":[0.9955218,0.0019007155,0.0019185339,0.00018999228,0.0003281269,0.00006772908,4.6542115e-7,0.0000092958035,0.00006337414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721885,0.0003685714,0.0016732753,0.00016615466,0.0004087758,0.0001643848],"domain_scores_gemma":[0.9962128,0.00059251266,0.0020406444,0.0001670153,0.0008308355,0.00015622213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003753478,0.00012535324,0.0009220334,0.000053512445,0.00009876068,0.0000030134956,0.000120043944,0.00009929057,0.00010099194],"category_scores_gemma":[0.0013707088,0.000059383998,0.0003012778,0.000130405,0.00032742516,0.00009678645,0.000046823297,0.0006666967,0.000004667119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003744321,0.0050389296,0.9131224,0.000017939072,0.0009190179,0.00007851167,0.0018631712,0.0001540351,0.0000147731935,0.000023151431,0.00005722256,0.0749665],"study_design_scores_gemma":[0.010679099,0.046476748,0.93968445,0.00012424123,0.0010208557,0.000047139732,0.00046815776,0.0007669479,0.000387192,0.0000351879,0.00025577343,0.000054211127],"about_ca_topic_score_codex":0.00024339755,"about_ca_topic_score_gemma":0.00009986907,"teacher_disagreement_score":0.07491229,"about_ca_system_score_codex":0.00027869098,"about_ca_system_score_gemma":0.002315875,"threshold_uncertainty_score":0.4108263},"labels":[],"label_agreement":null},{"id":"W2136160663","doi":"10.1200/jco.2003.09.534","title":"Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":783,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Quality of life (healthcare); Body mass index; Physical therapy; Waist; Lean body mass; Internal medicine; Mood; Physical fitness; Aerobic exercise; Cancer; Body weight","score_opus":0.09382559787215894,"score_gpt":0.4528234397176407,"score_spread":0.3589978418454818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136160663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795883,0.008661854,0.00016308115,0.0061195656,0.0012450251,0.00053432264,0.000003637953,0.0000060279276,0.003678139],"genre_scores_gemma":[0.9813014,0.014616658,0.0015938729,0.0010564281,0.00035129607,0.00004427798,0.00000124458,0.000016011987,0.001018768],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804443,0.00020977644,0.001260578,0.0001401086,0.00018097342,0.00016415621],"domain_scores_gemma":[0.99781656,0.000787373,0.00077654945,0.00011345142,0.00036626487,0.00013978952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031527833,0.000080966725,0.00078410096,0.000081556245,0.000023372495,0.0000058258865,0.00007223274,0.00019874184,0.000059679776],"category_scores_gemma":[0.0015677371,0.000060410162,0.00021830357,0.00015551501,0.00004903544,0.00008184788,0.0000062335307,0.00038076995,9.463983e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019078748,0.0006836402,0.5252457,0.000098028206,0.0001318436,0.000102497455,0.0009934175,0.000019999094,0.00034939314,0.00023914638,0.0073889373,0.44566864],"study_design_scores_gemma":[0.020705702,0.0035328534,0.37852564,0.0008052544,0.0001480996,0.000033527023,0.00064946985,0.000027919526,0.0014850871,0.0037354196,0.5901856,0.00016546337],"about_ca_topic_score_codex":0.00004821493,"about_ca_topic_score_gemma":0.0013777101,"teacher_disagreement_score":0.58279663,"about_ca_system_score_codex":0.00018321392,"about_ca_system_score_gemma":0.0012730794,"threshold_uncertainty_score":0.24634549},"labels":[],"label_agreement":null},{"id":"W2136207103","doi":"10.1200/jco.2009.22.5771","title":"Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Clinical trial; Medicine; Harmonization; Cancer; Work (physics); Public relations; Family medicine; Political science; Pathology","score_opus":0.8985797909397516,"score_gpt":0.8089079030536181,"score_spread":0.08967188788613345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136207103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002469495,0.95724696,0.00003563644,0.032986794,0.0070758844,0.0012617717,0.00005887618,0.000009628765,0.0010775154],"genre_scores_gemma":[0.00005200633,0.9853601,0.0024959159,0.0025880262,0.0067819012,0.00012910337,0.000015559914,0.000044657347,0.002532714],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97969395,0.0038561267,0.014080401,0.0005533529,0.0013832684,0.00043292897],"domain_scores_gemma":[0.88559765,0.099539414,0.012151298,0.00038613228,0.0018452879,0.0004801931],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.03981027,0.00042675505,0.012626665,0.00044318152,0.00003695532,0.000030048326,0.00070520566,0.0047610723,0.0004999169],"category_scores_gemma":[0.21243769,0.00024594838,0.002663887,0.00048096362,0.00029103368,0.00021975415,0.00012566263,0.011201905,0.000022589278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010311579,0.0010169689,0.0033925737,0.0010463481,0.0014917175,0.00031492044,0.000066593464,0.0000049222267,6.3833977e-7,0.00032308025,0.00099265,0.9903184],"study_design_scores_gemma":[0.0071976306,0.0049195993,0.0010300158,0.01288561,0.0029195594,0.000054833832,0.000040355695,0.000013405462,9.427502e-7,0.0021036721,0.96865624,0.00017813373],"about_ca_topic_score_codex":0.00036386636,"about_ca_topic_score_gemma":0.0016821548,"teacher_disagreement_score":0.9901403,"about_ca_system_score_codex":0.0044066217,"about_ca_system_score_gemma":0.044252582,"threshold_uncertainty_score":0.9999993},"labels":[],"label_agreement":null},{"id":"W2136242714","doi":"10.1200/jco.2005.05.0401","title":"Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Refractory (planetary science); Rituximab; Gastroenterology; Adverse effect; Phases of clinical research; Progressive disease; Oncology; Surgery; Clinical trial; Leukemia; Multiple myeloma; Toxicity; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.08788936020811099,"score_gpt":0.4740014396404239,"score_spread":0.3861120794323129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136242714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683726,0.000282214,0.000016076197,0.00019955999,0.00058768934,0.0011565504,0.000013792556,0.000011532239,0.00089530693],"genre_scores_gemma":[0.9970623,0.00024184767,0.00095001835,0.00013777957,0.0010332648,0.000005836869,0.000012003075,0.000047483623,0.00050943706],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98488015,0.0018514546,0.010536575,0.00054378656,0.0016079549,0.00058006815],"domain_scores_gemma":[0.9785803,0.012732493,0.0059758457,0.00083021476,0.0013975055,0.00048364443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012255038,0.00031622665,0.004192993,0.0005054991,0.00004540148,0.000005639384,0.00054025726,0.00080669543,0.00009619612],"category_scores_gemma":[0.020786814,0.00019437842,0.00070855615,0.0007089235,0.0010305744,0.0001742188,0.00023192736,0.002076835,0.00000916746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6936935,0.07128906,0.1234734,0.0003084982,0.0015275382,0.0047823857,0.00036317887,0.0011345446,0.00012901514,0.00001718336,0.0064390576,0.096842594],"study_design_scores_gemma":[0.514143,0.25493526,0.22547631,0.00060459605,0.0005839709,0.00010961775,0.00010092798,0.00081130245,0.00007255774,0.000018738832,0.0030046473,0.00013907178],"about_ca_topic_score_codex":0.0010074932,"about_ca_topic_score_gemma":0.00071637554,"teacher_disagreement_score":0.1836462,"about_ca_system_score_codex":0.032732297,"about_ca_system_score_gemma":0.13954276,"threshold_uncertainty_score":0.9874615},"labels":[],"label_agreement":null},{"id":"W2136268782","doi":"10.1200/jco.2014.60.2383","title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"Tissue microarray; Diffuse large B-cell lymphoma; Germinal center; Medicine; Vincristine; International Prognostic Index; Immunohistochemistry; Lymphoma; Pathology; Cancer research; Rituximab; Oncology; Internal medicine; Cyclophosphamide; B cell; Immunology; Chemotherapy; Antibody","score_opus":0.07129790435913139,"score_gpt":0.39625720036363743,"score_spread":0.324959296004506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136268782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659026,0.001305664,0.00013718216,0.00037940062,0.00043024262,0.00042590912,0.000049811082,0.000007810421,0.0006737111],"genre_scores_gemma":[0.99378484,0.00036857408,0.0052083726,0.00016178213,0.00018978523,0.000017373965,0.000019010593,0.00002051731,0.00022974507],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958205,0.00025720813,0.0028903692,0.00022951321,0.00047864267,0.00032371545],"domain_scores_gemma":[0.9942956,0.0020735743,0.0024684647,0.0002558796,0.00042885076,0.00047760457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012570482,0.00021646936,0.001842479,0.00015222137,0.000013459534,0.000009826428,0.00021060141,0.00037128924,0.000015022794],"category_scores_gemma":[0.0017738134,0.00014593294,0.00032671823,0.00017619609,0.00018104342,0.00019755783,0.00008106222,0.00020398364,0.000011153872],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012190247,0.112067625,0.7448246,0.00028586254,0.00021729118,0.0021831903,0.00073731586,0.000021374255,0.07863972,0.000016988522,0.008585016,0.040230777],"study_design_scores_gemma":[0.16717823,0.035870552,0.08895388,0.0004982932,0.00060117955,0.00023906888,0.00050954527,0.00026299866,0.6822872,0.00015713809,0.023116667,0.00032520134],"about_ca_topic_score_codex":0.000018466897,"about_ca_topic_score_gemma":0.000009523355,"teacher_disagreement_score":0.65587074,"about_ca_system_score_codex":0.00019658277,"about_ca_system_score_gemma":0.0014626385,"threshold_uncertainty_score":0.59509724},"labels":[],"label_agreement":null},{"id":"W2136521229","doi":"10.1200/jco.2014.59.2444","title":"Genomic Characterization of Non–Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"National Cancer Institute; National Institutes of Health; Ohio State University; Conquer Cancer Foundation","keywords":"Massive parallel sequencing; Anaplastic lymphoma kinase; Lung cancer; Genotyping; Cancer research; Medicine; Epidermal growth factor receptor; ROS1; Oncology; Somatic cell; Cancer; Biology; Gene; Internal medicine; Genetics; DNA sequencing; Genotype; Adenocarcinoma","score_opus":0.06095090667082268,"score_gpt":0.3852350261665054,"score_spread":0.3242841194956827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136521229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910095,0.0008565591,0.006614329,0.0005100465,0.000441247,0.00010044161,0.000022765124,0.0000018367066,0.0004433255],"genre_scores_gemma":[0.9943039,0.0012792103,0.0032411986,0.0004618914,0.00044067408,0.0000059596955,0.000018470571,0.000016191832,0.00023254247],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979091,0.00023663651,0.0013609476,0.00017522475,0.00013773199,0.00018032233],"domain_scores_gemma":[0.9976674,0.00006281001,0.0016568657,0.00012555195,0.00030631202,0.00018110649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00105639,0.00011116893,0.0006328527,0.000052067113,0.000012934837,0.000004672438,0.00020883922,0.00026433376,0.000016207165],"category_scores_gemma":[0.00030972052,0.00009518628,0.00016762549,0.00009693318,0.000093929164,0.000006197216,0.000050699833,0.00029443184,8.2629833e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006693818,0.00021661105,0.030641649,0.000021117932,0.00008601494,0.00001378293,0.00023280259,0.0033054466,0.9523319,7.3234924e-7,0.0011815596,0.011298994],"study_design_scores_gemma":[0.050363965,0.030691812,0.37781122,0.0006601012,0.0011532332,0.00021584658,0.0040911958,0.0927777,0.3203756,0.0002675072,0.11940018,0.0021916335],"about_ca_topic_score_codex":0.00014834179,"about_ca_topic_score_gemma":0.00006504646,"teacher_disagreement_score":0.63195634,"about_ca_system_score_codex":0.00021506207,"about_ca_system_score_gemma":0.0032632,"threshold_uncertainty_score":0.5788777},"labels":[],"label_agreement":null},{"id":"W2136536672","doi":"10.1200/jco.2005.02.106","title":"Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Epirubicin; Internal medicine; Hazard ratio; Breast cancer; Chemotherapy; Metastatic breast cancer; Oncology; Odds ratio; Surrogate endpoint; Cancer; Proportional hazards model; Surgery; Confidence interval","score_opus":0.1327136294108822,"score_gpt":0.5539587784090273,"score_spread":0.42124514899814514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136536672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.101194955,0.88578725,0.000004727161,0.0060836603,0.00427663,0.0018048037,0.0002671573,0.000007644749,0.00057317264],"genre_scores_gemma":[0.010269109,0.9861728,0.00036548867,0.0012757382,0.0013549592,0.000040756568,0.000012629477,0.00005271745,0.00045579288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916138,0.002847933,0.0043117492,0.00034616716,0.0005214012,0.00035893446],"domain_scores_gemma":[0.99082977,0.0040604905,0.0037730988,0.00019088524,0.0006530485,0.00049273623],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046902983,0.00038318627,0.0072026765,0.0005991506,0.000017949735,0.000004922739,0.00024725226,0.00053829415,0.0018783804],"category_scores_gemma":[0.0011888664,0.00026258963,0.0016517608,0.00041816477,0.00018322097,0.00007147182,0.0000679832,0.0014317165,0.00003070042],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04731336,0.0067047216,0.0011534841,0.0005874768,0.0024193907,0.00080387463,0.00017950601,0.0000072898138,0.0000046283535,0.0000022202025,0.000976587,0.93984747],"study_design_scores_gemma":[0.026196828,0.026434133,0.03838312,0.0037932144,0.005925289,0.00078938785,0.000052350846,0.0000020316127,0.000003526611,0.000029011107,0.8981411,0.00025001113],"about_ca_topic_score_codex":0.00021966462,"about_ca_topic_score_gemma":0.00027910952,"teacher_disagreement_score":0.9395974,"about_ca_system_score_codex":0.001210922,"about_ca_system_score_gemma":0.008666298,"threshold_uncertainty_score":0.99998266},"labels":[],"label_agreement":null},{"id":"W2136654252","doi":"10.1200/jco.2006.09.9788","title":"Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Capecitabine; Pancreatic cancer; Chemotherapy; Internal medicine; Oncology; Deoxycytidine; Cancer; Clinical trial; Antimetabolite; Colorectal cancer","score_opus":0.09493279013770002,"score_gpt":0.4967432506448731,"score_spread":0.4018104605071731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136654252","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1331886,0.0007334333,0.00007908178,0.85203564,0.0008442013,0.0009865353,0.000005513748,0.000010221706,0.012116763],"genre_scores_gemma":[0.0045228475,0.003009415,0.0025525335,0.95051265,0.008218844,0.00005943105,0.000019987954,0.00007160621,0.031032696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993393,0.0012497922,0.0034508181,0.00034068179,0.00094629976,0.00061940245],"domain_scores_gemma":[0.98921144,0.007060557,0.0020903696,0.00043781244,0.00084856956,0.0003512785],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009053662,0.0003024739,0.0038260391,0.00051114487,0.000056585242,0.000013074798,0.0005240964,0.0020040513,0.0022113735],"category_scores_gemma":[0.0053910813,0.00018258319,0.0005938561,0.0004564282,0.00039210668,0.00007349369,0.00007201831,0.0066573387,0.0002881896],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005461552,0.0007214828,0.054430395,0.00008434711,0.00054857397,0.002640787,0.00019927286,0.0000066115645,0.000034356326,0.00000318643,0.84220815,0.0936613],"study_design_scores_gemma":[0.010517252,0.009326144,0.15734608,0.0005436849,0.00053616683,0.0002973689,0.00003715613,0.00012501242,0.0000052989785,0.00016377668,0.82095045,0.00015162451],"about_ca_topic_score_codex":0.000039729908,"about_ca_topic_score_gemma":0.000049894104,"teacher_disagreement_score":0.12866576,"about_ca_system_score_codex":0.0008318133,"about_ca_system_score_gemma":0.0043865284,"threshold_uncertainty_score":0.99929154},"labels":[],"label_agreement":null},{"id":"W2136655134","doi":"10.1200/jco.2008.18.1024","title":"Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":535,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Internal medicine; Docetaxel; Oncology; Immunohistochemistry; Cyclophosphamide; Triple-negative breast cancer; Trastuzumab; Estrogen receptor; Hazard ratio; Population; Cancer; Chemotherapy; Confidence interval","score_opus":0.06568569234966365,"score_gpt":0.42025055763997266,"score_spread":0.354564865290309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136655134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864839,0.0006631644,0.0000049392324,0.012188482,0.0002396635,0.00021144167,0.00016160957,0.0000013575984,0.000045449004],"genre_scores_gemma":[0.99555695,0.0015752772,0.00040174223,0.0019290656,0.0004933527,0.000019645573,0.000009023187,0.000008139286,0.000006783801],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974389,0.0008411023,0.0010989248,0.00023892401,0.00017808408,0.00020403138],"domain_scores_gemma":[0.9982223,0.0006436627,0.00061195996,0.00017332152,0.00024070819,0.00010806073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015524285,0.00014872754,0.0006906039,0.000091745576,0.00003145023,0.000010660396,0.0001886088,0.00027945984,0.000011924389],"category_scores_gemma":[0.0004166115,0.00010357543,0.00014378062,0.00014011105,0.0001966845,0.000022464665,0.0000399198,0.00035644032,5.0134025e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77410257,0.0051414324,0.06520399,0.0000097439415,0.00029800966,0.00017575145,0.0006884835,0.00011139974,0.03390787,0.000042591106,0.0011235975,0.11919455],"study_design_scores_gemma":[0.028268032,0.004500941,0.964934,0.000080977654,0.000105761945,0.0004224149,0.00012146729,0.0000053524464,0.00052708504,0.00009457708,0.00082059787,0.000118822834],"about_ca_topic_score_codex":0.00082906324,"about_ca_topic_score_gemma":0.0010815818,"teacher_disagreement_score":0.89972997,"about_ca_system_score_codex":0.00015616522,"about_ca_system_score_gemma":0.0007130571,"threshold_uncertainty_score":0.42236835},"labels":[],"label_agreement":null},{"id":"W2136796708","doi":"10.1200/jco.2005.03.8331","title":"Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Cardiotoxicity; Trastuzumab; Ejection fraction; Metastatic breast cancer; Internal medicine; Regimen; Doxorubicin; Heart failure; Neutropenia; Breast cancer; Chemotherapy; Oncology; Cancer; Cardiology; Surgery","score_opus":0.08057736448296554,"score_gpt":0.46457495833009443,"score_spread":0.3839975938471289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136796708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370944,0.00043654518,0.000087084474,0.004420955,0.0006071951,0.00037902428,0.00001130851,0.000008472789,0.00033998123],"genre_scores_gemma":[0.99574476,0.0002666358,0.0011598945,0.0009806842,0.0017394458,0.0000056345184,0.0000039154943,0.000016495644,0.00008253507],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969194,0.00040179037,0.0019792751,0.0001903571,0.00028403685,0.00022514128],"domain_scores_gemma":[0.9977493,0.00072456384,0.0010480719,0.0000989674,0.0001783339,0.00020073382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015802706,0.00014535173,0.0013426803,0.00014789586,0.00004938371,0.000014145238,0.0000645774,0.00026818158,0.00013034978],"category_scores_gemma":[0.0004172071,0.00011073827,0.00033613323,0.00013446307,0.00015022796,0.00017406877,0.000023550563,0.0008579188,0.0000010020797],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29081753,0.015864803,0.0061895847,0.000079933634,0.0006064995,0.0011505956,0.00049196166,0.000062588704,0.21483287,0.000028536251,0.0010059071,0.46886918],"study_design_scores_gemma":[0.82718784,0.045002356,0.09464983,0.0009312282,0.0012002487,0.002385231,0.00039080204,0.0016181614,0.018978175,0.00039105272,0.0069574113,0.00030763765],"about_ca_topic_score_codex":0.00019036404,"about_ca_topic_score_gemma":0.00013665353,"teacher_disagreement_score":0.53637034,"about_ca_system_score_codex":0.00022790884,"about_ca_system_score_gemma":0.0007895654,"threshold_uncertainty_score":0.45157754},"labels":[],"label_agreement":null},{"id":"W2136844102","doi":"10.1200/jco.2010.34.0711","title":"Adverse Effect of Older Age on the Recurrence of Soft Tissue Sarcoma of the Extremities and Trunk","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trunk; Soft tissue; Soft tissue sarcoma; Sarcoma; Adverse effect; Surgery; Internal medicine; Pathology","score_opus":0.13493433675280622,"score_gpt":0.4277882390413158,"score_spread":0.2928539022885096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136844102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939401,0.0010696148,0.0000037564075,0.0013852912,0.000407632,0.00023857609,0.0000036348267,0.0000012288597,0.0029501303],"genre_scores_gemma":[0.99877524,0.0005230563,0.0002403813,0.00029654845,0.00010321916,0.0000036226816,1.9610883e-7,0.0000059325675,0.000051777322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977246,0.0006197261,0.0012231738,0.00008969995,0.00024429843,0.00009849591],"domain_scores_gemma":[0.99083203,0.007258973,0.0014550955,0.0002306869,0.00014087837,0.00008235939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019544638,0.00009607652,0.0010483087,0.000045651752,0.00001902496,7.5079544e-7,0.00015643945,0.0001473369,0.00016774847],"category_scores_gemma":[0.0027875167,0.000039463255,0.0003478044,0.000068751,0.0005740093,0.000024756604,0.000063510204,0.00036541058,0.0000014618561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032748478,0.002878114,0.67793155,0.000102072314,0.00044964132,0.00022171046,0.00079366326,6.464952e-7,0.0003257884,0.00064733624,0.0017922727,0.31158236],"study_design_scores_gemma":[0.004506086,0.017049707,0.9644438,0.000557869,0.00058037695,0.00010915286,0.00014538472,0.0000039015945,0.009875528,0.00044357372,0.002249844,0.00003479287],"about_ca_topic_score_codex":0.000031099466,"about_ca_topic_score_gemma":0.000015380876,"teacher_disagreement_score":0.31154755,"about_ca_system_score_codex":0.000021359207,"about_ca_system_score_gemma":0.00018118563,"threshold_uncertainty_score":0.33371192},"labels":[],"label_agreement":null},{"id":"W2136977965","doi":"10.1200/jco.2007.15.9947","title":"Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":510,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Genentech; American Society of Clinical Oncology","keywords":"Medicine; Bevacizumab; Hepatocellular carcinoma; Internal medicine; Vascular endothelial growth factor; Gastroenterology; Angiogenesis; Oncology; Adverse effect; Phases of clinical research; Clinical trial; Chemotherapy; VEGF receptors","score_opus":0.40168009669027327,"score_gpt":0.4960715878263401,"score_spread":0.09439149113606682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136977965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185634,0.0040623965,0.000018528188,0.0016032637,0.0010834795,0.0010762642,0.0000016663166,0.0000063555035,0.00029172926],"genre_scores_gemma":[0.99566853,0.0015516388,0.0011662522,0.00038134583,0.0010914007,0.000019500882,0.0000032543237,0.000015584574,0.000102474216],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99253625,0.002671067,0.0037680706,0.00028577299,0.00042659583,0.00031224097],"domain_scores_gemma":[0.98810655,0.009186596,0.0017723384,0.00028353598,0.00032708127,0.0003239289],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010106039,0.00019869463,0.0023098274,0.00016398454,0.00011946957,0.000004371761,0.00020130638,0.0005821028,0.000049828544],"category_scores_gemma":[0.012803715,0.00011130134,0.00079208484,0.00025779984,0.00074100395,0.000080372236,0.00012694206,0.001275356,0.0000040589653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08437687,0.007767074,0.8354099,0.00005293622,0.00026285448,0.0027482137,0.00019856096,2.8748215e-7,0.00045733986,0.000021733276,0.00024939678,0.06845483],"study_design_scores_gemma":[0.3689402,0.41826957,0.20309299,0.00016105594,0.0010618982,0.0008910018,0.00007255894,0.00359278,0.0010955229,0.0003475517,0.0023209485,0.00015388856],"about_ca_topic_score_codex":0.000048071866,"about_ca_topic_score_gemma":0.000008579749,"teacher_disagreement_score":0.6323169,"about_ca_system_score_codex":0.00006531567,"about_ca_system_score_gemma":0.0018561858,"threshold_uncertainty_score":0.99551183},"labels":[],"label_agreement":null},{"id":"W2137156235","doi":"10.1200/jco.2009.24.6314","title":"Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nomogram; Medicine; Brain metastasis; Breast cancer; Oncology; Internal medicine; Metastasis; Metastatic breast cancer; Cancer; Population; Multivariate analysis; Receiver operating characteristic","score_opus":0.06318838039762008,"score_gpt":0.44209371635205585,"score_spread":0.37890533595443576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137156235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969906,0.00006589473,0.00013103875,0.028170701,0.00091830926,0.0005379243,0.00008363225,0.000007463194,0.00017906885],"genre_scores_gemma":[0.97472036,0.000037031266,0.01968114,0.0050309957,0.00040208394,0.000023389483,0.000009202555,0.00002530844,0.00007047874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965399,0.00041844323,0.0018916754,0.0002552258,0.0005552244,0.00033953995],"domain_scores_gemma":[0.9962391,0.0011957976,0.0009834997,0.0002697348,0.00053012173,0.000781705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033127165,0.00019934872,0.0016170716,0.0002464963,0.000026882672,0.000012164501,0.00016117678,0.00015299158,0.0005875933],"category_scores_gemma":[0.0013816045,0.00011518075,0.00036858916,0.00031888488,0.00015284008,0.00011080451,0.000044557426,0.0011534276,0.000016269987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065120133,0.005767083,0.7033841,0.000021085467,0.0009716586,0.00071228755,0.000051153474,0.000039104223,0.000019316483,0.00006586459,0.0024212638,0.28003505],"study_design_scores_gemma":[0.017658241,0.016549038,0.93722934,0.00009342786,0.0009211899,0.0002907102,0.00003901145,0.000016671658,0.000015696465,0.000061685234,0.027017502,0.000107509186],"about_ca_topic_score_codex":0.0001523898,"about_ca_topic_score_gemma":0.0011081632,"teacher_disagreement_score":0.27992752,"about_ca_system_score_codex":0.00017068208,"about_ca_system_score_gemma":0.0013421506,"threshold_uncertainty_score":0.6433735},"labels":[],"label_agreement":null},{"id":"W2137372444","doi":"10.1200/jco.2008.20.0923","title":"Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":334,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Diabetes mellitus; Hazard ratio; Internal medicine; Cohort; Myocardial infarction; Sudden cardiac death; Proportional hazards model; Cancer; Endocrinology; Confidence interval","score_opus":0.13411804558813858,"score_gpt":0.4945700752033169,"score_spread":0.3604520296151783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137372444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98966944,0.007815381,0.0000064531464,0.002028891,0.00007449886,0.00014535546,0.0000021930257,0.0000023753914,0.00025539903],"genre_scores_gemma":[0.9890381,0.010167071,0.00012155827,0.00030393465,0.00033682646,8.593197e-7,0.0000020383181,0.0000042442625,0.000025387964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876124,0.00017560102,0.00059956126,0.00008962378,0.00025973906,0.00011426681],"domain_scores_gemma":[0.9986446,0.00042481138,0.0002917682,0.00013374149,0.00020741824,0.00029768952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001257068,0.000065068874,0.0007330934,0.00008011666,0.00001559575,0.000003177193,0.000045759098,0.000097736134,0.000020517784],"category_scores_gemma":[0.0007635726,0.00003490416,0.0006559482,0.00006937384,0.0000933423,0.00004746023,0.0000072244775,0.00025758278,0.000001109414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062538395,0.0009997024,0.51857865,0.0000067580118,0.0015593512,0.00014760629,0.000020840556,0.000026412301,0.00025326893,0.000010175812,0.0003555216,0.4717879],"study_design_scores_gemma":[0.008182454,0.026416356,0.9617642,0.000048060305,0.00025005874,0.000011774417,0.0000034708378,0.0000377264,0.0002999318,0.00060850277,0.002347016,0.000030424904],"about_ca_topic_score_codex":0.0000035864125,"about_ca_topic_score_gemma":1.0575965e-7,"teacher_disagreement_score":0.47175747,"about_ca_system_score_codex":0.00006877271,"about_ca_system_score_gemma":0.0007753295,"threshold_uncertainty_score":0.14233501},"labels":[],"label_agreement":null},{"id":"W2137383164","doi":"10.1200/jco.2007.14.6217","title":"Cancer Survivors’ Adherence to Lifestyle Behavior Recommendations and Associations With Health-Related Quality of Life: Results From the American Cancer Society's SCS-II","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1025,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Cancer; Gerontology; Cancer survivor; Demography; Internal medicine; Psychiatry","score_opus":0.24266289197625004,"score_gpt":0.5096895033310943,"score_spread":0.2670266113548443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137383164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8951995,0.001286388,0.000029783627,0.101790726,0.0008640035,0.00025021512,0.0004852839,0.000008935639,0.00008518597],"genre_scores_gemma":[0.98027855,0.0078010205,0.0010657652,0.0099027725,0.00062649854,0.000030360385,0.000021673399,0.000014775347,0.00025860293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560976,0.000885278,0.0026335767,0.0002307891,0.00042150696,0.00021908586],"domain_scores_gemma":[0.989977,0.0043171565,0.0041402504,0.0002321491,0.00084729446,0.00048616002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032126494,0.00013008485,0.0015177642,0.000038181523,0.00030618836,0.000004847263,0.00016178576,0.00016057781,0.0000961685],"category_scores_gemma":[0.0027178528,0.000082526014,0.00029805524,0.00043385566,0.00044650817,0.00007221673,0.00008151335,0.00091216434,0.0000011314075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019111544,0.0006713128,0.923956,0.000008681105,0.00048536158,0.000009090442,0.008307294,0.000014032543,0.000022228705,0.000007882909,0.020289458,0.044317547],"study_design_scores_gemma":[0.0036819403,0.0056856857,0.9704759,0.00014848416,0.00024423184,0.000012953213,0.0019087972,0.000007969063,0.0000061352125,0.000012127448,0.01772531,0.000090477326],"about_ca_topic_score_codex":0.16382922,"about_ca_topic_score_gemma":0.22069433,"teacher_disagreement_score":0.09188795,"about_ca_system_score_codex":0.000278804,"about_ca_system_score_gemma":0.0048249247,"threshold_uncertainty_score":0.855921},"labels":[],"label_agreement":null},{"id":"W2137411979","doi":"10.1200/jco.2007.11.0726","title":"Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":407,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Bio-Imaging Technologies","keywords":"Anastrozole; Medicine; Tolerability; Tamoxifen; Bone mineral; Aromatase inhibitor; Internal medicine; Breast cancer; Osteopenia; Osteoporosis; Urology; Oncology; Surgery; Cancer; Adverse effect","score_opus":0.0419538519594452,"score_gpt":0.37960135826541275,"score_spread":0.33764750630596757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137411979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970064,0.0001776058,0.000021166006,0.0012328688,0.0008832747,0.00030306913,0.000014281899,0.0000027802207,0.0003585472],"genre_scores_gemma":[0.99728847,0.00057414995,0.0004234531,0.0004283466,0.0010454468,0.000003268861,0.00004321204,0.000014070207,0.00017960434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956499,0.0017687933,0.0018370886,0.00023107546,0.00029906104,0.00021408562],"domain_scores_gemma":[0.9957527,0.0022236058,0.0014573376,0.00026438423,0.00015945116,0.00014251198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036360966,0.00016581909,0.0009691897,0.00007209612,0.000049821316,0.000004991694,0.0002448768,0.00058323686,0.000012064148],"category_scores_gemma":[0.005427768,0.00009421775,0.00039887417,0.00014220603,0.00026846305,0.000008351353,0.0000717174,0.00080364547,0.000009617915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87222457,0.003001559,0.018682014,0.00001110116,0.0005544641,0.0011216056,0.000107239706,0.00018738412,0.03832733,0.000012458127,0.04201722,0.023753036],"study_design_scores_gemma":[0.4373546,0.28844061,0.14959258,0.00018484892,0.00043256977,0.00054476486,0.000077915516,0.00016171079,0.10360041,0.000059806862,0.0191552,0.00039498665],"about_ca_topic_score_codex":0.00004649007,"about_ca_topic_score_gemma":0.000048345657,"teacher_disagreement_score":0.43487,"about_ca_system_score_codex":0.000032954074,"about_ca_system_score_gemma":0.0004421233,"threshold_uncertainty_score":0.64979374},"labels":[],"label_agreement":null},{"id":"W2137488285","doi":"10.1200/jco.2008.16.2545","title":"Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Angiogenesis; Lung cancer; Cancer research; Cancer; Oncology; Clinical trial; Internal medicine","score_opus":0.15655623511511305,"score_gpt":0.5619253721958037,"score_spread":0.40536913708069067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137488285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948757,0.0014382956,0.000009123764,0.0017420923,0.00066251383,0.0007454227,0.000014739736,0.0000018751482,0.0005101801],"genre_scores_gemma":[0.9981288,0.0004281685,0.0005337677,0.00036516268,0.00040971392,0.00004297613,0.0000036242798,0.000011383535,0.00007641626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99461555,0.0019813017,0.0027275223,0.00015200026,0.00037677295,0.00014682469],"domain_scores_gemma":[0.99171966,0.0053421496,0.0020727713,0.000109729765,0.0006099678,0.00014570284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010131494,0.000116274714,0.0014903243,0.0004755802,0.000021683656,0.0000020540672,0.00005663746,0.0001799861,0.000115936426],"category_scores_gemma":[0.007831185,0.00007633319,0.0005292348,0.0003686381,0.00007205556,0.00007900826,0.000009468838,0.0003305524,0.0000019845488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057170942,0.00428515,0.879879,0.000040933013,0.00069722114,0.0009420976,0.0033632421,0.0059497184,0.0028115357,0.0000024314727,0.0019260822,0.042931672],"study_design_scores_gemma":[0.021877924,0.009315553,0.9653507,0.00031184577,0.00083420984,0.00006607665,0.00034819264,0.0003594357,0.0012979516,0.00002993546,0.00014669528,0.00006148735],"about_ca_topic_score_codex":0.00046475645,"about_ca_topic_score_gemma":0.00029097844,"teacher_disagreement_score":0.08547172,"about_ca_system_score_codex":0.0014053995,"about_ca_system_score_gemma":0.007863837,"threshold_uncertainty_score":0.99776065},"labels":[],"label_agreement":null},{"id":"W2137552823","doi":"10.1200/jco.2002.03.084","title":"Function and Health Status Outcomes in a Randomized Trial Comparing Preoperative and Postoperative Radiotherapy in Extremity Soft Tissue Sarcoma","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Randomized controlled trial; Quality of life (healthcare); Soft tissue sarcoma; Surgery; Sarcoma; Randomization; Soft tissue; Radiation therapy; Rehabilitation; Physical therapy","score_opus":0.16662261108611304,"score_gpt":0.47429604075684445,"score_spread":0.3076734296707314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137552823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680387,0.011823843,0.00008532063,0.018419968,0.00034987152,0.0010857432,0.0000011166077,0.000003872134,0.00019160457],"genre_scores_gemma":[0.98711187,0.008383435,0.0016895141,0.002566481,0.00016728332,0.000024019651,0.000001026733,0.00000855024,0.000047799294],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959197,0.0014457313,0.0020575537,0.00019481647,0.00017184563,0.00021032675],"domain_scores_gemma":[0.99462974,0.004184646,0.0007625137,0.00007942055,0.0000812587,0.00026243666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036123416,0.00014399525,0.0031929573,0.00018150455,0.000034107827,0.000013986401,0.000031497046,0.00016556542,0.00008104719],"category_scores_gemma":[0.0016635155,0.00008933733,0.00016810838,0.000087354434,0.00018469109,0.000109875145,0.00001935592,0.00058881694,0.000001003442],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25973296,0.002915611,0.6180375,0.000006586426,0.00020212034,0.00012507224,0.0007988577,0.0000047581143,0.000003527679,0.000058836875,0.0001265386,0.11798762],"study_design_scores_gemma":[0.4988706,0.00788804,0.4916778,0.00005780757,0.000059936105,0.000054159176,0.00010798499,0.00053806434,0.0000015238173,0.00007927734,0.0006237514,0.00004102813],"about_ca_topic_score_codex":0.00027071952,"about_ca_topic_score_gemma":0.00076305267,"teacher_disagreement_score":0.23913765,"about_ca_system_score_codex":0.00027470838,"about_ca_system_score_gemma":0.00029017884,"threshold_uncertainty_score":0.36430705},"labels":[],"label_agreement":null},{"id":"W2137586470","doi":"10.1200/jco.2012.44.4661","title":"Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":344,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Dexamethasone; Nausea; Anxiety; Internal medicine; Distress; Depression (economics); Randomized controlled trial; Adverse effect; Cancer; Quality of life (healthcare); Physical therapy; Psychiatry; Clinical psychology","score_opus":0.06391303078724235,"score_gpt":0.4280336928858857,"score_spread":0.36412066209864336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137586470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885515,0.0007655857,0.00004639444,0.0024509106,0.0025547333,0.0048743705,0.0000022127995,0.000010626348,0.00074369507],"genre_scores_gemma":[0.99694145,0.00076727365,0.00072158844,0.00018868325,0.0005463369,0.00060283643,0.0000033814254,0.000027099775,0.0002013424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948172,0.00083785615,0.0032026437,0.00025443453,0.0006185016,0.00026938386],"domain_scores_gemma":[0.99238414,0.0018405059,0.003848839,0.00020084498,0.0014387682,0.0002868806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028491619,0.0002196276,0.003970216,0.00025679386,0.000023985687,0.000008229063,0.00013820762,0.00042496013,0.0004272026],"category_scores_gemma":[0.0008968237,0.00012136087,0.00050875475,0.00038564377,0.00030956412,0.00022383814,0.000018344403,0.0011295893,0.000001866878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9260746,0.0018515704,0.027768552,0.00003721163,0.0014249386,0.000016837945,0.0004180941,0.00049724174,0.000010530612,0.000013580986,0.00010618797,0.041780625],"study_design_scores_gemma":[0.9655803,0.018419141,0.0133323595,0.00045873682,0.0014204517,0.000012687841,0.00021953585,0.00007087022,0.00004764088,0.000041435844,0.00026232837,0.00013454798],"about_ca_topic_score_codex":0.0023113743,"about_ca_topic_score_gemma":0.00276507,"teacher_disagreement_score":0.04164608,"about_ca_system_score_codex":0.00033759698,"about_ca_system_score_gemma":0.0027040823,"threshold_uncertainty_score":0.49489525},"labels":[],"label_agreement":null},{"id":"W2137694455","doi":"10.1200/jco.2006.05.9923","title":"Polymorphisms in<i>XRCC1</i>,<i>XRCC3</i>, and<i>CCND1</i>and Survival After Treatment for Metastatic Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern Cancer Foundation; NOSM University; Sudbury Regional Hospital","funders":"","keywords":"XRCC1; Medicine; Internal medicine; XRCC3; Oncology; Hazard ratio; Breast cancer; Single-nucleotide polymorphism; Metastatic breast cancer; Genotype; Cancer; Progression-free survival; Chemotherapy; Gastroenterology; Confidence interval; Biology; Genetics; Gene","score_opus":0.04504424120103617,"score_gpt":0.39289086295906456,"score_spread":0.3478466217580284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137694455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215066,0.0035780834,0.00041791383,0.0026050722,0.0007707566,0.00022734844,0.000062945204,0.000003461597,0.00018372787],"genre_scores_gemma":[0.9909998,0.0019138637,0.004712488,0.000863852,0.0010148364,0.00004845721,0.000006405725,0.000025430038,0.00041487606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779457,0.00026571343,0.0012390396,0.0002925369,0.00013348296,0.0002746296],"domain_scores_gemma":[0.99853176,0.00035011454,0.0006370153,0.0001489598,0.00014966448,0.0001824659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012722438,0.0001873041,0.0008481603,0.00006880448,0.000028419483,0.000013780448,0.000099078345,0.00025577677,0.00002291011],"category_scores_gemma":[0.000184031,0.00013952365,0.0002810052,0.000052788186,0.0001619255,0.000010941001,0.0000635471,0.00017044535,9.828215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024550164,0.0060488977,0.45311123,0.000108396554,0.0016861385,0.0008225545,0.00014132756,0.00015514073,0.14653976,0.00116426,0.0032443244,0.3624278],"study_design_scores_gemma":[0.034922164,0.026495796,0.7255848,0.00012864391,0.0010961686,0.0016254786,0.00014218054,0.00018933052,0.017117033,0.0052383286,0.18664363,0.00081642513],"about_ca_topic_score_codex":0.00014553081,"about_ca_topic_score_gemma":0.0011148067,"teacher_disagreement_score":0.3616114,"about_ca_system_score_codex":0.00005779647,"about_ca_system_score_gemma":0.00046037073,"threshold_uncertainty_score":0.5689609},"labels":[],"label_agreement":null},{"id":"W2137723371","doi":"10.1200/jco.2007.12.7837","title":"Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":700,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Internal medicine; Clinical trial; Oncology; Multivariate analysis; Progression-free survival; Clinical endpoint; Cancer; Randomized controlled trial; Overall survival","score_opus":0.3381739698257792,"score_gpt":0.5079362980495256,"score_spread":0.16976232822374637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137723371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150485,0.0023990097,0.0024029613,0.0013818789,0.00062637357,0.00093625375,0.0006548919,0.0000018659733,0.00009194635],"genre_scores_gemma":[0.9800194,0.0008993881,0.01675012,0.00067934033,0.0010802968,0.00007867885,0.00018965836,0.000019847712,0.0002832868],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.98882425,0.0043808664,0.0057352744,0.00042697813,0.00033993126,0.00029267522],"domain_scores_gemma":[0.99006414,0.004545237,0.0041067633,0.0003907689,0.00050135795,0.00039175726],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025434284,0.00028986717,0.0073251184,0.00031569682,0.000116140465,0.00001025304,0.00037180955,0.00044019485,0.0002765723],"category_scores_gemma":[0.023055086,0.00017914841,0.0027207572,0.00024233265,0.00017080388,0.000020131685,0.00023082894,0.00033280117,1.8701097e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14311723,0.037729345,0.0022051495,0.00017598817,0.30331725,0.0013850279,0.0018854546,0.00036035123,0.36831465,0.0010487166,0.020337716,0.1201231],"study_design_scores_gemma":[0.16624027,0.40032333,0.0025983555,0.000038251557,0.1869288,0.00019297458,0.00060673984,0.00072073116,0.03701869,0.00047236445,0.20389876,0.0009607392],"about_ca_topic_score_codex":0.000011263765,"about_ca_topic_score_gemma":0.00026949597,"teacher_disagreement_score":0.362594,"about_ca_system_score_codex":0.000021261907,"about_ca_system_score_gemma":0.0006620433,"threshold_uncertainty_score":0.9851741},"labels":[],"label_agreement":null},{"id":"W2137853125","doi":"10.1200/jco.2009.25.6529","title":"American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4267,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Estrogen receptor; Guideline; Internal medicine; Progesterone receptor; Cancer; Estrogen; Immunohistochemistry; Gynecology; Pathology","score_opus":0.10446544455493771,"score_gpt":0.4879802130540102,"score_spread":0.38351476849907246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137853125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603964,0.00032272586,0.00011826617,0.012219645,0.00066770014,0.00025478276,0.00033150383,0.0000027752953,0.000042936834],"genre_scores_gemma":[0.84644824,0.0014394531,0.15089957,0.0004939849,0.00063771877,0.000031712076,0.000019404913,0.000019120407,0.0000107842525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948829,0.00037481627,0.0040335315,0.0003194029,0.00015017379,0.00023919762],"domain_scores_gemma":[0.9909925,0.001822445,0.0057643224,0.00023588665,0.0010316886,0.00015314689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034042087,0.00018482703,0.0019812575,0.000059727572,0.00003174711,0.0000013533888,0.00026387486,0.00037540728,0.000009760822],"category_scores_gemma":[0.0032744484,0.0001491973,0.00051753566,0.00021012007,0.0023768868,0.000010115489,0.00018021936,0.00060908956,1.0187937e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029974666,0.0019867294,0.58411217,0.000032865344,0.00053084636,0.0000033716879,0.000061865125,0.000006380851,0.037814904,0.000014583029,0.0064200917,0.3660187],"study_design_scores_gemma":[0.015002353,0.024975257,0.84887195,0.00019142254,0.0007313594,0.0003361797,0.001651339,0.00013007793,0.009862926,0.00017586426,0.09766392,0.000407377],"about_ca_topic_score_codex":0.0003387775,"about_ca_topic_score_gemma":0.000293365,"teacher_disagreement_score":0.3656113,"about_ca_system_score_codex":0.00006722041,"about_ca_system_score_gemma":0.0016532356,"threshold_uncertainty_score":0.87577385},"labels":[],"label_agreement":null},{"id":"W2138047520","doi":"10.1200/jco.2005.01.3490","title":"Systemic Treatment of Bone Metastases From Breast Cancer: Is It All That It’s Cracked Up to Be?","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine","score_opus":0.2881467450389312,"score_gpt":0.5117922965454741,"score_spread":0.22364555150654292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138047520","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.073376544,0.0053315335,0.000006228547,0.91426486,0.0038416751,0.0008021879,0.0020083943,0.000010583935,0.00035800823],"genre_scores_gemma":[0.042356167,0.020382661,0.0014007178,0.9181643,0.0103347115,0.000055252905,0.00023831025,0.00007947913,0.0069883997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919635,0.0008181897,0.005096554,0.00053119706,0.0009541161,0.0006364274],"domain_scores_gemma":[0.9890346,0.003338922,0.0053999443,0.0005914027,0.00062141486,0.0010137255],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010836055,0.00055022526,0.0065734703,0.00034364872,0.00004239847,0.000011092802,0.00023662743,0.0019275952,0.0020740866],"category_scores_gemma":[0.00038058416,0.00035611898,0.0016797646,0.00012713681,0.0001693998,0.000086748776,0.0000522218,0.0019523972,0.00012866194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060390965,0.0019264888,0.010541792,0.00018015096,0.004865658,0.0064225555,0.00042380634,0.0000015601279,0.000008975985,4.786769e-7,0.90139526,0.068194166],"study_design_scores_gemma":[0.016086979,0.014033291,0.011315964,0.001086803,0.007321433,0.0029724813,0.00013707082,0.0000033706292,0.000032836,0.000013611931,0.9467853,0.00021087979],"about_ca_topic_score_codex":0.0031910262,"about_ca_topic_score_gemma":0.0009896,"teacher_disagreement_score":0.067983285,"about_ca_system_score_codex":0.0014754526,"about_ca_system_score_gemma":0.0048361327,"threshold_uncertainty_score":0.9998891},"labels":[],"label_agreement":null},{"id":"W2138163136","doi":"10.1200/jco.2007.15.7123","title":"Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Osteoporosis; Odds ratio; Hip fracture; Population; Internal medicine; Univariate analysis; Context (archaeology); Cancer; Multivariate analysis","score_opus":0.15785453619767512,"score_gpt":0.49011519599491327,"score_spread":0.3322606597972382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138163136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929924,0.00041961754,0.00028768304,0.009500279,0.00018932705,0.00019142612,0.000004707855,0.000008003244,0.00009969039],"genre_scores_gemma":[0.98612314,0.0009604628,0.0056011965,0.006636173,0.00049604796,0.000001995044,0.000010488214,0.000011726931,0.00015875397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961582,0.0007441953,0.002094262,0.00019174833,0.00054284575,0.0002687607],"domain_scores_gemma":[0.99144286,0.0051595317,0.001580879,0.00022743733,0.00064842065,0.000940845],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031383175,0.00011584864,0.001668501,0.00038624989,0.00012069926,0.000010527937,0.00008548311,0.00047996893,0.00025616572],"category_scores_gemma":[0.014118712,0.000077940254,0.0005759465,0.00045825192,0.00015427495,0.00013660222,0.000023002096,0.001571691,0.00000971965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002238098,0.00055927807,0.9835959,0.000022849981,0.00041262206,0.0005541257,0.000050670853,0.000173509,0.0000042584065,0.000002493165,0.0020058437,0.010380337],"study_design_scores_gemma":[0.004907977,0.0050927373,0.9720079,0.000021310594,0.0011698684,0.0003162746,0.000020942043,0.0014374369,0.000005090378,0.000048018916,0.014907895,0.00006457369],"about_ca_topic_score_codex":0.0006630293,"about_ca_topic_score_gemma":0.0004016923,"teacher_disagreement_score":0.012902051,"about_ca_system_score_codex":0.000103657716,"about_ca_system_score_gemma":0.0020457637,"threshold_uncertainty_score":0.9941858},"labels":[],"label_agreement":null},{"id":"W2138216054","doi":"10.1200/jco.2012.42.3301","title":"Linking Toxicity to the Target","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Toxicity; Oncology; Internal medicine","score_opus":0.21353725129848272,"score_gpt":0.5256858018184358,"score_spread":0.3121485505199531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138216054","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009285312,0.0017641516,0.00009217328,0.96734464,0.01322902,0.00036033135,0.000011147336,0.000009995244,0.007903232],"genre_scores_gemma":[0.007977826,0.0005254255,0.0025419823,0.87532854,0.10850636,0.00000926416,0.000018580347,0.00003377111,0.005058237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574375,0.00081762957,0.0023125561,0.00020221555,0.00047546273,0.00044837344],"domain_scores_gemma":[0.9928217,0.004037399,0.0020921326,0.00028004835,0.00038636124,0.00038236205],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0037985563,0.0002398103,0.0022740774,0.00015045304,0.00005936666,0.000009680074,0.00037742962,0.0017741148,0.0015667912],"category_scores_gemma":[0.0011852852,0.00012818795,0.0010861795,0.00013358609,0.00015684376,0.000051849504,0.00010778874,0.007059212,0.00025758418],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012323479,0.00072996435,0.006648711,0.000039164857,0.0008484442,0.0021006193,0.00009977308,0.0000029781156,0.000016404285,0.0000047916974,0.9554788,0.032798033],"study_design_scores_gemma":[0.0029083346,0.010320789,0.006779897,0.00009604859,0.0016162856,0.0008976687,0.000007925344,0.0000027903243,0.000026242888,0.00017537695,0.977055,0.00011365002],"about_ca_topic_score_codex":0.000010908862,"about_ca_topic_score_gemma":0.000013168983,"teacher_disagreement_score":0.09527734,"about_ca_system_score_codex":0.0003317563,"about_ca_system_score_gemma":0.0020427534,"threshold_uncertainty_score":0.9995218},"labels":[],"label_agreement":null},{"id":"W2138602439","doi":"10.1200/jco.2003.08.137","title":"Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Epirubicin; Medicine; Cyclophosphamide; Internal medicine; Breast cancer; Chemotherapy; Oncology; Cancer; Leukemia; Fluorouracil; Surgery","score_opus":0.11639455466887023,"score_gpt":0.4745238978335926,"score_spread":0.3581293431647224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138602439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975444,0.0019291743,0.00058022107,0.0029965823,0.0038733706,0.00018954292,0.00019074742,0.0000017065062,0.0004842399],"genre_scores_gemma":[0.99141943,0.0016950065,0.002801806,0.0026243122,0.001367618,0.000010162001,0.000019398456,0.000015369405,0.000046868903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930116,0.0018099083,0.0042106807,0.00027703735,0.00049900217,0.00019176882],"domain_scores_gemma":[0.9894277,0.003721486,0.0058686314,0.0002483916,0.00058884645,0.00014497063],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012111903,0.00017825038,0.0018779509,0.000026707728,0.00006572463,0.000003534606,0.0002813187,0.0003508148,0.000040480016],"category_scores_gemma":[0.017624717,0.00010863676,0.0011656448,0.00009615429,0.0003252511,0.000007660093,0.000041154322,0.00045417534,2.3602466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066492944,0.0010654035,0.8826379,0.000011193291,0.016773632,0.00029085952,0.000044081153,0.0006648442,0.0037038517,0.000052097115,0.051669322,0.0364375],"study_design_scores_gemma":[0.017498499,0.0020789087,0.7233317,0.00010377286,0.0024638763,0.00006690105,0.000060677234,0.000036547226,0.0071267146,0.00044450155,0.24657863,0.00020929649],"about_ca_topic_score_codex":0.02350761,"about_ca_topic_score_gemma":0.068468764,"teacher_disagreement_score":0.19490932,"about_ca_system_score_codex":0.00023872542,"about_ca_system_score_gemma":0.0139345,"threshold_uncertainty_score":0.9916556},"labels":[],"label_agreement":null},{"id":"W2138694790","doi":"10.1200/jco.2006.07.9988","title":"Randomized Controlled Trial of the Effects of Print Materials and Step Pedometers on Physical Activity and Quality of Life in Breast Cancer Survivors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Cancer Institute; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale; Canada Research Chairs","keywords":"Medicine; Breast cancer; Randomized controlled trial; Physical activity; Quality of life (healthcare); Cancer; Gerontology; Physical therapy; Internal medicine","score_opus":0.06463378852608911,"score_gpt":0.45519118271316766,"score_spread":0.3905573941870786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138694790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953701,0.00013969532,0.000018388766,0.001181868,0.0019647998,0.0012145917,0.000008749322,0.0000012361222,0.000100596066],"genre_scores_gemma":[0.9988602,0.00047609597,0.000017251901,0.00016832155,0.00044753455,0.000011520258,1.05734095e-7,0.0000067464293,0.00001221404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937952,0.0031291472,0.0024105532,0.00012925918,0.00040533286,0.0001304636],"domain_scores_gemma":[0.9727787,0.023219835,0.0034511252,0.00014454145,0.00025279415,0.00015304214],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014241751,0.00011922626,0.0053753806,0.00009966842,0.000009702007,0.000002240935,0.000082869265,0.00021327932,0.00001127393],"category_scores_gemma":[0.010598824,0.00006152915,0.00063647516,0.000102134654,0.0005622223,0.000032950316,0.00004779852,0.0004152248,3.9515676e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95096517,0.0020274462,0.025784578,0.00034710852,0.000499988,0.0000063935076,0.00030473727,0.0000010979469,0.009486694,0.00008932167,0.000004602423,0.010482856],"study_design_scores_gemma":[0.62810725,0.0031198913,0.36553806,0.00020753333,0.00034058816,0.000003909733,0.00007632275,0.000004537952,0.002520537,0.000037420563,0.0000078345,0.000036152276],"about_ca_topic_score_codex":0.00254206,"about_ca_topic_score_gemma":0.0021730075,"teacher_disagreement_score":0.33975348,"about_ca_system_score_codex":0.000049518214,"about_ca_system_score_gemma":0.00057035,"threshold_uncertainty_score":0.9977353},"labels":[],"label_agreement":null},{"id":"W2138709573","doi":"10.1200/jco.2009.27.1916","title":"Prognostic Factors in Patients With Advanced Cancer: Use of the Patient-Generated Subjective Global Assessment in Survival Prediction","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Concordance; Multivariate analysis; Palliative care; Statistic; Univariate; Cohort; Multivariate statistics; Dysphagia; Cancer; Performance status; Univariate analysis; Disease; Internal medicine; Statistics; Surgery","score_opus":0.10100750291745605,"score_gpt":0.46877210591788465,"score_spread":0.36776460300042857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138709573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957392,0.000013295417,0.000013094958,0.0012355719,0.0024021587,0.00047872882,0.000025083356,0.0000033829654,0.00008943265],"genre_scores_gemma":[0.9982318,0.000055040207,0.0012239068,0.0003568156,0.0001122489,0.000006588964,0.000004461448,0.000006033631,0.0000030790513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997423,0.00040794,0.0015307172,0.000119598386,0.0003584261,0.00016032973],"domain_scores_gemma":[0.9971857,0.00073829124,0.0012306186,0.00009965336,0.0005969148,0.00014882199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079146295,0.000084853986,0.0006918667,0.00007888144,0.000022229591,0.0000034293064,0.00006620413,0.00019498519,0.000023848912],"category_scores_gemma":[0.0017943311,0.000048091955,0.00009157631,0.0002929366,0.00011746504,0.00011486964,0.00002148699,0.0012404037,1.4974428e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027586233,0.0021974158,0.98251796,0.00002139225,0.000035516245,0.00001243518,0.000058980328,0.00010237031,0.000054327025,0.000028570923,0.000038622253,0.012173806],"study_design_scores_gemma":[0.009725521,0.006367851,0.98259246,0.00024166441,0.000050499886,0.000004293278,0.00007697205,0.00011077727,0.000037376256,0.000039192277,0.00071505737,0.000038349182],"about_ca_topic_score_codex":0.0001493162,"about_ca_topic_score_gemma":0.002336979,"teacher_disagreement_score":0.012135456,"about_ca_system_score_codex":0.00033071073,"about_ca_system_score_gemma":0.001822355,"threshold_uncertainty_score":0.5389006},"labels":[],"label_agreement":null},{"id":"W2138886135","doi":"10.1200/jco.2009.23.4708","title":"Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor–Associated Joint Symptoms in Women With Early-Stage Breast Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acupuncture Treatment Research Studies","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acupuncture; Discontinuation; Breast cancer; Randomized controlled trial; Brief Pain Inventory; Osteoarthritis; Physical therapy; WOMAC; Joint pain; Internal medicine; Clinical endpoint; Stage (stratigraphy); Cancer; Chronic pain; Alternative medicine","score_opus":0.0606523002187671,"score_gpt":0.43815296968809564,"score_spread":0.37750066946932853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138886135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249906,0.00025729244,0.0000428267,0.010175562,0.0008470072,0.0058739805,0.000059335904,0.000005734104,0.0002391988],"genre_scores_gemma":[0.996425,0.0009075848,0.0006007255,0.00031368036,0.0007442818,0.0006108842,0.0000028190855,0.00002112561,0.00037391175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948164,0.0006051138,0.0031464496,0.00021919662,0.00081520336,0.000397644],"domain_scores_gemma":[0.98650897,0.008768579,0.0033892603,0.00030184307,0.00079933886,0.00023201374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010586908,0.00033281086,0.005776033,0.00020504204,0.000045770685,0.000008253615,0.00024183566,0.00038055875,0.00014402067],"category_scores_gemma":[0.0037192113,0.00010260646,0.0011109927,0.00022846862,0.00074378354,0.0000764368,0.000099280835,0.0012417481,7.336363e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9708557,0.003448743,0.0037654329,0.00012215407,0.011105124,0.00021591295,0.000306103,0.000021179898,0.00007830723,0.00007184157,0.0006488631,0.00936061],"study_design_scores_gemma":[0.92403483,0.01240233,0.05907157,0.00029192018,0.0027410751,0.000031760224,0.00036602595,0.000056973484,0.000044344233,0.00014450413,0.0007319908,0.000082673774],"about_ca_topic_score_codex":0.00007776604,"about_ca_topic_score_gemma":0.00025596897,"teacher_disagreement_score":0.05530614,"about_ca_system_score_codex":0.00025848858,"about_ca_system_score_gemma":0.0009811085,"threshold_uncertainty_score":0.5394847},"labels":[],"label_agreement":null},{"id":"W2139124456","doi":"10.1200/jco.2008.20.0295","title":"Health-Related Quality of Life As a Survival Predictor for Patients With Localized Head and Neck Cancer Treated With Radiation Therapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Head and neck cancer; Quality of life (healthcare); Radiation therapy; Internal medicine; Proportional hazards model; Hazard ratio; Multivariate analysis; Oncology; Cancer; Health related quality of life; Clinical endpoint; Randomized controlled trial; Physical therapy; Confidence interval","score_opus":0.1279571167003949,"score_gpt":0.4863926928638655,"score_spread":0.3584355761634706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139124456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787928,0.002455821,0.000045427136,0.017764507,0.00020524622,0.00054981187,0.000015844478,0.00000830912,0.00016223794],"genre_scores_gemma":[0.9914157,0.004056613,0.0006227928,0.0035963017,0.00023885198,0.000007814663,0.0000065009635,0.000010777758,0.00004469222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699795,0.00038191443,0.001964246,0.00015605462,0.00031411034,0.00018571394],"domain_scores_gemma":[0.995714,0.0011011774,0.0020031482,0.000093701485,0.0006546632,0.0004332768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015350662,0.00012559613,0.002201928,0.000059819653,0.00004482993,0.0000028533805,0.000045901532,0.00018303032,0.00002023967],"category_scores_gemma":[0.0015985784,0.00006865678,0.00013924645,0.00013053477,0.00013822237,0.000063309715,0.0000049394444,0.00030946132,2.2614259e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08064004,0.0017842619,0.790583,0.000041457635,0.0005840794,0.000005111433,0.0002174138,0.0000061614146,0.0000047813264,0.000024743815,0.0010062652,0.1251027],"study_design_scores_gemma":[0.055645972,0.106553055,0.8303601,0.00019662693,0.00010183724,0.000005171847,0.000031598807,0.000024148607,0.0000054777274,0.000050897605,0.006965427,0.000059672326],"about_ca_topic_score_codex":0.00034498126,"about_ca_topic_score_gemma":0.00022822646,"teacher_disagreement_score":0.12504302,"about_ca_system_score_codex":0.00011139861,"about_ca_system_score_gemma":0.0025325643,"threshold_uncertainty_score":0.44926605},"labels":[],"label_agreement":null},{"id":"W2139176812","doi":"10.1200/jco.2009.26.1693","title":"Prognostic Factors in Follicular Lymphoma","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Chemoimmunotherapy; Medicine; Follicular lymphoma; Rituximab; Lymphoma; Oncology; Internal medicine; International Prognostic Index; Stage (stratigraphy); Obinutuzumab","score_opus":0.21296917113921873,"score_gpt":0.5163045012523486,"score_spread":0.30333533011312985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139176812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017339224,0.9776844,0.0000012263374,0.00039484812,0.0024987108,0.0007122019,0.000006248884,0.000007809823,0.001355352],"genre_scores_gemma":[0.0018931681,0.9956005,0.00065932353,0.00026970953,0.0013697856,0.000027313705,0.000017690201,0.00004117476,0.000121335106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99321765,0.00065193715,0.005071524,0.0003063912,0.0004273461,0.00032517267],"domain_scores_gemma":[0.9882696,0.0066524865,0.003930474,0.0003313204,0.00023187844,0.00058420707],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002354499,0.00039127792,0.008438457,0.00036202665,0.00002145285,0.000012631749,0.00026374904,0.0019874766,0.00011642834],"category_scores_gemma":[0.0074920957,0.00021164404,0.003097414,0.00025190425,0.00015248048,0.00005771355,0.00006845832,0.0014050378,0.00007478422],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010774439,0.004897271,0.042277306,0.001032717,0.000719345,0.0060421512,0.000012117091,4.7699782e-8,3.128508e-8,0.000042480628,0.00071594847,0.94415283],"study_design_scores_gemma":[0.0057171914,0.005611473,0.05691527,0.007167256,0.0048240325,0.0016864173,0.000008331694,5.27673e-7,3.6237356e-7,0.000038867587,0.9178803,0.0001499785],"about_ca_topic_score_codex":0.000019825999,"about_ca_topic_score_gemma":0.000039887393,"teacher_disagreement_score":0.94400287,"about_ca_system_score_codex":0.00059934135,"about_ca_system_score_gemma":0.007633004,"threshold_uncertainty_score":0.99930817},"labels":[],"label_agreement":null},{"id":"W2139271855","doi":"10.1200/jco.2009.27.3698","title":"Screening for Distress in Lung and Breast Cancer Outpatients: A Randomized Controlled Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Distress; Referral; Anxiety; Breast cancer; Triage; Psychosocial; Lung cancer; Cancer screening; Cancer; Lung cancer screening; Randomized controlled trial; Physical therapy; Emergency medicine; Internal medicine; Family medicine; Psychiatry; Clinical psychology","score_opus":0.0588845248813589,"score_gpt":0.46544318108915234,"score_spread":0.4065586562077934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139271855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834622,0.0004973373,0.0005051386,0.0075078765,0.0058522355,0.0017667655,0.000018617711,0.0000038456537,0.00038598955],"genre_scores_gemma":[0.99508864,0.00031242307,0.0005576717,0.0009974486,0.0027376502,0.00014339539,0.000002051109,0.000010872163,0.00014982352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99675864,0.0004209157,0.0023098213,0.00013432786,0.00020994764,0.0001663607],"domain_scores_gemma":[0.9914449,0.006419521,0.0014407869,0.00008772542,0.0003610612,0.00024599084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059593767,0.00010438634,0.0033463105,0.000100649195,0.00002310789,0.000010126166,0.00007577244,0.00030502983,0.00010533309],"category_scores_gemma":[0.006592935,0.0000629158,0.0008093334,0.000057932273,0.0001948535,0.00006592026,0.000021996575,0.00087024615,1.7516413e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9070656,0.0005044803,0.023153748,0.000027457205,0.00033385542,0.00003458357,0.00012539938,0.0000014379436,0.000015016772,0.00006201208,0.00029231235,0.06838411],"study_design_scores_gemma":[0.9783613,0.0020841404,0.014623921,0.00012843388,0.0007522359,0.000060394003,0.00009897435,0.00064389483,0.0000016792809,0.0001074549,0.0030745775,0.000062992374],"about_ca_topic_score_codex":0.00021539872,"about_ca_topic_score_gemma":0.0025123344,"teacher_disagreement_score":0.071295716,"about_ca_system_score_codex":0.000041208954,"about_ca_system_score_gemma":0.00062229624,"threshold_uncertainty_score":0.7892835},"labels":[],"label_agreement":null},{"id":"W2139582914","doi":"10.1200/jco.2003.09.057","title":"Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mantle cell lymphoma; Nausea; Toxicity; Gastroenterology; Vomiting; Internal medicine; Progressive disease; Lymphoma; Phases of clinical research; Surgery; Chemotherapy","score_opus":0.28585878921707086,"score_gpt":0.5286928873413912,"score_spread":0.24283409812432033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139582914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293506,0.00026654065,0.000001123797,0.0021927147,0.0021460252,0.0007603496,0.00007533957,0.000001665634,0.001621167],"genre_scores_gemma":[0.9979268,0.00053390086,0.00024837677,0.0006040915,0.0003054607,0.000015526273,0.0000030964818,0.000010428808,0.00035235117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98736453,0.0027743562,0.008555513,0.00024603403,0.0008556305,0.00020390787],"domain_scores_gemma":[0.9832163,0.008801968,0.0066062524,0.00025409448,0.0008774404,0.0002439699],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013244783,0.00017501043,0.0031637808,0.0001393632,0.000041380063,0.0000019267577,0.0002214777,0.0003276524,0.000084328254],"category_scores_gemma":[0.03243627,0.00009036017,0.00058891607,0.00038995387,0.00026592574,0.00006200932,0.000056678415,0.00035789784,3.8568308e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13002938,0.26181722,0.49300897,0.00013919824,0.0039500985,0.0017182364,0.0006593691,0.0002589271,0.00043870346,0.00025820325,0.042368166,0.06535355],"study_design_scores_gemma":[0.42739287,0.066512205,0.4605074,0.00047768737,0.0016916649,0.00011030355,0.00042720896,0.00006896562,0.001656658,0.00007944084,0.040943637,0.00013196588],"about_ca_topic_score_codex":0.026277944,"about_ca_topic_score_gemma":0.1787989,"teacher_disagreement_score":0.29736352,"about_ca_system_score_codex":0.0006062127,"about_ca_system_score_gemma":0.017195089,"threshold_uncertainty_score":0.9883765},"labels":[],"label_agreement":null},{"id":"W2139658312","doi":"10.1200/jco.2007.10.8993","title":"Fertility and Risk Factors for Elevated Infertility Concern in 10-Year Hematopoietic Cell Transplant Survivors and Case-Matched Controls","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Research Society","keywords":"Medicine; Infertility; Fertility; Hematopoietic cell; Oncology; Fertility preservation; Risk factor; Gynecology; Internal medicine; Pregnancy; Haematopoiesis; Environmental health; Stem cell; Population; Genetics","score_opus":0.1005625782590094,"score_gpt":0.420494694400343,"score_spread":0.3199321161413336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139658312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711555,0.000732214,0.0006106039,0.00044556084,0.00034104887,0.0005734748,0.000028441327,0.000009612068,0.00014350245],"genre_scores_gemma":[0.9991007,0.00021237586,0.00040392377,0.00012933851,0.000102023754,0.0000030706085,0.0000041192056,0.000009705863,0.000034746063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600524,0.00076197117,0.0024025266,0.00037871537,0.00013525247,0.00031627112],"domain_scores_gemma":[0.99010307,0.007903941,0.0009929235,0.00021775234,0.00038773898,0.0003945561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012794982,0.0001827619,0.0017973261,0.000087281674,0.00005939928,0.0000051722245,0.00007192603,0.00065918424,0.000052419924],"category_scores_gemma":[0.0077407826,0.00012288897,0.00025642163,0.00009047265,0.00067121634,0.00008221788,0.000023737977,0.0009573711,0.0000010930478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046978462,0.0009909099,0.9470515,0.000089997084,0.00015965798,0.00044380673,0.0005462271,6.7814915e-7,0.00084788003,0.0000056840495,0.000013265961,0.0028718982],"study_design_scores_gemma":[0.010307645,0.0053290846,0.98051,0.00002745059,0.00033285352,0.00028788685,0.00064012466,0.00004080423,0.0012077866,0.00068073295,0.0005352515,0.00010037919],"about_ca_topic_score_codex":0.00027017927,"about_ca_topic_score_gemma":0.00078296254,"teacher_disagreement_score":0.03667082,"about_ca_system_score_codex":0.00007562861,"about_ca_system_score_gemma":0.0003393376,"threshold_uncertainty_score":0.9266999},"labels":[],"label_agreement":null},{"id":"W2139836848","doi":"10.1200/jco.2014.55.5714","title":"Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lenalidomide; Diffuse large B-cell lymphoma; Internal medicine; Rituximab; Vincristine; Oncology; Lymphoma; CHOP; Gastroenterology; Cyclophosphamide; Prednisone; Chemotherapy; Multiple myeloma","score_opus":0.0370089595624113,"score_gpt":0.41043221897205295,"score_spread":0.37342325940964166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139836848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967331,0.00012594838,0.00004959996,0.0005507959,0.00031954682,0.001171011,0.00002005505,0.000009423986,0.0010204798],"genre_scores_gemma":[0.9979539,0.00017812001,0.00078269455,0.00056750193,0.00033651994,0.000037091257,0.000007596619,0.000038245707,0.00009831155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99485767,0.000882915,0.0027921395,0.00037340104,0.00058387953,0.0005099785],"domain_scores_gemma":[0.9901493,0.005867294,0.0024946402,0.00036962784,0.00051714276,0.0006019828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021700964,0.00038765176,0.0029951446,0.00028900895,0.00006562872,0.000015461546,0.00024089121,0.00028742198,0.000078685815],"category_scores_gemma":[0.0023137892,0.00022581988,0.0007873523,0.00030991802,0.00020378685,0.00017272588,0.000117485426,0.0005040945,0.000013922097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028617315,0.3116232,0.6359593,0.000038964,0.0006322577,0.0024166554,0.0008672249,0.000009874993,0.000078926,0.0000059384656,0.0006622619,0.019088075],"study_design_scores_gemma":[0.32713178,0.16102602,0.5097007,0.0001689926,0.00076347863,0.000073922834,0.00029752622,0.0001979282,0.00011410961,0.000025825513,0.0003772075,0.00012250122],"about_ca_topic_score_codex":0.00023623688,"about_ca_topic_score_gemma":0.0002458697,"teacher_disagreement_score":0.29851446,"about_ca_system_score_codex":0.0005134011,"about_ca_system_score_gemma":0.0019215958,"threshold_uncertainty_score":0.9208667},"labels":[],"label_agreement":null},{"id":"W2139882513","doi":"10.1200/jco.2004.07.018","title":"Compliance With Consensus Recommendations for Systemic Therapy Is Associated With Improved Survival of Women With Node-Negative Breast Cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Hazard ratio; Breast cancer; Proportional hazards model; Internal medicine; Systemic therapy; Population; Survival analysis; Cancer; Gynecology; Confidence interval","score_opus":0.0935733134891994,"score_gpt":0.41657212723250714,"score_spread":0.32299881374330774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139882513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503864,0.00023828553,0.00074100064,0.013174124,0.00017222267,0.0003363622,0.00023256037,0.000004214714,0.000062590196],"genre_scores_gemma":[0.9946399,0.0005161161,0.0034994895,0.0009843059,0.00022096682,0.00006805686,0.000009468006,0.000024331131,0.000037402617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834144,0.00017581234,0.00082990265,0.00023125151,0.00015097208,0.00027064694],"domain_scores_gemma":[0.995802,0.0005491004,0.0019652452,0.00015396184,0.0013936601,0.00013602615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007123562,0.00018138482,0.0009849186,0.00003124987,0.00006959061,0.0000058284704,0.00014563992,0.00017931132,0.00001246463],"category_scores_gemma":[0.00018622419,0.00010614232,0.00011351669,0.00011029172,0.00039733242,0.000006513683,0.000019378767,0.0002054668,2.6469053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3479775,0.01205083,0.48003227,0.00024306693,0.04985732,0.00021032087,0.004426416,0.0024026714,0.018796254,0.00017094445,0.0046458174,0.079186596],"study_design_scores_gemma":[0.1438795,0.08237041,0.7476397,0.0018130786,0.0011062813,0.0019115647,0.005079942,0.00003636274,0.009717955,0.00034069456,0.005206366,0.0008981035],"about_ca_topic_score_codex":0.00014793276,"about_ca_topic_score_gemma":0.00066393154,"teacher_disagreement_score":0.26760748,"about_ca_system_score_codex":0.00031677293,"about_ca_system_score_gemma":0.0019031509,"threshold_uncertainty_score":0.43283582},"labels":[],"label_agreement":null},{"id":"W2139891818","doi":"10.1200/jco.2011.38.0402","title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":990,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Neutropenia; Antibody-drug conjugate; Phases of clinical research; Refractory (planetary science); Oncology; CD30; Adverse effect; Lymphoma; Gastroenterology; Chemotherapy; Immunology; Antibody; Monoclonal antibody","score_opus":0.05924066866749524,"score_gpt":0.41006241614011024,"score_spread":0.350821747472615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139891818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971379,0.0005109746,0.000004516281,0.00018845529,0.00100257,0.0006911681,0.000027150243,0.0000073936017,0.0004298814],"genre_scores_gemma":[0.99875647,0.00013315381,0.00034993954,0.00020628865,0.00036667794,0.000013015241,0.00000985361,0.000023724284,0.00014087895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99438477,0.0007306376,0.0035979068,0.00024496255,0.0006275878,0.00041416753],"domain_scores_gemma":[0.9929075,0.0027028867,0.0031453818,0.0003277029,0.00042622755,0.00049025624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031918501,0.00022700508,0.0021299236,0.00024783175,0.00004543801,0.0000043003715,0.00015453361,0.00030489435,0.00004138225],"category_scores_gemma":[0.0028118868,0.00012684174,0.00027053713,0.00026170842,0.00009434174,0.00016913434,0.00007828018,0.00038957753,0.000013932532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08750263,0.26959702,0.6161203,0.00005500649,0.0004323373,0.00069923874,0.00062389625,0.0000024122594,0.000007249552,0.0000026690773,0.001331133,0.023626119],"study_design_scores_gemma":[0.29137155,0.1708482,0.53301424,0.000354415,0.00071040366,0.00008739443,0.0004292887,0.000011269102,0.00001855691,9.616061e-7,0.0030699698,0.000083739484],"about_ca_topic_score_codex":0.00003538698,"about_ca_topic_score_gemma":0.00008038376,"teacher_disagreement_score":0.20386894,"about_ca_system_score_codex":0.000583372,"about_ca_system_score_gemma":0.0015837235,"threshold_uncertainty_score":0.5172456},"labels":[],"label_agreement":null},{"id":"W2140014443","doi":"10.1200/jco.2014.60.3845","title":"Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III Non–Small-Cell Lung Cancer: Is There an Impact on Radiation Pneumonitis Rates?","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; Etoposide; Chemoradiotherapy; Lung cancer; Radiation therapy; Veterans Affairs; Mucositis; Pneumonitis; Surgery; Cisplatin; Chemotherapy; Lung","score_opus":0.1505962876777015,"score_gpt":0.525359451233374,"score_spread":0.3747631635556725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140014443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79770976,0.014473512,0.00007732865,0.18269984,0.001764805,0.0021190455,0.00042063353,0.000013847381,0.00072118477],"genre_scores_gemma":[0.8591137,0.039044686,0.00077063736,0.0813073,0.017512081,0.0002164094,0.00025000842,0.00018967336,0.0015955442],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616086,0.00058145536,0.0016041751,0.00046667753,0.0007102019,0.0004766108],"domain_scores_gemma":[0.99058,0.0050704777,0.0026768001,0.0002460163,0.0008880161,0.00053869036],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002475898,0.00041411447,0.0022857953,0.00024299111,0.00010210813,0.000058104055,0.00014798611,0.00095513236,0.00005625218],"category_scores_gemma":[0.0011930758,0.00026440123,0.0002827659,0.000112394024,0.00028676755,0.00018668697,0.000053863314,0.0030478658,0.0000010200692],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028516233,0.00048680196,0.080550864,0.0011579435,0.003387826,0.0012636377,0.0014831184,0.0000778561,0.00006201543,0.0000053252693,0.7033712,0.17963713],"study_design_scores_gemma":[0.12339273,0.1721302,0.22527057,0.0017785984,0.0055423784,0.00021734703,0.00066277804,0.0058349934,0.00017392762,0.00006159452,0.4640148,0.0009200962],"about_ca_topic_score_codex":0.0004698599,"about_ca_topic_score_gemma":0.00022623395,"teacher_disagreement_score":0.23935644,"about_ca_system_score_codex":0.0012662169,"about_ca_system_score_gemma":0.004658927,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W2140055441","doi":"10.1200/jco.2008.20.6847","title":"Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"F. Hoffmann-La Roche; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Anastrozole; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Hazard ratio; Oncology; Breast cancer; Aromatase inhibitor; Gynecology; Cancer; Tamoxifen; Confidence interval","score_opus":0.11580627615224622,"score_gpt":0.47668609962928,"score_spread":0.3608798234770338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140055441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97077835,0.0010881997,0.00049559196,0.020548416,0.0006116487,0.0045135417,0.0018284846,0.0000152234115,0.000120574296],"genre_scores_gemma":[0.9937772,0.0020087,0.0014094501,0.00061375956,0.0017335201,0.00024216641,0.000076864024,0.000045072127,0.00009327806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99110466,0.0027716924,0.0036937261,0.00053027924,0.001140434,0.0007592262],"domain_scores_gemma":[0.9754562,0.019104429,0.0029651925,0.00047365561,0.0013577172,0.00064285484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053987373,0.00046579607,0.004309883,0.00014632133,0.00030576973,0.000037925,0.0005020463,0.00021140395,0.00026733108],"category_scores_gemma":[0.0016871078,0.00022356385,0.00062498654,0.0003559278,0.0009306339,0.00017837674,0.00004351179,0.0010581925,0.0000035300995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86924887,0.012952169,0.0004964037,0.0000064242704,0.008329374,0.0002063151,0.0053148167,0.000050077284,0.0015050139,0.0000149211355,0.0024772997,0.09939834],"study_design_scores_gemma":[0.6699985,0.24951392,0.07060336,0.0001101166,0.002884705,0.00006199613,0.0047472655,0.00012977561,0.0006227593,0.000032678938,0.0011049231,0.0001899796],"about_ca_topic_score_codex":0.0014147405,"about_ca_topic_score_gemma":0.00041513468,"teacher_disagreement_score":0.23656176,"about_ca_system_score_codex":0.0021523093,"about_ca_system_score_gemma":0.0031180016,"threshold_uncertainty_score":0.9116669},"labels":[],"label_agreement":null},{"id":"W2140233040","doi":"10.1200/jco.2003.06.073","title":"Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Referral; Cancer; Family medicine; Geriatric oncology; Population; Stage (stratigraphy); Primary care; Internal medicine","score_opus":0.13280513112628645,"score_gpt":0.45928651477175775,"score_spread":0.3264813836454713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140233040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832775,0.00013650664,0.00011135781,0.008428584,0.0028760133,0.0007255489,0.000025443098,0.000015698906,0.004403347],"genre_scores_gemma":[0.9830113,0.00008518478,0.0040247943,0.011227599,0.00047828656,0.000037551268,0.000015959115,0.000034224646,0.0010851101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949142,0.0008430871,0.0027303577,0.00037097625,0.0007532031,0.00038822263],"domain_scores_gemma":[0.99282086,0.0007198002,0.0028582977,0.00035165364,0.0025152736,0.00073409564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021263135,0.0002574637,0.0017812693,0.00023740204,0.00006113758,0.000011359623,0.00024114878,0.00050773146,0.00030956825],"category_scores_gemma":[0.008074564,0.00019226513,0.00044261155,0.00021991805,0.00010711111,0.00018909216,0.00008753815,0.001346955,0.000021546984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034978825,0.0019943449,0.9257944,0.00018471302,0.0003693188,0.0002543807,0.0046837716,0.00017574345,0.00006797536,0.000013915586,0.009795411,0.053168103],"study_design_scores_gemma":[0.0079668695,0.011037276,0.91507864,0.0019350385,0.00036759072,0.00008918304,0.0008365135,0.0000016326994,0.00013519172,0.000065218424,0.062308215,0.00017863701],"about_ca_topic_score_codex":0.0019078486,"about_ca_topic_score_gemma":0.046089843,"teacher_disagreement_score":0.052989464,"about_ca_system_score_codex":0.004415084,"about_ca_system_score_gemma":0.006339586,"threshold_uncertainty_score":0.9994068},"labels":[],"label_agreement":null},{"id":"W2140238199","doi":"10.1200/jco.2007.12.8322","title":"Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":334,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Comorbidity; Lung cancer; Hazard ratio; Cancer; Performance status; Proportional hazards model; Randomized controlled trial; Chemotherapy; Clinical trial; Oncology; Surgery; Confidence interval","score_opus":0.48900328896336825,"score_gpt":0.6102820471332314,"score_spread":0.12127875816986317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140238199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023902504,0.96731144,0.0000033622734,0.0008891615,0.0029696135,0.00429146,0.00030224578,0.0000014435583,0.00032874985],"genre_scores_gemma":[0.0053731967,0.9921875,0.00014793636,0.0006013686,0.0013613978,0.00021458174,0.000046416397,0.000023937127,0.000043665757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9743721,0.0063888603,0.017207196,0.00042545056,0.0012943875,0.00031203314],"domain_scores_gemma":[0.93727183,0.04140627,0.019778918,0.00033293053,0.0008090113,0.0004010237],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.039282065,0.00047258195,0.018252656,0.00024079392,0.00002894319,0.0000056833283,0.00034161712,0.00080702436,0.00015672171],"category_scores_gemma":[0.01871847,0.00022792,0.0030535383,0.00034418682,0.0003382983,0.000048087146,0.000049064394,0.0010872874,2.384878e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012311472,0.009144474,0.06174371,0.044401452,0.0060579423,0.0009751161,0.000098552526,0.0000026967268,2.4162895e-7,0.000029769304,0.0055270544,0.87078786],"study_design_scores_gemma":[0.013070472,0.01144065,0.03288098,0.08495442,0.022453299,0.00008380782,0.000029420804,0.00000152816,0.000003907862,0.000015651083,0.83488727,0.00017857441],"about_ca_topic_score_codex":0.061042238,"about_ca_topic_score_gemma":0.15215994,"teacher_disagreement_score":0.8706093,"about_ca_system_score_codex":0.0021903405,"about_ca_system_score_gemma":0.035479113,"threshold_uncertainty_score":0.9963224},"labels":[],"label_agreement":null},{"id":"W2140244530","doi":"10.1200/jco.2010.31.7255","title":"Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Charles A. King Trust; Sanofi; National Cancer Institute; National Institutes of Health; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Internal medicine; Colorectal cancer; Hazard ratio; Vitamin D and neurology; vitamin D deficiency; Gastroenterology; Cancer; Population; Proportional hazards model; Cohort; Chemotherapy; Oncology; Confidence interval","score_opus":0.10818035435994174,"score_gpt":0.444764433277868,"score_spread":0.3365840789179263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140244530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959606,0.00012108246,0.000015322075,0.0005899402,0.001548667,0.00052345515,0.00003219711,0.00000783733,0.0012008969],"genre_scores_gemma":[0.9966202,0.0004992213,0.0016235592,0.00036655396,0.00063439173,0.000018567955,0.000005521833,0.000021999238,0.00021000982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960082,0.00051187025,0.0020978488,0.00025715685,0.00065273896,0.00047219457],"domain_scores_gemma":[0.99565405,0.0021083283,0.001076919,0.00015311824,0.000530006,0.00047759592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021028821,0.00017919583,0.0017533388,0.00023521355,0.000035831676,0.000007511317,0.00022415585,0.00032921773,0.00053041795],"category_scores_gemma":[0.0059559424,0.000110770445,0.0002641075,0.0002020048,0.00044595485,0.00016521745,0.00014835775,0.0016132795,0.00001797167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18030155,0.0033866824,0.7970142,0.000013843148,0.00051016576,0.0005553728,0.0007108473,4.980938e-7,0.000030582887,0.0000047026447,0.0017552879,0.015716309],"study_design_scores_gemma":[0.13760939,0.052154068,0.806173,0.00016322239,0.00014374779,0.0000031192665,0.00032287554,0.0000063754633,0.00006242241,0.000034494242,0.0032358195,0.00009145152],"about_ca_topic_score_codex":0.0004941539,"about_ca_topic_score_gemma":0.0013885372,"teacher_disagreement_score":0.048767384,"about_ca_system_score_codex":0.0004994189,"about_ca_system_score_gemma":0.0015269022,"threshold_uncertainty_score":0.713025},"labels":[],"label_agreement":null},{"id":"W2140288225","doi":"10.1200/jco.2014.55.6977","title":"How Long to Treat Acute Venous Thrombosis in Cancer: Can Treatment Be Personalized?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Thrombosis; Cancer; Prospective cohort study; Pulmonary embolism; Deep vein; Low molecular weight heparin; Venous thrombosis; Surgery; Internal medicine","score_opus":0.19785282621352349,"score_gpt":0.4768120913772595,"score_spread":0.27895926516373604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140288225","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.075196184,0.0008825655,0.00002915529,0.91886455,0.002407886,0.00086659763,0.000043088687,0.00001593101,0.0016940153],"genre_scores_gemma":[0.021591676,0.02214456,0.00070143276,0.9294169,0.017043173,0.00013406659,0.00005812862,0.00011682404,0.00879324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99461484,0.00070379,0.0025311343,0.0005979371,0.0008015387,0.00075077015],"domain_scores_gemma":[0.9947994,0.0014344263,0.0023035407,0.000511719,0.00036708792,0.0005838788],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014758385,0.00055938336,0.006975999,0.0005425967,0.0000608497,0.00005225399,0.00042079182,0.0016736055,0.00031422504],"category_scores_gemma":[0.0005906665,0.0003888983,0.0015016755,0.00023282578,0.00022067362,0.00006936197,0.00009865498,0.0026408392,0.000019582802],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005419351,0.0037603225,0.0053491998,0.00017633279,0.0029147556,0.012286423,0.0004982823,0.000010633384,0.0000094131565,0.00001488037,0.9071279,0.06730989],"study_design_scores_gemma":[0.007292239,0.038417272,0.031215845,0.00055522495,0.0059755994,0.00030720799,0.00008752488,0.000004321817,0.0000166056,0.000034523942,0.91578853,0.00030510023],"about_ca_topic_score_codex":0.0012676816,"about_ca_topic_score_gemma":0.0017146212,"teacher_disagreement_score":0.06700479,"about_ca_system_score_codex":0.0023318653,"about_ca_system_score_gemma":0.002347869,"threshold_uncertainty_score":0.9998563},"labels":[],"label_agreement":null},{"id":"W2140292625","doi":"10.1200/jco.2005.02.1790","title":"Identification in Administrative Databases of Women Dying of Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Palliative care; Population; Predictive value; Chart; Cancer; Breast cancer; Health care; Database; Gerontology; Internal medicine; Statistics; Nursing","score_opus":0.4530295831205463,"score_gpt":0.6124617611444091,"score_spread":0.15943217802386278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140292625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652797,0.0008665909,0.00014131582,0.0012931444,0.00027271025,0.000070039845,0.000038050326,0.0000012671185,0.0007889278],"genre_scores_gemma":[0.9970298,0.0012576617,0.0011818472,0.00010290034,0.00034036423,0.0000025237873,0.000004261733,0.0000047572335,0.00007587896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701583,0.00021138634,0.0023361254,0.000089259884,0.0002274751,0.000119898934],"domain_scores_gemma":[0.99512047,0.0016594515,0.0024561035,0.0001065603,0.00057058857,0.00008683686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001992604,0.00006377846,0.001093204,0.00012379487,0.000006018164,9.2576676e-7,0.00008744601,0.00010547156,0.00011260658],"category_scores_gemma":[0.0018580346,0.00004786084,0.00014718265,0.00015339821,0.00021745804,0.00009165042,0.000019114774,0.00027744853,8.554093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003441079,0.0017634935,0.95708805,0.00016183827,0.00019452567,0.00009123557,0.00080919836,0.000035100304,0.011568925,0.00030680146,0.0008406626,0.023699107],"study_design_scores_gemma":[0.003403934,0.002131559,0.977848,0.0008482535,0.00012709961,0.00003437378,0.0015285474,0.000029504326,0.007888056,0.00023384356,0.0058799926,0.000046839697],"about_ca_topic_score_codex":0.0003275546,"about_ca_topic_score_gemma":0.00024060851,"teacher_disagreement_score":0.023652267,"about_ca_system_score_codex":0.00015858782,"about_ca_system_score_gemma":0.0011497155,"threshold_uncertainty_score":0.22243752},"labels":[],"label_agreement":null},{"id":"W2140304070","doi":"10.1200/jco.2009.26.8169","title":"TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Choroid plexus; Medicine; Germline; Single-nucleotide polymorphism; Copy-number variation; Internal medicine; Cancer research; Germline mutation; Oncology; Mdm2; Pathology; Mutation; Biology; Genetics; Gene; Genotype; Genome","score_opus":0.0683807268885795,"score_gpt":0.43846223767611914,"score_spread":0.37008151078753965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140304070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592304,0.00005509947,0.000050763403,0.0011613583,0.0015813725,0.0002266144,0.000008968348,0.000005864703,0.0009869302],"genre_scores_gemma":[0.99200076,0.000091535665,0.0064252703,0.0005667014,0.0007831572,0.000002378204,0.000010931049,0.000015535727,0.000103752805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631876,0.0004362515,0.0025408755,0.00020962175,0.00030003948,0.00019447441],"domain_scores_gemma":[0.9942893,0.0025552313,0.0018257655,0.0002321837,0.00063495175,0.00046259412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025903825,0.00014854282,0.0017082948,0.00010090389,0.000051872965,0.0000051903617,0.00011658224,0.00049049774,0.00012779121],"category_scores_gemma":[0.0034570016,0.000092836235,0.00031355323,0.000091744085,0.0006911489,0.00012022598,0.000049140675,0.0013856655,0.0000075849043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00415132,0.004378107,0.94558424,0.000013387792,0.00045620158,0.00039916852,0.000027479507,5.3051446e-7,0.000040935338,0.00011201461,0.00018061377,0.04465601],"study_design_scores_gemma":[0.017907742,0.028276697,0.9463215,0.000036408277,0.00065634213,0.00022192462,0.000017528839,0.000022036515,0.00003510176,0.00015631651,0.006273083,0.00007532207],"about_ca_topic_score_codex":0.000006840392,"about_ca_topic_score_gemma":0.00020690632,"teacher_disagreement_score":0.044580687,"about_ca_system_score_codex":0.00002572089,"about_ca_system_score_gemma":0.0009487552,"threshold_uncertainty_score":0.60201037},"labels":[],"label_agreement":null},{"id":"W2140485109","doi":"10.1200/jco.2010.30.0368","title":"Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Concordance; Medicine; Tissue microarray; Diffuse large B-cell lymphoma; Rituximab; Microarray; Lymphoma; CHOP; Vincristine; Oncology; International Prognostic Index; Internal medicine; Hazard ratio; Immunohistochemistry; Algorithm; Cyclophosphamide; Chemotherapy; Biology; Confidence interval; Computer science; Gene; Gene expression; Genetics","score_opus":0.035121574967914466,"score_gpt":0.41735122554648185,"score_spread":0.3822296505785674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140485109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824876,0.00015919605,0.00018632111,0.00020578137,0.000253183,0.00040200932,0.000013066176,0.0000053582894,0.00052635185],"genre_scores_gemma":[0.95133066,0.00006154031,0.048283737,0.00010918908,0.00013344837,0.000013522298,0.0000092287555,0.00002051076,0.00003817499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976696,0.00022911318,0.0014235609,0.00021207113,0.00022081319,0.00024486764],"domain_scores_gemma":[0.9948338,0.0030520882,0.0012593402,0.00017911944,0.00041793223,0.00025769195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018049298,0.00016938103,0.0015608275,0.00010485631,0.000029076904,0.000005514094,0.00009216863,0.00032194355,0.0000124346725],"category_scores_gemma":[0.0007860864,0.00009652405,0.00018437074,0.00010711755,0.00018354609,0.000068670466,0.00003247373,0.00036959923,5.3535086e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014624187,0.043580975,0.9126264,0.000056628585,0.00019349626,0.000071926945,0.000070648544,1.9486166e-7,0.000644183,0.000019517447,0.000046459238,0.028065369],"study_design_scores_gemma":[0.21863566,0.021486387,0.7536017,0.000091065696,0.00061097683,0.000043330438,0.000050143324,0.00008536479,0.0022978156,0.000017445414,0.0029873054,0.00009281065],"about_ca_topic_score_codex":0.000041126874,"about_ca_topic_score_gemma":0.00003612886,"teacher_disagreement_score":0.20401148,"about_ca_system_score_codex":0.00012660398,"about_ca_system_score_gemma":0.0006967043,"threshold_uncertainty_score":0.39361364},"labels":[],"label_agreement":null},{"id":"W2140507579","doi":"10.1200/jco.2012.41.9770","title":"Follow-Up of Breast Cancer Survivors","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Worry; Breast cancer; Survivorship curve; Cancer; Odds ratio; Quality of life (healthcare); Confidence interval; Internal medicine; Family medicine; Oncology; Patient satisfaction; Nursing; Psychiatry; Anxiety","score_opus":0.11618508586514231,"score_gpt":0.4484688553174539,"score_spread":0.3322837694523116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140507579","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06736786,0.0051161456,0.00003272076,0.87482196,0.044513542,0.00025933696,0.00018654388,0.000014277241,0.0076876217],"genre_scores_gemma":[0.15592007,0.0048783207,0.00019823456,0.74726224,0.081901215,0.000011770698,0.000039904582,0.00012141133,0.009666797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99370635,0.00076701376,0.0038375352,0.00025819056,0.0009504791,0.0004804537],"domain_scores_gemma":[0.9902407,0.0025382638,0.0049178116,0.00042187478,0.0014445693,0.00043678036],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003414398,0.00031956582,0.004285703,0.00026200977,0.000023328455,0.000006088571,0.00039816202,0.0028795155,0.0023825502],"category_scores_gemma":[0.0009110272,0.00022560058,0.0021237622,0.00020936455,0.00036273955,0.00010045656,0.00008703153,0.006222003,0.000028555309],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028101355,0.00036401043,0.078118354,0.0003768947,0.0012100765,0.00096669473,0.0001705679,4.3866925e-7,0.000012796682,0.0000067294745,0.83397055,0.081992745],"study_design_scores_gemma":[0.0042350413,0.0024447208,0.07033334,0.0004960989,0.0019897642,0.0009701865,0.00007691922,9.4255836e-7,0.000010245453,0.00005291533,0.91920567,0.00018418283],"about_ca_topic_score_codex":0.0021268453,"about_ca_topic_score_gemma":0.0030554896,"teacher_disagreement_score":0.12755969,"about_ca_system_score_codex":0.00030675743,"about_ca_system_score_gemma":0.0041935276,"threshold_uncertainty_score":0.99852943},"labels":[],"label_agreement":null},{"id":"W2140715519","doi":"10.1200/jco.2003.99.101","title":"Benefit of Paclitaxel in Estrogen Receptor-Negative Versus Estrogen Receptor-Positive Early Breast Cancer","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Paclitaxel; Estrogen receptor; Estrogen; Breast cancer; Internal medicine; Oncology; Cancer","score_opus":0.03723400547780807,"score_gpt":0.38005725362003845,"score_spread":0.34282324814223036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140715519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236355,0.005389631,0.000009855366,0.06382246,0.0047192127,0.00048068145,0.00046011928,0.0000058130363,0.0014767743],"genre_scores_gemma":[0.5273653,0.076946534,0.020991854,0.29848215,0.06656148,0.00028025432,0.0016698721,0.0011666081,0.0065359133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936458,0.0014775018,0.0030716474,0.000623449,0.00053129566,0.00065029465],"domain_scores_gemma":[0.9930211,0.0012915422,0.004064214,0.0004242369,0.0008815372,0.00031742366],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018287902,0.00054459687,0.002330192,0.00022391026,0.00004954569,0.000016594924,0.0006588069,0.004714131,0.00015695882],"category_scores_gemma":[0.0012722325,0.00045131336,0.0013530985,0.0002564964,0.0005752723,0.000019041376,0.0001519972,0.004580879,0.00002829807],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028608458,0.0019100761,0.032449335,0.00015777361,0.009018377,0.001316759,0.00022424797,0.00015626926,0.018680189,0.00011161655,0.8472796,0.060087305],"study_design_scores_gemma":[0.031859256,0.054806665,0.01479566,0.0011507894,0.0020759713,0.00071978424,0.00027180222,0.000008678338,0.03302371,0.0004138641,0.8589977,0.0018761021],"about_ca_topic_score_codex":0.00021372813,"about_ca_topic_score_gemma":0.000026715245,"teacher_disagreement_score":0.39627013,"about_ca_system_score_codex":0.00027489243,"about_ca_system_score_gemma":0.0023398136,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W2140772483","doi":"10.1200/jco.2006.08.1604","title":"Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Cognition; Cognitive impairment; Neuropsychology; Breast cancer; Cancer; Clinical psychology; Psychiatry; Internal medicine","score_opus":0.5991410845735161,"score_gpt":0.6616925470374004,"score_spread":0.06255146246388432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140772483","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000105186904,0.98720527,0.00004788751,0.007936422,0.0008491413,0.003220991,0.000045152046,0.000004238671,0.0005857123],"genre_scores_gemma":[0.00014767796,0.99738574,0.0003122297,0.0007184797,0.001119354,0.0001307184,0.00006756225,0.000030587842,0.000087675355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906665,0.0032533251,0.0042023337,0.0002870175,0.001359046,0.00023177212],"domain_scores_gemma":[0.93352413,0.026038766,0.008531609,0.00015535431,0.031596866,0.00015327764],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0635366,0.00024005752,0.0059154127,0.0005444966,0.00007109602,0.0000044615917,0.00009126821,0.00063055696,0.00009996611],"category_scores_gemma":[0.099219,0.00014510335,0.00077376235,0.0008406064,0.0006191832,0.00012193457,0.000051210496,0.0016848767,5.985615e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017971414,0.00087335106,0.00006240303,0.022397833,0.012784983,0.0000039563306,0.00010762374,1.9330495e-8,4.001607e-8,0.000009753282,0.017711136,0.9442518],"study_design_scores_gemma":[0.009907747,0.02569696,0.0015721563,0.31777105,0.042747326,0.00006321758,0.0010604155,0.0000013530697,3.5921752e-7,0.00024801807,0.6008227,0.00010874515],"about_ca_topic_score_codex":0.0000020017544,"about_ca_topic_score_gemma":0.00003157349,"teacher_disagreement_score":0.944143,"about_ca_system_score_codex":0.0006382813,"about_ca_system_score_gemma":0.005681038,"threshold_uncertainty_score":0.99995583},"labels":[],"label_agreement":null},{"id":"W2140832617","doi":"10.1200/jco.2014.57.3055","title":"Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Guideline; Anaplastic lymphoma kinase; Lung cancer; Oncology; Epidermal growth factor receptor; Internal medicine; Cancer; Family medicine; Pathology","score_opus":0.03833756373049924,"score_gpt":0.4406086431182212,"score_spread":0.40227107938772194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140832617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809075,0.00012826218,0.010575802,0.0034818375,0.00083556975,0.0027992872,0.001262083,0.0000037067744,0.000005953695],"genre_scores_gemma":[0.9811685,0.00011946459,0.017497899,0.0004152975,0.0003750844,0.00034617606,0.00003521311,0.00002582218,0.000016552276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508923,0.00055097754,0.00338401,0.00027844828,0.000458265,0.00023904466],"domain_scores_gemma":[0.97225595,0.010031066,0.012195023,0.00013648428,0.005288399,0.000093085495],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003315947,0.00018258601,0.0018365066,0.000092677816,0.00007726572,0.0000026110595,0.00016301195,0.00021623455,0.0000033683325],"category_scores_gemma":[0.015259832,0.0001138831,0.00059550593,0.00027064353,0.00032816196,0.00005789033,0.000047554495,0.00018859639,6.3628587e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078051924,0.0045519965,0.9325947,0.0002529024,0.003116772,0.0000010485151,0.00031103834,0.00080994744,0.0040024435,0.000058702728,0.0016613802,0.04483386],"study_design_scores_gemma":[0.045105122,0.07324171,0.85099566,0.00025098372,0.006529385,0.0000035271894,0.0009285247,0.015458695,0.0052972343,0.00006292257,0.0019622077,0.0001640441],"about_ca_topic_score_codex":0.00042114066,"about_ca_topic_score_gemma":0.00034089028,"teacher_disagreement_score":0.08159907,"about_ca_system_score_codex":0.00090907275,"about_ca_system_score_gemma":0.0017562691,"threshold_uncertainty_score":0.9930351},"labels":[],"label_agreement":null},{"id":"W2141242886","doi":"10.1200/jco.2006.09.8046","title":"Age, Health, and Education Determine Supportive Care Needs of Men Younger Than 70 Years With Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"U.S. Department of Veterans Affairs","keywords":"Medicine; Prostate cancer; Human sexuality; Logistic regression; Family medicine; Population; Gerontology; Cancer; Needs assessment; Health care; Demography; Gynecology; Internal medicine","score_opus":0.058062746833671235,"score_gpt":0.4644157433339809,"score_spread":0.40635299650030965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141242886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98902607,0.003298328,0.00001148215,0.0038616485,0.0008272172,0.00020357386,0.0000052818173,0.0000034454104,0.0027629368],"genre_scores_gemma":[0.99426645,0.0018101175,0.00033637477,0.0021636602,0.0006984486,0.0000035298247,0.000004359905,0.000012658634,0.00070441],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982182,0.0001109038,0.0011426455,0.00009087414,0.00026637904,0.00017102575],"domain_scores_gemma":[0.9974244,0.00027641407,0.0012524521,0.000100361634,0.0005493629,0.0003969775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012904293,0.00008352958,0.00081295526,0.0001431552,0.00001639672,0.0000033896183,0.000054817447,0.00014500668,0.000034815166],"category_scores_gemma":[0.00020833152,0.000058060963,0.00011615151,0.00015247843,0.00019924257,0.00007306209,0.000017336115,0.00042302822,3.9623046e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008109273,0.00031035318,0.40261585,0.00015188142,0.00012425313,0.00015640397,0.012218784,5.9129025e-7,0.00007028085,0.000014613792,0.0015611899,0.57466656],"study_design_scores_gemma":[0.0035728614,0.015286767,0.9121555,0.00037836825,0.00021986479,0.0002326581,0.026633248,7.5704224e-7,0.00014010533,0.000051577244,0.04124929,0.00007899157],"about_ca_topic_score_codex":0.0005505533,"about_ca_topic_score_gemma":0.0028531416,"teacher_disagreement_score":0.5745875,"about_ca_system_score_codex":0.00016942355,"about_ca_system_score_gemma":0.0045619626,"threshold_uncertainty_score":0.8092726},"labels":[],"label_agreement":null},{"id":"W2141381346","doi":"10.1200/jco.2005.04.4420","title":"Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor Therapy","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Epidermal growth factor receptor; Gefitinib; Internal medicine; Oncology; Exon; Lung cancer; Clinical trial; Retrospective cohort study; Predictive marker; Cancer; Gene; Genetics; Biology","score_opus":0.09442976966772315,"score_gpt":0.4454575769674457,"score_spread":0.35102780729972255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141381346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73113465,0.0017080486,0.0000723363,0.2641816,0.0015806869,0.0007183587,0.000091797716,0.0000051618595,0.000507352],"genre_scores_gemma":[0.8911889,0.002050608,0.0006299347,0.10001383,0.005489838,0.000019661633,0.000088082386,0.000050926315,0.00046821963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996333,0.0005783619,0.0023034518,0.00020248986,0.00036035725,0.00022234273],"domain_scores_gemma":[0.99079645,0.0062410305,0.0023028243,0.00013869858,0.0004234174,0.000097600976],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00081809645,0.00021671096,0.0017269609,0.00018982058,0.000031565334,0.000008461283,0.00013624637,0.0009035034,0.000059581307],"category_scores_gemma":[0.0016051867,0.000109125154,0.0004188097,0.00010888821,0.00025902162,0.00007391997,0.000026789778,0.0024958705,0.0000013953511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011754726,0.0009744003,0.7952894,0.00016733969,0.0018260948,0.0007227849,0.00092072104,0.000008555449,0.000027502658,0.0000049920036,0.18437707,0.014505652],"study_design_scores_gemma":[0.0068522943,0.010112025,0.82349384,0.0005515424,0.0008932497,0.000105160594,0.00016868113,0.00001342826,0.00004197336,0.00020902057,0.15743642,0.00012237982],"about_ca_topic_score_codex":0.000082388804,"about_ca_topic_score_gemma":0.0000127181975,"teacher_disagreement_score":0.16416779,"about_ca_system_score_codex":0.00019503241,"about_ca_system_score_gemma":0.001641901,"threshold_uncertainty_score":0.9998054},"labels":[],"label_agreement":null},{"id":"W2141469774","doi":"10.1200/jco.2005.05.140","title":"Psychoactive Medications and Risk of Delirium in Hospitalized Cancer Patients","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; Michel-Sarrazin; Centre hospitalier universitaire de Québec","funders":"","keywords":"Delirium; Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Anesthesia; Intensive care medicine; Confidence interval","score_opus":0.047524780903498626,"score_gpt":0.47091373112686374,"score_spread":0.4233889502233651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141469774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783148,0.00047357645,0.0000819241,0.017691512,0.00049689354,0.0001724233,0.0000120454315,0.000001822865,0.00275499],"genre_scores_gemma":[0.9807861,0.0049980786,0.0012523571,0.012650359,0.0002608692,0.000004250975,0.0000023397822,0.000008259935,0.00003739724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977878,0.00029588063,0.0014716763,0.00010868088,0.00021950579,0.00011646473],"domain_scores_gemma":[0.98699605,0.0014472445,0.0015116318,0.000075432894,0.009793825,0.00017579287],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010592339,0.00007602656,0.00082789443,0.00017505075,0.00001294186,0.0000011365014,0.00006392035,0.00021135481,0.00011440374],"category_scores_gemma":[0.035763208,0.000056298428,0.00018537119,0.00012337926,0.00030724204,0.00007221164,0.000019484254,0.0007176842,0.0000029928553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019376728,0.001393706,0.8639748,0.000008155576,0.0004020897,0.000013191721,0.00032279483,0.0000033371355,0.00002038391,0.000019266954,0.006148314,0.12575626],"study_design_scores_gemma":[0.01126619,0.0044494234,0.97234803,0.00012654177,0.0004741965,0.000010651677,0.000704292,0.000050027527,0.000045659413,0.00016798933,0.010307281,0.000049714334],"about_ca_topic_score_codex":0.00007250477,"about_ca_topic_score_gemma":0.00021462823,"teacher_disagreement_score":0.12570655,"about_ca_system_score_codex":0.00009801383,"about_ca_system_score_gemma":0.00066632184,"threshold_uncertainty_score":0.97235894},"labels":[],"label_agreement":null},{"id":"W2141604895","doi":"10.1200/jco.2014.57.2909","title":"Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Hippocampal formation; Compartment (ship); Whole brain radiotherapy; Radiation therapy; Neural stem cell; Internal medicine; Stem cell; Brain metastasis; Cancer; Metastasis; Biology","score_opus":0.12311120281589091,"score_gpt":0.43792476007359177,"score_spread":0.3148135572577009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141604895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768874,0.0003547644,0.008110475,0.012415231,0.00071322237,0.0013781061,0.00009141537,0.000005506979,0.00004385052],"genre_scores_gemma":[0.9844293,0.000018634199,0.012972303,0.0014939855,0.00069654005,0.000032517248,0.000018896575,0.000015665484,0.00032213723],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957158,0.0009420718,0.002395016,0.00019174081,0.0005175458,0.00023785028],"domain_scores_gemma":[0.9928264,0.0033171717,0.0029376282,0.00027853562,0.00042741327,0.00021284503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044534667,0.0002068579,0.0016649758,0.000091883056,0.00013151481,0.000006492632,0.00021385863,0.00014830241,0.00003683979],"category_scores_gemma":[0.001091238,0.0001084049,0.000749111,0.00011446858,0.00047847742,0.0001825258,0.000045039866,0.00042747913,3.868195e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74169576,0.051041465,0.007177013,0.0008360696,0.0046660174,0.00014374284,0.00114117,0.010515156,0.016620059,0.0015808202,0.007299225,0.15728348],"study_design_scores_gemma":[0.75042737,0.14655066,0.018255383,0.00030248327,0.0014288797,0.00032773946,0.00026288794,0.01053824,0.009872632,0.00006550801,0.061752122,0.00021609249],"about_ca_topic_score_codex":0.000013342432,"about_ca_topic_score_gemma":0.000029349943,"teacher_disagreement_score":0.1570674,"about_ca_system_score_codex":0.00011245494,"about_ca_system_score_gemma":0.0010794632,"threshold_uncertainty_score":0.44206238},"labels":[],"label_agreement":null},{"id":"W2141628791","doi":"10.1200/jco.2005.05.011","title":"Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"MALT lymphoma; Chromosomal translocation; Pathogenesis; Mucosa-associated lymphoid tissue; Biology; Lymphoma; BCL10; Marginal zone; Helicobacter pylori; Immunology; Lymphatic system; Pathology; Cytogenetics; Cancer research; B cell; Genetics; Gene; Medicine; Chromosome; Antibody","score_opus":0.15851001432194722,"score_gpt":0.505749278314124,"score_spread":0.34723926399217675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141628791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051518697,0.99033415,0.0000074934305,0.00051878684,0.0012446298,0.00056674186,0.00005092633,0.000013067366,0.002112338],"genre_scores_gemma":[0.0028424086,0.99346346,0.0014094455,0.0006904423,0.0012415969,0.00002428198,0.00004269589,0.00007491058,0.00021075836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98989224,0.0013650638,0.00719032,0.00039635712,0.00075472635,0.00040126752],"domain_scores_gemma":[0.98522425,0.0036309154,0.009211985,0.000498836,0.0007672684,0.0006667202],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031120544,0.00052662106,0.01127343,0.0003607599,0.000032244414,0.000009279601,0.0003926213,0.0019432771,0.00021553086],"category_scores_gemma":[0.004635971,0.00034075708,0.004155633,0.00037712947,0.00021832701,0.000058523263,0.00011451614,0.00045283054,0.00008335061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025189028,0.0083868,0.0007488434,0.0011347961,0.0039092517,0.005109969,0.00001100408,8.378402e-7,0.000003187575,0.00004886204,0.0020370798,0.9783575],"study_design_scores_gemma":[0.009517544,0.008979602,0.003935522,0.006682551,0.015002165,0.0030017,0.0000073419683,0.0000016417459,0.000021116544,0.000021258555,0.9525977,0.00023185542],"about_ca_topic_score_codex":0.000025201865,"about_ca_topic_score_gemma":0.000010933488,"teacher_disagreement_score":0.97812563,"about_ca_system_score_codex":0.0014383207,"about_ca_system_score_gemma":0.009550673,"threshold_uncertainty_score":0.99990445},"labels":[],"label_agreement":null},{"id":"W2141629941","doi":"10.1200/jco.2006.09.1033","title":"Supratentorial Primitive Neuroectodermal Tumors in Young Children","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Primitive neuroectodermal tumor; Pathology; Sarcoma","score_opus":0.07758834929119006,"score_gpt":0.41951355546207175,"score_spread":0.3419252061708817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141629941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6024928,0.00053648005,0.0000022356091,0.38759667,0.0052861962,0.00043882133,0.000019121131,0.000009950106,0.0036177286],"genre_scores_gemma":[0.5003611,0.00055307697,0.0006639891,0.4361612,0.061308987,0.000022122678,0.00018460497,0.00009938719,0.0006455856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936956,0.0009350527,0.0038045486,0.00038339422,0.0007060045,0.0004753803],"domain_scores_gemma":[0.9936987,0.0026947707,0.0027740188,0.00025467083,0.00036009116,0.00021774822],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013942306,0.0003521968,0.0033258938,0.0003644177,0.00002657568,0.000018446979,0.00024108929,0.0017304012,0.0001420479],"category_scores_gemma":[0.0015059491,0.0002486948,0.0012538368,0.00014876081,0.00019774924,0.00008387507,0.000068147034,0.006308419,0.000046001274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006138687,0.0017730512,0.4870788,0.000012596324,0.00034568147,0.028934382,0.000010642582,0.0000026704388,0.00000145581,0.0000040029167,0.47688612,0.0043367227],"study_design_scores_gemma":[0.011280927,0.0064117536,0.8137813,0.00020926323,0.00083833525,0.0029957949,0.000004234323,0.000002927995,0.000010245436,0.00007070097,0.1642403,0.00015420673],"about_ca_topic_score_codex":0.00029163618,"about_ca_topic_score_gemma":0.00012271303,"teacher_disagreement_score":0.32670254,"about_ca_system_score_codex":0.00045422924,"about_ca_system_score_gemma":0.0022670056,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W2141704546","doi":"10.1200/jco.2003.11.105","title":"Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Supraclavicular lymph nodes; Oncology; Cancer; Internal medicine; Radiology","score_opus":0.041820272828931186,"score_gpt":0.39698370152776863,"score_spread":0.35516342869883744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141704546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704313,0.0016791706,0.000034560184,0.00039229824,0.0004481862,0.00010131972,0.00017681092,0.0000010686952,0.00012345552],"genre_scores_gemma":[0.9970867,0.0020510259,0.00046901856,0.00014877866,0.00017723294,0.000010049428,0.00001714975,0.000015493712,0.000024518657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769866,0.0004385003,0.0012116104,0.00019064562,0.00028326162,0.0001773453],"domain_scores_gemma":[0.99670035,0.0003893137,0.0017935,0.0001993803,0.0007852987,0.00013218736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068493723,0.0001556245,0.0010124195,0.00004249755,0.000029486182,0.000001987924,0.00015601845,0.0001886793,0.00015608434],"category_scores_gemma":[0.00050662295,0.0001022991,0.00034928494,0.00008442156,0.00033382128,0.000008076163,0.00007447097,0.00014811571,9.2772103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003057081,0.0020067515,0.9855846,0.000027574564,0.0015494174,0.000023273507,0.000014670493,0.000029231243,0.00020706454,0.000015566102,0.00050914945,0.0069756303],"study_design_scores_gemma":[0.0056465277,0.003444225,0.9797659,0.000048643233,0.00059953076,0.000032823027,0.00002002516,7.63543e-8,0.006247654,0.000008311104,0.0040874607,0.00009884457],"about_ca_topic_score_codex":0.00003328485,"about_ca_topic_score_gemma":0.00037337403,"teacher_disagreement_score":0.006876786,"about_ca_system_score_codex":0.000057412894,"about_ca_system_score_gemma":0.00049736403,"threshold_uncertainty_score":0.4171636},"labels":[],"label_agreement":null},{"id":"W2141714190","doi":"10.1200/jco.2005.12.514","title":"Communicating Quality of Life Information to Cancer Patients: A Study of Six Presentation Formats","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Saskatchewan; Princess Margaret Cancer Centre; Queen's University; University of Toronto","funders":"","keywords":"Helpfulness; Medicine; Quality of life (healthcare); Multivariate analysis; Cancer; Internal medicine; Psychology; Social psychology","score_opus":0.2013851227151426,"score_gpt":0.5480567071194953,"score_spread":0.34667158440435264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141714190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952985,0.00008655536,0.00008764442,0.0025831854,0.0004563388,0.00032471586,0.000007334644,0.0000031214079,0.0011525956],"genre_scores_gemma":[0.99688065,0.00010950009,0.0006187068,0.002112436,0.00025344788,0.0000074860413,0.0000036062404,0.0000040239224,0.00001011441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99532884,0.0004979563,0.003580714,0.000048773763,0.0004502449,0.00009346865],"domain_scores_gemma":[0.9937578,0.0011983466,0.0033137614,0.00019368067,0.0013467744,0.00018964104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027999936,0.00006395931,0.0009253828,0.000109917244,0.000020021445,0.0000032149567,0.00016205701,0.000120593446,0.000052694966],"category_scores_gemma":[0.0044787447,0.000048680617,0.00018266994,0.00015637155,0.00004590058,0.00032989195,0.00007103672,0.00037771044,0.0000026394982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046897978,0.0031542971,0.7416886,0.00010338295,0.00019143253,3.9729818e-7,0.011391416,0.00021866555,0.00002850692,0.000023366103,0.0012955567,0.23721458],"study_design_scores_gemma":[0.008733689,0.011267934,0.9585639,0.00010057152,0.0001369115,0.0000012920565,0.0073458315,0.00008440393,0.000060543705,0.000011727421,0.013642677,0.000050474697],"about_ca_topic_score_codex":0.0011407722,"about_ca_topic_score_gemma":0.004619678,"teacher_disagreement_score":0.2371641,"about_ca_system_score_codex":0.00011429304,"about_ca_system_score_gemma":0.0006084663,"threshold_uncertainty_score":0.5361799},"labels":[],"label_agreement":null},{"id":"W2141768150","doi":"10.1200/jco.2004.05.063","title":"American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1451,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Disease; Oncology; Guideline; Colorectal cancer; Chemotherapy; Adjuvant therapy; Clinical trial; Cancer; Adjuvant; Adjuvant chemotherapy; Perforation; Intensive care medicine; Surgery; Breast cancer; Pathology","score_opus":0.45463365464482497,"score_gpt":0.6437214622989518,"score_spread":0.1890878076541268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141768150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042647375,0.9481853,0.00015146138,0.03144551,0.008617907,0.0039913934,0.00058164063,0.000041004034,0.0027210354],"genre_scores_gemma":[0.00028792227,0.97632647,0.012998588,0.0050373403,0.0033695989,0.0002137484,0.0000684639,0.00010572523,0.0015921654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9861624,0.0015357838,0.010413365,0.00071069127,0.00062073336,0.00055698474],"domain_scores_gemma":[0.96436405,0.016835922,0.016430171,0.00050306274,0.0010113787,0.00085539423],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007224507,0.0006111965,0.01628766,0.00021571374,0.000111280555,0.00000694556,0.0005078822,0.0019726995,0.0006741751],"category_scores_gemma":[0.0038797208,0.0004065831,0.008391111,0.0005231593,0.0010751977,0.00007114918,0.00014453159,0.0035534129,0.000013131442],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007903441,0.008619397,0.0004367138,0.0021805456,0.0047997297,0.00011647492,0.000056961573,0.0000042766546,3.249903e-7,0.000050219936,0.020634085,0.9551978],"study_design_scores_gemma":[0.016763996,0.100587554,0.0011568351,0.006644451,0.004232417,0.00010014934,0.00004988907,0.000009508611,0.0000016742335,0.00006485807,0.8701337,0.00025499729],"about_ca_topic_score_codex":0.0001107262,"about_ca_topic_score_gemma":0.00013087835,"teacher_disagreement_score":0.9549428,"about_ca_system_score_codex":0.0028003324,"about_ca_system_score_gemma":0.023918224,"threshold_uncertainty_score":0.9998386},"labels":[],"label_agreement":null},{"id":"W2141786207","doi":"10.1200/jco.2004.09.106","title":"Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Medicine; Febrile neutropenia; Neutropenia; Internal medicine; Placebo; Granulocyte colony-stimulating factor; Chemotherapy; Gastroenterology; Randomized controlled trial; Randomization; Surgery; Pathology","score_opus":0.18450394573005494,"score_gpt":0.49794973398858816,"score_spread":0.3134457882585332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141786207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15061067,0.83756554,0.00011112763,0.00036890054,0.0004009613,0.010590256,0.00026534993,0.000020844092,0.00006633977],"genre_scores_gemma":[0.37928417,0.617525,0.0010502931,0.00041114583,0.00053139904,0.00094970455,0.000024572613,0.00010541615,0.00011832594],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97382915,0.008963444,0.014730491,0.0008689523,0.0010038425,0.0006041151],"domain_scores_gemma":[0.95506924,0.022662297,0.019808877,0.0005520102,0.0010174838,0.0008900812],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.013435685,0.0011097303,0.0760588,0.0014893711,0.00011188672,0.00007858912,0.00035094723,0.0012189237,0.0019031969],"category_scores_gemma":[0.01467535,0.0005720764,0.018177668,0.001378572,0.00070344826,0.00021452188,0.00008421054,0.0028005186,0.000002994763],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40673804,0.0020199632,0.02120066,0.0027999466,0.4681349,0.00053787715,0.00013738591,0.0009777388,0.000012213363,0.000009608722,0.000010063841,0.09742159],"study_design_scores_gemma":[0.3427574,0.00523758,0.011597195,0.0016063188,0.6347627,0.000281925,0.000006199038,0.00011788473,0.000003945015,0.000013307628,0.0031616597,0.00045388608],"about_ca_topic_score_codex":0.0009883716,"about_ca_topic_score_gemma":0.0006032826,"teacher_disagreement_score":0.22867349,"about_ca_system_score_codex":0.0007719876,"about_ca_system_score_gemma":0.007023324,"threshold_uncertainty_score":0.99967307},"labels":[],"label_agreement":null},{"id":"W2141966658","doi":"10.1200/jco.2001.19.3.657","title":"Structured Exercise Improves Physical Functioning in Women With Stages I and II Breast Cancer: Results of a Randomized Controlled Trial","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":578,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Physical therapy; Randomized controlled trial; Aerobic exercise; Aerobic capacity; Weight loss; Clinical trial; Post-hoc analysis; Cancer; Obesity; Internal medicine; Nursing","score_opus":0.025484694556067555,"score_gpt":0.3808875602375415,"score_spread":0.35540286568147395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141966658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938033,0.00054684863,0.000013988465,0.0032538155,0.0009850449,0.00095114915,0.000008262069,0.0000048978422,0.00043267713],"genre_scores_gemma":[0.9958823,0.0020867349,0.000076400785,0.00026161908,0.0013662948,0.00006197313,6.8997036e-7,0.000010601547,0.00025343383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963528,0.00058314623,0.0023473203,0.0001736529,0.00034189364,0.00020119193],"domain_scores_gemma":[0.99416244,0.0029128173,0.0021542313,0.00011653712,0.00041356162,0.00024039582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043889754,0.00013935757,0.004879565,0.00014239573,0.000029063489,0.000007115883,0.00006838292,0.00020015123,0.000042727163],"category_scores_gemma":[0.0020630644,0.000076157135,0.00040737406,0.00016015893,0.000317697,0.00008494394,0.00002914549,0.0006607003,1.1111107e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8966438,0.0007685685,0.0019943714,0.000022121243,0.0005200339,0.00010320672,0.001211884,0.000016966213,0.0001480491,0.000012124494,0.00006650422,0.09849237],"study_design_scores_gemma":[0.95594364,0.01347748,0.02777933,0.00025838628,0.00075058395,0.000115883115,0.00070218847,0.00009325307,0.0000128047595,0.00026002762,0.00053271296,0.000073698146],"about_ca_topic_score_codex":0.00027097124,"about_ca_topic_score_gemma":0.0005774202,"teacher_disagreement_score":0.098418675,"about_ca_system_score_codex":0.00011867338,"about_ca_system_score_gemma":0.0011757811,"threshold_uncertainty_score":0.3335573},"labels":[],"label_agreement":null},{"id":"W2142101030","doi":"10.1200/jco.2006.06.7330","title":"Meta-Analysis and Meta-Review of Thyroid Cancer Gene Expression Profiling Studies Identifies Important Diagnostic Biomarkers","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; St. Paul's Hospital; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Michael Smith Health Research BC","keywords":"Medicine; Thyroid cancer; Thyroid nodules; Thyroid; Meta-analysis; Concordance; Oncology; Population; Gene expression profiling; Pathology; Internal medicine; Bioinformatics; Gene expression; Gene; Biology; Genetics","score_opus":0.44438840671522584,"score_gpt":0.5636054897186852,"score_spread":0.11921708300345935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142101030","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001334652,0.99625635,0.000010951967,0.0016961913,0.0005505002,0.0011301235,0.00017678723,0.0000068001473,0.00003881958],"genre_scores_gemma":[0.00006671734,0.995678,0.0025510371,0.0005951716,0.00044504408,0.00042119334,0.000038612416,0.00004144703,0.00016274517],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9871802,0.0015149895,0.009643987,0.00057294685,0.0007907235,0.00029719374],"domain_scores_gemma":[0.9715564,0.012672169,0.013888815,0.00052520225,0.0010168348,0.00034054118],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0066068037,0.0006428748,0.031156447,0.000492123,0.00005264358,0.000011995713,0.000251369,0.0005227777,0.00034632403],"category_scores_gemma":[0.0052262163,0.00030174846,0.015801825,0.00064198626,0.00037654312,0.000095141426,0.00016248223,0.00082809996,0.0000022471856],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090574984,0.0010099702,0.0007279783,0.03788761,0.87136275,0.0007094049,0.000009383281,0.0000014780026,0.0000023865077,0.0000038037342,0.0074672448,0.08072741],"study_design_scores_gemma":[0.00086043775,0.001489232,0.00021417439,0.006039844,0.78478885,0.00012297346,0.000012276634,1.7871929e-7,0.000060280963,0.000026528282,0.20621458,0.00017062345],"about_ca_topic_score_codex":0.00008392648,"about_ca_topic_score_gemma":0.00010482051,"teacher_disagreement_score":0.19874732,"about_ca_system_score_codex":0.00026434765,"about_ca_system_score_gemma":0.0019381413,"threshold_uncertainty_score":0.99994344},"labels":[],"label_agreement":null},{"id":"W2142506642","doi":"10.1200/jco.2012.44.4489","title":"Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Incyte; American Society of Clinical Oncology; Sanofi","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Placebo; Quality of life (healthcare); Internal medicine; Physical therapy; Clinical trial; Randomized controlled trial; Bone marrow; Alternative medicine; Pathology","score_opus":0.063216412113048,"score_gpt":0.4266609432678403,"score_spread":0.3634445311547923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142506642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855899,0.00035449414,0.0000021885803,0.002238324,0.0009103692,0.008481663,0.000002359104,0.0000101942305,0.0024104933],"genre_scores_gemma":[0.99717665,0.00045276058,0.00012587539,0.0011956546,0.00020520043,0.00066055264,0.0000028806508,0.000028159497,0.00015227677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909469,0.0024754754,0.0054751877,0.00028781625,0.0005178312,0.00029678576],"domain_scores_gemma":[0.9727474,0.02243426,0.003934484,0.0002377752,0.00029764598,0.0003484217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064125606,0.0003405589,0.0067238114,0.00032050503,0.000034297394,0.000016742859,0.00009671381,0.0005650525,0.00040614264],"category_scores_gemma":[0.0043715364,0.00016861866,0.0013173851,0.00013278608,0.00033687623,0.00009023882,0.000027625385,0.0008000955,0.0000130552635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8145205,0.00457236,0.1479082,0.000016726768,0.003433068,0.000111345835,0.00017553761,0.000009027394,0.000020817268,0.00015773633,0.00010123725,0.028973486],"study_design_scores_gemma":[0.9001879,0.08093502,0.01665851,0.00018852278,0.0008630017,0.0000795253,0.000019771935,0.0000838306,0.00034791642,0.00014757886,0.00037375288,0.00011467799],"about_ca_topic_score_codex":0.00011836878,"about_ca_topic_score_gemma":0.0000151227405,"teacher_disagreement_score":0.1312497,"about_ca_system_score_codex":0.00009805093,"about_ca_system_score_gemma":0.00046666144,"threshold_uncertainty_score":0.68760693},"labels":[],"label_agreement":null},{"id":"W2142614346","doi":"10.1200/jco.2005.04.074","title":"<i>TP53</i> Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Osteosarcoma; Internal medicine; Chemotherapy; Oncology; Prospective cohort study; Missense mutation; Pathology; Mutation; Gene; Genetics","score_opus":0.12418961088098104,"score_gpt":0.4956620940259617,"score_spread":0.3714724831449806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142614346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859637,0.00059657573,0.0000052455534,0.011649511,0.00023624787,0.00049146375,0.0000011339032,0.0000051052652,0.0010510267],"genre_scores_gemma":[0.9941131,0.00011036172,0.0035866492,0.0017116847,0.0003769833,0.000017058725,4.6433937e-7,0.0000091629945,0.0000745308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742335,0.00024551267,0.0018288895,0.00015315738,0.00020135337,0.00014771488],"domain_scores_gemma":[0.9973648,0.0015604212,0.00058118266,0.00011092924,0.00016775899,0.00021489488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001428825,0.00009907345,0.0010017549,0.00013041552,0.000023859193,0.000007618135,0.000056375287,0.000119811906,0.00004997532],"category_scores_gemma":[0.0014861255,0.00006497152,0.00019386991,0.00009671899,0.00008777997,0.00009599194,0.000037052076,0.00053762563,0.000017712813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081795244,0.015908353,0.8954776,0.000004540506,0.00016162806,0.0011748972,0.00035906545,0.000003605556,0.0000046255745,0.000024865425,0.0001410638,0.0859218],"study_design_scores_gemma":[0.024825089,0.007869623,0.95928013,0.000028879576,0.00034162475,0.00021130581,0.00060015544,0.0000467031,0.000010361437,0.000057082016,0.006679265,0.00004976316],"about_ca_topic_score_codex":0.000020271704,"about_ca_topic_score_gemma":0.00034417326,"teacher_disagreement_score":0.08587204,"about_ca_system_score_codex":0.00015572562,"about_ca_system_score_gemma":0.00021638852,"threshold_uncertainty_score":0.2649462},"labels":[],"label_agreement":null},{"id":"W2142629844","doi":"10.1200/jco.2014.57.7510","title":"Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Cancer Institute; Memorial University of Newfoundland; University of Toronto; Queen's University; Cardiff University; University College London; James Cook University; Canadian Cancer Society Research Institute; National Institute for Health and Care Research; McGill University","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Randomized controlled trial; Radiation therapy; Urology; Internal medicine; Oncology; Prostate-specific antigen; Cancer; Confidence interval","score_opus":0.1338352212696052,"score_gpt":0.4468865361738342,"score_spread":0.313051314904229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142629844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98591363,0.0054572118,0.000097082266,0.004373154,0.0015471235,0.0025364326,0.0000040440423,0.000007205158,0.000064137086],"genre_scores_gemma":[0.97851366,0.019960305,0.0006372693,0.00048016154,0.0002023766,0.00013836166,0.0000058756614,0.000025769008,0.000036199486],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99413174,0.0010348074,0.0036972072,0.0002787497,0.0006496606,0.00020782121],"domain_scores_gemma":[0.9925607,0.0015085049,0.004319359,0.0003960604,0.0010372073,0.00017817308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004919776,0.0002232754,0.0026432015,0.0001596984,0.000027356788,0.000007001486,0.0002225845,0.00021182472,0.00003037819],"category_scores_gemma":[0.001658401,0.00012699598,0.0004890502,0.00035737487,0.0002964958,0.00014957595,0.000040581806,0.0005045264,3.2103938e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6003308,0.0072737946,0.2671813,0.00001557165,0.0016149858,0.00027786693,0.0020366705,0.00079449406,0.00048481976,0.0000223465,0.0002045313,0.119762816],"study_design_scores_gemma":[0.8124971,0.04454982,0.13558543,0.000267278,0.0002521562,0.00009807228,0.0005772097,0.00030297635,0.0031952034,0.00030937622,0.0022357074,0.00012971768],"about_ca_topic_score_codex":0.00023295023,"about_ca_topic_score_gemma":0.00021304445,"teacher_disagreement_score":0.21216625,"about_ca_system_score_codex":0.0005735408,"about_ca_system_score_gemma":0.0024945862,"threshold_uncertainty_score":0.51787454},"labels":[],"label_agreement":null},{"id":"W2142773939","doi":"10.1200/jco.2014.58.2973","title":"Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Androgen deprivation therapy; Medicine; Castration; Testosterone (patch); Prostate cancer; Androgen; Internal medicine; Oncology; Hormone; Cancer","score_opus":0.15996917641647573,"score_gpt":0.44433369786254656,"score_spread":0.28436452144607083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142773939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944344,0.0003726557,0.000022656908,0.003314019,0.00068389595,0.0007779376,0.000024791547,0.00000254393,0.00036709],"genre_scores_gemma":[0.99765897,0.000040207917,0.0014972534,0.0000670826,0.0005388756,0.000012612971,0.0000037549814,0.0000075678295,0.00017365614],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99709266,0.00021616791,0.0020289607,0.00015615892,0.00040480972,0.00010121169],"domain_scores_gemma":[0.99492043,0.0009806538,0.0023551383,0.00020711056,0.0013931425,0.00014354174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026984147,0.000098175624,0.0014350456,0.00013761478,0.000026820126,0.0000022506351,0.00013889467,0.00014268488,0.000023383547],"category_scores_gemma":[0.0053569246,0.000051472973,0.000498802,0.00028766046,0.00028030574,0.000044738557,0.00005259296,0.00023798719,8.4676515e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8350609,0.0057775807,0.048639312,0.000117705524,0.011379588,0.000035301466,0.0030412888,0.00012793975,0.0060919924,0.00007335733,0.005466056,0.084188975],"study_design_scores_gemma":[0.19459127,0.2073157,0.564035,0.00049125147,0.005055837,0.00003485977,0.0019810975,0.00017178971,0.0065345163,0.00022745522,0.019383714,0.00017750195],"about_ca_topic_score_codex":0.000008620412,"about_ca_topic_score_gemma":0.000045356806,"teacher_disagreement_score":0.6404696,"about_ca_system_score_codex":0.000060559545,"about_ca_system_score_gemma":0.0011728598,"threshold_uncertainty_score":0.64131266},"labels":[],"label_agreement":null},{"id":"W2142795777","doi":"10.1200/jco.2008.16.1703","title":"“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With <i>BRCA1</i> and <i>BRCA2</i> Mutations","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":472,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Ovarian cancer; Cancer; Epithelial ovarian cancer; Oncology; Internal medicine; Gynecology","score_opus":0.07705207349366407,"score_gpt":0.3834546873547229,"score_spread":0.3064026138610588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142795777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635124,0.00080390956,0.00012150426,0.0014879038,0.00046995492,0.0005938144,0.00013718326,0.000003114717,0.000031348514],"genre_scores_gemma":[0.99769926,0.00038055918,0.0006263785,0.0009217033,0.00025811946,0.00004701735,0.000005484051,0.000028902608,0.000032573742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601805,0.0011128555,0.0019190378,0.00037492916,0.00031032678,0.00026478156],"domain_scores_gemma":[0.99593073,0.0012337826,0.0017944052,0.00024676506,0.0006114531,0.0001828914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026128904,0.00021876738,0.0010975435,0.00008844518,0.00015981497,0.000016124395,0.00022133898,0.00037561156,0.00001219433],"category_scores_gemma":[0.00146169,0.00013393535,0.00013777768,0.00022848554,0.00076690246,0.000023867606,0.000074615,0.0008082282,1.3835715e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024846725,0.0011242874,0.9857981,0.000007616097,0.0011018675,0.0008587671,0.000404676,0.00055050035,0.000049829236,0.0000056357303,0.0001336618,0.0074803387],"study_design_scores_gemma":[0.017946122,0.007162031,0.97207975,0.00005819125,0.00056850456,0.0012563141,0.00042736222,0.0000231703,0.000026576714,0.00001861355,0.00026431878,0.00016901777],"about_ca_topic_score_codex":0.00044240616,"about_ca_topic_score_gemma":0.00819155,"teacher_disagreement_score":0.015461449,"about_ca_system_score_codex":0.00011456665,"about_ca_system_score_gemma":0.0016795916,"threshold_uncertainty_score":0.5461725},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2143021447","doi":"10.1200/jco.2013.50.6105","title":"Pro–Surfactant Protein B As a Biomarker for Lung Cancer Prediction","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Brock University; St. Paul's Hospital","funders":"National Cancer Institute; Terry Fox Research Institute; Canary Foundation; Partenariat Canadien Contre Le Cancer; LUNGevity Foundation; U.S. Department of Defense","keywords":"Medicine; Biomarker; Lung cancer; Pulmonary surfactant; Cancer; Internal medicine; Oncology; Lung; Cancer research; Biochemistry; Biology","score_opus":0.26952411159677664,"score_gpt":0.5924945551386073,"score_spread":0.32297044354183063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143021447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583997,0.0024440486,0.00044292005,0.032656785,0.001135933,0.0031036804,0.000011084043,0.000015747015,0.0017900764],"genre_scores_gemma":[0.9791455,0.0010062298,0.007074482,0.0061686877,0.0026987852,0.0005801324,0.0000027098947,0.000049253184,0.003274208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961735,0.00038168058,0.0022650128,0.00020206926,0.0005943727,0.00038334134],"domain_scores_gemma":[0.9945578,0.0016926923,0.0011792289,0.00017774,0.0015647821,0.0008277533],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048855534,0.00011468678,0.0009751668,0.0001501774,0.000057889632,0.000012051283,0.00015200418,0.00044242875,0.001131346],"category_scores_gemma":[0.012286211,0.00007513265,0.00035067718,0.00015092206,0.0001659014,0.00019395749,0.00004310742,0.0010365964,0.000042072086],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012593014,0.0012844267,0.033972297,0.0007385057,0.00044164597,0.0002225701,0.000041938263,0.0000022168608,0.012630862,0.0000767394,0.032050204,0.9059456],"study_design_scores_gemma":[0.013933445,0.028441759,0.2464515,0.00054966105,0.000216631,0.00025356145,0.000051770683,0.0050590234,0.0011094422,0.00064712984,0.7031657,0.00012037843],"about_ca_topic_score_codex":0.000114587885,"about_ca_topic_score_gemma":0.000020605261,"teacher_disagreement_score":0.9058252,"about_ca_system_score_codex":0.00040600536,"about_ca_system_score_gemma":0.0069383173,"threshold_uncertainty_score":0.9997817},"labels":[],"label_agreement":null},{"id":"W2143274699","doi":"10.1200/jco.2009.27.4449","title":"Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":374,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Sanofi","keywords":"Tirapazamine; Medicine; Radiation therapy; Cisplatin; Head and neck cancer; Hazard ratio; Head and neck squamous-cell carcinoma; Urology; Larynx; Oncology; Chemotherapy; Internal medicine; Surgery; Confidence interval","score_opus":0.061766046743761925,"score_gpt":0.4350159016102489,"score_spread":0.373249854866487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143274699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798174,0.0015476703,0.000081903796,0.0060735457,0.0027213595,0.001209405,0.00002826411,0.0000040224572,0.00035208595],"genre_scores_gemma":[0.996531,0.0010694729,0.000927458,0.0003981971,0.0009994508,0.000022333947,0.000006188582,0.00001641295,0.000029482788],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686074,0.00041730842,0.001985422,0.00023531004,0.00027743782,0.00022376544],"domain_scores_gemma":[0.9928415,0.0043801097,0.0021396081,0.00019900757,0.00024164384,0.0001981643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020625764,0.0001791106,0.0014425606,0.0001032483,0.00013757571,0.0000063908237,0.00011206688,0.00042211675,0.0000102270715],"category_scores_gemma":[0.0026087342,0.00011145265,0.00029954754,0.00015310536,0.000464626,0.00013180659,0.00003497747,0.0007372702,1.0982431e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2044121,0.002399505,0.025734538,0.00020229658,0.00018379786,0.000008566346,0.0020062549,0.000012877724,0.0141625395,0.0002319539,0.001211507,0.74943405],"study_design_scores_gemma":[0.54969144,0.09852203,0.31137517,0.00007156616,0.0011492616,0.00008174201,0.00041883747,0.0015413217,0.0035244897,0.00019071907,0.033260655,0.00017277696],"about_ca_topic_score_codex":0.00004163363,"about_ca_topic_score_gemma":0.0004669883,"teacher_disagreement_score":0.74926126,"about_ca_system_score_codex":0.00008603553,"about_ca_system_score_gemma":0.00069232844,"threshold_uncertainty_score":0.45449075},"labels":[],"label_agreement":null},{"id":"W2143351802","doi":"10.1200/jco.2014.59.6627","title":"Profound Answers to Simple Questions","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Simple (philosophy); Epistemology","score_opus":0.4277175936691339,"score_gpt":0.624463814871625,"score_spread":0.19674622120249102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143351802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7403647,0.0011753754,0.0010184299,0.21985318,0.006076038,0.00036644048,0.0000041814446,0.00002331534,0.031118356],"genre_scores_gemma":[0.96194357,0.0002786006,0.0140299145,0.017407106,0.0052713193,0.0000023653824,0.0000015797274,0.00001279905,0.0010527406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705,0.00040459665,0.0017803386,0.00012480318,0.00043352082,0.00020674634],"domain_scores_gemma":[0.9944807,0.0016410932,0.0006309051,0.00017996092,0.0015614406,0.0015058579],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077081253,0.00007796277,0.00088651845,0.000116392526,0.00003132535,0.000007820759,0.00013306404,0.00044484535,0.00006356434],"category_scores_gemma":[0.028018884,0.00005518701,0.00021833496,0.00019930217,0.000106744825,0.00007151094,0.00004309928,0.0016366525,0.00008101028],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004411035,0.0025934533,0.26028585,0.00011507197,0.00029611777,0.002835125,0.002543856,0.00009648029,0.000022448156,0.006709211,0.43334293,0.28674844],"study_design_scores_gemma":[0.0022394592,0.015302876,0.029130148,0.000037462396,0.0001230787,0.0002637841,0.00039133275,0.00002486809,0.0000033664703,0.0034197168,0.94900554,0.000058384154],"about_ca_topic_score_codex":0.00011768248,"about_ca_topic_score_gemma":0.00009016946,"teacher_disagreement_score":0.5156626,"about_ca_system_score_codex":0.00019342161,"about_ca_system_score_gemma":0.0056341244,"threshold_uncertainty_score":0.99946946},"labels":[],"label_agreement":null},{"id":"W2143418376","doi":"10.1200/jco.2003.01.119","title":"Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":378,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; North York General Hospital","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Internal medicine; Chemotherapy; Incidence (geometry); Cognition; Cancer-related fatigue; Cancer; Adjuvant chemotherapy; Oncology; Physical therapy; Psychiatry","score_opus":0.0695634970965898,"score_gpt":0.44396078098476377,"score_spread":0.37439728388817395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143418376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98592407,0.0019326607,0.0006040369,0.008350689,0.001315404,0.00054455403,0.000021383128,0.000009136593,0.0012980484],"genre_scores_gemma":[0.9888133,0.003795534,0.00025861975,0.006065112,0.0007105889,0.00006469961,7.726336e-7,0.000022717883,0.00026866584],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99755085,0.0002586862,0.0014472816,0.00021648667,0.00020704043,0.00031967583],"domain_scores_gemma":[0.9955684,0.0024127464,0.00094860606,0.00005700486,0.0007536226,0.00025960474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025254362,0.00015509044,0.0012735473,0.00015201152,0.000053166175,0.0000067991705,0.000040982974,0.00024361083,0.00030941487],"category_scores_gemma":[0.002787702,0.0001172978,0.000114606766,0.00017383382,0.00023989203,0.0001124337,0.000016117108,0.0006500882,0.0000016902977],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028202849,0.0013752643,0.2769097,0.00006683392,0.001941581,0.00006899507,0.0007879991,0.000005907634,0.0001888157,0.00004885806,0.0028891775,0.687514],"study_design_scores_gemma":[0.032379564,0.01794138,0.9315136,0.00059638993,0.0005281602,0.00031577735,0.0011848743,0.000020345811,0.00003609695,0.0006341552,0.014716238,0.00013340903],"about_ca_topic_score_codex":0.0000115317125,"about_ca_topic_score_gemma":0.000050797335,"teacher_disagreement_score":0.6873806,"about_ca_system_score_codex":0.00038447243,"about_ca_system_score_gemma":0.0010301011,"threshold_uncertainty_score":0.47832656},"labels":[],"label_agreement":null},{"id":"W2143555626","doi":"10.1200/jco.2010.33.5216","title":"Negotiations and Love Songs","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Leadership and Management in Organizations","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Negotiation; Law","score_opus":0.23601074570302294,"score_gpt":0.38730837064207296,"score_spread":0.15129762493905002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143555626","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36022103,0.0002486008,0.011196417,0.06761709,0.006541233,0.00028461806,9.596815e-7,0.000059483322,0.55383056],"genre_scores_gemma":[0.9808574,0.00009541701,0.0023738137,0.013677911,0.002209928,3.495356e-7,8.9119976e-7,0.000011899795,0.00077241025],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987721,0.00002859902,0.0008708543,0.00008965892,0.000119905984,0.00011887358],"domain_scores_gemma":[0.99830985,0.0002557235,0.0010378516,0.00008307153,0.00028491308,0.000028601726],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012224767,0.00006721708,0.00033386194,0.00014437023,0.000042887426,0.000037164304,0.0001709876,0.00011982932,0.00094615645],"category_scores_gemma":[0.0017596699,0.000052325657,0.00010281561,0.00018688911,0.00010819995,0.0007621586,0.000093549424,0.00026303343,0.00031939708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036013746,0.0023373493,0.40756705,0.00010544092,0.00051048776,0.00021052932,0.0014178449,0.000007977045,0.00002978277,0.23759712,0.25357708,0.0962792],"study_design_scores_gemma":[0.0019766865,0.0003299403,0.24086484,0.000014968668,0.00038569854,0.000016784914,0.0023807369,0.00014012534,0.000005613514,0.027626384,0.7261173,0.00014088208],"about_ca_topic_score_codex":0.000031382493,"about_ca_topic_score_gemma":0.000042233594,"teacher_disagreement_score":0.62063634,"about_ca_system_score_codex":0.000012289949,"about_ca_system_score_gemma":0.00007867268,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2143695921","doi":"10.1200/jco.2007.14.4741","title":"Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Queen's University; University of Ottawa","funders":"","keywords":"Medicine; Paclitaxel; Vascular endothelial growth factor; Pharmacokinetics; Carboplatin; Tyrosine-kinase inhibitor; Tyrosine kinase; Kinase; Cancer research; VEGF receptors; Internal medicine; Lung cancer; Pharmacology; Oncology; Chemotherapy; Cancer; Receptor; Cisplatin; Biochemistry; Biology","score_opus":0.06787892216051723,"score_gpt":0.41647834295751407,"score_spread":0.34859942079699685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143695921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768424,0.0012393169,0.0000295712,0.00007419324,0.0003008131,0.0005502135,0.00011261672,4.897307e-7,0.0000085475995],"genre_scores_gemma":[0.9974327,0.0019359423,0.00025119368,0.00013268585,0.00019957092,0.000021107135,0.0000107121205,0.000012081278,0.0000040184846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965009,0.00075398886,0.00201152,0.00023115707,0.000363546,0.00013886401],"domain_scores_gemma":[0.9968104,0.00040484456,0.001963156,0.00009485105,0.0006149662,0.00011181643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020740307,0.00014811133,0.0011007263,0.000073388284,0.000029596773,0.0000025927568,0.00013619759,0.00014870905,0.0000059908834],"category_scores_gemma":[0.0006540045,0.00009171075,0.000092969436,0.00012998754,0.00028249045,0.00002379326,0.000043268123,0.00024317522,3.8407184e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009695278,0.005604571,0.9672837,0.000051494466,0.00027136898,0.000013103475,0.00015442383,0.0004192331,0.0068671517,0.0000031452507,0.00008855532,0.009547958],"study_design_scores_gemma":[0.060574066,0.021475822,0.9137301,0.000087598775,0.0002111701,0.0000034831564,0.00012300728,0.00019117308,0.0030971186,0.0000031297131,0.00037753605,0.00012578834],"about_ca_topic_score_codex":0.012472307,"about_ca_topic_score_gemma":0.08163271,"teacher_disagreement_score":0.06916041,"about_ca_system_score_codex":0.000066723944,"about_ca_system_score_gemma":0.0020277093,"threshold_uncertainty_score":0.9941037},"labels":[],"label_agreement":null},{"id":"W2143743735","doi":"10.1200/jco.2007.14.9930","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Capecitabine; Clinical endpoint; Chemotherapy; Placebo; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.10032620962901219,"score_gpt":0.4668804551886769,"score_spread":0.3665542455596647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143743735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894973,0.0010727308,0.000028763197,0.0067369626,0.00028001895,0.0020215225,0.0000025117722,0.000008942112,0.00035127162],"genre_scores_gemma":[0.99354494,0.0043964577,0.0004809159,0.001158344,0.00013901165,0.00019486519,0.0000032065975,0.000019979527,0.000062311825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959361,0.0007750411,0.0023511024,0.00023966507,0.0004640964,0.00023401061],"domain_scores_gemma":[0.9944037,0.0035787716,0.0013833796,0.00010873473,0.00037026175,0.00015515681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028083373,0.00022612332,0.0033394857,0.000286936,0.00006611537,0.0000053485924,0.00009952614,0.00012385468,0.00018440916],"category_scores_gemma":[0.0010214963,0.00013234394,0.00034813175,0.0003948616,0.00032037956,0.000078022385,0.000012706113,0.0006461031,0.0000015203648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7567224,0.028157866,0.14377367,0.000010695034,0.0012264624,0.0025547906,0.0022262488,0.00019738635,0.000017768783,0.0000059417284,0.000072901385,0.06503387],"study_design_scores_gemma":[0.7232818,0.09068837,0.18356398,0.00009112885,0.00027607734,0.00013630629,0.0003486132,0.00084381143,0.00006469574,0.000079419675,0.00052256853,0.00010323081],"about_ca_topic_score_codex":0.0007931033,"about_ca_topic_score_gemma":0.0043758964,"teacher_disagreement_score":0.06493064,"about_ca_system_score_codex":0.00046774998,"about_ca_system_score_gemma":0.0021127136,"threshold_uncertainty_score":0.5396829},"labels":[],"label_agreement":null},{"id":"W2143757227","doi":"10.1200/jco.2006.07.7792","title":"Obesity and Outcome in Pediatric Acute Lymphoblastic Leukemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Lymphoblastic Leukemia; Obesity; Pediatrics; Acute lymphocytic leukemia; Pediatric cancer; Leukemia; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.10215578156863693,"score_gpt":0.4749654988861562,"score_spread":0.3728097173175193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143757227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905027,0.000570036,0.00040265507,0.0051692314,0.0015757456,0.0001251972,0.0000012363539,0.000010108877,0.0016431038],"genre_scores_gemma":[0.98662955,0.0010547007,0.0032420496,0.0062352126,0.002682933,4.4959157e-7,5.733907e-7,0.000014201102,0.00014031041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493945,0.00032541773,0.0037644648,0.00020455619,0.00045477602,0.00031133342],"domain_scores_gemma":[0.99212784,0.005284221,0.0015956544,0.00017672866,0.00020961458,0.00060593465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011913034,0.00014002675,0.001723721,0.0002748213,0.000025598029,0.000006381921,0.00014905882,0.00045318127,0.00004530727],"category_scores_gemma":[0.0073238933,0.000109615146,0.0003210573,0.00024312706,0.00015978166,0.00010659084,0.00007807013,0.0012175869,0.00001961874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021757334,0.00066903053,0.97962564,0.00005963751,0.00010307541,0.0016125111,0.00018303363,0.0000029463815,0.000009739813,0.00006207205,0.0010398995,0.014456707],"study_design_scores_gemma":[0.009330252,0.004351937,0.9796577,0.0000468677,0.00042565152,0.0008269063,0.00010507795,0.00001865193,0.000008825355,0.00034342526,0.0047868304,0.00009786209],"about_ca_topic_score_codex":0.0000686927,"about_ca_topic_score_gemma":0.0003821754,"teacher_disagreement_score":0.014358846,"about_ca_system_score_codex":0.0004734125,"about_ca_system_score_gemma":0.0020047105,"threshold_uncertainty_score":0.8767913},"labels":[],"label_agreement":null},{"id":"W2143775811","doi":"10.1200/jco.2012.46.6193","title":"Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Department of Defense; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; U.S. Navy; U.S. Public Health Service","keywords":"Medicine; Transplantation; Internal medicine; Cord blood; Myelodysplastic syndromes; Hematopoietic stem cell transplantation; Population; Myeloid leukemia; Surgery; Myeloid; Cohort; Bone marrow","score_opus":0.056780740902339956,"score_gpt":0.3408962704935819,"score_spread":0.2841155295912419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143775811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982195,0.0000775088,0.00023359017,0.00030975934,0.00026960223,0.00078987126,0.0000142773315,0.000005880103,0.00008000273],"genre_scores_gemma":[0.9947791,0.0012774969,0.0036663106,0.00011762074,0.000051337236,0.000022102147,0.000009218833,0.000025626074,0.00005119942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99464434,0.00061272754,0.0037335164,0.00027198216,0.0004687316,0.00026870338],"domain_scores_gemma":[0.9952665,0.0021552409,0.0016289225,0.00020189711,0.00041954766,0.00032791647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282424,0.00020890466,0.0015527682,0.00031724403,0.000017131946,0.000014169081,0.000095105745,0.0004122136,0.0001328203],"category_scores_gemma":[0.00042739644,0.00016251812,0.00028877443,0.00020518844,0.00023573835,0.00022494963,0.000018045755,0.000566942,0.0000033201866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007073213,0.0024154296,0.71027756,0.0013547785,0.00029166872,0.0018590431,0.002342742,0.000072504896,0.2727264,0.000022339134,0.000012421973,0.0015519012],"study_design_scores_gemma":[0.010454814,0.0034964327,0.9617771,0.0007007168,0.0005895197,0.00022074686,0.00047674918,0.000042441367,0.0220484,0.000031107855,0.000022109487,0.0001398942],"about_ca_topic_score_codex":0.0004275945,"about_ca_topic_score_gemma":0.00014718287,"teacher_disagreement_score":0.2514995,"about_ca_system_score_codex":0.00008972873,"about_ca_system_score_gemma":0.00055826834,"threshold_uncertainty_score":0.6627297},"labels":[],"label_agreement":null},{"id":"W2144166819","doi":"10.1200/jco.2005.02.7482","title":"Risk Factors and Therapy for Isolated Central Nervous System Relapse of Pediatric Acute Myeloid Leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Myeloid leukemia; Central nervous system; Oncology; Pediatrics; Intensive care medicine; Internal medicine","score_opus":0.062822204268044,"score_gpt":0.41274447062483166,"score_spread":0.3499222663567877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144166819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941895,0.0016641242,0.0006073779,0.0019198363,0.0007467663,0.0005554794,0.00002967631,0.00002004281,0.00026720308],"genre_scores_gemma":[0.9724894,0.017729504,0.005918497,0.00034074113,0.00323144,0.0000045410025,0.0000052729047,0.000038255323,0.00024233217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953326,0.00055003347,0.0029226232,0.00025891315,0.0004441189,0.0004917219],"domain_scores_gemma":[0.99162686,0.004099937,0.0025941567,0.00025191772,0.00072611216,0.0007010369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003530964,0.00021810185,0.0020075063,0.00027259917,0.000070801056,0.000010146703,0.00026219612,0.00075041555,0.00003893122],"category_scores_gemma":[0.0028358782,0.00013844848,0.00068658014,0.00024175356,0.00022225165,0.00015612827,0.00006358949,0.0017114609,0.0000058762985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038000457,0.0013762825,0.62093633,0.00022956227,0.003155914,0.0005580728,0.0006733179,0.00016086643,0.0012654538,0.0001161064,0.023237107,0.31029055],"study_design_scores_gemma":[0.042141616,0.045429446,0.84466165,0.00009468397,0.0025652072,0.0012726729,0.000518136,0.006886336,0.00069976447,0.00007287215,0.055360135,0.00029749546],"about_ca_topic_score_codex":0.00005712347,"about_ca_topic_score_gemma":0.000009715265,"teacher_disagreement_score":0.30999306,"about_ca_system_score_codex":0.0008489632,"about_ca_system_score_gemma":0.0037357553,"threshold_uncertainty_score":0.7435541},"labels":[],"label_agreement":null},{"id":"W2144216228","doi":"10.1200/jco.2009.25.9606","title":"Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Maximum tolerated dose; Medicine; Clinical trial; Therapeutic index; Cancer; Toxicity; Effective dose (radiation); Pharmacology; Limiting; Oncology; Internal medicine; Nuclear medicine; Drug","score_opus":0.9418097147584127,"score_gpt":0.8078207380371335,"score_spread":0.13398897672127918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144216228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065476224,0.9377735,0.017346103,0.001263565,0.02343373,0.011995731,0.0011724478,0.000041532192,0.00042577204],"genre_scores_gemma":[0.000099415585,0.74033946,0.25459158,0.00032918647,0.004186805,0.00023687915,0.00001246305,0.00014825547,0.000055954948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8869807,0.050398972,0.059434272,0.0010391803,0.0012304325,0.00091640843],"domain_scores_gemma":[0.279314,0.6701155,0.047177587,0.00094228785,0.0015776163,0.00087301346],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.28726527,0.0007824951,0.031130519,0.00068699755,0.000061149345,0.000033467728,0.0015868972,0.0051844907,0.00064439874],"category_scores_gemma":[0.90636283,0.00055483193,0.006962605,0.0007349363,0.00071261957,0.00013422176,0.00025814434,0.008258378,0.000006247647],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002601364,0.0082651,0.00028719107,0.0055851904,0.0013487713,0.0002501738,0.000028758095,0.0000040638743,0.0000053061362,0.001575973,0.0020856739,0.97796243],"study_design_scores_gemma":[0.049909662,0.012542689,0.00025284736,0.017352125,0.009235348,0.000012781342,0.0000133280255,0.00035610178,0.0000055019523,0.19221698,0.71743304,0.0006695904],"about_ca_topic_score_codex":0.000060843253,"about_ca_topic_score_gemma":0.00047269254,"teacher_disagreement_score":0.97729284,"about_ca_system_score_codex":0.0004157843,"about_ca_system_score_gemma":0.0058192615,"threshold_uncertainty_score":0.99981683},"labels":[],"label_agreement":null},{"id":"W2144293828","doi":"10.1200/jco.2014.57.7999","title":"Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Internal medicine; Immunohistochemistry; Hazard ratio; Cohort; Progesterone receptor; Cytokeratin; Estrogen receptor; Risk factor; Radiation therapy; Lapatinib; Cancer; Pathology; Trastuzumab; Confidence interval","score_opus":0.05554085207723424,"score_gpt":0.407798687810348,"score_spread":0.35225783573311376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144293828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903159,0.002174133,0.00033254412,0.004696083,0.0016137281,0.00012888986,0.0006499515,0.0000039620763,0.00008478035],"genre_scores_gemma":[0.9916675,0.0043398323,0.0006041986,0.00050240144,0.002713031,0.000014003942,0.000025593246,0.000022380955,0.00011104646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973194,0.00029400052,0.0015291771,0.00030044754,0.00035532948,0.00020167054],"domain_scores_gemma":[0.9959066,0.00023371272,0.0025927862,0.00029804916,0.0007154107,0.00025342454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015523441,0.00018375716,0.00094472297,0.000055522243,0.000038553448,0.000010843296,0.0003041623,0.00036220605,0.000054208867],"category_scores_gemma":[0.00025960698,0.0001416733,0.00040645775,0.000077342,0.0003110231,0.000015111825,0.00007431511,0.0003017722,0.000004890498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00852684,0.0009796824,0.8953083,0.000008087598,0.002122139,0.00002449012,0.0001210834,0.000113842776,0.0074997544,0.000010429458,0.0046352837,0.08065005],"study_design_scores_gemma":[0.0053980136,0.0012032802,0.98081905,0.00004145577,0.00047555094,0.0003033358,0.00014124643,0.000028427763,0.0039948747,0.000099408775,0.007350516,0.00014486707],"about_ca_topic_score_codex":0.0007226077,"about_ca_topic_score_gemma":0.0003756804,"teacher_disagreement_score":0.0855107,"about_ca_system_score_codex":0.00014991961,"about_ca_system_score_gemma":0.00088813656,"threshold_uncertainty_score":0.57772696},"labels":[],"label_agreement":null},{"id":"W2144530367","doi":"10.1200/jco.2003.11.045","title":"Safety and Toxicity Analysis of Oxaliplatin Combined With Fluorouracil or as a Single Agent in Patients With Previously Treated Advanced Colorectal Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oxaliplatin; Medicine; Irinotecan; Mucositis; Regimen; Internal medicine; Fluorouracil; Colorectal cancer; Population; Cohort; Surgery; Toxicity; Oncology; Chemotherapy; Gastroenterology; Cancer","score_opus":0.04753629034186599,"score_gpt":0.390635002410347,"score_spread":0.34309871206848097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144530367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972399,0.00029305185,0.000008142593,0.00033765126,0.00008304623,0.0005393858,0.0000103820985,0.000004377529,0.0014840845],"genre_scores_gemma":[0.9980937,0.0005990644,0.00090309425,0.00020284837,0.000019431227,0.000014727739,0.0000045044376,0.000010805309,0.00015181719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975406,0.00028613335,0.001428906,0.0002119779,0.0003279752,0.00020443992],"domain_scores_gemma":[0.996991,0.00088377425,0.0013042671,0.000097630706,0.00051579427,0.00020753947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006258096,0.00017454945,0.0021756382,0.00018376799,0.000037816695,0.0000039986953,0.000048431888,0.00013803277,0.0001611623],"category_scores_gemma":[0.0009762129,0.00008967086,0.00018032681,0.00062288844,0.00020545174,0.000072759336,0.000019750845,0.0002934739,2.7139487e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1876962,0.0036330845,0.7767598,0.000017671764,0.0035780878,0.00017115299,0.00030985972,0.00013759534,0.00003648329,0.000006659566,0.00001570728,0.027637703],"study_design_scores_gemma":[0.042669315,0.10491938,0.84805566,0.00013534407,0.003152257,0.00001920543,0.00014453208,0.000028203724,0.00021734559,0.0000052717683,0.00056203303,0.00009144948],"about_ca_topic_score_codex":0.000117844844,"about_ca_topic_score_gemma":0.005286241,"teacher_disagreement_score":0.14502689,"about_ca_system_score_codex":0.00038909825,"about_ca_system_score_gemma":0.0008058163,"threshold_uncertainty_score":0.36566713},"labels":[],"label_agreement":null},{"id":"W2144595333","doi":"10.1200/jco.2011.41.2734","title":"Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Radioactive iodine; Thyroid cancer; Stage (stratigraphy); Randomized controlled trial; Adjuvant; Oncology; Cancer; Papillary thyroid cancer; Thyroid; Internal medicine; Nuclear medicine","score_opus":0.07421182032355828,"score_gpt":0.43787931138421055,"score_spread":0.36366749106065227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144595333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775953,0.0018714808,0.00041614496,0.0013957132,0.0024331613,0.0058569512,0.00004378777,0.0000067238702,0.000216525],"genre_scores_gemma":[0.986119,0.0053195264,0.0055385637,0.0006842405,0.0016690695,0.00053092506,0.00000962684,0.000027618406,0.000101459955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952335,0.0007449557,0.002973578,0.0002133514,0.0005250437,0.00030957596],"domain_scores_gemma":[0.98187053,0.013148045,0.0037305364,0.00021816803,0.0005878663,0.0004448786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002589144,0.0002811697,0.0066146124,0.00014772295,0.000043268432,0.0000064246738,0.00009401296,0.00025306482,0.000077796],"category_scores_gemma":[0.001697931,0.00013097964,0.0018153379,0.00007773807,0.0001869828,0.00009919945,0.000019103705,0.00027437066,0.0000023239274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9096054,0.017909616,0.015448984,0.0000129846485,0.0046870615,0.000032035354,0.0001385224,0.000027512911,0.000008056731,0.00005236937,0.0005495209,0.05152794],"study_design_scores_gemma":[0.8394293,0.12759459,0.020675668,0.00022336422,0.0032343094,0.0000062661393,0.000016468046,0.000038941387,0.00010042297,0.00002714462,0.008555568,0.00009792631],"about_ca_topic_score_codex":0.000040028357,"about_ca_topic_score_gemma":0.000009413247,"teacher_disagreement_score":0.10968497,"about_ca_system_score_codex":0.00051129627,"about_ca_system_score_gemma":0.00092782144,"threshold_uncertainty_score":0.5341194},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2144702324","doi":"10.1200/jco.2005.09.064","title":"Humor and Oncology","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Humor Studies and Applications","field":"Psychology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Specialty; Patient care; Alternative medicine; MEDLINE; Family medicine; Oncology; Nursing; Pathology","score_opus":0.2542699197166042,"score_gpt":0.5961172221865416,"score_spread":0.34184730246993744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144702324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67167294,0.001707761,0.00019745786,0.060767572,0.0020086989,0.00012967744,0.0000033892327,0.000014334725,0.26349816],"genre_scores_gemma":[0.98143065,0.0007070045,0.0062623955,0.005699714,0.0035664367,0.000009743756,3.8928496e-7,0.000011409656,0.0023122458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972805,0.0003793632,0.0018207924,0.00017283563,0.00011586514,0.00023069122],"domain_scores_gemma":[0.99577105,0.0023881418,0.0012649155,0.00016730014,0.00013535694,0.00027322286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025995558,0.000096168704,0.00093173364,0.00006578407,0.000077836936,0.0000057422253,0.00020819656,0.00032270057,0.001292085],"category_scores_gemma":[0.0007089802,0.0000710806,0.000224766,0.00008161554,0.00031144384,0.000035660232,0.00007524291,0.00079140125,0.00029659536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000406954,0.0015240303,0.0065424093,0.000002222226,0.00026903217,0.00013360608,0.0013593433,0.000002772011,0.000028825383,0.026333783,0.094929606,0.8684674],"study_design_scores_gemma":[0.0024266527,0.0036406575,0.09260606,0.000004004323,0.00008598044,0.00038295373,0.0014753436,0.000008364109,0.0000026325024,0.0007782148,0.8985226,0.000066520115],"about_ca_topic_score_codex":0.000010601358,"about_ca_topic_score_gemma":0.000103771796,"teacher_disagreement_score":0.8684009,"about_ca_system_score_codex":0.0000781845,"about_ca_system_score_gemma":0.0002886267,"threshold_uncertainty_score":0.99962085},"labels":[],"label_agreement":null},{"id":"W2145069806","doi":"10.1200/jco.2007.11.6798","title":"Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Letrozole; Tamoxifen; Hazard ratio; Breast cancer; Cohort; Internal medicine; Gynecology; Cancer; Oncology; Confidence interval","score_opus":0.03888033570412189,"score_gpt":0.3622892193645039,"score_spread":0.323408883660382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145069806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985623,0.0006292522,0.000017295219,0.0003241305,0.00012357564,0.00015041727,0.000023102803,0.0000025933841,0.00016737425],"genre_scores_gemma":[0.9963776,0.0021815596,0.0005138893,0.00022892632,0.00019984445,0.000010125524,0.000002511579,0.000020890333,0.00046464903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980881,0.00022188592,0.0010218502,0.00020446054,0.00018045536,0.00028322946],"domain_scores_gemma":[0.9983708,0.00011531659,0.00097652094,0.00018252467,0.00013818372,0.00021660347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005022663,0.00015947266,0.0009829099,0.000069840404,0.00002496688,0.0000036737886,0.00016396743,0.00029819185,0.000015624211],"category_scores_gemma":[0.00003973388,0.00009818607,0.00016249949,0.00009512965,0.00031348574,0.000009867721,0.000040146366,0.0003773855,0.0000019533968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037239473,0.0026846605,0.76976013,0.00003629649,0.0018374074,0.002451782,0.0006482471,0.0007246888,0.08258705,0.000011298855,0.00018164776,0.101837285],"study_design_scores_gemma":[0.009492449,0.03136616,0.9515805,0.000049103197,0.00007881991,0.00035619555,0.00005851731,0.00002922947,0.001627799,0.0000062758622,0.0052073877,0.00014754626],"about_ca_topic_score_codex":0.0001467719,"about_ca_topic_score_gemma":0.000080242775,"teacher_disagreement_score":0.18182036,"about_ca_system_score_codex":0.00009685951,"about_ca_system_score_gemma":0.0007378035,"threshold_uncertainty_score":0.4003912},"labels":[],"label_agreement":null},{"id":"W2145099193","doi":"10.1200/jco.2013.53.1186","title":"Cost Effectiveness of <i>EML4-ALK</i> Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced <i>ALK</i>-Positive Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Home and Community Care Support Services","funders":"Canadian Centre for Applied Research in Cancer Control; Cancer Care Ontario","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Population; Internal medicine; ALK inhibitor; Cost effectiveness; Environmental health","score_opus":0.055664576065031,"score_gpt":0.45262045482489144,"score_spread":0.39695587875986044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145099193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926348,0.00037247312,0.0029084443,0.00054445764,0.0005014418,0.001729141,0.00005579138,0.000006787795,0.0012466928],"genre_scores_gemma":[0.98662394,0.0004270066,0.0120618045,0.00035055232,0.00031510828,0.00010710965,0.000020312084,0.000026810168,0.00006734971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810684,0.00019938497,0.001061983,0.00023983444,0.0001818628,0.00021011966],"domain_scores_gemma":[0.9903983,0.006738959,0.001378691,0.00012714256,0.0010969545,0.00025997235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007922361,0.00018993794,0.0012650769,0.00007226359,0.00009187258,0.0000059940157,0.00005937832,0.00016298583,0.00000719723],"category_scores_gemma":[0.0010807683,0.00011481555,0.00019337397,0.00011351841,0.000116334806,0.00008319107,0.000024836283,0.00021260287,3.9554746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014607049,0.0047524357,0.6368268,0.00039775623,0.0007343163,0.00002613412,0.00023279618,0.0005859544,0.00043401576,0.000009297824,0.00006865631,0.34132478],"study_design_scores_gemma":[0.090396464,0.109815024,0.7842705,0.0018744888,0.0043626647,0.00003148142,0.00006003622,0.0011147063,0.0018354758,0.00006551593,0.005979819,0.00019382377],"about_ca_topic_score_codex":0.000085893764,"about_ca_topic_score_gemma":0.00008381766,"teacher_disagreement_score":0.34113094,"about_ca_system_score_codex":0.0003139423,"about_ca_system_score_gemma":0.00085056864,"threshold_uncertainty_score":0.46820423},"labels":[],"label_agreement":null},{"id":"W2145136050","doi":"10.1200/jco.2005.04.1558","title":"Trastuzumab Cardiac Side Effects: Only Time Will Tell","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Internal medicine; Oncology; Cancer; Breast cancer; Chemotherapy","score_opus":0.10497524475678915,"score_gpt":0.5073804816476659,"score_spread":0.40240523689087676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145136050","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076884283,0.0046102307,0.000033978493,0.9195149,0.007057326,0.0009390633,0.000038255323,0.000040681763,0.06007714],"genre_scores_gemma":[0.0015504728,0.005363125,0.0037538197,0.8183977,0.13721003,0.00001823912,0.00004781715,0.00022101137,0.03343777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884752,0.0029046955,0.0049186344,0.00060039666,0.0020980383,0.0010030144],"domain_scores_gemma":[0.9770658,0.017298874,0.0029508823,0.0007621483,0.001050146,0.00087215134],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.008202267,0.0005217475,0.0062826695,0.00048611965,0.00005549763,0.000031683805,0.0008043576,0.0046676993,0.0013418689],"category_scores_gemma":[0.012796869,0.00038202005,0.0027687976,0.0002701342,0.0006766565,0.00015420793,0.00017098324,0.019432193,0.0013761832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010540544,0.0005344368,0.0010537755,0.0003098582,0.0011842184,0.014120271,0.000025492867,0.000001958964,0.000047066515,0.000001550411,0.7378998,0.24376756],"study_design_scores_gemma":[0.005121254,0.022050893,0.0071697,0.00085288595,0.001421723,0.0018634967,0.0000068319227,0.00001346146,0.00003336976,0.000082845276,0.9610841,0.00029942955],"about_ca_topic_score_codex":0.000030329713,"about_ca_topic_score_gemma":0.00000826873,"teacher_disagreement_score":0.24346814,"about_ca_system_score_codex":0.0017978736,"about_ca_system_score_gemma":0.01548875,"threshold_uncertainty_score":0.99986315},"labels":[],"label_agreement":null},{"id":"W2145147251","doi":"10.1200/jco.2010.34.4010","title":"Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"American Society of Clinical Oncology","keywords":"Letrozole; Medicine; Placebo; Hazard ratio; Internal medicine; Breast cancer; Tamoxifen; Proportional hazards model; Oncology; Cancer; Confidence interval","score_opus":0.3494892352734993,"score_gpt":0.5207366562885289,"score_spread":0.17124742101502965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145147251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976046,0.000782142,0.000041330903,0.00019304181,0.00062971195,0.0002832921,0.000026648928,0.0000011368147,0.00043806978],"genre_scores_gemma":[0.9976592,0.00030285792,0.0013781657,0.00016628871,0.00036600823,0.00003913083,0.00000416772,0.000011275725,0.00007287572],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99788296,0.00025734917,0.0013549977,0.00016799063,0.00015336713,0.00018336011],"domain_scores_gemma":[0.9970118,0.0012267242,0.0013166822,0.00022792173,0.00016297701,0.000053942007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010123801,0.00013721797,0.000982278,0.000061634506,0.000018610865,0.000003481185,0.00022305457,0.00021809549,0.000025885194],"category_scores_gemma":[0.001176449,0.00008455084,0.0006471637,0.000062157684,0.0002303878,0.0000075138964,0.000059104,0.00010520124,7.8640034e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56885034,0.0054472284,0.36070117,0.000041865558,0.004249823,0.00014119873,0.0019068258,0.000044632703,0.0012071986,0.000022147713,0.0011528212,0.056234773],"study_design_scores_gemma":[0.100887544,0.018328106,0.8737591,0.00002706856,0.00093218667,0.000013370312,0.00052964425,0.0000026988619,0.0027548778,0.000054879278,0.0025958263,0.0001147309],"about_ca_topic_score_codex":0.00006261171,"about_ca_topic_score_gemma":0.00031991728,"teacher_disagreement_score":0.5130579,"about_ca_system_score_codex":0.000056501365,"about_ca_system_score_gemma":0.00031559228,"threshold_uncertainty_score":0.34478834},"labels":[],"label_agreement":null},{"id":"W2145304413","doi":"10.1200/jco.2005.09.137","title":"Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":989,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; International Prognostic Index; Internal medicine; Vincristine; Diffuse large B-cell lymphoma; Prednisone; CHOP; Population; Cyclophosphamide; Lymphoma; Gastroenterology; Oncology; Surgery; Chemotherapy","score_opus":0.04227816456457361,"score_gpt":0.3824355696899724,"score_spread":0.34015740512539877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145304413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991711,0.0005832715,0.000025130315,0.0063381996,0.00058096007,0.00037507524,0.000010409748,0.000006846654,0.00036907743],"genre_scores_gemma":[0.9926847,0.0015692906,0.0033438383,0.0011061616,0.0008824282,0.000009096997,0.0000055400783,0.00001814962,0.00038079973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490464,0.00032456702,0.00394853,0.00020948488,0.0003516822,0.00026107987],"domain_scores_gemma":[0.99574536,0.0011140881,0.002159519,0.00026001726,0.00047622502,0.00024480806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00222366,0.00012312084,0.0023938287,0.00009560715,0.000023740935,0.000017088558,0.00016048174,0.0003865047,0.00030982276],"category_scores_gemma":[0.001804552,0.00012290696,0.0005880951,0.00016615033,0.00018939351,0.000115874005,0.00004495206,0.0003204963,0.000008702478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045747403,0.13870041,0.58617836,0.00009498622,0.0004222497,0.00032031653,0.00012929432,0.0000033427427,0.00052684185,0.000039214523,0.0055613923,0.26344886],"study_design_scores_gemma":[0.20721722,0.013385055,0.75928354,0.00008078486,0.00022583731,0.00020870838,0.00008532662,0.00031825138,0.00028166,0.00009412729,0.018729296,0.00009022317],"about_ca_topic_score_codex":0.0009784792,"about_ca_topic_score_gemma":0.004751514,"teacher_disagreement_score":0.26335865,"about_ca_system_score_codex":0.00042997947,"about_ca_system_score_gemma":0.00091239496,"threshold_uncertainty_score":0.5012},"labels":[],"label_agreement":null},{"id":"W2145311197","doi":"10.1200/jco.2012.47.3520","title":"Prospective Multicenter Study Evaluating the Survival of Patients With Locally Advanced Cervical Cancer Undergoing Laparoscopic Para-Aortic Lymphadenectomy Before Chemoradiotherapy in the Era of Positron Emission Tomography Imaging","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Achieve Life Sciences (Canada); Institut national de psychiatrie légale Philippe-Pinel","funders":"","keywords":"Medicine; Cervical cancer; Chemoradiotherapy; Lymphadenectomy; Prospective cohort study; Carcinosis; Positron emission tomography; Metastasis; Radiology; Radiation therapy; Stage (stratigraphy); Adenosquamous carcinoma; Adenocarcinoma; Cancer; Nuclear medicine; Surgery; Internal medicine","score_opus":0.043118099752622194,"score_gpt":0.43644305035438874,"score_spread":0.39332495060176653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145311197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952645,0.0005432764,0.000027901184,0.002281196,0.00030453174,0.0014928475,0.0000023039818,0.0000035867945,0.00007986577],"genre_scores_gemma":[0.99829197,0.00009219663,0.0006817184,0.0006441933,0.00020546763,0.00005937086,0.0000014048711,0.000016740249,0.000006940544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606967,0.0008249464,0.0018068108,0.00021810654,0.00083451346,0.00024596235],"domain_scores_gemma":[0.99486065,0.002434543,0.0016113597,0.00022292635,0.0007387621,0.00013175538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017157273,0.00017804748,0.0013523984,0.00009613914,0.000051299707,0.000010309891,0.00025815397,0.00009838752,0.00009071891],"category_scores_gemma":[0.00091239705,0.00007713782,0.00027590315,0.00049834413,0.00020716451,0.00014318318,0.00003991679,0.0006401688,5.3562655e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009690828,0.0045937696,0.9088157,0.000049670398,0.00044313172,0.000013429045,0.0009345407,0.00004333103,0.0001965929,0.000002187525,0.0000044629146,0.07521239],"study_design_scores_gemma":[0.043323852,0.024663277,0.9296126,0.00037017386,0.00044275532,0.0000034188236,0.001053715,0.00020684116,0.00015169338,0.00010335807,0.0000055694045,0.00006276592],"about_ca_topic_score_codex":0.0003000878,"about_ca_topic_score_gemma":0.00026506186,"teacher_disagreement_score":0.075149626,"about_ca_system_score_codex":0.0002292944,"about_ca_system_score_gemma":0.00070285186,"threshold_uncertainty_score":0.3145589},"labels":[],"label_agreement":null},{"id":"W2145606621","doi":"10.1200/jco.2005.03.9628","title":"Health-Related Quality of Life Among Child and Adolescent Survivors of Childhood Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Public Health Agency of Canada; Children’s Health Research Institute; Hospital for Sick Children; University of Toronto; Western University","funders":"","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Radiation therapy; Pediatrics; Cancer; Late effect; Cohort; Childhood cancer; Population; Pediatric cancer; Internal medicine; Psychiatry","score_opus":0.09717660806242057,"score_gpt":0.4545275591094161,"score_spread":0.35735095104699555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145606621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9476954,0.008711968,0.000046211502,0.04046408,0.0012256992,0.00034823018,0.00002754819,0.000013324782,0.0014675575],"genre_scores_gemma":[0.991288,0.0023935256,0.0005533764,0.0045229304,0.0011467909,0.0000020490083,0.0000051054244,0.000027782287,0.000060438953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98782,0.0018262209,0.008873883,0.00029893804,0.0008448272,0.00033608015],"domain_scores_gemma":[0.987011,0.0019852826,0.009352437,0.0003372922,0.0006354885,0.00067849417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011043937,0.00022774865,0.0042794445,0.00019983189,0.000052074567,0.0000044170124,0.00021884197,0.00051009294,0.00010754552],"category_scores_gemma":[0.0049120197,0.00018280257,0.0007550959,0.000286751,0.0007491757,0.00011096894,0.00008747778,0.001485659,0.0000014766894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025493326,0.0047084903,0.9683786,0.00060464395,0.00060499134,0.000014957388,0.00050208555,0.000052992,0.000025757718,0.00026155665,0.0049855863,0.01731099],"study_design_scores_gemma":[0.009900564,0.0044665886,0.98058796,0.0010966572,0.0002012899,0.000061558436,0.0002933504,0.000011717165,0.00005768414,0.00036616012,0.0028182478,0.00013824813],"about_ca_topic_score_codex":0.009982878,"about_ca_topic_score_gemma":0.0068284445,"teacher_disagreement_score":0.04359262,"about_ca_system_score_codex":0.00014062565,"about_ca_system_score_gemma":0.0029005841,"threshold_uncertainty_score":0.99660975},"labels":[],"label_agreement":null},{"id":"W2145672767","doi":"10.1200/jco.2004.08.015","title":"Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Medicine; Etoposide; Germ cell tumors; Regimen; Cisplatin; Chemotherapy; Bleomycin; Surgery; Internal medicine; Urology; Gastroenterology; Oncology","score_opus":0.01662651094571887,"score_gpt":0.3580601541987576,"score_spread":0.3414336432530387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145672767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294436,0.0041313376,0.00012666147,0.00043462022,0.00012471463,0.002191159,0.00003003874,0.0000127212725,0.0000043966315],"genre_scores_gemma":[0.99021745,0.0070266854,0.002128951,0.0002245249,0.00030035825,0.000039089693,0.00001137482,0.000046477984,0.0000050963595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554217,0.0008895215,0.0022475743,0.00048497642,0.0005145115,0.00032126496],"domain_scores_gemma":[0.99472433,0.0008903661,0.0034367114,0.0001987852,0.00030968874,0.00044010716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018368552,0.00038573018,0.003248604,0.00037645546,0.00006788663,0.000023414572,0.000119878365,0.0002903236,0.000016337632],"category_scores_gemma":[0.00042777145,0.0002190905,0.00015849563,0.0003385292,0.00035413817,0.00015306911,0.0000737509,0.0008128395,4.2353724e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2054822,0.010774426,0.77026546,0.0000909182,0.0006100737,0.0003385701,0.00031451706,0.000030974934,0.000004078782,0.000014326953,0.0000119645165,0.012062467],"study_design_scores_gemma":[0.36094925,0.03607633,0.59940284,0.00023441255,0.002795235,0.00019099384,0.00009499409,0.000015956111,0.000007525006,0.00009315729,0.000001488635,0.00013782007],"about_ca_topic_score_codex":0.0013133708,"about_ca_topic_score_gemma":0.0008906016,"teacher_disagreement_score":0.17086263,"about_ca_system_score_codex":0.00023396197,"about_ca_system_score_gemma":0.00094061776,"threshold_uncertainty_score":0.89342517},"labels":[],"label_agreement":null},{"id":"W2145717684","doi":"10.1200/jco.2009.24.1893","title":"Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"CHOP; Medicine; BCL6; International Prognostic Index; Diffuse large B-cell lymphoma; Lymphoma; Internal medicine; Rituximab; Germinal center; Oncology; Tissue microarray; Cyclophosphamide; Immunohistochemistry; Cancer research; Gastroenterology; Immunology; B cell; Chemotherapy; Antibody","score_opus":0.02339374818953702,"score_gpt":0.32019685495722044,"score_spread":0.2968031067676834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145717684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666923,0.00019508097,0.00006398911,0.000074706935,0.002066039,0.00021225725,0.00003699708,0.0000061892597,0.000675497],"genre_scores_gemma":[0.99639183,0.0002891848,0.0007965997,0.00025868378,0.0018789229,0.0000067883493,0.000023540859,0.000037235037,0.00031720693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997442,0.00030472135,0.0011208783,0.00037093472,0.00036284924,0.00039860926],"domain_scores_gemma":[0.9977957,0.0001769085,0.000871437,0.00037097954,0.00039258436,0.00039239338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008632406,0.00023892836,0.0009235458,0.00010051962,0.000052496576,0.000018422836,0.00030888204,0.0006658184,0.000045113153],"category_scores_gemma":[0.0005756747,0.00015080509,0.00020224634,0.00012474375,0.00016801251,0.000024707624,0.000090419526,0.00063120114,0.0000038108672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013041421,0.013212729,0.8332864,0.000017894838,0.00014721013,0.00005162295,0.000082179715,0.0000061580995,0.11788034,0.0000055658465,0.0010160094,0.021252446],"study_design_scores_gemma":[0.05318265,0.007837743,0.7767092,0.000032884116,0.000077497105,0.000022675236,0.000047698122,0.000004035541,0.015001004,0.0000040490504,0.14686397,0.00021659046],"about_ca_topic_score_codex":0.000024362324,"about_ca_topic_score_gemma":0.0003944159,"teacher_disagreement_score":0.14584796,"about_ca_system_score_codex":0.00002878134,"about_ca_system_score_gemma":0.0009852941,"threshold_uncertainty_score":0.6149653},"labels":[],"label_agreement":null},{"id":"W2145795643","doi":"10.1200/jco.2011.38.1103","title":"Prospective Study of 2-[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Sentinel lymph node; Axilla; Axillary Lymph Node Dissection; Positron emission tomography; Axillary lymph nodes; Lymph; Lymph node; Radiology; Biopsy; Fluorodeoxyglucose; Prospective cohort study; Nuclear medicine; Cancer; Internal medicine; Pathology","score_opus":0.04850449148532905,"score_gpt":0.42628123085373093,"score_spread":0.3777767393684019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145795643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799746,0.00020944665,0.0000087212675,0.00031710407,0.00024296052,0.0011085211,0.000036912264,0.0000015624732,0.00007733764],"genre_scores_gemma":[0.9988364,0.00010102552,0.0004949971,0.00012333275,0.00034521418,0.00006135835,0.00001611566,0.000017776336,0.0000038037065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934664,0.0023465392,0.0028417138,0.00040012534,0.0006223542,0.0003228658],"domain_scores_gemma":[0.9954108,0.0006542735,0.0026322976,0.00042522236,0.00061040104,0.00026702086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036441493,0.00026484547,0.0016739414,0.0001601368,0.000041800024,0.0000035740663,0.00044758376,0.000295147,0.000018216968],"category_scores_gemma":[0.00021983952,0.0001615067,0.0003394161,0.00023265892,0.00042781568,0.000041483487,0.00018527184,0.0007767878,9.943783e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02566717,0.0999753,0.86362964,0.000015168618,0.00089716696,0.000022315053,0.0018182332,0.000120814155,0.000028630959,0.000007760739,0.000078739926,0.0077390466],"study_design_scores_gemma":[0.021296,0.063249454,0.91209173,0.00007233816,0.0005717703,0.0000080542795,0.002429216,0.0000067429023,0.000008412273,0.000021766431,0.00011315828,0.00013136328],"about_ca_topic_score_codex":0.0043423143,"about_ca_topic_score_gemma":0.02288181,"teacher_disagreement_score":0.048462074,"about_ca_system_score_codex":0.00030602945,"about_ca_system_score_gemma":0.0016894126,"threshold_uncertainty_score":0.994948},"labels":[],"label_agreement":null},{"id":"W2145856054","doi":"10.1200/jco.2012.43.7376","title":"Proof of Efficacy Is Not Enough: Contemporary Management of Patients With Metastatic Renal Cell Carcinoma With Targeted Therapy","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Targeted therapy; Oncology; Internal medicine; Systemic therapy; Sunitinib; Cancer","score_opus":0.13195757438961989,"score_gpt":0.3748429429331296,"score_spread":0.2428853685435097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145856054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940627,0.0030110409,0.000072717135,0.0501543,0.0005261012,0.0021980905,0.00008700854,0.0000074100803,0.003316349],"genre_scores_gemma":[0.94315994,0.00018171158,0.008963762,0.04549473,0.0010526584,0.000020834272,0.00013684985,0.00010544305,0.0008840589],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99208945,0.00092486,0.00434171,0.00044613107,0.0017152017,0.00048266642],"domain_scores_gemma":[0.98704416,0.0016277893,0.008873876,0.0006955789,0.0013887087,0.0003698748],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016100035,0.0005855161,0.0046598217,0.00036523954,0.000027823715,0.0000059747294,0.0004096655,0.0007502787,0.00026146008],"category_scores_gemma":[0.00008379313,0.00031685468,0.0009629965,0.00024748247,0.00046456038,0.00011974782,0.000079043784,0.0026334045,0.0000061956443],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13711879,0.03267549,0.27399102,0.004359688,0.021281267,0.02123631,0.0009886994,0.000019021256,0.00012899919,0.0000071006207,0.46711323,0.041080393],"study_design_scores_gemma":[0.06276009,0.12393426,0.5525869,0.00096667116,0.0059326566,0.00017911755,0.00007687761,0.0000025691536,0.0069258013,0.000011883238,0.24620038,0.00042280747],"about_ca_topic_score_codex":0.000027673934,"about_ca_topic_score_gemma":0.0000011148235,"teacher_disagreement_score":0.27859586,"about_ca_system_score_codex":0.00024192629,"about_ca_system_score_gemma":0.001973102,"threshold_uncertainty_score":0.99992836},"labels":[],"label_agreement":null},{"id":"W2145863615","doi":"10.1200/jco.2003.04.171","title":"Does Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review","year":2003,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Confidence interval; Head and neck cancer; Breast cancer; Radiation therapy; Odds ratio; Cancer; Distant metastasis; Metastasis; Observational study; Surgery; Internal medicine; Retrospective cohort study; Oncology","score_opus":0.25284811535777557,"score_gpt":0.5745341733220236,"score_spread":0.32168605796424804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145863615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093336,0.9937134,0.000003941105,0.002788971,0.0010087335,0.0020521476,0.0000035498772,0.0000029077503,0.00033300873],"genre_scores_gemma":[0.000024556608,0.99671745,0.00034728073,0.0022134637,0.00028225596,0.00007963436,6.17668e-7,0.000024764111,0.00030995155],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98820543,0.0035446372,0.0074986764,0.00018232505,0.0003403321,0.00022861482],"domain_scores_gemma":[0.98004967,0.0123832,0.006863099,0.00037255665,0.00018545643,0.00014599206],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009591449,0.00032178249,0.01968891,0.00013065708,0.00002581826,0.000003335441,0.00020727469,0.00036426738,0.00004613076],"category_scores_gemma":[0.007262253,0.000095320225,0.002909232,0.00022937884,0.00014596595,0.00002656278,0.000022113703,0.0009137052,0.0000039891847],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008457747,0.00083830504,0.00082445925,0.5050971,0.004380313,0.00038409856,0.00008694186,9.8070736e-8,2.9010161e-8,0.000010096887,0.0008225174,0.48747146],"study_design_scores_gemma":[0.0018186533,0.006714187,0.00011390675,0.4315514,0.011075573,0.00022924677,0.000031798103,4.4122078e-7,5.049076e-8,0.000007922686,0.54837555,0.00008123469],"about_ca_topic_score_codex":0.000012014621,"about_ca_topic_score_gemma":0.000071608025,"teacher_disagreement_score":0.54755306,"about_ca_system_score_codex":0.00057908025,"about_ca_system_score_gemma":0.0025107958,"threshold_uncertainty_score":0.9948648},"labels":[],"label_agreement":null},{"id":"W2145936943","doi":"10.1200/jco.2011.37.7242","title":"Art of Oncology: New Voices Wanted","year":2011,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Empathy and Medical Education","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Family medicine","score_opus":0.14195515813698825,"score_gpt":0.524313960483588,"score_spread":0.3823588023465998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145936943","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007332144,0.0013891216,0.00007107078,0.007168415,0.9552052,0.00023092862,0.0000116196825,0.0000125148135,0.028578961],"genre_scores_gemma":[0.0018724434,0.0072925375,0.004464007,0.001466445,0.9716353,0.000002802241,0.00006049923,0.000040206778,0.01316575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920968,0.00073294726,0.005443594,0.00029537443,0.0011085304,0.0003227623],"domain_scores_gemma":[0.97086096,0.0147178145,0.009961925,0.0004422809,0.0024419648,0.0015750756],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0077921357,0.00027052173,0.0043521696,0.00028783077,0.000024323943,0.000003852778,0.00044662767,0.004868537,0.0012361996],"category_scores_gemma":[0.0835872,0.00018578017,0.0011698671,0.0001789912,0.0005552186,0.00010172504,0.00007685012,0.0059314906,0.00013096911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005375724,0.0030583784,0.00014724095,0.0001521452,0.00063814054,0.00036288908,0.001185729,1.07734486e-7,0.000012338875,0.000016429616,0.8432475,0.14580338],"study_design_scores_gemma":[0.008209149,0.03704986,0.0014792061,0.00081731926,0.0019815678,0.0001427525,0.0006320058,0.0000015085363,0.00003775496,0.00057644723,0.9489415,0.00013087614],"about_ca_topic_score_codex":0.00008321583,"about_ca_topic_score_gemma":0.000076180506,"teacher_disagreement_score":0.1456725,"about_ca_system_score_codex":0.00030252198,"about_ca_system_score_gemma":0.044437014,"threshold_uncertainty_score":0.9996768},"labels":[],"label_agreement":null},{"id":"W2146341139","doi":"10.1200/jco.2014.57.6264","title":"Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; KWF Kankerbestrijding; Royal Adelaide Hospital","keywords":"Medicine; Brief Pain Inventory; Quality of life (healthcare); Mood; Visual analogue scale; Physical therapy; Profile of mood states; Clinical endpoint; Randomized controlled trial; Internal medicine; Chronic pain","score_opus":0.12489938975539847,"score_gpt":0.48114991891316977,"score_spread":0.35625052915777133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146341139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595034,0.00028146143,0.00081244996,0.0011971282,0.00039326394,0.0005417723,0.000043461245,0.0000021452663,0.0007779868],"genre_scores_gemma":[0.9984795,0.00012493011,0.00058415905,0.00054657174,0.00020361519,0.0000032627463,0.000008453009,0.000007202921,0.000042346186],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98813504,0.0056176893,0.005254782,0.00015511127,0.00072248775,0.00011489671],"domain_scores_gemma":[0.9729163,0.016018398,0.0096837925,0.00042371635,0.0007129369,0.00024485815],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025891265,0.00013578302,0.004615048,0.0003976068,0.000017507253,0.0000028407517,0.0001499458,0.00015082042,0.00046932953],"category_scores_gemma":[0.060954597,0.0000748275,0.0026373337,0.00042892798,0.00052804756,0.0000628211,0.000044529468,0.00037893208,3.7685945e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91769993,0.0029729449,0.04352902,0.00022528498,0.0144954035,0.0000041356293,0.000081247716,0.00042631212,0.000098101744,0.0003135965,0.0010605267,0.019093517],"study_design_scores_gemma":[0.4658379,0.013763574,0.5032287,0.000055358014,0.015113559,0.0000016101397,0.0000959485,0.0010351584,0.000018974404,0.0005471142,0.00025134956,0.000050724346],"about_ca_topic_score_codex":0.00008720595,"about_ca_topic_score_gemma":0.000035354507,"teacher_disagreement_score":0.45969972,"about_ca_system_score_codex":0.000040767278,"about_ca_system_score_gemma":0.0012367809,"threshold_uncertainty_score":0.9469554},"labels":[],"label_agreement":null},{"id":"W2146473694","doi":"10.1200/jco.2004.08.080","title":"Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Cisplatin; Medicine; Paclitaxel; Oncology; Cyclophosphamide; Internal medicine; Randomized controlled trial; Ovarian cancer; Chemotherapy; Cancer; Gynecology","score_opus":0.14607261429325288,"score_gpt":0.5286768606947838,"score_spread":0.3826042464015309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146473694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948682,0.0008088852,0.00007946041,0.0015188655,0.0006689575,0.0013865125,0.000011524267,0.0000036304973,0.00065395684],"genre_scores_gemma":[0.9978346,0.00026767008,0.0010347321,0.0005621148,0.00019850083,0.000046608973,0.000004583087,0.000017083798,0.0000340561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98996276,0.002265871,0.006721901,0.00023085119,0.00054439326,0.00027421836],"domain_scores_gemma":[0.9876339,0.006251672,0.005104192,0.00018701541,0.00054303603,0.0002802288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073130177,0.00022038227,0.0063223485,0.00029045192,0.000021941314,0.0000026887215,0.00016966707,0.00032516773,0.00014545604],"category_scores_gemma":[0.004947216,0.00014691245,0.00045575673,0.00040832727,0.0003906114,0.000093173796,0.00005037543,0.0013452697,0.0000012683741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35486874,0.01483512,0.6217692,0.00007796135,0.0006838659,0.00009300907,0.003080136,0.0019717074,0.000038975733,0.000040016104,0.00008110253,0.0024601491],"study_design_scores_gemma":[0.43948475,0.01693889,0.54171735,0.00020116067,0.0004134242,0.000003857748,0.00087103754,0.000049840062,0.00003779009,0.00016324138,0.000043519183,0.00007514982],"about_ca_topic_score_codex":0.007701736,"about_ca_topic_score_gemma":0.01436617,"teacher_disagreement_score":0.084616005,"about_ca_system_score_codex":0.0008021116,"about_ca_system_score_gemma":0.0045803376,"threshold_uncertainty_score":0.9989061},"labels":[],"label_agreement":null},{"id":"W2146488048","doi":"10.1200/jco.2013.53.5633","title":"Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":832,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Cetuximab; Medicine; Common Terminology Criteria for Adverse Events; Mucositis; Rash; Radiation therapy; Internal medicine; Oncology; Cisplatin; Head and neck cancer; Nasopharyngeal carcinoma; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.19146328025452744,"score_gpt":0.5090353940439152,"score_spread":0.31757211378938777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146488048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815715,0.00033453325,0.00394059,0.003664013,0.0012181394,0.0020989059,0.0000120811865,0.000008243763,0.0005663186],"genre_scores_gemma":[0.99438685,0.00035183964,0.0021958451,0.0011331158,0.0014684096,0.000052548654,0.0000057166135,0.000018807455,0.0003868909],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957687,0.00057433994,0.0028421,0.00023367268,0.00032698677,0.00025420042],"domain_scores_gemma":[0.9917262,0.005028547,0.0020256808,0.00014237362,0.00065620587,0.00042097847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049242442,0.00019188655,0.004717557,0.00013480113,0.00006579076,0.000009590556,0.00009182001,0.00022742401,0.00005386102],"category_scores_gemma":[0.0060547194,0.0001072182,0.0003318311,0.0001379648,0.00025503116,0.0000836587,0.000034559336,0.00046023785,8.675748e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91071475,0.0013018482,0.0011096254,0.00007977691,0.00042127408,0.000026334363,0.0005330158,0.000008923266,0.00008658304,0.00006555962,0.0018520983,0.08380019],"study_design_scores_gemma":[0.8740112,0.09652808,0.0012359219,0.00017358524,0.00084145064,0.00003944148,0.00012759655,0.0028470624,0.00014664639,0.000013530148,0.023926822,0.000108617736],"about_ca_topic_score_codex":0.00005517038,"about_ca_topic_score_gemma":0.0001482936,"teacher_disagreement_score":0.095226236,"about_ca_system_score_codex":0.000121438854,"about_ca_system_score_gemma":0.0018136408,"threshold_uncertainty_score":0.7248502},"labels":[],"label_agreement":null},{"id":"W2146512589","doi":"10.1200/jco.2007.11.8851","title":"Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"American Society of Clinical Oncology","keywords":"Medicine; Chemotherapy; Carboplatin; Hazard ratio; Breast cancer; Metastatic breast cancer; Surgery; Internal medicine; ThioTEPA; Oncology; Anthracycline; Autologous stem-cell transplantation; Cyclophosphamide; Cancer; Confidence interval; Cisplatin","score_opus":0.04313492712664521,"score_gpt":0.41637395395101684,"score_spread":0.3732390268243716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146512589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900371,0.00045928083,0.0002742137,0.0058520795,0.00052600924,0.002081164,0.00003463306,0.00002080275,0.00071473955],"genre_scores_gemma":[0.9903064,0.0020258243,0.0032490317,0.0029718517,0.0006130178,0.00009274804,0.000006676684,0.000070116315,0.00066436845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940459,0.0008604437,0.0032578236,0.00040940917,0.0007526089,0.00067377265],"domain_scores_gemma":[0.99256223,0.002378337,0.0035548,0.00029151363,0.0006322655,0.0005808478],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059737507,0.00044523124,0.0060281553,0.00031398077,0.00004393272,0.00001211124,0.00024035598,0.00029646588,0.0014899565],"category_scores_gemma":[0.000046434696,0.00024576334,0.00037041013,0.00044351144,0.00090767554,0.00013215397,0.000017928227,0.0010551861,0.000001535343],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91803044,0.01090329,0.009282416,0.000108143584,0.0042593232,0.0021661688,0.0013958111,0.000079142716,0.00017157807,0.000009708926,0.00054197083,0.053052],"study_design_scores_gemma":[0.87128335,0.09992177,0.020352533,0.00017138,0.0020293044,0.0015938109,0.000556134,0.000015248801,0.0005360862,0.000045074044,0.003258172,0.00023710735],"about_ca_topic_score_codex":0.0003672522,"about_ca_topic_score_gemma":0.0008307095,"teacher_disagreement_score":0.08901848,"about_ca_system_score_codex":0.0011301866,"about_ca_system_score_gemma":0.0058452715,"threshold_uncertainty_score":0.99999946},"labels":[],"label_agreement":null},{"id":"W2146639594","doi":"10.1200/jco.2005.04.002","title":"Talking to a Patient","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.5609945587834297,"score_gpt":0.6285387450555678,"score_spread":0.0675441862721381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146639594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81615674,0.0013421285,0.00031457012,0.14765975,0.0063922615,0.0007641151,0.000005447132,0.00003608896,0.027328882],"genre_scores_gemma":[0.92463464,0.00015033792,0.031155039,0.041633315,0.0021171197,0.000028739998,9.4125215e-7,0.000017484186,0.00026236073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909694,0.0031443879,0.0049562566,0.0001539732,0.00038455235,0.00039139678],"domain_scores_gemma":[0.98641235,0.007834717,0.0034616832,0.00045584698,0.0011473891,0.0006880413],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028024327,0.00010580399,0.0009166567,0.00016363502,0.00027276005,0.0000033110812,0.00052373,0.00045795733,0.00048178603],"category_scores_gemma":[0.01370454,0.00008180193,0.00025295667,0.00019548328,0.0000677291,0.00016826962,0.00030314602,0.0024104088,0.00067955465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001098769,0.00075352483,0.098319344,0.000042358784,0.00007002966,0.000028896013,0.009744835,0.0001329681,0.000026890566,0.0009842813,0.07687124,0.81192684],"study_design_scores_gemma":[0.0017498836,0.0036113118,0.050295133,0.00019061507,0.000023600054,0.000013694158,0.0034071377,0.0000855003,0.0000052628643,0.00041052935,0.94012433,0.000082978346],"about_ca_topic_score_codex":0.000050236813,"about_ca_topic_score_gemma":0.000272198,"teacher_disagreement_score":0.8632531,"about_ca_system_score_codex":0.0005286202,"about_ca_system_score_gemma":0.0028113576,"threshold_uncertainty_score":0.99989104},"labels":[],"label_agreement":null},{"id":"W2146742275","doi":"10.1200/jco.2006.08.7874","title":"Symptom Prevalence, Intensity, and Distress in Patients With Inoperable Lung Cancer in Relation to Time of Death","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Distress; Lung cancer; Quality of life (healthcare); Concordance; Internal medicine; Cancer; Clinical psychology","score_opus":0.030712704215928907,"score_gpt":0.4063740782691529,"score_spread":0.375661374053224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146742275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997907,0.0002725695,0.00004571657,0.00059517066,0.0002876674,0.00016760096,0.000003817582,0.0000014193537,0.00071907585],"genre_scores_gemma":[0.9989668,0.00015577833,0.0001605327,0.00046866137,0.000108978034,0.0000011997447,0.0000011153551,0.0000055607616,0.00013136769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845076,0.000086927095,0.0010231717,0.000105171915,0.00021006138,0.00012388699],"domain_scores_gemma":[0.9985553,0.00044743347,0.0004241096,0.00007322376,0.00034948115,0.0001504704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015682454,0.000061875515,0.00065878977,0.00015085141,0.000006833187,0.000002042417,0.000051221934,0.00015165463,0.000046422323],"category_scores_gemma":[0.0005187595,0.00004302701,0.00004775576,0.0001712212,0.000050841067,0.00007255396,0.000030979052,0.000427382,5.827325e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064672395,0.00039317194,0.97461873,0.000059564998,0.000033343436,0.00004930707,0.00040824877,0.00003893973,0.00001174357,0.000008949854,0.00007970577,0.017831065],"study_design_scores_gemma":[0.004307002,0.0034798377,0.9909434,0.00066557055,0.00007692262,0.000007996572,0.00005627356,0.000052832685,0.000017630347,0.000013353385,0.000335081,0.00004410505],"about_ca_topic_score_codex":0.00029523738,"about_ca_topic_score_gemma":0.0022728995,"teacher_disagreement_score":0.01778696,"about_ca_system_score_codex":0.00018618656,"about_ca_system_score_gemma":0.00028151626,"threshold_uncertainty_score":0.1856786},"labels":[],"label_agreement":null},{"id":"W2146864950","doi":"10.1200/jco.2014.55.5383","title":"End-of-Life Care for Older Patients With Ovarian Cancer Is Intensive Despite High Rates of Hospice Use","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Centers for Medicare and Medicaid Services; Conquer Cancer Foundation; National Palliative Care Research Center; American Cancer Society","keywords":"Medicine; Cancer; Intensive care unit; Ovarian cancer; Hospice care; End-of-life care; Odds ratio; Emergency medicine; Emergency department; Palliative care; Internal medicine; Nursing","score_opus":0.23648612057476326,"score_gpt":0.5245523438265971,"score_spread":0.28806622325183384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146864950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945543,0.0008889072,0.0009290081,0.0023007775,0.0008594856,0.00028419684,0.00005896757,0.0000028040429,0.00012158911],"genre_scores_gemma":[0.98242015,0.00079128786,0.012114181,0.0040600854,0.000520332,0.0000056916947,0.0000098646415,0.00001939103,0.00005900949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972747,0.0002019738,0.0018598957,0.00016300095,0.00031929847,0.0001811362],"domain_scores_gemma":[0.98630905,0.004262635,0.0027171823,0.00018322279,0.0062826993,0.0002452178],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006622288,0.0001440988,0.0018944565,0.00011001886,0.000018770852,0.0000028189588,0.00014027013,0.0002809694,0.00009146777],"category_scores_gemma":[0.010549284,0.00009167839,0.0003606796,0.000115720155,0.00031095956,0.0001074309,0.000033812084,0.00037092782,9.893079e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006409555,0.00047596675,0.9514457,0.00023877624,0.00074346346,0.000009400683,0.0019341272,0.000014422572,0.000051410203,0.00010210182,0.0031416996,0.035433408],"study_design_scores_gemma":[0.0155284265,0.01667672,0.8876635,0.0014146094,0.0007960741,0.0000024478343,0.0010743556,0.000022247485,0.0019185039,0.00007629875,0.074721806,0.00010504003],"about_ca_topic_score_codex":0.00030593813,"about_ca_topic_score_gemma":0.000119798504,"teacher_disagreement_score":0.07158011,"about_ca_system_score_codex":0.00007009539,"about_ca_system_score_gemma":0.0010961698,"threshold_uncertainty_score":0.9977853},"labels":[],"label_agreement":null},{"id":"W2146905270","doi":"10.1200/jco.2005.03.3654","title":"Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK; Pfizer","keywords":"Medicine; Exemestane; Tamoxifen; Postmenopausal women; Breast cancer; Oncology; Gynecology; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Antiestrogen; Cancer","score_opus":0.022301312288951606,"score_gpt":0.38066357738156653,"score_spread":0.35836226509261493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146905270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762654,0.00046887185,0.000012050673,0.00036680631,0.00032315217,0.00096637633,0.000016361855,0.0000010766905,0.00021875676],"genre_scores_gemma":[0.999007,0.00018578673,0.00026018734,0.00019170053,0.00025346712,0.00006034659,0.000003989283,0.000013675484,0.000023866507],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940502,0.002293675,0.0028634027,0.00020317931,0.00036084905,0.0002287079],"domain_scores_gemma":[0.99612623,0.0013341727,0.0019410583,0.00023923766,0.0002499965,0.00010933001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007201275,0.00015215171,0.0020045803,0.000116564515,0.000006752878,0.0000039820015,0.00031256798,0.0003200947,0.000012729086],"category_scores_gemma":[0.0012362943,0.00009445723,0.0002385986,0.00020584969,0.00031963503,0.000009248848,0.000085044034,0.00044023397,2.9164744e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9585262,0.004046751,0.020034887,0.000027477488,0.00047877873,0.00011300141,0.00049703795,0.000049585466,0.012129013,0.0000111320915,0.000081831466,0.0040043225],"study_design_scores_gemma":[0.62624866,0.034209233,0.33829233,0.00007140683,0.00014478689,0.000018151959,0.0004675223,0.0000019971926,0.00022461032,0.00003705743,0.00016628513,0.000117992065],"about_ca_topic_score_codex":0.00038212424,"about_ca_topic_score_gemma":0.0004924182,"teacher_disagreement_score":0.33227754,"about_ca_system_score_codex":0.000065955384,"about_ca_system_score_gemma":0.0008555388,"threshold_uncertainty_score":0.3851854},"labels":[],"label_agreement":null},{"id":"W2146924352","doi":"10.1200/jco.2009.22.9799","title":"Prognostic Acceptance and the Well-Being of Patients Receiving Palliative Care for Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Feeling; Palliative care; Coping (psychology); Anxiety; Cancer; Social support; Family medicine; Psychiatry; Internal medicine; Psychology; Psychotherapist; Nursing","score_opus":0.06312100378231976,"score_gpt":0.4521724547542932,"score_spread":0.3890514509719734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146924352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858526,0.0025527738,0.00017355343,0.007163516,0.001203331,0.0004293653,0.0000035417354,0.0000030416645,0.002618288],"genre_scores_gemma":[0.9945539,0.0018015607,0.00048563463,0.0023941272,0.00069197844,0.000008275185,0.0000012429441,0.000006490393,0.0000567922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828196,0.0001825813,0.001096878,0.000107489286,0.00020126339,0.00012981429],"domain_scores_gemma":[0.9949165,0.0028279966,0.0011744625,0.0000874151,0.0008822074,0.000111398156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010612274,0.000079235346,0.0009169147,0.00003514786,0.000039211503,0.00000472613,0.000096745585,0.00014803202,0.000025515345],"category_scores_gemma":[0.0035010234,0.0000448608,0.0002824723,0.00008029467,0.00016813408,0.0000497561,0.00001729104,0.00040098556,2.780958e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006317393,0.00018740169,0.65254694,0.00008277054,0.00012082613,0.000007429752,0.0034899826,0.000006751158,0.0000036597703,0.00023554752,0.0003828831,0.3366184],"study_design_scores_gemma":[0.009780196,0.0059764334,0.962726,0.0003176411,0.00043097927,0.0000028270083,0.0011946375,0.000045786062,0.000037444373,0.0009696513,0.018466454,0.00005197869],"about_ca_topic_score_codex":0.000023582903,"about_ca_topic_score_gemma":0.00038289075,"teacher_disagreement_score":0.33656642,"about_ca_system_score_codex":0.00007842915,"about_ca_system_score_gemma":0.00046533198,"threshold_uncertainty_score":0.4191305},"labels":[],"label_agreement":null},{"id":"W2146996443","doi":"10.1200/jco.2012.45.3886","title":"<i>Journal of Clinical Oncology</i> Update on Progress in Cancer Survivorship Care and Research","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Survivorship curve; Cancer survivorship; Clinical Oncology; Oncology; Internal medicine; Cancer; Family medicine","score_opus":0.35785561960753043,"score_gpt":0.607077040947653,"score_spread":0.2492214213401226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146996443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531939,0.021087794,0.0000051092456,0.013175629,0.008485096,0.00024847605,0.0000074384125,0.000004951437,0.0037915816],"genre_scores_gemma":[0.97649014,0.011177481,0.00065697165,0.0028286835,0.008712912,0.0000084336825,0.0000017161611,0.00003137216,0.0000922713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98801106,0.004603129,0.0052571767,0.00026653116,0.001172635,0.0006894803],"domain_scores_gemma":[0.984887,0.008158656,0.0030353947,0.0002906621,0.002332849,0.0012954286],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.038345214,0.00021074509,0.0029924717,0.00047047003,0.000059585414,0.000016370755,0.0003776651,0.0011559294,0.00016984902],"category_scores_gemma":[0.0071226475,0.00014461059,0.0007186449,0.00044623305,0.0009914418,0.00024572216,0.00014480001,0.005884993,0.000012954217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010185481,0.0018528121,0.6157991,0.00008120719,0.00017840133,0.00058107625,0.0010834767,0.0000012696088,0.0000036238353,0.00011063809,0.0045151883,0.36560768],"study_design_scores_gemma":[0.010009714,0.028645933,0.64485544,0.00053089496,0.00027419382,0.00046743418,0.0032400137,0.00000439092,0.000043409804,0.00013545236,0.3116628,0.0001303241],"about_ca_topic_score_codex":0.0002547311,"about_ca_topic_score_gemma":0.003531502,"teacher_disagreement_score":0.36547735,"about_ca_system_score_codex":0.0005218617,"about_ca_system_score_gemma":0.0055223163,"threshold_uncertainty_score":0.99640846},"labels":[],"label_agreement":null},{"id":"W2147013683","doi":"10.1200/jco.2012.43.2674","title":"Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University","funders":"National Cancer Institute","keywords":"Medicine; Procarbazine; Lomustine; Internal medicine; Hazard ratio; Oligodendroglial Tumor; Vincristine; Oligodendroglioma; Gastroenterology; Chemoradiotherapy; Radiation therapy; Proportional hazards model; Nuclear medicine; Oncology; Chemotherapy; Glioma; Confidence interval; Astrocytoma","score_opus":0.146231725299461,"score_gpt":0.5003239368345028,"score_spread":0.35409221153504183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147013683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387825,0.0011151232,0.00021907162,0.0016171595,0.0021888919,0.0005908707,0.00002948301,0.000004137467,0.00035702361],"genre_scores_gemma":[0.99412495,0.00058314746,0.0024532708,0.0002021808,0.0025550418,0.000012975492,0.000008627022,0.000018446366,0.00004134852],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99556816,0.0001853849,0.0034825264,0.00014260542,0.00034311472,0.00027821003],"domain_scores_gemma":[0.9912486,0.004271647,0.0033415474,0.00023782211,0.00047171407,0.00042865012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028297782,0.00015284921,0.0024358951,0.00020617082,0.000020467676,0.0000027643964,0.00013670184,0.00034640013,0.00006646437],"category_scores_gemma":[0.003322693,0.0001018997,0.00095191866,0.00015028627,0.00020379406,0.00009353562,0.000019984287,0.00028671953,0.0000023424188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71809596,0.072680786,0.022168025,0.00013254357,0.0022187524,0.00033691493,0.00020979965,0.000004659501,0.003558793,0.00015510412,0.005648852,0.17478979],"study_design_scores_gemma":[0.81230724,0.12773037,0.03623569,0.00018220756,0.0016325626,0.0003124365,0.000027399887,0.000039529503,0.015753597,0.00004901924,0.005629741,0.000100180165],"about_ca_topic_score_codex":0.000006332171,"about_ca_topic_score_gemma":0.000008947304,"teacher_disagreement_score":0.1746896,"about_ca_system_score_codex":0.00009394892,"about_ca_system_score_gemma":0.00058674574,"threshold_uncertainty_score":0.4155349},"labels":[],"label_agreement":null},{"id":"W2147017584","doi":"10.1200/jco.2004.04.199","title":"Skeletal Morbidity in Childhood Acute Lymphoblastic Leukemia","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; McMaster University; University of Toronto","funders":"Pediatric Oncology Group of Ontario","keywords":"Medicine; Bone mineral; Femoral neck; Densitometry; Corticosteroid; Osteoporosis; Methotrexate; Femur; Internal medicine; Urology; Surgery","score_opus":0.060739828873712626,"score_gpt":0.4297235373931537,"score_spread":0.36898370851944107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147017584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98661596,0.00017283134,0.00096614286,0.00624265,0.0012247018,0.00025456716,0.0000043079413,0.000017546146,0.0045013092],"genre_scores_gemma":[0.9877062,0.00068523514,0.0069370703,0.0025324733,0.0019017032,0.000004432363,0.0000033624465,0.000033405446,0.00019613879],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947485,0.00034884698,0.0031376234,0.00031115912,0.00088515686,0.00056871603],"domain_scores_gemma":[0.9949351,0.002268303,0.0012022003,0.00032486412,0.00044709083,0.00082242273],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036103402,0.00022191566,0.001990557,0.00036303632,0.0000399702,0.000012690018,0.0003950915,0.0007228106,0.00017976403],"category_scores_gemma":[0.009027145,0.00016109875,0.00067513,0.00043415773,0.0004449077,0.00019808902,0.00015343045,0.002098921,0.00019131218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.036121007,0.03399731,0.21014196,0.00037061365,0.0069884495,0.16353028,0.0019443625,0.006083279,0.005231459,0.00374391,0.03318584,0.49866155],"study_design_scores_gemma":[0.066181555,0.019474374,0.8862369,0.00035217765,0.00058814883,0.010315752,0.00011693019,0.00040313418,0.00033919487,0.002974449,0.012775627,0.00024176088],"about_ca_topic_score_codex":0.00011367037,"about_ca_topic_score_gemma":0.000071854854,"teacher_disagreement_score":0.67609495,"about_ca_system_score_codex":0.004510956,"about_ca_system_score_gemma":0.024470534,"threshold_uncertainty_score":0.99932027},"labels":[],"label_agreement":null},{"id":"W2147058464","doi":"10.1200/jco.2004.04.188","title":"Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Prophylactic Mastectomy; Breast cancer; Prophylactic Surgery; Mastectomy; Oophorectomy; Cancer; BRCA mutation; Gynecology; Surgery; Germline mutation; Ovarian cancer; Oncology; Internal medicine; Hysterectomy; Mutation","score_opus":0.03248792481459869,"score_gpt":0.39058686787524616,"score_spread":0.3580989430606475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147058464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937656,0.0012656435,0.000069243375,0.0033818462,0.00095743296,0.0004604259,0.000014081172,0.0000033268072,0.00008242478],"genre_scores_gemma":[0.9968079,0.00062417315,0.00073316175,0.00061325147,0.0011203119,0.000049952665,0.0000021358487,0.000019341727,0.000029805395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735755,0.0006536652,0.001253076,0.0003024815,0.00022309169,0.00021013203],"domain_scores_gemma":[0.9980645,0.00017128995,0.0011709837,0.00020626945,0.00026468487,0.00012223041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023926129,0.00015294243,0.00047165772,0.000070933704,0.0000880026,0.000031837215,0.00024561185,0.00025573673,0.000010023078],"category_scores_gemma":[0.0006262752,0.000097724325,0.00013755917,0.00018147084,0.00032165408,0.000024323794,0.00008834069,0.0006711644,0.0000014004113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010047892,0.0054297843,0.5439049,0.00006330664,0.0014777947,0.00047605124,0.005088087,0.011450877,0.025916738,0.00004147607,0.0009221074,0.39518097],"study_design_scores_gemma":[0.01734451,0.013393087,0.95295566,0.000060000973,0.00041134673,0.0010870056,0.0030684911,0.00003492547,0.0035881281,0.0011288149,0.0066001676,0.0003278782],"about_ca_topic_score_codex":0.00016839578,"about_ca_topic_score_gemma":0.0009877654,"teacher_disagreement_score":0.40905073,"about_ca_system_score_codex":0.00019016374,"about_ca_system_score_gemma":0.0013802113,"threshold_uncertainty_score":0.39850822},"labels":[],"label_agreement":null},{"id":"W2147436556","doi":"10.1200/jco.2012.46.5492","title":"Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Cochrane Library; Oncology; Hazard ratio; Internal medicine; Cancer; Sexual function; Meta-analysis; Confidence interval","score_opus":0.3671423601141902,"score_gpt":0.5729585546394367,"score_spread":0.20581619452524647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147436556","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023586747,0.9859134,0.00000659377,0.00082188955,0.0007292463,0.012002469,0.000036492987,0.000004219823,0.0002498342],"genre_scores_gemma":[0.000051385952,0.9971489,0.00043218728,0.00006506617,0.00043129828,0.0010936934,0.000026966252,0.000035095145,0.0007154096],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97996444,0.0060730223,0.012759952,0.00025570122,0.00070593506,0.00024094508],"domain_scores_gemma":[0.9566231,0.018217165,0.022405986,0.00043399128,0.0019745887,0.00034519492],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011752444,0.0004081909,0.040416315,0.0002599637,0.000016817012,0.000007635687,0.00022670659,0.00044689284,0.00020628997],"category_scores_gemma":[0.01627757,0.00016019885,0.0050336393,0.0002571162,0.00045346725,0.00005800554,0.000039386192,0.0005180797,0.000007370453],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07111262,0.001038974,0.00003512344,0.48679757,0.016644023,0.0002495348,0.00003891275,5.6031826e-8,1.08182086e-7,0.0000072752177,0.00028669654,0.42378908],"study_design_scores_gemma":[0.21328624,0.021158079,0.000003110733,0.60511595,0.070816115,0.00033069527,0.000026897127,0.0000010753811,0.0000049153164,0.0000066886028,0.089141175,0.000109068016],"about_ca_topic_score_codex":0.00003202238,"about_ca_topic_score_gemma":0.000004136073,"teacher_disagreement_score":0.42368004,"about_ca_system_score_codex":0.0006171335,"about_ca_system_score_gemma":0.007149823,"threshold_uncertainty_score":0.9984787},"labels":[],"label_agreement":null},{"id":"W2147541782","doi":"10.1200/jco.2006.06.5953","title":"Looking Beyond Survival: How Are We Looking at Survivorship?","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Survivorship curve; Medicine; Cancer survivorship; Gerontology; Cancer; Internal medicine","score_opus":0.23457575216762877,"score_gpt":0.4915516387642937,"score_spread":0.2569758865966649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147541782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028423275,0.967081,0.00008307272,0.0046506873,0.016461845,0.0005338395,0.000043873733,0.000042866814,0.01081858],"genre_scores_gemma":[0.00057855103,0.9783392,0.0002077451,0.0008413172,0.012501594,0.000014854731,0.000050963805,0.0001811066,0.007284674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882264,0.0027830831,0.006093273,0.0007286858,0.0013752669,0.0007932674],"domain_scores_gemma":[0.9769645,0.008908028,0.011472273,0.0007756899,0.0009590117,0.000920553],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009279785,0.0008293606,0.013367652,0.00058258325,0.00012953766,0.000062725674,0.00074738427,0.0029457891,0.0003218474],"category_scores_gemma":[0.0032412924,0.000590209,0.005708946,0.0006015463,0.0004103385,0.00016273599,0.00034525033,0.0051694317,0.00006484294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050316,0.0006002742,0.0048533985,0.0090438975,0.0012805262,0.0036156955,0.000055745746,9.963175e-7,1.8140915e-7,0.00006538306,0.025309913,0.95467085],"study_design_scores_gemma":[0.002406544,0.002347117,0.00061629486,0.01674316,0.006004453,0.0017092755,0.0001478036,0.0000014370851,5.086225e-7,0.00012966081,0.96940035,0.0004934096],"about_ca_topic_score_codex":0.0001579373,"about_ca_topic_score_gemma":0.0070083723,"teacher_disagreement_score":0.95417744,"about_ca_system_score_codex":0.0014103339,"about_ca_system_score_gemma":0.0043898467,"threshold_uncertainty_score":0.99965495},"labels":[],"label_agreement":null},{"id":"W2147627229","doi":"10.1200/jco.2011.36.8373","title":"Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Ministry of Research and Innovation; Canadian Breast Cancer Research Alliance; Ontario Institute for Cancer Research","keywords":"Medicine; Survivorship curve; Breast cancer; Cancer; Quality of life (healthcare); Randomized controlled trial; Distress; Intervention (counseling); Physical therapy; Internal medicine; Family medicine; Nursing","score_opus":0.24716430819197643,"score_gpt":0.5056468380245014,"score_spread":0.25848252983252495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147627229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907709,0.00039159646,0.00004334691,0.00048201336,0.0041249525,0.0008352495,0.00016512982,0.000006334023,0.003180498],"genre_scores_gemma":[0.9963025,0.0005037312,0.0011680366,0.00032561977,0.0015978434,0.000014689372,0.000012164174,0.000024032215,0.000051419844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98749536,0.0035972714,0.007360282,0.00028689043,0.0010073953,0.00025277073],"domain_scores_gemma":[0.97918826,0.009127601,0.0074513606,0.00036357171,0.0034820456,0.00038717827],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020033445,0.00019890885,0.0045396243,0.00015222946,0.000023390212,0.000003058073,0.0002692092,0.000557207,0.00018967516],"category_scores_gemma":[0.014090008,0.00011846646,0.0014061009,0.00020434563,0.0007050371,0.000094829484,0.000057601454,0.0011172264,0.0000017241001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6821143,0.0018453937,0.23355421,0.00008931778,0.0007404349,0.000030290044,0.0012253802,0.0000030321257,8.788259e-7,0.000015809706,0.00013723396,0.0802437],"study_design_scores_gemma":[0.6798073,0.032234095,0.28427765,0.0004994519,0.0018005294,0.000018695653,0.0006957877,0.000013061466,0.000016444023,0.00005607008,0.0004794439,0.00010147781],"about_ca_topic_score_codex":0.0016873595,"about_ca_topic_score_gemma":0.0036853808,"teacher_disagreement_score":0.080142215,"about_ca_system_score_codex":0.000093651535,"about_ca_system_score_gemma":0.0031479027,"threshold_uncertainty_score":0.9942147},"labels":[],"label_agreement":null},{"id":"W2147684739","doi":"10.1200/jco.2007.11.6103","title":"Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Irinotecan; Refractory (planetary science); Oncology; Internal medicine; Solid tumor; Pediatric oncology; Cancer; Colorectal cancer","score_opus":0.052244014317144954,"score_gpt":0.4488011985010773,"score_spread":0.3965571841839324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147684739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972894,0.00020977738,0.0006175068,0.00017676015,0.00062604726,0.00064566423,0.000008114813,0.0000032497971,0.00042346024],"genre_scores_gemma":[0.9962953,0.0003161325,0.00092707516,0.00054134737,0.0018418496,0.000007291949,0.0000108569975,0.000026759288,0.00003340711],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99605364,0.00045727045,0.002506578,0.00032748093,0.00030239785,0.00035262713],"domain_scores_gemma":[0.9966888,0.00020059667,0.0023053514,0.0003195824,0.00023131045,0.00025438954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053764726,0.00020402296,0.0013233939,0.00017804319,0.000045742585,0.000005117375,0.00039515848,0.00051508745,0.000024576862],"category_scores_gemma":[0.00038101134,0.0001550945,0.0003287004,0.00014984988,0.00021938693,0.000010136254,0.00014112353,0.00081036653,7.768698e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.257375,0.08601234,0.026248863,0.0000054495713,0.0016350923,0.00021696863,0.00028306767,0.000024830215,0.038191177,0.00008346863,0.00019457606,0.5897292],"study_design_scores_gemma":[0.23636992,0.6684301,0.0754456,0.000028882407,0.0002744567,0.00032139986,0.00031091267,0.000002861889,0.0060078227,0.00009675363,0.012463132,0.00024814042],"about_ca_topic_score_codex":0.000066954795,"about_ca_topic_score_gemma":0.00065754674,"teacher_disagreement_score":0.58948106,"about_ca_system_score_codex":0.00009737264,"about_ca_system_score_gemma":0.0012920594,"threshold_uncertainty_score":0.632457},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2147786645","doi":"10.1200/jco.2004.01.077","title":"Inpatient Versus Outpatient Management of Low-Risk Pediatric Febrile Neutropenia: Measuring Parents' and Healthcare Professionals' Preferences","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Medicine; Respondent; Febrile neutropenia; Anxiety; Preference; Outpatient clinic; Inpatient care; Ambulatory care; Family medicine; Health care; Emergency medicine; Neutropenia; Internal medicine; Psychiatry; Chemotherapy","score_opus":0.1315454162914021,"score_gpt":0.4494758093621739,"score_spread":0.3179303930707718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147786645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928936,0.0010635145,0.000039916737,0.0019643044,0.0028799353,0.00038981807,0.0000062666045,0.000007495699,0.000755147],"genre_scores_gemma":[0.9922664,0.005789768,0.0010796348,0.00025050598,0.0005580187,0.000014490946,0.0000018544723,0.00001102404,0.000028298658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969616,0.000299844,0.0018653001,0.00019818636,0.00047432326,0.00020076954],"domain_scores_gemma":[0.99678147,0.0004116045,0.0018317791,0.00015840655,0.00046819577,0.00034854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011398802,0.00012770595,0.00093210005,0.00013271466,0.00008018427,0.0000056581734,0.00011819416,0.0001881587,0.000034039167],"category_scores_gemma":[0.0003030687,0.00008847726,0.0002397975,0.00017613497,0.000101211604,0.00009904684,0.00010848642,0.0008333738,0.000005918635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011744153,0.0057073655,0.885767,0.00083078694,0.0007191156,0.0002153774,0.000555718,0.0002967767,0.00001292822,0.000461762,0.0005683691,0.09312069],"study_design_scores_gemma":[0.01866002,0.024561053,0.9519729,0.0005526244,0.0009047213,0.000044632434,0.0009169053,0.0000023176779,0.00011997941,0.00038791195,0.0017636452,0.00011326713],"about_ca_topic_score_codex":0.000072013936,"about_ca_topic_score_gemma":0.000077885314,"teacher_disagreement_score":0.09300742,"about_ca_system_score_codex":0.0001963985,"about_ca_system_score_gemma":0.0009840035,"threshold_uncertainty_score":0.3620641},"labels":[],"label_agreement":null},{"id":"W2147837077","doi":"10.1200/jco.2007.12.6094","title":"Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non–Small-Cell Lung Cancer: Results From a Randomized Trial, JBR.10","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Nausea; Vinorelbine; Randomized controlled trial; Chemotherapy; Stage (stratigraphy); Internal medicine; Physical therapy; Surgery; Cisplatin","score_opus":0.1737663741942309,"score_gpt":0.5047715335469496,"score_spread":0.3310051593527187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147837077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791075,0.0018216721,0.00016413318,0.01463247,0.0014908868,0.002037823,0.00009280238,0.000007009693,0.00064571056],"genre_scores_gemma":[0.9760773,0.01358726,0.0043312055,0.0033425754,0.0011824413,0.00015287218,0.000012200814,0.00003014611,0.0012839641],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992348,0.0008101588,0.005847607,0.0003137413,0.0003989998,0.00028148663],"domain_scores_gemma":[0.9739771,0.020662162,0.0042792293,0.0003084976,0.00040266948,0.0003703249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006319286,0.00022740616,0.0058129495,0.00014310489,0.000035644636,0.0000055187816,0.0001930893,0.00043101714,0.00017561784],"category_scores_gemma":[0.008182361,0.00014173132,0.0017045196,0.00011529094,0.00021763763,0.0000638406,0.000027650764,0.00056157843,0.0000034584366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7734735,0.004301567,0.21125035,0.000059529924,0.0013728051,0.00012993865,0.0005481106,0.00002317074,0.000013246059,0.000011815788,0.0050730407,0.0037429053],"study_design_scores_gemma":[0.7887657,0.00589722,0.1967797,0.00017469766,0.00057358854,0.0000026961136,0.000048439822,0.00011630544,0.00011597256,0.0000671563,0.0073502418,0.00010823226],"about_ca_topic_score_codex":0.0023067358,"about_ca_topic_score_gemma":0.0005900572,"teacher_disagreement_score":0.019852003,"about_ca_system_score_codex":0.00038483823,"about_ca_system_score_gemma":0.0033518637,"threshold_uncertainty_score":0.9795641},"labels":[],"label_agreement":null},{"id":"W2147859079","doi":"10.1200/jco.2006.05.9212","title":"Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Dairy Farmers of Canada","keywords":"Medicine; Zoledronic acid; Bisphosphonate; N-terminal telopeptide; Palliative care; Breast cancer; Bone pain; Internal medicine; Urology; Bone remodeling; Oncology; Cancer; Osteoporosis","score_opus":0.09509900927046033,"score_gpt":0.4882822545423567,"score_spread":0.39318324527189635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147859079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887817,0.0045316857,0.000007003893,0.00424375,0.00047557493,0.0018023116,0.0001252115,0.000007420271,0.00002536229],"genre_scores_gemma":[0.99699754,0.000983663,0.00056412985,0.00081598444,0.0002175231,0.000111427864,0.00002826121,0.000034741763,0.0002467442],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99454147,0.00051521295,0.00358353,0.00028085714,0.000661362,0.00041754715],"domain_scores_gemma":[0.9926904,0.001307847,0.004617939,0.00021062545,0.000917558,0.00025563946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002557979,0.00028549202,0.0019051502,0.00014321487,0.00011060276,0.000006171764,0.00014070047,0.00028627683,0.0007999289],"category_scores_gemma":[0.0004981878,0.00013193491,0.00040415165,0.00040838556,0.00023851555,0.000118450786,0.000042535667,0.0009690152,0.0000032471353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5502387,0.04557985,0.06853128,0.000059311125,0.0016933287,0.00041292622,0.00027730435,0.0002591636,0.000032041233,0.000010812057,0.00014694057,0.3327583],"study_design_scores_gemma":[0.4734312,0.23399211,0.28820962,0.00063081103,0.00092728273,0.0000928352,0.000026284135,0.0003815284,0.00017568175,0.00026831802,0.0017123626,0.00015195982],"about_ca_topic_score_codex":0.00033026622,"about_ca_topic_score_gemma":0.0021457453,"teacher_disagreement_score":0.33260635,"about_ca_system_score_codex":0.00031261565,"about_ca_system_score_gemma":0.0025747223,"threshold_uncertainty_score":0.87586606},"labels":[],"label_agreement":null},{"id":"W2148012189","doi":"10.1200/jco.2004.12.142","title":"Autologous Hematopoietic Stem-Cell Transplantation for Children With Acute Myeloid Leukemia in First or Second Complete Remission: A Prognostic Factor Analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Transplantation; Internal medicine; Leukemia; Surgery; Multivariate analysis","score_opus":0.07018696342816678,"score_gpt":0.40033568973615213,"score_spread":0.33014872630798536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148012189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908347,0.00014555553,0.0055886614,0.0037321835,0.00013291591,0.0010565894,0.00006365871,0.000019208926,0.00017777085],"genre_scores_gemma":[0.9839249,0.00060867507,0.013860652,0.0007574866,0.00031234924,0.00003137825,0.000044771707,0.000036065077,0.00042372252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574256,0.00028116096,0.0025474788,0.00039972743,0.0005387848,0.00049027364],"domain_scores_gemma":[0.9941468,0.0031419445,0.0014204715,0.0002788587,0.00044467443,0.00056722603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017142202,0.0002598917,0.0024118635,0.0005438207,0.000085019834,0.000019655747,0.00032267597,0.0005679292,0.00027059604],"category_scores_gemma":[0.0005464741,0.00015767955,0.00061838044,0.0007926279,0.00024949657,0.0001515706,0.000033030337,0.0014909791,0.0000127301855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11729193,0.004836874,0.77766556,0.0014990522,0.016362252,0.024169076,0.00417064,0.0051252777,0.0020862252,0.000090282694,0.0028559165,0.043846935],"study_design_scores_gemma":[0.043035645,0.027145874,0.9120427,0.00036803397,0.005531471,0.0074478877,0.00020596788,0.00068398635,0.0006159481,0.00012770097,0.0025032691,0.00029155143],"about_ca_topic_score_codex":0.000042853746,"about_ca_topic_score_gemma":0.0008787852,"teacher_disagreement_score":0.13437712,"about_ca_system_score_codex":0.001458944,"about_ca_system_score_gemma":0.008375721,"threshold_uncertainty_score":0.99724585},"labels":[],"label_agreement":null},{"id":"W2148121052","doi":"10.1200/jco.2004.09.108","title":"Predictors of Viridans Streptococcal Shock Syndrome in Bacteremic Children With Cancer and Stem-Cell Transplant Recipients","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Bacteremia; Mucositis; Odds ratio; Internal medicine; Septic shock; Retrospective cohort study; Gastroenterology; Surgery; Sepsis; Chemotherapy","score_opus":0.04033837441949072,"score_gpt":0.37291533201788146,"score_spread":0.33257695759839073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148121052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755925,0.00021939357,0.00003373367,0.0010034846,0.00048813559,0.00027142948,0.000019725036,0.0000044377393,0.00040043885],"genre_scores_gemma":[0.997974,0.0013505027,0.00016033852,0.0002015841,0.00020889856,0.000007472785,0.0000016604135,0.000012741397,0.0000828049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980168,0.00010020736,0.0013440199,0.00015960739,0.00021172296,0.00016765847],"domain_scores_gemma":[0.99861145,0.00020758965,0.00070559373,0.00010804672,0.000109771914,0.0002575564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005485073,0.00011277124,0.0009906364,0.00012743162,0.000017519898,0.0000031945017,0.00008736677,0.00021120437,0.00007230144],"category_scores_gemma":[0.000024808898,0.00007423039,0.000154959,0.00013905608,0.00018733215,0.0000913115,0.000013632784,0.00078852853,0.0000014202769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022980997,0.0011852506,0.98821044,0.000023139142,0.0002644197,0.00025268033,0.00015335211,0.00016620033,0.00053805584,0.000010192346,0.000049059236,0.0068491246],"study_design_scores_gemma":[0.013504612,0.012979064,0.96992046,0.00046645547,0.00043641732,0.0016934844,0.000034738994,0.0000013845087,0.0004247587,0.000018286944,0.0004519237,0.00006840239],"about_ca_topic_score_codex":0.00014318505,"about_ca_topic_score_gemma":0.00052126526,"teacher_disagreement_score":0.018289955,"about_ca_system_score_codex":0.00016744169,"about_ca_system_score_gemma":0.0012599722,"threshold_uncertainty_score":0.3425808},"labels":[],"label_agreement":null},{"id":"W2148264387","doi":"10.1200/jco.2007.14.3420","title":"Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Imatinib mesylate; Internal medicine; Tolerability; Imatinib; Gynecologic oncology; Vascular endothelial growth factor; Platelet-derived growth factor receptor; Oncology; Ovarian carcinoma; Carcinoma; Gastroenterology; Pathology; Ovarian cancer; Cancer; Growth factor; Receptor; Adverse effect","score_opus":0.3437575897750259,"score_gpt":0.5152730711735055,"score_spread":0.1715154813984796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148264387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003536,0.0012042383,0.000003589208,0.0046697957,0.001220098,0.0020627102,0.000022677532,0.0000038658086,0.00077766017],"genre_scores_gemma":[0.99453765,0.0026616573,0.0015537462,0.0003656301,0.0006541382,0.00015526224,0.000010660058,0.00001450879,0.00004675124],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99198014,0.0028159556,0.0036693185,0.00032671975,0.0009190241,0.0002888703],"domain_scores_gemma":[0.9921452,0.0038173224,0.0027688502,0.00036049134,0.0006984358,0.0002097414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068262387,0.00025043436,0.002659635,0.00022028075,0.000098867386,0.0000034110758,0.00022168817,0.00032223665,0.00047996896],"category_scores_gemma":[0.0016669501,0.00011857569,0.0008471726,0.00028573046,0.0003431111,0.00007260824,0.0000467889,0.00047364517,0.000002663183],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05196578,0.3104579,0.063684955,0.000049808186,0.0016054767,0.0036242842,0.010796999,0.000037226462,0.00006845822,0.000018442366,0.00041961728,0.55727106],"study_design_scores_gemma":[0.088585176,0.49791795,0.40096706,0.00005180928,0.0030334026,0.0008196865,0.002215537,0.00024850495,0.000028788283,0.000023250546,0.0060293553,0.00007948877],"about_ca_topic_score_codex":0.00013737114,"about_ca_topic_score_gemma":0.0005538935,"teacher_disagreement_score":0.55719155,"about_ca_system_score_codex":0.0016670376,"about_ca_system_score_gemma":0.005873441,"threshold_uncertainty_score":0.99976236},"labels":[],"label_agreement":null},{"id":"W2148372168","doi":"10.1200/jco.2011.40.4830","title":"High Incidence of Vertebral Fractures in Children With Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"University of Alberta; Children's Health Research Institute; Canadian Institutes of Health Research; Women and Children's Health Research Institute; University of Ottawa","keywords":"Medicine; Incidence (geometry); Odds ratio; Osteoporosis; Surgery; Vertebra; Internal medicine","score_opus":0.03580865801269143,"score_gpt":0.3948021269802402,"score_spread":0.35899346896754875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148372168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971537,0.0005778531,0.00037211555,0.0010784838,0.0002762397,0.00033195526,0.0000059763574,0.0000035159371,0.0002001875],"genre_scores_gemma":[0.9951394,0.00083500554,0.0017468771,0.0014468426,0.0007785401,0.000010017134,0.000002760084,0.000020414609,0.000020102807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961463,0.0005598023,0.0020256767,0.00013812007,0.0007887958,0.00034128726],"domain_scores_gemma":[0.99400985,0.003272627,0.001750439,0.00028156533,0.0004335544,0.00025197814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028648863,0.00016171554,0.0012725663,0.00019984152,0.000020604299,0.000004526557,0.00031283018,0.00038829743,0.00017846211],"category_scores_gemma":[0.0023724574,0.000081574835,0.0002457376,0.0002417654,0.00048091527,0.0002697824,0.00007785486,0.00092021195,0.0000060481116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023860091,0.0010939164,0.95079225,0.000015870643,0.00090976077,0.00015252382,0.00049913203,0.00013992628,0.00044806313,0.000053986136,0.00071927375,0.02131523],"study_design_scores_gemma":[0.013621635,0.008124941,0.97495997,0.00015508359,0.0003014015,0.00096675503,0.000061012903,0.00018079461,0.0012103699,0.0001501254,0.00019278681,0.00007510413],"about_ca_topic_score_codex":0.00020105497,"about_ca_topic_score_gemma":0.00006413248,"teacher_disagreement_score":0.024167765,"about_ca_system_score_codex":0.00063842745,"about_ca_system_score_gemma":0.004763058,"threshold_uncertainty_score":0.844946},"labels":[],"label_agreement":null},{"id":"W2148422235","doi":"10.1200/jco.2003.99.217","title":"Staging Reclassification Affects Breast Cancer Survival","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Internal medicine","score_opus":0.13402706969850994,"score_gpt":0.45144524831578087,"score_spread":0.31741817861727095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148422235","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018892193,0.0031919272,0.00021790562,0.9625296,0.011377821,0.00022676686,0.00016292656,0.000009193322,0.0033916726],"genre_scores_gemma":[0.060992915,0.01688293,0.0017369413,0.8555812,0.061158646,0.000058833913,0.00022005186,0.00018365911,0.00318481],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99617016,0.001118825,0.0015058065,0.00043985553,0.00039118546,0.0003741519],"domain_scores_gemma":[0.9953275,0.000607476,0.0029761216,0.00036131786,0.00058492465,0.00014266248],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016415115,0.00033211906,0.001500514,0.00009149035,0.00006923459,0.000017549197,0.00036611845,0.0017791733,0.00009455796],"category_scores_gemma":[0.00073887664,0.0002586424,0.000700123,0.00009237764,0.00026420463,0.0000072378202,0.000090756235,0.0020152775,0.000011238197],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005549043,0.00023126343,0.019747544,0.00003996117,0.0012504174,0.00025722687,0.0000099085155,0.0000067074275,0.00019419951,0.0000044227086,0.931745,0.045958433],"study_design_scores_gemma":[0.0022902782,0.0009668749,0.052565,0.00007593812,0.00047490865,0.00025758825,0.000028606746,9.888455e-7,0.00011368429,0.00004447158,0.94293857,0.00024308878],"about_ca_topic_score_codex":0.00003855037,"about_ca_topic_score_gemma":0.00006634487,"teacher_disagreement_score":0.10694838,"about_ca_system_score_codex":0.00022247936,"about_ca_system_score_gemma":0.0020985638,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W2148504560","doi":"10.1200/jco.2011.34.5843","title":"Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":228,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Vinblastine; Vinca alkaloid; Chemotherapy; Refractory (planetary science); Surgery; Regimen; Glioma; Chemotherapy regimen; Internal medicine; Progression-free survival; Radiation therapy; Toxicity; Gastroenterology; Vincristine; Cyclophosphamide","score_opus":0.16486171065416128,"score_gpt":0.5032065506864968,"score_spread":0.3383448400323355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148504560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943641,0.001562549,0.0000023098141,0.0016547138,0.0018723146,0.00038333907,0.000003503014,0.000005546981,0.0001516334],"genre_scores_gemma":[0.9966035,0.00064311037,0.0003401882,0.00016538608,0.0021909012,0.000010762541,0.000001575474,0.000016328137,0.000028261758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953007,0.00052036456,0.0032167023,0.00016888262,0.00047339965,0.00031993774],"domain_scores_gemma":[0.99422777,0.0025004388,0.0022278382,0.00022323322,0.0002771305,0.00054359285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028372456,0.00017198562,0.0017856993,0.00044957784,0.000030705738,0.0000027390304,0.00014212471,0.00026558895,0.00024236848],"category_scores_gemma":[0.0038766738,0.00010318579,0.0003502419,0.00043016006,0.000069039794,0.00013077098,0.00008331731,0.00080732914,0.000011670116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010636992,0.35295233,0.5380983,0.0000523507,0.00035352228,0.0023061223,0.0005420651,0.0000034649202,0.00034875068,0.000007883953,0.0041552437,0.09054298],"study_design_scores_gemma":[0.08020384,0.2676014,0.64012885,0.0001159404,0.0011844676,0.00031552528,0.00054148724,0.000019216503,0.00020983952,0.000013133943,0.009554452,0.00011185448],"about_ca_topic_score_codex":0.000019208503,"about_ca_topic_score_gemma":0.000061428094,"teacher_disagreement_score":0.102030545,"about_ca_system_score_codex":0.00018050392,"about_ca_system_score_gemma":0.0006886991,"threshold_uncertainty_score":0.46410206},"labels":[],"label_agreement":null},{"id":"W2148505042","doi":"10.1200/jco.2007.15.2488","title":"A Multicenter Randomized Trial of Breast Intensity-Modulated Radiation Therapy to Reduce Acute Radiation Dermatitis","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":758,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Hôpital Notre-Dame; Regional Municipality of Durham; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Desquamation; Radiation therapy; Breast cancer; Randomized controlled trial; Quality of life (healthcare); Internal medicine; Nuclear medicine; Dermatology; Cancer","score_opus":0.05347375338888518,"score_gpt":0.4308164706943025,"score_spread":0.37734271730541735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148505042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97293204,0.00022527746,0.0006342698,0.022044096,0.0025014523,0.0014281423,0.0000060528955,0.000015712061,0.0002129675],"genre_scores_gemma":[0.9873489,0.0027437406,0.0031156342,0.0048678233,0.0017861482,0.000012490852,0.000012845457,0.000020032978,0.00009235332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944499,0.00139872,0.0032896742,0.00017381956,0.0005029012,0.00018498268],"domain_scores_gemma":[0.9917761,0.0034265968,0.003012947,0.00021882163,0.0011798124,0.00038569336],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037899062,0.00015702636,0.0025956724,0.0003235265,0.000042771608,0.0000058233913,0.00014127434,0.0004160615,0.00008555836],"category_scores_gemma":[0.009948806,0.000113383925,0.0008487472,0.00023962141,0.0002054067,0.00020731904,0.000019778074,0.00063620013,0.000021364238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8584291,0.0015900333,0.004158534,0.000010232205,0.0011950154,0.00021325272,0.00053218106,0.00006993664,0.0020922597,0.000007313971,0.008345958,0.12335619],"study_design_scores_gemma":[0.7737276,0.009808787,0.20803764,0.000052608422,0.00042022634,0.0011789401,0.000014257111,0.0009265395,0.0010649739,0.000029938692,0.004652142,0.00008637367],"about_ca_topic_score_codex":0.000023499113,"about_ca_topic_score_gemma":0.000002079508,"teacher_disagreement_score":0.2038791,"about_ca_system_score_codex":0.00015768805,"about_ca_system_score_gemma":0.0009517521,"threshold_uncertainty_score":0.9983908},"labels":[],"label_agreement":null},{"id":"W2148572592","doi":"10.1200/jco.2011.37.5824","title":"Quantitative Reverse Transcriptase Polymerase Chain Reaction and the Onco<i>type</i> DX Test for Assessment of Human Epidermal Growth Factor Receptor 2 Status: Time to Reflect Again?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Reverse transcriptase; Epidermal growth factor receptor; Polymerase chain reaction; Real-time polymerase chain reaction; Receptor; Cancer research; Molecular biology; Virology; Internal medicine; Biology; Genetics; Gene","score_opus":0.3018020567412538,"score_gpt":0.5489705288848127,"score_spread":0.24716847214355886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148572592","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035982516,0.00084295316,0.00026022462,0.95110184,0.0025154736,0.003248551,0.0006722931,0.000022576174,0.0053535705],"genre_scores_gemma":[0.033852752,0.006400503,0.032866534,0.89120525,0.019773277,0.00024380597,0.0003854465,0.0004002355,0.014872213],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913979,0.0027295032,0.003766128,0.00050755305,0.00094788347,0.0006510208],"domain_scores_gemma":[0.9781704,0.015994633,0.0031132242,0.00044270154,0.0016912522,0.00058782205],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009022688,0.0003904223,0.0034108264,0.00040049932,0.00011334188,0.000018133129,0.00038777036,0.0013229345,0.0009049745],"category_scores_gemma":[0.015886778,0.00024959358,0.0009005709,0.00026812733,0.00088880677,0.00013667495,0.00007211799,0.0054759113,0.000028891038],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014034374,0.0010178824,0.0009927623,0.00047901832,0.00096391764,0.00049545476,0.0005357327,1.6235963e-7,0.013274223,0.00007260301,0.9568207,0.011313128],"study_design_scores_gemma":[0.014666909,0.06772722,0.0037283264,0.0006273959,0.0009870917,0.0001409208,0.00016322163,0.00002606431,0.0005040103,0.0002886017,0.91085976,0.00028049754],"about_ca_topic_score_codex":0.00036816156,"about_ca_topic_score_gemma":0.00004128241,"teacher_disagreement_score":0.06670934,"about_ca_system_score_codex":0.00067398703,"about_ca_system_score_gemma":0.0046843225,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2148587874","doi":"10.1200/jco.2005.05.514","title":"Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke","funders":"Université Laval","keywords":"Medicine; Head and neck cancer; Adverse effect; Radiation therapy; Cancer; Randomized controlled trial; Head and neck; Antioxidant; Internal medicine; Oncology; Surgery","score_opus":0.04586419365783004,"score_gpt":0.45555417844793716,"score_spread":0.4096899847901071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148587874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934884,0.0012448332,0.0000091728725,0.00319964,0.0009001142,0.0010244914,0.0000026975779,0.0000014721614,0.00012920046],"genre_scores_gemma":[0.977147,0.02092182,0.00046954994,0.00090887636,0.0004904958,0.000019888445,4.0008857e-7,0.0000062225245,0.00003577202],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997011,0.0004950169,0.0020332602,0.00010443377,0.00023504962,0.000121245415],"domain_scores_gemma":[0.99631196,0.002046437,0.0012198347,0.00007109368,0.00020644283,0.00014424691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019465929,0.000089045294,0.0023274135,0.00012943112,0.000010108543,7.583218e-7,0.00004933088,0.00014288988,0.000012562753],"category_scores_gemma":[0.0024874914,0.000056564913,0.00031450365,0.00010308937,0.00010426352,0.000057323585,0.000020279778,0.00024944873,5.506568e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6462576,0.003386922,0.020567099,0.00003788336,0.0004316879,0.000014452635,0.00046603903,0.0000069391917,0.00041403974,0.000004346767,0.0003472983,0.32806572],"study_design_scores_gemma":[0.6706336,0.027399832,0.29754707,0.0002774273,0.00021471761,0.0000023096163,0.00000832448,0.000016180871,0.0012300794,0.000011569306,0.0026225615,0.000036331166],"about_ca_topic_score_codex":0.00004827284,"about_ca_topic_score_gemma":0.00009765916,"teacher_disagreement_score":0.3280294,"about_ca_system_score_codex":0.000097624776,"about_ca_system_score_gemma":0.00050063984,"threshold_uncertainty_score":0.2977939},"labels":[],"label_agreement":null},{"id":"W2148641795","doi":"10.1200/jco.2012.47.9220","title":"Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Head and neck cancer; Head and neck; Oncology; Cancer research; Cancer; Internal medicine; Pathology; Surgery","score_opus":0.12650158949069934,"score_gpt":0.43904507828276185,"score_spread":0.3125434887920625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148641795","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35522228,0.0013167978,0.000010281818,0.6423938,0.00048488178,0.00016796116,0.000021395097,0.0000064876804,0.00037605106],"genre_scores_gemma":[0.144726,0.011143378,0.002785734,0.81260175,0.024354499,0.0000124746175,0.00005556153,0.000082981496,0.0042376355],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939105,0.0011759636,0.0035492056,0.00034936587,0.00053953705,0.0004754304],"domain_scores_gemma":[0.99150664,0.0044026976,0.0030490858,0.00019128683,0.0005323419,0.0003179529],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0024651047,0.00031966268,0.002772904,0.00022426326,0.00008636466,0.000035386875,0.00024278364,0.0015899271,0.0015181745],"category_scores_gemma":[0.0038073214,0.00019132817,0.00084639207,0.00016119254,0.00036310026,0.00015436945,0.000099697565,0.007283379,0.0000450972],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002493064,0.0001987357,0.055235982,0.00014543708,0.0004305406,0.0011583001,0.0001992259,0.0000061588876,0.00013949015,0.0000020847635,0.9324195,0.00981525],"study_design_scores_gemma":[0.004785335,0.0016704268,0.037471067,0.0021359033,0.00048665554,0.00023762259,0.0003385729,0.00019474536,0.00004862976,0.000060935694,0.952302,0.0002681052],"about_ca_topic_score_codex":0.00046485392,"about_ca_topic_score_gemma":0.0001429694,"teacher_disagreement_score":0.21049629,"about_ca_system_score_codex":0.00028357535,"about_ca_system_score_gemma":0.0011473318,"threshold_uncertainty_score":0.9997062},"labels":[],"label_agreement":null},{"id":"W2148842308","doi":"10.1200/jco.2004.05.186","title":"Change in Neurocognitive Functioning After Treatment With Cranial Radiation in Childhood","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":412,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Neurocognitive; Medicine; Context (archaeology); Pediatrics; Audiology; Cognition; Psychiatry","score_opus":0.07599243299316256,"score_gpt":0.41314417244491475,"score_spread":0.3371517394517522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148842308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914314,0.0004395347,0.000010020965,0.007129646,0.0003183113,0.0003475398,0.0000013364203,0.000003278762,0.0003189344],"genre_scores_gemma":[0.9964338,0.00063020404,0.00037777453,0.001715655,0.0007679594,0.000058960835,0.0000022813113,0.0000098819155,0.0000034683976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850273,0.00013496213,0.0009167902,0.00013874806,0.00015512429,0.00015164496],"domain_scores_gemma":[0.99885356,0.00039803662,0.00045125236,0.00006197279,0.00008822599,0.00014694252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000431362,0.0001040479,0.0007366479,0.00021701292,0.000012309618,0.000005009367,0.000022066797,0.00015014375,0.000048709753],"category_scores_gemma":[0.00025276505,0.00006412729,0.00016086822,0.00016395944,0.000044146796,0.000109548746,0.0000070757947,0.00032623592,0.000009789479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036589955,0.007142008,0.73176575,0.0000027621127,0.00011140997,0.004710237,0.0005665384,0.0000387823,0.00000670955,0.000009950385,0.0000037028194,0.25198317],"study_design_scores_gemma":[0.040607676,0.031803187,0.9256416,0.00016661467,0.00019877589,0.00029862326,0.000078492965,0.000007658761,0.00005020183,0.000080173435,0.0010182097,0.0000487852],"about_ca_topic_score_codex":0.0001240366,"about_ca_topic_score_gemma":0.0010101978,"teacher_disagreement_score":0.25193438,"about_ca_system_score_codex":0.00042828723,"about_ca_system_score_gemma":0.0005471332,"threshold_uncertainty_score":0.26150352},"labels":[],"label_agreement":null},{"id":"W2148853193","doi":"10.1200/jco.2005.04.4602","title":"Treatment Complications in Children Diagnosed With Neuroblastoma During a Screening Program","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Children's Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Neuroblastoma; Pediatrics; Chemotherapy; Surgery","score_opus":0.07599174509370793,"score_gpt":0.45632952018816886,"score_spread":0.38033777509446093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148853193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995717,0.000056437184,0.000029605919,0.0023069154,0.000035888726,0.0006608298,0.000002743702,0.000022331415,0.0011682602],"genre_scores_gemma":[0.992674,0.00009724633,0.0066078557,0.00012745339,0.00030586007,0.00004364756,0.000005914081,0.000018548291,0.000119479046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783754,0.00022855205,0.0011543004,0.00019819956,0.0002871486,0.00029423484],"domain_scores_gemma":[0.9980833,0.00067948835,0.0005964807,0.0001743763,0.00016032376,0.00030602375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026573922,0.00013518841,0.0008110962,0.00020917456,0.000048268277,0.0000120932955,0.00009467336,0.00010852112,0.000016315033],"category_scores_gemma":[0.0002714077,0.00008369569,0.0002369856,0.00022919393,0.00015254723,0.000079924466,0.000025670799,0.00050549745,0.000011929277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034583192,0.0099571925,0.89196295,0.000005623342,0.00023518823,0.0040231072,0.000010168275,0.000077420045,0.00015829131,0.000015003125,0.00007074345,0.09002599],"study_design_scores_gemma":[0.022252804,0.034647018,0.93838066,0.00006773131,0.00012195064,0.002909762,0.000009658855,0.00006258021,0.0001453867,0.000018466013,0.0013278245,0.000056144683],"about_ca_topic_score_codex":0.00014276427,"about_ca_topic_score_gemma":0.00027146094,"teacher_disagreement_score":0.08996984,"about_ca_system_score_codex":0.00015374186,"about_ca_system_score_gemma":0.000539566,"threshold_uncertainty_score":0.3413011},"labels":[],"label_agreement":null},{"id":"W2148881212","doi":"10.1200/jco.2011.37.2151","title":"Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"DOTA; Medicine; Nuclear medicine; Toxicity; Radionuclide therapy; Internal medicine; Chelation; Chemistry","score_opus":0.10206876813312239,"score_gpt":0.4514493292812904,"score_spread":0.349380561148168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148881212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360443,0.0015553037,0.000048606755,0.005994007,0.001051861,0.0054983622,0.000076179786,0.00013037382,0.0020408682],"genre_scores_gemma":[0.9871983,0.0019646678,0.003211553,0.003331893,0.0028219859,0.0004063677,0.00003624571,0.00036510054,0.00066387444],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97845,0.004434632,0.008111032,0.0016833826,0.004063684,0.003257287],"domain_scores_gemma":[0.97746724,0.0114622805,0.004524863,0.002041974,0.0016592413,0.0028443758],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005078877,0.001546272,0.0072976546,0.0015034527,0.00030344902,0.000098053904,0.001939022,0.00023263262,0.00091092265],"category_scores_gemma":[0.0088094985,0.0011790446,0.0013374251,0.0019176108,0.0018027015,0.0012043467,0.00046598722,0.0065441662,0.00010269667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10932781,0.015214213,0.7483701,0.00035290333,0.002851752,0.039754532,0.0011848339,0.060761508,0.0002740753,0.00006847556,0.009195401,0.0126443645],"study_design_scores_gemma":[0.30448398,0.21511933,0.29362574,0.001514658,0.0032016768,0.015348293,0.017617907,0.024283756,0.0018729279,0.00015984903,0.119918935,0.0028529437],"about_ca_topic_score_codex":0.0011997487,"about_ca_topic_score_gemma":0.00102017,"teacher_disagreement_score":0.4547444,"about_ca_system_score_codex":0.0019163401,"about_ca_system_score_gemma":0.0076835747,"threshold_uncertainty_score":0.99972856},"labels":[],"label_agreement":null},{"id":"W2148923175","doi":"10.1200/jco.2009.26.5520","title":"Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Medicine; Glioma; Concomitant; Internal medicine; Nausea; Anaplastic astrocytoma; Dacarbazine; Oncology; Progression-free survival; Phases of clinical research; Vomiting; Tumor progression; Radiation therapy; Surgery; Chemotherapy; Gastroenterology; Cancer; Astrocytoma; Cancer research","score_opus":0.11629810862350227,"score_gpt":0.49104052562284334,"score_spread":0.3747424169993411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148923175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973817,0.00020299079,0.00000108714,0.0043552364,0.0043569873,0.001029374,0.000005795977,0.0000062199506,0.00030411268],"genre_scores_gemma":[0.9980364,0.00012397797,0.00043226767,0.00021656686,0.0011201457,0.000021445483,0.0000017096842,0.000016126234,0.000031393854],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941282,0.0006233446,0.004245575,0.0002638169,0.00045891464,0.00028014832],"domain_scores_gemma":[0.99451894,0.0021154543,0.0019879788,0.00035593894,0.0006143216,0.0004073874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063325395,0.00018654959,0.002620433,0.00034390422,0.00003472485,0.0000061064115,0.0001962033,0.00038356558,0.00011868044],"category_scores_gemma":[0.007826502,0.00011690475,0.0006769033,0.00023537604,0.0002014364,0.000062981824,0.00009355683,0.0013230953,0.000007828495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37882885,0.27661753,0.08412441,0.000023330485,0.0009878732,0.018164149,0.00058554934,0.0000014191617,0.01124001,0.000098909135,0.003728151,0.22559983],"study_design_scores_gemma":[0.5554785,0.34113672,0.09229756,0.00014348573,0.0008516581,0.0006250708,0.00055256527,0.000020394678,0.0015754309,0.00012619296,0.0070793047,0.00011312477],"about_ca_topic_score_codex":0.00008159429,"about_ca_topic_score_gemma":0.0005625366,"teacher_disagreement_score":0.2254867,"about_ca_system_score_codex":0.000089071225,"about_ca_system_score_gemma":0.00096460065,"threshold_uncertainty_score":0.93696195},"labels":[],"label_agreement":null},{"id":"W2148963596","doi":"10.1200/jco.2011.40.7791","title":"Prospective Study of Falls and Risk Factors for Falls in Adults With Advanced Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Balance, Gait, and Falls Prevention","field":"Health Professions","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CARE Canada","funders":"","keywords":"Medicine; Cancer; Hazard ratio; Internal medicine; Proportional hazards model; Multivariate analysis; Population; Prospective cohort study; Incidence (geometry); Confidence interval","score_opus":0.09101319495960998,"score_gpt":0.5199459504642259,"score_spread":0.4289327555046159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148963596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649227,0.0004258943,0.000075440454,0.000106034386,0.0011796356,0.001400852,0.000019287017,0.000004648216,0.00029592772],"genre_scores_gemma":[0.99654233,0.0016551048,0.0010047782,0.000097501295,0.00052649894,0.00007635873,9.790399e-7,0.0000139543035,0.00008247085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626607,0.0010670008,0.0020055969,0.00015447068,0.00018437725,0.0003224713],"domain_scores_gemma":[0.9920296,0.0039916583,0.0032395518,0.00010779202,0.00042799316,0.00020339902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034511297,0.0001185487,0.0011392903,0.00008966554,0.00008707754,0.0000012946294,0.000113350376,0.00031600797,0.00000954639],"category_scores_gemma":[0.0017994647,0.00007412644,0.000111072084,0.00011175507,0.00008751473,0.00023830596,0.00004158748,0.0011082898,0.0000012065461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057096737,0.0047114235,0.9622639,0.00007967107,0.0001815415,0.0000023554683,0.008706354,0.0000033707795,0.000027627102,0.00004782653,0.000105269224,0.018160991],"study_design_scores_gemma":[0.018907188,0.01282444,0.9496624,0.00031548657,0.00015248347,0.0000012301194,0.016868671,0.00001400435,0.0000011956083,0.00018678176,0.0009898272,0.000076319186],"about_ca_topic_score_codex":0.00034073388,"about_ca_topic_score_gemma":0.0050854636,"teacher_disagreement_score":0.018084671,"about_ca_system_score_codex":0.00013536635,"about_ca_system_score_gemma":0.00050577393,"threshold_uncertainty_score":0.48150295},"labels":[],"label_agreement":null},{"id":"W2149095868","doi":"10.1200/jco.2008.18.4408","title":"Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Performance status; Clinical endpoint; Chemotherapy; Population; Adverse effect; Oncology; Gastroenterology; Cancer; Randomized controlled trial; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.031070941737457582,"score_gpt":0.4432891018328478,"score_spread":0.41221816009539025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149095868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963565,0.00036868072,0.0000312209,0.00068366865,0.00011146742,0.0017826108,0.000007120671,0.000003876411,0.00065485627],"genre_scores_gemma":[0.9963315,0.00076711236,0.0020134808,0.0006730714,0.000073771334,0.000032607793,0.000004915867,0.000012444779,0.00009108449],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978361,0.00015684582,0.0013663331,0.00017666748,0.000258571,0.00020545429],"domain_scores_gemma":[0.9971585,0.000573584,0.0015014807,0.00010738597,0.00044546093,0.00021355611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064357487,0.00015722746,0.0018214273,0.00011834378,0.00004422091,0.000004102969,0.00006033603,0.000087086366,0.00002922175],"category_scores_gemma":[0.000115885116,0.000087246786,0.00008882543,0.00014053058,0.00012400947,0.00010830263,0.000011200419,0.00038289613,1.4620741e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5406404,0.016434407,0.37240905,0.000036304664,0.00070917787,0.00006545591,0.00280591,0.0003453835,0.000017961864,9.167978e-7,0.000057145735,0.06647788],"study_design_scores_gemma":[0.6344917,0.06243427,0.3005382,0.00021688297,0.0009896151,0.000007893718,0.00058590993,0.00044695052,0.0000329112,0.000002133239,0.00018258578,0.00007093917],"about_ca_topic_score_codex":0.00005819415,"about_ca_topic_score_gemma":0.00010674156,"teacher_disagreement_score":0.09385128,"about_ca_system_score_codex":0.00015079773,"about_ca_system_score_gemma":0.0010898223,"threshold_uncertainty_score":0.35578206},"labels":[],"label_agreement":null},{"id":"W2149179641","doi":"10.1200/jco.2012.46.7043","title":"Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada)","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Interquartile range; Metformin; Hazard ratio; Proportional hazards model; Prostate cancer; Diabetes mellitus; Cohort; Internal medicine; Retrospective cohort study; Cumulative dose; Population; Cancer; Cohort study; Confidence interval; Endocrinology","score_opus":0.08862765161089718,"score_gpt":0.39434372567447007,"score_spread":0.3057160740635729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149179641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439803,0.05520748,0.000009570773,0.00018083928,0.00022661668,0.00019410053,0.000009102651,0.0000026403675,0.00018937074],"genre_scores_gemma":[0.8088594,0.18861407,0.00077190227,0.0008598786,0.0006533455,0.000026871841,0.0000046297637,0.000018308932,0.00019157959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981861,0.00023989426,0.0009013751,0.0002511274,0.00015980507,0.00026169146],"domain_scores_gemma":[0.9981542,0.0002040556,0.0008120655,0.00018061943,0.00030983752,0.00033919507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011740787,0.00015323475,0.00069430855,0.000035353663,0.00003661399,0.000050308707,0.00012134713,0.00026250404,0.000051261668],"category_scores_gemma":[0.00034593488,0.000099660705,0.000099390905,0.00004411514,0.00042765783,0.000046429308,0.00007894722,0.0003098849,0.0000013096319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028968407,0.00018085353,0.7483987,0.00002227454,0.0012005074,0.000018505354,0.000057318284,0.0000071147515,0.0037050792,0.000030779425,0.008568356,0.23752078],"study_design_scores_gemma":[0.0026914952,0.002522857,0.68730104,0.000029326286,0.00036361747,0.000012695038,0.0000941388,0.000034438355,0.0032181873,0.0002062858,0.30334184,0.00018409919],"about_ca_topic_score_codex":0.00006556248,"about_ca_topic_score_gemma":0.00015652635,"teacher_disagreement_score":0.29477346,"about_ca_system_score_codex":0.00001508987,"about_ca_system_score_gemma":0.0002463434,"threshold_uncertainty_score":0.40640455},"labels":[],"label_agreement":null},{"id":"W2149248338","doi":"10.1200/jco.2010.33.7006","title":"Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McMaster University; BC Cancer Agency; Ottawa Hospital; Occupational Cancer Research Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Novartis Pharmaceuticals Canada; Israel Cancer Research Fund","keywords":"Medicine; Octreotide; Tamoxifen; Breast cancer; Internal medicine; Hazard ratio; Oncology; Adjuvant therapy; Antiestrogen; Cancer; Gastroenterology; Somatostatin; Gynecology; Confidence interval","score_opus":0.12698743642812726,"score_gpt":0.4147902996388228,"score_spread":0.28780286321069554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149248338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412274,0.0010899693,0.0000017885465,0.0016435692,0.00094197324,0.0012252086,0.000026258573,0.000004012458,0.0009444665],"genre_scores_gemma":[0.9911148,0.007945897,0.00011902227,0.0003938402,0.0002892392,0.000050198825,0.000002308192,0.000019785246,0.00006489652],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99391717,0.0016238586,0.00343821,0.00022300506,0.00044087748,0.0003569095],"domain_scores_gemma":[0.99368274,0.0034271753,0.002114444,0.00026778565,0.00025594168,0.00025190637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00511962,0.0002535059,0.003491813,0.0002933607,0.00002065812,0.0000047989315,0.0002287091,0.00035912715,0.00019244337],"category_scores_gemma":[0.0009774393,0.00013674916,0.0004507684,0.0002590404,0.0005149493,0.00012466789,0.000031872132,0.0006267466,0.0000016631486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.900379,0.00627441,0.07018141,0.000018547142,0.0006827839,0.00035734623,0.004353709,0.0000014035029,0.0003252509,0.00006035738,0.00004609387,0.01731968],"study_design_scores_gemma":[0.6078526,0.06924426,0.32152322,0.00004647273,0.00020929618,0.000027576063,0.0003481141,0.000009693013,0.0001995116,0.00018832709,0.00027200946,0.00007895281],"about_ca_topic_score_codex":0.0008481257,"about_ca_topic_score_gemma":0.0001206657,"teacher_disagreement_score":0.29252645,"about_ca_system_score_codex":0.00021664287,"about_ca_system_score_gemma":0.0010707922,"threshold_uncertainty_score":0.5576469},"labels":[],"label_agreement":null},{"id":"W2149249248","doi":"10.1200/jco.2006.08.1497","title":"Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Oligodendroglioma; Grading (engineering); Internal medicine; Histology; Oligodendroglial Tumor; Univariate analysis; Oncology; Glioma; Pathology; Fluorescence in situ hybridization; Multivariate analysis; Gastroenterology; Astrocytoma; Biology; Cancer research; Chromosome","score_opus":0.0712405151170058,"score_gpt":0.4019741419732169,"score_spread":0.3307336268562111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149249248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726105,0.0010892429,0.000009491804,0.00060859753,0.00043117593,0.0005211796,0.000008748946,0.0000037826055,0.0000667204],"genre_scores_gemma":[0.99573654,0.0007437314,0.0031749986,0.00007451439,0.00023356573,0.000015002643,0.0000010716755,0.00001534634,0.0000052052087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99404716,0.0006487415,0.0044021346,0.00026636288,0.00040406603,0.00023154992],"domain_scores_gemma":[0.9913268,0.004553025,0.0034375608,0.00024046398,0.0002682547,0.0001738974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016880406,0.00018513582,0.0026819904,0.00037484383,0.00001800305,0.000003879552,0.00016271565,0.0003162614,0.000016190768],"category_scores_gemma":[0.0016348152,0.0001354159,0.00037370747,0.0003268108,0.00035724597,0.00005508943,0.00006218017,0.00043738817,6.360452e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017247782,0.021502191,0.95277476,0.000066748995,0.00021808832,0.0036300484,0.00023891537,0.00027968315,0.0049083466,0.00005382957,0.00012962635,0.014472966],"study_design_scores_gemma":[0.028213644,0.03504503,0.9292961,0.00018657553,0.0007314695,0.0002006651,0.0004367435,0.000036374386,0.0051222695,0.00058192556,0.0000643951,0.000084806925],"about_ca_topic_score_codex":0.0007820264,"about_ca_topic_score_gemma":0.00071296404,"teacher_disagreement_score":0.026488867,"about_ca_system_score_codex":0.00007014581,"about_ca_system_score_gemma":0.0004232747,"threshold_uncertainty_score":0.55221003},"labels":[],"label_agreement":null},{"id":"W2149415769","doi":"10.1200/jco.2006.06.4840","title":"Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Chemoradiotherapy; Radiation therapy; Surgery; Adenocarcinoma; Cancer; Regimen; Dissection (medical); Stage (stratigraphy); Chemotherapy; Oncology; Internal medicine","score_opus":0.11003615795079984,"score_gpt":0.44045589038315214,"score_spread":0.3304197324323523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149415769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970124,0.00013697898,0.00012452755,0.0017280984,0.00018161563,0.0007114309,0.0000076082415,0.0000034965337,0.00009385517],"genre_scores_gemma":[0.99819213,0.00009644684,0.0012854935,0.00023366685,0.00012348428,0.0000051066872,0.0000074249897,0.0000066535395,0.000049621256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953736,0.0013367468,0.0025889766,0.00016597754,0.0003932709,0.00014141499],"domain_scores_gemma":[0.995396,0.0014518354,0.002491725,0.00016011336,0.0004077045,0.00009259785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005250284,0.00012543362,0.0016717296,0.00020253148,0.000021087926,0.0000031442369,0.00008935207,0.00018206099,0.000028405757],"category_scores_gemma":[0.0019955104,0.000080456135,0.00019742869,0.00027636564,0.00025523364,0.00009256271,0.000036580896,0.00035279608,1.554825e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44798982,0.008082226,0.53345823,0.000018302633,0.00007006059,0.000025516258,0.000070280716,0.000011496083,0.00004245995,0.00003373253,0.00007360558,0.010124286],"study_design_scores_gemma":[0.2972983,0.0909956,0.6112394,0.000020073177,0.00008426724,0.0000027782178,0.000039233564,0.000030499014,0.000041020437,0.00014939462,0.000060256785,0.000039163337],"about_ca_topic_score_codex":0.00007793569,"about_ca_topic_score_gemma":0.000020364907,"teacher_disagreement_score":0.1506915,"about_ca_system_score_codex":0.000102345024,"about_ca_system_score_gemma":0.00051301264,"threshold_uncertainty_score":0.32809058},"labels":[],"label_agreement":null},{"id":"W2149568734","doi":"10.1200/jco.2006.08.2024","title":"Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Ottawa; University of British Columbia","funders":"","keywords":"Medicine; Aerobic exercise; Breast cancer; Quality of life (healthcare); Physical therapy; Randomized controlled trial; Internal medicine; Psychosocial; Lymphedema; Cancer; Lean body mass; Nursing","score_opus":0.018233824119267262,"score_gpt":0.3822727521623391,"score_spread":0.3640389280430718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149568734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011695,0.0036031187,0.00003812437,0.0014867006,0.0024822762,0.0019498019,0.0000013114837,0.0000034534082,0.000318264],"genre_scores_gemma":[0.99213505,0.006113519,0.0002734772,0.0007748717,0.0005192831,0.00003416701,4.2049882e-7,0.0000146609145,0.00013457742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955418,0.00067564595,0.003074129,0.00016111525,0.0003351239,0.00021218156],"domain_scores_gemma":[0.9892471,0.007722902,0.0022435426,0.00009508434,0.0004662916,0.00022509367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007334075,0.00014013489,0.0043259193,0.00016191497,0.000013945797,0.0000042126594,0.000082355626,0.00028430932,0.000043421256],"category_scores_gemma":[0.0033804947,0.000088369976,0.0006807531,0.00012280607,0.00021053311,0.00006287647,0.00001996597,0.00057225965,3.9359105e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9227537,0.0018006881,0.031746786,0.00015854713,0.00027845288,0.00008707842,0.00046326048,3.207009e-7,0.00011141564,0.000003637837,0.00016862227,0.042427514],"study_design_scores_gemma":[0.78335446,0.0012308441,0.21308571,0.0012698263,0.0005371044,0.000004961703,0.00005043536,0.000009109059,0.00006536905,0.000029910081,0.00030200736,0.00006027563],"about_ca_topic_score_codex":0.00010262865,"about_ca_topic_score_gemma":0.0009856554,"teacher_disagreement_score":0.18133892,"about_ca_system_score_codex":0.00014053399,"about_ca_system_score_gemma":0.00046910127,"threshold_uncertainty_score":0.4047012},"labels":[],"label_agreement":null},{"id":"W2149583511","doi":"10.1200/jco.2014.60.1914","title":"Hospitalization Rates Among Survivors of Young Adult Malignancies","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Rainbow Health Ontario","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.11599617012633864,"score_gpt":0.45448826086438676,"score_spread":0.3384920907380481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149583511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852659,0.0005432375,0.0006143757,0.006542908,0.0031897037,0.00017286887,0.0000039106753,0.000014850656,0.0036522597],"genre_scores_gemma":[0.9937897,0.0003958558,0.0023830899,0.0016562784,0.0014550007,0.0000018096774,0.0000046583837,0.000021834412,0.00029181357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945469,0.0007487331,0.0035343042,0.00017518848,0.0007801519,0.00021472613],"domain_scores_gemma":[0.9917649,0.0014385944,0.0034560743,0.0002500452,0.0025331804,0.00055719545],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007038157,0.00014907264,0.0017889076,0.00014668996,0.000021928929,0.0000084612175,0.00021261944,0.0003957368,0.000052446132],"category_scores_gemma":[0.020304436,0.00011432459,0.00048390316,0.00024277071,0.0004281845,0.00023046519,0.000058330595,0.0005804019,0.000011418086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014551271,0.0009800249,0.98148024,0.00007568015,0.00027808046,0.0001167246,0.0014546132,0.000028315742,0.000045995388,0.00045293424,0.00991478,0.0037175042],"study_design_scores_gemma":[0.006507063,0.010885487,0.9727165,0.00035705368,0.00032549005,0.00016331347,0.0025476443,0.00009050019,0.00048102209,0.0010225995,0.004767965,0.00013537805],"about_ca_topic_score_codex":0.0008123106,"about_ca_topic_score_gemma":0.00137542,"teacher_disagreement_score":0.013266278,"about_ca_system_score_codex":0.00012107572,"about_ca_system_score_gemma":0.0019643279,"threshold_uncertainty_score":0.98794794},"labels":[],"label_agreement":null},{"id":"W2149624927","doi":"10.1200/jco.2012.43.6766","title":"Effects of Melatonin on Appetite and Other Symptoms in Patients With Advanced Cancer and Cachexia: A Double-Blind Placebo-Controlled Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Dietary Effects on Health","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute","keywords":"Medicine; Appetite; Cachexia; Melatonin; Anorexia; Placebo; Internal medicine; Weight loss; Cancer; Interim analysis; Quality of life (healthcare); Randomized controlled trial; Gastroenterology; Obesity; Pathology","score_opus":0.03731447183105706,"score_gpt":0.4168356568200104,"score_spread":0.3795211849889533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149624927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992916,0.00060687884,0.0000027951182,0.0014474209,0.00053421245,0.003940715,8.9219526e-7,0.0000041337717,0.00054695056],"genre_scores_gemma":[0.9974676,0.00026888098,0.00038932764,0.0013871447,0.0002836511,0.00010155628,4.3497013e-7,0.000021086962,0.000080360296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99709505,0.00046162462,0.0016585969,0.00021109213,0.0003383175,0.00023530866],"domain_scores_gemma":[0.9932342,0.0045323134,0.0015304219,0.000120648285,0.00021778165,0.0003646211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017682047,0.0001707253,0.0022799517,0.00019556623,0.000014365759,0.0000055829505,0.00006716191,0.00031080068,0.00003188223],"category_scores_gemma":[0.0011776794,0.00009942757,0.0001358628,0.000108423104,0.00019854362,0.00011187982,0.00002360838,0.0008192795,0.0000029072064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7870119,0.0021184252,0.17131859,0.00013959692,0.00037190277,0.000034398527,0.00006640325,0.000016592036,0.000022796836,0.000026071493,0.000059591282,0.03881369],"study_design_scores_gemma":[0.69854844,0.06576894,0.2342397,0.000619612,0.00027951956,0.0000075645985,0.000008767833,0.000050696188,0.000034236113,0.000021575934,0.00035286127,0.00006806903],"about_ca_topic_score_codex":0.00010072869,"about_ca_topic_score_gemma":0.00007443932,"teacher_disagreement_score":0.08846347,"about_ca_system_score_codex":0.00009334834,"about_ca_system_score_gemma":0.00061213324,"threshold_uncertainty_score":0.40545386},"labels":[],"label_agreement":null},{"id":"W2149626092","doi":"10.1200/jco.2003.04.075","title":"Phase III Study of <i>N,N</i>-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Doxorubicin; Metastatic breast cancer; Breast cancer; Cancer; Internal medicine; Oncology; Chemotherapy","score_opus":0.2747917362226942,"score_gpt":0.5594949828497567,"score_spread":0.28470324662706253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149626092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98190194,0.0013077358,0.000033736054,0.0063818046,0.0067285304,0.003170277,0.00022427461,0.000009634471,0.00024209176],"genre_scores_gemma":[0.995193,0.0014720102,0.00047215662,0.0009610047,0.001517415,0.00020599178,0.00002965975,0.00004419275,0.00010454113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9837889,0.003376413,0.009806866,0.00067259633,0.0017138295,0.0006413902],"domain_scores_gemma":[0.9833116,0.006685628,0.0073489803,0.0003667716,0.0013892282,0.00089781743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015566899,0.00054192013,0.0072734295,0.00048211584,0.00008117861,0.000008903732,0.0004669891,0.00031742282,0.00043464787],"category_scores_gemma":[0.0032139788,0.00037723788,0.000653825,0.0009092126,0.0006027579,0.00022869938,0.00012803939,0.0018347828,9.2393265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55446136,0.22178516,0.119002,0.00018854099,0.016340645,0.0028363992,0.0017739078,0.0031713052,0.00059296197,0.000099777906,0.0060694166,0.07367855],"study_design_scores_gemma":[0.60832703,0.23890713,0.13557163,0.000317425,0.008161793,0.00013028333,0.0032304432,0.000084985724,0.00022743821,0.00010258237,0.0045336764,0.00040555486],"about_ca_topic_score_codex":0.26996073,"about_ca_topic_score_gemma":0.85247415,"teacher_disagreement_score":0.5825134,"about_ca_system_score_codex":0.0020698484,"about_ca_system_score_gemma":0.019759707,"threshold_uncertainty_score":0.999868},"labels":[],"label_agreement":null},{"id":"W2149725504","doi":"10.1200/jco.2006.09.8525","title":"Evidence-Based Recommendations for Local Therapy for Soft Tissue Sarcomas","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rhabdomyosarcoma; Radiation therapy; Soft tissue; Sarcoma; Soft tissue sarcoma; Chemotherapy; Disease; Surgery; Amputation; Radical surgery; Randomized controlled trial; Clinical trial; Adjuvant therapy; Oncology; Internal medicine; Cancer; Pathology","score_opus":0.6517110801828637,"score_gpt":0.6260880592766624,"score_spread":0.025623020906201277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149725504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000049448345,0.9493387,0.029512145,0.016350439,0.0021719702,0.0024864175,0.000042759886,0.000011338308,0.00008133133],"genre_scores_gemma":[0.000045702553,0.9566373,0.034740873,0.004615095,0.003373935,0.00028475584,0.00007288679,0.000063491236,0.00016593242],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936907,0.0005187263,0.004776842,0.0003428854,0.00030235224,0.00036844515],"domain_scores_gemma":[0.94862056,0.04593048,0.0038251206,0.0003166541,0.00084587594,0.00046131914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006476948,0.00036203823,0.0058785486,0.0003139352,0.00007928961,0.000015037683,0.00027567978,0.001158983,0.00019793786],"category_scores_gemma":[0.006171832,0.00022019944,0.0035092973,0.00017363172,0.0001903114,0.00007647926,0.00002291004,0.0009414161,0.000021803558],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016801071,0.0039151916,0.00012866144,0.0014501177,0.0011200807,0.0001505875,0.0000051473053,7.309227e-7,4.592113e-8,0.00008045992,0.04138991,0.95007896],"study_design_scores_gemma":[0.008283359,0.026451627,0.00012250351,0.012918681,0.0041348045,0.00028169475,0.000009233249,0.000018188552,0.0000030796773,0.00017286492,0.9474367,0.00016726779],"about_ca_topic_score_codex":0.000005587162,"about_ca_topic_score_gemma":0.000012440408,"teacher_disagreement_score":0.9499117,"about_ca_system_score_codex":0.00057476247,"about_ca_system_score_gemma":0.0059094653,"threshold_uncertainty_score":0.9997261},"labels":[],"label_agreement":null},{"id":"W2149803846","doi":"10.1200/jco.2006.09.4482","title":"Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Letrozole; Medicine; Tamoxifen; Internal medicine; Anastrozole; Oncology; Hazard ratio; Estrogen receptor; Breast cancer; Progesterone receptor; Placebo; Cancer; Gynecology; Confidence interval; Pathology","score_opus":0.125162219222643,"score_gpt":0.4679131589890779,"score_spread":0.3427509397664349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149803846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925432,0.003204525,0.000067052606,0.0015481929,0.0019684623,0.0003759222,0.00012593121,0.0000013708167,0.00016534411],"genre_scores_gemma":[0.99131364,0.0028366442,0.0036416342,0.0010284137,0.0011073957,0.000010197238,0.000011449836,0.000015123963,0.0000355175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994959,0.00069490523,0.003358244,0.00024950533,0.00045383576,0.00028453703],"domain_scores_gemma":[0.9938578,0.0015914532,0.003461258,0.00019337103,0.00064988906,0.00024621736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006419076,0.00016803441,0.001567394,0.000052837568,0.00004538649,0.0000031615068,0.00027355604,0.00021356643,0.000019260664],"category_scores_gemma":[0.0057795485,0.000107060034,0.00041392585,0.0001207828,0.00042217533,0.00001200465,0.00016484484,0.00030672175,1.514099e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029832423,0.0023268417,0.51378405,0.000053300977,0.0025295338,0.000010380048,0.000089165245,0.000062440384,0.0805518,0.000083982806,0.011498118,0.35917795],"study_design_scores_gemma":[0.011017068,0.0044739326,0.837243,0.00012725001,0.00017004556,0.000021131505,0.00013781711,9.250181e-7,0.022125445,0.0000248774,0.12452476,0.00013373037],"about_ca_topic_score_codex":0.0027837362,"about_ca_topic_score_gemma":0.009719311,"teacher_disagreement_score":0.35904422,"about_ca_system_score_codex":0.00020143593,"about_ca_system_score_gemma":0.005032462,"threshold_uncertainty_score":0.89273715},"labels":[],"label_agreement":null},{"id":"W2149879397","doi":"10.1200/jco.2014.55.1143","title":"Role of Radiation Therapy in Palliative Care of the Patient With Cancer","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Subspecialty; Radiation therapy; Palliative care; Specialty; Quality of life (healthcare); Psychological intervention; Cancer; Intensive care medicine; Disease; Intervention (counseling); Systemic therapy; Internal medicine; Family medicine; Nursing; Breast cancer","score_opus":0.14068128589184276,"score_gpt":0.5139428543851448,"score_spread":0.373261568493302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149879397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007970092,0.9892477,0.0000075644857,0.0004394363,0.0003910702,0.0008843569,0.000016213471,0.0000010744077,0.0010424859],"genre_scores_gemma":[0.013671709,0.985381,0.00028303062,0.00039672392,0.00019912979,0.000019956593,0.0000047568674,0.000017744222,0.000025950014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948743,0.0012036934,0.0031613396,0.00013594904,0.0005123274,0.00011240426],"domain_scores_gemma":[0.98987323,0.0014873666,0.007845949,0.00025695082,0.00042505146,0.00011145805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014412624,0.00016476083,0.0038229742,0.00014846856,0.000007909876,0.0000015171785,0.00021472099,0.00024424942,0.000099804354],"category_scores_gemma":[0.0014162392,0.00007633457,0.0008487396,0.00020720245,0.00015113753,0.000023985309,0.000037867692,0.00073855574,9.114943e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088701845,0.00067939167,0.007455679,0.0030762386,0.0007290976,0.000022338292,0.00025767967,0.000009790486,1.2957663e-7,0.000034891807,0.00028525526,0.9865625],"study_design_scores_gemma":[0.0046135597,0.008718802,0.032425858,0.009879544,0.0025389052,0.0000056109566,0.00025986292,0.000006787867,0.000002135248,0.000045765813,0.94142646,0.00007672545],"about_ca_topic_score_codex":0.00003381476,"about_ca_topic_score_gemma":0.000048769078,"teacher_disagreement_score":0.9864858,"about_ca_system_score_codex":0.00017607686,"about_ca_system_score_gemma":0.002986654,"threshold_uncertainty_score":0.52981955},"labels":[],"label_agreement":null},{"id":"W2149951063","doi":"10.1200/jco.2004.99.042","title":"A Recent Illustration of Some Essentials of Circadian Chronotherapy Study Design","year":2004,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Chronotherapy (sleep phase); Medicine; Circadian rhythm; Intensive care medicine; Internal medicine","score_opus":0.2496642569734486,"score_gpt":0.48006366982699133,"score_spread":0.23039941285354273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149951063","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05605049,0.005229615,0.00047510225,0.931671,0.0041476404,0.0019790882,0.000021438127,0.0000075171956,0.00041811058],"genre_scores_gemma":[0.41303992,0.06073131,0.009895329,0.48201936,0.033560947,0.00007121891,0.00004851755,0.00015969669,0.000473696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934205,0.00097461115,0.004448044,0.0002719619,0.00065788045,0.00022704102],"domain_scores_gemma":[0.9906357,0.0019517704,0.0061172666,0.00034852512,0.0007718336,0.00017492418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030559248,0.00024444133,0.003443106,0.0002727541,0.000018616915,0.0000060196653,0.00019954143,0.0012216195,0.000588997],"category_scores_gemma":[0.00075392926,0.00017438605,0.0008063279,0.00013882869,0.00022642722,0.00007533439,0.000018349003,0.0017620738,0.00000681288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058745723,0.025754286,0.012780203,0.00041931428,0.010837161,0.007142532,0.00059002475,0.00025438468,0.000108012246,0.000075208685,0.57064015,0.36552417],"study_design_scores_gemma":[0.037945587,0.11773827,0.07684676,0.001130547,0.005112695,0.00026954577,0.00011429502,0.0000053444487,0.000601173,0.000946715,0.7590347,0.00025439306],"about_ca_topic_score_codex":0.000057788457,"about_ca_topic_score_gemma":0.000019781452,"teacher_disagreement_score":0.44965166,"about_ca_system_score_codex":0.00056078465,"about_ca_system_score_gemma":0.0071299314,"threshold_uncertainty_score":0.99849874},"labels":[],"label_agreement":null},{"id":"W2149989622","doi":"10.1200/jco.2014.59.3160","title":"<i>PIK3CA</i> Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Genotyping; Personalized medicine; Breast cancer; Exome sequencing; Precision medicine; Multiplex; Genotype; Exome; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Oncology; Bioinformatics; Internal medicine; Cancer; Mutation; Genetics; Gene; Pathology; Biology","score_opus":0.13853819431666028,"score_gpt":0.468478089078549,"score_spread":0.3299398947618887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149989622","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1442967,0.004819925,0.00006459507,0.84603,0.002828291,0.00065267243,0.0005024784,0.000019343033,0.0007860266],"genre_scores_gemma":[0.10490509,0.016330432,0.006874147,0.81825113,0.05041287,0.000078893514,0.0001433906,0.00026987726,0.002734164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99469304,0.0007989374,0.0029188194,0.00047584416,0.0006054802,0.00050786743],"domain_scores_gemma":[0.99211967,0.0033581224,0.00255814,0.00028229476,0.0011286109,0.0005531548],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010737097,0.0004635044,0.0036035127,0.00033539534,0.00005792151,0.000014677385,0.00023316043,0.0017168705,0.00046766913],"category_scores_gemma":[0.0010629498,0.00031471354,0.000574933,0.00016954663,0.00049236976,0.00017319924,0.00008496034,0.0038954376,0.000017126704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009074041,0.0012950079,0.034508906,0.0000403373,0.0017344647,0.006216509,0.00045123795,0.0000056332055,0.00023404526,0.000011111942,0.3036513,0.6427774],"study_design_scores_gemma":[0.014434765,0.010068456,0.16561647,0.00056608906,0.00065147656,0.002283842,0.000054747612,0.000002327609,0.000040270617,0.00053467555,0.80543804,0.00030886376],"about_ca_topic_score_codex":0.00031255384,"about_ca_topic_score_gemma":0.00024138876,"teacher_disagreement_score":0.6424685,"about_ca_system_score_codex":0.0019378446,"about_ca_system_score_gemma":0.003831393,"threshold_uncertainty_score":0.9999305},"labels":[],"label_agreement":null},{"id":"W2150173061","doi":"10.1200/jco.2001.19.9.2367","title":"Weight Gain in Early-Stage Breast Cancer: Where Do We Go From Here?","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Citation; Medicine; Breast cancer; Clinical Oncology; Stage (stratigraphy); Oncology; Library science; Cancer; Gerontology; Internal medicine","score_opus":0.08425822997479838,"score_gpt":0.43845600733029433,"score_spread":0.35419777735549596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150173061","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12356068,0.013150542,0.000018131504,0.8538977,0.0061879875,0.00027118306,0.00031111648,0.000014145147,0.002588497],"genre_scores_gemma":[0.03320873,0.26902902,0.00073343795,0.56169915,0.11773982,0.00002322931,0.00004601141,0.00022048272,0.017300136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933907,0.0006938685,0.0040347017,0.00050232525,0.0007823939,0.0005960596],"domain_scores_gemma":[0.99284536,0.0023627663,0.0035075094,0.00045760602,0.00035307434,0.00047365986],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014930866,0.00043742458,0.0041207517,0.00031910435,0.000030355002,0.000028813774,0.00046772978,0.003468233,0.006097437],"category_scores_gemma":[0.00029120786,0.00031301955,0.001261506,0.00024226532,0.00028819538,0.00012609606,0.00009243418,0.01138804,0.00010029144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019143064,0.00035346983,0.28945938,0.00005860207,0.00043458934,0.014656606,0.00007141955,0.0000039125066,0.0000027903382,0.0000012582277,0.6093187,0.083725005],"study_design_scores_gemma":[0.0068306457,0.00190589,0.18305147,0.0012564885,0.00047759552,0.000414247,0.00004566338,0.000008372464,0.000001067099,0.0001524247,0.805618,0.00023817328],"about_ca_topic_score_codex":0.004715812,"about_ca_topic_score_gemma":0.0025496439,"teacher_disagreement_score":0.2921986,"about_ca_system_score_codex":0.00097462826,"about_ca_system_score_gemma":0.0034554405,"threshold_uncertainty_score":0.99993217},"labels":[],"label_agreement":null},{"id":"W2150307384","doi":"10.1200/jco.2009.27.5933","title":"Is Mammographic Breast Density a Breast Cancer Risk Factor in Women With <i>BRCA</i> Mutations?","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; MAMMOGRAPHIC DENSITY; Oncology; BRCA mutation; Gynecology; Risk factor; Breast density; Internal medicine; Mammography; Cancer; Obstetrics","score_opus":0.0303247694819749,"score_gpt":0.3796676870308949,"score_spread":0.34934291754892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150307384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881059,0.00006117171,0.000041182506,0.01010099,0.00062632404,0.00013582884,0.00010761708,0.000013473107,0.00080749043],"genre_scores_gemma":[0.99502784,0.00021264328,0.00096690067,0.0030107787,0.0007171136,0.0000064055052,9.057638e-7,0.000018649807,0.000038767885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747056,0.00016424728,0.0013914108,0.00022873587,0.00038094918,0.00036412218],"domain_scores_gemma":[0.9966803,0.000740173,0.0012281673,0.00019974334,0.0005336974,0.00061788986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014885204,0.00017331642,0.0011317036,0.0003936042,0.000046846795,0.000026912783,0.00016392056,0.00027345895,0.00032959782],"category_scores_gemma":[0.0003246603,0.000113864495,0.00036723693,0.0005995173,0.00047767875,0.0003344349,0.000028986673,0.0021361818,0.000007673905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043476056,0.0010309748,0.66470766,0.000012705097,0.0002724407,0.00041118206,0.00016091076,0.0000015993458,0.0001026768,0.000009390618,0.00023861555,0.32870427],"study_design_scores_gemma":[0.0062183407,0.0021234718,0.97844696,0.00012803527,0.000191616,0.009352086,0.00018546065,0.00002180094,0.000016580876,0.00044925997,0.0027424018,0.00012398377],"about_ca_topic_score_codex":0.00016377935,"about_ca_topic_score_gemma":0.00053183665,"teacher_disagreement_score":0.3285803,"about_ca_system_score_codex":0.00008322519,"about_ca_system_score_gemma":0.0012532402,"threshold_uncertainty_score":0.92807657},"labels":[],"label_agreement":null},{"id":"W2150358925","doi":"10.1200/jco.2005.03.045","title":"Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Chemotherapy; Lung cancer; Oncology; Platinum; Internal medicine; Platinum compounds; Cisplatin","score_opus":0.12789743782114668,"score_gpt":0.5192591901018222,"score_spread":0.3913617522806755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150358925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013089707,0.9893638,0.000112417285,0.004162874,0.001423325,0.001712352,0.00021536244,0.00000831854,0.001692592],"genre_scores_gemma":[0.004079608,0.98286045,0.00804326,0.0027111997,0.0009488706,0.00023858361,0.00017464963,0.00009405794,0.0008493058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922595,0.00078016776,0.005368066,0.00053675077,0.000668169,0.00038736576],"domain_scores_gemma":[0.9848885,0.0048738755,0.008236869,0.0007973324,0.0008729164,0.00033053313],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023230368,0.0005894454,0.011768058,0.0009018185,0.000054717286,0.000037479767,0.0006132148,0.0012059397,0.0008200602],"category_scores_gemma":[0.001071344,0.00030597835,0.009738038,0.002372407,0.00015042194,0.00013758636,0.00004182385,0.0024652912,0.0000019412034],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035556701,0.004140803,0.0018374104,0.003661356,0.21137683,0.00028779026,0.00027785898,0.0039491556,0.0000021994622,0.0000057760158,0.0025394422,0.76836574],"study_design_scores_gemma":[0.021498106,0.0022036165,0.0012128698,0.002265183,0.48368323,0.000009275382,0.000018880737,0.0008953847,0.0000045407605,0.0000026714933,0.4879714,0.00023486816],"about_ca_topic_score_codex":0.00006601089,"about_ca_topic_score_gemma":0.00053146924,"teacher_disagreement_score":0.76813084,"about_ca_system_score_codex":0.0010405022,"about_ca_system_score_gemma":0.013734577,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W2150505942","doi":"10.1200/jco.2006.06.3875","title":"Impact of a Multi-Disciplinary Patient Education Session on Accrual to a Difficult Clinical Trial: The Toronto Experience With the Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"American Society of Clinical Oncology","keywords":"Medicine; Prostatectomy; Randomized controlled trial; Prostate cancer; Specialty; Brachytherapy; Accrual; Radiation oncologist; Clinical trial; Informed consent; Radiation therapy; Family medicine; General surgery; Surgery; Cancer; Internal medicine; Alternative medicine","score_opus":0.13432040161957073,"score_gpt":0.5429328990849628,"score_spread":0.4086124974653921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150505942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029195,0.00031511358,0.000059704733,0.0033636584,0.00374422,0.0020393494,0.000007700272,0.000007043281,0.00017126053],"genre_scores_gemma":[0.99685836,0.00022090682,0.00019250707,0.0001589046,0.0023250296,0.00017754865,0.000012727152,0.000013334094,0.000040684834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99566007,0.0010107012,0.002424862,0.00025258464,0.00045990688,0.00019185634],"domain_scores_gemma":[0.99419415,0.0026695419,0.0021669695,0.0002545876,0.0004905297,0.0002242351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956348,0.00017610309,0.0009234309,0.00005041394,0.00007891381,0.000021881013,0.00016597605,0.00020132745,0.0000632848],"category_scores_gemma":[0.0012920339,0.00007156567,0.0008194489,0.0001414162,0.00022352871,0.00014224187,0.00006504038,0.00050946104,0.0000031263692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7185037,0.016531745,0.005944305,0.000006337684,0.00024102302,0.000052524156,0.00076718524,0.00007349692,0.000008199752,0.000012775464,0.0028123169,0.25504637],"study_design_scores_gemma":[0.39117253,0.35202968,0.24649271,0.00034059925,0.00040435191,0.000056007382,0.0015656442,0.000067795525,0.00006768255,0.000008455865,0.007691239,0.00010327368],"about_ca_topic_score_codex":0.00038933565,"about_ca_topic_score_gemma":0.00038343997,"teacher_disagreement_score":0.33549795,"about_ca_system_score_codex":0.0008108254,"about_ca_system_score_gemma":0.00153347,"threshold_uncertainty_score":0.29183635},"labels":[],"label_agreement":null},{"id":"W2150567242","doi":"10.1200/jco.2006.08.8229","title":"<i>CHEK2</i> Mutation and Hereditary Breast Cancer","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health","funders":"","keywords":"Medicine; CHEK2; Breast cancer; Mutation; Cancer; Oncology; Internal medicine; Germline mutation; Cancer research; Genetics; Gene","score_opus":0.043193441037464315,"score_gpt":0.4053422227949283,"score_spread":0.362148781757464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150567242","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09539064,0.0091065345,0.0004158709,0.8836863,0.008624914,0.00023243467,0.00030472243,0.000007962124,0.0022306263],"genre_scores_gemma":[0.046350025,0.0036335161,0.004638774,0.85727614,0.08432953,0.000029638863,0.000349923,0.00011901498,0.0032734475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996924,0.00042995426,0.0017637662,0.00034428138,0.00029507373,0.00024295787],"domain_scores_gemma":[0.9966396,0.00033810563,0.0020932218,0.00023202004,0.0005912489,0.00010581106],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011138327,0.00022969779,0.00090396503,0.00008818761,0.000043119762,0.000017944109,0.00028187892,0.0021822078,0.00008779592],"category_scores_gemma":[0.00028233923,0.00019451906,0.00032656267,0.00006797374,0.00032330534,0.000008118861,0.00009468214,0.0019417774,0.0000058280293],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019529015,0.0000829494,0.0015026741,0.000037492162,0.0003519961,0.00079837634,0.000006916255,0.000073582734,0.00021063785,0.0000010165217,0.94530404,0.051435053],"study_design_scores_gemma":[0.0016944768,0.0015587731,0.009944713,0.00004871635,0.0003206222,0.0020399527,0.00001122196,0.000011597535,0.00013059539,0.00026215467,0.98376507,0.0002121054],"about_ca_topic_score_codex":0.000068033165,"about_ca_topic_score_gemma":0.00012104254,"teacher_disagreement_score":0.07570461,"about_ca_system_score_codex":0.00014374281,"about_ca_system_score_gemma":0.0027905242,"threshold_uncertainty_score":0.99911314},"labels":[],"label_agreement":null},{"id":"W2150601737","doi":"10.1200/jco.2011.35.2500","title":"Occult Metastases in Lymph Nodes Predict Survival in Resectable Non–Small-Cell Lung Cancer: Report of the ACOSOG Z0040 Trial","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Tobacco-Related Disease Research Program","keywords":"Medicine; Occult; Lymph; Lung; Lung cancer; Oncology; Cancer; Internal medicine; Radiology; Pathology","score_opus":0.15101336573386032,"score_gpt":0.45987328095120916,"score_spread":0.30885991521734885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150601737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873088,0.0013058163,0.0000071465847,0.0018107182,0.0027750207,0.00060290284,0.00001361095,0.000003444465,0.006172533],"genre_scores_gemma":[0.9954307,0.0024417266,0.00075472496,0.00029598307,0.00075662456,0.000045559125,0.0000019364124,0.000015678494,0.0002570768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951503,0.00068065175,0.0032043615,0.00024742447,0.0004341833,0.00028305603],"domain_scores_gemma":[0.99512875,0.0016870464,0.0023231541,0.00035130527,0.00031097306,0.0001987498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005208413,0.00015875284,0.0018322924,0.00014317257,0.000023581553,0.0000044886497,0.00026251102,0.00029618724,0.00019177857],"category_scores_gemma":[0.0024697974,0.00008943874,0.0005826337,0.0002762241,0.00016494565,0.000083546314,0.00009640494,0.0006679371,0.0000012732337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034357633,0.0061344327,0.9512289,0.00009032216,0.00045096924,0.0024082153,0.00020986002,0.000040758005,0.00004168136,0.000015537584,0.0017927664,0.003228913],"study_design_scores_gemma":[0.10933668,0.0054753358,0.8789635,0.0006164054,0.0011350816,0.00019324718,0.00018953148,0.00006324207,0.0012260253,0.00008256267,0.0026242,0.00009423861],"about_ca_topic_score_codex":0.002577109,"about_ca_topic_score_gemma":0.0028067646,"teacher_disagreement_score":0.07497905,"about_ca_system_score_codex":0.0006027325,"about_ca_system_score_gemma":0.004339497,"threshold_uncertainty_score":0.7698081},"labels":[],"label_agreement":null},{"id":"W2150640476","doi":"10.1200/jco.2003.05.165","title":"Markers of Coagulation and Angiogenesis in Cancer-Associated Venous Thromboembolism","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Montreal General Hospital","funders":"McGill University","keywords":"Medicine; Venous thrombosis; Cancer; Coagulation; Internal medicine; Gastroenterology; Plasminogen activator; Fibrinolysis; Fibrinogen; Thrombosis; Hemostasis; Malignancy; Antithrombin; Heparin","score_opus":0.1083184840281362,"score_gpt":0.4479734727842721,"score_spread":0.33965498875613587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150640476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922093,0.0016012467,0.00001599618,0.0016559426,0.000674878,0.00019359814,0.0000020013833,0.0000035027074,0.003643544],"genre_scores_gemma":[0.9932878,0.005035312,0.0006874589,0.00081367884,0.00012126941,0.0000035842331,9.598078e-7,0.000011183364,0.000038727925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747133,0.00038638688,0.001611476,0.00012537041,0.0002332075,0.00017222234],"domain_scores_gemma":[0.99746984,0.0007484324,0.0012933207,0.00009844918,0.00023325392,0.00015667277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030203632,0.00009237062,0.0017682626,0.00017008344,0.000019470663,0.0000032259318,0.00005988439,0.00024928717,0.00014527129],"category_scores_gemma":[0.0021513943,0.00007428481,0.00022950977,0.00018789459,0.0001202529,0.000060068098,0.000020863663,0.0002638766,0.000001152031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012941449,0.012652943,0.7484253,0.00014656971,0.0016538545,0.00034927367,0.0004823362,0.00021972727,0.00059967546,0.0017755205,0.0060712695,0.2263294],"study_design_scores_gemma":[0.0043720147,0.006062512,0.980631,0.0001303034,0.00055670255,0.00002750042,0.00017498019,0.000043062933,0.000122993,0.00055472204,0.007261427,0.00006278835],"about_ca_topic_score_codex":0.00019883616,"about_ca_topic_score_gemma":0.00024577093,"teacher_disagreement_score":0.23220572,"about_ca_system_score_codex":0.00013920075,"about_ca_system_score_gemma":0.000612943,"threshold_uncertainty_score":0.3029247},"labels":[],"label_agreement":null},{"id":"W2150688669","doi":"10.1200/jco.2007.12.0352","title":"Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":261,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; Concordance; Lung cancer; Microarray; Hazard ratio; TaqMan; Gene; Gene expression; Real-time polymerase chain reaction; Biology; Confidence interval","score_opus":0.09386054127647486,"score_gpt":0.4408110976917573,"score_spread":0.34695055641528244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150688669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88142264,0.0012037295,0.1125662,0.00091945415,0.002006256,0.00035791539,0.000009867813,0.000004035161,0.001509926],"genre_scores_gemma":[0.98498523,0.0007138617,0.007989392,0.0011997828,0.0028756976,0.000031760337,0.000010197547,0.000027785685,0.0021662703],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977186,0.00008623155,0.0014350897,0.00027795273,0.00017752322,0.00030465293],"domain_scores_gemma":[0.9972496,0.00031653445,0.0013803978,0.00023461181,0.0005202805,0.00029857905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002558634,0.00014359033,0.00049983495,0.000073004434,0.00006143702,0.000013831344,0.00030933315,0.00056421116,0.00004643822],"category_scores_gemma":[0.0007385784,0.000112239766,0.00040773032,0.00008937676,0.00009878676,0.0000064498995,0.00006171369,0.00037298957,0.0000031776735],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048260465,0.0012372856,0.32768482,0.00008753243,0.00035249747,0.000045098946,0.00006989689,0.000112766524,0.49709347,0.000069835805,0.04253277,0.12588799],"study_design_scores_gemma":[0.0064228475,0.0058858762,0.34317434,0.00004684032,0.00026464206,0.000020153318,0.00009807933,0.00032050486,0.11210016,0.00012141962,0.5312649,0.0002802556],"about_ca_topic_score_codex":0.000011691987,"about_ca_topic_score_gemma":0.00017826348,"teacher_disagreement_score":0.48873213,"about_ca_system_score_codex":0.000051272382,"about_ca_system_score_gemma":0.0011564704,"threshold_uncertainty_score":0.4577005},"labels":[],"label_agreement":null},{"id":"W2150789685","doi":"10.1200/jco.2010.29.5261","title":"The Birth of the Subspecialty of Medical Oncology and Examples of Its Early Scientific Foundations","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Subspecialty; Medicine; Oncology; Internal medicine; Clinical Oncology; Clinical trial; Disease; Breast cancer; Cancer; Family medicine","score_opus":0.12061638032616627,"score_gpt":0.5350157937418557,"score_spread":0.4143994134156894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150789685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97034043,0.0010327705,0.00017745042,0.0196184,0.006954855,0.00018809918,0.000005861816,0.0000023288871,0.0016798214],"genre_scores_gemma":[0.9917189,0.0029616607,0.0029160846,0.0005006543,0.0014399644,0.0000019899373,4.558799e-7,0.000008879208,0.00045144523],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604183,0.00066429615,0.0023598277,0.00014118146,0.0006207909,0.0001720911],"domain_scores_gemma":[0.98329026,0.012286265,0.0030362501,0.00032233342,0.0008483238,0.00021654424],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.009539398,0.000089972455,0.0011455683,0.0000929164,0.00015943461,0.000004462559,0.00051650585,0.00063731294,0.00031142778],"category_scores_gemma":[0.015410258,0.000042815635,0.00032890943,0.00023543726,0.0058506234,0.00007329979,0.00010078421,0.0015367832,0.0000013384836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050320528,0.0035882404,0.27449384,0.00010409742,0.0007960532,0.00008147769,0.001215828,0.0000056518643,0.013068783,0.05115218,0.004655746,0.6458061],"study_design_scores_gemma":[0.004321127,0.006411692,0.41766074,0.00006773525,0.00016321609,0.00043331872,0.00019381075,0.000045958815,0.0006887084,0.003450285,0.5665193,0.000044050423],"about_ca_topic_score_codex":0.000010554735,"about_ca_topic_score_gemma":0.00069224375,"teacher_disagreement_score":0.64576197,"about_ca_system_score_codex":0.000040446834,"about_ca_system_score_gemma":0.004428178,"threshold_uncertainty_score":0.9968549},"labels":[],"label_agreement":null},{"id":"W2150849651","doi":"10.1200/jco.2009.27.3383","title":"Active Surveillance in Young Patients With Prostate Cancer: The Unanswered Question","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.039734515128851414,"score_gpt":0.41029506094895013,"score_spread":0.37056054582009873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150849651","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42881534,0.0004952283,0.0000015021875,0.5667772,0.0026720224,0.00075779855,0.00007266388,0.00000528041,0.00040291285],"genre_scores_gemma":[0.5764485,0.012976704,0.00043440532,0.3995117,0.009489634,0.00020194413,0.00018090392,0.00009658298,0.0006596147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639463,0.0006504752,0.0017887702,0.00029148746,0.00054879725,0.00032581657],"domain_scores_gemma":[0.9937702,0.0017960988,0.003097468,0.00027401754,0.00092258124,0.0001396304],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0015225576,0.00026024575,0.0018374629,0.00011599839,0.00003851646,0.00001453386,0.0001905497,0.001417899,0.000060840353],"category_scores_gemma":[0.00085348915,0.0001262946,0.00030266284,0.00014875185,0.00029673468,0.00009014311,0.000034139437,0.008022226,0.000004994638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044762087,0.0008453166,0.77907556,0.000048601527,0.00049403467,0.0011309894,0.00010457548,0.0000051578827,8.0471006e-7,0.0000016645465,0.1413316,0.072485514],"study_design_scores_gemma":[0.0073076547,0.006565577,0.6385872,0.00039596492,0.00024354181,0.000045717257,0.0000097860075,0.0000020062673,0.000006976597,0.00005162003,0.34669787,0.00008613794],"about_ca_topic_score_codex":0.00042840187,"about_ca_topic_score_gemma":0.0030039477,"teacher_disagreement_score":0.20536627,"about_ca_system_score_codex":0.0006772138,"about_ca_system_score_gemma":0.002862839,"threshold_uncertainty_score":0.99987847},"labels":[],"label_agreement":null},{"id":"W2151063703","doi":"10.1200/jco.2010.32.8815","title":"Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Prednisone; Internal medicine; Adverse effect; Hazard ratio; Clinical endpoint; Urology; Interim analysis; Calcitriol; Oncology; Randomized controlled trial; Surgery; Chemotherapy; Cancer; Confidence interval; Vitamin D and neurology","score_opus":0.27565016283390886,"score_gpt":0.5186674086071955,"score_spread":0.24301724577328665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151063703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763967,0.00077711034,0.00013154362,0.0012314391,0.0021433914,0.006944992,0.00018052112,0.000008773458,0.00094254693],"genre_scores_gemma":[0.98943526,0.0017805076,0.0058511184,0.0001697475,0.00080512476,0.000442904,0.00005219921,0.0000406991,0.001422425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99449676,0.00057512894,0.0033663595,0.00036196798,0.0007307876,0.00046899557],"domain_scores_gemma":[0.99107164,0.0027971286,0.003344361,0.00029610444,0.0019245961,0.0005661864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038296203,0.00028469609,0.0036196534,0.00018031998,0.00010495312,0.000025489875,0.0003756361,0.00034231774,0.00018456992],"category_scores_gemma":[0.0025883834,0.00016196708,0.00044127717,0.00021570249,0.00070044136,0.00031274158,0.00009876664,0.00069425965,0.000002810875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9605397,0.012742624,0.00029312895,0.00010463167,0.0026572451,0.00020995548,0.0005021489,0.000008624326,0.000066983,0.0001627152,0.0011813989,0.021530846],"study_design_scores_gemma":[0.8853643,0.10889498,0.0007845353,0.0002159731,0.0021044558,0.000009145885,0.00011325895,0.00015173272,0.0002355053,0.00020106556,0.0017732787,0.00015180136],"about_ca_topic_score_codex":0.0006016528,"about_ca_topic_score_gemma":0.0002204091,"teacher_disagreement_score":0.09615236,"about_ca_system_score_codex":0.00054577546,"about_ca_system_score_gemma":0.008719676,"threshold_uncertainty_score":0.99689996},"labels":[],"label_agreement":null},{"id":"W2151232297","doi":"10.1200/jco.2000.18.7.1440","title":"Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Suramin; Placebo; Analgesic; Internal medicine; Hydrocortisone; Randomized controlled trial; Adverse effect; Anesthesia; Pathology","score_opus":0.04748725106251546,"score_gpt":0.4028778245394156,"score_spread":0.3553905734769002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151232297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885366,0.002601036,0.0001247265,0.0012618916,0.00071601395,0.0064817946,0.00004269421,0.000024034742,0.00021121238],"genre_scores_gemma":[0.9868059,0.009488067,0.00069292466,0.00042991585,0.0012377304,0.00033905546,0.00003369139,0.00006025084,0.0009124761],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99066204,0.0012023865,0.006333418,0.00042087727,0.0008269668,0.0005543171],"domain_scores_gemma":[0.9859212,0.0076239677,0.0047282176,0.00041157886,0.0007378484,0.00057718257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005073543,0.00040075037,0.0064270073,0.00030921664,0.00009368253,0.000023189183,0.00030692393,0.00038310376,0.000080065176],"category_scores_gemma":[0.0035797595,0.00026701347,0.0010582198,0.00030252835,0.0004947444,0.00020181217,0.000027687032,0.00077850814,0.0000051896036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7914778,0.0046309577,0.00070179923,0.000058882433,0.001076289,0.00009431515,0.0009503553,0.00042315476,0.00011425634,0.0000010712101,0.0014755663,0.19899555],"study_design_scores_gemma":[0.8905255,0.07695641,0.0070828577,0.0005910484,0.00090165425,0.00008418526,0.00010234504,0.0032771607,0.00008259308,0.000011733138,0.020118069,0.00026643634],"about_ca_topic_score_codex":0.00040839848,"about_ca_topic_score_gemma":0.00010777284,"teacher_disagreement_score":0.19872911,"about_ca_system_score_codex":0.00050956337,"about_ca_system_score_gemma":0.003660562,"threshold_uncertainty_score":0.9999782},"labels":[],"label_agreement":null},{"id":"W2151287754","doi":"10.1200/jco.2014.57.7122","title":"Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Nomogram; Gynecologic oncology; Cervical cancer; Oncology; Internal medicine; Proportional hazards model; Radiation therapy; Stage (stratigraphy); Cancer","score_opus":0.179029111553638,"score_gpt":0.48464357591905993,"score_spread":0.30561446436542195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151287754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921501,0.0027780335,0.00014886177,0.00075326796,0.0021913885,0.0016675349,0.00015873693,0.000013116385,0.00013894742],"genre_scores_gemma":[0.9893865,0.00310065,0.0066723134,0.0002270337,0.0003120447,0.00009102412,0.00017571554,0.000028386221,0.0000063042403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98147666,0.0077806176,0.0084868185,0.00068552984,0.0010770063,0.0004933759],"domain_scores_gemma":[0.9487708,0.041028686,0.0077550733,0.00042207097,0.0012588428,0.00076452433],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.019184059,0.00041585404,0.012042419,0.00077730394,0.000032444408,0.000016228109,0.0005448633,0.001061439,0.00030710152],"category_scores_gemma":[0.06705775,0.0002715368,0.0009515846,0.0014187283,0.00062545424,0.0003082549,0.00019489261,0.0011714394,6.2278724e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17941993,0.008547191,0.7093908,0.0000377661,0.0025155814,0.00009138297,0.00044094163,0.00013818323,0.00006322474,0.0000067683764,0.000016263206,0.09933195],"study_design_scores_gemma":[0.28925472,0.01485179,0.6903519,0.0003214177,0.0029931262,0.000001098174,0.00043510774,0.00060497446,0.000055859004,0.00079857145,0.00016435931,0.00016707735],"about_ca_topic_score_codex":0.0060407347,"about_ca_topic_score_gemma":0.013916267,"teacher_disagreement_score":0.109834775,"about_ca_system_score_codex":0.0011333219,"about_ca_system_score_gemma":0.0032310658,"threshold_uncertainty_score":0.99997365},"labels":[],"label_agreement":null},{"id":"W2151423894","doi":"10.1200/jco.2009.23.0508","title":"High Rate of Febrile Neutropenia in Patients With Operable Breast Cancer Receiving Docetaxel and Cyclophosphamide","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital","funders":"","keywords":"Medicine; Docetaxel; Febrile neutropenia; Cyclophosphamide; Breast cancer; Oncology; Internal medicine; Neutropenia; Cancer; Chemotherapy","score_opus":0.03246827216693339,"score_gpt":0.3717157371307822,"score_spread":0.33924746496384883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151423894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75137466,0.00043081268,0.0000026848595,0.24573766,0.0013191149,0.0003369844,0.00003437923,0.0000052776704,0.00075844885],"genre_scores_gemma":[0.534162,0.0058857435,0.0010266649,0.45040634,0.006681209,0.000018891606,0.000024396017,0.00008385313,0.0017108897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961369,0.0004600346,0.0024214305,0.00031616498,0.00032939104,0.00033605003],"domain_scores_gemma":[0.9955162,0.00076467975,0.002502484,0.00024105459,0.0007651483,0.00021043865],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001173278,0.00027082252,0.0028193176,0.00022741307,0.000039430462,0.000015960914,0.00018469663,0.0008383407,0.00037203362],"category_scores_gemma":[0.0002561107,0.00017965831,0.00026656338,0.0002441729,0.00023003145,0.00017802519,0.00005020184,0.0038881688,0.0000038057813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067781205,0.0009394338,0.6362313,0.0001477184,0.00049689383,0.0010724053,0.00002636796,0.00009651192,0.000021489654,0.0000055564774,0.32064247,0.033541754],"study_design_scores_gemma":[0.01155783,0.0061246627,0.7865905,0.0008630803,0.0005617259,0.00023549268,0.000004664924,0.0000011815387,0.000012322986,0.000043002558,0.19385865,0.00014685892],"about_ca_topic_score_codex":0.0007369706,"about_ca_topic_score_gemma":0.00023390574,"teacher_disagreement_score":0.21721265,"about_ca_system_score_codex":0.00028320798,"about_ca_system_score_gemma":0.0020002949,"threshold_uncertainty_score":0.9984099},"labels":[],"label_agreement":null},{"id":"W2151638388","doi":"10.1200/jco.2006.09.4490","title":"Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Takeda Oncology; Genentech","keywords":"Tissue microarray; Immunohistochemistry; Medicine; Concordance; Lymphoma; Biomarker; Pathology; Diffuse large B-cell lymphoma; Oncology; CD20; Follicular lymphoma; Internal medicine; Biology","score_opus":0.05768192276787162,"score_gpt":0.43886856693056936,"score_spread":0.38118664416269776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151638388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99160534,0.0018129253,0.00070989184,0.0014413754,0.000730179,0.0031167835,0.000039798837,0.00001304804,0.0005306631],"genre_scores_gemma":[0.99483573,0.00034049834,0.0027481753,0.0010648966,0.0006476149,0.00016723975,0.000048972546,0.000034219534,0.00011264043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921595,0.0007962921,0.00558059,0.0004958096,0.00051854644,0.00044924725],"domain_scores_gemma":[0.97727543,0.018012408,0.003091934,0.0005839339,0.0006567223,0.00037954617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009112061,0.00028815473,0.001982887,0.00016303675,0.00007933076,0.000017874365,0.00039681498,0.0006243238,0.000060289116],"category_scores_gemma":[0.0052163624,0.00018853912,0.0007964844,0.00030688447,0.0003734727,0.000095899035,0.000117331634,0.00031915112,0.000024132372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015647117,0.107266955,0.73761123,0.00003609994,0.000921881,0.00030395272,0.0002340681,2.7799965e-7,0.0014534466,0.000028107075,0.0022520234,0.13424483],"study_design_scores_gemma":[0.10836441,0.009905345,0.8406499,0.00012170533,0.0015445784,0.00011978219,0.00062113605,0.000021361615,0.0022902219,0.00016490341,0.036035497,0.00016118836],"about_ca_topic_score_codex":0.00016685887,"about_ca_topic_score_gemma":0.00005712818,"teacher_disagreement_score":0.13408363,"about_ca_system_score_codex":0.0004892108,"about_ca_system_score_gemma":0.0016642933,"threshold_uncertainty_score":0.76884025},"labels":[],"label_agreement":null},{"id":"W2151651942","doi":"10.1200/jco.2010.28.3291","title":"Reply to J.B. Aragon-Ching","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.11486492398111812,"score_gpt":0.4996086523454194,"score_spread":0.38474372836430126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151651942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90551543,0.00014105158,0.000071255025,0.08472678,0.0034885397,0.00014241156,0.0000014170772,0.000007042038,0.0059060776],"genre_scores_gemma":[0.9436175,0.00028369945,0.012134218,0.041174047,0.0024766445,0.000004916674,6.3860483e-7,0.000011227047,0.00029707333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800795,0.00008003159,0.0014083496,0.0001376727,0.00020331622,0.00016268063],"domain_scores_gemma":[0.9970625,0.0011396944,0.00072134944,0.0001988252,0.00029383114,0.0005838173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022098986,0.00008078945,0.00089049945,0.00007645175,0.000025746922,0.0000073954116,0.000096874595,0.00016485188,0.00019499894],"category_scores_gemma":[0.004361722,0.00005137726,0.00034533106,0.00007844708,0.00006135336,0.0000691505,0.000035256835,0.0009912449,0.00006591315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025589583,0.002629175,0.25459602,0.000015630134,0.00037019295,0.0021874732,0.00013902284,0.0000062406075,0.00155769,0.0006127198,0.071825035,0.66350186],"study_design_scores_gemma":[0.003094698,0.010361323,0.30952275,0.000050299084,0.00014743433,0.00044714072,0.000020073581,0.000004877179,0.00061476784,0.00030447968,0.6753891,0.000043028005],"about_ca_topic_score_codex":0.000018321602,"about_ca_topic_score_gemma":0.000021067812,"teacher_disagreement_score":0.6634588,"about_ca_system_score_codex":0.00007425331,"about_ca_system_score_gemma":0.001004927,"threshold_uncertainty_score":0.52217036},"labels":[],"label_agreement":null},{"id":"W2151694080","doi":"10.1200/jco.2012.44.0693","title":"Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Follicular lymphoma; Stem cell; Lymphoma; Transplantation; Oncology; Internal medicine; Biology","score_opus":0.037860650969018014,"score_gpt":0.33635820775871983,"score_spread":0.2984975567897018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151694080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104786,0.001167877,0.00005977627,0.0062792045,0.0002806102,0.0007278649,0.000021267158,0.0000029264259,0.0004126389],"genre_scores_gemma":[0.99563795,0.0020668234,0.0013719792,0.00071055704,0.000092640425,0.000035590056,0.0000068336994,0.000010532131,0.00006709826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978924,0.00014439876,0.0014188269,0.00016295836,0.00018229873,0.00019910916],"domain_scores_gemma":[0.9978273,0.0008072731,0.0006820043,0.00011821494,0.00017297112,0.0003922649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010074378,0.00012507774,0.00089826196,0.00007558702,0.00007246464,0.000008628103,0.000071230104,0.00032136554,0.000014994929],"category_scores_gemma":[0.00007482842,0.000070281814,0.00035147747,0.000053934113,0.00017784882,0.00006142693,0.0000036830772,0.00012393577,4.435628e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018643778,0.003160474,0.7202569,0.00048018765,0.0015489818,0.00466174,0.0007450181,0.0000034587233,0.003142981,0.00028325428,0.0006357986,0.2632168],"study_design_scores_gemma":[0.02008822,0.0063106315,0.9493055,0.00012374809,0.002807963,0.013250853,0.00006526283,0.000025959933,0.0020109296,0.00019542886,0.005730455,0.00008508143],"about_ca_topic_score_codex":0.0050184918,"about_ca_topic_score_gemma":0.021471754,"teacher_disagreement_score":0.2631317,"about_ca_system_score_codex":0.000085966734,"about_ca_system_score_gemma":0.0013489292,"threshold_uncertainty_score":0.99638385},"labels":[],"label_agreement":null},{"id":"W2151726776","doi":"10.1200/jco.2012.30.15_suppl.lba506","title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Breast cancer; Oncology; Protocol (science); Internal medicine; Clinical Oncology; Trastuzumab; Cancer; Family medicine; Gynecology; Medical physics; Alternative medicine; Pathology","score_opus":0.45636250260094796,"score_gpt":0.651772909540381,"score_spread":0.19541040693943307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151726776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94013697,0.00091584394,0.00008974701,0.012276723,0.0012081746,0.04212932,0.00004195896,0.0000070123288,0.0031942797],"genre_scores_gemma":[0.9838424,0.00048173394,0.0027831194,0.0008897895,0.0021485768,0.009691785,0.0000022954962,0.00003328781,0.00012705813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936948,0.0013379408,0.0028573277,0.000158161,0.0015871547,0.0003646521],"domain_scores_gemma":[0.99112034,0.0018459149,0.0022361148,0.0002704108,0.0040997355,0.00042748955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024644936,0.00013708453,0.0016154298,0.00013298602,0.000032825636,0.0000043454224,0.0002488505,0.0003251904,0.0016335975],"category_scores_gemma":[0.0034152688,0.000091467584,0.00048161933,0.0001625422,0.0002609333,0.00013134308,0.000045521723,0.0007153476,0.0000077601535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020236887,0.006634393,0.09463601,0.0002627431,0.00066728826,0.000008745417,0.0003462345,0.00011119784,0.005010878,0.00008480216,0.008060211,0.8639406],"study_design_scores_gemma":[0.0700965,0.05195431,0.5099943,0.0012002937,0.0008726258,0.00049257034,0.00036410222,0.0022832728,0.010746404,0.0006732101,0.35109973,0.00022263138],"about_ca_topic_score_codex":0.00033248847,"about_ca_topic_score_gemma":0.00004430386,"teacher_disagreement_score":0.863718,"about_ca_system_score_codex":0.00045304434,"about_ca_system_score_gemma":0.007840122,"threshold_uncertainty_score":0.999279},"labels":[],"label_agreement":null},{"id":"W2151883851","doi":"10.1200/jco.2010.33.3419","title":"Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Genentech; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Medicine; International Prognostic Index; Internal medicine; Rituximab; Bone marrow; Vincristine; Diffuse large B-cell lymphoma; Cyclophosphamide; Lymphoma; Oncology; Prednisone; Gastroenterology; Chemotherapy","score_opus":0.11400188818165757,"score_gpt":0.4166145084204617,"score_spread":0.30261262023880414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151883851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973756,0.00031705556,0.0000063348366,0.00039260593,0.00014166889,0.0003049228,0.0000139079975,0.0000048759484,0.0014429955],"genre_scores_gemma":[0.99767476,0.0007923775,0.0007582566,0.00055944914,0.000091153495,0.000008800194,0.0000030660624,0.000019017398,0.00009311395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667895,0.00025279474,0.002246317,0.0002243223,0.00030399716,0.00029360093],"domain_scores_gemma":[0.99667424,0.0008771409,0.0015973913,0.00023844773,0.0001696676,0.0004430867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012248768,0.00022598519,0.0019832505,0.00020334974,0.000020086047,0.000004748618,0.000088170724,0.00016208066,0.00007174933],"category_scores_gemma":[0.00035179977,0.00011547859,0.00044119856,0.00012900938,0.00018329854,0.00007406889,0.000046950885,0.00026036493,0.0000056833132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013834055,0.06253034,0.9059805,0.00003063932,0.0004510961,0.0051657753,0.00017556311,5.059133e-7,0.000110081186,0.00007037447,0.0001704872,0.01148055],"study_design_scores_gemma":[0.10021521,0.05970799,0.8381906,0.00018957253,0.000418127,0.00028243635,0.00013775876,0.00001907063,0.0003952241,0.000035731362,0.00031291074,0.0000953261],"about_ca_topic_score_codex":0.0004597524,"about_ca_topic_score_gemma":0.0002282881,"teacher_disagreement_score":0.08638116,"about_ca_system_score_codex":0.0004200059,"about_ca_system_score_gemma":0.00075000024,"threshold_uncertainty_score":0.47090805},"labels":[],"label_agreement":null},{"id":"W2151929173","doi":"10.1200/jco.2014.57.2461","title":"Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Cohort; Hazard ratio; Estrogen receptor; Oncology; Cancer; Population; Biomarker; Stage (stratigraphy); Human Epidermal Growth Factor Receptor 2; Gynecology; Confidence interval","score_opus":0.08795738046564154,"score_gpt":0.45897141024842303,"score_spread":0.3710140297827815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151929173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550825,0.0004813775,0.00024205369,0.002475584,0.0003477779,0.00010810692,0.0008064667,0.0000018366544,0.000028548387],"genre_scores_gemma":[0.9974407,0.00023980904,0.0008289871,0.000731084,0.00069986406,0.0000050296926,0.00003613958,0.000010606826,0.000007761241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800426,0.00021679858,0.0011914946,0.00027482514,0.00015055014,0.00016207265],"domain_scores_gemma":[0.9981194,0.00045468644,0.0007541402,0.00015403391,0.0002117266,0.00030597535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030106574,0.00015310285,0.0010644395,0.00004193213,0.000032302563,0.0000064861897,0.00014755805,0.00021723713,0.000018157489],"category_scores_gemma":[0.00045715776,0.00011617256,0.000104864965,0.00004919823,0.000097652126,0.000005934429,0.00015821368,0.0001840434,0.0000022303916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078970066,0.00027246538,0.8885646,0.0000042694164,0.00027793794,0.00000128948,0.000086699976,0.000005733988,0.00031469148,3.9585183e-7,0.0018741126,0.10780814],"study_design_scores_gemma":[0.002832908,0.0025982987,0.9876895,0.00006453563,0.00020972628,0.000001750436,0.000029875015,0.0000034278894,0.00063792814,0.00002204109,0.0057988586,0.0001111286],"about_ca_topic_score_codex":0.0023358543,"about_ca_topic_score_gemma":0.0015045489,"teacher_disagreement_score":0.10769702,"about_ca_system_score_codex":0.00003564767,"about_ca_system_score_gemma":0.00008330687,"threshold_uncertainty_score":0.47373793},"labels":[],"label_agreement":null},{"id":"W2152105599","doi":"10.1200/jco.2012.43.7509","title":"Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Rituximab; Hepatitis B; Cost effectiveness; Virology; Oncology; Immunology; Intensive care medicine; Internal medicine; Antibody","score_opus":0.10066762345893622,"score_gpt":0.44100951960693013,"score_spread":0.3403418961479939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152105599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8723559,0.012684155,0.00021383015,0.108738445,0.0030924953,0.0018660686,0.000040911018,0.0000222261,0.0009859747],"genre_scores_gemma":[0.8487289,0.009900798,0.0023171061,0.12623952,0.012429373,0.00012892147,0.000037276637,0.00009619212,0.00012190841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99469817,0.0023301493,0.0016700418,0.0004057993,0.00048294844,0.00041287876],"domain_scores_gemma":[0.9845786,0.012438539,0.0018020229,0.00024385212,0.00045824886,0.00047872547],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0043323804,0.0003994184,0.003794802,0.00021039422,0.0000756648,0.000031201365,0.000119238335,0.0020556357,0.000050988216],"category_scores_gemma":[0.002298399,0.0002631468,0.0005851978,0.00009354994,0.0005063473,0.00014416523,0.0001256904,0.002764341,0.000015586755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021306446,0.0016869815,0.5844155,0.00078129617,0.0014956351,0.006884301,0.000017946271,1.6712546e-7,0.0000049274454,0.000013269816,0.042831518,0.3597378],"study_design_scores_gemma":[0.016810657,0.013372158,0.6028025,0.000999478,0.0013937511,0.002475342,0.0000029727464,0.0000023722582,0.000028518287,0.00007504686,0.36188507,0.00015213803],"about_ca_topic_score_codex":0.00017396967,"about_ca_topic_score_gemma":0.000014675336,"teacher_disagreement_score":0.35958567,"about_ca_system_score_codex":0.00031701487,"about_ca_system_score_gemma":0.000789278,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W2152121934","doi":"10.1200/jco.2007.15.8659","title":"Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":299,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Breast Cancer Research Alliance","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Tissue microarray; Estrogen receptor; Cohort; Human Epidermal Growth Factor Receptor 2; Cancer; Pathology","score_opus":0.04727276535948091,"score_gpt":0.39044453015629893,"score_spread":0.343171764796818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152121934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973031,0.00038969298,0.000025041545,0.0010604128,0.0004258701,0.00020303729,0.00020480873,0.000004030985,0.00038395348],"genre_scores_gemma":[0.99649864,0.0006736715,0.0016442095,0.00032749167,0.0006610497,0.000013479686,0.000013518276,0.000022481212,0.00014547046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971487,0.00046162112,0.00153662,0.00029815742,0.00023194015,0.0003229547],"domain_scores_gemma":[0.99732655,0.00035390895,0.0015213554,0.00016776776,0.00044403243,0.00018640241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036727145,0.00022868741,0.001093998,0.00008440898,0.000085501844,0.000004062653,0.00023529996,0.00040848335,0.00020677893],"category_scores_gemma":[0.0017255965,0.00017467915,0.00029323588,0.000104724626,0.00039986332,0.000024952456,0.00013616658,0.0004306966,0.000006206482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047749435,0.002001014,0.8179857,0.00006588333,0.00074195134,0.00020797375,0.0011165255,0.000010559646,0.1643852,0.000031907457,0.0047077234,0.0039705825],"study_design_scores_gemma":[0.006102966,0.0049280403,0.91793597,0.00014804224,0.000053359905,0.00046073017,0.00026158046,5.3957757e-7,0.063615285,0.000070367,0.0062218024,0.00020133544],"about_ca_topic_score_codex":0.0003056039,"about_ca_topic_score_gemma":0.00038286595,"teacher_disagreement_score":0.10076991,"about_ca_system_score_codex":0.00016157985,"about_ca_system_score_gemma":0.0011773028,"threshold_uncertainty_score":0.7123209},"labels":[],"label_agreement":null},{"id":"W2152124092","doi":"10.1200/jco.2013.48.7934","title":"International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Onyx Pharmaceuticals; National University Health System; Nagoya City University; Gil Medical Center, Gachon University; Genentech; Sahlgrenska Universitetssjukhuset; Università degli Studi di Pavia; Keio University; Cedars-Sinai Medical Center; Weill Cornell Medical College; Abbott Laboratories; Queen Mary University of London; University of Pittsburgh; Ankara Universitesi; University of Arkansas for Medical Sciences; Array BioPharma; Tel Aviv University; Gachon University; York University; Northwestern University; Emory University; American Society of Clinical Oncology; Universität Wien; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; National and Kapodistrian University of Athens; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Daiichi-Sankyo; Takeda Oncology; Massachusetts General Hospital; Sanofi; Amgen","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Transplantation; Adverse effect; Lenalidomide; Disease; Anemia; Autologous stem-cell transplantation; Concomitant; Internal medicine; Surgery","score_opus":0.13404119822155605,"score_gpt":0.4758519201022766,"score_spread":0.3418107218807206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152124092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033876333,0.922648,0.009571438,0.0012592336,0.0034604094,0.022602145,0.004447453,0.000035816247,0.00209917],"genre_scores_gemma":[0.029177662,0.9605842,0.008793362,0.000060270268,0.00027339958,0.00028657622,0.0005481403,0.00005032787,0.00022602083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958103,0.0003582326,0.0027304653,0.00034532585,0.00042834913,0.00032734463],"domain_scores_gemma":[0.9896354,0.0055093807,0.0036538176,0.00020276707,0.0007852373,0.00021339199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013774537,0.00034117358,0.00298638,0.00024190701,0.00009200837,0.000020611784,0.00019983626,0.0003079281,0.000015361213],"category_scores_gemma":[0.0001396436,0.00017340427,0.00080279977,0.00008306872,0.00022613058,0.00003915123,0.00003473046,0.0003329147,0.0000012181642],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019575594,0.0007614676,0.004021038,0.006469491,0.005743888,0.00015687662,0.00013175826,0.0000015530363,1.7937451e-7,0.000040999785,0.0002316047,0.96286553],"study_design_scores_gemma":[0.033848394,0.035893362,0.00919635,0.0028899224,0.009665203,0.00009304732,0.0002390722,0.000015536438,0.000010299879,0.000012569713,0.9079782,0.0001580814],"about_ca_topic_score_codex":0.000005673255,"about_ca_topic_score_gemma":0.000025796731,"teacher_disagreement_score":0.96270746,"about_ca_system_score_codex":0.0004769188,"about_ca_system_score_gemma":0.00089472294,"threshold_uncertainty_score":0.70712215},"labels":[],"label_agreement":null},{"id":"W2152144762","doi":"10.1200/jco.2008.16.3964","title":"Quality Control in Sentinel Lymph Node Biopsy in Cervical Cancer","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sentinel lymph node; Biopsy; Cervical cancer; Cancer; Lymph node; Oncology; Radiology; Pathology; Internal medicine; Breast cancer","score_opus":0.17207718403151806,"score_gpt":0.4936050907138527,"score_spread":0.32152790668233466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152144762","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20312148,0.0026001434,0.000020142219,0.7861498,0.0036985865,0.00033643938,0.00004378333,0.000011233676,0.0040183994],"genre_scores_gemma":[0.18837312,0.004321771,0.0003827661,0.78893334,0.017080644,0.000033710865,0.000026860682,0.00005260163,0.0007951637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99000907,0.0017587363,0.0061514247,0.00047970604,0.00097516726,0.0006258751],"domain_scores_gemma":[0.98882186,0.006946623,0.003066329,0.0003268128,0.0004429505,0.00039539326],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003288888,0.0003918208,0.005545478,0.0006243822,0.000022503664,0.000008474031,0.00034831822,0.0029731398,0.0007550474],"category_scores_gemma":[0.004744545,0.00027028949,0.0013490899,0.00060269126,0.00029545123,0.000077358745,0.0000675563,0.006220624,0.000044931527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009364886,0.0023788216,0.8372932,0.00020085197,0.00065378007,0.028963348,0.000025647667,0.000008760081,0.000012373166,0.000003428354,0.0990304,0.02206449],"study_design_scores_gemma":[0.047312103,0.0008011892,0.73570657,0.000382234,0.00033367716,0.00060420233,0.000009216516,0.00001948182,0.0000012707197,0.0001368049,0.21450143,0.00019182007],"about_ca_topic_score_codex":0.0014991655,"about_ca_topic_score_gemma":0.00011572094,"teacher_disagreement_score":0.11547103,"about_ca_system_score_codex":0.0012780444,"about_ca_system_score_gemma":0.003955791,"threshold_uncertainty_score":0.9999749},"labels":[],"label_agreement":null},{"id":"W2152166519","doi":"10.1200/jco.2005.04.4685","title":"5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Ondansetron; Dexamethasone; Nausea; Placebo; Vomiting; Anesthesia; Radiation therapy; Randomized controlled trial; Internal medicine","score_opus":0.16250470023183025,"score_gpt":0.4846521060971862,"score_spread":0.32214740586535595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152166519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862814,0.00015445493,0.0000999909,0.0064867586,0.0022455854,0.004006885,0.00001447097,0.0000027444614,0.0007077269],"genre_scores_gemma":[0.99569815,0.00021806742,0.00095050427,0.00060749886,0.0022139663,0.00011022694,0.000004045979,0.000014587293,0.00018292741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98119944,0.007846481,0.0090168035,0.00024176852,0.0014601322,0.00023536805],"domain_scores_gemma":[0.9698417,0.02021548,0.008759572,0.00025569086,0.0008072974,0.000120222445],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05774265,0.00020513567,0.005506913,0.00016157104,0.000048704787,0.000008027685,0.0003641632,0.00036553582,0.000051996918],"category_scores_gemma":[0.049196783,0.000086208056,0.0009972255,0.0004329464,0.00060597656,0.0000889571,0.000037461043,0.0009981574,1.3611805e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95347595,0.0033213403,0.02078179,0.00006873079,0.0015307093,0.000025607957,0.000064097905,0.000109096734,0.00033211394,0.00018629718,0.002118652,0.017985601],"study_design_scores_gemma":[0.9535836,0.01090319,0.029406538,0.0003201948,0.0021534208,0.000019719979,0.00015943973,0.00035765037,0.00037721798,0.00008026627,0.002535026,0.00010372174],"about_ca_topic_score_codex":0.011875298,"about_ca_topic_score_gemma":0.06395322,"teacher_disagreement_score":0.052077927,"about_ca_system_score_codex":0.00023487599,"about_ca_system_score_gemma":0.011012731,"threshold_uncertainty_score":0.9947047},"labels":[],"label_agreement":null},{"id":"W2152175171","doi":"10.1200/jco.2014.55.6092","title":"Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Saskatchewan; Saskatoon City Hospital; University of British Columbia; Health Sciences Centre; Ottawa Hospital; Kingston General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Breast cancer; Cancer; Epidermal growth factor receptor; Internal medicine; Gynecology","score_opus":0.19290715174566359,"score_gpt":0.5111243683464978,"score_spread":0.3182172166008342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152175171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98282707,0.000072643845,0.0000040056743,0.010448518,0.00031887877,0.0008913515,0.00003186771,0.0000049952205,0.0054007],"genre_scores_gemma":[0.9964626,0.000018884217,0.0012200809,0.0011713249,0.0010501142,0.00003189872,5.8440816e-7,0.000022981145,0.000021565944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936507,0.0021918234,0.0026152227,0.00026396287,0.0007963075,0.0004820232],"domain_scores_gemma":[0.9898365,0.0069625685,0.0011757537,0.00023449225,0.0013484474,0.00044219533],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013325313,0.00015981137,0.0016882103,0.0002966168,0.000063830215,0.000013695964,0.00039441398,0.00024702094,0.0002364558],"category_scores_gemma":[0.026222568,0.00010227962,0.00016281987,0.0007169801,0.00029684472,0.00009612106,0.00006250345,0.003117137,0.000002639405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011096586,0.0013335547,0.91298574,0.00005576673,0.00008590631,0.00044726027,0.00087211805,0.000012392303,0.00031656743,0.000014594544,0.0004906073,0.08227581],"study_design_scores_gemma":[0.009220016,0.0108512165,0.9778371,0.00037719336,0.000059567985,0.00019263176,0.0005126063,0.00004440057,0.00001612877,0.00014341169,0.00065680005,0.00008893865],"about_ca_topic_score_codex":0.041980904,"about_ca_topic_score_gemma":0.09512591,"teacher_disagreement_score":0.08218687,"about_ca_system_score_codex":0.001726287,"about_ca_system_score_gemma":0.011022792,"threshold_uncertainty_score":0.9991827},"labels":[],"label_agreement":null},{"id":"W2152318410","doi":"10.1200/jco.2013.49.0466","title":"To Your Health: How Does the Latest Research on Alcohol and Breast Cancer Inform Clinical Practice?","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute; American Cancer Society","keywords":"Medicine; Breast cancer; Cancer; Internal medicine; Estrogen receptor; Endocrinology; Physiology; Menopause; Oncology","score_opus":0.6459067737017185,"score_gpt":0.67168534908046,"score_spread":0.02577857537874151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152318410","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017715538,0.00089521374,0.000003902343,0.97242403,0.005415565,0.0015910433,0.000031049785,0.000015306281,0.0019083773],"genre_scores_gemma":[0.0083367145,0.017127605,0.0008238762,0.9349763,0.03472208,0.000060938964,0.0000079806105,0.000055814555,0.0038887316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98780954,0.0047376887,0.0042489,0.0005101625,0.0017837223,0.0009100143],"domain_scores_gemma":[0.9485523,0.041783713,0.004346622,0.0006324779,0.0031656947,0.001519181],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.033615183,0.00034171029,0.0031008031,0.00044634406,0.0002763202,0.00009844686,0.00048118754,0.0025777495,0.00039243413],"category_scores_gemma":[0.028647926,0.00016262704,0.00059601857,0.00027586904,0.00083312264,0.00021734585,0.00022512299,0.02183808,0.000330492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027883933,0.00042081042,0.0084955925,0.00024116991,0.00036951716,0.00085885887,0.00010700767,5.6218107e-7,3.1208714e-7,0.000024940093,0.805526,0.18116681],"study_design_scores_gemma":[0.0037408604,0.012888843,0.20644768,0.00080622744,0.00021628958,0.0015448313,0.00014267808,0.000011414556,1.2803055e-7,0.000050052917,0.7740274,0.00012360596],"about_ca_topic_score_codex":0.000328243,"about_ca_topic_score_gemma":0.0001416122,"teacher_disagreement_score":0.19795208,"about_ca_system_score_codex":0.0005798074,"about_ca_system_score_gemma":0.0096823005,"threshold_uncertainty_score":0.9987171},"labels":[],"label_agreement":null},{"id":"W2152377119","doi":"10.1200/jco.2010.28.9918","title":"Do We Have to Change the Way Targeted Drugs Are Developed?","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacology; Intensive care medicine","score_opus":0.1740761113745458,"score_gpt":0.4673023573426959,"score_spread":0.29322624596815006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152377119","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035893947,0.00498674,0.00014836834,0.9818713,0.0077634505,0.00063441356,0.000025706328,0.000021479113,0.0009591123],"genre_scores_gemma":[0.0032522313,0.002053442,0.007857998,0.9190873,0.06406877,0.00004932172,0.0000094857705,0.0001078,0.003513663],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943702,0.00067076524,0.0030122872,0.00042185828,0.00092633045,0.00059850904],"domain_scores_gemma":[0.98937684,0.0039387825,0.004289565,0.00065960264,0.0012752941,0.00045991832],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003266876,0.00043196577,0.0031762638,0.00027507692,0.00008788683,0.000022203456,0.00080815115,0.003738131,0.00079308223],"category_scores_gemma":[0.0036822143,0.00023873786,0.00093110034,0.00020756152,0.00045442348,0.000116579904,0.00018850823,0.018216396,0.00016970382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014189001,0.00014936185,0.0008388785,0.00005223573,0.00049049663,0.0022639195,0.00058575254,4.9300326e-7,0.000014490263,0.0000037981881,0.56513983,0.42904183],"study_design_scores_gemma":[0.0035193404,0.0029550567,0.0150168175,0.0006034641,0.00047035114,0.0011984438,0.00028173972,0.0000012527513,0.000025709796,0.00064097246,0.9750345,0.0002523752],"about_ca_topic_score_codex":0.0000135457285,"about_ca_topic_score_gemma":0.00006520728,"teacher_disagreement_score":0.42878944,"about_ca_system_score_codex":0.00035916854,"about_ca_system_score_gemma":0.0019525385,"threshold_uncertainty_score":0.9975552},"labels":[],"label_agreement":null},{"id":"W2152419134","doi":"10.1200/jco.2005.08.091","title":"Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; Gastroenterology; Adverse effect; Toxicity; Population; Nausea; Cancer; Phases of clinical research; Oncology","score_opus":0.23491025272936084,"score_gpt":0.6057291711774904,"score_spread":0.37081891844812953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152419134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657034,0.0017330146,0.0007336203,0.023994429,0.0023731932,0.0041575613,0.000036603768,0.00001772184,0.0012504256],"genre_scores_gemma":[0.96532345,0.0052163326,0.021364292,0.0018798789,0.00423308,0.00022134178,0.000009130766,0.00005080979,0.0017016589],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99273556,0.0012130417,0.0047062174,0.0002732845,0.0006079123,0.00046398578],"domain_scores_gemma":[0.98810834,0.0069230874,0.0027811455,0.00029486744,0.001281871,0.0006106652],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011092048,0.00020160343,0.0040885448,0.00020382706,0.00005732,0.0000070876063,0.00029103292,0.00046648033,0.0008751375],"category_scores_gemma":[0.025545185,0.0001342186,0.0014445033,0.00018611678,0.00046595128,0.00013138639,0.000063913096,0.0010301482,0.000006413042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6134435,0.0063762655,0.00019437597,0.000054887372,0.0006353855,0.000050324838,0.00010755679,0.000025563299,0.00049445045,0.00001873059,0.0042274836,0.37437147],"study_design_scores_gemma":[0.71761715,0.045378864,0.00010202765,0.0002148242,0.00091009703,0.000029651053,0.000026454763,0.0012975384,0.0007498118,0.000049149963,0.23354167,0.00008274385],"about_ca_topic_score_codex":0.00008493864,"about_ca_topic_score_gemma":0.00017589497,"teacher_disagreement_score":0.37428874,"about_ca_system_score_codex":0.00040864042,"about_ca_system_score_gemma":0.0036335278,"threshold_uncertainty_score":0.98266304},"labels":[],"label_agreement":null},{"id":"W2152427545","doi":"10.1200/jco.2014.57.1547","title":"Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Yale University; National Institutes of Health; Yale Cancer Center; State of Connecticut Department of Public Health; Breast Cancer Research Foundation","keywords":"Medicine; Physical therapy; Dash; Randomized controlled trial; Brief Pain Inventory; Breast cancer; WOMAC; Aerobic exercise; Clinical endpoint; Osteoarthritis; Chronic pain; Cancer; Internal medicine; Alternative medicine","score_opus":0.07102554796172635,"score_gpt":0.4432071863044008,"score_spread":0.3721816383426745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152427545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900287,0.0011773298,0.000016958124,0.0061075394,0.0015538449,0.0005546519,0.000007862169,0.0000056447343,0.0005474782],"genre_scores_gemma":[0.9749499,0.023585774,0.00027286154,0.00023475413,0.000884499,0.000018727394,0.000002221852,0.0000149674925,0.000036299833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937779,0.0018280438,0.003410753,0.00015954312,0.00054381375,0.00027999817],"domain_scores_gemma":[0.9932773,0.0040442008,0.0016295628,0.00020627026,0.0004119611,0.00043067435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01237277,0.0001377696,0.0035135504,0.0002615749,0.000021636886,0.000008174987,0.00016257107,0.0003198587,0.00030147933],"category_scores_gemma":[0.006406186,0.00009007653,0.0007310339,0.00017096246,0.0004083254,0.00012781321,0.00004145811,0.000934053,0.000011078183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79711866,0.0017791445,0.0064078784,0.000029346944,0.0001759523,0.000116724215,0.00009709907,0.0000033367621,0.00035774414,0.00009621502,0.0007681611,0.19304976],"study_design_scores_gemma":[0.96454066,0.0061431825,0.02300281,0.00079071743,0.000051344676,0.0001544841,0.00007264232,0.00013626655,0.00025270996,0.0008859905,0.003877083,0.00009213325],"about_ca_topic_score_codex":0.00045813096,"about_ca_topic_score_gemma":0.00040368302,"teacher_disagreement_score":0.19295762,"about_ca_system_score_codex":0.000053262564,"about_ca_system_score_gemma":0.0012652964,"threshold_uncertainty_score":0.76692665},"labels":[],"label_agreement":null},{"id":"W2152473494","doi":"10.1200/jco.2012.45.6574","title":"Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nasolacrimal Duct Obstruction Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Beef Cattle Research Council; Sanofi","keywords":"Medicine; Docetaxel; Chemotherapy; Breast cancer; Internal medicine; Surgery; Asymptomatic; Cancer","score_opus":0.04263958597450385,"score_gpt":0.40705891068014344,"score_spread":0.3644193247056396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152473494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946007,0.00022140105,0.000038250117,0.004320265,0.00031329613,0.00027501592,0.00000349806,0.0000063164725,0.00022125787],"genre_scores_gemma":[0.99448335,0.00047628416,0.0036321096,0.0008054193,0.00032140178,0.000021563805,1.280481e-7,0.00001899755,0.0002407347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973928,0.00022083579,0.0015913708,0.00018534658,0.00034546,0.00026420783],"domain_scores_gemma":[0.99639344,0.00068591995,0.0018420913,0.00016823792,0.00062181184,0.00028848287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009699347,0.00013660414,0.0011802712,0.00016147614,0.000017661121,0.0000072648886,0.00014566565,0.00019582594,0.00088211003],"category_scores_gemma":[0.0005282834,0.00007949263,0.00012962651,0.000196659,0.00021995004,0.00023366277,0.000018477478,0.00067564094,0.000008052447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059431707,0.0009239073,0.7941632,0.000113223236,0.00020804028,0.00010323356,0.00024505862,0.000039244213,0.0009151089,0.0000012727618,0.00006163481,0.1972829],"study_design_scores_gemma":[0.013311879,0.006284794,0.978496,0.00070958753,0.00011023696,0.00022248605,0.00013639513,0.00004358694,0.0003983181,0.00007475641,0.00013562522,0.000076294986],"about_ca_topic_score_codex":0.00021502392,"about_ca_topic_score_gemma":0.000014006315,"teacher_disagreement_score":0.1972066,"about_ca_system_score_codex":0.0004348014,"about_ca_system_score_gemma":0.0013134793,"threshold_uncertainty_score":0.9658486},"labels":[],"label_agreement":null},{"id":"W2152525304","doi":"10.1200/jco.2006.09.6495","title":"Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Internal medicine; Prostate-specific antigen; Adjuvant; Incidence (geometry); Urology; Surgery; Oncology; Cancer","score_opus":0.04996125635904672,"score_gpt":0.4234592621821444,"score_spread":0.37349800582309767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152525304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639344,0.00031932487,0.000083325656,0.0020912164,0.00017461277,0.0006883915,0.00011850196,0.0000033632143,0.00012782379],"genre_scores_gemma":[0.9958992,0.0027358609,0.00088930805,0.00027349318,0.000075753465,0.000022279302,0.00003905176,0.0000194975,0.000045536508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994498,0.00026106412,0.004116553,0.00033441233,0.0003931801,0.00039678303],"domain_scores_gemma":[0.99509585,0.0013389884,0.0024447686,0.0003290166,0.00045228036,0.00033907266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013499805,0.00029089669,0.0033103086,0.00089817244,0.0000142759345,0.000003919173,0.00012472703,0.00038100904,0.00018573788],"category_scores_gemma":[0.00025886024,0.00018182783,0.0010635128,0.00069494854,0.00015552223,0.00008653839,0.000036479432,0.00033547453,0.0000028338332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005699634,0.013346079,0.8485866,0.000042824006,0.002915885,0.00075657805,0.0009801183,0.00017434613,0.00004008002,0.000009161855,0.00008354326,0.12736511],"study_design_scores_gemma":[0.029812327,0.060633987,0.89480585,0.0003161552,0.0030616568,0.00001702853,0.0007185781,0.00007933724,0.0023300743,0.000024123954,0.008083744,0.00011711131],"about_ca_topic_score_codex":0.0013557037,"about_ca_topic_score_gemma":0.018535802,"teacher_disagreement_score":0.127248,"about_ca_system_score_codex":0.0020731997,"about_ca_system_score_gemma":0.0010514428,"threshold_uncertainty_score":0.9993734},"labels":[],"label_agreement":null},{"id":"W2152612574","doi":"10.1200/jco.2014.59.1669","title":"Prostate Cancer and Vasectomy: Déjà Vu!","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Male Reproductive Health Studies","field":"Health Professions","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Déjà vu; Vasectomy; Cancer; Prostate cancer; Gynecology; General surgery; Oncology; Internal medicine; Population; Research methodology; Family planning; Psychiatry","score_opus":0.5005495774271668,"score_gpt":0.6559033511997472,"score_spread":0.15535377377258042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152612574","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013444612,0.012413729,0.0000043172386,0.94500595,0.017356021,0.001011587,0.00006366133,0.000023407561,0.01067674],"genre_scores_gemma":[0.00056929886,0.023174332,0.00096309476,0.87035817,0.07999072,0.00012159812,0.000008680715,0.000085912325,0.024728186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9869861,0.004931426,0.0058947266,0.0005663376,0.00074977713,0.00087164243],"domain_scores_gemma":[0.9749548,0.011520682,0.009354862,0.00041943282,0.003231592,0.0005186242],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.016314607,0.00036862135,0.004152143,0.00024704722,0.00031109137,0.0000059129297,0.00035167203,0.0030759913,0.00046976018],"category_scores_gemma":[0.016786972,0.00024887387,0.00035743712,0.00016336402,0.0005654824,0.00012847195,0.0003743221,0.01782964,0.000120166274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007480723,0.000109301895,0.059283733,0.00094257185,0.00043825622,0.0009037066,0.0006840549,5.6264463e-7,3.8036544e-7,0.00001068508,0.9064414,0.030437253],"study_design_scores_gemma":[0.0037047057,0.002748905,0.03431619,0.00062834227,0.00036074937,0.00006100312,0.00024312908,0.0000020583593,1.3038513e-7,0.0011592617,0.9565681,0.00020737882],"about_ca_topic_score_codex":0.00030199133,"about_ca_topic_score_gemma":0.0002743715,"teacher_disagreement_score":0.074647754,"about_ca_system_score_codex":0.00082493236,"about_ca_system_score_gemma":0.017358309,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2152647863","doi":"10.1200/jco.2007.13.5467","title":"Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":545,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Trastuzumab; Medicine; Ejection fraction; Heart failure; Internal medicine; Breast cancer; Cyclophosphamide; Cardiac function curve; Cardiology; Cardiotoxicity; Oncology; Paclitaxel; Cancer; Surgery; Chemotherapy","score_opus":0.11133423106210778,"score_gpt":0.47525447235477447,"score_spread":0.3639202412926667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152647863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886541,0.0031885693,0.000025445344,0.006069997,0.000548415,0.0009791497,0.00034298058,0.000005115723,0.0001862351],"genre_scores_gemma":[0.96280223,0.035162617,0.0002486367,0.0006255523,0.0008317106,0.00007386308,0.000014782782,0.000025795693,0.00021479669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99420196,0.0012147679,0.0026250535,0.00038188926,0.0010083987,0.0005679351],"domain_scores_gemma":[0.99504733,0.0023958362,0.0013536145,0.0003398576,0.00034016947,0.0005231797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025908414,0.0002804208,0.003697306,0.0002533825,0.00008055151,0.000008652992,0.00025103416,0.00029152815,0.0002584341],"category_scores_gemma":[0.0004613649,0.00013362928,0.0007527096,0.001007721,0.00065279496,0.00009560601,0.000034615012,0.0010193486,5.8799765e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19290383,0.0021697988,0.7532604,0.00002272634,0.003701412,0.0006226674,0.0009912968,0.00009813567,0.000050260853,0.0000021666617,0.0017451862,0.044432145],"study_design_scores_gemma":[0.07699766,0.022044957,0.8792937,0.00012106622,0.004063047,0.0001806988,0.00048406865,0.00012097494,0.00001913991,0.0000017908902,0.016537732,0.00013520369],"about_ca_topic_score_codex":0.007729495,"about_ca_topic_score_gemma":0.027723093,"teacher_disagreement_score":0.12603328,"about_ca_system_score_codex":0.0012004686,"about_ca_system_score_gemma":0.0051494525,"threshold_uncertainty_score":0.9988781},"labels":[],"label_agreement":null},{"id":"W2152816062","doi":"10.1200/jco.2009.26.3996","title":"Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma","year":2010,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Cancer research; Receptor; Cancer; Pathology; Human Epidermal Growth Factor Receptor 2; Internal medicine; Oncology; Breast cancer","score_opus":0.04852154863458824,"score_gpt":0.4610932813893908,"score_spread":0.4125717327548026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152816062","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4586406,0.0013889942,0.00001861899,0.0027298476,0.53492737,0.000925588,0.00015817901,0.000013593555,0.0011972119],"genre_scores_gemma":[0.18050778,0.008846953,0.00549429,0.0014066664,0.8022387,0.00017934317,0.00025490904,0.00018244327,0.0008888955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925841,0.0008737086,0.004605573,0.00060173793,0.0007368321,0.0005980265],"domain_scores_gemma":[0.9893009,0.0050333478,0.0035840615,0.00037777016,0.00090313336,0.0008007731],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0027684467,0.00048605487,0.0035854762,0.0008222636,0.000047713962,0.000030739993,0.00043005781,0.0033551895,0.00026556544],"category_scores_gemma":[0.0057502,0.00037125472,0.00075271947,0.0003712969,0.00021226708,0.00025027388,0.00008916289,0.005626162,0.000011907047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011972926,0.0069772317,0.18661866,0.0006606172,0.0021669716,0.0040275436,0.0014889626,0.000009437595,0.00042655447,0.0000029711161,0.73802906,0.047619052],"study_design_scores_gemma":[0.049464222,0.01277929,0.090269245,0.0016221886,0.0019611237,0.00008445737,0.00029718224,0.00013546739,0.000075041105,0.000051672167,0.84266573,0.0005943582],"about_ca_topic_score_codex":0.0025006018,"about_ca_topic_score_gemma":0.010053934,"teacher_disagreement_score":0.27813283,"about_ca_system_score_codex":0.0015390811,"about_ca_system_score_gemma":0.01684635,"threshold_uncertainty_score":0.99987394},"labels":[],"label_agreement":null},{"id":"W2152922562","doi":"10.1200/jco.2010.34.3467","title":"Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Medicine; Anthracycline; Cardiotoxicity; Cohort; Pharmacogenomics; Single-nucleotide polymorphism; Oncology; Internal medicine; Pharmacogenetics; Odds ratio; SNP; KRAS; Bioinformatics; Pharmacology; Gene; Genetics; Cancer; Genotype; Biology; Chemotherapy; Breast cancer","score_opus":0.19569586693162994,"score_gpt":0.4453945722068734,"score_spread":0.24969870527524346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152922562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510676,0.00014138807,0.00013958687,0.000294635,0.0007921773,0.00030207264,0.000007809967,0.000008854732,0.0032067243],"genre_scores_gemma":[0.9962104,0.00076843624,0.0012618349,0.00053733675,0.0011857485,0.000002205882,0.0000031646862,0.00001481414,0.000016055134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664086,0.00036797562,0.0023810156,0.00016352438,0.00027735584,0.00016927849],"domain_scores_gemma":[0.9975519,0.00031879207,0.0014634025,0.00016950161,0.0002768565,0.0002195567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032530713,0.00011767655,0.0013994657,0.0002054176,0.000016844999,0.0000016560907,0.00012827796,0.0004486729,0.00010021741],"category_scores_gemma":[0.0009367716,0.000096795295,0.0006439684,0.00017110253,0.00013316062,0.00013151366,0.000024070121,0.00096549396,0.0000045341135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003238534,0.002011397,0.57835674,0.000022001019,0.00071201194,0.00009890709,0.000333726,0.000005584398,0.32910904,0.000019815103,0.00021958048,0.08587265],"study_design_scores_gemma":[0.008934831,0.0041024694,0.7528472,0.00007054037,0.00027566077,0.0005502927,0.000058322315,0.00003567542,0.23260145,0.00014853272,0.00031830277,0.0000567422],"about_ca_topic_score_codex":0.00006593275,"about_ca_topic_score_gemma":0.0000068615905,"teacher_disagreement_score":0.17449044,"about_ca_system_score_codex":0.00014956604,"about_ca_system_score_gemma":0.0008492568,"threshold_uncertainty_score":0.41946447},"labels":[],"label_agreement":null},{"id":"W2153119854","doi":"10.1200/jco.2005.04.022","title":"Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":267,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antiemetic; Dexamethasone; Antagonist; Chemotherapy; Placebo; Pharmacology; Number needed to treat; Ondansetron; Anesthesia; Internal medicine; Vomiting; Relative risk; Confidence interval; Receptor","score_opus":0.304948631792158,"score_gpt":0.5414375225598353,"score_spread":0.23648889076767737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153119854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89723045,0.001154497,0.00030805965,0.09813066,0.0008237725,0.0019885525,0.000010424288,0.000012564665,0.00034103557],"genre_scores_gemma":[0.97671133,0.001405434,0.010494675,0.009533151,0.0012762764,0.00009597259,0.000004505615,0.000028692064,0.00044995855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9910429,0.0017788976,0.00559575,0.00039033257,0.00091558363,0.00027652486],"domain_scores_gemma":[0.9896492,0.004703683,0.0033654969,0.00053572777,0.00111027,0.00063561636],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021880062,0.00021786992,0.0021923718,0.00019572894,0.000049775354,0.000023429824,0.00027600772,0.00036174562,0.00021381497],"category_scores_gemma":[0.01268556,0.00016256889,0.0005510072,0.00021637882,0.0001988759,0.00017871497,0.000098922144,0.00070519815,0.000017464383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028064182,0.021123609,0.26752627,0.0058775116,0.0051366347,0.00014141008,0.002461718,0.00009498805,0.001750223,0.00025079536,0.1811051,0.48646754],"study_design_scores_gemma":[0.02452494,0.024208087,0.87642515,0.010898627,0.008646445,0.00027115006,0.0010021551,0.0012847412,0.0011121407,0.0003400952,0.05067902,0.0006074419],"about_ca_topic_score_codex":0.0000055839037,"about_ca_topic_score_gemma":0.0000793363,"teacher_disagreement_score":0.6088989,"about_ca_system_score_codex":0.00025219563,"about_ca_system_score_gemma":0.0011894188,"threshold_uncertainty_score":0.995631},"labels":[],"label_agreement":null},{"id":"W2153293603","doi":"10.1200/jco.2011.39.1540","title":"Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":317,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; American Society of Clinical Oncology","keywords":"Notch signaling pathway; Pharmacodynamics; Medicine; Pharmacokinetics; Dosing; Nausea; Pharmacology; Vomiting; Toxicity; Internal medicine; Oncology; Receptor","score_opus":0.024539455213650224,"score_gpt":0.4088820948697082,"score_spread":0.38434263965605797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153293603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856246,0.00019336726,0.00001198407,0.00014426089,0.00067826477,0.00034002197,0.000007032015,0.0000014367259,0.00006114949],"genre_scores_gemma":[0.9989409,0.00012921923,0.00021757725,0.0004386464,0.00022475985,0.0000067520505,0.000010940143,0.000008401091,0.000022805072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977987,0.0005379569,0.0011553749,0.00015898868,0.00014686088,0.00020212289],"domain_scores_gemma":[0.9982582,0.00012385464,0.0011702009,0.000102682905,0.00020772107,0.00013737155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010984692,0.00013045291,0.0005183127,0.000049748378,0.000040698644,0.000002137125,0.00015909449,0.00019468955,0.000011622072],"category_scores_gemma":[0.00036557543,0.000076914686,0.000091774345,0.00009735696,0.00019694249,0.000017803866,0.00010877586,0.0003277014,8.0190483e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074958308,0.00961705,0.8397849,0.000013329568,0.00022337008,0.000012207751,0.000193651,0.00007508217,0.06169364,0.0000025880654,0.0001762452,0.08071206],"study_design_scores_gemma":[0.03477794,0.019878324,0.9191703,0.00003340524,0.00014387023,0.000037644917,0.00035994037,0.000040427574,0.023809336,0.00001541856,0.00157105,0.00016234232],"about_ca_topic_score_codex":0.0000022509464,"about_ca_topic_score_gemma":0.000034105728,"teacher_disagreement_score":0.08054972,"about_ca_system_score_codex":0.00002872383,"about_ca_system_score_gemma":0.00022623494,"threshold_uncertainty_score":0.313649},"labels":[],"label_agreement":null},{"id":"W2153398041","doi":"10.1200/jco.2009.27.4324","title":"Medulloblastoma Comprises Four Distinct Molecular Variants","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1353,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Deutsche Kinderkrebsstiftung; Pediatric Brain Tumor Foundation; Sontag Foundation; American Brain Tumor Association","keywords":"Medulloblastoma; Medicine; Oncology; Cancer research","score_opus":0.0885155091889863,"score_gpt":0.44747480753785884,"score_spread":0.3589592983488725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153398041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023814,0.00011489769,0.00014188609,0.011355307,0.0023061251,0.00012230057,0.000002500096,0.000009796828,0.005709049],"genre_scores_gemma":[0.99113595,0.000052672054,0.0061486345,0.0016203829,0.0009815915,0.0000031709124,0.0000013086711,0.000014947219,0.000041319738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756247,0.00018464727,0.00155863,0.00015409714,0.0003391071,0.00020103759],"domain_scores_gemma":[0.99610025,0.0016535756,0.001077046,0.00022591096,0.00039454264,0.0005486493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014879133,0.00012655166,0.0011795934,0.00009451678,0.000033722208,0.000009680468,0.00014871344,0.0003246276,0.00044281673],"category_scores_gemma":[0.004686345,0.00008105686,0.0005642304,0.00009427004,0.0001707464,0.000051445844,0.000048132206,0.0009885639,0.00006122397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027848405,0.012568237,0.58479,0.000032341944,0.0017279438,0.02768352,0.000047475813,0.000007495217,0.026666505,0.0018271895,0.016456848,0.3254076],"study_design_scores_gemma":[0.0098202,0.008473942,0.87696475,0.000054430857,0.0006826098,0.002318716,0.000016742533,0.000065286404,0.0018160156,0.00081597717,0.098880924,0.00009042353],"about_ca_topic_score_codex":0.000007869576,"about_ca_topic_score_gemma":0.000035075398,"teacher_disagreement_score":0.32531714,"about_ca_system_score_codex":0.000039416438,"about_ca_system_score_gemma":0.00071957195,"threshold_uncertainty_score":0.56103307},"labels":[],"label_agreement":null},{"id":"W2153623611","doi":"10.1200/jco.2011.39.2316","title":"Cancer Genomics: Technology, Discovery, and Translation","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Genomics; Exome sequencing; Medicine; Exome; Precision medicine; Cancer; Personalized medicine; Genotyping; Carcinogenesis; Computational biology; Somatic cell; Genome; Mutation; Bioinformatics; Genetics; Biology; Genotype; Gene; Internal medicine; Pathology","score_opus":0.15173236793619208,"score_gpt":0.48215329253171035,"score_spread":0.3304209245955183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153623611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009981456,0.9958524,0.00024089971,0.00040533402,0.0018993109,0.0002010017,0.00006299987,0.0000018574447,0.0003380326],"genre_scores_gemma":[0.0004020706,0.9938016,0.0014630161,0.00020833968,0.0039244415,0.0000134209995,0.000022201953,0.000034325225,0.00013061575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722934,0.00018737683,0.0020170189,0.00024672956,0.00009381617,0.00022571134],"domain_scores_gemma":[0.9966992,0.000432107,0.0023186037,0.00022368396,0.00013452076,0.00019188042],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012928182,0.00023575469,0.0020954867,0.00013343571,0.000032644468,0.000020107847,0.00028514853,0.001444574,0.000015917261],"category_scores_gemma":[0.00051454146,0.00017832688,0.0006684127,0.000084313804,0.00024996957,0.000008100749,0.00012767565,0.00073166564,0.000005151696],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008019161,0.00013405397,0.00018286961,0.00037998846,0.0004248179,0.000010327343,0.0000051813545,0.0000016687495,0.000021756787,0.00006139759,0.00089773315,0.9978],"study_design_scores_gemma":[0.00070898875,0.0013420803,0.000049741255,0.00042569262,0.0015516446,0.00018543065,0.000009154197,8.64861e-7,0.000010054315,0.00011197092,0.9954177,0.00018666242],"about_ca_topic_score_codex":0.000007962142,"about_ca_topic_score_gemma":0.000078985686,"teacher_disagreement_score":0.9976134,"about_ca_system_score_codex":0.000081079714,"about_ca_system_score_gemma":0.002423662,"threshold_uncertainty_score":0.99985176},"labels":[],"label_agreement":null},{"id":"W2153625246","doi":"10.1200/jco.2012.42.5496","title":"NEW and RENEW: Building the Case for Weight Loss in Breast Cancer","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Weight loss; Observational study; Randomized controlled trial; Cancer; Calorie; Obesity; Weight change; Internal medicine; Oncology","score_opus":0.11610727733228356,"score_gpt":0.4866438675642553,"score_spread":0.3705365902319718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153625246","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058724362,0.004768356,0.00014282209,0.931489,0.004420966,0.00028333327,0.000043418037,0.0000031492564,0.00012460607],"genre_scores_gemma":[0.07919906,0.013382826,0.0025377579,0.78919965,0.11406713,0.000018292252,0.000006055643,0.00007666315,0.0015125723],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972058,0.0002135674,0.0018466619,0.00019190452,0.00020001589,0.00034203636],"domain_scores_gemma":[0.9943658,0.0032543004,0.0017043197,0.00018311095,0.00019563895,0.00029681256],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020731355,0.00019246164,0.0017244327,0.00013104669,0.000038612172,0.000011192921,0.00014838403,0.0012652115,0.00025111123],"category_scores_gemma":[0.0004601982,0.00010369396,0.00049713545,0.00008270719,0.00017227155,0.00007315414,0.000051905834,0.0037433985,0.0000012208659],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012670704,0.00006948366,0.042094212,0.00006654962,0.00023020066,0.0074654887,0.000051096824,7.94461e-7,0.0000023835926,0.000009276898,0.75015354,0.19858992],"study_design_scores_gemma":[0.0050445935,0.0010631907,0.03918958,0.0002587415,0.00080224284,0.023737844,0.000015116789,0.000008781806,0.0000014729204,0.0002396024,0.9295321,0.000106701904],"about_ca_topic_score_codex":0.0015558663,"about_ca_topic_score_gemma":0.00074292696,"teacher_disagreement_score":0.19848321,"about_ca_system_score_codex":0.0002790246,"about_ca_system_score_gemma":0.0022071018,"threshold_uncertainty_score":0.998555},"labels":[],"label_agreement":null},{"id":"W2153716923","doi":"10.1200/jco.2011.36.2723","title":"Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Obesity; Internal medicine; Oncology; Stage (stratigraphy); Cancer","score_opus":0.07153760939497186,"score_gpt":0.40477666541764423,"score_spread":0.33323905602267234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153716923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682176,0.00063092407,0.000018521388,0.0010942342,0.00028698926,0.00015402248,0.00006244219,0.0000041835006,0.00092692015],"genre_scores_gemma":[0.99746627,0.001710705,0.00040967364,0.00011999423,0.00010931212,0.0000018192907,0.000002265222,0.0000075883777,0.00017237135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982018,0.0001646359,0.0012952514,0.000100850644,0.00012061036,0.000116879426],"domain_scores_gemma":[0.997066,0.0012562224,0.0011506517,0.000066919936,0.00026886197,0.00019130459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012595484,0.0000759103,0.0008303096,0.00010095686,0.00002690542,0.000003353171,0.00004541859,0.00029009982,0.00019896016],"category_scores_gemma":[0.0009701076,0.00005748098,0.000097148724,0.00014682503,0.00019987125,0.000092409675,0.000026787344,0.00061782566,0.0000019448603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042611026,0.0009969394,0.98902047,0.000012137721,0.00020538848,0.00004331761,0.0006477259,0.0000067991623,0.000021492488,0.00020576343,0.00015946041,0.008254402],"study_design_scores_gemma":[0.0038635866,0.0017914615,0.9924061,0.00012799772,0.00037893894,0.00008302213,0.00008445588,0.0003206063,0.000003204203,0.00043240516,0.0004580251,0.000050241182],"about_ca_topic_score_codex":0.0007109937,"about_ca_topic_score_gemma":0.00026366545,"teacher_disagreement_score":0.008204161,"about_ca_system_score_codex":0.00006994377,"about_ca_system_score_gemma":0.0009429391,"threshold_uncertainty_score":0.26841795},"labels":[],"label_agreement":null},{"id":"W2153787064","doi":"10.1200/jco.2008.16.9607","title":"Medical Care in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":419,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"American Lebanese Syrian Associated Charities; National Cancer Institute; Children's Cancer Research Fund; University of Minnesota; U.S. Department of Health and Human Services","keywords":"Medicine; Breast cancer; Cancer; Cohort; Childhood cancer; Health care; Survivorship curve; Family medicine; Cancer survivor; Pediatrics; Internal medicine","score_opus":0.09311338238424599,"score_gpt":0.4708593133996443,"score_spread":0.37774593101539833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153787064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96215796,0.012234087,0.000016410253,0.019413432,0.0045941067,0.0010384895,0.000060185954,0.000025135596,0.00046019678],"genre_scores_gemma":[0.98125046,0.00854279,0.00016383913,0.0045897537,0.0052624336,0.00004229728,0.000018582286,0.00006471884,0.00006514704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98532575,0.0027653521,0.007834741,0.00069137523,0.002791034,0.0005917253],"domain_scores_gemma":[0.98522097,0.00673903,0.005065397,0.0009783864,0.0010863458,0.000909881],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009527759,0.00044017268,0.004340904,0.00023108842,0.00012821592,0.000010689586,0.0010371932,0.000837079,0.0009344967],"category_scores_gemma":[0.012228555,0.00029124727,0.001116653,0.0006403359,0.0007855761,0.00017290462,0.00029316632,0.0034915828,0.000008231629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019945956,0.008647891,0.92403364,0.00005223441,0.001388967,0.0068021906,0.014710942,0.000017910095,0.0000031921868,0.0000024542378,0.0016327635,0.040713213],"study_design_scores_gemma":[0.016064167,0.006142315,0.9682836,0.00095762993,0.0006949705,0.0013905199,0.0033322757,0.0000036791876,0.000026239435,0.000029553132,0.0028157397,0.00025931143],"about_ca_topic_score_codex":0.031429835,"about_ca_topic_score_gemma":0.21636811,"teacher_disagreement_score":0.18493828,"about_ca_system_score_codex":0.0004430862,"about_ca_system_score_gemma":0.014840012,"threshold_uncertainty_score":0.9999788},"labels":[],"label_agreement":null},{"id":"W2153865661","doi":"10.1200/jco.2007.14.4824","title":"Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":573,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; AstraZeneca","keywords":"Medicine; Gefitinib; Docetaxel; Internal medicine; Performance status; Lung cancer; Interim analysis; Placebo; Chemoradiotherapy; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","score_opus":0.08398044194763006,"score_gpt":0.4845825549230046,"score_spread":0.40060211297537457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153865661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932073,0.0016221028,0.0003108735,0.0017676705,0.0009521753,0.00095195486,0.000030245887,0.0000046228697,0.0011530906],"genre_scores_gemma":[0.9819543,0.012620065,0.0010099318,0.0010910253,0.00061172975,0.00006880928,0.0000060044213,0.000016248949,0.0026218856],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971541,0.00016774787,0.002037222,0.00020570266,0.00020715935,0.00022807757],"domain_scores_gemma":[0.9971268,0.0007732587,0.0013995349,0.00013131066,0.0003219937,0.00024708794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010032034,0.00015619295,0.0015409532,0.00012594702,0.000039573566,0.0000063521115,0.00008021138,0.00022095951,0.00040860902],"category_scores_gemma":[0.00033492595,0.00010258904,0.00019341627,0.00013747666,0.00024543217,0.000120985154,0.000019907453,0.00051655015,0.0000011032946],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77789944,0.021290556,0.06148108,0.00039560205,0.0015086216,0.003328592,0.004371811,0.00010884271,0.0015085334,0.00006294561,0.008458226,0.11958572],"study_design_scores_gemma":[0.9239024,0.024809206,0.010209826,0.00043750135,0.0008062646,0.00029657927,0.0003865482,0.0009541483,0.0009024261,0.000009952805,0.037099432,0.00018569913],"about_ca_topic_score_codex":0.00017407222,"about_ca_topic_score_gemma":0.00015517029,"teacher_disagreement_score":0.14600295,"about_ca_system_score_codex":0.00028528617,"about_ca_system_score_gemma":0.0032393443,"threshold_uncertainty_score":0.57464576},"labels":[],"label_agreement":null},{"id":"W2153895104","doi":"10.1200/jco.2004.05.144","title":"Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Kallikrein; Ovarian cancer; Internal medicine; Oncology; Breast cancer; Ovary; Biomarker; Stage (stratigraphy); Population; Cancer; Endocrinology; Biology; Enzyme","score_opus":0.11791919114630176,"score_gpt":0.4490103192795383,"score_spread":0.3310911281332365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153895104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701595,0.0014441042,0.00033989912,0.02375949,0.00070312095,0.0006580003,0.0000017601275,0.000019131638,0.0029150257],"genre_scores_gemma":[0.9867863,0.00016889027,0.0052607884,0.0022525494,0.002247683,0.000016872242,0.0000027521032,0.00003142896,0.0032327324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960364,0.00025162444,0.002645944,0.0002637485,0.00040650577,0.000395741],"domain_scores_gemma":[0.99716556,0.00044790376,0.00134008,0.00020637317,0.00027166583,0.0005684332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024106896,0.0001944706,0.0014342532,0.0001922179,0.000058519847,0.000019130104,0.0001956916,0.0004737484,0.0006311124],"category_scores_gemma":[0.0026033844,0.00015034134,0.00043238775,0.00029623858,0.00015315192,0.00018757171,0.00004630193,0.0010337762,0.000030643674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041611004,0.0045677694,0.8619023,0.00014561955,0.00059299386,0.0028333596,0.00065795146,0.00051770505,0.0034017959,0.0028757907,0.0061980025,0.112145595],"study_design_scores_gemma":[0.019023653,0.006323668,0.9269244,0.0010476108,0.00026759665,0.00024978098,0.00007679794,0.000050446546,0.0003252403,0.009706329,0.03580964,0.00019481337],"about_ca_topic_score_codex":0.0013137681,"about_ca_topic_score_gemma":0.002210256,"teacher_disagreement_score":0.111950785,"about_ca_system_score_codex":0.0003204934,"about_ca_system_score_gemma":0.0051221563,"threshold_uncertainty_score":0.90864855},"labels":[],"label_agreement":null},{"id":"W2154122152","doi":"10.1200/jco.2007.10.8399","title":"Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Sanofi; Bristol-Myers Squibb","keywords":"Taxane; Medicine; Docetaxel; Epirubicin; Internal medicine; Oncology; Hazard ratio; Paclitaxel; Cyclophosphamide; Metastatic breast cancer; Breast cancer; Anthracycline; Progression-free survival; Chemotherapy; Cancer; Confidence interval","score_opus":0.2078138191094805,"score_gpt":0.5426035441105482,"score_spread":0.33478972500106774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154122152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06287918,0.9323711,0.000006136359,0.0024888378,0.0007451874,0.0013323284,0.000079364785,0.0000062176937,0.00009166238],"genre_scores_gemma":[0.005896131,0.992181,0.00050164864,0.0005181566,0.00053800474,0.000054611795,0.00005517254,0.000045764646,0.00020948124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99502593,0.00060854707,0.0034019859,0.00025993743,0.00047210616,0.00023149735],"domain_scores_gemma":[0.98959035,0.003211855,0.005975296,0.00017029126,0.0008318487,0.000220361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007066498,0.00036900086,0.006405951,0.00035925081,0.000030196594,0.000003329845,0.00017300052,0.00037458175,0.0005469063],"category_scores_gemma":[0.00033326063,0.00017057577,0.0005270578,0.00045640583,0.0003877855,0.00010588816,0.000021696222,0.0009962864,0.0000040423756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0316479,0.015390473,0.035642438,0.0014643989,0.0027799252,0.0013087706,0.00005645093,0.000007605263,5.4155272e-8,0.000002371651,0.0010043909,0.91069525],"study_design_scores_gemma":[0.051421147,0.06883681,0.054794908,0.0076214746,0.0036666258,0.0020061505,0.000012664492,0.0000032203607,9.847099e-7,0.000013644495,0.8114039,0.00021850341],"about_ca_topic_score_codex":0.00017457522,"about_ca_topic_score_gemma":0.0007464924,"teacher_disagreement_score":0.91047674,"about_ca_system_score_codex":0.00028857638,"about_ca_system_score_gemma":0.0051188692,"threshold_uncertainty_score":0.90806544},"labels":[],"label_agreement":null},{"id":"W2154143304","doi":"10.1200/jco.2006.05.8156","title":"Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver Metastases","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":512,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Oxaliplatin; Chemotherapy; Colorectal cancer; Perioperative; Steatosis; Internal medicine; Fluorouracil; Gastroenterology; Surgery; Cancer","score_opus":0.09593084241687191,"score_gpt":0.38049114376317494,"score_spread":0.28456030134630306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154143304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98939663,0.0057635442,0.00001580567,0.0036976018,0.00015841474,0.0003421386,0.0000088012885,0.0000072608937,0.0006097783],"genre_scores_gemma":[0.99417245,0.0014099969,0.0028917985,0.00069625676,0.0003751464,0.000035776204,0.000004942772,0.00001783889,0.00039579626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744433,0.0005531675,0.0012708199,0.00023668751,0.0002467274,0.00024826836],"domain_scores_gemma":[0.99726325,0.0016360044,0.00058987323,0.00007940578,0.00022944195,0.00020201222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010016537,0.00020611388,0.001707754,0.00013331218,0.000028843699,0.00000944915,0.00006304311,0.00033293135,0.0006045224],"category_scores_gemma":[0.00017759639,0.00012042911,0.00027567014,0.00011291523,0.00034445373,0.000120298144,0.000027089674,0.0006101407,0.000006269037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013114435,0.0010785516,0.9496619,0.000020660644,0.00038344366,0.014028403,0.00024735724,0.000003938683,0.000021082296,0.000041349358,0.0004372238,0.020961663],"study_design_scores_gemma":[0.017663367,0.007655574,0.9600996,0.00006169827,0.0005482862,0.0013287979,0.00004832305,0.00038488404,0.0002558591,0.000022594184,0.0117951855,0.00013586441],"about_ca_topic_score_codex":0.00056327577,"about_ca_topic_score_gemma":0.0020916979,"teacher_disagreement_score":0.020825798,"about_ca_system_score_codex":0.00025550302,"about_ca_system_score_gemma":0.00090388063,"threshold_uncertainty_score":0.66190964},"labels":[],"label_agreement":null},{"id":"W2154574630","doi":"10.1200/jco.2004.12.082","title":"Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":586,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Irinotecan; Internal medicine; Clinical endpoint; Pancreatic cancer; Gastroenterology; Population; Phases of clinical research; Progression-free survival; Chemotherapy; Oncology; Cancer; Surgery; Randomized controlled trial; Colorectal cancer","score_opus":0.07414236306649465,"score_gpt":0.44050574192881725,"score_spread":0.3663633788623226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154574630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940095,0.00020241427,0.0004293151,0.0030647984,0.00023827972,0.0016691365,0.000041647654,0.000018957135,0.00032596916],"genre_scores_gemma":[0.9778899,0.00046140424,0.019001843,0.0020331913,0.00018247444,0.000089305366,0.000017390084,0.000067059846,0.00025741188],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99056596,0.0031771078,0.0039533675,0.00056299585,0.0009178797,0.0008226874],"domain_scores_gemma":[0.98631376,0.009025669,0.002171516,0.00048439964,0.0012431504,0.0007615137],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010657931,0.00044458202,0.0043366137,0.00063655537,0.00006236892,0.000016554612,0.00036097917,0.00025791605,0.00015674742],"category_scores_gemma":[0.010951978,0.00026027526,0.00020041568,0.00089133804,0.00067766954,0.00029049075,0.00006247687,0.0018081582,0.000018203164],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57450217,0.0038681717,0.41165745,0.000070744485,0.000458773,0.00496904,0.00021581305,0.0016393685,0.0001353004,0.0000068729255,0.000027802571,0.0024484922],"study_design_scores_gemma":[0.20056473,0.06072179,0.7352111,0.0011580018,0.00038137956,0.00011251322,0.0002520697,0.00052070717,0.000028287805,0.00003938739,0.0007682057,0.000241856],"about_ca_topic_score_codex":0.0007833523,"about_ca_topic_score_gemma":0.005871951,"teacher_disagreement_score":0.37393746,"about_ca_system_score_codex":0.0016565857,"about_ca_system_score_gemma":0.012216615,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W2154634067","doi":"10.1200/jco.2004.05.122","title":"Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Hôpital du Saint-Sacrement; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Tamoxifen; Antiestrogen; Medicine; Breast cancer; Internal medicine; Estrogen receptor; Mammary gland; Estrogen; Cancer; Endometrium; Endometrial cancer; Oncology; Endocrinology; Gynecology","score_opus":0.0210743214959124,"score_gpt":0.3658850163303833,"score_spread":0.3448106948344709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154634067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954192,0.0012262155,0.000017870969,0.0025489347,0.00034330317,0.00020586383,0.00003358227,8.571561e-7,0.00020418494],"genre_scores_gemma":[0.99710196,0.0023381098,0.00015475426,0.00016511658,0.00018838089,0.0000031474688,6.3643574e-7,0.000009516719,0.000038381953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998076,0.0005196102,0.000911089,0.00014873651,0.00018049945,0.00016401682],"domain_scores_gemma":[0.99784756,0.00027526892,0.0013845435,0.00019517263,0.00020960257,0.00008784623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012393296,0.00011875955,0.00060319446,0.000030682786,0.000040933573,0.000003751932,0.00029928534,0.0004136498,0.00000542569],"category_scores_gemma":[0.00048149124,0.00006131672,0.00030826955,0.000124601,0.0004525888,0.000009689236,0.00013841774,0.00058788265,2.2475493e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03537706,0.0024204096,0.06764598,0.00007529271,0.0014886507,0.000053169995,0.0004588534,0.0013432216,0.7634632,0.00028151003,0.00036784876,0.12702481],"study_design_scores_gemma":[0.005270687,0.004190821,0.8597106,0.00014246358,0.00019854742,0.00014267526,0.00014793292,0.000009895309,0.12812854,0.0002930358,0.0016581775,0.00010666192],"about_ca_topic_score_codex":0.0000896682,"about_ca_topic_score_gemma":0.00034578794,"teacher_disagreement_score":0.79206455,"about_ca_system_score_codex":0.00004615823,"about_ca_system_score_gemma":0.0013172816,"threshold_uncertainty_score":0.31904462},"labels":[],"label_agreement":null},{"id":"W2154661082","doi":"10.1200/jco.2014.57.4673","title":"PISCES: A Horoscope for First-Line Targeted Therapy of Metastatic Renal Cell Carcinoma","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; Internal medicine; Cancer research; Cancer","score_opus":0.19823876607313895,"score_gpt":0.4354693582588855,"score_spread":0.23723059218574655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154661082","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39009872,0.010408154,0.0018668518,0.5889289,0.003591935,0.0024865824,0.000112482485,0.00002138874,0.0024849933],"genre_scores_gemma":[0.4892676,0.003539295,0.030513594,0.4540859,0.019016467,0.00008570923,0.00025056466,0.0002393269,0.0030015516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911416,0.0010511612,0.0058047986,0.00050788734,0.00092200196,0.0005725411],"domain_scores_gemma":[0.98091155,0.008772477,0.007781596,0.00065055635,0.0014582728,0.0004255273],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0038894028,0.0005710648,0.006039509,0.00040796414,0.000051829957,0.00001249882,0.000516925,0.0016218197,0.00033536137],"category_scores_gemma":[0.0021185458,0.00036182746,0.0028301985,0.00016900408,0.00040377874,0.00006465284,0.00005758795,0.0034657726,0.000020192858],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011458806,0.0025696985,0.0035297233,0.0010512441,0.002035651,0.004831364,0.000107213964,0.00002643935,0.0006498637,0.0000040928708,0.96044,0.013295947],"study_design_scores_gemma":[0.024069678,0.09472941,0.006025676,0.000309913,0.0025792622,0.0007353433,0.00001692668,0.000070776674,0.0033913574,0.00036249866,0.86742616,0.000282973],"about_ca_topic_score_codex":0.000040271174,"about_ca_topic_score_gemma":0.000015379122,"teacher_disagreement_score":0.134843,"about_ca_system_score_codex":0.00032304396,"about_ca_system_score_gemma":0.0031403818,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W2154662831","doi":"10.1200/jco.2011.36.8456","title":"First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":735,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Cisplatin; Internal medicine; Adenocarcinoma; Lung cancer; Chemotherapy; Lung; Cancer","score_opus":0.13184785630743598,"score_gpt":0.4544081414491074,"score_spread":0.32256028514167145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154662831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860841,0.0022600668,0.00006485897,0.008937546,0.0012828631,0.00045281465,0.0000036649483,0.0000033832018,0.0009107091],"genre_scores_gemma":[0.9973752,0.00023096762,0.00091932947,0.00043031716,0.00087097724,0.000007946593,0.0000016215406,0.000013879521,0.00014975379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978109,0.00018811847,0.001355249,0.00012091652,0.00030673936,0.00021805742],"domain_scores_gemma":[0.9963461,0.001955316,0.0011276263,0.00015883545,0.00016594416,0.00024616873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011324952,0.0001242383,0.00086899096,0.0000857998,0.00004878544,0.000004700831,0.00009673184,0.00020474492,0.00008877162],"category_scores_gemma":[0.0010150899,0.00006643039,0.00020929142,0.00016460552,0.00021401158,0.00015342022,0.00004498988,0.0005127918,0.000001102197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14444748,0.0041270605,0.83191586,0.00008146858,0.0010015037,0.00015859051,0.0008542404,0.00023280377,0.000014709575,0.00012574879,0.0025645313,0.014476014],"study_design_scores_gemma":[0.17770204,0.022010269,0.78033406,0.0002598517,0.001713976,0.00014097615,0.00024147796,0.00017275281,0.000036245736,0.000034171146,0.01726624,0.0000879452],"about_ca_topic_score_codex":0.00006605978,"about_ca_topic_score_gemma":0.00021213164,"teacher_disagreement_score":0.051581793,"about_ca_system_score_codex":0.000259805,"about_ca_system_score_gemma":0.0006019919,"threshold_uncertainty_score":0.27089527},"labels":[],"label_agreement":null},{"id":"W2154780929","doi":"10.1200/jco.2010.33.2536","title":"Tumor-to-Tumor Metastasis: Report of a Case of Renal Cell Carcinoma Metastasizing to a Pancreatic Endocrine Neoplasm","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Renal cell carcinoma; Metastasis; Neoplasm; Endocrine system; Pathology; Oncology; Pancreatic carcinoma; Internal medicine; Cancer research; Cancer; Pancreatic cancer; Hormone","score_opus":0.1652536060947018,"score_gpt":0.4404883882909823,"score_spread":0.2752347821962805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154780929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403363,0.000917678,0.00014662495,0.0012131925,0.00053144124,0.00046386875,0.000025531746,0.0000053860617,0.0026626587],"genre_scores_gemma":[0.9611117,0.00006839473,0.037323885,0.0010253375,0.00032729615,0.0000256698,0.0000013710792,0.000024515239,0.00009183627],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9944247,0.00033479164,0.0042090476,0.00029967164,0.00040263106,0.00032917043],"domain_scores_gemma":[0.9933895,0.0014018443,0.0031528648,0.00044955596,0.00076754246,0.00083867664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027698323,0.00021758948,0.0029155135,0.00033466713,0.000025937283,0.0000034450952,0.00015388535,0.00007768189,0.00029914023],"category_scores_gemma":[0.0029480436,0.00015207852,0.00089526817,0.00031027946,0.0001190774,0.00006584483,0.00010905189,0.00045706125,0.000011094632],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014558645,0.01447413,0.2148919,0.0004568947,0.0039014407,0.66840535,0.0014938999,0.000041576302,0.0022140713,0.00017447874,0.007593219,0.07179439],"study_design_scores_gemma":[0.026185537,0.11010253,0.40785617,0.0008950209,0.018839503,0.30610058,0.0016985548,0.000025124367,0.08867292,0.00028360612,0.038895294,0.00044517653],"about_ca_topic_score_codex":0.0010608382,"about_ca_topic_score_gemma":0.00045386332,"teacher_disagreement_score":0.36230478,"about_ca_system_score_codex":0.00017568936,"about_ca_system_score_gemma":0.0016770457,"threshold_uncertainty_score":0.6201582},"labels":[],"label_agreement":null},{"id":"W2154845873","doi":"10.1200/jco.2011.38.4255","title":"Clinical Impact of Pathology Reviews of Outside Material: A Patient-Focused Approach","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Digital Imaging in Medicine","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pathology; Medical physics","score_opus":0.27132611863799366,"score_gpt":0.5118675191998511,"score_spread":0.2405414005618574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154845873","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5045654,0.008353438,0.0010292383,0.25508228,0.03781734,0.005541266,0.00039745044,0.000099133955,0.1871144],"genre_scores_gemma":[0.112902515,0.015922382,0.10709301,0.7175951,0.043552674,0.000044148703,0.00038571825,0.000494444,0.0020100053],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9774165,0.0035463718,0.01697781,0.00057492073,0.00088282354,0.0006015461],"domain_scores_gemma":[0.971256,0.004321861,0.021147333,0.001137685,0.001586785,0.0005503035],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012789708,0.00058913877,0.013056125,0.00054606353,0.000014048868,0.000007496151,0.0008083313,0.0034072816,0.0006476945],"category_scores_gemma":[0.028596776,0.00035620132,0.0047094454,0.00024310563,0.0020491653,0.00015347448,0.00024518187,0.0071812207,0.000038330516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004235252,0.0033130352,0.025485273,0.0008629073,0.0014247999,0.006197517,0.00011461827,4.1395606e-7,0.00006324997,0.000004805662,0.79620653,0.16209161],"study_design_scores_gemma":[0.00941961,0.07250867,0.033892304,0.0018420942,0.003416157,0.005200621,0.00002430325,0.000007958327,0.000037565434,0.00037469374,0.8729422,0.0003337915],"about_ca_topic_score_codex":0.000040670493,"about_ca_topic_score_gemma":8.2306485e-7,"teacher_disagreement_score":0.46251282,"about_ca_system_score_codex":0.00018528278,"about_ca_system_score_gemma":0.0033887425,"threshold_uncertainty_score":0.999889},"labels":[],"label_agreement":null},{"id":"W2154868186","doi":"10.1200/jco.2010.34.3202","title":"Can Quantifying Hormone Receptor Levels Guide the Choice of Adjuvant Endocrine Therapy for Breast Cancer?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Hormone receptor; Oncology; Adjuvant; Endocrine system; Hormone; Internal medicine; Cancer; Hormone therapy; Adjuvant therapy","score_opus":0.1507434648887912,"score_gpt":0.44799749135751327,"score_spread":0.29725402646872207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154868186","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2955942,0.041301828,0.00020797968,0.65237993,0.0075465427,0.0013202298,0.00091429707,0.000011679955,0.0007233251],"genre_scores_gemma":[0.27649674,0.12860337,0.0053979666,0.50987905,0.07321317,0.00016386023,0.0003034262,0.00038930637,0.005553109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563086,0.00075708155,0.002516015,0.00035930777,0.0002905372,0.00044618215],"domain_scores_gemma":[0.99333537,0.0012957825,0.0039661573,0.00043748287,0.0008102923,0.00015491826],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0020342465,0.0003469889,0.0016529814,0.00008061355,0.00007962092,0.000010584337,0.0008334173,0.0018838046,0.00006090777],"category_scores_gemma":[0.0010642796,0.00020057768,0.0012578474,0.00008229127,0.00038824836,0.0000058082323,0.00011426621,0.002433799,0.0000026252146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023488055,0.0002812,0.0009254408,0.00005183769,0.001897569,0.00007816496,0.000026349635,0.0000062461213,0.036779206,0.000007660548,0.84793603,0.10966146],"study_design_scores_gemma":[0.004351367,0.009019825,0.0068487786,0.00010065879,0.00037194035,0.00030892872,0.000014607623,0.000004841227,0.0077966256,0.000046513724,0.9708888,0.0002471305],"about_ca_topic_score_codex":0.00020176123,"about_ca_topic_score_gemma":0.000045857865,"teacher_disagreement_score":0.14250085,"about_ca_system_score_codex":0.000056707337,"about_ca_system_score_gemma":0.0019359142,"threshold_uncertainty_score":0.9998676},"labels":[],"label_agreement":null},{"id":"W2154943084","doi":"10.1200/jco.2014.60.1492","title":"Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i>-Mutant Lung Adenocarcinoma","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Epidermal growth factor receptor; Cancer research; Lung cancer; Adenocarcinoma; Targeted therapy; Cetuximab; Cancer; Pathology; Internal medicine","score_opus":0.12799527912535108,"score_gpt":0.4583505217761397,"score_spread":0.33035524265078864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154943084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928137,0.0021095974,0.00004736105,0.0030803464,0.0007859349,0.00051872304,0.00002281501,0.0000047196977,0.00061681814],"genre_scores_gemma":[0.989244,0.00026405216,0.009754434,0.0005205745,0.00017633435,0.000010093045,0.000003027869,0.000012547005,0.0000149533935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950421,0.0005087133,0.003619916,0.00025122284,0.00036474838,0.00021331251],"domain_scores_gemma":[0.99524665,0.0013519421,0.0018640565,0.0002220642,0.000701921,0.00061338657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027866587,0.00014218272,0.0016392842,0.00017196155,0.0000166151,0.0000037447992,0.00012202511,0.00027869703,0.000018080635],"category_scores_gemma":[0.0034288252,0.00010161306,0.000319815,0.0002291181,0.0003474889,0.00008862828,0.00007729634,0.00038656313,0.0000010744683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008821121,0.0026056704,0.91902375,0.00012346866,0.00049749285,0.00040828087,0.0007425661,0.0000011285985,0.0004914674,0.000012996951,0.002206405,0.06506564],"study_design_scores_gemma":[0.012625811,0.01579769,0.96130866,0.00047829334,0.0007348066,0.000063181804,0.0007669505,0.00006891928,0.00088827003,0.00018518462,0.006982151,0.00010009501],"about_ca_topic_score_codex":0.000044167962,"about_ca_topic_score_gemma":0.00018807873,"teacher_disagreement_score":0.06496554,"about_ca_system_score_codex":0.00012941533,"about_ca_system_score_gemma":0.0017824525,"threshold_uncertainty_score":0.41436607},"labels":[],"label_agreement":null},{"id":"W2154948351","doi":"10.1200/jco.2003.06.099","title":"Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vinorelbine; Medicine; Gemcitabine; Internal medicine; Lung cancer; Cisplatin; Hazard ratio; Oncology; Chemotherapy; Cancer; Ototoxicity; Confidence interval","score_opus":0.13445089668490903,"score_gpt":0.4988893839233714,"score_spread":0.3644384872384624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154948351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979955,0.0012238241,0.0006266955,0.0085923225,0.0039755977,0.0044982666,0.00042017878,0.000007723353,0.0007003593],"genre_scores_gemma":[0.9879938,0.0009658096,0.005588133,0.0019456282,0.0014162933,0.00037831947,0.00004237795,0.000049763963,0.0016199114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904595,0.0012539995,0.0064387955,0.00045173016,0.0009573686,0.00043859117],"domain_scores_gemma":[0.9819936,0.008372605,0.0071638785,0.00035072642,0.0015216639,0.0005975136],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008695245,0.00041561358,0.0044325786,0.0001483532,0.00021757623,0.0000169745,0.00037048073,0.0003645746,0.0001445388],"category_scores_gemma":[0.013186333,0.00019996225,0.0007563995,0.0004998442,0.0012216162,0.00017612749,0.00007759123,0.0009439896,2.0691397e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91587603,0.0047756764,0.014443163,0.00077817787,0.008402985,0.00016914771,0.0011905843,0.010012126,0.0006961839,0.0017471488,0.027060553,0.01484823],"study_design_scores_gemma":[0.93217695,0.01555582,0.004896937,0.00088256126,0.007670435,0.00012915811,0.00052406586,0.008075931,0.0003279492,0.00015794889,0.029250577,0.00035163897],"about_ca_topic_score_codex":0.013296367,"about_ca_topic_score_gemma":0.11462382,"teacher_disagreement_score":0.10132745,"about_ca_system_score_codex":0.0012872192,"about_ca_system_score_gemma":0.038524438,"threshold_uncertainty_score":0.995126},"labels":[],"label_agreement":null},{"id":"W2155012968","doi":"10.1200/jco.2008.16.9847","title":"Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":908,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Renal cell carcinoma; Clinical endpoint; Hazard ratio; Gastroenterology; Proteinuria; Oncology; Surgery; Randomized controlled trial; Chemotherapy; Confidence interval; Kidney","score_opus":0.0995623420053774,"score_gpt":0.3685206473544246,"score_spread":0.2689583053490472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155012968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555355,0.00056638505,0.0004151025,0.0010201877,0.00037771338,0.00070975034,0.000009431445,0.000013008503,0.0013348553],"genre_scores_gemma":[0.9920803,0.00012401995,0.006304625,0.000798632,0.00027779833,0.000016023205,0.000029017181,0.00006228898,0.00030733863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454457,0.0007490009,0.0029097095,0.00046092627,0.00082257576,0.0005132266],"domain_scores_gemma":[0.99537724,0.0009734219,0.0019584228,0.00043588303,0.0006257118,0.0006293469],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010283698,0.00043398357,0.002862043,0.00036885057,0.000060031132,0.000011949888,0.0003050606,0.00026487204,0.00018846341],"category_scores_gemma":[0.00016788284,0.00025776733,0.0004058017,0.00027148915,0.00044762256,0.00019441576,0.000064677915,0.0015474814,0.000025559648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21510307,0.009415489,0.7473314,0.000098034805,0.0009463314,0.009744462,0.0014172432,0.0004485412,0.00014519315,0.0000052102005,0.0027738872,0.012571142],"study_design_scores_gemma":[0.08819126,0.1456011,0.75993973,0.0002485718,0.00070931646,0.0011146133,0.00022081105,0.00022348398,0.00074265077,0.000021944965,0.0026980764,0.0002884491],"about_ca_topic_score_codex":0.00017927427,"about_ca_topic_score_gemma":0.00028378287,"teacher_disagreement_score":0.1361856,"about_ca_system_score_codex":0.0012232348,"about_ca_system_score_gemma":0.002030297,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W2155090470","doi":"10.1200/jco.2005.02.048","title":"Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"Medical Research Council; Medical Research Council Canada; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Leptin; Medicine; Internal medicine; Breast cancer; Tamoxifen; Oncology; Cancer; Aromatase; Endocrinology; Body mass index; Obesity","score_opus":0.05920323585087346,"score_gpt":0.41688849143158885,"score_spread":0.3576852555807154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155090470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415594,0.000070683236,0.000018204346,0.0047394214,0.00052989915,0.00014486047,0.0000068471386,0.000003319043,0.0003308496],"genre_scores_gemma":[0.9974246,0.00053986046,0.00054175453,0.0009942133,0.00044297447,0.0000015860386,8.423573e-8,0.0000059289896,0.000049024122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969205,0.0005333123,0.0018491084,0.0001586765,0.00037462474,0.00016372559],"domain_scores_gemma":[0.9931605,0.0042651067,0.0020886431,0.0001280048,0.0001907396,0.00016701824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014977019,0.00009025261,0.00090249476,0.00013361606,0.000016797529,0.0000014794178,0.00027785878,0.00022255466,0.00015865453],"category_scores_gemma":[0.004273658,0.000069599555,0.0002940395,0.00022618173,0.00027824688,0.00017540551,0.00005729813,0.0004393456,0.000012108238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010560312,0.0027575432,0.9386596,0.000108078784,0.000023466642,0.00011047712,0.00023179023,0.00019445176,0.019881885,0.00016380631,0.0008196108,0.035993267],"study_design_scores_gemma":[0.0028881838,0.0014049382,0.9346382,0.00016190176,0.00004705218,0.000042162847,0.0000149920315,0.00024605353,0.057730623,0.00016012481,0.0026051898,0.000060604703],"about_ca_topic_score_codex":0.000023588877,"about_ca_topic_score_gemma":0.00006819545,"teacher_disagreement_score":0.037848737,"about_ca_system_score_codex":0.00007188702,"about_ca_system_score_gemma":0.00075135735,"threshold_uncertainty_score":0.5116277},"labels":[],"label_agreement":null},{"id":"W2155114029","doi":"10.1200/jco.2012.47.1227","title":"Ethical Issues for Control-Arm Patients After Revelation of Benefits of Experimental Therapy: A Framework Modeled in Neuroblastoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Children’s Oncology Group","keywords":"Medicine; Neuroblastoma; Context (archaeology); Randomized controlled trial; Data monitoring committee; Transplantation; Clinical trial; Oncology; Internal medicine","score_opus":0.09938289100960696,"score_gpt":0.47720889870058786,"score_spread":0.3778260076909809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155114029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481386,0.00044528223,0.00014637569,0.0035596145,0.00020685469,0.0007512494,0.000008425622,0.0000027905644,0.00006553634],"genre_scores_gemma":[0.99411106,0.00023054608,0.004152598,0.0012396687,0.00018048998,0.000042467793,0.0000016547535,0.00001666727,0.000024852756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968693,0.00043353555,0.0019083313,0.00015569743,0.00042396065,0.00020913672],"domain_scores_gemma":[0.99519587,0.0026920433,0.0009990942,0.00014111724,0.0007448259,0.00022706152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008683511,0.00011923311,0.0012160765,0.00015994196,0.000011897387,0.0000037966108,0.000104998086,0.00049455353,0.00014181454],"category_scores_gemma":[0.0029657048,0.00008131099,0.00036917973,0.00010350219,0.00015785244,0.00010525251,0.000027779097,0.0008844452,0.0000051025063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15266342,0.03863192,0.65474945,0.00014575981,0.0010865912,0.00016288954,0.0008548899,0.00027064083,0.00597165,0.0005383713,0.0015770072,0.14334738],"study_design_scores_gemma":[0.030066302,0.067691974,0.89562404,0.0002798546,0.00006410695,0.000012834285,0.000027401507,0.0008219664,0.0036275387,0.0013849777,0.00033194106,0.00006704979],"about_ca_topic_score_codex":0.000021565556,"about_ca_topic_score_gemma":0.0000056303866,"teacher_disagreement_score":0.24087459,"about_ca_system_score_codex":0.000058661328,"about_ca_system_score_gemma":0.000316987,"threshold_uncertainty_score":0.38425234},"labels":[],"label_agreement":null},{"id":"W2155139481","doi":"10.1200/jco.2014.55.3818","title":"Pain in Patients With Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Cancer; Cancer pain; Internal medicine; Oncology; Family medicine","score_opus":0.05856750037573908,"score_gpt":0.43411666034243496,"score_spread":0.37554915996669586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155139481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990049,0.000041621544,0.00037473862,0.0053310986,0.00041384672,0.000097227785,1.7744891e-7,0.0000032069013,0.0036890788],"genre_scores_gemma":[0.9900743,0.000091111324,0.0020231341,0.0068737864,0.00062549405,0.0000014562128,7.5009325e-7,0.000006758275,0.00030324605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826735,0.00041950183,0.0009042613,0.00007754922,0.00020880559,0.00012251173],"domain_scores_gemma":[0.99794537,0.0010567905,0.0006043085,0.000089650035,0.0001613731,0.00014248169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00524478,0.000056594494,0.0006453641,0.00008828675,0.000008533741,0.0000025061543,0.00007771184,0.00011654619,0.0001141066],"category_scores_gemma":[0.0032667872,0.00003350525,0.00010057503,0.00008654178,0.000056944093,0.000043972097,0.000016254402,0.00044636018,0.0000072526013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016527505,0.0006044707,0.76807696,0.000010302952,0.000050865234,0.000028903167,0.000013558823,0.000010458271,5.086607e-7,0.000033817087,0.0056956895,0.22382173],"study_design_scores_gemma":[0.008326795,0.009855335,0.81876487,0.000079912366,0.00006503943,3.6498653e-7,0.000009733701,0.00014766323,4.7845447e-7,0.00010345112,0.16261351,0.00003284286],"about_ca_topic_score_codex":0.0000116242445,"about_ca_topic_score_gemma":0.00006106657,"teacher_disagreement_score":0.22378889,"about_ca_system_score_codex":0.000059160277,"about_ca_system_score_gemma":0.00024350759,"threshold_uncertainty_score":0.39108852},"labels":[],"label_agreement":null},{"id":"W2155180872","doi":"10.1200/jco.2012.46.9460","title":"Off-Label Use of Cancer Drugs: A Benchmark Is Established","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Off-label use; Cancer drugs; Oncology; Pharmacology; Internal medicine; Intensive care medicine","score_opus":0.34653663956543823,"score_gpt":0.5593770695602268,"score_spread":0.21284042999478858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155180872","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03101392,0.009476978,0.0000048561983,0.9481692,0.004508932,0.00034329644,0.000048945836,0.000006757374,0.006427145],"genre_scores_gemma":[0.0014034337,0.05500101,0.002389118,0.92106444,0.015027666,0.000011476465,0.000009681192,0.000042099906,0.0050510685],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932872,0.0008215193,0.0041991887,0.0003185458,0.00090939907,0.00046411395],"domain_scores_gemma":[0.97575945,0.015471385,0.006442313,0.0003270648,0.0015760234,0.0004237377],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0026329656,0.000319822,0.0039002618,0.00016563367,0.00004677621,0.000029578487,0.00035452427,0.0019819534,0.0052450225],"category_scores_gemma":[0.009241539,0.00020373217,0.0009796668,0.000201481,0.000502104,0.000372438,0.0001820471,0.007990264,0.000049165057],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015762795,0.0007162045,0.004971615,0.00021242068,0.00222076,0.00089904957,0.000072671326,3.5647616e-7,0.000012146412,0.0000025865954,0.8006202,0.18869574],"study_design_scores_gemma":[0.005433978,0.0048193205,0.006056121,0.0004407095,0.0032595606,0.00012315257,0.000034214434,0.00006199273,0.000016113167,0.000103316816,0.9794729,0.00017866254],"about_ca_topic_score_codex":0.00044323,"about_ca_topic_score_gemma":0.000021372813,"teacher_disagreement_score":0.18851708,"about_ca_system_score_codex":0.00019836269,"about_ca_system_score_gemma":0.0021244949,"threshold_uncertainty_score":0.9993137},"labels":[],"label_agreement":null},{"id":"W2155217624","doi":"10.1200/jco.2005.10.072","title":"Physician/Patient Decision Aids for Adjuvant Therapy","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Decision aids; Medicine; Health care; Patient participation; Informed consent; Clinical decision making; Disease; Information needs; Clinical trial; Family medicine; Alternative medicine; Pathology","score_opus":0.7602298932665824,"score_gpt":0.689464734505679,"score_spread":0.07076515876090339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155217624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007438333,0.98236203,0.00023942864,0.0014923213,0.011021881,0.0033546023,0.00007497081,0.000026530963,0.001353825],"genre_scores_gemma":[0.000049344802,0.95988214,0.026146747,0.007071974,0.006116959,0.00042845163,0.00003638757,0.0001060048,0.00016199297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9758906,0.008368674,0.013936718,0.00044044488,0.0006683511,0.0006952137],"domain_scores_gemma":[0.91963995,0.05707537,0.01949023,0.001123459,0.002072792,0.00059818116],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0052877753,0.00048953417,0.007997931,0.00038085226,0.00048419368,0.0000081786375,0.0015314658,0.002575278,0.00018423841],"category_scores_gemma":[0.011979322,0.00031868822,0.0030172342,0.00032772488,0.00015471385,0.00019616964,0.00035795005,0.006094301,0.00026982412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076433906,0.0008217761,0.000058686914,0.0017988145,0.00028023776,0.000008589844,0.0003866477,0.0000017460228,2.3315431e-8,0.00019900185,0.028987741,0.9666924],"study_design_scores_gemma":[0.0036319776,0.010063823,0.00006187769,0.014430663,0.00046676135,0.000014650483,0.00046109548,0.0000100008365,2.9703852e-8,0.0009242275,0.9696807,0.00025415415],"about_ca_topic_score_codex":0.0000143185425,"about_ca_topic_score_gemma":0.000036477257,"teacher_disagreement_score":0.96643823,"about_ca_system_score_codex":0.0011646937,"about_ca_system_score_gemma":0.01402926,"threshold_uncertainty_score":0.9999265},"labels":[],"label_agreement":null},{"id":"W2155357724","doi":"10.1200/jco.2008.19.5594","title":"Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Aromatase; Emperor; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Aromatase inhibitor; Cancer; Gynecology; Surgery; Ancient history","score_opus":0.07064086470873959,"score_gpt":0.4096899320417811,"score_spread":0.3390490673330415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155357724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987402,0.0038368413,0.000038957503,0.00698314,0.0013308496,0.00027434935,0.000052564243,0.0000031668515,0.000078095894],"genre_scores_gemma":[0.9867801,0.007814697,0.0006848979,0.002718823,0.0017109109,0.0000068248714,0.000008938073,0.000016623224,0.00025820028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979313,0.00032211328,0.0012049926,0.00017442457,0.00015830624,0.00020886304],"domain_scores_gemma":[0.99756604,0.0005003714,0.0011781439,0.0002290788,0.00035771084,0.00016863536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012278915,0.00014848623,0.00065886334,0.0000330808,0.000070846,0.000015763537,0.00026469192,0.0004874863,0.00002527443],"category_scores_gemma":[0.0008246828,0.00008084976,0.0006085788,0.000039867675,0.00026799552,0.0000105011895,0.000030857605,0.00038411614,0.000005519213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024864504,0.0021311927,0.0052702078,0.000016962207,0.0011244863,0.000062102525,0.00013925032,0.00015097093,0.24179725,0.00007924179,0.13226722,0.5920966],"study_design_scores_gemma":[0.012572071,0.054713763,0.06667448,0.00014070525,0.00036527377,0.0006515766,0.00010573648,0.00009474737,0.09225865,0.00044930956,0.7716211,0.00035255996],"about_ca_topic_score_codex":0.000027457367,"about_ca_topic_score_gemma":0.0000106187545,"teacher_disagreement_score":0.63935393,"about_ca_system_score_codex":0.000020427164,"about_ca_system_score_gemma":0.00088277605,"threshold_uncertainty_score":0.3759941},"labels":[],"label_agreement":null},{"id":"W2155400940","doi":"10.1200/jco.2012.46.7787","title":"Vanishing Bile Duct Syndrome Arising in a Patient With T-Cell–Rich Large B-Cell Lymphoma","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Lymphoma; Bile duct; Cancer research; Internal medicine; Pathology; Gastroenterology","score_opus":0.1300349653574392,"score_gpt":0.43884085934652944,"score_spread":0.30880589398909025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155400940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051608384,0.94094354,0.000014123854,0.0003635223,0.0014232417,0.0007379991,0.000007135139,0.000011387403,0.004890648],"genre_scores_gemma":[0.023076648,0.9732619,0.0016209962,0.00069489423,0.0009008208,0.000033453016,0.000008296997,0.000075356525,0.0003276595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99317783,0.00075009547,0.004454876,0.00046109402,0.0005939316,0.0005621991],"domain_scores_gemma":[0.99197084,0.0024275521,0.0043992014,0.00037804423,0.00038494074,0.00043944857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022989276,0.00048255667,0.0074753985,0.0004172025,0.00006397794,0.000033393146,0.00031167286,0.0008892772,0.00010048769],"category_scores_gemma":[0.0008340591,0.00028726077,0.0013227232,0.0004457003,0.0001346285,0.00015785501,0.00019354944,0.0021236537,0.00006746634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035993048,0.005501084,0.0028831086,0.004814461,0.000754609,0.01972459,0.00032297484,6.003956e-7,4.1974175e-7,0.0000030802278,0.007312698,0.95832247],"study_design_scores_gemma":[0.01019924,0.012921922,0.001747454,0.009342204,0.0027323316,0.01037799,0.0003498275,0.000002252158,6.938168e-7,0.000013149503,0.952006,0.0003069797],"about_ca_topic_score_codex":0.000045701858,"about_ca_topic_score_gemma":0.000055144028,"teacher_disagreement_score":0.95801544,"about_ca_system_score_codex":0.0006912524,"about_ca_system_score_gemma":0.004350886,"threshold_uncertainty_score":0.999958},"labels":[],"label_agreement":null},{"id":"W2155481602","doi":"10.1200/jco.2005.01.2757","title":"Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cisplatin; Hazard ratio; Internal medicine; Chemotherapy; Cyclophosphamide; Oncology; Ovarian cancer; Tumor progression; Paclitaxel; Progression-free survival; Ovarian carcinoma; Cancer; Urology; Gastroenterology; Confidence interval","score_opus":0.17813556036093378,"score_gpt":0.5249395145190848,"score_spread":0.346803954158151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155481602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906683,0.003935035,0.000022002967,0.004104774,0.00029226707,0.0003478128,0.000054895074,8.53288e-7,0.00057407434],"genre_scores_gemma":[0.9898109,0.006357114,0.003578111,0.000067698435,0.00016627293,0.000009428848,0.0000018645688,0.000006099031,0.0000025547567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691486,0.00029707316,0.0022623031,0.00012666883,0.00029068423,0.0001084138],"domain_scores_gemma":[0.9940246,0.0034550598,0.00208185,0.00012277807,0.00021115714,0.00010458097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018681143,0.000103954415,0.0014785011,0.000100090074,0.000018627368,0.0000030401382,0.00006278898,0.00019139651,0.000052055588],"category_scores_gemma":[0.0010762367,0.00006314997,0.00013962822,0.000118360964,0.0004091685,0.000054902637,0.000039663606,0.0003600054,6.949222e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.116302006,0.0040341914,0.50620353,0.0001853676,0.00055629516,0.000036097335,0.0015017346,0.000022157792,0.00019125435,0.0012205159,0.0005318683,0.36921495],"study_design_scores_gemma":[0.1455122,0.047294874,0.8007967,0.0011384145,0.0010679457,0.000032997777,0.00086112134,0.00012929467,0.0007201607,0.00043899714,0.0019359816,0.00007135011],"about_ca_topic_score_codex":0.0001144231,"about_ca_topic_score_gemma":0.000577507,"teacher_disagreement_score":0.3691436,"about_ca_system_score_codex":0.000059075814,"about_ca_system_score_gemma":0.00050126313,"threshold_uncertainty_score":0.2575181},"labels":[],"label_agreement":null},{"id":"W2155516738","doi":"10.1200/jco.2009.24.6520","title":"Local Control, Survival, and the Fisher Hypothesis","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Lumpectomy; Medicine; Axilla; Radiation therapy; Breast cancer; Mastectomy; Cancer; Surgery; Incidence (geometry); Internal medicine","score_opus":0.06334804459067692,"score_gpt":0.3729395679819596,"score_spread":0.3095915233912827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155516738","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024171653,0.0056518647,0.00048048567,0.9856703,0.0016784106,0.00016847673,0.000021749614,0.0000033323897,0.003908192],"genre_scores_gemma":[0.0896899,0.0076607806,0.000481028,0.883007,0.018184265,0.00001018457,0.000011670458,0.000040824107,0.00091432716],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963463,0.0013202108,0.0015021255,0.00028655177,0.0002781523,0.000266642],"domain_scores_gemma":[0.99447036,0.0031228657,0.0017267939,0.00029454648,0.00029295072,0.00009247217],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022303306,0.00026889262,0.0018123591,0.00003814674,0.00006571738,0.000017874947,0.00036056043,0.0014808826,0.000027938882],"category_scores_gemma":[0.002094637,0.00014655483,0.00074788777,0.00003577711,0.0011575207,0.0000034730379,0.0000876496,0.0016667926,0.000006452403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00306329,0.00012783981,0.00086600875,0.000009399238,0.0015236714,0.00029640947,0.000008054782,0.0000035264952,0.000004763673,0.000010342121,0.90580356,0.08828311],"study_design_scores_gemma":[0.011418517,0.0021632055,0.016553545,0.000024611616,0.00081880833,0.00026112376,0.000024738747,0.0000023140021,0.000009870553,0.00059970136,0.967974,0.00014953567],"about_ca_topic_score_codex":0.00002316226,"about_ca_topic_score_gemma":0.000046200727,"teacher_disagreement_score":0.10266331,"about_ca_system_score_codex":0.000042444623,"about_ca_system_score_gemma":0.0005782053,"threshold_uncertainty_score":0.9998154},"labels":[],"label_agreement":null},{"id":"W2155568574","doi":"10.1200/jco.2006.05.9055","title":"Comparison of Long-Term Neurocognitive Outcomes in Young Children With Acute Lymphoblastic Leukemia Treated With Cranial Radiation or High-Dose or Very High-Dose Intravenous Methotrexate","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Hospital for Sick Children; University of Toronto; Pediatric Oncology Group of Ontario; American Society of Clinical Oncology","keywords":"Medicine; Neurocognitive; Methotrexate; Cohort; Pediatrics; Chemotherapy; Retrospective cohort study; Population; Acute lymphocytic leukemia; Internal medicine; Leukemia; Lymphoblastic Leukemia; Cognition","score_opus":0.04696036296061799,"score_gpt":0.4126862246074022,"score_spread":0.36572586164678417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155568574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639314,0.00004124065,0.0013997313,0.0005708869,0.00035483486,0.0009974858,0.000039910254,0.000028069908,0.00017470134],"genre_scores_gemma":[0.993959,0.0002635809,0.0041850456,0.0002976144,0.0007906788,0.000020090625,0.000061088176,0.00008183875,0.00034104584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928871,0.0011088566,0.0036670584,0.0005199442,0.0011399616,0.0006770764],"domain_scores_gemma":[0.98888075,0.006351205,0.0030744637,0.00034654586,0.00086949207,0.00047754266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015924351,0.00047949128,0.0039290157,0.00069075346,0.000071649796,0.000029455661,0.0003828704,0.00063322583,0.00014157123],"category_scores_gemma":[0.002454085,0.0002590643,0.00029741842,0.00082936673,0.00071160274,0.00028824786,0.00009391981,0.0014964032,0.000015494046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14332308,0.004205093,0.8072281,0.000056364137,0.0020334087,0.01184037,0.00014014005,0.00056848215,0.000355216,0.000011582783,0.00019611245,0.030042076],"study_design_scores_gemma":[0.07382645,0.04731909,0.86944044,0.0003192276,0.0022898584,0.004928017,0.000050181014,0.00067210634,0.0008791011,0.00001726918,0.0000110725305,0.00024720916],"about_ca_topic_score_codex":0.0017795822,"about_ca_topic_score_gemma":0.0026406292,"teacher_disagreement_score":0.06949664,"about_ca_system_score_codex":0.0020838524,"about_ca_system_score_gemma":0.010190944,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W2155902341","doi":"10.1200/jco.2005.07.096","title":"Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Amenorrhea; Hazard ratio; Breast cancer; Internal medicine; Cyclophosphamide; Epirubicin; Gynecology; Incidence (geometry); Oncology; Cumulative incidence; Cancer; Chemotherapy; Cohort; Pregnancy; Confidence interval","score_opus":0.15255482749609434,"score_gpt":0.5236406910052744,"score_spread":0.3710858635091801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155902341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566686,0.0019280524,0.000010781449,0.0011052033,0.000550358,0.00058439095,0.00013834763,0.0000020099735,0.000014011266],"genre_scores_gemma":[0.9949494,0.0039679958,0.00022419155,0.00009141707,0.0007322183,0.000014747762,0.0000030420601,0.0000070607134,0.000009908015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99030274,0.002611098,0.0059519405,0.00036147758,0.0005498347,0.00022290187],"domain_scores_gemma":[0.988709,0.0040216944,0.005548038,0.0002271215,0.0012506917,0.00024346793],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019647935,0.00017537376,0.0040087937,0.00030715062,0.000031811505,0.0000019671204,0.0001868265,0.0002906515,0.00014354431],"category_scores_gemma":[0.014266322,0.00011106654,0.00048789682,0.00052352046,0.0005849883,0.00014415903,0.000057286245,0.00089088484,8.2601844e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046729494,0.0036305627,0.8997232,0.000031026644,0.0058074286,0.000040188654,0.00014972089,0.0012800626,0.00082197995,0.000003637254,0.000054275995,0.041728444],"study_design_scores_gemma":[0.009942859,0.0106239,0.9769783,0.00011537677,0.0018091234,0.00003379946,0.00006088501,0.0002080506,0.00006451288,0.000042323536,0.000040958737,0.00007990496],"about_ca_topic_score_codex":0.10436959,"about_ca_topic_score_gemma":0.299013,"teacher_disagreement_score":0.1946434,"about_ca_system_score_codex":0.0005678985,"about_ca_system_score_gemma":0.008478501,"threshold_uncertainty_score":0.9971425},"labels":[],"label_agreement":null},{"id":"W2156059498","doi":"10.1200/jco.2005.11.181","title":"Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Genentech; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Placebo; Quality of life (healthcare); Vasomotor; Tamoxifen; Adverse effect; Randomized controlled trial; Physical therapy; Menopause; Discontinuation; Sexual function; Internal medicine; Breast cancer; Cancer","score_opus":0.09664402269657305,"score_gpt":0.5049638227154725,"score_spread":0.40831980001889945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156059498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938231,0.0004475476,0.000012420686,0.001950408,0.00036282,0.0018972591,0.000014649779,0.000001611253,0.0014901673],"genre_scores_gemma":[0.99604106,0.000456876,0.0022901504,0.0007674947,0.0002693834,0.00005613659,0.0000015936525,0.000013659415,0.00010361891],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866506,0.002768861,0.009363021,0.00017190144,0.00070869806,0.0003369468],"domain_scores_gemma":[0.9842218,0.008099596,0.0066566505,0.00025810013,0.00034530257,0.00041852708],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021009522,0.0001664896,0.0071657887,0.000420657,0.00000550537,0.0000016413034,0.00014806655,0.0003797497,0.0004835288],"category_scores_gemma":[0.010811359,0.0001147485,0.00026157202,0.0001913603,0.00028739884,0.00009032564,0.000047736972,0.0006785708,0.0000013492254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94194627,0.011014982,0.039778326,0.00019058771,0.000887494,0.00008809196,0.00033846407,0.00004781158,0.00058686535,0.000066465815,0.000071019924,0.004983642],"study_design_scores_gemma":[0.70113194,0.037679754,0.2603002,0.00016553166,0.00026280616,0.000007314057,0.000074921154,0.000038782073,0.000019903217,0.00010901585,0.00016066608,0.000049176208],"about_ca_topic_score_codex":0.00029279193,"about_ca_topic_score_gemma":0.00019534134,"teacher_disagreement_score":0.24081431,"about_ca_system_score_codex":0.00039659478,"about_ca_system_score_gemma":0.0037296093,"threshold_uncertainty_score":0.997521},"labels":[],"label_agreement":null},{"id":"W2156145449","doi":"10.1200/jco.2010.31.4047","title":"Parent Reports of Quality of Life for Pediatric Patients With Cancer With No Realistic Chance of Cure","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Cancer; Cohort; Pediatrics; Pediatric cancer; Physical therapy; Internal medicine; Psychiatry","score_opus":0.23853866345419453,"score_gpt":0.4913288463071661,"score_spread":0.2527901828529716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156145449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601644,0.00050181994,0.00047628512,0.0010195753,0.0009677025,0.0004956476,0.00006333933,0.00000465862,0.00045454857],"genre_scores_gemma":[0.9917865,0.00045307787,0.006032891,0.00073165866,0.00092099624,0.000011646955,0.0000065762197,0.00002293248,0.000033720327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99302554,0.00041679523,0.005264374,0.00024491877,0.00083455007,0.00021382287],"domain_scores_gemma":[0.98089445,0.0020450966,0.012938362,0.00040025703,0.0033452539,0.00037658124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046172035,0.00016988521,0.0028098251,0.00011664607,0.000016992462,0.000001030606,0.00016915904,0.00025786,0.00009852989],"category_scores_gemma":[0.008307971,0.0001074982,0.0003909524,0.00019807908,0.00033929822,0.00008233951,0.00003717761,0.00047049645,3.410788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026207263,0.0038746593,0.9638167,0.0011681075,0.00055397354,0.000023346012,0.00067814236,0.000011495529,0.0000069068906,0.00006611291,0.0020142552,0.0015790539],"study_design_scores_gemma":[0.00927718,0.02726863,0.96062297,0.00044790658,0.00086575194,0.000013003566,0.00012426394,0.0000034515506,0.000056855322,0.00018112856,0.0010255428,0.00011332591],"about_ca_topic_score_codex":0.00077500433,"about_ca_topic_score_gemma":0.0007139059,"teacher_disagreement_score":0.02339397,"about_ca_system_score_codex":0.000071192335,"about_ca_system_score_gemma":0.0035093296,"threshold_uncertainty_score":0.9946018},"labels":[],"label_agreement":null},{"id":"W2156282221","doi":"10.1200/jco.2011.37.3068","title":"Opioid Prescription After Pain Assessment: A Population-Based Cohort of Elderly Patients With Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ontario Ministry of Health and Long-Term Care; Government of Ontario; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Pain assessment; Medical prescription; Cohort; Cancer; Opioid; Cancer pain; Population; Breakthrough Pain; Physical therapy; Cohort study; Internal medicine; Pain management","score_opus":0.04208153321695613,"score_gpt":0.41666315457878333,"score_spread":0.3745816213618272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156282221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569297,0.00016690553,0.0016703636,0.0008252225,0.00073251774,0.00033651874,0.0000033117856,0.000005542856,0.00056664395],"genre_scores_gemma":[0.99160016,0.00006316892,0.005619241,0.0018727543,0.0006621763,0.000015645886,0.000014044756,0.000011958742,0.00014082782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975015,0.00049022003,0.0012891748,0.000095221025,0.000440277,0.00018363415],"domain_scores_gemma":[0.99717194,0.00077198865,0.0013160153,0.00013895477,0.00038188687,0.0002192166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003909159,0.00009688538,0.00075091183,0.00011652547,0.000017676704,0.000004236063,0.00007447663,0.00017137389,0.00033994293],"category_scores_gemma":[0.0008924242,0.00006293733,0.0001973438,0.00009856455,0.000058011152,0.0001651149,0.000014693719,0.0003880475,0.000002061331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025724266,0.0017457131,0.9610968,0.00006851436,0.0002492385,0.000009867238,0.000028085671,0.000021228649,0.000004760488,0.000019366838,0.0015059737,0.032678027],"study_design_scores_gemma":[0.005370372,0.0060851956,0.97457975,0.00017393856,0.0005304179,4.4196767e-7,0.000014076812,0.00023889802,0.0000027028782,0.000029948065,0.012910413,0.00006387189],"about_ca_topic_score_codex":0.00006722752,"about_ca_topic_score_gemma":0.000033999204,"teacher_disagreement_score":0.032614157,"about_ca_system_score_codex":0.00013789519,"about_ca_system_score_gemma":0.00044212045,"threshold_uncertainty_score":0.3722137},"labels":[],"label_agreement":null},{"id":"W2156673479","doi":"10.1200/jco.2008.18.7393","title":"Heterogeneity and Power in Clinical Biomarker Studies","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Biomarker; Medicine; Outcome (game theory); Statistical power; Oncology; Internal medicine; Bioinformatics; Statistics; Biology; Genetics; Mathematics","score_opus":0.8560006059980471,"score_gpt":0.7383915548441444,"score_spread":0.11760905115390263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156673479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813635,0.001004428,0.002810797,0.008727789,0.0039782003,0.00024770913,0.000004006613,0.000016525755,0.0018470953],"genre_scores_gemma":[0.5734432,0.0020408477,0.42022195,0.0034356967,0.0008053049,0.0000015153322,5.40327e-8,0.000014177644,0.000037261136],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98142344,0.0071231853,0.010246865,0.00039104896,0.00045300144,0.00036247616],"domain_scores_gemma":[0.747104,0.24758369,0.0038555379,0.0003686948,0.0005571623,0.0005309501],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.060786806,0.00021724621,0.003956576,0.00014160445,0.000034718527,0.000015201555,0.00035092176,0.00082618324,0.000059914],"category_scores_gemma":[0.5528802,0.00014664297,0.00073870365,0.00019870291,0.00080656377,0.0001119084,0.00013871989,0.0016914307,0.000010759386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053167273,0.0057730847,0.12190486,0.000047094705,0.00091681833,0.0013559157,0.00012501018,7.432476e-7,0.000036095727,0.02072094,0.0189648,0.8248379],"study_design_scores_gemma":[0.0049866005,0.0073625087,0.3886976,0.00009904463,0.00016489554,0.00008244432,0.0000788568,0.000019577661,0.000010478655,0.59397477,0.004395707,0.00012754109],"about_ca_topic_score_codex":9.40655e-7,"about_ca_topic_score_gemma":0.000015306914,"teacher_disagreement_score":0.82471037,"about_ca_system_score_codex":0.000075341726,"about_ca_system_score_gemma":0.00038817863,"threshold_uncertainty_score":0.9671176},"labels":[],"label_agreement":null},{"id":"W2156863320","doi":"10.1200/jco.2006.07.1175","title":"On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer research; Immunology; Internal medicine","score_opus":0.053653849231979855,"score_gpt":0.37480435385777006,"score_spread":0.3211505046257902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156863320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852978,0.0021524113,0.0001604397,0.011380932,0.00047432238,0.00021209945,0.00012219316,0.000001238037,0.00019859122],"genre_scores_gemma":[0.95997,0.00079952617,0.00084609934,0.0345922,0.00346615,0.000010674131,0.000016793727,0.00004184131,0.00025669497],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973438,0.00045396062,0.0014168778,0.0002700948,0.00030738724,0.00020790151],"domain_scores_gemma":[0.99641937,0.00071677554,0.0022403584,0.00028049125,0.00028730446,0.00005568198],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000959846,0.00024887078,0.0011020155,0.000054087206,0.00002925153,0.000007147607,0.00017753967,0.0013375676,0.000042668016],"category_scores_gemma":[0.0001676411,0.00012938786,0.00069834956,0.000054527238,0.00025061241,0.0000027016263,0.00004714894,0.0009354951,5.57349e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014404459,0.0051215994,0.06390915,0.0011574528,0.0281531,0.0054212078,0.00045619337,0.0014695382,0.3700168,0.00019920937,0.3567255,0.15296575],"study_design_scores_gemma":[0.00467127,0.018070806,0.011534087,0.0003941571,0.0012583738,0.00012076937,0.000036006495,0.00002609102,0.033078466,0.000102299324,0.93033844,0.00036923567],"about_ca_topic_score_codex":0.000023942008,"about_ca_topic_score_gemma":0.000015419948,"teacher_disagreement_score":0.5736129,"about_ca_system_score_codex":0.000052122217,"about_ca_system_score_gemma":0.00059386273,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W2156914405","doi":"10.1200/jco.2012.42.4895","title":"Adoption of Robotic Surgery: An Analogy From Urologic Oncology","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Robotic surgery; Analogy; Surgery; General surgery; Oncology; Internal medicine; Medical physics","score_opus":0.2520049676049517,"score_gpt":0.47036278283756705,"score_spread":0.21835781523261533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156914405","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.228949,0.0073599224,0.00030133838,0.73660684,0.021495217,0.00060893706,0.000081914994,0.00003564407,0.0045611947],"genre_scores_gemma":[0.28006968,0.004830804,0.0059960405,0.651487,0.05648351,0.000013742462,0.0006222243,0.00008949183,0.00040749038],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99018097,0.0028180862,0.0052770446,0.00041223955,0.00074059103,0.0005710954],"domain_scores_gemma":[0.97542804,0.015590029,0.0071241776,0.00046621854,0.0007704305,0.00062112685],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0042125965,0.00038583012,0.006964935,0.00059401453,0.00003107436,0.0000058528285,0.00036280375,0.0046294513,0.0018456939],"category_scores_gemma":[0.0052368287,0.0002589657,0.001911226,0.0003495886,0.00046528643,0.00015277034,0.00008565604,0.0053574364,0.00009068423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0131476605,0.006811212,0.12376628,0.00018667037,0.0038636236,0.009003053,0.0000564216,0.000016117658,0.000051387407,0.000019383337,0.49265134,0.35042685],"study_design_scores_gemma":[0.0071096006,0.032249417,0.14590737,0.00011949017,0.004655233,0.0006045594,0.00002062659,0.0000077059185,0.000010546172,0.0008884137,0.80823135,0.00019569452],"about_ca_topic_score_codex":0.00021278566,"about_ca_topic_score_gemma":0.000052678024,"teacher_disagreement_score":0.35023114,"about_ca_system_score_codex":0.00053131947,"about_ca_system_score_gemma":0.003392045,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W2156964551","doi":"10.1200/jco.2008.20.4057","title":"Bisphosphonates and Bone Turnover in Premenopausal Women Receiving Adjuvant Chemotherapy","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bone remodeling; Chemotherapy; Adjuvant chemotherapy; Adjuvant; Oncology; Internal medicine; Cancer; Gynecology; Breast cancer","score_opus":0.07034054164176257,"score_gpt":0.43359834963150423,"score_spread":0.36325780798974167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156964551","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5070402,0.003730575,0.0000013291929,0.48701748,0.0009917611,0.00031032058,0.0000038699536,0.000008589916,0.00089586567],"genre_scores_gemma":[0.09335991,0.010751869,0.0019364171,0.8872883,0.0034153801,0.000010857714,0.000013664863,0.000058870854,0.0031647466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949799,0.00037555528,0.003243368,0.0003339523,0.0004743359,0.0005928873],"domain_scores_gemma":[0.9949843,0.0017229144,0.0023904657,0.00021859241,0.00021680801,0.00046686828],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0028717015,0.0003073319,0.0033395113,0.0002676446,0.000027385193,0.000011730489,0.00011957591,0.001948969,0.00020567793],"category_scores_gemma":[0.0011111083,0.00021386382,0.00024270969,0.00014444623,0.00015764618,0.00008942524,0.000024170053,0.005270208,0.000013404544],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006421958,0.0016143231,0.06552358,0.00019503731,0.0004994771,0.015520468,0.00036005024,3.2395062e-7,0.00001720944,0.000001291889,0.51762146,0.39222482],"study_design_scores_gemma":[0.012569961,0.01414967,0.31562236,0.00040608307,0.00014282714,0.00105359,0.000012861326,0.0000035954913,0.000005517546,0.0003407778,0.6555714,0.00012139331],"about_ca_topic_score_codex":0.00006425385,"about_ca_topic_score_gemma":0.00005682439,"teacher_disagreement_score":0.41368032,"about_ca_system_score_codex":0.0006293576,"about_ca_system_score_gemma":0.0019724914,"threshold_uncertainty_score":0.99934673},"labels":[],"label_agreement":null},{"id":"W2156990854","doi":"10.1200/jco.2012.44.9488","title":"Is Intensive Care Unit Admission an Indicator of Patient-Centered Care for Patients With Advanced Lung Cancer in SEER-Medicare?","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Intensive care unit; Lung cancer; Cancer; Unit (ring theory); Intensive care medicine; Emergency medicine; Oncology; Internal medicine","score_opus":0.1746510142200632,"score_gpt":0.53011351941009,"score_spread":0.35546250519002676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156990854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439523,0.013969375,0.00002012938,0.037719797,0.002486059,0.0010988237,0.0006260213,0.0000065259715,0.00012096357],"genre_scores_gemma":[0.80161935,0.0037469957,0.0034051698,0.18650687,0.0037408539,0.00005067323,0.0007696952,0.000111063666,0.000049306887],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951403,0.00042708035,0.0028858725,0.00034060283,0.0007938239,0.00041229322],"domain_scores_gemma":[0.9861826,0.0016373082,0.0050757495,0.00032150093,0.0063285,0.000454373],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00037826228,0.00034175534,0.0031561824,0.00039814788,0.000025439787,0.0000027460242,0.00030220873,0.0015282548,0.00016182938],"category_scores_gemma":[0.0037880877,0.00022727837,0.00055614515,0.00016625588,0.00027755805,0.00014238677,0.000073804236,0.0025376987,8.173586e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007340639,0.0004965398,0.8338464,0.0015307837,0.00063239253,0.00018513123,0.011595955,0.0000024359551,0.000005597527,2.9396023e-7,0.06216025,0.082203574],"study_design_scores_gemma":[0.019689338,0.027728477,0.119892284,0.010537984,0.0015691791,0.0000095690075,0.013401305,0.0000056584804,0.00017024869,0.000004685229,0.8067094,0.0002818309],"about_ca_topic_score_codex":0.00005583777,"about_ca_topic_score_gemma":0.00007461788,"teacher_disagreement_score":0.7445492,"about_ca_system_score_codex":0.0004476328,"about_ca_system_score_gemma":0.0027922925,"threshold_uncertainty_score":0.99976796},"labels":[],"label_agreement":null},{"id":"W2157030933","doi":"10.1200/jco.2012.47.7265","title":"Mindfulness-Based Stress Reduction Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia Comorbid With Cancer: A Randomized, Partially Blinded, Noninferiority Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sleep and related disorders","field":"Psychology","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Mindfulness-based stress reduction; Medicine; Insomnia; Sleep onset latency; Actigraphy; Sleep onset; Cognitive behavioral therapy for insomnia; Mindfulness; Randomized controlled trial; Mood; Physical therapy; Sleep disorder; Sleep diary; Cognitive behavioral therapy; Pittsburgh Sleep Quality Index; Internal medicine; Psychiatry; Sleep quality; Clinical psychology","score_opus":0.1378428600589572,"score_gpt":0.4848448545654197,"score_spread":0.3470019945064625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157030933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846372,0.0007437421,0.007073397,0.0018567977,0.003159309,0.0022583492,0.000030245033,0.000009673477,0.00023128808],"genre_scores_gemma":[0.99767005,0.00024185659,0.0003212004,0.00017802871,0.0010537048,0.00045540693,0.000009056959,0.000024111136,0.000046553036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99566,0.0017315327,0.0018119582,0.0002467371,0.00028856896,0.00026117283],"domain_scores_gemma":[0.9888968,0.0071098097,0.0029037225,0.00020973213,0.00072461675,0.00015533116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002222681,0.000228939,0.0020930928,0.00009962226,0.000110654226,0.0000141706405,0.00019745018,0.00042678387,0.00022094244],"category_scores_gemma":[0.0002157414,0.00010575605,0.00063849165,0.00014698089,0.0011128742,0.000054471526,0.0000052696664,0.0004729828,0.0000019428132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7446112,0.013433067,0.0027039652,0.0000032400542,0.0027391098,0.000016644273,0.000636238,0.0004904728,0.0000014652808,0.0000607503,0.000115605275,0.23518826],"study_design_scores_gemma":[0.892242,0.09593384,0.0020932185,0.000071952134,0.0034201427,0.000029976909,0.0010919373,0.00030932977,0.00039988317,0.000085981264,0.0041754255,0.00014628455],"about_ca_topic_score_codex":0.00052377273,"about_ca_topic_score_gemma":0.0008516461,"teacher_disagreement_score":0.23504198,"about_ca_system_score_codex":0.000066251145,"about_ca_system_score_gemma":0.001070606,"threshold_uncertainty_score":0.43126068},"labels":[],"label_agreement":null},{"id":"W2157191370","doi":"10.1200/jco.2012.47.7927","title":"Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Refractory (planetary science); Chemotherapy; Oncology; Palliative chemotherapy; Ovarian cancer; Internal medicine; Cancer; Clinical trial","score_opus":0.26245118894999153,"score_gpt":0.5288915851924206,"score_spread":0.2664403962424291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157191370","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06900549,0.001511326,0.000029574123,0.9217019,0.004018769,0.0021447076,0.00021355176,0.000014372268,0.0013603083],"genre_scores_gemma":[0.016089324,0.021319013,0.00825604,0.9058583,0.038777232,0.00018286864,0.000081361046,0.00021105382,0.009224811],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9797367,0.004398431,0.013678032,0.0006684472,0.00097573554,0.0005426851],"domain_scores_gemma":[0.9545935,0.03083719,0.0124550145,0.0006370042,0.0008365234,0.00064078445],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012936209,0.00057938905,0.0116643915,0.0004487212,0.000028362387,0.00002243954,0.00051811937,0.0033539718,0.012264675],"category_scores_gemma":[0.014140538,0.00033236854,0.0022137032,0.0002742487,0.00029426173,0.00008765639,0.00009131316,0.0057289894,0.00015615817],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018278807,0.0039979015,0.017704252,0.00015662824,0.0038344008,0.0022904337,0.00016113934,0.0000021850135,0.000028756234,0.000006213233,0.7297609,0.22377841],"study_design_scores_gemma":[0.02542614,0.028397137,0.257184,0.0019249325,0.0014967815,0.000018065313,0.000020881265,0.00001486939,0.00001732271,0.00016910458,0.6850828,0.00024798364],"about_ca_topic_score_codex":0.00027494718,"about_ca_topic_score_gemma":0.00013382072,"teacher_disagreement_score":0.23947975,"about_ca_system_score_codex":0.0009914379,"about_ca_system_score_gemma":0.007153478,"threshold_uncertainty_score":0.99991286},"labels":[],"label_agreement":null},{"id":"W2157199957","doi":"10.1200/jco.2014.58.0480","title":"Bronchoalveolar Lavage and Lung Biopsy in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review and Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"National Institute for Health and Care Research","keywords":"Medicine; Bronchoalveolar lavage; Biopsy; Lung cancer; Hematopoietic stem cell transplantation; Lung biopsy; Complication; Transplantation; Lung transplantation; Lung; Internal medicine; Surgery","score_opus":0.14735396432823117,"score_gpt":0.4729752651617598,"score_spread":0.32562130083352864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157199957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016835502,0.996131,0.000014396354,0.00028587336,0.000107778375,0.0016426101,0.000043750184,0.0000033209888,0.00008769683],"genre_scores_gemma":[0.0007370151,0.9982592,0.000119849894,0.00048947823,0.00004638224,0.000105887586,0.00001133729,0.000022812816,0.00020807562],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947085,0.0011189781,0.0033445747,0.00031750105,0.00035123425,0.0001592445],"domain_scores_gemma":[0.9948543,0.0008788827,0.0033130855,0.00021457975,0.0003852847,0.00035390336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030454807,0.00030210373,0.012916468,0.0003326548,0.000028725914,0.000017908678,0.00008700357,0.00034923552,0.00005005638],"category_scores_gemma":[0.00012805709,0.00015846697,0.0009179036,0.0004040154,0.00012437337,0.00012358115,0.000025502222,0.00089114223,0.0000012761942],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028796206,0.00072580366,0.008179548,0.8900521,0.084037885,0.00023303786,0.00012400521,6.2980274e-7,2.0552132e-8,0.0000054984694,0.0002534408,0.016100097],"study_design_scores_gemma":[0.002778718,0.0017537101,0.0015652135,0.039528836,0.9400204,0.00046797775,0.00001293548,5.226314e-7,2.4463077e-8,0.0000028293316,0.013709647,0.00015918235],"about_ca_topic_score_codex":0.00002537584,"about_ca_topic_score_gemma":0.000073720985,"teacher_disagreement_score":0.85598254,"about_ca_system_score_codex":0.0001709242,"about_ca_system_score_gemma":0.0007744036,"threshold_uncertainty_score":0.8829439},"labels":[],"label_agreement":null},{"id":"W2157229055","doi":"10.1200/jco.2013.50.4035","title":"Reply to I.H. Sahin","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Internal medicine; Dermatology","score_opus":0.19593561537049156,"score_gpt":0.5137739602377467,"score_spread":0.31783834486725515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157229055","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014407762,0.00035856705,0.00005417423,0.9688559,0.0074811936,0.00029284199,0.0000076275514,0.00001107433,0.008530824],"genre_scores_gemma":[0.0012211237,0.00059095037,0.0023795879,0.93784475,0.045660265,0.00000496976,0.0000079553965,0.000045123856,0.012245278],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948784,0.000323441,0.0035770542,0.00028170095,0.0005999218,0.00033949417],"domain_scores_gemma":[0.99350244,0.0021507225,0.0026786963,0.00041691947,0.0006865076,0.00056470715],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021446228,0.00022925934,0.0031076835,0.0002518454,0.000021629428,0.000016002334,0.0003023232,0.0018978874,0.001928303],"category_scores_gemma":[0.0048394264,0.00014962394,0.0012325724,0.00012029632,0.00013587825,0.00005999303,0.00007781472,0.007412021,0.00051237346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006147152,0.00017456959,0.002221254,0.000039188617,0.0003205442,0.0035389904,0.000030367437,5.8097913e-7,0.000005149828,0.0000022092163,0.8945233,0.09852914],"study_design_scores_gemma":[0.0023086804,0.012877304,0.022472361,0.00020106114,0.000489076,0.00076915004,0.000012481356,0.0000017829108,0.0000037609655,0.00012596973,0.9605992,0.00013916605],"about_ca_topic_score_codex":0.00025491157,"about_ca_topic_score_gemma":0.000012087131,"teacher_disagreement_score":0.09838997,"about_ca_system_score_codex":0.00031345087,"about_ca_system_score_gemma":0.0027912664,"threshold_uncertainty_score":0.9993979},"labels":[],"label_agreement":null},{"id":"W2157285395","doi":"10.1200/jco.2005.04.9148","title":"Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Quality of life (healthcare); Head and neck cancer; Incidence (geometry); Radiation therapy; Randomized controlled trial; Larynx; Clinical trial; Cancer; Internal medicine; Basal cell; Dermatology; Surgery; Nursing","score_opus":0.06547735070166047,"score_gpt":0.448775745838322,"score_spread":0.38329839513666153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157285395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440646,0.0005848507,0.000108252316,0.0009841876,0.0008104607,0.0030271802,0.000033479126,0.0000015557137,0.000043572494],"genre_scores_gemma":[0.99803853,0.00031674036,0.0010071499,0.00011108949,0.00044458432,0.00003281477,0.000030941894,0.000011518148,0.0000066509583],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948215,0.00092437357,0.0035959317,0.00015094918,0.00034988558,0.0001573763],"domain_scores_gemma":[0.9896537,0.0032895582,0.006424102,0.00019318282,0.0003619014,0.000077566096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023110325,0.0001199159,0.0013580814,0.0001224082,0.000035014964,0.0000014826159,0.000101787795,0.00025871582,0.000003830502],"category_scores_gemma":[0.00084267475,0.00006646462,0.00022827879,0.00015042219,0.00017108028,0.00012151852,0.000013349399,0.000286436,2.1654575e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57979965,0.009120968,0.018996526,0.000049607574,0.000035435292,0.0000020274756,0.00022015198,0.0001167669,0.00015987696,0.0000068110458,0.000038169917,0.39145398],"study_design_scores_gemma":[0.48588857,0.22730857,0.28441074,0.000063769345,0.00015534266,0.0000025162553,0.000064013664,0.00028910965,0.0014212588,0.000054581204,0.00031439,0.000027150336],"about_ca_topic_score_codex":0.0003434999,"about_ca_topic_score_gemma":0.0005358396,"teacher_disagreement_score":0.39142683,"about_ca_system_score_codex":0.00024479956,"about_ca_system_score_gemma":0.0008880616,"threshold_uncertainty_score":0.27103487},"labels":[],"label_agreement":null},{"id":"W2157358984","doi":"10.1200/jco.2006.10.1659","title":"Economic Evaluation in the <i>Journal of Clinical Oncology</i>: Past, Present, and Future","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Audience measurement; Trastuzumab; Bevacizumab; Breast cancer; Cancer; Internal medicine; Political science","score_opus":0.2084116742169275,"score_gpt":0.478109565835067,"score_spread":0.2696978916181395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157358984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9259008,0.006474609,0.0004663302,0.021944454,0.008094407,0.00024009967,0.000011867162,0.0000020545363,0.036865346],"genre_scores_gemma":[0.96269304,0.009444223,0.0013358009,0.003053277,0.023391707,0.000001478452,9.810528e-7,0.000016278711,0.000063228996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989621,0.00064431323,0.009039802,0.00022744449,0.00011784878,0.00034959536],"domain_scores_gemma":[0.98445207,0.0047375835,0.00998943,0.00023551146,0.00028674462,0.00029867628],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07805417,0.00016185665,0.0022128706,0.00030263537,0.000049554474,0.000026944299,0.00056834775,0.00077104114,0.00021243261],"category_scores_gemma":[0.0024148833,0.00012258806,0.00055911235,0.00011365046,0.0003408832,0.0005419011,0.00006184645,0.0016817322,0.000037434856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024110484,0.0008554491,0.35658583,0.000009148353,0.00020984739,0.00008476918,0.0005650014,0.00012169622,8.743393e-7,0.0058866786,0.030343603,0.6029261],"study_design_scores_gemma":[0.004362713,0.003416808,0.46333957,0.000010350655,0.000057000318,0.00014816862,0.00036332925,0.00014356837,0.000001012987,0.008922867,0.5191526,0.00008201897],"about_ca_topic_score_codex":0.000062921405,"about_ca_topic_score_gemma":0.00028273108,"teacher_disagreement_score":0.60284406,"about_ca_system_score_codex":0.00033707113,"about_ca_system_score_gemma":0.0014327813,"threshold_uncertainty_score":0.94933724},"labels":[],"label_agreement":null},{"id":"W2157591656","doi":"10.1200/jco.2009.26.8748","title":"Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radioimmunotherapy; Ibritumomab tiuxetan; Medicine; Rituximab; Lymphoma; Oncology; Clinical trial; Non-Hodgkin's lymphoma; CD20; Internal medicine; Monoclonal antibody; Immunology; Antibody","score_opus":0.09311115547889183,"score_gpt":0.4318470478798739,"score_spread":0.33873589240098206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157591656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945415,0.0026693814,0.000014405914,0.00238574,0.0006605637,0.00043680813,0.000036885325,0.00000826188,0.00433379],"genre_scores_gemma":[0.98735857,0.005315474,0.004279302,0.00050115323,0.0006940683,0.00001613513,0.000015531956,0.000028753546,0.0017909998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961219,0.00028739197,0.0027037796,0.00023543427,0.00039512504,0.00025639852],"domain_scores_gemma":[0.99473476,0.0017698037,0.00232963,0.00034005175,0.00047935237,0.00034637685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014075147,0.00023572623,0.0025487912,0.00012467355,0.000029807718,0.0000053097133,0.00019875713,0.0005047209,0.0005594734],"category_scores_gemma":[0.0006149971,0.00013037874,0.0007378251,0.00016162074,0.00021032122,0.00008723524,0.000030263998,0.00026592132,0.00004029188],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027803048,0.09405153,0.09563569,0.00018946928,0.006461067,0.0009932827,0.000612204,0.0000089332525,0.0397276,0.00029029563,0.024025062,0.7102018],"study_design_scores_gemma":[0.11190558,0.09233961,0.30884725,0.0002595052,0.0025484553,0.0028119215,0.00012139829,0.0003600536,0.039903976,0.00003147199,0.44055477,0.00031602688],"about_ca_topic_score_codex":0.000022255219,"about_ca_topic_score_gemma":0.000006411627,"teacher_disagreement_score":0.7098858,"about_ca_system_score_codex":0.00017014626,"about_ca_system_score_gemma":0.0018224024,"threshold_uncertainty_score":0.6125842},"labels":[],"label_agreement":null},{"id":"W2157727387","doi":"10.1200/jco.2009.27.0835","title":"Prospective Study of Breast Cancer Incidence in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation Under Surveillance With and Without Magnetic Resonance Imaging","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":277,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Myriad Genetics; American Society of Clinical Oncology","keywords":"Medicine; Breast cancer; Breast MRI; Cumulative incidence; Mammography; Magnetic resonance imaging; Hazard ratio; Cohort; Incidence (geometry); Stage (stratigraphy); Oncology; Internal medicine; Cancer; Breast cancer screening; Prospective cohort study; Gynecology; Radiology; Confidence interval","score_opus":0.03512354457907717,"score_gpt":0.372259718670011,"score_spread":0.3371361740909338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157727387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733245,0.0015091196,0.00021070818,0.00030484603,0.00012158484,0.00031989216,0.000007884002,0.0000026073733,0.00019089985],"genre_scores_gemma":[0.9965133,0.00044515787,0.0023199958,0.00045506124,0.00013781253,0.000055338023,3.8902405e-7,0.000021050257,0.00005187577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979349,0.0003331453,0.0009721741,0.00031972272,0.00022981544,0.00021027829],"domain_scores_gemma":[0.9979537,0.00014125677,0.0010195528,0.00019685937,0.00057944516,0.00010919431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012951754,0.00014917011,0.00062127755,0.000073167386,0.000029936022,0.000007723486,0.00018648627,0.000116497366,0.000025807934],"category_scores_gemma":[0.00019322563,0.00009744738,0.000030093735,0.00023258796,0.00038282922,0.000023852888,0.00006354452,0.00031714657,2.6404246e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020273149,0.0008972342,0.9400919,0.000012998876,0.000098299024,0.00008534447,0.0014556568,0.00018049081,0.00060245924,0.0000043267187,0.000055327168,0.036242824],"study_design_scores_gemma":[0.007998726,0.014326175,0.97355884,0.000077891455,0.000044992747,0.00057639624,0.0026069505,0.00002927943,0.00027657844,0.00008763988,0.00027651698,0.00014001149],"about_ca_topic_score_codex":0.00018053921,"about_ca_topic_score_gemma":0.0056064175,"teacher_disagreement_score":0.036102813,"about_ca_system_score_codex":0.00015383307,"about_ca_system_score_gemma":0.0016806709,"threshold_uncertainty_score":0.39737886},"labels":[],"label_agreement":null},{"id":"W2157753937","doi":"10.1200/jco.2013.54.8149","title":"Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Palliative care; Medicine; Reimbursement; Nursing; Service delivery framework; Service (business); Family medicine; Health care; Business; Marketing","score_opus":0.4601234023420744,"score_gpt":0.5915266903365471,"score_spread":0.13140328799447276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157753937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8479511,0.01770641,0.0070986454,0.113354735,0.0016676511,0.00041224706,0.000041522504,0.00002542475,0.011742235],"genre_scores_gemma":[0.9256992,0.010629099,0.025100216,0.036516074,0.0015958116,0.000011138816,0.00000867062,0.000033195935,0.00040661474],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973849,0.0003514065,0.0014446263,0.000190015,0.000396467,0.00023258169],"domain_scores_gemma":[0.99298155,0.002920805,0.0015592078,0.00021446476,0.0021522753,0.00017169084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010801941,0.00018541895,0.0014693844,0.000059087077,0.00006121824,0.000009000456,0.00031896264,0.0003519052,0.00007663367],"category_scores_gemma":[0.001991471,0.00010037825,0.00042346655,0.0001775263,0.00019788463,0.000096357384,0.00008265981,0.00091190205,0.000033352913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043471726,0.00046910974,0.61186445,0.0007835476,0.0025310558,0.00011438713,0.10209294,0.00096449914,0.00039763344,0.0010678364,0.026886217,0.24848117],"study_design_scores_gemma":[0.0114833545,0.0064508617,0.069647565,0.0046551046,0.0020060893,0.000034689958,0.033434924,0.011521422,0.00676012,0.0030936815,0.85040337,0.0005088312],"about_ca_topic_score_codex":0.00014112462,"about_ca_topic_score_gemma":0.0005084129,"teacher_disagreement_score":0.82351714,"about_ca_system_score_codex":0.00032184343,"about_ca_system_score_gemma":0.0023898112,"threshold_uncertainty_score":0.42394227},"labels":[],"label_agreement":null},{"id":"W2157799421","doi":"10.1200/jco.2011.36.8647","title":"Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Febrile neutropenia; Cost effectiveness; Internal medicine; Chemotherapy; Guideline; Quality-adjusted life year; Oncology; Cost-effectiveness analysis; Surgery; Intensive care medicine; Neutropenia; Pathology","score_opus":0.09080905945233365,"score_gpt":0.40482754313159514,"score_spread":0.3140184836792615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157799421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973502,0.00016900794,0.00020396014,0.00021596004,0.00049068796,0.0008164015,0.0000239205,0.000009841003,0.0007200342],"genre_scores_gemma":[0.9979835,0.000102944476,0.0013656449,0.0002667313,0.00019229931,0.00002429312,0.000011829284,0.000025050493,0.00002769822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996219,0.0005612039,0.0019821634,0.00028109833,0.0005837356,0.0003728286],"domain_scores_gemma":[0.9929034,0.001882016,0.0034490481,0.00028404922,0.0010977252,0.0003837718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010702813,0.00024745968,0.0022657467,0.00039143153,0.00006917075,0.000010839469,0.00015099511,0.00030103882,0.00020731713],"category_scores_gemma":[0.0012680868,0.00015100988,0.00044784177,0.0008841507,0.00038688502,0.00034427355,0.000039780436,0.000977735,0.0000015881042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031771537,0.004263623,0.740699,0.000051130228,0.001766908,0.00005601042,0.00053517066,0.000034065248,0.00008201327,0.0000013860633,0.000020461699,0.22071873],"study_design_scores_gemma":[0.030868853,0.047240518,0.9194661,0.00020686365,0.0009996257,0.000023938805,0.00015884338,0.00005085178,0.00018735291,0.0000031736045,0.00064713386,0.00014679541],"about_ca_topic_score_codex":0.00008172403,"about_ca_topic_score_gemma":0.0003193299,"teacher_disagreement_score":0.22057194,"about_ca_system_score_codex":0.0006586195,"about_ca_system_score_gemma":0.0016127105,"threshold_uncertainty_score":0.61580044},"labels":[],"label_agreement":null},{"id":"W2157996158","doi":"10.1200/jco.2009.24.2180","title":"Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1069,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Watchful waiting; Prostate cancer; Hazard ratio; Cohort; Cancer; Prostate-specific antigen; Internal medicine; Prostate; Prospective cohort study; Proportional hazards model; Cohort study; Oncology; Gynecology; Surgery; Confidence interval","score_opus":0.06908816564333845,"score_gpt":0.4725403227283844,"score_spread":0.403452157085046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157996158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989824,0.0013457047,0.000059993676,0.006148477,0.000911842,0.00065627287,0.00012579646,0.000007708967,0.00092020194],"genre_scores_gemma":[0.98264164,0.014352365,0.0009775371,0.0012604265,0.00048007176,0.000012763712,0.000016451568,0.0000172694,0.00024147046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939204,0.00057938276,0.0042779646,0.0003390645,0.0005538839,0.00032931456],"domain_scores_gemma":[0.99069774,0.0023065666,0.0047966926,0.00033786503,0.0014249152,0.0004361918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042643403,0.00021286221,0.0032086445,0.000099183424,0.000024770923,0.00000397466,0.00017041572,0.00035779082,0.000060944338],"category_scores_gemma":[0.0022766932,0.00012927617,0.0007107067,0.00023093588,0.0003876704,0.00009716644,0.00003506448,0.00080289383,0.0000021486183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07416782,0.004370728,0.73640615,0.000046428333,0.0013982324,0.0007094818,0.000100453304,0.0000103074535,0.000019946794,0.000014189722,0.0019339095,0.18082234],"study_design_scores_gemma":[0.056068197,0.047878552,0.88800186,0.0006326925,0.0007527356,0.00008831901,0.000033978093,0.000012358176,0.00064976286,0.000052302854,0.0057226815,0.000106557],"about_ca_topic_score_codex":0.00005144843,"about_ca_topic_score_gemma":0.00036046584,"teacher_disagreement_score":0.18071578,"about_ca_system_score_codex":0.00020117708,"about_ca_system_score_gemma":0.0028590322,"threshold_uncertainty_score":0.5271729},"labels":[],"label_agreement":null},{"id":"W2158036326","doi":"10.1200/jco.2006.06.9591","title":"American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":743,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Aprepitant; Medicine; Ondansetron; NK1 receptor antagonist; Dexamethasone; Oncology; Internal medicine; Antiemetic; Granisetron; Pharmacology; Chemotherapy; Vomiting; Substance P; Receptor","score_opus":0.21840631364669108,"score_gpt":0.5674643416019726,"score_spread":0.3490580279552815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158036326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8461874,0.00053905015,0.012018258,0.12491181,0.0037988357,0.0009965352,0.000031635103,0.000030239491,0.011486231],"genre_scores_gemma":[0.596875,0.0031185225,0.36245182,0.029243287,0.0072949543,0.000013877899,0.00003517146,0.000058176112,0.00090914045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98604286,0.0011104539,0.011427305,0.00040112674,0.00047608884,0.0005421737],"domain_scores_gemma":[0.9818645,0.007870648,0.0082364855,0.00035994276,0.0012817492,0.00038666377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023693088,0.0002467074,0.004733124,0.00024601244,0.000041995696,0.0000061720298,0.00038053826,0.00089702284,0.00008553914],"category_scores_gemma":[0.007111067,0.00019034841,0.0018256682,0.00040984037,0.0010745928,0.000083243765,0.00016067704,0.0017661792,0.000012199169],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005740127,0.007131858,0.15983275,0.00006796174,0.0004938047,0.00029476776,0.000022635732,0.0000892868,0.0001247216,0.0004459574,0.42848715,0.397269],"study_design_scores_gemma":[0.020454057,0.031177886,0.1180436,0.00007125709,0.0007392914,0.00008770553,0.00031318777,0.0011813712,0.00006547905,0.0011555918,0.8265641,0.00014652353],"about_ca_topic_score_codex":0.0001711381,"about_ca_topic_score_gemma":0.00028782492,"teacher_disagreement_score":0.39807692,"about_ca_system_score_codex":0.00037648296,"about_ca_system_score_gemma":0.0039307713,"threshold_uncertainty_score":0.8513125},"labels":[],"label_agreement":null},{"id":"W2158097218","doi":"10.1200/jco.2011.36.0107","title":"Determining True <i>HER2</i> Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-<i>HER2</i> Targeted Therapy","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"","keywords":"Polysomy; Chromosome 17 (human); Locus (genetics); Breast cancer; Fluorescence in situ hybridization; Copy-number variation; Biology; Gene dosage; Oncology; Gene duplication; Gene; Chromosome; Genetics; Cancer; Cancer research; Medicine; Pathology; Gene expression","score_opus":0.11395882551219773,"score_gpt":0.40900613327341256,"score_spread":0.29504730776121485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158097218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944614,0.0026250924,0.0013854806,0.00047430064,0.00029172457,0.00027708453,0.00025858486,0.0000051064135,0.00022120506],"genre_scores_gemma":[0.98225826,0.0056810817,0.0103729665,0.0010535673,0.00049676775,0.000048351416,0.000037654343,0.00003598069,0.000015364361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976973,0.00021210112,0.0011588148,0.00038601863,0.00012639967,0.00041936987],"domain_scores_gemma":[0.9975101,0.00021874136,0.0013961397,0.00024872014,0.00041634514,0.00020999415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005025426,0.0002429755,0.00085079344,0.0000693802,0.00008724891,0.00000983205,0.00029108906,0.00027801073,0.00001553792],"category_scores_gemma":[0.00009529921,0.00018217406,0.00019469172,0.00012725622,0.00024316562,0.000023559456,0.00006009836,0.00027355595,5.229505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006394165,0.0015502743,0.7568757,0.0000139847025,0.0016955535,0.000054546676,0.00046798785,0.00023515114,0.1392633,0.00002177674,0.0013678229,0.09205972],"study_design_scores_gemma":[0.022735074,0.012037725,0.87402576,0.00012036987,0.0003608645,0.0008018875,0.0004885979,0.000083441984,0.05509998,0.00021483205,0.03331505,0.00071644044],"about_ca_topic_score_codex":0.0005973222,"about_ca_topic_score_gemma":0.0004739338,"teacher_disagreement_score":0.11715002,"about_ca_system_score_codex":0.00022166083,"about_ca_system_score_gemma":0.0015465012,"threshold_uncertainty_score":0.7428842},"labels":[],"label_agreement":null},{"id":"W2158134441","doi":"10.1200/jco.2006.07.9525","title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3859,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Internal medicine; Pancreatic cancer; Erlotinib Hydrochloride; Oncology; Hazard ratio; Adverse effect; Placebo; Clinical endpoint; Clinical trial; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.19184608866475933,"score_gpt":0.5307549424111981,"score_spread":0.3389088537464388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158134441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198073,0.00032860137,0.0001746345,0.002784062,0.0017375558,0.0020814408,0.000066170745,0.0000040333043,0.00084279943],"genre_scores_gemma":[0.994629,0.00054728484,0.002550357,0.00086496037,0.0011356262,0.000046126737,0.000012697746,0.000022876282,0.00019103744],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9876862,0.0016753213,0.007968129,0.00033191664,0.0018284187,0.0005099968],"domain_scores_gemma":[0.9797404,0.010260746,0.0068386104,0.00029462972,0.0023195792,0.00054604997],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02207563,0.00026483697,0.0059449496,0.0002294809,0.00006618838,0.000003674724,0.00039223325,0.00039513438,0.00018525822],"category_scores_gemma":[0.017087242,0.00013933754,0.00043833937,0.0006201845,0.0011337849,0.00014640894,0.00007600649,0.0015161645,3.4337523e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48999077,0.005494729,0.485451,0.0000693579,0.0013225724,0.00009491313,0.00007185235,0.00018179753,0.000030424935,0.000046299778,0.0010952126,0.016151043],"study_design_scores_gemma":[0.40747905,0.023293475,0.5636791,0.0005423991,0.0009696356,0.00001965223,0.0000751813,0.00019776197,0.000018756893,0.000027999598,0.0035910185,0.00010598502],"about_ca_topic_score_codex":0.020193046,"about_ca_topic_score_gemma":0.24167137,"teacher_disagreement_score":0.22147831,"about_ca_system_score_codex":0.001004669,"about_ca_system_score_gemma":0.026936987,"threshold_uncertainty_score":0.9911922},"labels":[],"label_agreement":null},{"id":"W2158234071","doi":"10.1200/jco.2009.24.9557","title":"Alberta Physical Activity and Breast Cancer Prevention Trial: Sex Hormone Changes in a Year-Long Exercise Intervention Among Postmenopausal Women","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"Fondation pour la Recherche Médicale; Canada Research Chairs; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Estrone; Medicine; Androstenedione; Sex hormone-binding globulin; Testosterone (patch); Internal medicine; Aerobic exercise; Breast cancer; Endocrinology; Randomized controlled trial; Estrogen; Hormone; Cancer; Androgen","score_opus":0.05245767495701068,"score_gpt":0.45425418025735487,"score_spread":0.40179650530034416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158234071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960379,0.000074476346,0.000006101391,0.0024788536,0.0009179384,0.00034789598,0.0000047314397,0.0000046496884,0.00012742866],"genre_scores_gemma":[0.9970171,0.0007579727,0.00003527083,0.0000718032,0.0015135702,0.0000273298,0.0000012031143,0.00001414371,0.00056162814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99853945,0.00018436213,0.0006925323,0.00017788325,0.00020325824,0.00020252101],"domain_scores_gemma":[0.99817467,0.00042476424,0.0008967582,0.000112729285,0.00010328478,0.00028778467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015910688,0.00011470391,0.0010559262,0.00011897656,0.000019529269,0.000012288781,0.000069907466,0.00028532112,0.00014428828],"category_scores_gemma":[0.0003732017,0.00008473462,0.00019289393,0.00009929208,0.00015692002,0.00016784441,0.0000503273,0.0011291441,0.0000019806503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07591085,0.0048054047,0.17513816,0.000037090496,0.00016602007,0.00008216278,0.00058161136,5.870619e-7,0.0022898344,0.0000065777294,0.00028349893,0.7406982],"study_design_scores_gemma":[0.03925304,0.011097063,0.94804525,0.00013752576,0.00018800491,0.000069573536,0.00012554956,0.00006827498,0.00008379325,0.00011182929,0.00074170524,0.00007838512],"about_ca_topic_score_codex":0.0015783226,"about_ca_topic_score_gemma":0.010539984,"teacher_disagreement_score":0.7729071,"about_ca_system_score_codex":0.00015358618,"about_ca_system_score_gemma":0.00033141806,"threshold_uncertainty_score":0.58815587},"labels":[],"label_agreement":null},{"id":"W2158370459","doi":"10.1200/jco.2005.04.5963","title":"Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Temozolomide; Medicine; Internal medicine; Radiation therapy; Recursive partitioning; Clinical endpoint; Oncology; Concomitant; Randomized controlled trial; Survival analysis","score_opus":0.05001179342421992,"score_gpt":0.4383411381791488,"score_spread":0.3883293447549289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158370459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843401,0.001482566,0.0007319118,0.011062514,0.0008306611,0.0014085687,0.00001647027,0.0000056509048,0.00012160151],"genre_scores_gemma":[0.99543065,0.0007874174,0.001895323,0.00060459337,0.001127966,0.00008155968,0.000007841097,0.000015292735,0.0000493657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951461,0.0008539411,0.0032286583,0.00021944578,0.00032666046,0.00022520318],"domain_scores_gemma":[0.98490125,0.01082257,0.0034332543,0.00021999548,0.00042052308,0.00020240287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004192598,0.00017612446,0.0037355942,0.00029066336,0.00008759394,0.000013906903,0.00012008569,0.00029226224,0.00009693086],"category_scores_gemma":[0.0049414877,0.00009762529,0.0022846425,0.00042729403,0.00043680536,0.00006923707,0.000019988682,0.00033199287,3.843293e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9519898,0.008074671,0.007998809,0.00001366265,0.007592324,0.00017202858,0.00010366667,0.00035110206,0.00027945937,0.00061550795,0.0048556556,0.017953271],"study_design_scores_gemma":[0.9488731,0.015738899,0.014075589,0.00008807395,0.014251623,0.000046743968,0.0000436148,0.0010882216,0.00061083306,0.0011687087,0.0039266157,0.00008798288],"about_ca_topic_score_codex":0.00009514392,"about_ca_topic_score_gemma":0.00022313511,"teacher_disagreement_score":0.017865287,"about_ca_system_score_codex":0.00013732242,"about_ca_system_score_gemma":0.0005405993,"threshold_uncertainty_score":0.59157795},"labels":[],"label_agreement":null},{"id":"W2158499570","doi":"10.1200/jco.2014.58.5380","title":"Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Genentech; National Cancer Institute; National Institutes of Health; GlaxoSmithKline; Astex Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Hazard ratio; Chemotherapy; Cancer; Proportional hazards model; Port (circuit theory); Radiation therapy; Internal medicine; Surgery; Population; Cancer registry; Oncology; Adjuvant; Confidence interval","score_opus":0.27633474923395523,"score_gpt":0.5529607302462247,"score_spread":0.2766259810122695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158499570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015821225,0.9846426,0.000034493187,0.010058318,0.0006754979,0.0034066767,0.00079479394,0.000004813899,0.0002245913],"genre_scores_gemma":[0.000021146352,0.9839499,0.0025822714,0.010987921,0.0014183403,0.00045799403,0.000093624614,0.00006234449,0.00042643302],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99483716,0.0007859689,0.0030183082,0.0004928449,0.0006110806,0.0002546338],"domain_scores_gemma":[0.98964095,0.0018668756,0.0055687437,0.00057609385,0.0020702565,0.0002770626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040040966,0.00043819958,0.0065866187,0.00009294692,0.000046147128,0.000008265663,0.00066265307,0.00051514007,0.00026067052],"category_scores_gemma":[0.0007893536,0.0001851321,0.001203078,0.00030001474,0.00022049929,0.00007290268,0.000078719924,0.00091243733,8.297025e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012573643,0.0023175494,0.002213011,0.027522407,0.0044252104,0.00013788693,0.000045147317,0.0000048621014,7.1030047e-7,0.000003904252,0.11919617,0.8428758],"study_design_scores_gemma":[0.009746799,0.006323811,0.00032720482,0.09227279,0.011569125,0.00027958342,0.0000061409587,0.000054334596,0.0000030749084,0.000002886072,0.87923694,0.00017733952],"about_ca_topic_score_codex":0.00007181539,"about_ca_topic_score_gemma":0.00010342689,"teacher_disagreement_score":0.84269845,"about_ca_system_score_codex":0.0018342367,"about_ca_system_score_gemma":0.020872077,"threshold_uncertainty_score":0.9846787},"labels":[],"label_agreement":null},{"id":"W2158568897","doi":"10.1200/jco.2007.15.8006","title":"Do Available Questionnaires Measure the Communication Factors That Patients and Families Consider Important at End of Life?","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Medicine; Measure (data warehouse); Gerontology; Family medicine; Data mining","score_opus":0.5344905558995899,"score_gpt":0.5462536268466918,"score_spread":0.011763070947101828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158568897","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025662629,0.9719351,0.0000017121157,0.0003698089,0.00051507284,0.00032255438,0.000027098726,0.0000038164394,0.0011622162],"genre_scores_gemma":[0.015049724,0.9840081,0.00039155083,0.00022674468,0.00015511879,0.000003723926,0.000022529646,0.0000197546,0.00012277786],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941207,0.001380732,0.003658936,0.00016767462,0.0005228816,0.0001490504],"domain_scores_gemma":[0.9808579,0.010877326,0.00673301,0.00038592995,0.0009196883,0.0002261516],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020826657,0.00025006745,0.0042862725,0.00014317194,0.00006856625,0.000004652666,0.00025874376,0.00067113066,0.00012004553],"category_scores_gemma":[0.017005255,0.00012617961,0.0008726146,0.00011754483,0.0010468294,0.00007205671,0.00013521423,0.0010803753,0.0000052282653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040284568,0.00062000676,0.5641339,0.0017786922,0.0014902415,0.00003378107,0.0007274857,1.3137021e-7,2.3495814e-7,0.000031020812,0.026829574,0.4039521],"study_design_scores_gemma":[0.0016009987,0.0018242764,0.023952046,0.011684232,0.0014887825,0.000083879495,0.00025615573,4.889513e-7,0.000003127748,0.000047141468,0.95895654,0.00010235674],"about_ca_topic_score_codex":0.00009902314,"about_ca_topic_score_gemma":0.000102559025,"teacher_disagreement_score":0.93212694,"about_ca_system_score_codex":0.00014050087,"about_ca_system_score_gemma":0.002286725,"threshold_uncertainty_score":0.99127495},"labels":[],"label_agreement":null},{"id":"W2158664495","doi":"10.1200/jco.2004.00.6650","title":"Side Effects Related to Cancer Treatment","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","score_opus":0.07315946024600528,"score_gpt":0.5540068520501057,"score_spread":0.4808473918041004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158664495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9140566,0.0015832025,0.000040548828,0.060411993,0.001454517,0.00032568828,0.0000024745711,0.000012230907,0.022112766],"genre_scores_gemma":[0.97980213,0.0010700632,0.00559269,0.0065138964,0.001254686,0.000019044885,0.0000014420608,0.000013408865,0.0057326085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983564,0.000113538605,0.0011072519,0.000115834526,0.00015645694,0.00015051881],"domain_scores_gemma":[0.9979511,0.0008107908,0.0004958171,0.00011155216,0.00019523929,0.00043553897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041300134,0.00009253297,0.00083020364,0.000080420534,0.000028289993,0.0000037407208,0.00004912735,0.00016955515,0.00015481462],"category_scores_gemma":[0.0006481226,0.00005499584,0.00032563607,0.00010111334,0.000038117923,0.000055267006,0.000010714338,0.00024320045,0.0001021231],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009987323,0.0019510423,0.024191102,0.000008026124,0.001149928,0.00050173263,0.00033429143,0.00020643896,0.00018741128,0.00009717245,0.0056558126,0.9647183],"study_design_scores_gemma":[0.012858614,0.021404395,0.2637152,0.00010813801,0.001523656,0.00022248378,0.000036216094,0.000033551383,0.00040598793,0.00012245914,0.6995048,0.000064510736],"about_ca_topic_score_codex":0.00004917512,"about_ca_topic_score_gemma":0.00010459135,"teacher_disagreement_score":0.9646538,"about_ca_system_score_codex":0.0007361392,"about_ca_system_score_gemma":0.00165336,"threshold_uncertainty_score":0.29329896},"labels":[],"label_agreement":null},{"id":"W2158770026","doi":"10.1200/jco.2014.55.4139","title":"Past, Present, and Future Challenges in Breast Cancer Treatment","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; Genentech; AstraZeneca","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine","score_opus":0.08132865229469918,"score_gpt":0.4242177245564884,"score_spread":0.3428890722617892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158770026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8292267,0.02180462,0.000011531082,0.14515342,0.0012275125,0.0001108273,0.000015334756,0.0000032965752,0.0024468116],"genre_scores_gemma":[0.89725626,0.088051215,0.00031001176,0.0005070659,0.013795864,0.000013262165,0.0000018233292,0.000011853431,0.000052655258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985973,0.00028905785,0.00065810763,0.00020233374,0.000090640824,0.00016256164],"domain_scores_gemma":[0.998973,0.00019012851,0.0004661218,0.00013078649,0.00010854787,0.00013143288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005739919,0.00012807513,0.0006166989,0.000038336984,0.000023085933,0.000004053266,0.00009221582,0.0002470056,0.000014291374],"category_scores_gemma":[0.00003947568,0.00008465779,0.00015072277,0.000029520199,0.00011646387,0.0000048801767,0.00005611486,0.00015229752,0.0000012362528],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011606778,0.0006718174,0.17655998,0.0000083039895,0.00031253544,0.000022340022,0.00007888909,0.000009246556,0.00010769213,0.000053342854,0.002270529,0.81874466],"study_design_scores_gemma":[0.0032402915,0.0018663428,0.569133,0.000011817963,0.00005739769,0.00012492371,0.000104912266,0.0000038689655,0.000048566242,0.00007653137,0.42527437,0.000058010937],"about_ca_topic_score_codex":0.000041407988,"about_ca_topic_score_gemma":0.0002610363,"teacher_disagreement_score":0.8186866,"about_ca_system_score_codex":0.00005382731,"about_ca_system_score_gemma":0.00019515403,"threshold_uncertainty_score":0.34522444},"labels":[],"label_agreement":null},{"id":"W2158785906","doi":"10.1200/jco.2011.35.0165","title":"A Case-Match Study Comparing Unilateral With Synchronous Bilateral Breast Cancer Outcomes","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Lymphovascular invasion; Cohort; Internal medicine; Oncology; Proportional hazards model; Lymph node; Cancer; Stage (stratigraphy); Hazard ratio; Gynecology; Confidence interval; Metastasis","score_opus":0.12429988346538012,"score_gpt":0.42338690894807596,"score_spread":0.29908702548269583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158785906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976606,0.00014966667,0.000046238314,0.0005508266,0.00072013587,0.00016691825,0.000011024562,0.000006784734,0.0006878246],"genre_scores_gemma":[0.9978489,0.00008925149,0.0009443977,0.0004315066,0.0005736677,0.000014929985,0.0000015614679,0.000023098402,0.00007267252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782765,0.00028489382,0.0011745078,0.00027053006,0.0001678144,0.0002745937],"domain_scores_gemma":[0.99819255,0.00010993719,0.000943785,0.0002337663,0.0003233108,0.000196646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067933527,0.00021847157,0.0011003631,0.00005376918,0.000079586614,0.0000105759145,0.00021657876,0.00018466587,0.00006292937],"category_scores_gemma":[0.00006370419,0.00013288464,0.0002482079,0.000067463094,0.00020512899,0.000012814776,0.00013812198,0.00034107274,0.000004259833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003311236,0.0023128807,0.9780898,0.000006313052,0.0018964523,0.0041682366,0.0005147531,0.000028476332,0.00003553897,0.0000049369596,0.00020824872,0.009423107],"study_design_scores_gemma":[0.0069884486,0.0066513508,0.9743245,0.000022795972,0.0004519806,0.010088645,0.00058580976,0.000008094306,0.00006443856,0.000015794092,0.00062802626,0.00017009086],"about_ca_topic_score_codex":0.0007915991,"about_ca_topic_score_gemma":0.0025042554,"teacher_disagreement_score":0.009253017,"about_ca_system_score_codex":0.00007799003,"about_ca_system_score_gemma":0.00050909864,"threshold_uncertainty_score":0.5418878},"labels":[],"label_agreement":null},{"id":"W2159100092","doi":"10.1200/jco.2002.11.080","title":"Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":378,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary General Hospital","funders":"","keywords":"Medicine; Breast cancer; Placebo; Hazard ratio; Clinical endpoint; Bisphosphonate; Surgery; Internal medicine; Chemotherapy; Randomized controlled trial; Confidence interval; Urology; Oncology; Cancer; Osteoporosis; Pathology","score_opus":0.05479743558820683,"score_gpt":0.41037865871765683,"score_spread":0.35558122312945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159100092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871014,0.00049293175,0.0000030665876,0.0048484565,0.00088790676,0.0019938604,0.000005379343,0.0000030333044,0.004663974],"genre_scores_gemma":[0.99548465,0.0011920431,0.0005474264,0.0016347707,0.00028668018,0.000051375435,0.0000017134616,0.00001306476,0.0007883028],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535507,0.00082973257,0.003044084,0.00013669369,0.00040000386,0.0002344006],"domain_scores_gemma":[0.994824,0.0022949392,0.0020418842,0.00012626735,0.00039012788,0.0003227604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031981706,0.00012929272,0.0038515895,0.0001320542,0.000019293782,0.0000024048488,0.00007849525,0.0002633221,0.0004237523],"category_scores_gemma":[0.0011443207,0.00006863663,0.00044335157,0.00010762375,0.00016989521,0.00008816028,0.000015503067,0.0006778185,0.000007658702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8467452,0.0069649303,0.10268985,0.000026054888,0.0005686423,0.00010690008,0.00003180029,0.0000123190275,2.2823357e-7,0.000005528297,0.0005103415,0.04233823],"study_design_scores_gemma":[0.8480362,0.012236167,0.1381315,0.00013475897,0.0005713033,0.00003629905,0.0000039000943,0.00006811195,5.2652535e-7,0.000019489094,0.00071470486,0.000047033736],"about_ca_topic_score_codex":0.0001276963,"about_ca_topic_score_gemma":0.00005624297,"teacher_disagreement_score":0.042291198,"about_ca_system_score_codex":0.00020201186,"about_ca_system_score_gemma":0.0011206499,"threshold_uncertainty_score":0.46397904},"labels":[],"label_agreement":null},{"id":"W2159273458","doi":"10.1200/jco.2011.37.0726","title":"Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Hazard ratio; Androgen suppression; Internal medicine; Proportional hazards model; Cohort; Radiation therapy; Prostate; Gynecology; Cancer; Androgen; Oncology; Confidence interval; Hormone","score_opus":0.14392601180667686,"score_gpt":0.4617927192312874,"score_spread":0.31786670742461054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159273458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018097,0.006775022,0.000004826147,0.0018359674,0.00023732678,0.00037613302,0.000024978905,0.000001317432,0.00056346937],"genre_scores_gemma":[0.92065036,0.07851278,0.0005232936,0.00016363483,0.00010550662,0.000011771273,0.000001250211,0.000006668664,0.000024755815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974934,0.00037870093,0.0017134533,0.00010087581,0.00022136928,0.000092239025],"domain_scores_gemma":[0.99604756,0.000956758,0.0022198625,0.00015017446,0.00051741744,0.00010824025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002178724,0.00008379571,0.0010176864,0.000040449304,0.000018760862,0.0000012968331,0.000071147355,0.00013641959,0.000061071645],"category_scores_gemma":[0.0007063885,0.00003906594,0.0002532979,0.000058649803,0.00035818084,0.000056818848,0.000022701826,0.00026296263,2.2709261e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032638412,0.0017881254,0.81727284,0.00003380015,0.0009598343,0.00004367524,0.0015577538,0.000004528792,0.0004331464,0.00017524182,0.00038705027,0.14470558],"study_design_scores_gemma":[0.018565921,0.01771641,0.93044895,0.00029823606,0.0010227222,0.000054824803,0.0002179038,0.000038083457,0.028644895,0.0014166607,0.0015326585,0.00004276064],"about_ca_topic_score_codex":0.00032857113,"about_ca_topic_score_gemma":0.000048175134,"teacher_disagreement_score":0.14466283,"about_ca_system_score_codex":0.000029086437,"about_ca_system_score_gemma":0.00075976824,"threshold_uncertainty_score":0.15930629},"labels":[],"label_agreement":null},{"id":"W2159432644","doi":"10.1200/jco.2012.43.3441","title":"Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate cancer screening; Prostate-specific antigen; Cancer; Oncology; Life expectancy; Population; Prostate biopsy; Prostate; Gynecology; Clinical trial; Internal medicine; Intensive care medicine","score_opus":0.3686353779000254,"score_gpt":0.549440210622352,"score_spread":0.18080483272232667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159432644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718887,0.0037827964,0.0010213541,0.017042864,0.003610389,0.00209892,0.000106653344,0.00003098344,0.00041729514],"genre_scores_gemma":[0.7759799,0.022126686,0.18947797,0.0040386,0.007956553,0.0001573225,0.000039388135,0.000084138715,0.00013949334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9896362,0.0009378923,0.007301831,0.0005873111,0.00072926795,0.00080751034],"domain_scores_gemma":[0.9755512,0.012123337,0.008687569,0.0003729481,0.0019932827,0.0012716748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012397297,0.00037748818,0.004440468,0.00010976995,0.00011855192,0.000014766015,0.00027225344,0.0006271425,0.000054947322],"category_scores_gemma":[0.0035743557,0.00023768442,0.0016422259,0.00038768369,0.0016608328,0.00028700454,0.00013256336,0.0018119563,0.000005173988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018734155,0.005430933,0.52009785,0.000073274474,0.0009685207,0.000034094268,0.0001322456,0.000020513693,0.00003626463,0.00002379351,0.015097383,0.439351],"study_design_scores_gemma":[0.015664684,0.068397895,0.5552475,0.0004283543,0.00040647486,0.00009801317,0.00029119587,0.00017115711,0.000071477974,0.000034889876,0.3590223,0.00016608016],"about_ca_topic_score_codex":0.00008828042,"about_ca_topic_score_gemma":0.000023215087,"teacher_disagreement_score":0.4391849,"about_ca_system_score_codex":0.00031636143,"about_ca_system_score_gemma":0.005985221,"threshold_uncertainty_score":0.99964994},"labels":[],"label_agreement":null},{"id":"W2159455435","doi":"10.1200/jco.2011.35.7533","title":"Long-Term Follow-Up of Children Treated for High-Grade Gliomas: Children's Oncology Group L991 Final Study Report","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Neuropsychology; Pediatrics; Glioma; Internal medicine; Cognition; Psychiatry","score_opus":0.11069532384939981,"score_gpt":0.4507361020803583,"score_spread":0.34004077823095846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159455435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930488,0.0010074244,0.000053676522,0.0019927635,0.0020808969,0.0015921282,0.000024306479,0.000020730786,0.00017929907],"genre_scores_gemma":[0.9947768,0.00021599131,0.0016460997,0.0003808611,0.002686247,0.00006280412,0.000088085646,0.000045932884,0.00009718525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934375,0.0006434792,0.004375788,0.0003880233,0.00056134636,0.00059384195],"domain_scores_gemma":[0.9912591,0.0026112236,0.0043110913,0.0004927838,0.0005641205,0.00076167594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042695343,0.00034589504,0.0033545787,0.00037145053,0.00008324382,0.000009166428,0.00027641578,0.0006736905,0.00014091693],"category_scores_gemma":[0.0027514074,0.0002352663,0.0012527694,0.00028662343,0.0002548218,0.00017976137,0.00009859456,0.0007461706,0.000011034004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051215407,0.04114509,0.9007431,0.000017535254,0.003991005,0.0019854025,0.0001026896,0.000001146649,0.00016291862,0.00007344902,0.0024277607,0.044228345],"study_design_scores_gemma":[0.050911214,0.059685763,0.8781738,0.000077225755,0.004355575,0.005219293,0.000055395987,0.0000010540309,0.00052418164,0.000055321292,0.0007781427,0.00016303247],"about_ca_topic_score_codex":0.000112252776,"about_ca_topic_score_gemma":0.00011022534,"teacher_disagreement_score":0.045789674,"about_ca_system_score_codex":0.00032746172,"about_ca_system_score_gemma":0.00071283994,"threshold_uncertainty_score":0.9593881},"labels":[],"label_agreement":null},{"id":"W2159862107","doi":"10.1200/jco.2011.41.0985","title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":973,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Michael Smith Health Research BC","keywords":"Vincristine; Medicine; Chromosomal translocation; International Prognostic Index; Immunohistochemistry; Rituximab; Lymphoma; Cyclophosphamide; Prednisone; Diffuse large B-cell lymphoma; Cancer research; CHOP; Internal medicine; Oncology; Cohort; Immunophenotyping; Pathology; Chemotherapy; Immunology; Flow cytometry; Biology; Gene","score_opus":0.04353290157636887,"score_gpt":0.38137566916005605,"score_spread":0.3378427675836872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159862107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886658,0.009759297,0.000026002797,0.00046397865,0.0002325973,0.0002844362,0.000015263275,0.0000063479156,0.0005462398],"genre_scores_gemma":[0.99413466,0.004234363,0.0010071269,0.00031428237,0.00022303413,0.000009576138,0.000005179845,0.000016957372,0.000054805085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726564,0.00026264053,0.0016623312,0.00020017834,0.00028735658,0.00032184532],"domain_scores_gemma":[0.9964409,0.0014274409,0.0012608339,0.00015631874,0.0001885627,0.00052597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011386602,0.00020334151,0.0018172668,0.00012424744,0.000032123116,0.0000063425214,0.00006476943,0.00029118438,0.000024158917],"category_scores_gemma":[0.00053305144,0.00011977463,0.0001419042,0.00011307087,0.00022244519,0.00013775697,0.0000766683,0.00024636943,0.0000023169907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004259559,0.042658456,0.91595995,0.00010511476,0.00014569373,0.00037279128,0.00027750517,4.2529493e-7,0.00033465793,0.000057755104,0.00057015324,0.035257924],"study_design_scores_gemma":[0.16740967,0.01219377,0.80979145,0.0004038129,0.00045495684,0.0004354477,0.00016970818,0.000040479412,0.003333733,0.000011964593,0.0056496006,0.00010540844],"about_ca_topic_score_codex":0.000054872322,"about_ca_topic_score_gemma":0.000030639098,"teacher_disagreement_score":0.16315012,"about_ca_system_score_codex":0.0001969788,"about_ca_system_score_gemma":0.00045566587,"threshold_uncertainty_score":0.48842674},"labels":[],"label_agreement":null},{"id":"W2159964983","doi":"10.1200/jco.2006.09.8194","title":"Survival and Late Mortality in Long-Term Survivors of Pediatric CNS Tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Malignancy; Sepsis; Pediatrics; Cause of death; Disease; Population; Surgery; Internal medicine","score_opus":0.11801880575200212,"score_gpt":0.4684250251471721,"score_spread":0.35040621939516997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159964983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966258,0.00067963183,0.000016730404,0.00067054067,0.00072834484,0.00012829714,0.0000022077618,0.000003056185,0.0011454353],"genre_scores_gemma":[0.99770904,0.0013411816,0.00019890958,0.0001337685,0.0005895708,7.1187526e-7,0.0000014008153,0.000008861829,0.000016546646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665934,0.0002393187,0.002440578,0.00014378334,0.0003030341,0.00021394035],"domain_scores_gemma":[0.9955416,0.0024604762,0.0013258205,0.0001328327,0.00020530708,0.00033399553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059975963,0.00010879101,0.001418171,0.00022686922,0.000012745294,0.0000029430303,0.00007649992,0.00024055039,0.000050354185],"category_scores_gemma":[0.0014948183,0.000075644304,0.00028050723,0.00020733952,0.00013852681,0.000054656,0.000040015973,0.00049445516,0.0000025462814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007397009,0.0027621565,0.97792614,0.000043073553,0.00017073461,0.0032481966,0.00004154284,0.000003581231,0.000039665723,0.000057031193,0.00003254046,0.014935642],"study_design_scores_gemma":[0.0067454726,0.0038788223,0.98846895,0.000044828106,0.00039089608,0.0000917632,0.000037584392,0.0000048488637,0.000086113556,0.000114605245,0.00008036874,0.000055727713],"about_ca_topic_score_codex":0.00012827416,"about_ca_topic_score_gemma":0.00161767,"teacher_disagreement_score":0.014879914,"about_ca_system_score_codex":0.00006707112,"about_ca_system_score_gemma":0.0004026413,"threshold_uncertainty_score":0.30846852},"labels":[],"label_agreement":null},{"id":"W2159979641","doi":"10.1200/jco.2008.16.1190","title":"Resolving the Optimal Timing of Radiotherapy After Radical Prostatectomy: The Need for Further Research","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Cancer Research UK","keywords":"Medicine; Prostatectomy; Radiation therapy; Prostate cancer; Urology; Surgery; Internal medicine; Cancer","score_opus":0.2570221097938991,"score_gpt":0.517922968570161,"score_spread":0.26090085877626185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159979641","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04506056,0.012813534,0.00014762217,0.93844783,0.0013330664,0.0018410449,0.000029483845,0.0000066221983,0.00032022325],"genre_scores_gemma":[0.07237541,0.043108694,0.017014394,0.8182093,0.045903563,0.0006434242,0.00003182742,0.00026318326,0.0024501933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935896,0.0016135655,0.0028089865,0.00033274473,0.0010454878,0.0006096151],"domain_scores_gemma":[0.9786674,0.017430162,0.0020146165,0.0005496979,0.0011554289,0.00018273752],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008418044,0.00027938612,0.002228814,0.00020622986,0.00014880208,0.000023942934,0.00052049075,0.0011891618,0.00020780574],"category_scores_gemma":[0.002867043,0.000122302,0.0013548196,0.00021444715,0.0016351431,0.000059863218,0.00008734156,0.0060955253,0.0000046007885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010550115,0.00070352945,0.002441669,0.00014437664,0.0017645869,0.0025743598,0.0009905692,0.000010761376,0.000016156908,0.000006856066,0.9376424,0.043154605],"study_design_scores_gemma":[0.008185777,0.016932601,0.0061385115,0.00056311657,0.0005631385,0.0007142174,0.00015621597,0.00010438773,0.0000669201,0.0001394949,0.9663214,0.000114223585],"about_ca_topic_score_codex":0.000023500479,"about_ca_topic_score_gemma":0.000004716423,"teacher_disagreement_score":0.12023853,"about_ca_system_score_codex":0.0005044291,"about_ca_system_score_gemma":0.0038706225,"threshold_uncertainty_score":0.99619746},"labels":[],"label_agreement":null},{"id":"W2160028603","doi":"10.1200/jco.2015.62.5715","title":"Reply to J.J. Beitler et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.17197422739283363,"score_gpt":0.5675292840060916,"score_spread":0.39555505661325796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160028603","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027401312,0.0034010825,0.00025767932,0.91045463,0.026873099,0.00041146344,0.000050456045,0.000009211627,0.055802226],"genre_scores_gemma":[0.0013982183,0.0014589927,0.008572338,0.93063635,0.022128649,0.000011903011,0.000042247888,0.00006253439,0.035688758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99251324,0.0012319055,0.0043679303,0.00041689648,0.00091674575,0.000553282],"domain_scores_gemma":[0.9894114,0.0038408514,0.0031510289,0.0004613204,0.0018054507,0.0013299425],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006577298,0.0003548053,0.0031532876,0.00026025466,0.000047605154,0.000025281392,0.00035517945,0.00122615,0.0016254626],"category_scores_gemma":[0.009239821,0.0002477347,0.0010974259,0.00020000398,0.00026361988,0.0001448816,0.00011651444,0.0048980955,0.0014567885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012119821,0.001312507,0.0035662462,0.000036265563,0.002218865,0.0077429735,0.00034804427,0.00003267794,0.0000039793044,0.00010248751,0.8732368,0.110187195],"study_design_scores_gemma":[0.008479346,0.025355237,0.011731726,0.00063641614,0.0033122823,0.0012178998,0.00011011929,0.00000738332,0.000002110117,0.00039487638,0.94854987,0.00020272515],"about_ca_topic_score_codex":0.00016931405,"about_ca_topic_score_gemma":0.000038682134,"teacher_disagreement_score":0.109984465,"about_ca_system_score_codex":0.0013266434,"about_ca_system_score_gemma":0.015112439,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W2160116963","doi":"10.1200/jco.2010.33.3922","title":"Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical Practice","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"American Society of Clinical Oncology; Sanofi; Exelixis; AstraZeneca","keywords":"Medicine; Clinical trial; Compendium; Clinical Oncology; Alternative medicine; MEDLINE; Cancer; Internal medicine; Family medicine; Clinical Practice; Oncology; Pathology","score_opus":0.837188135174939,"score_gpt":0.7522143554525743,"score_spread":0.08497377972236464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160116963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502232,0.00020600035,0.00011798796,0.015980994,0.0028517116,0.000632487,0.000020969712,0.000009511886,0.02995711],"genre_scores_gemma":[0.97183704,0.006256239,0.013708548,0.005889197,0.002069569,0.000004752846,0.000005699961,0.000031477317,0.000197477],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9640409,0.013316357,0.019955022,0.00056562474,0.0015363266,0.0005857938],"domain_scores_gemma":[0.34814638,0.62265307,0.020773683,0.0010156791,0.00514343,0.0022677714],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.2454223,0.000270862,0.00783086,0.00049039844,0.00003721568,0.000018956816,0.0005457117,0.002597558,0.0007887614],"category_scores_gemma":[0.7068669,0.00017001196,0.0014125826,0.00033923498,0.0016742477,0.00031742288,0.00025682888,0.011306181,0.000029215114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31285137,0.056571055,0.21776721,0.00016257852,0.0022420676,0.0066928966,0.00059244793,7.910805e-7,0.00016367834,0.0040735686,0.009898139,0.3889842],"study_design_scores_gemma":[0.08458736,0.22519694,0.6201191,0.000612991,0.0012950265,0.00078488543,0.00062029756,0.00009554699,0.00007457437,0.0071213963,0.05927548,0.0002163896],"about_ca_topic_score_codex":0.00007389457,"about_ca_topic_score_gemma":0.000054809265,"teacher_disagreement_score":0.6158945,"about_ca_system_score_codex":0.00030010007,"about_ca_system_score_gemma":0.0104400655,"threshold_uncertainty_score":0.9986973},"labels":[],"label_agreement":null},{"id":"W2160151619","doi":"10.1200/jco.2006.06.2935","title":"Breaking Bad News: More Than Just Guidelines","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.7056878235673061,"score_gpt":0.642438326600561,"score_spread":0.06324949696674509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160151619","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027083505,0.0045093857,0.000116939125,0.96142536,0.0191631,0.0008405791,0.00006644926,0.00006685734,0.011102977],"genre_scores_gemma":[0.0025259568,0.0013935121,0.013236167,0.9239911,0.05255049,0.00006428785,0.00015684425,0.00013997666,0.0059417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97205245,0.009705697,0.015443118,0.0005278881,0.001213019,0.001057798],"domain_scores_gemma":[0.9489316,0.02368661,0.019891558,0.001538443,0.0055096783,0.0004421341],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0051279687,0.00052539154,0.0039442386,0.000489982,0.000595705,0.000016680799,0.0022229527,0.006992792,0.00054906966],"category_scores_gemma":[0.019700471,0.00040576071,0.0013152485,0.00031606792,0.00042769455,0.00025536589,0.0006822991,0.023943083,0.00038163504],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019651749,0.00015746726,0.04406141,0.00037015372,0.00017403076,0.0005145328,0.0004627714,0.000013072306,5.1025825e-7,0.0000316874,0.9348559,0.019161938],"study_design_scores_gemma":[0.0027798105,0.001304888,0.018208973,0.0016855923,0.00031330538,0.00007174631,0.0014435455,0.000055233093,1.7026149e-7,0.0010145616,0.97279865,0.00032355599],"about_ca_topic_score_codex":0.0020170053,"about_ca_topic_score_gemma":0.0011071491,"teacher_disagreement_score":0.03794271,"about_ca_system_score_codex":0.0009972326,"about_ca_system_score_gemma":0.012003955,"threshold_uncertainty_score":0.9998394},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2160186787","doi":"10.1200/jco.2004.99.103","title":"Improved Outcome With Dose-Dense Chemotherapy","year":2004,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Chemotherapy; Adjuvant; Granulocyte colony-stimulating factor; Inflammation; Cancer; Oncology; Immune system; Internal medicine; Immunology","score_opus":0.10068112727740769,"score_gpt":0.44572660063656666,"score_spread":0.34504547335915897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160186787","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04800742,0.00050427596,0.00010583743,0.94414663,0.0034665992,0.00075637345,0.000011948238,0.000051154333,0.0029497724],"genre_scores_gemma":[0.010399067,0.00036896658,0.014650995,0.95200527,0.020779418,0.000016557251,0.00001765024,0.00016070361,0.001601398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99271834,0.0005397081,0.0048293406,0.00044532574,0.0009141401,0.0005531402],"domain_scores_gemma":[0.9902201,0.0018720069,0.00569745,0.00061931077,0.0010506229,0.0005404503],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0033278954,0.0004954634,0.004027791,0.00032407138,0.000047717676,0.00002392449,0.00049459544,0.0034094576,0.00055927644],"category_scores_gemma":[0.0023724374,0.00031196224,0.0017493338,0.00017315001,0.0007035172,0.00010109257,0.00006382118,0.007631852,0.000057868245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019512905,0.0013608355,0.057184137,0.0005345262,0.0041133957,0.04461072,0.000041482654,8.3774995e-7,0.000041023424,0.0000047940675,0.8313195,0.041275837],"study_design_scores_gemma":[0.024600618,0.015009051,0.047985353,0.00053690356,0.0023325242,0.0030723459,0.000016722113,0.000006990975,0.000036917034,0.00018081923,0.905863,0.00035875398],"about_ca_topic_score_codex":0.0000073076676,"about_ca_topic_score_gemma":0.000004587898,"teacher_disagreement_score":0.0745435,"about_ca_system_score_codex":0.0006668954,"about_ca_system_score_gemma":0.0070389514,"threshold_uncertainty_score":0.99993324},"labels":[],"label_agreement":null},{"id":"W2160315259","doi":"10.1200/jco.2003.04.069","title":"Effect of Upper Extremity Exercise on Secondary Lymphedema in Breast Cancer Patients: A Pilot Study","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lymphedema; Physical therapy; Quality of life (healthcare); Breast cancer; Anthropometry; Upper limb; Aerobic exercise; Cancer; Physical medicine and rehabilitation; Internal medicine; Nursing","score_opus":0.05543743603089556,"score_gpt":0.43600281236296873,"score_spread":0.38056537633207316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160315259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938307,0.0005197908,0.0000011460431,0.00027723445,0.0011613824,0.000578911,0.000009674197,0.0000042597435,0.0036168934],"genre_scores_gemma":[0.9987875,0.00015381665,0.000032539218,0.0006574002,0.00025995637,0.000016643278,7.381837e-7,0.000014273676,0.00007708636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99510914,0.0016334209,0.0024107597,0.00019212652,0.00045785547,0.00019668667],"domain_scores_gemma":[0.9946293,0.003123054,0.0013493382,0.00020388656,0.00033317,0.00036119882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041299015,0.00015909424,0.0020075222,0.00016480082,0.000018730152,0.0000036863871,0.000115349234,0.00014445324,0.00059299514],"category_scores_gemma":[0.0035420936,0.000096717384,0.00032135425,0.00016060055,0.00010082833,0.00008030857,0.00002276788,0.000111013906,0.000012761654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020531537,0.020640315,0.9004486,0.0001380015,0.0001540826,0.00022372647,0.00008049136,0.0000034217373,0.000014139898,0.000006576977,0.0011446715,0.056614406],"study_design_scores_gemma":[0.036109935,0.057377536,0.9046622,0.00064126315,0.00052915316,0.00007366414,0.00014980006,0.0000037109298,0.00004906798,0.000023495084,0.00030700766,0.00007318023],"about_ca_topic_score_codex":0.000076079334,"about_ca_topic_score_gemma":0.000022164133,"teacher_disagreement_score":0.056541227,"about_ca_system_score_codex":0.00026315576,"about_ca_system_score_gemma":0.0018555705,"threshold_uncertainty_score":0.64928806},"labels":[],"label_agreement":null},{"id":"W2160511242","doi":"10.1200/jco.2010.28.1709","title":"Adoption of Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: A Population-Based Outcomes Study","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Queen's University; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Cancer Care Ontario","keywords":"Medicine; Cancer registry; Cohort; Population; Lung cancer; Internal medicine; Chemotherapy; Cancer; Surgery","score_opus":0.06814877217105841,"score_gpt":0.4818316539883329,"score_spread":0.4136828818172745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160511242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981315,0.0001470487,0.00017068241,0.0071754665,0.0016712182,0.0009213225,0.000008080988,0.000004961621,0.00008809411],"genre_scores_gemma":[0.99167913,0.00018692268,0.0058010574,0.0014883596,0.00068264414,0.00005751939,0.000004925128,0.000017254737,0.000082186554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997755,0.00007878025,0.0016497524,0.00015077309,0.00022767218,0.00013802531],"domain_scores_gemma":[0.99588835,0.0016187463,0.0016640476,0.00018370486,0.00046446812,0.00018065405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013911901,0.00011838797,0.0013610824,0.000087928645,0.000027411066,0.0000040672658,0.000095794225,0.00021299186,0.00010082687],"category_scores_gemma":[0.00046701616,0.00007515391,0.00054656115,0.00006618023,0.00003605011,0.000035345627,0.000009252183,0.00040323148,9.511627e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019991861,0.007669473,0.9453801,0.00008145087,0.00048971066,0.000022770906,0.000081826925,0.0000439055,0.00011191201,0.000008657241,0.0008839458,0.043227084],"study_design_scores_gemma":[0.027429007,0.012545674,0.9557267,0.000079412595,0.0011952557,0.00000486487,0.000061975494,0.00054325094,0.0002202124,0.000026241023,0.0021046207,0.00006282934],"about_ca_topic_score_codex":0.00019474114,"about_ca_topic_score_gemma":0.00078694645,"teacher_disagreement_score":0.043164253,"about_ca_system_score_codex":0.00019150556,"about_ca_system_score_gemma":0.0012758204,"threshold_uncertainty_score":0.30646876},"labels":[],"label_agreement":null},{"id":"W2160542415","doi":"10.1200/jco.2006.07.8659","title":"Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Neutropenia; Internal medicine; Gastroenterology; Macroglobulinemia; Waldenstrom macroglobulinemia; Discontinuation; Toxicity; Peripheral neuropathy; Cancer; Surgery; Multiple myeloma; Lymphoma","score_opus":0.21261765092660903,"score_gpt":0.5550014234986691,"score_spread":0.3423837725720601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160542415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519473,0.00003963551,0.000008689992,0.0018221588,0.0013198009,0.0011724993,0.000057105914,0.0000024574344,0.00038289608],"genre_scores_gemma":[0.99760425,0.000078012104,0.00028295486,0.00112422,0.000632164,0.0000073363203,0.000004133919,0.000016961714,0.00024996157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890547,0.0014381893,0.0069305566,0.0003009573,0.0019012162,0.00037439854],"domain_scores_gemma":[0.98377055,0.008171303,0.005116515,0.00027739938,0.0022436806,0.0004205699],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016091866,0.00019415298,0.0029045132,0.00018276439,0.000058946196,0.0000030476501,0.00037727912,0.0004734146,0.0002297011],"category_scores_gemma":[0.029912842,0.00009738651,0.00037489823,0.0006508601,0.00054619723,0.00010797423,0.00014883715,0.0016455421,4.0178486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.36759195,0.044738762,0.44545725,0.00008497951,0.0036677357,0.0018076489,0.000718366,0.00014906153,0.000050594157,0.000019074481,0.014928369,0.1207862],"study_design_scores_gemma":[0.38408527,0.07017474,0.5374634,0.0003767346,0.00077955995,0.00009663308,0.00045830768,0.0002682148,0.00020769324,0.000021743554,0.0059426306,0.00012506962],"about_ca_topic_score_codex":0.04760831,"about_ca_topic_score_gemma":0.36352855,"teacher_disagreement_score":0.31592026,"about_ca_system_score_codex":0.008150875,"about_ca_system_score_gemma":0.09189509,"threshold_uncertainty_score":0.99565667},"labels":[],"label_agreement":null},{"id":"W2160569045","doi":"10.1200/jco.2009.26.7294","title":"Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison With Two-Dimensional Echocardiography, Multiple-Gated Acquisition Scans, and Cardiac Magnetic Resonance Imaging","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital","funders":"","keywords":"Medicine; Ejection fraction; Trastuzumab; Cardiology; Internal medicine; Magnetic resonance imaging; Breast cancer; Nuclear medicine; Radiology; Cancer; Heart failure","score_opus":0.018506331307161072,"score_gpt":0.34272191730727103,"score_spread":0.32421558600010997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160569045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143296,0.005685374,0.00002980707,0.0016949897,0.0005862251,0.00035808753,0.00004923287,0.000015235751,0.00014808119],"genre_scores_gemma":[0.9943101,0.00040621788,0.003959829,0.0005396081,0.00073367293,0.0000084488765,0.000011664898,0.000027624303,0.0000028300508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664426,0.00034740858,0.0017036147,0.00034679385,0.00065610785,0.00030183638],"domain_scores_gemma":[0.99670154,0.0009686651,0.001009543,0.00024753052,0.00073435326,0.0003383959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023881686,0.00023654077,0.0019069274,0.00046825793,0.000060786126,0.000011611582,0.00011883059,0.00035607888,0.000032641445],"category_scores_gemma":[0.00014177064,0.00018669327,0.0007126473,0.0005487338,0.0006126442,0.00017883646,0.000042301665,0.0015255836,8.283877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004500177,0.00045132762,0.7870227,0.00001855301,0.00023900987,0.00006355916,0.000042860254,0.0005042529,0.07413225,0.000015858068,0.000200507,0.13280894],"study_design_scores_gemma":[0.0111595,0.0015903054,0.9772204,0.00040751905,0.00043123754,0.0004130796,0.00007384263,0.0032416068,0.0042302455,0.000233156,0.0008186039,0.0001804884],"about_ca_topic_score_codex":0.00039320087,"about_ca_topic_score_gemma":0.00021229975,"teacher_disagreement_score":0.19019772,"about_ca_system_score_codex":0.00007310963,"about_ca_system_score_gemma":0.00075483386,"threshold_uncertainty_score":0.7613131},"labels":[],"label_agreement":null},{"id":"W2160609571","doi":"10.1200/jco.2009.23.0755","title":"Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Chemotherapy; Surgery; Testicular cancer; Population; Cancer; Teratoma; Internal medicine","score_opus":0.035505919355251415,"score_gpt":0.40197953058539987,"score_spread":0.36647361123014843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160609571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348414,0.001276679,0.00019214358,0.0041818074,0.0001292628,0.00034997403,0.0000132114255,0.000021349586,0.00035143568],"genre_scores_gemma":[0.9916863,0.0006663286,0.0056186225,0.0015610158,0.00006816303,0.0000035707994,0.000010731866,0.000031268857,0.00035402513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964179,0.0004949489,0.0020733518,0.0002471286,0.0004865682,0.00028011273],"domain_scores_gemma":[0.992935,0.0027149876,0.0032140398,0.0003384175,0.00033511294,0.00046242317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022219832,0.00024236926,0.0017256775,0.00015881607,0.000037717073,0.0000076144775,0.00014879591,0.00022720141,0.00008751005],"category_scores_gemma":[0.0006334473,0.00015811936,0.0007861945,0.00025680478,0.0001483849,0.000047272675,0.000008243112,0.00036877504,0.000004574501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11933234,0.01995065,0.67583174,0.0001310865,0.0017486422,0.011407012,0.00006186348,0.00001809829,0.0034175944,0.0000042730567,0.024433285,0.14366342],"study_design_scores_gemma":[0.021931367,0.017782487,0.94824684,0.00052095164,0.0011540363,0.0002870339,0.0000635739,0.000054731285,0.0068446165,0.000038402603,0.00290353,0.00017244901],"about_ca_topic_score_codex":0.00000956614,"about_ca_topic_score_gemma":5.6571383e-7,"teacher_disagreement_score":0.2724151,"about_ca_system_score_codex":0.0001346355,"about_ca_system_score_gemma":0.0011725691,"threshold_uncertainty_score":0.6447921},"labels":[],"label_agreement":null},{"id":"W2160681961","doi":"10.1200/jco.2006.09.1926","title":"Impact of Adoption of Chemoradiotherapy on the Outcome of Cervical Cancer in Ontario: Results of a Population-Based Cohort Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Queen's University","funders":"","keywords":"Medicine; Cohort; Cancer registry; Chemoradiotherapy; Cervical cancer; Population; Radiation therapy; Internal medicine; Cancer; Relative survival; Cervix; Cohort study; Oncology; Surgery; Gynecology","score_opus":0.15362638422476999,"score_gpt":0.5126476052379529,"score_spread":0.35902122101318296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160681961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979916,0.000070173184,0.0000123594045,0.0007092895,0.00028731168,0.0004892635,0.000015855994,0.0000012847623,0.00042285133],"genre_scores_gemma":[0.9993323,0.00004381293,0.0002568674,0.00018298489,0.00014076283,0.0000030624155,0.000003731968,0.000008224548,0.000028261276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99488443,0.0003112925,0.0039439388,0.00012962527,0.00059222407,0.0001384958],"domain_scores_gemma":[0.9916605,0.004316528,0.0032003259,0.0002200207,0.00047484762,0.00012778104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051268404,0.000115705596,0.0020600872,0.00024001833,0.000008159425,7.8419015e-7,0.00013770153,0.00021995939,0.00030136763],"category_scores_gemma":[0.0023057694,0.000060853537,0.0006321631,0.00038452694,0.00010909619,0.00002788741,0.000012289711,0.0005528658,3.2155907e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051963832,0.0077616335,0.9285587,0.000026528342,0.00059270905,0.000026986918,0.00012679404,0.00037138734,0.00016688352,0.000010601239,0.000017443079,0.010376476],"study_design_scores_gemma":[0.024785263,0.032556627,0.94183195,0.00012740643,0.00030346448,0.0000032692863,0.000055450048,0.000022921746,0.00020635073,0.000039502662,0.000029123878,0.00003866645],"about_ca_topic_score_codex":0.06640713,"about_ca_topic_score_gemma":0.054257493,"teacher_disagreement_score":0.027178567,"about_ca_system_score_codex":0.00067637156,"about_ca_system_score_gemma":0.0010324852,"threshold_uncertainty_score":0.9629998},"labels":[],"label_agreement":null},{"id":"W2160698388","doi":"10.1200/jco.2010.34.3897","title":"Spinal Instability Neoplastic Score: An Analysis of Reliability and Validity From the Spine Oncology Study Group","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":541,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"National Institutes of Health; AOSpine; American Society of Clinical Oncology; Stryker; Scoliosis Research Society; U.S. Department of Defense","keywords":"Medicine; Intraclass correlation; Reliability (semiconductor); Validity; Surgery; Nuclear medicine; Physical therapy; Psychometrics","score_opus":0.2960853008632298,"score_gpt":0.4840547626567088,"score_spread":0.187969461793479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160698388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955373,0.0001103033,0.0011493396,0.0014439408,0.00066627434,0.00057597685,0.000015827321,0.000008989689,0.00049204746],"genre_scores_gemma":[0.991616,0.00009194239,0.00691858,0.0010622462,0.00027814214,0.0000060452658,0.000007140719,0.000010495267,0.000009403853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914518,0.0035899295,0.0036765295,0.00042633084,0.00062808575,0.00022733178],"domain_scores_gemma":[0.9919886,0.0031866317,0.0028068163,0.0008021708,0.0006274914,0.0005882624],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016366841,0.00019555111,0.0027514042,0.00019212448,0.00005477257,0.000007381873,0.00037119482,0.00022672789,0.0006435729],"category_scores_gemma":[0.016615398,0.000116497424,0.0006452313,0.0004614116,0.0008309873,0.000169731,0.00020461627,0.0009461132,0.0000026741814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010764865,0.020325448,0.9253266,0.000038680842,0.002499662,0.00034801685,0.0006378506,0.000009719621,0.00001537076,0.000097088465,0.00010778215,0.039828938],"study_design_scores_gemma":[0.0066138417,0.05248025,0.9195934,0.000023893657,0.0170201,0.000013203478,0.0017460621,0.00064706604,0.0000023453242,0.0009984891,0.00077645225,0.00008487988],"about_ca_topic_score_codex":0.00059317134,"about_ca_topic_score_gemma":0.0011366295,"teacher_disagreement_score":0.03974406,"about_ca_system_score_codex":0.00013748223,"about_ca_system_score_gemma":0.0008497238,"threshold_uncertainty_score":0.99166805},"labels":[],"label_agreement":null},{"id":"W2160708645","doi":"10.1200/jco.2009.26.1685","title":"Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Sanofi; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Carboplatin; Hazard ratio; Chemotherapy; Lung cancer; Surgery; Clinical endpoint; Stage (stratigraphy); Internal medicine; Oncology; Randomized controlled trial; Confidence interval; Cisplatin","score_opus":0.07160498391081993,"score_gpt":0.45290114257278724,"score_spread":0.3812961586619673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160708645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885017,0.00032744536,0.000068786256,0.0016973619,0.005266465,0.0035530985,0.000020137133,0.000013311809,0.00055167155],"genre_scores_gemma":[0.9911964,0.001831555,0.0017143973,0.00078650925,0.0035785686,0.00043379943,0.000011669409,0.000046214816,0.0004008996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99312574,0.0016586862,0.0038466917,0.0005313707,0.0003862805,0.00045120856],"domain_scores_gemma":[0.9864631,0.009261493,0.002835484,0.00031698254,0.0003531989,0.0007697403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007898086,0.00038677725,0.00558969,0.00028132365,0.00007209268,0.000042216987,0.0001693026,0.00075762474,0.00025150552],"category_scores_gemma":[0.00258219,0.0002147785,0.0006066556,0.0001850982,0.0006049658,0.00024855565,0.000064893684,0.0021274597,0.0000017402625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8449718,0.010946309,0.12683551,0.00006182685,0.0009338143,0.0015778694,0.0017337354,0.000002176715,0.000050444803,0.000018320974,0.00033371753,0.012534479],"study_design_scores_gemma":[0.89878815,0.0887275,0.006938093,0.0002863397,0.0021155372,0.00014751888,0.00050027546,0.00033251467,0.000048801878,0.00001133781,0.001881955,0.00022196752],"about_ca_topic_score_codex":0.002366367,"about_ca_topic_score_gemma":0.03079732,"teacher_disagreement_score":0.11989742,"about_ca_system_score_codex":0.00045806592,"about_ca_system_score_gemma":0.0051404857,"threshold_uncertainty_score":0.9868881},"labels":[],"label_agreement":null},{"id":"W2160719528","doi":"10.1200/jco.2009.24.0143","title":"Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Clinical Oncology Group; University of Toronto; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Cyclophosphamide; Internal medicine; Metastatic breast cancer; Prednisone; Vascular endothelial growth factor; Chemotherapy; Gastroenterology; Clinical endpoint; Breast cancer; Phases of clinical research; Oncology; Progressive disease; Methotrexate; Cancer; Surgery; Clinical trial","score_opus":0.08840411151474677,"score_gpt":0.4399860116120404,"score_spread":0.3515819000972936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160719528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916575,0.0030165347,0.0003069877,0.0021831724,0.00063110667,0.0017359693,0.00043211956,0.000010795163,0.000025790021],"genre_scores_gemma":[0.97407264,0.013212669,0.010957803,0.0008591062,0.0006675549,0.000032531305,0.0000068459476,0.00006035999,0.00013049616],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99533814,0.0011099189,0.0021676198,0.00051391934,0.00043714323,0.0004332839],"domain_scores_gemma":[0.9921198,0.004246203,0.0023633698,0.00022197001,0.00054056355,0.00050810573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029689393,0.00044291222,0.003023461,0.00031259234,0.000115339935,0.000020163277,0.00017611087,0.00033307535,0.00031390996],"category_scores_gemma":[0.0010446403,0.00031403193,0.0005817726,0.00019342422,0.0005601697,0.00028204935,0.00004178569,0.00051790284,3.0003366e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76820713,0.0071963603,0.0063708536,0.00010622295,0.006018931,0.00004690453,0.00068443577,0.0000043856785,0.1335539,0.00001911917,0.00018401559,0.07760774],"study_design_scores_gemma":[0.61076075,0.25363556,0.09459596,0.0002052459,0.0035518666,0.0003504487,0.0002288768,0.00013890717,0.029498894,0.00038987584,0.0062081763,0.0004354336],"about_ca_topic_score_codex":0.00043243263,"about_ca_topic_score_gemma":0.000020812962,"teacher_disagreement_score":0.2464392,"about_ca_system_score_codex":0.00022936691,"about_ca_system_score_gemma":0.002471365,"threshold_uncertainty_score":0.99993116},"labels":[],"label_agreement":null},{"id":"W2160841753","doi":"10.1200/jco.2003.05.057","title":"Shared Treatment Decision Making: What Does It Mean to Physicians?","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Congruence (geometry); Conceptual framework; Meaning (existential); Patient participation; Family medicine; MEDLINE; Psychology; Social psychology","score_opus":0.5348454839583044,"score_gpt":0.6186131780005701,"score_spread":0.0837676940422657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160841753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8526706,0.0036682126,0.0011291184,0.1004969,0.026152035,0.0021172531,0.000021036212,0.000057872756,0.013686935],"genre_scores_gemma":[0.9361086,0.0018314864,0.03277228,0.027695512,0.0010146622,0.00006583206,0.000002578664,0.000032303265,0.000476774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9890525,0.005173723,0.0045275823,0.00029224672,0.0004746522,0.0004792945],"domain_scores_gemma":[0.97596985,0.018143466,0.0033951919,0.00080210593,0.0011783243,0.0005110831],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030312126,0.00019665141,0.0014058059,0.00018715003,0.0004091382,0.000021040472,0.0005942559,0.0005724635,0.0006565587],"category_scores_gemma":[0.012326219,0.00012454505,0.00043153696,0.00026401473,0.00008850131,0.0004689121,0.00014617066,0.0014316974,0.0004008219],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032890737,0.002412919,0.052285478,0.00007352121,0.00026340867,0.000098693796,0.029703451,0.00008216934,0.00003000874,0.0026033872,0.026756892,0.882401],"study_design_scores_gemma":[0.0051937024,0.00764474,0.026070591,0.0016997793,0.00010531351,0.000012996023,0.048882473,0.00004286709,0.000016879638,0.007937492,0.9021981,0.00019506563],"about_ca_topic_score_codex":0.000025677069,"about_ca_topic_score_gemma":0.0016703302,"teacher_disagreement_score":0.8822059,"about_ca_system_score_codex":0.0010204453,"about_ca_system_score_gemma":0.0026627388,"threshold_uncertainty_score":0.9959934},"labels":[],"label_agreement":null},{"id":"W2160863701","doi":"10.1200/jco.2010.31.5028","title":"Reply to D.J. Stewart","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.2478123107896604,"score_gpt":0.46123378653787805,"score_spread":0.21342147574821765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160863701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9412462,0.0000727239,0.000047532412,0.044670958,0.0021186194,0.00015839287,7.57963e-7,0.000009440719,0.011675352],"genre_scores_gemma":[0.9664083,0.000045321383,0.014911141,0.015290769,0.0022319807,0.0000027440465,9.204063e-7,0.000011688694,0.0010971223],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784523,0.00014403442,0.0014678024,0.00013008574,0.00024563132,0.00016718537],"domain_scores_gemma":[0.99721354,0.0009522695,0.0005689376,0.00021426917,0.00036612,0.00068483385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029253226,0.00008651877,0.0009293016,0.00010480892,0.00002375097,0.0000064236096,0.00011242906,0.00026478944,0.00051562255],"category_scores_gemma":[0.004203925,0.000056819474,0.00049610884,0.00011233776,0.000071996554,0.000052294912,0.00003264301,0.0009939015,0.00020894058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014226387,0.000968634,0.7750473,0.0000067115116,0.00017227302,0.0016676098,0.000058509562,8.8289625e-8,0.0014637839,0.000108678396,0.034105152,0.1849786],"study_design_scores_gemma":[0.0027869674,0.011221358,0.22754082,0.000017848746,0.00024059681,0.00060865335,0.00001901376,0.00001734702,0.00078250916,0.00012530354,0.7565895,0.00005007506],"about_ca_topic_score_codex":0.000012821304,"about_ca_topic_score_gemma":0.000015766764,"teacher_disagreement_score":0.72248435,"about_ca_system_score_codex":0.000030773495,"about_ca_system_score_gemma":0.0009325535,"threshold_uncertainty_score":0.5645705},"labels":[],"label_agreement":null},{"id":"W2161107831","doi":"10.1200/jco.2012.45.8661","title":"Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":450,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"American Society of Clinical Oncology","keywords":"Medicine; Febrile neutropenia; Neutropenia; Guideline; Regimen; Internal medicine; Intensive care medicine; Chemotherapy","score_opus":0.1011847216422177,"score_gpt":0.4924941369195078,"score_spread":0.3913094152772901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161107831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813067,0.00025161327,0.00022683405,0.01501862,0.000935043,0.0013325219,0.000013907071,0.000006790445,0.00090800214],"genre_scores_gemma":[0.9003961,0.009388698,0.08295328,0.0063000866,0.0007464745,0.00003248203,0.000005942311,0.000027977823,0.00014892292],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9899221,0.001078443,0.007978238,0.00043700263,0.00028008927,0.0003041293],"domain_scores_gemma":[0.98770595,0.0041921237,0.005801879,0.00027126467,0.0015998912,0.00042891584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067699077,0.00021557401,0.0032359022,0.00011661206,0.00003807041,0.00000792824,0.00016496108,0.0005815068,0.000050321592],"category_scores_gemma":[0.0024915296,0.00015557253,0.0007994733,0.0002595904,0.0011307424,0.00020668449,0.00016627922,0.0012306615,0.0000031848995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016712463,0.00784241,0.35422578,0.00031401377,0.0011015616,0.00013130775,0.00012574744,0.000007344671,0.00017157928,0.00007639358,0.030807095,0.5884843],"study_design_scores_gemma":[0.03349128,0.071764275,0.71364397,0.0004761186,0.0011943294,0.0002659021,0.0007426339,0.0002055741,0.00006962321,0.00006430003,0.17790517,0.00017681549],"about_ca_topic_score_codex":0.0003776275,"about_ca_topic_score_gemma":0.000082597064,"teacher_disagreement_score":0.5883075,"about_ca_system_score_codex":0.000106631625,"about_ca_system_score_gemma":0.0010875817,"threshold_uncertainty_score":0.6344064},"labels":[],"label_agreement":null},{"id":"W2161118624","doi":"10.1200/jco.2001.19.15.3490","title":"Screening Sensitivity and Sojourn Time From Breast Cancer Early Detection Clinical Trials: Mammograms and Physical Examinations","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Cancer; Mammography; Clinical trial; Oncology; Radiology; Gynecology; Internal medicine","score_opus":0.3825598002486553,"score_gpt":0.556551499758299,"score_spread":0.17399169950964366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161118624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969126,0.00047119148,0.0034060879,0.0054211915,0.0005828437,0.0001633581,0.000019000356,0.000015722782,0.00022936576],"genre_scores_gemma":[0.9898289,0.0015223698,0.002127796,0.0011722384,0.005267164,0.0000024114586,0.0000020798852,0.000014295029,0.00006277419],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943054,0.002328696,0.00241136,0.00029318716,0.00041539743,0.0002459837],"domain_scores_gemma":[0.98792523,0.009012071,0.0018248487,0.00013324637,0.00046836864,0.0006362253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014251168,0.0001622442,0.0020910844,0.000095906726,0.00010351335,0.000038024442,0.00006524616,0.00043683496,0.000072171475],"category_scores_gemma":[0.0072049988,0.00011881371,0.000507225,0.00016277903,0.00037729935,0.0003004514,0.00006666779,0.0014556082,0.000006894065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032774603,0.0002919224,0.3176451,0.000003021949,0.00028528838,0.00046439236,0.00006342706,0.0000034789307,0.0007236404,0.000003561749,0.00021942909,0.67701924],"study_design_scores_gemma":[0.005936195,0.0041812407,0.9771612,0.0002032243,0.0010209488,0.0019581877,0.00016727214,0.004507951,0.000026857182,0.00023400997,0.0044847666,0.00011812296],"about_ca_topic_score_codex":0.00069683394,"about_ca_topic_score_gemma":0.00038096038,"teacher_disagreement_score":0.67690116,"about_ca_system_score_codex":0.000077033124,"about_ca_system_score_gemma":0.0004142191,"threshold_uncertainty_score":0.8625577},"labels":[],"label_agreement":null},{"id":"W2161395451","doi":"10.1200/jco.2014.55.9070","title":"Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Neoadjuvant therapy; Lymphovascular invasion; Esophagectomy; Esophagogastric junction; Adenocarcinoma; Esophageal cancer; Esophagus; Resection margin; Internal medicine; Oncology; Proportional hazards model; T-stage; Hazard ratio; Cancer; Surgery; Metastasis; Resection; Confidence interval","score_opus":0.07944163182131575,"score_gpt":0.41997475031418313,"score_spread":0.3405331184928674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161395451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063415,0.0144980205,0.00021907731,0.003114183,0.0011176007,0.0003733331,0.000010157617,0.0000043414375,0.00002911971],"genre_scores_gemma":[0.9960256,0.00033833695,0.00073126156,0.0012886877,0.0012311584,0.000033080454,9.0648587e-7,0.000020364949,0.00033060217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973884,0.0003937813,0.0013854767,0.00019025114,0.0003834953,0.0002585805],"domain_scores_gemma":[0.9952019,0.0029263988,0.0009662279,0.0002214184,0.0003769562,0.00030714064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025965518,0.0001488064,0.0012346493,0.00012415592,0.000033147462,0.000008752475,0.0000996612,0.00015378572,0.00010286959],"category_scores_gemma":[0.0019320756,0.00008190025,0.0006347638,0.00011668449,0.0002634683,0.000080372054,0.00004384651,0.0003937419,0.0000020422194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016623395,0.0005456176,0.90313023,0.000107662636,0.00019920348,0.00030131303,0.000030419964,0.0000010343645,0.000008996244,0.000009964417,0.00031754773,0.07872462],"study_design_scores_gemma":[0.007354318,0.008792538,0.9807149,0.0000811206,0.00023162598,0.0002209399,0.00002147946,0.000057283312,0.00047045056,0.00014438677,0.001855442,0.00005547384],"about_ca_topic_score_codex":0.000020593581,"about_ca_topic_score_gemma":0.000040490504,"teacher_disagreement_score":0.078669146,"about_ca_system_score_codex":0.000089926325,"about_ca_system_score_gemma":0.0009014374,"threshold_uncertainty_score":0.33397952},"labels":[],"label_agreement":null},{"id":"W2161479848","doi":"10.1200/jco.2014.59.7401","title":"Germline <i>BRCA</i> Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Oncology; Family history; Pancreatic cancer; Genetic testing; Internal medicine; BRCA mutation; Cancer; Cohort; Sanger sequencing; Germline mutation; Breast cancer; Genetic counseling; Ovarian cancer; Adenocarcinoma; Mutation; Genetics; Gene","score_opus":0.11766316755585275,"score_gpt":0.46802045403138004,"score_spread":0.3503572864755273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161479848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241644,0.00030626944,0.00047765183,0.0020157646,0.00025869464,0.00056350103,0.000015859012,0.000006375245,0.0039394354],"genre_scores_gemma":[0.9886266,0.00007737951,0.009482024,0.0012113464,0.00026880665,0.000014205961,0.000025760404,0.000019890811,0.00027400863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99442554,0.0009017653,0.0033271366,0.00021475028,0.0007743183,0.00035649614],"domain_scores_gemma":[0.991081,0.0043388614,0.0019317237,0.0002914923,0.0016991821,0.00065775577],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0075950217,0.00015553439,0.0026676876,0.0003090617,0.000024189272,0.0000036255606,0.000196559,0.00043105733,0.00025218847],"category_scores_gemma":[0.010410606,0.00010180646,0.00029434785,0.00036844987,0.00045723256,0.000094241215,0.000043012595,0.0011390987,0.000031149317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011252569,0.0063840426,0.9784598,0.000049692953,0.00039224108,0.0004912091,0.0001137419,0.000012717176,0.0000021897163,0.000027666603,0.0014880283,0.0013261104],"study_design_scores_gemma":[0.03724043,0.026324434,0.93210846,0.00017076744,0.00095333025,0.000047357877,0.00017704899,0.00047963153,0.0000055240143,0.0001647821,0.002243458,0.00008477768],"about_ca_topic_score_codex":0.000039157432,"about_ca_topic_score_gemma":0.000104731975,"teacher_disagreement_score":0.046351336,"about_ca_system_score_codex":0.00023247203,"about_ca_system_score_gemma":0.0072183073,"threshold_uncertainty_score":0.99840987},"labels":[],"label_agreement":null},{"id":"W2161501889","doi":"10.1200/jco.2009.27.4498","title":"Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":808,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Sanofi","keywords":"Medicine; Radiation therapy; Head and neck cancer; Cancer; Protocol (science); Adverse effect; Stage (stratigraphy); Surgery; Internal medicine","score_opus":0.2689069860913622,"score_gpt":0.6179384109577818,"score_spread":0.3490314248664196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161501889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859916,0.000988501,0.00000525788,0.008648435,0.00020345987,0.003843933,0.000048080798,0.0000018702008,0.00026886884],"genre_scores_gemma":[0.9926103,0.0029845168,0.0030079356,0.0004135273,0.0004990888,0.0004657169,6.165109e-7,0.00000667483,0.000011628998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713063,0.00040159255,0.0019397241,0.00016553131,0.00020113312,0.00016136645],"domain_scores_gemma":[0.99336576,0.0051825205,0.00085931836,0.00018267731,0.00023954184,0.0001701499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015528196,0.00012149622,0.0018149553,0.000039994622,0.000025592904,0.0000035431847,0.00008124045,0.00018093683,0.0000284249],"category_scores_gemma":[0.0021926123,0.000061832834,0.00023810053,0.000074483556,0.0005800226,0.00005596692,0.000010900676,0.0004921813,1.3242222e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05354221,0.004761672,0.528985,0.000095759715,0.00038372228,0.000075829776,0.002255635,0.000003944507,0.005601153,0.00008700042,0.00032535597,0.40388268],"study_design_scores_gemma":[0.031118948,0.043395557,0.91323197,0.0002404752,0.00007165429,0.00003093594,0.00012633823,0.00003796515,0.00021756142,0.00023316315,0.011243493,0.00005191157],"about_ca_topic_score_codex":0.0009722289,"about_ca_topic_score_gemma":0.0015588765,"teacher_disagreement_score":0.40383077,"about_ca_system_score_codex":0.000093246985,"about_ca_system_score_gemma":0.0006860398,"threshold_uncertainty_score":0.262492},"labels":[],"label_agreement":null},{"id":"W2161574596","doi":"10.1200/jco.2006.07.0250","title":"Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Brain metastasis; Oncology; Internal medicine; Univariate analysis; Hazard ratio; Cancer; Proportional hazards model; Cohort; Risk factor; Metastasis; Multivariate analysis; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.090147832628851,"score_gpt":0.4303173565525126,"score_spread":0.34016952392366157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161574596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795686,0.00076083257,0.0028368088,0.015244968,0.00041839213,0.0008484083,0.00026100836,0.0000046898604,0.000056314264],"genre_scores_gemma":[0.97763014,0.00006191846,0.02082274,0.00066674437,0.0006294015,0.00009264476,0.0000091919055,0.000019405617,0.00006781778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959883,0.00053110183,0.002643271,0.00019919037,0.0003775683,0.00026053787],"domain_scores_gemma":[0.98743486,0.009262111,0.0022189608,0.00016533885,0.0007376042,0.000181105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002870331,0.00018322386,0.001534024,0.000082714396,0.00006387397,0.0000054717525,0.00015339337,0.00017084049,0.0003342477],"category_scores_gemma":[0.0016562442,0.000103243714,0.00068668055,0.00012882266,0.00029736353,0.00007296025,0.000038584447,0.0003550695,0.0000015116872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009482195,0.008404083,0.57234496,0.00035416434,0.0032039543,0.00019106074,0.00032920475,0.000027205078,0.0044392045,0.00026254423,0.006004865,0.3949566],"study_design_scores_gemma":[0.007169819,0.0045613544,0.9783387,0.00014834011,0.00108121,0.000051185176,0.000071786555,0.000009428517,0.004008274,0.00015473433,0.004308412,0.00009673992],"about_ca_topic_score_codex":0.00019569448,"about_ca_topic_score_gemma":0.00043514944,"teacher_disagreement_score":0.40599376,"about_ca_system_score_codex":0.00014900728,"about_ca_system_score_gemma":0.001521164,"threshold_uncertainty_score":0.42101565},"labels":[],"label_agreement":null},{"id":"W2161612574","doi":"10.1200/jco.2004.00.7542","title":"Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":448,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Internal medicine; Randomized controlled trial; Radiation therapy; Cisplatin; Oncology; Chemoradiotherapy; Chemotherapy; Fluorouracil; Gastroenterology; Urology","score_opus":0.11770559651297519,"score_gpt":0.46706817166567327,"score_spread":0.3493625751526981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161612574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516716,0.013355753,0.000057384375,0.025541887,0.0022318987,0.0068024555,0.000055489963,0.000015374746,0.0002681703],"genre_scores_gemma":[0.9898099,0.0024484838,0.00011735792,0.003771574,0.002913861,0.0004830613,0.000008945084,0.000047549296,0.00039927135],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911157,0.002273306,0.004778871,0.00051961513,0.0008526697,0.00045984602],"domain_scores_gemma":[0.9818376,0.013465804,0.0034020946,0.00037240994,0.0006245565,0.0002975807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010823507,0.0004011251,0.0050120964,0.0001155423,0.00016346945,0.000012200301,0.00042046054,0.00027720918,0.0000308042],"category_scores_gemma":[0.0024986167,0.0002259998,0.0012397772,0.00018488208,0.0005115802,0.000117845564,0.000064888416,0.0012352507,0.0000014802482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7887962,0.018932736,0.0019786623,0.000025788575,0.0022474336,0.000047233494,0.0021806115,0.000009214504,0.00017055684,0.000011512487,0.03042537,0.1551747],"study_design_scores_gemma":[0.7989147,0.16886806,0.012316899,0.00012391641,0.0015512989,0.000021111138,0.0017246886,0.00016334653,0.000114698974,0.000029786297,0.015993018,0.0001785048],"about_ca_topic_score_codex":0.000073193936,"about_ca_topic_score_gemma":0.00011725691,"teacher_disagreement_score":0.15499619,"about_ca_system_score_codex":0.000325162,"about_ca_system_score_gemma":0.0010140784,"threshold_uncertainty_score":0.92160046},"labels":[],"label_agreement":null},{"id":"W2161664263","doi":"10.1200/jco.2006.08.1935","title":"Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Surrogate endpoint; Internal medicine; Hazard ratio; Colorectal cancer; Oncology; Randomized controlled trial; Progression-free survival; Proportional hazards model; Clinical endpoint; Population; Chemotherapy; Cancer; Confidence interval; Surgery","score_opus":0.21302436686318926,"score_gpt":0.5334961922847858,"score_spread":0.3204718254215966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161664263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064996323,0.981919,0.0002974667,0.0025619739,0.002375025,0.0053677857,0.0008252991,0.0000072515413,0.00014655944],"genre_scores_gemma":[0.004460642,0.98986083,0.0028708102,0.00042739275,0.0015617464,0.0004308372,0.00025842557,0.00005096326,0.000078373916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9760242,0.0060236757,0.016245693,0.00049827556,0.0007736031,0.00043455116],"domain_scores_gemma":[0.84874314,0.13370137,0.01588521,0.0002278042,0.0010918659,0.0003506327],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.043392614,0.0007128843,0.06840818,0.0013150364,0.000041631538,0.000021368054,0.00027861987,0.0009242506,0.0005458934],"category_scores_gemma":[0.03810213,0.00036572924,0.01960921,0.00085037906,0.00039696533,0.000056932822,0.00003285708,0.0012326412,8.1964396e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50697786,0.0019019274,0.00079248525,0.0012412559,0.07391882,0.00032539788,0.00010833829,0.000012830708,2.9780287e-7,0.000008617473,0.000107749,0.41460443],"study_design_scores_gemma":[0.6976409,0.00705968,0.0006638183,0.0063966536,0.12357852,0.0000118152,0.000018027189,0.00025489635,0.0000035133914,0.00029107663,0.16381484,0.00026628637],"about_ca_topic_score_codex":0.00043124976,"about_ca_topic_score_gemma":0.0048825955,"teacher_disagreement_score":0.41433814,"about_ca_system_score_codex":0.00068522093,"about_ca_system_score_gemma":0.0043024146,"threshold_uncertainty_score":0.9998795},"labels":[],"label_agreement":null},{"id":"W2161672937","doi":"10.1200/jco.2002.20.24.4611","title":"Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Citation; Breast cancer; Clinical Oncology; Paradigm shift; Oncology; Adjuvant; Cancer; Internal medicine; Family medicine; Gerontology; Library science","score_opus":0.06970489147845542,"score_gpt":0.39403780888381634,"score_spread":0.3243329174053609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161672937","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016428981,0.003430547,0.0005022302,0.9754691,0.0012780154,0.0011606818,0.0014458195,0.000008507147,0.00027610027],"genre_scores_gemma":[0.019508107,0.008061346,0.0022711987,0.9281198,0.0363139,0.00093462114,0.0001407406,0.0002517975,0.00439849],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967771,0.00021059415,0.0015459207,0.0005511046,0.0002917725,0.00062349415],"domain_scores_gemma":[0.9960848,0.0006948787,0.0023495378,0.00035572302,0.0003719598,0.00014309317],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00082938187,0.00046280876,0.0019926839,0.00006904652,0.00008655888,0.000021111202,0.0004602167,0.0014062658,0.00041453942],"category_scores_gemma":[0.000097423814,0.00030296674,0.00053553766,0.00005282668,0.00029694918,0.000009496733,0.000053715383,0.00079567573,0.0000088953775],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014043786,0.0005700501,0.0014484713,0.000055916145,0.004370501,0.00006161149,0.00012125467,0.000005170112,0.00007031801,0.0000016006798,0.9437821,0.03546922],"study_design_scores_gemma":[0.011468701,0.019695492,0.0072149877,0.00008951873,0.00044265573,0.00017496014,0.0000112185635,0.0000044239887,0.00007594616,0.00020768984,0.960262,0.00035242992],"about_ca_topic_score_codex":0.000017924187,"about_ca_topic_score_gemma":0.000025771293,"teacher_disagreement_score":0.04734932,"about_ca_system_score_codex":0.00023235199,"about_ca_system_score_gemma":0.0012622343,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W2161697947","doi":"10.1200/jco.2009.25.0712","title":"Screening for Founder Mutations in <i>BRCA1</i> and <i>BRCA2</i> in Unselected Jewish Women","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; BRCA mutation; Genetic testing; Family history; Population; Genetic counseling; Christian ministry; Cancer; Gynecology; Demography; Family medicine; Breast cancer; Internal medicine; Genetics; Environmental health","score_opus":0.0683974024698686,"score_gpt":0.42752078961890727,"score_spread":0.3591233871490387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161697947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98902273,0.0010542555,0.005628403,0.0032547128,0.00032451138,0.0001981327,0.0000049698606,0.0000027627282,0.0005095095],"genre_scores_gemma":[0.97933203,0.00027927582,0.016313793,0.0034880158,0.0004733393,0.000016632886,0.0000121842495,0.000011116487,0.00007361989],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979372,0.00021603513,0.0012821216,0.0002115071,0.000102293685,0.00025083634],"domain_scores_gemma":[0.99853265,0.00047765468,0.00055123994,0.00011330686,0.00020250629,0.00012264185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002029982,0.000100317506,0.00049178663,0.00012719886,0.00002985066,0.000012982724,0.00015032379,0.00033803846,0.000007776662],"category_scores_gemma":[0.0017784652,0.0000948129,0.000111791975,0.00018447827,0.0001076755,0.000012617074,0.000023986358,0.00035590367,4.4525504e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047194143,0.0017378998,0.06875225,0.000026093696,0.00031549134,0.00009949168,0.0008534516,0.003406302,0.025890535,0.00042285875,0.009457168,0.88431907],"study_design_scores_gemma":[0.03035608,0.022229824,0.64298844,0.00010398253,0.00011126184,0.00035164464,0.0010150964,0.0010112999,0.0034214817,0.028275447,0.2695464,0.0005890329],"about_ca_topic_score_codex":0.0000035489486,"about_ca_topic_score_gemma":0.00021417078,"teacher_disagreement_score":0.88373,"about_ca_system_score_codex":0.00013177963,"about_ca_system_score_gemma":0.0009289152,"threshold_uncertainty_score":0.38663578},"labels":[],"label_agreement":null},{"id":"W2161799794","doi":"10.1200/jco.2007.11.9529","title":"Aromatase Inhibitors and Arthralgias: A New Frontier in Symptom Management for Breast Cancer Survivors","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Aromatase; Internal medicine; Tamoxifen; Cancer; Adjuvant therapy; Oncology; Osteoporosis; Aromatase inhibitor; Gynecology","score_opus":0.0794309878059873,"score_gpt":0.4553437313056401,"score_spread":0.3759127434996528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161799794","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.068885416,0.0038155795,0.000097317876,0.91959494,0.005545025,0.0012850292,0.00014714082,0.000011264508,0.0006182701],"genre_scores_gemma":[0.0052553965,0.009172271,0.008770288,0.9564737,0.013974573,0.00004616713,0.000095907824,0.00009629067,0.006115382],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954984,0.0002163872,0.0030159333,0.0003436847,0.00039983873,0.0005257493],"domain_scores_gemma":[0.995789,0.0013042946,0.001917029,0.00020760644,0.0001671066,0.0006149548],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0020827996,0.00029007328,0.0024805039,0.00043979674,0.000029869963,0.000009784958,0.000111385045,0.0015885967,0.000098972814],"category_scores_gemma":[0.00024688267,0.00020840688,0.00047311708,0.00012859987,0.0001306826,0.0000748999,0.00004730363,0.0025413288,0.000008397654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032666298,0.00046598795,0.06365573,0.0003354336,0.0005937279,0.0056433277,0.000028276287,4.3745388e-7,7.5424225e-8,0.0000023344423,0.69387394,0.23213412],"study_design_scores_gemma":[0.014748517,0.002832693,0.2198214,0.00078607764,0.00084030954,0.0006561758,0.00002508532,0.000004500313,5.193613e-7,0.00022407247,0.75992876,0.00013189492],"about_ca_topic_score_codex":0.0008732178,"about_ca_topic_score_gemma":0.0013110412,"teacher_disagreement_score":0.23200223,"about_ca_system_score_codex":0.00038899426,"about_ca_system_score_gemma":0.0017269915,"threshold_uncertainty_score":0.99975985},"labels":[],"label_agreement":null},{"id":"W2161891567","doi":"10.1200/jco.2013.51.4265","title":"Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Medicine; Tirapazamine; Cisplatin; Gynecologic oncology; Urology; Cervical carcinoma; Stage (stratigraphy); Cervical cancer; Oncology; Chemotherapy; Internal medicine; Cancer; In vitro","score_opus":0.09783166404539811,"score_gpt":0.44375628296523045,"score_spread":0.34592461891983234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161891567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98843664,0.0010739075,0.000051458086,0.0070512565,0.00086278765,0.0021809877,0.00000814694,0.0000073562046,0.00032743323],"genre_scores_gemma":[0.99638325,0.0012422003,0.00068242854,0.00079021516,0.0007845635,0.000059428425,0.000008248126,0.000015414975,0.000034275407],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99347156,0.0026140062,0.002839248,0.0003998421,0.00039619967,0.00027915114],"domain_scores_gemma":[0.974563,0.022891594,0.0016896242,0.00018396799,0.00020960771,0.0004622237],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008321486,0.00025563512,0.0030669465,0.00039966745,0.000085948304,0.000022620947,0.000112068934,0.00045032566,0.000045969504],"category_scores_gemma":[0.014911904,0.00015569896,0.00019095383,0.0003739345,0.00038207587,0.00012704142,0.000120657554,0.00073683995,9.960959e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7225841,0.004570033,0.029090151,0.000038857666,0.00037501226,0.000084434614,0.0008791081,0.000003990322,0.00007892116,0.00009963169,0.00005779624,0.24213795],"study_design_scores_gemma":[0.56556493,0.09484496,0.336574,0.000024164194,0.0008281521,0.00003597362,0.00047460478,0.0007094263,0.000002567614,0.00016191498,0.00069584564,0.00008348785],"about_ca_topic_score_codex":0.00021031109,"about_ca_topic_score_gemma":0.0006579277,"teacher_disagreement_score":0.30748382,"about_ca_system_score_codex":0.00015974737,"about_ca_system_score_gemma":0.00029250266,"threshold_uncertainty_score":0.9933859},"labels":[],"label_agreement":null},{"id":"W2161938647","doi":"10.1200/jco.2014.58.3518","title":"Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Minimal residual disease; Internal medicine; Oncology; Myeloid leukemia; Bone marrow; Myeloid; Complete response; Leukemia; Refractory (planetary science); Immunology; Chemotherapy","score_opus":0.1883688330891963,"score_gpt":0.5171872309117762,"score_spread":0.32881839782257993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161938647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868116,0.00040903306,0.000015595155,0.011750378,0.00037122742,0.00040697335,0.000016849452,0.0000075487064,0.00021081649],"genre_scores_gemma":[0.99611974,0.0005973242,0.0015340502,0.00080717064,0.00070400105,0.000003793214,0.0000044043136,0.000025304864,0.00020418887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915778,0.0029407956,0.004242815,0.00033264994,0.0005641009,0.0003418638],"domain_scores_gemma":[0.9769296,0.018844191,0.001800179,0.00030510747,0.00055257865,0.0015683646],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022390805,0.00021914979,0.0022261473,0.00039077952,0.000025604091,0.000011800044,0.00018151883,0.00062804826,0.000018715407],"category_scores_gemma":[0.07406512,0.00013116591,0.00038435514,0.00022378987,0.00073630403,0.00018111039,0.00016020752,0.0024435937,0.000008032887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18485585,0.00069770915,0.79029256,0.00002699476,0.00030772478,0.0016818595,0.00019093795,0.000019370797,0.00011914498,0.000022392807,0.002315283,0.01947016],"study_design_scores_gemma":[0.018533396,0.03408454,0.94361013,0.00017159246,0.0003174698,0.000417784,0.0001871643,0.0008908248,0.000014124635,0.00037352013,0.0012960045,0.000103455255],"about_ca_topic_score_codex":0.00002188474,"about_ca_topic_score_gemma":0.000009903266,"teacher_disagreement_score":0.16632245,"about_ca_system_score_codex":0.00058791897,"about_ca_system_score_gemma":0.009587015,"threshold_uncertainty_score":0.9998578},"labels":[],"label_agreement":null},{"id":"W2161995947","doi":"10.1200/jco.2009.24.2396","title":"Early Salvage Radiotherapy After Radical Prostatectomy","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Salvage therapy; Salvage surgery; Urology; Surgery; Cancer; Internal medicine; Chemotherapy","score_opus":0.06478940767158416,"score_gpt":0.4345690729198919,"score_spread":0.36977966524830774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161995947","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07605032,0.010781818,0.000055914617,0.9075351,0.0029336754,0.0008235677,0.000028078619,0.000026204461,0.0017653559],"genre_scores_gemma":[0.014844319,0.013422014,0.0055048945,0.9349126,0.029613316,0.00004928069,0.00002988572,0.00009109221,0.00153257],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938156,0.00067825534,0.003651627,0.00044960534,0.0008394302,0.0005654528],"domain_scores_gemma":[0.9939594,0.0018347701,0.0027726684,0.00043879868,0.00045605426,0.00053829426],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001845732,0.000442793,0.0039630854,0.00026615552,0.000031852724,0.000032529657,0.00026975662,0.002505841,0.00063929695],"category_scores_gemma":[0.00067921577,0.0002862215,0.001795927,0.00014410769,0.00040970143,0.000112713795,0.000031836673,0.0068849167,0.0000582961],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004789714,0.0013670379,0.012209473,0.000084227126,0.0013743741,0.053628433,0.000050926014,3.3923186e-7,0.0000042148345,0.000003484637,0.76876223,0.15772554],"study_design_scores_gemma":[0.011752921,0.034033652,0.12959248,0.00051549566,0.0009940009,0.0011858797,0.0000023493085,0.0000016587343,0.00001616065,0.00027265953,0.821428,0.00020474815],"about_ca_topic_score_codex":0.000011556175,"about_ca_topic_score_gemma":0.0000017332839,"teacher_disagreement_score":0.1575208,"about_ca_system_score_codex":0.0007745537,"about_ca_system_score_gemma":0.00326893,"threshold_uncertainty_score":0.999959},"labels":[],"label_agreement":null},{"id":"W2162037713","doi":"10.1200/jco.2006.09.9515","title":"Advances in Image-Guided Radiation Therapy","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":416,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Image-guided radiation therapy; Medicine; Radiation therapy; Radiation treatment planning; Medical physics; Medical imaging; Population; Radiology; Nuclear medicine","score_opus":0.1767025187560949,"score_gpt":0.5806919309106168,"score_spread":0.4039894121545219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162037713","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008110595,0.96946186,0.022506468,0.00006565843,0.0010153408,0.0003515091,0.0000049347705,0.0000112945345,0.006574815],"genre_scores_gemma":[0.000006990689,0.9695386,0.026747635,0.00014668044,0.003431403,0.000013222249,0.0000073639903,0.00004328352,0.000064791646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939368,0.00079073966,0.0045433724,0.00023070359,0.00022982949,0.00026857652],"domain_scores_gemma":[0.99035627,0.003164519,0.0059254467,0.00021774095,0.00018527216,0.00015075455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039826115,0.00029526377,0.0041541755,0.0003291343,0.000022764947,0.00001265423,0.0004519662,0.00051775045,0.00028376927],"category_scores_gemma":[0.0002513383,0.00020306792,0.0013412051,0.00027755392,0.000121661724,0.00037015232,0.000024929268,0.0019193408,0.0000066489856],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006592337,0.00042635098,0.0004350472,0.00012936637,0.0001260781,0.000040201292,0.000009541528,0.0000017360923,2.1828363e-7,0.00037817625,0.00085583335,0.99753153],"study_design_scores_gemma":[0.0013282766,0.0011497735,0.0000515566,0.0009483472,0.000085433974,0.000024546467,0.0000048273046,0.0000023402938,0.0000019777162,0.0019989964,0.99422246,0.0001814563],"about_ca_topic_score_codex":0.0000059002937,"about_ca_topic_score_gemma":0.0000015533908,"teacher_disagreement_score":0.9973501,"about_ca_system_score_codex":0.0002074198,"about_ca_system_score_gemma":0.0013974956,"threshold_uncertainty_score":0.83386874},"labels":[],"label_agreement":null},{"id":"W2162339522","doi":"10.1200/jco.2007.10.9298","title":"Topotecan Is Active Against Wilms’ Tumor: Results of a Multi-Institutional Phase II Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Topotecan; Wilms' tumor; Wilms tumour; Oncology; Internal medicine; Cancer research; Chemotherapy","score_opus":0.07067044566039024,"score_gpt":0.45800256967178943,"score_spread":0.38733212401139916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162339522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945014,0.00031655148,0.00046989473,0.00056086126,0.0010350572,0.0001519296,0.000028149669,0.0000023240655,0.0029338493],"genre_scores_gemma":[0.9963966,0.00033962436,0.0010417905,0.0010573869,0.0008535643,0.0000011156876,0.0000074125587,0.000008261889,0.0002942485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712074,0.0001917599,0.0019973854,0.000224895,0.000260072,0.00020514865],"domain_scores_gemma":[0.99728966,0.00017988474,0.0016714926,0.00017479231,0.00044535077,0.00023883287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002605833,0.00013455088,0.00066840515,0.000080168924,0.00007893352,0.0000029651449,0.0002533071,0.00035452726,0.000011176658],"category_scores_gemma":[0.0014162011,0.000091921196,0.00042946253,0.00010936286,0.00032346288,0.00000795258,0.00009854741,0.0006040047,0.000002372019],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055899996,0.022896556,0.0027133957,0.000022005166,0.0021998277,0.001619903,0.0007984394,0.00065471104,0.13564976,0.000026887543,0.00743316,0.77008533],"study_design_scores_gemma":[0.11670945,0.18996266,0.033511583,0.00015320047,0.0006181324,0.00063566596,0.0026670357,0.00024259748,0.18421891,0.0001103475,0.47055003,0.0006203994],"about_ca_topic_score_codex":0.000020885236,"about_ca_topic_score_gemma":0.00007871055,"teacher_disagreement_score":0.76946497,"about_ca_system_score_codex":0.000059688984,"about_ca_system_score_gemma":0.0012388028,"threshold_uncertainty_score":0.37484375},"labels":[],"label_agreement":null},{"id":"W2162479033","doi":"10.1200/jco.2008.20.0725","title":"Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; Mount Sinai Hospital","funders":"","keywords":"Medicine; Vitamin D and neurology; Breast cancer; Hazard ratio; Internal medicine; vitamin D deficiency; Prospective cohort study; Calcitriol receptor; Cancer; Cohort; Vitamin; Proportional hazards model; Oncology; Gastroenterology; Endocrinology; Confidence interval","score_opus":0.09360390896365003,"score_gpt":0.49335817801247367,"score_spread":0.3997542690488236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162479033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832545,0.001199426,0.000024067658,0.01386394,0.0005495326,0.00032866152,0.000003834812,0.000005172202,0.0007708545],"genre_scores_gemma":[0.9966836,0.00087552646,0.0005801563,0.0008305338,0.00078196696,0.000005833458,2.0685889e-7,0.000009875925,0.00023230126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964666,0.0004935711,0.001999382,0.00016410758,0.0005397038,0.00033668813],"domain_scores_gemma":[0.9933861,0.004534107,0.0010253545,0.00015401347,0.0005829928,0.00031744965],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002766177,0.00013196238,0.0017719548,0.0002497717,0.000019482308,0.00000385968,0.00019014505,0.0002992072,0.00004087429],"category_scores_gemma":[0.012282611,0.000087139844,0.0003456441,0.0002877322,0.0002995948,0.00010068855,0.000054052856,0.0012411644,0.000008121269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048287178,0.002847327,0.79420793,0.00016798031,0.00028766194,0.0023145035,0.0002402064,0.000006729687,0.0018530348,0.000039536273,0.0017131905,0.195839],"study_design_scores_gemma":[0.008163621,0.017555637,0.97165805,0.0008361823,0.00019659371,0.00028556224,0.00003680829,0.000025829757,0.00024849677,0.00030953204,0.00061470806,0.00006895662],"about_ca_topic_score_codex":0.000039945702,"about_ca_topic_score_gemma":0.000043547072,"teacher_disagreement_score":0.19577006,"about_ca_system_score_codex":0.00017732546,"about_ca_system_score_gemma":0.0013252618,"threshold_uncertainty_score":0.99603736},"labels":[],"label_agreement":null},{"id":"W2162557472","doi":"10.1200/jco.2003.05.024","title":"Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":299,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cytarabine; Carmustine; Chemotherapy; Etoposide; Melphalan; Surgery; Transplantation; Induction chemotherapy; Internal medicine; Autologous stem-cell transplantation; Oncology","score_opus":0.02621191449198174,"score_gpt":0.34311092684310324,"score_spread":0.3168990123511215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162557472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561596,0.0004942564,0.00016710369,0.0026663558,0.00015968591,0.0006656111,0.00001564317,0.000013903171,0.0002014827],"genre_scores_gemma":[0.9840697,0.0007625369,0.009388188,0.005460358,0.00005853034,0.000026307778,0.00003299212,0.000045447967,0.00015592542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958406,0.0008418402,0.0018780973,0.00054967555,0.00047401252,0.00041577863],"domain_scores_gemma":[0.99513197,0.0016042975,0.001156836,0.00040571622,0.0009016267,0.0007995356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013526377,0.00037632894,0.0030870629,0.00048636665,0.000048878002,0.000022643228,0.00014905319,0.000342026,0.000044751698],"category_scores_gemma":[0.0005528817,0.00022109777,0.00034328422,0.0007311539,0.00022521087,0.00015905578,0.000035219404,0.00038323025,0.000004482079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020416945,0.011314046,0.8017257,0.00001917161,0.0018331667,0.0020714798,0.0002818401,0.00008111956,0.00007177735,0.000008495294,0.0009851257,0.16119112],"study_design_scores_gemma":[0.07859423,0.04160955,0.8740524,0.0000993168,0.0029829105,0.000108906715,0.0002904574,0.000023332635,0.000290118,0.0000105533645,0.0017248458,0.00021338552],"about_ca_topic_score_codex":0.00034640287,"about_ca_topic_score_gemma":0.00043448588,"teacher_disagreement_score":0.16097774,"about_ca_system_score_codex":0.0006151725,"about_ca_system_score_gemma":0.00090619206,"threshold_uncertainty_score":0.9016105},"labels":[],"label_agreement":null},{"id":"W2162605078","doi":"10.1200/jco.2004.06.082","title":"Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":895,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Randomization; Quality of life (healthcare); Internal medicine; Wilcoxon signed-rank test; Glioblastoma; Clinical endpoint; Randomized controlled trial; Survival analysis; Surgery; Prospective cohort study; Mann–Whitney U test","score_opus":0.04764455615456314,"score_gpt":0.4428320914777188,"score_spread":0.39518753532315565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162605078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946068,0.00036720277,0.00004543316,0.0017516984,0.00078824884,0.0023431368,0.0000040707373,0.000006041615,0.00008738181],"genre_scores_gemma":[0.99721754,0.0011122199,0.00072022504,0.00043399583,0.00044794052,0.000042382486,0.000005276129,0.000016800941,0.0000036446459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940295,0.0010025973,0.004144452,0.00021400063,0.00041388773,0.000195555],"domain_scores_gemma":[0.99086344,0.0044199377,0.0035270245,0.00017061022,0.0007607966,0.00025819778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057534883,0.00018103125,0.0033432797,0.00017780434,0.000018962048,0.0000053045765,0.000093634124,0.0003987755,0.000052150765],"category_scores_gemma":[0.0052900813,0.0000953875,0.0008859016,0.0002501283,0.00034343265,0.00011129928,0.000014440843,0.0006714412,0.000004398133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5461571,0.024534253,0.34124795,0.000005218936,0.00074820576,0.000104523555,0.00010712781,0.00002032847,0.0000019558004,0.00002425873,0.000054796597,0.08699428],"study_design_scores_gemma":[0.5099235,0.039435096,0.44985464,0.00011776489,0.0002688116,0.000010145174,0.000018768584,0.000012989234,0.00009275085,0.000103315724,0.00011747712,0.000044691064],"about_ca_topic_score_codex":0.000022310784,"about_ca_topic_score_gemma":0.000054402874,"teacher_disagreement_score":0.10860669,"about_ca_system_score_codex":0.00020251633,"about_ca_system_score_gemma":0.0015800105,"threshold_uncertainty_score":0.6333104},"labels":[],"label_agreement":null},{"id":"W2162723956","doi":"10.1200/jco.2013.52.6863","title":"Prevalence and Functional Consequence of <i>TP53</i> Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"National Cancer Institute; Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Adrenocortical carcinoma; Medicine; Oncology; Internal medicine; Pediatric oncology; Carcinoma; Cancer","score_opus":0.1108907264178765,"score_gpt":0.41814089917920855,"score_spread":0.30725017276133204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162723956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946284,0.0016098218,0.00029059767,0.0014876999,0.00081580016,0.0005493095,0.00000682018,0.00000744088,0.0006040946],"genre_scores_gemma":[0.9966918,0.00040833576,0.0017948778,0.00043214508,0.0006200445,0.000012617599,0.000002993454,0.000014296731,0.000022891585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561286,0.00085241196,0.0025336104,0.00027604974,0.0004959898,0.00022908776],"domain_scores_gemma":[0.9953863,0.001887731,0.0013646189,0.00018757921,0.00063368963,0.00054008607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035527444,0.00014278712,0.0012613303,0.00029134247,0.000021941501,0.000004043878,0.00012201305,0.00039685878,0.000038807295],"category_scores_gemma":[0.006803101,0.000118204436,0.00020269827,0.00033880648,0.0004834069,0.0000979859,0.000087909866,0.0013211113,0.000005932292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003601369,0.005012899,0.9812458,0.000037002552,0.0001324429,0.0024666796,0.00023388027,0.00006613574,0.0001562005,0.00008759636,0.0005466709,0.0064132875],"study_design_scores_gemma":[0.01693287,0.033701144,0.9426919,0.0000344753,0.0009783856,0.0046914336,0.00021980504,0.00006628715,0.000015364825,0.00029836065,0.00028068887,0.000089274545],"about_ca_topic_score_codex":0.00005805028,"about_ca_topic_score_gemma":0.00010807842,"teacher_disagreement_score":0.038553923,"about_ca_system_score_codex":0.00030199802,"about_ca_system_score_gemma":0.0051354794,"threshold_uncertainty_score":0.911012},"labels":[],"label_agreement":null},{"id":"W2162786141","doi":"10.1200/jco.2012.43.5750","title":"Positron Emission Tomography Use and Stage Migration in Lung Cancer: A False Sense of Accomplishment?","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Positron emission tomography; Medicine; Lung cancer; Stage (stratigraphy); Nuclear medicine; Positron Emission Tomography-Computed Tomography; Radiology; Medical physics; Oncology","score_opus":0.09077376688521854,"score_gpt":0.45727021644664695,"score_spread":0.3664964495614284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162786141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75393176,0.0057359836,0.0000036391689,0.23886564,0.0009887016,0.00036862036,0.000034750603,0.00000359413,0.00006727312],"genre_scores_gemma":[0.7463897,0.03266396,0.0015286002,0.21170157,0.007021955,0.00003693752,0.000072136594,0.000060483457,0.00052465475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631053,0.00047486994,0.0022997349,0.0002358331,0.00041397518,0.000265059],"domain_scores_gemma":[0.99442494,0.0020058078,0.0027910154,0.00021176749,0.00032704175,0.00023940907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012587471,0.0002280971,0.0020687205,0.0003334867,0.00001864048,0.000014255375,0.000072723364,0.0010796803,0.00007187389],"category_scores_gemma":[0.0004551114,0.00015422002,0.0005280118,0.00013132593,0.000120452176,0.00018772461,0.00004861159,0.001969953,5.191943e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013271436,0.00093526347,0.68362755,0.00036057783,0.00062267756,0.0011222267,0.000100237165,0.0000022365775,0.00004322793,0.0000016504115,0.30363235,0.008224858],"study_design_scores_gemma":[0.006019601,0.0036922991,0.6106036,0.0015047397,0.0016456508,0.00013558616,0.00001832462,0.00002031794,0.00008652748,0.000013438739,0.37614125,0.0001186788],"about_ca_topic_score_codex":0.0006155217,"about_ca_topic_score_gemma":0.00028626653,"teacher_disagreement_score":0.07302396,"about_ca_system_score_codex":0.0005084335,"about_ca_system_score_gemma":0.00085016247,"threshold_uncertainty_score":0.8558576},"labels":[],"label_agreement":null},{"id":"W2162815290","doi":"10.1200/jco.2004.02.166","title":"Treatment Decision Aids in Advanced Cancer: When the Goal Is Not Cure and the Answer Is Not Clear","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decision aids; Cancer; Intensive care medicine; Family medicine; Oncology; Internal medicine; Alternative medicine; Pathology","score_opus":0.261925318343954,"score_gpt":0.5641432574478414,"score_spread":0.30221793910388745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162815290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8983178,0.0045060934,0.000078061465,0.095700584,0.0006030405,0.00019547339,0.000008093697,0.0000024089386,0.00058845745],"genre_scores_gemma":[0.931447,0.046966426,0.0046225553,0.015933119,0.00076928496,0.0000051938996,4.24289e-7,0.000010864668,0.00024510614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977831,0.00024624105,0.0013414746,0.00015294683,0.00031155997,0.00016468187],"domain_scores_gemma":[0.99474573,0.003946803,0.0007430698,0.00018853944,0.00023778106,0.00013808915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013972415,0.00012465894,0.0011602713,0.000057026427,0.000037020603,0.000005720832,0.00014994164,0.00022611911,0.000114774004],"category_scores_gemma":[0.0017408065,0.000053279182,0.00035431643,0.00009483068,0.00039561803,0.0000701203,0.000039803304,0.0006014363,0.0000075907165],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03963265,0.00089883007,0.115134366,0.000016522148,0.000494126,0.0002836903,0.008762437,0.00009780802,0.0001219089,0.00036790463,0.0037969055,0.83039284],"study_design_scores_gemma":[0.05214874,0.019056574,0.13038291,0.00070002826,0.0005461245,0.00010177199,0.0015713758,0.00006844971,0.0012303051,0.0032367143,0.7908512,0.000105835716],"about_ca_topic_score_codex":0.00027450753,"about_ca_topic_score_gemma":0.00031718155,"teacher_disagreement_score":0.83028704,"about_ca_system_score_codex":0.00020863686,"about_ca_system_score_gemma":0.00068438676,"threshold_uncertainty_score":0.2612975},"labels":[],"label_agreement":null},{"id":"W2162827359","doi":"10.1200/jco.2005.06.091","title":"Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":531,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"","keywords":"Medicine; Zoledronic acid; Internal medicine; Bisphosphonate; Bone resorption; Bone remodeling; Multiple myeloma; Creatinine; N-terminal telopeptide; Urology; Oncology; Osteoporosis; Alkaline phosphatase; Osteocalcin","score_opus":0.04317013668209051,"score_gpt":0.4043354095504389,"score_spread":0.3611652728683484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162827359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256635,0.0018670971,0.000067466586,0.0048502767,0.00017362829,0.0003278972,0.000010098344,0.0000028955608,0.00013431505],"genre_scores_gemma":[0.9946563,0.0028869607,0.0015691888,0.00077438814,0.00006213543,0.0000097107395,0.0000043998125,0.000007877135,0.000028994362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976021,0.00033592674,0.001513221,0.00009896999,0.00028344794,0.00016631663],"domain_scores_gemma":[0.9972593,0.0006694826,0.0015764511,0.00008529588,0.00024914287,0.0001603162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002044961,0.0000890354,0.0007375855,0.00010971213,0.000032839347,0.0000027791807,0.00003485672,0.00013435009,0.000026200521],"category_scores_gemma":[0.0006647395,0.000048001348,0.00009211848,0.00013764134,0.00013335411,0.00021972023,0.000019262476,0.0004894042,0.0000011607438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01989315,0.0016260517,0.6091449,0.00005992076,0.00024007203,0.000036208996,0.00027134395,0.00007449955,0.000026072368,0.000011855619,0.0004043845,0.3682115],"study_design_scores_gemma":[0.013707653,0.009517085,0.97251165,0.0003122525,0.00036359028,0.00006733543,0.00007902378,0.0005385179,0.00016316555,0.00005018739,0.0026501243,0.000039439314],"about_ca_topic_score_codex":0.00021562578,"about_ca_topic_score_gemma":0.000997703,"teacher_disagreement_score":0.36817208,"about_ca_system_score_codex":0.00026032707,"about_ca_system_score_gemma":0.0006276164,"threshold_uncertainty_score":0.21262448},"labels":[],"label_agreement":null},{"id":"W2162848902","doi":"10.1200/jco.2005.09.085","title":"Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Radiation therapy; Vinblastine; Internal medicine; Randomized controlled trial; Lymphoma; Surgery; Bleomycin; Cancer; Chemotherapy; Oncology; Vincristine; Cyclophosphamide","score_opus":0.16870968164632547,"score_gpt":0.47590214868908043,"score_spread":0.30719246704275494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162848902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990829,0.0016312092,0.000069179805,0.0053449697,0.00036688798,0.0014032312,0.00001926813,0.0000025957422,0.000333651],"genre_scores_gemma":[0.9914296,0.0051480336,0.00076452247,0.0021332873,0.00039837518,0.00006263551,0.0000149960615,0.000014583387,0.000033932345],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912717,0.003459637,0.00409868,0.00024317815,0.00072781765,0.00019898341],"domain_scores_gemma":[0.9819484,0.0116195185,0.005381975,0.00013614849,0.0007201502,0.0001938238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010661525,0.00023280605,0.0047033164,0.00012640677,0.00004919144,0.000012728841,0.00014236003,0.00031869902,0.000030375322],"category_scores_gemma":[0.0020788836,0.00010610036,0.0003274459,0.00016127004,0.00089460256,0.00021954636,0.00002413544,0.00037165426,1.6310031e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3655764,0.0060684346,0.45299244,0.000010267002,0.0017264775,0.000020322199,0.0003134716,0.00023744951,0.0000015831305,0.00024979818,0.00025698697,0.17254637],"study_design_scores_gemma":[0.50972205,0.014777339,0.46918967,0.00011483918,0.00030902424,0.000010325595,0.00015062488,0.0006007643,0.000039836563,0.000025206433,0.0049860985,0.00007424381],"about_ca_topic_score_codex":0.011077495,"about_ca_topic_score_gemma":0.12686111,"teacher_disagreement_score":0.17247213,"about_ca_system_score_codex":0.000664122,"about_ca_system_score_gemma":0.0072456673,"threshold_uncertainty_score":0.99838233},"labels":[],"label_agreement":null},{"id":"W2163123363","doi":"10.1200/jco.2005.09.133","title":"Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Cytarabine; Gastroenterology; Etoposide; Induction chemotherapy; Mitoxantrone; Chills; CD33; Refractory (planetary science); Chemotherapy regimen; Surgery; Oncology","score_opus":0.046368179104427636,"score_gpt":0.427938840716764,"score_spread":0.3815706616123364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163123363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940905,0.000055410957,0.00012892262,0.0023551073,0.00025688313,0.0029706655,0.0000040568516,0.0000143763045,0.00012408498],"genre_scores_gemma":[0.9931631,0.00092053023,0.004617224,0.00074195775,0.0002973711,0.00003338881,0.000024588231,0.00006929159,0.00013256427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926005,0.0011428748,0.0041452968,0.00046063564,0.0011533896,0.0004973249],"domain_scores_gemma":[0.99120927,0.003900321,0.0030885735,0.00040990012,0.001061922,0.00033001814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005047583,0.00038770845,0.0045129694,0.00072057586,0.00005320824,0.00001570366,0.0003994564,0.0005150393,0.0002610913],"category_scores_gemma":[0.0015220986,0.00023228937,0.00034073126,0.0005746804,0.0005427134,0.00036248338,0.00006658578,0.0022233794,0.000005501581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.856476,0.04472093,0.069772415,0.00003386283,0.0020840396,0.0005953176,0.0017797688,0.000084845895,0.00022287246,0.0000026958696,0.00020125673,0.024026008],"study_design_scores_gemma":[0.7625263,0.08067385,0.15218373,0.00025621746,0.0004369463,0.000022220069,0.0003326894,0.002387144,0.0001434745,0.0000030765855,0.0008437696,0.00019063732],"about_ca_topic_score_codex":0.00020609071,"about_ca_topic_score_gemma":0.00079033873,"teacher_disagreement_score":0.09394974,"about_ca_system_score_codex":0.0019065482,"about_ca_system_score_gemma":0.0029958286,"threshold_uncertainty_score":0.96596},"labels":[],"label_agreement":null},{"id":"W2163307336","doi":"10.1200/jco.2004.99.066","title":"Delay of Radiation Therapy and Outcomes of Breast Cancer","year":2004,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Quebec Population Health Research Network; Hôpital Charles-Le Moyne; McGill University Health Centre; Université Laval; Institut National de Santé Publique du Québec","funders":"","keywords":"Medicine; Radiation therapy; Breast cancer; Oncology; Cancer; Internal medicine","score_opus":0.05723613634360466,"score_gpt":0.4197873384491441,"score_spread":0.3625512021055395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163307336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5431757,0.014117738,0.000036726855,0.44030407,0.0017434652,0.00018292574,0.00023318503,0.0000020401724,0.00020417842],"genre_scores_gemma":[0.7300233,0.06388968,0.0008422656,0.19738466,0.007560566,0.000013424462,0.000050436563,0.00005351354,0.00018216028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976658,0.00022941203,0.0015570963,0.00019011482,0.00021106724,0.00014650084],"domain_scores_gemma":[0.9960387,0.0003656047,0.0029893494,0.00017177124,0.00037773163,0.00005688238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005362421,0.00018952906,0.001478498,0.00006976354,0.00001671587,0.0000024165897,0.00017899318,0.0010089086,0.000028455417],"category_scores_gemma":[0.00022546224,0.00012895047,0.00047695934,0.000041054853,0.00033233623,0.0000042908673,0.000056886125,0.00062103925,3.646303e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002502979,0.0007531019,0.41714677,0.00010511664,0.005952189,0.0001267992,0.000080068836,0.00002967125,0.0005754069,0.0000106578555,0.20509174,0.3676255],"study_design_scores_gemma":[0.00553209,0.0026999884,0.73311317,0.00006693145,0.00036487423,0.00016686939,0.000010667452,3.0365157e-7,0.00062487565,0.00012933755,0.25715962,0.00013126811],"about_ca_topic_score_codex":0.00012763226,"about_ca_topic_score_gemma":0.000039759194,"teacher_disagreement_score":0.36749423,"about_ca_system_score_codex":0.000057385543,"about_ca_system_score_gemma":0.0011490133,"threshold_uncertainty_score":0.7781627},"labels":[],"label_agreement":null},{"id":"W2163352737","doi":"10.1200/jco.2005.02.8506","title":"Patient-Controlled Methylphenidate for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Methylphenidate; Medicine; Placebo; Clinical endpoint; Cancer-related fatigue; Randomized controlled trial; Internal medicine; Physical therapy; Anesthesia; Cancer; Psychiatry; Attention deficit hyperactivity disorder","score_opus":0.1207098110658092,"score_gpt":0.467517941654457,"score_spread":0.3468081305886478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163352737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337442,0.0047719656,0.0032850348,0.015888222,0.017537702,0.014439941,0.000017095987,0.000034094464,0.010281778],"genre_scores_gemma":[0.9800692,0.0006513605,0.0014931808,0.002674927,0.010605315,0.0020387578,0.000012091557,0.00004911638,0.002406026],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99067956,0.0014367601,0.006421606,0.00033088485,0.0006811736,0.0004500335],"domain_scores_gemma":[0.97880894,0.014048551,0.0051016593,0.000262451,0.0013689154,0.00040949337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011336991,0.00031464163,0.008496668,0.00026018274,0.00007989498,0.000030636154,0.00020638977,0.0006878186,0.00039856337],"category_scores_gemma":[0.006036211,0.0001898346,0.0046302415,0.00018168706,0.000267275,0.00013063916,0.000036114776,0.0010162373,0.000006533846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9581729,0.0017913486,0.00013479638,0.000033422846,0.0023378294,0.00009265236,0.00012644997,0.00009757191,0.000032584452,0.00042999387,0.00581669,0.030933771],"study_design_scores_gemma":[0.9298789,0.010715969,0.00002832873,0.000081682716,0.004607387,0.000037563917,0.000110259905,0.00033232174,0.000071238515,0.0010247532,0.052936323,0.00017526421],"about_ca_topic_score_codex":0.00052559027,"about_ca_topic_score_gemma":0.0016268876,"teacher_disagreement_score":0.047119632,"about_ca_system_score_codex":0.00022952392,"about_ca_system_score_gemma":0.0030373551,"threshold_uncertainty_score":0.774123},"labels":[],"label_agreement":null},{"id":"W2163383249","doi":"10.1200/jco.2002.05.046","title":"Prophylaxis of Radiation-Associated Mucositis in Conventionally Treated Patients With Head and Neck Cancer: A Double-Blind, Phase III, Randomized, Controlled Trial Evaluating the Clinical Efficacy of an Antimicrobial Lozenge Using a Validated Mucositis Scoring System","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Mucositis; Medicine; Lozenge; Radiation therapy; Head and neck cancer; Placebo; Surgery; Clinical trial; Randomized controlled trial; Internal medicine; Cancer; Pathology","score_opus":0.22591685126370098,"score_gpt":0.5245057569877363,"score_spread":0.2985889057240353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163383249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898767,0.00061640004,0.000021669848,0.00046586385,0.0011931073,0.0077490946,0.000034468205,0.000011483316,0.00003119629],"genre_scores_gemma":[0.99766606,0.00043025892,0.0010290862,0.00013297616,0.0005912649,0.00008744866,0.000021531127,0.000029867506,0.000011489477],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98595065,0.0044386154,0.008110558,0.0003604798,0.00078145077,0.0003582432],"domain_scores_gemma":[0.98213136,0.006832435,0.009025852,0.00023719914,0.0014081633,0.00036501585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012167353,0.00027778174,0.006141554,0.00028353967,0.000099161385,0.000016188511,0.00015795101,0.0004845262,0.00005450862],"category_scores_gemma":[0.0034498519,0.00016405669,0.0007829434,0.0004456787,0.00048967265,0.00016967309,0.000035302233,0.00090551836,4.4970932e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8694707,0.0115687875,0.07793234,0.00011287774,0.001843187,0.00010134675,0.0001892074,0.00018796403,0.0000329247,0.0000045408633,0.000012836102,0.038543265],"study_design_scores_gemma":[0.88779604,0.069821574,0.027023144,0.0017534571,0.0027194675,0.000048713122,0.000035727637,0.010616914,0.00006234489,0.0000023021778,0.000005132109,0.00011515834],"about_ca_topic_score_codex":0.0008703426,"about_ca_topic_score_gemma":0.00021714119,"teacher_disagreement_score":0.058252785,"about_ca_system_score_codex":0.00079209177,"about_ca_system_score_gemma":0.002289143,"threshold_uncertainty_score":0.6690038},"labels":[],"label_agreement":null},{"id":"W2163450464","doi":"10.1200/jco.2014.59.2139","title":"Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20<sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BC Cancer Agency; Weill Cornell Medical College; Houston Methodist Research Institute; Università di Bologna; Queen's University; National Cancer Institute; University of Rochester; University of Toronto; Memorial Sloan-Kettering Cancer Center; F. Hoffmann-La Roche; Sveučilište u Zagrebu; Pharmacyclics; Genentech; Università degli Studi del Piemonte Orientale; Celgene","keywords":"Obinutuzumab; Medicine; Rituximab; CD20; Lymphoma; Internal medicine; Oncology; Nuclear medicine","score_opus":0.10196309160295615,"score_gpt":0.4113322242863002,"score_spread":0.30936913268334404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163450464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621934,0.00010019713,0.00003288555,0.00045206893,0.00036779325,0.0022184106,0.000006560491,0.000005809972,0.0005969648],"genre_scores_gemma":[0.9987317,0.000028525255,0.00059274543,0.0002749185,0.00022474074,0.00005941674,0.000010783662,0.00002191421,0.000055277196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99228823,0.0018823578,0.0039015112,0.0003701227,0.0012178705,0.00033990483],"domain_scores_gemma":[0.9921346,0.0025185712,0.0035811355,0.00050134317,0.0008193961,0.00044500025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005759041,0.00032612105,0.005766459,0.00044326193,0.00007462882,0.00001535731,0.00032273066,0.00026293632,0.000028973765],"category_scores_gemma":[0.0016756671,0.00015374029,0.0010418937,0.00088187185,0.00037734062,0.00012015989,0.00013923984,0.0005577585,0.0000032299297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5811405,0.09005007,0.31850636,0.000008015765,0.00390182,0.00027119182,0.0009518921,0.0011974307,1.9800451e-7,0.0000031375055,0.00018739811,0.003782],"study_design_scores_gemma":[0.7151914,0.08914223,0.18173993,0.00012657653,0.010635556,0.000015672527,0.0005510519,0.0022970983,0.00001189501,0.0000071458194,0.00016619927,0.00011519402],"about_ca_topic_score_codex":0.0002740895,"about_ca_topic_score_gemma":0.00022853032,"teacher_disagreement_score":0.13676642,"about_ca_system_score_codex":0.0010147598,"about_ca_system_score_gemma":0.0038948096,"threshold_uncertainty_score":0.6909225},"labels":[],"label_agreement":null},{"id":"W2163615944","doi":"10.1200/jco.2008.17.7568","title":"Phase II Study of an Outpatient Palliative Care Intervention in Patients With Metastatic Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Palliative care; Nausea; Constipation; Distress; Anxiety; Cancer; Depression (economics); Patient satisfaction; Outpatient clinic; Physical therapy; Internal medicine; Surgery; Nursing; Psychiatry","score_opus":0.4155296378419515,"score_gpt":0.6054164206439689,"score_spread":0.18988678280201743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163615944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983785,0.0006870958,0.0000423176,0.000093659124,0.00032384618,0.00037272816,0.00001277131,0.000002010112,0.00008707503],"genre_scores_gemma":[0.99808973,0.0002743036,0.0013930532,0.000106601045,0.000094143754,0.000007046547,0.00000818598,0.000009103071,0.000017832244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967373,0.000513105,0.002074755,0.00013372093,0.00042290788,0.000118181124],"domain_scores_gemma":[0.9958631,0.000497546,0.0021466222,0.00012226847,0.0012175264,0.00015296905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006542598,0.00010786283,0.0013928768,0.00016231328,0.000021139196,7.859681e-7,0.00009745277,0.00009148419,0.00004736314],"category_scores_gemma":[0.001225649,0.000068998655,0.00019897368,0.00016027404,0.00013687371,0.000107342574,0.0000311497,0.00044535327,4.6723713e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013227078,0.040058866,0.85875386,0.000060784776,0.00047682365,0.00018639585,0.015792118,0.000056189532,0.000003748298,0.0000017600968,0.000056106634,0.07132625],"study_design_scores_gemma":[0.055418886,0.28024665,0.65391695,0.0005858307,0.00040078166,0.0000018577581,0.008584318,0.00002616838,0.00007841909,0.000007171458,0.00067793817,0.000055024193],"about_ca_topic_score_codex":0.00022543751,"about_ca_topic_score_gemma":0.0007264974,"teacher_disagreement_score":0.24018776,"about_ca_system_score_codex":0.00016132806,"about_ca_system_score_gemma":0.0004639959,"threshold_uncertainty_score":0.28136835},"labels":[],"label_agreement":null},{"id":"W2163715666","doi":"10.1200/jco.2014.57.1190","title":"Recommendation for Omitting Axillary Lymph Node Dissection Should Be Individualized in Patients With Breast Cancer With One or Two Positive Sentinel Lymph Nodes","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Medicine; Sentinel lymph node; Breast cancer; Lymph; Axillary Lymph Node Dissection; Axillary Dissection; Lymph node; Dissection (medical); Axillary lymph nodes; Cancer; Oncology; Internal medicine; Radiology; Pathology","score_opus":0.07643406066230142,"score_gpt":0.4087026218571434,"score_spread":0.332268561194842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163715666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56622285,0.00010806832,0.0012522879,0.42976886,0.0010920202,0.00066241063,0.0005600544,0.000011462075,0.0003219718],"genre_scores_gemma":[0.5017873,0.0008506877,0.008780652,0.46991056,0.014840138,0.0002609592,0.0031206973,0.00023606801,0.00021294723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965226,0.0005783531,0.0015995688,0.00054346706,0.00034663224,0.00040940102],"domain_scores_gemma":[0.99485505,0.00086039165,0.0030531676,0.00020652481,0.0009193963,0.000105452345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010188073,0.00041136748,0.0015620253,0.00015227868,0.00010344965,0.000026861826,0.00021780496,0.0010019043,0.00004038354],"category_scores_gemma":[0.0003977119,0.00026390998,0.00029404965,0.00012650562,0.00019946958,0.000022784025,0.00009628674,0.0007818476,6.581647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029558904,0.0012390552,0.9010631,0.0001164725,0.0031734502,0.000065573266,0.00005227882,0.000052853535,0.000027319014,9.718741e-7,0.022365851,0.042284157],"study_design_scores_gemma":[0.035268016,0.0020598392,0.9259674,0.00049303006,0.0012177272,0.00021886286,0.000046171757,0.000016916034,0.000067284,0.0000132678115,0.034187816,0.00044365812],"about_ca_topic_score_codex":0.00015585321,"about_ca_topic_score_gemma":0.00015779544,"teacher_disagreement_score":0.06443559,"about_ca_system_score_codex":0.00035081277,"about_ca_system_score_gemma":0.0010601499,"threshold_uncertainty_score":0.9999813},"labels":[],"label_agreement":null},{"id":"W2163767437","doi":"10.1200/jco.2009.22.8858","title":"Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Gary Bennett Family Fund; National Cancer Institute; Entertainment Industry Foundation","keywords":"Microsatellite instability; Colorectal cancer; Internal medicine; Loss of heterozygosity; KRAS; Hazard ratio; Oncology; Proportional hazards model; Medicine; Cancer; Biology; Cancer research; Microsatellite; Genetics; Confidence interval; Allele","score_opus":0.06302792289154693,"score_gpt":0.4188159355750057,"score_spread":0.3557880126834587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163767437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974037,0.0006241836,0.0000488766,0.00036447862,0.00038535157,0.0007967261,0.000020771273,0.0000036207155,0.0003522806],"genre_scores_gemma":[0.9970856,0.00033607337,0.0022499321,0.00020672844,0.00008607043,0.000005909513,0.0000016065698,0.000011126693,0.000016961436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607897,0.00043275298,0.00252953,0.00020799319,0.00054420956,0.00020656812],"domain_scores_gemma":[0.99400073,0.001597132,0.0029715698,0.00017566368,0.00105465,0.00020027108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021372675,0.00013987484,0.0019466701,0.00012755243,0.000021364736,0.0000034338905,0.0001587002,0.00026645747,0.000027154998],"category_scores_gemma":[0.0031641235,0.00011608069,0.00025372984,0.00025949674,0.00036583917,0.000046427504,0.00004027285,0.000535054,3.1885102e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022882402,0.0027787364,0.9559695,0.000062655745,0.00066525297,0.000105420964,0.00040984133,0.00013529902,0.03388814,0.0000077923205,0.000099905476,0.0035891843],"study_design_scores_gemma":[0.0043384293,0.041807737,0.9370158,0.00011789372,0.0008359942,0.00004652531,0.00020660234,0.000028751912,0.015251377,0.00014317183,0.00012824291,0.0000794852],"about_ca_topic_score_codex":0.00015144494,"about_ca_topic_score_gemma":0.00014780283,"teacher_disagreement_score":0.039029,"about_ca_system_score_codex":0.00027090943,"about_ca_system_score_gemma":0.001844382,"threshold_uncertainty_score":0.4733633},"labels":[],"label_agreement":null},{"id":"W2163787988","doi":"10.1200/jco.2006.09.5570","title":"Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Vinorelbine; Medicine; Internal medicine; Chemotherapy; Hazard ratio; Cisplatin; Cancer; Oncology; Clinical trial; Adjuvant; Surgery; Confidence interval","score_opus":0.05553002165538677,"score_gpt":0.45116193876418736,"score_spread":0.3956319171088006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163787988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959628,0.0004942025,0.0000050633175,0.0019378201,0.00081438443,0.00020173035,0.0000063325924,9.2819755e-7,0.0005767251],"genre_scores_gemma":[0.9983512,0.00039175278,0.00025849283,0.00067529257,0.00024492617,0.0000039975353,0.0000016064278,0.0000050146327,0.000067701774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785894,0.00006622854,0.0014803937,0.00012591256,0.00034410946,0.00012440232],"domain_scores_gemma":[0.9977824,0.00080313475,0.0007426008,0.000054009783,0.00042162908,0.00019621456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014375681,0.00008483058,0.00078833353,0.000096741984,0.000015642507,0.0000024752499,0.000043556764,0.00009371176,0.00005691701],"category_scores_gemma":[0.0010344863,0.000057473266,0.000054482272,0.00008128033,0.000092848255,0.00006916757,0.000032173415,0.00029988444,1.5226688e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001785565,0.0023691093,0.8810917,0.000021936332,0.00022709063,0.00024226698,0.00012273548,0.000006274286,0.0000031017516,0.000023926455,0.0020001328,0.11210613],"study_design_scores_gemma":[0.013818892,0.014023723,0.9631761,0.00016140255,0.00014822403,0.00002330762,0.000115581344,0.000012051349,0.000012598101,0.000048009748,0.008415128,0.000045015007],"about_ca_topic_score_codex":0.038349073,"about_ca_topic_score_gemma":0.6967755,"teacher_disagreement_score":0.6584264,"about_ca_system_score_codex":0.00056387315,"about_ca_system_score_gemma":0.0020760521,"threshold_uncertainty_score":0.96805465},"labels":[],"label_agreement":null},{"id":"W2163954169","doi":"10.1200/jco.2005.06.154","title":"Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Radiation therapy; Biopsy; Urology; Cancer; Prostate; Surgery; Hazard ratio; External beam radiation; Nuclear medicine; Radiology; Internal medicine","score_opus":0.06113025692909965,"score_gpt":0.41670137312597977,"score_spread":0.3555711161968801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163954169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98064244,0.009018435,0.00021202788,0.0060029146,0.0012613843,0.0027451448,0.000010580396,0.000008170999,0.00009892393],"genre_scores_gemma":[0.9393899,0.056169588,0.0008200712,0.0021814422,0.0011410608,0.00020914277,0.0000035306357,0.000027811097,0.000057473415],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99508935,0.0008023223,0.0029074303,0.00028685844,0.0005944938,0.0003195519],"domain_scores_gemma":[0.99266684,0.0025673136,0.0038680155,0.00024731233,0.00043250874,0.0002180358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003125657,0.00026974923,0.0026892074,0.00014813535,0.000054015538,0.000017082615,0.00020936893,0.00020835835,0.000053606214],"category_scores_gemma":[0.00059779384,0.00014073314,0.0005544419,0.0002173516,0.00029333387,0.00023698363,0.000026336724,0.0007718059,0.0000017732315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7376042,0.0017695519,0.038164012,0.000012590595,0.0005633081,0.00007045833,0.00073119515,0.0064029205,0.00071638555,0.000008073879,0.00014597161,0.21381135],"study_design_scores_gemma":[0.84727347,0.01014605,0.12225948,0.0005532291,0.00022957775,0.00007877903,0.00004603105,0.0010461784,0.016142352,0.00012433888,0.001961224,0.00013926887],"about_ca_topic_score_codex":0.00042722683,"about_ca_topic_score_gemma":0.0003309343,"teacher_disagreement_score":0.21367209,"about_ca_system_score_codex":0.0008762708,"about_ca_system_score_gemma":0.0024991143,"threshold_uncertainty_score":0.57389313},"labels":[],"label_agreement":null},{"id":"W2163971584","doi":"10.1200/jco.2012.46.6615","title":"Insights From Mixture Cure Modeling of Molecular Markers for Prognosis in Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Disease; Cohort; Oncology; Internal medicine; Cancer; Lymph node","score_opus":0.03973715688218864,"score_gpt":0.3838912396739792,"score_spread":0.34415408279179055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163971584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888688,0.0031952336,0.00069631374,0.00636586,0.0004460931,0.0002458292,0.000044634417,0.0000016269641,0.00013562758],"genre_scores_gemma":[0.99331796,0.0011978785,0.0041881925,0.0006523514,0.00054790865,0.000060614566,0.000010518331,0.000016305426,0.000008246369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981573,0.0001626273,0.0011765521,0.0002117511,0.00013261208,0.00015911988],"domain_scores_gemma":[0.99826306,0.00020802008,0.0007820298,0.00012219687,0.00051671895,0.00010797275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024561188,0.00013743668,0.000746109,0.00005221921,0.000018430166,0.000004849612,0.00018960735,0.00038190273,0.000024126644],"category_scores_gemma":[0.00026068388,0.0001007704,0.00035404792,0.00006582131,0.00009782385,0.000010151321,0.00006581987,0.0002331818,8.968339e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015341455,0.005112293,0.6044336,0.00015551329,0.0058947816,0.000119322955,0.00038338586,0.008878746,0.13096955,0.0001436634,0.02015042,0.20841727],"study_design_scores_gemma":[0.029456036,0.008390885,0.91250575,0.00068455463,0.001283867,0.00010615139,0.0009695488,0.0073413756,0.018945955,0.0075025856,0.011965615,0.0008477074],"about_ca_topic_score_codex":0.00032197795,"about_ca_topic_score_gemma":0.0001981536,"teacher_disagreement_score":0.30807212,"about_ca_system_score_codex":0.0000473077,"about_ca_system_score_gemma":0.00046559115,"threshold_uncertainty_score":0.41092977},"labels":[],"label_agreement":null},{"id":"W2164035913","doi":"10.1200/jco.2012.46.0543","title":"Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"National Health and Medical Research Council; Bristol-Myers Squibb; Centre Hospitalier Universitaire de Québec; National Cancer Institute; University of Toronto; Flinders University; Monash University; Peter MacCallum Cancer Centre; University of New South Wales; Medical Research Council; University of Ottawa; Queen's University; Amgen","keywords":"Medicine; Cetuximab; Internal medicine; Clinical endpoint; Placebo; Hazard ratio; Colorectal cancer; Oncology; Population; Phases of clinical research; Chemotherapy; Gastroenterology; Urology; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","score_opus":0.1050762737576454,"score_gpt":0.45377447154223627,"score_spread":0.3486981977845909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164035913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98216265,0.0009137638,0.000015537371,0.0012281945,0.002362078,0.012654319,0.00001768051,0.000013806243,0.00063198624],"genre_scores_gemma":[0.9971595,0.0006899997,0.0002377611,0.0006344902,0.00081532996,0.00030935346,0.000013158764,0.000049014965,0.00009142505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9819146,0.007849547,0.008120363,0.000573912,0.0010182739,0.00052333396],"domain_scores_gemma":[0.9517732,0.039680995,0.0068047447,0.00037767642,0.0009047,0.0004586766],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.020570688,0.00055753475,0.012468972,0.00024354697,0.00013989667,0.00004433325,0.00032870992,0.00038847877,0.00016837414],"category_scores_gemma":[0.015662206,0.0002761071,0.0012208665,0.00029066607,0.0009881468,0.00022647901,0.00011485098,0.0015681995,0.0000049988635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9277554,0.029247442,0.013419245,0.000022462335,0.00760806,0.00021280073,0.0011163643,0.0000083625655,0.000008065091,0.0000051671504,0.0015254882,0.019071098],"study_design_scores_gemma":[0.772921,0.19990113,0.019952836,0.00005301671,0.0047514997,0.0000222405,0.0012641003,0.00027648904,0.0000047927983,0.000025237261,0.00063279667,0.00019481764],"about_ca_topic_score_codex":0.0003675432,"about_ca_topic_score_gemma":0.0005450744,"teacher_disagreement_score":0.1706537,"about_ca_system_score_codex":0.00046131518,"about_ca_system_score_gemma":0.0018236963,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W2164122193","doi":"10.1200/jco.2005.09.423","title":"Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McMaster University; University of Toronto; University of Calgary","funders":"","keywords":"Medicine; Epirubicin; Fluorouracil; Cyclophosphamide; Cancer; Methotrexate; Randomized controlled trial; Breast cancer; Oncology; Internal medicine; Clinical trial; Chemotherapy","score_opus":0.06580843522190036,"score_gpt":0.41356538848312363,"score_spread":0.34775695326122325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164122193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923602,0.0028338078,0.00011220112,0.002187309,0.00096513325,0.0011110869,0.00019339782,0.0000033249066,0.00023358324],"genre_scores_gemma":[0.9881949,0.006871738,0.002642751,0.0005702448,0.001480922,0.00015829406,0.000019202567,0.000027393071,0.000034591125],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98987633,0.0035506876,0.0050096735,0.0004905806,0.00065252115,0.0004201821],"domain_scores_gemma":[0.9896453,0.0038416807,0.0050496375,0.00018556378,0.0009415975,0.0003361937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.017809145,0.00038742393,0.004687978,0.00010870771,0.000090761336,0.000014242835,0.00023594654,0.0003760759,0.000027857788],"category_scores_gemma":[0.0036499805,0.00025351672,0.00024388611,0.00018764132,0.0010319622,0.000059837945,0.00014692686,0.0007268087,9.979333e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92237324,0.0011855393,0.031961758,0.000040622643,0.0032777854,0.00003526028,0.00014108482,0.0007697423,0.00023685569,0.000033391818,0.0003974549,0.03954726],"study_design_scores_gemma":[0.882282,0.006924451,0.10699526,0.0002220491,0.0006904078,0.00010568674,0.00014317625,0.000052198044,0.00053056626,0.000068455585,0.0017086157,0.00027713363],"about_ca_topic_score_codex":0.024969645,"about_ca_topic_score_gemma":0.16741976,"teacher_disagreement_score":0.14245012,"about_ca_system_score_codex":0.0004029212,"about_ca_system_score_gemma":0.005740599,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W2164130095","doi":"10.1200/jco.2009.22.6449","title":"Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out","year":2009,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anthracycline; Topoisomerase; Chemotherapy; Cancer research; Jury; Oncology; Internal medicine; Pharmacology; Cancer; DNA; Genetics; Breast cancer; Biology; Law","score_opus":0.16040805004886502,"score_gpt":0.5645761933137886,"score_spread":0.40416814326492356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164130095","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012543816,0.0047174105,0.0003269053,0.18791893,0.7908926,0.0010350109,0.00009210869,0.00003153722,0.002441709],"genre_scores_gemma":[0.009570504,0.020559441,0.0016939811,0.015189566,0.9508021,0.000013856346,0.000037862865,0.00008028083,0.0020524159],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929044,0.0009535135,0.003510545,0.00046999782,0.0017319565,0.0004295777],"domain_scores_gemma":[0.9786445,0.014879885,0.003260383,0.0007098921,0.0018550684,0.0006502646],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009624848,0.00033624395,0.0026172735,0.00023256466,0.00008515495,0.000050549635,0.00057456375,0.0023349868,0.00036603282],"category_scores_gemma":[0.021457948,0.00020208767,0.0007292997,0.00017970074,0.0007294815,0.00007993211,0.000058781032,0.006384262,0.000043358945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004005304,0.0008404614,0.00046247503,0.000083238214,0.00021375091,0.00015013681,0.000095198964,9.184947e-7,0.00003840543,0.0000034345946,0.730341,0.26376566],"study_design_scores_gemma":[0.008426649,0.011034365,0.005279296,0.0003599215,0.0004489876,0.00004390932,0.00003837487,0.000052299893,0.000075883596,0.00027384877,0.9737953,0.000171183],"about_ca_topic_score_codex":0.000034932917,"about_ca_topic_score_gemma":0.00004201038,"teacher_disagreement_score":0.26359448,"about_ca_system_score_codex":0.0004468727,"about_ca_system_score_gemma":0.010513439,"threshold_uncertainty_score":0.9989602},"labels":[],"label_agreement":null},{"id":"W2164147551","doi":"10.1200/jco.2005.10.126","title":"Phenotypic Heterogeneity in Multiple Myeloma Families","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Creighton University; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; University of Nebraska Medical Center; Nebraska Department of Health and Human Services","keywords":"Medicine; Proband; Multiple myeloma; Family history; Family aggregation; Population; Observational study; Family studies; Genetics; Pathology; Internal medicine; Mutation; Biology; Gene","score_opus":0.18286004531166014,"score_gpt":0.4861984207155332,"score_spread":0.3033383754038731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164147551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910233,0.0006282911,0.000057420326,0.0047641695,0.00033266112,0.00018913805,0.0000025906406,0.000008184571,0.0029942633],"genre_scores_gemma":[0.98720473,0.0007783928,0.009527984,0.0011554221,0.0011243564,0.000004252199,0.0000024793367,0.000012363101,0.00019004905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688244,0.00039518953,0.0018464377,0.00016989301,0.00038339547,0.00032265694],"domain_scores_gemma":[0.99661136,0.001866433,0.0005920321,0.00018930799,0.00024228978,0.00049855124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002054128,0.00012173007,0.0011594801,0.00021112508,0.000030222052,0.000006177026,0.00014818671,0.00028138247,0.00015185885],"category_scores_gemma":[0.005500299,0.00008276199,0.00040439315,0.00014213589,0.00017786336,0.00012714059,0.0000553776,0.0008781989,0.00012438752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036716028,0.0019387439,0.55230325,0.000010411947,0.0001618911,0.000756286,0.00004053257,0.000021687918,0.00020238216,0.000012623281,0.0005059955,0.44037455],"study_design_scores_gemma":[0.016744884,0.004848434,0.91527426,0.000047115005,0.000059450504,0.000255211,0.000058926093,0.00070887164,0.00052429765,0.00005962076,0.061356667,0.000062278334],"about_ca_topic_score_codex":0.000039159033,"about_ca_topic_score_gemma":0.00086294033,"teacher_disagreement_score":0.4403123,"about_ca_system_score_codex":0.00024269409,"about_ca_system_score_gemma":0.00090320973,"threshold_uncertainty_score":0.6584769},"labels":[],"label_agreement":null},{"id":"W2164152182","doi":"10.1200/jco.2012.48.1903","title":"Quality of Life in Long-Term Breast Cancer Survivors","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Survivorship curve; Breast cancer; Gynecology; Cancer; Pediatrics; Gerontology; Physical therapy; Internal medicine","score_opus":0.14781950845530983,"score_gpt":0.5105891591839099,"score_spread":0.36276965072860007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164152182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97580016,0.00081906887,0.000032313703,0.020016434,0.0013564483,0.00027504863,0.000008898164,0.0000052646164,0.0016863935],"genre_scores_gemma":[0.9937967,0.0023695196,0.00011644912,0.0025512597,0.00092084735,0.000010442086,7.7958305e-7,0.000011846492,0.00022216658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995278,0.00058374484,0.0033760597,0.00015064648,0.0003790075,0.00023252107],"domain_scores_gemma":[0.9936428,0.0025048323,0.0023231439,0.00013285088,0.0010604826,0.00033586426],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030511268,0.00012437248,0.0020518915,0.00015326827,0.000016711667,0.0000032620028,0.00012078136,0.0002982803,0.001323108],"category_scores_gemma":[0.004219729,0.00008808237,0.00041593975,0.00019890463,0.00036194656,0.00012687744,0.0000659881,0.0009628063,0.000026269998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028334118,0.001469245,0.9095349,0.000080178266,0.00046003508,0.00005162734,0.00008393503,0.000005363964,0.00009030781,0.000009344797,0.002271283,0.0831104],"study_design_scores_gemma":[0.0085650245,0.0025753467,0.9876366,0.00027970222,0.0001372965,0.00006909746,0.00015171894,0.00000806177,0.000011886551,0.000093598675,0.0003942419,0.00007740561],"about_ca_topic_score_codex":0.002130527,"about_ca_topic_score_gemma":0.0034980215,"teacher_disagreement_score":0.083032995,"about_ca_system_score_codex":0.00023057245,"about_ca_system_score_gemma":0.001540569,"threshold_uncertainty_score":0.9995898},"labels":[],"label_agreement":null},{"id":"W2164337941","doi":"10.1200/jco.2013.53.0774","title":"Barriers to Immediate Breast Reconstruction in the Canadian Universal Health Care System","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Mastectomy; Odds ratio; Breast reconstruction; Breast cancer; Population; Odds; Logistic regression; Retrospective cohort study; Cohort; Gynecology; Demography; Surgery; Cancer; Internal medicine","score_opus":0.03778109373857308,"score_gpt":0.37522767350690356,"score_spread":0.3374465797683305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164337941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545104,0.0000789503,0.000046933885,0.03555175,0.0047368812,0.00020973776,0.000009914914,0.0000064723017,0.0048489533],"genre_scores_gemma":[0.9953438,0.000018826202,0.00068436144,0.0021939997,0.0017352964,9.150057e-7,0.0000022566537,0.0000062895524,0.000014237821],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99754995,0.0007622824,0.0011548521,0.000110315545,0.00018822755,0.00023435151],"domain_scores_gemma":[0.99754244,0.0003951213,0.0006451907,0.000109660104,0.00022636984,0.0010812175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035095583,0.00007953832,0.00072377024,0.0002761944,0.00010254882,0.000009216639,0.000120035256,0.00026834503,0.000028219521],"category_scores_gemma":[0.00039137478,0.000049278562,0.00017049894,0.00016769914,0.000111324334,0.00006341225,0.000008096172,0.00080375717,0.000014580837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077249063,0.000020468298,0.10124155,0.000029376119,0.000046150242,0.00013176596,0.000731603,0.0000098358905,0.0000013471425,0.0005526013,0.0011827633,0.89528006],"study_design_scores_gemma":[0.006256337,0.004764137,0.6469207,0.00040260286,0.00013795607,0.2712096,0.022410128,0.00011576796,0.0000022719985,0.0000406619,0.047620364,0.00011951167],"about_ca_topic_score_codex":0.013042158,"about_ca_topic_score_gemma":0.15544018,"teacher_disagreement_score":0.89516056,"about_ca_system_score_codex":0.00073845696,"about_ca_system_score_gemma":0.0067767063,"threshold_uncertainty_score":0.9988539},"labels":[],"label_agreement":null},{"id":"W2164459955","doi":"10.1200/jco.2009.25.5463","title":"Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor α and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Loss of heterozygosity; PDGFRA; SNP; Single-nucleotide polymorphism; Glioma; Cancer research; Pathology; Genetics; Biology; Gene; Genotype","score_opus":0.03541201253881517,"score_gpt":0.35150209585534004,"score_spread":0.3160900833165249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164459955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98125875,0.004711319,0.000020170468,0.010771019,0.002714476,0.00040070663,0.000038991177,0.00001912585,0.000065468696],"genre_scores_gemma":[0.9910264,0.0018632403,0.0019186353,0.00059718284,0.0044902717,0.00000719348,0.000021480038,0.00004113736,0.00003448469],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959881,0.00029183246,0.0024497686,0.00035408905,0.0005031125,0.0004131345],"domain_scores_gemma":[0.9950599,0.001158902,0.002189526,0.00026180802,0.00057573983,0.00075412955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091514643,0.00031754488,0.0018807453,0.00044983363,0.00008515499,0.000022804361,0.00020628188,0.0006112096,0.00024980068],"category_scores_gemma":[0.0013310695,0.0002113906,0.0005633176,0.0002624012,0.00026307843,0.00016804159,0.000095291325,0.0011348545,0.000025406867],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061893775,0.00926429,0.08430419,0.00009200955,0.0014875825,0.0025345641,0.00023529344,3.6544657e-7,0.8549873,0.00031018892,0.0003100018,0.04028481],"study_design_scores_gemma":[0.04506421,0.027381629,0.7606605,0.00005785479,0.0022345274,0.0015157837,0.00012096337,0.000014751336,0.14850236,0.00047274123,0.013506728,0.00046792207],"about_ca_topic_score_codex":0.000034827706,"about_ca_topic_score_gemma":0.000012059932,"teacher_disagreement_score":0.706485,"about_ca_system_score_codex":0.0000621016,"about_ca_system_score_gemma":0.0008258175,"threshold_uncertainty_score":0.8620258},"labels":[],"label_agreement":null},{"id":"W2164589152","doi":"10.1200/jco.2005.05.516","title":"Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Lymphovascular invasion; Medicine; Cystectomy; Proportional hazards model; Lymph node; Urology; Internal medicine; Stage (stratigraphy); Bladder cancer; Oncology; Retrospective cohort study; Cancer; Metastasis","score_opus":0.061425761275025755,"score_gpt":0.351058263771608,"score_spread":0.28963250249658223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164589152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968572,0.00089456764,0.00013894419,0.001245398,0.00024423192,0.0003254649,0.000017966382,0.000008103356,0.0002680821],"genre_scores_gemma":[0.99697345,0.0018003387,0.00038330385,0.0005861601,0.00015496068,0.0000051019033,0.00000888409,0.000026995087,0.000060791124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660456,0.00059834024,0.0012798143,0.00039429683,0.00080968934,0.00031331723],"domain_scores_gemma":[0.99683774,0.0012802591,0.0008712096,0.00018376664,0.0003664796,0.00046057964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014089266,0.0002570901,0.0015170038,0.00012161475,0.00007299905,0.000019525889,0.00010420723,0.00036754418,0.00007633091],"category_scores_gemma":[0.00051523466,0.00015676249,0.00012891155,0.00018157018,0.00060094165,0.00020399818,0.00007902227,0.0005842151,0.0000034698828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015465373,0.0020213218,0.9553369,0.000019262377,0.00068407867,0.00043358412,0.0002500916,0.000008179367,0.0000043260266,0.000018462242,0.0001593098,0.02559906],"study_design_scores_gemma":[0.057652876,0.0079541635,0.93095094,0.00042655825,0.00035624884,0.000115141025,0.00011151498,0.00005076744,0.000031297248,0.00005683084,0.002123057,0.00017061182],"about_ca_topic_score_codex":0.00009292458,"about_ca_topic_score_gemma":0.0006014804,"teacher_disagreement_score":0.042187504,"about_ca_system_score_codex":0.00084505684,"about_ca_system_score_gemma":0.0008824727,"threshold_uncertainty_score":0.6392589},"labels":[],"label_agreement":null},{"id":"W2164674436","doi":"10.1200/jco.2011.37.0536","title":"Survival Benefit From Up-Front Fluorouracil, Leucovorin, and Irinotecan/Cetuximab in Metastatic Colorectal Cancer: Is It Just a Now-or-Never Result?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital","funders":"","keywords":"Medicine; Cetuximab; Irinotecan; Fluorouracil; Colorectal cancer; Oncology; Internal medicine; FOLFIRI; Oxaliplatin; Chemotherapy; Cancer","score_opus":0.2747234193955875,"score_gpt":0.46964278345466254,"score_spread":0.19491936405907506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164674436","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33383742,0.016576467,0.000007888293,0.63577974,0.007948828,0.0008515579,0.0005400989,0.000019424546,0.004438534],"genre_scores_gemma":[0.053951345,0.09938027,0.0028344316,0.79869944,0.017299177,0.00019127088,0.00012093977,0.00022046633,0.027302684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930686,0.0005611314,0.0040321494,0.00077098253,0.0008646945,0.00070245675],"domain_scores_gemma":[0.99150234,0.004115642,0.0029094855,0.0003525025,0.000721576,0.00039847783],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0015809116,0.00067055743,0.005679556,0.00032843318,0.00009021862,0.000029788054,0.00035998525,0.0014940238,0.0024598096],"category_scores_gemma":[0.0014858468,0.00043779105,0.0008734364,0.00018746799,0.00048355083,0.00024486624,0.00026526608,0.005058884,0.00004648339],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026454234,0.0012611117,0.019261777,0.00015887328,0.004314333,0.013174587,0.0013380824,0.0000012324199,0.00000621631,0.0000025017698,0.856254,0.07777304],"study_design_scores_gemma":[0.018100504,0.01765901,0.12846166,0.000615005,0.003275139,0.00037050116,0.00038669363,0.000015421261,0.000021403339,0.00014497465,0.8305505,0.0003992022],"about_ca_topic_score_codex":0.0053286375,"about_ca_topic_score_gemma":0.018966038,"teacher_disagreement_score":0.2798861,"about_ca_system_score_codex":0.0010876898,"about_ca_system_score_gemma":0.0032753942,"threshold_uncertainty_score":0.99980736},"labels":[],"label_agreement":null},{"id":"W2164796487","doi":"10.1200/jco.2005.03.1179","title":"Quality of Randomized Controlled Trials Reporting in the Primary Treatment of Brain Tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre","funders":"","keywords":"Blinding; Medicine; Randomized controlled trial; MEDLINE; Sample size determination; Critical appraisal; Quality (philosophy); Quality Score; Clinical trial; Impact factor; Family medicine; Alternative medicine; Internal medicine; Pathology; Statistics","score_opus":0.9076205592877421,"score_gpt":0.7085055440715269,"score_spread":0.19911501521621522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164796487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664359,0.0025317406,0.0018359404,0.0080626495,0.0004934532,0.0018326355,0.0000027713043,4.946713e-7,0.018804386],"genre_scores_gemma":[0.9941523,0.00013486942,0.003816823,0.00045895082,0.00041494396,0.000023478668,7.199065e-7,0.0000035175922,0.0009943739],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.09730755,0.4999954,0.39417335,0.000566938,0.007672319,0.00028442702],"domain_scores_gemma":[0.02834103,0.60314757,0.36513174,0.001211572,0.0020821171,0.00008600292],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.9216833,0.00018439766,0.06965418,0.00034473612,0.000024377427,0.000049360813,0.0008955604,0.00019715675,0.0007913564],"category_scores_gemma":[0.9023536,0.00005154907,0.024178388,0.00050772616,0.00027298514,0.00008297841,0.000028447483,0.00025568294,0.0000102559325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36166796,0.012125359,0.28195605,0.00013872194,0.009856466,0.0004598676,0.0017204323,0.0010009396,0.00078862044,0.012066728,0.036147412,0.28207144],"study_design_scores_gemma":[0.6233571,0.0036259464,0.28907806,0.00012443741,0.003917095,0.000110204506,0.0012762052,0.0006171373,0.000030646774,0.059335526,0.01837699,0.0001506444],"about_ca_topic_score_codex":0.000096359814,"about_ca_topic_score_gemma":0.00009908759,"teacher_disagreement_score":0.2819208,"about_ca_system_score_codex":0.0000575521,"about_ca_system_score_gemma":0.0010619488,"threshold_uncertainty_score":0.9855942},"labels":[],"label_agreement":null},{"id":"W2164880450","doi":"10.1200/jco.2014.55.7215","title":"Reply to J. Menczer","year":2014,"lang":"pl","type":"letter","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine","score_opus":0.37427549489530204,"score_gpt":0.5469662051920533,"score_spread":0.17269071029675126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164880450","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011359849,0.0015988741,0.001267689,0.9317497,0.01727214,0.00042365532,0.000008702475,0.000014742335,0.036304638],"genre_scores_gemma":[0.021397606,0.0010190803,0.007026903,0.88919973,0.074424185,0.0000052707815,0.000008118663,0.00006252616,0.0068566035],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9849489,0.002054133,0.009369464,0.0007073795,0.0019325732,0.0009876016],"domain_scores_gemma":[0.97906214,0.00797398,0.0081147365,0.00087483955,0.0022407542,0.0017335396],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.018394267,0.0005602621,0.006603087,0.0004230885,0.00009360657,0.00004472347,0.0011824555,0.0031135485,0.0021450873],"category_scores_gemma":[0.029610593,0.00041007405,0.002315928,0.00036636068,0.00040028658,0.00017653138,0.0002561385,0.010437435,0.0018248325],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004172968,0.00030045395,0.008875447,0.00009483294,0.00085287757,0.010708727,0.00011083559,0.000022932278,0.000015901069,0.00003500976,0.88217235,0.092637666],"study_design_scores_gemma":[0.0048556007,0.040572695,0.014319226,0.001699702,0.0018255813,0.0024917007,0.00009015783,0.000021173642,0.000010669515,0.0002960122,0.9334611,0.00035635792],"about_ca_topic_score_codex":0.00020899787,"about_ca_topic_score_gemma":0.000028029508,"teacher_disagreement_score":0.09228131,"about_ca_system_score_codex":0.0007530365,"about_ca_system_score_gemma":0.0064512338,"threshold_uncertainty_score":0.99983513},"labels":[],"label_agreement":null},{"id":"W2164900174","doi":"10.1200/jco.2012.43.4803","title":"Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"ABVD; Medicine; Dacarbazine; Internal medicine; Vinblastine; Clinical endpoint; Regimen; Hazard ratio; Oncology; Randomized controlled trial; Surgery; Chemotherapy; Vincristine; Confidence interval","score_opus":0.10115284983228293,"score_gpt":0.4710100978370195,"score_spread":0.3698572480047366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164900174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933804,0.0011935591,0.00029404042,0.000814479,0.0009689992,0.0031624287,0.000007463873,0.000007221969,0.00017135718],"genre_scores_gemma":[0.9961233,0.002208088,0.00036438226,0.00065727194,0.0003720385,0.00013417935,0.0000112605185,0.000023136605,0.00010634134],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99356,0.0029160022,0.0025781505,0.00026514,0.00037109863,0.00030958626],"domain_scores_gemma":[0.9898547,0.0064298785,0.002579922,0.00023234125,0.00056077325,0.0003423881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00547649,0.00028027286,0.0033672277,0.00013824803,0.00005607937,0.000017681821,0.00015198607,0.00028608463,0.000029111487],"category_scores_gemma":[0.001866011,0.0001291992,0.00022983497,0.0002037231,0.0005120072,0.0004242623,0.000042734773,0.00038287637,9.600788e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6848746,0.027884712,0.014439757,0.0000043494574,0.0012874046,0.00025989383,0.0019268787,0.0000049113646,0.000031416082,0.00003259741,0.000073307994,0.26918018],"study_design_scores_gemma":[0.738669,0.24793047,0.0045858733,0.000055175427,0.0006491664,0.00010282461,0.00523291,0.00022764123,0.00006766918,0.00000452223,0.002372566,0.00010218048],"about_ca_topic_score_codex":0.000188951,"about_ca_topic_score_gemma":0.0006127618,"teacher_disagreement_score":0.26907802,"about_ca_system_score_codex":0.00042890993,"about_ca_system_score_gemma":0.0012931284,"threshold_uncertainty_score":0.526859},"labels":[],"label_agreement":null},{"id":"W2164975192","doi":"10.1200/jco.2006.07.9376","title":"A Simple and Innovative Device to Measure Arm Volume at Home for Patients With Lymphedema After Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège de Maisonneuve","funders":"","keywords":"Medicine; Lymphedema; Breast cancer; Tape measure; Standard deviation; Limits of agreement; Nuclear medicine; Displacement (psychology); Surgery; Biomedical engineering; Cancer; Mathematics; Internal medicine; Statistics","score_opus":0.04613511791494382,"score_gpt":0.3970852644883205,"score_spread":0.35095014657337664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164975192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945843,0.00033658842,0.0001509464,0.003714278,0.0003161582,0.00045980385,0.000077143115,0.0000057244597,0.00035506525],"genre_scores_gemma":[0.99301994,0.000009608252,0.00086492655,0.004587787,0.0011378961,0.000040203235,0.0000058908863,0.000017451977,0.00031629548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979039,0.000115737086,0.0012635903,0.00017706017,0.00033234924,0.00020740059],"domain_scores_gemma":[0.9961844,0.00073623686,0.0008322405,0.00010509884,0.0017812025,0.000360812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000728669,0.00013031268,0.0010143728,0.000084726744,0.00003864648,0.000009053263,0.00006238089,0.00016439077,0.00015556526],"category_scores_gemma":[0.0007448069,0.00007794765,0.0001339461,0.00018690637,0.000098302924,0.00008543154,0.000036613008,0.00003385713,0.00000964045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018460106,0.0013045925,0.949113,0.000073572366,0.0002003729,0.0000666079,0.000044924323,0.0000032678454,0.000007603072,0.000010807983,0.013590756,0.01712436],"study_design_scores_gemma":[0.014776559,0.005350627,0.9582325,0.00019725734,0.00036159292,0.00013636121,0.000046549034,0.000011715886,0.0000037264613,0.00008856407,0.020696409,0.00009813761],"about_ca_topic_score_codex":0.00006643289,"about_ca_topic_score_gemma":0.0002086714,"teacher_disagreement_score":0.017026223,"about_ca_system_score_codex":0.00028417673,"about_ca_system_score_gemma":0.0012245536,"threshold_uncertainty_score":0.3178613},"labels":[],"label_agreement":null},{"id":"W2165132221","doi":"10.1200/jco.2002.02.108","title":"Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Chemotherapy; Lung cancer; Clinical trial; Cancer; Placebo; Oncology; Surgery; Gastroenterology; Pathology","score_opus":0.178127568875417,"score_gpt":0.49852558092779165,"score_spread":0.3203980120523746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165132221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97067356,0.0011829471,0.00001806581,0.013673843,0.00063947204,0.013633878,0.00006289367,0.0000011561153,0.000114195675],"genre_scores_gemma":[0.9907297,0.0072169006,0.00018040017,0.0001558299,0.0007875434,0.00063082046,0.0000011887166,0.000022969109,0.00027468646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98981786,0.004807645,0.003915358,0.00025342577,0.000977283,0.0002284244],"domain_scores_gemma":[0.97579134,0.01832875,0.0029234965,0.00016627541,0.0026319353,0.00015819707],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029734695,0.00016734446,0.0036044004,0.00019818988,0.00006853603,0.0000071622826,0.00017823557,0.00013597928,0.000054264136],"category_scores_gemma":[0.020426136,0.000075353375,0.00033829702,0.00039236946,0.001091987,0.00005437798,0.00007774579,0.00040211738,2.4956018e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93656266,0.0033355374,0.051255878,0.00009506011,0.0021000744,0.000003990027,0.0006396473,0.000094230265,0.000012287283,0.000013912172,0.00041213882,0.0054745874],"study_design_scores_gemma":[0.93505305,0.021736128,0.041039705,0.0002757648,0.0007529698,9.3447824e-7,0.00003163455,0.00008900388,0.00007727125,0.00002722772,0.00085814326,0.000058177447],"about_ca_topic_score_codex":0.010227991,"about_ca_topic_score_gemma":0.08033637,"teacher_disagreement_score":0.07010838,"about_ca_system_score_codex":0.00071293866,"about_ca_system_score_gemma":0.0040410515,"threshold_uncertainty_score":0.99909234},"labels":[],"label_agreement":null},{"id":"W2165181124","doi":"10.1200/jco.2007.12.5807","title":"Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; Pfizer Pharmaceuticals; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Neutropenia; Clinical endpoint; Lung cancer; Oncology; Phases of clinical research; Gastroenterology; Surgery; Cancer; Urology; Breast cancer; Randomized controlled trial","score_opus":0.0432886893044225,"score_gpt":0.382074831658081,"score_spread":0.3387861423536585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165181124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876256,0.0012137761,0.0027525357,0.0026876507,0.0022564286,0.0020208333,0.000021280195,0.000011121875,0.00027379193],"genre_scores_gemma":[0.98483485,0.0075928904,0.002409691,0.00046513334,0.00030201866,0.00016580128,0.000058171685,0.000036245412,0.004135185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99478173,0.00096596044,0.0035509125,0.00025145116,0.000107699496,0.0003422302],"domain_scores_gemma":[0.98996955,0.004865504,0.004372136,0.00021308807,0.00052159984,0.000058108868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004146063,0.00025232675,0.0027018392,0.00025132383,0.0001813113,0.000005382371,0.00028539685,0.0006624674,0.00030959092],"category_scores_gemma":[0.0018877683,0.0001843744,0.00061108347,0.00017789532,0.0004976434,0.00020168922,0.000042067226,0.00071323995,0.000004482183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9545649,0.0042449934,0.00012952478,0.000076233875,0.0005677472,0.000028435956,0.00085819303,0.0005828069,0.019233892,0.000051888637,0.0023429482,0.017318383],"study_design_scores_gemma":[0.9024838,0.027983915,0.00012854721,0.00017202138,0.00023742436,0.000050937684,0.00011110092,0.0005709468,0.026193004,0.000029085366,0.04184314,0.00019608342],"about_ca_topic_score_codex":0.00007387407,"about_ca_topic_score_gemma":0.00021274034,"teacher_disagreement_score":0.052081157,"about_ca_system_score_codex":0.00020698426,"about_ca_system_score_gemma":0.0020297908,"threshold_uncertainty_score":0.7518569},"labels":[],"label_agreement":null},{"id":"W2165254737","doi":"10.1200/jco.2008.18.0612","title":"Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; University of California, Los Angeles; Genentech; American Society of Clinical Oncology; Bristol-Myers Squibb","keywords":"Medicine; Erlotinib; Temozolomide; Internal medicine; Oncology; Clinical endpoint; Radiation therapy; PTEN; Rash; Epidermal growth factor receptor; Cancer; EGFR inhibitors; Clinical trial; PI3K/AKT/mTOR pathway","score_opus":0.09951748353643922,"score_gpt":0.43970996842307203,"score_spread":0.3401924848866328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165254737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486727,0.0012174883,0.0000015574918,0.0013208459,0.00031142184,0.0022401337,0.00001667231,0.0000035753885,0.000021062036],"genre_scores_gemma":[0.9787773,0.020302808,0.00016162793,0.00012053322,0.00048141045,0.00012958478,0.0000052414625,0.000013878264,0.0000076425595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665964,0.0005217116,0.0019811194,0.00021470453,0.00038324218,0.00023960785],"domain_scores_gemma":[0.9956104,0.002079701,0.0017540313,0.00021854116,0.00013127823,0.00020604678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005826423,0.00022854378,0.001782995,0.00016946466,0.00006681469,0.000003831807,0.00008995304,0.00014206975,0.000018816558],"category_scores_gemma":[0.00019827644,0.00010553591,0.00036958183,0.00021273844,0.00022314883,0.000077157725,0.000007901391,0.00017293153,3.0358285e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12063844,0.1287613,0.45273247,0.000003231336,0.0008687993,0.0009526982,0.0035183723,0.000025838068,0.000031615837,0.0000016971134,0.000048443097,0.29241708],"study_design_scores_gemma":[0.2814705,0.31848207,0.39753607,0.000018190407,0.0003820771,0.000060421633,0.00031810463,0.00002116314,0.00018068631,0.0000015953482,0.0014904131,0.000038695885],"about_ca_topic_score_codex":0.0007489067,"about_ca_topic_score_gemma":0.0041576615,"teacher_disagreement_score":0.2923784,"about_ca_system_score_codex":0.00031011808,"about_ca_system_score_gemma":0.0007558416,"threshold_uncertainty_score":0.43036294},"labels":[],"label_agreement":null},{"id":"W2165451160","doi":"10.1200/jco.2013.50.9695","title":"Second-Hand Smoke As a Predictor of Smoking Cessation Among Lung Cancer Survivors","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Smoke; Cancer; Oncology; Internal medicine; Environmental health; Pathology","score_opus":0.0852780981936999,"score_gpt":0.45384026252148046,"score_spread":0.36856216432778055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165451160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931408,0.000103021455,0.0003564973,0.0007111691,0.0025618032,0.00012499247,0.0000033723934,0.000008745906,0.0029895848],"genre_scores_gemma":[0.9976484,0.00013323947,0.00008181974,0.0004885957,0.0013916794,0.0000046508912,0.000003966578,0.000016119177,0.00023150911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968588,0.00039585133,0.0019286277,0.00014917545,0.0005037778,0.00016377604],"domain_scores_gemma":[0.9954023,0.0012777376,0.0023187643,0.00015932006,0.00061219453,0.00022968596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040453766,0.00010882915,0.0010387581,0.00015607769,0.000043241394,0.000010415124,0.00012383732,0.00045839453,0.00092637446],"category_scores_gemma":[0.0026570072,0.00008235122,0.00032224844,0.00013739365,0.00023182489,0.00015826346,0.000025679128,0.00076829724,5.1783917e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061772484,0.0003481835,0.9702493,0.00006372813,0.00018350325,0.000023635552,0.00025884272,0.000022685628,0.00024835876,0.00006741025,0.00057436404,0.027342292],"study_design_scores_gemma":[0.004675061,0.0028968223,0.9851085,0.00024170526,0.0007494373,0.000046149904,0.00008800934,0.00025666604,0.0008824705,0.00018176493,0.0048022685,0.00007114405],"about_ca_topic_score_codex":0.0003629447,"about_ca_topic_score_gemma":0.00039178712,"teacher_disagreement_score":0.027271148,"about_ca_system_score_codex":0.00013931365,"about_ca_system_score_gemma":0.0007828921,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W2165542862","doi":"10.1200/jco.2007.12.4008","title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Urology; Survival analysis; Surgery; Oncology; Cancer; Chemotherapy","score_opus":0.20676789271621865,"score_gpt":0.5167604900016837,"score_spread":0.309992597285465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165542862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974713,0.0027082488,0.00006985968,0.017001703,0.001462082,0.0035992416,0.000066397624,0.000018153296,0.000361289],"genre_scores_gemma":[0.98142266,0.008455556,0.001385774,0.00077120087,0.001422002,0.00030698892,0.000023227036,0.000042837302,0.0061697457],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942851,0.00099088,0.0027223425,0.00041445647,0.00089960586,0.00068759645],"domain_scores_gemma":[0.99424523,0.002771704,0.0014208771,0.0003801434,0.0007916718,0.0003903717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045718937,0.0002888795,0.0023629623,0.00020041993,0.00018180477,0.000018434077,0.00046124574,0.00032010593,0.00012747008],"category_scores_gemma":[0.002215875,0.00014776443,0.0004292662,0.00048626825,0.0004479719,0.00021415002,0.000092367016,0.0014098625,0.000008555526],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49875766,0.023978107,0.29092452,0.00026995083,0.0034496777,0.013247127,0.009835739,0.0009790984,0.0006565691,0.00003900536,0.044140358,0.11372218],"study_design_scores_gemma":[0.29112107,0.122660264,0.4361692,0.00034545487,0.00137869,0.0011819766,0.008484102,0.0011277983,0.00030725304,0.00019777715,0.13655102,0.00047540772],"about_ca_topic_score_codex":0.00017276965,"about_ca_topic_score_gemma":0.0010640036,"teacher_disagreement_score":0.2076366,"about_ca_system_score_codex":0.0007896245,"about_ca_system_score_gemma":0.007858319,"threshold_uncertainty_score":0.9977662},"labels":[],"label_agreement":null},{"id":"W2165790389","doi":"10.1200/jco.2010.30.7173","title":"Trajectory of Performance Status and Symptom Scores for Patients With Cancer During the Last Six Months of Life","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":465,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Cohort; Palliative care; Cancer; Population; Nausea; Anxiety; Performance status; Cohort study; Depression (economics); Physical therapy; Internal medicine; Psychiatry","score_opus":0.19664481966173877,"score_gpt":0.46769670000483327,"score_spread":0.27105188034309446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165790389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997588,0.0015416723,0.0000147893215,0.000086227636,0.000248905,0.00015593185,0.00001306537,0.0000013173369,0.00035010083],"genre_scores_gemma":[0.9946889,0.0037214595,0.0012464161,0.00011608221,0.0001940249,0.000003631888,5.618048e-7,0.000007748197,0.000021127735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984751,0.00007741624,0.0010626441,0.00007340725,0.00018651695,0.00012492099],"domain_scores_gemma":[0.9965729,0.0012419706,0.0013754253,0.0000864266,0.0005897158,0.00013353795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050703774,0.00007289604,0.0008369869,0.00005366276,0.000017269958,6.951672e-7,0.00007666867,0.00009986114,0.000028799986],"category_scores_gemma":[0.0012988017,0.000037859012,0.00012910673,0.000051909054,0.00032621532,0.00006197374,0.000019406982,0.00022697759,1.3064114e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007777542,0.0004873028,0.9818542,0.00021936223,0.0003342692,0.0000024009903,0.0011186764,0.000010346297,0.000055290377,0.000009806696,0.000089676534,0.008041137],"study_design_scores_gemma":[0.006619913,0.011186153,0.977743,0.0005963389,0.0002291955,0.0000015976201,0.0003135526,0.000016386704,0.00075811514,0.000008340286,0.0024898266,0.00003755313],"about_ca_topic_score_codex":0.00005900363,"about_ca_topic_score_gemma":0.00013142462,"teacher_disagreement_score":0.010698849,"about_ca_system_score_codex":0.000028351405,"about_ca_system_score_gemma":0.0005908458,"threshold_uncertainty_score":0.15548809},"labels":[],"label_agreement":null},{"id":"W2165824128","doi":"10.1200/jco.2005.04.1764","title":"Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":484,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Metastatic breast cancer; Carboplatin; Oncology; Breast cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin","score_opus":0.1106490242730566,"score_gpt":0.49162201900925406,"score_spread":0.38097299473619745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165824128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955129,0.001266957,0.00010166724,0.0012574489,0.000087597975,0.0013282793,0.000026186628,0.0000070898413,0.0004118642],"genre_scores_gemma":[0.99757576,0.00032152951,0.0015092655,0.00017626336,0.00024198148,0.0000804974,0.0000013444973,0.00003608923,0.000057253525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99329275,0.0018297257,0.003149078,0.00037473452,0.0008749313,0.00047878112],"domain_scores_gemma":[0.992612,0.0043118168,0.0018930077,0.00022459314,0.00048584776,0.000472747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006595757,0.00028274744,0.0043945657,0.00030356363,0.000054791646,0.000027099351,0.00013799377,0.00015864869,0.0001369904],"category_scores_gemma":[0.00062026334,0.0001683255,0.000117828575,0.00033680644,0.0010064676,0.0001759819,0.000050569786,0.0012211322,2.39146e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8510159,0.013153989,0.07557525,0.00026270453,0.0016169542,0.0015903512,0.004553001,0.00021981512,0.0005077478,0.000012159934,0.00026472355,0.051227354],"study_design_scores_gemma":[0.76101846,0.03697765,0.18938826,0.0008845881,0.00086673535,0.00097484875,0.008674904,0.0006541506,0.000025567308,0.00013481824,0.0002043644,0.0001956741],"about_ca_topic_score_codex":0.0020770035,"about_ca_topic_score_gemma":0.0019356859,"teacher_disagreement_score":0.11381302,"about_ca_system_score_codex":0.00047373818,"about_ca_system_score_gemma":0.0021978612,"threshold_uncertainty_score":0.68641144},"labels":[],"label_agreement":null},{"id":"W2165862193","doi":"10.1200/jco.2008.16.5282","title":"Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500?","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lapatinib; Medicine; Realm; Internal medicine; Cancer; Trastuzumab; Breast cancer","score_opus":0.4819093635843679,"score_gpt":0.6027211488448957,"score_spread":0.12081178526052777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165862193","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034723967,0.00094963424,0.000034313543,0.9192411,0.0019759783,0.00075410644,0.00002563354,0.000009882067,0.04228541],"genre_scores_gemma":[0.015914062,0.016362634,0.013370673,0.91339713,0.03542701,0.000044189386,0.000035119476,0.0001918672,0.0052573103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98833644,0.00218765,0.0064241397,0.00031910278,0.002128137,0.0006045319],"domain_scores_gemma":[0.9761247,0.017418632,0.0044318717,0.00084019854,0.00093937793,0.00024524445],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012402029,0.00031563843,0.0040238593,0.00043525358,0.00003796912,0.000011180024,0.0011564455,0.002699958,0.00066210335],"category_scores_gemma":[0.016035426,0.0001844187,0.0011164743,0.0003981977,0.00088287913,0.00005762569,0.000139465,0.01401528,0.00009117587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006315122,0.0013803701,0.0039275396,0.00057412544,0.00030950853,0.012510821,0.0005760377,0.000002505352,0.000009496916,0.00002430702,0.9574203,0.022633472],"study_design_scores_gemma":[0.0040383893,0.011441911,0.008573782,0.0010421391,0.00030525035,0.0032219558,0.00016828628,0.000027621638,0.000013068061,0.00078102585,0.970239,0.00014756976],"about_ca_topic_score_codex":0.000081987804,"about_ca_topic_score_gemma":0.00006349143,"teacher_disagreement_score":0.037028097,"about_ca_system_score_codex":0.00040061335,"about_ca_system_score_gemma":0.0067331595,"threshold_uncertainty_score":0.99889773},"labels":[],"label_agreement":null},{"id":"W2165908865","doi":"10.1200/jco.2009.27.2336","title":"Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Germline; Pharmacogenetics; Germline mutation; Pharmacogenomics; Medicine; Irinotecan; DPYD; Colorectal cancer; Genetics; Genetic variation; Oncology; Cancer; Bioinformatics; Biology; Internal medicine; Mutation; Pharmacology; Genotype; Gene","score_opus":0.32257850106419395,"score_gpt":0.5977282615389726,"score_spread":0.2751497604747787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165908865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003439173,0.9857666,0.00008861935,0.00083608995,0.0088912,0.0005547018,0.000023585226,0.000009304005,0.00039071767],"genre_scores_gemma":[0.00027179925,0.9776488,0.013855156,0.0012840708,0.006382762,0.00002413385,0.0000038791386,0.00007303682,0.00045635932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922278,0.000577603,0.005999325,0.00037078094,0.0005137955,0.00031070298],"domain_scores_gemma":[0.9900008,0.002803912,0.0053609204,0.00032306786,0.00079679326,0.00071449764],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025749246,0.00040593583,0.006167832,0.0002509589,0.000038264967,0.000014960789,0.0003205241,0.0018211332,0.00076763897],"category_scores_gemma":[0.0040425905,0.0002707936,0.0012237428,0.00021528469,0.00032033806,0.00002961513,0.00013515724,0.003772203,0.000020682572],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018783659,0.00033500997,0.007008879,0.0021743462,0.00070627494,0.00023942081,0.0000140958045,0.0000012573774,0.000004656948,0.0000029071407,0.0017848784,0.9875404],"study_design_scores_gemma":[0.0024838203,0.0030221865,0.018256653,0.0014134002,0.008329602,0.001597962,0.0000016961677,0.000012945917,0.0000010093704,0.000036006342,0.9646258,0.00021891798],"about_ca_topic_score_codex":0.000008505326,"about_ca_topic_score_gemma":0.000028657167,"teacher_disagreement_score":0.9873215,"about_ca_system_score_codex":0.00025580407,"about_ca_system_score_gemma":0.0069800112,"threshold_uncertainty_score":0.9999744},"labels":[],"label_agreement":null},{"id":"W2165947030","doi":"10.1200/jco.2014.59.2311","title":"The Long and Winding Road","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Olaparib; PARP inhibitor; Ovarian cancer; Oncology; Breast cancer; Prostate cancer; Internal medicine; Cancer; Cancer research; Poly ADP ribose polymerase; Polymerase; Biology","score_opus":0.20132819445398942,"score_gpt":0.5190743910872542,"score_spread":0.31774619663326475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165947030","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009074296,0.0022193806,0.00017542568,0.9773986,0.004629064,0.00015209851,0.0000014472571,0.000008106073,0.0063415836],"genre_scores_gemma":[0.00990423,0.0048556784,0.00054588483,0.934871,0.04720031,0.000003870666,0.0000034865457,0.00003787643,0.0025776553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563974,0.0008341517,0.0025598567,0.00018975197,0.00050085876,0.0002756501],"domain_scores_gemma":[0.98874545,0.0070991656,0.0033034857,0.0002708218,0.00037594957,0.00020510478],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0057768477,0.00017657307,0.0017501632,0.0001028604,0.000095397,0.000024900286,0.00022435586,0.0015434901,0.00010962502],"category_scores_gemma":[0.0028297526,0.00009823657,0.00056236127,0.00006190888,0.00056309404,0.000048459136,0.00004194331,0.006348624,0.000027948692],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006570406,0.00004681818,0.0030385226,0.000033768123,0.00036839317,0.0016367435,0.000016414695,3.200562e-7,0.0000053959943,0.000011843481,0.8625701,0.13161466],"study_design_scores_gemma":[0.004262102,0.0043020328,0.013766062,0.00031024296,0.00033910247,0.003222157,0.000009179662,0.000008801533,0.000007121104,0.000627206,0.9730543,0.00009169558],"about_ca_topic_score_codex":0.000003838521,"about_ca_topic_score_gemma":0.0000041512794,"teacher_disagreement_score":0.13152297,"about_ca_system_score_codex":0.0001780202,"about_ca_system_score_gemma":0.001242847,"threshold_uncertainty_score":0.9997527},"labels":[],"label_agreement":null},{"id":"W2166077616","doi":"10.1200/jco.2004.12.188","title":"Role of Lung Transplantation in the Treatment of Bronchogenic Carcinomas for Patients With End-Stage Pulmonary Disease","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Transplantation: Methods and Outcomes","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Bronchogenic carcinoma; Stage (stratigraphy); Lung; Lung transplantation; Carcinoma; Transplantation; Respiratory disease; Surgery; Internal medicine","score_opus":0.06272939773961156,"score_gpt":0.4312822881086241,"score_spread":0.36855289036901256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166077616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720186,0.00048049632,0.000795827,0.0007685319,0.000116164185,0.0004601855,0.00006363566,0.0000014029516,0.00011190537],"genre_scores_gemma":[0.9912004,0.0007849439,0.007690112,0.00014748305,0.000117777636,0.000009165276,0.000027443346,0.000007400175,0.000015295327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981533,0.00021136938,0.0012093963,0.000091122136,0.00022944648,0.000105363004],"domain_scores_gemma":[0.9972381,0.0016600492,0.00073683163,0.00010035324,0.00015654124,0.00010811125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000702898,0.00008464275,0.00069744093,0.00008160643,0.000014827485,0.0000012671285,0.00007300021,0.00008968103,0.000013813365],"category_scores_gemma":[0.00011343629,0.00004390186,0.0003230372,0.000076914366,0.000090041875,0.000055834225,0.0000012408482,0.00012999815,1.5379604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019150682,0.004398927,0.94873023,0.00016185366,0.00013390963,0.00016761501,0.0009907511,0.00014418291,0.00015038456,0.00021561261,0.000001505105,0.025754374],"study_design_scores_gemma":[0.016248595,0.01398433,0.9673559,0.00008101449,0.0009646882,0.000028557732,0.00016770422,0.000023711385,0.00020262538,0.00027566226,0.00062789064,0.000039303624],"about_ca_topic_score_codex":0.000035755893,"about_ca_topic_score_gemma":0.00006923287,"teacher_disagreement_score":0.02571507,"about_ca_system_score_codex":0.000074749136,"about_ca_system_score_gemma":0.0006330891,"threshold_uncertainty_score":0.17902659},"labels":[],"label_agreement":null},{"id":"W2166271896","doi":"10.1200/jco.2011.38.9247","title":"Impact of Routine Pathology Review on Treatment for Node-Negative Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Pathology; Cancer; Internal medicine","score_opus":0.11808860223241507,"score_gpt":0.5145466373553407,"score_spread":0.3964580351229256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166271896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97212344,0.019682137,0.00012053537,0.005768928,0.0010861534,0.0003982914,0.00033880374,0.0000028200739,0.0004789093],"genre_scores_gemma":[0.9615037,0.034339856,0.00097433414,0.0012325819,0.0018136258,0.000042980504,0.000011564217,0.000017078733,0.00006427495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979203,0.00031251382,0.0012138372,0.00016860454,0.00010951324,0.00027527218],"domain_scores_gemma":[0.9969228,0.0006191695,0.0016258697,0.00019405436,0.0004510271,0.0001870664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010098362,0.00019583874,0.0013029613,0.000036366673,0.000030267907,0.0000013196817,0.00012854223,0.00023669444,0.000066200344],"category_scores_gemma":[0.0009401492,0.00011185968,0.0009759204,0.000055517274,0.00017035243,0.000006722078,0.00004090984,0.00014237793,0.000003203752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013736314,0.007102412,0.6156609,0.00013770381,0.0047122585,0.000023411543,0.00014240986,0.00005408716,0.0014696723,0.00005448245,0.019126523,0.33777982],"study_design_scores_gemma":[0.0077986745,0.019234292,0.9582741,0.0002840074,0.00081550766,0.00029666958,0.000023721073,0.0000015283475,0.0010982603,0.0000421662,0.011990801,0.00014022944],"about_ca_topic_score_codex":0.00006852342,"about_ca_topic_score_gemma":0.000036278918,"teacher_disagreement_score":0.34261322,"about_ca_system_score_codex":0.00022032001,"about_ca_system_score_gemma":0.0006976121,"threshold_uncertainty_score":0.4561505},"labels":[],"label_agreement":null},{"id":"W2166317024","doi":"10.1200/jco.2010.29.5071","title":"Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Cancer research; Epidermal growth factor; Receptor; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.41265828075769156,"score_gpt":0.5553228378694964,"score_spread":0.14266455711180487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166317024","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012987008,0.0009205565,0.000012694098,0.9684516,0.0075991247,0.00048490954,0.000054985583,0.00004113035,0.009447997],"genre_scores_gemma":[0.005675014,0.0024819404,0.01095034,0.81075996,0.15306675,0.000025771456,0.0000329542,0.0003019365,0.016705343],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98935306,0.0017829065,0.0054293196,0.00062918407,0.0018305818,0.0009749182],"domain_scores_gemma":[0.9790979,0.009934111,0.0062915077,0.0007160623,0.0029318684,0.00102857],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0054147844,0.0005219983,0.004789971,0.00045477768,0.00012483305,0.000046184505,0.0010645518,0.008931633,0.0075347973],"category_scores_gemma":[0.028077966,0.00037931875,0.0014724006,0.00029343105,0.0008911403,0.00013141689,0.00025224502,0.04866324,0.00035970882],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036280943,0.0005458743,0.037543528,0.0006212558,0.0004489729,0.010946811,0.00002994757,1.4653365e-7,0.00025418797,0.000003821592,0.9121981,0.037044525],"study_design_scores_gemma":[0.0039548283,0.011499518,0.03029109,0.0011011644,0.00035617192,0.0014796385,0.000024872737,0.0000031293523,0.0000422611,0.00028007873,0.95065653,0.00031073138],"about_ca_topic_score_codex":0.00007359951,"about_ca_topic_score_gemma":0.00009193201,"teacher_disagreement_score":0.15769164,"about_ca_system_score_codex":0.0006396926,"about_ca_system_score_gemma":0.0074138436,"threshold_uncertainty_score":0.9998659},"labels":[],"label_agreement":null},{"id":"W2166380979","doi":"10.1200/jco.2012.47.4957","title":"Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Cohort; Cohort study; Logistic regression; Internal medicine; Oncology; Intensive care medicine","score_opus":0.9252008630115631,"score_gpt":0.7254269325999303,"score_spread":0.19977393041163283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166380979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019590817,0.9568084,0.017504282,0.000071308066,0.0077064713,0.015837945,0.00006354763,0.000012287899,0.00003666356],"genre_scores_gemma":[0.00004583405,0.74084413,0.25739616,0.00007913565,0.0010400552,0.000465024,0.0000025078605,0.00007451032,0.00005262672],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.68759257,0.17608342,0.1316426,0.0011965028,0.0026421116,0.0008428021],"domain_scores_gemma":[0.23571268,0.6754257,0.0850163,0.0011832855,0.0019633216,0.0006986855],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.3512823,0.000831803,0.05703247,0.00081514166,0.000027379983,0.00002670182,0.0013843845,0.0028846355,0.00029671023],"category_scores_gemma":[0.8766392,0.0005260966,0.005510323,0.0009800323,0.0005760416,0.0002695302,0.00027880943,0.0040945103,0.000021214193],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015223668,0.011674939,0.00012281412,0.54544395,0.0019913204,0.00015567934,0.000043936074,0.0000013024347,5.2206656e-7,0.0004687542,0.0015803627,0.42329273],"study_design_scores_gemma":[0.060406614,0.0099120205,0.00007697757,0.8886558,0.015637234,0.00002947085,0.00001688669,0.000015310754,0.00000360352,0.0136139905,0.011087072,0.00054502353],"about_ca_topic_score_codex":0.00005996812,"about_ca_topic_score_gemma":0.000045658977,"teacher_disagreement_score":0.5253569,"about_ca_system_score_codex":0.0012324709,"about_ca_system_score_gemma":0.012328556,"threshold_uncertainty_score":0.9997191},"labels":[],"label_agreement":null},{"id":"W2166536412","doi":"10.1200/jco.2011.38.6672","title":"Reply to P.G. Tsoutsou et al and A.H. Trainer et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Gynecology","score_opus":0.320163013477212,"score_gpt":0.5827577782536111,"score_spread":0.2625947647763991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166536412","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08466159,0.013686916,0.00029810134,0.8622751,0.0072224736,0.00036083453,0.00001931439,0.000011637334,0.031464037],"genre_scores_gemma":[0.15962273,0.029314097,0.0120751625,0.78993046,0.0024687208,0.000010552696,0.000001179817,0.000051501214,0.0065256115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933534,0.0018932145,0.0028962407,0.0004076916,0.00075554074,0.0006939003],"domain_scores_gemma":[0.9908132,0.005383461,0.0011778583,0.00031917822,0.0008092204,0.0014970867],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017446138,0.00025252003,0.0021613855,0.00020234444,0.00005879112,0.00001791668,0.00029192638,0.00031296283,0.0010092511],"category_scores_gemma":[0.02390034,0.00018249587,0.0005160841,0.00020129666,0.0009752757,0.000229798,0.00033436192,0.003002527,0.0001461152],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006578634,0.0015203794,0.03063108,0.00004853283,0.0010961051,0.0030205257,0.0028929082,0.0000024571848,0.00006676375,0.0010656482,0.8271615,0.12591548],"study_design_scores_gemma":[0.0062869047,0.027925286,0.17866753,0.0003997529,0.00031948605,0.0008485297,0.00058047875,0.000018159519,0.00001586878,0.00048860785,0.78431576,0.00013362229],"about_ca_topic_score_codex":0.00031279578,"about_ca_topic_score_gemma":0.00022261255,"teacher_disagreement_score":0.14803645,"about_ca_system_score_codex":0.00029851604,"about_ca_system_score_gemma":0.003345225,"threshold_uncertainty_score":0.999904},"labels":[],"label_agreement":null},{"id":"W2166928505","doi":"10.1200/jco.2014.57.2198","title":"Meaning-Centered Group Psychotherapy: An Effective Intervention for Improving Psychological Well-Being in Patients With Advanced Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Religion, Spirituality, and Psychology","field":"Social Sciences","cited_by":544,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; McGill University","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Distress; Anxiety; Depression (economics); Clinical psychology; Death anxiety; Randomized controlled trial; Intervention (counseling); Psychotherapist; Psychiatry; Psychology; Internal medicine","score_opus":0.10568531863548551,"score_gpt":0.5190309588889356,"score_spread":0.41334564025345005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166928505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863575,0.0001718698,0.0027924392,0.0020594683,0.004273514,0.0006724006,0.0000019042676,0.000015127234,0.0036557813],"genre_scores_gemma":[0.99385905,0.0001706254,0.0030418108,0.0017426603,0.0010981581,0.000037648348,0.0000028661307,0.00001640738,0.000030767507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99532795,0.0021228592,0.0015149494,0.00033082766,0.00035031603,0.00035308072],"domain_scores_gemma":[0.996303,0.0009891572,0.0016065796,0.00014327887,0.00059114414,0.00036684546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007897732,0.00014051913,0.0008311285,0.00012844762,0.000092377915,0.000027170207,0.00036166297,0.000447652,0.000036915804],"category_scores_gemma":[0.0011487372,0.000101906146,0.00027514275,0.00018567155,0.0003208147,0.00038518204,0.000012146741,0.0005928591,0.0000028689117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017296448,0.0040980303,0.4514749,0.000010985087,0.00008212126,0.000012102017,0.00484963,0.000020472176,0.000008593079,0.0020036653,0.0007314666,0.51941156],"study_design_scores_gemma":[0.04172178,0.05771079,0.8392236,0.00014739309,0.00008184713,0.0000044050453,0.0019006042,0.000030737257,0.0000024627584,0.035963483,0.022950266,0.0002626266],"about_ca_topic_score_codex":0.0005922146,"about_ca_topic_score_gemma":0.010133372,"teacher_disagreement_score":0.51914895,"about_ca_system_score_codex":0.00023646181,"about_ca_system_score_gemma":0.00018688699,"threshold_uncertainty_score":0.5654659},"labels":[],"label_agreement":null},{"id":"W2167123965","doi":"10.1200/jco.2010.31.9624","title":"Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Drug; Adverse effect; Clinical trial; Pharmacology; Oncology; Anticancer drug; Intensive care medicine; Internal medicine","score_opus":0.82530059686524,"score_gpt":0.7434084139838205,"score_spread":0.08189218288141953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167123965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980907,0.000031895222,0.0051594116,0.001121595,0.0105582485,0.0006860569,0.00005086851,0.000016011736,0.0014688923],"genre_scores_gemma":[0.62633204,0.00023119645,0.3715071,0.00018811428,0.0016131159,0.000006232854,7.810293e-7,0.000029144816,0.000092258284],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.91335315,0.015236014,0.069282316,0.000546659,0.001069141,0.00051271473],"domain_scores_gemma":[0.34541962,0.53549963,0.114624895,0.0011504312,0.0022781778,0.0010272594],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.25353324,0.00027668578,0.009627188,0.0002845674,0.00004088845,0.000007126963,0.00060036,0.0012078368,0.0010377354],"category_scores_gemma":[0.9197891,0.0002053695,0.0024566662,0.00044584955,0.001165199,0.0001686365,0.00017708019,0.0042025954,0.0000059825875],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04653506,0.052814234,0.14190546,0.0006766058,0.0037521725,0.0026712005,0.00055524625,0.00004754908,0.015953222,0.02026852,0.018966056,0.69585466],"study_design_scores_gemma":[0.122320466,0.019128827,0.18539733,0.0012592324,0.0038924366,0.0004183523,0.0007187808,0.0015362432,0.004911718,0.64156014,0.017993432,0.0008630422],"about_ca_topic_score_codex":0.00005694648,"about_ca_topic_score_gemma":0.00010869844,"teacher_disagreement_score":0.69499165,"about_ca_system_score_codex":0.00006996134,"about_ca_system_score_gemma":0.0022559285,"threshold_uncertainty_score":0.9998754},"labels":[],"label_agreement":null},{"id":"W2167372595","doi":"10.1200/jco.2008.17.6545","title":"Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"National Cancer Institute","keywords":"Medicine; Busulfan; Cyclophosphamide; Acute leukemia; Internal medicine; Immunology; Myeloid leukemia; Bone marrow; Relative risk; Total body irradiation; Leukemia; Acute lymphocytic leukemia; Graft-versus-host disease; Sibling; Human leukocyte antigen; Gastroenterology; Transplantation; Chemotherapy; Confidence interval; Antigen","score_opus":0.10496162673355532,"score_gpt":0.4389153360620108,"score_spread":0.3339537093284555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167372595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806398,0.000120515906,0.016562812,0.0005006077,0.0010072245,0.0009222652,0.00012799544,0.00002238544,0.00009638778],"genre_scores_gemma":[0.9874352,0.0012952598,0.009781069,0.00030861702,0.000916846,0.000036342004,0.0000544258,0.000051053175,0.00012118247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960038,0.00019546019,0.0024950637,0.00035175364,0.0005118982,0.00044200168],"domain_scores_gemma":[0.9925788,0.004488955,0.0012670862,0.0002163157,0.00056494545,0.00088390894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013874929,0.00026758676,0.0015642616,0.00020102171,0.00016850652,0.000011809823,0.0001776897,0.00040840544,0.000058976853],"category_scores_gemma":[0.0011417207,0.00018307344,0.00090059935,0.00012755631,0.0003193394,0.00019097353,0.000009328036,0.0007052326,0.000006630571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27672884,0.0016901614,0.7085281,0.0006231824,0.002986541,0.0046590995,0.001781242,0.000052704014,0.0005591501,0.00007839967,0.00097548944,0.0013371012],"study_design_scores_gemma":[0.065165274,0.023632014,0.8967968,0.0007786152,0.00654817,0.0006631878,0.00030156827,0.0005071905,0.0014306519,0.00009655564,0.003736794,0.00034313512],"about_ca_topic_score_codex":0.000016072829,"about_ca_topic_score_gemma":0.000074927615,"teacher_disagreement_score":0.21156356,"about_ca_system_score_codex":0.00019753644,"about_ca_system_score_gemma":0.0017141363,"threshold_uncertainty_score":0.7465518},"labels":[],"label_agreement":null},{"id":"W2167494200","doi":"10.1200/jco.2014.59.7351","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1373,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"National Heart, Lung, and Blood Institute; University of North Carolina at Chapel Hill; Wilmot Cancer Institute, University of Rochester Medical Center; Universidad de Granada; McMaster University; School of Medicine, Emory University; Pennsylvania State University; University of Pennsylvania; Penn State Hershey Cancer Institute; University of Rochester; Emory University; Cleveland Clinic; University of Washington; University of Southern California","keywords":"Medicine; Guideline; Cancer; Pulmonary embolism; Deep vein; Intensive care medicine; Randomized controlled trial; Clinical trial; Low molecular weight heparin; Thrombosis; Malignancy; Internal medicine; Surgery","score_opus":0.1164542965855454,"score_gpt":0.4944507079326678,"score_spread":0.3779964113471224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167494200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96682674,0.00094308605,0.000094204435,0.027520893,0.002053355,0.0009822779,0.000015870444,0.000014112494,0.0015494882],"genre_scores_gemma":[0.8777012,0.033341963,0.065952845,0.019912582,0.002913833,0.000032226613,0.000019010895,0.00006132099,0.000064988235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98788655,0.0020614164,0.008151847,0.00058608723,0.0008283826,0.0004857418],"domain_scores_gemma":[0.9845097,0.0039368016,0.007852227,0.00047903825,0.002128354,0.0010939001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0144385435,0.00034290567,0.0068534533,0.00014789225,0.00004407462,0.0000121124585,0.00027350106,0.00069812103,0.000058895737],"category_scores_gemma":[0.0063417936,0.0002185321,0.00080596685,0.000291931,0.0013255381,0.00023594762,0.0001925225,0.0016248892,0.000014648478],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008167796,0.030232817,0.39073905,0.000025835969,0.0017832627,0.00021994126,0.0002579114,0.000036663965,6.039344e-7,0.00004234979,0.063464954,0.5050288],"study_design_scores_gemma":[0.01934911,0.11507748,0.4858748,0.000070363705,0.0011961232,0.000029230685,0.0004785007,0.00005944811,0.0000013479515,0.000049678376,0.37769058,0.0001233472],"about_ca_topic_score_codex":0.001291433,"about_ca_topic_score_gemma":0.0005247903,"teacher_disagreement_score":0.50490546,"about_ca_system_score_codex":0.0005236376,"about_ca_system_score_gemma":0.0063845287,"threshold_uncertainty_score":0.9992483},"labels":[],"label_agreement":null},{"id":"W2167555906","doi":"10.1200/jco.2005.05.016","title":"State-of-the-Art Therapeutics: Hodgkin's Lymphoma","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; ABVD; Dacarbazine; Bleomycin; Vinblastine; Disease; Chemotherapy; Lymphoma; Internal medicine; Oncology; Adverse effect; Regimen; Radiation therapy; Surgery; Intensive care medicine; Vincristine; Cyclophosphamide","score_opus":0.24525710644478751,"score_gpt":0.5256802401579725,"score_spread":0.28042313371318506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167555906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041901835,0.99074817,0.000005357728,0.0021561515,0.0024316148,0.00051703025,0.000014276148,0.0000060384828,0.0037023227],"genre_scores_gemma":[0.00027598202,0.99364436,0.0010601876,0.001870608,0.0018015361,0.000013249638,0.000004522545,0.000042899333,0.0012866388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99270266,0.0009635031,0.005236624,0.00024479447,0.0005699735,0.00028242654],"domain_scores_gemma":[0.9878857,0.0041858614,0.0066833072,0.0005133569,0.00040535245,0.00032643272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023594238,0.0003571139,0.00681086,0.00015479655,0.00003453244,0.000009031867,0.000435504,0.0007942741,0.00015151393],"category_scores_gemma":[0.00090972387,0.00016984071,0.0042406316,0.00020942416,0.0003087526,0.000049672602,0.000110729525,0.00075318373,0.00013000317],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002638948,0.0035773874,0.0007586218,0.0007548652,0.0026962692,0.00040602707,0.00001530402,3.6000566e-7,4.210777e-8,0.000029035802,0.0070238984,0.9844743],"study_design_scores_gemma":[0.005399999,0.005672301,0.00460176,0.0055983164,0.008580249,0.001609031,0.000003941689,0.0000010765933,0.0000015772804,0.00007337919,0.96833104,0.00012735152],"about_ca_topic_score_codex":0.0000041504927,"about_ca_topic_score_gemma":0.0000119328315,"teacher_disagreement_score":0.9843469,"about_ca_system_score_codex":0.00064885616,"about_ca_system_score_gemma":0.008008186,"threshold_uncertainty_score":0.9976155},"labels":[],"label_agreement":null},{"id":"W2167674154","doi":"10.1200/jco.2006.08.8575","title":"American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":539,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Health Canada","keywords":"Medicine; Breast cancer; Physical examination; Mammography; Guideline; Asymptomatic; Cancer; Radiology; Internal medicine; Pathology","score_opus":0.06919923087578418,"score_gpt":0.4612869214665749,"score_spread":0.39208769059079074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167674154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94298285,0.0024952793,0.00006885015,0.05246498,0.0009526117,0.00021453064,0.000062065345,0.0000017601074,0.00075708807],"genre_scores_gemma":[0.9772218,0.011969336,0.0039193956,0.0054138084,0.0013296739,0.000012962475,0.0000040273026,0.000013402111,0.00011561484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953887,0.0008335015,0.003028029,0.0002544291,0.0002646393,0.0002307395],"domain_scores_gemma":[0.99533695,0.00065059063,0.0032426582,0.0002730244,0.0004369501,0.000059826794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041713086,0.00016407245,0.0012175441,0.000029088495,0.000052428615,0.0000040729246,0.00040707868,0.00024825617,0.000007686791],"category_scores_gemma":[0.00038143992,0.00008764355,0.0006898488,0.00015641794,0.00096373557,0.000006799849,0.0002789017,0.00041074885,3.8816336e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014346784,0.00079025695,0.59922904,0.000031026568,0.0007283939,0.000016659922,0.000050445888,0.000107941254,0.00025931787,0.00006528834,0.061360884,0.33592603],"study_design_scores_gemma":[0.0048833876,0.0011720294,0.8627748,0.00006407574,0.0003526958,0.00008722557,0.000518778,0.000030180172,0.00011048129,0.00014177908,0.1297786,0.00008599826],"about_ca_topic_score_codex":0.0007688105,"about_ca_topic_score_gemma":0.0022343246,"teacher_disagreement_score":0.33584005,"about_ca_system_score_codex":0.000048367292,"about_ca_system_score_gemma":0.00060550147,"threshold_uncertainty_score":0.35740003},"labels":[],"label_agreement":null},{"id":"W2167726338","doi":"10.1200/jco.2011.35.1965","title":"Androgen-Producing Testicular Germ Cell Tumors","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen; Germ cell; Cancer research; Germ cell tumors; Oncology; Internal medicine; Chemotherapy; Hormone; Biology; Genetics; Gene","score_opus":0.17582815133848168,"score_gpt":0.44112078049286474,"score_spread":0.26529262915438306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167726338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046206,0.0021542315,0.00010626721,0.00041653594,0.0006517373,0.00013826037,0.000001527323,0.000013670096,0.006055683],"genre_scores_gemma":[0.9856761,0.00014016425,0.012404068,0.00092341314,0.0006503801,0.0000016411384,0.0000012771555,0.000016823788,0.00018613669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976441,0.00017479579,0.0015388826,0.00018235162,0.0002570306,0.00020280607],"domain_scores_gemma":[0.99686724,0.00054538395,0.0014207619,0.00023438287,0.00033063922,0.0006015865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012207818,0.000121778496,0.0010197769,0.000074874035,0.00003114868,0.0000042251336,0.00010530556,0.00017008084,0.0002939576],"category_scores_gemma":[0.004279654,0.00007928524,0.0005586312,0.00009366912,0.00011557145,0.00006434701,0.00003638805,0.00045298118,0.00007465048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014712905,0.0065166154,0.90064144,0.00005653812,0.00044291114,0.0143176215,0.00012499875,0.000003420231,0.00014320869,0.0000615439,0.0011094497,0.07511098],"study_design_scores_gemma":[0.0068942537,0.011838305,0.97086215,0.00011493352,0.0013885541,0.0019300072,0.00006093346,0.000032165015,0.0006765467,0.0006245602,0.0054819086,0.000095665935],"about_ca_topic_score_codex":0.000023209128,"about_ca_topic_score_gemma":0.0000020913708,"teacher_disagreement_score":0.075015314,"about_ca_system_score_codex":0.00006453022,"about_ca_system_score_gemma":0.0012723008,"threshold_uncertainty_score":0.5123455},"labels":[],"label_agreement":null},{"id":"W2167741645","doi":"10.1200/jco.2007.12.6441","title":"Ontario Cancer Research Ethics Board: Lessons Learned From Developing a Multicenter Regional Institutional Review Board","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cambridge Memorial Hospital; Ottawa Hospital; University Health Network","funders":"","keywords":"Institutional review board; Medicine; Clinical trial; Clinical Oncology; Ethics committee; Quality (philosophy); Clinical research; Cancer; Medical education; Family medicine; Political science; Internal medicine; Public administration; Surgery","score_opus":0.945884848093559,"score_gpt":0.745323091595735,"score_spread":0.20056175649782404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167741645","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25669408,0.009282544,0.00032845978,0.72604644,0.0019377104,0.00044778644,0.00000829252,0.00001451515,0.0052402047],"genre_scores_gemma":[0.15960805,0.66982794,0.053722005,0.09950624,0.005709087,0.000048544363,0.000019566767,0.000057757894,0.0115008475],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98584646,0.0035810766,0.0047408175,0.0006286557,0.0044957967,0.0007071834],"domain_scores_gemma":[0.8529777,0.1329411,0.00231173,0.00084216386,0.009349172,0.0015781656],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.048981354,0.00022243806,0.0022830714,0.00025771133,0.00045161817,0.000017715778,0.0007845592,0.0021825864,0.0012719391],"category_scores_gemma":[0.20605378,0.00016549493,0.0009115319,0.00043295283,0.0030065756,0.00019507413,0.0004256741,0.03185424,0.00022153686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027474811,0.008062733,0.3772126,0.0021861668,0.0037825692,0.01622648,0.0040290244,0.000039577506,0.00038105092,0.01930999,0.3606999,0.18059511],"study_design_scores_gemma":[0.0055589043,0.0020992537,0.18086448,0.0075476654,0.00018749676,0.0002253082,0.00007860771,0.000013384861,0.000022925415,0.010509287,0.7927431,0.00014958905],"about_ca_topic_score_codex":0.012161365,"about_ca_topic_score_gemma":0.08226689,"teacher_disagreement_score":0.66054535,"about_ca_system_score_codex":0.0021658707,"about_ca_system_score_gemma":0.09136486,"threshold_uncertainty_score":0.9997067},"labels":[],"label_agreement":null},{"id":"W2167923186","doi":"10.1200/jco.2010.30.2729","title":"Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":452,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Temozolomide; Medicine; Bevacizumab; Internal medicine; Cohort; Oncology; Radiation therapy; Prospective cohort study; Glioblastoma; Cancer; Phases of clinical research; Toxicity; Surgery; Chemotherapy; Cancer research","score_opus":0.030032197029782447,"score_gpt":0.39776993168176245,"score_spread":0.36773773465198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167923186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977869,0.0000941167,0.0000052821306,0.0005532167,0.00041346884,0.0011237136,0.000009457045,0.000004642474,0.000009236203],"genre_scores_gemma":[0.9983647,0.00012583382,0.00093529734,0.00016523113,0.00032319044,0.0000605135,0.0000024128105,0.000016703196,0.0000061255378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801695,0.0000886332,0.0013173762,0.0001684737,0.0002487421,0.00015983263],"domain_scores_gemma":[0.9966832,0.0012636515,0.0012418508,0.00015176774,0.00041792865,0.00024160506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059165765,0.00013573165,0.0010212805,0.00014176396,0.000058971422,0.00000629105,0.00006187693,0.00018579166,0.000029956935],"category_scores_gemma":[0.0009564712,0.000080306134,0.00017971107,0.000072791525,0.00008804646,0.000113015565,0.000024892486,0.00034393193,5.8650124e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06603684,0.04438905,0.65843934,0.000018176728,0.0005973466,0.00021084785,0.00058101444,0.000005428894,0.00037511584,0.0000019422434,0.000071274786,0.2292736],"study_design_scores_gemma":[0.19396867,0.17086299,0.6334238,0.0000281208,0.00027984835,0.00002413796,0.00009574637,0.000040188825,0.00040542212,0.000008057883,0.00081046997,0.000052524167],"about_ca_topic_score_codex":0.000011562698,"about_ca_topic_score_gemma":0.00020163224,"teacher_disagreement_score":0.22922108,"about_ca_system_score_codex":0.000061764906,"about_ca_system_score_gemma":0.00027246005,"threshold_uncertainty_score":0.32747892},"labels":[],"label_agreement":null},{"id":"W2168041710","doi":"10.1200/jco.2014.58.2700","title":"First Site of Failure Analysis Incompletely Addresses Issues of Late and Unexpected Metastases in p16-Positive Oropharyngeal Cancer","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Internal medicine; Oncology","score_opus":0.1518838321242156,"score_gpt":0.47773759520363124,"score_spread":0.3258537630794156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168041710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55975544,0.022068318,0.000008839336,0.41635108,0.0005591451,0.0002877708,0.000554328,0.0000057549546,0.0004093458],"genre_scores_gemma":[0.8142557,0.04085947,0.005467305,0.13003483,0.008301674,0.000027742137,0.00018797483,0.00009496025,0.0007703559],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943372,0.0008191183,0.0035694342,0.00032484139,0.00065169466,0.00029768248],"domain_scores_gemma":[0.990408,0.0037559634,0.0037447673,0.00022688697,0.0016547253,0.00020963413],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017243832,0.0003122234,0.0075072944,0.00076005573,0.000027146738,0.000005505954,0.00017928265,0.000909689,0.00021728718],"category_scores_gemma":[0.0024211754,0.00021573412,0.0007894694,0.0007066464,0.0006281931,0.000095455944,0.00013902641,0.0023739676,0.0000013592153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061121355,0.0010741169,0.18752345,0.0010297432,0.017512392,0.0052520675,0.0015149864,0.000071426635,0.00015111246,0.0000039783786,0.7731942,0.006560373],"study_design_scores_gemma":[0.010220937,0.017280951,0.3833614,0.0020460638,0.015993947,0.00010025935,0.00037524436,0.00006200732,0.00018295823,0.00009060147,0.5699541,0.00033151932],"about_ca_topic_score_codex":0.0015751033,"about_ca_topic_score_gemma":0.0070151226,"teacher_disagreement_score":0.28631625,"about_ca_system_score_codex":0.00018192275,"about_ca_system_score_gemma":0.0016407816,"threshold_uncertainty_score":0.9999276},"labels":[],"label_agreement":null},{"id":"W2168111444","doi":"10.1200/jco.2006.06.8866","title":"Increasing Negative Lymph Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Dalhousie University; St. Michael's Hospital","funders":"","keywords":"Medicine; Lymph; Stage (stratigraphy); Internal medicine; Colorectal cancer; Lymph node; Cancer; Proportional hazards model; Oncology; Survival analysis; Disease; Gastroenterology; Surgery; Pathology","score_opus":0.06698265246425135,"score_gpt":0.4229626330922533,"score_spread":0.35597998062800196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168111444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511856,0.00050002197,0.00001258741,0.0017908025,0.00051789306,0.00034828988,0.000027827877,0.000011549831,0.0016724494],"genre_scores_gemma":[0.99733925,0.00043328467,0.00024025257,0.0010090851,0.00038753028,0.000013796997,0.0000059840713,0.000026653683,0.00054414885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635434,0.00067991414,0.001751161,0.00031140554,0.0005373118,0.0003658959],"domain_scores_gemma":[0.99380004,0.0034762765,0.0017843606,0.00012770112,0.00049819535,0.0003133952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024862904,0.00022865325,0.0018102136,0.00014925287,0.000049783714,0.000020584761,0.00011080584,0.00047874165,0.00018666596],"category_scores_gemma":[0.0017431553,0.00015932656,0.00020239782,0.0002850174,0.0003071386,0.00015674229,0.000069434,0.0009189121,0.00000189483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018639248,0.0017488411,0.96768075,0.000023156636,0.0005394347,0.0023011,0.00008430606,0.000014230894,0.00019269521,0.000007144817,0.000028791323,0.008740317],"study_design_scores_gemma":[0.029879292,0.00580635,0.962628,0.0003506563,0.00040915277,0.00018828851,0.000053074324,0.00014732727,0.000110925874,0.000057469457,0.00022397962,0.00014548794],"about_ca_topic_score_codex":0.002646195,"about_ca_topic_score_gemma":0.0083000325,"teacher_disagreement_score":0.011240046,"about_ca_system_score_codex":0.0015892729,"about_ca_system_score_gemma":0.002190084,"threshold_uncertainty_score":0.6497149},"labels":[],"label_agreement":null},{"id":"W2168150041","doi":"10.1200/jco.2007.14.1226","title":"Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Radiation therapy; Lung cancer; Adjuvant therapy; Stage (stratigraphy); Cancer; Chemotherapy; Randomized controlled trial; Clinical trial; Adjuvant; Guideline; Pathology","score_opus":0.09049530245510579,"score_gpt":0.5091828531438559,"score_spread":0.41868755068875013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168150041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538631,0.027843772,0.00032870632,0.015515818,0.001148614,0.0009716301,0.000031159776,0.000007805851,0.00028941574],"genre_scores_gemma":[0.71602434,0.2534085,0.01730499,0.010247223,0.0025332745,0.000062205305,0.000015254735,0.000045585955,0.00035862724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948873,0.00021934698,0.0037195631,0.00043561804,0.00032412837,0.00041407178],"domain_scores_gemma":[0.9914178,0.0030318024,0.0035485562,0.00022283992,0.0012510321,0.0005279182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048282547,0.00026325055,0.0029383497,0.00009000166,0.00007920415,0.0000099641,0.00013119026,0.00051961065,0.0001585116],"category_scores_gemma":[0.00032044086,0.00018023042,0.00065906974,0.00014286494,0.000450452,0.00008437955,0.000046343008,0.00085020537,2.3624793e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006481896,0.0011022433,0.5031526,0.00007426883,0.0008798572,0.000027565338,0.00097319117,0.000013485665,0.000117699645,0.0000022078043,0.015248851,0.47192612],"study_design_scores_gemma":[0.03121101,0.022942223,0.6100585,0.0001432372,0.00083938934,0.000019830048,0.00071451324,0.0001823629,0.00064015575,0.000016338332,0.33309373,0.0001387568],"about_ca_topic_score_codex":0.01168476,"about_ca_topic_score_gemma":0.05015178,"teacher_disagreement_score":0.47178736,"about_ca_system_score_codex":0.0013157163,"about_ca_system_score_gemma":0.0071523334,"threshold_uncertainty_score":0.9984762},"labels":[],"label_agreement":null},{"id":"W2168272173","doi":"10.1200/jco.2005.00.141","title":"Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":599,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Tolerability; Population; Geriatric oncology; Protocol (science); Comorbidity; Cancer; Alternative medicine; Gerontology; Intensive care medicine; Family medicine; Internal medicine; Pathology","score_opus":0.4656382711515077,"score_gpt":0.6193314779074455,"score_spread":0.15369320675593778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168272173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034248133,0.9803101,0.000026119265,0.005172212,0.0028497083,0.0111851115,0.000085489315,0.000004876103,0.00033215762],"genre_scores_gemma":[0.000024367186,0.9896096,0.0011930257,0.006404765,0.001940549,0.00031125118,0.000012610202,0.00006015113,0.0004437034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9548182,0.0138750905,0.029011976,0.00042653232,0.0015165183,0.00035169764],"domain_scores_gemma":[0.9304633,0.030179024,0.034447014,0.0011417437,0.0024777448,0.0012911713],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.057481173,0.00051344826,0.030299114,0.00021159498,0.000029125622,0.000005849752,0.00089738425,0.001095623,0.0006760046],"category_scores_gemma":[0.17309903,0.00021547276,0.005157745,0.00042587184,0.0003602385,0.00006519208,0.0001350906,0.0024253398,0.000026402098],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059834373,0.0009817354,0.00030827324,0.41668987,0.0042904182,0.000027537619,0.000036222656,5.5659024e-7,4.0917802e-9,0.000006679367,0.02156207,0.5554983],"study_design_scores_gemma":[0.003121191,0.007085506,0.00027256203,0.4779479,0.022830168,0.000052572614,0.000015625707,2.8137836e-7,4.5562597e-8,0.0000011002273,0.48857084,0.00010222641],"about_ca_topic_score_codex":0.000019402316,"about_ca_topic_score_gemma":0.00007420011,"teacher_disagreement_score":0.5553961,"about_ca_system_score_codex":0.0005433406,"about_ca_system_score_gemma":0.013166636,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W2168277549","doi":"10.1200/jco.2007.13.6259","title":"Randomized Trials in Oncology Stopped Early for Benefit","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"American Society of Clinical Oncology","keywords":"Medicine; Randomized controlled trial; Oncology; Internal medicine","score_opus":0.5832471168048358,"score_gpt":0.6369056377210007,"score_spread":0.053658520916164965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168277549","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033674837,0.977935,0.00024108312,0.0030519245,0.004121943,0.0037179198,0.000010120336,0.000012719143,0.010572548],"genre_scores_gemma":[0.000023170483,0.98536706,0.0045706267,0.0018786737,0.0053898967,0.00009569871,0.000016032067,0.00006646652,0.00259237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96415275,0.011715462,0.022386057,0.00045882157,0.00065420923,0.00063271436],"domain_scores_gemma":[0.65381384,0.3325129,0.012018665,0.000328114,0.0006056484,0.0007208437],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.16010496,0.00053879194,0.07228582,0.0009322588,0.00003130977,0.000016219803,0.0003774465,0.0038149513,0.00018688905],"category_scores_gemma":[0.1721782,0.00030132468,0.027897062,0.00035130556,0.0004328386,0.00006880007,0.00005685357,0.0031357217,0.000039400533],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1738174,0.00094954454,0.000085556654,0.0014167025,0.0023519527,0.0024924257,0.000027359789,3.5305774e-7,3.4385362e-8,0.0015717581,0.00065615936,0.8166308],"study_design_scores_gemma":[0.24863856,0.0059287166,0.0001646309,0.0027745625,0.011288963,0.0013529754,0.000012544045,0.0000012070674,5.5097814e-8,0.00023741236,0.7294131,0.00018729693],"about_ca_topic_score_codex":0.000017735583,"about_ca_topic_score_gemma":0.00002426551,"teacher_disagreement_score":0.81644344,"about_ca_system_score_codex":0.0006390113,"about_ca_system_score_gemma":0.006679506,"threshold_uncertainty_score":0.9999439},"labels":[],"label_agreement":null},{"id":"W2168372454","doi":"10.1200/jco.2014.56.9590","title":"Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Hazard ratio; Breast cancer; Docetaxel; Clinical endpoint; Pertuzumab; Cancer; Clinical trial; Confidence interval","score_opus":0.3663924786049742,"score_gpt":0.5653644802031109,"score_spread":0.19897200159813672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168372454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701577,0.000698577,0.00021655275,0.023228085,0.0019270469,0.0012988972,0.00086208724,0.00001995906,0.0015910998],"genre_scores_gemma":[0.98441476,0.0018609967,0.006523249,0.0015882119,0.0037401663,0.000072370385,0.000031092266,0.00006282827,0.0017063344],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99316204,0.0008637575,0.0039016365,0.00042803574,0.0010235514,0.0006209902],"domain_scores_gemma":[0.98731804,0.0049543716,0.0031305163,0.00031962976,0.0032607939,0.0010166349],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051754755,0.00029352197,0.002657166,0.00022613673,0.000078471894,0.000012650956,0.00047101485,0.0005803033,0.00051870506],"category_scores_gemma":[0.009260351,0.00019574934,0.0006668935,0.0002989958,0.0005606575,0.00019932124,0.00007393187,0.0015994053,0.00001191243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3210934,0.003299223,0.011080873,0.00019652773,0.0009435716,0.00045986383,0.0011180202,0.00004823882,0.003423689,0.00007210546,0.06657383,0.59169066],"study_design_scores_gemma":[0.21080253,0.21438357,0.36308277,0.0014007081,0.00051106274,0.0015418527,0.0014301983,0.00021435325,0.010291003,0.0006419319,0.19500262,0.00069741486],"about_ca_topic_score_codex":0.00032206925,"about_ca_topic_score_gemma":0.0002705607,"teacher_disagreement_score":0.5909932,"about_ca_system_score_codex":0.0012830805,"about_ca_system_score_gemma":0.012791321,"threshold_uncertainty_score":0.99908507},"labels":[],"label_agreement":null},{"id":"W2168460655","doi":"10.1200/jco.2008.17.3781","title":"Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":582,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Hazard ratio; Chemotherapy; Fluorouracil; Surgery; Clinical trial; Randomized controlled trial; Adjuvant; Internal medicine; Cancer; Gastroenterology; Confidence interval","score_opus":0.15554352422905104,"score_gpt":0.5032767936248416,"score_spread":0.3477332693957905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168460655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921793,0.0036822136,0.0006041469,0.0014989537,0.0008655573,0.00068251626,0.00017164466,0.000006673216,0.00030902412],"genre_scores_gemma":[0.9890949,0.0063222246,0.003480356,0.00045762275,0.00050886767,0.000046897218,0.00001629241,0.000016144251,0.000056679502],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98859704,0.004405582,0.005805744,0.00027219713,0.0007217675,0.00019765428],"domain_scores_gemma":[0.9764023,0.015359246,0.00653986,0.00018241261,0.001258619,0.00025756547],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0075939544,0.00022119338,0.010245872,0.00047798952,0.000027952974,0.0000034078814,0.00013946815,0.0003027823,0.0017586084],"category_scores_gemma":[0.011693747,0.00013430142,0.004352882,0.0007712975,0.0006614893,0.000112158974,0.000038026596,0.00054456684,0.0000017215579],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8387894,0.0028072256,0.06258686,0.000012005573,0.05529145,0.0006283993,0.00037204527,0.00015107244,0.0027892883,0.000006938338,0.00027931147,0.036285978],"study_design_scores_gemma":[0.49936235,0.020269137,0.4054986,0.00018443527,0.059879508,0.00009341562,0.00008119151,0.00060002215,0.012416075,0.00034246978,0.0011039104,0.00016887367],"about_ca_topic_score_codex":0.0010216038,"about_ca_topic_score_gemma":0.0010122261,"teacher_disagreement_score":0.34291175,"about_ca_system_score_codex":0.00024783163,"about_ca_system_score_gemma":0.0018355966,"threshold_uncertainty_score":0.9991539},"labels":[],"label_agreement":null},{"id":"W2168533928","doi":"10.1200/jco.2005.04.8207","title":"Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Hope Foundation; American Society of Clinical Oncology","keywords":"Medicine; Estramustine; Docetaxel; Prostate cancer; Quality of life (healthcare); Mitoxantrone; Performance status; Internal medicine; Prednisone; Palliative care; Analgesic; Oncology; Cancer; Physical therapy; Anesthesia; Chemotherapy; Nursing","score_opus":0.08837867639219621,"score_gpt":0.45006755649640967,"score_spread":0.36168888010421346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168533928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992544,0.0016301788,0.00026560455,0.003766336,0.00024703806,0.001295279,0.00002090364,0.000005287897,0.00022536697],"genre_scores_gemma":[0.98972005,0.002090758,0.0073912297,0.00031247034,0.00035999532,0.000018045892,0.0000049169375,0.000009988265,0.00009252584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992675,0.0019789382,0.004581156,0.0002602568,0.00026846235,0.00023619164],"domain_scores_gemma":[0.98809105,0.00823481,0.0030642967,0.00013405608,0.00019598364,0.0002798088],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019938558,0.00016004541,0.003722978,0.0002154006,0.000021851147,0.000006754918,0.000081827784,0.00022996587,0.0000043561045],"category_scores_gemma":[0.015263524,0.00011845295,0.00016927185,0.00014814363,0.0004841829,0.00007833613,0.000089513225,0.0005085181,9.6349076e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75800425,0.0012881503,0.21213414,0.00024231698,0.00019660585,0.000038765615,0.0002904035,0.000112484035,0.00037288727,0.00014748455,0.00012806575,0.027044425],"study_design_scores_gemma":[0.62472326,0.013050185,0.3590169,0.000163177,0.0001699405,0.0000024562555,0.0003076557,0.0004480718,0.000008937452,0.00020558393,0.001827555,0.000076269236],"about_ca_topic_score_codex":0.0006912364,"about_ca_topic_score_gemma":0.0020641624,"teacher_disagreement_score":0.14688276,"about_ca_system_score_codex":0.000059277125,"about_ca_system_score_gemma":0.0004557728,"threshold_uncertainty_score":0.9930313},"labels":[],"label_agreement":null},{"id":"W2168581409","doi":"10.1200/jco.2008.19.7251","title":"Insulin Resistance and Risk Factors for Cardiovascular Disease in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Center for Research Resources; National Institutes of Health; National Cancer Institute; Georgia Clinical and Translational Science Alliance","keywords":"Medicine; Insulin resistance; Internal medicine; Cohort; Odds ratio; Pediatrics; Insulin","score_opus":0.03748562097272653,"score_gpt":0.37225735373764196,"score_spread":0.33477173276491545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168581409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917979,0.004011901,0.0006904433,0.002002568,0.00079800875,0.00045776073,0.000064502914,0.000011280449,0.00016563128],"genre_scores_gemma":[0.98797554,0.007614663,0.002986886,0.0006234383,0.0007280134,0.000003878207,0.0000066504444,0.000023475051,0.00003745208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99450517,0.00080370356,0.0033260428,0.00036454006,0.00067429146,0.00032628368],"domain_scores_gemma":[0.9926396,0.003654309,0.0020535162,0.0004213876,0.00056570186,0.0006654737],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004928166,0.00024079563,0.0027292937,0.00021802339,0.00004750803,0.0000086072605,0.00022316507,0.0003688025,0.0000075489766],"category_scores_gemma":[0.018872516,0.00019167722,0.0015226742,0.00024371875,0.00024590746,0.00014552311,0.00003757119,0.00082536053,9.2292737e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016560342,0.0023572075,0.9490436,0.00022678768,0.0041206134,0.00032975108,0.0017994591,0.00048254026,0.000014794463,0.00023137227,0.0006043271,0.024229215],"study_design_scores_gemma":[0.015407168,0.0047621867,0.973317,0.0004438921,0.002455461,0.00004036697,0.00028227697,0.00010738926,0.00002488204,0.0016031143,0.0013841393,0.00017206969],"about_ca_topic_score_codex":0.00064342516,"about_ca_topic_score_gemma":0.001550533,"teacher_disagreement_score":0.024273464,"about_ca_system_score_codex":0.00031954944,"about_ca_system_score_gemma":0.002407314,"threshold_uncertainty_score":0.9893919},"labels":[],"label_agreement":null},{"id":"W2168598415","doi":"10.1200/jco.2004.07.199","title":"Quality of Abstracts Describing Randomized Trials in the Proceedings of American Society of Clinical Oncology Meetings: Guidelines for Improved Reporting","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Randomized controlled trial; Quality Score; Presentation (obstetrics); Quality (philosophy); Sample size determination; Family medicine; Medical physics; Clinical trial; MEDLINE; Identification (biology); Internal medicine; Surgery; Statistics","score_opus":0.9698960864647505,"score_gpt":0.7487930374191814,"score_spread":0.2211030490455691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168598415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"reporting","domain_gemma":"reporting","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":"reporting","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680478,0.00035463742,0.0063431347,0.021337962,0.000789741,0.0017000068,0.0000074022823,0.0000014932041,0.0014178299],"genre_scores_gemma":[0.76580256,0.0004221786,0.23112547,0.0018535999,0.00071647926,0.000020433741,6.000937e-7,0.000009455036,0.00004922107],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.23180401,0.09618848,0.6605762,0.0018314986,0.008683057,0.00091672654],"domain_scores_gemma":[0.019811677,0.4270374,0.5318048,0.0009939837,0.020082677,0.00026945188],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.93195474,0.00027432916,0.04301779,0.00025462962,0.000050954422,0.0000540114,0.0018986902,0.0005448345,0.000073908675],"category_scores_gemma":[0.96665484,0.00010897763,0.021472376,0.00093878235,0.0011633761,0.00021957907,0.00013243525,0.00094988686,0.0000019412828],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080758885,0.006090171,0.070348136,0.000601272,0.0062330626,0.000014865915,0.0037488106,0.00078893924,0.006306962,0.0024463178,0.05233079,0.7703318],"study_design_scores_gemma":[0.47416186,0.028399462,0.18234968,0.0019820263,0.011693334,0.00026651323,0.06612876,0.0067110984,0.0014704168,0.11955677,0.106302254,0.0009778145],"about_ca_topic_score_codex":0.00018267345,"about_ca_topic_score_gemma":0.0001042601,"teacher_disagreement_score":0.769354,"about_ca_system_score_codex":0.00007220602,"about_ca_system_score_gemma":0.00282359,"threshold_uncertainty_score":0.9883273},"labels":[],"label_agreement":null},{"id":"W2168658644","doi":"10.1200/jco.2005.05.4155","title":"Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":211,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Immunohistochemistry; Monoclonal antibody; Lymphovascular invasion; Internal medicine; Oncology; Estrogen receptor; Cancer; Tissue microarray; Population; Antibody; Pathology; Immunology; Metastasis","score_opus":0.038010499012506097,"score_gpt":0.4174769809453533,"score_spread":0.3794664819328472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168658644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945995,0.001132948,0.0003690114,0.0027714977,0.0008330574,0.00019093031,0.0000640394,0.00000325646,0.000035739537],"genre_scores_gemma":[0.9953585,0.00045845212,0.0019243386,0.00025788628,0.0019211516,0.000007000422,0.0000147520095,0.000025516967,0.000032397245],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99688596,0.00032158417,0.0018441658,0.00032661812,0.00028256836,0.00033912406],"domain_scores_gemma":[0.99825,0.0002669591,0.00089106447,0.00020321466,0.0002557207,0.00013304963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011349206,0.00022061962,0.0009108325,0.00011602456,0.00005487292,0.000010429792,0.00029578837,0.00038241822,0.000036086927],"category_scores_gemma":[0.0003166135,0.0001689786,0.00035530992,0.0002336694,0.0002046245,0.000017893439,0.00016202223,0.0005290077,0.0000013306133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030747121,0.00042739857,0.49145636,0.0000070529186,0.00016214696,0.00001392283,0.000087535336,0.00058833323,0.49963105,0.0000022140337,0.00018290973,0.004366351],"study_design_scores_gemma":[0.0063776327,0.0013649865,0.8887118,0.00012642783,0.00016097057,0.00024571814,0.00024160456,0.0002869204,0.09871665,0.000040377457,0.0034625402,0.0002643883],"about_ca_topic_score_codex":0.004332328,"about_ca_topic_score_gemma":0.0009290426,"teacher_disagreement_score":0.4009144,"about_ca_system_score_codex":0.00028692928,"about_ca_system_score_gemma":0.0010534019,"threshold_uncertainty_score":0.6890747},"labels":[],"label_agreement":null},{"id":"W2168746889","doi":"10.1200/jco.2010.28.4455","title":"Decrease in Depression Symptoms Is Associated With Longer Survival in Patients With Metastatic Breast Cancer: A Secondary Analysis","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":468,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"National Institute of Mental Health; National Cancer Institute; Fetzer Institute; National Institute on Aging; John D. and Catherine T. MacArthur Foundation","keywords":"Medicine; Depression (economics); Breast cancer; Center for Epidemiologic Studies Depression Scale; Internal medicine; Cancer; Proportional hazards model; Comorbidity; Randomized controlled trial; Metastatic breast cancer; Oncology; Depressive symptoms; Psychiatry; Anxiety","score_opus":0.02716479896768952,"score_gpt":0.3821664483470535,"score_spread":0.35500164937936396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168746889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783385,0.00009581524,0.00001807864,0.000919001,0.0005317674,0.00016723321,0.00004620478,0.000005161582,0.0003828913],"genre_scores_gemma":[0.99814934,0.000043085427,0.00014204466,0.0014177512,0.00015268501,0.000007940038,0.000016682967,0.000018793815,0.000051694722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696594,0.00046507764,0.0014694663,0.00025205323,0.0005752776,0.00027216293],"domain_scores_gemma":[0.99618506,0.0011904626,0.0012787838,0.00021117256,0.00062964874,0.0005048709],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021800569,0.00016917314,0.0018881466,0.00042208104,0.000020279283,0.000010219176,0.00014027972,0.00027256052,0.000982886],"category_scores_gemma":[0.0008829609,0.00010181922,0.00029761263,0.0008977787,0.00015217153,0.00014687693,0.00003090101,0.001796785,0.0000015978801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010362135,0.0021652158,0.9426929,0.000012063827,0.0014992387,0.0005547327,0.00024001955,0.000026186852,0.000004041722,0.0000014477007,0.000095475545,0.04234659],"study_design_scores_gemma":[0.018557923,0.002803221,0.9756875,0.00019786842,0.002021691,0.000037488146,0.00011153771,0.000092968934,0.000004735592,0.000013788138,0.0003497447,0.0001215497],"about_ca_topic_score_codex":0.0012892244,"about_ca_topic_score_gemma":0.08400173,"teacher_disagreement_score":0.0827125,"about_ca_system_score_codex":0.00021793501,"about_ca_system_score_gemma":0.0024385503,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2168937900","doi":"10.1200/jco.2010.32.8401","title":"Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Tumor microenvironment; Immune system; Medicine; Lymphoma; Chemokine; Cancer research; Immunology; Disease; Phenotype; Pathology; Biology; Gene","score_opus":0.1796136450142673,"score_gpt":0.4531361394043717,"score_spread":0.2735224943901044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168937900","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18121292,0.81712765,0.0000029421733,0.00040327723,0.0005618374,0.00051707064,0.000014646642,0.000001015564,0.00015865033],"genre_scores_gemma":[0.11412295,0.8845423,0.00083178567,0.00028722585,0.00016135248,0.0000106027865,6.3121564e-7,0.000025246833,0.000017939547],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9918569,0.0019588298,0.005171596,0.00025009658,0.0005634287,0.00019920149],"domain_scores_gemma":[0.982309,0.0037816733,0.01261705,0.00086774165,0.00025909103,0.00016543387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003739005,0.0002994338,0.0051022274,0.00007994766,0.000027948588,0.000001956064,0.0006913526,0.00058905163,0.00004834657],"category_scores_gemma":[0.0041097673,0.00013153937,0.0037048643,0.0002108901,0.0006594347,0.000037083963,0.00031249496,0.000376842,0.0000020996886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005826586,0.0037695235,0.100312926,0.0038523315,0.0018409055,0.000244523,0.00003596735,9.986902e-7,0.00011853713,0.00008143114,0.00014648189,0.8890137],"study_design_scores_gemma":[0.005159005,0.006834492,0.4901486,0.05858161,0.022750817,0.0022512446,0.000031723765,8.5022594e-7,0.00096301915,0.00011065055,0.41294172,0.00022628416],"about_ca_topic_score_codex":0.00004801632,"about_ca_topic_score_gemma":0.000008864934,"teacher_disagreement_score":0.88878745,"about_ca_system_score_codex":0.00040059997,"about_ca_system_score_gemma":0.0036678463,"threshold_uncertainty_score":0.6506602},"labels":[],"label_agreement":null},{"id":"W2168962374","doi":"10.1200/jco.2004.11.918","title":"Economics of Preoperative Radiotherapy With Total Mesorectal Excision: What Can We Learn From the Dutch Experience?","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Total mesorectal excision; Radiation therapy; General surgery; Surgery; Colorectal cancer; Cancer; Internal medicine","score_opus":0.0938235751560439,"score_gpt":0.4144315799026736,"score_spread":0.3206080047466297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168962374","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6208181,0.0041574854,0.000017283986,0.371189,0.0025858164,0.00045002863,0.000023815855,0.000005349452,0.00075317855],"genre_scores_gemma":[0.1877294,0.057718173,0.006205701,0.7223004,0.021633623,0.000085880136,0.0000667609,0.00020900204,0.0040510576],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945287,0.0012361623,0.0027940057,0.0004783792,0.0005926477,0.0003700682],"domain_scores_gemma":[0.9884955,0.007168992,0.003070953,0.00047820076,0.0004947082,0.000291624],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010514539,0.00043247498,0.0035847796,0.00009488358,0.00006130322,0.0000464475,0.0004058017,0.0014057426,0.0013918554],"category_scores_gemma":[0.00078242854,0.00022088368,0.0010100949,0.0001631846,0.0008678479,0.00022451635,0.00006110952,0.004061102,0.0000065220133],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047952756,0.003065911,0.08253742,0.00007873202,0.012047433,0.014676748,0.011222226,0.00014077128,0.000026793505,0.000018442148,0.46856788,0.3596649],"study_design_scores_gemma":[0.014022816,0.037646353,0.025795288,0.0006558483,0.00097456865,0.0024334511,0.0019214267,0.000035156332,0.00010901335,0.00019127106,0.9158702,0.00034464477],"about_ca_topic_score_codex":0.000109162735,"about_ca_topic_score_gemma":0.00014377177,"teacher_disagreement_score":0.44730228,"about_ca_system_score_codex":0.00069332565,"about_ca_system_score_gemma":0.0036268476,"threshold_uncertainty_score":0.9998906},"labels":[],"label_agreement":null},{"id":"W2169007954","doi":"10.1200/jco.2008.19.6550","title":"Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"American Society of Clinical Oncology","keywords":"Medicine; Decitabine; Myelodysplastic syndromes; International Prognostic Scoring System; Dosing; Regimen; Hypomethylating agent; Internal medicine; Complete response; Clinical trial; Clinical endpoint; Oncology; Chemotherapy; Bone marrow","score_opus":0.16209615505307287,"score_gpt":0.4795324990879281,"score_spread":0.3174363440348552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169007954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848749,0.00005390539,0.002667083,0.0051872656,0.0009596711,0.0061405525,0.000028565208,0.00000633703,0.00008173213],"genre_scores_gemma":[0.9884652,0.000052069736,0.008857443,0.0009963788,0.0012579595,0.00014843447,0.0000066780512,0.000028235414,0.00018759226],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99532807,0.0004847489,0.0027828251,0.0003520757,0.00063804997,0.0004142219],"domain_scores_gemma":[0.98577094,0.010319616,0.0018275215,0.00036570535,0.0012513743,0.00046486137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026264363,0.00025573123,0.0019813702,0.00021756177,0.00008939236,0.000016509568,0.000343284,0.0002158903,0.000014151565],"category_scores_gemma":[0.0074773254,0.00012821448,0.0005039326,0.0001698571,0.0001363502,0.00009801447,0.000053071646,0.00054996257,0.0000028359987],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8756524,0.01931164,0.002850909,0.000041793526,0.0016592524,0.0003412777,0.0042477865,0.0001729037,0.000064276916,0.000012574061,0.0012568246,0.09438841],"study_design_scores_gemma":[0.35122272,0.603657,0.033759646,0.0003519291,0.0012715135,0.000113877526,0.003749894,0.0012089099,0.00011273479,0.000029330833,0.004399091,0.00012332576],"about_ca_topic_score_codex":0.000024787889,"about_ca_topic_score_gemma":0.00008724515,"teacher_disagreement_score":0.5843454,"about_ca_system_score_codex":0.00077945343,"about_ca_system_score_gemma":0.0018660885,"threshold_uncertainty_score":0.8951597},"labels":[],"label_agreement":null},{"id":"W2169171106","doi":"10.1200/jco.2014.59.9431","title":"Reply to D. Adkins et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine","score_opus":0.27227177173858214,"score_gpt":0.5513947171704373,"score_spread":0.2791229454318552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169171106","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059460616,0.007867733,0.000087486085,0.8902504,0.039310765,0.0003162154,0.00003023192,0.000012303541,0.05617882],"genre_scores_gemma":[0.0013268499,0.009265429,0.0043370016,0.9244097,0.046201162,0.00000819304,0.00000811455,0.0000688501,0.014374716],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98823917,0.002319948,0.00667944,0.00055364746,0.0013105767,0.0008972268],"domain_scores_gemma":[0.9827093,0.00886174,0.0038923067,0.0005481999,0.002249098,0.0017393387],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.017134052,0.00048461495,0.0069657955,0.0003140493,0.00006645621,0.000019267125,0.0005684004,0.0017520062,0.0009450435],"category_scores_gemma":[0.033013184,0.0003494287,0.0015315877,0.00027817546,0.0005426366,0.00012644513,0.00031591795,0.010022079,0.0011755844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003239059,0.0009882106,0.0039908453,0.00008114917,0.0012115773,0.011797691,0.00041420016,0.0000064424294,0.000008950099,0.000050381226,0.83389187,0.14431964],"study_design_scores_gemma":[0.0076745884,0.058564518,0.014192704,0.0015745655,0.001046918,0.0015131836,0.0001501221,0.0000067050682,0.0000032650141,0.00017010594,0.9148129,0.0002903935],"about_ca_topic_score_codex":0.00013400704,"about_ca_topic_score_gemma":0.00012606799,"teacher_disagreement_score":0.14402924,"about_ca_system_score_codex":0.0010869618,"about_ca_system_score_gemma":0.014144944,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W2169331014","doi":"10.1200/jco.2006.05.8073","title":"Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Quality of life (healthcare); Internal medicine; Clinical trial; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.14253774717634815,"score_gpt":0.5537721827973425,"score_spread":0.4112344356209944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169331014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637693,0.00021840476,0.000010576268,0.0012435209,0.00082241005,0.0008197322,0.0002010047,0.0000015797804,0.0003058639],"genre_scores_gemma":[0.9987954,0.00011553101,0.000103135164,0.0005216958,0.0003009438,0.000033253775,0.000014962229,0.0000086964765,0.000106398256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904421,0.0012828021,0.0069155577,0.00021122985,0.000986626,0.00016167913],"domain_scores_gemma":[0.988065,0.0026898049,0.007290568,0.0001696327,0.0016198246,0.00016515527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067304373,0.0001444575,0.0030737598,0.00019767767,0.00003150133,0.0000026235004,0.00016732058,0.00016325638,0.00009020392],"category_scores_gemma":[0.0042031533,0.00007717467,0.0006343728,0.00071686564,0.00022299206,0.00007296077,0.00003544106,0.0003843391,3.2227522e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004355916,0.008839361,0.9705483,0.000045154575,0.009505124,0.000006469825,0.00009394702,0.0019059558,0.000033730088,0.000037476242,0.0009166035,0.0037119635],"study_design_scores_gemma":[0.022092713,0.0045556556,0.9653901,0.00011607865,0.006992354,3.5451893e-7,0.00011437024,0.00015871854,0.00002572333,0.0000096216445,0.00048080002,0.0000635504],"about_ca_topic_score_codex":0.3290504,"about_ca_topic_score_gemma":0.70178264,"teacher_disagreement_score":0.37273222,"about_ca_system_score_codex":0.0007936584,"about_ca_system_score_gemma":0.01227504,"threshold_uncertainty_score":0.99332446},"labels":[],"label_agreement":null},{"id":"W2169366622","doi":"10.1200/jco.2010.30.8742","title":"Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Cognition; Visual memory; Verbal fluency test; Cognitive flexibility; Verbal memory; Neuropsychology; Cognitive decline; Cohort; Gerontology; Internal medicine; Cancer; Dementia; Disease; Psychiatry","score_opus":0.07663721529002063,"score_gpt":0.47039807504060294,"score_spread":0.3937608597505823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169366622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605906,0.00019503287,0.000051308336,0.0014139764,0.00036361572,0.0005252116,0.000010117927,0.0000045664333,0.0013771167],"genre_scores_gemma":[0.99706733,0.0017860485,0.00014820337,0.0005605366,0.00032281684,0.000019043395,0.000002982193,0.00001541329,0.000077618875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794793,0.00020135925,0.0012323075,0.00014787374,0.00030344827,0.00016708554],"domain_scores_gemma":[0.99601877,0.0014264234,0.0015435636,0.000077061144,0.0008024472,0.00013171644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014458317,0.00013128734,0.0009803569,0.00021076207,0.000021875077,0.000003161974,0.000043485572,0.00016338973,0.00018662246],"category_scores_gemma":[0.0014202945,0.00007654584,0.00023016227,0.00023705202,0.00023869229,0.00010708984,0.000012152277,0.0010850161,0.0000043668806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06023166,0.0020937503,0.7133251,0.00001513702,0.0014794815,0.00008167687,0.00035904,0.000043831587,0.0011053489,0.0000057613593,0.00046705722,0.22079216],"study_design_scores_gemma":[0.023574725,0.059238836,0.9151978,0.00029997705,0.00039384243,0.000064932865,0.00017263606,0.00005257939,0.0003797038,0.00012882707,0.00042643215,0.00006970507],"about_ca_topic_score_codex":0.00010486041,"about_ca_topic_score_gemma":0.00017693656,"teacher_disagreement_score":0.22072245,"about_ca_system_score_codex":0.00014338538,"about_ca_system_score_gemma":0.001568762,"threshold_uncertainty_score":0.4713915},"labels":[],"label_agreement":null},{"id":"W2169458356","doi":"10.1200/jco.2011.36.9504","title":"Molecular Detection of Tumor Cells in Regional Lymph Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative Colorectal Cancer: A Systematic Review and Meta-Analysis","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Deutsche Forschungsgemeinschaft","keywords":"Medicine; Colorectal cancer; Meta-analysis; Hazard ratio; Lymph node; Oncology; Internal medicine; Subgroup analysis; Lymph; Disease; Cancer; Pathology; Confidence interval","score_opus":0.19138679453393814,"score_gpt":0.45471550400017763,"score_spread":0.2633287094662395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169458356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013999771,0.98382044,0.0000048111356,0.0002519834,0.0000869464,0.0016646716,0.00012939429,0.0000034435204,0.000038544702],"genre_scores_gemma":[0.03229763,0.9668486,0.00012256864,0.0004156594,0.000023148908,0.00024372783,0.0000066734615,0.000025573037,0.000016379532],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99087447,0.0034413685,0.0044259587,0.0004942496,0.0005182788,0.0002456884],"domain_scores_gemma":[0.98701376,0.005199989,0.0065916623,0.00020330636,0.00056140235,0.0004298942],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0039576134,0.00044313635,0.018832799,0.00049991644,0.000017818724,0.0000071990808,0.00017153434,0.00036984688,0.00006902004],"category_scores_gemma":[0.004629753,0.0002546558,0.0022433647,0.0012261169,0.00035095456,0.00008049493,0.00007321921,0.000915266,8.5293584e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007536993,0.0049659247,0.012676697,0.5566243,0.37120688,0.0065990114,0.00018653135,0.0000066345415,0.0000017586916,0.000012722712,0.000018797668,0.040163744],"study_design_scores_gemma":[0.0035805148,0.0028185388,0.011595547,0.079191305,0.90171874,0.00020322438,0.000017489674,0.00003551324,0.000003421964,0.000037086273,0.0005042106,0.00029442928],"about_ca_topic_score_codex":0.00024534206,"about_ca_topic_score_gemma":0.00051913393,"teacher_disagreement_score":0.53051186,"about_ca_system_score_codex":0.0006549497,"about_ca_system_score_gemma":0.0021839938,"threshold_uncertainty_score":0.9999906},"labels":[],"label_agreement":null},{"id":"W2169508471","doi":"10.1200/jco.2002.06.077","title":"Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Population; Myeloid leukemia; Transplantation; Internal medicine; Bone marrow; Leukemia; Surgery","score_opus":0.06492735229229302,"score_gpt":0.40848794997173904,"score_spread":0.343560597679446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169508471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971133,0.0009924077,0.00006530927,0.0008575366,0.00036664927,0.00032902215,0.000021750328,0.000006686886,0.00024735028],"genre_scores_gemma":[0.9954217,0.002171516,0.001220511,0.0004886701,0.00020407718,0.000009041594,0.00002630661,0.000027077176,0.0004310685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460316,0.00051166094,0.003108356,0.00027475492,0.0012190001,0.0002830894],"domain_scores_gemma":[0.99501777,0.0015877457,0.0022503515,0.00026331792,0.00029367744,0.0005871609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017303654,0.00022640449,0.0021789612,0.00015399311,0.000025317086,0.0000040032414,0.00014906665,0.0004968145,0.002368749],"category_scores_gemma":[0.00093026867,0.00015464473,0.00043595265,0.0001122201,0.00043948548,0.00010808307,0.000057003323,0.00064549927,0.000010548572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058128773,0.0015270069,0.96314913,0.00029483897,0.001021642,0.0006035955,0.00009181684,0.0000075511166,0.000083186475,0.0000059612516,0.00015025586,0.02725215],"study_design_scores_gemma":[0.042975575,0.008572742,0.9466373,0.00029993212,0.00078596803,0.00011658009,0.000007800917,0.00005050783,0.00002306355,0.0000028615968,0.00040481915,0.00012285884],"about_ca_topic_score_codex":0.000027549922,"about_ca_topic_score_gemma":0.00046591513,"teacher_disagreement_score":0.0371627,"about_ca_system_score_codex":0.0014208455,"about_ca_system_score_gemma":0.0028206457,"threshold_uncertainty_score":0.9985432},"labels":[],"label_agreement":null},{"id":"W2169700609","doi":"10.1200/jco.2012.46.4149","title":"Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Takeda Oncology; Sanofi; Teva Pharmaceutical Industries; Genentech; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Docetaxel; Placebo; Prostate cancer; Internal medicine; Clinical endpoint; Peripheral edema; Adverse effect; Nausea; Hazard ratio; Oncology; Urology; Cancer; Randomized controlled trial; Surgery; Confidence interval; Pathology","score_opus":0.060853889279274966,"score_gpt":0.45027940075978057,"score_spread":0.3894255114805056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169700609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924314,0.00020301674,0.000011502484,0.0013129194,0.00010729813,0.005773655,0.0000036610904,0.0000024157048,0.00015411121],"genre_scores_gemma":[0.9987964,0.00017206665,0.00038878043,0.00008594815,0.00003376148,0.00030926018,0.0000065748363,0.000012858089,0.00019432034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535364,0.0010019552,0.0026058003,0.0001770096,0.00063370017,0.00022787493],"domain_scores_gemma":[0.9952708,0.001606284,0.0018825709,0.00012040028,0.00093575974,0.00018419897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031521975,0.00015422625,0.0027530836,0.00032596913,0.000022533379,0.000011985587,0.000085826294,0.00007831486,0.00010412284],"category_scores_gemma":[0.0007071514,0.00007535779,0.0001435016,0.00027989972,0.00022363785,0.00021783909,0.000014772213,0.00057897205,0.0000011488384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7737049,0.027316546,0.18752968,0.00003296595,0.0009662188,0.0002771661,0.00074493204,0.00010714904,0.00002854777,0.0000064134547,0.00003967753,0.009245807],"study_design_scores_gemma":[0.7675517,0.05361736,0.17663562,0.00019020338,0.00054391206,0.000005478219,0.00101928,0.00028572502,0.000016955246,0.0000659518,0.000008252604,0.000059551647],"about_ca_topic_score_codex":0.00075145246,"about_ca_topic_score_gemma":0.0015869406,"teacher_disagreement_score":0.02630081,"about_ca_system_score_codex":0.00027367906,"about_ca_system_score_gemma":0.0014732932,"threshold_uncertainty_score":0.30730015},"labels":[],"label_agreement":null},{"id":"W2169754983","doi":"10.1200/jco.2004.11.151","title":"Survey on Use of Palliative Radiotherapy in Hospice Care","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Radiation therapy; Life expectancy; Hospice care; Family medicine; Nursing; End-of-life care; Oncology; Internal medicine; Population","score_opus":0.2630132467077339,"score_gpt":0.5209646891336456,"score_spread":0.25795144242591167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169754983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993723,0.00044856634,0.0004132869,0.0040941564,0.0005139786,0.00024565778,0.000008466575,0.0000030725712,0.0005498109],"genre_scores_gemma":[0.98540974,0.0008312802,0.009122665,0.0043499116,0.00017379622,0.0000013014806,0.00000495427,0.000012677121,0.00009367214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967179,0.0006648803,0.001930539,0.00013531605,0.00040805555,0.00014334588],"domain_scores_gemma":[0.9948032,0.0029202134,0.0014268347,0.00019211469,0.0004319983,0.00022563424],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027767636,0.000101880534,0.0012840723,0.00017998836,0.000008114606,0.000003824542,0.00012036422,0.0001540357,0.00009476868],"category_scores_gemma":[0.0090824505,0.000074016454,0.00030205835,0.00017676628,0.00012983427,0.00007102851,0.000018409743,0.0005854109,0.0000054020647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012400452,0.004420359,0.9198632,0.000072068025,0.00046876955,0.0012005558,0.0005650993,0.0007016161,0.000020585825,0.00027900722,0.002194716,0.05781353],"study_design_scores_gemma":[0.015431014,0.012865497,0.9628191,0.00019498673,0.00013683777,0.0000027420813,0.00019344315,0.000019123001,0.000020567632,0.00013027023,0.008130007,0.000056440407],"about_ca_topic_score_codex":0.00016206825,"about_ca_topic_score_gemma":0.00026697532,"teacher_disagreement_score":0.057757087,"about_ca_system_score_codex":0.00022910845,"about_ca_system_score_gemma":0.0010381388,"threshold_uncertainty_score":0.9992645},"labels":[],"label_agreement":null},{"id":"W2169907889","doi":"10.1200/jco.2008.17.7139","title":"American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Guideline; Medicine; Timeline; Clinical Oncology; Medical education; Clinical Practice; Family medicine; Cancer; Pathology; Internal medicine","score_opus":0.8875596565938666,"score_gpt":0.6938473908040095,"score_spread":0.19371226578985712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169907889","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46033418,0.005258912,0.0008749347,0.5222145,0.004148412,0.0005371082,0.000014298048,0.000039840674,0.0065778825],"genre_scores_gemma":[0.13588855,0.50911885,0.269828,0.075741604,0.00903527,0.0000067128653,0.000010978478,0.00005915117,0.0003108887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9634814,0.0056314776,0.028362893,0.00069936545,0.0013070751,0.00051778374],"domain_scores_gemma":[0.84017754,0.1162737,0.029678753,0.0008525556,0.01106057,0.0019569034],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.070916675,0.00037834662,0.0063751237,0.00017454168,0.00011503886,0.000009494195,0.00042096546,0.0013473452,0.00015430669],"category_scores_gemma":[0.3236003,0.00028964024,0.0023732386,0.0002580615,0.003956594,0.00066763913,0.0003358112,0.0039484445,0.000021735872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009670679,0.005845781,0.038993802,0.00008308872,0.0016767437,0.0011690691,0.00023502702,0.0000034554992,0.0000100308835,0.00024987015,0.13000043,0.812062],"study_design_scores_gemma":[0.013111117,0.04294773,0.16334502,0.00010510058,0.001640173,0.0038104167,0.009649359,0.00029135516,0.000003244446,0.00016295825,0.7647347,0.0001988462],"about_ca_topic_score_codex":0.00018030792,"about_ca_topic_score_gemma":0.000079893594,"teacher_disagreement_score":0.8118632,"about_ca_system_score_codex":0.00014885115,"about_ca_system_score_gemma":0.013035741,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W2169921837","doi":"10.1200/jco.2005.01.628","title":"Couples Who Get Closer After Breast Cancer: Frequency and Predictors in a Prospective Investigation","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Institut universitaire en santé mentale de Montréal; Hôpital du Saint-Sacrement","funders":"","keywords":"Spouse; Medicine; Breast cancer; Feeling; Coping (psychology); Prospective cohort study; Disease; Cancer; Affection; Family medicine; Gynecology; Clinical psychology; Internal medicine; Psychology; Social psychology","score_opus":0.03943300351913509,"score_gpt":0.39611681097504037,"score_spread":0.3566838074559053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169921837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97687876,0.0023442623,0.000007513825,0.019162532,0.000616354,0.0001655673,0.000011408072,0.0000062113395,0.0008073869],"genre_scores_gemma":[0.9915855,0.0025748743,0.0003547027,0.0032138322,0.002114427,0.000016890308,0.0000010384055,0.00001111269,0.00012761896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807125,0.00017027033,0.001203172,0.00016007274,0.00023895457,0.0001562711],"domain_scores_gemma":[0.99837244,0.0003682636,0.0005690703,0.00008874561,0.00030945445,0.00029201052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012477525,0.000101313475,0.0007930711,0.00010892942,0.000014807372,0.0000075009248,0.000059359754,0.00028190194,0.00021016423],"category_scores_gemma":[0.00043058576,0.00007406177,0.00014040542,0.0001314045,0.0002355957,0.00017666862,0.000023186523,0.00075822324,0.0000033486585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018367077,0.00019771096,0.9342294,0.000025494403,0.000079820245,0.00012258049,0.0009016807,0.0000041925123,0.000035336652,0.00005587052,0.00055361475,0.0619576],"study_design_scores_gemma":[0.0036879655,0.0018206264,0.9835502,0.0002438892,0.00013656904,0.0002552839,0.00016623201,0.00005441532,0.000022767508,0.00063298346,0.009359248,0.0000698246],"about_ca_topic_score_codex":0.00034924535,"about_ca_topic_score_gemma":0.01056742,"teacher_disagreement_score":0.06188778,"about_ca_system_score_codex":0.00030324605,"about_ca_system_score_gemma":0.0012397682,"threshold_uncertainty_score":0.5896868},"labels":[],"label_agreement":null},{"id":"W2169923083","doi":"10.1200/jco.2014.55.3628","title":"Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Gemtuzumab ozogamicin; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Induction chemotherapy; Randomized controlled trial; Calicheamicin; Myeloid leukemia; Oncology; Confidence interval; CD33","score_opus":0.022563698295226035,"score_gpt":0.37694985155636374,"score_spread":0.3543861532611377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169923083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877671,0.00043625146,0.0008419689,0.007205451,0.0009147219,0.0024136237,0.00014034247,0.000026736401,0.0002537748],"genre_scores_gemma":[0.986454,0.004420017,0.0033243182,0.0015892587,0.0038804596,0.000028246948,0.00010621251,0.00007517614,0.00012231339],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9836039,0.008410789,0.0052206977,0.0008478055,0.0009931435,0.0009236983],"domain_scores_gemma":[0.97916067,0.014068983,0.0045411866,0.0009907273,0.00036816281,0.00087024615],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03040837,0.00050336745,0.004731571,0.00028241033,0.00019441367,0.00004932956,0.0010801639,0.0012103468,0.000021119167],"category_scores_gemma":[0.034837868,0.00029383172,0.000724497,0.00036369392,0.0014201347,0.0002496355,0.00045464677,0.0061171483,0.0000072321054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8850654,0.0021459535,0.0151983835,0.000006923554,0.0019350748,0.00029084002,0.00033430092,0.00001940579,0.0008496751,0.000017471903,0.0064233956,0.08771323],"study_design_scores_gemma":[0.8606508,0.030385157,0.10286517,0.0003293573,0.002118804,0.0010149564,0.00011033015,0.00082469865,0.00009368915,0.00027946776,0.0010583209,0.0002692472],"about_ca_topic_score_codex":0.003975934,"about_ca_topic_score_gemma":0.0005699129,"teacher_disagreement_score":0.08766678,"about_ca_system_score_codex":0.0018784131,"about_ca_system_score_gemma":0.0053206896,"threshold_uncertainty_score":0.99995136},"labels":[],"label_agreement":null},{"id":"W2169947883","doi":"10.1200/jco.2006.07.6554","title":"Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Epidermal growth factor receptor; Head and neck squamous-cell carcinoma; Cancer research; EGFR inhibitors; Internal medicine; Oncology; Pathology; Head and neck cancer; Cancer","score_opus":0.09179712853265751,"score_gpt":0.47614567131897656,"score_spread":0.384348542786319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169947883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997461,0.00162651,0.000017484772,0.00020204685,0.00008399499,0.00049102586,0.000033902328,0.0000012346047,0.000082753504],"genre_scores_gemma":[0.9983022,0.00023075267,0.0013274839,0.000076817174,0.000022474542,0.0000039692095,0.000002263055,0.000008172653,0.00002587024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854046,0.00015338323,0.00090336875,0.00012401916,0.0001673657,0.00011138204],"domain_scores_gemma":[0.99722004,0.0013809146,0.00092801126,0.00006320807,0.00029709286,0.00011072172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005365342,0.000106338426,0.0008136249,0.00009509695,0.000025200556,0.0000016734647,0.00003220952,0.00003871343,0.000005281925],"category_scores_gemma":[0.00030514778,0.000046027784,0.000036332098,0.00013672563,0.00048435005,0.00004831559,0.000025057205,0.00017918738,3.03885e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01689358,0.0017979353,0.9470022,0.00016580505,0.00043387944,0.00013951748,0.0010350414,0.0000035355874,0.000036374146,0.000002235859,0.000029872012,0.03246006],"study_design_scores_gemma":[0.023384944,0.02824064,0.9452848,0.00021309721,0.001382011,0.00010093311,0.00096379203,0.000030644147,0.00018908884,0.000011671315,0.00015567362,0.000042708885],"about_ca_topic_score_codex":0.00008353699,"about_ca_topic_score_gemma":0.00055633,"teacher_disagreement_score":0.03241735,"about_ca_system_score_codex":0.00006804018,"about_ca_system_score_gemma":0.00035017077,"threshold_uncertainty_score":0.18769586},"labels":[],"label_agreement":null},{"id":"W2170071316","doi":"10.1200/jco.2005.02.129","title":"Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Gefitinib; Cancer; Rash; Chemotherapy; Prostate-specific antigen; Randomized controlled trial; Clinical trial; Oncology; Epidermal growth factor receptor","score_opus":0.3188633390056988,"score_gpt":0.5975672502723148,"score_spread":0.27870391126661603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170071316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657084,0.003121604,0.0000017334987,0.0053992034,0.0018600745,0.0025795999,0.00012013648,0.0000016767549,0.00034512376],"genre_scores_gemma":[0.9886882,0.009074048,0.0001448683,0.0002488692,0.0014843335,0.00008613583,0.0000033887668,0.000012625761,0.0002575855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98420644,0.0040978403,0.009764312,0.00022965475,0.0014355248,0.00026625174],"domain_scores_gemma":[0.9794281,0.010322381,0.008339437,0.00019936656,0.0014720542,0.00023862981],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028839096,0.00018164748,0.005386187,0.00022797336,0.000041107585,0.0000022250504,0.0003180621,0.00024450125,0.0001291607],"category_scores_gemma":[0.023107901,0.000096027,0.0010044044,0.00033934452,0.00095946173,0.00013099599,0.00010489592,0.0010411034,1.03420454e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89534706,0.023013934,0.010138986,0.00006323003,0.0021854034,0.000041148523,0.0005334127,0.00019459709,0.0009083469,0.000038924183,0.0024028742,0.06513207],"study_design_scores_gemma":[0.943438,0.032658283,0.013442193,0.00030647538,0.0010497698,0.0000070391548,0.00020794004,0.00009592615,0.00051596673,0.000119673845,0.0080813365,0.00007739686],"about_ca_topic_score_codex":0.030582199,"about_ca_topic_score_gemma":0.11561924,"teacher_disagreement_score":0.085037045,"about_ca_system_score_codex":0.00046039326,"about_ca_system_score_gemma":0.02108077,"threshold_uncertainty_score":0.9995113},"labels":[],"label_agreement":null},{"id":"W2170373770","doi":"10.1200/jco.2009.22.7504","title":"Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Anthracycline; Metastatic breast cancer; Tolerability; Internal medicine; Breast cancer; Regimen; Cyclophosphamide; Cardiotoxicity; Surgery; Doxorubicin; Chemotherapy; Oncology; Neutropenia; Phases of clinical research; Taxane; Cancer; Adverse effect","score_opus":0.13392950609814425,"score_gpt":0.49925669367392583,"score_spread":0.3653271875757816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170373770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977602,0.0042006946,0.0001754374,0.0149160605,0.0005796363,0.0023117801,0.00012575985,0.000018666417,0.00006996141],"genre_scores_gemma":[0.96432054,0.030207954,0.003225541,0.00081123423,0.0011631604,0.00005229769,0.00003297604,0.000042638556,0.00014363167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947332,0.00034932827,0.003676044,0.00037365087,0.00043897794,0.00042876782],"domain_scores_gemma":[0.9913203,0.0021450853,0.004456506,0.00028259234,0.0013998918,0.00039558482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001465147,0.00040149904,0.0038531914,0.0002266774,0.000076797136,0.0000043557584,0.00020887452,0.0003125055,0.0002391899],"category_scores_gemma":[0.00037769947,0.00022355437,0.00065906346,0.0003095473,0.000441955,0.00016830402,0.000021532927,0.0006420072,5.39394e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7371123,0.048668355,0.0045307237,0.00010807468,0.0028737427,0.00046150645,0.00036710897,0.00019545085,0.0024376037,0.00000512422,0.00038504176,0.202855],"study_design_scores_gemma":[0.57287806,0.39789906,0.014395643,0.00067446637,0.0034850228,0.00042558135,0.0000815599,0.0006514793,0.0056047263,0.000034403693,0.0036664458,0.00020358492],"about_ca_topic_score_codex":0.00011934403,"about_ca_topic_score_gemma":0.00037314586,"teacher_disagreement_score":0.3492307,"about_ca_system_score_codex":0.00018980159,"about_ca_system_score_gemma":0.0018258,"threshold_uncertainty_score":0.91162825},"labels":[],"label_agreement":null},{"id":"W2170587302","doi":"10.1200/jco.2014.58.4680","title":"American Society of Clinical Oncology Position Statement on Obesity and Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":524,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Teachable moment; Cancer; Obesity; Disease; Intensive care medicine; Internal medicine","score_opus":0.1957474660295623,"score_gpt":0.570136586730619,"score_spread":0.3743891207010567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170587302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97224575,0.00017206985,0.00036664307,0.024387013,0.0013699036,0.0001464634,0.000008645573,0.00000577652,0.0012977142],"genre_scores_gemma":[0.9756879,0.008080647,0.0031785597,0.010889322,0.0020389438,0.000002632288,0.0000020745997,0.000012166637,0.00010772105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952359,0.00071470934,0.0032780513,0.00022148824,0.0003470381,0.00020277889],"domain_scores_gemma":[0.99220496,0.003056607,0.0037018436,0.00016395922,0.00040215076,0.0004705016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061731017,0.00012775877,0.0022947742,0.00005514429,0.000035814835,0.0000036986619,0.000097417746,0.00035372618,0.00013130129],"category_scores_gemma":[0.0012373065,0.0000873165,0.00070465007,0.00009432962,0.00069937593,0.00005332645,0.00005040913,0.001184603,0.0000039721813],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044277953,0.0020646597,0.33436784,0.000031128162,0.00038075523,0.00002428982,0.00009482626,0.000011724054,0.000108021886,0.00008532088,0.021532394,0.6368712],"study_design_scores_gemma":[0.0058542336,0.040998388,0.6552437,0.00007543635,0.0003301647,0.00003158201,0.00013091533,0.0002123715,0.0000519738,0.00013670028,0.29687104,0.000063475076],"about_ca_topic_score_codex":0.00040414566,"about_ca_topic_score_gemma":0.00018757247,"teacher_disagreement_score":0.63680774,"about_ca_system_score_codex":0.00028123803,"about_ca_system_score_gemma":0.001799911,"threshold_uncertainty_score":0.5146576},"labels":[],"label_agreement":null},{"id":"W2170605215","doi":"10.1200/jco.2014.60.6475","title":"Reply to A. Molfino et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Anorexia; Appetite; Medicine; Cachexia; Cancer; Weight loss; Internal medicine; Constipation; Megestrol acetate; Obesity","score_opus":0.39816619795854996,"score_gpt":0.5949110165857858,"score_spread":0.19674481862723586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170605215","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002742029,0.003633255,0.00038316962,0.9276852,0.03987587,0.00041961356,0.000022161736,0.000015769192,0.025222912],"genre_scores_gemma":[0.00052721036,0.004694198,0.022036664,0.9162402,0.0455433,0.000006556926,0.000018593548,0.00006580667,0.010867459],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98571026,0.003193327,0.008394845,0.00049547426,0.0013144276,0.0008916865],"domain_scores_gemma":[0.9806598,0.008496554,0.0051874495,0.0005291314,0.0024420132,0.0026850414],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.026834346,0.0003928852,0.0048006508,0.0004965779,0.00006714906,0.00002617984,0.0005366756,0.0020445278,0.0018977856],"category_scores_gemma":[0.024491768,0.00031635095,0.001181135,0.0002779132,0.00036908503,0.0001374081,0.00017524725,0.013192316,0.001933364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031337384,0.0012866261,0.0051487624,0.00023346304,0.00032592093,0.0119828675,0.00014385604,0.0000075478506,0.000008303188,0.00023995068,0.9088903,0.06859864],"study_design_scores_gemma":[0.010200734,0.02446618,0.009170284,0.0022020899,0.00051679445,0.0035887915,0.00008011455,0.000024978885,0.0000027398353,0.0011798647,0.9483161,0.0002513154],"about_ca_topic_score_codex":0.00006590151,"about_ca_topic_score_gemma":0.000019218807,"teacher_disagreement_score":0.06834733,"about_ca_system_score_codex":0.0011190084,"about_ca_system_score_gemma":0.013428475,"threshold_uncertainty_score":0.99992883},"labels":[],"label_agreement":null},{"id":"W2170684315","doi":"10.1200/jco.2009.24.9516","title":"Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lymphoma; Medicine; Hodgkin lymphoma; Stage (stratigraphy); Internal medicine; Cancer; Oncology; Pathology; Biology","score_opus":0.05360879883891786,"score_gpt":0.42688598487018903,"score_spread":0.3732771860312712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170684315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982442,0.00034234917,0.000077103046,0.010401091,0.0024296113,0.00045274943,0.0000061948995,0.000012833264,0.0038360222],"genre_scores_gemma":[0.9893242,0.0007611708,0.00475914,0.004011928,0.001001842,0.000027038946,0.000005061017,0.000023716004,0.000085871536],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956002,0.00027439298,0.0029243412,0.00027869843,0.0005244336,0.00039789328],"domain_scores_gemma":[0.9953876,0.0013446646,0.0017309611,0.00033126713,0.00045314105,0.0007523491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025898656,0.00024112068,0.0017904916,0.0003695983,0.000050486255,0.00001970496,0.00024645656,0.00062252465,0.00020399243],"category_scores_gemma":[0.0032982565,0.00016607207,0.0006600967,0.00029267676,0.00015153355,0.00020170063,0.000048038768,0.00031319904,0.00015425413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061111776,0.0058907513,0.05364031,0.000025183652,0.00024313084,0.0050972104,0.00052903255,0.000016297274,0.00082337804,0.00042133252,0.0016452938,0.9255569],"study_design_scores_gemma":[0.049241703,0.01104489,0.74398494,0.0002822238,0.00035879508,0.0034847986,0.00019879156,0.00020250508,0.003614198,0.00026426814,0.18712594,0.00019693928],"about_ca_topic_score_codex":0.000108809174,"about_ca_topic_score_gemma":0.00027253374,"teacher_disagreement_score":0.92535996,"about_ca_system_score_codex":0.00069446,"about_ca_system_score_gemma":0.0029816888,"threshold_uncertainty_score":0.6772223},"labels":[],"label_agreement":null},{"id":"W2170736348","doi":"10.1200/jco.2004.05.128","title":"Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; Pharmacyclics","keywords":"Neurocognitive; Medicine; Lung cancer; Randomized controlled trial; Internal medicine; Brain tumor; Radiation therapy; Oncology; Cognition; Pathology; Psychiatry","score_opus":0.04990121165153473,"score_gpt":0.4145447004232671,"score_spread":0.36464348877173236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170736348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424225,0.00030584636,0.00032724702,0.0030347607,0.000107252716,0.0018480438,0.000028017463,0.0000044906906,0.00010209491],"genre_scores_gemma":[0.9970157,0.000098477154,0.0020901386,0.0005778716,0.000097286436,0.00002111346,0.00004833985,0.000014330452,0.000036709775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941945,0.0028841181,0.0021583166,0.0002545017,0.00034594713,0.00016259751],"domain_scores_gemma":[0.99063593,0.0061880895,0.0024514147,0.00010743537,0.00037143353,0.00024567326],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062033376,0.00018337542,0.0022153105,0.00023462827,0.00003122832,0.000009311021,0.0000264265,0.00017227842,0.000011109294],"category_scores_gemma":[0.008730709,0.00009655169,0.00017550074,0.00020312576,0.0003362949,0.00013414821,0.000010796579,0.00041683955,2.9007097e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86419594,0.006230014,0.011949285,0.000018093819,0.00066674664,0.00016188403,0.00007858073,0.000004974376,0.0000136277795,0.00003073654,0.00023859719,0.11641152],"study_design_scores_gemma":[0.8401291,0.10885857,0.047609374,0.00021839218,0.0015230447,0.000060340284,0.00007778086,0.000046787973,0.000058979607,0.00007790877,0.0012643188,0.00007540794],"about_ca_topic_score_codex":0.000017467739,"about_ca_topic_score_gemma":0.00001708111,"teacher_disagreement_score":0.116336115,"about_ca_system_score_codex":0.00003781458,"about_ca_system_score_gemma":0.00044436235,"threshold_uncertainty_score":0.9996192},"labels":[],"label_agreement":null},{"id":"W2170889235","doi":"10.1200/jco.2012.44.6518","title":"Parenteral Hydration in Patients With Advanced Cancer: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thermal Regulation in Medicine","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute","keywords":"Medicine; Placebo; Delirium; Randomized controlled trial; Quality of life (healthcare); Internal medicine; Adverse effect; Cancer; Physical therapy; Intensive care medicine; Nursing","score_opus":0.0794621213743557,"score_gpt":0.46786913077650055,"score_spread":0.38840700940214484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170889235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895615,0.0003801651,0.00015616577,0.0026512998,0.003687002,0.0032076568,8.3998367e-7,0.000012910909,0.00034247473],"genre_scores_gemma":[0.99508244,0.00018183306,0.0012483548,0.0009554111,0.0022695088,0.00012621957,0.000007040362,0.000025452331,0.000103716106],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943322,0.001048582,0.0035601237,0.00014319435,0.0006132701,0.00030265463],"domain_scores_gemma":[0.9926865,0.0031425683,0.0030807185,0.00015065014,0.0005221869,0.00041734357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063011954,0.00017264935,0.0031966106,0.00021682287,0.000019871968,0.00000573653,0.00010382617,0.0002701994,0.00016926834],"category_scores_gemma":[0.0050356314,0.000095998,0.00045725153,0.00013140935,0.00019329583,0.00029938054,0.000020014566,0.00081827666,0.0000050043936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8628237,0.0042454465,0.113411844,0.0000119965325,0.0004363878,0.000014622947,0.0002605196,0.00009229713,0.0000072614816,0.000019011462,0.000074446936,0.018602435],"study_design_scores_gemma":[0.91971976,0.009459819,0.06771418,0.00021973428,0.00074199215,0.000007937657,0.0000518023,0.00026422416,0.000009775809,0.000009299993,0.0017212748,0.00008020416],"about_ca_topic_score_codex":0.000014622414,"about_ca_topic_score_gemma":0.000026697568,"teacher_disagreement_score":0.056896027,"about_ca_system_score_codex":0.0002527838,"about_ca_system_score_gemma":0.0006329671,"threshold_uncertainty_score":0.60284853},"labels":[],"label_agreement":null},{"id":"W2170961171","doi":"10.1200/jco.2012.42.0489","title":"American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review–Based Consensus Methodology","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Clinical Oncology; Clinical Practice; Oncology; Medical physics; Internal medicine; Family medicine; Cancer","score_opus":0.9113190571093236,"score_gpt":0.7679947053105922,"score_spread":0.14332435179873138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170961171","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000331226,0.9338649,0.005423144,0.04410434,0.010429738,0.005098568,0.00007686309,0.000052841347,0.00091651105],"genre_scores_gemma":[0.0000072336275,0.58779377,0.34229913,0.061912887,0.007612545,0.00006508967,0.00007723053,0.00012696552,0.00010517181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.793944,0.07637811,0.12396434,0.0014810654,0.002704461,0.0015280617],"domain_scores_gemma":[0.32284454,0.48464638,0.16885152,0.0025320794,0.018204324,0.002921158],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","research_integrity"],"consensus_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"category_scores_codex":[0.36616722,0.0013515563,0.057031985,0.00047679257,0.00012381106,0.000020964237,0.0015936242,0.0054648453,0.00038037758],"category_scores_gemma":[0.7820922,0.0009002597,0.021356028,0.0012694726,0.0033614524,0.00053816894,0.0006865262,0.014142556,0.00023408596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030962666,0.005808276,0.00019925678,0.21246614,0.0075299414,0.00046268557,0.000014868018,8.711667e-7,1.255644e-7,0.00004768641,0.08728391,0.68309],"study_design_scores_gemma":[0.008334673,0.025949452,0.00012084735,0.10312412,0.11176979,0.0050717145,0.00051481783,0.000092143884,9.74524e-8,0.000027435159,0.7444878,0.00050708867],"about_ca_topic_score_codex":0.00012970793,"about_ca_topic_score_gemma":0.0000465475,"teacher_disagreement_score":0.6825829,"about_ca_system_score_codex":0.00085642736,"about_ca_system_score_gemma":0.05009446,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W2171015116","doi":"10.1200/jco.2009.24.9284","title":"Breast Cancer Subtypes and the Risk of Local and Regional Relapse","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1242,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Progesterone receptor; Cytokeratin; Oncology; Internal medicine; Tissue microarray; Immunohistochemistry; Estrogen receptor; Cancer; Epidermal growth factor receptor; Proportional hazards model; Lymph node; Basal (medicine); Mastectomy; Pathology","score_opus":0.026518152637373865,"score_gpt":0.37872429632532145,"score_spread":0.35220614368794756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171015116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869154,0.0029948547,0.000081480524,0.009304854,0.00046251595,0.000045283636,0.000017090684,8.2022837e-7,0.00017768067],"genre_scores_gemma":[0.98751473,0.010867486,0.00043343983,0.00047171448,0.0006672092,0.000002719591,6.9834874e-7,0.0000057343595,0.00003624029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887365,0.00022224434,0.00059909915,0.00012052171,0.000095651245,0.00008885783],"domain_scores_gemma":[0.99816656,0.0006156912,0.00080810394,0.000110167915,0.00021259252,0.00008691063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012629932,0.00007893658,0.0004632554,0.000016456888,0.00004528732,0.0000031737231,0.000094879266,0.00021058424,0.000013193063],"category_scores_gemma":[0.00038954124,0.000042049574,0.00014590005,0.000025588773,0.00142069,0.0000037488512,0.00008294502,0.00039682753,3.430741e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013670019,0.00042718824,0.6851854,0.000014799635,0.0014313578,0.000018331275,0.00012733763,0.000013237907,0.0012979476,0.000994703,0.0058041634,0.29101554],"study_design_scores_gemma":[0.0071442635,0.000810461,0.96552086,0.000014149895,0.00034675325,0.00077861577,0.00013442524,0.000013851912,0.00027794385,0.00081697723,0.024078717,0.000062962834],"about_ca_topic_score_codex":0.00014827099,"about_ca_topic_score_gemma":0.0006803799,"teacher_disagreement_score":0.29095256,"about_ca_system_score_codex":0.000006373131,"about_ca_system_score_gemma":0.00029099733,"threshold_uncertainty_score":0.52345914},"labels":[],"label_agreement":null},{"id":"W2171074831","doi":"10.1200/jco.2013.49.3726","title":"Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH</i>","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute of Neurological Disorders and Stroke; Mayo Clinic","keywords":"Medicine; Lomustine; Procarbazine; Oligodendroglial Tumor; Internal medicine; Hazard ratio; Oncology; Vincristine; Progression-free survival; Radiation therapy; Gastroenterology; Oligodendroglioma; Overall survival; Chemotherapy; Glioma; Confidence interval; Cancer research; Astrocytoma","score_opus":0.041834041385767164,"score_gpt":0.37633772476174265,"score_spread":0.33450368337597547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171074831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957464,0.00019641114,0.000023646275,0.0029620007,0.00014638185,0.00014714964,0.000012879522,0.000004467194,0.0007606816],"genre_scores_gemma":[0.99699265,0.00008078625,0.001645831,0.0009454618,0.0002901605,0.0000034570742,0.000011135875,0.000012404958,0.000018131877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762064,0.00015423205,0.0016325517,0.00016154116,0.00028748132,0.00014352414],"domain_scores_gemma":[0.9956207,0.0020906953,0.0016049612,0.00010030907,0.00038664715,0.00019665921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011827925,0.00011989716,0.0013529004,0.000119293814,0.000014375809,0.000004586521,0.00005967749,0.00021341232,0.000035142653],"category_scores_gemma":[0.0031540007,0.0000782925,0.00013471878,0.00014915754,0.00012207452,0.000055981855,0.000021554555,0.00037713762,0.000001923644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005905955,0.0038490607,0.93829113,0.000025991907,0.0005154151,0.0011723893,0.00019628028,0.000043777844,0.0003359855,0.00012421781,0.0008240532,0.048715744],"study_design_scores_gemma":[0.019224524,0.021617034,0.9549968,0.000427204,0.00056366867,0.00015982831,0.000047828282,0.00059426256,0.001050002,0.0005956824,0.0006460698,0.00007706615],"about_ca_topic_score_codex":0.00011800184,"about_ca_topic_score_gemma":0.0005549002,"teacher_disagreement_score":0.04863868,"about_ca_system_score_codex":0.00007769078,"about_ca_system_score_gemma":0.00030449883,"threshold_uncertainty_score":0.37758613},"labels":[],"label_agreement":null},{"id":"W2171100121","doi":"10.1200/jco.2008.20.4883","title":"Primary Care Physicians' Views of Routine Follow-Up Care of Cancer Survivors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; Sunnybrook Health Science Centre","funders":"University of Toronto","keywords":"Medicine; Family medicine; Cancer; Primary care; Modalities; Prostate cancer; Health care; Internal medicine","score_opus":0.08259077427696965,"score_gpt":0.4509615687948332,"score_spread":0.36837079451786353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171100121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9608954,0.019055584,0.000047137477,0.0022762178,0.0039281314,0.00021800006,0.00003606621,0.000008009205,0.013535405],"genre_scores_gemma":[0.9923682,0.0025765784,0.00032554285,0.0028583785,0.0015549511,0.000002473974,0.000013548998,0.000017912815,0.00028241036],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958981,0.00035956263,0.0027276229,0.00020203134,0.00056871126,0.00024395465],"domain_scores_gemma":[0.99450386,0.0006116395,0.0026375225,0.00031076206,0.0017029191,0.00023329927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010578505,0.00018234007,0.002698372,0.00012836848,0.000023352155,0.0000026911212,0.00025101006,0.00039616757,0.00010618931],"category_scores_gemma":[0.000501263,0.00013711055,0.0011966999,0.00027579482,0.00019260283,0.00007987918,0.000037918668,0.0008154746,0.000002126936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051240344,0.0006264643,0.19274049,0.00047967915,0.00031197528,0.00010229134,0.004809297,0.00001842081,0.0008984802,0.000054335287,0.0015190735,0.7933155],"study_design_scores_gemma":[0.012100579,0.019205764,0.82443434,0.0012632762,0.0014432707,0.000036590158,0.00807019,0.0000054599823,0.0021271582,0.000093497365,0.13099737,0.00022250578],"about_ca_topic_score_codex":0.0009191584,"about_ca_topic_score_gemma":0.008606759,"teacher_disagreement_score":0.79309297,"about_ca_system_score_codex":0.00028775865,"about_ca_system_score_gemma":0.0020709785,"threshold_uncertainty_score":0.5591206},"labels":[],"label_agreement":null},{"id":"W2171149934","doi":"10.1200/jco.2010.31.7305","title":"Comparison of Health-Related Quality of Life 5 Years After SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostatectomy; Quality of life (healthcare); Prostate cancer; Randomization; Physical therapy; Randomized controlled trial; Surgery; Cancer; Urology; Internal medicine; Nursing","score_opus":0.22597793849069125,"score_gpt":0.558603515266112,"score_spread":0.3326255767754207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171149934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958856,0.0009884619,0.000025687787,0.0037168064,0.005066761,0.00045038483,0.000013219404,0.0000050477406,0.00014506358],"genre_scores_gemma":[0.99865425,0.0002655079,0.00038115983,0.000085147316,0.0005693885,0.000010886511,0.000012305278,0.00000902731,0.0000123128775],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99338806,0.0007618592,0.0052133827,0.00014437948,0.00034312985,0.0001492004],"domain_scores_gemma":[0.99297476,0.0015874626,0.0046913037,0.00014616852,0.00033449783,0.00026578206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004977468,0.00010015933,0.00200379,0.00011505105,0.000012893482,0.0000041406815,0.000081395636,0.00031192298,0.0002987217],"category_scores_gemma":[0.0030249844,0.000076345656,0.00073962857,0.000103778424,0.00024428195,0.00007884028,0.000032508273,0.0008418677,0.0000046396276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43506533,0.009120451,0.24316457,0.00013401634,0.00073117495,0.00008584367,0.00034795282,0.0000063929315,0.000047111233,0.00012534558,0.0008706984,0.31030113],"study_design_scores_gemma":[0.24896547,0.069407314,0.66810244,0.00020963974,0.00026861756,0.000018161896,0.00012839465,0.000037214963,0.00023062297,0.00008394398,0.012473897,0.00007425592],"about_ca_topic_score_codex":0.00015730226,"about_ca_topic_score_gemma":0.00013289478,"teacher_disagreement_score":0.42493787,"about_ca_system_score_codex":0.00014445803,"about_ca_system_score_gemma":0.0011733546,"threshold_uncertainty_score":0.3657543},"labels":[],"label_agreement":null},{"id":"W2171227985","doi":"10.1200/jco.2008.17.5604","title":"Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Gemcitabine; Pemetrexed; Radiation therapy; Chemotherapy; Vinorelbine; Cisplatin; Induction chemotherapy; Oncology; Pneumonectomy; Internal medicine; Surgery; Lung cancer","score_opus":0.062086810660895456,"score_gpt":0.41697655579619075,"score_spread":0.3548897451352953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171227985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572886,0.0011154603,0.00027937503,0.012139469,0.00023388695,0.00042506334,0.000017670487,0.000011969871,0.00004823235],"genre_scores_gemma":[0.99321944,0.0013677581,0.0015060148,0.0032103783,0.0005138742,0.00000904179,0.000032365468,0.000015160529,0.00012598679],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99808466,0.00020023082,0.0010266043,0.00020849035,0.00030381855,0.0001761855],"domain_scores_gemma":[0.9981979,0.00042941907,0.00088073575,0.000106420215,0.00009900053,0.00028650073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010140978,0.00015800563,0.0008481839,0.0000706701,0.00006474815,0.000010904701,0.00006544675,0.0001998069,0.000037365346],"category_scores_gemma":[0.00022081003,0.000097612494,0.00025551723,0.000085763844,0.0001334037,0.00018253316,0.000005194618,0.00030566592,0.0000012419404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07093366,0.0040738694,0.21856554,0.000019685667,0.00041537653,0.00007944833,0.000080712685,0.000011666628,0.040818427,0.00010998563,0.004951336,0.6599403],"study_design_scores_gemma":[0.01906721,0.024893684,0.9444896,0.000036389516,0.00020730354,0.00022819525,0.000044691973,0.00007947591,0.0029961944,0.0007578499,0.007076802,0.0001226327],"about_ca_topic_score_codex":0.0000087084545,"about_ca_topic_score_gemma":0.0000018780655,"teacher_disagreement_score":0.725924,"about_ca_system_score_codex":0.00010322509,"about_ca_system_score_gemma":0.00027167756,"threshold_uncertainty_score":0.3980522},"labels":[],"label_agreement":null},{"id":"W2171367970","doi":"10.1200/jco.2012.44.7888","title":"Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":363,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California, Los Angeles; Peter MacCallum Cancer Centre; Plexxikon; Vanderbilt University; Moffitt Cancer Center; Genentech; University of Pittsburgh; F. Hoffmann-La Roche; Vanderbilt-Ingram Cancer Center; York University; University of Pennsylvania; Massachusetts General Hospital; GlaxoSmithKline","keywords":"Vemurafenib; Medicine; Neuroblastoma RAS viral oncogene homolog; MAPK/ERK pathway; Cancer research; Melanoma; Kinase; Phosphorylation; Internal medicine; Cancer; Metastatic melanoma; KRAS; Biology; Colorectal cancer; Cell biology","score_opus":0.019358797503458477,"score_gpt":0.34063784778405976,"score_spread":0.3212790502806013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171367970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997168,0.00012016012,0.0015799872,0.00026113805,0.0002641339,0.00026115196,0.0000035459652,0.0000010002342,0.00034087015],"genre_scores_gemma":[0.99127984,0.000036774138,0.007975697,0.0005242741,0.00006681668,0.000007728568,0.000003103973,0.000010087004,0.000095654286],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983845,0.0002828089,0.00088178826,0.00015468501,0.00014641356,0.00014982477],"domain_scores_gemma":[0.9985882,0.0002571171,0.000637396,0.000118790274,0.00021441461,0.00018407872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007347963,0.000100219644,0.0005939146,0.000068560934,0.000011791734,0.0000040507225,0.0001404532,0.00011900918,0.000013273589],"category_scores_gemma":[0.0005284789,0.000069375834,0.00008124469,0.000066899695,0.00006388313,0.000008220682,0.000054121443,0.00018039695,0.0000034777997],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017111143,0.004916823,0.4016236,0.00050686,0.0012459223,0.00030721634,0.00024906517,0.00009365167,0.4269823,0.0017570001,0.0046780687,0.14052834],"study_design_scores_gemma":[0.012986026,0.027684538,0.9277217,0.00011484357,0.0001396783,0.000019495037,0.000046786678,0.000024008345,0.024548126,0.0016353779,0.004867116,0.00021234476],"about_ca_topic_score_codex":0.000007110828,"about_ca_topic_score_gemma":0.000056425597,"teacher_disagreement_score":0.5260981,"about_ca_system_score_codex":0.000014056975,"about_ca_system_score_gemma":0.00018153028,"threshold_uncertainty_score":0.28290644},"labels":[],"label_agreement":null},{"id":"W2171402256","doi":"10.1200/jco.2013.50.4399","title":"Selective Application of a Test Based on Risk: Using Limited Resources Wisely","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Test (biology); Risk analysis (engineering); Intensive care medicine","score_opus":0.13296286630038429,"score_gpt":0.4579898186727269,"score_spread":0.32502695237234264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171402256","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23985066,0.0008351604,0.0006844981,0.74761844,0.001401744,0.001009751,0.00004792568,0.000026066717,0.008525768],"genre_scores_gemma":[0.34313962,0.00096467644,0.008191469,0.6274901,0.019676276,0.000027153057,0.000016272297,0.00009046738,0.000403979],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538076,0.00068606396,0.002785168,0.00028811695,0.00059037143,0.00026955007],"domain_scores_gemma":[0.98092246,0.0114238765,0.005742539,0.00028854524,0.0014508002,0.00017175861],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002108513,0.00024479174,0.0031023268,0.0003285181,0.00005707918,0.000005544089,0.00019614077,0.0015272202,0.000042174153],"category_scores_gemma":[0.010990513,0.00016722889,0.00071208057,0.00025967148,0.00033273036,0.00003915582,0.000033950597,0.0049389284,0.000015903008],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027288564,0.0016016624,0.062198203,0.00025611845,0.00076612254,0.0003047124,0.00013464205,0.000058647645,0.0001963106,9.628584e-7,0.8754132,0.056340557],"study_design_scores_gemma":[0.005486533,0.029927945,0.10550015,0.0008146154,0.0014018437,0.000075465316,0.000030590178,0.0029238549,0.0000698429,0.000074535914,0.8535235,0.00017114499],"about_ca_topic_score_codex":0.00011803255,"about_ca_topic_score_gemma":0.00001448453,"teacher_disagreement_score":0.12012835,"about_ca_system_score_codex":0.00030926222,"about_ca_system_score_gemma":0.0017933263,"threshold_uncertainty_score":0.99976903},"labels":[],"label_agreement":null},{"id":"W2171496318","doi":"10.1200/jco.2010.33.5281","title":"Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Colorectal cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Phases of clinical research; Oxaliplatin; Pooled analysis; Surgery; Meta-analysis","score_opus":0.13214019892101253,"score_gpt":0.4969753498436035,"score_spread":0.36483515092259095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171496318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740624,0.0009750269,0.000008546512,0.00022924886,0.00025477223,0.0005772524,0.0001909785,0.0000032006799,0.00035474484],"genre_scores_gemma":[0.98897314,0.010437163,0.0003099158,0.00006600121,0.00013595038,0.000014891979,0.00002514031,0.000011477533,0.00002629131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958625,0.0003374677,0.003149706,0.0002289783,0.000243139,0.00017823788],"domain_scores_gemma":[0.9938577,0.0026661542,0.0028437567,0.00013810306,0.00029040486,0.0002039209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010955333,0.00022365483,0.004851301,0.0003135482,0.000024788424,0.0000018071485,0.00007425581,0.00019564747,0.00046830854],"category_scores_gemma":[0.0014322061,0.00012425639,0.0010899686,0.0003625595,0.00017091833,0.00004502223,0.000022565799,0.00023292458,2.2897153e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22366239,0.0139711965,0.49522206,0.0000052438527,0.015001024,0.000101515136,0.001293945,0.00006213684,0.00019395833,0.0000010297096,0.000023027846,0.25046247],"study_design_scores_gemma":[0.11242806,0.09963717,0.78109765,0.000086526954,0.006092747,0.0000015297861,0.000046195797,0.00007041188,0.00033596417,0.000014204677,0.00012190179,0.000067654466],"about_ca_topic_score_codex":0.002089265,"about_ca_topic_score_gemma":0.0033799328,"teacher_disagreement_score":0.28587556,"about_ca_system_score_codex":0.0005972919,"about_ca_system_score_gemma":0.00046838514,"threshold_uncertainty_score":0.51276505},"labels":[],"label_agreement":null},{"id":"W2171816585","doi":"10.1200/jco.2009.23.9616","title":"Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of Environmental Health Sciences; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Breast Cancer Research Foundation","keywords":"Breast cancer; Estrogen receptor; Estrogen; Internal medicine; Medicine; Endocrinology; Cancer; Gene expression; Anastrozole; Oncology; Gene; Aromatase; Biology","score_opus":0.03864979548454755,"score_gpt":0.39125268538340313,"score_spread":0.3526028898988556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171816585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757713,0.0006473155,0.000017375227,0.0009057095,0.00050109415,0.00020336245,0.00007531458,0.000003229926,0.00006945991],"genre_scores_gemma":[0.99638706,0.00025044676,0.0023902315,0.00012690913,0.00075689226,0.000014924067,0.000013802367,0.000023148606,0.00003659208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997064,0.00076206506,0.0013215179,0.00031810548,0.0001739477,0.0003603824],"domain_scores_gemma":[0.9973799,0.001120326,0.0007988204,0.00016568514,0.00015261259,0.0003826386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021260683,0.00019907672,0.000732273,0.00015821145,0.00004956229,0.000013296566,0.00021395364,0.0010742816,0.000024660483],"category_scores_gemma":[0.0013356985,0.00016215838,0.00013012553,0.00014112164,0.00024065597,0.000023511311,0.00009807953,0.0016326732,0.0000043274304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026585679,0.00026761752,0.67712975,0.000005342025,0.00009234756,0.00013514688,0.00013395133,0.000046014662,0.30337542,0.00004166807,0.000059922942,0.016054237],"study_design_scores_gemma":[0.0047344924,0.004204739,0.94611555,0.00005593477,0.00005042339,0.0004948993,0.00010250788,0.000015952503,0.043111235,0.00019181609,0.0007211307,0.00020131232],"about_ca_topic_score_codex":0.000017743414,"about_ca_topic_score_gemma":0.00002139738,"teacher_disagreement_score":0.2689858,"about_ca_system_score_codex":0.00009418042,"about_ca_system_score_gemma":0.0010773002,"threshold_uncertainty_score":0.82858443},"labels":[],"label_agreement":null},{"id":"W2171873783","doi":"10.1200/jco.2012.44.7524","title":"Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Disease; Lymphoma; Oncology; Peripheral; Internal medicine; Peripheral T-cell lymphoma; T cell; Immunology; Immune system","score_opus":0.02960347864657775,"score_gpt":0.35222057892783,"score_spread":0.32261710028125223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171873783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639374,0.00063865725,0.0000040717846,0.0018590587,0.00044500674,0.00045428931,0.000014579101,0.0000039729975,0.0001866429],"genre_scores_gemma":[0.99827135,0.0005587531,0.00054891343,0.00018166882,0.00023279617,0.000019338477,0.0000066362263,0.000018549197,0.00016201186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734926,0.00021939138,0.0015739625,0.0001986736,0.00045289166,0.00020583121],"domain_scores_gemma":[0.99638873,0.00091502926,0.0014657605,0.00022323354,0.0004170682,0.0005901916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044076817,0.00017846885,0.0013636786,0.00007283003,0.000027254395,0.00000846386,0.00009897753,0.00018767892,0.000581934],"category_scores_gemma":[0.00039498362,0.000090633344,0.00028321965,0.000094489165,0.00034159078,0.00013599999,0.00006660569,0.00015625135,0.000004433263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024922773,0.011470129,0.94090354,0.00019607435,0.0002816871,0.0008499911,0.000082103325,7.5588594e-7,0.0000012180958,0.0000038422186,0.00024740852,0.02104046],"study_design_scores_gemma":[0.025904063,0.021969968,0.9504644,0.00042902792,0.00055732264,0.000034348443,0.00003551358,0.000006376046,0.000038843227,0.000018662227,0.00045093743,0.00009048995],"about_ca_topic_score_codex":0.000032557575,"about_ca_topic_score_gemma":0.0002018022,"teacher_disagreement_score":0.02094997,"about_ca_system_score_codex":0.00010937623,"about_ca_system_score_gemma":0.0008478273,"threshold_uncertainty_score":0.63717693},"labels":[],"label_agreement":null},{"id":"W2172050766","doi":"10.1200/jco.2006.06.1218","title":"Multi-Institutional Validation of a New Renal Cancer–Specific Survival Nomogram","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":555,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nomogram; Medicine; Nephrectomy; Proportional hazards model; Oncology; Internal medicine; Cancer; Overall survival; Urology; Surgery; Kidney","score_opus":0.2880847023148972,"score_gpt":0.49738998525522954,"score_spread":0.20930528294033235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172050766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807842,0.0011942254,0.011465823,0.001886633,0.0023563064,0.00020143721,0.0000034794336,0.000008203085,0.002099694],"genre_scores_gemma":[0.9659327,0.000559734,0.030058652,0.00022373172,0.0026904515,0.0000012027883,0.0000068302265,0.000012267124,0.0005144189],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960472,0.00019625337,0.0027397166,0.00017943743,0.00060517906,0.00023223495],"domain_scores_gemma":[0.9954309,0.0013009051,0.001868239,0.00017264164,0.0006738569,0.00055344176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041672536,0.00014684202,0.0013107331,0.00018905556,0.00003307114,0.0000048993957,0.00013770135,0.00032656817,0.00026945808],"category_scores_gemma":[0.0012299024,0.00009826566,0.0006663351,0.00019930632,0.0002448858,0.00009138475,0.000032242464,0.0006771135,0.00001639646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019913398,0.0047200546,0.25365722,0.00005378796,0.0011108867,0.0028091113,0.00020563493,0.00064778473,0.010059434,0.00041112292,0.004420895,0.70199066],"study_design_scores_gemma":[0.01572573,0.011393795,0.8754642,0.0001574847,0.0004918913,0.0006083682,0.00007192188,0.00005706744,0.007665507,0.00015089005,0.08810083,0.00011230409],"about_ca_topic_score_codex":0.000095507494,"about_ca_topic_score_gemma":0.00010584892,"teacher_disagreement_score":0.70187837,"about_ca_system_score_codex":0.0004119914,"about_ca_system_score_gemma":0.0031744835,"threshold_uncertainty_score":0.56313974},"labels":[],"label_agreement":null},{"id":"W2172122039","doi":"10.1200/jco.2008.18.3087","title":"Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research","funders":"National Institute of Neurological Disorders and Stroke; National Eye Institute; Takeda Oncology; Celgene","keywords":"Medicine; Bortezomib; Multiple myeloma; Polyneuropathy; Peripheral neuropathy; Internal medicine; Surgery; Oncology; Gastroenterology","score_opus":0.05753808831090486,"score_gpt":0.3811943247090732,"score_spread":0.3236562363981684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172122039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656665,0.00019101547,0.00020634985,0.0024324793,0.000077828205,0.0004429383,0.0000052104238,0.0000073616325,0.00007017054],"genre_scores_gemma":[0.99805975,0.0003677464,0.0010053715,0.00043184822,0.00006511437,0.0000023262066,0.000010106565,0.000014366507,0.000043365864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708545,0.0009755376,0.0012434031,0.00020973099,0.0002718771,0.00021397173],"domain_scores_gemma":[0.9973177,0.0011344312,0.00075436215,0.00014863575,0.0002740117,0.00037090608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011378686,0.00014266568,0.0008826179,0.00019907884,0.000032006596,0.000011845079,0.000059701164,0.00015472599,0.000008928803],"category_scores_gemma":[0.0038456083,0.000099417695,0.0001008261,0.00019663815,0.0001873295,0.00010645592,0.000027020675,0.00047893485,7.8304754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06518052,0.004271807,0.6448014,0.000024484996,0.00013381951,0.006459406,0.00033290402,0.000029030629,0.12507011,0.000009793034,0.00001227761,0.15367447],"study_design_scores_gemma":[0.018576292,0.033421166,0.94421595,0.00012659641,0.0001497947,0.00083872885,0.000022312237,0.0014376296,0.0006355015,0.0000067213155,0.0005014855,0.000067789144],"about_ca_topic_score_codex":0.000008607211,"about_ca_topic_score_gemma":0.000013218186,"teacher_disagreement_score":0.2994146,"about_ca_system_score_codex":0.00007447685,"about_ca_system_score_gemma":0.00046580573,"threshold_uncertainty_score":0.460383},"labels":[],"label_agreement":null},{"id":"W2172132286","doi":"10.1200/jco.2012.47.5699","title":"Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing","year":2013,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Drug development; Drug approval; Regulatory science; Drug; Marketing authorization; Marketing; Pharmacology; Bioinformatics; Business; Pathology","score_opus":0.24574358216935557,"score_gpt":0.4648385795789579,"score_spread":0.21909499740960234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172132286","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11695845,0.0068024714,0.000011922038,0.8716293,0.0030495767,0.0003122129,9.004603e-7,0.000010442668,0.001224728],"genre_scores_gemma":[0.030805603,0.04916074,0.066969156,0.80786264,0.03979353,0.000019058467,0.00006455721,0.00015513523,0.0051696054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98919636,0.002550716,0.0063730804,0.00051370286,0.0009820774,0.0003840759],"domain_scores_gemma":[0.9830425,0.011707403,0.0038487124,0.00027122055,0.0006441415,0.0004860534],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.029835694,0.00029858146,0.0029518043,0.0003505709,0.000049479928,0.000009744099,0.0001870245,0.00509136,0.00014819433],"category_scores_gemma":[0.007189875,0.00020033,0.0005578614,0.00009515301,0.0016010646,0.00008466724,0.00018448179,0.01156755,0.000022962242],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076391624,0.0006117548,0.004461904,0.0004095914,0.00035021885,0.0014072771,0.0000919018,2.4801616e-7,0.0000043531277,0.000041260853,0.41706607,0.5747915],"study_design_scores_gemma":[0.0036805957,0.00074959284,0.3337438,0.00089570996,0.00012780198,0.00035763514,0.0000466107,0.00008900998,8.807734e-7,0.0002652256,0.659901,0.00014209378],"about_ca_topic_score_codex":0.0000060529983,"about_ca_topic_score_gemma":0.000016833323,"teacher_disagreement_score":0.5746494,"about_ca_system_score_codex":0.00015131923,"about_ca_system_score_gemma":0.00397247,"threshold_uncertainty_score":0.99898833},"labels":[],"label_agreement":null},{"id":"W2172256329","doi":"10.1200/jco.2008.21.6333","title":"Prevalence, Natural Course, and Risk Factors of Insomnia Comorbid With Cancer Over a 2-Month Period","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Insomnia; Anxiety; Perioperative; Cancer; Incidence (geometry); Breast cancer; Internal medicine; Sleep disorder; Population; Pediatrics; Surgery; Psychiatry","score_opus":0.044737317953471786,"score_gpt":0.42943102463721744,"score_spread":0.38469370668374564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172256329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906709,0.0054737306,0.0000076631495,0.0018108038,0.0009920485,0.00012616295,0.000017859276,0.0000054885113,0.0008953206],"genre_scores_gemma":[0.9921453,0.0060622967,0.0001846821,0.0007529516,0.00054235524,0.0000010124447,9.198239e-7,0.000008860879,0.0003016202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980263,0.00020963926,0.001070105,0.0001514316,0.00037289242,0.00016960151],"domain_scores_gemma":[0.99726075,0.0005301727,0.0013903285,0.0001433269,0.0003955551,0.00027989422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008586767,0.00013167648,0.0011631954,0.00006812913,0.000029565017,0.000005716893,0.00010569695,0.00022934968,0.00016280518],"category_scores_gemma":[0.00048930553,0.00007768543,0.00024025513,0.000119871984,0.000278525,0.000100703954,0.00001795951,0.0010315722,4.302529e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004766654,0.0006066963,0.9394768,0.00004709823,0.00030502825,0.00014291547,0.0005722363,0.0000050559747,0.00004395411,0.000023687779,0.0012132594,0.052796625],"study_design_scores_gemma":[0.0052099507,0.014432867,0.9653296,0.00023118853,0.00085314235,0.0001495714,0.00035555678,0.00003171946,0.00004676337,0.00004091616,0.013232973,0.00008576807],"about_ca_topic_score_codex":0.00032032546,"about_ca_topic_score_gemma":0.001253965,"teacher_disagreement_score":0.052710857,"about_ca_system_score_codex":0.00007524239,"about_ca_system_score_gemma":0.0011651702,"threshold_uncertainty_score":0.44817254},"labels":[],"label_agreement":null},{"id":"W2172909145","doi":"10.1200/jco.2015.62.3918","title":"Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Randomized controlled trial; Regimen; Tyrosine-kinase inhibitor; Internal medicine; Epidermal growth factor receptor; Pharmacology; Oncology; Dermatology; Cancer","score_opus":0.14144659934668885,"score_gpt":0.5190120435884947,"score_spread":0.3775654442418059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172909145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910117,0.00029272473,0.000006017386,0.0020749941,0.0010583934,0.005319082,0.000057212685,0.0000051879506,0.00017470813],"genre_scores_gemma":[0.9980574,0.000056538192,0.00033549592,0.00028293167,0.0008422773,0.00027196744,0.00002363981,0.000031662647,0.00009805976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935182,0.0024175001,0.0027709913,0.00025862767,0.0006558696,0.00037883827],"domain_scores_gemma":[0.9921718,0.0032615338,0.002844218,0.00023621992,0.00084117556,0.00064503175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003586109,0.00030857924,0.0029022004,0.00034503508,0.00007155827,0.000021391259,0.00012360715,0.00017947609,0.0001172818],"category_scores_gemma":[0.0060875504,0.00014179978,0.00073354837,0.00028646152,0.00020635466,0.0001684059,0.000014557279,0.000532826,0.0000014698521],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94809806,0.0072068986,0.003996161,0.00001789323,0.0026569096,0.00008224183,0.0021620577,0.00007926491,0.000020645253,0.0000076259194,0.00042188293,0.035250355],"study_design_scores_gemma":[0.83646774,0.15284598,0.0072794887,0.00019690036,0.0024124186,0.000007844013,0.00028476238,0.00019574494,0.00011728125,0.000031307387,0.00004463931,0.00011586064],"about_ca_topic_score_codex":0.04639325,"about_ca_topic_score_gemma":0.008089385,"teacher_disagreement_score":0.14563908,"about_ca_system_score_codex":0.0033405344,"about_ca_system_score_gemma":0.016956924,"threshold_uncertainty_score":0.988616},"labels":[],"label_agreement":null},{"id":"W2173121992","doi":"10.1200/jco.2015.61.8736","title":"Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","score_opus":0.6455804736146742,"score_gpt":0.6181926204129479,"score_spread":0.02738785320172632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173121992","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012480069,0.9831463,0.00021057208,0.008661706,0.0031248848,0.0003987745,0.0001409982,0.000009851754,0.0041821105],"genre_scores_gemma":[0.00002991032,0.9902899,0.003904022,0.0028618067,0.0024794089,0.000022981427,0.000004198587,0.00004373077,0.0003639962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99300015,0.00035662513,0.0057453704,0.00045157693,0.00006951604,0.0003767843],"domain_scores_gemma":[0.9892389,0.0039029254,0.0056164176,0.00022945904,0.00023507973,0.00077721744],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008823883,0.00036998434,0.008587727,0.00044073584,0.000047752983,0.000051926672,0.00057258975,0.00082208513,0.00013045612],"category_scores_gemma":[0.011655809,0.00026548203,0.00070855947,0.00027416414,0.00023560057,0.0001645421,0.00022515608,0.0011898938,0.000073902884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008537916,0.00015349753,0.00072116824,0.0025552092,0.00046117185,0.000043615208,0.00005559047,0.0000023099228,1.8289095e-8,0.0019634732,0.012431621,0.981527],"study_design_scores_gemma":[0.0011268234,0.0010645243,0.00007916171,0.0007558966,0.0006084512,0.00009761869,0.000010921669,0.0000058849646,1.8967862e-7,0.007720141,0.988259,0.00027136807],"about_ca_topic_score_codex":0.00009296312,"about_ca_topic_score_gemma":0.000047092697,"teacher_disagreement_score":0.9812556,"about_ca_system_score_codex":0.00035184238,"about_ca_system_score_gemma":0.0029823328,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2173721297","doi":"10.1200/jco.2015.61.7696","title":"The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Harmonization; Global health; Public health; Public relations; Oncology; Internal medicine; Political science; Nursing","score_opus":0.447051616460453,"score_gpt":0.5745529417287312,"score_spread":0.12750132526827818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173721297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008346222,0.95033646,0.00012423945,0.00960837,0.012922195,0.0005611752,0.0003261321,0.000009745955,0.025277086],"genre_scores_gemma":[0.0003170913,0.9832078,0.0011211886,0.0055575315,0.0088172555,0.000027908145,0.000007301865,0.00005246814,0.000891431],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9801662,0.0005498147,0.017742626,0.0006450126,0.00020527965,0.0006910655],"domain_scores_gemma":[0.95884967,0.004932864,0.03362088,0.00066712487,0.0007269403,0.0012025416],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.032494973,0.0005151104,0.017103584,0.00014818739,0.000098799355,0.00002318463,0.0015881878,0.0014401918,0.0002595007],"category_scores_gemma":[0.009483401,0.00034028463,0.0041670958,0.0005541804,0.0020126775,0.00019178944,0.0003298994,0.0024130659,0.00020955142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037405442,0.0002925041,0.0035439143,0.0002134838,0.0010320419,0.000027527885,0.000030240404,0.000006472284,2.216832e-9,0.002093121,0.24580997,0.74657667],"study_design_scores_gemma":[0.0020553255,0.014108452,0.0044646906,0.00073048123,0.0006349304,0.00005791425,0.000051001545,0.0000094885445,1.1030755e-8,0.0028110428,0.9747556,0.00032107168],"about_ca_topic_score_codex":0.00062584394,"about_ca_topic_score_gemma":0.0004707218,"teacher_disagreement_score":0.7462556,"about_ca_system_score_codex":0.0015984436,"about_ca_system_score_gemma":0.011603534,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W2173804501","doi":"10.1200/jco.2015.61.1947","title":"Clinical Impact of Additional Cytogenetic Aberrations, <i>cKIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Barncancerfonden; Hospital for Sick Children; European Organisation for Research and Treatment of Cancer; Erasmus Medisch Centrum; National Cancer Institute; Newcastle University","keywords":"Cytarabine; Medicine; Etoposide; Internal medicine; Cumulative incidence; Retrospective cohort study; Oncology; Anthracycline; Gastroenterology; Idarubicin; Myeloid leukemia; Cohort; Chemotherapy; Cancer","score_opus":0.12033803460152205,"score_gpt":0.4976702984608705,"score_spread":0.3773322638593485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173804501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993924,0.00017401252,0.000017838125,0.0028195968,0.00074190483,0.00097498414,0.00095748826,0.0000064164988,0.00038375516],"genre_scores_gemma":[0.9947745,0.0010171504,0.001412453,0.0004102821,0.0018265538,0.000037839975,0.0003961055,0.000021412216,0.00010367699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925858,0.0016287515,0.0039278986,0.0005023554,0.0011261769,0.0002290626],"domain_scores_gemma":[0.99223083,0.0040190713,0.0019105157,0.00031841776,0.0010200135,0.00050114654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072473204,0.00023072031,0.0011741613,0.00028601935,0.00005941062,0.000046058572,0.00039323294,0.00024759193,0.00018382951],"category_scores_gemma":[0.0064353137,0.00014686059,0.00026114727,0.00022403938,0.00031465795,0.00034276478,0.00018280945,0.0010188142,0.0000054955094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009198277,0.013423571,0.9471346,0.000001246659,0.0013405066,0.00021022656,0.0011369255,0.00001874278,0.000016037997,0.000004607261,0.013481551,0.014033712],"study_design_scores_gemma":[0.04282793,0.040458083,0.91098756,0.000016706948,0.00047202912,0.00009475584,0.0020645733,0.0005320651,0.0000017413853,0.00017945662,0.0022626787,0.00010240831],"about_ca_topic_score_codex":0.00051736,"about_ca_topic_score_gemma":0.0010265481,"teacher_disagreement_score":0.036147024,"about_ca_system_score_codex":0.0009287441,"about_ca_system_score_gemma":0.002073707,"threshold_uncertainty_score":0.77041364},"labels":[],"label_agreement":null},{"id":"W2174039028","doi":"10.1200/jco.2012.30.15_suppl.e14032","title":"Long-term outcomes of stenting as a bridge to surgery for acute left-sided malignant colonic obstruction.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Surgery; Endoscopic stenting; Bridge (graph theory); Emergency surgery; Survival rate; Stent","score_opus":0.21943088693373936,"score_gpt":0.5090437297879256,"score_spread":0.2896128428541862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174039028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141335,0.00032003265,0.00014746343,0.0031785115,0.004124975,0.0005204091,0.0000100922125,0.000011798065,0.0002733611],"genre_scores_gemma":[0.99471766,0.00021172463,0.0021744673,0.0013392065,0.0009655187,0.000016142905,0.000004510349,0.000025765974,0.000545021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957942,0.00025064894,0.002882728,0.0001939641,0.000421321,0.00045716445],"domain_scores_gemma":[0.98900694,0.0074443026,0.002046366,0.00021105571,0.00057715515,0.00071420486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030039516,0.00018197813,0.002565131,0.00019640088,0.000041684907,0.0000068474465,0.00013585492,0.00031400414,0.00020788795],"category_scores_gemma":[0.007659241,0.000125597,0.001368482,0.0001571413,0.00012406983,0.0001619757,0.0000854437,0.0004108358,0.00002520859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070519857,0.0014423127,0.94120616,0.0000427485,0.0019090949,0.00032485655,0.00008312946,0.0000013263497,0.00021709589,0.00003126331,0.00082301494,0.046867035],"study_design_scores_gemma":[0.0050440384,0.007122547,0.9811998,0.00016018137,0.0014531208,0.0013043688,0.0000199318,0.0000025823247,0.00061320775,0.000071665505,0.0029026335,0.00010594372],"about_ca_topic_score_codex":0.000028700008,"about_ca_topic_score_gemma":0.000042183277,"teacher_disagreement_score":0.04676109,"about_ca_system_score_codex":0.00032284588,"about_ca_system_score_gemma":0.0010891466,"threshold_uncertainty_score":0.916938},"labels":[],"label_agreement":null},{"id":"W2174658577","doi":"10.1200/jco.2015.62.1615","title":"Provision of Palliative Care in Low- and Middle-Income Countries: Overcoming Obstacles for Effective Treatment Delivery","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Palliative care; Medicine; Context (archaeology); Health care; Nursing; Public health; Global health; Service delivery framework; Economic growth; Service (business); Business","score_opus":0.4052349233828427,"score_gpt":0.5882106557152279,"score_spread":0.18297573233238518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174658577","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037595604,0.95997965,0.00002107503,0.00006657491,0.0005189765,0.0015611897,0.00010728175,0.000002876194,0.00014675247],"genre_scores_gemma":[0.0028265717,0.99373674,0.0027319773,0.000049249276,0.00053740473,0.00004162345,0.000019433835,0.000027389538,0.000029577219],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950379,0.00069318194,0.003476332,0.00026275538,0.00032085227,0.00020897575],"domain_scores_gemma":[0.97803104,0.015817152,0.0043504597,0.0001651065,0.001396406,0.00023982857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019539443,0.00032179622,0.007401162,0.00029587583,0.00001753421,0.0000041534868,0.00013135225,0.00081059255,0.000005437919],"category_scores_gemma":[0.0055415086,0.00019746921,0.001089185,0.00013905375,0.00026679278,0.00007356939,0.00005682107,0.0005922041,0.0000012420576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041877963,0.000607561,0.016542982,0.034725856,0.001267356,0.00023234116,0.0020707492,0.000001764067,2.2390837e-7,0.000023981958,0.00004494555,0.94029444],"study_design_scores_gemma":[0.010039388,0.03246738,0.0024346483,0.14865036,0.0032215388,0.000019077603,0.0010559034,0.000008147234,0.000011582292,0.000072335584,0.80185986,0.00015976302],"about_ca_topic_score_codex":0.000045520894,"about_ca_topic_score_gemma":0.000089642235,"teacher_disagreement_score":0.9401347,"about_ca_system_score_codex":0.0011451811,"about_ca_system_score_gemma":0.0037075775,"threshold_uncertainty_score":0.8052561},"labels":[],"label_agreement":null},{"id":"W2174969218","doi":"10.1200/jco.2015.63.0152","title":"Medical Education and Training: Building In-Country Capacity at All Levels","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Workforce; Capacity building; Referral; Developing country; Training (meteorology); Health care; Leverage (statistics); Public health; Workforce development; Nursing; Medical education; Economic growth","score_opus":0.49730048345890676,"score_gpt":0.6024003784765894,"score_spread":0.10509989501768269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174969218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008888129,0.9798849,0.000003894517,0.0031130246,0.0046920213,0.00028573172,0.0000068585155,0.000005403892,0.0031200207],"genre_scores_gemma":[0.00069123565,0.9875694,0.0011507059,0.007338404,0.0030624748,0.000005867037,0.000008656183,0.00002153761,0.00015172127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924652,0.0011327917,0.004950643,0.000265973,0.00074192695,0.00044345684],"domain_scores_gemma":[0.99012285,0.004093812,0.0029349593,0.00017535234,0.0003808307,0.0022921888],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.019038584,0.00024603622,0.006219664,0.0002788841,0.000024440973,0.0000058605924,0.00017813707,0.002055635,0.00014380284],"category_scores_gemma":[0.02819841,0.00016420799,0.00059979083,0.0001915647,0.0002487172,0.00006772104,0.00008127293,0.0030226423,0.000013578604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021954518,0.00066317496,0.0011912591,0.0026549879,0.00012447726,0.0006181891,0.000057551395,1.9174193e-8,1.6172594e-8,0.000120959616,0.019622102,0.9747277],"study_design_scores_gemma":[0.001703148,0.001516926,0.0019812444,0.008393274,0.00067124836,0.009485708,0.00003313561,0.0000037005427,6.1311654e-9,0.0002894047,0.9758059,0.00011630084],"about_ca_topic_score_codex":0.000029095321,"about_ca_topic_score_gemma":0.00006429978,"teacher_disagreement_score":0.9746114,"about_ca_system_score_codex":0.00096252287,"about_ca_system_score_gemma":0.043701578,"threshold_uncertainty_score":0.9992774},"labels":[],"label_agreement":null},{"id":"W2176674225","doi":"10.1200/jco.2015.62.8503","title":"Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cohort; Population; Cancer","score_opus":0.1695730177799674,"score_gpt":0.48397104948317093,"score_spread":0.3143980317032036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176674225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528056,0.00093635963,0.00029822663,0.0010917678,0.0016097489,0.0003217616,0.000024828189,6.784429e-7,0.00043605806],"genre_scores_gemma":[0.99729955,0.00008147338,0.0018842318,0.00023229767,0.0004441068,0.000033586748,0.0000012350855,0.0000068606423,0.00001668338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807703,0.00033894932,0.00093630655,0.00017741414,0.0003422902,0.00012801177],"domain_scores_gemma":[0.9966013,0.00049030804,0.0011397202,0.00015779969,0.0015482412,0.0000626552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004545785,0.00009317207,0.00047597193,0.000032033808,0.000027071792,0.0000035916676,0.00020752613,0.0001893765,0.000015194528],"category_scores_gemma":[0.0042541674,0.000057894176,0.00022086465,0.00008100137,0.00013521401,0.000007634361,0.00009401819,0.00024439153,3.5456304e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034377654,0.00044392553,0.8248576,0.0000031571772,0.00020412494,0.0000018165391,0.00019128867,0.00063319464,0.00023286055,0.000013948733,0.0010860511,0.16889426],"study_design_scores_gemma":[0.0048593655,0.0010308822,0.98888385,0.0001422896,0.00019847369,0.000051167284,0.000080055834,0.00004948146,0.00054949184,0.0024738486,0.0016179639,0.0000631122],"about_ca_topic_score_codex":0.0006532772,"about_ca_topic_score_gemma":0.07061443,"teacher_disagreement_score":0.16883115,"about_ca_system_score_codex":0.0005227545,"about_ca_system_score_gemma":0.005228192,"threshold_uncertainty_score":0.94634444},"labels":[],"label_agreement":null},{"id":"W2178680838","doi":"10.1200/jco.2000.18.9.1867","title":"Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Medicine; Mitoxantrone; Etoposide; Gastroenterology; Internal medicine; Myeloid leukemia; Toxicity; Cytarabine; Pharmacology; Refractory (planetary science); Pharmacokinetics; Chemotherapy","score_opus":0.05112776183792007,"score_gpt":0.4122730866566613,"score_spread":0.36114532481874123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178680838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411696,0.00089704397,0.0000037953168,0.00277092,0.0003699626,0.00042151814,0.000004979037,0.0000105641775,0.0014042471],"genre_scores_gemma":[0.9258827,0.0659047,0.0033568146,0.0016837736,0.0019257814,0.00000836265,0.000008556652,0.000043121643,0.0011861897],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99587137,0.0004754182,0.0022102213,0.00032435643,0.0006769745,0.00044164516],"domain_scores_gemma":[0.995956,0.0017596385,0.0009636284,0.00026624845,0.0004457933,0.0006086739],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021422727,0.00022993467,0.0016044708,0.00030803418,0.00004100048,0.000012163659,0.00023204421,0.00046794978,0.0006264879],"category_scores_gemma":[0.0010161558,0.00012979163,0.00019262136,0.00040294765,0.00024141127,0.00021871379,0.00004950957,0.0024737192,0.0000278828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047090936,0.0014644086,0.45777896,0.00002046726,0.00020491381,0.0013862061,0.00006949653,0.0000037170846,0.000014460132,0.0000028064428,0.0036073185,0.4883563],"study_design_scores_gemma":[0.030227588,0.040234566,0.86977524,0.000065876484,0.00020157,0.00024375066,0.000019640702,0.000031522606,0.0000100758,0.000031890086,0.05902501,0.00013329132],"about_ca_topic_score_codex":0.000028565195,"about_ca_topic_score_gemma":0.00006474061,"teacher_disagreement_score":0.48822302,"about_ca_system_score_codex":0.00078810466,"about_ca_system_score_gemma":0.004199668,"threshold_uncertainty_score":0.9998276},"labels":[],"label_agreement":null},{"id":"W2179992916","doi":"10.1200/jco.2015.61.9338","title":"Survival and Clinical Outcomes in Surgically Treated Patients With Metastatic Epidural Spinal Cord Compression: Results of the Prospective Multicenter AOSpine Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of Texas MD Anderson Cancer Center; University of Toronto; AOSpine; University of Pennsylvania; West Virginia University; Thomas Jefferson University; Johns Hopkins University","keywords":"Medicine; Oswestry Disability Index; Quality of life (healthcare); Surgery; Spinal cord compression; Prospective cohort study; McNemar's test; Spinal cord; Low back pain","score_opus":0.177830307593649,"score_gpt":0.4955333716544217,"score_spread":0.31770306406077264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179992916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945036,0.00003557758,0.000020101574,0.002731492,0.0007205151,0.0014089552,0.000013620332,0.0000054110997,0.00056070596],"genre_scores_gemma":[0.99730295,0.000019988855,0.0020293507,0.00037957195,0.00008918798,0.0000055268174,0.0000033964493,0.0000149862235,0.00015504836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916622,0.0025280197,0.004278419,0.00030833556,0.0009964223,0.00022660304],"domain_scores_gemma":[0.99246407,0.0025964715,0.0030111214,0.00035501175,0.0010537676,0.0005195353],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007913113,0.00021105222,0.0025108655,0.00012302498,0.00002418302,0.000009163808,0.00023839383,0.00010562073,0.00001975171],"category_scores_gemma":[0.014359455,0.000099971156,0.00035350287,0.00022401851,0.0004836059,0.00011874767,0.00018864799,0.0008735512,0.000002247288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11530514,0.019363845,0.8542939,0.000025371257,0.00095010374,0.00049014407,0.00007646995,0.0000043730442,1.9646936e-7,0.000010809701,0.0002504844,0.009229196],"study_design_scores_gemma":[0.10313796,0.057138506,0.83707047,0.0001579124,0.0012680411,0.000009599359,0.0007068268,0.000089308734,5.7515e-7,0.00003552018,0.0003033774,0.000081918755],"about_ca_topic_score_codex":0.00005994306,"about_ca_topic_score_gemma":0.00015018406,"teacher_disagreement_score":0.037774663,"about_ca_system_score_codex":0.00008177561,"about_ca_system_score_gemma":0.00058145943,"threshold_uncertainty_score":0.99394304},"labels":[],"label_agreement":null},{"id":"W2181635864","doi":"10.1200/jco.2015.64.7552","title":"Radiation of the Internal Mammary Nodes: Is There a Benefit?","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lumpectomy; Breast cancer; Radiation therapy; Oncology; Mastectomy; Internal medicine; Randomized controlled trial; Axillary lymph nodes; Cancer; Stage (stratigraphy); Surgery","score_opus":0.06533578424706342,"score_gpt":0.4030812999065756,"score_spread":0.33774551565951216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2181635864","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053573683,0.012814372,0.00018481148,0.9218325,0.0062312162,0.00022249596,0.000121335346,0.0000038938456,0.0050157164],"genre_scores_gemma":[0.15235811,0.009361794,0.0016853877,0.8026519,0.030013058,0.00001432915,0.000060717834,0.00008293558,0.0037717524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972383,0.00039831034,0.0015846726,0.00022726187,0.00036725737,0.0001841949],"domain_scores_gemma":[0.9953336,0.00032637865,0.0032391618,0.000408317,0.00061914703,0.00007339926],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000997231,0.00021104144,0.001055611,0.00004671604,0.000027392874,0.000007597509,0.0007069584,0.0013278819,0.000029934381],"category_scores_gemma":[0.00085469964,0.00012472074,0.0008744664,0.00005649013,0.00024048913,0.000005688395,0.00027985923,0.0013506848,0.0000047431636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004605603,0.00017635246,0.015127582,0.000025934047,0.0012720149,0.0000803951,0.00004790222,0.0000036281988,0.00004356029,0.00000465063,0.9304208,0.05233663],"study_design_scores_gemma":[0.0022731554,0.0017219108,0.03784683,0.00009452174,0.00033703205,0.0001924348,0.00001988076,0.0000029181163,0.00034407355,0.00055789534,0.9564928,0.000116544965],"about_ca_topic_score_codex":0.00003763408,"about_ca_topic_score_gemma":0.000021243139,"teacher_disagreement_score":0.119180575,"about_ca_system_score_codex":0.00010015597,"about_ca_system_score_gemma":0.001424327,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W2182385064","doi":"10.1200/jco.2015.33.15_suppl.8552","title":"CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD30; Medicine; Anaplastic large-cell lymphoma; CHOP; Internal medicine; Pathology; Brentuximab vedotin; Biopsy; Prospective cohort study; Oncology; Lymphoma","score_opus":0.12346976728067173,"score_gpt":0.4418044659431663,"score_spread":0.3183346986624946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182385064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807014,0.0011141521,0.000043686916,0.0069250385,0.0008960407,0.00033155747,0.000014726021,0.000007817159,0.009965615],"genre_scores_gemma":[0.9930682,0.0005953089,0.0031960409,0.0017346138,0.0010088428,0.00002564763,0.000019233585,0.000012742726,0.00033936062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669254,0.00047261117,0.0017518116,0.0002768651,0.0006037842,0.00020238267],"domain_scores_gemma":[0.99599165,0.0016909499,0.0012861942,0.0002678173,0.00048707906,0.00027631808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020870082,0.00016779697,0.0012766364,0.00017909803,0.000030786625,0.000029303821,0.00030691462,0.0002843285,0.00017300235],"category_scores_gemma":[0.0013847856,0.00008938946,0.0006850624,0.00037800212,0.000121421785,0.00012789064,0.000102252234,0.00046044606,0.000021456477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041174316,0.007270099,0.9623885,0.0000032357668,0.0008612816,0.0010001723,0.0009931092,0.000048778835,0.00023042376,0.000017887802,0.016558528,0.0065105273],"study_design_scores_gemma":[0.028473374,0.006008031,0.9113122,0.000077812234,0.0017250564,0.00008074414,0.0018320105,0.00050577126,0.0015994221,0.00058343075,0.04766688,0.0001352168],"about_ca_topic_score_codex":0.00048532587,"about_ca_topic_score_gemma":0.00045492637,"teacher_disagreement_score":0.051076274,"about_ca_system_score_codex":0.00094054756,"about_ca_system_score_gemma":0.0024148123,"threshold_uncertainty_score":0.42837736},"labels":[],"label_agreement":null},{"id":"W2187039533","doi":"10.1200/jco.2007.25.18_suppl.6538","title":"The use of telemedicine to care for cancer patients at remote sites","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Breast cancer; Population; Colorectal cancer; Stage (stratigraphy); Telemedicine; Family medicine; Internal medicine; Health care","score_opus":0.26087812631470236,"score_gpt":0.5638752100803393,"score_spread":0.3029970837656369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187039533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97960836,0.0004382785,0.00095738703,0.016588701,0.0015606345,0.00072560814,0.000013648345,0.000004010753,0.00010335392],"genre_scores_gemma":[0.96658725,0.0008660927,0.014872899,0.014593391,0.0027170347,0.0000042302463,0.000019131867,0.00001893897,0.00032103044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630725,0.000098293276,0.0027958916,0.00011372619,0.00040673962,0.0002780711],"domain_scores_gemma":[0.99010414,0.005884719,0.0017824688,0.00014068901,0.0016697984,0.0004181867],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028786336,0.00009007969,0.00086409185,0.00011148204,0.00009029266,0.0000022297988,0.00009869274,0.00014545248,0.00005284322],"category_scores_gemma":[0.009597584,0.000049614056,0.00021550602,0.000146294,0.00011063568,0.000048482892,0.000036905894,0.00031456797,0.000001993586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005835284,0.0001532643,0.35963234,0.000060737617,0.00009200435,0.000015837913,0.0003720011,0.000001851786,0.00016294219,0.0000104248265,0.042606294,0.591057],"study_design_scores_gemma":[0.0055111633,0.015389605,0.42623827,0.000062707266,0.00017857992,0.000011720673,0.0002890089,0.000007649818,0.00029482448,0.000015544525,0.55197346,0.000027473001],"about_ca_topic_score_codex":0.00011337376,"about_ca_topic_score_gemma":0.002247521,"teacher_disagreement_score":0.5910295,"about_ca_system_score_codex":0.00024647286,"about_ca_system_score_gemma":0.0006304325,"threshold_uncertainty_score":0.998745},"labels":[],"label_agreement":null},{"id":"W2187815530","doi":"10.1200/jco.2013.31.6_suppl.3","title":"High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Goserelin; Urology; Clinical endpoint; Hazard ratio; Randomized controlled trial; Bicalutamide; Prostate; Radiation therapy; Cancer; Proportional hazards model; Internal medicine; Surgery; Confidence interval","score_opus":0.0717215730904065,"score_gpt":0.46243297186220134,"score_spread":0.39071139877179484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187815530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907708,0.0046980064,0.000006383952,0.0019371462,0.00021881153,0.0021177197,0.00003484939,0.0000062265894,0.00021005905],"genre_scores_gemma":[0.9777585,0.020446803,0.0007994381,0.000045605775,0.0002593229,0.000061779174,0.000004866019,0.00002019762,0.0006034312],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99550635,0.00091582775,0.0026457498,0.00023144236,0.00045224137,0.00024839258],"domain_scores_gemma":[0.99217904,0.003545427,0.002764237,0.00021064088,0.00094554,0.00035513213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031347165,0.0001861012,0.0031099152,0.00018453805,0.000037369162,0.000007831063,0.00011173251,0.00019533787,0.0001645433],"category_scores_gemma":[0.0013908554,0.00009547882,0.00029679577,0.00022010048,0.00072297663,0.000100278805,0.00002712245,0.0005734029,8.440876e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86247945,0.004808984,0.03404777,0.000036868336,0.0048155254,0.00029460515,0.00086722174,0.00001784355,0.00041866,0.0000012721989,0.0010046865,0.09120714],"study_design_scores_gemma":[0.8988499,0.078457594,0.017551327,0.00014913153,0.0019366512,0.00003890001,0.00048990804,0.00024399212,0.0012956088,0.000031597883,0.00086561096,0.00008977105],"about_ca_topic_score_codex":0.0022192588,"about_ca_topic_score_gemma":0.0001366553,"teacher_disagreement_score":0.09111737,"about_ca_system_score_codex":0.0001289397,"about_ca_system_score_gemma":0.0014435153,"threshold_uncertainty_score":0.38935134},"labels":[],"label_agreement":null},{"id":"W2189982580","doi":"10.1200/jco.2015.61.0733","title":"Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Regione Emilia-Romagna","keywords":"Medicine; Morphine; Opioid; Cancer pain; Randomized controlled trial; Analgesic; Adverse effect; Anesthesia; Odds ratio; Internal medicine; Cancer","score_opus":0.2002138842292879,"score_gpt":0.4887562121665237,"score_spread":0.2885423279372358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189982580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778029,0.00068875484,0.0004764742,0.01122745,0.0042592757,0.0007236295,0.0000012805028,0.0000072070334,0.0048130457],"genre_scores_gemma":[0.99050975,0.002155176,0.002029772,0.0015998762,0.0025186443,0.000019696186,0.000002602629,0.000016846958,0.0011476113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938493,0.0021359131,0.0031758193,0.00015254239,0.0004659326,0.00022053643],"domain_scores_gemma":[0.99093574,0.0062689474,0.0018229954,0.00018899936,0.0004228637,0.00036047387],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027183708,0.00013738868,0.002857237,0.00022839803,0.0000106310945,0.0000056582603,0.00018403101,0.00030561525,0.00011130755],"category_scores_gemma":[0.02797038,0.000092183145,0.00060893747,0.00018694306,0.00023989912,0.00009117669,0.000057596193,0.0007747865,0.0000067999063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9612328,0.0016298839,0.0041077225,0.00003776051,0.0004230611,0.00024421982,0.000104040875,0.00036376892,0.000015141332,0.00015307523,0.009451049,0.022237489],"study_design_scores_gemma":[0.96568,0.0097247595,0.0029202069,0.00015286969,0.0004080907,0.0000017244176,0.000120756195,0.007865908,0.000013222919,0.0009645195,0.012065723,0.00008224057],"about_ca_topic_score_codex":0.00009766695,"about_ca_topic_score_gemma":0.000096778116,"teacher_disagreement_score":0.02215525,"about_ca_system_score_codex":0.00016108128,"about_ca_system_score_gemma":0.0017780488,"threshold_uncertainty_score":0.98021746},"labels":[],"label_agreement":null},{"id":"W2190577147","doi":"10.1200/jco.2015.64.7545","title":"Does Pregabalin Still Have a Role in Treating Cancer-Induced Bone Pain?","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pregabalin; Medicine; Gabapentin; Neuropathic pain; Bone pain; Postherpetic neuralgia; Randomized controlled trial; Palliative care; Analgesic; Placebo; Peripheral neuropathy; Anesthesia; Surgery; Diabetes mellitus","score_opus":0.15055240058684466,"score_gpt":0.4732951226186193,"score_spread":0.3227427220317746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190577147","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08319151,0.0010728036,0.0000663221,0.90633905,0.0030033917,0.0009356091,0.000035734378,0.000024032386,0.005331562],"genre_scores_gemma":[0.047227662,0.00060314883,0.005308392,0.91632116,0.021015415,0.00006924355,0.00006371992,0.00013436847,0.009256894],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.989787,0.0028524688,0.0050736363,0.0004737562,0.0012613027,0.00055185816],"domain_scores_gemma":[0.988257,0.0045894324,0.0053079394,0.00047853542,0.0007927957,0.0005742943],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.013920939,0.0004092439,0.004205358,0.0005321659,0.000019433299,0.00002304739,0.0003636218,0.0014976572,0.00049849617],"category_scores_gemma":[0.021410603,0.00023617194,0.0009147059,0.00017232403,0.00015820745,0.00012120874,0.00013045277,0.0058368216,0.00001938617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025831263,0.0014080721,0.0263949,0.0004570393,0.0008872794,0.018594075,0.00020980829,0.000010069023,0.000007948184,0.000002758407,0.74959135,0.19985355],"study_design_scores_gemma":[0.013209332,0.0069886553,0.007920591,0.0012519172,0.0020843206,0.000089153145,0.00040908757,0.0005155104,0.0000034459667,0.00065002363,0.96659994,0.0002780022],"about_ca_topic_score_codex":0.00036047155,"about_ca_topic_score_gemma":0.00036516372,"teacher_disagreement_score":0.21700859,"about_ca_system_score_codex":0.00065680826,"about_ca_system_score_gemma":0.0048075123,"threshold_uncertainty_score":0.9997986},"labels":[],"label_agreement":null},{"id":"W2192442514","doi":"10.1200/jco.2007.25.18_suppl.6530","title":"Source of funding, conflict of interest (COI), and the interpretation of cancer clinical trials","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Academic Publishing and Open Access","field":"Decision Sciences","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Logistic regression; Family medicine; Randomized controlled trial; Clinical trial; Clinical endpoint; Cancer; Internal medicine","score_opus":0.7416514714306276,"score_gpt":0.6880788519112794,"score_spread":0.05357261951934822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2192442514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735315,0.0012318627,0.014304233,0.0053114486,0.0029079283,0.0001625385,0.0000061550377,0.0000019629804,0.002542393],"genre_scores_gemma":[0.9962782,0.001085497,0.0005427177,0.0009959202,0.000792208,7.0559366e-7,2.008627e-7,0.000006049844,0.0002984865],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9689448,0.0089244265,0.020354794,0.00031719895,0.001210418,0.00024834828],"domain_scores_gemma":[0.7427363,0.22496328,0.029385604,0.00039486575,0.0021692081,0.0003507466],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.29931936,0.00010721025,0.0032567403,0.0002646475,0.000031552834,0.000047154568,0.0016903557,0.00060680055,0.00018010342],"category_scores_gemma":[0.37305838,0.00005160289,0.00092143664,0.00035651308,0.0019043656,0.00046358872,0.00030711901,0.0014928126,0.0000019593126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010289529,0.00025901172,0.27915397,0.000009345217,0.0002871539,0.000003667231,0.0009812339,0.00005306895,0.00004964951,0.001649166,0.0092146555,0.69804955],"study_design_scores_gemma":[0.027481375,0.007751578,0.7372936,0.0006293669,0.0009397823,0.000078800644,0.0076097003,0.00504841,0.00079963024,0.027866123,0.18425605,0.0002455768],"about_ca_topic_score_codex":0.00018528585,"about_ca_topic_score_gemma":0.00028740495,"teacher_disagreement_score":0.697804,"about_ca_system_score_codex":0.000027338612,"about_ca_system_score_gemma":0.000814224,"threshold_uncertainty_score":0.7214982},"labels":[],"label_agreement":null},{"id":"W2192694230","doi":"10.1200/jco.2015.63.8767","title":"To RCT or Not to RCT: How to Change Practice for Rare Cancers?","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Observational study; Radiation therapy; Internal medicine; Overall survival; Oncology; Progression-free survival","score_opus":0.42155396846925436,"score_gpt":0.5377856551422362,"score_spread":0.11623168667298184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2192694230","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020392933,0.0010167971,0.00017819095,0.98372203,0.009094655,0.0019401191,0.00012674564,0.00001821139,0.001863966],"genre_scores_gemma":[0.0019665181,0.0004155827,0.013250468,0.89596736,0.078321174,0.00020981325,0.00001645343,0.0000845105,0.009768103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951873,0.0004164108,0.002077599,0.00059667614,0.001013164,0.0007088438],"domain_scores_gemma":[0.9867798,0.0064910594,0.0018853077,0.00050675706,0.003105772,0.0012313145],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0036897678,0.00043761378,0.0037612568,0.00041512496,0.0000722231,0.00004288776,0.00052177976,0.0013646117,0.00011079214],"category_scores_gemma":[0.035926312,0.00029467183,0.00089614675,0.00034210848,0.00008458977,0.00018222062,0.0002650538,0.0031928695,0.00010088468],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021837434,0.00020921172,0.00033400243,0.00017246175,0.0009905763,0.004821846,0.0012561448,0.0000010630437,0.00000550857,0.0000012400936,0.900275,0.07009553],"study_design_scores_gemma":[0.0053570694,0.046950486,0.005530419,0.0004919368,0.0016866814,0.0008218623,0.0006336318,0.0000010299362,0.000008419059,0.000009978715,0.93818945,0.00031901844],"about_ca_topic_score_codex":0.00014768109,"about_ca_topic_score_gemma":0.00073506066,"teacher_disagreement_score":0.087754644,"about_ca_system_score_codex":0.0014858452,"about_ca_system_score_gemma":0.005147262,"threshold_uncertainty_score":0.9999505},"labels":[],"label_agreement":null},{"id":"W2196580706","doi":"10.1200/jco.2010.28.18_suppl.lba7005","title":"A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Placebo; Lung cancer; Rash; Gastroenterology; Hazard ratio; Epidermal growth factor receptor; Surgery; Cancer; Oncology; Pathology; Confidence interval","score_opus":0.08185732026370005,"score_gpt":0.4656413726622132,"score_spread":0.3837840523985132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196580706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791389,0.00033899114,0.00011464264,0.0058799153,0.006153411,0.006600056,0.00007337106,0.00001209869,0.0016886168],"genre_scores_gemma":[0.9932891,0.0003654821,0.00094813114,0.00091716147,0.0030427238,0.00036611396,0.000012781382,0.000039567432,0.0010189384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921389,0.0013599338,0.005062396,0.0003515222,0.0006207322,0.00046649465],"domain_scores_gemma":[0.98600125,0.0076379715,0.004528978,0.00035298645,0.00093564996,0.0005431314],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0050072423,0.0003280309,0.0043405048,0.00024545324,0.00011324487,0.00002175134,0.000366362,0.000635457,0.00080830685],"category_scores_gemma":[0.005140983,0.00018368849,0.0015688743,0.00032834642,0.0004926254,0.00014698062,0.000092051305,0.0025541522,0.0000053298454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98039925,0.0067294217,0.002954127,0.00008255801,0.0012943731,0.00010744569,0.0007466001,0.000016399274,0.0035166962,0.000048448976,0.0017193314,0.0023853602],"study_design_scores_gemma":[0.98506004,0.0068465914,0.0011650583,0.0002121033,0.0020036045,0.000029270079,0.00012334296,0.00035819938,0.0010302262,0.00003223841,0.0029748287,0.00016449158],"about_ca_topic_score_codex":0.00085439393,"about_ca_topic_score_gemma":0.0012905326,"teacher_disagreement_score":0.014150202,"about_ca_system_score_codex":0.00035493128,"about_ca_system_score_gemma":0.006604158,"threshold_uncertainty_score":0.999747},"labels":[],"label_agreement":null},{"id":"W2196970594","doi":"10.1200/jco.2015.64.0268","title":"Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Marie Curie; Cancer Research UK","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Randomized controlled trial; Cancer; Low molecular weight heparin; Metastasis; Surgery; Oncology; Heparin; Confidence interval","score_opus":0.05948341372265083,"score_gpt":0.45003520664791186,"score_spread":0.39055179292526104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196970594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902976,0.0007266946,0.0005222193,0.0020506263,0.0023068865,0.0032507519,0.0000039452293,0.000005387474,0.0008358456],"genre_scores_gemma":[0.99526745,0.001960018,0.000827346,0.0010007807,0.0008230113,0.00007141765,0.000004345855,0.000021418322,0.000024235846],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939295,0.001191816,0.0035701294,0.00018690346,0.00088032946,0.00024134145],"domain_scores_gemma":[0.99463814,0.0012906009,0.0028588932,0.0002277136,0.0006246012,0.00036003703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007735604,0.00018112412,0.005051923,0.00020261036,0.00001604858,0.0000083027735,0.00018037096,0.0002542034,0.00013225939],"category_scores_gemma":[0.0025503433,0.000106513806,0.0005876945,0.00016985608,0.00021990476,0.000088804285,0.000040702867,0.00058669446,0.000001027213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9564758,0.01285413,0.0015165478,0.00003691205,0.0014560563,0.00018026396,0.00025950666,0.00013765697,0.0000017455648,0.00010595053,0.0030588682,0.023916572],"study_design_scores_gemma":[0.93322414,0.060913943,0.0010878087,0.0002644173,0.0010021918,0.0000020310263,0.00003380439,0.00025760467,0.000030940642,0.00019473952,0.0028889794,0.00009940899],"about_ca_topic_score_codex":0.000102403814,"about_ca_topic_score_gemma":0.000034983113,"teacher_disagreement_score":0.048059814,"about_ca_system_score_codex":0.00033000257,"about_ca_system_score_gemma":0.0028819551,"threshold_uncertainty_score":0.51124644},"labels":[],"label_agreement":null},{"id":"W2198521976","doi":"10.1200/jco.2009.27.15_suppl.cra6501","title":"Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Childhood cancer; Cancer; Clinical Oncology; Family medicine; Oncology; Internal medicine","score_opus":0.10048766199695885,"score_gpt":0.4741930810908936,"score_spread":0.37370541909393473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198521976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9166862,0.010250319,0.000049199985,0.0679873,0.00328057,0.0011410965,0.000093948365,0.000030813644,0.0004805667],"genre_scores_gemma":[0.96623033,0.008742709,0.0006889082,0.018584883,0.0055104657,0.000048881815,0.000009623518,0.00006097849,0.00012320818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9865488,0.002246086,0.007902014,0.00077948486,0.0018139251,0.0007096868],"domain_scores_gemma":[0.9852425,0.004900041,0.006863956,0.0009567196,0.0013849813,0.0006518291],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009949588,0.0005160792,0.004423379,0.0002794613,0.00012113418,0.000026082875,0.0009099391,0.0006384446,0.00057997095],"category_scores_gemma":[0.008494178,0.00035427278,0.0011139464,0.0008865283,0.00034656358,0.00031695134,0.00015809613,0.0032299194,0.0000040842374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028457746,0.008230656,0.856883,0.00002212363,0.0016380505,0.00086559367,0.0057088626,0.00027197282,0.000027779375,0.000010994341,0.0054953927,0.117999785],"study_design_scores_gemma":[0.015264228,0.0058126845,0.96221226,0.0012982781,0.001101527,0.00017657045,0.003174955,0.000037198573,0.00006753131,0.00014914435,0.0103746485,0.0003309403],"about_ca_topic_score_codex":0.08700713,"about_ca_topic_score_gemma":0.16985045,"teacher_disagreement_score":0.117668845,"about_ca_system_score_codex":0.0003432273,"about_ca_system_score_gemma":0.006004901,"threshold_uncertainty_score":0.9998909},"labels":[],"label_agreement":null},{"id":"W2199256428","doi":"10.1200/jco.2009.27.15_suppl.9613","title":"The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Dysphagia; Esophageal cancer; Neoadjuvant therapy; Swallowing; Chemotherapy; Internal medicine; Regimen; Esophageal stent; Surgery; Cancer; Oncology; Esophagus","score_opus":0.060878707996649996,"score_gpt":0.4229418907302294,"score_spread":0.3620631827335794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199256428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97365236,0.0021615466,0.00002440786,0.01991632,0.0011141266,0.00026455458,0.0000020479563,0.000005342416,0.0028592958],"genre_scores_gemma":[0.98145944,0.008475763,0.0013443369,0.0077595655,0.0004643809,0.0000030017193,8.666503e-7,0.000012379471,0.00048025127],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964257,0.00023608176,0.0024335647,0.0002017208,0.00038136027,0.0003215665],"domain_scores_gemma":[0.99620277,0.0014547901,0.0016455214,0.00017784565,0.00032237917,0.00019672346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022870225,0.00015210298,0.0011760682,0.00011603413,0.000055483597,0.0000065720355,0.0002511036,0.00029605228,0.00008094575],"category_scores_gemma":[0.0006508728,0.00009341269,0.0003317021,0.00021703856,0.00019538862,0.00010284468,0.000055357563,0.0007897314,0.000006427669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045220866,0.0022714518,0.37987092,0.000107283435,0.00062798907,0.0020807118,0.00066007714,0.00002217243,0.00022577553,0.0006821998,0.0035664814,0.60536283],"study_design_scores_gemma":[0.012803949,0.010816871,0.97045344,0.00045523688,0.00023025692,0.000073074625,0.00022101615,0.000032851134,0.0004736361,0.0024076425,0.0019504086,0.00008160587],"about_ca_topic_score_codex":0.000011434674,"about_ca_topic_score_gemma":0.000041634605,"teacher_disagreement_score":0.60528123,"about_ca_system_score_codex":0.00019610523,"about_ca_system_score_gemma":0.0006143869,"threshold_uncertainty_score":0.38092586},"labels":[],"label_agreement":null},{"id":"W2199389393","doi":"10.1200/jco.2013.31.15_suppl.6007","title":"p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Immunohistochemistry; Hazard ratio; Human papillomavirus; Proportional hazards model; Stage (stratigraphy); Biomarker; HPV infection; Cancer; Cervical cancer; Confidence interval; Biology","score_opus":0.07954209336095655,"score_gpt":0.43158110740791267,"score_spread":0.35203901404695614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199389393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727319,0.0011494767,0.000013475848,0.002612401,0.0013305781,0.00070290465,0.00000177064,0.000012281607,0.021445222],"genre_scores_gemma":[0.99522567,0.00026862323,0.0006016634,0.0019541436,0.00094110344,0.00004770062,0.000002435754,0.000036710007,0.00092196546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950084,0.00044020225,0.0030030918,0.0003826627,0.00061033614,0.00055532623],"domain_scores_gemma":[0.9955784,0.0016049562,0.0013394916,0.00029686769,0.00046520217,0.00071509654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020315358,0.00028644787,0.0023507508,0.00026438123,0.000099896366,0.000018128749,0.00027331294,0.00059505046,0.0008098534],"category_scores_gemma":[0.0014858184,0.00019483856,0.0005324946,0.00019300252,0.00023785046,0.0001971055,0.00017945276,0.0015104013,0.00027797543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039982195,0.006947278,0.76350695,0.0002656618,0.00013480645,0.007360265,0.000893925,0.0000031600468,0.06040885,0.0000055305777,0.03877993,0.117695436],"study_design_scores_gemma":[0.016559668,0.020713834,0.95264286,0.00021169511,0.00019419692,0.0003020137,0.0003409284,0.00006530931,0.0016111127,0.0001688128,0.0069918996,0.00019764966],"about_ca_topic_score_codex":0.00042691053,"about_ca_topic_score_gemma":0.00010989628,"teacher_disagreement_score":0.18913594,"about_ca_system_score_codex":0.0002934123,"about_ca_system_score_gemma":0.0013451448,"threshold_uncertainty_score":0.88673264},"labels":[],"label_agreement":null},{"id":"W2199584453","doi":"10.1200/jco.2009.27.15_suppl.e17572","title":"Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Economic evaluation; CLARITY; Oncology; Health care; Equity (law); Population; Internal medicine","score_opus":0.5802869236348253,"score_gpt":0.6028075483643242,"score_spread":0.022520624729498895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199584453","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12137411,0.005678397,0.0029948468,0.86583966,0.0018582726,0.0017805407,0.000088591085,0.000013701978,0.0003718778],"genre_scores_gemma":[0.8398979,0.0020553672,0.14481238,0.012461804,0.000520632,0.000118116746,0.0000045197717,0.000017519284,0.000111770445],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98637,0.00044746054,0.0123243015,0.00038418864,0.000069428235,0.00040458667],"domain_scores_gemma":[0.98405856,0.0026413903,0.012294231,0.00034398824,0.00051845016,0.0001433832],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.051903978,0.00015180916,0.0022231552,0.00064227206,0.00014969632,0.000016365646,0.0004927142,0.0005528033,0.000009450131],"category_scores_gemma":[0.030648338,0.0001374494,0.00021305468,0.00018758496,0.00023947685,0.00022902843,0.00004197444,0.00045091304,0.000004207488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034446543,0.000636626,0.05015151,0.0005147239,0.00022336877,0.0000027750127,0.0014573864,0.0030836612,0.0000063167627,0.4520033,0.05573424,0.43584165],"study_design_scores_gemma":[0.004786881,0.0069397115,0.048381496,0.00020234147,0.000020951982,0.000028646464,0.0040357364,0.005546241,0.000009894686,0.2616688,0.66816336,0.00021591794],"about_ca_topic_score_codex":0.0057506086,"about_ca_topic_score_gemma":0.058928013,"teacher_disagreement_score":0.8533779,"about_ca_system_score_codex":0.0027392511,"about_ca_system_score_gemma":0.008273198,"threshold_uncertainty_score":0.99734896},"labels":[],"label_agreement":null},{"id":"W2199700205","doi":"10.1200/jco.2010.28.18_suppl.cra4504","title":"Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Hazard ratio; Urology; Radiation therapy; Interim analysis; Randomized controlled trial; Internal medicine; Oncology; Goserelin; Surgery; Cancer; Confidence interval","score_opus":0.07664262798473125,"score_gpt":0.4912143294757997,"score_spread":0.4145717014910684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199700205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98692214,0.005127053,0.00009355847,0.0030897409,0.0013705518,0.0031623752,0.0000064449637,0.000013865189,0.00021429065],"genre_scores_gemma":[0.9514823,0.046440337,0.00035489348,0.00063905405,0.0006197872,0.00018536506,0.000015771657,0.00003509863,0.00022740857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939256,0.0010934924,0.003554085,0.0003660251,0.00067673216,0.00038408462],"domain_scores_gemma":[0.9939725,0.0019998562,0.0024691655,0.0003308172,0.0008856476,0.00034201462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061688465,0.00028089108,0.0028094922,0.00042437424,0.000058364287,0.000017355891,0.00028717233,0.00041626117,0.0003539658],"category_scores_gemma":[0.0013929681,0.00017484749,0.0004904362,0.0004119478,0.00039320695,0.00025976796,0.00005345947,0.0016940506,0.0000042673537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49366903,0.0062936805,0.042316835,0.000017517714,0.0009240975,0.0001893237,0.0020819735,0.00006376689,0.003933594,0.000014012482,0.00026416025,0.450232],"study_design_scores_gemma":[0.9239531,0.029642181,0.03247879,0.00015976885,0.0002295813,0.00004580804,0.0005676269,0.0008364804,0.004414396,0.0004288483,0.0070462856,0.00019713333],"about_ca_topic_score_codex":0.00033758464,"about_ca_topic_score_gemma":0.0004905811,"teacher_disagreement_score":0.4500349,"about_ca_system_score_codex":0.00036117688,"about_ca_system_score_gemma":0.0029484627,"threshold_uncertainty_score":0.7359901},"labels":[],"label_agreement":null},{"id":"W2200087787","doi":"10.1200/jco.2015.33.15_suppl.7504","title":"Results from a randomized study of carboplatin and etoposide (CE) with or without palifosfamide (Pa) in extensive stage small cell lung cancer (ES-SCLC): The MATISSE study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"","keywords":"Medicine; Etoposide; Carboplatin; Internal medicine; Ifosfamide; Clinical endpoint; Regimen; Oncology; Chemotherapy; Lung cancer; Cisplatin; Randomized controlled trial","score_opus":0.1812571299523963,"score_gpt":0.5058153914415326,"score_spread":0.32455826148913636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200087787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906052,0.0021568409,0.000015723648,0.003177594,0.00030657297,0.0032006905,0.000022973496,0.0000068673507,0.00050755055],"genre_scores_gemma":[0.9966183,0.0010344005,0.00096511305,0.00045161886,0.00040759635,0.00007016496,9.511446e-7,0.000026867627,0.0004250228],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99175245,0.003394732,0.003263003,0.00036329657,0.00091571483,0.00031079035],"domain_scores_gemma":[0.98188937,0.013537667,0.002562641,0.00039323588,0.0012257423,0.00039131928],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011270785,0.00024314951,0.0039042733,0.0001647651,0.000046050583,0.000016704822,0.0002477494,0.00016796832,0.000024455723],"category_scores_gemma":[0.014685104,0.000108833716,0.00016247295,0.0002614395,0.00050567754,0.00007957782,0.00021170934,0.0014428404,7.483053e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46838787,0.0026808325,0.50448745,0.000042637632,0.0015591176,0.0019774325,0.01828588,0.00013299183,0.00003965542,0.0000014558957,0.00066549086,0.0017391678],"study_design_scores_gemma":[0.4936204,0.02557286,0.4461376,0.00038560625,0.0017295589,0.00004059407,0.031270728,0.00086451566,0.00002994796,0.000024140567,0.00020204032,0.000121982506],"about_ca_topic_score_codex":0.012075462,"about_ca_topic_score_gemma":0.04874004,"teacher_disagreement_score":0.058349855,"about_ca_system_score_codex":0.00027425526,"about_ca_system_score_gemma":0.0031503416,"threshold_uncertainty_score":0.9945032},"labels":[],"label_agreement":null},{"id":"W2202284367","doi":"10.1200/jco.2013.31.31_suppl.58","title":"Development and implementation of communities of practice at Cancer Care Ontario (CCO).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Checklist; Brachytherapy; Multidisciplinary approach; Radiation Therapist; Medical physics; Radiation therapy; Best practice; Cancer; External beam radiation; Surgery; Internal medicine; Management","score_opus":0.41806919260022185,"score_gpt":0.6208711448952361,"score_spread":0.20280195229501424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202284367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990566,0.00034310904,0.000049548045,0.007452306,0.00045208822,0.00033210823,0.0000039048778,0.0000024503327,0.00079848134],"genre_scores_gemma":[0.949454,0.00074952707,0.0471455,0.002344398,0.00018495473,0.00000924944,0.000012778928,0.000009880575,0.000089707435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942472,0.0004451119,0.0046873754,0.000087490786,0.00040315514,0.00012964336],"domain_scores_gemma":[0.9855653,0.006640833,0.0052169827,0.00014730681,0.0022548463,0.00017471539],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00330688,0.000097801065,0.0009814089,0.00009168957,0.000040734052,0.00000493775,0.00009737497,0.00016643632,0.001425319],"category_scores_gemma":[0.0034506312,0.00007571382,0.00015084284,0.0000653021,0.00017571088,0.0003527282,0.00012249633,0.00057564286,0.00000503848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014894485,0.00048377365,0.57671934,0.0001010112,0.00049622526,0.000013686707,0.010135059,0.000005171309,0.0004451929,0.00003949824,0.0029504786,0.4071211],"study_design_scores_gemma":[0.0064363014,0.004087943,0.7386852,0.00009565833,0.0006417778,0.00010962849,0.049357716,0.0000055672213,0.00086058787,0.000034658275,0.19962177,0.00006319107],"about_ca_topic_score_codex":0.04000102,"about_ca_topic_score_gemma":0.1517265,"teacher_disagreement_score":0.4070579,"about_ca_system_score_codex":0.00046428634,"about_ca_system_score_gemma":0.003988879,"threshold_uncertainty_score":0.9994875},"labels":[],"label_agreement":null},{"id":"W2202400394","doi":"10.1200/jco.2012.30.15_suppl.4509","title":"Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Credit Valley Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Interim analysis; Internal medicine; Oncology; Urology; Radiation therapy; Randomized controlled trial; Cancer; Gynecology; Surgery; Confidence interval","score_opus":0.12790433469173054,"score_gpt":0.5098900642798907,"score_spread":0.38198572958816013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202400394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428965,0.012174877,0.0002274709,0.0009134143,0.0004619157,0.0018258205,0.000009567051,0.0000059014887,0.0000913575],"genre_scores_gemma":[0.9502,0.04872194,0.00026124177,0.00027638115,0.00029440038,0.00010041808,0.000024380606,0.000019185536,0.000102024096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99371123,0.001371162,0.003659538,0.00024654964,0.0006567298,0.00035478026],"domain_scores_gemma":[0.99365336,0.0019702408,0.0030544156,0.0002625883,0.0007774511,0.00028196184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006664393,0.00022377734,0.0034715412,0.0007978365,0.000035129542,0.0000068711465,0.00020356846,0.00026670363,0.0002442265],"category_scores_gemma":[0.001055206,0.00014006117,0.0007427277,0.00092953397,0.00028488354,0.00026000515,0.0000421208,0.00071907055,0.0000011133263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47537792,0.008140675,0.20918334,0.000019208841,0.005347213,0.000044904522,0.003296742,0.00041835738,0.0008919905,0.000008447753,0.00008722817,0.29718396],"study_design_scores_gemma":[0.79371524,0.022597613,0.1748784,0.0001367629,0.0018605189,0.0000112966145,0.0008787092,0.001861019,0.0025714065,0.00009092719,0.0012430542,0.0001550272],"about_ca_topic_score_codex":0.00036547324,"about_ca_topic_score_gemma":0.0002302639,"teacher_disagreement_score":0.31833735,"about_ca_system_score_codex":0.0004472785,"about_ca_system_score_gemma":0.0016343773,"threshold_uncertainty_score":0.57115287},"labels":[],"label_agreement":null},{"id":"W2202753625","doi":"10.1200/jco.2006.24.18_suppl.17560","title":"Ten year retrospective analysis of BOP (bleomycin, vincristine, predinisone)—A novel non-myelosuppressive chemotherapy regimen for treatment of non-Hodgkin’s lymphoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Internal medicine; Regimen; Follicular lymphoma; International Prognostic Index; Vincristine; Rituximab; Population; Gastroenterology; Chemotherapy; Surgery; Oncology; Lymphoma; Cyclophosphamide","score_opus":0.044257092865388356,"score_gpt":0.4109944625329651,"score_spread":0.36673736966757675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202753625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036187,0.0003088807,0.0007430602,0.0027493788,0.00043646173,0.0007531928,0.00016648666,0.0000077906225,0.004472882],"genre_scores_gemma":[0.9797157,0.00075312814,0.017585788,0.00028111832,0.0010560016,0.000044313078,0.00003635381,0.000030658695,0.00049692165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957804,0.00009051156,0.0030038229,0.00035947343,0.00046463954,0.0003011533],"domain_scores_gemma":[0.991889,0.002049489,0.0039448696,0.00040598927,0.0014665646,0.00024411429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089061854,0.00028059073,0.0038364707,0.0003957523,0.00003997278,0.00000693037,0.00017744473,0.00044386866,0.00009011644],"category_scores_gemma":[0.0007306678,0.00018632419,0.0019297746,0.00045353218,0.00025539685,0.00007256503,0.000027897322,0.00009306324,0.0000023059922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011924831,0.025312344,0.9030275,0.000055208417,0.0155791445,0.00017437268,0.00028649572,0.0000820376,0.0019155941,0.0002069844,0.008587249,0.03284825],"study_design_scores_gemma":[0.04364229,0.036894824,0.8960233,0.00010031967,0.009166446,0.000052149197,0.00014311931,0.0006660582,0.00695843,0.0001736922,0.0060502104,0.00012921155],"about_ca_topic_score_codex":0.00038255862,"about_ca_topic_score_gemma":0.000069651396,"teacher_disagreement_score":0.03271904,"about_ca_system_score_codex":0.0008504506,"about_ca_system_score_gemma":0.0013225155,"threshold_uncertainty_score":0.759808},"labels":[],"label_agreement":null},{"id":"W2202891164","doi":"10.1200/jco.2005.23.16_suppl.3198","title":"The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bone remodeling; Bisphosphonate; Internal medicine; N-terminal telopeptide; Chemotherapy; Bone resorption; Cancer; Breast cancer; Osteosarcoma; Doxycycline; Alkaline phosphatase; Oncology; Gastroenterology; Pathology; Osteocalcin; Osteoporosis; Antibiotics","score_opus":0.022802485760634546,"score_gpt":0.4099566355831254,"score_spread":0.38715414982249086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202891164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891818,0.00046377073,5.5107256e-7,0.00957143,0.00024800812,0.00027955443,0.000017484354,0.0000019013137,0.0002354711],"genre_scores_gemma":[0.99795234,0.00039439424,0.00022657041,0.0011518038,0.0002047926,0.0000060122393,0.0000019084957,0.000010304638,0.000051893076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976215,0.00041071876,0.0013407562,0.00012177554,0.00029930868,0.0002059793],"domain_scores_gemma":[0.99544597,0.0029501487,0.0010831256,0.00010922774,0.0001331176,0.00027838565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018267017,0.00012237854,0.0010876798,0.00007615885,0.000030370285,0.0000029889784,0.000049305694,0.000100922945,0.000047332993],"category_scores_gemma":[0.0007408384,0.00005391432,0.00015087544,0.00009121874,0.00021341424,0.000060136193,0.000017285101,0.00057840755,0.0000028962243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032163028,0.0010432698,0.72717124,0.000028005028,0.00021678882,0.00013865498,0.0000066487464,0.000006410588,0.0000013806598,0.000003276771,0.00079717534,0.23842415],"study_design_scores_gemma":[0.026493963,0.024821064,0.9372569,0.00018125486,0.00032851554,0.00016015476,0.0000059619447,0.000017051183,0.000019866464,0.000005199137,0.010668463,0.000041629806],"about_ca_topic_score_codex":0.00017865389,"about_ca_topic_score_gemma":0.00066948944,"teacher_disagreement_score":0.23838252,"about_ca_system_score_codex":0.00011730431,"about_ca_system_score_gemma":0.00042346978,"threshold_uncertainty_score":0.2512925},"labels":[],"label_agreement":null},{"id":"W2203437270","doi":"10.1200/jco.2005.23.16_suppl.3017","title":"Phase III trial of antioxidant vitamins to prevent acute side effects of radiation therapy in head and neck cancer (HNC) patients","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Hazard ratio; Placebo; Internal medicine; Randomized controlled trial; Radiation therapy; Head and neck cancer; Confidence interval; Odds ratio; Population; Vitamin E; Interim analysis; Surgery; Antioxidant; Pathology","score_opus":0.062057523293176806,"score_gpt":0.48559010117506896,"score_spread":0.42353257788189214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203437270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934748,0.0012938781,0.000011565463,0.0036119665,0.0008318732,0.0006253479,0.000005435829,0.0000016363456,0.000143539],"genre_scores_gemma":[0.98385525,0.013853978,0.0003927249,0.0011581571,0.00068339944,0.000011788263,5.943115e-7,0.000007251345,0.00003688247],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99739194,0.00023466031,0.0018660314,0.00011906017,0.00024518734,0.00014315006],"domain_scores_gemma":[0.99747807,0.0009853226,0.001073413,0.00008541248,0.00020130981,0.00017646818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010202414,0.000094509225,0.0015626607,0.0001297615,0.00001316529,0.00000128053,0.000056639466,0.00014771623,0.000009008739],"category_scores_gemma":[0.0010797407,0.000064715576,0.00019284325,0.00011980916,0.000073624375,0.000066195316,0.000022975137,0.00028476608,5.17778e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09979828,0.011054688,0.022931997,0.000045147095,0.0003525577,0.00003307658,0.0005824754,0.0000059066756,0.0027922792,0.0000037139866,0.0008129858,0.86158687],"study_design_scores_gemma":[0.33284137,0.1220694,0.52714014,0.00040807703,0.00020258657,0.000005780794,0.000015845328,0.000021205855,0.006038405,0.0000141386145,0.011181511,0.00006155496],"about_ca_topic_score_codex":0.00006462744,"about_ca_topic_score_gemma":0.0002097796,"teacher_disagreement_score":0.86152536,"about_ca_system_score_codex":0.000121131154,"about_ca_system_score_gemma":0.0005729299,"threshold_uncertainty_score":0.26390246},"labels":[],"label_agreement":null},{"id":"W2203461104","doi":"10.1200/jco.2014.32.31_suppl.180","title":"The routine use of the Edmonton classification system for cancer pain in an outpatient supportive care center.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer pain; Cancer; Opioid; Pain assessment; Delirium; Physical therapy; Internal medicine; Pain management; Intensive care medicine","score_opus":0.1575821213432789,"score_gpt":0.4594355852524674,"score_spread":0.30185346390918855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203461104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900784,0.00010731328,0.00064967974,0.0070643364,0.001266969,0.00057151844,0.000005301825,0.0000038162807,0.00025268202],"genre_scores_gemma":[0.9980137,0.00012346252,0.000361842,0.0008137591,0.00054115785,0.000016905287,0.000003840893,0.000008065573,0.000117316114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966929,0.0012338691,0.0015980708,0.00010728631,0.000220864,0.0001470205],"domain_scores_gemma":[0.9946257,0.0027087233,0.0018160156,0.0002320522,0.00052252924,0.000094978765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060847723,0.000073368225,0.00056656153,0.000043146178,0.000046768208,0.000008271829,0.00018569587,0.00014889092,0.0000030442884],"category_scores_gemma":[0.0052025723,0.00003535617,0.00025824783,0.00007352979,0.00010367851,0.00006486726,0.000031426713,0.00034131022,4.1090595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002151907,0.00043416533,0.8736181,0.00010241108,0.000067808374,0.000002771689,0.0004485157,0.0000352714,0.000045160858,0.0005892963,0.0018755497,0.12062903],"study_design_scores_gemma":[0.003474602,0.0054528527,0.885001,0.00023118714,0.00014180927,7.687893e-7,0.0024364635,0.0042495294,0.0000291547,0.000026266733,0.09891985,0.000036509657],"about_ca_topic_score_codex":0.000043529963,"about_ca_topic_score_gemma":0.0010184434,"teacher_disagreement_score":0.12059252,"about_ca_system_score_codex":0.00023774471,"about_ca_system_score_gemma":0.0003141533,"threshold_uncertainty_score":0.6228341},"labels":[],"label_agreement":null},{"id":"W2203531103","doi":"10.1200/jco.2001.19.14.3392","title":"Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Queen's University","funders":"","keywords":"Guideline; Medicine; Process (computing); Closing (real estate); Advisory committee; Drug development; Process management; Phase (matter); Management science; Political science; Public administration; Computer science; Business; Drug","score_opus":0.5868238880216848,"score_gpt":0.6385990321426819,"score_spread":0.05177514412099704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203531103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68037444,0.00040470398,0.00029828955,0.31538853,0.0012521085,0.00029954378,1.6657756e-7,0.000003905154,0.0019782956],"genre_scores_gemma":[0.83515894,0.0021998659,0.04048034,0.118001476,0.0032445618,0.000014353827,0.0000033473789,0.000026255391,0.0008708601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903266,0.001256891,0.0070779137,0.00022391068,0.00076241395,0.00035227762],"domain_scores_gemma":[0.9691024,0.02542174,0.0038421832,0.00029775864,0.0010914282,0.00024451528],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03094009,0.00015330789,0.00090176775,0.00014163528,0.000075855125,0.000033265318,0.00035585713,0.00024757395,0.00035948885],"category_scores_gemma":[0.079572804,0.00008299868,0.00023037795,0.00040302318,0.000094539566,0.0004525236,0.0000880189,0.0025532658,0.000020751113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041215997,0.0011622949,0.33428758,0.000006652459,0.00015895457,0.0006159417,0.0029671183,0.00041122176,0.000023935812,0.00006194291,0.024718473,0.6314643],"study_design_scores_gemma":[0.0058112484,0.0008485849,0.3665508,0.00015880025,0.00023267965,0.0005943965,0.005358112,0.00018319953,0.0000039558477,0.00033091626,0.6198506,0.00007670139],"about_ca_topic_score_codex":0.04330381,"about_ca_topic_score_gemma":0.2968882,"teacher_disagreement_score":0.6313876,"about_ca_system_score_codex":0.0009459089,"about_ca_system_score_gemma":0.010556724,"threshold_uncertainty_score":0.9997479},"labels":[],"label_agreement":null},{"id":"W2204221336","doi":"10.1200/jco.2012.30.15_suppl.4510","title":"Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Placebo; Clinical endpoint; Surgery; Prostate cancer; Population; Urology; Internal medicine; Bone metastasis; Cancer; Randomized controlled trial; Osteoporosis; Pathology","score_opus":0.07110886579197705,"score_gpt":0.4521721102600956,"score_spread":0.38106324446811857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2204221336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993633,0.0020493292,0.000014348061,0.0015392893,0.00023887059,0.0010171554,0.00003069324,0.0000067185097,0.0014706007],"genre_scores_gemma":[0.9971235,0.0008441282,0.001262704,0.00005639018,0.00036441945,0.00005663378,0.0000063815583,0.000042880678,0.00024298752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951701,0.001178113,0.0017248841,0.00027146656,0.00096108945,0.00069435127],"domain_scores_gemma":[0.9932542,0.0029993076,0.0025235487,0.00030387353,0.0004449168,0.0004741891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004597979,0.00028776098,0.002055059,0.00032691885,0.00004641961,0.000015390746,0.00020363425,0.00017607766,0.000061254075],"category_scores_gemma":[0.0017418772,0.00014933909,0.00023220881,0.00038750362,0.00043114505,0.00019497477,0.00007862106,0.0011403572,0.0000029202263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13518758,0.0035889721,0.7937876,0.0008221029,0.0021370582,0.0059295343,0.0009379112,0.0003791594,0.0015586987,0.00002177213,0.00038964293,0.055259965],"study_design_scores_gemma":[0.08670447,0.15948501,0.7179799,0.0033673223,0.0032221642,0.0008718056,0.0008302125,0.0002379111,0.025359895,0.000056831104,0.0014349719,0.0004495057],"about_ca_topic_score_codex":0.00017963517,"about_ca_topic_score_gemma":0.00036665838,"teacher_disagreement_score":0.15589604,"about_ca_system_score_codex":0.00032442264,"about_ca_system_score_gemma":0.0012066604,"threshold_uncertainty_score":0.6089871},"labels":[],"label_agreement":null},{"id":"W2204619207","doi":"10.1200/jco.2006.24.18_suppl.6544","title":"Outcome of salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), and diffuse large B-cell lymphoma (DLBCL)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anaplastic large-cell lymphoma; Internal medicine; Salvage therapy; Etoposide; Regimen; Chemotherapy; Lymphoma; Oncology; Progressive disease; Chemotherapy regimen; Peripheral T-cell lymphoma; Anthracycline; Surgery; Gastroenterology; Cancer; T cell; Immunology; Breast cancer","score_opus":0.0552286787571971,"score_gpt":0.3841384925059169,"score_spread":0.3289098137487198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2204619207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878369,0.0051814555,0.00023315073,0.0010695657,0.0016831397,0.0009374729,0.00016492986,0.000040476658,0.0028529197],"genre_scores_gemma":[0.9854551,0.0038384267,0.003535662,0.0028266893,0.0014076321,0.000050541454,0.000045855915,0.000119039294,0.0027210363],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920453,0.0006295602,0.0048471396,0.00070404104,0.0007777882,0.0009961849],"domain_scores_gemma":[0.9884072,0.0059121368,0.003613143,0.00062919984,0.00062877114,0.00080956455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026667542,0.00066721183,0.0036553491,0.00033256286,0.00020046432,0.0000435656,0.00039979242,0.0011095746,0.0001701443],"category_scores_gemma":[0.0010180377,0.00044265657,0.0015351338,0.00028118578,0.0003395148,0.00025677326,0.00013538517,0.00031762445,0.000024900313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05172445,0.36492994,0.45774594,0.0005830088,0.00091069454,0.0040052733,0.0003822616,0.0000046689293,0.0017031807,0.00032995787,0.02058546,0.09709516],"study_design_scores_gemma":[0.3840834,0.036419757,0.37049955,0.0001379965,0.0009846024,0.0004118669,0.00024323924,0.00026321723,0.0017703329,0.00014596617,0.20462017,0.00041989243],"about_ca_topic_score_codex":0.000100446996,"about_ca_topic_score_gemma":0.00017351103,"teacher_disagreement_score":0.33235896,"about_ca_system_score_codex":0.00085030386,"about_ca_system_score_gemma":0.0021818406,"threshold_uncertainty_score":0.99980253},"labels":[],"label_agreement":null},{"id":"W2206625824","doi":"10.1200/jco.2009.27.15_suppl.4102","title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Pseudomyxoma peritonei; Hyperthermic intraperitoneal chemotherapy; Perioperative; Peritoneal mesothelioma; Surgery; Adenocarcinoma; Cytoreductive surgery; Cancer; Appendix; Internal medicine; Mesothelioma; Oncology; Ovarian cancer; Pathology","score_opus":0.10414431847685565,"score_gpt":0.409337591048692,"score_spread":0.30519327257183637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2206625824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995277,0.00013273416,0.0002523546,0.0019148565,0.000565596,0.0016461367,0.0000664636,0.0000072350103,0.00013762184],"genre_scores_gemma":[0.9922059,0.00023853465,0.00648891,0.00051692897,0.00043023852,0.00004452677,0.000013716856,0.00001646964,0.000044755452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964838,0.0002561406,0.002116017,0.00029281207,0.00058576255,0.00026548613],"domain_scores_gemma":[0.99419165,0.0022741142,0.0017660828,0.00018978864,0.0013923411,0.00018603093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008658072,0.0002775816,0.0021083409,0.00010515196,0.00014708225,0.0000103271295,0.00021757877,0.00018922456,0.00004294168],"category_scores_gemma":[0.0002974512,0.00013524399,0.00045012546,0.00022245155,0.0007651575,0.00015153053,0.00003257681,0.0004894096,6.111107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29422247,0.060326558,0.485681,0.00023573994,0.011254568,0.0010295972,0.016220702,0.000139987,0.0011036157,0.001157205,0.00041601385,0.12821254],"study_design_scores_gemma":[0.021872897,0.062082034,0.9017779,0.000351954,0.0010626452,0.000050459363,0.010647567,0.00014431482,0.001171412,0.000017399714,0.0006735224,0.00014785102],"about_ca_topic_score_codex":0.0001039064,"about_ca_topic_score_gemma":0.000037148122,"teacher_disagreement_score":0.41609696,"about_ca_system_score_codex":0.00016036328,"about_ca_system_score_gemma":0.0012864312,"threshold_uncertainty_score":0.551509},"labels":[],"label_agreement":null},{"id":"W2208002514","doi":"10.1200/jco.2006.24.18_suppl.5556","title":"Derangement of p53 and MDM2 is involved in transformation of differentiated into anaplastic thyroid cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; BC Cancer Agency","funders":"","keywords":"Anaplastic thyroid cancer; Thyroid cancer; Cancer research; Thyroid carcinoma; Mdm2; Medicine; Tissue microarray; Anaplastic carcinoma; Cancer; Immunohistochemistry; Thyroid; Pathology; Carcinoma; Biology; Internal medicine; Gene","score_opus":0.06378218238629654,"score_gpt":0.42297104177915623,"score_spread":0.3591888593928597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208002514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085224,0.004061374,0.000093990995,0.004368743,0.0002356426,0.00016970526,0.0000064536475,0.0000017717077,0.00021010492],"genre_scores_gemma":[0.99373364,0.0054071127,0.00038518017,0.00031687136,0.00012856151,0.00000728581,0.000003348087,0.0000059737854,0.000012005528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759924,0.00011219368,0.0018777422,0.00009124853,0.00021438324,0.00010516453],"domain_scores_gemma":[0.99814016,0.0004915853,0.0010022045,0.000070170674,0.00020541229,0.00009048956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005420323,0.00008841182,0.0010052962,0.00014088763,0.000009996427,0.000002065112,0.000046111447,0.00014897317,0.00008429619],"category_scores_gemma":[0.000113475966,0.000060578466,0.00017946486,0.00010934621,0.000102975246,0.000062031286,0.000011272394,0.00022130515,5.423093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005599074,0.00476825,0.89763004,0.00028935308,0.000545191,0.00006160246,0.0008074761,0.00009075781,0.0029427118,0.00020711665,0.002496301,0.08456216],"study_design_scores_gemma":[0.015348366,0.008685569,0.9684877,0.00031573113,0.0004723103,0.000008181847,0.00013767538,0.00017989472,0.0041246964,0.0005529832,0.0016346314,0.00005229251],"about_ca_topic_score_codex":0.00062141975,"about_ca_topic_score_gemma":0.002768701,"teacher_disagreement_score":0.084509864,"about_ca_system_score_codex":0.00013922357,"about_ca_system_score_gemma":0.00035417662,"threshold_uncertainty_score":0.24703181},"labels":[],"label_agreement":null},{"id":"W2209143428","doi":"10.1200/jco.2005.23.16_suppl.3680","title":"FOLFIRI vs FOLFOX in the general practice for metastatic colorectal carcinoma (MCRC) - Impact of 1st-line or 2nd-line treatment","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FOLFOX; Medicine; FOLFIRI; Colorectal cancer; Oncology; Internal medicine; Oxaliplatin; Cancer","score_opus":0.23931300643676617,"score_gpt":0.554949095557554,"score_spread":0.31563608912078783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209143428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97526747,0.0018571197,0.00006823193,0.02040869,0.00042077614,0.0009257748,0.000040447187,0.0000046261903,0.0010068362],"genre_scores_gemma":[0.98388386,0.001561716,0.0109897135,0.0014849679,0.0015866465,0.00006264006,0.0000084923895,0.000019578614,0.0004023827],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99604887,0.0005509951,0.0024819542,0.00022013878,0.0003598461,0.00033821267],"domain_scores_gemma":[0.9890288,0.008197452,0.0017948467,0.00019355185,0.00058313564,0.00020220183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026850693,0.00025035813,0.0021912404,0.00014410204,0.00005987613,0.000009290472,0.00016683988,0.00016869011,0.00012942897],"category_scores_gemma":[0.005217317,0.00011173991,0.0011232004,0.0002264131,0.00018991386,0.00014831251,0.00003472948,0.00042389773,0.0000029581906],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28607208,0.040122114,0.10555949,0.00009134698,0.008565952,0.0030670248,0.0033574656,0.00088518095,0.00028933963,0.00018018528,0.010554551,0.5412553],"study_design_scores_gemma":[0.05694373,0.46786427,0.34834102,0.00007804196,0.0052443463,0.0024995503,0.0011530898,0.0018201765,0.0003057129,0.00019250133,0.115343556,0.00021400614],"about_ca_topic_score_codex":0.00039763586,"about_ca_topic_score_gemma":0.0022267094,"teacher_disagreement_score":0.54104125,"about_ca_system_score_codex":0.000836055,"about_ca_system_score_gemma":0.0025086564,"threshold_uncertainty_score":0.6245993},"labels":[],"label_agreement":null},{"id":"W2210721194","doi":"10.1200/jco.2006.24.18_suppl.7009","title":"Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Chemotherapy; Internal medicine; Toxicity; Cisplatin; Adjuvant; Young adult; Univariate analysis; Cancer; Gastroenterology; Multivariate analysis; Oncology; Surgery","score_opus":0.1391649794315419,"score_gpt":0.49661206891576,"score_spread":0.3574470894842181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210721194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574894,0.00044306286,0.00006601764,0.0015500855,0.0011455044,0.00017067592,0.000056569454,0.0000015947744,0.0008175492],"genre_scores_gemma":[0.99508166,0.0008812086,0.00083930546,0.0023590836,0.0006895638,0.0000028457432,0.000036255085,0.000008607239,0.000101456935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99222183,0.0008632618,0.0060207737,0.00021242505,0.0005201475,0.00016153023],"domain_scores_gemma":[0.9925826,0.0027229695,0.0036369672,0.00013329224,0.0006886104,0.0002355588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008688191,0.00012806461,0.0032679597,0.00032530626,0.000015291782,0.0000034179575,0.00014601281,0.00030262314,0.0005750047],"category_scores_gemma":[0.0037129421,0.000093896924,0.00057659927,0.0003042271,0.00028766098,0.00018024251,0.000022763561,0.00056838995,1.1430802e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009154133,0.0021199451,0.777764,0.000032574124,0.001631985,0.000038997267,0.000050180417,0.00025072205,0.00010220587,0.00007025416,0.005724465,0.20306052],"study_design_scores_gemma":[0.017128974,0.006748569,0.93345034,0.00006760287,0.00072926865,0.0000049544165,0.000047048085,0.00087974017,0.0000204039,0.000085766005,0.04075793,0.00007941773],"about_ca_topic_score_codex":0.044849753,"about_ca_topic_score_gemma":0.44334087,"teacher_disagreement_score":0.3984911,"about_ca_system_score_codex":0.00037642213,"about_ca_system_score_gemma":0.0056208,"threshold_uncertainty_score":0.9971057},"labels":[],"label_agreement":null},{"id":"W2211107270","doi":"10.1200/jco.2009.27.15_suppl.5104","title":"A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sorafenib; Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Dosing; Toxicity; Urology; Pazopanib; Progressive disease; Pharmacokinetics; Oncology; Gastroenterology; Hepatocellular carcinoma; Chemotherapy","score_opus":0.1727772208750895,"score_gpt":0.4757522930892986,"score_spread":0.3029750722142091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211107270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516773,0.0009699468,0.00017732359,0.0013589539,0.000243947,0.0008354436,0.000005997056,0.000004811841,0.0012358148],"genre_scores_gemma":[0.99059385,0.0001054636,0.007991769,0.00053594034,0.00040284323,0.000004616784,0.0000025140698,0.000017845221,0.0003451731],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9959507,0.00046163137,0.0027006492,0.0002492186,0.0003808321,0.0002569804],"domain_scores_gemma":[0.99490273,0.0018719841,0.0020529085,0.00024369366,0.00044811607,0.00048054734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024822787,0.00019180539,0.00209701,0.0001797213,0.00003827668,0.000006979649,0.00013423339,0.00016729708,0.000042133248],"category_scores_gemma":[0.0006924483,0.00013051102,0.0005102302,0.000116909876,0.000117501375,0.00007459383,0.000029005201,0.0005579972,0.0000033840442],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17832382,0.29906,0.04572985,0.00060756085,0.0018312455,0.013549635,0.0039154585,0.000066004766,0.04874112,0.00007672041,0.01595026,0.39214832],"study_design_scores_gemma":[0.16386744,0.6948166,0.118206315,0.00005185966,0.0044615543,0.00073366874,0.0014714182,0.00030042694,0.009262165,0.00042519427,0.006211546,0.00019180962],"about_ca_topic_score_codex":0.000013938417,"about_ca_topic_score_gemma":0.00000644139,"teacher_disagreement_score":0.3957566,"about_ca_system_score_codex":0.000094403156,"about_ca_system_score_gemma":0.00074050174,"threshold_uncertainty_score":0.5322085},"labels":[],"label_agreement":null},{"id":"W2211130158","doi":"10.1200/jco.2007.25.18_suppl.4590","title":"Phase I study of stereotactic radiotherapy for unresectable hepatobiliary cancer and liver metastases","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Gastroenterology; Cirrhosis; Internal medicine; Portal vein thrombosis; Toxicity","score_opus":0.17605632732860355,"score_gpt":0.5151503754669934,"score_spread":0.33909404813838984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211130158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98069054,0.016954582,0.00021777661,0.000870488,0.000647829,0.00047048277,0.000008013845,0.000003531782,0.00013677537],"genre_scores_gemma":[0.99336666,0.0033774201,0.0014012755,0.00081582705,0.0009064257,0.000008082612,5.0498267e-7,0.000012989165,0.00011081223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781513,0.00014326975,0.0014889988,0.00015111164,0.00021708163,0.00018438807],"domain_scores_gemma":[0.9951517,0.003101032,0.0009876024,0.00012492927,0.00042785195,0.00020687291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003054277,0.0001092181,0.0013958743,0.00012386884,0.00003713531,0.000003977646,0.000074534466,0.000108846616,0.000053529846],"category_scores_gemma":[0.0009153934,0.00007317932,0.0002665937,0.000101104546,0.00014075793,0.000084354266,0.000027065187,0.0003335517,1.926656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030271243,0.013829448,0.59629685,0.00012900899,0.0032249484,0.00065469724,0.0013123945,0.0000015543059,0.0005862312,0.000012252243,0.004105841,0.34957555],"study_design_scores_gemma":[0.09154675,0.1446617,0.70525587,0.0001153399,0.0026706452,0.00039176227,0.002826578,0.00007910206,0.0006448471,0.000052915002,0.05160445,0.00015004023],"about_ca_topic_score_codex":0.0001548474,"about_ca_topic_score_gemma":0.000489932,"teacher_disagreement_score":0.34942552,"about_ca_system_score_codex":0.0000865622,"about_ca_system_score_gemma":0.00047838024,"threshold_uncertainty_score":0.2984166},"labels":[],"label_agreement":null},{"id":"W2211214375","doi":"10.1200/jco.2014.32.18_suppl.lba9000","title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Ipilimumab; Gastroenterology; Cancer; Immunotherapy","score_opus":0.06520723822404939,"score_gpt":0.4496459923851462,"score_spread":0.3844387541610968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211214375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174863,0.0001006752,0.000041632862,0.0035057203,0.000368192,0.0003350598,0.0000027549718,0.0000029521802,0.0038943528],"genre_scores_gemma":[0.99750984,0.00043327868,0.00065108255,0.00069821626,0.00041581912,0.0000010513176,0.000002138836,0.000018429388,0.00027014344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617636,0.0008931564,0.0018305146,0.00019716751,0.0006366635,0.00026614626],"domain_scores_gemma":[0.9946498,0.0032388621,0.0011251979,0.00028757262,0.00042288948,0.00027566223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042777155,0.00013601054,0.0014420429,0.00014189156,0.000036368023,0.0000063583593,0.00025711066,0.0002939214,0.0002818805],"category_scores_gemma":[0.0030645144,0.000072930794,0.0002371335,0.00022674704,0.000524759,0.00006618251,0.000113665534,0.0012779676,0.000004675183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014248909,0.0019523678,0.8535339,0.000030066009,0.00019219934,0.00006454307,0.00010268153,0.000014732821,0.0017227608,0.000073415846,0.00025653918,0.12780784],"study_design_scores_gemma":[0.024825325,0.0149651505,0.9255873,0.00018215852,0.000101930316,0.00013435124,0.000029759924,0.000120252014,0.00022674388,0.00007886152,0.033678908,0.00006928737],"about_ca_topic_score_codex":0.00003019323,"about_ca_topic_score_gemma":0.00004712237,"teacher_disagreement_score":0.12773855,"about_ca_system_score_codex":0.00009246082,"about_ca_system_score_gemma":0.0007629121,"threshold_uncertainty_score":0.5552204},"labels":[],"label_agreement":null},{"id":"W2212917847","doi":"10.1200/jco.2015.33.18_suppl.lba4","title":"NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Radiosurgery; Neurocognitive; Randomized controlled trial; Internal medicine; Lung cancer; Verbal fluency test; Cumulative incidence; Oncology; Radiation therapy; Cognition; Cohort; Neuropsychology","score_opus":0.09733898496823448,"score_gpt":0.4525646395301359,"score_spread":0.35522565456190147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2212917847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733671,0.00026538636,0.00071095355,0.022140251,0.0007718365,0.0025764857,0.00005567597,0.000005329854,0.00010696818],"genre_scores_gemma":[0.98561466,0.00010645335,0.0052815555,0.0080652125,0.00062362244,0.00009202214,0.00009263296,0.000025504392,0.0000983278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926563,0.0026033234,0.0035215938,0.00027081202,0.00066273316,0.00028522007],"domain_scores_gemma":[0.9901848,0.0066006104,0.0018950641,0.00023845227,0.00044011636,0.0006409968],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015229839,0.0002109201,0.0033828812,0.00047039552,0.000014777625,0.000009357138,0.00012116659,0.00021287265,0.00012184058],"category_scores_gemma":[0.014681742,0.00013522377,0.0005074726,0.0005631254,0.00011024113,0.00017088484,0.000022850412,0.00048811393,0.0000095629675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75922245,0.009800352,0.004218875,0.0000067956903,0.00038332772,0.00023202493,0.0002655974,0.00021987411,0.000012078564,0.000016869548,0.02668167,0.19894011],"study_design_scores_gemma":[0.8801995,0.05090428,0.016970431,0.00015309427,0.00019581307,0.000014457881,0.000074491,0.000048720165,0.000036694368,0.0001242906,0.05116383,0.00011438982],"about_ca_topic_score_codex":0.000096049705,"about_ca_topic_score_gemma":0.000102685975,"teacher_disagreement_score":0.19882572,"about_ca_system_score_codex":0.0003543006,"about_ca_system_score_gemma":0.0014961112,"threshold_uncertainty_score":0.993618},"labels":[],"label_agreement":null},{"id":"W2213105167","doi":"10.1200/jco.2015.33.18_suppl.lba8502","title":"GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Medicine; Obinutuzumab; Bendamustine; Rituximab; Internal medicine; Clinical endpoint; Refractory (planetary science); Neutropenia; Gastroenterology; Surgery; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.09359959574866157,"score_gpt":0.40353619201802515,"score_spread":0.3099365962693636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2213105167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967416,0.00023078556,0.000022218772,0.00047597234,0.000519135,0.0012472098,0.00012205113,0.000013454281,0.0006275998],"genre_scores_gemma":[0.9953513,0.000069284615,0.0032302828,0.0005312804,0.0005389474,0.000023404926,0.00018619263,0.00004077383,0.000028493869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926614,0.00056120387,0.0045247213,0.00053266075,0.0013020254,0.0004179949],"domain_scores_gemma":[0.9911011,0.0019248915,0.00420284,0.00055741577,0.001356527,0.0008572441],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002048253,0.00041522202,0.0041306727,0.00034703032,0.000040465973,0.000012407366,0.0002835122,0.00034002506,0.000029981402],"category_scores_gemma":[0.0011145304,0.0002523614,0.00023748739,0.00038307445,0.0002803644,0.00019627945,0.00013255232,0.0006609939,0.000007870681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3666448,0.14237383,0.43739995,0.000033743716,0.0015932041,0.0037622298,0.0023895947,0.00039669633,0.000008195033,0.0000010397345,0.0020206412,0.04337607],"study_design_scores_gemma":[0.40138125,0.09015692,0.5049401,0.00038999206,0.0008486646,0.000050708706,0.0006947863,0.000115019284,0.000021160553,0.0000035085407,0.0012584452,0.00013946886],"about_ca_topic_score_codex":0.0014688489,"about_ca_topic_score_gemma":0.0008764546,"teacher_disagreement_score":0.067540124,"about_ca_system_score_codex":0.002213396,"about_ca_system_score_gemma":0.006587294,"threshold_uncertainty_score":0.99999285},"labels":[],"label_agreement":null},{"id":"W2214632401","doi":"10.1200/jco.2006.24.18_suppl.3059","title":"A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; XIAP; Peripheral blood mononuclear cell; Apoptosis; Internal medicine; Gastroenterology; Pharmacology; Programmed cell death; In vitro; Caspase","score_opus":0.027735004688050503,"score_gpt":0.4094865877177187,"score_spread":0.38175158302966816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214632401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808216,0.00014917032,0.000069798116,0.00023704325,0.00025811273,0.00037681547,0.0000084376,0.0000019100466,0.0008165262],"genre_scores_gemma":[0.9981748,0.00009013725,0.00092055154,0.00026931328,0.00040399763,0.0000045003476,0.000030889365,0.000016623508,0.00008917084],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698454,0.00035375316,0.0017939097,0.0002453603,0.0003520963,0.00027032135],"domain_scores_gemma":[0.9975704,0.0001513335,0.0012254474,0.00020799905,0.00066224614,0.00018256553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010241889,0.00014703718,0.0009234652,0.00009175801,0.000019499501,0.0000068247145,0.00023778148,0.00039467018,0.000016473505],"category_scores_gemma":[0.0020898674,0.00010617854,0.00026576457,0.00012683378,0.0002718648,0.0000064292494,0.00009859858,0.00046624514,0.0000020798739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51834387,0.026247501,0.008009145,0.00004189421,0.00018148162,0.00038948574,0.000022327478,0.000014904764,0.26248887,0.000047091926,0.001323644,0.18288979],"study_design_scores_gemma":[0.42893076,0.28892136,0.023326483,0.00016784889,0.00009468285,0.000077947785,0.00004931835,0.000008204876,0.21925713,0.00026585406,0.038563438,0.00033695967],"about_ca_topic_score_codex":0.000029525705,"about_ca_topic_score_gemma":0.00003060277,"teacher_disagreement_score":0.26267385,"about_ca_system_score_codex":0.000025315236,"about_ca_system_score_gemma":0.000840929,"threshold_uncertainty_score":0.4329835},"labels":[],"label_agreement":null},{"id":"W2214920690","doi":"10.1200/jco.2015.64.8097","title":"Can Stereotactic Body Radiotherapy Effectively Treat Hepatocellular Carcinoma?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Radiation therapy; Oncology; Internal medicine; Radiology","score_opus":0.22098842658835713,"score_gpt":0.41326602485971675,"score_spread":0.19227759827135962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214920690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840576,0.0032453744,0.0001017345,0.0072833295,0.0011245237,0.0004681198,0.0000033993115,0.000021618072,0.0036942812],"genre_scores_gemma":[0.9938814,0.00033986746,0.0016794797,0.0014941368,0.001858152,0.000010437374,0.000006273522,0.00004182029,0.0006884064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958092,0.0011066403,0.0019190247,0.00027396219,0.00053292833,0.00035821754],"domain_scores_gemma":[0.9951398,0.0014355074,0.0012577119,0.0003020962,0.0006368584,0.0012280192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003513086,0.00026164658,0.0020923691,0.00021483588,0.00004293819,0.000017974284,0.00018081938,0.0004977022,0.00012345352],"category_scores_gemma":[0.0016814152,0.00017858001,0.00091999344,0.00020692225,0.00018829593,0.00012605931,0.0000323238,0.00091148703,0.000039146536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047272965,0.0017258824,0.94886565,0.000030831612,0.00068805355,0.008045337,0.0002610521,3.5686466e-7,0.0003638327,0.00004376793,0.0034086094,0.03183935],"study_design_scores_gemma":[0.044690628,0.07807737,0.7552533,0.00011788084,0.002635285,0.0044705863,0.00018224269,0.0023237492,0.0022934324,0.00046875063,0.10911172,0.00037502398],"about_ca_topic_score_codex":0.00014016559,"about_ca_topic_score_gemma":0.000010485581,"teacher_disagreement_score":0.1936123,"about_ca_system_score_codex":0.00058249815,"about_ca_system_score_gemma":0.002753971,"threshold_uncertainty_score":0.72822815},"labels":[],"label_agreement":null},{"id":"W2215699720","doi":"10.1200/jco.2015.33.15_suppl.8508","title":"ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Bortezomib; Discontinuation; Interim analysis; Refractory (planetary science); Tolerability; Phases of clinical research; Progression-free survival; Gastroenterology; Neutropenia; Oncology; Surgery; Toxicity; Adverse effect; Randomized controlled trial; Chemotherapy","score_opus":0.19891199795524195,"score_gpt":0.49089901292909666,"score_spread":0.2919870149738547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2215699720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922737,0.00033941705,0.00011111973,0.00047293105,0.0003841248,0.0043641184,0.000012313291,0.000015077509,0.002027189],"genre_scores_gemma":[0.99131155,0.00016852407,0.007205997,0.0003136684,0.00023438137,0.00014226307,0.000018448096,0.000069651156,0.00053552125],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98870575,0.003415419,0.004793334,0.00061005907,0.0017814549,0.00069398317],"domain_scores_gemma":[0.9857099,0.00597557,0.004169148,0.00068674464,0.002003934,0.0014546717],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010651864,0.00047404022,0.0059446846,0.00056495017,0.00006923966,0.000035360183,0.0006646511,0.00044438645,0.000105758445],"category_scores_gemma":[0.012755571,0.00027322947,0.0003063248,0.0005232677,0.00068339385,0.00048490157,0.00027842444,0.0019210037,0.000021078045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5486248,0.07437428,0.31947914,0.000024548004,0.0020890431,0.0020944655,0.00076110946,0.000011304955,0.000016203156,0.0000055314067,0.00030890372,0.052210692],"study_design_scores_gemma":[0.7732262,0.13228711,0.089863084,0.00040372665,0.000922161,0.00016979178,0.00129223,0.00024853708,0.000044703855,0.000031350723,0.0012925144,0.00021858464],"about_ca_topic_score_codex":0.0010315278,"about_ca_topic_score_gemma":0.0012022723,"teacher_disagreement_score":0.22961603,"about_ca_system_score_codex":0.00072221627,"about_ca_system_score_gemma":0.0046335203,"threshold_uncertainty_score":0.999972},"labels":[],"label_agreement":null},{"id":"W2216473413","doi":"10.1200/jco.2001.19.9.2579","title":"Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer?: Letter 4","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Anastrozole; Medicine; Tamoxifen; Citation; Breast cancer; Oncology; Internal medicine; Clinical Oncology; Cancer; Family medicine; Library science","score_opus":0.043873665360790084,"score_gpt":0.4193162424992711,"score_spread":0.375442577138481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216473413","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28007072,0.0022113025,0.00024627292,0.7137725,0.0027472489,0.0005801495,0.00015008748,0.000006640991,0.00021511664],"genre_scores_gemma":[0.012109473,0.012936702,0.0017866581,0.93249947,0.037194096,0.00007857599,0.00011472701,0.000117413256,0.0031629123],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963751,0.00029868798,0.0018859942,0.0005378262,0.00031720093,0.00058520143],"domain_scores_gemma":[0.99682754,0.00042718335,0.0014194672,0.0004033503,0.0005724726,0.0003499911],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009522161,0.00042548554,0.0016074397,0.00012342898,0.00008666762,0.000024488269,0.0006280756,0.0028767518,0.00020066796],"category_scores_gemma":[0.00039905868,0.0003146756,0.0013134612,0.000112723705,0.00016072554,0.000009748895,0.00010448111,0.0022414248,0.000031061354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056963195,0.0002862542,0.0008008529,0.00002861681,0.00088756136,0.00044226478,0.000019130857,0.00006938022,0.0048591564,4.295387e-7,0.9050732,0.08183683],"study_design_scores_gemma":[0.005775613,0.016663237,0.0007441004,0.00010094529,0.00019650786,0.0006056224,0.0000052258065,0.000006700434,0.003162084,0.000037373906,0.97236055,0.0003420536],"about_ca_topic_score_codex":0.00002162727,"about_ca_topic_score_gemma":0.00001493247,"teacher_disagreement_score":0.26796123,"about_ca_system_score_codex":0.0000855703,"about_ca_system_score_gemma":0.001184966,"threshold_uncertainty_score":0.99993056},"labels":[],"label_agreement":null},{"id":"W2218904682","doi":"10.1200/jco.2013.31.4_suppl.lba148","title":"Randomized phase III study of weekly <i>nab</i>-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Gastroenterology; Paclitaxel; Pancreatic cancer; Clinical endpoint; Metastatic breast cancer; Urology; Metastatic adenocarcinoma; Performance status; Lung cancer; Oncology; Cancer; Adenocarcinoma; Randomized controlled trial; Breast cancer","score_opus":0.1119123410746926,"score_gpt":0.4517142053431383,"score_spread":0.33980186426844566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2218904682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921612,0.000504925,0.00005473761,0.0023777115,0.00050652545,0.0032828848,0.000008866026,0.0000050987237,0.0010980145],"genre_scores_gemma":[0.9974595,0.00015242727,0.001562387,0.0002607655,0.00019035245,0.00005963577,0.000004642746,0.000028598877,0.00028174234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895885,0.0032156743,0.005182047,0.00029747275,0.0012348082,0.00048148356],"domain_scores_gemma":[0.98150545,0.011430834,0.0041898126,0.000614121,0.001761247,0.00049852],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008123824,0.00029305136,0.00667757,0.0003509704,0.000050299117,0.000007115765,0.00047084107,0.000283249,0.00046121972],"category_scores_gemma":[0.013161006,0.00014902346,0.0006394329,0.0005492518,0.0011743238,0.00020125126,0.00015703792,0.0014257428,0.000009904121],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5008109,0.016300267,0.4762071,0.00006976932,0.0024562818,0.00011477373,0.00066193927,0.000012966757,0.000029755633,0.00002681356,0.0006541673,0.0026552225],"study_design_scores_gemma":[0.5106108,0.03938299,0.44621855,0.00012074636,0.0021923962,0.00002448566,0.001022696,0.00020830984,0.000008926603,0.00008861559,0.000046201312,0.000075289565],"about_ca_topic_score_codex":0.0010218673,"about_ca_topic_score_gemma":0.00020845486,"teacher_disagreement_score":0.029988544,"about_ca_system_score_codex":0.00025785135,"about_ca_system_score_gemma":0.0026189121,"threshold_uncertainty_score":0.9951516},"labels":[],"label_agreement":null},{"id":"W2219488898","doi":"10.1200/jco.2012.30.15_suppl.lba671","title":"Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Interior Health; Ottawa Hospital; Hamilton Health Sciences; University of Toronto","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Taxane; Pertuzumab; Oncology; Internal medicine; Metastatic breast cancer; Interim analysis; Breast cancer; Interim; Chemotherapy; Clinical trial; Cancer","score_opus":0.17811336086588878,"score_gpt":0.5349206746260675,"score_spread":0.3568073137601787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219488898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98205435,0.00070023106,0.002573482,0.005142067,0.0007211114,0.008425652,0.00006130563,0.000013467371,0.0003083396],"genre_scores_gemma":[0.98790944,0.0011820191,0.004144889,0.0025289946,0.0011697647,0.0021687117,0.00002446388,0.000056736197,0.0008149933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930134,0.001275507,0.0042184866,0.00036505834,0.00051759306,0.0006099977],"domain_scores_gemma":[0.9831392,0.008726741,0.0063419775,0.0002936758,0.0008214707,0.00067689025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0078026266,0.00047134038,0.011557043,0.00039839002,0.000096005446,0.000028685366,0.00042253383,0.00024317672,0.002797169],"category_scores_gemma":[0.0006000467,0.00023893538,0.0010315706,0.00056513725,0.0005272892,0.0002245381,0.000033775967,0.00065084867,0.0000017234495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8905068,0.040001653,0.001997892,0.00007456607,0.03872723,0.00009661402,0.0005549273,0.00014973045,0.00025273635,0.0000066575058,0.00045477608,0.027176436],"study_design_scores_gemma":[0.8526409,0.12647872,0.0005807919,0.00013942113,0.014728511,0.00016743883,0.00020299929,0.0014783831,0.00034191433,0.000019382729,0.0030004352,0.00022105951],"about_ca_topic_score_codex":0.00029067363,"about_ca_topic_score_gemma":0.00056052534,"teacher_disagreement_score":0.08647706,"about_ca_system_score_codex":0.0005679249,"about_ca_system_score_gemma":0.0042346427,"threshold_uncertainty_score":0.9981144},"labels":[],"label_agreement":null},{"id":"W2219564762","doi":"10.1200/jco.2013.31.15_suppl.lba10504","title":"MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Osteosarcoma; Medical physics; Nuclear medicine; Internal medicine; Oncology; Surgery; Pathology","score_opus":0.042201322848694926,"score_gpt":0.3435523951003569,"score_spread":0.30135107225166197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219564762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92999893,0.00059449003,0.000014071759,0.06661888,0.0010173235,0.0016329795,0.000031147098,0.000010652157,0.00008151515],"genre_scores_gemma":[0.9958242,0.0001157755,0.0021030423,0.00072654244,0.00010960004,0.00007612058,0.000010799171,0.000030287241,0.0010036426],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99268407,0.0032537822,0.0026487948,0.0004503623,0.000533603,0.0004293693],"domain_scores_gemma":[0.98513865,0.011297041,0.001779912,0.0005019406,0.00089699187,0.0003854846],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0041705775,0.0003102555,0.0019200344,0.00025338426,0.00010358081,0.000025568044,0.00032120914,0.0003842353,0.000080167294],"category_scores_gemma":[0.009622391,0.00017019792,0.0002468294,0.00029461135,0.00038957654,0.00018701731,0.00019736325,0.0008863119,0.00004092566],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85828674,0.0043229447,0.12073863,0.00004364153,0.00048692196,0.0005623591,0.0008947851,0.0002088559,0.00009564105,0.000023399856,0.012064522,0.002271567],"study_design_scores_gemma":[0.18958774,0.059732933,0.7357212,0.0007048989,0.00030987101,0.00006523939,0.00033560136,0.00009103846,0.00028074998,0.000049459402,0.012955493,0.00016582698],"about_ca_topic_score_codex":0.00038462362,"about_ca_topic_score_gemma":0.0009894959,"teacher_disagreement_score":0.66869897,"about_ca_system_score_codex":0.00086883426,"about_ca_system_score_gemma":0.00088252244,"threshold_uncertainty_score":0.99872},"labels":[],"label_agreement":null},{"id":"W2220367249","doi":"10.1200/jco.2007.25.18_suppl.4030","title":"XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Capecitabine; Oxaliplatin; Medicine; Irinotecan; Bevacizumab; Internal medicine; Colorectal cancer; Population; Oncology; Fluorouracil; Chemotherapy; Cancer","score_opus":0.1377486985361567,"score_gpt":0.4849429064891192,"score_spread":0.3471942079529625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220367249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906638,0.00039231539,0.00040644364,0.0033827133,0.0012832705,0.003261304,0.00042079622,0.000007976166,0.00018136816],"genre_scores_gemma":[0.9935703,0.0006199582,0.0046969675,0.0001970209,0.0006090818,0.000121395984,0.000036545593,0.000022677064,0.00012601039],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947482,0.0006145986,0.0035019629,0.00034364223,0.00046979438,0.00032180647],"domain_scores_gemma":[0.9720991,0.024051432,0.0022875862,0.00016027784,0.00093199743,0.00046955905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052372282,0.0002899047,0.004486106,0.00018572787,0.00008946294,0.000008599008,0.00009426596,0.00015780242,0.000032726635],"category_scores_gemma":[0.007985661,0.00016199586,0.00063249643,0.00017721204,0.00033413773,0.00006008571,0.000043320575,0.00023371511,6.289941e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9261898,0.010310664,0.005015427,0.000013278969,0.0044151894,0.00012262855,0.0010537008,0.0000138539435,0.00003310869,0.000004128429,0.00033135837,0.052496865],"study_design_scores_gemma":[0.8132035,0.14176506,0.03478398,0.00012572968,0.0032719858,0.0000065517597,0.00024930254,0.000075488635,0.00013762614,0.000043348995,0.006212039,0.00012539313],"about_ca_topic_score_codex":0.0007646924,"about_ca_topic_score_gemma":0.006039229,"teacher_disagreement_score":0.13145441,"about_ca_system_score_codex":0.00047665698,"about_ca_system_score_gemma":0.0010949961,"threshold_uncertainty_score":0.95601594},"labels":[],"label_agreement":null},{"id":"W2220812750","doi":"10.1200/jco.2006.24.18_suppl.13070","title":"Cullin-3 is a potential novel target for breast cancer chemoprevention and treatment","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Breast cancer; Cancer research; Cancer; Tissue microarray; Ubiquitin ligase; Gene silencing; Cell culture; Transfection; Biology; Molecular biology; Cancer cell; Medicine; Ubiquitin; Internal medicine; Gene; Biochemistry","score_opus":0.045037957272389934,"score_gpt":0.4022045204585807,"score_spread":0.3571665631861908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220812750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798513,0.001006919,0.0071206265,0.0027654152,0.0005709595,0.00016946123,0.00020031331,0.0000017220083,0.00017947775],"genre_scores_gemma":[0.98434216,0.0011442596,0.009611921,0.0005112587,0.003669114,0.000012474132,0.00002875463,0.000014534654,0.0006655135],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998602,0.000052478463,0.0008830422,0.00021519307,0.000077956494,0.00016938015],"domain_scores_gemma":[0.99867827,0.000066711786,0.0007709176,0.000099937744,0.00026814902,0.00011604256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004277307,0.0001243922,0.0005043617,0.000025636198,0.00003944429,0.000009713248,0.00010120186,0.00029738675,0.00003820423],"category_scores_gemma":[0.00008863639,0.00009603086,0.00038590422,0.00002130601,0.00012929284,0.000005283184,0.000035960034,0.00011530197,8.1194435e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049575903,0.0030078525,0.02017145,0.000033392105,0.0007813481,0.0000129697355,0.000030962765,0.00019245752,0.82584506,0.00009217638,0.016238024,0.12863675],"study_design_scores_gemma":[0.024724595,0.012409554,0.20382662,0.000052512,0.00062992214,0.00039037273,0.000089881694,0.0003733032,0.28929263,0.003689455,0.4640191,0.00050205213],"about_ca_topic_score_codex":0.00003380239,"about_ca_topic_score_gemma":0.000041542684,"teacher_disagreement_score":0.53655237,"about_ca_system_score_codex":0.00004223527,"about_ca_system_score_gemma":0.00033465947,"threshold_uncertainty_score":0.3916025},"labels":[],"label_agreement":null},{"id":"W2222036196","doi":"10.1200/jco.2005.23.16_suppl.9007","title":"Long-term results of a prospective trial of preoperative radiation and postoperative brachytherapy for retroperitoneal sarcoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Surgery; Radiation therapy; Abdomen; Prospective cohort study; Brachytherapy; Sarcoma; Proportional hazards model; Statistical significance; Internal medicine","score_opus":0.0871969559251806,"score_gpt":0.4623934213008231,"score_spread":0.3751964653756425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222036196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887562,0.001475109,0.000054667056,0.0078103477,0.0003105746,0.0012055666,0.000029090173,0.0000026794453,0.00035578696],"genre_scores_gemma":[0.9916504,0.0015305267,0.0052765007,0.00041911262,0.0010121152,0.000025630894,0.0000065406775,0.000011139359,0.00006803643],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969333,0.0003328119,0.002203479,0.00017913962,0.00022758963,0.00012371142],"domain_scores_gemma":[0.99483836,0.0023266738,0.0017720568,0.0001246941,0.00079053914,0.0001476864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015966743,0.00012126811,0.0014470164,0.00009442918,0.000030267924,0.0000049730634,0.000060748498,0.00022509914,0.000017433491],"category_scores_gemma":[0.002590797,0.000077344,0.00035753887,0.00007700266,0.00022502009,0.00012736609,0.0000169419,0.00029321728,6.2248785e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3782791,0.008581036,0.28969294,0.000023328774,0.0009970753,0.00006519304,0.0012432428,0.0000056756357,0.0004750965,0.00023174816,0.00053426006,0.3198713],"study_design_scores_gemma":[0.19611336,0.089192234,0.70837456,0.00009171033,0.00032749874,0.000109379085,0.0000757997,0.00005059521,0.0043778326,0.000052032636,0.0011799354,0.000055084303],"about_ca_topic_score_codex":0.000009024563,"about_ca_topic_score_gemma":0.00003713133,"teacher_disagreement_score":0.4186816,"about_ca_system_score_codex":0.00014066198,"about_ca_system_score_gemma":0.00071711716,"threshold_uncertainty_score":0.31539968},"labels":[],"label_agreement":null},{"id":"W2222174334","doi":"10.1200/jco.2007.25.18_suppl.1102","title":"Mechanisms of bone metastasis (BM) growth in patients with metastatic breast cancer (MBC): An exploratory study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osteoprotegerin; RANKL; Breast cancer; Bone metastasis; Metastatic breast cancer; Cancer; Osteoclast; Lymph node; Metastasis; Stromal cell; Internal medicine; Oncology; Pathology; Cancer research; Activator (genetics); Receptor","score_opus":0.1148123257825129,"score_gpt":0.4665545464682075,"score_spread":0.3517422206856946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222174334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777436,0.00012601209,0.000284287,0.00073155994,0.00042946672,0.0005513854,0.000019013745,0.0000052037344,0.00007869264],"genre_scores_gemma":[0.9935716,0.00006779509,0.005228927,0.0010088349,0.00007356382,0.000008941323,0.0000034152054,0.000022695283,0.000014233846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953245,0.0006075509,0.0028924507,0.00021273908,0.00063472666,0.00032805034],"domain_scores_gemma":[0.99555117,0.0007011752,0.002071958,0.00018651136,0.0008176636,0.000671539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053714565,0.00017134486,0.002015311,0.00032677595,0.000027148459,0.0000027815179,0.00009548339,0.00014145534,0.00009230674],"category_scores_gemma":[0.00046198824,0.00010619225,0.00018456634,0.00031802105,0.00010661489,0.00020785816,0.000027731927,0.0006687218,0.0000037848556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021386757,0.030247362,0.88828903,0.000052916417,0.0008316346,0.0012478661,0.00035843722,0.000002545489,0.000011229772,0.00005407069,0.000058798778,0.057459332],"study_design_scores_gemma":[0.030920492,0.047621056,0.9188282,0.00009482499,0.0010659057,0.00007905608,0.0009294422,0.000002667651,0.00005662585,0.00026597275,0.000057497502,0.00007824838],"about_ca_topic_score_codex":0.000250683,"about_ca_topic_score_gemma":0.0021603429,"teacher_disagreement_score":0.057381086,"about_ca_system_score_codex":0.0002378528,"about_ca_system_score_gemma":0.0015001468,"threshold_uncertainty_score":0.43303943},"labels":[],"label_agreement":null},{"id":"W2222254507","doi":"10.1200/jco.2002.20.9.2409","title":"Opioid Rotation to Methadone: Proceed With Caution","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methadone; Citation; Medicine; Clinical Oncology; Opioid; Family medicine; Psychiatry; Library science; Internal medicine; Receptor; Computer science; Cancer","score_opus":0.11848424484897774,"score_gpt":0.4371982671377202,"score_spread":0.31871402228874246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222254507","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03784444,0.00022325105,0.0017025087,0.9496075,0.0017962017,0.00086763053,0.000002393075,0.000027364189,0.007928714],"genre_scores_gemma":[0.0068782507,0.0006050444,0.019689154,0.9408502,0.019337844,0.000020302115,0.000035857745,0.00006128446,0.012522083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99601984,0.00039019162,0.0022111028,0.00028460572,0.00077685475,0.00031742261],"domain_scores_gemma":[0.9951156,0.0011943416,0.0023943756,0.00023364094,0.00077419507,0.00028787673],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028173048,0.00024347797,0.0019439261,0.00041975913,0.000035121007,0.000018346633,0.00023197473,0.0012623436,0.00025485663],"category_scores_gemma":[0.0030923227,0.00016002546,0.0004518681,0.0002670768,0.00010249487,0.000103243925,0.00004184511,0.0038203262,0.00013547698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016181065,0.00036811427,0.013403236,0.00018540524,0.0005466833,0.0030651146,0.00009037651,0.000008226804,0.0000071460076,0.000008968054,0.95226765,0.028430961],"study_design_scores_gemma":[0.0041982513,0.013519308,0.077178195,0.000377663,0.001168399,0.00011062973,0.0000315677,0.00006580547,0.0000054900784,0.000109663786,0.90307415,0.00016085622],"about_ca_topic_score_codex":0.0000084798385,"about_ca_topic_score_gemma":0.0000068179615,"teacher_disagreement_score":0.06377496,"about_ca_system_score_codex":0.00025468954,"about_ca_system_score_gemma":0.0008298008,"threshold_uncertainty_score":0.9984779},"labels":[],"label_agreement":null},{"id":"W2222499720","doi":"10.1200/jco.2012.30.15_suppl.5005","title":"Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Debulking; Serous fluid; Surgery; Stage (stratigraphy); Overdiagnosis; Retrospective cohort study; Internal medicine; Ovarian cancer; Cancer","score_opus":0.10897268076587172,"score_gpt":0.4540927503844166,"score_spread":0.3451200696185449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222499720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920009,0.00010503974,0.000021473232,0.0056354865,0.001118479,0.00050011073,0.00001766559,0.0000022081945,0.00059867435],"genre_scores_gemma":[0.9960395,0.000027514556,0.0024498417,0.00083991565,0.00054577616,0.000003851902,0.0000020184336,0.000013009393,0.00007858163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958963,0.00039127914,0.0029160294,0.00012260962,0.00047986006,0.00019393208],"domain_scores_gemma":[0.99445814,0.0011961414,0.0029957471,0.0003335521,0.0007826463,0.0002337524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022115952,0.00012615291,0.001387368,0.000062969324,0.000021567868,0.00000219777,0.00016091233,0.00013096047,0.00006394551],"category_scores_gemma":[0.0025892637,0.000058358575,0.000358244,0.00013250553,0.00015608138,0.00008251468,0.00006483742,0.00047362846,0.000002819177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008586649,0.022881586,0.95494026,0.000022478953,0.00069945276,0.000029053064,0.0002846686,0.000015149341,0.0000024402455,0.000015807742,0.00065322936,0.011869236],"study_design_scores_gemma":[0.0371653,0.01759214,0.9381597,0.00014619468,0.00089868065,0.000009931913,0.00017169103,0.0000045886463,0.0000441778,0.000005414724,0.0057541234,0.000048031026],"about_ca_topic_score_codex":0.000067900335,"about_ca_topic_score_gemma":0.000078564,"teacher_disagreement_score":0.02857865,"about_ca_system_score_codex":0.000095603566,"about_ca_system_score_gemma":0.0003907827,"threshold_uncertainty_score":0.30997774},"labels":[],"label_agreement":null},{"id":"W2222506336","doi":"10.1200/jco.2009.27.15_suppl.e15093","title":"Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Ottawa Hospital","funders":"","keywords":"Medicine; Adenocarcinoma; Immunohistochemistry; Colorectal cancer; Pathology; Angiogenesis; Transcription factor; Cancer research; Internal medicine; Cancer; Biology; Gene","score_opus":0.08342183204518047,"score_gpt":0.3857681545739208,"score_spread":0.3023463225287403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222506336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934246,0.0015132586,0.0000795562,0.0037323574,0.00017716785,0.000192441,0.000010160747,0.0000056922436,0.0008647536],"genre_scores_gemma":[0.9958262,0.00037757444,0.0028068544,0.000637779,0.00018988397,0.0000010465411,0.0000042490274,0.000007816673,0.00014863444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709165,0.00040190434,0.0017509322,0.0001425442,0.00044760018,0.00016539328],"domain_scores_gemma":[0.9964867,0.0007748012,0.0019069443,0.0000828058,0.0005469182,0.00020181542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019473209,0.00012773529,0.0017424917,0.000108525055,0.00003067916,0.000005446472,0.00005233288,0.00014367363,0.00006756797],"category_scores_gemma":[0.0009635222,0.00008021954,0.0002797567,0.00013568057,0.00012257184,0.00011188527,0.000009292779,0.00047545583,0.0000010599565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021567184,0.0031288543,0.75116915,0.00023210283,0.003129848,0.0013672485,0.00088050024,0.000005979638,0.024793487,0.00014861647,0.0040388815,0.18953817],"study_design_scores_gemma":[0.007093479,0.02510692,0.96345294,0.00009453743,0.0013731,0.0006254759,0.00015234666,0.000025195426,0.00091276783,0.00009930972,0.000992567,0.000071373586],"about_ca_topic_score_codex":0.0000041944218,"about_ca_topic_score_gemma":0.000010443373,"teacher_disagreement_score":0.2122838,"about_ca_system_score_codex":0.00013357359,"about_ca_system_score_gemma":0.00054437976,"threshold_uncertainty_score":0.3271258},"labels":[],"label_agreement":null},{"id":"W2222583773","doi":"10.1200/jco.2012.30.15_suppl.e11079","title":"Population-based outcomes of patients (pt) with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab (T).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Trastuzumab; Oncology; Stage (stratigraphy); Population; Proportional hazards model; Tolerability; Cancer; Hazard ratio; Adverse effect; Confidence interval","score_opus":0.028162747929419422,"score_gpt":0.37286789831249606,"score_spread":0.34470515038307664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222583773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837196,0.00024711454,0.00008564862,0.00058115437,0.00020118747,0.00016161545,0.00019332451,0.0000034749025,0.00015454767],"genre_scores_gemma":[0.99842477,0.00011729365,0.0006475595,0.0003814297,0.000289929,0.000012442162,0.00004343194,0.000024334757,0.000058832484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980925,0.00023999819,0.0009457726,0.00018184025,0.00027623566,0.00026369208],"domain_scores_gemma":[0.9973187,0.00025742708,0.0014827684,0.0001638234,0.0005754747,0.00020182216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035010467,0.00020849911,0.0010008563,0.000053440563,0.000045831726,0.0000041449675,0.00012663702,0.00021151177,0.000041804502],"category_scores_gemma":[0.00011122274,0.00011931006,0.00022443988,0.00008889097,0.00018886554,0.000017010923,0.000029861512,0.00020927374,0.0000012169253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00704772,0.0020938904,0.9800428,0.000009666263,0.0011262466,0.000010763902,0.000051326624,0.000089375324,0.00002758053,0.000004930959,0.000116235606,0.009379463],"study_design_scores_gemma":[0.007813804,0.006355113,0.9839291,0.000049122664,0.0004284692,0.000015463393,0.00005294532,0.000002169784,0.00054830004,0.000001476268,0.0006648838,0.00013912859],"about_ca_topic_score_codex":0.00072525174,"about_ca_topic_score_gemma":0.0005546735,"teacher_disagreement_score":0.009240335,"about_ca_system_score_codex":0.000121642566,"about_ca_system_score_gemma":0.00046471914,"threshold_uncertainty_score":0.4865323},"labels":[],"label_agreement":null},{"id":"W2222700722","doi":"10.1200/jco.2012.30.15_suppl.4","title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; INT; Androgen deprivation therapy; Oncology; Clinical trial; Internal medicine; Urology; Gynecology; Cancer","score_opus":0.1729421620923322,"score_gpt":0.5120540794502855,"score_spread":0.33911191735795326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222700722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934441,0.0006219124,0.00001915737,0.0018422384,0.0024052695,0.0009373596,0.00009690278,0.000006126306,0.0006269585],"genre_scores_gemma":[0.99453074,0.0035924108,0.0005045685,0.0002226187,0.0007945776,0.000026524505,0.0001027949,0.00001852907,0.00020721905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952964,0.00063657673,0.0028317615,0.00022820351,0.00064854755,0.00035846536],"domain_scores_gemma":[0.99487585,0.0011759815,0.0021985276,0.00018254592,0.0011285009,0.00043860672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037216102,0.00017376206,0.0013245204,0.00029559268,0.000027542967,0.000010232351,0.00016661161,0.00019182524,0.00004613736],"category_scores_gemma":[0.0034070897,0.000120640965,0.00029177617,0.00018968443,0.00022315986,0.00044417073,0.00007833581,0.00072656514,0.00000547742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68147695,0.011973097,0.03601251,0.000019378656,0.0010948738,0.0002743037,0.0013385097,0.0000066521484,0.00042971558,0.000013358064,0.0013057294,0.26605493],"study_design_scores_gemma":[0.7445533,0.057390727,0.18490441,0.00022063473,0.00064184755,0.00004205645,0.0008200637,0.00019787595,0.0015401971,0.000048629856,0.009474208,0.00016602082],"about_ca_topic_score_codex":0.00015738637,"about_ca_topic_score_gemma":0.00007980786,"teacher_disagreement_score":0.2658889,"about_ca_system_score_codex":0.0005476855,"about_ca_system_score_gemma":0.0009862907,"threshold_uncertainty_score":0.49195957},"labels":[],"label_agreement":null},{"id":"W2222894682","doi":"10.1200/jco.2012.30.15_suppl.e13027","title":"Impact of weight and creatinine measurements in carboplatin dosing.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Carboplatin; Creatinine; Medicine; Dosing; Urology; Body mass index; Renal function; Body weight; Internal medicine; Chemotherapy","score_opus":0.2047773093033168,"score_gpt":0.5068231520708133,"score_spread":0.30204584276749646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222894682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959284,0.00048042438,0.00002027813,0.0012264639,0.0002666646,0.00010588524,8.8178047e-7,0.0000027338945,0.0019682662],"genre_scores_gemma":[0.995778,0.00016209223,0.0029844325,0.00028210753,0.00075425574,4.281033e-7,8.249826e-7,0.0000121662,0.000025665331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975307,0.00025908722,0.0016758272,0.000079249854,0.0002822684,0.00017287424],"domain_scores_gemma":[0.9972336,0.0008477718,0.001300646,0.0001017721,0.00021971916,0.0002964736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033771454,0.00009308113,0.0010247175,0.00014732238,0.00000931685,0.000002096087,0.000052552536,0.00027621954,0.00015198317],"category_scores_gemma":[0.0034520251,0.000064666325,0.00022138465,0.00013403856,0.00011050105,0.00012347022,0.00001699543,0.00055015605,0.0000020107343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012972377,0.0012076324,0.899511,0.000014785076,0.00018892981,0.00001092599,0.0003304519,0.0000015250146,0.057294924,0.000004632257,0.00026864657,0.039869305],"study_design_scores_gemma":[0.008061406,0.005016626,0.97435164,0.00012036914,0.00012701422,0.00018291053,0.00003672499,0.000023769624,0.011717874,0.0000498684,0.0002621694,0.000049646824],"about_ca_topic_score_codex":0.000041335552,"about_ca_topic_score_gemma":0.000017902386,"teacher_disagreement_score":0.07484061,"about_ca_system_score_codex":0.00020762242,"about_ca_system_score_gemma":0.00061420206,"threshold_uncertainty_score":0.41326457},"labels":[],"label_agreement":null},{"id":"W2222964070","doi":"10.1200/jco.2009.27.15_suppl.8098","title":"Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Erlotinib; Medicine; Rash; Internal medicine; KRAS; Lung cancer; Oncology; T790M; EGFR inhibitors; Epidermal growth factor receptor; Cancer; Gastroenterology; Colorectal cancer","score_opus":0.03416316718002527,"score_gpt":0.44370908392750447,"score_spread":0.4095459167474792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222964070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997635,0.0005018213,0.000045018194,0.0072821067,0.000352668,0.0004994832,0.0000066413995,0.0000054989505,0.0013304095],"genre_scores_gemma":[0.9963918,0.00042948854,0.00043070212,0.0020854783,0.00029887928,0.000009274325,0.000011268607,0.0000133435005,0.00032978266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797773,0.00027134572,0.0011274861,0.00019185773,0.00024852515,0.0001830351],"domain_scores_gemma":[0.9976299,0.0005510701,0.0011794426,0.00011847662,0.0003251765,0.0001959794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080259,0.00015259319,0.00069115584,0.00012565285,0.00005985325,0.000013225209,0.000079005666,0.00013541682,0.000048109297],"category_scores_gemma":[0.00015746262,0.00007314773,0.0001325273,0.00019365485,0.00008323318,0.00011736249,0.000016245449,0.00046507685,0.0000019459085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005233576,0.0024802042,0.8096323,0.00003678814,0.00024960077,0.00034987574,0.00039783103,0.000031082433,0.0012023471,0.0000021127244,0.0056788125,0.17470549],"study_design_scores_gemma":[0.020721024,0.005394959,0.9676145,0.00040631663,0.00096514175,0.000049320734,0.000094124305,0.0009659965,0.00045027264,0.00001075758,0.0032333715,0.00009423464],"about_ca_topic_score_codex":0.00006206595,"about_ca_topic_score_gemma":0.000053251148,"teacher_disagreement_score":0.17461126,"about_ca_system_score_codex":0.00028397547,"about_ca_system_score_gemma":0.000739973,"threshold_uncertainty_score":0.29828778},"labels":[],"label_agreement":null},{"id":"W2223063298","doi":"10.1200/jco.2005.23.16_suppl.8198","title":"Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Lakeridge Health","funders":"","keywords":"Medicine; Discontinuation; Topotecan; Adverse effect; Internal medicine; Ovarian cancer; Chemotherapy; Cancer; Oncology","score_opus":0.036870141243463994,"score_gpt":0.43978071508882915,"score_spread":0.40291057384536516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223063298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99090904,0.00014169446,0.0000638469,0.006138413,0.0007997915,0.00152394,0.000006406102,0.000018971512,0.00039790617],"genre_scores_gemma":[0.98585147,0.00015427479,0.011502421,0.0015643486,0.00074127695,0.000022360928,0.00000495996,0.00004041989,0.00011849784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99533576,0.00053394673,0.0027571463,0.00031112143,0.0006238078,0.00043819332],"domain_scores_gemma":[0.99513686,0.0012873756,0.001752471,0.00025195873,0.0005238072,0.0010475416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015282942,0.0002519025,0.0018044758,0.0002650614,0.0000252395,0.0000064327396,0.00019730374,0.0004946234,0.0002579696],"category_scores_gemma":[0.0044171102,0.0001619517,0.00031884114,0.00040817953,0.00018537346,0.00011401508,0.000033861957,0.0013056239,0.0000076463175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05764462,0.023643246,0.066242106,0.00009011324,0.00041179673,0.00042134427,0.0004908931,0.00010238635,0.0007864559,0.0000042641923,0.0010478224,0.84911495],"study_design_scores_gemma":[0.050005864,0.09653874,0.8281757,0.00380951,0.00085563044,0.00018250615,0.000027633012,0.00018283332,0.008095599,0.000047566155,0.011800605,0.00027779065],"about_ca_topic_score_codex":0.0000575806,"about_ca_topic_score_gemma":0.00034437422,"teacher_disagreement_score":0.84883714,"about_ca_system_score_codex":0.00071037497,"about_ca_system_score_gemma":0.0035814764,"threshold_uncertainty_score":0.6604198},"labels":[],"label_agreement":null},{"id":"W2223073505","doi":"10.1200/jco.2012.30.15_suppl.tps1136","title":"ANZ1001 SORBET: Study of estrogen receptor beta and efficacy of tamoxifen, a single arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Tamoxifen; Triple-negative breast cancer; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Metastatic breast cancer; Progesterone receptor; Clinical endpoint; Estrogen; Cancer; Clinical trial","score_opus":0.05189851969657101,"score_gpt":0.40410946892799665,"score_spread":0.35221094923142565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223073505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951675,0.0023617323,0.000008404552,0.0002377803,0.0005967516,0.0014289402,0.00015257276,0.0000026810592,0.000043654072],"genre_scores_gemma":[0.9986055,0.0003512864,0.0005635413,0.000038136648,0.000348498,0.000019155355,0.000009841009,0.00003622409,0.000027848375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9929051,0.002528446,0.003285217,0.00037753483,0.00049450225,0.0004092274],"domain_scores_gemma":[0.9924674,0.0016221772,0.004525572,0.00043399347,0.00063501403,0.00031586137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029126396,0.00034687587,0.0022034894,0.00016712552,0.000073048424,0.000005076542,0.000522963,0.00042996163,0.000035418077],"category_scores_gemma":[0.001635088,0.00023518423,0.0005738524,0.00039981978,0.0006291717,0.000031402014,0.00033719908,0.0007785965,6.871403e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033989944,0.1909805,0.217685,0.000116981006,0.008699417,0.000032226682,0.007662206,0.00028092045,0.48907033,0.000031095453,0.00043825907,0.051013123],"study_design_scores_gemma":[0.10278968,0.2393642,0.25055692,0.00040880474,0.004564173,0.00015956126,0.0067842947,0.00003093043,0.3944249,0.000031659903,0.0003286211,0.00055625313],"about_ca_topic_score_codex":0.00021502882,"about_ca_topic_score_gemma":0.00005543752,"teacher_disagreement_score":0.09464543,"about_ca_system_score_codex":0.00007248452,"about_ca_system_score_gemma":0.0007062064,"threshold_uncertainty_score":0.9590534},"labels":[],"label_agreement":null},{"id":"W2223234570","doi":"10.1200/jco.2006.24.18_suppl.2078","title":"Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Neutropenia; Prostate cancer; Internal medicine; Oncology; Toxicity; Cancer; Febrile neutropenia","score_opus":0.08929568132442707,"score_gpt":0.49107641314776757,"score_spread":0.4017807318233405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223234570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970761,0.00054074434,0.000003943255,0.0009294901,0.00020468542,0.0011259263,0.00008203414,0.000002602375,0.000034505534],"genre_scores_gemma":[0.9989214,0.0002926374,0.00039163014,0.0001601788,0.00015098265,0.00001410734,0.000014341749,0.000015818521,0.000038900173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964124,0.00061057083,0.0022405672,0.0001930974,0.00036036762,0.000183003],"domain_scores_gemma":[0.9960699,0.00063838885,0.0022976985,0.000188471,0.00060386985,0.00020167533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015040761,0.00016131307,0.0014345917,0.0002592667,0.000033604676,0.000002874257,0.00009865563,0.00008385232,0.000047697773],"category_scores_gemma":[0.0002830402,0.000095950076,0.000115627096,0.0003152193,0.00026287782,0.00015192963,0.000038009915,0.00041256598,2.830514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16164818,0.19876075,0.4755101,0.00011896276,0.0014100344,0.00046345807,0.004195979,0.0004888906,0.015638912,0.000009203586,0.0015401536,0.14021537],"study_design_scores_gemma":[0.12455975,0.22816277,0.6430393,0.0000902146,0.0018419633,0.000023542938,0.0005022121,0.00011680426,0.0005631892,0.00003099843,0.0009790711,0.00009020084],"about_ca_topic_score_codex":0.0008939523,"about_ca_topic_score_gemma":0.0010798714,"teacher_disagreement_score":0.1675292,"about_ca_system_score_codex":0.00009082002,"about_ca_system_score_gemma":0.0006551741,"threshold_uncertainty_score":0.39127305},"labels":[],"label_agreement":null},{"id":"W2223593075","doi":"10.1200/jco.2006.24.18_suppl.6565","title":"Fatigue in older adults with acute myeloid leukemia (AML): Predictors and impact on quality of life (QOL) and functional status","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Depression (economics); Anemia; Cancer; Myeloid leukemia; Physical therapy","score_opus":0.07087920437950193,"score_gpt":0.43787409845773245,"score_spread":0.3669948940782305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223593075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961849,0.00037333168,0.0001345642,0.0019157088,0.00016511187,0.0003169804,0.000025851099,0.0000067356073,0.0008768012],"genre_scores_gemma":[0.9963899,0.0010780878,0.0011499408,0.0005904141,0.0006213206,0.0000041885523,0.000012807149,0.000020177054,0.00013312315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956285,0.0006044622,0.0023891144,0.00028249,0.00071938965,0.00037605283],"domain_scores_gemma":[0.9935208,0.0037542004,0.001393116,0.00018922583,0.000487108,0.00065552973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003391375,0.00019983947,0.0016949464,0.00029532294,0.000030894727,0.000009213212,0.000080978636,0.00045050652,0.00010215069],"category_scores_gemma":[0.0022615474,0.00011952142,0.00020660977,0.0002315699,0.0005819532,0.00015013707,0.000051225223,0.0016474938,0.0000017120719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05739605,0.0009459902,0.9245,0.000086632346,0.000502719,0.00038023395,0.00016690564,0.00014020993,0.00021123308,0.0000687052,0.0043922924,0.011209036],"study_design_scores_gemma":[0.027823662,0.015046896,0.9552319,0.0002160014,0.00013985646,0.00027126115,0.0001986298,0.00024234326,0.000046228713,0.00008665982,0.00059677643,0.00009979837],"about_ca_topic_score_codex":0.00075469,"about_ca_topic_score_gemma":0.00030515614,"teacher_disagreement_score":0.030731896,"about_ca_system_score_codex":0.00069879676,"about_ca_system_score_gemma":0.0055751824,"threshold_uncertainty_score":0.98901343},"labels":[],"label_agreement":null},{"id":"W2223712877","doi":"10.1200/jco.2007.25.18_suppl.7527","title":"A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Clinical endpoint; Vinorelbine; Concomitant; Internal medicine; Randomization; Placebo; non-small cell lung cancer (NSCLC); Chemoradiotherapy; Chemotherapy; Cisplatin; Performance status; Lung cancer; Randomized controlled trial; Urology; Pathology","score_opus":0.0719299591436853,"score_gpt":0.48674956615895193,"score_spread":0.41481960701526666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223712877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892338,0.0011854443,0.004506822,0.0016960179,0.000762423,0.0018580946,0.000018570987,0.000011502288,0.00072731485],"genre_scores_gemma":[0.99028534,0.0013835242,0.004515079,0.0014718253,0.0011832076,0.000050853483,0.000005196871,0.00004848983,0.0010564865],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968524,0.0000978535,0.0020829635,0.00031843965,0.00032350028,0.00032485145],"domain_scores_gemma":[0.9957276,0.00076173403,0.0022152737,0.00023070983,0.00067021215,0.0003944919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018984921,0.00025302466,0.0018457201,0.00017694534,0.00009059788,0.00001254181,0.00012551752,0.000307965,0.00010474916],"category_scores_gemma":[0.00010116809,0.00016810492,0.00026048403,0.00020007759,0.00019882561,0.000121223995,0.00001537905,0.0005769896,2.9549227e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1687811,0.066059366,0.26613462,0.0005656694,0.010358254,0.0010112327,0.020449892,0.00011353167,0.022637727,0.000057153953,0.0073931767,0.43643826],"study_design_scores_gemma":[0.6463841,0.18237294,0.10606399,0.00051468884,0.0054990863,0.00033077013,0.010983159,0.0006296856,0.010783465,0.000045952675,0.035832897,0.00055927207],"about_ca_topic_score_codex":0.00039840388,"about_ca_topic_score_gemma":0.000620185,"teacher_disagreement_score":0.477603,"about_ca_system_score_codex":0.00046259203,"about_ca_system_score_gemma":0.0021164222,"threshold_uncertainty_score":0.685512},"labels":[],"label_agreement":null},{"id":"W2224500197","doi":"10.1200/jco.2012.30.15_suppl.5001","title":"Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Clinical endpoint; Internal medicine; Carboplatin; Urology; Maintenance therapy; Oncology; Randomization; PARP inhibitor; Randomized controlled trial; Surgery; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.12501870968713022,"score_gpt":0.4775891494285547,"score_spread":0.35257043974142444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224500197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855176,0.00096932345,0.00039847757,0.0038706937,0.0027341996,0.004649425,0.00013532849,0.000021477357,0.0017034361],"genre_scores_gemma":[0.9923612,0.00072216964,0.0020896757,0.002483563,0.001040085,0.00046460083,0.000038240636,0.000071459464,0.0007290374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99067736,0.0024620618,0.0044819973,0.0005856297,0.00090193324,0.0008910257],"domain_scores_gemma":[0.9903983,0.0030905935,0.004214016,0.00045959817,0.00091333775,0.00092416385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006448229,0.0005761161,0.005370609,0.0002273752,0.00017471114,0.00003638481,0.00034941867,0.0005264153,0.00018281458],"category_scores_gemma":[0.0019463557,0.00037471106,0.0004556436,0.00040115335,0.00046618632,0.00047229533,0.00015968672,0.0016051352,0.000012788614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.806567,0.05635656,0.041434493,0.00002561439,0.0029328952,0.0005558006,0.0065790983,0.00005413389,0.000079715595,0.00007111912,0.01103491,0.07430863],"study_design_scores_gemma":[0.88835627,0.089004844,0.008548818,0.0005799383,0.0013126459,0.00012581155,0.0009806812,0.00044009686,0.000087756096,0.000051678853,0.010113623,0.00039781115],"about_ca_topic_score_codex":0.0010968571,"about_ca_topic_score_gemma":0.0011337699,"teacher_disagreement_score":0.08178926,"about_ca_system_score_codex":0.004406521,"about_ca_system_score_gemma":0.0039432105,"threshold_uncertainty_score":0.9998705},"labels":[],"label_agreement":null},{"id":"W2224577761","doi":"10.1200/jco.2013.31.15_suppl.cra8007","title":"A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Ottawa Hospital","funders":"","keywords":"Docetaxel; Medicine; Oncology; Internal medicine; Clinical Oncology; Adenocarcinoma; Medical physics; Chemotherapy; Cancer","score_opus":0.07307915311204514,"score_gpt":0.4146076731411589,"score_spread":0.3415285200291137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224577761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927518,0.0012564585,0.00033488683,0.0007766619,0.00019199357,0.0045486996,0.0000062672366,0.0000027818787,0.00013049324],"genre_scores_gemma":[0.9969268,0.0002052993,0.0019835583,0.00007570692,0.0003216832,0.00032500774,0.00000955269,0.000031521282,0.00012089831],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99418575,0.0016335826,0.0029889024,0.00034097506,0.0005002605,0.00035056093],"domain_scores_gemma":[0.9954421,0.0012727908,0.0013284029,0.00035645635,0.001390382,0.00020984921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005743255,0.00022969887,0.0021597247,0.00022988488,0.000034008557,0.000013202728,0.00040137715,0.0004853739,0.00008542036],"category_scores_gemma":[0.0034327353,0.00015847078,0.0004135165,0.00021489077,0.00033901562,0.000027686574,0.00010483992,0.0006244569,0.0000013332779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7115364,0.011674525,0.022967933,0.00019689793,0.0016333784,0.000049138962,0.00035149322,0.00013423721,0.23952009,0.00003773278,0.0005912583,0.011306933],"study_design_scores_gemma":[0.74689436,0.12290299,0.018676236,0.0001221229,0.000113661816,0.00003427898,0.00038141574,0.0007489669,0.10890552,0.0002196061,0.0007393689,0.00026146948],"about_ca_topic_score_codex":0.00016364452,"about_ca_topic_score_gemma":0.00031780146,"teacher_disagreement_score":0.13061456,"about_ca_system_score_codex":0.00006711996,"about_ca_system_score_gemma":0.0012952919,"threshold_uncertainty_score":0.6462251},"labels":[],"label_agreement":null},{"id":"W2224741384","doi":"10.1200/jco.2001.19.5.1326","title":"Phase I Study of a Decision Aid for Patients With Locally Advanced Non–Small-Cell Lung Cancer","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Preference; Radiation therapy; Lung cancer; Cancer; Internal medicine; Oncology; Family medicine","score_opus":0.30725656803181073,"score_gpt":0.5979759990446498,"score_spread":0.2907194310128391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224741384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898626,0.00062622025,0.0024916488,0.0012246118,0.0020651824,0.0033326803,0.000019846171,0.000010426663,0.0003667462],"genre_scores_gemma":[0.9764831,0.0005606357,0.020737275,0.0014654846,0.00034383708,0.0002641301,0.0000051883535,0.00003471131,0.00010562609],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99220246,0.0016333796,0.0049839923,0.00026157073,0.0004980463,0.00042056685],"domain_scores_gemma":[0.976933,0.0121414745,0.00639197,0.00058635836,0.0035290325,0.00041817015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020495,0.0001804312,0.0014773585,0.00017488113,0.0002904613,0.0000028876386,0.00065803056,0.00042041042,0.000105508676],"category_scores_gemma":[0.0040354272,0.00012572958,0.00021089478,0.0002746724,0.000091475056,0.00018647319,0.00017911854,0.0015455503,0.000005271386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029003147,0.015822297,0.81864566,0.0001646536,0.00012956129,0.000016600474,0.0029202674,0.0002138574,0.000005121451,0.000006328477,0.0016199001,0.13145259],"study_design_scores_gemma":[0.34368902,0.20705451,0.33562043,0.002300647,0.0007905221,0.000005954954,0.018940566,0.0024345727,0.000008444972,0.00034848409,0.08836581,0.0004410037],"about_ca_topic_score_codex":0.00013039383,"about_ca_topic_score_gemma":0.0011077236,"teacher_disagreement_score":0.48302522,"about_ca_system_score_codex":0.00037432532,"about_ca_system_score_gemma":0.004040255,"threshold_uncertainty_score":0.7167239},"labels":[],"label_agreement":null},{"id":"W2224743185","doi":"10.1200/jco.2007.25.18_suppl.9539","title":"Research, policy and practice related to survivors of childhood, adolescent and young adult cancers in British Columbia (BC), Canada: A population-based approach","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Interior Health","funders":"","keywords":"Medicine; Specialty; Population; Family medicine; Cohort; Pediatrics; Health care; Gerontology; Demography; Internal medicine","score_opus":0.08205902933652282,"score_gpt":0.46374474650440234,"score_spread":0.3816857171678795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224743185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805314,0.00053477654,0.00004084307,0.016381513,0.000496887,0.0005158304,0.000013152294,0.000005741963,0.0014798341],"genre_scores_gemma":[0.9891005,0.0004763747,0.003381728,0.0064161373,0.00049766974,0.0000030798676,0.0000058121295,0.000023777484,0.00009489494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99323237,0.0016830558,0.0031832566,0.00033582747,0.0011071464,0.0004583732],"domain_scores_gemma":[0.98910016,0.0069994475,0.0014313473,0.00021083382,0.0013724213,0.0008858117],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01948495,0.00011794933,0.0014166923,0.00029635918,0.00007537221,0.000028623692,0.00015444391,0.00037920065,0.000014011074],"category_scores_gemma":[0.05756323,0.00014915863,0.00012080017,0.00077721005,0.00027739137,0.0001233293,0.00007280554,0.0017536673,2.786688e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021230031,0.0012090898,0.9607869,0.00015215864,0.00015662701,0.00039263023,0.000694616,0.00008153341,0.0000044812114,0.000046117882,0.0036429712,0.0307099],"study_design_scores_gemma":[0.0064968616,0.002717255,0.98285204,0.0006665347,0.000085929685,0.0006828381,0.0030935474,0.000056046196,0.0000018005252,0.00008118677,0.0031441723,0.000121807105],"about_ca_topic_score_codex":0.98637635,"about_ca_topic_score_gemma":0.99705744,"teacher_disagreement_score":0.038078282,"about_ca_system_score_codex":0.0015734101,"about_ca_system_score_gemma":0.013603604,"threshold_uncertainty_score":0.99198836},"labels":[],"label_agreement":null},{"id":"W2225191295","doi":"10.1200/jco.2009.27.15_suppl.e19003","title":"MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Heart failure; Myocardial infarction; Clinical endpoint; Deep vein; Incidence (geometry); Cardiology; Pulmonary embolism; Bevacizumab; Surgery; Chemotherapy; Thrombosis; Clinical trial","score_opus":0.04870700257340295,"score_gpt":0.44227736221896935,"score_spread":0.3935703596455664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225191295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221916,0.0026934159,0.00008194604,0.013881471,0.00031312765,0.00062482903,0.0000070284364,0.0000061051946,0.00017293419],"genre_scores_gemma":[0.98794776,0.004681073,0.0031490496,0.0038017468,0.00033138192,0.000017747967,0.000002718925,0.00001614038,0.000052374988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975414,0.00023935507,0.0014219742,0.0002695245,0.0002436279,0.00028410103],"domain_scores_gemma":[0.99655676,0.0013635134,0.0012247505,0.00015647503,0.0004123803,0.00028609822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008504886,0.00022078893,0.001823099,0.00016554641,0.000033846118,0.0000033410984,0.0001345671,0.0003074291,0.00015648307],"category_scores_gemma":[0.00021644727,0.00015075969,0.00021059877,0.00023072699,0.00019811744,0.00010936484,0.000019177945,0.00082436245,0.0000014197072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02470689,0.005321939,0.9197152,0.00010689835,0.0003033954,0.00040967946,0.00041412783,0.001336565,0.003539504,0.000005306881,0.0015409603,0.042599533],"study_design_scores_gemma":[0.04636535,0.044238344,0.901897,0.000568061,0.0004403223,0.00009728713,0.00005969797,0.0004387124,0.0024419853,0.00009091651,0.0032140154,0.00014829672],"about_ca_topic_score_codex":0.00012718314,"about_ca_topic_score_gemma":0.0013172034,"teacher_disagreement_score":0.042451236,"about_ca_system_score_codex":0.00023251075,"about_ca_system_score_gemma":0.0024433616,"threshold_uncertainty_score":0.6147802},"labels":[],"label_agreement":null},{"id":"W2225304791","doi":"10.1200/jco.2006.24.18_suppl.5066","title":"The prognostic effects of performance status (PS) and quality of life (QoL) scores on progression-free survival (PFS) and overall survival (OS) in advanced ovarian cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Quality of life (healthcare); Performance status; Ovarian cancer; Chemotherapy; Proportional hazards model; Progression-free survival; Prognostic variable; Cancer","score_opus":0.06749624071936033,"score_gpt":0.4418462204754326,"score_spread":0.37434997975607226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225304791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891564,0.005321602,0.0000067540655,0.0036538728,0.00088876206,0.0005204428,0.000010736678,0.0000035745927,0.0004378008],"genre_scores_gemma":[0.9884989,0.010275854,0.0006218488,0.00016694596,0.00037077413,0.000026141272,0.0000014010384,0.000013178952,0.000024900708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627656,0.00069149834,0.0020247223,0.00021990227,0.0005119874,0.0002753319],"domain_scores_gemma":[0.98752,0.009973931,0.0017525869,0.00023786779,0.00027655077,0.00023906397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002965348,0.00016426931,0.0015051025,0.000079339916,0.000047495476,0.0000087021335,0.00011978561,0.00019279936,0.000010803712],"category_scores_gemma":[0.005309775,0.00009317971,0.00015624728,0.00011564804,0.00038259028,0.00008374185,0.000073452924,0.0005090377,2.7731727e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089247655,0.0018053715,0.8686017,0.0003200589,0.00020181865,0.000047789126,0.000048184305,0.00004489614,0.00006665832,0.0011003081,0.000101638754,0.118736856],"study_design_scores_gemma":[0.020652344,0.011368829,0.9647858,0.00090052286,0.00017774345,0.0000060366206,0.000030933694,0.000047299203,0.0001822011,0.00037879637,0.0013901702,0.000079282974],"about_ca_topic_score_codex":0.0004117016,"about_ca_topic_score_gemma":0.0013014626,"teacher_disagreement_score":0.11865757,"about_ca_system_score_codex":0.000114554714,"about_ca_system_score_gemma":0.0011322416,"threshold_uncertainty_score":0.635668},"labels":[],"label_agreement":null},{"id":"W2225455784","doi":"10.1200/jco.2009.27.15_suppl.6038","title":"Higher dose per fraction and shorter overall treatment time using intensity-modulated radiation therapy versus conventional radiation therapy with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma: A comparison of toxicity and efficacy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Carboplatin; Radiation therapy; Concomitant; Fluorouracil; Nuclear medicine; Stage (stratigraphy); Dose fractionation; Chemotherapy; Internal medicine; Surgery; Urology; Cisplatin","score_opus":0.13347195828705274,"score_gpt":0.4540419569224864,"score_spread":0.3205699986354337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225455784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224395,0.0053161397,0.00015334244,0.00147255,0.00030740802,0.00046905453,0.000004866595,0.000005153938,0.000027543827],"genre_scores_gemma":[0.9955266,0.0029632081,0.0008498847,0.00031314846,0.00031493028,0.0000030671738,0.000009855538,0.000008091704,0.000011219706],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985169,0.00013590725,0.0008675627,0.00018137001,0.00017341283,0.0001248458],"domain_scores_gemma":[0.997935,0.0007439888,0.00078029325,0.000057225065,0.00033985815,0.00014362503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004062181,0.00014596073,0.001212736,0.00006563331,0.00006144936,0.000007919827,0.000019635578,0.00015971383,0.00001670395],"category_scores_gemma":[0.000097646676,0.000096254844,0.00011000356,0.000040285853,0.00012548885,0.00012449182,0.0000060776206,0.00021367548,1.2510608e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06672399,0.002042995,0.07078409,0.000013901969,0.00055154786,0.0000143413545,0.00044883657,0.000049670623,0.008588636,0.000010698878,0.00008438022,0.8506869],"study_design_scores_gemma":[0.06621867,0.06534139,0.86017144,0.00005359328,0.00025267267,0.00003904885,0.000037315513,0.0053785928,0.00065832515,0.000018458695,0.0017410374,0.00008944107],"about_ca_topic_score_codex":0.000019075562,"about_ca_topic_score_gemma":0.0000067019864,"teacher_disagreement_score":0.85059744,"about_ca_system_score_codex":0.00019193866,"about_ca_system_score_gemma":0.00030624992,"threshold_uncertainty_score":0.39251587},"labels":[],"label_agreement":null},{"id":"W2225516900","doi":"10.1200/jco.2006.24.18_suppl.10020","title":"Telomere maintenance predicts progression and survival in pediatric intracranial ependymoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Telomere; Telomerase; Telomerase reverse transcriptase; Medicine; Ependymoma; Oncology; Multivariate analysis; Pathological; Internal medicine; Cancer research; Pathology; Biology; Genetics; DNA; Gene","score_opus":0.04992802329220643,"score_gpt":0.4105057662867384,"score_spread":0.360577742994532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225516900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98980826,0.0013149198,0.000068788555,0.0039441306,0.001585537,0.00022029935,0.0000028240054,0.00001611424,0.0030391125],"genre_scores_gemma":[0.9899959,0.00182483,0.0036629708,0.00042658614,0.0038699487,0.0000027416786,0.0000021039614,0.000018637953,0.00019631092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594843,0.00039282657,0.0025060114,0.000272741,0.00049872015,0.00038127863],"domain_scores_gemma":[0.99647987,0.001417337,0.0012650726,0.00015906186,0.00031046238,0.00036819046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032312067,0.00017740348,0.0014172647,0.00025242922,0.000039745304,0.000012618924,0.00015865393,0.0004795276,0.00005279324],"category_scores_gemma":[0.0028897962,0.00012273216,0.0002185699,0.00029790105,0.00025490634,0.00016077016,0.00006142867,0.0012853642,0.000010217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003206487,0.0015070052,0.82576126,0.00007345572,0.000025788742,0.006702726,0.00003658474,0.0000034564275,0.00009799064,0.0001983061,0.0022046622,0.16018228],"study_design_scores_gemma":[0.009129431,0.00504745,0.97413725,0.00013774414,0.00013264317,0.0020598217,0.00005820228,0.000116496434,0.000027567625,0.00060732896,0.008425458,0.000120606244],"about_ca_topic_score_codex":0.00003919235,"about_ca_topic_score_gemma":0.00021749418,"teacher_disagreement_score":0.16006167,"about_ca_system_score_codex":0.00009095592,"about_ca_system_score_gemma":0.00100546,"threshold_uncertainty_score":0.55843395},"labels":[],"label_agreement":null},{"id":"W2225863772","doi":"10.1200/jco.2007.25.18_suppl.550","title":"A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Hazard ratio; Paclitaxel; Gastroenterology; Proportional hazards model; Confidence interval; Cancer","score_opus":0.06350505833528398,"score_gpt":0.4623515918723846,"score_spread":0.39884653353710064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225863772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98109186,0.00023541653,0.0009527688,0.010530946,0.0018239291,0.003099795,0.0018687032,0.00003599772,0.0003606038],"genre_scores_gemma":[0.9872481,0.00033692198,0.0047351765,0.005796981,0.00089633453,0.00027149203,0.00007674778,0.000078467565,0.00055973063],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899444,0.0014221218,0.005272675,0.00092535914,0.0010867451,0.0013487134],"domain_scores_gemma":[0.985886,0.006417894,0.0039467607,0.00045561013,0.001263586,0.0020301857],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047666347,0.0007583135,0.0056550098,0.00057591504,0.00014186148,0.000023124674,0.0005342914,0.00068703236,0.00092361605],"category_scores_gemma":[0.0017419925,0.000534214,0.0006179344,0.00124915,0.0006728689,0.00024426432,0.00013670062,0.0018058406,0.000020449332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8772106,0.015891915,0.011416705,0.000050969862,0.0026200295,0.0022977842,0.003447528,0.00022338117,0.029643489,0.0000046069117,0.040740926,0.016452037],"study_design_scores_gemma":[0.76129985,0.15000351,0.064579524,0.0011300539,0.0028915848,0.0004383127,0.0034455804,0.00020761648,0.008207018,0.00009032029,0.006698458,0.0010081967],"about_ca_topic_score_codex":0.00433128,"about_ca_topic_score_gemma":0.00406796,"teacher_disagreement_score":0.1341116,"about_ca_system_score_codex":0.0029922281,"about_ca_system_score_gemma":0.004327425,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W2225869670","doi":"10.1200/jco.2006.24.18_suppl.7155","title":"An economic analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Population; Randomized controlled trial; Clinical trial; Randomization; Internal medicine; Indirect costs; Cancer; Chemotherapy; Surgery; Oncology; Cisplatin","score_opus":0.17578918958915843,"score_gpt":0.4369175766368772,"score_spread":0.2611283870477188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225869670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873907,0.0014278666,0.000842079,0.00039848045,0.0059632724,0.0007322749,0.0008331871,0.0000026165994,0.0024095364],"genre_scores_gemma":[0.99466294,0.0023396104,0.000920909,0.00016331224,0.0015392081,0.00003912302,0.000034941804,0.0000228493,0.00027709428],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9834012,0.000699086,0.014931347,0.00043745828,0.0001808715,0.00035006914],"domain_scores_gemma":[0.97359663,0.0060426677,0.019351384,0.000289056,0.0004912818,0.00022898229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0251096,0.00026819442,0.007956921,0.0007336761,0.000034782835,0.000017028382,0.000517014,0.0005940015,0.0006004177],"category_scores_gemma":[0.005783895,0.00025646185,0.0016911945,0.00042783594,0.00035526417,0.00051634555,0.000050938903,0.0006246651,0.0000016356544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6092789,0.0013684176,0.26529652,0.0000764732,0.0028153232,0.000013156066,0.00013662639,0.10943634,0.000020281694,0.005636795,0.0014765644,0.0044446127],"study_design_scores_gemma":[0.5528898,0.0028138412,0.3889566,0.000070824426,0.0010101484,3.2501802e-7,0.000027781538,0.049051072,0.00003211671,0.0008030853,0.0040509184,0.00029347112],"about_ca_topic_score_codex":0.35402906,"about_ca_topic_score_gemma":0.52645254,"teacher_disagreement_score":0.17242348,"about_ca_system_score_codex":0.0014593034,"about_ca_system_score_gemma":0.009286538,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W2226295209","doi":"10.1200/jco.2009.27.15_suppl.11113","title":"Dependence of malignant proliferation associated with loss of PTEN on glucose concentration in the hyperglycemic range: Relevance to population studies linking hyperglycemia to unfavorable cancer prognosis","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"PTEN; Glucose uptake; Population; Endocrinology; Cancer research; Internal medicine; Null cell; Cell growth; Medicine; Carbohydrate metabolism; Biology; Cell culture; PI3K/AKT/mTOR pathway; Insulin; Signal transduction; Cell biology; Biochemistry","score_opus":0.062137358003514366,"score_gpt":0.40701880273732255,"score_spread":0.34488144473380816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226295209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431133,0.0014337921,0.00014956693,0.0025121067,0.0011484835,0.0003940435,0.000006528115,0.0000018249566,0.000042327498],"genre_scores_gemma":[0.99280953,0.0030643358,0.0006069193,0.001666281,0.0018012666,0.000018356664,0.0000067952315,0.000007332113,0.000019184805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977233,0.00036936297,0.0012236611,0.00019713842,0.0003157906,0.00017078842],"domain_scores_gemma":[0.99772185,0.00029930216,0.0011384696,0.00013992828,0.00062798394,0.000072456074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018549995,0.000114980954,0.0006594169,0.0000571498,0.00003289933,0.0000063014872,0.00018654949,0.00020583367,0.0000014447153],"category_scores_gemma":[0.0025517393,0.00007423973,0.00010942034,0.0002206519,0.000058862905,0.000016590895,0.000018383587,0.00023921816,2.9593193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029136607,0.0022210102,0.59571934,0.00007882093,0.00048483518,0.000009309682,0.0018913342,0.025454108,0.19386204,0.0003379381,0.0032531421,0.1475515],"study_design_scores_gemma":[0.007933979,0.024844201,0.9118476,0.0011733574,0.00032314777,0.00003560445,0.00048008276,0.00014484146,0.04100133,0.00032589718,0.011582443,0.00030749786],"about_ca_topic_score_codex":0.000041219133,"about_ca_topic_score_gemma":0.00092182716,"teacher_disagreement_score":0.31612825,"about_ca_system_score_codex":0.00008651514,"about_ca_system_score_gemma":0.00048162107,"threshold_uncertainty_score":0.30548546},"labels":[],"label_agreement":null},{"id":"W2226426266","doi":"10.1200/jco.2014.32.15_suppl.5008","title":"Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prednisone; Placebo; Chemotherapy; Internal medicine; Oncology; Randomized controlled trial; Clinical trial; Cancer; Urology; Pathology; Alternative medicine","score_opus":0.07938703583573291,"score_gpt":0.4593268820083639,"score_spread":0.379939846172631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226426266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653835,0.0003992889,0.00016344993,0.0029187165,0.0009663336,0.008476098,0.000020218318,0.0000077357045,0.0005097824],"genre_scores_gemma":[0.995611,0.0011565288,0.00085924263,0.00035091836,0.0006671627,0.0004466448,0.000017000822,0.000037154387,0.00085433037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916262,0.0021525954,0.0045260936,0.00032561,0.000943494,0.00042602353],"domain_scores_gemma":[0.9902128,0.0044962307,0.0037585835,0.00026838793,0.0008632772,0.00040073466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008666844,0.00029716836,0.005264259,0.0003011743,0.0000482171,0.000019282426,0.00018660682,0.00025151562,0.00016399175],"category_scores_gemma":[0.0038173993,0.00016189771,0.00073281256,0.000246989,0.0005013623,0.00016504942,0.000024617386,0.0008361728,0.000003241793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.945304,0.0145963915,0.00050484104,0.00008521212,0.0022792488,0.00013274745,0.0004758201,0.00009674783,0.000071979935,0.000018471208,0.00024662408,0.036187913],"study_design_scores_gemma":[0.88929164,0.10650922,0.0005955603,0.00024385354,0.0014236916,0.000009414063,0.000091723894,0.0007416988,0.000107134794,0.00012391372,0.0007332279,0.00012892504],"about_ca_topic_score_codex":0.00012556335,"about_ca_topic_score_gemma":0.00020151884,"teacher_disagreement_score":0.091912836,"about_ca_system_score_codex":0.0004672476,"about_ca_system_score_gemma":0.004321841,"threshold_uncertainty_score":0.76667607},"labels":[],"label_agreement":null},{"id":"W2226506305","doi":"10.1200/jco.2007.25.18_suppl.15104","title":"Adjuvant treatment in resected pancreatic adenocarcinoma: A retrospective analysis of survival and prognostic factors in 141 patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Internal medicine; Adenocarcinoma; Retrospective cohort study; Lymphovascular invasion; Radiation therapy; Adjuvant; Oncology; Survival analysis; Pancreatic cancer; Gastroenterology; Cohort; Log-rank test; Adjuvant therapy; Chemotherapy; Surgery; Cancer; Metastasis","score_opus":0.12705911050529606,"score_gpt":0.4784643517663743,"score_spread":0.35140524126107825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226506305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728066,0.00041342506,0.000031873973,0.0002514205,0.00015671135,0.00047707267,0.000007348544,0.0000030252686,0.0013784608],"genre_scores_gemma":[0.99864644,0.00055497914,0.000581743,0.000035634865,0.00007991863,0.000004796316,0.000009390847,0.000009728893,0.000077366545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952191,0.0007503291,0.0029179105,0.00025141978,0.0004896417,0.0003716142],"domain_scores_gemma":[0.98985034,0.007859565,0.0012079442,0.00017830287,0.0005419246,0.00036194248],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050409464,0.00016224959,0.0037566489,0.0011753031,0.000019414994,0.0000030341255,0.0001012662,0.00041573957,0.000077908175],"category_scores_gemma":[0.012685178,0.00010541175,0.00035412164,0.0011064934,0.00034751568,0.000059507867,0.000044356082,0.00075950404,9.2824206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053251227,0.004350514,0.98268235,0.000022866347,0.0017148509,0.00080898736,0.00070247875,0.0000031588054,0.000037602826,0.000029429242,0.000012085248,0.00431058],"study_design_scores_gemma":[0.013222431,0.025376529,0.95726275,0.000094570714,0.0028037261,0.000015057295,0.0006918789,0.0003175052,0.000017735609,0.00009583107,0.00003088682,0.000071088456],"about_ca_topic_score_codex":0.0005498081,"about_ca_topic_score_gemma":0.004395741,"teacher_disagreement_score":0.025419563,"about_ca_system_score_codex":0.00076862884,"about_ca_system_score_gemma":0.0012256127,"threshold_uncertainty_score":0.9956314},"labels":[],"label_agreement":null},{"id":"W2226828119","doi":"10.1200/jco.2009.27.15_suppl.e13000","title":"Investigation of cognitive screening measures in patients with brain tumors: Diagnostic accuracy and correlation with quality of life","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Montreal Cognitive Assessment; Medicine; McNemar's test; Receiver operating characteristic; Cutoff; Quality of life (healthcare); Rank correlation; Correlation; Neuropsychology; Gold standard (test); Cognition; Internal medicine; Cognitive impairment; Psychiatry; Statistics","score_opus":0.12504196986757185,"score_gpt":0.43571165460726413,"score_spread":0.31066968473969225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226828119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994902,0.00017899337,0.0011248759,0.0031680234,0.000054018023,0.00041787646,0.00000529836,0.0000033483316,0.00014557473],"genre_scores_gemma":[0.9977112,0.00008156156,0.0008064507,0.001290778,0.000091615955,0.000002270958,0.0000057747507,0.0000064968426,0.0000038702324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680215,0.0005861155,0.0019095532,0.00013153108,0.00045454278,0.00011612926],"domain_scores_gemma":[0.9778427,0.017062357,0.0033668992,0.000063145686,0.0014812863,0.00018360007],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024111501,0.00010872948,0.0011621845,0.00016600973,0.00002112032,0.0000024594722,0.00003712741,0.00013662211,0.000006781897],"category_scores_gemma":[0.0688416,0.00007248192,0.00007482292,0.0002232487,0.0004201246,0.0001801855,0.00001503269,0.0005515213,2.4882107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018049365,0.0005781713,0.93748975,0.00003121639,0.00023388588,0.00001443544,0.00048413436,0.000044305856,0.000014472899,0.0000124646485,0.00007586668,0.042971943],"study_design_scores_gemma":[0.021909349,0.030930208,0.94393504,0.0021418703,0.00029107276,0.0000091707425,0.0004854741,0.000028387247,0.00004071051,0.00015269464,0.000008016839,0.000067990964],"about_ca_topic_score_codex":0.00004031184,"about_ca_topic_score_gemma":0.000076852215,"teacher_disagreement_score":0.06643045,"about_ca_system_score_codex":0.000056050518,"about_ca_system_score_gemma":0.0007169696,"threshold_uncertainty_score":0.9390019},"labels":[],"label_agreement":null},{"id":"W2226900876","doi":"10.1200/jco.2014.32.26_suppl.152","title":"Everolimus plus exemestane in patients with advanced invasive lobular carcinoma: Efficacy and safety results from BOLERO-2.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Hazard ratio; Population; Oncology; Gastroenterology; Urology; Breast cancer; Cancer; Aromatase; Confidence interval","score_opus":0.035515576600396746,"score_gpt":0.3611832219876269,"score_spread":0.3256676453872302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226900876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561286,0.00048376748,0.00037281206,0.0022906607,0.00044915828,0.0003313466,0.000015591575,0.000009261755,0.00043451466],"genre_scores_gemma":[0.98822874,0.000236064,0.00926096,0.0016756892,0.00052105414,0.0000023629384,0.000014621233,0.000026522055,0.000033986464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964413,0.0003946815,0.0021432405,0.0003296851,0.00040630723,0.00028476844],"domain_scores_gemma":[0.99304116,0.004062223,0.0017142479,0.0003015,0.00047958997,0.00040130856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013073091,0.00020076451,0.0017089769,0.000115156494,0.00003267694,0.0000055257383,0.00014960744,0.00028081273,0.000020686048],"category_scores_gemma":[0.0051572863,0.00013780448,0.00011880269,0.00013969243,0.00030191924,0.00018239672,0.0000613336,0.00096370204,0.0000045552956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23351786,0.0014028283,0.38408518,0.000024626079,0.00026255954,0.00044353484,0.0005298232,0.00050441653,0.000083587904,0.000028046341,0.00008221775,0.37903532],"study_design_scores_gemma":[0.11173183,0.015924565,0.8579216,0.00029300185,0.00015260428,0.000048189875,0.00008444629,0.000036199355,0.000032489537,0.00022820446,0.013422095,0.00012475891],"about_ca_topic_score_codex":0.00003767013,"about_ca_topic_score_gemma":0.000096970194,"teacher_disagreement_score":0.47383645,"about_ca_system_score_codex":0.0003121679,"about_ca_system_score_gemma":0.0009265749,"threshold_uncertainty_score":0.6174126},"labels":[],"label_agreement":null},{"id":"W2227374189","doi":"10.1200/jco.2015.33.3_suppl.216","title":"Impact of first-line fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with advanced gastroesophageal adenocarcinoma: A retrospective analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Oxaliplatin; Regimen; Internal medicine; Fluorouracil; Oncology; Progression-free survival; Gastroenterology; Phases of clinical research; Chemotherapy; Cancer; Surgery; Colorectal cancer","score_opus":0.0740813241841159,"score_gpt":0.42748385960257257,"score_spread":0.3534025354184567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227374189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637926,0.00034389764,0.0016444395,0.0007041269,0.00026481383,0.0004242712,0.000021123475,0.0000068242193,0.0002112376],"genre_scores_gemma":[0.9898019,0.00011135129,0.009341353,0.00014022329,0.00044856832,0.0000056495387,0.000012844477,0.000015302458,0.00012282022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972705,0.0000974828,0.0016786838,0.00023147347,0.00046307352,0.0002587392],"domain_scores_gemma":[0.9949636,0.0007413081,0.0021521377,0.00019892609,0.0014842706,0.0004597772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014774101,0.00018449588,0.0021672437,0.00028963407,0.000030438601,0.00000850512,0.00012038019,0.00015034665,0.000032754448],"category_scores_gemma":[0.002765013,0.00011338149,0.00070467865,0.00039995162,0.00015986215,0.0001830259,0.00005684334,0.00041372332,7.154048e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013268889,0.001024388,0.9706441,0.000031221643,0.0028369094,0.0000617641,0.00008399671,0.00025260585,9.244336e-7,0.000015608612,0.001194344,0.010585256],"study_design_scores_gemma":[0.027768398,0.06310951,0.90478975,0.000029973568,0.0033569944,0.000022582168,0.00006309952,0.0002636085,0.0000020325397,0.00012483123,0.0003959718,0.000073246534],"about_ca_topic_score_codex":0.00003224976,"about_ca_topic_score_gemma":0.00007930375,"teacher_disagreement_score":0.06585434,"about_ca_system_score_codex":0.00032180318,"about_ca_system_score_gemma":0.00058083225,"threshold_uncertainty_score":0.4623563},"labels":[],"label_agreement":null},{"id":"W2227444605","doi":"10.1200/jco.2000.18.9.1900","title":"Phase I Trials in Pediatric Oncology: Perceptions of Pediatricians From the United Kingdom Children’s Cancer Study Group and the Pediatric Oncology Group","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital","funders":"","keywords":"Medicine; Altruism (biology); Family medicine; Pediatric oncology; Feeling; Informed consent; Clinical trial; Cancer; Pediatrics; Alternative medicine; Internal medicine; Psychology; Social psychology","score_opus":0.5132974174111685,"score_gpt":0.6453900164050936,"score_spread":0.13209259899392511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227444605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603349,0.0024240785,0.000039476927,0.033014428,0.001453005,0.0020302741,0.000062029605,0.000015767471,0.00062605337],"genre_scores_gemma":[0.89138764,0.09192925,0.00070963573,0.004464664,0.011279319,0.0000816761,0.000013058337,0.000041764662,0.000092994065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9626991,0.022541475,0.011490375,0.00073689286,0.0017831301,0.0007489972],"domain_scores_gemma":[0.69732094,0.2951211,0.005219732,0.00072700006,0.0009718614,0.00063935434],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.10539009,0.00036869416,0.005361559,0.0006946378,0.00023660807,0.000030549236,0.0011327525,0.0019505344,0.0014352564],"category_scores_gemma":[0.12001776,0.00019265639,0.0012397621,0.0016539854,0.0018053409,0.0001431402,0.00030795304,0.010792233,0.000023950755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026266247,0.021819318,0.8694335,0.00003385311,0.0006043072,0.00034575086,0.001747893,0.00003945712,0.0000070898627,0.00036227916,0.002640877,0.076699406],"study_design_scores_gemma":[0.09379872,0.0420227,0.8476097,0.000046678775,0.0051685483,0.00011834359,0.0016480508,0.00009814547,3.118183e-7,0.0030912252,0.006217114,0.00018044352],"about_ca_topic_score_codex":0.0037960496,"about_ca_topic_score_gemma":0.006633721,"teacher_disagreement_score":0.2725796,"about_ca_system_score_codex":0.00053927436,"about_ca_system_score_gemma":0.0058726487,"threshold_uncertainty_score":0.99976313},"labels":[],"label_agreement":null},{"id":"W2227540121","doi":"10.1200/jco.2006.24.18_suppl.6093","title":"The potential for lost productivity in lung cancer patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Spouse; Lung cancer; Cancer; Quality of life (healthcare); Productivity; Sick leave; Family medicine; Physical therapy; Internal medicine; Nursing","score_opus":0.05154172580612853,"score_gpt":0.4454557059098907,"score_spread":0.39391398010376216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227540121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813385,0.0008068902,0.000096825635,0.012962398,0.0028489875,0.000368293,0.000007059565,0.0000019925344,0.0015690544],"genre_scores_gemma":[0.9942975,0.00038127255,0.00048563935,0.001157003,0.0029094252,0.000008648272,0.000003128968,0.000009054156,0.0007483455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795806,0.00016319449,0.0013718623,0.00012355196,0.00019485605,0.00018849823],"domain_scores_gemma":[0.9975867,0.0010024942,0.00085349375,0.00009942637,0.0003663396,0.00009153997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019908461,0.00007123866,0.0006309835,0.000046689514,0.00004615355,0.0000061473647,0.0001007946,0.0001549427,0.000059972936],"category_scores_gemma":[0.0013927288,0.00004158916,0.00028412603,0.00006505903,0.00012995965,0.00008749966,0.000020213478,0.0005362404,0.000001439793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010103442,0.0016568226,0.6767248,0.000049757808,0.0001490436,0.00006522235,0.000024455392,0.00018593323,0.00016160344,0.00006194366,0.051832333,0.25898466],"study_design_scores_gemma":[0.009101788,0.0025451106,0.808244,0.000026865257,0.000118252196,0.000014057626,0.000011714417,0.00047062783,0.000047255777,0.00023407697,0.17914067,0.000045599103],"about_ca_topic_score_codex":0.000077343706,"about_ca_topic_score_gemma":0.0005110455,"teacher_disagreement_score":0.25893906,"about_ca_system_score_codex":0.00025930878,"about_ca_system_score_gemma":0.0016284742,"threshold_uncertainty_score":0.28888434},"labels":[],"label_agreement":null},{"id":"W2227580668","doi":"10.1200/jco.2007.25.18_suppl.1044","title":"Alterations in calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer (MBC): A potential therapeutic target?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Vitamin D and neurology; Calcium metabolism; Gastroenterology; Metastatic breast cancer; Endocrinology; Calcium; Bone remodeling; Cancer; Breast cancer","score_opus":0.10706080548234266,"score_gpt":0.4930036384257479,"score_spread":0.38594283294340526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227580668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990102,0.0014015008,0.0006688619,0.00491322,0.0019428022,0.00087477086,0.000030506719,0.000004736608,0.000061591934],"genre_scores_gemma":[0.99009836,0.000837923,0.001480016,0.0071698306,0.00024703096,0.000033379634,0.00001366854,0.000023226248,0.000096543576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965114,0.00025491536,0.0022791366,0.00020912327,0.000321012,0.0004243915],"domain_scores_gemma":[0.9973081,0.0008966964,0.0009524072,0.00013205282,0.0003411606,0.00036957953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022421507,0.00017245373,0.0012561374,0.0002995549,0.000041109717,0.000007281968,0.00009602194,0.00022576997,0.00011835934],"category_scores_gemma":[0.00023028206,0.00011527143,0.00034975333,0.00021095652,0.00007552822,0.00010479048,0.000011062309,0.00071280514,0.0000061406686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03020538,0.009132368,0.6173922,0.00002249891,0.00034170484,0.00034587266,0.00011109891,0.000034841054,0.000025459816,0.00004638729,0.00010689846,0.3422353],"study_design_scores_gemma":[0.037696697,0.0065262965,0.9532227,0.00008477199,0.00018387093,0.000050491948,0.000011721992,0.00007046713,0.000088718996,0.00034081808,0.001640731,0.00008270785],"about_ca_topic_score_codex":0.0002993795,"about_ca_topic_score_gemma":0.00090174685,"teacher_disagreement_score":0.3421526,"about_ca_system_score_codex":0.00030296738,"about_ca_system_score_gemma":0.0012884353,"threshold_uncertainty_score":0.47006324},"labels":[],"label_agreement":null},{"id":"W2227724781","doi":"10.1200/jco.2009.27.15_suppl.9574","title":"Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) to characterize cachexia in newly diagnosed advanced cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Lung cancer; Hazard ratio; Cachexia; Performance status; Quality of life (healthcare); Weight loss; Anorexia; Population; Gastroenterology; Cancer; Surgery; Confidence interval; Adverse effect; Obesity","score_opus":0.1768617022744624,"score_gpt":0.5069527238027045,"score_spread":0.3300910215282421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227724781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98272216,0.00006467041,0.000042801563,0.014624507,0.0017703047,0.00059208006,0.0000306976,0.000005165723,0.0001476059],"genre_scores_gemma":[0.97647214,0.0002672947,0.0035473218,0.019442983,0.00023094754,0.000009988715,0.0000049738574,0.000007338831,0.00001703937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962084,0.0005636908,0.0023714087,0.0001804262,0.00041497353,0.00026106002],"domain_scores_gemma":[0.9961783,0.00071355887,0.001738689,0.00015968535,0.00083865924,0.00037105667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082534377,0.00012796954,0.001113811,0.00009641428,0.000037596365,0.0000072200723,0.00013155286,0.00021823327,0.00005250053],"category_scores_gemma":[0.002922249,0.00008487951,0.0002373046,0.00039431552,0.000084181505,0.0001314767,0.000036447746,0.0007319656,0.0000015246538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004692243,0.003592771,0.8263544,0.000019322322,0.00005310303,0.0000864636,0.00014068093,0.000094089955,0.0010392886,0.00006709108,0.0014963936,0.16236417],"study_design_scores_gemma":[0.010997083,0.009614271,0.9740572,0.00044069302,0.000063249456,0.000010701228,0.00004132674,0.00007198635,0.00017047394,0.00017679525,0.0042838412,0.000072357536],"about_ca_topic_score_codex":0.00011336927,"about_ca_topic_score_gemma":0.0002843335,"teacher_disagreement_score":0.16229181,"about_ca_system_score_codex":0.00075888925,"about_ca_system_score_gemma":0.0018009832,"threshold_uncertainty_score":0.3498416},"labels":[],"label_agreement":null},{"id":"W2227999920","doi":"10.1200/jco.2006.24.18_suppl.3511","title":"Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemoradiotherapy; Radiation therapy; Total mesorectal excision; Colorectal cancer; Rectum; Surgery; Stage (stratigraphy); Adenocarcinoma; Resection margin; Oxaliplatin; Clinical endpoint; Chemotherapy; Cancer; Randomized controlled trial; Internal medicine; Resection","score_opus":0.09054909591289372,"score_gpt":0.4798508798286749,"score_spread":0.3893017839157812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227999920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815174,0.0021987343,0.00009462264,0.010998711,0.002849227,0.0038432789,0.000091346876,0.000021292211,0.0017510763],"genre_scores_gemma":[0.98553526,0.0012988624,0.0030276005,0.0010618982,0.0054286877,0.00021535595,0.000012372784,0.00006707841,0.0033528851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936816,0.0008852411,0.0037951425,0.0004357997,0.00072000903,0.00048220693],"domain_scores_gemma":[0.9872736,0.0080265505,0.0026420953,0.00040179037,0.0013583243,0.00029767514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004613843,0.00032726527,0.0032039066,0.00011443667,0.00010630704,0.000013288968,0.00038666953,0.00063320034,0.00017272604],"category_scores_gemma":[0.0052061835,0.0001784881,0.0015460292,0.00045809677,0.0004210822,0.0001260495,0.00004230697,0.0009935517,5.6578085e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9295251,0.0053823404,0.0055681304,0.00004096887,0.0015542802,0.00014667519,0.0001951236,0.0001420358,0.0013654189,0.000006547193,0.011176316,0.04489706],"study_design_scores_gemma":[0.69343436,0.16787754,0.096444875,0.00024894372,0.0012710966,0.00040515666,0.00004323153,0.0005095694,0.005340489,0.00009181047,0.034119066,0.00021387488],"about_ca_topic_score_codex":0.00039452215,"about_ca_topic_score_gemma":0.00035477852,"teacher_disagreement_score":0.23609075,"about_ca_system_score_codex":0.00090664544,"about_ca_system_score_gemma":0.005602699,"threshold_uncertainty_score":0.99389476},"labels":[],"label_agreement":null},{"id":"W2228210401","doi":"10.1200/jco.2015.33.7_suppl.471","title":"Preoperative renal parenchymal volumetrics and prediction of renal insufficiency following radical nephrectomy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Nephrectomy; Urology; Renal cell carcinoma; Renal function; Muscle hypertrophy; Parenchyma; Kidney disease; Exact test; Creatinine; Kidney; Nuclear medicine; Surgery; Internal medicine; Pathology","score_opus":0.1793229976329214,"score_gpt":0.4263482714645569,"score_spread":0.2470252738316355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228210401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120593,0.0021799714,0.0013293481,0.0008188202,0.0010718277,0.00024122199,0.0000055349983,0.000010132198,0.0031372085],"genre_scores_gemma":[0.9835806,0.00025199726,0.014809353,0.00022432992,0.0009128573,0.0000033337253,0.000004658722,0.000013674749,0.00019923194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552053,0.0006087944,0.0025646912,0.00024164445,0.0008230496,0.00024128243],"domain_scores_gemma":[0.9955789,0.0013729088,0.0013868377,0.00017820093,0.0006713832,0.0008117893],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043899138,0.00016975462,0.0015502288,0.00030397656,0.000039083887,0.000010148089,0.00012829667,0.00041076657,0.000031421463],"category_scores_gemma":[0.008674939,0.00011513457,0.00049196766,0.00038462295,0.0003479267,0.00018128326,0.00007590083,0.0009435759,0.0000042748084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008295352,0.005935942,0.8839667,0.000044101867,0.0011645746,0.0025504807,0.0008235813,0.00012281144,0.0014107988,0.000090547845,0.010104094,0.085491024],"study_design_scores_gemma":[0.025455695,0.116105676,0.8169705,0.00026853394,0.0018338439,0.0023700972,0.0003982871,0.002233664,0.0011018355,0.0002716902,0.032820273,0.00016986797],"about_ca_topic_score_codex":0.000021261745,"about_ca_topic_score_gemma":0.0000062855406,"teacher_disagreement_score":0.11016973,"about_ca_system_score_codex":0.00027832948,"about_ca_system_score_gemma":0.0027525965,"threshold_uncertainty_score":0.9996754},"labels":[],"label_agreement":null},{"id":"W2228250908","doi":"10.1200/jco.2015.33.7_suppl.267","title":"Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Denosumab; Prostate cancer; Bone remodeling; Internal medicine; Proportional hazards model; Oncology; Confidence interval; Zoledronic acid; Urology; Osteoporosis; Cancer","score_opus":0.0881619817833897,"score_gpt":0.447418176557408,"score_spread":0.3592561947740183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228250908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97671103,0.016606113,0.0000055048763,0.0050506475,0.00024418818,0.000551102,0.000013932896,0.0000138207515,0.0008036515],"genre_scores_gemma":[0.9901411,0.004318365,0.004630194,0.0005422922,0.000115577066,0.000037238737,0.0000084639605,0.000031084095,0.00017569047],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99693847,0.00038556976,0.001542774,0.00028361782,0.00041435155,0.00043523614],"domain_scores_gemma":[0.99656653,0.00053941546,0.0013078557,0.0001815253,0.00041365135,0.0009910221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001593859,0.00023956494,0.0019570547,0.00022098281,0.000037483405,0.000009126484,0.0000627598,0.00021026486,0.00002488264],"category_scores_gemma":[0.0006444634,0.00013534761,0.000110845314,0.00030890352,0.0003054,0.00022123233,0.000028767494,0.0006465855,0.0000047274175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41680434,0.0034348946,0.29463866,0.0000899301,0.0038689573,0.009373921,0.00040972806,0.00004944317,0.00014086938,0.000026079899,0.0012899442,0.26987323],"study_design_scores_gemma":[0.33189583,0.080615625,0.5370851,0.0005186828,0.004641096,0.0025460732,0.0010681107,0.00008972559,0.00066053896,0.000078716635,0.040420044,0.00038043177],"about_ca_topic_score_codex":0.0005627981,"about_ca_topic_score_gemma":0.0020744277,"teacher_disagreement_score":0.2694928,"about_ca_system_score_codex":0.00034916037,"about_ca_system_score_gemma":0.0035928546,"threshold_uncertainty_score":0.637357},"labels":[],"label_agreement":null},{"id":"W2228324969","doi":"10.1200/jco.2015.33.3_suppl.6","title":"Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dysphagia; Swallowing; Nausea; Clinical endpoint; Palliative care; Vomiting; Quality of life (healthcare); Radiation therapy; Internal medicine; Esophageal cancer; Cancer; Concomitant; Surgery; Gastroenterology; Randomized controlled trial","score_opus":0.1552904561335558,"score_gpt":0.4934869880398065,"score_spread":0.3381965319062507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228324969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980821,0.00063973357,0.000047636608,0.0003985117,0.00019176699,0.0005881152,0.000005467736,0.000002447168,0.00004420122],"genre_scores_gemma":[0.9979313,0.000119574346,0.0015829116,0.00019239013,0.00010052827,0.0000089881805,0.0000035111207,0.00001092316,0.00004987704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950189,0.0007782673,0.0034035034,0.00019196197,0.00046579077,0.00014159764],"domain_scores_gemma":[0.99412286,0.00085588,0.00401627,0.00017777791,0.0006691443,0.00015807759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036767602,0.00013500705,0.0021440554,0.00014950549,0.000012263434,0.0000014556466,0.00012386397,0.00018805453,0.000028980643],"category_scores_gemma":[0.0022093302,0.00007650051,0.000119838514,0.00030045197,0.0002603848,0.00008819855,0.000023258737,0.000468921,5.4994025e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06939597,0.008344172,0.9125397,0.00005021783,0.00021849992,0.00015396652,0.00094376836,0.0003051905,0.0003737611,0.000005253145,0.000016646574,0.007652838],"study_design_scores_gemma":[0.101826966,0.02157779,0.875427,0.000093339404,0.00008515339,0.00003596819,0.00019782936,0.00048283886,0.00019035155,0.00000951059,0.00002029395,0.000052927662],"about_ca_topic_score_codex":0.00026885123,"about_ca_topic_score_gemma":0.0011099007,"teacher_disagreement_score":0.03711269,"about_ca_system_score_codex":0.0001821268,"about_ca_system_score_gemma":0.0012195092,"threshold_uncertainty_score":0.31196004},"labels":[],"label_agreement":null},{"id":"W2228349767","doi":"10.1200/jco.2013.31.15_suppl.10007","title":"Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Blinatumomab; Medicine; Cytokine release syndrome; Refractory (planetary science); Bone marrow; Internal medicine; Acute lymphocytic leukemia; Gastroenterology; Hematopoietic stem cell transplantation; Oncology; Leukemia; Transplantation; Immunotherapy; Lymphoblastic Leukemia; Cancer","score_opus":0.0480128185871402,"score_gpt":0.3921392321694054,"score_spread":0.3441264135822652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228349767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107736,0.00038052278,0.000047751513,0.0067032687,0.00017031956,0.0005517881,0.000002779039,0.000010672691,0.0010555171],"genre_scores_gemma":[0.98987824,0.001714995,0.0051733,0.0015578232,0.00029500984,0.000034754186,0.0000033804222,0.00003303234,0.0013094879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955044,0.00061706087,0.0023782684,0.00041627348,0.0004979362,0.0005861029],"domain_scores_gemma":[0.99383104,0.00394785,0.00079802604,0.00027459682,0.00028221973,0.00086625596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015649768,0.0002827894,0.001953345,0.0005301946,0.000028208358,0.000020767866,0.00018804597,0.00078665675,0.0006689139],"category_scores_gemma":[0.0032031727,0.00014865532,0.0002064219,0.0004498295,0.00031270523,0.00018310652,0.00012770896,0.0013595788,0.000042109605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05026402,0.0069926246,0.6659675,0.0002245436,0.0010598088,0.22500156,0.00048963854,0.00011000658,0.004021804,0.00008968704,0.010095648,0.03568313],"study_design_scores_gemma":[0.074381076,0.05153537,0.8441909,0.00024799214,0.00091790286,0.019097479,0.00016266844,0.0024855668,0.00026689505,0.0005735331,0.005794361,0.00034626367],"about_ca_topic_score_codex":0.000056668396,"about_ca_topic_score_gemma":0.00018373846,"teacher_disagreement_score":0.20590408,"about_ca_system_score_codex":0.0023368536,"about_ca_system_score_gemma":0.00718683,"threshold_uncertainty_score":0.9984415},"labels":[],"label_agreement":null},{"id":"W2228560864","doi":"10.1200/jco.2007.25.18_suppl.6555","title":"Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Guideline; Randomized controlled trial; Gemcitabine; Lung cancer; Clinical endpoint; Internal medicine; Oncology; Cancer; Family medicine; Chemotherapy; Pathology","score_opus":0.37975122270478584,"score_gpt":0.5914904204564964,"score_spread":0.21173919775171052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228560864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97155654,0.008611141,0.011189504,0.0057829097,0.00023058578,0.000743477,0.000007275169,0.0000021155843,0.0018764253],"genre_scores_gemma":[0.99113595,0.0011039212,0.0045709186,0.002780407,0.0002612847,0.000036560796,0.0000010143654,0.000010243452,0.00009972017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969888,0.00027516388,0.0021531826,0.00017601321,0.00019615961,0.00021072254],"domain_scores_gemma":[0.991339,0.007361511,0.0007017853,0.00015739453,0.000333856,0.00010643002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044465438,0.0001285192,0.0019665654,0.00019205837,0.000025151805,0.000004462388,0.00016553457,0.00019321723,0.00010175506],"category_scores_gemma":[0.0007329548,0.00006565712,0.0013764421,0.00049071264,0.000093886214,0.00011549333,0.0000084748335,0.0004287814,4.8751957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015382197,0.012761891,0.6399545,0.00055930385,0.14195639,0.0004915202,0.07553447,0.0075948806,0.0005807435,0.0001762661,0.00088182575,0.104125984],"study_design_scores_gemma":[0.024253385,0.007242297,0.74498,0.00025324532,0.2111018,0.000017947841,0.0024379203,0.003488771,0.0007826124,0.00027873993,0.0049550342,0.00020826184],"about_ca_topic_score_codex":0.0001903126,"about_ca_topic_score_gemma":0.002254116,"teacher_disagreement_score":0.10502546,"about_ca_system_score_codex":0.00016426407,"about_ca_system_score_gemma":0.0013862078,"threshold_uncertainty_score":0.26774195},"labels":[],"label_agreement":null},{"id":"W2228950742","doi":"10.1200/jco.2015.33.29_suppl.233","title":"Financial burden among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Survivorship curve; Confidence interval; Logistic regression; Cancer; Odds ratio; Demography; Distress; Finance; Marital status; Gerontology; Environmental health; Clinical psychology; Internal medicine; Population","score_opus":0.11837080312852302,"score_gpt":0.38419564668991235,"score_spread":0.26582484356138936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228950742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733689,0.007877935,0.00011149464,0.004592445,0.008107674,0.00041574615,0.00024998514,0.000010697684,0.0052651614],"genre_scores_gemma":[0.9899431,0.002443153,0.00020159698,0.000933915,0.0060567246,0.000026478963,0.0000040309465,0.00003889752,0.00035214092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929426,0.00025776253,0.0057196105,0.00046889874,0.00018116433,0.000430018],"domain_scores_gemma":[0.98853385,0.0012798113,0.0087236455,0.00055323285,0.00051514636,0.0003942819],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008387713,0.00028130726,0.0028162813,0.00014993532,0.00008975774,0.000040302664,0.00093555497,0.0005038974,0.00036571876],"category_scores_gemma":[0.009054043,0.00022070801,0.0007223913,0.00028342108,0.0003800679,0.0004574016,0.00017999327,0.0011725462,0.00003809797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040578775,0.0013039385,0.95054704,0.000003827169,0.0005531782,0.000115837145,0.0024357054,0.00040644468,4.3348282e-7,0.000655527,0.010405244,0.033167034],"study_design_scores_gemma":[0.00417424,0.0018285498,0.8834016,0.000048671536,0.00011873969,0.000019069701,0.00051503355,0.00003534769,0.000004218092,0.0092839645,0.10033956,0.00023105815],"about_ca_topic_score_codex":0.048485905,"about_ca_topic_score_gemma":0.025311014,"teacher_disagreement_score":0.08993432,"about_ca_system_score_codex":0.000324236,"about_ca_system_score_gemma":0.0030784076,"threshold_uncertainty_score":0.9992931},"labels":[],"label_agreement":null},{"id":"W2229126747","doi":"10.1200/jco.2012.30.30_suppl.37","title":"Discovery of a biomarker signature that predicts upgrading or upstaging in patients with low-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Stage (stratigraphy); Biomarker; Oncology; Receiver operating characteristic; Cancer; Biopsy; Prostate; Internal medicine; Urology","score_opus":0.08199600246753193,"score_gpt":0.44670757782869425,"score_spread":0.36471157536116233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229126747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958445,0.0017257187,0.000025522255,0.001041463,0.00064200046,0.00043780284,0.00002769674,0.0000042686975,0.00025105165],"genre_scores_gemma":[0.9959839,0.00258252,0.0004217674,0.00020087075,0.00032580356,0.000009105031,0.000005967644,0.000020107616,0.00044997493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736476,0.00033746552,0.0012373317,0.00014453645,0.0005206983,0.00039523572],"domain_scores_gemma":[0.99654543,0.0012766718,0.0014753363,0.00013629603,0.0002787849,0.00028749026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002291355,0.00014100612,0.0010662815,0.0002068795,0.000029314597,0.000008133022,0.00011303295,0.00023168455,0.000045145673],"category_scores_gemma":[0.0012051302,0.00006867428,0.00018515295,0.00026755998,0.00023392936,0.00042257996,0.00005053892,0.0009857325,0.0000010619165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036514755,0.0021322458,0.9159862,0.00010537086,0.000413617,0.00014752324,0.00043178844,0.000008914507,0.000045337238,0.0000026130176,0.00065598154,0.043555662],"study_design_scores_gemma":[0.019624542,0.0074944696,0.9693469,0.0008510874,0.0002745068,0.000016521815,0.00019726223,0.000030759376,0.00031833348,0.000025407218,0.0017418544,0.000078351746],"about_ca_topic_score_codex":0.000044401546,"about_ca_topic_score_gemma":0.000041608382,"teacher_disagreement_score":0.05336071,"about_ca_system_score_codex":0.00028300326,"about_ca_system_score_gemma":0.0015339728,"threshold_uncertainty_score":0.42825723},"labels":[],"label_agreement":null},{"id":"W2229282452","doi":"10.1200/jco.2009.27.15_suppl.e15565","title":"A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Interim analysis; Pancreatic cancer; Gemcitabine; Internal medicine; Cancer; Randomized controlled trial; Oncology; Gastroenterology; Surgery; Nuclear medicine","score_opus":0.0500040928609981,"score_gpt":0.4792300571090282,"score_spread":0.4292259642480301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229282452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97728276,0.00068007124,0.00013727689,0.003964725,0.00019048502,0.00035154683,0.000008965749,0.0000065160107,0.017377673],"genre_scores_gemma":[0.9888427,0.0012727821,0.006142518,0.0016931539,0.0002928352,0.000012701218,0.0000015430697,0.0000122044685,0.0017295269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953105,0.0007429501,0.002746835,0.0002764577,0.0005299544,0.00039329787],"domain_scores_gemma":[0.9928825,0.003685051,0.0020172363,0.0002924645,0.00074899785,0.00037373463],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037626284,0.00017387925,0.0046327454,0.00039065667,0.00002913002,0.000005604032,0.00021861983,0.0003382376,0.0011680018],"category_scores_gemma":[0.015378203,0.00011891264,0.00067975157,0.0011117484,0.00030329192,0.000104100916,0.0000349658,0.0011664431,0.0000073359006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010122352,0.0017709525,0.9749606,0.000019140998,0.0030230572,0.00089693145,0.00026821083,0.000058926482,0.001240989,0.00054323097,0.0002510525,0.0068445504],"study_design_scores_gemma":[0.009760048,0.018242976,0.96179307,0.00022398662,0.004948632,0.00010228558,0.00030688723,0.0007958473,0.000041682793,0.002516513,0.0011663849,0.00010171581],"about_ca_topic_score_codex":0.0003305959,"about_ca_topic_score_gemma":0.00026285864,"teacher_disagreement_score":0.016472023,"about_ca_system_score_codex":0.00042488798,"about_ca_system_score_gemma":0.0030399293,"threshold_uncertainty_score":0.9997451},"labels":[],"label_agreement":null},{"id":"W2229326747","doi":"10.1200/jco.2004.22.14_suppl.6611","title":"A randomized phase I clinical and biologic study of two schedules of BAY 43–9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Nausea; Gastroenterology; Regimen; Myelodysplastic syndromes; Vomiting; Oncology; Surgery; Adverse effect; Bone marrow","score_opus":0.2024794012292822,"score_gpt":0.55521098114729,"score_spread":0.35273157991800774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229326747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282265,0.00038392894,0.00017322582,0.0005997927,0.00161394,0.004279133,0.00009157678,0.000009423973,0.000026318512],"genre_scores_gemma":[0.99301744,0.0024637391,0.003332868,0.00030975018,0.000656859,0.0001395281,0.0000111410045,0.00003917351,0.000029512743],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9712965,0.008970998,0.016634256,0.0007726108,0.0018045071,0.0005211593],"domain_scores_gemma":[0.96170247,0.024923917,0.009796541,0.00042253852,0.0024977336,0.00065681594],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.051218554,0.00045738564,0.0115532745,0.0007791193,0.000055717894,0.0000113268325,0.0005830922,0.0007777878,0.00013348181],"category_scores_gemma":[0.054276943,0.0002535016,0.0009918801,0.00084844965,0.002895971,0.00030010688,0.00030461457,0.0028305615,0.000001946286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42975104,0.027593069,0.52487713,0.000076873665,0.0056622857,0.00062221417,0.00017371718,0.00028825866,0.00002959359,0.000049726958,0.000035398556,0.010840672],"study_design_scores_gemma":[0.5019066,0.07764101,0.41658285,0.00045501164,0.0026200153,0.000054486092,0.00027036646,0.00012199268,0.000007444793,0.00014648416,0.000051705858,0.000142047],"about_ca_topic_score_codex":0.000900886,"about_ca_topic_score_gemma":0.002923052,"teacher_disagreement_score":0.108294286,"about_ca_system_score_codex":0.0007966036,"about_ca_system_score_gemma":0.015852598,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W2229389948","doi":"10.1200/jco.2012.30.27_suppl.43","title":"Radiation therapy after breast-conserving surgery: When are we missing the mark?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Breast-conserving surgery; Logistic regression; Breast cancer; Odds ratio; Radiation therapy; Odds; Internal medicine; Disease; Stage (stratigraphy); Multivariate analysis; Chemotherapy; Cancer; Mastectomy; Surgery","score_opus":0.09318156980586145,"score_gpt":0.403294746938398,"score_spread":0.31011317713253655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229389948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9165801,0.02513027,0.00013924613,0.05588962,0.0018889507,0.00008523648,0.000007790446,0.000003877115,0.0002749358],"genre_scores_gemma":[0.9845853,0.007011764,0.00043671046,0.0040267543,0.003852884,0.000007920153,0.000002636304,0.000015579077,0.0000604946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798477,0.00061329204,0.0008789085,0.00012443468,0.00015210525,0.00024647213],"domain_scores_gemma":[0.9973704,0.0009788338,0.0011365672,0.00019295915,0.00017199012,0.00014920537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023154086,0.00012891438,0.0005367144,0.0000340607,0.000074980315,0.000012856872,0.00015275476,0.00023670678,0.000071146904],"category_scores_gemma":[0.0006254713,0.00007588678,0.00040746958,0.000045255558,0.00014462013,0.000014921068,0.000065527696,0.00025587482,0.0000064863184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001678047,0.00033166492,0.62626785,0.0000043538544,0.00038796387,0.000013000212,0.00013720803,0.0000010185769,0.00018428653,0.0000027938224,0.020256527,0.35073528],"study_design_scores_gemma":[0.0009813101,0.00022899616,0.758906,0.000026554919,0.00007308375,0.00026129757,0.00009245653,0.0000016206568,0.0002345622,0.00012657318,0.23899214,0.000075368815],"about_ca_topic_score_codex":0.000015577614,"about_ca_topic_score_gemma":0.000023767421,"teacher_disagreement_score":0.3506599,"about_ca_system_score_codex":0.000045534438,"about_ca_system_score_gemma":0.00034827332,"threshold_uncertainty_score":0.30945733},"labels":[],"label_agreement":null},{"id":"W2229652473","doi":"10.1200/jco.2013.31.15_suppl.e20581","title":"Characteristics and outcomes of patients admitted to the acute palliative care unit (APUC) from the emergency center (EC) versus inpatient transfers (IP).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Internal medicine; Cohort; Palliative care; Retrospective cohort study; Demographics; Cancer; Log-rank test; Overall survival","score_opus":0.2769371243139936,"score_gpt":0.5164563954834751,"score_spread":0.23951927116948152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229652473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891484,0.00028381488,0.00005190302,0.007574211,0.0020880413,0.0003742234,0.00020473996,0.0000027701258,0.00027191523],"genre_scores_gemma":[0.9938283,0.0036151067,0.0005018163,0.0016676625,0.00030414527,0.00000665575,0.000031808282,0.000011792788,0.00003271577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712265,0.0003651653,0.00183452,0.00013518245,0.00037390043,0.0001685603],"domain_scores_gemma":[0.9944102,0.0028157125,0.0010734885,0.00020549832,0.0012585447,0.00023656143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038761992,0.00015041816,0.0011236287,0.000049236838,0.000038946764,0.0000040420855,0.00023671755,0.00018471219,0.00023142502],"category_scores_gemma":[0.0029725595,0.00007224203,0.00033200337,0.000114697,0.00017133991,0.0000620599,0.0000631131,0.0005275962,0.000011180881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026055973,0.00043341928,0.94917685,0.000015300253,0.0010092161,0.0000088859915,0.0059449747,6.498751e-7,0.000012539108,0.000010072894,0.0018858209,0.038896676],"study_design_scores_gemma":[0.0060066874,0.008450737,0.94633454,0.00013471743,0.00062665937,3.5973312e-7,0.0025643348,0.000007160234,0.00005114854,0.00002560991,0.035732172,0.00006588532],"about_ca_topic_score_codex":0.00010722056,"about_ca_topic_score_gemma":0.000101520855,"teacher_disagreement_score":0.03883079,"about_ca_system_score_codex":0.00004771822,"about_ca_system_score_gemma":0.0002259676,"threshold_uncertainty_score":0.3558646},"labels":[],"label_agreement":null},{"id":"W2229819180","doi":"10.1200/jco.2013.31.31_suppl.15","title":"A population-based study examining the impact of a multidisciplinary rapid access clinic on utilization of initial treatment options for patients with localized prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Radiation oncologist; Prostate cancer; Cancer; Prostatectomy; Population; Internal medicine; Radiation therapy; Cancer registry; Oncology; Gynecology","score_opus":0.5247053078881156,"score_gpt":0.651339459318252,"score_spread":0.12663415143013634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229819180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939159,0.000028626631,0.00053784956,0.0016172623,0.00034504101,0.0034717147,0.00005219558,0.000005874624,0.000025495418],"genre_scores_gemma":[0.99668866,0.00008857793,0.0024546413,0.0002201059,0.00028442295,0.00015317163,0.000074122916,0.000023742148,0.000012558728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934384,0.0009825262,0.004740862,0.00021468653,0.00044504675,0.00017845533],"domain_scores_gemma":[0.9759285,0.0154379895,0.0061639515,0.000271612,0.0020208438,0.00017712577],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031562934,0.00017731985,0.0013800829,0.00016811621,0.00007329546,0.0000127323565,0.00015969468,0.00015578454,0.00032724295],"category_scores_gemma":[0.010351797,0.00008944501,0.00044637924,0.0002507701,0.00012797504,0.00028003752,0.00003682444,0.00033794125,0.0000016936245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024616526,0.012069928,0.8304501,0.000024310266,0.0006592387,0.0000037901052,0.0001987662,0.0026894216,0.0000070842184,0.0000013041972,0.00015885718,0.12912065],"study_design_scores_gemma":[0.034763075,0.13524102,0.82451254,0.00012700785,0.00093349046,0.0000018947509,0.00052521494,0.003711019,0.000011669263,0.000060166352,0.000047240657,0.00006568442],"about_ca_topic_score_codex":0.0010525314,"about_ca_topic_score_gemma":0.00024345625,"teacher_disagreement_score":0.12905496,"about_ca_system_score_codex":0.00030271217,"about_ca_system_score_gemma":0.002415942,"threshold_uncertainty_score":0.9979844},"labels":[],"label_agreement":null},{"id":"W2230021832","doi":"10.1200/jco.2014.32.26_suppl.108","title":"Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Malay; Medicine; Focus group; Ethnic group; Breast cancer; Clinical trial; Family medicine; Cancer; Pathology; Internal medicine","score_opus":0.5056347237290967,"score_gpt":0.6579018119930955,"score_spread":0.15226708826399882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230021832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855936,0.000021812673,0.0004462763,0.010793153,0.001871607,0.00074465515,0.000030495592,0.000008926524,0.00048947],"genre_scores_gemma":[0.9935967,0.00041700937,0.0019842794,0.0016299682,0.0021516935,0.000026129912,0.0000033197227,0.000020829155,0.00017010953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934333,0.0013275193,0.0035736223,0.00036897135,0.0009312759,0.00036531064],"domain_scores_gemma":[0.9524421,0.04087453,0.002147955,0.00030710065,0.002433397,0.0017949194],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02548241,0.00015460612,0.0016643663,0.00009923696,0.00010649873,0.00001847374,0.00021381301,0.0010325636,0.00014754168],"category_scores_gemma":[0.15291888,0.00009850373,0.0004991571,0.00011808596,0.0014962463,0.00017373504,0.000089889734,0.0028395576,0.000004824958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11651219,0.00071299885,0.73362964,0.000042206208,0.00026962272,0.000011680923,0.00005015979,0.000002485051,2.5974913e-7,0.00021978928,0.0011307559,0.14741823],"study_design_scores_gemma":[0.11159491,0.04548028,0.83250004,0.00014850033,0.0004546553,0.0000050043386,0.00012848274,0.00013601551,8.4409425e-7,0.0013491157,0.008108289,0.000093861854],"about_ca_topic_score_codex":0.000027840842,"about_ca_topic_score_gemma":0.00032105568,"teacher_disagreement_score":0.14732437,"about_ca_system_score_codex":0.00011858276,"about_ca_system_score_gemma":0.0024539612,"threshold_uncertainty_score":0.99946094},"labels":[],"label_agreement":null},{"id":"W2230094502","doi":"10.1200/jco.2009.27.15_suppl.11029","title":"Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"GERD; Medicine; Gastroenterology; Internal medicine; Single-nucleotide polymorphism; Risk factor; Odds ratio; Genotype; Oncology; Disease; Reflux; Biology; Genetics; Gene","score_opus":0.08256795837662112,"score_gpt":0.43242615724488725,"score_spread":0.34985819886826613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230094502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635363,0.022982653,0.0001584504,0.012029405,0.00047931113,0.00039444905,0.00006657026,0.000027292876,0.00032555006],"genre_scores_gemma":[0.9866122,0.0030117044,0.0034012278,0.0035834268,0.0029918202,0.0000057386683,0.000011888488,0.000030563086,0.00035140716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99473333,0.0008753506,0.0023362585,0.00047408024,0.00086790236,0.0007130888],"domain_scores_gemma":[0.9934199,0.0013459964,0.0014434084,0.00035707184,0.00047745358,0.0029561645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019650299,0.00034209428,0.0018973878,0.00026899966,0.0001439999,0.000031391763,0.00025939307,0.00034212705,0.00032178272],"category_scores_gemma":[0.0036180892,0.00024122933,0.0007839821,0.00018649113,0.00039386755,0.00027202192,0.00008887109,0.0018449173,0.000042359912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015146645,0.0025517354,0.8411894,0.000041329535,0.0005682783,0.042075872,0.00008745964,0.00000416863,0.000065007414,0.00014865128,0.0023728895,0.095748566],"study_design_scores_gemma":[0.0133929225,0.027921693,0.9541571,0.000046561094,0.0006744964,0.0017294445,0.000013359936,0.00006458943,0.0002964097,0.0012469159,0.00032849936,0.00012798821],"about_ca_topic_score_codex":0.000035422472,"about_ca_topic_score_gemma":0.0000055564183,"teacher_disagreement_score":0.11296772,"about_ca_system_score_codex":0.00032570714,"about_ca_system_score_gemma":0.0022491994,"threshold_uncertainty_score":0.9837047},"labels":[],"label_agreement":null},{"id":"W2230230385","doi":"10.1200/jco.2009.27.15_suppl.2520","title":"Global drug development in cancer: A cross-sectional study of clinical trial registries","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Incidence (geometry); Cancer; Drug development; Phases of clinical research; Oncology; Drug; Pharmacology","score_opus":0.1464294512101629,"score_gpt":0.5228973589878285,"score_spread":0.3764679077776656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230230385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517494,0.0005860784,0.000051484323,0.00041404561,0.0029895846,0.00024714117,0.0000114530785,0.0000015634971,0.0005236925],"genre_scores_gemma":[0.99496895,0.0009869852,0.0008893455,0.00057812565,0.0024736582,0.000005475954,0.0000046975833,0.0000057502293,0.00008702081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434644,0.00038637535,0.0044985055,0.00028334133,0.00028963565,0.00019568844],"domain_scores_gemma":[0.99634767,0.00054170797,0.0022823617,0.00019799937,0.000437788,0.00019249255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049349708,0.00012973101,0.0010201164,0.000046121564,0.0000348638,0.00001573993,0.00033649296,0.00040674125,0.000017705248],"category_scores_gemma":[0.004853228,0.00011016061,0.00035903996,0.000115285584,0.00016971838,0.0000062843733,0.00009346942,0.00040408078,0.0000011356468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05539836,0.0057930276,0.87884474,0.0000036974452,0.00017378098,0.000057600246,0.000039736777,0.00041960657,0.0000318547,0.00004708946,0.0030568764,0.056133654],"study_design_scores_gemma":[0.051673952,0.018688887,0.8595627,0.0000111122,0.00003465913,0.000017752194,0.00006107404,0.0000054721977,0.00007596564,0.00019591113,0.06956967,0.00010282652],"about_ca_topic_score_codex":0.00011208302,"about_ca_topic_score_gemma":0.0022902675,"teacher_disagreement_score":0.06651279,"about_ca_system_score_codex":0.000108509674,"about_ca_system_score_gemma":0.004282567,"threshold_uncertainty_score":0.759709},"labels":[],"label_agreement":null},{"id":"W2230618937","doi":"10.1200/jco.2006.24.18_suppl.6029","title":"Diagnostic assessment of suspected cancer: Prospective cohort study of diagnostic delay intervals across three disease sites","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Ottawa Hospital","funders":"","keywords":"Medicine; Prospective cohort study; Cancer; Colorectal cancer; Referral; Cohort; Lung cancer; Disease; Internal medicine; Prostate cancer; Quality of life (healthcare)","score_opus":0.21581094512360732,"score_gpt":0.599939361358556,"score_spread":0.38412841623494864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230618937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921684,0.00038351025,0.0008267755,0.003500417,0.0010178341,0.0018378609,0.000053196767,0.000012935209,0.00019902893],"genre_scores_gemma":[0.9960226,0.0005810125,0.0015845656,0.0004029344,0.0012684675,0.00006457343,0.000018654502,0.000028940798,0.000028297574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9891255,0.0009878624,0.00822879,0.00035728567,0.0009929305,0.0003076569],"domain_scores_gemma":[0.90869135,0.079812825,0.007721517,0.0004197156,0.0029422545,0.0004123733],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007822236,0.00022389318,0.0024707206,0.0001265587,0.000049884904,0.000011502827,0.00026465135,0.00021458151,0.00031896582],"category_scores_gemma":[0.15755521,0.00016820873,0.0005660941,0.00033689194,0.00036227697,0.00022992324,0.00016835063,0.0010777181,0.000003602359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030425112,0.016878767,0.96491265,0.00007792518,0.0010356203,0.0007579372,0.00009480612,0.00046022265,0.00008491762,0.00005253476,0.0016081318,0.010993975],"study_design_scores_gemma":[0.014096382,0.020508375,0.9595544,0.00024094478,0.0030556398,0.00004416023,0.0007292084,0.00034826514,0.000028835038,0.00089987897,0.00036799905,0.00012593243],"about_ca_topic_score_codex":0.0011980605,"about_ca_topic_score_gemma":0.0056735473,"teacher_disagreement_score":0.14973296,"about_ca_system_score_codex":0.00039824352,"about_ca_system_score_gemma":0.002437457,"threshold_uncertainty_score":0.84954107},"labels":[],"label_agreement":null},{"id":"W2230741172","doi":"10.1200/jco.2014.32.4_suppl.14","title":"Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Oncology; Progression-free survival; Antiandrogen; Antiandrogens; Population; Chemotherapy; Cancer; Androgen deprivation therapy; Urology","score_opus":0.08509615953393661,"score_gpt":0.4753897718246746,"score_spread":0.390293612290738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230741172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429345,0.00062296295,0.000005935845,0.0031659915,0.00032316134,0.0011182285,0.00021970188,0.000008200054,0.00024236183],"genre_scores_gemma":[0.9942146,0.0038347787,0.0011880435,0.00021854362,0.0003357386,0.000033436663,0.000055355875,0.00003599078,0.00008354407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505985,0.000824744,0.0022984713,0.0003593894,0.0010420043,0.00041553675],"domain_scores_gemma":[0.9936024,0.0024923214,0.0021705271,0.00041788036,0.00091910217,0.00039775373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023283958,0.00028249942,0.001802808,0.00034058734,0.000048266564,0.00001545165,0.00026714566,0.00015846819,0.00011167256],"category_scores_gemma":[0.0014135265,0.00014655336,0.00045845952,0.00041660413,0.00036903747,0.00013261217,0.000029715873,0.00090566283,0.0000022609574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2122491,0.006255208,0.58884513,0.00003240264,0.0016415638,0.0002804125,0.00054711924,0.00007518796,0.00041534487,0.000007629583,0.000755205,0.18889572],"study_design_scores_gemma":[0.10136415,0.06908202,0.8269855,0.0005262812,0.0001654795,0.000008734947,0.000054709933,0.00006874904,0.0003969178,0.00017565637,0.0010468957,0.00012494999],"about_ca_topic_score_codex":0.00067525933,"about_ca_topic_score_gemma":0.00045792633,"teacher_disagreement_score":0.23814033,"about_ca_system_score_codex":0.00035279285,"about_ca_system_score_gemma":0.0023700097,"threshold_uncertainty_score":0.5976272},"labels":[],"label_agreement":null},{"id":"W2231255144","doi":"10.1200/jco.2007.25.18_suppl.5057","title":"The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cancer; Disease; Prostate; Oncology; Internal medicine; Phases of clinical research","score_opus":0.6791850158428799,"score_gpt":0.6901554039621502,"score_spread":0.010970388119270313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231255144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8689723,0.016548619,0.00082518026,0.080221534,0.021064524,0.011408152,0.0005491292,0.00004470549,0.0003658549],"genre_scores_gemma":[0.89381397,0.047908567,0.012048909,0.0048799543,0.034650426,0.0011266412,0.00008818996,0.00016109864,0.0053222654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96814936,0.008001404,0.020948427,0.00078091683,0.00087648584,0.0012433897],"domain_scores_gemma":[0.84713227,0.1371807,0.011121583,0.00047433173,0.0027101361,0.0013809763],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.25951427,0.00044674645,0.0064482214,0.00019871384,0.000671678,0.00011355165,0.00041272904,0.0010601113,0.0001320845],"category_scores_gemma":[0.12550075,0.00023843518,0.003677899,0.00029395713,0.0013379377,0.00012631997,0.000106563784,0.0020624457,0.0000032872317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30635577,0.003782134,0.01180688,0.000107848864,0.0027935011,0.00033287925,0.00016892966,0.0000037849184,0.001302383,0.00016519261,0.04608409,0.6270966],"study_design_scores_gemma":[0.1633517,0.07909093,0.014646721,0.0007108624,0.0037164064,0.00008160368,0.0006156746,0.00037525344,0.0005299794,0.0019596473,0.7345742,0.0003470059],"about_ca_topic_score_codex":0.0000669713,"about_ca_topic_score_gemma":0.0008225264,"teacher_disagreement_score":0.68849015,"about_ca_system_score_codex":0.00049575267,"about_ca_system_score_gemma":0.009199196,"threshold_uncertainty_score":0.9964177},"labels":[],"label_agreement":null},{"id":"W2231307019","doi":"10.1200/jco.2006.24.18_suppl.7580","title":"A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Fludarabine; Mantle cell lymphoma; Chronic lymphocytic leukemia; Bendamustine; Follicular lymphoma; Internal medicine; Neutropenia; Gastroenterology; Macroglobulinemia; Oncology; Leukopenia; Lymphoma; Toxicity; Surgery; Leukemia; Chemotherapy; Multiple myeloma; Cyclophosphamide","score_opus":0.0743556789712439,"score_gpt":0.4604413004812773,"score_spread":0.3860856215100334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231307019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295765,0.0038753997,0.00022909621,0.00073574245,0.0006970928,0.0009862497,0.000011094439,0.000009631712,0.0004980391],"genre_scores_gemma":[0.99117196,0.003676751,0.0019626128,0.00031805012,0.0024264373,0.000022745813,0.0000063628245,0.000039005885,0.0003760786],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950858,0.00033306758,0.0031500862,0.00040353983,0.00057339296,0.00045414895],"domain_scores_gemma":[0.99180084,0.005053421,0.001794358,0.00030785953,0.0004988662,0.0005446344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004723805,0.00025526475,0.002306454,0.0002872231,0.000070691174,0.000019226287,0.00015984014,0.0007051959,0.000025466696],"category_scores_gemma":[0.0038466835,0.00019118458,0.00034931413,0.00015567895,0.00096065906,0.00015402655,0.00014061503,0.0005404495,0.0000017930477],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.47405687,0.0040950933,0.00060849363,0.0010833148,0.0008428428,0.0012381831,0.0002307059,0.000032701544,0.007958043,0.0002479271,0.008205729,0.5014001],"study_design_scores_gemma":[0.84020305,0.111719705,0.0040000784,0.00037414083,0.0007082366,0.0021098251,0.0000699586,0.011369084,0.0010545112,0.00055571366,0.027650323,0.00018535435],"about_ca_topic_score_codex":0.00027618153,"about_ca_topic_score_gemma":0.00008594412,"teacher_disagreement_score":0.50121474,"about_ca_system_score_codex":0.018416345,"about_ca_system_score_gemma":0.05863346,"threshold_uncertainty_score":0.9853518},"labels":[],"label_agreement":null},{"id":"W2231643541","doi":"10.1200/jco.2015.33.3_suppl.473","title":"Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FOLFIRINOX; Gemcitabine; Medicine; Pancreatic cancer; Internal medicine; Adenocarcinoma; Oncology; Regimen; Progression-free survival; Irinotecan; Surgery; Cancer; Chemotherapy","score_opus":0.07596397106750746,"score_gpt":0.4462083880287536,"score_spread":0.37024441696124616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231643541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975575,0.002486067,0.000108019725,0.0023360862,0.00017176018,0.00032131962,0.00000869915,0.0000063831676,0.0048058885],"genre_scores_gemma":[0.9891814,0.00023362119,0.008932214,0.00045348934,0.00048752318,0.000017903083,0.0000046749624,0.000017269527,0.0006719235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99459195,0.00076701865,0.0032896714,0.00029783198,0.0006575361,0.0003959881],"domain_scores_gemma":[0.9941016,0.0018257911,0.0016902621,0.00037168586,0.0013222652,0.0006884092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005714883,0.00019321882,0.004338961,0.0006671973,0.00001532391,0.000004535066,0.00023393829,0.00055589195,0.00067502767],"category_scores_gemma":[0.008118282,0.00013836025,0.00073504716,0.0009035943,0.00039525217,0.00015128758,0.000100252946,0.0014695675,0.00002140752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010881627,0.0017351191,0.98020387,0.000036253445,0.0019665323,0.00094996917,0.00037814822,0.000025089334,0.00025902188,0.000082623206,0.00042865015,0.003053076],"study_design_scores_gemma":[0.014540334,0.017680397,0.95943743,0.00008425665,0.0027759417,0.00022555304,0.00080374983,0.00052146614,0.000046619018,0.0017716918,0.0020082628,0.000104320476],"about_ca_topic_score_codex":0.000049610873,"about_ca_topic_score_gemma":0.0013808812,"teacher_disagreement_score":0.020766482,"about_ca_system_score_codex":0.00046160925,"about_ca_system_score_gemma":0.0029129433,"threshold_uncertainty_score":0.9718929},"labels":[],"label_agreement":null},{"id":"W2231692455","doi":"10.1200/jco.2006.24.18_suppl.8524","title":"Patients’ characteristics and outcomes of palliative care inpatient consults at a comprehensive cancer center","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Delirium; Constipation; Psychological intervention; Anxiety; Cancer; Family medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.24767516071549664,"score_gpt":0.5301755269413612,"score_spread":0.2825003662258645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231692455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959859,0.0015021866,0.00001123749,0.0007506828,0.00078423053,0.0001655106,0.00015028034,0.0000024706158,0.0006474898],"genre_scores_gemma":[0.9951056,0.0025847799,0.0010732957,0.0008943672,0.00023933573,0.0000021863077,0.000026596448,0.000009296624,0.00006451536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972632,0.00017083251,0.0020088977,0.00012556289,0.00029184076,0.00013967979],"domain_scores_gemma":[0.9933578,0.0019428087,0.0024540767,0.00009672871,0.0020011985,0.00014742887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017985897,0.0001292853,0.0016857919,0.00007715523,0.000019628764,0.0000016790374,0.000066108354,0.00020230569,0.000043962882],"category_scores_gemma":[0.0013782303,0.000086725064,0.0002680742,0.00005960943,0.00033166455,0.00003509187,0.0000668531,0.00031781258,0.0000016763018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021049285,0.0008442461,0.9793035,0.00012045471,0.00032815547,0.000046115598,0.0010456912,0.0000015655893,0.000049255752,0.00002142932,0.0011444577,0.014990212],"study_design_scores_gemma":[0.009037981,0.00431755,0.9287545,0.00040923283,0.00026901806,0.0000024871454,0.0004366341,0.0000062773856,0.0002321603,0.000019990102,0.05644791,0.00006627591],"about_ca_topic_score_codex":0.0000933469,"about_ca_topic_score_gemma":0.000087906265,"teacher_disagreement_score":0.05530345,"about_ca_system_score_codex":0.0001577563,"about_ca_system_score_gemma":0.00028518407,"threshold_uncertainty_score":0.35365456},"labels":[],"label_agreement":null},{"id":"W2231859057","doi":"10.1200/jco.2006.24.18_suppl.17047","title":"Effects of presurgical exercise training on exercise capacity in operable lung cancer: A pilot study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Lung cancer; VO2 max; Physical therapy; Surgery; Internal medicine; Heart rate; Blood pressure","score_opus":0.09363290924795424,"score_gpt":0.44396230979379053,"score_spread":0.3503294005458363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231859057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343467,0.0011953692,0.00009123605,0.0021649834,0.0010020119,0.0006073069,7.9028644e-7,0.000009929064,0.0014937245],"genre_scores_gemma":[0.99586374,0.0010306459,0.0016406516,0.00047211855,0.0007562129,0.000019185609,5.740959e-7,0.000022026117,0.0001948588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583435,0.0005945245,0.0024612357,0.0002478816,0.0005412005,0.00032082634],"domain_scores_gemma":[0.995221,0.0029875694,0.001108643,0.00016556436,0.00019412204,0.00032307536],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005221714,0.0001717203,0.002371736,0.00023570217,0.000037302125,0.000008926746,0.00021293516,0.00023393931,0.00006040899],"category_scores_gemma":[0.0034196912,0.000121117584,0.0002768628,0.00022109269,0.00021138851,0.00007922565,0.0000442287,0.0026436518,0.0000016994373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018453887,0.03617905,0.56587076,0.0005710516,0.0003622035,0.005519852,0.0013869505,0.0042594187,0.0016609229,0.00016062516,0.0052984757,0.3602768],"study_design_scores_gemma":[0.032930654,0.028446864,0.92104876,0.0030038143,0.0009776587,0.00012264942,0.0001916752,0.008986375,0.00020164896,0.00017963698,0.003719181,0.00019110722],"about_ca_topic_score_codex":0.0008028063,"about_ca_topic_score_gemma":0.00005735159,"teacher_disagreement_score":0.36008567,"about_ca_system_score_codex":0.00015468201,"about_ca_system_score_gemma":0.00082196493,"threshold_uncertainty_score":0.9996573},"labels":[],"label_agreement":null},{"id":"W2232001085","doi":"10.1200/jco.2007.25.18_suppl.5042","title":"Use of carbonic anhydrase IX (CAIX) expression and Von Hippel Lindau (VHL) gene mutation status to predict survival in renal cell carcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Renal cell carcinoma; Medicine; Cancer research; Mutation; Clear cell renal cell carcinoma; Proportional hazards model; Oncology; Gene; Internal medicine; Pathology; Biology; Genetics","score_opus":0.11369077192466372,"score_gpt":0.4046915844846835,"score_spread":0.2910008125600198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232001085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969789,0.00070711353,0.00028638967,0.00046736098,0.0006707763,0.00042427576,0.000012244997,0.000006511196,0.0004464299],"genre_scores_gemma":[0.9909276,0.00025531425,0.0078100613,0.00027139275,0.00059362536,0.0000028436743,0.00001192985,0.000027129066,0.00010013828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950732,0.0005811827,0.0029514814,0.00032182172,0.0006269215,0.00044539335],"domain_scores_gemma":[0.9940701,0.002799769,0.0015161284,0.00026925953,0.00045265057,0.0008920518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036439674,0.00021700532,0.0014920171,0.00044064183,0.000025899608,0.000009317038,0.0001046316,0.00045903592,0.000026204723],"category_scores_gemma":[0.0021992994,0.0001624214,0.00029426647,0.00024113884,0.00015123129,0.0001542376,0.00008956612,0.0008703966,0.0000035035748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017246494,0.0021889515,0.8667434,0.00008546541,0.00008597153,0.0062558046,0.000665031,0.00024184097,0.07342593,0.0000055550167,0.00025755644,0.032797996],"study_design_scores_gemma":[0.009956199,0.020408787,0.9106302,0.0001542896,0.00028063878,0.00030666468,0.00021213872,0.0001962213,0.056566656,0.000033565542,0.0011340186,0.00012061911],"about_ca_topic_score_codex":0.00033029405,"about_ca_topic_score_gemma":0.0003574596,"teacher_disagreement_score":0.043886803,"about_ca_system_score_codex":0.00046055403,"about_ca_system_score_gemma":0.001234743,"threshold_uncertainty_score":0.6623353},"labels":[],"label_agreement":null},{"id":"W2232080041","doi":"10.1200/jco.2007.25.18_suppl.10521","title":"Ki-67 is a Luminal B marker that identifies a high-risk subgroup in hormone receptor positive and node negative breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Breast cancer; Immunohistochemistry; Ki-67; Medicine; Tissue microarray; Pathology; Cancer; Population; Hormone receptor; Proliferation Marker; Internal medicine; Lymph node; Oncology","score_opus":0.02818813654408817,"score_gpt":0.3772282114124573,"score_spread":0.34904007486836913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232080041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908512,0.0026563655,0.000100597994,0.0051010773,0.0007948855,0.000120970726,0.00013397349,0.0000025649224,0.00023832699],"genre_scores_gemma":[0.98687524,0.0093384925,0.00107786,0.0012987612,0.0012428793,0.0000084202065,0.0000060750012,0.000017764905,0.00013448221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997744,0.00034414942,0.0010629074,0.00032205074,0.00021439264,0.00031247953],"domain_scores_gemma":[0.99749875,0.00069776626,0.001154096,0.00013577129,0.0003180506,0.00019555086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018170025,0.00020195768,0.0007927465,0.00009125763,0.00006749664,0.000014192922,0.00014944641,0.00038145043,0.000053687203],"category_scores_gemma":[0.0004799987,0.0001559617,0.00022918264,0.000103859085,0.00044935633,0.000019734962,0.00014609235,0.00050207495,0.0000041763096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014582724,0.00067879504,0.9043533,0.000009057381,0.0010094465,0.00016001219,0.00046327207,0.0000023223483,0.0028539435,0.00000839978,0.007376306,0.06850238],"study_design_scores_gemma":[0.0055119856,0.001643457,0.98644817,0.00005812632,0.00021207838,0.00019829758,0.00074591907,0.0000018439191,0.002273811,0.00014779196,0.0026015167,0.00015703222],"about_ca_topic_score_codex":0.0013535442,"about_ca_topic_score_gemma":0.0020488277,"teacher_disagreement_score":0.0820948,"about_ca_system_score_codex":0.0001352796,"about_ca_system_score_gemma":0.0003235213,"threshold_uncertainty_score":0.6359933},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2232522393","doi":"10.1200/jco.2013.31.31_suppl.147","title":"Patient-reported symptoms obtained through telephonic nursing services in an oncology disease management program.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Logistic regression; Physical therapy; Cancer","score_opus":0.08419595142694755,"score_gpt":0.4849789391208091,"score_spread":0.40078298769386156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232522393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97203183,0.0009696301,0.000014255291,0.013087933,0.0014113841,0.0009330014,7.730601e-7,0.000034519882,0.011516649],"genre_scores_gemma":[0.9867991,0.0010656137,0.006447276,0.0048272777,0.00065622793,0.00007846122,0.000005091858,0.000022479291,0.000098443306],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954405,0.00047372965,0.0029183999,0.00031269013,0.00039964617,0.0004550583],"domain_scores_gemma":[0.9965311,0.00052000355,0.0015507784,0.00028377766,0.00048733567,0.0006269641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011147344,0.00019845809,0.0017689695,0.00015393982,0.000058722588,0.000016473039,0.00017207142,0.0002940795,0.00015478532],"category_scores_gemma":[0.00034689347,0.00013881634,0.00033257774,0.00026502836,0.00027342426,0.00033038354,0.0000684539,0.00081567006,0.000026395574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00298759,0.008944461,0.124130666,0.00010878853,0.00042476968,0.0026843038,0.000899799,0.000009116414,0.000024505198,0.00008969895,0.0014684504,0.85822785],"study_design_scores_gemma":[0.010670779,0.035004653,0.855541,0.0007232902,0.0006179927,0.0001762731,0.0019122536,0.000318101,0.0000074654795,0.0015870669,0.09327781,0.00016332734],"about_ca_topic_score_codex":0.00005299357,"about_ca_topic_score_gemma":0.00009777916,"teacher_disagreement_score":0.85806453,"about_ca_system_score_codex":0.0005205113,"about_ca_system_score_gemma":0.0010984945,"threshold_uncertainty_score":0.5660766},"labels":[],"label_agreement":null},{"id":"W2232535406","doi":"10.1200/jco.2006.24.18_suppl.14072","title":"A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Chemotherapy; Doxorubicin; Gastroenterology; Neutropenia; Toxicity; Cirrhosis; Oncology","score_opus":0.04230621950700921,"score_gpt":0.39943087208564215,"score_spread":0.35712465257863296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232535406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768115,0.00003894963,0.00028247506,0.00043198367,0.00030044094,0.010483315,0.0000030101814,0.0000036181307,0.0007750607],"genre_scores_gemma":[0.995258,0.000013310435,0.0026873082,0.00013775412,0.00037692065,0.001323089,0.000011439014,0.000022666216,0.00016954548],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99592143,0.00064329884,0.0025265499,0.0003011621,0.00032239474,0.00028516594],"domain_scores_gemma":[0.99716014,0.00018282978,0.0019658976,0.00026526826,0.00030920838,0.000116630756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028668446,0.00018657949,0.0010723331,0.00019825362,0.000024913159,0.000005441305,0.00027161418,0.00052000664,0.000016861766],"category_scores_gemma":[0.0007093946,0.00014962043,0.00027335362,0.00021227889,0.00015770727,0.000017969473,0.00009522339,0.0005172908,0.0000013068773],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32719043,0.037821833,0.0392853,0.00009026946,0.00013011692,0.00082106557,0.00008430581,0.00028358863,0.553099,0.00039621163,0.0007410691,0.040056843],"study_design_scores_gemma":[0.5280418,0.21736336,0.007618191,0.00012235437,0.00008786377,0.00010584573,0.00013302184,0.0010138989,0.20937328,0.0012660793,0.03452719,0.00034713568],"about_ca_topic_score_codex":0.00006362965,"about_ca_topic_score_gemma":0.0002799678,"teacher_disagreement_score":0.3437257,"about_ca_system_score_codex":0.000085821506,"about_ca_system_score_gemma":0.0011263818,"threshold_uncertainty_score":0.6101344},"labels":[],"label_agreement":null},{"id":"W2232585277","doi":"10.1200/jco.2015.61.2259","title":"Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); AstraZeneca (Canada)","funders":"University of Texas MD Anderson Cancer Center; Ipsen; Swiss Cancer Research Foundation; Fondazione Salvatore Maugeri; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Pfizer; Oncosuisse; Centre Hospitalier Universitaire Vaudois; National Cancer Institute; Sahlgrenska Universitetssjukhuset","keywords":"Exemestane; Triptorelin; Medicine; Breast cancer; Tamoxifen; Internal medicine; Estrone; Oncology; Population; Gynecology; Endocrinology; Urology; Cancer; Estrogen; Luteinizing hormone; Hormone; Gonadotropin-releasing hormone","score_opus":0.03578145893804555,"score_gpt":0.3566345712045894,"score_spread":0.32085311226654384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232585277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457055,0.0011644841,0.00023193768,0.0024402656,0.00071740034,0.0007755778,0.000028307028,0.000003457424,0.00006804311],"genre_scores_gemma":[0.997078,0.0014405432,0.00014524939,0.00024413822,0.0008960895,0.00006682903,0.0000050265303,0.00002590082,0.00009819224],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99525195,0.0018424707,0.001760034,0.00032920195,0.00040876,0.00040757275],"domain_scores_gemma":[0.9964704,0.0012440721,0.0015580406,0.00029828885,0.00027095145,0.0001582602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052571106,0.0002405361,0.00093407504,0.00007238519,0.00007037997,0.00001459319,0.00046428823,0.0005753659,0.00004726376],"category_scores_gemma":[0.0010739018,0.00009637461,0.0001611163,0.00024860227,0.00030700275,0.000030097222,0.000096187025,0.00079739984,0.0000019807144],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74273795,0.0021618868,0.016275661,0.000014421104,0.0006993966,0.00018795818,0.0010505029,0.00017401873,0.116573654,0.000016710817,0.0015021081,0.118605755],"study_design_scores_gemma":[0.1230089,0.080201976,0.7849019,0.0004750421,0.00038133122,0.00039793085,0.0012991052,0.000043349723,0.0038859057,0.00009670793,0.0049295924,0.0003782696],"about_ca_topic_score_codex":0.00011146705,"about_ca_topic_score_gemma":0.00035639535,"teacher_disagreement_score":0.7686262,"about_ca_system_score_codex":0.00021695493,"about_ca_system_score_gemma":0.0016674512,"threshold_uncertainty_score":0.44377488},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2234766563","doi":"10.1200/jco.2015.33.7_suppl.79","title":"Quality of life (QOL) and acute toxicities of a pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiotherapy; Prostate; Cryotherapy; Radiation therapy; Urology; Radiology; Surgery; Cancer; Internal medicine","score_opus":0.10530822959950775,"score_gpt":0.42491665239463094,"score_spread":0.3196084227951232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234766563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962679,0.0019839366,0.00016962204,0.00039655712,0.00026535545,0.00084132294,0.000051732106,0.0000028146976,0.000020716101],"genre_scores_gemma":[0.99544793,0.0025589217,0.0012121294,0.00062844134,0.0000898788,0.000033530796,0.0000028348632,0.00001906452,0.000007235481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951507,0.0009739503,0.0028830776,0.00025173917,0.0005256009,0.00021492166],"domain_scores_gemma":[0.9942001,0.0015851263,0.002755946,0.00021198559,0.0008930033,0.00035384452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027666683,0.0002096617,0.0023686748,0.00015234726,0.000011483895,0.0000048952056,0.000108662105,0.00012513406,0.000016207023],"category_scores_gemma":[0.0006130855,0.00013385573,0.00013001912,0.00016475009,0.00058325235,0.00015599527,0.00004195718,0.0004893485,3.0455692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13716651,0.017694898,0.81441927,0.00006158313,0.00089244545,0.00017109903,0.0018144792,0.00002603737,0.00004969338,0.000019317353,0.000052424723,0.027632225],"study_design_scores_gemma":[0.05073963,0.2038548,0.74381,0.00031828915,0.00016362205,0.000008583543,0.0005341283,0.000006728586,0.0002537111,0.00018728706,0.000036256773,0.00008698209],"about_ca_topic_score_codex":0.00032598188,"about_ca_topic_score_gemma":0.0002805025,"teacher_disagreement_score":0.1861599,"about_ca_system_score_codex":0.00018583851,"about_ca_system_score_gemma":0.0012595456,"threshold_uncertainty_score":0.54584783},"labels":[],"label_agreement":null},{"id":"W2235229882","doi":"10.1200/jco.2006.24.18_suppl.6090","title":"Systemic therapy (ST) in cancer patients ≥ 80 years of age: A Manitoba population-based assessment","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Cancer; Cancer registry; Cohort; Internal medicine; Population; Breast cancer; Palliative care; Colorectal cancer; Lung cancer; Retrospective cohort study","score_opus":0.09107905903535152,"score_gpt":0.4594505018145112,"score_spread":0.3683714427791597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2235229882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703974,0.0004656065,0.000022707203,0.00060099846,0.0009816695,0.0002351395,0.000009762365,0.0000033564556,0.0006410111],"genre_scores_gemma":[0.9966625,0.00033991807,0.0009228925,0.0015005855,0.0005028288,0.000005924356,0.00001895303,0.000011399581,0.000035029647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996972,0.00029466758,0.0021366682,0.000120077675,0.00033652122,0.00014001461],"domain_scores_gemma":[0.9972594,0.0008069641,0.0014775584,0.000116115654,0.00024152374,0.000098460885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154242,0.00008524869,0.0010475903,0.00015405843,0.000010814462,0.0000034256639,0.00010087918,0.00021368821,0.0001673078],"category_scores_gemma":[0.00023691688,0.00006748253,0.0002755593,0.00011407227,0.000054110187,0.00006094875,0.000010163419,0.00052002113,0.0000011861279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014170519,0.0012423672,0.8976608,0.000040256637,0.00006690522,0.00015387649,0.000015209995,0.0004309453,0.00013206716,0.000012730951,0.001079736,0.09774806],"study_design_scores_gemma":[0.013391735,0.003520812,0.9759578,0.00017029644,0.000055275745,0.000009145766,0.00002810692,0.0001860226,0.00001530749,0.00005652794,0.006552056,0.000056888188],"about_ca_topic_score_codex":0.0016338488,"about_ca_topic_score_gemma":0.0012768905,"teacher_disagreement_score":0.09769118,"about_ca_system_score_codex":0.00060790265,"about_ca_system_score_gemma":0.0019442814,"threshold_uncertainty_score":0.34490716},"labels":[],"label_agreement":null},{"id":"W2235582661","doi":"10.1200/jco.2007.25.18_suppl.5084","title":"Combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel in patients with cisplatin-refractory or relapsed germ cell tumors (gct)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oxaliplatin; Gemcitabine; Cisplatin; Chemotherapy; Refractory (planetary science); Internal medicine; Paclitaxel; Oncology; Progressive disease; Gastroenterology; Toxicity; Progression-free survival; Urology; Surgery; Cancer; Colorectal cancer","score_opus":0.04387084198947501,"score_gpt":0.4158554860321698,"score_spread":0.3719846440426948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2235582661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995159,0.00010325987,0.00005052941,0.0012834932,0.00029881997,0.00039980974,0.0000020603222,0.000007545131,0.0026955302],"genre_scores_gemma":[0.99468964,0.00015797385,0.0023968911,0.0018499506,0.00026751606,0.0000032189735,0.0000073635883,0.000023833054,0.0006036176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975402,0.00018662322,0.0014928959,0.0001962864,0.00033104888,0.00025296723],"domain_scores_gemma":[0.99555063,0.0021833389,0.0015427704,0.00010902714,0.0003222962,0.00029191526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019739766,0.00017319006,0.0010924037,0.00020406806,0.000031625164,0.000005754867,0.00006732218,0.0002702351,0.0001985521],"category_scores_gemma":[0.0003103958,0.00009792395,0.00009117348,0.00020475409,0.00020493694,0.00013196068,0.000013761,0.0008310713,0.0000029108464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06531159,0.0063496735,0.8874862,0.000033687524,0.0001654366,0.00058076525,0.00026296228,0.00000249271,0.000099123674,0.000018706864,0.00078339403,0.038905945],"study_design_scores_gemma":[0.07307945,0.0603787,0.86036974,0.000090341375,0.00019586785,0.00007265876,0.000091137204,0.000012915798,0.00009539003,0.00004072351,0.0054706815,0.00010241265],"about_ca_topic_score_codex":0.00002292951,"about_ca_topic_score_gemma":0.00017545217,"teacher_disagreement_score":0.054029025,"about_ca_system_score_codex":0.00023053201,"about_ca_system_score_gemma":0.0008308842,"threshold_uncertainty_score":0.39932227},"labels":[],"label_agreement":null},{"id":"W2236205422","doi":"10.1200/jco.2006.24.18_suppl.6091","title":"Gemcitabine-related thrombocytosis: Does it increase the risk of thrombosis?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thrombocytosis; Medicine; Gemcitabine; Internal medicine; Gastroenterology; Antimetabolite; Chemotherapy; Malignancy; Cancer; Surgery; Platelet","score_opus":0.08832522565417754,"score_gpt":0.4604334897423903,"score_spread":0.37210826408821274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236205422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783499,0.0005510466,0.000025614578,0.0117951585,0.00050361187,0.0002845927,0.000016087524,0.000008959018,0.008465006],"genre_scores_gemma":[0.9951886,0.0018868396,0.0012054377,0.0005190871,0.0007088515,0.000004900535,0.0000051190987,0.00001638611,0.00046479277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950629,0.0011230186,0.0027186424,0.00017293527,0.0006204041,0.0003020976],"domain_scores_gemma":[0.9916318,0.00486336,0.002234439,0.0003338929,0.0006048478,0.0003316297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004452507,0.00015658763,0.0015541157,0.00012181557,0.00008098942,0.000008816142,0.00025972957,0.00034859992,0.0005021227],"category_scores_gemma":[0.006913588,0.00006680745,0.0008348372,0.00021166992,0.0005702791,0.0001024766,0.00007922748,0.001205469,0.00004449963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038433436,0.0052114483,0.9518306,0.000038505525,0.0026916778,0.0005042374,0.00008972331,0.000025348325,0.00069277803,0.00030674908,0.011953561,0.022812014],"study_design_scores_gemma":[0.01265427,0.006351617,0.9657939,0.00010469155,0.0012020317,0.0001523143,0.0001818302,0.00013351643,0.00040075602,0.0022589487,0.010698625,0.00006746771],"about_ca_topic_score_codex":0.0007051688,"about_ca_topic_score_gemma":0.00033454527,"teacher_disagreement_score":0.022744546,"about_ca_system_score_codex":0.00010964794,"about_ca_system_score_gemma":0.0010769871,"threshold_uncertainty_score":0.827671},"labels":[],"label_agreement":null},{"id":"W2236644222","doi":"10.1200/jco.2015.33.15_suppl.9612","title":"The conversion ratio (CR) for opioid rotation (OR) from strong opioids to transdermal fentanyl (TDF) in cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Opioid; Fentanyl; Cancer pain; Constipation; Cancer; Anesthesia; Morphine; Internal medicine","score_opus":0.2160608326753055,"score_gpt":0.5227664102218722,"score_spread":0.3067055775465667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236644222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778892,0.0004127674,0.00037290264,0.016313525,0.0040298714,0.0006957325,0.000024306039,0.000004305241,0.00025742655],"genre_scores_gemma":[0.9929501,0.0005994384,0.0008217176,0.0035291247,0.0016119875,0.000050351184,0.000020986838,0.000012263063,0.00040406923],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786675,0.00024283293,0.0013000234,0.00014410137,0.0002385761,0.00020771513],"domain_scores_gemma":[0.9965899,0.0019762183,0.0005802596,0.0000766864,0.00042477087,0.00035216415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010871527,0.00010448464,0.0006907385,0.000068130576,0.000047005786,0.000008890277,0.00011978947,0.00019547607,0.00014466116],"category_scores_gemma":[0.00075263594,0.00006135674,0.00020347488,0.000095861236,0.000078249344,0.000103952865,0.00001832335,0.0003865302,0.000007474757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096694775,0.004414653,0.54574096,0.000029739202,0.0006161197,0.00012985196,0.0021122517,0.0002837035,0.00052250404,0.000067744,0.08134861,0.26803905],"study_design_scores_gemma":[0.07249316,0.049860436,0.42170095,0.000106568645,0.0007916085,0.000012848564,0.0009393625,0.0009994435,0.00092423975,0.0002767025,0.45173717,0.0001574949],"about_ca_topic_score_codex":0.00019943225,"about_ca_topic_score_gemma":0.001264036,"teacher_disagreement_score":0.37038857,"about_ca_system_score_codex":0.0005103913,"about_ca_system_score_gemma":0.0020266634,"threshold_uncertainty_score":0.35952136},"labels":[],"label_agreement":null},{"id":"W2237789671","doi":"10.1200/jco.2009.27.15_suppl.e15126","title":"Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory colorectal carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Capecitabine; Medicine; Prednisone; Internal medicine; Interim analysis; Colorectal cancer; Gastroenterology; Clinical endpoint; Oncology; Randomized controlled trial; Cancer; Surgery","score_opus":0.05244632566660147,"score_gpt":0.4197010216440323,"score_spread":0.3672546959774308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2237789671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859463,0.0038914566,0.000013266216,0.0033559399,0.0014452979,0.0008493443,0.0000058463515,0.0000063738353,0.004486176],"genre_scores_gemma":[0.9955995,0.002535526,0.00074057706,0.0002834791,0.0007175856,0.000016544569,0.000003888379,0.000012321597,0.000090569796],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955978,0.0005688355,0.00290119,0.00025764547,0.00040370377,0.0002708643],"domain_scores_gemma":[0.995207,0.0024074041,0.0015513329,0.00015946817,0.00037956223,0.00029521837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002381398,0.0002286177,0.003728413,0.00021663868,0.00004548978,0.0000045950646,0.00010790648,0.0003308415,0.00007691893],"category_scores_gemma":[0.004591714,0.00015440313,0.00067162747,0.00018794507,0.00041802853,0.000093137474,0.000059274287,0.00068681815,8.677069e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9111722,0.010218681,0.0013419433,0.000018369426,0.00065291894,0.0011220681,0.0002648354,0.0000020169628,0.0007262351,0.000081179394,0.00035829723,0.07404122],"study_design_scores_gemma":[0.83886725,0.13481057,0.022469504,0.00006692152,0.00086424226,0.000082759434,0.00007654293,0.000105560925,0.00029942984,0.00015616274,0.002092795,0.00010826911],"about_ca_topic_score_codex":0.000059967995,"about_ca_topic_score_gemma":0.00009125382,"teacher_disagreement_score":0.124591894,"about_ca_system_score_codex":0.00023843924,"about_ca_system_score_gemma":0.00094441406,"threshold_uncertainty_score":0.6296377},"labels":[],"label_agreement":null},{"id":"W2238983210","doi":"10.1200/jco.2014.32.4_suppl.298","title":"Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Mount Sinai Hospital; University of British Columbia","funders":"","keywords":"Medicine; Cisplatin; Regimen; Chemotherapy; Cystectomy; Multimodal therapy; Internal medicine; Chemotherapy regimen; Oncology; Cancer; Bladder cancer","score_opus":0.11481107534141441,"score_gpt":0.46490110204930074,"score_spread":0.35009002670788636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2238983210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205047,0.00048048134,0.00040454246,0.0026295832,0.0012249494,0.0006312647,0.00017570429,0.0000046343785,0.0023983542],"genre_scores_gemma":[0.99190784,0.00008524605,0.001902311,0.0052366764,0.0007761944,0.000024889327,0.0000126289815,0.000013943137,0.000040295625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973165,0.0004485471,0.0013487018,0.00020389898,0.0004908726,0.0001914763],"domain_scores_gemma":[0.9945447,0.0012990485,0.001220601,0.0002150072,0.002416874,0.00030377062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006143708,0.00016706235,0.0011045686,0.00006366795,0.0000772554,0.000005095397,0.00017536797,0.00020930162,0.000104434446],"category_scores_gemma":[0.0023551255,0.00008141626,0.00031097286,0.000117924814,0.00033822632,0.000085126965,0.000054457978,0.00057057326,0.00000789285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008905141,0.0015130725,0.88211006,0.00011458697,0.0013176422,0.00003616923,0.005273629,0.00008522119,0.00009492281,0.00009385973,0.00071870664,0.09973702],"study_design_scores_gemma":[0.016166953,0.015606948,0.95302474,0.00014596715,0.0006416827,0.0000058050828,0.0017248297,0.0000029862235,0.0005947184,0.000026835582,0.011959291,0.000099261546],"about_ca_topic_score_codex":0.0002636067,"about_ca_topic_score_gemma":0.0014390635,"teacher_disagreement_score":0.099637754,"about_ca_system_score_codex":0.00032313628,"about_ca_system_score_gemma":0.0038356679,"threshold_uncertainty_score":0.680431},"labels":[],"label_agreement":null},{"id":"W2239598309","doi":"10.1200/jco.2007.25.18_suppl.9011","title":"Angiotensin-converting enzyme gene polymorphism (ACEGP) and cancer cachexia (CC): Is there a link?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University; McGill University Health Centre","funders":"","keywords":"Medicine; Lean body mass; Angiotensin-converting enzyme; Internal medicine; Endocrinology; Insulin resistance; Skeletal muscle; Cachexia; Allele; Cancer; Insulin; Biology; Gene; Genetics","score_opus":0.19409400277006542,"score_gpt":0.5127702332792153,"score_spread":0.31867623050914995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2239598309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84113514,0.018536927,0.0003338659,0.13672239,0.0016591521,0.00014643813,0.0000026867651,0.00001504965,0.0014483623],"genre_scores_gemma":[0.9247967,0.0059619243,0.009290848,0.053860404,0.0054575554,9.518247e-7,7.7229816e-7,0.000022423614,0.0006084221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690694,0.000151042,0.00214534,0.00018021095,0.00026876747,0.00034772122],"domain_scores_gemma":[0.9963426,0.0011381746,0.001276914,0.00013062284,0.00042206957,0.00068963494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044089705,0.00012487937,0.0011128985,0.00014981294,0.0000761919,0.0000071538075,0.0000813052,0.00047328303,0.00029332415],"category_scores_gemma":[0.0009283225,0.00009325376,0.00028744657,0.00012383671,0.00018444241,0.000066017376,0.0000386934,0.0012819112,0.0000135878745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047529507,0.0017094829,0.2619343,0.0001454644,0.00049568113,0.0029529277,0.0007336846,5.7129716e-7,0.0035723282,0.00015375612,0.027326813,0.696222],"study_design_scores_gemma":[0.023208514,0.004065909,0.46425787,0.0004937088,0.00046745388,0.0023370902,0.00021589604,0.00019882739,0.0023861034,0.00056107715,0.50163496,0.00017256763],"about_ca_topic_score_codex":0.00009415691,"about_ca_topic_score_gemma":0.00005222425,"teacher_disagreement_score":0.69604945,"about_ca_system_score_codex":0.00013739377,"about_ca_system_score_gemma":0.00093973876,"threshold_uncertainty_score":0.55693376},"labels":[],"label_agreement":null},{"id":"W2240235803","doi":"10.1200/jco.2009.27.15_suppl.5591","title":"A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Aflibercept; Leiomyosarcoma; Adverse effect; Bevacizumab; Internal medicine; Surgery; Phases of clinical research; Sarcoma; Gastroenterology; Oncology; Chemotherapy; Pathology","score_opus":0.10955290086047274,"score_gpt":0.47449794559071623,"score_spread":0.3649450447302435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240235803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933003,0.0005553959,0.000026896718,0.003136035,0.0007758013,0.0020754016,0.000008318389,0.000009024218,0.000112786256],"genre_scores_gemma":[0.9985915,0.00011441313,0.00047592333,0.00045283913,0.0002119342,0.000017791706,0.0000016275749,0.000018329814,0.000115645154],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99190617,0.0017417822,0.004775883,0.00036656036,0.0008243122,0.0003853036],"domain_scores_gemma":[0.9938894,0.0014018528,0.003426144,0.00050342234,0.00045855276,0.0003206284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044051767,0.00029589498,0.0032234532,0.0002642383,0.00010566559,0.000006771482,0.0005652063,0.00020055317,0.00020717051],"category_scores_gemma":[0.004602668,0.00016181046,0.00069325673,0.0005737393,0.00029711012,0.000120674966,0.00019237516,0.0013038915,0.0000011682125],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012521105,0.5747164,0.040488843,0.000067143985,0.0010644734,0.00371091,0.009209121,0.00002080413,0.00034420818,0.000023740004,0.0006781207,0.3571551],"study_design_scores_gemma":[0.11465892,0.6549279,0.21487072,0.00019677736,0.0016397517,0.00026734243,0.010343699,0.000086937136,0.000085983855,0.0001642615,0.0025853924,0.00017230982],"about_ca_topic_score_codex":0.000028122386,"about_ca_topic_score_gemma":0.00039808577,"teacher_disagreement_score":0.35698283,"about_ca_system_score_codex":0.000116636176,"about_ca_system_score_gemma":0.0011290491,"threshold_uncertainty_score":0.65984386},"labels":[],"label_agreement":null},{"id":"W2240250507","doi":"10.1200/jco.2014.32.15_suppl.10004","title":"Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Rhabdomyosarcoma; Clinical endpoint; Vincristine; Cyclophosphamide; Surgery; Soft tissue sarcoma; Confidence interval; Sarcoma; Internal medicine; Urology; Randomized controlled trial; Chemotherapy; Soft tissue; Pathology","score_opus":0.06352236513762528,"score_gpt":0.4101846896637332,"score_spread":0.34666232452610796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240250507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638324,0.0028684968,0.0024135564,0.020730965,0.0071526887,0.0013830212,0.00008941848,0.000061631166,0.0014678417],"genre_scores_gemma":[0.97577554,0.0012342965,0.011240195,0.0044719274,0.0068518077,0.00012031868,0.00013106603,0.00008923359,0.00008558757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912409,0.0016332247,0.0049074264,0.00074455986,0.00070028653,0.00077360624],"domain_scores_gemma":[0.95442796,0.03748915,0.005522411,0.0010705105,0.00064116344,0.0008487984],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0066185957,0.0005600874,0.0035879556,0.00016339622,0.00029136092,0.00004465601,0.0008339017,0.0009468247,0.00023888565],"category_scores_gemma":[0.02064137,0.00035498897,0.0014160358,0.00020599578,0.0006467641,0.00014902657,0.00031939562,0.0024050502,0.000068559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014456445,0.0042934767,0.47404408,0.000015900461,0.0017409655,0.0023506505,0.00016100184,0.000008760754,0.000019536914,0.00010228932,0.038278505,0.46452838],"study_design_scores_gemma":[0.028378729,0.024488088,0.60055655,0.00009345071,0.0019696094,0.0018360424,0.00013018431,0.00011520849,0.00007887186,0.00071984256,0.3414116,0.00022185162],"about_ca_topic_score_codex":0.0013489854,"about_ca_topic_score_gemma":0.0023300576,"teacher_disagreement_score":0.46430653,"about_ca_system_score_codex":0.0009511446,"about_ca_system_score_gemma":0.0021128252,"threshold_uncertainty_score":0.99989647},"labels":[],"label_agreement":null},{"id":"W2240303510","doi":"10.1200/jco.2009.27.15_suppl.9502","title":"A survey of U.S. and Canadian oncologists’ attitudes toward the cost, cost-effectiveness (CE), and reimbursement of cancer drugs","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Health care; Cancer drugs; Cost sharing; Cancer; Nursing; Internal medicine","score_opus":0.25633309607712723,"score_gpt":0.4537598952257487,"score_spread":0.1974267991486215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240303510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778886,0.011578982,0.000096560885,0.004894144,0.000733221,0.00035771372,0.00014177103,0.0000016431629,0.0043073646],"genre_scores_gemma":[0.98887473,0.009579936,0.0001214029,0.0012041056,0.00017224367,0.0000062059726,0.0000011810761,0.0000075455846,0.00003266938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972633,0.0001987657,0.0020593358,0.00019312439,0.000047048674,0.00023838547],"domain_scores_gemma":[0.9950229,0.0017496537,0.0025407383,0.00015119917,0.00025788732,0.00027762647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007845746,0.00012343076,0.0015210751,0.00014436942,0.000044393557,0.000015309215,0.00024235758,0.00027171453,0.000075478965],"category_scores_gemma":[0.0022294675,0.00009649683,0.00015944954,0.0001127517,0.00043911804,0.00014937214,0.00003808309,0.00041314663,0.0000019816434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005348126,0.00018483901,0.7718412,0.000023918632,0.00017374947,0.000006877657,0.00022262374,0.00006697552,0.0000025997276,0.0042963144,0.00072589656,0.22192013],"study_design_scores_gemma":[0.00191812,0.0022452031,0.9665383,0.000049484595,0.000033745888,0.0000060322623,0.00004872144,0.00007883342,0.000013556141,0.003169726,0.02580056,0.00009772718],"about_ca_topic_score_codex":0.059463687,"about_ca_topic_score_gemma":0.054049395,"teacher_disagreement_score":0.22182241,"about_ca_system_score_codex":0.0003113249,"about_ca_system_score_gemma":0.0011552323,"threshold_uncertainty_score":0.9632117},"labels":[],"label_agreement":null},{"id":"W2240321911","doi":"10.1200/jco.2009.27.15_suppl.6550","title":"Trends in the application of dynamic allocation methods in multiarm cancer clinical trials","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Clinical trial; Randomization; Oncology; Medical physics; Internal medicine","score_opus":0.8598207331158435,"score_gpt":0.8010714738024179,"score_spread":0.05874925931342556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240321911","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13214532,0.0006525447,0.81858057,0.04042479,0.0045098583,0.0014088728,0.000026950484,0.000021833599,0.0022292908],"genre_scores_gemma":[0.3118966,0.00079521973,0.6850563,0.0013826905,0.0008073681,0.000022733831,8.1486087e-7,0.000013135772,0.000025083025],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8994354,0.07195773,0.026762078,0.0005441711,0.00085596915,0.000444671],"domain_scores_gemma":[0.5105754,0.4768828,0.011245002,0.00058744283,0.00049389794,0.00021548767],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.29416162,0.00020743886,0.0047952393,0.00037515984,0.000021505872,0.000011313243,0.00084833964,0.0010530093,0.000115777795],"category_scores_gemma":[0.5544535,0.00012530202,0.0012003041,0.0007977036,0.00036689115,0.00010070848,0.00004687934,0.0023627093,0.000002803028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018977524,0.0034274051,0.003838375,0.000017224318,0.00009807669,0.000020275571,0.00012462979,0.000029775434,0.00018209244,0.012235125,0.000640423,0.9774889],"study_design_scores_gemma":[0.008951329,0.004201981,0.30941558,0.00012381683,0.00044792716,0.000014844693,0.00013752092,0.0061566355,0.0000486549,0.6668636,0.0034824715,0.00015560874],"about_ca_topic_score_codex":0.00003752086,"about_ca_topic_score_gemma":0.0002383119,"teacher_disagreement_score":0.97733325,"about_ca_system_score_codex":0.00016904663,"about_ca_system_score_gemma":0.0006328181,"threshold_uncertainty_score":0.9999389},"labels":[],"label_agreement":null},{"id":"W2240337674","doi":"10.1200/jco.2005.23.16_suppl.6071","title":"Change in symptoms after paracentesis for symptomatic malignant ascites","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Paracentesis; Ascites; Quality of life (healthcare); Malignancy; Palliative care; Internal medicine; Physical therapy; Surgery","score_opus":0.16486953947158686,"score_gpt":0.5107921108826589,"score_spread":0.34592257141107197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240337674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779061,0.0013977111,0.00003232259,0.01952876,0.00035354507,0.00041159775,0.000003158044,0.000005658129,0.00036112487],"genre_scores_gemma":[0.9884512,0.00091185584,0.00369174,0.0043383045,0.0020565928,0.000044885004,0.0000014962848,0.000016127668,0.00048783238],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99707216,0.00022066367,0.0018802873,0.0001533777,0.0003303715,0.00034313597],"domain_scores_gemma":[0.996429,0.0022497314,0.00054921716,0.00015444857,0.00030011425,0.0003174632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036244334,0.00011021293,0.0011443015,0.00026293317,0.000017104914,0.0000091274605,0.00014162116,0.00031849564,0.0002809828],"category_scores_gemma":[0.0025807023,0.00007136778,0.00045846496,0.00016169903,0.00010856079,0.0001672726,0.000041044255,0.00057651545,0.00006232104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005340599,0.0028695622,0.42891908,0.00012016918,0.00027370214,0.00065309723,0.00025799614,0.0000022240822,0.00020208309,0.00006602701,0.002393621,0.55890185],"study_design_scores_gemma":[0.009135763,0.01169867,0.8839691,0.00035675796,0.0001811568,0.00029191314,0.000047641206,0.0015288547,0.0001336911,0.00010172992,0.09246098,0.00009373703],"about_ca_topic_score_codex":0.000012358584,"about_ca_topic_score_gemma":0.00010462596,"teacher_disagreement_score":0.5588081,"about_ca_system_score_codex":0.00016140482,"about_ca_system_score_gemma":0.0005018111,"threshold_uncertainty_score":0.3089528},"labels":[],"label_agreement":null},{"id":"W2240377554","doi":"10.1200/jco.2009.27.15_suppl.8075","title":"The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Queen's University; University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Cohort; Clinical trial; Carboplatin; Chemotherapy","score_opus":0.2640487010725791,"score_gpt":0.5739680460484807,"score_spread":0.3099193449759016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240377554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784069,0.0031337072,0.000059291848,0.01179284,0.004412887,0.0012843607,0.00027048585,0.000003835523,0.0006357088],"genre_scores_gemma":[0.9860163,0.0077526057,0.0011692081,0.0028744692,0.0019930317,0.000029276676,0.000018787074,0.00002507325,0.000121246216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9630474,0.016185576,0.018269353,0.0005673956,0.0012775105,0.0006527573],"domain_scores_gemma":[0.90383035,0.08322732,0.010962643,0.0004316835,0.00083201414,0.0007159722],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1214484,0.00040576476,0.007863558,0.00027547672,0.000057189176,0.000012972444,0.0004395639,0.00043225155,0.00021827458],"category_scores_gemma":[0.09140673,0.00022610393,0.0029441412,0.00039290753,0.0003624173,0.00015183855,0.00006125264,0.0021262618,9.096186e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08308302,0.013443919,0.4753732,0.00010264173,0.004306896,0.001635357,0.00006581192,0.008439594,0.00026153759,0.00065005023,0.038650062,0.3739879],"study_design_scores_gemma":[0.068048015,0.02037778,0.8940223,0.00073759345,0.0011192429,0.00003666338,0.00007371963,0.0007208952,0.000099080695,0.0005854123,0.013934155,0.00024514704],"about_ca_topic_score_codex":0.042223595,"about_ca_topic_score_gemma":0.21814968,"teacher_disagreement_score":0.41864908,"about_ca_system_score_codex":0.0012455418,"about_ca_system_score_gemma":0.027243277,"threshold_uncertainty_score":0.97827137},"labels":[],"label_agreement":null},{"id":"W2240443346","doi":"10.1200/jco.2015.33.7_suppl.279","title":"IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Clinical endpoint; Prostate cancer; Internal medicine; Nausea; Prednisone; Adverse effect; Phases of clinical research; Progressive disease; Oncology; Gastroenterology; Chemotherapy; Cancer; Urology; Androgen deprivation therapy; Clinical trial","score_opus":0.14860207523103347,"score_gpt":0.4968250447685502,"score_spread":0.34822296953751675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240443346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953567,0.00029354834,0.0000015730399,0.0015103045,0.00056144147,0.0021979765,0.00003660479,0.000005856706,0.000036006797],"genre_scores_gemma":[0.99892855,0.0000977862,0.00033711529,0.00022572618,0.00018696567,0.00008333113,0.000007072495,0.00002450415,0.00010897543],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99622,0.0007931179,0.0018195573,0.00030935678,0.000590627,0.00026734755],"domain_scores_gemma":[0.996299,0.00032134022,0.0022674534,0.00019054097,0.0006129656,0.00030865346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012996068,0.0002509642,0.0013865893,0.0001511931,0.00006704283,0.0000137229745,0.00011217585,0.00014126503,0.000028263692],"category_scores_gemma":[0.00025473628,0.000116192314,0.00007443507,0.00025690952,0.00028020557,0.00015722994,0.00005883526,0.00070376997,5.880156e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4463268,0.048371844,0.42639104,0.000098547476,0.0009743978,0.00035670132,0.0054266592,0.00005047014,0.00075896183,0.0000029655093,0.0012168165,0.070024796],"study_design_scores_gemma":[0.15745,0.48634028,0.35140815,0.00074778154,0.0010964337,0.00003813609,0.0012748097,0.00002912574,0.0004570566,0.000013336358,0.001009236,0.00013561394],"about_ca_topic_score_codex":0.00009348697,"about_ca_topic_score_gemma":0.0031435047,"teacher_disagreement_score":0.43796846,"about_ca_system_score_codex":0.00032621733,"about_ca_system_score_gemma":0.0017718975,"threshold_uncertainty_score":0.4738185},"labels":[],"label_agreement":null},{"id":"W2240448657","doi":"10.1200/jco.2015.33.7_suppl.142","title":"Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Abiraterone acetate; Gastroenterology; Proportional hazards model; Urology; Multivariate analysis; Prednisone; Survival analysis; Prostate cancer; Surgery; Oncology; Confidence interval; Cancer; Androgen deprivation therapy","score_opus":0.2511046048727409,"score_gpt":0.5233176796087526,"score_spread":0.27221307473601175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240448657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890589,0.000045358258,0.0012542901,0.008980072,0.000058611426,0.00023168908,0.00000918298,0.000006653298,0.00035522264],"genre_scores_gemma":[0.99600124,0.00009753883,0.0027288017,0.00088671065,0.00019436769,0.0000043394675,0.000008071382,0.000008858814,0.00007007082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740285,0.00044442085,0.0013240495,0.0001595027,0.00048483227,0.00018436993],"domain_scores_gemma":[0.99586964,0.0022120494,0.0009733702,0.00022469832,0.00037160673,0.00034860903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047242986,0.00013105388,0.0012205337,0.00014259017,0.000019281533,0.000011811647,0.00016599831,0.00016161836,0.000070235226],"category_scores_gemma":[0.0035678698,0.00006006337,0.00027913717,0.00029119753,0.0003603991,0.000060886076,0.000029820289,0.00087213045,0.0000018404646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004683261,0.002461757,0.9801195,0.000015777816,0.00067293603,0.00021633529,0.00019040765,0.00015595544,0.000097224525,0.00013445433,0.007883014,0.0033693295],"study_design_scores_gemma":[0.006975383,0.013081498,0.97371525,0.00007069723,0.0009526578,0.00008844048,0.000063725936,0.0016461964,0.000018850622,0.00027613738,0.0030403163,0.000070831185],"about_ca_topic_score_codex":0.00011643324,"about_ca_topic_score_gemma":0.00005689926,"teacher_disagreement_score":0.010619742,"about_ca_system_score_codex":0.00007290746,"about_ca_system_score_gemma":0.0008105577,"threshold_uncertainty_score":0.42713308},"labels":[],"label_agreement":null},{"id":"W2240613603","doi":"10.1200/jco.2007.25.18_suppl.10587","title":"Gamma-Secretase, ErbB4 nuclear localization and neuregulin expression correlates with prostate cancer patient clinical outcome","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"ERBB4; Neuregulin 1; Tissue microarray; Prostate cancer; Neuregulin; ErbB; Cancer research; ERBB3; Cancer; Medicine; Nuclear receptor; Prostate; Pathology; Biology; Receptor; Internal medicine; Epidermal growth factor receptor","score_opus":0.15648146223078616,"score_gpt":0.5332042680161554,"score_spread":0.3767228057853692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240613603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987641,0.0009448253,0.0007426911,0.007873727,0.0014588643,0.0004939773,0.000005569832,0.000020127936,0.00081922335],"genre_scores_gemma":[0.9873858,0.002518083,0.0033764446,0.004975485,0.0014589997,0.0000046715923,0.000003859032,0.0000499717,0.00022666327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402624,0.0006530443,0.0037471133,0.00034353885,0.0008109415,0.00041914007],"domain_scores_gemma":[0.9934637,0.002553736,0.0019215562,0.000255013,0.0008466678,0.0009593154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007297441,0.00018861519,0.0014622249,0.00015682874,0.00007905651,0.000019805062,0.00015551689,0.00058932917,0.0003131229],"category_scores_gemma":[0.004276243,0.000116942894,0.0002569821,0.00022411083,0.00064089027,0.00013738235,0.00010950476,0.0021557705,0.000018720277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017902961,0.000903584,0.74086124,0.00007547082,0.00012716003,0.0013767261,0.00021177255,0.000075253825,0.00011230767,0.000017858209,0.01043503,0.22790065],"study_design_scores_gemma":[0.012698096,0.03528589,0.5725037,0.00074269716,0.00035482954,0.0006986607,0.0004131659,0.0012261912,0.00018545093,0.0001087277,0.37556428,0.0002183027],"about_ca_topic_score_codex":0.000031657586,"about_ca_topic_score_gemma":0.00006611559,"teacher_disagreement_score":0.36512926,"about_ca_system_score_codex":0.00018960937,"about_ca_system_score_gemma":0.0012520178,"threshold_uncertainty_score":0.936587},"labels":[],"label_agreement":null},{"id":"W2240654612","doi":"10.1200/jco.2015.33.7_suppl.261","title":"Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oxycodone; Adverse effect; Internal medicine; Androgen deprivation therapy; Pharmacology; Drug; Cancer; Oncology; Androgen receptor; Opioid","score_opus":0.16516455246892495,"score_gpt":0.5001147418595853,"score_spread":0.33495018939066035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240654612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988011,0.00041248562,0.0000065540767,0.0094799725,0.0011312396,0.0005291534,0.000030982734,0.000002743203,0.00039585112],"genre_scores_gemma":[0.99694467,0.0011369534,0.00057165464,0.00023629582,0.00045803416,0.00003065891,0.000007016568,0.000011016713,0.000603675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973747,0.00042872282,0.001595741,0.00011748728,0.00029081994,0.00019250462],"domain_scores_gemma":[0.9950869,0.0020948458,0.0016016103,0.00011794556,0.0009027496,0.00019592477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003731524,0.00008686673,0.0006892386,0.00011016076,0.00004718246,0.000009036016,0.000111692105,0.00004987489,0.000015183433],"category_scores_gemma":[0.0037750164,0.000048106023,0.00022640316,0.00013587951,0.00013428819,0.00015244656,0.000031003503,0.00070394657,0.0000015373461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017722504,0.0012322,0.8988626,0.000051039184,0.0003132737,0.000032739663,0.0022199138,0.000040310813,0.0005272726,0.000010918038,0.003020581,0.07596666],"study_design_scores_gemma":[0.013993078,0.0034530777,0.95822597,0.0003472995,0.00025524944,0.000009004312,0.0012120485,0.00012401037,0.0007775861,0.0002591899,0.021284498,0.000058972844],"about_ca_topic_score_codex":0.00029993948,"about_ca_topic_score_gemma":0.0013355013,"teacher_disagreement_score":0.07590769,"about_ca_system_score_codex":0.00037380055,"about_ca_system_score_gemma":0.0021056551,"threshold_uncertainty_score":0.45193198},"labels":[],"label_agreement":null},{"id":"W2240656553","doi":"10.1200/jco.2007.25.18_suppl.14046","title":"Preliminary results of a phase II study of continuous low dose metronomic (LDM) cyclophosphamide (CTX) and celecoxib (CEL) for asymptomatic hormone refractory prostate cancer (HRPC) with assessment of anti-angiogenic biomarkers","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Celecoxib; Angiogenesis; Prostate cancer; Asymptomatic; Internal medicine; Cancer; Cyclophosphamide; Chemotherapy; Clinical endpoint; Oncology; Cancer research; Pharmacology; Clinical trial","score_opus":0.03252530381420718,"score_gpt":0.42207948388033434,"score_spread":0.3895541800661272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240656553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954986,0.0018706744,0.00008267449,0.00017096882,0.00047538715,0.0017817619,0.000036044545,0.0000065632858,0.00007730521],"genre_scores_gemma":[0.9957378,0.00087351515,0.0029943907,0.00006213338,0.00023530758,0.000023447865,0.000005196385,0.000033288656,0.00003491069],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994366,0.00035893824,0.0041850936,0.0002816719,0.00046087845,0.00034742372],"domain_scores_gemma":[0.98914486,0.0035756438,0.005897652,0.00029301638,0.0007299984,0.00035885163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007957736,0.00024244102,0.0026812635,0.00034610796,0.00004543789,0.0000029119458,0.00015544263,0.00028633833,0.000008423623],"category_scores_gemma":[0.0014361487,0.00016648855,0.00038505357,0.00021906506,0.0003696424,0.000111484595,0.0000656823,0.00045503414,1.6552082e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37508985,0.048367642,0.279754,0.0014757944,0.0087873535,0.0011729761,0.0028705497,0.00011330655,0.06888962,0.0000072939956,0.001888273,0.21158332],"study_design_scores_gemma":[0.08836646,0.27002665,0.63365513,0.00044351225,0.002014311,0.00007430725,0.00086646975,0.00029580764,0.003599646,0.000007084577,0.00050484174,0.00014579199],"about_ca_topic_score_codex":0.000088382556,"about_ca_topic_score_gemma":0.00007476797,"teacher_disagreement_score":0.35390112,"about_ca_system_score_codex":0.00018748651,"about_ca_system_score_gemma":0.0017253238,"threshold_uncertainty_score":0.6789206},"labels":[],"label_agreement":null},{"id":"W2240693911","doi":"10.1200/jco.2007.25.18_suppl.9070","title":"Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Colorectal cancer; Anxiety; Cancer; Depression (economics); Gastroenterology; Oncology; Psychiatry","score_opus":0.10155358223882026,"score_gpt":0.4323404604201113,"score_spread":0.33078687818129104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240693911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297863,0.0006313574,0.00027171284,0.0049450547,0.00034004397,0.0004414523,0.000053689964,0.0000051939433,0.00033289014],"genre_scores_gemma":[0.99732,0.00043826623,0.000107680054,0.0016801757,0.00037761073,0.000014006952,0.0000018276496,0.000013267547,0.00004714656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837977,0.000110922425,0.00091361825,0.0002088594,0.00018156174,0.000205254],"domain_scores_gemma":[0.9961984,0.0022253986,0.0005825824,0.00003323015,0.00066713855,0.00029321914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012970984,0.00014618498,0.00077513343,0.00019592921,0.000064803484,0.000006999472,0.000022443226,0.00020220428,0.00002869872],"category_scores_gemma":[0.001184912,0.00009549581,0.000045135777,0.0002123606,0.00030221135,0.00012800534,0.000043879885,0.0006898797,5.8518515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016684122,0.00032109782,0.77720195,0.000016515283,0.0003139588,0.000027185522,0.00042332688,0.000002813421,0.000022513614,0.0000065203535,0.00012975236,0.20485023],"study_design_scores_gemma":[0.016200315,0.011594682,0.96975935,0.00058989704,0.00045910917,0.00012747101,0.0006590035,0.00001141953,0.000029927549,0.000062109066,0.00040488434,0.00010181395],"about_ca_topic_score_codex":0.00011445652,"about_ca_topic_score_gemma":0.002189697,"teacher_disagreement_score":0.2047484,"about_ca_system_score_codex":0.00019380185,"about_ca_system_score_gemma":0.0003806806,"threshold_uncertainty_score":0.3894206},"labels":[],"label_agreement":null},{"id":"W2240717263","doi":"10.1200/jco.2007.25.18_suppl.5581","title":"Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Kallikrein; Ovarian cancer; Oncology; Internal medicine; Debulking; Paclitaxel; Cancer; Chemotherapy; Prognostic variable; Multivariate analysis; Survival analysis; Univariate analysis; Stage (stratigraphy); Pathology; Biology","score_opus":0.2299143316127219,"score_gpt":0.5278391694267235,"score_spread":0.2979248378140016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240717263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957767,0.00083621073,0.0013335195,0.00047701728,0.00015009283,0.0013067012,0.000008942542,0.000009304313,0.00010151021],"genre_scores_gemma":[0.993459,0.000008417825,0.006291308,0.00005385057,0.000096087184,0.000019687275,0.0000029976118,0.000013482861,0.00005517506],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99423814,0.0012571489,0.003074944,0.00021148629,0.0010035873,0.0002146921],"domain_scores_gemma":[0.9928648,0.0009612868,0.0042044003,0.00020321147,0.0016426664,0.00012363729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011792554,0.00014104783,0.0013309212,0.0002709517,0.000050915147,0.000003970157,0.00017329211,0.00027836664,0.000103354265],"category_scores_gemma":[0.006471435,0.000094277704,0.00040787892,0.000899019,0.00025605215,0.00013910249,0.000033480625,0.00043209104,2.7098167e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017691688,0.0016062744,0.24887565,0.00008951926,0.0007448116,0.000017073193,0.0005515059,0.004545761,0.7189984,0.00010778497,0.000039176422,0.022654906],"study_design_scores_gemma":[0.0060873115,0.0024337159,0.8618499,0.0011140471,0.0017164284,0.000003910816,0.00023882458,0.018265804,0.107626766,0.0005103877,0.000050834064,0.000102062506],"about_ca_topic_score_codex":0.00030745572,"about_ca_topic_score_gemma":0.0005746894,"teacher_disagreement_score":0.6129742,"about_ca_system_score_codex":0.0002856731,"about_ca_system_score_gemma":0.0019640792,"threshold_uncertainty_score":0.77473795},"labels":[],"label_agreement":null},{"id":"W2240796172","doi":"10.1200/jco.2009.27.15_suppl.e17539","title":"Sunitinib, sorafenib, temsirolimus, or bevacizumab in the treatment of metastatic renal cell carcinoma (RCC): A review of health economic evaluations","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Temsirolimus; Medicine; Sunitinib; Sorafenib; Bevacizumab; Renal cell carcinoma; Oncology; Internal medicine; Cost effectiveness; Kidney cancer; Discovery and development of mTOR inhibitors; Hepatocellular carcinoma; Chemotherapy; PI3K/AKT/mTOR pathway","score_opus":0.4362555027478233,"score_gpt":0.5691585290781784,"score_spread":0.1329030263303551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240796172","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039365995,0.9886979,0.0000057362604,0.0025745016,0.00038050947,0.003201559,0.000078948695,0.0000034652608,0.0011207984],"genre_scores_gemma":[0.0027230277,0.99390423,0.0016248852,0.00081342517,0.000514918,0.000082741506,0.00009242039,0.000045380195,0.0001989556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9773835,0.00773932,0.01324454,0.0004270511,0.00075897825,0.00044663265],"domain_scores_gemma":[0.97466177,0.008756339,0.014894935,0.00086602505,0.0004566889,0.00036422798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011944967,0.00059728127,0.014277241,0.0005804186,0.000044057106,0.0000064968012,0.0005227773,0.00043350528,0.00030965268],"category_scores_gemma":[0.0014147985,0.0002918371,0.003732854,0.00042721556,0.00026671155,0.000064142405,0.00003231269,0.0011024656,0.000024880253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081085786,0.006933007,0.000070423586,0.030356802,0.00077535573,0.0008380665,0.00016825052,0.0000033958777,2.0219731e-7,0.000020739384,0.0018984538,0.95812446],"study_design_scores_gemma":[0.009929973,0.09570189,0.0017596373,0.041641492,0.014731054,0.0026722506,0.000108021035,0.0000051698685,0.0000033245196,0.000056973422,0.83318764,0.00020257945],"about_ca_topic_score_codex":0.00013361938,"about_ca_topic_score_gemma":0.0001387486,"teacher_disagreement_score":0.95792186,"about_ca_system_score_codex":0.0020827146,"about_ca_system_score_gemma":0.025363082,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W2240827233","doi":"10.1200/jco.2007.25.18_suppl.15568","title":"Sorafenib for the treatment of metastatic renal cancer (MRC) in the real world: The Princess Margaret Hospital (PMH) experience","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Rash; Internal medicine; Adverse effect; Surgery; Placebo; Common Terminology Criteria for Adverse Events; Neutropenia; Gastroenterology; Toxicity; Pathology","score_opus":0.19185557726083624,"score_gpt":0.5128229503819305,"score_spread":0.32096737312109425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240827233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761574,0.0021072368,0.0002959121,0.018329905,0.00087569695,0.001109714,0.0000058356572,0.000003032029,0.0011152604],"genre_scores_gemma":[0.9935919,0.002929458,0.0012197698,0.0008289843,0.00093757367,0.00009894964,0.0000014993309,0.000014253053,0.00037759377],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963309,0.00045625502,0.0021609145,0.00018882219,0.0005339143,0.00032914974],"domain_scores_gemma":[0.9869437,0.0106485505,0.001609405,0.00036818098,0.00028555744,0.00014457338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004604459,0.00018030385,0.001091666,0.00010171149,0.00008063288,0.000010966204,0.00040909648,0.0001039117,0.0000675533],"category_scores_gemma":[0.000701828,0.00006411209,0.0006566708,0.00028592124,0.00053150614,0.000060008464,0.00002653023,0.0004422359,0.0000015878435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022047902,0.012803006,0.4627408,0.00006608938,0.0022737554,0.0025993797,0.016520713,0.0002669618,0.00023746808,0.0013597524,0.002798633,0.47628552],"study_design_scores_gemma":[0.009712955,0.027339019,0.86476594,0.00008498241,0.0012390516,0.00014942071,0.0040374147,0.00010060992,0.000841029,0.0003413946,0.09129137,0.000096798256],"about_ca_topic_score_codex":0.00043811573,"about_ca_topic_score_gemma":0.0024290052,"teacher_disagreement_score":0.47618872,"about_ca_system_score_codex":0.00041578742,"about_ca_system_score_gemma":0.0009412743,"threshold_uncertainty_score":0.26144153},"labels":[],"label_agreement":null},{"id":"W2240836645","doi":"10.1200/jco.2006.24.18_suppl.14566","title":"A ligand-independent androgen receptor function protects from inositol hexakisphosphate-induced cell death","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phytase and its Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Androgen receptor; LNCaP; DU145; Programmed cell death; Apoptosis; Cancer research; Cell culture; DNA fragmentation; Prostate cancer; Androgen; Biology; Medicine; Endocrinology; Internal medicine; Cancer; Biochemistry; Hormone; Genetics","score_opus":0.07652367717162947,"score_gpt":0.34416344285585576,"score_spread":0.2676397656842263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240836645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469197,0.00029507742,0.000030025041,0.0025707912,0.00065193546,0.00023480004,0.000020170351,0.00001816137,0.0014871006],"genre_scores_gemma":[0.9960017,0.00011077945,0.00044369657,0.0006958289,0.0025829289,0.000012737138,0.000023526154,0.0000014578055,0.00012733614],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978021,0.00021985226,0.0012748315,0.00022379727,0.00027125207,0.00020819185],"domain_scores_gemma":[0.9975272,0.0008108188,0.0011870868,0.00006375097,0.00021361657,0.00019755692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084730156,0.00012448992,0.0005688435,0.000013920698,0.00011752609,0.0000311578,0.000262239,0.00037670435,0.00026544876],"category_scores_gemma":[0.0001356335,0.00004811896,0.00030272268,0.00016076303,0.000031823987,0.00015510479,0.000048707218,0.0005102624,0.000103285805],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012533101,0.003067411,0.041283783,0.0000044025123,0.000102028716,0.000050563118,0.000021650718,0.000007813354,0.70055336,0.00040732598,0.016326495,0.23692185],"study_design_scores_gemma":[0.0017508873,0.006986921,0.5501105,0.000026891525,0.000115547125,0.000017800903,0.00007886723,0.000024822722,0.08977989,0.00523882,0.34565902,0.00021005301],"about_ca_topic_score_codex":0.0005383836,"about_ca_topic_score_gemma":0.00039564245,"teacher_disagreement_score":0.6107735,"about_ca_system_score_codex":0.000054023483,"about_ca_system_score_gemma":0.0001329598,"threshold_uncertainty_score":0.29064777},"labels":[],"label_agreement":null},{"id":"W2240846239","doi":"10.1200/jco.2014.32.4_suppl.16","title":"Independent validation of a genomic classifier in an at-risk population of men conservatively managed after radical prostatectomy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Nomogram; Population; Cohort; Internal medicine; Oncology; Cumulative incidence; Proportional hazards model; Metastasis; Radiation therapy; Bone metastasis; Surgery; Cancer","score_opus":0.11385262494906857,"score_gpt":0.46056466779482513,"score_spread":0.3467120428457566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240846239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977473,0.00011184001,0.00007269946,0.0010413565,0.00014012147,0.000361439,0.000006415927,0.0000026332316,0.00051618763],"genre_scores_gemma":[0.9981163,0.00028829143,0.0011296778,0.000111762565,0.00015646091,0.000008487654,0.000012764847,0.000010743343,0.00016552169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962496,0.0011647125,0.0018881825,0.00015242671,0.00038761992,0.00015742701],"domain_scores_gemma":[0.9969053,0.0008583107,0.0015882441,0.00014207681,0.00031704525,0.00018898501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043635103,0.00008995277,0.000977512,0.0002187574,0.000017227001,0.0000032188198,0.000093139395,0.00026955875,0.0001243753],"category_scores_gemma":[0.0010941634,0.00006102798,0.00018397628,0.00011307517,0.0002235669,0.00011471969,0.000048421083,0.000601661,0.0000037497562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020786388,0.0010669134,0.9562087,0.000064967186,0.00015627715,0.00008661657,0.00024386967,0.000022707138,0.0020855758,0.00003956319,0.000082760685,0.019155627],"study_design_scores_gemma":[0.01296331,0.008775919,0.9746068,0.00009086116,0.00015650557,0.000023696579,0.00006821365,0.00043547514,0.0012771564,0.0008376881,0.0007148076,0.0000495298],"about_ca_topic_score_codex":0.000081560785,"about_ca_topic_score_gemma":0.00009777533,"teacher_disagreement_score":0.019106098,"about_ca_system_score_codex":0.0003014354,"about_ca_system_score_gemma":0.0005262223,"threshold_uncertainty_score":0.26139513},"labels":[],"label_agreement":null},{"id":"W2240848187","doi":"10.1200/jco.2009.27.15_suppl.10028","title":"A longitudinal study of processing speed among children treated for medulloblastoma (MB), supratentorial primitive neuroectodermal tumor (SPNET), or atypical teratoid rhabdoid tumor (ATRT)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Medulloblastoma; Neuropsychology; Vincristine; Cyclophosphamide; Pediatrics; Surgery; Chemotherapy; Cognition; Pathology; Psychiatry","score_opus":0.06283909300766193,"score_gpt":0.4142618151005339,"score_spread":0.35142272209287195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240848187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800813,0.0001681432,0.00036298065,0.00017608369,0.0005805612,0.00061237585,0.0000140182165,0.000010548258,0.00006716952],"genre_scores_gemma":[0.9952117,0.000033258846,0.0011838693,0.00035767586,0.00310125,0.0000074669993,0.000014087251,0.000028962138,0.0000617041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99598944,0.00044148005,0.0023705473,0.00045890198,0.00035883553,0.0003807704],"domain_scores_gemma":[0.9963846,0.00026482574,0.0020548361,0.00022751364,0.00077691243,0.00029131546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001200476,0.0002846342,0.0013094973,0.00009119376,0.00009791137,0.00003051223,0.00037358262,0.0002884324,0.000020790849],"category_scores_gemma":[0.0018519723,0.00020346306,0.00050061906,0.00014775709,0.00020366575,0.000023561635,0.000070128975,0.00053235213,9.1462357e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14109066,0.019201748,0.6806035,0.00010284738,0.0016376218,0.0008301631,0.0003690424,0.0016413929,0.08733257,0.000010457524,0.0053882156,0.06179178],"study_design_scores_gemma":[0.021249974,0.085500024,0.8756309,0.00012489298,0.0005804337,0.0008262202,0.00023436554,0.001344906,0.0133891655,0.000040893356,0.0007059964,0.00037219233],"about_ca_topic_score_codex":0.000015392168,"about_ca_topic_score_gemma":0.000111480214,"teacher_disagreement_score":0.19502744,"about_ca_system_score_codex":0.000057584653,"about_ca_system_score_gemma":0.0013132461,"threshold_uncertainty_score":0.82969826},"labels":[],"label_agreement":null},{"id":"W2240894135","doi":"10.1200/jco.2005.23.16_suppl.6692","title":"The effect of chemotherapy on cognitive and cerebellar function in patients with acute myeloid leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Induction chemotherapy; Cytarabine; Cognition; Neuropsychology; Myeloid leukemia; Internal medicine; Chemotherapy; Oncology; Audiology; Psychiatry","score_opus":0.01924257586628786,"score_gpt":0.37460303815042795,"score_spread":0.3553604622841401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240894135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512845,0.00023205769,0.000020803789,0.002645804,0.00027764693,0.00040317877,0.0000022271704,0.0000031581358,0.0012866876],"genre_scores_gemma":[0.9965173,0.0015698799,0.000051518677,0.0013899134,0.00035940725,0.000004500872,0.0000010775478,0.000011211718,0.00009521204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821436,0.0003037531,0.0009369325,0.00011991846,0.00028001898,0.00014500128],"domain_scores_gemma":[0.9947404,0.003832407,0.00094153883,0.00006332301,0.00032726387,0.000095029114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015092551,0.00011518612,0.00084600516,0.00008049325,0.00004266027,0.0000030528497,0.00004105319,0.00016701892,0.000019158593],"category_scores_gemma":[0.0011469529,0.000057519544,0.00012771453,0.00010839446,0.0003109942,0.000055210254,0.000017664463,0.0007167413,0.000003950243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083258346,0.00034485065,0.52626234,0.0000112925945,0.00091086293,0.000018530223,0.000060914346,0.0000052313585,0.000008829804,0.000002562936,0.00055930734,0.38855693],"study_design_scores_gemma":[0.037449945,0.09417223,0.8625823,0.00028096573,0.0006059587,0.000021118454,0.00004974238,0.000013601049,0.00026070187,0.000015271175,0.004499363,0.000048767546],"about_ca_topic_score_codex":0.0000040748932,"about_ca_topic_score_gemma":0.000029644236,"teacher_disagreement_score":0.38850814,"about_ca_system_score_codex":0.00020087676,"about_ca_system_score_gemma":0.00030947351,"threshold_uncertainty_score":0.31139243},"labels":[],"label_agreement":null},{"id":"W2240998307","doi":"10.1200/jco.2014.32.4_suppl.10","title":"Validation of a genomic classifier for predicting biochemical failure following postoperative radiation therapy in high-risk prostate cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Nomogram; Internal medicine; Cumulative incidence; Prostatectomy; Receiver operating characteristic; Radiation therapy; Incidence (geometry); Oncology; Proportional hazards model; Area under the curve; Urology; Gastroenterology; Cancer; Cohort","score_opus":0.034872784798522585,"score_gpt":0.41785314156680636,"score_spread":0.3829803567682838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240998307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843395,0.00030329087,0.0023532745,0.011769071,0.00084047706,0.00033490345,0.0000036094118,0.0000056590143,0.00005021015],"genre_scores_gemma":[0.9868267,0.00081981305,0.010439606,0.0008899769,0.0009609373,0.000011846797,0.000009068965,0.000017700377,0.000024324136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971119,0.00047228282,0.0018572711,0.0001662455,0.00021839296,0.00017387874],"domain_scores_gemma":[0.99518025,0.0025663753,0.0017650222,0.00009286433,0.00023942614,0.00015605472],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005466836,0.000102093,0.0009854217,0.00013218405,0.000037138485,0.000008194919,0.00009922172,0.00025255827,0.000014537165],"category_scores_gemma":[0.010936517,0.00007353222,0.0003228852,0.000097660864,0.00009361977,0.00009103207,0.000016802782,0.0009597136,5.7871085e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021529668,0.00035259553,0.5688692,0.000027354678,0.0002558322,0.00001242597,0.00054267194,0.00070138375,0.025934177,0.00005455009,0.0008015772,0.40029532],"study_design_scores_gemma":[0.049974147,0.021566894,0.83031785,0.00055475143,0.0006403006,0.000071461756,0.00035162392,0.05477195,0.008596957,0.0014907371,0.03140393,0.0002593676],"about_ca_topic_score_codex":0.00007991659,"about_ca_topic_score_gemma":0.0000075991825,"teacher_disagreement_score":0.40003595,"about_ca_system_score_codex":0.00014126222,"about_ca_system_score_gemma":0.0006908082,"threshold_uncertainty_score":0.9973948},"labels":[],"label_agreement":null},{"id":"W2241006167","doi":"10.1200/jco.2009.27.15_suppl.10584","title":"Clinical features, treatment, and outcome in 108 patients with localized, high-grade synovial sarcoma (SS)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; SickKids Foundation; Mount Sinai Hospital","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Synovial sarcoma; Radiation therapy; Gastroenterology; Sarcoma; Surgery; Pathology","score_opus":0.09371803718169501,"score_gpt":0.4572897425326535,"score_spread":0.36357170535095845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241006167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836579,0.001022056,0.000008764581,0.013582026,0.00085349014,0.0004114229,0.000006902086,0.000011129351,0.00044631466],"genre_scores_gemma":[0.9888979,0.0013066932,0.004150743,0.004518232,0.00095652137,0.000005069954,0.00001004896,0.000018325758,0.00013645506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99536645,0.0005764645,0.0030119177,0.00034666044,0.00035870704,0.00033976813],"domain_scores_gemma":[0.9949145,0.002700323,0.0013110616,0.00026517973,0.00019613387,0.00061281177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014397461,0.00026959772,0.0025963048,0.00018270857,0.000038872848,0.000014698398,0.00012162223,0.00053571316,0.000049113783],"category_scores_gemma":[0.0012993851,0.00015010963,0.00048984576,0.00015726498,0.000253091,0.000101690865,0.000028221886,0.0009072761,0.000010797703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006181899,0.015977066,0.73225194,0.0000048045304,0.00029367686,0.0018700236,0.000019076248,0.000001546643,6.222833e-7,0.00010994516,0.001330835,0.24195859],"study_design_scores_gemma":[0.05463722,0.053827304,0.8552165,0.000093364324,0.00061530253,0.00028624307,0.000018161236,0.000004640658,0.0000045606184,0.00026340026,0.034915045,0.000118236116],"about_ca_topic_score_codex":0.00007730131,"about_ca_topic_score_gemma":0.0001417713,"teacher_disagreement_score":0.24184035,"about_ca_system_score_codex":0.00027452866,"about_ca_system_score_gemma":0.0005491713,"threshold_uncertainty_score":0.6121293},"labels":[],"label_agreement":null},{"id":"W2241018235","doi":"10.1200/jco.2007.25.18_suppl.7589","title":"A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Everolimus; Internal medicine; Lung cancer; Clinical endpoint; Adverse effect; Response Evaluation Criteria in Solid Tumors; Progressive disease; Phases of clinical research; Oncology; Chemotherapy; Cancer; non-small cell lung cancer (NSCLC); Pharmacodynamics; Urology; Surgery; Pharmacokinetics; Clinical trial","score_opus":0.03359885154060354,"score_gpt":0.44575969787648095,"score_spread":0.4121608463358774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241018235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966334,0.00035397135,0.00032880637,0.0005702848,0.00035993927,0.0016050391,0.0000064562405,0.000008599539,0.00013352143],"genre_scores_gemma":[0.99210787,0.00033231292,0.0060448498,0.0010700419,0.00027188216,0.000024651412,0.0000026723633,0.00004153296,0.0001041696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665654,0.00012740126,0.002217562,0.00030762758,0.00037787153,0.00031301717],"domain_scores_gemma":[0.99617076,0.0009371405,0.0019546205,0.00019078286,0.0004338071,0.0003128623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011884772,0.00024453772,0.0014436747,0.00026443708,0.00007747024,0.0000072203648,0.00011305536,0.00023674074,0.000059512102],"category_scores_gemma":[0.0001918738,0.00015377373,0.00016156709,0.00029405215,0.000109285524,0.00013056885,0.00002101984,0.0005843173,3.0468902e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06126902,0.02978878,0.53037596,0.000077350735,0.0005252919,0.00021143716,0.0040702336,0.00022035364,0.0003911558,3.4148042e-7,0.00006483176,0.37300524],"study_design_scores_gemma":[0.39193174,0.16903654,0.43182948,0.0006660981,0.00088295504,0.000013315859,0.001851359,0.0004571559,0.0013834226,0.0000035711864,0.0017091882,0.00023519041],"about_ca_topic_score_codex":0.00013812304,"about_ca_topic_score_gemma":0.00079759635,"teacher_disagreement_score":0.37277004,"about_ca_system_score_codex":0.00045657775,"about_ca_system_score_gemma":0.0021282334,"threshold_uncertainty_score":0.6270711},"labels":[],"label_agreement":null},{"id":"W2241038962","doi":"10.1200/jco.2006.24.18_suppl.4557","title":"Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Quality of life (healthcare); Internal medicine; Prostate cancer; Refractory (planetary science); Cancer; Oncology; Chemotherapy","score_opus":0.15289443433840882,"score_gpt":0.5043596204495797,"score_spread":0.3514651861111709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241038962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495167,0.0017527229,0.0000078009625,0.0015499765,0.00025427897,0.0012152245,0.00003077888,0.0000034368916,0.00023413649],"genre_scores_gemma":[0.9974766,0.00086187705,0.00066741026,0.00036363557,0.00025794926,0.00006582636,0.0000071778463,0.000018563105,0.00028096107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490786,0.0012194203,0.0027643973,0.00022105452,0.0006234259,0.00026385],"domain_scores_gemma":[0.9936488,0.002515012,0.0030967467,0.00022020328,0.0003624064,0.00015681969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022631676,0.00022482361,0.0024342805,0.00014006987,0.000033256543,0.000004248001,0.00014779618,0.00010548362,0.00006484227],"category_scores_gemma":[0.00031908482,0.00009699478,0.00031847795,0.00029484165,0.00022836184,0.00010637324,0.000019710069,0.00047200284,6.8654106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08614017,0.043542333,0.8455856,0.000052728665,0.0027433827,0.0006093831,0.0011957063,0.00006823073,0.00021301967,0.0000035042126,0.0007316921,0.019114258],"study_design_scores_gemma":[0.0739852,0.13470688,0.7835007,0.000064913205,0.0023040106,0.000015256247,0.0010618912,0.000005288424,0.000030964748,0.000015775866,0.0042195553,0.0000896118],"about_ca_topic_score_codex":0.0025077409,"about_ca_topic_score_gemma":0.0080056805,"teacher_disagreement_score":0.09116455,"about_ca_system_score_codex":0.00034674144,"about_ca_system_score_gemma":0.0024753583,"threshold_uncertainty_score":0.44673577},"labels":[],"label_agreement":null},{"id":"W2241085418","doi":"10.1200/jco.2006.24.18_suppl.6051","title":"Impact of patient and physician factors on oncologists’ recommendations for adjuvant chemotherapy in stage III colon cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Cancer; Population; Colorectal cancer; Cohort; Physical therapy; Family medicine","score_opus":0.1183117707958049,"score_gpt":0.48930640023825583,"score_spread":0.37099462944245093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241085418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350095,0.00017372712,0.000010409462,0.005010779,0.00030787353,0.00027593438,0.00002937531,0.0000028549828,0.0006880917],"genre_scores_gemma":[0.9980531,0.00028855886,0.00024719848,0.00092552166,0.00034387503,0.000006923137,0.000006619207,0.000009019546,0.00011923146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981535,0.00011765273,0.0013166005,0.00012341757,0.00013262752,0.00015617897],"domain_scores_gemma":[0.9970011,0.001397185,0.0012070873,0.00006706467,0.00020686342,0.000120677454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000591216,0.00010758485,0.0011150159,0.00011735657,0.000022364971,0.0000028066174,0.000052442127,0.00017591091,0.00006586545],"category_scores_gemma":[0.00033251397,0.000067410976,0.00041397888,0.00010578671,0.00011987402,0.00004301818,0.000014548713,0.00038753252,2.6200618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017355803,0.005676711,0.7023874,0.000039105114,0.00025074917,0.000064244894,0.00036445286,0.00014041182,0.0020900187,0.00014384455,0.0073604197,0.26412684],"study_design_scores_gemma":[0.00870135,0.048856605,0.92699873,0.000095927935,0.000079264406,0.0000067743795,0.00022237899,0.00010220103,0.000503717,0.00028547103,0.014078419,0.00006917213],"about_ca_topic_score_codex":0.0005495591,"about_ca_topic_score_gemma":0.0006590827,"teacher_disagreement_score":0.26405767,"about_ca_system_score_codex":0.00032146668,"about_ca_system_score_gemma":0.00072614447,"threshold_uncertainty_score":0.27489397},"labels":[],"label_agreement":null},{"id":"W2241104881","doi":"10.1200/jco.2007.25.18_suppl.581","title":"Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Distributed File System; Breast cancer; Internal medicine; Oncology; Sample size determination; Randomized controlled trial; Clinical trial; Cancer; Radiation therapy; Statistics","score_opus":0.11226134890142471,"score_gpt":0.4381263274155151,"score_spread":0.3258649785140904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241104881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902068,0.0015874148,0.00009843978,0.005526959,0.001714109,0.00019578804,0.0004338243,0.000003642034,0.00023303693],"genre_scores_gemma":[0.9910321,0.00396651,0.00031033513,0.0003246906,0.0042266226,0.000007051576,0.000040594827,0.00002146665,0.00007058759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964471,0.0008534215,0.001767682,0.00033417155,0.0002839585,0.00031365704],"domain_scores_gemma":[0.9959095,0.0023090425,0.0011430507,0.00021273403,0.00016499413,0.00026069343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00506993,0.00020366893,0.0014822274,0.000117653384,0.00003127762,0.0000110914725,0.00018896854,0.0004131241,0.0000768225],"category_scores_gemma":[0.002978877,0.00014822131,0.0002055442,0.000107542466,0.00016591411,0.000014366363,0.00016645556,0.00042023446,0.000002460609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0141178025,0.00036909338,0.95330757,0.000008639169,0.0002962807,0.0001553052,0.000045846402,0.00002506046,0.00014790289,0.000022156533,0.00078202353,0.030722326],"study_design_scores_gemma":[0.013529441,0.00088815304,0.97929996,0.00008331412,0.00021155167,0.000009672588,0.00017043257,0.0000047928897,0.000060721326,0.00034160842,0.005243844,0.00015648654],"about_ca_topic_score_codex":0.000727293,"about_ca_topic_score_gemma":0.024409864,"teacher_disagreement_score":0.03056584,"about_ca_system_score_codex":0.00013963095,"about_ca_system_score_gemma":0.00061167835,"threshold_uncertainty_score":0.9933921},"labels":[],"label_agreement":null},{"id":"W2241202567","doi":"10.1200/jco.2009.27.15_suppl.9640","title":"Placebo and nocebo effects in randomized double-blind clinical trials for fatigue in advanced cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Nocebo; Nausea; Nocebo Effect; Internal medicine; Randomized controlled trial; Clinical trial; Cancer-related fatigue; Physical therapy; Cancer","score_opus":0.3903949492872185,"score_gpt":0.6278195739453415,"score_spread":0.23742462465812297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241202567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825335,0.001876181,0.00008967499,0.008533802,0.002803962,0.0036247168,0.0000042205365,0.0000052654536,0.00052863394],"genre_scores_gemma":[0.9873602,0.0054054842,0.0018530916,0.0036976468,0.0013586509,0.00016152118,0.0000066969046,0.00001392916,0.00014280554],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903786,0.0029436476,0.005883807,0.0002890023,0.00020305954,0.00030186132],"domain_scores_gemma":[0.9582765,0.03826576,0.002720119,0.00009721927,0.00028196623,0.00035844458],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022661485,0.00019847609,0.0059748814,0.0002747872,0.000020534115,0.0000068358854,0.00010217546,0.0005870773,0.000058153306],"category_scores_gemma":[0.019302178,0.00013043755,0.00090712943,0.00015356301,0.00019781907,0.00011155736,0.000020039577,0.0009866252,0.0000013341361],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67358613,0.0038966092,0.08252588,0.000034950852,0.00029622056,0.00009921449,0.000070011105,0.000021427823,0.000027798418,0.000042171097,0.001104315,0.23829527],"study_design_scores_gemma":[0.8347072,0.021482322,0.1367734,0.00022949415,0.0009162588,0.000011574609,0.000010951306,0.00018152369,0.0000629615,0.0007802012,0.004743408,0.000100687364],"about_ca_topic_score_codex":0.000029363642,"about_ca_topic_score_gemma":0.00021356446,"teacher_disagreement_score":0.23819457,"about_ca_system_score_codex":0.00020508,"about_ca_system_score_gemma":0.0011703378,"threshold_uncertainty_score":0.98895866},"labels":[],"label_agreement":null},{"id":"W2241207331","doi":"10.1200/jco.2009.27.15_suppl.e11632","title":"Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Regimen; Breast cancer; Internal medicine; Chemotherapy; Logistic regression; Oncology; Hormonal therapy; Univariate analysis; Chemotherapy regimen; Odds ratio; Multivariate analysis; Stage (stratigraphy); Cancer","score_opus":0.023235639129722933,"score_gpt":0.371953217361765,"score_spread":0.3487175782320421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241207331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918619,0.0017037474,0.000017357002,0.005803017,0.00025743514,0.00009022584,0.000028268229,0.0000016708009,0.00023637184],"genre_scores_gemma":[0.98883724,0.006824114,0.00069560733,0.003275915,0.00032982088,0.0000036396275,0.000003941093,0.0000091485235,0.000020586545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826986,0.00011592983,0.0011340794,0.0001784583,0.00015669699,0.00014496488],"domain_scores_gemma":[0.99822885,0.00007623113,0.001263253,0.0001271055,0.00018848176,0.000116084346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037879465,0.0001311222,0.0008032711,0.000046716585,0.000018014869,0.0000026420867,0.000100522564,0.00018750582,0.0000073508772],"category_scores_gemma":[0.0001560208,0.000090326204,0.00013956513,0.000045443965,0.00013999487,0.000007240554,0.000047847054,0.00022258381,1.8997973e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015569917,0.002870428,0.4191331,0.000034573262,0.00040012697,0.00014020398,0.00040307632,0.00007811551,0.018511746,0.000020169178,0.005584437,0.5372541],"study_design_scores_gemma":[0.004355097,0.00420253,0.9862499,0.00016947897,0.000072937684,0.00020019546,0.000054721757,0.00007655456,0.0012462043,0.00015683213,0.0031108134,0.00010472974],"about_ca_topic_score_codex":0.000013190854,"about_ca_topic_score_gemma":0.000007258284,"teacher_disagreement_score":0.5671168,"about_ca_system_score_codex":0.000066590495,"about_ca_system_score_gemma":0.00066102704,"threshold_uncertainty_score":0.36833957},"labels":[],"label_agreement":null},{"id":"W2241208632","doi":"10.1200/jco.2007.25.18_suppl.10552","title":"Breast cancer survival in carriers of BRCA1 and BRCA2 mutations","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hazard ratio; Cancer; Population; Mutation; Gynecology; Confidence interval; Genetics; Gene","score_opus":0.06672060263637215,"score_gpt":0.45535095333309566,"score_spread":0.3886303506967235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241208632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944126,0.0010261605,0.00077407574,0.0014692327,0.0010734306,0.000060304046,0.000021786733,0.0000010057058,0.0011613991],"genre_scores_gemma":[0.99600524,0.0007958436,0.0021766257,0.00030368337,0.00064562034,0.0000016895555,0.0000027540334,0.000009658844,0.000058913225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809873,0.00016882597,0.0012965765,0.00014379268,0.00014059083,0.00015145911],"domain_scores_gemma":[0.99824846,0.00035889994,0.00079694786,0.0001138996,0.00034447058,0.00013730626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027101021,0.000076234035,0.0004452927,0.00009082218,0.000018954888,0.0000032720156,0.00013662687,0.00029283224,0.000041002353],"category_scores_gemma":[0.00068729604,0.000066912755,0.00013348946,0.00012077652,0.00029999486,0.0000061892097,0.000046340785,0.0002888431,4.7836915e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023006569,0.0005620874,0.6002193,0.000028610322,0.00044209804,0.0000847883,0.00034862317,0.0008727024,0.02557434,0.00021752303,0.0020660607,0.3672832],"study_design_scores_gemma":[0.003604442,0.0013409486,0.96498144,0.000028163078,0.00008058918,0.0002583048,0.0007679881,0.000029230501,0.004143861,0.0003089414,0.024337672,0.00011841789],"about_ca_topic_score_codex":0.000073007424,"about_ca_topic_score_gemma":0.0013119911,"teacher_disagreement_score":0.36716476,"about_ca_system_score_codex":0.00007075232,"about_ca_system_score_gemma":0.0014446345,"threshold_uncertainty_score":0.27286232},"labels":[],"label_agreement":null},{"id":"W2241239684","doi":"10.1200/jco.2007.25.18_suppl.5011","title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Sorafenib; Sunitinib; Renal cell carcinoma; Internal medicine; Expanded access; Chromophobe cell; Adverse effect; Surgery; Clinical trial; Urology; Oncology; Clear cell; Hepatocellular carcinoma","score_opus":0.10360630427762922,"score_gpt":0.44745187823647703,"score_spread":0.3438455739588478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241239684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089634,0.0011529304,0.00012358099,0.0027755965,0.0010341957,0.0006662711,0.0000019181962,0.0000072539706,0.0033418913],"genre_scores_gemma":[0.99534434,0.0013798599,0.0010336031,0.0007288531,0.0012316585,0.000004418966,0.000004407572,0.000020818352,0.00025205297],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947987,0.00057025615,0.003370941,0.0002935394,0.00050251954,0.00046402306],"domain_scores_gemma":[0.9890922,0.007789256,0.0019513326,0.00030856827,0.00028213495,0.00057655195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041521415,0.00021845114,0.001637169,0.00017114874,0.00010041056,0.000022241686,0.0003109724,0.00027835005,0.000031101667],"category_scores_gemma":[0.0025762985,0.00012505567,0.00045912166,0.00032080698,0.00042418487,0.00014323815,0.00013026356,0.0013762012,0.000007790624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4157186,0.00227014,0.12050636,0.000016313936,0.00012311526,0.0031486878,0.00020007647,0.000045348046,0.00018334339,0.000010314138,0.00033443666,0.45744327],"study_design_scores_gemma":[0.14315705,0.02164337,0.7992028,0.000024302593,0.00022285234,0.0002450816,0.00018816751,0.000017265009,0.00028924088,0.000034730056,0.034869026,0.00010612902],"about_ca_topic_score_codex":0.00003283299,"about_ca_topic_score_gemma":0.0004598402,"teacher_disagreement_score":0.6786964,"about_ca_system_score_codex":0.00031995843,"about_ca_system_score_gemma":0.0011569884,"threshold_uncertainty_score":0.5978986},"labels":[],"label_agreement":null},{"id":"W2241342024","doi":"10.1200/jco.2006.24.18_suppl.14660","title":"Cost-effectiveness of zoledronic acid vs. pamidronate in the management of hormone refractory prostate cancer (HRPC) patients with bone metastases","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Zoledronic acid; Bone pain; Prostate cancer; Bisphosphonate; Quality of life (healthcare); Cost effectiveness; Internal medicine; Bone metastasis; Refractory (planetary science); Surgery; Cancer; Oncology; Urology; Osteoporosis","score_opus":0.07305014863098074,"score_gpt":0.44323362172832975,"score_spread":0.370183473097349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241342024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935039,0.0040009087,0.000017264296,0.00078927615,0.00018658092,0.0010530162,0.000026979822,0.0000026041555,0.00041941542],"genre_scores_gemma":[0.9959549,0.002919803,0.00068910746,0.00027654407,0.00004448931,0.000049283317,0.000014018284,0.000013053144,0.000038855163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965082,0.00075908727,0.0018613312,0.00014952564,0.00047497824,0.0002469023],"domain_scores_gemma":[0.99650794,0.0008799161,0.0019494105,0.00018772588,0.00035280388,0.00012223041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029205473,0.0001378098,0.0013358063,0.00011881596,0.000021478454,0.0000020041955,0.000106324405,0.00012976846,0.000013605332],"category_scores_gemma":[0.0000870596,0.00007245419,0.00018770281,0.0002048639,0.00020451118,0.00008799432,0.000028349506,0.0005145338,0.0000016495694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05261985,0.0137248775,0.78468794,0.000547648,0.0010591237,0.0009698438,0.00008548379,0.00007198088,0.00005398203,0.00010529275,0.00041181417,0.14566217],"study_design_scores_gemma":[0.027563347,0.017057007,0.9478026,0.00038330953,0.00076878746,0.000026005937,0.000050983483,0.000004379472,0.000111743415,0.0001407704,0.0060350965,0.000055989643],"about_ca_topic_score_codex":0.00035169662,"about_ca_topic_score_gemma":0.00019436223,"teacher_disagreement_score":0.16311465,"about_ca_system_score_codex":0.00022953106,"about_ca_system_score_gemma":0.0006816356,"threshold_uncertainty_score":0.2954596},"labels":[],"label_agreement":null},{"id":"W2241369966","doi":"10.1200/jco.2009.27.15_suppl.e22063","title":"Protective effect of metformin in lung cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Metformin; Internal medicine; Lung cancer; Proportional hazards model; Cancer; Pleural effusion; Type 2 diabetes; Oncology; Diabetes mellitus; Stage (stratigraphy); Survival analysis; Insulin; Endocrinology","score_opus":0.02435614764289424,"score_gpt":0.43278674730740524,"score_spread":0.408430599664511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241369966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601778,0.03838621,0.00005046368,0.00006608073,0.000692341,0.00020934186,0.0000044818353,8.5566086e-7,0.00041243865],"genre_scores_gemma":[0.98661196,0.012006114,0.00017156395,0.00052855397,0.00064333767,0.000009402833,0.000001998247,0.000006739902,0.000020347836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99784493,0.00047995907,0.001199649,0.00014216,0.00016355948,0.00016974348],"domain_scores_gemma":[0.9982636,0.0001828955,0.0010874534,0.000110630725,0.0002503932,0.00010505123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021087045,0.00010270159,0.00083653716,0.00006204205,0.000011077995,0.000002383907,0.00017861446,0.00032293852,0.000028684033],"category_scores_gemma":[0.0018376719,0.00007131504,0.00029080742,0.00008571017,0.00007033967,0.0000072174785,0.00002730321,0.00034461825,6.338265e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002611171,0.0005821331,0.06944194,0.00002673869,0.00013744547,0.000008332015,0.00003132798,0.000041753785,0.0029514416,0.0000119273955,0.0014532777,0.9227025],"study_design_scores_gemma":[0.023708878,0.061752234,0.55163133,0.00020421356,0.00041819128,0.000011527763,0.000026598515,0.000076721495,0.132838,0.0006954616,0.22826453,0.0003723262],"about_ca_topic_score_codex":0.0000151925815,"about_ca_topic_score_gemma":0.00004492953,"teacher_disagreement_score":0.9223302,"about_ca_system_score_codex":0.000041046365,"about_ca_system_score_gemma":0.0004502389,"threshold_uncertainty_score":0.29081428},"labels":[],"label_agreement":null},{"id":"W2241411834","doi":"10.1200/jco.2006.24.18_suppl.8631","title":"Exercise in patients with advanced non-small cell lung cancer (NSCLC): Compliance and population characteristics of patients referred to the McGill Cancer Nutrition-Rehabilitation Program (CNRP)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Physical therapy; Quality of life (healthcare); Weight loss; Lung cancer; Population; Referral; Cancer; Univariate analysis; Internal medicine; Medical prescription; Stage (stratigraphy); Multivariate analysis; Obesity; Family medicine","score_opus":0.04036918221042736,"score_gpt":0.41075519282033457,"score_spread":0.3703860106099072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241411834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955015,0.00046471582,0.0000060238685,0.0018147969,0.0004286578,0.0016349243,0.00012257857,0.0000036234676,0.000023152465],"genre_scores_gemma":[0.99556065,0.00094311236,0.0028243032,0.00021622113,0.00014382307,0.00025353418,0.000033859702,0.000013781333,0.00001072081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997962,0.000086201166,0.0013642176,0.00018075923,0.0002548808,0.00015194778],"domain_scores_gemma":[0.9973104,0.0005019248,0.0012249082,0.00012321524,0.000722051,0.00011750365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030262684,0.0001221831,0.00083109894,0.00008287698,0.000036240064,0.000004107524,0.000060353763,0.00011278498,0.000011866853],"category_scores_gemma":[0.00017619172,0.00007639818,0.000102968355,0.00014874728,0.000057624555,0.00007695639,0.000019776557,0.00023606658,4.255333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00394619,0.0057532312,0.77648175,0.000169652,0.000030829055,0.0000026634712,0.00004497902,0.00010983434,0.0000021364363,0.0000022253598,0.00045429013,0.21300222],"study_design_scores_gemma":[0.013493051,0.007964775,0.9735812,0.0017805899,0.00026785638,3.5432947e-7,0.000016414386,0.00006624475,0.000014107592,0.000013876105,0.002727416,0.000074120064],"about_ca_topic_score_codex":0.00066617905,"about_ca_topic_score_gemma":0.0010834283,"teacher_disagreement_score":0.2129281,"about_ca_system_score_codex":0.00034644993,"about_ca_system_score_gemma":0.0001827136,"threshold_uncertainty_score":0.31154272},"labels":[],"label_agreement":null},{"id":"W2241441680","doi":"10.1200/jco.2014.32.26_suppl.82","title":"Contralateral mastectomy in young women with breast cancer: A population-based analysis of predictive factors and clinical impact.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; Institute for Clinical Evaluative Sciences; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Proportional hazards model; Hazard ratio; Mastectomy; Internal medicine; Population; Cancer; Oncology; Cohort; Gynecology; Confidence interval","score_opus":0.021402976766203584,"score_gpt":0.39475130401192143,"score_spread":0.37334832724571787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241441680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989854,0.00008578262,0.00018271012,0.00036841483,0.00016569355,0.00008440426,0.00007876778,0.0000018757598,0.00004694222],"genre_scores_gemma":[0.9992333,0.00016102837,0.00020462301,0.00012279814,0.00024413831,0.000006065566,0.000014340816,0.000009679521,0.0000040149075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975484,0.00047775896,0.0013887472,0.00022369686,0.0001562029,0.00020517527],"domain_scores_gemma":[0.997407,0.0006600207,0.0013278758,0.00013649034,0.0002762054,0.00019238083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012091099,0.00015356044,0.0014032075,0.00014890403,0.00002174273,0.0000055517244,0.00010595462,0.00026273046,0.00002556603],"category_scores_gemma":[0.0004382718,0.00009241044,0.00032357994,0.00019606159,0.0002159595,0.00001003947,0.000034581943,0.00025931426,8.052165e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007584146,0.00046767024,0.9809288,0.000005399004,0.0037925714,0.000005476115,0.000064047665,0.0010079538,0.00003968051,0.0000019573538,0.000014635152,0.0060876743],"study_design_scores_gemma":[0.006192606,0.005778476,0.9863209,0.000025791509,0.00096301484,0.000013831086,0.00008767483,0.00045653104,0.000016552303,0.000013826971,0.000042343294,0.00008845508],"about_ca_topic_score_codex":0.0009319935,"about_ca_topic_score_gemma":0.0036580134,"teacher_disagreement_score":0.0059992196,"about_ca_system_score_codex":0.00012388846,"about_ca_system_score_gemma":0.00044942272,"threshold_uncertainty_score":0.37683883},"labels":[],"label_agreement":null},{"id":"W2241465756","doi":"10.1200/jco.2007.25.18_suppl.9115","title":"Effect of chemotherapy on exercise capacity in patients with advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Chemotherapy; Stage (stratigraphy); Internal medicine; Cancer; Surgery","score_opus":0.02958702611088326,"score_gpt":0.39446484825953737,"score_spread":0.3648778221486541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241465756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578846,0.00028584516,0.00007899176,0.00025556062,0.0011117222,0.0004231888,0.0000030423375,0.000003608574,0.002049567],"genre_scores_gemma":[0.99797225,0.00040234777,0.0003282789,0.0008920122,0.00031616102,0.0000047644553,9.977102e-7,0.000019796735,0.00006337121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977034,0.00017661686,0.0013555763,0.00016650521,0.00035862954,0.00023930988],"domain_scores_gemma":[0.99659836,0.0014550928,0.0011784722,0.00017341817,0.0003439956,0.0002506638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029492176,0.00015001085,0.0014666175,0.00014414128,0.00001250918,0.0000018503492,0.00012101681,0.00029243817,0.00006850028],"category_scores_gemma":[0.00027130375,0.00009445472,0.00028539178,0.00018850005,0.000103118895,0.000047313806,0.000012891527,0.00089040084,0.0000013303588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04826247,0.0011280135,0.716824,0.00015193307,0.00005969047,0.000061069535,0.0002834459,0.000026081005,0.00008468204,8.7749265e-7,0.00014892893,0.23296882],"study_design_scores_gemma":[0.03169895,0.038498558,0.9210114,0.0009378563,0.00022257476,0.0000034379182,0.000048915143,0.000011688551,0.0059188553,0.000003825986,0.0015430913,0.000100838755],"about_ca_topic_score_codex":0.00015193435,"about_ca_topic_score_gemma":0.0007627602,"teacher_disagreement_score":0.23286799,"about_ca_system_score_codex":0.0002479584,"about_ca_system_score_gemma":0.00054308167,"threshold_uncertainty_score":0.3868398},"labels":[],"label_agreement":null},{"id":"W2241511433","doi":"10.1200/jco.2007.25.18_suppl.17044","title":"A 10-year history of lung cancer practice guideline development: Process, productivity and impact","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Lung cancer; Family medicine; Oncology; Internal medicine; Pathology","score_opus":0.2933136204604434,"score_gpt":0.6219206969372016,"score_spread":0.32860707647675824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241511433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95471764,0.0039271316,0.002219503,0.02818823,0.0018602659,0.0006301834,0.000004466535,0.00001730636,0.008435288],"genre_scores_gemma":[0.92486995,0.0007151955,0.06566758,0.0042910874,0.0029782571,0.000004496885,0.000007881749,0.00003649089,0.001429054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919478,0.00041273423,0.0064746803,0.00025848116,0.00065049535,0.0002557762],"domain_scores_gemma":[0.9804211,0.00811004,0.007096915,0.00020332247,0.0037221063,0.00044651324],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.028309146,0.00015520201,0.0013048016,0.00017395974,0.00002471501,0.000003852608,0.000119027674,0.00029690773,0.0011840308],"category_scores_gemma":[0.114524476,0.00011394888,0.00024284811,0.00017673786,0.00025141973,0.0005315133,0.0000611762,0.0010216421,0.0000070389247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037070476,0.0038159655,0.15990578,0.00022801141,0.001238334,0.00030557372,0.0006503627,0.000023712353,0.0005217268,0.000021898733,0.15012138,0.64609677],"study_design_scores_gemma":[0.0074448674,0.00572733,0.14325859,0.00012248519,0.0010734178,0.000531775,0.00037806912,0.000096223135,0.00011947149,0.000043803895,0.8410806,0.00012337994],"about_ca_topic_score_codex":0.00011592559,"about_ca_topic_score_gemma":0.00013941132,"teacher_disagreement_score":0.6909592,"about_ca_system_score_codex":0.0009830332,"about_ca_system_score_gemma":0.013193391,"threshold_uncertainty_score":0.99972904},"labels":[],"label_agreement":null},{"id":"W2241551650","doi":"10.1200/jco.2012.30.15_suppl.6014","title":"Adjuvant chemotherapy (AC) initiation and early discontinuation in elderly patients (EPs) with stage III colon cancer (CC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Capecitabine; FOLFOX; Internal medicine; Cancer; Cohort; Stage (stratigraphy); Regimen; Oncology; Oxaliplatin; Colorectal cancer","score_opus":0.07744776296947654,"score_gpt":0.4421887471721476,"score_spread":0.3647409842026711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241551650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949475,0.0013035273,0.000019036726,0.0020681482,0.00043342734,0.00027994532,0.0000032434725,0.0000034332274,0.00094173575],"genre_scores_gemma":[0.99664295,0.0018546389,0.0002759693,0.00062912307,0.0003965886,0.000015630767,0.000001839691,0.000009536375,0.00017375233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984955,0.00012185211,0.0008944454,0.00010202772,0.00021289742,0.00017323032],"domain_scores_gemma":[0.99833375,0.00036595465,0.0008587224,0.000054734708,0.00023597645,0.00015088197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077036803,0.00009996232,0.0008207839,0.000076946075,0.000030179379,0.0000061893784,0.00003122781,0.00013081699,0.000036216043],"category_scores_gemma":[0.00024572824,0.000060419366,0.000077823344,0.00008639576,0.00009186187,0.00021754944,0.000014552829,0.00031779308,0.0000010509617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005732213,0.0025607417,0.77919006,0.000008125069,0.0001528673,0.000018387433,0.0010726199,6.353341e-7,0.000009829273,0.000011114039,0.00015268785,0.2110907],"study_design_scores_gemma":[0.029031502,0.020028932,0.94227415,0.00009634878,0.0001532807,0.000007175328,0.00021152906,0.000006920771,0.000027759841,0.000015039331,0.008087122,0.00006022394],"about_ca_topic_score_codex":0.00017578313,"about_ca_topic_score_gemma":0.0008938903,"teacher_disagreement_score":0.21103048,"about_ca_system_score_codex":0.00020652644,"about_ca_system_score_gemma":0.00029047386,"threshold_uncertainty_score":0.24638303},"labels":[],"label_agreement":null},{"id":"W2241631729","doi":"10.1200/jco.2006.24.18_suppl.6098","title":"A comparison of patient and physician attributes that promote patient involvement in treatment decision making in the oncology consultation","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Patient participation; Cancer; MEDLINE; Internal medicine","score_opus":0.49301566459167423,"score_gpt":0.5909902458761473,"score_spread":0.09797458128447312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241631729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855376,0.0021316041,0.000058313977,0.006523851,0.00071391615,0.0014338362,0.000009845944,0.0000047851195,0.00057010277],"genre_scores_gemma":[0.9930568,0.00035782834,0.004596357,0.0017453788,0.000113806884,0.00010776703,0.000009645839,0.000010179119,0.0000022386462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98844,0.005532924,0.005062647,0.00020591605,0.0004305162,0.00032804758],"domain_scores_gemma":[0.974596,0.019098433,0.0054068607,0.00031120438,0.00050323724,0.00008424826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024245053,0.00015665193,0.0013264831,0.00023681008,0.00016078203,0.0000047213653,0.0002653363,0.00040284795,0.000011258927],"category_scores_gemma":[0.0021723316,0.00010034908,0.00013732183,0.00027606412,0.00018448471,0.00012240194,0.00013872587,0.0011851469,0.0000038488793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013255553,0.003518189,0.62473917,0.000051500556,0.000023303175,0.00002223245,0.028121931,0.00023458646,0.000017925318,0.00032304335,0.00049143075,0.34113115],"study_design_scores_gemma":[0.010356331,0.023159899,0.83761644,0.0012937372,0.00007536847,0.000008050316,0.07308583,0.0014191546,0.000059980863,0.0061262003,0.046645146,0.00015383569],"about_ca_topic_score_codex":0.00065310247,"about_ca_topic_score_gemma":0.0065673827,"teacher_disagreement_score":0.3409773,"about_ca_system_score_codex":0.0010700544,"about_ca_system_score_gemma":0.0014435904,"threshold_uncertainty_score":0.51489395},"labels":[],"label_agreement":null},{"id":"W2241633362","doi":"10.1200/jco.2008.26.15_suppl.6554","title":"Canadian oncologist communication about prognosis disclosure with their terminally-ill patients","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Terminally ill; Family medicine; Incentive; Internal medicine; Palliative care; Nursing","score_opus":0.29500106004595394,"score_gpt":0.5086924713510693,"score_spread":0.21369141130511538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241633362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98190296,0.00088296825,0.000019404584,0.008666694,0.00025018692,0.00020626036,0.000013438927,0.0000061542332,0.008051928],"genre_scores_gemma":[0.9855732,0.0052217874,0.0057570376,0.0028770387,0.0003386345,0.0000054587545,0.000015187725,0.000014052915,0.00019760217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739194,0.0003969995,0.0015763271,0.00012899333,0.00028331086,0.00022241786],"domain_scores_gemma":[0.99426216,0.0015022565,0.0016239078,0.00024531697,0.0018653083,0.0005010354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011290024,0.00013516241,0.0012093064,0.00013398437,0.00008087503,0.0000036885392,0.00026447125,0.0003257686,0.00005297799],"category_scores_gemma":[0.0035989687,0.00007962812,0.00027824874,0.00014930952,0.00045587472,0.00010522732,0.00003441293,0.0007759198,0.0000058927717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010222847,0.001083466,0.96143895,0.000022810933,0.00020827675,0.00025712763,0.0006293793,0.000002773499,0.0000031873217,0.000018026389,0.006635869,0.028677827],"study_design_scores_gemma":[0.003617804,0.010760609,0.8006037,0.00034964122,0.0002025146,0.00011109659,0.00029125062,0.000006390112,0.000059466027,0.000038256414,0.18388228,0.00007698714],"about_ca_topic_score_codex":0.0028986477,"about_ca_topic_score_gemma":0.021016106,"teacher_disagreement_score":0.1772464,"about_ca_system_score_codex":0.00030057994,"about_ca_system_score_gemma":0.0032118314,"threshold_uncertainty_score":0.9968478},"labels":[],"label_agreement":null},{"id":"W2241641236","doi":"10.1200/jco.2007.25.18_suppl.5062","title":"The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: Secondary analysis of RTOG 85–31","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Hormonal therapy; Radiation therapy; Hormone therapy; Internal medicine; Proportional hazards model; Adjuvant therapy; Adjuvant; Cancer; Prostate cancer; Hormone; Oncology; Surgery; Breast cancer","score_opus":0.04711708049919901,"score_gpt":0.44102455459167295,"score_spread":0.39390747409247395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241641236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616957,0.0018790397,0.000008003737,0.0010126546,0.00004666167,0.00068776304,0.000029197945,0.0000016221834,0.00016550074],"genre_scores_gemma":[0.9957384,0.003874175,0.00014572544,0.000054269913,0.000050046325,0.000009414108,0.000008394569,0.000012350473,0.000107261505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708396,0.00030840028,0.0016982673,0.00013149709,0.00054200506,0.00023588045],"domain_scores_gemma":[0.9954633,0.0008589106,0.0023183462,0.0001892506,0.0010499539,0.00012019968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024048171,0.00013370698,0.001274825,0.0002550265,0.000040814506,0.0000045289075,0.00015652142,0.00013830753,0.000054401055],"category_scores_gemma":[0.0001472635,0.000047038448,0.00043599904,0.0010555234,0.0006005629,0.000090126145,0.000013853826,0.00050757895,5.8876044e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060478296,0.0019777047,0.84951866,0.000014991568,0.005466395,0.000017096105,0.0003038591,0.00025943798,0.0005127692,0.0000020383422,0.00012377964,0.081324965],"study_design_scores_gemma":[0.017609973,0.032461133,0.94670874,0.00012647283,0.00067486026,0.000003832519,0.00009899984,0.00012962052,0.0019769769,0.0000122706515,0.0001492928,0.00004785576],"about_ca_topic_score_codex":0.00059467787,"about_ca_topic_score_gemma":0.00063780486,"teacher_disagreement_score":0.097190045,"about_ca_system_score_codex":0.00032647778,"about_ca_system_score_gemma":0.0029700072,"threshold_uncertainty_score":0.52686656},"labels":[],"label_agreement":null},{"id":"W2241649014","doi":"10.1200/jco.2015.33.3_suppl.768","title":"Time to adjuvant chemotherapy (TTAC) after open or laparoscopic resection surgeries in colorectal cancers (CRC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Surgery; Colorectal cancer; Complication; Laparoscopic surgery; Chemotherapy; General surgery; Cancer; Laparoscopy; Internal medicine","score_opus":0.17566854186286682,"score_gpt":0.5020913002946933,"score_spread":0.32642275843182644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241649014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98172045,0.00024855035,0.0000030598517,0.007942142,0.001789355,0.00064594334,0.000005344305,0.000010905166,0.007634244],"genre_scores_gemma":[0.9893173,0.00022120168,0.0011120366,0.003445411,0.0008138341,0.00007391113,0.0000023044192,0.000029004528,0.004984999],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966281,0.00049246295,0.0018222531,0.00028509396,0.00044343947,0.00032862238],"domain_scores_gemma":[0.9967009,0.0012011518,0.0006855235,0.00016883049,0.00042865958,0.0008149529],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030184283,0.00018124348,0.0019996364,0.00019149079,0.000021212603,0.000023712184,0.00024702962,0.00034408536,0.0018957722],"category_scores_gemma":[0.0034646797,0.00011871154,0.00024639588,0.00044681245,0.0001836662,0.00022079129,0.00014014285,0.00066215044,0.00017178233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44469914,0.0026714252,0.3905643,0.000030006036,0.0005480354,0.0054825475,0.00086492096,0.000075858494,0.00017779111,0.0000035001206,0.048706975,0.10617551],"study_design_scores_gemma":[0.029152658,0.060725614,0.56621283,0.00029531296,0.00013082745,0.00046798761,0.00018835237,0.0000634308,0.0005554141,0.00010190218,0.34191394,0.0001916921],"about_ca_topic_score_codex":0.00027204782,"about_ca_topic_score_gemma":0.002127687,"teacher_disagreement_score":0.41554648,"about_ca_system_score_codex":0.0017448914,"about_ca_system_score_gemma":0.005205561,"threshold_uncertainty_score":0.99901664},"labels":[],"label_agreement":null},{"id":"W2241688186","doi":"10.1200/jco.2007.25.18_suppl.10555","title":"<i>MMP1 1G/2G</i> promoter polymorphism and risk of esophageal adenocarcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Genotype; MMP1; Odds ratio; Genotyping; Gastroenterology; Internal medicine; Adenocarcinoma; Lung cancer; Allele; Esophageal cancer; Body mass index; Oncology; Cancer; Biology; Genetics; Gene","score_opus":0.0858267802345803,"score_gpt":0.46017296418883485,"score_spread":0.37434618395425456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241688186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97866285,0.01569579,0.000161388,0.0025929355,0.00040561796,0.00023885883,0.0000070972546,0.00000586985,0.0022295658],"genre_scores_gemma":[0.99129486,0.0027952548,0.0037811236,0.00064297696,0.0011501916,0.0000014328066,0.0000012211306,0.000015303955,0.00031763042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676126,0.00030859237,0.0019042447,0.00018633089,0.0005095889,0.00033000007],"domain_scores_gemma":[0.995595,0.0017202458,0.0013499707,0.00019619202,0.00036258396,0.0007760173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005114417,0.00013443202,0.0012603556,0.00016959221,0.000037876227,0.0000050426484,0.00012422481,0.00030359477,0.00014794586],"category_scores_gemma":[0.0018052238,0.00008751112,0.00039711694,0.00012778801,0.0004005163,0.00008497389,0.0000654338,0.0010894558,0.000011603618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066065076,0.0012508514,0.82102484,0.00004080146,0.0006317648,0.005102467,0.00009787827,3.0636352e-7,0.00006464597,0.000090103465,0.0009893187,0.1641005],"study_design_scores_gemma":[0.010685133,0.025881937,0.9565982,0.00006008756,0.00056806597,0.0013728334,0.000046715842,0.000008170857,0.001152242,0.00054128637,0.003028632,0.00005670334],"about_ca_topic_score_codex":0.000090752794,"about_ca_topic_score_gemma":0.00005216261,"teacher_disagreement_score":0.1640438,"about_ca_system_score_codex":0.00011913244,"about_ca_system_score_gemma":0.0010437801,"threshold_uncertainty_score":0.4733204},"labels":[],"label_agreement":null},{"id":"W2241776649","doi":"10.1200/jco.2007.25.18_suppl.19575","title":"Efficacy and compliance of small-bore chest tube insertion and pleurodesis protocols for the treatment of malignant pleural effusions","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Health Canada","funders":"","keywords":"Pleurodesis; Medicine; Chest tube; Pneumothorax; Surgery; Malignant pleural effusion; Chest pain; Pleural effusion; Catheter; Thoracoscopy; Anesthesia","score_opus":0.32206598449247265,"score_gpt":0.5015120283746474,"score_spread":0.17944604388217472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241776649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99086404,0.00076691556,0.00012970499,0.0048559066,0.000098004326,0.0032101825,0.000021975535,0.000002949165,0.000050330444],"genre_scores_gemma":[0.99575084,0.0012933918,0.002125421,0.0003052375,0.00032151182,0.00009153667,0.0000029482762,0.000008035175,0.00010109451],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981083,0.00010739509,0.0013964713,0.00011686478,0.00013297066,0.0001379879],"domain_scores_gemma":[0.9940303,0.004444131,0.0009452244,0.00011702198,0.0002463052,0.00021703367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001035678,0.000101144346,0.0008843831,0.000048445072,0.00004825718,0.000002751422,0.00007362626,0.000118260905,0.0000105772215],"category_scores_gemma":[0.0010904697,0.00005067197,0.00023225816,0.000068889785,0.0002637335,0.000032664473,0.000019856521,0.00013376893,2.7309437e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044175006,0.00725025,0.29856774,0.00036677264,0.00041635227,0.0001858631,0.00022833278,0.000010653955,0.009240728,0.00010845429,0.00034099777,0.63910884],"study_design_scores_gemma":[0.00863278,0.027473524,0.9400125,0.00025314587,0.00045662507,0.00019347551,0.0000768441,0.00020595799,0.0008714442,0.00009392735,0.021683631,0.00004612779],"about_ca_topic_score_codex":0.000018515093,"about_ca_topic_score_gemma":0.000049020473,"teacher_disagreement_score":0.6414448,"about_ca_system_score_codex":0.000033374658,"about_ca_system_score_gemma":0.00024858848,"threshold_uncertainty_score":0.2066343},"labels":[],"label_agreement":null},{"id":"W2241845951","doi":"10.1200/jco.2006.24.18_suppl.5501","title":"Impact of age on treatment effect in locally advanced head and neck cancer (HNC): Two individual patient data meta-analyses","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Concomitant; Confidence interval; Hazard ratio; Head and neck cancer; Radiation therapy; Lung cancer; Internal medicine; Cancer; Randomized controlled trial; Chemotherapy; Stage (stratigraphy); Surgery; Oncology","score_opus":0.42021147475404674,"score_gpt":0.6079886255106417,"score_spread":0.18777715075659496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241845951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974216,0.0075501264,0.00000442375,0.0014069304,0.0002414619,0.00027207885,0.00007703229,0.0000031375112,0.0007026397],"genre_scores_gemma":[0.9961529,0.0021174985,0.0007844959,0.00053591613,0.0003304909,0.0000114197655,0.000011608034,0.000011618497,0.0000440657],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965092,0.00052300363,0.0021126438,0.00026061424,0.00036176702,0.00023278878],"domain_scores_gemma":[0.99548995,0.002666544,0.0012099,0.0002997169,0.0001384553,0.0001954533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014846273,0.00022016482,0.0036918668,0.00015850764,0.000022953665,0.0000049490864,0.00013741454,0.0001447795,0.00006812155],"category_scores_gemma":[0.0011307696,0.00010481116,0.0006995438,0.0001517551,0.00017371261,0.000084925174,0.00008400949,0.00044336639,0.0000013430111],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013900398,0.004671982,0.41305742,0.000039728086,0.012979854,0.0013621692,0.00015568196,0.000961162,0.0003843441,0.0000065148565,0.004057265,0.54842347],"study_design_scores_gemma":[0.019669196,0.10965025,0.85755736,0.00016046433,0.007585542,0.000040714593,0.000020200028,0.00005039303,0.00022101578,0.000053956515,0.0048965625,0.000094357136],"about_ca_topic_score_codex":0.0019073217,"about_ca_topic_score_gemma":0.004489224,"teacher_disagreement_score":0.5483291,"about_ca_system_score_codex":0.00028000455,"about_ca_system_score_gemma":0.0009944896,"threshold_uncertainty_score":0.4274075},"labels":[],"label_agreement":null},{"id":"W2241922694","doi":"10.1200/jco.2015.33.7_suppl.204","title":"Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Concomitant; Proportional hazards model; Hazard ratio; Internal medicine; Prostate cancer; Oncology; Overall survival; Cancer; Survival analysis; Confidence interval","score_opus":0.26717341114004217,"score_gpt":0.4870697250051652,"score_spread":0.21989631386512304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241922694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587898,0.010203462,0.00029119046,0.0065514934,0.022460822,0.0004842367,0.00008066223,0.000007663443,0.0011306434],"genre_scores_gemma":[0.91245526,0.03834175,0.004569738,0.0028770308,0.040751096,0.000031461608,0.00010483822,0.00004602287,0.0008227739],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971456,0.00038873905,0.0016324832,0.000319167,0.00026996835,0.0002440206],"domain_scores_gemma":[0.99736255,0.00029034773,0.0013165517,0.00042240764,0.00035027054,0.00025785706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004218323,0.0001335236,0.00075719605,0.00006337026,0.000031331496,0.000018119235,0.0005370732,0.0003288952,0.000016442395],"category_scores_gemma":[0.0055068666,0.000104413666,0.00012778268,0.00011486037,0.00018450498,0.000035741385,0.0003341878,0.0005060081,0.0000035086891],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005134703,0.00088815024,0.18876426,0.00004771449,0.00032917017,0.000023345474,0.00044852693,0.00018325249,0.0024769842,0.00005922462,0.664796,0.1368487],"study_design_scores_gemma":[0.005293935,0.0015523501,0.013654413,0.00006906036,0.00008030682,0.000074412135,0.00029129614,0.00017794674,0.00010963921,0.00007115858,0.9785004,0.00012506594],"about_ca_topic_score_codex":0.00054305367,"about_ca_topic_score_gemma":0.0067196125,"teacher_disagreement_score":0.31370443,"about_ca_system_score_codex":0.00010924526,"about_ca_system_score_gemma":0.005296288,"threshold_uncertainty_score":0.9395388},"labels":[],"label_agreement":null},{"id":"W2241927486","doi":"10.1200/jco.2004.22.90140.4195","title":"A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Toxicity; Chemotherapy; Internal medicine; Surgery; Radiation therapy; Gastroenterology; Cancer; Urology","score_opus":0.22569437050080954,"score_gpt":0.5302029612387457,"score_spread":0.3045085907379361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241927486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965186,0.0012092916,0.00001996654,0.007989111,0.00014673136,0.0005081939,0.0000031518446,0.0000027354308,0.00046898238],"genre_scores_gemma":[0.9978424,0.00040702507,0.0004218634,0.000977888,0.00023797217,0.000010857636,5.760559e-7,0.000009655693,0.00009181774],"study_design_codex":"nonrandomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99672556,0.00021495235,0.0023807979,0.00015036181,0.00036835624,0.00015997104],"domain_scores_gemma":[0.9970237,0.0009945194,0.0012134786,0.00029060352,0.00027232905,0.00020539637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001821625,0.00011891998,0.0012489518,0.000063720865,0.000045964698,0.000002306761,0.00031137362,0.00013994699,0.0001444391],"category_scores_gemma":[0.0015770853,0.00006921571,0.000326008,0.00034728344,0.0002632663,0.000053890933,0.000053349675,0.0009426347,0.0000022853574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042742502,0.4255467,0.35921353,0.00034424683,0.0031134752,0.0022084678,0.004910068,0.004372711,0.05192175,0.0008215883,0.0005885412,0.10421642],"study_design_scores_gemma":[0.2778675,0.2187133,0.3880293,0.00043541312,0.0017380423,0.0013832373,0.0017829607,0.00021087613,0.09739584,0.004881789,0.0072860327,0.00027573222],"about_ca_topic_score_codex":0.00004125939,"about_ca_topic_score_gemma":0.000018681349,"teacher_disagreement_score":0.23512499,"about_ca_system_score_codex":0.00008020251,"about_ca_system_score_gemma":0.0010200685,"threshold_uncertainty_score":0.4095331},"labels":[],"label_agreement":null},{"id":"W2241992350","doi":"10.1200/jco.2007.25.18_suppl.8577","title":"Clinical outcome of metastatic melanoma involving the CNS with or without (w/o) intracranial hemorrhage (IHC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Craniotomy; Brain metastasis; Malignancy; Surgery; Melanoma; Radiation therapy; Retrospective cohort study; Internal medicine; Metastasis; Cancer","score_opus":0.21265123183466633,"score_gpt":0.5103226981831172,"score_spread":0.2976714663484508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241992350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868541,0.00042429668,0.004546101,0.005613014,0.0011801035,0.0004202527,0.000005730627,0.000009804366,0.0009466307],"genre_scores_gemma":[0.90008986,0.00017765479,0.09479764,0.0034240317,0.0012420306,0.0000021778558,0.0000018829172,0.000026733485,0.00023798972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99240345,0.00097421656,0.005367431,0.00024331639,0.00064434775,0.00036725032],"domain_scores_gemma":[0.9836472,0.011441677,0.0034578117,0.00040091967,0.000520186,0.000532195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019184507,0.00022733296,0.0028706442,0.00012130211,0.00006436885,0.000010003794,0.0002820198,0.00026590133,0.00038207896],"category_scores_gemma":[0.0069306046,0.000095880765,0.0008459753,0.00023641138,0.00067224936,0.00009650426,0.00007046322,0.0015462072,0.000015643258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020940466,0.0038631244,0.68747795,0.00007733925,0.0016645126,0.011171227,0.00011747963,0.0000055123546,0.00001885328,0.00018128115,0.00033704942,0.27414522],"study_design_scores_gemma":[0.03517244,0.07972657,0.85115993,0.00022002893,0.005977588,0.0120493015,0.0015250229,0.00046064515,0.0000755255,0.00029662374,0.013103695,0.00023263582],"about_ca_topic_score_codex":0.000039732597,"about_ca_topic_score_gemma":0.00037460006,"teacher_disagreement_score":0.27391258,"about_ca_system_score_codex":0.00009310783,"about_ca_system_score_gemma":0.0013238863,"threshold_uncertainty_score":0.82970816},"labels":[],"label_agreement":null},{"id":"W2242036825","doi":"10.1200/jco.2015.65.8633","title":"Reply to N. Osazuwa-Peters et al","year":2016,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Suicide and Self-Harm Studies","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychosocial; Survivorship curve; Population; Distress; Health care; Family medicine; Gerontology; Head and neck cancer; Cancer; Psychiatry; Clinical psychology; Environmental health","score_opus":0.20825509048762506,"score_gpt":0.5272669725532021,"score_spread":0.31901188206557707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242036825","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010142329,0.00203476,0.00044557438,0.8768505,0.049137313,0.0003630554,0.00006287242,0.000023816148,0.060939807],"genre_scores_gemma":[0.0018416404,0.0036804993,0.0031187169,0.93501586,0.028373912,0.000020619598,0.0000065958275,0.00011877036,0.027823415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.980187,0.007493794,0.008889572,0.0010500812,0.0009622464,0.001417333],"domain_scores_gemma":[0.9608257,0.029039817,0.0070409575,0.0009470923,0.0012002916,0.0009461838],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.015999144,0.000789093,0.005886866,0.0005718669,0.00014009408,0.00004624981,0.0015302625,0.0028173795,0.0054654037],"category_scores_gemma":[0.011425935,0.0005454142,0.0028973734,0.00027191613,0.0007629232,0.00021150836,0.00046086436,0.00874823,0.0061324183],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003920345,0.0007963601,0.00952416,0.000027519607,0.003355048,0.011095452,0.00074109656,0.0000016511541,0.000026558437,0.00035324748,0.8723137,0.0978449],"study_design_scores_gemma":[0.0071894717,0.019869294,0.024940966,0.0001852419,0.00080865854,0.0015206723,0.00024593176,5.732437e-7,0.000003928472,0.0010194113,0.94364023,0.000575628],"about_ca_topic_score_codex":0.00017324378,"about_ca_topic_score_gemma":0.00009147081,"teacher_disagreement_score":0.097269274,"about_ca_system_score_codex":0.00047517137,"about_ca_system_score_gemma":0.0021400338,"threshold_uncertainty_score":0.9996997},"labels":[],"label_agreement":null},{"id":"W2242086095","doi":"10.1200/jco.2006.24.18_suppl.7159","title":"Determining incidence and predictors of deep vein thrombosis in patients with non-small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Deep vein; Incidence (geometry); Retrospective cohort study; Confidence interval; Cohort; Stage (stratigraphy); Cancer; Thrombosis; Chemotherapy; Oncology; Surgery","score_opus":0.02858200315909857,"score_gpt":0.3874200943881223,"score_spread":0.3588380912290237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242086095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979716,0.0005052082,0.000028889372,0.0004332547,0.0003245622,0.00020311965,0.0000024130616,0.0000019766169,0.00052895804],"genre_scores_gemma":[0.9972194,0.0005338622,0.0016958434,0.00025830985,0.00025918655,0.000008539136,0.0000010917757,0.000010560513,0.000013211953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981269,0.00008780211,0.0012612082,0.00014501654,0.00022782282,0.00015123056],"domain_scores_gemma":[0.9976695,0.00073998264,0.0011265336,0.00009601101,0.0002314693,0.00013650327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005603404,0.00010280128,0.0009611566,0.00009012949,0.000014412806,0.0000036516174,0.00006619521,0.0001591691,0.000025651436],"category_scores_gemma":[0.00015016044,0.00006497037,0.000106511856,0.00009585398,0.000110477755,0.000072082694,0.000030205376,0.00031740966,3.1204618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006672045,0.0016963944,0.98834646,0.0000772675,0.00013012042,0.0000769477,0.00012404256,0.00007782577,0.0000097418715,0.0000014662439,0.00023579398,0.0085567245],"study_design_scores_gemma":[0.011225326,0.009534378,0.9777044,0.00048687027,0.0005300379,0.000005855318,0.00002885879,0.00012865699,0.00013527661,0.000009636436,0.00015456765,0.0000561519],"about_ca_topic_score_codex":0.00023477114,"about_ca_topic_score_gemma":0.000980774,"teacher_disagreement_score":0.010642086,"about_ca_system_score_codex":0.00025901667,"about_ca_system_score_gemma":0.0006072105,"threshold_uncertainty_score":0.26494148},"labels":[],"label_agreement":null},{"id":"W2242136787","doi":"10.1200/jco.2005.23.16_suppl.4561","title":"Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer; analysis by baseline pain","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Brief Pain Inventory; Placebo; Zoledronic acid; Prostate cancer; Bone pain; Cancer pain; Cancer; Internal medicine; Physical therapy; Chronic pain","score_opus":0.018222358052365977,"score_gpt":0.41371154025705176,"score_spread":0.39548918220468576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242136787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952542,0.0010862192,0.00006921033,0.0030619507,0.000075085554,0.00039947339,0.000019667094,0.000003960899,0.000030195322],"genre_scores_gemma":[0.99678606,0.00072481815,0.0007411935,0.0015775332,0.00008321183,0.000011944887,0.000019613055,0.000011666316,0.000043935226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951469,0.0023917155,0.0016764137,0.00019911044,0.00032972972,0.0002561736],"domain_scores_gemma":[0.9947047,0.0032549396,0.0013481575,0.00013834207,0.00017447164,0.00037936657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011571195,0.0001548176,0.0017832754,0.0001927055,0.000021277172,0.000001923585,0.000046620382,0.00018858476,0.00004156277],"category_scores_gemma":[0.0032778867,0.0000929588,0.00022038103,0.00028530447,0.00011530499,0.00007204548,0.000013460205,0.0006453977,0.0000013724709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012373166,0.0015803331,0.53698105,0.00004953405,0.00033492557,0.000047448946,0.000014027661,0.0000706056,0.0000074047502,2.535948e-7,0.00022660139,0.44831464],"study_design_scores_gemma":[0.036319222,0.102483906,0.8543512,0.00020106365,0.0011897725,0.0000056775475,0.0000068867243,0.0011649901,0.00012419325,0.0000037636287,0.0040619234,0.000087397246],"about_ca_topic_score_codex":0.000096297634,"about_ca_topic_score_gemma":0.0006275739,"teacher_disagreement_score":0.44822723,"about_ca_system_score_codex":0.00022609049,"about_ca_system_score_gemma":0.00048374495,"threshold_uncertainty_score":0.40103683},"labels":[],"label_agreement":null},{"id":"W2242175800","doi":"10.1200/jco.2014.32.4_suppl.27","title":"Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Internal medicine; Prostate cancer; Oncology; Enzalutamide; Proportional hazards model; Clinical endpoint; Prednisone; Hazard ratio; Prostate-specific antigen; Chemotherapy; Docetaxel; Quartile; Androgen deprivation therapy; Gastroenterology; Confidence interval; Cancer; Randomized controlled trial; Androgen receptor","score_opus":0.07434432422303437,"score_gpt":0.44626457041811074,"score_spread":0.37192024619507635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242175800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815272,0.00021288915,0.00014892538,0.016656158,0.0006384652,0.0003875915,0.00020272928,0.000008554241,0.00021748639],"genre_scores_gemma":[0.9841779,0.00080941775,0.009635403,0.004533721,0.00036579103,0.000012026793,0.000064189626,0.000021725094,0.00037981232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936899,0.0010943769,0.0038619125,0.00032617102,0.00073854317,0.00028911003],"domain_scores_gemma":[0.9849315,0.00864317,0.004736391,0.00023822309,0.0011306403,0.00032004848],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066786017,0.0002175552,0.0025265466,0.000103933955,0.00003889907,0.000006949993,0.00013797215,0.00026705864,0.00005799231],"category_scores_gemma":[0.014738435,0.00012275841,0.0002444896,0.00017614836,0.00045500093,0.00010615698,0.00002552649,0.0011510674,0.000005496347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022538051,0.0032130254,0.9420134,0.000031399588,0.0015146708,0.00025763776,0.00050989375,0.000038175705,0.00001837568,0.000008067109,0.0048735775,0.024983743],"study_design_scores_gemma":[0.056191273,0.01770021,0.915343,0.00040793544,0.0011249281,0.000011147468,0.00021575089,0.00013730764,0.000054020373,0.000109152024,0.0085719135,0.00013340557],"about_ca_topic_score_codex":0.00041887272,"about_ca_topic_score_gemma":0.0016241646,"teacher_disagreement_score":0.033653222,"about_ca_system_score_codex":0.0001661967,"about_ca_system_score_gemma":0.0010768113,"threshold_uncertainty_score":0.99356085},"labels":[],"label_agreement":null},{"id":"W2242180794","doi":"10.1200/jco.2006.24.18_suppl.20078","title":"Homocysteine (HC) level as possible predictor of pemetrexed efficacy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Oncology; Breast cancer; Lung cancer; Thymidylate synthase; Clinical trial; Clinical endpoint; Cancer; non-small cell lung cancer (NSCLC); Chemotherapy; Cisplatin","score_opus":0.1174673415127637,"score_gpt":0.5064209303012609,"score_spread":0.3889535887884972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242180794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963348,0.0009569682,0.00020039028,0.006004923,0.0010449379,0.00021204309,0.000016985909,0.0000099537965,0.028205814],"genre_scores_gemma":[0.986903,0.00014302168,0.005598279,0.000580109,0.0014371595,0.0000024957233,0.000009345059,0.000014311689,0.0053122807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971533,0.0001330273,0.0020640306,0.00012853966,0.0003547751,0.00016632737],"domain_scores_gemma":[0.99642426,0.001146296,0.0014538724,0.00017214831,0.0005780766,0.0002253558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009273285,0.00010607821,0.0011459098,0.00015183892,0.000030184035,0.0000046592645,0.000109747896,0.00023036626,0.00030536114],"category_scores_gemma":[0.001631783,0.00006955132,0.00047650476,0.00018475314,0.000158299,0.00007437115,0.00002417082,0.00039126692,0.000025187597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013220066,0.02968225,0.5512913,0.00022258134,0.0042309132,0.0029610381,0.00042549227,0.00021989265,0.0029358563,0.0036166965,0.10288427,0.28830963],"study_design_scores_gemma":[0.024075018,0.019978445,0.8755248,0.0001620812,0.0015437828,0.0004987278,0.000075141266,0.000027779633,0.0005888529,0.0008116418,0.07663653,0.00007716336],"about_ca_topic_score_codex":0.00018648706,"about_ca_topic_score_gemma":0.00004144849,"teacher_disagreement_score":0.32423353,"about_ca_system_score_codex":0.00014477682,"about_ca_system_score_gemma":0.002257071,"threshold_uncertainty_score":0.40039468},"labels":[],"label_agreement":null},{"id":"W2242192297","doi":"10.1200/jco.2007.25.18_suppl.4031","title":"Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2<sup>nd</sup>-line treatment for patients with metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Oxaliplatin; Medicine; Capecitabine; Internal medicine; Irinotecan; FOLFOX; Fluorouracil; Regimen; Oncology; Colorectal cancer; Clinical endpoint; Folinic acid; Chemotherapy; Hazard ratio; Gastroenterology; Cancer; Clinical trial; Confidence interval","score_opus":0.09282949187002007,"score_gpt":0.454005148675823,"score_spread":0.3611756568058029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242192297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322915,0.0012787317,0.00020680412,0.0015042629,0.00074629765,0.0021552516,0.00013255201,0.000014050919,0.00073291507],"genre_scores_gemma":[0.9910642,0.0014186001,0.005261666,0.00033952662,0.0012054929,0.00011395709,0.00003974014,0.000043313597,0.00051349105],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946361,0.00024348791,0.0034873479,0.00043176615,0.000681331,0.00051995076],"domain_scores_gemma":[0.9912687,0.004270089,0.002630272,0.00019678519,0.0010907328,0.0005434241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023030564,0.0004404499,0.003386233,0.00022347768,0.00013937488,0.000013695713,0.000124959,0.00028158972,0.00019727551],"category_scores_gemma":[0.0019352186,0.00026748868,0.0006128211,0.000250753,0.0004076478,0.00015668229,0.000055298373,0.00047387928,0.0000021644296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5943476,0.01714753,0.023130853,0.000076999226,0.0033730231,0.0003198648,0.0008045492,0.00004095826,0.00007244397,0.000062297724,0.0005774999,0.36004642],"study_design_scores_gemma":[0.56861794,0.3679176,0.035847064,0.00018173084,0.003987691,0.000112901515,0.00049558113,0.00033082272,0.0005878699,0.00013178478,0.021509098,0.0002799311],"about_ca_topic_score_codex":0.00044809052,"about_ca_topic_score_gemma":0.00153339,"teacher_disagreement_score":0.35976648,"about_ca_system_score_codex":0.0007004281,"about_ca_system_score_gemma":0.0017529898,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W2242211041","doi":"10.1200/jco.2007.25.18_suppl.lba4509","title":"Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Cetuximab; Clinical endpoint; Hazard ratio; Pancreatic cancer; Oncology; Performance status; Phases of clinical research; Chemotherapy; Randomization; Cancer; Clinical trial; Confidence interval; Colorectal cancer","score_opus":0.15502078437868838,"score_gpt":0.5070348059410741,"score_spread":0.3520140215623857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242211041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376893,0.00030792135,0.0003777698,0.00034726798,0.0005964022,0.0034694755,0.000006220492,0.000015440053,0.0011105584],"genre_scores_gemma":[0.9949495,0.00011636239,0.003960368,0.00023289428,0.00032159942,0.000043661563,0.000008255425,0.000052583466,0.0003147364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.989413,0.001409138,0.0061343387,0.0005631147,0.0016424125,0.0008379465],"domain_scores_gemma":[0.98571503,0.008061748,0.0030559027,0.0006395741,0.001679663,0.00084809744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009519364,0.00043787836,0.005721632,0.0007308765,0.00008444939,0.000010209859,0.0005017217,0.00033418424,0.000290071],"category_scores_gemma":[0.007968915,0.00027051682,0.0003160997,0.000983642,0.00050749653,0.0002375035,0.0001752994,0.001961233,0.000013199482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30229908,0.07830156,0.5790786,0.00008132004,0.0019312626,0.005341287,0.0012771499,0.000028517366,0.00001215608,0.000007047698,0.00010120051,0.03154084],"study_design_scores_gemma":[0.27192083,0.2799581,0.43740022,0.00013155791,0.0019603306,0.000082312756,0.0081632035,0.00013501951,0.000005070395,0.0000096933045,0.00010448022,0.00012916791],"about_ca_topic_score_codex":0.00020834673,"about_ca_topic_score_gemma":0.00212297,"teacher_disagreement_score":0.20165655,"about_ca_system_score_codex":0.0007586085,"about_ca_system_score_gemma":0.004547394,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W2242214733","doi":"10.1200/jco.2014.32.31_suppl.215","title":"Oral oncolytics: Patient-monitoring improvements in private practice.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Audit; Medical prescription; Adverse effect; Private practice; Patient education; Quality management; Emergency medicine; Internal medicine; Family medicine; Nursing","score_opus":0.19602206512092982,"score_gpt":0.5319561167904352,"score_spread":0.3359340516695054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242214733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708629,0.000114531,0.00070406497,0.009807721,0.0024656872,0.00018955872,2.0643155e-7,0.000007274201,0.015848046],"genre_scores_gemma":[0.9746104,0.00029981593,0.017653773,0.005906375,0.0011396285,0.000004988711,4.6410125e-7,0.000008620893,0.00037595845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677306,0.00038508337,0.0021069916,0.00013596787,0.0004116605,0.00018722017],"domain_scores_gemma":[0.99550027,0.0016084417,0.0019839117,0.00018893312,0.0003937376,0.0003247222],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038255178,0.000083823455,0.0008054979,0.00008832315,0.000018414004,0.000006758171,0.00015171485,0.00020578408,0.00015154752],"category_scores_gemma":[0.014188443,0.000061843166,0.00014946531,0.0001285421,0.00008091564,0.0001745664,0.000043125176,0.0009475958,0.00017825153],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013168221,0.0015537385,0.19059528,0.000019238652,0.00007445454,0.0001749876,0.00007025105,0.0000039275574,0.00031657523,0.00017545794,0.0024351333,0.80326414],"study_design_scores_gemma":[0.008162713,0.014513977,0.2584105,0.00029768597,0.00011940327,0.00012895252,0.00029293046,0.00023355137,0.0002579703,0.0006483812,0.71685165,0.000082275394],"about_ca_topic_score_codex":0.000009045315,"about_ca_topic_score_gemma":0.0000018497758,"teacher_disagreement_score":0.8031818,"about_ca_system_score_codex":0.00013549588,"about_ca_system_score_gemma":0.0007964393,"threshold_uncertainty_score":0.9941155},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2242231555","doi":"10.1200/jco.2009.27.15_suppl.e11556","title":"Trastuzumab and vinorelbine (TV) in early stages of breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Vinorelbine; Trastuzumab; Chemotherapy; Regimen; Stage (stratigraphy); Internal medicine; Surgery; Neutropenia; Breast cancer; Cancer; Oncology","score_opus":0.09143339380531963,"score_gpt":0.5095466933966074,"score_spread":0.4181132995912878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242231555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784343,0.0015983848,0.0000033860267,0.018457659,0.00042960013,0.00010764429,0.0000083878185,0.0000027388853,0.0009578555],"genre_scores_gemma":[0.9933496,0.003847552,0.00029800727,0.001608086,0.0006643635,0.0000013629225,5.830244e-7,0.0000052816326,0.00022517529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981235,0.000150961,0.0013207025,0.000108634275,0.00014698751,0.00014920557],"domain_scores_gemma":[0.99822575,0.0005850656,0.0007551198,0.00006401356,0.00017034351,0.00019968663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082912995,0.000089244495,0.0011435042,0.00013190175,0.000009572046,0.0000019997476,0.00006222662,0.00020319977,0.00030569674],"category_scores_gemma":[0.00014970044,0.000061952225,0.00017281204,0.00011100629,0.00014417524,0.00006566585,0.000012300244,0.00053097197,0.0000012461845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008166832,0.0029959509,0.72548336,0.000019112902,0.0002071326,0.00049785996,0.00021111286,0.000005966565,0.0015631259,0.000050529416,0.0026524682,0.25814652],"study_design_scores_gemma":[0.012836566,0.021124598,0.9599675,0.00007566301,0.0002948441,0.00036105688,0.000030054536,0.000008482105,0.0001301087,0.00021080159,0.004914006,0.00004632362],"about_ca_topic_score_codex":0.00014885234,"about_ca_topic_score_gemma":0.00012338493,"teacher_disagreement_score":0.2581002,"about_ca_system_score_codex":0.00012266144,"about_ca_system_score_gemma":0.0007747556,"threshold_uncertainty_score":0.3347165},"labels":[],"label_agreement":null},{"id":"W2242232812","doi":"10.1200/jco.2006.24.18_suppl.7506","title":"Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Thrombosis; Internal medicine; Gastroenterology; Venous thrombosis; Pulmonary embolism; Adverse effect; Placebo; Population; Surgery","score_opus":0.07507461435833444,"score_gpt":0.4346187648664301,"score_spread":0.35954415050809563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242232812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964754,0.000211155,0.00022383415,0.0016953511,0.000030393521,0.00022022512,0.0000034758903,0.0000029462403,0.0011372069],"genre_scores_gemma":[0.9837424,0.00055725325,0.01547867,0.000080355414,0.00009474863,0.0000031110462,0.0000036025097,0.000010190935,0.000029638642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975949,0.0006081204,0.0011214674,0.0001304421,0.000380417,0.00016466243],"domain_scores_gemma":[0.99546534,0.0026942084,0.001166189,0.00011055812,0.00037074988,0.0001929784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024811563,0.0000978687,0.0010969964,0.00017110599,0.000021443308,0.0000044445787,0.00005306691,0.00015348964,0.000041758984],"category_scores_gemma":[0.0018063613,0.000054122924,0.00009552232,0.00017732618,0.0003960176,0.00007895552,0.000018559867,0.0005602695,0.0000014107972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014082814,0.00325642,0.9568428,0.00003052908,0.00035284378,0.00042497047,0.000024836589,0.000009979075,0.00018885966,0.000050996634,0.00014251347,0.024592457],"study_design_scores_gemma":[0.040788162,0.023219641,0.93401843,0.00017027477,0.00031725297,0.00019725732,0.000084060935,0.0001063366,0.00043356855,0.00029906983,0.00031781266,0.000048130947],"about_ca_topic_score_codex":0.0014985254,"about_ca_topic_score_gemma":0.0011574074,"teacher_disagreement_score":0.026705347,"about_ca_system_score_codex":0.000087284745,"about_ca_system_score_gemma":0.0006817044,"threshold_uncertainty_score":0.24341235},"labels":[],"label_agreement":null},{"id":"W2242250048","doi":"10.1200/jco.2013.31.15_suppl.10503","title":"Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Regorafenib; Medicine; PDGFRA; KRAS; Sunitinib; GiST; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Pazopanib; Cancer research; Cancer; Stromal cell; Colorectal cancer","score_opus":0.12255423432683973,"score_gpt":0.46507298537371955,"score_spread":0.3425187510468798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242250048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978336,0.000044410877,0.0000133235735,0.0006619821,0.00039144084,0.0008848047,0.000025861349,0.0000032027922,0.00014136922],"genre_scores_gemma":[0.9980006,0.000022706183,0.0015427552,0.000113693015,0.00022012931,0.000016248003,0.000051354524,0.000014712487,0.000017750743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99268025,0.0013682191,0.004296023,0.00030370522,0.0010554794,0.0002963362],"domain_scores_gemma":[0.9814439,0.013960153,0.003040057,0.0003225646,0.0008908689,0.00034248302],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034308822,0.00021244235,0.002323747,0.0004975716,0.000032468557,0.000009095852,0.00026234856,0.00017325171,0.0001874491],"category_scores_gemma":[0.010612238,0.00011991116,0.0004872379,0.0006780948,0.00034963986,0.00014411275,0.000073510884,0.0014708724,0.000008524107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05012044,0.035447452,0.89838684,0.000010190867,0.0018367149,0.0013013014,0.00044067323,0.00032900475,0.000026666577,0.000004689161,0.00019430372,0.011901721],"study_design_scores_gemma":[0.11486364,0.06269319,0.81823444,0.00010527848,0.0014949092,0.00001643004,0.0013837324,0.001055416,0.000011049915,0.00001405303,0.00005654228,0.00007132476],"about_ca_topic_score_codex":0.000996795,"about_ca_topic_score_gemma":0.0020478002,"teacher_disagreement_score":0.08015241,"about_ca_system_score_codex":0.0002252557,"about_ca_system_score_gemma":0.0009335285,"threshold_uncertainty_score":0.9977218},"labels":[],"label_agreement":null},{"id":"W2242303298","doi":"10.1200/jco.2006.24.18_suppl.647","title":"Is tamoxifen prevention in younger women underutilized? Analysis of competing causes of mortality","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; BC Cancer Agency","funders":"","keywords":"Tamoxifen; Medicine; Breast cancer; Oncology; Population; Proportional hazards model; Gynecology; Demography; Mortality rate; Internal medicine; Cancer; Obstetrics; Environmental health","score_opus":0.6768087129999506,"score_gpt":0.6024433985444637,"score_spread":0.07436531445548689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242303298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99132663,0.0006691018,0.0007076896,0.003945468,0.00046889976,0.00016274484,0.00006106136,0.0000030413507,0.0026553585],"genre_scores_gemma":[0.99602056,0.00021341718,0.0017738487,0.0015832902,0.00026221448,0.000005209448,0.0000057748257,0.000009251396,0.0001264213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98108435,0.0012183245,0.017049668,0.00024732586,0.0001547345,0.00024561453],"domain_scores_gemma":[0.97669935,0.0045906124,0.018073946,0.00027585184,0.00023675576,0.00012346181],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05770431,0.000111062225,0.0037549604,0.0007571481,0.000024762769,0.0000081805865,0.0002527163,0.00031277092,0.0006091398],"category_scores_gemma":[0.00789607,0.00012121224,0.0006581649,0.00052835606,0.00016701149,0.00030163882,0.000041822874,0.00034151177,0.000017776825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012463891,0.0009875715,0.98559475,0.00011176808,0.0010330175,0.0000032178407,0.00058341527,0.0011843304,0.0000055407904,0.009247759,0.0008322305,0.0002917312],"study_design_scores_gemma":[0.0019074886,0.0006381712,0.96507174,0.000053684038,0.0001656824,0.0000018560374,0.00075829047,0.0019778498,0.0000064922137,0.025839878,0.003482757,0.0000961172],"about_ca_topic_score_codex":0.0013511303,"about_ca_topic_score_gemma":0.0012175468,"teacher_disagreement_score":0.04980824,"about_ca_system_score_codex":0.00052564655,"about_ca_system_score_gemma":0.00064109894,"threshold_uncertainty_score":0.97029173},"labels":[],"label_agreement":null},{"id":"W2242358350","doi":"10.1200/jco.2005.23.16_suppl.3085","title":"A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clusterin; Docetaxel; Medicine; Toxicity; Internal medicine; Peripheral blood mononuclear cell; Phases of clinical research; Oncology; Chemotherapy; Apoptosis; Biology","score_opus":0.13743907630658406,"score_gpt":0.4899005935502139,"score_spread":0.35246151724362984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242358350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938601,0.000064633205,0.000292929,0.003870055,0.0005234497,0.00085074495,0.0000057147554,0.000009958234,0.00052236987],"genre_scores_gemma":[0.99181396,0.00003122311,0.004903764,0.002316018,0.00077027373,0.000014413947,0.000004199917,0.000026741978,0.0001193821],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951321,0.00086211314,0.0030356098,0.00029636815,0.00041688464,0.0002569444],"domain_scores_gemma":[0.9963696,0.00072160637,0.001643604,0.00031353647,0.00054743106,0.00040419464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027710889,0.00018170266,0.001668464,0.0004965739,0.000027383694,0.00000910637,0.0001681075,0.00026799855,0.0002487668],"category_scores_gemma":[0.0019979286,0.00014348987,0.00018398341,0.00034465414,0.00013712523,0.0001669016,0.00009858402,0.00074843096,0.000020094041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086591996,0.15971074,0.26777795,0.00026772748,0.0010788802,0.0112385955,0.007047454,0.0026169359,0.033359967,0.000093746305,0.0075347684,0.42268124],"study_design_scores_gemma":[0.12457734,0.18763448,0.671558,0.0002186399,0.00064549124,0.0023471292,0.0011410078,0.0026927267,0.0009316419,0.00005054268,0.007932688,0.00027031152],"about_ca_topic_score_codex":0.0000168912,"about_ca_topic_score_gemma":0.0017721901,"teacher_disagreement_score":0.42241094,"about_ca_system_score_codex":0.0002358979,"about_ca_system_score_gemma":0.0007565499,"threshold_uncertainty_score":0.5851347},"labels":[],"label_agreement":null},{"id":"W2242426121","doi":"10.1200/jco.2004.22.14_suppl.9599","title":"Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Univariate analysis; Temozolomide; Internal medicine; Radiation therapy; Performance status; Hazard ratio; Oncology; Proportional hazards model; Surgery; Toxicity; Multivariate analysis; Gastroenterology; Chemotherapy; Confidence interval","score_opus":0.06641120751578772,"score_gpt":0.4136619400437039,"score_spread":0.34725073252791616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242426121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627763,0.00006833678,0.00003634826,0.0011919205,0.0015747964,0.0006391078,0.0000038303438,0.000017523997,0.00019048784],"genre_scores_gemma":[0.99634904,0.0000775749,0.002501267,0.00042567117,0.0005969093,0.00000618809,0.0000057422462,0.000032946897,0.000004647443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486285,0.00051626354,0.0032337278,0.00033506926,0.00061918265,0.00043291046],"domain_scores_gemma":[0.98890984,0.007726881,0.0019620508,0.000229276,0.00049248,0.0006794861],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027428716,0.00026653064,0.0022224213,0.0002429276,0.000049736536,0.000015736156,0.00016254107,0.000501568,0.000042185857],"category_scores_gemma":[0.011725925,0.00015855284,0.0006430764,0.00030878227,0.00022606431,0.0001668729,0.00005699442,0.0013435014,0.000022504251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004519147,0.016548034,0.9382839,0.000019024968,0.00040135073,0.0018696067,0.00012528287,0.0001319892,0.0000027771325,0.00001543096,0.00006573655,0.038017727],"study_design_scores_gemma":[0.064434305,0.048208512,0.8855925,0.00038316468,0.00039783376,0.000033517743,0.00019327903,0.000008784996,0.000035493984,0.00004046448,0.0005362196,0.00013587959],"about_ca_topic_score_codex":0.000056957422,"about_ca_topic_score_gemma":0.000576109,"teacher_disagreement_score":0.059915155,"about_ca_system_score_codex":0.00034319668,"about_ca_system_score_gemma":0.0012350718,"threshold_uncertainty_score":0.9965987},"labels":[],"label_agreement":null},{"id":"W2242645455","doi":"10.1200/jco.2007.25.18_suppl.19673","title":"Usefulness of frailty markers in the assessment of the health and functional status in older cancer patient referred for chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Activities of daily living; Geriatric oncology; Adverse effect; Cancer; Mood; Gerontology; Geriatrics; Physical therapy; Internal medicine; Psychiatry","score_opus":0.17701296870439762,"score_gpt":0.5045272127969481,"score_spread":0.3275142440925505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242645455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97287613,0.00030565183,0.0004091449,0.024778882,0.00079164875,0.0005758051,0.00000975808,9.01958e-7,0.00025205076],"genre_scores_gemma":[0.99097174,0.00046542851,0.0018060858,0.00653971,0.0001687062,0.000010521373,0.0000015504289,0.0000071573363,0.00002912191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967216,0.00040247678,0.0021460734,0.00011473655,0.00040127686,0.0002138313],"domain_scores_gemma":[0.99427974,0.0035317459,0.0016493459,0.00015195619,0.000260046,0.00012715544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005384572,0.000083114064,0.0008196931,0.000095059615,0.00001822582,0.0000017566226,0.000093471324,0.00017010463,0.000045697747],"category_scores_gemma":[0.0013968047,0.000043391312,0.0001780834,0.00017050751,0.00020643484,0.000038919246,0.000022409216,0.0006645351,3.9147935e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00574367,0.0017409399,0.71737903,0.00010332203,0.000112448935,0.000009392148,0.0010818638,0.000043473992,0.00004432622,0.00007325944,0.005349478,0.26831883],"study_design_scores_gemma":[0.011876981,0.0062232055,0.96120256,0.00026057631,0.000028672812,0.000027303913,0.0012043463,0.00009824894,0.000041645253,0.00016131318,0.018840073,0.000035087436],"about_ca_topic_score_codex":0.00019004589,"about_ca_topic_score_gemma":0.0014725388,"teacher_disagreement_score":0.26828372,"about_ca_system_score_codex":0.00027592224,"about_ca_system_score_gemma":0.0024739034,"threshold_uncertainty_score":0.43885982},"labels":[],"label_agreement":null},{"id":"W2242665894","doi":"10.1200/jco.2009.27.15_suppl.8108","title":"An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Progressive disease; Chemotherapy; Phases of clinical research; Gastroenterology; Oncology; Surgery; Adverse effect","score_opus":0.12108365241612293,"score_gpt":0.5261446769068916,"score_spread":0.40506102449076864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242665894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772794,0.00016074102,0.0000049200644,0.008598958,0.0008640344,0.0013633744,0.000016384944,0.0000034058546,0.0012602243],"genre_scores_gemma":[0.9956638,0.000321207,0.00072360237,0.0019843876,0.0010264524,0.000009507691,0.0000016892268,0.000014473119,0.0002548375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99621147,0.00086822425,0.0017975521,0.00022971888,0.0005981203,0.0002949068],"domain_scores_gemma":[0.9959019,0.0009415755,0.00164477,0.0002874454,0.0009279962,0.00029633744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031012644,0.00015107065,0.0015080626,0.00012267295,0.00007423618,0.000010028924,0.0003907218,0.00023149373,0.000026475207],"category_scores_gemma":[0.0022746304,0.00007889233,0.00014896423,0.00029928723,0.00028555523,0.00017345212,0.00019754967,0.0013663856,7.490719e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7047566,0.053074945,0.15520573,0.00006569104,0.0006246476,0.00044867772,0.0015642644,0.000035365454,0.00090740516,0.00002277976,0.010892062,0.07240184],"study_design_scores_gemma":[0.4817266,0.23238184,0.280714,0.00055559416,0.0004706322,0.000009121798,0.00018988289,0.00007474868,0.0006431852,0.00004821795,0.0030623523,0.00012383344],"about_ca_topic_score_codex":0.00016219041,"about_ca_topic_score_gemma":0.00045110236,"teacher_disagreement_score":0.22303,"about_ca_system_score_codex":0.00040665088,"about_ca_system_score_gemma":0.0034483632,"threshold_uncertainty_score":0.61172485},"labels":[],"label_agreement":null},{"id":"W2242669247","doi":"10.1200/jco.2012.30.15_suppl.3572","title":"Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>k-RAS</i> wild-type (WT), metastatic colorectal carcinoma (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; University of Toronto; Moncton Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; Niagara Health System; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Cetuximab; Bevacizumab; Internal medicine; Clinical endpoint; Oncology; Placebo; Randomized controlled trial; Phases of clinical research; Colorectal cancer; Clinical trial; Cancer; Chemotherapy; Pathology","score_opus":0.04399735343700889,"score_gpt":0.3877906369926702,"score_spread":0.3437932835556613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242669247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613714,0.000703239,0.000023708952,0.00030830593,0.00031844398,0.0017926114,0.000053628777,0.000007969524,0.0006549796],"genre_scores_gemma":[0.9982356,0.00043513186,0.000786602,0.00017762685,0.0000891365,0.00003141594,0.00004486455,0.00004245409,0.00015721189],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931125,0.0015441199,0.0036228807,0.0003542189,0.0008492667,0.00051699043],"domain_scores_gemma":[0.99023217,0.0037143743,0.0047786576,0.00024650813,0.00074972503,0.0002785744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043965452,0.00038720726,0.006354402,0.0007586787,0.000043257085,0.000008807521,0.0002103842,0.00029118356,0.0001406029],"category_scores_gemma":[0.0024947717,0.00022793097,0.0008903572,0.0015243591,0.0006239246,0.00018200128,0.00003675267,0.0005425017,7.7448664e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7865916,0.011106724,0.17922248,0.000032391268,0.018433323,0.00031417597,0.0008150825,0.000025231919,0.000093350835,0.0000017153807,0.00016921893,0.0031947205],"study_design_scores_gemma":[0.76828533,0.038622927,0.1830324,0.00022294732,0.0087979045,0.000016266238,0.00021726564,0.00017518715,0.00013745895,0.000003989305,0.00029708663,0.00019124264],"about_ca_topic_score_codex":0.0002563889,"about_ca_topic_score_gemma":0.005155844,"teacher_disagreement_score":0.027516205,"about_ca_system_score_codex":0.00071761647,"about_ca_system_score_gemma":0.0018992099,"threshold_uncertainty_score":0.92947555},"labels":[],"label_agreement":null},{"id":"W2242679039","doi":"10.1200/jco.2007.25.18_suppl.7596","title":"A phase I/II study of OGX-011 and a gemcitabine (GEM)/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Neutropenia; Chills; Carboplatin; Chemotherapy; Gastroenterology; Nausea; Regimen; Chemotherapy regimen; Phases of clinical research; Surgery; Oncology; Cisplatin","score_opus":0.0563263400088554,"score_gpt":0.4597641198050049,"score_spread":0.40343777979614953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242679039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959329,0.0006486864,0.000088697474,0.0010186301,0.0004809435,0.0011947099,0.0000067466553,0.000006629554,0.00062210095],"genre_scores_gemma":[0.9962028,0.00065753196,0.0017176565,0.00089847366,0.00033715018,0.000020080033,0.000003018567,0.000032021864,0.00013121322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961078,0.00024326635,0.0026040804,0.00032684667,0.00037259253,0.00034537155],"domain_scores_gemma":[0.9950885,0.0014434278,0.0021683814,0.0002940778,0.00059466856,0.00041091177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022512584,0.00022645826,0.0017822442,0.00027148964,0.0000424612,0.0000032081487,0.00017560342,0.0002889726,0.00012495815],"category_scores_gemma":[0.0009949887,0.00015726262,0.00015291845,0.000251416,0.00023983921,0.00008872349,0.0001232907,0.0008644192,0.0000010482082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06871003,0.03718584,0.7980355,0.00008834451,0.00027824767,0.0014302789,0.0019550489,0.0000767588,0.00026502984,0.000001216777,0.00018556145,0.09178812],"study_design_scores_gemma":[0.13960864,0.1826861,0.6751743,0.00023574683,0.00032913015,0.00006817514,0.00050622097,0.00012148925,0.000094236704,0.000025541824,0.001015638,0.00013479228],"about_ca_topic_score_codex":0.00007333835,"about_ca_topic_score_gemma":0.00075361645,"teacher_disagreement_score":0.14550027,"about_ca_system_score_codex":0.00015384889,"about_ca_system_score_gemma":0.0006841943,"threshold_uncertainty_score":0.64129835},"labels":[],"label_agreement":null},{"id":"W2242698841","doi":"10.1200/jco.2015.33.7_suppl.487","title":"cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Papillary renal cell carcinomas; Medicine; Internal medicine; Cabozantinib; Oncology; Cohort; Cancer; Renal cell carcinoma; Clear cell renal cell carcinoma; Chromosome 7 (human); Cancer research; Pathology; Chromosome; Biology","score_opus":0.16531898721272034,"score_gpt":0.4756816781265127,"score_spread":0.3103626909137923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242698841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928543,0.00060609326,0.00001555794,0.00050189235,0.0008343841,0.003339129,0.00010522235,0.00001196618,0.0017314417],"genre_scores_gemma":[0.99511826,0.00014097031,0.0028794545,0.0004204945,0.0010702651,0.000079787904,0.000040094306,0.000088317596,0.0001623288],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9837135,0.0027188896,0.009817613,0.0010020061,0.0018430151,0.00090496935],"domain_scores_gemma":[0.9854756,0.0035595205,0.006543875,0.0008723664,0.0019088637,0.0016397972],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00813337,0.00065240683,0.0055396254,0.0008939025,0.000041709653,0.0000130758535,0.00052692386,0.0006584954,0.00005389032],"category_scores_gemma":[0.0037701805,0.00044197234,0.0006358697,0.0009940441,0.0004443854,0.00026970747,0.00019369653,0.0022197608,0.000007026949],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5964584,0.06605433,0.2907297,0.00012562831,0.00039629693,0.0042034253,0.0018142537,0.0004051867,0.00029076415,0.0000017663976,0.001099912,0.038420353],"study_design_scores_gemma":[0.41753092,0.4288896,0.14782687,0.000585551,0.00079898385,0.000048265054,0.0013289119,0.000035329842,0.0012363107,0.000011475314,0.0013983478,0.00030942872],"about_ca_topic_score_codex":0.00041747253,"about_ca_topic_score_gemma":0.0006627059,"teacher_disagreement_score":0.3628353,"about_ca_system_score_codex":0.000847958,"about_ca_system_score_gemma":0.0058539636,"threshold_uncertainty_score":0.9998032},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2242698910","doi":"10.1200/jco.2009.27.15_suppl.6585","title":"Adjuvant trastuzumab for breast cancer outside of clinical trials: Cardiotoxicity and economic evaluation","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Population; Cohort; Internal medicine; Clinical trial; Cardiotoxicity; Ejection fraction; Oncology; Cancer; Chemotherapy; Heart failure","score_opus":0.2815357367496858,"score_gpt":0.5791869458118583,"score_spread":0.29765120906217246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242698910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98847526,0.0033102783,0.00043955303,0.005219496,0.0016717211,0.00040507686,0.00019141487,0.0000021647452,0.0002850283],"genre_scores_gemma":[0.99085015,0.003960275,0.0011723312,0.000605587,0.0033662952,0.000015197122,0.000006758592,0.000009399094,0.000014028236],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99456096,0.0013662936,0.003462444,0.00027611278,0.00016571283,0.00016846681],"domain_scores_gemma":[0.99454075,0.0016530148,0.002982295,0.0001642829,0.00048790316,0.00017172704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015576071,0.00014692725,0.0021189523,0.00004091671,0.000036343485,0.000005568306,0.00013847879,0.00041356616,0.000024884377],"category_scores_gemma":[0.004895046,0.00010664419,0.0009072034,0.000023257342,0.0002052027,0.000009549529,0.000036602967,0.00023180079,6.1692833e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008403706,0.00059951935,0.054710582,0.0000107468095,0.0012616041,0.000003468167,0.000029259385,0.00018006469,0.00088766025,0.00002625502,0.0040440313,0.9298431],"study_design_scores_gemma":[0.015177908,0.0073601087,0.9645613,0.00004053595,0.0013024462,0.000096450036,0.000084683415,0.00023813728,0.0009361882,0.00057348044,0.009494514,0.00013423956],"about_ca_topic_score_codex":0.000034058143,"about_ca_topic_score_gemma":0.00015714021,"teacher_disagreement_score":0.92970884,"about_ca_system_score_codex":0.00009689665,"about_ca_system_score_gemma":0.0018320807,"threshold_uncertainty_score":0.5860181},"labels":[],"label_agreement":null},{"id":"W2242712018","doi":"10.1200/jco.2004.22.90140.6145","title":"Venous thrombosis in breast cancer patients receiving tamoxifen and/or chemotherapy: A systematic review","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Internal medicine; Chemotherapy; Oncology; Inclusion and exclusion criteria; Cancer; Grading (engineering); Grading scale; Gynecology; Surgery; Pathology; Alternative medicine","score_opus":0.18865759497152587,"score_gpt":0.5531279521266581,"score_spread":0.3644703571551322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242712018","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002477073,0.9933073,4.1483594e-7,0.0028472636,0.0011997999,0.0021527219,0.00002216362,0.0000071629897,0.00021549696],"genre_scores_gemma":[0.00014174762,0.9946931,0.0001184327,0.0039368956,0.0007761052,0.00013147283,0.0000068609984,0.000051301864,0.00014406406],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9927147,0.0010958958,0.005260037,0.00030847886,0.00032155265,0.00029931113],"domain_scores_gemma":[0.99153143,0.0022643155,0.0053568585,0.00020866322,0.00029332258,0.00034538502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026566682,0.00038867502,0.012829104,0.00022878188,0.000025841937,0.000007792632,0.00022187272,0.000744786,0.0004261329],"category_scores_gemma":[0.0010965064,0.00021526501,0.0012031541,0.00034445635,0.00013077255,0.00007286166,0.000052927797,0.0015110252,0.000014299849],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041008522,0.0038197886,0.00071462436,0.5924372,0.0017577215,0.00030628836,0.000056316298,5.9432583e-8,4.0476692e-8,7.762963e-7,0.0013520094,0.3991451],"study_design_scores_gemma":[0.007147146,0.007544656,0.0028626958,0.8150718,0.019413702,0.0013328015,0.0000040747586,3.1211326e-7,2.913296e-8,0.000012490217,0.14641927,0.00019102899],"about_ca_topic_score_codex":0.000053032174,"about_ca_topic_score_gemma":0.000046762965,"teacher_disagreement_score":0.39895406,"about_ca_system_score_codex":0.0013507194,"about_ca_system_score_gemma":0.005676363,"threshold_uncertainty_score":0.99996054},"labels":[],"label_agreement":null},{"id":"W2242741199","doi":"10.1200/jco.2006.24.18_suppl.4615","title":"Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Grip strength; Prostate cancer; Androgen deprivation therapy; Prospective cohort study; Timed Up and Go test; Muscle strength; Physical therapy; Cancer; Internal medicine","score_opus":0.06673752220993559,"score_gpt":0.4557290388157098,"score_spread":0.38899151660577425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242741199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919213,0.0008894617,0.00007431355,0.005587151,0.0001150413,0.00050100905,0.0000070905708,0.000007238671,0.0008973935],"genre_scores_gemma":[0.9961698,0.0017903156,0.00024985595,0.0005663542,0.00048285737,0.00003170339,0.000018620334,0.000017394443,0.0006731109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812347,0.00022639328,0.00085039216,0.00018055266,0.0003843817,0.00023480956],"domain_scores_gemma":[0.99838823,0.0004165977,0.000640363,0.000103178325,0.00030320478,0.00014841968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088611897,0.00012547625,0.000843248,0.00012097906,0.000030825708,0.0000101366595,0.00006618948,0.00011437625,0.000056107783],"category_scores_gemma":[0.00008897884,0.000071586706,0.00015176924,0.00029465492,0.00013517529,0.00013341023,0.000012332409,0.0005821715,0.0000061792493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03730949,0.006509821,0.6106733,0.000054007614,0.00075501885,0.000527613,0.00032987702,0.000059068312,0.007978627,0.000012312978,0.026768865,0.30902198],"study_design_scores_gemma":[0.046630006,0.030060343,0.90162176,0.00016433258,0.00028699322,0.00007186436,0.00011716227,0.0011994613,0.004996228,0.0007233817,0.013992867,0.00013558731],"about_ca_topic_score_codex":0.00020108355,"about_ca_topic_score_gemma":0.00006737186,"teacher_disagreement_score":0.30888638,"about_ca_system_score_codex":0.00025324913,"about_ca_system_score_gemma":0.0011299364,"threshold_uncertainty_score":0.29192212},"labels":[],"label_agreement":null},{"id":"W2242828348","doi":"10.1200/jco.2006.24.18_suppl.13529","title":"Outcomes of patients with metastatic colorectal carcinoma (MCRC) treated with first and second line chemotherapy at a multicenter cancer clinic","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FOLFOX; FOLFIRI; Medicine; Colorectal cancer; Regimen; Internal medicine; Chemotherapy; Surgery; Chemotherapy regimen; Population; Oncology; Irinotecan; Cancer; Oxaliplatin","score_opus":0.04496853518422443,"score_gpt":0.3897170291278443,"score_spread":0.34474849394361984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242828348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964669,0.0006876357,0.0000027422188,0.0016225383,0.00014988225,0.00042632627,0.000040743438,0.0000053152894,0.00059797114],"genre_scores_gemma":[0.9969948,0.00035833652,0.001000453,0.0005615407,0.00013037985,0.000016506843,0.000007520697,0.000022053271,0.00090839306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977542,0.000090525486,0.0014531185,0.00020997088,0.00028686825,0.00020531919],"domain_scores_gemma":[0.99648494,0.0012303393,0.0014909499,0.00010679992,0.00052115077,0.00016583058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034770707,0.00021121843,0.0019324226,0.00008495206,0.00005472443,0.000004387092,0.00005936477,0.00011523714,0.0004676831],"category_scores_gemma":[0.00014586013,0.00010567151,0.00022555186,0.00010825941,0.00036814433,0.00006238002,0.000032320317,0.0002781689,0.0000014695723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03748696,0.0028082957,0.9522402,0.00006047182,0.0017540044,0.00016699874,0.0001278075,0.000004342193,0.000007174064,8.0998996e-7,0.0006866617,0.0046562245],"study_design_scores_gemma":[0.04153814,0.03549031,0.9170491,0.00008021309,0.001187755,0.00003312063,0.000053879216,0.00001869009,0.00011037341,0.0000047445874,0.004335988,0.000097658085],"about_ca_topic_score_codex":0.0002244201,"about_ca_topic_score_gemma":0.008332885,"teacher_disagreement_score":0.035191122,"about_ca_system_score_codex":0.0002151948,"about_ca_system_score_gemma":0.0003946496,"threshold_uncertainty_score":0.5120802},"labels":[],"label_agreement":null},{"id":"W2242926421","doi":"10.1200/jco.2007.25.18_suppl.14560","title":"Capecitabine (X) compared to X + erlotinib (E) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Interim efficacy results from a randomized phase II study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Nausea; Adverse effect; Oxaliplatin; Colorectal cancer; Gastroenterology; Clinical endpoint; Discontinuation; Interim analysis; Oncology; Randomized controlled trial; Cancer","score_opus":0.11433778558321292,"score_gpt":0.4856005969043074,"score_spread":0.3712628113210945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242926421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121344,0.00031251542,0.000033276923,0.0032639096,0.0009784247,0.003395432,0.000081001956,0.00001495239,0.0007070167],"genre_scores_gemma":[0.9971148,0.00025851306,0.0011642375,0.00060021813,0.0005006971,0.00011122584,0.000030079322,0.000028768127,0.00019145767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99382746,0.00058072165,0.0041170814,0.00046739654,0.00058370415,0.00042365925],"domain_scores_gemma":[0.99008477,0.0066593825,0.0018145154,0.00021865913,0.00064400735,0.0005786607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029770928,0.00038240725,0.0047229766,0.00029271,0.00010464889,0.0000121780595,0.00015805905,0.00012724716,0.00017954003],"category_scores_gemma":[0.004437269,0.00021312034,0.00051276875,0.00036911637,0.00022207404,0.00007656616,0.00009676012,0.00051376416,0.000010451289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76780534,0.06204803,0.043593608,0.000005234648,0.0037557397,0.0015662243,0.00586496,0.00008027845,0.0000105901,0.0000010682369,0.0002672703,0.115001686],"study_design_scores_gemma":[0.56316465,0.19979094,0.2306896,0.00015150668,0.0017734792,0.0000167932,0.00077683455,0.00004161714,0.00004580868,0.000009387434,0.0034075915,0.00013177293],"about_ca_topic_score_codex":0.0031970274,"about_ca_topic_score_gemma":0.031880077,"teacher_disagreement_score":0.20464064,"about_ca_system_score_codex":0.0011531797,"about_ca_system_score_gemma":0.00095177477,"threshold_uncertainty_score":0.9857856},"labels":[],"label_agreement":null},{"id":"W2242926713","doi":"10.1200/jco.2004.22.90140.7529","title":"A meta-analysis of biochemotherapy (BCT) for the treatment of metastatic malignant melanoma (MM)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Randomized controlled trial; Meta-analysis; Oncology; Cochrane Library; Clinical trial; Immunotherapy; Relative risk; Surgery; Cancer; Confidence interval","score_opus":0.2551563295747263,"score_gpt":0.4505082426026526,"score_spread":0.19535191302792632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242926713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758529,0.008879948,0.012410151,0.0019300658,0.0003447448,0.0003401289,0.000089338304,0.0000013265524,0.00015136128],"genre_scores_gemma":[0.98584706,0.0029703155,0.010278654,0.0004399293,0.00024121172,0.00001959363,0.000012900487,0.000012689939,0.00017765138],"study_design_codex":"meta_analysis","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973443,0.00024861275,0.001897148,0.0001793205,0.00017454829,0.00015603976],"domain_scores_gemma":[0.9962477,0.0008720462,0.0020808047,0.00034239108,0.00035268973,0.000104369145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001734198,0.00014697062,0.0020658574,0.00010477868,0.00002709389,0.000003488196,0.00026659213,0.0001883663,0.000058993446],"category_scores_gemma":[0.000353508,0.00007334088,0.0036857822,0.00015679469,0.00018944065,0.000003067675,0.000018269833,0.000076574404,6.9945776e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063503645,0.00855509,0.0020470233,0.000051993255,0.7595048,0.00006823068,0.00046749864,0.0027993743,0.17432266,0.0016138233,0.000793922,0.04342521],"study_design_scores_gemma":[0.012464724,0.08583178,0.0057287547,0.000006989453,0.36904573,0.00008189609,0.00029572612,0.000114223556,0.38739884,0.0015705496,0.13720722,0.0002535551],"about_ca_topic_score_codex":0.000034350553,"about_ca_topic_score_gemma":0.00011074899,"teacher_disagreement_score":0.39045906,"about_ca_system_score_codex":0.00002302979,"about_ca_system_score_gemma":0.0006074283,"threshold_uncertainty_score":0.371721},"labels":[],"label_agreement":null},{"id":"W2243051347","doi":"10.1200/jco.2014.32.31_suppl.131","title":"Frequency and characteristics of cancer-related drowsiness (CRD or excessive daytime sleepiness) in patients with advanced cancer: Results of a prospective survey at a tertiary cancer center.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Epworth Sleepiness Scale; Pittsburgh Sleep Quality Index; Hospital Anxiety and Depression Scale; Internal medicine; Anxiety; Cancer; Depression (economics); Prospective cohort study; Center for Epidemiologic Studies Depression Scale; Physical therapy; Polysomnography; Insomnia; Apnea; Psychiatry; Sleep quality","score_opus":0.03169074607459509,"score_gpt":0.3947152384691481,"score_spread":0.363024492394553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243051347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962533,0.00062506524,0.000009781452,0.00074800657,0.0013366892,0.00044884247,0.00041958314,0.0000063454877,0.00015238336],"genre_scores_gemma":[0.9969773,0.0022211059,0.0001144235,0.0002847746,0.00022608512,0.000029233686,0.000028506862,0.000027197462,0.00009134161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574125,0.00053406396,0.0027159837,0.0003263933,0.00042046222,0.00026187612],"domain_scores_gemma":[0.9921092,0.0012653173,0.003969492,0.00022338262,0.0021867324,0.00024590822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013900873,0.00021930315,0.0021396605,0.00015590772,0.000026224547,0.0000036552385,0.00016676872,0.00032621255,0.000086466214],"category_scores_gemma":[0.002374495,0.00014165972,0.00012863775,0.0004347658,0.00031810402,0.0001424198,0.00007345285,0.0006373893,3.5801838e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039904304,0.0012568294,0.8990977,0.00021638653,0.0003997469,0.000047479934,0.00058740523,0.000010874584,0.00008180954,0.0000035012263,0.000070152855,0.05832384],"study_design_scores_gemma":[0.028638562,0.0067505185,0.9619045,0.0015732101,0.0003146505,0.000011064222,0.00003502765,0.00004924779,0.0001368753,0.000021184056,0.00041828418,0.00014686235],"about_ca_topic_score_codex":0.006244087,"about_ca_topic_score_gemma":0.052218936,"teacher_disagreement_score":0.062806845,"about_ca_system_score_codex":0.00045895128,"about_ca_system_score_gemma":0.0018445357,"threshold_uncertainty_score":0.9650756},"labels":[],"label_agreement":null},{"id":"W2243057854","doi":"10.1200/jco.2007.25.18_suppl.14004","title":"Pharmacodynamic and safety study of reolysin in patients with advanced solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Chills; Internal medicine; Pharmacodynamics; Antibody; Gastroenterology; Cancer; Viral load; Immunology; Pharmacokinetics; Virology; Virus","score_opus":0.028127335470981986,"score_gpt":0.4637454153844524,"score_spread":0.4356180799134704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243057854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99922,0.00015140414,0.000042503445,0.00004846393,0.000090335394,0.00019700165,0.0000033636018,5.8206814e-7,0.00024634178],"genre_scores_gemma":[0.9992906,0.00022428297,0.0003102011,0.000066992165,0.00007594341,0.0000012363022,0.000003600572,0.000006962027,0.000020176096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830836,0.00016079623,0.0010431436,0.0001377778,0.00018747804,0.00016243511],"domain_scores_gemma":[0.99876463,0.00013893959,0.0006592098,0.000096958254,0.00019137282,0.00014889409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013045109,0.00007548511,0.00050574535,0.000070402224,0.000015419006,0.0000018863059,0.000098909375,0.00008665735,0.0000062022395],"category_scores_gemma":[0.00031903078,0.000052185158,0.000063566134,0.00007784689,0.000099202836,0.000006153922,0.000054349763,0.00024096719,3.009886e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024201922,0.0038915633,0.84491813,0.0000057646735,0.00022752299,0.00011167166,0.000041122483,0.000055043143,0.0012192768,0.0000011422861,0.000028704695,0.12529814],"study_design_scores_gemma":[0.021544801,0.035909913,0.9407124,0.000018346052,0.000036773243,0.000009264667,0.00012591458,0.0000044680673,0.0007210163,0.000011309786,0.00085317984,0.000052614523],"about_ca_topic_score_codex":0.000033141576,"about_ca_topic_score_gemma":0.0008998885,"teacher_disagreement_score":0.12524553,"about_ca_system_score_codex":0.000038041846,"about_ca_system_score_gemma":0.00027362522,"threshold_uncertainty_score":0.2128049},"labels":[],"label_agreement":null},{"id":"W2243142335","doi":"10.1200/jco.2006.24.18_suppl.7581","title":"High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin—A CALGB 59804 correlative study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Vinorelbine; Gemcitabine; Internal medicine; Oncology; Hazard ratio; Univariate analysis; Nucleoside transporter; Chemotherapy; Gastroenterology; Confidence interval; Multivariate analysis","score_opus":0.016671083742944293,"score_gpt":0.30181980880264714,"score_spread":0.28514872505970285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243142335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983906,0.00050604634,0.00016840236,0.00009408056,0.0003220074,0.00031009974,0.000022835406,0.000004568902,0.00018135793],"genre_scores_gemma":[0.9985625,0.00009927094,0.0006331863,0.000081963946,0.00045810622,0.0000064710152,0.000033553773,0.000028641296,0.00009631653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963398,0.00061544013,0.0020587505,0.00034773466,0.00037484223,0.0002634088],"domain_scores_gemma":[0.9972736,0.0003875187,0.0015376584,0.0002776233,0.00034661707,0.00017696981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092511316,0.0002524419,0.0010410913,0.00013132863,0.000039715585,0.000006724569,0.0002659304,0.00045740983,0.000021248086],"category_scores_gemma":[0.00040664972,0.0001772965,0.00018845752,0.00015025036,0.00020217203,0.000021183594,0.00008978122,0.00039797887,5.6904815e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010996838,0.0060425065,0.97291106,0.00001530298,0.0001727035,0.0002991855,0.00012919545,0.0004538175,0.00599352,0.000010947008,0.0012755815,0.0016993281],"study_design_scores_gemma":[0.026976975,0.02434635,0.9443926,0.00012975863,0.0002124193,0.000029513789,0.00017998533,0.00002578864,0.003004735,0.00006399089,0.00044737576,0.00019047516],"about_ca_topic_score_codex":0.0003408186,"about_ca_topic_score_gemma":0.00035109452,"teacher_disagreement_score":0.02851844,"about_ca_system_score_codex":0.00004154627,"about_ca_system_score_gemma":0.00032008384,"threshold_uncertainty_score":0.72299415},"labels":[],"label_agreement":null},{"id":"W2243168506","doi":"10.1200/jco.2009.27.15_suppl.5576","title":"A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Regimen; Phases of clinical research; Endometrial cancer; Oncology; Gastroenterology; Clinical endpoint; Urology; Cancer; Surgery; Chemotherapy; Clinical trial","score_opus":0.2843529791827545,"score_gpt":0.5407086601337543,"score_spread":0.2563556809509998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243168506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010533,0.00036825734,0.000004642806,0.005317597,0.0022189403,0.0016648818,0.000025098769,0.0000025253253,0.0002927451],"genre_scores_gemma":[0.99805,0.00026651358,0.00033725487,0.00040404045,0.0008591243,0.000020529615,0.0000017149438,0.00000915462,0.000051665724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930427,0.0013072708,0.0046165367,0.00021271239,0.000590677,0.00023007783],"domain_scores_gemma":[0.991222,0.0041899225,0.0035928555,0.00032784665,0.0004154755,0.00025189613],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004305975,0.00017820465,0.0027989675,0.00032724824,0.000052449035,0.0000035892049,0.00022148989,0.00014840788,0.00023549199],"category_scores_gemma":[0.009925148,0.00009357289,0.00070796075,0.00057630165,0.00018375799,0.000059434184,0.000070601694,0.00077148573,6.732863e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42677167,0.31115606,0.0032631743,0.000020526246,0.0007590329,0.0010357609,0.0008385635,0.0000033364072,0.00006622807,0.000054819866,0.0010617771,0.25496906],"study_design_scores_gemma":[0.51333076,0.47042885,0.010085682,0.0001019353,0.0016572444,0.0000825437,0.00043554814,0.000011388949,0.00017092709,0.00007067301,0.0035742405,0.000050216204],"about_ca_topic_score_codex":0.000051943534,"about_ca_topic_score_gemma":0.0001302053,"teacher_disagreement_score":0.25491884,"about_ca_system_score_codex":0.00017573139,"about_ca_system_score_gemma":0.002843056,"threshold_uncertainty_score":0.9984147},"labels":[],"label_agreement":null},{"id":"W2243244322","doi":"10.1200/jco.2013.31.15_suppl.10003","title":"Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children’s Oncology Group (COG) study (AALL07P1).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Bortezomib; Vincristine; Internal medicine; Chemotherapy; Etoposide; Oncology; Cyclophosphamide; Gastroenterology; Surgery; Multiple myeloma","score_opus":0.09729871132330872,"score_gpt":0.46819686961421547,"score_spread":0.3708981582909068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243244322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633738,0.00034030914,0.000030582014,0.03239269,0.0012278294,0.002382644,0.0000016748337,0.000015323321,0.00023518802],"genre_scores_gemma":[0.99018085,0.0017093596,0.0019984439,0.003450938,0.0021809002,0.00015257615,0.0000025955835,0.000047873826,0.00027645522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99082536,0.003062492,0.004123519,0.00056374987,0.0007262458,0.0006986311],"domain_scores_gemma":[0.98760897,0.009113574,0.00143975,0.00045986503,0.00058901776,0.0007887956],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014148597,0.00028814704,0.002155551,0.0011163043,0.00004510441,0.000024520165,0.00048488207,0.00095044874,0.0002764941],"category_scores_gemma":[0.01704692,0.00020919896,0.00032758055,0.00080801465,0.00016475994,0.00029820812,0.00019640253,0.0029485999,0.0001924061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078531794,0.016337525,0.8026815,0.000020985812,0.0004971111,0.0034143648,0.0015338492,0.00007487354,0.0013305024,0.000010689731,0.018141784,0.07742499],"study_design_scores_gemma":[0.040049564,0.08152242,0.8689361,0.000036853256,0.00015211296,0.0005412254,0.0004519715,0.00015017323,0.00002274634,0.00012388082,0.007848449,0.00016447926],"about_ca_topic_score_codex":0.00088714936,"about_ca_topic_score_gemma":0.0011486987,"teacher_disagreement_score":0.07726051,"about_ca_system_score_codex":0.0023577686,"about_ca_system_score_gemma":0.005043869,"threshold_uncertainty_score":0.9993516},"labels":[],"label_agreement":null},{"id":"W2243288580","doi":"10.1200/jco.2004.22.90140.8009","title":"Providing audiotapes of primary adjuvant treatment consultations to men with prostate cancer: Impact on recall, mood, satisfaction, and quality of life","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Mood; Randomized controlled trial; Quality of life (healthcare); Family medicine; Patient satisfaction; Breast cancer; Cancer; Physical therapy; Internal medicine; Clinical psychology; Nursing","score_opus":0.3930731575537353,"score_gpt":0.5773877042605567,"score_spread":0.18431454670682146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243288580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97570544,0.0010221561,0.000045019526,0.0207307,0.00028654016,0.0013522283,0.00010002422,0.000011078267,0.00074681983],"genre_scores_gemma":[0.98913795,0.0026656555,0.006752743,0.0011384548,0.00013379424,0.00010379747,0.000004582212,0.000016960827,0.000046058307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927344,0.002395864,0.0040313723,0.00020003828,0.00037341434,0.00026495926],"domain_scores_gemma":[0.9838951,0.008257135,0.005455304,0.00034344057,0.0015381902,0.0005108249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001965826,0.00016475642,0.0016403395,0.00015956542,0.00020760999,0.0000029859746,0.00015803712,0.00026650116,0.000030239014],"category_scores_gemma":[0.0052027386,0.00010269085,0.00015447341,0.00022685225,0.00021624815,0.0001547631,0.00007181793,0.0008015672,0.0000032440105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013695683,0.0008375989,0.9232001,0.0003258568,0.00039704985,0.00000261897,0.009081244,0.0015865375,0.00033995064,0.00033540858,0.0003671154,0.04983089],"study_design_scores_gemma":[0.009856347,0.01625006,0.96793294,0.0007284176,0.000100528174,0.000003267119,0.0037149144,0.000010931519,0.00006043955,0.00031530048,0.0009316844,0.00009514541],"about_ca_topic_score_codex":0.0052741496,"about_ca_topic_score_gemma":0.0038284992,"teacher_disagreement_score":0.049735747,"about_ca_system_score_codex":0.0013205543,"about_ca_system_score_gemma":0.011798295,"threshold_uncertainty_score":0.9938039},"labels":[],"label_agreement":null},{"id":"W2243310500","doi":"10.1200/jco.2009.27.15_suppl.e11635","title":"Case report of a 27-year-old male with DCIS","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Gynecomastia; Medicine; Male breast cancer; Family history; Malignancy; Population; Breast enlargement; Breast cancer; Ductal carcinoma; Cancer; Mastectomy; Gynecology; Genetic testing; Internal medicine; Oncology; Surgery","score_opus":0.1611977987851308,"score_gpt":0.5158234559222616,"score_spread":0.35462565713713085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243310500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94972897,0.00027207087,0.00008763827,0.026054854,0.0005737878,0.0001799748,0.0000015686468,0.0000068805034,0.023094269],"genre_scores_gemma":[0.97769517,0.00021358144,0.01484834,0.0034832326,0.0011311051,8.6028604e-7,4.916447e-7,0.000008981645,0.0026182304],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9961509,0.00018771469,0.0029109442,0.00015505447,0.00037433743,0.00022101097],"domain_scores_gemma":[0.9945476,0.0011589061,0.0027958495,0.00025352024,0.0008318911,0.00041220043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036416296,0.000109844405,0.001733698,0.00010746905,0.000028339404,0.000001859512,0.00007869545,0.0002462654,0.00023558785],"category_scores_gemma":[0.004342464,0.00006790656,0.00029058693,0.00014655308,0.00021387872,0.00005229982,0.000024764773,0.0008354184,0.000010233183],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009176273,0.0023394688,0.248362,0.00009924556,0.00034885717,0.6566709,0.00013735524,0.0000042544934,0.00002313234,0.00021437462,0.024152985,0.05847115],"study_design_scores_gemma":[0.0059235306,0.026173519,0.2848908,0.00014813771,0.00036670218,0.6436637,0.00018993008,0.0000074231702,0.000016062939,0.00011785059,0.03844142,0.000060945076],"about_ca_topic_score_codex":0.000033103315,"about_ca_topic_score_gemma":0.000042644882,"teacher_disagreement_score":0.058410205,"about_ca_system_score_codex":0.000073178046,"about_ca_system_score_gemma":0.0015117546,"threshold_uncertainty_score":0.51986486},"labels":[],"label_agreement":null},{"id":"W2243326152","doi":"10.1200/jco.2007.25.18_suppl.8098","title":"Alemtuzumab in clinical practice: A British Columbia experience","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; Vancouver General Hospital; Royal Columbian Hospital; BC Cancer Agency","funders":"","keywords":"Alemtuzumab; Medicine; Neutropenia; Internal medicine; Adverse effect; Surgery; Chronic lymphocytic leukemia; Gastroenterology; Chemotherapy; Leukemia; Transplantation","score_opus":0.15489513185330978,"score_gpt":0.574852698958226,"score_spread":0.4199575671049162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243326152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97588396,0.0007528581,0.00022909553,0.0024139779,0.002028293,0.00030181676,9.908118e-7,0.000012206232,0.01837682],"genre_scores_gemma":[0.9739848,0.0019041448,0.013933826,0.0056847828,0.002780135,0.0000036459871,0.0000010303995,0.000025557045,0.0016820712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9901568,0.0009249143,0.0068043866,0.00036842367,0.0011126149,0.0006328077],"domain_scores_gemma":[0.9781963,0.017214952,0.002148142,0.00036586125,0.0010727571,0.0010019542],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031584997,0.00011060916,0.0019135354,0.000116727264,0.00004627451,0.000057491117,0.0003868597,0.0008758644,0.00066997594],"category_scores_gemma":[0.0989624,0.00012629511,0.00064088707,0.00041440505,0.0008082847,0.00030815002,0.00015967684,0.0029589448,0.000060397473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008051984,0.0055394466,0.2183878,0.0000402075,0.00023255669,0.07186558,0.00026894116,0.0000027319186,0.000022556795,0.000025234624,0.042749833,0.65281314],"study_design_scores_gemma":[0.053196948,0.014020084,0.5047949,0.00026259403,0.00013157727,0.022098,0.0010090065,0.00024053881,0.0000071008526,0.00018089393,0.40392295,0.00013540295],"about_ca_topic_score_codex":0.005357619,"about_ca_topic_score_gemma":0.018541664,"teacher_disagreement_score":0.6526777,"about_ca_system_score_codex":0.0058681355,"about_ca_system_score_gemma":0.032228712,"threshold_uncertainty_score":0.9993674},"labels":[],"label_agreement":null},{"id":"W2243327792","doi":"10.1200/jco.2009.27.15_suppl.6513","title":"Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) in breast and colorectal cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Colorectal cancer; Breast cancer; Randomized controlled trial; Clinical trial; Absolute risk reduction; Metastatic breast cancer; Internal medicine; Cancer; Oncology; Confidence interval","score_opus":0.5984683884755875,"score_gpt":0.6308930628261773,"score_spread":0.03242467435058982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243327792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92089546,0.014321506,0.00008757274,0.06176995,0.0016085721,0.0007712345,0.000046391426,0.000004250041,0.0004950875],"genre_scores_gemma":[0.97918874,0.010099012,0.00078266603,0.008559191,0.0013018269,0.000034720168,0.0000022851532,0.000012264195,0.000019278783],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9549738,0.009191819,0.03483064,0.00040912483,0.000241164,0.00035341416],"domain_scores_gemma":[0.945082,0.03866511,0.015521435,0.00015908739,0.00012654638,0.00044581186],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.30875352,0.0001878789,0.009491558,0.00043800342,0.000031111176,0.000016413058,0.00032305732,0.0007553066,0.00068545184],"category_scores_gemma":[0.06976486,0.0001656074,0.00074527255,0.0001619713,0.0004675658,0.00030318557,0.00004618261,0.00094663753,0.000014574719],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32230204,0.019971417,0.2929344,0.00013276063,0.0016580645,0.00013678904,0.0067815855,0.00023392118,0.00003492111,0.05522738,0.01124364,0.2893431],"study_design_scores_gemma":[0.6157186,0.004943353,0.35740298,0.0004826697,0.00006498854,0.00011876744,0.0010814978,0.0059241387,0.000010946838,0.009413522,0.004487513,0.00035102543],"about_ca_topic_score_codex":0.00044838223,"about_ca_topic_score_gemma":0.00044606536,"teacher_disagreement_score":0.29341656,"about_ca_system_score_codex":0.00028727014,"about_ca_system_score_gemma":0.001363775,"threshold_uncertainty_score":0.9380709},"labels":[],"label_agreement":null},{"id":"W2243412420","doi":"10.1200/jco.2013.31.15_suppl.2574","title":"Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma (B-NHL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Gastroenterology; Neutropenia; Rituximab; Internal medicine; Calicheamicin; Febrile neutropenia; Toxicity; Lymphoma; Gemcitabine; Regimen; Chemotherapy","score_opus":0.07489875581887857,"score_gpt":0.43374164324938835,"score_spread":0.3588428874305098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243412420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361694,0.0001246108,0.00009564321,0.0022894193,0.00066806126,0.0018720885,0.0000077824025,0.00001068821,0.001314756],"genre_scores_gemma":[0.9940428,0.000120296914,0.0037973304,0.0010487647,0.00042240557,0.00008658502,0.0000065299737,0.000035790694,0.00043945544],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9954311,0.0003179933,0.0031032814,0.0003077102,0.00049592933,0.00034395032],"domain_scores_gemma":[0.991989,0.0033812185,0.0027271747,0.00040308337,0.0010056564,0.0004938611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015403207,0.00026874628,0.0025841792,0.00019315249,0.000058631544,0.000013662768,0.00023516885,0.00035438847,0.00013966681],"category_scores_gemma":[0.00088240666,0.00016137217,0.0005540073,0.00018846647,0.00018388349,0.00014642192,0.0000555141,0.00030729393,0.000032669563],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06483603,0.2999313,0.27170694,0.00015934321,0.0030212929,0.001588211,0.0010052554,0.000026225836,0.001007153,0.00006977425,0.029002966,0.32764554],"study_design_scores_gemma":[0.3244532,0.41190994,0.2527269,0.00015106415,0.0017556995,0.00020784598,0.0010697296,0.0002740798,0.0018072597,0.00012473855,0.0053554745,0.0001640476],"about_ca_topic_score_codex":0.0002204055,"about_ca_topic_score_gemma":0.0000776655,"teacher_disagreement_score":0.3274815,"about_ca_system_score_codex":0.00034244513,"about_ca_system_score_gemma":0.0017428005,"threshold_uncertainty_score":0.6580566},"labels":[],"label_agreement":null},{"id":"W2243443090","doi":"10.1200/jco.2009.27.15_suppl.2067","title":"Short-course irradiation as adjuvant treatment of surgically resected single brain metastases","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Brain metastasis; Radiation therapy; Primary tumor; Metastasis; Radiology; Surgery; Cancer; Internal medicine","score_opus":0.17974230474329422,"score_gpt":0.5025964022344901,"score_spread":0.32285409749119587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243443090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96843857,0.0024660025,0.000092874034,0.026077002,0.0004697372,0.00032138845,0.000018573663,0.000012481153,0.0021034048],"genre_scores_gemma":[0.9908462,0.00092483865,0.005652832,0.0015736229,0.0006762546,0.0000025024967,0.000026093128,0.0000129951595,0.00028464224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99565333,0.00084986904,0.0025504981,0.00021442941,0.0004773472,0.0002545198],"domain_scores_gemma":[0.9944486,0.0029375558,0.0013530331,0.00027157133,0.0004989221,0.00049033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023803508,0.00019245822,0.0020656039,0.00014770155,0.00003341464,0.000007653116,0.000097421755,0.0002633507,0.00026826025],"category_scores_gemma":[0.0026842128,0.00011905039,0.0009390936,0.00019523442,0.00014574973,0.00008829085,0.000010996052,0.00029775378,0.000013454119],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00808628,0.024262035,0.008914436,0.00001093684,0.0013990606,0.0038773487,0.00009280877,0.000045229033,0.0014835425,0.0005422078,0.004046732,0.9472394],"study_design_scores_gemma":[0.019152934,0.20875968,0.6313798,0.00010432863,0.0027114186,0.0016007107,0.00012335929,0.00005746362,0.0015474672,0.0009540764,0.13345811,0.00015070674],"about_ca_topic_score_codex":0.000025168632,"about_ca_topic_score_gemma":0.000028025941,"teacher_disagreement_score":0.94708866,"about_ca_system_score_codex":0.00023595308,"about_ca_system_score_gemma":0.0011598615,"threshold_uncertainty_score":0.4854734},"labels":[],"label_agreement":null},{"id":"W2243481686","doi":"10.1200/jco.2005.23.16_suppl.4730","title":"Factors influencing late rectal toxicity after radiotherapy of localized prostate cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Rectum; Radiation therapy; Prostate cancer; Prostate; Univariate analysis; Colorectal cancer; Rectal examination; Surgery; Urology; Internal medicine; Cancer; Multivariate analysis","score_opus":0.08300539684050483,"score_gpt":0.4533227359607381,"score_spread":0.37031733912023324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243481686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877702,0.0050041815,0.000023909686,0.0061014113,0.00061357406,0.00024631468,0.000013934614,0.000007394079,0.00021909343],"genre_scores_gemma":[0.98522,0.009183284,0.0018920068,0.0027778735,0.00074429443,0.00001369926,0.0000011033909,0.00001797953,0.00014975555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971176,0.00020003879,0.0020069277,0.00016255984,0.00028758036,0.00022528922],"domain_scores_gemma":[0.9969986,0.0006995593,0.0014880267,0.00014158161,0.00035012132,0.00032207827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010502219,0.00015437338,0.0015224696,0.00009181036,0.000018832367,0.0000051972793,0.00008428777,0.00023519727,0.00045052334],"category_scores_gemma":[0.00042876514,0.00009355321,0.00051828084,0.000110777895,0.00017748284,0.00013188894,0.0000216533,0.0005153654,0.0000025823526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006731548,0.0014142384,0.76678014,0.000038269394,0.00076350896,0.00016987404,0.0007692221,0.00016618465,0.0007655829,0.000005025552,0.0007916864,0.22160475],"study_design_scores_gemma":[0.012752701,0.013304161,0.87954485,0.0003567222,0.00044183736,0.000038528528,0.000081029,0.00010004274,0.0088329045,0.00006368279,0.08435984,0.00012372616],"about_ca_topic_score_codex":0.00006496405,"about_ca_topic_score_gemma":0.00012119079,"teacher_disagreement_score":0.22148101,"about_ca_system_score_codex":0.00050756463,"about_ca_system_score_gemma":0.0013189861,"threshold_uncertainty_score":0.49329147},"labels":[],"label_agreement":null},{"id":"W2243527806","doi":"10.1200/jco.2007.25.18_suppl.19566","title":"Relationship between fatigue and cytokine levels in patients age 50+ with acute myeloid leukemia (AML)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cancer-related fatigue; Cancer; Cytokine; Chemotherapy; Malignancy; Oncology; Gastroenterology","score_opus":0.18758518186517248,"score_gpt":0.47077759836317057,"score_spread":0.2831924164979981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243527806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246806,0.000059963935,0.0013504361,0.0027149545,0.00018290247,0.00033146655,0.000009058515,0.000009946094,0.0028731832],"genre_scores_gemma":[0.9861618,0.0000707031,0.011556928,0.0009244987,0.00083405466,0.0000018344501,0.000012763324,0.000029554905,0.00040784164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955438,0.00041550334,0.0026226235,0.00026635587,0.0006897323,0.00046203414],"domain_scores_gemma":[0.9904552,0.0069316234,0.0012127142,0.00024018346,0.00046576117,0.00069447805],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007236433,0.0001874455,0.0015143735,0.00045399656,0.000056213416,0.000012718742,0.00021277161,0.00064667343,0.00003574812],"category_scores_gemma":[0.0059353854,0.00012826214,0.00017072557,0.00039898904,0.0004265747,0.00021544084,0.000103276674,0.0029354796,0.000013144897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050502503,0.00029899398,0.9556726,0.00002309676,0.00021771998,0.0023398958,0.00012822708,0.000004405546,0.000052098832,0.00007938839,0.00086746935,0.035265807],"study_design_scores_gemma":[0.018898554,0.011260608,0.9612265,0.00011639938,0.00027309463,0.0002416192,0.00006378979,0.000007947212,0.00007288471,0.00033703545,0.0073808418,0.00012071824],"about_ca_topic_score_codex":0.00004297897,"about_ca_topic_score_gemma":0.00011560821,"teacher_disagreement_score":0.03514509,"about_ca_system_score_codex":0.0011187193,"about_ca_system_score_gemma":0.0026433265,"threshold_uncertainty_score":0.9993648},"labels":[],"label_agreement":null},{"id":"W2243568521","doi":"10.1200/jco.2006.24.18_suppl.1540","title":"Phase II study of concurrent temozolomide and whole brain radiation therapy in patients with brain metastasis","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Temozolomide; Internal medicine; Docetaxel; Brain metastasis; Performance status; Lung cancer; Chemotherapy; Radiation therapy; Cancer; Phases of clinical research; Oncology; Surgery; Metastasis; Gastroenterology","score_opus":0.07318462203450028,"score_gpt":0.45206234282322966,"score_spread":0.3788777207887294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243568521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161106,0.0005346909,0.000039753842,0.0069855307,0.00018038502,0.0005821379,0.0000143488,0.0000027738545,0.00004929844],"genre_scores_gemma":[0.998306,0.000057476773,0.0005681895,0.00083549257,0.0001599176,0.0000052182177,0.0000139794265,0.000010825547,0.000042921445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968613,0.0007194787,0.0017774428,0.00016791627,0.00032703244,0.00014686208],"domain_scores_gemma":[0.99650586,0.0015851681,0.0014212086,0.00012867308,0.00021382685,0.00014523923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025389264,0.0001302852,0.0012751854,0.00016158141,0.000030460456,0.0000045216498,0.00005824829,0.00010602307,0.00003204144],"category_scores_gemma":[0.00071625697,0.000078130026,0.00014467764,0.0001492814,0.00011391619,0.0000826686,0.000022911447,0.00035411748,6.771364e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060560764,0.04496777,0.38613984,0.000007879598,0.0004405719,0.0001270276,0.0001704896,0.000015843738,0.00002501071,0.00002740245,0.002552595,0.5594695],"study_design_scores_gemma":[0.11292908,0.23668137,0.63506866,0.000030376908,0.00024690654,0.000017424021,0.00015690552,0.000018995466,0.00002956806,0.000052632444,0.014711903,0.00005614233],"about_ca_topic_score_codex":0.00007941558,"about_ca_topic_score_gemma":0.00012123956,"teacher_disagreement_score":0.5594134,"about_ca_system_score_codex":0.000073517425,"about_ca_system_score_gemma":0.0003005779,"threshold_uncertainty_score":0.31860498},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2243576609","doi":"10.1200/jco.2008.26.15_suppl.8065","title":"Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Concomitant; Cancer; Clinical trial; Placebo; Surgery; Pathology","score_opus":0.35633809878384715,"score_gpt":0.5545972493015215,"score_spread":0.1982591505176744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243576609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872692,0.0013384754,0.00008729413,0.008086663,0.0023922392,0.00041484917,0.00004457097,0.0000014444247,0.00036524097],"genre_scores_gemma":[0.9893092,0.008001406,0.00037856668,0.0012296782,0.0010074049,0.000007191983,0.000002633598,0.000006836431,0.00005711723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9889616,0.0016908017,0.008179461,0.0001703162,0.0008537659,0.00014405565],"domain_scores_gemma":[0.9810746,0.007360122,0.010089412,0.00013601899,0.0011559689,0.00018388973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027339594,0.000117220654,0.005762714,0.00025235242,0.00004783522,0.0000023675684,0.00016374436,0.00024778512,0.00021074124],"category_scores_gemma":[0.030934209,0.00006855992,0.0012947378,0.0004913694,0.00039508563,0.000082700644,0.00006611255,0.00037845774,3.57816e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029128038,0.002556541,0.9139807,0.00017492988,0.027658742,0.000026925221,0.00017778433,0.0024574404,0.0009488505,0.001069565,0.028268004,0.019767711],"study_design_scores_gemma":[0.0065875147,0.0010453687,0.9636122,0.00022790725,0.018648017,0.000007647354,0.000034790814,0.00161897,0.00016380133,0.000071337825,0.0079236515,0.0000587732],"about_ca_topic_score_codex":0.023048881,"about_ca_topic_score_gemma":0.054382853,"teacher_disagreement_score":0.049631517,"about_ca_system_score_codex":0.00018371799,"about_ca_system_score_gemma":0.005752137,"threshold_uncertainty_score":0.9998843},"labels":[],"label_agreement":null},{"id":"W2243598500","doi":"10.1200/jco.2010.28.15_suppl.4677","title":"Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) ± strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Prostate cancer; Docetaxel; Zoledronic acid; Surgery; Cancer; Oncology","score_opus":0.1711104149319097,"score_gpt":0.5361155780872329,"score_spread":0.36500516315532316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243598500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879111,0.00095743506,0.000008716817,0.0066503854,0.001560984,0.002595345,0.00012579409,0.000010108475,0.00018014818],"genre_scores_gemma":[0.99040484,0.007205786,0.00051206443,0.00066695525,0.0009757885,0.00005903741,0.00006999746,0.000025969217,0.000079571204],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99248224,0.0013719421,0.0042366376,0.0006028357,0.00081484544,0.000491515],"domain_scores_gemma":[0.9941763,0.0021608805,0.0017280374,0.0003501941,0.00090869016,0.00067588215],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010167368,0.00027956965,0.0019800044,0.00028237907,0.00008109582,0.000024902332,0.00022517757,0.00059696723,0.00009788164],"category_scores_gemma":[0.004731436,0.00017764016,0.00026786848,0.00030696788,0.0005164966,0.00034697173,0.00011194328,0.0031628823,0.0000031282104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6176216,0.017501783,0.103116214,0.0000056699537,0.00021347098,0.00018272905,0.0005628156,0.0000043877094,0.00020807647,0.0000026742764,0.00035745002,0.26022312],"study_design_scores_gemma":[0.46547905,0.117497414,0.41138607,0.00010119752,0.00010500084,0.0000053413924,0.00007446527,0.00010051955,0.0000565298,0.00014285573,0.0049307873,0.00012077029],"about_ca_topic_score_codex":0.00044693335,"about_ca_topic_score_gemma":0.0033323716,"teacher_disagreement_score":0.30826986,"about_ca_system_score_codex":0.00059978355,"about_ca_system_score_gemma":0.004633936,"threshold_uncertainty_score":0.99913687},"labels":[],"label_agreement":null},{"id":"W2243635794","doi":"10.1200/jco.2009.27.15_suppl.e15112","title":"Downregulation of RIZ1 protein expression in left-sided versus right-sided primary colorectal carcinomas and their distant metastases and the association with NF-B activation","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Ottawa Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Immunostaining; Immunohistochemistry; Downregulation and upregulation; Cancer research; Cancer; Primary tumor; Apoptosis; Pathology; Oncology; Internal medicine; Metastasis; Biology; Gene","score_opus":0.020938350492448132,"score_gpt":0.3217687378106275,"score_spread":0.30083038731817935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243635794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711704,0.0004271456,0.0004490346,0.0013992671,0.00010231009,0.00033602503,0.0000036988429,0.000002073953,0.00016337742],"genre_scores_gemma":[0.99873394,0.00017677978,0.0007765713,0.000057112462,0.00020220119,0.0000038622957,0.00002314559,0.000006524149,0.000019862264],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979708,0.0006425632,0.0009131191,0.00017081652,0.00018817515,0.00011449637],"domain_scores_gemma":[0.99719226,0.00077122,0.0016503681,0.00010630803,0.00022277088,0.00005709117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001986155,0.00011317077,0.0005264579,0.00006288063,0.00004320501,0.000010557184,0.00006887209,0.00030753258,0.0000034608986],"category_scores_gemma":[0.0014892479,0.00006498871,0.00009747564,0.0000795103,0.00015215708,0.00002637876,0.000029793824,0.00025791716,6.089557e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03496559,0.0002745759,0.007272241,0.000011983531,0.00016919532,0.0000039086935,0.00017184115,0.00045371603,0.93521124,0.0001091152,0.000112659116,0.02124393],"study_design_scores_gemma":[0.016956097,0.0061331172,0.61882806,0.00011494966,0.00010317674,0.00002874812,0.00010458031,0.00024457506,0.35579598,0.0008007218,0.0007760582,0.00011392567],"about_ca_topic_score_codex":0.00001298503,"about_ca_topic_score_gemma":0.00012170135,"teacher_disagreement_score":0.6115558,"about_ca_system_score_codex":0.00011911812,"about_ca_system_score_gemma":0.000339106,"threshold_uncertainty_score":0.26501626},"labels":[],"label_agreement":null},{"id":"W2243724727","doi":"10.1200/jco.2014.32.31_suppl.159","title":"Integration of system-level patient-reported outcome measurement into everyday clinical care: Lessons learned from the cancer care Ontario experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; Élisabeth Bruyère Hospital; Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Family medicine; Cancer; Feeling; Health care; Population; Intervention (counseling); Ambulatory; Ambulatory care; MEDLINE; Nursing; Physical therapy; Surgery","score_opus":0.7637324675953446,"score_gpt":0.6196594017123942,"score_spread":0.14407306588295044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243724727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96814793,0.00048596293,0.004618878,0.018843742,0.0068150763,0.00058323424,0.000014783082,0.000017063008,0.00047334871],"genre_scores_gemma":[0.9851263,0.00021554947,0.00888281,0.0038362234,0.0018266245,0.000023551667,0.000029548031,0.000026398217,0.000032971137],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9829549,0.0026034059,0.0121488925,0.00046836023,0.0015568077,0.00026759435],"domain_scores_gemma":[0.9744185,0.009994355,0.009440606,0.00070445583,0.005024614,0.00041746415],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013287397,0.00025024393,0.0022643355,0.000084970496,0.00011165022,0.000021473992,0.0004136322,0.0005844042,0.00018559425],"category_scores_gemma":[0.06490471,0.00015151681,0.0010161103,0.00017341506,0.00035800418,0.00022987458,0.00014864457,0.0020656935,0.0000118309335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032007429,0.00055746466,0.48576945,0.000044797514,0.0005014397,0.000040573497,0.0067990073,0.00003085854,0.0004214652,0.000042140895,0.0013777352,0.5012143],"study_design_scores_gemma":[0.011112952,0.008714986,0.8303217,0.00060366845,0.002246067,0.000044513996,0.031910468,0.00013194041,0.00025732553,0.00014088683,0.11432408,0.00019136604],"about_ca_topic_score_codex":0.03859356,"about_ca_topic_score_gemma":0.121526375,"teacher_disagreement_score":0.50102293,"about_ca_system_score_codex":0.0017038577,"about_ca_system_score_gemma":0.0053882324,"threshold_uncertainty_score":0.96780854},"labels":[],"label_agreement":null},{"id":"W2243728887","doi":"10.1200/jco.2007.25.18_suppl.6581","title":"Potential budget impact of capecitabine versus 5-FU/LV as adjuvant chemotherapy for stage III (SIII) colon cancer in Canada and its provinces","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Capecitabine; Medicine; Regimen; Colorectal cancer; Population; Internal medicine; Cancer; Stage (stratigraphy); Oncology; Surgery; Environmental health","score_opus":0.29098303997764396,"score_gpt":0.541425157649749,"score_spread":0.250442117672105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243728887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98206556,0.0036544087,0.0002608448,0.010795949,0.0021340349,0.000533581,0.00022705895,0.0000023066495,0.0003262664],"genre_scores_gemma":[0.99401027,0.0018040871,0.0006310106,0.0026182043,0.0007549054,0.000010701201,0.0000030917029,0.000017732153,0.0001500041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906851,0.00025528923,0.008291897,0.00026314726,0.00012688291,0.0003777016],"domain_scores_gemma":[0.98573816,0.0052672913,0.008279884,0.00013667926,0.00024819656,0.00032978738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025990823,0.00014882372,0.002330051,0.00021983463,0.000044399392,0.000010386105,0.00023075026,0.00026392602,0.0003653193],"category_scores_gemma":[0.0067818775,0.00014488517,0.000270339,0.00010955128,0.000080243015,0.00023662143,0.000027268681,0.00038669637,0.0000048467477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033632856,0.0019388341,0.8389393,0.00075835496,0.0018928031,0.00018625504,0.001773857,0.0050314255,0.000110031724,0.007920317,0.025562428,0.08225353],"study_design_scores_gemma":[0.025566652,0.0077741747,0.9238449,0.00009029314,0.00003829137,0.000021532629,0.0008427529,0.0058374563,0.000039224647,0.00090024003,0.0347466,0.00029788254],"about_ca_topic_score_codex":0.45299396,"about_ca_topic_score_gemma":0.8273478,"teacher_disagreement_score":0.37435386,"about_ca_system_score_codex":0.00258148,"about_ca_system_score_gemma":0.009029511,"threshold_uncertainty_score":0.99658835},"labels":[{"model":"gpt","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"},{"model":"grok","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"},{"model":"opus","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2243806734","doi":"10.1200/jco.2006.24.18_suppl.4505","title":"Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Calcitriol; Internal medicine; Placebo; Prostate cancer; Adverse effect; Gastroenterology; Oncology; Cancer; Pharmacology; Urology; Vitamin D and neurology; Pathology","score_opus":0.12886978719081835,"score_gpt":0.4588298682468206,"score_spread":0.3299600810560023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243806734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935051,0.0015447995,0.000021199854,0.0029150504,0.00073172175,0.0009863444,0.000067121706,0.0000068794748,0.00022174678],"genre_scores_gemma":[0.99130833,0.0037009662,0.0025099276,0.0002044741,0.0011750858,0.000033394397,0.000009448389,0.00003108065,0.0010272705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966089,0.00021183521,0.0022392503,0.00025709256,0.00034971198,0.00033317457],"domain_scores_gemma":[0.9953699,0.0010767952,0.0025951318,0.00019329776,0.00044190107,0.00032297074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057583494,0.00023983924,0.002792395,0.00017704745,0.00003253799,0.0000028549096,0.00012656704,0.00030501778,0.00012115381],"category_scores_gemma":[0.0001464317,0.00015019916,0.0006104234,0.00017128912,0.00018373184,0.000062593106,0.000017690512,0.00021536405,0.0000018712539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0876693,0.028607048,0.4658744,0.00025466955,0.0062913927,0.00064943184,0.0004676251,0.00024447922,0.025444094,0.00009937286,0.008048344,0.37634984],"study_design_scores_gemma":[0.09552648,0.09910391,0.737189,0.00029621855,0.006270677,0.00044281842,0.00007932868,0.00006848101,0.03704121,0.00095702003,0.022799792,0.00022505455],"about_ca_topic_score_codex":0.0013570405,"about_ca_topic_score_gemma":0.0005925064,"teacher_disagreement_score":0.37612477,"about_ca_system_score_codex":0.00037770465,"about_ca_system_score_gemma":0.0043705963,"threshold_uncertainty_score":0.775325},"labels":[],"label_agreement":null},{"id":"W2243903821","doi":"10.1200/jco.2014.32.4_suppl.109","title":"Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cabazitaxel; Internal medicine; Docetaxel; Prostate cancer; Discontinuation; Adverse effect; Population; Cohort; Incidence (geometry); Cancer; Androgen deprivation therapy","score_opus":0.06467713322226828,"score_gpt":0.4438116790079496,"score_spread":0.3791345457856813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243903821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948528,0.0003676004,0.00005010878,0.00073633075,0.0000903017,0.00365045,0.00004676487,0.00004552399,0.00016015496],"genre_scores_gemma":[0.9925143,0.00048732565,0.0054170378,0.00032454083,0.00010384608,0.0005982534,0.00014841613,0.0000509716,0.00035529502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952715,0.00073297106,0.0020785022,0.0006027244,0.00073398004,0.00058032916],"domain_scores_gemma":[0.9952562,0.0008117434,0.0022947118,0.0002703616,0.00066342176,0.00070354773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011760059,0.00045683654,0.002895684,0.0003746545,0.00009917085,0.00012440457,0.00020787733,0.00023206518,0.00006826459],"category_scores_gemma":[0.00014680211,0.00025361773,0.00023423253,0.0009759473,0.0006095262,0.0005238529,0.000049212376,0.0009027904,9.631631e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04785558,0.010689672,0.8738016,0.00011324556,0.0061131776,0.0007900812,0.00022637342,0.00026351455,0.000023697985,0.000004586984,0.0005373554,0.05958115],"study_design_scores_gemma":[0.044065893,0.08823302,0.85055083,0.00025048063,0.010121429,0.00006963153,0.00003821711,0.0006025071,0.000014708926,0.0000062744048,0.0057802373,0.00026675905],"about_ca_topic_score_codex":0.0032333257,"about_ca_topic_score_gemma":0.017864678,"teacher_disagreement_score":0.07754334,"about_ca_system_score_codex":0.0004896668,"about_ca_system_score_gemma":0.0009965973,"threshold_uncertainty_score":0.9999916},"labels":[],"label_agreement":null},{"id":"W2243923021","doi":"10.1200/jco.2009.27.15_suppl.581","title":"Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Number needed to treat; Anthracycline; Breast cancer; Letrozole; Randomized controlled trial; Oncology; Internal medicine; Taxane; Tamoxifen; Confidence interval; Cancer; Relative risk","score_opus":0.023167478790460258,"score_gpt":0.36408180952853636,"score_spread":0.3409143307380761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243923021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924243,0.0001556094,0.000058000303,0.009398236,0.00011531989,0.0002737562,0.00008122951,0.0000030479955,0.00067234447],"genre_scores_gemma":[0.9922055,0.0001777682,0.001630679,0.0055574453,0.00032905643,0.000012809015,0.00001234296,0.000021894602,0.00005251707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979728,0.00013667882,0.0009873607,0.0003180248,0.0002802189,0.00030493908],"domain_scores_gemma":[0.99804425,0.00010823668,0.00071678264,0.00020864094,0.0006500852,0.00027199305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002655521,0.00024854438,0.0011548573,0.00007649263,0.000034085486,0.0000067693827,0.00021886178,0.000102801,0.000040978866],"category_scores_gemma":[0.000066312095,0.0001628931,0.0001591707,0.00020901917,0.00010848662,0.000012327271,0.000047790105,0.00023405258,0.0000050307717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029492294,0.002996375,0.84451365,0.00000945135,0.00043084437,0.000058756985,0.00025243574,0.0018064342,0.0003186125,0.0000099168055,0.0045287996,0.11558241],"study_design_scores_gemma":[0.013605108,0.010024092,0.97052276,0.0002067683,0.00012656343,0.00010387693,0.00015869805,0.0000019143843,0.0028829984,0.00000564237,0.0021646884,0.00019688769],"about_ca_topic_score_codex":0.0006421083,"about_ca_topic_score_gemma":0.0016304251,"teacher_disagreement_score":0.12600909,"about_ca_system_score_codex":0.00018888897,"about_ca_system_score_gemma":0.0004363152,"threshold_uncertainty_score":0.6642588},"labels":[],"label_agreement":null},{"id":"W2243951255","doi":"10.1200/jco.2005.23.16_suppl.8134","title":"A prospective comparison of Karnofsky (KPS) with ECOG performance status in patients with non-small cell lung cancer (NSCLC): A COMET group study investigating sensitivity and specificity issues important in clinical decision making","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Performance status; Lung cancer; Docetaxel; Chemotherapy; Oncology; Prospective cohort study; Cancer; Stage (stratigraphy)","score_opus":0.048724069456037626,"score_gpt":0.47034381034725353,"score_spread":0.4216197408912159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243951255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978933,0.0004351684,0.000077204335,0.00018136446,0.00014986371,0.0010936585,0.000007760562,0.000004393881,0.00015730297],"genre_scores_gemma":[0.9825458,0.00028627328,0.016776979,0.00015481138,0.00019708216,0.000013106325,0.000002040079,0.000018114037,0.000005771814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956085,0.00040687062,0.0029605927,0.00032658377,0.00042025198,0.00027716343],"domain_scores_gemma":[0.9950966,0.0016495077,0.0024269745,0.0001580281,0.00043254395,0.00023630443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028829747,0.00019272129,0.0018192934,0.0001996789,0.00004613819,0.000011510855,0.00006262589,0.00016914649,0.000009432286],"category_scores_gemma":[0.00051050907,0.000121149205,0.00009246669,0.00029610767,0.0002225883,0.00019528014,0.000054042484,0.0010595748,3.34106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00837882,0.009428395,0.92494214,0.000055221888,0.00024714853,0.00013350065,0.0023566817,0.00047792663,0.0000047044714,0.0000018832485,0.000021536795,0.05395205],"study_design_scores_gemma":[0.027675457,0.02333356,0.94290733,0.0010955071,0.00046474184,0.000010792431,0.0011943633,0.0031315342,0.0000151031045,0.000006275197,0.000047683603,0.000117618656],"about_ca_topic_score_codex":0.0002703942,"about_ca_topic_score_gemma":0.007906584,"teacher_disagreement_score":0.05383443,"about_ca_system_score_codex":0.0004630772,"about_ca_system_score_gemma":0.0011483885,"threshold_uncertainty_score":0.4940321},"labels":[],"label_agreement":null},{"id":"W2243974396","doi":"10.1200/jco.2013.31.31_suppl.23","title":"Complementary and alternative medicine and other health behaviors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Logistic regression; Cancer; Overweight; Breast cancer; Odds ratio; Internal medicine; Smoking cessation; Obesity; Lung cancer; Physical therapy; Pathology","score_opus":0.3720883224537969,"score_gpt":0.5821128940459566,"score_spread":0.21002457159215965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243974396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9129896,0.002264997,0.000093064475,0.08190839,0.00075378723,0.00030056573,0.0000048048014,0.000004685298,0.0016800835],"genre_scores_gemma":[0.9706688,0.002083268,0.0025929704,0.022334332,0.0021814408,0.0000039918045,0.0000021802434,0.0000099683675,0.0001230685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973661,0.000289477,0.0017266417,0.00015973045,0.00027409795,0.00018395658],"domain_scores_gemma":[0.99661815,0.0015297389,0.0011048102,0.000084593754,0.0002278118,0.0004348694],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019588796,0.00012780841,0.0013751013,0.000118909855,0.00006562137,0.0000034731354,0.00007297502,0.00002596309,0.0011418966],"category_scores_gemma":[0.00070711615,0.00007578294,0.00008954757,0.000053251417,0.0006637534,0.000084194144,0.00009744718,0.0005112985,0.0000042451106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003866946,0.00045780846,0.647624,0.000040443647,0.00046807283,0.000113282185,0.0011662394,1.0367783e-7,0.000093968054,0.0004935834,0.026372243,0.32278353],"study_design_scores_gemma":[0.011379988,0.03459212,0.75274915,0.0002711335,0.00023606837,0.0005364896,0.003480205,0.00002857315,0.000009421159,0.0016982593,0.1949432,0.00007536881],"about_ca_topic_score_codex":0.000875898,"about_ca_topic_score_gemma":0.00010255902,"teacher_disagreement_score":0.32270816,"about_ca_system_score_codex":0.000052704258,"about_ca_system_score_gemma":0.00016154029,"threshold_uncertainty_score":0.9997712},"labels":[],"label_agreement":null},{"id":"W2243998178","doi":"10.1200/jco.2004.22.90140.7549","title":"Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Eyelid; Merkel cell carcinoma; Sentinel lymph node; Biopsy; Lymph; Melanoma; Sebaceous carcinoma; Carcinoma; Dermatology; Surgery; Cancer; Pathology; Internal medicine","score_opus":0.10249141754552535,"score_gpt":0.4485865986441934,"score_spread":0.3460951810986681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243998178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847678,0.0007634556,0.0021581051,0.010202211,0.0006889159,0.0001427895,0.0000022659142,0.00000702653,0.0012674395],"genre_scores_gemma":[0.9729481,0.00041984586,0.022760596,0.0026034366,0.0010873555,0.000012581438,4.3003968e-7,0.000015043368,0.00015265458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821055,0.000049342085,0.001109322,0.000184957,0.00022950897,0.00021635032],"domain_scores_gemma":[0.9974535,0.00095084007,0.00083860225,0.00012439121,0.00040909732,0.00022352925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008483834,0.00012684338,0.0011040586,0.000060176193,0.00005943243,0.000007661255,0.000083235616,0.00015810445,0.000015130657],"category_scores_gemma":[0.0015146638,0.00007801108,0.00018224891,0.0000772653,0.0005869463,0.00008680864,0.000045215158,0.0002518155,0.000002589892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008453943,0.0006925632,0.97730416,0.00007795707,0.00043791498,0.0008823693,0.0005435977,0.000013007968,0.00082187523,0.00045199163,0.00042774234,0.009892883],"study_design_scores_gemma":[0.01785249,0.003799504,0.9611044,0.000228636,0.00026272578,0.0030039412,0.0008044556,0.000006577849,0.00045081726,0.0004655036,0.011911533,0.000109407265],"about_ca_topic_score_codex":0.000009897737,"about_ca_topic_score_gemma":0.0000028857087,"teacher_disagreement_score":0.02060249,"about_ca_system_score_codex":0.000114982206,"about_ca_system_score_gemma":0.0010343363,"threshold_uncertainty_score":0.31811994},"labels":[],"label_agreement":null},{"id":"W2244039917","doi":"10.1200/jco.2010.28.15_suppl.5593","title":"Effects of aprepitant use in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with high-dose cisplatin and radiation (RT).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aprepitant; Medicine; Cisplatin; Nausea; Vomiting; Internal medicine; Regimen; Docetaxel; Chemotherapy; Oncology; Gastroenterology; Antiemetic","score_opus":0.016504466033093957,"score_gpt":0.322521005805384,"score_spread":0.30601653977229004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244039917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99894047,0.00005971327,0.000018471925,0.00026527018,0.00011770276,0.00047693757,0.0000013048981,0.0000023655566,0.00011775084],"genre_scores_gemma":[0.99797297,0.000037664107,0.0017399648,0.00015378749,0.000048193408,0.0000025967781,8.5091284e-7,0.000011675445,0.00003231225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982454,0.00027525565,0.0009743313,0.0001434686,0.00023779982,0.00012370977],"domain_scores_gemma":[0.9960568,0.0021579447,0.0012853779,0.00014786152,0.00022129761,0.00013072533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008003017,0.00010923051,0.0007855564,0.00009836928,0.000018004885,0.0000047154067,0.0000677667,0.00016493052,0.0000023875673],"category_scores_gemma":[0.0013222534,0.00005776648,0.000058807622,0.00012666851,0.00023298313,0.000087999506,0.000038098697,0.000547338,1.4661522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011225723,0.001622733,0.9492606,0.00015483756,0.000044107128,0.0001162943,0.0000839216,0.000025158026,0.0012008876,0.00003237992,0.00002743061,0.036205955],"study_design_scores_gemma":[0.04056349,0.024261255,0.9320434,0.00019712471,0.0002815874,0.000025548336,0.0000202868,0.000084801344,0.0023176472,0.000019762596,0.00013036006,0.000054741842],"about_ca_topic_score_codex":0.000081497674,"about_ca_topic_score_gemma":0.00018264935,"teacher_disagreement_score":0.03615121,"about_ca_system_score_codex":0.000031380965,"about_ca_system_score_gemma":0.00022761738,"threshold_uncertainty_score":0.23779416},"labels":[],"label_agreement":null},{"id":"W2244050098","doi":"10.1200/jco.2010.28.15_suppl.e12002","title":"Does delaying the onset of pap smear screening in Newfoundland (NL) impact on cervical cancer rates?","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Cervical cancer; Gynecology; Stage (stratigraphy); Obstetrics; Cancer; Cancer registry; Internal medicine","score_opus":0.1516983022539446,"score_gpt":0.5569938342892552,"score_spread":0.4052955320353106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244050098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975408,0.0001759285,0.000028252327,0.019990403,0.0009359317,0.00017699595,0.0000075741373,0.0000035347414,0.0032733746],"genre_scores_gemma":[0.9947446,0.0005195824,0.00040163234,0.0023781008,0.0018433987,0.0000044954572,0.0000010175202,0.000015524196,0.000091662616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966933,0.00046404835,0.0017346353,0.00017252966,0.00059634453,0.00033912985],"domain_scores_gemma":[0.9924702,0.005575498,0.0007594843,0.0002496056,0.0005155353,0.0004296465],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052825203,0.0001340441,0.0012197087,0.00015370602,0.0000504388,0.000014943045,0.0002972691,0.00039348664,0.0036438499],"category_scores_gemma":[0.003946503,0.00005311561,0.00051914883,0.0002512973,0.00036068546,0.00007372147,0.00007965106,0.0035808722,0.0000082119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010251012,0.000548576,0.7789817,0.000026019256,0.00016112663,0.00021021016,0.000080623286,0.000057021432,0.00016480369,0.000046052915,0.00065986597,0.208813],"study_design_scores_gemma":[0.005589366,0.00461251,0.9779252,0.00007187451,0.00009911659,0.00010178831,0.00008745305,0.0004230846,0.000057641693,0.00039867737,0.010568151,0.00006514469],"about_ca_topic_score_codex":0.0020665815,"about_ca_topic_score_gemma":0.010331532,"teacher_disagreement_score":0.20874785,"about_ca_system_score_codex":0.00013653398,"about_ca_system_score_gemma":0.0019950294,"threshold_uncertainty_score":0.9987179},"labels":[],"label_agreement":null},{"id":"W2244102040","doi":"10.1200/jco.2007.25.18_suppl.9065","title":"Pre-admission escalation rate of daily opioid consumption (PERDOC), and total morphine equivalent daily dose on the first complete day of admission (D1-MEDD) to a tertiary-level palliative care unit (TPCU): Correlates and predictors in patients with advan","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Odds ratio; Confidence interval; Opioid; Logistic regression; Cancer pain; Internal medicine; Morphine; Multivariate analysis; Cancer; Emergency medicine","score_opus":0.07987011067913986,"score_gpt":0.3864675239981222,"score_spread":0.3065974133189823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244102040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680066,0.00017590882,0.0005114806,0.0014365904,0.00021504448,0.00077615,0.000019513489,0.000004825928,0.000059824662],"genre_scores_gemma":[0.99833727,0.00028015042,0.0006636456,0.0005358015,0.00008402315,0.0000030773083,0.000025162239,0.000013671935,0.00005720799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972823,0.00032440864,0.0015992331,0.00021647423,0.000383967,0.00019356617],"domain_scores_gemma":[0.9953434,0.0024877186,0.0013048322,0.00017120226,0.0003618226,0.0003310223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024421185,0.00017723734,0.0007999777,0.00023553729,0.000057819343,0.0000064836154,0.00010688881,0.00019673687,0.000051860035],"category_scores_gemma":[0.0020994602,0.000101446385,0.000090054724,0.00014949395,0.00022435254,0.000097942866,0.00010749732,0.0005287488,0.0000010139356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0144456485,0.0007556401,0.9700245,0.00015848818,0.00011621196,0.000032007512,0.0020048614,0.00012669232,0.00020489562,0.000024552897,0.00021656905,0.011889894],"study_design_scores_gemma":[0.010695027,0.013204963,0.9723679,0.0012885312,0.00021399083,0.0000021482997,0.0004393833,0.00079847564,0.0000780337,0.000049521634,0.0007672316,0.00009482805],"about_ca_topic_score_codex":0.00002113382,"about_ca_topic_score_gemma":0.00007054836,"teacher_disagreement_score":0.012449322,"about_ca_system_score_codex":0.00008738721,"about_ca_system_score_gemma":0.0001586667,"threshold_uncertainty_score":0.41368634},"labels":[],"label_agreement":null},{"id":"W2244136156","doi":"10.1200/jco.2006.24.18_suppl.4518","title":"Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Chemotherapy; Regimen; Placebo; Internal medicine; Chemotherapy regimen; Prostate cancer; Clinical trial; Surgery; Phases of clinical research; Cancer; Oncology; Urology; Pathology","score_opus":0.13366036448960994,"score_gpt":0.5048630603889855,"score_spread":0.3712026958993756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244136156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97608256,0.0019714823,0.000015303245,0.018935163,0.001073586,0.00045522515,0.000060237307,0.000008042161,0.0013983943],"genre_scores_gemma":[0.9911654,0.004282461,0.0008681889,0.0013790104,0.001342346,0.000017612228,0.00003137952,0.000022412603,0.00089119334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956302,0.00041378185,0.0027360115,0.00028081477,0.00057966425,0.00035951054],"domain_scores_gemma":[0.99703646,0.00095597375,0.0011812776,0.00018273061,0.00034769494,0.00029584585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023212747,0.00017321385,0.0013483102,0.00019226773,0.000026994274,0.00001649987,0.00015919267,0.00020770503,0.00023675087],"category_scores_gemma":[0.0005395872,0.000111135334,0.00038921335,0.00016828993,0.00019017988,0.000105073486,0.00004874453,0.0010684335,0.000016553733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08584773,0.0076393825,0.2422197,0.000045808953,0.0011444894,0.010715069,0.00058748346,0.00007189187,0.00067729375,0.000028294211,0.011579482,0.6394434],"study_design_scores_gemma":[0.10377798,0.011064084,0.80128,0.00048903783,0.00040616718,0.00023381216,0.0002993231,0.00028886757,0.0032087187,0.0015592412,0.077179596,0.00021316933],"about_ca_topic_score_codex":0.0009865423,"about_ca_topic_score_gemma":0.0007976637,"teacher_disagreement_score":0.6392302,"about_ca_system_score_codex":0.0005639535,"about_ca_system_score_gemma":0.0022916535,"threshold_uncertainty_score":0.46418715},"labels":[],"label_agreement":null},{"id":"W2244319654","doi":"10.1200/jco.2009.27.15_suppl.3506","title":"OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Hsp27; Chills; Breast cancer; Internal medicine; Heat shock protein; Chemotherapy; Docetaxel; Oncology; Urology; Cancer; Endocrinology; Gastroenterology; Hsp70; Biology","score_opus":0.10153842433712292,"score_gpt":0.48176161088183056,"score_spread":0.38022318654470766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244319654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885187,0.00035259905,0.00011664408,0.0036390733,0.00049421785,0.00043359835,0.000013019147,0.000004272774,0.006427839],"genre_scores_gemma":[0.99253124,0.0009820632,0.0038235292,0.0006980865,0.0016670306,0.0000039075067,0.000009506666,0.000019847832,0.0002647873],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99329025,0.0015095071,0.0038652646,0.0003812997,0.0004838887,0.00046981248],"domain_scores_gemma":[0.99609464,0.00088863395,0.0015953557,0.0005024932,0.0005227268,0.00039613195],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009733114,0.00020057058,0.0014013111,0.00023798758,0.0000589774,0.000013475573,0.0005800279,0.0008403209,0.00002168323],"category_scores_gemma":[0.016869793,0.00016648186,0.0006821008,0.00024012262,0.00029130717,0.000012367821,0.00014959116,0.0011205437,0.0000063025027],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24174613,0.008565289,0.0045813737,0.0000692751,0.0004493226,0.0019492325,0.0002023757,0.0003939176,0.48912975,0.00012239312,0.016204214,0.23658672],"study_design_scores_gemma":[0.27900323,0.12921919,0.050291386,0.00034942167,0.000135967,0.00025082778,0.0001735838,0.00022612498,0.1403724,0.0011716571,0.39809686,0.0007093481],"about_ca_topic_score_codex":0.000039268583,"about_ca_topic_score_gemma":0.00017221553,"teacher_disagreement_score":0.38189265,"about_ca_system_score_codex":0.00007013267,"about_ca_system_score_gemma":0.0011628753,"threshold_uncertainty_score":0.9914115},"labels":[],"label_agreement":null},{"id":"W2244350111","doi":"10.1200/jco.2009.27.15_suppl.e13027","title":"The temozolomide O6-methylguanine-DNA methyltransferase (MGMT) study: A phase II trial to evaluate the effect of low-dose preoperative neoadjuvant temozolomide on brain tumour MGMT activity in glioma patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Temozolomide; Methyltransferase; Methylation; Glioma; Medicine; O-6-methylguanine-DNA methyltransferase; DNA methylation; Cancer research; Oncology; DNA methyltransferase; Internal medicine; Biology; Gene; Gene expression; Genetics","score_opus":0.060773001221169555,"score_gpt":0.47305040370625706,"score_spread":0.4122774024850875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244350111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551505,0.0001663843,0.0000064698484,0.038606446,0.0010787011,0.0048568835,0.000015428703,0.000010527517,0.00010867313],"genre_scores_gemma":[0.9971463,0.0000769642,0.00006293084,0.001968841,0.00056866737,0.0001245853,0.0000026212003,0.000027687107,0.000021422691],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.98717713,0.007330295,0.003395206,0.00049224246,0.0010748158,0.00053032755],"domain_scores_gemma":[0.97109073,0.02597319,0.0013352716,0.00056754146,0.00051241356,0.00052083813],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015650237,0.00045661724,0.0030246659,0.00032942565,0.00024244258,0.000029070661,0.0004722335,0.00031507466,0.000025490766],"category_scores_gemma":[0.026906613,0.00019242428,0.0009835706,0.00059739803,0.00022265832,0.00013488835,0.000094255374,0.0014748201,0.000012782674],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.501714,0.05706944,0.015995197,0.000012696949,0.0014256705,0.001665311,0.00092945446,0.000112709204,0.014766073,0.000013036098,0.0029539908,0.40334243],"study_design_scores_gemma":[0.29807854,0.43211615,0.23008616,0.00019205357,0.0011006623,0.00003582597,0.00011319115,0.00008237727,0.037308577,0.00006404015,0.0006666068,0.00015581655],"about_ca_topic_score_codex":0.00004749461,"about_ca_topic_score_gemma":0.0003102926,"teacher_disagreement_score":0.4031866,"about_ca_system_score_codex":0.00040937657,"about_ca_system_score_gemma":0.0009578997,"threshold_uncertainty_score":0.98129016},"labels":[],"label_agreement":null},{"id":"W2244426249","doi":"10.1200/jco.2008.26.15_suppl.8054","title":"The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vinorelbine; Gemcitabine; Internal medicine; Carboplatin; Lung cancer; Pemetrexed; Oncology; Chemotherapy; Toxicity; Cisplatin","score_opus":0.16680126201493473,"score_gpt":0.5176512512286201,"score_spread":0.3508499892136854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244426249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367064,0.0019029556,0.000010481333,0.0022845806,0.00091190496,0.00078089256,0.00007067167,0.0000015677261,0.00036632657],"genre_scores_gemma":[0.97498393,0.022982096,0.00034833295,0.0009068276,0.00056637934,0.000029059533,0.000002523271,0.0000105975905,0.00017025924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927262,0.0011715645,0.0052615013,0.00020418846,0.00045001548,0.00018650427],"domain_scores_gemma":[0.9813773,0.013112253,0.0044878176,0.00015773223,0.00064217823,0.00022269793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008360242,0.00017060318,0.0029117744,0.00010438491,0.000059132013,0.0000025554523,0.00014133163,0.0002632413,0.00003163354],"category_scores_gemma":[0.0048011434,0.000094926,0.00052790105,0.00015553558,0.00040870623,0.00006260665,0.000020184842,0.0003942078,1.148527e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032089036,0.008734538,0.7683935,0.00017534765,0.005095934,0.00020111722,0.0012173505,0.006289782,0.0026659914,0.00007734268,0.004479353,0.17058071],"study_design_scores_gemma":[0.04826359,0.010706121,0.9262703,0.0004587404,0.0011178519,0.00002565259,0.0000965323,0.00020818473,0.002114412,0.000039233153,0.01058694,0.000112435264],"about_ca_topic_score_codex":0.04673337,"about_ca_topic_score_gemma":0.079658434,"teacher_disagreement_score":0.17046827,"about_ca_system_score_codex":0.0009097512,"about_ca_system_score_gemma":0.023060815,"threshold_uncertainty_score":0.98247755},"labels":[],"label_agreement":null},{"id":"W2244447797","doi":"10.1200/jco.2012.30.15_suppl.2073","title":"Bevacizumab use and central nervous system (CNS) hemorrhage.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Bleed; Subarachnoid hemorrhage; Bevacizumab; Stroke (engine); Intracerebral hemorrhage; Adverse effect; Glioma; Complication; Cancer; Chemotherapy; Surgery; Internal medicine","score_opus":0.1293239910810815,"score_gpt":0.42789756681607194,"score_spread":0.29857357573499044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244447797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238354,0.0017215341,0.00003173363,0.0030109622,0.0019362407,0.00013952648,0.0000026869807,0.000010997997,0.0007627769],"genre_scores_gemma":[0.99426115,0.00024732057,0.002667379,0.00088881067,0.0018622095,0.000002427509,0.0000013865885,0.000013248182,0.000056085624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765766,0.00025946682,0.0014004626,0.00011027819,0.00023763523,0.00033452592],"domain_scores_gemma":[0.9964921,0.0014511221,0.00085497013,0.00014865732,0.00019294929,0.00086018647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011007554,0.000119628145,0.0011348765,0.00007720047,0.00003700861,0.000014537505,0.000059213125,0.0002698178,0.000052415373],"category_scores_gemma":[0.0015099251,0.00007532683,0.00034140662,0.000064354106,0.00009323316,0.00020382357,0.000039784914,0.00045474095,0.000023521552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011508323,0.002825742,0.8435758,0.00006579721,0.00040514753,0.0025482299,0.00009041809,0.000002484561,0.000113650225,0.0004928103,0.0035956453,0.1451335],"study_design_scores_gemma":[0.0075840186,0.004109266,0.9513614,0.00008688873,0.00085603114,0.004876641,0.00015837302,0.000070824375,0.000121630044,0.000011161789,0.03069607,0.0000677012],"about_ca_topic_score_codex":0.000019017556,"about_ca_topic_score_gemma":0.0000062771223,"teacher_disagreement_score":0.14506578,"about_ca_system_score_codex":0.0001888434,"about_ca_system_score_gemma":0.00029324213,"threshold_uncertainty_score":0.3071739},"labels":[],"label_agreement":null},{"id":"W2244459559","doi":"10.1200/jco.2007.25.18_suppl.15560","title":"Cost of illness of renal cell carcinoma in Canada","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Productivity; Stage (stratigraphy); Indirect costs; Cancer; Kidney cancer; Total cost; Economic cost; Demography; Gerontology; Internal medicine","score_opus":0.1214059529280938,"score_gpt":0.3666677328898527,"score_spread":0.2452617799617589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244459559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96422,0.0011805347,0.00077483297,0.00040393008,0.0016317043,0.00007462551,0.000035314297,5.464167e-7,0.031678516],"genre_scores_gemma":[0.9983429,0.00032165353,0.0005058761,0.00042003737,0.0003137733,5.083585e-7,5.5734824e-7,0.0000091087595,0.00008558652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949348,0.000036207708,0.004598812,0.00013196822,0.00005114534,0.00024708675],"domain_scores_gemma":[0.99374306,0.0009849002,0.004786736,0.00014779886,0.00015281659,0.00018466337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045793992,0.000090453774,0.0015882483,0.00019989093,0.000011666516,0.0000022758043,0.00028951128,0.00021538569,0.00018585964],"category_scores_gemma":[0.0012009953,0.00009077696,0.00024072538,0.00014151666,0.00012579864,0.00013362335,0.000036037025,0.00046332396,0.000005362883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009205861,0.00039591198,0.93761516,0.00003247895,0.000041562842,0.000106990636,0.00020018876,0.00050124625,0.000020719937,0.0052321716,0.002285527,0.05264744],"study_design_scores_gemma":[0.0030396008,0.0011603349,0.9234882,0.000019941275,0.000010964407,0.000011168786,0.00022783222,0.00008715617,0.0006444176,0.002870632,0.06832184,0.00011792918],"about_ca_topic_score_codex":0.24349527,"about_ca_topic_score_gemma":0.47339538,"teacher_disagreement_score":0.22990009,"about_ca_system_score_codex":0.0005391229,"about_ca_system_score_gemma":0.0028145318,"threshold_uncertainty_score":0.7615424},"labels":[],"label_agreement":null},{"id":"W2244528295","doi":"10.1200/jco.2004.22.14_suppl.6526","title":"CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; CHOP; Internal medicine; Oncology; Lymphoma; Stage (stratigraphy); Rituximab; Biology","score_opus":0.053011621939452344,"score_gpt":0.40569978897706094,"score_spread":0.3526881670376086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244528295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933491,0.0019183612,0.0000079386655,0.0035502098,0.00031819945,0.0003692672,0.0000033459135,0.000005826222,0.00047777506],"genre_scores_gemma":[0.9918164,0.0050408253,0.00060894946,0.0022333676,0.00023170956,0.000014316388,0.0000010299213,0.000012937532,0.0000404813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690807,0.00032286078,0.0019369511,0.00017243081,0.00040537486,0.00025431017],"domain_scores_gemma":[0.9953539,0.0024936649,0.001429491,0.00027396705,0.00022683376,0.00022217874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016151316,0.00015844665,0.0011323602,0.00010961145,0.000037601683,0.0000045853812,0.00021508617,0.0002850798,0.00002611621],"category_scores_gemma":[0.0018079606,0.00007920429,0.0004716337,0.00016871252,0.00018111487,0.00012781669,0.0000583242,0.00032897305,0.000014991039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036477274,0.086351134,0.8731461,0.00003458794,0.0001744607,0.0013224476,0.00051408756,0.000105451494,0.00085857906,0.00012219018,0.0003942691,0.03332894],"study_design_scores_gemma":[0.11555936,0.0063386187,0.8629396,0.0003422294,0.00011509977,0.00013717913,0.00015612523,0.0000063422804,0.0014793478,0.000299119,0.012560745,0.000066208166],"about_ca_topic_score_codex":0.00004335996,"about_ca_topic_score_gemma":0.000034133518,"teacher_disagreement_score":0.11191163,"about_ca_system_score_codex":0.0002669558,"about_ca_system_score_gemma":0.0014584194,"threshold_uncertainty_score":0.32298574},"labels":[],"label_agreement":null},{"id":"W2244529370","doi":"10.1200/jco.2009.27.15_suppl.1022","title":"Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Tolerability; Internal medicine; Oncology; Metastatic breast cancer; Adverse effect; Breast cancer; Cancer; Pharmacology","score_opus":0.06210822724411943,"score_gpt":0.48343892075951683,"score_spread":0.4213306935153974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244529370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862758,0.00024142474,0.000051926596,0.012395793,0.00019637145,0.0005382972,0.0000167145,0.0000075712355,0.00027609704],"genre_scores_gemma":[0.9970405,0.0003024792,0.0009584936,0.0014392704,0.00020406119,0.000011632367,0.0000017194026,0.000017421822,0.000024437895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99726295,0.000555268,0.0010616848,0.00031079992,0.00047828312,0.00033100712],"domain_scores_gemma":[0.99734575,0.0011763128,0.0005769065,0.00018997818,0.00031416898,0.00039687715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012027026,0.00019303562,0.0015548593,0.00013190672,0.00004511292,0.000011280819,0.000097011456,0.00025399393,0.00007252801],"category_scores_gemma":[0.00035399487,0.00012366344,0.0002882431,0.00018198042,0.00016861976,0.00017210844,0.000009363599,0.000819459,8.918722e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025421828,0.003702798,0.4704886,0.0000074021896,0.00012341139,0.00016773105,0.000103422586,0.00004547987,0.00008322527,9.613908e-7,0.000014856114,0.49984026],"study_design_scores_gemma":[0.030116856,0.052213315,0.9162807,0.0002462883,0.00010689039,0.000026782709,0.00003092231,0.00016404752,0.00013379545,0.000031197855,0.0005453129,0.000103890205],"about_ca_topic_score_codex":0.00023865719,"about_ca_topic_score_gemma":0.00030860005,"teacher_disagreement_score":0.49973637,"about_ca_system_score_codex":0.0017431912,"about_ca_system_score_gemma":0.0028555593,"threshold_uncertainty_score":0.50656396},"labels":[],"label_agreement":null},{"id":"W2244533749","doi":"10.1200/jco.2006.24.18_suppl.4511","title":"Single versus sequential high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ-cell tumors (GCT)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Ifosfamide; Clinical endpoint; Chemotherapy; Refractory (planetary science); Internal medicine; Cyclophosphamide; Phases of clinical research; Surgery; Randomization; Urology; Gastroenterology; Cisplatin; Randomized controlled trial","score_opus":0.05523091218416017,"score_gpt":0.3859071546432486,"score_spread":0.33067624245908844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244533749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972341,0.00021827391,0.000013024514,0.0006330698,0.0007825932,0.00025778057,0.000004740723,0.000012624758,0.000843792],"genre_scores_gemma":[0.99585223,0.000044473658,0.0025341464,0.0005585456,0.0006329466,0.0000028131453,0.000017948341,0.000031267104,0.00032565653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726254,0.00024419973,0.0015714365,0.00021833771,0.00044110493,0.00026238247],"domain_scores_gemma":[0.99668646,0.00094479264,0.0015888542,0.00020415688,0.00027014042,0.0003055713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005028996,0.00018024172,0.0010781595,0.00012212218,0.000027591308,0.000009741384,0.00010576457,0.00026180546,0.00021999207],"category_scores_gemma":[0.00078817515,0.000108189335,0.0002869501,0.00015357585,0.00014778624,0.000108550616,0.000020764595,0.00057160325,0.000019246228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12269868,0.031341802,0.787351,0.000036955043,0.00037737223,0.0050972207,0.000026074295,0.000037245623,0.00009367617,0.000019182298,0.0015945551,0.051326226],"study_design_scores_gemma":[0.09601069,0.042875443,0.8539265,0.00010622893,0.0004096468,0.0000347585,0.000016169111,0.000008330761,0.00006147808,0.000058129663,0.0063857664,0.00010684734],"about_ca_topic_score_codex":0.000105387626,"about_ca_topic_score_gemma":0.00008741031,"teacher_disagreement_score":0.06657549,"about_ca_system_score_codex":0.00039661588,"about_ca_system_score_gemma":0.0015291668,"threshold_uncertainty_score":0.4411833},"labels":[],"label_agreement":null},{"id":"W2244578188","doi":"10.1200/jco.2014.32.15_suppl.9625","title":"Outcomes of early palliative care referrals for patients with advanced lung cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Palliative care; Lung cancer; Hospital Anxiety and Depression Scale; Distress; Cancer; Performance status; Quality of life (healthcare); Anxiety; Internal medicine; Physical therapy; Emergency medicine; Family medicine; Nursing; Psychiatry","score_opus":0.29669055859612886,"score_gpt":0.5932543202232607,"score_spread":0.2965637616271319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244578188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953726,0.0010966157,0.0005099614,0.0010443983,0.00063657254,0.00030342944,0.000027694688,0.0000037761588,0.0010049649],"genre_scores_gemma":[0.98327863,0.0007988345,0.014885493,0.0006097854,0.0003008027,0.000009265087,0.0000056527842,0.0000148979425,0.00009663912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758637,0.00016899162,0.0016296149,0.00013229188,0.00031839882,0.00016435853],"domain_scores_gemma":[0.99172795,0.0034019342,0.0024262574,0.00013972133,0.002124919,0.00017921068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063611113,0.00012270489,0.0018619463,0.000074289484,0.000018115545,0.0000015064253,0.00012767085,0.00020543447,0.000023732418],"category_scores_gemma":[0.0051866383,0.00007287736,0.00037328704,0.000079611746,0.00015608913,0.00007741278,0.000020934434,0.0003289048,5.519059e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005787649,0.00041468054,0.9420694,0.00015592927,0.0005529983,0.00000428941,0.00082308555,0.000018952864,0.000017613533,0.00007920563,0.00049977965,0.04957638],"study_design_scores_gemma":[0.013715921,0.026487047,0.932018,0.0008139975,0.00053394993,3.642491e-7,0.0003539815,0.000015371506,0.00021136287,0.0000815757,0.025692124,0.00007632404],"about_ca_topic_score_codex":0.000029920973,"about_ca_topic_score_gemma":0.000055658755,"teacher_disagreement_score":0.049500056,"about_ca_system_score_codex":0.000103372615,"about_ca_system_score_gemma":0.0005659518,"threshold_uncertainty_score":0.6209265},"labels":[],"label_agreement":null},{"id":"W2244657340","doi":"10.1200/jco.2006.24.18_suppl.8551","title":"Characterization of cancer pain syndromes (PS) seen at a Comprehensive Cancer Center (CCC) and pain response (PR) to palliative care consultation (PCC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Palliative care; Cancer; Cancer pain; Lung cancer; Internal medicine; Univariate analysis; Opioid; Performance status; Multivariate analysis","score_opus":0.08544353987274424,"score_gpt":0.44797371905343886,"score_spread":0.36253017918069463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244657340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865511,0.00057815196,0.0005635542,0.011378012,0.0003540045,0.00045916406,0.000045006083,0.000007731351,0.00006325895],"genre_scores_gemma":[0.990304,0.0013235182,0.0007570661,0.006577901,0.00043145914,0.000018474671,0.000029445739,0.000015530066,0.0005426367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995949,0.001998227,0.0014064,0.00018747115,0.00027921976,0.000179718],"domain_scores_gemma":[0.9932514,0.0042705373,0.001336568,0.00010286835,0.0008610167,0.00017765355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033479193,0.00013676871,0.0009570619,0.00017518134,0.000043225777,0.000007374418,0.0000776867,0.00020116808,0.00010006868],"category_scores_gemma":[0.003104374,0.000106187894,0.00015898592,0.00016613716,0.00013120454,0.00006800084,0.000053228596,0.00027720907,0.000003123228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01559533,0.00034915883,0.9253456,0.0001936582,0.00032937177,0.00016487934,0.0016071143,0.000050244566,0.012196413,0.00001823668,0.0033825978,0.04076742],"study_design_scores_gemma":[0.005130911,0.003075699,0.8962087,0.00038974633,0.00022214327,0.0000025049487,0.00067241763,0.0003591439,0.00021653695,0.000018411403,0.093613304,0.00009045257],"about_ca_topic_score_codex":0.00021553456,"about_ca_topic_score_gemma":0.00046260818,"teacher_disagreement_score":0.0902307,"about_ca_system_score_codex":0.00037237437,"about_ca_system_score_gemma":0.0004163208,"threshold_uncertainty_score":0.43302166},"labels":[],"label_agreement":null},{"id":"W2244683785","doi":"10.1200/jco.2013.31.15_suppl.tps5103","title":"Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clusterin; Docetaxel; Cabazitaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Urology; Population; Prednisone; Phases of clinical research; Enzalutamide; Chemotherapy; Surgery; Cancer; Androgen deprivation therapy; Randomized controlled trial; Androgen receptor","score_opus":0.17614610818270585,"score_gpt":0.47859328309662114,"score_spread":0.30244717491391526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244683785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882811,0.0003026296,0.00037429683,0.0021598346,0.0014770242,0.0072853635,0.00003460243,0.000010091777,0.000075112],"genre_scores_gemma":[0.99594086,0.00015517774,0.0026487154,0.00044686682,0.00029261818,0.00030525288,0.000002638778,0.00004499367,0.00016285239],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98864794,0.00336466,0.0063439864,0.00043176254,0.0008091209,0.00040250304],"domain_scores_gemma":[0.98559654,0.0069906362,0.0052817673,0.00060561433,0.001162197,0.00036327337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007751452,0.00037781283,0.0048365262,0.0003060334,0.00005872964,0.000015155369,0.00041376174,0.0002682729,0.00062657107],"category_scores_gemma":[0.006921698,0.00024315226,0.00058312877,0.00047079194,0.00070117455,0.00017348681,0.00019864023,0.0011636142,0.000004113177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9054365,0.054109577,0.0019850857,0.00017183,0.0027287344,0.0007119236,0.00795896,0.0036662568,0.017143596,0.0000041801363,0.00040408364,0.005679277],"study_design_scores_gemma":[0.91632783,0.050329152,0.017481033,0.00023949039,0.0022468367,0.0001722689,0.007861743,0.004372019,0.00063042704,0.00006285284,0.000058566322,0.00021780591],"about_ca_topic_score_codex":0.0014234179,"about_ca_topic_score_gemma":0.00307093,"teacher_disagreement_score":0.016513169,"about_ca_system_score_codex":0.00037236136,"about_ca_system_score_gemma":0.0038116705,"threshold_uncertainty_score":0.9915461},"labels":[],"label_agreement":null},{"id":"W2244807134","doi":"10.1200/jco.2006.24.18_suppl.5018","title":"Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Gastroenterology; Ovarian cancer; Erlotinib; Refractory (planetary science); Phases of clinical research; Vascular endothelial growth factor; Cancer; Urology; Chemotherapy; Surgery; Epidermal growth factor receptor; VEGF receptors","score_opus":0.1005680349449474,"score_gpt":0.4501131593538547,"score_spread":0.3495451244089073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244807134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98735565,0.00067531475,0.00010082434,0.007439536,0.001869261,0.0019104771,0.00027260868,0.000008097034,0.00036822679],"genre_scores_gemma":[0.99017215,0.0008374955,0.0066442774,0.0003928054,0.0015734356,0.000090901085,0.00005540416,0.000027622344,0.00020593053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959159,0.00021694551,0.0028508306,0.00035206036,0.00036943445,0.00029483697],"domain_scores_gemma":[0.9952201,0.001148594,0.0023720218,0.0002205881,0.00070330134,0.00033536565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011588075,0.00022792646,0.0017401741,0.00012760455,0.00007602032,0.000009135553,0.00011732583,0.00030243077,0.000025000432],"category_scores_gemma":[0.00092537206,0.00014712976,0.00041660195,0.00010131867,0.00019068542,0.00009661132,0.000056027777,0.00044539844,6.784112e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66855204,0.052776847,0.013522608,0.00008660061,0.0007391935,0.00015572362,0.0002389321,0.000018652036,0.0000032359378,0.0000521725,0.006603029,0.25725093],"study_design_scores_gemma":[0.60144776,0.26951545,0.04815945,0.00042915196,0.001020966,0.000051426334,0.000027465752,0.0002374551,0.000026377942,0.000026034608,0.0789462,0.00011223931],"about_ca_topic_score_codex":0.00018263662,"about_ca_topic_score_gemma":0.00040670947,"teacher_disagreement_score":0.2571387,"about_ca_system_score_codex":0.00036151794,"about_ca_system_score_gemma":0.0016947397,"threshold_uncertainty_score":0.59997773},"labels":[],"label_agreement":null},{"id":"W2244837175","doi":"10.1200/jco.2012.30.15_suppl.5502","title":"A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Chemoradiotherapy; Clinical endpoint; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Mucositis; Radiation therapy; Urology; Surgery; Nuclear medicine; Head and neck cancer; Randomized controlled trial","score_opus":0.0642510424917845,"score_gpt":0.42087450018513745,"score_spread":0.35662345769335296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244837175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954768,0.0011961396,0.000040958774,0.00071924523,0.000466284,0.0014883915,0.000005043475,0.0000041854973,0.00060299103],"genre_scores_gemma":[0.99691236,0.00042171287,0.0015380464,0.0005662986,0.00039170697,0.000024982879,8.070546e-7,0.000026735273,0.00011733446],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958198,0.0007019469,0.0024219325,0.00019760075,0.00052049046,0.00033822007],"domain_scores_gemma":[0.9942673,0.0022009255,0.0024150112,0.00024984925,0.00058024866,0.0002867008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021647613,0.00023662527,0.0041929143,0.000112553374,0.000049978513,0.000002971591,0.00016517116,0.00023871016,0.00003367976],"category_scores_gemma":[0.0018467477,0.000104235136,0.00030876644,0.0002745773,0.0008311665,0.0001288037,0.000053049567,0.00074954034,2.2171808e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7982728,0.009690617,0.16488726,0.00008452696,0.00019708124,0.00002717817,0.0009341576,0.0000037581392,0.00010571902,0.0000033049287,0.00011763207,0.025676003],"study_design_scores_gemma":[0.80600584,0.15153688,0.03985594,0.00031704133,0.00041875034,0.000054664615,0.00017330694,0.000054079617,0.0005723153,0.0000056661797,0.0008995203,0.00010599907],"about_ca_topic_score_codex":0.000088816996,"about_ca_topic_score_gemma":0.00036346703,"teacher_disagreement_score":0.14184627,"about_ca_system_score_codex":0.00013651498,"about_ca_system_score_gemma":0.0018587158,"threshold_uncertainty_score":0.42505854},"labels":[],"label_agreement":null},{"id":"W2244870397","doi":"10.1200/jco.2014.32.4_suppl.101","title":"Comparison of FRAX score to bone mineral density for estimating fracture risk in patients with CRPC on androgen-deprivation therapy (ADT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"FRAX; Medicine; Bone mineral; Cohort; Internal medicine; Framingham Risk Score; Osteoporosis; Osteoporotic fracture; Disease","score_opus":0.13285728703072666,"score_gpt":0.5078158858947506,"score_spread":0.37495859886402394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244870397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925562,0.00004550264,0.0030981086,0.0033856311,0.00025140189,0.0006059434,0.0000030180481,0.0000034050825,0.000050770795],"genre_scores_gemma":[0.96036464,0.00002341214,0.03590141,0.0032302178,0.00044662526,0.0000054310176,0.000006972958,0.000013179754,0.000008104201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969042,0.00037572952,0.0018423416,0.00016550523,0.00047506372,0.00023715346],"domain_scores_gemma":[0.99437076,0.0026557532,0.0016305314,0.00017001545,0.00080591824,0.00036699622],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035427432,0.0001066817,0.0013617744,0.00017087666,0.0000459343,0.0000045534016,0.000088616674,0.00030486667,0.00001643185],"category_scores_gemma":[0.008397924,0.0000670174,0.00015030497,0.00014370363,0.00007269713,0.000051628544,0.000018143588,0.0010015906,0.0000024430738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020786775,0.0018843926,0.8034473,0.000039247054,0.000033830307,0.0000042929714,0.00012208302,0.00035391335,0.000036259495,0.0000060715183,0.0015546939,0.17173114],"study_design_scores_gemma":[0.015900254,0.04933459,0.9281366,0.00017931493,0.00003536706,0.0000055191153,0.000021967577,0.0023387207,0.00017751717,0.0000955794,0.0037178516,0.000056736946],"about_ca_topic_score_codex":0.000040862975,"about_ca_topic_score_gemma":0.000097066564,"teacher_disagreement_score":0.1716744,"about_ca_system_score_codex":0.00008896664,"about_ca_system_score_gemma":0.0005120266,"threshold_uncertainty_score":0.99995476},"labels":[],"label_agreement":null},{"id":"W2244983407","doi":"10.1200/jco.2004.22.14_suppl.3605","title":"Thymidylate synthase and thymidine phosphorylase expression in resected colorectal liver metastases do not predict overall survival nor response to chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Alberta","funders":"","keywords":"Thymidylate synthase; Thymidine phosphorylase; Medicine; Internal medicine; Chemotherapy; Colorectal cancer; Immunohistochemistry; Dihydropyrimidine dehydrogenase; Adjuvant; Gastroenterology; Oncology; Fluorouracil; Cancer","score_opus":0.06968501851244657,"score_gpt":0.4153702742355094,"score_spread":0.3456852557230628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244983407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887314,0.0019214724,0.000026840342,0.007801288,0.00062978803,0.0004883058,0.000037832353,0.000015300997,0.00034780582],"genre_scores_gemma":[0.9918616,0.00384412,0.0023287528,0.0014242996,0.00039350387,0.000018639968,0.000002499222,0.000024492161,0.000102107435],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99662745,0.0006284021,0.0016053081,0.00034496898,0.00046517167,0.00032868524],"domain_scores_gemma":[0.9953774,0.002967038,0.0006595303,0.00017501334,0.00030151935,0.0005194612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033223657,0.00024444622,0.0017085876,0.00023459135,0.00006974089,0.000017512268,0.00012378543,0.00026874518,0.00013419567],"category_scores_gemma":[0.004506009,0.00016072465,0.00030788954,0.00022422885,0.00021708055,0.00012995052,0.000113351445,0.0007134803,0.000006698575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77471423,0.007388814,0.06833907,0.000061194994,0.0010814779,0.010510542,0.001763658,0.00013493835,0.035814162,0.000029859986,0.0021299988,0.09803206],"study_design_scores_gemma":[0.03917801,0.05210202,0.87543845,0.00044139416,0.0002897848,0.00035404164,0.00026317334,0.00002066978,0.013738751,0.00011451434,0.017857961,0.00020122157],"about_ca_topic_score_codex":0.00011877588,"about_ca_topic_score_gemma":0.0003114185,"teacher_disagreement_score":0.8070994,"about_ca_system_score_codex":0.00043564834,"about_ca_system_score_gemma":0.0010421245,"threshold_uncertainty_score":0.65541613},"labels":[],"label_agreement":null},{"id":"W2245032433","doi":"10.1200/jco.2004.22.90140.5105","title":"Metastatic uterine sarcoma: A systematic review of the literature","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Uterine Myomas and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Oncology; Internal medicine; Ifosfamide; Sarcoma; Randomized controlled trial; Soft tissue sarcoma; Cochrane Library; Uterine sarcoma; Progression-free survival; Chemotherapy; Surgery; Pathology","score_opus":0.16681373294550028,"score_gpt":0.5339274188256189,"score_spread":0.3671136858801186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245032433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000103017355,0.9953434,0.0000052528667,0.001392653,0.0011707101,0.001710827,0.000027569171,0.0000039066053,0.00033537683],"genre_scores_gemma":[0.000022842429,0.99591017,0.0016460947,0.0011809476,0.0004048802,0.000027928409,0.000010491075,0.000034146826,0.000762511],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9896813,0.0017016435,0.00769965,0.00019636007,0.0005313072,0.00018973762],"domain_scores_gemma":[0.9863354,0.0018373418,0.010375858,0.00066392816,0.0005349426,0.00025253967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034817867,0.00036457827,0.014423481,0.00013734424,0.000021022526,0.000008344548,0.00046181265,0.00039783138,0.00009065352],"category_scores_gemma":[0.006085835,0.00014412851,0.0048446003,0.00042588965,0.00013667371,0.00005108663,0.00014298676,0.0015735383,0.000019648378],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046699122,0.0010833411,0.000005318636,0.9031695,0.0031368244,0.0018663781,0.000010306415,1.7999804e-8,2.0744125e-8,0.000055169498,0.00044471168,0.09018168],"study_design_scores_gemma":[0.0013233743,0.0025493235,0.000018105802,0.57944685,0.020207461,0.008537148,0.0000013208085,6.850034e-8,4.909831e-8,0.000040035593,0.38781998,0.00005626058],"about_ca_topic_score_codex":0.0000018411332,"about_ca_topic_score_gemma":9.01218e-7,"teacher_disagreement_score":0.38737527,"about_ca_system_score_codex":0.000248281,"about_ca_system_score_gemma":0.0035529437,"threshold_uncertainty_score":0.9859603},"labels":[],"label_agreement":null},{"id":"W2245059224","doi":"10.1200/jco.2007.25.18_suppl.7068","title":"Induction of remission in patients with acute myeloid leukemia without prolonged myelosuppression using diphtheria toxin-interleukin 3 fusion protein","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Diphtheria toxin; Chills; Internal medicine; Gastroenterology; Myeloid leukemia; Hypoalbuminemia; Surgery; Toxicity; Toxin","score_opus":0.051952352948129124,"score_gpt":0.41707898878654437,"score_spread":0.36512663583841526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245059224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984773,0.00007572147,0.00045289556,0.0001394598,0.00027324408,0.00045310822,0.0000026383873,0.000002911136,0.00012276364],"genre_scores_gemma":[0.9951764,0.00006313325,0.004125482,0.00010323083,0.0004128525,0.0000029150074,0.000009923172,0.00002895487,0.000077126766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965731,0.00064549263,0.0017142702,0.00028540497,0.000474013,0.0003077317],"domain_scores_gemma":[0.99722683,0.00008526233,0.0016609753,0.0002740103,0.00054482836,0.00020810038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042749415,0.0001724456,0.00070217164,0.00018046936,0.000043387918,0.0000067869773,0.0002930384,0.00061897363,0.00002958799],"category_scores_gemma":[0.0006995379,0.00011845074,0.00017350152,0.00018500687,0.00019423732,0.000021111598,0.00012216647,0.00075751875,9.952169e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093383335,0.0006964413,0.06668788,0.000015425789,0.00012459666,0.000038120466,0.000047038,0.0000825214,0.7794232,8.165013e-7,0.000052273426,0.059448354],"study_design_scores_gemma":[0.013338572,0.06321334,0.18720536,0.0003561243,0.00007010873,0.00005332751,0.000067238805,0.00008838822,0.73337024,0.00006340692,0.0019475153,0.00022635596],"about_ca_topic_score_codex":0.000014144699,"about_ca_topic_score_gemma":0.00011758665,"teacher_disagreement_score":0.12051748,"about_ca_system_score_codex":0.0002094701,"about_ca_system_score_gemma":0.0013030664,"threshold_uncertainty_score":0.4830281},"labels":[],"label_agreement":null},{"id":"W2245212464","doi":"10.1200/jco.2007.25.18_suppl.5021","title":"Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Germ cell tumors; Population; Orchiectomy; Internal medicine; Surgery; Cancer; Seminoma; Multivariate analysis; Oncology; Chemotherapy","score_opus":0.07523602951675029,"score_gpt":0.46610439014131816,"score_spread":0.39086836062456787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245212464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932307,0.00033406098,0.00014030776,0.0011663239,0.0006082601,0.00029981975,0.000016140955,0.000011707519,0.0041926876],"genre_scores_gemma":[0.99583,0.00059120357,0.0020715464,0.00073462387,0.0006104639,0.0000029395285,0.000006327787,0.000027556185,0.0001253334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658525,0.00023356012,0.0020603263,0.00023928788,0.00045006117,0.0004314899],"domain_scores_gemma":[0.99347395,0.0031792114,0.0020787707,0.00025667986,0.00030434923,0.0007070481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020938925,0.00022271645,0.0015988916,0.000259517,0.000036497284,0.000008880187,0.0001454063,0.00026994958,0.000073564355],"category_scores_gemma":[0.0039988146,0.0001434958,0.00037666553,0.0003108625,0.00015910796,0.00006786971,0.000043398864,0.000873715,0.000020925216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019568339,0.003450605,0.9160507,0.000028665225,0.00033495133,0.013447199,0.00007129742,0.00003392623,0.000008096376,0.000009101405,0.00012841976,0.04686874],"study_design_scores_gemma":[0.037669383,0.014826535,0.9427739,0.000083349565,0.0002631812,0.00019015241,0.00016240776,0.00004575215,0.00004012652,0.000016598684,0.0037993956,0.00012925219],"about_ca_topic_score_codex":0.00033792108,"about_ca_topic_score_gemma":0.0007892659,"teacher_disagreement_score":0.04673949,"about_ca_system_score_codex":0.0003918597,"about_ca_system_score_gemma":0.003084126,"threshold_uncertainty_score":0.5851589},"labels":[],"label_agreement":null},{"id":"W2245304554","doi":"10.1200/jco.2011.29.27_suppl.10","title":"Silver in situ hybridization compared with immunohistochemistry in assessing HER2/neu status in fine-needle aspiration cytology.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Lesions and Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; HER2/neu; Concordance; Immunohistochemistry; Fine-needle aspiration; Cytology; Surgical pathology; Trastuzumab; Breast cancer; Pathology; Internal medicine; Biopsy; Cancer","score_opus":0.1218960637277209,"score_gpt":0.4215706106573158,"score_spread":0.29967454692959494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245304554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203354,0.00022773723,0.00018932413,0.0005761578,0.00021205161,0.00012843133,5.5012873e-7,0.0000046055075,0.0066276276],"genre_scores_gemma":[0.99610174,0.00003439559,0.00327226,0.00039461683,0.00013687892,0.0000038394583,0.000006880847,0.00001174997,0.000037643083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972564,0.00031726563,0.0018305818,0.00017112063,0.00018542993,0.00023918421],"domain_scores_gemma":[0.9981803,0.00040056245,0.0009203804,0.00014755002,0.00020530896,0.00014587076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016223775,0.00011469402,0.0009779183,0.00023292501,0.000016109563,0.0000061325863,0.000090403475,0.00031142705,0.00009186542],"category_scores_gemma":[0.00080905954,0.000088595676,0.00010140358,0.00028553148,0.00013542973,0.00018580897,0.000026589762,0.0010464652,0.0000037573163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034784484,0.0022313825,0.9484431,0.000028742905,0.000029721688,0.0016937788,0.00037421472,0.00007324046,0.01726114,0.000024668818,0.000098068565,0.026263466],"study_design_scores_gemma":[0.009021951,0.0023519425,0.986136,0.00023597252,0.0000495597,0.00045771207,0.00045217844,0.00026008167,0.000534512,0.00007834626,0.00033568838,0.00008601444],"about_ca_topic_score_codex":0.00021505271,"about_ca_topic_score_gemma":0.00068574725,"teacher_disagreement_score":0.037692916,"about_ca_system_score_codex":0.000340787,"about_ca_system_score_gemma":0.0015235392,"threshold_uncertainty_score":0.4546429},"labels":[],"label_agreement":null},{"id":"W2245311357","doi":"10.1200/jco.2006.24.18_suppl.17074","title":"Stereotactic body radiotherapy (SBRT) and medical inoperability of early stage non-small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Comorbidity; Stage (stratigraphy); Cohort; Retrospective cohort study; Lung cancer; DLCO; Performance status; Radiation therapy; Radiosurgery; Medical record; Cancer; Internal medicine; Surgery; Lung; Diffusing capacity; Lung function","score_opus":0.04953308046769939,"score_gpt":0.44525062488593425,"score_spread":0.39571754441823487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245311357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727155,0.0054477225,0.000068541995,0.005369618,0.0006389285,0.00025952578,0.0000069283556,0.000003778895,0.00093341013],"genre_scores_gemma":[0.9878227,0.008627004,0.0009868835,0.0011566139,0.0010659748,0.000009207045,8.5290276e-7,0.000014693323,0.00031603873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699533,0.0002497867,0.0019484718,0.00019613173,0.00041570677,0.00019455052],"domain_scores_gemma":[0.99626875,0.0017264177,0.0011655407,0.00017673525,0.0002821466,0.00038039603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018673703,0.00013494944,0.001467743,0.00007606789,0.000023486116,0.000007414226,0.00010317584,0.00032656538,0.00068020524],"category_scores_gemma":[0.00034944227,0.000088789086,0.00033281025,0.000088092725,0.00022905983,0.00006186347,0.00003120184,0.00066730904,0.0000011663126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019527317,0.003570846,0.9663992,0.00011789178,0.0003797209,0.00046971496,0.00009263793,0.000006117587,0.00018529686,0.000020301872,0.0020214762,0.024784047],"study_design_scores_gemma":[0.012816609,0.010327373,0.95954245,0.00015523973,0.00047114975,0.00007951622,0.000019796322,0.00017165794,0.00029120056,0.000021033777,0.016030142,0.0000738557],"about_ca_topic_score_codex":0.001509063,"about_ca_topic_score_gemma":0.0005033684,"teacher_disagreement_score":0.024710191,"about_ca_system_score_codex":0.0003186574,"about_ca_system_score_gemma":0.0021592828,"threshold_uncertainty_score":0.744777},"labels":[],"label_agreement":null},{"id":"W2245359169","doi":"10.1200/jco.2013.31.4_suppl.337","title":"Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Capecitabine; Hazard ratio; Bevacizumab; Clinical endpoint; Internal medicine; Colorectal cancer; Confidence interval; Randomized controlled trial; Cancer; Cape; Surgery; Oncology; Chemotherapy","score_opus":0.06477086103378332,"score_gpt":0.42692281901596413,"score_spread":0.3621519579821808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245359169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877995,0.00042796126,0.0001588474,0.006960743,0.0006419651,0.003722311,0.00006710602,0.0000028110417,0.0002187335],"genre_scores_gemma":[0.9970176,0.001039115,0.0009832067,0.00009256604,0.00022284164,0.00049976277,0.000026415095,0.000012872521,0.00010562619],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963458,0.00021251116,0.002652379,0.0001769705,0.0004496284,0.0001626883],"domain_scores_gemma":[0.98988366,0.005530194,0.0028647624,0.00010946958,0.001520388,0.000091526796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011419724,0.00018357346,0.002529928,0.00014954165,0.000040301096,0.0000064107953,0.00010787308,0.000090658454,0.00008669266],"category_scores_gemma":[0.0015208569,0.00007977393,0.00043784615,0.0001491922,0.00035266162,0.00010218849,0.000016981325,0.00017691357,3.5952306e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8538798,0.013273129,0.004275214,0.000019451189,0.0036247182,0.000018446228,0.0006190609,0.000063982356,0.0000070629535,0.000019815967,0.00019563295,0.12400371],"study_design_scores_gemma":[0.82073915,0.14076741,0.033873662,0.00012133537,0.0018207432,0.000009716966,0.00017144572,0.00072630716,0.000062446925,0.00008501454,0.0015586481,0.00006409414],"about_ca_topic_score_codex":0.0007480468,"about_ca_topic_score_gemma":0.003004656,"teacher_disagreement_score":0.12749429,"about_ca_system_score_codex":0.00035957937,"about_ca_system_score_gemma":0.00075523334,"threshold_uncertainty_score":0.32530862},"labels":[],"label_agreement":null},{"id":"W2245384963","doi":"10.1200/jco.2007.25.18_suppl.15572","title":"A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Sunitinib; Medicine; Internal medicine; Population; Group B; Cancer; Renal cell carcinoma; Oncology; Gastroenterology","score_opus":0.2170691400457521,"score_gpt":0.47416104228890277,"score_spread":0.2570919022431507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245384963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585485,0.00018542445,0.00021794136,0.00085266045,0.00045348896,0.0015993483,0.000040009683,0.000028903454,0.0007673428],"genre_scores_gemma":[0.9923412,0.000033632456,0.004287348,0.0012410209,0.0007928439,0.00004178842,0.00012953025,0.000082329294,0.0010502969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915418,0.001327111,0.0047550574,0.0005158066,0.0012270313,0.0006331726],"domain_scores_gemma":[0.98610526,0.0067876643,0.0039707343,0.00045931985,0.0018880966,0.00078893744],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006258511,0.00051187316,0.0029019923,0.00047770166,0.00015094063,0.000026442034,0.00028461966,0.00029932355,0.0019136522],"category_scores_gemma":[0.0023410697,0.00030300836,0.0005021997,0.00050969166,0.00014836779,0.00017747047,0.000067256595,0.001421064,0.000022729439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1165567,0.020505494,0.8014373,0.00016801532,0.0018660799,0.0044096615,0.0006012586,0.0010508217,0.00018418024,8.638026e-7,0.00033201178,0.052887574],"study_design_scores_gemma":[0.056126885,0.19098376,0.74565846,0.00043883122,0.0035363082,0.00015567133,0.00054274005,0.00060260063,0.001141651,0.000014503069,0.00050297554,0.00029560234],"about_ca_topic_score_codex":0.0009008279,"about_ca_topic_score_gemma":0.012405627,"teacher_disagreement_score":0.17047827,"about_ca_system_score_codex":0.0008336301,"about_ca_system_score_gemma":0.001968412,"threshold_uncertainty_score":0.9999422},"labels":[],"label_agreement":null},{"id":"W2245414171","doi":"10.1200/jco.2007.25.18_suppl.20002","title":"Patient weight and event-free survival for children under 2 years of age at diagnosis with favorable histology Wilms tumor","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Medicine; Percentile; Wilms' tumor; Univariate analysis; Proportional hazards model; Vincristine; Internal medicine; Body mass index; Pediatrics; Underweight; Chemotherapy; Multivariate analysis; Overweight; Cyclophosphamide","score_opus":0.0663155598786412,"score_gpt":0.41213430957210395,"score_spread":0.34581874969346277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245414171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891116,0.0013550121,0.0007420798,0.0068108854,0.0011499719,0.0004297917,0.000021036829,0.000008857532,0.00037073347],"genre_scores_gemma":[0.9872209,0.0003235096,0.0069793,0.0044333455,0.00087966496,0.0000071464706,0.0000075346907,0.00003319355,0.0001154121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959117,0.00035872613,0.0025857044,0.00027262035,0.00052628864,0.00034493717],"domain_scores_gemma":[0.9907212,0.005766109,0.0023649568,0.00034675404,0.00033625137,0.00046472173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004762153,0.00016944153,0.0019389208,0.00015069553,0.000045404548,0.000003858995,0.00020780589,0.0002955732,0.00009770417],"category_scores_gemma":[0.0035361021,0.0001310736,0.0003860241,0.00012347043,0.0005213058,0.00007348272,0.00013011968,0.0005980192,0.0000023230643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015626991,0.0038314026,0.9203999,0.0001207144,0.0013095951,0.00082916557,0.00064896425,0.000020446323,0.000058479418,0.00047441918,0.02316484,0.03351507],"study_design_scores_gemma":[0.014688843,0.024887184,0.92652005,0.0001771484,0.0005608888,0.0007802003,0.00025639654,0.000002958966,0.0002192476,0.0008729071,0.03088084,0.00015334929],"about_ca_topic_score_codex":0.00017575818,"about_ca_topic_score_gemma":0.0015589648,"teacher_disagreement_score":0.03336172,"about_ca_system_score_codex":0.00022797158,"about_ca_system_score_gemma":0.0007927052,"threshold_uncertainty_score":0.5345026},"labels":[],"label_agreement":null},{"id":"W2245414184","doi":"10.1200/jco.2009.27.15_suppl.10579","title":"Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Quinazolinone synthesis and applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Sarcoma; Adverse effect; Oncology; Clinical endpoint; Soft tissue sarcoma; Phases of clinical research; Rhabdomyosarcoma; Surgery; Chemotherapy; Clinical trial; Pathology","score_opus":0.08092407875851858,"score_gpt":0.46936573452629854,"score_spread":0.38844165576777995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245414184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849297,0.00016994939,0.00006339921,0.003057295,0.00020011772,0.00013049411,0.00003220933,0.000006143331,0.007847446],"genre_scores_gemma":[0.9964414,0.00020985582,0.002324166,0.00012901732,0.0005877855,0.0000041434855,0.0000025422578,0.000009245565,0.00029183994],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99445474,0.00018015158,0.004647307,0.00020397107,0.00029742313,0.00021638058],"domain_scores_gemma":[0.99242526,0.002834139,0.0039013543,0.0003350716,0.00031738883,0.00018676977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022612747,0.00013291604,0.0015441009,0.00009703585,0.000029377372,0.0000036855697,0.00038489437,0.0004162957,0.00017742814],"category_scores_gemma":[0.0055003474,0.000110160705,0.00039060856,0.0001522267,0.00022548232,0.000092639944,0.00004355347,0.0007001641,0.000005018255],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13910438,0.019514687,0.00034491546,0.000028277655,0.00010567122,0.00010473041,0.0002169371,0.000040795214,0.14196827,0.00052457355,0.0018741214,0.69617265],"study_design_scores_gemma":[0.5187508,0.07474576,0.020290213,0.0004713098,0.00041257212,0.00010905736,0.0003053445,0.00015397591,0.14454909,0.006612655,0.23312208,0.0004771813],"about_ca_topic_score_codex":0.000018935367,"about_ca_topic_score_gemma":0.000014181625,"teacher_disagreement_score":0.69569546,"about_ca_system_score_codex":0.00004880063,"about_ca_system_score_gemma":0.0006854602,"threshold_uncertainty_score":0.6584827},"labels":[],"label_agreement":null},{"id":"W2245424203","doi":"10.1200/jco.2009.27.15_suppl.7085","title":"Role of serum erythropoietin, erythropoietin-independent erythroid colony formation, and bone marrow assessment in the diagnosis of polycythemia vera in patients with JAK2 V617F mutation","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erythropoietin; Polycythemia vera; Medicine; Bone marrow; Hemoglobin; Internal medicine; Gastroenterology; Pathology","score_opus":0.025857141244275687,"score_gpt":0.3723206368833043,"score_spread":0.3464634956390286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245424203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98510087,0.00039456907,0.000016939264,0.0131955985,0.000109777204,0.0006880921,0.000013355303,0.000002634507,0.0004781945],"genre_scores_gemma":[0.99585724,0.0010319205,0.0020338122,0.0009344107,0.00009156286,0.000023712084,0.000010770382,0.000010324293,0.0000062577533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957916,0.00056647224,0.002520699,0.00019782622,0.0006972525,0.00022610811],"domain_scores_gemma":[0.9954422,0.0015528587,0.002145474,0.00018999206,0.0005317724,0.00013771557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023425217,0.00019020967,0.0013830116,0.00022109976,0.000039014267,0.0000099665585,0.000113303126,0.00024916997,0.0000806312],"category_scores_gemma":[0.0006720457,0.00011349598,0.00017989764,0.0002556445,0.00021322515,0.00020415174,0.000028580775,0.00070039736,0.0000011669067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002678968,0.0072837314,0.94582516,0.000042497304,0.00012696255,0.00012707252,0.0010054206,0.00004383128,0.00003675164,0.00017583516,0.00038831856,0.04226547],"study_design_scores_gemma":[0.01658781,0.027272807,0.95244366,0.00032025573,0.00022189043,0.00011626878,0.0011794425,0.000062775136,0.0006911554,0.000471946,0.0005416906,0.000090315654],"about_ca_topic_score_codex":0.00004009705,"about_ca_topic_score_gemma":0.0002860732,"teacher_disagreement_score":0.042175155,"about_ca_system_score_codex":0.00023448863,"about_ca_system_score_gemma":0.0006125241,"threshold_uncertainty_score":0.46282318},"labels":[],"label_agreement":null},{"id":"W2245461570","doi":"10.1200/jco.2014.32.26_suppl.1","title":"Improving screening mammography return rates in overdue women: A randomized study of signed reminder letters from family physicians.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Saint John Regional Hospital","funders":"","keywords":"Medicine; Family medicine; Mammography; Asymptomatic; Randomized controlled trial; Breast cancer; Cancer; Surgery; Internal medicine","score_opus":0.10278358594952874,"score_gpt":0.42944380250712144,"score_spread":0.3266602165575927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245461570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932493,0.0003151163,0.0037178053,0.0012578196,0.0006462346,0.00042632764,0.0000015965346,0.0000081262715,0.00037770616],"genre_scores_gemma":[0.98772395,0.00005350725,0.0050687958,0.006106904,0.0010052854,0.00001122557,0.0000013591841,0.000017896771,0.000011050176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935315,0.0016513047,0.0034990779,0.0002926963,0.0006673573,0.00035806498],"domain_scores_gemma":[0.99018574,0.00583057,0.0031437767,0.00026084468,0.00034108068,0.00023798257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010070572,0.0001996318,0.0035200492,0.00028462845,0.00003462547,0.000013836701,0.00026315253,0.0002743917,0.000033617667],"category_scores_gemma":[0.006414717,0.0001470637,0.00068496773,0.00035473768,0.00026750218,0.00019999365,0.000071050345,0.001176197,0.0000012941898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37712342,0.002802203,0.4039801,0.000046108926,0.0015026585,0.0007078923,0.003037982,0.00026280258,0.03118097,0.000017678636,0.0013182749,0.1780199],"study_design_scores_gemma":[0.41454735,0.017952532,0.55189633,0.00070787134,0.0008168548,0.000033081415,0.0099703735,0.002352191,0.00026649726,0.0005144283,0.0006729843,0.00026946372],"about_ca_topic_score_codex":0.0007748197,"about_ca_topic_score_gemma":0.000140258,"teacher_disagreement_score":0.17775042,"about_ca_system_score_codex":0.00011984976,"about_ca_system_score_gemma":0.0003418641,"threshold_uncertainty_score":0.7679479},"labels":[],"label_agreement":null},{"id":"W2245516491","doi":"10.1200/jco.2004.22.90140.860","title":"Preliminary clinical results of accelerated IMRT with concomitant boost after breast conserving therapy (BCT)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Nuclear medicine; Radiation therapy; Breast-conserving surgery; Prone position; Concomitant; Stage (stratigraphy); Radiology; Mastectomy; Cancer; Surgery; Internal medicine","score_opus":0.07845400968856585,"score_gpt":0.4397908093032171,"score_spread":0.36133679961465126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245516491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97905415,0.00041648888,0.014390713,0.0032964763,0.0005065901,0.0003250776,0.000052691415,0.000025324232,0.0019324672],"genre_scores_gemma":[0.95773804,0.00046630154,0.039493285,0.0010329911,0.0011696798,0.000008759547,0.0000041001545,0.000035736688,0.00005111184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946907,0.00056564517,0.003875991,0.0002902159,0.0002857797,0.0002916577],"domain_scores_gemma":[0.9925487,0.0024735439,0.0036447227,0.00035453463,0.000698204,0.00028028572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028549675,0.00023834525,0.0016984056,0.00009085711,0.000044204713,0.000015167982,0.0004171412,0.00031268806,0.00017142494],"category_scores_gemma":[0.0002023191,0.00015707832,0.00056595175,0.00016736073,0.0006171061,0.00026783015,0.00006000697,0.001265489,0.000002641768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112187296,0.0074198144,0.49253273,0.000017557899,0.0019908561,0.0006099494,0.00036912435,0.00033185325,0.00096841133,0.00086172717,0.002272519,0.38043815],"study_design_scores_gemma":[0.07096241,0.07377696,0.7828298,0.0007770205,0.00032143778,0.0006331947,0.00036647913,0.000106695734,0.00408237,0.006570695,0.058829505,0.0007434248],"about_ca_topic_score_codex":0.00006236383,"about_ca_topic_score_gemma":0.000008837897,"teacher_disagreement_score":0.37969473,"about_ca_system_score_codex":0.00007800596,"about_ca_system_score_gemma":0.0016671522,"threshold_uncertainty_score":0.6405468},"labels":[],"label_agreement":null},{"id":"W2245519076","doi":"10.1200/jco.2009.27.15_suppl.e16104","title":"Characterization of lymphoid infiltrates in prostatectomy specimens post neoadjuvant hormonal therapy using quantitative immunofluorescence and RNA FISH","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; FOXP3; Prostate cancer; Immune system; Hormonal therapy; Population; Oncology; CD8; Prostate; Prostatectomy; Multiplex; Cancer; Pathology; Cancer research; Internal medicine; Immunology; Biology; Bioinformatics","score_opus":0.07130391402996104,"score_gpt":0.3913964147019715,"score_spread":0.32009250067201045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245519076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921335,0.0057585654,0.000066612774,0.001113948,0.000621854,0.00020941986,0.000018310458,0.000005595181,0.00007219336],"genre_scores_gemma":[0.98831606,0.01015335,0.00055774243,0.0008442338,0.000051627805,0.0000011539171,0.000013824601,0.000010447141,0.00005154678],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962162,0.0011025186,0.0021751085,0.00017096076,0.00007091971,0.0002642936],"domain_scores_gemma":[0.996213,0.0012896879,0.0019263523,0.00013449496,0.00040530067,0.000031139993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019974287,0.0001792892,0.0011444913,0.00025399285,0.00006647739,0.0000122740785,0.00022191761,0.0004138786,0.00009913841],"category_scores_gemma":[0.0008002677,0.00013512593,0.00020621433,0.00018800575,0.0004767075,0.0003292937,0.000027626538,0.00064736954,0.000004086484],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017497329,0.00087188574,0.007050107,0.000004318343,0.00020405518,0.000038394068,0.0007184845,0.000003719559,0.893564,0.0001206335,0.000018053699,0.07990905],"study_design_scores_gemma":[0.009310131,0.017771862,0.71470255,0.00016260029,0.0000363532,0.00077093067,0.00033294095,0.000017992561,0.25161943,0.00016861269,0.0049346657,0.0001719328],"about_ca_topic_score_codex":0.000045888715,"about_ca_topic_score_gemma":0.000006894722,"teacher_disagreement_score":0.70765245,"about_ca_system_score_codex":0.00006692556,"about_ca_system_score_gemma":0.0008200617,"threshold_uncertainty_score":0.5510276},"labels":[],"label_agreement":null},{"id":"W2245645247","doi":"10.1200/jco.2004.22.90140.8138","title":"Oncologists' attitudes towards recommending exercise to cancer patients: A Canadian national survey","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Family medicine; Cancer; Internal medicine; Psychological intervention; Physical therapy; Nursing","score_opus":0.227794771566648,"score_gpt":0.5154839772775656,"score_spread":0.28768920571091755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245645247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550635,0.00035264928,0.0000538694,0.03003545,0.0066995528,0.00028974202,0.000088390916,0.000010788289,0.0074060233],"genre_scores_gemma":[0.98258054,0.00057177205,0.0009206411,0.014527559,0.0011630583,0.00001370224,0.000015619125,0.000016878437,0.00019025049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971258,0.00025939447,0.0015517212,0.00020383953,0.00053782307,0.00032141985],"domain_scores_gemma":[0.9955169,0.00070628,0.00067233853,0.00011279322,0.0018411083,0.0011505742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004290622,0.00013672152,0.0010980243,0.00027904357,0.00006523975,0.000015154904,0.00021204606,0.00035697996,0.00043613938],"category_scores_gemma":[0.0059412043,0.000107430526,0.00032329521,0.00030995868,0.000090629896,0.00010333062,0.000045093006,0.00077942776,0.000031999003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023122726,0.001178251,0.7827023,0.000024394183,0.00020517064,0.00017807425,0.00033780345,0.00011131782,0.0000037348648,0.00007476726,0.026440924,0.18643098],"study_design_scores_gemma":[0.0039490294,0.0043671513,0.85193145,0.00021743754,0.00009193318,0.000023880852,0.00006353863,0.0000012564543,0.0000139915055,0.00015221287,0.13908222,0.00010589977],"about_ca_topic_score_codex":0.15692832,"about_ca_topic_score_gemma":0.7590438,"teacher_disagreement_score":0.60211545,"about_ca_system_score_codex":0.0029251475,"about_ca_system_score_gemma":0.014475345,"threshold_uncertainty_score":0.99111164},"labels":[],"label_agreement":null},{"id":"W2245653899","doi":"10.1200/jco.2007.25.18_suppl.9003","title":"Donepezil for cancer-related fatigue: A double-blind, randomized, placebo-controlled study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Contraindication; Clinical endpoint; Internal medicine; Randomized controlled trial; Donepezil; Randomization; Physical therapy; Nausea; Dementia; Disease","score_opus":0.23903560687445433,"score_gpt":0.5671675735379793,"score_spread":0.32813196666352495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245653899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97089416,0.0017692101,0.00048744588,0.009274151,0.005735889,0.0063809045,0.0000029121086,0.00003064556,0.0054246793],"genre_scores_gemma":[0.99021965,0.00093162246,0.0015060357,0.0017992536,0.0029315674,0.0002847535,0.0000036853025,0.000030464706,0.0022929914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934313,0.00070867816,0.004801503,0.00026941247,0.00037978194,0.00040928673],"domain_scores_gemma":[0.9811065,0.014221561,0.0031618655,0.00016641199,0.0008139589,0.0005296953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01828174,0.0002442984,0.0050260527,0.00029056903,0.000077050834,0.00000992309,0.00018353655,0.0005376761,0.0005251644],"category_scores_gemma":[0.0020408458,0.00015193356,0.0017398584,0.00020795169,0.00021959622,0.000085708074,0.000032146174,0.0010492341,0.00001040789],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9324588,0.010935151,0.0062623424,0.00002262257,0.007911663,0.0006162018,0.0005043307,0.000026774482,0.00004559538,0.000101362464,0.004290613,0.036824502],"study_design_scores_gemma":[0.93533736,0.025327638,0.0020950567,0.000038915427,0.008697984,0.00016458918,0.00024188533,0.00013939488,0.00006313377,0.00022050977,0.027548298,0.00012523464],"about_ca_topic_score_codex":0.0000878379,"about_ca_topic_score_gemma":0.00043191324,"teacher_disagreement_score":0.036699265,"about_ca_system_score_codex":0.00034562135,"about_ca_system_score_gemma":0.0021793325,"threshold_uncertainty_score":0.6336123},"labels":[],"label_agreement":null},{"id":"W2245655230","doi":"10.1200/jco.2007.25.18_suppl.15506","title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Renal cell carcinoma; Adverse effect; Population; Clinical endpoint; Clinical trial; Surgery; Oncology","score_opus":0.11061946773674892,"score_gpt":0.4725009566384316,"score_spread":0.3618814889016827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245655230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486506,0.0004638534,0.00068858074,0.0023734823,0.0005010834,0.0005336756,0.00005167671,0.0000057422008,0.0005168663],"genre_scores_gemma":[0.9953142,0.00017723502,0.0029157086,0.0010469052,0.0003092047,0.0000065804365,0.00005278388,0.000020174442,0.00015723905],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994294,0.00096098654,0.0032947827,0.00027444022,0.00078688416,0.00038890578],"domain_scores_gemma":[0.98524374,0.009218216,0.0037699859,0.00043325973,0.0008626342,0.00047217758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008162683,0.0002276186,0.002382191,0.00035322912,0.00009585617,0.00001911454,0.00034730218,0.00020437528,0.00013624955],"category_scores_gemma":[0.0027980497,0.00011295115,0.0011954748,0.0007791643,0.00035656092,0.00015046945,0.000076296485,0.00064792053,0.0000023055215],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41035205,0.011771772,0.313289,0.000040084,0.009401431,0.0012937073,0.00014583314,0.0002196495,0.000096847776,0.000104655155,0.00441181,0.24887317],"study_design_scores_gemma":[0.16241895,0.052871034,0.73591346,0.000035748075,0.012596858,0.000036238624,0.000322895,0.00003412382,0.0012046151,0.00008820405,0.03431733,0.00016055738],"about_ca_topic_score_codex":0.00004398253,"about_ca_topic_score_gemma":0.0004712075,"teacher_disagreement_score":0.42262447,"about_ca_system_score_codex":0.0001368807,"about_ca_system_score_gemma":0.0009200497,"threshold_uncertainty_score":0.46060145},"labels":[],"label_agreement":null},{"id":"W2245716453","doi":"10.1200/jco.2005.23.16_suppl.3662","title":"A phase II study of neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for resectable liver metastases from colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastasectomy; Irinotecan; Colorectal cancer; Chemotherapy; Perioperative; Regimen; Internal medicine; Neoadjuvant therapy; Surgery; Progressive disease; Chemotherapy regimen; Fluorouracil; Clinical endpoint; Phases of clinical research; Gastroenterology; Oncology; Cancer; Clinical trial; Breast cancer","score_opus":0.2709697348091951,"score_gpt":0.46431690530323205,"score_spread":0.19334717049403694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245716453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951805,0.006723709,0.00009466106,0.0021563175,0.00037917704,0.0009181396,0.00009209534,0.00000987374,0.00010798341],"genre_scores_gemma":[0.99085414,0.0015428703,0.0055151354,0.00029731705,0.001463617,0.000053860756,0.00001161316,0.000024482075,0.00023696826],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996416,0.00049165083,0.0020991366,0.0003040199,0.00038436207,0.00030485637],"domain_scores_gemma":[0.9949336,0.0025567745,0.0013624318,0.00018048826,0.00053247844,0.00043419813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002167657,0.00021833787,0.0019842698,0.00015014566,0.00010188136,0.000013840597,0.0001456654,0.00028166885,0.00030804204],"category_scores_gemma":[0.001322557,0.00015378813,0.00047822058,0.00013401303,0.00016189268,0.00022566822,0.00009451551,0.0005176494,0.0000025197658],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02267546,0.031278558,0.33096197,0.000051140138,0.0018944847,0.0012869048,0.001135007,0.0000071732493,0.0023089459,0.000020345748,0.0031351966,0.6052448],"study_design_scores_gemma":[0.16213027,0.4902573,0.11577449,0.00030059367,0.009622825,0.00041355097,0.0015257575,0.005609837,0.01692251,0.000109492066,0.1968643,0.0004690653],"about_ca_topic_score_codex":0.0012940104,"about_ca_topic_score_gemma":0.0037727277,"teacher_disagreement_score":0.6047757,"about_ca_system_score_codex":0.0001752732,"about_ca_system_score_gemma":0.0010409534,"threshold_uncertainty_score":0.6271298},"labels":[],"label_agreement":null},{"id":"W2245716731","doi":"10.1200/jco.2007.25.18_suppl.6518","title":"A tool for assessing adverse events in phase I/II oncology clinical trials","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Causality (physics); Clinical trial; Thematic analysis; Terminology; Common Terminology Criteria for Adverse Events; Adverse effect; Oncology; Qualitative research; Family medicine; Internal medicine","score_opus":0.881449410048825,"score_gpt":0.8054104386192672,"score_spread":0.07603897142955784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245716731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521286,0.0001981,0.007782627,0.028318642,0.0062998487,0.0012954546,0.000006801712,0.000016878335,0.0039530867],"genre_scores_gemma":[0.9233862,0.0012669651,0.056898467,0.00952352,0.007885355,0.000017179886,0.000005423048,0.000049767743,0.0009671216],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9547102,0.010600559,0.030539714,0.0008638612,0.002011883,0.0012737681],"domain_scores_gemma":[0.22164424,0.75590837,0.014267016,0.0009737949,0.004641879,0.0025646759],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.4985817,0.00027071446,0.0065794596,0.0005359918,0.00011894791,0.0000067218775,0.00063265226,0.004317233,0.00028531713],"category_scores_gemma":[0.75235903,0.00019668644,0.0029338028,0.00042662918,0.0008733988,0.00020983742,0.00029569925,0.0118459305,0.000032949913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06825151,0.02950644,0.1435917,0.00013995598,0.0007299909,0.002727164,0.000120860626,0.000009146925,0.00035021311,0.0015000796,0.0031350218,0.7499379],"study_design_scores_gemma":[0.19171643,0.1770524,0.2948574,0.0011584501,0.0013406236,0.0006484827,0.00081367814,0.00056410197,0.00013565292,0.037727207,0.29356968,0.00041590031],"about_ca_topic_score_codex":0.000011818544,"about_ca_topic_score_gemma":0.00025647943,"teacher_disagreement_score":0.74952203,"about_ca_system_score_codex":0.00076734216,"about_ca_system_score_gemma":0.016513497,"threshold_uncertainty_score":0.99697536},"labels":[],"label_agreement":null},{"id":"W2245717755","doi":"10.1200/jco.2007.25.18_suppl.18099","title":"Hormone replacement use, age, and prognosis for women with non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Sudbury Regional Hospital","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Cancer; Proportional hazards model; Performance status; Hormone replacement therapy (female-to-male); Univariate analysis; Stage (stratigraphy); Oncology; Gynecology; Multivariate analysis; Testosterone (patch)","score_opus":0.033592683858954496,"score_gpt":0.3805327919891974,"score_spread":0.34694010813024295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245717755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947599,0.0022671823,0.001506318,0.00030704695,0.00027793887,0.00035603653,0.0000031282973,0.0000025183544,0.00051991374],"genre_scores_gemma":[0.9871798,0.0030173534,0.0075587826,0.00061980385,0.0006665444,0.000027525108,0.0000033362487,0.000021282576,0.00090555043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842554,0.000087554654,0.0008651318,0.00021031048,0.00010755755,0.00030392988],"domain_scores_gemma":[0.9982238,0.000354766,0.0007870377,0.00011293182,0.00021922676,0.00030228088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002256816,0.00012892026,0.0005085869,0.00004445052,0.000046043864,0.000014017454,0.000110563145,0.00044103613,0.000003312424],"category_scores_gemma":[0.00026058807,0.00008596245,0.00012838072,0.00005316021,0.000116013885,0.0000064890555,0.000051566658,0.00035139642,3.543129e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09507605,0.003861311,0.40972036,0.00028679226,0.0035458088,0.0010854198,0.0005680577,0.00017812809,0.2848414,0.00003397269,0.042290874,0.15851185],"study_design_scores_gemma":[0.035874873,0.1457356,0.38875464,0.00014109915,0.00091792207,0.00035691244,0.00044320873,0.00015950434,0.060790222,0.000058347465,0.36608425,0.00068341993],"about_ca_topic_score_codex":0.0000075635244,"about_ca_topic_score_gemma":0.000031404565,"teacher_disagreement_score":0.32379338,"about_ca_system_score_codex":0.000048502905,"about_ca_system_score_gemma":0.0004415155,"threshold_uncertainty_score":0.3505447},"labels":[],"label_agreement":null},{"id":"W2245804800","doi":"10.1200/jco.2006.24.18_suppl.7211","title":"Prognostic significance of immunohistochemical markers in non-small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tissue microarray; Immunohistochemistry; Oncology; Adenocarcinoma; Internal medicine; Cancer; Carcinoma; Pathology; Biomarker; Small-cell carcinoma; Population; Biology","score_opus":0.03203882266499846,"score_gpt":0.4396795485552337,"score_spread":0.40764072589023526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245804800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98034745,0.002239558,0.00014032396,0.0016721019,0.000614251,0.0003899172,0.0000053183057,0.000003405704,0.014587686],"genre_scores_gemma":[0.9940771,0.00030701596,0.0042363843,0.000288321,0.00042601573,0.000023074013,0.0000033444742,0.000012250509,0.0006265027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976074,0.00010376161,0.0017942904,0.00013410588,0.00018466431,0.00017577635],"domain_scores_gemma":[0.9973404,0.0009838833,0.0011746027,0.000113790404,0.0002642738,0.00012306377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000748149,0.00009882601,0.0009194597,0.000099528406,0.000013690945,0.000002464124,0.00010038739,0.00021280962,0.00009681332],"category_scores_gemma":[0.00042125254,0.00007263016,0.00028075447,0.0001484233,0.0001412638,0.00003651872,0.000017107848,0.0005051485,0.0000020003245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002529783,0.0035156922,0.9607712,0.00018466797,0.00027721786,0.0004590528,0.00011933166,0.00018841354,0.008295196,0.000035983623,0.0073205167,0.016302926],"study_design_scores_gemma":[0.011271609,0.0037213385,0.97497654,0.00035920317,0.0010578509,0.000050578215,0.000115714814,0.00020719127,0.0012210273,0.00011681062,0.0068051117,0.00009699897],"about_ca_topic_score_codex":0.00043767353,"about_ca_topic_score_gemma":0.00008858562,"teacher_disagreement_score":0.016205927,"about_ca_system_score_codex":0.00038224485,"about_ca_system_score_gemma":0.0024143993,"threshold_uncertainty_score":0.42830405},"labels":[],"label_agreement":null},{"id":"W2245911170","doi":"10.1200/jco.2008.26.15_suppl.6605","title":"Integrating primary care and the cancer system: Program evaluation of the UPCON Network in Manitoba, Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cronbach's alpha; Outreach; Family medicine; Scale (ratio); Primary care; Cancer; Test (biology); Internal medicine; Psychometrics","score_opus":0.16434384468979188,"score_gpt":0.3731700093289811,"score_spread":0.2088261646391892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245911170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555353,0.01573295,0.000014971088,0.0014732782,0.0026232777,0.0005097892,0.000011404474,0.0000018357232,0.024097227],"genre_scores_gemma":[0.99623185,0.0016829853,0.0003881949,0.0007593751,0.0008795446,0.00002920932,4.9951785e-7,0.0000075117814,0.000020807098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712044,0.00024200429,0.0022539143,0.00013131551,0.00008683465,0.00016549267],"domain_scores_gemma":[0.99588233,0.00066232646,0.0029814711,0.00015041624,0.00026331158,0.00006016823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005631927,0.00008458599,0.0009904185,0.000035552563,0.00007719872,0.000008821106,0.00026964518,0.00015214771,0.000013796733],"category_scores_gemma":[0.0012508611,0.00005213323,0.0001755104,0.00011373413,0.00026638157,0.00010888698,0.00005466906,0.0005119815,6.522744e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003602391,0.00006129705,0.6420927,0.00005218414,0.00009102011,0.0000068208888,0.0004415947,0.0011556008,1.6942279e-7,0.0072491746,0.0017908507,0.3466983],"study_design_scores_gemma":[0.0041471813,0.00041456684,0.9512709,0.00016743325,0.000059050963,0.00003256227,0.00066668703,0.001670606,0.0000018613273,0.0014681888,0.040014684,0.00008628885],"about_ca_topic_score_codex":0.12706776,"about_ca_topic_score_gemma":0.51354456,"teacher_disagreement_score":0.3864768,"about_ca_system_score_codex":0.0010168782,"about_ca_system_score_gemma":0.002938184,"threshold_uncertainty_score":0.87874514},"labels":[],"label_agreement":null},{"id":"W2245926507","doi":"10.1200/jco.2006.24.18_suppl.10553","title":"Clinical and pathological correlations in male breast cancer (MBC): Intratumoral aromatase expression (ITA) via tissue microarray (TMA)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Aromatase; Breast cancer; Immunohistochemistry; Tissue microarray; Pathology; Internal medicine; Cancer; Oncology; Stage (stratigraphy); Biology","score_opus":0.08051061079834408,"score_gpt":0.4769438763363855,"score_spread":0.3964332655380414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245926507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697337,0.0018471415,0.00031372925,0.025103264,0.0015657331,0.00033643786,0.000039631504,0.000015257318,0.0010450918],"genre_scores_gemma":[0.98298746,0.0012266166,0.010067198,0.0021328987,0.0030996392,0.000013998302,0.00001003028,0.00001891819,0.0004432196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937361,0.0009627014,0.004196132,0.00036904003,0.00033321342,0.00040284428],"domain_scores_gemma":[0.99490565,0.0023439606,0.001687769,0.00021195698,0.00033246388,0.0005182037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043320074,0.00021246627,0.0020734689,0.00016274775,0.000083117644,0.000009838811,0.00014301241,0.00072185026,0.0004009387],"category_scores_gemma":[0.0016391276,0.00014797063,0.00025591816,0.00018485227,0.0006830393,0.00013226092,0.000120558856,0.0020319736,0.000024548814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002998307,0.002474959,0.9039705,0.000058153626,0.000031513126,0.002722131,0.000035037956,0.000008948472,0.00090500736,0.00004460207,0.021692201,0.06505864],"study_design_scores_gemma":[0.007210642,0.0033119381,0.96497506,0.00029522396,0.00015556146,0.007014358,0.0000699853,0.000101781676,0.000023400533,0.0004288886,0.016281793,0.00013134442],"about_ca_topic_score_codex":0.00015791309,"about_ca_topic_score_gemma":0.000342641,"teacher_disagreement_score":0.064927295,"about_ca_system_score_codex":0.00015816747,"about_ca_system_score_gemma":0.0009544908,"threshold_uncertainty_score":0.8828027},"labels":[],"label_agreement":null},{"id":"W2245968194","doi":"10.1200/jco.2005.23.16_suppl.8219","title":"A phase II randomized trial of three loading doses of epoetin alfa followed by every three-week (q3w) dosing in cancer patients receiving chemotherapy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; Dosing; Epoetin alfa; Interim analysis; Randomized controlled trial; Chemotherapy; Interim; Internal medicine; Cancer; Quality of life (healthcare); Surgery; Nursing","score_opus":0.08505545587685685,"score_gpt":0.4492922610313472,"score_spread":0.3642368051544903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245968194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98808366,0.0016518665,0.00010226616,0.0076865614,0.0010083044,0.00080240064,0.000006013958,0.000006066346,0.00065287796],"genre_scores_gemma":[0.9904931,0.0034280128,0.0043600844,0.0006918309,0.0008752541,0.000014447774,0.000004052048,0.000024648994,0.00010852945],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941843,0.00051352376,0.0043061776,0.00022207251,0.00049419445,0.00027969864],"domain_scores_gemma":[0.9914928,0.0040959916,0.0037024522,0.00016954284,0.00032584844,0.00021335704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046070847,0.00021112351,0.0034890876,0.00017590993,0.000040407736,0.000004361163,0.00015334802,0.00038253958,0.00028358278],"category_scores_gemma":[0.0040940247,0.00014333634,0.0009959673,0.00018059748,0.00034386542,0.000110774774,0.000041917276,0.00068245584,0.0000013044091],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7120774,0.025602115,0.023971649,0.000040665782,0.00060112186,0.0000390965,0.00033023846,0.0000093213785,0.0022506597,0.0000042059532,0.0025534197,0.2325201],"study_design_scores_gemma":[0.9543582,0.035007693,0.0028530234,0.00084151246,0.0005808261,0.000014825028,0.00005719276,0.00014623912,0.0028907568,0.000120841556,0.003011759,0.0001171174],"about_ca_topic_score_codex":0.00015686452,"about_ca_topic_score_gemma":0.000289547,"teacher_disagreement_score":0.24228081,"about_ca_system_score_codex":0.00029578546,"about_ca_system_score_gemma":0.000898056,"threshold_uncertainty_score":0.5845086},"labels":[],"label_agreement":null},{"id":"W2246017458","doi":"10.1200/jco.2015.33.3_suppl.286","title":"Next-generation sequencing: Profiling gallbladder cancer (GBC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Amplicon; Gallbladder cancer; Medicine; IDH1; Gemcitabine; Intrahepatic Cholangiocarcinoma; Adenocarcinoma; Gallbladder; Cancer; Internal medicine; Pathology; Oncology; Cancer research; Mutation; Gene; Biology; Genetics; Polymerase chain reaction; Colorectal cancer","score_opus":0.5338523391489167,"score_gpt":0.49501486053945076,"score_spread":0.03883747860946596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246017458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619524,0.00684788,0.00020711179,0.016415648,0.0043058353,0.00019773237,0.0000018244427,0.00001817387,0.010053402],"genre_scores_gemma":[0.97916865,0.0009911152,0.005729167,0.0051970617,0.008250913,0.000008356503,0.0000027874212,0.00001876839,0.00063318916],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721545,0.00022365354,0.0016910005,0.00018767561,0.000453053,0.00022916062],"domain_scores_gemma":[0.9968225,0.0003376888,0.0010260902,0.00015816143,0.0011510135,0.00050454494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025039332,0.00013636917,0.0011472191,0.00009952267,0.000042020292,0.000016418126,0.000115004594,0.00027165542,0.000084407184],"category_scores_gemma":[0.0027633666,0.000094760595,0.00037353724,0.00013725949,0.00013657704,0.00019219429,0.000048446327,0.0007962497,0.000019369094],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039262236,0.0010104052,0.5596051,0.00007473078,0.0015873476,0.0015978076,0.0015106066,0.00016299421,0.011457367,0.00025638164,0.1940809,0.22473007],"study_design_scores_gemma":[0.042923965,0.03715254,0.32157522,0.00048313235,0.0035707378,0.0030983377,0.0056745815,0.0045286757,0.008592353,0.0009673206,0.5705909,0.0008422224],"about_ca_topic_score_codex":0.00007061122,"about_ca_topic_score_gemma":0.00013299128,"teacher_disagreement_score":0.37651,"about_ca_system_score_codex":0.00047771833,"about_ca_system_score_gemma":0.0050366623,"threshold_uncertainty_score":0.8934823},"labels":[],"label_agreement":null},{"id":"W2246040050","doi":"10.1200/jco.2007.25.18_suppl.6502","title":"Risk-based care in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cancer; Breast cancer; Cohort; Health care; Radiation therapy; Disease; Logistic regression; Pediatrics; Internal medicine","score_opus":0.07706585593197521,"score_gpt":0.4722616599338876,"score_spread":0.39519580400191234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246040050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692598,0.013354248,0.0000823368,0.010917772,0.0043934807,0.0012636327,0.00013297639,0.000027457723,0.00056830776],"genre_scores_gemma":[0.98707527,0.002234068,0.0006391012,0.005861017,0.0040408447,0.000026187021,0.000015469757,0.00007050309,0.000037546037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9860363,0.0027106435,0.008164106,0.00068346754,0.0017413861,0.00066407444],"domain_scores_gemma":[0.97693497,0.01191714,0.008173831,0.0010351189,0.0012904843,0.0006484697],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.020818165,0.0004477782,0.0038778915,0.00032006405,0.00011673225,0.000016211046,0.00079521356,0.0006752888,0.00038544726],"category_scores_gemma":[0.012781363,0.0003045546,0.0011826435,0.00082002993,0.00044243445,0.00016349003,0.00015348049,0.0033939283,0.000005755118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043403986,0.007958328,0.9194455,0.000041007625,0.0011991111,0.0012828152,0.008396779,0.00020415623,0.000009155652,0.0000025537176,0.0015993312,0.05552085],"study_design_scores_gemma":[0.018007929,0.0075373724,0.9443258,0.0005726342,0.0011973125,0.00009200351,0.0090310825,0.000010155134,0.00012013247,0.000054824202,0.01877946,0.0002712904],"about_ca_topic_score_codex":0.07431871,"about_ca_topic_score_gemma":0.36224458,"teacher_disagreement_score":0.28792587,"about_ca_system_score_codex":0.0005936516,"about_ca_system_score_gemma":0.008315595,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W2246147839","doi":"10.1200/jco.2007.25.18_suppl.5508","title":"VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Vascular endothelial growth factor; Proteinuria; Gastroenterology; Adverse effect; Oncology; Urology; Kidney; VEGF receptors","score_opus":0.07443637575174555,"score_gpt":0.46063096622025007,"score_spread":0.3861945904685045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246147839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077433,0.00045999515,0.00028803886,0.0029613147,0.001876097,0.0031267686,0.00016596244,0.0000068744116,0.00034060064],"genre_scores_gemma":[0.99215114,0.00038098064,0.0057535605,0.00036254257,0.0011176956,0.00010553194,0.00001507508,0.000028292943,0.00008516967],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937414,0.00046169703,0.004496916,0.00034754135,0.00060669077,0.00034575156],"domain_scores_gemma":[0.9883257,0.0058115567,0.0039977552,0.00027224128,0.0011758532,0.00041689366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006732468,0.00024917323,0.0029375034,0.00018006569,0.00007747269,0.0000068360177,0.00015261816,0.00024231127,0.00005485219],"category_scores_gemma":[0.0034864729,0.00014509333,0.0007289988,0.00013490937,0.00023247814,0.000085702566,0.000050731927,0.0005257321,0.0000012160967],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7146103,0.052830596,0.012393914,0.00005067038,0.0022429489,0.00028944563,0.0007329241,0.0000060539223,0.000019847881,0.000016390168,0.0011217194,0.21568519],"study_design_scores_gemma":[0.6102799,0.2994413,0.07749893,0.00047254193,0.0030727312,0.000012236647,0.0001971758,0.00004802907,0.00010640194,0.000026188274,0.008740719,0.00010382346],"about_ca_topic_score_codex":0.0001139663,"about_ca_topic_score_gemma":0.00030311677,"teacher_disagreement_score":0.2466107,"about_ca_system_score_codex":0.0003072784,"about_ca_system_score_gemma":0.0010826727,"threshold_uncertainty_score":0.59167343},"labels":[],"label_agreement":null},{"id":"W2246187004","doi":"10.1200/jco.2005.23.16_suppl.5601","title":"Hyalinizing trabecular tumors of the thyroid: Clinicopathologic characteristics and treatment outcomes","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Thyroid; Thyroid carcinoma; Biopsy; Thyroid cancer; Nodule (geology); Thyroidectomy; Radiology; Pathology; Internal medicine","score_opus":0.12304710541556343,"score_gpt":0.4490654438052344,"score_spread":0.326018338389671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246187004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781879,0.0017353812,0.0000079586425,0.018807976,0.00060008356,0.00021294839,0.0000081283515,0.0000053002714,0.000434278],"genre_scores_gemma":[0.9895685,0.004696803,0.0021159055,0.0027623354,0.000688649,0.000005814815,9.4692547e-7,0.000012448442,0.00014859969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966495,0.00033830988,0.0024260792,0.00016749822,0.0002444962,0.00017413286],"domain_scores_gemma":[0.9955727,0.0016370201,0.002139123,0.0002497297,0.00017825021,0.00022317404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016152108,0.00015991672,0.0018060945,0.000054973356,0.00004133602,0.0000056353333,0.00012112699,0.00021844407,0.0000388913],"category_scores_gemma":[0.0015388317,0.00007645856,0.0007472394,0.00006835316,0.00026656713,0.000047892157,0.000044168828,0.00040705904,0.0000048708484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055255427,0.002637268,0.7402737,0.000009333781,0.00032605577,0.00021642046,0.000112348906,0.0000037734196,0.00010221462,0.000109859466,0.00024112109,0.25541532],"study_design_scores_gemma":[0.00776668,0.014390448,0.9500259,0.00009401396,0.0008388773,0.00033040004,0.00008401502,0.000016968712,0.0003073249,0.00008450841,0.025997054,0.00006376745],"about_ca_topic_score_codex":0.000010060135,"about_ca_topic_score_gemma":0.000021784828,"teacher_disagreement_score":0.25535157,"about_ca_system_score_codex":0.00017746586,"about_ca_system_score_gemma":0.00068951084,"threshold_uncertainty_score":0.31178895},"labels":[],"label_agreement":null},{"id":"W2246194414","doi":"10.1200/jco.2014.32.26_suppl.157","title":"A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Metastatic breast cancer; Gemcitabine; Hazard ratio; Eribulin; Vinorelbine; Proportional hazards model; Performance status; Capecitabine; Breast cancer; Discontinuation; Chemotherapy; Cancer; Confidence interval","score_opus":0.15795871854991653,"score_gpt":0.5153220941193895,"score_spread":0.35736337556947295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246194414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703145,0.00015861777,0.00017603123,0.00071262516,0.0007676134,0.00037841348,0.000044661236,0.0000030164194,0.00072755956],"genre_scores_gemma":[0.9985383,0.00016190513,0.00049124844,0.00054431177,0.0001914429,0.000018194205,0.000008121166,0.000008377661,0.000038088187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954292,0.0018471672,0.0020453068,0.00019074221,0.00029441464,0.00019313907],"domain_scores_gemma":[0.9903548,0.006465818,0.0021265552,0.00010804977,0.0007152586,0.00022956032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002376033,0.00015713491,0.0033244109,0.00049850484,0.000018225059,0.0000029416017,0.00010424935,0.00015353721,0.00029731865],"category_scores_gemma":[0.000938096,0.00010916766,0.00071692304,0.00078691856,0.00025101684,0.00007660923,0.000030504449,0.00051402085,0.0000028807324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026400331,0.02095693,0.90165174,0.000086444175,0.013294824,0.00010029935,0.0009406007,0.0011900134,0.0015579461,0.000053183634,0.00043313293,0.033334557],"study_design_scores_gemma":[0.022734122,0.017932128,0.9476763,0.000101620564,0.008484937,0.000016556207,0.00008697999,0.0009324292,0.0009214896,0.00011315677,0.00091356906,0.0000866974],"about_ca_topic_score_codex":0.00017986279,"about_ca_topic_score_gemma":0.0006838283,"teacher_disagreement_score":0.046024576,"about_ca_system_score_codex":0.00050718104,"about_ca_system_score_gemma":0.0007430566,"threshold_uncertainty_score":0.4451728},"labels":[],"label_agreement":null},{"id":"W2246365566","doi":"10.1200/jco.2007.25.18_suppl.6558","title":"Cost-effectiveness of primary prophylaxis (PP) with colony-simulating factor (CSF) when compared with secondary prophylaxis (SP) in elderly patients with diffuse aggressive lymphoma undergoing curative chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Regional Municipality of Durham; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Febrile neutropenia; Chemotherapy; Internal medicine; Lymphoma; Discounting; Cost effectiveness; Emergency medicine; Neutropenia; Surgery; Pathology","score_opus":0.06812966370086287,"score_gpt":0.3873435732113825,"score_spread":0.31921390951051964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246365566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951225,0.0002463823,0.0011036396,0.00012787883,0.00033432207,0.0023937207,0.000015539736,0.000015299109,0.00064070657],"genre_scores_gemma":[0.9880278,0.0000468531,0.011286219,0.00035746858,0.00015800912,0.00002916369,0.000008756542,0.000069816604,0.000015915011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948782,0.0008547081,0.0022716632,0.00047961116,0.0010020811,0.0005137747],"domain_scores_gemma":[0.9853639,0.0075966106,0.004474351,0.0003140348,0.0018528004,0.00039828237],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018655547,0.00042059817,0.0026650117,0.00028104265,0.00006695506,0.000017306456,0.0002691202,0.0005024383,0.00006513138],"category_scores_gemma":[0.0017167988,0.0002497497,0.0002110102,0.00047280086,0.00079434196,0.00025763523,0.000061694045,0.0013013664,0.0000011694829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10963563,0.00396636,0.71234334,0.00036780364,0.0006521014,0.00058362866,0.0011854881,0.00020771779,0.00044841584,0.0000018147355,0.000018213334,0.1705895],"study_design_scores_gemma":[0.055359297,0.1360833,0.80394053,0.0017450268,0.00012110099,0.0001283962,0.00036291656,0.000032465796,0.0017360017,0.000045615296,0.00019326336,0.0002520575],"about_ca_topic_score_codex":0.000057563462,"about_ca_topic_score_gemma":0.00071701274,"teacher_disagreement_score":0.17033745,"about_ca_system_score_codex":0.0013332339,"about_ca_system_score_gemma":0.0052347807,"threshold_uncertainty_score":0.99999547},"labels":[],"label_agreement":null},{"id":"W2246470904","doi":"10.1200/jco.2007.25.18_suppl.2553","title":"Phase II stopping rules employing response rates and early progression","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Relative risk; Phases of clinical research; Drug; Clinical endpoint; Drug development; Clinical trial; Oncology; Internal medicine; Pharmacology; Confidence interval","score_opus":0.7518050735852627,"score_gpt":0.7262127178139379,"score_spread":0.025592355771324793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246470904","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95210296,0.00023960533,0.042946663,0.0022518085,0.0017470504,0.0002385684,0.0000043429823,0.000025966514,0.00044305835],"genre_scores_gemma":[0.348722,0.000099882665,0.6494699,0.0003657989,0.0012364428,0.0000018221374,6.7318865e-8,0.000023751953,0.000080322694],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9879961,0.004654337,0.0060927705,0.00029088327,0.0005494826,0.000416438],"domain_scores_gemma":[0.6971316,0.29800445,0.003592476,0.0002279447,0.0004798907,0.00056366343],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09140257,0.0001901854,0.0021020488,0.00017828657,0.00016215582,0.000029341885,0.00030087505,0.0006419313,0.000079123696],"category_scores_gemma":[0.52906233,0.00013093643,0.0003948003,0.00014821731,0.00055395835,0.00015522717,0.00021733719,0.001471871,0.000006784423],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03555992,0.0049193786,0.006335344,0.000048544716,0.0002241053,0.00090906175,0.00031776325,1.8434108e-7,0.0014482614,0.007946088,0.0012308946,0.9410605],"study_design_scores_gemma":[0.024815606,0.07006334,0.062012035,0.0006505233,0.00046911908,0.00027545975,0.00022330867,0.000046662357,0.0010796399,0.81778616,0.022243418,0.00033475578],"about_ca_topic_score_codex":0.0000016058262,"about_ca_topic_score_gemma":0.0000020588798,"teacher_disagreement_score":0.9407257,"about_ca_system_score_codex":0.00007315089,"about_ca_system_score_gemma":0.00047933645,"threshold_uncertainty_score":0.93559223},"labels":[],"label_agreement":null},{"id":"W2246539308","doi":"10.1200/jco.2007.25.18_suppl.8004","title":"Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cyclophosphamide; Fludarabine; Vincristine; Gastroenterology; Internal medicine; Randomized controlled trial; Randomization; Prednisone; Surgery; Chemotherapy","score_opus":0.07671177949783103,"score_gpt":0.43714446991985567,"score_spread":0.36043269042202464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246539308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805476,0.002092035,0.000024695315,0.012976786,0.0024233563,0.00043894508,0.000012709157,0.0000077178065,0.0014761342],"genre_scores_gemma":[0.9895291,0.003124169,0.0016470238,0.0037721915,0.0018322384,0.0000070697392,0.000008963233,0.000014302104,0.0000649748],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951118,0.00034247054,0.0035685438,0.00029805562,0.00036670192,0.00031241024],"domain_scores_gemma":[0.9875169,0.010062913,0.0015730067,0.0002798789,0.00017607489,0.0003912257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052379505,0.00019215255,0.0014849105,0.0000953157,0.00004254478,0.000013036053,0.00017554713,0.0003826344,0.000033426593],"category_scores_gemma":[0.0069706626,0.00010576144,0.00039453455,0.00015325227,0.00021945109,0.00009557227,0.00009689347,0.00052088825,0.000014324798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25939775,0.0052089584,0.09732447,0.00000428,0.00031056252,0.0026337288,0.00029355625,0.000004022542,0.000035310914,0.00004968454,0.0022044922,0.6325332],"study_design_scores_gemma":[0.26202312,0.011981304,0.6859673,0.00017063796,0.00020524336,0.00015507337,0.00020453459,0.0000120462255,0.00017305529,0.00028426564,0.038746558,0.00007683982],"about_ca_topic_score_codex":0.00021472461,"about_ca_topic_score_gemma":0.0006991801,"teacher_disagreement_score":0.63245636,"about_ca_system_score_codex":0.0004318192,"about_ca_system_score_gemma":0.0007470053,"threshold_uncertainty_score":0.83450377},"labels":[],"label_agreement":null},{"id":"W2246597450","doi":"10.1200/jco.2005.23.16_suppl.8035","title":"Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health","funders":"","keywords":"Medicine; Psychosocial; Profile of mood states; Quality of life (healthcare); Visual analogue scale; Mood; Physical therapy; Breast cancer; Cancer; Internal medicine; Clinical psychology; Oncology; Psychiatry; Nursing","score_opus":0.40717242683751986,"score_gpt":0.5705889595383912,"score_spread":0.1634165327008713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246597450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707896,0.0019161648,0.00013849302,0.025709389,0.00060577184,0.0006183321,0.00001129888,0.0000016472089,0.00020926763],"genre_scores_gemma":[0.9946577,0.00054593023,0.00028479547,0.0031660064,0.0013120539,0.000018784054,4.0130936e-7,0.000009424797,0.000004912004],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952069,0.0015097818,0.0019421411,0.00016058829,0.0010534205,0.00012716925],"domain_scores_gemma":[0.99425477,0.0013816933,0.0015235215,0.00015450062,0.0024450358,0.00024049357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017273763,0.0000988485,0.0012702479,0.00013916328,0.00002784804,0.0000028410827,0.00015115661,0.00021527,0.000024361361],"category_scores_gemma":[0.0064497064,0.00006705812,0.00019062322,0.0002857032,0.0001552254,0.0000609289,0.000030963944,0.00026531008,2.6218544e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042807557,0.0010481548,0.073446654,0.00016121757,0.0003681784,9.676987e-7,0.023585483,0.000024291836,0.0046100607,0.00008094711,0.0004600876,0.8534064],"study_design_scores_gemma":[0.007190906,0.011262802,0.9677572,0.00030410683,0.00029406272,0.000005662498,0.0031121674,0.000009833283,0.0008077449,0.00029389106,0.008875606,0.00008598951],"about_ca_topic_score_codex":0.0002021297,"about_ca_topic_score_gemma":0.0039038975,"teacher_disagreement_score":0.8943106,"about_ca_system_score_codex":0.0000683376,"about_ca_system_score_gemma":0.00095063995,"threshold_uncertainty_score":0.7721367},"labels":[],"label_agreement":null},{"id":"W2246654777","doi":"10.1200/jco.2009.27.15_suppl.e16015","title":"Identification of factors predicting loss of renal differential function on the operated kidney after laparoscopic partial nephrectomy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Nephrectomy; Renal function; Urology; Surgery; Kidney; Internal medicine","score_opus":0.07715690072910142,"score_gpt":0.3919120475108434,"score_spread":0.314755146781742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246654777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588484,0.00006865544,0.00021576685,0.0021788597,0.0010954118,0.00030458366,0.0000070499973,0.0000063925404,0.00023842459],"genre_scores_gemma":[0.9985234,0.000056916684,0.0000511786,0.00051427406,0.00073603634,0.0000054189663,0.0000075505427,0.000009272422,0.00009592156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960411,0.0005454113,0.0025926554,0.0001669975,0.00049021945,0.0001635845],"domain_scores_gemma":[0.9960185,0.00091758254,0.0021265724,0.00023666985,0.0004579464,0.00024268725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013364166,0.00014387224,0.0010438977,0.000115338466,0.000034576842,0.000008104523,0.00012586282,0.0002654058,0.00025154726],"category_scores_gemma":[0.0023833162,0.00007761363,0.000452886,0.00014837705,0.00017569598,0.00007986584,0.000019262774,0.0006282286,0.00000512752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05155927,0.0073194746,0.773709,0.00009301771,0.0016720443,0.000259973,0.0005273796,0.00015052804,0.14292872,0.00027179913,0.0023340867,0.019174693],"study_design_scores_gemma":[0.0055935406,0.019727038,0.9079032,0.0001969837,0.00093063625,0.000038170965,0.000058709727,0.00021952827,0.064227104,0.00010343105,0.00094208703,0.000059599253],"about_ca_topic_score_codex":0.000009336875,"about_ca_topic_score_gemma":0.0000031305392,"teacher_disagreement_score":0.13419417,"about_ca_system_score_codex":0.00010234475,"about_ca_system_score_gemma":0.0006221849,"threshold_uncertainty_score":0.3164992},"labels":[],"label_agreement":null},{"id":"W2246824654","doi":"10.1200/jco.2007.25.18_suppl.14529","title":"Prognostic importance of primary tumor resection in patients with advanced colorectal cancer (CRC): A Canadian province’s experience","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Primary tumor; Colorectal cancer; Surgery; Proportional hazards model; Perforation; Chemotherapy; Internal medicine; Medical record; Cancer; Multivariate analysis; Population; Metastasis","score_opus":0.040372876837821065,"score_gpt":0.40414725564362514,"score_spread":0.3637743788058041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246824654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542326,0.0005613007,0.000004443354,0.0004924203,0.0005222522,0.0005991324,0.0000066502553,0.0000038434114,0.0023866866],"genre_scores_gemma":[0.99829787,0.00013769743,0.00082354597,0.000493572,0.00017352392,0.000022775066,0.0000022818028,0.000011739809,0.00003697984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997537,0.00007238662,0.0015283475,0.00019351857,0.00035843672,0.00031029864],"domain_scores_gemma":[0.99723834,0.00052575767,0.0012055861,0.00008982205,0.0006095707,0.0003309083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009325307,0.00012898425,0.0010718127,0.00018813148,0.000038583305,0.0000026623802,0.000087150496,0.0001226611,0.000039883824],"category_scores_gemma":[0.0012452771,0.00008409512,0.00012327179,0.0002674933,0.00024012396,0.00012206159,0.000021897264,0.0004679919,5.096578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022316817,0.0010564377,0.92615086,0.000033751003,0.00011964378,0.0005702298,0.00028610448,0.000006772361,0.000031705415,0.000005247659,0.00009481771,0.049327638],"study_design_scores_gemma":[0.00818057,0.02756655,0.96169573,0.00022016329,0.00009878187,0.00003660142,0.00023454468,0.0000034587895,0.00008339379,0.000012051094,0.0017899916,0.00007819121],"about_ca_topic_score_codex":0.004237204,"about_ca_topic_score_gemma":0.37465128,"teacher_disagreement_score":0.37041408,"about_ca_system_score_codex":0.0012937465,"about_ca_system_score_gemma":0.00475348,"threshold_uncertainty_score":0.843247},"labels":[],"label_agreement":null},{"id":"W2246874359","doi":"10.1200/jco.2004.22.90140.3656","title":"The costs of managing patients with stage 3 and 4 colorectal cancer and the influence of patient factors at presentation","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Colorectal cancer; Stage (stratigraphy); Cancer; Medical record; Univariate analysis; Multivariate analysis; Surgery; Internal medicine","score_opus":0.031815053472540746,"score_gpt":0.3992446635441665,"score_spread":0.3674296100716257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246874359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968696,0.0009529628,0.0000012643003,0.0015963024,0.00012347977,0.0002875574,0.0000064283595,9.5313686e-7,0.00016143148],"genre_scores_gemma":[0.99730146,0.002487108,0.000047936646,0.00011190462,0.000023773033,0.0000054286584,4.5851172e-7,0.0000036956615,0.000018236527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881613,0.00009506819,0.00070464367,0.00007267245,0.00022987176,0.000081588616],"domain_scores_gemma":[0.99707544,0.0014364739,0.0010572552,0.00005042715,0.00031707803,0.0000633127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037202815,0.00006796773,0.0005280126,0.000023011668,0.00007359858,0.0000031440154,0.000039202234,0.000045207526,0.000002742332],"category_scores_gemma":[0.00051271624,0.000026426604,0.00006633753,0.00005290735,0.00068672805,0.000046687852,0.000056277524,0.00015808374,5.066757e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014918683,0.00024868132,0.95584726,0.000018094785,0.00041965576,0.000008939669,0.0013146241,0.00017970556,0.000015178006,0.00009471557,0.000015616606,0.026918836],"study_design_scores_gemma":[0.011188936,0.009026864,0.97810644,0.00009050698,0.00022977212,0.0000056412746,0.00068161194,0.000005112012,0.0001260604,0.00008849284,0.0004249369,0.000025643873],"about_ca_topic_score_codex":0.00029849386,"about_ca_topic_score_gemma":0.00085067505,"teacher_disagreement_score":0.026893191,"about_ca_system_score_codex":0.00013656142,"about_ca_system_score_gemma":0.0002026609,"threshold_uncertainty_score":0.2530278},"labels":[],"label_agreement":null},{"id":"W2246903319","doi":"10.1200/jco.2004.22.14_suppl.9652","title":"Chemopredictive diagnostic project in patients (pts) receiving capecitabine (X) or 5-FU/leucovorin (LV) as first-line chemotherapy for metastatic colorectal cancer (MCRC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Colorectal cancer; Dihydropyrimidine dehydrogenase; Thymidylate synthase; Oncology; Immunohistochemistry; Regimen; Thymidine phosphorylase; Chemotherapy; Fluorouracil; Cancer","score_opus":0.09194507561271979,"score_gpt":0.45739552513309006,"score_spread":0.36545044952037026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246903319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887747,0.0010672936,0.00010313674,0.00638084,0.0013837416,0.0016740765,0.000047094592,0.000015566606,0.0005535346],"genre_scores_gemma":[0.98653555,0.007496778,0.002837606,0.0015718249,0.0010264101,0.00028627683,0.000010655994,0.00004179718,0.00019309483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644995,0.00013943264,0.0021897494,0.00035763337,0.0004314852,0.00043172942],"domain_scores_gemma":[0.9924006,0.0052618226,0.0013026622,0.00013096539,0.00065998884,0.00024398512],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012972526,0.0002949772,0.0021545584,0.00020548828,0.00008940152,0.000011355316,0.00015577505,0.00020752902,0.00014758071],"category_scores_gemma":[0.012082121,0.00018700346,0.0004927731,0.00035883172,0.00020329401,0.00014435081,0.000053407304,0.00067245733,0.0000039414967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11019508,0.018011155,0.47179794,0.00029624908,0.003317287,0.0016216022,0.002291866,0.00042938459,0.000035379027,0.000047623416,0.0027450244,0.38921142],"study_design_scores_gemma":[0.08953633,0.08439802,0.803141,0.0006715767,0.0010076583,0.00015342419,0.00033859708,0.00008727746,0.0003394788,0.00057341787,0.019500189,0.00025305504],"about_ca_topic_score_codex":0.0005678039,"about_ca_topic_score_gemma":0.0049890904,"teacher_disagreement_score":0.38895836,"about_ca_system_score_codex":0.001537625,"about_ca_system_score_gemma":0.0030340678,"threshold_uncertainty_score":0.99623954},"labels":[],"label_agreement":null},{"id":"W2247002444","doi":"10.1200/jco.2013.31.26_suppl.106","title":"The impact treatment has on cardiovascular risks factors for breast cancer survivors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Concordia University","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Cancer; Blood pressure; Waist; Internal medicine; Hormonal therapy; Hormone therapy; Lean body mass; Surgery; Body mass index","score_opus":0.4425307331913037,"score_gpt":0.5727424154629736,"score_spread":0.13021168227166985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247002444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9463146,0.0018292577,0.00008550135,0.0485257,0.002016569,0.00062890217,0.00002533543,0.000008837857,0.0005653254],"genre_scores_gemma":[0.9903226,0.005428397,0.00026243573,0.00136865,0.0023659929,0.000031411237,0.0000015431743,0.000015577432,0.00020339737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977297,0.00033223536,0.0012916238,0.00012313665,0.0002494114,0.00027389658],"domain_scores_gemma":[0.9944323,0.0036932067,0.0006985446,0.00020012046,0.0004997808,0.00047605793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021710542,0.00012366152,0.0012459715,0.000060414317,0.00016653248,0.000021075626,0.000093413284,0.00021845267,0.00025880046],"category_scores_gemma":[0.00083444384,0.000054525703,0.0015647996,0.000058934576,0.00014458303,0.000051082563,0.000009223423,0.0004937176,0.000018629104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002934403,0.0014454706,0.2820793,0.000029321023,0.0021776545,0.000039836086,0.0001071798,0.000080429214,0.000011212957,0.00004462927,0.019228924,0.69182163],"study_design_scores_gemma":[0.0062513417,0.008382554,0.7447871,0.000062597515,0.00030256525,0.00011550833,0.00013020882,0.0001002301,0.000017834283,0.0002836065,0.23951681,0.00004964474],"about_ca_topic_score_codex":0.0023485424,"about_ca_topic_score_gemma":0.00019782304,"teacher_disagreement_score":0.691772,"about_ca_system_score_codex":0.00047466642,"about_ca_system_score_gemma":0.0013287526,"threshold_uncertainty_score":0.35503092},"labels":[],"label_agreement":null},{"id":"W2247004227","doi":"10.1200/jco.2009.27.15_suppl.8517","title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Bortezomib; Regimen; Thalidomide; Internal medicine; Pharmacology; Gastroenterology","score_opus":0.13401828864569137,"score_gpt":0.48564311807315114,"score_spread":0.35162482942745976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247004227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290645,0.0005679432,0.000037462392,0.003985466,0.00065459183,0.0009671753,0.000036275633,0.00001491557,0.0008296938],"genre_scores_gemma":[0.9928522,0.0009904098,0.0038967526,0.00054805673,0.0015546586,0.000009026845,0.000026737915,0.000022580813,0.00009954659],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99228525,0.0009328032,0.0049870694,0.00043017798,0.00078352116,0.0005811971],"domain_scores_gemma":[0.98838174,0.0074134353,0.0023444798,0.00033842382,0.000565554,0.0009563428],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004990066,0.0003091238,0.0029370708,0.000548586,0.000073845724,0.000014516687,0.00023483376,0.00067439146,0.00005124441],"category_scores_gemma":[0.032335438,0.00022761498,0.00057615945,0.0004324291,0.00037224006,0.00025482624,0.00009225392,0.001592747,0.0000062575423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6387614,0.019270655,0.0101606175,0.000021617527,0.00044050606,0.007492026,0.00023668588,0.0000108299855,0.0027762672,0.000011253766,0.0007549334,0.3200632],"study_design_scores_gemma":[0.7043479,0.13204695,0.1551389,0.00023413828,0.0003502057,0.00042291722,0.000100307436,0.00072819,0.0034899472,0.00018046418,0.0027914064,0.00016865274],"about_ca_topic_score_codex":0.00027420316,"about_ca_topic_score_gemma":0.00032832593,"teacher_disagreement_score":0.31989455,"about_ca_system_score_codex":0.00018420554,"about_ca_system_score_gemma":0.0018247517,"threshold_uncertainty_score":0.9758156},"labels":[],"label_agreement":null},{"id":"W2247026242","doi":"10.1200/jco.2009.27.15_suppl.6560","title":"Are cancer cost-effectiveness analyses presented at major conferences published timely without bias? A systematic review","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; EconLit; MEDLINE; Family medicine; Meta-analysis; Pharmacoeconomics; Breast cancer; Cost effectiveness; Cancer; Internal medicine; Medical physics; Oncology; Intensive care medicine","score_opus":0.908090256816764,"score_gpt":0.6949624499515468,"score_spread":0.21312780686521726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247026242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005699323,0.97949964,0.00016155343,0.010622721,0.0025465894,0.0055607855,0.0003287332,0.00002428601,0.0011987112],"genre_scores_gemma":[0.00008029144,0.9866442,0.00031439934,0.010006721,0.001474597,0.00065115973,0.000042958396,0.00006488817,0.0007207963],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.94305015,0.016031137,0.03896454,0.0009358091,0.00040326233,0.0006150774],"domain_scores_gemma":[0.8648322,0.028567236,0.104021706,0.0009038425,0.0009550906,0.0007198903],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.12301852,0.0007131318,0.03603717,0.00086942245,0.00015576585,0.00015113324,0.001464218,0.0014029172,0.0010446378],"category_scores_gemma":[0.15589349,0.00055647537,0.0034855797,0.0006328119,0.0002480662,0.0006550806,0.00017131209,0.0018551624,0.0009889837],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104350234,0.00069173705,0.0039018728,0.9138456,0.0043379813,0.000061954415,0.000027952352,0.000008420521,4.6552375e-9,0.0007337575,0.05899328,0.017293073],"study_design_scores_gemma":[0.0011965521,0.00056066643,0.0012841488,0.35696802,0.0031274287,0.00012336946,0.000028739229,0.000045214856,1.6997342e-8,0.0004914378,0.63576096,0.00041347535],"about_ca_topic_score_codex":0.00024803498,"about_ca_topic_score_gemma":0.00042625392,"teacher_disagreement_score":0.5767677,"about_ca_system_score_codex":0.0027037314,"about_ca_system_score_gemma":0.005422257,"threshold_uncertainty_score":0.9998935},"labels":[],"label_agreement":null},{"id":"W2247083811","doi":"10.1200/jco.2007.25.18_suppl.4032","title":"RTOG 0315: A randomized, double-blind, placebo-controlled phase III study to determine the efficacy of octreotide acetate in preventing or reducing the severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Placebo; Octreotide; Clinical endpoint; Diarrhea; Internal medicine; Gastroenterology; Surgery; Randomized controlled trial; Somatostatin","score_opus":0.0927251574017431,"score_gpt":0.4431802084459262,"score_spread":0.3504550510441831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247083811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946899,0.000045934143,0.000014705656,0.0013270925,0.00031698088,0.0034904368,0.0000019386218,0.0000028870502,0.00011014062],"genre_scores_gemma":[0.9990886,0.000018944575,0.00016907814,0.00021280492,0.00037038844,0.000044502573,0.0000010335337,0.000013660076,0.00008099193],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99403375,0.0010477102,0.0038701745,0.00022673036,0.0005210266,0.00030060406],"domain_scores_gemma":[0.9860161,0.010351961,0.0027833427,0.00019591505,0.00045737275,0.00019531639],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014551549,0.00019093535,0.0029879685,0.00027537666,0.00004587744,0.0000071699137,0.00023871408,0.000117195865,0.00006288866],"category_scores_gemma":[0.008492914,0.000078658144,0.00043357295,0.0006845848,0.0001642912,0.00009059185,0.00007358618,0.0009399959,3.6623743e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.821659,0.005687942,0.13678375,0.000021668731,0.00046419297,0.00019116818,0.0018981885,0.00012747565,0.000115617884,6.1611894e-7,0.000009109483,0.033041243],"study_design_scores_gemma":[0.7209659,0.013694573,0.26286063,0.00023535565,0.0006718178,0.000034435936,0.00059567613,0.0004180166,0.00043636077,0.0000032418664,0.000007667053,0.00007630015],"about_ca_topic_score_codex":0.00062372943,"about_ca_topic_score_gemma":0.0073249214,"teacher_disagreement_score":0.12607688,"about_ca_system_score_codex":0.00018077968,"about_ca_system_score_gemma":0.0014301515,"threshold_uncertainty_score":0.999859},"labels":[],"label_agreement":null},{"id":"W2247100049","doi":"10.1200/jco.2006.24.18_suppl.2014","title":"Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Celator Pharmaceuticals (Canada); Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; Internal medicine; Urology; Cohort; Phases of clinical research; Gastroenterology; Oncology; Clinical trial","score_opus":0.031925487508165595,"score_gpt":0.4006621124109691,"score_spread":0.3687366249028035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247100049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99868166,0.0000954253,0.0007318886,0.000061402265,0.00013356515,0.00023459068,0.0000063328093,7.736227e-7,0.000054343625],"genre_scores_gemma":[0.9988695,0.000053075946,0.00085000414,0.00006511994,0.00012719545,0.0000028498323,0.000009632179,0.000009147674,0.000013506157],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998172,0.00011409694,0.0013180498,0.0001324117,0.00015514082,0.00010833657],"domain_scores_gemma":[0.9981705,0.000069681024,0.0012905216,0.00011898797,0.00029330168,0.00005701828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000605424,0.00009036529,0.00061276625,0.00006950192,0.0000137969055,0.0000024558292,0.00008501866,0.00012588844,0.0000040446735],"category_scores_gemma":[0.000114646005,0.00006850936,0.00007795739,0.00007046454,0.000052296953,0.000008350354,0.000033540775,0.00014463726,5.046455e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0516433,0.045203984,0.24094893,0.000077851604,0.0006056022,0.000045758956,0.0004037862,0.0040230947,0.4027624,0.0002859352,0.00013487271,0.25386447],"study_design_scores_gemma":[0.10184308,0.27830082,0.516958,0.00009500755,0.00024378343,0.000014861404,0.0003315701,0.00044110918,0.09819161,0.0005212028,0.0027751252,0.00028383583],"about_ca_topic_score_codex":0.000024273306,"about_ca_topic_score_gemma":0.00028359512,"teacher_disagreement_score":0.3045708,"about_ca_system_score_codex":0.000018760264,"about_ca_system_score_gemma":0.00024209694,"threshold_uncertainty_score":0.27937308},"labels":[],"label_agreement":null},{"id":"W2247146814","doi":"10.1200/jco.2012.30.15_suppl.9002","title":"Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Internal medicine; Nausea; Randomized controlled trial; Depression (economics); Physical therapy","score_opus":0.23482131557825994,"score_gpt":0.5115427765538753,"score_spread":0.27672146097561534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247146814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9259083,0.010640708,0.0026076867,0.016602188,0.02691084,0.0076422826,0.000007054118,0.00005001406,0.009630905],"genre_scores_gemma":[0.9836337,0.0019745876,0.0021958905,0.0022325038,0.007479015,0.00055639376,0.0000035717137,0.000042711672,0.0018816098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99266857,0.0013642863,0.0046809735,0.00022252578,0.0005364301,0.00052719563],"domain_scores_gemma":[0.9780777,0.016194832,0.003730771,0.00025956988,0.0009222748,0.0008148254],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021714933,0.00025433893,0.0057810256,0.00021659184,0.00006392413,0.0000145291115,0.00021337796,0.00088877394,0.0005590084],"category_scores_gemma":[0.009544667,0.0001616887,0.0028338097,0.00022129163,0.00024408089,0.00018521574,0.00003659627,0.0013214776,0.000013469149],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.947115,0.002247236,0.000916948,0.000048242902,0.002701879,0.00002978623,0.00047960566,0.000012500793,0.000012833875,0.00044499524,0.003372354,0.042618636],"study_design_scores_gemma":[0.9039813,0.0064794905,0.0001961414,0.00010088041,0.004116124,0.00010928233,0.00017539496,0.00014693315,0.000042314146,0.00031310963,0.08418736,0.00015166489],"about_ca_topic_score_codex":0.00013794747,"about_ca_topic_score_gemma":0.00022845723,"teacher_disagreement_score":0.08081501,"about_ca_system_score_codex":0.00029419485,"about_ca_system_score_gemma":0.002687199,"threshold_uncertainty_score":0.9987984},"labels":[],"label_agreement":null},{"id":"W2247205325","doi":"10.1200/jco.2004.22.90140.8001","title":"Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Internal medicine; Quality of life (healthcare); Chemotherapy; Cognition; Cancer; Prospective cohort study; Adjuvant chemotherapy; Cancer-related fatigue; Oncology; Physical therapy; Gynecology; Psychiatry","score_opus":0.049250527410215426,"score_gpt":0.42462944453714524,"score_spread":0.37537891712692983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247205325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292535,0.00095918967,0.00021324985,0.00281269,0.00060887286,0.0022943967,0.000024277553,0.0000075491316,0.00015439966],"genre_scores_gemma":[0.9976645,0.0007123387,0.00014435206,0.00079215935,0.00042001103,0.00018957286,6.4730466e-7,0.000022299877,0.00005412864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973005,0.0001957858,0.00167064,0.0002670354,0.00029896555,0.00026706033],"domain_scores_gemma":[0.9960918,0.0016826517,0.0012044936,0.0000628993,0.0007547549,0.0002034176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022829575,0.00018359024,0.0024654623,0.00018757685,0.000053893153,0.000006945877,0.000045675,0.00015172361,0.00002681458],"category_scores_gemma":[0.0015797475,0.00013866286,0.00018645497,0.00017734156,0.000246316,0.00011394543,0.000036559628,0.0005093651,3.375819e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2724899,0.005914603,0.5930465,0.00006034168,0.011141012,0.00009921493,0.0049264687,0.000009680873,0.0003636839,0.00004770256,0.000050803454,0.111850135],"study_design_scores_gemma":[0.29809234,0.045220193,0.64863753,0.0004977952,0.0016077383,0.00003785638,0.0050361594,0.0000068035442,0.000023956942,0.00072142045,0.000024899738,0.0000932716],"about_ca_topic_score_codex":0.00007180492,"about_ca_topic_score_gemma":0.00029347168,"teacher_disagreement_score":0.11175686,"about_ca_system_score_codex":0.000413609,"about_ca_system_score_gemma":0.00093964406,"threshold_uncertainty_score":0.5654507},"labels":[],"label_agreement":null},{"id":"W2247209014","doi":"10.1200/jco.2009.27.15_suppl.11107","title":"Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; Queen's University; University Health Network","funders":"","keywords":"Telomere; Chromosome instability; PTEN; Genome instability; Carcinogenesis; Biology; Prostate; TMPRSS2; Chromothripsis; Prostate cancer; Locus (genetics); Trisomy; Pathology; Cancer research; Aneuploidy; Cancer; Chromosome; Medicine; Genetics; Gene; DNA damage; Apoptosis; Disease","score_opus":0.05042587459494897,"score_gpt":0.401389667350636,"score_spread":0.35096379275568707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247209014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957995,0.00043231537,0.0001536433,0.0031210708,0.00009382466,0.00017970461,0.0000039221873,0.000005814498,0.00021019702],"genre_scores_gemma":[0.997,0.00045324315,0.0019482947,0.00048327522,0.00008732268,9.435489e-7,0.0000033058238,0.000005340429,0.0000183251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708277,0.00028670437,0.0019658643,0.00020572795,0.0002835313,0.00017541563],"domain_scores_gemma":[0.99722576,0.0009877392,0.0010787818,0.00017654976,0.00031639938,0.00021475833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021451318,0.000121447214,0.0016688182,0.0005602253,0.000023277824,0.000006065054,0.000084290055,0.00027004548,0.000021902963],"category_scores_gemma":[0.001227667,0.000080280275,0.00026964425,0.0007982852,0.00037735965,0.00012025742,0.00001712444,0.00078158866,7.170119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005147574,0.0012472848,0.92322963,0.000022660239,0.00041136847,0.00013593261,0.00032252347,0.00017042385,0.0010626868,0.00022346068,0.000019257157,0.06800717],"study_design_scores_gemma":[0.0040267324,0.008453874,0.98322654,0.000055955355,0.0009100474,0.00007873232,0.00030227072,0.001016067,0.000044675184,0.0003370785,0.001469559,0.000078455145],"about_ca_topic_score_codex":0.00005384596,"about_ca_topic_score_gemma":0.0004609684,"teacher_disagreement_score":0.06792872,"about_ca_system_score_codex":0.00011907852,"about_ca_system_score_gemma":0.0005703377,"threshold_uncertainty_score":0.33956572},"labels":[],"label_agreement":null},{"id":"W2247282293","doi":"10.1200/jco.2006.24.18_suppl.13511","title":"Metastatic Colorectal Cancer Treatment to progression or Not?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Colorectal cancer; Internal medicine; Hazard ratio; Chemotherapy; Clinical endpoint; Surgery; Oxaliplatin; Oncology; Discontinuation; Retrospective cohort study; Progression-free survival; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.1707404288875903,"score_gpt":0.5378189336224191,"score_spread":0.3670785047348287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247282293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809459,0.0010882943,0.000022080643,0.013114449,0.0011796368,0.00045312103,0.000009995423,0.000011741654,0.0031747953],"genre_scores_gemma":[0.98870707,0.0009387705,0.0053484095,0.0013612442,0.0014348704,0.000064405955,0.0000018107228,0.0000148824165,0.0021285582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99764633,0.00015621714,0.0014713304,0.00018017016,0.00031436695,0.00023160895],"domain_scores_gemma":[0.9975833,0.00094975985,0.0007624659,0.00008470677,0.0003305854,0.0002891696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006198438,0.00015922422,0.0015166221,0.00009550963,0.000058978316,0.000007992929,0.00006691033,0.00011311249,0.00030446716],"category_scores_gemma":[0.0006110724,0.00007711976,0.00041335874,0.00015999684,0.00010268272,0.00004801828,0.000033776214,0.00023059537,0.000018774936],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054597117,0.0053771436,0.08503083,0.000021322443,0.0011939383,0.0026306654,0.00017840834,0.000030280971,0.00049606804,0.00003799042,0.012468235,0.837938],"study_design_scores_gemma":[0.012018071,0.09195896,0.61557233,0.00012692779,0.001229618,0.00037933383,0.00011280311,0.000024225481,0.0013485188,0.000058536927,0.27706066,0.00010999847],"about_ca_topic_score_codex":0.00022263928,"about_ca_topic_score_gemma":0.0015834325,"teacher_disagreement_score":0.837828,"about_ca_system_score_codex":0.00062100356,"about_ca_system_score_gemma":0.0016996767,"threshold_uncertainty_score":0.3333702},"labels":[],"label_agreement":null},{"id":"W2247329814","doi":"10.1200/jco.2005.23.16_suppl.3583","title":"An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Irinotecan; Rash; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Discontinuation; Adverse effect; Nausea; Oxaliplatin; Phases of clinical research; Colorectal cancer; Oncology; Cancer; Surgery; Chemotherapy; Breast cancer; Trastuzumab","score_opus":0.19885144002157376,"score_gpt":0.5231931102536629,"score_spread":0.32434167023208915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247329814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966775,0.00027936275,0.0000019689776,0.00089231506,0.000393979,0.0012526936,0.00002496846,0.000004897456,0.00047227286],"genre_scores_gemma":[0.996607,0.00017498994,0.0016420692,0.0011724504,0.00018507468,0.000042945798,0.000006483334,0.000023097686,0.00014590201],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996636,0.00044193133,0.002008334,0.00026706324,0.0003982514,0.00024842581],"domain_scores_gemma":[0.9969273,0.00043678275,0.0015742021,0.00016592436,0.000644671,0.000251093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010932002,0.0002103256,0.0018982062,0.0001304651,0.00006394205,0.000011754121,0.00023165363,0.000100295954,0.0006709559],"category_scores_gemma":[0.00033496934,0.00012334283,0.00009919966,0.00018081539,0.00015013402,0.00027222853,0.00009312866,0.0004704014,0.0000026542145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11511575,0.18294774,0.29927167,0.000008915938,0.0014771194,0.0001611117,0.0016575392,0.000015769117,0.00022213225,0.0000013436187,0.00030317876,0.39881772],"study_design_scores_gemma":[0.16174203,0.47054657,0.36208504,0.000055336077,0.00038605885,0.000008221867,0.00053293246,0.00006143431,0.00016708669,0.0000055582263,0.0043161153,0.000093631425],"about_ca_topic_score_codex":0.0002508485,"about_ca_topic_score_gemma":0.0070995335,"teacher_disagreement_score":0.39872408,"about_ca_system_score_codex":0.00028414917,"about_ca_system_score_gemma":0.00068418845,"threshold_uncertainty_score":0.73464966},"labels":[],"label_agreement":null},{"id":"W2247343443","doi":"10.1200/jco.2004.22.90140.4651","title":"Screening with prostate specific antigen and metastatic prostate cancer risk: A population-based case-control study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Odds ratio; Population; Asymptomatic; Cancer; Prostate cancer screening; Internal medicine; Confidence interval; Prostate; Oncology; Gynecology; Environmental health","score_opus":0.11857304626281617,"score_gpt":0.4734006581948243,"score_spread":0.3548276119320081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247343443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211866,0.0021646635,0.00045971482,0.003535483,0.00018261689,0.0014479248,0.000041048672,0.000012579206,0.000037316833],"genre_scores_gemma":[0.9911162,0.0010911332,0.0070227133,0.00031719817,0.0003047552,0.00003383818,0.0000036233644,0.000028065371,0.000082428574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690276,0.00054623536,0.0014556185,0.0002791029,0.00048474516,0.00033154213],"domain_scores_gemma":[0.9965441,0.001069805,0.0012950882,0.00016807248,0.00047152498,0.0004514147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030416788,0.0001884626,0.0012941543,0.00020181181,0.00014506423,0.000030433706,0.00007098507,0.00009566984,0.000057449488],"category_scores_gemma":[0.00047841744,0.00010728976,0.00017617829,0.00023685509,0.00019594708,0.00014994132,0.000019412262,0.00091924577,0.0000022316456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029010624,0.0016870387,0.8575422,0.000032624648,0.0010829659,0.019675063,0.00044076864,0.0014621991,0.00001806033,0.000003117306,0.000035914014,0.08900942],"study_design_scores_gemma":[0.059727967,0.03140615,0.9045315,0.00019196284,0.0009554426,0.0012747705,0.0007744278,0.0002051415,0.000022136883,0.00011723188,0.00067540957,0.00011787185],"about_ca_topic_score_codex":0.00080918643,"about_ca_topic_score_gemma":0.00073305017,"teacher_disagreement_score":0.08889154,"about_ca_system_score_codex":0.00021590765,"about_ca_system_score_gemma":0.0018820057,"threshold_uncertainty_score":0.43751493},"labels":[],"label_agreement":null},{"id":"W2247345771","doi":"10.1200/jco.2006.24.18_suppl.7092","title":"Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Topotecan; Internal medicine; Lung cancer; Docetaxel; Tolerability; Etoposide; Chemotherapy; Population; Regimen; Performance status; Oncology; Surgery; Adverse effect","score_opus":0.06969167848800148,"score_gpt":0.4408552272446751,"score_spread":0.37116354875667357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247345771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865457,0.0043488187,0.00014478131,0.0034631626,0.00044487833,0.0008169596,0.000016534788,0.000010585722,0.004208571],"genre_scores_gemma":[0.99147445,0.0017121568,0.0034719752,0.0012230551,0.0008480595,0.00004672708,0.0000031109712,0.000046418627,0.0011740245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965314,0.00026387733,0.0015535323,0.00041959403,0.00059625175,0.00063531636],"domain_scores_gemma":[0.99642503,0.0007603278,0.0012586208,0.00023923932,0.0008895214,0.0004272311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012285364,0.00029422936,0.0017803459,0.00018303921,0.00008279862,0.000021960572,0.00024543997,0.00026898112,0.0000840209],"category_scores_gemma":[0.00015802383,0.00018667271,0.00014960892,0.000306718,0.0004588323,0.00012578676,0.00012510292,0.0016366458,0.0000017463227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007686077,0.0013833039,0.97653073,0.00045299338,0.00024710584,0.0004293594,0.00017595348,0.00028329698,0.000042520704,0.0000034799625,0.0052096876,0.0075554973],"study_design_scores_gemma":[0.02798005,0.008169633,0.9559415,0.0011518553,0.0005268542,0.000017449955,0.00008894793,0.00044193896,0.00011051236,0.000011837036,0.005325822,0.00023357826],"about_ca_topic_score_codex":0.0031170156,"about_ca_topic_score_gemma":0.013504718,"teacher_disagreement_score":0.020589205,"about_ca_system_score_codex":0.00086850004,"about_ca_system_score_gemma":0.0034522132,"threshold_uncertainty_score":0.7612293},"labels":[],"label_agreement":null},{"id":"W2247411625","doi":"10.1200/jco.2012.30.15_suppl.512","title":"Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Bone remodeling; N-terminal telopeptide; Denosumab; Everolimus; Bone resorption; Clinical endpoint; Bisphosphonate; Bone mineral; Endocrinology; Osteoporosis; Oncology; Clinical trial; Osteocalcin; Alkaline phosphatase","score_opus":0.03234412571618997,"score_gpt":0.413646612018509,"score_spread":0.381302486302319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247411625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925442,0.0054587694,0.000023863175,0.0011461437,0.00028379518,0.00046449393,0.000003952917,0.0000049623195,0.000069842186],"genre_scores_gemma":[0.99616957,0.00043420185,0.0022268682,0.0008674681,0.0002397505,0.000013657557,0.0000026508187,0.000023777686,0.000022055468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668294,0.00061794365,0.0016815795,0.00018919099,0.000490037,0.000338289],"domain_scores_gemma":[0.995452,0.0021111774,0.0015463002,0.00016154227,0.00017024542,0.00055875955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021566227,0.00018665957,0.0016547799,0.0003095832,0.000015808711,0.00000267985,0.000060533486,0.0001708626,0.000022990836],"category_scores_gemma":[0.0023958003,0.00011889452,0.00015778233,0.00021078138,0.00029441845,0.00023250363,0.000049357564,0.0007305812,0.0000019783388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085643806,0.0065294025,0.64626956,0.00019764974,0.00012926705,0.0006296425,0.00008607396,0.000009513338,0.00011543902,0.000012164217,0.00008091712,0.26029655],"study_design_scores_gemma":[0.0329428,0.013236923,0.94908714,0.0012774245,0.0002941935,0.00007459458,0.000042882602,0.000010142871,0.00017254204,0.00009157,0.0026618976,0.000107866974],"about_ca_topic_score_codex":0.000008579303,"about_ca_topic_score_gemma":0.0000118540775,"teacher_disagreement_score":0.30281758,"about_ca_system_score_codex":0.00019264016,"about_ca_system_score_gemma":0.0003858705,"threshold_uncertainty_score":0.48483777},"labels":[],"label_agreement":null},{"id":"W2247455113","doi":"10.1200/jco.2006.24.18_suppl.3627","title":"Mathematization of risk and benefit for first-line treatment of metastatic colorectal cancer: A graphical decision aid for patients and physicians","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Mucositis; Nausea; Regimen; Internal medicine; Vomiting; Leukopenia; Neutropenia; Adverse effect; Colorectal cancer; Toxicity; Oncology; Cancer; Surgery","score_opus":0.054481312071423475,"score_gpt":0.4246920429362346,"score_spread":0.3702107308648111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247455113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955924,0.001626889,0.0012801645,0.00047835734,0.00019230648,0.0006340704,0.00017136111,0.00000189715,0.000022552],"genre_scores_gemma":[0.9816863,0.006698234,0.0113440715,0.00002991333,0.00016570941,0.000045592355,0.000009149226,0.000009321274,0.0000117095105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983503,0.000027708742,0.0012524121,0.00012570116,0.00014159983,0.000102276485],"domain_scores_gemma":[0.99436647,0.0036703362,0.0013694877,0.00004405777,0.00048752665,0.000062148276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000314899,0.00010742481,0.0013076325,0.00007877603,0.000048098293,0.0000022477843,0.000024957164,0.000086692395,0.0000037002685],"category_scores_gemma":[0.0006642925,0.000066610846,0.00029479142,0.000073332856,0.00014803029,0.000035700607,0.000012111597,0.00005709195,2.9431042e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01964905,0.0059927013,0.4340947,0.00013572144,0.0008024655,0.000004337414,0.00031790763,0.00005131142,0.00003209739,0.00031838077,0.0001589976,0.5384423],"study_design_scores_gemma":[0.041976247,0.1027368,0.8263236,0.00022139506,0.0032058095,0.00001407159,0.000109784014,0.0009776722,0.0004210729,0.020387102,0.0035381806,0.000088245666],"about_ca_topic_score_codex":0.0000763686,"about_ca_topic_score_gemma":0.0009434758,"teacher_disagreement_score":0.5383541,"about_ca_system_score_codex":0.000076904915,"about_ca_system_score_gemma":0.00009797328,"threshold_uncertainty_score":0.27163115},"labels":[],"label_agreement":null},{"id":"W2247521924","doi":"10.1200/jco.2006.24.18_suppl.4651","title":"A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Neutropenia; Docetaxel; Febrile neutropenia; Internal medicine; Prostate cancer; Gastroenterology; Chemotherapy; Performance status; Surgery; Cancer","score_opus":0.06767201698211162,"score_gpt":0.4794413760339556,"score_spread":0.411769359051844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247521924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975877,0.00042816048,0.0000037349798,0.00073715346,0.0001801373,0.0008502976,0.000006030755,0.0000027835445,0.00020400029],"genre_scores_gemma":[0.9991366,0.00018117945,0.0002498414,0.00020274153,0.00008755732,0.000031448002,0.000006997306,0.0000131339175,0.00009047537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972804,0.00036700198,0.0016824742,0.0001542457,0.00033947814,0.000176378],"domain_scores_gemma":[0.997289,0.0005492216,0.0015948905,0.000089418034,0.00037498202,0.000102470156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094597985,0.00012974524,0.0012707998,0.00027619392,0.000012025558,0.0000027323326,0.00006742163,0.00008464603,0.00004658677],"category_scores_gemma":[0.000098808676,0.000078319106,0.000074179814,0.00028814937,0.00011990706,0.00013148368,0.000012693911,0.0005733815,7.8847523e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056886118,0.10723658,0.80786544,0.00002432287,0.00034711938,0.0005585469,0.00046017297,0.00013123259,0.000047730424,0.000005326813,0.00037204343,0.026065337],"study_design_scores_gemma":[0.17141265,0.15104726,0.67588246,0.000060695013,0.000501476,0.00000955181,0.00016320485,0.000025573274,0.000011486439,0.000034618435,0.0007966648,0.00005438813],"about_ca_topic_score_codex":0.0007182598,"about_ca_topic_score_gemma":0.0029825307,"teacher_disagreement_score":0.13198304,"about_ca_system_score_codex":0.00028555727,"about_ca_system_score_gemma":0.0009760468,"threshold_uncertainty_score":0.31937605},"labels":[],"label_agreement":null},{"id":"W2247522494","doi":"10.1200/jco.2009.27.15_suppl.4112","title":"Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oxaliplatin; Fluorouracil; Internal medicine; FOLFOX; Colorectal cancer; Population; Oncology; Gastroenterology; Chemotherapy; Cancer","score_opus":0.28986688795897325,"score_gpt":0.49708066469851614,"score_spread":0.2072137767395429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247522494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850191,0.0032991688,0.003836554,0.002493537,0.00064390217,0.0041283076,0.00023383663,0.000011496989,0.00033410263],"genre_scores_gemma":[0.9951697,0.0012970126,0.0022257974,0.0004997278,0.00026109602,0.00036271306,0.000106601394,0.000016631433,0.000060730214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989898,0.0016995091,0.006992931,0.00040326494,0.0006872724,0.00031899288],"domain_scores_gemma":[0.96863157,0.023335967,0.0061962795,0.00016249526,0.0014335166,0.00024017548],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011156241,0.00042579713,0.016938677,0.0006253498,0.000085898646,0.000018607538,0.00019229398,0.00022373007,0.0013988384],"category_scores_gemma":[0.0059362547,0.00021383828,0.005433714,0.00045788754,0.0003881132,0.00013959408,0.00004229922,0.00046262718,7.790323e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6901831,0.003386211,0.0029186595,0.00003250397,0.28616863,0.0002400762,0.0001254618,0.003487873,0.00019708165,0.000060977112,0.00010644232,0.013092967],"study_design_scores_gemma":[0.6696093,0.021931382,0.008537263,0.0000678765,0.26831183,0.000035868503,0.000057369798,0.030709915,0.0001710507,0.00015245135,0.00023930785,0.0001763706],"about_ca_topic_score_codex":0.00016167262,"about_ca_topic_score_gemma":0.0034291334,"teacher_disagreement_score":0.027222041,"about_ca_system_score_codex":0.0005042124,"about_ca_system_score_gemma":0.0018450976,"threshold_uncertainty_score":0.99951404},"labels":[],"label_agreement":null},{"id":"W2247663207","doi":"10.1200/jco.2007.25.18_suppl.15132","title":"Assessment of intra and interfractional organ motion during adjuvant radiochemotherapy in gastric cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Diaphragm (acoustics); Pancreas; Hilum (anatomy); Nuclear medicine; Radiation therapy; Radiation treatment planning; Stomach; Radiology; Internal medicine","score_opus":0.0857529171744179,"score_gpt":0.5143090208770436,"score_spread":0.42855610370262565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247663207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930807,0.0009492264,0.0005749327,0.004005929,0.00061251246,0.000071944894,7.336079e-7,0.0000020695238,0.0007019577],"genre_scores_gemma":[0.9912312,0.005032873,0.0024862497,0.00048969575,0.0007171617,9.3878447e-7,2.3550214e-7,0.000006024295,0.000035597852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981201,0.000084200336,0.0013829205,0.00009394945,0.00019006204,0.0001287364],"domain_scores_gemma":[0.9982758,0.0006158785,0.00073109206,0.000048928174,0.00019658529,0.00013169103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021962433,0.00006547759,0.000906127,0.00015888648,0.000014615939,0.0000014259344,0.000036899582,0.00012985882,0.00009181416],"category_scores_gemma":[0.00049017527,0.000047391968,0.000101314334,0.00012355983,0.0001007775,0.00005358021,0.000016279422,0.0005903572,2.4829262e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017366405,0.00070045853,0.74899614,0.00004223568,0.00014870249,0.00013431053,0.00010792571,0.0000076073934,0.007044617,0.000017460245,0.00015308741,0.24091078],"study_design_scores_gemma":[0.006765919,0.004021039,0.98626024,0.00018955024,0.00005607244,0.00025463576,0.00015374462,0.000046477162,0.0008600454,0.000035368685,0.001322007,0.000034894503],"about_ca_topic_score_codex":0.000034817116,"about_ca_topic_score_gemma":0.00013613769,"teacher_disagreement_score":0.2408759,"about_ca_system_score_codex":0.0002673768,"about_ca_system_score_gemma":0.0005841101,"threshold_uncertainty_score":0.2564841},"labels":[],"label_agreement":null},{"id":"W2247699922","doi":"10.1200/jco.2007.25.18_suppl.6508","title":"A randomized trial of computer and pamphlet-based versions of the Decision Board (DB)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Breast cancer; Medical physics; Decision aids; Flexibility (engineering); Multiple choice; Clinical trial; Physical therapy; Cancer; Family medicine; Surgery; Alternative medicine; Internal medicine","score_opus":0.4170039727801553,"score_gpt":0.584505698246184,"score_spread":0.16750172546602876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247699922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740461,0.00053943973,0.004509534,0.0121769365,0.006372067,0.0014702035,0.000006515564,0.0000061896294,0.00087302894],"genre_scores_gemma":[0.9717942,0.00027752505,0.024271548,0.0030532733,0.00055957225,0.00000848236,8.3861073e-7,0.000010135992,0.000024465473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98586285,0.0070205987,0.00625,0.00012937796,0.00049965765,0.00023751671],"domain_scores_gemma":[0.89944786,0.09180388,0.006845866,0.00050367793,0.0011533528,0.00024537495],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014401581,0.0001040582,0.0018885164,0.00015547438,0.00020081778,0.0000014708573,0.0005261786,0.0005636787,0.00007130808],"category_scores_gemma":[0.0236634,0.00005956012,0.00063550315,0.00019579809,0.0006236661,0.00005926942,0.00027687108,0.001607873,0.000004260486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92531455,0.0007919105,0.022558305,0.00008265069,0.00010323668,0.000004603992,0.0008740862,0.00002550408,0.00001267968,0.0005416591,0.0034991305,0.046191696],"study_design_scores_gemma":[0.93502676,0.0040770355,0.036457006,0.0006135899,0.00017510763,0.0000026137805,0.00072364113,0.00061399816,0.000015745312,0.0017854708,0.020443032,0.000066025124],"about_ca_topic_score_codex":0.00010036043,"about_ca_topic_score_gemma":0.00013715928,"teacher_disagreement_score":0.086415,"about_ca_system_score_codex":0.000111705194,"about_ca_system_score_gemma":0.00262475,"threshold_uncertainty_score":0.98456067},"labels":[],"label_agreement":null},{"id":"W2247800806","doi":"10.1200/jco.2006.24.18_suppl.679","title":"Urinary n-telopeptide (NTX) predicts palliative pain response in metastatic breast cancer patients receiving second-line zoledronic acid","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Zoledronic acid; Palliative care; Bisphosphonate; Bone pain; Internal medicine; Breast cancer; N-terminal telopeptide; Urinary system; Cancer; Urology; Oncology; Surgery; Osteoporosis","score_opus":0.07899250175781042,"score_gpt":0.44921930650444536,"score_spread":0.37022680474663494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247800806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98939145,0.000998933,0.00004258799,0.0079176705,0.0007202126,0.00042560647,0.000042638378,0.000012361831,0.00044854745],"genre_scores_gemma":[0.99285716,0.0005129992,0.0021547964,0.0034218957,0.00041386072,0.000023095788,0.000014260577,0.000028933797,0.00057301123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99269086,0.0028080833,0.0032988805,0.00027366992,0.00043824816,0.0004902781],"domain_scores_gemma":[0.9924983,0.004325468,0.0020127345,0.00018005821,0.0004661638,0.0005172894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008131015,0.00022228662,0.0016516555,0.00025852042,0.000056150184,0.000006772733,0.0001324805,0.00029599253,0.0004009096],"category_scores_gemma":[0.004026627,0.00016166545,0.00032407543,0.00027276468,0.0001490427,0.00017147535,0.000048752998,0.0012700991,0.000025904292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04484063,0.008301864,0.8787414,0.000098314515,0.00030836332,0.0026330585,0.00012571624,0.00004251821,0.00003451199,0.0000048994616,0.0033760578,0.06149269],"study_design_scores_gemma":[0.021603435,0.021203062,0.9500789,0.0004917771,0.00025634805,0.00026385044,0.000043208525,0.00016452544,0.000022940949,0.00027421745,0.005485702,0.00011204164],"about_ca_topic_score_codex":0.00018522915,"about_ca_topic_score_gemma":0.0011289243,"teacher_disagreement_score":0.07133752,"about_ca_system_score_codex":0.0008759306,"about_ca_system_score_gemma":0.003704283,"threshold_uncertainty_score":0.6592525},"labels":[],"label_agreement":null},{"id":"W2247834034","doi":"10.1200/jco.2006.09.4706","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine","score_opus":0.20937171666797774,"score_gpt":0.5675597065475614,"score_spread":0.35818798987958367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247834034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9030512,0.0007599422,0.00006971526,0.039027806,0.00186368,0.000051711504,1.2623109e-7,0.00000304244,0.055172782],"genre_scores_gemma":[0.96863574,0.0008034256,0.0028880632,0.024902986,0.0019949109,2.8869198e-7,6.1451885e-8,0.000005087846,0.0007694611],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770415,0.00007983998,0.0018225479,0.00007311339,0.00016538418,0.00015497132],"domain_scores_gemma":[0.99733335,0.0016622304,0.0005495648,0.000078269,0.00017707252,0.00019951796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066739414,0.000046581798,0.0010202678,0.00009695624,0.000010086666,9.246004e-7,0.000052066967,0.00014382062,0.00009812654],"category_scores_gemma":[0.004840926,0.000030647916,0.00020534289,0.000108237604,0.00008929878,0.00004528409,0.000018741455,0.00070569495,0.000018158955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007870885,0.0018202593,0.41842052,0.00002342301,0.00015925297,0.008071694,0.00029002057,7.6767003e-7,0.0002592407,0.0002911875,0.08892903,0.47386372],"study_design_scores_gemma":[0.0037350184,0.0066660005,0.47519106,0.000045129338,0.000030245097,0.00028518218,0.00008358805,0.00000156849,0.00006041014,0.00021621276,0.5136634,0.000022182778],"about_ca_topic_score_codex":0.000014314366,"about_ca_topic_score_gemma":0.00009910102,"teacher_disagreement_score":0.47384155,"about_ca_system_score_codex":0.0000968955,"about_ca_system_score_gemma":0.00069028966,"threshold_uncertainty_score":0.579539},"labels":[],"label_agreement":null},{"id":"W2247870335","doi":"10.1200/jco.2005.23.16_suppl.6087","title":"Medical oncologists’ perceptions of the effect of drug funding decisions for new cancer drugs on their practice: A qualitative study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Thematic analysis; Family medicine; Disengagement theory; Drug; Qualitative research; Pharmacology; Gerontology","score_opus":0.19944133791582028,"score_gpt":0.5309295953225944,"score_spread":0.3314882574067741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247870335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670471,0.0009884684,0.0010384695,0.02248922,0.0021078608,0.00054643257,0.00007993822,0.0000035835556,0.005698946],"genre_scores_gemma":[0.9945303,0.0010820408,0.0010221062,0.0013801771,0.0014672067,0.000020665402,5.0059106e-7,0.000017195038,0.0004797662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99489385,0.00060999184,0.003860341,0.00024036069,0.00014457366,0.00025090686],"domain_scores_gemma":[0.96802706,0.025204929,0.0059584905,0.00027527346,0.0002537948,0.00028044602],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01623846,0.0001628813,0.0019745205,0.00016701754,0.00009181197,0.0000112470225,0.0006176275,0.000324726,0.00041145837],"category_scores_gemma":[0.03984407,0.00010545606,0.0008738297,0.00017483534,0.00033054178,0.000283514,0.000093819865,0.0008286413,0.000017879145],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012188344,0.0061174617,0.13440166,0.000050041876,0.0019774474,0.000008946333,0.05962373,0.0013934245,0.000009954097,0.028887443,0.06571079,0.68963075],"study_design_scores_gemma":[0.034505095,0.05549579,0.27613834,0.0005212742,0.0006180208,0.000032173433,0.04023886,0.0007591009,0.00012730178,0.022352535,0.56862426,0.0005872299],"about_ca_topic_score_codex":0.0003026743,"about_ca_topic_score_gemma":0.00057057827,"teacher_disagreement_score":0.6890435,"about_ca_system_score_codex":0.00042279297,"about_ca_system_score_gemma":0.0014104693,"threshold_uncertainty_score":0.9682437},"labels":[],"label_agreement":null},{"id":"W2247903747","doi":"10.1200/jco.2009.27.15_suppl.6556","title":"Differences in uptake of postoperative adjuvant chemotherapy for lung cancer: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Cancer registry; Adjuvant chemotherapy; Cohort; Internal medicine; Cancer; Oncology; Surgery; Breast cancer","score_opus":0.40986751675000577,"score_gpt":0.5574711810993861,"score_spread":0.14760366434938033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247903747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96376395,0.0010453591,0.00024714172,0.032251682,0.00054509746,0.002057416,0.000033442146,0.0000047424533,0.000051178835],"genre_scores_gemma":[0.9843461,0.000312019,0.0034573383,0.011284221,0.00046136402,0.00006331038,0.000006301058,0.000008478171,0.000060871807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949203,0.00046810956,0.0034795408,0.00033385944,0.0004735984,0.00032460588],"domain_scores_gemma":[0.9924017,0.0033936067,0.0028838336,0.0002917328,0.00081642927,0.00021264909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00965933,0.00016568448,0.0020259996,0.00006889654,0.00010376517,0.000020911284,0.0002824207,0.00017954916,0.0000125249],"category_scores_gemma":[0.0050333617,0.000094040726,0.00033760443,0.0001499768,0.00010069096,0.0001729435,0.000012041246,0.00063933467,4.8670497e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114143446,0.0030147433,0.70926046,0.000019695362,0.0004339749,0.00023952321,0.019064875,0.00008252208,0.00008729061,0.000009887037,0.007158809,0.14648475],"study_design_scores_gemma":[0.01667119,0.12335159,0.8482855,0.0007379334,0.00013126268,0.000028066694,0.005478045,0.00027916115,0.00002507457,0.00009672176,0.004825856,0.00008960958],"about_ca_topic_score_codex":0.023081979,"about_ca_topic_score_gemma":0.0863518,"teacher_disagreement_score":0.14639513,"about_ca_system_score_codex":0.001049604,"about_ca_system_score_gemma":0.014558042,"threshold_uncertainty_score":0.9910285},"labels":[],"label_agreement":null},{"id":"W2247940093","doi":"10.1200/jco.2013.31.31_suppl.102","title":"What type of feedback to clinicians best improves conformance to supportive care quality measures?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality management; Documentation; PDCA; Palliative care; Quality of life (healthcare); Psychological intervention; Baseline (sea); Constipation; Internal medicine; Nursing; Management system; Operations management; Computer science","score_opus":0.5666035870291687,"score_gpt":0.6494798717013951,"score_spread":0.08287628467222641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247940093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93236744,0.0002001038,0.00030828064,0.060866725,0.0044016726,0.00087316206,0.0000067671817,0.000008702493,0.00096711604],"genre_scores_gemma":[0.9585736,0.0008253301,0.011217562,0.027400574,0.0014952545,0.000008700359,0.000007965774,0.000023483055,0.0004475321],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9895693,0.0006578549,0.008449681,0.0002753882,0.00072600535,0.0003217665],"domain_scores_gemma":[0.9797533,0.007798218,0.0047431206,0.00041628766,0.006349109,0.0009399254],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008156811,0.00017985812,0.0019835434,0.00016293403,0.000033154483,0.00002937221,0.00029109797,0.00040338715,0.00043505835],"category_scores_gemma":[0.07355066,0.00013559713,0.0005100343,0.00031888764,0.00017212048,0.0007323212,0.00013320208,0.0010150751,0.00050389126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009562552,0.0016405616,0.08243521,0.00012003552,0.00043733837,0.00004954376,0.0014497067,0.00003208735,0.002662821,0.00005147039,0.032856908,0.86870176],"study_design_scores_gemma":[0.008667757,0.058514986,0.63219047,0.00042559297,0.00070670363,0.00008045143,0.030030372,0.000021564978,0.0007882931,0.00027284859,0.2680433,0.0002576392],"about_ca_topic_score_codex":0.00036091157,"about_ca_topic_score_gemma":0.0005669311,"teacher_disagreement_score":0.86844414,"about_ca_system_score_codex":0.00018815565,"about_ca_system_score_gemma":0.0027575006,"threshold_uncertainty_score":0.9342532},"labels":[],"label_agreement":null},{"id":"W2248013871","doi":"10.1200/jco.2007.25.18_suppl.17057","title":"Regional models of care for systemic therapy: Standards for organization and delivery","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Systemic therapy; Medicine; Service delivery framework; Quality assurance; Multidisciplinary approach; Documentation; Service (business); Best practice; Family medicine; Nursing; Cancer; Business; Pathology","score_opus":0.4065023464295647,"score_gpt":0.5896595719918424,"score_spread":0.1831572255622777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248013871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81058013,0.001623754,0.18107174,0.005372401,0.00052479975,0.00073916785,0.000026617827,0.000005680467,0.00005567797],"genre_scores_gemma":[0.9626295,0.0024538394,0.031313483,0.002343151,0.0011980591,0.0000026453401,0.000023416966,0.000019466306,0.000016434804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99584943,0.00012394872,0.0034260384,0.00012801739,0.0003457798,0.00012681422],"domain_scores_gemma":[0.9782466,0.01214558,0.002641843,0.0000988272,0.00670167,0.00016546789],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009379842,0.00007982711,0.0009204662,0.000094125535,0.000037030164,0.000004169487,0.00006749093,0.0002751851,0.0000142449535],"category_scores_gemma":[0.017867353,0.00005992875,0.00024234492,0.00009213119,0.00009434,0.00016034406,0.000014772775,0.00024048,1.5549419e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067955926,0.0012259679,0.027546281,0.00078207144,0.00086892146,0.000055324697,0.0010978736,0.00023747433,0.0028979725,0.0022806693,0.017223347,0.8778282],"study_design_scores_gemma":[0.18157528,0.17374474,0.069051765,0.0014366865,0.0045906277,0.004798123,0.020070374,0.0054197353,0.002985158,0.013363784,0.52231044,0.00065325585],"about_ca_topic_score_codex":0.000007638183,"about_ca_topic_score_gemma":0.000023927772,"teacher_disagreement_score":0.8771749,"about_ca_system_score_codex":0.00016641649,"about_ca_system_score_gemma":0.002625144,"threshold_uncertainty_score":0.99040556},"labels":[],"label_agreement":null},{"id":"W2248026357","doi":"10.1200/jco.2009.27.15_suppl.4074","title":"Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)—Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Cetuximab; Univariate analysis; Randomization; KRAS; Multivariate analysis; Gastroenterology; Randomized controlled trial; Cancer; Colorectal cancer","score_opus":0.08489329341673717,"score_gpt":0.45907254501494643,"score_spread":0.37417925159820925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248026357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933899,0.0006943714,0.0000017743205,0.000742126,0.0011400685,0.00090366986,0.000520028,0.000009197957,0.0025988326],"genre_scores_gemma":[0.9974486,0.0014990219,0.00023807332,0.0001848579,0.0004524353,0.0000165264,0.00010993622,0.000016175605,0.0000343459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959718,0.00033797458,0.0023685605,0.0004055471,0.0005617922,0.000354322],"domain_scores_gemma":[0.99453324,0.0020001947,0.0021117677,0.00016634825,0.000850288,0.00033814795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060145755,0.00030976182,0.0027950543,0.00013793318,0.00006273512,0.0000087647095,0.0001241392,0.00031473607,0.00007269472],"category_scores_gemma":[0.0013187559,0.00020912712,0.00031105874,0.00018743303,0.00034447032,0.00015537757,0.000045897188,0.0007515464,0.0000010918455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8029552,0.010188677,0.08281532,0.000012735363,0.0007957763,0.0005342361,0.0009867043,0.000010844128,0.000051575127,0.0000024008646,0.00038916536,0.10125733],"study_design_scores_gemma":[0.48795334,0.13020226,0.3789044,0.00014262336,0.0006913197,0.000004823079,0.00054146163,0.000012386242,0.00015315348,0.000014396402,0.0012461378,0.00013369587],"about_ca_topic_score_codex":0.0009631952,"about_ca_topic_score_gemma":0.0038224647,"teacher_disagreement_score":0.3150019,"about_ca_system_score_codex":0.00062471256,"about_ca_system_score_gemma":0.001300745,"threshold_uncertainty_score":0.85279566},"labels":[],"label_agreement":null},{"id":"W2248059207","doi":"10.1200/jco.2008.26.15_suppl.5012","title":"Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: A propensity-matched analysis of 20,000 patients","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Hazard ratio; Proportional hazards model; Propensity score matching; Confidence interval; Internal medicine; Diabetes mellitus; Myocardial infarction; Prostate cancer; Logistic regression; Surgery; Cancer; Endocrinology","score_opus":0.1754602754664063,"score_gpt":0.4750601057769342,"score_spread":0.2995998303105279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248059207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783224,0.0011488696,0.0000139177455,0.0003773609,0.00007715895,0.00031419587,0.000015268686,0.0000026344087,0.00021836656],"genre_scores_gemma":[0.99213576,0.0073429644,0.0002360559,0.00012002942,0.00006505277,0.0000027125898,0.000015259404,0.0000089302985,0.00007323015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997325,0.00033833884,0.0014750398,0.00015314201,0.0005462182,0.00016227522],"domain_scores_gemma":[0.99707,0.0006990866,0.0009959855,0.00023890965,0.00078431016,0.00021167716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012556952,0.00011946511,0.0025559193,0.0003831491,0.000027818947,0.0000020714501,0.000076837525,0.00014011576,0.00004929951],"category_scores_gemma":[0.0009595884,0.00006392156,0.001506977,0.00038481224,0.00021611793,0.000067847104,0.00003166201,0.00034513898,8.963647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007595106,0.0024809611,0.9357264,0.000015532589,0.016084008,0.00023380683,0.00012583195,0.00007426431,0.00013684694,0.0000012149906,0.00018384319,0.03734218],"study_design_scores_gemma":[0.016595677,0.016816624,0.9635671,0.000028521452,0.0016732524,0.00005088295,0.000013389522,0.000044542954,0.000341913,0.000016259708,0.000803169,0.00004869471],"about_ca_topic_score_codex":0.000100415775,"about_ca_topic_score_gemma":0.000007585168,"teacher_disagreement_score":0.037293486,"about_ca_system_score_codex":0.00012500868,"about_ca_system_score_gemma":0.00074598513,"threshold_uncertainty_score":0.26066455},"labels":[],"label_agreement":null},{"id":"W2248113534","doi":"10.1200/jco.2006.24.18_suppl.10640","title":"A population-based study of trastuzumab-mediated cardiotoxicity among early stage breast cancer patients treated with adjuvant trastuzumab","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Internal medicine; Regimen; Ejection fraction; Breast cancer; Oncology; Population; Adjuvant; Chemotherapy; Heart failure; Cancer; Surgery","score_opus":0.043554243560170694,"score_gpt":0.40963950692009754,"score_spread":0.36608526335992686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248113534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979567,0.00007321997,0.000009848965,0.0002786482,0.00040378261,0.0008799082,0.0001315426,0.0000177932,0.00024858158],"genre_scores_gemma":[0.99891675,0.00002524122,0.000064420296,0.0001790944,0.0005554881,0.000028719398,0.000044667348,0.000031201587,0.00015444208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580187,0.00058540347,0.002422994,0.00027801402,0.00061270763,0.00029902646],"domain_scores_gemma":[0.995283,0.0010039016,0.0024039957,0.00017037286,0.0008280688,0.00031062806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007234252,0.00025476236,0.002284519,0.00023700688,0.00005457406,0.00000667077,0.00012965052,0.0003020769,0.00029204393],"category_scores_gemma":[0.00013422975,0.00016680371,0.00037790672,0.0003391966,0.0001599513,0.00011678044,0.000015990108,0.0006758562,0.0000019323677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016716193,0.023037938,0.9538116,0.000027893237,0.0010914503,0.00039503977,0.00012501767,0.0004611508,0.00008498472,8.7772855e-7,0.00033148084,0.0039163884],"study_design_scores_gemma":[0.042495,0.051071726,0.904089,0.000078671066,0.0017368092,0.000017913824,0.00008694151,0.000087579894,0.000070357324,0.0000025273785,0.0001350422,0.00012843184],"about_ca_topic_score_codex":0.010199896,"about_ca_topic_score_gemma":0.0056279292,"teacher_disagreement_score":0.049722586,"about_ca_system_score_codex":0.0006413786,"about_ca_system_score_gemma":0.001322305,"threshold_uncertainty_score":0.9963913},"labels":[],"label_agreement":null},{"id":"W2248222071","doi":"10.1200/jco.2014.32.15_suppl.4041","title":"A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Gastroenterology; Cancer; Adverse effect; Anemia; Phases of clinical research; Oncology; Surgery; Toxicity; Clinical trial","score_opus":0.06547192002458377,"score_gpt":0.4543494135352635,"score_spread":0.3888774935106797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248222071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949024,0.0008476283,0.0014941499,0.00014011591,0.0017020103,0.000846218,0.000033095832,0.0000036644535,0.000030733852],"genre_scores_gemma":[0.9944407,0.0004827256,0.0016230923,0.0004426021,0.0028306146,0.000060595274,0.000016381742,0.00002813058,0.00007519791],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962449,0.00077784073,0.0021016821,0.00037757913,0.00024985307,0.00024811557],"domain_scores_gemma":[0.9959781,0.0004662664,0.0024333566,0.00024087766,0.0006508896,0.00023051978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024500012,0.00022354197,0.0012746267,0.00012167136,0.0000714967,0.000008849584,0.0002431171,0.0003449755,0.000054004875],"category_scores_gemma":[0.001069015,0.00017568248,0.00028747017,0.0001359376,0.00021184559,0.000027141066,0.0000774271,0.00036538256,2.1578906e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29890496,0.013888005,0.0010971595,0.000035363995,0.000703784,0.000011622198,0.0002554019,0.00027109488,0.46724957,0.00000961312,0.00064257614,0.21693085],"study_design_scores_gemma":[0.23174411,0.710497,0.0010043362,0.00004307551,0.00023908158,0.000043180185,0.00025493093,0.00019383957,0.043941725,0.00005332016,0.011804496,0.00018087457],"about_ca_topic_score_codex":0.00001579672,"about_ca_topic_score_gemma":0.0001264976,"teacher_disagreement_score":0.696609,"about_ca_system_score_codex":0.00004808353,"about_ca_system_score_gemma":0.0007184607,"threshold_uncertainty_score":0.71641237},"labels":[],"label_agreement":null},{"id":"W2248255966","doi":"10.1200/jco.2005.23.16_suppl.4088","title":"Small bowel adenocarcinoma and associated malignancies","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adenocarcinoma; Malignancy; Duodenal cancer; Cancer; Internal medicine; Colorectal cancer; Gastroenterology; Family history; Oncology","score_opus":0.1990782110685379,"score_gpt":0.4545054970441013,"score_spread":0.2554272859755634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248255966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765352,0.0012489768,0.00003087922,0.019393003,0.00012497141,0.00010539111,0.0000017135525,0.000007843561,0.002552011],"genre_scores_gemma":[0.98681355,0.00035526726,0.009870537,0.0013080082,0.00076191605,0.000001463306,0.000001204088,0.000009166645,0.0008788746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798685,0.0002307226,0.0011567932,0.00011936342,0.00025463497,0.00025162572],"domain_scores_gemma":[0.9970739,0.0012076263,0.0006670115,0.00009189079,0.00038602197,0.00057357043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020807295,0.00009394543,0.0008171938,0.000083986284,0.00003174354,0.000008706277,0.0000765781,0.00012308254,0.00009095318],"category_scores_gemma":[0.00671227,0.00006124928,0.0002503869,0.00006276,0.00018504125,0.000053952215,0.00004503228,0.0006787075,0.000028611767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001957696,0.0020318248,0.912948,0.000014627565,0.00030049996,0.004113368,0.00003902696,0.0000017631563,0.00019010302,0.00010552809,0.0043437295,0.07395381],"study_design_scores_gemma":[0.0068261293,0.021443093,0.9557645,0.000105079744,0.00020478177,0.0032975292,0.000064089894,0.00006733497,0.00008637894,0.00018783845,0.011908401,0.00004484511],"about_ca_topic_score_codex":0.000011716876,"about_ca_topic_score_gemma":0.000053247484,"teacher_disagreement_score":0.07390896,"about_ca_system_score_codex":0.00014245001,"about_ca_system_score_gemma":0.0008104515,"threshold_uncertainty_score":0.8035699},"labels":[],"label_agreement":null},{"id":"W2248375839","doi":"10.1200/jco.2009.27.15_suppl.6527","title":"Costs of treatments for local/regional prostate cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Prostate cancer; Hormonal therapy; Radiation therapy; Cancer; Prostate; Hormone; Oncology; Internal medicine; Gynecology; Surgery","score_opus":0.15039062257503227,"score_gpt":0.513428604025581,"score_spread":0.3630379814505487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248375839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9356641,0.0065550334,0.0005777115,0.05396757,0.0010836144,0.0009500262,0.00005169214,0.000008295647,0.0011419617],"genre_scores_gemma":[0.9838846,0.00909564,0.0025483998,0.0035724808,0.0005701339,0.000027657072,0.0000071669238,0.000009835746,0.00028408846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978212,0.00007594532,0.0015493085,0.00014090908,0.00022661922,0.0001860259],"domain_scores_gemma":[0.99682087,0.00083884253,0.0013602525,0.00011100018,0.0005822391,0.00028678594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057195185,0.00011458342,0.001196768,0.000066961795,0.000021117343,0.0000025896031,0.000071237475,0.00017072057,0.0000504567],"category_scores_gemma":[0.00030520165,0.00007229424,0.00051726116,0.00007366436,0.00014203138,0.000060624447,0.000008290987,0.00021485401,0.0000023473274],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008137459,0.004385846,0.0640678,0.000020557334,0.0009019129,0.00021648128,0.000070036636,0.000041581017,0.000067115085,0.000290302,0.013803891,0.907997],"study_design_scores_gemma":[0.05083681,0.13377635,0.6433579,0.0008269441,0.0027747073,0.00032562233,0.00015065979,0.00020956855,0.0016191314,0.0028993583,0.16305003,0.00017297026],"about_ca_topic_score_codex":0.000026295913,"about_ca_topic_score_gemma":0.00001831181,"teacher_disagreement_score":0.90782404,"about_ca_system_score_codex":0.0004355816,"about_ca_system_score_gemma":0.0015536327,"threshold_uncertainty_score":0.29480737},"labels":[],"label_agreement":null},{"id":"W2248440650","doi":"10.1200/jco.2012.30.5_suppl.14","title":"Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Dutasteride; Finasteride; Urology; Doubling time; Nadir; Prostate; Internal medicine; Gynecology; Cancer","score_opus":0.037348898462060943,"score_gpt":0.4343492008136843,"score_spread":0.3970003023516233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248440650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617326,0.0021708552,6.906165e-7,0.0004972792,0.00037688395,0.00035762295,0.00006824282,0.0000019397755,0.00035322102],"genre_scores_gemma":[0.99672174,0.002571145,0.00024375717,0.00004533267,0.0003386516,0.0000077521145,0.0000075752223,0.000013096676,0.00005093629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971795,0.00039914867,0.0015894625,0.00011458599,0.0004293289,0.00028794067],"domain_scores_gemma":[0.99575204,0.0009856073,0.002101305,0.00013057883,0.00073074707,0.00029970947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018751818,0.00011195805,0.0011808258,0.0001528055,0.00001528901,0.000001381023,0.00009365987,0.0001699703,0.00005759567],"category_scores_gemma":[0.0013773331,0.00006546413,0.00017556417,0.00024207638,0.00034172725,0.00015286972,0.000037780188,0.0007093643,0.0000015371913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021848736,0.0035615065,0.866208,0.00005457505,0.00028230797,0.000020570758,0.0005483531,0.000011564092,0.0003244311,0.0000030152187,0.00021349531,0.10692342],"study_design_scores_gemma":[0.013932511,0.009617209,0.9684709,0.00022381997,0.000102914266,0.0000054516545,0.0003290934,0.0000055563833,0.005313231,0.000044742144,0.001894341,0.000060237082],"about_ca_topic_score_codex":0.00017229823,"about_ca_topic_score_gemma":0.00011218286,"teacher_disagreement_score":0.106863186,"about_ca_system_score_codex":0.00021630475,"about_ca_system_score_gemma":0.0015567419,"threshold_uncertainty_score":0.30818743},"labels":[],"label_agreement":null},{"id":"W2248519216","doi":"10.1200/jco.2014.32.4_suppl.58","title":"Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Docetaxel; Prostate cancer; Chemotherapy; Pharmacokinetics; Population; Internal medicine; Oncology; Pharmacology; Cancer; Androgen deprivation therapy","score_opus":0.06588766860972486,"score_gpt":0.46431214464099524,"score_spread":0.3984244760312704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248519216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378383,0.0008479372,0.000015339001,0.004761285,0.000112423804,0.00041476358,0.000017466604,0.0000036327979,0.00004333751],"genre_scores_gemma":[0.99220693,0.006237809,0.00052068505,0.0008506815,0.00005920634,0.000009834385,0.000023425357,0.000014596229,0.00007683921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972975,0.000405846,0.0015745137,0.00021195746,0.00029768696,0.0002124953],"domain_scores_gemma":[0.9977751,0.00047822008,0.0010226725,0.0000949299,0.0003889815,0.0002401272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014595473,0.00014287754,0.0014196233,0.00041478017,0.000028414086,0.000009369465,0.000053414264,0.00010592526,0.00006916149],"category_scores_gemma":[0.00027438617,0.000097003875,0.00015007061,0.00045730406,0.00019857958,0.000105313185,0.000015073861,0.00034017826,3.243088e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020214316,0.00088646787,0.8685229,0.000118198965,0.001911303,0.000023420096,0.0006538944,0.00014901359,0.0008103233,0.000005193556,0.00006620043,0.10663881],"study_design_scores_gemma":[0.023597803,0.009492288,0.9607591,0.00008411311,0.0013358936,0.0000050333274,0.000078851415,0.0039730812,0.00018109313,0.000067627574,0.0003506322,0.00007446792],"about_ca_topic_score_codex":0.0006012664,"about_ca_topic_score_gemma":0.0004953433,"teacher_disagreement_score":0.10656434,"about_ca_system_score_codex":0.0001707815,"about_ca_system_score_gemma":0.00031027608,"threshold_uncertainty_score":0.39557034},"labels":[],"label_agreement":null},{"id":"W2248705884","doi":"10.1200/jco.2009.27.15_suppl.e17515","title":"Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Concordance; Randomized controlled trial; Internal medicine; Meta-analysis; Clinical endpoint; MEDLINE; Relative risk; Confidence interval","score_opus":0.7604661029641409,"score_gpt":0.7133037812364109,"score_spread":0.04716232172772994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248705884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88845325,0.043177795,0.05640698,0.0042468677,0.0042157164,0.0033062028,0.0000071562263,0.000029764602,0.0001562882],"genre_scores_gemma":[0.6725219,0.012543802,0.3137086,0.0003261026,0.00082682824,0.000025248213,1.0951172e-7,0.000018943043,0.000028481374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9423247,0.03184071,0.023924906,0.00040761687,0.0010656283,0.00043645868],"domain_scores_gemma":[0.2575087,0.71872675,0.02010644,0.00040446097,0.0028466429,0.00040699466],"candidate_categories":["metaresearch","metaepi_broad","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14064842,0.00044762122,0.036677472,0.00025289852,0.00015065723,0.000025334586,0.0003834145,0.0005875273,0.00004377823],"category_scores_gemma":[0.7928216,0.00024130094,0.0033949479,0.00017876989,0.0035151227,0.00015549289,0.00017218501,0.0012152654,0.0000013247568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8680482,0.0038138868,0.00007140415,0.00022596643,0.014024701,0.00009492946,0.0016709511,0.0000115526755,0.00029362153,0.099651754,0.000277067,0.011815963],"study_design_scores_gemma":[0.54249734,0.0043049688,0.0000068840222,0.00059928355,0.0064214375,0.00006211368,0.0014657846,0.00092587643,0.000060324517,0.44351685,0.000013542583,0.000125627],"about_ca_topic_score_codex":0.0000019046536,"about_ca_topic_score_gemma":0.0000017568,"teacher_disagreement_score":0.6868861,"about_ca_system_score_codex":0.00014987447,"about_ca_system_score_gemma":0.0004797019,"threshold_uncertainty_score":0.99919677},"labels":[],"label_agreement":null},{"id":"W2248813510","doi":"10.1200/jco.2004.22.90140.5053","title":"Epithelial ovarian cancer (EOC) without macroscopic residual tumour: Long-term, population-based outcomes","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Stage (stratigraphy); Epithelial ovarian cancer; Radiation therapy; Incidence (geometry); Internal medicine; Chemotherapy; Population; Oncology; Ovarian cancer; Disease; Gynecology; Surgery; Cancer","score_opus":0.09649344784847107,"score_gpt":0.48111578164589974,"score_spread":0.38462233379742866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248813510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94381183,0.00040518647,0.00020915273,0.05227623,0.0026900084,0.00029505367,0.000022903281,0.000017136665,0.00027247937],"genre_scores_gemma":[0.98564684,0.00030390816,0.0053280876,0.0061198007,0.0023597728,0.000017798453,0.00001147662,0.00003025559,0.00018207886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649346,0.00022851951,0.002186893,0.00027569674,0.00050161796,0.0003137893],"domain_scores_gemma":[0.99654096,0.00087069365,0.0015363209,0.00025273152,0.0003193799,0.00047990412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012001469,0.00021792957,0.0017603283,0.00014088019,0.0000748228,0.000021179074,0.00015988656,0.00036237674,0.0004782835],"category_scores_gemma":[0.0009897898,0.00014521775,0.0005958663,0.0001206436,0.00012619713,0.0001008491,0.000028622122,0.0007427089,0.000034444445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016472318,0.0021833193,0.9682707,0.00003301669,0.0005661675,0.0011403448,0.000033195505,0.0002659213,0.000051154326,0.00015471944,0.00029083915,0.025363376],"study_design_scores_gemma":[0.02656056,0.005355563,0.9645245,0.00032602914,0.00092906377,0.000103960396,0.000007759963,0.0000056353647,0.00035567372,0.00035247378,0.0013527826,0.00012599297],"about_ca_topic_score_codex":0.0006692632,"about_ca_topic_score_gemma":0.0011101923,"teacher_disagreement_score":0.04615643,"about_ca_system_score_codex":0.0007157301,"about_ca_system_score_gemma":0.0038990113,"threshold_uncertainty_score":0.69166785},"labels":[],"label_agreement":null},{"id":"W2248833360","doi":"10.1200/jco.2006.24.18_suppl.4517","title":"Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Urology; Internal medicine; Proportional hazards model; Cancer; Oncology; Biomarker; Hazard ratio; Prostate-specific antigen; Multivariate analysis; Gynecology; Gastroenterology; Confidence interval","score_opus":0.18630700911989892,"score_gpt":0.47589138088765387,"score_spread":0.289584371767755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248833360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852775,0.00490414,0.00023168835,0.005551904,0.0017838309,0.0014185739,0.0005153994,0.000010077084,0.00030693974],"genre_scores_gemma":[0.988456,0.003994767,0.003603024,0.00043008526,0.0024690905,0.000060913382,0.00027063463,0.000045983597,0.0006694614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933361,0.00094360975,0.0037186737,0.00053113606,0.0009623425,0.0005081292],"domain_scores_gemma":[0.9946139,0.0018388046,0.0021898414,0.0005289433,0.00036681688,0.00046172965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040485887,0.00026872582,0.0022580386,0.00028489836,0.000034555793,0.000020774294,0.00047588817,0.00048419932,0.0006634948],"category_scores_gemma":[0.001054247,0.00019005213,0.00037431763,0.0002749277,0.000299278,0.00032175359,0.00023442032,0.001323881,0.000014430529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33916935,0.0073344135,0.5468965,0.00012387546,0.002449057,0.0023491113,0.0009089572,0.000058230642,0.00046660108,0.000045897028,0.0077716843,0.09242628],"study_design_scores_gemma":[0.23939599,0.020389086,0.68451476,0.00038716904,0.0018524434,0.00006580979,0.0004267861,0.00067515054,0.00017824578,0.0018432973,0.050008874,0.00026238637],"about_ca_topic_score_codex":0.0048161163,"about_ca_topic_score_gemma":0.009000898,"teacher_disagreement_score":0.13761821,"about_ca_system_score_codex":0.00068647624,"about_ca_system_score_gemma":0.007486796,"threshold_uncertainty_score":0.99813986},"labels":[],"label_agreement":null},{"id":"W2248847637","doi":"10.1200/jco.2004.22.14_suppl.552","title":"Impact of reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancers","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Breast cancer; Anthracycline; Internal medicine; Population; Oncology; Cyclophosphamide; Retrospective cohort study; Chemotherapy; Cancer; Surgery","score_opus":0.03835756768666998,"score_gpt":0.4281462656102045,"score_spread":0.38978869792353454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248847637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998231,0.00020195518,0.00011535498,0.0009589086,0.00020945922,0.0001632497,0.000084080035,0.0000015333133,0.00003444082],"genre_scores_gemma":[0.9975042,0.00029198223,0.0018154801,0.00019040525,0.00014972736,0.0000025938477,0.000028567885,0.000013208541,0.0000038363755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738723,0.00017606081,0.0018755192,0.00019198148,0.00020576688,0.00016344967],"domain_scores_gemma":[0.9964925,0.00016450026,0.0024417571,0.00022672492,0.00057394704,0.00010056313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011057181,0.00015421493,0.0013401558,0.000113140806,0.000017474655,0.0000010004337,0.00015111249,0.00027288654,0.00003181481],"category_scores_gemma":[0.0006154325,0.000115518276,0.0005565162,0.00014724536,0.00024643046,0.000008116561,0.00003887639,0.00022064315,1.0306495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016263705,0.0024013314,0.9142136,0.00002966592,0.00054603774,0.000016664964,0.000039447506,0.0052445224,0.05318225,0.000002455368,0.00005580288,0.008004519],"study_design_scores_gemma":[0.01308534,0.007019919,0.9587089,0.00011902425,0.00010859645,0.000019698035,0.000026904781,0.00008600963,0.02067463,0.000027836237,0.00003837271,0.00008478663],"about_ca_topic_score_codex":0.0027215926,"about_ca_topic_score_gemma":0.0007467928,"teacher_disagreement_score":0.04449529,"about_ca_system_score_codex":0.00029811714,"about_ca_system_score_gemma":0.002227653,"threshold_uncertainty_score":0.47106987},"labels":[],"label_agreement":null},{"id":"W2248854698","doi":"10.1200/jco.2007.25.18_suppl.9548","title":"A phase Ib study of oxaliplatin in combination with fluorouracil (5FU) and leucovorin (LV) in pediatric patients (pts) with advanced solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Oxaliplatin; FOLFOX; Bolus (digestion); Regimen; Tolerability; Toxicity; Pharmacokinetics; Fluorouracil; Internal medicine; Pediatric cancer; Colorectal cancer; Gastroenterology; Chemotherapy; Urology; Oncology; Surgery; Cancer; Adverse effect","score_opus":0.06768361388423799,"score_gpt":0.4851574908015795,"score_spread":0.4174738769173415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248854698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983027,0.00012586836,0.000018753737,0.00034743888,0.00020645703,0.0006096673,0.0000013143299,0.000003386674,0.00038439746],"genre_scores_gemma":[0.99875873,0.00018232857,0.0006720904,0.0001626786,0.00016848069,0.000007686753,0.0000029670275,0.000011903998,0.00003310989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971217,0.00025788054,0.0019137667,0.00018111093,0.00031440586,0.00021111559],"domain_scores_gemma":[0.99661773,0.0012802331,0.001519387,0.000084993575,0.0003082388,0.00018942707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020141525,0.0001359617,0.001264106,0.00037911907,0.000016689348,0.0000024457977,0.00006593672,0.00013772515,0.000023807735],"category_scores_gemma":[0.00040530492,0.00009026581,0.000056697234,0.0003698637,0.00009004627,0.00012708458,0.000022572287,0.0006608233,6.5462535e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037772987,0.041171778,0.841649,0.000031617812,0.00009383562,0.0011314854,0.0008696434,0.00004256971,0.000041632502,0.000005045745,0.000040203333,0.07715023],"study_design_scores_gemma":[0.13342616,0.16255756,0.7027862,0.00005560047,0.0002663825,0.000057851146,0.00053806393,0.000029325496,0.000052736366,0.000021046728,0.0001447034,0.000064349755],"about_ca_topic_score_codex":0.00006072579,"about_ca_topic_score_gemma":0.0018926352,"teacher_disagreement_score":0.13886276,"about_ca_system_score_codex":0.00021458234,"about_ca_system_score_gemma":0.00057684054,"threshold_uncertainty_score":0.36809328},"labels":[],"label_agreement":null},{"id":"W2248861770","doi":"10.1200/jco.2007.25.18_suppl.2037","title":"Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Radiosurgery; Nuclear medicine; Occult; Radiation treatment planning; Radiology; Breast cancer; Lesion; Radiation therapy; Cancer; Surgery; Internal medicine; Pathology","score_opus":0.08777594282707768,"score_gpt":0.4479209966574854,"score_spread":0.36014505383040774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248861770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344874,0.0015794088,0.0034143268,0.009419053,0.00058091746,0.0011814875,0.00032024563,0.000010365534,0.000045446297],"genre_scores_gemma":[0.9916357,0.00026827055,0.005881312,0.0013497183,0.00036223454,0.000018287268,0.00007310666,0.000047134778,0.0003642545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908301,0.0016502427,0.005751137,0.00048472596,0.00083466485,0.00044911852],"domain_scores_gemma":[0.9768948,0.014914199,0.006597578,0.00055739965,0.00043411372,0.00060194166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.014041571,0.0003796065,0.0034415717,0.0006712145,0.00009180107,0.00001533572,0.0001717468,0.00024974125,0.000080135236],"category_scores_gemma":[0.004126276,0.00026453403,0.0007466926,0.00053301366,0.00033582962,0.00020362857,0.00003586911,0.00048433794,6.3541967e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7534652,0.04486339,0.0076503204,0.00027676387,0.006293543,0.0018471635,0.0012906488,0.0006140592,0.027721982,0.000018286502,0.02776823,0.12819046],"study_design_scores_gemma":[0.5014692,0.33003813,0.009066786,0.0006467239,0.0036937238,0.00091543695,0.0011323539,0.00057725597,0.021413462,0.000024482442,0.13053991,0.00048254585],"about_ca_topic_score_codex":0.00011225491,"about_ca_topic_score_gemma":0.000014915226,"teacher_disagreement_score":0.28517476,"about_ca_system_score_codex":0.00036623454,"about_ca_system_score_gemma":0.001458693,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W2248882779","doi":"10.1200/jco.2015.33.3_suppl.725","title":"The impact of perioperative red blood cell transfusion on long-term survival after hepatectomy for colorectal liver metastases.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Perioperative; Colorectal cancer; Proportional hazards model; Subgroup analysis; Hepatectomy; Internal medicine; Retrospective cohort study; Overall survival; Blood transfusion; Surgery; Resection; Cancer; Confidence interval","score_opus":0.07599614301314948,"score_gpt":0.45189815767609653,"score_spread":0.37590201466294704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248882779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366665,0.0006215383,0.00083020143,0.0024612988,0.00094611716,0.00035813928,0.000008537981,0.0000052078267,0.0011023377],"genre_scores_gemma":[0.9958086,0.0009244244,0.0019108424,0.0002802105,0.0008681979,0.000005808937,0.0000036876768,0.000021018124,0.00017723741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702346,0.0007293903,0.0014576562,0.00016318912,0.0003864857,0.00023979695],"domain_scores_gemma":[0.9945718,0.0032835123,0.00087178504,0.00014494445,0.0006480077,0.00047995299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005537036,0.00015298274,0.0012168629,0.000078436664,0.000056584955,0.000014055125,0.00017054332,0.0002122938,0.00007971923],"category_scores_gemma":[0.004973167,0.00007629894,0.00090030953,0.00008940277,0.00033847787,0.000059356742,0.00002838681,0.0011221195,0.000002903949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14033441,0.0088807,0.54857457,0.00014862619,0.003537353,0.003485409,0.0019124403,0.00041246702,0.0067264084,0.00007296615,0.003663502,0.28225112],"study_design_scores_gemma":[0.053739633,0.12853631,0.79835224,0.0002675255,0.002235608,0.00085769244,0.00022932654,0.0042546215,0.0020594234,0.00010103618,0.009108536,0.00025805496],"about_ca_topic_score_codex":0.00004870271,"about_ca_topic_score_gemma":0.000030274388,"teacher_disagreement_score":0.28199306,"about_ca_system_score_codex":0.000107226726,"about_ca_system_score_gemma":0.001467527,"threshold_uncertainty_score":0.5953705},"labels":[],"label_agreement":null},{"id":"W2248890491","doi":"10.1200/jco.2015.33.3_suppl.771","title":"Assessing alternative dosing strategies for granulocyte-colony stimulating factor (G-CSF) use with FOLFOX6 therapy for treatment of colorectal cancer in a prospective cohort.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Granulocyte colony-stimulating factor; Dosing; Neutropenia; Regimen; Chemotherapy; Internal medicine; Febrile neutropenia; Colorectal cancer; Filgrastim; Surgery; Cancer; Gastroenterology; Oncology","score_opus":0.29437251279085347,"score_gpt":0.5386508785746241,"score_spread":0.24427836578377066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248890491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382716,0.00021372524,0.0027961174,0.0005392516,0.000667902,0.001701354,0.000024726773,0.0000071844593,0.00022259935],"genre_scores_gemma":[0.9918913,0.00022266629,0.0069404584,0.00011743296,0.0005593549,0.00020997906,0.0000021770513,0.000022874263,0.000033759832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796623,0.00016600346,0.0012338212,0.00020299634,0.0002175163,0.00021341613],"domain_scores_gemma":[0.99445766,0.002645106,0.001457581,0.000076993325,0.0011875806,0.00017508876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000757093,0.00015632191,0.0014176528,0.00012246627,0.000048576752,0.00003952153,0.00005982981,0.00016576838,0.000013350552],"category_scores_gemma":[0.0006244247,0.000098014054,0.00029902603,0.0001344284,0.00016718757,0.00046892854,0.000007828447,0.0002173658,1.2351317e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027209003,0.0018129748,0.9356684,0.0000208074,0.0008399919,0.00004879636,0.0011547168,0.0021149851,0.0015786769,0.00009454808,0.00004045314,0.029416645],"study_design_scores_gemma":[0.043135364,0.07873375,0.8697073,0.00022440181,0.0004693851,0.000073708965,0.0009892666,0.0012157145,0.003146438,0.0007771818,0.0013952736,0.00013221042],"about_ca_topic_score_codex":0.00047899128,"about_ca_topic_score_gemma":0.0014489605,"teacher_disagreement_score":0.07692078,"about_ca_system_score_codex":0.00084527145,"about_ca_system_score_gemma":0.004281529,"threshold_uncertainty_score":0.75952494},"labels":[],"label_agreement":null},{"id":"W2248910050","doi":"10.1200/jco.2009.27.15_suppl.e16040","title":"Cardiovascular events (CVEs) associated with tyrosine kinase inhibitor (TKI) therapy in patients with metastatic renal cell carcinoma (mRCC) at a regional cancer center","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Sunitinib; Heart failure; Internal medicine; Incidence (geometry); Renal cell carcinoma; Sorafenib; Cancer; Cardiology","score_opus":0.07257628835990974,"score_gpt":0.3557312884349298,"score_spread":0.28315500007502004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248910050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947458,0.0018868948,0.0000097898155,0.0020966597,0.00024693678,0.00066894083,0.000013840047,0.000008394479,0.0003227347],"genre_scores_gemma":[0.9963912,0.00033396774,0.00075723405,0.0018240407,0.0003697601,0.00001457684,0.00003698979,0.000037928086,0.00023430662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952134,0.00083437626,0.0018462894,0.0004037597,0.001239969,0.00046221173],"domain_scores_gemma":[0.9963307,0.0004850824,0.0015385954,0.00034704575,0.0007765788,0.0005220257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015121889,0.00034484247,0.0022362852,0.00023119299,0.00005294724,0.000008212431,0.00016603443,0.00025749052,0.00008299545],"category_scores_gemma":[0.00025740356,0.00019862741,0.0007973098,0.00032077174,0.00015187732,0.0001409117,0.000031235704,0.000903201,0.0000061236683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030328197,0.009286149,0.9404518,0.00001740927,0.0015315013,0.0029510984,0.000114782735,0.00015022553,0.00009926664,0.0000019795677,0.0013280845,0.013739522],"study_design_scores_gemma":[0.06432213,0.046194363,0.884154,0.00030806678,0.000886813,0.0001295079,0.00001723136,0.000011213946,0.00041802903,0.000018584398,0.0033579345,0.00018210763],"about_ca_topic_score_codex":0.00006883166,"about_ca_topic_score_gemma":0.00012920433,"teacher_disagreement_score":0.056297764,"about_ca_system_score_codex":0.0013203841,"about_ca_system_score_gemma":0.0012753679,"threshold_uncertainty_score":0.8099791},"labels":[],"label_agreement":null},{"id":"W2248932904","doi":"10.1200/jco.2009.27.15_suppl.e12006","title":"HER-2 gene amplification in circulating tumor cells (CTCs): Concordance with amplification status in primary breast cancers and metastatic lesions","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Circulating tumor cell; Medicine; Concordance; Metastatic breast cancer; Breast cancer; DAPI; Cancer; Primary tumor; Pathology; Oncology; Fish <Actinopterygii>; Immunohistochemistry; Gene duplication; Liquid biopsy; Internal medicine; Metastasis; Staining; Gene; Biology","score_opus":0.15562619119841944,"score_gpt":0.4837212781029476,"score_spread":0.32809508690452815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248932904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226695,0.0007640425,0.0007019495,0.004744386,0.00016332412,0.00048628676,0.000010744907,0.0000073239485,0.00085498864],"genre_scores_gemma":[0.982409,0.0012064792,0.014389703,0.0017094908,0.000223577,0.000012701255,0.0000069968974,0.000016957514,0.000025073681],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961373,0.0005825312,0.0021015538,0.0003029281,0.00049068773,0.0003849537],"domain_scores_gemma":[0.99628717,0.0014816031,0.0012230985,0.00023205546,0.00036906038,0.0004070036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036926407,0.00014198145,0.0011249123,0.00027285644,0.000034997433,0.000016307147,0.00013222184,0.00012740357,0.000028632],"category_scores_gemma":[0.0009912447,0.00011044271,0.00008816998,0.00045549232,0.0002424595,0.0001569652,0.000021099591,0.0011991744,0.0000041039134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006235893,0.0016709286,0.47599012,0.00016975061,0.000104005194,0.0014975282,0.0005151285,0.0013059872,0.024512544,0.00018848,0.00036793927,0.48744172],"study_design_scores_gemma":[0.0067013926,0.004093448,0.9847996,0.0003796247,0.000072220726,0.0008629379,0.0003158315,0.0005352851,0.00015273612,0.00032190053,0.0016540817,0.00011091932],"about_ca_topic_score_codex":0.00030968347,"about_ca_topic_score_gemma":0.0004146533,"teacher_disagreement_score":0.5088095,"about_ca_system_score_codex":0.0013654198,"about_ca_system_score_gemma":0.0049095647,"threshold_uncertainty_score":0.8709357},"labels":[],"label_agreement":null},{"id":"W2248974608","doi":"10.1200/jco.2009.27.15_suppl.10012","title":"Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Sorafenib; Rash; Internal medicine; Refractory (planetary science); Gastroenterology; Renal cell carcinoma; Neutropenia; Mucositis; Pharmacokinetics; Hepatocellular carcinoma; Toxicity","score_opus":0.08539427579535198,"score_gpt":0.49273625971611,"score_spread":0.40734198392075804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248974608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469113,0.0004881017,0.000009780671,0.0014834603,0.00043779676,0.0016306429,0.000010399292,0.000012369308,0.0012363056],"genre_scores_gemma":[0.99707335,0.0003863698,0.00035101708,0.0008100947,0.0012990404,0.000020881313,0.0000075898315,0.000017674567,0.000033960223],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9943653,0.00074664317,0.0036693916,0.00035907258,0.0004940897,0.00036553098],"domain_scores_gemma":[0.9949737,0.0009775674,0.0030661153,0.00026516037,0.00035809714,0.00035935998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022491752,0.00028187074,0.003658202,0.00031338615,0.00005624414,0.0000065985596,0.00020155119,0.00032613397,0.00009493737],"category_scores_gemma":[0.001334778,0.00017832773,0.00042202938,0.00028778074,0.00033876675,0.00014068036,0.00004659499,0.0012962277,0.0000025455543],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41706595,0.19169082,0.11260814,0.0000046199157,0.0018822348,0.0014245189,0.0006696899,0.0000043592486,0.00007579476,0.000011710927,0.0005370202,0.27402514],"study_design_scores_gemma":[0.31925574,0.3848378,0.29364038,0.00004665327,0.0007184315,0.00040742895,0.00041817524,0.0000032204114,0.000015165855,0.00002675542,0.0005455066,0.00008472524],"about_ca_topic_score_codex":0.00009003955,"about_ca_topic_score_gemma":0.00024521846,"teacher_disagreement_score":0.2739404,"about_ca_system_score_codex":0.000365245,"about_ca_system_score_gemma":0.0018570364,"threshold_uncertainty_score":0.7271993},"labels":[],"label_agreement":null},{"id":"W2248991318","doi":"10.1200/jco.2013.31.31_suppl.199","title":"Optimizing patient scheduling for ambulatory chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare Operations and Scheduling Optimization","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ambulatory; Value stream mapping; Scheduling (production processes); Chemotherapy; Pharmacy; Operations management; Emergency medicine; Nursing; Internal medicine; Lean manufacturing","score_opus":0.2428042457675686,"score_gpt":0.5607206504418373,"score_spread":0.3179164046742687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248991318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8834313,0.00034396048,0.080705576,0.027200336,0.0046745804,0.001205821,0.0000028454294,0.000024937914,0.0024106198],"genre_scores_gemma":[0.58171284,0.00032147564,0.4033588,0.012366665,0.0018867399,0.000066597015,0.0000032494668,0.000026467185,0.00025720685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949185,0.00092295656,0.003469076,0.00015467191,0.00019700729,0.0003377465],"domain_scores_gemma":[0.9913254,0.0039631957,0.002240807,0.00016396442,0.0019463846,0.00036027597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047127316,0.000107818,0.00083942513,0.000101289195,0.00038884653,0.000012149159,0.00015111486,0.00059582025,0.0005920156],"category_scores_gemma":[0.0050373855,0.00007953948,0.0002792626,0.000102309394,0.00005876667,0.0002574711,0.000030993364,0.0011987269,0.000073658855],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012308783,0.0014245838,0.032365605,0.00021992272,0.0003507715,0.000015506337,0.006179212,0.027284523,0.00046714416,0.0029572987,0.032229263,0.8952753],"study_design_scores_gemma":[0.021050835,0.01841446,0.046569582,0.0008673265,0.00020624849,0.000033548746,0.011754192,0.17339364,0.00008498401,0.004039894,0.7229083,0.00067696726],"about_ca_topic_score_codex":0.000040860716,"about_ca_topic_score_gemma":0.000016890113,"teacher_disagreement_score":0.8945983,"about_ca_system_score_codex":0.0001829222,"about_ca_system_score_gemma":0.0027474584,"threshold_uncertainty_score":0.6482156},"labels":[],"label_agreement":null},{"id":"W2249012585","doi":"10.1200/jco.2007.25.18_suppl.8003","title":"Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom’s macroglobulinemia at well-tolerated doses","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Macroglobulinemia; Multiple myeloma; Proteasome inhibitor; Internal medicine; Waldenstrom macroglobulinemia; Oncology; Progressive disease; Dosing; Adverse effect; Gastroenterology; Pharmacology; Lymphoma; Chemotherapy","score_opus":0.2234053623912945,"score_gpt":0.5196783874375903,"score_spread":0.2962730250462958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249012585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623764,0.0011647894,0.000019074203,0.00114286,0.00017342187,0.0005925886,0.0000093283525,0.0000060107736,0.0006543047],"genre_scores_gemma":[0.99652547,0.00048298683,0.002462867,0.00019857792,0.00013988215,0.000009105721,0.000009758633,0.0000120835675,0.00015929287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99407595,0.0012653628,0.0030708627,0.0002816159,0.0008369733,0.00046923553],"domain_scores_gemma":[0.99146396,0.005924673,0.0011123464,0.00018529304,0.00085247407,0.00046128273],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012529458,0.00018173149,0.0016540157,0.0004434738,0.0000384954,0.000006606956,0.00012456393,0.00049428875,0.00024035599],"category_scores_gemma":[0.02020689,0.00012650425,0.00022476607,0.00033945878,0.0003949462,0.00009991114,0.00009776351,0.00074826146,0.000010605067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0668936,0.005855544,0.8404814,0.000067687244,0.0001714633,0.008499221,0.00019940005,0.000014717143,0.007971744,0.000022823882,0.00033130377,0.069491126],"study_design_scores_gemma":[0.07861572,0.0119325435,0.89888084,0.00024886322,0.0001700863,0.0013332099,0.00051202363,0.0017639707,0.0052553494,0.00010516125,0.0010818299,0.00010042121],"about_ca_topic_score_codex":0.000099879064,"about_ca_topic_score_gemma":0.0009805192,"teacher_disagreement_score":0.0693907,"about_ca_system_score_codex":0.00050667336,"about_ca_system_score_gemma":0.0013254755,"threshold_uncertainty_score":0.98804635},"labels":[],"label_agreement":null},{"id":"W2249025931","doi":"10.1200/jco.2011.29.18_suppl.lba9014","title":"The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Pulmonary embolism; Randomized controlled trial; Cancer; Surgery; Low molecular weight heparin; Chemotherapy; Thrombosis; Confidence interval","score_opus":0.06119164249588717,"score_gpt":0.3998249583038266,"score_spread":0.33863331580793943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249025931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946477,0.00027763788,0.00034700122,0.0009142717,0.0008406678,0.0016249735,0.0000024304302,0.0000067051756,0.0013386443],"genre_scores_gemma":[0.9962651,0.0012942147,0.001380973,0.0006277412,0.00026264493,0.00006636167,0.0000020274056,0.000035948637,0.00006498226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996399,0.0004013118,0.0021667047,0.0002552846,0.00044946052,0.00032826568],"domain_scores_gemma":[0.9961765,0.00072238577,0.0020997596,0.00030585635,0.0005311278,0.00016440464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029917748,0.00019070292,0.0019453858,0.00012349371,0.000065889726,0.000008652786,0.00027506804,0.00020952438,0.000068992435],"category_scores_gemma":[0.00062315335,0.000115446106,0.00036707128,0.00017855722,0.00019056047,0.00010030242,0.000042726795,0.0005307453,0.0000015238111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008314948,0.03857552,0.6283032,0.00013173095,0.0023803685,0.000084313346,0.0025860597,0.00006193042,0.00010474425,0.0003439363,0.0011578219,0.31795546],"study_design_scores_gemma":[0.014281872,0.028655404,0.9512673,0.00035808492,0.0007406057,0.0000044710387,0.00036964356,0.000021010012,0.00042704298,0.0005901861,0.0031637615,0.00012061353],"about_ca_topic_score_codex":0.00019981,"about_ca_topic_score_gemma":0.00072143716,"teacher_disagreement_score":0.32296413,"about_ca_system_score_codex":0.00019992326,"about_ca_system_score_gemma":0.0005911993,"threshold_uncertainty_score":0.47077554},"labels":[],"label_agreement":null},{"id":"W2249038033","doi":"10.1200/jco.2007.25.18_suppl.4039","title":"Treatment patterns and outcomes of patients with pT3N0 rectal cancer in a population-based setting","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Total mesorectal excision; Cancer; Population; Internal medicine; Proportional hazards model; Rectum; Oncology; Surgery; Gastroenterology; Urology","score_opus":0.06226062808177138,"score_gpt":0.46045905893105793,"score_spread":0.3981984308492865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249038033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981242,0.00007281041,0.000024236582,0.0010549866,0.00026220255,0.00024706929,0.0000131809265,0.0000034570216,0.00019785044],"genre_scores_gemma":[0.9985214,0.00005534712,0.0009890436,0.00028581606,0.00010621623,0.0000044639,0.000004589491,0.000010430801,0.000022702856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782205,0.00012647126,0.0014627721,0.00013895429,0.00028039332,0.00016933685],"domain_scores_gemma":[0.9962843,0.0021648738,0.0010676509,0.00008189105,0.00019742924,0.00020385318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007625264,0.000118133736,0.0011638115,0.00013908482,0.000013475263,0.0000021505166,0.000037267404,0.00015584246,0.000070666385],"category_scores_gemma":[0.00061398634,0.00006783841,0.00017647292,0.00011319963,0.000055337,0.000047468875,0.000012714008,0.00025010022,3.5342518e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068972236,0.0016685645,0.8232435,0.0000139790955,0.00020382335,0.00023728103,0.000047670383,0.00001562147,0.0000013148751,0.0000016732155,0.0000021011351,0.16766723],"study_design_scores_gemma":[0.018680604,0.01456979,0.9660355,0.00011375152,0.00021388973,0.000011533946,0.000023970271,0.00003094703,0.000026276519,0.000011780664,0.00022646565,0.000055491317],"about_ca_topic_score_codex":0.0006455649,"about_ca_topic_score_gemma":0.002665002,"teacher_disagreement_score":0.16761173,"about_ca_system_score_codex":0.00049021177,"about_ca_system_score_gemma":0.00048283944,"threshold_uncertainty_score":0.276637},"labels":[],"label_agreement":null},{"id":"W2249094632","doi":"10.1200/jco.2015.33.3_suppl.675","title":"Surgical management of the primary tumor in stage IV colorectal cancer: A validation study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Bevacizumab; Hazard ratio; FOLFOX; FOLFIRI; Internal medicine; Colorectal cancer; Proportional hazards model; Surgery; Chemotherapy; Stage (stratigraphy); Cancer; Oxaliplatin; Confidence interval","score_opus":0.15057754095999562,"score_gpt":0.4799504670193218,"score_spread":0.3293729260593262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249094632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858382,0.00065719767,0.0000012067078,0.002508834,0.0010250459,0.00050540303,0.0000035680346,0.000003137493,0.009457443],"genre_scores_gemma":[0.9983839,0.00046531638,0.00019438553,0.0002038552,0.00025199534,0.000020568294,5.2915675e-7,0.0000068220584,0.00047264024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732625,0.0004019523,0.0015311377,0.00013148786,0.00046955107,0.00013962688],"domain_scores_gemma":[0.9979683,0.000472558,0.0010267018,0.00011027341,0.00028180695,0.00014034499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002457053,0.00009738865,0.0011035234,0.00006327252,0.000021625016,0.0000031703103,0.00013051907,0.00007637064,0.000045686033],"category_scores_gemma":[0.00030655426,0.00005236664,0.0002542773,0.00020911958,0.00014052274,0.000048779973,0.00012862642,0.00040652775,0.0000015444441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011327601,0.0045260494,0.9431586,0.000041338048,0.0006599214,0.0017882895,0.00043026925,0.00004656178,0.000006864548,0.00004473705,0.00085256994,0.037117146],"study_design_scores_gemma":[0.01638167,0.013123561,0.95570564,0.00010298726,0.00038509656,0.00007515139,0.0013799851,0.0000136534,0.000038556118,0.000053629887,0.012692986,0.00004705889],"about_ca_topic_score_codex":0.000117819734,"about_ca_topic_score_gemma":0.0002727478,"teacher_disagreement_score":0.037070084,"about_ca_system_score_codex":0.0005094462,"about_ca_system_score_gemma":0.0010661681,"threshold_uncertainty_score":0.21354495},"labels":[],"label_agreement":null},{"id":"W2249147923","doi":"10.1200/jco.2009.27.15_suppl.6567","title":"Evaluation of factors associated with recruitment in hematological clinical trials: A retrospective study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Protocol (science); Population; Inclusion and exclusion criteria; Clinical trial; Retrospective cohort study; Internal medicine; Hematology; Population study; Pathology; Alternative medicine","score_opus":0.9634962074522775,"score_gpt":0.7869043354843658,"score_spread":0.1765918719679117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249147923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795736,0.00019070909,0.00003979074,0.006432156,0.00064756494,0.0022116336,0.0000028983302,0.000009911154,0.0025079788],"genre_scores_gemma":[0.9979552,0.00031471078,0.0006270802,0.0005878988,0.0004322412,0.000015170525,0.0000022364911,0.000013401637,0.000052032767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9369189,0.038888853,0.016681295,0.0006668096,0.0063445764,0.000499548],"domain_scores_gemma":[0.7055763,0.26279932,0.015179231,0.000905904,0.014369443,0.0011697769],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.4587799,0.00021314959,0.0060531828,0.00029957097,0.000033945962,0.000010032397,0.0003775332,0.0017357889,0.00023877289],"category_scores_gemma":[0.8012415,0.00011977374,0.001067382,0.00059176754,0.0006135087,0.00010167588,0.00007625703,0.0077208183,0.000003727148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099107465,0.03121231,0.9048411,0.000008173569,0.0012446574,0.00039852274,0.00030624314,0.000016767228,0.000013545184,0.00032582076,0.00021639011,0.051505707],"study_design_scores_gemma":[0.030583868,0.115346834,0.8329249,0.0003811499,0.0016104557,0.00001928914,0.0010871342,0.00018981045,0.000016272366,0.017689195,0.00006213304,0.00008897765],"about_ca_topic_score_codex":0.000011077773,"about_ca_topic_score_gemma":0.00043627457,"teacher_disagreement_score":0.34246165,"about_ca_system_score_codex":0.0009182877,"about_ca_system_score_gemma":0.008451949,"threshold_uncertainty_score":0.9995602},"labels":[],"label_agreement":null},{"id":"W2249185594","doi":"10.1200/jco.2004.22.14_suppl.4635","title":"Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Vancouver General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostatectomy; Prostate cancer; Oncology; Urology; Prostate; Hormone therapy; Internal medicine; Hormonal therapy; Cancer; Gynecology; Breast cancer","score_opus":0.083241931915468,"score_gpt":0.4775061391273902,"score_spread":0.39426420721192224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249185594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97289205,0.003303144,0.00003950463,0.02070672,0.00054263265,0.0024306765,0.00002880946,0.000009318484,0.00004713653],"genre_scores_gemma":[0.9688061,0.027983801,0.0021282078,0.0004620278,0.00036421412,0.000060291684,0.000007947111,0.000022812275,0.0001646211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958762,0.00051103777,0.0023248605,0.00029403708,0.00060990395,0.0003839512],"domain_scores_gemma":[0.9966471,0.00072619505,0.001362844,0.00016749905,0.00052954245,0.0005667769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028710011,0.00020138052,0.0017316455,0.0002942784,0.000076874225,0.000011932034,0.00013466364,0.00032054953,0.000035953275],"category_scores_gemma":[0.0016857157,0.00012800364,0.0002491845,0.0003348505,0.00039304968,0.00014354062,0.00006803305,0.0010816716,0.0000026689677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.532869,0.017069012,0.009815392,0.00004209702,0.0004066678,0.0005987835,0.0011558146,0.000048266476,0.00139102,0.000053446143,0.00027785488,0.43627265],"study_design_scores_gemma":[0.75662166,0.13950305,0.09192781,0.00028557112,0.00024937926,0.00004427786,0.00020697809,0.00010601371,0.0014800505,0.0010930116,0.008342819,0.00013937269],"about_ca_topic_score_codex":0.000504599,"about_ca_topic_score_gemma":0.00010617731,"teacher_disagreement_score":0.4361333,"about_ca_system_score_codex":0.0004280064,"about_ca_system_score_gemma":0.0027227201,"threshold_uncertainty_score":0.5219837},"labels":[],"label_agreement":null},{"id":"W2249194542","doi":"10.1200/jco.2007.25.18_suppl.1531","title":"Participant characteristics on an international NCIC CTG breast cancer prevention trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Tamoxifen; Placebo; Gynecology; Internal medicine; Cancer; Cohort; Anastrozole; Oncology; Pathology","score_opus":0.1626001679161715,"score_gpt":0.5191073005492702,"score_spread":0.35650713263309874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249194542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992292,0.000075133794,0.0002597679,0.0021208078,0.0045231027,0.00010623163,0.000029079665,0.0000034829018,0.0005904121],"genre_scores_gemma":[0.9902124,0.0006615572,0.00038532674,0.0009632659,0.007616726,0.000007139408,0.00001761217,0.00001218935,0.00012380756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99779534,0.0002088411,0.0013768019,0.00019250537,0.00022747136,0.00019906393],"domain_scores_gemma":[0.99789095,0.00018541464,0.00124729,0.00014909117,0.00033941935,0.0001878526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021971967,0.00011718553,0.0005240791,0.00004889647,0.000038952596,0.000009369882,0.00020241055,0.00025114036,0.00007193291],"category_scores_gemma":[0.00068341504,0.00008824618,0.0002727443,0.000037678383,0.00010901782,0.000011762465,0.000051447794,0.00026783935,0.0000066808475],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24054731,0.0063555515,0.09858338,0.000006488791,0.0014947943,0.0001466339,0.0001065044,0.00002316847,0.002049089,0.00015883757,0.001551299,0.6489769],"study_design_scores_gemma":[0.029408406,0.010362069,0.9149039,0.00003453288,0.00023397578,0.00011122909,0.00008015217,0.000007218694,0.00041927837,0.000086771426,0.044232417,0.000120078475],"about_ca_topic_score_codex":0.00001374693,"about_ca_topic_score_gemma":0.000133576,"teacher_disagreement_score":0.8163205,"about_ca_system_score_codex":0.000083376195,"about_ca_system_score_gemma":0.00052785745,"threshold_uncertainty_score":0.3598575},"labels":[],"label_agreement":null},{"id":"W2249258003","doi":"10.1200/jco.2005.23.16_suppl.8096","title":"What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia","funders":"","keywords":"Medicine; Respondent; Population; Family medicine; Socioeconomic status; Attendance; Demography; Cancer registry; Breast cancer; Cancer; Gerontology; Internal medicine; Environmental health","score_opus":0.08455753554189092,"score_gpt":0.4486518302439994,"score_spread":0.36409429470210847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249258003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984134,0.0007159113,0.0000024319286,0.012413268,0.0020862238,0.00044697177,0.00003905409,0.0000037530447,0.00015834572],"genre_scores_gemma":[0.99546015,0.0004362851,0.000040697192,0.0032504778,0.00073674106,0.0000090584035,0.000019796566,0.000012664023,0.00003412959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959498,0.000643898,0.0025929064,0.00012202926,0.00054359133,0.00014776453],"domain_scores_gemma":[0.9914766,0.0019102668,0.0037546922,0.00025104466,0.0024484503,0.00015892232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017002197,0.000118156364,0.0011529267,0.00012765106,0.000027570444,0.0000063099887,0.00017990488,0.00021787168,0.00008481256],"category_scores_gemma":[0.0020371703,0.000072546434,0.00034243078,0.00036642808,0.000054751436,0.00017168197,0.00003723425,0.00055057625,0.0000013072212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00987308,0.002580654,0.8853991,0.000077195225,0.00019924744,0.0000196728,0.00868445,0.0001765066,0.0000057974116,0.0000013484878,0.00077089254,0.092212066],"study_design_scores_gemma":[0.013222762,0.009205593,0.9191174,0.00041013144,0.0005681132,0.0000019302493,0.04824078,0.000028664339,0.00007863288,0.000005016033,0.00905841,0.00006256083],"about_ca_topic_score_codex":0.0014749126,"about_ca_topic_score_gemma":0.030580815,"teacher_disagreement_score":0.0921495,"about_ca_system_score_codex":0.00024462014,"about_ca_system_score_gemma":0.0009045744,"threshold_uncertainty_score":0.9871086},"labels":[],"label_agreement":null},{"id":"W2249291309","doi":"10.1200/jco.2005.23.16_suppl.818","title":"Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cyclophosphamide; Anthracycline; Breast cancer; Regimen; Chemotherapy; Internal medicine; Randomized controlled trial; Radiation therapy; Oncology; Surgery; Urology; Cancer","score_opus":0.13803021745123692,"score_gpt":0.49999805762428723,"score_spread":0.3619678401730503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249291309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97804177,0.0021532378,0.0006680764,0.0079623945,0.005973985,0.0043298802,0.00038411273,0.000034764915,0.00045175164],"genre_scores_gemma":[0.97748184,0.0059589376,0.010065554,0.0010231044,0.003991078,0.00026118945,0.00005116311,0.00007656817,0.0010905929],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990406,0.0010996391,0.0065872013,0.0005518817,0.00059077964,0.00076450984],"domain_scores_gemma":[0.9784912,0.011335431,0.007504764,0.00030225978,0.0017579683,0.0006084133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008713234,0.00050654495,0.006532189,0.0003492208,0.0001728599,0.000009841685,0.00035895038,0.00072632276,0.0006003045],"category_scores_gemma":[0.0032852865,0.0003791333,0.002253904,0.00041841972,0.0007012222,0.00018604401,0.00012602491,0.0009828326,0.0000012120727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90507746,0.005862818,0.0013276412,0.00020433986,0.0048457514,0.00005905433,0.00034801103,0.0010523903,0.009813788,0.00012730905,0.002232144,0.06904929],"study_design_scores_gemma":[0.90014404,0.045966737,0.004626541,0.00027129712,0.0059053004,0.00009596519,0.00014181423,0.0033972985,0.019631587,0.00012651732,0.019383008,0.0003098716],"about_ca_topic_score_codex":0.0007264437,"about_ca_topic_score_gemma":0.001288887,"teacher_disagreement_score":0.068739414,"about_ca_system_score_codex":0.0009017387,"about_ca_system_score_gemma":0.0036174378,"threshold_uncertainty_score":0.99986607},"labels":[],"label_agreement":null},{"id":"W2249309584","doi":"10.1200/jco.2006.24.18_suppl.4101","title":"Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Gemcitabine; Pancreatic cancer; Radiation therapy; Internal medicine; Hazard ratio; Population; Gastroenterology; Cancer; Surgery; Nuclear medicine; Oncology; Confidence interval","score_opus":0.08927768269564956,"score_gpt":0.495964844759825,"score_spread":0.40668716206417543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249309584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860129,0.004727898,0.0034869032,0.0038445892,0.0005663334,0.0008027438,0.000059413465,0.000010735605,0.00048852863],"genre_scores_gemma":[0.9630755,0.020411475,0.013281217,0.0003071256,0.0012610018,0.00004150455,0.000014137665,0.000029491719,0.0015785501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484926,0.00079091464,0.0032461167,0.0002933612,0.00044187464,0.00037844095],"domain_scores_gemma":[0.9828382,0.01293349,0.0025262178,0.00024072459,0.0010955876,0.00036573948],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045685424,0.00020154275,0.0028286085,0.00018361639,0.00006047562,0.0000078314115,0.00018416026,0.00052561826,0.0001467126],"category_scores_gemma":[0.008560803,0.00012477425,0.0003294065,0.00019460353,0.00079688133,0.00008362628,0.000040583167,0.0009092861,9.680108e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08900955,0.0022006575,0.61154765,0.0002600318,0.0012005696,0.00044883194,0.000081021055,0.000034351993,0.0014081514,0.0001592356,0.0063603083,0.28728965],"study_design_scores_gemma":[0.06578233,0.038323924,0.8834784,0.00053946074,0.0012204907,0.0002924563,0.000032733144,0.00078727247,0.00018734581,0.00030028107,0.008925761,0.00012956488],"about_ca_topic_score_codex":0.00019106337,"about_ca_topic_score_gemma":0.0005200592,"teacher_disagreement_score":0.2871601,"about_ca_system_score_codex":0.00021556385,"about_ca_system_score_gemma":0.0033240386,"threshold_uncertainty_score":0.9997905},"labels":[],"label_agreement":null},{"id":"W2249358575","doi":"10.1200/jco.2006.24.18_suppl.5566","title":"A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Oncology; Chemotherapy; Adverse effect; Gastroenterology; Cancer; Breast cancer; Trastuzumab","score_opus":0.09390375300937577,"score_gpt":0.4973413336384716,"score_spread":0.40343758062909585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249358575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975406,0.00066923624,0.00003371259,0.0007573344,0.00030380228,0.00049228355,0.000014751737,0.0000020988593,0.00018619365],"genre_scores_gemma":[0.9977794,0.00014391833,0.0016341931,0.000142268,0.00015488984,0.000012608655,0.0000020610828,0.000010728416,0.000119901066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970014,0.0003701441,0.0020789173,0.00015236872,0.00025328933,0.00014387653],"domain_scores_gemma":[0.99654347,0.0014784493,0.0015580999,0.00014414552,0.00015610366,0.000119757504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011488138,0.00012300919,0.0012121189,0.00011783058,0.00005033374,0.0000054518696,0.00008968434,0.000074771175,0.000039592695],"category_scores_gemma":[0.0010824625,0.000058279453,0.00012071606,0.00017135758,0.00016689781,0.00007244722,0.00007181589,0.00033528794,1.6093493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06890755,0.1195146,0.46844885,0.000922488,0.0022880554,0.004833681,0.013433961,0.00016137931,0.0038957945,0.000067900655,0.0022374077,0.31528834],"study_design_scores_gemma":[0.11253824,0.1824012,0.6894363,0.0021079283,0.0039115064,0.0009995629,0.0057562394,0.0004898086,0.0003968576,0.00029493272,0.0014896939,0.00017771944],"about_ca_topic_score_codex":0.00016866696,"about_ca_topic_score_gemma":0.00036052355,"teacher_disagreement_score":0.31511062,"about_ca_system_score_codex":0.00007352005,"about_ca_system_score_gemma":0.0010056703,"threshold_uncertainty_score":0.23765671},"labels":[],"label_agreement":null},{"id":"W2249380127","doi":"10.1200/jco.2015.33.3_suppl.543","title":"Reflex Lynch syndrome screening by example: A review of existing programs.","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Referral; Population; Best practice; Family medicine; Thematic analysis; Health care; Lynch syndrome; Genetic testing; Genetic counseling; Government (linguistics); Nursing; Qualitative research; Cancer; Environmental health; Management","score_opus":0.6839010978000604,"score_gpt":0.6196392089208139,"score_spread":0.06426188887924644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249380127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006491823,0.99089736,0.000060264872,0.00042936188,0.0017771602,0.0012630267,0.000015468713,0.000015981868,0.005476465],"genre_scores_gemma":[0.000018365145,0.9735208,0.023734193,0.0008917327,0.00106436,0.00003564704,0.000044483197,0.000086404165,0.00060397375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863508,0.0018500577,0.009628946,0.00046745178,0.0012421872,0.0004605748],"domain_scores_gemma":[0.9803869,0.0037057237,0.012675177,0.00059522764,0.001772569,0.00086438993],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.015763994,0.00050102745,0.013856986,0.000214527,0.0000272603,0.0000090463645,0.00065806357,0.0014542476,0.0003267236],"category_scores_gemma":[0.016413383,0.00033228536,0.0025478671,0.00058879226,0.00042523185,0.00006108339,0.00023270775,0.0033901744,0.00002246379],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017558127,0.0005294696,0.000061981424,0.06856544,0.00079832773,0.0005650382,0.000008379451,3.443514e-8,2.534313e-7,0.000004481113,0.035944067,0.89334697],"study_design_scores_gemma":[0.0012826733,0.0153254755,0.000025307643,0.20005977,0.0047450494,0.0065675713,0.0000081457265,5.982348e-7,1.730783e-7,0.000020789112,0.7717746,0.00018985248],"about_ca_topic_score_codex":0.000023086095,"about_ca_topic_score_gemma":0.0000036729714,"teacher_disagreement_score":0.89315706,"about_ca_system_score_codex":0.0005539854,"about_ca_system_score_gemma":0.009342523,"threshold_uncertainty_score":0.9999129},"labels":[],"label_agreement":null},{"id":"W2249444889","doi":"10.1200/jco.2007.25.18_suppl.5009","title":"Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mitoxantrone; Surrogate endpoint; Prostate cancer; Docetaxel; Proportional hazards model; Internal medicine; Prostate-specific antigen; Hazard ratio; Prednisone; Oncology; Chemotherapy; Gynecology; Urology; Cancer","score_opus":0.1697459293748511,"score_gpt":0.5162281980362494,"score_spread":0.3464822686613983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249444889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851999,0.0097345915,0.00015763298,0.002963637,0.0006068078,0.000881911,0.00006818508,0.0000074095847,0.0003798921],"genre_scores_gemma":[0.9611514,0.03489091,0.0024597293,0.00041183777,0.0003707646,0.000022615326,0.00003036315,0.000030973322,0.0006313706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942148,0.00038620242,0.0037366007,0.00033091535,0.0007446986,0.0005867949],"domain_scores_gemma":[0.9919295,0.0039373375,0.002153579,0.00024768728,0.0012389506,0.00049295893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009168439,0.00022386397,0.0027854103,0.00091367227,0.000039878552,0.00001224291,0.00021522002,0.00025682154,0.00013609324],"category_scores_gemma":[0.0017567333,0.00015126298,0.0009987421,0.0009176775,0.00033220262,0.0001708103,0.00006894397,0.00086172554,0.0000043645805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09921313,0.0045874594,0.70562947,0.00012215959,0.0065935417,0.0022304214,0.00074971264,0.00025929578,0.0027708567,0.00006140313,0.00085628586,0.17692627],"study_design_scores_gemma":[0.025513068,0.016676825,0.9036697,0.00012211558,0.0018790453,0.00002389881,0.00034775244,0.00025394425,0.00036922147,0.00045477273,0.050535064,0.00015457968],"about_ca_topic_score_codex":0.00037379726,"about_ca_topic_score_gemma":0.0011502277,"teacher_disagreement_score":0.19804025,"about_ca_system_score_codex":0.00043507892,"about_ca_system_score_gemma":0.0026862693,"threshold_uncertainty_score":0.61683255},"labels":[],"label_agreement":null},{"id":"W2249447277","doi":"10.1200/jco.2004.22.90140.9663","title":"Aglycone Protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Protopanaxadiol; P-glycoprotein; Pharmacology; MCF-7; Cancer cell; Multiple drug resistance; Aglycone; Medicine; Chemistry; Ginsenoside; Cancer; Biochemistry; Ginseng; Internal medicine; Stereochemistry; Glycoside","score_opus":0.034171279591753784,"score_gpt":0.3733129262987917,"score_spread":0.33914164670703795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249447277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987925,0.0012254025,0.000024916893,0.009612415,0.0005107554,0.00040483286,0.000013333968,0.000005751322,0.00027757967],"genre_scores_gemma":[0.9895593,0.0033137945,0.0025935476,0.0025286137,0.0015972864,0.000013129576,0.0000017900979,0.000027192738,0.00036533937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977707,0.00025368595,0.0011035979,0.00035957995,0.00023551448,0.00027690546],"domain_scores_gemma":[0.9981463,0.00025195893,0.0009391832,0.00022673269,0.0002105906,0.00022522121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016289986,0.00021302426,0.0008217325,0.00006719372,0.000080341866,0.000020153886,0.00015516211,0.0004508329,0.000017345665],"category_scores_gemma":[0.00075185875,0.00015431656,0.00029509622,0.00007102785,0.00028663818,0.000012020679,0.000058620524,0.0006079136,0.0000030285437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069519826,0.00047037101,0.000118256685,0.000028222554,0.00024993802,0.00008754105,0.00012927236,0.00006875388,0.89434415,0.00005320672,0.0011381574,0.09636017],"study_design_scores_gemma":[0.005349265,0.0056274706,0.002059306,0.00013130743,0.00005198994,0.000080812395,0.00018117849,0.000007980584,0.92941695,0.00024069646,0.056616515,0.00023649771],"about_ca_topic_score_codex":0.00011445479,"about_ca_topic_score_gemma":0.000085243904,"teacher_disagreement_score":0.09612367,"about_ca_system_score_codex":0.00007897227,"about_ca_system_score_gemma":0.0006541858,"threshold_uncertainty_score":0.6292847},"labels":[],"label_agreement":null},{"id":"W2249501726","doi":"10.1200/jco.2009.27.15_suppl.e22066","title":"Molecular changes in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) biopsies at time of progression compared to initial biopsy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Lung cancer; Exon; Medicine; Epidermal growth factor receptor; Missense mutation; Biopsy; Liquid biopsy; Oncology; T790M; Mutation; Pathology; Cancer research; Internal medicine; Cancer; Gene; Gefitinib; Biology; Genetics","score_opus":0.05801625254943917,"score_gpt":0.4727867438395973,"score_spread":0.41477049129015814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249501726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842948,0.0008535064,0.000027851785,0.01297196,0.00045540827,0.00051499606,0.000022246062,0.000005569855,0.0008536621],"genre_scores_gemma":[0.9946885,0.00033572922,0.0028711576,0.0016183942,0.00033213518,0.000016725371,0.000009454698,0.00001347223,0.00011441215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759924,0.00022651741,0.0014899021,0.00017749156,0.00024350926,0.0002633496],"domain_scores_gemma":[0.9979798,0.00042101575,0.0009131401,0.0001143683,0.00028381412,0.0002878617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057220424,0.00015452276,0.0012467455,0.00030885797,0.000020329135,0.000004517388,0.00012457793,0.00026344176,0.00019519351],"category_scores_gemma":[0.00042919966,0.0001106609,0.00019448188,0.0002655125,0.000077372126,0.000059537895,0.00004209294,0.00040153856,0.0000086004175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012334021,0.0074068177,0.77131075,0.0002645882,0.00041960212,0.0023815767,0.0041635972,0.00020378186,0.11365461,0.000014221842,0.0034359975,0.084410414],"study_design_scores_gemma":[0.016987715,0.0105769755,0.941622,0.0014389796,0.0003652397,0.000092399074,0.00021030291,0.00024511665,0.026588598,0.000022562941,0.0016486183,0.00020144862],"about_ca_topic_score_codex":0.000078459656,"about_ca_topic_score_gemma":0.00014948731,"teacher_disagreement_score":0.17031127,"about_ca_system_score_codex":0.0004851387,"about_ca_system_score_gemma":0.00092650007,"threshold_uncertainty_score":0.45126203},"labels":[],"label_agreement":null},{"id":"W2249582782","doi":"10.1200/jco.2005.23.16_suppl.7555","title":"Clinical activity of celecoxib (CXB) in metastatic malignant melanoma (MMM)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Island Health","funders":"","keywords":"Medicine; Celecoxib; Gastroenterology; Cancer; Melanoma; Internal medicine; Surgery; Oncology; Pathology; Cancer research","score_opus":0.12635769081212062,"score_gpt":0.4849761872546758,"score_spread":0.35861849644255517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249582782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924688,0.00036477638,0.00012228101,0.003424135,0.0015864542,0.00026938165,0.0000021926655,0.0000063524208,0.0017556462],"genre_scores_gemma":[0.9902134,0.00060160266,0.0057962188,0.0012381135,0.00196542,0.0000034079997,7.2661226e-7,0.000019353332,0.00016176298],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993022,0.0015601402,0.0044003786,0.00022296232,0.0004609559,0.0003335597],"domain_scores_gemma":[0.9903811,0.0057075676,0.0028063955,0.00026468272,0.00031904122,0.0005211717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013726651,0.0001726414,0.002873614,0.00023209986,0.000017997663,0.0000033729889,0.00019769798,0.00047341644,0.00026454765],"category_scores_gemma":[0.007932043,0.00011869135,0.0008753487,0.0001880784,0.0002945404,0.00014757947,0.000055206794,0.0016516919,0.00004898673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008500435,0.005873113,0.37243712,0.00012980541,0.00045334804,0.0023366867,0.00010283268,0.000025198775,0.0014652176,0.0001310741,0.0032460298,0.6052991],"study_design_scores_gemma":[0.01786162,0.019675817,0.89027166,0.00023971166,0.00053883233,0.00053118344,0.00004454733,0.00060973293,0.0025350156,0.00017532324,0.0673607,0.00015587169],"about_ca_topic_score_codex":0.000016370617,"about_ca_topic_score_gemma":0.00012929854,"teacher_disagreement_score":0.60514325,"about_ca_system_score_codex":0.00014098058,"about_ca_system_score_gemma":0.0021182033,"threshold_uncertainty_score":0.9495969},"labels":[],"label_agreement":null},{"id":"W2249613567","doi":"10.1200/jco.2009.27.15_suppl.4044","title":"Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of <i>Numeracy</i> (NUM) and <i>ADJUVANT! Online</i> (ADJ!)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Internal medicine; Population; Stage (stratigraphy); Confidence interval; Oncology; Proportional hazards model; Colorectal cancer; Surgery; Cancer","score_opus":0.0934914164902395,"score_gpt":0.45553253298878016,"score_spread":0.36204111649854065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249613567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282944,0.0015022055,0.00068358245,0.0040442348,0.00014085486,0.000596602,0.00013463576,0.000005973968,0.00006248226],"genre_scores_gemma":[0.9951262,0.00062407006,0.0029759526,0.0010353549,0.00012557769,0.000018983754,0.00004554606,0.000008773563,0.000039554307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973978,0.00014901902,0.0018128705,0.00020637386,0.00027903577,0.00015493648],"domain_scores_gemma":[0.9950985,0.001980747,0.0019280125,0.00011210923,0.0007231317,0.00015753615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010580012,0.00014995883,0.0019654362,0.00023901045,0.0000675739,0.000004785603,0.000056230485,0.00018537251,0.000016081172],"category_scores_gemma":[0.0008900687,0.00010703733,0.00040235705,0.00030753462,0.00012256828,0.00008662199,0.000017544939,0.00020811384,2.2715547e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016722735,0.008636616,0.83876103,0.00017503947,0.0029435826,0.000030985306,0.00024468292,0.008421634,0.0005365674,0.0000666951,0.00025092272,0.12320952],"study_design_scores_gemma":[0.04194842,0.038665876,0.7971954,0.00029435134,0.012486213,0.000005297982,0.000106942236,0.1071381,0.000454666,0.00029900606,0.0012352976,0.00017047104],"about_ca_topic_score_codex":0.00015738724,"about_ca_topic_score_gemma":0.0006410431,"teacher_disagreement_score":0.12303905,"about_ca_system_score_codex":0.00010085614,"about_ca_system_score_gemma":0.0009043359,"threshold_uncertainty_score":0.4364856},"labels":[],"label_agreement":null},{"id":"W2249623145","doi":"10.1200/jco.2010.28.15_suppl.e18564","title":"Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): A review of the literature.","year":2010,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rituximab; Diffuse large B-cell lymphoma; Population; Oncology; Lymphoma; Internal medicine; Intensive care medicine; Environmental health","score_opus":0.058520778799501134,"score_gpt":0.43620388201748145,"score_spread":0.3776831032179803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249623145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032622465,0.98795426,6.877209e-7,0.0011144308,0.0036281766,0.0010318153,0.000116233176,0.0000043666437,0.0028878136],"genre_scores_gemma":[0.0011543554,0.99447185,0.00037961212,0.001110225,0.0022244374,0.000027943335,0.000025740319,0.000060905153,0.00054496306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900397,0.0011795033,0.007549695,0.0003916151,0.000489171,0.00035030543],"domain_scores_gemma":[0.9793066,0.004835482,0.013788644,0.0010901656,0.0005319627,0.00044718443],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004480032,0.00052635116,0.010453634,0.00021654539,0.00003969859,0.000010163483,0.0007884479,0.0018271588,0.00020988539],"category_scores_gemma":[0.0028010393,0.00026254388,0.0061690686,0.00022647243,0.00031230637,0.000089028516,0.00024596465,0.0018085705,0.0000570185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027516836,0.014649976,0.00037292417,0.04260355,0.0012541832,0.00046130188,0.000049675346,4.0171127e-8,8.776633e-7,0.00005222328,0.016088355,0.9241917],"study_design_scores_gemma":[0.016098721,0.0045359326,0.00086263684,0.13261399,0.0075653982,0.0008555579,0.0000064165506,7.160212e-7,0.0000041425865,0.000020235304,0.8372788,0.00015750191],"about_ca_topic_score_codex":0.000016205187,"about_ca_topic_score_gemma":0.000010825722,"teacher_disagreement_score":0.92403424,"about_ca_system_score_codex":0.00056290376,"about_ca_system_score_gemma":0.008649386,"threshold_uncertainty_score":0.99998266},"labels":[],"label_agreement":null},{"id":"W2249678649","doi":"10.1200/jco.2009.27.15_suppl.e16090","title":"A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heme Oxygenase-1 and Carbon Monoxide","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; University of Calgary","funders":"","keywords":"Prostate cancer; Medicine; Cancer research; Metastasis; Heme oxygenase; Cancer; Prostate; Cancer cell; Internal medicine; Heme; Biology","score_opus":0.07589128519641783,"score_gpt":0.4135915839716307,"score_spread":0.3377002987752129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249678649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955532,0.0017580756,0.0008182092,0.0008747522,0.0002004011,0.00027261476,0.000008203898,0.00000549313,0.0005090697],"genre_scores_gemma":[0.9952546,0.0008378881,0.0015146352,0.0016731501,0.0004199381,0.00000995667,0.000005542533,0.000022494436,0.00026184614],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99668103,0.00053988234,0.0017038919,0.00037765107,0.00026659295,0.0004309283],"domain_scores_gemma":[0.9975863,0.000107170556,0.0014960998,0.00020305175,0.00033917834,0.0002681963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024838452,0.00023869808,0.0009962895,0.00011089227,0.00006355496,0.000015647878,0.0002571704,0.00039686658,0.000013023764],"category_scores_gemma":[0.00034772357,0.00019477193,0.00042270694,0.0001562,0.000101668935,0.000028453562,0.000050114726,0.0008663036,0.0000014068479],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019452483,0.002177436,0.0057281572,0.000015005372,0.00030965768,0.00012194288,0.00019861842,0.00095092936,0.9493384,0.000022522556,0.00043806672,0.03875406],"study_design_scores_gemma":[0.043428905,0.055877738,0.51434153,0.00045379138,0.00092436426,0.0005481376,0.0005299059,0.003998483,0.34220347,0.0068019875,0.028617017,0.0022746613],"about_ca_topic_score_codex":0.00027429708,"about_ca_topic_score_gemma":0.0011245601,"teacher_disagreement_score":0.6071349,"about_ca_system_score_codex":0.00018741004,"about_ca_system_score_gemma":0.0016831191,"threshold_uncertainty_score":0.79425687},"labels":[],"label_agreement":null},{"id":"W2249698993","doi":"10.1200/jco.2006.24.18_suppl.3003","title":"Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer—NCIC IND 160","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"PTEN; Temsirolimus; PI3K/AKT/mTOR pathway; Medicine; Cancer research; Protein kinase B; Cancer; Internal medicine; Progressive disease; Oncology; Phosphorylation; Chemotherapy; Biology; Signal transduction; Discovery and development of mTOR inhibitors","score_opus":0.06290830684452114,"score_gpt":0.42764797393753207,"score_spread":0.3647396670930109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249698993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978886,0.000553453,0.00011246038,0.00006875435,0.000703388,0.0005619678,0.000029662655,0.0000035362534,0.00007816635],"genre_scores_gemma":[0.9990744,0.00006845119,0.00031483048,0.00012523768,0.00029330517,0.000025224354,0.000024166635,0.00003300188,0.000041401283],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9956297,0.00084059953,0.0022817263,0.00034679653,0.00057532394,0.0003258034],"domain_scores_gemma":[0.99506897,0.0006969001,0.0031095361,0.00023638201,0.00073088636,0.00015734119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018575841,0.00024971625,0.0014024462,0.00022306514,0.000042066473,0.00000954828,0.00032127727,0.00029368544,0.00004697234],"category_scores_gemma":[0.0025557408,0.0001603955,0.00019295777,0.00048332405,0.00019307339,0.0000130666,0.00008751031,0.0006589555,5.198455e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11778281,0.0618642,0.7564016,0.000039638297,0.0037091107,0.0007575599,0.00021336066,0.007796974,0.0045021926,0.000010156988,0.0011362704,0.045786124],"study_design_scores_gemma":[0.21140864,0.55463994,0.22282086,0.00042465518,0.0017819968,0.000039158833,0.00022810366,0.00016506622,0.004185436,0.00008715529,0.0035891638,0.0006297976],"about_ca_topic_score_codex":0.00012048106,"about_ca_topic_score_gemma":0.0012889043,"teacher_disagreement_score":0.5335807,"about_ca_system_score_codex":0.00017087956,"about_ca_system_score_gemma":0.001518604,"threshold_uncertainty_score":0.6540739},"labels":[],"label_agreement":null},{"id":"W2249898544","doi":"10.1200/jco.2014.32.31_suppl.28","title":"Change in symptom burden within one day of palliative care consultation in a cohort of gynecologic oncology inpatients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecologic oncology; Palliative care; Cohort; Demographics; Emergency medicine; Internal medicine","score_opus":0.33707251388106474,"score_gpt":0.5474905045690951,"score_spread":0.21041799068803035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249898544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938198,0.0009536979,0.0000635905,0.001410451,0.0006363894,0.0004830312,0.000010884689,0.0000032524106,0.002618925],"genre_scores_gemma":[0.9928858,0.0019395194,0.004218158,0.00059328595,0.00030464714,0.000016435133,0.000013546522,0.0000108976,0.000017660988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941823,0.0013309197,0.0036935196,0.00019918286,0.00038916126,0.00020495262],"domain_scores_gemma":[0.98452026,0.00963387,0.0041749473,0.00015872442,0.0013584202,0.00015379346],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004102716,0.00014641897,0.002704193,0.00038743598,0.000009189383,0.0000010486899,0.00018310659,0.0006207002,0.00006415856],"category_scores_gemma":[0.025071926,0.00011470739,0.00024087318,0.00035149758,0.00043646496,0.000083301195,0.00006038705,0.0008205826,0.0000029851826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002495878,0.001447704,0.93244255,0.00018107335,0.00022842982,0.00007829444,0.016816197,0.00007883056,0.00030247192,0.00020298519,0.000049378308,0.045676228],"study_design_scores_gemma":[0.013262906,0.023621345,0.9520518,0.0012648862,0.00026516448,0.000003912845,0.004011992,0.00023663593,0.0007882425,0.00034395442,0.0040559224,0.00009322627],"about_ca_topic_score_codex":0.0003834362,"about_ca_topic_score_gemma":0.0012808922,"teacher_disagreement_score":0.045583,"about_ca_system_score_codex":0.0003724588,"about_ca_system_score_gemma":0.0011056117,"threshold_uncertainty_score":0.9831403},"labels":[],"label_agreement":null},{"id":"W2249972968","doi":"10.1200/jco.2014.32.26_suppl.106","title":"Correlation between Nottingham grade and Oncotype DX score in breast cancer: Implications for cost-effective incorporation of oncotype in the clinic.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Spearman's rank correlation coefficient; Internal medicine; Breast cancer; Oncology; Concordance; Correlation; Grading (engineering); Confidence interval; Gynecology; Cancer","score_opus":0.0915783646259423,"score_gpt":0.4539383220606147,"score_spread":0.3623599574346724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249972968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590875,0.00028466812,0.0014362455,0.011157579,0.0002896755,0.00069589267,0.000047989433,0.0000014744945,0.00017773203],"genre_scores_gemma":[0.99749106,0.00057815114,0.00060644426,0.00046771154,0.00071681343,0.00010037827,0.00002480773,0.000008799066,0.000005824234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979595,0.0004988188,0.0011533308,0.00017886897,0.00008516726,0.00012434665],"domain_scores_gemma":[0.9960383,0.0021370673,0.001365699,0.00013351039,0.00027396868,0.00005143148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025398768,0.00010144976,0.0005801474,0.00006673846,0.000038911217,0.000004634746,0.00012467813,0.00028278978,0.0000017635493],"category_scores_gemma":[0.0011578377,0.000071264214,0.0001284722,0.00012377545,0.00017482661,0.000011725946,0.000042223728,0.0002899119,4.8438096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007829101,0.00028739928,0.83606356,0.000011296451,0.00007589836,6.187987e-7,0.00009221158,0.00009021576,0.00020109172,0.000118271,0.0003980572,0.16187844],"study_design_scores_gemma":[0.0036719085,0.0022922242,0.9878651,0.000047099544,0.00011728183,0.000021969052,0.00007028408,0.00005256188,0.00006523878,0.001492474,0.004239868,0.00006401044],"about_ca_topic_score_codex":0.00009394363,"about_ca_topic_score_gemma":0.0010481974,"teacher_disagreement_score":0.16181444,"about_ca_system_score_codex":0.000071483606,"about_ca_system_score_gemma":0.00034976003,"threshold_uncertainty_score":0.29060704},"labels":[],"label_agreement":null},{"id":"W2249973911","doi":"10.1200/jco.2015.33.3_suppl.214","title":"Retrospective analysis of preoperative chemoradiation therapy for esophageal and gastroesophageal junction (GEJ) cancer: Lessons to be learned from expanding inclusion criteria in this patient population.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Carboplatin; Population; Internal medicine; Esophageal cancer; Retrospective cohort study; Cancer; Surgery; Hazard ratio; Survival analysis; Chemotherapy; Confidence interval","score_opus":0.19290477061533726,"score_gpt":0.5148791523436714,"score_spread":0.32197438172833415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249973911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904149,0.0014568074,0.00035335496,0.0067753014,0.00031315518,0.00057435664,0.000052963722,0.0000037959835,0.00005533119],"genre_scores_gemma":[0.9950102,0.0006860472,0.0031352027,0.0006691501,0.00035876496,0.000043841006,0.00004904014,0.0000110385035,0.00003674749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754226,0.00033307355,0.0012406975,0.0002525497,0.00045024356,0.00018115104],"domain_scores_gemma":[0.9975488,0.00049917295,0.000841612,0.000115334566,0.00060849974,0.00038658333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017303621,0.00012426465,0.0013055884,0.00050424994,0.00006813022,0.000011031916,0.000066073204,0.00017172341,0.000097469354],"category_scores_gemma":[0.001582157,0.00009096748,0.0002433851,0.00051494566,0.000057616693,0.0001617206,0.000083130624,0.00033780496,3.501773e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017163364,0.0010191246,0.8780714,0.000010379041,0.0011555501,0.000082439044,0.004809596,0.00046511326,0.00028047813,0.00002112824,0.00054523366,0.09637617],"study_design_scores_gemma":[0.0107067395,0.020418137,0.964669,0.00004700686,0.0005621753,0.0000035416413,0.00028701313,0.001904126,0.00082750706,0.00040947943,0.00011164907,0.000053648047],"about_ca_topic_score_codex":0.0014050145,"about_ca_topic_score_gemma":0.0008421788,"teacher_disagreement_score":0.09632252,"about_ca_system_score_codex":0.00096318405,"about_ca_system_score_gemma":0.00070323003,"threshold_uncertainty_score":0.3709546},"labels":[],"label_agreement":null},{"id":"W2250038003","doi":"10.1200/jco.2008.26.15_suppl.14581","title":"Clinical development of huARH460–16–2: A therapeutic antibody targeting the CD44 cancer stem cell antigen on high-incidence adenocarcinomas","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Medicine; Stem cell; CD44; Cancer; Cancer research; Pathology; Humanized antibody; Antibody; Immunology; Internal medicine; Cell; Biology; Monoclonal antibody","score_opus":0.13616894217807865,"score_gpt":0.4666692631040759,"score_spread":0.33050032092599724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250038003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927385,0.0030227338,0.0013001697,0.0013314106,0.0007775704,0.00023145974,0.0000034627828,0.0000032866703,0.0005914358],"genre_scores_gemma":[0.9912327,0.004378785,0.0018798179,0.0008690137,0.00095644785,0.000006584113,0.0000060820507,0.000019349745,0.0006512526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950928,0.0011120568,0.0026275413,0.00030420654,0.0005466053,0.00031679365],"domain_scores_gemma":[0.99634993,0.00073949713,0.0017346394,0.0003088774,0.0006389284,0.00022815513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050183586,0.00016962331,0.00080884114,0.00007108846,0.00016953451,0.0000086565315,0.0006068101,0.00044785917,0.000091286965],"category_scores_gemma":[0.0006524235,0.00010591155,0.00042820245,0.00014282593,0.00050958863,0.000009469281,0.0001505606,0.00089094706,0.000019057925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054089576,0.0024468286,0.58766836,0.00005750785,0.000711598,0.00023273566,0.00037689347,0.00028442152,0.13167697,0.00012872342,0.0065214536,0.26448557],"study_design_scores_gemma":[0.0045779743,0.008828996,0.65228397,0.00008093616,0.000066360466,0.00008106358,0.00025930675,0.00008663236,0.09846964,0.000072241026,0.23491256,0.00028031712],"about_ca_topic_score_codex":0.000029640678,"about_ca_topic_score_gemma":0.00004121495,"teacher_disagreement_score":0.26420525,"about_ca_system_score_codex":0.000055319997,"about_ca_system_score_gemma":0.0029842618,"threshold_uncertainty_score":0.5293952},"labels":[],"label_agreement":null},{"id":"W2250063510","doi":"10.1200/jco.2009.27.15_suppl.e16145","title":"The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Sorafenib; Renal cell carcinoma; N-terminal telopeptide; Internal medicine; Bone metastasis; Oncology; Bone remodeling; Clinical endpoint; Urology; Gastroenterology; Cancer; Metastasis; Hepatocellular carcinoma; Alkaline phosphatase; Randomized controlled trial","score_opus":0.036201160474266525,"score_gpt":0.36648156550195804,"score_spread":0.3302804050276915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250063510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918969,0.0020499735,0.000010001798,0.0046931524,0.00036944455,0.00016005145,0.0000059924796,0.0000027042645,0.0008117562],"genre_scores_gemma":[0.99609953,0.00030886466,0.00079837063,0.0024919126,0.00021661125,0.0000010106468,0.0000034949949,0.000006690877,0.00007350732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973653,0.00065393955,0.001291123,0.00014978884,0.0003413103,0.00019855026],"domain_scores_gemma":[0.9903037,0.008119983,0.001012765,0.00014709294,0.00020237558,0.0002140944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019860247,0.00012859053,0.0012660121,0.00009001066,0.000041937205,0.0000037205937,0.0000747033,0.00016286089,0.000011055479],"category_scores_gemma":[0.0048838397,0.0000639869,0.00014312648,0.00008943661,0.000543644,0.00003609718,0.000025712165,0.0009487202,0.0000013249579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020332497,0.0029685698,0.8359871,0.000040670016,0.00022004395,0.0021699718,0.00018066342,9.140459e-7,0.00022701896,0.000017585873,0.008036047,0.12981896],"study_design_scores_gemma":[0.0174349,0.033300616,0.9456496,0.00022030115,0.0003892984,0.000038021935,0.000062132865,0.0000034723078,0.00019617371,0.00015396487,0.0024924842,0.000059038866],"about_ca_topic_score_codex":0.000019500592,"about_ca_topic_score_gemma":0.000020863623,"teacher_disagreement_score":0.12975992,"about_ca_system_score_codex":0.000027334474,"about_ca_system_score_gemma":0.00024239127,"threshold_uncertainty_score":0.5846765},"labels":[],"label_agreement":null},{"id":"W2250077480","doi":"10.1200/jco.2013.31.31_suppl.48","title":"Health care practitioner prescribing patterns and perspectives on oral chemotherapy management: A survey of cancer centers in Toronto, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Medical prescription; Family medicine; Nausea; Patient education; Cancer; Nursing; Internal medicine","score_opus":0.11113061659727257,"score_gpt":0.49419965760988194,"score_spread":0.38306904101260936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250077480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97670984,0.0035472438,0.000004533149,0.017484535,0.000549991,0.0003368854,0.000020849235,0.0000018050715,0.0013443038],"genre_scores_gemma":[0.98421144,0.011151158,0.00018542822,0.0041627376,0.00016229058,0.000009445258,0.0000047606973,0.000008377027,0.000104331346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998342,0.00037269818,0.0008348708,0.00013308531,0.00016166951,0.0001557124],"domain_scores_gemma":[0.9983358,0.00044469463,0.0007506518,0.000067635076,0.00023056824,0.00017067569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061486237,0.000086029824,0.00077918416,0.00004875223,0.00001677059,0.00000323743,0.000051137013,0.00007796185,0.0006443757],"category_scores_gemma":[0.00009655871,0.00006362374,0.000068807756,0.000046212088,0.000053270956,0.000082553364,0.000015062152,0.00028526952,2.6084243e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033340799,0.0011810914,0.8249991,0.00007929281,0.00051669363,0.00007502036,0.0012995851,0.000006476967,0.000009400153,0.000018045075,0.0114179775,0.15706322],"study_design_scores_gemma":[0.0083077075,0.004639357,0.97793686,0.00012615164,0.000066965265,0.000012940988,0.0033803736,0.000011207886,0.000010864948,0.0000029102696,0.005460268,0.000044373875],"about_ca_topic_score_codex":0.8533664,"about_ca_topic_score_gemma":0.9482106,"teacher_disagreement_score":0.15701884,"about_ca_system_score_codex":0.001461504,"about_ca_system_score_gemma":0.0013800696,"threshold_uncertainty_score":0.7055462},"labels":[],"label_agreement":null},{"id":"W2250113678","doi":"10.1200/jco.2007.25.18_suppl.2010","title":"Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Lung cancer; Randomized controlled trial; Brain metastasis; Adverse effect; Radiation therapy; Oncology; Cancer; Gastroenterology; Metastasis","score_opus":0.045423903806889654,"score_gpt":0.44656207108538964,"score_spread":0.4011381672785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250113678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817881,0.0005907557,0.0028433271,0.010407561,0.00016131031,0.0040916186,0.000044315886,0.00001031639,0.000062707484],"genre_scores_gemma":[0.9867982,0.000088844354,0.006590304,0.0059754825,0.00021127326,0.00008224608,0.000103170336,0.00003399175,0.00011644114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98952144,0.0043206196,0.004640361,0.00043001494,0.00065858953,0.0004289604],"domain_scores_gemma":[0.9813437,0.011752574,0.005460082,0.00031553427,0.00066545507,0.0004626862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028275017,0.00035143274,0.006266202,0.0008946416,0.000042458192,0.000015331541,0.000195105,0.00028118692,0.000228356],"category_scores_gemma":[0.0040336796,0.00018165873,0.001018906,0.0011459247,0.00020509568,0.00010593924,0.000035588135,0.0007148422,0.0000030007748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78697026,0.01336424,0.06060068,0.000032177104,0.0069188382,0.00048130233,0.00028622657,0.0011331233,0.00040532197,0.000002698997,0.00082766183,0.12897748],"study_design_scores_gemma":[0.81469965,0.072289236,0.09468114,0.00017190307,0.013701669,0.000010790095,0.000030154155,0.002834896,0.00047801336,0.000012999289,0.00089051377,0.00019903772],"about_ca_topic_score_codex":0.000111845235,"about_ca_topic_score_gemma":0.000185454,"teacher_disagreement_score":0.12877844,"about_ca_system_score_codex":0.00014952675,"about_ca_system_score_gemma":0.0010299481,"threshold_uncertainty_score":0.9799613},"labels":[],"label_agreement":null},{"id":"W2250122614","doi":"10.1200/jco.2009.27.15_suppl.9557","title":"Cognitive function and fatigue in colorectal cancer (CRC) patients: Baseline assessments prior to chemotherapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Anxiety; Depression (economics); Cognition; Cambridge Neuropsychological Test Automated Battery; Quality of life (healthcare); Colorectal cancer; Cancer; Oncology; Psychiatry","score_opus":0.09580210969489211,"score_gpt":0.49950564838429923,"score_spread":0.4037035386894071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250122614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98442835,0.00027550795,0.0006256647,0.012231518,0.0009198402,0.0006011524,0.000009174553,0.000008329777,0.00090048875],"genre_scores_gemma":[0.98158896,0.0012026567,0.0005781535,0.015835645,0.00069333776,0.000013916296,0.0000040026403,0.000011500594,0.00007183579],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99749935,0.000275353,0.0014685558,0.00021845946,0.00031733103,0.00022095427],"domain_scores_gemma":[0.9967462,0.0012491328,0.00081366114,0.000043592558,0.00086643203,0.00028097094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014868032,0.00014983556,0.001060437,0.00019980637,0.00003750328,0.0000066918565,0.00004665915,0.00023167,0.0001424407],"category_scores_gemma":[0.0031325053,0.00011505304,0.00014920399,0.00023831887,0.000101276186,0.0001236063,0.000023794082,0.0007411054,0.000004799657],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020058861,0.0023189834,0.4143912,0.000008350523,0.00030431082,0.00004310983,0.000115640374,0.000004350899,0.00012945982,0.000003251693,0.001995059,0.5606274],"study_design_scores_gemma":[0.0245631,0.040385526,0.9306479,0.00039256297,0.00036767614,0.000016327222,0.00019382183,0.000057925383,0.00009231275,0.000105649575,0.0030773699,0.000099827834],"about_ca_topic_score_codex":0.000023481065,"about_ca_topic_score_gemma":0.00011427331,"teacher_disagreement_score":0.56052756,"about_ca_system_score_codex":0.00030990905,"about_ca_system_score_gemma":0.0006527172,"threshold_uncertainty_score":0.46917266},"labels":[],"label_agreement":null},{"id":"W2250123711","doi":"10.1200/jco.2006.24.18_suppl.7223","title":"Factors impacting survival of patients with post-surgical disease recurrence in non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Asymptomatic; Surgery; Pneumonectomy; Adenocarcinoma; Stage (stratigraphy); Lung cancer; Wedge resection; Population; Cancer; Medical record; Disease; Internal medicine; Resection","score_opus":0.048830304523288834,"score_gpt":0.44922290567546,"score_spread":0.4003926011521712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250123711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628216,0.0004419862,0.00003170387,0.0007176876,0.00066993036,0.00025916743,0.000041500516,0.000003068314,0.0015527763],"genre_scores_gemma":[0.9990239,0.000098978395,0.00031603043,0.00009101713,0.00033311735,0.000004004684,0.000017302056,0.000012580329,0.00010306885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782306,0.00015195852,0.0013719165,0.00015057375,0.00029710005,0.00020541815],"domain_scores_gemma":[0.996728,0.0010377566,0.0012789557,0.00010752,0.0005324694,0.00031526882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005058416,0.00012951653,0.0009083548,0.000106282416,0.00002442932,0.0000046381247,0.000084469386,0.00013090915,0.000078607125],"category_scores_gemma":[0.00038714483,0.00007528868,0.00024415785,0.00015056382,0.00009288692,0.000093435774,0.000020208714,0.00048000077,6.580123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003236611,0.0029434,0.9856952,0.000056083303,0.00012229085,0.00022838109,0.00012253193,0.00013734473,0.0000057632533,0.000007737469,0.000114442526,0.007330229],"study_design_scores_gemma":[0.011482416,0.00349156,0.9830242,0.0002621002,0.00059024227,0.0000027342478,0.00010013382,0.000043615935,0.000014945305,0.000012103874,0.0009020164,0.00007396311],"about_ca_topic_score_codex":0.00037989218,"about_ca_topic_score_gemma":0.00026901677,"teacher_disagreement_score":0.008245804,"about_ca_system_score_codex":0.00025147543,"about_ca_system_score_gemma":0.002390736,"threshold_uncertainty_score":0.4241063},"labels":[],"label_agreement":null},{"id":"W2250142723","doi":"10.1200/jco.2004.22.90140.8266","title":"Physical and psychological well-being in patients with stage IV GI cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Depression (economics); Stage (stratigraphy); Cancer; Beck Depression Inventory; Disease; Referral; Brief Pain Inventory; Palliative care; Internal medicine; Physical therapy; Psychiatry; Chronic pain; Anxiety; Family medicine","score_opus":0.07204679316725171,"score_gpt":0.46382505629176807,"score_spread":0.39177826312451636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250142723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200714,0.00009164708,0.00003176862,0.003489845,0.0006430709,0.000118102114,0.0000015305573,0.000005039134,0.0036118368],"genre_scores_gemma":[0.9961254,0.00020747747,0.0002886061,0.0025466369,0.0007298069,0.0000028929537,8.420551e-7,0.000010246444,0.00008807829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983898,0.00013267288,0.0008231132,0.00017754883,0.0002903581,0.000186531],"domain_scores_gemma":[0.99861056,0.00036184513,0.00047597775,0.000104094564,0.00017817237,0.00026933657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006601744,0.00010399118,0.000924159,0.000069192356,0.00001784746,0.000005551705,0.00007610437,0.00020704494,0.000069049514],"category_scores_gemma":[0.00029232248,0.00006282325,0.00014430739,0.00012726992,0.00019048569,0.000075385775,0.00002682308,0.00096525747,0.0000049542896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007202167,0.00280394,0.9392472,0.000020988633,0.00007798603,0.00039232327,0.00043940629,0.000034915618,0.000010323511,0.00022287686,0.0001244522,0.049423445],"study_design_scores_gemma":[0.016185861,0.016938413,0.95724887,0.00014238912,0.00009455998,0.000026340516,0.0001066481,0.0000051900493,0.000011437754,0.00061951287,0.008542421,0.00007834342],"about_ca_topic_score_codex":0.00009969546,"about_ca_topic_score_gemma":0.00075531733,"teacher_disagreement_score":0.0493451,"about_ca_system_score_codex":0.00014703421,"about_ca_system_score_gemma":0.00036293257,"threshold_uncertainty_score":0.4193617},"labels":[],"label_agreement":null},{"id":"W2250153760","doi":"10.1200/jco.2009.27.15_suppl.5137","title":"Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Oncology; Chemotherapy; Prednisone; Logistic regression; Mitoxantrone; Concordance; Cancer","score_opus":0.19076603759104613,"score_gpt":0.4922645871125438,"score_spread":0.3014985495214977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250153760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903936,0.00044136887,0.00011480064,0.008201541,0.00014120074,0.0005371692,0.000022425693,0.0000019068525,0.0001460266],"genre_scores_gemma":[0.9940899,0.0015190069,0.0037894223,0.0002313837,0.00006142206,0.000015688778,0.0000034543589,0.000005962667,0.0002837726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965188,0.00033439277,0.0024238366,0.00014097085,0.00040936106,0.00017262257],"domain_scores_gemma":[0.99658275,0.00080541224,0.0017623038,0.00014916473,0.0005649055,0.0001354433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036303797,0.00009695855,0.0008084114,0.00015507676,0.00003486418,0.000004400232,0.00012613226,0.00007518981,0.00003265539],"category_scores_gemma":[0.0009776714,0.00005448705,0.00016141814,0.00027971235,0.00014045657,0.00007623127,0.0000128209695,0.0004181124,0.0000023732464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033600982,0.0026847634,0.010651188,0.00007547934,0.0008275767,0.000097693,0.02097341,0.00020711847,0.055563074,0.000090723785,0.00053299457,0.874695],"study_design_scores_gemma":[0.0087195225,0.004967877,0.9521678,0.00017952688,0.00019042364,0.00001210128,0.002392861,0.000043432847,0.025238419,0.0009140899,0.005102394,0.00007152835],"about_ca_topic_score_codex":0.00007330905,"about_ca_topic_score_gemma":0.00039479107,"teacher_disagreement_score":0.94151664,"about_ca_system_score_codex":0.00028601257,"about_ca_system_score_gemma":0.002158557,"threshold_uncertainty_score":0.38291875},"labels":[],"label_agreement":null},{"id":"W2252336919","doi":"10.1200/jco.2010.28.15_suppl.3547","title":"Outcome of 123 patients (pts) with peritoneal carcinomatosis (PC)—Limited metastases from colorectal cancer (CRC) and appendiceal adenocarcinoma (ADC): The British Columbia Cancer Agency (BCCA) experience.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; FOLFIRI; Colorectal cancer; Bevacizumab; FOLFOX; Debulking; Univariate analysis; Proportional hazards model; Internal medicine; Log-rank test; Cancer; Chemotherapy; Surgery; Oxaliplatin; Multivariate analysis; Ovarian cancer","score_opus":0.05576827009622833,"score_gpt":0.3808282203105848,"score_spread":0.32505995021435646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252336919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939901,0.0014346109,0.0000033108445,0.0015116067,0.0020002509,0.0004917202,0.0003414928,0.000014394449,0.0002124683],"genre_scores_gemma":[0.9958783,0.00076721417,0.0007344976,0.0011686444,0.0011822985,0.000052275394,0.000015186579,0.000035955458,0.00016562159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555516,0.00033639415,0.002477517,0.00040607408,0.0007593672,0.00046546885],"domain_scores_gemma":[0.9953465,0.0011749999,0.0019770458,0.00023839706,0.00073680404,0.0005262653],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087653456,0.00025255454,0.0020148533,0.000061459206,0.00032706978,0.00011300702,0.00037807244,0.00042904203,0.0012458762],"category_scores_gemma":[0.0006954803,0.0001915554,0.00040945908,0.00023727241,0.0015043609,0.00022293806,0.00013438465,0.001489143,0.0000036653712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019501108,0.0010384489,0.9659592,0.00006004047,0.00050195016,0.00054066745,0.00068619166,9.39365e-7,0.0022824733,0.0000072217267,0.0015867807,0.025385993],"study_design_scores_gemma":[0.0061471793,0.006188969,0.9772186,0.00019035615,0.00092127896,0.0004851491,0.00083368353,0.000041450985,0.0005612106,0.000030282965,0.0071688476,0.00021295756],"about_ca_topic_score_codex":0.05823313,"about_ca_topic_score_gemma":0.09284677,"teacher_disagreement_score":0.034613643,"about_ca_system_score_codex":0.00008879544,"about_ca_system_score_gemma":0.0010553772,"threshold_uncertainty_score":0.9996671},"labels":[],"label_agreement":null},{"id":"W2252494760","doi":"10.1200/jco.2006.24.18_suppl.10565","title":"Adjuvant trastuzumab (T) therapy in HER2+ breast cancer after ASCO 2005: Patients’ attitudes and immediate economic burden","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adjuvant; Trastuzumab; Breast cancer; Adjuvant therapy; Internal medicine; Cancer; Disease; Clinical trial; Oncology; Chemotherapy; Medical record; Adjuvant chemotherapy; Gynecology; Family medicine","score_opus":0.0655376748397551,"score_gpt":0.47146357321154275,"score_spread":0.40592589837178766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252494760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98220026,0.0031920848,0.0000028061088,0.012735291,0.00092741835,0.0002851772,0.000028914994,0.0000052359746,0.00062281615],"genre_scores_gemma":[0.9848848,0.010324781,0.00023119687,0.0011145471,0.0031386816,0.000024757328,0.0000025472002,0.000028188027,0.00025049222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965559,0.00036681743,0.0020347724,0.0002620087,0.00035445174,0.0004260143],"domain_scores_gemma":[0.9978576,0.0007041372,0.0006819409,0.00016639191,0.00021984495,0.00037009924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024129318,0.00016599138,0.0013224134,0.00019047389,0.000021797341,0.000016663222,0.00016413427,0.0003444073,0.0012481933],"category_scores_gemma":[0.00019832225,0.00011833984,0.00024064578,0.000072865776,0.0003081044,0.00013453384,0.000054644588,0.0011317846,0.00003178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004794337,0.00089587196,0.77275777,0.00002617996,0.000107289314,0.0002945058,0.00005687646,0.000039697527,0.000027046772,0.000004356936,0.004513743,0.21648233],"study_design_scores_gemma":[0.012327402,0.0043777754,0.9416498,0.00016880357,0.00004148649,0.00012957284,0.00002710187,0.00005998203,0.0000133271105,0.00009846854,0.04100137,0.00010493986],"about_ca_topic_score_codex":0.0014744347,"about_ca_topic_score_gemma":0.0030674357,"teacher_disagreement_score":0.21637739,"about_ca_system_score_codex":0.00083784264,"about_ca_system_score_gemma":0.0025340104,"threshold_uncertainty_score":0.9996648},"labels":[],"label_agreement":null},{"id":"W2252794970","doi":"10.1200/jco.2015.63.4550","title":"<i>CELF4</i> Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; U.S. Public Health Service; McGill University; Leukemia and Lymphoma Society","keywords":"Medicine; Anthracycline; Cardiomyopathy; Internal medicine; Oncology; Cardiotoxicity; Genetic association; Genome-wide association study; Cardiology; Genetics; Cancer; Single-nucleotide polymorphism; Chemotherapy; Heart failure; Genotype; Gene; Breast cancer; Biology","score_opus":0.03813427735143199,"score_gpt":0.3835905785204843,"score_spread":0.3454563011690523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252794970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773151,0.00040214704,0.0005705402,0.018203748,0.0012463512,0.0005937157,0.00000666172,0.000025892321,0.0016358438],"genre_scores_gemma":[0.9910596,0.0029149163,0.0006456429,0.003387481,0.0017202598,0.000007994538,0.0000041421317,0.000027502638,0.00023246888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493337,0.0012881277,0.0026334429,0.00032938976,0.0005045639,0.00031108662],"domain_scores_gemma":[0.9910466,0.005199873,0.0026049884,0.0002332656,0.00049435155,0.00042090807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072618844,0.0001990534,0.002029027,0.00018517155,0.00007805416,0.000013173092,0.000137005,0.0008426735,0.00007677274],"category_scores_gemma":[0.008246603,0.00012836164,0.0005888728,0.0001826404,0.0001565125,0.00019849774,0.00006329067,0.0009813173,0.000019662892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022655174,0.0034868186,0.7820734,0.0000084807,0.0024277356,0.00093674596,0.0004325218,0.000002025392,0.014820765,0.000047459656,0.0014088005,0.19208974],"study_design_scores_gemma":[0.025788391,0.01879323,0.92729414,0.00006357778,0.00090025226,0.0011284549,0.00019818638,0.0000042172214,0.00042244006,0.0005262958,0.02472332,0.00015748515],"about_ca_topic_score_codex":0.000022540878,"about_ca_topic_score_gemma":0.000033585504,"teacher_disagreement_score":0.19193225,"about_ca_system_score_codex":0.0008098167,"about_ca_system_score_gemma":0.00095553073,"threshold_uncertainty_score":0.987255},"labels":[],"label_agreement":null},{"id":"W2253488702","doi":"10.1200/jco.2014.32.26_suppl.36","title":"Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Ethnic group; Population; Estrogen receptor; Cancer; Gastroenterology","score_opus":0.10899668210342114,"score_gpt":0.4372458209153141,"score_spread":0.328249138811893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253488702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573064,0.0021012733,0.00023827147,0.0012851221,0.00043838337,0.00005737347,0.00001738867,0.0000016362895,0.00012991436],"genre_scores_gemma":[0.9901424,0.007842514,0.0009468038,0.00065015483,0.00037575117,0.0000024538813,0.000004118847,0.0000076079205,0.000028164635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776554,0.00048950495,0.0012482012,0.00021198444,0.00010733122,0.00017746216],"domain_scores_gemma":[0.99765605,0.00071398343,0.0010942441,0.00014519916,0.00022038768,0.00017013264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024066847,0.000119867516,0.00089312857,0.000022560962,0.00003395833,0.0000048795264,0.000120115015,0.00028155505,0.000005584445],"category_scores_gemma":[0.0049947943,0.000088036715,0.00010891763,0.000035224504,0.00054094504,0.000006098982,0.00013992032,0.0002768155,0.000001062105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014033808,0.00054036465,0.7693937,0.000030096748,0.00015845719,0.000012806066,0.00006525829,5.7154233e-7,0.005822473,0.00003687347,0.0023568822,0.22017919],"study_design_scores_gemma":[0.0026899793,0.0073805973,0.9642717,0.000053639003,0.00018680928,0.00008402491,0.00004742178,0.000013609346,0.0014882494,0.00020113305,0.023469618,0.00011320048],"about_ca_topic_score_codex":0.0000047599183,"about_ca_topic_score_gemma":0.000011465828,"teacher_disagreement_score":0.22006598,"about_ca_system_score_codex":0.00000883925,"about_ca_system_score_gemma":0.00014937767,"threshold_uncertainty_score":0.59795964},"labels":[],"label_agreement":null},{"id":"W2253592130","doi":"10.1200/jco.2006.24.18_suppl.14516","title":"Degarelix: A gonadotropin-releasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Urology; Prostate-specific antigen; Testosterone (patch); Hormone antagonist; Cancer; Internal medicine; Gynecology; Hormone; Endocrine system","score_opus":0.14801550605174538,"score_gpt":0.5026991636283441,"score_spread":0.3546836575765987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253592130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981836,0.012251399,0.000002036581,0.0032872271,0.0010527725,0.0012308828,0.000008762343,0.000010902051,0.0003200025],"genre_scores_gemma":[0.96999115,0.026371814,0.0020488354,0.00028865956,0.00073093927,0.000066863075,0.000011505052,0.000031186202,0.00045903664],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99432606,0.001008824,0.003238231,0.0003097435,0.0005713398,0.0005458197],"domain_scores_gemma":[0.99446213,0.002946423,0.0014384222,0.00013465417,0.00078148016,0.0002368864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026682406,0.00023262601,0.0026115198,0.0004646971,0.000054654018,0.00001582424,0.00014524147,0.0001876049,0.000038043032],"category_scores_gemma":[0.004431169,0.00015694287,0.00040001847,0.00041759678,0.000501395,0.00016573543,0.00009158405,0.0013424614,0.000012348957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2682912,0.0051824176,0.70241886,0.00009478882,0.00056988146,0.0005483002,0.00047479518,0.00004823272,0.0006396934,0.000016164415,0.0015611293,0.020154549],"study_design_scores_gemma":[0.5419412,0.0038140286,0.45008346,0.0012359374,0.00028097277,0.000012686222,0.0003082618,0.00018222172,0.0001264514,0.000189782,0.0016648435,0.00016014816],"about_ca_topic_score_codex":0.0009165014,"about_ca_topic_score_gemma":0.00067088497,"teacher_disagreement_score":0.27365002,"about_ca_system_score_codex":0.0012619987,"about_ca_system_score_gemma":0.0011992601,"threshold_uncertainty_score":0.63999444},"labels":[],"label_agreement":null},{"id":"W2253719211","doi":"10.1200/jco.2007.25.18_suppl.18010","title":"Treatment patterns and clinical outcomes in lung cancer patients with brain metastasis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Brain metastasis; Radiosurgery; Lung cancer; Univariate analysis; Cancer; Multivariate analysis; Internal medicine; Odds ratio; Oncology; Metastasis; Radiation therapy; Surgery","score_opus":0.07409255344312178,"score_gpt":0.538988027168225,"score_spread":0.46489547372510326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253719211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904455,0.0002421319,0.00014582626,0.0077824118,0.0006027305,0.00031744098,0.00001711914,0.000004261393,0.0004425953],"genre_scores_gemma":[0.9948099,0.00077474606,0.0016814156,0.0021550078,0.0002960784,0.000005848201,0.000005026152,0.000013268782,0.00025867324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973379,0.00017597077,0.0018748996,0.00017802279,0.00022834653,0.00020489043],"domain_scores_gemma":[0.9958953,0.0025226471,0.0009001055,0.00010927252,0.00021647036,0.0003561892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013335061,0.00013247265,0.0012959263,0.00012632589,0.000024710145,0.0000058434616,0.00004836266,0.0001811264,0.00007071763],"category_scores_gemma":[0.0006889077,0.00006984884,0.00027769065,0.00008474909,0.00010479889,0.00008346643,0.00001691672,0.00036479137,0.0000012121741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016987814,0.0034933873,0.7816967,0.000008934388,0.0014030599,0.00039029345,0.000100987476,0.000001618333,1.8642416e-7,0.000011699633,0.00016137313,0.21103302],"study_design_scores_gemma":[0.024868064,0.016241135,0.94888335,0.00006424939,0.0014835079,0.000028688213,0.00008799698,0.000008983172,0.000002256477,0.000012207123,0.0082559325,0.000063629595],"about_ca_topic_score_codex":0.00036053063,"about_ca_topic_score_gemma":0.0025798585,"teacher_disagreement_score":0.21096939,"about_ca_system_score_codex":0.00038979997,"about_ca_system_score_gemma":0.00089989137,"threshold_uncertainty_score":0.2848353},"labels":[],"label_agreement":null},{"id":"W2254016336","doi":"10.1200/jco.2005.23.16_suppl.1023","title":"PSA screening rate and prostate cancer mortality reduction in the province of Quebec","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Demography; Mortality rate; Population; Prostate cancer; Cause of death; Cancer; Internal medicine; Environmental health; Disease","score_opus":0.40409189082213975,"score_gpt":0.6509092135970678,"score_spread":0.24681732277492802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254016336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222648,0.00080849533,0.00003362998,0.074194916,0.0009885764,0.00043227655,0.00000385765,0.000002766562,0.0012706514],"genre_scores_gemma":[0.9930864,0.0015535306,0.0007962774,0.0019080737,0.0019441041,0.0000147637265,3.5470882e-7,0.00000584589,0.00069062924],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9882508,0.008252479,0.0029623057,0.00011750391,0.00020522429,0.00021172114],"domain_scores_gemma":[0.9902721,0.0053198067,0.0038274603,0.00012324433,0.0003364409,0.00012093068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028624438,0.000069261216,0.00069625897,0.000056429257,0.00011885198,0.0000044156604,0.00012650256,0.00029516965,0.00005973385],"category_scores_gemma":[0.0037321623,0.000039455528,0.00007948823,0.000104915394,0.0001230909,0.0003281723,0.000030839936,0.0017620756,0.0000029568166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001339648,0.00028163294,0.39875165,0.00024794365,0.00007257225,0.000047970574,0.0045196135,0.000068458736,0.00006197977,0.00050709484,0.005868922,0.5882325],"study_design_scores_gemma":[0.001337936,0.00075261906,0.6559345,0.0002753435,0.00003810051,0.000018969753,0.0032269335,0.00006672287,0.0000037219663,0.0001383516,0.3381672,0.000039615734],"about_ca_topic_score_codex":0.012526949,"about_ca_topic_score_gemma":0.08668726,"teacher_disagreement_score":0.5881929,"about_ca_system_score_codex":0.000104329534,"about_ca_system_score_gemma":0.003636733,"threshold_uncertainty_score":0.9940487},"labels":[],"label_agreement":null},{"id":"W2254206427","doi":"10.1200/jco.2009.27.15_suppl.10531","title":"Utility of total body FDG PET/CT imaging in the initial staging of soft-tissue sarcoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Lakeshore General Hospital; Montreal General Hospital","funders":"","keywords":"Medicine; Sarcoma; Radiology; Leiomyosarcoma; Soft tissue; Synovial sarcoma; Chondrosarcoma; Soft tissue sarcoma; Stage (stratigraphy); Liposarcoma; Rhabdomyosarcoma; Biopsy; Alveolar soft part sarcoma; Primary tumor; Physical examination; Cancer; Metastasis; Pathology; Internal medicine","score_opus":0.11785991876947141,"score_gpt":0.4975992828684204,"score_spread":0.37973936409894904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254206427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832287,0.0009838542,0.00003823389,0.012096115,0.00034724502,0.00018405404,0.0000042591632,0.0000032748158,0.003114289],"genre_scores_gemma":[0.9969455,0.00014533523,0.0010490323,0.0014700753,0.00037221014,0.000001332976,0.0000016175363,0.0000063744346,0.0000085174315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618316,0.000590179,0.002455914,0.00014385144,0.00041553206,0.0002113674],"domain_scores_gemma":[0.9947367,0.0032795821,0.0013720358,0.00023344785,0.00024343861,0.00013479468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003384848,0.00012279811,0.001345701,0.00013170528,0.00002213553,0.000004899487,0.00016758654,0.00003774874,0.00013658412],"category_scores_gemma":[0.0023376474,0.000073869174,0.0004326639,0.0001468303,0.00021646007,0.0000870544,0.00003339694,0.0006639532,0.0000025199336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013312845,0.006883771,0.6432936,0.000019355859,0.000096751515,0.00820331,0.00014409167,0.0000034138602,0.00016642355,0.00015948998,0.0007207333,0.33897778],"study_design_scores_gemma":[0.0065780138,0.005526961,0.97993565,0.00014607229,0.0002746522,0.0030516824,0.0004236059,0.0001567357,0.0007703298,0.0007300178,0.0023508715,0.000055416633],"about_ca_topic_score_codex":0.000067173576,"about_ca_topic_score_gemma":0.0000171198,"teacher_disagreement_score":0.33892235,"about_ca_system_score_codex":0.000048557395,"about_ca_system_score_gemma":0.00065529905,"threshold_uncertainty_score":0.30122977},"labels":[],"label_agreement":null},{"id":"W2254400861","doi":"10.1200/jco.2015.33.18_suppl.lba8512","title":"Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Neutropenia; Pomalidomide; Population; Refractory (planetary science); Nausea; Gastroenterology; Clinical endpoint; Adverse effect; Carfilzomib; Multiple myeloma; Phases of clinical research; Surgery; Lenalidomide; Clinical trial; Chemotherapy","score_opus":0.23382234559224524,"score_gpt":0.5029430214787639,"score_spread":0.26912067588651867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254400861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972486,0.00041056125,0.000013060766,0.000378979,0.00034668884,0.001334729,0.000010960735,0.0000075156836,0.0002489303],"genre_scores_gemma":[0.99695575,0.0003407628,0.0019817518,0.0001342288,0.00028044265,0.000017213595,0.000007509793,0.00003398349,0.0002483797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99482226,0.0005988742,0.0029096806,0.00028393848,0.0010435123,0.00034174847],"domain_scores_gemma":[0.9937434,0.0013062145,0.0023497932,0.00042907332,0.0015925767,0.0005789128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022097349,0.00024713314,0.0022590305,0.00037162774,0.000044579752,0.0000058004816,0.00028631746,0.00030632032,0.000097684286],"category_scores_gemma":[0.0019312686,0.0001360269,0.0002466184,0.00036033004,0.00026226195,0.00020692796,0.00006445282,0.0008494111,0.000003694526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27060616,0.08668393,0.4664149,0.000017703784,0.0007486548,0.00040747138,0.000781256,0.000013349996,0.000106884894,7.851802e-7,0.00033860424,0.17388032],"study_design_scores_gemma":[0.29903257,0.28654668,0.4085755,0.00009664093,0.00008708244,0.000016971257,0.0004106607,0.00007646403,0.00036178404,0.0000069409043,0.0047023348,0.00008633796],"about_ca_topic_score_codex":0.00016801302,"about_ca_topic_score_gemma":0.00045999303,"teacher_disagreement_score":0.19986276,"about_ca_system_score_codex":0.00018997694,"about_ca_system_score_gemma":0.0021580022,"threshold_uncertainty_score":0.55470157},"labels":[],"label_agreement":null},{"id":"W2254803621","doi":"10.1200/jco.2006.24.18_suppl.10029","title":"Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"","keywords":"TMPRSS2; Fusion gene; Cancer research; Chromoplexy; Erg; Biology; Exon; ETS transcription factor family; Prostate cancer; Gene; Prostate; Genetics; Cancer; Transcription factor; Medicine; Pathology; PCA3; Disease","score_opus":0.1431247354124861,"score_gpt":0.46111072018170046,"score_spread":0.31798598476921436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254803621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091154,0.0018892774,0.0030188386,0.0022574677,0.0011811194,0.0005179935,0.00003610368,0.0000063192792,0.0001813109],"genre_scores_gemma":[0.993517,0.0034970916,0.0016159932,0.000090124384,0.00050557405,0.000011447738,0.000009660317,0.000017790368,0.00073536445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99669904,0.00022556694,0.002160174,0.00019629908,0.0004585902,0.00026035786],"domain_scores_gemma":[0.99710697,0.00043842898,0.0013947674,0.0001486275,0.0007024531,0.00020875604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014403855,0.00014061997,0.0010059206,0.00028035365,0.000052374246,0.0000068345553,0.000118068645,0.00029511715,0.000079640595],"category_scores_gemma":[0.00021192325,0.00009636563,0.00036077568,0.0002501334,0.00019215894,0.000100697725,0.000027278289,0.0006761829,0.0000025580293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02308209,0.02207862,0.17545961,0.00043931056,0.0013419164,0.000988197,0.00060816604,0.0035428891,0.6038909,0.00032940527,0.0006150169,0.16762388],"study_design_scores_gemma":[0.06649753,0.016302943,0.8690746,0.00037970342,0.0011069665,0.0005492097,0.00015105122,0.0046477946,0.027685897,0.00018778541,0.013192144,0.0002244158],"about_ca_topic_score_codex":0.00054271135,"about_ca_topic_score_gemma":0.00074655336,"teacher_disagreement_score":0.69361496,"about_ca_system_score_codex":0.00045533304,"about_ca_system_score_gemma":0.0027898834,"threshold_uncertainty_score":0.4949133},"labels":[],"label_agreement":null},{"id":"W2254809488","doi":"10.1200/jco.2013.31.26_suppl.102","title":"Are high mastectomy rates associated with unwanted variation in other aspects of breast cancer treatment? An overview of practice patterns in Alberta, Canada in 2009-2010.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Medicine; Mastectomy; Breast cancer; Guideline; Cancer; Adjuvant therapy; Cohort; Family medicine; Internal medicine; Pathology","score_opus":0.053928615758874636,"score_gpt":0.392207291402269,"score_spread":0.33827867564339437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254809488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948709,0.00057948194,0.000002569017,0.0039950777,0.0001690293,0.0001871582,0.00007716254,6.3226514e-7,0.00011800109],"genre_scores_gemma":[0.9983502,0.00090404984,0.000086004904,0.00048934214,0.00009557382,0.000020897529,0.000008780159,0.000013646709,0.000031479776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976635,0.0006421421,0.0011632434,0.00018765448,0.00015957972,0.00018386787],"domain_scores_gemma":[0.99630076,0.00070342055,0.0023911672,0.00013535915,0.0003980583,0.00007124337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049664953,0.0001477285,0.000915893,0.00007951925,0.000008908098,0.0000032973594,0.00011151208,0.00021660679,0.000074632575],"category_scores_gemma":[0.00076760683,0.00010375742,0.00007000203,0.00017539534,0.000058691327,0.00002772766,0.000024145145,0.00019316972,2.979296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014843638,0.0022025963,0.99139446,0.000016122744,0.0005303085,0.00007039978,0.00011519879,0.000265351,0.00048393273,0.000010163767,0.00008931078,0.0033377626],"study_design_scores_gemma":[0.007498912,0.0018059019,0.9891299,0.00024946692,0.000107530206,0.000026825865,0.000207359,0.000016759292,0.0005356228,0.00003123487,0.00029904375,0.00009141287],"about_ca_topic_score_codex":0.7236522,"about_ca_topic_score_gemma":0.97712606,"teacher_disagreement_score":0.25347388,"about_ca_system_score_codex":0.00037914465,"about_ca_system_score_gemma":0.0016310907,"threshold_uncertainty_score":0.42311049},"labels":[],"label_agreement":null},{"id":"W2255123514","doi":"10.1200/jco.2007.25.18_suppl.6562","title":"Primary care physician willingness to provide follow-up care for adult cancer survivors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Referral; Family medicine; Cancer; Modalities; Primary care; Confidence interval; Health care; Colorectal cancer; Internal medicine","score_opus":0.2539365942704065,"score_gpt":0.5793756899947161,"score_spread":0.3254390957243096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255123514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600677,0.00071029033,0.008064056,0.020208575,0.007810536,0.0013879613,0.000041279163,0.000024455381,0.001685138],"genre_scores_gemma":[0.89699316,0.00033696715,0.027992634,0.06551773,0.008762605,0.000033370638,0.000060152433,0.00006348395,0.00023989155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932846,0.00026391022,0.005042834,0.00034334228,0.00062167586,0.00044366252],"domain_scores_gemma":[0.9805841,0.009071004,0.0028010514,0.00027234457,0.0066018505,0.00066965184],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050549875,0.00020963163,0.0017724201,0.0001335425,0.000089754016,0.000013941542,0.0002447326,0.00042546086,0.000030406345],"category_scores_gemma":[0.026956689,0.00016468277,0.00082660455,0.00025599834,0.0001047128,0.00023267823,0.00007261236,0.0009658399,0.000013112023],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016722951,0.00051070104,0.10022894,0.00037858202,0.00029285962,0.00012539366,0.0013194178,0.00004558218,0.0003952869,0.000040022984,0.0069791083,0.87296116],"study_design_scores_gemma":[0.025154343,0.02159642,0.22404261,0.0005509349,0.0018855839,0.00007080338,0.018752296,0.000033932938,0.0006584274,0.00017291286,0.70673776,0.0003439547],"about_ca_topic_score_codex":0.00067390804,"about_ca_topic_score_gemma":0.014296705,"teacher_disagreement_score":0.8726172,"about_ca_system_score_codex":0.0007763286,"about_ca_system_score_gemma":0.0037876659,"threshold_uncertainty_score":0.9812397},"labels":[],"label_agreement":null},{"id":"W2255227919","doi":"10.1200/jco.2013.31.15_suppl.8027","title":"Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Trametinib; KRAS; Internal medicine; Lung cancer; Tolerability; Oncology; Response Evaluation Criteria in Solid Tumors; MEK inhibitor; Adverse effect; Cancer; Phases of clinical research; Chemotherapy; Gastroenterology; Colorectal cancer; Cisplatin; Kinase; MAPK/ERK pathway","score_opus":0.05341897179698591,"score_gpt":0.47188179646885986,"score_spread":0.41846282467187396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255227919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876654,0.0009221398,0.00048410837,0.0063791024,0.0015090107,0.002495528,0.000012634368,0.000009764959,0.00052229746],"genre_scores_gemma":[0.9845537,0.0009323355,0.011802641,0.0013614517,0.00062716013,0.00020752329,0.00001632183,0.000033775803,0.00046512522],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721307,0.00019661839,0.0017433187,0.00028971513,0.0002602401,0.00029702904],"domain_scores_gemma":[0.9959612,0.0014062615,0.0013432786,0.00014779287,0.00077812927,0.0003633633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011849971,0.00020715338,0.0014062554,0.00019160598,0.000057488876,0.000024686267,0.00009371799,0.00027183417,0.00010406035],"category_scores_gemma":[0.00092131144,0.00013549229,0.00022193963,0.00028272436,0.0001198244,0.0002363555,0.000021175165,0.0005469988,0.000002224213],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25946203,0.029273856,0.05855913,0.00048667475,0.0019304254,0.00051539904,0.0017807306,0.00013363738,0.0083856005,0.0000806984,0.011856322,0.62753546],"study_design_scores_gemma":[0.8078932,0.113139935,0.030028302,0.0007724127,0.0033475435,0.000084726686,0.00092233834,0.0019327247,0.0014499907,0.0002587118,0.039796166,0.00037390296],"about_ca_topic_score_codex":0.00013215543,"about_ca_topic_score_gemma":0.00024693864,"teacher_disagreement_score":0.62716156,"about_ca_system_score_codex":0.0003224486,"about_ca_system_score_gemma":0.0023606494,"threshold_uncertainty_score":0.5525215},"labels":[],"label_agreement":null},{"id":"W2255387339","doi":"10.1200/jco.2012.30.15_suppl.7511","title":"A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC):  NCIC Clinical Trials Group study BR29.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université Laval; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; Juravinski Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Clinical endpoint; Placebo; Progression-free survival; Interim analysis; Toxicity; Randomized controlled trial; Urology; Surgery; Chemotherapy; Confidence interval; Pathology","score_opus":0.11957790843673835,"score_gpt":0.4782846970651768,"score_spread":0.3587067886284384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255387339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596346,0.00042999798,0.00011759313,0.00010950711,0.0020741336,0.0110006025,0.00008757576,0.00001596813,0.00020114846],"genre_scores_gemma":[0.9940466,0.0008118658,0.0029197983,0.000118882985,0.0015366821,0.0003275977,0.000045345707,0.00008335939,0.000109831715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9839493,0.0057046935,0.008136025,0.000557121,0.0010426841,0.0006101554],"domain_scores_gemma":[0.9818214,0.00853391,0.0073181908,0.0004526226,0.0010274961,0.00084633555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0134463925,0.00054545625,0.00820332,0.00037780683,0.000059797494,0.000017372231,0.00028984694,0.0006560523,0.00022621774],"category_scores_gemma":[0.0052137375,0.0002914649,0.0010762524,0.0004693614,0.00041278958,0.0004359267,0.000051837345,0.0012233147,0.0000015014598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72536844,0.019816373,0.24069123,0.00012303445,0.0026874645,0.00006074015,0.0019591774,0.000054789965,0.000032842272,0.0000025650222,0.0000660015,0.009137349],"study_design_scores_gemma":[0.8540016,0.09223245,0.043710545,0.0005818217,0.00819582,0.000008860887,0.00062836445,0.000044510478,0.00010147059,0.0000026927733,0.00022503673,0.00026682916],"about_ca_topic_score_codex":0.0009506859,"about_ca_topic_score_gemma":0.0015525526,"teacher_disagreement_score":0.19698068,"about_ca_system_score_codex":0.0005387549,"about_ca_system_score_gemma":0.0049940078,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W2255593359","doi":"10.1200/jco.2007.25.18_suppl.4068","title":"Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Development Research Centre","funders":"","keywords":"Medicine; Irinotecan; Bevacizumab; FOLFIRI; Regimen; Colorectal cancer; Internal medicine; Oncology; Phases of clinical research; Fluorouracil; Surgery; Chemotherapy; Cancer","score_opus":0.08033455945256691,"score_gpt":0.46179922526821926,"score_spread":0.38146466581565236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255593359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973516,0.0006799092,0.000017834895,0.0007013638,0.00034145813,0.00064064795,0.000014338462,0.0000037883408,0.00024905277],"genre_scores_gemma":[0.998613,0.0005091747,0.00045721713,0.00018982033,0.00017849522,0.000011083774,0.0000027555438,0.0000126498335,0.00002581108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690133,0.00014872229,0.0020017526,0.0002070359,0.0005026216,0.00023851387],"domain_scores_gemma":[0.9963893,0.001473418,0.0012640659,0.000094642346,0.000522366,0.00025616895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014754726,0.0001768104,0.0017538988,0.00020698027,0.00005392982,0.0000037111001,0.0000830826,0.000112467584,0.000069231945],"category_scores_gemma":[0.000780587,0.000108078275,0.0001345818,0.00023278566,0.00023977082,0.000076047465,0.000077358345,0.000566132,5.274075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07222779,0.023672814,0.71649295,0.000034956982,0.0008090021,0.0008237204,0.00088471343,0.000029825815,0.000004448191,0.00000384342,0.00007561663,0.18494031],"study_design_scores_gemma":[0.08905548,0.15688874,0.75157195,0.000093422,0.00061905023,0.000044759694,0.00049292704,0.00006246654,0.000012813779,0.000015366842,0.001066259,0.00007675106],"about_ca_topic_score_codex":0.00038095034,"about_ca_topic_score_gemma":0.01449056,"teacher_disagreement_score":0.18486355,"about_ca_system_score_codex":0.00038747813,"about_ca_system_score_gemma":0.00078305876,"threshold_uncertainty_score":0.8086073},"labels":[],"label_agreement":null},{"id":"W2255616997","doi":"10.1200/jco.2009.27.15_suppl.e17502","title":"Cost-effectiveness of capecitabine in combination with oxaliplatin (XELOX) compared with FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Ottawa Hospital","funders":"","keywords":"Capecitabine; Oxaliplatin; Medicine; FOLFOX; Regimen; Oncology; Colorectal cancer; Internal medicine; Fluorouracil; Chemotherapy; Cost effectiveness; Cancer","score_opus":0.19113846991881533,"score_gpt":0.4913025290660242,"score_spread":0.30016405914720884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255616997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932936,0.0012784827,0.00012869424,0.002458276,0.00016746549,0.002359321,0.000024107432,0.0000015327845,0.00028852036],"genre_scores_gemma":[0.99829406,0.000492698,0.00087138976,0.00007391842,0.000057171543,0.00018451952,0.000009755423,0.000006836838,0.000009674128],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980647,0.00036211772,0.0009888336,0.00012216612,0.00030692262,0.00015526416],"domain_scores_gemma":[0.9947217,0.0030585756,0.0010063269,0.00008111017,0.0010172344,0.00011503684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018116339,0.00012420163,0.0013507343,0.00014049446,0.000041456307,0.000002742336,0.000055914246,0.00006572299,0.000020924756],"category_scores_gemma":[0.00040138158,0.0000605018,0.00016077851,0.00022015524,0.0001534296,0.00004552561,0.0000026823982,0.00012498719,9.4892506e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.099660195,0.009093254,0.34714597,0.00009770616,0.003196309,0.00010639587,0.0018770918,0.0029895462,0.00023336886,0.00018871858,0.00010694262,0.5353045],"study_design_scores_gemma":[0.039726656,0.105877526,0.84853554,0.00020796397,0.0017817015,0.00004361524,0.0004745565,0.0020230399,0.00044504466,0.00013618833,0.00069250044,0.000055661767],"about_ca_topic_score_codex":0.00985608,"about_ca_topic_score_gemma":0.21628095,"teacher_disagreement_score":0.5352488,"about_ca_system_score_codex":0.001078332,"about_ca_system_score_gemma":0.0030614987,"threshold_uncertainty_score":0.99673736},"labels":[],"label_agreement":null},{"id":"W2256261346","doi":"10.1200/jco.2007.25.18_suppl.8089","title":"Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non- Hodgkin lymphoma (NHL)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Cost effectiveness; Oncology; Internal medicine; Regimen; Progression-free survival; Overall survival","score_opus":0.1402994411472832,"score_gpt":0.4780220877665644,"score_spread":0.3377226466192812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256261346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926651,0.0032549652,0.00013521835,0.0008227304,0.00043480992,0.0008057479,0.000006269097,0.000005237123,0.0018699251],"genre_scores_gemma":[0.995791,0.0025875322,0.0010681864,0.00022376544,0.00024456502,0.00001916497,0.000003985173,0.000020145966,0.000041658986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958777,0.0005227472,0.002616327,0.00028174085,0.00037039895,0.0003311166],"domain_scores_gemma":[0.99207014,0.0052727326,0.0016972905,0.0002854047,0.00032913778,0.00034529882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035529274,0.0002577167,0.0026912636,0.000307758,0.000026691027,0.0000050496674,0.00012402737,0.0003884984,0.00002564361],"category_scores_gemma":[0.0003433586,0.00017022854,0.00062012015,0.0002469044,0.00031371068,0.000087980894,0.000041810254,0.0001682566,0.0000032460732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019446315,0.016650243,0.51259726,0.000114739116,0.0011771021,0.0020181632,0.00027937663,0.000014490231,0.002763521,0.00017554489,0.000049660062,0.4447136],"study_design_scores_gemma":[0.050340377,0.046162326,0.8759785,0.00041759116,0.00088882924,0.0007942579,0.0001540718,0.00004143073,0.022383882,0.00014402623,0.0025812762,0.00011341201],"about_ca_topic_score_codex":0.0001857874,"about_ca_topic_score_gemma":0.0000873095,"teacher_disagreement_score":0.44460016,"about_ca_system_score_codex":0.00076143135,"about_ca_system_score_gemma":0.0010501185,"threshold_uncertainty_score":0.69417185},"labels":[],"label_agreement":null},{"id":"W2256341952","doi":"10.1200/jco.2015.63.0970","title":"Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":361,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation Gustave Roussy; Canadian Cancer Society Research Institute; Institut Gustave-Roussy; National Cancer Institute; Institut National Du Cancer; Princess Margaret Cancer Foundation; Sanofi","keywords":"Medicine; Lung cancer; Internal medicine; Hazard ratio; Proportional hazards model; Cisplatin; Oncology; Adjuvant; Chemotherapy; Gastroenterology; Confidence interval","score_opus":0.04683284203138601,"score_gpt":0.42856472358863434,"score_spread":0.38173188155724835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256341952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944017,0.0015224006,0.00007802504,0.001573808,0.0009097582,0.00038953597,0.0000020817613,0.0000035527146,0.0011191614],"genre_scores_gemma":[0.9970511,0.0013736801,0.00024649952,0.00049803057,0.0005097824,0.000014898991,3.8480533e-7,0.000012102464,0.0002934831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971031,0.00042003766,0.0019190288,0.00013158927,0.00022682134,0.00019941285],"domain_scores_gemma":[0.9944416,0.0037018335,0.0013736961,0.00013423829,0.00021674675,0.00013184204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038517695,0.00010686,0.0011024148,0.00015457378,0.000013438649,0.0000033129497,0.000118597025,0.0002101078,0.00021225293],"category_scores_gemma":[0.0025026598,0.000056880905,0.00032209046,0.00019181539,0.00014295668,0.00008575125,0.00001915015,0.00030673906,0.0000035632181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03810779,0.00050814456,0.8187844,0.00027464767,0.00023354572,0.0002801115,0.00006287997,0.000010813086,0.056476016,0.0000023066802,0.0017298254,0.08352953],"study_design_scores_gemma":[0.067854345,0.04149085,0.8413135,0.0025060747,0.0007073568,0.00031455114,0.000033437154,0.0003564497,0.03811988,0.00003402751,0.0071102204,0.00015933107],"about_ca_topic_score_codex":0.00016846383,"about_ca_topic_score_gemma":0.0001915559,"teacher_disagreement_score":0.0833702,"about_ca_system_score_codex":0.00061850064,"about_ca_system_score_gemma":0.0036286002,"threshold_uncertainty_score":0.6436981},"labels":[],"label_agreement":null},{"id":"W2256348337","doi":"10.1200/jco.2014.32.31_suppl.177","title":"Association of high symptom burden with oral oncolytic agents.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cancer; Intensive care medicine; Physical therapy; Emergency medicine","score_opus":0.09281297926713751,"score_gpt":0.48303408801951325,"score_spread":0.39022110875237576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256348337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743512,0.00008577178,0.00009707026,0.01717136,0.0013209777,0.00014294365,0.000002078944,0.00000683145,0.0068217167],"genre_scores_gemma":[0.9912698,0.00023136697,0.0016254451,0.0019645905,0.0019301089,0.0000023898108,0.0000032407002,0.000011747853,0.002961255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975311,0.00043123125,0.0014004535,0.00011453898,0.00034941998,0.0001732517],"domain_scores_gemma":[0.99460804,0.0022836265,0.0022855396,0.00010667625,0.0004856294,0.00023049697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025008365,0.00009875938,0.0014080092,0.00009128632,0.000018930483,0.0000030334677,0.00009821889,0.0003043486,0.0005734767],"category_scores_gemma":[0.0012721383,0.000063681786,0.00027613857,0.00011256693,0.00009588764,0.000059963753,0.000021022852,0.0005347921,0.000021370895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014957982,0.004699049,0.62120175,0.000074341326,0.0038961568,0.0003462948,0.00026105042,0.00014625907,0.00042465585,0.00036500854,0.085580885,0.2680466],"study_design_scores_gemma":[0.03096048,0.054915097,0.5468093,0.00009436492,0.0029430857,0.00017674355,0.0000331475,0.00017780514,0.00022032583,0.0005634149,0.36301214,0.000094095776],"about_ca_topic_score_codex":0.00006807408,"about_ca_topic_score_gemma":0.00007944965,"teacher_disagreement_score":0.27743125,"about_ca_system_score_codex":0.00036763508,"about_ca_system_score_gemma":0.0009996814,"threshold_uncertainty_score":0.6279168},"labels":[],"label_agreement":null},{"id":"W2256373696","doi":"10.1200/jco.2004.22.90140.1534","title":"Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O<sub>2</sub>), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Clinical endpoint; Hazard ratio; Radiation therapy; Internal medicine; Brain metastasis; Population; Breast cancer; Cancer; Randomized controlled trial; Surgery; Oncology; Urology; Metastasis; Confidence interval","score_opus":0.04056882420307413,"score_gpt":0.38717402405283513,"score_spread":0.346605199849761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256373696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796492,0.0001319833,0.00024118058,0.015538573,0.00015917492,0.004035311,0.0001748324,0.000010502083,0.00005926531],"genre_scores_gemma":[0.99264723,0.00007887755,0.0050124726,0.0018434597,0.00017845786,0.000059759368,0.00007175616,0.000050603227,0.0000573687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919112,0.0027440211,0.0031300362,0.00044954993,0.0013602593,0.00040496464],"domain_scores_gemma":[0.9921173,0.002964328,0.0034896568,0.0005217066,0.0005932097,0.00031383513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009616597,0.00039531713,0.003314113,0.0002249088,0.000090296046,0.000022602058,0.0002608332,0.00017797916,0.000030471605],"category_scores_gemma":[0.0019371873,0.00015943627,0.00043516475,0.0005290406,0.0005235035,0.00021048092,0.0000494956,0.0008549866,0.0000018247897],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7383971,0.011091095,0.22268172,0.000020596777,0.0030125978,0.00039322017,0.0010603836,0.00022656862,0.000074110074,0.000019977391,0.00097287615,0.022049712],"study_design_scores_gemma":[0.6319653,0.114289336,0.24799688,0.00023776141,0.0011625026,0.00010878956,0.00090800336,0.000007627136,0.000623627,0.000052379528,0.0024794368,0.00016839932],"about_ca_topic_score_codex":0.00015890584,"about_ca_topic_score_gemma":0.0015648722,"teacher_disagreement_score":0.10643189,"about_ca_system_score_codex":0.00042367648,"about_ca_system_score_gemma":0.002661772,"threshold_uncertainty_score":0.6501622},"labels":[],"label_agreement":null},{"id":"W2256449171","doi":"10.1200/jco.2007.25.18_suppl.14584","title":"Additional variables other than AJCC staging show clinical utility for predicting survival in colon cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Lymphovascular invasion; Univariate analysis; Colorectal cancer; Stage (stratigraphy); Cancer; Multivariate analysis; Internal medicine; Pathological; Resection margin; Survival analysis; Oncology; Cohort; Lymph node; Disease; Surgery; Metastasis; Resection","score_opus":0.20677684237006544,"score_gpt":0.4985943907539183,"score_spread":0.2918175483838529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256449171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845479,0.00016422676,0.00083248917,0.0036865019,0.0026689381,0.00030742484,0.0004941975,0.000012000273,0.007286312],"genre_scores_gemma":[0.98785007,0.00007679137,0.0032714792,0.0020228373,0.006043598,0.000012474017,0.00003502761,0.00002016776,0.0006675524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953264,0.00041759486,0.0031992462,0.00027367153,0.0003914768,0.00039161195],"domain_scores_gemma":[0.9804822,0.017034445,0.001409927,0.00011836441,0.0005291171,0.0004259493],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014038266,0.00014672325,0.0014766201,0.00013418641,0.000055107528,0.000008076989,0.00015309517,0.0005060726,0.0065905303],"category_scores_gemma":[0.011334191,0.00010975475,0.00069083314,0.00017829308,0.00026304633,0.00010310134,0.000057435856,0.0013728712,0.000004493811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012535508,0.0015000843,0.8830587,0.00004136058,0.00021456252,0.00022688384,0.000058817444,0.000006706104,0.000043085493,0.00011044058,0.017886681,0.08431714],"study_design_scores_gemma":[0.0057897624,0.0058117434,0.8005283,0.00021813223,0.00016453196,0.00005975454,0.00021236176,0.00090146554,0.00001470257,0.00054586853,0.18566053,0.00009283502],"about_ca_topic_score_codex":0.00010238938,"about_ca_topic_score_gemma":0.0024064071,"teacher_disagreement_score":0.16777384,"about_ca_system_score_codex":0.00019434466,"about_ca_system_score_gemma":0.0020764568,"threshold_uncertainty_score":0.9969938},"labels":[],"label_agreement":null},{"id":"W2256567725","doi":"10.1200/jco.2007.25.18_suppl.6529","title":"Screening cancer patients for clinical trial eligibility: A randomized study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Randomized controlled trial; Cancer; Family medicine; Physical therapy; Internal medicine","score_opus":0.8279927699718553,"score_gpt":0.7766646548168723,"score_spread":0.051328115154983034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256567725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745825,0.0002966166,0.004551656,0.00620089,0.0074767834,0.004859384,0.000005831952,0.000017520793,0.0020088474],"genre_scores_gemma":[0.96618503,0.0019848219,0.016128786,0.0050788177,0.009750717,0.000063086314,0.0000027818112,0.000044376673,0.00076157117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97493815,0.004258995,0.017036801,0.0006829464,0.0023630958,0.0007199981],"domain_scores_gemma":[0.3934576,0.5863457,0.008906129,0.00087743514,0.0083055515,0.0021076058],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.2973646,0.00023278949,0.0059660375,0.00024179461,0.00010340906,0.000022177514,0.000557036,0.0017708348,0.00013867304],"category_scores_gemma":[0.619531,0.00015044838,0.0032619662,0.0002621655,0.0012371701,0.000114106035,0.00022683042,0.007291021,0.000010361702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65328944,0.014419097,0.19295628,0.000032640677,0.0011077153,0.000086181244,0.000068617024,8.428426e-7,6.723811e-7,0.00013347155,0.0022554926,0.13564953],"study_design_scores_gemma":[0.7975481,0.08355808,0.096801534,0.00015256323,0.001239932,0.0000071849313,0.00019517116,0.000057240464,0.0000042283095,0.0045610974,0.015756145,0.00011869],"about_ca_topic_score_codex":0.00005380601,"about_ca_topic_score_gemma":0.00041858817,"teacher_disagreement_score":0.5820867,"about_ca_system_score_codex":0.00021039514,"about_ca_system_score_gemma":0.005661929,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2256596578","doi":"10.1200/jco.2005.23.16_suppl.8016","title":"Do women with primary breast cancer who experience chemotherapy-induced menopause have worse symptoms than those due to natural menopause?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Menopause; Breast cancer; Chemotherapy; Premature Menopause; Surgical Menopause; Adjuvant chemotherapy; Internal medicine; Gynecology; Clinical endpoint; Cancer; Oncology; Clinical trial","score_opus":0.0510057890791539,"score_gpt":0.4475324177660498,"score_spread":0.3965266286868959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256596578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683451,0.00080038933,0.000009216044,0.027764969,0.0011550034,0.00048727982,0.000011839494,0.000024860685,0.001401343],"genre_scores_gemma":[0.97036475,0.000932508,0.0010911522,0.021680746,0.003941874,0.00008724453,0.0000020655013,0.00004674604,0.0018529008],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965058,0.00029977493,0.0016262132,0.0004130726,0.0005341894,0.0006209383],"domain_scores_gemma":[0.99642766,0.00068914396,0.0011375628,0.00030121286,0.0004551746,0.0009892621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012325771,0.00033301834,0.002017061,0.000192716,0.000078883946,0.000023309909,0.00032009793,0.00033549342,0.0012688836],"category_scores_gemma":[0.00011245875,0.00021237762,0.000181057,0.00025639823,0.00022948184,0.0002703331,0.00007702521,0.0011813955,0.000025578729],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1032846,0.007060155,0.07104868,0.000052375573,0.0028618644,0.002920507,0.012763871,0.00004174133,0.021842033,0.000024902696,0.012724028,0.76537526],"study_design_scores_gemma":[0.04160051,0.050967388,0.7205322,0.00046118296,0.0008968918,0.0049680043,0.001188957,0.00003545241,0.0024893805,0.000038532264,0.17625421,0.0005673172],"about_ca_topic_score_codex":0.000052437597,"about_ca_topic_score_gemma":0.0002110127,"teacher_disagreement_score":0.76480794,"about_ca_system_score_codex":0.0014319217,"about_ca_system_score_gemma":0.0020459339,"threshold_uncertainty_score":0.9996441},"labels":[],"label_agreement":null},{"id":"W2256636924","doi":"10.1200/jco.2009.27.15_suppl.5012","title":"Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Clinical endpoint; Prednisone; Internal medicine; Clusterin; Urology; Gastroenterology; Prostate cancer; Oncology; Surgery; Chemotherapy; Cancer; Randomized controlled trial; Apoptosis","score_opus":0.06752239049819722,"score_gpt":0.4470934402889443,"score_spread":0.3795710497907471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256636924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946601,0.0002642954,0.0000206947,0.0019938182,0.0003162256,0.002472993,0.000061335224,0.000006724215,0.00020380922],"genre_scores_gemma":[0.99708784,0.00011530634,0.002468877,0.00014136605,0.000060170827,0.000043068063,0.000024371997,0.000020174479,0.00003882448],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920473,0.0015410383,0.004923459,0.0003537497,0.00083365024,0.00030081585],"domain_scores_gemma":[0.991166,0.0021207717,0.004970532,0.0003381655,0.0011716874,0.00023287292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004318278,0.00026880842,0.003814285,0.00049814483,0.00003013533,0.000006664032,0.00018950674,0.0002173735,0.000033219167],"category_scores_gemma":[0.004368929,0.00017367542,0.00024021351,0.0005577745,0.00038309436,0.00018920156,0.000044455333,0.0008724113,4.3769677e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9174012,0.047136486,0.021590006,0.00009682215,0.0007261122,0.00085844233,0.002439697,0.00064152054,0.00018195734,0.000022257364,0.00009154728,0.008813953],"study_design_scores_gemma":[0.603809,0.12581736,0.26769707,0.00041232014,0.0011825683,0.000022399334,0.00065677264,0.0001506961,0.000041572326,0.000080241436,0.000025006992,0.00010500509],"about_ca_topic_score_codex":0.00016474337,"about_ca_topic_score_gemma":0.0012706015,"teacher_disagreement_score":0.31359223,"about_ca_system_score_codex":0.00023260484,"about_ca_system_score_gemma":0.0013770472,"threshold_uncertainty_score":0.7082278},"labels":[],"label_agreement":null},{"id":"W2256750332","doi":"10.1200/jco.2008.26.15_suppl.22047","title":"Statins and superficial bladder cancer evolution after diagnosis: A population-based study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Hazard ratio; Statin; Proportional hazards model; Internal medicine; Cohort; Cancer registry; Medical prescription; Cancer; Population; Incidence (geometry); Surgery; Confidence interval","score_opus":0.05440899082685702,"score_gpt":0.41096478104563117,"score_spread":0.35655579021877415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256750332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897139,0.0029574018,0.00020142294,0.000575761,0.006336812,0.00015813381,0.000015253787,0.0000027009303,0.00003862937],"genre_scores_gemma":[0.9797526,0.0015040347,0.00039510464,0.0010051421,0.017213885,0.000037553007,0.0000042208494,0.000012650509,0.000074797106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980892,0.0003450402,0.001017014,0.00019923937,0.00018836396,0.00016112963],"domain_scores_gemma":[0.9987493,0.00018176758,0.00050802156,0.00012497067,0.00026302823,0.0001729229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078204705,0.00011172453,0.00053479354,0.000057388454,0.00006239001,0.000006053631,0.00009252178,0.0002424894,0.00007097423],"category_scores_gemma":[0.0008256561,0.00008971769,0.00019055793,0.000058327525,0.00009744204,0.000008913255,0.000035024106,0.00026523453,0.0000014087492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016002079,0.0010155467,0.97654563,0.000004458985,0.00015087384,0.000005449051,0.00009899963,0.00011424021,0.00027299084,0.000005195764,0.008004192,0.012182239],"study_design_scores_gemma":[0.0031827863,0.0033739766,0.87393314,0.000008608517,0.00013827899,0.00001844921,0.00010532298,0.000021124783,0.00003517601,0.000024483374,0.11906161,0.000097053846],"about_ca_topic_score_codex":0.0003005261,"about_ca_topic_score_gemma":0.0021179304,"teacher_disagreement_score":0.11105742,"about_ca_system_score_codex":0.000042934094,"about_ca_system_score_gemma":0.001100316,"threshold_uncertainty_score":0.3658581},"labels":[],"label_agreement":null},{"id":"W2256921387","doi":"10.1200/jco.2009.27.15_suppl.e20743","title":"The use of cannabinoids (CBs) for the treatment of chemotherapy-induced peripheral neuropathy (CIPN): A retrospective review","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"","keywords":"Medicine; Chemotherapy-induced peripheral neuropathy; Vinca; Peripheral neuropathy; Chemotherapy; Internal medicine; Adverse effect; Retrospective cohort study; Oncology; Pharmacology","score_opus":0.38711644627992725,"score_gpt":0.5653654352153523,"score_spread":0.17824898893542507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256921387","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052109594,0.9865542,0.000007705016,0.008064254,0.0018194119,0.00286009,0.00003762013,0.0000047122635,0.0001308959],"genre_scores_gemma":[0.00009222932,0.99425644,0.00025018954,0.0021132573,0.002067297,0.00010992339,0.000006491689,0.00004447667,0.0010596896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934754,0.0011428944,0.004451382,0.00028162368,0.0003415089,0.00030723377],"domain_scores_gemma":[0.9845787,0.00712008,0.0067517166,0.00049779704,0.0008408354,0.00021084986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020878606,0.00041532595,0.007463418,0.00008384636,0.000082877676,0.000007819109,0.00034890065,0.0005238634,0.00009823268],"category_scores_gemma":[0.0015833292,0.00017276099,0.0043408293,0.0002656781,0.000366674,0.000045145476,0.000020992517,0.0008581749,0.0000013758889],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028519267,0.0030371596,0.000083531406,0.0020990863,0.003006497,0.00008125602,0.000058189304,3.678291e-7,0.000003059388,0.00002747089,0.016527496,0.97222394],"study_design_scores_gemma":[0.0056294785,0.07098272,0.0010223531,0.0044974294,0.014158315,0.0003144077,0.000006363391,0.0000048167494,0.0000038782005,0.000021145406,0.90325445,0.000104649574],"about_ca_topic_score_codex":0.000047809477,"about_ca_topic_score_gemma":0.000059710484,"teacher_disagreement_score":0.97211933,"about_ca_system_score_codex":0.00075806986,"about_ca_system_score_gemma":0.0041282466,"threshold_uncertainty_score":0.73233324},"labels":[],"label_agreement":null},{"id":"W2256933781","doi":"10.1200/jco.2013.31.31_suppl.54","title":"Impact of a dedicated supportive care center telephone triaging program (SCCTP) for patients with advanced cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Delirium; Anxiety; Psychological intervention; Quality of life (healthcare); Cancer; Hospital Anxiety and Depression Scale; Ambulatory care; Lung cancer; Internal medicine; Emergency medicine; Physical therapy; Intensive care medicine; Health care; Nursing; Psychiatry","score_opus":0.051078841175563904,"score_gpt":0.4872535682132865,"score_spread":0.43617472703772264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256933781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962218,0.00034178307,0.000088298395,0.0008648109,0.0008683652,0.0012683369,0.00004650554,0.000012325993,0.00028781162],"genre_scores_gemma":[0.9967864,0.00019063905,0.0019943716,0.00037350532,0.00046663024,0.00009761826,0.000029249682,0.000024887268,0.00003667864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973334,0.00013525035,0.0017055899,0.00018102174,0.00034383038,0.0003008998],"domain_scores_gemma":[0.9939965,0.00066316046,0.002105584,0.00015581274,0.0026590733,0.0004198689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004708563,0.00015624061,0.001465356,0.000108349115,0.00002485083,0.000006390961,0.0001297206,0.00022889978,0.00025141955],"category_scores_gemma":[0.00094205287,0.00009074748,0.0006756614,0.00018466919,0.00017141993,0.00014019628,0.00002498891,0.0005120233,0.0000020169387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010291546,0.0017251725,0.5604373,0.000073368436,0.0004899495,0.0000139981385,0.000445099,0.000004929232,0.000024928184,6.060218e-7,0.0013668211,0.42512625],"study_design_scores_gemma":[0.028800681,0.076822996,0.8831664,0.00032029458,0.00043262925,0.000017731303,0.000745463,0.000021749629,0.00006893227,0.000017434844,0.009475692,0.00011001805],"about_ca_topic_score_codex":0.00034623442,"about_ca_topic_score_gemma":0.00032854828,"teacher_disagreement_score":0.42501625,"about_ca_system_score_codex":0.0003209672,"about_ca_system_score_gemma":0.0021864586,"threshold_uncertainty_score":0.38786837},"labels":[],"label_agreement":null},{"id":"W2256968204","doi":"10.1200/jco.2013.31.15_suppl.506","title":"Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Cancer","score_opus":0.03249705643624021,"score_gpt":0.3471294723811669,"score_spread":0.31463241594492675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256968204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809074,0.00090408354,0.000020840358,0.00019364219,0.00011653304,0.00040453667,0.0002626682,0.0000016364756,0.0000053114245],"genre_scores_gemma":[0.99492127,0.0043697497,0.00046479152,0.00010320526,0.00006817874,0.000014573615,0.000041754363,0.000015258012,0.0000012173723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688107,0.000654732,0.0016638198,0.00033794608,0.00024852357,0.00021392251],"domain_scores_gemma":[0.99504125,0.0010856005,0.0025569363,0.00019591386,0.0010017024,0.00011858793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053807057,0.00021307793,0.001175011,0.00012584306,0.000055607932,0.000014532091,0.00017116885,0.00017147086,0.000010233501],"category_scores_gemma":[0.00065011566,0.00012623335,0.0001591594,0.0003058459,0.0005217667,0.0000289597,0.000147651,0.00035113297,1.9565103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072266054,0.001408912,0.96457034,0.000009398316,0.0032919869,0.000009437959,0.00019874985,0.000013967655,0.000428297,0.0000013623021,0.000007205439,0.022833744],"study_design_scores_gemma":[0.008219309,0.007661323,0.98165727,0.00015759414,0.0017948959,0.000005617425,0.000067847184,0.00006485851,0.00021170109,0.000037276062,0.0000035117562,0.00011881635],"about_ca_topic_score_codex":0.0029094093,"about_ca_topic_score_gemma":0.0008383936,"teacher_disagreement_score":0.022714928,"about_ca_system_score_codex":0.00005071103,"about_ca_system_score_gemma":0.00023601964,"threshold_uncertainty_score":0.51476467},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2257032663","doi":"10.1200/jco.2001.19.12.3160","title":"Prostate-Specific Antigen Levels in Nipple Aspirate Fluid","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Urologic and reproductive health conditions","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Citation; Medicine; Prostate-specific antigen; Oncology; Prostate cancer; Library science; Internal medicine; Cancer; Computer science","score_opus":0.33135188850640485,"score_gpt":0.500159103940491,"score_spread":0.16880721543408617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257032663","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.075452894,0.0028146878,0.00007063403,0.9079388,0.0049557895,0.0006578535,0.000029259294,0.000017156462,0.008062968],"genre_scores_gemma":[0.023002082,0.008431849,0.0020675082,0.9193165,0.04030201,0.00001850543,0.000070955466,0.00006992578,0.00672067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925165,0.0011437754,0.0046594,0.00052875833,0.00055669004,0.00059487775],"domain_scores_gemma":[0.99330246,0.0019576983,0.0031053184,0.00045056763,0.0008702727,0.000313682],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0053450745,0.00029986174,0.0031276343,0.00047616698,0.00006267512,0.000010056179,0.00027777383,0.0027232154,0.0011010615],"category_scores_gemma":[0.0030099824,0.0002047534,0.0007186978,0.00032684507,0.0005133173,0.000100239515,0.00006542525,0.009623802,0.00019331288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011846948,0.0009109264,0.020944064,0.00007288172,0.0002116633,0.021930395,0.000051038198,0.0000057341704,0.000068273504,0.000012863925,0.9314092,0.023198258],"study_design_scores_gemma":[0.003789091,0.011370502,0.1602443,0.00014133057,0.00013272543,0.0019123048,0.000021326188,0.0000026096272,0.000006927461,0.0008800234,0.82135206,0.00014680046],"about_ca_topic_score_codex":0.000018931582,"about_ca_topic_score_gemma":0.000009398881,"teacher_disagreement_score":0.13930023,"about_ca_system_score_codex":0.00031337654,"about_ca_system_score_gemma":0.0040352447,"threshold_uncertainty_score":0.99981207},"labels":[],"label_agreement":null},{"id":"W2257053422","doi":"10.1200/jco.2015.33.7_suppl.154","title":"A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Cohort; Internal medicine; Oncology; Adjuvant therapy; Biochemical recurrence; Metastasis; Stage (stratigraphy); Cancer; Surgical margin","score_opus":0.07712546034363023,"score_gpt":0.4076424814212207,"score_spread":0.3305170210775905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257053422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994287,0.0012846226,0.000022933062,0.0016365665,0.00095555425,0.0014443677,0.0003388485,0.000008494661,0.000021587266],"genre_scores_gemma":[0.99548423,0.002238153,0.00095134345,0.0005830104,0.00020246362,0.00018427076,0.000024874973,0.00003697534,0.00029469148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952115,0.00096771994,0.002395271,0.0003352479,0.0007228237,0.00036747058],"domain_scores_gemma":[0.9956643,0.000976164,0.0015549874,0.00019976476,0.0006301585,0.00097465434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003536319,0.00020650194,0.0015726874,0.00031685887,0.000021152959,0.0000122095225,0.00012233813,0.00014271072,0.000043850934],"category_scores_gemma":[0.002925765,0.0001340364,0.00028454687,0.0002947479,0.0003080924,0.00017249335,0.000064177984,0.0009613423,0.000007842268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08012782,0.0026975065,0.86871785,0.00006602846,0.0005920283,0.000551746,0.00087701256,0.000049926686,0.00015046385,9.276817e-7,0.002852166,0.043316513],"study_design_scores_gemma":[0.028644433,0.009321575,0.9580585,0.0002876736,0.00037364993,0.000006163054,0.00016967436,0.00018862245,0.00029021248,0.00033046296,0.0022048429,0.000124213],"about_ca_topic_score_codex":0.00027594308,"about_ca_topic_score_gemma":0.00006154416,"teacher_disagreement_score":0.08934061,"about_ca_system_score_codex":0.00061773194,"about_ca_system_score_gemma":0.003615938,"threshold_uncertainty_score":0.64145184},"labels":[],"label_agreement":null},{"id":"W2257109151","doi":"10.1200/jco.2008.26.15_suppl.1026","title":"Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Rash; Internal medicine; Clinical endpoint; Mucositis; Gastroenterology; Metastatic breast cancer; Phases of clinical research; Nausea; Oncology; Cancer; Clinical trial; Breast cancer; Chemotherapy","score_opus":0.13427893998033577,"score_gpt":0.4944826051640951,"score_spread":0.36020366518375935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257109151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490935,0.00055048504,0.000009960394,0.002539209,0.00024368567,0.0013565696,0.00012934428,0.000005688503,0.00025568568],"genre_scores_gemma":[0.99542934,0.0031083187,0.0007814906,0.00014414126,0.00036223934,0.000037529524,0.0000055312094,0.000039098286,0.000092314294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932857,0.0010085368,0.003685377,0.00038315827,0.0011940539,0.00044316743],"domain_scores_gemma":[0.99395156,0.0015692427,0.002517158,0.00027401082,0.0012468998,0.00044113284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026965842,0.00026854995,0.0028171774,0.00038050953,0.00007786016,0.000005912281,0.00024024902,0.00027327467,0.00007956419],"category_scores_gemma":[0.0014501027,0.00017694385,0.00034271943,0.000447778,0.0008861643,0.00018107441,0.00006367017,0.0013020441,5.3385173e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7115776,0.046046194,0.035539318,0.0001711593,0.0011122539,0.0010005321,0.0028524913,0.000019573807,0.0004336694,0.00000305375,0.00039278998,0.20085135],"study_design_scores_gemma":[0.40983406,0.24039856,0.34606293,0.00093148125,0.0002317678,0.00051206886,0.00023330894,0.000073574505,0.0009734442,0.000011562111,0.00059004413,0.00014720025],"about_ca_topic_score_codex":0.0003552867,"about_ca_topic_score_gemma":0.00017462112,"teacher_disagreement_score":0.31052363,"about_ca_system_score_codex":0.0006182542,"about_ca_system_score_gemma":0.0047405814,"threshold_uncertainty_score":0.8409588},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2257179848","doi":"10.1200/jco.2009.27.15_suppl.6584","title":"Integration between primary care providers and the cancer system: Gaps and opportunities","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cancer; Family medicine; Health care; Nursing; Internal medicine","score_opus":0.308957690486238,"score_gpt":0.48883279424126314,"score_spread":0.17987510375502513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257179848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291505,0.016981436,0.00016873314,0.04366097,0.00035416422,0.00022961153,0.0000031202367,0.000008578046,0.009442847],"genre_scores_gemma":[0.986464,0.004938486,0.0006795519,0.0067924894,0.001051598,0.0000021333055,0.0000018417211,0.0000034880136,0.00006640815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99831474,0.00026331408,0.0009940963,0.00009742536,0.00022446652,0.00010595413],"domain_scores_gemma":[0.9979172,0.0007698688,0.000717271,0.00007759445,0.00033470613,0.00018337765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002143377,0.00007565417,0.00082624,0.000043334803,0.000055163022,0.00001810622,0.00007180564,0.0001621547,0.0000047156577],"category_scores_gemma":[0.0005839599,0.000039470535,0.00011996717,0.00003561337,0.00028422064,0.00013965191,0.000020524423,0.00052107475,3.0314968e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002953119,0.000024437391,0.03762367,0.00011086986,0.000113791866,0.00017720407,0.0007439601,0.0000014279946,0.00003015127,0.0010756225,0.0021355252,0.95501024],"study_design_scores_gemma":[0.012963972,0.010589117,0.9109927,0.0016858428,0.0014671277,0.0008726564,0.014056692,0.000053776395,0.000039211467,0.00067207747,0.046477843,0.00012898055],"about_ca_topic_score_codex":0.00009106014,"about_ca_topic_score_gemma":0.00004125943,"teacher_disagreement_score":0.95488125,"about_ca_system_score_codex":0.00015131201,"about_ca_system_score_gemma":0.0009967774,"threshold_uncertainty_score":0.22638395},"labels":[],"label_agreement":null},{"id":"W2257258831","doi":"10.1200/jco.2005.23.16_suppl.9563","title":"Limited penetration of anticancer drugs to cells in solid tumors: A neglected and modifiable cause of drug resistance","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Penetration (warfare); Doxorubicin; Medicine; Extracellular matrix; Drug; Pharmacology; Cancer research; Drug delivery; Pathology; Chemotherapy; Chemistry; Internal medicine; Biochemistry","score_opus":0.04709226743414463,"score_gpt":0.381576224352677,"score_spread":0.3344839569185324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257258831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965068,0.00021024402,0.00011324383,0.0024841048,0.00031117574,0.00017077327,0.000008186501,0.0000053907456,0.00019009577],"genre_scores_gemma":[0.9880126,0.00015507004,0.011048881,0.00046046716,0.00019235388,0.0000027657388,2.944537e-7,0.000009740488,0.00011778708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958532,0.00059324235,0.0027287204,0.0002007066,0.0003799966,0.0002441706],"domain_scores_gemma":[0.9953939,0.0020244552,0.0016752165,0.00019119456,0.000507814,0.00020742678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029206816,0.0001059898,0.0010305031,0.00019220043,0.000019891033,0.0000118176495,0.00023101651,0.00013357798,0.00008332398],"category_scores_gemma":[0.0018129317,0.00009001455,0.00009568179,0.0003430019,0.0002200795,0.0002732235,0.000057712412,0.0002771201,0.000011079553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032666833,0.0010580329,0.0018993047,0.00004207448,0.000019964147,0.000044700315,0.0008032517,0.0049198605,0.984039,0.00008673293,0.0018517077,0.0019686832],"study_design_scores_gemma":[0.0047271224,0.0020464102,0.025962949,0.00032554462,0.00008712752,0.000011740067,0.00021841528,0.0020800903,0.9625103,0.00032636305,0.0015433988,0.00016055304],"about_ca_topic_score_codex":0.00008241466,"about_ca_topic_score_gemma":0.0005195652,"teacher_disagreement_score":0.024063643,"about_ca_system_score_codex":0.000116657415,"about_ca_system_score_gemma":0.00086272677,"threshold_uncertainty_score":0.3670687},"labels":[],"label_agreement":null},{"id":"W2257268550","doi":"10.1200/jco.2006.24.18_suppl.14502","title":"The importance of etoposide dose intensity in the management of metastatic germ cell tumours and the role of paclitaxel in salvage treatment of relapsing patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Etoposide; Regimen; Germ cell tumors; Oncology; Salvage therapy; Internal medicine; Chemotherapy; Paclitaxel; Cisplatin; Chemotherapy regimen; Surgery","score_opus":0.03467800567726286,"score_gpt":0.3839559033065329,"score_spread":0.34927789762927003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257268550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925535,0.0056742043,0.0000034178279,0.00075665885,0.000075964635,0.00041833997,0.0000061040478,6.0407984e-7,0.0005112288],"genre_scores_gemma":[0.9978149,0.0013640977,0.00070128124,0.00007657866,0.000018694658,0.0000044107655,0.0000017695681,0.000005381631,0.000012891698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970928,0.00042590182,0.0019850489,0.00009428029,0.00028304834,0.00011892517],"domain_scores_gemma":[0.995071,0.002097892,0.0024024723,0.0002131249,0.00016915122,0.00004634226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001758551,0.00009675626,0.0009866202,0.00005422954,0.000017446388,0.0000020512819,0.00010677807,0.000051365467,0.0000025420527],"category_scores_gemma":[0.00033311223,0.000040120838,0.0003072283,0.00011798571,0.00039366412,0.000027291255,0.00003333553,0.0001642507,1.3545964e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00406738,0.0058135875,0.97172403,0.000065122214,0.00026029852,0.00018887973,0.0003127969,0.000021352145,0.000021431666,0.00044552927,0.00001575672,0.01706383],"study_design_scores_gemma":[0.015204225,0.00449965,0.97367084,0.00018653508,0.0011122848,0.000017403967,0.0012646359,0.000063966334,0.00014385082,0.0037274042,0.000082353305,0.000026876822],"about_ca_topic_score_codex":0.0003140604,"about_ca_topic_score_gemma":0.00021445919,"teacher_disagreement_score":0.017036954,"about_ca_system_score_codex":0.00006626914,"about_ca_system_score_gemma":0.00014743749,"threshold_uncertainty_score":0.16360803},"labels":[],"label_agreement":null},{"id":"W2257288783","doi":"10.1200/jco.2009.27.15_suppl.e13509","title":"Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Regimen; Chemotherapy; Lung cancer; Ovarian cancer; Oncology; Endometrial cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Adenocarcinoma; Progressive disease; Gastroenterology","score_opus":0.04456309385165381,"score_gpt":0.511309083828003,"score_spread":0.4667459899763492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257288783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971012,0.000039527167,0.000026707263,0.001212423,0.00021133093,0.0004366153,0.0000016623385,0.0000032117098,0.00096731924],"genre_scores_gemma":[0.9987322,0.000018966413,0.00072296005,0.0004021251,0.00006935969,0.0000027108836,0.0000052120627,0.0000056757676,0.000040807143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978706,0.000121681536,0.001527775,0.000100533005,0.0002743547,0.000105010964],"domain_scores_gemma":[0.997782,0.00024500504,0.0012372922,0.00010367385,0.0005055497,0.00012651375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005501068,0.000077667566,0.00093427696,0.0001408677,0.000015485082,0.0000018920041,0.00005732477,0.000071644135,0.000021907916],"category_scores_gemma":[0.000573299,0.000048805417,0.00008522082,0.0001695669,0.000041499392,0.000112287824,0.0000067187775,0.00029380407,0.0000010690843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013702704,0.11017899,0.5594785,0.000009478378,0.00027858096,0.0002274254,0.0006313071,0.00011446788,0.00002560003,0.000046981495,0.0001415185,0.3151644],"study_design_scores_gemma":[0.096022375,0.18585709,0.7170678,0.00007057603,0.0002676115,0.0000071705585,0.00028818997,0.000019617019,0.000014082508,0.000099114164,0.0002531378,0.000033260556],"about_ca_topic_score_codex":0.0000064805076,"about_ca_topic_score_gemma":0.00001563193,"teacher_disagreement_score":0.31513113,"about_ca_system_score_codex":0.00013747462,"about_ca_system_score_gemma":0.0005216608,"threshold_uncertainty_score":0.19902273},"labels":[],"label_agreement":null},{"id":"W2258068384","doi":"10.1200/jco.2006.24.18_suppl.6018","title":"NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Letrozole; Aromatase inhibitor; Breast cancer; Tamoxifen; Internal medicine; Tolerability; Quality of life (healthcare); Gynecology; Oncology; Cancer; Adverse effect","score_opus":0.03808750703918833,"score_gpt":0.39370593789811953,"score_spread":0.3556184308589312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258068384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910894,0.0018564904,0.00008664364,0.00027615554,0.0006461638,0.0001036694,0.0000039088727,0.0000038081669,0.0059337853],"genre_scores_gemma":[0.9968346,0.0003293626,0.0006644506,0.00022321906,0.0011477241,0.0000031214902,0.0000062258796,0.000010757824,0.0007805905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967902,0.0006021097,0.0018727893,0.00022020127,0.00021718732,0.00029755654],"domain_scores_gemma":[0.9974053,0.00035200611,0.0014561041,0.0002693205,0.0002945469,0.00022275075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003203794,0.00014534226,0.00090777286,0.00005313335,0.000031712156,0.0000045780384,0.00028450953,0.0008520922,0.000054269698],"category_scores_gemma":[0.000983425,0.00011127771,0.00053940434,0.000109696135,0.00041700236,0.00000825574,0.000094433155,0.00074898655,0.000005730888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064844415,0.005782929,0.70350605,0.00011331958,0.0009249791,0.0002627997,0.000094058705,0.0005862391,0.17270821,0.00017008306,0.032686196,0.07668067],"study_design_scores_gemma":[0.004814383,0.0144045325,0.90745395,0.000025689318,0.0001408912,0.00012417795,0.00007979156,0.000053751937,0.02198494,0.00078404037,0.049890533,0.00024334082],"about_ca_topic_score_codex":0.000044026187,"about_ca_topic_score_gemma":0.00004262741,"teacher_disagreement_score":0.20394786,"about_ca_system_score_codex":0.00006292734,"about_ca_system_score_gemma":0.00055955263,"threshold_uncertainty_score":0.6572116},"labels":[],"label_agreement":null},{"id":"W2258101701","doi":"10.1200/jco.2009.27.15_suppl.567","title":"Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reproducibility; Concordance; Medicine; Estrogen receptor; Kappa; Breast cancer; Gold standard (test); Nuclear medicine; Internal medicine; Cancer; Pathology; Oncology; Chromatography; Chemistry; Mathematics","score_opus":0.275148876913577,"score_gpt":0.5129683890879859,"score_spread":0.23781951217440894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258101701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951274,0.004439177,0.0008723563,0.0039856583,0.0006450043,0.00032353762,0.000017568827,0.0000018607439,0.00020210502],"genre_scores_gemma":[0.9842631,0.00033866867,0.015259574,0.000100776604,0.000023573724,9.19018e-7,2.199992e-7,0.000004141811,0.000009024793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99238497,0.004703461,0.0023841374,0.00015396324,0.00021233218,0.00016114388],"domain_scores_gemma":[0.9931433,0.0017733811,0.002855375,0.00015296496,0.0020469648,0.000027968954],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023252374,0.00011352936,0.0014040131,0.00019120445,0.000027327176,0.000001379146,0.00021743933,0.00059425866,0.00008389136],"category_scores_gemma":[0.018738769,0.000068681904,0.00021255572,0.00028503148,0.0009952997,0.000057774145,0.000055482767,0.0006359993,5.457587e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004275955,0.0011747038,0.0077581615,0.000022166021,0.00081633957,0.0000028921456,0.0002694959,0.000072663635,0.7628078,0.0026033097,0.00017073115,0.22002582],"study_design_scores_gemma":[0.015704485,0.020369958,0.06853198,0.0005339033,0.0017205662,0.000045994686,0.0011875781,0.00020324442,0.8390625,0.04726466,0.005190811,0.00018428265],"about_ca_topic_score_codex":0.000025120891,"about_ca_topic_score_gemma":0.00004123651,"teacher_disagreement_score":0.21984154,"about_ca_system_score_codex":0.00011773442,"about_ca_system_score_gemma":0.0011015543,"threshold_uncertainty_score":0.9895268},"labels":[],"label_agreement":null},{"id":"W2258258382","doi":"10.1200/jco.2009.27.15_suppl.3585","title":"Advancement to the clinic of an RNAi therapeutic for solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Small interfering RNA; Medicine; Systemic administration; Cancer research; In vivo; Hepatocellular carcinoma; RNA interference; Liver tumor; Liver cancer; Cancer; Pharmacology; Pathology; Cell culture; Internal medicine; RNA; Biology; Transfection; Gene; Biochemistry","score_opus":0.10428789038136597,"score_gpt":0.49280689455262033,"score_spread":0.38851900417125435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258258382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863725,0.000568407,0.0052182116,0.0063439077,0.00083341607,0.00020561375,0.0000056432386,0.000001390801,0.00045096735],"genre_scores_gemma":[0.98571295,0.0005819446,0.0023190507,0.009793967,0.0012403999,0.0000040953532,0.0000036714102,0.00000691592,0.0003370316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978195,0.00020778205,0.0015191879,0.00015616001,0.00012747169,0.00016992759],"domain_scores_gemma":[0.9980329,0.00021392162,0.0009798104,0.00024818451,0.00038394128,0.0001412177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022391663,0.000093366536,0.00055751175,0.000033580316,0.00003215298,0.0000057127304,0.00042525018,0.00018024883,0.00002618252],"category_scores_gemma":[0.00075684965,0.000056965997,0.00038400368,0.000044598266,0.00007031854,0.0000064947403,0.000032901262,0.00019383107,0.000006777841],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065274094,0.0014302498,0.0007781824,0.000007188025,0.00026399855,0.000012781911,0.00008470166,0.00040097424,0.08464647,0.00009100444,0.009355977,0.89640105],"study_design_scores_gemma":[0.0048064287,0.18400684,0.05341281,0.000064468884,0.00022531196,0.00009969736,0.00045159948,0.00014575596,0.06882337,0.002629363,0.6850665,0.0002678616],"about_ca_topic_score_codex":0.0000013493682,"about_ca_topic_score_gemma":0.000020790221,"teacher_disagreement_score":0.8961332,"about_ca_system_score_codex":0.000011777361,"about_ca_system_score_gemma":0.00042563715,"threshold_uncertainty_score":0.2323006},"labels":[],"label_agreement":null},{"id":"W2258401109","doi":"10.1200/jco.2007.25.18_suppl.18092","title":"Costs associated with intravenous (IV) chemotherapy administration in patients with lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Route of administration; Internal medicine; Cancer; Administration (probate law); Oncology; Intensive care medicine","score_opus":0.04721964115355841,"score_gpt":0.4744088246118512,"score_spread":0.42718918345829276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258401109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944706,0.0001450354,0.000049389153,0.003053206,0.00045381504,0.00031753563,0.0000029958817,0.0000058777114,0.001501547],"genre_scores_gemma":[0.9960976,0.00019079701,0.00034687543,0.0027033063,0.0004777028,0.000003937811,0.000009243719,0.000014721817,0.00015579548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981752,0.00012732085,0.0010784573,0.00012719988,0.00026896258,0.00022287278],"domain_scores_gemma":[0.9973858,0.0008069137,0.0011216772,0.00006522282,0.00039899236,0.000221384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013753826,0.000112717156,0.00084560766,0.00010557924,0.000019924779,0.000003805969,0.00005952578,0.0002533939,0.00021319166],"category_scores_gemma":[0.000226139,0.000069578746,0.00008962884,0.00018360374,0.00011224508,0.00006680066,0.0000052654423,0.0006328156,0.0000010319395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04119661,0.005671895,0.8706204,0.0000069583207,0.00057082466,0.0005278849,0.00010803201,0.0000052597507,0.000018020926,0.0000061680958,0.0009318712,0.08033602],"study_design_scores_gemma":[0.035877876,0.04475932,0.9158947,0.00013422823,0.00035787738,0.000033485583,0.00002250204,0.0000151676095,0.00008761707,0.0000060426,0.0027413531,0.0000698647],"about_ca_topic_score_codex":0.000041705698,"about_ca_topic_score_gemma":0.002047185,"teacher_disagreement_score":0.080266155,"about_ca_system_score_codex":0.0007994811,"about_ca_system_score_gemma":0.0017910734,"threshold_uncertainty_score":0.31772873},"labels":[],"label_agreement":null},{"id":"W2258788178","doi":"10.1200/jco.2000.18.24.4045","title":"Germline BRCA1/2 Mutations and p27<sup>Kip1</sup> Protein Levels Independently Predict Outcome After Breast Cancer","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Breast cancer; Confidence interval; Internal medicine; Mutation; Germline mutation; Odds ratio; Oncology; Cancer; Immunohistochemistry; Cancer research; Genetics; Gene; Biology","score_opus":0.05354724689279104,"score_gpt":0.4166459840642993,"score_spread":0.36309873717150826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258788178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192923,0.0010433075,0.0002808497,0.005257267,0.00037750843,0.00025185203,0.00019189886,0.000006738657,0.00066135486],"genre_scores_gemma":[0.99065715,0.00028593256,0.0027180996,0.0020124877,0.0020837823,0.000054710355,0.000013317165,0.000030217217,0.0021443286],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968636,0.0003599403,0.0018585445,0.0003408679,0.0002968536,0.00028019305],"domain_scores_gemma":[0.9981498,0.00015157604,0.0007316217,0.00026059028,0.00041353726,0.00029284228],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013953239,0.00019491802,0.0006561804,0.000080602826,0.00007087375,0.00002653526,0.00027181007,0.00057645305,0.0015403494],"category_scores_gemma":[0.00046706892,0.00016102662,0.0002882624,0.00011274919,0.00034433,0.000023506514,0.00008614324,0.0006502953,0.000020464968],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00520371,0.0014938856,0.42526606,0.00007545916,0.0012309751,0.0003341427,0.0003437511,0.0051615774,0.0046365657,0.000032714477,0.006211915,0.55000925],"study_design_scores_gemma":[0.007213993,0.0031076332,0.84907436,0.00006740382,0.0003532029,0.0011693024,0.00011606923,0.00041851375,0.0009932641,0.0004636551,0.1366309,0.0003916964],"about_ca_topic_score_codex":0.000027116219,"about_ca_topic_score_gemma":0.00011030133,"teacher_disagreement_score":0.5496176,"about_ca_system_score_codex":0.000115190596,"about_ca_system_score_gemma":0.001544972,"threshold_uncertainty_score":0.99937236},"labels":[],"label_agreement":null},{"id":"W2258915230","doi":"10.1200/jco.2015.33.7_suppl.435","title":"Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Renal cell carcinoma; Hazard ratio; Sunitinib; Oncology; Bevacizumab; Proportional hazards model; Sorafenib; Statin; Progression-free survival; Hepatocellular carcinoma; Overall survival; Chemotherapy; Confidence interval; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.0627589196817629,"score_gpt":0.41237659653855835,"score_spread":0.34961767685679546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258915230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734753,0.00034255005,0.00008748386,0.000068822774,0.001726832,0.00008084882,0.000022075534,5.812509e-7,0.00032325365],"genre_scores_gemma":[0.9971882,0.00010638821,0.0015292407,0.0000827695,0.0010034293,9.2000687e-7,0.0000066799416,0.000009760425,0.00007261305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981344,0.0003404429,0.0010364321,0.000132119,0.00020123817,0.00015541168],"domain_scores_gemma":[0.9981378,0.0001918404,0.0009319348,0.00012510717,0.00036567767,0.00024765378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013644202,0.000108647175,0.00088378857,0.000063949825,0.000008042597,0.000003931138,0.00011308078,0.0001231878,0.0000072960443],"category_scores_gemma":[0.00085285056,0.000067358786,0.00018784826,0.000053371787,0.00014064247,0.000008364527,0.00004772739,0.00022908942,4.3304158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029613406,0.00085565256,0.9887393,0.0000072735916,0.000130923,0.0000016510046,0.00006834984,0.000072184506,0.0003952481,0.0000045987235,0.0021739781,0.0045895106],"study_design_scores_gemma":[0.012070258,0.014584965,0.9632677,0.0000052794408,0.00009109256,0.0000054163456,0.00007090731,0.000003966932,0.000091101894,0.000036865582,0.009694848,0.00007758724],"about_ca_topic_score_codex":0.000111115965,"about_ca_topic_score_gemma":0.00021429856,"teacher_disagreement_score":0.025471577,"about_ca_system_score_codex":0.000029233708,"about_ca_system_score_gemma":0.0013257621,"threshold_uncertainty_score":0.27468115},"labels":[],"label_agreement":null},{"id":"W2258924505","doi":"10.1200/jco.2013.31.31_suppl.78","title":"Determinants of survivorship care plan implementation in U.S. cancer programs.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Survivorship curve; Medicine; Family medicine; Descriptive statistics; Quarter (Canadian coin); Commission; Cancer; Health care; Cancer survivor; Breast cancer; Nursing; Gerontology; Business; Internal medicine","score_opus":0.15847844478451578,"score_gpt":0.5161473772268554,"score_spread":0.35766893244233966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258924505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995585,0.00089769246,0.0000036836136,0.0010276323,0.0014445762,0.0003129519,0.000004713839,0.000003800563,0.0007198965],"genre_scores_gemma":[0.99815094,0.00046597622,0.0002320015,0.00054206257,0.0005289969,0.000022674152,0.0000046981513,0.000011296527,0.000041335505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997071,0.00028745746,0.0020240718,0.00012261241,0.00029251364,0.00020232776],"domain_scores_gemma":[0.9973399,0.00044620674,0.0012798005,0.000121113604,0.00060460897,0.00020838072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012401948,0.00009484075,0.0010589422,0.00012731423,0.000011287873,0.0000054741918,0.00012166617,0.00024134209,0.00045318736],"category_scores_gemma":[0.00029973526,0.00006960039,0.00027060846,0.00015785787,0.00009673377,0.0001088388,0.000027477085,0.00048813716,0.0000057451734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037742197,0.00020058204,0.60024595,0.00006914126,0.000026613456,0.000047615187,0.00075944734,6.1197966e-7,0.000029896453,0.0000049470937,0.00022063739,0.39801714],"study_design_scores_gemma":[0.004106123,0.0059720394,0.97507495,0.00019513944,0.000109888104,0.00004239158,0.005626201,0.000009561046,0.00031077798,0.00010119957,0.0083823735,0.00006934585],"about_ca_topic_score_codex":0.010157592,"about_ca_topic_score_gemma":0.09409471,"teacher_disagreement_score":0.3979478,"about_ca_system_score_codex":0.00016585358,"about_ca_system_score_gemma":0.0012673022,"threshold_uncertainty_score":0.99643385},"labels":[],"label_agreement":null},{"id":"W2259099698","doi":"10.1200/jco.2007.25.18_suppl.5596","title":"Endometrial cancer survivorship in obese patients: A lifestyle intervention program","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Quality of life (healthcare); Body mass index; Weight loss; Endometrial cancer; Internal medicine; Randomized controlled trial; Cancer; Obesity; Physical therapy; Survivorship curve","score_opus":0.14105401524325864,"score_gpt":0.5232912884978804,"score_spread":0.38223727325462176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259099698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910684,0.0010291622,0.0000412242,0.0011609618,0.0038345924,0.0004652339,0.000003215447,0.000012835042,0.0023843807],"genre_scores_gemma":[0.9944765,0.00074350287,0.0013442851,0.0007296011,0.0025111043,0.000015540587,0.000005185497,0.000014357846,0.00015993736],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954569,0.00044683067,0.0030766611,0.0001841342,0.00050919,0.00032630787],"domain_scores_gemma":[0.99377143,0.0036087283,0.0014920288,0.00011967272,0.000538119,0.00046999299],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0069535533,0.00013401257,0.0013628504,0.0004985009,0.000017937316,0.000008466295,0.00013857732,0.00037818353,0.0003628516],"category_scores_gemma":[0.01424303,0.00009014463,0.00070788217,0.00083456904,0.00010310143,0.00012260157,0.000044885746,0.0009250243,0.00001632343],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012126207,0.00700494,0.47844508,0.00002434347,0.00014759085,0.00021970912,0.000021483458,5.958159e-7,0.000004138987,0.000012292908,0.0001279602,0.5018657],"study_design_scores_gemma":[0.049862973,0.029217426,0.8969497,0.00023621606,0.00023272682,0.00002162069,0.000049383212,0.0000039294287,0.000059908303,0.00027270842,0.023018006,0.000075367476],"about_ca_topic_score_codex":0.00091860304,"about_ca_topic_score_gemma":0.0034181676,"teacher_disagreement_score":0.5017903,"about_ca_system_score_codex":0.0004757108,"about_ca_system_score_gemma":0.0005012462,"threshold_uncertainty_score":0.9940604},"labels":[],"label_agreement":null},{"id":"W2259227988","doi":"10.1200/jco.2006.24.18_suppl.14042","title":"Late toxicity after adjuvant radiochemotherapy for gastric adenocarcinoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Toxicity; Gastroenterology; Internal medicine; Radiation therapy; Chemotherapy; Cancer; Urology; Surgery","score_opus":0.07049810433650043,"score_gpt":0.4176016678089084,"score_spread":0.34710356347240795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259227988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781584,0.0017495699,0.003502508,0.013296484,0.0012731822,0.00031494774,0.0000031643071,0.000011699147,0.001690055],"genre_scores_gemma":[0.9766018,0.0003476113,0.010742142,0.0054447576,0.0037511794,0.000008004994,0.0000023595398,0.00001764339,0.0030845501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976064,0.00008993701,0.0016552726,0.00015474392,0.00024563685,0.00024799426],"domain_scores_gemma":[0.99772745,0.0007518034,0.00096319366,0.00014706785,0.00022889825,0.00018157234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015602491,0.000122064805,0.0011752753,0.00014962853,0.000022620969,0.000008641652,0.000121991754,0.00020238025,0.00021148249],"category_scores_gemma":[0.0004610542,0.000085445754,0.00072024815,0.000134332,0.000091142,0.00006836052,0.000023468052,0.00039310564,0.000009152869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009941465,0.0010855481,0.7693041,0.000054608765,0.00032903912,0.00053226174,0.000021622958,0.000018541357,0.0001376784,0.0000974741,0.06334075,0.15513691],"study_design_scores_gemma":[0.011240824,0.0072622113,0.8417596,0.000028893717,0.00038617477,0.00014780533,0.000014310894,0.00008880995,0.00006659735,0.0006752623,0.1382601,0.00006941129],"about_ca_topic_score_codex":0.000011731258,"about_ca_topic_score_gemma":0.000017775517,"teacher_disagreement_score":0.1550675,"about_ca_system_score_codex":0.00013175512,"about_ca_system_score_gemma":0.00041336456,"threshold_uncertainty_score":0.34843767},"labels":[],"label_agreement":null},{"id":"W2259357916","doi":"10.1200/jco.2007.25.18_suppl.9544","title":"Long-term complications of neuroblastoma: A report from the Childhood Cancer Survivor Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children","funders":"","keywords":"Medicine; Standardized mortality ratio; Internal medicine; Cancer; Cohort; Pediatrics; Incidence (geometry); Cancer registry; Radiation therapy; Medical record; Surgery","score_opus":0.15368232202446594,"score_gpt":0.5250672565484897,"score_spread":0.37138493452402377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259357916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99182636,0.00020061972,0.00010858204,0.005847535,0.00060655514,0.00050047267,0.000010409252,0.0000072876446,0.00089216634],"genre_scores_gemma":[0.9978585,0.00016072074,0.0002494444,0.00084229896,0.0007358261,0.0000064720152,0.0000031105012,0.000015206493,0.0001283695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625516,0.0004273625,0.0023158898,0.00020275067,0.00056635594,0.00023245196],"domain_scores_gemma":[0.9919644,0.00484659,0.0017861866,0.00041780117,0.0006024355,0.00038256406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002765347,0.00011459579,0.00096826174,0.00008425162,0.000058644157,0.0000060580874,0.00025830627,0.00011674798,0.00010381551],"category_scores_gemma":[0.0030578892,0.00006384899,0.00037751373,0.00020250664,0.00023511381,0.00005374812,0.00008831821,0.0009105282,0.000013380721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002156582,0.011260476,0.9340099,0.0000047309077,0.00084592553,0.00626647,0.00011631847,0.000001697412,0.00027895963,0.0000039949387,0.0010856376,0.043969326],"study_design_scores_gemma":[0.0068163853,0.010774401,0.97920036,0.000055074044,0.00041409218,0.0010460599,0.00007646486,0.0000018822273,0.00014964299,0.00003859086,0.001386354,0.00004069925],"about_ca_topic_score_codex":0.00024047274,"about_ca_topic_score_gemma":0.0018891903,"teacher_disagreement_score":0.045190472,"about_ca_system_score_codex":0.00007002216,"about_ca_system_score_gemma":0.0012490683,"threshold_uncertainty_score":0.39558426},"labels":[],"label_agreement":null},{"id":"W2259441487","doi":"10.1200/jco.2006.24.18_suppl.18579","title":"Assessing rectal toxicity in a pilot study using intrarectal amifostine and concurrent radiation","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Amifostine; Prostate cancer; Rectum; Toxicity; Proctitis; Radiation proctitis; Radiation therapy; Urology; Quality of life (healthcare); Colorectal cancer; Internal medicine; Surgery; Oncology; Cancer; Ulcerative colitis; Disease","score_opus":0.1553101319589364,"score_gpt":0.5034021511919993,"score_spread":0.3480920192330629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259441487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963169,0.00046598047,0.0003230976,0.001122699,0.0010214401,0.00034331792,8.5124464e-7,0.000009505732,0.00039617956],"genre_scores_gemma":[0.99619496,0.000043269938,0.0019489024,0.00027747164,0.0015112536,0.000001469384,0.000001813813,0.000011999365,0.000008841408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643445,0.0008939262,0.0020131175,0.00017490084,0.0003095587,0.00017402014],"domain_scores_gemma":[0.99572194,0.0023975899,0.0014046135,0.00008109337,0.00022133307,0.00017345962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004397095,0.000118172284,0.0010485374,0.00022473343,0.000035470148,0.000029122724,0.00006060927,0.00015072445,0.000022584027],"category_scores_gemma":[0.0052081277,0.00009518227,0.000096693424,0.00019081062,0.00010435642,0.00033936164,0.00002944646,0.00090803986,0.0000014225395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012572812,0.0057791187,0.78675574,0.000021322094,0.00007615685,0.00063303096,0.00008896785,0.00013614939,0.0035956386,0.000023907467,0.00023913436,0.20139354],"study_design_scores_gemma":[0.010533178,0.03105441,0.9544469,0.00008122054,0.00017380345,0.00050737197,0.00016536687,0.002435994,0.00011037394,0.00006468848,0.00034483947,0.00008186121],"about_ca_topic_score_codex":0.00009703293,"about_ca_topic_score_gemma":0.00017016535,"teacher_disagreement_score":0.2013117,"about_ca_system_score_codex":0.00026960846,"about_ca_system_score_gemma":0.0007848506,"threshold_uncertainty_score":0.62349916},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2259666820","doi":"10.1200/jco.2015.33.29_suppl.108","title":"Defining high-quality palliative care in oncology practice: An ASCO/AAHPM Guidance Statement.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Palliative care; Medicine; Referral; Family medicine; Quality of life (healthcare); Psychosocial; Subspecialty; Delphi method; Nursing","score_opus":0.5643635023240383,"score_gpt":0.6735263988608403,"score_spread":0.109162896536802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259666820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581148,0.00923863,0.00044202557,0.011194472,0.002050141,0.00025472397,0.00001794529,0.000013632191,0.018673621],"genre_scores_gemma":[0.91274077,0.0034171222,0.07838558,0.0044107446,0.0009171488,0.0000068260715,0.000018063642,0.000021425767,0.000082318504],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914051,0.0029679504,0.0043328265,0.00028842507,0.00066627894,0.0003393839],"domain_scores_gemma":[0.98274565,0.008816118,0.004694737,0.00028184737,0.002813774,0.00064788177],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01151381,0.00019272206,0.0023889428,0.00018230677,0.000025379988,0.000007295773,0.00025724244,0.0005614845,0.000056035522],"category_scores_gemma":[0.049365018,0.00014873687,0.00028550235,0.00025573332,0.0003051718,0.00038597963,0.00008829875,0.00143733,0.000025074673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020959439,0.004082837,0.7716988,0.0001283715,0.00063715153,0.0024238762,0.013544341,0.00019789573,0.00010350549,0.0028500676,0.0068215965,0.17655213],"study_design_scores_gemma":[0.020922199,0.04572502,0.27883542,0.0006474798,0.0004030224,0.000056736648,0.032964606,0.0000308736,0.0003082348,0.0012552213,0.61864597,0.00020523036],"about_ca_topic_score_codex":0.0003642399,"about_ca_topic_score_gemma":0.0007678593,"teacher_disagreement_score":0.61182433,"about_ca_system_score_codex":0.0009900564,"about_ca_system_score_gemma":0.0059896423,"threshold_uncertainty_score":0.9996455},"labels":[],"label_agreement":null},{"id":"W2259669113","doi":"10.1200/jco.2012.30.18_suppl.lba3500","title":"Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; FOLFOX; FOLFIRI; Internal medicine; Erlotinib; Oncology; Regimen; Clinical endpoint; Colorectal cancer; Maintenance therapy; Chemotherapy regimen; Chemotherapy; Randomized controlled trial; Surgery; Irinotecan; Cancer; Oxaliplatin; Epidermal growth factor receptor","score_opus":0.08769956509549208,"score_gpt":0.4415433121029494,"score_spread":0.3538437470074573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259669113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207765,0.0003677322,0.000017728235,0.0044110734,0.0013141928,0.0014052134,0.000019354155,0.000006164982,0.00038087514],"genre_scores_gemma":[0.99621344,0.0018220835,0.00054684986,0.000598884,0.00049612037,0.000046503563,0.0000054581556,0.000024133844,0.00024655488],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996923,0.00022837702,0.0017659866,0.00024163556,0.0005655692,0.00027538114],"domain_scores_gemma":[0.9962258,0.001141535,0.0019043275,0.00014505693,0.00040441068,0.00017886863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016423168,0.00023188525,0.001579861,0.0001062189,0.00008647974,0.000009433733,0.00015423562,0.00013703856,0.00005305739],"category_scores_gemma":[0.0011683768,0.00010408179,0.00022162352,0.00024548013,0.00028539903,0.0001912445,0.000047338104,0.0005672167,4.4890902e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7746536,0.0061496664,0.09160085,0.000011904629,0.001849534,0.000037909293,0.001694822,0.00002587998,0.000024330904,0.00000455291,0.00017134479,0.12377558],"study_design_scores_gemma":[0.6052282,0.06720999,0.31840646,0.00042501796,0.00056307623,0.00010531678,0.00040196322,0.00004591777,0.00016914222,0.000010484529,0.0073031527,0.00013128291],"about_ca_topic_score_codex":0.00029007377,"about_ca_topic_score_gemma":0.0016609862,"teacher_disagreement_score":0.22680561,"about_ca_system_score_codex":0.00054897176,"about_ca_system_score_gemma":0.0011820615,"threshold_uncertainty_score":0.4244332},"labels":[],"label_agreement":null},{"id":"W2259828625","doi":"10.1200/jco.2005.23.16_suppl.7017","title":"Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Topotecan; Docetaxel; Medicine; Maximum tolerated dose; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Cancer; Pharmacology; Chemotherapy","score_opus":0.2571557998899412,"score_gpt":0.5700849347029274,"score_spread":0.31292913481298623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259828625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980897,0.00041548276,0.00014997719,0.0129539445,0.0014146412,0.0022618969,0.00004941836,0.000029581224,0.0018280612],"genre_scores_gemma":[0.9867579,0.0006655584,0.007659666,0.0018205809,0.0027263241,0.00005122763,0.0000074630825,0.000052386356,0.00025891504],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98885226,0.0025135532,0.0057159644,0.0010012115,0.0008832502,0.0010337539],"domain_scores_gemma":[0.9902375,0.0040601613,0.0023823893,0.0007690283,0.00078856945,0.0017623634],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015472764,0.00045086438,0.004713522,0.0003240842,0.00019475607,0.00010214974,0.0013156785,0.0006233588,0.000090634836],"category_scores_gemma":[0.0056306003,0.00036705876,0.0002916878,0.00056316727,0.00046894402,0.00042174855,0.0008221199,0.0046096477,0.000015148816],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11881702,0.060543418,0.35262313,0.000047470538,0.0013815892,0.0029319464,0.002338783,0.00049705856,0.0013144223,0.000005727129,0.0054334574,0.45406598],"study_design_scores_gemma":[0.2721773,0.11339304,0.5946032,0.0005486831,0.0012848096,0.0000680311,0.0017267122,0.008208861,0.00061657303,0.00009403558,0.006661496,0.000617254],"about_ca_topic_score_codex":0.008254884,"about_ca_topic_score_gemma":0.07156658,"teacher_disagreement_score":0.4534487,"about_ca_system_score_codex":0.0016686268,"about_ca_system_score_gemma":0.006848208,"threshold_uncertainty_score":0.9998781},"labels":[],"label_agreement":null},{"id":"W2260261261","doi":"10.1200/jco.2007.25.18_suppl.7577","title":"P53 protein over-expression but not <i>p53</i> gene mutation is a poor prognostic marker and a predictive marker for survival benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the JBR.10 Trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; University of Alberta; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Immunohistochemistry; Oncology; Internal medicine; ERCC1; Chemotherapy; Cisplatin; Vinorelbine; Hazard ratio; Lung cancer; Cancer research; Gene; DNA repair; Biology; Nucleotide excision repair","score_opus":0.026788264030543213,"score_gpt":0.36106150458406017,"score_spread":0.3342732405535169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260261261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932779,0.0012636948,0.0018487001,0.0010971806,0.0006709145,0.0015316868,0.00018073016,0.0000013924683,0.00012779981],"genre_scores_gemma":[0.99219847,0.001288714,0.002097265,0.002319935,0.0018257769,0.00011875802,0.00003165857,0.000027778518,0.000091655085],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974811,0.00018374898,0.0014598982,0.00035754242,0.0002115127,0.00030619878],"domain_scores_gemma":[0.9967129,0.0017457173,0.0010101391,0.00017200325,0.00022111091,0.00013812471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032331697,0.00019417347,0.0006640404,0.000071597926,0.00003994187,0.00002434447,0.00023621137,0.0005237195,0.000031500047],"category_scores_gemma":[0.0011357587,0.00014242945,0.00023914903,0.000080886566,0.00009011778,0.000010769888,0.000070975366,0.0004206658,3.6603657e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.489635,0.0042293537,0.12792335,0.00010822725,0.00041757312,0.0002542531,0.00090774184,0.00033262762,0.29396057,0.0000081417065,0.0048486525,0.077374525],"study_design_scores_gemma":[0.13467069,0.01460509,0.7543984,0.00028509638,0.0002963963,0.000018896813,0.00035047752,0.002669649,0.07617835,0.00038055313,0.01568919,0.00045717778],"about_ca_topic_score_codex":0.00020089553,"about_ca_topic_score_gemma":0.0010886492,"teacher_disagreement_score":0.6264751,"about_ca_system_score_codex":0.000088424305,"about_ca_system_score_gemma":0.0007044832,"threshold_uncertainty_score":0.5808104},"labels":[],"label_agreement":null},{"id":"W2260320054","doi":"10.1200/jco.2000.18.14.2685","title":"MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Osteosarcoma; Medicine; Chemotherapy; Oncology; Prospective cohort study; Internal medicine; Multivariate analysis; Biopsy; Pathology","score_opus":0.0791322321686776,"score_gpt":0.4462627075796174,"score_spread":0.3671304754109398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260320054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620587,0.0002899695,0.000030257206,0.0011666069,0.00039971294,0.00040527617,8.328577e-7,0.000006357259,0.0014951467],"genre_scores_gemma":[0.99361366,0.00024418993,0.0044184276,0.000506655,0.00032389222,0.0000045866077,4.436762e-7,0.00001152247,0.0008765981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972944,0.00021053181,0.0018770442,0.00018084126,0.0002621427,0.00017499676],"domain_scores_gemma":[0.99878997,0.00031796336,0.0004235459,0.0001264734,0.000105057865,0.0002370184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019520781,0.00010867748,0.0011425841,0.00009554962,0.000024769215,0.0000049573996,0.0000856176,0.00020111367,0.0002760943],"category_scores_gemma":[0.00026335035,0.000067205474,0.00018792083,0.00008342564,0.0000853474,0.00008101881,0.000015591912,0.0007635155,0.000009742968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068617244,0.004904564,0.95448387,0.000017288823,0.000060231105,0.0024289857,0.00043239814,0.000002220962,0.0009936403,0.0000046267337,0.000047117388,0.029763337],"study_design_scores_gemma":[0.021852314,0.007395848,0.9652542,0.00008544146,0.00014622041,0.0001004259,0.000448548,0.000014805047,0.00029719624,0.00010328223,0.0042333496,0.0000683797],"about_ca_topic_score_codex":0.0000061850046,"about_ca_topic_score_gemma":0.00008583812,"teacher_disagreement_score":0.029694958,"about_ca_system_score_codex":0.000055469456,"about_ca_system_score_gemma":0.00018561022,"threshold_uncertainty_score":0.33171374},"labels":[],"label_agreement":null},{"id":"W2260384536","doi":"10.1200/jco.2014.32.31_suppl.199","title":"Association between feeling of well-being and overall survival in advanced lung or non-colonic gastrointestinal patients receiving palliative care.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Univariate analysis; Palliative care; Multivariate analysis; Logistic regression; Performance status; Cancer; Gastroenterology; Oncology","score_opus":0.041017406092869226,"score_gpt":0.4040645931746464,"score_spread":0.36304718708177713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260384536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959364,0.00007457548,0.0004057261,0.0006891089,0.0008623029,0.00016057189,0.0000021114834,0.000004172071,0.0018650091],"genre_scores_gemma":[0.99700075,0.00019840705,0.0018358545,0.0002328483,0.0006540253,0.0000014502263,0.0000045211355,0.000014142008,0.000058011465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968308,0.0005113482,0.0018365834,0.00017881994,0.000400056,0.00024235663],"domain_scores_gemma":[0.99123025,0.0055692405,0.0021645946,0.0000941997,0.00074907974,0.00019265423],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031127415,0.00012443725,0.0013542521,0.00012365494,0.000028360304,0.000006728424,0.000094783085,0.000218072,0.000023833112],"category_scores_gemma":[0.008541076,0.00009755809,0.00020312,0.00013118428,0.000049877544,0.00010829751,0.000053962187,0.0009158572,0.000001031818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021163407,0.00016205882,0.9691495,0.000096694275,0.000097178745,0.000018903478,0.0011667361,0.000039028047,0.000037209113,0.0000065432614,0.000049963317,0.027059844],"study_design_scores_gemma":[0.008500884,0.0076919375,0.980908,0.00092201744,0.00023885064,0.0000052773285,0.0006033164,0.00021070648,0.00003551512,0.00010162684,0.0006996508,0.00008222555],"about_ca_topic_score_codex":0.00014518817,"about_ca_topic_score_gemma":0.001692457,"teacher_disagreement_score":0.02697762,"about_ca_system_score_codex":0.00053518795,"about_ca_system_score_gemma":0.00056026474,"threshold_uncertainty_score":0.9998104},"labels":[],"label_agreement":null},{"id":"W2260397345","doi":"10.1200/jco.2006.24.18_suppl.14040","title":"Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Irinotecan; Bolus (digestion); Surgery; Internal medicine; Gastroenterology; Adenocarcinoma; Phases of clinical research; Bortezomib; Urology; Cancer; Toxicity; Colorectal cancer; Multiple myeloma","score_opus":0.06678361614358176,"score_gpt":0.42752969639868726,"score_spread":0.3607460802551055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260397345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685675,0.000066556415,0.00011399673,0.0006086032,0.00027933923,0.0008412726,0.000001948084,0.000009814171,0.0012217163],"genre_scores_gemma":[0.99597955,0.000036949,0.002692573,0.00032677525,0.0003461873,0.000009654307,0.0000032913033,0.000026489153,0.0005785537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960116,0.00021203732,0.00244186,0.00028378534,0.0007192754,0.0003314146],"domain_scores_gemma":[0.99629915,0.0004295858,0.002293097,0.0002843201,0.00047152134,0.00022233748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010537363,0.00022666741,0.0020686705,0.00043512083,0.000040172632,0.0000061260016,0.0002161793,0.00014514317,0.00008002841],"category_scores_gemma":[0.00034812078,0.00012834158,0.00016414585,0.00062880793,0.0001664621,0.00015692043,0.00007561476,0.00078020827,0.0000016928673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048048053,0.028065959,0.8396863,0.00003319555,0.00024285789,0.0006957756,0.00012741164,0.00011484155,0.0000058994788,0.0000054985485,0.0005728282,0.08240143],"study_design_scores_gemma":[0.10287234,0.25969204,0.6342456,0.00009499202,0.0005283098,0.000053964635,0.00051272253,0.000026925794,0.000006283958,0.0000059829526,0.0018723656,0.00008848921],"about_ca_topic_score_codex":0.00014042972,"about_ca_topic_score_gemma":0.0012952716,"teacher_disagreement_score":0.23162608,"about_ca_system_score_codex":0.0002206904,"about_ca_system_score_gemma":0.0008592396,"threshold_uncertainty_score":0.52336174},"labels":[],"label_agreement":null},{"id":"W2260952436","doi":"10.1200/jco.2006.24.18_suppl.6042","title":"Use of health administrative databases in the analysis of waiting times and costs for the diagnosis of non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Timeline; Chart; Cancer registry; Diagnosis code; Database; Cohort; Population; Lung cancer; Medical diagnosis; Emergency medicine; Radiology; Internal medicine; Statistics; Environmental health","score_opus":0.4175565398046406,"score_gpt":0.554466961964825,"score_spread":0.13691042216018445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260952436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888834,0.004237368,0.00047473013,0.0057895547,0.000079776044,0.00029904695,0.00007936558,6.351154e-7,0.00015613188],"genre_scores_gemma":[0.9934333,0.002696341,0.002619004,0.0010647925,0.0001540506,0.000010984371,0.0000048346383,0.0000040049185,0.000012679665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997013,0.0003913034,0.0020982965,0.000108425214,0.00024588243,0.00014313872],"domain_scores_gemma":[0.98345137,0.013200193,0.0027620557,0.00014095618,0.0003871166,0.000058302034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004421331,0.000078903344,0.0012730121,0.00011337071,0.000031503492,0.0000038448547,0.00013841873,0.000067018205,0.000021707492],"category_scores_gemma":[0.0019153844,0.000041601306,0.00032926715,0.00032177387,0.00021642631,0.00007988126,0.000029052251,0.00029997312,2.6509028e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012198288,0.00048108774,0.9592617,0.00008582002,0.0005266503,0.000017713086,0.00028005242,0.0004294274,0.000048549216,0.000114813825,0.0034127994,0.034121573],"study_design_scores_gemma":[0.0020287505,0.0032584069,0.98386264,0.0005112502,0.0024153492,0.00001014031,0.0017509637,0.0040519806,0.000433225,0.000013743354,0.0016200955,0.000043478005],"about_ca_topic_score_codex":0.0057870536,"about_ca_topic_score_gemma":0.0067275735,"teacher_disagreement_score":0.034078095,"about_ca_system_score_codex":0.00006532365,"about_ca_system_score_gemma":0.001215551,"threshold_uncertainty_score":0.8748332},"labels":[],"label_agreement":null},{"id":"W2261084173","doi":"10.1200/jco.2006.24.18_suppl.10096","title":"ErbB3, Cyclin D1 and Ki67 nuclear staining predicts biochemical recurrence in prostate cancer treated by radical prostatectomy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Biochemical recurrence; Medicine; Prostatectomy; Cyclin D1; Tissue microarray; Immunohistochemistry; Oncology; Cancer; Urology; Pathology; Cancer research; Internal medicine; Cell cycle","score_opus":0.02199783072903475,"score_gpt":0.363741757478796,"score_spread":0.34174392674976123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261084173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724985,0.007690781,0.000019650646,0.0012435005,0.0031231171,0.00023670192,0.0000474298,0.000007556212,0.0003814143],"genre_scores_gemma":[0.97846204,0.011564511,0.0007046175,0.0006981068,0.008166123,0.000016597702,0.000033878576,0.00003292934,0.0003211732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969499,0.0003590147,0.0016906677,0.00038831524,0.00022493312,0.00038714355],"domain_scores_gemma":[0.9982814,0.00019090353,0.00088413176,0.00015690514,0.00019565069,0.00029099433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015086074,0.00020117927,0.0008655235,0.00007998755,0.00004303045,0.000020958718,0.00020453375,0.00049212854,0.000024769772],"category_scores_gemma":[0.00096025324,0.00016464303,0.00018789902,0.00013904338,0.00047821284,0.000015946565,0.00009852121,0.0007392054,0.000001615548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011738719,0.0023025658,0.19294679,0.000098386416,0.0002805187,0.00004494455,0.00019239151,0.00007187154,0.21323639,0.00009589899,0.44849446,0.13049705],"study_design_scores_gemma":[0.008870184,0.0029212146,0.04865182,0.000109507906,0.00008896407,0.00010735087,0.00006662308,0.000083063285,0.0036784639,0.00019335843,0.9349778,0.0002516206],"about_ca_topic_score_codex":0.00018005156,"about_ca_topic_score_gemma":0.00010112856,"teacher_disagreement_score":0.48648337,"about_ca_system_score_codex":0.000062824925,"about_ca_system_score_gemma":0.0007600494,"threshold_uncertainty_score":0.6713948},"labels":[],"label_agreement":null},{"id":"W2261454441","doi":"10.1200/jco.2015.33.3_suppl.753","title":"Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Oxaliplatin; Medicine; Colorectal cancer; Internal medicine; Chemotherapy; Oncology; Clinical endpoint; Cancer; Clinical trial","score_opus":0.18698340295509497,"score_gpt":0.5141498129059925,"score_spread":0.3271664099508975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261454441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9284397,0.001233731,0.00009352253,0.06810411,0.0007364984,0.0007336834,0.000016294876,0.0000048351326,0.0006376444],"genre_scores_gemma":[0.97655165,0.000112720816,0.0045878906,0.017382631,0.0010674174,0.00016635236,0.0000018996328,0.000013962177,0.0001154925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763703,0.00028640087,0.0013402109,0.00017158315,0.00032898612,0.00023578656],"domain_scores_gemma":[0.9956387,0.0027497567,0.0007708663,0.00012032929,0.00050238636,0.00021791099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003044263,0.00014459435,0.0011072024,0.000072966555,0.000038307735,0.000009070581,0.0001227908,0.00018155048,0.000041810992],"category_scores_gemma":[0.0024635962,0.0000786595,0.00029797104,0.00016113691,0.00008134432,0.00003658194,0.000019644785,0.0004440629,0.0000025870097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05501081,0.001882608,0.6825468,0.00004964345,0.00052421493,0.0004348003,0.0064657372,0.00035699556,0.000084482315,0.000023399773,0.022042137,0.23057838],"study_design_scores_gemma":[0.02159297,0.03973822,0.83806735,0.0002138821,0.00025851178,0.000017469622,0.0015664035,0.00020770909,0.000065691725,0.00021564907,0.09794321,0.00011292477],"about_ca_topic_score_codex":0.00006364153,"about_ca_topic_score_gemma":0.0012337983,"teacher_disagreement_score":0.23046546,"about_ca_system_score_codex":0.00036695955,"about_ca_system_score_gemma":0.0014927592,"threshold_uncertainty_score":0.32076412},"labels":[],"label_agreement":null},{"id":"W2261580129","doi":"10.1200/jco.2015.33.7_suppl.295","title":"Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Ramucirumab; Taxane; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Paclitaxel; Oncology; Regimen; Interim analysis; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Chemotherapy regimen; Concomitant; Progression-free survival; Chemotherapy; Urology; Clinical trial; Cancer; Breast cancer; Bladder cancer; Urothelial carcinoma","score_opus":0.24961236287668484,"score_gpt":0.5155956843028914,"score_spread":0.2659833214262065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261580129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437296,0.0004862,0.000108466345,0.00072615966,0.0010138828,0.0014970643,0.00004026285,0.000005967006,0.0017490581],"genre_scores_gemma":[0.9958761,0.00011534175,0.0031551996,0.00020932862,0.00028792737,0.000030481797,0.0000048611673,0.000026922875,0.00029388146],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99235964,0.0014182514,0.005016838,0.0002894944,0.0006532272,0.00026252546],"domain_scores_gemma":[0.9909129,0.003636373,0.003715377,0.0003474102,0.00096239283,0.00042551596],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005486579,0.0002571316,0.0050273906,0.0003117282,0.000013455439,0.0000049146934,0.00023260836,0.00016084389,0.0001366528],"category_scores_gemma":[0.00853889,0.00014184523,0.0004922696,0.0003163441,0.00037686963,0.00015128167,0.000055246852,0.00072859577,0.0000030387914],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95314795,0.020574864,0.0015486282,0.00006717337,0.0021033532,0.0015806613,0.0016979221,0.000080550206,0.00012815683,0.0000068423196,0.0002298617,0.018834056],"study_design_scores_gemma":[0.7998972,0.19166091,0.0017444206,0.00016418888,0.0022814095,0.00020309142,0.0022652752,0.00011473943,0.00055822346,0.000068975176,0.0009382393,0.000103331346],"about_ca_topic_score_codex":0.0002225474,"about_ca_topic_score_gemma":0.0008819293,"teacher_disagreement_score":0.17108604,"about_ca_system_score_codex":0.00017824941,"about_ca_system_score_gemma":0.0039949496,"threshold_uncertainty_score":0.9998126},"labels":[],"label_agreement":null},{"id":"W2261906384","doi":"10.1200/jco.2007.25.18_suppl.2046","title":"Intra-arterial chemotherapy and osmotic blood-brain barrier disruption for primitive neuroectodermal tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Radiation therapy; Internal medicine; Medulloblastoma; Confidence interval; Surgery; Oncology; Gastroenterology; Cisplatin; Pathology","score_opus":0.05971547965653052,"score_gpt":0.4335652207828249,"score_spread":0.3738497411262944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261906384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98309124,0.0001395529,0.00038286904,0.014901731,0.00085878203,0.0003575253,0.0000043249775,0.0000066528755,0.00025734803],"genre_scores_gemma":[0.9896771,0.00014135613,0.0022174441,0.006039921,0.0018700998,0.0000053890662,0.0000030692872,0.000017524191,0.000028135884],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785745,0.00013207307,0.0014229588,0.00017274891,0.00017917468,0.00023557535],"domain_scores_gemma":[0.9954764,0.0030219106,0.0007983912,0.00009217376,0.0002180012,0.0003930808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002069577,0.0001265825,0.00096335757,0.00010225519,0.000042181844,0.000010841201,0.000052550593,0.00021539084,0.00005308063],"category_scores_gemma":[0.002333207,0.000087307424,0.00034263806,0.00005672401,0.00016309465,0.000074525226,0.000014281331,0.00033616074,0.0000018877944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02971179,0.011940891,0.25948858,0.000113096554,0.0019958634,0.0049110404,0.0006889171,0.000005129268,0.044502,0.0010637688,0.0058867265,0.6396922],"study_design_scores_gemma":[0.033077344,0.023811212,0.9208335,0.00008001581,0.0007417624,0.0012489534,0.00009928602,0.00003856792,0.0048816325,0.0005509551,0.014535791,0.000100979676],"about_ca_topic_score_codex":0.0000024459905,"about_ca_topic_score_gemma":0.000010882297,"teacher_disagreement_score":0.66134495,"about_ca_system_score_codex":0.000051716688,"about_ca_system_score_gemma":0.00031264842,"threshold_uncertainty_score":0.35602933},"labels":[],"label_agreement":null},{"id":"W2261925730","doi":"10.1200/jco.2007.25.18_suppl.10512","title":"BRCA1/2 mutations and cancer risk in Asian-Americans","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Penetrance; Mutation; Cancer; Epidemiology; Genetics; Internal medicine; Oncology; Breast cancer; Demography; Gene; Biology; Phenotype","score_opus":0.06045686947230045,"score_gpt":0.4700434792467186,"score_spread":0.40958660977441813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261925730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804015,0.0019361067,0.0039420626,0.0022080175,0.000855855,0.000070735245,0.000009080421,0.0000017651653,0.0029362522],"genre_scores_gemma":[0.98562604,0.0032591103,0.009073721,0.0009766701,0.00092488923,0.000003559049,0.0000024086153,0.000010922315,0.00012268312],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981927,0.00020798853,0.0011545768,0.00016166626,0.00011363477,0.000169418],"domain_scores_gemma":[0.998266,0.00036885915,0.000906946,0.00011719501,0.00019385034,0.00014714555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00253879,0.000078772064,0.0003744541,0.0000893209,0.000031562144,0.000005617744,0.00013002643,0.00026506357,0.000032750755],"category_scores_gemma":[0.0018624439,0.00006803503,0.00012246218,0.00013401132,0.00025959508,0.0000055270725,0.000042136955,0.0004387722,0.0000020635302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051810715,0.00027866208,0.31682917,0.00000421877,0.00015549092,0.000064647924,0.0001583335,0.00037900044,0.003364098,0.00003490091,0.0031640276,0.6750493],"study_design_scores_gemma":[0.0025164054,0.0020042825,0.77020806,0.000013823156,0.00007839102,0.00009726572,0.0004942553,0.00003489376,0.0015350941,0.0005470329,0.22235855,0.0001119433],"about_ca_topic_score_codex":0.000076561075,"about_ca_topic_score_gemma":0.0017783721,"teacher_disagreement_score":0.67493737,"about_ca_system_score_codex":0.00008887583,"about_ca_system_score_gemma":0.0011504266,"threshold_uncertainty_score":0.2774388},"labels":[],"label_agreement":null},{"id":"W2261955899","doi":"10.1200/jco.2015.65.1158","title":"Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Colorectal cancer; Cancer; Adjuvant; Internal medicine; Clinical trial; Oncology; Clinical endpoint; Database","score_opus":0.37252569342620556,"score_gpt":0.5711322924020138,"score_spread":0.19860659897580824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261955899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427843,0.0005893368,0.0000071020168,0.0014991381,0.0019114031,0.0011105519,0.00049869483,0.000009305454,0.00009604035],"genre_scores_gemma":[0.9954146,0.0027025884,0.0001175231,0.00074852497,0.00078676513,0.000102751736,0.00000830456,0.00003225738,0.00008665224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98671174,0.004554151,0.006812209,0.0005176537,0.00090209517,0.00050214276],"domain_scores_gemma":[0.9744437,0.017416902,0.0061056386,0.000536776,0.00083686295,0.00066015904],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011313157,0.00031680078,0.004630519,0.00008160268,0.000045944176,0.000010190826,0.00039323233,0.00056153635,0.000725972],"category_scores_gemma":[0.017177364,0.00014197321,0.00071788067,0.00030810706,0.00095849106,0.000261392,0.00016583972,0.001055782,0.000009001249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038345825,0.0028848276,0.83613694,0.000016561162,0.0008626104,0.0004688022,0.000094848445,0.0000024836547,0.000056367742,0.0000014623955,0.0006757678,0.12045354],"study_design_scores_gemma":[0.0368511,0.014210467,0.9433478,0.0017331063,0.0016026914,0.000004437152,0.000022305585,0.000044251843,0.00036236606,0.000049424507,0.0016137066,0.0001583183],"about_ca_topic_score_codex":0.0037583285,"about_ca_topic_score_gemma":0.022374757,"teacher_disagreement_score":0.12029521,"about_ca_system_score_codex":0.00049092463,"about_ca_system_score_gemma":0.0024858832,"threshold_uncertainty_score":0.9954644},"labels":[],"label_agreement":null},{"id":"W2262014445","doi":"10.1200/jco.2009.27.15_suppl.e11515","title":"Racial differences in acute toxicities of FEC 100 chemotherapy in patients with breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Chemotherapy; Epirubicin; Internal medicine; Oncology; Cancer; Cyclophosphamide","score_opus":0.06449901478663041,"score_gpt":0.47127521299723507,"score_spread":0.4067761982106047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262014445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923767,0.00019697438,0.0000018813204,0.009470173,0.0003915751,0.00016226235,0.000008485939,0.0000021492988,0.0005288397],"genre_scores_gemma":[0.99556285,0.0012499118,0.00016684225,0.002495421,0.00040645924,0.0000026744108,0.0000014002768,0.0000054559464,0.00010895497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819845,0.00014882801,0.0011781726,0.00010715187,0.00020261841,0.0001647829],"domain_scores_gemma":[0.9984897,0.00035853146,0.0008072263,0.000059273825,0.0001737377,0.00011153909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043703985,0.00010433094,0.0012628912,0.00016026472,0.000008589963,0.0000020154407,0.00008725807,0.00019049911,0.00036188847],"category_scores_gemma":[0.000049796887,0.000063678825,0.00014103943,0.00015067715,0.00014590405,0.0000744306,0.0000075635626,0.00046767786,7.783212e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029224169,0.0043481095,0.8209163,0.000005981932,0.00020839463,0.00010946202,0.00030392205,0.0000025906031,0.00006215674,0.000009248755,0.00037151392,0.14443816],"study_design_scores_gemma":[0.02755623,0.026901046,0.94435453,0.00010554154,0.00013780207,0.000023394452,0.00003291743,0.000006244532,0.00006856085,0.00010198656,0.0006570108,0.00005471957],"about_ca_topic_score_codex":0.000079218924,"about_ca_topic_score_gemma":0.00038114836,"teacher_disagreement_score":0.14438345,"about_ca_system_score_codex":0.00017180214,"about_ca_system_score_gemma":0.0008555652,"threshold_uncertainty_score":0.3962425},"labels":[],"label_agreement":null},{"id":"W2262026236","doi":"10.1200/jco.2009.27.15_suppl.6535","title":"Cardiovascular risk factor control among cancer survivors: A population-based survey","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Comorbidity; National Health and Nutrition Examination Survey; Internal medicine; Blood pressure; Population; Risk factor; Disease; Cancer registry; Physical therapy; Environmental health","score_opus":0.08675413223647366,"score_gpt":0.4248241676036239,"score_spread":0.33807003536715025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262026236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934051,0.0006549478,0.0029808355,0.0014869247,0.0009416567,0.00027908245,0.00003706678,0.000015936663,0.00019846055],"genre_scores_gemma":[0.9947849,0.0005264931,0.00034919142,0.0026240575,0.0016574893,0.0000025027152,0.000008624491,0.000014572053,0.000032153817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958272,0.0015323107,0.0016945482,0.00019622452,0.0005392205,0.00021047058],"domain_scores_gemma":[0.9950627,0.0022800474,0.0013840422,0.00025556612,0.00066341605,0.00035419385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005914426,0.00014846072,0.0018832074,0.000114570634,0.000051895036,0.00001143493,0.00011050049,0.00052865705,0.00011630052],"category_scores_gemma":[0.005396248,0.00011231037,0.0015736242,0.00017284078,0.000076998745,0.00010894415,0.0000043000996,0.0010239198,0.000003899045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016882467,0.00038000796,0.809211,0.000007841016,0.0010301209,0.000070965296,0.000026352387,0.0009875215,0.0002821847,0.0000026236025,0.00016384582,0.18614928],"study_design_scores_gemma":[0.010081207,0.0027294247,0.9820114,0.00006719834,0.00063920824,0.000021519103,0.000010447394,0.00039278736,0.0005324349,0.000080991274,0.0033258155,0.00010759476],"about_ca_topic_score_codex":0.002326419,"about_ca_topic_score_gemma":0.001353823,"teacher_disagreement_score":0.18604168,"about_ca_system_score_codex":0.0002413343,"about_ca_system_score_gemma":0.001073547,"threshold_uncertainty_score":0.64602023},"labels":[],"label_agreement":null},{"id":"W2262285930","doi":"10.1200/jco.2007.25.18_suppl.14573","title":"Altered circadian rhythm in rest and activity (CircAct): Independent prognostic value for survival in patients (pts) with metastatic colorectal cancer (MCC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Circadian rhythm; Colorectal cancer; Hazard ratio; Oncology; Cancer; Survival analysis; Gastroenterology; Confidence interval","score_opus":0.08239835167421516,"score_gpt":0.43105184348661746,"score_spread":0.3486534918124023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262285930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607897,0.00018082753,0.00020388365,0.0009868473,0.0014673416,0.000773586,0.000014588386,0.000004479597,0.0002894796],"genre_scores_gemma":[0.99852514,0.0001288691,0.00032461208,0.00044535383,0.0005043065,0.000025198413,0.000003804487,0.000022982653,0.000019716532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970423,0.0004148503,0.0014533602,0.00027058058,0.0004266051,0.00039228413],"domain_scores_gemma":[0.9948911,0.0033068892,0.0009485478,0.00010579083,0.0003394088,0.00040823437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046383394,0.0001671038,0.0013800457,0.00026591896,0.000026273714,0.0000103865,0.000089337685,0.0002620343,0.00001800936],"category_scores_gemma":[0.0021027096,0.00012519097,0.00016509494,0.0002464057,0.0001620868,0.00013333127,0.000032227672,0.0010562224,7.335255e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019791052,0.0015144531,0.88408893,0.000081975886,0.00015166885,0.00040955062,0.00034957417,0.000019791953,0.000030265257,0.00003139033,0.000026772736,0.09350458],"study_design_scores_gemma":[0.018907273,0.012841827,0.96579415,0.00023590405,0.00021315466,0.00009030811,0.00023657143,0.00006799092,0.00007662535,0.00007865045,0.0013301593,0.00012740534],"about_ca_topic_score_codex":0.0013120177,"about_ca_topic_score_gemma":0.08875088,"teacher_disagreement_score":0.09337717,"about_ca_system_score_codex":0.00044273873,"about_ca_system_score_gemma":0.0014494124,"threshold_uncertainty_score":0.92787707},"labels":[],"label_agreement":null},{"id":"W2262351582","doi":"10.1200/jco.2005.23.16_suppl.5005","title":"Prognostic value of clinical and molecular markers in advanced ovarian cancer (AOC): importance of residual (Rs) disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 Phase III Randomized Clinical Trial (RCT)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Randomized controlled trial; Population; Concordance; Ovarian cancer; Context (archaeology); Breast cancer; Univariate analysis; Cancer; Multivariate analysis","score_opus":0.11169151791978289,"score_gpt":0.5102172237063687,"score_spread":0.3985257057865858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262351582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868779,0.003169185,0.00022456789,0.0048571234,0.0015621544,0.003109985,0.000092001545,0.0000074089803,0.00009964774],"genre_scores_gemma":[0.98209,0.0015295859,0.012920285,0.00084099994,0.0024897016,0.00006404739,0.0000151571785,0.00003917051,0.000011070144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9814922,0.004159117,0.012313545,0.0007039824,0.00095648697,0.00037467392],"domain_scores_gemma":[0.9775048,0.01486903,0.00589344,0.00042121753,0.0005020665,0.00080944004],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.016258074,0.0003602713,0.006311685,0.00022299869,0.000040689552,0.000010361821,0.0002269504,0.00040451658,0.0003931444],"category_scores_gemma":[0.011482968,0.00027117832,0.001507016,0.00025494045,0.0009235045,0.00018054967,0.000066193,0.001322463,0.0000010498208],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5174274,0.016685273,0.43363538,0.000023700728,0.0018462978,0.0010819435,0.0000841032,0.00022188353,0.000019649058,0.00008592005,0.00007234499,0.028816106],"study_design_scores_gemma":[0.5364348,0.009490114,0.4479048,0.0003324663,0.0035787753,0.00001559414,0.00008729441,0.001346132,0.000012040998,0.00034122035,0.00032245947,0.00013426214],"about_ca_topic_score_codex":0.0001550005,"about_ca_topic_score_gemma":0.0002936665,"teacher_disagreement_score":0.028681844,"about_ca_system_score_codex":0.00016041723,"about_ca_system_score_gemma":0.005426344,"threshold_uncertainty_score":0.999974},"labels":[],"label_agreement":null},{"id":"W2262407495","doi":"10.1200/jco.2009.27.15_suppl.e16016","title":"Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Waterloo","funders":"","keywords":"Medicine; Renal cell carcinoma; N-terminal telopeptide; Internal medicine; Confidence interval; Creatinine; Zoledronic acid; Urology; Osteolysis; Oncology; Surgery; Alkaline phosphatase","score_opus":0.05175891864653746,"score_gpt":0.3936366074072193,"score_spread":0.3418776887606818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262407495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809706,0.0004680442,0.000032700646,0.0003567789,0.00013187235,0.00020855671,0.000012816991,0.000001658906,0.00069049187],"genre_scores_gemma":[0.99454653,0.00011849577,0.0048942696,0.00031502426,0.000064301355,4.925046e-7,0.000017243941,0.000007738512,0.000035931218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977219,0.00028971568,0.0014000385,0.00013092901,0.0003201929,0.00013722459],"domain_scores_gemma":[0.9966377,0.0009917474,0.0016203936,0.00011112807,0.0004118412,0.0002272141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007350639,0.000110968285,0.0012435288,0.000114291644,0.000015982336,0.0000017878609,0.000042497617,0.00018155381,0.000041354193],"category_scores_gemma":[0.00043957587,0.00006529039,0.000069674956,0.00014745638,0.000116117364,0.00006791248,0.000010446652,0.00030433576,0.0000010676044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03184222,0.0021736773,0.9458912,0.000021422,0.00011488,0.00029660857,0.00010039464,0.000051404524,0.000050040755,0.0000049688992,0.0002478248,0.019205336],"study_design_scores_gemma":[0.01964608,0.049569204,0.9293817,0.00011527778,0.00040810625,0.000026395379,0.000058153182,0.000027886743,0.00024702863,0.00006251197,0.00040804496,0.00004959856],"about_ca_topic_score_codex":0.00030076448,"about_ca_topic_score_gemma":0.00042662898,"teacher_disagreement_score":0.047395527,"about_ca_system_score_codex":0.00006753426,"about_ca_system_score_gemma":0.0010563135,"threshold_uncertainty_score":0.2662465},"labels":[],"label_agreement":null},{"id":"W2262509800","doi":"10.1200/jco.2007.25.18_suppl.5093","title":"Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Progressive disease; Clinical endpoint; Phases of clinical research; Internal medicine; Adverse effect; Gastroenterology; Performance status; Toxicity; Response Evaluation Criteria in Solid Tumors; Surgery; Urology; Cancer; Clinical trial; Chemotherapy","score_opus":0.10328772005201765,"score_gpt":0.44693138477118566,"score_spread":0.343643664719168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262509800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256355,0.0014014519,0.000019122623,0.0012421815,0.0015213585,0.0027910832,0.000019891213,0.0000050008193,0.00043637067],"genre_scores_gemma":[0.9980145,0.000058646598,0.0007232591,0.00019613943,0.000669652,0.00003558667,0.0000021067342,0.00003246838,0.000267639],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913723,0.0013012448,0.0054094377,0.0003629311,0.0010843265,0.00046979907],"domain_scores_gemma":[0.9893631,0.0033190495,0.0054412093,0.0006859986,0.0008248734,0.00036580628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050898967,0.00032626747,0.0025466543,0.00030662096,0.00016080031,0.000005225006,0.00052117114,0.0002748284,0.00007620027],"category_scores_gemma":[0.0039972547,0.00016734855,0.001210018,0.0008261062,0.0005370249,0.00010311171,0.0003169033,0.0010500667,9.838326e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56686234,0.27569807,0.057527687,0.00023352994,0.0013219514,0.0046503497,0.0020698307,0.0002393067,0.015504838,0.0000096212225,0.0010223183,0.07486017],"study_design_scores_gemma":[0.5176642,0.37898088,0.04756337,0.000281886,0.0026099607,0.00032790535,0.0009994883,0.000066886176,0.04980574,0.00004210643,0.0014874118,0.00017017174],"about_ca_topic_score_codex":0.00006777198,"about_ca_topic_score_gemma":0.0003738741,"teacher_disagreement_score":0.10328281,"about_ca_system_score_codex":0.00028786034,"about_ca_system_score_gemma":0.0021814057,"threshold_uncertainty_score":0.6824276},"labels":[],"label_agreement":null},{"id":"W2262688947","doi":"10.1200/jco.2014.32.31_suppl.18","title":"The benefits of early integration of palliative care as a part of standard outpatient oncology care.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Psychological intervention; Palliative care; Population; Internal medicine; Outpatient clinic; Family medicine; Oncology; Health care; Ambulatory care; Emergency medicine; Nursing","score_opus":0.3003042961966484,"score_gpt":0.5506314571133539,"score_spread":0.25032716091670554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262688947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98642564,0.004990287,0.00027491015,0.0012912888,0.0011062233,0.00022635932,0.0000364491,0.0000026842401,0.005646184],"genre_scores_gemma":[0.99267316,0.003964509,0.0026419866,0.00021693391,0.0004382734,0.000003593346,0.000006156754,0.000011196063,0.000044174863],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951786,0.0007814544,0.0031603852,0.00014038471,0.0005677178,0.00017145734],"domain_scores_gemma":[0.98436075,0.0063250735,0.0046553863,0.00023324635,0.0042573162,0.00016821442],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002065284,0.00013803014,0.00204808,0.00011035838,0.000028132292,0.0000019364745,0.00021903303,0.0004222367,0.00003061879],"category_scores_gemma":[0.01245357,0.000081380436,0.00056449487,0.00014233042,0.00057238643,0.000051050847,0.000054247095,0.00065106596,0.0000019329996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01749667,0.0009269107,0.36068684,0.00026473464,0.00084953435,0.000020416692,0.025973272,0.000089660694,0.0005260388,0.0029565005,0.0014756414,0.5887338],"study_design_scores_gemma":[0.0146913,0.22683153,0.36865827,0.0032424794,0.0013786564,0.0000105105955,0.0340256,0.000033012806,0.023202993,0.0011031518,0.3266369,0.00018561052],"about_ca_topic_score_codex":0.00011473591,"about_ca_topic_score_gemma":0.0004128412,"teacher_disagreement_score":0.5885482,"about_ca_system_score_codex":0.0002084849,"about_ca_system_score_gemma":0.0016683835,"threshold_uncertainty_score":0.9958649},"labels":[],"label_agreement":null},{"id":"W2262699108","doi":"10.1200/jco.2007.25.18_suppl.7649","title":"IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Gemcitabine; Toxicity; Adverse effect; Internal medicine; Pharmacokinetics; Dosing; Gastroenterology; Urology; Chemotherapy; Pharmacology","score_opus":0.06008348037096114,"score_gpt":0.46732605000908123,"score_spread":0.4072425696381201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262699108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952094,0.00014391172,0.00009956182,0.00014636466,0.00066202803,0.00367713,0.000028351204,0.0000035403966,0.000029694122],"genre_scores_gemma":[0.9985855,0.000113683884,0.00090627314,0.000101156045,0.0001999969,0.00004780236,0.0000051414977,0.000027856542,0.000012580294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925494,0.0016000457,0.0045618373,0.0003454176,0.0006858353,0.00025742227],"domain_scores_gemma":[0.9923689,0.002702745,0.0037686871,0.00024023667,0.0006975744,0.00022187123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064040096,0.00024306038,0.0025209633,0.00024212414,0.00004084135,0.0000071335426,0.00016574938,0.00024297436,0.000023943867],"category_scores_gemma":[0.0022296987,0.00013103106,0.0002267976,0.00046597028,0.00016448332,0.00016889811,0.000055541477,0.00095728564,1.8430103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032843027,0.059939653,0.87608486,0.00006592434,0.00068728195,0.000054709766,0.0037722874,0.000025989319,0.00010124315,0.0000017736405,0.00001624775,0.026406994],"study_design_scores_gemma":[0.20080517,0.089796506,0.7053638,0.00027508475,0.0011139454,0.0000019437564,0.0024274443,0.000024247558,0.00005429648,0.0000043082346,0.000043006123,0.000090263224],"about_ca_topic_score_codex":0.00034190348,"about_ca_topic_score_gemma":0.00360162,"teacher_disagreement_score":0.17072108,"about_ca_system_score_codex":0.00028803584,"about_ca_system_score_gemma":0.0009968886,"threshold_uncertainty_score":0.5343292},"labels":[],"label_agreement":null},{"id":"W2262825750","doi":"10.1200/jco.2007.25.18_suppl.18093","title":"Image-guided lung radiotherapy: Bringing technology into routine clinical practice","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Nuclear medicine; Radiation therapy; Cone beam ct; Radiation treatment planning; Image registration; Radiology; Computed tomography; Artificial intelligence; Computer science; Image (mathematics); Oncology","score_opus":0.048531956555590026,"score_gpt":0.5143775417620451,"score_spread":0.4658455852064551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262825750","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09918919,0.0012638527,0.8775769,0.009847031,0.0018945377,0.00024668392,0.0000012265084,0.000093311945,0.0098873],"genre_scores_gemma":[0.23598307,0.00052995136,0.75600404,0.0020387208,0.0052382555,0.0000030511444,0.000001100756,0.000051741248,0.00015006967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932148,0.0006080036,0.004967265,0.00035598944,0.00034946072,0.0005045095],"domain_scores_gemma":[0.987566,0.006216301,0.0045863744,0.00041186326,0.00086372544,0.0003557176],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015892088,0.0002548581,0.0017394024,0.0003213976,0.00010431777,0.000025473566,0.00063477736,0.0005561963,0.00030979898],"category_scores_gemma":[0.0036289091,0.00021119714,0.00074012956,0.00041104647,0.000561314,0.00053124013,0.00010402647,0.0025753665,0.0000064144356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012706461,0.0017587654,0.23422416,0.000009520355,0.0010158384,0.00038231362,0.00011722879,0.00001592785,0.0014216688,0.005386018,0.009981119,0.7444168],"study_design_scores_gemma":[0.008474577,0.0054397364,0.014784608,0.00009301104,0.00030573137,0.00047487213,0.00043230236,0.0011231401,0.0010638394,0.008160213,0.9591865,0.0004614738],"about_ca_topic_score_codex":0.000032801552,"about_ca_topic_score_gemma":0.000002966558,"teacher_disagreement_score":0.9492054,"about_ca_system_score_codex":0.0002340188,"about_ca_system_score_gemma":0.0007841084,"threshold_uncertainty_score":0.99972576},"labels":[],"label_agreement":null},{"id":"W2262858020","doi":"10.1200/jco.2009.27.15_suppl.2504","title":"Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Bilirubin; Population; Tolerability; Pharmacology; Adverse effect","score_opus":0.12026165016198466,"score_gpt":0.5070889860882271,"score_spread":0.3868273359262424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262858020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667746,0.004264199,0.00011014209,0.02467512,0.0012748818,0.00022656829,0.000005656156,0.000014383264,0.0026544454],"genre_scores_gemma":[0.97502065,0.012633656,0.0015288313,0.008300544,0.0022150916,0.0000015428136,0.0000029082516,0.000012205443,0.000284575],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751073,0.00029333698,0.0015114746,0.00020010846,0.00024165113,0.00024271119],"domain_scores_gemma":[0.99773455,0.0007632216,0.0005981519,0.000114784154,0.00021487557,0.00057442964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011132705,0.00016001835,0.0011599811,0.00010134783,0.000044814897,0.0000058650876,0.00010325995,0.0002854429,0.0003055165],"category_scores_gemma":[0.00039182536,0.00011414299,0.00028180686,0.000103518476,0.00017705266,0.00009006897,0.000017807986,0.000813265,0.000010000336],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031186473,0.006194765,0.042510923,0.000055917466,0.0005662799,0.0024102728,0.00021343536,0.0000450895,0.035663452,0.00007595723,0.033043563,0.84803385],"study_design_scores_gemma":[0.03695702,0.062442318,0.5458927,0.00017825911,0.0017928554,0.0015777966,0.000024082836,0.00036204924,0.012345856,0.00048122913,0.33776078,0.00018504677],"about_ca_topic_score_codex":0.0000028279303,"about_ca_topic_score_gemma":0.0000031190018,"teacher_disagreement_score":0.84784883,"about_ca_system_score_codex":0.00006598672,"about_ca_system_score_gemma":0.0006316969,"threshold_uncertainty_score":0.4654616},"labels":[],"label_agreement":null},{"id":"W2262955378","doi":"10.1200/jco.2006.24.18_suppl.11509","title":"Determination of human brain tumour therapy response using an <i>ex vivo</i> invasion assay provides a potential step toward individualized treatment","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Ex vivo; Chemotherapy; In vivo; Oncology; Pathology; Internal medicine; Biology","score_opus":0.1671113860062545,"score_gpt":0.4673711458936067,"score_spread":0.3002597598873522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262955378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994678,0.00027935338,0.0003330864,0.0038047084,0.00030235326,0.00046463392,0.000009310783,0.000010149725,0.000118376855],"genre_scores_gemma":[0.98935044,0.00011180835,0.009276968,0.00054034655,0.00062938244,0.00000764148,0.000010593361,0.000023023982,0.000049784427],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946877,0.0021031932,0.0022882398,0.00022854414,0.00047623535,0.0002161021],"domain_scores_gemma":[0.99485797,0.0019916866,0.002311191,0.00019633392,0.00040819027,0.00023461501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004430258,0.00019843072,0.0014164278,0.00028810775,0.00006714284,0.000019409088,0.00011892505,0.00033478468,0.00007875912],"category_scores_gemma":[0.001034276,0.00012912496,0.0005994424,0.00013301658,0.00014894351,0.00016949399,0.000026952224,0.00025459495,0.0000016882686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027192637,0.033257958,0.09043322,0.000033430526,0.00057888875,0.0030585164,0.0004880538,0.0000633866,0.56537265,0.00006033527,0.00088300975,0.27857795],"study_design_scores_gemma":[0.079868615,0.14365004,0.6745202,0.00034974172,0.0015866344,0.0011536338,0.00039101913,0.0011431852,0.08429216,0.0010559276,0.011682387,0.00030646272],"about_ca_topic_score_codex":0.0002397553,"about_ca_topic_score_gemma":0.00010902247,"teacher_disagreement_score":0.584087,"about_ca_system_score_codex":0.00033589432,"about_ca_system_score_gemma":0.0010561665,"threshold_uncertainty_score":0.5265563},"labels":[],"label_agreement":null},{"id":"W2263012629","doi":"10.1200/jco.2005.23.16_suppl.890","title":"Do clinical trials of neoadjuvant chemotherapy for locally advanced breast cancer (LABC) overestimate the actual response rates observed in clinical practice?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anthracycline; Taxane; Breast cancer; Internal medicine; Regimen; Chemotherapy; Oncology; Clinical trial; Inflammatory breast cancer; Neoadjuvant therapy; Chemotherapy regimen; Stage (stratigraphy); Cancer; Surgery","score_opus":0.3706597621708674,"score_gpt":0.637973111732331,"score_spread":0.2673133495614636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263012629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8340005,0.0029757866,0.00014834818,0.15826063,0.0031054867,0.0012665726,0.00007108816,0.0000110773435,0.00016046289],"genre_scores_gemma":[0.9320154,0.021492355,0.015545347,0.023228554,0.0071629165,0.00007410401,0.000006731034,0.000057254118,0.00041731],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.97756946,0.0086006345,0.012396866,0.00046064804,0.00048520396,0.0004871862],"domain_scores_gemma":[0.87659025,0.11273525,0.008502329,0.00039539332,0.0012654089,0.0005113376],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07545433,0.00031308984,0.00492605,0.00014782866,0.000056119286,0.000016251093,0.0004208272,0.0009044686,0.0006849597],"category_scores_gemma":[0.06609322,0.00018000047,0.0021074533,0.00024630505,0.0007459704,0.00028569947,0.00007144884,0.0020030707,0.000010182533],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37369242,0.0076776617,0.05008275,0.000023942013,0.0013702019,0.00017261623,0.00013375947,0.0001443677,0.00047162877,0.0000418686,0.0140985,0.5520903],"study_design_scores_gemma":[0.085498646,0.030940702,0.5425759,0.00028529734,0.0016384281,0.0003899989,0.00018248452,0.00065132696,0.00021229478,0.00019252086,0.33725986,0.00017252986],"about_ca_topic_score_codex":0.000042352025,"about_ca_topic_score_gemma":0.00022742669,"teacher_disagreement_score":0.55191773,"about_ca_system_score_codex":0.0003168149,"about_ca_system_score_gemma":0.0068587875,"threshold_uncertainty_score":0.9987714},"labels":[],"label_agreement":null},{"id":"W2263077335","doi":"10.1200/jco.2006.24.18_suppl.7543","title":"Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Gastroenterology; Neutropenia; Multiple myeloma; Rituximab; Nausea; Progressive disease; Marginal zone B-cell lymphoma; Surgery; Lymphoma; Chemotherapy; Immunology; B cell; Antibody; Marginal zone","score_opus":0.11259471274370103,"score_gpt":0.5001755884203875,"score_spread":0.3875808756766864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263077335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944601,0.00017416786,0.0000018748106,0.0024337182,0.00035121464,0.00080913503,0.00014263719,0.0000040468917,0.0016231269],"genre_scores_gemma":[0.99771935,0.00021537307,0.0002391409,0.00029714845,0.00039898584,0.000017809596,0.000018644449,0.00001751358,0.0010760198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99295276,0.00044775242,0.0046264715,0.00032949937,0.0011968565,0.0004466565],"domain_scores_gemma":[0.99402684,0.0017270364,0.0022609236,0.00023028947,0.0014631909,0.00029173467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027037933,0.0002198989,0.0022279038,0.00039000422,0.000029861869,0.000003528775,0.00028385612,0.0003694505,0.00020272002],"category_scores_gemma":[0.0052331304,0.00015459134,0.0002225074,0.00079662737,0.00032086525,0.0001261085,0.00009815491,0.0009946765,8.073513e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.44363052,0.0722813,0.24601103,0.00044102353,0.0032906563,0.036359318,0.0031267197,0.0056081447,0.0020231514,0.00003913237,0.07586854,0.11132046],"study_design_scores_gemma":[0.62035096,0.066514716,0.28603178,0.0011430627,0.0006317327,0.00090561574,0.000792191,0.006763939,0.003874649,0.000084999534,0.012558803,0.00034750573],"about_ca_topic_score_codex":0.52552205,"about_ca_topic_score_gemma":0.83803904,"teacher_disagreement_score":0.312517,"about_ca_system_score_codex":0.018334663,"about_ca_system_score_gemma":0.13663687,"threshold_uncertainty_score":0.98543376},"labels":[],"label_agreement":null},{"id":"W2263167034","doi":"10.1200/jco.2014.32.31_suppl.208","title":"Outcomes of supportive/palliative care (SPC) for advanced cancer patients (AdCa) in a general public hospital and a comprehensive cancer center.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Lung cancer; Internal medicine; Cancer; Psychosocial; Palliative care; Anxiety; Distress; Psychiatry; Nursing","score_opus":0.09417114169619213,"score_gpt":0.4801382264568842,"score_spread":0.3859670847606921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263167034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907667,0.0011665191,0.00005653098,0.0049101375,0.0023833362,0.0004375227,0.00010597708,0.000003645481,0.00016962913],"genre_scores_gemma":[0.99576956,0.0011747157,0.0005856656,0.001906769,0.0004303941,0.000045621073,0.000012322933,0.000017697623,0.00005725033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974488,0.00020529272,0.0015821685,0.00021862557,0.00028114655,0.0002639897],"domain_scores_gemma":[0.99533254,0.0010196082,0.0015961525,0.00011085711,0.0016639347,0.00027692172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039235238,0.00015854093,0.0016814485,0.00012456109,0.000023208973,0.0000053476488,0.00011482601,0.00022915039,0.00004041239],"category_scores_gemma":[0.001268416,0.00011642554,0.00037801755,0.00010708818,0.00019156921,0.00011431383,0.000054031618,0.00043927282,2.975133e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019201833,0.0007007576,0.89066976,0.00012595339,0.00023856401,0.000010339725,0.0013738514,0.000008753295,0.000020203654,0.00004657924,0.00039205304,0.10449302],"study_design_scores_gemma":[0.017243315,0.009682004,0.9366487,0.00016945413,0.00015185114,0.0000015747676,0.001080996,0.00003976684,0.000060273876,0.00007302105,0.034740202,0.000108795844],"about_ca_topic_score_codex":0.00032109112,"about_ca_topic_score_gemma":0.0043375143,"teacher_disagreement_score":0.10438422,"about_ca_system_score_codex":0.00026544195,"about_ca_system_score_gemma":0.00086542906,"threshold_uncertainty_score":0.47476956},"labels":[],"label_agreement":null},{"id":"W2263184680","doi":"10.1200/jco.2007.25.18_suppl.5096","title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Renal cell carcinoma; Internal medicine; Nephrectomy; Placebo; Progression-free survival; Surgery; Oncology; Urology; Overall survival; Kidney; Hepatocellular carcinoma; Pathology","score_opus":0.16033879753363142,"score_gpt":0.4765897460965622,"score_spread":0.3162509485629308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263184680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905094,0.00056819554,0.00008127039,0.0033311131,0.0026546407,0.001039076,0.000002894314,0.000011493115,0.001801907],"genre_scores_gemma":[0.9963884,0.000535268,0.00045380177,0.0009038075,0.0009520499,0.000015335736,0.000009417129,0.000036617184,0.00070533814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99302596,0.0005078092,0.0046676113,0.00035182922,0.00083095324,0.00061583763],"domain_scores_gemma":[0.98832756,0.007119574,0.002840213,0.0004814923,0.0006063985,0.00062478293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052541313,0.00031419357,0.0021352316,0.00026301143,0.00011204369,0.00003089447,0.0005616186,0.00047185516,0.00007443845],"category_scores_gemma":[0.003598199,0.00017438471,0.0009196323,0.00026086956,0.00026173153,0.00022697417,0.00017569237,0.0014280496,0.00002166134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.106713004,0.0049939463,0.7817747,0.00002706175,0.00013600594,0.0021115001,0.000068369045,0.000016747385,0.000036203146,0.0000049715186,0.00030228705,0.1038152],"study_design_scores_gemma":[0.1493548,0.023796026,0.82283515,0.00006055443,0.00026921928,0.00006849714,0.00003341703,0.000005747074,0.00070476485,0.00009018656,0.0026498006,0.00013186043],"about_ca_topic_score_codex":0.000029139583,"about_ca_topic_score_gemma":0.0007512353,"teacher_disagreement_score":0.10368334,"about_ca_system_score_codex":0.000635883,"about_ca_system_score_gemma":0.0009756761,"threshold_uncertainty_score":0.71112025},"labels":[],"label_agreement":null},{"id":"W2263314754","doi":"10.1200/jco.2007.25.18_suppl.17051","title":"Self-directed learning module for radiation therapy treatment planning","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Radiation treatment planning; Radiation oncology; Medicine; Medical physics; Specialty; Dosimetry; Radiation therapy; Radiation oncologist; Computer science; Nuclear medicine; Radiology; Pathology","score_opus":0.11542970969496684,"score_gpt":0.5505652575007689,"score_spread":0.43513554780580205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263314754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9514263,0.008354157,0.025657082,0.004191606,0.0048063896,0.0006633164,0.0000012488109,0.00015871515,0.0047411746],"genre_scores_gemma":[0.6780922,0.01790692,0.2846318,0.0046958495,0.013061704,0.000013671368,0.00001136567,0.000052648113,0.0015338588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978421,0.00022645573,0.0014181093,0.00014023685,0.00014116037,0.00023195993],"domain_scores_gemma":[0.9924253,0.005681466,0.0013378551,0.000087713874,0.0002554117,0.00021225779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035106884,0.00011555783,0.0010227846,0.00012218008,0.00008977398,0.0000030792003,0.00007211491,0.00044643317,0.00004359353],"category_scores_gemma":[0.001643069,0.000075543685,0.00039715928,0.00009382427,0.0000924262,0.000080198915,0.0000044964013,0.00057441264,0.0000031130726],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01370442,0.0019131318,0.13026433,0.000008677823,0.0007753191,0.0002839378,0.00038944118,0.00027381885,0.00016468264,0.00006904448,0.0014705828,0.8506826],"study_design_scores_gemma":[0.018363979,0.044322602,0.12734161,0.000021305219,0.00014308958,0.0003500186,0.00007773668,0.0017154436,0.0002503828,0.0002696943,0.8070695,0.00007468695],"about_ca_topic_score_codex":0.0000011906011,"about_ca_topic_score_gemma":0.0000020725406,"teacher_disagreement_score":0.85060793,"about_ca_system_score_codex":0.00039710052,"about_ca_system_score_gemma":0.0007530831,"threshold_uncertainty_score":0.34433016},"labels":[],"label_agreement":null},{"id":"W2263368480","doi":"10.1200/jco.2009.27.15_suppl.e20502","title":"Can prognostic factors identify women receiving anthracycline plus cyclophosphamide-based chemotherapy (MEC) who do not require an NK<sub>1</sub> receptor antagonist?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pregnancy and Medication Impact","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Medicine; Ondansetron; Antiemetic; Internal medicine; Placebo; NK1 receptor antagonist; Chemotherapy; Mucositis; Regimen; Gastroenterology; Oncology; Anesthesia; Nausea","score_opus":0.07092152066909709,"score_gpt":0.43435126972082555,"score_spread":0.3634297490517285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263368480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715018,0.00026452198,0.0006282472,0.025607279,0.001275724,0.00044832018,0.0000084281,0.00006302904,0.00020264958],"genre_scores_gemma":[0.98210645,0.0022511808,0.0015375437,0.012736141,0.0012462194,0.000009707518,0.000017493814,0.0000358827,0.000059408772],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99431854,0.00060365326,0.003222434,0.00042599856,0.00075712113,0.00067225547],"domain_scores_gemma":[0.99253684,0.0022873778,0.002556355,0.00047658695,0.0005583812,0.0015844402],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049353866,0.0003143861,0.0019448219,0.00024122295,0.0001632454,0.0000459879,0.00039651353,0.00057043793,0.00028771113],"category_scores_gemma":[0.012820604,0.0002321558,0.00047649094,0.0003852105,0.00039068903,0.00060993404,0.0000236148,0.0014014429,0.000016926191],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012007905,0.004416378,0.23058183,0.00008542259,0.00031628017,0.0005556954,0.0019966094,0.00004331504,0.10823241,0.00006031766,0.0012204491,0.6404834],"study_design_scores_gemma":[0.015999964,0.019187087,0.92292386,0.0008722885,0.00016345936,0.00021747862,0.0005509477,0.00013647482,0.032575417,0.0005526332,0.0065270867,0.00029332406],"about_ca_topic_score_codex":0.000009611082,"about_ca_topic_score_gemma":0.000012439737,"teacher_disagreement_score":0.692342,"about_ca_system_score_codex":0.000671426,"about_ca_system_score_gemma":0.0034896976,"threshold_uncertainty_score":0.99549484},"labels":[],"label_agreement":null},{"id":"W2263699408","doi":"10.1200/jco.2007.25.18_suppl.15564","title":"Relapse patterns and outcomes in a population-based study of Nova Scotia patients with germ cell tumors (GCT)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Chemotherapy; Incidence (geometry); Population; Surgery; Retrospective cohort study; Cohort; Germ cell tumors; Internal medicine","score_opus":0.044960628149617356,"score_gpt":0.41729323446540545,"score_spread":0.3723326063157881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263699408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992446,0.00004600276,0.000022806815,0.00015074332,0.0001661218,0.00032787738,0.000003637438,0.0000026836872,0.000035549627],"genre_scores_gemma":[0.9990494,0.0000022040203,0.0006064308,0.0002744174,0.000043723827,5.2027565e-7,0.000004153565,0.0000105402405,0.000008594089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977362,0.00013462466,0.0015530037,0.00012798447,0.0003156946,0.00013248877],"domain_scores_gemma":[0.9968067,0.0012447779,0.001381773,0.00012524732,0.00020223796,0.00023929887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008174889,0.00010319239,0.0009558038,0.00014968422,0.000010458633,0.0000026529947,0.00004843856,0.00009874954,0.000027255854],"category_scores_gemma":[0.0010096701,0.00006180582,0.00012773844,0.00009148174,0.000033514476,0.000042284886,0.000016437496,0.00028742565,0.0000013474859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002740482,0.01775627,0.97290295,0.00003118777,0.00013911871,0.0008998867,0.000056134013,0.000019995834,5.69993e-7,0.0000011994513,0.0000043765904,0.0054478236],"study_design_scores_gemma":[0.028702898,0.020698382,0.9498615,0.000112304886,0.00041895392,0.000008744192,0.000120047385,0.000009105535,0.000002396695,0.000009667006,0.0000057435755,0.000050222006],"about_ca_topic_score_codex":0.00060054555,"about_ca_topic_score_gemma":0.0020280667,"teacher_disagreement_score":0.025962414,"about_ca_system_score_codex":0.00007545172,"about_ca_system_score_gemma":0.00031148203,"threshold_uncertainty_score":0.2520368},"labels":[],"label_agreement":null},{"id":"W2264080550","doi":"10.1200/jco.2009.27.15_suppl.6612","title":"Employment status among low-income Caucasian and Latina breast cancer survivors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Breast cancer; Ethnic group; Survivorship curve; Quality of life (healthcare); Cancer; Health care; Prospective cohort study; Gerontology; Longitudinal study; Demography; Family medicine; Internal medicine; Nursing; Pathology","score_opus":0.05895420993056313,"score_gpt":0.4380438941558217,"score_spread":0.37908968422525857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264080550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98037744,0.0005449676,0.000020204234,0.012116561,0.0010645031,0.0001518676,0.000015143154,0.0000100209,0.005699321],"genre_scores_gemma":[0.9884123,0.0034827276,0.00069389323,0.0057722,0.0011896349,0.0000016180369,0.000002214491,0.000012503411,0.0004328885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972588,0.00023130116,0.0016938756,0.00019186783,0.00030253443,0.00032166325],"domain_scores_gemma":[0.99725,0.00057157053,0.0010177238,0.00015429358,0.0002464155,0.00075997884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013481401,0.00014790168,0.0013087399,0.0001111167,0.00004540357,0.0000111797,0.00009259173,0.00027435212,0.00047665814],"category_scores_gemma":[0.00035435992,0.00010544604,0.00028054122,0.00010131219,0.00020830239,0.00016581702,0.000027419683,0.0009054098,0.0000041730295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020314194,0.0003723998,0.66549224,0.000019407275,0.0001506869,0.0005153353,0.00013952103,0.000011705886,0.00005340655,0.000018717612,0.0010658045,0.33012936],"study_design_scores_gemma":[0.0057819127,0.0049075997,0.9575913,0.00012639335,0.00018143447,0.00042509616,0.00010612337,0.00008185673,0.000012800685,0.00009748313,0.03058582,0.00010220302],"about_ca_topic_score_codex":0.00051153713,"about_ca_topic_score_gemma":0.001217306,"teacher_disagreement_score":0.33002713,"about_ca_system_score_codex":0.00029819406,"about_ca_system_score_gemma":0.0016886,"threshold_uncertainty_score":0.5219072},"labels":[],"label_agreement":null},{"id":"W2264286082","doi":"10.1200/jco.2006.24.18_suppl.7154","title":"Compliance of adjuvant chemotherapy in non-small cell lung cancer (NSCLC); No longer an issue","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Carboplatin; Vinorelbine; Chemotherapy; Internal medicine; Febrile neutropenia; Neutropenia; Lung cancer; Oncology; Surgery; Cisplatin","score_opus":0.06479395018166687,"score_gpt":0.4942472899670299,"score_spread":0.42945333978536304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264286082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776303,0.0022053989,0.0001971935,0.003806388,0.0010686495,0.0002984931,0.000008646482,0.0000045695183,0.014780338],"genre_scores_gemma":[0.9867919,0.0010769292,0.006109514,0.002162494,0.001608877,0.000008698242,0.000004941398,0.000019632762,0.0022170087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775994,0.00010545828,0.0016093081,0.00015587344,0.00018304195,0.00018635431],"domain_scores_gemma":[0.99779266,0.00033415406,0.0011070743,0.00015997469,0.0004383379,0.00016778022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066465815,0.00011539746,0.0011065159,0.000090681155,0.000017338712,0.0000037463224,0.00011792759,0.00021104624,0.00042529125],"category_scores_gemma":[0.00008409267,0.000081844686,0.00022970288,0.00011867902,0.000103056314,0.00007944824,0.000012033029,0.0004322378,0.0000116813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035341606,0.008706448,0.838797,0.0002142379,0.0003652111,0.00057268684,0.0005621533,0.00038672335,0.0024261898,0.000029024884,0.018853905,0.12555225],"study_design_scores_gemma":[0.01835197,0.005744454,0.9225043,0.00039514675,0.00042684228,0.00004110352,0.00009191717,0.00074772374,0.00058924046,0.00007059382,0.05093079,0.000105903615],"about_ca_topic_score_codex":0.0005270506,"about_ca_topic_score_gemma":0.0003843045,"teacher_disagreement_score":0.12544635,"about_ca_system_score_codex":0.00021898844,"about_ca_system_score_gemma":0.0013548348,"threshold_uncertainty_score":0.4656641},"labels":[],"label_agreement":null},{"id":"W2264413708","doi":"10.1200/jco.2015.33.7_suppl.8","title":"A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Oncology; Prostatectomy; Cancer; Biomarker; Radiation therapy; Metastasis; Cohort; Biochemical recurrence; Clinical significance","score_opus":0.1191811030429419,"score_gpt":0.45489174974573615,"score_spread":0.33571064670279427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264413708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514437,0.0005674634,0.000011893551,0.0007331879,0.00011439745,0.0031769236,0.00014385402,0.0000073448464,0.00010059305],"genre_scores_gemma":[0.9983089,0.00052396185,0.000380796,0.00016648296,0.000033572134,0.00027475096,0.000108688524,0.00004016293,0.00016266937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617726,0.0004946292,0.0018522847,0.00029599146,0.0006821761,0.00049764384],"domain_scores_gemma":[0.99506557,0.0009795622,0.00157777,0.00013771035,0.0018539929,0.00038538544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027658395,0.00022670816,0.0018025326,0.0003312819,0.000022920523,0.000009904582,0.00011470957,0.00019579516,0.000020841564],"category_scores_gemma":[0.0024412554,0.00012131611,0.00017114545,0.00065797043,0.00025907537,0.00014690793,0.000022996552,0.00050347863,5.3958576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08435343,0.010893851,0.8914797,0.00007343366,0.0013517423,0.00038826864,0.0004894843,0.000010479405,0.000013139283,0.0000021310527,0.0002532404,0.010691157],"study_design_scores_gemma":[0.09773389,0.05183761,0.84743613,0.00063870917,0.00042220345,0.000009567435,0.00013021733,0.00013228091,0.00009503091,0.000031934935,0.0014075271,0.00012491488],"about_ca_topic_score_codex":0.00023986839,"about_ca_topic_score_gemma":0.0008679385,"teacher_disagreement_score":0.04404353,"about_ca_system_score_codex":0.0009573386,"about_ca_system_score_gemma":0.0034612648,"threshold_uncertainty_score":0.6140135},"labels":[],"label_agreement":null},{"id":"W2264484328","doi":"10.1200/jco.2006.24.18_suppl.13128","title":"Investigation of peptomimetics of GD2 antibodies as targeted therapy against human small cell lung cancer in-vitro","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Monoclonal antibody; Lung cancer; Antibody; Medicine; Cell culture; Cancer research; Flow cytometry; Cell; Cell growth; Neuroblastoma; In vivo; Immunogenicity; Cancer; Immunology; Molecular biology; Biology; Pathology; Internal medicine; Biochemistry","score_opus":0.09693819887458502,"score_gpt":0.4583821937581042,"score_spread":0.3614439948835192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264484328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953482,0.0011909083,0.000004646295,0.0009325788,0.0001880266,0.00020845169,0.000006835803,0.0000032222918,0.0021170864],"genre_scores_gemma":[0.99593693,0.0020954795,0.0012022299,0.00031096349,0.0002534942,0.0000023019445,0.0000060834013,0.00001334611,0.00017919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721336,0.0003710485,0.0017855006,0.00012099441,0.00031740585,0.00019167301],"domain_scores_gemma":[0.99695414,0.00082203303,0.0014680077,0.00012117069,0.00046111146,0.00017350788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009738459,0.00010664353,0.0010432262,0.00023264225,0.000019606145,0.0000027706146,0.00011160787,0.0001894453,0.000062934414],"category_scores_gemma":[0.00045303052,0.00007584777,0.00027675237,0.00016562705,0.00028977098,0.000048916543,0.00002681116,0.00054455973,0.0000016194531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034391151,0.0015200423,0.5578318,0.00007668481,0.00021074958,0.00036997936,0.000081810795,0.0000382934,0.42595726,0.000017165357,0.0006459579,0.009811119],"study_design_scores_gemma":[0.010141249,0.0063235043,0.67868555,0.00009422484,0.00007994062,0.000014105458,0.000027435246,0.00007222208,0.30381337,0.00032437217,0.00037549128,0.000048501854],"about_ca_topic_score_codex":0.00019765849,"about_ca_topic_score_gemma":0.00008937003,"teacher_disagreement_score":0.12214387,"about_ca_system_score_codex":0.00009090462,"about_ca_system_score_gemma":0.0011825694,"threshold_uncertainty_score":0.30929822},"labels":[],"label_agreement":null},{"id":"W2264492492","doi":"10.1200/jco.2006.24.18_suppl.6566","title":"Quality of life (QOL) of older adults with acute myeloid leukemia (AML): Effects of treatment and time","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Referral; Cancer; Physical therapy; Gerontology; Internal medicine; Population; Family medicine","score_opus":0.03837030684735885,"score_gpt":0.4168341794211532,"score_spread":0.3784638725737943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264492492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571085,0.00072906655,0.00010699366,0.0011739638,0.00011976087,0.00049351365,0.00001209555,0.0000053953345,0.001648355],"genre_scores_gemma":[0.99324703,0.0010635526,0.0043897773,0.00023036948,0.00042796586,0.0000050980875,0.0000053934846,0.000022681284,0.00060810806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949319,0.0007741127,0.0032463623,0.0002327121,0.0005390936,0.00027582786],"domain_scores_gemma":[0.98915803,0.006092153,0.003156274,0.00032033672,0.0008710115,0.0004021646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026081323,0.00020069465,0.0030735594,0.00019138028,0.00001930606,0.0000024729356,0.000176156,0.0004561583,0.00006773312],"category_scores_gemma":[0.0024284173,0.00012084472,0.0004486154,0.00020750522,0.000756144,0.000083080165,0.000071104536,0.0006615165,0.000004656974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18238112,0.013060758,0.5095175,0.0030604685,0.009270058,0.0021470357,0.0012211617,0.00009478402,0.06726269,0.00047616073,0.012949465,0.1985588],"study_design_scores_gemma":[0.059242025,0.06921769,0.85443103,0.00069045124,0.0011375779,0.00038579514,0.00011417218,0.00015823211,0.012729035,0.00013100197,0.0016102792,0.00015271478],"about_ca_topic_score_codex":0.00052836974,"about_ca_topic_score_gemma":0.00005062658,"teacher_disagreement_score":0.3449135,"about_ca_system_score_codex":0.00055301836,"about_ca_system_score_gemma":0.0056748027,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W2264649996","doi":"10.1200/jco.2012.30.27_suppl.12","title":"Digital versus screen film mammography: Impact on positive predictive values following transition.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Lesions and Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Medicine; Mammography; Digital mammography; Biopsy; Radiology; Calcification; Breast cancer; Predictive value; Nuclear medicine; Cancer; Internal medicine","score_opus":0.07747756259316654,"score_gpt":0.4387845082512967,"score_spread":0.36130694565813015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264649996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96912277,0.00042542344,0.00037725753,0.0022205287,0.0015718855,0.00014937633,0.000048966675,0.00001376705,0.026070043],"genre_scores_gemma":[0.99589115,0.00004481549,0.0005619954,0.00086757133,0.002500714,0.0000013511213,0.000014333904,0.00001798347,0.00010008614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977396,0.0002600594,0.0011107037,0.00013712571,0.00042608223,0.00032641276],"domain_scores_gemma":[0.9961636,0.002146032,0.0005641722,0.00014487088,0.00023505055,0.0007462905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015663023,0.00016342178,0.0010453542,0.00016994469,0.00005992015,0.000013554023,0.00009941215,0.00033547217,0.0001505013],"category_scores_gemma":[0.00084310764,0.00010332681,0.0017231839,0.00014778766,0.00015308663,0.00031372227,0.000020992247,0.000936132,0.000031330706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15054691,0.013033376,0.47602206,0.00002422489,0.008828938,0.0026601586,0.0013314605,0.00014995997,0.00017097163,0.00023023017,0.023888202,0.3231135],"study_design_scores_gemma":[0.010152849,0.034091644,0.9514721,0.0001402588,0.00091454026,0.0004403626,0.0004788193,0.00006366519,0.000024727384,0.00009244755,0.0020278615,0.00010070838],"about_ca_topic_score_codex":0.0000071674167,"about_ca_topic_score_gemma":7.4350095e-7,"teacher_disagreement_score":0.47545004,"about_ca_system_score_codex":0.00015881535,"about_ca_system_score_gemma":0.00054169795,"threshold_uncertainty_score":0.42135453},"labels":[],"label_agreement":null},{"id":"W2264781158","doi":"10.1200/jco.2006.24.18_suppl.13054","title":"A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nimotuzumab; Tolerability; Internal medicine; Toxicity; Gastroenterology; Phases of clinical research; Cancer; Mucositis; Oncology; Epidermal growth factor receptor; Pharmacology; Adverse effect","score_opus":0.04981963900224151,"score_gpt":0.44141290511850023,"score_spread":0.3915932661162587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264781158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683005,0.00022876047,0.000004650913,0.00079891604,0.0005943691,0.00087406096,0.000018114797,0.0000064408587,0.00064466835],"genre_scores_gemma":[0.99887335,0.00009866552,0.00030110267,0.0002674349,0.0003273115,0.000010763566,0.00000552411,0.000023602419,0.00009226689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575007,0.0004846542,0.002594672,0.0002725046,0.00059392146,0.0003041717],"domain_scores_gemma":[0.99589485,0.00078831374,0.0022869427,0.00021389918,0.0006845005,0.00013151449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006815651,0.00025132325,0.0022833864,0.0001358705,0.000091645954,0.0000075684193,0.0002126503,0.00014732203,0.00018112657],"category_scores_gemma":[0.000611915,0.00012840061,0.00037087736,0.00027131225,0.0002527728,0.00013836342,0.000083138606,0.0007308231,0.0000028309696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02395353,0.033830512,0.92232895,0.000020239127,0.0005971894,0.00014221449,0.0004981502,0.00001925688,0.00028428793,0.000011960138,0.00019245534,0.018121235],"study_design_scores_gemma":[0.06965514,0.06840866,0.86040854,0.0001285305,0.0002597278,0.000015753094,0.00039933214,0.000013046588,0.00013765013,0.000040999632,0.00042257327,0.000110031295],"about_ca_topic_score_codex":0.00012917511,"about_ca_topic_score_gemma":0.00021676625,"teacher_disagreement_score":0.06192042,"about_ca_system_score_codex":0.00028370434,"about_ca_system_score_gemma":0.0007011554,"threshold_uncertainty_score":0.5236025},"labels":[],"label_agreement":null},{"id":"W2264815712","doi":"10.1200/jco.2007.25.18_suppl.7693","title":"Patterns of practice in radiation therapy for non-small cell lung cancer among members of American Society of Therapeutic Radiology and Oncology","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Radiation oncologist; Radiation therapy; Radiation oncology; Oncology; Internal medicine; Cancer; Radiology; Nuclear medicine","score_opus":0.0590549928605199,"score_gpt":0.47555943303332265,"score_spread":0.41650444017280275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264815712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903893,0.0033508192,0.00053155626,0.0045310287,0.00039156454,0.00052817736,0.000007785882,0.0000014138176,0.0002683761],"genre_scores_gemma":[0.951201,0.04287334,0.0037350028,0.0018601704,0.000284787,0.00001653884,0.0000018937837,0.000013016994,0.000014208303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971711,0.00030185725,0.0020162177,0.00016191218,0.00015285567,0.00019603282],"domain_scores_gemma":[0.9867841,0.00852646,0.0040193927,0.0001183253,0.00042077064,0.00013097256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035977366,0.000115561284,0.0016646305,0.00010653993,0.000011725616,0.0000010306093,0.0000851225,0.00028789713,0.00002183036],"category_scores_gemma":[0.00035016562,0.00008188231,0.00039920965,0.00012268996,0.00028699206,0.000059544647,0.0000159647,0.00037763725,4.087434e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046420433,0.002285034,0.76560134,0.00012700896,0.0008735374,0.000019920653,0.0014124684,0.00004012338,0.0006136804,0.000012556715,0.00035050377,0.22402178],"study_design_scores_gemma":[0.016893392,0.023932556,0.9448784,0.00011869547,0.00076370366,0.000033545955,0.0009914387,0.00020383576,0.0024003186,0.000020817695,0.009699832,0.000063468724],"about_ca_topic_score_codex":0.00094922056,"about_ca_topic_score_gemma":0.0006822567,"teacher_disagreement_score":0.22395831,"about_ca_system_score_codex":0.00038538096,"about_ca_system_score_gemma":0.0011876967,"threshold_uncertainty_score":0.33390635},"labels":[],"label_agreement":null},{"id":"W2264841567","doi":"10.1200/jco.2009.27.15_suppl.5534","title":"Microsatellite instability and loss of PTEN expression in early versus late-stage endometrial cancer: Results from studies of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"PTEN; Medicine; Microsatellite instability; Endometrial cancer; Internal medicine; Univariate analysis; Oncology; Cancer; Stage (stratigraphy); Breast cancer; Multivariate analysis; Biology; Gene; Microsatellite; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.275152611644581,"score_gpt":0.516910184547653,"score_spread":0.24175757290307204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264841567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879446,0.005613135,0.000012495444,0.0009211215,0.0046527614,0.0002147547,0.00056095753,9.0198205e-7,0.00007928219],"genre_scores_gemma":[0.9902058,0.0077250795,0.00057530444,0.00026126244,0.0011885945,0.000003844562,0.0000065574027,0.0000070835654,0.00002644994],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99217355,0.0017399648,0.0050535686,0.00032603342,0.0005147304,0.00019216204],"domain_scores_gemma":[0.9880859,0.0057320427,0.004968577,0.00022808807,0.00085885683,0.00012648328],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011571082,0.00016028766,0.0017925473,0.00006837127,0.000032656902,0.000003981833,0.00039461363,0.00047128907,0.000010683116],"category_scores_gemma":[0.038120568,0.00010664685,0.00042002116,0.0001847628,0.00070980337,0.000018871122,0.00014419582,0.00055682176,3.8792166e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1990786,0.0019750618,0.3218239,0.0001093709,0.0023170633,0.000043848457,0.00050429103,0.004106582,0.39769328,0.000055114942,0.0038460933,0.0684468],"study_design_scores_gemma":[0.0632664,0.011289536,0.7205925,0.0007274165,0.0004212229,0.00000308881,0.00015353895,0.00005266667,0.14384481,0.0006647011,0.058623586,0.00036053266],"about_ca_topic_score_codex":0.013616273,"about_ca_topic_score_gemma":0.076059334,"teacher_disagreement_score":0.3987686,"about_ca_system_score_codex":0.00019615276,"about_ca_system_score_gemma":0.00463841,"threshold_uncertainty_score":0.99295217},"labels":[],"label_agreement":null},{"id":"W2265055002","doi":"10.1200/jco.2010.28.15_suppl.6018","title":"Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida Initiative for Quality Cancer Care (FIQCC).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Audit; Psychological intervention; Quality Score; Oncology; Quality management; Internal medicine; Nursing","score_opus":0.12708235944740387,"score_gpt":0.5220726029293185,"score_spread":0.3949902434819146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265055002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98223925,0.0050364737,0.000027694283,0.007280563,0.0034661652,0.0007767794,0.0003871277,0.000004044824,0.00078191113],"genre_scores_gemma":[0.9920562,0.0021275093,0.0011663577,0.0024356032,0.0019998315,0.00014859127,0.000017848468,0.000021095975,0.00002695922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960393,0.00045135187,0.0025867287,0.00029328893,0.0003555642,0.00027379673],"domain_scores_gemma":[0.98838305,0.0077936323,0.00205519,0.00030615157,0.0012305699,0.0002313976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022764022,0.00019575027,0.0018736357,0.000049375958,0.000058947895,0.000008695136,0.00026811493,0.0004567351,0.00019887404],"category_scores_gemma":[0.0017316389,0.0001180556,0.0007231703,0.0001276579,0.00019403234,0.000074082964,0.00006374692,0.0012789135,0.0000012317029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004411163,0.00065807626,0.96224904,0.00033991563,0.0004599896,0.00002868317,0.0066688536,0.00001813626,0.00031394398,0.00004616558,0.0023138283,0.02249219],"study_design_scores_gemma":[0.015275594,0.0027811935,0.96721953,0.00045343064,0.00068812974,0.0000015586977,0.0037880393,0.000012562032,0.002095569,0.00008399251,0.007475329,0.00012508016],"about_ca_topic_score_codex":0.0061718733,"about_ca_topic_score_gemma":0.061059646,"teacher_disagreement_score":0.054887775,"about_ca_system_score_codex":0.00081477786,"about_ca_system_score_gemma":0.004037029,"threshold_uncertainty_score":0.9560736},"labels":[],"label_agreement":null},{"id":"W2265087310","doi":"10.1200/jco.2007.25.18_suppl.14535","title":"Effect of hyperthermia on the pharmacokinetic profile of oxaliplatin administered by intraperitoneal route in rats","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Oxaliplatin; Medicine; Peritoneum; Pharmacokinetics; Hyperthermia; Perfusion; Intraperitoneal injection; Mesentery; In vivo; Chemotherapy; Pharmacology; Surgery; Internal medicine; Cancer; Colorectal cancer; Biology","score_opus":0.08793512567251474,"score_gpt":0.5115380316999573,"score_spread":0.42360290602744255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265087310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898084,0.00040425462,0.000004323575,0.0036673367,0.00090045115,0.0004235677,0.000009112581,0.0000028778168,0.004779673],"genre_scores_gemma":[0.99744916,0.0002318999,0.0001279522,0.0013793567,0.0005348767,0.00000605482,0.0000032799617,0.0000123581385,0.00025507426],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965677,0.0007823169,0.0020646844,0.00012487303,0.00025737134,0.00020305286],"domain_scores_gemma":[0.99024385,0.007959543,0.0013863384,0.0001222977,0.00012466795,0.00016331184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047040726,0.00013426236,0.0013612382,0.000111717505,0.000014591238,0.0000014106665,0.00015110364,0.00024168887,0.0005478],"category_scores_gemma":[0.00085531373,0.00007350489,0.0003354949,0.000165009,0.00027373256,0.000027872507,0.000023745422,0.0007717447,0.0000053297026],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119008735,0.0071602818,0.15946949,0.00019339292,0.0009524642,0.00095940736,0.0003660639,0.000009976018,0.20178667,0.000050836898,0.018194534,0.49184817],"study_design_scores_gemma":[0.05130989,0.21297571,0.20379215,0.00037975155,0.0015032319,0.00040504895,0.00010841183,0.00016594633,0.47613314,0.0000524864,0.052983474,0.00019075247],"about_ca_topic_score_codex":0.000021460872,"about_ca_topic_score_gemma":0.000024586247,"teacher_disagreement_score":0.4916574,"about_ca_system_score_codex":0.00009736211,"about_ca_system_score_gemma":0.00047149436,"threshold_uncertainty_score":0.59980255},"labels":[],"label_agreement":null},{"id":"W2265262314","doi":"10.1200/jco.2007.25.18_suppl.7678","title":"Cost-effectiveness analysis (CEA) of third-line erlotinib therapy compared to best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Oncology; Lung cancer; Internal medicine; Cost effectiveness; Docetaxel; Clinical endpoint; Cost-effectiveness analysis; Cancer; Surgery; Epidermal growth factor receptor; Randomized controlled trial","score_opus":0.08738385517410992,"score_gpt":0.5118081672593614,"score_spread":0.4244243120852515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265262314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989819,0.0015542414,0.004422558,0.00035385293,0.00070768205,0.0022879196,0.00012901083,0.0000058677,0.0007198902],"genre_scores_gemma":[0.99242425,0.0007699563,0.0053962055,0.0006191663,0.0003194305,0.00011767807,0.000039242124,0.000024654808,0.00028940695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968118,0.00018754962,0.0021376847,0.00028595983,0.0002509517,0.0003260669],"domain_scores_gemma":[0.99418765,0.0022681141,0.0014337626,0.00016965656,0.0015731597,0.00036762768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017955675,0.00013506819,0.0021332204,0.00020769506,0.00005460324,0.000015564761,0.00014492405,0.0002554415,0.0000975602],"category_scores_gemma":[0.0004985158,0.0001438831,0.00071629987,0.00057856017,0.00009602451,0.000073846684,0.000024296098,0.0004066262,9.425645e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00585629,0.0028115485,0.83197725,0.00014793962,0.0019326059,0.0002632109,0.001060944,0.0021133758,0.00033434623,8.0285446e-7,0.00036199688,0.15313968],"study_design_scores_gemma":[0.028867394,0.011145282,0.9472187,0.00045651945,0.0030881402,0.000016678781,0.0023656054,0.00017157556,0.00071469916,0.000012803959,0.00580122,0.00014137637],"about_ca_topic_score_codex":0.008797059,"about_ca_topic_score_gemma":0.18080623,"teacher_disagreement_score":0.17200917,"about_ca_system_score_codex":0.0006312995,"about_ca_system_score_gemma":0.0022151645,"threshold_uncertainty_score":0.99780345},"labels":[],"label_agreement":null},{"id":"W2265497904","doi":"10.1200/jco.2007.25.18_suppl.6513","title":"Randomized trials in oncology stopped early for benefit: A systematic review","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Sample size determination; Interim; Interim analysis; Internal medicine; Odds ratio; Oncology","score_opus":0.940011980333068,"score_gpt":0.7790016656310121,"score_spread":0.16101031470205585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265497904","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001210766,0.943238,0.027804293,0.000867925,0.0072670667,0.019705711,0.000101188314,0.000025822495,0.0009887636],"genre_scores_gemma":[1.5195442e-7,0.6615704,0.33363137,0.0012089849,0.002484932,0.0007726762,0.0000026631276,0.0001091069,0.00021970787],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.63256943,0.21263391,0.14977339,0.0014211108,0.0020311885,0.0015709781],"domain_scores_gemma":[0.06520087,0.85487956,0.07648799,0.0010190551,0.0016011602,0.0008113657],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.64996517,0.0010599096,0.1511652,0.0008948037,0.00005478961,0.000039766714,0.0019400553,0.005172512,0.00026507393],"category_scores_gemma":[0.9774013,0.00059885596,0.023286428,0.0007668483,0.0007775292,0.00011177861,0.0002461451,0.0054089446,0.000057684767],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021860667,0.0011999034,1.5534908e-7,0.47105387,0.0027012806,0.00028402996,0.000013806789,4.2141632e-8,5.583545e-9,0.014044585,0.0018959156,0.48694575],"study_design_scores_gemma":[0.0968565,0.003554117,1.6357396e-7,0.3731712,0.041197542,0.00019218183,0.0000064158635,0.0000025237396,2.685345e-8,0.23445433,0.25024062,0.00032438672],"about_ca_topic_score_codex":0.0000051251286,"about_ca_topic_score_gemma":0.000017721079,"teacher_disagreement_score":0.64224565,"about_ca_system_score_codex":0.0009657874,"about_ca_system_score_gemma":0.006020595,"threshold_uncertainty_score":0.9996463},"labels":[],"label_agreement":null},{"id":"W2265622440","doi":"10.1200/jco.2012.30.15_suppl.4558","title":"Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Placebo; Clinical endpoint; Prostate cancer; Internal medicine; Discontinuation; Prednisone; Oncology; Tolerability; Docetaxel; Randomization; Hazard ratio; Urology; Gastroenterology; Randomized controlled trial; Androgen deprivation therapy; Cancer; Confidence interval; Adverse effect","score_opus":0.22405257462937547,"score_gpt":0.516633520639768,"score_spread":0.29258094601039253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265622440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307275,0.0048100753,0.0000073816723,0.00052660477,0.00021622067,0.0012496231,0.000066856315,0.0000032169564,0.00004726892],"genre_scores_gemma":[0.99487185,0.0043753437,0.0002965056,0.000031496835,0.000093642455,0.00009870952,0.000011629739,0.000017677294,0.00020316569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948796,0.00070459495,0.0031706765,0.00026266035,0.0005792715,0.00040320796],"domain_scores_gemma":[0.9961268,0.0009876314,0.0018224295,0.00022920694,0.00044808743,0.00038584523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034462258,0.00023182924,0.0031464894,0.00072079897,0.000030784333,0.000008429482,0.00010617199,0.0001371335,0.0000834857],"category_scores_gemma":[0.00025429772,0.00015161867,0.00027258493,0.0007679134,0.00025477514,0.0002529111,0.00004828821,0.0004232025,6.6846127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085291855,0.040865317,0.75866926,0.00023011958,0.010435177,0.0011166816,0.019460013,0.00093750964,0.0046657394,0.000015795702,0.000025613883,0.07828692],"study_design_scores_gemma":[0.15135811,0.038762394,0.7914103,0.00019557805,0.006697717,0.00001809219,0.009305402,0.0009011396,0.00093603745,0.00002760643,0.0002190611,0.00016854616],"about_ca_topic_score_codex":0.001063458,"about_ca_topic_score_gemma":0.010013349,"teacher_disagreement_score":0.07811838,"about_ca_system_score_codex":0.0006488058,"about_ca_system_score_gemma":0.0019254058,"threshold_uncertainty_score":0.61828303},"labels":[],"label_agreement":null},{"id":"W2265676821","doi":"10.1200/jco.2013.31.4_suppl.540","title":"Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; FOLFIRI; Internal medicine; Colorectal cancer; Population; Oncology; Surgery; Multivariate analysis; Gastroenterology; Chemotherapy; Cancer; Irinotecan","score_opus":0.06803244901962165,"score_gpt":0.41579489835632,"score_spread":0.34776244933669836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265676821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594754,0.0003138277,0.000008656977,0.0017202384,0.00026251344,0.0007605117,0.0000046797577,0.000007882792,0.0009741229],"genre_scores_gemma":[0.9980085,0.00020996365,0.0009003681,0.0004966547,0.00012678617,0.00006085066,0.0000041655635,0.000022016622,0.00017072276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974597,0.0002173083,0.0013387508,0.00022019663,0.0004585791,0.00030545107],"domain_scores_gemma":[0.99724275,0.0006858665,0.0010156251,0.00011075651,0.0006651151,0.00027986703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004181096,0.00021277413,0.0018775713,0.00013146731,0.000042942473,0.000005893498,0.000098952434,0.00012468208,0.00034113746],"category_scores_gemma":[0.00035083725,0.00010740464,0.000188285,0.00025511906,0.00019128223,0.00016628321,0.000033170832,0.00053822086,0.00001538354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016121965,0.002496342,0.9506393,0.00002169396,0.0015541748,0.00021980375,0.00016410733,0.000051517854,0.000003278072,0.0000033490148,0.00045567047,0.028268775],"study_design_scores_gemma":[0.034629337,0.04619414,0.9173168,0.00020063619,0.0008779258,0.000048949747,0.00014214653,0.000048888247,0.000011015527,0.00004468696,0.0003747168,0.0001107598],"about_ca_topic_score_codex":0.00054182485,"about_ca_topic_score_gemma":0.0015220746,"teacher_disagreement_score":0.0436978,"about_ca_system_score_codex":0.00069666485,"about_ca_system_score_gemma":0.0013285807,"threshold_uncertainty_score":0.43798342},"labels":[],"label_agreement":null},{"id":"W2265986268","doi":"10.1200/jco.2013.31.31_suppl.10","title":"Access to personalized medicine: Factors influencing the use and value of gene expression profiling in treatment decision making.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; McMaster University; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Gatekeeping; Personalized medicine; Profiling (computer programming); Family medicine; Breast cancer; Oncology; Internal medicine; Cancer; Bioinformatics","score_opus":0.15447147627288618,"score_gpt":0.4809666928900493,"score_spread":0.3264952166171631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265986268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654055,0.00055793504,0.001278979,0.0009868143,0.00036075237,0.00024025688,0.0000018920097,9.430247e-7,0.000031871597],"genre_scores_gemma":[0.97683847,0.00046782245,0.021557184,0.000816854,0.00028409497,0.000011055514,0.0000013543068,0.000008941839,0.000014246947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811876,0.0003065679,0.0011157875,0.0001672684,0.00016883142,0.00012276284],"domain_scores_gemma":[0.99758554,0.001146445,0.0007297964,0.00016950046,0.00027450462,0.00009421584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095654285,0.00009844492,0.00046004716,0.00008063406,0.0000341658,0.00001510728,0.00022261057,0.00020262635,0.000031296786],"category_scores_gemma":[0.0034774453,0.000052397514,0.00010597714,0.00009040503,0.00015967677,0.000020440297,0.00009911047,0.00016723172,6.0950686e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015267925,0.00029360582,0.52034295,0.000012574727,0.00015104249,0.000013611515,0.0012790618,0.0024738288,0.3570296,0.000017266259,0.002056549,0.114803135],"study_design_scores_gemma":[0.0048787086,0.0064792586,0.8621598,0.0002535389,0.00010014538,0.000053184467,0.001189324,0.0002169917,0.111312225,0.00036628853,0.012840087,0.00015043504],"about_ca_topic_score_codex":0.00005901154,"about_ca_topic_score_gemma":0.00003806338,"teacher_disagreement_score":0.34181687,"about_ca_system_score_codex":0.000099033816,"about_ca_system_score_gemma":0.0004755733,"threshold_uncertainty_score":0.4163078},"labels":[],"label_agreement":null},{"id":"W2266092419","doi":"10.1200/jco.2012.30.27_suppl.7","title":"Stratification of 5-year cancer detection rate in an organized breast screening program based on Gail model risk factors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Mammography; Confidence interval; Demography; Population; Family history; Breast cancer screening; Cancer; Family medicine; Gynecology; Internal medicine; Environmental health","score_opus":0.2948668614808272,"score_gpt":0.521323779637222,"score_spread":0.2264569181563948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266092419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940377,0.00005598373,0.0046317824,0.000506067,0.00030449108,0.0002213425,0.000007608537,0.000011822649,0.00022321641],"genre_scores_gemma":[0.9912997,0.00007891522,0.0077299834,0.00033667733,0.0005230492,0.000005825727,0.0000039309807,0.000013235871,0.0000086720875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997245,0.0005217324,0.0015188656,0.00013995061,0.00034519823,0.00022924018],"domain_scores_gemma":[0.99682164,0.0005123576,0.0016744564,0.0001601696,0.00051190064,0.00031947598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038265896,0.00011324911,0.0007960072,0.00014386266,0.00003338071,0.000007704743,0.000106923435,0.00030111618,0.000077665216],"category_scores_gemma":[0.001470989,0.00008290098,0.0001954417,0.00023629767,0.00008555221,0.00029575976,0.000010946896,0.0008739626,0.000001816837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006272869,0.0013977544,0.7746126,0.000014183013,0.00005221608,0.000008496426,0.00012040535,0.007105673,0.0020379205,0.00001297388,0.00005190102,0.20831303],"study_design_scores_gemma":[0.0044692694,0.0066054864,0.92639416,0.00014470608,0.00020788288,0.000015244869,0.00030660853,0.06026615,0.0013024317,0.000045276098,0.00016310284,0.00007964964],"about_ca_topic_score_codex":0.00029448036,"about_ca_topic_score_gemma":0.00031939827,"teacher_disagreement_score":0.20823339,"about_ca_system_score_codex":0.00018273354,"about_ca_system_score_gemma":0.00082702824,"threshold_uncertainty_score":0.37969813},"labels":[],"label_agreement":null},{"id":"W2266509911","doi":"10.1200/jco.2005.23.16_suppl.7122","title":"Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in stage III non small cell lung cancer (NSCLC): Preliminary report","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Neutropenia; Carboplatin; Internal medicine; Gastroenterology; Regimen; Chemotherapy; Concomitant; Radiation therapy; Febrile neutropenia; Lung cancer; Surgery; Induction chemotherapy; Cisplatin","score_opus":0.0381603091578196,"score_gpt":0.4129525719892461,"score_spread":0.3747922628314265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266509911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721181,0.0046951454,0.00030343802,0.01863367,0.001005031,0.0020745108,0.000021212158,0.00002557567,0.0011233299],"genre_scores_gemma":[0.9837809,0.0046713566,0.0044413847,0.0019526765,0.0026959728,0.00018096819,0.000028316603,0.000091583504,0.002156807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945201,0.0003313169,0.0033327355,0.0006186751,0.0006621667,0.0005349567],"domain_scores_gemma":[0.99429995,0.0008301517,0.0034170868,0.00046878285,0.00043026017,0.0005537433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002553981,0.00047357855,0.0027678579,0.00023624269,0.00009768575,0.000020174892,0.00019859844,0.00040474127,0.0003600739],"category_scores_gemma":[0.00020315165,0.00030052828,0.00045109692,0.00038342597,0.0002385632,0.00027204948,0.000029484012,0.0013861647,0.0000010482203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67237794,0.04680352,0.14613743,0.00015455179,0.0030687663,0.008599539,0.000980833,0.00040444313,0.0021421583,0.00001034762,0.027101783,0.09221869],"study_design_scores_gemma":[0.66523445,0.2278172,0.019894298,0.0007660486,0.0015654811,0.0011502906,0.00020271188,0.00059025345,0.0024010118,0.000003126491,0.079926796,0.0004483703],"about_ca_topic_score_codex":0.0005756524,"about_ca_topic_score_gemma":0.0009309368,"teacher_disagreement_score":0.18101367,"about_ca_system_score_codex":0.0018319982,"about_ca_system_score_gemma":0.0040223747,"threshold_uncertainty_score":0.9999447},"labels":[],"label_agreement":null},{"id":"W2266547135","doi":"10.1200/jco.2005.23.16_suppl.571","title":"Carbonic anhydrase IX (CA IX) as a predictive marker for benefit from post-mastectomy adjuvant locoregional radiation (RT): Results from the British Columbia (BC) Randomized Radiation Trial","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Breast cancer; Oncology; Context (archaeology); Population; Tissue microarray; Mastectomy; Radiation therapy; Cancer","score_opus":0.021722003514523563,"score_gpt":0.33340088856623457,"score_spread":0.311678885051711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266547135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979827,0.0074118655,0.000525593,0.0036711728,0.005753639,0.0014450381,0.0010271615,0.000007544519,0.0003309923],"genre_scores_gemma":[0.9438438,0.009458504,0.0012678374,0.0038308217,0.03960063,0.0001267033,0.0009843541,0.000040558876,0.00084678404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99540085,0.0008642006,0.0025672955,0.00047451313,0.00037924497,0.00031391883],"domain_scores_gemma":[0.99222887,0.0039747856,0.0025434075,0.00031325675,0.0006586887,0.00028101748],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039030318,0.00019196318,0.0014408699,0.00003211301,0.0001884504,0.00013928108,0.00035501996,0.0007452178,0.00012551689],"category_scores_gemma":[0.012215547,0.00017810338,0.0011638128,0.00007622968,0.00029143048,0.0000331324,0.00007073901,0.00054606376,0.0000066779958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6911542,0.0005908962,0.00034491206,0.0000022982222,0.0009695288,0.000010104193,0.00008345832,0.00033360164,0.0009339249,0.0000054649854,0.05522065,0.25035095],"study_design_scores_gemma":[0.50972635,0.004354284,0.02466288,0.00003656406,0.00074949913,0.00003650395,0.00005804044,0.0011097598,0.0001470359,0.00073455466,0.45819604,0.000188477],"about_ca_topic_score_codex":0.009508686,"about_ca_topic_score_gemma":0.029018052,"teacher_disagreement_score":0.40297538,"about_ca_system_score_codex":0.00011238972,"about_ca_system_score_gemma":0.0019430066,"threshold_uncertainty_score":0.99708706},"labels":[],"label_agreement":null},{"id":"W2266606434","doi":"10.1200/jco.2012.30.15_suppl.e19591","title":"Aprepitant in multiple-day cisplatin-based chemotherapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Aprepitant; Medicine; Nausea; Antiemetic; Vomiting; Chemotherapy; Anesthesia; Internal medicine; Ondansetron; Dexamethasone; Oncology","score_opus":0.19964462159638405,"score_gpt":0.4915359409257308,"score_spread":0.29189131932934675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266606434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810153,0.00025591213,0.0008515019,0.010565066,0.0013257153,0.00019042054,4.7819015e-7,0.000009905835,0.005785657],"genre_scores_gemma":[0.98434615,0.00007713837,0.0068973675,0.0068199593,0.0016226036,0.0000021854055,7.420697e-7,0.000014487144,0.00021938437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970844,0.0003800761,0.0018759288,0.00010358977,0.00027180227,0.00028421092],"domain_scores_gemma":[0.99479645,0.0035396176,0.0010336725,0.00016419053,0.00012907143,0.00033700775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007985932,0.00009918548,0.000983179,0.00015739878,0.00001720737,0.0000037971768,0.00010936927,0.00024083836,0.00021872963],"category_scores_gemma":[0.006005465,0.00006929407,0.0003339875,0.00012519723,0.00008778115,0.00007350487,0.00002315142,0.00074720784,0.000034791734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021630165,0.0028403208,0.7789678,0.000029028291,0.00012249546,0.00024392981,0.00010341798,0.000021070355,0.00031718382,0.00008970184,0.0036048573,0.21149716],"study_design_scores_gemma":[0.015775116,0.0034072057,0.8472436,0.00010868508,0.00013017596,0.000050276805,0.000066280445,0.0006570022,0.00032048865,0.00008133757,0.13208014,0.00007966584],"about_ca_topic_score_codex":0.000007694607,"about_ca_topic_score_gemma":0.0000100017905,"teacher_disagreement_score":0.21141748,"about_ca_system_score_codex":0.00012931552,"about_ca_system_score_gemma":0.00040923432,"threshold_uncertainty_score":0.71895367},"labels":[],"label_agreement":null},{"id":"W2266655876","doi":"10.1200/jco.2007.25.18_suppl.10007","title":"Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; GiST; Placebo; Internal medicine; Sunitinib malate; Gastroenterology; Bristol-Myers; Clinical trial; Oncology; Sunitinib; Surgery; Pharmacology; Cancer; Stromal cell; Pathology","score_opus":0.12702449138078858,"score_gpt":0.49672314152938224,"score_spread":0.36969865014859365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266655876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574137,0.0000939204,0.00016716524,0.0008224913,0.00022213839,0.00091402,0.0000060513316,0.000004975974,0.0020278818],"genre_scores_gemma":[0.9932138,0.00005149641,0.0061854883,0.00011790795,0.00014294386,0.000013304297,0.000022300925,0.000019797071,0.00023297398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591035,0.0004912292,0.0019431639,0.00019843051,0.0010440157,0.0004128043],"domain_scores_gemma":[0.99318576,0.0014663751,0.0014306675,0.00015352861,0.003339466,0.0004242036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010576014,0.00014941834,0.0010148443,0.00024459613,0.00003097942,0.0000067267056,0.00010574708,0.00013494112,0.0001620933],"category_scores_gemma":[0.007866597,0.00010033269,0.00028416715,0.00020077008,0.00019295473,0.00011096897,0.000031116317,0.00053734693,0.000008481557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079609945,0.0076077827,0.67050785,0.00006158467,0.0005163423,0.0017017538,0.000036662947,0.00016711678,0.0004826774,0.000028185948,0.00020332588,0.2390768],"study_design_scores_gemma":[0.05920946,0.06658738,0.86987793,0.00036333431,0.00075768837,0.00046969432,0.00012669989,0.00053362583,0.00055050454,0.00037203464,0.0010683953,0.00008326102],"about_ca_topic_score_codex":0.00006118496,"about_ca_topic_score_gemma":0.00029503834,"teacher_disagreement_score":0.23899354,"about_ca_system_score_codex":0.00036665992,"about_ca_system_score_gemma":0.0017596488,"threshold_uncertainty_score":0.941762},"labels":[],"label_agreement":null},{"id":"W2266888319","doi":"10.1200/jco.2004.22.90140.4545","title":"Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Etoposide; Radiation therapy; Bladder cancer; Chemotherapy; Oncology; Small-cell carcinoma; Cancer; Internal medicine; Urology","score_opus":0.2044064087881561,"score_gpt":0.5058095085636323,"score_spread":0.3014030997754762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266888319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057728216,0.98443645,0.0000013166152,0.0063288794,0.0009936421,0.0013941444,0.0001238854,0.0000053588165,0.0009434993],"genre_scores_gemma":[0.0007183047,0.9942544,0.00015370645,0.0007684082,0.002103715,0.00006705546,0.000019921014,0.00006393811,0.0018505553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212456,0.0020857737,0.004109438,0.0005233742,0.00065923086,0.00049763214],"domain_scores_gemma":[0.9897335,0.0034275937,0.005018598,0.00054078974,0.00068229734,0.0005972142],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019144749,0.00051112135,0.0068981694,0.00017708271,0.000068141424,0.000007404228,0.0004281961,0.00015274643,0.00040453603],"category_scores_gemma":[0.0013910135,0.00025871294,0.0022851285,0.00020539165,0.000558765,0.000058494974,0.00028388057,0.0020647608,0.000011769691],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023559325,0.00468613,0.07315531,0.147242,0.002296524,0.027493916,0.000044011656,0.000001023925,0.0000021935411,0.00002839109,0.0127803795,0.7299142],"study_design_scores_gemma":[0.004601166,0.01937781,0.0066128224,0.043566238,0.002922064,0.008994654,0.000015048326,1.6579327e-7,0.0000034805814,0.00001849919,0.91372013,0.00016794726],"about_ca_topic_score_codex":0.00023149331,"about_ca_topic_score_gemma":0.00043583577,"teacher_disagreement_score":0.9009397,"about_ca_system_score_codex":0.0020947533,"about_ca_system_score_gemma":0.0063415007,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W2267201863","doi":"10.1200/jco.2007.25.18_suppl.19523","title":"Association of physical and psychological symptom burden with time to death among palliative cancer outpatients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Breast cancer; Internal medicine; Cancer; Lung cancer; Outpatient clinic; Hazard ratio; Disease; Confidence interval","score_opus":0.08654321415588455,"score_gpt":0.47677882591130394,"score_spread":0.3902356117554194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267201863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936719,0.00007609949,0.00012197993,0.0025666396,0.00032484866,0.00015505143,0.00000527331,0.000004823571,0.0030734004],"genre_scores_gemma":[0.9967047,0.000060685685,0.00034935123,0.0009061882,0.0011516499,0.0000025613765,0.0000010405878,0.000008958598,0.0008148527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980991,0.00015983921,0.0009563979,0.0001553149,0.00044417422,0.00018519955],"domain_scores_gemma":[0.9961904,0.0015540761,0.0012124534,0.00008592945,0.0006121348,0.00034500306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017223299,0.00009811674,0.0010111345,0.00007314587,0.000017235023,0.0000037469258,0.00007646389,0.00025768386,0.00010942343],"category_scores_gemma":[0.0011417188,0.00006136474,0.00018465903,0.00013614692,0.00009007278,0.00005127919,0.000027700175,0.000546133,0.000008439776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005147565,0.0008030111,0.92354876,0.000013314768,0.00035336966,0.00007592871,0.0009692888,0.000010717505,0.00011440798,0.000015516684,0.0010553772,0.06789273],"study_design_scores_gemma":[0.0037574726,0.020319637,0.96834993,0.00015089447,0.00034829648,0.000009582048,0.00012737502,0.000027552269,0.000068056564,0.00006739967,0.0067049363,0.00006888216],"about_ca_topic_score_codex":0.00009352253,"about_ca_topic_score_gemma":0.0003630155,"teacher_disagreement_score":0.06782385,"about_ca_system_score_codex":0.00023258048,"about_ca_system_score_gemma":0.00020720952,"threshold_uncertainty_score":0.25023815},"labels":[],"label_agreement":null},{"id":"W2267245142","doi":"10.1200/jco.2014.32.31_suppl.19","title":"Differences in performance status assessments between palliative care specialists, nurses, and oncologists.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Performance status; Distress; Family medicine; Cancer; Internal medicine; Nursing","score_opus":0.45239271421672766,"score_gpt":0.601282253761279,"score_spread":0.1488895395445513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267245142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882148,0.0015072658,0.00008749636,0.0007040469,0.00079715636,0.00012570851,0.000008088943,0.000004216764,0.00855122],"genre_scores_gemma":[0.9850176,0.008599723,0.004796914,0.00034479864,0.0011441578,0.0000019449096,0.0000062131253,0.0000080800155,0.00008057502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699104,0.0004970291,0.0017596787,0.00017372525,0.00033587115,0.00024266257],"domain_scores_gemma":[0.99406976,0.0036499957,0.0014529153,0.00011502944,0.0004277849,0.00028451846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013963238,0.00013777147,0.0018162957,0.00013412265,0.000024350955,0.000006195859,0.00013252407,0.0003249559,0.000036373953],"category_scores_gemma":[0.003681322,0.00009466642,0.00016687837,0.0001238026,0.00038037205,0.000099055134,0.00004785014,0.0007906734,0.0000030524345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006497099,0.00022939444,0.7948387,0.00006893401,0.00010697019,0.000039695133,0.0007323543,7.2683997e-7,0.000005967658,0.00006352826,0.00022843598,0.20303555],"study_design_scores_gemma":[0.00470633,0.012233361,0.89446974,0.0005292191,0.00016592906,0.000003946865,0.001312212,0.000030848863,0.00005588943,0.0001390431,0.0862737,0.000079767924],"about_ca_topic_score_codex":0.00006996407,"about_ca_topic_score_gemma":0.00013185889,"teacher_disagreement_score":0.20295578,"about_ca_system_score_codex":0.00022166489,"about_ca_system_score_gemma":0.0008653588,"threshold_uncertainty_score":0.44071525},"labels":[],"label_agreement":null},{"id":"W2267461577","doi":"10.1200/jco.2015.33.3_suppl.119","title":"Impact of radiotherapy duration on outcomes in patients with esophageal cancer treated with definitive concurrent radiotherapy and chemotherapy on RTOG trials 8501 and 9405.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Chemoradiotherapy; Esophageal cancer; Cumulative incidence; Proportional hazards model; Internal medicine; Cohort; Univariate analysis; Cisplatin; Multivariate analysis; Cancer; Surgery; Chemotherapy; Oncology","score_opus":0.15354123394932162,"score_gpt":0.5135099737298264,"score_spread":0.3599687397805048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267461577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949247,0.0022826241,0.000021869791,0.0018150746,0.00008912156,0.00076394225,0.000027947404,0.000004109413,0.00007058296],"genre_scores_gemma":[0.99511206,0.0035073957,0.00043516431,0.00069278455,0.00017831853,0.000016538132,0.000005909274,0.0000224323,0.000029383957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700886,0.0007157576,0.0013360332,0.00021657802,0.00051036605,0.0002123981],"domain_scores_gemma":[0.995798,0.0018937486,0.0013336965,0.00011661347,0.00040266078,0.00045527567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018685515,0.00021814411,0.00218385,0.00021564757,0.000019466974,0.000010706082,0.000053590495,0.00017116762,0.0000559406],"category_scores_gemma":[0.0006456497,0.000103609396,0.0001847063,0.00013002615,0.00025685967,0.000091558635,0.0000050279,0.00046595512,3.4819595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09348492,0.0029147628,0.7923156,0.000010582224,0.0014472931,0.00015389362,0.00021799373,0.000023639535,0.000004615162,0.000018294259,0.00014074189,0.109267674],"study_design_scores_gemma":[0.08865494,0.1584388,0.7523901,0.00013680712,0.00011410496,0.000018853963,0.00001940712,0.000023046532,0.00005915838,0.000016697802,0.00006452883,0.00006359022],"about_ca_topic_score_codex":0.000224632,"about_ca_topic_score_gemma":0.000083675244,"teacher_disagreement_score":0.15552403,"about_ca_system_score_codex":0.0006708778,"about_ca_system_score_gemma":0.0013881637,"threshold_uncertainty_score":0.42250687},"labels":[],"label_agreement":null},{"id":"W2267479587","doi":"10.1200/jco.2004.22.90140.8555","title":"Identification of immune evasion strategies of pediatric pre-B acute lymphoblastic leukemia after bone marrow transplantation","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Immune system; Immunology; Bone marrow; Immunosuppression; Leukemia; T cell; Transplantation; Acute lymphocytic leukemia; B cell; Human leukocyte antigen; Oncology; Lymphoblastic Leukemia; Antigen; Antibody; Internal medicine","score_opus":0.03679472496176489,"score_gpt":0.3861622613803333,"score_spread":0.34936753641856844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267479587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823194,0.000506713,0.015566987,0.00037683215,0.0006891909,0.00026096203,0.000011800173,0.000007741641,0.00026037567],"genre_scores_gemma":[0.99248797,0.0042215795,0.002846098,0.00004231142,0.00032453364,0.000005629532,0.000012119019,0.000016444954,0.000043313004],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9944409,0.00022809395,0.004467051,0.00016272507,0.0005455204,0.00015571844],"domain_scores_gemma":[0.995018,0.00095210643,0.003101447,0.0001858733,0.00059513166,0.00014743074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023222975,0.00013614581,0.0011840238,0.00025781593,0.000017783943,0.0000058729343,0.000118287106,0.0003872679,0.00005242875],"category_scores_gemma":[0.00039797425,0.000107916916,0.0004536995,0.00023376067,0.00015971111,0.00023959088,0.000007955841,0.00036861337,0.0000085343545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06364018,0.006074239,0.07514115,0.006971083,0.0018432605,0.003198783,0.0058962777,0.0053046755,0.8104638,0.0016842544,0.000096895834,0.019685416],"study_design_scores_gemma":[0.017094769,0.007846464,0.9115698,0.00058052316,0.004452278,0.0015902013,0.0003492601,0.000114387396,0.054824196,0.0014150726,0.000031410833,0.00013164568],"about_ca_topic_score_codex":0.000016640524,"about_ca_topic_score_gemma":0.000010748475,"teacher_disagreement_score":0.83642864,"about_ca_system_score_codex":0.0001888702,"about_ca_system_score_gemma":0.0027218417,"threshold_uncertainty_score":0.482843},"labels":[],"label_agreement":null},{"id":"W2267533929","doi":"10.1200/jco.2015.33.15_suppl.4508","title":"Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sunitinib; Rash; Renal cell carcinoma; Sorafenib; Adverse effect; Discontinuation; Placebo; Internal medicine; Clinical endpoint; Toxicity; Urology; Adjuvant; Neutropenia; Surgery; Randomized controlled trial; Hepatocellular carcinoma; Pathology","score_opus":0.38941716373687607,"score_gpt":0.5368922467804587,"score_spread":0.1474750830435826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267533929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232846,0.00063388934,0.00046620815,0.0019691314,0.0014334995,0.0010777195,0.00008572499,0.000017333146,0.0019880023],"genre_scores_gemma":[0.9862576,0.0001479863,0.00936885,0.0007034913,0.0020358758,0.000032481694,0.00010318009,0.000049396644,0.0013011228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915522,0.0013213548,0.0052009523,0.00048038567,0.0008986953,0.00054642296],"domain_scores_gemma":[0.9870572,0.0039241635,0.0042295544,0.0006982887,0.0024414463,0.0016493099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00949103,0.00037685074,0.005178286,0.00078901794,0.00006348393,0.00002180559,0.00040669774,0.0006651135,0.00055752724],"category_scores_gemma":[0.007726329,0.00024037507,0.0021036041,0.000832449,0.00031663998,0.0002605648,0.00007441494,0.0009514784,0.000013209568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84056187,0.024945095,0.018749004,0.00012330867,0.010591934,0.005015403,0.00051975297,0.00043218327,0.0014351673,0.00009839158,0.012683799,0.084844105],"study_design_scores_gemma":[0.5278747,0.31278735,0.03730462,0.00011951876,0.03672733,0.0007524098,0.001218934,0.00313338,0.0024396537,0.00034168654,0.07685633,0.00044410265],"about_ca_topic_score_codex":0.000121576064,"about_ca_topic_score_gemma":0.00037958828,"teacher_disagreement_score":0.3126872,"about_ca_system_score_codex":0.0004323811,"about_ca_system_score_gemma":0.006534469,"threshold_uncertainty_score":0.9990976},"labels":[],"label_agreement":null},{"id":"W2267551299","doi":"10.1200/jco.2014.32.31_suppl.25","title":"A systematic and interdisciplinary approach to the measurement of outcomes over the disease trajectory in a unique specialized cachexia clinic.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Concordia University; McGill University Health Centre","funders":"","keywords":"Medicine; Cachexia; Grip strength; Quality of life (healthcare); Weight loss; Physical therapy; Cancer cachexia; Disease; Population; Cancer; Gerontology; Internal medicine; Obesity","score_opus":0.23211256271755712,"score_gpt":0.5091962182731216,"score_spread":0.27708365555556447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267551299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91453534,0.0010114942,0.0010190043,0.074758664,0.001257349,0.0017211812,0.0000022630347,0.0000073733013,0.00568732],"genre_scores_gemma":[0.9903273,0.00012380368,0.0011310154,0.007804732,0.00052143086,0.000022724158,2.5478485e-7,0.000008917668,0.00005981898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99475753,0.0017387511,0.0027898254,0.00012678493,0.0004398929,0.00014722251],"domain_scores_gemma":[0.99485743,0.0031185118,0.0012133053,0.00024326457,0.00023109121,0.00033638877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018474443,0.00009808402,0.0014744714,0.00011926889,0.00004524145,0.000005945635,0.0001785644,0.00012118916,0.000023547576],"category_scores_gemma":[0.006191239,0.000043715565,0.00031776103,0.00011443606,0.00016309996,0.00002979824,0.000093230046,0.0007656488,0.000003000467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038003795,0.01601178,0.8403602,0.031221112,0.0016868231,0.00028925104,0.010594331,0.00009918776,0.00006917388,0.0054914407,0.03523061,0.020942276],"study_design_scores_gemma":[0.0068367682,0.002255076,0.98026663,0.0030220118,0.00037518144,0.000053704716,0.00092276686,0.0005454084,0.000001132771,0.0012563443,0.0044044154,0.00006058191],"about_ca_topic_score_codex":0.000006982836,"about_ca_topic_score_gemma":0.00006397437,"teacher_disagreement_score":0.13990639,"about_ca_system_score_codex":0.00013065843,"about_ca_system_score_gemma":0.0006218158,"threshold_uncertainty_score":0.7411939},"labels":[],"label_agreement":null},{"id":"W2268024701","doi":"10.1200/jco.2009.27.15_suppl.e11550","title":"Trastuzumab-mediated cardiotoxicity in the nontrial setting: Evaluation of patients receiving adjuvant trastuzumab at an academic centre","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cardiotoxicity; Trastuzumab; Ejection fraction; Internal medicine; Discontinuation; Breast cancer; Incidence (geometry); Hazard ratio; Oncology; Cancer; Heart failure; Chemotherapy; Confidence interval","score_opus":0.25340602469883244,"score_gpt":0.5571225239931855,"score_spread":0.30371649929435307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268024701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938185,0.00033886422,0.000012301156,0.007189529,0.00090497936,0.0009154036,0.000013324088,0.0000062329987,0.0012374992],"genre_scores_gemma":[0.99641067,0.00042549995,0.00022807704,0.0012430777,0.0016399825,0.00000451837,0.00001849646,0.000014446166,0.00001521739],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98798716,0.005272851,0.0035457336,0.00027852398,0.002473436,0.00044228754],"domain_scores_gemma":[0.9917496,0.00425409,0.0019662078,0.00030340324,0.0013497648,0.0003769425],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033445,0.00016797752,0.0015893546,0.00021981476,0.00005341184,0.000007152079,0.0004348447,0.00068172044,0.00016697888],"category_scores_gemma":[0.03104263,0.00010784672,0.00043407618,0.0003613269,0.00018854487,0.00018663354,0.00004280002,0.0027099554,0.000008514824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009941703,0.002958659,0.4169782,0.000028363107,0.00014403199,0.00012855131,0.0021451013,0.00019707407,0.00083697215,0.000005189694,0.004576226,0.56205994],"study_design_scores_gemma":[0.020296533,0.014220902,0.9586867,0.0002058722,0.00036942452,0.000055609835,0.000431315,0.0013434114,0.00015881234,0.00018768811,0.003950866,0.000092880604],"about_ca_topic_score_codex":0.00002575342,"about_ca_topic_score_gemma":0.0001677859,"teacher_disagreement_score":0.561967,"about_ca_system_score_codex":0.0016173795,"about_ca_system_score_gemma":0.0037188793,"threshold_uncertainty_score":0.9995908},"labels":[],"label_agreement":null},{"id":"W2268434221","doi":"10.1200/jco.2015.33.3_suppl.149","title":"The relationship between health utility, quality of life, and symptom scores in Canadian patients with esophageal cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Toronto General Hospital; University of Toronto; University Health Network; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dysphagia; Quality of life (healthcare); Esophageal cancer; Stage (stratigraphy); Cancer; Disease; Correlation; Esophageal disease; Physical therapy; Internal medicine; Surgery; Esophagus","score_opus":0.7559131250920357,"score_gpt":0.5974098775536653,"score_spread":0.15850324753837042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268434221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9286683,0.0027923072,0.00005384008,0.06701902,0.00059571967,0.00028740274,0.00011777785,0.000002189079,0.0004634157],"genre_scores_gemma":[0.9948733,0.00016862279,0.0004986103,0.004041063,0.00036633754,0.0000059802815,0.000004690431,0.0000096463455,0.00003176711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9869671,0.0021380503,0.010194673,0.00020904053,0.00015568161,0.0003354787],"domain_scores_gemma":[0.969648,0.017968493,0.010665388,0.00024994471,0.0003152323,0.0011529225],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.085486926,0.00010077965,0.0019309915,0.00022897616,0.000111765316,0.000019959578,0.00025622649,0.00022616381,0.000015897363],"category_scores_gemma":[0.060190875,0.0000823887,0.00009832083,0.00016906978,0.00027440555,0.00024671145,0.00003376197,0.00057753077,0.000012954346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015953567,0.00009234929,0.9839613,0.000048559956,0.00005128719,5.0016774e-7,0.00040628857,0.000023243461,5.044823e-10,0.010665843,0.0031538212,0.0014372754],"study_design_scores_gemma":[0.003025214,0.001051789,0.97649163,0.000049984497,0.0000049650303,5.9324293e-7,0.0002247795,0.000063236555,8.226807e-9,0.010727925,0.008289797,0.00007007368],"about_ca_topic_score_codex":0.1670647,"about_ca_topic_score_gemma":0.42434463,"teacher_disagreement_score":0.25727993,"about_ca_system_score_codex":0.00086034194,"about_ca_system_score_gemma":0.0085542435,"threshold_uncertainty_score":0.9970663},"labels":[],"label_agreement":null},{"id":"W2268755353","doi":"10.1200/jco.2014.32.3_suppl.178","title":"Updated survival from a randomized phase III trial (MPACT) of <i>nab</i>-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Gastroenterology; Post-hoc analysis; Nab-paclitaxel; Paclitaxel; Pancreatic cancer; Adenocarcinoma; Cancer; Oncology; Randomized controlled trial; Urology","score_opus":0.12426132426370842,"score_gpt":0.4585752383556481,"score_spread":0.33431391409193967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268755353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932445,0.0003538323,0.0023597628,0.0023234363,0.0017564502,0.0028071008,0.00011236475,0.000008328152,0.00095426966],"genre_scores_gemma":[0.990271,0.00020608297,0.007860423,0.00032236354,0.000972314,0.000056255718,0.000065176406,0.00003919786,0.00020722955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894708,0.0034616184,0.005101753,0.00034649004,0.0011250194,0.0004943585],"domain_scores_gemma":[0.95954347,0.031573907,0.005542117,0.0006214208,0.002144835,0.0005742426],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01216318,0.00032518394,0.008166192,0.00020737847,0.00007744548,0.000007750301,0.0005013761,0.00042166206,0.00028397058],"category_scores_gemma":[0.035703205,0.0001703075,0.0013803096,0.00033421945,0.0014872764,0.00012584492,0.00011716208,0.0010153074,0.0000038674602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9624709,0.006768289,0.019481434,0.00008019098,0.004840612,0.000032718413,0.00019898744,0.000007914527,0.000119690776,0.00024956602,0.0013816931,0.0043680444],"study_design_scores_gemma":[0.89572465,0.06943084,0.022159956,0.00016957794,0.008554671,0.000020898233,0.00018113335,0.0014017452,0.00009280247,0.00069482904,0.0014263903,0.00014251503],"about_ca_topic_score_codex":0.00037545504,"about_ca_topic_score_gemma":0.00011412233,"teacher_disagreement_score":0.06674623,"about_ca_system_score_codex":0.00020976484,"about_ca_system_score_gemma":0.0034650348,"threshold_uncertainty_score":0.9724195},"labels":[],"label_agreement":null},{"id":"W2268844795","doi":"10.1200/jco.2005.23.16_suppl.4166","title":"A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] Phase II Consortium","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Vomiting; Internal medicine; Gemcitabine; Anorexia; Phases of clinical research; Gastroenterology; Progressive disease; Pancreatic cancer; Cancer; Surgery; Clinical trial; Chemotherapy","score_opus":0.08575577194021687,"score_gpt":0.5070077517415977,"score_spread":0.42125197980138085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268844795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856211,0.000600055,0.00010176517,0.009025122,0.0011921249,0.0031581842,0.00005537748,0.0000071887334,0.00023906975],"genre_scores_gemma":[0.99394923,0.00077411643,0.0011230548,0.00092287693,0.0022554758,0.000106799744,0.0000032415485,0.000034386776,0.000830801],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99399775,0.00056630134,0.0039135274,0.00030610137,0.00083269126,0.00038361232],"domain_scores_gemma":[0.9905586,0.0035636546,0.0036999,0.00045802759,0.0013496444,0.00037015686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033331348,0.00024134664,0.0026295711,0.00013942462,0.00012487383,0.0000056301137,0.0005219858,0.0003404676,0.00058103533],"category_scores_gemma":[0.0075150123,0.00013922282,0.0007070165,0.00027844682,0.00058005995,0.00013786038,0.00017838266,0.00093568943,9.915908e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61033696,0.13338877,0.0013206556,0.00009777508,0.0018920942,0.00013036716,0.0016802012,0.00003824645,0.0040294537,0.000035539575,0.002858301,0.24419165],"study_design_scores_gemma":[0.5283013,0.43703744,0.0010665029,0.00014106267,0.0005984573,0.00007980724,0.00055478985,0.0006774153,0.002946529,0.00004612263,0.028449375,0.00010119665],"about_ca_topic_score_codex":0.000033809934,"about_ca_topic_score_gemma":0.00009043268,"teacher_disagreement_score":0.30364868,"about_ca_system_score_codex":0.0004468377,"about_ca_system_score_gemma":0.0077608237,"threshold_uncertainty_score":0.99786425},"labels":[],"label_agreement":null},{"id":"W2269050882","doi":"10.1200/jco.2013.31.15_suppl.1518","title":"Aspirin use in prostate cancer and the risk of death and metastasis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Aspirin; Internal medicine; Cancer; Oncology; Prostate; Metastasis; Cohort; Relative risk; Population; Cohort study; Cancer registry; Confidence interval","score_opus":0.055847009893721516,"score_gpt":0.39798069024418375,"score_spread":0.3421336803504622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269050882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98818696,0.008658994,0.000021449012,0.0012633507,0.0015886851,0.00015854622,0.000010132521,5.4609654e-7,0.0001113575],"genre_scores_gemma":[0.9365416,0.05885674,0.001016471,0.0008726476,0.0024833684,0.000011770264,8.662481e-7,0.00000791073,0.0002086246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982664,0.00044971093,0.00094750634,0.00012690458,0.00008619581,0.00012328387],"domain_scores_gemma":[0.9982741,0.0004518835,0.0008710683,0.000115931354,0.00018117366,0.000105868676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021415686,0.00008042415,0.00063392863,0.00003465525,0.000018663559,0.000010768556,0.00009414241,0.00013819986,0.000012403091],"category_scores_gemma":[0.0014991243,0.000045120454,0.00014419368,0.00003741803,0.0003438211,0.000011516865,0.00007689889,0.00030403625,4.098438e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036462683,0.0003054725,0.6582997,0.000028855176,0.0005632151,0.0000016785826,0.00018440664,0.00006607348,0.004379271,0.00033901434,0.010853347,0.3213327],"study_design_scores_gemma":[0.0072175525,0.0011134747,0.61913115,0.000018315866,0.0001940709,0.00003542278,0.00007874993,0.00003037197,0.00036592004,0.00065147143,0.37109447,0.00006902272],"about_ca_topic_score_codex":0.0009328186,"about_ca_topic_score_gemma":0.0010075037,"teacher_disagreement_score":0.36024112,"about_ca_system_score_codex":0.0000074600302,"about_ca_system_score_gemma":0.00030355324,"threshold_uncertainty_score":0.18399587},"labels":[],"label_agreement":null},{"id":"W2269124464","doi":"10.1200/jco.2013.31.4_suppl.527","title":"Time from surgery to first adjuvant chemotherapy: Experiences at an inner-city Canadian hospital.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Referral; Colorectal cancer; Surgery; Chemotherapy regimen; Cancer; Population; Chemotherapy; Regimen; Internal medicine","score_opus":0.0828181852918471,"score_gpt":0.40557073396876986,"score_spread":0.32275254867692277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269124464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667972,0.00022178731,0.000002032778,0.028587092,0.001693716,0.0003296444,0.000008556739,0.000013991308,0.0023459934],"genre_scores_gemma":[0.9886836,0.00017275484,0.00085204263,0.008278087,0.0013284567,0.000036707603,0.0000079261845,0.000021393902,0.0006190234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969663,0.00023089987,0.0016520703,0.00030521545,0.0003882144,0.00045729027],"domain_scores_gemma":[0.9936371,0.0024213963,0.0007188204,0.00027064775,0.00039079867,0.0025612616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011950003,0.00018684175,0.0017108405,0.00015600202,0.000079358266,0.000018388064,0.00021963805,0.0003755836,0.013204639],"category_scores_gemma":[0.0025737775,0.00012895568,0.000473282,0.00020203034,0.00022456275,0.00021132393,0.000055015455,0.00044931067,0.00052920275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024971098,0.0019389759,0.7028233,0.0000052659893,0.00046694564,0.0013675323,0.0021714834,0.0000037985676,0.000049924856,0.0000010689823,0.088860855,0.19981375],"study_design_scores_gemma":[0.0021236474,0.008854762,0.7961476,0.000056092344,0.000073923744,0.000064383355,0.00030834883,0.000045689383,0.00009484406,0.00006128112,0.1920298,0.00013966147],"about_ca_topic_score_codex":0.027237576,"about_ca_topic_score_gemma":0.033178903,"teacher_disagreement_score":0.19967408,"about_ca_system_score_codex":0.0010314801,"about_ca_system_score_gemma":0.0021214124,"threshold_uncertainty_score":0.9876974},"labels":[],"label_agreement":null},{"id":"W2269217367","doi":"10.1200/jco.2006.24.18_suppl.7507","title":"Recommendations for revised response criteria for malignant lymphoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Mantle cell lymphoma; Follicular lymphoma; Internal medicine; Oncology; Clinical endpoint; Clinical trial; Non-Hodgkin's lymphoma; PET-CT; Nuclear medicine; Positron emission tomography","score_opus":0.17071722134882844,"score_gpt":0.5605959368862315,"score_spread":0.3898787155374031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269217367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6065307,0.0011666092,0.027498715,0.35085154,0.0061424375,0.0024701522,0.00023703474,0.000033303942,0.005069462],"genre_scores_gemma":[0.8022125,0.00023904993,0.17949128,0.0074366517,0.0038771413,0.00013704952,0.00007670374,0.000036424528,0.0064932522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778056,0.00025142287,0.0016046112,0.00011902866,0.00009297626,0.00015142621],"domain_scores_gemma":[0.9937888,0.0043897945,0.0009369627,0.00011511733,0.00062534073,0.00014400882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003042526,0.0000790572,0.0007225033,0.00008678462,0.000081250735,0.000009535622,0.00006274411,0.0001624138,0.000092155286],"category_scores_gemma":[0.0036789335,0.0000543786,0.00049611006,0.00006105659,0.000058326354,0.000067328685,0.000008427922,0.000099188415,0.0000040659615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049392886,0.00418645,0.0032668307,0.00008110505,0.00070399715,0.00010955088,0.00010789896,0.000005410155,0.0013293491,0.0024803118,0.58792233,0.35041386],"study_design_scores_gemma":[0.019098105,0.011344182,0.04618002,0.00009804962,0.0008871921,0.00014255696,0.0000731011,0.000075193406,0.00013295164,0.0029295348,0.9189832,0.000055875782],"about_ca_topic_score_codex":0.000009709366,"about_ca_topic_score_gemma":0.000008252932,"teacher_disagreement_score":0.35035798,"about_ca_system_score_codex":0.0002130841,"about_ca_system_score_gemma":0.0017351034,"threshold_uncertainty_score":0.44042927},"labels":[],"label_agreement":null},{"id":"W2269230994","doi":"10.1200/jco.2005.23.16_suppl.5136","title":"Efficacy of third-line chemotherapy for recurrent ovarian, peritoneal and fallopian tube carcinoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Topotecan; Fallopian tube; Fallopian tube cancer; Chemotherapy; Ovarian cancer; Ovarian carcinoma; Regimen; Clinical endpoint; Internal medicine; Surgery; Chemotherapy regimen; Oncology; Gynecology; Gastroenterology; Cancer; Randomized controlled trial","score_opus":0.11460759853702733,"score_gpt":0.462665828266809,"score_spread":0.3480582297297817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269230994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9327137,0.0021112887,0.000194165,0.06283543,0.0008269402,0.00042507923,0.000009650506,0.000005448505,0.00087832694],"genre_scores_gemma":[0.9730302,0.0021620996,0.019154957,0.0024677531,0.0030109196,0.000008804423,0.0000032479718,0.00001723538,0.00014478972],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975128,0.00010837787,0.0017995312,0.00018890976,0.000205641,0.0001847259],"domain_scores_gemma":[0.99668956,0.0014995818,0.0009984892,0.00016307265,0.00033430933,0.00031499824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013711822,0.00013434154,0.0013726867,0.00007792297,0.000028673641,0.000005744632,0.00008908244,0.0002614826,0.0000957659],"category_scores_gemma":[0.00076274085,0.00009181637,0.00047617158,0.00006474535,0.00014955483,0.00005468568,0.000021155765,0.00038250012,0.0000020367027],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015178053,0.0054467213,0.08125991,0.000066074324,0.0006645346,0.00007748112,0.00024214917,0.000009270436,0.00008089269,0.0007051406,0.005812192,0.8904576],"study_design_scores_gemma":[0.038303632,0.03274923,0.61524606,0.00012225134,0.00055851083,0.00022862945,0.00003772473,0.00021615003,0.0006070413,0.00012864608,0.31171632,0.00008581795],"about_ca_topic_score_codex":0.000011108289,"about_ca_topic_score_gemma":0.000032109925,"teacher_disagreement_score":0.8903718,"about_ca_system_score_codex":0.00013105513,"about_ca_system_score_gemma":0.00086431066,"threshold_uncertainty_score":0.3744163},"labels":[],"label_agreement":null},{"id":"W2269255206","doi":"10.1200/jco.2006.24.18_suppl.6117","title":"Survival and cost-effectiveness of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC): A population-based evaluation","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Metastatic breast cancer; Taxane; Confidence interval; Internal medicine; Anthracycline; Population; Breast cancer; Paclitaxel; Log-rank test; Oncology; Chemotherapy; Cancer; Gastroenterology; Urology; Overall survival; Surgery","score_opus":0.10178530269329276,"score_gpt":0.5114907116261588,"score_spread":0.409705408932866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269255206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977717,0.00042901927,0.00003556632,0.0006989249,0.00026541666,0.0006438529,0.00002639804,0.0000017948761,0.00012733528],"genre_scores_gemma":[0.9992615,0.00006171734,0.00038751462,0.000111639005,0.00011974418,0.000022509765,0.000019689804,0.000008142991,0.0000075420644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761707,0.0008846923,0.0009534745,0.0001350821,0.00029498394,0.000114702125],"domain_scores_gemma":[0.9962925,0.0021848874,0.00086242065,0.000056625428,0.0004994172,0.000104198356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027317223,0.00009985859,0.0009801994,0.00013437645,0.000016231937,0.0000031990303,0.000027170248,0.00009844769,0.00006930911],"category_scores_gemma":[0.00025806893,0.00006619106,0.00007624505,0.00012445614,0.00012097361,0.000077949495,0.000009115013,0.00023838009,1.8317265e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014380469,0.0027446689,0.9460546,0.00008628288,0.00019439653,0.000020185269,0.000010765665,0.00029788236,0.000040730007,0.0000288139,0.000029782057,0.03611147],"study_design_scores_gemma":[0.044931028,0.006211659,0.94687873,0.00015250132,0.0009842954,0.000018710996,0.000012024718,0.00042328594,0.000013675006,0.00023233323,0.00008672207,0.00005500701],"about_ca_topic_score_codex":0.0009782694,"about_ca_topic_score_gemma":0.0009463353,"teacher_disagreement_score":0.036056463,"about_ca_system_score_codex":0.00023338739,"about_ca_system_score_gemma":0.00079232355,"threshold_uncertainty_score":0.2699193},"labels":[],"label_agreement":null},{"id":"W2269305268","doi":"10.1200/jco.2006.24.18_suppl.7604","title":"Effect of complete response pre- and post- autologous stem cell transplantation in multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Surgery; Oncology; Stem cell; Urology","score_opus":0.062212870772762045,"score_gpt":0.42869730620342866,"score_spread":0.3664844354306666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269305268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789953,0.00036867437,0.000041078885,0.0008553317,0.00013517831,0.00037576514,0.000019481693,0.0000050944986,0.00029983808],"genre_scores_gemma":[0.9984825,0.00018674892,0.0009687882,0.00009307929,0.00010138483,0.0000044311046,0.000007706006,0.0000098555965,0.00014546367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587405,0.0019316458,0.0015582492,0.00014472687,0.0002843339,0.00020699605],"domain_scores_gemma":[0.98734915,0.011440134,0.00071611383,0.00010789181,0.00018489221,0.00020180127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040566344,0.00011331558,0.0011555413,0.00021448804,0.000022617658,0.0000037866514,0.00007545532,0.00024731667,0.000014940914],"category_scores_gemma":[0.0011321896,0.00007529432,0.00021406493,0.000096987686,0.00018572343,0.000063436266,0.000017061117,0.0005037642,0.0000047422254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18702179,0.001200953,0.6290362,0.00023480228,0.000099230696,0.0032304379,0.00011331519,0.000026105356,0.024865245,0.000004878189,0.00007362672,0.1540934],"study_design_scores_gemma":[0.02624316,0.041633014,0.92607635,0.0000983023,0.00015557244,0.00046871835,0.000020107549,0.00039979146,0.004448279,0.000016676628,0.00039264833,0.000047378933],"about_ca_topic_score_codex":0.00015923814,"about_ca_topic_score_gemma":0.00012935816,"teacher_disagreement_score":0.29704013,"about_ca_system_score_codex":0.00008135054,"about_ca_system_score_gemma":0.00044039238,"threshold_uncertainty_score":0.30704132},"labels":[],"label_agreement":null},{"id":"W2269406332","doi":"10.1200/jco.2006.24.18_suppl.7528","title":"A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin’s lymphoma (NHL)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Bendamustine; Mantle cell lymphoma; Rituximab; Medicine; Internal medicine; Population; Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Chemotherapy","score_opus":0.05246717604675004,"score_gpt":0.41230813439612307,"score_spread":0.359840958349373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269406332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455816,0.0008110556,0.00000858711,0.001140923,0.0005499618,0.00069310004,0.000008174338,0.000006081458,0.0022239555],"genre_scores_gemma":[0.9971372,0.00034975962,0.0012967493,0.00050069793,0.00041762815,0.000016073418,0.0000045949027,0.000022925668,0.00025438797],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99526566,0.00033583475,0.0033204486,0.00032335313,0.00044100732,0.00031368292],"domain_scores_gemma":[0.99589986,0.0013311974,0.0019291918,0.0002580675,0.000276836,0.00030485253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016365319,0.00024657394,0.002198317,0.00027304923,0.000047846548,0.000008245393,0.00014434465,0.00033520782,0.00008078122],"category_scores_gemma":[0.0003539918,0.0001735101,0.00034741362,0.00015938471,0.00014936402,0.00006999005,0.00013267892,0.00041585616,0.00000876936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023504246,0.5130571,0.35376891,0.00012671025,0.00035566124,0.00849538,0.0009970205,0.000039954095,0.00049241673,0.0000084382145,0.0030840915,0.09607007],"study_design_scores_gemma":[0.45666102,0.08955601,0.4466957,0.00016240016,0.0008504846,0.0001681231,0.0007397125,0.00057945325,0.0007866523,0.000021605583,0.0036417674,0.00013710164],"about_ca_topic_score_codex":0.00047932693,"about_ca_topic_score_gemma":0.00032457508,"teacher_disagreement_score":0.43315676,"about_ca_system_score_codex":0.00037768277,"about_ca_system_score_gemma":0.0007888505,"threshold_uncertainty_score":0.7075537},"labels":[],"label_agreement":null},{"id":"W2269708877","doi":"10.1200/jco.2006.24.18_suppl.13540","title":"A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Capecitabine; Irinotecan; Neutropenia; Nausea; Oxaliplatin; Internal medicine; Adverse effect; Toxicity; Colorectal cancer; Vomiting; Phases of clinical research; Gastroenterology; Oncology; Cancer","score_opus":0.07546783028022801,"score_gpt":0.45331674826773055,"score_spread":0.37784891798750253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269708877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964651,0.00081278133,0.000003107154,0.001197293,0.00023454265,0.00093790225,0.000013785274,0.000005218185,0.0003303122],"genre_scores_gemma":[0.99774784,0.0011761904,0.00049636327,0.00021213229,0.0001708587,0.000050596074,0.0000029895348,0.000018195275,0.00012485757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704194,0.00018857785,0.0019133517,0.00023705876,0.00039617,0.00022287424],"domain_scores_gemma":[0.99695927,0.0009471543,0.0013715101,0.000105374165,0.00046792757,0.0001487618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062510994,0.00021037058,0.0019111193,0.00015943446,0.00006654682,0.0000042345014,0.000077988014,0.00009425617,0.00013268868],"category_scores_gemma":[0.00049457035,0.000114122275,0.00012680385,0.00027611633,0.00019349859,0.00008896393,0.000048416852,0.00041707684,4.2710468e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12905374,0.062014084,0.41512758,0.000029143883,0.0009207604,0.00057073904,0.0008971667,0.000098956465,0.000058008893,0.000004633804,0.00012794754,0.39109725],"study_design_scores_gemma":[0.11126795,0.39402232,0.49177402,0.00008940931,0.00032924933,0.000035000918,0.00042795658,0.000030376104,0.00006502616,0.00003059268,0.0018440837,0.00008400856],"about_ca_topic_score_codex":0.0008655219,"about_ca_topic_score_gemma":0.016164402,"teacher_disagreement_score":0.39101323,"about_ca_system_score_codex":0.00020631033,"about_ca_system_score_gemma":0.0006694461,"threshold_uncertainty_score":0.9020116},"labels":[],"label_agreement":null},{"id":"W2269947569","doi":"10.1200/jco.2012.30.15_suppl.5020","title":"Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Veliparib; PARP inhibitor; Ovarian cancer; Surgery; Randomized controlled trial; Cancer; Poly ADP ribose polymerase","score_opus":0.06851753896149007,"score_gpt":0.3946114848879246,"score_spread":0.3260939459264345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269947569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899785,0.0004735072,0.00009006242,0.0033692713,0.0029306267,0.0029136187,0.000077930286,0.000020275875,0.00014620456],"genre_scores_gemma":[0.9782995,0.0002556097,0.017139403,0.001447339,0.0024139616,0.00012068464,0.00008217208,0.00008841804,0.0001529121],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909077,0.0022444278,0.004264405,0.00059810985,0.0011409112,0.0008444188],"domain_scores_gemma":[0.99139786,0.0025946533,0.0035468077,0.00052801153,0.0006912774,0.001241368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041012065,0.0006259845,0.0060381535,0.00033747675,0.00009473606,0.000033346998,0.00028688757,0.00064996857,0.00029537617],"category_scores_gemma":[0.0012669727,0.0003087862,0.00051770714,0.0005501157,0.00068851025,0.0005778605,0.00009552009,0.0013839558,0.0000046558703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67151195,0.0224498,0.26920974,0.00005386128,0.0013566238,0.0009874178,0.0004978886,0.0000031390398,0.0000047270046,0.000038911985,0.00027817578,0.033607762],"study_design_scores_gemma":[0.55300987,0.07774992,0.36523443,0.00036457376,0.0020252035,0.00024318135,0.00010172256,0.000012540374,0.000110433204,0.0000073916844,0.0008870938,0.00025363266],"about_ca_topic_score_codex":0.0019786395,"about_ca_topic_score_gemma":0.0014144923,"teacher_disagreement_score":0.11850207,"about_ca_system_score_codex":0.0008669597,"about_ca_system_score_gemma":0.007040646,"threshold_uncertainty_score":0.9999364},"labels":[],"label_agreement":null},{"id":"W2270007049","doi":"10.1200/jco.2006.24.18_suppl.7051","title":"Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Vinorelbine; Medicine; Chemotherapy; Oncology; Internal medicine; Regimen; Cisplatin; Lung cancer; Chemotherapy regimen; Paclitaxel; Cancer","score_opus":0.07838231343958373,"score_gpt":0.47967867436520883,"score_spread":0.4012963609256251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270007049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927764,0.00208955,0.00004195116,0.002550362,0.0011328774,0.0006827137,0.0001619091,0.0000020360992,0.0005622106],"genre_scores_gemma":[0.99562794,0.001317585,0.00076248863,0.0007714898,0.00078325794,0.00003071811,0.00002294632,0.000014070595,0.00066951703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99361336,0.0005040677,0.0047515947,0.0003078842,0.0006230033,0.00020006679],"domain_scores_gemma":[0.99271214,0.0027792894,0.0034563416,0.000206116,0.00065649854,0.00018962873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042822766,0.00018960111,0.0029757938,0.0001902351,0.00006382919,0.0000073045035,0.00022039135,0.00028066587,0.0003818155],"category_scores_gemma":[0.0006823177,0.000111736575,0.0005510406,0.00046145383,0.00015678222,0.00009231708,0.000059590646,0.00060699653,1.15943735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035783702,0.0036656163,0.9659996,0.000029168024,0.0031885288,0.000039365415,0.00022355706,0.0069320314,0.00086317165,0.000012180687,0.003937605,0.011530819],"study_design_scores_gemma":[0.026433256,0.0016521297,0.9578468,0.00023325763,0.0057668905,0.000002224585,0.00015705214,0.003191604,0.00031796205,0.00004362649,0.0042547975,0.000100352554],"about_ca_topic_score_codex":0.21805777,"about_ca_topic_score_gemma":0.558818,"teacher_disagreement_score":0.34076023,"about_ca_system_score_codex":0.0005613783,"about_ca_system_score_gemma":0.005694687,"threshold_uncertainty_score":0.9999421},"labels":[],"label_agreement":null},{"id":"W2270211286","doi":"10.1200/jco.2005.23.16_suppl.542","title":"Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gene knockdown; Cancer research; Growth factor; Medicine; Breast cancer; Insulin-like growth factor-binding protein; Insulin-like growth factor 1 receptor; Insulin-like growth factor; Cancer; Transfection; PTEN; Cell culture; Biology; Internal medicine; Signal transduction; Receptor; PI3K/AKT/mTOR pathway; Cell biology","score_opus":0.09270148088919371,"score_gpt":0.3862109127085511,"score_spread":0.2935094318193574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270211286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98826116,0.0009992603,0.000019620073,0.009488912,0.000106466876,0.00086981466,0.00012680722,0.0000048857996,0.00012305513],"genre_scores_gemma":[0.9949051,0.0033919723,0.0011526506,0.00023655496,0.00021397513,0.000051123105,0.0000024956203,0.000024200486,0.000021918908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953598,0.0003589142,0.003094201,0.00032063096,0.0005372296,0.0003292601],"domain_scores_gemma":[0.9956187,0.0005593589,0.0026285478,0.00016018558,0.00082741614,0.0002057778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018565466,0.00025646354,0.0017883633,0.00036456433,0.000030517607,0.000008796195,0.00025439277,0.00043927194,0.000025236877],"category_scores_gemma":[0.0006132423,0.00017145446,0.00019339025,0.00067523436,0.0004971215,0.0003817574,0.000059166934,0.0010195929,1.9060785e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072126756,0.0036906397,0.8685983,0.00092636654,0.00024413252,0.000036494344,0.0014205264,0.000023497558,0.09474912,0.00016884127,0.00013794895,0.022791468],"study_design_scores_gemma":[0.007843845,0.0017310125,0.9734454,0.0010474116,0.00018781601,0.000068959,0.00019194886,0.00066082587,0.01443225,0.00018360997,0.00003835269,0.00016855708],"about_ca_topic_score_codex":0.00038441317,"about_ca_topic_score_gemma":0.00051769457,"teacher_disagreement_score":0.104847126,"about_ca_system_score_codex":0.0001718077,"about_ca_system_score_gemma":0.0013628377,"threshold_uncertainty_score":0.699171},"labels":[],"label_agreement":null},{"id":"W2270275021","doi":"10.1200/jco.2016.34.2_suppl.4","title":"Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Metastasis; Internal medicine; Oncology; Radiation therapy; Prostatectomy; Salvage therapy; Proportional hazards model; Cancer; Chemotherapy","score_opus":0.2183303458427812,"score_gpt":0.4968435459335903,"score_spread":0.27851320009080915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270275021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130756,0.00086380093,0.0016405482,0.0049295085,0.0005804403,0.00039656393,0.000044491717,0.0000027076376,0.00023436463],"genre_scores_gemma":[0.9953244,0.0022524702,0.0016913617,0.00012407094,0.00032704376,0.000009215812,0.000008990715,0.000009266198,0.00025318313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796146,0.00028471855,0.001323067,0.00009733889,0.00022705358,0.000106373365],"domain_scores_gemma":[0.99664515,0.0015980899,0.0010793551,0.000089245164,0.00049151457,0.00009662989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024799567,0.00006560964,0.0007518101,0.00013236697,0.000021327105,0.0000020686048,0.000058883346,0.00016229821,0.000060480266],"category_scores_gemma":[0.0013108043,0.000033733064,0.0004895131,0.00006821666,0.00008315081,0.00013324281,0.000010559262,0.00014171975,0.0000014094287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014501924,0.0011364456,0.09596297,0.00003225014,0.0018728459,0.000020243837,0.0003080875,0.0000051145576,0.2799332,0.00009161009,0.0015736448,0.6045616],"study_design_scores_gemma":[0.055636946,0.056135513,0.63733906,0.00024752953,0.001073453,0.000038166876,0.00022350618,0.0000820217,0.21701656,0.00094449107,0.031169599,0.00009315941],"about_ca_topic_score_codex":0.000003216458,"about_ca_topic_score_gemma":8.280703e-7,"teacher_disagreement_score":0.60446846,"about_ca_system_score_codex":0.0001606453,"about_ca_system_score_gemma":0.0009909588,"threshold_uncertainty_score":0.17579183},"labels":[],"label_agreement":null},{"id":"W2270614059","doi":"10.1200/jco.2009.27.15_suppl.7071","title":"Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Myeloid leukemia","score_opus":0.036350333947076326,"score_gpt":0.3984694869978367,"score_spread":0.36211915305076037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270614059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990562,0.00034880085,0.000050540748,0.0067171566,0.00069670356,0.0005363381,0.000004675004,0.000020868592,0.0010629094],"genre_scores_gemma":[0.99218786,0.0026947842,0.002924054,0.0012016941,0.00065960275,0.0000074251648,0.000011163975,0.000020795474,0.0002926108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948491,0.00052657264,0.0032406445,0.00040377578,0.0005441529,0.0004357877],"domain_scores_gemma":[0.9959486,0.0016603357,0.0015139455,0.0003190733,0.00017281644,0.00038519694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024020122,0.0002775964,0.0019670934,0.00033919583,0.00004125734,0.000017449998,0.00023106023,0.00055691565,0.00007602955],"category_scores_gemma":[0.004507721,0.00016191347,0.00025874702,0.0002554368,0.00021779818,0.00036248265,0.000083206105,0.0014701048,0.0000072021703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035049007,0.0016131079,0.6561566,0.000114764814,0.00014002062,0.0016408595,0.00041924807,0.00023416441,0.0060260203,0.000036129903,0.0009988234,0.32911536],"study_design_scores_gemma":[0.02207988,0.0077759973,0.96315336,0.0008102916,0.00015322276,0.0002629406,0.00006512548,0.0015287773,0.0012861154,0.000418945,0.0023086958,0.0001566755],"about_ca_topic_score_codex":0.000054357362,"about_ca_topic_score_gemma":0.0004027368,"teacher_disagreement_score":0.32895866,"about_ca_system_score_codex":0.00360704,"about_ca_system_score_gemma":0.0046912176,"threshold_uncertainty_score":0.9432284},"labels":[],"label_agreement":null},{"id":"W2270696152","doi":"10.1200/jco.2006.24.18_suppl.18561","title":"The use of Internet as an information resource among cancer patients at a Canadian cancer centre","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"The Internet; Medicine; Cancer; Psychological intervention; Family medicine; Breast cancer; Internet access; Internal medicine; Nursing; World Wide Web","score_opus":0.1598074828340726,"score_gpt":0.5437868917378704,"score_spread":0.38397940890379784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270696152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892066,0.000042418225,0.000016224534,0.0043721558,0.0019373394,0.00037778198,0.00006957931,0.0000054804136,0.003972437],"genre_scores_gemma":[0.98162025,0.00019017006,0.0002160052,0.015731258,0.00060651696,0.000016002816,0.00003577263,0.0000069704674,0.001577057],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918998,0.001587194,0.0057510156,0.000076232995,0.00031306737,0.00037269952],"domain_scores_gemma":[0.98896587,0.002605085,0.0061507574,0.00018578793,0.0015744037,0.00051812147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044106054,0.00009297329,0.00051847263,0.00011341671,0.0003553434,0.000018554527,0.00027866487,0.00041841905,0.0007824338],"category_scores_gemma":[0.00417876,0.00005519416,0.0001312154,0.00013557562,0.00016060464,0.001946539,0.000067556364,0.001107128,0.00004267563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006796558,0.00009133862,0.8256546,0.000043432836,0.000018005281,0.0000010337258,0.001539182,0.000072447416,6.992336e-8,0.00016525429,0.10776277,0.06397218],"study_design_scores_gemma":[0.00088916393,0.00024815538,0.47223008,0.00008230728,0.000010680081,3.5763418e-7,0.0001821552,0.0006609936,8.682035e-7,0.000046790858,0.5256182,0.000030266825],"about_ca_topic_score_codex":0.25771353,"about_ca_topic_score_gemma":0.5922804,"teacher_disagreement_score":0.4178554,"about_ca_system_score_codex":0.0010263325,"about_ca_system_score_gemma":0.0047507784,"threshold_uncertainty_score":0.8567101},"labels":[],"label_agreement":null},{"id":"W2270737067","doi":"10.1200/jco.2009.27.15_suppl.e15634","title":"A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Eribulin; Medicine; Gemcitabine; Internal medicine; Gastroenterology; Neutropenia; Pancreatic cancer; Progressive disease; Oncology; Adverse effect; Cancer; Metastatic breast cancer; Toxicity; Surgery; Chemotherapy; Breast cancer","score_opus":0.08946331562877648,"score_gpt":0.5214411670188722,"score_spread":0.43197785139009576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270737067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410266,0.000980088,0.000018671599,0.002491285,0.0007088448,0.0013692728,0.000028913797,0.0000089110845,0.0002913341],"genre_scores_gemma":[0.99406815,0.0012210658,0.0009803955,0.0025751386,0.00050983054,0.000043826694,0.000014018552,0.000019274617,0.00056827435],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9969514,0.00024303999,0.001997839,0.00024660418,0.00029287263,0.00026826424],"domain_scores_gemma":[0.995737,0.00091933884,0.0020518512,0.00018433582,0.0007965231,0.0003109198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000788727,0.00021375017,0.0020660614,0.00014423237,0.000059441227,0.0000032907471,0.0001445327,0.00019837233,0.0006827921],"category_scores_gemma":[0.00034207394,0.00013277745,0.00033959156,0.00019095509,0.00010218639,0.00010027235,0.000016153697,0.00048557002,0.0000015928853],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2788845,0.1131894,0.094162144,0.000030590607,0.002760898,0.00023622243,0.0008263092,0.00006156957,0.0011668209,0.000014814869,0.0023332508,0.5063335],"study_design_scores_gemma":[0.16879742,0.6576076,0.14471658,0.00006902098,0.0012579701,0.000026619937,0.00009693426,0.00003334577,0.00039455426,0.0001840244,0.026698358,0.00011754601],"about_ca_topic_score_codex":0.000028431867,"about_ca_topic_score_gemma":0.00017039645,"teacher_disagreement_score":0.5444182,"about_ca_system_score_codex":0.00013872159,"about_ca_system_score_gemma":0.0011022531,"threshold_uncertainty_score":0.7476095},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2270943787","doi":"10.1200/jco.2014.32.31_suppl.124","title":"Improving the final year of life at the institutional level: Quality dying initiative (QDI).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Coaching; Psychological intervention; Population; Advance care planning; Documentation; Family medicine; Intervention (counseling); Health care; Surprise; Nursing; Psychology","score_opus":0.717314934755145,"score_gpt":0.6012936091054804,"score_spread":0.11602132564966461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270943787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773622,0.000724837,0.002911665,0.009869878,0.00080935453,0.00010403995,0.000009862549,0.000003360299,0.008204808],"genre_scores_gemma":[0.99218845,0.00034880254,0.0024596637,0.0036162504,0.0012426445,0.0000013627027,0.0000019231181,0.0000060202715,0.00013487366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643695,0.000955193,0.0019188143,0.00010432643,0.00044701295,0.00013772144],"domain_scores_gemma":[0.98591703,0.010618175,0.0024046411,0.00019204705,0.00072467845,0.0001434399],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007217976,0.00009012747,0.00095294556,0.000045012264,0.00008106398,0.0000032206488,0.00021232606,0.00018867728,0.000119047785],"category_scores_gemma":[0.033295214,0.00004363044,0.000390859,0.00009946124,0.00076407427,0.00006951271,0.00010775329,0.00076447224,0.0000121086405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011013247,0.0014692391,0.70514154,0.00025465403,0.0014246661,0.000088418055,0.0036678577,0.00021221316,0.0018841302,0.009223056,0.008871148,0.25674984],"study_design_scores_gemma":[0.008682854,0.0059109204,0.775066,0.00046949068,0.00042840626,0.00008091285,0.0019319216,0.00027812243,0.0010253518,0.0011601376,0.20484115,0.00012471665],"about_ca_topic_score_codex":0.00006814396,"about_ca_topic_score_gemma":0.00007489836,"teacher_disagreement_score":0.25662512,"about_ca_system_score_codex":0.00009448253,"about_ca_system_score_gemma":0.0016503083,"threshold_uncertainty_score":0.97484773},"labels":[],"label_agreement":null},{"id":"W2271164338","doi":"10.1200/jco.2009.27.15_suppl.e17506","title":"Assessing compliance with practice treatment guidelines by treatment centers and the reasons for noncompliance","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Concordance; Capecitabine; Cancer; Stage (stratigraphy); Population; Colorectal cancer; Clinical trial; Family medicine; Internal medicine; Environmental health; Pathology","score_opus":0.6552460874429481,"score_gpt":0.6663402915650016,"score_spread":0.01109420412205353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271164338","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16519952,0.0024643885,0.02493315,0.8028739,0.0008611001,0.0017526137,0.000020383897,0.000022770131,0.0018721664],"genre_scores_gemma":[0.6504424,0.0081948275,0.28631172,0.052121356,0.002336091,0.000035450048,0.000024842997,0.000032478634,0.00050083816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99496657,0.00066862773,0.0035006374,0.00028089478,0.00032952297,0.0002537677],"domain_scores_gemma":[0.97140557,0.022513602,0.003986145,0.00026935304,0.001503749,0.00032156322],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055190898,0.00021443937,0.0015270871,0.00004113509,0.00013192091,0.000056884917,0.000115219336,0.00015922402,0.000012533336],"category_scores_gemma":[0.024646413,0.00010376663,0.00037284254,0.00010469773,0.00032705767,0.00049817987,0.000014251058,0.0003596914,0.0000030283545],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036564056,0.0033980894,0.0066259457,0.000012547148,0.0008117859,0.00014423554,0.00010073477,0.000032454536,0.000099958095,0.00022035924,0.02248401,0.9295058],"study_design_scores_gemma":[0.081286,0.063356586,0.026597932,0.0002789208,0.0034609663,0.0021190345,0.0015378307,0.0017734604,0.000041456577,0.00040515632,0.8189745,0.00016813699],"about_ca_topic_score_codex":0.00010119991,"about_ca_topic_score_gemma":0.000051742303,"teacher_disagreement_score":0.9293377,"about_ca_system_score_codex":0.00037049758,"about_ca_system_score_gemma":0.0013507277,"threshold_uncertainty_score":0.9835694},"labels":[],"label_agreement":null},{"id":"W2271169392","doi":"10.1200/jco.2010.28.15_suppl.e19675","title":"Quality of life and quality of care in cancer survivors: Fear of cancer recurrence—Preliminary results of a transcultural availability of validated tools.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Coping (psychology); Medicine; Distress; Quality of life (healthcare); Clinical psychology; Cancer recurrence; Cancer; Psychological distress; Psychiatry; Anxiety; Nursing","score_opus":0.21315613649935966,"score_gpt":0.5099873152109475,"score_spread":0.2968311787115879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271169392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925588,0.0034730795,0.0000055069827,0.0011574699,0.0013070382,0.00031142842,0.0007290581,0.0000029548721,0.00045469592],"genre_scores_gemma":[0.9970931,0.0022515657,0.00032991674,0.000073607924,0.00020264169,0.000006090334,0.000010948211,0.0000103082875,0.000021813155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99008775,0.0017323206,0.0069679534,0.00029546255,0.0007041838,0.00021231208],"domain_scores_gemma":[0.9866803,0.003995969,0.005778812,0.00042686408,0.0028464713,0.00027156775],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009047582,0.00018806181,0.0035735124,0.00013853014,0.000012662831,0.0000019159904,0.0002753454,0.0006280546,0.00014850403],"category_scores_gemma":[0.0108112935,0.00013822567,0.0007015348,0.00038743127,0.001104952,0.00013090734,0.00006364156,0.0011930496,1.0678413e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070925824,0.0016783915,0.86695826,0.0027293882,0.0003201618,0.000004969792,0.007310327,0.000020467143,0.014503211,0.000053775384,0.000109068,0.03538616],"study_design_scores_gemma":[0.010084494,0.009084284,0.9681041,0.0006162027,0.00023739654,0.000004376314,0.0035047345,0.0000087515045,0.0076557323,0.00005686602,0.0005228306,0.00012019208],"about_ca_topic_score_codex":0.06356589,"about_ca_topic_score_gemma":0.25240472,"teacher_disagreement_score":0.18883882,"about_ca_system_score_codex":0.00009395767,"about_ca_system_score_gemma":0.0028829766,"threshold_uncertainty_score":0.99752104},"labels":[],"label_agreement":null},{"id":"W2271188424","doi":"10.1200/jco.2006.24.18_suppl.8571","title":"Predictors of fatigue and quality of life in a prospective palliative care cohort","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Palliative care; Anxiety; Physical therapy; Constipation; Hospital Anxiety and Depression Scale; Population; Distress; Depression (economics); Cohort; Bayesian multivariate linear regression; Prospective cohort study; Internal medicine; Linear regression; Psychiatry; Clinical psychology; Nursing","score_opus":0.37918164938057897,"score_gpt":0.5755915863031891,"score_spread":0.1964099369226101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271188424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99108154,0.003517779,0.00009215796,0.00040925728,0.0002483191,0.00024132167,0.0000198923,0.0000024356855,0.0043873196],"genre_scores_gemma":[0.9959525,0.0014391216,0.0021140906,0.00010952914,0.000338703,0.000002758146,0.000003374154,0.0000069384714,0.000032969034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958239,0.00045149802,0.003101705,0.00014009501,0.00036043863,0.00012235768],"domain_scores_gemma":[0.9927123,0.0031442489,0.0027789667,0.00011253321,0.0011070553,0.00014487102],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001972311,0.000105191175,0.0021773668,0.0001285131,0.000008009903,9.774828e-7,0.00008408771,0.00028857624,0.000019128589],"category_scores_gemma":[0.0091921305,0.00007564564,0.00028036165,0.00016456371,0.00046349733,0.00005450037,0.000034022512,0.00049904804,2.5481938e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002777563,0.0007769203,0.9922456,0.00021381817,0.00034286326,0.000026747044,0.0016333597,0.000017510223,0.00018243973,0.00031448496,0.00024349155,0.0012251749],"study_design_scores_gemma":[0.0064312904,0.0056277416,0.98291236,0.00056715624,0.00018982873,0.0000018881104,0.001990074,0.000008195405,0.00082388154,0.00033712963,0.0010555765,0.000054866534],"about_ca_topic_score_codex":0.0005841771,"about_ca_topic_score_gemma":0.000547848,"teacher_disagreement_score":0.009333256,"about_ca_system_score_codex":0.00010805565,"about_ca_system_score_gemma":0.0009994832,"threshold_uncertainty_score":0.99915385},"labels":[],"label_agreement":null},{"id":"W2271448827","doi":"10.1200/jco.2013.31.31_suppl.225","title":"The frequency of falls in patients with advanced cancer followed in an outpatient palliative care center.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Depression (economics); Quality of life (healthcare); Logistic regression; Cancer; Internal medicine; Physical therapy; Emergency medicine","score_opus":0.18757989745845813,"score_gpt":0.530508057297529,"score_spread":0.3429281598390709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271448827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656194,0.0014042481,0.000008287696,0.00067114073,0.00047458772,0.00039150004,0.000009960543,0.0000015984933,0.0004767027],"genre_scores_gemma":[0.99615353,0.0014474357,0.0019208067,0.0003464632,0.00009042915,0.0000141163555,0.0000048321363,0.000009885047,0.000012507558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708635,0.000356138,0.0018840188,0.00013245826,0.0003449123,0.00019614852],"domain_scores_gemma":[0.9954929,0.0012467854,0.0016713243,0.00015664923,0.0012771966,0.0001551655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000519123,0.000114650175,0.001103242,0.00009354739,0.000013892515,0.0000026485002,0.00017090043,0.0001780197,0.000033334814],"category_scores_gemma":[0.0017396535,0.00006156761,0.00016387796,0.00015719199,0.00018600529,0.00014189475,0.000026039354,0.00057451054,0.0000014420845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022025572,0.0012123365,0.93156016,0.000029849893,0.000097358694,0.000020650661,0.0027975265,0.000028813913,0.000025769197,0.0000146716975,0.000054065928,0.06195623],"study_design_scores_gemma":[0.012415799,0.016034598,0.9659317,0.0009197732,0.000049717397,2.6928524e-7,0.0030112492,0.000009912289,0.00006933301,0.00007970064,0.0014169666,0.000060969425],"about_ca_topic_score_codex":0.00031073682,"about_ca_topic_score_gemma":0.0026862805,"teacher_disagreement_score":0.061895262,"about_ca_system_score_codex":0.00024164013,"about_ca_system_score_gemma":0.0006483758,"threshold_uncertainty_score":0.25106543},"labels":[],"label_agreement":null},{"id":"W2271807638","doi":"10.1200/jco.2005.23.16_suppl.5548","title":"Locally advanced squamous cell carcinoma of the head and neck (SCCHN): Can the treatment results achieved in clinical trials be reproduced in an unselected patient population?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Head and neck cancer; Clinical trial; Cancer; Population; Surgery; Oncology","score_opus":0.17973663341551463,"score_gpt":0.49851433970147147,"score_spread":0.3187777062859568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271807638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96609265,0.00089338934,7.692319e-7,0.031459674,0.00055404444,0.0007916726,0.000009809358,0.0000037661332,0.00019422057],"genre_scores_gemma":[0.99572283,0.000863192,0.00055164006,0.0021162545,0.00065906835,0.000011878516,0.0000042503566,0.000013115973,0.000057748864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9893056,0.003668532,0.0061147404,0.00034653404,0.0003130124,0.00025156475],"domain_scores_gemma":[0.9909643,0.005460783,0.0026140905,0.00044278108,0.00029925426,0.00021879964],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00919967,0.0001719285,0.0023730048,0.000092729766,0.000053818407,0.0000046236914,0.00015170065,0.00029648666,0.000004945163],"category_scores_gemma":[0.014216024,0.000082999926,0.00039103066,0.0002644851,0.00021372354,0.000049070848,0.00004256701,0.0008696514,3.0417266e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029870925,0.005236373,0.61395997,0.000011836251,0.00005509332,0.000067620036,0.0014902346,0.00021438363,0.00019659643,0.000005743748,0.00032592085,0.3485653],"study_design_scores_gemma":[0.03203305,0.047868144,0.91253877,0.00008601065,0.00015155287,0.000029514309,0.0002678109,0.00014625587,0.0003187514,0.000028578212,0.006457739,0.00007381653],"about_ca_topic_score_codex":0.0003952418,"about_ca_topic_score_gemma":0.018570287,"teacher_disagreement_score":0.3484915,"about_ca_system_score_codex":0.000282958,"about_ca_system_score_gemma":0.0012870436,"threshold_uncertainty_score":0.99933827},"labels":[],"label_agreement":null},{"id":"W2271808854","doi":"10.1200/jco.2007.25.18_suppl.11009","title":"Sensitivity of surveillance mammography for contralateral breast cancers and ipsilateral recurrences in survivors under 50","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Mammography; Breast cancer; Stage (stratigraphy); Cancer; Prospective cohort study; Gynecology; Radiology; Internal medicine","score_opus":0.041536515712242636,"score_gpt":0.39983568806792413,"score_spread":0.3582991723556815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271808854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663097,0.000960527,0.00055732724,0.00083938526,0.0007377363,0.00010542617,0.000051818733,0.0000013856734,0.000115398856],"genre_scores_gemma":[0.9977354,0.0008271572,0.0008546297,0.00018978835,0.00036738114,0.000001937124,0.0000059168624,0.0000072455628,0.000010564842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814785,0.00028898093,0.0010469853,0.00018461696,0.000102392536,0.00022917183],"domain_scores_gemma":[0.9978399,0.00094666897,0.00078179635,0.000083501305,0.00024047228,0.000107614185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036009343,0.00011924946,0.0007348608,0.0000721076,0.000023414299,0.000003841742,0.00006956063,0.0002255385,0.0000027620993],"category_scores_gemma":[0.00029136412,0.000092284965,0.00022360405,0.000072794275,0.00033978478,0.000007798824,0.000036297155,0.0001728359,8.041369e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004884243,0.00020076321,0.96645784,0.000015266134,0.00027260205,0.000014796233,0.00004132075,0.00004543738,0.0014840137,0.000031053016,0.00021285738,0.026339823],"study_design_scores_gemma":[0.003349355,0.001518426,0.9919495,0.000027508435,0.000033564196,0.00014291759,0.00010745109,0.000007034461,0.00043156242,0.00023788358,0.0021027185,0.000092090195],"about_ca_topic_score_codex":0.00060358725,"about_ca_topic_score_gemma":0.016956829,"teacher_disagreement_score":0.026247732,"about_ca_system_score_codex":0.00004090031,"about_ca_system_score_gemma":0.00029049837,"threshold_uncertainty_score":0.9462308},"labels":[],"label_agreement":null},{"id":"W2271826103","doi":"10.1200/jco.2012.30.15_suppl.6005","title":"Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Willingness to pay; Cancer; Toxicity; Willingness to accept; Test (biology); Internal medicine; Intensive care medicine; Oncology; Family medicine","score_opus":0.8352119414106242,"score_gpt":0.6229876398499291,"score_spread":0.21222430156069505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271826103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8830925,0.0064988676,0.03730276,0.061899588,0.008621517,0.00085794274,0.000099014585,0.000013626863,0.001614156],"genre_scores_gemma":[0.94968164,0.0005090734,0.020762235,0.025815418,0.0030583045,0.00004626912,8.964428e-7,0.00002523958,0.00010090168],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99189293,0.00035034685,0.0070309225,0.00023209339,0.000087037115,0.00040668718],"domain_scores_gemma":[0.9850061,0.0077211126,0.006332151,0.00013322051,0.00018993909,0.00061751175],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026089018,0.00012971282,0.0015835111,0.00015429966,0.00011847016,0.00002574452,0.00017690747,0.00020660574,0.00015061875],"category_scores_gemma":[0.017193902,0.00011758648,0.00018184677,0.00013227736,0.00006789227,0.0003341675,0.000048720292,0.0003249508,0.00004760229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002791896,0.0004777611,0.8943314,0.00016745475,0.00024507075,0.0000021628487,0.0014027263,0.0003856121,0.000010013296,0.007727477,0.050268877,0.044702277],"study_design_scores_gemma":[0.0038242515,0.0028264201,0.18773682,0.00014967425,0.00007934635,0.00003263367,0.0011869249,0.0018059055,0.000011076594,0.013547481,0.78844506,0.0003543979],"about_ca_topic_score_codex":0.000040937204,"about_ca_topic_score_gemma":0.000045487828,"teacher_disagreement_score":0.73817617,"about_ca_system_score_codex":0.0006420672,"about_ca_system_score_gemma":0.00050799776,"threshold_uncertainty_score":0.9910847},"labels":[],"label_agreement":null},{"id":"W2271944552","doi":"10.1200/jco.2006.24.18_suppl.17570","title":"Clinical findings in a large cohort of adult patients (pts) with Hodgkin’s disease (Hd) in Argentina: A report from two institutions","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Cohort; Disease; Pediatrics; Notice; Medical record; Demography; Family medicine; Surgery; Internal medicine","score_opus":0.06136422203749658,"score_gpt":0.4459844748784273,"score_spread":0.3846202528409307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271944552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956391,0.00016360586,0.000034044693,0.0017740688,0.00062416255,0.00042116438,0.000036572375,0.000005486916,0.0013018253],"genre_scores_gemma":[0.99636847,0.00032245737,0.0019194043,0.00076014013,0.00048066318,0.000018495311,0.00006441493,0.000012678998,0.000053249987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938708,0.00035328988,0.0046669184,0.0003281881,0.0005005376,0.0002802891],"domain_scores_gemma":[0.9952735,0.0014890585,0.0020319396,0.0002780147,0.000530405,0.00039710978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021988952,0.00016769595,0.0018618015,0.00020736527,0.000025512136,0.000005762258,0.00012247865,0.00026194775,0.00007477028],"category_scores_gemma":[0.0047911583,0.000111850706,0.0005173898,0.00024976794,0.00024052316,0.00011560384,0.000057800968,0.0006167694,0.000010395428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046973224,0.023420429,0.95460206,0.000013235741,0.00024597475,0.0107827075,0.000021209244,0.000019927165,9.573658e-7,0.00028108497,0.0013688962,0.0045461897],"study_design_scores_gemma":[0.04124996,0.0036775367,0.9443965,0.00041271863,0.00058457715,0.00008334495,0.0000207918,0.000038188056,0.0000057779343,0.0003051342,0.009131269,0.00009422514],"about_ca_topic_score_codex":0.0009041795,"about_ca_topic_score_gemma":0.0030141755,"teacher_disagreement_score":0.036552638,"about_ca_system_score_codex":0.0003559607,"about_ca_system_score_gemma":0.00260858,"threshold_uncertainty_score":0.57358104},"labels":[],"label_agreement":null},{"id":"W2272230149","doi":"10.1200/jco.2009.27.15_suppl.7518","title":"CALGB 140803—Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cardiorespiratory fitness; Medicine; Hazard ratio; Lung cancer; Internal medicine; VO2 max; Proportional hazards model; Physical fitness; Metabolic equivalent; Prospective cohort study; Surgery; Physical therapy; Confidence interval; Heart rate; Blood pressure; Physical activity","score_opus":0.0630751888019344,"score_gpt":0.46902397091951115,"score_spread":0.40594878211757673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272230149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192935,0.00040368456,0.000014708253,0.0011174694,0.0001789015,0.005565199,0.00004612966,0.0000041948356,0.0007403557],"genre_scores_gemma":[0.99792284,0.00021610828,0.00015463235,0.0005076181,0.0006763802,0.0003937842,0.000010876237,0.000012922632,0.00010485032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952331,0.0009600445,0.002336574,0.000261686,0.00087858434,0.00032998336],"domain_scores_gemma":[0.99535155,0.0013556561,0.0015246669,0.00018593305,0.0011884862,0.0003937258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004250014,0.00014945849,0.002229992,0.00043567206,0.00003383447,0.000008777435,0.00015384294,0.0004103984,0.00014170971],"category_scores_gemma":[0.0031999683,0.00011898271,0.00050870475,0.0005961718,0.000121776095,0.0001930533,0.00006258737,0.0009404487,6.897515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017950055,0.001026548,0.9436886,0.000120686695,0.0016899488,0.00011524627,0.00005441113,0.00017123543,0.000038089318,0.000008511402,0.00056845293,0.050723273],"study_design_scores_gemma":[0.009734567,0.002220623,0.9805237,0.00012928291,0.0017338131,0.0000016867091,0.00002725057,0.0008172096,0.000013232013,0.00004273116,0.004656761,0.00009916347],"about_ca_topic_score_codex":0.00018431494,"about_ca_topic_score_gemma":0.00013947306,"teacher_disagreement_score":0.05062411,"about_ca_system_score_codex":0.0015553575,"about_ca_system_score_gemma":0.0023922229,"threshold_uncertainty_score":0.48519742},"labels":[],"label_agreement":null},{"id":"W2272598965","doi":"10.1200/jco.2010.28.15_suppl.4079","title":"Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Gemcitabine; Erlotinib; Proportional hazards model; Univariate analysis; Cancer; Oncology; Multivariate analysis; Epidermal growth factor receptor","score_opus":0.11547380202249154,"score_gpt":0.47364379674193235,"score_spread":0.35816999471944083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272598965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263555,0.00019162177,0.00002165626,0.0021147525,0.0026810556,0.0011402493,0.00012136966,0.000010546344,0.0010831981],"genre_scores_gemma":[0.99396926,0.001245624,0.0030375612,0.0002204396,0.0012621414,0.000023218887,0.000057875422,0.000031199168,0.00015266438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934841,0.0008217756,0.003783779,0.00046002568,0.0009337342,0.00051661336],"domain_scores_gemma":[0.9853901,0.009801908,0.002658493,0.00047577635,0.0009600663,0.00071361853],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004958586,0.00030537735,0.0040265005,0.00023850526,0.000059790833,0.000009904452,0.0002857846,0.0006788636,0.0003193317],"category_scores_gemma":[0.01238135,0.00020939912,0.00027669134,0.00024446694,0.0008191699,0.0002049759,0.00011893723,0.0023959025,0.000004908122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7213645,0.0053410176,0.24951653,0.00003398169,0.00070632773,0.0002837141,0.00020028063,0.000009233995,0.00020660226,0.00003512168,0.0003678514,0.021934863],"study_design_scores_gemma":[0.48718694,0.03629159,0.47373542,0.00014186255,0.00071234436,0.0000097344055,0.000060737744,0.0002130683,0.000021190739,0.00008542337,0.0014142407,0.00012745449],"about_ca_topic_score_codex":0.0012083029,"about_ca_topic_score_gemma":0.0026667025,"teacher_disagreement_score":0.23417754,"about_ca_system_score_codex":0.00025017236,"about_ca_system_score_gemma":0.0033661942,"threshold_uncertainty_score":0.9999056},"labels":[],"label_agreement":null},{"id":"W2272680342","doi":"10.1200/jco.2000.18.24.4038","title":"Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Topotecan; Medicine; Cisplatin; Debulking; Paclitaxel; Ovarian cancer; Oncology; Chemotherapy; Regimen; Internal medicine; Surgery; Cancer; Urology","score_opus":0.2597301339149043,"score_gpt":0.5603606752653596,"score_spread":0.3006305413504553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272680342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879478,0.00064344204,0.000030470199,0.002532016,0.002711017,0.0044575366,0.001405279,0.00000606189,0.0002663336],"genre_scores_gemma":[0.99556714,0.0011264632,0.001119698,0.00042656265,0.0011504759,0.0002938851,0.000045807457,0.00003148819,0.00023847606],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9863505,0.0018125226,0.009493202,0.00061779324,0.0013444404,0.00038156047],"domain_scores_gemma":[0.9852433,0.005679476,0.0067808507,0.00042947623,0.0013103597,0.00055653625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011101879,0.00038671592,0.0058247163,0.00013271467,0.00012333537,0.000006325307,0.00027350226,0.0003742,0.0007889494],"category_scores_gemma":[0.0045888205,0.00027888265,0.001221485,0.00026270148,0.0003119804,0.00015645481,0.000053398508,0.00053125975,3.6564734e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13254781,0.20224674,0.16049436,0.00013456159,0.010225438,0.0003114763,0.0007096341,0.00049965805,0.0011138313,0.000046695273,0.004729493,0.4869403],"study_design_scores_gemma":[0.3753598,0.39155936,0.19654049,0.00037386082,0.007494104,0.000034238998,0.00057131593,0.00015639793,0.00074703444,0.00018598096,0.026638966,0.00033845322],"about_ca_topic_score_codex":0.0714855,"about_ca_topic_score_gemma":0.17584208,"teacher_disagreement_score":0.48660186,"about_ca_system_score_codex":0.0019247837,"about_ca_system_score_gemma":0.019667625,"threshold_uncertainty_score":0.9999663},"labels":[],"label_agreement":null},{"id":"W2272934960","doi":"10.1200/jco.2005.23.16_suppl.5521","title":"An expanded study of the relationship between osteopontin, tumor pO<sub>2</sub> and prognosis in head and neck squamous cell carcinomas","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone and Dental Protein Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Osteopontin; Internal medicine; Proportional hazards model; Univariate analysis; Correlation; Head and neck; Head and neck squamous-cell carcinoma; Tumor progression; Gastroenterology; Spearman's rank correlation coefficient; Urology; Oncology; Multivariate analysis; Cancer; Nuclear medicine; Head and neck cancer; Surgery","score_opus":0.1249138823365725,"score_gpt":0.42130404808936356,"score_spread":0.2963901657527911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272934960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961868,0.0010549471,0.0000011526545,0.0018243924,0.00012340065,0.0005374564,0.0000012058025,0.000003866088,0.00026677817],"genre_scores_gemma":[0.99879915,0.000041176663,0.00030234433,0.0003291008,0.00049443747,0.000006900527,2.976106e-7,0.000010033637,0.000016571339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722356,0.0005638365,0.001647445,0.0001493823,0.00024894296,0.00016683902],"domain_scores_gemma":[0.99651664,0.0021033518,0.0009205213,0.00013248673,0.00012784146,0.00019913298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020305894,0.00011093915,0.0010275088,0.0000948537,0.00006175244,0.0000060457714,0.00007949009,0.00016138141,0.0000015677393],"category_scores_gemma":[0.0018808496,0.000068918016,0.000116395815,0.00013753671,0.00019384475,0.00013199342,0.00008734405,0.0007666431,9.91261e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008640827,0.0026502835,0.9852528,0.000031296757,0.000033117274,0.000056473727,0.0010158708,0.0000010151301,0.00024903403,0.0000037941966,0.00013164678,0.009710572],"study_design_scores_gemma":[0.010365463,0.015751425,0.9702084,0.00006146051,0.00026771025,0.00012936856,0.0020249886,0.000004340507,0.00094388425,0.000076131604,0.00010568838,0.000061156825],"about_ca_topic_score_codex":0.000048696274,"about_ca_topic_score_gemma":0.0005738931,"teacher_disagreement_score":0.01504443,"about_ca_system_score_codex":0.00004365064,"about_ca_system_score_gemma":0.00017943558,"threshold_uncertainty_score":0.33307254},"labels":[],"label_agreement":null},{"id":"W2272976337","doi":"10.1200/jco.2006.24.18_suppl.14625","title":"Application of the International Germ Cell Consensus Classification (IGCCC) to the Nova Scotia population of patients with germ cell tumors (GCT)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Cohort; Oncology; Internal medicine; Population; Germ cell tumors; Nova scotia; Chemotherapy; Retrospective cohort study","score_opus":0.04238035363323307,"score_gpt":0.3784975436344541,"score_spread":0.33611719000122103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272976337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995043,0.00006401428,0.00031601434,0.0028890017,0.000423217,0.00045114232,0.00001936737,0.0000032236992,0.0007910221],"genre_scores_gemma":[0.9981116,0.000004502741,0.00119606,0.00032931127,0.00024535012,0.000002861764,0.000028096461,0.000010298516,0.00007189195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768305,0.00015719997,0.001443737,0.00013175665,0.0004902683,0.00009399114],"domain_scores_gemma":[0.9952246,0.0006205748,0.003094301,0.00024361459,0.00072316837,0.00009375894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061184546,0.00009357522,0.00045076408,0.00006329338,0.000025733814,0.0000046998975,0.00018042856,0.00010422941,0.000023320224],"category_scores_gemma":[0.0005889328,0.000046569694,0.00023519323,0.00014761383,0.000112769325,0.000028786964,0.000033016095,0.00021761564,0.000008034234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012025856,0.0027154884,0.986186,0.0000226276,0.000070898765,0.000005481207,0.000018268734,0.0002855622,0.0002844869,0.00012671934,0.00072370935,0.008358123],"study_design_scores_gemma":[0.0038312688,0.001515337,0.99201334,0.000049408995,0.00038213583,0.000011448947,0.000026364369,0.00030861783,0.00029762616,0.00012976116,0.0013933092,0.000041358257],"about_ca_topic_score_codex":0.00027391533,"about_ca_topic_score_gemma":0.00014703843,"teacher_disagreement_score":0.008316765,"about_ca_system_score_codex":0.00012406259,"about_ca_system_score_gemma":0.00044945863,"threshold_uncertainty_score":0.18990569},"labels":[],"label_agreement":null},{"id":"W2273027008","doi":"10.1200/jco.2004.22.14_suppl.581","title":"Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Gefitinib; Medicine; Breast cancer; Lung cancer; Pharmacokinetics; Internal medicine; Cancer; Adenocarcinoma; Oncology; Colorectal cancer; Epidermal growth factor receptor","score_opus":0.14831609006630797,"score_gpt":0.48750950387369624,"score_spread":0.33919341380738827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273027008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845714,0.0002686808,0.000001824143,0.009457051,0.00060182717,0.0005515142,0.0001607316,0.00000586946,0.00049536314],"genre_scores_gemma":[0.9973455,0.0005942558,0.00073419866,0.00061601383,0.0006505777,0.000015145489,0.000008545325,0.000015408998,0.00002036426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947932,0.0007607155,0.0031804207,0.0003040799,0.0006735688,0.00028806418],"domain_scores_gemma":[0.9948031,0.002469732,0.0012552612,0.00020956207,0.0006438021,0.0006185621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025856316,0.00014802604,0.0013263623,0.00014593585,0.00003058895,0.0000098715645,0.00019278345,0.00033093742,0.00009086655],"category_scores_gemma":[0.0049506417,0.00011342236,0.0001523055,0.00022755374,0.00069668447,0.00015329002,0.00010449066,0.0015891779,0.0000030956153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03159426,0.008777791,0.94087195,0.00003608258,0.00023206937,0.001080526,0.001348892,0.0001135346,0.00009480638,0.000050118015,0.002187704,0.013612237],"study_design_scores_gemma":[0.039546635,0.023106936,0.9341145,0.00048652652,0.00016099204,0.000096253956,0.00050826767,0.00010140201,0.00006025362,0.00024906074,0.0014794135,0.00008975811],"about_ca_topic_score_codex":0.0008887728,"about_ca_topic_score_gemma":0.00054123445,"teacher_disagreement_score":0.014329145,"about_ca_system_score_codex":0.00036873698,"about_ca_system_score_gemma":0.0051861536,"threshold_uncertainty_score":0.9200014},"labels":[],"label_agreement":null},{"id":"W2273249800","doi":"10.1200/jco.2009.27.15_suppl.9597","title":"Is patient self-reporting more accurate than clinician reporting of symptoms for predicting survival in patients with cancer? Meta-analysis of 30 closed EORTC randomized controlled trials","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Constipation; Vomiting; Diarrhea; Internal medicine; Randomized controlled trial; Cancer","score_opus":0.27666963205692885,"score_gpt":0.5480638072808044,"score_spread":0.27139417522387554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273249800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199265,0.0009938837,0.00007545163,0.0027273055,0.00084530027,0.0030764958,0.000046622856,0.000010771502,0.00023153248],"genre_scores_gemma":[0.99667734,0.00026911742,0.0014748821,0.0010030479,0.00040589194,0.00009855572,0.000019492045,0.000019701785,0.00003196162],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9572608,0.003043525,0.03816433,0.00038509755,0.00078446814,0.0003617976],"domain_scores_gemma":[0.84640384,0.023972182,0.1269184,0.0002648098,0.0021829552,0.00025783776],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.054196622,0.00033155776,0.031548742,0.00059770595,0.00004205829,0.000007386377,0.00014904578,0.00042495367,0.00024482337],"category_scores_gemma":[0.07496759,0.00017548323,0.010238685,0.0005500925,0.00016863042,0.00010390913,0.000027026073,0.0006710606,1.2078577e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34700978,0.003450645,0.42387828,0.000037070116,0.21753863,0.00007676883,0.00068166014,0.00047714968,0.000025190233,0.0000041770604,0.000054642886,0.006766002],"study_design_scores_gemma":[0.3719814,0.013898837,0.23121905,0.000071157716,0.38112164,0.000004760832,0.00014537826,0.001235465,0.00011640222,0.000045845245,0.000054290802,0.000105758954],"about_ca_topic_score_codex":0.00016586004,"about_ca_topic_score_gemma":0.00012884341,"teacher_disagreement_score":0.19265923,"about_ca_system_score_codex":0.0001859872,"about_ca_system_score_gemma":0.0020262874,"threshold_uncertainty_score":0.99967355},"labels":[],"label_agreement":null},{"id":"W2273379187","doi":"10.1200/jco.2015.33.7_suppl.391","title":"Cardiovascular disease (CVD) risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of U.S. and Canadian patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Overweight; Body mass index; Internal medicine; Waist; Chemotherapy; Cancer; Testicular cancer; Surgery","score_opus":0.11550107269369801,"score_gpt":0.4171516728049692,"score_spread":0.30165060011127115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273379187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978257,0.0003417483,0.000012634201,0.0002792661,0.0007165839,0.00072816556,0.000036023368,0.000009734111,0.000050160386],"genre_scores_gemma":[0.9986435,0.00034720852,0.00021218268,0.000251859,0.00047804805,0.0000041817057,0.000008878791,0.000036811194,0.00001732192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99440295,0.001401795,0.0028302106,0.00035147098,0.0007232567,0.00029032663],"domain_scores_gemma":[0.9925679,0.0015555875,0.0018572499,0.00034673917,0.0013842753,0.002288275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004024105,0.00022964366,0.002008819,0.00021748885,0.000050916835,0.000011311419,0.00015589365,0.00042616174,0.00003383157],"category_scores_gemma":[0.0158975,0.00016865885,0.00061460736,0.00024156086,0.00034134783,0.00013751899,0.000047348327,0.0011063946,0.0000027042229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013556327,0.0031641568,0.97157836,0.000018075798,0.0022372997,0.00023153664,0.0005645695,0.00016154145,0.0000063984844,3.146049e-7,0.00023518341,0.020446956],"study_design_scores_gemma":[0.018924851,0.007511846,0.96792036,0.00008870593,0.002902013,0.0000061459978,0.0006665309,0.0006443451,0.000049711114,0.000014018109,0.0011295943,0.00014189658],"about_ca_topic_score_codex":0.1000566,"about_ca_topic_score_gemma":0.058015853,"teacher_disagreement_score":0.04204075,"about_ca_system_score_codex":0.0003547021,"about_ca_system_score_gemma":0.0020298464,"threshold_uncertainty_score":0.992392},"labels":[],"label_agreement":null},{"id":"W2273510718","doi":"10.1200/jco.2014.32.26_suppl.72","title":"Do women younger than 40 treated in the hormone-therapy era benefit from a radiotherapy boost as a part of adjuvant breast radiotherapy?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Radiation therapy; Lumpectomy; Lymphovascular invasion; Breast cancer; Population; Mastectomy; Hormonal therapy; Oncology; Breast-conserving surgery; Internal medicine; Cancer; Gynecology; Metastasis","score_opus":0.033978353512418645,"score_gpt":0.36716133558301045,"score_spread":0.3331829820705918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273510718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785035,0.015477723,0.000056726785,0.004975516,0.0003959897,0.00020780864,0.00004641538,0.0000042605343,0.00033201888],"genre_scores_gemma":[0.9691792,0.024843222,0.00054542854,0.0034374187,0.0018542324,0.00003232935,0.000015153736,0.00003358471,0.00005942242],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99653405,0.0008365808,0.0016082247,0.00034435367,0.0003159671,0.000360827],"domain_scores_gemma":[0.99706286,0.0007557449,0.001342232,0.00045410905,0.0002190894,0.00016594847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020822736,0.0002789709,0.0013796751,0.000083187326,0.00005220369,0.000018021201,0.0005096116,0.0004334147,0.000112502545],"category_scores_gemma":[0.00023033885,0.00016916954,0.00048044184,0.00014670844,0.00032160283,0.000015679843,0.000039150284,0.00044362206,0.000003111573],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046848442,0.0047415737,0.24024838,0.00000812986,0.0041194637,0.00011487918,0.0031719587,0.000072184244,0.026551958,0.00012180535,0.0054035774,0.66859764],"study_design_scores_gemma":[0.017286237,0.013064371,0.78852713,0.00004140957,0.00008937481,0.00026789246,0.00035651503,0.000016208882,0.00063359,0.0005460042,0.1789449,0.00022634192],"about_ca_topic_score_codex":0.0004123233,"about_ca_topic_score_gemma":0.00016366712,"teacher_disagreement_score":0.6683713,"about_ca_system_score_codex":0.0001296129,"about_ca_system_score_gemma":0.00033013776,"threshold_uncertainty_score":0.68985337},"labels":[],"label_agreement":null},{"id":"W2273531508","doi":"10.1200/jco.2006.24.18_suppl.6039","title":"Randomized clinical trials in oncology stopped early for benefit (RCTSEB)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical trial; Psychological intervention; Meta-analysis; Intervention (counseling); Internal medicine; Psychiatry","score_opus":0.937779014996416,"score_gpt":0.7365026944634103,"score_spread":0.2012763205330057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273531508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8888967,0.0021470622,0.04626661,0.028554758,0.0101613775,0.0035910455,0.000018977184,0.000005272449,0.020358179],"genre_scores_gemma":[0.9236812,0.0006513166,0.05367638,0.0040913145,0.0068092877,0.00010144097,0.000004671625,0.00003278776,0.010951585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.2604042,0.45419365,0.27567035,0.0018578582,0.0068859877,0.0009879362],"domain_scores_gemma":[0.10077343,0.7783288,0.113476925,0.0019347911,0.004830032,0.0006560532],"candidate_categories":["metaresearch","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.92108095,0.0003744059,0.048906352,0.0008249862,0.000075787335,0.00023326531,0.0024382798,0.0013169928,0.0031631438],"category_scores_gemma":[0.8587609,0.00016319925,0.023773033,0.00082424557,0.0005144127,0.00029659632,0.00014470067,0.0014851666,0.00053090724],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10403511,0.003160215,0.06559182,0.000022321135,0.0015976272,0.00019469905,0.000108823624,0.000292716,0.000013102033,0.014477153,0.17091481,0.6395916],"study_design_scores_gemma":[0.20488667,0.0038004282,0.0393985,0.000040075738,0.0015704854,0.000053292977,0.000120991754,0.002357771,0.0000019353622,0.11793242,0.629655,0.0001824135],"about_ca_topic_score_codex":0.00004719458,"about_ca_topic_score_gemma":0.00045163356,"teacher_disagreement_score":0.6394092,"about_ca_system_score_codex":0.00014556032,"about_ca_system_score_gemma":0.0019486945,"threshold_uncertainty_score":0.9999795},"labels":[],"label_agreement":null},{"id":"W2273733269","doi":"10.1200/jco.2005.23.16_suppl.9636","title":"Mesothelioma: Incidence and survival rates in Nova Scotia, Canada 1990–2002","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mesothelioma; Medicine; Cancer registry; Incidence (geometry); Asbestos; Population; Nova scotia; Peritoneal mesothelioma; Pleural disease; Lung cancer; Surgery; Epidemiology; Demography; Internal medicine; Respiratory disease; Pathology; Lung","score_opus":0.06333742324850097,"score_gpt":0.42107381327402893,"score_spread":0.35773639002552793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273733269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985378,0.0010416544,0.000004040154,0.011134272,0.00042632734,0.00005571724,0.0000043857276,0.0000016062853,0.0019539832],"genre_scores_gemma":[0.9945017,0.0002334504,0.0010721671,0.0033542113,0.0005726564,3.1281675e-7,0.0000013416212,0.000005765032,0.0002583593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829626,0.00012959185,0.0010459041,0.000105589,0.00029264475,0.00012998868],"domain_scores_gemma":[0.9981218,0.0010852882,0.00039540962,0.00006473664,0.00005051503,0.0002822533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009136036,0.00007591188,0.0005907416,0.00005715446,0.000013330309,0.0000032323796,0.00006757695,0.00010208561,0.00053660467],"category_scores_gemma":[0.0011359997,0.000054725453,0.00008441607,0.00007296867,0.00013720471,0.00009056824,0.000033669763,0.00034603392,0.000022114535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010610559,0.00056204235,0.96621567,0.000010999985,0.000045078188,0.00044635014,0.000010326363,0.000045765766,0.00007476191,0.00003640581,0.0052963123,0.026195219],"study_design_scores_gemma":[0.0026888822,0.0011660468,0.97381806,0.000049997157,0.00006324809,0.00018524505,0.000047147278,0.00008850127,0.000037215497,0.0000660755,0.021736844,0.000052734984],"about_ca_topic_score_codex":0.039767504,"about_ca_topic_score_gemma":0.47860923,"teacher_disagreement_score":0.43884173,"about_ca_system_score_codex":0.00019818224,"about_ca_system_score_gemma":0.0013252422,"threshold_uncertainty_score":0.96662676},"labels":[],"label_agreement":null},{"id":"W2273823362","doi":"10.1200/jco.2006.24.18_suppl.10014","title":"Is mammography adequate for screening BRCA mutation carriers with low breast density?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Breast density; Mammography; BRCA mutation; Breast MRI; Breast cancer screening; Oncology; Magnetic resonance imaging; Cancer; Internal medicine; Gynecology; Radiology","score_opus":0.034680718807942566,"score_gpt":0.4069471157934525,"score_spread":0.37226639698550995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273823362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86245376,0.00017712002,0.11087645,0.024616424,0.00067812117,0.00020710725,0.0000042838474,0.000015775151,0.00097093947],"genre_scores_gemma":[0.9406225,0.00002880447,0.052511852,0.004642184,0.0018591108,0.0000030699,0.000008076676,0.000024746218,0.00029966602],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977037,0.00014996706,0.0013450601,0.00018302219,0.00036227398,0.00025597858],"domain_scores_gemma":[0.9965947,0.0011785752,0.001231438,0.00011892356,0.0005239892,0.00035237477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024935016,0.00012333965,0.0009274478,0.00017624168,0.000072461255,0.000016586026,0.00010269381,0.0002191865,0.000039653674],"category_scores_gemma":[0.0009810121,0.00008409854,0.0004753761,0.00016575523,0.00026651245,0.000099965895,0.000014866675,0.00094878464,0.0000028988966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007133876,0.0007398318,0.40030786,0.00008020116,0.00077505474,0.0019496236,0.00013572384,0.0005127018,0.00013782016,0.0003860117,0.018604053,0.56923723],"study_design_scores_gemma":[0.023953194,0.01178475,0.88566583,0.00047848347,0.0014241836,0.008108456,0.00031103613,0.013714764,0.000102370504,0.0014048081,0.052790616,0.00026150423],"about_ca_topic_score_codex":0.0000678879,"about_ca_topic_score_gemma":0.000015038091,"teacher_disagreement_score":0.56897575,"about_ca_system_score_codex":0.000047415917,"about_ca_system_score_gemma":0.0005224909,"threshold_uncertainty_score":0.412205},"labels":[],"label_agreement":null},{"id":"W2273848714","doi":"10.1200/jco.2005.23.16_suppl.706","title":"Use of fast orthogonal search to predict chemotherapy-induced leukopenia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Leukopenia; Incidence (geometry); Chemotherapy; Internal medicine; Homogeneous; Oncology; Surgery","score_opus":0.25657918801720475,"score_gpt":0.5051623253841494,"score_spread":0.24858313736694465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273848714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771989,0.00003217088,0.00024607652,0.018260978,0.00065411744,0.00021354403,0.0000042587994,0.000007988347,0.0033819582],"genre_scores_gemma":[0.9859615,0.00019942626,0.0042863484,0.006078258,0.0024013848,0.0000030511853,8.452088e-7,0.000017944163,0.0010512568],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971947,0.00022955578,0.0018020977,0.00015281417,0.0004083375,0.0002124991],"domain_scores_gemma":[0.99716115,0.00087485235,0.0006326481,0.00020218054,0.0006219915,0.0005071764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001613727,0.00010813547,0.0011263913,0.00015836983,0.000030696818,0.000008607307,0.00014818649,0.00024523886,0.0007992633],"category_scores_gemma":[0.00083800254,0.00007571524,0.0004595427,0.00021253333,0.00010566344,0.0001580352,0.00004586903,0.0009209358,0.000056035307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009806638,0.002946724,0.15141682,0.000026736476,0.0006474747,0.00018563769,0.00022465839,0.00023356077,0.029800197,0.00024599678,0.02468825,0.7797773],"study_design_scores_gemma":[0.0064267237,0.017618697,0.49565095,0.00009988891,0.00022712917,0.00061089615,0.00005048805,0.000067200104,0.0066779265,0.000014848328,0.4724631,0.00009218144],"about_ca_topic_score_codex":0.000022087715,"about_ca_topic_score_gemma":0.00007279407,"teacher_disagreement_score":0.77968514,"about_ca_system_score_codex":0.00014919798,"about_ca_system_score_gemma":0.0020740938,"threshold_uncertainty_score":0.87513727},"labels":[],"label_agreement":null},{"id":"W2273852090","doi":"10.1200/jco.2016.34.4_suppl.283","title":"Molecular profiling of advanced biliary cancer: Lost in translation from bench to bedside.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Amplicon; Medicine; IDH1; Gallbladder cancer; Internal medicine; Oncology; Cancer; Targeted therapy; Molecular diagnostics; Pathology; Gene; Bioinformatics; Mutation; Polymerase chain reaction; Genetics; Biology; Colorectal cancer","score_opus":0.10385655122472233,"score_gpt":0.45313495812586596,"score_spread":0.34927840690114365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273852090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97087294,0.0040066014,0.00038483957,0.023048777,0.00066352426,0.00020961218,0.000011470858,0.000002978024,0.00079928234],"genre_scores_gemma":[0.99033266,0.001328645,0.0066013304,0.0012563601,0.00044184536,0.0000054753095,8.6962626e-7,0.000010277085,0.000022508628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765223,0.00014379647,0.0016361701,0.00016653366,0.0002471758,0.0001541017],"domain_scores_gemma":[0.99752975,0.001253466,0.00063396466,0.00013149751,0.0002789854,0.00017234017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085046125,0.00009503312,0.0010829332,0.00013206709,0.000008793864,0.0000012951157,0.00009722146,0.0001695358,0.0000734842],"category_scores_gemma":[0.0011862316,0.000057976926,0.00027398393,0.00015297177,0.00008459589,0.000078598016,0.000025646854,0.00030245885,0.0000047180265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003384268,0.00033372585,0.47235867,0.00002119745,0.00019052456,0.00022111204,0.00024504607,0.00004431758,0.06690916,0.000018573537,0.00028356854,0.45598984],"study_design_scores_gemma":[0.011256339,0.0067569544,0.94925386,0.0006458987,0.00028952828,0.000020711965,0.00020548818,0.000018345077,0.023142887,0.0006558362,0.007641402,0.00011276294],"about_ca_topic_score_codex":0.00008829089,"about_ca_topic_score_gemma":0.00034545915,"teacher_disagreement_score":0.47689518,"about_ca_system_score_codex":0.00012741113,"about_ca_system_score_gemma":0.00076075573,"threshold_uncertainty_score":0.23642305},"labels":[],"label_agreement":null},{"id":"W2273887450","doi":"10.1200/jco.2000.18.12.2363","title":"Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mitoxantrone; Carboplatin; Cyclophosphamide; Metastatic breast cancer; Breast cancer; Peripheral blood; Oncology; Internal medicine; Cancer; Chemotherapy; Cisplatin","score_opus":0.03848341136592249,"score_gpt":0.4150591416245636,"score_spread":0.3765757302586411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273887450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960385,0.0011729953,0.0000011948574,0.0016623752,0.0003337032,0.00047522556,0.00010834411,0.000004179063,0.00020349621],"genre_scores_gemma":[0.9944992,0.0041500567,0.0002370169,0.00037118146,0.00021093144,0.000018986342,0.0000034023053,0.00001765832,0.0004915511],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964813,0.0003857978,0.0023902352,0.00019515964,0.00026944646,0.0002780864],"domain_scores_gemma":[0.9969835,0.00084328634,0.0015408797,0.000111568195,0.00019775996,0.00032295028],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010184317,0.00018280538,0.002224028,0.00011225049,0.00002057159,0.0000026811454,0.000087684086,0.0001996126,0.0018094368],"category_scores_gemma":[0.000036736474,0.00012258458,0.00015747023,0.00023509192,0.0003209366,0.00008131924,0.000016384933,0.0005138874,4.4131005e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64675707,0.03325793,0.014921525,0.000114373564,0.0025689849,0.0007449598,0.0008286705,0.000054972745,0.027641336,0.0000013997128,0.0017913195,0.27131748],"study_design_scores_gemma":[0.7378876,0.20568818,0.03631204,0.00024665523,0.0030504775,0.00048505535,0.00031925656,0.00010097272,0.009257807,0.000022490876,0.0064318627,0.00019760881],"about_ca_topic_score_codex":0.0003095854,"about_ca_topic_score_gemma":0.0001223307,"teacher_disagreement_score":0.27111986,"about_ca_system_score_codex":0.00013996378,"about_ca_system_score_gemma":0.0014882109,"threshold_uncertainty_score":0.99910307},"labels":[],"label_agreement":null},{"id":"W2273934916","doi":"10.1200/jco.2015.33.15_suppl.tps3090","title":"Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tremelimumab; Medicine; Durvalumab; Immunogenicity; Immunotherapy; Oncology; Immune checkpoint; Antigen; Internal medicine; Ipilimumab; Cancer research; Cancer; Immunology; Nivolumab","score_opus":0.14280103901378716,"score_gpt":0.4669355917007312,"score_spread":0.324134552686944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273934916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954229,0.00033214668,0.0000048502066,0.0029953949,0.00015793806,0.0009774159,0.0000028142003,8.403974e-7,0.00010570428],"genre_scores_gemma":[0.9994723,0.00005224479,0.00018002806,0.00024487017,0.000028560657,0.0000048350607,4.172867e-7,0.000007172966,0.000009565398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700046,0.0007999926,0.0014367015,0.00013470305,0.0005007159,0.00012743713],"domain_scores_gemma":[0.9968041,0.0017002888,0.0007094134,0.00014545504,0.00048796594,0.00015273216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035786405,0.0001077921,0.0012159875,0.00009860908,0.000023527195,0.0000021270787,0.00009338077,0.000041422227,0.0000038007477],"category_scores_gemma":[0.0022914095,0.000041827065,0.000045039124,0.00026324077,0.0002165026,0.000040558512,0.000060840193,0.00040346984,1.4408117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09316166,0.020362211,0.8286913,0.00005127031,0.000082984196,0.000044194363,0.006040173,0.000021859229,0.0000035881628,0.000003390061,0.00010467671,0.0514327],"study_design_scores_gemma":[0.11686499,0.16681136,0.7141298,0.00015170373,0.0002828236,0.000009536702,0.0014886803,0.000052460477,0.00001282339,0.000009820033,0.00015003195,0.000035975016],"about_ca_topic_score_codex":0.000078080484,"about_ca_topic_score_gemma":0.0013575683,"teacher_disagreement_score":0.14644915,"about_ca_system_score_codex":0.00010033395,"about_ca_system_score_gemma":0.0008937785,"threshold_uncertainty_score":0.27431968},"labels":[],"label_agreement":null},{"id":"W2273978427","doi":"10.1200/jco.2016.34.4_suppl.382","title":"Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Biliary tract cancer; Cohort; Prospective cohort study; Cancer; Combination therapy; Surgery; Gastroenterology; Gemcitabine","score_opus":0.07543798592068375,"score_gpt":0.4322219471538359,"score_spread":0.35678396123315215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273978427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414415,0.013384036,0.000008688723,0.001708771,0.00022901346,0.00031516163,0.000011262346,0.0000037373154,0.00019517537],"genre_scores_gemma":[0.9872809,0.012026727,0.000095780204,0.00032527826,0.00016082669,0.00001680321,3.2741522e-7,0.000012685258,0.00008064721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764556,0.0001973363,0.0014766905,0.00022120994,0.00029064855,0.00016855255],"domain_scores_gemma":[0.9959978,0.0015245137,0.0013846591,0.00014926928,0.00082783034,0.00011595578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009665806,0.0001437292,0.002182844,0.00025129507,0.000020325258,0.0000020134173,0.000077247096,0.00013825968,0.000043131608],"category_scores_gemma":[0.0006863933,0.00006742587,0.00030744993,0.00033385513,0.00030641712,0.000098563374,0.000021585616,0.00027927812,7.3434694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006586222,0.0007848532,0.82946324,0.000027546366,0.004900972,0.00004809351,0.0005631268,0.0000033726844,0.00016108279,0.000003036676,0.00017955109,0.15727888],"study_design_scores_gemma":[0.0161813,0.016788233,0.9636788,0.00037021638,0.0015951943,0.000014014243,0.00040079793,0.0000019021452,0.000086427506,0.000038988495,0.0007632516,0.00008088637],"about_ca_topic_score_codex":0.000039662227,"about_ca_topic_score_gemma":0.00041334188,"teacher_disagreement_score":0.157198,"about_ca_system_score_codex":0.00023538293,"about_ca_system_score_gemma":0.00044510193,"threshold_uncertainty_score":0.2749547},"labels":[],"label_agreement":null},{"id":"W2274103071","doi":"10.1200/jco.2005.23.16_suppl.4516","title":"Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Urology; Placebo; Clinical endpoint; Interim analysis; Internal medicine; Prostate cancer; Calcitriol; Chemotherapy; Statistical significance; Cancer; Oncology; Clinical trial; Vitamin D and neurology; Pathology","score_opus":0.1600227770498614,"score_gpt":0.489695076619122,"score_spread":0.3296722995692606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274103071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818052,0.003120276,0.000015855216,0.008872096,0.0013927193,0.00396505,0.00007629422,0.000019835912,0.0007326858],"genre_scores_gemma":[0.98869294,0.007179034,0.0005830879,0.00055348163,0.0013937585,0.00016375406,0.000029655055,0.000049251354,0.0013550145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9884947,0.0018834725,0.0067546894,0.00070209923,0.0014091166,0.0007559098],"domain_scores_gemma":[0.99001735,0.003932026,0.0037219815,0.0005391258,0.0009878478,0.00080164836],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009328561,0.00046051102,0.0056447512,0.0006081752,0.000073851916,0.00003812879,0.0005207893,0.00066101307,0.00030607442],"category_scores_gemma":[0.0026770812,0.00029556509,0.00090733496,0.0004831197,0.00052824564,0.0002836186,0.00026602898,0.0025175824,0.000024942623],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9343325,0.0090753,0.010983005,0.000060560928,0.0026348818,0.0023224582,0.0040755393,0.0007213563,0.0001370023,0.000013176613,0.0008949067,0.0347493],"study_design_scores_gemma":[0.9501021,0.0128495945,0.027539691,0.00057153794,0.0012894587,0.00010912059,0.001201698,0.0012973297,0.0007486401,0.00012435982,0.0038947407,0.00027174695],"about_ca_topic_score_codex":0.0039480254,"about_ca_topic_score_gemma":0.0049739014,"teacher_disagreement_score":0.03447755,"about_ca_system_score_codex":0.0016937802,"about_ca_system_score_gemma":0.006045497,"threshold_uncertainty_score":0.99994963},"labels":[],"label_agreement":null},{"id":"W2274356777","doi":"10.1200/jco.2005.23.16_suppl.7033","title":"Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Hazard ratio; Regimen; Univariate analysis; Placebo; Performance status; Proportional hazards model; Multivariate analysis; Cancer; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.04783894533645828,"score_gpt":0.41836067420291057,"score_spread":0.3705217288664523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274356777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252033,0.0013229963,0.0007891143,0.0013735921,0.001410977,0.00054421014,0.00013517207,0.0000062783333,0.0018972995],"genre_scores_gemma":[0.98848325,0.0002689,0.00825387,0.00093418086,0.0013420548,0.000029797706,0.000026069205,0.000028844186,0.0006330422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793506,0.00006188473,0.0012651044,0.00021222443,0.00033734072,0.00018839112],"domain_scores_gemma":[0.996017,0.000969414,0.001825263,0.00016011528,0.0007822817,0.0002459522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003806692,0.00014803515,0.0010180154,0.000079466896,0.00003820088,0.0000026273312,0.0001194661,0.00025214275,0.00019470128],"category_scores_gemma":[0.00017271987,0.00009588299,0.00032032264,0.00004625439,0.000103525395,0.00011443573,0.000027853597,0.00038999197,6.3679596e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008081551,0.003060949,0.9464616,0.00006285203,0.00094829866,0.000016750977,0.0027537602,0.00019976932,0.00012041231,0.000004097223,0.0074430783,0.030846864],"study_design_scores_gemma":[0.029283766,0.00985712,0.91879725,0.0007032587,0.0027152675,0.0000023755028,0.00032889156,0.0004158558,0.00057631434,0.000023444605,0.037172418,0.00012401446],"about_ca_topic_score_codex":0.00018132257,"about_ca_topic_score_gemma":0.00011446628,"teacher_disagreement_score":0.030722851,"about_ca_system_score_codex":0.00083437166,"about_ca_system_score_gemma":0.0018253656,"threshold_uncertainty_score":0.3909995},"labels":[],"label_agreement":null},{"id":"W2274396712","doi":"10.1200/jco.2007.25.18_suppl.21073","title":"Use of nuclear androgen receptor status to predict early biochemical recurrence of prostate cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Cancer; Prostate; Staining; Immunohistochemistry; Stage (stratigraphy); Pathology; Internal medicine; Oncology; Biology","score_opus":0.1279145844002026,"score_gpt":0.47322708987640905,"score_spread":0.34531250547620645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274396712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707574,0.00050053134,0.0000051098746,0.0010785848,0.00065726344,0.00041450566,0.000083631334,0.0000043194186,0.00018031808],"genre_scores_gemma":[0.9937747,0.0028695283,0.0025910866,0.00028938398,0.00028549484,0.0000028465552,0.000007240652,0.000017423296,0.0001622935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967488,0.00014845266,0.0020065843,0.00017525638,0.00057117234,0.0003497311],"domain_scores_gemma":[0.9957114,0.0009310204,0.0011883898,0.00015296019,0.0013308625,0.00068537856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015769448,0.00011234493,0.0010240664,0.00017284283,0.000018167337,0.000004299885,0.00013285925,0.00025339198,0.00013988718],"category_scores_gemma":[0.0030088094,0.00007494065,0.00026572836,0.00026887766,0.0003164594,0.00011125618,0.000077172954,0.0005881313,0.000007112899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027414886,0.0022971432,0.8375525,0.000073874624,0.00034611078,0.000058089816,0.0004552379,0.0000016865245,0.0037334675,0.000007081548,0.012521069,0.11553889],"study_design_scores_gemma":[0.009849284,0.038878288,0.8323358,0.0005506488,0.00023437246,0.000010101414,0.00008359702,0.000006944293,0.014776044,0.000028046523,0.10314327,0.0001035562],"about_ca_topic_score_codex":0.00009369205,"about_ca_topic_score_gemma":0.00000950174,"teacher_disagreement_score":0.115435325,"about_ca_system_score_codex":0.00021758916,"about_ca_system_score_gemma":0.0012522147,"threshold_uncertainty_score":0.3602043},"labels":[],"label_agreement":null},{"id":"W2274402945","doi":"10.1200/jco.2007.25.18_suppl.17072","title":"A survey of Canadian medical oncologists on internet use for medical information and a needs assessment for an oncology education website","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"The Internet; Medicine; Family medicine; Medical education; Medical information; Resource (disambiguation); World Wide Web; Computer science","score_opus":0.4223304626900674,"score_gpt":0.6306965290303078,"score_spread":0.2083660663402404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274402945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9361285,0.000057072186,0.0023741918,0.038737554,0.017524928,0.0016051892,0.000021972282,0.000009294959,0.0035412856],"genre_scores_gemma":[0.9774178,0.0007412686,0.008802603,0.009687097,0.0031809297,0.00008734094,0.000040232488,0.000010618663,0.000032069795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936239,0.0019395679,0.0029746296,0.0001338561,0.0009065308,0.0004215092],"domain_scores_gemma":[0.92933,0.06303011,0.002589786,0.00011686112,0.002499524,0.0024337203],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.060360882,0.00010670973,0.00086475525,0.0008265378,0.00014710805,0.000027512648,0.0003858585,0.0015364678,0.00013929435],"category_scores_gemma":[0.24299349,0.000093474584,0.00013914164,0.000488947,0.0006565875,0.0005218667,0.000023388653,0.0008208206,0.0000024562767],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012147899,0.0010791072,0.10636608,0.000029065644,0.000046887966,0.00000309157,0.004954447,7.130113e-7,3.6898675e-7,0.009468991,0.0134858275,0.86335063],"study_design_scores_gemma":[0.0014830285,0.008157336,0.45335355,0.000049684313,0.000030581636,0.000007884383,0.0023283812,0.00013182314,7.488308e-7,0.0002680996,0.5341289,0.000059953625],"about_ca_topic_score_codex":0.21021388,"about_ca_topic_score_gemma":0.8116505,"teacher_disagreement_score":0.86329067,"about_ca_system_score_codex":0.0014285423,"about_ca_system_score_gemma":0.08563716,"threshold_uncertainty_score":0.99975973},"labels":[],"label_agreement":null},{"id":"W2274522613","doi":"10.1200/jco.2009.27.15_suppl.6004","title":"Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Radiation therapy; Cancer; Oncology; Cisplatin; Stage (stratigraphy); Head and neck cancer; Chemotherapy","score_opus":0.07798056288339138,"score_gpt":0.47193294506681255,"score_spread":0.39395238218342116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274522613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519724,0.00023605103,0.0000075677062,0.0022114546,0.000508451,0.00042243066,0.000022463688,0.0000028816107,0.0013914914],"genre_scores_gemma":[0.99751484,0.0007690823,0.00017545087,0.0010162598,0.00045658942,0.0000073046003,0.000003856408,0.0000059585072,0.000050649658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978783,0.00014561818,0.0013176671,0.0001465469,0.00031884675,0.00019300623],"domain_scores_gemma":[0.99781173,0.00070601195,0.00086934934,0.00006366956,0.000358125,0.00019113069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006866777,0.00010254923,0.0012710965,0.00011753984,0.00001674642,0.0000027207388,0.000058608683,0.00012045885,0.000109637665],"category_scores_gemma":[0.0011803611,0.00006286575,0.000095433476,0.000111479,0.00010472154,0.00006186062,0.000012149736,0.00044867603,5.495239e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38355199,0.009606624,0.39152265,0.000011763163,0.00021916015,0.00018096573,0.00016072048,0.0000024188278,0.000025350762,0.000018974477,0.00069296564,0.21400644],"study_design_scores_gemma":[0.2563556,0.07939135,0.66119474,0.00012263595,0.00012300977,0.0000029945809,0.000029015268,0.000020352383,0.000021680567,0.00001453135,0.0026803769,0.00004367238],"about_ca_topic_score_codex":0.000031938995,"about_ca_topic_score_gemma":0.00008885726,"teacher_disagreement_score":0.2696721,"about_ca_system_score_codex":0.00014076708,"about_ca_system_score_gemma":0.0008228555,"threshold_uncertainty_score":0.2563591},"labels":[],"label_agreement":null},{"id":"W2274673955","doi":"10.1200/jco.2004.22.90140.6031","title":"Practitioner feedback on clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Family medicine; Lung cancer; Clinical Practice; Disease; Oncology; Pathology","score_opus":0.3964733657283305,"score_gpt":0.6104939820988058,"score_spread":0.21402061637047531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274673955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7732041,0.002887845,0.003912441,0.21223433,0.005389998,0.0011941358,0.0000539566,0.000024352606,0.0010988214],"genre_scores_gemma":[0.84397244,0.007091197,0.044199806,0.09959982,0.004589684,0.000040455045,0.00010899207,0.00006771538,0.00032989398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9861102,0.0013151751,0.010410709,0.0004733864,0.0013231854,0.00036733013],"domain_scores_gemma":[0.96838987,0.015747227,0.009243683,0.00053189794,0.0053354334,0.0007518781],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01540764,0.00027057165,0.001609445,0.00011942778,0.00014600261,0.000030115894,0.00033674986,0.0004033965,0.0003982124],"category_scores_gemma":[0.11444771,0.00018559459,0.0008561111,0.0002760008,0.0003459838,0.00068653136,0.0001591646,0.0024083077,0.000036834892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036816686,0.0112127075,0.2460751,0.00021204673,0.0025355043,0.0010094087,0.0009818606,0.0015969719,0.0003358563,0.00040444618,0.23483826,0.46398115],"study_design_scores_gemma":[0.0154347895,0.0071076336,0.34139654,0.00052396645,0.0027183944,0.00010853745,0.001800724,0.000063671876,0.000031431773,0.00027056958,0.6303373,0.00020645378],"about_ca_topic_score_codex":0.0048647244,"about_ca_topic_score_gemma":0.011556654,"teacher_disagreement_score":0.4637747,"about_ca_system_score_codex":0.0012554954,"about_ca_system_score_gemma":0.0091747,"threshold_uncertainty_score":0.9998932},"labels":[],"label_agreement":null},{"id":"W2274771262","doi":"10.1200/jco.2012.30.15_suppl.4621","title":"Prognostic role of body composition parameters in renal cell carcinoma (RCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Interquartile range; Proportional hazards model; Nuclear medicine; Renal cell carcinoma; Internal medicine; Adipose tissue; Population; Log-rank test; Body mass index; Survival analysis; Urology; Oncology","score_opus":0.0470825908929736,"score_gpt":0.41663999952045583,"score_spread":0.3695574086274822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274771262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335694,0.00074958656,0.00029730235,0.0022883553,0.00063248,0.00011683367,5.46087e-7,0.0000035033347,0.0025544434],"genre_scores_gemma":[0.98735315,0.000083429346,0.010986917,0.00087116845,0.0006664947,0.0000013594015,0.0000025092108,0.000011159024,0.000023839946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972047,0.0004253018,0.0017516087,0.00009200867,0.00028271964,0.00024365481],"domain_scores_gemma":[0.99636865,0.0018307366,0.0011748499,0.000104248174,0.00013879547,0.00038270326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003658372,0.000087535846,0.0009699456,0.00015562367,0.000014669564,0.0000030794106,0.000108843604,0.00020941984,0.00003633225],"category_scores_gemma":[0.0025451842,0.00006426261,0.00027344353,0.00010685295,0.00017883709,0.00008929851,0.00003121906,0.0012931691,0.0000063874686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010310231,0.0022080427,0.9492982,0.000041352407,0.000048930764,0.00016436916,0.000184295,0.000071353476,0.009110668,0.00006871067,0.000575455,0.037197594],"study_design_scores_gemma":[0.005335695,0.005734565,0.9780737,0.00013620565,0.000270044,0.00043695638,0.00011381159,0.0024777513,0.0014541313,0.00018778758,0.005708604,0.00007074269],"about_ca_topic_score_codex":0.00003053987,"about_ca_topic_score_gemma":0.0000011802144,"teacher_disagreement_score":0.03712685,"about_ca_system_score_codex":0.00007618846,"about_ca_system_score_gemma":0.00040114037,"threshold_uncertainty_score":0.5618248},"labels":[],"label_agreement":null},{"id":"W2274816690","doi":"10.1200/jco.2007.25.18_suppl.15631","title":"Development and psychometric properties of the Prostate Cancer Radiation Toxicity Questionnaire","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Cronbach's alpha; Construct validity; Intraclass correlation; Prostate cancer; Quality of life (healthcare); Discriminant validity; Gynecology; Psychometrics; Clinical psychology; Cancer; Internal medicine; Internal consistency","score_opus":0.12736271286084586,"score_gpt":0.37716542707652695,"score_spread":0.2498027142156811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274816690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829681,0.010707243,0.00035172427,0.0022566938,0.0018195054,0.00011154605,0.0000039472193,0.0000023589043,0.0017789091],"genre_scores_gemma":[0.99513906,0.0026800425,0.00082900666,0.00075105473,0.0003833072,0.000002090555,8.473217e-8,0.0000069823354,0.00020833923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972794,0.000030977404,0.0023707955,0.00012032868,0.00004494177,0.00015355158],"domain_scores_gemma":[0.9965485,0.00012191921,0.0029914593,0.00009380627,0.00013459721,0.000109724635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044170264,0.0000771296,0.00067877077,0.00016713666,0.000052885294,0.000010418235,0.0001601957,0.00017709895,0.000020209125],"category_scores_gemma":[0.0019667149,0.000054387187,0.00013786156,0.00019132915,0.000166105,0.00020435033,0.00003434482,0.00030252658,0.0000050771264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031988116,0.00019058197,0.57019746,0.000024208974,0.000076973956,0.0000012322519,0.0005037311,0.000021539796,0.000029766443,0.0046633203,0.0003821881,0.4235891],"study_design_scores_gemma":[0.0010559487,0.0003310209,0.86626977,0.000056567034,0.000009760328,0.000006314133,0.000038327074,0.000020152413,0.0006348326,0.0017505721,0.12975614,0.000070584996],"about_ca_topic_score_codex":0.00006574549,"about_ca_topic_score_gemma":0.00017203862,"teacher_disagreement_score":0.42351854,"about_ca_system_score_codex":0.00019175706,"about_ca_system_score_gemma":0.00046326514,"threshold_uncertainty_score":0.23544836},"labels":[],"label_agreement":null},{"id":"W2274984007","doi":"10.1200/jco.2014.32.3_suppl.225","title":"BRM promoter insertion/deletion polymorphisms in hepatocellular carcinoma risk and survival.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Oncology; Hepatocellular carcinoma; Internal medicine; Odds ratio; Proportional hazards model; Hazard ratio; Logistic regression; Confidence interval","score_opus":0.04545840384446346,"score_gpt":0.3579251426679666,"score_spread":0.3124667388235031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274984007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946046,0.00065285544,0.00292558,0.00065233454,0.00057452277,0.00006167425,0.0000014905735,0.000002193235,0.0005247466],"genre_scores_gemma":[0.9965877,0.0008015986,0.0011837423,0.00042509008,0.0009056248,0.0000017467764,0.000003803221,0.00000976378,0.00008091068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979165,0.00056756596,0.0010489314,0.00018148347,0.00014394984,0.00014153385],"domain_scores_gemma":[0.9987259,0.00014095695,0.0007036979,0.00014616274,0.0001545809,0.00012868116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031091855,0.00009403696,0.00046138902,0.0000481154,0.000028007275,0.0000075286885,0.00011319569,0.00038013834,0.000013008888],"category_scores_gemma":[0.0011756824,0.000074664946,0.00015786778,0.000044928423,0.00009675328,0.0000053751874,0.000048376016,0.00040097523,0.000002804395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007503652,0.0003428747,0.8267799,0.000012548082,0.00004962502,0.000022240065,0.000042314015,0.00010680804,0.024188872,0.000043717377,0.00047327133,0.14718747],"study_design_scores_gemma":[0.007442799,0.008622202,0.87864536,0.000057475638,0.00010498157,0.00017742683,0.000047796682,0.010007599,0.0059574926,0.0014463388,0.08721201,0.00027850212],"about_ca_topic_score_codex":0.000079066005,"about_ca_topic_score_gemma":0.00009689819,"teacher_disagreement_score":0.14690897,"about_ca_system_score_codex":0.000023861452,"about_ca_system_score_gemma":0.0002633827,"threshold_uncertainty_score":0.30447483},"labels":[],"label_agreement":null},{"id":"W2275193007","doi":"10.1200/jco.2007.25.18_suppl.9107","title":"Prospective study of specialist oncology community nursing resulting in improvements in key patient supportive care outcomes","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Family medicine; Nursing; Prospective cohort study; Intervention (counseling); Internal medicine","score_opus":0.12835327083264325,"score_gpt":0.5186801927438711,"score_spread":0.39032692191122786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275193007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853235,0.00009755788,0.000009548736,0.0005624805,0.0019510648,0.0006979719,0.00000519389,0.000004168278,0.011348515],"genre_scores_gemma":[0.99884844,0.000023336393,0.0002669982,0.0005076973,0.0003137612,0.0000052157266,0.0000027715994,0.000013855994,0.00001793714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349093,0.0014235368,0.004118849,0.00018314726,0.00046199068,0.00032155175],"domain_scores_gemma":[0.9932298,0.0029491563,0.002563152,0.00023749775,0.00080958515,0.00021079805],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006957317,0.00015339196,0.0019952294,0.00035663624,0.00004570558,0.0000037596974,0.00018619713,0.0003487245,0.000024945537],"category_scores_gemma":[0.0042986306,0.000121160134,0.00026894134,0.00033407082,0.00022361698,0.00008570989,0.00008804992,0.0024600737,8.559766e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007995397,0.010127095,0.7385381,0.000027242433,0.00010616731,0.00076436275,0.065666966,0.0000051199872,0.000042142055,0.000014730611,0.00003596491,0.17667672],"study_design_scores_gemma":[0.01314635,0.0359929,0.73945004,0.00020459479,0.00010216648,0.000021765856,0.21032628,0.0000015980473,0.0001001737,0.00010769481,0.00047711172,0.00006930817],"about_ca_topic_score_codex":0.003975692,"about_ca_topic_score_gemma":0.11084026,"teacher_disagreement_score":0.17660742,"about_ca_system_score_codex":0.0020216939,"about_ca_system_score_gemma":0.0013599084,"threshold_uncertainty_score":0.9998413},"labels":[],"label_agreement":null},{"id":"W2275221823","doi":"10.1200/jco.2006.24.18_suppl.6569","title":"Diptheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Diphtheria toxin; Refractory (planetary science); Internal medicine; Myeloid leukemia; Leukemia; Gastroenterology; Toxin","score_opus":0.0363657849640958,"score_gpt":0.37756674330452455,"score_spread":0.34120095834042874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275221823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976892,0.0004302563,0.00014346388,0.00052106817,0.00031256242,0.00040456702,0.000016095039,0.0000052032383,0.00047757165],"genre_scores_gemma":[0.99523765,0.0008917719,0.0014240278,0.00046996513,0.0008123508,0.000011941382,0.000026633852,0.000046425648,0.001079232],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99630314,0.00075988803,0.0017849926,0.00031380824,0.000499527,0.0003386551],"domain_scores_gemma":[0.99667484,0.00022391435,0.0017835895,0.00040224564,0.0007225904,0.00019282846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782507,0.00022978887,0.00088671857,0.00010291765,0.00005350146,0.000013397286,0.0005218709,0.0005809808,0.00021409993],"category_scores_gemma":[0.00035297417,0.00014106571,0.0003642406,0.00013984766,0.0003316242,0.00001696003,0.00008889416,0.0006904871,0.0000075710695],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19273767,0.0027228848,0.012986154,0.000015393443,0.00069286214,0.00011021825,0.000034456967,0.000050328646,0.61728156,0.000008187177,0.0050931727,0.16826709],"study_design_scores_gemma":[0.028784404,0.36091945,0.064055175,0.00010554731,0.00008749997,0.000042410993,0.000046176414,0.0000108540735,0.30189493,0.00018747745,0.24344921,0.00041686257],"about_ca_topic_score_codex":0.000028053562,"about_ca_topic_score_gemma":0.00030485613,"teacher_disagreement_score":0.35819656,"about_ca_system_score_codex":0.000119674034,"about_ca_system_score_gemma":0.0021838308,"threshold_uncertainty_score":0.5752493},"labels":[],"label_agreement":null},{"id":"W2275293745","doi":"10.1200/jco.2005.23.16_suppl.3185","title":"Altered metabolism of cyclophosphamide given in a low-dose metronomic manner does not account for eventual resistance","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cyclophosphamide; Matrigel; Pharmacology; Cancer; Chemotherapy; Perfusion; Cancer research; Angiogenesis; Internal medicine","score_opus":0.07720551855147771,"score_gpt":0.4686328702862741,"score_spread":0.39142735173479637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275293745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97405535,0.0021113178,0.00004771627,0.020716881,0.0021022477,0.00041279366,0.000029622222,0.000004533754,0.0005195454],"genre_scores_gemma":[0.9837785,0.0014376035,0.0071831234,0.0026987633,0.0029771237,0.000024284427,0.000004169753,0.000019055828,0.0018774088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651545,0.0002324489,0.0025690305,0.00020702275,0.00019818498,0.00027785142],"domain_scores_gemma":[0.99547416,0.0021612665,0.0017288123,0.00015657903,0.00026724677,0.00021191238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023012834,0.00015365367,0.0018279464,0.00019856529,0.00001924567,0.0000033810625,0.00018164361,0.00027256642,0.0002706631],"category_scores_gemma":[0.00087530346,0.00010123282,0.00062478083,0.00010570049,0.00016702904,0.00013031377,0.000036514994,0.00053280266,0.000008141601],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35673603,0.033717044,0.10095508,0.0006505954,0.006383524,0.0008320309,0.0018906795,0.0009264334,0.019413074,0.0019168161,0.091775544,0.38480315],"study_design_scores_gemma":[0.04720883,0.0056440607,0.36373502,0.00015876615,0.0011999129,0.000043315675,0.00011874367,0.00013027815,0.005311467,0.0007359972,0.5755522,0.00016135388],"about_ca_topic_score_codex":0.000029804749,"about_ca_topic_score_gemma":0.0006536237,"teacher_disagreement_score":0.48377672,"about_ca_system_score_codex":0.00034265305,"about_ca_system_score_gemma":0.0011030635,"threshold_uncertainty_score":0.41281545},"labels":[],"label_agreement":null},{"id":"W2275410382","doi":"10.1200/jco.2005.23.16_suppl.4666","title":"A retrospective review of prostate specific antigen doubling time (PSA-DT) in men with hormone refractory prostate cancer (HRPC)","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Asymptomatic; Internal medicine; Oncology; Urology; Population; Retrospective cohort study; Cancer; Survival analysis; Log-rank test","score_opus":0.17566258617002448,"score_gpt":0.5208299196594822,"score_spread":0.3451673334894577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275410382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006263031,0.98854077,7.1423983e-7,0.0020333226,0.00024770375,0.0030277744,0.00007208265,0.000012267302,0.005439035],"genre_scores_gemma":[0.00009057753,0.9943575,0.0007046568,0.00025035845,0.0015104905,0.0001095476,0.000054115342,0.00009985083,0.0028228934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99032277,0.0011316561,0.00612476,0.00062309374,0.0011397467,0.00065797043],"domain_scores_gemma":[0.9893837,0.0010079544,0.007077182,0.0005059246,0.0014705895,0.00055464206],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007041523,0.00057894463,0.010311236,0.0006270512,0.00004379699,0.00001642094,0.0004164604,0.0007753569,0.0003908996],"category_scores_gemma":[0.0009722747,0.00032383399,0.0013092664,0.0010054795,0.0005504871,0.00023772148,0.00012654693,0.0038541278,0.000045975587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007425568,0.0016906995,0.0011405965,0.018710366,0.0017347588,0.002149741,0.00011843583,6.839329e-7,0.0000051364864,0.000005575812,0.011526273,0.95549214],"study_design_scores_gemma":[0.008172385,0.013614916,0.0030841597,0.13172132,0.0016531011,0.0003163041,0.00002015374,0.0000018288266,0.0000011918893,0.000014593148,0.8411432,0.00025685088],"about_ca_topic_score_codex":0.00004448255,"about_ca_topic_score_gemma":0.00002206442,"teacher_disagreement_score":0.9552353,"about_ca_system_score_codex":0.0022465356,"about_ca_system_score_gemma":0.012995148,"threshold_uncertainty_score":0.9999214},"labels":[],"label_agreement":null},{"id":"W2275527108","doi":"10.1200/jco.2009.27.15_suppl.3583","title":"Dose escalation and pharmacodynamic study of intravenous adminstration of Reolysin, a live replication competent RNA virus in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Viral shedding; Chills; Neutralizing antibody; Antibody; Virology; Saliva; Viral load; Oncolytic virus; Immunology; Virus; Internal medicine","score_opus":0.036547360494993686,"score_gpt":0.42780514445512113,"score_spread":0.39125778396012745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275527108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924916,0.00009401804,0.00006644149,0.00011287677,0.00004624071,0.00039468516,0.0000032535884,0.0000011374789,0.00003220626],"genre_scores_gemma":[0.9991782,0.0002397356,0.00040489496,0.00008836084,0.00006344448,0.0000030840413,0.00001161579,0.000007039605,0.0000036621552],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99759686,0.0004215724,0.0014214801,0.00020153515,0.00024364308,0.000114881965],"domain_scores_gemma":[0.99763364,0.00009703888,0.0014994356,0.0002048108,0.00047565342,0.0000894387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013327787,0.00009113302,0.0005482835,0.00010208803,0.000017286748,0.000002868876,0.00012932271,0.00012452414,0.0000046776368],"category_scores_gemma":[0.00037124014,0.000072336705,0.00006635914,0.00009822982,0.000094003604,0.000012973622,0.000022618124,0.0002572678,2.3824747e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061741214,0.009751985,0.051073056,0.000014554741,0.00017995805,0.000014521515,0.00031259912,0.0019199287,0.441837,0.000004897496,0.000007678839,0.43314257],"study_design_scores_gemma":[0.011485888,0.18184376,0.771561,0.00003542104,0.000053441792,0.0000063294697,0.0001294064,0.0003420592,0.03438727,0.000063166786,0.000013631882,0.00007862573],"about_ca_topic_score_codex":0.000009632631,"about_ca_topic_score_gemma":0.0001940445,"teacher_disagreement_score":0.72048795,"about_ca_system_score_codex":0.000036876736,"about_ca_system_score_gemma":0.00035775985,"threshold_uncertainty_score":0.29498053},"labels":[],"label_agreement":null},{"id":"W2275787628","doi":"10.1200/jco.2005.23.16_suppl.7217","title":"Referral patterns for adjuvant therapy in non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Adjuvant therapy; Cancer; Clinical trial; Oncology; Stage (stratigraphy); Chemotherapy; Surgery; Randomized controlled trial","score_opus":0.1588420955598737,"score_gpt":0.5043537792806883,"score_spread":0.34551168372081453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275787628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97180843,0.0034606496,0.00010413713,0.022500647,0.00096696237,0.0004154974,0.000009123213,0.0000031610427,0.00073140865],"genre_scores_gemma":[0.97255796,0.015944734,0.001944284,0.006404639,0.0027600308,0.000058756632,0.0000021412004,0.000016467411,0.000310992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979111,0.000081914906,0.001487394,0.00015395723,0.00014505668,0.00022056313],"domain_scores_gemma":[0.9977919,0.00090211135,0.00077345554,0.00012059067,0.00018890809,0.00022304695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010564444,0.00011170927,0.0011041298,0.00008350937,0.000016027083,0.0000047724297,0.00009169578,0.00022390911,0.00026039674],"category_scores_gemma":[0.0001345323,0.00007256254,0.00045962617,0.000050303723,0.000030862062,0.00004799327,0.00001554278,0.0004709949,0.0000036345134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024966483,0.0026471333,0.580503,0.00002634056,0.0001575273,0.00012822208,0.00013415668,0.000056000838,0.00004763705,0.0000051421107,0.008261455,0.4055367],"study_design_scores_gemma":[0.02600522,0.011849784,0.8171432,0.000195118,0.00022348613,0.000034117966,0.000049182643,0.00032146205,0.00044882257,0.000020357846,0.14363088,0.000078397745],"about_ca_topic_score_codex":0.00015710284,"about_ca_topic_score_gemma":0.0017137802,"teacher_disagreement_score":0.40545833,"about_ca_system_score_codex":0.00040764388,"about_ca_system_score_gemma":0.0009851012,"threshold_uncertainty_score":0.29590145},"labels":[],"label_agreement":null},{"id":"W2275911521","doi":"10.1200/jco.2012.30.15_suppl.559","title":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Anastrozole; Hazard ratio; Internal medicine; Aromatase inhibitor; Letrozole; Clinical endpoint; Interim analysis; Progression-free survival; Breast cancer; Oncology; Population; Cancer; Randomized controlled trial; Tamoxifen; Confidence interval; Chemotherapy","score_opus":0.07042906341995182,"score_gpt":0.46638610420318527,"score_spread":0.39595704078323346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275911521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98406804,0.0007380778,0.00023104035,0.011354074,0.002202441,0.0009641104,0.00014632811,0.000012400124,0.00028347707],"genre_scores_gemma":[0.9916926,0.00022866923,0.0027782887,0.0024393674,0.0025043923,0.000054946868,0.0000042853026,0.00003560059,0.00026182042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996006,0.00030129362,0.0025578937,0.00019028258,0.00043809926,0.0005064172],"domain_scores_gemma":[0.9931341,0.0012960196,0.0038315207,0.00035158216,0.00090263964,0.00048416763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029048477,0.00020335962,0.0018278902,0.000081108716,0.000058924034,0.0000034684408,0.00027416906,0.0002585684,0.00010154957],"category_scores_gemma":[0.000939713,0.00010827658,0.00027197337,0.00023217479,0.00039662872,0.0002615234,0.000049028247,0.00071188185,0.0000014573701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72810733,0.0034437221,0.0010231823,0.000020883066,0.00075461296,0.000013188295,0.0003289932,0.000046125577,0.0024237975,0.000030029503,0.0008234362,0.26298472],"study_design_scores_gemma":[0.7021199,0.06587335,0.05328062,0.0002468354,0.0007891543,0.0007983108,0.0005252707,0.000016770382,0.0012489981,0.00018648135,0.17472717,0.00018712926],"about_ca_topic_score_codex":0.00001465127,"about_ca_topic_score_gemma":0.000014526218,"teacher_disagreement_score":0.2627976,"about_ca_system_score_codex":0.00040798838,"about_ca_system_score_gemma":0.0020737099,"threshold_uncertainty_score":0.44153908},"labels":[],"label_agreement":null},{"id":"W2275927258","doi":"10.1200/jco.2007.25.18_suppl.18001","title":"A phase II trial of motexafin gadolinium (MGd) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-based chemotherapy: Preliminary results of stage 1","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Regimen; Chemotherapy; Gastroenterology; Adenocarcinoma; Chemotherapy regimen; Gemcitabine; Cancer","score_opus":0.07306642473584814,"score_gpt":0.4786876028976498,"score_spread":0.40562117816180165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275927258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942047,0.00017683793,0.000624862,0.0015099961,0.0003454507,0.00088034215,0.00006350755,0.000005736472,0.0021885403],"genre_scores_gemma":[0.99412245,0.00025454798,0.0039179106,0.00071074563,0.00057603227,0.000014507989,0.000014191316,0.000022229542,0.00036740364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944755,0.00016354478,0.00437775,0.00027582573,0.00039569862,0.0003117119],"domain_scores_gemma":[0.9926827,0.002787402,0.003322454,0.00029535964,0.0005161451,0.0003959637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003144747,0.00019468078,0.0016886377,0.00013779015,0.000030816296,0.0000021001833,0.00024643933,0.0004977519,0.00009394671],"category_scores_gemma":[0.001863791,0.00015811932,0.0004653216,0.00029476365,0.00023287321,0.00006301442,0.000038363894,0.0011574422,6.8475214e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8315542,0.042210884,0.015352633,0.00040515434,0.00018380249,0.0001249242,0.00036919702,0.0004912668,0.024030497,0.000004110772,0.0011248175,0.08414853],"study_design_scores_gemma":[0.72225,0.07445156,0.04276995,0.00072096323,0.00041527412,0.000004273155,0.0001131145,0.0039962437,0.14531504,0.000017968976,0.009729555,0.00021605517],"about_ca_topic_score_codex":0.000016942564,"about_ca_topic_score_gemma":0.000010521572,"teacher_disagreement_score":0.12128453,"about_ca_system_score_codex":0.00015562239,"about_ca_system_score_gemma":0.0015418851,"threshold_uncertainty_score":0.6447919},"labels":[],"label_agreement":null},{"id":"W2275948361","doi":"10.1200/jco.2006.24.18_suppl.14557","title":"A dose and schedule optimizing evaluation of MG98 given as either a 2 hour IV infusion twice weekly or as a 7 day continuous infusion in combination with interferon alpha (INF) in nephrectomized patients (pts) with advanced renal cell carcinoma (RCC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Chills; Nausea; Tolerability; Vomiting; Adverse effect; Regimen; Gastroenterology; Internal medicine; Pharmacokinetics","score_opus":0.02023000518055343,"score_gpt":0.3370273800073786,"score_spread":0.31679737482682513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275948361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975908,0.0003692157,0.00007409261,0.00028814678,0.00013251758,0.00045137998,0.000001718064,0.0000021144986,0.0010900171],"genre_scores_gemma":[0.9977666,0.00023427409,0.0016176213,0.00015123436,0.00007537195,0.000013763311,0.000019374655,0.000017344983,0.00010440579],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971955,0.0007458377,0.0012442742,0.0002578328,0.0003683714,0.00018822156],"domain_scores_gemma":[0.99749726,0.00020029425,0.0014949897,0.000120366174,0.0005927366,0.000094351366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020243155,0.00016901673,0.00068715704,0.00017194143,0.000026691068,0.000010331928,0.00012662096,0.00039189568,0.000020716516],"category_scores_gemma":[0.00047391577,0.00010608526,0.00008997032,0.00018595177,0.0001381942,0.000032684355,0.00006680532,0.00046681965,0.000001040282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21945956,0.006386424,0.17245403,0.00009886585,0.00026023813,0.00022562659,0.0008123538,0.012203161,0.20177408,0.000012509165,0.00046904266,0.3858441],"study_design_scores_gemma":[0.19567376,0.25013605,0.51599497,0.0011226293,0.00048437357,0.00014773294,0.0007387464,0.00372293,0.028356442,0.00021155065,0.0028763087,0.0005344674],"about_ca_topic_score_codex":0.00024230008,"about_ca_topic_score_gemma":0.0006455318,"teacher_disagreement_score":0.38530964,"about_ca_system_score_codex":0.00012532568,"about_ca_system_score_gemma":0.00093239825,"threshold_uncertainty_score":0.43260315},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2275987706","doi":"10.1200/jco.2009.27.15_suppl.6565","title":"What price for a year of life? A survey of U.S. and Canadian oncologists","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Context (archaeology); Randomized controlled trial; Randomization; Quality of life (healthcare); Willingness to pay; Psychological intervention; Family medicine; Internal medicine; Nursing","score_opus":0.7137023736638612,"score_gpt":0.5860470777964704,"score_spread":0.12765529586739088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275987706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9353332,0.0038179308,0.0006886679,0.05619694,0.0018034714,0.00044413362,0.00015871642,0.0000027303065,0.0015542115],"genre_scores_gemma":[0.98023194,0.0016799747,0.0066395495,0.010958488,0.00038634546,0.0000031018344,0.000004023543,0.000008740297,0.000087825014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9894413,0.000732227,0.009320531,0.0001936926,0.0000693599,0.00024289131],"domain_scores_gemma":[0.97850317,0.010052401,0.0102607,0.00018921516,0.00046502613,0.0005294718],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06523184,0.00009176648,0.0025127977,0.00029873356,0.000034409022,0.0000162093,0.00024540367,0.0003793477,0.00007742311],"category_scores_gemma":[0.06959535,0.00009622703,0.00022388095,0.00012507809,0.00015132224,0.0003372087,0.000016500846,0.00027443387,0.000016944687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014792036,0.001251302,0.8575476,0.00033396718,0.00047937987,0.0000075780745,0.0011790494,0.00013416666,0.0000030714348,0.034516864,0.07403053,0.029037317],"study_design_scores_gemma":[0.0026111836,0.0041299528,0.92953175,0.00006125933,0.0000144345495,0.0000069231996,0.00030386914,0.00044762908,6.763983e-7,0.007198594,0.055600777,0.00009291761],"about_ca_topic_score_codex":0.0117794825,"about_ca_topic_score_gemma":0.03808502,"teacher_disagreement_score":0.07198422,"about_ca_system_score_codex":0.00028703583,"about_ca_system_score_gemma":0.0035182412,"threshold_uncertainty_score":0.99480116},"labels":[],"label_agreement":null},{"id":"W2276330794","doi":"10.1200/jco.2013.31.15_suppl.9537","title":"Opportunities for improved end-of-life (EOL) care for adult patients with advanced cancer: Results of a longitudinal assessment of care provided by Quality Oncology Practice Initiative (QOPI) participants.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Palliative care; Referral; Hospice care; Family medicine; Psychological intervention; End-of-life care; Quality of life (healthcare); Cancer; Nursing; Emergency medicine; Internal medicine","score_opus":0.4530028845657584,"score_gpt":0.599564537293914,"score_spread":0.14656165272815563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276330794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838438,0.002033077,0.0012167785,0.006961182,0.0006745951,0.002433365,0.0015762121,0.0000071373784,0.0012538388],"genre_scores_gemma":[0.9605571,0.0020939372,0.03560353,0.0011310859,0.00021370541,0.00021087969,0.00013743357,0.000025012372,0.000027338085],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99332255,0.0008103701,0.0046972577,0.0003023592,0.0004984851,0.000368997],"domain_scores_gemma":[0.95665514,0.014028049,0.010689314,0.00026739214,0.017969254,0.0003908501],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018555457,0.00024616392,0.003297641,0.00012595086,0.000041061925,0.0000035563328,0.00021896459,0.0003968348,0.000024349043],"category_scores_gemma":[0.033738416,0.00017244843,0.0004987666,0.00012547732,0.00056709937,0.00033664133,0.00005972345,0.00050626264,1.2193887e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18730432,0.009704721,0.4500319,0.005995788,0.0056845634,0.000029518027,0.017785504,0.00009738597,0.001274266,0.00060336833,0.0075401245,0.31394854],"study_design_scores_gemma":[0.14120547,0.29672956,0.25621143,0.0042030057,0.004736561,0.0000074046484,0.1678108,0.00024763023,0.008500043,0.00020968547,0.11955421,0.00058416696],"about_ca_topic_score_codex":0.00063280005,"about_ca_topic_score_gemma":0.00075287226,"teacher_disagreement_score":0.31336436,"about_ca_system_score_codex":0.00038548277,"about_ca_system_score_gemma":0.008174777,"threshold_uncertainty_score":0.99744797},"labels":[],"label_agreement":null},{"id":"W2276389168","doi":"10.1200/jco.2009.27.15_suppl.e20542","title":"Impact of an outpatient interdisciplinary team (IDT) consultation on symptom clusters in advanced cancer patients seen at a supportive care outpatient clinic (OSC) in a tertiary cancer center","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Cancer; Lung cancer; Outpatient clinic; Nausea; Anxiety; Palliative care; Depression (economics); Physical therapy; Internal medicine; Psychiatry","score_opus":0.11554284512748746,"score_gpt":0.5591231296328337,"score_spread":0.44358028450534626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276389168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676275,0.000485437,0.000003289542,0.0005920883,0.0008502614,0.00064712984,0.00011038661,0.0000047824083,0.000543877],"genre_scores_gemma":[0.99747026,0.0009989894,0.00026730922,0.00096760556,0.0001601544,0.000019165924,0.000059289716,0.000017910024,0.000039302293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947146,0.00061106007,0.0035614916,0.0003223843,0.00046189566,0.00032854325],"domain_scores_gemma":[0.9943949,0.0012474193,0.0029352964,0.00019648719,0.00090878253,0.00031712218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007743894,0.0002475351,0.0017762104,0.0003916377,0.000020637455,0.000002683499,0.00017148255,0.00038629601,0.00008152995],"category_scores_gemma":[0.001587598,0.00017626409,0.0005397277,0.0002132868,0.000167995,0.00017299048,0.00009391563,0.000876579,0.0000030079589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024937313,0.0053500016,0.85735285,0.00006592461,0.00017575461,0.00008389478,0.01426234,0.0004928544,0.000048813235,3.160419e-7,0.0003387286,0.0968912],"study_design_scores_gemma":[0.020295681,0.06135628,0.91223884,0.0027166568,0.00013491862,0.000003943147,0.0025084892,0.0001660709,0.0001405551,0.000017209468,0.0002818648,0.00013948903],"about_ca_topic_score_codex":0.00018641347,"about_ca_topic_score_gemma":0.0013948937,"teacher_disagreement_score":0.09675171,"about_ca_system_score_codex":0.0018719014,"about_ca_system_score_gemma":0.0011618152,"threshold_uncertainty_score":0.7187841},"labels":[],"label_agreement":null},{"id":"W2276562648","doi":"10.1200/jco.2007.25.18_suppl.9022","title":"Does NSCLC patient-rated performance status predict survival more accurately than physician ratings?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Performance status; Wilcoxon signed-rank test; Proportional hazards model; Stage (stratigraphy); Overall survival; Survival analysis; Oncology; Mann–Whitney U test","score_opus":0.1029918418834251,"score_gpt":0.4452310801047796,"score_spread":0.3422392382213545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276562648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023987,0.00015971894,0.000101644604,0.0019383385,0.0042668213,0.00023920904,0.000012044045,0.00002252879,0.013019832],"genre_scores_gemma":[0.989267,0.000721772,0.0013385509,0.0059497743,0.0023810884,0.0000017572897,0.000016121943,0.000025139449,0.00029881648],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99558717,0.00026003452,0.0027969647,0.00024465343,0.00058231136,0.00052887044],"domain_scores_gemma":[0.9945992,0.0016782687,0.0021658314,0.00023440043,0.0006679957,0.00065426924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029338254,0.00020814741,0.0014626423,0.00013664334,0.00008395649,0.00001435695,0.00018572375,0.00037139407,0.00020155006],"category_scores_gemma":[0.0017106157,0.00011554303,0.00044984158,0.00021668385,0.00029591925,0.00034505693,0.000053623215,0.0014812229,0.000016640055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012358031,0.0008669488,0.34625444,0.000052794447,0.00038295382,0.0005813559,0.00050545525,0.000032937744,0.0009153819,0.0000100348125,0.0028029145,0.63523674],"study_design_scores_gemma":[0.009980384,0.015364404,0.83468384,0.000152264,0.0002291776,0.000080713195,0.0013410937,0.0005482026,0.0014290753,0.00002133527,0.13598762,0.00018189948],"about_ca_topic_score_codex":0.000023886138,"about_ca_topic_score_gemma":0.000061033523,"teacher_disagreement_score":0.6350548,"about_ca_system_score_codex":0.00026685066,"about_ca_system_score_gemma":0.0025030859,"threshold_uncertainty_score":0.64352584},"labels":[],"label_agreement":null},{"id":"W2276833300","doi":"10.1200/jco.2007.25.18_suppl.15158","title":"First-line physician’s choice (PC1) or standard of care (SOC) then second-line PC2 chemotherapy (CT) in metastatic esophago-gastric adenocarcinoma (MEGA): BC Cancer Agency experience","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Irinotecan; Regimen; Vinorelbine; Internal medicine; Cancer; Chemotherapy regimen; Chemotherapy; Cisplatin; Surgery; Colorectal cancer","score_opus":0.10439721113536099,"score_gpt":0.457264900377084,"score_spread":0.352867689241723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276833300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541564,0.006980705,0.00090248405,0.0040488825,0.0013127223,0.0005448504,0.000018606164,0.000013956958,0.0007621618],"genre_scores_gemma":[0.98788536,0.00316903,0.003142729,0.0033711302,0.0014934621,0.0000133701315,0.00000362559,0.000037013935,0.0008842779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99500626,0.00018054148,0.0032709646,0.00033988417,0.0007008637,0.0005014736],"domain_scores_gemma":[0.99447083,0.0020196387,0.0023329295,0.00033169187,0.0005124668,0.0003324469],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020218557,0.000291757,0.0024626006,0.00039358393,0.00004680235,0.000010071571,0.00040768122,0.00015169948,0.0016175471],"category_scores_gemma":[0.0012259207,0.00020124564,0.00059657166,0.00071917585,0.0002580159,0.00019633627,0.00008372695,0.0009384173,0.000004032772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01879302,0.0014543794,0.5745152,0.0004693221,0.0007169957,0.0022633541,0.0027815388,0.00021967838,0.00008245976,0.000045157867,0.0026619527,0.3959969],"study_design_scores_gemma":[0.023803208,0.019567043,0.8920218,0.0003448325,0.00062685576,0.00011088615,0.0024046402,0.000086163825,0.0006120165,0.00015226922,0.060044177,0.0002261022],"about_ca_topic_score_codex":0.00027488195,"about_ca_topic_score_gemma":0.0029721593,"teacher_disagreement_score":0.3957708,"about_ca_system_score_codex":0.00058956275,"about_ca_system_score_gemma":0.0014530217,"threshold_uncertainty_score":0.9992951},"labels":[],"label_agreement":null},{"id":"W2277293591","doi":"10.1200/jco.2007.25.18_suppl.11072","title":"Adjuvant trastuzumab (T) in early stage breast cancer (EBC): Is cardiac dysfunction (CD) clinically significant?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Ejection fraction; Trastuzumab; Internal medicine; Anthracycline; Cardiotoxicity; Heart failure; Breast cancer; Regimen; Taxane; Chemotherapy; Cancer; Surgery","score_opus":0.10078801541897237,"score_gpt":0.4937749407274828,"score_spread":0.3929869253085104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277293591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98061883,0.000635978,0.000106263644,0.009275514,0.0048903013,0.00038684925,0.000051618365,0.000016432616,0.004018181],"genre_scores_gemma":[0.984702,0.0039303796,0.00039928203,0.0049595265,0.0040221154,0.000009530459,0.0000044823973,0.000031355274,0.0019413312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941135,0.0004738733,0.004048702,0.0003582615,0.00049038534,0.00051529735],"domain_scores_gemma":[0.9939547,0.00271576,0.0019275555,0.00021121364,0.0005152289,0.0006755307],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006626025,0.00024014465,0.0022873727,0.00028260215,0.000041954187,0.000009732469,0.00017619171,0.0006894411,0.0014279711],"category_scores_gemma":[0.00049710163,0.00017958095,0.0009067325,0.00032069653,0.00028642113,0.00015746594,0.000041763542,0.0018654471,0.000049562936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025976067,0.0034147555,0.74516714,0.000026709067,0.0006917417,0.001433569,0.0002760553,0.000011935447,0.00094478246,0.000017719709,0.010726393,0.21131314],"study_design_scores_gemma":[0.015223933,0.016957609,0.8890438,0.00008599246,0.0007525861,0.00011219398,0.000192497,0.000020691514,0.00014152192,0.00004826351,0.07727421,0.00014671935],"about_ca_topic_score_codex":0.00055833725,"about_ca_topic_score_gemma":0.00032695377,"teacher_disagreement_score":0.21116643,"about_ca_system_score_codex":0.00076976395,"about_ca_system_score_gemma":0.0028171442,"threshold_uncertainty_score":0.99948484},"labels":[],"label_agreement":null},{"id":"W2277339257","doi":"10.1200/jco.2009.27.15_suppl.7501","title":"Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Internal medicine; Hazard ratio; Log-rank test; Randomization; Cisplatin; Randomized controlled trial; Lung cancer; Oncology; Stage (stratigraphy); Chemotherapy; Survival analysis; Adjuvant therapy; Surgery; Confidence interval","score_opus":0.13055816293999017,"score_gpt":0.5077501815159932,"score_spread":0.377192018576003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277339257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528354,0.0003389656,0.00028672683,0.0013783517,0.0005737355,0.000845049,0.000049004844,0.000004288777,0.0012403328],"genre_scores_gemma":[0.99696624,0.00061476295,0.001590364,0.0001623029,0.00021674948,0.000010375826,0.00008252372,0.000008732099,0.00034792835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99528134,0.0006465141,0.0033573036,0.00019630509,0.00034038245,0.00017812975],"domain_scores_gemma":[0.9928418,0.0030418239,0.0030230505,0.00017066783,0.0007360634,0.00018662047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028988945,0.00015289534,0.003286666,0.00046298536,0.00003596165,0.0000049253476,0.000102077174,0.00025696552,0.00030147133],"category_scores_gemma":[0.0018390827,0.00010897697,0.00060238707,0.0007505036,0.00015447906,0.00008684616,0.000025048887,0.00041991513,2.0278597e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9716196,0.004715554,0.0074002785,0.000031158288,0.0040849065,0.000085948246,0.00050529116,0.00052357087,0.0013271192,0.000044398887,0.00034611727,0.009316032],"study_design_scores_gemma":[0.8905328,0.018473316,0.068365425,0.000087914115,0.0113026295,0.0000014277168,0.000115223826,0.010389953,0.00013986934,0.000017048855,0.0004919538,0.00008244548],"about_ca_topic_score_codex":0.0006832875,"about_ca_topic_score_gemma":0.00079198886,"teacher_disagreement_score":0.08108683,"about_ca_system_score_codex":0.00018694522,"about_ca_system_score_gemma":0.0015508009,"threshold_uncertainty_score":0.44439518},"labels":[],"label_agreement":null},{"id":"W2277452134","doi":"10.1200/jco.2009.27.15_suppl.e15550","title":"Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Ottawa Hospital","funders":"","keywords":"Medicine; Febrile neutropenia; Neutropenia; Surgery; Esophageal cancer; Irinotecan; Clinical endpoint; Sunitinib; Phases of clinical research; Internal medicine; Chemoradiotherapy; Gastroenterology; Cancer; Radiation therapy; Chemotherapy; Randomized controlled trial; Colorectal cancer","score_opus":0.1939870724979187,"score_gpt":0.5480896276649482,"score_spread":0.3541025551670295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277452134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604121,0.016057009,0.00009757797,0.021450048,0.0010841247,0.0007113574,0.000011080401,0.000011749796,0.0001649675],"genre_scores_gemma":[0.984882,0.0045265635,0.0017570634,0.0045272526,0.003960795,0.000027773192,0.000006340671,0.000017491782,0.0002947214],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970577,0.00022759226,0.0017493039,0.00021557583,0.00037911974,0.0003707332],"domain_scores_gemma":[0.9950867,0.0029421702,0.0008721125,0.00013937979,0.00025205503,0.00070757885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003427633,0.00016199713,0.002179527,0.00015378848,0.00010767689,0.000013840347,0.00009335304,0.0002505307,0.000106835825],"category_scores_gemma":[0.0022518423,0.0001118129,0.0010002845,0.00011942098,0.00011067356,0.00011828595,0.000014832378,0.000592071,9.663412e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21293302,0.0057308306,0.0041815,0.000026022455,0.0006593622,0.0025404138,0.00007634464,7.273846e-7,0.00007891162,0.00004226563,0.0074101593,0.76632047],"study_design_scores_gemma":[0.61018836,0.30411118,0.027881509,0.00024177667,0.0010304746,0.0004947626,0.000057828413,0.00012275575,0.00069529767,0.0010913229,0.05388077,0.00020398104],"about_ca_topic_score_codex":0.000019902134,"about_ca_topic_score_gemma":0.000014656606,"teacher_disagreement_score":0.76611644,"about_ca_system_score_codex":0.000214009,"about_ca_system_score_gemma":0.0029919003,"threshold_uncertainty_score":0.5307503},"labels":[],"label_agreement":null},{"id":"W2277668470","doi":"10.1200/jco.2006.24.18_suppl.6118","title":"Evaluation of comparative survival based on the AJCC 5th and 6th editions for breast cancer staging: 25 year experience in two southwest Washington state community cancer programs","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Cancer; Breast cancer; Cancer staging; Retrospective cohort study; Internal medicine; Oncology","score_opus":0.24570436822861683,"score_gpt":0.5217803704162056,"score_spread":0.27607600218758876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277668470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614054,0.00022444181,0.00012716951,0.0024611517,0.0003490827,0.00029567067,0.00019094233,0.0000016349707,0.0002093556],"genre_scores_gemma":[0.99893063,0.00013938024,0.00022531672,0.0001850801,0.00037665453,0.00011057573,0.000017192582,0.0000073649235,0.00000778257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773,0.0010441452,0.00067814894,0.00012822771,0.0002754517,0.00014402987],"domain_scores_gemma":[0.99762803,0.0007012089,0.00074302196,0.00013596688,0.00074401824,0.00004773107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031155776,0.00010775933,0.00044366668,0.00003379354,0.0000961775,0.000009080565,0.00013669801,0.00007020513,0.00001418253],"category_scores_gemma":[0.00023226754,0.00007079025,0.00010979913,0.00007307092,0.0003639755,0.0000088607,0.000040652198,0.00027841903,1.3527128e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00317003,0.0027311011,0.93491215,0.000021592827,0.00036952313,0.0000019363831,0.0014691913,0.007184622,0.00085153873,0.00012924503,0.00076368346,0.048395414],"study_design_scores_gemma":[0.007933617,0.001707463,0.98323256,0.0001097248,0.00023336698,0.000003118744,0.0024366041,0.0012288715,0.00094602717,0.00045488877,0.0016003764,0.00011340271],"about_ca_topic_score_codex":0.0018134844,"about_ca_topic_score_gemma":0.018525276,"teacher_disagreement_score":0.048320416,"about_ca_system_score_codex":0.00011764985,"about_ca_system_score_gemma":0.0008150624,"threshold_uncertainty_score":0.9993841},"labels":[],"label_agreement":null},{"id":"W2278057905","doi":"10.1200/jco.2004.22.90140.7022","title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Erlotinib Hydrochloride; Regimen; Chemotherapy; Pemetrexed; Oncology; Carboplatin; Chemotherapy regimen; Placebo; Randomized controlled trial; Gastroenterology; Epidermal growth factor receptor; Cancer; Cisplatin; Pathology","score_opus":0.0520902160985434,"score_gpt":0.4512543726723138,"score_spread":0.39916415657377036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278057905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838412,0.00062289083,0.00038221007,0.0030237855,0.002516264,0.009243582,0.00015756475,0.000008217088,0.00020429921],"genre_scores_gemma":[0.98917866,0.0007391328,0.005961256,0.0008584893,0.0023913484,0.00052405015,0.000048729453,0.000057456837,0.000240867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98441225,0.0018985777,0.011313321,0.00050311023,0.0013955138,0.00047724225],"domain_scores_gemma":[0.9779771,0.010378094,0.009172579,0.0003022794,0.0016901628,0.0004797676],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013263103,0.00047327485,0.00976462,0.00037981503,0.000064212196,0.000009384715,0.00033355007,0.00067011465,0.00020640588],"category_scores_gemma":[0.01694616,0.00028304636,0.002164645,0.0005172906,0.00035768843,0.00023383838,0.000043651595,0.0011681177,2.8714894e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94185287,0.009386052,0.0054785777,0.00015338098,0.0059142946,0.00009509577,0.0005438735,0.02916705,0.00001501774,0.000015084484,0.00039538692,0.0069832886],"study_design_scores_gemma":[0.9635171,0.025429364,0.0013542911,0.0012232303,0.0049834717,0.000005418561,0.00014106379,0.0016688167,0.000046356283,0.000046523783,0.001354061,0.00023030085],"about_ca_topic_score_codex":0.0104246745,"about_ca_topic_score_gemma":0.044781245,"teacher_disagreement_score":0.04032827,"about_ca_system_score_codex":0.0011164735,"about_ca_system_score_gemma":0.041444745,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W2278132373","doi":"10.1200/jco.2014.32.26_suppl.44","title":"The impact of Angelina Jolie's (AJ) story on genetic referral and testing at an academic cancer centre.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Family history; Breast cancer; Genetic counseling; Referral; Family medicine; Genetic testing; Ovarian cancer; Christian ministry; Cancer; BRCA mutation; Gynecology; Internal medicine","score_opus":0.12953345682362777,"score_gpt":0.48913600353650555,"score_spread":0.3596025467128778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278132373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952232,0.0023784996,0.00004313609,0.0011849083,0.0006380858,0.000070392074,0.0000072910157,0.000001976906,0.00045248427],"genre_scores_gemma":[0.9941591,0.002165343,0.0012200153,0.00046962846,0.0018045091,0.0000025510578,0.0000018531202,0.000016736309,0.0001602548],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99778634,0.0007048531,0.0009564552,0.00019184966,0.00015754304,0.00020296015],"domain_scores_gemma":[0.99701375,0.000993004,0.0012381407,0.00023011163,0.00033230134,0.00019270569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002199292,0.00011645354,0.00041264758,0.000035464025,0.000099263714,0.0000057356797,0.00026490338,0.00038034536,0.00001580942],"category_scores_gemma":[0.0033436604,0.00007308,0.00018472936,0.00005647696,0.00032132113,0.000005462979,0.00009439856,0.00060246437,0.0000017046913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023742963,0.00025242573,0.2893424,0.000012659227,0.000360556,0.000008453614,0.00013163881,0.0046511083,0.05857788,0.000025187763,0.019644924,0.6246185],"study_design_scores_gemma":[0.002340767,0.011898565,0.9026412,0.000042546522,0.00011230591,0.00010343675,0.00006999781,0.0007932375,0.0034512514,0.00033904152,0.07805396,0.00015373401],"about_ca_topic_score_codex":0.000028134433,"about_ca_topic_score_gemma":0.00015637137,"teacher_disagreement_score":0.6244647,"about_ca_system_score_codex":0.00017066479,"about_ca_system_score_gemma":0.0010016091,"threshold_uncertainty_score":0.40029153},"labels":[],"label_agreement":null},{"id":"W2278333377","doi":"10.1200/jco.2009.27.15_suppl.e20015","title":"Invasive melanoma of the face: Patterns of local and regional disease in 261 patients managed at a single institution","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Sentinel node; Surgery; Biopsy; Neck dissection; Dissection (medical); Melanoma; Histopathology; Parotidectomy; Population; Radiology; Facial nerve; Cancer; Internal medicine; Pathology","score_opus":0.06350776590265066,"score_gpt":0.36028762465741193,"score_spread":0.29677985875476126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278333377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950864,0.00007229227,0.00024464476,0.003619992,0.00034367965,0.00020539806,0.0000026661075,0.0000018648908,0.00042308614],"genre_scores_gemma":[0.9981836,0.00016480299,0.00006321726,0.001360084,0.00007142633,6.971458e-7,0.0000013433755,0.0000030724466,0.0001517618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982285,0.00020291992,0.001120417,0.000098758464,0.00026233884,0.00008707649],"domain_scores_gemma":[0.99833024,0.00031015856,0.0009605003,0.00011525459,0.00013899214,0.000144837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049781357,0.00006817254,0.00052176026,0.00010300991,0.000019862222,0.0000016378897,0.00007733821,0.00010726328,0.000024506613],"category_scores_gemma":[0.0008326784,0.000043646247,0.0001836733,0.000081737795,0.00016503791,0.00003908942,0.000056449066,0.0002696447,9.828921e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008943526,0.003901317,0.8734114,0.00010876691,0.00013136433,0.0005230601,0.00020011401,0.00015745159,0.00033714066,0.00029796892,0.00075685204,0.11123104],"study_design_scores_gemma":[0.0050533214,0.0058609378,0.9829558,0.00019985417,0.00013963744,0.00008364128,0.00013338063,0.000056459867,0.00015130216,0.000170343,0.0051569724,0.000038356466],"about_ca_topic_score_codex":0.000014317793,"about_ca_topic_score_gemma":0.000153355,"teacher_disagreement_score":0.11119267,"about_ca_system_score_codex":0.00014771716,"about_ca_system_score_gemma":0.00021669651,"threshold_uncertainty_score":0.17798422},"labels":[],"label_agreement":null},{"id":"W2278581713","doi":"10.1200/jco.2013.31.15_suppl.tps664","title":"Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Tolerability; Discontinuation; Internal medicine; Metastatic breast cancer; Clinical endpoint; Oncology; Breast cancer; Chemotherapy; Cancer; Adverse effect; Clinical trial","score_opus":0.07742957421473282,"score_gpt":0.46198266660637854,"score_spread":0.3845530923916457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278581713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604602,0.0001137906,0.000027012158,0.03738217,0.0005027834,0.00067920337,0.00012265067,0.000005050135,0.0007071247],"genre_scores_gemma":[0.9948636,0.00016057793,0.0007604458,0.0030759973,0.00073617283,0.00007702653,0.00001439586,0.000019552554,0.0002921864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967791,0.0008652142,0.0015575152,0.00020076895,0.0003253012,0.00027211494],"domain_scores_gemma":[0.9960281,0.0015803053,0.0013561344,0.00012120716,0.00059554545,0.00031870752],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008408718,0.00018207384,0.0013329247,0.0001471453,0.000050533028,0.0000070981255,0.0001568711,0.00017061242,0.0080519235],"category_scores_gemma":[0.00024767424,0.000096899654,0.0002593148,0.00020319156,0.00023385022,0.00016925571,0.000035427107,0.00079798076,0.000029092138],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032367416,0.020265551,0.26954374,0.0002713419,0.0036585934,0.00072196074,0.005308784,0.0001512391,0.02332081,0.00015385513,0.2885274,0.3557093],"study_design_scores_gemma":[0.011211645,0.021361435,0.9598702,0.00027340808,0.0005606086,0.0002305562,0.00039008464,0.00002160164,0.0015340791,0.00008120929,0.004347302,0.00011788039],"about_ca_topic_score_codex":0.0008728133,"about_ca_topic_score_gemma":0.0007354123,"teacher_disagreement_score":0.69032645,"about_ca_system_score_codex":0.00030474784,"about_ca_system_score_gemma":0.0007353666,"threshold_uncertainty_score":0.99285483},"labels":[],"label_agreement":null},{"id":"W2278618830","doi":"10.1200/jco.2006.24.18_suppl.8563","title":"Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Epirubicin; Medicine; Chemotherapy; Cyclophosphamide; Protein C; Breast cancer; Internal medicine; Gastroenterology; Tissue factor pathway inhibitor; Cancer; Endothelial protein C receptor; Antithrombin; Oncology; Endocrinology; Coagulation; Thrombin; Heparin; Tissue factor; Platelet","score_opus":0.034334344026758216,"score_gpt":0.35598921586728927,"score_spread":0.32165487184053104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278618830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947214,0.000040537154,0.00005064641,0.004167685,0.00021115977,0.0005697352,0.000005149938,0.0000041472267,0.0002295454],"genre_scores_gemma":[0.9980097,0.000022311753,0.00028807978,0.0013194642,0.00023415992,0.000007735376,7.5881815e-7,0.000015303895,0.00010247682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783856,0.00030975486,0.0011559055,0.000120307785,0.00041985567,0.00015562776],"domain_scores_gemma":[0.99768186,0.00058686273,0.0012232896,0.00013684985,0.00027660004,0.000094535746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010450814,0.00011297358,0.00096921466,0.000085493535,0.000018093333,0.000004184722,0.00010362979,0.00017821944,0.00008422109],"category_scores_gemma":[0.00017249855,0.000055582204,0.00016470534,0.00013525989,0.00010422878,0.000044213117,0.000012614338,0.0005271494,0.0000027526328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012865248,0.011648915,0.9103811,0.00011170543,0.00034790448,0.00017396163,0.00011100046,0.000034686727,0.0069220033,0.0030648555,0.00021627666,0.054122385],"study_design_scores_gemma":[0.014579058,0.011048029,0.9649189,0.0004453327,0.00006130611,0.0000061732458,0.000010613388,0.000021255615,0.008096767,0.00020738733,0.00054555637,0.000059600334],"about_ca_topic_score_codex":0.00011091163,"about_ca_topic_score_gemma":0.000046941208,"teacher_disagreement_score":0.054537863,"about_ca_system_score_codex":0.00006007557,"about_ca_system_score_gemma":0.00046590882,"threshold_uncertainty_score":0.22902311},"labels":[],"label_agreement":null},{"id":"W2278797968","doi":"10.1200/jco.2005.23.16_suppl.9039","title":"Effect of depsipeptide (NSC 630176), a histone deacetylase inhibitor, on human synovial sarcoma <i>in vitro</i>","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Synovial sarcoma; Cancer research; Histone deacetylase inhibitor; Apoptosis; Depsipeptide; Molecular biology; Cell culture; Cytotoxic T cell; MTT assay; Medicine; Histone deacetylase; Sarcoma; In vitro; Histone; Biology; Pathology; Biochemistry","score_opus":0.048962547608463594,"score_gpt":0.4719109771773958,"score_spread":0.4229484295689322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278797968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945445,0.000672425,0.000031482246,0.00095853175,0.0006643731,0.00026397576,0.00001062769,0.0000055660016,0.0028485346],"genre_scores_gemma":[0.99500424,0.00015112868,0.00089240994,0.0005758253,0.0028422251,0.00001003801,0.000013531858,0.000041639196,0.00046898288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9938189,0.0018865281,0.0028172268,0.00040753084,0.0005974408,0.00047237138],"domain_scores_gemma":[0.9961691,0.0012075561,0.0014774168,0.00044884486,0.00029287144,0.0004042122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006750569,0.00027671896,0.001499356,0.0002854482,0.00006456106,0.00000877705,0.0005180484,0.0008007628,0.00004135934],"category_scores_gemma":[0.0044931187,0.00022766241,0.0008022454,0.00017944702,0.0005076136,0.00001486138,0.00016566378,0.0013685423,0.000040759027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013881427,0.002150776,0.0008996313,0.00004511198,0.00011913467,0.0002996441,0.00003306378,0.000114803166,0.89186877,0.000017667777,0.013666821,0.07690315],"study_design_scores_gemma":[0.010586134,0.032465026,0.00096273946,0.00008551794,0.000059262857,0.00016862107,0.000011127616,0.000027983957,0.86781704,0.000011629771,0.087606706,0.0001982166],"about_ca_topic_score_codex":0.0000357697,"about_ca_topic_score_gemma":0.0001944591,"teacher_disagreement_score":0.076704934,"about_ca_system_score_codex":0.00028974348,"about_ca_system_score_gemma":0.00091440417,"threshold_uncertainty_score":0.92838037},"labels":[],"label_agreement":null},{"id":"W2279037316","doi":"10.1200/jco.2009.27.15_suppl.6032","title":"ERCC1 polymorphism in patients with locally advanced head and neck squamous cell carcinoma treated with concomitant chemoradiation: Prevalence and impact on treatment efficacy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"ERCC1; Medicine; Concomitant; Head and neck squamous-cell carcinoma; Internal medicine; Head and neck cancer; Oncology; Nucleotide excision repair; Carboplatin; Cisplatin; DNA repair; Chemotherapy; Gastroenterology; Radiation therapy; Surgery; Gene; Biology","score_opus":0.017500236862620124,"score_gpt":0.3267750307897679,"score_spread":0.30927479392714774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279037316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865824,0.0004831704,0.000015568996,0.00026549824,0.000045698725,0.00032069377,0.0000066752814,0.0000035362846,0.00020089699],"genre_scores_gemma":[0.9981927,0.00018562052,0.0010757305,0.0003662819,0.000095491334,0.0000028063544,0.000007146286,0.00001376853,0.00006042052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984414,0.00018168351,0.0007101176,0.0002949835,0.00015933585,0.00021248937],"domain_scores_gemma":[0.99858147,0.0001914379,0.0006446547,0.00018527372,0.00013535337,0.00026179553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030298752,0.00021520011,0.00068226055,0.000058423782,0.000026519976,0.000010166643,0.00009190812,0.00024130462,0.000005271518],"category_scores_gemma":[0.00015266064,0.00012450496,0.00009672298,0.00006665827,0.00010129503,0.0000122238935,0.000016378472,0.00020975935,6.547063e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036911212,0.0038349046,0.8868015,0.0000130097,0.00007353456,0.0002388252,0.00005855282,0.00025093567,0.0036297606,0.000005904504,0.000035558613,0.06814632],"study_design_scores_gemma":[0.027720917,0.15779673,0.8090245,0.000033546847,0.00007633691,0.000055875564,0.000008454068,0.000036152924,0.0049816156,0.000009024328,0.0001301873,0.00012666253],"about_ca_topic_score_codex":0.000010933597,"about_ca_topic_score_gemma":0.000020758112,"teacher_disagreement_score":0.15396182,"about_ca_system_score_codex":0.00011753399,"about_ca_system_score_gemma":0.0004135382,"threshold_uncertainty_score":0.50771654},"labels":[],"label_agreement":null},{"id":"W2279042614","doi":"10.1200/jco.2015.33.29_suppl.78","title":"Comparison of prevalence of pain symptoms and completion rates using a patient-reported outcomes (PRO) tool of pain in palliative and curative patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Brief Pain Inventory; Palliative care; Physical therapy; Cancer pain; Quality of life (healthcare); Cancer; Chronic pain; Internal medicine; Nursing","score_opus":0.517023540615233,"score_gpt":0.6105213841199505,"score_spread":0.09349784350471746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279042614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959495,0.00021288494,0.0018106456,0.0012840003,0.0001942943,0.00051703304,0.000011926604,0.0000020587981,0.000017628796],"genre_scores_gemma":[0.98941314,0.00011628008,0.009981804,0.00042875268,0.00004005545,0.0000022923957,0.0000071111326,0.000008274179,0.000002270815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98947084,0.0026501664,0.0070572463,0.00017886989,0.000512233,0.00013063365],"domain_scores_gemma":[0.9711147,0.017060967,0.00948938,0.00013157545,0.002035223,0.00016814058],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0143332565,0.00013020725,0.00189572,0.00015674629,0.00001305249,0.0000029563287,0.00006603199,0.00019904572,0.000017688537],"category_scores_gemma":[0.107490435,0.00009640597,0.00014786886,0.00016800764,0.00037792188,0.00021346714,0.00007066684,0.0004723045,1.2061963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033075472,0.002100776,0.90426314,0.0001798287,0.00020756696,0.000009841922,0.0011145601,0.000046409343,0.00021485626,0.000018411683,0.00014553168,0.08839154],"study_design_scores_gemma":[0.011226114,0.025909798,0.95148623,0.0004328276,0.00041294124,0.00000780092,0.00239514,0.0073641664,0.00015532256,0.0003487746,0.00018371275,0.000077176875],"about_ca_topic_score_codex":0.00012787462,"about_ca_topic_score_gemma":0.0000606271,"teacher_disagreement_score":0.09315718,"about_ca_system_score_codex":0.000100971265,"about_ca_system_score_gemma":0.0007246395,"threshold_uncertainty_score":0.9000276},"labels":[],"label_agreement":null},{"id":"W2279610918","doi":"10.1200/jco.2006.24.18_suppl.13071","title":"Uridine glucuronosyltransferase 2B7 polymorphisms and epirubicin pharmacokinetics","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Glucuronidation; Pharmacokinetics; Anthracycline; Pharmacology; Pharmacogenetics; UGT2B7; Glucuronosyltransferase; SN-38; Genotype; Irinotecan; Colorectal cancer; Cancer; Breast cancer; Chemistry; Biochemistry; In vitro","score_opus":0.09516175521980748,"score_gpt":0.4731237570156215,"score_spread":0.377962001795814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279610918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664051,0.0031037757,0.00012526046,0.02280975,0.0015698425,0.00017485427,0.0000064148685,0.000012511283,0.00579249],"genre_scores_gemma":[0.98668176,0.002723136,0.0014092649,0.0044659576,0.0036917187,0.0000025299012,0.0000052367463,0.000018037605,0.0010023778],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974719,0.00022694375,0.0016906831,0.00017148584,0.00020283154,0.00023613319],"domain_scores_gemma":[0.99750966,0.0012023038,0.00062582426,0.00009687563,0.00019586438,0.000369478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010782236,0.00015502407,0.0012352745,0.00012786372,0.000035434055,0.000005921049,0.00008229843,0.0002447782,0.0006591741],"category_scores_gemma":[0.00023253886,0.000112741465,0.00033150823,0.00010147852,0.00026350628,0.00006798352,0.000022343298,0.0006881434,0.00001523158],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02401085,0.013694567,0.46137464,0.00009008562,0.0014891218,0.0059967297,0.0001263627,0.000051527666,0.068644404,0.0008221358,0.115671396,0.3080282],"study_design_scores_gemma":[0.03828369,0.025607504,0.31575665,0.000052005496,0.0024460505,0.0024016548,0.000020165498,0.00015445129,0.008929061,0.0007627172,0.6053946,0.00019141848],"about_ca_topic_score_codex":0.00006757809,"about_ca_topic_score_gemma":0.00003206382,"teacher_disagreement_score":0.48972324,"about_ca_system_score_codex":0.000084710584,"about_ca_system_score_gemma":0.0006518652,"threshold_uncertainty_score":0.7217494},"labels":[],"label_agreement":null},{"id":"W2279886967","doi":"10.1200/jco.2009.27.15_suppl.e20625","title":"Pediatric sibling donor bone marrow transplant: Assessing distress in donors and family members","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Sibling; Medicine; Distress; Coping (psychology); Grounded theory; Qualitative research; Bone marrow transplant; Bone marrow transplantation; Clinical psychology; Family medicine; Transplantation; Developmental psychology; Psychology; Surgery","score_opus":0.10098683601022211,"score_gpt":0.4546886884064117,"score_spread":0.35370185239618956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279886967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973986,0.0023415147,0.00016277627,0.020309493,0.0009771046,0.00014237693,0.000004408553,0.000014191771,0.0020621116],"genre_scores_gemma":[0.98144525,0.0063151782,0.0033621541,0.006654759,0.0021718268,8.620524e-7,0.0000032084745,0.000015334443,0.00003141581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950918,0.0005948751,0.0032227112,0.0002744513,0.00048360307,0.00033256234],"domain_scores_gemma":[0.9947794,0.0028277915,0.0015286145,0.00017240609,0.00015641707,0.00053536386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058045955,0.00018817987,0.0018523348,0.00036064186,0.00004749269,0.000030452986,0.0001502244,0.00043174482,0.00003007292],"category_scores_gemma":[0.0019552994,0.0001534753,0.00036328795,0.0003373985,0.00013511388,0.00028258862,0.000021387357,0.0015495024,0.0000024651517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003061822,0.0019318578,0.86768126,0.00017041973,0.00012034803,0.0024232718,0.0009953028,0.00006533267,0.00021731686,0.000056432124,0.001721,0.12155563],"study_design_scores_gemma":[0.009320032,0.0036571966,0.98090905,0.0003170218,0.00040077558,0.0005587999,0.00052710087,0.00010492343,0.00001240909,0.0003333806,0.003690583,0.00016870919],"about_ca_topic_score_codex":0.00013035524,"about_ca_topic_score_gemma":0.00033810126,"teacher_disagreement_score":0.121386915,"about_ca_system_score_codex":0.00012553447,"about_ca_system_score_gemma":0.00092521484,"threshold_uncertainty_score":0.6731903},"labels":[],"label_agreement":null},{"id":"W2280019140","doi":"10.1200/jco.2006.24.18_suppl.20083","title":"Inhibition of tumor growth in a murine xenograft model by thalidomide","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Thalidomide; Angiogenesis; Radiation therapy; Chemotherapy; Cancer research; Urology; Internal medicine; Multiple myeloma","score_opus":0.136374678023274,"score_gpt":0.3885123995553968,"score_spread":0.25213772153212277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280019140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183154,0.00056580105,0.00024638473,0.0030922303,0.00012113552,0.00017378245,0.0000059682975,0.000005206705,0.003957972],"genre_scores_gemma":[0.9947493,0.00017432263,0.0040133824,0.00054457376,0.0003284486,0.0000045157026,0.000011267816,0.000012428923,0.00016174563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700373,0.00023574363,0.0022045544,0.00012481134,0.00025851163,0.00017267436],"domain_scores_gemma":[0.99778223,0.00060493127,0.0011120909,0.00008856203,0.0002591751,0.00015303689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018372711,0.000109593406,0.0011832094,0.00017210867,0.000011603027,0.000002908074,0.00005966105,0.000215435,0.000051811985],"category_scores_gemma":[0.00062353973,0.00007940178,0.0004393055,0.00015611823,0.00011963509,0.000083909064,0.000022726876,0.00048247766,0.0000054889497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002568863,0.0038589397,0.97838837,0.000050176728,0.00008869454,0.0014646637,0.000036826044,0.000016712658,0.0033988028,0.00017940906,0.006318463,0.0036300602],"study_design_scores_gemma":[0.10860796,0.05132353,0.6878919,0.0010989577,0.0024054537,0.0019695556,0.00020801133,0.026145397,0.08425399,0.021412222,0.014015874,0.0006671603],"about_ca_topic_score_codex":0.00012607536,"about_ca_topic_score_gemma":0.000037793587,"teacher_disagreement_score":0.2904965,"about_ca_system_score_codex":0.00009068082,"about_ca_system_score_gemma":0.0005271399,"threshold_uncertainty_score":0.3237911},"labels":[],"label_agreement":null},{"id":"W2280282551","doi":"10.1200/jco.2007.25.18_suppl.17031","title":"The Oncology Symptom Control and Information Resource (OSCIR): Using information technology to improve the management of cancer treatment-related side effects","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Documentation; Workgroup; Mucositis; Common Terminology Criteria for Adverse Events; Adverse effect; Radiation therapy; Internal medicine; Computer science","score_opus":0.02517999940861822,"score_gpt":0.45291415959047115,"score_spread":0.42773416018185295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280282551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96631527,0.0012284789,0.00066764804,0.02487213,0.0015567695,0.0012983544,0.000005962058,0.000014506329,0.004040905],"genre_scores_gemma":[0.9925506,0.002176752,0.0010182237,0.003816487,0.00027627035,0.000032689055,0.0000024484643,0.000007903797,0.00011861944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970927,0.00021963172,0.002098411,0.00009097895,0.00021134,0.0002869292],"domain_scores_gemma":[0.99448955,0.0028266709,0.0020011226,0.00017172098,0.00032506484,0.00018589833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027331524,0.00014758507,0.000861734,0.00025771552,0.00013256041,0.000011053721,0.00015160478,0.00039080236,0.000009680265],"category_scores_gemma":[0.00036701045,0.00007574595,0.00019263192,0.00030553792,0.0003365311,0.00026026194,0.00006190825,0.00048540378,0.0000065975833],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008574422,0.00039659088,0.00730976,0.000053209304,0.0019356331,0.000070775255,0.0004560719,0.00010869812,0.00067959377,0.0008657075,0.0003673601,0.9791822],"study_design_scores_gemma":[0.03955893,0.033839356,0.14597335,0.00014751498,0.0037276363,0.00037410826,0.0013816465,0.0006128703,0.0015352179,0.00037136918,0.77234286,0.00013515692],"about_ca_topic_score_codex":0.00007531538,"about_ca_topic_score_gemma":0.00007236492,"teacher_disagreement_score":0.979047,"about_ca_system_score_codex":0.0006339271,"about_ca_system_score_gemma":0.0006096348,"threshold_uncertainty_score":0.30888304},"labels":[],"label_agreement":null},{"id":"W2280287330","doi":"10.1200/jco.2014.32.31_suppl.164","title":"The conversion ratio for opioid rotation from hydrocodone to other strong opioids in cancer patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hydrocodone; Medicine; Opioid; Anesthesia; Oxycodone; Internal medicine","score_opus":0.07326305864838696,"score_gpt":0.4372749396728502,"score_spread":0.36401188102446325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280287330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975326,0.00008506993,0.0068699736,0.010641946,0.0015091549,0.0005446499,0.000003333388,0.0000043016125,0.0005883252],"genre_scores_gemma":[0.9894887,0.0001934812,0.002102388,0.006173728,0.0014647695,0.000023280825,0.000006294375,0.000012463897,0.0005348577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981027,0.00025013968,0.0011502629,0.00012213425,0.00021389409,0.00016081995],"domain_scores_gemma":[0.9961212,0.0027067112,0.0006815164,0.00011306072,0.0002280879,0.00014939878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024764934,0.000077329176,0.00052701234,0.00007267412,0.00004714858,0.000010686493,0.00013801322,0.00013820916,0.00005564693],"category_scores_gemma":[0.0030086082,0.000047925318,0.00016350759,0.00007504673,0.000049798116,0.00007109353,0.000030708954,0.00029594582,0.000012796482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049097617,0.0007076523,0.7841017,0.000021787155,0.00014757141,0.0000041085677,0.00026105586,0.00018798432,0.00016767715,0.00037721964,0.023762155,0.18535133],"study_design_scores_gemma":[0.008592285,0.0046417876,0.59235513,0.000074893695,0.00010919488,1.03468615e-7,0.00010297585,0.0044532456,0.00007883764,0.00047038114,0.38906547,0.000055668777],"about_ca_topic_score_codex":0.00008067967,"about_ca_topic_score_gemma":0.00024734318,"teacher_disagreement_score":0.3653033,"about_ca_system_score_codex":0.00013075817,"about_ca_system_score_gemma":0.00022975741,"threshold_uncertainty_score":0.36018023},"labels":[],"label_agreement":null},{"id":"W2280343247","doi":"10.1200/jco.2013.31.31_suppl.104","title":"The use of PET scans in the management of non-small cell lung cancer patients relative to evidence-based indications across Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Lung cancer; Cancer; Stage (stratigraphy); Radiation treatment planning; Radiation therapy; Palliative care; Radiology; Oncology; Internal medicine; Nursing","score_opus":0.08639910602653088,"score_gpt":0.44986891835432175,"score_spread":0.36346981232779085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280343247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556238,0.00017105274,0.0008430848,0.04226745,0.0004169171,0.0004736827,0.0000042521206,8.313011e-7,0.0001989457],"genre_scores_gemma":[0.9893321,0.0005797984,0.0050275354,0.0047967494,0.00009608315,0.000021103178,9.702046e-7,0.000007364645,0.00013833787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973073,0.00040329114,0.0015524912,0.00010476856,0.00043988752,0.00019226871],"domain_scores_gemma":[0.9924807,0.005244696,0.0014339722,0.00019823706,0.000464055,0.00017832346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023832337,0.00007750862,0.0005264324,0.000041152234,0.000059438702,0.000009907181,0.00032501997,0.00006388265,0.000027136219],"category_scores_gemma":[0.0029229056,0.000039804236,0.00013448916,0.00022306273,0.00019105182,0.00008034741,0.00005472846,0.0008589232,8.6362877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004296544,0.00082557823,0.8929709,0.00011807803,0.00024406894,0.00007747418,0.000883414,0.0024337773,0.00002971144,0.000043843822,0.01886525,0.083078235],"study_design_scores_gemma":[0.0022043318,0.0010968534,0.9783987,0.0006952953,0.00019057981,0.0000038971593,0.00036260317,0.004898548,0.0000123072095,0.000020045562,0.012075458,0.00004137129],"about_ca_topic_score_codex":0.039677244,"about_ca_topic_score_gemma":0.022284184,"teacher_disagreement_score":0.08542779,"about_ca_system_score_codex":0.00019598116,"about_ca_system_score_gemma":0.0015298682,"threshold_uncertainty_score":0.9955566},"labels":[],"label_agreement":null},{"id":"W2280415345","doi":"10.1200/jco.2009.27.15_suppl.5117","title":"Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; The Scarborough Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prospective cohort study; Urology; Prostate; Single Center; Cancer; Biopsy; Radiation therapy; Surgery; Nuclear medicine; Median follow-up; Internal medicine; Overall survival","score_opus":0.0514613310778428,"score_gpt":0.398783466118972,"score_spread":0.3473221350411292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280415345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933775,0.00021204504,0.000030312876,0.0025492075,0.0019777333,0.001694182,0.000059509162,0.000012920808,0.00008655684],"genre_scores_gemma":[0.99588835,0.00014905568,0.0026041563,0.00071154896,0.00055029854,0.000040815874,0.000016185764,0.000024023566,0.000015576254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627286,0.00022277336,0.002231229,0.0003660461,0.00054834504,0.00035877104],"domain_scores_gemma":[0.99523914,0.0013373875,0.0016571317,0.0003035675,0.0011153477,0.00034744613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012079548,0.0002334367,0.0022700266,0.0001052585,0.000045952576,0.000013981637,0.00021312606,0.00021629412,0.000015969545],"category_scores_gemma":[0.0029568481,0.00017041221,0.00070190063,0.00017768994,0.00013674326,0.000115511386,0.000060601902,0.0005342905,0.0000010104666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019395744,0.028668096,0.9137573,0.000022959135,0.0015701702,0.00020964927,0.00057160534,0.000009905528,0.0004816498,0.000020193898,0.0036264441,0.031666264],"study_design_scores_gemma":[0.12057687,0.110649444,0.7602349,0.00031988128,0.0015161687,0.000021689619,0.0005281194,0.0000064062465,0.0020999755,0.0010673616,0.0027708458,0.00020836429],"about_ca_topic_score_codex":0.00014718178,"about_ca_topic_score_gemma":0.00019281979,"teacher_disagreement_score":0.15352245,"about_ca_system_score_codex":0.0006163338,"about_ca_system_score_gemma":0.0006016117,"threshold_uncertainty_score":0.69492084},"labels":[],"label_agreement":null},{"id":"W2280692149","doi":"10.1200/jco.2004.22.90140.3103","title":"Antisense inhibition of methylenetetrahydrofolate reductase (MTHFR) reduces survival of cancer cells in vitro and in vivo","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Methylenetetrahydrofolate reductase; In vivo; Methionine; Cancer research; Medicine; Cancer; Lung cancer; Cisplatin; Molecular biology; Biology; Internal medicine; Chemotherapy; Biochemistry; Gene","score_opus":0.10294361009661353,"score_gpt":0.4796759823007024,"score_spread":0.3767323722040889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280692149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559546,0.0012139189,0.0000026520474,0.0023491231,0.0004030647,0.00014520723,0.0000145643135,0.0000014523107,0.0002745793],"genre_scores_gemma":[0.991972,0.006471669,0.0011976886,0.00009822417,0.00020970004,0.0000012088923,9.619171e-7,0.000009816104,0.000038683193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99663955,0.00041758188,0.0022177515,0.00015990176,0.00035157762,0.00021361394],"domain_scores_gemma":[0.9975935,0.00089881936,0.0009373736,0.00010748931,0.0002723791,0.0001904149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036763153,0.00009907021,0.0013780197,0.00041920046,0.000009030096,0.0000024663104,0.00007028718,0.0003170885,0.000045861947],"category_scores_gemma":[0.001155609,0.00007520321,0.0001850696,0.00033838858,0.00033783293,0.00010175592,0.000040825966,0.00084118935,7.8230477e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074572107,0.0015013197,0.008640612,0.00008957824,0.00009810492,0.0009118928,0.00018372311,0.00008655487,0.96244943,0.000007730392,0.00007366817,0.018500173],"study_design_scores_gemma":[0.011305217,0.0048555764,0.06438623,0.00040634617,0.00009663814,0.000081381564,0.00020722974,0.00004740616,0.9178738,0.0003006084,0.00036890974,0.000070652335],"about_ca_topic_score_codex":0.0005635358,"about_ca_topic_score_gemma":0.00033496012,"teacher_disagreement_score":0.055745624,"about_ca_system_score_codex":0.00012143514,"about_ca_system_score_gemma":0.001308569,"threshold_uncertainty_score":0.3654596},"labels":[],"label_agreement":null},{"id":"W2280700389","doi":"10.1200/jco.2009.27.15_suppl.6581","title":"A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Lung cancer; Internal medicine; Willingness to pay; Cancer; Oncology; Family medicine; Vascular endothelial growth factor; Chemotherapy; VEGF receptors","score_opus":0.014572970921400735,"score_gpt":0.32994368235405114,"score_spread":0.3153707114326504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280700389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997678,0.0002133583,0.00044863156,0.000111041554,0.00093361014,0.00047093918,0.00002926303,0.0000020043146,0.00011314802],"genre_scores_gemma":[0.99677336,0.0005836399,0.0011645447,0.0005102193,0.0009097228,0.000008234159,0.000004236448,0.00002173128,0.000024299014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977019,0.00013166391,0.0013766197,0.00028504524,0.00026356732,0.0002412408],"domain_scores_gemma":[0.99716175,0.00023352074,0.0013461191,0.0002272947,0.00073973625,0.0002915672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046514883,0.00018827317,0.0008318228,0.00006586246,0.00003719307,0.000010018252,0.00028981717,0.00025200972,0.000008972691],"category_scores_gemma":[0.00071748276,0.00012817832,0.00027328357,0.00010932845,0.000066278735,0.000008734906,0.00006981144,0.0003581148,5.599246e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002068892,0.003595185,0.9703111,0.000016960828,0.00023917301,0.000022848237,0.00022786367,0.0013963539,0.0051081884,0.000001264936,0.00039578252,0.016616402],"study_design_scores_gemma":[0.011640665,0.036258977,0.9406535,0.00005465655,0.00023401275,0.0000012745047,0.00010713995,0.000018094064,0.00719252,0.000011572606,0.0036173728,0.0002102271],"about_ca_topic_score_codex":0.000071309994,"about_ca_topic_score_gemma":0.00028394535,"teacher_disagreement_score":0.032663792,"about_ca_system_score_codex":0.000055198805,"about_ca_system_score_gemma":0.00077217974,"threshold_uncertainty_score":0.522696},"labels":[],"label_agreement":null},{"id":"W2280859858","doi":"10.1200/jco.2007.25.18_suppl.3513","title":"A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Breast cancer; Clinical endpoint; Internal medicine; Pneumonitis; Oncology; Phases of clinical research; Metastatic breast cancer; Cancer; Gastroenterology; Clinical trial; Lung","score_opus":0.07323034241048873,"score_gpt":0.527863117070832,"score_spread":0.45463277466034324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280859858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975676,0.00026831872,0.00013342903,0.00047930476,0.00053217524,0.00088215136,0.000018961804,0.000001970314,0.00011607495],"genre_scores_gemma":[0.9985923,0.00011987406,0.0010253801,0.00009310397,0.00011722841,0.000011923761,0.0000041320723,0.0000100630095,0.00002597284],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996243,0.0004070223,0.002666025,0.00012710283,0.0004009082,0.00015595605],"domain_scores_gemma":[0.9953609,0.0014075297,0.0023217492,0.00012522022,0.00059715885,0.00018743811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019808062,0.00012484804,0.00228704,0.00021718872,0.00001991487,0.0000015728626,0.00007815858,0.00006135277,0.00009706268],"category_scores_gemma":[0.00060032576,0.00006592379,0.00025627387,0.00017348323,0.00018413755,0.000060292714,0.000024723591,0.00036672596,2.8767943e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36758283,0.057023864,0.4499117,0.000037000802,0.0017873037,0.000074827614,0.0006810778,0.000018035958,0.0000073442984,0.00003466288,0.000025640285,0.12281569],"study_design_scores_gemma":[0.55996376,0.034131043,0.40322825,0.00022959635,0.001945117,0.000010292665,0.00032928886,0.000019125924,0.000010357859,0.000054418284,0.00003893019,0.000039810562],"about_ca_topic_score_codex":0.00013567592,"about_ca_topic_score_gemma":0.0004575952,"teacher_disagreement_score":0.19238093,"about_ca_system_score_codex":0.00016244249,"about_ca_system_score_gemma":0.0007258959,"threshold_uncertainty_score":0.2688294},"labels":[],"label_agreement":null},{"id":"W2280878155","doi":"10.1200/jco.2009.27.15_suppl.e16161","title":"A review of the patterns of docetaxel use for hormone refractory prostate cancer (HRPC) at the Princess Margaret Hospital","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Mitoxantrone; Internal medicine; Discontinuation; Regimen; Prostate cancer; Oncology; Chemotherapy; Randomized controlled trial; Clinical trial; Surgery; Cancer","score_opus":0.2383777072622688,"score_gpt":0.5475200020060633,"score_spread":0.3091422947437945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280878155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014350797,0.9864806,0.0000024299907,0.007516924,0.00089082064,0.0032829097,0.00028527805,0.0000029557598,0.00010303052],"genre_scores_gemma":[0.00012994587,0.995463,0.00009473124,0.0011481773,0.00079480273,0.000121712415,0.00002700056,0.00003884996,0.0021817528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931966,0.0010407399,0.004425282,0.0002886035,0.00069454266,0.000354225],"domain_scores_gemma":[0.98594385,0.0037685346,0.0082239555,0.0006077434,0.0012176502,0.00023824128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004337138,0.00033274436,0.0056096376,0.000092220514,0.000061473824,0.000007681957,0.0006392197,0.0005358718,0.00009261159],"category_scores_gemma":[0.0036510138,0.00012818766,0.002863225,0.00024509843,0.00047499788,0.00009375801,0.00021362133,0.0016930412,0.000002078983],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012690381,0.0011334405,0.0017320295,0.04426322,0.0014321443,0.00006782236,0.00004023308,1.1315574e-7,7.468145e-7,0.0000071594714,0.025188852,0.9248652],"study_design_scores_gemma":[0.0032297752,0.008256934,0.0069516036,0.09825097,0.0045361915,0.0000949703,0.000009173151,2.761637e-7,0.0000022246286,0.000020682688,0.8785388,0.00010841411],"about_ca_topic_score_codex":0.000039638766,"about_ca_topic_score_gemma":0.000039091286,"teacher_disagreement_score":0.92475677,"about_ca_system_score_codex":0.0006038272,"about_ca_system_score_gemma":0.006333342,"threshold_uncertainty_score":0.9992998},"labels":[],"label_agreement":null},{"id":"W2280900900","doi":"10.1200/jco.2014.32.26_suppl.142","title":"Overall survival (OS) in metastatic breast cancer (MBC): Are we using the right endpoint in the right way?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Clinical endpoint; Oncology; Progression-free survival; Metastatic breast cancer; Randomized controlled trial; Cancer; Chemotherapy; Breast cancer","score_opus":0.1726119135008372,"score_gpt":0.5092724751579168,"score_spread":0.33666056165707964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280900900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.867107,0.0010884466,0.000080618884,0.12638403,0.0025500334,0.0003374974,0.000014559204,0.000004418255,0.0024333964],"genre_scores_gemma":[0.9874318,0.0017229497,0.00030503073,0.008190081,0.0021398508,0.000012119656,0.0000016272272,0.000015184926,0.00018134053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949927,0.0023045787,0.001803853,0.00019500528,0.00036718522,0.00033670667],"domain_scores_gemma":[0.9929261,0.0052714916,0.0012792376,0.00020907476,0.00015089073,0.00016317904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0057872646,0.00017978462,0.0014386155,0.00013948308,0.00005806394,0.000012576217,0.0002975418,0.00019131902,0.0013318136],"category_scores_gemma":[0.0004184774,0.00008132763,0.0004016478,0.00021141655,0.00025389748,0.00009501713,0.000047327354,0.0014851775,0.000008468949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034011923,0.021743096,0.73826003,0.00025660617,0.0030336634,0.011123172,0.0036600137,0.0021282996,0.0010403271,0.004607062,0.05500914,0.12512666],"study_design_scores_gemma":[0.01973137,0.0033172716,0.7141136,0.000224844,0.0011467373,0.00127888,0.00029098496,0.001496076,0.00004708864,0.003037845,0.25516048,0.00015480493],"about_ca_topic_score_codex":0.00039828947,"about_ca_topic_score_gemma":0.0048775827,"teacher_disagreement_score":0.20015135,"about_ca_system_score_codex":0.00040430247,"about_ca_system_score_gemma":0.0008676486,"threshold_uncertainty_score":0.9995811},"labels":[],"label_agreement":null},{"id":"W2281237368","doi":"10.1200/jco.2009.27.15_suppl.e20545","title":"Use of complementary medicine (CAM) among women receiving chemotherapy for ovarian cancer: A comparison of attitudes between two patient populations","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Internal medicine; Ovarian cancer; Family medicine; Traditional medicine","score_opus":0.4639572470086575,"score_gpt":0.5852231374513978,"score_spread":0.12126589044274028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281237368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98517203,0.00031898048,0.0010920629,0.012131841,0.00064739754,0.0004771101,0.000036482725,0.000005164811,0.00011889857],"genre_scores_gemma":[0.98722,0.0002885754,0.009718744,0.0011446854,0.0015692135,0.0000073642614,0.000019822557,0.000009996051,0.000021637275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953448,0.00023615116,0.0036031536,0.00016514,0.0004154637,0.00023530272],"domain_scores_gemma":[0.9930283,0.0028134526,0.003153659,0.00015779259,0.00062046206,0.00022632151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016834433,0.00015751892,0.002474904,0.00019031447,0.000064642365,0.000001993756,0.00014410415,0.00004404377,0.0003178492],"category_scores_gemma":[0.0013887316,0.000108826345,0.00028903273,0.00015737207,0.00036741197,0.000106168896,0.000038191196,0.00039894256,1.3002958e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001578832,0.000981309,0.73891085,0.000044778986,0.00076477334,0.000005455106,0.0014975448,0.00003461931,0.0002400753,0.00009100078,0.0025755246,0.25327525],"study_design_scores_gemma":[0.011543594,0.036321484,0.9333606,0.0006021868,0.0005167506,0.000005378928,0.0011943603,0.00011188499,0.00018313005,0.00061379554,0.01546933,0.000077505276],"about_ca_topic_score_codex":0.0004555256,"about_ca_topic_score_gemma":0.00033197552,"teacher_disagreement_score":0.25319773,"about_ca_system_score_codex":0.00017623133,"about_ca_system_score_gemma":0.00022962158,"threshold_uncertainty_score":0.44378096},"labels":[],"label_agreement":null},{"id":"W2281421996","doi":"10.1200/jco.2015.33.7_suppl.456","title":"Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Salvage therapy; Targeted therapy; Retrospective cohort study; Oncology; Cohort; Gastroenterology; Cancer; Chemotherapy","score_opus":0.09063368928562746,"score_gpt":0.39000812939261165,"score_spread":0.2993744401069842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281421996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930436,0.0027775608,0.00013746531,0.0006451452,0.00097283104,0.00068720715,0.000008132836,0.000010629484,0.0017174071],"genre_scores_gemma":[0.9900825,0.00018313577,0.008640116,0.000278668,0.0005177186,0.00001449472,0.0000063767484,0.0000328129,0.00024419473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99423593,0.0010349816,0.0032170117,0.000364985,0.00077874115,0.00036832175],"domain_scores_gemma":[0.99498445,0.000961989,0.002242094,0.00033103483,0.0008815911,0.00059886393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038055799,0.0002937423,0.0023083652,0.0003764379,0.000025902003,0.000009480864,0.0001799034,0.0003858652,0.0000935827],"category_scores_gemma":[0.0020018066,0.00020554112,0.00074105186,0.00034995886,0.0004498717,0.000171656,0.00007251998,0.0012835804,0.000033258584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031642508,0.008331426,0.945794,0.000082237835,0.00041186553,0.0041731307,0.0013790153,0.00012091373,0.0041187145,0.000014195653,0.00092442444,0.0030075705],"study_design_scores_gemma":[0.029486757,0.023458105,0.93439704,0.00011119921,0.00081690814,0.00018513785,0.00040430264,0.00013532086,0.009092534,0.000093939554,0.0016561012,0.00016267026],"about_ca_topic_score_codex":0.00017857083,"about_ca_topic_score_gemma":0.00008743248,"teacher_disagreement_score":0.015126678,"about_ca_system_score_codex":0.0009860005,"about_ca_system_score_gemma":0.0022735829,"threshold_uncertainty_score":0.8381724},"labels":[],"label_agreement":null},{"id":"W2281554724","doi":"10.1200/jco.2007.25.18_suppl.17503","title":"Pleural effusions in patients treated with dasatinib: Results from two institutions, risk factors and management","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Discontinuation; Internal medicine; Dosing; Imatinib; Incidence (geometry); Oncology; Drug; Gastroenterology; Pharmacology","score_opus":0.09354951623553806,"score_gpt":0.43307475504671666,"score_spread":0.3395252388111786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281554724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956642,0.000065805434,0.000031988235,0.00035705895,0.00030701904,0.00034968008,0.00003649209,0.000010444402,0.003177331],"genre_scores_gemma":[0.99430424,0.00071654614,0.0043992028,0.00022368523,0.00021448311,0.0000012007481,0.000049739934,0.000011798119,0.000079100646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685305,0.00023398043,0.0020839747,0.00024246519,0.0003436072,0.00024292462],"domain_scores_gemma":[0.9957576,0.002177496,0.001332948,0.00020858929,0.00014993556,0.00037343378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015554694,0.00016584479,0.0009535575,0.0002115119,0.00005512126,0.000005928401,0.000091914364,0.00020525068,0.000028362803],"category_scores_gemma":[0.0018241191,0.00009835093,0.00013669116,0.00019201297,0.00019882232,0.00009302721,0.00006014597,0.0007897016,0.000006999543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010870316,0.001403608,0.93802613,0.000005106924,0.00042609582,0.00095347496,0.00015211958,0.000023975796,0.000001970257,0.000020609217,0.00023616911,0.04788045],"study_design_scores_gemma":[0.0668162,0.0067312187,0.91875136,0.00016703243,0.0005294895,0.000024311139,0.00013092837,0.000031178202,0.000017322238,0.000024416062,0.0066969907,0.000079574274],"about_ca_topic_score_codex":0.0010112075,"about_ca_topic_score_gemma":0.0013956806,"teacher_disagreement_score":0.05594589,"about_ca_system_score_codex":0.00071519,"about_ca_system_score_gemma":0.00057162414,"threshold_uncertainty_score":0.40106344},"labels":[],"label_agreement":null},{"id":"W2281669217","doi":"10.1200/jco.2004.22.90140.8010","title":"Ten-year breast cancer survival - at what cost in human and physical terms? A case-control study of long-term survivors of breast cancer and their physical and functional well-being","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Internal medicine; Lumpectomy; Tamoxifen; Cancer; Gastroenterology; Surgery; Oncology; Mastectomy","score_opus":0.055928901774349934,"score_gpt":0.41369198685626324,"score_spread":0.3577630850819133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281669217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737155,0.00034622726,0.0000074124177,0.0013517131,0.00044245936,0.0003748405,0.0000718546,0.0000035377507,0.000030422481],"genre_scores_gemma":[0.99762815,0.0010275737,0.0000043737296,0.0001522551,0.0011416642,0.000009674011,0.0000011952991,0.000020796975,0.0000143154775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977327,0.00024441245,0.0011895385,0.0002951271,0.00030281712,0.00023540985],"domain_scores_gemma":[0.9973556,0.0010127521,0.0009405829,0.00013525333,0.00023488453,0.00032096836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008771334,0.00021665102,0.0018811427,0.00013259478,0.00006215095,0.000015984137,0.00006388292,0.00017815437,0.00005613539],"category_scores_gemma":[0.00006190816,0.00014285077,0.0002053804,0.00012342886,0.00054191385,0.00023521633,0.000088131725,0.0007191328,2.2253226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059154774,0.0032447192,0.9273976,0.00007584448,0.0005149908,0.00059619243,0.0020424044,0.000067991394,0.0007963849,0.0000199905,0.000007997829,0.0593204],"study_design_scores_gemma":[0.022070639,0.0039975164,0.9688371,0.0003354084,0.00046381488,0.0021890143,0.0017716764,0.000070838745,0.000039217754,0.00009235438,0.0000108300555,0.00012160674],"about_ca_topic_score_codex":0.0025188786,"about_ca_topic_score_gemma":0.013894548,"teacher_disagreement_score":0.059198797,"about_ca_system_score_codex":0.0002141553,"about_ca_system_score_gemma":0.0003674358,"threshold_uncertainty_score":0.7753484},"labels":[],"label_agreement":null},{"id":"W2281673453","doi":"10.1200/jco.2005.23.16_suppl.3664","title":"Impact of reduced dose intensity of adjuvant bolus 5-FU based chemotherapy for stage 2 and 3 colon cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Folinic acid; Cohort; Colorectal cancer; Cancer; Internal medicine; Stage (stratigraphy); Proportional hazards model; Cancer registry; Surgery","score_opus":0.13016367077504656,"score_gpt":0.5254182091263728,"score_spread":0.3952545383513263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281673453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912987,0.0021768184,0.000027939503,0.0056694127,0.00026407422,0.00029265342,0.000033821245,0.0000025188017,0.00023410855],"genre_scores_gemma":[0.9938558,0.0026044827,0.0021161614,0.00086175615,0.00040379376,0.000006172382,0.0000011101278,0.000009215824,0.00014151858],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982835,0.00006822055,0.001242892,0.00011563685,0.00015009791,0.00013964635],"domain_scores_gemma":[0.9968115,0.0009017217,0.0013437577,0.000093398885,0.0006910147,0.00015857858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009092454,0.000106482636,0.001642459,0.00006676,0.000021162465,0.0000015203475,0.000052115032,0.00015619093,0.0001195],"category_scores_gemma":[0.0008813683,0.000064478634,0.0005028298,0.00006315465,0.00021240662,0.00003738213,0.000018282786,0.00023111748,1.6725438e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09652672,0.0034434309,0.22458543,0.000119197495,0.0019659156,0.000062156796,0.0003839055,0.000054216653,0.0062553613,0.000009164186,0.00597942,0.6606151],"study_design_scores_gemma":[0.021225931,0.041313954,0.9232405,0.000106529405,0.00045334743,0.000029177578,0.000059990438,0.00051213737,0.0022843564,0.000020778933,0.010694426,0.000058908146],"about_ca_topic_score_codex":0.00017676388,"about_ca_topic_score_gemma":0.0002242879,"teacher_disagreement_score":0.698655,"about_ca_system_score_codex":0.00025338423,"about_ca_system_score_gemma":0.0013971439,"threshold_uncertainty_score":0.26293623},"labels":[],"label_agreement":null},{"id":"W2281806191","doi":"10.1200/jco.2009.27.15_suppl.8074","title":"ABT-869 in non-small cell lung cancer (NSCLC): Interim results","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Interim analysis; Clinical endpoint; Internal medicine; Population; Toxicity; Progression-free survival; Surgery; Phases of clinical research; Lung cancer; Gastroenterology; Oncology; Urology; Clinical trial; Overall survival","score_opus":0.07936534600916437,"score_gpt":0.5235844798026544,"score_spread":0.4442191337934901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281806191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91999805,0.0014439088,0.00017705273,0.026083436,0.0017270487,0.00028932787,0.000008405575,0.00000778224,0.050264984],"genre_scores_gemma":[0.98767567,0.001398478,0.0027509273,0.005394221,0.0011192281,0.000004578167,0.0000033100923,0.000009530609,0.0016440836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99740016,0.0001237145,0.0019298369,0.00016656736,0.00016979572,0.00020991918],"domain_scores_gemma":[0.9977827,0.0005369785,0.0010078872,0.00014769683,0.0002482727,0.00027646538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011381055,0.00011201669,0.0009290105,0.00013614207,0.000021537751,0.0000071093223,0.00011688318,0.00025191353,0.00008347078],"category_scores_gemma":[0.0006116635,0.00007663676,0.00029253014,0.00013808037,0.00005209248,0.000076047385,0.000017236849,0.0007455701,0.000010778011],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016134238,0.009440715,0.15558228,0.00008517888,0.00069055095,0.0044896756,0.002405133,0.00022946202,0.0010589323,0.00008937818,0.06749642,0.74229807],"study_design_scores_gemma":[0.033539638,0.015848998,0.86525714,0.0005773833,0.00085566565,0.00014790922,0.00022871517,0.00028871722,0.00022573315,0.00021426042,0.08267899,0.00013683946],"about_ca_topic_score_codex":0.00009776046,"about_ca_topic_score_gemma":0.00016621634,"teacher_disagreement_score":0.7421612,"about_ca_system_score_codex":0.00038531213,"about_ca_system_score_gemma":0.002037486,"threshold_uncertainty_score":0.36144128},"labels":[],"label_agreement":null},{"id":"W2281834806","doi":"10.1200/jco.2005.23.16_suppl.6005","title":"Comparison of elapsed times from breast cancer detection to first adjuvant therapy in a Canadian province, 1999–2000 and 2003–2004","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Breast cancer; Interquartile range; Cohort; Referral; Cancer; Adjuvant therapy; Retrospective cohort study; Surgery; Internal medicine; Family medicine","score_opus":0.06814813399239247,"score_gpt":0.3751655077824422,"score_spread":0.3070173737900497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281834806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97842544,0.008812241,0.000108483575,0.008076449,0.0010193966,0.00020901364,0.00024640228,0.0000031074114,0.0030994844],"genre_scores_gemma":[0.99405545,0.0027678069,0.0006173527,0.0015771098,0.0008030024,0.000006083913,0.0000013106692,0.000014548968,0.00015736409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968804,0.00004160142,0.0024715753,0.00022333895,0.000038221362,0.0003448631],"domain_scores_gemma":[0.9972979,0.00024271307,0.001697811,0.00013081256,0.00013498156,0.0004957763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015173903,0.00012997472,0.0014577258,0.00033299343,0.000041012754,0.000017627,0.0001942284,0.00031937336,0.0005892487],"category_scores_gemma":[0.0005719265,0.00012654747,0.00013115942,0.00019011009,0.00009883747,0.0002735873,0.000020050336,0.0004456364,0.000038611743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078397174,0.00028349683,0.6502827,0.0000040765485,0.00007145711,0.0000067083274,0.00034138383,0.00071062054,0.000007830101,0.00024357575,0.0029666773,0.34429753],"study_design_scores_gemma":[0.0020486063,0.0010550149,0.6388029,0.000030927367,0.000007883067,0.0000056015906,0.000026732372,0.00092033355,0.000027556536,0.00046344503,0.35650313,0.00010789587],"about_ca_topic_score_codex":0.20000224,"about_ca_topic_score_gemma":0.7019577,"teacher_disagreement_score":0.5019555,"about_ca_system_score_codex":0.00088759966,"about_ca_system_score_gemma":0.0019968762,"threshold_uncertainty_score":0.80532503},"labels":[],"label_agreement":null},{"id":"W2281851327","doi":"10.1200/jco.2006.24.18_suppl.5026","title":"Phase II study of exemestane (E) in refractory ovarian cancer (ROC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; Chemotherapy; Clinical endpoint; Taxane; Phases of clinical research; Gastroenterology; Surgery; Cancer; Oncology; Breast cancer; Clinical trial","score_opus":0.13074082257249003,"score_gpt":0.5139407353670817,"score_spread":0.3831999127945917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281851327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989902,0.0012130612,0.000008616587,0.0051420797,0.00094659283,0.00030767065,0.0000041251396,0.0000037961834,0.0024720372],"genre_scores_gemma":[0.9965573,0.00088143896,0.00058550714,0.00052242633,0.0011152123,0.000013187382,0.0000014131779,0.000013204721,0.0003102968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963501,0.0002813535,0.0026713994,0.00017951765,0.0003362642,0.00018133504],"domain_scores_gemma":[0.9968875,0.0007761406,0.001664852,0.00019717755,0.00029626212,0.00017803731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001675688,0.00012126209,0.0015600497,0.00016591212,0.000024477697,0.0000027069182,0.000103258935,0.0002185532,0.00036690762],"category_scores_gemma":[0.0004389888,0.00008419356,0.0002595851,0.00018143297,0.00008478283,0.00006775932,0.00003557885,0.0006137301,0.0000024199526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009106567,0.17013988,0.45880657,0.000031645428,0.00063679554,0.003968423,0.00038385598,0.00005033117,0.00021186742,0.00016254172,0.007913462,0.34858805],"study_design_scores_gemma":[0.08241572,0.12423926,0.71679074,0.00017004143,0.0006766905,0.00007979407,0.0002833453,0.000018876923,0.00007062456,0.00019689996,0.074976176,0.000081830134],"about_ca_topic_score_codex":0.0009528833,"about_ca_topic_score_gemma":0.0016220602,"teacher_disagreement_score":0.34850624,"about_ca_system_score_codex":0.00033358333,"about_ca_system_score_gemma":0.0015159731,"threshold_uncertainty_score":0.4017381},"labels":[],"label_agreement":null},{"id":"W2281953817","doi":"10.1200/jco.2005.23.16_suppl.9555","title":"The protective role of erythropoietin against doxorubicin-induced cardiomyopathy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Erythropoietin; Medicine; Apoptosis; Doxorubicin; LY294002; Pharmacology; PI3K/AKT/mTOR pathway; Protein kinase B; Internal medicine; Endocrinology; Chemotherapy; Biology; Biochemistry","score_opus":0.05998803803123118,"score_gpt":0.4186555670772213,"score_spread":0.3586675290459901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281953817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93270177,0.001718439,0.000027728178,0.043765407,0.00072097284,0.00040322414,0.0000017524817,0.000011483173,0.020649243],"genre_scores_gemma":[0.99212956,0.0013454485,0.0029549943,0.0009981352,0.0022217296,0.0000072138546,7.2904544e-7,0.000018725745,0.00032345808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962919,0.00052575633,0.0022879888,0.00017270132,0.00045373052,0.00026795195],"domain_scores_gemma":[0.9953981,0.0014844743,0.0018852651,0.00029140132,0.00064664596,0.00029409368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035311126,0.00016004412,0.001411884,0.000071902854,0.00009705403,0.000006716564,0.00019155318,0.00034500385,0.00004644183],"category_scores_gemma":[0.0026302815,0.00008549425,0.000854325,0.00013773156,0.00037921075,0.000060091006,0.00006002545,0.001101212,0.00003321988],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003920899,0.0025843969,0.010835715,0.000023882436,0.00089590147,0.0002930595,0.00045952355,0.000023152434,0.01277629,0.00032787936,0.004633013,0.96322626],"study_design_scores_gemma":[0.020243624,0.039329026,0.09212915,0.00038019955,0.0010179116,0.0011361466,0.004564429,0.00013304666,0.033992626,0.0010143354,0.80580145,0.0002580343],"about_ca_topic_score_codex":0.000016786766,"about_ca_topic_score_gemma":0.000030471676,"teacher_disagreement_score":0.96296823,"about_ca_system_score_codex":0.00022395159,"about_ca_system_score_gemma":0.0013370712,"threshold_uncertainty_score":0.47842795},"labels":[],"label_agreement":null},{"id":"W2281990109","doi":"10.1200/jco.2007.25.18_suppl.11053","title":"Adjuvant hormonal therapy (AHT) in women with early stage breast cancer (BC).","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Letrozole; Stage (stratigraphy); Breast cancer; Tamoxifen; Anastrozole; Internal medicine; Cancer; Hormonal therapy; Retrospective cohort study; Adjuvant therapy; Surgery","score_opus":0.045092028922631,"score_gpt":0.4123026134591799,"score_spread":0.3672105845365489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281990109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952427,0.0013748736,0.00009200899,0.0021140564,0.00036280937,0.000092126946,0.000020744386,0.0000028624356,0.00069779373],"genre_scores_gemma":[0.9927734,0.0038999452,0.0004980709,0.0015189301,0.0011324033,0.000009969361,0.0000015998559,0.000018834671,0.00014683901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979601,0.00014947246,0.001067724,0.00022263538,0.0002280917,0.00037197827],"domain_scores_gemma":[0.9983491,0.00021742743,0.0008054222,0.00015127267,0.00025784547,0.0002189619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017875342,0.00016425466,0.00071823195,0.000069855414,0.000032294138,0.000006944032,0.00020039525,0.00026585287,0.000078752484],"category_scores_gemma":[0.00009617615,0.00010640566,0.00013958944,0.000105171406,0.00023219164,0.000009848145,0.00005509132,0.0004095481,0.000003183498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033278737,0.00112807,0.66034603,0.000004672609,0.00067724905,0.00037875687,0.00022578936,0.000039385774,0.0014022897,0.000015798734,0.0007756571,0.30172756],"study_design_scores_gemma":[0.0075096413,0.006219926,0.94393575,0.000023569446,0.000023089166,0.00012069555,0.00022463409,6.985549e-7,0.0004460441,0.000034088862,0.041340206,0.000121670324],"about_ca_topic_score_codex":0.00027148754,"about_ca_topic_score_gemma":0.0011249698,"teacher_disagreement_score":0.3016059,"about_ca_system_score_codex":0.0001755719,"about_ca_system_score_gemma":0.00088439224,"threshold_uncertainty_score":0.43390968},"labels":[],"label_agreement":null},{"id":"W2282179321","doi":"10.1200/jco.2013.31.15_suppl.2002","title":"Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temozolomide; Bevacizumab; Glioblastoma; Internal medicine; Oncology; Nuclear medicine; Radiation therapy; Chemotherapy","score_opus":0.07252561260517967,"score_gpt":0.4693601163359318,"score_spread":0.39683450373075213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282179321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843331,0.00044864506,0.000028013306,0.012827339,0.0005009626,0.0017173031,0.000010588402,0.000005632547,0.00012840627],"genre_scores_gemma":[0.9943185,0.00039766514,0.003118891,0.0017151273,0.00030179883,0.00011212042,0.0000034782213,0.000024460813,0.000007969392],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99211514,0.0028029524,0.0036932672,0.0003176199,0.00074870605,0.00032232102],"domain_scores_gemma":[0.98462594,0.011918171,0.00246078,0.0003918095,0.00030855977,0.0002947306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006568049,0.00027816492,0.0025478953,0.00062046933,0.000034977493,0.000018225672,0.0002643451,0.00034647045,0.00031511867],"category_scores_gemma":[0.0032371948,0.00016432024,0.00045765916,0.00037976814,0.0003115651,0.00011745628,0.000040615934,0.00094614155,0.0000015428301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8608707,0.026733294,0.01727377,0.00007194426,0.0003271259,0.005307412,0.0004287649,0.00024441158,0.0053491155,0.00004183838,0.0032836804,0.080067895],"study_design_scores_gemma":[0.5500656,0.111556746,0.32065943,0.0007549978,0.0002343367,0.00019952268,0.000305218,0.013680175,0.0007665995,0.00006291172,0.0015769091,0.00013759395],"about_ca_topic_score_codex":0.00015323098,"about_ca_topic_score_gemma":0.000119943244,"teacher_disagreement_score":0.3108052,"about_ca_system_score_codex":0.0005192102,"about_ca_system_score_gemma":0.0022808658,"threshold_uncertainty_score":0.6700785},"labels":[],"label_agreement":null},{"id":"W2282244000","doi":"10.1200/jco.2015.33.3_suppl.447","title":"A retrospective review of the University Health Network (UHN) multimodal treatment experience with extended resection of pancreatic ductal adenocarcinoma (PDAC) in patients with arterial involvement.","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; University of British Columbia; University of Toronto; Toronto General Hospital; McMaster University","funders":"","keywords":"Medicine; Neoadjuvant therapy; Surgery; Retrospective cohort study; Adenocarcinoma; Cohort; Cancer; Internal medicine; Breast cancer","score_opus":0.15804455150189592,"score_gpt":0.47294563536675915,"score_spread":0.31490108386486326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282244000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1534577,0.8420769,0.000017857421,0.00041206807,0.0004867472,0.003125248,0.000027088978,0.00000379841,0.00039256524],"genre_scores_gemma":[0.014067608,0.9837391,0.0014996269,0.00012546408,0.0004055617,0.000016659125,0.000017362512,0.000022426802,0.00010623446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923602,0.0029784064,0.0030779862,0.00034756478,0.0008716277,0.00036423135],"domain_scores_gemma":[0.9912437,0.0007502663,0.0060592126,0.00048452246,0.0011046716,0.0003576243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036679814,0.00031187534,0.0078080986,0.0001818571,0.000058795384,0.0000022706186,0.0003218849,0.00042829354,0.00006891444],"category_scores_gemma":[0.0012213391,0.00015296538,0.00062044,0.00067812426,0.000790779,0.00008440109,0.00009882682,0.001115867,0.000001399682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019604241,0.0053392285,0.8502255,0.014867455,0.0023854093,0.00031368033,0.000538968,0.0000013487204,8.5596504e-8,0.000033384655,0.0010401387,0.10565053],"study_design_scores_gemma":[0.020120176,0.11443289,0.7079368,0.09355801,0.004972062,0.0002411607,0.00027351442,0.000007192798,1.0701724e-7,0.000021621354,0.05825802,0.00017839261],"about_ca_topic_score_codex":0.00020267013,"about_ca_topic_score_gemma":0.00025969397,"teacher_disagreement_score":0.14228868,"about_ca_system_score_codex":0.0024707087,"about_ca_system_score_gemma":0.013586931,"threshold_uncertainty_score":0.9920051},"labels":[],"label_agreement":null},{"id":"W2282340687","doi":"10.1200/jco.2009.27.15_suppl.5098","title":"Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Sorafenib; Temsirolimus; Everolimus; Bevacizumab; Internal medicine; Targeted therapy; Renal cell carcinoma; Oncology; Axitinib; Population; Cancer; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.14372453274965388,"score_gpt":0.4492427574818181,"score_spread":0.30551822473216417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282340687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849582,0.0058405953,0.000030142248,0.0071351253,0.00059987156,0.00034242668,0.0000015520417,0.0000059813497,0.0010861582],"genre_scores_gemma":[0.9886316,0.0019542275,0.0063924943,0.0022763878,0.0006586114,0.0000030340452,0.0000061487763,0.000019570041,0.00005793975],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994544,0.00086001545,0.0033687064,0.00025209007,0.0006244558,0.0003506968],"domain_scores_gemma":[0.99515235,0.0015713848,0.0020672001,0.00029835277,0.00048188912,0.0004288316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025486092,0.00024369684,0.002317592,0.0003472004,0.000023636216,0.00002549046,0.00025295714,0.00035693578,0.00023596353],"category_scores_gemma":[0.000741711,0.00016614638,0.0008193887,0.00029404036,0.00018444275,0.00050153845,0.000028732658,0.0012125706,0.0000134931715],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035652675,0.016671997,0.0820158,0.00012323876,0.0007623337,0.02069533,0.0015644259,0.000107687345,0.039176833,0.00013473662,0.004005387,0.79908955],"study_design_scores_gemma":[0.035409465,0.103940494,0.8204574,0.00025473916,0.00060598744,0.0011040403,0.0013140826,0.00006462157,0.027363265,0.0014614197,0.007798836,0.00022565985],"about_ca_topic_score_codex":0.000025904048,"about_ca_topic_score_gemma":0.000029914461,"teacher_disagreement_score":0.7988639,"about_ca_system_score_codex":0.00022043698,"about_ca_system_score_gemma":0.0018556501,"threshold_uncertainty_score":0.6775253},"labels":[],"label_agreement":null},{"id":"W2282391237","doi":"10.1200/jco.2007.25.18_suppl.3576","title":"A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Capecitabine; Tolerability; Vomiting; Gastroenterology; Internal medicine; Vorinostat; Toxicity; Pharmacology; Adverse effect; Colorectal cancer; Cancer; Histone deacetylase","score_opus":0.03325700206045453,"score_gpt":0.4390823767019945,"score_spread":0.40582537464154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282391237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886006,0.000051595056,0.00014410105,0.00009066728,0.00014848856,0.0004171756,0.0000023342016,0.0000013164778,0.00028424355],"genre_scores_gemma":[0.99894696,0.000028963015,0.0007936473,0.00005860216,0.0001034085,0.000005263169,0.000008380225,0.000017294791,0.000037501646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967116,0.0003946306,0.0019251882,0.000238157,0.00045014647,0.0002802937],"domain_scores_gemma":[0.997551,0.00028078633,0.0011692347,0.0001964921,0.00063273986,0.00016972543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028194105,0.00013281191,0.0008177448,0.0002643415,0.000018237346,0.0000034144807,0.0002061262,0.00019396479,0.000006719092],"category_scores_gemma":[0.0012285671,0.00009693561,0.00007494685,0.000290536,0.00017711413,0.000015298296,0.000057029585,0.0006051835,0.0000010745961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06035691,0.0697112,0.7336031,0.000031213287,0.00016581234,0.0009556566,0.00061993545,0.00068868796,0.0102510145,0.00000833412,0.00018928529,0.1234188],"study_design_scores_gemma":[0.12699573,0.32461864,0.52954286,0.00013172302,0.00003917954,0.000044880915,0.0011993558,0.000058833604,0.015314379,0.0000124922135,0.0018146454,0.00022724805],"about_ca_topic_score_codex":0.00003954151,"about_ca_topic_score_gemma":0.00216998,"teacher_disagreement_score":0.25490746,"about_ca_system_score_codex":0.00010500136,"about_ca_system_score_gemma":0.0006105698,"threshold_uncertainty_score":0.39529192},"labels":[],"label_agreement":null},{"id":"W2282452816","doi":"10.1200/jco.2009.27.15_suppl.3579","title":"A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Clinical endpoint; Adverse effect; Internal medicine; Phases of clinical research; Randomized controlled trial; Myeloid leukemia; Gastroenterology; Clinical trial; Surgery","score_opus":0.03596982520855698,"score_gpt":0.393713692261301,"score_spread":0.357743867052744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282452816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942492,0.00020377879,0.000111193556,0.0030737533,0.00027754984,0.0010417766,0.0000051584157,0.000010351177,0.0010272006],"genre_scores_gemma":[0.99317044,0.00090779504,0.0039958498,0.0009852361,0.000701156,0.0000040930163,0.000008498848,0.000024843137,0.00020208077],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99456286,0.00067747774,0.0032585799,0.00031648562,0.0007328918,0.00045170236],"domain_scores_gemma":[0.9949969,0.0015537498,0.0018911263,0.00027587079,0.00076185475,0.00052050856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037606484,0.00023109964,0.0023276026,0.00035288106,0.00004051715,0.000011869512,0.00021357038,0.00063818076,0.000052507494],"category_scores_gemma":[0.0032833791,0.00015061171,0.00027410494,0.00044540406,0.00032648072,0.00021845393,0.00007852823,0.001955181,0.0000053331364],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5895244,0.003834832,0.18873933,0.00007950297,0.00092891173,0.0017818725,0.00042110815,0.000026631258,0.00064974,0.00006339934,0.0015559671,0.21239433],"study_design_scores_gemma":[0.38189277,0.07577841,0.53500116,0.00072422816,0.0006122586,0.00034650942,0.00008806554,0.00030244055,0.00020221765,0.00010029071,0.0047551193,0.00019652849],"about_ca_topic_score_codex":0.000034041317,"about_ca_topic_score_gemma":0.000042173422,"teacher_disagreement_score":0.34626183,"about_ca_system_score_codex":0.0012515456,"about_ca_system_score_gemma":0.0061347364,"threshold_uncertainty_score":0.99949956},"labels":[],"label_agreement":null},{"id":"W2282505148","doi":"10.1200/jco.2015.65.2438","title":"Reply to T.J. Kruser et al","year":2016,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.147593596821745,"score_gpt":0.49916361450473284,"score_spread":0.35157001768298785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282505148","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024515003,0.0028078728,0.00009920591,0.9371506,0.025908154,0.0004586757,0.000045333207,0.000010774138,0.009004357],"genre_scores_gemma":[0.0058392007,0.0051043285,0.0030140327,0.9454989,0.035712916,0.000020199075,0.000009747398,0.000085827756,0.00471487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887953,0.002143763,0.0064510317,0.0006340965,0.0010483472,0.00092749554],"domain_scores_gemma":[0.9759477,0.015912596,0.004821225,0.00071593624,0.0011153667,0.001487218],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.008839724,0.00054198824,0.004917013,0.00040965577,0.000057585763,0.000029947118,0.00054217613,0.0018685719,0.0036960095],"category_scores_gemma":[0.012642931,0.00031814753,0.0023645754,0.00019138126,0.00041037085,0.00014852347,0.00021910232,0.004698522,0.0031195274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015004424,0.002188846,0.020603077,0.00003359545,0.0019748234,0.025975103,0.00004907765,0.0000031755962,0.00005757651,0.00020073618,0.7554533,0.19196026],"study_design_scores_gemma":[0.012596206,0.029229516,0.046217836,0.001903892,0.0017684625,0.001505197,0.000018407296,0.0000018323982,0.00005939288,0.0003172793,0.90610677,0.00027518117],"about_ca_topic_score_codex":0.00005457296,"about_ca_topic_score_gemma":0.000026443198,"teacher_disagreement_score":0.19168508,"about_ca_system_score_codex":0.0008702407,"about_ca_system_score_gemma":0.004139514,"threshold_uncertainty_score":0.99992704},"labels":[],"label_agreement":null},{"id":"W2282592010","doi":"10.1200/jco.2006.24.18_suppl.6065","title":"Agreement between physicians and patients about what constitutes shared decision making","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Deliberation; Family medicine; Patient participation; Medical decision making; Information exchange; Decision aids; MEDLINE; Alternative medicine; Pathology","score_opus":0.3696672425076418,"score_gpt":0.5680799426696944,"score_spread":0.1984127001620526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282592010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820349,0.0035506212,0.00044754575,0.0064966786,0.004144151,0.0006496618,0.000024855224,0.000018256984,0.0026333067],"genre_scores_gemma":[0.9823723,0.001071188,0.011141758,0.0038916797,0.0014291481,0.000016071288,0.000016030592,0.000015482692,0.000046372614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925871,0.001959078,0.0043848185,0.0002188335,0.00047232694,0.00037785817],"domain_scores_gemma":[0.97867143,0.015011582,0.004539217,0.00037359667,0.0012022076,0.00020198242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019582582,0.00015100965,0.0011259518,0.00013896608,0.0004573834,0.000023654216,0.00041995413,0.00049626187,0.0001364348],"category_scores_gemma":[0.0041213636,0.00012177452,0.0001969802,0.00013718376,0.00026448898,0.00061660365,0.00031547382,0.0016214288,0.00006108894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024502317,0.0002655589,0.667332,0.000040056057,0.000036140464,0.000006294274,0.00050573,0.0000058125406,0.0000010837302,0.0002547914,0.006907466,0.32440004],"study_design_scores_gemma":[0.0039475956,0.001392397,0.897957,0.001767334,0.00007629187,0.0000015593142,0.0015763377,0.000046190806,0.0000010144464,0.0045708125,0.08855389,0.00010953004],"about_ca_topic_score_codex":0.00008044236,"about_ca_topic_score_gemma":0.00027687673,"teacher_disagreement_score":0.3242905,"about_ca_system_score_codex":0.00030682073,"about_ca_system_score_gemma":0.0010966455,"threshold_uncertainty_score":0.7044391},"labels":[],"label_agreement":null},{"id":"W2283426841","doi":"10.1200/jco.2012.30.27_suppl.14","title":"Outcomes of an organized breast cancer screening program over the past 15 years.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Demography; Breast cancer; Mammography; Population; Breast cancer screening; Inflation (cosmology); Cancer; Gerontology; Environmental health","score_opus":0.2158035783298749,"score_gpt":0.5340100328475877,"score_spread":0.31820645451771284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283426841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99153954,0.0005730928,0.000058023732,0.0061655953,0.0009162676,0.00017649632,0.000005869237,0.000011418894,0.0005536947],"genre_scores_gemma":[0.987103,0.00013873166,0.0062691304,0.0036576665,0.0027370204,0.000003801481,0.0000010312696,0.000014949781,0.0000746709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972555,0.00029853912,0.0015227484,0.00010368945,0.0005191957,0.00030035063],"domain_scores_gemma":[0.9968079,0.00070833554,0.0014243077,0.00020573707,0.0004442701,0.0004094753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034637433,0.00011075831,0.0011241025,0.000057316374,0.00003554603,0.000008655802,0.00024276371,0.00023803455,0.0005322678],"category_scores_gemma":[0.0009896364,0.00006075615,0.0003837917,0.00018936458,0.00022868623,0.0002620836,0.000065273925,0.00079573697,0.000006604293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012561097,0.0006061132,0.73206216,0.00000642195,0.00025311828,0.000048589794,0.00010829217,0.000004241106,0.00004081205,0.00002674283,0.0024725469,0.26311487],"study_design_scores_gemma":[0.0035810135,0.002644821,0.96166325,0.00007288325,0.00041924976,0.0004692409,0.0003030104,0.00002859619,0.00001307802,0.000023988763,0.030718988,0.00006190509],"about_ca_topic_score_codex":0.0001881093,"about_ca_topic_score_gemma":0.00006962286,"teacher_disagreement_score":0.26305297,"about_ca_system_score_codex":0.00007458934,"about_ca_system_score_gemma":0.00060462195,"threshold_uncertainty_score":0.5827959},"labels":[],"label_agreement":null},{"id":"W2283549843","doi":"10.1200/jco.2007.25.18_suppl.3527","title":"Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Nausea; Cmax; Rash; Internal medicine; Adverse effect; Vomiting; Gastroenterology; Constipation; Pharmacokinetics; Oncology","score_opus":0.07873978654957317,"score_gpt":0.49693701003246216,"score_spread":0.418197223482889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283549843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781513,0.00006426574,0.00009777136,0.0003916178,0.000343015,0.0007933355,0.0000016156879,0.0000064184574,0.00048680927],"genre_scores_gemma":[0.9971653,0.000045829107,0.0019340762,0.00037938473,0.0003579404,0.0000044050207,0.0000026012792,0.000030147878,0.00008031548],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934444,0.00060732727,0.0039444095,0.00031040306,0.0012407444,0.00045272085],"domain_scores_gemma":[0.9939022,0.0020994798,0.0019203118,0.00031176384,0.0010410944,0.0007251306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053502405,0.00019631613,0.00197526,0.0005421281,0.000031236865,0.000004821101,0.00023985207,0.00030702946,0.00010111213],"category_scores_gemma":[0.0059657013,0.00013194678,0.00027445587,0.00048730953,0.00024359382,0.00011982748,0.0001234241,0.0016799158,0.000012577825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09646694,0.09531361,0.39375815,0.00006817579,0.00016322068,0.007084965,0.00039491904,0.00004293886,0.005056677,0.000004279651,0.0005713257,0.4010748],"study_design_scores_gemma":[0.12943578,0.33787262,0.5233128,0.00039508092,0.00016114936,0.00009714171,0.0013361187,0.00010613787,0.004743893,0.000021911308,0.0023621535,0.0001552009],"about_ca_topic_score_codex":0.000018933666,"about_ca_topic_score_gemma":0.00013058257,"teacher_disagreement_score":0.4009196,"about_ca_system_score_codex":0.00030714352,"about_ca_system_score_gemma":0.0012485337,"threshold_uncertainty_score":0.72984916},"labels":[],"label_agreement":null},{"id":"W2283712724","doi":"10.1200/jco.2015.33.3_suppl.439","title":"Phase III study of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; BC Cancer Agency; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Regional Health Centre; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Gastroenterology; Subgroup analysis; Surgery; Urology; Randomized controlled trial; Chemotherapy; Confidence interval","score_opus":0.1065864754308413,"score_gpt":0.3965711963184914,"score_spread":0.28998472088765015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283712724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650306,0.0012847815,0.000058297,0.0003478523,0.0007328277,0.00066281646,0.00021305327,0.0000013348237,0.00019595967],"genre_scores_gemma":[0.99823284,0.0004436936,0.00042936913,0.00037165786,0.0003627796,0.00001346729,0.00010418793,0.00002481135,0.00001719497],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99525267,0.0008200772,0.0027180668,0.00035935213,0.00048545207,0.00036436282],"domain_scores_gemma":[0.99392045,0.0017272801,0.0024520922,0.00060021324,0.000726421,0.00057355966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027338816,0.000259593,0.0021705271,0.00044363635,0.00004078556,0.000017088892,0.0005456351,0.00024705078,0.0000279156],"category_scores_gemma":[0.0036542036,0.000176971,0.00045915943,0.0008372499,0.00024006971,0.000016159282,0.000112399095,0.0004389035,0.0000012908545],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40840498,0.019509709,0.53393596,0.000021903092,0.015493139,0.00033325274,0.0019331531,0.0051357974,0.00032125393,0.000023937822,0.0059847976,0.008902121],"study_design_scores_gemma":[0.5394441,0.13955978,0.30179107,0.000043710024,0.010231266,0.0000059730273,0.0034365465,0.00038550975,0.00016466921,0.00006492421,0.0045016133,0.00037082378],"about_ca_topic_score_codex":0.052060675,"about_ca_topic_score_gemma":0.26161098,"teacher_disagreement_score":0.23214489,"about_ca_system_score_codex":0.00024703617,"about_ca_system_score_gemma":0.0028785693,"threshold_uncertainty_score":0.9542517},"labels":[],"label_agreement":null},{"id":"W2283838201","doi":"10.1200/jco.2009.27.15_suppl.e14514","title":"Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Chills; Gastroenterology; Internal medicine; Nausea; Phases of clinical research; Adverse effect; Progressive disease; Clinical endpoint; Chemotherapy; Surgery; Oncology; Clinical trial","score_opus":0.06084854402511377,"score_gpt":0.48337296793723744,"score_spread":0.4225244239121237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283838201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941159,0.000091296126,0.000052919957,0.0043775695,0.000121252735,0.0012044453,0.0000031025695,0.000002395179,0.00003114877],"genre_scores_gemma":[0.9968527,0.00027492523,0.0016670722,0.0011029927,0.00007312839,0.000012149453,0.000003620284,0.00000658149,0.0000068111985],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99473846,0.0021271578,0.0021800476,0.00022545476,0.00041349974,0.00031538328],"domain_scores_gemma":[0.99722195,0.0009129644,0.0010298184,0.00019669464,0.0004142825,0.00022428922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00515567,0.00014076749,0.0017434665,0.00023293018,0.0000199355,0.0000017423396,0.00020386877,0.00012166938,0.0000057775237],"category_scores_gemma":[0.006123893,0.00006896827,0.000116633695,0.00039916334,0.0002922927,0.0000761765,0.000028572907,0.00085367844,2.4584756e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3854242,0.030632699,0.3426392,0.000027615299,0.00019914725,0.00064351456,0.00071658636,0.00058410055,0.0024150792,0.0000087099925,0.00032070035,0.23638844],"study_design_scores_gemma":[0.08356137,0.38711664,0.52863675,0.00026070484,0.000027694945,0.000016430693,0.000099876175,0.000097380165,0.00007251132,0.000032495576,0.0000439337,0.000034246965],"about_ca_topic_score_codex":0.0000912573,"about_ca_topic_score_gemma":0.000441971,"teacher_disagreement_score":0.35648394,"about_ca_system_score_codex":0.00030534543,"about_ca_system_score_gemma":0.0006634706,"threshold_uncertainty_score":0.73313147},"labels":[],"label_agreement":null},{"id":"W2283893450","doi":"10.1200/jco.2012.30.5_suppl.46","title":"Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Internal medicine; Cancer; Oncology; Prospective cohort study; Urology; Cohort; Androgen; Hormone","score_opus":0.21067304210148521,"score_gpt":0.5605945311655919,"score_spread":0.3499214890641067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283893450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988214,0.0054497593,0.000002650957,0.004529659,0.00073334854,0.0005909958,0.000036219586,0.0000063408906,0.00043698968],"genre_scores_gemma":[0.99543434,0.0023194728,0.0007960343,0.00021545611,0.00062440074,0.000029834977,0.000009333619,0.000023433271,0.0005477149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966409,0.00038308953,0.0017435781,0.00018501325,0.00056597235,0.00048143064],"domain_scores_gemma":[0.9960417,0.0010791727,0.001310867,0.00023805545,0.0003633992,0.0009667943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001846357,0.00018766269,0.0013099324,0.00022542114,0.000030208674,0.000004560446,0.00014637638,0.00021824094,0.00017304912],"category_scores_gemma":[0.0019110448,0.00010266397,0.0003848878,0.00022526892,0.00024971468,0.00026261373,0.00007726817,0.00094738713,0.0000088172055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04359796,0.004832605,0.71407115,0.00008859179,0.00013770438,0.00032067776,0.0001649804,0.000039167917,0.0020542992,0.0000032205257,0.0012971255,0.23339249],"study_design_scores_gemma":[0.016769644,0.025603889,0.9524324,0.0014283488,0.00013719924,0.00004864549,0.00004885045,0.000027255524,0.0012219559,0.000048710863,0.0021390712,0.0000940118],"about_ca_topic_score_codex":0.000022854849,"about_ca_topic_score_gemma":0.000008223099,"teacher_disagreement_score":0.23836124,"about_ca_system_score_codex":0.0004987201,"about_ca_system_score_gemma":0.0025491728,"threshold_uncertainty_score":0.45221233},"labels":[],"label_agreement":null},{"id":"W2284289551","doi":"10.1200/jco.2006.24.18_suppl.14626","title":"The effect of androgen deprivation therapy (ADT) on cognition in men with prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Cognition; Oncology; Population; Neuropsychology; Cancer; Internal medicine; Radiation therapy; Psychiatry","score_opus":0.042498022441985576,"score_gpt":0.43339518536787797,"score_spread":0.3908971629258924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284289551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879547,0.00091883057,0.000010473099,0.0061346195,0.00020001802,0.00058849686,0.0000025205968,0.000004289659,0.004186079],"genre_scores_gemma":[0.99553376,0.0034536098,0.000034545516,0.00039960764,0.00040424947,0.000030839325,0.00000198035,0.000010375858,0.0001310348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794793,0.00040479493,0.0011154176,0.00010354988,0.0002857238,0.00014255993],"domain_scores_gemma":[0.9954663,0.0029093742,0.0011797132,0.000070668255,0.00032449485,0.00004944665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021493537,0.00009855043,0.00072362577,0.00008436989,0.00004048705,0.0000036264048,0.00005080722,0.000122965,0.000014634579],"category_scores_gemma":[0.00070483796,0.000047428333,0.00013577878,0.00014994452,0.00022057576,0.000050252285,0.000010911278,0.0005022866,0.0000020189095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07556247,0.0006238331,0.6545373,0.000021212527,0.0005108582,0.000095019335,0.000065871725,0.00011089557,0.0003482171,0.000013346807,0.002818533,0.2652924],"study_design_scores_gemma":[0.028426584,0.051008645,0.9061287,0.0003921024,0.00027880256,0.000049459068,0.00006186102,0.00004320362,0.004860152,0.00025291828,0.00843706,0.000060502127],"about_ca_topic_score_codex":0.00006855376,"about_ca_topic_score_gemma":0.00017601823,"teacher_disagreement_score":0.2652319,"about_ca_system_score_codex":0.00015235785,"about_ca_system_score_gemma":0.00042657385,"threshold_uncertainty_score":0.21822134},"labels":[],"label_agreement":null},{"id":"W2284852360","doi":"10.1200/jco.2007.25.18_suppl.7555","title":"Number of lymph nodes harvested from a mediastinal lymphadenectomy: Results of the randomized, prospective ACOSOG Z0030 trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lymphadenectomy; Lymph node; Lymph; Mediastinal lymph node; Adenocarcinoma; Stage (stratigraphy); Lung cancer; Surgery; Cancer; Oncology; Internal medicine; Metastasis; Pathology","score_opus":0.07245749585521973,"score_gpt":0.46312309562623233,"score_spread":0.3906655997710126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284852360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98752475,0.00039990444,0.00007503077,0.004046778,0.002637639,0.00079151907,0.000032427735,0.000005344666,0.0044866325],"genre_scores_gemma":[0.9940661,0.00049613434,0.0025494092,0.0005033313,0.0021824148,0.000013240156,0.0000030906097,0.00001563152,0.00017065209],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99359924,0.0008546276,0.0043989387,0.00022920687,0.00069322484,0.00022476522],"domain_scores_gemma":[0.97845083,0.015707297,0.0043854844,0.0003151935,0.0008690715,0.00027210888],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0074145254,0.0001757499,0.0031047538,0.00007407696,0.000030280315,0.0000051435386,0.00023573931,0.0003769564,0.000118626376],"category_scores_gemma":[0.01738533,0.00008923626,0.0013821757,0.00020782385,0.0006722366,0.000077515215,0.00006918759,0.0004254106,0.000005903311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79406685,0.004098816,0.18709514,0.000021040041,0.0018263685,0.00018693485,0.0002648286,0.0000042359957,0.000060401846,0.00015970624,0.0006842676,0.011531422],"study_design_scores_gemma":[0.57884437,0.0026335707,0.41383055,0.00033387798,0.0015456945,0.000093815404,0.00007383662,0.000010018733,0.0013345919,0.0006034071,0.00064526557,0.000050978935],"about_ca_topic_score_codex":0.0004218555,"about_ca_topic_score_gemma":0.00019504831,"teacher_disagreement_score":0.22673541,"about_ca_system_score_codex":0.00044140103,"about_ca_system_score_gemma":0.0025552555,"threshold_uncertainty_score":0.99089164},"labels":[],"label_agreement":null},{"id":"W2284997115","doi":"10.1200/jco.2008.26.15_suppl.6528","title":"A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cetuximab; Medicine; Colorectal cancer; Internal medicine; Oncology; Randomization; Randomized controlled trial; Cancer","score_opus":0.5921651819707295,"score_gpt":0.5854382782549227,"score_spread":0.0067269037158068645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284997115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216986,0.00085386744,0.00061105535,0.0015699733,0.001219968,0.001784074,0.0015762848,0.0000027152098,0.00021218549],"genre_scores_gemma":[0.9971847,0.00048461094,0.0009471325,0.00075673376,0.00042220356,0.00014843092,0.000024352585,0.000015341351,0.00001651796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9889507,0.0015845392,0.008799765,0.00033792233,0.00011087381,0.00021619345],"domain_scores_gemma":[0.95454335,0.0315221,0.013206807,0.00019758752,0.00037168094,0.0001584998],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027850684,0.00015560929,0.0042584655,0.0002967244,0.000097151875,0.000010637643,0.0002917029,0.00021314455,0.0001469564],"category_scores_gemma":[0.014514669,0.00013233566,0.00078269147,0.00018373772,0.00042317758,0.00023794107,0.00003990784,0.0003117782,0.000008483468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025181958,0.001584443,0.95950466,0.00009371814,0.006060514,0.0000017833586,0.0011166582,0.0009949094,0.0000030930366,0.0017128243,0.0027265195,0.001018897],"study_design_scores_gemma":[0.046108685,0.005378339,0.93794626,0.000044758704,0.00074572535,0.0000023470047,0.00021600633,0.002904708,0.000022029395,0.003794817,0.002697636,0.00013868246],"about_ca_topic_score_codex":0.0011605454,"about_ca_topic_score_gemma":0.00077548495,"teacher_disagreement_score":0.03440738,"about_ca_system_score_codex":0.0006449832,"about_ca_system_score_gemma":0.0013338409,"threshold_uncertainty_score":0.9937865},"labels":[],"label_agreement":null},{"id":"W2285196294","doi":"10.1200/jco.2007.25.18_suppl.7708","title":"Impact of induction chemotherapy and adjuvant radiation therapy on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Gemcitabine; Pemetrexed; Induction chemotherapy; Chemotherapy; Vinorelbine; Cisplatin; Mesothelioma; Pneumonectomy; Radiation therapy; Surgery; Oncology; Lung cancer; Pathology","score_opus":0.10844276474336613,"score_gpt":0.48222366537517825,"score_spread":0.37378090063181213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285196294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997402,0.00052352133,0.00009004649,0.0013111826,0.00033668708,0.00025573035,0.000013708491,0.0000039541164,0.0000631833],"genre_scores_gemma":[0.99726105,0.0004899598,0.00055478007,0.0010298018,0.00058280653,0.0000039878028,0.000006290581,0.000013985309,0.000057349236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981048,0.00009179719,0.001295375,0.00012279623,0.00023880065,0.00014641308],"domain_scores_gemma":[0.998023,0.0007291006,0.00086053717,0.00008236118,0.00008909088,0.00021593207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001389133,0.000115189745,0.0007040333,0.00013287514,0.000022418477,0.0000032843507,0.000044157987,0.0001717778,0.0000935338],"category_scores_gemma":[0.00033025193,0.00006887914,0.0005192871,0.00005755662,0.00012395481,0.00009007286,0.000006610712,0.00023928913,0.000001762017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032175593,0.0011523587,0.7620978,0.0000116902365,0.00020015903,0.00003217069,0.0000501537,0.000007703101,0.004291496,0.000015039055,0.00015409366,0.19981179],"study_design_scores_gemma":[0.008739235,0.023193112,0.9653891,0.000023803968,0.000099349396,0.000115080074,0.000021687694,0.000033920103,0.00072633335,0.00020512103,0.0013884252,0.000064885346],"about_ca_topic_score_codex":0.000011020104,"about_ca_topic_score_gemma":0.000002830544,"teacher_disagreement_score":0.20329128,"about_ca_system_score_codex":0.00012145058,"about_ca_system_score_gemma":0.00014929535,"threshold_uncertainty_score":0.280881},"labels":[],"label_agreement":null},{"id":"W2285479831","doi":"10.1200/jco.2009.27.15_suppl.11082","title":"Correlation of primary tumor engraftment in immune deficient mice and relapse rate in patients with early-stage non-small cell lung carcinoma (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Immune system; Primary tumor; Lung cancer; Pathology; Cancer; Cancer research; Oncology; Internal medicine; Metastasis; Immunology; Biology","score_opus":0.013338773946015871,"score_gpt":0.2849186322372811,"score_spread":0.27157985829126524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285479831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979847,0.0008629593,0.00018685687,0.00011138245,0.00021456339,0.00021122076,0.0000069269886,4.893174e-7,0.0004208964],"genre_scores_gemma":[0.99816793,0.00042859328,0.0009045673,0.00038339238,0.000066984154,0.0000016475932,0.000011149447,0.000007776288,0.00002797169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982564,0.00014781553,0.0011820578,0.0001674376,0.00009514482,0.00015115876],"domain_scores_gemma":[0.9984422,0.00023119638,0.0009596969,0.00012219997,0.00015502544,0.000089682624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010378354,0.00010273685,0.00050991675,0.00008066223,0.000013053573,0.000005527742,0.000103885206,0.00016948549,0.0000020540062],"category_scores_gemma":[0.00026480388,0.00008466943,0.0000892601,0.00006968064,0.000059320428,0.0000057427847,0.000049418664,0.00030243077,3.6743236e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003947138,0.0015534436,0.98199046,0.000022383874,0.000021150083,0.000064658496,0.000114943745,0.0014485733,0.0062857503,0.000013996047,0.00007419917,0.0044632857],"study_design_scores_gemma":[0.008294069,0.009578286,0.97948277,0.000043794138,0.00003795144,0.0000034959137,0.000031125015,0.0001489638,0.0017123712,0.000015111089,0.0005619311,0.00009010767],"about_ca_topic_score_codex":0.0000475993,"about_ca_topic_score_gemma":0.00008155689,"teacher_disagreement_score":0.0080248425,"about_ca_system_score_codex":0.000083490755,"about_ca_system_score_gemma":0.00052746537,"threshold_uncertainty_score":0.34527192},"labels":[],"label_agreement":null},{"id":"W2285582134","doi":"10.1200/jco.2006.24.18_suppl.7005","title":"An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Placebo; Erlotinib Hydrochloride; Cancer; Gastroenterology; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.11025402821699447,"score_gpt":0.5157098089888925,"score_spread":0.40545578077189803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285582134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621564,0.0007617159,0.000017991972,0.0005654433,0.00047934114,0.0015577418,0.00020674366,5.5028886e-7,0.0001948545],"genre_scores_gemma":[0.99887186,0.00060685986,0.00015000047,0.00008432778,0.00017782376,0.00007849132,0.000015730207,0.0000057704865,0.000009142146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936763,0.0015648038,0.0038208447,0.00017591917,0.0006215957,0.00014055043],"domain_scores_gemma":[0.9870601,0.007548816,0.004531719,0.00017486421,0.00062064367,0.000063848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047104387,0.00012555016,0.0016852737,0.00016741345,0.000027177028,0.0000024858834,0.0001668968,0.00012649554,0.000014254435],"category_scores_gemma":[0.0017019506,0.000060248927,0.0003147763,0.0005626794,0.00027171097,0.00006558745,0.000011719398,0.00025694157,6.579362e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074415654,0.009162172,0.96079504,0.000044429395,0.0023566694,0.000025764264,0.0032410861,0.014536311,0.00003552256,0.000023653973,0.000086903936,0.002250858],"study_design_scores_gemma":[0.024316082,0.012771655,0.94967586,0.000085874635,0.007559978,0.0000022303172,0.0035163786,0.0018827464,0.000034675006,0.000022145077,0.00009259361,0.000039755483],"about_ca_topic_score_codex":0.10721837,"about_ca_topic_score_gemma":0.6863764,"teacher_disagreement_score":0.57915807,"about_ca_system_score_codex":0.00043306383,"about_ca_system_score_gemma":0.0057648052,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W2285761451","doi":"10.1200/jco.2015.65.5860","title":"Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cargill (Canada)","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Adverse effect; Clinical trial; Bacteremia; Myeloid leukemia; Oncology; Antibiotics","score_opus":0.6798991998697116,"score_gpt":0.7018386983777062,"score_spread":0.021939498507994593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285761451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500863,0.00051245006,0.0023037905,0.041118227,0.0037602969,0.0013414779,0.0000298537,0.000009511883,0.0008380729],"genre_scores_gemma":[0.9386215,0.040735044,0.010916381,0.0026458977,0.0057549276,0.000029969126,0.0000020832617,0.000039676288,0.0012544886],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9689299,0.0057894876,0.022275131,0.0005753407,0.001773572,0.0006566111],"domain_scores_gemma":[0.30141038,0.67710495,0.0154308025,0.0009873533,0.0034507792,0.001615743],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.2115293,0.0002285824,0.005138012,0.0003789542,0.00003207293,0.000003766866,0.0006945556,0.002116338,0.0003633509],"category_scores_gemma":[0.70402354,0.00012597999,0.0032449763,0.00029475612,0.00067884865,0.0001610156,0.00025819242,0.0041898754,0.00004362586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05118055,0.0056803552,0.3883166,0.00030597567,0.0013654387,0.00070538186,0.00006891068,0.000013536498,0.0006129349,0.002051967,0.009762595,0.53993577],"study_design_scores_gemma":[0.10230265,0.076305784,0.7015052,0.0011879826,0.0028810385,0.00016072247,0.00020123979,0.000127446,0.0004959446,0.04018093,0.07429135,0.00035970594],"about_ca_topic_score_codex":0.000013139734,"about_ca_topic_score_gemma":0.00007162365,"teacher_disagreement_score":0.67131543,"about_ca_system_score_codex":0.000749368,"about_ca_system_score_gemma":0.017730528,"threshold_uncertainty_score":0.9991791},"labels":[],"label_agreement":null},{"id":"W2285793395","doi":"10.1200/jco.2012.30.27_suppl.51","title":"Estimation of additional MRI resources needed in British Columbia for screening high-risk women for breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; B.C. Women's Hospital & Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Mammography; Family history; Gynecology; Estimation; Population; Breast cancer screening; Breast MRI; Lifetime risk; Family medicine; Demography; Cancer; Obstetrics; Environmental health; Internal medicine","score_opus":0.03756156464595888,"score_gpt":0.4153957006641971,"score_spread":0.37783413601823823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285793395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810512,0.00017327689,0.012053669,0.0053339377,0.00068192615,0.0002699196,0.00038103838,0.0000055944315,0.000049441816],"genre_scores_gemma":[0.91921824,0.0001878049,0.07674566,0.0012312235,0.0023732914,0.000044763245,0.000032430933,0.000017933025,0.0001486394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99755794,0.00018530393,0.0016191715,0.00010940236,0.00024203178,0.00028617962],"domain_scores_gemma":[0.99322665,0.004443098,0.0016471759,0.00006651398,0.00028855202,0.00032799743],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051114326,0.000063227766,0.0009772353,0.000078246136,0.00005731436,0.000017788547,0.00010200548,0.00020998158,0.0006886909],"category_scores_gemma":[0.009159512,0.00007180554,0.00025150215,0.00009673787,0.00016980167,0.00013528,0.000021148322,0.00065903144,4.211181e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014916284,0.00062148087,0.18212229,0.00007864563,0.0001786991,0.000010729824,0.0001613863,0.00086185645,0.000013711558,0.00001267371,0.04718747,0.7672594],"study_design_scores_gemma":[0.011401542,0.0027957337,0.9137633,0.00049544487,0.00021089119,0.0003388313,0.00039188325,0.024216322,0.0000022821596,0.0007383157,0.04556215,0.00008332604],"about_ca_topic_score_codex":0.0020225474,"about_ca_topic_score_gemma":0.0007151294,"teacher_disagreement_score":0.7671761,"about_ca_system_score_codex":0.00014046703,"about_ca_system_score_gemma":0.00045299664,"threshold_uncertainty_score":0.99918675},"labels":[],"label_agreement":null},{"id":"W2285794240","doi":"10.1200/jco.2014.32.4_suppl.111","title":"A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Concordance; Biopsy; Prostate; Hazard ratio; Multivariate analysis; Univariate analysis; Internal medicine; Cohort; Oncology; Prostate biopsy; Univariate; Multivariate statistics; Prostate-specific antigen; Urology; Cancer; Confidence interval; Statistics","score_opus":0.1332415599036091,"score_gpt":0.5188932745661937,"score_spread":0.38565171466258463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285794240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596465,0.00017154383,0.0008553072,0.001374857,0.00014857367,0.0010828185,0.00007057648,0.000008560807,0.00032312862],"genre_scores_gemma":[0.9574718,0.0018057777,0.04028785,0.00012842838,0.00015584812,0.00010690294,0.000014513897,0.000016326007,0.000012548866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993808,0.001394833,0.003895813,0.0003440197,0.00026180458,0.00029558392],"domain_scores_gemma":[0.9872199,0.00794246,0.003533091,0.00021735998,0.000819211,0.00026794805],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010730312,0.00017073493,0.002990004,0.0003633735,0.000025154664,0.000009340989,0.00013941589,0.0002866,0.0000055957357],"category_scores_gemma":[0.011151019,0.000118680175,0.0007959206,0.0004598135,0.00031146893,0.00018855196,0.00003899856,0.0007541732,5.987516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020416234,0.0059333434,0.8509195,0.000036203055,0.0011554651,0.00003685252,0.0005778684,0.0020191453,0.00003774966,0.00003333587,0.000040743766,0.1187936],"study_design_scores_gemma":[0.018945156,0.039061323,0.7318191,0.00009426941,0.00085767236,0.000002941744,0.0004767527,0.20772986,0.00008545915,0.0007390974,0.00010333555,0.000085013155],"about_ca_topic_score_codex":0.00007685824,"about_ca_topic_score_gemma":0.0012138559,"teacher_disagreement_score":0.20571072,"about_ca_system_score_codex":0.00018445277,"about_ca_system_score_gemma":0.00094426255,"threshold_uncertainty_score":0.9971785},"labels":[],"label_agreement":null},{"id":"W2285955673","doi":"10.1200/jco.2007.25.18_suppl.2511","title":"Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ERCC1; Nucleotide excision repair; Single-nucleotide polymorphism; XRCC1; Base excision repair; Hazard ratio; DNA repair; Medicine; Internal medicine; Genotype; Cisplatin; Cancer research; Esophageal cancer; SNP; Oncology; Xeroderma pigmentosum; Proportional hazards model; Cancer; Confidence interval; Biology; Genetics; Gene; Chemotherapy","score_opus":0.06661110890946402,"score_gpt":0.4668430125661221,"score_spread":0.40023190365665806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285955673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281794,0.002387663,0.0001426414,0.0030245848,0.0006483251,0.00032011027,0.000006205787,0.000010401576,0.0006421372],"genre_scores_gemma":[0.9880846,0.0012377313,0.0088603,0.0010434675,0.00058548746,0.0000039493393,0.000001966621,0.000018973735,0.00016351897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703014,0.00016999329,0.0020281237,0.00021903715,0.00033334002,0.00021935167],"domain_scores_gemma":[0.99639106,0.0016817476,0.0011333898,0.0001621321,0.00029209052,0.00033955282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024694637,0.00012514445,0.0009839007,0.00020436198,0.000034559635,0.0000039373876,0.00008137114,0.0002659578,0.00014344574],"category_scores_gemma":[0.0016283612,0.00008778534,0.00025627165,0.00020633863,0.00020771727,0.000105523315,0.00003764209,0.0004732121,0.000003667454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010177369,0.0039300323,0.6217596,0.0000730458,0.00046291458,0.0038303598,0.0007441401,0.00006512042,0.007150976,0.00018743177,0.0023768134,0.3492422],"study_design_scores_gemma":[0.0075398516,0.007737255,0.97579813,0.00027027327,0.00047154454,0.00023152745,0.00011931726,0.000119755576,0.00044414736,0.00019236133,0.00699733,0.00007849777],"about_ca_topic_score_codex":0.00013286313,"about_ca_topic_score_gemma":0.000094949704,"teacher_disagreement_score":0.35403854,"about_ca_system_score_codex":0.00022952928,"about_ca_system_score_gemma":0.0010341458,"threshold_uncertainty_score":0.35797822},"labels":[],"label_agreement":null},{"id":"W2286020305","doi":"10.1200/jco.2012.30.15_suppl.e19599","title":"Frequency, indications, outcomes, and factors associated with successful opioid rotation in cancer patients presenting to an outpatient supportive care center.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer pain; Opioid; Ambulatory; Delirium; Cancer; Brief Pain Inventory; Physical therapy; Emergency medicine; Internal medicine; Chronic pain; Intensive care medicine","score_opus":0.11283822869512349,"score_gpt":0.49259876485983006,"score_spread":0.37976053616470656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286020305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975005,0.00018479145,0.0000041048934,0.0008307151,0.00081290863,0.00046335044,0.000034753044,0.0000054291995,0.00016346065],"genre_scores_gemma":[0.9986425,0.00008386148,0.00018596346,0.0007515645,0.00019377373,0.000022728993,0.00008124894,0.000012181334,0.000026199312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978725,0.00034054005,0.0011395033,0.00014123318,0.000250274,0.0002559706],"domain_scores_gemma":[0.99724674,0.00059122953,0.0012240025,0.0000679593,0.0004232046,0.00044686208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058042485,0.0001218558,0.000751028,0.0001700484,0.000037951777,0.000006259689,0.0000698403,0.00019207402,0.00008645119],"category_scores_gemma":[0.00091020553,0.00008095743,0.000085693784,0.00014100756,0.00006465905,0.0002574999,0.000028220335,0.0004439431,0.0000010684848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004188426,0.004385095,0.9830122,0.0000145184995,0.00023481727,0.00001364318,0.0051903375,0.0000034375635,0.000011495799,0.000004282226,0.00015031958,0.0065610385],"study_design_scores_gemma":[0.007716725,0.0072631673,0.9830814,0.000057634315,0.00028613553,0.0000022516838,0.00092690164,0.0000033661352,0.00005160698,0.000009748594,0.0005249647,0.00007607956],"about_ca_topic_score_codex":0.00029215077,"about_ca_topic_score_gemma":0.0016606484,"teacher_disagreement_score":0.0072978823,"about_ca_system_score_codex":0.0005403008,"about_ca_system_score_gemma":0.0005956923,"threshold_uncertainty_score":0.33013478},"labels":[],"label_agreement":null},{"id":"W2286081607","doi":"10.1200/jco.2006.24.18_suppl.6011","title":"A randomized controlled trial to evaluate the impact of an educational DVD on cancer patients considering participation in a phase I clinical trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Placebo; Informed consent; Family medicine; Randomized controlled trial; Intervention (counseling); Cancer; Alternative medicine; Internal medicine; Nursing; Pathology","score_opus":0.6867292286897998,"score_gpt":0.7599909803876146,"score_spread":0.07326175169781479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286081607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97554934,0.000055615248,0.000021709673,0.01488293,0.0030554973,0.005451434,0.0000064214582,0.0000036441359,0.00097342674],"genre_scores_gemma":[0.9925533,0.00019036442,0.00045394964,0.0013001433,0.0050208187,0.00032936595,0.0000051893717,0.000018765904,0.00012810824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9740586,0.011166741,0.012295327,0.00035661962,0.0017376839,0.000384979],"domain_scores_gemma":[0.6516578,0.33742344,0.005667634,0.0005488461,0.0038554803,0.0008467572],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.10623977,0.00019494827,0.0053348946,0.000277889,0.00005019338,0.000019489462,0.00031534547,0.0007670102,0.00046590943],"category_scores_gemma":[0.4720562,0.00009819405,0.0023808582,0.00026574288,0.0007629537,0.0000974623,0.00006304751,0.0034176165,0.00001099308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9445788,0.03515504,0.007893277,0.000008772438,0.0006268494,0.000022460976,0.000079090176,0.0005169452,0.000013115415,0.00046169714,0.0006407443,0.010003202],"study_design_scores_gemma":[0.8611601,0.090983406,0.035821747,0.00016874091,0.00056154106,0.0000027750868,0.000014200769,0.0014094101,0.000008330984,0.009719631,0.00007556985,0.00007453114],"about_ca_topic_score_codex":0.00036802882,"about_ca_topic_score_gemma":0.0005546364,"teacher_disagreement_score":0.36581644,"about_ca_system_score_codex":0.00036056805,"about_ca_system_score_gemma":0.013270671,"threshold_uncertainty_score":0.9988815},"labels":[],"label_agreement":null},{"id":"W2286152207","doi":"10.1200/jco.2015.33.7_suppl.141","title":"Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Docetaxel; Brief Pain Inventory; Randomization; Mitoxantrone; Internal medicine; Population; Enzalutamide; Cabazitaxel; Cabozantinib; Oncology; Cancer; Randomized controlled trial; Urology; Androgen deprivation therapy; Chemotherapy; Chronic pain; Physical therapy; Androgen receptor","score_opus":0.14749090854508987,"score_gpt":0.4478939216211045,"score_spread":0.3004030130760146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286152207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962498,0.000892875,0.00003965815,0.0017537555,0.00011833767,0.0007713788,0.00009293404,0.0000065011714,0.000074743795],"genre_scores_gemma":[0.9954915,0.0009926835,0.0025255126,0.00049212907,0.000083447536,0.000040709165,0.000025951053,0.000023415349,0.00032462802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963111,0.00076627586,0.0018074716,0.00035503486,0.00041044012,0.00034966107],"domain_scores_gemma":[0.9958315,0.0012871611,0.0014446282,0.00015515876,0.00070651417,0.00057506474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018643752,0.0002812113,0.0025512308,0.00038703697,0.000039660583,0.000019889923,0.000089027526,0.00014974637,0.000065838736],"category_scores_gemma":[0.00046818462,0.00016765963,0.00013044475,0.00065037207,0.0002532119,0.00017470609,0.000034396926,0.00044169615,6.0919575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34433997,0.0032936854,0.6108156,0.00013902562,0.0067586866,0.00096314313,0.001418455,0.002775552,0.00028957726,0.0000072785747,0.00062974263,0.028569292],"study_design_scores_gemma":[0.15128465,0.13510188,0.6902743,0.0005486959,0.015795287,0.00013106177,0.000940042,0.0032759411,0.00024869136,0.00001576703,0.0020015198,0.0003821953],"about_ca_topic_score_codex":0.0009010533,"about_ca_topic_score_gemma":0.014938246,"teacher_disagreement_score":0.19305533,"about_ca_system_score_codex":0.0002559726,"about_ca_system_score_gemma":0.0018334563,"threshold_uncertainty_score":0.8335892},"labels":[],"label_agreement":null},{"id":"W2286173468","doi":"10.1200/jco.2015.63.8049","title":"Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology; AstraZeneca Canada; American Society of Clinical Oncology","keywords":"Medicine; Cancer; Cancer research; Oncology; Internal medicine","score_opus":0.06750101670510644,"score_gpt":0.5144393905794349,"score_spread":0.44693837387432844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286173468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040505645,0.98770165,0.000091488444,0.0037508963,0.0013956198,0.0012183897,0.000027102778,0.0000060010852,0.0017583014],"genre_scores_gemma":[0.0044532055,0.9919846,0.0011066783,0.0005710863,0.0011123728,0.00009824242,0.000012029008,0.000035453846,0.0006263554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946053,0.00044060944,0.00418172,0.0002544612,0.00025871696,0.0002591815],"domain_scores_gemma":[0.99097383,0.0028467705,0.005120401,0.00028082723,0.00058549317,0.00019267008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001973834,0.00027513478,0.0036925033,0.00023976021,0.000033376462,0.0000073990864,0.000197831,0.00062572584,0.00052925345],"category_scores_gemma":[0.0010515595,0.00013351737,0.0012228705,0.00025228033,0.00014890617,0.00009755189,0.00006775235,0.0014094881,0.0000050250233],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046609904,0.00093682023,0.0011414444,0.004422588,0.0007742358,0.0002525806,0.00010813834,0.0000010557919,0.0000044405415,0.000008171875,0.0014374319,0.990447],"study_design_scores_gemma":[0.014213359,0.0091076,0.0017887454,0.06020055,0.0060777115,0.00032031068,0.00011022861,0.00003360483,0.000071272654,0.0000664951,0.9077687,0.00024140676],"about_ca_topic_score_codex":0.00001806362,"about_ca_topic_score_gemma":0.00012298724,"teacher_disagreement_score":0.9902056,"about_ca_system_score_codex":0.0005856696,"about_ca_system_score_gemma":0.0060256035,"threshold_uncertainty_score":0.9996093},"labels":[],"label_agreement":null},{"id":"W2286363045","doi":"10.1200/jco.2007.25.18_suppl.8037","title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Diffuse large B-cell lymphoma; Population; Lymphoma; Chemotherapy; Oncology; Univariate analysis; Surgery; Gastroenterology; Multivariate analysis","score_opus":0.021960227721177387,"score_gpt":0.36132483607590504,"score_spread":0.33936460835472765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286363045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867225,0.000097305776,0.000055155204,0.0002498974,0.00020045157,0.00061343226,0.00006084132,0.0000019445856,0.00004874219],"genre_scores_gemma":[0.99925476,0.00015167904,0.00032799068,0.0001396464,0.00010351063,0.0000044252197,0.0000023226344,0.000010213663,0.0000054746024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979651,0.00019033239,0.001250934,0.00011584839,0.00026091922,0.0002168444],"domain_scores_gemma":[0.99535966,0.002377598,0.0016398799,0.00017677764,0.00026302136,0.00018307297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014412742,0.000117557465,0.00088212866,0.000064360895,0.00003720512,0.000003516144,0.00011477325,0.00016074676,0.0000057139464],"category_scores_gemma":[0.0009345482,0.000047072695,0.0003451245,0.00013002446,0.000101831225,0.000051569685,0.00002586172,0.00016382559,3.063978e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008211952,0.015463438,0.96091604,0.000027444257,0.00022728987,0.000016801094,0.0004170647,0.0000075789726,0.000007546159,0.000016112757,0.0003017903,0.014386933],"study_design_scores_gemma":[0.0671291,0.012774212,0.9189537,0.00018702132,0.00024380394,0.000018269946,0.00024435553,0.000027632159,0.0001880589,0.000014186254,0.0001783761,0.00004129048],"about_ca_topic_score_codex":0.00026533037,"about_ca_topic_score_gemma":0.00014436203,"teacher_disagreement_score":0.05891715,"about_ca_system_score_codex":0.0004360029,"about_ca_system_score_gemma":0.0004591568,"threshold_uncertainty_score":0.19195688},"labels":[],"label_agreement":null},{"id":"W2286490579","doi":"10.1200/jco.2015.64.7909","title":"Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Medicine; Germ cell tumors; Clinical endpoint; Internal medicine; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.07604676010132218,"score_gpt":0.40219090120389717,"score_spread":0.326144141102575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286490579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971147,0.0002459507,0.000893301,0.0011054301,0.00007636905,0.00032089287,0.00007888954,0.0000069564167,0.0001574861],"genre_scores_gemma":[0.9969919,0.00014886828,0.0023892182,0.00023719089,0.00010033429,0.0000066401435,0.000027645776,0.000019966523,0.00007824031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976331,0.00027158676,0.0012370382,0.0001728121,0.00051251147,0.0001729774],"domain_scores_gemma":[0.99289745,0.0033915788,0.0020912099,0.00015403696,0.0011037632,0.00036195962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004100547,0.00017873406,0.0012418227,0.000080815866,0.000030722946,0.00000337243,0.00007912263,0.000081907776,0.00023839496],"category_scores_gemma":[0.001368908,0.00007267817,0.00026923267,0.00012407331,0.00030679288,0.00009909675,0.000012244958,0.00019177208,0.000008266988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012898302,0.009503301,0.96712095,0.000028000837,0.0013658905,0.0012227847,0.000017300294,0.000028030898,0.000025660742,0.000043238666,0.00013118802,0.007615336],"study_design_scores_gemma":[0.041373555,0.048341732,0.9076717,0.00024913318,0.001016943,0.0000803938,0.000019161453,0.000010187819,0.00018150806,0.00020817002,0.00075765664,0.000089856956],"about_ca_topic_score_codex":0.000009303615,"about_ca_topic_score_gemma":0.000013186361,"teacher_disagreement_score":0.059449263,"about_ca_system_score_codex":0.00008028144,"about_ca_system_score_gemma":0.0012831324,"threshold_uncertainty_score":0.296373},"labels":[],"label_agreement":null},{"id":"W2286522949","doi":"10.1200/jco.2009.27.15_suppl.e11614","title":"Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Anthracycline; Stage (stratigraphy); Breast-conserving surgery; Surgery; Taxane; Internal medicine; Cancer; Oncology","score_opus":0.024930647102942637,"score_gpt":0.38186192180149353,"score_spread":0.3569312746985509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286522949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195606,0.0041051107,0.000017476637,0.0032024423,0.00031435714,0.00009660602,0.00016953418,7.6579346e-7,0.00013766227],"genre_scores_gemma":[0.99672717,0.0023481487,0.0001546828,0.0004422853,0.0001561216,0.0000021612345,0.0000032028697,0.000007569016,0.00015867331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827826,0.000118802556,0.0011145731,0.0001643347,0.00017809219,0.00014595612],"domain_scores_gemma":[0.9975311,0.0001637909,0.0015454228,0.00018973694,0.00048808672,0.0000818624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002592505,0.00013476305,0.00091525854,0.000023266459,0.00002464636,0.0000014595197,0.00018808784,0.00017214287,0.00006217902],"category_scores_gemma":[0.00008648466,0.00007924922,0.0003125132,0.000029655976,0.00019020146,0.0000048916336,0.00010634533,0.00017247189,1.9014743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024101327,0.000253487,0.87855726,0.00002877126,0.0005297053,0.0000049571945,0.00062051596,0.00008511289,0.0013812089,0.000004797135,0.00007853011,0.11604552],"study_design_scores_gemma":[0.0035776389,0.0019797958,0.987788,0.000116357245,0.0002816101,0.000024266985,0.00067306793,6.759106e-7,0.0028066775,0.000016212092,0.002666222,0.00006943789],"about_ca_topic_score_codex":0.0025795223,"about_ca_topic_score_gemma":0.09466693,"teacher_disagreement_score":0.11597608,"about_ca_system_score_codex":0.00006137898,"about_ca_system_score_gemma":0.0007038826,"threshold_uncertainty_score":0.92185307},"labels":[],"label_agreement":null},{"id":"W2286585674","doi":"10.1200/jco.2015.33.3_suppl.399","title":"Effect of body mass index on outcomes in biliary tract cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Body mass index; Biliary tract cancer; Univariate analysis; Cancer; Proportional hazards model; Gastroenterology; Prostate cancer; Lung cancer; Oncology; Multivariate analysis; Gemcitabine","score_opus":0.1297782309302534,"score_gpt":0.5043338648636027,"score_spread":0.37455563393334923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286585674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850052,0.0011777962,0.000005056813,0.0077421106,0.0017399978,0.00017100271,0.0000030488914,0.0000043845757,0.0041514137],"genre_scores_gemma":[0.99750465,0.00041082784,0.00008109722,0.0011249227,0.0006884712,0.000005477891,4.6616626e-7,0.000010965176,0.00017313348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711484,0.00049894786,0.001677256,0.00013853394,0.0003916105,0.00017879406],"domain_scores_gemma":[0.9949629,0.0034161322,0.00097255677,0.00015366114,0.00022363658,0.00027117017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003996324,0.00013186008,0.002080816,0.00017456035,0.0000093801345,0.0000022352206,0.00012577017,0.00026151727,0.00003263144],"category_scores_gemma":[0.0046030288,0.0000776095,0.00047017413,0.00013097287,0.00014378836,0.000057256453,0.00002910005,0.0009233681,0.0000057267403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008258851,0.0008751517,0.937223,0.000044696164,0.000274414,0.0006548275,0.00008860182,0.000018708817,0.00005497269,0.0000065617573,0.0043142466,0.048185922],"study_design_scores_gemma":[0.014691602,0.03619967,0.94173235,0.00013736698,0.00025920838,0.000058728736,0.000080589205,0.000028894121,0.00021653096,0.00007582618,0.0064574345,0.0000617814],"about_ca_topic_score_codex":0.00012229665,"about_ca_topic_score_gemma":0.00008254941,"teacher_disagreement_score":0.048124142,"about_ca_system_score_codex":0.00022447313,"about_ca_system_score_gemma":0.0011174633,"threshold_uncertainty_score":0.55105877},"labels":[],"label_agreement":null},{"id":"W2286650625","doi":"10.1200/jco.2015.33.3_suppl.296","title":"The association of epithelial expression of hENT1 and survival from adjuvant gemcitabine in pancreatic ductal adenocarcinoma (PDAC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); BC Cancer Agency","funders":"","keywords":"Gemcitabine; Medicine; Internal medicine; Oncology; Cohort; Tissue microarray; Immunohistochemistry; Pancreatic cancer; Adjuvant; Chemotherapy; Pathology; Gastroenterology; Cancer","score_opus":0.12669672337469462,"score_gpt":0.4522374385424117,"score_spread":0.3255407151677171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286650625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915993,0.0023075778,0.000040363164,0.0035985156,0.0006619911,0.00019138838,0.000010375616,0.0000020683733,0.001588419],"genre_scores_gemma":[0.9954105,0.0018465571,0.0017276796,0.00008077036,0.00065206626,0.0000029623372,0.0000031046845,0.00000862864,0.00026773312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951536,0.0013805575,0.0024271146,0.0001384574,0.0006766732,0.00022358166],"domain_scores_gemma":[0.9872564,0.009441681,0.0021070393,0.00017597649,0.0007197738,0.00029910618],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0094114,0.00010114016,0.0019180871,0.0001041655,0.00002595442,0.0000036798594,0.0001608655,0.0003889063,0.00003715902],"category_scores_gemma":[0.01866849,0.000058385573,0.0001925988,0.00011956524,0.0003364149,0.00007104003,0.00009392465,0.0007725431,0.0000034170146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007056626,0.0007197117,0.9844534,0.000020443526,0.00023438013,0.0001364792,0.00034960487,0.0000015220364,0.0022663,0.000083459,0.00078285363,0.003895264],"study_design_scores_gemma":[0.01272935,0.007024748,0.9753174,0.0001553619,0.00041540302,0.000050292576,0.00080423977,0.0001589454,0.00033982785,0.0014444154,0.0015132042,0.00004676457],"about_ca_topic_score_codex":0.00024589963,"about_ca_topic_score_gemma":0.00016841273,"teacher_disagreement_score":0.009257088,"about_ca_system_score_codex":0.00020537879,"about_ca_system_score_gemma":0.002073045,"threshold_uncertainty_score":0.9895977},"labels":[],"label_agreement":null},{"id":"W2286653960","doi":"10.1200/jco.2012.30.15_suppl.7009","title":"Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"SABR volatility model; Medicine; Propensity score matching; Lung cancer; Surgery; Radiation therapy; Pneumonectomy; VATS lobectomy; Radiosurgery; Internal medicine","score_opus":0.1583481930270514,"score_gpt":0.4659117846465146,"score_spread":0.30756359161946323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286653960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276453,0.004076201,0.00023839166,0.0014208897,0.00070105714,0.0006604062,0.000024459592,0.0000126478935,0.00010143649],"genre_scores_gemma":[0.9940102,0.002317137,0.0017210507,0.0010132203,0.00031882967,0.0000228449,0.0000068388113,0.00004242875,0.0005474337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951108,0.00083754485,0.0028008542,0.00031921786,0.000456953,0.00047464197],"domain_scores_gemma":[0.9907573,0.0036922898,0.0039892956,0.00035640682,0.00069915917,0.0005055706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002544954,0.00034747465,0.0046312856,0.00032762915,0.000083569124,0.00001634272,0.00015115755,0.00039383504,0.0005805418],"category_scores_gemma":[0.0005876644,0.00019599037,0.0010945416,0.00070998096,0.00019037,0.0002501636,0.00005236758,0.0005951758,0.0000015266899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004523984,0.0064206566,0.96464396,0.00015824754,0.015911402,0.00018377775,0.00041510368,0.000039180173,0.0007017108,4.135086e-7,0.0017543229,0.0052472334],"study_design_scores_gemma":[0.007926015,0.003137696,0.97321993,0.00033847257,0.01218565,0.000035884324,0.00006150283,0.00024626372,0.001913613,9.3113283e-7,0.00074709277,0.00018697063],"about_ca_topic_score_codex":0.0020594138,"about_ca_topic_score_gemma":0.00074145535,"teacher_disagreement_score":0.0085759405,"about_ca_system_score_codex":0.0011947359,"about_ca_system_score_gemma":0.0022750027,"threshold_uncertainty_score":0.79922557},"labels":[],"label_agreement":null},{"id":"W2286785822","doi":"10.1200/jco.2009.27.15_suppl.6564","title":"Clinical benefit in oncology trials: Is this a patient-centered or tumor-centered endpoint?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Internal medicine; Oncology; Gemcitabine; Cancer; Pancreatic cancer","score_opus":0.401715668614225,"score_gpt":0.5790329003493775,"score_spread":0.17731723173515251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286785822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93601406,0.00084782817,0.000082851424,0.04152679,0.002490496,0.0009689278,0.000019669666,0.000022849528,0.018026508],"genre_scores_gemma":[0.9322762,0.006860379,0.012857825,0.042841397,0.003087186,0.000017153867,0.000009965687,0.000038463684,0.0020114328],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9798066,0.0051077898,0.012732992,0.0006045391,0.0008759659,0.0008721207],"domain_scores_gemma":[0.9703613,0.020917015,0.005756982,0.0006026133,0.0009860299,0.0013760398],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.027333306,0.0003668508,0.008566093,0.00055088254,0.0000707613,0.000018929204,0.00055633736,0.0014568026,0.0043217815],"category_scores_gemma":[0.052714407,0.000231676,0.0018464981,0.00042879654,0.00058518973,0.00018935556,0.00014885144,0.003903933,0.00019120617],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0780799,0.014364632,0.2894169,0.000031903663,0.0007906796,0.009570334,0.00044330262,7.1763446e-7,0.00006215493,0.0001205456,0.051988076,0.55513084],"study_design_scores_gemma":[0.05334311,0.12773679,0.4325205,0.00041724724,0.001022857,0.002091051,0.00048596904,0.00033420516,0.00003264393,0.0015900303,0.38017958,0.00024601066],"about_ca_topic_score_codex":0.000040893032,"about_ca_topic_score_gemma":0.00015478699,"teacher_disagreement_score":0.55488485,"about_ca_system_score_codex":0.000714519,"about_ca_system_score_gemma":0.007325104,"threshold_uncertainty_score":0.99983954},"labels":[],"label_agreement":null},{"id":"W2287073069","doi":"10.1200/jco.2015.33.7_suppl.403","title":"Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sunitinib; Sorafenib; Interim analysis; Discontinuation; Internal medicine; Renal cell carcinoma; Adverse effect; Rash; Clinical endpoint; Hazard ratio; Placebo; Urology; Oncology; Surgery; Randomized controlled trial; Hepatocellular carcinoma; Confidence interval; Pathology","score_opus":0.38162319503794323,"score_gpt":0.5198697579504836,"score_spread":0.1382465629125404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287073069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821455,0.0004578465,0.00036359447,0.0048833843,0.0046176855,0.001587954,0.00032219416,0.000039085677,0.0055827927],"genre_scores_gemma":[0.9732165,0.00011998209,0.011827416,0.0017221915,0.01104474,0.000045585257,0.00034055448,0.00007998103,0.0016030896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898781,0.0016063987,0.006124215,0.0006872234,0.0009837182,0.0007203502],"domain_scores_gemma":[0.98422986,0.0067293327,0.0039911405,0.00075918407,0.0020093962,0.002281093],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009206544,0.00048650854,0.004014176,0.00029604606,0.000118185635,0.000050045703,0.00048268208,0.0009727174,0.0003967715],"category_scores_gemma":[0.014329897,0.00032032822,0.0011420159,0.00024930396,0.0003410603,0.00039799782,0.00010830798,0.0016363828,0.000054848755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8727107,0.010558662,0.0005625288,0.000025309175,0.000924612,0.009062297,0.0004867174,0.000034488137,0.00046438468,0.000030940493,0.03632952,0.06880986],"study_design_scores_gemma":[0.6386263,0.18997146,0.0028636479,0.00014119262,0.0025446592,0.0010073237,0.00086413155,0.0004752879,0.002039616,0.0006623654,0.1604564,0.000347648],"about_ca_topic_score_codex":0.0003604131,"about_ca_topic_score_gemma":0.00046501687,"teacher_disagreement_score":0.23408441,"about_ca_system_score_codex":0.00057362916,"about_ca_system_score_gemma":0.009788455,"threshold_uncertainty_score":0.9999249},"labels":[],"label_agreement":null},{"id":"W2287184838","doi":"10.1200/jco.2007.25.18_suppl.7539","title":"Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada); Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Cetuximab; Carboplatin; Internal medicine; Regimen; Lung cancer; Clinical endpoint; Chemotherapy; Pleural effusion; Oncology; Chemotherapy regimen; Progression-free survival; Phases of clinical research; Gastroenterology; Cisplatin; Urology; Cancer; Randomized controlled trial; Colorectal cancer","score_opus":0.060468335524432794,"score_gpt":0.48103428015090904,"score_spread":0.42056594462647623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287184838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818638,0.00075803493,0.0051719123,0.006677626,0.0007759677,0.0013149215,0.000012324168,0.000010234749,0.0034152074],"genre_scores_gemma":[0.97514844,0.0010776317,0.019203333,0.0011650681,0.0006147082,0.00008665776,0.000018867544,0.00003118,0.0026541103],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751896,0.00005159403,0.0016839824,0.00022480088,0.00021578108,0.00030490162],"domain_scores_gemma":[0.9958834,0.0019659642,0.0012248277,0.00014385293,0.0005035744,0.0002783699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010019849,0.00018420827,0.0011894099,0.00017377034,0.00005762938,0.000006948334,0.00007729462,0.0002300282,0.00008884764],"category_scores_gemma":[0.00044493837,0.00010725618,0.00023657299,0.00019880947,0.000064436,0.00011000494,0.000012078528,0.00031009706,0.000003274744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08039589,0.023672735,0.36336616,0.00028401194,0.0016897592,0.0025483859,0.0016328152,0.0014556155,0.0003323059,0.000106822474,0.0015760163,0.5229395],"study_design_scores_gemma":[0.34287998,0.18211587,0.38051093,0.0011241527,0.0042950846,0.00043249287,0.00094360067,0.0016226653,0.0021989858,0.0002752055,0.08317705,0.000423969],"about_ca_topic_score_codex":0.00022748872,"about_ca_topic_score_gemma":0.005620761,"teacher_disagreement_score":0.52251554,"about_ca_system_score_codex":0.0010848921,"about_ca_system_score_gemma":0.0028348956,"threshold_uncertainty_score":0.50289834},"labels":[],"label_agreement":null},{"id":"W2287295988","doi":"10.1200/jco.2006.24.18_suppl.10534","title":"Understanding decision supports (DS) for women with breast cancer eligible for clinical trials (CT)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Radiation oncologist; Clinical trial; Preference; Cancer; Focus group; Medical physics; Internal medicine; Oncology; Radiation therapy","score_opus":0.8772111135867082,"score_gpt":0.7403522598123068,"score_spread":0.13685885377440143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287295988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7868608,0.00067275006,0.10949567,0.08844068,0.0067441068,0.0033983453,0.00017663166,0.000043713342,0.0041673128],"genre_scores_gemma":[0.9464145,0.005192884,0.030621056,0.004295796,0.010695913,0.000119036165,0.00000748434,0.00008246905,0.0025708901],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98563045,0.001423216,0.010176656,0.0005748279,0.0013897796,0.0008050933],"domain_scores_gemma":[0.6266496,0.36252156,0.005746745,0.0005130365,0.0032801419,0.0012888869],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15605572,0.00024545597,0.004439762,0.00024400924,0.00014319325,0.000044023378,0.0004142632,0.0011654304,0.00040934217],"category_scores_gemma":[0.17160882,0.00014803302,0.0014633853,0.00024716952,0.0008037857,0.00016614309,0.000098041026,0.0034848896,0.0000074152017],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24653548,0.0074143447,0.29629055,0.0005368481,0.002195781,0.00095695775,0.00006512883,0.00013971435,0.00009603737,0.01261451,0.19421315,0.2389415],"study_design_scores_gemma":[0.08024448,0.069873005,0.14454392,0.0014288245,0.001450089,0.0011755456,0.0007383297,0.00045260944,0.000059629863,0.4530443,0.24656378,0.00042551005],"about_ca_topic_score_codex":0.0000325241,"about_ca_topic_score_gemma":0.0004862995,"teacher_disagreement_score":0.44042978,"about_ca_system_score_codex":0.0010305371,"about_ca_system_score_gemma":0.011106518,"threshold_uncertainty_score":0.9988141},"labels":[],"label_agreement":null},{"id":"W2287508718","doi":"10.1200/jco.2009.27.15_suppl.3528","title":"Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decitabine; Neutropenia; Internal medicine; Gastroenterology; Febrile neutropenia; Pharmacokinetics; Adverse effect; Leukopenia; Tolerability; Oncology; Toxicity","score_opus":0.021230536163726742,"score_gpt":0.40559108074494665,"score_spread":0.38436054458121993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287508718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999228,0.000047172904,0.00005723675,0.00013165311,0.00007795392,0.0003784004,0.0000027131662,0.0000010865234,0.00007578112],"genre_scores_gemma":[0.998895,0.000049234102,0.0008909371,0.00007668235,0.000055442222,0.0000036247386,0.000008019275,0.000011457631,0.000009603451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975909,0.00035243225,0.001293553,0.00022800911,0.000315921,0.00021919562],"domain_scores_gemma":[0.9983502,0.00014794075,0.0007880439,0.00015772728,0.000407005,0.00014906723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012352042,0.00013025812,0.0007994868,0.00018694266,0.000020082618,0.0000053873623,0.00015065915,0.00016749075,0.0000026542787],"category_scores_gemma":[0.0006332499,0.00009493972,0.000046580335,0.00019403937,0.00015658986,0.00001732178,0.000039394305,0.0003749265,2.6472733e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051497843,0.05817475,0.5520285,0.00002038997,0.00012906735,0.00066523807,0.000725295,0.0004660256,0.0053416393,0.0000072285125,0.00008682271,0.33085722],"study_design_scores_gemma":[0.07009876,0.2366667,0.6897913,0.000064690365,0.00002294535,0.000028526361,0.00027782575,0.000046533365,0.0027071962,0.000022382797,0.00015726863,0.000115873234],"about_ca_topic_score_codex":0.000023485689,"about_ca_topic_score_gemma":0.00037571782,"teacher_disagreement_score":0.33074135,"about_ca_system_score_codex":0.00007376257,"about_ca_system_score_gemma":0.0005637516,"threshold_uncertainty_score":0.38715297},"labels":[],"label_agreement":null},{"id":"W2287537024","doi":"10.1200/jco.2007.25.18_suppl.18527","title":"Outcome of localized and advanced diffuse large B-cell non-Hodgkin bone lymphoma (DBL)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Boréal; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Cyclophosphamide; Vincristine; Hazard ratio; Internal medicine; CHOP; Prednisone; Regimen; Chemotherapy; Anthracycline; Rituximab; Surgery; Median follow-up; Gastroenterology; Lymphoma; Cancer; Confidence interval; Breast cancer","score_opus":0.06283831123038348,"score_gpt":0.4535946498689129,"score_spread":0.39075633863852943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287537024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248797,0.0014463969,0.0006503295,0.0016344938,0.00073039497,0.00020954717,0.0000051838674,0.0000068229792,0.0028288758],"genre_scores_gemma":[0.9867887,0.0013850343,0.008913628,0.002233026,0.0003663418,0.0000021918406,0.0000019090328,0.000017579014,0.00029161066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583226,0.0001423803,0.0031574413,0.0001948623,0.0003569607,0.0003160882],"domain_scores_gemma":[0.9943831,0.0027131224,0.0018332904,0.00022102884,0.0003039578,0.00054547505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003447297,0.00017096025,0.0021071816,0.00014624206,0.000031416657,0.0000038246494,0.00009003061,0.0003762077,0.000059776543],"category_scores_gemma":[0.001560867,0.00011188731,0.00054002553,0.00012131261,0.00018692204,0.00007416518,0.000069675356,0.00026712182,0.00001303496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007942902,0.026471639,0.7139109,0.00007470057,0.00030641526,0.0030879201,0.000093072005,0.000001073793,0.0004322248,0.00016420479,0.000949106,0.24656583],"study_design_scores_gemma":[0.12275108,0.013496517,0.7675433,0.000106246436,0.00057746866,0.00054849917,0.00015868523,0.000042577107,0.0015914236,0.00009768487,0.092978634,0.00010784879],"about_ca_topic_score_codex":0.000019257803,"about_ca_topic_score_gemma":0.000040258878,"teacher_disagreement_score":0.246458,"about_ca_system_score_codex":0.00017835831,"about_ca_system_score_gemma":0.00045966305,"threshold_uncertainty_score":0.4562632},"labels":[],"label_agreement":null},{"id":"W2287642617","doi":"10.1200/jco.2015.65.7759","title":"Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Toronto Western Hospital; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Cancer Care Ontario; Genomic Health; American Society of Clinical Oncology; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Guideline; Prostate cancer; Management of prostate cancer; Cancer; Family medicine; Prostate; Oncology; Internal medicine; Gynecology; Pathology","score_opus":0.15415843768717144,"score_gpt":0.5453464745926612,"score_spread":0.39118803690548976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287642617","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.466209,0.02019496,0.011887479,0.47143722,0.016380997,0.009053584,0.0010917955,0.000051697694,0.0036932803],"genre_scores_gemma":[0.4340603,0.32185256,0.20498909,0.03163244,0.00537041,0.0007336914,0.000042412583,0.0001186031,0.0012004995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9841617,0.0013151721,0.012386808,0.0006765499,0.00089638616,0.0005633985],"domain_scores_gemma":[0.9634058,0.015901783,0.014034503,0.00065336353,0.005446431,0.0005581255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014588272,0.0003887446,0.0046412577,0.00006688534,0.00008227902,0.0000072152316,0.00049198704,0.00050646625,0.00032084377],"category_scores_gemma":[0.0035492114,0.00019779823,0.0026260442,0.00024290856,0.0015303371,0.00016252566,0.0002537997,0.001111509,0.0000035120308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029978678,0.003935518,0.1579261,0.00012090095,0.008300447,0.00010092702,0.00033091617,0.00007039627,0.000016922611,0.00005478885,0.081937134,0.7172273],"study_design_scores_gemma":[0.03215141,0.027431933,0.12756148,0.00048637914,0.0032944703,0.000025019175,0.0021254777,0.00007645196,0.00015826274,0.00006716334,0.80644673,0.000175203],"about_ca_topic_score_codex":0.004839383,"about_ca_topic_score_gemma":0.008444234,"teacher_disagreement_score":0.7245096,"about_ca_system_score_codex":0.0016808922,"about_ca_system_score_gemma":0.009772067,"threshold_uncertainty_score":0.9958416},"labels":[],"label_agreement":null},{"id":"W2287692022","doi":"10.1200/jco.2007.25.18_suppl.lba7514","title":"Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Carboplatin; Bevacizumab; Clinical endpoint; Placebo; Oncology; Cisplatin; Chemotherapy; Lung cancer; Progression-free survival; Neutropenia; Surgery; Randomized controlled trial; Pathology","score_opus":0.03669029450550364,"score_gpt":0.44934336801465313,"score_spread":0.4126530735091495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287692022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995102,0.0002965372,0.00020109925,0.00031068738,0.0002673432,0.0034916436,0.0000050008957,0.0000032939074,0.00032239273],"genre_scores_gemma":[0.99795,0.00029055835,0.0013781787,0.00014422946,0.000082748615,0.0000547036,0.000011098752,0.000023667255,0.00006481787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697095,0.00011060075,0.002038619,0.00026300075,0.00035774976,0.00025904956],"domain_scores_gemma":[0.99631983,0.0009718197,0.0017686711,0.00014292638,0.0005668871,0.0002298658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011327979,0.00020783437,0.001399698,0.0002853929,0.000032686436,0.000006488763,0.00008343526,0.00016595724,0.000031328098],"category_scores_gemma":[0.00013673208,0.00012271368,0.00008182452,0.00032612338,0.000081750186,0.00013696266,0.000019056006,0.0005627473,2.2680472e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5068745,0.0256417,0.3734148,0.00007803748,0.0002794692,0.00024851094,0.0032256222,0.00014897337,0.000024943742,6.928568e-7,0.000018105704,0.09004462],"study_design_scores_gemma":[0.6400554,0.036057197,0.32109496,0.0003513751,0.0006345056,0.000009338645,0.0012597808,0.0002958951,0.00008003884,0.0000014726216,0.00006343899,0.000096566044],"about_ca_topic_score_codex":0.00021931362,"about_ca_topic_score_gemma":0.0046747425,"teacher_disagreement_score":0.13318092,"about_ca_system_score_codex":0.00042050733,"about_ca_system_score_gemma":0.0012423685,"threshold_uncertainty_score":0.50041187},"labels":[],"label_agreement":null},{"id":"W2287841863","doi":"10.1200/jco.2012.30.15_suppl.e13126","title":"Improved 5-year overall survival (OS) in breast cancer (CA) patients from 1994 to 2008.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vinorelbine; Trastuzumab; Internal medicine; Capecitabine; Cohort; Docetaxel; Breast cancer; Oncology; Hormonal therapy; Metastatic breast cancer; Cancer; Chemotherapy; Overall survival; Aromatase","score_opus":0.0951984904795451,"score_gpt":0.4846176165296104,"score_spread":0.3894191260500653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287841863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821668,0.00037901883,0.000006751922,0.009109112,0.0062367264,0.00023729178,0.00007482345,0.000005457723,0.0017839698],"genre_scores_gemma":[0.9870626,0.0006591456,0.00067445415,0.0063077845,0.004874229,0.000010325122,0.000012055562,0.000018874174,0.00038054038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740165,0.00032164875,0.0014751845,0.00016570032,0.00025120092,0.00038461838],"domain_scores_gemma":[0.99731296,0.0009586655,0.00070920045,0.0001259291,0.00018493432,0.00070832507],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011354017,0.00014757115,0.0012475224,0.00012366002,0.000018958412,0.000004317792,0.0001286291,0.00032372063,0.0029784823],"category_scores_gemma":[0.00030656112,0.000108645436,0.00030040377,0.000119374825,0.00006535529,0.00014010388,0.000061635576,0.00076528767,0.000060657574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011228795,0.004645822,0.90954804,0.0000061984815,0.00031627828,0.000057328736,0.0001319009,0.000003919144,0.00040859773,0.000008109677,0.03715908,0.036485914],"study_design_scores_gemma":[0.018700816,0.0038460726,0.8732861,0.00004026452,0.00029658532,0.000017620307,0.000024809711,0.000015767726,0.00003325461,0.00003415139,0.10361359,0.00009095449],"about_ca_topic_score_codex":0.0012305231,"about_ca_topic_score_gemma":0.00069054466,"teacher_disagreement_score":0.066454515,"about_ca_system_score_codex":0.00044968413,"about_ca_system_score_gemma":0.00079117174,"threshold_uncertainty_score":0.9979329},"labels":[],"label_agreement":null},{"id":"W2288155488","doi":"10.1200/jco.2005.23.16_suppl.6048","title":"A study of surveillance mammography (SM) of the contralateral breast (CLB) following total mastectomy (TM) for breast cancer (BC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palpation; Breast cancer; Mammography; Cohort; Cancer registry; Stage (stratigraphy); Mastectomy; Population; Cancer; Breast-conserving surgery; Surgery; Gynecology; Radiology; Internal medicine","score_opus":0.04061461387727091,"score_gpt":0.4001186904220299,"score_spread":0.359504076544759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288155488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949232,0.00056591653,0.00003372035,0.0027552398,0.0010825685,0.00035531618,0.00017025157,0.000002449937,0.00011135721],"genre_scores_gemma":[0.99811625,0.0001300115,0.00034909716,0.00019608224,0.0011171179,0.000023360495,0.0000019384413,0.000018630444,0.000047536432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973456,0.00032527396,0.0015928106,0.00023434444,0.00024577184,0.00025615963],"domain_scores_gemma":[0.9972111,0.00034431016,0.0016238611,0.00025520005,0.0004629302,0.00010259727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009153654,0.00018471811,0.0011050077,0.0000511821,0.00005799262,0.000005140436,0.0003100333,0.00021830368,0.000017540806],"category_scores_gemma":[0.0001871206,0.00011622612,0.0009815899,0.00012657479,0.00020654782,0.000011098749,0.00012298295,0.00022992076,2.8800733e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048342748,0.0024648076,0.9454149,0.000020709436,0.0025154145,0.000011987309,0.00013698623,0.00020778939,0.0022909879,0.000007630866,0.00061819796,0.041476313],"study_design_scores_gemma":[0.011665456,0.003107769,0.9817051,0.00004767693,0.00032098466,0.0002526418,0.00025770263,0.000008331117,0.0007081474,0.000018076582,0.0017914784,0.00011662193],"about_ca_topic_score_codex":0.00015792224,"about_ca_topic_score_gemma":0.0010803278,"teacher_disagreement_score":0.04135969,"about_ca_system_score_codex":0.00004597319,"about_ca_system_score_gemma":0.0004195574,"threshold_uncertainty_score":0.47395635},"labels":[],"label_agreement":null},{"id":"W2290633618","doi":"10.1200/jco.2015.65.3949","title":"First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Barbara Ann Karmanos Cancer Institute","keywords":"Medicine; Tolerability; Pharmacokinetics; Nausea; Response Evaluation Criteria in Solid Tumors; Vomiting; Adverse effect; Pharmacodynamics; Dosing; Anorexia; Internal medicine; Gastroenterology; Pharmacology; Hyponatremia; Toxicity; Phases of clinical research","score_opus":0.01798342769741563,"score_gpt":0.3535464819057588,"score_spread":0.3355630542083432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290633618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99918133,0.00002421851,0.000009944893,0.00015426017,0.0002307955,0.00025529557,0.0000042075776,0.0000013893003,0.00013855136],"genre_scores_gemma":[0.9993872,0.00005198626,0.00026103426,0.000082612285,0.00018103301,0.0000027771232,0.0000018574864,0.00001851004,0.00001298088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736035,0.00020287327,0.0018258448,0.00023317971,0.00019558433,0.00018214005],"domain_scores_gemma":[0.9978228,0.0001520006,0.0014787265,0.00017046386,0.0002899024,0.00008609057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073147553,0.00013172357,0.00087218714,0.00014569073,0.000018081402,0.0000018354107,0.00015608613,0.00024719173,0.00002407374],"category_scores_gemma":[0.0006732338,0.000085118096,0.000120774406,0.00014529914,0.00011557745,0.000017013746,0.000055948338,0.00031367503,6.344913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027193628,0.013962444,0.92114204,0.000033774526,0.0001999074,0.00011496134,0.00046454233,0.00025200273,0.016882764,0.000016884085,0.0006415609,0.0190955],"study_design_scores_gemma":[0.044589125,0.09267167,0.85521895,0.00018685934,0.000049285267,0.000009824928,0.00036312875,0.000016390108,0.0019366998,0.00007810861,0.0047179973,0.00016197981],"about_ca_topic_score_codex":0.000020325493,"about_ca_topic_score_gemma":0.0010006916,"teacher_disagreement_score":0.07870923,"about_ca_system_score_codex":0.00006412677,"about_ca_system_score_gemma":0.00019650882,"threshold_uncertainty_score":0.3471015},"labels":[],"label_agreement":null},{"id":"W2292562657","doi":"10.1200/jco.2015.65.0218","title":"Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ramucirumab; Metastatic Urothelial Carcinoma; Docetaxel; Urothelial carcinoma; Randomized controlled trial; Urology; Oncology; Internal medicine; Phases of clinical research; Chemotherapy; Cancer; Bladder cancer","score_opus":0.1909879434777271,"score_gpt":0.502909767407231,"score_spread":0.31192182392950396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292562657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96915275,0.0004296104,0.0028889624,0.0077981693,0.0013590385,0.017871793,0.00011181216,0.000026143898,0.00036170267],"genre_scores_gemma":[0.9674345,0.0011474103,0.015525383,0.003798947,0.0012841366,0.0017208527,0.000015056104,0.00012020329,0.0089535015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99144715,0.001623023,0.005191938,0.0006204561,0.0005145374,0.00060291804],"domain_scores_gemma":[0.98392475,0.010956918,0.0031997394,0.0004942524,0.0006811413,0.0007432109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048207254,0.0006053159,0.009857548,0.00027149206,0.00013237598,0.000043558102,0.00047769715,0.0003640465,0.0026073891],"category_scores_gemma":[0.0047520553,0.00021979633,0.0007583892,0.00022325607,0.000425762,0.0004278666,0.000053910615,0.00044068936,0.000009179697],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75091434,0.04641236,0.000037422353,0.000019739895,0.0037679235,0.0016617815,0.0001390746,0.0000039201213,0.00035472843,0.00007488226,0.00012725688,0.19648656],"study_design_scores_gemma":[0.5620873,0.4300595,0.000020441823,0.00015319561,0.002195502,0.00028441648,0.00004944261,0.00019781747,0.0002974137,0.0005349582,0.0039417134,0.0001783049],"about_ca_topic_score_codex":0.000117078984,"about_ca_topic_score_gemma":0.003352679,"teacher_disagreement_score":0.38364714,"about_ca_system_score_codex":0.00060770084,"about_ca_system_score_gemma":0.013506635,"threshold_uncertainty_score":0.99830437},"labels":[],"label_agreement":null},{"id":"W2292759384","doi":"10.1200/jco.2011.29.7_suppl.1","title":"Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Bicalutamide; Urology; Clinical endpoint; Androgen deprivation therapy; Radiation therapy; Internal medicine; Placebo; Incidence (geometry); Randomized controlled trial; Cancer; Gynecology; Androgen receptor; Pathology","score_opus":0.05894315479136175,"score_gpt":0.43886286633248833,"score_spread":0.3799197115411266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292759384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949812,0.0023659882,0.0000047727776,0.00013923863,0.000079778125,0.0023761957,0.00004680255,0.0000037392867,0.0000022580853],"genre_scores_gemma":[0.9969349,0.0025991043,0.00023809393,0.0000261922,0.00005656658,0.00010664436,0.000015060983,0.00002113091,0.0000022916074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963553,0.00071221055,0.0017850088,0.00032885224,0.00058699393,0.0002316408],"domain_scores_gemma":[0.996964,0.0007835086,0.0014915541,0.00015825739,0.00019119917,0.00041152447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016293105,0.00021718668,0.0015538888,0.0002870508,0.000025861455,0.00000689864,0.00006570671,0.00009140866,0.000014079754],"category_scores_gemma":[0.00071394164,0.00011655744,0.0001207507,0.0002371702,0.00055682455,0.00020389115,0.00003445823,0.00043238606,3.3442014e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4406889,0.0021669546,0.5373168,0.00010149621,0.00034742214,0.00246019,0.00039084585,0.0000045965053,0.00031870758,2.3532967e-7,4.6609395e-7,0.016203383],"study_design_scores_gemma":[0.27901623,0.037744395,0.6774547,0.0011530248,0.00029931177,0.000016109023,0.000015734448,0.00009365851,0.00408142,0.00003698568,0.0000037797092,0.00008463701],"about_ca_topic_score_codex":0.00018936282,"about_ca_topic_score_gemma":0.00003601491,"teacher_disagreement_score":0.1616727,"about_ca_system_score_codex":0.000099383564,"about_ca_system_score_gemma":0.0014464607,"threshold_uncertainty_score":0.47530743},"labels":[],"label_agreement":null},{"id":"W2292883957","doi":"10.1200/jco.2005.23.16_suppl.4644","title":"What happens to men with prostate cancer whose PSA starts to rise while on neo-adjuvant androgen ablation therapy prior to external radiation?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Urology; Radiation therapy; Androgen suppression; External beam radiation; Cancer; Internal medicine; Gynecology","score_opus":0.09703080406941084,"score_gpt":0.4772025214035026,"score_spread":0.3801717173340918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292883957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8909093,0.0018328293,0.00007832012,0.104655385,0.0004895064,0.0014163201,0.000011360202,0.000011327117,0.0005956544],"genre_scores_gemma":[0.9593014,0.011407757,0.0045641814,0.016130136,0.002888325,0.00011581262,0.0000058820865,0.000047188496,0.0055393097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719137,0.00023742404,0.0011838811,0.00031044864,0.00067695644,0.00039992537],"domain_scores_gemma":[0.997129,0.0004340038,0.0005147542,0.0002230971,0.0005927985,0.0011063413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016569126,0.0001867333,0.0009184581,0.00025402426,0.000084110994,0.00006098137,0.00015651902,0.00015497477,0.0003550319],"category_scores_gemma":[0.000266132,0.00011174459,0.00016162694,0.00026271705,0.000057781654,0.00033687157,0.00004004374,0.000523222,0.0001004276],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056200743,0.0012374051,0.04583344,0.00000953035,0.0003112963,0.00034897384,0.0021997597,0.0017571963,0.0008015222,0.000008133639,0.018396638,0.87289536],"study_design_scores_gemma":[0.017278455,0.04525455,0.3195372,0.0005704509,0.0001327626,0.00007601989,0.00031532708,0.00016863042,0.003312332,0.000046514415,0.61311644,0.00019132819],"about_ca_topic_score_codex":0.000048237747,"about_ca_topic_score_gemma":0.00025249718,"teacher_disagreement_score":0.872704,"about_ca_system_score_codex":0.0006563006,"about_ca_system_score_gemma":0.001710999,"threshold_uncertainty_score":0.45568123},"labels":[],"label_agreement":null},{"id":"W2293619873","doi":"10.1200/jco.2006.24.18_suppl.4093","title":"Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Neuroendocrine tumors; Radiation therapy; Internal medicine; Retrospective cohort study; Cancer; Disease; Surgery; Oncology","score_opus":0.05301960164858342,"score_gpt":0.43194785427761295,"score_spread":0.3789282526290295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293619873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98179924,0.00021901554,0.00002024474,0.015743256,0.00042897154,0.00034804663,0.000004903897,0.0000059163367,0.0014303741],"genre_scores_gemma":[0.997256,0.000098232274,0.0009514332,0.00042315503,0.00055176986,0.0000065961917,5.5571314e-7,0.00001896929,0.0006933344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951344,0.0005884536,0.0026807198,0.00022331333,0.0009621017,0.00041097906],"domain_scores_gemma":[0.9925759,0.0033246889,0.002877629,0.0004252306,0.00056108873,0.00023548976],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009023756,0.00016945595,0.0011592411,0.00008324783,0.00006214265,0.0000060151883,0.00073271943,0.000016318118,0.000153173],"category_scores_gemma":[0.009629556,0.000083549356,0.0006047223,0.00028353394,0.0015918574,0.00012479736,0.00031909885,0.0013349879,0.0000034386906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025742091,0.002295137,0.97707325,0.00006200679,0.000023232782,0.007522359,0.000039977487,0.000097982345,0.00358929,0.00016392885,0.0035482356,0.0030103787],"study_design_scores_gemma":[0.0034219248,0.013175487,0.929331,0.00020934093,0.00008653995,0.02721515,0.00018270736,0.000035307145,0.011329694,0.0002785135,0.01466683,0.00006750404],"about_ca_topic_score_codex":0.000056391138,"about_ca_topic_score_gemma":0.000084470914,"teacher_disagreement_score":0.04774226,"about_ca_system_score_codex":0.00009063876,"about_ca_system_score_gemma":0.0009578089,"threshold_uncertainty_score":0.9987128},"labels":[],"label_agreement":null},{"id":"W2293716668","doi":"10.1200/jco.2015.64.3437","title":"Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Hazard ratio; Soft tissue sarcoma; Clinical endpoint; Internal medicine; End point; Oncology; Toxicity; Odds ratio; Sarcoma; Surgery; Confidence interval; Soft tissue; Pathology","score_opus":0.3724244643656675,"score_gpt":0.5884246678821383,"score_spread":0.2160002035164708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293716668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015007033,0.98191404,0.00036058077,0.00048158955,0.0006270221,0.0014617493,0.000013773706,0.0000039091874,0.00013030371],"genre_scores_gemma":[0.027103242,0.9669935,0.005395739,0.000032408007,0.00037564678,0.00004087048,0.000004439864,0.000021285692,0.000032852626],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9535087,0.012819894,0.03259419,0.0003202248,0.0005286371,0.00022837803],"domain_scores_gemma":[0.8135417,0.10901869,0.07587733,0.0002816101,0.0010185114,0.000262162],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09797928,0.00028251566,0.027212149,0.0004508857,0.000017876575,0.0000036766858,0.00009849453,0.00048120331,0.00011554429],"category_scores_gemma":[0.29195875,0.00014952138,0.003091799,0.00024279495,0.00034461473,0.00008553839,0.000050124316,0.0007211527,0.0000019162076],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02044719,0.002353491,0.010114124,0.0045165787,0.0017779795,0.00019086148,0.000019979778,4.8423846e-7,0.000007696,0.00017567967,0.00009525825,0.9603007],"study_design_scores_gemma":[0.5703213,0.014134023,0.034242526,0.07213572,0.025856532,0.0032934144,0.00013811159,0.000005734844,0.00005631381,0.0044135205,0.27493826,0.00046449833],"about_ca_topic_score_codex":0.00009729223,"about_ca_topic_score_gemma":0.00006961668,"teacher_disagreement_score":0.9598362,"about_ca_system_score_codex":0.00042774153,"about_ca_system_score_gemma":0.003317171,"threshold_uncertainty_score":0.9872299},"labels":[],"label_agreement":null},{"id":"W2294103278","doi":"10.1200/jco.2006.24.18_suppl.9513","title":"Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Sunitinib; Placebo; Interim analysis; Clinical endpoint; Internal medicine; Sunitinib malate; Gastroenterology; Phases of clinical research; Tyrosine-kinase inhibitor; Urology; Oncology; Clinical trial; Cancer; Pathology","score_opus":0.19470161076841178,"score_gpt":0.4899372835827932,"score_spread":0.29523567281438146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294103278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903465,0.00006629053,0.00029969364,0.007866882,0.00036497752,0.0015810273,0.000273145,0.000007726366,0.00050561],"genre_scores_gemma":[0.97758627,0.000037779737,0.020598587,0.00044237985,0.0007871421,0.000042044067,0.00014740226,0.000020857113,0.0003375202],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405533,0.0005417398,0.004186603,0.0003052745,0.0005329289,0.00037814173],"domain_scores_gemma":[0.99122816,0.004831317,0.002173046,0.0002831816,0.0010845,0.00039977752],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027619977,0.00019461717,0.002013217,0.00020683282,0.00006195812,0.000022798391,0.00023374344,0.00016330823,0.0001001626],"category_scores_gemma":[0.011399386,0.00012569726,0.0003886975,0.00028565654,0.00031026892,0.00009079651,0.00003436249,0.0006221102,0.000006249472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9334817,0.016768204,0.0052523855,0.000017021945,0.00015694593,0.0013508229,0.00012417251,0.000009358284,0.00022857546,0.000019056748,0.010904043,0.031687744],"study_design_scores_gemma":[0.7479139,0.11656641,0.09169842,0.0005048372,0.00009448715,0.00003178602,0.00009337416,0.00007722727,0.0005341396,0.00060568977,0.041763145,0.000116591895],"about_ca_topic_score_codex":0.00041184295,"about_ca_topic_score_gemma":0.0021000607,"teacher_disagreement_score":0.18556778,"about_ca_system_score_codex":0.00019648443,"about_ca_system_score_gemma":0.0019055505,"threshold_uncertainty_score":0.99692804},"labels":[],"label_agreement":null},{"id":"W2294431406","doi":"10.1200/jco.2009.27.15_suppl.534","title":"Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University; Jewish General Hospital; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Clinical endpoint; Vitamin D and neurology; Oncology; Hazard ratio; Population; Gastroenterology; Cancer; Endocrinology; Clinical trial; Confidence interval","score_opus":0.07805111853518344,"score_gpt":0.4708612578553881,"score_spread":0.3928101393202047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294431406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775253,0.00028122263,0.000002183142,0.019863868,0.0011084047,0.0005307753,0.000034572156,0.0000061973183,0.0006474655],"genre_scores_gemma":[0.99333483,0.00090580666,0.0008984763,0.0040083574,0.0006999563,0.0000062064782,0.0000036812794,0.000011187999,0.00013146934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965883,0.00027910588,0.0023083107,0.00018127314,0.00036075208,0.0002822907],"domain_scores_gemma":[0.99636215,0.00064767996,0.0017214997,0.00012195202,0.00054480677,0.00060188805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011724933,0.00014846823,0.0015059396,0.00011077217,0.000036300487,0.0000044106405,0.000077713514,0.00037512663,0.0001257517],"category_scores_gemma":[0.0008024619,0.000098578224,0.00022334038,0.00011849015,0.0001358138,0.00010532778,0.000022681137,0.00059718534,0.0000057642637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0982246,0.007767305,0.46331868,0.000038391718,0.0002694525,0.00016700602,0.000044546927,2.783695e-7,0.000015377058,0.000027954235,0.001753846,0.42837256],"study_design_scores_gemma":[0.10399803,0.06427902,0.8268424,0.0001249288,0.000518678,0.00016246429,0.000015740592,0.0000051555335,0.000026426238,0.00012140846,0.0038447625,0.00006098341],"about_ca_topic_score_codex":0.0001375455,"about_ca_topic_score_gemma":0.00007265953,"teacher_disagreement_score":0.4283116,"about_ca_system_score_codex":0.00013667217,"about_ca_system_score_gemma":0.0013573109,"threshold_uncertainty_score":0.40199035},"labels":[],"label_agreement":null},{"id":"W2294562171","doi":"10.1200/jco.2013.31.15_suppl.tps7131","title":"A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Idelalisib; Ofatumumab; Medicine; Internal medicine; Chronic lymphocytic leukemia; Bendamustine; Alemtuzumab; Fludarabine; Oncology; Ibrutinib; CD20; IGHV@; Gastroenterology; Leukemia; Immunology; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.08759778079866323,"score_gpt":0.4827884970728645,"score_spread":0.3951907162742012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294562171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98391956,0.0014247312,0.00033478788,0.0008538251,0.0001784006,0.012941419,0.0000013750464,0.000010108978,0.00033579394],"genre_scores_gemma":[0.9975759,0.00062498514,0.0005458167,0.00022254333,0.00031773417,0.00041841267,0.0000043041496,0.000032000848,0.0002583101],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989578,0.003072881,0.005630534,0.00033595398,0.00092792144,0.00045472794],"domain_scores_gemma":[0.957783,0.036311343,0.0036543866,0.00038816596,0.0015570652,0.0003060718],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025687708,0.00027032505,0.0055729602,0.00026938147,0.000085050466,0.000028190203,0.0002903233,0.00032262306,0.00010986811],"category_scores_gemma":[0.026687367,0.00013286881,0.0006021178,0.00032572213,0.0007606447,0.00017546955,0.000083690655,0.00081851473,0.000003254927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9245104,0.0034059228,0.00048197768,0.00013267456,0.0020820398,0.000118536984,0.0008528499,0.00082663016,0.00023070247,0.000073060255,0.00023606994,0.06704912],"study_design_scores_gemma":[0.7466191,0.081435,0.00122218,0.000380589,0.0018336308,0.00030593423,0.00040127386,0.16747652,0.00002510048,0.00015816333,0.00005020406,0.00009229791],"about_ca_topic_score_codex":0.001023037,"about_ca_topic_score_gemma":0.00021370342,"teacher_disagreement_score":0.1778913,"about_ca_system_score_codex":0.021513993,"about_ca_system_score_gemma":0.05445847,"threshold_uncertainty_score":0.9822422},"labels":[],"label_agreement":null},{"id":"W2295405522","doi":"10.1200/jco.2006.24.18_suppl.8525","title":"Physiological correlates of cancer-related fatigue in advanced non-small cell lung cancer (NSCLC) patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Cardiorespiratory fitness; Physical therapy; Cancer-related fatigue; Lung cancer; Rehabilitation; Rating scale; Cancer; Psychological intervention; Internal medicine; Psychology; Psychiatry","score_opus":0.07204476907053457,"score_gpt":0.4461705492828151,"score_spread":0.3741257802122805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295405522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888002,0.004631988,0.0000112706975,0.0011225453,0.0017555066,0.0003104628,0.000008050791,0.000009079997,0.003350882],"genre_scores_gemma":[0.9932386,0.0049039344,0.0007394303,0.0004642623,0.00041024978,0.000017371127,0.0000031171235,0.000015826678,0.00020716437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961094,0.00021616228,0.0028601773,0.00022772912,0.00026906858,0.0003174144],"domain_scores_gemma":[0.9961929,0.0010173453,0.0019277541,0.00012620837,0.0005612638,0.00017457678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078366924,0.00018170828,0.0021682335,0.00012038139,0.000030793406,0.0000020228206,0.00015288692,0.00045409397,0.00012807261],"category_scores_gemma":[0.00057495886,0.00012252567,0.00040361105,0.00024893097,0.00017359541,0.00006519833,0.00005810669,0.0010799483,0.0000026556606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017880828,0.0030820314,0.96243304,0.00010556256,0.00017425872,0.00009436957,0.00017695302,0.0006943518,0.0008684567,0.000011126106,0.0032810622,0.027290702],"study_design_scores_gemma":[0.015443193,0.0072499816,0.9731408,0.00065005047,0.00029157818,0.0000036598638,0.00006014579,0.00047775623,0.00040795188,0.00008472763,0.0020701708,0.000119997974],"about_ca_topic_score_codex":0.00041397678,"about_ca_topic_score_gemma":0.0004887762,"teacher_disagreement_score":0.027170703,"about_ca_system_score_codex":0.00028279584,"about_ca_system_score_gemma":0.001287216,"threshold_uncertainty_score":0.4996452},"labels":[],"label_agreement":null},{"id":"W2296026603","doi":"10.1200/jco.2009.27.15_suppl.8597","title":"A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Refractory (planetary science); Internal medicine; Proteasome inhibitor; Lenalidomide; Oncology; Gastroenterology; Pharmacology","score_opus":0.29832626792209627,"score_gpt":0.5394487551109878,"score_spread":0.2411224871888915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296026603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272424,0.00036383737,0.000024710143,0.004267273,0.0005464268,0.00062689936,0.0000031072614,0.000006595504,0.0014369261],"genre_scores_gemma":[0.9958917,0.00041576783,0.002205726,0.0006368616,0.0007792706,0.0000044319336,0.0000034408208,0.000008796204,0.0000540225],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941022,0.0013267825,0.0035961103,0.00021616135,0.00048993557,0.00026882382],"domain_scores_gemma":[0.9820162,0.01473994,0.0020925663,0.00023348017,0.00051071023,0.0004070932],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008934711,0.00013903655,0.0014969538,0.00018048167,0.000051202434,0.000009183331,0.00016943665,0.000402911,0.00002607654],"category_scores_gemma":[0.053441767,0.00008218956,0.00037152474,0.00022777375,0.00036228672,0.00009814376,0.00004260412,0.0016060761,0.00000474699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11499598,0.016898546,0.1818444,0.000011716637,0.00016621572,0.0006848355,0.000060389728,0.0000015023616,0.00029477585,0.000041249154,0.00042516482,0.6845752],"study_design_scores_gemma":[0.29531616,0.08572406,0.6131395,0.000096574884,0.00013679767,0.00014135455,0.000059217757,0.0012659824,0.000028660343,0.00034341664,0.0036967918,0.000051449344],"about_ca_topic_score_codex":0.000026213767,"about_ca_topic_score_gemma":0.000030164614,"teacher_disagreement_score":0.68452376,"about_ca_system_score_codex":0.00009882839,"about_ca_system_score_gemma":0.001273934,"threshold_uncertainty_score":0.9545315},"labels":[],"label_agreement":null},{"id":"W2296845301","doi":"10.1200/jco.2013.31.15_suppl.10000","title":"Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vincristine; Stage (stratigraphy); Cyclophosphamide; Radiation therapy; Surgery; Prednisone; Chemotherapy; Lymphoma; Internal medicine; Lymph node; Gastroenterology","score_opus":0.06882586978832474,"score_gpt":0.40914644701508807,"score_spread":0.34032057722676334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296845301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808728,0.0053186747,0.000021925502,0.009657103,0.0015611447,0.0008812176,0.000018903434,0.00001362214,0.0016545801],"genre_scores_gemma":[0.97777647,0.012845555,0.0038476088,0.0010147041,0.0041792034,0.00007824062,0.000026726744,0.00002938326,0.00020208556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993761,0.00074948266,0.0041588433,0.00039541957,0.0005399097,0.00039533369],"domain_scores_gemma":[0.9872958,0.006477526,0.004516916,0.00063472573,0.0005382624,0.00053678936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014016661,0.00031993387,0.0027894038,0.00012712204,0.000075924574,0.00001573303,0.00028984362,0.0006203244,0.0005055678],"category_scores_gemma":[0.001979936,0.00015968706,0.0013517612,0.00020914605,0.00033650317,0.00011877415,0.000087393295,0.00021671399,0.00011639228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002127013,0.012106835,0.5308311,0.000005201995,0.0015068465,0.0033781796,0.00015425467,0.0000020663272,0.000035032932,0.000035489622,0.008443899,0.4413741],"study_design_scores_gemma":[0.033276103,0.033509832,0.8617353,0.000032354408,0.0027514542,0.0051892675,0.00010151425,0.000024528703,0.00015851032,0.0002559715,0.06284469,0.00012047594],"about_ca_topic_score_codex":0.0020875544,"about_ca_topic_score_gemma":0.00010535976,"teacher_disagreement_score":0.44125363,"about_ca_system_score_codex":0.0013477536,"about_ca_system_score_gemma":0.004064236,"threshold_uncertainty_score":0.72097796},"labels":[],"label_agreement":null},{"id":"W2296869626","doi":"10.1200/jco.2006.24.18_suppl.3566","title":"Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Stage (stratigraphy); Cancer; Perforation; Internal medicine; Lymphovascular invasion; Gastroenterology; Mesentery; Radiation therapy; Abdominoperineal resection; Chemotherapy; Adjuvant therapy; Radiology; Metastasis; Oncology; Pathology","score_opus":0.043013957711142935,"score_gpt":0.37969077407285196,"score_spread":0.33667681636170904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296869626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629164,0.0007240176,0.000017347498,0.0008869066,0.00045046463,0.00033360292,0.000010907987,0.000004390938,0.001280706],"genre_scores_gemma":[0.9984556,0.00008844595,0.0005973423,0.00028487638,0.0004453878,0.0000133069925,0.0000024147707,0.000012946412,0.00009970972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975138,0.00014134312,0.0016181621,0.00016231024,0.00035748066,0.00020693276],"domain_scores_gemma":[0.99720716,0.00068673596,0.0014064243,0.00008947509,0.00050031015,0.00010989956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006056522,0.0001258047,0.0013262441,0.0001168996,0.000018056804,0.000003266517,0.00010222956,0.00009728615,0.00005162941],"category_scores_gemma":[0.00048194182,0.0000806241,0.00019973339,0.00020069904,0.0002731094,0.000080622645,0.00003336159,0.00047669892,0.0000014929565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008156744,0.0019384564,0.98457235,0.000057617952,0.00018283361,0.00028578035,0.00007188656,0.000029473293,0.00012097108,0.000013236479,0.0009086933,0.003661966],"study_design_scores_gemma":[0.012204882,0.010486687,0.97468233,0.00018004922,0.00020592622,0.000015517424,0.00009470078,0.000011017323,0.0001488091,0.000015778813,0.0018777271,0.00007658018],"about_ca_topic_score_codex":0.00031556413,"about_ca_topic_score_gemma":0.0008942732,"teacher_disagreement_score":0.009890015,"about_ca_system_score_codex":0.00014883289,"about_ca_system_score_gemma":0.0009203928,"threshold_uncertainty_score":0.32877555},"labels":[],"label_agreement":null},{"id":"W2296942186","doi":"10.1200/jco.2015.33.18_suppl.lba502","title":"PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Metastatic breast cancer; Internal medicine; Goserelin; Clinical endpoint; Oncology; Breast cancer; Interim analysis; Tolerability; Cancer; Gynecology; Tamoxifen; Clinical trial; Adverse effect","score_opus":0.12490245384450548,"score_gpt":0.4693961585716095,"score_spread":0.344493704727104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296942186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99142057,0.00078722555,0.00005910977,0.0049602245,0.00021045886,0.0024250338,0.00005452728,0.00001521389,0.00006763446],"genre_scores_gemma":[0.99233747,0.0013149625,0.004834241,0.0006063688,0.0005061004,0.00023381753,0.0000050446956,0.000059535116,0.000102459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957074,0.0006184732,0.00192642,0.0004193924,0.0008372167,0.0004911132],"domain_scores_gemma":[0.9940129,0.0013265074,0.0027231604,0.00025342102,0.0009862756,0.000697761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019816512,0.00039451465,0.0028617608,0.00024015228,0.00003775841,0.000017671435,0.00018575898,0.00017150486,0.00007843775],"category_scores_gemma":[0.00023870269,0.00020507367,0.00008488177,0.00035471338,0.00078289775,0.0003336707,0.000034464098,0.0010887937,8.1218e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8186631,0.007367932,0.0057429066,0.000040638177,0.0017420787,0.0006571252,0.0030987642,0.000022390714,0.001536369,0.000008522107,0.000012245684,0.16110788],"study_design_scores_gemma":[0.66150737,0.28378028,0.048710357,0.0005600611,0.00038900485,0.0014317615,0.0019047624,0.000010213095,0.0008728873,0.000046885627,0.00057278096,0.00021360202],"about_ca_topic_score_codex":0.00018419589,"about_ca_topic_score_gemma":0.00033254418,"teacher_disagreement_score":0.27641237,"about_ca_system_score_codex":0.00040349682,"about_ca_system_score_gemma":0.003907904,"threshold_uncertainty_score":0.8362661},"labels":[],"label_agreement":null},{"id":"W2296977397","doi":"10.1200/jco.2007.25.18_suppl.2043","title":"Evaluation of clinical markup with CT simulation in whole brain radiation therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Nuclear medicine; Radiation therapy; Radiology","score_opus":0.14679921838095505,"score_gpt":0.5587365373118514,"score_spread":0.4119373189308963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296977397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8698671,0.00017728259,0.12713185,0.0009463479,0.00032059135,0.0002724231,0.0000016411532,0.000005709969,0.0012770832],"genre_scores_gemma":[0.98327446,0.000045354347,0.01524028,0.0002982402,0.0010889894,0.0000027160881,0.000003251228,0.000014304857,0.000032380165],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949329,0.0012815889,0.0029347748,0.00015075097,0.00054729317,0.00015269016],"domain_scores_gemma":[0.9907101,0.0052531827,0.0031156668,0.00015098139,0.00067035534,0.00009973869],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.030245816,0.000103270315,0.00086157763,0.00014019996,0.00001822881,0.000004871245,0.00014339104,0.00013504583,0.00015595433],"category_scores_gemma":[0.001136833,0.00007527387,0.00025534755,0.0001824249,0.00010709013,0.00023620062,0.000009521566,0.0006327474,9.3080774e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010493628,0.00068111194,0.33217108,9.402981e-7,0.000099719015,0.000004554218,0.000037387883,0.005555912,0.00006980713,0.00012442896,0.00018398755,0.6600217],"study_design_scores_gemma":[0.0138355605,0.0069643683,0.8888412,0.000046903126,0.00008904165,0.000004797301,0.00007364476,0.017537775,0.0004234035,0.0062515265,0.06579391,0.00013786672],"about_ca_topic_score_codex":0.000021318176,"about_ca_topic_score_gemma":0.00002209404,"teacher_disagreement_score":0.65988386,"about_ca_system_score_codex":0.000101297126,"about_ca_system_score_gemma":0.0008895734,"threshold_uncertainty_score":0.99856603},"labels":[],"label_agreement":null},{"id":"W2296991627","doi":"10.1200/jco.2014.32.15_suppl.tps1144","title":"A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Enzalutamide; Medicine; Androgen receptor; Triple-negative breast cancer; Tolerability; Breast cancer; Clinical endpoint; Oncology; Cancer; Internal medicine; Adverse effect; Clinical trial; Prostate cancer","score_opus":0.022321275948322863,"score_gpt":0.38109818501857134,"score_spread":0.3587769090702485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296991627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871796,0.00011806648,0.000024139834,0.00019245985,0.00035081455,0.00046124888,0.000030228988,0.0000010180815,0.00010404547],"genre_scores_gemma":[0.9992365,0.00027961502,0.00022954064,0.00008655867,0.00014207124,0.0000035839673,0.0000019073171,0.000011683574,0.000008531551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961738,0.0017898963,0.0014368563,0.00023422837,0.00021148195,0.00015376603],"domain_scores_gemma":[0.99619085,0.0009171663,0.0021776548,0.00018794424,0.00038714393,0.0001392644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001933152,0.00014281149,0.0009890574,0.000040361498,0.00003452973,0.0000026285068,0.00018714185,0.000358861,0.0000043362224],"category_scores_gemma":[0.0014231054,0.000083247476,0.00021181295,0.00012949627,0.00040965868,0.000012648808,0.00010625177,0.0006217374,1.4441197e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07320248,0.027584558,0.57812595,0.000015378922,0.00084149325,0.0000062577733,0.00018862856,0.000089276946,0.0101571465,0.000004834005,0.00005091083,0.3097331],"study_design_scores_gemma":[0.05263326,0.11699665,0.81722826,0.00012729043,0.00023769279,0.000014733722,0.00014249525,0.000025305839,0.012223297,0.000018738387,0.00022869685,0.00012360631],"about_ca_topic_score_codex":0.00003100871,"about_ca_topic_score_gemma":0.00011194536,"teacher_disagreement_score":0.3096095,"about_ca_system_score_codex":0.00003663337,"about_ca_system_score_gemma":0.0003960943,"threshold_uncertainty_score":0.33947334},"labels":[],"label_agreement":null},{"id":"W2297369765","doi":"10.1200/jco.2006.24.18_suppl.3571","title":"Adjuvant therapy (AT) with raltitrexed (RAL) in colorectal cancer (CRC) patients (pts) intolerant of 5-fluorouracil (5FU)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Fluorouracil; Toxicity; Colorectal cancer; Gastroenterology; Surgery; Cancer","score_opus":0.06205477603510838,"score_gpt":0.4144693016037476,"score_spread":0.3524145255686392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297369765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105746,0.0028057762,0.0000025629408,0.0020282245,0.0005659598,0.00035913402,0.000012268012,0.0000059417407,0.003162699],"genre_scores_gemma":[0.9955912,0.002821142,0.00045413594,0.00046192072,0.00039644708,0.00002135886,0.0000049075684,0.000017518061,0.00023136911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690074,0.00020878656,0.0019854256,0.00020483158,0.00043645725,0.00026376965],"domain_scores_gemma":[0.9969299,0.0006843079,0.0015363026,0.00010388882,0.00059579324,0.000149815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006980272,0.0001921517,0.0019032134,0.00012980957,0.000040220384,0.0000035170606,0.00010770821,0.00021153715,0.00021238967],"category_scores_gemma":[0.0002547944,0.00010912354,0.0003318929,0.00019797088,0.00026057172,0.00007907974,0.00004666075,0.0004929016,0.000003388771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031084025,0.003812074,0.8038172,0.000018218401,0.00040505503,0.00029974454,0.00022863969,0.00003810521,0.00034780998,0.000010871516,0.0017321855,0.15820608],"study_design_scores_gemma":[0.027942728,0.029504705,0.9288258,0.00016367,0.00017945109,0.000047230194,0.00007261355,0.000027205382,0.00082089275,0.00006120137,0.012249529,0.00010495625],"about_ca_topic_score_codex":0.0011286403,"about_ca_topic_score_gemma":0.0059344494,"teacher_disagreement_score":0.15810113,"about_ca_system_score_codex":0.0006164727,"about_ca_system_score_gemma":0.0009880177,"threshold_uncertainty_score":0.44499287},"labels":[],"label_agreement":null},{"id":"W2297549254","doi":"10.1200/jco.2009.27.15_suppl.e20519","title":"Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Radiation therapy; Chemotherapy; Cognition; Oncology; Oligodendroglioma; Glioblastoma; Psychiatry","score_opus":0.1022068974369418,"score_gpt":0.44635529527904466,"score_spread":0.3441483978421029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297549254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979899,0.006188648,0.00040693654,0.011527178,0.0007895161,0.0010955202,0.000015640764,0.000009463738,0.00006809361],"genre_scores_gemma":[0.9760356,0.014483239,0.0026947476,0.0051864553,0.0015167709,0.000044387773,0.000012589496,0.000019299505,0.000006898294],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961928,0.00062697235,0.0023784775,0.00027646593,0.00029012823,0.0002351545],"domain_scores_gemma":[0.9931171,0.004009465,0.0020004956,0.00014741672,0.0003262927,0.00039924827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027346197,0.00021587936,0.0022508886,0.0002170243,0.000045771732,0.000014716132,0.00007369572,0.0006027689,0.00006701024],"category_scores_gemma":[0.0015427249,0.00015295189,0.00046820313,0.00012734212,0.00022501074,0.00012223545,0.000008451061,0.00035286866,5.661751e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44715178,0.0059167533,0.0138031,0.00004835121,0.0011893163,0.0000879376,0.00027178563,0.000003127174,0.0018763132,0.00022531462,0.0012648724,0.52816135],"study_design_scores_gemma":[0.3748272,0.12852082,0.48066422,0.00007450879,0.00049354846,0.00013694803,0.00007648643,0.00015461733,0.00070041063,0.0010810094,0.013109188,0.00016104306],"about_ca_topic_score_codex":0.0000072659946,"about_ca_topic_score_gemma":0.000035994875,"teacher_disagreement_score":0.5280003,"about_ca_system_score_codex":0.00015265192,"about_ca_system_score_gemma":0.00066629465,"threshold_uncertainty_score":0.6237197},"labels":[],"label_agreement":null},{"id":"W2297570718","doi":"10.1200/jco.2006.24.18_suppl.1563","title":"A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Oncolytics Biotech (Canada); University of Calgary","funders":"","keywords":"Medicine; Anaplastic astrocytoma; Oncolytic virus; Chemotherapy; Adverse effect; Internal medicine; Toxicity; Gastroenterology; Radiation therapy; Cancer; Surgery; Glioma; Oncology; Astrocytoma; Cancer research","score_opus":0.07004858599582411,"score_gpt":0.4401573996440536,"score_spread":0.37010881364822945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297570718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998327,0.00019386728,0.00006021993,0.0002730247,0.00043028343,0.0003679841,0.000016610193,0.0000014009955,0.00032960737],"genre_scores_gemma":[0.9987254,0.00009983819,0.0006508846,0.000073324954,0.00037225184,0.000006542165,0.000030433132,0.000010937094,0.000030364392],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9958521,0.00080682954,0.0024904201,0.00021900139,0.00040992914,0.00022171342],"domain_scores_gemma":[0.9966098,0.00023503287,0.0021889987,0.0002184714,0.0006207942,0.00012688024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024633163,0.0001377755,0.0009315349,0.00012848336,0.000015550206,0.000004407823,0.0002755881,0.0003602818,0.000034997443],"category_scores_gemma":[0.0010173452,0.00009720464,0.00025045604,0.00015716565,0.00038848538,0.000007778609,0.00003990508,0.00038260917,7.849056e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8977643,0.016462626,0.008087881,0.000020147827,0.000119995784,0.000122717,0.000010430677,0.00002510485,0.044863563,0.000062549974,0.0005367014,0.031923983],"study_design_scores_gemma":[0.23568039,0.66120607,0.0278636,0.000063442916,0.000085021,0.00002496625,0.000018672317,0.000019261097,0.068674736,0.00021775407,0.0059549683,0.00019114594],"about_ca_topic_score_codex":0.000014110806,"about_ca_topic_score_gemma":0.00036291336,"teacher_disagreement_score":0.6620839,"about_ca_system_score_codex":0.00004994576,"about_ca_system_score_gemma":0.001748889,"threshold_uncertainty_score":0.396389},"labels":[],"label_agreement":null},{"id":"W2297570742","doi":"10.1200/jco.2009.27.15_suppl.e15019","title":"A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Capecitabine; Bevacizumab; Clinical endpoint; Irinotecan; Internal medicine; Colorectal cancer; Oncology; FOLFIRI; Phases of clinical research; Progression-free survival; Gastroenterology; Toxicity; Cancer; Chemotherapy; Surgery; Clinical trial","score_opus":0.06320891869052882,"score_gpt":0.44045099126666,"score_spread":0.3772420725761312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297570742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961615,0.0009647378,0.0000020476216,0.0013077619,0.00017665027,0.00085638196,0.000008742306,0.000005690774,0.00051647215],"genre_scores_gemma":[0.99858254,0.00062420254,0.00028616775,0.00031878782,0.000100892285,0.000018693756,0.0000020463376,0.00001122173,0.000055473487],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99701566,0.0002594697,0.001841933,0.00024185909,0.0003917045,0.00024938592],"domain_scores_gemma":[0.99732953,0.00047563727,0.0012491775,0.00011461218,0.00059551053,0.00023551055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067539833,0.00020520146,0.0020829204,0.00018684042,0.000053899803,0.000004741966,0.00008493383,0.00010966519,0.000050912942],"category_scores_gemma":[0.00062286487,0.00012300575,0.00014473313,0.0002852134,0.00015520694,0.000089430694,0.000041888023,0.00048390354,4.4671933e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054906376,0.059759293,0.37875763,0.000028907207,0.0012691082,0.00067053677,0.0020710428,0.000017475513,0.000032113036,0.0000038094665,0.00024736943,0.50223637],"study_design_scores_gemma":[0.07835748,0.3550256,0.56426543,0.00011148141,0.00097195496,0.000046094272,0.00047393996,0.000024175495,0.000020702828,0.000018228535,0.00060768495,0.00007722369],"about_ca_topic_score_codex":0.0002880975,"about_ca_topic_score_gemma":0.00307452,"teacher_disagreement_score":0.5021591,"about_ca_system_score_codex":0.00028439073,"about_ca_system_score_gemma":0.00075983227,"threshold_uncertainty_score":0.50160295},"labels":[],"label_agreement":null},{"id":"W2297946465","doi":"10.1200/jco.2002.20.6.1704","title":"Quality of Life at the End of Life: How Is the Solution Far Away?","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Citation; Library science; Medicine; Norwegian; Computer science","score_opus":0.2570727516262406,"score_gpt":0.47803614427047475,"score_spread":0.22096339264423415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297946465","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07159533,0.006183248,0.000107458196,0.91591126,0.003663029,0.00047195767,0.0000974653,0.000009730808,0.0019605104],"genre_scores_gemma":[0.12198258,0.0042429296,0.00040665932,0.84804326,0.02194568,0.000006560239,0.000019392011,0.00006161433,0.0032912942],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9833139,0.005762755,0.007659494,0.00042858676,0.0023405582,0.0004946813],"domain_scores_gemma":[0.958689,0.0227377,0.015654622,0.001246943,0.0012629894,0.00040878024],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.017027166,0.00041613253,0.0052338573,0.00016176228,0.00011960241,0.000014075524,0.0010305726,0.0024702821,0.0014453538],"category_scores_gemma":[0.030546019,0.00022317383,0.0028684172,0.00025453678,0.002243795,0.00009633889,0.00031373,0.0073779724,0.000035675424],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020687787,0.0007015427,0.012738999,0.0004740376,0.0019060986,0.000068657435,0.0007251783,0.0000022470392,0.000026143802,0.000023529345,0.97259104,0.008673764],"study_design_scores_gemma":[0.0051550134,0.004578138,0.0877708,0.00028790775,0.0009869414,0.00012998255,0.00028348228,0.000013623865,0.000023702154,0.00025120532,0.90032476,0.000194425],"about_ca_topic_score_codex":0.00044124533,"about_ca_topic_score_gemma":0.0004299902,"teacher_disagreement_score":0.075031795,"about_ca_system_score_codex":0.0003276048,"about_ca_system_score_gemma":0.003926367,"threshold_uncertainty_score":0.99946743},"labels":[],"label_agreement":null},{"id":"W2297965911","doi":"10.1200/jco.2009.27.15_suppl.e19526","title":"Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Coronary artery disease; Cardiology; Gastroenterology; Lymphoma; Surgery","score_opus":0.0708993329576082,"score_gpt":0.4043826024593845,"score_spread":0.3334832695017763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297965911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890863,0.00017331465,0.0009441352,0.0059798374,0.0017559787,0.00016445285,8.9560393e-7,0.000015133311,0.0018799811],"genre_scores_gemma":[0.9922088,0.0005403247,0.0009846856,0.0029987898,0.003181006,0.0000013935096,0.000004079461,0.000010338725,0.00007063192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99696356,0.00051999575,0.0017858485,0.00015953844,0.00036791022,0.00020316507],"domain_scores_gemma":[0.99712837,0.0011894144,0.0011203019,0.000115551105,0.00021143595,0.00023494467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045286114,0.00011619825,0.0009670841,0.00022559674,0.000029333078,0.000008589994,0.00007974038,0.00044589816,0.000066625835],"category_scores_gemma":[0.003920034,0.00009671541,0.00041110947,0.00022595537,0.00006291989,0.00018262528,0.0000072416515,0.0005705554,0.000008771555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052300678,0.0008338546,0.029207392,0.000008181621,0.00008017303,0.00017562612,0.00020220484,0.00003324285,0.023148336,0.000050164363,0.000498012,0.94053274],"study_design_scores_gemma":[0.013475554,0.010895054,0.9566553,0.000116091134,0.00013764526,0.0005324907,0.00013006388,0.00022832776,0.005384091,0.0009858118,0.011361159,0.00009838397],"about_ca_topic_score_codex":0.00003623287,"about_ca_topic_score_gemma":0.0000844033,"teacher_disagreement_score":0.94043434,"about_ca_system_score_codex":0.00033962252,"about_ca_system_score_gemma":0.0010642994,"threshold_uncertainty_score":0.469293},"labels":[],"label_agreement":null},{"id":"W2298496254","doi":"10.1200/jco.2004.22.90140.8123","title":"FACT-Gastric: A new international measure of QOL in gastric cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cronbach's alpha; Cancer; Scale (ratio); Rating scale; Family medicine; Internal medicine; Psychometrics; Clinical psychology; Psychology","score_opus":0.1580850044457385,"score_gpt":0.4830705074917702,"score_spread":0.3249855030460317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298496254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.935115,0.00091861706,0.0026635402,0.049938448,0.0036276348,0.0002531648,0.0000028822758,0.000008445142,0.0074722813],"genre_scores_gemma":[0.9895057,0.0013104903,0.00506568,0.0017729782,0.0015336525,0.0000018116036,9.3121315e-7,0.000009495174,0.0007992318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722004,0.00007426937,0.0018989898,0.00012798785,0.00049844827,0.00018024021],"domain_scores_gemma":[0.9976677,0.00035089088,0.00134574,0.000106786836,0.00028906864,0.00023986195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012778301,0.00010237039,0.0010366548,0.00036983422,0.00000816893,0.000004703039,0.00021853439,0.00017510339,0.00037750506],"category_scores_gemma":[0.0018274307,0.00007517245,0.00038655504,0.00031891954,0.00007072038,0.000105976695,0.00005236439,0.0006929041,0.000006401816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021717981,0.0007864562,0.66653734,0.000018687288,0.00034876552,0.0003636244,0.000088503264,0.00044862277,0.00008181827,0.00012726948,0.007686519,0.32134062],"study_design_scores_gemma":[0.018466227,0.0037627793,0.92224497,0.00019529842,0.00024644204,0.00016534179,0.00010908843,0.000013320606,0.000031199015,0.0004948678,0.05421097,0.000059503105],"about_ca_topic_score_codex":0.00031704918,"about_ca_topic_score_gemma":0.00026795798,"teacher_disagreement_score":0.3212811,"about_ca_system_score_codex":0.0003940353,"about_ca_system_score_gemma":0.0025246292,"threshold_uncertainty_score":0.4478584},"labels":[],"label_agreement":null},{"id":"W2299028002","doi":"10.1200/jco.2013.31.15_suppl.tps5101","title":"The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Tumor progression; Oncology; Prostate; Cancer; Endocrinology; Androgen deprivation therapy","score_opus":0.07866189705111337,"score_gpt":0.4640489815275771,"score_spread":0.38538708447646375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299028002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931731,0.0010074467,0.000026091773,0.0023990585,0.00011009818,0.0031306632,0.0000037578898,0.0000019614447,0.00014779405],"genre_scores_gemma":[0.9966453,0.0017289561,0.0007631655,0.00003232777,0.00012928869,0.00038678883,0.0000023503878,0.000018081668,0.00029376568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940075,0.002841312,0.0022123102,0.0002587108,0.0003869084,0.00029324507],"domain_scores_gemma":[0.99668825,0.0009440583,0.0013996352,0.00023241257,0.00054620864,0.00018942238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008444805,0.00015819489,0.0011934506,0.00008126218,0.00012297592,0.000040791576,0.00021161504,0.00014209442,0.00002710088],"category_scores_gemma":[0.002233229,0.00008043884,0.00012300143,0.00014038851,0.00039957074,0.000024895582,0.0001182159,0.0004980593,7.173118e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78119546,0.0045045177,0.0011220732,0.00004297418,0.00075740897,0.00008204886,0.0010550352,0.00006398932,0.0803602,0.0000037812988,0.0005438122,0.13026871],"study_design_scores_gemma":[0.8922718,0.09186156,0.002544722,0.00016394258,0.00022332632,0.000037432615,0.0028010532,0.0004477778,0.0062906244,0.00011515504,0.0030541397,0.00018842371],"about_ca_topic_score_codex":0.0001893107,"about_ca_topic_score_gemma":0.0007834867,"teacher_disagreement_score":0.13008028,"about_ca_system_score_codex":0.00003967857,"about_ca_system_score_gemma":0.0010920925,"threshold_uncertainty_score":0.32802007},"labels":[],"label_agreement":null},{"id":"W2299152083","doi":"10.1200/jco.2013.31.15_suppl.7053","title":"Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Myeloid leukemia; Imatinib; Gastroenterology","score_opus":0.05615508806723663,"score_gpt":0.39863005748680974,"score_spread":0.3424749694195731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299152083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928742,0.00043291086,0.00012310645,0.0026967027,0.0009954441,0.0021667131,0.00001593785,0.00005107357,0.0006439348],"genre_scores_gemma":[0.9924714,0.00030309244,0.0015972254,0.0024624981,0.0021341117,0.00013635124,0.00005085231,0.00014274042,0.0007017034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919317,0.0006901225,0.0038219308,0.0009279295,0.0014621683,0.0011661511],"domain_scores_gemma":[0.99169916,0.0020713948,0.0026100953,0.000830459,0.00072592514,0.002062978],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017738004,0.0007363591,0.002881543,0.0005474246,0.00014667002,0.000063156855,0.00059548754,0.00047730329,0.0005515318],"category_scores_gemma":[0.0022387127,0.00048019856,0.00047747063,0.0005390239,0.000313392,0.00052586984,0.00017854829,0.002541883,0.00035766524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.057362985,0.007940176,0.54669434,0.0004320894,0.0013491346,0.0065489644,0.0004468309,0.0013766488,0.0007303003,0.000038020768,0.0043264837,0.37275404],"study_design_scores_gemma":[0.14482859,0.10029146,0.7466665,0.0027943368,0.00095349865,0.00031538814,0.000055320932,0.0004100854,0.00026030044,0.000055537606,0.0027970104,0.000572019],"about_ca_topic_score_codex":0.00027740348,"about_ca_topic_score_gemma":0.0014431854,"teacher_disagreement_score":0.372182,"about_ca_system_score_codex":0.016010385,"about_ca_system_score_gemma":0.02214479,"threshold_uncertainty_score":0.999765},"labels":[],"label_agreement":null},{"id":"W2299224211","doi":"10.1200/jco.2006.24.18_suppl.6043","title":"Who are the users of publicly reported cancer treatment wait times (WT)?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Facilitator; Medicine; Referral; Family medicine; Focus group; Health care; Phone; Usability; Nursing; Psychology","score_opus":0.16881116789673406,"score_gpt":0.3984334977195637,"score_spread":0.22962232982282965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299224211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9304028,0.0056878934,0.00010727557,0.013509092,0.00200861,0.00014719751,0.00006959654,0.0000065170725,0.048060976],"genre_scores_gemma":[0.9891142,0.0041050627,0.0002258139,0.0011066762,0.0015780374,0.0000071095305,0.0000015071372,0.000018200668,0.003843372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99548405,0.00006471135,0.0039199307,0.00021749263,0.000054409953,0.00025941228],"domain_scores_gemma":[0.9908351,0.0006652324,0.007840492,0.00029154573,0.0002324152,0.00013524377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024351177,0.00014729015,0.0017739434,0.00013700116,0.00005720266,0.000027759586,0.00031825618,0.00030471204,0.00056091195],"category_scores_gemma":[0.0011710048,0.00010328571,0.00064400875,0.00014158819,0.00026450213,0.0002876414,0.000034862333,0.0003539163,0.000035840694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040319795,0.0006953493,0.8959108,0.000008618616,0.0004966226,0.000044926488,0.00007359746,0.00033717262,0.0000027979206,0.03643316,0.034490317,0.031103453],"study_design_scores_gemma":[0.0018079022,0.0011987806,0.52411133,0.000022341133,0.000053550895,0.000017503862,0.000057108504,0.00010519414,0.000024949402,0.01256455,0.45994002,0.00009676707],"about_ca_topic_score_codex":0.0022568926,"about_ca_topic_score_gemma":0.0011608013,"teacher_disagreement_score":0.4254497,"about_ca_system_score_codex":0.000338562,"about_ca_system_score_gemma":0.00062165677,"threshold_uncertainty_score":0.6141592},"labels":[],"label_agreement":null},{"id":"W2299405794","doi":"10.1200/jco.2005.23.16_suppl.4520","title":"Should surveillance be considered the standard of care in stage I seminoma?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Stage (stratigraphy); Radiation therapy; Surgery; Watchful waiting; Chemotherapy; Internal medicine; Cancer","score_opus":0.15002512651554265,"score_gpt":0.4965168547371962,"score_spread":0.3464917282216535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299405794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747929,0.008077501,0.0000118053895,0.015302,0.00023643806,0.0001641316,0.00003281288,0.0000035361388,0.0013789054],"genre_scores_gemma":[0.99622506,0.00049601536,0.0012761747,0.001616949,0.00028395106,0.0000012998806,0.000002483916,0.000007811547,0.000090252586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977983,0.00028711776,0.0013892102,0.00009842773,0.00029282874,0.00013408267],"domain_scores_gemma":[0.99633396,0.0019829604,0.0009810405,0.00017777481,0.0003441039,0.00018016074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011522801,0.00008301136,0.0010102844,0.000047810794,0.000016108575,0.0000030855435,0.00009080477,0.0001596915,0.00014319901],"category_scores_gemma":[0.0033730029,0.00004601646,0.00033239886,0.000075927186,0.00018028809,0.0000346434,0.000028395916,0.0004375629,0.0000024913875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050296322,0.0008961984,0.88733345,0.00004425551,0.0002480929,0.0009596443,0.00018697386,0.000074685086,0.000017417768,0.00011501465,0.0014782024,0.103616446],"study_design_scores_gemma":[0.0101675205,0.00946256,0.89435875,0.00008910809,0.00020450457,0.00013194323,0.0005262063,0.00003113244,0.000071159906,0.0000583978,0.08485029,0.000048404556],"about_ca_topic_score_codex":0.00001888768,"about_ca_topic_score_gemma":0.00057635305,"teacher_disagreement_score":0.10356804,"about_ca_system_score_codex":0.00013683406,"about_ca_system_score_gemma":0.0015169326,"threshold_uncertainty_score":0.4038043},"labels":[],"label_agreement":null},{"id":"W2300100795","doi":"10.1200/jco.2009.27.15_suppl.e19532","title":"Snk/Plk2 CpG methylation in patients with multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; CpG site; Medicine; DNA methylation; Population; CDKN2B; Molecular biology; Cancer research; Internal medicine; Cancer; Biology; CDKN2A; Gene; Genetics; Gene expression","score_opus":0.09568431572473651,"score_gpt":0.4643688400629813,"score_spread":0.3686845243382448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300100795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939726,0.00007378052,0.00014231139,0.0031489257,0.00019258149,0.00030416748,0.0000022915922,0.0000065825675,0.0021567324],"genre_scores_gemma":[0.9929189,0.000055206383,0.0057776035,0.0008283155,0.000293188,0.0000027567494,0.000009488208,0.000009112562,0.000105442545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972351,0.0003460075,0.0014499984,0.00016135516,0.00053868926,0.00026884433],"domain_scores_gemma":[0.99689376,0.0012650697,0.00077718095,0.00015895367,0.00047865705,0.00042636183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001520034,0.00011757812,0.0009908413,0.00021853263,0.000025930323,0.000006746173,0.00010130652,0.00024292294,0.00010779559],"category_scores_gemma":[0.0042973123,0.00007118405,0.00020667074,0.0001964828,0.00008099686,0.00015221919,0.000016604625,0.0007738624,0.000025817537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01105949,0.0028782205,0.6707494,0.000004415319,0.00010818934,0.00041137874,0.000023561968,0.000008616136,0.000022139398,0.000017264987,0.000276733,0.31444058],"study_design_scores_gemma":[0.033327438,0.027699964,0.93442047,0.00006672544,0.00007541952,0.000026988164,0.000016487164,0.00015460992,0.00005883987,0.00021690107,0.0038761431,0.00006003738],"about_ca_topic_score_codex":0.00001476673,"about_ca_topic_score_gemma":0.000048831953,"teacher_disagreement_score":0.31438056,"about_ca_system_score_codex":0.00019647567,"about_ca_system_score_gemma":0.0006861765,"threshold_uncertainty_score":0.5144595},"labels":[],"label_agreement":null},{"id":"W2300122958","doi":"10.1200/jco.2005.23.16_suppl.4611","title":"First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Mitoxantrone; Medicine; Internal medicine; Chemotherapy; Oncology; Regimen; Prostate cancer; Performance status; Progression-free survival; Surgery; Gastroenterology; Cancer","score_opus":0.04831283444831135,"score_gpt":0.42675120801868766,"score_spread":0.3784383735703763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300122958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768976,0.0011683783,0.00000436263,0.021073086,0.00024325398,0.000420488,0.000018726741,0.0000064994715,0.00016760614],"genre_scores_gemma":[0.9830289,0.0057225693,0.0019242392,0.0070207166,0.0008363368,0.000021223164,0.000003894069,0.000025941434,0.0014161692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798954,0.000115443545,0.0011422953,0.00023739645,0.0002355255,0.00027981363],"domain_scores_gemma":[0.99779457,0.00054450386,0.0010193315,0.00011908528,0.00023858112,0.00028395082],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004942091,0.00019692506,0.0011856959,0.00011276988,0.000033021606,0.000008388538,0.00008893641,0.00019746479,0.0014118048],"category_scores_gemma":[0.000043757616,0.00009201564,0.000082182945,0.000120764365,0.0002874764,0.00021123081,0.000018987816,0.00072690804,0.0000047701274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08101359,0.0037696117,0.8375789,0.000052572774,0.0005382423,0.0003515425,0.00031638154,0.000036773403,0.00014695304,0.000001060271,0.0034030078,0.072791405],"study_design_scores_gemma":[0.04987787,0.031031523,0.8087394,0.0001331599,0.00028131425,0.00010898783,0.000037135127,0.000029749794,0.000072181894,0.00000994627,0.10955353,0.00012518946],"about_ca_topic_score_codex":0.000056282715,"about_ca_topic_score_gemma":0.0025075343,"teacher_disagreement_score":0.10615052,"about_ca_system_score_codex":0.00029436007,"about_ca_system_score_gemma":0.001029617,"threshold_uncertainty_score":0.99950105},"labels":[],"label_agreement":null},{"id":"W2300659078","doi":"10.1200/jco.2013.31.4_suppl.lba5","title":"REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Ramucirumab; Medicine; Internal medicine; Clinical endpoint; Hazard ratio; Progression-free survival; Gastroenterology; Placebo; Cancer; Oncology; Phases of clinical research; Randomized controlled trial; Toxicity; Chemotherapy; Pathology; Confidence interval","score_opus":0.1596108721350184,"score_gpt":0.4579740626354947,"score_spread":0.2983631905004763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300659078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313784,0.0012285039,0.000085483334,0.0013536259,0.0005091003,0.0036219738,0.0000029936207,0.0000046245295,0.000055872584],"genre_scores_gemma":[0.9968948,0.0019232698,0.0006758935,0.000071547984,0.00023198662,0.00012834797,0.000013060952,0.000012764746,0.000048331887],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965442,0.00059370324,0.0019923567,0.0002329167,0.00043510387,0.0002017213],"domain_scores_gemma":[0.99331367,0.004323004,0.0018210659,0.00014368742,0.00019585967,0.00020273252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019741377,0.00021657356,0.001925614,0.00030867688,0.00006810124,0.00002102319,0.00007323847,0.00010828801,0.000044449698],"category_scores_gemma":[0.0012683208,0.00010700606,0.00034756452,0.00018698072,0.0001799799,0.00016481764,0.000026216254,0.0002890525,2.520078e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83058,0.003324181,0.010273129,0.00006669713,0.0005450641,0.00034789188,0.0013677002,0.000010035522,0.0000032638998,0.000014008398,0.000033389384,0.15343465],"study_design_scores_gemma":[0.8399232,0.14210586,0.012352795,0.00020279115,0.001858928,0.000035802244,0.0027634385,0.00057683984,0.000019179619,0.000034287226,0.000063443455,0.00006342118],"about_ca_topic_score_codex":0.00007648911,"about_ca_topic_score_gemma":0.000080728765,"teacher_disagreement_score":0.15337123,"about_ca_system_score_codex":0.00014764165,"about_ca_system_score_gemma":0.00039882708,"threshold_uncertainty_score":0.43635803},"labels":[],"label_agreement":null},{"id":"W2300704109","doi":"10.1200/jco.2014.32.31_suppl.155","title":"A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Zoledronic acid; Breast cancer; Bone pain; N-terminal telopeptide; Internal medicine; Palliative care; Bone remodeling; Surgery; Metastatic breast cancer; Clinical endpoint; Cancer; Randomized controlled trial","score_opus":0.12915264970744808,"score_gpt":0.482953833299391,"score_spread":0.3538011835919429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300704109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915122,0.00016766021,0.00006629463,0.004028388,0.0007068655,0.0034549222,0.000030923187,0.000004709536,0.00002806144],"genre_scores_gemma":[0.9973539,0.00010378339,0.00096926274,0.0008932325,0.0004633306,0.00013528316,0.000004215592,0.000026693906,0.000050284354],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923752,0.0028026525,0.0033921585,0.00028235125,0.0008203697,0.00032725095],"domain_scores_gemma":[0.98290753,0.011435449,0.004364755,0.00028567703,0.00071890483,0.00028769905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012900491,0.00023906918,0.0030051365,0.000123734,0.00009458842,0.000015664982,0.00020465057,0.00015830001,0.00010323882],"category_scores_gemma":[0.0034714744,0.00009337495,0.00033397056,0.00024351447,0.00014324572,0.000098604934,0.00007457765,0.0010936236,0.0000039740576],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.673617,0.002340137,0.2086775,0.000006722422,0.001264018,0.000023608085,0.00092285406,0.00019867788,0.0000011385316,0.000010341765,0.000007714883,0.11293027],"study_design_scores_gemma":[0.5971966,0.019594673,0.3802769,0.00023881091,0.0020513937,0.0000041179683,0.00020885355,0.00017040469,0.0000023321072,0.00013146474,0.000061416584,0.000063046835],"about_ca_topic_score_codex":0.0052941786,"about_ca_topic_score_gemma":0.0067159524,"teacher_disagreement_score":0.1715994,"about_ca_system_score_codex":0.00015969138,"about_ca_system_score_gemma":0.0007751312,"threshold_uncertainty_score":0.8003249},"labels":[],"label_agreement":null},{"id":"W2300740433","doi":"10.1200/jco.2009.27.15_suppl.5017","title":"Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lymphovascular invasion; Cystectomy; Internal medicine; Bladder cancer; Randomization; Randomized controlled trial; Lymph node; Oncology; Clinical endpoint; Population; Urology; Stage (stratigraphy); Adjuvant therapy; Cancer; Gastroenterology","score_opus":0.06812904040344381,"score_gpt":0.43027706456962816,"score_spread":0.36214802416618436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300740433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833662,0.00053178257,0.0005305507,0.0076559754,0.0020764868,0.0039083026,0.00008105955,0.000015174119,0.0018344866],"genre_scores_gemma":[0.9879717,0.001656091,0.003257528,0.004747111,0.0018867443,0.00007561643,0.0000110474875,0.000034128985,0.00036001118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99549454,0.00062373513,0.0027684001,0.00026485592,0.0005476018,0.00030084737],"domain_scores_gemma":[0.99207044,0.0030223262,0.0027832508,0.00020245621,0.0015990766,0.00032243138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018611164,0.0002709773,0.0036576162,0.00012977941,0.000048077745,0.000007488263,0.00017329169,0.00037523668,0.0005118977],"category_scores_gemma":[0.003149208,0.0001487033,0.0009393451,0.0001566266,0.00036075126,0.00009395697,0.00001091546,0.0005284267,0.0000031525458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.901242,0.006205119,0.0018771703,0.000011164755,0.0021285396,0.000032106473,0.00026803656,0.000006912468,0.00016403769,0.000031530137,0.0018242341,0.08620912],"study_design_scores_gemma":[0.88576245,0.09343455,0.01081673,0.00010060443,0.001387105,0.0000126929635,0.000039107876,0.000032583393,0.0014137453,0.0006243761,0.0062396335,0.00013641987],"about_ca_topic_score_codex":0.00008564909,"about_ca_topic_score_gemma":0.000025087475,"teacher_disagreement_score":0.08722943,"about_ca_system_score_codex":0.00013336955,"about_ca_system_score_gemma":0.003161144,"threshold_uncertainty_score":0.60639447},"labels":[],"label_agreement":null},{"id":"W2300829931","doi":"10.1200/jco.2007.25.18_suppl.5074","title":"C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Prostate cancer; C-reactive protein; Hazard ratio; Proportional hazards model; Biomarker; Docetaxel; Oncology; Cancer; Inflammation; Confidence interval","score_opus":0.07054018737188011,"score_gpt":0.43762848070260446,"score_spread":0.36708829333072435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300829931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776792,0.0003675477,0.000095633906,0.012967615,0.0009166767,0.005529001,0.000080581034,0.000018212502,0.0023455098],"genre_scores_gemma":[0.9906765,0.00007143846,0.0037122562,0.0015718794,0.0031796093,0.00029355104,0.000015892181,0.00004444036,0.0004343979],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994657,0.0005861422,0.0030040448,0.0003984638,0.00087323476,0.00048115355],"domain_scores_gemma":[0.98819095,0.006559111,0.0031775825,0.00033609895,0.0011531254,0.0005831144],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010578859,0.00025297413,0.0012437392,0.00008716213,0.00010939395,0.000026160538,0.00028796057,0.00043706322,0.00008480018],"category_scores_gemma":[0.012069796,0.00013364416,0.0005739048,0.00015888155,0.00036854044,0.00012240135,0.00007190824,0.0010262091,0.000010230083],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8159246,0.002343396,0.107004516,0.000030638756,0.0022427645,0.0013293013,0.00032668613,0.0000014804277,0.00020345527,0.000026107553,0.005078916,0.06548813],"study_design_scores_gemma":[0.33498222,0.037525266,0.51554716,0.0009402269,0.003065198,0.00025823864,0.0009811055,0.00009895793,0.0022180742,0.00072552694,0.10333002,0.00032801158],"about_ca_topic_score_codex":0.0000834465,"about_ca_topic_score_gemma":0.00017715245,"teacher_disagreement_score":0.4809424,"about_ca_system_score_codex":0.00040404414,"about_ca_system_score_gemma":0.0042981277,"threshold_uncertainty_score":0.99625194},"labels":[],"label_agreement":null},{"id":"W2300851431","doi":"10.1200/jco.2007.25.18_suppl.556","title":"International comparison of the cost-effectiveness of 5 years letrozole or anastrozole compared to 5 years tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Belgium, Canada, UK, and US analyses","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Anastrozole; Medicine; Letrozole; Tamoxifen; Breast cancer; Discontinuation; Nice; Quality-adjusted life year; Population; Gynecology; Oncology; Cancer; Adverse effect; Internal medicine; Cohort; Cost effectiveness; Demography","score_opus":0.4028637660764713,"score_gpt":0.5613474758066116,"score_spread":0.1584837097301403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300851431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923723,0.00026746473,0.00046823904,0.0042507555,0.001112981,0.00056647003,0.0008484789,0.0000012443543,0.000112079666],"genre_scores_gemma":[0.99731153,0.000049429014,0.0010048366,0.0012912966,0.00027966173,0.000021932012,0.0000043007044,0.0000111746085,0.000025858397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936902,0.00053037464,0.0051543624,0.00020626062,0.00015998866,0.0002588106],"domain_scores_gemma":[0.9894868,0.005157325,0.004696695,0.00013791672,0.0003014358,0.00021980169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01724802,0.00010514271,0.0018047856,0.00025443285,0.000029968433,0.000010023754,0.00031490246,0.00015030365,0.000078327976],"category_scores_gemma":[0.0028226804,0.00009741361,0.00011892413,0.00021352211,0.00013252218,0.00012296226,0.00006725606,0.00029921898,0.000002121094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052853255,0.000474285,0.9832247,0.000050725925,0.000419934,0.000004348428,0.0010363641,0.0017538425,0.00019043982,0.00028358874,0.0036178834,0.0036586015],"study_design_scores_gemma":[0.0031643482,0.0013939872,0.98863083,0.000095769974,0.000017662498,0.0000061754286,0.0007505364,0.00026312107,0.000043299304,0.00009551004,0.005449213,0.00008956375],"about_ca_topic_score_codex":0.051173612,"about_ca_topic_score_gemma":0.09205955,"teacher_disagreement_score":0.04088594,"about_ca_system_score_codex":0.0013460497,"about_ca_system_score_gemma":0.0012919336,"threshold_uncertainty_score":0.9551447},"labels":[],"label_agreement":null},{"id":"W2300863317","doi":"10.1200/jco.2006.24.18_suppl.7510","title":"The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prednisone; Internal medicine; Vincristine; Stage (stratigraphy); Follicular lymphoma; Cyclophosphamide; Bleomycin; Chlorambucil; Lymphoma; Nodular sclerosis; Gastroenterology; Oncology; Vindesine; Etoposide; B symptoms; Chemotherapy; Hodgkin lymphoma","score_opus":0.07673498519144932,"score_gpt":0.47602369118546567,"score_spread":0.39928870599401634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300863317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943928,0.0005083793,0.000014934164,0.0015477146,0.00021976723,0.00034446095,0.0000420158,0.000001791862,0.0029280991],"genre_scores_gemma":[0.9959511,0.0036284642,0.000113912916,0.000049944032,0.00021098783,0.000007747642,0.0000032033101,0.0000067158685,0.000027898175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967257,0.00045955283,0.002272999,0.00007495566,0.0003318431,0.00013499653],"domain_scores_gemma":[0.9918338,0.0047387136,0.0028405949,0.00020310731,0.0002994089,0.000084376275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012990702,0.0001232327,0.0011085869,0.000063710475,0.000041405605,0.0000026151763,0.00009700101,0.00014601983,0.000039678132],"category_scores_gemma":[0.0005647344,0.00004694424,0.0010485157,0.00008967835,0.00023915518,0.000047013404,0.000007526826,0.000111618145,0.0000018336438],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021768115,0.02026821,0.14720073,0.000025168722,0.0020781185,0.00008840985,0.00066414895,0.0012437854,0.00033410144,0.0013721049,0.0004308286,0.80452627],"study_design_scores_gemma":[0.021711119,0.06460224,0.8991264,0.00009436132,0.00057408056,0.00003772263,0.00030321584,0.00008490406,0.009936965,0.00036776616,0.0031225253,0.000038687824],"about_ca_topic_score_codex":0.00035364195,"about_ca_topic_score_gemma":0.000056545487,"teacher_disagreement_score":0.8044876,"about_ca_system_score_codex":0.00034614722,"about_ca_system_score_gemma":0.0010011998,"threshold_uncertainty_score":0.19143306},"labels":[],"label_agreement":null},{"id":"W2301205426","doi":"10.1200/jco.2006.24.18_suppl.4614","title":"Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Incidence (geometry); Chemotherapy; Zoledronic acid; Surgery; Oncology; Urology; Gastroenterology","score_opus":0.06414390364074851,"score_gpt":0.4350035956280465,"score_spread":0.370859691987298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301205426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699,0.0016771189,0.00000955475,0.009521603,0.00024171597,0.0007381895,0.00007936002,0.000015814443,0.00072665897],"genre_scores_gemma":[0.9955405,0.0013886443,0.00086479285,0.00051277684,0.00027803492,0.000024550118,0.00010375915,0.00003760089,0.0012493305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521244,0.00059355696,0.002602708,0.00038091722,0.00076106313,0.00044933058],"domain_scores_gemma":[0.99648726,0.000910052,0.0015683117,0.00023994356,0.00043586234,0.0003585578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021556925,0.00025174028,0.0015864689,0.00026346566,0.0000413743,0.00001312288,0.00016802369,0.00029594908,0.00020308107],"category_scores_gemma":[0.00036837286,0.00014864533,0.00034232947,0.00040134494,0.00022044698,0.00011637908,0.000025566651,0.0011860102,0.000013605714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082417235,0.006726952,0.8341302,0.000045664634,0.001662194,0.006485734,0.00017534079,0.0005947275,0.00035878125,0.0000072992284,0.0015140714,0.06588178],"study_design_scores_gemma":[0.13276371,0.011730059,0.84287465,0.0005538108,0.0006784328,0.000109775414,0.000080048434,0.0006275251,0.001836098,0.00043846772,0.008099233,0.0002082269],"about_ca_topic_score_codex":0.0017768446,"about_ca_topic_score_gemma":0.0010271566,"teacher_disagreement_score":0.06567355,"about_ca_system_score_codex":0.0006696787,"about_ca_system_score_gemma":0.0030658692,"threshold_uncertainty_score":0.6061581},"labels":[],"label_agreement":null},{"id":"W2303023826","doi":"10.1200/jco.2007.25.18_suppl.1017","title":"Central nervous system (CNS) metastases (mets) in HER2+ metastatic breast cancer (MBC) patients (pts): Patterns of relapse and impact on survival","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Breast cancer; Trastuzumab; Cancer; Oncology","score_opus":0.08275607319581818,"score_gpt":0.47835817984924983,"score_spread":0.39560210665343165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303023826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958264,0.0004770929,0.0000329113,0.00092527235,0.0019231528,0.00031338428,0.00017413328,0.000006242992,0.00032137622],"genre_scores_gemma":[0.997814,0.00083987013,0.00018094169,0.0005189704,0.0005633963,0.000003747845,0.000010242654,0.00002112517,0.00004772702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995854,0.00069108815,0.0024137849,0.00021922315,0.0004010921,0.0004208208],"domain_scores_gemma":[0.9952003,0.0022004154,0.001694823,0.00013764667,0.00029719863,0.00046961362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002852008,0.00022275255,0.00207443,0.00028167982,0.000022881264,0.00000503368,0.00011082366,0.00019835283,0.00025892333],"category_scores_gemma":[0.0003295307,0.00014193892,0.0004786027,0.00018106731,0.00012697662,0.00011215035,0.00003691101,0.00073990296,0.00000214735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018672507,0.0054984605,0.88312846,0.00014518309,0.0011881345,0.0013711079,0.00012370918,0.000083352694,0.0000715073,0.000034690223,0.0006181236,0.08906478],"study_design_scores_gemma":[0.018982109,0.016669294,0.96066594,0.0002885835,0.0012915797,0.00036559388,0.00021749377,0.000037167625,0.000074495496,0.00001088101,0.0012945381,0.00010229989],"about_ca_topic_score_codex":0.0013607033,"about_ca_topic_score_gemma":0.0011678895,"teacher_disagreement_score":0.08896247,"about_ca_system_score_codex":0.000705026,"about_ca_system_score_gemma":0.0008293617,"threshold_uncertainty_score":0.5788101},"labels":[],"label_agreement":null},{"id":"W2303984794","doi":"10.1200/jco.2010.28.15_suppl.tps189","title":"PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type <i>KRAS</i>.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Panitumumab; Bevacizumab; Medicine; KRAS; Colorectal cancer; Internal medicine; Oncology; Cetuximab; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Cancer","score_opus":0.07185874467844428,"score_gpt":0.4433127540103353,"score_spread":0.37145400933189104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303984794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991828,0.0006261867,0.000027406642,0.0014502702,0.0011311041,0.004414256,0.000022230213,0.000015976477,0.00048454528],"genre_scores_gemma":[0.997711,0.00014746978,0.00082176883,0.00063006044,0.00032682592,0.00017621795,0.0000071934787,0.000042722455,0.00013672901],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937537,0.001188529,0.0031166894,0.00048087546,0.00088630995,0.00057394494],"domain_scores_gemma":[0.99151236,0.0043788515,0.0018955419,0.00038476882,0.0012859554,0.0005425475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032403828,0.0004317705,0.0047350246,0.00029865163,0.00023002656,0.000031050207,0.00040946086,0.00011497994,0.00017401723],"category_scores_gemma":[0.0058195507,0.00022594612,0.0004847543,0.00076575845,0.00038942855,0.00014161583,0.00027646538,0.0012580947,0.000005462723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8551662,0.021573856,0.06663702,0.000056258443,0.0035405946,0.0005035467,0.013273256,0.00086798676,0.00025078142,0.0000078139265,0.0013066622,0.036816027],"study_design_scores_gemma":[0.74501115,0.12513039,0.118301064,0.0005806283,0.0043881834,0.000088920606,0.0023405408,0.00022144876,0.00017717814,0.000020144402,0.0034118877,0.0003284507],"about_ca_topic_score_codex":0.0018552035,"about_ca_topic_score_gemma":0.014843809,"teacher_disagreement_score":0.11015504,"about_ca_system_score_codex":0.00068816415,"about_ca_system_score_gemma":0.0029351546,"threshold_uncertainty_score":0.92138153},"labels":[],"label_agreement":null},{"id":"W2304250174","doi":"10.1200/jco.2015.65.8609","title":"Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Oncology; Internal medicine; Lymphovascular invasion; Guideline; Breast cancer; Adjuvant therapy; Cancer; Disease; Stage (stratigraphy); Gynecology; Lymph node; Pathology; Metastasis","score_opus":0.06730005817841994,"score_gpt":0.46422119515041244,"score_spread":0.3969211369719925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304250174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926316,0.0039490424,0.00020931178,0.0018509576,0.00048732024,0.0003512007,0.00050356844,0.0000013149881,0.000015661293],"genre_scores_gemma":[0.97742116,0.017974924,0.0039825705,0.00032281355,0.0002135757,0.00004389954,0.000010143666,0.0000152569855,0.000015650741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569917,0.00034108,0.0032677755,0.00029515175,0.00018967313,0.00020713896],"domain_scores_gemma":[0.9941357,0.0011012722,0.0034737403,0.00020243591,0.00090387283,0.00018297645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010445954,0.00017325713,0.0015189636,0.000055519482,0.000035587764,0.0000021888593,0.00018271153,0.00021028372,0.000045149867],"category_scores_gemma":[0.00048946554,0.00010721655,0.00054312777,0.000069384354,0.0003509804,0.000013199195,0.00013163607,0.00018963235,6.4729534e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004758857,0.0006011576,0.59364015,0.00001969054,0.0004444201,0.0000011231465,0.00039201457,0.000079547695,0.0013184213,0.0000027375368,0.0005183383,0.39822352],"study_design_scores_gemma":[0.010196194,0.007933731,0.93573046,0.0005733439,0.0002620972,0.00000616642,0.0027678092,0.000016779073,0.001535554,0.00005026061,0.040774055,0.00015358103],"about_ca_topic_score_codex":0.007714361,"about_ca_topic_score_gemma":0.025552219,"teacher_disagreement_score":0.39806995,"about_ca_system_score_codex":0.00034425224,"about_ca_system_score_gemma":0.002983014,"threshold_uncertainty_score":0.9988934},"labels":[],"label_agreement":null},{"id":"W2305245841","doi":"10.1200/jco.2005.23.16_suppl.5137","title":"Weekly paclitaxel treatment of patients with progressive platinum resistant epithelial ovarian cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Public Health","funders":"","keywords":"Medicine; Paclitaxel; Taxane; Chemotherapy; Internal medicine; Ovarian cancer; Quality of life (healthcare); Oncology; Cancer; Progression-free survival; Surgery; Gastroenterology; Breast cancer","score_opus":0.07164226877409904,"score_gpt":0.4345814840692362,"score_spread":0.3629392152951372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305245841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97738326,0.0014017321,0.000014527888,0.018711878,0.0005712321,0.00050879637,0.00008439301,0.00000636579,0.0013177969],"genre_scores_gemma":[0.98789084,0.00089250365,0.00856305,0.00057645224,0.0017431787,0.00003203007,0.000007172721,0.000021919132,0.0002728816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969357,0.00019539625,0.001958132,0.00021891457,0.0004496354,0.00024219506],"domain_scores_gemma":[0.9955936,0.00076494314,0.0023753678,0.00022376646,0.0006774119,0.0003648878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005065073,0.00018955352,0.0016174132,0.0000938688,0.0000361191,0.0000062168947,0.00008635787,0.00023510553,0.00046363167],"category_scores_gemma":[0.00028408927,0.00010278552,0.00036115618,0.00011214974,0.00020089422,0.00008889493,0.000015708236,0.00026269414,0.00000791936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020871954,0.013468727,0.5244365,0.00002273131,0.001757056,0.00041317422,0.0002257606,0.000022657789,0.00002099896,0.000119005395,0.0012726774,0.43736878],"study_design_scores_gemma":[0.03264956,0.07433349,0.7845809,0.00022407238,0.0011689402,0.000024370534,0.000051185816,0.000008573528,0.00024857937,0.000045884426,0.1065761,0.00008836563],"about_ca_topic_score_codex":0.000066499335,"about_ca_topic_score_gemma":0.00015144494,"teacher_disagreement_score":0.43728042,"about_ca_system_score_codex":0.00061704,"about_ca_system_score_gemma":0.0020874483,"threshold_uncertainty_score":0.5076442},"labels":[],"label_agreement":null},{"id":"W2305470966","doi":"10.1200/jco.2013.31.6_suppl.357","title":"Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Immunotherapy; Internal medicine; Oncology; Surgery; Cancer","score_opus":0.09453903908394395,"score_gpt":0.4038148977188659,"score_spread":0.30927585863492196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305470966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223113,0.0005384859,0.0001326106,0.0039452235,0.00019007194,0.00095181976,0.0000017844026,0.000008760401,0.002000103],"genre_scores_gemma":[0.9897883,0.00058817706,0.00851062,0.00051865424,0.000104010345,0.000040687937,0.0000073384745,0.000034617704,0.00040760462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950394,0.0017859522,0.0019923244,0.00024819118,0.00058483396,0.00034928552],"domain_scores_gemma":[0.9947367,0.0024359268,0.0017924038,0.00022638269,0.00054948806,0.00025915122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004429639,0.00022960073,0.0019443186,0.00033371744,0.00003365249,0.000019117875,0.00015077178,0.000203649,0.00035403937],"category_scores_gemma":[0.0009166283,0.00013321015,0.00020768319,0.00041602025,0.00030503847,0.00023588736,0.00001752563,0.001398481,0.0000231413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029242156,0.007157309,0.91932756,0.000056681823,0.0008695763,0.0028304243,0.00088507787,0.000100818586,0.0003156923,0.00013017566,0.00021021774,0.038874287],"study_design_scores_gemma":[0.062294167,0.041075524,0.89190066,0.0002238426,0.0003279842,0.00056165486,0.0010685408,0.00022246271,0.00012077002,0.00048428957,0.0015693938,0.00015072469],"about_ca_topic_score_codex":0.000739116,"about_ca_topic_score_gemma":0.0009300246,"teacher_disagreement_score":0.038723562,"about_ca_system_score_codex":0.00039585464,"about_ca_system_score_gemma":0.0016167276,"threshold_uncertainty_score":0.60757816},"labels":[],"label_agreement":null},{"id":"W2307898326","doi":"10.1200/jco.2006.24.18_suppl.4580","title":"Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada)","funders":"","keywords":"Medicine; Transitional cell carcinoma; Urology; Cystoscopy; Bladder cancer; Pharmacokinetics; Internal medicine; Cancer; Urinary system","score_opus":0.02729806887473103,"score_gpt":0.3925414354252629,"score_spread":0.36524336655053186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307898326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987727,0.00004683378,0.00002336181,0.00037513103,0.00009845244,0.00028346962,0.00017927226,4.346863e-7,0.00022036584],"genre_scores_gemma":[0.9995639,0.000010354665,0.000057296616,0.000040428295,0.00021642692,0.000003331423,0.00007695054,0.0000066336183,0.000024681218],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99769676,0.00034078042,0.001317988,0.00016120625,0.00034238896,0.00014087907],"domain_scores_gemma":[0.9986521,0.00011417006,0.0007213392,0.00013994008,0.00028641778,0.00008604111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055107,0.00009558873,0.00043807644,0.00004222654,0.00003299329,0.0000029861567,0.0001622347,0.00015780669,0.000009974915],"category_scores_gemma":[0.00013998868,0.00006041588,0.00014050827,0.0000894664,0.00017362692,0.000007709568,0.00003117786,0.00026287074,1.7858885e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25081652,0.35936198,0.30338728,0.000035261797,0.0005238244,0.00015371048,0.00045836554,0.00012449455,0.05136918,0.000016835125,0.008801417,0.024951134],"study_design_scores_gemma":[0.16738214,0.4003446,0.360383,0.00001892041,0.00017459157,0.00001103692,0.00022554421,0.0000188888,0.06905681,0.00003529294,0.002224053,0.0001251007],"about_ca_topic_score_codex":0.00012414907,"about_ca_topic_score_gemma":0.00080384396,"teacher_disagreement_score":0.083434395,"about_ca_system_score_codex":0.000030668776,"about_ca_system_score_gemma":0.0008749469,"threshold_uncertainty_score":0.24636883},"labels":[],"label_agreement":null},{"id":"W2308167615","doi":"10.1200/jco.2015.65.9797","title":"Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society","funders":"","keywords":"Medicine; Cystectomy; Guideline; Bladder cancer; Oncology; Internal medicine; Carboplatin; Clinical trial; Chemotherapy; Chemoradiotherapy; Cancer; Cisplatin; Pathology","score_opus":0.15246535138942274,"score_gpt":0.5239426716527221,"score_spread":0.3714773202632994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308167615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5090241,0.0027806908,0.0083978325,0.45586777,0.008840749,0.0018483916,0.00033213166,0.000059457387,0.01284891],"genre_scores_gemma":[0.6784429,0.0499169,0.14909346,0.11318199,0.008321438,0.000023396078,0.000029131153,0.00012595842,0.0008648259],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97339565,0.0063163275,0.0178476,0.0007277559,0.0011462925,0.00056636625],"domain_scores_gemma":[0.94879323,0.025823977,0.019175192,0.00056180015,0.004802379,0.0008433901],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.035168413,0.00042562067,0.005147182,0.00018097849,0.00005978379,0.000006747173,0.00038316025,0.0006785695,0.00051469373],"category_scores_gemma":[0.056278158,0.00026236882,0.0018929266,0.00027643476,0.0011894079,0.00020066558,0.00022338991,0.00162044,0.000024656956],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009647143,0.006627515,0.05505438,0.000031417716,0.0057666022,0.00032541918,0.00011494509,0.000024021016,0.00046783866,0.000061559236,0.24430943,0.67756975],"study_design_scores_gemma":[0.032123044,0.065229006,0.0646405,0.00014599606,0.00561288,0.00016677416,0.0004997896,0.00011731788,0.00012469251,0.00023367305,0.8308757,0.00023066215],"about_ca_topic_score_codex":0.0003306194,"about_ca_topic_score_gemma":0.00023015968,"teacher_disagreement_score":0.6773391,"about_ca_system_score_codex":0.0005158007,"about_ca_system_score_gemma":0.0065532373,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W2308876932","doi":"10.1200/jco.2009.27.15_suppl.e11532","title":"Validation of Adjuvant!Online on Slovenian collective of early breast cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adjuvant; Internal medicine; Adjuvant therapy; Breast cancer; Oncology; Systemic therapy; Cancer","score_opus":0.04537345949372771,"score_gpt":0.4177925682652058,"score_spread":0.37241910877147805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308876932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712586,0.00018759874,0.000021561753,0.0014646103,0.0004479284,0.00009053475,0.00014377735,0.0000011162737,0.0005170015],"genre_scores_gemma":[0.9982907,0.00041185637,0.0003159082,0.00040026967,0.00050635793,0.0000014374991,0.000012275632,0.0000070774568,0.000054115877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981681,0.00022481386,0.0011476504,0.00014291223,0.00019933951,0.00011719841],"domain_scores_gemma":[0.997103,0.00019304903,0.0017166857,0.00011607162,0.0007888409,0.000082353836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042138848,0.000107386055,0.0007092328,0.000058615107,0.000020119574,0.0000015775536,0.00013476807,0.00021387471,0.000018651943],"category_scores_gemma":[0.00051441067,0.000080747195,0.0002704001,0.000094381045,0.000120648925,0.0000060536922,0.000028843177,0.00017624999,7.6816065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013180343,0.008231589,0.7113319,0.000014248484,0.0010085307,0.0000112401385,0.0002235697,0.00016466282,0.0086394055,0.000027571625,0.0032742703,0.25389266],"study_design_scores_gemma":[0.0044076503,0.014375331,0.9696085,0.000055514753,0.00014298313,0.000007175328,0.000025331381,0.0000017892461,0.010355663,0.00013348433,0.00082076056,0.00006583467],"about_ca_topic_score_codex":0.000028855427,"about_ca_topic_score_gemma":0.00002728582,"teacher_disagreement_score":0.25827658,"about_ca_system_score_codex":0.00007308928,"about_ca_system_score_gemma":0.0006357338,"threshold_uncertainty_score":0.3292775},"labels":[],"label_agreement":null},{"id":"W2309349001","doi":"10.1200/jco.2011.29.15_suppl.8001","title":"Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; CHOP; Gastroenterology; Randomization; Randomized controlled trial; Clinical endpoint; Surgery; Confidence interval; Chemotherapy","score_opus":0.07212641106862692,"score_gpt":0.39454719560265206,"score_spread":0.3224207845340251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309349001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820696,0.00015235353,0.0022263182,0.002298576,0.004499032,0.0079881195,0.0006955565,0.000024342342,0.000046086265],"genre_scores_gemma":[0.9838942,0.0005133219,0.009878016,0.0018565573,0.0016655405,0.0017091449,0.00029003213,0.00009814202,0.00009500429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937479,0.00031396674,0.0039385543,0.00064741785,0.00044945697,0.00090271974],"domain_scores_gemma":[0.98560303,0.008215291,0.0034939519,0.00036101553,0.0006767586,0.001649969],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020784172,0.00059323444,0.0051775933,0.0004130131,0.00021023951,0.000048780592,0.00046840782,0.00058524637,0.000070612325],"category_scores_gemma":[0.003127851,0.00034729223,0.0016511274,0.00013505435,0.00031095423,0.00021347175,0.00004923399,0.0002971244,0.000006174733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9229385,0.017494688,0.0058391676,0.00009397008,0.0035056344,0.00036253163,0.00055343437,0.0000019847264,0.000020175905,0.000100621786,0.01590713,0.03318211],"study_design_scores_gemma":[0.8991956,0.066993885,0.020540422,0.00079987344,0.0040405104,0.000050384282,0.00007074004,0.00021961884,0.00060324906,0.000286415,0.006803645,0.0003956485],"about_ca_topic_score_codex":0.0019971568,"about_ca_topic_score_gemma":0.0073089213,"teacher_disagreement_score":0.0494992,"about_ca_system_score_codex":0.00083433074,"about_ca_system_score_gemma":0.0017928322,"threshold_uncertainty_score":0.9998979},"labels":[],"label_agreement":null},{"id":"W2309537020","doi":"10.1200/jco.2004.22.90140.7018","title":"A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Febrile neutropenia; Lung cancer; Vinorelbine; Regimen; Nausea; Surgery; Chemotherapy; Gastroenterology; Oncology; Cisplatin","score_opus":0.05815052593919202,"score_gpt":0.4588959697301544,"score_spread":0.4007454437909624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309537020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334645,0.0010795044,0.00016985288,0.0018215048,0.00047349298,0.0013125096,0.00002075429,0.0000047123767,0.0017712327],"genre_scores_gemma":[0.99603724,0.001005863,0.0017747232,0.00026202743,0.0003703144,0.00003640759,0.0000045066004,0.000016031447,0.00049286307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972136,0.00020277356,0.0019529598,0.00022598935,0.00020854,0.00019612155],"domain_scores_gemma":[0.99684024,0.0011007008,0.0013616821,0.00011911233,0.00033584403,0.00024244706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012106617,0.00015752162,0.0016166356,0.00017866214,0.000045230114,0.0000072728703,0.00007465685,0.0002301119,0.00010129344],"category_scores_gemma":[0.0010626479,0.000107447944,0.00020513611,0.00014757446,0.00020519282,0.00008270228,0.00006309081,0.00062323327,5.100889e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88753074,0.008023661,0.06471552,0.00025714317,0.0011726052,0.0007856088,0.0034993626,0.000108480504,0.0032815584,0.000099672354,0.00050104095,0.030024601],"study_design_scores_gemma":[0.7518973,0.042219553,0.20217645,0.00053334696,0.000964164,0.000055130724,0.00024889444,0.0002884321,0.00038969063,0.0001802914,0.0009357546,0.000110999434],"about_ca_topic_score_codex":0.00044603398,"about_ca_topic_score_gemma":0.0011552607,"teacher_disagreement_score":0.13746093,"about_ca_system_score_codex":0.00035003686,"about_ca_system_score_gemma":0.0016837567,"threshold_uncertainty_score":0.43816},"labels":[],"label_agreement":null},{"id":"W2311232889","doi":"10.1200/jco.2016.34.18_suppl.lba2","title":"A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temozolomide; Concomitant; Internal medicine; Radiation therapy; Randomized controlled trial; Adjuvant; Gastroenterology; Phases of clinical research; Biopsy; Surgery; Chemotherapy; Oncology","score_opus":0.031848700679403555,"score_gpt":0.4014256609215283,"score_spread":0.3695769602421248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311232889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902028,0.0008343083,0.00019125004,0.0029998187,0.00050083036,0.005103775,0.000012136628,0.000012503106,0.00014261344],"genre_scores_gemma":[0.9961308,0.0012712772,0.0014415581,0.00039424753,0.00044280835,0.00019625822,0.0000020377238,0.00004668975,0.0000742964],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920447,0.0014107072,0.0049379976,0.00041729605,0.00074833096,0.00044098243],"domain_scores_gemma":[0.98511696,0.009490724,0.0037236963,0.00034039357,0.0007060798,0.0006221716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047461297,0.0004400494,0.00985887,0.00033014335,0.00004312823,0.000015270643,0.00016882211,0.00042217347,0.00016811972],"category_scores_gemma":[0.0025821712,0.00016930186,0.0008419666,0.00019862811,0.0009268016,0.00017631268,0.000024687495,0.000546276,0.000001431563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82205117,0.021399586,0.08132585,0.000014475058,0.003636267,0.0012151306,0.00012909686,0.0000018871649,0.00019631961,0.000023962373,0.0001763279,0.06982995],"study_design_scores_gemma":[0.79354775,0.19327742,0.00861725,0.0006166651,0.0027328394,0.0002215578,0.00008119415,0.00008214467,0.00016948437,0.000029352219,0.0004474728,0.00017687278],"about_ca_topic_score_codex":0.000023975772,"about_ca_topic_score_gemma":0.0003611809,"teacher_disagreement_score":0.17187783,"about_ca_system_score_codex":0.00021367117,"about_ca_system_score_gemma":0.0021041383,"threshold_uncertainty_score":0.690393},"labels":[],"label_agreement":null},{"id":"W2311270482","doi":"10.1200/jco.2006.24.18_suppl.524","title":"Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Octreotide; Tamoxifen; Oncology; Antiestrogen; Univariate analysis; Proportional hazards model; Cancer; Gynecology; Multivariate analysis; Somatostatin","score_opus":0.047408308047997685,"score_gpt":0.38184700997947413,"score_spread":0.33443870193147646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311270482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848245,0.0018728317,0.000107740605,0.0032519859,0.007802664,0.0005025606,0.0012195644,0.000008513871,0.0004096611],"genre_scores_gemma":[0.9751218,0.0012902236,0.0008019763,0.0013784311,0.015637936,0.000100541845,0.00012854415,0.00006944456,0.0054710764],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99570644,0.0005455348,0.0022413186,0.0004390547,0.00038654482,0.0006811226],"domain_scores_gemma":[0.99637365,0.00042108548,0.0018964278,0.0003239967,0.000675733,0.00030907465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035650183,0.00028813994,0.0015625596,0.000098820936,0.00006812404,0.000022046772,0.00045672982,0.0006928811,0.000058041052],"category_scores_gemma":[0.0018998595,0.00023072517,0.0002903434,0.00021458574,0.00020349659,0.000020033918,0.00008660615,0.0005580122,0.0000013654924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3034905,0.0048992164,0.0096291285,0.00004282824,0.0011074621,0.000021593409,0.000100811354,0.000251537,0.04429102,0.000042573258,0.622587,0.013536319],"study_design_scores_gemma":[0.21651535,0.015575563,0.26998922,0.00020865868,0.00038863902,0.00006867142,0.00012837534,0.00004366737,0.0021885382,0.0008896472,0.49331036,0.0006932897],"about_ca_topic_score_codex":0.00018735616,"about_ca_topic_score_gemma":0.004785756,"teacher_disagreement_score":0.2603601,"about_ca_system_score_codex":0.00034069328,"about_ca_system_score_gemma":0.002998205,"threshold_uncertainty_score":0.94087},"labels":[],"label_agreement":null},{"id":"W2311347322","doi":"10.1200/jco.2015.33.15_suppl.5003","title":"Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Metastasis; Histology; Prostate; Cancer; PTEN; Biopsy; Adenocarcinoma; Pathology; Oncology; Cancer research; Internal medicine; Androgen receptor; Biology; PI3K/AKT/mTOR pathway","score_opus":0.09730843137049108,"score_gpt":0.4203768187639266,"score_spread":0.32306838739343546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311347322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97284275,0.00088852283,0.000005785499,0.019602796,0.00088905985,0.0033929609,0.0022950901,0.00002088283,0.0000621776],"genre_scores_gemma":[0.9898043,0.0056956173,0.00053826615,0.0010425125,0.00056116143,0.00041270407,0.000340015,0.00009071494,0.0015146995],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99185616,0.0011795843,0.004003243,0.00071684225,0.0014348526,0.0008093298],"domain_scores_gemma":[0.99200493,0.0010782909,0.003255028,0.0005301299,0.0023408623,0.0007907345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002410527,0.0004941561,0.0020618755,0.00026637912,0.000120522265,0.000061267085,0.0003758946,0.00015592047,0.00006713665],"category_scores_gemma":[0.0018321101,0.00026790297,0.00019232748,0.0008491337,0.00046059652,0.00051404635,0.00016390848,0.0012182037,0.0000059384683],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6072332,0.0031668001,0.33680335,0.00024114284,0.0008555103,0.0016552979,0.004032588,0.0011164509,0.009654006,0.000004285999,0.00334403,0.03189335],"study_design_scores_gemma":[0.048030358,0.047268655,0.885244,0.0019504676,0.00083374704,0.00003628312,0.00093064934,0.00011698436,0.003222635,0.000037715407,0.011996501,0.00033201592],"about_ca_topic_score_codex":0.005516983,"about_ca_topic_score_gemma":0.01787622,"teacher_disagreement_score":0.55920285,"about_ca_system_score_codex":0.0012092981,"about_ca_system_score_gemma":0.008923767,"threshold_uncertainty_score":0.9999773},"labels":[],"label_agreement":null},{"id":"W2311612417","doi":"10.1200/jco.2015.33.7_suppl.169","title":"Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Incidence (geometry); Adverse effect; Gastroenterology; Prednisone; MedDRA; Urology; Cancer; Androgen deprivation therapy","score_opus":0.10421399605321649,"score_gpt":0.45806930629196396,"score_spread":0.3538553102387475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311612417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944863,0.00015559737,0.000093648596,0.0026850344,0.00041054434,0.0019261264,0.00010453138,0.000012052604,0.00012619491],"genre_scores_gemma":[0.9949469,0.00015392392,0.003310038,0.00044755772,0.00011668965,0.00010340976,0.00004705267,0.000047736776,0.0008267184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484146,0.0005927663,0.0022330524,0.00039500653,0.0013986763,0.0005390368],"domain_scores_gemma":[0.9933681,0.00033926588,0.002026852,0.00031156515,0.0026514928,0.0013027346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016835766,0.0003143245,0.0018094315,0.00024093511,0.00005799936,0.000014875874,0.00022671501,0.000158814,0.000070488386],"category_scores_gemma":[0.0005939449,0.00018748308,0.00019125376,0.00042919003,0.00018081465,0.00025844004,0.00009238407,0.00062376994,0.000013086333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05368268,0.0070387363,0.9191589,0.00018139166,0.0023886717,0.0014632116,0.0010452123,0.00091608247,0.0016942675,0.0000015944024,0.00058455754,0.011844735],"study_design_scores_gemma":[0.041862436,0.09210963,0.86294967,0.0009640297,0.0009388549,0.000037974343,0.00030376037,0.00003047364,0.0004345604,0.0000079776855,0.00018154568,0.00017906833],"about_ca_topic_score_codex":0.000070228285,"about_ca_topic_score_gemma":0.0011563926,"teacher_disagreement_score":0.08507089,"about_ca_system_score_codex":0.0011214083,"about_ca_system_score_gemma":0.0050861295,"threshold_uncertainty_score":0.9022575},"labels":[],"label_agreement":null},{"id":"W2311987714","doi":"10.1200/jco.2010.28.15_suppl.e18081","title":"Asian ethnicity and survival outcomes in advanced non-small cell lung cancer (NSCLC) patients receiving systemic therapy: A regional Canadian experience.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Cancer registry; Population; Oncology; Systemic therapy; Stage (stratigraphy); Cancer; Breast cancer","score_opus":0.0570699073644474,"score_gpt":0.45676593031620727,"score_spread":0.3996960229517599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311987714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901807,0.00046526897,0.000010010172,0.003960103,0.002283636,0.0003695663,0.000006597041,0.000004122716,0.0027200035],"genre_scores_gemma":[0.99618167,0.00097236765,0.0008722267,0.0014213728,0.0002955334,0.000025885543,0.0000026340476,0.000015430003,0.00021291111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800086,0.00015289271,0.0011702566,0.00020112947,0.00021091591,0.00026395483],"domain_scores_gemma":[0.9977151,0.0005588457,0.00072451186,0.00013974906,0.00032381038,0.0005379607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077349175,0.00013755406,0.0009431026,0.00015981581,0.000060465307,0.000009571015,0.000114434115,0.000289458,0.00006688922],"category_scores_gemma":[0.0005516889,0.00009433704,0.00016916427,0.00011180266,0.000105340754,0.000110801,0.0000176118,0.00088535715,0.0000012347873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035194054,0.00046693208,0.93115276,0.00001855535,0.0001107426,0.000097261014,0.0018210824,0.0000049489718,0.00014744246,0.0000071455124,0.00013719402,0.065683976],"study_design_scores_gemma":[0.010193216,0.0012743828,0.983292,0.00015977351,0.000104565624,0.000034658846,0.0006844012,0.000035046447,0.000013486881,0.000014532905,0.0041041123,0.00008984954],"about_ca_topic_score_codex":0.011897677,"about_ca_topic_score_gemma":0.13555105,"teacher_disagreement_score":0.12365338,"about_ca_system_score_codex":0.00036524015,"about_ca_system_score_gemma":0.0036665865,"threshold_uncertainty_score":0.9946822},"labels":[],"label_agreement":null},{"id":"W2313623943","doi":"10.1200/jco.2006.24.18_suppl.522","title":"Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Queen's University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Epirubicin; Ejection fraction; Breast cancer; Internal medicine; Cardiotoxicity; Cyclophosphamide; Cardiac function curve; Cancer; Chemotherapy; Oncology; Cardiology; Heart failure","score_opus":0.07001898704877614,"score_gpt":0.4792698093658994,"score_spread":0.4092508223171233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313623943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629711,0.0033983148,0.000543247,0.027890101,0.0043769036,0.0003816886,0.000007434501,0.00001097043,0.00042022776],"genre_scores_gemma":[0.9879661,0.00070404576,0.00034798385,0.0055054803,0.0046569067,0.000025408946,0.0000031883171,0.000015838956,0.0007750215],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980813,0.00014384053,0.0011551268,0.00015771529,0.00022621088,0.0002358024],"domain_scores_gemma":[0.99777025,0.0009166868,0.000858125,0.00011569834,0.00020527255,0.00013398146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011113653,0.00012244743,0.00085227535,0.000055586177,0.00008857284,0.00000782273,0.00012295955,0.00020361009,0.0004958191],"category_scores_gemma":[0.00011883122,0.00006936867,0.0007765211,0.0000947182,0.00011240281,0.00007842221,0.0000142425015,0.00039573273,0.000004961318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021972505,0.0040363017,0.3655133,0.000037859314,0.0015163837,0.0008401974,0.0002540559,0.00012330474,0.0025777523,0.00011731971,0.073807076,0.52920395],"study_design_scores_gemma":[0.015133307,0.005963419,0.58142334,0.000046010162,0.0010737202,0.000720846,0.00011351479,0.00012411708,0.00034957752,0.0003636295,0.39460075,0.000087771165],"about_ca_topic_score_codex":0.00008086248,"about_ca_topic_score_gemma":0.0000696233,"teacher_disagreement_score":0.52911615,"about_ca_system_score_codex":0.00023880295,"about_ca_system_score_gemma":0.00075282995,"threshold_uncertainty_score":0.5428871},"labels":[],"label_agreement":null},{"id":"W2314661020","doi":"10.1200/jco.2007.25.18_suppl.9500","title":"Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Loss of heterozygosity; Oncology; Internal medicine; Genotyping; SNP array; Medicine; SNP; Malignancy; Single-nucleotide polymorphism; Neuroblastoma; Genotype; Genetics; Allele; Biology; Gene","score_opus":0.055852293534760185,"score_gpt":0.40971573657445687,"score_spread":0.3538634430396967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314661020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538285,0.0002881379,0.002620381,0.00011894852,0.0003589446,0.0012111173,0.0000070559927,0.000009254986,0.000003339766],"genre_scores_gemma":[0.99778825,0.00020777153,0.001512901,0.00014929079,0.00030978088,0.0000041232233,8.0295416e-7,0.000024472758,0.0000025844583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942054,0.0020459394,0.0027033305,0.00037353317,0.00030999276,0.0003617693],"domain_scores_gemma":[0.9913107,0.0053387447,0.0023940313,0.00019094763,0.0002916044,0.000473981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0084706545,0.00019675297,0.0014253978,0.00048174273,0.000089851266,0.00001470335,0.00011182866,0.00036287628,0.000005738582],"category_scores_gemma":[0.005213092,0.00015585888,0.00015223055,0.00016703186,0.0003818771,0.0001440521,0.000114568065,0.0015337035,0.0000011316744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04589713,0.008328547,0.78488016,0.0000768884,0.0014775007,0.048453268,0.0007876852,0.00032798172,0.031226797,0.000008968457,0.000014699685,0.07852036],"study_design_scores_gemma":[0.023217045,0.035044495,0.93045586,0.000089565474,0.0009935853,0.0060217828,0.00030194852,0.00323119,0.00047553817,0.00008067845,0.0000022995216,0.000085999796],"about_ca_topic_score_codex":0.00018041431,"about_ca_topic_score_gemma":0.0006075816,"teacher_disagreement_score":0.1455757,"about_ca_system_score_codex":0.00018854727,"about_ca_system_score_gemma":0.00054976594,"threshold_uncertainty_score":0.6663264},"labels":[],"label_agreement":null},{"id":"W2315082559","doi":"10.1200/jco.2016.34.3_suppl.157","title":"Management of aromatase inhibitor-associated musculoskeletal symptoms: A systematic review.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Jadad scale; Randomized controlled trial; Psychological intervention; Observational study; Internal medicine; Cohort; Acupuncture; MEDLINE; Physical therapy; Cohort study; Breast cancer; Alternative medicine; Cochrane Library; Cancer; Pathology; Psychiatry","score_opus":0.06270303492056029,"score_gpt":0.48423382119029706,"score_spread":0.4215307862697368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315082559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625017,0.017301073,0.00004495197,0.01324433,0.0020210515,0.0013351012,0.000022517537,0.000019349918,0.00350995],"genre_scores_gemma":[0.9710964,0.025200218,0.00032955583,0.0017158046,0.00045611218,0.000024388619,0.000004437848,0.00001646711,0.0011565993],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.995412,0.00064001884,0.0032505873,0.00014331428,0.0003633115,0.0001907679],"domain_scores_gemma":[0.9944553,0.0016713265,0.0030629428,0.00021036093,0.00033541507,0.00026470225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033587916,0.00013701772,0.0025629296,0.00009547038,0.000015611588,0.0000014366726,0.00014830417,0.00020778857,0.00032541144],"category_scores_gemma":[0.0014835484,0.00007005168,0.0008613984,0.00014540555,0.00015864927,0.00006933637,0.000051657586,0.00026880275,0.000044733857],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014007889,0.04610268,0.052983373,0.45585114,0.044826303,0.016891966,0.00017870041,0.0000010303403,0.0029036324,0.0013042181,0.21134895,0.15360013],"study_design_scores_gemma":[0.10622259,0.11965637,0.10946022,0.55909514,0.06725016,0.0020034558,0.00019947714,0.000011264259,0.0006842206,0.000904421,0.033866394,0.00064627494],"about_ca_topic_score_codex":0.0000026896296,"about_ca_topic_score_gemma":0.000003224223,"teacher_disagreement_score":0.17748256,"about_ca_system_score_codex":0.0002601524,"about_ca_system_score_gemma":0.00041156085,"threshold_uncertainty_score":0.3563027},"labels":[],"label_agreement":null},{"id":"W2315163783","doi":"10.1200/jco.2005.23.16_suppl.2078","title":"Evaluation of Cockcroft-Gault (CG) and abbreviated Modified Diet in Renal Disease Study (MDRD) formulas for carboplatin dosing in gynecological malignancies","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Carboplatin; Renal function; Urology; Body surface area; Creatinine; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.22501619389180239,"score_gpt":0.49184193287750755,"score_spread":0.26682573898570516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315163783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943979,0.0003194495,0.00011537526,0.0036969106,0.00014838397,0.0012262075,0.0000049612063,0.0000056297135,0.000085224376],"genre_scores_gemma":[0.99713624,0.00010388809,0.0019255979,0.00045813393,0.00032443268,0.000020619065,0.000004799401,0.000014434178,0.000011877147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542326,0.0008578772,0.0026788807,0.00022433535,0.0006030909,0.00021253192],"domain_scores_gemma":[0.99484223,0.0026740995,0.0013899703,0.0001359771,0.00073782203,0.00021991413],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011468183,0.0001437213,0.001271984,0.00023634227,0.000025238382,0.000007056219,0.00009007935,0.0003168399,0.000042702584],"category_scores_gemma":[0.016271612,0.00011173191,0.00018842907,0.00020584598,0.0001252312,0.00014491,0.000030944753,0.00056222617,5.932391e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02962365,0.014662486,0.65373814,0.00015332371,0.00043139386,0.00016206961,0.002389468,0.0037404161,0.03753285,0.000080624864,0.00026644208,0.25721914],"study_design_scores_gemma":[0.03251849,0.010516436,0.93131053,0.00020907888,0.0005200537,0.000019785659,0.00032655758,0.021612262,0.0018174179,0.00094646076,0.00010029851,0.00010259762],"about_ca_topic_score_codex":0.0000191406,"about_ca_topic_score_gemma":0.0006317903,"teacher_disagreement_score":0.27757242,"about_ca_system_score_codex":0.00048001387,"about_ca_system_score_gemma":0.0012826412,"threshold_uncertainty_score":0.99201477},"labels":[],"label_agreement":null},{"id":"W2315566794","doi":"10.1200/jco.2015.33.15_suppl.8100","title":"Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Lung cancer; Erlotinib; Chemotherapy; Gastroenterology; Surgery; Cancer","score_opus":0.12256242700886709,"score_gpt":0.46623995907749505,"score_spread":0.34367753206862794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315566794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151593,0.00080284703,0.00015830428,0.0022510977,0.0017691491,0.0023442626,0.00046282864,0.000011936743,0.00068363966],"genre_scores_gemma":[0.99615294,0.000029385606,0.0018622814,0.0010741135,0.00042508772,0.00003165864,0.00026436916,0.00003622435,0.00012394605],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99415493,0.00041324136,0.0038606406,0.00041615628,0.00085456466,0.00030044708],"domain_scores_gemma":[0.9900979,0.0022226493,0.0055115977,0.0010440386,0.00075618137,0.00036763737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010234895,0.00035671794,0.002161074,0.00006377445,0.000101326594,0.000011296466,0.00045158877,0.00025970268,0.00014294653],"category_scores_gemma":[0.001768261,0.00016505415,0.0006977147,0.0003329474,0.00020711056,0.00016496723,0.000084422405,0.00037735727,0.0000015860014],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18451405,0.022453304,0.755447,0.000048809878,0.0019676082,0.0002672419,0.0011468601,0.00047491494,0.000024824423,0.000003578235,0.0017522102,0.031899616],"study_design_scores_gemma":[0.7445276,0.107762516,0.12283439,0.00018863236,0.0071950266,0.00002595062,0.0006367508,0.0018709904,0.00067858555,0.000040513703,0.013987409,0.00025164997],"about_ca_topic_score_codex":0.00036215724,"about_ca_topic_score_gemma":0.0003619479,"teacher_disagreement_score":0.6326126,"about_ca_system_score_codex":0.0006249154,"about_ca_system_score_gemma":0.0036830057,"threshold_uncertainty_score":0.67307127},"labels":[],"label_agreement":null},{"id":"W2315911875","doi":"10.1200/jco.2007.25.18_suppl.6623","title":"Cost-effectiveness (CE) analysis of CHOP and rituximab for diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; CHOP; Population; Diffuse large B-cell lymphoma; Vincristine; Internal medicine; Oncology; Clinical endpoint; Surgery; Lymphoma; Cyclophosphamide; Chemotherapy; Clinical trial","score_opus":0.08858813902838873,"score_gpt":0.44731816839298244,"score_spread":0.3587300293645937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315911875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710435,0.0009920545,0.00033438572,0.00022637392,0.0003251658,0.0005857109,0.000039156716,0.000004386116,0.00038840316],"genre_scores_gemma":[0.9967323,0.0011049074,0.0013140006,0.0005286389,0.00018870365,0.00001751958,0.000009666802,0.0000143563175,0.0000898931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967794,0.00027193673,0.0021394242,0.00024286636,0.00025326875,0.000313148],"domain_scores_gemma":[0.9913597,0.006525738,0.0012083562,0.00015703976,0.00039933497,0.00034979937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005203134,0.000109239125,0.0024620867,0.00022755649,0.000039406812,0.00002212029,0.00009434437,0.00039103554,0.000049087983],"category_scores_gemma":[0.0018581543,0.000116848496,0.00078344287,0.00039179606,0.00014711363,0.00007679604,0.000044610817,0.00019513794,0.0000013692007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022382895,0.05640761,0.7566884,0.00006704899,0.0012977606,0.001009959,0.00004234162,0.0000013434701,0.00001834548,0.000011603575,0.00042615502,0.18179111],"study_design_scores_gemma":[0.15271689,0.005477347,0.82831115,0.00012513236,0.0028858187,0.0001391063,0.00010674337,0.00015850831,0.00005835768,0.000079683414,0.009861573,0.00007970393],"about_ca_topic_score_codex":0.002178787,"about_ca_topic_score_gemma":0.038470812,"teacher_disagreement_score":0.1817114,"about_ca_system_score_codex":0.00036215116,"about_ca_system_score_gemma":0.000571515,"threshold_uncertainty_score":0.9790746},"labels":[],"label_agreement":null},{"id":"W2317448102","doi":"10.1200/jco.2015.33.29_suppl.177","title":"A cross-sectional view of radiation fractionation schemes used for painful bone metastases (PBM) cases within the Veterans Health Administration Radiation Oncology Centers.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiation therapy; Radiation oncology; Dose fractionation; Oncology; Internal medicine","score_opus":0.2603070849537492,"score_gpt":0.5401943119841458,"score_spread":0.2798872270303966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317448102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9330735,0.002021435,0.023192866,0.036649954,0.0031442307,0.0016003615,0.00010642368,0.00002174895,0.00018944073],"genre_scores_gemma":[0.9858155,0.00034601404,0.008533124,0.0040284405,0.00094743294,0.000037819646,0.0001826659,0.000017423019,0.00009156474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937299,0.0014736088,0.0036161346,0.0002248762,0.00076205854,0.00019345286],"domain_scores_gemma":[0.9881242,0.0046928087,0.005542366,0.00019956772,0.0010594657,0.00038159947],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014631352,0.00015744628,0.0011538677,0.00023015017,0.00009553311,0.000026990185,0.00012609696,0.00020748931,0.00009304074],"category_scores_gemma":[0.016671512,0.000112125,0.00049217546,0.00019391814,0.0002109735,0.00036736848,0.000020778229,0.00045048635,0.0000048606926],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043687344,0.010969837,0.25223613,0.0007685853,0.0024657198,0.0002888852,0.0011705098,0.0010744813,0.00023925808,0.0043434044,0.027539754,0.6552161],"study_design_scores_gemma":[0.03565315,0.04802738,0.4359248,0.00013147204,0.0012700885,0.00079975673,0.0013048715,0.0042432686,0.00038290257,0.0011595472,0.47089133,0.00021141043],"about_ca_topic_score_codex":0.000046323625,"about_ca_topic_score_gemma":0.00007044222,"teacher_disagreement_score":0.6550047,"about_ca_system_score_codex":0.00049636845,"about_ca_system_score_gemma":0.005293239,"threshold_uncertainty_score":0.9916115},"labels":[],"label_agreement":null},{"id":"W2320043670","doi":"10.1200/jco.2004.22.90140.8530","title":"Risk of rare adult-type carcinomas as a subsequent malignant neoplasm in survivors of childhood cancer: The Childhood Cancer Survivor Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Cohort; Radiation therapy; Incidence (geometry); Malignancy; Cumulative incidence; Standardized mortality ratio; Oncology; Internal medicine","score_opus":0.06508506924943604,"score_gpt":0.4226466047167732,"score_spread":0.35756153546733715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320043670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772362,0.0049685724,0.000008745864,0.012483611,0.0033784295,0.0014552622,0.00008509692,0.000017444478,0.0003666111],"genre_scores_gemma":[0.9879642,0.008176224,0.00026723932,0.0020653561,0.001367663,0.000035485697,0.0000041771978,0.00006899475,0.00005063514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98749965,0.0027674255,0.006892949,0.00059239386,0.0016018756,0.0006456876],"domain_scores_gemma":[0.9864689,0.0035483185,0.0067643416,0.0008917846,0.0017354762,0.0005911737],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009770689,0.00048482334,0.0042681866,0.0003855522,0.00009630095,0.000012339862,0.00088029064,0.0005880203,0.00018542242],"category_scores_gemma":[0.008545938,0.00031937842,0.001110152,0.0010035443,0.0005982437,0.00017390364,0.0002184427,0.0026349225,0.00000929408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043181274,0.010846996,0.95359874,0.00013097111,0.002013993,0.00039334066,0.01564632,0.0010623359,0.000056955745,0.00012358457,0.00020717035,0.011601455],"study_design_scores_gemma":[0.021643309,0.016961556,0.9488965,0.0010174199,0.0013729667,0.00023361164,0.007701962,0.000008266748,0.0004152977,0.00055227685,0.000916817,0.00027997786],"about_ca_topic_score_codex":0.08054584,"about_ca_topic_score_gemma":0.15037625,"teacher_disagreement_score":0.0698304,"about_ca_system_score_codex":0.0005811706,"about_ca_system_score_gemma":0.010789083,"threshold_uncertainty_score":0.99992585},"labels":[],"label_agreement":null},{"id":"W2322778337","doi":"10.1200/jco.2007.25.18_suppl.8120","title":"Outcome following multiple lines of salvage chemotherapy prior to autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Salvage therapy; Chemotherapy; Internal medicine; Oncology; Etoposide; Surgery; Refractory (planetary science); Rituximab; Chemotherapy regimen; Progressive disease; Lymphoma","score_opus":0.0879643907061783,"score_gpt":0.42701208812698166,"score_spread":0.3390476974208034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322778337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992641,0.0005898265,0.0019097186,0.0019661593,0.001744215,0.000815971,0.000033229782,0.000023710933,0.00027617512],"genre_scores_gemma":[0.97870636,0.00042549445,0.015581758,0.0037391444,0.0006401,0.000015069494,0.0000058075357,0.000049056816,0.0008371824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99476784,0.0001829289,0.0038040127,0.00031857274,0.00041702273,0.0005096178],"domain_scores_gemma":[0.98894894,0.008052266,0.0017684161,0.00031936195,0.00028503328,0.0006259966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00373741,0.0002816126,0.002504201,0.00021197506,0.000067718254,0.000007502021,0.00023825621,0.00062760507,0.000023975641],"category_scores_gemma":[0.0008961975,0.00017441866,0.0014587912,0.00015429303,0.0000640851,0.000079423495,0.000029058487,0.00030515026,0.000011520671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049277127,0.08616024,0.53685886,0.00031245276,0.0009958143,0.0048132367,0.0012331177,0.000003204482,0.0044268225,0.000017622448,0.0021130538,0.31378844],"study_design_scores_gemma":[0.25882563,0.040396277,0.5166242,0.00029136808,0.0014285068,0.00026660776,0.00045221843,0.00008357042,0.01462889,0.000012521958,0.16669548,0.0002947371],"about_ca_topic_score_codex":0.000017924405,"about_ca_topic_score_gemma":0.00010273818,"teacher_disagreement_score":0.3134937,"about_ca_system_score_codex":0.00036767864,"about_ca_system_score_gemma":0.0010110441,"threshold_uncertainty_score":0.71125865},"labels":[],"label_agreement":null},{"id":"W2324365995","doi":"10.1200/jco.2007.25.18_suppl.15176","title":"Consequences of modifying an adjuvant treatment protocol for resected gastric carcinoma: A retrospective study at a single institution in western Canada","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Surgery; Stage (stratigraphy); Retrospective cohort study; Cancer; Adenocarcinoma; Protocol (science); Chemotherapy; Internal medicine; Pathology","score_opus":0.24904557284574033,"score_gpt":0.49759305174162727,"score_spread":0.24854747889588694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324365995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726894,0.000014556754,0.00014898425,0.0005321022,0.00027327274,0.026032148,0.0000031737443,0.0000036704134,0.00030267317],"genre_scores_gemma":[0.9969679,0.0000028429765,0.00075558765,0.00013367501,0.00028554344,0.001739387,0.0000012904416,0.0000068747004,0.00010687987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971495,0.00019539417,0.001902896,0.00018273937,0.0003402972,0.0002291581],"domain_scores_gemma":[0.99736834,0.0005536083,0.0013976039,0.00013102878,0.00036487344,0.00018453982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002263334,0.00011717558,0.0011642881,0.00022994928,0.00003532659,0.000003950216,0.000081896644,0.000103203376,0.00001318512],"category_scores_gemma":[0.0011081971,0.000080132646,0.00015293962,0.00024669722,0.00012607423,0.00008298114,0.000030045134,0.00023763366,1.5102239e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013697153,0.003280667,0.967213,0.000039680603,0.00013001461,0.0011674324,0.00025201536,0.000026713486,0.00030294794,0.000008433865,0.00010643571,0.013775532],"study_design_scores_gemma":[0.026773596,0.058906842,0.91089845,0.00006297762,0.00018187542,0.00011610581,0.00074026943,0.000025628648,0.00024559154,0.00002752884,0.001966654,0.000054474436],"about_ca_topic_score_codex":0.0469022,"about_ca_topic_score_gemma":0.66692513,"teacher_disagreement_score":0.6200229,"about_ca_system_score_codex":0.0027096607,"about_ca_system_score_gemma":0.0029667688,"threshold_uncertainty_score":0.9594446},"labels":[],"label_agreement":null},{"id":"W2324434746","doi":"10.1200/jco.2009.27.15_suppl.589","title":"Evaluation of the incidence and of risk factors associated with trastuzumab-associated cardiac toxicity in routine clinical practice","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Ejection fraction; Trastuzumab; Internal medicine; Tact; Coronary artery disease; Cancer; Surgery; Cardiology; Oncology; Breast cancer; Heart failure","score_opus":0.19299448141732994,"score_gpt":0.537578305884106,"score_spread":0.3445838244667761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324434746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953589,0.00047280797,0.000004394072,0.0025711395,0.00057593314,0.0003462505,0.000015519074,0.0000028703598,0.0006521853],"genre_scores_gemma":[0.99837947,0.0008306227,0.00013446959,0.00045543016,0.00017631084,0.0000012997214,0.0000026219334,0.0000058767478,0.000013885415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912934,0.005092981,0.002490178,0.00015623786,0.00081121863,0.00015602045],"domain_scores_gemma":[0.98065203,0.0123754535,0.005092386,0.00012785317,0.0016074952,0.00014475788],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023778576,0.000118429794,0.001653243,0.00007749401,0.000027363858,0.000002369787,0.00010976696,0.0004049192,0.000032486794],"category_scores_gemma":[0.065172024,0.000067215864,0.00035449458,0.000303728,0.00029233194,0.00011602033,0.000025321919,0.0011359443,1.9641804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003420692,0.0056511844,0.9519427,0.000003061525,0.0010087597,0.000018768567,0.0004073994,0.00007035583,0.00013171445,0.000008023021,0.0003388632,0.036998525],"study_design_scores_gemma":[0.014284084,0.018381614,0.9611506,0.0001285112,0.0049557816,0.000011886248,0.0002244513,0.0002446429,0.00018894143,0.00022100181,0.00015547153,0.000053027386],"about_ca_topic_score_codex":0.00014207707,"about_ca_topic_score_gemma":0.00049716776,"teacher_disagreement_score":0.041393448,"about_ca_system_score_codex":0.00043574412,"about_ca_system_score_gemma":0.0025117872,"threshold_uncertainty_score":0.9427024},"labels":[],"label_agreement":null},{"id":"W2324451228","doi":"10.1200/jco.2013.31.15_suppl.e17563","title":"A review of the Inuit oncology patients treated at the Ottawa Hospital Cancer Centre.","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cancer; Colorectal cancer; Lung cancer; Radiation therapy; Population; Internal medicine; Chemotherapy; Breast cancer; Disease","score_opus":0.11992890011560192,"score_gpt":0.480044359604187,"score_spread":0.3601154594885851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324451228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026502593,0.9848688,5.9782315e-7,0.0048182853,0.004419914,0.001626169,0.000033976405,0.000008127495,0.0015738668],"genre_scores_gemma":[0.00032510137,0.9940128,0.000047272628,0.002549184,0.0014903161,0.00005778859,0.000007884044,0.000036613008,0.0014730539],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915611,0.0023961666,0.0048919087,0.00029604163,0.0005587695,0.00029600668],"domain_scores_gemma":[0.9845107,0.003435497,0.0100239,0.00049665174,0.0012453783,0.00028783182],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030560163,0.0003459821,0.005882886,0.00009720354,0.0000780682,0.0000056105255,0.0005183774,0.0010206845,0.0010216582],"category_scores_gemma":[0.0066936826,0.00014331649,0.0030407482,0.00047233,0.0004344519,0.000050077317,0.0002489546,0.002421853,0.00004436003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050874415,0.00062244973,0.0016298606,0.0075719636,0.0007448508,0.000019901605,0.000039007748,1.15767136e-7,6.0530716e-8,0.0000013906271,0.09014044,0.8987212],"study_design_scores_gemma":[0.001847924,0.015236059,0.003235647,0.052191053,0.0056429883,0.00018631537,0.000008845179,9.59582e-7,8.7363304e-7,0.000005251961,0.92152196,0.00012212737],"about_ca_topic_score_codex":0.00023966441,"about_ca_topic_score_gemma":0.0007922943,"teacher_disagreement_score":0.8985991,"about_ca_system_score_codex":0.0017381094,"about_ca_system_score_gemma":0.005725557,"threshold_uncertainty_score":0.99991107},"labels":[],"label_agreement":null},{"id":"W2325803459","doi":"10.1200/jco.2012.30.15_suppl.lba1000","title":"NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Gemcitabine; Paclitaxel; Adjuvant; Oncology; Internal medicine; Doxorubicin; Randomized controlled trial; Chemotherapy","score_opus":0.03819735924230556,"score_gpt":0.39348291623592246,"score_spread":0.3552855569936169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325803459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986399,0.007695861,0.00009508774,0.002897356,0.00030101853,0.0015391214,0.00015449703,0.000012551186,0.0009055014],"genre_scores_gemma":[0.9929539,0.0041743726,0.0007915882,0.0013370028,0.00030189115,0.0001811393,0.000028178605,0.00004712164,0.00018481462],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99426013,0.0012633968,0.0026554829,0.00050200114,0.0005836119,0.00073536765],"domain_scores_gemma":[0.99079597,0.004916541,0.002636763,0.0002145704,0.0005624108,0.000873738],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004024803,0.0005135082,0.0074242586,0.00041538227,0.00009397135,0.000024385456,0.00015172544,0.0003781756,0.00016509903],"category_scores_gemma":[0.0004278764,0.00029813417,0.0004025629,0.0008063667,0.0010378313,0.0003428393,0.000077042845,0.0010959572,8.1629406e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7535577,0.0030663651,0.22384888,0.00004355062,0.013768224,0.00037482704,0.0016749554,0.000076338176,0.0006436544,0.000008203855,0.0011982478,0.0017390549],"study_design_scores_gemma":[0.78772116,0.02326969,0.17062934,0.00038378534,0.015191079,0.00041725516,0.0011278231,0.00021418546,0.0001700003,0.000008120061,0.0005140674,0.00035347306],"about_ca_topic_score_codex":0.0012608009,"about_ca_topic_score_gemma":0.001076372,"teacher_disagreement_score":0.053219534,"about_ca_system_score_codex":0.0006438565,"about_ca_system_score_gemma":0.0015229619,"threshold_uncertainty_score":0.9999471},"labels":[],"label_agreement":null},{"id":"W23274571","doi":"10.1200/jco.2009.27.15_suppl.3527","title":"Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Placebo; Proportional hazards model; Adverse effect; Confidence interval","score_opus":0.10256373920177174,"score_gpt":0.46136241685791207,"score_spread":0.3587986776561403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23274571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353284,0.00026148025,0.000020204872,0.00031546358,0.0012551903,0.0044175526,0.00012600873,0.000002962749,0.000068292786],"genre_scores_gemma":[0.9971623,0.00052509794,0.001420703,0.00022932935,0.00049433345,0.00008628861,0.00002051377,0.000024640758,0.000036829057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921999,0.0013737004,0.0049106814,0.00038315263,0.0008748394,0.00025773325],"domain_scores_gemma":[0.9923708,0.0024997399,0.003643613,0.00017414468,0.0009867316,0.00032500434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050921193,0.0002936318,0.004420123,0.00028149557,0.00004108325,0.0000055927717,0.00013338617,0.0002951396,0.000073712115],"category_scores_gemma":[0.0025226707,0.0001637301,0.00030286633,0.00030618662,0.00025309063,0.00025054105,0.000023498853,0.00064731407,3.42861e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8678154,0.01634005,0.099014156,0.000057721576,0.000990592,0.00007433253,0.00070078525,0.00020690082,0.00011687381,0.0000032897954,0.000089740526,0.014590164],"study_design_scores_gemma":[0.8646563,0.07092003,0.061485104,0.00045972262,0.0016855648,0.000004232065,0.00023742273,0.000106138374,0.000093128896,0.0000068335803,0.00019138608,0.00015412718],"about_ca_topic_score_codex":0.027000632,"about_ca_topic_score_gemma":0.1598694,"teacher_disagreement_score":0.13286877,"about_ca_system_score_codex":0.00038436928,"about_ca_system_score_gemma":0.009273638,"threshold_uncertainty_score":0.99634284},"labels":[],"label_agreement":null},{"id":"W2327860874","doi":"10.1200/jco.2007.25.18_suppl.9099","title":"Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Depression (economics); Cancer; Colorectal cancer; Anxiety; Prospective cohort study; Oncology; Physical therapy; Psychiatry","score_opus":0.0576675429311623,"score_gpt":0.43314728204532343,"score_spread":0.3754797391141611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327860874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967272,0.0002715237,0.000022854088,0.00040403684,0.0007677388,0.0015574542,0.000010708391,0.0000053921945,0.00023306823],"genre_scores_gemma":[0.998188,0.00032380284,0.000028908496,0.0010011286,0.0003178045,0.00009142341,0.0000030643052,0.000022206028,0.000023661945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698776,0.00021791854,0.0016301819,0.00032266768,0.00051768514,0.00032377246],"domain_scores_gemma":[0.9968514,0.00089226285,0.0009992766,0.00005494757,0.0009984123,0.00020369129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017678981,0.00020679922,0.0012892482,0.000301838,0.000031700263,0.000006254346,0.000045363093,0.00023238311,0.00014046261],"category_scores_gemma":[0.0007480401,0.00014650614,0.00010133687,0.0003442036,0.00025726692,0.00015538912,0.000041081086,0.0010035931,0.000001388125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083668455,0.008301855,0.8605455,0.000015370048,0.00091449183,0.00014042572,0.00041991472,0.0000024147243,7.4477424e-7,2.3408953e-7,0.000069479196,0.0459211],"study_design_scores_gemma":[0.052802492,0.038972422,0.9064639,0.00045771702,0.0007056171,0.000003458535,0.00037054403,0.0000039956426,0.0000046553973,0.000010045487,0.000070405375,0.00013474534],"about_ca_topic_score_codex":0.0003951082,"about_ca_topic_score_gemma":0.010605944,"teacher_disagreement_score":0.045918383,"about_ca_system_score_codex":0.0006418059,"about_ca_system_score_gemma":0.0005637195,"threshold_uncertainty_score":0.5974347},"labels":[],"label_agreement":null},{"id":"W2328690495","doi":"10.1200/jco.2013.31.15_suppl.9624","title":"Risk of arterial (ATE) and venous thromboembolism (VTE) in a population-based cohort of bevacizumab-treated metastatic colorectal cancer (mCRC) patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Colorectal cancer; Internal medicine; Cohort; Incidence (geometry); Population; Venous thromboembolism; Cancer; Oncology; Surgery; Chemotherapy; Thrombosis","score_opus":0.033500789246145926,"score_gpt":0.3775969711679279,"score_spread":0.344096181921782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328690495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747294,0.00018686571,0.000012374697,0.0005409381,0.00066300615,0.000855677,0.000023649935,0.0000050042263,0.0002395229],"genre_scores_gemma":[0.99775827,0.0008534039,0.00082298106,0.00032750878,0.0001665793,0.000030871957,0.000014931838,0.00001866236,0.000006790957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959109,0.0005087802,0.0027584312,0.00020150508,0.00039206818,0.00022834308],"domain_scores_gemma":[0.99511534,0.0011951104,0.002727905,0.00014986702,0.000597829,0.00021396799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014900273,0.00016764308,0.0028472398,0.00024779578,0.000026697173,0.000006670739,0.00011282981,0.00021120076,0.00035722659],"category_scores_gemma":[0.0015947941,0.00012368022,0.0002941345,0.00018257351,0.00019270918,0.00011021618,0.00004335591,0.00041553055,0.000003558342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012026,0.0065239444,0.96178144,0.00011055518,0.0009351132,0.000033198456,0.00018293544,0.0001451429,0.00021393519,0.0000386838,0.0005502062,0.028282227],"study_design_scores_gemma":[0.010340948,0.008942475,0.97773683,0.00018794763,0.0015089555,0.000006021217,0.000058614372,0.00036201632,0.00018069959,0.0003431254,0.00023776482,0.00009457614],"about_ca_topic_score_codex":0.0058611925,"about_ca_topic_score_gemma":0.0007614517,"teacher_disagreement_score":0.02818765,"about_ca_system_score_codex":0.00015201523,"about_ca_system_score_gemma":0.0005269299,"threshold_uncertainty_score":0.88604087},"labels":[],"label_agreement":null},{"id":"W2329810662","doi":"10.1200/jco.2014.32.15_suppl.3006","title":"Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.03842021234552484,"score_gpt":0.3947987274807241,"score_spread":0.35637851513519925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329810662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995223,0.0021010526,0.00004847175,0.0010879416,0.00066821044,0.00047439005,0.0000082448105,0.000010985835,0.00037773122],"genre_scores_gemma":[0.99908006,0.00023076884,0.00017935384,0.00021328047,0.000031475043,0.00001046989,0.000025961495,0.000029402276,0.0001992125],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98460186,0.011673084,0.0027781574,0.00027341506,0.0002943116,0.00037918834],"domain_scores_gemma":[0.99040663,0.0045946217,0.0031448647,0.0004326773,0.0013796715,0.000041537707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018562537,0.00028128002,0.0016078262,0.00029391618,0.00012717693,0.000011359752,0.0004983746,0.00061872194,0.00036089926],"category_scores_gemma":[0.0035216578,0.00015361853,0.00031851797,0.0003543404,0.00083729776,0.00024350223,0.000055963657,0.0011378436,0.000027121945],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33772343,0.0051346393,0.16513011,0.00001776032,0.0028662395,0.000042936397,0.0010756507,0.0004404266,0.26649812,0.00008425966,0.00032712778,0.2206593],"study_design_scores_gemma":[0.03779032,0.036661554,0.90597665,0.00019121362,0.00048687722,0.00015433102,0.00023767051,0.000073000876,0.00906911,0.000054559154,0.0091031445,0.00020159179],"about_ca_topic_score_codex":0.000044383236,"about_ca_topic_score_gemma":0.00002253056,"teacher_disagreement_score":0.7408465,"about_ca_system_score_codex":0.00014757992,"about_ca_system_score_gemma":0.0012366944,"threshold_uncertainty_score":0.64334416},"labels":[],"label_agreement":null},{"id":"W2330257105","doi":"10.1200/jco.2006.24.18_suppl.6046","title":"Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Internal medicine; Hazard ratio; Indirect costs; Cohort; Oncology; Quality-adjusted life year; Chemotherapy; Cancer; Surgery; Cost effectiveness; Confidence interval","score_opus":0.13966758254003417,"score_gpt":0.5021745728242512,"score_spread":0.36250699028421696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330257105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98195744,0.0035881684,0.0000030397541,0.004291175,0.0016784868,0.00031183058,0.00001008218,0.0000033141228,0.008156459],"genre_scores_gemma":[0.9952673,0.0030520984,0.00020967492,0.00023168226,0.00090058416,0.000016140646,0.000003255419,0.000010510374,0.0003087779],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972633,0.0002150155,0.0018706699,0.00015429474,0.00032786897,0.00016881902],"domain_scores_gemma":[0.99720204,0.0008075505,0.0014090933,0.00011085505,0.0003828609,0.00008761452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002584068,0.00011849245,0.0014209033,0.00011533864,0.000021419664,0.0000027421768,0.000077172044,0.00018295184,0.0006470685],"category_scores_gemma":[0.00036250462,0.00008599974,0.0002822223,0.00008459991,0.00014047704,0.00006149588,0.000020918333,0.0003280097,0.0000033269187],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057831906,0.0035135045,0.35658044,0.00003796819,0.0011146719,0.0001673992,0.0003011235,0.0016167895,0.00045387918,0.00016919724,0.006974734,0.5712384],"study_design_scores_gemma":[0.069324434,0.015170147,0.87647045,0.00007911626,0.0006315003,0.000013518389,0.00022125355,0.0008795125,0.00029152224,0.00016618216,0.036663204,0.00008917196],"about_ca_topic_score_codex":0.0012601236,"about_ca_topic_score_gemma":0.01150772,"teacher_disagreement_score":0.57114923,"about_ca_system_score_codex":0.0013715792,"about_ca_system_score_gemma":0.0023920357,"threshold_uncertainty_score":0.7084946},"labels":[],"label_agreement":null},{"id":"W2330426903","doi":"10.1200/jco.2012.45.9800","title":"Epilogue: The Peril and the Promise of Comparative Effectiveness Research in Oncology","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Citation; Clinical Oncology; Medicine; Oncology; Internal medicine; Library science; Cancer; Computer science","score_opus":0.6859659515364368,"score_gpt":0.5902431444118819,"score_spread":0.09572280712455494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330426903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029011602,0.972178,0.000017976177,0.0013416882,0.0017953704,0.00095356454,0.00003058613,0.0000013799072,0.020780293],"genre_scores_gemma":[0.055930007,0.94253397,0.000090315145,0.00012916724,0.0011403682,0.000064034386,0.0000013085529,0.000020691194,0.000090134214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898739,0.0037681768,0.005543748,0.00030016602,0.00008170763,0.000432333],"domain_scores_gemma":[0.96299857,0.029263709,0.006956369,0.0003568489,0.00024818466,0.00017631309],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0553926,0.00024509142,0.008117247,0.000358979,0.000091399066,0.000023521816,0.0008424729,0.0009339961,0.000085026586],"category_scores_gemma":[0.0037192944,0.00013269325,0.00093426503,0.0003348517,0.002435886,0.00019241229,0.0002540923,0.0033119977,0.000063778665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015646875,0.00058227143,0.0017973235,0.001052989,0.00049477414,0.000016386171,0.0006020658,0.0000033400665,1.15432375e-8,0.107896075,0.00054896384,0.8854411],"study_design_scores_gemma":[0.003473021,0.0019532538,0.006987924,0.0008584851,0.00016878129,0.00007391259,0.000098806195,0.000009474095,7.007927e-8,0.023270411,0.962977,0.00012886015],"about_ca_topic_score_codex":0.00015581885,"about_ca_topic_score_gemma":0.00012811618,"teacher_disagreement_score":0.96242803,"about_ca_system_score_codex":0.00053408334,"about_ca_system_score_gemma":0.002014519,"threshold_uncertainty_score":0.9989874},"labels":[],"label_agreement":null},{"id":"W2333494261","doi":"10.1200/jco.2015.33.15_suppl.tps8599","title":"A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Ibrutinib; Medicine; Bruton's tyrosine kinase; Waldenstrom macroglobulinemia; Tolerability; Rituximab; Macroglobulinemia; Internal medicine; Placebo; Oncology; Phases of clinical research; Gastroenterology; Pharmacology; Clinical trial; Tyrosine kinase; Adverse effect; Lymphoma; Chronic lymphocytic leukemia; Pathology; Leukemia; Receptor","score_opus":0.26018308480509883,"score_gpt":0.5382811004902589,"score_spread":0.27809801568516007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333494261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98425454,0.00038001256,0.0012929894,0.0026175373,0.0009566965,0.008135935,0.0000112340995,0.000022385924,0.0023286685],"genre_scores_gemma":[0.9859473,0.00012443398,0.008744675,0.0005133291,0.002100929,0.00029650185,0.000007545358,0.00006883538,0.0021964412],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894448,0.0013391986,0.0063144267,0.0005087682,0.0016863123,0.0007065183],"domain_scores_gemma":[0.97809947,0.012220934,0.0044918247,0.0006366321,0.0031975782,0.0013535375],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020888232,0.0004218873,0.009033533,0.00037818617,0.00006588522,0.000030885618,0.0005657394,0.0006481648,0.0002268983],"category_scores_gemma":[0.017009648,0.00022249119,0.0011849572,0.00035193647,0.0009839141,0.00018220235,0.00014991417,0.00151582,0.000030450103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9576291,0.02147625,0.00076285854,0.00012725167,0.0038782323,0.0020137143,0.00061712565,0.00008770081,0.000019802663,0.00003086478,0.0065373387,0.0068197707],"study_design_scores_gemma":[0.86942804,0.10715751,0.000008585616,0.00020633182,0.0040817983,0.0031700328,0.001951129,0.007823009,0.00006981667,0.00007465309,0.0058330656,0.00019603416],"about_ca_topic_score_codex":0.00022289298,"about_ca_topic_score_gemma":0.00033166027,"teacher_disagreement_score":0.08820106,"about_ca_system_score_codex":0.0029914016,"about_ca_system_score_gemma":0.049827375,"threshold_uncertainty_score":0.9912705},"labels":[],"label_agreement":null},{"id":"W2334564347","doi":"10.1200/jco.2004.22.14_suppl.6588","title":"Long-term follow up of limited stage primary testicular lymphoma: Outcome and patterns of relapse after combined-modality treatment","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Modality (human–computer interaction); Lymphoma; Internal medicine; Term (time); Primary treatment","score_opus":0.08707164086731019,"score_gpt":0.4117274669052473,"score_spread":0.32465582603793713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334564347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498504,0.0010426752,0.0000494684,0.0028166892,0.00054631877,0.00035153964,0.00003750842,0.000006760198,0.00016401034],"genre_scores_gemma":[0.9962581,0.0012706266,0.0013369352,0.00075668667,0.00014771592,0.000012559189,0.000011680413,0.000017606164,0.0001881387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960904,0.00022923594,0.0028501502,0.0002317895,0.00038242963,0.0002159991],"domain_scores_gemma":[0.9955954,0.0014456165,0.0018892436,0.00033091646,0.00034247388,0.0003963306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094699074,0.00022431942,0.0023318266,0.00012375355,0.000020582876,0.000005296105,0.0000946027,0.00033866343,0.000055866203],"category_scores_gemma":[0.0008529264,0.00014071264,0.0007584148,0.00008582252,0.00021927849,0.000082759114,0.000063581574,0.00017005895,0.0000033283354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006467549,0.014322976,0.94148606,0.0001766155,0.0011042558,0.0036463789,0.0001075421,0.0000051118895,0.00006878701,0.00009223064,0.000016492973,0.03250597],"study_design_scores_gemma":[0.063483015,0.028854022,0.9045528,0.0002841133,0.0015432321,0.0003211162,0.000027311116,0.0000020992256,0.00048379725,0.00011268989,0.00024281674,0.00009294339],"about_ca_topic_score_codex":0.0001145967,"about_ca_topic_score_gemma":0.00007067281,"teacher_disagreement_score":0.057015464,"about_ca_system_score_codex":0.0006239524,"about_ca_system_score_gemma":0.001259968,"threshold_uncertainty_score":0.5738095},"labels":[],"label_agreement":null},{"id":"W2335244965","doi":"10.1200/jco.2007.25.18_suppl.14018","title":"A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cetuximab; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Irinotecan; Urology; Pharmacokinetics; Pharmacology; Colorectal cancer; Cancer","score_opus":0.04923117680282855,"score_gpt":0.39806231602944087,"score_spread":0.3488311392266123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335244965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840146,0.000075922755,0.00009101913,0.00034131072,0.000115368035,0.0009319327,0.0000029559835,0.0000057478987,0.000034296736],"genre_scores_gemma":[0.99655485,0.00005686362,0.0031088863,0.00014077466,0.0000858634,0.000005765516,0.000006447872,0.000018815892,0.000021735888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965997,0.00025998743,0.0020727487,0.00024557125,0.00054533716,0.00027669175],"domain_scores_gemma":[0.99659294,0.00053211534,0.0018752235,0.00016235882,0.00065641,0.00018096427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002091038,0.00020126464,0.0015524937,0.0004250481,0.000021099664,0.000007914154,0.00011251778,0.0000928109,0.000014303405],"category_scores_gemma":[0.0006676315,0.00013445911,0.00007562187,0.00043756058,0.00019510764,0.00025008968,0.0000449731,0.000504756,1.809127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078006536,0.029385904,0.8097235,0.00005048212,0.00008137541,0.000605784,0.00046362184,0.000022530969,0.0003663505,0.000012390382,0.000034856632,0.08124666],"study_design_scores_gemma":[0.13459976,0.21361244,0.6497141,0.00034905097,0.00009581354,0.000059167643,0.0012719581,0.000044161752,0.00009448254,0.000009218585,0.00007451521,0.000075336226],"about_ca_topic_score_codex":0.00009621489,"about_ca_topic_score_gemma":0.0015054331,"teacher_disagreement_score":0.18422653,"about_ca_system_score_codex":0.00015150955,"about_ca_system_score_gemma":0.000353522,"threshold_uncertainty_score":0.5483084},"labels":[],"label_agreement":null},{"id":"W2335947880","doi":"10.1200/jco.2007.25.18_suppl.19501","title":"A phase 2 study to evaluate the efficacy of darbepoetin-alfa administered using an extended dose schedule versus weekly dosing in cancer patients with chemotherapy-induced anemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Dosing; Clinical endpoint; Anemia; Chemotherapy; Interim analysis; Internal medicine; Randomization; Darbepoetin alfa; Surgery; Gastroenterology; Clinical trial","score_opus":0.21046210438239735,"score_gpt":0.5407258610822141,"score_spread":0.3302637566998168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335947880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959736,0.000067389534,0.000019444748,0.002084064,0.00068574806,0.00092059234,0.0000019679337,0.0000060204316,0.000241164],"genre_scores_gemma":[0.9951858,0.00002013771,0.0035617417,0.00069683354,0.00048713537,0.0000035807325,0.0000018003772,0.00002793481,0.000015055704],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99608266,0.00053606776,0.0021449714,0.00027899095,0.0006273982,0.00032993083],"domain_scores_gemma":[0.9960115,0.0015003945,0.0012309303,0.00031718044,0.00052236917,0.0004176058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043410836,0.00020871841,0.0012629965,0.0001670476,0.00006164163,0.000010318368,0.00019456875,0.00017434437,0.00007320302],"category_scores_gemma":[0.001229104,0.0001168653,0.0001996209,0.0003247034,0.00015780433,0.00007997288,0.00004222211,0.00073189876,0.0000016012787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26014575,0.1479324,0.23371337,0.00004028853,0.0009541263,0.00093730795,0.0044653695,0.00006737351,0.006057111,0.000005041058,0.00008984877,0.345592],"study_design_scores_gemma":[0.19749965,0.18331376,0.6128438,0.00032892905,0.00086362346,0.00004551452,0.002895199,0.00006674376,0.0016865517,0.0000050039116,0.00030135806,0.00014987387],"about_ca_topic_score_codex":0.0001203244,"about_ca_topic_score_gemma":0.0003572124,"teacher_disagreement_score":0.37913042,"about_ca_system_score_codex":0.0004076018,"about_ca_system_score_gemma":0.0015532152,"threshold_uncertainty_score":0.4765629},"labels":[],"label_agreement":null},{"id":"W2335948334","doi":"10.1200/jco.2007.25.18_suppl.5144","title":"Testosterone recovery after two years of androgen suppression in prostate cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Urology; Prostate cancer; Prostatectomy; Testosterone (patch); Prostate; Proportional hazards model; Androgen suppression; Androgen; Biopsy; Prostate-specific antigen; Gynecology; Cancer; Internal medicine; Hormone","score_opus":0.06321472230097684,"score_gpt":0.4526573120713138,"score_spread":0.38944258977033697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335948334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583167,0.0015265829,0.0000021664434,0.00096507976,0.0008873866,0.00014176483,0.000004117432,0.0000014854231,0.0006397775],"genre_scores_gemma":[0.9973219,0.0011564603,0.00047024776,0.0003164188,0.00052613014,0.0000020562588,7.0820187e-7,0.0000070938063,0.00019899885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789613,0.000109332235,0.0014829874,0.00012548038,0.00023328805,0.00015280217],"domain_scores_gemma":[0.99806714,0.00056343264,0.0007909987,0.00007867654,0.0003805686,0.0001191683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020290336,0.00006661309,0.00083869405,0.00010983544,0.000007732836,9.331868e-7,0.00004900008,0.00009876271,0.000031660613],"category_scores_gemma":[0.0016336704,0.000042720047,0.00016637552,0.000103722785,0.00015849256,0.00006418894,0.00005224555,0.00043586674,0.0000032075272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011874111,0.0011544802,0.727008,0.000014018508,0.00009940656,0.00031017783,0.00018611162,0.0000032000023,0.00036843086,4.919929e-7,0.00037100885,0.25861058],"study_design_scores_gemma":[0.0056381235,0.00874836,0.9730714,0.00018045164,0.00008147088,0.0000220504,0.00007925283,6.3799627e-7,0.0006049098,0.00010954128,0.011420978,0.000042821946],"about_ca_topic_score_codex":0.000033301556,"about_ca_topic_score_gemma":0.00008567084,"teacher_disagreement_score":0.25856775,"about_ca_system_score_codex":0.00007621196,"about_ca_system_score_gemma":0.00033938052,"threshold_uncertainty_score":0.19557741},"labels":[],"label_agreement":null},{"id":"W2336020194","doi":"10.1200/jco.2009.27.15_suppl.e17564","title":"Implementation of an integrated cancer care network","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; Ministry of Health","funders":"","keywords":"Medicine; Multidisciplinary approach; Health care; Mandate; Coaching; Family medicine; Medical education; Nursing; Management","score_opus":0.39025211326889103,"score_gpt":0.6686919872028798,"score_spread":0.2784398739339888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336020194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816713,0.0004092079,0.00091441,0.014884476,0.0014157104,0.00025845654,0.0000079513065,0.000009362514,0.00042917693],"genre_scores_gemma":[0.964584,0.0005962416,0.024292272,0.00790578,0.0025654053,0.0000016535872,0.00002591145,0.000009913345,0.000018819108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9937322,0.00059033645,0.004966821,0.00014697478,0.00037721626,0.00018641236],"domain_scores_gemma":[0.9920427,0.0018706173,0.0039209044,0.00016977749,0.0017029367,0.00029303084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043732123,0.00010469801,0.001121644,0.000081332044,0.000026381125,0.000005578877,0.0001285383,0.00024395544,0.00063803955],"category_scores_gemma":[0.004361673,0.00007693999,0.0003367047,0.00021513469,0.00007553857,0.00026517684,0.000017089294,0.0007641374,0.0000036539818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028798648,0.000535865,0.08268704,0.0000119957285,0.00014430702,0.00007292405,0.00016484008,0.00016746236,0.00020090435,0.000063185485,0.006654439,0.9064172],"study_design_scores_gemma":[0.012155703,0.036010444,0.83579564,0.00010240013,0.0010068169,0.00012393367,0.005271398,0.00016672986,0.0002900888,0.0006160763,0.10836043,0.00010034423],"about_ca_topic_score_codex":0.00033572607,"about_ca_topic_score_gemma":0.0010408437,"teacher_disagreement_score":0.9063168,"about_ca_system_score_codex":0.0001767385,"about_ca_system_score_gemma":0.0030493708,"threshold_uncertainty_score":0.6986086},"labels":[],"label_agreement":null},{"id":"W2336162936","doi":"10.1200/jco.2013.31.15_suppl.9013","title":"An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Internal medicine; Dacarbazine; Hazard ratio; Progression-free survival; Oncology; Vemurafenib; Melanoma; Clinical endpoint; Adverse effect; Phases of clinical research; Gastroenterology; Chemotherapy; Randomized controlled trial; Confidence interval; Cancer; Cancer research; Metastatic melanoma; Kinase","score_opus":0.03970374677695072,"score_gpt":0.3917280835614726,"score_spread":0.3520243367845219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336162936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995331,0.00007406998,0.0008337799,0.0005992551,0.0010966866,0.0012162032,0.000019587176,0.0000056173453,0.0008238344],"genre_scores_gemma":[0.996008,0.00008332621,0.0020299258,0.0009813447,0.0005660587,0.000047455498,0.00021018994,0.000028567387,0.00004516681],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99494255,0.0017910551,0.002246648,0.00036722605,0.00034358085,0.00030896955],"domain_scores_gemma":[0.9957676,0.0011580365,0.0019172457,0.00030792257,0.0004999573,0.00034925272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00265814,0.00025598018,0.0016852785,0.00015252747,0.000044319884,0.000030560128,0.0002881155,0.00033622794,0.00011822826],"category_scores_gemma":[0.0021077623,0.00017091485,0.00036660634,0.00012192697,0.00022819216,0.00004263883,0.000043689655,0.00049289817,0.00002300716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.956968,0.0051388843,0.00044886844,0.0000063084253,0.00062762684,0.00014841021,0.0000703799,0.00007125195,0.0010710389,0.00011767962,0.000704245,0.0346273],"study_design_scores_gemma":[0.9184589,0.07360778,0.0041041262,0.000031186442,0.00036422347,0.000025299087,0.00005674515,0.0002354481,0.0013683906,0.000247665,0.0012833718,0.00021691351],"about_ca_topic_score_codex":0.00004434656,"about_ca_topic_score_gemma":0.00007887163,"teacher_disagreement_score":0.0684689,"about_ca_system_score_codex":0.000051278734,"about_ca_system_score_gemma":0.0005879678,"threshold_uncertainty_score":0.6969705},"labels":[],"label_agreement":null},{"id":"W2336309730","doi":"10.1200/jco.2008.26.15_suppl.511","title":"Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1–3, N0–1, M0 B","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Vitamin D and neurology; Tamoxifen; Internal medicine; Cohort; vitamin D deficiency; Prospective cohort study; Body mass index; Estrogen receptor; Gastroenterology; Cancer; Gynecology","score_opus":0.054309958244127814,"score_gpt":0.4055531898277791,"score_spread":0.3512432315836513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336309730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828523,0.0006853144,0.00000772174,0.0002261291,0.00014027189,0.0004721049,0.00005450414,0.0000013892188,0.00012734352],"genre_scores_gemma":[0.98829114,0.0114283115,0.00016481095,0.000018518665,0.000059896345,0.000016480311,5.034853e-7,0.0000068452478,0.000013500398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997435,0.0002484145,0.0015705046,0.00019108137,0.0004199998,0.00013502865],"domain_scores_gemma":[0.994978,0.0013476196,0.0029031092,0.0001056486,0.00054123165,0.00012439178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001671488,0.0001065011,0.0013877405,0.00011095602,0.00002881908,0.0000014300599,0.000060200928,0.00016210653,0.000024675683],"category_scores_gemma":[0.0013460828,0.000069918664,0.000093902185,0.00020912604,0.00021431425,0.00007893736,0.000034916793,0.0004747745,8.4775074e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019598184,0.003110852,0.9885079,0.000041852138,0.00025415263,0.00006390501,0.0013620664,0.000006158154,0.000035956637,0.00000917236,0.000055843848,0.004592313],"study_design_scores_gemma":[0.0065353247,0.012195034,0.9798312,0.00022346788,0.0005447174,0.000086690365,0.00036747046,0.000009456841,0.00006887454,0.00005873681,0.000016465743,0.00006253429],"about_ca_topic_score_codex":0.0060585514,"about_ca_topic_score_gemma":0.009245031,"teacher_disagreement_score":0.010742997,"about_ca_system_score_codex":0.00043759402,"about_ca_system_score_gemma":0.00066684664,"threshold_uncertainty_score":0.91587573},"labels":[],"label_agreement":null},{"id":"W2336389733","doi":"10.1200/jco.2006.24.18_suppl.13100","title":"Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lapatinib; Erlotinib; Tyrosine-kinase inhibitor; Cancer research; Hsp90 inhibitor; Trastuzumab; SKBR3; EGFR inhibitors; Medicine; Apoptosis; Breast cancer; ErbB; Epidermal growth factor receptor; Transfection; Growth inhibition; MTT assay; Cell culture; Pharmacology; Cancer; Internal medicine; Biology; Hsp90; Heat shock protein; Human breast; Biochemistry","score_opus":0.06359530791566989,"score_gpt":0.43699860877867275,"score_spread":0.3734033008630029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336389733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757505,0.00093114027,0.000065619184,0.009584352,0.00036100813,0.00031079154,0.00003452923,0.0000038870567,0.0011336158],"genre_scores_gemma":[0.99716896,0.00074060814,0.00040253,0.00017610921,0.0013194282,0.000008871258,0.0000031253687,0.000020614647,0.00015974807],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99613404,0.00046202823,0.0022591702,0.00017073964,0.0007751303,0.00019889865],"domain_scores_gemma":[0.9935233,0.001961035,0.002477636,0.00018182136,0.0016976206,0.00015856198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027216282,0.00013901557,0.0012534079,0.00014037368,0.00003001414,0.000005414017,0.000099944395,0.00029726615,0.00008884508],"category_scores_gemma":[0.0006961026,0.00008107002,0.00020738448,0.00027196883,0.00090049027,0.0001065113,0.00006247104,0.00069216476,7.516941e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04211944,0.02165462,0.31100702,0.0041144327,0.0010310578,0.0007801366,0.0011014042,0.00043980178,0.45003736,0.0016543377,0.04830498,0.117755406],"study_design_scores_gemma":[0.04297218,0.05614202,0.77184826,0.00393563,0.0016243221,0.00087160605,0.0013959911,0.00062522414,0.1096279,0.0009532783,0.009633117,0.00037047267],"about_ca_topic_score_codex":0.0007655989,"about_ca_topic_score_gemma":0.000716637,"teacher_disagreement_score":0.4608412,"about_ca_system_score_codex":0.00017162156,"about_ca_system_score_gemma":0.0019245815,"threshold_uncertainty_score":0.34141248},"labels":[],"label_agreement":null},{"id":"W2336457573","doi":"10.1200/jco.2015.33.3_suppl.9","title":"INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Regorafenib; Population; Placebo; Ramucirumab; Adverse effect; Phases of clinical research; Gastroenterology; Cancer; Progression-free survival; Refractory (planetary science); Surgery; Oncology; Chemotherapy; Clinical trial; Colorectal cancer; Pathology","score_opus":0.2245218974730568,"score_gpt":0.5075961454477481,"score_spread":0.28307424797469133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336457573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98137707,0.0007514011,0.00011933597,0.0075261146,0.0016207263,0.007805664,0.000012153947,0.000017395932,0.0007701496],"genre_scores_gemma":[0.9963288,0.0002984415,0.0005051663,0.00024598787,0.0009894784,0.00023819707,0.000007379104,0.000031250773,0.001355352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98293555,0.0047648847,0.0101104975,0.0005023432,0.0011840911,0.0005026396],"domain_scores_gemma":[0.975643,0.01315169,0.009205404,0.0005268203,0.00092121836,0.0005518918],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.045691404,0.0004397943,0.008225978,0.00061533577,0.00009283836,0.000029871233,0.00060057675,0.00021964413,0.00010983209],"category_scores_gemma":[0.035119034,0.00023351818,0.0011672404,0.00077457225,0.00036292794,0.00024608354,0.00017028267,0.0020607065,0.0000028380216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9189835,0.028522946,0.01619661,0.00001838071,0.0016044792,0.0007619645,0.0014202312,0.00022034641,0.000015995205,0.0000059473896,0.010940312,0.021309262],"study_design_scores_gemma":[0.88234544,0.09528596,0.0041982844,0.00019472434,0.0032871454,0.000101540674,0.010491582,0.00013826966,0.0000041904937,0.000029224539,0.0037897748,0.00013383811],"about_ca_topic_score_codex":0.0008533328,"about_ca_topic_score_gemma":0.0026215327,"teacher_disagreement_score":0.06676301,"about_ca_system_score_codex":0.00053134374,"about_ca_system_score_gemma":0.0016215738,"threshold_uncertainty_score":0.98266155},"labels":[],"label_agreement":null},{"id":"W2336769999","doi":"10.1200/jco.2006.24.18_suppl.17078","title":"Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Achieve Life Sciences (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; Clusterin; Cancer research; Stage (stratigraphy); Oncology; Deoxycytidine; Oligonucleotide; Internal medicine; Chemotherapy; Molecular biology; Apoptosis; Biology; DNA; Genetics","score_opus":0.05611860557962895,"score_gpt":0.4137367067407564,"score_spread":0.35761810116112747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336769999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463636,0.00008588713,0.00075523864,0.0008939019,0.000396344,0.0029481428,0.00011932831,0.000009487887,0.00015528963],"genre_scores_gemma":[0.99239707,0.00006452408,0.005538357,0.00057741976,0.00056616036,0.000100240366,0.000036138706,0.000051516,0.0006685621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662125,0.00022917376,0.0021237792,0.00041086721,0.0002981412,0.00031680192],"domain_scores_gemma":[0.9957469,0.0009319627,0.0017667572,0.000307303,0.00082180847,0.00042525333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064871955,0.00030575774,0.0018369427,0.00020541849,0.00007696165,0.000013659794,0.00010581994,0.00020024671,0.00012653948],"category_scores_gemma":[0.00028439774,0.00018968554,0.00017127971,0.00015735462,0.00013571106,0.00008493726,0.000072517985,0.00026717273,0.0000014994364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16511287,0.068201244,0.73809683,0.00047930513,0.0011779184,0.0016938228,0.0011881371,0.0026848475,0.002534258,0.0000045467477,0.0020843048,0.016741924],"study_design_scores_gemma":[0.21418439,0.3644539,0.4120891,0.00021659562,0.0020862652,0.00010747131,0.00022498553,0.00363112,0.000703619,0.0000057584202,0.002025364,0.0002714172],"about_ca_topic_score_codex":0.00015885649,"about_ca_topic_score_gemma":0.0044240425,"teacher_disagreement_score":0.32600772,"about_ca_system_score_codex":0.00022585593,"about_ca_system_score_gemma":0.0006914535,"threshold_uncertainty_score":0.7735152},"labels":[],"label_agreement":null},{"id":"W2336852147","doi":"10.1200/jco.2004.22.90140.2","title":"Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain &amp; RT Groups and NCIC Clinical Trials Group","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Western University","funders":"","keywords":"Temozolomide; Medicine; Glioblastoma; Concomitant; Radiation therapy; Oncology; Adjuvant; Internal medicine; Clinical trial; Phases of clinical research; Randomized controlled trial; Cancer research","score_opus":0.10882569204817598,"score_gpt":0.4899773576361529,"score_spread":0.3811516655879769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336852147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536103,0.009352423,0.0009062587,0.029492706,0.0011836776,0.0052774297,0.00013541413,0.000012220864,0.000029561468],"genre_scores_gemma":[0.97523004,0.014919401,0.0037887362,0.0040969616,0.0017168298,0.00015859408,0.000023940596,0.000040096038,0.000025403377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9844741,0.0042830775,0.009796537,0.00055058394,0.00047962627,0.00041605055],"domain_scores_gemma":[0.8709482,0.120233305,0.0072083618,0.0003434065,0.00046433735,0.0008024087],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04444258,0.00041292916,0.008663319,0.0001779268,0.00015038489,0.000039239305,0.00018702148,0.0007654667,0.000019502753],"category_scores_gemma":[0.08250928,0.00021984876,0.0016938415,0.00013583447,0.001826676,0.00014242475,0.000086479406,0.0008630553,7.0488665e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86635965,0.0061332025,0.0007740813,0.000031189516,0.002970165,0.00030201633,0.0005513277,0.000002809137,0.0011364813,0.00023854256,0.0068027866,0.114697754],"study_design_scores_gemma":[0.9116125,0.06033237,0.001966774,0.00025751998,0.0027799867,0.0005022039,0.0002745937,0.00018208969,0.00020154369,0.0010878072,0.020610353,0.0001922268],"about_ca_topic_score_codex":0.00010515397,"about_ca_topic_score_gemma":0.0003043958,"teacher_disagreement_score":0.11595023,"about_ca_system_score_codex":0.0001562605,"about_ca_system_score_gemma":0.0009282457,"threshold_uncertainty_score":0.98394746},"labels":[],"label_agreement":null},{"id":"W2337192146","doi":"10.1200/jco.2009.27.15_suppl.4513","title":"Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oxaliplatin; Phases of clinical research; Surgery; Fluorouracil; Internal medicine; Radiation therapy; Chemotherapy; Nuclear medicine; Gastroenterology; Oncology; Cancer; Colorectal cancer","score_opus":0.06464634567170173,"score_gpt":0.4280665787199666,"score_spread":0.3634202330482649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337192146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98285425,0.0032172913,0.0038417077,0.005696376,0.0006756194,0.0035867302,0.000024394107,0.000029053072,0.000074581054],"genre_scores_gemma":[0.9866783,0.00035630606,0.009339408,0.0016175181,0.0016407454,0.00013472048,0.000047709826,0.00003867259,0.00014663603],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99457276,0.0005961158,0.0027984323,0.0005233571,0.00083316985,0.0006761881],"domain_scores_gemma":[0.992974,0.00269067,0.002059567,0.0002662871,0.0007286177,0.001280865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039683795,0.0003620766,0.0023096001,0.00041174068,0.00024688643,0.00005046352,0.00019665051,0.00062475563,0.00008821018],"category_scores_gemma":[0.003542625,0.0002566644,0.00059128966,0.00031024768,0.00018423023,0.00031344692,0.000071189614,0.001246167,0.000007689175],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47150302,0.009153054,0.015735097,0.00006790072,0.0005863319,0.006903141,0.00038816218,0.00011005813,0.001510548,0.00006805911,0.001008998,0.49296564],"study_design_scores_gemma":[0.31183437,0.49251035,0.18559548,0.00038563137,0.0015116696,0.0022450571,0.00011900612,0.000722158,0.0012277035,0.00046577572,0.003014709,0.00036810263],"about_ca_topic_score_codex":0.00007112103,"about_ca_topic_score_gemma":0.000048869693,"teacher_disagreement_score":0.49259755,"about_ca_system_score_codex":0.0006924335,"about_ca_system_score_gemma":0.004509226,"threshold_uncertainty_score":0.99998856},"labels":[],"label_agreement":null},{"id":"W2337335671","doi":"10.1200/jco.2012.30.15_suppl.539","title":"BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Internal medicine; Breast cancer; Aromatase inhibitor; Quality of life (healthcare); Placebo; Everolimus; Hazard ratio; Oncology; Clinical endpoint; Interim analysis; Proportional hazards model; Cancer; Randomized controlled trial; Confidence interval; Aromatase","score_opus":0.21813842384889356,"score_gpt":0.5185650640622901,"score_spread":0.3004266402133965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337335671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899223,0.0038733361,0.0000027347642,0.00445571,0.0009547204,0.00035845427,0.000024809577,0.0000070175643,0.00040093213],"genre_scores_gemma":[0.99530256,0.002772922,0.000400926,0.001156018,0.00022994619,0.000010237679,0.000010760413,0.000020406344,0.00009621618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952156,0.0009246075,0.0029601352,0.00017184044,0.0003363529,0.0003914688],"domain_scores_gemma":[0.9942317,0.001986747,0.0025933906,0.000117039745,0.00033469326,0.00073643436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023409897,0.00019084757,0.0023061652,0.0001861682,0.000028974197,0.0000028106956,0.000077294404,0.00020043607,0.00032809615],"category_scores_gemma":[0.0005263522,0.000126743,0.00018299776,0.00026773245,0.0002600217,0.00016185972,0.00002757833,0.00067227555,0.0000031836846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05517687,0.006010473,0.90505195,0.00009436855,0.0010230426,0.00008685094,0.0003462069,0.0000059171475,0.000025092433,0.000035635145,0.00079355016,0.031350024],"study_design_scores_gemma":[0.05811237,0.01854743,0.9203546,0.00014131686,0.0006575535,0.0001303896,0.0001260215,0.000012205149,0.000008191196,0.00001311173,0.0017951512,0.000101646154],"about_ca_topic_score_codex":0.0013297534,"about_ca_topic_score_gemma":0.0007422463,"teacher_disagreement_score":0.031248378,"about_ca_system_score_codex":0.0003771868,"about_ca_system_score_gemma":0.0017491155,"threshold_uncertainty_score":0.516843},"labels":[],"label_agreement":null},{"id":"W2337338294","doi":"10.1200/jco.2004.22.90140.6139","title":"Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Anxiety; Breast cancer; Medical information; Family medicine; Cancer; Patient satisfaction; Lung cancer; Information needs; Intervention (counseling); Internal medicine; Physical therapy; Surgery; Nursing; Psychiatry","score_opus":0.1948323392622773,"score_gpt":0.55349651941195,"score_spread":0.3586641801496727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337338294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811349,0.00023256893,0.0020491024,0.007900086,0.0031495579,0.005027473,0.000023701046,0.000007981518,0.0004746209],"genre_scores_gemma":[0.96646863,0.00017850113,0.00042946576,0.031882275,0.00052785774,0.00045801618,0.000012899783,0.0000049808805,0.00003739974],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9828939,0.0090654,0.00729775,0.00012752865,0.0003917134,0.00022370894],"domain_scores_gemma":[0.9809461,0.0113842925,0.006291522,0.00014848218,0.0009947901,0.00023479214],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02608239,0.00014339505,0.0017161148,0.0000730148,0.00020772974,0.00004831587,0.00021944815,0.00021914564,0.0001536151],"category_scores_gemma":[0.020932024,0.000062320105,0.00035040829,0.00007929653,0.00023973065,0.0013113486,0.00016427446,0.0011024982,0.00001944391],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6589954,0.0002212543,0.0014518143,0.000030289846,0.00011846973,1.7183264e-7,0.043896962,0.000011484147,1.2043023e-7,0.00014674061,0.0006091222,0.29451817],"study_design_scores_gemma":[0.9545351,0.004687027,0.017393615,0.00037360165,0.00015964292,3.852418e-7,0.0032763127,0.004181215,5.7308745e-7,0.0018427402,0.013475606,0.00007417008],"about_ca_topic_score_codex":0.0021012102,"about_ca_topic_score_gemma":0.00063482026,"teacher_disagreement_score":0.29553974,"about_ca_system_score_codex":0.00020930664,"about_ca_system_score_gemma":0.00052641786,"threshold_uncertainty_score":0.98731506},"labels":[],"label_agreement":null},{"id":"W2337473115","doi":"10.1200/jco.2004.22.90140.9500","title":"Effect of age and temporal patterns over 5 years in a Magnetic Resonance Imaging (MRI)-based breast surveillance study for BRCA mutation carriers","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetics, Bioinformatics, and Biomedical Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Mammography; BRCA mutation; Magnetic resonance imaging; Cancer; Breast MRI; Stage (stratigraphy); Internal medicine; Oncology; Confidence interval; Gynecology; Radiology","score_opus":0.022791920721256718,"score_gpt":0.40012606179993443,"score_spread":0.3773341410786777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337473115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977972,0.00057268556,0.00066764577,0.00034367995,0.00022232259,0.00034525036,0.000030607083,0.000001219036,0.000019411205],"genre_scores_gemma":[0.99856555,0.00014965297,0.0008947457,0.00016950135,0.00018289822,0.0000066375746,0.000011582466,0.00000928419,0.0000101541755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978939,0.00035431725,0.0011289425,0.00016155004,0.0002534573,0.00020781056],"domain_scores_gemma":[0.998593,0.00046672623,0.0004921467,0.0001298004,0.00015637244,0.0001619617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038683892,0.00010176169,0.00054147624,0.00009142646,0.000017345312,0.000010496115,0.000167804,0.00017418007,0.000004497082],"category_scores_gemma":[0.0016748881,0.00007981978,0.00015349273,0.00007164471,0.00024855317,0.0000062905656,0.000053872736,0.00023489409,3.22718e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030714863,0.0004867284,0.7504052,0.00009154641,0.000029607041,0.00019609196,0.00010982236,0.0000627157,0.0012569621,0.0000012567282,0.00011875706,0.24416986],"study_design_scores_gemma":[0.014560046,0.02380891,0.9582392,0.000057869238,0.000026781816,0.00004508285,0.00014936368,0.00033004576,0.0005951397,0.000051105893,0.0020355075,0.00010095225],"about_ca_topic_score_codex":0.00008883594,"about_ca_topic_score_gemma":0.0005049981,"teacher_disagreement_score":0.2440689,"about_ca_system_score_codex":0.00003491337,"about_ca_system_score_gemma":0.0004949764,"threshold_uncertainty_score":0.32549563},"labels":[],"label_agreement":null},{"id":"W2337530873","doi":"10.1200/jco.2007.25.18_suppl.4054","title":"Impact of timing of initiation of adjuvant chemotherapy on survival after resection of colorectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Chemotherapy; Adjuvant; Stage (stratigraphy); Surgery; Cancer; Adjuvant chemotherapy; Internal medicine; Radiation therapy; Oncology; Breast cancer","score_opus":0.15577274455929913,"score_gpt":0.5343850402172475,"score_spread":0.3786122956579484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337530873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960167,0.00029584893,0.0000533931,0.00020348401,0.00073978934,0.00020629144,0.000019751113,0.0000023491684,0.0024624176],"genre_scores_gemma":[0.9984776,0.0005971344,0.0005030523,0.00006164154,0.00032218336,0.0000026465032,0.0000019730833,0.000014354037,0.000019413477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627376,0.000255315,0.002642851,0.0001295244,0.00052967016,0.00016886144],"domain_scores_gemma":[0.9929781,0.0025482706,0.0032454429,0.000120792596,0.0009429501,0.00016444061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027509579,0.00012484792,0.0017602803,0.00023731736,0.000008123452,7.5009973e-7,0.00008417423,0.00032712152,0.00046942907],"category_scores_gemma":[0.0015233699,0.00008514143,0.00078202185,0.0002763201,0.0002418767,0.00006561527,0.00002123852,0.00043599648,6.514979e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.124524735,0.003156486,0.7861178,0.000084732295,0.0010069171,0.000084117826,0.0002395094,0.00006950075,0.0101799015,0.000008828998,0.00007202598,0.07445544],"study_design_scores_gemma":[0.008885627,0.058017723,0.9071859,0.0003161526,0.0002530315,0.00003139753,0.000043717497,0.000045195604,0.02501828,0.0000548269,0.00009841091,0.000049736285],"about_ca_topic_score_codex":0.0002655592,"about_ca_topic_score_gemma":0.00023590906,"teacher_disagreement_score":0.121068105,"about_ca_system_score_codex":0.00040004417,"about_ca_system_score_gemma":0.0010857111,"threshold_uncertainty_score":0.5139919},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2337704846","doi":"10.1200/jco.2009.27.15_suppl.1099","title":"Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Cisplatin; Regimen; Metastatic breast cancer; Anthracycline; Response Evaluation Criteria in Solid Tumors; Oncology; Breast cancer; Chemotherapy regimen; Progressive disease; Cancer; Gastroenterology; Surgery","score_opus":0.13381379519778763,"score_gpt":0.540320516122561,"score_spread":0.4065067209247734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337704846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9286628,0.0014691578,0.0000164437,0.066736,0.0004431757,0.0003223653,0.000015614638,0.000002127388,0.0023323246],"genre_scores_gemma":[0.98445964,0.0063975183,0.0005915012,0.0073988503,0.0008886216,0.0000072784915,0.0000022137515,0.0000068164277,0.00024756108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99723494,0.0005367702,0.0016578368,0.00013101358,0.0002654461,0.00017399716],"domain_scores_gemma":[0.99601066,0.002289827,0.0012138213,0.00013298074,0.00022425123,0.00012845549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013605735,0.00013095875,0.0014283201,0.00011864876,0.00001769966,0.0000036575016,0.0001250609,0.00013202764,0.00046899548],"category_scores_gemma":[0.00011248713,0.00006668434,0.00048492628,0.0001991548,0.00013103917,0.00004896478,0.0000035616422,0.00033221938,0.000003741644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016826069,0.025045926,0.061608408,0.000009112061,0.0011459294,0.0011095864,0.0019728343,0.00003523412,0.0008777297,0.00014009558,0.0044273906,0.88680166],"study_design_scores_gemma":[0.023976061,0.055580296,0.89377606,0.000050483442,0.0009411573,0.0007057714,0.00017739023,0.00004776121,0.00040235784,0.0006454988,0.023637122,0.000060047612],"about_ca_topic_score_codex":0.00009541633,"about_ca_topic_score_gemma":0.00013473135,"teacher_disagreement_score":0.88674164,"about_ca_system_score_codex":0.00032817808,"about_ca_system_score_gemma":0.0009498111,"threshold_uncertainty_score":0.51351714},"labels":[],"label_agreement":null},{"id":"W2337713950","doi":"10.1200/jco.2007.25.18_suppl.9000","title":"Financial burden from wage losses after early breast cancer: Extent and determinants among Canadian women","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut National de Santé Publique du Québec; Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Breast cancer; Wage; Demography; Cancer; Workforce; Prospective cohort study; Gynecology; Gerontology; Surgery; Internal medicine","score_opus":0.04661920328599803,"score_gpt":0.3397852798615216,"score_spread":0.2931660765755236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337713950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909109,0.002259526,0.00007478902,0.001153755,0.002700254,0.000105643965,0.00033389305,0.0000047273465,0.0024565384],"genre_scores_gemma":[0.9928609,0.0016020836,0.0002535562,0.001793143,0.0031231476,0.000007081787,7.1410284e-7,0.00002344386,0.00033591606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622446,0.000036908747,0.0027379864,0.0003183363,0.000053259013,0.0006290256],"domain_scores_gemma":[0.9963123,0.00044741566,0.0020484845,0.0001867985,0.00013674746,0.00086820964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030966126,0.00018983085,0.0014814821,0.00027341858,0.00007682928,0.000056526696,0.0002937605,0.00053530606,0.0007647998],"category_scores_gemma":[0.00088335347,0.0001864894,0.00025218632,0.00009835148,0.00030921656,0.0005187446,0.000059837017,0.0006583455,0.000071748276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072735845,0.00007469292,0.857601,0.0000047475783,0.000073777286,0.00036243186,0.0004901268,0.0000036321298,0.000001016393,0.0003917646,0.00053033367,0.1397391],"study_design_scores_gemma":[0.0016399061,0.00074174476,0.9265387,0.000041033825,0.000020247511,0.000030175228,0.00006825068,0.00001994617,0.0000032138412,0.0072431914,0.063445896,0.0002077149],"about_ca_topic_score_codex":0.11724877,"about_ca_topic_score_gemma":0.17494221,"teacher_disagreement_score":0.13953139,"about_ca_system_score_codex":0.00068199006,"about_ca_system_score_gemma":0.0009932612,"threshold_uncertainty_score":0.88862956},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2338289830","doi":"10.1200/jco.2009.27.15_suppl.5584","title":"High interstitial fluid pressure (IFP) and hypoxia as biomarkers of cisplatin chemoradiation response in advanced cervix cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Chemoradiotherapy; Cervix; Cisplatin; Internal medicine; Prospective cohort study; Radiation therapy; Lymph node; Cancer; Cohort; Urology; Hypoxia (environmental); Oncology; Chemotherapy","score_opus":0.06663057229426822,"score_gpt":0.46781187880610725,"score_spread":0.40118130651183903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338289830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616426,0.0032051408,0.000047269245,0.033708718,0.0008291257,0.00011034458,0.0000036871463,0.000005005745,0.00044806322],"genre_scores_gemma":[0.99177897,0.0015096687,0.0029915753,0.0031976765,0.0003708323,0.0000018751183,0.0000010741364,0.000005569035,0.00014273658],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99743015,0.00053289364,0.0015105298,0.00015482935,0.00021457442,0.00015702903],"domain_scores_gemma":[0.9964192,0.002178691,0.0008850508,0.00010271998,0.0002132288,0.00020110016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032474862,0.000102708414,0.00114947,0.00015404032,0.000019239647,0.0000022103134,0.00007933711,0.0002780128,0.000075791824],"category_scores_gemma":[0.010900867,0.00007505525,0.00013419421,0.0001224807,0.00034006868,0.00006883303,0.00002552297,0.00061443576,0.0000017210593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13154581,0.0016050136,0.16337472,0.00011868461,0.0007255496,0.0015526053,0.0010156941,0.00009159389,0.025290847,0.000087318316,0.008886424,0.66570574],"study_design_scores_gemma":[0.011202573,0.017060949,0.961393,0.00034967865,0.00033105686,0.00022902519,0.00015603927,0.0001761204,0.00054239045,0.00040630045,0.0080771865,0.000075668264],"about_ca_topic_score_codex":0.000038424903,"about_ca_topic_score_gemma":0.000015619382,"teacher_disagreement_score":0.7980183,"about_ca_system_score_codex":0.000047912494,"about_ca_system_score_gemma":0.0005751052,"threshold_uncertainty_score":0.99743074},"labels":[],"label_agreement":null},{"id":"W2338292049","doi":"10.1200/jco.2013.31.15_suppl.tps4161","title":"Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Sorafenib; Oncolytic virus; Hepatocellular carcinoma; Hazard ratio; Internal medicine; Oncology; Randomized controlled trial; Gastroenterology; Cancer; Surgery; Confidence interval","score_opus":0.045303507085140235,"score_gpt":0.3894889658126659,"score_spread":0.34418545872752565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338292049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458283,0.00089711393,0.00008435145,0.0001863411,0.00054344913,0.0034565546,0.000092251285,0.000005724923,0.00015139677],"genre_scores_gemma":[0.9972906,0.00077653636,0.0007563393,0.00011157311,0.000479658,0.00018904477,0.0002007466,0.00006933594,0.00012617762],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992214,0.002183727,0.003522332,0.0006739872,0.00071621576,0.00068968895],"domain_scores_gemma":[0.99332935,0.0011028704,0.0028072707,0.00061979814,0.0015414446,0.00059926324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001962743,0.0005219245,0.0034232272,0.00028709677,0.00007978903,0.000023345036,0.00051273825,0.0007397614,0.00025793308],"category_scores_gemma":[0.00204321,0.00038332827,0.000991608,0.00023377407,0.0004571498,0.000039558163,0.00012786807,0.00069030764,0.000019904193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9448132,0.006761763,0.009541337,0.000025593597,0.0013686953,0.00021195714,0.00035649072,0.00023002803,0.012595842,7.741281e-7,0.000118835116,0.023975467],"study_design_scores_gemma":[0.724204,0.22852033,0.0021224157,0.000040044826,0.00045109447,0.0000053325343,0.0003707781,0.0004498285,0.042999953,0.000008569332,0.00053003035,0.00029761967],"about_ca_topic_score_codex":0.000300066,"about_ca_topic_score_gemma":0.0009570266,"teacher_disagreement_score":0.22175857,"about_ca_system_score_codex":0.00061196875,"about_ca_system_score_gemma":0.0040724673,"threshold_uncertainty_score":0.99986184},"labels":[],"label_agreement":null},{"id":"W2338387150","doi":"10.1200/jco.2009.27.15_suppl.8009","title":"Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Gastroenterology; Cancer; Epidermal growth factor receptor; Sorafenib","score_opus":0.04300033028782617,"score_gpt":0.43502298832109537,"score_spread":0.3920226580332692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338387150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252933,0.00051847793,0.00009754177,0.0018872123,0.0007827755,0.003298375,0.000011988403,0.000005967826,0.00086835586],"genre_scores_gemma":[0.9952002,0.00040265868,0.0027472412,0.0006792875,0.0005863569,0.00010034693,0.000014359649,0.000026250724,0.00024330804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99631417,0.00020966791,0.0024507488,0.0002849483,0.00043634413,0.0003041129],"domain_scores_gemma":[0.9958616,0.0008540002,0.0022389514,0.00021902683,0.0005012482,0.0003252044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001022039,0.000248571,0.002633755,0.00018513855,0.00003760979,0.000008226235,0.00013007165,0.00032524142,0.0003640171],"category_scores_gemma":[0.0002067077,0.00015999663,0.0005554034,0.00021523041,0.00016297514,0.00014531978,0.00001958004,0.0006284663,0.0000021695066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.950812,0.010905972,0.014897884,0.000037559963,0.0009946054,0.000103736624,0.0005570777,0.000051603754,0.00009795053,0.0000027080375,0.00010869289,0.021430245],"study_design_scores_gemma":[0.93892,0.034413736,0.02280854,0.00035125983,0.0022703959,0.0000061320366,0.000059735103,0.000028552524,0.00025671374,0.0000072123044,0.0007347578,0.00014294505],"about_ca_topic_score_codex":0.000024955234,"about_ca_topic_score_gemma":0.00026593942,"teacher_disagreement_score":0.023507766,"about_ca_system_score_codex":0.0005218173,"about_ca_system_score_gemma":0.0022089023,"threshold_uncertainty_score":0.65244734},"labels":[],"label_agreement":null},{"id":"W2338824946","doi":"10.1200/jco.2012.30.15_suppl.2008b","title":"Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University of Calgary","funders":"","keywords":"Medicine; Procarbazine; Lomustine; Internal medicine; Hazard ratio; Oligodendroglioma; Vincristine; Confidence interval; Radiation therapy; Oligodendroglial Tumor; Oncology; Gastroenterology; Progression-free survival; Chemotherapy; Glioma; Astrocytoma; Cancer research","score_opus":0.08047231681068197,"score_gpt":0.4435064915576044,"score_spread":0.36303417474692246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338824946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406725,0.00059537607,0.00007824927,0.0016337701,0.0021496199,0.0013338709,0.000025459607,0.0000072301737,0.00010919812],"genre_scores_gemma":[0.9973351,0.00024225724,0.0008678682,0.0004247961,0.0010187756,0.000027874792,0.00000846089,0.000035480265,0.000039383125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963913,0.0002802904,0.002151838,0.00022538823,0.000570933,0.0003802272],"domain_scores_gemma":[0.99322367,0.0031011966,0.0023649596,0.00039683265,0.0005001818,0.00041318085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014890726,0.00024204722,0.0018302293,0.00014041564,0.00007341623,0.0000083321365,0.00024108992,0.00016753038,0.000053416195],"category_scores_gemma":[0.0010183371,0.0001257226,0.0005739959,0.00023030692,0.00023277222,0.00012227372,0.00003214123,0.0004075906,0.0000024254375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21398339,0.060683448,0.6523139,0.00003306545,0.0041431775,0.0002563043,0.0005389173,0.000019084402,0.00006674649,0.00001420973,0.0029462045,0.06500156],"study_design_scores_gemma":[0.34017232,0.0785673,0.5765565,0.000094646355,0.0012277617,0.00008410748,0.000065274406,0.000026271286,0.00039310876,0.000003382305,0.0027077447,0.00010152963],"about_ca_topic_score_codex":0.000016079282,"about_ca_topic_score_gemma":0.00006727136,"teacher_disagreement_score":0.12618895,"about_ca_system_score_codex":0.0003051301,"about_ca_system_score_gemma":0.00059717044,"threshold_uncertainty_score":0.51268184},"labels":[],"label_agreement":null},{"id":"W2338955601","doi":"10.1200/jco.2006.24.18_suppl.9048","title":"Online pediatric oncology education: A novel teaching tool for oncology residents","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Radiation oncology; Pediatric oncology; Curriculum; Oncology; Internal medicine; Medical education; Medical physics; Radiation therapy; Psychology; Cancer","score_opus":0.09350724042738723,"score_gpt":0.5670198273684995,"score_spread":0.4735125869411123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338955601","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8428391,0.0060940357,0.033759404,0.067792155,0.024803268,0.0014430912,0.000038561717,0.00006749494,0.023162894],"genre_scores_gemma":[0.24207236,0.005408272,0.6314161,0.03389295,0.07843025,0.00006693532,0.00006937224,0.00010169546,0.0085421195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99381274,0.0007369268,0.0042108195,0.00039659344,0.00035368706,0.0004892041],"domain_scores_gemma":[0.983926,0.010603886,0.0038804386,0.00031724048,0.00091768557,0.00035473696],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0062044547,0.00026766915,0.002557487,0.0003677094,0.00018264787,0.000008569358,0.00039573704,0.0015094423,0.0001444501],"category_scores_gemma":[0.008453689,0.00020398256,0.0008422419,0.00019743323,0.00040999602,0.00022400891,0.00006231829,0.0025387385,0.000016268028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011880567,0.0447196,0.092746116,0.000098815086,0.00044962572,0.0004824257,0.00013790783,0.00009710727,0.00043813727,0.0045508575,0.16203496,0.68236387],"study_design_scores_gemma":[0.018300435,0.028687973,0.12813121,0.00004718151,0.0007305838,0.0027936576,0.00015348745,0.00007336278,0.000010183926,0.0034367188,0.81745803,0.00017719227],"about_ca_topic_score_codex":0.000032033717,"about_ca_topic_score_gemma":0.00010279,"teacher_disagreement_score":0.6821867,"about_ca_system_score_codex":0.0012643225,"about_ca_system_score_gemma":0.014721158,"threshold_uncertainty_score":0.99989855},"labels":[],"label_agreement":null},{"id":"W2339055365","doi":"10.1200/jco.2005.23.16_suppl.3684","title":"Anemia and FOLFOX chemotherapy for colorectal carcinoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Anemia; Colorectal cancer; Oxaliplatin; Internal medicine; Chemotherapy; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.08102434544239487,"score_gpt":0.4526832334807355,"score_spread":0.3716588880383407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339055365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94512445,0.00076880876,0.000070771086,0.05088366,0.000377249,0.00019668714,0.0000016891482,0.0000065239865,0.0025701697],"genre_scores_gemma":[0.9612101,0.00083266763,0.03022614,0.0045884904,0.002434248,0.0000037164975,0.0000015020872,0.000013350999,0.0006897975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843514,0.00006775533,0.0010768014,0.00012590866,0.000131974,0.00016239836],"domain_scores_gemma":[0.99767035,0.0011847573,0.0005864489,0.000076370074,0.00019277948,0.0002893068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011075907,0.0000971454,0.00089203933,0.000046050478,0.00003309634,0.0000046471564,0.000053908952,0.00027815995,0.0001182395],"category_scores_gemma":[0.0006765615,0.000064150016,0.00032432383,0.00003574219,0.00016999154,0.00004367886,0.000013248961,0.00035509243,0.0000062107515],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0086922925,0.0025300342,0.21389629,0.000054037406,0.0002750489,0.00029424301,0.00024278044,0.0000014668301,0.0010854026,0.000236113,0.041988976,0.7307033],"study_design_scores_gemma":[0.03368333,0.03881007,0.3922042,0.00005476081,0.00041686592,0.0020015484,0.00017290177,0.0001384469,0.0016973411,0.00028803488,0.53041786,0.00011463681],"about_ca_topic_score_codex":0.0000032193338,"about_ca_topic_score_gemma":0.000010238934,"teacher_disagreement_score":0.7305887,"about_ca_system_score_codex":0.000104392064,"about_ca_system_score_gemma":0.0005941388,"threshold_uncertainty_score":0.26159617},"labels":[],"label_agreement":null},{"id":"W2339149872","doi":"10.1200/jco.2015.64.3171","title":"Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Boehringer Ingelheim (Canada)","funders":"National Cancer Institute; Cancer Research UK","keywords":"Exemestane; Medicine; Tamoxifen; Breast cancer; Oncology; Internal medicine; Population; Gynecology; Estrogen receptor; Cancer","score_opus":0.056784274357323854,"score_gpt":0.38798646153857724,"score_spread":0.3312021871812534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339149872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117553,0.0017494063,0.0002589392,0.005050148,0.0002900632,0.000473352,0.0009520612,0.0000048633065,0.000045605462],"genre_scores_gemma":[0.991899,0.0045444495,0.0018067218,0.00021352187,0.0012285548,0.00011229047,0.000006710407,0.00003237462,0.00015637993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99691725,0.00042227743,0.001738022,0.00034269114,0.00021193796,0.0003678475],"domain_scores_gemma":[0.9945484,0.0017151966,0.0024653394,0.00015243787,0.0008863548,0.00023230507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013310635,0.00026911747,0.0017699534,0.00006292741,0.000090665104,0.000009774271,0.00019390405,0.00022397743,0.00010280541],"category_scores_gemma":[0.0009468802,0.00014735114,0.00022881855,0.000054956083,0.00056430296,0.000029420715,0.00009760611,0.00017879167,0.0000010659651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07177687,0.0014304287,0.095915124,0.000053556512,0.008323931,0.000014759673,0.00074585277,0.000001944824,0.3654054,0.0001646669,0.003113887,0.45305356],"study_design_scores_gemma":[0.01974136,0.029660512,0.92368305,0.00012626924,0.00032518918,0.0000654262,0.00016185228,2.3710119e-7,0.019307014,0.00038331674,0.00628676,0.0002590294],"about_ca_topic_score_codex":0.00011405838,"about_ca_topic_score_gemma":0.00010331765,"teacher_disagreement_score":0.8277679,"about_ca_system_score_codex":0.0001304326,"about_ca_system_score_gemma":0.00040961377,"threshold_uncertainty_score":0.6008805},"labels":[],"label_agreement":null},{"id":"W2339221030","doi":"10.1200/jco.2009.27.15_suppl.e14525","title":"Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265–101)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neutropenia; Pharmacokinetics; Toxicity; Pharmacodynamics; Internal medicine; Gastroenterology; Tyrosine-kinase inhibitor; Pharmacology; Oncology; Cancer","score_opus":0.09897926098553333,"score_gpt":0.5188007457300592,"score_spread":0.41982148474452585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339221030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968619,0.000063000436,0.00001834949,0.0010234917,0.0004478902,0.0009945187,0.0000057587613,0.000004621202,0.00058052334],"genre_scores_gemma":[0.9982459,0.000038357295,0.00076669466,0.0006145086,0.00023654003,0.000007126857,0.0000030734777,0.000008203461,0.00007959943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683845,0.00028225945,0.0021349331,0.00017347229,0.00041723676,0.00015363329],"domain_scores_gemma":[0.9963951,0.00054191716,0.0018332867,0.00017373888,0.0008053106,0.0002506548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009057133,0.00013640839,0.0014825742,0.000147969,0.000022897075,0.0000023013522,0.00012202433,0.00011130155,0.00008342355],"category_scores_gemma":[0.000510282,0.00008996831,0.00016398412,0.00021144198,0.000070022244,0.000090318405,0.000018029637,0.00031201565,0.00000208657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10654009,0.2130676,0.53760254,0.000018058972,0.0007258052,0.00045407543,0.0016442069,0.000029098994,0.0010701093,0.0000064532255,0.0009902384,0.13785172],"study_design_scores_gemma":[0.05266565,0.42348,0.5209751,0.00003320764,0.0006942675,0.00001540846,0.00069761934,0.000001529922,0.0003055106,0.000011640221,0.0010738407,0.000046180583],"about_ca_topic_score_codex":0.000013699177,"about_ca_topic_score_gemma":0.00012298673,"teacher_disagreement_score":0.2104124,"about_ca_system_score_codex":0.00007714999,"about_ca_system_score_gemma":0.0008696758,"threshold_uncertainty_score":0.3668801},"labels":[],"label_agreement":null},{"id":"W2339423589","doi":"10.1200/jco.2010.28.15_suppl.e12510","title":"Safety and efficacy of presurgical neoadjuvant low-dose temozolomide in glioma patients.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Temozolomide; Medicine; Glioma; Internal medicine; Chemotherapy; Oncology; Adverse effect; Phases of clinical research; Methyltransferase; Toxicity; Surgery; Methylation; Cancer research","score_opus":0.042957188258334986,"score_gpt":0.4142874986789697,"score_spread":0.3713303104206347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339423589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421155,0.00017458493,0.0000016067831,0.0036558572,0.0008303673,0.0002399269,0.000004365211,0.0000033807141,0.0008783377],"genre_scores_gemma":[0.9982131,0.00032975918,0.00083902344,0.00028862222,0.00030161167,0.0000018310454,0.00000263988,0.000010177718,0.000013230762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659014,0.00023189605,0.0025289012,0.00017362139,0.00028416055,0.00019127158],"domain_scores_gemma":[0.99424285,0.003680142,0.0012242604,0.00018352231,0.0002812271,0.00038800132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019058846,0.00012428456,0.0015325529,0.00017390582,0.000017474316,0.000004002893,0.00010081518,0.00038388633,0.00010739611],"category_scores_gemma":[0.005366475,0.00007131817,0.0003322781,0.00013344617,0.00026252482,0.000061758714,0.00006455159,0.00089640793,0.0000055205674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008777326,0.010914723,0.68516505,0.000020370397,0.00017703607,0.0012965418,0.00005807517,0.0000044734265,0.0009671416,0.000129354,0.00043407094,0.29205585],"study_design_scores_gemma":[0.039083272,0.008483668,0.93555146,0.00010666054,0.00019121947,0.00021356951,0.000014134342,0.000033362525,0.0006203047,0.00009550461,0.015546242,0.000060617553],"about_ca_topic_score_codex":0.000019343774,"about_ca_topic_score_gemma":0.000053015294,"teacher_disagreement_score":0.29199523,"about_ca_system_score_codex":0.000044890625,"about_ca_system_score_gemma":0.0004093024,"threshold_uncertainty_score":0.64245594},"labels":[],"label_agreement":null},{"id":"W2339464282","doi":"10.1200/jco.2004.22.90140.6606","title":"RECIST (Response Evaluation Criteria in Solid Tumors) applied to response in lymphoma","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Nuclear medicine; Clinical trial; Cru; Cancer; Target lesion; Internal medicine; Phases of clinical research","score_opus":0.71470487039843,"score_gpt":0.6984320786943826,"score_spread":0.016272791704047385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339464282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97314525,0.000024114834,0.013079356,0.009676232,0.002093322,0.00081207044,0.0000099675035,0.000014350541,0.0011453651],"genre_scores_gemma":[0.5932961,0.00001585873,0.4043505,0.0017304415,0.00051847036,0.000032735767,1.893201e-7,0.000026733542,0.000028975139],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9606497,0.024359696,0.012354925,0.0006137916,0.0013604509,0.0006614166],"domain_scores_gemma":[0.7253841,0.27017042,0.0027472822,0.0005060338,0.0006337471,0.000558411],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18271142,0.00024498248,0.0030473366,0.00056141027,0.00003243662,0.000026773037,0.00059259,0.0007408009,0.00039529894],"category_scores_gemma":[0.7665177,0.00020417388,0.00038017024,0.00063945795,0.00025441794,0.00010248608,0.00015979305,0.0010342015,0.00010011536],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5436344,0.008295631,0.0008698915,0.000048725273,0.00013301345,0.0022409523,0.0010737024,0.0008498147,0.0045320564,0.010668537,0.0023221795,0.4253311],"study_design_scores_gemma":[0.025297925,0.009386841,0.18509758,0.00035457825,0.000108831504,0.00009617605,0.0001886516,0.00014093639,0.0004212433,0.7767027,0.0019602808,0.00024422916],"about_ca_topic_score_codex":0.000013221879,"about_ca_topic_score_gemma":0.000081029444,"teacher_disagreement_score":0.7660342,"about_ca_system_score_codex":0.001287638,"about_ca_system_score_gemma":0.004075038,"threshold_uncertainty_score":0.84157056},"labels":[],"label_agreement":null},{"id":"W2339550887","doi":"10.1200/jco.2009.27.15_suppl.5563","title":"A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Taxane; Ovarian cancer; Vomiting; Nausea; Refractory (planetary science); Fallopian tube cancer; Surgery; Internal medicine; Adverse effect; Gastroenterology; Urology; Cancer; Breast cancer","score_opus":0.13520955569290882,"score_gpt":0.5222127716911457,"score_spread":0.38700321599823684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339550887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941236,0.00034732814,0.0000033465462,0.0040241578,0.00034117498,0.00083179836,0.00001016829,0.000003911791,0.00031454992],"genre_scores_gemma":[0.9972012,0.00028085362,0.00063240185,0.0012393608,0.00043958772,0.0000066471503,0.0000041531825,0.000010737975,0.00018502856],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99651283,0.0006331003,0.0020152563,0.00020294539,0.00042876654,0.00020711348],"domain_scores_gemma":[0.99584323,0.001895952,0.0015813373,0.00015419362,0.00034676274,0.00017853822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002387038,0.00015795317,0.0014322983,0.00009456168,0.00007960771,0.0000044874355,0.00011429659,0.00016021993,0.00016758837],"category_scores_gemma":[0.00079698954,0.00007853954,0.00012304906,0.00018964347,0.00016958316,0.00007846267,0.000043429623,0.0008240984,3.198268e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3649176,0.04657432,0.2485601,0.00002165386,0.00059764093,0.00031117655,0.0013332207,0.000020390888,0.00042645322,0.000005414524,0.00026038836,0.33697164],"study_design_scores_gemma":[0.0941851,0.2875281,0.6156106,0.00008910005,0.00062400044,0.000015713564,0.00009559701,0.000026617394,0.0000046345476,0.00000674035,0.0017604263,0.00005337023],"about_ca_topic_score_codex":0.000066719396,"about_ca_topic_score_gemma":0.00027479776,"teacher_disagreement_score":0.36705053,"about_ca_system_score_codex":0.0002602392,"about_ca_system_score_gemma":0.0018506147,"threshold_uncertainty_score":0.35803434},"labels":[],"label_agreement":null},{"id":"W2339584422","doi":"10.1200/jco.2009.27.15_suppl.e19535","title":"A retrospective chart review study of relapsed or refractory multiple myeloma (MM) patients (Pts): A look into historical treatment (Tx) patterns","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Internal medicine; Oncology; Prednisone; Multiple myeloma; Bortezomib; Refractory (planetary science); Surgery","score_opus":0.14024492262626512,"score_gpt":0.4711736823009262,"score_spread":0.33092875967466107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339584422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165636,0.0021428412,0.000016911104,0.0034425638,0.00063581223,0.001655673,0.000010123869,0.000015433921,0.00042429462],"genre_scores_gemma":[0.9871924,0.009495963,0.0008417634,0.0011250786,0.0005650296,0.0000289012,0.000011904567,0.000024403127,0.00071457913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935081,0.0010639109,0.0035462987,0.00042616716,0.0010569552,0.00039857827],"domain_scores_gemma":[0.9935613,0.0014384893,0.0025200837,0.0005160755,0.0011379103,0.0008261354],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017269491,0.0003113467,0.003213193,0.00023746783,0.00007076446,0.000005660737,0.00024106116,0.00033192922,0.00027813957],"category_scores_gemma":[0.009526195,0.00018115727,0.00077404815,0.00025257553,0.00008868949,0.00014114766,0.000057277208,0.00097094284,0.000029814555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016423324,0.046309683,0.6242769,0.000109123546,0.00087132363,0.0020715673,0.00039381027,1.8803382e-7,0.0000316151,0.0000012412967,0.004069974,0.30544126],"study_design_scores_gemma":[0.037751965,0.22702527,0.7158356,0.00068322633,0.00067945465,0.000071570925,0.000115775394,0.000011857271,0.00001883465,0.00002150572,0.017676862,0.000108129745],"about_ca_topic_score_codex":0.00019357547,"about_ca_topic_score_gemma":0.00029846368,"teacher_disagreement_score":0.30533314,"about_ca_system_score_codex":0.0036214157,"about_ca_system_score_gemma":0.0013497006,"threshold_uncertainty_score":0.99881697},"labels":[],"label_agreement":null},{"id":"W2339800992","doi":"10.1200/jco.2006.24.18_suppl.3054","title":"Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Mucositis; Tolerability; Neutropenia; Internal medicine; Gastroenterology; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Carboplatin; Toxicity; Phases of clinical research; Surgery; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.07360003561611962,"score_gpt":0.4515215525426398,"score_spread":0.3779215169265202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339800992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621683,0.00009148216,0.000012608265,0.00011783294,0.0008482601,0.0023387456,0.00030474775,0.000001620252,0.00006789589],"genre_scores_gemma":[0.99917233,0.000043369844,0.00047612019,0.000038582282,0.00015827634,0.000055594086,0.000018361749,0.000019432377,0.000017950522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909957,0.0014989396,0.0057959105,0.00031364363,0.0011890972,0.0002067336],"domain_scores_gemma":[0.9893478,0.0016026015,0.006876031,0.00021994357,0.0018172106,0.00013642243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036558514,0.00022758255,0.0026042268,0.00027225097,0.000029903273,0.000002618106,0.00021728767,0.00018635324,0.000013286173],"category_scores_gemma":[0.0023164714,0.00013548422,0.00023760094,0.0005282436,0.00023471641,0.00018387582,0.000038265738,0.0005654777,1.535443e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037468437,0.052085374,0.90148246,0.0001225319,0.0007593458,0.000019930092,0.0017757398,0.0018716693,0.0002394861,0.0000056309127,0.00008199836,0.00408742],"study_design_scores_gemma":[0.1736455,0.049761154,0.77352434,0.00050511013,0.0009319992,8.5016836e-7,0.0011011711,0.0001115858,0.00027345325,0.0000088030865,0.000041484807,0.00009454529],"about_ca_topic_score_codex":0.1312,"about_ca_topic_score_gemma":0.4975339,"teacher_disagreement_score":0.3663339,"about_ca_system_score_codex":0.0006373166,"about_ca_system_score_gemma":0.008868809,"threshold_uncertainty_score":0.99675},"labels":[],"label_agreement":null},{"id":"W2340184725","doi":"10.1200/jco.2006.24.18_suppl.9053","title":"Carboplatin hypersensitivity reaction in pediatric low grade glioma (LGG) patients: A national experience. On behalf of the Canadian Pediatric Brain Tumor Consortium","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Children's Hospital; Children's Hospital of Western Ontario","funders":"","keywords":"Carboplatin; Medicine; Chemotherapy; Incidence (geometry); Cumulative incidence; Desensitization (medicine); Retrospective cohort study; Radiation therapy; Surgery; Pediatrics; Internal medicine; Cohort; Cisplatin","score_opus":0.05935112257257866,"score_gpt":0.4049325844076246,"score_spread":0.3455814618350459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340184725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932124,0.000022338576,2.7537675e-7,0.0035054097,0.00060985197,0.0002678449,0.000014850744,0.0000030704643,0.0023639628],"genre_scores_gemma":[0.99830884,0.000018820096,0.000057362133,0.0007083056,0.00083932007,0.0000053336903,0.000003866763,0.0000105696445,0.00004759862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967727,0.00057584856,0.0013654196,0.00017954537,0.00082727126,0.00027923041],"domain_scores_gemma":[0.99597514,0.0019838067,0.0010538718,0.00012528151,0.0005320003,0.00032988694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012052904,0.0001173007,0.0006062815,0.00051094417,0.000062430736,0.000006170204,0.00010575879,0.00017944108,0.000015339596],"category_scores_gemma":[0.006198812,0.000078401805,0.00027158487,0.0005112277,0.00015549352,0.000088499255,0.000023932662,0.0008315591,0.000007819813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011179073,0.0034440332,0.9908847,0.000017389817,0.000025305122,0.0012749258,0.00004387893,0.000021495678,0.00029982437,0.000054795066,0.001772806,0.0010429205],"study_design_scores_gemma":[0.0062417546,0.0037614156,0.98884094,0.000018951445,0.00007000643,0.0002031887,0.000023773173,0.000033156874,0.0002727604,0.000109195695,0.0003694292,0.00005540444],"about_ca_topic_score_codex":0.007930612,"about_ca_topic_score_gemma":0.044192884,"teacher_disagreement_score":0.03626227,"about_ca_system_score_codex":0.0005854739,"about_ca_system_score_gemma":0.0039897896,"threshold_uncertainty_score":0.99867564},"labels":[],"label_agreement":null},{"id":"W2340243242","doi":"10.1200/jco.2015.33.15_suppl.e17679","title":"A comparison of comorbidity measures for predicting one-year mortality in cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Comorbidity; Breast cancer; Lung cancer; Colorectal cancer; Internal medicine; Cancer; Cancer registry; Medical prescription; Cohort; Logistic regression; Population; Environmental health","score_opus":0.5565164529080885,"score_gpt":0.5920690059092145,"score_spread":0.03555255300112603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340243242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269503,0.000285166,0.00013169942,0.001172009,0.0010234397,0.00036054573,0.000012690815,0.0000060635093,0.004313324],"genre_scores_gemma":[0.9983201,0.000101636935,0.0007563411,0.0002148044,0.0005615675,0.000008132444,0.0000049942387,0.0000085847905,0.000023838767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967276,0.00024118523,0.0022432741,0.00012523982,0.0004975992,0.00016508767],"domain_scores_gemma":[0.99628186,0.00079227035,0.0017669427,0.0001340701,0.0007667478,0.00025808657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037054322,0.00008451051,0.0013584681,0.000090933245,0.0000117545715,0.0000043872496,0.00013376119,0.00016146722,0.000040781262],"category_scores_gemma":[0.006202983,0.00006746037,0.0002650759,0.000098990524,0.0001615593,0.00009384066,0.000051243987,0.00043887505,0.0000010951771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028094356,0.004772659,0.97220623,0.00013061144,0.00031737113,0.000009985128,0.00018388825,0.00017100363,0.0000051272086,0.00015519327,0.0073444624,0.011894006],"study_design_scores_gemma":[0.014624089,0.007750198,0.9647114,0.00019286554,0.0005760641,7.569576e-7,0.00070674083,0.00060807064,0.000028741273,0.00066580274,0.010078462,0.000056768375],"about_ca_topic_score_codex":0.00019200446,"about_ca_topic_score_gemma":0.0005996799,"teacher_disagreement_score":0.011837238,"about_ca_system_score_codex":0.0002785309,"about_ca_system_score_gemma":0.002031836,"threshold_uncertainty_score":0.74259984},"labels":[],"label_agreement":null},{"id":"W2340310616","doi":"10.1200/jco.2006.24.18_suppl.10728","title":"Trends in systemic management (SM) for the treatment of locally advanced breast cancer: Data from a regional cancer centre","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Anastrozole; Internal medicine; Oncology; Breast cancer; Vinorelbine; Tamoxifen; Docetaxel; Capecitabine; Exemestane; Fulvestrant; Cancer; Letrozole; Epirubicin; Gynecology; Gemcitabine; Chemotherapy; Colorectal cancer","score_opus":0.1761259780921647,"score_gpt":0.5163225580688612,"score_spread":0.3401965799766965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340310616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8753219,0.03637463,0.00016748616,0.08135104,0.0036476445,0.0011843047,0.0010700721,0.00001213756,0.000870765],"genre_scores_gemma":[0.95016724,0.04145617,0.0011259114,0.001108639,0.003280668,0.00009010029,0.000121226934,0.000024074288,0.0026259779],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99732137,0.00016525232,0.0017644952,0.00027235888,0.00023667855,0.00023984213],"domain_scores_gemma":[0.99641097,0.0016273024,0.0013241478,0.00031812978,0.00019710722,0.0001223463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054623664,0.00016568827,0.0012943138,0.00013693192,0.000029506426,0.0000036695333,0.00028227497,0.00017568698,0.0004684383],"category_scores_gemma":[0.000019244182,0.000095225696,0.00037999608,0.00017579185,0.00014655317,0.000066272114,0.00003842563,0.00021223229,0.0000016514316],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02526367,0.0066181575,0.11399168,0.000054615215,0.0020949282,0.00032933752,0.00010219335,0.0008096325,0.00016435776,0.00007180611,0.0491616,0.801338],"study_design_scores_gemma":[0.05155933,0.006691956,0.51306665,0.00044478904,0.0036373313,0.00015669558,0.000254724,0.0012929357,0.000045105477,0.0001458702,0.42257512,0.00012949265],"about_ca_topic_score_codex":0.0026158798,"about_ca_topic_score_gemma":0.009107798,"teacher_disagreement_score":0.80120856,"about_ca_system_score_codex":0.0006861664,"about_ca_system_score_gemma":0.0007853093,"threshold_uncertainty_score":0.5129071},"labels":[],"label_agreement":null},{"id":"W2340315849","doi":"10.1200/jco.2013.31.15_suppl.7501","title":"A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Chemoradiotherapy; Cetuximab; Nuclear medicine; Radiation therapy; Adverse effect; Internal medicine; Surgery; Chemotherapy; Gastroenterology; Urology; Cancer; Cisplatin; Colorectal cancer","score_opus":0.07258877949904582,"score_gpt":0.46533133539336696,"score_spread":0.39274255589432117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340315849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98853296,0.00085507415,0.00046237587,0.0037137333,0.001374051,0.0041818167,0.00009187136,0.000012727759,0.00077540654],"genre_scores_gemma":[0.9900518,0.0033695288,0.004198343,0.0007674366,0.0008019235,0.00035999014,0.000033672513,0.000044703138,0.00037260287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99411017,0.00039775934,0.004053861,0.00038927156,0.00058551435,0.00046339928],"domain_scores_gemma":[0.9887755,0.0052386806,0.004450151,0.0003527577,0.0007101417,0.00047277202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00327195,0.00037272857,0.005176332,0.00027056894,0.00006369685,0.000027175138,0.0002105451,0.0004172696,0.00025673045],"category_scores_gemma":[0.00078483904,0.00022031681,0.0005875393,0.00020751724,0.00028281307,0.00021541807,0.000024499475,0.0008074432,0.0000026714267],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9190764,0.0080807805,0.006989362,0.0002079664,0.0014248672,0.00015331514,0.0012688126,0.0005024073,0.000076456614,0.000029072055,0.003887562,0.05830304],"study_design_scores_gemma":[0.91132927,0.066149175,0.0041524186,0.0005308545,0.0014816994,0.000010665315,0.00033117412,0.0074246363,0.0023780777,0.000012017235,0.005976892,0.00022312286],"about_ca_topic_score_codex":0.0010665759,"about_ca_topic_score_gemma":0.0008842532,"teacher_disagreement_score":0.058079917,"about_ca_system_score_codex":0.0012807773,"about_ca_system_score_gemma":0.003769496,"threshold_uncertainty_score":0.8984259},"labels":[],"label_agreement":null},{"id":"W2340335756","doi":"10.1200/jco.2004.22.90140.8277","title":"A longitudinal assessment of the quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML): A pilot study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Cancer; Anemia; Physical therapy; Cognition; Internal medicine; Population; Psychiatry","score_opus":0.12524729031981305,"score_gpt":0.48500015376294525,"score_spread":0.3597528634431322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340335756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252486,0.0001334173,0.00064252404,0.0045099338,0.00035498585,0.0012224516,0.000015557393,0.0000067784886,0.00058951235],"genre_scores_gemma":[0.99200094,0.0003182322,0.0065237135,0.000600566,0.00043144185,0.000016446336,0.0000016967391,0.000031228305,0.00007574169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903007,0.0015777859,0.005440311,0.00035890756,0.0019168829,0.00040537782],"domain_scores_gemma":[0.9859164,0.004677887,0.005949272,0.0007651977,0.0021427579,0.0005485134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008654574,0.0002679604,0.0034531541,0.00021658083,0.000050404626,0.000005902344,0.0007468673,0.0002923837,0.000099103054],"category_scores_gemma":[0.006964078,0.00014666295,0.00065389375,0.0005934344,0.0010165499,0.00013826926,0.0002921041,0.0022678212,0.0000021989863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046087205,0.020048738,0.9187183,0.0003189883,0.0035862185,0.00071629445,0.0009969403,0.00040453466,0.0015453389,0.00018451558,0.00073025416,0.0066626887],"study_design_scores_gemma":[0.062287506,0.08466046,0.8495586,0.00054879807,0.00086859573,0.00015362383,0.0013128005,0.000035707344,0.00031633105,0.00006104927,0.00008781694,0.00010870218],"about_ca_topic_score_codex":0.0011488487,"about_ca_topic_score_gemma":0.0007959386,"teacher_disagreement_score":0.06915968,"about_ca_system_score_codex":0.0010147427,"about_ca_system_score_gemma":0.020950345,"threshold_uncertainty_score":0.9852681},"labels":[],"label_agreement":null},{"id":"W2340451576","doi":"10.1200/jco.2007.25.18_suppl.3587","title":"Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"In vivo; Pharmacokinetics; In vitro; Pharmacology; Monoclonal antibody; Cancer research; Medicine; Antibody; Chemistry; Biology; Immunology; Biochemistry","score_opus":0.10525257120987759,"score_gpt":0.4633845711058634,"score_spread":0.3581319998959858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340451576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930083,0.00086144765,0.000015754376,0.0022186637,0.0024557458,0.00028354602,0.0000049083083,0.0000053740946,0.0011462583],"genre_scores_gemma":[0.99619305,0.0010493529,0.00016632299,0.0018009606,0.0006562243,0.0000016612646,0.0000016485666,0.000019334428,0.00011146151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546736,0.00027861563,0.0031625673,0.00017892168,0.0005604271,0.00035210256],"domain_scores_gemma":[0.996548,0.0005178988,0.0018781609,0.0001726613,0.0006213696,0.00026194105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027440856,0.0001724335,0.0013474276,0.00021307956,0.00003948479,0.0000040848363,0.0003060045,0.00036084885,0.00006440349],"category_scores_gemma":[0.0017025967,0.00009556231,0.00051684777,0.00033124472,0.00035599837,0.00015387333,0.00009208286,0.0013901446,0.0000060576526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002719975,0.0027188037,0.94789773,0.00005557438,0.0002007867,0.00009511986,0.00020008405,0.000015166359,0.024840038,0.000012802484,0.0007876006,0.02045634],"study_design_scores_gemma":[0.00765464,0.0033747468,0.97336096,0.0002494895,0.00021429332,0.000038343624,0.00008388915,0.00010130617,0.008085411,0.00003075215,0.0067069517,0.00009920706],"about_ca_topic_score_codex":0.00013634267,"about_ca_topic_score_gemma":0.000074240605,"teacher_disagreement_score":0.025463263,"about_ca_system_score_codex":0.00020426788,"about_ca_system_score_gemma":0.0015057233,"threshold_uncertainty_score":0.6039564},"labels":[],"label_agreement":null},{"id":"W2340770670","doi":"10.1200/jco.2005.23.16_suppl.3149","title":"Preclinical evaluation of apoptosis induction by the novel small molecule BCL-2 inhibitor, GX015–070, in ex vivo chronic lymphoid leukemia (CLL) cells","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Immunophenotyping; Medicine; Ex vivo; CD38; Apoptosis; Chronic lymphocytic leukemia; Flow cytometry; Leukemia; Stage (stratigraphy); Pathology; Cancer research; Immunology; In vivo; Internal medicine; Biology; CD34; Stem cell","score_opus":0.18310686263895748,"score_gpt":0.4718065075792079,"score_spread":0.2886996449402504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340770670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881552,0.0018421619,0.00025263004,0.0053158267,0.0013900477,0.0008070984,0.000006787707,0.000010808373,0.002219432],"genre_scores_gemma":[0.9925819,0.0015243924,0.0012078058,0.0009253664,0.0032494504,0.000022448321,0.0000056063036,0.00004116381,0.00044188474],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99046856,0.0016896018,0.0049592745,0.0004589278,0.0018645684,0.00055904064],"domain_scores_gemma":[0.99073124,0.004447725,0.0024208364,0.0005831447,0.0013816953,0.00043534514],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021689676,0.00026382625,0.0016910046,0.0002713605,0.000052411535,0.000017080383,0.0005353978,0.0010635543,0.0003864146],"category_scores_gemma":[0.009295799,0.00017878509,0.00066919596,0.00049633346,0.0006522177,0.00020841352,0.00018497491,0.0019908103,0.000046716585],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012358234,0.011384864,0.0030481238,0.00030961115,0.0012966391,0.000084843676,0.0007577578,0.012237022,0.31731978,0.00009022827,0.058557604,0.5825553],"study_design_scores_gemma":[0.28520107,0.034150247,0.008611685,0.0012755704,0.002832021,0.0023246806,0.0007384309,0.20612742,0.3515311,0.00033299177,0.106123455,0.0007513351],"about_ca_topic_score_codex":0.0003522855,"about_ca_topic_score_gemma":0.00039231384,"teacher_disagreement_score":0.5818039,"about_ca_system_score_codex":0.030967623,"about_ca_system_score_gemma":0.057356052,"threshold_uncertainty_score":0.9990493},"labels":[],"label_agreement":null},{"id":"W2341118262","doi":"10.1200/jco.2013.31.15_suppl.4005","title":"Results of a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Metastatic adenocarcinoma; Gastroenterology; Nab-paclitaxel; Pancreatic cancer; Phases of clinical research; Adenocarcinoma; Cancer; Oncology; Randomized controlled trial; Surgery; Chemotherapy","score_opus":0.03374288525051676,"score_gpt":0.34874965240327166,"score_spread":0.3150067671527549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341118262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548393,0.0010156934,0.00044751418,0.0006151818,0.00058934407,0.0015175088,0.00021095567,0.0000010271975,0.000118857504],"genre_scores_gemma":[0.9956429,0.00063088426,0.0032171542,0.000115883864,0.00024281637,0.00003168796,0.00003597337,0.00002174162,0.000060935196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996265,0.00038559205,0.002612489,0.00023175919,0.00028563375,0.00021952037],"domain_scores_gemma":[0.99038345,0.0036100852,0.004276585,0.00032363544,0.001215735,0.00019050427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020957151,0.00020060403,0.0022436916,0.00006303947,0.000032198208,0.000007694036,0.00024819846,0.00016502595,0.00001055531],"category_scores_gemma":[0.0075381976,0.00011084557,0.00048053343,0.000101411475,0.0007529198,0.0000141621185,0.000092756505,0.000251164,1.9087051e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99053925,0.0017664911,0.0018062076,0.000053719905,0.0014485002,0.00000635197,0.000080178004,0.00011877353,0.0008115234,0.000055561144,0.0014726226,0.0018407891],"study_design_scores_gemma":[0.93144107,0.058790635,0.0055286763,0.000082597704,0.0017337324,0.00002478244,0.00012197553,0.00017937832,0.0010072646,0.00016459587,0.0007869481,0.00013836476],"about_ca_topic_score_codex":0.00020717987,"about_ca_topic_score_gemma":0.00011280035,"teacher_disagreement_score":0.059098233,"about_ca_system_score_codex":0.000032728025,"about_ca_system_score_gemma":0.0011955547,"threshold_uncertainty_score":0.90244716},"labels":[],"label_agreement":null},{"id":"W2341475099","doi":"10.1200/jco.2005.23.16_suppl.3127","title":"A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Topotecan; Medicine; Neutropenia; Ovarian cancer; Internal medicine; Febrile neutropenia; Chemotherapy; Phases of clinical research; Oncology; Anemia; Toxicity; Surgery; Cancer; Gastroenterology","score_opus":0.06667616169456882,"score_gpt":0.4599364877177345,"score_spread":0.3932603260231657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341475099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193776,0.00014458923,0.000014963583,0.0052247792,0.00055442867,0.0019414984,0.000012821101,0.0000047634708,0.00016437196],"genre_scores_gemma":[0.99821705,0.00022127466,0.00086715934,0.0002799774,0.00027429248,0.00009784041,0.00000788073,0.000016380429,0.000018121787],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99600834,0.00040458582,0.0025061972,0.00029701888,0.00053795363,0.00024591017],"domain_scores_gemma":[0.99642897,0.00043718814,0.0022545732,0.00021402499,0.00041987997,0.00024535824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013831917,0.00019045742,0.0017295198,0.00026038048,0.00004495165,0.000005137565,0.00012981352,0.00016627392,0.00011413238],"category_scores_gemma":[0.0004071225,0.00012465128,0.00012033866,0.0003384106,0.00011700477,0.00016636642,0.000046353533,0.00069719297,3.7875702e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27209204,0.19272268,0.15614691,0.000014622548,0.00027950527,0.00018324044,0.0005735951,0.00007485985,0.0000013334991,0.000022958668,0.000069413734,0.37781882],"study_design_scores_gemma":[0.46811995,0.35037038,0.17775266,0.00028817743,0.00029238063,0.0000058866267,0.00014392931,0.000041951585,0.000017466667,0.000012078681,0.0028796396,0.00007550381],"about_ca_topic_score_codex":0.00013787713,"about_ca_topic_score_gemma":0.003731952,"teacher_disagreement_score":0.37774333,"about_ca_system_score_codex":0.0006527339,"about_ca_system_score_gemma":0.0017727294,"threshold_uncertainty_score":0.5083132},"labels":[],"label_agreement":null},{"id":"W2341568259","doi":"10.1200/jco.2011.29.7_suppl.22","title":"Utilizing metformin to enhance the efficacy of androgen-deprivation therapy in the treatment of prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"DU145; Bicalutamide; Metformin; Hyperinsulinemia; LNCaP; Prostate cancer; Medicine; Endocrinology; Internal medicine; Cancer research; In vivo; Cancer; Cell growth; Pharmacology; Insulin; Androgen receptor; Insulin resistance; Biology; Biochemistry","score_opus":0.12363465401350751,"score_gpt":0.45271449789064017,"score_spread":0.3290798438771326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341568259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94352025,0.055397887,0.000028315064,0.00020471963,0.0003290274,0.00024267902,0.0000039617116,5.319462e-7,0.00027265842],"genre_scores_gemma":[0.83844024,0.16027002,0.00037713937,0.0005675259,0.00030228795,0.000017516872,9.502184e-7,0.0000057623165,0.00001857853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981726,0.0003614242,0.0010831602,0.0001174701,0.0001344569,0.00013093608],"domain_scores_gemma":[0.9983137,0.0002900539,0.00094894075,0.00021693084,0.00018104108,0.000049291382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017686615,0.00008598169,0.0004880541,0.00003286658,0.00001877333,0.0000023250539,0.0002701662,0.00012751743,0.000023810757],"category_scores_gemma":[0.00037797922,0.000041664855,0.00023019448,0.000107039654,0.00011959736,0.0000050152007,0.000017203281,0.00011568838,5.5874034e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020823977,0.0010507888,0.012851503,0.0000044343906,0.00015142254,0.0000030952365,0.0015926891,0.000018694958,0.0071570766,0.000043785807,0.00021171334,0.9748324],"study_design_scores_gemma":[0.003606342,0.017000925,0.08283732,0.000030353394,0.00009370626,0.00000780756,0.0005219409,0.000005418069,0.39574125,0.0002751409,0.4997876,0.00009217116],"about_ca_topic_score_codex":0.00006806846,"about_ca_topic_score_gemma":0.00012416653,"teacher_disagreement_score":0.9747402,"about_ca_system_score_codex":0.000018074588,"about_ca_system_score_gemma":0.0004350357,"threshold_uncertainty_score":0.16990435},"labels":[],"label_agreement":null},{"id":"W2341693810","doi":"10.1200/jco.2015.65.1505","title":"Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University Health Network","funders":"Institut canadien d'information sur la santé","keywords":"Medicine; Breast cancer; Anthracycline; Trastuzumab; Cardiotoxicity; Internal medicine; Hazard ratio; Population; Cancer; Interquartile range; Chemotherapy; Oncology; Retrospective cohort study; Confidence interval","score_opus":0.04943456281297619,"score_gpt":0.4444805010966196,"score_spread":0.39504593828364337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341693810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856279,0.000086786815,0.000019549294,0.011650805,0.0012284637,0.0009472864,0.000007638269,0.000018215775,0.00041335312],"genre_scores_gemma":[0.9953129,0.001397338,0.000113268245,0.0019905195,0.00096289284,0.000053410593,0.00000574251,0.000026691954,0.00013720932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992652,0.002383855,0.0037919048,0.0003471775,0.00052667264,0.00029837177],"domain_scores_gemma":[0.9928408,0.0038410118,0.0019611414,0.0002501248,0.0008061184,0.00030076437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011128468,0.00019017355,0.0020103136,0.00027288983,0.000027858167,0.000008407968,0.00010088097,0.0007053177,0.0002037799],"category_scores_gemma":[0.0048682094,0.00011992921,0.00047294176,0.00044929326,0.00009805061,0.00025453742,0.000014008597,0.0011714646,0.00000873037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0131473895,0.004183831,0.75304437,0.0000046040936,0.0005816218,0.00017616707,0.00013101856,0.000023392342,0.0003732897,0.000005201558,0.00011804557,0.22821105],"study_design_scores_gemma":[0.03975364,0.006873107,0.9513001,0.00019103555,0.00021929912,0.00009618053,0.00032404976,0.00006810958,0.00008792279,0.000044247536,0.0009175707,0.00012477422],"about_ca_topic_score_codex":0.00079389254,"about_ca_topic_score_gemma":0.00031161789,"teacher_disagreement_score":0.22808628,"about_ca_system_score_codex":0.0012875466,"about_ca_system_score_gemma":0.0013438263,"threshold_uncertainty_score":0.5828053},"labels":[],"label_agreement":null},{"id":"W2341824340","doi":"10.1200/jco.2007.25.18_suppl.13510","title":"Therapeutic monoclonal antibodies target phenotypically-differing human breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Breast cancer; CD44; Cancer research; Monoclonal antibody; Antigen; Cancer; Medicine; Antibody; Epithelial cell adhesion molecule; Immunohistochemistry; Cancer cell; CA 15-3; Cancer stem cell; CA15-3; Pathology; Immunology; Cell; Internal medicine; Biology","score_opus":0.16342465890457802,"score_gpt":0.5244196762881165,"score_spread":0.36099501738353845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341824340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736963,0.0018810736,0.0005328899,0.015638035,0.0010702321,0.0001505934,0.0000122456695,0.000016987531,0.0070016603],"genre_scores_gemma":[0.98408306,0.0011547956,0.004511375,0.003641256,0.0047496436,0.0000018197549,0.0000036329182,0.000027575838,0.0018268531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99573517,0.00023870662,0.0024503504,0.00024199339,0.0007620521,0.0005717353],"domain_scores_gemma":[0.9957804,0.001607407,0.0009651236,0.00018012978,0.0007341566,0.0007327985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004225614,0.0002145874,0.001579599,0.00020609406,0.00013831527,0.000015357316,0.0002933906,0.0003983564,0.0013093655],"category_scores_gemma":[0.00040889406,0.000138747,0.00073567603,0.00016973731,0.0005088313,0.00011349002,0.0001129122,0.0017539521,0.00003638154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010416966,0.0017015953,0.7446057,0.00008005378,0.0009338492,0.001473089,0.00010354455,0.000009014157,0.012429011,0.0012835125,0.0022603234,0.22470334],"study_design_scores_gemma":[0.0032664211,0.0035599677,0.92590284,0.00011803703,0.00017391975,0.0012389506,0.000071867384,0.00006591324,0.00062757195,0.0013539993,0.06347594,0.00014457037],"about_ca_topic_score_codex":0.000084698375,"about_ca_topic_score_gemma":0.000059514394,"teacher_disagreement_score":0.22455877,"about_ca_system_score_codex":0.000152815,"about_ca_system_score_gemma":0.0009310092,"threshold_uncertainty_score":0.99960357},"labels":[],"label_agreement":null},{"id":"W2341997585","doi":"10.1200/jco.2005.23.16_suppl.5538","title":"Does CT/MRI fusion improve volume delineation in the treatment planning for nasopharyngeal carcinoma?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Contouring; Medicine; Nasopharyngeal carcinoma; Radiation treatment planning; Nuclear medicine; Magnetic resonance imaging; Radiology; Radiation therapy; Stage (stratigraphy); Image fusion; Fusion","score_opus":0.11596784366274755,"score_gpt":0.47428675137054627,"score_spread":0.35831890770779873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341997585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95512974,0.0012536292,0.00024985976,0.041132588,0.0011942931,0.00035416763,0.000003895966,0.0000042755605,0.00067753484],"genre_scores_gemma":[0.98680836,0.0011036701,0.0031414153,0.0035667075,0.004802553,0.000021291882,0.0000032782464,0.000008171347,0.00054453546],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979681,0.00016171687,0.0013747062,0.00013061709,0.00017853286,0.00018633454],"domain_scores_gemma":[0.9975141,0.0015137546,0.0005685858,0.000102835445,0.00019278572,0.00010789315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019608398,0.00010059167,0.00091221114,0.00006766442,0.00005804318,0.000005354885,0.00008427565,0.00011176012,0.00002445272],"category_scores_gemma":[0.00077689486,0.000041638763,0.0003128291,0.00005881947,0.0000612238,0.000069044014,0.000012400378,0.00035811783,0.000004180563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005118339,0.0019217874,0.22112218,0.000025413221,0.00013644258,0.00031862562,0.0015531206,0.000063607855,0.00019125648,0.000023105305,0.008372525,0.7611536],"study_design_scores_gemma":[0.014046291,0.031841233,0.31937563,0.00007394515,0.0002901533,0.00011122197,0.00073762547,0.0027893852,0.00017408964,0.00006517581,0.6304232,0.00007205727],"about_ca_topic_score_codex":0.00003126873,"about_ca_topic_score_gemma":0.00017945048,"teacher_disagreement_score":0.7610815,"about_ca_system_score_codex":0.00025963233,"about_ca_system_score_gemma":0.0005621382,"threshold_uncertainty_score":0.16979794},"labels":[],"label_agreement":null},{"id":"W2342067795","doi":"10.1200/jco.2009.27.15_suppl.e16537","title":"Susceptibility of ascites tumor cells to ex-vivo killing by the oncolytic virus JX-963 in epithelial ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Oncolytic virus; Medicine; Ascites; Ovarian cancer; Flow cytometry; Ex vivo; Multiplicity of infection; Cancer; Viability assay; Cancer research; Pathology; Virus; In vivo; Cell; Virology; Immunology; Internal medicine; Biology","score_opus":0.06033577379372134,"score_gpt":0.44534863568239497,"score_spread":0.3850128618886736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342067795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926693,0.00085827627,0.00013154872,0.005138523,0.0005850996,0.00028079434,0.000043049346,0.0000022442573,0.00029120085],"genre_scores_gemma":[0.993312,0.00088869873,0.0005921611,0.0039400696,0.0010225028,0.0000051563825,0.000002137918,0.000016086373,0.00022118363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959857,0.0010371816,0.0018879893,0.00031683146,0.00038476093,0.0003875372],"domain_scores_gemma":[0.99734616,0.0006995405,0.00089215365,0.00039546948,0.0003794794,0.00028718114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006204736,0.00017120964,0.00085885986,0.00009027424,0.00004473111,0.000013449187,0.0006842222,0.00032069627,0.00017648614],"category_scores_gemma":[0.001542937,0.00011689432,0.00038279372,0.00022508162,0.0002486116,0.000008505688,0.00009189255,0.000741933,0.000008642373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010877486,0.00096522784,0.003865122,0.0000074214463,0.00009168347,0.000032748507,0.00007852936,0.0006533075,0.9245229,0.000005137244,0.0045404127,0.054360025],"study_design_scores_gemma":[0.004712216,0.047206536,0.018180843,0.000057011606,0.000062354455,0.00002590501,0.00012016996,0.00013006589,0.8698152,0.00042499107,0.059028197,0.0002365541],"about_ca_topic_score_codex":0.00015992756,"about_ca_topic_score_gemma":0.0034859357,"teacher_disagreement_score":0.054707743,"about_ca_system_score_codex":0.00011827649,"about_ca_system_score_gemma":0.0016065843,"threshold_uncertainty_score":0.4766812},"labels":[],"label_agreement":null},{"id":"W2342132516","doi":"10.1200/jco.2009.27.15_suppl.1083","title":"Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Taxane; Metastatic breast cancer; Progressive disease; Internal medicine; Clinical endpoint; Adverse effect; Anthracycline; Performance status; Breast cancer; Stage (stratigraphy); Cancer; Surgery; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.13989923692366021,"score_gpt":0.5438389371707747,"score_spread":0.40393970024711445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342132516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938782,0.00035840165,0.0000039132497,0.0042054253,0.00075567124,0.0005389378,0.000015647374,0.0000036998526,0.00024009713],"genre_scores_gemma":[0.9979518,0.0002927617,0.00030913186,0.0009975095,0.00035431076,0.000007478494,0.0000038096186,0.000009128627,0.00007403678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99681765,0.00037839205,0.0020446258,0.00017701511,0.00037062305,0.00021167511],"domain_scores_gemma":[0.99709445,0.00045695785,0.0016224366,0.00013185927,0.00043411297,0.00026020088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009820821,0.00015086873,0.0017183829,0.00019471465,0.000025910498,0.0000020684706,0.00010947073,0.00010173632,0.00037927562],"category_scores_gemma":[0.0001680643,0.00009387682,0.00018289975,0.00024159114,0.00009379887,0.000085616455,0.000023787448,0.0006715383,0.0000017625928],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056517832,0.18559016,0.3622244,0.000018071869,0.00082330074,0.00043877814,0.00051682006,0.000018733364,0.000049526618,0.0000044641483,0.001862661,0.39193526],"study_design_scores_gemma":[0.0960299,0.28073376,0.62031066,0.00008971023,0.0010845035,0.00004384758,0.000098543984,0.000009676155,0.000011121566,0.000029836356,0.0014986297,0.000059761715],"about_ca_topic_score_codex":0.00008043071,"about_ca_topic_score_gemma":0.00033152307,"teacher_disagreement_score":0.39187548,"about_ca_system_score_codex":0.00024736687,"about_ca_system_score_gemma":0.0009833138,"threshold_uncertainty_score":0.41528022},"labels":[],"label_agreement":null},{"id":"W2342231480","doi":"10.1200/jco.2005.23.16_suppl.7218","title":"Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Carboplatin; Medicine; Cisplatin; Internal medicine; Oncology; Lung cancer; Chemotherapy; Confidence interval; Meta-analysis; Relative risk; Survival analysis; Survival rate","score_opus":0.1327738122868268,"score_gpt":0.5022415155505532,"score_spread":0.36946770326372635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342231480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831371,0.004735957,0.0006227238,0.00840005,0.00013287537,0.00023673924,0.000003588008,0.000004476679,0.0027265232],"genre_scores_gemma":[0.9781294,0.00038327192,0.01791363,0.0029566132,0.00023540539,0.000015794441,0.0000028891914,0.000011999402,0.00035102543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783355,0.00012299039,0.0015189602,0.00018103742,0.00017683496,0.00016660607],"domain_scores_gemma":[0.9973961,0.0010401225,0.0010412422,0.00013180023,0.00017612487,0.00021459787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009509459,0.00013033171,0.0021992205,0.00022070699,0.00002648795,0.000007307438,0.0000672984,0.00015620817,0.00026548948],"category_scores_gemma":[0.00012863078,0.00008707758,0.0007983547,0.00026220884,0.000052770014,0.00006077981,0.000011266354,0.00045941467,0.0000011122786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015791871,0.0016642526,0.86025256,0.00004325871,0.053854268,0.00015516017,0.00055622123,0.029730357,0.00021719237,0.000008045998,0.00026373073,0.051675767],"study_design_scores_gemma":[0.025075419,0.002176127,0.7061726,0.000040705083,0.21996053,0.000016203745,0.0001188973,0.040367737,0.0003786206,0.00001639299,0.0055160015,0.00016081144],"about_ca_topic_score_codex":0.00013511392,"about_ca_topic_score_gemma":0.0012330139,"teacher_disagreement_score":0.16610625,"about_ca_system_score_codex":0.00022486338,"about_ca_system_score_gemma":0.0009793931,"threshold_uncertainty_score":0.35509205},"labels":[],"label_agreement":null},{"id":"W2342533617","doi":"10.1200/jco.2007.25.18_suppl.15117","title":"Adenocarcinoma (AC) small intestine (SI). Review of prognostic factors and treatment outcomes","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Stage (stratigraphy); Adenocarcinoma; Adjuvant chemotherapy; Gastroenterology; Cancer; Log-rank test; Surgery; Survival analysis; Breast cancer","score_opus":0.26309820375742626,"score_gpt":0.5058844862291199,"score_spread":0.2427862824716936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342533617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832914,0.010027574,0.00008150682,0.0051706512,0.00016688072,0.00045235056,0.0000030615488,0.0000070746196,0.0007995215],"genre_scores_gemma":[0.98272103,0.006668226,0.009635528,0.0005970384,0.0001927098,0.0000028159343,0.0000037985906,0.000013516299,0.00016535935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966635,0.00021605805,0.0023252433,0.0001692641,0.0003274654,0.00029846202],"domain_scores_gemma":[0.99116004,0.0060029696,0.0013271898,0.00017494564,0.0005858704,0.000748996],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002788694,0.00018569276,0.001959678,0.00014308172,0.000021224414,0.0000033324097,0.00009881391,0.000092534654,0.00007799118],"category_scores_gemma":[0.01896224,0.00009627126,0.00051544915,0.00012089563,0.00025874382,0.00003584321,0.0000492449,0.0004921703,0.0000060285847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001017583,0.0023324944,0.9333957,0.00043388287,0.00034924963,0.0028143139,0.000020960133,4.9179228e-8,0.00003455681,0.000032918284,0.00013952586,0.0594288],"study_design_scores_gemma":[0.0047336426,0.056860786,0.93036324,0.0024721988,0.00071819284,0.0023352334,0.00007231623,0.000002555798,0.00013589127,0.000052489355,0.0021998212,0.00005364196],"about_ca_topic_score_codex":0.00004580415,"about_ca_topic_score_gemma":0.000055459644,"teacher_disagreement_score":0.05937516,"about_ca_system_score_codex":0.00017692366,"about_ca_system_score_gemma":0.00087601185,"threshold_uncertainty_score":0.98930144},"labels":[],"label_agreement":null},{"id":"W2343233260","doi":"10.1200/jco.2009.27.15_suppl.e11536","title":"Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Oncology; Cost effectiveness; Adjuvant; Internal medicine; Cohort; Chemotherapy; Quality-adjusted life year; Gynecology; Cancer","score_opus":0.12473086203923427,"score_gpt":0.5050240656214242,"score_spread":0.38029320358218993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343233260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672693,0.00062075304,0.000318296,0.0011809972,0.00045914648,0.00016728783,0.000028498158,0.00000144264,0.000496632],"genre_scores_gemma":[0.9973672,0.0010648478,0.0006903555,0.0003862056,0.00040154406,0.000011539593,0.0000074199174,0.000007436384,0.00006343982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758726,0.0005425563,0.0013548428,0.00020290945,0.0001518715,0.00016058442],"domain_scores_gemma":[0.9978783,0.00032682615,0.0010342535,0.0002102279,0.00043430668,0.00011609249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014520325,0.00011730891,0.0009980248,0.00021007571,0.000015534111,0.0000045893808,0.00018402193,0.00033896958,0.00004916368],"category_scores_gemma":[0.00036601388,0.00009118726,0.0005282195,0.00042026662,0.00010686682,0.000006605793,0.00002229227,0.0002009416,0.0000013328165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003997652,0.002076656,0.61702645,0.0000069190346,0.0030898475,0.000065628614,0.00013015777,0.013707395,0.01726061,0.0000443735,0.00058814255,0.34200615],"study_design_scores_gemma":[0.0032256427,0.005652656,0.9774678,0.000018541625,0.0008258548,0.000028486329,0.000026322045,0.00010337862,0.004412655,0.0000884715,0.008059987,0.00009024009],"about_ca_topic_score_codex":0.00019548833,"about_ca_topic_score_gemma":0.00070698536,"teacher_disagreement_score":0.3604413,"about_ca_system_score_codex":0.00036535977,"about_ca_system_score_gemma":0.0017549631,"threshold_uncertainty_score":0.37185085},"labels":[],"label_agreement":null},{"id":"W2343288766","doi":"10.1200/jco.2016.34.2_suppl.75","title":"Association of chronic baseline prostate inflammation with lower tumor grade in men with prostate cancer on repeat biopsy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Prostate biopsy; Prostate; Biopsy; Cancer; Internal medicine; Urology; Dutasteride; Rectal examination; Oncology; Gastroenterology","score_opus":0.03431084134906395,"score_gpt":0.3867615541977142,"score_spread":0.35245071284865026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343288766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96185416,0.00032824717,0.000025649468,0.036561392,0.00023172512,0.00060391374,0.000016104648,0.0000069709367,0.00037183348],"genre_scores_gemma":[0.99375343,0.0041064266,0.0004477716,0.0003298559,0.0005458332,0.00006466906,0.000004348695,0.000021856324,0.0007258037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714106,0.000284335,0.0016489299,0.00021559131,0.0004643009,0.00024579026],"domain_scores_gemma":[0.9952728,0.0010241964,0.0027605204,0.00016312934,0.00060099544,0.00017836437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022834563,0.00015475336,0.0010487842,0.00014292834,0.000017401237,0.000005091462,0.00006358813,0.00013393743,0.000088349334],"category_scores_gemma":[0.0008230114,0.00007149808,0.00012930896,0.00018374059,0.00010777829,0.00015718867,0.000014278595,0.0003614685,0.000004957065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028048296,0.002417567,0.80620605,0.000092957926,0.0006616693,0.0011973018,0.0001644035,0.00020697073,0.0009830068,0.000020990934,0.0014705362,0.15853024],"study_design_scores_gemma":[0.050417,0.067925625,0.85023737,0.0034870845,0.0006999186,0.00017140125,0.00006747526,0.00020368923,0.0070731286,0.00013336417,0.019386653,0.00019729848],"about_ca_topic_score_codex":0.000047480353,"about_ca_topic_score_gemma":0.0005273031,"teacher_disagreement_score":0.15833294,"about_ca_system_score_codex":0.0016484116,"about_ca_system_score_gemma":0.0019571725,"threshold_uncertainty_score":0.4310539},"labels":[],"label_agreement":null},{"id":"W2343357842","doi":"10.1200/jco.2006.24.18_suppl.6102","title":"Delays in diagnosis and initiating treatment for patients with lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Referral; Cancer; Stage (stratigraphy); Cohort; Prospective cohort study; Radiation therapy; Surgery; Internal medicine; Family medicine","score_opus":0.07356683456888244,"score_gpt":0.5099142626954823,"score_spread":0.4363474281265999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343357842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506193,0.0009082823,0.000068423105,0.00257166,0.00020419326,0.00037871092,0.000013575825,0.0000022955821,0.00079093326],"genre_scores_gemma":[0.9941288,0.00061421917,0.00424242,0.00047526296,0.00037689344,0.00008575766,0.000007166986,0.0000085906695,0.000060868424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891555,0.000042624015,0.00075424905,0.00009038778,0.000087845154,0.00010935192],"domain_scores_gemma":[0.99818325,0.0009799923,0.00051285286,0.000040560753,0.00019442002,0.00008893907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021854376,0.00006889493,0.0005363947,0.000060510967,0.000026132027,0.0000041544636,0.000018310286,0.00008670415,0.00001818111],"category_scores_gemma":[0.00020957435,0.0000396266,0.0000890324,0.000051400693,0.000039742932,0.00006048336,0.0000049971095,0.00010648198,1.7778764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009711905,0.0018620077,0.88692015,0.000014061249,0.00021797334,0.000047474958,0.00007370017,0.000039806662,4.93556e-7,0.000033943685,0.00046172852,0.10935744],"study_design_scores_gemma":[0.022114536,0.013359155,0.9527793,0.00013072528,0.00081118656,0.000010082868,0.000036152825,0.000101645004,0.0000068141485,0.00008924473,0.010518802,0.00004234304],"about_ca_topic_score_codex":0.00023735214,"about_ca_topic_score_gemma":0.0006190947,"teacher_disagreement_score":0.10931509,"about_ca_system_score_codex":0.00031850042,"about_ca_system_score_gemma":0.0006672974,"threshold_uncertainty_score":0.16159259},"labels":[],"label_agreement":null},{"id":"W2343367320","doi":"10.1200/jco.2007.25.18_suppl.6638","title":"Sustainable improvement in quality indicators in Ontario's surgical oncology program (SOP)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University Health Network; Toronto General Hospital; Ottawa Hospital; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Quality management; Population; Total mesorectal excision; Colorectal cancer; General partnership; Multidisciplinary approach; Pancreatic cancer; Service (business); Cancer; Internal medicine; Marketing","score_opus":0.34352701349290826,"score_gpt":0.6340549805800244,"score_spread":0.29052796708711615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343367320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700306,0.00011910111,0.00008093657,0.010790172,0.0010504411,0.0010918112,5.9472404e-7,0.000015450836,0.016820876],"genre_scores_gemma":[0.98472285,0.00021593414,0.010465744,0.003212768,0.0008124948,0.000017754046,0.000011060667,0.000020570702,0.00052082055],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9847114,0.0012316185,0.012089621,0.00040057398,0.0007669632,0.0007998408],"domain_scores_gemma":[0.9800825,0.0134535665,0.0046828906,0.00029706722,0.0007835114,0.0007004533],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.048664436,0.00020937061,0.0022881264,0.0009346936,0.00003417308,0.000012886621,0.0002548289,0.0009319848,0.0004733773],"category_scores_gemma":[0.019117916,0.0001680601,0.0005199066,0.00077519217,0.00029071447,0.00029620517,0.00016700153,0.0039510285,0.000013967231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010462865,0.0064278827,0.44422716,0.00003580889,0.00007079771,0.0060850168,0.00038560043,0.000005630096,0.000015220516,0.0004147061,0.00031814075,0.5315512],"study_design_scores_gemma":[0.016844198,0.021822045,0.49918735,0.000032388438,0.000095605086,0.00018198961,0.0048272456,0.0000050522076,0.000021893582,0.00037104383,0.45651427,0.00009692467],"about_ca_topic_score_codex":0.021594169,"about_ca_topic_score_gemma":0.23297013,"teacher_disagreement_score":0.53145427,"about_ca_system_score_codex":0.0041435473,"about_ca_system_score_gemma":0.011220021,"threshold_uncertainty_score":0.9996794},"labels":[],"label_agreement":null},{"id":"W2343744001","doi":"10.1200/jco.2014.32.15_suppl.tps5632","title":"A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cervical cancer; Carboplatin; Radiation therapy; Oncology; Internal medicine; Cancer; Chemotherapy; Chemoradiotherapy; Cisplatin; Clinical trial; Clinical endpoint; Randomized controlled trial; Gynecology","score_opus":0.09377666103427255,"score_gpt":0.4786340619463525,"score_spread":0.3848574009120799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343744001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98006517,0.0005937179,0.0020294194,0.011066751,0.0026838947,0.0022963616,0.00002635914,0.000022199561,0.001216153],"genre_scores_gemma":[0.98212177,0.00073841756,0.0073509593,0.005696894,0.003425445,0.00017831956,0.000059873237,0.000047850866,0.0003804634],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99484724,0.00028743452,0.0033404382,0.00041868392,0.0007002205,0.00040601203],"domain_scores_gemma":[0.9936016,0.0023793315,0.0023258526,0.00031418234,0.00061069697,0.00076832727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020572292,0.00033033147,0.0036477814,0.00023160352,0.000068645175,0.000013209859,0.00021719845,0.00043820488,0.00017355669],"category_scores_gemma":[0.0024122177,0.00023777991,0.0014197853,0.0003880267,0.00009096103,0.00015572082,0.000030118174,0.00035142558,0.000013266582],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37865368,0.009117977,0.0012192292,0.00006292627,0.0010241203,0.000028758446,0.00020052683,0.00011926024,0.0021114477,0.000017840983,0.00070151256,0.60674274],"study_design_scores_gemma":[0.79961634,0.11599277,0.010513185,0.0002173658,0.0016109281,0.000023089902,0.00007079524,0.0007081313,0.0048593543,0.00028832207,0.06584579,0.00025395484],"about_ca_topic_score_codex":0.00015264594,"about_ca_topic_score_gemma":0.000062917585,"teacher_disagreement_score":0.60648876,"about_ca_system_score_codex":0.0010912973,"about_ca_system_score_gemma":0.0021257016,"threshold_uncertainty_score":0.96963835},"labels":[],"label_agreement":null},{"id":"W2343845238","doi":"10.1200/jco.2012.30.5_suppl.286","title":"A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Tolerability; Urology; Internal medicine; Progressive disease; Adverse effect; Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.09718729656403201,"score_gpt":0.4771249404635241,"score_spread":0.3799376438994921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343845238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250376,0.0016311677,0.0013167533,0.0018109377,0.0008927533,0.0016896577,0.0000442382,0.0000019232207,0.000108800756],"genre_scores_gemma":[0.9886702,0.0031659717,0.0034419277,0.00012499621,0.004347752,0.00009435001,0.0000071607087,0.000029991146,0.00011766951],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99599755,0.00066029775,0.0022616603,0.00023055784,0.00034851194,0.00050139544],"domain_scores_gemma":[0.99602485,0.0016180612,0.0010329224,0.00032614614,0.0006336813,0.0003643259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033311648,0.00020174673,0.0011847165,0.000071019036,0.00007099372,0.0000074573372,0.00033206705,0.00047736132,0.00005254645],"category_scores_gemma":[0.0049036243,0.00012382084,0.0008257238,0.00010521621,0.00042045893,0.000013696366,0.00008222775,0.00036333356,0.0000020767075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064244464,0.010098171,0.0004888982,0.00006280269,0.0010049742,0.000023859016,0.0002136666,0.00005367586,0.79324114,0.000019825293,0.0019425144,0.128606],"study_design_scores_gemma":[0.08506574,0.10314758,0.00076580024,0.0000680434,0.0003200088,0.000030374962,0.00021747692,0.00022592486,0.7285863,0.000033061126,0.08136061,0.00017904231],"about_ca_topic_score_codex":0.0000773338,"about_ca_topic_score_gemma":0.00004558571,"teacher_disagreement_score":0.12842697,"about_ca_system_score_codex":0.000092319904,"about_ca_system_score_gemma":0.0019725894,"threshold_uncertainty_score":0.587045},"labels":[],"label_agreement":null},{"id":"W2343867010","doi":"10.1200/jco.2015.33.15_suppl.8503","title":"Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Toxicity; Gastroenterology; Follicular lymphoma; Surgery; Animal science; Lymphoma","score_opus":0.08271772342329124,"score_gpt":0.40698990089155107,"score_spread":0.3242721774682598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343867010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938047,0.0014847035,0.0000039145034,0.0017898517,0.0012579088,0.00045313075,0.000023084427,0.0000136353765,0.0011690503],"genre_scores_gemma":[0.9954467,0.0011284511,0.0013425193,0.0011902457,0.0003280495,0.0000073586516,0.000020277177,0.00004502624,0.00049138285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99394417,0.001041585,0.0031657843,0.0004210528,0.0009495722,0.00047783818],"domain_scores_gemma":[0.99219036,0.0027749208,0.0027140481,0.0004877288,0.0010747876,0.00075815484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028333052,0.0003602169,0.0026384564,0.00034161002,0.000060431885,0.000015147778,0.00026412267,0.0004238482,0.0000787937],"category_scores_gemma":[0.0038931118,0.00023091368,0.00055903074,0.00031909902,0.0004212419,0.00027192186,0.00014060769,0.0004841667,0.00005427619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054234944,0.017403994,0.9069878,0.000036188616,0.0006399716,0.0041226572,0.00026815955,0.000040000865,0.00031432195,0.000042399082,0.0048969355,0.011012667],"study_design_scores_gemma":[0.09522986,0.025797656,0.8425434,0.00051186234,0.00046183847,0.00034449674,0.00018654935,0.000019427373,0.001019935,0.000053620977,0.033620182,0.00021113144],"about_ca_topic_score_codex":0.00044763915,"about_ca_topic_score_gemma":0.00023959763,"teacher_disagreement_score":0.06444432,"about_ca_system_score_codex":0.0012742963,"about_ca_system_score_gemma":0.0039508175,"threshold_uncertainty_score":0.94163865},"labels":[],"label_agreement":null},{"id":"W2344399638","doi":"10.1200/jco.2007.25.18_suppl.7585","title":"Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): Final analysis of JBR.10 randomized trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Vinorelbine; Nausea; Quality of life (healthcare); Internal medicine; Clinical endpoint; Randomized controlled trial; Chemotherapy; Stage (stratigraphy); Cancer; Oncology; Surgery; Physical therapy; Cisplatin","score_opus":0.1197165307642956,"score_gpt":0.5607811755889253,"score_spread":0.44106464482462965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344399638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897978,0.00085735804,0.006287058,0.0004650901,0.00046624002,0.0011380195,0.0001279605,0.0000026404107,0.0008578846],"genre_scores_gemma":[0.99405175,0.0006986825,0.0037348352,0.00023829132,0.00055884116,0.000015525045,0.000011575359,0.000016016547,0.0006744709],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937839,0.00041071794,0.005012743,0.00017511094,0.00038487726,0.00023267315],"domain_scores_gemma":[0.9845491,0.007163504,0.006522834,0.00022650776,0.0012130686,0.00032500582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008451729,0.00016712943,0.0050229556,0.00034308154,0.00002137115,0.0000030226388,0.00014840816,0.0003162727,0.00056685193],"category_scores_gemma":[0.0028894162,0.00010314867,0.0036790941,0.0003574647,0.00024639023,0.000057432007,0.000014944892,0.00032400966,2.8354765e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8587385,0.003578349,0.10865118,0.00012858858,0.016183328,0.000011229452,0.0005387858,0.00027754952,0.00058616814,0.000014293303,0.0005103332,0.010781696],"study_design_scores_gemma":[0.65838367,0.011813851,0.3188324,0.000061319115,0.009662769,8.8181025e-7,0.00008552002,0.00039878718,0.0003795948,0.00002315887,0.0002875567,0.00007052416],"about_ca_topic_score_codex":0.0014489705,"about_ca_topic_score_gemma":0.00027572917,"teacher_disagreement_score":0.2101812,"about_ca_system_score_codex":0.00024758434,"about_ca_system_score_gemma":0.0047463384,"threshold_uncertainty_score":0.84198},"labels":[],"label_agreement":null},{"id":"W2344487323","doi":"10.1200/jco.2016.34.2_suppl.309","title":"The utility of serum CA9 in prognostication in prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Docetaxel; Chemotherapy; Biochemical recurrence; Internal medicine; Prostatectomy; Oncology; Cancer; Prostate; Urology; Gastroenterology","score_opus":0.05878831566481291,"score_gpt":0.43569366132400417,"score_spread":0.37690534565919126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344487323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892547,0.0036455449,0.000033833945,0.004901236,0.0015901972,0.00014970392,0.000012016093,7.358156e-7,0.0004119958],"genre_scores_gemma":[0.9807311,0.017867269,0.0001290025,0.00018144083,0.0008798064,0.000009375642,4.9095416e-7,0.0000053168114,0.00019616235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99793637,0.0003558076,0.0012974212,0.00013037423,0.000113590315,0.00016646087],"domain_scores_gemma":[0.99824893,0.0004435105,0.0008505335,0.00015608969,0.00022643966,0.000074486714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002853765,0.000065307926,0.0004046994,0.00003314174,0.000014545764,0.0000026709884,0.00018844995,0.00017639609,0.000017494238],"category_scores_gemma":[0.0030875406,0.00003467106,0.00013281846,0.00007634111,0.00022742464,0.0000059704303,0.000049046856,0.00020502579,8.3399294e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014869737,0.00029172286,0.2736093,0.000008654565,0.00003669435,0.000004189519,0.000037295777,0.0000036166289,0.012447448,0.00004678205,0.0018499958,0.7101773],"study_design_scores_gemma":[0.0024482089,0.0009383396,0.726033,0.00003985925,0.000017636516,0.000010044706,0.000037873146,0.000010289649,0.0045044115,0.00041835735,0.26549637,0.00004562948],"about_ca_topic_score_codex":0.000048386082,"about_ca_topic_score_gemma":0.0021774215,"teacher_disagreement_score":0.7101317,"about_ca_system_score_codex":0.000023691402,"about_ca_system_score_gemma":0.001190584,"threshold_uncertainty_score":0.36962974},"labels":[],"label_agreement":null},{"id":"W2344914144","doi":"10.1200/jco.2010.28.15_suppl.6021","title":"End-of-life care for elderly patients with advanced lung cancer in the United States and Ontario.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Health care; Lung cancer; Cancer; Cancer registry; End-of-life care; Family medicine; Disease; Gerontology; Emergency medicine; Internal medicine; Nursing","score_opus":0.13442280380513888,"score_gpt":0.5175002871460425,"score_spread":0.3830774833409036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344914144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966718,0.0009630411,0.000040281284,0.0014365742,0.0004168796,0.00027220347,0.000019831257,0.0000014076103,0.00017799738],"genre_scores_gemma":[0.9937809,0.0011253682,0.0038666772,0.0010068592,0.00017091702,0.000007680205,0.0000140779375,0.000007897745,0.000019636176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843204,0.00011350026,0.0010260745,0.00009335768,0.00020684324,0.00012818798],"domain_scores_gemma":[0.994966,0.00297761,0.0009560559,0.00009952353,0.00087674445,0.00012411032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007153555,0.000086458225,0.0008446914,0.000094894174,0.000018382792,0.0000024215308,0.00010402784,0.0001596132,0.000041498002],"category_scores_gemma":[0.0019550337,0.000045820194,0.00011211925,0.00010347059,0.0002013065,0.000057152673,0.000013584812,0.0006644705,8.369551e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044119437,0.00032993229,0.9422496,0.00008675853,0.00014583876,0.000013710921,0.0044954773,0.000033130276,0.000025872958,0.000029149163,0.00028943628,0.04788917],"study_design_scores_gemma":[0.012264827,0.011743412,0.8202385,0.00041002533,0.00025167162,0.0000035086655,0.0022846377,0.000036254798,0.00005221387,0.0000584362,0.15259713,0.00005941089],"about_ca_topic_score_codex":0.0021712028,"about_ca_topic_score_gemma":0.053578068,"teacher_disagreement_score":0.1523077,"about_ca_system_score_codex":0.000056219502,"about_ca_system_score_gemma":0.0013639021,"threshold_uncertainty_score":0.96369165},"labels":[],"label_agreement":null},{"id":"W2345090413","doi":"10.1200/jco.2007.25.18_suppl.6516","title":"Statistical power of negative randomized clinical trials (RCTs) presented at the American Society of Clinical Oncology (ASCO) Annual Meetings","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sample size determination; Medicine; Randomized controlled trial; Clinical endpoint; Post-hoc analysis; Odds ratio; Hazard ratio; Logistic regression; Internal medicine; Post hoc; Confidence interval; Clinical trial; Statistical power; Statistics","score_opus":0.8424090538305719,"score_gpt":0.7224287215753777,"score_spread":0.11998033225519411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345090413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8946213,0.00090347,0.06177005,0.023829585,0.0057113697,0.0024583887,0.00015309897,0.000006030712,0.010546681],"genre_scores_gemma":[0.9105847,0.0019127957,0.075266816,0.0065773437,0.0026344624,0.000015080755,0.000005201694,0.000034555236,0.0029690273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.19384015,0.541877,0.24765418,0.0020832773,0.013381982,0.001163411],"domain_scores_gemma":[0.030246135,0.77985215,0.17633224,0.0022723814,0.01017326,0.00112382],"candidate_categories":["metaresearch","metaepi_broad","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.914957,0.0005363086,0.051485308,0.0003202682,0.00014361824,0.00006657402,0.0033176853,0.0012290723,0.005652196],"category_scores_gemma":[0.9068714,0.00020916548,0.028215684,0.0014133485,0.0086184405,0.00023530897,0.0007379786,0.003206042,0.0002293265],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13027534,0.0036070016,0.0738641,0.00003074136,0.00824086,0.00009711291,0.00087937544,0.000030963303,0.000030264795,0.0013875123,0.48277456,0.29878217],"study_design_scores_gemma":[0.13174975,0.016894998,0.21882069,0.00011648661,0.0069103064,0.00014169244,0.00837343,0.0016610761,0.000046906975,0.009215923,0.60567343,0.0003953309],"about_ca_topic_score_codex":0.00008544113,"about_ca_topic_score_gemma":0.0001747086,"teacher_disagreement_score":0.29838684,"about_ca_system_score_codex":0.00013249204,"about_ca_system_score_gemma":0.003554604,"threshold_uncertainty_score":0.9990936},"labels":[],"label_agreement":null},{"id":"W2345488406","doi":"10.1200/jco.2015.33.7_suppl.178","title":"Comparison of active surveillance with other treatment options for low-risk prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; SABR volatility model; Salvage therapy; Brachytherapy; Radiation therapy; Surgery; Cohort; Internal medicine; Urology; Cancer; Chemotherapy","score_opus":0.29605898496414546,"score_gpt":0.5816284992766806,"score_spread":0.28556951431253513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345488406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903309,0.0022270645,0.00019642153,0.005230518,0.00040114045,0.0006889316,0.000100502926,0.00000569538,0.0008188401],"genre_scores_gemma":[0.9915826,0.0026938997,0.0037788686,0.00010145244,0.00054068625,0.000050822535,0.000006945864,0.0000180367,0.0012267246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979643,0.00025377123,0.0011657435,0.00013823257,0.0002754543,0.00020247104],"domain_scores_gemma":[0.99549353,0.001379329,0.0015565851,0.00012965062,0.001085256,0.00035564267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013163066,0.00011167533,0.0013299999,0.000074006064,0.00003203187,0.00000395489,0.000074609154,0.00014384408,0.000030217498],"category_scores_gemma":[0.0008330909,0.00005845345,0.0002464665,0.00011148026,0.00026039386,0.000058327067,0.00001296394,0.00031965374,0.0000026165144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05384937,0.003942161,0.7624999,0.00003825046,0.0013736202,0.00004188565,0.0008643243,0.00032818117,0.0000824437,0.000027928349,0.0023971526,0.17455477],"study_design_scores_gemma":[0.09200791,0.21444775,0.42494214,0.0003655239,0.0012301267,0.000083395025,0.002413734,0.0007520631,0.004701803,0.00044925188,0.2583837,0.00022261804],"about_ca_topic_score_codex":0.00017765554,"about_ca_topic_score_gemma":0.0005061778,"teacher_disagreement_score":0.3375578,"about_ca_system_score_codex":0.00043963292,"about_ca_system_score_gemma":0.0036328724,"threshold_uncertainty_score":0.64445597},"labels":[],"label_agreement":null},{"id":"W2345828629","doi":"10.1200/jco.2015.33.18_suppl.lba2","title":"Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"","keywords":"Medicine; Poisson regression; Cumulative incidence; Relative risk; Cancer; Internal medicine; Confidence interval; Incidence (geometry); Late effect; Radiation therapy; Pediatrics; Surgery; Cohort; Population","score_opus":0.164555365109398,"score_gpt":0.4833955497835233,"score_spread":0.3188401846741253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345828629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757912,0.003010777,0.000010199928,0.013009791,0.0062764115,0.0010904539,0.00005284094,0.000027194472,0.0007311185],"genre_scores_gemma":[0.9919621,0.0017716504,0.00021253485,0.001377776,0.0044358745,0.00003776023,0.000012014781,0.000054398217,0.00013593386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9875176,0.00302413,0.006688896,0.0006251039,0.0016739686,0.00047031228],"domain_scores_gemma":[0.98876756,0.0021363425,0.006243847,0.00094943965,0.0011784297,0.0007243547],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019053781,0.00036776203,0.0033699402,0.0001999599,0.00006599589,0.000020106218,0.0005939994,0.00056297815,0.00023133744],"category_scores_gemma":[0.0089454455,0.00025497415,0.00076382054,0.00067319174,0.000540026,0.0003534888,0.00019141515,0.0024612295,0.0000065413997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018359198,0.0073919734,0.9679427,0.000021443142,0.0016353882,0.00050413725,0.008993737,0.00034326388,0.000010954087,0.0000055758383,0.0047914945,0.0065234215],"study_design_scores_gemma":[0.012323058,0.004199559,0.9717831,0.000404693,0.001027896,0.00011273237,0.0053698244,0.000021286292,0.00004340383,0.0004105498,0.0040734923,0.00023037977],"about_ca_topic_score_codex":0.10915892,"about_ca_topic_score_gemma":0.11624312,"teacher_disagreement_score":0.016170844,"about_ca_system_score_codex":0.00048086044,"about_ca_system_score_gemma":0.0065226895,"threshold_uncertainty_score":0.9999902},"labels":[],"label_agreement":null},{"id":"W2346194474","doi":"10.1200/jco.2007.25.18_suppl.7513","title":"Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gefitinib; Docetaxel; Internal medicine; Hazard ratio; Interim analysis; Regimen; Randomization; Lung cancer; Surgery; Clinical endpoint; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval; Epidermal growth factor receptor","score_opus":0.02211199768896288,"score_gpt":0.4177544959195442,"score_spread":0.39564249823058134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346194474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933582,0.00026769438,0.0025886921,0.00022745797,0.000593751,0.0017118325,0.00013026947,0.000004077351,0.001118026],"genre_scores_gemma":[0.99680966,0.00033055025,0.0020380886,0.0002883082,0.0001010452,0.0000651567,0.000110403234,0.000018478186,0.00023829514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954281,0.00028120793,0.0032853533,0.00025415653,0.00044238393,0.00030882587],"domain_scores_gemma":[0.991981,0.0024547454,0.004096697,0.00017573292,0.0010350022,0.00025677567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002493039,0.00020762814,0.0031577074,0.00040125806,0.00002104927,0.0000042073652,0.00010523631,0.00027741087,0.00016051944],"category_scores_gemma":[0.0010458234,0.0001387921,0.0006981139,0.00065351574,0.00021603443,0.00012489542,0.000019850626,0.00046873075,4.5329827e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9529507,0.005988196,0.028841786,0.00003123184,0.0054779667,0.00011176354,0.00044424535,0.00037854747,0.000056538865,0.000005873015,0.0001923283,0.005520779],"study_design_scores_gemma":[0.94603735,0.013351998,0.02702634,0.0001587598,0.011921967,6.2982804e-7,0.00021672025,0.00067670195,0.00020698083,0.0000027408157,0.00027680496,0.00012299242],"about_ca_topic_score_codex":0.00020352838,"about_ca_topic_score_gemma":0.0006069446,"teacher_disagreement_score":0.007363802,"about_ca_system_score_codex":0.0004696637,"about_ca_system_score_gemma":0.001741514,"threshold_uncertainty_score":0.56597775},"labels":[],"label_agreement":null},{"id":"W2346236028","doi":"10.1200/jco.2015.33.15_suppl.5503","title":"Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Ascites; Internal medicine; Clinical endpoint; Progression-free survival; Gastroenterology; Placebo; Paclitaxel; Randomized controlled trial; Toxicity; Ovarian cancer; Overall survival; Cancer; Pathology","score_opus":0.17850757050419325,"score_gpt":0.48757933274483095,"score_spread":0.3090717622406377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346236028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904504,0.00038693467,0.000003088354,0.006970154,0.00086590427,0.00066420913,0.00017036207,0.0000032443627,0.0004857471],"genre_scores_gemma":[0.99830353,0.0005035597,0.00011097311,0.00042820486,0.0005780772,0.000012075739,0.000015282858,0.000013548785,0.000034735982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959916,0.0006248925,0.0022148641,0.00031415463,0.00061769434,0.00023681622],"domain_scores_gemma":[0.9938597,0.0029798925,0.0018994756,0.0003193826,0.0004953199,0.00044620814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028306441,0.00021602583,0.0017781493,0.00011030946,0.000026983595,0.000013712248,0.00015029463,0.000178071,0.000046912264],"category_scores_gemma":[0.0017998995,0.0001045755,0.0002752992,0.00018100724,0.00014127743,0.00009220441,0.000043561944,0.0007273332,0.0000022282725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12755911,0.019746302,0.7335923,0.000004111592,0.0013523216,0.00026986815,0.0011845458,0.000062537285,5.923712e-7,0.000017971015,0.00604088,0.11016951],"study_design_scores_gemma":[0.19281372,0.09953171,0.70491046,0.00021767468,0.00049288914,0.000004825291,0.00027920198,0.00002348829,0.00000108359,0.00005425554,0.001598115,0.00007259205],"about_ca_topic_score_codex":0.0048428667,"about_ca_topic_score_gemma":0.0029849142,"teacher_disagreement_score":0.11009692,"about_ca_system_score_codex":0.0008284566,"about_ca_system_score_gemma":0.0026791827,"threshold_uncertainty_score":0.73209983},"labels":[],"label_agreement":null},{"id":"W2346394494","doi":"10.1200/jco.2000.18.19.3454","title":"Prophylactic Surgery: Oophorectomy or Adnexectomy?","year":2000,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Citation; Gynecologic oncology; General surgery; Oophorectomy; Fallopian tube; Clinical Oncology; Library science; Gynecology; Cancer; Surgery; Internal medicine; Hysterectomy","score_opus":0.11167854636045599,"score_gpt":0.4342598122254288,"score_spread":0.3225812658649728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346394494","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08427601,0.007564434,0.00019455743,0.8750985,0.020450955,0.000725628,0.00009214889,0.000026144175,0.01157157],"genre_scores_gemma":[0.041245,0.0067738197,0.0045884093,0.8556296,0.0775045,0.00004419407,0.00019846154,0.0002028091,0.013813198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99402684,0.0012452285,0.003238657,0.00051810755,0.0005090032,0.00046219234],"domain_scores_gemma":[0.9933406,0.0018207984,0.0034119831,0.000584228,0.00063320727,0.00020918521],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025780695,0.00037475635,0.002032618,0.00023074418,0.000058049198,0.000031510997,0.0006730348,0.003459084,0.0010231797],"category_scores_gemma":[0.004517299,0.00026812527,0.0013039651,0.00020863899,0.000389949,0.000008276165,0.000101224556,0.0036816702,0.00008515853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002092408,0.00021303198,0.00032298066,0.00007010985,0.00050158,0.0016980026,0.00000912308,0.000013795202,0.00012635939,2.862154e-7,0.8896352,0.1053171],"study_design_scores_gemma":[0.0013439116,0.0045291604,0.0005857651,0.000050542767,0.000353578,0.0011960675,0.000008180145,0.000002571028,0.00043743433,0.00008986087,0.99107945,0.00032345875],"about_ca_topic_score_codex":0.000009470608,"about_ca_topic_score_gemma":0.00002496947,"teacher_disagreement_score":0.10499364,"about_ca_system_score_codex":0.00022135214,"about_ca_system_score_gemma":0.013969945,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W2346632551","doi":"10.1200/jco.2012.30.15_suppl.8002","title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup  randomized phase III clinical trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; ABVD; Internal medicine; Clinical endpoint; Randomization; Discontinuation; Stage (stratigraphy); Clinical trial; Hazard ratio; Gastroenterology; Surgery; Chemotherapy; Confidence interval; Vincristine; Cyclophosphamide","score_opus":0.1127364686926511,"score_gpt":0.4625864656085583,"score_spread":0.34984999691590724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346632551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842439,0.0018684504,0.00020119012,0.003111838,0.007609778,0.0016827871,0.00009698497,0.000032439857,0.0011525818],"genre_scores_gemma":[0.981501,0.010851114,0.0028955773,0.0006701399,0.003600587,0.000055443328,0.000070809794,0.0000566537,0.00029869933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9788518,0.0049288413,0.01382602,0.0006170737,0.00092468737,0.00085158664],"domain_scores_gemma":[0.9443547,0.043820374,0.009090123,0.00075993105,0.0006303506,0.0013444923],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03427537,0.00056120765,0.0078037707,0.00049545453,0.00008735015,0.000025926649,0.0004457891,0.0013864498,0.0002741859],"category_scores_gemma":[0.03741164,0.00037999722,0.0027226815,0.00042282298,0.0008817015,0.00044148113,0.00019515934,0.001223253,0.000046073732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7830634,0.04064268,0.0231834,0.000029553565,0.0024039093,0.0009544119,0.00019469163,0.000022997134,0.000011637801,0.0001313518,0.0062531983,0.14310874],"study_design_scores_gemma":[0.8563985,0.025937932,0.09178139,0.00040001483,0.0030506542,0.00008096605,0.0001459763,0.0004919043,0.00014179313,0.000057739824,0.02123539,0.00027769204],"about_ca_topic_score_codex":0.00091834384,"about_ca_topic_score_gemma":0.0006446221,"teacher_disagreement_score":0.14283104,"about_ca_system_score_codex":0.0006617175,"about_ca_system_score_gemma":0.0016602358,"threshold_uncertainty_score":0.99990994},"labels":[],"label_agreement":null},{"id":"W2346791303","doi":"10.1200/jco.2015.33.18_suppl.lba5002","title":"A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Docetaxel; Hazard ratio; Prostate cancer; Prednisone; Urology; Clinical endpoint; Radiation therapy; Stage (stratigraphy); Chemotherapy; Internal medicine; Androgen deprivation therapy; Oncology; Cancer; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.08920992381682366,"score_gpt":0.5058327657049976,"score_spread":0.4166228418881739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346791303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710548,0.0027451168,0.00007570154,0.0045967754,0.00022022185,0.02101848,0.00007589716,0.00001134768,0.00020164094],"genre_scores_gemma":[0.9703576,0.012015693,0.0046308334,0.0007226423,0.0007030254,0.008755605,0.00003167586,0.00009755234,0.0026853879],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969944,0.00027860122,0.0014332185,0.00039277272,0.00051669695,0.00038435264],"domain_scores_gemma":[0.99585444,0.0010226187,0.0014175926,0.00019452094,0.0006386836,0.0008721753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020335023,0.00026906905,0.0016758803,0.00011424295,0.000086790475,0.000024930518,0.0001138304,0.00026544536,0.000059646798],"category_scores_gemma":[0.00087853696,0.00015745482,0.00014738431,0.00013265149,0.00069174723,0.00019818089,0.00007337298,0.00057403604,8.1988844e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.700618,0.0044689607,0.040912498,0.00042536305,0.0020365762,0.00049950636,0.0008124583,0.0000045856127,0.0024053429,0.000024830226,0.027544878,0.22024696],"study_design_scores_gemma":[0.6227087,0.16485152,0.0011865462,0.0005582624,0.0012087441,0.00048604544,0.00049162534,0.00029829695,0.013473718,0.00079699495,0.19365528,0.00028428735],"about_ca_topic_score_codex":0.00031006965,"about_ca_topic_score_gemma":0.000054294047,"teacher_disagreement_score":0.21996267,"about_ca_system_score_codex":0.00014826252,"about_ca_system_score_gemma":0.0024224578,"threshold_uncertainty_score":0.6420821},"labels":[],"label_agreement":null},{"id":"W2351438759","doi":"10.1200/jco.2004.22.90140.773","title":"Palliative chemotherapy with vinorelbine or capecitabine in women with anthracycline and taxane refractory metastatic breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Vinorelbine; Capecitabine; Medicine; Taxane; Anthracycline; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Surgery; Colorectal cancer","score_opus":0.07887157768887255,"score_gpt":0.4760803488222091,"score_spread":0.3972087711333366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2351438759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96554744,0.00095881626,0.000043974003,0.032767367,0.00019926777,0.00030157002,0.000014680209,0.0000068780255,0.00016002757],"genre_scores_gemma":[0.9789658,0.011101593,0.0038821395,0.00504928,0.0006585735,0.000029727544,0.0000020495065,0.000027011456,0.00028379247],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978353,0.00015885776,0.0012223495,0.00022766531,0.0002533762,0.00030247952],"domain_scores_gemma":[0.99715763,0.000838756,0.001217458,0.00010906453,0.00028409425,0.00039297197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008651546,0.00020463901,0.0016549879,0.00015321953,0.00002636248,0.000005403294,0.00007762238,0.00014462773,0.0009209123],"category_scores_gemma":[0.0001339789,0.00010351794,0.000071221424,0.00025937255,0.0003997474,0.00013115567,0.000015891063,0.00081204914,0.0000020987165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43287912,0.01854933,0.23100473,0.00016647369,0.0043729865,0.010622286,0.002254036,0.00027429234,0.0013134835,0.00002359312,0.00091068476,0.297629],"study_design_scores_gemma":[0.10438372,0.078323,0.8004852,0.0003953665,0.00073047646,0.002079975,0.00056357,0.000014013811,0.00011990736,0.00010142841,0.012630161,0.00017318879],"about_ca_topic_score_codex":0.00022665507,"about_ca_topic_score_gemma":0.0015642392,"teacher_disagreement_score":0.5694805,"about_ca_system_score_codex":0.00065635354,"about_ca_system_score_gemma":0.0027196533,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W2365981309","doi":"10.1200/jco.2016.66.6313","title":"Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; American Society of Clinical Oncology; Breast Cancer Research Foundation; Conquer Cancer Foundation","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Population; Internal medicine; Cancer; Carcinoembryonic antigen; Odds ratio; Positron emission tomography; Oncology; Radiology","score_opus":0.0652389570776558,"score_gpt":0.4147329348760741,"score_spread":0.3494939777984183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2365981309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996611,0.0007744169,0.000036589463,0.0023138302,0.00017182027,0.000049282222,0.00003086244,7.61107e-7,0.000011436688],"genre_scores_gemma":[0.9955038,0.0036082047,0.0004755369,0.00013032556,0.00024500294,0.000009928826,2.0164862e-7,0.000007900039,0.000019135046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988807,0.00015852363,0.0005936181,0.00012600463,0.000102274724,0.00013887988],"domain_scores_gemma":[0.9986345,0.00037562993,0.0005374308,0.000093642004,0.00018429941,0.00017448553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045917317,0.00008353665,0.00046679954,0.000036452784,0.000011143565,0.0000030590643,0.00006959661,0.00005791008,0.000007904227],"category_scores_gemma":[0.00041683103,0.000044410364,0.000053370313,0.000040609648,0.0001985061,0.0000122481215,0.00004997939,0.00008362855,2.5383042e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010106463,0.00034887512,0.8414133,0.00000829142,0.00035012796,0.00005445872,0.000030842293,0.000007921633,0.0020796505,0.0000063251773,0.00006973027,0.14552398],"study_design_scores_gemma":[0.0042979307,0.0016669004,0.99233025,0.00017458062,0.00008898477,0.000037780388,0.000072482406,3.9118748e-7,0.00044418083,0.000032879972,0.000795173,0.000058455764],"about_ca_topic_score_codex":0.000046705078,"about_ca_topic_score_gemma":0.00008025335,"teacher_disagreement_score":0.15091692,"about_ca_system_score_codex":0.000094341274,"about_ca_system_score_gemma":0.0004470517,"threshold_uncertainty_score":0.1811002},"labels":[],"label_agreement":null},{"id":"W2369011410","doi":"10.1200/jco.2009.27.15_suppl.502","title":"Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Axillary lymph nodes; Axilla; Oncology; Neoadjuvant therapy; Chemotherapy; Cisplatin; Internal medicine; Cancer; Stage (stratigraphy); Surgery","score_opus":0.0345335455003703,"score_gpt":0.41338554671148203,"score_spread":0.37885200121111173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2369011410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923246,0.00061417115,0.00016023406,0.0052904687,0.0004998454,0.00012475901,0.00001844088,0.0000014605497,0.00096602645],"genre_scores_gemma":[0.9926941,0.0011207829,0.0013326582,0.0039191283,0.0008287813,0.0000040146624,0.000007125211,0.000011206056,0.00008219872],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99786323,0.00030532666,0.001192738,0.00021540941,0.0002387424,0.0001845566],"domain_scores_gemma":[0.9979144,0.00017140337,0.0010348547,0.00015872074,0.0005952126,0.00012541394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010235473,0.00012122623,0.00053258333,0.00007207075,0.000024635403,0.000009876672,0.00023421309,0.00029219897,0.000046990812],"category_scores_gemma":[0.0003069271,0.0000827439,0.00015922492,0.00013324495,0.000110004636,0.00000980537,0.000024164125,0.00040433923,0.000002533107],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006124784,0.0017828515,0.2712699,0.0000014702335,0.00019180577,0.00006148077,0.00011247419,0.0008526346,0.002938457,0.000021395885,0.005933386,0.7107094],"study_design_scores_gemma":[0.0065628584,0.010815775,0.96257627,0.000031788117,0.00002328149,0.0000740798,0.00003384186,0.000019190262,0.0015117658,0.00019788145,0.018035255,0.000118011754],"about_ca_topic_score_codex":0.000014528309,"about_ca_topic_score_gemma":0.0001408807,"teacher_disagreement_score":0.7105914,"about_ca_system_score_codex":0.00012799772,"about_ca_system_score_gemma":0.0013356727,"threshold_uncertainty_score":0.33741984},"labels":[],"label_agreement":null},{"id":"W2371477309","doi":"10.1200/jco.2006.24.18_suppl.14524","title":"The effect of warfarin on the risk of prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Warfarin; Odds ratio; Prostate cancer; Cancer; Population; Cancer registry; Internal medicine; Confidence interval; Cohort; Surgery; Gynecology; Atrial fibrillation","score_opus":0.02369685704464522,"score_gpt":0.390678262664013,"score_spread":0.36698140561936776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2371477309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663986,0.0038632187,0.000017672712,0.0016273112,0.006245758,0.00014957778,0.000015413538,8.636362e-7,0.0014403033],"genre_scores_gemma":[0.9795757,0.009496709,0.00005000104,0.00022928651,0.010010347,0.000007996285,0.0000011557598,0.000009812927,0.0006189816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975445,0.00084079616,0.0011782234,0.00010862923,0.00018025984,0.00014754504],"domain_scores_gemma":[0.99618006,0.0015283785,0.0018039763,0.00022867379,0.00020661812,0.000052325464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003949646,0.00009440714,0.0005735038,0.000019074716,0.000051298248,0.000003992426,0.00027332435,0.00019879143,0.000012795699],"category_scores_gemma":[0.0019183814,0.000041514504,0.00046306185,0.000053551947,0.00035872526,0.0000021046912,0.00005146624,0.00038917214,0.000001105804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018442785,0.0006820537,0.2566828,0.000051351904,0.0011523993,0.0000017833926,0.00006726218,0.0014733701,0.052267153,0.0008886292,0.25855866,0.40973175],"study_design_scores_gemma":[0.0024089054,0.007896315,0.102242626,0.000022044725,0.00019839137,0.000008088095,0.000019900652,0.000010907217,0.02837591,0.00027604384,0.8584853,0.000055600773],"about_ca_topic_score_codex":0.00019113839,"about_ca_topic_score_gemma":0.00034585068,"teacher_disagreement_score":0.5999266,"about_ca_system_score_codex":0.000013362012,"about_ca_system_score_gemma":0.0004188788,"threshold_uncertainty_score":0.22966203},"labels":[],"label_agreement":null},{"id":"W2373695127","doi":"10.1200/jco.2009.27.15_suppl.3558","title":"Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Tolerability; Paclitaxel; Temsirolimus; Regimen; Internal medicine; Chemotherapy; Oncology; Ovarian cancer; Urology; Cancer; Adverse effect; Cisplatin","score_opus":0.07709302058253897,"score_gpt":0.5078986007350953,"score_spread":0.4308055801525563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2373695127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969475,0.00031956704,0.0000026310345,0.0009386645,0.00032388986,0.00063475786,0.000003617075,0.000005316243,0.000824052],"genre_scores_gemma":[0.99803066,0.00020616665,0.0003380939,0.0009909637,0.00035004367,0.0000061010933,0.0000030635297,0.000012797033,0.00006211148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661714,0.0003501268,0.0022243808,0.00023134831,0.000322756,0.00025427935],"domain_scores_gemma":[0.9966582,0.00082450366,0.0017034573,0.00015480023,0.00033594813,0.00032310517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010284814,0.0001847349,0.001915679,0.00022772445,0.000024623228,0.0000036998451,0.000098662684,0.0002006159,0.000049930943],"category_scores_gemma":[0.0005547638,0.00012441652,0.00013426215,0.00021039786,0.00014238793,0.00011557496,0.000026101381,0.00079869846,0.0000016663397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05019672,0.064645395,0.5813077,0.000026794329,0.00042011574,0.001121206,0.001049723,0.000032085176,0.00035675286,0.000007702866,0.00039548895,0.3004403],"study_design_scores_gemma":[0.10730536,0.2595401,0.6310833,0.00009293441,0.00042202382,0.00007837802,0.00034634725,0.000025419677,0.000062240004,0.00008636255,0.0008746597,0.00008283424],"about_ca_topic_score_codex":0.00003698732,"about_ca_topic_score_gemma":0.00013132657,"teacher_disagreement_score":0.3003575,"about_ca_system_score_codex":0.0001547482,"about_ca_system_score_gemma":0.0006399765,"threshold_uncertainty_score":0.5073558},"labels":[],"label_agreement":null},{"id":"W2375203420","doi":"10.1200/jco.2006.24.18_suppl.5084","title":"Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Sorafenib; Clinical endpoint; Internal medicine; Phases of clinical research; Refractory (planetary science); Ovarian cancer; Oncology; Gastroenterology; Cancer; Clinical trial; Surgery; Hepatocellular carcinoma","score_opus":0.09325489722830269,"score_gpt":0.4701086753564609,"score_spread":0.37685377812815823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2375203420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869114,0.00042545723,0.000027002226,0.008965702,0.001666015,0.0015910402,0.000029308885,0.000006734903,0.00037730258],"genre_scores_gemma":[0.9976004,0.00037190443,0.0004059018,0.00023974598,0.0011755221,0.00009644577,0.0000131485485,0.00002058986,0.000076343065],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941955,0.0006896261,0.003918274,0.00033796768,0.000549195,0.00030941874],"domain_scores_gemma":[0.99555016,0.00095792743,0.002588376,0.00023661529,0.00044134448,0.00022555182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002968968,0.00023296534,0.0023293856,0.00040508906,0.00005780856,0.000007447823,0.0001462458,0.00027412514,0.00019299604],"category_scores_gemma":[0.00068921276,0.00016211918,0.00027311422,0.0004323897,0.00017209518,0.00012491948,0.00005491813,0.0008969902,0.0000014220069],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32887927,0.39238352,0.07474184,0.000032068114,0.00051660626,0.0018403415,0.0005515731,0.00009989496,0.00008908641,0.0002699302,0.001015202,0.19958068],"study_design_scores_gemma":[0.5810528,0.33888096,0.07169667,0.00024214768,0.0006397579,0.000041438685,0.0001789124,0.00011217033,0.00009590895,0.00018329325,0.0067655877,0.000110373985],"about_ca_topic_score_codex":0.0011405635,"about_ca_topic_score_gemma":0.006793523,"teacher_disagreement_score":0.25217354,"about_ca_system_score_codex":0.00056493777,"about_ca_system_score_gemma":0.0027040327,"threshold_uncertainty_score":0.66110283},"labels":[],"label_agreement":null},{"id":"W2382331405","doi":"10.1200/jco.2015.33.7_suppl.139","title":"Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Cabazitaxel; Enzalutamide; Urology; Prednisone; Oncology; Cancer; Gastroenterology; Randomized controlled trial; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.23504232106123368,"score_gpt":0.48438863708896096,"score_spread":0.24934631602772728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2382331405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956667,0.00252889,0.000006646971,0.0008427754,0.000120455865,0.0006369296,0.00007164066,0.0000053596427,0.00012058943],"genre_scores_gemma":[0.9940377,0.0039731977,0.0014071588,0.00007949541,0.000058122543,0.000027553268,0.000029408435,0.000017189599,0.0003702162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633616,0.00049207464,0.0019753422,0.00029126278,0.00057376776,0.00033137354],"domain_scores_gemma":[0.99590117,0.0010657113,0.0014205745,0.00016722335,0.0009300781,0.00051522546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019514596,0.00020952709,0.0020927538,0.00043928242,0.00003368887,0.000019717489,0.00009413657,0.0001502387,0.000049185484],"category_scores_gemma":[0.0011237322,0.000118708456,0.00015504542,0.000772021,0.00043276558,0.00019659863,0.00004646607,0.00048474857,6.741995e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14920783,0.002558464,0.8105881,0.00015108341,0.0044040647,0.00078720384,0.0008435394,0.00016864302,0.00018986828,0.0000085575275,0.00017947747,0.030913172],"study_design_scores_gemma":[0.07792339,0.04553999,0.8684732,0.0002879293,0.0056358986,0.00003937923,0.00059349247,0.00049236853,0.00020710696,0.00001843678,0.0006455524,0.0001432778],"about_ca_topic_score_codex":0.00062200194,"about_ca_topic_score_gemma":0.0032231384,"teacher_disagreement_score":0.07128445,"about_ca_system_score_codex":0.00022865357,"about_ca_system_score_gemma":0.002284281,"threshold_uncertainty_score":0.48407903},"labels":[],"label_agreement":null},{"id":"W2382461064","doi":"10.1200/jco.2013.31.15_suppl.cra9003","title":"Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"GNAQ; Medicine; Temozolomide; Melanoma; Selumetinib; Internal medicine; Oncology; Cancer; Cancer research; Mutation; Chemotherapy; Colorectal cancer","score_opus":0.11766408194807756,"score_gpt":0.4830187535876331,"score_spread":0.3653546716395555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2382461064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063253,0.0002488201,0.0000066804096,0.0031994286,0.0020918106,0.00089766906,0.00000440002,0.000013474859,0.0029051944],"genre_scores_gemma":[0.9967421,0.00015058366,0.0015586184,0.0005712395,0.00060640665,0.000022288143,0.0000046814444,0.000027330978,0.0003167128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99357814,0.0012116743,0.0039171576,0.00035443075,0.0004958682,0.00044274094],"domain_scores_gemma":[0.9929118,0.003205183,0.0024388132,0.000388531,0.0005234219,0.00053222285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00330978,0.00027482564,0.0028075017,0.00033270355,0.000077898585,0.0000063482785,0.00030582128,0.00075602095,0.00074510975],"category_scores_gemma":[0.0036582435,0.00019765785,0.00055010535,0.00030419233,0.0003202091,0.00018924366,0.0001468753,0.0014004292,0.00009484011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031646017,0.1161228,0.61526203,0.000040934938,0.0026787363,0.008763924,0.001125134,0.000012915213,0.0006325275,0.00006942903,0.0024564748,0.22118908],"study_design_scores_gemma":[0.20412199,0.37201276,0.40677533,0.00010573624,0.0016793173,0.0005771712,0.002146394,0.00009984397,0.00026840233,0.00023223892,0.011776781,0.00020401727],"about_ca_topic_score_codex":0.00027142494,"about_ca_topic_score_gemma":0.00063159154,"teacher_disagreement_score":0.25588998,"about_ca_system_score_codex":0.00028454055,"about_ca_system_score_gemma":0.0014350236,"threshold_uncertainty_score":0.8158429},"labels":[],"label_agreement":null},{"id":"W23939810","doi":"10.1200/jco.2010.28.15_suppl.e12521","title":"Temozolomide in combination with stereotactic radiosurgery for recurrent brain metastases: A phase I study.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); McGill University Health Centre","funders":"","keywords":"Medicine; Temozolomide; Radiosurgery; Clinical endpoint; Brain metastasis; Phases of clinical research; Melanoma; Nuclear medicine; Internal medicine; Clinical trial; Chemotherapy; Radiation therapy; Surgery; Oncology; Cancer; Metastasis","score_opus":0.1261825681617578,"score_gpt":0.4992786796051316,"score_spread":0.37309611144337385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23939810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98477894,0.00012481862,0.00043049696,0.012206028,0.0012886424,0.0010582457,0.000010633356,0.0000062648865,0.000095915864],"genre_scores_gemma":[0.9886304,0.000033836794,0.009582916,0.0012102674,0.0004158287,0.000036997582,0.000010426697,0.000018480498,0.00006085973],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99643105,0.00071507355,0.0021009156,0.00021665294,0.0003101597,0.00022611789],"domain_scores_gemma":[0.99057007,0.0069846534,0.0015514537,0.00022027915,0.0003528948,0.00032066394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009299563,0.00015550993,0.0015928473,0.00024456196,0.000033430682,0.000012320913,0.00009604249,0.00015808857,0.00008068855],"category_scores_gemma":[0.0066109053,0.00009483478,0.00038081867,0.00017495952,0.00011232536,0.00012778775,0.000018717852,0.0009912081,0.0000033303352],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053787872,0.075916275,0.13225076,0.00006829652,0.0018080645,0.0040445826,0.00027435878,0.0000042362276,0.00013793059,0.00040894796,0.006080183,0.7252185],"study_design_scores_gemma":[0.23949052,0.37616515,0.25204515,0.00019127816,0.0028175323,0.0025201638,0.0010413405,0.0003287701,0.00010128765,0.00095186615,0.12406975,0.0002771834],"about_ca_topic_score_codex":0.000012223862,"about_ca_topic_score_gemma":0.00026265794,"teacher_disagreement_score":0.7249413,"about_ca_system_score_codex":0.00010513989,"about_ca_system_score_gemma":0.0011405691,"threshold_uncertainty_score":0.7914349},"labels":[],"label_agreement":null},{"id":"W2396153198","doi":"10.1200/jco.2006.24.18_suppl.4631","title":"Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Tolerability; Neutropenia; Prostate cancer; Febrile neutropenia; Internal medicine; Clinical endpoint; Adverse effect; Nausea; Phases of clinical research; Oncology; Chemotherapy; Urology; Surgery; Gastroenterology; Cancer; Clinical trial","score_opus":0.08346536495370124,"score_gpt":0.4967239650883408,"score_spread":0.41325860013463955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396153198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873801,0.007993557,0.00004403839,0.0024985145,0.00050176703,0.001462573,0.000041372914,0.0000068188197,0.000071300485],"genre_scores_gemma":[0.9810031,0.017048337,0.0004186773,0.00017746621,0.00071355083,0.000055999884,0.000016947462,0.000019070885,0.00054685946],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711514,0.00037076094,0.0016716167,0.00021848816,0.00038352516,0.00024046168],"domain_scores_gemma":[0.99669284,0.00087744725,0.0015372649,0.0001425089,0.00052147784,0.00022846018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018390539,0.00014725912,0.0013216216,0.00013763247,0.00011285159,0.000008707039,0.00009162603,0.00021539147,0.00006916198],"category_scores_gemma":[0.00044011656,0.0000860446,0.00020411251,0.00011935461,0.00017182216,0.000109745495,0.00003904789,0.00043710927,7.349734e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10796746,0.015004804,0.074822776,0.000060499246,0.00090958533,0.00023793831,0.00096124486,0.000091151545,0.0017436182,0.000025519304,0.005077429,0.793098],"study_design_scores_gemma":[0.4977951,0.3438029,0.08470918,0.00019559289,0.0012707505,0.00009430972,0.0007509209,0.00085962005,0.008154274,0.002460334,0.05969397,0.00021302908],"about_ca_topic_score_codex":0.00072698906,"about_ca_topic_score_gemma":0.00009254045,"teacher_disagreement_score":0.79288495,"about_ca_system_score_codex":0.00015968029,"about_ca_system_score_gemma":0.0013903116,"threshold_uncertainty_score":0.3508797},"labels":[],"label_agreement":null},{"id":"W2397736565","doi":"10.1200/jco.2013.31.31_suppl.197","title":"High-needs hematology/oncology patients: A quality improvement project.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Emergency department; Cohort; Psychological intervention; Emergency medicine; Internal medicine; Family medicine; Nursing","score_opus":0.1572680980577798,"score_gpt":0.5089790896348976,"score_spread":0.35171099157711777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397736565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95079505,0.00016862474,0.00015553141,0.01869176,0.0028365036,0.00109361,0.0000044533517,0.000036285168,0.026218185],"genre_scores_gemma":[0.98635197,0.0002800584,0.0036114897,0.0075734747,0.0011590108,0.00005285812,0.0000138135265,0.000024668709,0.0009326818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99371886,0.0006765979,0.0043035247,0.0002731862,0.0005707687,0.00045705045],"domain_scores_gemma":[0.99296105,0.00176241,0.0032928775,0.0003933107,0.0011191117,0.00047122777],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031941743,0.00023442657,0.0023630685,0.00032238735,0.00004878125,0.000022466043,0.0003157758,0.00053490547,0.0013595073],"category_scores_gemma":[0.0042063463,0.00016377031,0.0006525463,0.00026569745,0.0004344676,0.00028517997,0.00020378311,0.0010701477,0.00020490658],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049108667,0.018503867,0.11027234,0.00044588625,0.0022470017,0.00053375907,0.0002746396,0.000006817098,0.0001600058,0.017277619,0.25945672,0.58591044],"study_design_scores_gemma":[0.039322574,0.06003966,0.5452524,0.00015633077,0.0011893641,0.00013637119,0.002670181,0.000049201633,0.00007177892,0.0065649454,0.3441918,0.00035540768],"about_ca_topic_score_codex":0.0002367256,"about_ca_topic_score_gemma":0.000033206208,"teacher_disagreement_score":0.5855551,"about_ca_system_score_codex":0.0005680185,"about_ca_system_score_gemma":0.003320275,"threshold_uncertainty_score":0.9995534},"labels":[],"label_agreement":null},{"id":"W2399551246","doi":"10.1200/jco.2005.23.16_suppl.7233","title":"Bimodality versus trimodality therapy for locally advanced non-small cell lung cancer (NSCLC) at the British Columbia Cancer Agency: Favorable outcomes and low treatment-related mortality with multidisciplinary patient selection","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Radiation therapy; Surgery; Cancer; Retrospective cohort study; Lung cancer; Induction chemotherapy; Stage (stratigraphy); Performance status; Chemotherapy; Internal medicine","score_opus":0.04526821462993005,"score_gpt":0.43913695265222485,"score_spread":0.39386873802229483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399551246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078685,0.0030197292,0.00015381513,0.0028705113,0.00084446743,0.0018185407,0.00010060144,0.000016421076,0.00038905462],"genre_scores_gemma":[0.99045193,0.0052901395,0.0011233628,0.00052527746,0.0002751305,0.00029646413,0.000017162758,0.000029131315,0.0019913714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974531,0.00023255557,0.0013860012,0.00035984753,0.00025526911,0.00031320838],"domain_scores_gemma":[0.9967375,0.0009022377,0.001335041,0.00019106503,0.00054386014,0.00029030576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068818335,0.00019694943,0.001113219,0.000025300767,0.000465904,0.000057674817,0.00008373025,0.00025609654,0.00017597825],"category_scores_gemma":[0.00011381058,0.00013701705,0.00038867816,0.0001449847,0.00020845467,0.00015380254,0.000028696846,0.0003507846,6.920027e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006141912,0.002617555,0.7421035,0.000033941564,0.0019703726,0.00003862015,0.0004508202,0.0010197234,0.00009924768,7.340596e-7,0.000670078,0.24485347],"study_design_scores_gemma":[0.051419,0.014272184,0.9263963,0.00014381699,0.002005964,0.000034240744,0.00017376084,0.0015142944,0.0001854259,0.000030012417,0.0036621357,0.00016284733],"about_ca_topic_score_codex":0.015686003,"about_ca_topic_score_gemma":0.14213511,"teacher_disagreement_score":0.24469063,"about_ca_system_score_codex":0.0014331666,"about_ca_system_score_gemma":0.0057971803,"threshold_uncertainty_score":0.999839},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":true,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2400126805","doi":"10.1200/jco.2015.65.3469","title":"Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Medicine; Vincristine; Cyclophosphamide; Stage (stratigraphy); Chemotherapy; Prednisone; Cohort; Surgery; Internal medicine; Lymphoma; Radiation therapy; Gastroenterology","score_opus":0.05331043239669568,"score_gpt":0.39750194928583704,"score_spread":0.34419151688914135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400126805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98499596,0.004545622,0.000060721468,0.007286365,0.001802399,0.0005381372,0.000074090494,0.000013920407,0.0006828053],"genre_scores_gemma":[0.9689442,0.023020238,0.002838433,0.00052787486,0.0044234693,0.00003596809,0.000012705337,0.000032294913,0.00016480705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99293995,0.0011379962,0.0044091656,0.00048139543,0.000590504,0.00044101063],"domain_scores_gemma":[0.9793788,0.013097238,0.005861396,0.00068583275,0.00042934832,0.0005473944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026455305,0.00035597506,0.002981926,0.00014577858,0.00008927361,0.000008783911,0.0003220635,0.00068705034,0.00030178498],"category_scores_gemma":[0.00453945,0.00015037972,0.0016153943,0.00019472442,0.00047634818,0.000098612996,0.00010045848,0.00019521176,0.000070554146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006196302,0.011258626,0.55699855,0.000004510956,0.001188508,0.0046493826,0.000102030346,5.4230793e-7,0.000057262016,0.000021698637,0.0035720805,0.41595054],"study_design_scores_gemma":[0.05557016,0.03914991,0.8508527,0.000092791626,0.003266555,0.0038741415,0.00006916457,0.000004855578,0.00047921686,0.00016673525,0.046333563,0.00014015881],"about_ca_topic_score_codex":0.0006787198,"about_ca_topic_score_gemma":0.00015226506,"teacher_disagreement_score":0.41581038,"about_ca_system_score_codex":0.0017451091,"about_ca_system_score_gemma":0.0048666573,"threshold_uncertainty_score":0.8633241},"labels":[],"label_agreement":null},{"id":"W2400393648","doi":"10.1200/jco.2015.33.15_suppl.tps4153","title":"<i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Interim analysis; Randomization; Internal medicine; Clinical endpoint; Adjuvant; Oncology; Pancreatic cancer; Cancer; Surgery; Clinical trial","score_opus":0.3161654030209988,"score_gpt":0.5648967411479329,"score_spread":0.24873133812693404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400393648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697676,0.0034023789,0.00037100303,0.016743207,0.0020280008,0.0032609666,0.000048633894,0.00003040621,0.004347857],"genre_scores_gemma":[0.9753225,0.0055095917,0.00439125,0.0029164767,0.0048605716,0.0005432842,0.0000426689,0.000078151395,0.0063354913],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905126,0.001470538,0.0052849883,0.0006057669,0.0010438522,0.0010822242],"domain_scores_gemma":[0.9856381,0.007880656,0.0024622825,0.00058434455,0.0015403418,0.0018942743],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0096836155,0.00047981748,0.006662425,0.0005388908,0.00010201592,0.000025606654,0.00040724588,0.0010609081,0.00051920285],"category_scores_gemma":[0.01898106,0.0003239459,0.0010227172,0.00051273336,0.0006138447,0.00022851549,0.00010962832,0.0015728717,0.000051701285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86213577,0.014750387,0.03142174,0.00010068099,0.0022245904,0.0035499143,0.0010895301,0.000037346505,0.0004671227,0.000102380676,0.032358997,0.051761515],"study_design_scores_gemma":[0.69477576,0.19093494,0.0101173995,0.0003805968,0.0028482615,0.00065954344,0.0007551323,0.0025649038,0.0001090178,0.0013584779,0.09517386,0.00032210667],"about_ca_topic_score_codex":0.001391314,"about_ca_topic_score_gemma":0.0012337205,"teacher_disagreement_score":0.17618456,"about_ca_system_score_codex":0.0026759717,"about_ca_system_score_gemma":0.017803937,"threshold_uncertainty_score":0.99992126},"labels":[],"label_agreement":null},{"id":"W2400927555","doi":"10.1200/jco.2016.66.5844","title":"Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CH</i><i>EK</i><i>2</i>*1100delC Carriers","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research and Materiel Command; David Geffen School of Medicine, University of California, Los Angeles; National Cancer Institute; Universitätsklinikum Hamburg-Eppendorf; Erasmus Universitair Medisch Centrum Rotterdam; Russian Academy of Sciences; Cancer Council South Australia; National Health and Medical Research Council; Medical Research Council; University of California, Los Angeles; U.S. Army; School of Medicine, Stanford University; National Institutes of Health; Universitätsklinikum Köln; Universität zu Köln; Deutsche Gesetzliche Unfallversicherung; Gentofte Hospital; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Technische Universität München; Sundhed og Sygdom, Det Frie Forskningsråd; Universitetet i Oslo; Leids Universitair Medisch Centrum; Karolinska Institutet; University of Oxford; Deutsche Krebshilfe; Medizinischen Hochschule Hannover; University of Toronto; Cancer Council NSW; Susan G. Komen for the Cure; Universität Heidelberg; Universiteit van Amsterdam; Cancer Council Victoria; University of Melbourne; London School of Hygiene and Tropical Medicine; Eberhard Karls Universität Tübingen; Universiteit Leiden; Kuopion Yliopistollinen Sairaala; Robert Bosch Stiftung; Bundesministerium für Bildung und Forschung; National Breast Cancer Foundation; QIMR Berghofer Medical Research Institute; Norges Forskningsråd; Pomorski Uniwersytet Medyczny W Szczecinie; Vrije Universiteit Amsterdam; Agency for Science, Technology and Research; King's College London; National Institute for Health and Care Research; Itä-Suomen Yliopisto; Lon V. Smith Foundation; Stockholms Läns Landsting; KWF Kankerbestrijding; Herlev Hospital; Cancer Research UK; Memorial Sloan-Kettering Cancer Center; Wellcome Trust; University of California, Irvine; Kreftforeningen; David F. and Margaret T. Grohne Family Foundation; Deutsches Krebsforschungszentrum; Helsingin ja Uudenmaan Sairaanhoitopiiri; Cancerfonden; U.S. Department of Health and Human Services; Mayo Clinic; Breast Cancer Research Foundation; Cancer Council Tasmania; Francis Crick Institute; Helsingin Yliopisto","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.04383019259390165,"score_gpt":0.3982020059877211,"score_spread":0.35437181339381946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400927555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97760373,0.005877855,0.0058867866,0.0067721433,0.0029255804,0.00025842167,0.00030687943,0.000008750756,0.00035983097],"genre_scores_gemma":[0.97628266,0.0070828027,0.0118390415,0.0015419411,0.0028803078,0.0000341088,0.000005218297,0.00004168228,0.00029223526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977659,0.00019826647,0.0012459271,0.00033742844,0.0001616967,0.00029078277],"domain_scores_gemma":[0.9967718,0.00083162944,0.001336117,0.0002441525,0.00052899844,0.00028726785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016610405,0.00017769677,0.0006742743,0.00005500508,0.00009007545,0.000020986445,0.00027090762,0.00032166348,0.00007110067],"category_scores_gemma":[0.0014366218,0.00011683733,0.00032292647,0.00006726866,0.0004924634,0.0000140337215,0.00008785914,0.00026509917,0.0000040242116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006357395,0.00046233909,0.14488332,0.00004450556,0.0012816347,0.00014626811,0.0000898631,0.0001492556,0.10711814,0.00019456803,0.14518443,0.5940883],"study_design_scores_gemma":[0.0077310456,0.0036340063,0.10140018,0.000077529985,0.00038357617,0.0005511043,0.00008729729,0.00002696866,0.011643884,0.0018691941,0.872248,0.00034724193],"about_ca_topic_score_codex":0.000017221384,"about_ca_topic_score_gemma":0.00009475123,"teacher_disagreement_score":0.72706354,"about_ca_system_score_codex":0.000115046845,"about_ca_system_score_gemma":0.0013697799,"threshold_uncertainty_score":0.4764488},"labels":[],"label_agreement":null},{"id":"W2400932267","doi":"10.1200/jco.2001.19.18.3795","title":"Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Citation; Medicine; Clinical Oncology; Breast cancer; Oncology; Cancer; Internal medicine; Library science","score_opus":0.3115095867459364,"score_gpt":0.5702496648245066,"score_spread":0.2587400780785702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400932267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09961685,0.0013694378,0.000049382103,0.8952749,0.0019254519,0.0012888869,0.00022620527,0.0000072088856,0.00024167616],"genre_scores_gemma":[0.018732114,0.058034714,0.006217168,0.8728094,0.03908669,0.00008431318,0.000028161492,0.00019282095,0.004814603],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933007,0.00081477186,0.003723821,0.00048846053,0.0009119313,0.00076031015],"domain_scores_gemma":[0.98638964,0.009558093,0.0018214816,0.0003853517,0.0013306923,0.00051473285],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0038312795,0.00035439548,0.0037854775,0.00062361866,0.000029544468,0.000021360682,0.0004168587,0.0014057396,0.00073503226],"category_scores_gemma":[0.004476731,0.00025874184,0.00062981306,0.00040043658,0.00031980738,0.00014438214,0.000099948295,0.0055910037,0.0000045177308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011581924,0.0005581209,0.02732311,0.00023717785,0.00054691284,0.0025443116,0.00010490624,0.000012785571,0.00014757644,0.0000031642867,0.77845055,0.17848948],"study_design_scores_gemma":[0.010109122,0.016548408,0.037890386,0.0008464818,0.00020047053,0.0019414674,0.00001894054,0.000018616656,0.000054401957,0.00009568752,0.9320783,0.00019773857],"about_ca_topic_score_codex":0.0006089751,"about_ca_topic_score_gemma":0.00075057254,"teacher_disagreement_score":0.17829174,"about_ca_system_score_codex":0.0006819207,"about_ca_system_score_gemma":0.005841567,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W2402233591","doi":"10.1200/jco.2016.67.0182","title":"Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Trastuzumab; Oncology; Docetaxel; Internal medicine; Guideline; Breast cancer; Taxane; Regimen; Carboplatin; Context (archaeology); Population; Anthracycline; Cancer; Gynecology; Chemotherapy; Pathology; Cisplatin","score_opus":0.1880175702403382,"score_gpt":0.5514264082407141,"score_spread":0.36340883800037593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402233591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329226,0.0007421565,0.012171488,0.048815522,0.0015765716,0.0029542288,0.0007120868,0.000016271726,0.00008907947],"genre_scores_gemma":[0.75926214,0.00762028,0.22333966,0.0057803537,0.0036120568,0.00010765647,0.000045619043,0.000095746,0.00013648567],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9857831,0.0028379154,0.009220058,0.00073130353,0.0008825757,0.000545053],"domain_scores_gemma":[0.96223456,0.013131504,0.011896664,0.00041848846,0.011749666,0.0005691337],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013102326,0.00038251103,0.004139156,0.00012355456,0.0001319188,0.000007853254,0.00048637573,0.00091737614,0.00030238484],"category_scores_gemma":[0.010687575,0.00022738789,0.0016564255,0.00031806013,0.00226991,0.0003214072,0.00009678935,0.0015335,3.6410424e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06594611,0.0035838727,0.121072486,0.000109341614,0.0028614192,0.0000065141126,0.0035146773,0.00007741615,0.00469206,0.00003460938,0.02716114,0.77094036],"study_design_scores_gemma":[0.061756637,0.1823955,0.5112915,0.00079109933,0.0014287973,0.000158994,0.009443157,0.002335298,0.008310781,0.00016828006,0.22142866,0.00049127836],"about_ca_topic_score_codex":0.022106655,"about_ca_topic_score_gemma":0.023698114,"teacher_disagreement_score":0.7704491,"about_ca_system_score_codex":0.0016789504,"about_ca_system_score_gemma":0.018711917,"threshold_uncertainty_score":0.9976458},"labels":[],"label_agreement":null},{"id":"W2403580696","doi":"10.1200/jco.2007.25.18_suppl.2011","title":"PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Glioma; Placebo; Randomized controlled trial; Hazard ratio; Low molecular weight heparin; Surgery; Internal medicine; Heparin; Confidence interval; Pathology","score_opus":0.03166533641121666,"score_gpt":0.3914233907369025,"score_spread":0.35975805432568586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403580696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884003,0.00018387233,0.0017911152,0.00049886224,0.0013652124,0.00685948,0.0000025119098,0.000010553513,0.00088810833],"genre_scores_gemma":[0.99387634,0.00015743208,0.0047885706,0.0004937746,0.0005516456,0.000060638664,0.0000060067478,0.000041603897,0.0000239894],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903511,0.0011668388,0.0064697335,0.00040988706,0.0010406979,0.0005617336],"domain_scores_gemma":[0.990154,0.0032705648,0.0049684457,0.0004091066,0.0007347389,0.00046313065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01365159,0.00034939093,0.007911976,0.0006221848,0.000050351846,0.000015175609,0.00027889607,0.0004364446,0.00009470595],"category_scores_gemma":[0.005398558,0.00021633052,0.0011470595,0.0004515268,0.0004114269,0.00015184257,0.0001015926,0.00082547386,0.0000034791033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9377938,0.035971943,0.00449208,0.00008165461,0.0019373143,0.0025974272,0.00019285962,0.00015570244,0.00033702858,0.00016677188,0.00014523265,0.016128186],"study_design_scores_gemma":[0.94514257,0.036000885,0.014946881,0.00041530587,0.0019408312,0.000026992768,0.000059866547,0.00038721264,0.00047354324,0.0001301857,0.0002711843,0.00020455351],"about_ca_topic_score_codex":0.00020490008,"about_ca_topic_score_gemma":0.00009547937,"teacher_disagreement_score":0.015923632,"about_ca_system_score_codex":0.00027197323,"about_ca_system_score_gemma":0.0013594314,"threshold_uncertainty_score":0.88217026},"labels":[],"label_agreement":null},{"id":"W2404692795","doi":"10.1200/jco.2015.65.7171","title":"Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Internal medicine; Hazard ratio; Placebo; Oncology; International Prognostic Index; Rituximab; Clinical endpoint; Diffuse large B-cell lymphoma; Gastroenterology; Cyclophosphamide; Maintenance therapy; Cumulative incidence; Surgery; Lymphoma; Randomized controlled trial; Chemotherapy; Transplantation; Confidence interval; Pathology","score_opus":0.08525202088888015,"score_gpt":0.42642757468919085,"score_spread":0.3411755538003107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404692795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924924,0.00040550693,0.00019803719,0.0020104288,0.0021568476,0.0025698876,0.00003939672,0.000006577252,0.00012091643],"genre_scores_gemma":[0.9923393,0.005412205,0.0006457387,0.00024002163,0.0010516266,0.00016417654,0.000009273313,0.000027444936,0.00011021917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994563,0.0006949363,0.0036715693,0.0002905205,0.0004390261,0.00034094165],"domain_scores_gemma":[0.9838414,0.012036146,0.003100725,0.0002829164,0.00037769278,0.00036107373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005031694,0.00024884462,0.002878804,0.00021061451,0.00004434269,0.0000071802665,0.00015708328,0.00047570182,0.00010032395],"category_scores_gemma":[0.003649469,0.00012515942,0.0010932292,0.000098698256,0.00014041281,0.00012472572,0.000058585603,0.0002249166,0.0000054013863],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7623263,0.075477384,0.020883866,0.000018526736,0.00042161503,0.000088180124,0.00006997849,5.687031e-7,0.000008398587,0.000017892644,0.00030318863,0.14038412],"study_design_scores_gemma":[0.92353547,0.056135885,0.0100383535,0.00027149692,0.00074182195,0.0000042571205,0.00001420218,0.000013869187,0.00057101686,0.00006802895,0.008487444,0.0001181734],"about_ca_topic_score_codex":0.000026121692,"about_ca_topic_score_gemma":0.000051916628,"teacher_disagreement_score":0.16120917,"about_ca_system_score_codex":0.0003543586,"about_ca_system_score_gemma":0.00072589796,"threshold_uncertainty_score":0.5103853},"labels":[],"label_agreement":null},{"id":"W2406217810","doi":"10.1200/jco.2016.34.2_suppl.179","title":"Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Androgen receptor; Internal medicine; Oncology; Urology; Androgen deprivation therapy; Dehydroepiandrosterone; Cancer; Chemotherapy; Androgen; Hormone","score_opus":0.13692311142152444,"score_gpt":0.465408239570739,"score_spread":0.3284851281492146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406217810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9275219,0.0023830205,0.000017556033,0.06766509,0.00075789425,0.0006472439,0.00026200124,0.000009171224,0.000736158],"genre_scores_gemma":[0.98850095,0.0073742056,0.0006022915,0.000784788,0.00091891346,0.00003448304,0.000022547492,0.000024042198,0.0017377549],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99512434,0.0008128998,0.0027264652,0.00032212524,0.0005847442,0.00042943493],"domain_scores_gemma":[0.9909874,0.006466932,0.0013986382,0.00033337806,0.0004154951,0.00039816363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036102186,0.00020314471,0.0012830948,0.00011505961,0.00008000046,0.000021366352,0.00026889602,0.00020074868,0.00012807436],"category_scores_gemma":[0.0031772638,0.000089999114,0.00028464745,0.00020764116,0.000491252,0.00020927702,0.00008578278,0.000870803,0.00003435847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2480444,0.0042417003,0.29138222,0.00007444298,0.0016429431,0.008492278,0.0018641239,0.00006492254,0.007974483,0.00004122206,0.044363,0.39181426],"study_design_scores_gemma":[0.06179132,0.034196522,0.84949374,0.0013834374,0.00069295074,0.00033028887,0.0008542073,0.000067791385,0.0011195489,0.0006640656,0.049197033,0.00020908772],"about_ca_topic_score_codex":0.00083663856,"about_ca_topic_score_gemma":0.0039800727,"teacher_disagreement_score":0.55811155,"about_ca_system_score_codex":0.00046778147,"about_ca_system_score_gemma":0.0035680227,"threshold_uncertainty_score":0.6329519},"labels":[],"label_agreement":null},{"id":"W2406780605","doi":"10.1200/jco.2009.27.15_suppl.8039","title":"Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Neutropenia; Placebo; Internal medicine; Gemcitabine; Bevacizumab; Adverse effect; Clinical endpoint; Gastroenterology; Phases of clinical research; Surgery; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.04465509602666898,"score_gpt":0.4493318156673473,"score_spread":0.4046767196406783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406780605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445045,0.00074514287,0.0001996731,0.0011187211,0.00037664623,0.002457285,0.00006300661,0.0000048003576,0.00058428023],"genre_scores_gemma":[0.99516314,0.0016973855,0.002572419,0.00017164307,0.00015127077,0.000035231024,0.00001879211,0.000016499676,0.00017362522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943867,0.00036941317,0.004231182,0.0003192367,0.0004344848,0.00025901903],"domain_scores_gemma":[0.99300164,0.002081286,0.0035437667,0.00024315422,0.0008497305,0.0002804506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017880986,0.0002527954,0.0031208515,0.00023253063,0.000049771246,0.0000044937287,0.0001279972,0.00019237153,0.000045559853],"category_scores_gemma":[0.0015099006,0.00014768331,0.00025692905,0.00030251849,0.00016724937,0.00011352248,0.000034987606,0.00061184424,3.2972554e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76651096,0.026564274,0.029584544,0.000095832766,0.00057410385,0.00021945177,0.0017460494,0.00039979536,0.000013638331,0.00000146949,0.00017854168,0.17411135],"study_design_scores_gemma":[0.7887407,0.10757202,0.0987974,0.0007479306,0.0023480076,0.000022229468,0.00032567873,0.0008667269,0.000034726407,0.000012440742,0.00040550975,0.00012663857],"about_ca_topic_score_codex":0.0001930574,"about_ca_topic_score_gemma":0.001459864,"teacher_disagreement_score":0.1739847,"about_ca_system_score_codex":0.0002857793,"about_ca_system_score_gemma":0.0014220135,"threshold_uncertainty_score":0.6022351},"labels":[],"label_agreement":null},{"id":"W2407327553","doi":"10.1200/jco.2014.32.15_suppl.tps8615","title":"A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Oncology; Rituximab; CHOP; Diffuse large B-cell lymphoma; Cyclophosphamide; Lymphoma; Chemotherapy; Chronic lymphocytic leukemia; Leukemia","score_opus":0.036916130827688375,"score_gpt":0.3859590774920135,"score_spread":0.34904294666432517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407327553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370617,0.0004350586,0.00019875163,0.00032451216,0.00019343515,0.004042871,0.0000054882453,0.000008842864,0.0010849036],"genre_scores_gemma":[0.9980373,0.00045165588,0.000888269,0.00017019719,0.00016450208,0.00009917517,0.000007848491,0.000050242947,0.00013080769],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99077666,0.0022238728,0.004714295,0.0005102861,0.0011607985,0.0006140799],"domain_scores_gemma":[0.98197204,0.012384391,0.0037726448,0.0004505396,0.00094387436,0.00047650124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011582868,0.0003980766,0.0057950662,0.0007262756,0.00003938156,0.00001821503,0.00032173953,0.000462487,0.000031392043],"category_scores_gemma":[0.004198484,0.00025276147,0.00033119574,0.0005891863,0.00061666756,0.00019509252,0.00012836557,0.0009925992,0.0000029591572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.790257,0.15586275,0.048118263,0.00029228692,0.0003459887,0.0018385987,0.00085431075,0.000029675679,0.00010385359,0.000023456472,0.000056665034,0.002217182],"study_design_scores_gemma":[0.9294102,0.05287841,0.008100301,0.0005002339,0.00081406423,0.00033927584,0.0006440511,0.006595395,0.00039137423,0.000026989657,0.00009491786,0.00020478838],"about_ca_topic_score_codex":0.0009779822,"about_ca_topic_score_gemma":0.002090629,"teacher_disagreement_score":0.13915323,"about_ca_system_score_codex":0.0013745647,"about_ca_system_score_gemma":0.0072329454,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W2409346424","doi":"10.1200/jco.2014.32.15_suppl.3000","title":"Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Refractory (planetary science); Clinical endpoint; Mallinckrodt; Clinical trial; Cancer; Immunotherapy; Family medicine","score_opus":0.07231325230553105,"score_gpt":0.4469057133558252,"score_spread":0.37459246105029415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409346424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207014,0.0015600916,0.0025661692,0.00051581004,0.0016012851,0.0004244138,0.000030143081,0.0000029944094,0.0012289749],"genre_scores_gemma":[0.99480313,0.0006702136,0.0028669524,0.00034242557,0.0011658818,0.000007513432,0.000014364959,0.00002178143,0.00010773152],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950808,0.0012995447,0.002767138,0.00029716533,0.00028277107,0.00027254145],"domain_scores_gemma":[0.9925041,0.0028511737,0.0035375638,0.00035812773,0.00054957904,0.00019945615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046069836,0.00023177224,0.0023892424,0.00007544985,0.000075175616,0.000009521377,0.00047474392,0.0005100248,0.000022120948],"category_scores_gemma":[0.0041064145,0.00014535624,0.0009974991,0.000067193694,0.00079518964,0.000013118941,0.00019193174,0.00045303168,0.0000012324082],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14205323,0.003590742,0.28353712,0.0002927309,0.002306146,0.000013835658,0.00044576603,0.00017293569,0.5163107,0.003068912,0.0057776743,0.042430237],"study_design_scores_gemma":[0.46801773,0.031412307,0.122126594,0.00034385544,0.0020662548,0.00023274135,0.00046610518,0.0022709032,0.2394758,0.0045552626,0.12825543,0.00077701244],"about_ca_topic_score_codex":0.000019279598,"about_ca_topic_score_gemma":0.00002674763,"teacher_disagreement_score":0.3259645,"about_ca_system_score_codex":0.000015232827,"about_ca_system_score_gemma":0.00062628504,"threshold_uncertainty_score":0.59274554},"labels":[],"label_agreement":null},{"id":"W2409359358","doi":"10.1200/jco.2016.34.3_suppl.e269","title":"Cognitive impairment and dementia in older cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dementia; Montreal Cognitive Assessment; Breast cancer; Cancer; Internal medicine; Malignancy; Depression (economics); Cognition; Psychiatry; Disease","score_opus":0.06803778689195594,"score_gpt":0.4559215713310946,"score_spread":0.3878837844391387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409359358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98519385,0.0011745848,0.0000536951,0.011141966,0.0009904195,0.0003569308,0.000009921064,0.000005017912,0.0010736107],"genre_scores_gemma":[0.99139535,0.005044003,0.00010898249,0.0027592923,0.00047679775,0.000015873777,5.943884e-7,0.000011598446,0.00018747585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754,0.00022186218,0.0015529303,0.0001786632,0.00027173015,0.00023482932],"domain_scores_gemma":[0.9963741,0.0017388448,0.0009591459,0.000050932114,0.000635906,0.0002411226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012625471,0.00012306657,0.00095325627,0.00014615325,0.000025317051,0.0000031076345,0.0000460882,0.00019029611,0.00038079274],"category_scores_gemma":[0.0022616566,0.00006959691,0.00018334202,0.000099571495,0.000287262,0.000110913985,0.00007077002,0.0004255809,0.000011500239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003127074,0.0017115253,0.7619249,0.000014984873,0.000566782,0.00009810439,0.000106304615,8.671416e-8,0.00001925465,0.0000050174417,0.003292287,0.22913367],"study_design_scores_gemma":[0.03238942,0.01162987,0.9473094,0.000861908,0.0006241488,0.00003202548,0.00013507396,0.0000018332685,0.000058844944,0.00010146391,0.0067742323,0.000081809194],"about_ca_topic_score_codex":0.000022272843,"about_ca_topic_score_gemma":0.00009985349,"teacher_disagreement_score":0.22905186,"about_ca_system_score_codex":0.00024877748,"about_ca_system_score_gemma":0.0006272653,"threshold_uncertainty_score":0.41694134},"labels":[],"label_agreement":null},{"id":"W2409515616","doi":"10.1200/jco.2012.30.15_suppl.9023","title":"Methylphenidate (MP) and nursing telephone intervention (NTI) for cancer-related fatigue (CRF) in advanced cancer patients: A double-blind randomized phase II trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Internal medicine; Cancer-related fatigue; Randomized controlled trial; Clinical endpoint; Breast cancer; Cancer; Physical therapy","score_opus":0.1755997938148669,"score_gpt":0.544786061668596,"score_spread":0.3691862678537291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409515616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764177,0.008377112,0.0006563566,0.0034777084,0.008700724,0.002102577,0.000014688663,0.000013022401,0.00024011724],"genre_scores_gemma":[0.99284863,0.003927154,0.0009082861,0.0005090645,0.0013348634,0.0002521254,0.000016452883,0.000028783294,0.00017460846],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949778,0.000713866,0.003400267,0.00023530365,0.00029784153,0.00037493932],"domain_scores_gemma":[0.9943766,0.0019381569,0.0025492536,0.00013173651,0.00059337384,0.0004108596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004816335,0.00020502594,0.0026372173,0.00025834012,0.000061942155,0.000010863309,0.0001074038,0.00044395594,0.00018094911],"category_scores_gemma":[0.0019123615,0.00015078095,0.00081758096,0.00026072512,0.00020491063,0.00034468263,0.000034831995,0.0008309701,7.2128546e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6601442,0.0062609892,0.0023881388,0.00005813233,0.0004476631,0.000005637351,0.0013956903,0.0000064444016,0.000057174268,0.000030535248,0.0002968066,0.32890856],"study_design_scores_gemma":[0.96729916,0.01503885,0.0014608768,0.0008941141,0.0015034196,0.000014854636,0.00030529898,0.00012143276,0.00025290763,0.00026715177,0.012687454,0.00015444699],"about_ca_topic_score_codex":0.00033755804,"about_ca_topic_score_gemma":0.0008474692,"teacher_disagreement_score":0.32875413,"about_ca_system_score_codex":0.00044946116,"about_ca_system_score_gemma":0.00065760576,"threshold_uncertainty_score":0.61486685},"labels":[],"label_agreement":null},{"id":"W2410528832","doi":"10.1200/jco.2016.66.7881","title":"Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Bacteremia; Poisson regression; Pneumonia; Incidence (geometry); Myeloid leukemia; Internal medicine; Neutropenia; Intensive care medicine; Randomized controlled trial; Antibiotics; Pediatrics; Environmental health; Chemotherapy; Population","score_opus":0.0740103076290985,"score_gpt":0.4388406558796,"score_spread":0.3648303482505015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410528832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998231,0.00006790553,0.00007533957,0.00056168094,0.0002669889,0.00047411313,0.000024596817,0.000003233853,0.0002951596],"genre_scores_gemma":[0.99899787,0.000584704,0.000034174518,0.00007539571,0.00027242873,0.000008995751,0.0000014334677,0.0000113023625,0.00001369923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629384,0.0014799885,0.0015345414,0.00019646357,0.000340234,0.00015494731],"domain_scores_gemma":[0.9955057,0.001614513,0.0019576785,0.00021306831,0.00059871527,0.00011035869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024295212,0.00013095398,0.0020020686,0.0003330811,0.00005389587,0.000003489615,0.0001608659,0.00028028025,0.000022119397],"category_scores_gemma":[0.0006619713,0.00006543011,0.00061443605,0.0007665007,0.0006615474,0.00014327856,0.000051817646,0.0005823043,4.213022e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073066995,0.0014426173,0.91015637,0.000017740176,0.005498861,0.000014317141,0.00008448528,0.00014912976,0.00496568,0.0002177683,0.000025055477,0.004360991],"study_design_scores_gemma":[0.04419606,0.022958035,0.92423123,0.000114152564,0.0065400307,0.00008636782,0.000046660603,0.0000024300964,0.001528889,0.00013519499,0.00009799275,0.00006294193],"about_ca_topic_score_codex":0.0005360453,"about_ca_topic_score_gemma":0.0007516689,"teacher_disagreement_score":0.028870933,"about_ca_system_score_codex":0.00025155832,"about_ca_system_score_gemma":0.0022789268,"threshold_uncertainty_score":0.4042718},"labels":[],"label_agreement":null},{"id":"W2411600241","doi":"10.1200/jco.2015.33.15_suppl.10569","title":"A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcoma; Internal medicine; Leiomyosarcoma; Gastroenterology; Pharmacodynamics; Neutropenia; Adverse effect; Phases of clinical research; Cancer; Pharmacokinetics; Oncology; Surgery; Chemotherapy; Pathology","score_opus":0.032360722516127934,"score_gpt":0.3802865582755736,"score_spread":0.3479258357594457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411600241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999304,0.00003087133,0.000047623427,0.000097777265,0.00013137802,0.0002544384,0.00000276077,0.0000023259536,0.00012880901],"genre_scores_gemma":[0.9979059,0.000012441074,0.0016679413,0.00017410498,0.00020136,0.0000019531203,0.000012784079,0.000017735416,0.000005790005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977524,0.0003492233,0.0012135966,0.0002633357,0.00025934388,0.0001620838],"domain_scores_gemma":[0.9979036,0.00008274631,0.001062401,0.00020634246,0.00055986503,0.00018505481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010828127,0.00013951589,0.00089780596,0.00019745938,0.000016475045,0.000005619066,0.00015073895,0.00022561522,0.0000054985794],"category_scores_gemma":[0.00056417566,0.0000934859,0.00012283665,0.0004418555,0.00010055507,0.000022420822,0.00003910299,0.0004195255,5.4072353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06485267,0.027520217,0.88903975,0.000005613293,0.0007975166,0.000097922275,0.00054918416,0.0011742488,0.00043940815,0.0000031259449,0.00028195255,0.015238372],"study_design_scores_gemma":[0.059204966,0.16438496,0.76964337,0.000020632426,0.00035369198,0.000010181372,0.00082120695,0.00012306195,0.00009035042,0.000008989036,0.005193297,0.00014530742],"about_ca_topic_score_codex":0.000021574533,"about_ca_topic_score_gemma":0.001248095,"teacher_disagreement_score":0.13686474,"about_ca_system_score_codex":0.000059585193,"about_ca_system_score_gemma":0.00042623965,"threshold_uncertainty_score":0.38122442},"labels":[],"label_agreement":null},{"id":"W2413116512","doi":"10.1200/jco.2016.34.2_suppl.92","title":"5α-reductase inhibitors and the risk of grade reclassification for men with long-term follow-up on active surveillance for prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Brampton Civic Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Hazard ratio; Internal medicine; Cohort; Prostate; Retrospective cohort study; Oncology; Cancer; Cohort study; Urology; Gynecology; Confidence interval","score_opus":0.11273512559925895,"score_gpt":0.4717229701598357,"score_spread":0.35898784456057675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413116512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582433,0.00067609537,0.0001736797,0.03867664,0.00051155325,0.0014824796,0.00012425373,0.000003501972,0.00010851147],"genre_scores_gemma":[0.98783845,0.00981426,0.00031844235,0.000118715034,0.0007317475,0.00014298657,0.0000058743594,0.000015727339,0.0010138003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981896,0.000341597,0.0008730025,0.00017968185,0.00022742219,0.00018865053],"domain_scores_gemma":[0.991765,0.0057861367,0.0015143834,0.00014103143,0.0006299534,0.00016344378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027319917,0.00010639838,0.0008394573,0.00006364674,0.0000670617,0.0000050703784,0.000085121086,0.00013435766,0.0000064934097],"category_scores_gemma":[0.0023684013,0.000040035684,0.00023750428,0.000074602634,0.00061840843,0.00006806882,0.000014910159,0.00026610246,3.557354e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2557552,0.0007278252,0.30688974,0.00010507731,0.0014019624,0.000018236857,0.00034372477,0.0000016678158,0.0011358025,0.00013235514,0.0052728616,0.42821553],"study_design_scores_gemma":[0.1482949,0.045447595,0.78129214,0.000671526,0.0009997711,0.00005124242,0.00028778592,0.000057617315,0.012213407,0.0016296105,0.008908986,0.0001453971],"about_ca_topic_score_codex":0.000021059315,"about_ca_topic_score_gemma":0.000095162664,"teacher_disagreement_score":0.4744024,"about_ca_system_score_codex":0.0001722751,"about_ca_system_score_gemma":0.0010903936,"threshold_uncertainty_score":0.28353685},"labels":[],"label_agreement":null},{"id":"W2413131438","doi":"10.1200/jco.2009.27.15_suppl.6576","title":"Patient out-of-pocket and insurer payment decisions for bevacizumab for metastatic colorectal cancer: A Canadian analysis","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Reimbursement; Bevacizumab; Receipt; Family medicine; Appeal; Medicaid; Health care; Finance; Internal medicine; Business; Accounting","score_opus":0.15259316666135053,"score_gpt":0.4171488468512136,"score_spread":0.2645556801898631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413131438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97757834,0.004313191,0.007161721,0.006697445,0.0015775346,0.0005069592,0.00095438823,0.000002621889,0.0012078254],"genre_scores_gemma":[0.9875217,0.0016935916,0.008168467,0.002269953,0.00025709617,0.000022952741,0.0000061724004,0.00001009374,0.00004997005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650204,0.00003561005,0.0028972814,0.00022659387,0.000039548268,0.00029894063],"domain_scores_gemma":[0.9949488,0.0015003864,0.002716896,0.000120699835,0.00028286775,0.00043036952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002186327,0.00012926324,0.0019213151,0.00043640647,0.000072196,0.00001994206,0.00016524685,0.00020091218,0.00009557417],"category_scores_gemma":[0.0034117845,0.00011802132,0.0007284354,0.00015814912,0.000088492525,0.00015858488,0.000015097236,0.0002081089,0.000002718291],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034318778,0.0011019816,0.09284594,0.00002412638,0.0038946238,0.000018822175,0.0011145923,0.0011457828,0.00000773008,0.029644545,0.014287534,0.85248244],"study_design_scores_gemma":[0.0073317424,0.014313502,0.391563,0.000035134355,0.0010231946,0.000007444848,0.0001499731,0.002471375,0.000031462787,0.0662753,0.5164627,0.00033519146],"about_ca_topic_score_codex":0.0018468304,"about_ca_topic_score_gemma":0.035135183,"teacher_disagreement_score":0.8521473,"about_ca_system_score_codex":0.0003238456,"about_ca_system_score_gemma":0.0010163466,"threshold_uncertainty_score":0.9824711},"labels":[],"label_agreement":null},{"id":"W2413224284","doi":"10.1200/jco.2015.65.7825","title":"Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; College of Medicine, Seoul National University; University of North Carolina at Chapel Hill; Rally Foundation; Medical Center, University of Pittsburgh; Chonnam National University Hwasun Hospital; University of Texas MD Anderson Cancer Center; National Institutes of Health; Lékařská fakulta, Masarykova univerzita; Pfizer; University of Washington; University of California, Los Angeles; Masarykova Univerzita; Hospital for Sick Children; Magyar Tudományos Akadémia; Erasmus Universitair Medisch Centrum Rotterdam; Genentech; Debreceni Egyetem; Chonnam National University; Semmelweis Egyetem; Medical School, University of Michigan; University of Cincinnati; University of Sydney; Making Headway Foundation; Sapienza Università di Roma; Emory University; Huntsman Cancer Institute; Children's National Hospital; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; Università degli Studi di Torino; Cincinnati Children's Hospital Medical Center; Alberta Innovates; Universidade de São Paulo; Children's Hospital of Philadelphia; NYU Langone Medical Center; CURE Childhood Cancer; University of Pittsburgh; Alex's Lemonade Stand Foundation for Childhood Cancer; Children's Hospital Los Angeles; National Cancer Institute; St. Baldrick's Foundation; Hudson Institute of Medical Research; York University; Università degli Studi di Napoli Federico II; Pediatric Brain Tumor Foundation; Vanderbilt University; Seattle Children's Research Institute; University of Pennsylvania; Deutsche Kinderkrebsstiftung; CERN; University of Toronto; Seoul National University","keywords":"Ependymoma; Medicine; Radiation therapy; Surgery; Proportional hazards model; Regimen; Adjuvant therapy; Oncology; Internal medicine; Chemotherapy","score_opus":0.07039884832997098,"score_gpt":0.45144797654849433,"score_spread":0.3810491282185233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413224284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957626,0.00070712576,0.00003301182,0.0031544478,0.00009161669,0.00018119306,0.000010934292,9.293042e-7,0.000058157428],"genre_scores_gemma":[0.99933547,0.0003089276,0.00015291745,0.00011261167,0.000077328725,0.0000044660287,9.1335954e-7,0.0000057571538,0.0000016394368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749213,0.00055623817,0.001436724,0.00012970102,0.0002649453,0.000120244156],"domain_scores_gemma":[0.994805,0.0030233809,0.0015432202,0.00016277134,0.00036859568,0.00009705843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023130563,0.00009794003,0.001536004,0.00032619011,0.000011457784,0.0000029320026,0.00006450846,0.0001548499,0.00003379045],"category_scores_gemma":[0.0018877771,0.000042981712,0.0008983333,0.00032578496,0.00019149584,0.00006749441,0.000014857682,0.00019966473,4.1918864e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001593714,0.0017146419,0.9390651,0.0000055546307,0.0037655404,0.0004107924,0.00020401162,0.0000060476555,0.004954997,0.00005271911,0.000022238695,0.04820467],"study_design_scores_gemma":[0.003571524,0.005865683,0.9868691,0.00005903342,0.002206087,0.00018720876,0.0001092027,0.000027280792,0.00073448726,0.00032335086,0.000008418594,0.00003863799],"about_ca_topic_score_codex":0.00012455478,"about_ca_topic_score_gemma":0.000044306526,"teacher_disagreement_score":0.048166033,"about_ca_system_score_codex":0.00018812092,"about_ca_system_score_gemma":0.00048134135,"threshold_uncertainty_score":0.2259982},"labels":[],"label_agreement":null},{"id":"W2414307865","doi":"10.1200/jco.2015.33.15_suppl.e13534","title":"Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to pegfilgrastim.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Biosimilar; Medicine; Pegfilgrastim; Cmax; Filgrastim; Oncology; Phases of clinical research; Confidence interval; Pharmacology; Internal medicine; Clinical trial; Pharmacokinetics; Chemotherapy; Neutropenia","score_opus":0.2740587639147554,"score_gpt":0.490525259223902,"score_spread":0.21646649530914658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414307865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777657,0.00024979893,0.0012536474,0.018372009,0.0011928725,0.00046035415,0.0000114818,0.000008237404,0.000685938],"genre_scores_gemma":[0.95652044,0.000050092873,0.040705502,0.0025200343,0.00016571858,0.0000029241482,0.0000020604293,0.000008111897,0.000025109644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942197,0.0020024362,0.0030808402,0.0002906009,0.00016827375,0.00023814231],"domain_scores_gemma":[0.9923624,0.004563234,0.0019082341,0.00022449676,0.0007555901,0.0001860663],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012170269,0.00018369654,0.0014066035,0.000096622214,0.00005871584,0.000005301743,0.0003733305,0.00053778634,0.00009001058],"category_scores_gemma":[0.009115195,0.00010052701,0.00035599415,0.0002290378,0.0010674688,0.000042636257,0.000115213305,0.0011201928,0.000006321792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02807922,0.020756401,0.05648147,0.0001726762,0.002454755,0.000050269147,0.0005114586,0.00005783556,0.45588976,0.00092441996,0.05591215,0.37870958],"study_design_scores_gemma":[0.015355317,0.03609084,0.09627247,0.00032614678,0.001410888,0.00007258333,0.0005688611,0.0006285869,0.75479096,0.0011285815,0.0928192,0.00053559174],"about_ca_topic_score_codex":0.0000019325696,"about_ca_topic_score_gemma":0.000005073711,"teacher_disagreement_score":0.378174,"about_ca_system_score_codex":0.00004719237,"about_ca_system_score_gemma":0.001837942,"threshold_uncertainty_score":0.99923146},"labels":[],"label_agreement":null},{"id":"W2415467905","doi":"","title":"Notes on the Ontario trial in the context of breast-conserving therapy for early-stage breast cancer.","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Context (archaeology); Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.10192976393166388,"score_gpt":0.4234571708490141,"score_spread":0.3215274069173502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415467905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724889,0.00036738778,0.0000053095787,0.025823887,0.00041752378,0.0003963716,0.000064368345,0.0000010822861,0.00043518373],"genre_scores_gemma":[0.9928151,0.0010917836,0.00006808103,0.0047686878,0.0010563153,0.0000477031,0.000002512789,0.000010826039,0.00013901449],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979329,0.00046657785,0.0010676484,0.00016977891,0.00017145304,0.00019162688],"domain_scores_gemma":[0.9966105,0.0021543782,0.0007701864,0.00023213017,0.00018344584,0.000049308517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018927361,0.00014421073,0.0006439729,0.000024599542,0.000066214925,0.0000097055,0.0003887791,0.0002121236,0.00020174036],"category_scores_gemma":[0.00029541727,0.00006942155,0.00045499127,0.00005658748,0.0002349471,0.000005669373,0.000025732299,0.0003581607,0.0000015710197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33470324,0.0030301681,0.19896057,0.0000089284895,0.0011906415,0.000026353324,0.001651723,0.00006141694,0.00048110244,0.00015607923,0.003250769,0.456479],"study_design_scores_gemma":[0.052593574,0.009680704,0.8741016,0.000052099113,0.000101342775,0.00009340234,0.00038761686,0.0000035353319,0.00051032763,0.00015754315,0.06220066,0.00011760283],"about_ca_topic_score_codex":0.0061877146,"about_ca_topic_score_gemma":0.030590724,"teacher_disagreement_score":0.67514104,"about_ca_system_score_codex":0.000068726215,"about_ca_system_score_gemma":0.00085567066,"threshold_uncertainty_score":0.98709846},"labels":[],"label_agreement":null},{"id":"W2415747453","doi":"10.1200/jco.2015.65.4194","title":"Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Population; Internal medicine; Dacarbazine; Relative survival; Proportional hazards model; Vinblastine; Stage (stratigraphy); Cancer; Cancer registry; Surgery; Pediatrics; Chemotherapy","score_opus":0.06695666980818155,"score_gpt":0.3981091551290772,"score_spread":0.33115248532089564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415747453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938137,0.00024337452,0.000004405268,0.0050344765,0.00032990568,0.0003519252,0.000014806529,0.0000015646275,0.00020583073],"genre_scores_gemma":[0.9991614,0.0002391108,0.00024014291,0.00007565821,0.00015511215,0.0000069005423,0.0000020499742,0.000009316371,0.00011030629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939287,0.0030782027,0.0017564973,0.00016775574,0.0009188936,0.00014998224],"domain_scores_gemma":[0.9944153,0.0029640885,0.0018602161,0.00025711904,0.00040414516,0.00009913684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00972505,0.000086317246,0.0011009071,0.0000438776,0.00003578285,0.000008475985,0.00015344056,0.00022565143,0.00007642371],"category_scores_gemma":[0.004791109,0.00004897033,0.0002106716,0.00014641022,0.00028956495,0.00006810968,0.0001240713,0.00019611967,0.0000014254359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012019486,0.0017598835,0.85717106,0.0000051204565,0.00017448385,0.000030573123,0.000040597693,0.000030038285,0.000041571904,0.0000145052445,0.0010780859,0.1384521],"study_design_scores_gemma":[0.031106662,0.0033131053,0.96257013,0.00027239157,0.0006715878,0.000102761645,0.00004333276,0.00085224374,0.000026859507,0.00077864237,0.00021016151,0.0000520942],"about_ca_topic_score_codex":0.003944905,"about_ca_topic_score_gemma":0.15017915,"teacher_disagreement_score":0.14623424,"about_ca_system_score_codex":0.00058135233,"about_ca_system_score_gemma":0.0007490451,"threshold_uncertainty_score":0.8653279},"labels":[],"label_agreement":null},{"id":"W2418296065","doi":"10.1200/jco.2015.33.7_suppl.269","title":"Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: Characterizing the scale of the problem.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Pharmacology; Abiraterone acetate; Internal medicine; CYP2D6; Adverse effect; Androgen deprivation therapy; CYP3A4; Drug; Cancer; Cytochrome P450","score_opus":0.12019595650274383,"score_gpt":0.4470968468812693,"score_spread":0.3269008903785255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418296065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97425216,0.00033210815,0.0000013704272,0.023981184,0.00042240924,0.00056160643,0.000006333463,0.000002616063,0.00044020213],"genre_scores_gemma":[0.99779814,0.0004906927,0.00023206415,0.00048792554,0.0002034139,0.000021171862,0.000002386748,0.000012102984,0.0007521006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778616,0.00041730076,0.0010973335,0.00011420804,0.0004038873,0.0001811085],"domain_scores_gemma":[0.9974619,0.0005447935,0.0010793075,0.00014851833,0.00062931835,0.00013613018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015786071,0.000096450094,0.0005291021,0.00006584176,0.000056763394,0.000013321644,0.00014280977,0.000039791084,0.000022853439],"category_scores_gemma":[0.0001685501,0.000038769016,0.0001202943,0.00019648376,0.00024683043,0.00016452894,0.000038363552,0.0007036425,0.0000014292289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013993623,0.0014387912,0.95930976,0.00003108476,0.00023314469,0.000023785318,0.002078659,0.00004539875,0.00068936957,0.000008037526,0.00095515384,0.021193216],"study_design_scores_gemma":[0.014070271,0.0027277889,0.97391146,0.00048148303,0.00008169367,0.00001157685,0.00078368635,0.00001272497,0.0008668154,0.00010628057,0.0068944506,0.000051765473],"about_ca_topic_score_codex":0.00020815145,"about_ca_topic_score_gemma":0.0027630809,"teacher_disagreement_score":0.023545971,"about_ca_system_score_codex":0.0002907244,"about_ca_system_score_gemma":0.0029764948,"threshold_uncertainty_score":0.5280174},"labels":[],"label_agreement":null},{"id":"W2424031403","doi":"10.1200/jco.2013.31.15_suppl.9640","title":"Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Denosumab; Medicine; Osteonecrosis of the jaw; Zoledronic acid; Multiple myeloma; Incidence (geometry); Placebo; Clinical trial; Internal medicine; Phases of clinical research; Cumulative incidence; Surgery; Bisphosphonate; Oncology; Osteoporosis; Pathology; Cohort","score_opus":0.18230443033503338,"score_gpt":0.47697845517249293,"score_spread":0.2946740248374595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2424031403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947654,0.0003339013,0.000077867386,0.0018363162,0.0009908169,0.0015402458,0.0004303534,0.000005037908,0.000020055913],"genre_scores_gemma":[0.9907221,0.00028144362,0.008204407,0.00054183335,0.00010851229,0.00004015372,0.000038366266,0.000022516026,0.00004065717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902056,0.0010617484,0.007550662,0.0003014487,0.0005143738,0.0003661987],"domain_scores_gemma":[0.9679261,0.022254629,0.008138952,0.00046102895,0.0008015581,0.00041775443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047042044,0.00022332436,0.003797869,0.00014446855,0.0000620398,0.0000074701875,0.00029623284,0.0003842795,0.00017093263],"category_scores_gemma":[0.065012835,0.00011212577,0.00068132725,0.00023713491,0.0002530924,0.00021035815,0.000113545844,0.0006915741,0.0000064021833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2383445,0.009871997,0.45022166,0.00008155768,0.0010053982,0.00013203439,0.00045306512,0.000010750131,0.0012018769,0.0000017138684,0.0017996568,0.2968758],"study_design_scores_gemma":[0.1655764,0.021500695,0.8061435,0.0008731582,0.0010249373,0.000015767668,0.00015041813,0.00024088917,0.0036761963,0.00030993388,0.00038870506,0.00009939998],"about_ca_topic_score_codex":0.006105619,"about_ca_topic_score_gemma":0.022913493,"teacher_disagreement_score":0.35592183,"about_ca_system_score_codex":0.00022249957,"about_ca_system_score_gemma":0.0026987924,"threshold_uncertainty_score":0.9949158},"labels":[],"label_agreement":null},{"id":"W2429135718","doi":"10.1200/jco.2015.65.7692","title":"Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Pancreatic Cancer UK; AstraZeneca; Celgene; Medical Research Council; Sanofi; Eli Lilly and Company; European Commission; Royal Marsden NHS Foundation Trust; Amgen","keywords":"Medicine; Epirubicin; Proportional hazards model; Lymph node; Chemotherapy; Internal medicine; Hazard ratio; Univariate analysis; Oncology; Multivariate analysis; Confidence interval; Cyclophosphamide","score_opus":0.230695636112675,"score_gpt":0.5133574957361673,"score_spread":0.28266185962349233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2429135718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97121793,0.00017846217,0.000013316483,0.02634827,0.00088264514,0.00045018326,0.0000030477488,0.0000032294308,0.00090294523],"genre_scores_gemma":[0.99544656,0.0014114261,0.00008518075,0.0018738232,0.0010092397,0.000008340412,2.8678497e-7,0.00000886839,0.00015627878],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9881341,0.0062961914,0.0018356419,0.00020911578,0.003148724,0.00037625976],"domain_scores_gemma":[0.95006454,0.048145737,0.0007424123,0.00020840352,0.0005574611,0.00028143782],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.098314196,0.0001269252,0.001346216,0.000256381,0.00003409512,0.0000063503744,0.00026316097,0.00023947535,0.00031232976],"category_scores_gemma":[0.08477113,0.000051352377,0.000278288,0.00030714113,0.0006042722,0.00004419447,0.000087908586,0.0012065592,0.000006815416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59430015,0.0010328883,0.11336901,0.000023309372,0.00006420855,0.0027882438,0.000083088,2.9275208e-7,0.00012030103,0.000048588903,0.004531373,0.28363854],"study_design_scores_gemma":[0.16042076,0.118360676,0.67635196,0.00016443602,0.00006593305,0.00032359498,0.00008845115,0.00000815688,0.000013465207,0.000118044925,0.044036366,0.00004815287],"about_ca_topic_score_codex":0.000021459833,"about_ca_topic_score_gemma":0.000041169405,"teacher_disagreement_score":0.562983,"about_ca_system_score_codex":0.00042577018,"about_ca_system_score_gemma":0.0041555227,"threshold_uncertainty_score":0.92847526},"labels":[],"label_agreement":null},{"id":"W2432860777","doi":"10.1200/jco.2013.31.15_suppl.1049","title":"A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Capecitabine; Eribulin; Medicine; Internal medicine; Hazard ratio; Taxane; Metastatic breast cancer; Regimen; Oncology; Chemotherapy; Chemotherapy regimen; Anthracycline; Gastroenterology; Progression-free survival; Breast cancer; Cancer; Confidence interval; Colorectal cancer","score_opus":0.14060218378077016,"score_gpt":0.5207636311247795,"score_spread":0.38016144734400936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2432860777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394125,0.0006614465,0.00002442448,0.0009392213,0.00023362288,0.004106277,0.000019588588,0.00000726327,0.00006691337],"genre_scores_gemma":[0.99602073,0.0014181765,0.0017165146,0.00030394987,0.00011861118,0.00023385703,0.000014374076,0.000030572002,0.00014319301],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949246,0.0009807512,0.0030036215,0.00036683163,0.00039160182,0.00033256668],"domain_scores_gemma":[0.9922583,0.0029479018,0.003088342,0.00020952843,0.0010860115,0.00040990347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014495143,0.0003357737,0.0047960253,0.000248948,0.000040748724,0.00001841256,0.00021147342,0.0001386367,0.0006776248],"category_scores_gemma":[0.00058097806,0.0001649437,0.00012899132,0.00048672897,0.000474013,0.00036331252,0.00006904642,0.00054690527,0.0000014645842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80037117,0.051300738,0.08917212,0.000048065904,0.0045490814,0.00058696495,0.00030562136,0.00006643267,0.000094765004,8.26801e-7,0.00013582809,0.05336841],"study_design_scores_gemma":[0.7702079,0.1518557,0.07128199,0.00024303905,0.0054070754,0.000076342876,0.00038773363,0.0002693122,0.000023212418,0.0000041916087,0.00009383383,0.00014971402],"about_ca_topic_score_codex":0.0024999396,"about_ca_topic_score_gemma":0.0049839974,"teacher_disagreement_score":0.10055496,"about_ca_system_score_codex":0.00018777791,"about_ca_system_score_gemma":0.001263796,"threshold_uncertainty_score":0.74195164},"labels":[],"label_agreement":null},{"id":"W2433470049","doi":"10.1200/jco.2005.23.16_suppl.4004","title":"Significant regional variation in treatment and survival of gastric cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Epidemiology; Cancer; Stage (stratigraphy); Relative survival; Surveillance, Epidemiology, and End Results; Lymph node; Proportional hazards model; Internal medicine; Population; Adenocarcinoma; Oncology; Demography; Cancer registry","score_opus":0.16350581630772457,"score_gpt":0.4666946796253154,"score_spread":0.3031888633175909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2433470049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788403,0.0005253492,0.0001418641,0.018899253,0.00041645384,0.00011605716,0.0000011181666,0.0000020420198,0.0010575671],"genre_scores_gemma":[0.992161,0.0040789447,0.0019103038,0.0005590776,0.00090663356,0.000002301427,5.5361716e-7,0.000004281156,0.0003769469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983018,0.0001241873,0.0012121011,0.000090312984,0.0001686659,0.00010293296],"domain_scores_gemma":[0.9981761,0.000708359,0.0008315652,0.00006186555,0.00011234986,0.000109753426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011686174,0.00006521505,0.0007782233,0.00015452363,0.0000074641684,0.0000020262719,0.000042026593,0.00009692264,0.000096113065],"category_scores_gemma":[0.00032278802,0.00004385437,0.00014980568,0.00012287364,0.00006282088,0.000052650208,0.0000135026585,0.00018984462,0.0000011184077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002012458,0.0009582031,0.65898055,0.000014642354,0.00020277547,0.000058091562,0.00011353279,0.000115170704,0.00012662624,0.00021189642,0.0009665718,0.33623952],"study_design_scores_gemma":[0.008085221,0.0050273184,0.94826055,0.00003300111,0.00023467316,0.000026852555,0.0000569543,0.00013896139,0.000008565105,0.00006038881,0.038036887,0.00003063047],"about_ca_topic_score_codex":0.0001280623,"about_ca_topic_score_gemma":0.00024985636,"teacher_disagreement_score":0.33620888,"about_ca_system_score_codex":0.00022509613,"about_ca_system_score_gemma":0.00060307555,"threshold_uncertainty_score":0.17883292},"labels":[],"label_agreement":null},{"id":"W2435490795","doi":"10.1200/jco.2014.32.15_suppl.2530","title":"A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; Gastroenterology; Cancer; Vomiting; Paclitaxel; Oncology; Discontinuation; Pharmacology","score_opus":0.11987352055479122,"score_gpt":0.4955037543018407,"score_spread":0.37563023374704946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2435490795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958003,0.0001258374,0.000018144901,0.0017904933,0.0005616537,0.0010064085,0.000008657712,0.000004144695,0.0006843214],"genre_scores_gemma":[0.9982065,0.000050597537,0.00039606076,0.00072692777,0.00033230914,0.000032359592,5.036456e-7,0.00003068161,0.000224084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509764,0.0009935979,0.0021911762,0.00028705617,0.0010843291,0.00034618526],"domain_scores_gemma":[0.99503696,0.0011681482,0.0020135546,0.0004809425,0.0009449821,0.0003554395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029723803,0.00017874477,0.001565992,0.00013117213,0.000035961915,0.000007350642,0.00037345738,0.00020187139,0.000051672556],"category_scores_gemma":[0.00078957697,0.000088639295,0.00016530616,0.0003796662,0.00038619738,0.000092628834,0.00010132732,0.001276138,0.0000024827455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032046616,0.031724308,0.8350182,0.00012377824,0.00017027625,0.00013617489,0.00081569643,0.000038676935,0.00011100583,0.0000037433247,0.0007544245,0.09905708],"study_design_scores_gemma":[0.13846304,0.23148575,0.6152222,0.00086802663,0.00025668158,0.000019065932,0.0015043404,0.00003290622,0.00049841113,0.000009885243,0.011501848,0.00013782691],"about_ca_topic_score_codex":0.000055990567,"about_ca_topic_score_gemma":0.0006959904,"teacher_disagreement_score":0.219796,"about_ca_system_score_codex":0.0003148879,"about_ca_system_score_gemma":0.0029051136,"threshold_uncertainty_score":0.55442554},"labels":[],"label_agreement":null},{"id":"W2435918492","doi":"10.1200/jco.2016.68.0926","title":"Reply to F. Felix et al and M.F. Fay et al","year":2016,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Genentech; National Cancer Institute; Celgene; Pfizer","keywords":"Medicine; Humanities; Philosophy","score_opus":0.08324012119421662,"score_gpt":0.4856046482209168,"score_spread":0.4023645270267002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2435918492","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.115821436,0.0025246853,0.0006414322,0.87134355,0.005122856,0.00031353132,0.000107992055,0.0000048862225,0.0041196],"genre_scores_gemma":[0.0065205325,0.010087771,0.0038224207,0.95913,0.008514639,0.000013062535,0.000046578883,0.00010399337,0.011761013],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98870236,0.004365018,0.0040505775,0.001021441,0.000922008,0.00093859993],"domain_scores_gemma":[0.9913354,0.003086924,0.002501312,0.0007531926,0.0012063532,0.0011168545],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012672091,0.0005439974,0.0023863176,0.0002716661,0.00010078184,0.000062825406,0.0008455882,0.0023099473,0.0002855707],"category_scores_gemma":[0.013049498,0.00041237264,0.0011066922,0.00013309256,0.0010612131,0.000023767157,0.0007975769,0.005523716,0.00027297516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020984747,0.0003823945,0.00048073937,0.00003077599,0.00051795546,0.0021251284,0.000052994452,0.0000037268167,0.023674851,0.000035433368,0.91532224,0.055275258],"study_design_scores_gemma":[0.0038801574,0.017780583,0.0007706286,0.00030276645,0.000109131804,0.0016860412,0.00001884531,0.000003190081,0.0025497433,0.00006175327,0.9723875,0.00044966905],"about_ca_topic_score_codex":0.00005662966,"about_ca_topic_score_gemma":0.00010626753,"teacher_disagreement_score":0.109300904,"about_ca_system_score_codex":0.00026025125,"about_ca_system_score_gemma":0.0049383244,"threshold_uncertainty_score":0.9998328},"labels":[],"label_agreement":null},{"id":"W2460175761","doi":"10.1200/jco.2016.34.3_suppl.e287","title":"An international, population-level initiative to promote healthy lifestyle practices among prostate cancer survivors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Health and Risk Factors","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Telehealth; Population; Quality of life (healthcare); Psychological intervention; General partnership; Gerontology; Telemedicine; Health care; Nursing; Environmental health","score_opus":0.20313196975490214,"score_gpt":0.5392088826642929,"score_spread":0.3360769129093908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460175761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9554045,0.00018644081,0.0001765235,0.039916173,0.0034481117,0.00043351346,0.000028407749,0.000013954304,0.00039238084],"genre_scores_gemma":[0.9856764,0.0031800848,0.002789302,0.0049513797,0.0030930568,0.0000143865645,0.000006814463,0.000021824964,0.00026676044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961523,0.0007438944,0.0020079503,0.0002516379,0.00056930655,0.00027491793],"domain_scores_gemma":[0.99313974,0.0013446973,0.0031795916,0.00023148122,0.0010659165,0.0010385892],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005193088,0.00013017518,0.0011091301,0.00019532714,0.00005995542,0.000013304808,0.00018083084,0.00028224423,0.00017975531],"category_scores_gemma":[0.0123327905,0.00007300901,0.00037578304,0.00015128728,0.00009323744,0.000565866,0.000036879366,0.00061968714,0.00003082601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033952687,0.00058078335,0.77843463,0.000020909043,0.00031739057,0.00014003353,0.00024776766,0.000009985533,0.0000246209,0.000013750223,0.00093876757,0.21587609],"study_design_scores_gemma":[0.0035724717,0.005789214,0.851198,0.00017600186,0.00014558977,0.000101500584,0.00009724081,0.00001856715,0.000015210034,0.00005539929,0.13874957,0.00008121969],"about_ca_topic_score_codex":0.001927902,"about_ca_topic_score_gemma":0.0033529284,"teacher_disagreement_score":0.21579488,"about_ca_system_score_codex":0.00032623328,"about_ca_system_score_gemma":0.0021897221,"threshold_uncertainty_score":0.99598676},"labels":[],"label_agreement":null},{"id":"W2461066853","doi":"10.1200/jco.2015.33.29_suppl.198","title":"Use of medical cannabis to reduce pain and improve quality of life in cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Nausea; Cancer pain; Quality of life (healthcare); Opioid; Anxiety; Cancer; Internal medicine; Psychiatry","score_opus":0.26985422087770305,"score_gpt":0.5469856654366468,"score_spread":0.2771314445589438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461066853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.909982,0.00037303602,0.000016489914,0.08877475,0.0005229922,0.00021731878,0.000012598981,0.0000014110561,0.000099401295],"genre_scores_gemma":[0.99433345,0.0003477121,0.0003361951,0.0039562387,0.00046556146,0.000008209239,0.0000010293625,0.00001093901,0.00054069445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939851,0.001229136,0.0031412453,0.00016925717,0.0012482386,0.00022697929],"domain_scores_gemma":[0.99470264,0.0006608952,0.0012796228,0.00017527166,0.0016702474,0.001511309],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018150816,0.00009395102,0.0016260253,0.00019002894,0.00000788372,0.0000043145255,0.00017378593,0.00041316292,0.00010137279],"category_scores_gemma":[0.08638562,0.000065311106,0.00020814355,0.00023327576,0.0003524436,0.00007473554,0.00013348476,0.000891691,6.595576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007915718,0.0024099343,0.59629756,0.0001374595,0.00010927951,0.000051979318,0.00037122777,0.000007372872,0.00027031047,0.000054880555,0.16204402,0.23033024],"study_design_scores_gemma":[0.009055817,0.01931716,0.85884726,0.00018066155,0.000045258206,0.00000835441,0.0003160377,0.00009608016,0.00014887592,0.000065352004,0.111843295,0.00007582673],"about_ca_topic_score_codex":0.00498057,"about_ca_topic_score_gemma":0.0018038714,"teacher_disagreement_score":0.2625497,"about_ca_system_score_codex":0.00018703566,"about_ca_system_score_gemma":0.008166445,"threshold_uncertainty_score":0.9974563},"labels":[],"label_agreement":null},{"id":"W2461111129","doi":"10.1200/jco.2010.28.18_suppl.lba7511","title":"Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Paclitaxel; Carboplatin; Internal medicine; Gemcitabine; Clinical endpoint; Nab-paclitaxel; Urology; Oncology; Gastroenterology; Randomized controlled trial; Chemotherapy; Cisplatin","score_opus":0.04164344622846952,"score_gpt":0.4491886765088216,"score_spread":0.40754523028035206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461111129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991183,0.0020580087,0.00011095908,0.0025455062,0.0005960911,0.0020495632,0.00006625868,0.00000567557,0.0013849797],"genre_scores_gemma":[0.9911676,0.002434626,0.0054920395,0.00032164875,0.00035427778,0.0000665119,0.000013035622,0.000027313756,0.00012293042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952058,0.00039285,0.0034447873,0.00032846048,0.0003675122,0.00026056843],"domain_scores_gemma":[0.99029326,0.00508244,0.0033544928,0.0002734885,0.00063314475,0.00036314034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030087798,0.00027111833,0.0033893706,0.00024376523,0.000045420056,0.000008667738,0.00011215088,0.0003569181,0.00003717699],"category_scores_gemma":[0.0020324534,0.00017197523,0.000359401,0.00020846074,0.00054282567,0.00008687323,0.000025228397,0.0008891783,1.7859341e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9538452,0.0045427997,0.011458334,0.00012640696,0.00077480107,0.00018086885,0.0014266616,0.00024243158,0.0026294836,0.000011699992,0.00009152826,0.024669785],"study_design_scores_gemma":[0.9558122,0.02845747,0.008982451,0.00048384833,0.0012999488,0.00003924143,0.00029987292,0.0025429765,0.0010917889,0.00007731453,0.00075534364,0.00015749873],"about_ca_topic_score_codex":0.0014072962,"about_ca_topic_score_gemma":0.0019865492,"teacher_disagreement_score":0.024512285,"about_ca_system_score_codex":0.00009656026,"about_ca_system_score_gemma":0.0028536909,"threshold_uncertainty_score":0.7012946},"labels":[],"label_agreement":null},{"id":"W2461149012","doi":"10.1200/jco.2013.31.15_suppl.8072","title":"A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Pemetrexed; Internal medicine; Carboplatin; Regimen; Pneumonitis; Chemotherapy; Gemcitabine; Chemotherapy regimen; Lung cancer; Vinorelbine; Phases of clinical research; Oncology; Gastroenterology; Cancer; Cisplatin; Lung; Immunotherapy","score_opus":0.05354189609253231,"score_gpt":0.4133180934351775,"score_spread":0.3597761973426452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461149012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912364,0.00065020606,0.00012542169,0.002962437,0.0014610812,0.00258426,0.00001564225,0.000018404648,0.0009461852],"genre_scores_gemma":[0.99122804,0.0008976978,0.0010931147,0.005504357,0.000766323,0.000087920125,0.000010102819,0.00008467557,0.00032774106],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99278265,0.0004989653,0.0047618947,0.00054583274,0.0007727889,0.0006378826],"domain_scores_gemma":[0.9927234,0.0011711138,0.004117054,0.00054937514,0.0009943239,0.0004447164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024720863,0.0004873536,0.003158247,0.0004762919,0.00007146638,0.000030179413,0.0005471187,0.0007053334,0.0016329741],"category_scores_gemma":[0.00023091651,0.00037428451,0.00088383886,0.0005677172,0.0003106487,0.00022870357,0.000054778528,0.0014830088,0.000013135513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11384483,0.06203807,0.5719007,0.00032135734,0.0020683953,0.00025870412,0.0038516982,0.00021654992,0.0060729417,0.000001441489,0.016016614,0.22340867],"study_design_scores_gemma":[0.4690957,0.06254989,0.45038927,0.0007778362,0.00057409174,0.000024933703,0.0012413956,0.002596315,0.0030793578,0.000016589027,0.009113374,0.0005412177],"about_ca_topic_score_codex":0.0023117447,"about_ca_topic_score_gemma":0.00050664885,"teacher_disagreement_score":0.3552509,"about_ca_system_score_codex":0.0009275375,"about_ca_system_score_gemma":0.0038697391,"threshold_uncertainty_score":0.9998709},"labels":[],"label_agreement":null},{"id":"W2461531801","doi":"10.1200/jco.2012.30.27_suppl.104","title":"Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Adverse effect; Tolerability; Breast cancer; Rash; Placebo; Population; Aromatase inhibitor; Oncology; Cancer; Aromatase","score_opus":0.058077749685863794,"score_gpt":0.43203815264828915,"score_spread":0.3739604029624254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461531801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912322,0.0014586101,0.0015433414,0.0020639354,0.0018642938,0.0005428104,0.00010342939,0.0000116310885,0.0011797504],"genre_scores_gemma":[0.98739207,0.000677807,0.008397038,0.0011068463,0.0015187924,0.00003419975,0.0000029019789,0.00004965981,0.0008206582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99608624,0.00017993672,0.0024853523,0.000200488,0.00050048216,0.0005474869],"domain_scores_gemma":[0.9934777,0.0015762445,0.0033310412,0.00030903178,0.0007618096,0.00054415886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020587898,0.00023472002,0.0025388284,0.00012897601,0.000032389682,0.0000021168116,0.00022212346,0.00032248424,0.00036658626],"category_scores_gemma":[0.00065615005,0.00015693795,0.0005213632,0.00015770305,0.00045554273,0.00033245803,0.000049428763,0.0006218717,0.0000013852466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2253658,0.0027381263,0.22250392,0.00032615318,0.0022740744,0.00006453985,0.0013996781,0.00026185557,0.0030544843,0.0001926666,0.00065134536,0.5411674],"study_design_scores_gemma":[0.052293032,0.016042631,0.7990797,0.0005410296,0.00057610305,0.00033470173,0.0005813028,0.000016770997,0.00053971855,0.00038067633,0.12941328,0.00020106108],"about_ca_topic_score_codex":0.00004304769,"about_ca_topic_score_gemma":0.0001292218,"teacher_disagreement_score":0.57657576,"about_ca_system_score_codex":0.00047701088,"about_ca_system_score_gemma":0.001388533,"threshold_uncertainty_score":0.6399744},"labels":[],"label_agreement":null},{"id":"W2461756240","doi":"10.1200/jco.2012.30.15_suppl.9557","title":"Diagnostic and treatment challenges of adolescent and young adult oncology patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Interquartile range; Malignancy; Young adult; Health care; Pediatrics; Cancer; Internal medicine","score_opus":0.15033550988280125,"score_gpt":0.4648743902497027,"score_spread":0.3145388803669014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461756240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96950924,0.010424885,0.000009888653,0.016772635,0.0016559949,0.000253193,0.000004969858,0.000005484152,0.0013637013],"genre_scores_gemma":[0.9581043,0.0374566,0.0010071513,0.0018375169,0.0015526172,0.000003969007,0.0000013741751,0.000014019215,0.00002242125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650645,0.00067639415,0.0020926206,0.00016410537,0.0003032591,0.00025717865],"domain_scores_gemma":[0.99199057,0.005044159,0.0017242146,0.00016087135,0.00042194722,0.00065826194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002311419,0.00015616872,0.0017761353,0.00009466601,0.00002565894,0.0000024557642,0.000067909285,0.00036370865,0.000024182309],"category_scores_gemma":[0.0083332285,0.00010932566,0.0002319233,0.000043128264,0.00033502787,0.00010348665,0.0000618824,0.00047910013,0.000003567457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013648029,0.005469085,0.6750518,0.00009542933,0.00028901274,0.00003775874,0.0016615092,1.2517373e-7,0.0000050776666,0.00026616408,0.0006551214,0.31510413],"study_design_scores_gemma":[0.011267472,0.029192373,0.9301577,0.00025117898,0.0005532527,0.00025612625,0.00086234655,0.0000023845785,0.000029127801,0.00008650404,0.0272566,0.0000849094],"about_ca_topic_score_codex":0.00008682829,"about_ca_topic_score_gemma":0.000317314,"teacher_disagreement_score":0.31501922,"about_ca_system_score_codex":0.00020468039,"about_ca_system_score_gemma":0.0005420894,"threshold_uncertainty_score":0.99762547},"labels":[],"label_agreement":null},{"id":"W2461813586","doi":"10.1200/jco.2016.67.8177","title":"Barriers to Quality End-of-Life Care for Patients With Blood Cancers","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Intensive care medicine; Quality of life (healthcare); Quality (philosophy); Cancer; Internal medicine; Oncology; Nursing","score_opus":0.257886643301438,"score_gpt":0.5561203330329239,"score_spread":0.29823368973148584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461813586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422276,0.00048620993,0.0004159983,0.0029413432,0.0007313659,0.00027350147,0.00007364119,0.000003825942,0.00085136987],"genre_scores_gemma":[0.9866068,0.00040077444,0.0105925,0.0017741537,0.00053525565,0.0000059239555,0.0000022580157,0.000013533431,0.00006881474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715143,0.00022670407,0.0018957464,0.00015335175,0.00037668293,0.00019608525],"domain_scores_gemma":[0.99170446,0.0039260504,0.0016558587,0.00017289547,0.0017465664,0.00079414534],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012473714,0.00011322115,0.0015576442,0.00008840175,0.000022011249,0.0000012812902,0.00014900276,0.00021273307,0.0001237139],"category_scores_gemma":[0.0227779,0.000059883252,0.00037330488,0.00009529376,0.00024539468,0.000060405,0.000026277177,0.00020758375,0.0000018984139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010978667,0.00028848098,0.92951745,0.00011613988,0.0005969106,0.000013447926,0.000791131,0.0000034711206,0.00013324166,0.00008000345,0.0017151326,0.05576592],"study_design_scores_gemma":[0.035801742,0.05271164,0.55106837,0.0015228564,0.00091146026,0.0000041899234,0.0021807435,6.74589e-7,0.0015177317,0.00010018171,0.35400122,0.00017916331],"about_ca_topic_score_codex":0.00007055549,"about_ca_topic_score_gemma":0.00019172687,"teacher_disagreement_score":0.37844905,"about_ca_system_score_codex":0.00016641797,"about_ca_system_score_gemma":0.0042758565,"threshold_uncertainty_score":0.98545367},"labels":[],"label_agreement":null},{"id":"W2463487711","doi":"10.1200/jco.2012.30.15_suppl.5530","title":"The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Head and neck cancer; Stage (stratigraphy); Proportional hazards model; Oncology; Radiation therapy; Cancer; Clinical trial; Head and neck; Surgery","score_opus":0.27818696941765864,"score_gpt":0.5656658750984052,"score_spread":0.2874789056807465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463487711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924854,0.0010692902,0.000009762844,0.0031395557,0.0023019381,0.00017834263,0.000019967203,0.0000034023417,0.00079235825],"genre_scores_gemma":[0.98992765,0.0057353545,0.00032523056,0.0013336402,0.0026087624,0.0000046303803,0.0000018043161,0.000007582577,0.00005534309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944082,0.0008943336,0.0036050864,0.00018835472,0.0006133345,0.00029070993],"domain_scores_gemma":[0.9901633,0.0063578393,0.0021308982,0.00024643616,0.00062437163,0.00047715058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008246605,0.00014926419,0.0026334275,0.00014930812,0.00009546891,0.000004756439,0.00018573884,0.00036071546,0.00005938555],"category_scores_gemma":[0.0073762327,0.00008520855,0.00074676715,0.00026350733,0.0010108805,0.00018653672,0.00008175422,0.00097125035,0.0000015919644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10914345,0.003462547,0.81162506,0.000023018998,0.0032150117,0.00002332585,0.00020282145,0.00028615445,0.000051583662,0.0015610688,0.00066517893,0.069740795],"study_design_scores_gemma":[0.034517985,0.020680787,0.91155094,0.000092836155,0.0018206758,0.0000126501955,0.000063547515,0.00007438423,0.000011021908,0.000042625084,0.031059707,0.00007282427],"about_ca_topic_score_codex":0.00021017926,"about_ca_topic_score_gemma":0.00080246734,"teacher_disagreement_score":0.09992592,"about_ca_system_score_codex":0.00010101287,"about_ca_system_score_gemma":0.0019030717,"threshold_uncertainty_score":0.88305724},"labels":[],"label_agreement":null},{"id":"W2463870580","doi":"10.1200/jco.2012.30.15_suppl.e16547","title":"A review of clinical endpoints and use of quality of life outcomes in phase III metastatic breast cancer clinical trials.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Clinical endpoint; Clinical trial; Quality of life (healthcare); Metastatic breast cancer; Internal medicine; Breast cancer; Disease; Cancer; Oncology; Intensive care medicine","score_opus":0.8346999713139278,"score_gpt":0.7451445904102004,"score_spread":0.08955538090372739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463870580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011715042,0.98022485,0.000008170245,0.002155099,0.0035022735,0.0018026677,0.00051766535,0.0000038680437,0.00007035841],"genre_scores_gemma":[0.0013623565,0.9926978,0.0011125223,0.002924889,0.0016963403,0.00003795664,0.000026154843,0.000042709828,0.00009926635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9271505,0.025669519,0.045617923,0.0004990414,0.00066079234,0.0004022347],"domain_scores_gemma":[0.8680835,0.08569573,0.043526374,0.00055096886,0.001016854,0.0011265803],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.092194855,0.0005558882,0.046551675,0.00039157536,0.000013979793,0.0000034474142,0.00036894504,0.0013691133,0.0013306774],"category_scores_gemma":[0.0667746,0.0003280807,0.0077566565,0.00038469752,0.0011980217,0.00016795399,0.00018788248,0.0031934741,0.000003961718],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012982778,0.019679135,0.053359225,0.05295381,0.008442193,0.00009621155,0.000019493878,6.192607e-8,4.1620194e-7,0.000025370327,0.0040996573,0.84834164],"study_design_scores_gemma":[0.057561982,0.012293609,0.037222948,0.053718373,0.046592508,0.00025937974,0.00001282398,0.0000019518816,3.3693908e-7,0.000027461965,0.7920472,0.00026143785],"about_ca_topic_score_codex":0.00024823245,"about_ca_topic_score_gemma":0.00014676005,"teacher_disagreement_score":0.8480802,"about_ca_system_score_codex":0.00015822583,"about_ca_system_score_gemma":0.010864497,"threshold_uncertainty_score":0.99992734},"labels":[],"label_agreement":null},{"id":"W2464620827","doi":"10.1200/jco.2016.66.9861","title":"Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Pemetrexed; Carboplatin; Tolerability; Gemcitabine; Lung cancer; Oncology; Internal medicine; Cisplatin; Chemotherapy; Paclitaxel; Adverse effect; Cancer; Immunotherapy","score_opus":0.06176889032220338,"score_gpt":0.424635470981647,"score_spread":0.3628665806594436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464620827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98032814,0.00070737046,0.0027269148,0.014901805,0.00041024014,0.0007352623,0.000010368782,0.000004320901,0.00017559587],"genre_scores_gemma":[0.9901904,0.003071555,0.005049092,0.0008619676,0.0002802976,0.0000490887,0.00000279956,0.000020982025,0.00047385864],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979666,0.00006703631,0.0014714038,0.00015320818,0.00016798855,0.0001737944],"domain_scores_gemma":[0.9965015,0.001409372,0.0015150313,0.00014011453,0.0003334626,0.00010049836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007934341,0.00013220894,0.0010825493,0.00012013133,0.00001955834,0.000002296959,0.000081686514,0.00021343918,0.00012877809],"category_scores_gemma":[0.000109494504,0.00006993033,0.00032384586,0.000121617784,0.00011748732,0.00005894275,0.000003925778,0.00012150599,3.6142313e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17878795,0.0062543573,0.15290467,0.00013314071,0.0005158485,0.000050658884,0.00019729779,0.00013048631,0.0091301855,0.000006192299,0.00060354744,0.65128565],"study_design_scores_gemma":[0.5029155,0.15535109,0.24689975,0.0013770468,0.0005401635,0.000037913753,0.00009142532,0.0011639111,0.028795585,0.00008537974,0.06250433,0.00023791568],"about_ca_topic_score_codex":0.0000623852,"about_ca_topic_score_gemma":0.0006493477,"teacher_disagreement_score":0.65104777,"about_ca_system_score_codex":0.0005265014,"about_ca_system_score_gemma":0.0014844622,"threshold_uncertainty_score":0.2851676},"labels":[],"label_agreement":null},{"id":"W2464671570","doi":"10.1200/jco.2016.34.3_suppl.5","title":"Using Canadian administrative data to evaluate primary and oncology care of breast cancer patients post-treatment: Subset of the CanIMPACT Study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; University of Toronto; Dalhousie University; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Specialty; Breast cancer; Family medicine; Health care; Survivorship curve; Population; Cancer; Internal medicine; Environmental health","score_opus":0.49427585593255996,"score_gpt":0.5791031548877439,"score_spread":0.08482729895518393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464671570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122155,0.00030504394,0.000001680876,0.0060787178,0.00050050236,0.00046930983,0.0008578905,0.0000010834251,0.00056420756],"genre_scores_gemma":[0.997808,0.00013224357,0.00031958875,0.0014582269,0.00024991072,0.0000021079516,0.0000047382528,0.000008960781,0.000016263979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718106,0.0005489561,0.0014228461,0.00021155029,0.00039749194,0.00023810925],"domain_scores_gemma":[0.9951746,0.00073641835,0.0013956362,0.00034212865,0.0017780911,0.00057313207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013508808,0.00013231626,0.0011913183,0.00009765051,0.0000493887,0.0000033140295,0.00032138563,0.00018178686,0.00008060108],"category_scores_gemma":[0.0019268736,0.000064033986,0.00014497516,0.00014254346,0.00023761464,0.00013215726,0.00013422106,0.00023977084,7.188327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041749864,0.00057526096,0.8660623,0.000014236832,0.0004242509,0.00011398468,0.001055511,0.0000050221274,0.00042195598,0.0000021347366,0.00033781418,0.12681253],"study_design_scores_gemma":[0.0059587667,0.028687635,0.95845425,0.00028571137,0.00082271604,0.00016800391,0.0024140978,0.000004456044,0.000060445043,0.0000047667327,0.0030765694,0.00006259227],"about_ca_topic_score_codex":0.06647679,"about_ca_topic_score_gemma":0.35543466,"teacher_disagreement_score":0.28895786,"about_ca_system_score_codex":0.0015632955,"about_ca_system_score_gemma":0.016977187,"threshold_uncertainty_score":0.98859566},"labels":[],"label_agreement":null},{"id":"W2465413205","doi":"10.1200/jco.2012.30.15_suppl.tps9149","title":"CATCH: A randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Warfarin; Pulmonary embolism; Deep vein; Randomized controlled trial; Internal medicine; Thrombosis; Cancer; Venous thromboembolism; Surgery; Atrial fibrillation","score_opus":0.22877757083892258,"score_gpt":0.5004514436580015,"score_spread":0.27167387281907895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465413205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987229,0.00083790376,0.000047760368,0.001223009,0.006420719,0.0022618915,0.000008202734,0.00000729024,0.0019642364],"genre_scores_gemma":[0.9923823,0.0038576322,0.001250077,0.00032753946,0.0019015869,0.00018044078,0.000010351534,0.000025835392,0.00006423223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99526477,0.0004510413,0.003296453,0.00019202118,0.00034258305,0.00045310718],"domain_scores_gemma":[0.99360484,0.0031596068,0.0023811946,0.00020473977,0.0003160482,0.000333581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033032512,0.00021664106,0.0062335483,0.00020254962,0.000035633926,0.0000060931843,0.0001540984,0.00030423934,0.00007442092],"category_scores_gemma":[0.001311767,0.00014764193,0.0011453991,0.00012415387,0.00019063747,0.000115239185,0.000055721575,0.0002631872,0.0000049926743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87302923,0.041199904,0.019205822,0.000058670405,0.0043057636,0.000024445304,0.0013042677,0.000031550673,0.000013201493,0.0005078557,0.0014632035,0.05885611],"study_design_scores_gemma":[0.84149885,0.03481243,0.10133886,0.00009280626,0.0049742586,0.0000047721587,0.000091943235,0.000087066954,0.00008134839,0.00009720462,0.016801488,0.000118976524],"about_ca_topic_score_codex":0.0005691836,"about_ca_topic_score_gemma":0.00019480048,"teacher_disagreement_score":0.08213305,"about_ca_system_score_codex":0.00049488415,"about_ca_system_score_gemma":0.0006978319,"threshold_uncertainty_score":0.6020663},"labels":[],"label_agreement":null},{"id":"W2465450552","doi":"10.1200/jco.2009.27.15_suppl.e12028","title":"Isolated tumor cells versus micro-metastasis in sentinel lymph node biopsy for T1, T2 breast cancer compared to macro-metastasis: Significance after complete axillary dissection","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Metastasis; Sentinel lymph node; Breast cancer; Biopsy; Cancer; Axillary Lymph Node Dissection; Pathology; Oncology; Internal medicine","score_opus":0.05543554314647443,"score_gpt":0.3958282736567905,"score_spread":0.3403927305103161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465450552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946524,0.0011937956,0.00092494965,0.005786274,0.0016454504,0.00035583228,0.0005642826,0.000009176924,0.000054975488],"genre_scores_gemma":[0.9913342,0.00042210476,0.004426411,0.0026602165,0.0009962913,0.000064292886,0.000035869227,0.00002975332,0.000030890893],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967755,0.00030641738,0.0017288906,0.00050080003,0.00020361303,0.0004847889],"domain_scores_gemma":[0.9976202,0.00029907265,0.0010285248,0.0002690124,0.0004975787,0.00028560928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081310153,0.00032160812,0.0012353784,0.0001450848,0.00007659429,0.000023629498,0.0002885206,0.00024170059,0.0000402911],"category_scores_gemma":[0.0002076525,0.00027279338,0.00054311985,0.00025902968,0.00014218412,0.000017320972,0.00008515658,0.00027344652,0.000009029977],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21380274,0.0065055816,0.2517407,0.00014181121,0.003886625,0.00090025127,0.0002911549,0.0021858662,0.39306286,0.000010113033,0.010327756,0.117144555],"study_design_scores_gemma":[0.017543532,0.0019709615,0.95884633,0.00012895826,0.000582337,0.00041016456,0.00022702474,0.00014648965,0.0049631367,0.000032111122,0.014687569,0.00046140276],"about_ca_topic_score_codex":0.00009357994,"about_ca_topic_score_gemma":0.00011402979,"teacher_disagreement_score":0.70710564,"about_ca_system_score_codex":0.00023477929,"about_ca_system_score_gemma":0.0005025507,"threshold_uncertainty_score":0.9999724},"labels":[],"label_agreement":null},{"id":"W2467627018","doi":"10.1200/jco.2007.25.18_suppl.5069","title":"A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Clusterin; Prednisone; Internal medicine; Clinical endpoint; Urology; Oncology; Chemotherapy; Prostate cancer; Gastroenterology; Endocrinology; Cancer; Randomized controlled trial; Apoptosis; Biology","score_opus":0.06795530814746775,"score_gpt":0.44901176138010984,"score_spread":0.3810564532326421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467627018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484825,0.0013772182,0.00009232491,0.0006748178,0.00013880765,0.00279364,0.000015047995,0.0000070600718,0.00005281818],"genre_scores_gemma":[0.9959356,0.0010778705,0.002506899,0.00024366283,0.00005800567,0.00006347761,0.000006460759,0.0000305876,0.00007741816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941835,0.0011225638,0.0033972422,0.00037615138,0.00057509524,0.0003454599],"domain_scores_gemma":[0.9931442,0.0028053499,0.0028557912,0.00022759744,0.00060107536,0.00036596926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065906895,0.00026733908,0.0034203604,0.00051420165,0.000039350565,0.000007775864,0.000108598724,0.00020134774,0.000028475182],"category_scores_gemma":[0.003111754,0.00015920169,0.00009364976,0.00036882897,0.00069401046,0.00023418508,0.000108789536,0.00086380116,2.7295894e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70337576,0.03689886,0.2261042,0.0001259079,0.00059507764,0.0012274248,0.0026263653,0.000018215316,0.00006591803,0.000003028582,0.000034725548,0.028924523],"study_design_scores_gemma":[0.4913157,0.08058098,0.4260347,0.00021656469,0.00085062155,0.00010731212,0.00060338504,0.00009801126,0.000007050777,0.00003815077,0.000050526767,0.00009701108],"about_ca_topic_score_codex":0.00016921741,"about_ca_topic_score_gemma":0.0013856074,"teacher_disagreement_score":0.21206006,"about_ca_system_score_codex":0.00017533464,"about_ca_system_score_gemma":0.0007987482,"threshold_uncertainty_score":0.6492057},"labels":[],"label_agreement":null},{"id":"W2468271251","doi":"10.1200/jco.2015.33.28_suppl.115","title":"The effect of neoadjuvant chemotherapy on short-term outcomes in breast surgery: A propensity score adjusted analysis of NSQIP data.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Propensity score matching; Breast cancer; Confounding; Logistic regression; Odds ratio; Surgery; Neoadjuvant therapy; Cohort; Cancer; Internal medicine","score_opus":0.20873516793760533,"score_gpt":0.4480905312908987,"score_spread":0.23935536335329338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468271251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967731,0.000475547,0.0000152569355,0.0020958104,0.00036616676,0.000146022,0.00004957427,0.0000014553717,0.000077070494],"genre_scores_gemma":[0.99896175,0.0005693643,0.00006235786,0.00017580538,0.00016979959,0.0000035450087,0.000031200532,0.000010298308,0.000015871421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688524,0.0007983963,0.0016110545,0.00023844141,0.00028563204,0.00018123267],"domain_scores_gemma":[0.9958816,0.0017983044,0.001322178,0.0005571113,0.00031814486,0.00012262298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044846623,0.00016221472,0.0019608976,0.00012378817,0.000023132747,0.0000045293455,0.0004241314,0.00022420018,0.0000038912617],"category_scores_gemma":[0.0019290199,0.000084848005,0.00054460415,0.00024952707,0.00031183564,0.000007772202,0.00017450702,0.0002516953,5.57676e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008660881,0.00057627656,0.92219895,0.000008974024,0.0034027647,0.00003221177,0.000024132078,0.000051155523,0.0003039023,0.0000020180535,0.0010019263,0.063736804],"study_design_scores_gemma":[0.0030955642,0.0037204234,0.98987556,0.000036573147,0.0009255643,0.00003132006,0.000027597514,0.000030160969,0.0013404316,0.000005933791,0.000835596,0.00007528935],"about_ca_topic_score_codex":0.00008552522,"about_ca_topic_score_gemma":0.00068423536,"teacher_disagreement_score":0.06767659,"about_ca_system_score_codex":0.000050127586,"about_ca_system_score_gemma":0.00053125236,"threshold_uncertainty_score":0.34600013},"labels":[],"label_agreement":null},{"id":"W2468990687","doi":"10.1200/jco.2013.31.15_suppl.tps7129","title":"EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Imatinib; Myeloid leukemia; Internal medicine; Oncology; Imatinib mesylate; Tyrosine-kinase inhibitor; Nilotinib; Cancer","score_opus":0.07600175076412469,"score_gpt":0.44549411153852037,"score_spread":0.3694923607743957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468990687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903865,0.00043555952,0.000023608454,0.00061221264,0.0008200656,0.0063462285,0.000010895091,0.000012391233,0.0013525637],"genre_scores_gemma":[0.9958444,0.00069560605,0.0020361484,0.00036669945,0.0004928046,0.00035246206,0.0000308128,0.00006137382,0.00011965816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98887324,0.0017641885,0.0070663597,0.0005980247,0.0009882393,0.00070996926],"domain_scores_gemma":[0.9837865,0.008880498,0.0050837523,0.00062859425,0.0010490373,0.0005715683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042553195,0.0004976489,0.006000519,0.00053008815,0.000048978716,0.000029418645,0.00076288235,0.000536796,0.00083822804],"category_scores_gemma":[0.0078063873,0.00033604176,0.00035617585,0.00062872993,0.00048286226,0.0005865325,0.00026343195,0.002013589,0.000043050837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.634416,0.072154,0.023167621,0.00012664137,0.0019844293,0.0015864167,0.0011309331,0.00026250674,0.00008629181,0.000040211948,0.000987855,0.2640571],"study_design_scores_gemma":[0.8489597,0.1227607,0.022289412,0.0006925101,0.00078588596,0.000037005608,0.00049252814,0.003327691,0.000032029642,0.00004596195,0.00033402973,0.00024256515],"about_ca_topic_score_codex":0.0025503698,"about_ca_topic_score_gemma":0.0040106815,"teacher_disagreement_score":0.26381454,"about_ca_system_score_codex":0.010542188,"about_ca_system_score_gemma":0.017626189,"threshold_uncertainty_score":0.99990916},"labels":[],"label_agreement":null},{"id":"W2469051128","doi":"10.1200/jco.2015.33.18_suppl.lba7005","title":"Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bendamustine; Ibrutinib; Internal medicine; Clinical endpoint; Rituximab; Chronic lymphocytic leukemia; Gastroenterology; Interim analysis; Progression-free survival; Neutropenia; Placebo; Phases of clinical research; Refractory (planetary science); Surgery; Randomized controlled trial; Lymphoma; Chemotherapy; Leukemia; Pathology","score_opus":0.12314359975747771,"score_gpt":0.42100886763294876,"score_spread":0.2978652678754711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469051128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839545,0.0033382182,0.000071535746,0.0012098871,0.00075182697,0.008234925,0.000026218593,0.000083590116,0.002329305],"genre_scores_gemma":[0.99358183,0.0019052868,0.0009669259,0.0004755577,0.001642443,0.00033545,0.00006934316,0.00013191275,0.00089126907],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98305017,0.002914036,0.009444287,0.0013165812,0.0018443366,0.0014306062],"domain_scores_gemma":[0.96993333,0.020177925,0.004840161,0.0011688521,0.0015357425,0.0023439701],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.020256573,0.0009645094,0.011336421,0.00092226185,0.00016255195,0.0001243079,0.00083336956,0.0011801277,0.000086719076],"category_scores_gemma":[0.01652396,0.000632597,0.0010075256,0.0009725812,0.0015353897,0.00036419267,0.00040905108,0.0014986065,0.00006597004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.962166,0.0075460337,0.00047658387,0.00012431672,0.0034122742,0.013317296,0.0015354601,0.0013465009,0.00001024452,0.00002552296,0.0008761676,0.009163601],"study_design_scores_gemma":[0.8554317,0.058499787,0.00017619721,0.000942875,0.0039143246,0.003154429,0.0008175948,0.07498184,0.000051433017,0.00007287004,0.001448995,0.00050795247],"about_ca_topic_score_codex":0.012386436,"about_ca_topic_score_gemma":0.008579248,"teacher_disagreement_score":0.1067343,"about_ca_system_score_codex":0.11048303,"about_ca_system_score_gemma":0.19253252,"threshold_uncertainty_score":0.9996125},"labels":[],"label_agreement":null},{"id":"W2470099850","doi":"10.1200/jco.2015.65.0770","title":"Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Rigshospitalet; American Society of Clinical Oncology","keywords":"Medicine; Randomized controlled trial; Breast cancer; Mindfulness; Mindfulness-based cognitive therapy; Cognition; Internal medicine; Oncology; Physical therapy; Cognitive therapy; Cancer; Psychiatry; Clinical psychology","score_opus":0.04717703960005973,"score_gpt":0.41712078063892233,"score_spread":0.36994374103886263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470099850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359007,0.00027922477,0.00019932122,0.010487513,0.00092328363,0.0042540752,0.00008737413,0.0000069763832,0.00017216054],"genre_scores_gemma":[0.99416596,0.0003373978,0.000024668807,0.0033234684,0.00087279663,0.0010095945,0.0000058582455,0.000022288441,0.00023794337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936724,0.0026621048,0.002865585,0.00021845136,0.00029882084,0.00028265276],"domain_scores_gemma":[0.9541819,0.04238788,0.00225804,0.00012788425,0.00079203764,0.00025226464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00907112,0.00021927891,0.0055067185,0.00023494387,0.000019127838,0.00000393496,0.00009281958,0.00034874148,0.0002679519],"category_scores_gemma":[0.0061774873,0.00010066932,0.0016650548,0.00011856066,0.00025575634,0.000037791266,0.0000067774076,0.00025179645,0.0000013895879],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5741828,0.003964734,0.00071314414,0.000011685389,0.0011225988,0.000060604496,0.00013902622,0.0000019624517,0.00007563153,0.0000055211804,0.000020761152,0.41970155],"study_design_scores_gemma":[0.91773134,0.069376394,0.009933881,0.0005698488,0.00061669893,0.000008138279,0.00007935377,0.000018245317,0.00045668962,0.000092794035,0.0010181472,0.00009844839],"about_ca_topic_score_codex":0.00015322216,"about_ca_topic_score_gemma":0.00022333013,"teacher_disagreement_score":0.4196031,"about_ca_system_score_codex":0.0006699959,"about_ca_system_score_gemma":0.0033031022,"threshold_uncertainty_score":0.73954755},"labels":[],"label_agreement":null},{"id":"W2470869103","doi":"10.1200/jco.2010.28.15_suppl.tps318","title":"The effect of dexamethasone on symptom burden in patients with advanced cancer.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Placebo; Anorexia; Dexamethasone; Internal medicine; Psychosocial; Randomized controlled trial; Quality of life (healthcare); Cancer; Physical therapy; Psychiatry; Alternative medicine","score_opus":0.02308255454775477,"score_gpt":0.4245950422538822,"score_spread":0.40151248770612746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470869103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936582,0.00019153736,0.0000032693313,0.0024261044,0.0023540284,0.00021354643,0.0000021725689,0.000002682914,0.0011484603],"genre_scores_gemma":[0.9986862,0.0002025084,0.00010332753,0.00032254515,0.0005983212,0.000006875021,6.171801e-7,0.000011304698,0.00006831092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979559,0.0003389435,0.0010575082,0.00011267681,0.00037301364,0.00016194706],"domain_scores_gemma":[0.99313223,0.0051730564,0.0010284651,0.00019999553,0.00030217587,0.00016407526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002462408,0.000097741315,0.0009843209,0.00006213609,0.00002199477,0.0000030941083,0.00015575289,0.00021712131,0.000041904925],"category_scores_gemma":[0.002809897,0.000046263878,0.0002021264,0.0001384589,0.000208164,0.000031577445,0.000020880458,0.0013577852,0.000001865525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017428668,0.0001681869,0.5627738,0.000014966298,0.00008283117,0.0000219426,0.000058019454,0.000018866634,0.00005818966,0.000015170752,0.00008673761,0.4192726],"study_design_scores_gemma":[0.015097613,0.05175244,0.90793145,0.00020053971,0.00015305854,0.000008256046,0.000044008426,0.000008559617,0.00035135838,0.000024863897,0.02437294,0.00005490729],"about_ca_topic_score_codex":0.00013476115,"about_ca_topic_score_gemma":0.002757491,"teacher_disagreement_score":0.4192177,"about_ca_system_score_codex":0.00007650509,"about_ca_system_score_gemma":0.00055274664,"threshold_uncertainty_score":0.58989763},"labels":[],"label_agreement":null},{"id":"W2470918530","doi":"10.1200/jco.2009.27.15_suppl.e17000","title":"Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital; Bristol-Myers Squibb (Canada); Royal Victoria Regional Health Centre; McGill University; University of British Columbia","funders":"","keywords":"Medicine; Cetuximab; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Radiation therapy; Head and neck cancer; Cancer","score_opus":0.14437362481663532,"score_gpt":0.44720206410300334,"score_spread":0.30282843928636805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470918530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881928,0.0034977777,0.000014953249,0.006972095,0.0003769743,0.00061480387,0.000013439436,4.9620934e-7,0.00031667587],"genre_scores_gemma":[0.9984579,0.00082160067,0.00010773362,0.00043968612,0.00014055168,0.000008296817,2.770857e-7,0.000004791858,0.000019179552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998094,0.0001962051,0.0013039649,0.00009230483,0.00017429717,0.00013922596],"domain_scores_gemma":[0.9929496,0.005672091,0.00089329056,0.00014921915,0.00026101293,0.000074765274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009934015,0.0000939382,0.0015087503,0.000034005065,0.000026876683,6.056321e-7,0.00009773974,0.00009578918,0.000004405023],"category_scores_gemma":[0.00076445076,0.000043702377,0.00024879895,0.0000975298,0.00015159538,0.000015860354,0.000018242159,0.00019570236,3.322323e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0154419225,0.0040343315,0.7725113,0.00032445957,0.0001643999,0.00007341104,0.00045167186,0.00016433261,0.0003410472,0.00003509314,0.00061087613,0.20584714],"study_design_scores_gemma":[0.01933168,0.037176322,0.9328509,0.00014068322,0.0002614033,0.000027114687,0.00015263357,0.00009799832,0.0031988895,0.00007713027,0.0066506625,0.000034606543],"about_ca_topic_score_codex":0.04044721,"about_ca_topic_score_gemma":0.26206014,"teacher_disagreement_score":0.22161292,"about_ca_system_score_codex":0.00032664146,"about_ca_system_score_gemma":0.00265436,"threshold_uncertainty_score":0.96594256},"labels":[],"label_agreement":null},{"id":"W2471272049","doi":"10.1200/jco.2014.32.15_suppl.8020","title":"Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Rash; Lung cancer; Adverse effect; Immunohistochemistry; Cancer; Oncology; Incidence (geometry); Gastroenterology","score_opus":0.04064561755296586,"score_gpt":0.4091944623600961,"score_spread":0.36854884480713024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471272049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955856,0.0004511373,0.00015332972,0.0011415812,0.0005176074,0.00040864147,0.000004637141,0.0000041776248,0.0017332381],"genre_scores_gemma":[0.99280524,0.005050916,0.00066154334,0.00092119764,0.0003733187,0.0000033222666,0.0000015257776,0.000018142948,0.0001647906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959868,0.0007129813,0.0025591198,0.0002422699,0.00025711124,0.00024172604],"domain_scores_gemma":[0.99465674,0.0022029777,0.0023047926,0.00020155043,0.00035367516,0.00028027783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042873854,0.00016548198,0.0018632971,0.00011143452,0.00002393754,0.000004595217,0.00013253,0.00045309443,0.00007193103],"category_scores_gemma":[0.0007957009,0.00010482933,0.00036464867,0.00016825735,0.0003403479,0.000081524566,0.00003900451,0.00094013434,8.779307e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04997785,0.0022092476,0.6923264,0.00007363534,0.00029327688,0.000028493076,0.00006968869,0.0000033428084,0.00014322493,8.749507e-7,0.00033215256,0.25454175],"study_design_scores_gemma":[0.04125335,0.023833433,0.92452323,0.0004808869,0.0004984207,0.000021288834,0.000017951346,0.00028389046,0.0001782211,0.0000041708577,0.0087995,0.000105683706],"about_ca_topic_score_codex":0.00033268819,"about_ca_topic_score_gemma":0.0008540206,"teacher_disagreement_score":0.25443608,"about_ca_system_score_codex":0.00018271785,"about_ca_system_score_gemma":0.0012025222,"threshold_uncertainty_score":0.4274816},"labels":[],"label_agreement":null},{"id":"W2472127675","doi":"10.1200/jco.2014.32.15_suppl.6549","title":"Burnout among Canadian oncologists and oncology residents.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Calgary; Health Sciences Centre; Baker Hughes (Canada)","funders":"","keywords":"Burnout; Medicine; Concordance; Spouse; Family medicine; Internal medicine; Clinical psychology","score_opus":0.07223541495944069,"score_gpt":0.5135547592218033,"score_spread":0.4413193442623626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472127675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86981004,0.0017447283,0.00094580994,0.033264905,0.0065833586,0.00030643732,0.0000026306664,0.000022400509,0.08731971],"genre_scores_gemma":[0.9545937,0.0039828853,0.015918955,0.019394306,0.0045173583,0.000004404509,0.000002234891,0.000026027872,0.001560098],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957213,0.0010569387,0.0022452332,0.00027921094,0.00025378237,0.00044355748],"domain_scores_gemma":[0.99083674,0.0053947587,0.0017568796,0.0002551601,0.00042036065,0.0013360888],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0067080376,0.00018782682,0.0021041818,0.0002844077,0.00012616126,0.000008357782,0.00025157345,0.0012973701,0.00027719993],"category_scores_gemma":[0.00964484,0.00013348166,0.0003339276,0.00013829158,0.0014122644,0.00015829783,0.000045544,0.0018917904,0.000026584143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022892754,0.0006641336,0.4898606,0.000021281754,0.0003389239,0.0020126684,0.0001556189,0.000015553995,0.000046460435,0.0011084763,0.019404124,0.48408288],"study_design_scores_gemma":[0.00529451,0.016453303,0.45277867,0.000045728142,0.00016773117,0.0015445435,0.00006805736,0.000071420785,0.000007457879,0.0015946358,0.5218863,0.00008766154],"about_ca_topic_score_codex":0.0023494628,"about_ca_topic_score_gemma":0.03633166,"teacher_disagreement_score":0.5024821,"about_ca_system_score_codex":0.00084429805,"about_ca_system_score_gemma":0.0047785845,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W2472847770","doi":"10.1200/jco.2015.65.1901","title":"Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medical Research Council; National Health and Medical Research Council; Bayer HealthCare","keywords":"Regorafenib; Medicine; Internal medicine; Hazard ratio; Placebo; Ramucirumab; Clinical endpoint; Performance status; Gastroenterology; Adverse effect; Chemotherapy; Surgery; Cancer; Randomized controlled trial; Confidence interval; Colorectal cancer; Pathology","score_opus":0.11831704648011558,"score_gpt":0.494835759791865,"score_spread":0.3765187133117494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472847770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9361039,0.0013888505,0.003862269,0.05120435,0.0040715453,0.0028647466,0.000025640296,0.000009163725,0.00046956545],"genre_scores_gemma":[0.9767584,0.005370339,0.003622545,0.0006271299,0.0037654592,0.0002696481,0.0000021472094,0.000016972383,0.009567353],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970683,0.00016191245,0.0021057967,0.00014987725,0.00031481235,0.000199305],"domain_scores_gemma":[0.9891377,0.0077163554,0.00227856,0.00015533413,0.00056239247,0.00014962994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017881003,0.00014095358,0.0016570741,0.0001366863,0.000060466373,0.0000036465467,0.00014440583,0.00013389518,0.00032827733],"category_scores_gemma":[0.003736228,0.000055605804,0.001115532,0.000119434175,0.00014960387,0.00007024648,0.000017413966,0.00014965188,0.0000017186355],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46239308,0.0037420096,0.00071451854,0.000006034595,0.00085100706,0.00001719661,0.00003987077,0.00001620936,0.00014128233,0.0000852917,0.00382604,0.5281674],"study_design_scores_gemma":[0.66837126,0.0888701,0.0024306907,0.000050765473,0.0013366585,0.000013872067,0.00007683118,0.00019966558,0.000068912144,0.00009785646,0.2384371,0.00004629585],"about_ca_topic_score_codex":0.000012111271,"about_ca_topic_score_gemma":0.000047700476,"teacher_disagreement_score":0.5281212,"about_ca_system_score_codex":0.00031096133,"about_ca_system_score_gemma":0.0011772958,"threshold_uncertainty_score":0.4472884},"labels":[],"label_agreement":null},{"id":"W2473053524","doi":"10.1200/jco.2011.29.7_suppl.240","title":"Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Perioperative; Bladder cancer; Chemotherapy; Neoadjuvant therapy; Lymphadenectomy; Cisplatin; Oncology; Retrospective cohort study; Internal medicine; Cancer; Urology; Surgery","score_opus":0.3090803812751522,"score_gpt":0.4821556244112892,"score_spread":0.17307524313613698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473053524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885263,0.00057737075,0.0045796772,0.00083274185,0.0010105729,0.0006010305,0.0004938185,0.0000030011702,0.0033755212],"genre_scores_gemma":[0.9739633,0.000085752145,0.024513554,0.0010515623,0.00031464966,0.000012341104,0.000013401269,0.000011499003,0.00003390482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684626,0.0004023884,0.002094478,0.00014784503,0.0003579118,0.00015112718],"domain_scores_gemma":[0.995066,0.0018263588,0.0017167532,0.00015699968,0.0010539654,0.000179907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096833764,0.00013945156,0.0011918758,0.000077432946,0.00005796331,0.0000013742405,0.00016596387,0.00019530475,0.00025043494],"category_scores_gemma":[0.0011675685,0.00008164969,0.001018413,0.000091760805,0.00051998446,0.00008655825,0.000021801507,0.00038208463,0.0000023344214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14234741,0.12266187,0.4333309,0.0040021227,0.009470699,0.0010402123,0.04344977,0.00009251142,0.030870648,0.0056517357,0.0046494994,0.20243263],"study_design_scores_gemma":[0.076325625,0.029829312,0.8626289,0.00018169456,0.0020799818,0.00009384286,0.0022100278,0.000036655558,0.022959815,0.00076138554,0.002740451,0.00015231592],"about_ca_topic_score_codex":0.000033376436,"about_ca_topic_score_gemma":0.00006112004,"teacher_disagreement_score":0.429298,"about_ca_system_score_codex":0.00008413236,"about_ca_system_score_gemma":0.0038842896,"threshold_uncertainty_score":0.68905634},"labels":[],"label_agreement":null},{"id":"W2473214082","doi":"10.1200/jco.2014.32.30_suppl.244","title":"The cancer imaging program quality framework at Cancer Care Ontario: The first five years.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiology practices and education","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Medical physics; Cancer; Quality (philosophy); Lung cancer; Family medicine; Radiology; Pathology","score_opus":0.13106840574971163,"score_gpt":0.5655801876687034,"score_spread":0.4345117819189918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473214082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8542193,0.0032552967,0.000017612501,0.13546094,0.005086493,0.00021456086,9.5196106e-7,0.0000072436374,0.001737561],"genre_scores_gemma":[0.98037916,0.002487726,0.0011862551,0.010816895,0.0043165428,0.000039900424,0.0000011021093,0.0000115938155,0.00076079584],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976617,0.0005662727,0.0011617151,0.00015460332,0.00022721491,0.000228511],"domain_scores_gemma":[0.9906122,0.006813175,0.0017095755,0.00028525759,0.00041487513,0.00016487946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042551607,0.00008961735,0.0005997511,0.000018815355,0.00024028496,0.00002214466,0.00026506445,0.0002460321,0.00025103093],"category_scores_gemma":[0.0049976474,0.000043321037,0.00029603578,0.00006937497,0.00037661986,0.000073705945,0.00005968514,0.0016394694,0.000012736437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008743121,0.00015100477,0.63350827,0.00000890282,0.0001539588,0.000011121451,0.0018716626,0.000021981086,8.220128e-7,0.000089893496,0.016468631,0.34683946],"study_design_scores_gemma":[0.0005674707,0.0006434751,0.49483457,0.000039550767,0.00017764696,0.00004157241,0.00058381335,0.000025792415,8.730919e-7,0.00028952042,0.5027667,0.000028977225],"about_ca_topic_score_codex":0.010175143,"about_ca_topic_score_gemma":0.11407893,"teacher_disagreement_score":0.4862981,"about_ca_system_score_codex":0.00067299686,"about_ca_system_score_gemma":0.0019142732,"threshold_uncertainty_score":0.9964162},"labels":[],"label_agreement":null},{"id":"W2473240362","doi":"10.1200/jco.2015.33.29_suppl.111","title":"Oncologists' attitudes towards patient and family-centered care.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Grounded theory; Autonomy; Family medicine; Health care; Coding (social sciences); Qualitative research; Affect (linguistics); Nursing; Psychology","score_opus":0.6962326038709171,"score_gpt":0.6159675507579242,"score_spread":0.08026505311299292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473240362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94157624,0.013110057,0.00006540477,0.015612771,0.008774503,0.0007194741,0.00001665179,0.00003943455,0.020085461],"genre_scores_gemma":[0.9795142,0.0013917497,0.009270563,0.008864199,0.00081864925,0.00003140713,0.000005485788,0.00002061252,0.00008317618],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98951554,0.0050403094,0.004281353,0.00023334149,0.00051112904,0.0004183018],"domain_scores_gemma":[0.98764324,0.004560025,0.003855305,0.0004926763,0.0024918912,0.0009568311],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0029495168,0.00016901824,0.0013332536,0.00013532174,0.00024426964,0.0000075338435,0.00051753776,0.0007565144,0.000048124057],"category_scores_gemma":[0.012816165,0.00012552424,0.00021578709,0.00013454731,0.00034611288,0.0001976821,0.00053724,0.0024639175,0.00006912847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024255507,0.0009425976,0.6277889,0.00018470394,0.00014153741,0.00010406697,0.017086858,0.000013374437,0.000010766135,0.00046548533,0.039092537,0.3117436],"study_design_scores_gemma":[0.007423392,0.012325957,0.37017033,0.00027924133,0.000076485776,0.000028907376,0.03954841,0.00003210934,0.0000027363192,0.00076003064,0.5691927,0.00015970752],"about_ca_topic_score_codex":0.00034085813,"about_ca_topic_score_gemma":0.00034910248,"teacher_disagreement_score":0.53010017,"about_ca_system_score_codex":0.00087203196,"about_ca_system_score_gemma":0.0076605785,"threshold_uncertainty_score":0.99983746},"labels":[],"label_agreement":null},{"id":"W2473317929","doi":"10.1200/jco.2015.33.3_suppl.512","title":"RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; FOLFIRI; Ramucirumab; Internal medicine; Clinical endpoint; Hazard ratio; Irinotecan; Progression-free survival; Phases of clinical research; KRAS; Oncology; Log-rank test; Gastroenterology; Colorectal cancer; Randomized controlled trial; Clinical trial; Proportional hazards model; Cancer; Chemotherapy; Confidence interval","score_opus":0.1348567628289724,"score_gpt":0.43279874035046867,"score_spread":0.29794197752149626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473317929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188024,0.0014089444,0.000027544085,0.00063637435,0.00027526208,0.0056997635,0.000008510855,0.00001496199,0.000048379825],"genre_scores_gemma":[0.9977482,0.00043316284,0.0012031803,0.000079630656,0.000113062255,0.00031232403,0.000010866471,0.000045028224,0.000054536184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944976,0.0008052456,0.002921004,0.00050936063,0.0008536356,0.0004131285],"domain_scores_gemma":[0.99333394,0.0023725564,0.0026726394,0.00021290166,0.00095896865,0.00044900115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002593082,0.00047140432,0.004109829,0.00034731143,0.00013897354,0.000034305434,0.00014099815,0.0002110717,0.000029060559],"category_scores_gemma":[0.0017317787,0.00024176527,0.0002532631,0.0003664379,0.00042168848,0.00032274108,0.0001320563,0.00072955916,5.0072424e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8525015,0.016543154,0.09581168,0.00010114718,0.0031813195,0.0022174134,0.005526056,0.0000339267,0.0000075814955,0.0000017639858,0.0000128596785,0.024061581],"study_design_scores_gemma":[0.7641538,0.19203138,0.037662446,0.00035942366,0.0019829276,0.00029921503,0.002588848,0.0005701176,0.00010320531,0.000009986718,0.000028623292,0.00021007129],"about_ca_topic_score_codex":0.00024259469,"about_ca_topic_score_gemma":0.002756661,"teacher_disagreement_score":0.17548822,"about_ca_system_score_codex":0.00052847597,"about_ca_system_score_gemma":0.0013691549,"threshold_uncertainty_score":0.98589015},"labels":[],"label_agreement":null},{"id":"W2473420009","doi":"10.1200/jco.2014.32.15_suppl.3514","title":"Phase I study of the selective BRAF<sup>V600 </sup>inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced <i>BRAF</i>-mutant colorectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Tolerability; Pharmacology; Vomiting; Internal medicine; Oncology; Colorectal cancer; Cancer; Adverse effect","score_opus":0.030565084492805924,"score_gpt":0.37144736432008657,"score_spread":0.34088227982728064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473420009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541104,0.0002336658,0.000010271431,0.0013523046,0.00036164257,0.002289963,0.000015600763,0.0000117623,0.00031376217],"genre_scores_gemma":[0.99856406,0.00017322737,0.00024994597,0.0004191619,0.0003818329,0.00010737445,0.0000017176803,0.00004279339,0.000059874073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590516,0.0007425688,0.0016529824,0.00046197904,0.0008367497,0.00040056292],"domain_scores_gemma":[0.9950707,0.0015268394,0.0019090814,0.0002983143,0.0009480307,0.00024706195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010416661,0.00040138082,0.0023737361,0.00011455737,0.00021513198,0.00002015673,0.00024048758,0.00017455203,0.000019995972],"category_scores_gemma":[0.00047047867,0.00015088177,0.00015241673,0.00060596596,0.0008661611,0.00016514001,0.00011002136,0.0011335835,5.2584403e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21486986,0.018239236,0.72373,0.000028957898,0.0011074069,0.00011721708,0.0041732998,0.00011274279,0.00006287111,0.000005708105,0.00022068448,0.03733201],"study_design_scores_gemma":[0.13632724,0.34925637,0.5079626,0.00038717745,0.00077879446,0.000108492204,0.00345594,0.00008399496,0.00023190332,0.000009744683,0.0012020565,0.00019568775],"about_ca_topic_score_codex":0.00009649771,"about_ca_topic_score_gemma":0.0034751988,"teacher_disagreement_score":0.33101714,"about_ca_system_score_codex":0.00036411427,"about_ca_system_score_gemma":0.0013338503,"threshold_uncertainty_score":0.61527795},"labels":[],"label_agreement":null},{"id":"W2473498748","doi":"10.1200/jco.2016.67.3467","title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":672,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Brentuximab vedotin; Pembrolizumab; Internal medicine; Oncology; Cohort; Adverse effect; Lymphoma; Gastroenterology; Cancer; Immunotherapy; Hodgkin lymphoma","score_opus":0.03249842587650171,"score_gpt":0.355362388881699,"score_spread":0.3228639630051973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473498748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850191,0.00011070023,0.000037026297,0.013729762,0.00022036921,0.00047456636,0.0000057790066,0.000013970893,0.0003887495],"genre_scores_gemma":[0.99467087,0.00006641378,0.0037192171,0.00085513014,0.00046727376,0.000052988536,0.000003313257,0.000032867814,0.000131901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964498,0.00033527514,0.0017284426,0.00034790658,0.000666781,0.00047176375],"domain_scores_gemma":[0.9964454,0.0011458733,0.0010879707,0.00028032254,0.00044713594,0.0005932893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006875096,0.00027325074,0.0016511795,0.0001691797,0.00002568998,0.000015575992,0.0001525682,0.00040966584,0.00011786823],"category_scores_gemma":[0.00060900464,0.00011742913,0.00032695712,0.00017328885,0.00028845787,0.00014626422,0.00005081731,0.00033439862,0.000032840126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031736113,0.011633422,0.707744,0.000011787429,0.0003671875,0.0021071937,0.000029735813,3.596223e-7,0.0000026322807,0.000030909338,0.00048191685,0.24585472],"study_design_scores_gemma":[0.10764057,0.039653048,0.82049805,0.0004685295,0.00044976588,0.00037089406,0.000017108907,0.0000026132739,0.00004660735,0.00004117181,0.030672066,0.00013955668],"about_ca_topic_score_codex":0.000014508818,"about_ca_topic_score_gemma":0.0002074225,"teacher_disagreement_score":0.24571517,"about_ca_system_score_codex":0.0006384597,"about_ca_system_score_gemma":0.0018428655,"threshold_uncertainty_score":0.4788621},"labels":[],"label_agreement":null},{"id":"W2474090921","doi":"10.1200/jco.2015.33.7_suppl.163","title":"Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Cohort; Median follow-up; Cancer; Progression-free survival; Surgery; Overall survival; Gastroenterology; Oncology","score_opus":0.15772649233795646,"score_gpt":0.466060687397871,"score_spread":0.30833419505991455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474090921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962861,0.000972409,0.000003200936,0.001213751,0.000606919,0.00020939927,0.000010890525,0.0000013591356,0.000695999],"genre_scores_gemma":[0.99526167,0.0042572613,0.00005015835,0.00014052057,0.00022157052,0.000006341991,0.000005441173,0.0000054998877,0.000051518186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973456,0.0008449782,0.0011151741,0.00013082648,0.0003891198,0.0001742765],"domain_scores_gemma":[0.9968612,0.001914847,0.0006132922,0.000116391835,0.00032987873,0.00016439226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002903102,0.00008252974,0.0007301318,0.00012296943,0.000013863774,0.00000413662,0.00012874411,0.0001521895,0.000024448025],"category_scores_gemma":[0.0020805574,0.00004604414,0.00009680306,0.00014263278,0.00042074436,0.00011498642,0.000053480242,0.00074969744,0.0000018141018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074629537,0.0013070141,0.96813995,0.000008308014,0.00004983651,0.00032944625,0.0028606951,0.0000046188384,0.000008468097,0.000023897039,0.00097271334,0.018832099],"study_design_scores_gemma":[0.012669139,0.006271469,0.9727579,0.000045975663,0.000013873056,0.000026118263,0.002234949,0.000019168156,0.000015028917,0.00034447358,0.0055603073,0.0000416136],"about_ca_topic_score_codex":0.00007639711,"about_ca_topic_score_gemma":0.0003217532,"teacher_disagreement_score":0.018790485,"about_ca_system_score_codex":0.00022834902,"about_ca_system_score_gemma":0.0007810918,"threshold_uncertainty_score":0.32571042},"labels":[],"label_agreement":null},{"id":"W2474138298","doi":"10.1200/jco.2016.34.7_suppl.141","title":"Safety of using escalated doses of enoxaparin prophylaxis in adults with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Dosing; Cohort; Asparaginase; Surgery; Internal medicine; Complication; Lymphoblastic Leukemia; Anesthesia; Leukemia","score_opus":0.06837712329272398,"score_gpt":0.39590985749567525,"score_spread":0.32753273420295126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474138298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913725,0.00012100601,0.00631061,0.0013552136,0.00021860804,0.0004251057,0.0000073303404,0.00000870999,0.00018089426],"genre_scores_gemma":[0.9908983,0.0006015673,0.008067785,0.00017931698,0.00017724473,0.00000419781,0.0000022926506,0.00003289588,0.000036396807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9945472,0.00072202587,0.0033422988,0.00030245297,0.000735435,0.00035062063],"domain_scores_gemma":[0.9884779,0.0060940767,0.0029217263,0.00037369513,0.0018375717,0.000295065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003279135,0.00020981874,0.0018988722,0.00047657415,0.000023891414,0.0000039509305,0.00029485102,0.00049968646,0.000073296826],"category_scores_gemma":[0.0070758187,0.000113064736,0.0002814614,0.0005833527,0.0006903435,0.00015357006,0.000056014753,0.00065382314,0.000003846437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24791344,0.003187439,0.22563115,0.00032499115,0.0013329585,0.0016317022,0.0004641893,0.00085924653,0.11659912,0.0000530841,0.00019512755,0.40180758],"study_design_scores_gemma":[0.10730394,0.057828378,0.7744672,0.008375422,0.0005798007,0.0014139491,0.00029197367,0.014317601,0.034336995,0.00014445644,0.0005903205,0.00034999108],"about_ca_topic_score_codex":0.00017236955,"about_ca_topic_score_gemma":0.000048469643,"teacher_disagreement_score":0.54883605,"about_ca_system_score_codex":0.0019887534,"about_ca_system_score_gemma":0.012237999,"threshold_uncertainty_score":0.9933617},"labels":[],"label_agreement":null},{"id":"W2474212125","doi":"10.1200/jco.2015.33.15_suppl.8002","title":"Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Erlotinib; Lung cancer; Oncology; Progression-free survival; Gefitinib; Chemotherapy; Gastroenterology; Cancer; Randomized controlled trial; Epidermal growth factor receptor","score_opus":0.050945110925988676,"score_gpt":0.436446730433968,"score_spread":0.3855016195079793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474212125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317163,0.00063849165,0.0002765706,0.0017870574,0.0014539964,0.0011417491,0.0001453846,0.000008319051,0.0013768104],"genre_scores_gemma":[0.99647087,0.00003379379,0.0011481177,0.0015743732,0.00057413883,0.0000142796525,0.000059953374,0.000027703658,0.00009677657],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99517167,0.0007513079,0.0025530448,0.00030438296,0.00094136386,0.0002782422],"domain_scores_gemma":[0.9920838,0.002552447,0.0037288822,0.00050176337,0.00081442564,0.00031870298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016493412,0.00029424965,0.0022179426,0.00008304887,0.00008188636,0.000012880906,0.00037640415,0.00027142774,0.00025248452],"category_scores_gemma":[0.00089033676,0.00014042953,0.0013872387,0.0005059499,0.0002151705,0.00012389595,0.000038635662,0.00055055175,9.4104445e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28395495,0.008935303,0.6878032,0.000019015404,0.0046264026,0.000069803464,0.0010988195,0.0010819703,0.000072429706,0.000019829304,0.00085758214,0.011460702],"study_design_scores_gemma":[0.6274205,0.03802318,0.32142884,0.000073251256,0.0066114087,0.000003942116,0.00046591164,0.0013045068,0.0006266571,0.00008319119,0.0037651767,0.00019342721],"about_ca_topic_score_codex":0.0003385132,"about_ca_topic_score_gemma":0.00025734247,"teacher_disagreement_score":0.36637437,"about_ca_system_score_codex":0.00038328863,"about_ca_system_score_gemma":0.0036104096,"threshold_uncertainty_score":0.64047116},"labels":[],"label_agreement":null},{"id":"W2474269477","doi":"10.1200/jco.2008.26.15_suppl.550","title":"Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Epirubicin; Internal medicine; Breast cancer; Oncology; Cyclophosphamide; Triple-negative breast cancer; Proportional hazards model; Anthracycline; Chemotherapy; Cancer","score_opus":0.18238580471422888,"score_gpt":0.510368495052706,"score_spread":0.3279826903384771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474269477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964504,0.0017141214,0.0000014616584,0.030019373,0.0022222388,0.0006899832,0.00002302125,0.00000479716,0.0008209922],"genre_scores_gemma":[0.9766253,0.015730975,0.00044938983,0.0035393112,0.0031256583,0.000057784895,0.0000026807686,0.000012030539,0.0004568257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967923,0.00086749136,0.001572597,0.000184578,0.00029152381,0.00029150496],"domain_scores_gemma":[0.99546,0.002934111,0.0010070957,0.00008674446,0.00022684896,0.00028522528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018420629,0.00014312973,0.0013004083,0.000116843265,0.000058743066,0.0000044864414,0.00010406209,0.00027367228,0.0007169611],"category_scores_gemma":[0.0009202481,0.00007898622,0.00029590385,0.00020783504,0.0003895947,0.00008905777,0.000027905595,0.0010586629,0.000008589101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3312757,0.0069680437,0.44952247,0.000023417215,0.0006987405,0.0013441178,0.0018812509,0.000002235973,0.00009683832,0.00002784439,0.04713081,0.16102853],"study_design_scores_gemma":[0.16330965,0.025394687,0.7252119,0.00006065451,0.00056612666,0.0011359454,0.00031130685,0.000011920241,0.0000437584,0.00007830871,0.0837862,0.00008952619],"about_ca_topic_score_codex":0.00021134083,"about_ca_topic_score_gemma":0.0002850108,"teacher_disagreement_score":0.27568945,"about_ca_system_score_codex":0.00025490767,"about_ca_system_score_gemma":0.0023378972,"threshold_uncertainty_score":0.78502214},"labels":[],"label_agreement":null},{"id":"W2474470599","doi":"10.1200/jco.2014.32.15_suppl.2527","title":"A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Cancer; Pharmacokinetics; Gastroenterology; Nausea; Toxicity; Discontinuation; Oncology; Pharmacology","score_opus":0.041501006961884884,"score_gpt":0.4388185764004371,"score_spread":0.39731756943855223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474470599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718255,0.00009132319,0.00014435635,0.001112017,0.0006051712,0.00076751556,0.0000053816057,0.0000074263903,0.00008426206],"genre_scores_gemma":[0.998029,0.000048897306,0.0008640885,0.0004872302,0.00047557274,0.000045478704,0.000002258185,0.000030375702,0.000017107111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953849,0.0004522425,0.0030204302,0.0002857316,0.00056308304,0.00029364304],"domain_scores_gemma":[0.99474984,0.0010971992,0.0026717808,0.0002448944,0.0009869068,0.00024939972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013292986,0.00020786142,0.0020943296,0.00028387018,0.000024889467,0.0000039846564,0.00015875802,0.00020270303,0.0000382522],"category_scores_gemma":[0.0017242725,0.00014539192,0.00014726825,0.00037564815,0.00016942123,0.00025528463,0.00003966211,0.0008702304,0.0000015834753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046664186,0.024370639,0.6087297,0.000090507114,0.00013315798,0.00016524828,0.0009423372,0.0016099554,0.0001438236,0.000009528474,0.000016923806,0.31712398],"study_design_scores_gemma":[0.14471775,0.062007457,0.78900146,0.0010915658,0.00014533056,0.00001820989,0.00077938626,0.00055623485,0.00013281513,0.00006460653,0.0013345267,0.00015066481],"about_ca_topic_score_codex":0.00010448715,"about_ca_topic_score_gemma":0.002709101,"teacher_disagreement_score":0.31697333,"about_ca_system_score_codex":0.00040828975,"about_ca_system_score_gemma":0.0008063878,"threshold_uncertainty_score":0.5928911},"labels":[],"label_agreement":null},{"id":"W2475102219","doi":"10.1200/jco.2016.34.4_suppl.627","title":"Association of <i>isocitrate dehydorgenase-1</i> (<i>IDH-1</i>) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Colorectal cancer; KRAS; Medicine; IDH1; Internal medicine; Isocitrate dehydrogenase; Cancer; IDH2; Oncology; Cancer research; Gastroenterology; Mutation; Biology; Genetics; Gene; Enzyme","score_opus":0.04391160603743826,"score_gpt":0.3967445206753128,"score_spread":0.35283291463787453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475102219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98269963,0.0014251522,0.000056032994,0.013690594,0.0007082174,0.00026119096,0.00003161956,0.000012008089,0.0011155326],"genre_scores_gemma":[0.9940222,0.0030408208,0.0011398463,0.00084630743,0.0004308806,0.000020232052,0.000002814218,0.000021898617,0.00047502707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963323,0.00037581375,0.0022574156,0.00022449494,0.00047079468,0.0003391931],"domain_scores_gemma":[0.9936651,0.0021657746,0.0027582312,0.00012863247,0.0010460161,0.00023625846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019488715,0.00018138143,0.0017904188,0.000203648,0.000037117814,0.0000048246916,0.00013211003,0.00028738502,0.000081180064],"category_scores_gemma":[0.0020222135,0.00010622794,0.00035258796,0.000500665,0.00020640444,0.00020662992,0.000030599098,0.000586124,0.0000065618765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006749561,0.0008345082,0.9339976,0.000033083637,0.0010960941,0.00021808424,0.00029593098,0.00005593127,0.023285896,0.00003266567,0.0013978449,0.03200283],"study_design_scores_gemma":[0.020117965,0.006715143,0.951473,0.0003333051,0.00065584306,0.000064251566,0.00017100025,0.000021696489,0.005184703,0.00015188735,0.014964689,0.00014649186],"about_ca_topic_score_codex":0.000078643934,"about_ca_topic_score_gemma":0.0012200994,"teacher_disagreement_score":0.031856336,"about_ca_system_score_codex":0.0005560557,"about_ca_system_score_gemma":0.0021690982,"threshold_uncertainty_score":0.43318498},"labels":[],"label_agreement":null},{"id":"W2475296082","doi":"10.1200/jco.2016.34.7_suppl.14","title":"Economic evaluations of patient-navigation programs in cancer care.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Economic evaluation; Telemedicine; Productivity; Intervention (counseling); MEDLINE; Indirect costs; Health care; Economic cost; Cost–benefit analysis; Randomized controlled trial; Perspective (graphical); Family medicine; Nursing; Business; Surgery; Computer science","score_opus":0.18253630633984744,"score_gpt":0.4450502199701999,"score_spread":0.2625139136303525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475296082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868281,0.0021899506,0.00024261403,0.0019905139,0.0021780538,0.00015895891,0.00004600314,0.0000029623777,0.00636287],"genre_scores_gemma":[0.99687964,0.0016851544,0.00068083836,0.00018865468,0.00046065272,0.000011908973,0.0000016664471,0.000011696975,0.00007981519],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960779,0.00006495365,0.0034552417,0.0001760645,0.000036512407,0.00018931815],"domain_scores_gemma":[0.99521244,0.00042684525,0.0039224843,0.0001489016,0.00016577684,0.00012358284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018202964,0.000092609334,0.0010688113,0.00018249045,0.00001714704,0.0000076148426,0.00019969273,0.0002503344,0.00029656076],"category_scores_gemma":[0.0007288398,0.0000742205,0.0003038842,0.000072391056,0.00015907185,0.00038292882,0.00003056456,0.00022105065,0.000078427045],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001967438,0.00022515815,0.49082485,0.0000113319875,0.000054669235,0.000003706677,0.00033195838,0.00013601777,0.000008712781,0.011336709,0.00028344934,0.49658668],"study_design_scores_gemma":[0.008065622,0.0063073714,0.6857437,0.00037565935,0.00004633359,0.000011705309,0.00036784966,0.0001205083,0.00014446174,0.06085514,0.23765615,0.00030552913],"about_ca_topic_score_codex":0.00032614375,"about_ca_topic_score_gemma":0.0005935561,"teacher_disagreement_score":0.49628115,"about_ca_system_score_codex":0.0006223962,"about_ca_system_score_gemma":0.00082643575,"threshold_uncertainty_score":0.32471323},"labels":[],"label_agreement":null},{"id":"W2475982136","doi":"10.1200/jco.2015.33.15_suppl.5506","title":"An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, <i>TP53</i>-mutant ovarian cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Carboplatin; Urology; Cancer; Gastroenterology; Nuclear medicine; Surgery; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.11064421412713171,"score_gpt":0.4511448396080807,"score_spread":0.340500625480949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475982136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912811,0.0007812772,0.0013456071,0.0026508481,0.0016873031,0.0016824948,0.000093030045,0.0000099802655,0.00046838034],"genre_scores_gemma":[0.9931498,0.0021223784,0.0034649645,0.00020258334,0.00088844897,0.00009353033,0.000009104708,0.000026066517,0.000043078067],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99603885,0.0006450232,0.0023829592,0.00022898534,0.00046530346,0.00023888733],"domain_scores_gemma":[0.991036,0.0042019663,0.002946605,0.00026037975,0.0011144622,0.0004406017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004668021,0.0001998281,0.0025590393,0.0001451135,0.00004439584,0.000007591909,0.00013940322,0.00029007118,0.000026455766],"category_scores_gemma":[0.0034446314,0.000107752516,0.0003928441,0.00014946591,0.00058546185,0.00008625286,0.000025572579,0.00029944154,1.6898106e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8827297,0.0042062136,0.00011699753,0.000016021491,0.0032107946,0.00017351718,0.0020617559,0.00015394852,0.002461239,0.000062247316,0.00016205387,0.10464551],"study_design_scores_gemma":[0.8549508,0.12259844,0.00034443403,0.00014038009,0.0016873374,0.00027068306,0.00072330615,0.00580382,0.0013206893,0.000105883846,0.0119508775,0.00010335387],"about_ca_topic_score_codex":0.0003359597,"about_ca_topic_score_gemma":0.00017750564,"teacher_disagreement_score":0.11839223,"about_ca_system_score_codex":0.00072720076,"about_ca_system_score_gemma":0.003509405,"threshold_uncertainty_score":0.6225534},"labels":[],"label_agreement":null},{"id":"W2477245600","doi":"10.1200/jco.2016.34.15_suppl.9513","title":"KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Internal medicine; Oncology; Family medicine; Immunotherapy; Cancer","score_opus":0.11140591642277498,"score_gpt":0.4643476528672035,"score_spread":0.3529417364444285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477245600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274105,0.0032879505,0.00021796017,0.0017477614,0.0011264826,0.00067478756,0.00001743718,0.0000069659695,0.00017963302],"genre_scores_gemma":[0.99389154,0.004226384,0.0010118482,0.00021652602,0.00042230388,0.000009934582,0.0000018804014,0.000023843708,0.00019572629],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962361,0.00034249178,0.0026066795,0.00024191916,0.00035655024,0.00021629749],"domain_scores_gemma":[0.9912105,0.005418573,0.00243198,0.00028161114,0.0004679412,0.0001893801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019475393,0.00018129236,0.0016962603,0.0001187895,0.00003708462,0.0000030033696,0.00019682026,0.00032709356,0.000104952596],"category_scores_gemma":[0.0017454671,0.000099582736,0.00047110024,0.0001059146,0.0002642558,0.00010466951,0.000045778335,0.00030518352,6.441251e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45913962,0.0057964954,0.0030559215,0.000037976457,0.00065937807,0.000016033779,0.00018999366,0.0000015527643,0.1526789,0.0000033210936,0.0023219394,0.37609884],"study_design_scores_gemma":[0.5390982,0.2671107,0.09363038,0.00053990015,0.00055730937,0.00007076773,0.0006518435,0.000014349756,0.036822382,0.00007863962,0.06119898,0.00022654686],"about_ca_topic_score_codex":0.000011835545,"about_ca_topic_score_gemma":0.0000128354495,"teacher_disagreement_score":0.3758723,"about_ca_system_score_codex":0.00008477764,"about_ca_system_score_gemma":0.00051880826,"threshold_uncertainty_score":0.40608662},"labels":[],"label_agreement":null},{"id":"W2477690934","doi":"10.1200/jco.2015.33.3_suppl.268","title":"Sarcopenia as a predictor of mortality in advanced pancreatic cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcopenia; Pancreatic cancer; Body mass index; Internal medicine; Cancer; Bioelectrical impedance analysis; Overweight; Cachexia; Malnutrition; Sarcopenic obesity; Weight loss; Surgery; Obesity","score_opus":0.34564003011480743,"score_gpt":0.5964883096270605,"score_spread":0.250848279512253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477690934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832415,0.0012959257,0.000018113873,0.009261765,0.0010434717,0.00019154018,0.0000030373453,0.000004797077,0.0049398625],"genre_scores_gemma":[0.9909129,0.0014830441,0.0034506836,0.0033157596,0.0006509117,0.0000053435497,8.562982e-7,0.000007608885,0.00017286674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661607,0.00034483368,0.0024417997,0.000101809004,0.0003337872,0.00016168602],"domain_scores_gemma":[0.9967065,0.0007756039,0.0013750512,0.00012557527,0.00048914686,0.00052811956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003913151,0.000068965724,0.0013928433,0.00010612977,0.000008811676,0.0000014181562,0.00009586266,0.0001960309,0.00017309898],"category_scores_gemma":[0.0051604034,0.000051141455,0.00016748528,0.00014506097,0.00012904692,0.000075533484,0.000023450291,0.00071680994,0.000008485273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054938276,0.0012049251,0.96423626,0.00014487063,0.00008427279,0.00036040173,0.00015413368,0.000013786618,0.0001305419,0.0001365208,0.0027068164,0.025333615],"study_design_scores_gemma":[0.018295396,0.009205268,0.9251551,0.0006708011,0.00016494158,0.00014987151,0.00022585041,0.00009218008,0.00009714317,0.002293697,0.043599043,0.000050729745],"about_ca_topic_score_codex":0.00015661323,"about_ca_topic_score_gemma":0.00016640851,"teacher_disagreement_score":0.040892225,"about_ca_system_score_codex":0.000213379,"about_ca_system_score_gemma":0.0037758267,"threshold_uncertainty_score":0.6698154},"labels":[],"label_agreement":null},{"id":"W2478062669","doi":"10.1200/jco.2016.68.9232","title":"When Do Late Effects in Childhood Cancer Survivors Cease Emerging? The Endocrine Answer","year":2016,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group; University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Medicine; Cancer; Childhood cancer; Endocrine system; Oncology; Pediatrics; Internal medicine; Hormone","score_opus":0.06097529369114402,"score_gpt":0.4385854749377376,"score_spread":0.37761018124659357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478062669","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1010229,0.004840034,0.000028654662,0.87868845,0.0126796225,0.0008304392,0.000042181025,0.000028575718,0.0018391411],"genre_scores_gemma":[0.020998523,0.0051040873,0.00038628248,0.90739095,0.063212946,0.000047169604,0.000015913947,0.00016158221,0.0026825261],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9866168,0.0040515894,0.0059415596,0.0007259962,0.0016276615,0.0010364234],"domain_scores_gemma":[0.9772388,0.015244553,0.005313003,0.0009961133,0.00064380415,0.00056376687],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008996162,0.00068338634,0.005102296,0.00048154674,0.00008174552,0.0000345947,0.0010565574,0.0019233265,0.0011422042],"category_scores_gemma":[0.009313966,0.00037997568,0.001849226,0.00029543566,0.0005936777,0.00018801149,0.00025730924,0.010996749,0.000088944274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014710183,0.00082124467,0.044602428,0.00040073166,0.00153979,0.008580048,0.00090804143,0.0000065409376,0.000004781731,0.000016612474,0.8618029,0.07984591],"study_design_scores_gemma":[0.01095107,0.0036549065,0.09491405,0.0022804548,0.0009758148,0.00046033703,0.00004440922,0.0000036654696,0.000010030726,0.001566463,0.8847584,0.00038036468],"about_ca_topic_score_codex":0.0014624015,"about_ca_topic_score_gemma":0.0024475902,"teacher_disagreement_score":0.08002438,"about_ca_system_score_codex":0.0005623457,"about_ca_system_score_gemma":0.0047029187,"threshold_uncertainty_score":0.99986523},"labels":[],"label_agreement":null},{"id":"W2478115115","doi":"10.1200/jco.2013.31.15_suppl.9009","title":"Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Ipilimumab; Internal medicine; Adverse effect; Progressive disease; Gastroenterology; Melanoma; Toxicity; Phases of clinical research; Surgery; Disease; Cancer; Immunotherapy","score_opus":0.03772999889311207,"score_gpt":0.42130256588563464,"score_spread":0.38357256699252257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478115115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956844,0.0005379549,0.00003864579,0.0019373996,0.00061858294,0.0004599249,0.0000050852254,0.000005440918,0.00071258645],"genre_scores_gemma":[0.9926462,0.0021885056,0.0038038068,0.0010117708,0.0002769808,0.0000018168821,0.000006951773,0.000018507219,0.000045468707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950143,0.00043776122,0.0036658426,0.00024976066,0.0003720506,0.00026028795],"domain_scores_gemma":[0.9948748,0.0020454458,0.0020765106,0.00022382621,0.00048097302,0.00029844046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023240177,0.00017492786,0.0019892042,0.0001561846,0.000025723022,0.000006575109,0.00016261222,0.00041863177,0.00018896797],"category_scores_gemma":[0.0010454239,0.00011109164,0.0003452401,0.00019363278,0.000562661,0.00018054052,0.000051583036,0.00093054085,0.0000061032542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052587412,0.0023537935,0.71674174,0.00002560959,0.0003598316,0.000055715132,0.000031117273,0.000004183792,0.00016861557,0.000011736506,0.00030693554,0.22735332],"study_design_scores_gemma":[0.061038673,0.027375087,0.9031253,0.0002770141,0.0001408375,0.000060206905,0.00003615125,0.000025145837,0.000022091997,0.000031976004,0.007759353,0.00010816621],"about_ca_topic_score_codex":0.000035175704,"about_ca_topic_score_gemma":0.000016136459,"teacher_disagreement_score":0.22724515,"about_ca_system_score_codex":0.000080541875,"about_ca_system_score_gemma":0.0008665647,"threshold_uncertainty_score":0.45301858},"labels":[],"label_agreement":null},{"id":"W2478392998","doi":"10.1200/jco.2013.31.15_suppl.4050","title":"A network meta-analysis (NMA) of randomized controlled trials (RCT) of chemotherapy regimens for metastatic pancreatic cancer (mPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; University of Ottawa","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Internal medicine; Oncology; Pancreatic cancer; Randomized controlled trial; Neutropenia; Febrile neutropenia; Eribulin; Chemotherapy; Irinotecan; Cancer; Metastatic breast cancer; Breast cancer","score_opus":0.39642698345748345,"score_gpt":0.5632123758157804,"score_spread":0.16678539235829698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478392998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82326806,0.055027638,0.03019666,0.067054786,0.0011413414,0.01829236,0.00007008317,0.000018586776,0.004930475],"genre_scores_gemma":[0.89512014,0.011149708,0.08229175,0.003973618,0.0013446682,0.001392539,0.0000088328125,0.00004477258,0.0046739858],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9757503,0.009537017,0.013221629,0.00026005434,0.0008013788,0.0004296108],"domain_scores_gemma":[0.83740747,0.14250894,0.016103877,0.0004336434,0.0030971942,0.00044886977],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.08008815,0.00028331208,0.054936614,0.00044197208,0.000039605828,0.00000819053,0.00028083703,0.00042596358,0.005077959],"category_scores_gemma":[0.0773908,0.00013694749,0.017539203,0.00049440446,0.0008188797,0.0000804931,0.000030858057,0.0006131289,0.0000048349757],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35973662,0.0014887811,0.005994149,0.00012922595,0.62042695,0.000019653287,0.00011420962,0.00015281836,0.00016280012,0.0003844147,0.00900546,0.0023849262],"study_design_scores_gemma":[0.38907313,0.005800232,0.0026659663,0.000043095937,0.59365696,0.0000187137,0.000091008966,0.0028832061,0.000044518558,0.0048911953,0.0007501718,0.00008180689],"about_ca_topic_score_codex":0.00029026784,"about_ca_topic_score_gemma":0.000046143094,"teacher_disagreement_score":0.13834284,"about_ca_system_score_codex":0.00009293201,"about_ca_system_score_gemma":0.0031306432,"threshold_uncertainty_score":0.99583155},"labels":[],"label_agreement":null},{"id":"W2478515289","doi":"10.1200/jco.2016.34.18_suppl.lba4500","title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Atezolizumab; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Cohort; Cisplatin; Urology; Clinical endpoint; Radiation therapy; Cancer; Chemotherapy; Nivolumab; Clinical trial; Bladder cancer; Immunotherapy; Urothelial carcinoma","score_opus":0.0732569150031822,"score_gpt":0.43176995279368185,"score_spread":0.35851303779049964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478515289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886862,0.0010790329,0.000828346,0.004069373,0.0006627139,0.00054346153,0.000045711688,0.000012300787,0.0040728836],"genre_scores_gemma":[0.9884313,0.006762967,0.002003993,0.0017249,0.00043170343,0.000028186365,0.000008394385,0.000038901228,0.00056967675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426,0.0004385049,0.0037689975,0.00039435056,0.00072300254,0.0004151029],"domain_scores_gemma":[0.993637,0.0027758519,0.002064533,0.00042722342,0.0006653651,0.0004300221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179047,0.00030488012,0.003434036,0.00064847706,0.000036305017,0.000006556434,0.000294331,0.0003317714,0.00083770073],"category_scores_gemma":[0.0016594689,0.0001765429,0.0010912542,0.0007731916,0.00032280677,0.00018044654,0.00005968664,0.0005914538,0.000032770084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02495585,0.0031616848,0.6990369,0.000045737903,0.004218373,0.0012005515,0.00009314463,0.00017335136,0.0013408085,0.00003796743,0.00040054446,0.26533508],"study_design_scores_gemma":[0.040697675,0.025331365,0.9198405,0.0002706157,0.0037208956,0.00024490204,0.00003204127,0.00012718923,0.0016229716,0.00078456127,0.0071088937,0.00021834759],"about_ca_topic_score_codex":0.0002788009,"about_ca_topic_score_gemma":0.00024942763,"teacher_disagreement_score":0.26511672,"about_ca_system_score_codex":0.00041247156,"about_ca_system_score_gemma":0.0034743438,"threshold_uncertainty_score":0.9172236},"labels":[],"label_agreement":null},{"id":"W2478905890","doi":"10.1200/jco.2015.33.28_suppl.109","title":"Results of a randomized controlled study of personalized care plans in breast cancer survivors from a single institution.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Regional Cancer Foundation; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Intervention (counseling); Physical therapy; Informed consent; Cancer; Internal medicine; Family medicine; Alternative medicine; Nursing","score_opus":0.10971596307256831,"score_gpt":0.4364549850756264,"score_spread":0.3267390220030581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478905890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901742,0.0026094266,0.000027037853,0.0019452609,0.0021348605,0.000880046,0.00013394756,0.0000046423534,0.0020906064],"genre_scores_gemma":[0.9984812,0.00043147267,0.00010953364,0.00027402033,0.0005976168,0.00002461775,0.0000064294836,0.00001041728,0.00006469197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920597,0.0022055674,0.004702238,0.00019141713,0.0006810958,0.00015996477],"domain_scores_gemma":[0.9897324,0.0046553668,0.0033973819,0.00019502442,0.0017254949,0.00029432855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067791105,0.00015271138,0.0063064587,0.00022696829,0.0000120444065,0.000003940564,0.00016518275,0.00030277966,0.00005925769],"category_scores_gemma":[0.007475639,0.00009707614,0.00089969847,0.00022897431,0.00037199698,0.00007086838,0.00003777464,0.0006138939,8.0417846e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8570046,0.003985711,0.11739782,0.000031685817,0.0012155208,0.00023473124,0.013954407,0.00010861843,0.000052891366,0.000015112983,0.00025174537,0.005747193],"study_design_scores_gemma":[0.91215944,0.0070304205,0.047041867,0.0003862643,0.001612975,0.00004087524,0.02955496,0.00007862549,0.000016803737,0.000057389523,0.0019285029,0.00009185879],"about_ca_topic_score_codex":0.026363613,"about_ca_topic_score_gemma":0.08284852,"teacher_disagreement_score":0.07035595,"about_ca_system_score_codex":0.00028006764,"about_ca_system_score_gemma":0.003224875,"threshold_uncertainty_score":0.98011994},"labels":[],"label_agreement":null},{"id":"W2479313949","doi":"10.1200/jco.2016.34.4_suppl.569","title":"Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Irinotecan; Internal medicine; Adverse effect; Regimen; Neutropenia; Colorectal cancer; Mucositis; Oncology; Gastroenterology; Tolerability; Phases of clinical research; Febrile neutropenia; Combination therapy; Cancer; Surgery; Chemotherapy","score_opus":0.05698833011345561,"score_gpt":0.4185624933571529,"score_spread":0.3615741632436973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479313949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971726,0.00040857654,0.000026512618,0.000714434,0.0003298901,0.001179176,0.00003151207,0.0000055981072,0.00013168287],"genre_scores_gemma":[0.9984554,0.000544653,0.0004713785,0.000171983,0.00013026128,0.00007559627,0.0000018792505,0.00003739063,0.00011146926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964283,0.00036186053,0.0018959307,0.00038764908,0.0006139176,0.000312311],"domain_scores_gemma":[0.9960758,0.0004759624,0.0022482555,0.00018596223,0.00068224873,0.000331763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009334889,0.0002623493,0.0018994763,0.0002568961,0.000028195764,0.000007709195,0.00011907694,0.00019444426,0.00005592937],"category_scores_gemma":[0.000101268284,0.00013584188,0.00008636675,0.00032009554,0.00030404984,0.00022370365,0.0000429058,0.0005598942,6.834141e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09468568,0.014414234,0.6346051,0.00007333744,0.00021668267,0.00017038443,0.00084685645,0.000016513508,0.0006266361,0.0000013264216,0.000033611374,0.25430962],"study_design_scores_gemma":[0.25949112,0.21307382,0.5196113,0.0012095419,0.00048498888,0.000034072164,0.0010750843,0.000013606822,0.003303956,0.000004609249,0.0014835611,0.00021437864],"about_ca_topic_score_codex":0.00025329573,"about_ca_topic_score_gemma":0.019894648,"teacher_disagreement_score":0.25409526,"about_ca_system_score_codex":0.00049719546,"about_ca_system_score_gemma":0.002208728,"threshold_uncertainty_score":0.9979897},"labels":[],"label_agreement":null},{"id":"W2480091379","doi":"10.1200/jco.2006.24.18_suppl.550","title":"Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Letrozole; Tamoxifen; Placebo; Hazard ratio; Internal medicine; Interim analysis; Breast cancer; Oncology; Randomized controlled trial; Chemotherapy; Hormone therapy; Gynecology; Confidence interval; Cancer","score_opus":0.07343197520050578,"score_gpt":0.4740857043753304,"score_spread":0.4006537291748246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480091379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97097737,0.00034892396,0.00018989491,0.017654406,0.0014645025,0.00037917294,0.000046305748,0.00002230327,0.008917102],"genre_scores_gemma":[0.98562217,0.0001589547,0.001836747,0.0064572445,0.0017636674,0.000009237694,0.000086756365,0.00003037657,0.004034876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946511,0.0005816305,0.003362428,0.00035575798,0.0005480775,0.00050100504],"domain_scores_gemma":[0.99364096,0.00242936,0.0022717882,0.0003023189,0.00078190176,0.00057366816],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029830134,0.00027948924,0.0031299954,0.0011943814,0.00007221024,0.00001371015,0.00031138965,0.0005440103,0.0030108115],"category_scores_gemma":[0.0009320819,0.00021983804,0.0012777968,0.001290704,0.00022352769,0.00012236685,0.00009968969,0.0010623632,0.000075347816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14455925,0.009470393,0.50320625,0.00006947134,0.013021816,0.002238769,0.00026311819,0.004362408,0.010477349,0.00022086872,0.2967374,0.015372905],"study_design_scores_gemma":[0.036835752,0.028793432,0.57495,0.000090905545,0.015972367,0.0002657375,0.00016509688,0.00083658873,0.0017388692,0.00006445678,0.33996898,0.00031782227],"about_ca_topic_score_codex":0.00033446366,"about_ca_topic_score_gemma":0.0009046296,"teacher_disagreement_score":0.10772349,"about_ca_system_score_codex":0.00050318724,"about_ca_system_score_gemma":0.001383111,"threshold_uncertainty_score":0.99790055},"labels":[],"label_agreement":null},{"id":"W2480887942","doi":"10.1200/jco.2012.30.4_suppl.604","title":"IXOA regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), and bevacizumab (A), as first-line therapy for advanced unresectable colorectal cancer (aCRC): Preliminary results.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Neutropenia; Regimen; Febrile neutropenia; Irinotecan; Internal medicine; Gastroenterology; Nausea; Oxaliplatin; Bevacizumab; Surgery; Toxicity; Colorectal cancer; Chemotherapy; Cancer","score_opus":0.10087768879335986,"score_gpt":0.4609581969056338,"score_spread":0.36008050811227393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480887942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957902,0.021761147,0.00003989139,0.014449306,0.001833482,0.00094939466,0.000058183003,0.000021301606,0.002985254],"genre_scores_gemma":[0.9714662,0.021246258,0.002540452,0.0009545455,0.002348534,0.00013056448,0.000012642485,0.00003868238,0.0012621307],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99647254,0.00018164616,0.0020867165,0.00032915332,0.00036684854,0.0005630945],"domain_scores_gemma":[0.99368864,0.0033785957,0.0015393818,0.00019397108,0.0006409435,0.0005584937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020600127,0.00029840338,0.0018615813,0.00012765618,0.00019162944,0.000011952867,0.0001380318,0.0003726105,0.0001258881],"category_scores_gemma":[0.0026301367,0.00019958384,0.0004361339,0.0001792623,0.00029537396,0.00023827322,0.000094249575,0.00066428474,0.0000044393055],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3177877,0.005131217,0.06179749,0.000101006895,0.0018919394,0.00017021596,0.0013299693,0.000037968326,0.00054685125,0.0001229499,0.012036676,0.59904605],"study_design_scores_gemma":[0.06543711,0.17924671,0.39156783,0.00026721825,0.0008541069,0.0006300035,0.00055830355,0.00012326213,0.0017860818,0.0004078709,0.35877988,0.00034163595],"about_ca_topic_score_codex":0.00013255255,"about_ca_topic_score_gemma":0.00030832505,"teacher_disagreement_score":0.5987044,"about_ca_system_score_codex":0.00039044349,"about_ca_system_score_gemma":0.000955616,"threshold_uncertainty_score":0.81387925},"labels":[],"label_agreement":null},{"id":"W2481576503","doi":"10.1200/jco.2016.34.15_suppl.2547","title":"A phase I/II study of TKM-080301, a <i>PLK1</i>-targeted RNAi in patients with adrenocortical cancer (ACC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Medicine; Missense mutation; Cancer research; Progressive disease; Primary tumor; Internal medicine; Cancer; Pathology; Mutation; Disease; Gene; Biology; Metastasis; Genetics","score_opus":0.07414349992997915,"score_gpt":0.460084287975562,"score_spread":0.38594078804558285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481576503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965532,0.00013826274,0.00004851709,0.0020850631,0.0005005069,0.00042759313,0.000011407943,0.0000063761004,0.00022906646],"genre_scores_gemma":[0.9983745,0.000038933562,0.00031305532,0.00064459455,0.0004339838,0.000009346949,0.000001304402,0.000017777988,0.00016646116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959094,0.00036956757,0.0026673786,0.00022116974,0.000538285,0.00029418818],"domain_scores_gemma":[0.99599147,0.001118805,0.0016685734,0.00020689421,0.0005876267,0.0004266136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012745059,0.00016676393,0.0017371825,0.00018571828,0.000027957854,0.0000020841912,0.00017660175,0.0002147621,0.00057075976],"category_scores_gemma":[0.0019343065,0.000080640944,0.0002285404,0.0002763027,0.00019374132,0.00011255766,0.00007010568,0.00067232474,0.000008705143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05002504,0.049736097,0.76863843,0.000019525087,0.0004853784,0.0037051165,0.00039234213,0.00000596341,0.000096476455,0.0000206104,0.0010721026,0.1258029],"study_design_scores_gemma":[0.090702645,0.16007799,0.7459633,0.00032180647,0.00038971615,0.00021908164,0.00012729915,0.000007859842,0.000076635944,0.000059470138,0.001947871,0.00010635314],"about_ca_topic_score_codex":0.000056570712,"about_ca_topic_score_gemma":0.0001584841,"teacher_disagreement_score":0.12569655,"about_ca_system_score_codex":0.000121475656,"about_ca_system_score_gemma":0.0013148703,"threshold_uncertainty_score":0.6249419},"labels":[],"label_agreement":null},{"id":"W2481652231","doi":"10.1200/jco.2016.34.15_suppl.e13521","title":"M011L-deficient oncolytic myxoma virus to induce apoptosis in brain tumor initiating cells and to enhance survival in a novel immunocompetent mouse model of glioblastoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Oncolytic virus; Myxoma virus; Temozolomide; Apoptosis; Glioma; Cancer research; Programmed cell death; Biology; Cell culture; Virus; Virology; Tumor cells","score_opus":0.07191316430412852,"score_gpt":0.422090392411331,"score_spread":0.3501772281072025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481652231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953261,0.00007876148,0.001399344,0.0025517119,0.00018932413,0.0003272044,0.0000314564,0.0000021507103,0.00009394714],"genre_scores_gemma":[0.9953833,0.00013460615,0.0026740243,0.0014983481,0.00014922905,0.000018876739,5.1266073e-7,0.000026074684,0.000115009345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99625003,0.0005416026,0.002051146,0.00037985216,0.00035454912,0.00042282726],"domain_scores_gemma":[0.9973954,0.000940471,0.0007348089,0.00029058068,0.0003090254,0.00032973074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048201536,0.00018386988,0.0009261925,0.00030186764,0.00002302445,0.000009745131,0.0004331335,0.0002659546,0.00000997318],"category_scores_gemma":[0.003005013,0.00014015762,0.00018160194,0.0002495637,0.00013856309,0.000012701266,0.00031502522,0.0004379441,0.0000063746643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011771652,0.0011454053,0.0009596195,0.0000123836435,0.0000489993,0.000012444472,0.0001735448,0.002313776,0.9680653,0.000009658249,0.00007329954,0.0154139],"study_design_scores_gemma":[0.0040942323,0.027397662,0.0019949207,0.00012977645,0.000010621002,0.0000108382965,0.00012139174,0.0003609256,0.9649444,0.000030747,0.00071389985,0.0001905492],"about_ca_topic_score_codex":0.00004002412,"about_ca_topic_score_gemma":0.0012841834,"teacher_disagreement_score":0.026252257,"about_ca_system_score_codex":0.0001891744,"about_ca_system_score_gemma":0.0014635033,"threshold_uncertainty_score":0.5715462},"labels":[],"label_agreement":null},{"id":"W2482095145","doi":"10.1200/jco.2015.33.7_suppl.490","title":"Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Nephrectomy; Multivariate analysis; Proportional hazards model; Log-rank test; Oncology; Gastroenterology; Urology; Kidney","score_opus":0.14045060979711352,"score_gpt":0.40196436166749167,"score_spread":0.2615137518703782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482095145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887634,0.00014497442,0.00016030799,0.008220218,0.00101088,0.00092141674,0.00007460201,0.000013645827,0.00057763763],"genre_scores_gemma":[0.9848115,0.00000865466,0.009225133,0.0040649967,0.0011253331,0.000027585933,0.000044041903,0.00006763117,0.0006251349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945937,0.000718,0.0024074141,0.00056912674,0.0011843127,0.00052749156],"domain_scores_gemma":[0.993321,0.00095118466,0.0014962481,0.0005226693,0.0015053127,0.0022035658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013950929,0.0004223507,0.0024340595,0.000376457,0.000058870373,0.000042957992,0.00032618505,0.00026417934,0.00012781449],"category_scores_gemma":[0.00081143144,0.0002763068,0.00047812748,0.00035116545,0.00015981763,0.00018414766,0.00013277438,0.0007506843,0.000078012636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056061998,0.003914087,0.8994305,0.000039027032,0.0018193208,0.0071549374,0.0045630247,0.0013500488,0.002085272,0.000024956507,0.013272001,0.01028483],"study_design_scores_gemma":[0.03151187,0.045837816,0.90669674,0.00011729267,0.0018916085,0.00016875907,0.00038898186,0.00003381248,0.006411305,0.00015174225,0.006481172,0.0003089104],"about_ca_topic_score_codex":0.0007793792,"about_ca_topic_score_gemma":0.00039574836,"teacher_disagreement_score":0.041923728,"about_ca_system_score_codex":0.0015353854,"about_ca_system_score_gemma":0.0028311824,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W2482770344","doi":"10.1200/jco.2012.30.15_suppl.3515","title":"BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University of the Fraser Valley; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; KRAS; PTEN; Oncology; Colorectal cancer; Internal medicine; Cetuximab; Biomarker; Population; Hazard ratio; Tissue microarray; Immunohistochemistry; Cancer; Biology; Confidence interval","score_opus":0.09449423026299256,"score_gpt":0.45487567060260126,"score_spread":0.3603814403396087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482770344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96658814,0.027251352,8.878603e-7,0.003182181,0.00056565274,0.00034750317,0.00027285964,0.000004347574,0.0017870956],"genre_scores_gemma":[0.9647398,0.033179875,0.0005195274,0.00057200674,0.0008316428,0.000021219792,0.000019414072,0.000012653292,0.00010388767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973575,0.0001880054,0.0015881128,0.00023887146,0.00029009214,0.00033745647],"domain_scores_gemma":[0.99430054,0.0040307133,0.0010627162,0.00015227581,0.00016125881,0.0002924969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006653486,0.00020922796,0.0016756585,0.000076301774,0.000057397327,0.000008700071,0.00008210132,0.00022399283,0.00007451676],"category_scores_gemma":[0.00053468323,0.0001147683,0.00020939505,0.000102870545,0.00032163152,0.00012373504,0.000036357684,0.0003009051,0.0000014729259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027485557,0.0033244344,0.6045949,0.0000073531855,0.00088076974,0.00014167478,0.0051616174,0.000005394133,0.0001850012,0.000014393672,0.00060236466,0.35759652],"study_design_scores_gemma":[0.026618928,0.017620632,0.9117498,0.000081696366,0.00067791,0.00003161485,0.0013445908,0.000017949204,0.00016321604,0.0002779426,0.041320536,0.000095197895],"about_ca_topic_score_codex":0.002608971,"about_ca_topic_score_gemma":0.00489811,"teacher_disagreement_score":0.35750133,"about_ca_system_score_codex":0.00034227298,"about_ca_system_score_gemma":0.0003464025,"threshold_uncertainty_score":0.46801153},"labels":[],"label_agreement":null},{"id":"W2483010876","doi":"10.1200/jco.2012.30.15_suppl.3504","title":"Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>K-RAS </i>wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Hôtel-Dieu de Québec; Ottawa Hospital; Princess Margaret Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Chemotherapy; Placebo; Gastroenterology; Refractory (planetary science); Phases of clinical research; Progression-free survival; Surgery; Chemotherapy regimen; Urology; Oncology; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.1747166709566492,"score_gpt":0.4922278301571239,"score_spread":0.3175111592004747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483010876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191993,0.00091907225,0.000026182364,0.001268741,0.0014444668,0.0040140883,0.000035807585,0.0000051604934,0.00036656318],"genre_scores_gemma":[0.99665993,0.0012953936,0.0002809957,0.0007861741,0.0007253825,0.00006073827,0.000011771416,0.00003012117,0.00014947251],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9836185,0.007797436,0.0069868616,0.00033960398,0.00085256336,0.00040505463],"domain_scores_gemma":[0.96603155,0.024991855,0.007763109,0.0003795838,0.0005392229,0.00029466327],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026686838,0.00037427997,0.009331148,0.0002735324,0.00009123465,0.000014333146,0.0003091897,0.0003350351,0.00021690066],"category_scores_gemma":[0.016336245,0.00015281804,0.001961974,0.00073031505,0.0012457687,0.00013501392,0.00008705842,0.0010235485,8.274175e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89241165,0.01210497,0.05786622,0.000023215258,0.011502174,0.00003877547,0.00064820517,0.0000045212305,0.000014841938,0.0000110662895,0.00070061896,0.024673713],"study_design_scores_gemma":[0.8221045,0.07517233,0.084380046,0.00007151335,0.015097194,0.00002349412,0.0002255887,0.00012060239,0.000032406842,0.000021525777,0.0026189939,0.00013179574],"about_ca_topic_score_codex":0.00016056607,"about_ca_topic_score_gemma":0.0004505462,"teacher_disagreement_score":0.070307165,"about_ca_system_score_codex":0.00024541112,"about_ca_system_score_gemma":0.0014881355,"threshold_uncertainty_score":0.99194956},"labels":[],"label_agreement":null},{"id":"W2483226555","doi":"10.1200/jco.2015.33.15_suppl.9591","title":"Prediction models of smoking cessation in lung and head and neck cancer patients: Role of second-hand smoke (SHS) exposure.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Head and neck cancer; Concordance; Logistic regression; Internal medicine; Multivariate analysis; Area under the curve; Cohort; Cancer; Univariate analysis; Confounding; Pathology","score_opus":0.14153813931656573,"score_gpt":0.43565999994052773,"score_spread":0.294121860623962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483226555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926459,0.005120909,0.00001763254,0.0005337338,0.00042771187,0.00011392149,0.000009508119,0.0000016797815,0.0011289974],"genre_scores_gemma":[0.99701834,0.002366196,0.0001725976,0.00019372693,0.0002255609,0.000003087596,0.0000011066468,0.0000058755118,0.000013519466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979977,0.00013736209,0.0014368577,0.00010491602,0.00022234865,0.00010083802],"domain_scores_gemma":[0.99802923,0.00035268112,0.00092301384,0.000055883767,0.00048810558,0.0001511004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013534854,0.00007120077,0.00096233026,0.00010640805,0.000015321306,0.0000024991718,0.00003228303,0.00018760076,0.000011819529],"category_scores_gemma":[0.00068713323,0.000053251802,0.00006256892,0.00007628385,0.0001493812,0.00016627363,0.000032409014,0.00031815894,2.8687502e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017676421,0.00044845254,0.9571808,0.000087209955,0.000117556,0.000005165475,0.001204018,0.00006691304,0.00011955218,0.00002575315,0.00029867166,0.038678285],"study_design_scores_gemma":[0.012278318,0.0095862495,0.97376305,0.00041807792,0.00014909281,0.000010916653,0.0004051097,0.0011143206,0.00016860095,0.0006206433,0.00144504,0.000040564657],"about_ca_topic_score_codex":0.00017112156,"about_ca_topic_score_gemma":0.0005454903,"teacher_disagreement_score":0.03863772,"about_ca_system_score_codex":0.00009362914,"about_ca_system_score_gemma":0.0006068419,"threshold_uncertainty_score":0.21715455},"labels":[],"label_agreement":null},{"id":"W2483478704","doi":"10.1200/jco.2007.25.18_suppl.15580","title":"Sunitinib-related macrocytosis in patients with advanced renal cell cancer (RCC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Macrocytosis; Medicine; Sunitinib; Internal medicine; Gastroenterology; Mean corpuscular volume; Concomitant; Anemia; Population; Oncology; Cancer; Hematocrit","score_opus":0.059895784475185204,"score_gpt":0.41925681068623427,"score_spread":0.35936102621104904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483478704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890475,0.0004140405,0.000024541974,0.00094999257,0.0005268831,0.00028942857,0.0000032473415,0.0000075176054,0.008736795],"genre_scores_gemma":[0.99511003,0.0002535336,0.003075656,0.0008980032,0.0002614688,0.0000033750732,0.0000067491073,0.00002521621,0.00036596012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962203,0.00021664429,0.002480609,0.00021374528,0.0005004393,0.00036825638],"domain_scores_gemma":[0.99584967,0.001237547,0.0016781008,0.00017827262,0.0005747945,0.00048161412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020721608,0.00017870356,0.0013406796,0.00023577594,0.000025354368,0.0000039270617,0.00012642413,0.0003548527,0.00028278492],"category_scores_gemma":[0.0004919212,0.000113507995,0.0002931698,0.00028443706,0.00015195063,0.000098097786,0.00003224244,0.0011888369,0.000017170367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022821562,0.00350074,0.8063686,0.000023176002,0.00023720594,0.002174071,0.00011574543,0.00007353734,0.00030840473,0.0000066748216,0.00044077085,0.16392954],"study_design_scores_gemma":[0.03051832,0.026164914,0.93258303,0.00018722132,0.0003330372,0.00007273865,0.000077302306,0.0000044331427,0.001968,0.000027142447,0.007952647,0.00011121851],"about_ca_topic_score_codex":0.000040567233,"about_ca_topic_score_gemma":0.00018129323,"teacher_disagreement_score":0.16381831,"about_ca_system_score_codex":0.0005382783,"about_ca_system_score_gemma":0.0010776522,"threshold_uncertainty_score":0.5164971},"labels":[],"label_agreement":null},{"id":"W2484375749","doi":"10.1200/jco.2016.34.2_suppl.405","title":"Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer research; Biology; KRAS; Gene; DNA methylation; APOBEC; CDKN2A; Germline mutation; Mutation; Genetics; Gene expression; Genome","score_opus":0.16875312405602524,"score_gpt":0.4365463415071847,"score_spread":0.26779321745115947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2484375749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950359,0.00017991733,0.00011646346,0.0031557002,0.0006807621,0.00034564929,0.00015287618,0.0000030408044,0.00032970528],"genre_scores_gemma":[0.99672717,0.0012795839,0.00016660163,0.00083490106,0.0006603425,0.000009698893,0.000004910076,0.000013572365,0.00030322222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969947,0.00040534345,0.0018420701,0.00018795178,0.00039944606,0.00017050818],"domain_scores_gemma":[0.9952484,0.00089642406,0.002490046,0.00027118443,0.00096836535,0.00012563063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005161989,0.00013597091,0.0015774567,0.00021975876,0.000030265406,0.0000026066284,0.0002305019,0.00022183584,0.00030576665],"category_scores_gemma":[0.0006351097,0.00006616346,0.0008753254,0.00045496807,0.00033179266,0.00008409746,0.000066154294,0.00027298322,0.0000026686182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052685,0.0014871213,0.6113658,0.000087745524,0.005700221,0.000070040405,0.0005784301,0.000015344327,0.3311027,0.00003293068,0.00018014856,0.04411103],"study_design_scores_gemma":[0.0063439067,0.0042267633,0.96960735,0.0001303674,0.0042263838,0.000018657869,0.00006113292,0.000010349425,0.005713662,0.00002869475,0.009568164,0.000064566666],"about_ca_topic_score_codex":0.00019953054,"about_ca_topic_score_gemma":0.0001331144,"teacher_disagreement_score":0.35824156,"about_ca_system_score_codex":0.00016922795,"about_ca_system_score_gemma":0.0030084662,"threshold_uncertainty_score":0.53368896},"labels":[],"label_agreement":null},{"id":"W2485901396","doi":"10.1200/jco.2015.33.29_suppl.148","title":"Multidisciplinary cancer conferences as a forum for early identification of patients who can benefit from palliative care.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Multidisciplinary approach; Advance care planning; Disease; Family medicine; Quality of life (healthcare); Surprise; Cancer; Intensive care medicine; Nursing; Internal medicine; Psychology","score_opus":0.41927493912767694,"score_gpt":0.581101884728927,"score_spread":0.16182694560125005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485901396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937008,0.001747486,0.000231081,0.0017987618,0.0009187709,0.00028343836,0.00015938946,0.0000033472309,0.0011569012],"genre_scores_gemma":[0.9959435,0.0008967705,0.0022675141,0.00017413222,0.0003244596,0.000012375288,0.000024525314,0.0000141774835,0.00034258276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747574,0.00011530052,0.0017923199,0.00014959334,0.00032952355,0.00013751438],"domain_scores_gemma":[0.9930791,0.0014735453,0.002643883,0.00012180698,0.002428036,0.00025360353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056845316,0.00010412218,0.0011518418,0.00008698822,0.000018111707,0.0000035566034,0.00014774001,0.00024085399,0.000043524196],"category_scores_gemma":[0.0035593251,0.000075121316,0.00029017197,0.00007576513,0.00018212221,0.00006889478,0.000040725685,0.00023231222,0.0000032396915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033917262,0.000470085,0.95584714,0.000034827433,0.0003550217,0.000007445145,0.00411979,0.000010161072,0.00006136107,0.00016581404,0.0010958187,0.03444079],"study_design_scores_gemma":[0.00881059,0.010594343,0.9554081,0.00054794364,0.00041551352,3.7352933e-7,0.005953896,0.00007205205,0.0016515503,0.0029746052,0.0134906825,0.00008038238],"about_ca_topic_score_codex":0.0009947233,"about_ca_topic_score_gemma":0.0010726355,"teacher_disagreement_score":0.03436041,"about_ca_system_score_codex":0.00012600877,"about_ca_system_score_gemma":0.0015051215,"threshold_uncertainty_score":0.42611018},"labels":[],"label_agreement":null},{"id":"W2486273864","doi":"10.1200/jco.2013.31.15_suppl.10030","title":"A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high-grade astrocytomas.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Medicine; Cetuximab; Rash; Irinotecan; Internal medicine; Neutropenia; Gastroenterology; Mucositis; Radiation therapy; Surgery; Oncology; Colorectal cancer; Cancer; Chemotherapy","score_opus":0.0323039908594066,"score_gpt":0.37200815862621,"score_spread":0.3397041677668034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486273864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940516,0.0006722411,0.00014700982,0.008025537,0.00022738238,0.0014650378,0.0000339823,0.000008952099,0.000014718279],"genre_scores_gemma":[0.9947657,0.00047719647,0.0035995692,0.00044725428,0.00056148355,0.00007441922,0.000028079061,0.0000244131,0.000021911384],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99724096,0.00016888963,0.0017859408,0.0002572411,0.00028803726,0.00025893186],"domain_scores_gemma":[0.99560326,0.0017353308,0.0018139045,0.00016500532,0.00022736767,0.00045512852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008030125,0.00021216755,0.0018685224,0.00015290348,0.00006767753,0.000017558034,0.000085718995,0.0002476429,0.000023781242],"category_scores_gemma":[0.0014613055,0.00013483722,0.00028433965,0.00010329212,0.00020577897,0.0001556198,0.00004003526,0.00033636895,7.1195217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1335928,0.10064988,0.095674805,0.00005518892,0.002437126,0.00025404608,0.00019165437,0.000003094167,0.0031557735,0.000087345514,0.020794928,0.64310336],"study_design_scores_gemma":[0.61868554,0.18069372,0.19597468,0.00007926495,0.0011508289,0.00018361713,0.00003440845,0.00007075256,0.0015267573,0.00007261208,0.0014172113,0.0001106293],"about_ca_topic_score_codex":0.000120521756,"about_ca_topic_score_gemma":0.000029999312,"teacher_disagreement_score":0.64299273,"about_ca_system_score_codex":0.00006672799,"about_ca_system_score_gemma":0.00037000971,"threshold_uncertainty_score":0.5498502},"labels":[],"label_agreement":null},{"id":"W2486369884","doi":"10.1200/jco.2016.34.15_suppl.6008","title":"BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Paclitaxel; Placebo; Head and neck; Internal medicine; Basal cell; Head and neck squamous-cell carcinoma; Oncology; Chemotherapy; Head and neck cancer; Surgery; Cancer; Pathology","score_opus":0.0411726922846111,"score_gpt":0.38239281850524354,"score_spread":0.3412201262206324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486369884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768674,0.00058665505,0.00007461274,0.00012388952,0.00045741678,0.0008285279,0.000044204622,0.000003639179,0.00019430715],"genre_scores_gemma":[0.99879456,0.000057046847,0.00064553856,0.00011409042,0.00022362296,0.000025006751,0.000007748734,0.000031252723,0.000101117956],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99541783,0.00090385025,0.0025095635,0.0004291253,0.00038657492,0.0003530292],"domain_scores_gemma":[0.99536103,0.0010933147,0.002403707,0.0003430311,0.00051191705,0.0002869942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017200026,0.0002884633,0.0017582962,0.000154657,0.00004880179,0.000009538397,0.0002979998,0.0003114052,0.000044966997],"category_scores_gemma":[0.0021434564,0.00017557768,0.0002304254,0.00014072935,0.00023280956,0.000020447887,0.00014037355,0.00042297915,0.0000013080421],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27221107,0.017752118,0.6726305,0.000052733227,0.00054335524,0.00019291604,0.00049565994,0.00010787146,0.0059400448,0.000002227373,0.0010686715,0.029002827],"study_design_scores_gemma":[0.5587651,0.28801337,0.14857136,0.00015231431,0.00057468435,0.000032694858,0.00029649027,0.00010309829,0.0018587095,0.000043921125,0.0011910456,0.00039718172],"about_ca_topic_score_codex":0.000044120487,"about_ca_topic_score_gemma":0.0002679905,"teacher_disagreement_score":0.5240592,"about_ca_system_score_codex":0.000115354575,"about_ca_system_score_gemma":0.0008601662,"threshold_uncertainty_score":0.71598494},"labels":[],"label_agreement":null},{"id":"W2486398720","doi":"10.1200/jco.2016.34.7_suppl.109","title":"Using a disease pathway management approach to improve the quality of breast cancer care in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Juravinski Cancer Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Multidisciplinary approach; Cancer; Standardization; Clinical pathway; Health care; Quality management; Care pathway; Nursing; Operations management; Management system; Internal medicine","score_opus":0.5300933061981676,"score_gpt":0.6152058826159923,"score_spread":0.08511257641782466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486398720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97120726,0.00009148235,0.0021223668,0.023981214,0.0009067228,0.00061264395,0.000030884465,0.0000030359895,0.0010443588],"genre_scores_gemma":[0.9867441,0.00009067474,0.008548737,0.0039048232,0.00054966734,0.00001260259,0.0000013681451,0.000011406873,0.00013662937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939278,0.0007749636,0.004389691,0.00021483586,0.0004966523,0.00019607524],"domain_scores_gemma":[0.9929849,0.00324424,0.002419726,0.0003050872,0.0006871922,0.00035885355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074515524,0.00010932525,0.00095468166,0.00009494266,0.00002236864,0.000004608093,0.00019537745,0.00012704266,0.00013411402],"category_scores_gemma":[0.0057557053,0.000054140513,0.00036918308,0.00013498741,0.00012815995,0.00013136835,0.00012897677,0.0005580709,0.0000032089172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016520439,0.0018634179,0.51648504,0.00010127313,0.00027236182,0.00008631455,0.00035461472,0.00008226327,0.000557219,0.00028746782,0.00043374754,0.4629558],"study_design_scores_gemma":[0.008706564,0.0013500578,0.97533983,0.0001938918,0.00038385828,0.000025129697,0.0011280556,0.00003496952,0.000012091176,0.00024514098,0.012507548,0.00007288388],"about_ca_topic_score_codex":0.008197172,"about_ca_topic_score_gemma":0.02335808,"teacher_disagreement_score":0.46288294,"about_ca_system_score_codex":0.0008322243,"about_ca_system_score_gemma":0.003425392,"threshold_uncertainty_score":0.9984073},"labels":[],"label_agreement":null},{"id":"W2486671466","doi":"10.1200/jco.2013.31.15_suppl.lba2009","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with <i>O<sup>6</sup>-methylguanine-DNA methyltransferase</i> (<i>MGMT</i>) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Glioblastoma; Methyltransferase; Temozolomide; Oncology; Methylation; O-6-methylguanine-DNA methyltransferase; Internal medicine; Family medicine; Medical physics; Cancer research; DNA; Genetics; Biology","score_opus":0.05012562409168991,"score_gpt":0.3811386982429238,"score_spread":0.3310130741512339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486671466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747695,0.00019909599,0.0005916335,0.004304905,0.00023544599,0.019586109,0.0001577226,0.000015336485,0.00014028778],"genre_scores_gemma":[0.99054676,0.00018237297,0.0073575918,0.0005556678,0.00020298231,0.0009814883,0.000030112968,0.00006487303,0.00007814905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915903,0.0019769983,0.0042044236,0.00058463507,0.00111156,0.00053208147],"domain_scores_gemma":[0.9798411,0.012257165,0.003661276,0.0006192771,0.003030877,0.000590305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034090215,0.00060677296,0.0058675944,0.00023592099,0.00018187941,0.00008113981,0.00043777385,0.00025243266,0.000070590664],"category_scores_gemma":[0.0027350027,0.00025017935,0.0007037408,0.0004631368,0.00048778945,0.00037943313,0.00006864545,0.0005468147,0.0000026835096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87115854,0.0726368,0.022635363,0.000033023334,0.008432647,0.00035978848,0.0007542081,0.00022682731,0.000039095477,0.000016052823,0.0006475875,0.02306009],"study_design_scores_gemma":[0.72185165,0.262631,0.0048736758,0.00033841172,0.007261023,0.00003525182,0.00038770365,0.0005463005,0.000957605,0.00002454369,0.000892472,0.00020037791],"about_ca_topic_score_codex":0.0001580994,"about_ca_topic_score_gemma":0.00026584353,"teacher_disagreement_score":0.18999419,"about_ca_system_score_codex":0.00038938096,"about_ca_system_score_gemma":0.0015796488,"threshold_uncertainty_score":0.99999505},"labels":[],"label_agreement":null},{"id":"W2486727023","doi":"10.1200/jco.2013.31.15_suppl.8507","title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Peripheral T-cell lymphoma; Adverse effect; Gastroenterology; Refractory (planetary science); Clinical endpoint; Lymphoma; CHOP; Clinical trial; Immunology; T cell; Immune system","score_opus":0.07275913997106148,"score_gpt":0.4122713724301568,"score_spread":0.33951223245909534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486727023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98886734,0.0013327638,0.00006937198,0.0051480453,0.0022280293,0.0007956837,0.00008704473,0.000009463248,0.0014622278],"genre_scores_gemma":[0.9838266,0.0011418611,0.0033478471,0.0022277704,0.00497669,0.00005213403,0.00006860887,0.00006783663,0.004290683],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918923,0.0016653236,0.0043868055,0.00067288184,0.00073384633,0.0006488543],"domain_scores_gemma":[0.99227303,0.0033163305,0.0023100341,0.0008234961,0.00075098244,0.00052611536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005404013,0.00036476058,0.0013390194,0.00013669397,0.00014562442,0.00005041805,0.0009178448,0.0012270457,0.00017220285],"category_scores_gemma":[0.016699063,0.00023626763,0.0006900263,0.0002786701,0.0006633445,0.00003106917,0.0003166155,0.0015320985,0.000107226464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23983014,0.014840607,0.0003616629,0.000020319678,0.00035919267,0.0006242208,0.00075221196,0.00006210852,0.38561186,0.000006172793,0.2724917,0.0850398],"study_design_scores_gemma":[0.30229095,0.03591807,0.007875714,0.0001422129,0.00012565803,0.00017511718,0.0008619698,0.00020813683,0.028653542,0.000059175527,0.6230516,0.0006379016],"about_ca_topic_score_codex":0.0009855533,"about_ca_topic_score_gemma":0.0015225246,"teacher_disagreement_score":0.35695833,"about_ca_system_score_codex":0.00035862697,"about_ca_system_score_gemma":0.004379693,"threshold_uncertainty_score":0.9915837},"labels":[],"label_agreement":null},{"id":"W2488212638","doi":"10.1200/jco.2013.31.6_suppl.111","title":"Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Docetaxel; Enzalutamide; Proportional hazards model; Oncology; Cancer; Sunitinib; Performance status; Charlson comorbidity index; Comorbidity; Placebo; Anemia; Urology; Pathology","score_opus":0.1683811252259598,"score_gpt":0.4779750371065477,"score_spread":0.30959391188058794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488212638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981408,0.00007948327,2.1081675e-7,0.00074701203,0.00013007615,0.0008405987,0.000009129389,7.9329027e-7,0.000051904954],"genre_scores_gemma":[0.9996911,0.00017412253,0.00002292152,0.000034073375,0.000034579207,0.000007730572,0.0000011341822,0.0000065796803,0.000027712444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790096,0.0004351228,0.0010019855,0.00010340854,0.0004304156,0.0001281081],"domain_scores_gemma":[0.997545,0.000625823,0.0009560101,0.00012459367,0.00062489754,0.00012369451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009111343,0.000089611494,0.0008983934,0.0000847309,0.000021572938,0.0000037508023,0.000068484675,0.000059821727,0.00002990251],"category_scores_gemma":[0.0004208639,0.000037117105,0.00010309589,0.00014760766,0.00016993292,0.000070116716,0.000027866387,0.00044020626,3.442786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013847156,0.0057033645,0.96944445,0.000025027392,0.00034871278,0.000051006453,0.00027943432,0.000069149006,0.00015856959,0.0000010709924,0.00010333274,0.00996872],"study_design_scores_gemma":[0.02151941,0.048598997,0.9290494,0.0001446894,0.00012315012,0.0000053195427,0.00039672904,0.000049342416,0.000050841678,0.000025236634,0.0000061232913,0.000030781168],"about_ca_topic_score_codex":0.0018214616,"about_ca_topic_score_gemma":0.0005595195,"teacher_disagreement_score":0.042895634,"about_ca_system_score_codex":0.00013486517,"about_ca_system_score_gemma":0.0010097455,"threshold_uncertainty_score":0.27535173},"labels":[],"label_agreement":null},{"id":"W2488329586","doi":"10.1200/jco.2012.30.15_suppl.9042","title":"Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Psychosocial; Breast cancer; Patient satisfaction; Breast reconstruction; Quality of life (healthcare); Informed consent; Data collection; Family medicine; Physical therapy; Medical physics; Surgery; Cancer; Alternative medicine; Nursing; Internal medicine; Psychiatry","score_opus":0.26312473592776475,"score_gpt":0.5219766859615654,"score_spread":0.2588519500338007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488329586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882234,0.0013048758,0.00018537654,0.0009657228,0.0084740445,0.00042980222,0.00004040409,0.0000084089415,0.00036799733],"genre_scores_gemma":[0.9939289,0.00027208833,0.0046013207,0.0003003717,0.0008524318,0.0000039913184,0.000013739956,0.000010887485,0.000016263179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951048,0.00060292636,0.0035438298,0.00026701464,0.00028128191,0.00020016436],"domain_scores_gemma":[0.9925422,0.0034604096,0.0022522933,0.0005065991,0.00082183705,0.0004166428],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0070584817,0.00011988589,0.0017118965,0.000069615155,0.000056614444,0.0000056424146,0.00013584281,0.00042595284,0.000094114315],"category_scores_gemma":[0.012362184,0.000086537664,0.0007796406,0.00012872832,0.00026323658,0.00031759212,0.00011404245,0.000602087,4.0227167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002528175,0.00061669847,0.6770399,0.000053251155,0.0003177865,0.0000045252527,0.00019833288,6.949117e-8,0.0000020656312,0.0000029243868,0.0003391399,0.3188971],"study_design_scores_gemma":[0.006590398,0.002946207,0.97572505,0.000033465156,0.0009866378,0.00047866133,0.002602374,0.00001166835,0.000008417132,0.00007582399,0.010467082,0.00007421691],"about_ca_topic_score_codex":0.00010302537,"about_ca_topic_score_gemma":0.00039138636,"teacher_disagreement_score":0.31882286,"about_ca_system_score_codex":0.00017290666,"about_ca_system_score_gemma":0.001262881,"threshold_uncertainty_score":0.99595714},"labels":[],"label_agreement":null},{"id":"W2489345005","doi":"10.1200/jco.2014.32.15_suppl.4509","title":"Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Cancer research; ARID1A; Epigenetics; Chromatin remodeling; DNA methylation; Exome sequencing; Gene; Genetics; Gene expression; Mutation","score_opus":0.13915660953287382,"score_gpt":0.4589655985544102,"score_spread":0.3198089890215364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489345005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891022,0.0014205287,0.00022745316,0.0051544704,0.0004765613,0.00085843616,0.000017155342,0.000006524964,0.002736671],"genre_scores_gemma":[0.9924519,0.00024557114,0.002660725,0.0029549384,0.0009392001,0.00003974558,0.0000010787122,0.00002729523,0.00067951274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997144,0.0005546956,0.0014586234,0.00021255977,0.00040393934,0.00022617074],"domain_scores_gemma":[0.9970001,0.00076373725,0.0012338901,0.00021751599,0.00059858104,0.00018619598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011726359,0.00017098727,0.0012025841,0.000072910094,0.000058938065,0.000007510663,0.00014257268,0.00026005812,0.00012794163],"category_scores_gemma":[0.001003616,0.00009476451,0.0003387023,0.00010706337,0.00044064422,0.00005697631,0.00008890593,0.0006149347,0.000004923889],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028224776,0.0040487493,0.07622116,0.0007389807,0.006207985,0.0008401502,0.0017107716,0.00008454954,0.32973197,0.0011858458,0.005797248,0.5452078],"study_design_scores_gemma":[0.065517545,0.062519796,0.1888701,0.0012194176,0.0045338487,0.0012769947,0.00073249283,0.0005810325,0.24087925,0.002776193,0.43041268,0.00068064575],"about_ca_topic_score_codex":0.00012324087,"about_ca_topic_score_gemma":0.000038617938,"teacher_disagreement_score":0.5445272,"about_ca_system_score_codex":0.000103690814,"about_ca_system_score_gemma":0.0015737966,"threshold_uncertainty_score":0.38643846},"labels":[],"label_agreement":null},{"id":"W2489494679","doi":"10.1200/jco.2016.34.2_suppl.468","title":"Baseline neutrophil to lymphocyte ratio as a prognostic marker for patients with muscle-invasive bladder cancer being treated with neoadjuvant chemotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Bladder cancer; Neutrophil to lymphocyte ratio; Hazard ratio; Chemotherapy; Proportional hazards model; Oncology; Cystectomy; Stage (stratigraphy); Gastroenterology; Cancer; Lymphocyte; Confidence interval","score_opus":0.035582961019515746,"score_gpt":0.3781707328350752,"score_spread":0.34258777181555944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489494679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98270893,0.00014353801,0.0012375474,0.013623017,0.0003480919,0.0014317612,0.000038082384,0.000018188104,0.00045084802],"genre_scores_gemma":[0.98418057,0.0005837621,0.00394441,0.008949107,0.0011823549,0.00013799244,0.000007047969,0.0000690017,0.00094572984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973832,0.0001919321,0.001273263,0.00036075435,0.00041914798,0.00037174477],"domain_scores_gemma":[0.994977,0.001953994,0.0009368696,0.00022547042,0.001322796,0.0005838869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006370163,0.0002709433,0.0012913436,0.00012340487,0.000060734405,0.000011836782,0.0001263674,0.00021872156,0.00032866411],"category_scores_gemma":[0.0013376294,0.00012460705,0.0002665217,0.00017194533,0.0001402489,0.00013462466,0.000019315607,0.00021357574,0.000014560794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06601326,0.0026044294,0.5187912,0.000034158882,0.0018172932,0.00035795424,0.00012927562,0.000013297308,0.00035745354,0.000010380989,0.0016122988,0.40825897],"study_design_scores_gemma":[0.0835317,0.08644614,0.7903112,0.0009307427,0.001968456,0.00011768287,0.00003659624,0.00002052328,0.00082602125,0.00007128148,0.035480753,0.00025890474],"about_ca_topic_score_codex":0.00007313485,"about_ca_topic_score_gemma":0.00014959575,"teacher_disagreement_score":0.40800008,"about_ca_system_score_codex":0.0004050182,"about_ca_system_score_gemma":0.0035253214,"threshold_uncertainty_score":0.6253769},"labels":[],"label_agreement":null},{"id":"W2489765770","doi":"10.1200/jco.2013.31.15_suppl.8034","title":"Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Clinical endpoint; Lung cancer; Placebo; Population; non-small cell lung cancer (NSCLC); Bevacizumab; Intention-to-treat analysis; Phases of clinical research; Hazard ratio; Surgery; Gastroenterology; Adverse effect; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Pathology","score_opus":0.034398276347925506,"score_gpt":0.4187136529175101,"score_spread":0.3843153765695846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489765770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894295,0.0010806483,0.00038085843,0.0006990236,0.00091569766,0.0071696835,0.000021830285,0.000010189404,0.00029261984],"genre_scores_gemma":[0.99557954,0.00048671194,0.0026795007,0.00022825139,0.00022050698,0.00051321875,0.000017764887,0.00005776148,0.00021673898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99450195,0.0003711838,0.0036328256,0.00041868043,0.0006578291,0.00041755787],"domain_scores_gemma":[0.9920316,0.002092368,0.0035065392,0.00038876472,0.001588208,0.0003925331],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011675743,0.00040213656,0.003655201,0.00047211078,0.000044836826,0.000012175705,0.00026198593,0.00032173184,0.0005111856],"category_scores_gemma":[0.00051121326,0.0002623138,0.00058404973,0.00045987306,0.000241309,0.00024191641,0.00006948055,0.00085727876,0.0000028213233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8444742,0.019470917,0.11876278,0.00019328333,0.002745209,0.00011191828,0.003227934,0.0009099035,0.000025270823,4.3304513e-7,0.00026044587,0.0098177325],"study_design_scores_gemma":[0.9350902,0.024537375,0.030296843,0.000579378,0.0039537502,0.000004409144,0.001698816,0.003359121,0.00011080293,0.0000011018161,0.00015366894,0.0002145438],"about_ca_topic_score_codex":0.0013406598,"about_ca_topic_score_gemma":0.003400065,"teacher_disagreement_score":0.09061602,"about_ca_system_score_codex":0.0008114474,"about_ca_system_score_gemma":0.0016688497,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W2489933219","doi":"10.1200/jco.2012.30.4_suppl.386","title":"Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory <i>K-RAS </i>wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Chemotherapy; Gastroenterology; Clinical endpoint; Placebo; Population; Progression-free survival; Colorectal cancer; Refractory (planetary science); Bevacizumab; Cetuximab; Surgery; Oncology; Urology; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.16035520289368077,"score_gpt":0.49182523893791696,"score_spread":0.3314700360442362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489933219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880178,0.0016746268,0.000026906351,0.001098053,0.0025515163,0.005825814,0.000021551094,0.000012069537,0.00077165815],"genre_scores_gemma":[0.99298316,0.0026668494,0.00068040064,0.0014197936,0.0018366541,0.00011018907,0.000014706757,0.00005467967,0.00023358912],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9825736,0.008088122,0.007532938,0.00042175804,0.000831543,0.00055203034],"domain_scores_gemma":[0.96240854,0.029599367,0.0066191135,0.00033967022,0.00052097836,0.0005123544],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03200101,0.00047247743,0.009407839,0.000221857,0.00010140148,0.000022522912,0.0002654653,0.0004507956,0.0002390449],"category_scores_gemma":[0.02012357,0.00021907834,0.001251572,0.00032696468,0.0011626305,0.00022218589,0.00008376519,0.0013629236,0.0000037983898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8999862,0.01954305,0.016592132,0.000034680834,0.0036940358,0.00013988353,0.0006755048,7.168909e-7,0.00001637411,0.000013653025,0.0020188552,0.057284907],"study_design_scores_gemma":[0.8002158,0.17335738,0.013183872,0.00010250149,0.0033074005,0.000071540235,0.0002711716,0.000029643452,0.000029851692,0.000037800062,0.009207299,0.0001857647],"about_ca_topic_score_codex":0.000106749285,"about_ca_topic_score_gemma":0.00017754498,"teacher_disagreement_score":0.15381433,"about_ca_system_score_codex":0.0003733473,"about_ca_system_score_gemma":0.0018444041,"threshold_uncertainty_score":0.99675864},"labels":[],"label_agreement":null},{"id":"W2491381880","doi":"10.1200/jco.2009.27.15_suppl.6072","title":"Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Surrogate endpoint; Clinical trial; Chemoradiotherapy; Radiation therapy; Surgery; Internal medicine; Randomized controlled trial; Head and neck cancer; Cancer; Oncology","score_opus":0.20474444169595968,"score_gpt":0.5439276544188255,"score_spread":0.33918321272286583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491381880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96548164,0.028842637,0.0006995385,0.003686451,0.0003380088,0.0008150689,0.0000063401017,0.0000027358712,0.00012759582],"genre_scores_gemma":[0.9606955,0.028015774,0.010480891,0.0004719878,0.00028832193,0.000011160468,3.9503973e-7,0.000012145728,0.000023805682],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98940235,0.0007508652,0.009259075,0.00018294966,0.00022461936,0.0001801637],"domain_scores_gemma":[0.9733584,0.013735701,0.012213711,0.00009921787,0.00045507232,0.00013793034],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016456764,0.00015731574,0.008630104,0.00014723164,0.000016118645,0.0000029926389,0.00006688781,0.00023372135,0.000025917952],"category_scores_gemma":[0.026674584,0.00009532239,0.00063143094,0.000104665036,0.000375865,0.00006500079,0.000009032461,0.00035243662,7.93021e-9],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32822362,0.0011148046,0.0088294735,0.00045531467,0.00032137317,0.00006114964,0.0010474735,0.000029152958,0.021459103,0.00003078589,0.00017568789,0.6382521],"study_design_scores_gemma":[0.88015753,0.037583243,0.04618937,0.0023838812,0.00072365435,0.00019412155,0.00041432917,0.00040002633,0.02437538,0.00034246346,0.007046928,0.00018907475],"about_ca_topic_score_codex":0.000040505416,"about_ca_topic_score_gemma":0.00009002385,"teacher_disagreement_score":0.638063,"about_ca_system_score_codex":0.000063482184,"about_ca_system_score_gemma":0.0012117309,"threshold_uncertainty_score":0.98152417},"labels":[],"label_agreement":null},{"id":"W2492293688","doi":"10.1200/jco.2016.34.2_suppl.24","title":"Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cancer Care Ontario; Dalhousie University","funders":"","keywords":"Medicine; Radiation therapy; Goserelin; Androgen deprivation therapy; Prostate cancer; Testosterone (patch); Internal medicine; Incidence (geometry); Oncology; Androgen suppression; Cancer; Urology; Gynecology","score_opus":0.08446186286263296,"score_gpt":0.4741246693844115,"score_spread":0.38966280652177854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492293688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989513,0.0009733457,0.00011918757,0.0083732065,0.00032017875,0.0005645126,0.000008946752,0.0000031032407,0.00012451201],"genre_scores_gemma":[0.9904201,0.0044885576,0.0038898694,0.00033000184,0.0002673193,0.000025464393,0.0000011870089,0.000017369597,0.0005601017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779046,0.0001686376,0.0013191891,0.00015745831,0.0003166534,0.00024762648],"domain_scores_gemma":[0.99614024,0.0017222709,0.0011387938,0.0001261928,0.0006760253,0.00019649636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016613617,0.00010158685,0.0010154922,0.00012644712,0.000019398854,0.0000034888767,0.000120208155,0.00015130024,0.00004147518],"category_scores_gemma":[0.0012890327,0.000048375798,0.00013852863,0.00013446517,0.00026269158,0.00012653721,0.00002055367,0.00028279278,8.6813105e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021881731,0.00078963384,0.6504122,0.000045550474,0.00014943354,0.0000485073,0.0001146845,0.0000022594973,0.0010086516,0.0000029649666,0.0004162122,0.32512814],"study_design_scores_gemma":[0.038438812,0.04347861,0.9100794,0.0010485372,0.00007821817,0.000025552303,0.00002524275,0.000013022739,0.00097550586,0.00009296929,0.0056744847,0.00006961899],"about_ca_topic_score_codex":0.000028549432,"about_ca_topic_score_gemma":0.00013849072,"teacher_disagreement_score":0.32505852,"about_ca_system_score_codex":0.00038550727,"about_ca_system_score_gemma":0.001959063,"threshold_uncertainty_score":0.34752938},"labels":[],"label_agreement":null},{"id":"W2492595798","doi":"10.1200/jco.2016.34.15_suppl.1016","title":"Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; Sunnybrook Health Science Centre; Queen's University; McMaster University; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Epirubicin; Ejection fraction; Cardiotoxicity; Anthracycline; Heart failure; Breast cancer; Internal medicine; Cyclophosphamide; Cardiology; Randomized controlled trial; Chemotherapy; Cancer; Surgery; Gastroenterology","score_opus":0.16339496123548153,"score_gpt":0.5082006822034575,"score_spread":0.34480572096797596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492595798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719383,0.00034653145,0.000005898384,0.023867775,0.0026412283,0.00068965595,0.00013480012,0.000006634148,0.00036917365],"genre_scores_gemma":[0.9929906,0.0014288404,0.00006935746,0.002959617,0.0021349513,0.000074604606,0.0000019558338,0.000023983537,0.00031605383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952724,0.0011631058,0.0022752117,0.00029539902,0.00048679995,0.0005071107],"domain_scores_gemma":[0.9945587,0.0021575405,0.0018186874,0.00024314901,0.0004892572,0.00073269143],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035408314,0.00023111766,0.002178557,0.00019858526,0.0001081473,0.000012877936,0.00025193818,0.00040644826,0.0012983324],"category_scores_gemma":[0.0008690323,0.00010215067,0.00043958114,0.00025210812,0.00037038873,0.00019114802,0.000034326396,0.0008585639,0.000007929038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013848046,0.00094943814,0.86945546,0.0000075377316,0.0005767233,0.00032600548,0.00028388502,0.0000035460241,0.00027318986,0.000012183443,0.0013381658,0.11292585],"study_design_scores_gemma":[0.025448104,0.0066684023,0.9317449,0.00016727537,0.00046807766,0.000038938153,0.000066519555,0.0000026930716,0.00015147118,0.000013958064,0.035099342,0.00013032452],"about_ca_topic_score_codex":0.092609316,"about_ca_topic_score_gemma":0.43037033,"teacher_disagreement_score":0.33776104,"about_ca_system_score_codex":0.001656892,"about_ca_system_score_gemma":0.006110328,"threshold_uncertainty_score":0.9996146},"labels":[],"label_agreement":null},{"id":"W2492729867","doi":"10.1200/jco.2016.66.9077","title":"Intellectual Outcome in Molecular Subgroups of Medulloblastoma","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medulloblastoma; Sonic hedgehog; Medicine; Incidence (geometry); Radiation therapy; Wnt signaling pathway; Internal medicine; Pediatrics; Oncology; Pathology; Biology; Genetics","score_opus":0.10735376341517469,"score_gpt":0.4573374633794889,"score_spread":0.3499836999643142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492729867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709834,0.00030584456,0.00023972496,0.010746914,0.00049219583,0.00009941921,0.0000013498448,0.0000029517419,0.0010132553],"genre_scores_gemma":[0.9974143,0.0002500432,0.0013473218,0.00076550536,0.00016595871,0.0000022885254,2.0764817e-7,0.000009822503,0.00004456772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967485,0.00025522272,0.0024396742,0.00011886374,0.00027156845,0.00016615876],"domain_scores_gemma":[0.99424744,0.00412997,0.0009898666,0.00015211717,0.00024424237,0.00023636708],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018007637,0.000096212294,0.0013655765,0.00020801411,0.00000575127,0.0000013934666,0.00011235006,0.0002424404,0.00031304217],"category_scores_gemma":[0.009535997,0.000049171,0.0004957716,0.00013411036,0.00017126916,0.000042913987,0.000039709805,0.0002668759,0.000022875354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002237252,0.0041071367,0.8370486,0.000015809565,0.0003375242,0.0027006771,0.000076559205,0.000002334955,0.007849192,0.00043050412,0.0014921853,0.14370225],"study_design_scores_gemma":[0.029050015,0.028387103,0.89748067,0.0004022979,0.0004362425,0.00064121775,0.00010946196,0.000013786524,0.016423054,0.00091826083,0.026016124,0.00012177863],"about_ca_topic_score_codex":0.0000069782086,"about_ca_topic_score_gemma":0.000029650422,"teacher_disagreement_score":0.14358048,"about_ca_system_score_codex":0.0001298485,"about_ca_system_score_gemma":0.0004445007,"threshold_uncertainty_score":0.9988071},"labels":[],"label_agreement":null},{"id":"W2493882687","doi":"10.1200/jco.2016.34.4_suppl.315","title":"Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gastroenterology; Ileum; Internal medicine; Rectum; Jejunum; Everolimus; Neuroendocrine tumors; Placebo; Clinical endpoint; Randomized controlled trial; Pathology","score_opus":0.04941480346985076,"score_gpt":0.42548839570345326,"score_spread":0.3760735922336025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493882687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260426,0.00041119877,0.000025668212,0.005810519,0.00020679092,0.00078311434,0.000020780952,0.0000028320883,0.0001348595],"genre_scores_gemma":[0.9982921,0.0006132911,0.000610663,0.00019492577,0.00016777051,0.0000072213943,9.355168e-7,0.000013791756,0.00009933932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99473745,0.0009814162,0.0029815242,0.00027591828,0.00070323836,0.000320473],"domain_scores_gemma":[0.9889768,0.006711951,0.0032495416,0.00033671848,0.00044342031,0.00028156754],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014250616,0.00018226614,0.0020685152,0.00034018437,0.00003744687,0.000003459265,0.0003117786,0.000022391692,0.000067018234],"category_scores_gemma":[0.012399671,0.000083779356,0.0005597284,0.00071796076,0.0013773142,0.00015456526,0.00017703447,0.0008319717,1.6940909e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40387258,0.007870864,0.48878878,0.00013784762,0.00061237614,0.0024295305,0.00002802068,0.000114817696,0.009964274,0.0001278379,0.00015099601,0.08590207],"study_design_scores_gemma":[0.15838932,0.022848316,0.8104859,0.0005137676,0.0008668428,0.004334766,0.00002439801,0.00008143547,0.0005682715,0.00007158257,0.0017518289,0.000063588544],"about_ca_topic_score_codex":0.000011307805,"about_ca_topic_score_gemma":0.0000485203,"teacher_disagreement_score":0.32169712,"about_ca_system_score_codex":0.000080265185,"about_ca_system_score_gemma":0.001200079,"threshold_uncertainty_score":0.9959193},"labels":[],"label_agreement":null},{"id":"W2494392860","doi":"10.1200/jco.2016.34.4_suppl.309","title":"Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Population; Gastroenterology; Progression-free survival; Randomized controlled trial; Sunitinib; Log-rank test; Placebo; Proportional hazards model; Overall survival; Urology; Surgery; Cancer; Pathology","score_opus":0.11626226889246061,"score_gpt":0.4805369080136349,"score_spread":0.3642746391211743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494392860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99081445,0.00019509556,0.00007600247,0.0030677444,0.0007486275,0.004767542,0.00013384758,0.000022184493,0.00017449087],"genre_scores_gemma":[0.995584,0.0002550053,0.0022997006,0.00047012776,0.000848794,0.0002010055,0.000026717527,0.000057014502,0.0002576225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99049896,0.0019804903,0.0048365667,0.00065370725,0.0012135974,0.00081665657],"domain_scores_gemma":[0.973215,0.020711016,0.0038460174,0.0004358815,0.0011146807,0.0006774118],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028195279,0.00040281517,0.0043320544,0.00031333035,0.000085800246,0.000026468744,0.00038496192,0.000036953017,0.00009916733],"category_scores_gemma":[0.036720894,0.00021710913,0.0005360929,0.00022855357,0.00056380476,0.00044646722,0.00021083289,0.0010611515,0.000004875299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87931216,0.014005621,0.053214453,0.00003078245,0.00053790957,0.012057528,0.00008269855,0.00002212421,0.00006129508,0.00002632217,0.00031413796,0.040334962],"study_design_scores_gemma":[0.82312405,0.07654388,0.09567392,0.00062529807,0.000477759,0.000216713,0.00017747779,0.000041858188,0.000110561225,0.00033403942,0.002474252,0.00020017882],"about_ca_topic_score_codex":0.00005863488,"about_ca_topic_score_gemma":0.000100511854,"teacher_disagreement_score":0.06253826,"about_ca_system_score_codex":0.00032508248,"about_ca_system_score_gemma":0.0012730766,"threshold_uncertainty_score":0.9713932},"labels":[],"label_agreement":null},{"id":"W2494437615","doi":"10.1200/jco.2016.34.18_suppl.lba2000","title":"Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Medicine; Interim analysis; Internal medicine; Oncology; Glioma; Adjuvant; Clinical endpoint; Chemotherapy; Randomized controlled trial; Cancer research","score_opus":0.11216341085667411,"score_gpt":0.48703062426084687,"score_spread":0.3748672134041727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494437615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196523,0.00020382508,0.00003903271,0.0047334135,0.0016301345,0.0012309374,0.000029577839,0.000002797392,0.0001650389],"genre_scores_gemma":[0.9990163,0.00033207366,0.000034029894,0.0002055194,0.00034576198,0.00002626609,0.0000036595795,0.000009566125,0.000026831834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917885,0.0027180968,0.00459147,0.00026331507,0.00046212587,0.00017649429],"domain_scores_gemma":[0.9853602,0.009229934,0.0044982173,0.0004012259,0.00030032688,0.00021011339],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006878501,0.00019158056,0.0037433705,0.00037213095,0.000032082775,0.000007021253,0.00024292967,0.00025207447,0.000059109418],"category_scores_gemma":[0.011983526,0.00007214299,0.0013455648,0.00039350515,0.000764393,0.00006501951,0.000070110626,0.00042954387,7.418747e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.951916,0.008303482,0.0038392548,0.00000774006,0.002318336,0.00008059539,0.00016985947,0.0000088043325,0.000698454,0.000086594206,0.0004226545,0.032148235],"study_design_scores_gemma":[0.93649966,0.040029563,0.015370699,0.000528679,0.005075816,0.000036144407,0.00008461329,0.00019208652,0.0014412851,0.00007364439,0.00059830875,0.00006952663],"about_ca_topic_score_codex":0.00005675212,"about_ca_topic_score_gemma":0.0004767881,"teacher_disagreement_score":0.03207871,"about_ca_system_score_codex":0.00015167912,"about_ca_system_score_gemma":0.0005109673,"threshold_uncertainty_score":0.99633896},"labels":[],"label_agreement":null},{"id":"W2494558159","doi":"10.1200/jco.2016.34.15_suppl.e16024","title":"Platinum retreatment in second line chemotherapy for metastatic urothelial carcinoma (UC): Assessing the concept of platinum sensitivity and predictors of survival.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Oxaliplatin; Internal medicine; Metastatic Urothelial Carcinoma; Chemotherapy; Cisplatin; Nedaplatin; Oncology; Progression-free survival; Multivariate analysis; Confidence interval; Proportional hazards model; Gastroenterology; Surgery; Cancer; Urothelial carcinoma; Bladder cancer; Colorectal cancer","score_opus":0.09961161169306863,"score_gpt":0.4375837362689387,"score_spread":0.33797212457587006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494558159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422973,0.00032191098,0.00079521484,0.0030633335,0.000618709,0.00052039913,0.00009699445,0.0000029284877,0.00035075416],"genre_scores_gemma":[0.9968539,0.00013418947,0.0019918452,0.00032429112,0.0005051121,0.000006267084,0.0000018908684,0.000018660612,0.00016386856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969879,0.0005524429,0.0018189667,0.00017307406,0.00026888656,0.00019876736],"domain_scores_gemma":[0.9910911,0.0067023225,0.0015983788,0.00016683206,0.0003044743,0.00013693258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028746475,0.00015447305,0.0015991708,0.00008050219,0.00002649025,0.000003965859,0.00006779045,0.00017152919,0.0000870132],"category_scores_gemma":[0.0014229459,0.000074888354,0.00031040216,0.00008392759,0.00040290313,0.000092405855,0.000025448677,0.0002588324,2.8402354e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008946179,0.0022221634,0.8268534,0.0001152817,0.0014590312,0.00018272243,0.0010162875,0.000007093492,0.010772362,0.00009911312,0.00041551335,0.14791088],"study_design_scores_gemma":[0.045246944,0.019537436,0.9106112,0.00030577998,0.0007733037,0.0001696148,0.00039444782,0.00010128832,0.020167302,0.00047508985,0.0021128089,0.000104763676],"about_ca_topic_score_codex":0.000047942947,"about_ca_topic_score_gemma":0.00014420491,"teacher_disagreement_score":0.14780611,"about_ca_system_score_codex":0.00010860999,"about_ca_system_score_gemma":0.0011332469,"threshold_uncertainty_score":0.30538586},"labels":[],"label_agreement":null},{"id":"W2494947788","doi":"10.1200/jco.2016.34.15_suppl.9007","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; ALK inhibitor; Internal medicine; Refractory (planetary science); Lung cancer; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Ceritinib; Gastroenterology; Randomized controlled trial; Phases of clinical research; Clinical trial; Surgery; Oncology; Malignant pleural effusion","score_opus":0.03449083937050493,"score_gpt":0.4326835096161204,"score_spread":0.39819267024561544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494947788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215627,0.00049340044,0.00028984982,0.002123949,0.0012845325,0.0016896056,0.00007185891,0.0000069452394,0.0018836053],"genre_scores_gemma":[0.9957739,0.0010255842,0.0015999734,0.0003256923,0.00088070973,0.000041418298,0.00002049846,0.000029406583,0.0003027763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99484736,0.00044573145,0.003684429,0.0003450892,0.00041642805,0.00026099087],"domain_scores_gemma":[0.9892729,0.0057114274,0.0037966585,0.0002557476,0.0005450705,0.00041820863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019432354,0.00023323183,0.0027203271,0.00013904201,0.000047470006,0.000007493285,0.00011763089,0.0003132405,0.0002659579],"category_scores_gemma":[0.0032003238,0.00012297918,0.00042148578,0.00011697531,0.00037756108,0.00014441053,0.000041748543,0.0005257368,0.0000021612198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8363082,0.009817798,0.104209885,0.00004650271,0.0012622293,0.0007389787,0.00046858334,0.0000051451093,0.00008740229,0.0000040221657,0.0007545349,0.04629673],"study_design_scores_gemma":[0.8462183,0.016296087,0.12802298,0.0008591945,0.0022644515,0.00004066063,0.00003708186,0.000023970877,0.000068507485,0.000019669811,0.0060209227,0.00012819978],"about_ca_topic_score_codex":0.00051354995,"about_ca_topic_score_gemma":0.00031436552,"teacher_disagreement_score":0.046168532,"about_ca_system_score_codex":0.0003012441,"about_ca_system_score_gemma":0.0029477396,"threshold_uncertainty_score":0.5229164},"labels":[],"label_agreement":null},{"id":"W2495105255","doi":"10.1200/jco.2013.31.15_suppl.6550","title":"Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; University of Ottawa; Canadian Partnership Against Cancer; Public Health Ontario; Statistics Canada; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cohort; Lung cancer screening; Context (archaeology); Quality-adjusted life year; Population; Lung cancer; Cost effectiveness; National Lung Screening Trial; Internal medicine; Environmental health","score_opus":0.07698492454349726,"score_gpt":0.4746590296180815,"score_spread":0.3976741050745842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2495105255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084145,0.0016456211,0.00003721045,0.0058404775,0.0005813558,0.0006109385,0.000006150384,0.0000016291797,0.0004351621],"genre_scores_gemma":[0.9977504,0.00051046506,0.00017674513,0.0012258276,0.00025521585,0.00004611118,0.0000014179128,0.000011632347,0.000022165847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973741,0.0005562249,0.0014208589,0.0001298016,0.0003084373,0.0002105398],"domain_scores_gemma":[0.99167746,0.0065868893,0.0010882152,0.00013708397,0.00030579732,0.00020455151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019943262,0.00010632534,0.0010849751,0.00004241154,0.000028856484,0.0000051212123,0.0001241176,0.00007209044,0.00017382388],"category_scores_gemma":[0.0011262187,0.00005977471,0.00019136255,0.00013372481,0.00008390647,0.000071557195,0.000035117977,0.000578458,7.2742245e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060833694,0.00043227102,0.8528613,0.00007546665,0.00036506224,0.00013487185,0.000026822403,0.0017862417,0.000057781595,0.0000059378076,0.0044136755,0.13923225],"study_design_scores_gemma":[0.008025377,0.0011427663,0.9827937,0.0010075828,0.00026744566,0.000027027447,0.000105529165,0.0033570773,0.0002793869,0.000020246778,0.0029133167,0.00006057901],"about_ca_topic_score_codex":0.54436576,"about_ca_topic_score_gemma":0.34081468,"teacher_disagreement_score":0.2035511,"about_ca_system_score_codex":0.0015416186,"about_ca_system_score_gemma":0.0049726455,"threshold_uncertainty_score":0.88212603},"labels":[],"label_agreement":null},{"id":"W2495512985","doi":"10.1200/jco.2016.34.4_suppl.192","title":"Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Interim analysis; Hazard ratio; Hepatocellular carcinoma; Internal medicine; Randomized controlled trial; Phases of clinical research; Oncology; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Confidence interval","score_opus":0.09144095418322526,"score_gpt":0.4539521059192045,"score_spread":0.36251115173597925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2495512985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369764,0.000519942,0.00007149702,0.0014428464,0.0018078302,0.0020252513,0.000009314782,0.000010378156,0.00041529353],"genre_scores_gemma":[0.99804336,0.000438167,0.00043700458,0.00027450098,0.0004362306,0.000048621514,0.0000054201537,0.000031785785,0.00028491102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99379575,0.0011506565,0.0036809056,0.00037224227,0.00058397837,0.00041643775],"domain_scores_gemma":[0.99143195,0.0042040264,0.002936865,0.00030967782,0.0006884864,0.00042901537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025598945,0.0003086816,0.0046649603,0.00022906317,0.000036317022,0.0000037800298,0.00024208297,0.00033198623,0.000339951],"category_scores_gemma":[0.0012336393,0.00016702278,0.0005433256,0.00026588075,0.00046674765,0.00017390925,0.00006183826,0.000710975,0.000010221005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75632375,0.024943324,0.18405491,0.000023377734,0.0010643794,0.0009913186,0.0003750847,0.00001237128,0.0004211707,0.0000131663855,0.0003548265,0.0314223],"study_design_scores_gemma":[0.8415822,0.11129418,0.042577665,0.00013767136,0.0016226838,0.000015229552,0.00020231384,0.00006609243,0.00037925196,0.00003259125,0.0019316319,0.00015847724],"about_ca_topic_score_codex":0.000095080686,"about_ca_topic_score_gemma":0.00017920736,"teacher_disagreement_score":0.14147726,"about_ca_system_score_codex":0.00052582385,"about_ca_system_score_gemma":0.0016577959,"threshold_uncertainty_score":0.6810991},"labels":[],"label_agreement":null},{"id":"W2496102636","doi":"10.1200/jco.2016.34.2_suppl.117","title":"Copy number alterations of <i>P53</i>, <i>RB1,</i> and <i>MDM2</i> as prognostic markers in intermediate-risk prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Cohort; Oncology; Image-guided radiation therapy; Internal medicine; Prostatectomy; Mdm2; Radiation therapy; Biology; Genetics; Gene","score_opus":0.021538221093914952,"score_gpt":0.38508725670004185,"score_spread":0.3635490356061269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2496102636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524206,0.0009812508,0.0001197864,0.0017669993,0.0009014519,0.00017876102,0.00007423965,0.00000152136,0.0007339567],"genre_scores_gemma":[0.96831733,0.02927,0.00070715876,0.0010015847,0.0005323957,0.000013284053,0.0000040361515,0.000015624824,0.00013858525],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976185,0.0002526967,0.0015854249,0.00021342188,0.00012650828,0.0002034497],"domain_scores_gemma":[0.996713,0.0013097082,0.001341246,0.00015498266,0.00028391188,0.0001971806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013813786,0.00012597477,0.0005871128,0.00004433169,0.00002391033,0.000011071331,0.0001653117,0.00024837055,0.00004250836],"category_scores_gemma":[0.0050387434,0.0000871172,0.00016942114,0.00006627099,0.00031634158,0.000010781966,0.00010906527,0.00025769754,0.0000047637764],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002200327,0.00037774237,0.882066,0.000018390729,0.00013814855,0.00004318622,0.0000549753,0.00002932345,0.007948641,0.0000679036,0.008066069,0.0989893],"study_design_scores_gemma":[0.024827747,0.024576848,0.40642262,0.00063594803,0.00051227194,0.00032625327,0.00025039222,0.000054287248,0.025797205,0.0036329555,0.5122916,0.0006718682],"about_ca_topic_score_codex":0.00009776319,"about_ca_topic_score_gemma":0.0006952856,"teacher_disagreement_score":0.50422555,"about_ca_system_score_codex":0.00003932281,"about_ca_system_score_gemma":0.0012454074,"threshold_uncertainty_score":0.60322106},"labels":[],"label_agreement":null},{"id":"W2497409075","doi":"10.1200/jco.2015.33.15_suppl.tps4573","title":"A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Queen's University; Hôpital Notre-Dame; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Oncology; Hazard ratio; Clinical trial; Regimen; Randomized controlled trial; Prostate cancer; Paclitaxel; Cancer; Adverse effect; Confidence interval","score_opus":0.26525811093850715,"score_gpt":0.5433718220890612,"score_spread":0.27811371115055405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2497409075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590624,0.0003760734,0.00021378927,0.0031421357,0.0040179584,0.005681782,0.00003165655,0.000027534099,0.0006028348],"genre_scores_gemma":[0.9843017,0.00009712529,0.006616731,0.0048652613,0.0033575054,0.00049106026,0.0000104973,0.00007566301,0.00018447205],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98389393,0.0054834974,0.008125543,0.00068038574,0.0011203912,0.00069627276],"domain_scores_gemma":[0.98416764,0.008592826,0.004626297,0.0004101907,0.00077950675,0.0014235676],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.021803891,0.0005236417,0.007778159,0.000348968,0.0000864429,0.000045587843,0.0002624602,0.0005845185,0.00016334839],"category_scores_gemma":[0.030342171,0.00029240773,0.0011722129,0.00026171523,0.00040548414,0.0003088464,0.00012336807,0.0017730095,0.000014049731],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79553187,0.015784055,0.07991455,0.000025434969,0.0012028175,0.00053563766,0.00084032293,0.000023718829,0.000004649277,0.0000040696227,0.00062641356,0.10550648],"study_design_scores_gemma":[0.7929991,0.18216608,0.014056664,0.0013550232,0.0014018815,0.000017480903,0.00024007322,0.00015670298,0.000009364867,0.000033993314,0.007300473,0.000263145],"about_ca_topic_score_codex":0.00007903972,"about_ca_topic_score_gemma":0.000339334,"teacher_disagreement_score":0.16638203,"about_ca_system_score_codex":0.00067107886,"about_ca_system_score_gemma":0.0033212462,"threshold_uncertainty_score":0.9999528},"labels":[],"label_agreement":null},{"id":"W2497752026","doi":"10.1200/jco.2016.34.2_suppl.536","title":"DNA methylation signature to define cell ontogeny of renal cell carcinomas.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"DNA methylation; Biology; Chromophobe cell; Clear cell renal cell carcinoma; Epigenetics; Clear cell; Methylation; Differentially methylated regions; Transcriptome; Cancer research; Genetics; Gene; Renal cell carcinoma; Pathology; Gene expression; Carcinoma; Medicine","score_opus":0.05351445371961458,"score_gpt":0.38343176269165663,"score_spread":0.3299173089720421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2497752026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802464,0.0021041739,0.012411956,0.0010040558,0.0008258684,0.00010625555,0.000011177223,0.0000016000591,0.003288496],"genre_scores_gemma":[0.98988473,0.00077890826,0.0071583707,0.000296798,0.0011380021,0.000001511909,0.000004971477,0.000014619735,0.00072209636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997392,0.00039696047,0.0015837597,0.00021283956,0.00023292223,0.00018149297],"domain_scores_gemma":[0.9968965,0.00044507816,0.0014230513,0.00023551307,0.0007510855,0.00024873836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023230712,0.00012420087,0.000575788,0.000085961066,0.000022572127,0.0000039093125,0.00023635363,0.00054273376,0.000056756217],"category_scores_gemma":[0.0019146624,0.00008081286,0.0003564232,0.00008683142,0.000074763164,0.0000062866507,0.00008117525,0.00021980223,0.0000099747285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007607829,0.00029879727,0.0071973973,0.000009035485,0.000042492542,0.000007980773,0.000020309148,0.00011028211,0.9446609,0.000019136227,0.002001935,0.044870958],"study_design_scores_gemma":[0.002246338,0.007666052,0.034952145,0.000017051963,0.00007547966,0.0000031486538,0.000011619726,0.0000042842616,0.8344073,0.00041322655,0.120091744,0.000111568326],"about_ca_topic_score_codex":0.0000056356293,"about_ca_topic_score_gemma":0.0000356261,"teacher_disagreement_score":0.11808981,"about_ca_system_score_codex":0.00003061971,"about_ca_system_score_gemma":0.00053856923,"threshold_uncertainty_score":0.41860595},"labels":[],"label_agreement":null},{"id":"W2497792808","doi":"10.1200/jco.2012.30.15_suppl.6082","title":"Comparison of drug approval between health Canada (HC) and the U.S. Food and Drug Administration (FDA).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Calgary","funders":"","keywords":"Medicine; Institutional review board; Food and drug administration; Drug; Clinical trial; Clinical research; Drug approval; Approved drug; Phases of clinical research; Internal medicine; Family medicine; Pharmacology; Surgery","score_opus":0.5916847287658685,"score_gpt":0.5714087282508495,"score_spread":0.020276000515018988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2497792808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83270216,0.007804399,0.00028109603,0.15715928,0.0010742169,0.00027803815,0.00004821144,0.0000022647903,0.0006503143],"genre_scores_gemma":[0.9905616,0.00039689025,0.0015401219,0.006211635,0.0012203115,0.000004099653,0.0000033825693,0.000009207061,0.000052769643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9879465,0.0015976968,0.009883622,0.00016956091,0.00013448302,0.00026813243],"domain_scores_gemma":[0.9763771,0.010938275,0.011981948,0.00017713722,0.00010075149,0.00042474052],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.065048605,0.000107855005,0.0025912758,0.00008592895,0.00011370881,0.000016168731,0.00017889592,0.00013656779,0.000024837482],"category_scores_gemma":[0.007861271,0.000090172725,0.00012908084,0.00006535998,0.0002757011,0.00024372927,0.000046565667,0.00053479424,0.000005467775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001859067,0.00022481773,0.91981834,0.00015016299,0.00017626186,3.2018806e-7,0.002158195,0.000006666781,4.423006e-8,0.026079848,0.04453861,0.0066608195],"study_design_scores_gemma":[0.0050932067,0.0015894214,0.7846112,0.000052752184,0.000046998914,0.000025178422,0.0035116642,0.0003740919,0.0000035482872,0.0052772122,0.19925939,0.00015532062],"about_ca_topic_score_codex":0.02259154,"about_ca_topic_score_gemma":0.078706875,"teacher_disagreement_score":0.1578594,"about_ca_system_score_codex":0.00026270593,"about_ca_system_score_gemma":0.0023608028,"threshold_uncertainty_score":0.9839171},"labels":[],"label_agreement":null},{"id":"W2498241992","doi":"10.1200/jco.2004.22.90140.6521","title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Follicular lymphoma; Radiation therapy; Internal medicine; Gastroenterology; Incidence (geometry); Surgery; Cumulative incidence; Lymphoma; Cohort","score_opus":0.09243860262198297,"score_gpt":0.42922491079748964,"score_spread":0.3367863081755067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498241992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890438,0.0028262176,0.00003602218,0.007304806,0.00030091556,0.0003288527,9.1782516e-7,0.000006826001,0.00015166463],"genre_scores_gemma":[0.9916319,0.0047928398,0.000994464,0.002231314,0.00024052117,0.000014346543,0.0000037815473,0.000012605603,0.000078224555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979858,0.00012245474,0.0012841241,0.00018544048,0.00023279851,0.00018939632],"domain_scores_gemma":[0.9981772,0.00071478897,0.00064535317,0.00015016405,0.00006048849,0.00025203367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007118253,0.00016234045,0.0012532055,0.00011839346,0.00004770564,0.000010620255,0.000053380358,0.00024450518,0.00002103408],"category_scores_gemma":[0.00022597102,0.00009244961,0.00036092856,0.000096869306,0.000047273257,0.00011081716,0.00001767896,0.00014023135,0.000002293812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021198501,0.0043744263,0.76070195,0.0000060128996,0.000556024,0.004613291,0.00016751893,0.000009664113,0.000027956703,0.000027174752,0.0000097464645,0.2273864],"study_design_scores_gemma":[0.07479484,0.046093486,0.875443,0.00010203848,0.00027927032,0.00016476713,0.000044824697,0.0000045979127,0.0006043441,0.00004829738,0.0023393768,0.00008120259],"about_ca_topic_score_codex":0.00017852792,"about_ca_topic_score_gemma":0.0003472666,"teacher_disagreement_score":0.2273052,"about_ca_system_score_codex":0.00063752214,"about_ca_system_score_gemma":0.00081430277,"threshold_uncertainty_score":0.37699857},"labels":[],"label_agreement":null},{"id":"W2499544841","doi":"10.1200/jco.2014.32.15_suppl.e15507","title":"Patterns of referral for peri-operative chemotherapy among patients with muscle-invasive bladder cancer (MIBC): A population-based study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cystectomy; Referral; Bladder cancer; Chemotherapy; Population; Internal medicine; Cancer registry; Multivariate analysis; Cancer; Logistic regression; Oncology; Family medicine","score_opus":0.0716785728482256,"score_gpt":0.4398960107893673,"score_spread":0.3682174379411417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2499544841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670184,0.000026150408,0.0005122942,0.0011666114,0.0004861524,0.00093368685,0.000034489618,0.0000059673657,0.00013279694],"genre_scores_gemma":[0.99589556,0.00002449105,0.0010490314,0.00215754,0.0006667855,0.000052463107,0.000014438694,0.0000318346,0.000107827655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751824,0.00029153982,0.0013987278,0.00021999217,0.00038080735,0.00019067457],"domain_scores_gemma":[0.996173,0.0010492486,0.0014049261,0.00018435808,0.0009676998,0.00022072667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068473344,0.00017705967,0.0013274677,0.00009031709,0.00004725234,0.000006549615,0.00011060524,0.00019394417,0.0002468127],"category_scores_gemma":[0.00061668723,0.00010729404,0.0003205813,0.00007592843,0.00006489655,0.00009353716,0.000011047981,0.00033536612,8.268327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067145196,0.0039833314,0.95602626,0.000032874414,0.0008664453,0.000009835189,0.00040130442,0.00006490655,0.000010198544,0.0000046999776,0.00017018226,0.03171546],"study_design_scores_gemma":[0.03533534,0.04475346,0.9177055,0.00013679468,0.00073279487,0.0000013964562,0.00019963735,0.0000589794,0.00008246723,0.000023261064,0.0008728973,0.0000975151],"about_ca_topic_score_codex":0.00041691825,"about_ca_topic_score_gemma":0.0014031186,"teacher_disagreement_score":0.04077013,"about_ca_system_score_codex":0.00016645117,"about_ca_system_score_gemma":0.0010528964,"threshold_uncertainty_score":0.43753242},"labels":[],"label_agreement":null},{"id":"W2500289888","doi":"10.1200/jco.2015.33.15_suppl.4507","title":"Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chromophobe cell; Everolimus; Sunitinib; Clinical endpoint; Internal medicine; Hazard ratio; Oncology; Renal cell carcinoma; Progression-free survival; Randomized controlled trial; Clear cell; Urology; Confidence interval; Chemotherapy","score_opus":0.16073283423972487,"score_gpt":0.4422219842839687,"score_spread":0.2814891500442438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500289888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906524,0.00009367563,0.000070392365,0.0009623534,0.0014155217,0.0013319097,0.0000422439,0.0000038586136,0.0054276474],"genre_scores_gemma":[0.99059826,0.00009296277,0.007909242,0.00026422867,0.00067269,0.000011494001,0.00004502793,0.000030093715,0.00037598028],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9862849,0.0025613178,0.00904219,0.00037557463,0.0014067518,0.00032927378],"domain_scores_gemma":[0.9826483,0.0064493045,0.00773524,0.0003975952,0.0020703478,0.000699224],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01465829,0.0003013224,0.0051821647,0.00045474543,0.000021424928,0.000006744476,0.00038637363,0.00036560063,0.000094993185],"category_scores_gemma":[0.009972151,0.00019326709,0.0013192773,0.00024387079,0.00066447794,0.00015859806,0.00014377238,0.0013075282,0.000009450189],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9331809,0.03340162,0.024545407,0.000045348632,0.0006102312,0.00096303946,0.0002801852,0.000047793015,0.000036295798,0.0000045257593,0.0015296349,0.0053549693],"study_design_scores_gemma":[0.759748,0.19268596,0.043927733,0.00012842713,0.0015028957,0.000042050007,0.000093226474,0.00020591806,0.00051177153,0.000059900878,0.0009762098,0.00011792177],"about_ca_topic_score_codex":0.00010069706,"about_ca_topic_score_gemma":0.000026042786,"teacher_disagreement_score":0.17343296,"about_ca_system_score_codex":0.00024198933,"about_ca_system_score_gemma":0.0037985742,"threshold_uncertainty_score":0.99836725},"labels":[],"label_agreement":null},{"id":"W2500755305","doi":"10.1200/jco.2016.67.9423","title":"Management Considerations After Cystectomy for Bladder Cancer","year":2016,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Radiation therapy; Randomized controlled trial; Stage (stratigraphy); Chemotherapy; Clinical trial; Cancer; Oncology; Surgery; Internal medicine","score_opus":0.13253901663200732,"score_gpt":0.4801574624115642,"score_spread":0.3476184457795569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500755305","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005467845,0.0018455951,0.0004621476,0.97955775,0.0057613794,0.0010260702,0.00017167671,0.00001410957,0.010614475],"genre_scores_gemma":[0.0075003034,0.0021301748,0.005099719,0.92514,0.0395591,0.00034911663,0.000013837363,0.000076132594,0.020131618],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625146,0.00024448257,0.0023742479,0.00031994455,0.00043192442,0.00037793376],"domain_scores_gemma":[0.9949866,0.0021461195,0.0016401521,0.0003001083,0.00070072425,0.00022632035],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008806467,0.00028073788,0.0020694076,0.00019232737,0.000046063207,0.000015663678,0.0001263958,0.0013100096,0.0024878564],"category_scores_gemma":[0.00041795356,0.00016591238,0.0011852646,0.000048022335,0.00019527618,0.00007164779,0.00004285527,0.0016221062,0.00005543523],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023306645,0.00024668782,0.00090679416,0.00016926738,0.0039407443,0.006636954,0.000019265479,2.5387249e-7,0.0000017751862,0.000023814644,0.92902213,0.05670167],"study_design_scores_gemma":[0.013453055,0.0054308563,0.0037290072,0.00048278703,0.0040747593,0.0004562861,0.0000072695443,9.4323804e-7,0.000011506689,0.0018333131,0.97035754,0.00016269475],"about_ca_topic_score_codex":0.000010798996,"about_ca_topic_score_gemma":0.000020723759,"teacher_disagreement_score":0.056538977,"about_ca_system_score_codex":0.00034462946,"about_ca_system_score_gemma":0.0024430633,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W2501728701","doi":"10.1200/jco.2016.34.18_suppl.lba1","title":"A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Moncton Hospital; Dalhousie University; BC Cancer Agency; Queen's University; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Letrozole; Medicine; Breast cancer; Aromatase inhibitor; Tamoxifen; Placebo; Randomization; Internal medicine; Clinical endpoint; Adjuvant therapy; Oncology; Randomized controlled trial; Cancer; Surgery; Gynecology","score_opus":0.036266681209852526,"score_gpt":0.39660188797864304,"score_spread":0.3603352067687905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501728701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980318,0.00047911503,0.00007324477,0.0001748479,0.00031256184,0.0006924883,0.00022422543,0.0000026006212,0.0000090951435],"genre_scores_gemma":[0.9976117,0.00076517806,0.0007690597,0.00013004226,0.0005784786,0.00007120594,0.000012724363,0.000027526377,0.000034112636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967153,0.00089208444,0.0016776462,0.00022484633,0.00020441395,0.0002857035],"domain_scores_gemma":[0.9968558,0.0009973915,0.0016447549,0.00015608396,0.00015420283,0.00019175118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029881794,0.00015329999,0.00143275,0.00008514372,0.000015165692,0.0000064915093,0.00018958788,0.00037968258,0.000042165553],"category_scores_gemma":[0.0006789921,0.000089620495,0.00021682211,0.00007442505,0.0003395854,0.000020275396,0.00004733215,0.0002517704,4.5454885e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169271,0.00094069773,0.0009878279,0.000012799255,0.00039629117,0.000074286734,0.00011915708,0.0000055010305,0.1546146,0.0000019586832,0.00011646375,0.025803361],"study_design_scores_gemma":[0.90998966,0.053782187,0.01251146,0.00022265148,0.000121575526,0.00008074014,0.000093561415,0.0000124206135,0.021695122,0.00002625409,0.0012563338,0.00020801375],"about_ca_topic_score_codex":0.000051196752,"about_ca_topic_score_gemma":0.000022782297,"teacher_disagreement_score":0.13291948,"about_ca_system_score_codex":0.00004973042,"about_ca_system_score_gemma":0.0005617556,"threshold_uncertainty_score":0.36546177},"labels":[],"label_agreement":null},{"id":"W2502183409","doi":"10.1200/jco.2015.33.7_suppl.3","title":"ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Clinical endpoint; Urology; Randomized controlled trial; Androgen deprivation therapy; External beam radiotherapy; Goserelin; Internal medicine; Radiation therapy; Cancer; Oncology","score_opus":0.11810769766377882,"score_gpt":0.4752221609193588,"score_spread":0.35711446325558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2502183409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824827,0.0056097303,0.0006574892,0.0033450595,0.0022960582,0.0052499156,0.000043890308,0.000025086883,0.00029011475],"genre_scores_gemma":[0.9437612,0.049143363,0.0030853609,0.00045451368,0.0020868818,0.0003455711,0.00004016939,0.00008493599,0.0009979876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99299747,0.0020326367,0.0032098389,0.00038405208,0.00084226165,0.0005337211],"domain_scores_gemma":[0.98805666,0.0050618392,0.004067308,0.00029833568,0.001765075,0.0007507898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010930025,0.00034245517,0.0034417356,0.00024725232,0.000084194035,0.00003105791,0.00025586164,0.00045657644,0.00007586495],"category_scores_gemma":[0.0032771,0.00019480863,0.00091437047,0.00030651875,0.0006250394,0.0002510292,0.000029308898,0.0010252771,0.0000040596783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8554539,0.0035182561,0.0045295525,0.00004895813,0.0030883509,0.00012219448,0.0005435856,0.0002633387,0.00045867366,0.000009385688,0.0008764916,0.13108733],"study_design_scores_gemma":[0.9176358,0.066282466,0.0027572303,0.00026417698,0.001028985,0.000020868143,0.00017997323,0.004154852,0.0015232437,0.00024279403,0.005728289,0.00018133041],"about_ca_topic_score_codex":0.00032025506,"about_ca_topic_score_gemma":0.000042572454,"teacher_disagreement_score":0.130906,"about_ca_system_score_codex":0.0005292007,"about_ca_system_score_gemma":0.0058609853,"threshold_uncertainty_score":0.9997749},"labels":[],"label_agreement":null},{"id":"W2502415174","doi":"10.1200/jco.2006.24.18_suppl.6053","title":"Early closure of clinical trials: The experience of the National Cancer Institute of Canada Clinical Trials Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Interim; Accrual; Closure (psychology); Interim analysis; Clinical trial; Surgery; Internal medicine; Accounting","score_opus":0.857267125498613,"score_gpt":0.7433236099046423,"score_spread":0.11394351559397065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2502415174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458471,0.0010493405,0.000104365514,0.036515076,0.011673773,0.00083138293,0.00008107818,0.0000041366707,0.0038937428],"genre_scores_gemma":[0.98304635,0.0027009253,0.0014697389,0.0033541224,0.008351455,0.000016729831,0.0000018330487,0.000023736833,0.0010350994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8903435,0.040780287,0.0591968,0.00085135567,0.008029058,0.0007990075],"domain_scores_gemma":[0.31634873,0.63231754,0.038796343,0.0012778799,0.010323392,0.00093612424],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.3687724,0.00025216822,0.007520582,0.00011745955,0.00010653268,0.000010935497,0.0016254269,0.0019489797,0.00036468633],"category_scores_gemma":[0.76167274,0.000121709636,0.00400261,0.0005556774,0.0052169533,0.00014559149,0.0003561002,0.007969038,0.0000017823567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020801999,0.0052749882,0.8612694,0.00019804972,0.0019405017,0.00009416875,0.00016544537,0.00013946531,0.00032313904,0.014983797,0.052971125,0.04183793],"study_design_scores_gemma":[0.015445854,0.007001108,0.86397773,0.00069108006,0.0008259175,0.00003871363,0.00020524584,0.000090620204,0.0002673301,0.012979328,0.09834289,0.0001342084],"about_ca_topic_score_codex":0.03290455,"about_ca_topic_score_gemma":0.12567197,"teacher_disagreement_score":0.59153724,"about_ca_system_score_codex":0.00022617418,"about_ca_system_score_gemma":0.044936102,"threshold_uncertainty_score":0.9993467},"labels":[],"label_agreement":null},{"id":"W2502507727","doi":"10.1200/jco.2015.33.15_suppl.4503","title":"First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Hôpital Notre-Dame; BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Bladder cancer; Chemotherapy; Placebo; Clinical endpoint; Gastroenterology; Cancer; Oncology; Cisplatin; Surgery; Randomized controlled trial; Pathology","score_opus":0.12148471512901843,"score_gpt":0.47163188908456355,"score_spread":0.3501471739555451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2502507727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909607,0.000147858,0.000044421602,0.0037685097,0.0017299743,0.0025662438,0.000037340447,0.0000060590796,0.00073889445],"genre_scores_gemma":[0.9974427,0.00029241084,0.00036118354,0.00063174346,0.0008317451,0.00011510851,0.000014007932,0.000022224118,0.00028883424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952523,0.00063826144,0.0028566683,0.00021159528,0.0008462605,0.00019491864],"domain_scores_gemma":[0.99383837,0.0023859052,0.002309714,0.00023611549,0.00094848,0.00028139877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035820277,0.00019672235,0.002323483,0.00014980501,0.000039732404,0.000006161726,0.00027814758,0.00017315798,0.00017246786],"category_scores_gemma":[0.004956995,0.00008978754,0.0002585748,0.00020653773,0.00020955999,0.00013338272,0.00007702808,0.00067304954,0.0000014774616],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9301344,0.014602253,0.022864254,0.0000073156375,0.0014285281,0.00012891747,0.0010954817,0.00042871758,6.086592e-7,0.0000069321354,0.0019666147,0.027335979],"study_design_scores_gemma":[0.87672293,0.10895766,0.0074138483,0.00009486702,0.0010151492,0.000012293973,0.0005400408,0.0002737119,0.0000063877324,0.000053224805,0.004826904,0.00008296041],"about_ca_topic_score_codex":0.00048419653,"about_ca_topic_score_gemma":0.0020273156,"teacher_disagreement_score":0.09435541,"about_ca_system_score_codex":0.0003296271,"about_ca_system_score_gemma":0.0028134654,"threshold_uncertainty_score":0.5934344},"labels":[],"label_agreement":null},{"id":"W2503710795","doi":"10.1200/jco.2016.34.15_suppl.3553","title":"Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Hazard ratio; Internal medicine; Quality of life (healthcare); Clinical endpoint; Maintenance therapy; Tolerability; Randomization; Proportional hazards model; Oncology; Randomized controlled trial; Visual analogue scale; Colorectal cancer; Confidence interval; Surgery; Cancer; Adverse effect; Chemotherapy","score_opus":0.1695286658192528,"score_gpt":0.4872432541027403,"score_spread":0.3177145882834875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503710795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97960955,0.0007063745,0.000003255173,0.017613633,0.00049051916,0.0013083306,0.000072009854,0.0000029331973,0.0001934183],"genre_scores_gemma":[0.9971468,0.0014584613,0.00020421323,0.0009736116,0.00007406001,0.000026196916,0.0000011071855,0.000010418014,0.00010517198],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9947515,0.0007509338,0.0036546777,0.0002113795,0.0004127513,0.00021875829],"domain_scores_gemma":[0.9930355,0.0022440692,0.0036915902,0.00016415237,0.00059834594,0.00026635677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034450702,0.00015104059,0.0024234443,0.00008797209,0.000036545454,0.0000020134246,0.00012246541,0.00010579619,0.000038460443],"category_scores_gemma":[0.004723792,0.00006251385,0.00024317828,0.00023728187,0.0003402036,0.00005284709,0.000047755228,0.00030031803,4.9457253e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70276535,0.0049458044,0.09736813,0.000022047014,0.0008892486,0.000013198106,0.0007658852,0.000001722615,0.000042936066,0.000033477656,0.00074212975,0.1924101],"study_design_scores_gemma":[0.3469371,0.07641081,0.57534397,0.00028690565,0.00009564063,0.0000049510627,0.00012993894,9.815058e-7,0.0000578822,0.00007954144,0.0006019281,0.00005034089],"about_ca_topic_score_codex":0.0011495163,"about_ca_topic_score_gemma":0.0019337485,"teacher_disagreement_score":0.47797585,"about_ca_system_score_codex":0.0002585048,"about_ca_system_score_gemma":0.0023973214,"threshold_uncertainty_score":0.5655161},"labels":[],"label_agreement":null},{"id":"W2503810356","doi":"10.1200/jco.2014.32.15_suppl.1522","title":"Founder effect and a high prevalence of BRCA1 mutations among young Mexican triple-negative breast cancer (TNBC) patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; BRCA mutation; Oncology; Cancer; Founder effect; Population; Cohort; Ovarian cancer; Internal medicine; Family history; Mutation; Gynecology; Genotype; Genetics; Gene; Haplotype","score_opus":0.02300947555755225,"score_gpt":0.3837027346209942,"score_spread":0.36069325906344196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503810356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592936,0.00023855164,0.0012962808,0.0006959151,0.0010889218,0.00020432021,0.000053293523,0.0000025706377,0.0004907574],"genre_scores_gemma":[0.9969065,0.0005160263,0.0013919686,0.00035114255,0.0006237144,0.000019290288,0.00000647977,0.000015658952,0.00016918535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745005,0.0007279811,0.0011947824,0.00024344173,0.00021892252,0.00016481243],"domain_scores_gemma":[0.9965777,0.00088484364,0.0015233351,0.00018488093,0.00063893327,0.00019034526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016466781,0.00013529281,0.0006034898,0.00006762002,0.000057314777,0.0000088197985,0.00020752783,0.00030249983,0.000050406285],"category_scores_gemma":[0.0031183441,0.00010662102,0.00021152303,0.000101523205,0.00058947556,0.000015892625,0.000078459096,0.00031169647,0.0000010216801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014108188,0.00045460757,0.9169766,0.00010399836,0.00052588625,0.000005030703,0.00014601368,0.00027535477,0.0013494984,0.000110146924,0.0022752879,0.07636681],"study_design_scores_gemma":[0.0047426242,0.0046975394,0.9867586,0.000046759702,0.00027313063,0.000038017166,0.00003503203,0.000106399275,0.0013157018,0.0003779457,0.0014909,0.00011733841],"about_ca_topic_score_codex":0.0001357092,"about_ca_topic_score_gemma":0.00022490382,"teacher_disagreement_score":0.07624947,"about_ca_system_score_codex":0.00009453911,"about_ca_system_score_gemma":0.00076136086,"threshold_uncertainty_score":0.4347879},"labels":[],"label_agreement":null},{"id":"W2505254690","doi":"10.1200/jco.2013.31.31_suppl.40","title":"Assessment of accuracy of data obtained from patient-reported questionnaire (PRQ) compared to electronic patient records (EPR) in patients with lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Alcohol consumption; Population; Cigarette smoking; Cancer; Alcohol; Internal medicine; Environmental health","score_opus":0.07481836040481929,"score_gpt":0.46487555590510704,"score_spread":0.3900571955002877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505254690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471337,0.00046591728,0.000113936105,0.0033300435,0.00042004496,0.0007061493,0.000060229042,0.0000039486035,0.00018633874],"genre_scores_gemma":[0.9933814,0.00040519724,0.0051637427,0.0007745777,0.00016925392,0.000019227027,0.00007038314,0.000012025634,0.0000041864414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955269,0.00026124314,0.003110417,0.00025562022,0.0005968256,0.0002489555],"domain_scores_gemma":[0.9935575,0.0011281506,0.0031298557,0.0003551268,0.0015825201,0.00024682225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007219083,0.00014340194,0.0015245534,0.00011474071,0.000025752292,0.0000041380263,0.0002171951,0.00014425078,0.00018526446],"category_scores_gemma":[0.0022311735,0.000098060445,0.0001399778,0.00022807943,0.000098784454,0.00019166806,0.0001659436,0.00055082067,9.4686067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003833071,0.0044473,0.9392542,0.000042765,0.0006128611,0.00002519005,0.000059759146,0.000056802655,0.000038389877,0.000018423501,0.0068133455,0.044797845],"study_design_scores_gemma":[0.009781817,0.016553042,0.9689288,0.00072169036,0.00028403636,0.0000040486007,0.00014285129,0.00035160626,0.0000118695625,0.00015799403,0.0029715658,0.000090660884],"about_ca_topic_score_codex":0.0020265593,"about_ca_topic_score_gemma":0.00077822385,"teacher_disagreement_score":0.044707187,"about_ca_system_score_codex":0.00040012962,"about_ca_system_score_gemma":0.0017946213,"threshold_uncertainty_score":0.3998789},"labels":[],"label_agreement":null},{"id":"W2507122509","doi":"10.1200/jco.2021.39.15_suppl.11548","title":"The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ifosfamide; Leiomyosarcoma; Soft tissue sarcoma; Sarcoma; Internal medicine; Proportional hazards model; Radiation therapy; Oncology; Surgery; Progressive disease; Soft tissue; Chemotherapy; Pathology; Cisplatin","score_opus":0.10142206794417302,"score_gpt":0.5073097137876953,"score_spread":0.40588764584352227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507122509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96504027,0.020707993,0.000008377736,0.011532849,0.00041615785,0.00035115314,0.0000026804614,0.000007411231,0.0019331313],"genre_scores_gemma":[0.99247974,0.0042957426,0.002091607,0.0005289336,0.00035720618,0.000045360353,0.0000017842762,0.000014345983,0.0001852785],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99584824,0.0010667945,0.0021176392,0.00020302869,0.00042228497,0.0003420262],"domain_scores_gemma":[0.99296916,0.004768277,0.001024346,0.00044977354,0.0005698169,0.00021864829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030176379,0.00018273806,0.0013008174,0.000028747725,0.00010184939,0.00003007246,0.00031478636,0.00023248392,0.0004256001],"category_scores_gemma":[0.0024261891,0.0000789272,0.0007090022,0.00016564551,0.00045667498,0.0001347297,0.000094555086,0.0006483087,0.000004725902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010998728,0.006026145,0.4907478,0.0000073438505,0.000447119,0.0005387503,0.00086883677,0.000010624491,0.0002000242,0.00010101602,0.00064524135,0.49930722],"study_design_scores_gemma":[0.005298552,0.008565929,0.9224103,0.00007974903,0.00011798657,0.00035369844,0.0019268362,0.00009778073,0.00029675098,0.00027638164,0.06050102,0.000075002914],"about_ca_topic_score_codex":0.0013098388,"about_ca_topic_score_gemma":0.0023412916,"teacher_disagreement_score":0.4992322,"about_ca_system_score_codex":0.00040093923,"about_ca_system_score_gemma":0.0017899426,"threshold_uncertainty_score":0.46600226},"labels":[],"label_agreement":null},{"id":"W2507235164","doi":"10.1200/jco.2011.29.15_suppl.e19698","title":"Frequency and predictors of response to outpatient palliative care in patients with moderate to severe cancer pain.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Cancer pain; Depression (economics); Anxiety; Quality of life (healthcare); Logistic regression; Cancer; Brief Pain Inventory; Delirium; Physical therapy; Internal medicine; Chronic pain; Intensive care medicine; Psychiatry","score_opus":0.23494391784683563,"score_gpt":0.49431143735790584,"score_spread":0.2593675195110702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507235164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977517,0.00049210765,0.00009147146,0.0006781093,0.0002806715,0.0003227166,0.000029724912,0.0000023291514,0.00035117578],"genre_scores_gemma":[0.9912001,0.0002465694,0.00728308,0.001131402,0.00009264536,0.000007610038,0.0000014573012,0.000010935733,0.00002623082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973983,0.00060633174,0.0013771693,0.00015659569,0.000303188,0.00015842365],"domain_scores_gemma":[0.99617016,0.0012966044,0.00084724044,0.00011974742,0.0012201503,0.00034608954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001422414,0.00011754142,0.0011088207,0.00017689541,0.0000111105,0.0000012483378,0.00009165175,0.00018617188,0.000035816578],"category_scores_gemma":[0.0051977914,0.000076718046,0.00010028852,0.00016441151,0.00010291207,0.000055843877,0.00003833095,0.0003625091,9.2269886e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050348837,0.0005828539,0.92126155,0.00005028222,0.00017449983,0.000052921347,0.015752712,0.000036499932,0.000017457505,0.00000516636,0.00023435084,0.011482866],"study_design_scores_gemma":[0.00646091,0.042783305,0.946004,0.0011377432,0.00011432561,6.080363e-7,0.0015506527,0.0000046357,0.00017409073,0.000039105733,0.0016544621,0.00007618655],"about_ca_topic_score_codex":0.00016907808,"about_ca_topic_score_gemma":0.00041919103,"teacher_disagreement_score":0.043887924,"about_ca_system_score_codex":0.00018385223,"about_ca_system_score_gemma":0.0008700572,"threshold_uncertainty_score":0.6222617},"labels":[],"label_agreement":null},{"id":"W2507868513","doi":"10.1200/jco.2015.33.29_suppl.179","title":"Hot stone therapy in palliative care.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Massage; Nausea; Anxiety; Palliative care; Depression (economics); Physical therapy; Cancer; Alternative medicine; Internal medicine; Nursing; Psychiatry","score_opus":0.640495301826233,"score_gpt":0.6338613659075386,"score_spread":0.0066339359186944336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507868513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760725,0.009841675,0.00009300217,0.004208904,0.0010205618,0.00011717857,0.0000020657785,0.0000041894946,0.008639936],"genre_scores_gemma":[0.9812368,0.009081352,0.0059268945,0.0026065912,0.0009921561,0.0000017017139,0.000001921603,0.000010605077,0.0001419893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972864,0.00039612062,0.0017053883,0.00011186492,0.00034358772,0.00015663212],"domain_scores_gemma":[0.9952227,0.0018730882,0.0011543524,0.00012534737,0.0013005073,0.00032404545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021473882,0.00009891474,0.001433084,0.00013203768,0.0000070761803,0.0000020252808,0.00012923496,0.0002891249,0.000052128024],"category_scores_gemma":[0.007470652,0.00006562855,0.00030106065,0.00015817776,0.0001880579,0.0000643612,0.000024234472,0.00073867413,0.0000135672235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00952174,0.0012750897,0.8181954,0.00002209178,0.00029035445,0.000796539,0.0057512363,0.000021343472,0.00012935839,0.000105408755,0.0075821267,0.15630929],"study_design_scores_gemma":[0.023030955,0.031685904,0.51979184,0.00048417877,0.000109691726,0.000030070514,0.00731571,0.000021540534,0.000788972,0.0006800464,0.41594976,0.000111289904],"about_ca_topic_score_codex":0.000055137447,"about_ca_topic_score_gemma":0.00007053144,"teacher_disagreement_score":0.40836763,"about_ca_system_score_codex":0.00018379923,"about_ca_system_score_gemma":0.0017964441,"threshold_uncertainty_score":0.8943608},"labels":[],"label_agreement":null},{"id":"W2508168573","doi":"10.1200/jco.2015.33.15_suppl.tps9634","title":"A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto","funders":"","keywords":"Medicine; Psychological intervention; Geriatric oncology; Randomized controlled trial; Intervention (counseling); Randomization; Life expectancy; Geriatrics; Palliative care; Advance care planning; Cancer; Physical therapy; Family medicine; Nursing; Internal medicine; Population","score_opus":0.22709674294730464,"score_gpt":0.5358723318071381,"score_spread":0.30877558885983347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508168573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242675,0.00034798976,0.00014713847,0.002485253,0.0029407982,0.0010461493,0.00004202684,0.000004985704,0.0005589096],"genre_scores_gemma":[0.9927268,0.00013995111,0.0056205313,0.0004275164,0.00095435977,0.000016911252,0.0000136269855,0.000011699836,0.00008860532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687636,0.00033187968,0.0021191142,0.00016982942,0.0003477255,0.00015509156],"domain_scores_gemma":[0.99414635,0.0016257855,0.0016413918,0.00014625225,0.0020348665,0.0004053308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023022026,0.00011103084,0.0013833126,0.0000928934,0.000014915694,0.000004626729,0.00010174476,0.0003342125,0.000034415727],"category_scores_gemma":[0.0065637985,0.00007293059,0.00028793287,0.000101750426,0.00014774594,0.00006731722,0.000037466787,0.0005598298,4.950975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123837896,0.0037984473,0.6637515,0.00015448079,0.00030924613,0.000025999876,0.00060070504,0.0000052290948,0.000010948774,0.000015523565,0.016525937,0.19096413],"study_design_scores_gemma":[0.30401188,0.05659547,0.61421037,0.00013806562,0.00062917965,0.000022174736,0.00074705796,0.0000709997,0.000022755172,0.00017054242,0.023292558,0.00008892481],"about_ca_topic_score_codex":0.000074506854,"about_ca_topic_score_gemma":0.000108886816,"teacher_disagreement_score":0.1908752,"about_ca_system_score_codex":0.00046054073,"about_ca_system_score_gemma":0.0046517565,"threshold_uncertainty_score":0.82520163},"labels":[],"label_agreement":null},{"id":"W2508919572","doi":"10.1200/jco.2013.31.15_suppl.2007","title":"Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Temozolomide; Medicine; Internal medicine; Clinical endpoint; Oncology; Radiation therapy; Chemotherapy; Glioma; Progression-free survival; Chemoradiotherapy; Phases of clinical research; Randomized controlled trial; Chemotherapy regimen","score_opus":0.04644971527527979,"score_gpt":0.42610732487533254,"score_spread":0.37965760960005274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508919572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969681,0.002273322,0.00025218743,0.021667153,0.0018541731,0.0040544923,0.000007231547,0.000029847668,0.0001805574],"genre_scores_gemma":[0.99150246,0.0018637364,0.00066648243,0.004346146,0.0010160146,0.0004313836,0.0000134236625,0.000077878205,0.00008248894],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902839,0.0025652624,0.005066509,0.00057648297,0.00082569115,0.0006821249],"domain_scores_gemma":[0.9885105,0.006534497,0.0031363543,0.00069242116,0.00045664216,0.0006695977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006209304,0.000574177,0.0052292203,0.00038685813,0.00009746584,0.000089433874,0.00060042477,0.00056406,0.0008093285],"category_scores_gemma":[0.002336237,0.00032549835,0.0017512182,0.00048344454,0.00065080787,0.0002878207,0.00007606745,0.0015866682,0.000042676606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.743113,0.0694846,0.016509434,0.000029803123,0.0097810505,0.007162383,0.001623871,0.000005593899,0.032596517,0.000059743037,0.008664557,0.11096943],"study_design_scores_gemma":[0.94350547,0.0277736,0.018002564,0.00013617561,0.0012438872,0.00056856347,0.0005305614,0.00042113627,0.0016102974,0.00013463308,0.0057449522,0.00032817264],"about_ca_topic_score_codex":0.0002888276,"about_ca_topic_score_gemma":0.00006816982,"teacher_disagreement_score":0.20039244,"about_ca_system_score_codex":0.00052061665,"about_ca_system_score_gemma":0.0006980941,"threshold_uncertainty_score":0.9999197},"labels":[],"label_agreement":null},{"id":"W2509754461","doi":"10.1200/jco.2014.32.15_suppl.3628","title":"Association of adjuvant chemotherapy with clinical outcomes in patients treated with neoadjuvant chemoradiation for locally advanced rectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Dr. H. Bliss Murphy Cancer Centre; University of Ottawa; BC Cancer Agency; Ottawa Hospital; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Colorectal cancer; Oxaliplatin; Cancer; Internal medicine; Oncology; Stage (stratigraphy); Univariate analysis; Chemotherapy; Multivariate analysis","score_opus":0.03703463129395641,"score_gpt":0.4021581897046447,"score_spread":0.3651235584106883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509754461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450743,0.000041070478,0.00013721555,0.0042537726,0.000305983,0.00044463782,0.000006037228,0.0000070367632,0.00029679344],"genre_scores_gemma":[0.9959281,0.00016843253,0.002053579,0.0011916001,0.00038303484,0.000012414698,0.000009265382,0.000020427198,0.00023311604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966504,0.0002715121,0.002243343,0.00021584335,0.00039981038,0.00021910884],"domain_scores_gemma":[0.9933277,0.0023074106,0.0030110967,0.0001170564,0.0010275533,0.00020919969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025452948,0.00015520309,0.0020655217,0.00010677319,0.00001932116,0.000003762288,0.000096316144,0.00033051622,0.000019535531],"category_scores_gemma":[0.003185739,0.00009017651,0.00037641698,0.00017559949,0.00010031012,0.0000977982,0.000011338172,0.000546334,8.5539494e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027080495,0.0015942695,0.74192154,0.00002207153,0.00028385888,0.000009709053,0.000030661642,0.000041440668,0.000028339664,0.000006846251,0.00014800555,0.22883278],"study_design_scores_gemma":[0.0422118,0.05910833,0.89506096,0.00017381682,0.00031090804,0.0000066418647,0.000024913737,0.0004659364,0.00013997463,0.0000379685,0.0023610431,0.00009768023],"about_ca_topic_score_codex":0.00004598618,"about_ca_topic_score_gemma":0.00056013087,"teacher_disagreement_score":0.2287351,"about_ca_system_score_codex":0.00029788484,"about_ca_system_score_gemma":0.0008479409,"threshold_uncertainty_score":0.3813857},"labels":[],"label_agreement":null},{"id":"W2510139173","doi":"10.1200/jco.2016.34.15_suppl.7012","title":"Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Oncology; Term (time); Pediatrics; Dermatology; Bone marrow","score_opus":0.0874416609574633,"score_gpt":0.41998745525088477,"score_spread":0.33254579429342146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510139173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927319,0.00011585993,0.000032589607,0.0057776086,0.00044650453,0.0003543292,0.000044547392,0.000005944432,0.0004906602],"genre_scores_gemma":[0.99398184,0.0019859776,0.0019749405,0.001656901,0.00026224,0.000011704849,0.000011378996,0.000023626495,0.00009136727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962582,0.00035587192,0.002366224,0.00025208647,0.00049730454,0.00027032287],"domain_scores_gemma":[0.9941208,0.0030145647,0.0018107855,0.0002744619,0.00045692682,0.00032248124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009035283,0.00021940927,0.0021474184,0.00014550776,0.00002262102,0.00000629572,0.00016635488,0.00029357063,0.0006754077],"category_scores_gemma":[0.00081343134,0.000101241676,0.00040845724,0.00010257182,0.00024224637,0.0001324433,0.000042608357,0.00038192078,0.000028347773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007886119,0.0050061806,0.8358387,0.000007567101,0.00072634214,0.00015677136,0.000054161894,3.8699156e-7,0.000024615994,0.00008404092,0.00043190483,0.14978321],"study_design_scores_gemma":[0.041351475,0.02422933,0.93096644,0.00036695032,0.00019446386,0.000010653564,0.000017169383,5.7269665e-7,0.00067979435,0.00015881367,0.0019202539,0.00010410502],"about_ca_topic_score_codex":0.000032565997,"about_ca_topic_score_gemma":0.000106210966,"teacher_disagreement_score":0.1496791,"about_ca_system_score_codex":0.00015997479,"about_ca_system_score_gemma":0.0005887836,"threshold_uncertainty_score":0.73952407},"labels":[],"label_agreement":null},{"id":"W2510269678","doi":"10.1200/jco.2016.67.6940","title":"Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in <i>TP53</i>-Associated Cancer Susceptibility","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ontario Ministry of Research and Innovation; Hospital for Sick Children; Royal Children's Hospital Foundation; Ontario Institute for Cancer Research; Children's Hospital Foundation","keywords":"DNA methylation; Epigenetics; Cancer research; Epigenome; Methylation; Cancer; CpG site; microRNA; Biology; Germline; Germline mutation; Medicine; Genetics; Gene; Mutation; Gene expression","score_opus":0.07211243156973939,"score_gpt":0.4241750836198261,"score_spread":0.3520626520500867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510269678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991254,0.0010788826,0.0024517346,0.0041754614,0.0005097525,0.00029601858,0.000017635304,0.000007986399,0.00020855757],"genre_scores_gemma":[0.9971993,0.0011284823,0.0008159689,0.00042206375,0.00025329078,0.0000047969847,0.000008287758,0.00001955108,0.0001482772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938911,0.0010894279,0.003964756,0.0003031916,0.00047278093,0.00027872907],"domain_scores_gemma":[0.9919038,0.0025845845,0.0038923172,0.0003385901,0.0010188968,0.0002618014],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0067549516,0.0001617718,0.0021212697,0.0005281231,0.000020930285,0.0000034640702,0.00016072996,0.0006465664,0.00037134936],"category_scores_gemma":[0.0093944445,0.00011291285,0.0009210301,0.0009569389,0.0002198126,0.000092954135,0.000043066146,0.0005589469,0.0000061538476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016860897,0.00083054736,0.59030783,0.000022914952,0.0015023332,0.000060732476,0.00009172047,0.00061026815,0.37465233,0.0000041881317,0.00012364253,0.030107386],"study_design_scores_gemma":[0.006654997,0.0024204876,0.9762346,0.00017761435,0.0022626726,0.000008524102,0.000018953884,0.000060971688,0.010360179,0.00048469906,0.0012077058,0.00010858977],"about_ca_topic_score_codex":0.000113520124,"about_ca_topic_score_gemma":0.0019093747,"teacher_disagreement_score":0.38592675,"about_ca_system_score_codex":0.0010958232,"about_ca_system_score_gemma":0.0015197181,"threshold_uncertainty_score":0.9989498},"labels":[],"label_agreement":null},{"id":"W2510304243","doi":"10.1200/jco.2016.34.7_suppl.67","title":"Does physical function impact the acceptability of routine patient-reported outcome surveys in cancer patients?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Patient-reported outcome; Breast cancer; Physical therapy; Head and neck cancer; Prom; Cancer; Family medicine; Quality of life (healthcare); Internal medicine; Obstetrics","score_opus":0.10657752345633686,"score_gpt":0.47467054638641343,"score_spread":0.36809302293007656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510304243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924299,0.000049547245,0.00009495332,0.003693864,0.003186594,0.00020023932,0.000018408864,0.000004606932,0.0003218465],"genre_scores_gemma":[0.9987065,0.00007536834,0.000009595849,0.00039354333,0.0007402062,0.0000057317206,0.0000015168399,0.000010243446,0.00005730122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99510336,0.0015646197,0.0025263103,0.00016935333,0.00043850282,0.00019785055],"domain_scores_gemma":[0.9937633,0.0028108652,0.0021865885,0.00025577212,0.0007986952,0.00018478086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054267687,0.00012477498,0.0012741558,0.000070524904,0.000017572784,0.0000031245877,0.000124392,0.00020169218,0.00083715166],"category_scores_gemma":[0.005220472,0.000041194664,0.00070581853,0.0001944523,0.00023930841,0.00011919826,0.00005046427,0.0005687109,0.000002469104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001760282,0.0012557232,0.61453396,0.0000093890785,0.000124803,0.000008952963,0.0001420337,0.0000019463018,0.000037771282,0.0000023993573,0.00011495513,0.3820078],"study_design_scores_gemma":[0.005180144,0.008129247,0.983876,0.00003279112,0.00021710075,0.0000047266712,0.00013698211,0.000006166208,0.00009444783,0.0001911575,0.0020722754,0.00005899685],"about_ca_topic_score_codex":0.0011976406,"about_ca_topic_score_gemma":0.0033077458,"teacher_disagreement_score":0.3819488,"about_ca_system_score_codex":0.00033119065,"about_ca_system_score_gemma":0.000839481,"threshold_uncertainty_score":0.91662234},"labels":[],"label_agreement":null},{"id":"W2510369693","doi":"10.1200/jco.2014.32.4_suppl.431","title":"A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Interim results.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Clinical trial; Progressive disease; Interim analysis; Sunitinib; Radiological weapon; Phases of clinical research; Toxicity; Gastroenterology; Oncology; Surgery; Urology; Disease; Cancer","score_opus":0.18065520807581548,"score_gpt":0.49023374752340076,"score_spread":0.3095785394475853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510369693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911523,0.00011914704,0.0007634792,0.0028039133,0.0016053569,0.0006302867,0.000020251315,0.00001631421,0.0028889482],"genre_scores_gemma":[0.99028754,0.000035511657,0.006456719,0.0015443254,0.0010296243,0.000009139269,0.000012345512,0.000033507415,0.00059129606],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9914579,0.001307003,0.005870671,0.00034743076,0.0005580007,0.000459005],"domain_scores_gemma":[0.98973465,0.004973486,0.0037505196,0.00036092644,0.0006372764,0.00054313854],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005863182,0.0002984862,0.0029720662,0.00043007082,0.000042926866,0.000010544822,0.00034178534,0.0003147777,0.00039235136],"category_scores_gemma":[0.018093292,0.00019410896,0.0007194389,0.00043520887,0.000485745,0.0001918792,0.00012580016,0.0012646877,0.00002173726],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75987947,0.026948819,0.000048336493,0.000097336895,0.00035524112,0.034806952,0.00041070252,0.000053830154,0.00058211846,0.000070511676,0.0007829495,0.17596371],"study_design_scores_gemma":[0.6237313,0.33474097,0.0009349998,0.0011135178,0.00073428947,0.012223094,0.0004117812,0.0012749557,0.003539287,0.0002964469,0.02071901,0.00028035414],"about_ca_topic_score_codex":0.000015467445,"about_ca_topic_score_gemma":0.00010250298,"teacher_disagreement_score":0.30779213,"about_ca_system_score_codex":0.0001382211,"about_ca_system_score_gemma":0.0011647278,"threshold_uncertainty_score":0.99017775},"labels":[],"label_agreement":null},{"id":"W2511578317","doi":"10.1200/jco.2015.33.29_suppl.194","title":"Outcomes of hypofractionated palliative radiotherapy for choroidal metastases.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enucleation; Radiation therapy; Visual acuity; External beam radiotherapy; Retrospective cohort study; Choroid; Primary tumor; Cancer; Surgery; Metastasis; Brachytherapy; Internal medicine","score_opus":0.2670923795232825,"score_gpt":0.5489794587954613,"score_spread":0.28188707927217876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511578317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97754174,0.0015275837,0.0022438648,0.014947842,0.0021458392,0.0004252449,0.000019343575,0.000008464399,0.0011400757],"genre_scores_gemma":[0.944958,0.00040414705,0.050418068,0.003001492,0.00058917823,0.000008226596,0.000009570735,0.00001635339,0.0005950053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975292,0.00033817923,0.0016295282,0.000116098265,0.00024749327,0.00013952053],"domain_scores_gemma":[0.9938851,0.002973979,0.0017978839,0.00012067521,0.0009075893,0.0003147597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027311186,0.000107585176,0.0016976655,0.00010421432,0.000019269552,0.0000016781396,0.00008843324,0.00033607372,0.00007529422],"category_scores_gemma":[0.0058091586,0.00006749305,0.0006366548,0.000082024446,0.00018333005,0.000109792454,0.000011942678,0.00040617862,0.0000061955966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017490344,0.0068508806,0.8533663,0.000018982404,0.007283362,0.00040647644,0.00012041316,0.000030786417,0.00012783136,0.00048158743,0.011180841,0.10264221],"study_design_scores_gemma":[0.046609886,0.03787136,0.68621016,0.000022536875,0.001474692,0.00018855096,0.00015072987,0.00008083417,0.00037554585,0.0016335412,0.22530285,0.00007933518],"about_ca_topic_score_codex":0.000009503774,"about_ca_topic_score_gemma":0.0000073806323,"teacher_disagreement_score":0.214122,"about_ca_system_score_codex":0.00019007239,"about_ca_system_score_gemma":0.0017526733,"threshold_uncertainty_score":0.6954525},"labels":[],"label_agreement":null},{"id":"W2511601841","doi":"10.1200/jco.2009.27.15_suppl.7575","title":"PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Mediastinoscopy; Radiology; Lung cancer; Stage (stratigraphy); Nuclear medicine; Thoracotomy; Mediastinum; Lung cancer staging; Surgery; Internal medicine","score_opus":0.058405502823529236,"score_gpt":0.4548734533558647,"score_spread":0.39646795053233547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511601841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954474,0.00039428088,0.0012542022,0.037711248,0.0013632795,0.00024339894,0.000001259359,0.000009594153,0.004548749],"genre_scores_gemma":[0.9661918,0.00051787903,0.013610629,0.017784294,0.0016757164,0.0000031480565,0.0000017845935,0.000017370085,0.00019735671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964441,0.00031414768,0.0021813072,0.00024688372,0.00040877066,0.00040480695],"domain_scores_gemma":[0.99552137,0.0021406866,0.0010596422,0.00016193501,0.00027726823,0.0008391179],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0037336797,0.00017104133,0.0015751537,0.0002940073,0.00003822955,0.000015316858,0.00028353627,0.00006940508,0.00014124802],"category_scores_gemma":[0.0057735033,0.00013119521,0.00030949988,0.0002517617,0.000098348886,0.000073564544,0.000053770167,0.0023580766,0.000010633926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002566591,0.0019177372,0.72468174,0.00011589219,0.00015200624,0.019626968,0.0008300785,0.0024383946,0.0023990513,0.000027493013,0.024242189,0.22100185],"study_design_scores_gemma":[0.016290383,0.005773427,0.9415709,0.0014344926,0.0003878327,0.001490286,0.00043806699,0.014340958,0.00021455456,0.00014986802,0.0176433,0.00026596553],"about_ca_topic_score_codex":0.00012386584,"about_ca_topic_score_gemma":0.00008721492,"teacher_disagreement_score":0.22073588,"about_ca_system_score_codex":0.00027326265,"about_ca_system_score_gemma":0.002306208,"threshold_uncertainty_score":0.9999435},"labels":[],"label_agreement":null},{"id":"W2512604775","doi":"10.1200/jco.2011.29.4_suppl.368","title":"Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Anal cancer; Fluorouracil; Radiation therapy; Anal canal; Mitomycin C; Urology; Bolus (digestion); Stage (stratigraphy); Surgery; Cancer; Internal medicine; Rectum; Nuclear medicine; Chemotherapy","score_opus":0.18335475445026825,"score_gpt":0.4580045344221791,"score_spread":0.27464977997191087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512604775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974529,0.000106711595,0.000016053053,0.0015032091,0.00022249503,0.00047046467,0.0000114189625,7.7350563e-7,0.00021596794],"genre_scores_gemma":[0.9994828,0.000041084328,0.00034553642,0.000038452563,0.000060826766,0.0000057656725,0.0000019967251,0.0000053124654,0.00001818723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972735,0.00048340048,0.0015918061,0.0001048694,0.00044745448,0.00009898977],"domain_scores_gemma":[0.9960174,0.00077472115,0.001896962,0.00013898549,0.0011141081,0.000057805533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005276024,0.00008542436,0.00094453146,0.0001641036,0.000020115443,7.9097856e-7,0.00011505688,0.00012487212,0.000023652769],"category_scores_gemma":[0.0015216318,0.000043800108,0.00024249901,0.00025702428,0.00032759932,0.000067568704,0.000037708945,0.0003650155,3.0891208e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018937683,0.0034657372,0.9507948,0.00007256506,0.00045428256,0.000010206935,0.0012991097,0.00003311577,0.0037365058,0.0002835569,0.000085798194,0.020826597],"study_design_scores_gemma":[0.021947742,0.017285919,0.9518657,0.00010810388,0.0010921544,0.00005495912,0.0010549376,0.0017660421,0.00426041,0.000515796,0.000010786316,0.000037480888],"about_ca_topic_score_codex":0.00189092,"about_ca_topic_score_gemma":0.0026315504,"teacher_disagreement_score":0.020789117,"about_ca_system_score_codex":0.00010447382,"about_ca_system_score_gemma":0.001016501,"threshold_uncertainty_score":0.2858518},"labels":[],"label_agreement":null},{"id":"W2513269552","doi":"10.1200/jco.2016.67.3616","title":"Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Cancer Institute; Regione Lombardia","keywords":"Myelodysplastic syndromes; Medicine; International Prognostic Scoring System; Oncology; Hematopoietic stem cell transplantation; Somatic cell; RUNX1; Myeloid; Internal medicine; Myeloid leukemia; Transplantation; Gene mutation; Germline mutation; Mutation; Stem cell; Haematopoiesis; Gene; Genetics; Biology; Bone marrow","score_opus":0.044660866679790384,"score_gpt":0.3809837326136119,"score_spread":0.33632286593382155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513269552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641967,0.000029895426,0.000673799,0.0018620552,0.00015941191,0.00066552934,0.000011857959,0.000007410486,0.00017038673],"genre_scores_gemma":[0.99826264,0.0002451726,0.00091558765,0.000269622,0.000057857997,0.000011575172,0.0000038823882,0.000027756943,0.0002058862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995114,0.0011230899,0.002510205,0.0002120101,0.0007957092,0.0002449483],"domain_scores_gemma":[0.968609,0.027917404,0.0022318258,0.00030533943,0.0006722406,0.00026422107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017281949,0.00019902854,0.001838999,0.00019575685,0.00003859188,0.0000035905755,0.00024944206,0.00029123537,0.00007097675],"category_scores_gemma":[0.0014915916,0.00007568337,0.00037845818,0.00019900422,0.0007995169,0.00008975357,0.000021555357,0.00061758864,0.000020715685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008011579,0.003365077,0.97562605,0.00035015578,0.0014268474,0.000468366,0.00018534712,0.0000181077,0.00035976662,0.00006840113,0.00013228858,0.009988028],"study_design_scores_gemma":[0.02240964,0.03540648,0.9380176,0.0007482267,0.0016503882,0.00011149173,0.00007331388,0.000015504267,0.0013797297,0.000056888653,0.00004199696,0.000088743465],"about_ca_topic_score_codex":0.0000044298995,"about_ca_topic_score_gemma":0.000008793286,"teacher_disagreement_score":0.03760844,"about_ca_system_score_codex":0.000126191,"about_ca_system_score_gemma":0.0012848373,"threshold_uncertainty_score":0.3086278},"labels":[],"label_agreement":null},{"id":"W2513422618","doi":"10.1200/jco.2012.30.15_suppl.e21099","title":"Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Gene; Gene expression; Cancer research; Breast cancer; Gene expression profiling; Biology; Transcription factor; Microarray analysis techniques; Cancer; Medicine; Genetics","score_opus":0.0677473818523388,"score_gpt":0.48026202625263503,"score_spread":0.4125146444002962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513422618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951707,0.00037752755,0.00003252632,0.0030740034,0.0008327586,0.00033499292,0.000030765823,0.000004003939,0.00014270264],"genre_scores_gemma":[0.99595195,0.0007059177,0.0014562056,0.0012082796,0.00053811196,0.00001564131,0.000023612862,0.0000140124275,0.000086251726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687815,0.0003833096,0.001843336,0.00018385841,0.0004010778,0.00031026118],"domain_scores_gemma":[0.99673575,0.0007535159,0.0013766858,0.00016948431,0.0004047462,0.0005598014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014542427,0.00016413057,0.0016759122,0.00043068948,0.00002029582,0.0000028736306,0.00013459683,0.00021090075,0.00078572624],"category_scores_gemma":[0.00016490665,0.000105493426,0.00040145355,0.0006169571,0.00009535638,0.0000961421,0.000065635104,0.000433594,0.0000057527313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037924364,0.010706904,0.92824787,0.000017675773,0.0023755871,0.00007788343,0.00019653897,0.00018549187,0.005063298,9.773527e-7,0.0047237137,0.010479666],"study_design_scores_gemma":[0.020894969,0.0133006545,0.957497,0.000062697974,0.0033779172,0.000032417796,0.00003461172,0.0000128229385,0.0028333303,0.0000018685861,0.0018575259,0.00009419926],"about_ca_topic_score_codex":0.00013784152,"about_ca_topic_score_gemma":0.00008408102,"teacher_disagreement_score":0.029249087,"about_ca_system_score_codex":0.0003769668,"about_ca_system_score_gemma":0.00049256603,"threshold_uncertainty_score":0.8603151},"labels":[],"label_agreement":null},{"id":"W2513654162","doi":"10.1200/jco.2015.33.7_suppl.184","title":"Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Taxane; Abiraterone acetate; Cabazitaxel; Docetaxel; Chemotherapy; Internal medicine; Post-hoc analysis; Oncology; Prostate cancer; Prednisone; Discontinuation; Regimen; Surgery; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.10662071090769616,"score_gpt":0.46189632758958854,"score_spread":0.3552756166818924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513654162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977452,0.0010803607,0.000008761427,0.020166658,0.0001927977,0.00097058184,0.000075630676,0.000005739081,0.00004746081],"genre_scores_gemma":[0.9941759,0.0017086507,0.0010955869,0.0020941,0.000072120245,0.00008578194,0.000020851818,0.000032502172,0.0007145056],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954303,0.00079781364,0.0020911144,0.00032088746,0.00095638615,0.00040350854],"domain_scores_gemma":[0.99513364,0.0006539646,0.0013168,0.0002975575,0.0019302974,0.00066772156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037906964,0.00024838996,0.0019102009,0.000645359,0.000030617895,0.000020798843,0.00017852185,0.00015920664,0.0003002059],"category_scores_gemma":[0.0006482671,0.00014713217,0.0003273409,0.00093251705,0.00026755265,0.00016832718,0.000030148827,0.00051489286,0.0000105473455],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69010794,0.0040464783,0.2636979,0.000040755036,0.0043582236,0.0013875815,0.0029180616,0.00070904585,0.0013643667,0.0000021326957,0.0004900526,0.030877447],"study_design_scores_gemma":[0.055766884,0.09599176,0.83534825,0.00022800623,0.0010912548,0.000021723801,0.00050914416,0.00007422354,0.000969528,0.000025701309,0.009783525,0.0001900075],"about_ca_topic_score_codex":0.00041367643,"about_ca_topic_score_gemma":0.0019758274,"teacher_disagreement_score":0.63434106,"about_ca_system_score_codex":0.0007950783,"about_ca_system_score_gemma":0.0038936639,"threshold_uncertainty_score":0.69071925},"labels":[],"label_agreement":null},{"id":"W2513984290","doi":"10.1200/jco.2012.30.15_suppl.5569","title":"Effects of vandetanib on body composition in patients with advanced medullary thyroid carcinomas: Results from a placebo-controlled study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Vandetanib; Medicine; Placebo; Sarcopenia; Internal medicine; Adipose tissue; Urology; Thyroid carcinoma; Gastroenterology; Thyroid; Endocrinology; Pathology; Tyrosine kinase; Receptor","score_opus":0.0256646794952616,"score_gpt":0.37043580089199074,"score_spread":0.34477112139672916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513984290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958595,0.0010242176,0.0000054716797,0.0005647527,0.00071769505,0.0014161606,0.0000108171125,0.00000504354,0.0003963374],"genre_scores_gemma":[0.9983738,0.00021035255,0.00049237756,0.00044741333,0.00040622993,0.000033812015,0.000011684389,0.000016323635,0.000007976234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996198,0.00075160805,0.002115139,0.00019380648,0.0005078204,0.00023363992],"domain_scores_gemma":[0.99114895,0.0061621796,0.0019312097,0.00020140376,0.00025444734,0.00030183105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014567988,0.00017931392,0.002161731,0.00013953914,0.000021030028,0.0000029800583,0.00009088852,0.00018496312,0.000011375479],"category_scores_gemma":[0.0012380738,0.00010557714,0.00028421098,0.00010552928,0.000069982074,0.000114259994,0.000024226794,0.0005599122,0.0000044969506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31073847,0.029510716,0.6503518,0.000014131312,0.00079958956,0.00022546107,0.00032229171,0.000030178224,0.00012595483,0.00000578608,0.00019255753,0.007683019],"study_design_scores_gemma":[0.25371218,0.06707647,0.67758095,0.00022584082,0.00079475326,0.000003847775,0.00008040768,0.0000051480065,0.00034476616,0.000010053291,0.00010485058,0.00006071573],"about_ca_topic_score_codex":0.000036881916,"about_ca_topic_score_gemma":0.000038051763,"teacher_disagreement_score":0.0570263,"about_ca_system_score_codex":0.00028807376,"about_ca_system_score_gemma":0.00032363518,"threshold_uncertainty_score":0.43053108},"labels":[],"label_agreement":null},{"id":"W2514555365","doi":"10.1200/jco.2012.30.15_suppl.tps8112","title":"ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Internal medicine; Refractory (planetary science); Multiple myeloma; Progression-free survival; Phases of clinical research; Gastroenterology; Tolerability; Urology; Surgery; Oncology; Clinical trial; Chemotherapy; Adverse effect","score_opus":0.2741734888740753,"score_gpt":0.5310445704647311,"score_spread":0.2568710815906558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514555365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892591,0.0009659859,0.00026941832,0.0013810962,0.0011341202,0.0046157953,0.00001835755,0.000020286945,0.0023358355],"genre_scores_gemma":[0.97059023,0.0014443803,0.022985995,0.00061082677,0.0012457407,0.0002163055,0.000016514967,0.00008071726,0.0028092742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866103,0.0041047917,0.0063331015,0.00052725745,0.0013664135,0.0010581511],"domain_scores_gemma":[0.9715715,0.02028654,0.004968037,0.0007163151,0.00085657503,0.0016010008],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018278131,0.0005206557,0.0075298375,0.00059018703,0.00009457235,0.000034094784,0.0006922432,0.0008186312,0.0012166097],"category_scores_gemma":[0.03545598,0.00027094496,0.0006685187,0.0005941749,0.0009809415,0.00054681586,0.00025517071,0.002296145,0.000038274247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8084455,0.038403556,0.015085003,0.0000765054,0.0024359962,0.0024335175,0.00043549092,0.0000016022784,0.00033807463,0.00003168189,0.00065055164,0.1316625],"study_design_scores_gemma":[0.90462375,0.07760609,0.004782674,0.00066914305,0.001184596,0.0008831638,0.00040146397,0.0004034977,0.00034650083,0.000034409222,0.008787827,0.00027690752],"about_ca_topic_score_codex":0.0006389987,"about_ca_topic_score_gemma":0.00062684255,"teacher_disagreement_score":0.1313856,"about_ca_system_score_codex":0.0006557284,"about_ca_system_score_gemma":0.0066214628,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W2514847446","doi":"10.1200/jco.2016.34.3_suppl.231","title":"Using eye-tracking to quantify the impact of prostate cancer treatments on male libido: A pilot study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Media Influence and Health","field":"Arts and Humanities","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Trinity Western University; Western University","funders":"","keywords":"Libido; Medicine; Eye tracking; Prostate cancer; Androgen deprivation therapy; Decreased Libido; Sexual dysfunction; Gynecology; Audiology; Cancer; Internal medicine; Artificial intelligence","score_opus":0.5729233468895222,"score_gpt":0.6015646773701818,"score_spread":0.028641330480659644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514847446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938002,0.00007078223,0.0000026926873,0.003495312,0.0012510407,0.00035322914,0.000015244084,0.0000035038947,0.0010079745],"genre_scores_gemma":[0.99635154,0.0002526553,0.00006519824,0.0008986857,0.00160853,0.000006799199,9.396427e-8,0.000012045407,0.0008044652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974159,0.00041012015,0.0015364776,0.00012837134,0.00026632834,0.00024278363],"domain_scores_gemma":[0.9962844,0.0015643049,0.0014399807,0.00016259849,0.00034808277,0.00020061535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021813896,0.00011717892,0.0007755541,0.0000938019,0.00012291793,0.000023159284,0.00021126906,0.000049515627,0.0010936803],"category_scores_gemma":[0.0007816824,0.000046151934,0.00023317778,0.000037342073,0.00019567474,0.00015834073,0.000031542706,0.00030828197,0.000034278237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006472947,0.005620102,0.8732914,0.000016205779,0.00071654347,0.00013136116,0.01649592,0.00020418176,0.00062255556,0.00091176777,0.0031540135,0.09236302],"study_design_scores_gemma":[0.005904523,0.13155778,0.8418137,0.00047724307,0.00026440778,0.000020348118,0.002178802,0.000021669028,0.000056977464,0.0005490312,0.017002307,0.000153251],"about_ca_topic_score_codex":0.0015182667,"about_ca_topic_score_gemma":0.0017873883,"teacher_disagreement_score":0.12593767,"about_ca_system_score_codex":0.00018130349,"about_ca_system_score_gemma":0.0010718426,"threshold_uncertainty_score":0.99981946},"labels":[],"label_agreement":null},{"id":"W2515167615","doi":"10.1200/jco.2015.33.28_suppl.72","title":"Adherence to osteoporosis screening guidelines in seniors with breast cancer treated with anti-estrogen therapy: A population-based study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Osteoporosis; Population; Cohort; Oncology; Cancer; Physical therapy; Gynecology","score_opus":0.22489731824736162,"score_gpt":0.5110116960663619,"score_spread":0.2861143778190003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515167615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99061906,0.00016827091,0.000038410224,0.008358494,0.000114210525,0.00063835504,0.0000074120726,0.000011538661,0.00004422085],"genre_scores_gemma":[0.9871015,0.0000334699,0.009674046,0.002866113,0.00020901982,0.000025982334,0.0000039374645,0.000021161548,0.00006478538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970774,0.0003157617,0.001685494,0.00021749722,0.00044954722,0.00025432173],"domain_scores_gemma":[0.99661285,0.00036598014,0.0010061351,0.00016492205,0.0010936261,0.00075650116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014678909,0.00016796641,0.0012827909,0.00017655923,0.00003073396,0.000007891628,0.00008580842,0.00015418955,0.00003432764],"category_scores_gemma":[0.00045341582,0.00008978594,0.00009862422,0.00039074314,0.00003811808,0.00008482703,0.000011105974,0.00040065442,0.0000035839612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017983798,0.0018766392,0.8815576,0.0000050605404,0.00020716697,0.0007044287,0.00010108215,0.00069750147,0.000002431415,2.9873286e-7,0.00015139615,0.09671261],"study_design_scores_gemma":[0.028399335,0.042031802,0.9278088,0.00027144415,0.00021691242,0.00022000515,0.00035734792,0.000118230535,0.0000070686365,0.000002261084,0.00048121065,0.000085589425],"about_ca_topic_score_codex":0.009522986,"about_ca_topic_score_gemma":0.006193049,"teacher_disagreement_score":0.09662702,"about_ca_system_score_codex":0.00020071186,"about_ca_system_score_gemma":0.0029256172,"threshold_uncertainty_score":0.9970727},"labels":[],"label_agreement":null},{"id":"W2515517339","doi":"10.1200/jco.2016.34.15_suppl.e13526","title":"Optimal management of leptomeningeal carcinomatosis in breast cancer patients - a systematic review.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Randomized controlled trial; Radiation therapy; Quality of life (healthcare); Observational study; MEDLINE; Oncology; Chemotherapy; Systematic review; Cancer; Meta-analysis; Surgery","score_opus":0.06814181625445764,"score_gpt":0.4478975210519311,"score_spread":0.37975570479747345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515517339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851287,0.0047802776,0.00003867241,0.00866271,0.00037349752,0.0006731222,0.000021185459,0.0000027682345,0.00031909195],"genre_scores_gemma":[0.9834108,0.0133857485,0.0021244565,0.0008486067,0.000093601884,0.0000259276,8.7157883e-7,0.00000998213,0.00010000085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961116,0.00042167047,0.00281711,0.00012775496,0.00035678726,0.00016512242],"domain_scores_gemma":[0.99678135,0.0006447499,0.0019335942,0.00016888171,0.0002802195,0.000191228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024554715,0.000109106455,0.002100402,0.000097634555,0.000008644381,0.000001404138,0.00011200994,0.000097858945,0.00017154597],"category_scores_gemma":[0.00031102248,0.00005292337,0.00042845722,0.00011925377,0.00007679451,0.00005550967,0.000047154157,0.0001794671,0.000008551955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026326515,0.006448073,0.874559,0.07150584,0.0028293554,0.001207228,0.000061070234,0.000003905132,0.000012530615,0.00011696162,0.0033020682,0.037321314],"study_design_scores_gemma":[0.01616703,0.005884814,0.8507051,0.12265107,0.0037388972,0.00025356244,0.00006383669,0.0000071033405,0.000015866428,0.000018288054,0.00040534145,0.00008913352],"about_ca_topic_score_codex":0.000016116326,"about_ca_topic_score_gemma":0.0000038164735,"teacher_disagreement_score":0.05114523,"about_ca_system_score_codex":0.00023472183,"about_ca_system_score_gemma":0.00025568402,"threshold_uncertainty_score":0.21581523},"labels":[],"label_agreement":null},{"id":"W2515619088","doi":"10.1200/jco.2012.30.15_suppl.e14565","title":"Factors predicting outcome of G1/2 GEP NET after PRRT with Lu177-octreotate.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Multivariate analysis; Neuroendocrine tumors; Radionuclide therapy; Retrospective cohort study; Progression-free survival; Proportional hazards model; Cohort; Oncology; Overall survival","score_opus":0.20667766753080957,"score_gpt":0.5214348825511329,"score_spread":0.31475721502032333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515619088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471897,0.00058071385,0.00003721431,0.0019488159,0.0008650885,0.00022549642,0.0000050821486,0.000012665509,0.0016059694],"genre_scores_gemma":[0.9955834,0.00014120454,0.0018983264,0.00065868377,0.0010913217,0.0000043956115,0.0000011894078,0.000028238355,0.00059319823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956879,0.00042824645,0.0024604248,0.00015728973,0.0007315932,0.00053455174],"domain_scores_gemma":[0.9943139,0.002766978,0.0015386564,0.00023793102,0.00044985415,0.0006927091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019442966,0.00017618686,0.0016524803,0.00017695116,0.000023802511,0.0000054669918,0.00019774452,0.000058099482,0.0003861414],"category_scores_gemma":[0.007029139,0.00009803216,0.00038263807,0.00016978501,0.00035855742,0.00033740338,0.000093013965,0.001524108,0.000016528882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052606915,0.0011913141,0.9859339,0.00007550733,0.0002230821,0.0017999375,0.00007022634,0.000008331482,0.00009376061,0.000010420224,0.00054257276,0.0047902516],"study_design_scores_gemma":[0.004393883,0.015290935,0.9365582,0.000107513595,0.00025984817,0.0016714726,0.00022512322,0.000013811897,0.000517505,0.00002248325,0.040853057,0.000086159795],"about_ca_topic_score_codex":0.000013545977,"about_ca_topic_score_gemma":0.000024104787,"teacher_disagreement_score":0.049375698,"about_ca_system_score_codex":0.00008868328,"about_ca_system_score_gemma":0.00054681627,"threshold_uncertainty_score":0.8415044},"labels":[],"label_agreement":null},{"id":"W2515804433","doi":"10.1200/jco.2016.68.1585","title":"Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Medicine; Vinblastine; Chemotherapy; Internal medicine; Progressive disease; Neurofibromatosis; Glioma; Performance status; Gastroenterology; Surgery; Cohort; Pilocytic astrocytoma; Oncology; Astrocytoma; Pathology","score_opus":0.04574011488441208,"score_gpt":0.41865653707849837,"score_spread":0.37291642219408627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515804433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523432,0.00033926204,0.000027962402,0.045001633,0.00039149556,0.001778887,0.00004995004,0.000013984137,0.00005358813],"genre_scores_gemma":[0.9943586,0.000039546652,0.0009020504,0.0022668669,0.0022259303,0.000096819254,0.0000046344035,0.00003686214,0.00006866654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671817,0.00022882455,0.0018249206,0.00035436652,0.00037236122,0.0005013734],"domain_scores_gemma":[0.99400115,0.0021172967,0.0018323131,0.00025662614,0.00063680456,0.0011557951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014816511,0.00026767544,0.001625821,0.00037883868,0.0001252502,0.0000135403325,0.00019484483,0.00020709501,0.00016727441],"category_scores_gemma":[0.0023964848,0.00013478637,0.00043597,0.00027005948,0.00020262954,0.000096328775,0.000029511963,0.0003711379,0.000009561468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0092434725,0.055913907,0.82518804,0.000020122558,0.0022838828,0.005611339,0.00016423971,8.4720324e-7,0.00027737493,0.000024233428,0.023513837,0.0777587],"study_design_scores_gemma":[0.16964093,0.2237015,0.5942963,0.00013248959,0.0018314105,0.0019478202,0.0001260816,0.000007805473,0.0005184256,0.000052703563,0.0075243665,0.0002201931],"about_ca_topic_score_codex":0.0003395411,"about_ca_topic_score_gemma":0.0029924659,"teacher_disagreement_score":0.23089178,"about_ca_system_score_codex":0.000289006,"about_ca_system_score_gemma":0.0036711998,"threshold_uncertainty_score":0.6512551},"labels":[],"label_agreement":null},{"id":"W2516113677","doi":"10.1200/jco.2016.34.7_suppl.120","title":"An approach to implementing meaningful change in a provincial health care system.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Northeast Cancer Centre; University Health Network; Regional Municipality of Durham; Queen's University; Cancer Care Ontario","funders":"","keywords":"Medicine; Government (linguistics); Quality (philosophy); Agency (philosophy); Health care; Political science","score_opus":0.21218864009626107,"score_gpt":0.4430625728730103,"score_spread":0.23087393277674925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516113677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93739754,0.002016663,0.007092714,0.0075271847,0.0028573615,0.00066116,0.00012107316,0.000020827662,0.04230546],"genre_scores_gemma":[0.99000776,0.00014975386,0.0044837105,0.002690064,0.0025946393,0.000018852896,0.0000011960987,0.00002098378,0.000033059718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954477,0.00013046911,0.0035794596,0.00031088898,0.000050696515,0.0004807668],"domain_scores_gemma":[0.995961,0.00021472276,0.0030629854,0.00020837919,0.000122043035,0.00043088236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064924117,0.00013137437,0.0015824273,0.00030441023,0.000054945514,0.000023522092,0.00037310415,0.00023145125,0.000038365226],"category_scores_gemma":[0.0009842805,0.00010438935,0.00024125773,0.00012741565,0.000049248094,0.00051388243,0.00006711702,0.00031973695,0.00006409064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059967,0.0005815844,0.39267373,0.00008453357,0.00006220417,0.000025605737,0.0038571628,0.000010566045,0.000003652492,0.09621915,0.0013001258,0.504582],"study_design_scores_gemma":[0.0068339077,0.0085235685,0.61663663,0.00019744174,0.000013305816,0.000043765373,0.002017846,0.00015511856,0.0000046584028,0.001609359,0.36358586,0.00037851604],"about_ca_topic_score_codex":0.00079549797,"about_ca_topic_score_gemma":0.0009917681,"teacher_disagreement_score":0.5042035,"about_ca_system_score_codex":0.0010431019,"about_ca_system_score_gemma":0.0007349911,"threshold_uncertainty_score":0.42568743},"labels":[],"label_agreement":null},{"id":"W2516660524","doi":"10.1200/jco.2016.34.15_suppl.9026","title":"Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.06154770022914629,"score_gpt":0.43853787942426264,"score_spread":0.37699017919511635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516660524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955787,0.00015160555,0.000085756845,0.0022283122,0.0005234664,0.0011344057,0.000004499331,0.0000031642016,0.00029006472],"genre_scores_gemma":[0.9980896,0.00023699219,0.00027187756,0.00097066676,0.00027900113,0.000025102729,0.0000013568417,0.000014899429,0.00011048721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669284,0.00043724448,0.002087932,0.00016491611,0.0004060147,0.00021106051],"domain_scores_gemma":[0.9939556,0.0034818684,0.0017410243,0.00025649194,0.00046619342,0.00009880255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024211458,0.00013273096,0.0012110354,0.00011869109,0.000028499026,0.0000038133253,0.00025455136,0.0001801967,0.00008153601],"category_scores_gemma":[0.0012936854,0.000054228174,0.0003125223,0.00014034218,0.0001776974,0.00009389331,0.000021226644,0.00033236013,0.0000015521556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2300427,0.010801066,0.46061733,0.000022016053,0.00042306326,0.00006731216,0.00019866017,8.186367e-7,0.0001957109,0.0000031138807,0.00040680534,0.2972214],"study_design_scores_gemma":[0.16591573,0.08262414,0.74809885,0.00017771742,0.00019820993,0.000031927073,0.00014939865,0.0000010343357,0.00001933404,0.000021761922,0.0027017575,0.00006014329],"about_ca_topic_score_codex":0.0000083103405,"about_ca_topic_score_gemma":0.00015564969,"teacher_disagreement_score":0.29716125,"about_ca_system_score_codex":0.00011504434,"about_ca_system_score_gemma":0.0006116277,"threshold_uncertainty_score":0.22113608},"labels":[],"label_agreement":null},{"id":"W2517401117","doi":"10.1200/jco.2006.24.18_suppl.8501","title":"Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Neuropsychology; Cognition; Internal medicine; Dementia; Oncology; Cancer; Psychiatry; Disease","score_opus":0.06944504072759018,"score_gpt":0.4430972734222472,"score_spread":0.373652232694657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517401117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910472,0.0002755962,0.0004383257,0.0050295126,0.00066017365,0.002029556,0.00023350118,0.0000315405,0.00025457097],"genre_scores_gemma":[0.9938908,0.00011085778,0.00013397959,0.0032982351,0.0022418557,0.00014807557,0.000004291619,0.00004672183,0.00012518166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626637,0.0006663795,0.0019379342,0.00030872045,0.00043635754,0.00038425572],"domain_scores_gemma":[0.99191236,0.0031266352,0.002155215,0.000120296856,0.0023645672,0.00032091772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035308995,0.00025913527,0.0019172945,0.00014904623,0.00012999437,0.000013113078,0.00008648787,0.0002732055,0.00015801257],"category_scores_gemma":[0.0008153741,0.0001751416,0.00039933212,0.00019846813,0.00028730952,0.00019429962,0.00001772065,0.0007774982,0.0000023755963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07514246,0.028469283,0.76216674,0.00002513974,0.007813009,0.006731208,0.00074280164,0.00004759611,0.000028636181,0.000006753526,0.0043947417,0.11443166],"study_design_scores_gemma":[0.090750515,0.08562116,0.8125081,0.00025693595,0.0033439242,0.0021068798,0.004690899,0.000100887264,0.000014697942,0.00007133693,0.0003524903,0.00018219113],"about_ca_topic_score_codex":0.0000860003,"about_ca_topic_score_gemma":0.0018713826,"teacher_disagreement_score":0.11424947,"about_ca_system_score_codex":0.0006131277,"about_ca_system_score_gemma":0.0017986196,"threshold_uncertainty_score":0.7142067},"labels":[],"label_agreement":null},{"id":"W2517432912","doi":"10.1200/jco.2014.32.30_suppl.67","title":"Evaluation of a system-level organizational approach to person-centered care education and implementation toolkit.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Procurement; Medicine; Test (biology); Government (linguistics); Agency (philosophy); Scale (ratio); Nursing; Quality (philosophy); Medical education; Public relations; Business; Marketing","score_opus":0.5678092572608445,"score_gpt":0.6096835503254804,"score_spread":0.04187429306463586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517432912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737502,0.00017623817,0.013788638,0.0044299294,0.0013815628,0.00091013516,0.000015060803,0.000008765836,0.0055394936],"genre_scores_gemma":[0.9535489,0.000021096848,0.043443207,0.0016867149,0.0011699585,0.000011813207,0.00008587109,0.000015243671,0.000017206818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99425167,0.0013027275,0.0030765363,0.00020858354,0.0010385022,0.00012196121],"domain_scores_gemma":[0.9892829,0.0016528119,0.0025524644,0.00016075674,0.0060776,0.00027343543],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014490964,0.00010666435,0.0007676929,0.0001898379,0.00004152634,0.000012038742,0.00009384906,0.00017815047,0.000077605386],"category_scores_gemma":[0.021194374,0.000088474895,0.00014975951,0.00020714114,0.00005450806,0.00019522384,0.000036084657,0.00029922163,0.0000062800414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010677865,0.0016169894,0.08272075,0.0002751057,0.00030719812,0.0000011230434,0.0015304562,0.00007763238,0.0005801196,0.0017410535,0.0039927238,0.90608907],"study_design_scores_gemma":[0.022365112,0.010870202,0.88858706,0.0003070467,0.0043346523,0.00049040915,0.05472984,0.0053201,0.00018825103,0.00034983427,0.012253574,0.00020392165],"about_ca_topic_score_codex":0.00007222171,"about_ca_topic_score_gemma":0.000055964272,"teacher_disagreement_score":0.90588516,"about_ca_system_score_codex":0.00044216096,"about_ca_system_score_gemma":0.0044120685,"threshold_uncertainty_score":0.98705053},"labels":[],"label_agreement":null},{"id":"W2517870508","doi":"10.1200/jco.2010.28.15_suppl.1095","title":"Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Antibody-drug conjugate; Breast cancer; Oncology; Correlation; Conjugate; Drug; Internal medicine; Cancer; Antibody; Monoclonal antibody; Immunology; Pharmacology","score_opus":0.08273252036991065,"score_gpt":0.494299588317368,"score_spread":0.41156706794745734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517870508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761976,0.000048126898,0.000044048786,0.0100658,0.00060811214,0.00045109415,0.000017669567,0.0000074069508,0.0011380021],"genre_scores_gemma":[0.9978116,0.0001893002,0.00043659078,0.0006986171,0.0004618415,0.0000114045115,0.000007097799,0.000031487012,0.0003520732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959275,0.0005931866,0.0020205367,0.00024344683,0.00088472536,0.0003306214],"domain_scores_gemma":[0.9943759,0.0017512386,0.0019750204,0.00033536195,0.00122215,0.00034032145],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030417785,0.00018755134,0.0013391216,0.00019421095,0.000051818162,0.000010681044,0.000293666,0.00034245607,0.0004535488],"category_scores_gemma":[0.0008857134,0.000089093875,0.00018257154,0.00033166344,0.0006176334,0.00017279264,0.000061919476,0.0026880717,0.000010811215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013123608,0.0013024865,0.96986884,0.00004873604,0.000122048514,0.00018667516,0.00015595445,0.000081022255,0.0009973027,0.000012354891,0.0019762742,0.012124713],"study_design_scores_gemma":[0.012483822,0.005494671,0.9749657,0.0004965317,0.00017959507,0.00015566725,0.00010918276,0.00025625396,0.00036803292,0.000013360147,0.0053747823,0.000102380116],"about_ca_topic_score_codex":0.001344718,"about_ca_topic_score_gemma":0.002052733,"teacher_disagreement_score":0.012022332,"about_ca_system_score_codex":0.0001747113,"about_ca_system_score_gemma":0.0017748801,"threshold_uncertainty_score":0.99961275},"labels":[],"label_agreement":null},{"id":"W2518121781","doi":"10.1200/jco.2009.27.15_suppl.e17517","title":"Retrospective assessment of adherence to ASCO Surveillance Guidelines following treatment for stage II and III colorectal cancer (CRC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cohort; Colorectal cancer; Stage (stratigraphy); Cancer registry; Colonoscopy; Cancer; Internal medicine; Retrospective cohort study; Prospective cohort study; Cohort study; Radiation therapy","score_opus":0.1857230442047789,"score_gpt":0.5520346238317869,"score_spread":0.366311579627008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518121781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871088,0.0016137178,0.00015928134,0.007937182,0.00093598955,0.00065481436,0.000036095753,0.0000071571544,0.0015469287],"genre_scores_gemma":[0.98782426,0.0027271225,0.00754064,0.0007604603,0.00057072646,0.000037303857,0.0000016827396,0.000009173778,0.00052865467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974297,0.000093815,0.0017242244,0.00025018572,0.000280982,0.0002210755],"domain_scores_gemma":[0.99708384,0.0006612688,0.0010500951,0.00010312153,0.000856961,0.00024468638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012636544,0.00017846242,0.0020138377,0.00007924882,0.000092661125,0.000005838285,0.00007428042,0.0001472706,0.000033432552],"category_scores_gemma":[0.0013865839,0.00011389847,0.000513938,0.0001284007,0.00007817997,0.00006707357,0.000039675222,0.00019384721,1.8607913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009960223,0.0020773874,0.7224995,0.00002115541,0.001836402,0.00015464834,0.0004701451,0.000035180994,0.0012878982,0.00022782486,0.0019610713,0.2594686],"study_design_scores_gemma":[0.011032679,0.12655625,0.8499535,0.00011631074,0.0003574882,0.00001859301,0.00016476739,0.00009029715,0.00018810782,0.00010405506,0.011325199,0.000092771756],"about_ca_topic_score_codex":0.00017479804,"about_ca_topic_score_gemma":0.0009849833,"teacher_disagreement_score":0.2593758,"about_ca_system_score_codex":0.00064464816,"about_ca_system_score_gemma":0.0012853678,"threshold_uncertainty_score":0.4644645},"labels":[],"label_agreement":null},{"id":"W2518765238","doi":"10.1200/jco.2016.68.5776","title":"PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Oxaliplatin; Medicine; Gemcitabine; Folinic acid; Fluorouracil; Regimen; Internal medicine; Clinical endpoint; Phases of clinical research; Progression-free survival; Pancreatic cancer; Chemotherapy; Oncology; Adverse effect; Performance status; Gastroenterology; Surgery; Cancer; Colorectal cancer; Clinical trial","score_opus":0.09762290404530811,"score_gpt":0.48999912213549435,"score_spread":0.39237621809018625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518765238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905491,0.00013391745,0.0018083121,0.002242582,0.00023275496,0.0047191917,0.00003238236,0.000010143163,0.00027163362],"genre_scores_gemma":[0.98917204,0.0005067277,0.00681768,0.00068876694,0.0003681009,0.00040763794,0.000004870087,0.000050069004,0.001984124],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922626,0.0015623083,0.004549511,0.00041838683,0.0006911082,0.0005160836],"domain_scores_gemma":[0.9801669,0.013764425,0.0035977825,0.00038642078,0.0016439015,0.00044054948],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071268566,0.00034022663,0.007210861,0.0003502315,0.0000518382,0.0000061465253,0.00026704886,0.00041798415,0.0008539981],"category_scores_gemma":[0.008659783,0.00016250262,0.00047228066,0.00025335397,0.0005443829,0.00016269808,0.00003274774,0.0007023922,0.0000018387167],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55040073,0.007855962,0.3766908,0.0000830258,0.0011090466,0.00006768531,0.00038264145,0.000012016034,0.00026583057,0.0000024340995,0.00014106657,0.06298875],"study_design_scores_gemma":[0.7849469,0.09378986,0.11588177,0.0008874309,0.0011387907,0.000016122309,0.00045715948,0.0014984843,0.0004211457,0.000057685847,0.0007236899,0.00018092943],"about_ca_topic_score_codex":0.000107543376,"about_ca_topic_score_gemma":0.0011713573,"teacher_disagreement_score":0.26080903,"about_ca_system_score_codex":0.00038132307,"about_ca_system_score_gemma":0.0036592092,"threshold_uncertainty_score":0.9996907},"labels":[],"label_agreement":null},{"id":"W2519239115","doi":"10.1200/jco.2016.69.4158","title":"Reply to F. Tomao et al","year":2016,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Medical Research Council; National Institutes of Health; Canadian Cancer Society Research Institute; St Vincent's Hospital Melbourne; Inselspital, Universitätsspital Bern; American College of Radiology Imaging Network; University of Melbourne; National Cancer Institute; Breast Cancer Trials; University of Chicago; Oncosuisse; Pfizer","keywords":"Medicine","score_opus":0.14005374317036054,"score_gpt":0.5119365093100703,"score_spread":0.3718827661397097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519239115","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057954346,0.0029682934,0.00061058014,0.91222066,0.04630429,0.0007095812,0.00006573774,0.000022777353,0.031302672],"genre_scores_gemma":[0.0018586722,0.009272837,0.001709415,0.8958294,0.060609065,0.000020287694,0.000006595485,0.000099322046,0.030594409],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862474,0.002718542,0.007689691,0.0007569295,0.0013606319,0.0012268057],"domain_scores_gemma":[0.9691856,0.020346025,0.006223407,0.00055957865,0.002457608,0.0012277747],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.012368082,0.0006580175,0.0058160992,0.00051283994,0.00010266379,0.000023793073,0.00059506315,0.0019943395,0.003687129],"category_scores_gemma":[0.036363773,0.00044101584,0.0022165768,0.00030578117,0.0009924722,0.00021236613,0.00043547503,0.009366429,0.0029220951],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056941765,0.0007472995,0.0063380394,0.00006907908,0.003063188,0.009805845,0.00012125495,0.000002245786,0.00003467037,0.00004124709,0.75397456,0.22010842],"study_design_scores_gemma":[0.012535837,0.046804328,0.03834758,0.0041451724,0.002232407,0.002243123,0.0000928454,0.0000025325658,0.000016009706,0.0002866307,0.8928903,0.00040326352],"about_ca_topic_score_codex":0.000054025128,"about_ca_topic_score_gemma":0.000034145298,"teacher_disagreement_score":0.21970515,"about_ca_system_score_codex":0.0017763735,"about_ca_system_score_gemma":0.0067243483,"threshold_uncertainty_score":0.99980414},"labels":[],"label_agreement":null},{"id":"W2519908811","doi":"10.1200/jco.2012.30.15_suppl.3578","title":"The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Capecitabine; Oxaliplatin; Internal medicine; Dihydropyrimidine dehydrogenase; Colorectal cancer; Fluorouracil; Thymidine phosphorylase; Oncology; Thymidylate synthase; Population; Clinical endpoint; Gastroenterology; Cancer; Randomized controlled trial","score_opus":0.09166070058760821,"score_gpt":0.45485487187350465,"score_spread":0.3631941712858964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519908811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746412,0.018560126,0.000009662103,0.0010783537,0.0040829913,0.0011682066,0.000075526434,0.000009821804,0.00037411306],"genre_scores_gemma":[0.9935431,0.0047127344,0.0002775392,0.0001408146,0.00091554737,0.00006359365,0.0000069496323,0.000031290205,0.00030846498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955662,0.0003446557,0.0026796227,0.00028135418,0.00067241554,0.00045579195],"domain_scores_gemma":[0.9928401,0.0042089242,0.0019570633,0.00024272669,0.00041178876,0.00033936414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023760519,0.00030201173,0.0024022015,0.00011306628,0.00020803971,0.000014545485,0.00022593836,0.0002985305,0.000107250904],"category_scores_gemma":[0.001828402,0.00018061476,0.00073222513,0.00015494805,0.0002759632,0.00017345983,0.00015052804,0.00050537445,0.0000014676223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07982487,0.0022212632,0.7767645,0.000022748238,0.0055843415,0.00009617809,0.0021976752,0.000006388662,0.0011661382,0.000034992485,0.00032543455,0.13175547],"study_design_scores_gemma":[0.053503543,0.032562625,0.8810151,0.00007334532,0.002118686,0.000018383827,0.005695074,0.000091801696,0.00056104065,0.00006212871,0.024127701,0.0001705333],"about_ca_topic_score_codex":0.0021184941,"about_ca_topic_score_gemma":0.0011039171,"teacher_disagreement_score":0.13158494,"about_ca_system_score_codex":0.00037892777,"about_ca_system_score_gemma":0.00091518933,"threshold_uncertainty_score":0.7365256},"labels":[],"label_agreement":null},{"id":"W2520616996","doi":"10.1200/jco.2015.33.3_suppl.tps496","title":"Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabozantinib; Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Oncology; Tolerability; Placebo; Response Evaluation Criteria in Solid Tumors; Discontinuation; Randomized controlled trial; Cancer; Adverse effect; Phases of clinical research; Gastroenterology; Clinical trial; Pathology","score_opus":0.2807922948578121,"score_gpt":0.43416961070038224,"score_spread":0.15337731584257014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520616996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872945,0.0012294719,0.000055575092,0.001236774,0.0009812091,0.00662083,0.000003980528,0.000017553091,0.002560087],"genre_scores_gemma":[0.99758846,0.00020556508,0.0008064917,0.00013823481,0.00072683115,0.00016096084,0.000013190019,0.00006045783,0.0002998233],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9893562,0.0031132046,0.0053603305,0.00051664864,0.0011005284,0.00055308855],"domain_scores_gemma":[0.9860972,0.006675011,0.0041638305,0.00049784244,0.0015796707,0.0009864469],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012160892,0.0004992069,0.007998815,0.0005018501,0.000055477885,0.000025102625,0.00033267424,0.00067374547,0.000073315256],"category_scores_gemma":[0.0053063426,0.00031728993,0.0010851475,0.00042283515,0.0004877444,0.00019970114,0.000079278754,0.0014637323,0.000014256122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.598574,0.013913331,0.3760386,0.000031214582,0.0015727098,0.0059327804,0.0010830904,0.000010997352,0.00003754415,0.000012049369,0.00014739539,0.002646311],"study_design_scores_gemma":[0.8951481,0.08929923,0.0036140087,0.00016626643,0.004492603,0.00022562646,0.0019283677,0.0034572422,0.00055116956,0.000016941129,0.0008425831,0.0002578759],"about_ca_topic_score_codex":0.00048675374,"about_ca_topic_score_gemma":0.0005920734,"teacher_disagreement_score":0.3724246,"about_ca_system_score_codex":0.00025910875,"about_ca_system_score_gemma":0.0043671755,"threshold_uncertainty_score":0.99992794},"labels":[],"label_agreement":null},{"id":"W2521137575","doi":"10.1200/jco.2013.31.15_suppl.8528","title":"Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Neutropenia; Internal medicine; Clinical endpoint; Febrile neutropenia; Discontinuation; Surgery; Multiple myeloma; Oncology; Clinical trial; Chemotherapy","score_opus":0.13740891986873646,"score_gpt":0.4642725011870012,"score_spread":0.32686358131826476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521137575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488086,0.0013209948,0.000075312935,0.0009945622,0.0010429638,0.0012036435,0.00002860848,0.000016919113,0.00043615728],"genre_scores_gemma":[0.9776167,0.0017771686,0.019425368,0.00023107346,0.00064399635,0.000039066043,0.000020671705,0.00007921202,0.00016673755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99000436,0.002047041,0.0050885896,0.0005945831,0.0011461816,0.0011192427],"domain_scores_gemma":[0.9792314,0.014824758,0.0027137734,0.0007905764,0.000947202,0.0014922563],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0047480115,0.00052960194,0.0038676092,0.0009981703,0.000048195954,0.00002491045,0.00056627946,0.0011453935,0.0008123199],"category_scores_gemma":[0.028534526,0.00039332375,0.0011340203,0.000835762,0.00065202004,0.0003108631,0.000243643,0.0028539412,0.00014219913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081799075,0.009658995,0.7109084,0.000110713794,0.0014692926,0.0053193206,0.00028674776,0.0013274691,0.007857421,0.000013316081,0.0010759473,0.18017332],"study_design_scores_gemma":[0.12085909,0.027491009,0.84617174,0.0003522282,0.00023184916,0.00022307764,0.00019303027,0.0024756473,0.001126112,0.00018869319,0.00041519635,0.00027232806],"about_ca_topic_score_codex":0.0039494387,"about_ca_topic_score_gemma":0.0017803464,"teacher_disagreement_score":0.17990099,"about_ca_system_score_codex":0.001975547,"about_ca_system_score_gemma":0.005299896,"threshold_uncertainty_score":0.9998519},"labels":[],"label_agreement":null},{"id":"W2521561070","doi":"10.1200/jco.2013.31.6_suppl.44","title":"The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prostate cancer; Oncology; Internal medicine; Prednisone; Cabazitaxel; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.17066052728771366,"score_gpt":0.48586772246307847,"score_spread":0.3152071951753648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521561070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809109,0.0010905544,0.0000063395037,0.0137250805,0.0009443236,0.0027813965,0.0003037283,0.000004672403,0.00023302589],"genre_scores_gemma":[0.9962103,0.0013424809,0.00017829544,0.0004706238,0.0010926215,0.00017772715,0.00007032659,0.00002451251,0.0004331404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969704,0.00039841825,0.0012762556,0.00031067716,0.00067196065,0.000372264],"domain_scores_gemma":[0.99244475,0.0048733116,0.0009696591,0.00048302082,0.0009780393,0.00025121056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028081243,0.00016830524,0.0008728823,0.00004854411,0.00014570566,0.000047547474,0.0005723082,0.0001645597,0.00012592177],"category_scores_gemma":[0.0023288117,0.00006679738,0.000132951,0.0001741532,0.00039813438,0.00024898222,0.00022135649,0.0009774115,0.000011073545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065289594,0.0021611168,0.8592424,0.000008323916,0.0010709694,0.00007968678,0.00024480448,0.000003863076,0.00000208168,0.000004703316,0.004621952,0.06727054],"study_design_scores_gemma":[0.028868254,0.0235927,0.93843263,0.00017665098,0.0003851365,0.0000068851805,0.0009853847,0.00015478567,0.000003733123,0.00038859757,0.00693146,0.00007380513],"about_ca_topic_score_codex":0.001319597,"about_ca_topic_score_gemma":0.0020454298,"teacher_disagreement_score":0.07919024,"about_ca_system_score_codex":0.00021074401,"about_ca_system_score_gemma":0.0020617135,"threshold_uncertainty_score":0.4246421},"labels":[],"label_agreement":null},{"id":"W2521733332","doi":"10.1200/jco.2004.22.90140.6111","title":"The cost of hospitalization secondary to severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Colorectal cancer; Discontinuation; Oxaliplatin; Cohort; Retrospective cohort study; Irinotecan; Chemotherapy; Internal medicine; Cancer; Diarrhea","score_opus":0.03426193008174406,"score_gpt":0.38047299696005626,"score_spread":0.3462110668783122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521733332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178004,0.0000905899,0.0000198146,0.006565894,0.00045608522,0.00037794278,0.000004082159,0.0000030037336,0.0007025705],"genre_scores_gemma":[0.9977203,0.00011567584,0.0001576099,0.0016837834,0.00027492948,0.000007475769,0.000001918666,0.000012131583,0.00002620277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981862,0.00010660785,0.0011330502,0.00011636561,0.00029375457,0.00016403582],"domain_scores_gemma":[0.99805063,0.00042067462,0.0007568256,0.0000802552,0.0004879059,0.00020373233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008143411,0.00009758146,0.00073705433,0.00007871312,0.000030962423,0.000004728022,0.000114585084,0.00017837112,0.000048224163],"category_scores_gemma":[0.00067188457,0.00005359076,0.00015484923,0.00025478096,0.0001094767,0.00006891331,0.00002493232,0.00055187836,0.0000019513168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016015284,0.0011263253,0.86894053,0.000014727473,0.0001291304,0.000048300175,0.00030158734,0.00010097912,0.00018522635,0.00004385466,0.00025644145,0.11283758],"study_design_scores_gemma":[0.013005878,0.022489365,0.9615933,0.00012785166,0.000051939805,0.000018707362,0.00007802366,0.0000056548847,0.0005857356,0.00013462192,0.0018431825,0.000065742075],"about_ca_topic_score_codex":0.000076107426,"about_ca_topic_score_gemma":0.00090570154,"teacher_disagreement_score":0.11277185,"about_ca_system_score_codex":0.00024584937,"about_ca_system_score_gemma":0.0016657563,"threshold_uncertainty_score":0.295498},"labels":[],"label_agreement":null},{"id":"W2521802479","doi":"10.1200/jco.2013.31.15_suppl.8583","title":"Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Population; Quality of life (healthcare); Multiple myeloma; Internal medicine; Lenalidomide; Environmental health","score_opus":0.12958121648736118,"score_gpt":0.45786709637234085,"score_spread":0.3282858798849797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521802479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960256,0.000341488,0.00005406505,0.0009077215,0.00042104736,0.0020053764,0.000024476547,0.0000063023876,0.00021387902],"genre_scores_gemma":[0.9913078,0.00036798956,0.0070836437,0.000731605,0.00021326491,0.00008824952,0.000017732033,0.000031890708,0.00015784826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99235195,0.0012769086,0.004730034,0.0003986691,0.0006777397,0.0005646999],"domain_scores_gemma":[0.98591626,0.009463455,0.002559586,0.00034483915,0.0008429354,0.00087292766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054422515,0.00026560636,0.002829541,0.00041917182,0.00003794791,0.000012394204,0.00022919636,0.0005907547,0.00011819278],"category_scores_gemma":[0.042288374,0.00019590542,0.00043845185,0.00024381155,0.00027875174,0.00022588402,0.00013551903,0.0010799611,0.000011900129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043831848,0.0073068,0.81942,0.00019120771,0.00040869636,0.00010729137,0.00018144508,0.000010096405,0.0018424442,0.0000065256413,0.00040445823,0.12628922],"study_design_scores_gemma":[0.15114322,0.011775885,0.83451396,0.00017202507,0.000057547848,0.000005978829,0.00016700322,0.0012087061,0.00017118015,0.00022792158,0.00042750066,0.00012909173],"about_ca_topic_score_codex":0.0009849643,"about_ca_topic_score_gemma":0.00076139503,"teacher_disagreement_score":0.12616013,"about_ca_system_score_codex":0.0005277768,"about_ca_system_score_gemma":0.0018146723,"threshold_uncertainty_score":0.9657788},"labels":[],"label_agreement":null},{"id":"W2521999419","doi":"10.1200/jco.2016.69.1188","title":"Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":349,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology; Cancer Care Ontario; Fred Hutchinson Cancer Research Center; American Society for Radiation Oncology","keywords":"Medicine; Radiation oncology; Clinical Oncology; Surgical oncology; Guideline; Oncology; Radiation therapy; Internal medicine; Medical physics; Cancer; Pathology","score_opus":0.11500906332382081,"score_gpt":0.5203546595878676,"score_spread":0.4053455962640468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521999419","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057866266,0.9636671,0.0031691561,0.020537702,0.003240287,0.0021388074,0.0010426989,0.000033740598,0.00038390522],"genre_scores_gemma":[0.00041299406,0.8949207,0.0942987,0.0028714768,0.0069756014,0.00009172745,0.00023608912,0.00012874296,0.00006398108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98314863,0.0035815584,0.010639067,0.0012804368,0.00050962286,0.0008406546],"domain_scores_gemma":[0.96709263,0.0077713677,0.02197552,0.0007811895,0.0016301391,0.0007491471],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012795961,0.00094617595,0.013300197,0.00010265046,0.00015927205,0.000013481414,0.0009810595,0.003200349,0.000040963958],"category_scores_gemma":[0.0009592981,0.00065436226,0.009676594,0.00039931227,0.006158213,0.000039091025,0.0004580728,0.0017802318,0.0000021409758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036086724,0.0030833115,0.0007145339,0.0005890671,0.009910222,0.000014902981,0.000108459215,0.0000023978819,0.000059181744,0.00002161734,0.08303375,0.8988539],"study_design_scores_gemma":[0.015545004,0.04761389,0.00068676914,0.0004288688,0.003367731,0.00036327072,0.00039118013,0.000047952093,0.000016797841,0.00004083366,0.9309594,0.0005383027],"about_ca_topic_score_codex":0.00011917904,"about_ca_topic_score_gemma":0.000099918914,"teacher_disagreement_score":0.8983156,"about_ca_system_score_codex":0.00092528504,"about_ca_system_score_gemma":0.0125098275,"threshold_uncertainty_score":0.99959075},"labels":[],"label_agreement":null},{"id":"W2522691612","doi":"10.1200/jco.2013.31.4_suppl.457","title":"Induction treatment in first-line with chemotherapy + bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Bevacizumab; Internal medicine; Oxaliplatin; Oncology; Neutropenia; Irinotecan; Colorectal cancer; Population; Erlotinib; Regimen; Surgery; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.12353795805988822,"score_gpt":0.4627823637892175,"score_spread":0.3392444057293293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522691612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97513443,0.00082675694,0.000005545776,0.021726655,0.00048298627,0.0014953725,0.000020467662,0.0000070218575,0.00030077645],"genre_scores_gemma":[0.9944066,0.003697036,0.00030777065,0.0006264655,0.00062209636,0.00019849272,0.000007639045,0.000017050257,0.00011683894],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99661463,0.00038943795,0.0021146664,0.00029864436,0.0003248548,0.00025776128],"domain_scores_gemma":[0.9958255,0.0024328837,0.0011430635,0.00018153082,0.00025578868,0.0001611926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010881468,0.00023236797,0.0017765621,0.00011845673,0.0000654218,0.00001409637,0.00011966066,0.00013612739,0.0001734752],"category_scores_gemma":[0.0005529138,0.000110536435,0.00021167226,0.00029907818,0.00017897977,0.00012697131,0.000027077911,0.0006351526,0.000005515156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103420116,0.022905413,0.24987459,0.0000051893753,0.002189069,0.0009930442,0.006442431,0.0001313497,0.000047769718,0.0000022430534,0.00072935125,0.61325943],"study_design_scores_gemma":[0.15408686,0.08342728,0.75419044,0.00010802511,0.00058061874,0.00007440683,0.0029442434,0.00014919687,0.00006870837,0.00011440189,0.00414718,0.000108656655],"about_ca_topic_score_codex":0.01548309,"about_ca_topic_score_gemma":0.07167791,"teacher_disagreement_score":0.6131508,"about_ca_system_score_codex":0.0010215992,"about_ca_system_score_gemma":0.0010983894,"threshold_uncertainty_score":0.9910729},"labels":[],"label_agreement":null},{"id":"W2522739347","doi":"10.1200/jco.2016.34.15_suppl.6566","title":"Impact of intermittent and maintenance chemotherapy on outcomes in metastatic colorectal cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Regimen; Internal medicine; Chemotherapy; Chemotherapy regimen; Cohort; Proportional hazards model; Quality of life (healthcare); Population; Univariate analysis; Oncology; Propensity score matching; Surgery; Cancer; Multivariate analysis","score_opus":0.10224206465013191,"score_gpt":0.5067430824922721,"score_spread":0.40450101784214015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522739347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890755,0.00039291653,0.000008385495,0.009495968,0.00032665193,0.00015240954,0.0000090122185,0.0000020383013,0.00053711125],"genre_scores_gemma":[0.9950504,0.003902555,0.00022442536,0.0005235588,0.00009242846,0.000006771997,9.1273336e-8,0.000007603428,0.00019219243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982833,0.0001163773,0.0011721905,0.00011911738,0.00015734699,0.00015165035],"domain_scores_gemma":[0.99719524,0.0016042535,0.00083184463,0.00006600729,0.00017128023,0.00013137609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000711846,0.000113674905,0.0015273901,0.0000962932,0.00000984749,0.0000016240401,0.000057046393,0.00007453452,0.00009840568],"category_scores_gemma":[0.001202809,0.00004750346,0.0003949011,0.00006330602,0.00021967807,0.000040790546,0.000022753944,0.00021502128,0.0000011238436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009007985,0.0010152707,0.6576802,0.0000072905023,0.0007583054,0.00014876174,0.00008942579,7.3886457e-7,0.00025143288,0.000015200335,0.00039711923,0.33062825],"study_design_scores_gemma":[0.013696438,0.035555877,0.94930434,0.00022211981,0.00012342466,0.00007191498,0.0000463954,0.000005264009,0.00010081527,0.00016435208,0.0006634458,0.000045622117],"about_ca_topic_score_codex":0.00009487701,"about_ca_topic_score_gemma":0.00022553549,"teacher_disagreement_score":0.33058265,"about_ca_system_score_codex":0.00035564989,"about_ca_system_score_gemma":0.0005720416,"threshold_uncertainty_score":0.1937135},"labels":[],"label_agreement":null},{"id":"W2523490165","doi":"10.1200/jco.2013.31.15_suppl.8510","title":"MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Thalidomide; Clinical endpoint; Neutropenia; Internal medicine; Dexamethasone; Phases of clinical research; Surgery; Population; Multiple myeloma; Gastroenterology; Randomized controlled trial; Toxicity","score_opus":0.18168473715271388,"score_gpt":0.4888007598015487,"score_spread":0.3071160226488348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523490165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874722,0.0010476647,0.00017460198,0.0012934412,0.0021723814,0.0073696217,0.00002638555,0.000030028776,0.0004137165],"genre_scores_gemma":[0.97677964,0.0010033257,0.019977078,0.0005224827,0.0006533363,0.00036047833,0.00002743827,0.00010482547,0.0005714191],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9821253,0.0059349756,0.008135602,0.00094915286,0.0016513536,0.0012036633],"domain_scores_gemma":[0.9552854,0.034623887,0.0053787837,0.0011858757,0.0016052255,0.001920857],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0124360565,0.0007333059,0.008160774,0.0009132959,0.0001375753,0.00007969446,0.0012366647,0.0009252912,0.00075236155],"category_scores_gemma":[0.048713233,0.00053168985,0.00090786594,0.0007298329,0.000965849,0.00073652697,0.0007304186,0.0031936292,0.00013236766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.720593,0.09657062,0.015983593,0.00008748903,0.0035841272,0.0047858167,0.00075152016,0.00005536697,0.002591672,0.000011803579,0.00079408096,0.15419091],"study_design_scores_gemma":[0.89602566,0.050959226,0.042342838,0.00040214875,0.0012725865,0.00014581344,0.0015712611,0.005739306,0.000499825,0.000073569034,0.00058693974,0.0003808149],"about_ca_topic_score_codex":0.0060449964,"about_ca_topic_score_gemma":0.0018253302,"teacher_disagreement_score":0.17543268,"about_ca_system_score_codex":0.0010509087,"about_ca_system_score_gemma":0.003189441,"threshold_uncertainty_score":0.9997135},"labels":[],"label_agreement":null},{"id":"W2523547317","doi":"10.1200/jco.2016.34.2_suppl.1","title":"NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Interim analysis; Internal medicine; Randomized controlled trial; Clinical endpoint; Oncology; Clinical trial; Cancer; Urology; Confidence interval","score_opus":0.07586299186364398,"score_gpt":0.5099397561842397,"score_spread":0.4340767643205957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523547317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324965,0.00019507116,0.0002782319,0.0029780667,0.00084271666,0.0020481711,0.0000098662895,0.000010705901,0.00038752917],"genre_scores_gemma":[0.9966603,0.0016508206,0.0007137603,0.00017156948,0.0005390341,0.00010581724,0.000006098769,0.000019532117,0.00013308696],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99460495,0.0014543826,0.0026446357,0.00030444292,0.0006316275,0.0003599833],"domain_scores_gemma":[0.99172467,0.004060558,0.0025083928,0.00018352458,0.0011484909,0.00037433684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006604412,0.00020115843,0.002751158,0.00029652513,0.00008428655,0.000012423678,0.00014217183,0.00022509361,0.00012825674],"category_scores_gemma":[0.0033629003,0.0000991074,0.00028514178,0.00023354181,0.000431284,0.00028893468,0.000065250344,0.0011589014,0.000011238635],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36915234,0.009082259,0.52281535,0.000011112358,0.00060263055,0.00019032318,0.00021100744,0.000017317847,0.000019352367,0.000005562944,0.000053537497,0.09783923],"study_design_scores_gemma":[0.5676119,0.018389745,0.41206217,0.00020900572,0.0004221443,0.00000743076,0.00015110716,0.00015858536,0.00003583394,0.00010371637,0.00076685246,0.000081539016],"about_ca_topic_score_codex":0.00038742763,"about_ca_topic_score_gemma":0.00089417293,"teacher_disagreement_score":0.19845955,"about_ca_system_score_codex":0.0011000608,"about_ca_system_score_gemma":0.0033559327,"threshold_uncertainty_score":0.59532803},"labels":[],"label_agreement":null},{"id":"W2523570479","doi":"10.1200/jco.2016.34.15_suppl.5549","title":"Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; PARP inhibitor; Response Evaluation Criteria in Solid Tumors; Serous fluid; Cancer; Cancer research; Progressive disease; Gene; Chemotherapy; Genetics; Biology; Poly ADP ribose polymerase","score_opus":0.15526079202072865,"score_gpt":0.4210538464934026,"score_spread":0.265793054472674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523570479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818878,0.000065990534,0.00015982283,0.01626259,0.00065232033,0.0008943224,0.0000067174883,0.000008192827,0.00006221719],"genre_scores_gemma":[0.9964724,0.000016679227,0.0014295495,0.0009654373,0.0010205383,0.000048987273,1.7412705e-7,0.000027888482,0.000018345685],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9937712,0.0022184409,0.0025990063,0.0002900757,0.0007513922,0.00036990223],"domain_scores_gemma":[0.9855657,0.010360825,0.0026887113,0.0005395481,0.0005662703,0.00027891077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011445463,0.00020497573,0.0015286717,0.00017446438,0.000063212516,0.000007468201,0.00029449395,0.0001963972,0.00004227506],"category_scores_gemma":[0.0073570204,0.00008545303,0.00018774839,0.00044040912,0.0004577384,0.00009965237,0.000043763986,0.00092519174,0.0000017935599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6913412,0.0012101217,0.20626055,0.000044545137,0.000313585,0.00043280938,0.0025709234,0.0003997286,0.091132216,0.000064348504,0.00009299345,0.006136983],"study_design_scores_gemma":[0.11579767,0.06719646,0.7637312,0.0018740675,0.00017446684,0.00034574443,0.0034764933,0.000029860488,0.046110783,0.0005343134,0.000505818,0.00022313576],"about_ca_topic_score_codex":0.000066598455,"about_ca_topic_score_gemma":0.00006220771,"teacher_disagreement_score":0.5755435,"about_ca_system_score_codex":0.0012905964,"about_ca_system_score_gemma":0.0029109966,"threshold_uncertainty_score":0.8807572},"labels":[],"label_agreement":null},{"id":"W2524005613","doi":"10.1200/jco.2012.30.15_suppl.3013","title":"A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Cancer Care Ontario; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Nausea; Pharmacokinetics; Tolerability; Dosing; Pharmacodynamics; Vomiting; Pharmacology; Anorexia; Diarrhea; Internal medicine; Adverse effect; Toxicity; Gastroenterology","score_opus":0.07582525028532743,"score_gpt":0.43907815041695913,"score_spread":0.3632529001316317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524005613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953102,0.0033197158,0.00010471313,0.00021792654,0.00069592195,0.00017346874,0.000017375149,7.7350364e-7,0.00015994214],"genre_scores_gemma":[0.99587035,0.002427425,0.0006364281,0.00015262197,0.0008790285,0.00000197489,0.000004183271,0.000009160179,0.000018798908],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99808943,0.0001875589,0.0013178972,0.00013422311,0.0001306994,0.00014016683],"domain_scores_gemma":[0.99804467,0.00025104472,0.001146124,0.00011636599,0.00022873735,0.0002130811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011227025,0.000102893646,0.0006341414,0.000046470876,0.0000185816,0.0000066155085,0.000086867076,0.00016739074,0.000011701093],"category_scores_gemma":[0.00048896053,0.00008575732,0.000107888685,0.00004069783,0.0001759122,0.000007874986,0.00008135868,0.00018888402,2.8304927e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021026028,0.033592854,0.1287917,0.00009602582,0.0009102005,0.00017940735,0.00092014135,0.000026206322,0.3943637,0.000112472924,0.011414984,0.40856627],"study_design_scores_gemma":[0.08208923,0.2575485,0.323393,0.00009270833,0.0011811238,0.001116509,0.0028483786,0.0000871467,0.07185697,0.00016861719,0.25906256,0.0005552741],"about_ca_topic_score_codex":0.0000080704485,"about_ca_topic_score_gemma":0.000021126632,"teacher_disagreement_score":0.408011,"about_ca_system_score_codex":0.000011188141,"about_ca_system_score_gemma":0.00023687417,"threshold_uncertainty_score":0.3497082},"labels":[],"label_agreement":null},{"id":"W2524341612","doi":"10.1200/jco.2015.33.15_suppl.tps8613","title":"The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Multicenter study; Randomized controlled trial","score_opus":0.15953253754496918,"score_gpt":0.47876826623604535,"score_spread":0.3192357286910762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524341612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967792,0.00010610062,0.000008697515,0.00044987226,0.00046623338,0.002004236,0.0000059429103,0.000006267271,0.00017342021],"genre_scores_gemma":[0.99867564,0.000024312398,0.0009072419,0.0000973416,0.00016082577,0.000027532607,0.000004674382,0.000022027358,0.00008037455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486923,0.0010874615,0.0023252163,0.00025830558,0.0010796767,0.000380102],"domain_scores_gemma":[0.99373704,0.002676739,0.0014620025,0.00038426137,0.0010923377,0.00064762234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028254576,0.00019711681,0.0013983165,0.00016764626,0.00005460402,0.000012223169,0.000267875,0.0001318475,0.000019986815],"category_scores_gemma":[0.0072220857,0.00010018765,0.00017571865,0.00022434976,0.00017877198,0.00012391074,0.00010591929,0.00072925276,0.000010277932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08570146,0.087795034,0.6927427,0.000008235733,0.0005802841,0.001036565,0.00077113655,0.000034302866,0.000012750227,2.2384546e-7,0.00015121062,0.13116607],"study_design_scores_gemma":[0.16838051,0.17977615,0.6460096,0.000052575284,0.00018667185,0.000011412124,0.003594642,0.00013258554,0.0000143767265,0.0000026195958,0.0017766624,0.00006219434],"about_ca_topic_score_codex":0.000068873174,"about_ca_topic_score_gemma":0.00088144664,"teacher_disagreement_score":0.13110389,"about_ca_system_score_codex":0.000291299,"about_ca_system_score_gemma":0.0007514542,"threshold_uncertainty_score":0.8646033},"labels":[],"label_agreement":null},{"id":"W2524796523","doi":"10.1200/jco.2007.25.18_suppl.9013","title":"Normalization of bone markers and improved survival during zoledronic acid therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Zoledronic acid; Internal medicine; Creatinine; N-terminal telopeptide; Urology; Prostate cancer; Oncology; Surgery; Cancer; Alkaline phosphatase; Osteocalcin","score_opus":0.0804548689730106,"score_gpt":0.4629371331444742,"score_spread":0.3824822641714636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524796523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953484,0.0014807121,0.00015818847,0.0012995277,0.0006426871,0.00014644183,7.910978e-7,0.0000043648297,0.00091887],"genre_scores_gemma":[0.9942704,0.0034520729,0.0013932952,0.0004977024,0.0002568174,5.583079e-7,0.0000012296971,0.000009525735,0.00011843726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975758,0.00014438044,0.001809454,0.00009245355,0.0001804423,0.00019744343],"domain_scores_gemma":[0.9974487,0.0005862121,0.001304718,0.000090895264,0.00022887676,0.00034060917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033824276,0.00007943854,0.0008904548,0.00010201413,0.000028387532,0.0000017799426,0.00003353996,0.00024178866,0.000041742],"category_scores_gemma":[0.00075019244,0.000055096833,0.00017260064,0.00008457153,0.00009051099,0.0000678082,0.000015452195,0.00038810447,0.0000015146754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027675992,0.0015167699,0.73167795,0.00008344008,0.0003747224,0.00039316816,0.000079546386,7.0304117e-7,0.0038913852,0.000031447715,0.00007102582,0.23420383],"study_design_scores_gemma":[0.017875938,0.009452785,0.967949,0.000046767353,0.000108636035,0.00035845788,0.000052762472,0.000025695432,0.0011055366,0.000043434764,0.002940536,0.000040465944],"about_ca_topic_score_codex":0.000031026408,"about_ca_topic_score_gemma":0.00007323193,"teacher_disagreement_score":0.23627101,"about_ca_system_score_codex":0.000074631935,"about_ca_system_score_gemma":0.0006051408,"threshold_uncertainty_score":0.22467837},"labels":[],"label_agreement":null},{"id":"W2524891404","doi":"10.1200/jco.2010.28.15_suppl.6102","title":"Treatment strategies for low-risk febrile neutropenia in adult cancer patients: A cost-utility analysis.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Febrile neutropenia; Neutropenia; Cancer; Intensive care medicine; Emergency medicine; Pediatrics; Internal medicine; Chemotherapy","score_opus":0.07356181675303874,"score_gpt":0.4790039828001701,"score_spread":0.40544216604713135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524891404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937799,0.000050666076,0.00014543506,0.001975227,0.0017987292,0.000596464,0.000051883755,0.0000075896196,0.0015941331],"genre_scores_gemma":[0.9966975,0.0007311331,0.0005823227,0.00081306027,0.00093616726,0.000095227515,0.000008392372,0.000011902559,0.00012433369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725324,0.00022908223,0.0018587817,0.00022828477,0.00018485496,0.0002457843],"domain_scores_gemma":[0.9961526,0.0010719438,0.0013153567,0.00021434716,0.0009364364,0.00030932692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008771666,0.00014642814,0.0015781323,0.00019538277,0.000057205823,0.000018478082,0.00011553884,0.00029500312,0.00042907492],"category_scores_gemma":[0.0010442482,0.00009644557,0.0008650361,0.0003237426,0.0001573677,0.00016125893,0.000018898776,0.0009246488,0.0000063915627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004553674,0.0039554513,0.90546954,0.00001464928,0.0010926151,0.00004015942,0.00009024203,0.0001762459,0.00013262132,0.0001570111,0.0012110185,0.08310679],"study_design_scores_gemma":[0.01556642,0.010537393,0.91798115,0.000020020185,0.0027815935,0.000019607984,0.00012653966,0.00048329524,0.000089446134,0.00022251565,0.052079633,0.00009236744],"about_ca_topic_score_codex":0.0011824616,"about_ca_topic_score_gemma":0.02815855,"teacher_disagreement_score":0.08301442,"about_ca_system_score_codex":0.00024232885,"about_ca_system_score_gemma":0.0024537302,"threshold_uncertainty_score":0.989575},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2525078780","doi":"10.1200/jco.2007.25.18_suppl.8016","title":"Late treatment mortality and secondary cancers after autologous stem cell transplant for relapsed or refractory Hodgkin lymphoma (HL)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Salvage therapy; Chemotherapy; Melphalan; Surgery; Refractory (planetary science); Oncology; Gastroenterology","score_opus":0.10626775221254174,"score_gpt":0.42888301977899046,"score_spread":0.3226152675664487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525078780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935988,0.0023323451,0.00007085313,0.0012116686,0.0011492847,0.00048125122,0.000053768854,0.0000140133725,0.0010879909],"genre_scores_gemma":[0.9911127,0.0039212625,0.0017702314,0.0017498697,0.0006242033,0.000032132168,0.0000065933277,0.000022413442,0.00076057663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99688435,0.00019074585,0.0020504291,0.00029241847,0.00022500151,0.00035705869],"domain_scores_gemma":[0.99479324,0.0031844901,0.0010842129,0.00020566488,0.0001640692,0.0005683323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001939688,0.00023296254,0.0016294689,0.000102116224,0.000053608906,0.000008931427,0.000073226875,0.0004933213,0.00010081834],"category_scores_gemma":[0.00010174238,0.00013439014,0.00055994594,0.000061921615,0.00018449314,0.00008174308,0.000013927629,0.0002268943,0.0000051773372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038577683,0.004345194,0.2317339,0.00010065386,0.0013094043,0.010807466,0.0005164662,0.0000029256325,0.00007011802,0.000013478577,0.0009052964,0.7116174],"study_design_scores_gemma":[0.03487825,0.041172653,0.82774293,0.00010042332,0.0016683495,0.0007553379,0.00012640993,0.000026656464,0.00075529976,0.000040344068,0.09260085,0.0001325066],"about_ca_topic_score_codex":0.00017185675,"about_ca_topic_score_gemma":0.0010548271,"teacher_disagreement_score":0.7114849,"about_ca_system_score_codex":0.0012399021,"about_ca_system_score_gemma":0.003162781,"threshold_uncertainty_score":0.56106377},"labels":[],"label_agreement":null},{"id":"W2525124319","doi":"10.1200/jco.2012.30.15_suppl.tps4134","title":"Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Medicine; Internal medicine; Gemcitabine; Phases of clinical research; Cancer; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Myeloid leukemia; Imatinib","score_opus":0.08178953788669324,"score_gpt":0.4010976613704846,"score_spread":0.31930812348379134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525124319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860402,0.00091214874,0.0016669648,0.0007617717,0.00061620044,0.008999095,0.0000056307117,0.00001663481,0.0009813725],"genre_scores_gemma":[0.98538756,0.00026861118,0.012646757,0.00038092994,0.0005605562,0.0003084325,0.000020267362,0.00006917205,0.0003577193],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898753,0.0021075099,0.0057699806,0.00041001316,0.0010885108,0.0007486624],"domain_scores_gemma":[0.98242444,0.009404374,0.0058571314,0.0005400196,0.00092869287,0.00084534765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009153599,0.00053500297,0.007976944,0.0004503294,0.00007090419,0.00001031416,0.00030608318,0.0005646883,0.0002161892],"category_scores_gemma":[0.0053538433,0.00030160058,0.00069370406,0.00043550887,0.00065627653,0.0003657524,0.00008098914,0.001402154,0.000011242732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9231045,0.026445225,0.036638465,0.00007912293,0.0030192526,0.0003422741,0.0003718474,0.00030331747,0.000017308597,0.00005347186,0.00018379345,0.009441387],"study_design_scores_gemma":[0.81409174,0.17552026,0.0049260324,0.0005620026,0.00379355,0.00015612972,0.000121334444,0.00037018766,0.00005851751,0.000028853008,0.00014460947,0.00022681219],"about_ca_topic_score_codex":0.000046094745,"about_ca_topic_score_gemma":0.000038204522,"teacher_disagreement_score":0.14907503,"about_ca_system_score_codex":0.0010288605,"about_ca_system_score_gemma":0.0046488247,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W2525261975","doi":"10.1200/jco.2015.33.3_suppl.276","title":"Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Everolimus; Medicine; Clinical endpoint; Neuroendocrine tumors; Internal medicine; Placebo; Concomitant; Randomized controlled trial; Gastroenterology; Progression-free survival; Oncology; Surgery; Pathology; Chemotherapy","score_opus":0.14391980294575496,"score_gpt":0.4773111673000061,"score_spread":0.33339136435425115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525261975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041444,0.00031483275,0.00020830566,0.0042135124,0.0009371037,0.0034559977,0.000007645173,0.00001008005,0.00043810598],"genre_scores_gemma":[0.9970684,0.00020735967,0.0009959198,0.00048383683,0.00081108045,0.00006363437,0.000002270782,0.000035738027,0.00033173306],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866832,0.00397323,0.0067112907,0.00037646238,0.0016805236,0.000575285],"domain_scores_gemma":[0.9778455,0.014574527,0.0045364634,0.00047414345,0.0017347685,0.00083462626],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010382143,0.00033389233,0.0049838885,0.0007587363,0.00004725502,0.000010233277,0.0005941068,0.000036737933,0.00013637608],"category_scores_gemma":[0.041617278,0.0001814572,0.0011068262,0.00086535676,0.0009349136,0.0002113581,0.00021164725,0.002505133,0.000002193538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8972102,0.013096664,0.074160546,0.00005888399,0.0004350733,0.010715831,0.00004927438,0.0011377702,0.000074777534,0.00003168928,0.0017535082,0.0012758146],"study_design_scores_gemma":[0.93023384,0.04392066,0.0032440673,0.0002531826,0.00084042636,0.016054537,0.0006916618,0.0039026318,0.000055587854,0.0000831256,0.0006088369,0.00011147728],"about_ca_topic_score_codex":0.00013190422,"about_ca_topic_score_gemma":0.0006161334,"teacher_disagreement_score":0.070916474,"about_ca_system_score_codex":0.00013385055,"about_ca_system_score_gemma":0.004523524,"threshold_uncertainty_score":0.99979615},"labels":[],"label_agreement":null},{"id":"W2525323356","doi":"10.1200/jco.2007.25.18_suppl.7594","title":"Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene mutations detected by denaturing high-performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Gefitinib; Denaturing high performance liquid chromatography; Medicine; Exon; Lung cancer; Epidermal growth factor receptor; Erlotinib; Point mutation; ROS1; Mutation; Internal medicine; Oncology; Gene mutation; Cancer research; Adenocarcinoma; Cancer; Gene; Biology; Genetics","score_opus":0.028761481619544903,"score_gpt":0.4024679377034675,"score_spread":0.3737064560839226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525323356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927945,0.0036077336,0.0005265151,0.0016554042,0.00049944955,0.0006158445,0.000056699057,0.0000156207,0.0002282048],"genre_scores_gemma":[0.9863364,0.0034686625,0.009278583,0.0004948872,0.00030200958,0.000038333554,0.00002381927,0.00002352556,0.0000337413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968535,0.00016272292,0.0021835677,0.0002734438,0.00019313472,0.0003336344],"domain_scores_gemma":[0.99538696,0.0019610012,0.0016185216,0.00016121687,0.0005532489,0.0003190567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010722226,0.00019418482,0.0010182391,0.0003391378,0.00008194143,0.000008461615,0.00014723922,0.0004144739,0.000033845336],"category_scores_gemma":[0.0009226641,0.00014544866,0.00022584057,0.00040211377,0.00022932902,0.00014003518,0.00004108892,0.0008358746,0.0000012878338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013890853,0.0015797287,0.95456195,0.00017440089,0.00030045438,0.000083305335,0.00037698093,0.000030945197,0.02454053,0.0000120431,0.00043360118,0.016516984],"study_design_scores_gemma":[0.0059491815,0.005040994,0.97253865,0.00023422448,0.00064082356,0.00014831696,0.00008333274,0.000025858406,0.015041131,0.000025700123,0.00014518262,0.00012661002],"about_ca_topic_score_codex":0.000109315544,"about_ca_topic_score_gemma":0.00015172384,"teacher_disagreement_score":0.017976705,"about_ca_system_score_codex":0.00019501781,"about_ca_system_score_gemma":0.000984809,"threshold_uncertainty_score":0.5931224},"labels":[],"label_agreement":null},{"id":"W2525472147","doi":"10.1200/jco.2015.33.7_suppl.377","title":"Outcomes of progression on surveillance for clinical stage I nonseminomatous germ cell tumours (NSGCT).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Oncology; Tumor progression; Internal medicine; Testicular cancer; Surgery; Cancer","score_opus":0.25963860555791185,"score_gpt":0.5661061883236217,"score_spread":0.30646758276570985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525472147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934028,0.0012494302,0.000091600086,0.0021903268,0.0015297402,0.00043996898,0.00002767336,0.000011944987,0.0010565326],"genre_scores_gemma":[0.991676,0.00024830678,0.006277831,0.00080885977,0.0005420318,0.000006781907,0.0000070715287,0.000022214994,0.0004109525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958128,0.0004686921,0.002808641,0.00021696319,0.00046463663,0.00022830575],"domain_scores_gemma":[0.9892375,0.005641763,0.003324578,0.00027715453,0.0007072428,0.0008117668],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0041533113,0.00016369163,0.0020039522,0.00007856481,0.000022292701,0.0000052129826,0.00015594132,0.00033257864,0.000020825826],"category_scores_gemma":[0.012050843,0.00009784796,0.0010160562,0.00006676331,0.00020577756,0.000043811622,0.000042595642,0.000464143,0.00001544199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070790797,0.007995277,0.9317203,0.00005780942,0.00022119789,0.00066992856,0.000017654365,0.0000061078645,0.0000046683126,0.000028657794,0.005498676,0.046700645],"study_design_scores_gemma":[0.019516557,0.03401247,0.93047124,0.00010620892,0.00041015501,0.00007472322,0.000057833946,0.00006362722,0.000051325507,0.000108753295,0.015043261,0.00008384556],"about_ca_topic_score_codex":0.000005048856,"about_ca_topic_score_gemma":0.0000045266183,"teacher_disagreement_score":0.0466168,"about_ca_system_score_codex":0.00008576087,"about_ca_system_score_gemma":0.0021795519,"threshold_uncertainty_score":0.9962711},"labels":[],"label_agreement":null},{"id":"W2525633824","doi":"10.1200/jco.2012.30.15_suppl.9065","title":"Clinical needs of patients referred early to supportive and palliative care.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Cancer; Internal medicine; Head and neck; Surgery","score_opus":0.44457090892374357,"score_gpt":0.5996004450568817,"score_spread":0.15502953613313813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525633824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322575,0.0013303029,0.000113271104,0.0010075415,0.0016472632,0.00019224812,0.000018385821,0.0000037181696,0.0024615454],"genre_scores_gemma":[0.99070203,0.0014793484,0.005631453,0.0010008253,0.0010585794,0.0000017769962,0.0000049981336,0.000013670219,0.000107287284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953928,0.0005270992,0.0033218185,0.000117393975,0.00038129647,0.00025959843],"domain_scores_gemma":[0.99031377,0.004772995,0.0024190494,0.0001656795,0.0015746469,0.00075385964],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024761083,0.00014056823,0.0020563938,0.00018325566,0.000016019043,0.000002138742,0.00012900955,0.00042047523,0.0000622494],"category_scores_gemma":[0.01482685,0.000098572425,0.0004751563,0.00019122113,0.0003245592,0.0001265721,0.000089805144,0.0007136241,0.000011216352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043492448,0.0012688233,0.9296501,0.00004656358,0.00039388088,0.000017178085,0.0054746456,2.905799e-7,0.00002090612,0.000052814492,0.0027046285,0.056020882],"study_design_scores_gemma":[0.0054458966,0.021160835,0.8935642,0.0002965015,0.00040327184,0.000003020212,0.00253977,8.3575003e-7,0.00018229966,0.00004322433,0.076282054,0.00007808734],"about_ca_topic_score_codex":0.000024248957,"about_ca_topic_score_gemma":0.000009154947,"teacher_disagreement_score":0.07357743,"about_ca_system_score_codex":0.0000756396,"about_ca_system_score_gemma":0.00054369296,"threshold_uncertainty_score":0.9934717},"labels":[],"label_agreement":null},{"id":"W2525861376","doi":"10.1200/jco.2012.30.15_suppl.tps4141","title":"TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemoradiotherapy; Randomized controlled trial; Regimen; Radiation therapy; Clinical endpoint; Perioperative; Cancer; Clinical trial; Chemotherapy; Surgery; Pathological staging; Chemotherapy regimen; Oncology; Internal medicine","score_opus":0.13758273965047668,"score_gpt":0.5136563494937297,"score_spread":0.37607360984325305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525861376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97728384,0.00092402805,0.0028838995,0.005661085,0.007928477,0.0025150718,0.000020197805,0.000013947463,0.0027694749],"genre_scores_gemma":[0.96904635,0.004936997,0.0120928995,0.0018514226,0.009589218,0.00018331251,0.000023139897,0.00004076717,0.0022358971],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99575293,0.00051828683,0.0025847084,0.00023757535,0.0005354183,0.0003711035],"domain_scores_gemma":[0.99336505,0.0029595897,0.0021933694,0.00022640517,0.0008913711,0.00036423138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0055893604,0.00023088025,0.0029015956,0.00024075565,0.000052771742,0.000020769889,0.00029987586,0.0002580562,0.0011676298],"category_scores_gemma":[0.0030928082,0.00015722962,0.00093143363,0.00021368793,0.0002903953,0.000537129,0.00003363084,0.0005536098,0.0000017390682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9328679,0.004139171,0.006516643,0.00002626707,0.0026558756,0.0000126033665,0.0007502346,0.000025150795,0.00016655549,0.00026496992,0.0044606775,0.04811397],"study_design_scores_gemma":[0.94238734,0.026596637,0.003879507,0.000055240067,0.0009545476,0.000025459129,0.00027652676,0.00062670984,0.0005825585,0.000050481663,0.024432043,0.00013295899],"about_ca_topic_score_codex":0.00005810233,"about_ca_topic_score_gemma":0.0000304452,"teacher_disagreement_score":0.04798101,"about_ca_system_score_codex":0.0003577572,"about_ca_system_score_gemma":0.0012954674,"threshold_uncertainty_score":0.9997454},"labels":[],"label_agreement":null},{"id":"W2525975938","doi":"10.1200/jco.2016.34.15_suppl.6091","title":"Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Papillary thyroid cancer; Thyroid cancer; Lenvatinib; Internal medicine; Follicular thyroid cancer; Cancer; Follicular phase; Oncology; Thyroid carcinoma; Thyroid; Immunotherapy","score_opus":0.1397906944189803,"score_gpt":0.49867223984660314,"score_spread":0.35888154542762285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525975938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9204683,0.007433956,0.00016022961,0.06829873,0.0018849906,0.0013257249,0.0002343825,0.000017915643,0.00017581417],"genre_scores_gemma":[0.9760307,0.014798401,0.0012433912,0.0038182002,0.0033335828,0.00017328073,0.000009044409,0.000037520927,0.0005558507],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99553066,0.0004900606,0.0027254315,0.0004207729,0.00047383286,0.00035925978],"domain_scores_gemma":[0.98337024,0.013040792,0.002119359,0.0005385289,0.00051682483,0.00041424457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020541935,0.00025425217,0.0017262765,0.000053699132,0.00011524245,0.000011789041,0.00033321802,0.0002891342,0.00012552206],"category_scores_gemma":[0.0056484486,0.0001023768,0.0007995286,0.00011514155,0.00018225804,0.00013522268,0.00008401799,0.0004672022,0.000013259416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29149702,0.015337653,0.009186697,0.000011828799,0.0019177351,0.001475617,0.0003162557,0.000012368857,0.00035273936,0.000017091617,0.05982324,0.62005174],"study_design_scores_gemma":[0.29159293,0.23008847,0.10967418,0.00051069714,0.0026684504,0.00015768356,0.00051225524,0.000021755452,0.00063573173,0.00035357216,0.36358064,0.00020364531],"about_ca_topic_score_codex":0.000107914166,"about_ca_topic_score_gemma":0.00022177404,"teacher_disagreement_score":0.61984813,"about_ca_system_score_codex":0.00039537798,"about_ca_system_score_gemma":0.0021386766,"threshold_uncertainty_score":0.67621285},"labels":[],"label_agreement":null},{"id":"W2526138506","doi":"10.1200/jco.2014.32.31_suppl.154","title":"Association between tobacco use and symptom expression, alcoholism, and illicit drug use in patients with advanced cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cancer; Lung cancer; Smoking cessation; Drug; Opioid; Psychiatry; Pathology","score_opus":0.0705904593874903,"score_gpt":0.4174380946009825,"score_spread":0.3468476352134922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526138506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593425,0.00020687559,0.000008795869,0.0033413698,0.00027984622,0.00014674428,0.0000060556645,0.0000047613075,0.00007128347],"genre_scores_gemma":[0.9950935,0.0017061266,0.001043385,0.0015845976,0.0004231053,0.000003765738,0.0000016609473,0.000010853273,0.00013300685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980579,0.00029041595,0.0010319075,0.00016287898,0.0002739073,0.0001830156],"domain_scores_gemma":[0.9946646,0.0035665706,0.0010125953,0.00008623743,0.00042233188,0.00024767686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00131691,0.0001060663,0.001209171,0.00007495086,0.000039275677,0.0000137862025,0.00004244452,0.00019782588,0.000007460886],"category_scores_gemma":[0.0047638537,0.000067454355,0.000058870002,0.00007805609,0.00007752541,0.0003120688,0.00004430885,0.0005525485,5.2650427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012457335,0.00019171146,0.9419114,0.000011301762,0.00013062592,0.0000068515783,0.00018132011,0.000002704559,0.000014032113,0.0000032502505,0.0016839308,0.054617133],"study_design_scores_gemma":[0.011788959,0.0037142525,0.9596868,0.00035912954,0.0001915929,0.0000017395613,0.000031951276,0.0000048491793,0.000022961502,0.000020568192,0.024104558,0.00007261268],"about_ca_topic_score_codex":0.00009001172,"about_ca_topic_score_gemma":0.0003561362,"teacher_disagreement_score":0.05454452,"about_ca_system_score_codex":0.00016035292,"about_ca_system_score_gemma":0.00019895328,"threshold_uncertainty_score":0.5703122},"labels":[],"label_agreement":null},{"id":"W2526148797","doi":"10.1200/jco.2014.32.15_suppl.7501","title":"A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Rash; Erlotinib; Clinical endpoint; Chemotherapy; Oncology; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.07699324678474728,"score_gpt":0.457988531164614,"score_spread":0.38099528437986674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526148797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894414,0.00010559755,0.00060476037,0.0013094757,0.0015385911,0.0047668843,0.00008203182,0.000011151572,0.0021401118],"genre_scores_gemma":[0.9953142,0.00020530679,0.0025063038,0.00061540416,0.0007356622,0.00014743321,0.00005103994,0.000059224643,0.00036544242],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99456406,0.0008432676,0.0030267795,0.00045364647,0.00068236346,0.0004298733],"domain_scores_gemma":[0.99194396,0.003064612,0.003553878,0.0002996294,0.00069130334,0.0004466377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003518157,0.00035454126,0.0035051613,0.00032328945,0.00009064153,0.000021736407,0.00018296311,0.00024756257,0.00004523801],"category_scores_gemma":[0.0008012451,0.00019964973,0.0005448634,0.00033016907,0.0002913903,0.0001918234,0.000028413757,0.00091760623,0.0000017167679],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97189426,0.0059893914,0.008774203,0.00007796742,0.0021286097,0.00032923667,0.0014135097,0.00020889787,0.000030355674,0.000005235836,0.00023795862,0.008910375],"study_design_scores_gemma":[0.9014938,0.08521643,0.0059884815,0.0009905865,0.0027980392,0.000023375704,0.0003094211,0.0012876539,0.00019290546,0.0000025047593,0.001484555,0.00021227554],"about_ca_topic_score_codex":0.00085173483,"about_ca_topic_score_gemma":0.0023392201,"teacher_disagreement_score":0.079227045,"about_ca_system_score_codex":0.00068535923,"about_ca_system_score_gemma":0.0035917433,"threshold_uncertainty_score":0.81414795},"labels":[],"label_agreement":null},{"id":"W2526157356","doi":"10.1200/jco.2016.34.7_suppl.298","title":"Time trends in opioid use in cancer and noncancer patients: Observations from administrative data.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University; Queen's University; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Medical prescription; Oxycodone; Opioid; Cancer pain; Population; Fentanyl; Internal medicine; Demography; Surgery; Pharmacology; Environmental health","score_opus":0.6716373880870075,"score_gpt":0.610185761158918,"score_spread":0.061451626928089476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526157356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324626,0.000710963,0.00001613346,0.0051701292,0.00033269703,0.000058149664,0.00021064203,0.0000016800019,0.00025335062],"genre_scores_gemma":[0.984868,0.0068059815,0.0055999625,0.0015018311,0.00060825207,0.0000045553234,0.000042624517,0.000010258467,0.00055855437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796975,0.00018585387,0.0014000541,0.00016294932,0.00016464302,0.00011677714],"domain_scores_gemma":[0.99485725,0.0037696296,0.0008109257,0.00016359339,0.00025978457,0.00013878653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006416859,0.000081738,0.00088999775,0.00012699945,0.0000069726766,0.0000027583956,0.00012486355,0.00018475438,0.00023448719],"category_scores_gemma":[0.0045780055,0.000049101393,0.0000720229,0.00014999406,0.00019859603,0.00030671203,0.00005650157,0.0003094058,0.0000029038813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012188095,0.0005755699,0.88020974,0.00000381853,0.00008607172,0.000059831727,0.00027024877,6.9355883e-7,0.00008197281,0.000009955256,0.0038953016,0.11358801],"study_design_scores_gemma":[0.007103188,0.0020669962,0.90130687,0.0006680376,0.00007834071,0.0000012326695,0.00007295988,0.000033154884,0.00003166975,0.00010775141,0.08847963,0.00005014294],"about_ca_topic_score_codex":0.0004301489,"about_ca_topic_score_gemma":0.003126088,"teacher_disagreement_score":0.11353787,"about_ca_system_score_codex":0.00013589647,"about_ca_system_score_gemma":0.0007204188,"threshold_uncertainty_score":0.5480631},"labels":[],"label_agreement":null},{"id":"W2526220138","doi":"10.1200/jco.2016.34.15_suppl.5003","title":"A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Hôpital Notre-Dame; Cancer Care Ontario; McMaster University; Health Sciences Centre; CancerCare Manitoba; Ontario Clinical Oncology Group; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Urology; Prostate; Radiation therapy; Regimen; Hazard ratio; Randomized controlled trial; Hormonal therapy; Dose fractionation; Nuclear medicine; Cancer; Internal medicine; Confidence interval","score_opus":0.15974073505868924,"score_gpt":0.5331915029740711,"score_spread":0.3734507679153819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526220138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527158,0.0037125947,0.0027196954,0.03569264,0.0015946405,0.0033589702,0.000027297552,0.000003784108,0.00017454509],"genre_scores_gemma":[0.9611235,0.03554931,0.00081600493,0.000113650705,0.0011271368,0.00024461938,0.0000038547546,0.000009672471,0.001012238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973344,0.00040819636,0.0017447444,0.00009556276,0.0002994065,0.00011769392],"domain_scores_gemma":[0.98897517,0.008346565,0.0017489099,0.000108244785,0.0007261007,0.00009503996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030413088,0.00007885311,0.0013664503,0.00009112014,0.00002614712,0.000002377836,0.000057205303,0.0001528014,0.00010824056],"category_scores_gemma":[0.0025807682,0.00002932065,0.0007372188,0.00007653627,0.00031172438,0.0000703613,0.0000054212846,0.00010251845,9.0587463e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6419394,0.0015693298,0.001206277,0.000013580908,0.0009688048,0.000003761602,0.00008884966,0.0000063223247,0.00024322649,0.000048917787,0.0003085415,0.35360295],"study_design_scores_gemma":[0.9233827,0.028023738,0.0016971658,0.00007863566,0.0010022358,0.000006594475,0.000040538944,0.00027480288,0.00319376,0.0005424959,0.041727055,0.000030254098],"about_ca_topic_score_codex":0.00003058512,"about_ca_topic_score_gemma":0.000012858741,"teacher_disagreement_score":0.3535727,"about_ca_system_score_codex":0.0002650967,"about_ca_system_score_gemma":0.0017974541,"threshold_uncertainty_score":0.31886065},"labels":[],"label_agreement":null},{"id":"W2526268649","doi":"10.1200/jco.2014.32.31_suppl.56","title":"Integrating palliative care into care of patients with kidney cancer and melanoma.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Referral; Psychosocial; Quality of life (healthcare); Advance care planning; Cancer; Family medicine; Internal medicine; Nursing; Psychiatry","score_opus":0.15829150040990306,"score_gpt":0.5263427106640544,"score_spread":0.36805121025415133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526268649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934734,0.0027178645,0.00018312929,0.00091429916,0.00035265269,0.00011608681,0.000015382238,0.0000028338823,0.0022243182],"genre_scores_gemma":[0.9862133,0.0009407459,0.011604405,0.0008168136,0.00038353365,0.0000021990022,0.000009026865,0.00001089261,0.000019083582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801767,0.00021021385,0.0012465531,0.00012956082,0.0002783633,0.00011761741],"domain_scores_gemma":[0.9946882,0.0013884003,0.0016343078,0.00010507118,0.0018984615,0.00028554798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045843577,0.00011620045,0.0012939358,0.00007768435,0.000021806634,0.0000022744553,0.0000905329,0.00020607721,0.00002891947],"category_scores_gemma":[0.005560901,0.000068934496,0.00016441585,0.000086792745,0.000255219,0.00005714372,0.000036472684,0.00048360732,5.892684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001504372,0.00014254832,0.88454574,0.00021496955,0.00024068986,0.000011237703,0.0069835037,0.0000026950763,0.000024094858,0.000060539063,0.00035323025,0.105916396],"study_design_scores_gemma":[0.010324242,0.020668732,0.8884744,0.0026024566,0.00058784825,0.0000019855675,0.009416532,0.00002194286,0.0007344009,0.000099195386,0.06695506,0.00011322549],"about_ca_topic_score_codex":0.00014763171,"about_ca_topic_score_gemma":0.00027999174,"teacher_disagreement_score":0.10580317,"about_ca_system_score_codex":0.000110932044,"about_ca_system_score_gemma":0.0009011025,"threshold_uncertainty_score":0.66573197},"labels":[],"label_agreement":null},{"id":"W2526413890","doi":"10.1200/jco.2004.22.90140.8251","title":"Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Health care; Cancer; Indirect costs; Demography; Family medicine; Environmental health; Internal medicine; Business","score_opus":0.10421508308918101,"score_gpt":0.36556001040901515,"score_spread":0.26134492731983416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526413890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915502,0.0002907991,0.00018881245,0.00081860356,0.004486224,0.00014435296,0.0002134128,6.6968767e-7,0.0023068995],"genre_scores_gemma":[0.9975374,0.00049289886,0.0007803752,0.00078845816,0.00025758275,0.000004259219,0.0000038283315,0.000010798297,0.00012441789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596786,0.00001823244,0.003637409,0.00013414113,0.00004253547,0.00019983118],"domain_scores_gemma":[0.9944266,0.00042407034,0.004644177,0.00010639822,0.0002655538,0.00013317079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013143566,0.00009658995,0.0015995597,0.0001059913,0.000013283861,0.000003838642,0.0002207843,0.00022114332,0.00015904386],"category_scores_gemma":[0.0015293183,0.00009798243,0.00023652492,0.00004961507,0.00008454042,0.00014938558,0.000025891883,0.00036360888,0.0000021446394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006842579,0.0005995315,0.96616316,0.00002200036,0.000090204274,0.0000059922613,0.0001695011,0.00007370066,9.94908e-7,0.004226163,0.0016003612,0.026364114],"study_design_scores_gemma":[0.004235414,0.0016540104,0.9026947,0.000055686036,0.000016179583,8.910932e-7,0.000012602593,0.0000070135093,0.000021849435,0.005199539,0.086007886,0.00009421083],"about_ca_topic_score_codex":0.694205,"about_ca_topic_score_gemma":0.96237636,"teacher_disagreement_score":0.26817137,"about_ca_system_score_codex":0.0014845596,"about_ca_system_score_gemma":0.004308379,"threshold_uncertainty_score":0.7642879},"labels":[],"label_agreement":null},{"id":"W2526983807","doi":"10.1200/jco.2013.31.15_suppl.8527","title":"Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Neutropenia; Dexamethasone; Clinical endpoint; Internal medicine; Population; Urology; Adverse effect; Surgery; Gastroenterology; Toxicity; Clinical trial","score_opus":0.07336388582057025,"score_gpt":0.39894167578969064,"score_spread":0.3255777899691204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526983807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959648,0.0003740847,0.00039374235,0.00096626166,0.0006159919,0.0013509346,0.000056639372,0.00002242118,0.00025512482],"genre_scores_gemma":[0.97781056,0.00053582,0.020478372,0.00038977622,0.00032333445,0.000071981915,0.00009144413,0.0000711307,0.00022756887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897158,0.0019756795,0.004740929,0.00076376187,0.0017499267,0.0010538863],"domain_scores_gemma":[0.98344827,0.008884888,0.0035949766,0.0008447681,0.0016726018,0.0015544991],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038010466,0.0005870598,0.0046083224,0.0014181957,0.000098576544,0.000037659196,0.00049534155,0.00079299737,0.0009177057],"category_scores_gemma":[0.008015175,0.00040404778,0.0011671573,0.001265315,0.0006223793,0.00043072843,0.00021554162,0.0021346668,0.00008189354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2195318,0.020294327,0.5914579,0.00011469618,0.013390099,0.0029023208,0.00040315854,0.0059141396,0.00077130395,0.000015581243,0.0009153256,0.14428936],"study_design_scores_gemma":[0.13645355,0.03504102,0.8070778,0.00023113182,0.0027164684,0.000038010592,0.00018437428,0.017077154,0.00041313338,0.000063113934,0.00038187427,0.0003223196],"about_ca_topic_score_codex":0.0018007397,"about_ca_topic_score_gemma":0.0017394476,"teacher_disagreement_score":0.21561997,"about_ca_system_score_codex":0.0015150626,"about_ca_system_score_gemma":0.0028417315,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W2526991509","doi":"10.1200/jco.2012.30.15_suppl.e19626","title":"Validation of the patient-generated part of the PG-SGA against the malnutrition screening tool (MST).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Malnutrition; Cancer; Lung cancer; Internal medicine; Quality of life (healthcare); Pediatrics; Nursing","score_opus":0.2530033035853168,"score_gpt":0.4717117750241689,"score_spread":0.21870847143885208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526991509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667049,0.00041790577,0.00016856655,0.029187165,0.002241595,0.00031804107,0.0000050288527,0.000003626587,0.000953188],"genre_scores_gemma":[0.989783,0.00039508156,0.0014612612,0.0069162347,0.0013604345,0.0000037449201,0.0000027713984,0.000008424396,0.00006906357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960442,0.001096566,0.0021772138,0.0000708351,0.0004266048,0.00018455784],"domain_scores_gemma":[0.9953295,0.0012021894,0.0025557636,0.0002344261,0.00055915146,0.000118985714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041623353,0.000078206955,0.0005843698,0.0000480431,0.00011152457,0.0000039968413,0.00017773407,0.00020590058,0.00008126212],"category_scores_gemma":[0.0026121598,0.000035032837,0.00039735623,0.00021560494,0.00027760683,0.00009496736,0.000056886853,0.0008111268,0.000002440616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030795683,0.0038543018,0.7534276,0.00025809446,0.00033488224,0.0000097291895,0.00070360804,0.00012703192,0.009514543,0.0011533208,0.044099573,0.18343775],"study_design_scores_gemma":[0.009595499,0.0030762837,0.6949112,0.0012396479,0.00053801556,0.00019925695,0.0006299786,0.00032802887,0.025063235,0.00048692056,0.26381612,0.00011581587],"about_ca_topic_score_codex":0.000004190378,"about_ca_topic_score_gemma":0.0000018878214,"teacher_disagreement_score":0.21971656,"about_ca_system_score_codex":0.00006059153,"about_ca_system_score_gemma":0.00042486,"threshold_uncertainty_score":0.35239872},"labels":[],"label_agreement":null},{"id":"W2527054903","doi":"10.1200/jco.2014.32.4_suppl.35","title":"Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Prostate cancer; Clinical endpoint; Spinal cord compression; Pathologic fracture; Oncology; Internal medicine; Bone metastasis; Urology; Randomized controlled trial; Osteoporosis; Surgery; Cancer; Spinal cord","score_opus":0.0386380936526964,"score_gpt":0.42494912897795495,"score_spread":0.38631103532525857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527054903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962738,0.0002336479,0.0002162432,0.0013880502,0.00028437897,0.0015437527,0.000006711926,0.000004737138,0.00004864115],"genre_scores_gemma":[0.99739796,0.00007917729,0.0021473002,0.00012272144,0.000042158365,0.00006403442,0.000015444073,0.00001841867,0.0001127609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655694,0.0003349674,0.0022699444,0.00016650159,0.00042257074,0.00024905358],"domain_scores_gemma":[0.9951767,0.0011116188,0.0028663957,0.00016491642,0.0004893367,0.00019104614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013611863,0.00015112771,0.0012070874,0.00009001197,0.00005560994,0.0000020495588,0.00009578625,0.00015980339,0.000014138841],"category_scores_gemma":[0.0005479518,0.000078324396,0.0001911083,0.0001692036,0.000102373044,0.00011145888,0.000011801147,0.0004328537,0.000001560964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017717566,0.0039079366,0.85689664,0.00017611052,0.0005743531,0.0000062238823,0.00012771832,0.00030634145,0.000007376969,0.0000356314,0.000032965505,0.12021112],"study_design_scores_gemma":[0.04353047,0.04275127,0.91092056,0.00072962634,0.00065805117,0.000014391604,0.000052667296,0.00047243547,0.0000115206985,0.00021582076,0.0005737701,0.000069401816],"about_ca_topic_score_codex":0.000060317154,"about_ca_topic_score_gemma":0.0007555317,"teacher_disagreement_score":0.12014172,"about_ca_system_score_codex":0.00018992047,"about_ca_system_score_gemma":0.0012296571,"threshold_uncertainty_score":0.31939763},"labels":[],"label_agreement":null},{"id":"W2527584789","doi":"10.1200/jco.2013.31.15_suppl.3620","title":"Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Mount Sinai Hospital","funders":"","keywords":"KRAS; Medicine; Colorectal cancer; Clinical endpoint; Internal medicine; Exon; Oncology; Panitumumab; Primary tumor; Randomized controlled trial; Cancer; Metastasis; Biology","score_opus":0.1059472628263756,"score_gpt":0.46782990879860425,"score_spread":0.36188264597222863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527584789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922139,0.0011056624,0.0011316938,0.0020067873,0.000664755,0.002528139,0.000059533326,0.000010012315,0.000279495],"genre_scores_gemma":[0.9958198,0.0009071676,0.0019447478,0.00025191804,0.0005166923,0.0003284296,0.000017298185,0.000024527157,0.00018940236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947601,0.0006627206,0.0033472313,0.0003432823,0.0005843466,0.0003023243],"domain_scores_gemma":[0.9861431,0.008808835,0.003161013,0.00020208664,0.0013723494,0.00031262523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002297435,0.00029696125,0.0065689064,0.00023311876,0.000090650996,0.000015102278,0.00017183275,0.00015185762,0.00078022893],"category_scores_gemma":[0.002062195,0.00016355184,0.0013376293,0.00034341728,0.0003102059,0.00013011051,0.00006204738,0.00046000304,0.0000024327717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79153043,0.023130773,0.059174623,0.00004082941,0.07872621,0.00023911978,0.0015064097,0.00026559812,0.00009836576,0.000017377126,0.000745287,0.044524997],"study_design_scores_gemma":[0.78024894,0.06967446,0.101363584,0.00007005573,0.04424632,0.000014504806,0.0010799052,0.0018187823,0.00009462786,0.0002987144,0.00089872984,0.00019134545],"about_ca_topic_score_codex":0.0036386375,"about_ca_topic_score_gemma":0.010336187,"teacher_disagreement_score":0.04654369,"about_ca_system_score_codex":0.00023880445,"about_ca_system_score_gemma":0.0010056709,"threshold_uncertainty_score":0.8542959},"labels":[],"label_agreement":null},{"id":"W2527747276","doi":"10.1200/jco.2010.28.15_suppl.8059","title":"Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cohort; Population; Relative risk; Chemotherapy; Risk factor; Cardiotoxicity; Cumulative incidence; Surgery; Gastroenterology; Confidence interval","score_opus":0.08153598012980946,"score_gpt":0.46023551347404956,"score_spread":0.3786995333442401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527747276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876107,0.000062987754,0.00032777808,0.0049171816,0.004548474,0.0011364904,0.000016529995,0.000022983892,0.0002065058],"genre_scores_gemma":[0.97992074,0.000051054376,0.015057866,0.002629661,0.002155872,0.000061566956,0.000016760554,0.000037088474,0.00006936891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947539,0.00044192025,0.0035566976,0.00037407447,0.0005379837,0.0003354519],"domain_scores_gemma":[0.98861814,0.007872955,0.0020246445,0.00041821154,0.00052296,0.000543106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067167166,0.0002474293,0.0024362507,0.00012475261,0.00010020773,0.000030152985,0.0002183809,0.0005698852,0.00005516246],"category_scores_gemma":[0.005784546,0.00016990183,0.0022054766,0.00013942787,0.00007282179,0.00011365422,0.000025546253,0.0005163437,0.000009117225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063052694,0.01315639,0.84950435,0.000010222551,0.001466192,0.00039608992,0.0000464192,0.000007863615,0.00023538459,0.00003614306,0.0014813157,0.12735437],"study_design_scores_gemma":[0.039521888,0.025000341,0.9204663,0.000033732504,0.0014577297,0.000016415124,0.00007191386,0.00016337502,0.00012075319,0.0001865262,0.0128079755,0.00015304041],"about_ca_topic_score_codex":0.00018595449,"about_ca_topic_score_gemma":0.00009325272,"teacher_disagreement_score":0.12720132,"about_ca_system_score_codex":0.00025133032,"about_ca_system_score_gemma":0.0026329102,"threshold_uncertainty_score":0.69283956},"labels":[],"label_agreement":null},{"id":"W2528188718","doi":"10.1200/jco.2016.68.2914","title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":494,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"Medicine; Discontinuation; Imatinib; Myeloid leukemia; Internal medicine; Surgery; Imatinib mesylate; Minimal residual disease; Population; Gastroenterology; Leukemia","score_opus":0.048477034347511404,"score_gpt":0.38468864223977933,"score_spread":0.33621160789226795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528188718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629706,0.00015093497,0.000030176392,0.00086435693,0.0012416999,0.00090259843,0.0000061892724,0.000007082322,0.00049989304],"genre_scores_gemma":[0.99805546,0.00008121226,0.00032398634,0.00020692065,0.0004324276,0.000011013439,0.0000015746077,0.00002900007,0.0008584196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949663,0.000624708,0.002913398,0.00029853432,0.0008274415,0.0003695681],"domain_scores_gemma":[0.99403805,0.0019065551,0.0026833587,0.0005947684,0.00050643994,0.0002708057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019618494,0.00024396673,0.0018368803,0.00015030391,0.000036925994,0.000004706883,0.0004357244,0.00032566767,0.0003249554],"category_scores_gemma":[0.002472494,0.00010636792,0.00043134298,0.00025125637,0.00036568593,0.0001438586,0.00015245628,0.0009050648,0.000022964932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033535082,0.003006061,0.887028,0.00003240398,0.0005348623,0.00019662766,0.00017646067,0.0000062781296,0.000043413515,0.0000036016622,0.00046437432,0.10515444],"study_design_scores_gemma":[0.08819403,0.028995112,0.8810015,0.00063784193,0.00051161164,0.000052933716,0.000028353166,0.0000052041205,0.00007295146,0.000025618961,0.00037402657,0.00010083835],"about_ca_topic_score_codex":0.00008376675,"about_ca_topic_score_gemma":0.0009278092,"teacher_disagreement_score":0.1050536,"about_ca_system_score_codex":0.0036875985,"about_ca_system_score_gemma":0.008302898,"threshold_uncertainty_score":0.9973191},"labels":[],"label_agreement":null},{"id":"W2528407746","doi":"10.1200/jco.2014.32.4_suppl.417","title":"Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Sunitinib; Renal cell carcinoma; Discontinuation; Internal medicine; Surgery","score_opus":0.14859220776025606,"score_gpt":0.4142551626451508,"score_spread":0.2656629548848947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528407746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901374,0.00012652863,0.00013958439,0.0029279313,0.00055840984,0.00023837601,0.0000024712292,0.000010679285,0.0058586253],"genre_scores_gemma":[0.99694663,0.000032107113,0.0013022146,0.00077890523,0.0002811508,0.0000044313465,0.000008929862,0.000033744975,0.0006118603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426293,0.0018242454,0.0025446278,0.0002660296,0.0006851047,0.00041707302],"domain_scores_gemma":[0.98968214,0.0069730873,0.0021580681,0.00028356313,0.00039131343,0.00051180075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004198279,0.00027589287,0.0028574418,0.00025697352,0.00003978827,0.00001352016,0.00017118634,0.00024934637,0.00008018555],"category_scores_gemma":[0.0035020402,0.00015806929,0.0005385796,0.00018922912,0.00020136376,0.00007973246,0.00005082311,0.0012766953,0.000008359495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025283284,0.003629239,0.9854821,0.00003023824,0.0004161228,0.0024663985,0.00012665478,0.000032571534,0.00026755297,0.00006179141,0.00023999995,0.004719026],"study_design_scores_gemma":[0.022618368,0.019170698,0.95489633,0.00014377649,0.0010065488,0.00019518888,0.00014395145,0.00009407721,0.0005924472,0.00012588133,0.0008667344,0.00014600709],"about_ca_topic_score_codex":0.000051456085,"about_ca_topic_score_gemma":0.00032214803,"teacher_disagreement_score":0.030585755,"about_ca_system_score_codex":0.00046709544,"about_ca_system_score_gemma":0.000838861,"threshold_uncertainty_score":0.6445879},"labels":[],"label_agreement":null},{"id":"W2528523331","doi":"10.1200/jco.2015.33.7_suppl.256","title":"Effect of lipid nanoparticle siRNA delivery systems on silencing clusterin and progression in enzalutamide resistant prostate cancer in vivo.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"LNCaP; Gene silencing; Clusterin; Small interfering RNA; Cancer research; In vivo; Prostate cancer; Enzalutamide; Medicine; Gene knockdown; Androgen receptor; Apoptosis; Cancer; Cell culture; Transfection; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.08094787129279679,"score_gpt":0.47167817607827667,"score_spread":0.3907303047854799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528523331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534243,0.0017537551,0.0000014513167,0.000955244,0.001108081,0.00055197184,0.000006021785,0.000005954866,0.00027508006],"genre_scores_gemma":[0.99883425,0.00039816438,0.00014157376,0.00020632507,0.00033798395,0.00002468116,2.8596338e-7,0.000016493788,0.000040258357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509656,0.0017240294,0.002326213,0.00022624056,0.00036013185,0.0002668272],"domain_scores_gemma":[0.995437,0.0025307878,0.0012543376,0.00017389566,0.00022781368,0.0003761327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075732474,0.00014491074,0.0015174543,0.00023965964,0.000012103972,0.000006088346,0.00010387757,0.00027672213,0.000012848687],"category_scores_gemma":[0.0052744984,0.00009911531,0.00012098823,0.00017309596,0.00021019987,0.000085909065,0.00011302059,0.00063909416,0.0000019153144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.116797075,0.001611592,0.7308835,0.0008939274,0.000087988024,0.0045886543,0.0009381623,0.0019973458,0.070238344,0.000008372422,0.0005288095,0.071426235],"study_design_scores_gemma":[0.08074781,0.1729732,0.6837223,0.012129142,0.00054610596,0.0013133123,0.001341404,0.010711577,0.03283908,0.00008111407,0.0031466726,0.00044825798],"about_ca_topic_score_codex":0.00010856318,"about_ca_topic_score_gemma":0.00019146256,"teacher_disagreement_score":0.17136161,"about_ca_system_score_codex":0.00038056838,"about_ca_system_score_gemma":0.0009210801,"threshold_uncertainty_score":0.6314449},"labels":[],"label_agreement":null},{"id":"W2528569069","doi":"10.1200/jco.2007.25.18_suppl.4551","title":"A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Gemcitabine; Medicine; Axitinib; Pancreatic cancer; Internal medicine; Chemotherapy; Cancer; Gastroenterology; Urology; Oncology","score_opus":0.1463345168828665,"score_gpt":0.5462088771475395,"score_spread":0.39987436026467305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528569069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895488,0.0035590094,0.0002211343,0.0022959323,0.0006825138,0.0021073164,0.000014972478,0.000011254501,0.0015590752],"genre_scores_gemma":[0.9920384,0.0048463084,0.0020851586,0.0002747286,0.00040851138,0.000064724416,0.000009848044,0.000025681069,0.00024658287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99142575,0.0015587176,0.0053483765,0.00037523123,0.0007249724,0.0005669386],"domain_scores_gemma":[0.98101044,0.014678747,0.0026161135,0.00029645656,0.00067436404,0.00072387856],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015364881,0.00028759724,0.0060493057,0.00042754298,0.00007786603,0.000005694447,0.00022914071,0.00041723094,0.0002889823],"category_scores_gemma":[0.011378687,0.00020374164,0.0003973069,0.00037876508,0.00077683956,0.00012742539,0.00013375713,0.0013870121,0.0000021526646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8109216,0.04090561,0.032841764,0.000092027796,0.001706331,0.0008057854,0.0010153177,0.0000045440943,0.0023688823,0.000036967536,0.00062386965,0.10867731],"study_design_scores_gemma":[0.8540497,0.1206252,0.017649196,0.00025598262,0.0020280578,0.00012264411,0.0016460044,0.0008025493,0.00013079931,0.00007759081,0.0024585817,0.00015372456],"about_ca_topic_score_codex":0.00037805445,"about_ca_topic_score_gemma":0.00048360074,"teacher_disagreement_score":0.10852359,"about_ca_system_score_codex":0.0002866515,"about_ca_system_score_gemma":0.0015792289,"threshold_uncertainty_score":0.9969489},"labels":[],"label_agreement":null},{"id":"W2528805584","doi":"10.1200/jco.2007.25.18_suppl.4521","title":"The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Gemcitabine; Oncology; Lung cancer; Erlotinib Hydrochloride; Cancer; Fluorescence in situ hybridization; Pancreatic cancer; Clinical trial; Epidermal growth factor receptor; Gefitinib; Gene; Biology","score_opus":0.4269591319114643,"score_gpt":0.6101011412263371,"score_spread":0.1831420093148728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528805584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417114,0.000022516228,0.000045049655,0.0023204105,0.00084016996,0.0014656238,0.000017854918,0.0000018662639,0.0011153945],"genre_scores_gemma":[0.9977485,0.00004785029,0.0009590031,0.0004973199,0.0004947478,0.000022652786,0.0000052131195,0.000009588755,0.00021510696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99041265,0.0021942903,0.006012854,0.0001912451,0.0009522636,0.00023668766],"domain_scores_gemma":[0.95412433,0.04141178,0.0026930727,0.00015905524,0.0012207371,0.0003910092],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032753266,0.00012346142,0.0022330007,0.00016120616,0.00008195492,0.000004149639,0.00014132686,0.00027210242,0.000044332202],"category_scores_gemma":[0.06839936,0.00006821436,0.0001801768,0.00032687455,0.00040720252,0.000055188884,0.00003190523,0.0009255712,0.000001357741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13165021,0.0038622397,0.8577613,0.0000079137135,0.0004915035,0.00007281049,0.00009108684,0.000020877149,0.0000011551707,0.0002068923,0.00071082497,0.005123167],"study_design_scores_gemma":[0.09224871,0.026067877,0.8798507,0.00006210202,0.00037888522,0.0000102953645,0.00018174105,0.000013797732,0.0000027539706,0.00009089906,0.0010408043,0.00005147425],"about_ca_topic_score_codex":0.008309518,"about_ca_topic_score_gemma":0.14222305,"teacher_disagreement_score":0.13391352,"about_ca_system_score_codex":0.00039096238,"about_ca_system_score_gemma":0.00630223,"threshold_uncertainty_score":0.9993311},"labels":[],"label_agreement":null},{"id":"W2529334145","doi":"10.1200/jco.2016.34.2_suppl.176","title":"Screen failure rates in contemporary phase II/III therapeutic trials in genitourinary malignancies.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Clinical trial; Prostate cancer; Cancer; Internal medicine; Genitourinary system; Oncology; Surgery; Androgen receptor","score_opus":0.794626540809855,"score_gpt":0.6896814474326043,"score_spread":0.10494509337725066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529334145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8638788,0.002488763,0.00020474123,0.12817702,0.0008588797,0.00060964713,0.00000880446,0.000010422802,0.0037629425],"genre_scores_gemma":[0.98637336,0.003521579,0.0017075504,0.0047861664,0.0017702762,0.000011949479,0.0000015227439,0.00002774975,0.0017998366],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98337823,0.005168809,0.009448474,0.00040122122,0.0010885437,0.0005146944],"domain_scores_gemma":[0.7793571,0.21344213,0.0042817686,0.00063368905,0.0013841873,0.0009011645],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.10959942,0.00021300143,0.0041419924,0.00050030893,0.000042182033,0.000011625007,0.00054006267,0.0016128742,0.00070056005],"category_scores_gemma":[0.19679332,0.00011558768,0.000937053,0.00036974082,0.0008503699,0.00023822137,0.00023459918,0.0047632013,0.000033701144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0980285,0.022217995,0.39615473,0.00013847376,0.0010674417,0.01728568,0.0003573278,0.000002473008,0.014548503,0.0032943333,0.023350308,0.4235542],"study_design_scores_gemma":[0.27209732,0.1493062,0.27164665,0.004949164,0.00041278068,0.0007972068,0.0009042141,0.000056172503,0.0022197624,0.11229106,0.18474641,0.00057304156],"about_ca_topic_score_codex":0.000062856765,"about_ca_topic_score_gemma":0.00040268127,"teacher_disagreement_score":0.42298117,"about_ca_system_score_codex":0.00024115566,"about_ca_system_score_gemma":0.008646483,"threshold_uncertainty_score":0.99968326},"labels":[],"label_agreement":null},{"id":"W2529426783","doi":"10.1200/jco.2016.34.7_suppl.138","title":"Hepatitis B reactivation in patients with solid tumors: A systematic review and meta-analysis.","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University Health Network; St. Michael's Hospital","funders":"","keywords":"Medicine; Hepatitis B virus; HBsAg; Internal medicine; Hepatitis B; Odds ratio; Immunosuppression; Chemotherapy; Viral hepatitis; Immunology; Virus","score_opus":0.23647302900648787,"score_gpt":0.5102666589732096,"score_spread":0.2737936299667217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529426783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005457106,0.99640036,0.00002095735,0.001005598,0.000085288855,0.0021607128,0.000028002622,0.000005337691,0.00023914753],"genre_scores_gemma":[0.00023906407,0.9972356,0.00043271907,0.0016107404,0.00013738727,0.000114339455,0.000011349403,0.00003407698,0.0001847528],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98766196,0.002563534,0.008550557,0.0003481604,0.0006309629,0.00024485597],"domain_scores_gemma":[0.9819213,0.004986298,0.011412284,0.00042759723,0.0009719712,0.00028050732],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.006513957,0.00041271187,0.036648747,0.00056913425,0.000026022786,0.000008985904,0.0001837342,0.00047162382,0.00014016063],"category_scores_gemma":[0.015432853,0.00017797282,0.0032413432,0.0005974821,0.00017141037,0.0001459733,0.000078741956,0.0011569738,0.000024870196],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012132255,0.0009553519,0.011919282,0.6182557,0.32769266,0.0004010243,0.000018876282,3.478164e-8,1.9347455e-9,0.000016171942,0.00074221095,0.039877374],"study_design_scores_gemma":[0.0011148807,0.0034345142,0.00692231,0.14470181,0.7924898,0.000090500944,0.000001001079,1.4544348e-7,5.4880163e-9,0.000011875953,0.05107476,0.00015839373],"about_ca_topic_score_codex":0.00006784491,"about_ca_topic_score_gemma":0.00040244602,"teacher_disagreement_score":0.4735539,"about_ca_system_score_codex":0.0003546343,"about_ca_system_score_gemma":0.0013761272,"threshold_uncertainty_score":0.99286056},"labels":[],"label_agreement":null},{"id":"W2529567741","doi":"10.1200/jco.2016.34.2_suppl.256","title":"The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostatectomy; Androgen receptor; Oncology; Prostate; Cohort; Internal medicine; Cancer; Metastasis","score_opus":0.067726577267008,"score_gpt":0.4298627577605361,"score_spread":0.36213618049352814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529567741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860924,0.004277309,0.000011238455,0.008633616,0.00045691853,0.00031241585,0.0000047142526,0.0000020996783,0.00020928608],"genre_scores_gemma":[0.9957175,0.002696593,0.0002578836,0.0003424054,0.00005852144,0.000008658301,2.3716053e-7,0.000007040506,0.0009111245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978766,0.00025372885,0.0014341569,0.00009704373,0.00020588451,0.00013260306],"domain_scores_gemma":[0.9950129,0.0035266168,0.001088314,0.00010784693,0.00017874631,0.00008558366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030025914,0.00006960294,0.0006652647,0.00008963565,0.00002264465,0.0000014521202,0.00007537601,0.00011859198,0.000025783624],"category_scores_gemma":[0.0027271796,0.000031387633,0.00014741429,0.00007001299,0.00018574279,0.00007048738,0.000033652443,0.0002666883,3.0382571e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012798226,0.00018482048,0.9506409,0.000030471283,0.00015950548,0.000015603719,0.0003540706,3.756037e-7,0.0069194967,0.000024729698,0.0014540191,0.027417744],"study_design_scores_gemma":[0.0093150055,0.0021368198,0.96635926,0.0005226378,0.00006005144,0.000020691443,0.00013905797,0.0000030934777,0.0008100647,0.00012235546,0.02046893,0.00004200784],"about_ca_topic_score_codex":0.00003822142,"about_ca_topic_score_gemma":0.00034386254,"teacher_disagreement_score":0.027375735,"about_ca_system_score_codex":0.00030229692,"about_ca_system_score_gemma":0.001145176,"threshold_uncertainty_score":0.32648858},"labels":[],"label_agreement":null},{"id":"W2529581827","doi":"10.1200/jco.2015.33.15_suppl.e20691","title":"Oral chemotherapy: Improved medication outcomes in private practice.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cohort; Medical prescription; Audit; Cohort study; Pharmacist; Retrospective cohort study; Intervention (counseling); Emergency medicine; Pharmacy; Internal medicine; Physical therapy; Family medicine; Nursing","score_opus":0.2898026382011882,"score_gpt":0.5593783639351732,"score_spread":0.26957572573398497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529581827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73728156,0.00033532738,0.002089308,0.24378456,0.0019995,0.00032531598,4.210374e-7,0.00001559896,0.014168398],"genre_scores_gemma":[0.9304623,0.00068280427,0.029721456,0.03652439,0.00076654454,0.000008181213,0.0000020327154,0.0000125249235,0.0018197484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970906,0.00034113182,0.0019004403,0.00012281857,0.000402703,0.00014230261],"domain_scores_gemma":[0.9957205,0.0011829488,0.0019039069,0.00019777197,0.00052780344,0.00046706886],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006516083,0.000079986436,0.00093623204,0.00008905354,0.000009000574,0.000004568718,0.00017328218,0.0002502248,0.00023079576],"category_scores_gemma":[0.020849263,0.000052885083,0.00014618214,0.00013650976,0.00012610438,0.00017920096,0.000021316891,0.000796503,0.00015266017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005011826,0.004100031,0.4405164,0.000019871559,0.0002762451,0.00029031935,0.0002886604,0.0000020572916,0.00024994093,0.0005076746,0.03621197,0.51252496],"study_design_scores_gemma":[0.014236684,0.005513672,0.40978354,0.0000620362,0.00009692865,0.00022376025,0.00033591434,0.00031298285,0.00003970949,0.0012045326,0.56812465,0.00006557705],"about_ca_topic_score_codex":0.000014720128,"about_ca_topic_score_gemma":0.00000640591,"teacher_disagreement_score":0.5319127,"about_ca_system_score_codex":0.00012860115,"about_ca_system_score_gemma":0.0023338527,"threshold_uncertainty_score":0.98739856},"labels":[],"label_agreement":null},{"id":"W2529603678","doi":"10.1200/jco.2012.30.15_suppl.8013","title":"Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Dosing; Urology; Multiple myeloma; Internal medicine; Clinical endpoint; Gastroenterology; Pharmacology; Clinical trial","score_opus":0.20799719870669567,"score_gpt":0.5220809802286622,"score_spread":0.3140837815219666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529603678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658144,0.000270848,0.0002073761,0.0007723327,0.0004109421,0.0013676872,0.000015744647,0.0000031197735,0.00037051184],"genre_scores_gemma":[0.9930047,0.00035118574,0.006064111,0.000034519268,0.00035387534,0.00003889576,0.00001682691,0.000014627851,0.00012129274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967116,0.00034953735,0.0021675548,0.000119947195,0.00036752815,0.0002838096],"domain_scores_gemma":[0.993814,0.003419986,0.0017547916,0.00017446741,0.00046910057,0.00036767047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002134543,0.00013026554,0.0017318715,0.00022434842,0.000017687344,0.0000018339931,0.00007626452,0.00024440652,0.00003248371],"category_scores_gemma":[0.0033145784,0.00007784494,0.00042421807,0.00014333779,0.00016575068,0.0001207804,0.000012001782,0.00018731502,0.000002108553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5311758,0.05290615,0.19433105,0.000049742623,0.00084639154,0.00012306678,0.0002015578,0.0000036992262,0.00064515765,0.000086644235,0.00012539931,0.21950535],"study_design_scores_gemma":[0.6449415,0.22162667,0.12393166,0.00008348483,0.00040319952,0.000060688042,0.00008021334,0.00039209682,0.0028602341,0.00008261617,0.0054802443,0.00005735985],"about_ca_topic_score_codex":0.000045450925,"about_ca_topic_score_gemma":0.00005774695,"teacher_disagreement_score":0.219448,"about_ca_system_score_codex":0.0002714948,"about_ca_system_score_gemma":0.0011211938,"threshold_uncertainty_score":0.39680994},"labels":[],"label_agreement":null},{"id":"W2529673068","doi":"10.1200/jco.2015.33.7_suppl.6","title":"PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Randomized controlled trial; Prostate; Urology; Radiation therapy; Quality of life (healthcare); Surgery; Internal medicine; Cancer","score_opus":0.2773814154203507,"score_gpt":0.5392107581566548,"score_spread":0.26182934273630404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529673068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99086714,0.0015043479,0.000009616023,0.0017891137,0.0017947416,0.0029663462,0.0000044500953,0.000013857234,0.0010503832],"genre_scores_gemma":[0.9949184,0.0019039911,0.0003795168,0.000097899225,0.0011292371,0.0000431902,0.000008769183,0.000028983653,0.0014900237],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936581,0.0019127926,0.0031223719,0.00025885773,0.0007112046,0.00033662346],"domain_scores_gemma":[0.9923177,0.003792959,0.002278608,0.00031238704,0.0006245044,0.00067387806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061510545,0.0002443367,0.004263572,0.00022732015,0.00006157836,0.000015839569,0.00017419142,0.00021072834,0.00011983399],"category_scores_gemma":[0.002294142,0.00013888051,0.00077022874,0.00014988633,0.0002617417,0.00014069726,0.00005759574,0.00057412154,0.000007834994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9278935,0.038326837,0.006338325,0.00001523031,0.004232876,0.0009916465,0.0017541699,0.00001723985,0.00008151882,0.000006756764,0.001447936,0.018893952],"study_design_scores_gemma":[0.70281947,0.2852665,0.0004837592,0.000042280317,0.0014265624,0.000043770546,0.0002776084,0.00044676106,0.000062016574,0.00003202207,0.009019431,0.0000798008],"about_ca_topic_score_codex":0.00014379183,"about_ca_topic_score_gemma":0.000032272237,"teacher_disagreement_score":0.24693966,"about_ca_system_score_codex":0.0007624319,"about_ca_system_score_gemma":0.0028264192,"threshold_uncertainty_score":0.5663383},"labels":[],"label_agreement":null},{"id":"W2529691076","doi":"10.1200/jco.2013.31.6_suppl.412","title":"Relative quantification of protein expression in metastatic renal cell carcinoma using iTRAQ LC-MS/MS analysis reveals galectin-1 as a potential prognostic marker and therapeutic target.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; York University; St. Michael's Hospital","funders":"","keywords":"Vimentin; Renal cell carcinoma; Western blot; Immunohistochemistry; Cancer research; Cell culture; Metastasis; Cancer; Blot; Transfection; Cell; Medicine; Pathology; Biology; Internal medicine; Gene","score_opus":0.06658882137109284,"score_gpt":0.37733052737027745,"score_spread":0.3107417059991846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529691076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915246,0.0043489896,0.002526937,0.00040064863,0.00038125736,0.0005320562,0.0000052445675,0.0000045124048,0.00027577058],"genre_scores_gemma":[0.99560696,0.00010338937,0.0037579846,0.00011159061,0.00006538945,0.000021966389,0.000007960873,0.000013178954,0.00031160223],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9939143,0.0029532702,0.0023898664,0.000332008,0.0000886667,0.00032188103],"domain_scores_gemma":[0.9951698,0.0013538889,0.0027700965,0.00019029414,0.00044141768,0.000074456286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002776306,0.0001930269,0.001467303,0.0004041721,0.00007775488,0.00001000267,0.00020330152,0.0005435182,0.00081174826],"category_scores_gemma":[0.0011002998,0.00013900182,0.00039891608,0.00041384363,0.00041299066,0.0001437592,0.00006258719,0.0009965219,0.000015026562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020181364,0.0012119368,0.19640979,0.000040453822,0.0009449127,0.0000379816,0.00026498307,0.00012774458,0.7918224,0.000053660628,0.00008742658,0.0069805705],"study_design_scores_gemma":[0.004669108,0.0073814876,0.9502879,0.000093560666,0.001496357,0.00024457488,0.00034328183,0.00032023003,0.03108302,0.0032581443,0.0006020633,0.00022030876],"about_ca_topic_score_codex":0.0003250018,"about_ca_topic_score_gemma":0.00005709883,"teacher_disagreement_score":0.7607394,"about_ca_system_score_codex":0.000073197574,"about_ca_system_score_gemma":0.00056076783,"threshold_uncertainty_score":0.8888074},"labels":[],"label_agreement":null},{"id":"W2529971012","doi":"10.1200/jco.2012.30.15_suppl.8517","title":"An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Vemurafenib; Medicine; Internal medicine; Clinical endpoint; Rash; Ipilimumab; Adverse effect; Melanoma; Oncology; Metastatic melanoma; Gastroenterology; Dermatology; Surgery; Cancer; Clinical trial; Cancer research; Immunotherapy","score_opus":0.09662255233445871,"score_gpt":0.43254964147480046,"score_spread":0.33592708914034175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529971012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800956,0.00011723728,0.00014370026,0.000059408612,0.0006198646,0.0004674045,0.000010636321,0.0000014410145,0.00057075266],"genre_scores_gemma":[0.9952546,0.00003528187,0.0040583424,0.00028575165,0.0002852418,0.000006275287,0.000017836346,0.000019614063,0.00003706475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963114,0.0010334299,0.0018925478,0.00021365561,0.00026007555,0.0002888748],"domain_scores_gemma":[0.9973038,0.00022684633,0.0014960384,0.00034127402,0.0003225707,0.00030950856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002838675,0.00016116395,0.0009902153,0.00007765586,0.000029956196,0.00000985274,0.0005443974,0.00019809717,0.000037428363],"category_scores_gemma":[0.0006274854,0.00010934517,0.00007219243,0.00009065487,0.000092662674,0.000041129628,0.00017469151,0.00036210605,0.000004109299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01146754,0.03257665,0.9363882,0.000012451722,0.00036352093,0.00003181745,0.00025078622,0.000020466205,0.0022353437,0.000024483024,0.00022858562,0.016400171],"study_design_scores_gemma":[0.03512168,0.075841345,0.87876713,0.000023935403,0.00018852517,0.000012703389,0.00042187967,0.000013968735,0.0005565075,0.000010799542,0.008881923,0.00015962093],"about_ca_topic_score_codex":0.00003322653,"about_ca_topic_score_gemma":0.0002318181,"teacher_disagreement_score":0.057621066,"about_ca_system_score_codex":0.000030500769,"about_ca_system_score_gemma":0.00033370566,"threshold_uncertainty_score":0.44589666},"labels":[],"label_agreement":null},{"id":"W2530057534","doi":"10.1200/jco.2007.25.18_suppl.9108","title":"Do most newly diagnosed advanced NSCLC patients need nutritional intervention?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Weight loss; Internal medicine; Malnutrition; Cancer; Lung cancer; Constipation; Physical therapy; Obesity","score_opus":0.11560267763897868,"score_gpt":0.5212399286198116,"score_spread":0.4056372509808329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530057534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761192,0.00052881584,0.0017995049,0.013014701,0.003339427,0.00029819048,0.0000059831405,0.00001703786,0.0048771054],"genre_scores_gemma":[0.97230035,0.0004397531,0.014634061,0.010764206,0.0016478592,0.0000032372702,0.000015912523,0.00001525915,0.00017936574],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957067,0.00022319781,0.0031736356,0.00015592137,0.00045811967,0.0002824348],"domain_scores_gemma":[0.99352396,0.003005454,0.0016157603,0.00012400046,0.0010818619,0.0006489909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004143928,0.00011066994,0.00096288754,0.00024333892,0.00006229009,0.000008463891,0.00012063241,0.00031304127,0.00060150475],"category_scores_gemma":[0.0056721754,0.00008993879,0.0004957929,0.00020944561,0.00012838509,0.0001388906,0.000032309494,0.001089631,0.000042339885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013106474,0.01146429,0.4454974,0.00013148517,0.00015219014,0.0008107283,0.00005236674,0.0000022240229,0.000049824892,0.0016132742,0.033742405,0.49337736],"study_design_scores_gemma":[0.053453334,0.010863135,0.7490194,0.0006489203,0.00010838252,0.00015647644,0.00019467526,0.000013654203,0.000029737905,0.0036626277,0.18175349,0.00009619392],"about_ca_topic_score_codex":0.000004067666,"about_ca_topic_score_gemma":0.000015867165,"teacher_disagreement_score":0.49328116,"about_ca_system_score_codex":0.0002134093,"about_ca_system_score_gemma":0.0005107495,"threshold_uncertainty_score":0.67905337},"labels":[],"label_agreement":null},{"id":"W2530236800","doi":"10.1200/jco.2013.31.15_suppl.4568","title":"<i>VHL</i>-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Stromal cell; Cancer research; Biology; Mesenchymal stem cell; Cancer stem cell; Cancer; Cancer cell; Pathology; Medicine; Cell biology; Genetics","score_opus":0.07281746736423177,"score_gpt":0.38389914641678535,"score_spread":0.3110816790525536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530236800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761044,0.001591025,0.00011323865,0.006195524,0.00094571785,0.0005557044,0.000005026822,0.000015094904,0.014474318],"genre_scores_gemma":[0.9884471,0.0005129201,0.004660756,0.0028076181,0.0017321132,0.00002374371,0.0000026434182,0.00004247554,0.001770608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956296,0.00044246227,0.00237336,0.00034448394,0.0007132124,0.0004968531],"domain_scores_gemma":[0.9944192,0.0012984214,0.0019523107,0.00034986497,0.0010216993,0.0009585025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014320742,0.00030242678,0.002062683,0.00014032907,0.000054884014,0.000021494698,0.00023992373,0.00042170737,0.001458985],"category_scores_gemma":[0.00026295718,0.00017452087,0.00057816226,0.00018072911,0.00032550155,0.00017325359,0.00006342219,0.0013360651,0.00017019626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027428849,0.011117404,0.4531108,0.0003392363,0.0035342965,0.02364078,0.0009606825,0.0005580288,0.224839,0.00019312497,0.06998391,0.18429388],"study_design_scores_gemma":[0.04451539,0.09001553,0.64247143,0.00045154674,0.003839697,0.0031178792,0.0006664861,0.00035867046,0.10849502,0.00047498537,0.104838826,0.0007545661],"about_ca_topic_score_codex":0.0005580936,"about_ca_topic_score_gemma":0.00012759247,"teacher_disagreement_score":0.18936059,"about_ca_system_score_codex":0.0004854581,"about_ca_system_score_gemma":0.0033239094,"threshold_uncertainty_score":0.99945384},"labels":[],"label_agreement":null},{"id":"W2530658621","doi":"10.1200/jco.2015.33.29_suppl.210","title":"Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Élisabeth Bruyère Hospital","funders":"","keywords":"Chemotherapy-induced nausea and vomiting; Medicine; Nausea; Vomiting; NK1 receptor antagonist; Anesthesia; Chemotherapy; Aprepitant; Internal medicine; Placebo; Antiemetic; Receptor","score_opus":0.21378210597080166,"score_gpt":0.474252360631228,"score_spread":0.26047025466042634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530658621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957463,0.00042727691,0.0010904735,0.0017589342,0.00018605201,0.0006492247,0.0000056848635,0.0000061101287,0.00012991556],"genre_scores_gemma":[0.9868188,0.0010055207,0.011390942,0.00034730884,0.00031409407,0.0000033337712,0.0000019287174,0.000025115662,0.00009298707],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99650407,0.00024094667,0.0025521333,0.00020021253,0.00031726767,0.0001853764],"domain_scores_gemma":[0.9939374,0.002383358,0.0027169948,0.00017017318,0.00056337,0.00022871699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039505567,0.00015487085,0.0016771713,0.00014961773,0.000025797006,0.000005202434,0.0001081386,0.000271332,0.000019455752],"category_scores_gemma":[0.0032405364,0.00010762671,0.00029786178,0.00010556422,0.00015182834,0.0000985804,0.000046465528,0.00027876676,1.819921e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25638297,0.0076494305,0.11629181,0.0011363201,0.0045623034,0.0000539109,0.0015212032,0.00008969091,0.10906207,0.0005989355,0.0017198367,0.5009315],"study_design_scores_gemma":[0.16784891,0.053294137,0.69669455,0.0009956338,0.001487039,0.00011405798,0.000636643,0.0042656106,0.06767618,0.0020717492,0.004617081,0.00029840367],"about_ca_topic_score_codex":0.000017880984,"about_ca_topic_score_gemma":0.000024137162,"teacher_disagreement_score":0.58040273,"about_ca_system_score_codex":0.000055670716,"about_ca_system_score_gemma":0.00047293896,"threshold_uncertainty_score":0.43888897},"labels":[],"label_agreement":null},{"id":"W2530836433","doi":"10.1200/jco.2006.24.18_suppl.8562","title":"A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto East General Hospital","funders":"","keywords":"Medicine; Denosumab; Bone resorption; Zoledronic acid; Internal medicine; Urology; Clinical endpoint; Creatinine; Gastroenterology; Randomized controlled trial; Osteoporosis","score_opus":0.09097436862594893,"score_gpt":0.4343519451164578,"score_spread":0.3433775764905089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530836433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993439,0.0032528336,0.00001122283,0.001290451,0.0007160044,0.0011896304,0.000013804226,0.0000055932055,0.0000814605],"genre_scores_gemma":[0.9948268,0.003630804,0.0010331869,0.0002576351,0.00013793605,0.00003193573,0.000010920857,0.000018308663,0.00005247454],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941021,0.0010611943,0.0036611997,0.00026012037,0.00061731145,0.00029804584],"domain_scores_gemma":[0.9875293,0.0076109776,0.0037049558,0.0001818609,0.0007119108,0.0002610192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00386758,0.00020997108,0.0032585154,0.00032219454,0.000029507342,0.000006395069,0.000079485195,0.0003241509,0.000052272862],"category_scores_gemma":[0.0063850884,0.0001322561,0.0002869096,0.0003467196,0.00039540068,0.00015651746,0.00002587018,0.00064701843,0.0000013908189],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94016814,0.007681207,0.021915194,0.00013144611,0.00040066373,0.00025962372,0.000062175226,0.000019489125,0.000120629535,0.0000246791,0.00025843506,0.028958313],"study_design_scores_gemma":[0.8729315,0.058170356,0.065318756,0.0010494494,0.0012141131,0.000033760494,0.000027631022,0.000057408102,0.00068921404,0.00014276695,0.00027041452,0.00009465991],"about_ca_topic_score_codex":0.0046575135,"about_ca_topic_score_gemma":0.0023267302,"teacher_disagreement_score":0.06723668,"about_ca_system_score_codex":0.0002710609,"about_ca_system_score_gemma":0.0016437903,"threshold_uncertainty_score":0.76440084},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2530931341","doi":"10.1200/jco.2014.32.4_suppl.470","title":"Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; BC Cancer Agency; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Proportional hazards model; Internal medicine; Cutoff; Gastroenterology; Neutrophil to lymphocyte ratio; Oncology; Lymphocyte; Urology","score_opus":0.05469654701879103,"score_gpt":0.3581217114640204,"score_spread":0.3034251644452294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530931341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456745,0.000092677314,0.00033799539,0.0029443565,0.00033485822,0.0015141359,0.000052921227,0.000005570337,0.00015002256],"genre_scores_gemma":[0.99564564,0.00002491556,0.001355152,0.002639197,0.00018895548,0.00007092449,0.000012516821,0.000024106848,0.000038565515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684566,0.00092498783,0.0013037707,0.0002283385,0.00050295517,0.00019426133],"domain_scores_gemma":[0.99240535,0.0049542473,0.0013502814,0.000262951,0.00078223017,0.00024495219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025941762,0.00019159875,0.00079085503,0.000100516474,0.00008203613,0.000012491301,0.00031045586,0.00010592499,0.000016890886],"category_scores_gemma":[0.0052254405,0.00008696775,0.0002820561,0.00011403243,0.0002008886,0.0000702782,0.000068990106,0.00030662134,0.0000019256354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10432616,0.0042042504,0.8654964,0.00023497443,0.0013147178,0.00007803539,0.00022634605,0.0010856136,0.00796715,0.00062976044,0.0036792336,0.010757369],"study_design_scores_gemma":[0.04291607,0.047673658,0.7658221,0.00028315236,0.0018592995,0.00005805168,0.000028843388,0.11552178,0.024074456,0.00012716395,0.0014076537,0.00022775165],"about_ca_topic_score_codex":0.0000029309504,"about_ca_topic_score_gemma":0.0000025358254,"teacher_disagreement_score":0.11443617,"about_ca_system_score_codex":0.000103437786,"about_ca_system_score_gemma":0.00084929675,"threshold_uncertainty_score":0.6255717},"labels":[],"label_agreement":null},{"id":"W2531276114","doi":"10.1200/jco.2013.31.15_suppl.2538","title":"A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Neutropenia; Sarcoma; Pharmacokinetics; Internal medicine; Rhabdomyosarcoma; Pazopanib; Toxicity; Gastroenterology; Oncology; Surgery; Urology; Sunitinib; Cancer; Pathology","score_opus":0.07080242788697226,"score_gpt":0.44727720956045525,"score_spread":0.37647478167348297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531276114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651897,0.0005724096,0.00004625361,0.00026428254,0.00044595863,0.0019072724,0.000019481682,0.000005747079,0.00021963792],"genre_scores_gemma":[0.9969628,0.00070053857,0.0005795267,0.00031521425,0.0012383551,0.000093116156,0.000030825675,0.000030144924,0.00004949939],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9938279,0.0013899053,0.0035826813,0.00051250757,0.0003124844,0.0003745354],"domain_scores_gemma":[0.99476755,0.000443562,0.0036897382,0.00034596788,0.00033834475,0.00041483808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029359974,0.0002964791,0.0017606817,0.00018752528,0.000045683984,0.000016212927,0.00033324736,0.00045152387,0.0001885214],"category_scores_gemma":[0.0020020078,0.00019959865,0.0002382178,0.00015609579,0.00037956244,0.000027376784,0.00014257924,0.0009433796,0.000002553325],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28610232,0.10593471,0.057741318,0.000033323402,0.001916523,0.0014185078,0.0004484122,0.0000091195325,0.033665523,0.0000069511693,0.0029300046,0.5097933],"study_design_scores_gemma":[0.42188653,0.50301236,0.06095645,0.00008811516,0.0005312701,0.004046611,0.00045347164,0.00003448321,0.003021867,0.000037214635,0.0055353325,0.0003962826],"about_ca_topic_score_codex":0.000106582396,"about_ca_topic_score_gemma":0.00019231498,"teacher_disagreement_score":0.509397,"about_ca_system_score_codex":0.0000575739,"about_ca_system_score_gemma":0.0013284922,"threshold_uncertainty_score":0.8139397},"labels":[],"label_agreement":null},{"id":"W2531329502","doi":"10.1200/jco.2013.31.15_suppl.3575","title":"Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Internal medicine; Neutropenia; Bevacizumab; Placebo; Clinical endpoint; Colorectal cancer; Gastroenterology; Febrile neutropenia; Regimen; Surgery; Randomized controlled trial; Oncology; Chemotherapy; Irinotecan; Oxaliplatin; Cancer; Pathology","score_opus":0.10364740438154886,"score_gpt":0.4599664402436699,"score_spread":0.35631903586212105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531329502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623854,0.00015794412,0.00014405481,0.002979047,0.0019123391,0.007929326,0.000031512056,0.000006212527,0.00060101564],"genre_scores_gemma":[0.9959194,0.0011406387,0.00070747454,0.00018535121,0.0009814843,0.00074457907,0.000007960385,0.000023738081,0.000289386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925312,0.0005174109,0.005960058,0.00028745816,0.00039823542,0.0003056525],"domain_scores_gemma":[0.98249453,0.010956006,0.004716789,0.00017514524,0.0013390172,0.00031851744],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004478093,0.00023133855,0.004969615,0.00033236897,0.000055809924,0.0000109380035,0.00015715207,0.000451725,0.000237917],"category_scores_gemma":[0.010733607,0.00014351103,0.00095231103,0.00024538764,0.0003535192,0.00018237183,0.00005462888,0.0007124313,0.0000013730645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9531503,0.0064698053,0.0017934307,0.00007621145,0.0010541913,0.00001652386,0.00018655331,0.000075100914,0.00008302433,0.000011572895,0.0017948586,0.035288434],"study_design_scores_gemma":[0.9394221,0.054904375,0.0012362893,0.00031304208,0.0015836037,0.000028214192,0.000048102473,0.0005805691,0.00018813896,0.00013310193,0.001441321,0.00012117453],"about_ca_topic_score_codex":0.0004745934,"about_ca_topic_score_gemma":0.0015061025,"teacher_disagreement_score":0.04843457,"about_ca_system_score_codex":0.00019250145,"about_ca_system_score_gemma":0.0017915561,"threshold_uncertainty_score":0.9975994},"labels":[],"label_agreement":null},{"id":"W2532062994","doi":"10.1200/jco.2006.24.18_suppl.20106","title":"Discordence of HER-2/neu overexpression and estrogen receptor between the primary breast cancer and axillary lymph node with metastasis","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatoon City Hospital","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Immunohistochemistry; Metastasis; Lymph node; Pathology; Primary tumor; Axillary lymph nodes; Fluorescence in situ hybridization; Cancer; Progesterone receptor; Lymph; Oncology; Internal medicine; Biology","score_opus":0.028782666383409865,"score_gpt":0.3604529537923015,"score_spread":0.33167028740889165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532062994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990025,0.0051603094,0.00005907636,0.004346719,0.00009133491,0.00007263238,0.00008821456,0.0000014779836,0.00015527576],"genre_scores_gemma":[0.9935118,0.003636816,0.0017910205,0.00031212237,0.000696222,0.0000055644527,0.0000074550626,0.000011842969,0.000027142356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986535,0.00016340696,0.000692233,0.00018826316,0.00016438139,0.00013823586],"domain_scores_gemma":[0.998414,0.0003251349,0.00087952317,0.00014027211,0.00015753158,0.00008358648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005008473,0.00013089592,0.0006080683,0.000020210367,0.000059298545,0.0000070841397,0.00012732827,0.0001449961,0.000007589266],"category_scores_gemma":[0.00007574259,0.000068938585,0.00011089832,0.00004730172,0.00048368008,0.000010811688,0.00014249692,0.0001532391,1.9444373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016523136,0.00019934672,0.92558014,0.000023000759,0.0005073311,0.000008299448,0.00001529425,0.00001621871,0.005712833,0.000012929822,0.00069458224,0.06557773],"study_design_scores_gemma":[0.0024760219,0.0009122918,0.98756176,0.00009664315,0.00033424082,0.00019543967,0.000060390645,9.094016e-7,0.0023923784,0.00006033766,0.0058203605,0.00008920745],"about_ca_topic_score_codex":0.0001398251,"about_ca_topic_score_gemma":0.000021293075,"teacher_disagreement_score":0.065488525,"about_ca_system_score_codex":0.000029245839,"about_ca_system_score_gemma":0.00035538117,"threshold_uncertainty_score":0.2811234},"labels":[],"label_agreement":null},{"id":"W2532256240","doi":"10.1200/jco.2009.27.15_suppl.6528","title":"Clinical-pathologic characteristics and outcomes of true interval compared to screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Cohort; Population; Gynecology; Family history; Confidence interval; Oncology; Breast cancer screening; Cancer registry; Cancer; Mammography","score_opus":0.08963097233985666,"score_gpt":0.4534730131008302,"score_spread":0.36384204076097354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532256240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961354,0.000129222,0.000044835593,0.0023374157,0.00031822178,0.0007217291,0.00028822426,0.000007788986,0.000017139153],"genre_scores_gemma":[0.99763423,0.000065720626,0.0009448698,0.0009263081,0.00036491573,0.00003496014,0.0000049969026,0.000017272125,0.000006719794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950105,0.0010359192,0.0028017717,0.00041095327,0.00018350338,0.0005573614],"domain_scores_gemma":[0.9965736,0.0004705318,0.0014217364,0.0002695302,0.0005044158,0.00076016557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026819818,0.0002756336,0.0020172172,0.00018449975,0.00006518041,0.000019030105,0.00025213824,0.00036868604,0.0000137318575],"category_scores_gemma":[0.0015720765,0.00020937576,0.00030525186,0.0002013528,0.00028466003,0.00001587935,0.00009052252,0.0005190058,6.780668e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024728607,0.001780178,0.7620914,0.000004147104,0.0005624475,0.0017504522,0.0001449645,0.000015848687,0.000040524108,4.6160787e-7,0.000032964716,0.23110375],"study_design_scores_gemma":[0.009185633,0.007456518,0.9808738,0.00007851993,0.0004518322,0.0011576521,0.00037258075,0.00014358976,0.0000037569614,0.0000041122375,0.00008773419,0.0001842671],"about_ca_topic_score_codex":0.022825282,"about_ca_topic_score_gemma":0.30006135,"teacher_disagreement_score":0.27723607,"about_ca_system_score_codex":0.00009270026,"about_ca_system_score_gemma":0.00073622394,"threshold_uncertainty_score":0.9836818},"labels":[],"label_agreement":null},{"id":"W2532258671","doi":"10.1200/jco.2016.34.15_suppl.e20527","title":"Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre Integre de Sante et de Services Sociaux de Laval; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Brain metastasis; Oncology; Neurocognitive; Lung cancer; Stage (stratigraphy); Systemic therapy; Performance status; Cancer; Breast cancer; Metastasis; Cognition","score_opus":0.0489489259364999,"score_gpt":0.47480463435842896,"score_spread":0.42585570842192905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532258671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239,0.002282757,0.00012729804,0.0024653361,0.00077319756,0.0004538715,0.000051776864,0.0000034812085,0.0014523168],"genre_scores_gemma":[0.9962136,0.0023820528,0.00034016278,0.00011186764,0.00038340414,0.000016130984,0.000001870574,0.000014623625,0.0005362808],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975646,0.00055809814,0.0013593908,0.00016064172,0.00020597351,0.00015125729],"domain_scores_gemma":[0.9920847,0.0058816816,0.0014328127,0.00015882084,0.00022061913,0.00022135413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010751596,0.00015106314,0.0016960265,0.00010981152,0.000023339393,0.0000026721318,0.00006589395,0.00016099717,0.000060054233],"category_scores_gemma":[0.0004957638,0.000070698035,0.00040517873,0.000063393534,0.00016517614,0.00003988105,0.000015696496,0.000120090466,0.0000021898882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011802705,0.0037224484,0.5065621,0.00066264725,0.00401971,0.00044704156,0.00046059338,0.00004975955,0.012797416,0.00008193067,0.0017837875,0.4576099],"study_design_scores_gemma":[0.17762476,0.3986034,0.32407224,0.0057017,0.021194443,0.0005049675,0.00038530145,0.0001481626,0.04478097,0.000045382407,0.026528342,0.00041032402],"about_ca_topic_score_codex":0.00013045885,"about_ca_topic_score_gemma":0.000055788965,"teacher_disagreement_score":0.45719954,"about_ca_system_score_codex":0.00031724284,"about_ca_system_score_gemma":0.0013105273,"threshold_uncertainty_score":0.28829822},"labels":[],"label_agreement":null},{"id":"W2532290530","doi":"10.1200/jco.2006.24.18_suppl.10627","title":"Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as 1<sup>st</sup>-line chemotherapy for metastatic breast cancer (MBC) patients previously treated with adjuvant anthracyclines","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Cardiotoxicity; Metastatic breast cancer; Anthracycline; Internal medicine; Doxorubicin; Cyclophosphamide; Epirubicin; Mucositis; Gastroenterology; Oncology; Chemotherapy; Neutropenia; Adjuvant; Regimen; Breast cancer; Febrile neutropenia; Discontinuation; Cancer","score_opus":0.042250708226388774,"score_gpt":0.4239758659361589,"score_spread":0.3817251577097701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532290530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875559,0.001102417,0.00010168562,0.0089020105,0.00036328752,0.0014203893,0.00012744084,0.000040808867,0.00038604246],"genre_scores_gemma":[0.98862684,0.0014993439,0.002978833,0.0035003882,0.001777482,0.00009609719,0.00011547202,0.000093705676,0.0013118603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955199,0.00040630793,0.0025688035,0.00042446406,0.00048053227,0.00060000265],"domain_scores_gemma":[0.993861,0.0016373348,0.0024027498,0.00023955297,0.0013690195,0.0004903496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009774539,0.00046775324,0.002737333,0.00019177527,0.00012630994,0.000017613935,0.00019906458,0.0003285078,0.0005106163],"category_scores_gemma":[0.00021072141,0.00026784322,0.0005103265,0.00036232616,0.00039926372,0.00019457415,0.000021781325,0.00092041964,0.000008555785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1635033,0.024364347,0.6822195,0.00021265693,0.004543437,0.001311864,0.00023680952,0.0017033934,0.00048012123,0.000019911055,0.010686524,0.11071812],"study_design_scores_gemma":[0.15905122,0.14909202,0.64141494,0.00073545607,0.008326995,0.0024634444,0.00015103864,0.0010521231,0.0018453193,0.00022224376,0.035058085,0.00058709196],"about_ca_topic_score_codex":0.0012953484,"about_ca_topic_score_gemma":0.0009465645,"teacher_disagreement_score":0.124727674,"about_ca_system_score_codex":0.00038314087,"about_ca_system_score_gemma":0.002068254,"threshold_uncertainty_score":0.99997735},"labels":[],"label_agreement":null},{"id":"W2532466048","doi":"10.1200/jco.2012.30.15_suppl.4006","title":"Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Sorafenib; Clinical endpoint; Population; Neutropenia; Placebo; Hepatocellular carcinoma; Progression-free survival; Oncology; Randomized controlled trial; Surgery; Chemotherapy; Pathology","score_opus":0.1568732221201914,"score_gpt":0.38788140448887265,"score_spread":0.23100818236868126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532466048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699063,0.002325503,0.000033334592,0.0010021903,0.0016262435,0.0065453434,0.0000149867155,0.000013391306,0.0014483554],"genre_scores_gemma":[0.9968012,0.00066618423,0.0006247248,0.0001639227,0.0013021493,0.00014751304,0.00003055187,0.000043348566,0.00022041216],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98723817,0.0040906435,0.0068326723,0.0003300972,0.0009429123,0.00056551886],"domain_scores_gemma":[0.9820976,0.010176165,0.0058307014,0.00039804095,0.00087323034,0.0006242081],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015460755,0.0004052084,0.009578159,0.00043421288,0.00006357278,0.000009798067,0.00021662224,0.0006717515,0.000110151086],"category_scores_gemma":[0.0094457725,0.00023738136,0.0018693056,0.0003002075,0.00034379208,0.00020254389,0.00005588554,0.0010139149,0.000011173839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6872504,0.015196091,0.2881499,0.000038039503,0.0023700674,0.00022901426,0.0005054341,4.886072e-7,0.00006604397,0.000018981525,0.00021820162,0.005957335],"study_design_scores_gemma":[0.8936853,0.094291076,0.006204859,0.00041738167,0.002745848,0.000027747437,0.000109859,0.00045330895,0.0003413392,0.000005295047,0.0015265746,0.00019146278],"about_ca_topic_score_codex":0.00006165222,"about_ca_topic_score_gemma":0.000008443102,"teacher_disagreement_score":0.28194505,"about_ca_system_score_codex":0.00022497342,"about_ca_system_score_gemma":0.00143111,"threshold_uncertainty_score":0.9988981},"labels":[],"label_agreement":null},{"id":"W2532810318","doi":"10.1200/jco.2016.34.7_suppl.65","title":"Bringing person-centered care to practice with CCO’s guideline for person-centred care in adult oncology services.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ottawa Hospital; Royal Victoria Regional Health Centre; McMaster University; London Health Sciences Centre; Cancer Care Ontario","funders":"","keywords":"Guideline; Medicine; Knowledge translation; Health care; Nursing; Family medicine; Relevance (law); Set (abstract data type); Medical education; Knowledge management","score_opus":0.2968682293021726,"score_gpt":0.5475325313628513,"score_spread":0.2506643020606787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532810318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5123477,0.0015004216,0.0051984624,0.46935654,0.0043121343,0.0027585088,0.000085281325,0.000054414406,0.0043865303],"genre_scores_gemma":[0.8027883,0.00038734247,0.15072875,0.042980213,0.0028272006,0.0000321764,0.000035760102,0.00006942551,0.00015084211],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921632,0.00083460665,0.005167356,0.0005587945,0.00066975283,0.0006063133],"domain_scores_gemma":[0.97474253,0.013259664,0.0042471685,0.000387361,0.0065673674,0.0007959071],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035709778,0.00030268898,0.001999437,0.00033110214,0.00007049599,0.000021486505,0.0003456356,0.00054245535,0.00016024425],"category_scores_gemma":[0.044426117,0.00019389798,0.0005248162,0.00028769934,0.00012423321,0.00056715636,0.000084762425,0.0009881889,0.000037453497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07111482,0.00211805,0.034676652,0.00030835677,0.0006415203,0.0014797725,0.012086389,0.000059795097,0.000523106,0.00004647298,0.019571284,0.8573738],"study_design_scores_gemma":[0.05573796,0.036487285,0.00872291,0.00093981624,0.0012757122,0.0009202812,0.19976097,0.00022148274,0.000069642265,0.000009401974,0.6955723,0.00028219895],"about_ca_topic_score_codex":0.0003681754,"about_ca_topic_score_gemma":0.0037939695,"teacher_disagreement_score":0.8570916,"about_ca_system_score_codex":0.0016762763,"about_ca_system_score_gemma":0.0042662383,"threshold_uncertainty_score":0.9636231},"labels":[],"label_agreement":null},{"id":"W2532831522","doi":"10.1200/jco.2009.27.15_suppl.4114","title":"Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oxaliplatin; Bevacizumab; Irinotecan; Internal medicine; Colorectal cancer; Clinical endpoint; Oncology; Cohort; Population; Cancer; Chemotherapy; Surgery; Clinical trial","score_opus":0.08256307246086182,"score_gpt":0.4775023724378114,"score_spread":0.3949392999769496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532831522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978357,0.00008807463,0.0000026406508,0.0006756395,0.00032114674,0.0006043788,0.00001624368,0.000004765415,0.00045139948],"genre_scores_gemma":[0.99929804,0.000036753903,0.00018672181,0.00029160036,0.00013868151,0.0000099891495,0.000005672242,0.000011901269,0.00002066559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685174,0.00041133366,0.0017222661,0.00020719005,0.00057824387,0.00022925343],"domain_scores_gemma":[0.9966624,0.0011656032,0.0013786977,0.00012429626,0.0004763751,0.00019266683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009175088,0.00020122225,0.001964778,0.00020614827,0.000032959982,0.0000051711163,0.00009194277,0.00010331773,0.00011606265],"category_scores_gemma":[0.00091386226,0.00011389102,0.00041153532,0.00022115716,0.000055089025,0.000069892005,0.000013563293,0.0005034064,0.0000012831409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057694033,0.0160446,0.8828375,0.000008509313,0.0009252932,0.0002118674,0.00017451322,0.00069802115,0.0000039181245,0.0000053841163,0.00009352111,0.041302864],"study_design_scores_gemma":[0.03506247,0.18030252,0.7838033,0.00009347552,0.00047155758,0.000004255934,0.000059427242,0.000053507447,0.0000033354333,0.00003793719,0.000030708372,0.000077531666],"about_ca_topic_score_codex":0.0008201482,"about_ca_topic_score_gemma":0.0026304417,"teacher_disagreement_score":0.16425791,"about_ca_system_score_codex":0.000947704,"about_ca_system_score_gemma":0.0014032825,"threshold_uncertainty_score":0.46443412},"labels":[],"label_agreement":null},{"id":"W2532989698","doi":"10.1200/jco.2009.27.15_suppl.8581","title":"Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; CHOP; International Prognostic Index; Oncology; Proportional hazards model; Vascular endothelial growth factor; Diffuse large B-cell lymphoma; Lymphoma; Kinase insert domain receptor; Pathology; Vascular endothelial growth factor A; VEGF receptors","score_opus":0.03100431380021391,"score_gpt":0.34267811404794263,"score_spread":0.3116738002477287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532989698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567217,0.0020921044,0.00004434579,0.0010514299,0.0001839238,0.00059017085,0.0000130535045,0.000013407976,0.00033942095],"genre_scores_gemma":[0.99101686,0.0062443367,0.0016884921,0.0007354426,0.00023071196,0.000012284791,0.0000051110233,0.000024967598,0.00004177042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630785,0.0005152923,0.001956365,0.0003499732,0.0004902474,0.00038026387],"domain_scores_gemma":[0.9959861,0.0016586429,0.0013246232,0.00028424617,0.00038039836,0.00036598174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012371622,0.0002992774,0.002117843,0.00019712241,0.00003992525,0.0000135251,0.00016646045,0.0004350624,0.000044710603],"category_scores_gemma":[0.0010877522,0.00019097397,0.0005549183,0.00025766392,0.00021914922,0.00012584514,0.000022943761,0.0004007764,0.0000038014014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060452875,0.051239822,0.86981696,0.0000718105,0.00078602234,0.0008912735,0.00030305528,7.7460174e-7,0.00161303,0.000049564995,0.00009372824,0.069088645],"study_design_scores_gemma":[0.10340776,0.020862253,0.86679965,0.00024720238,0.0005310751,0.00014643755,0.00007706714,0.000019060255,0.004477325,0.000103087674,0.003161076,0.0001679842],"about_ca_topic_score_codex":0.00010701903,"about_ca_topic_score_gemma":0.00003453554,"teacher_disagreement_score":0.09736247,"about_ca_system_score_codex":0.00029053472,"about_ca_system_score_gemma":0.00096428685,"threshold_uncertainty_score":0.7787692},"labels":[],"label_agreement":null},{"id":"W2533207351","doi":"10.1200/jco.2014.32.31_suppl.163","title":"Quality of life (QoL) in patients with malignant dysphagia: An international randomized trial comparing radiotherapy alone (RT) versus chemoradiotherapy (CRT)—TROG03.01 NCICCTG ES2.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Dysphagia; Quality of life (healthcare); Concomitant; Radiation therapy; Esophageal cancer; Chemoradiotherapy; Internal medicine; Randomized controlled trial; Surgery; Cancer","score_opus":0.11340345010849248,"score_gpt":0.4599696413790628,"score_spread":0.3465661912705703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533207351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916804,0.00024944855,0.0017998313,0.0020383925,0.0028444342,0.00065243983,0.000003555369,0.000011580445,0.0007199373],"genre_scores_gemma":[0.9875059,0.0003176708,0.008579818,0.0016165987,0.0018892082,0.000009548809,0.00001376785,0.00002748164,0.00003997391],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919009,0.0025676617,0.004289604,0.00031339983,0.0006319158,0.00029649178],"domain_scores_gemma":[0.990417,0.004616473,0.0036366044,0.00032052526,0.0005700894,0.0004393319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0110236155,0.0002330477,0.00495816,0.00022770737,0.000026817987,0.000009648008,0.0003553877,0.00046165666,0.00020783152],"category_scores_gemma":[0.006246188,0.00014992506,0.0005932628,0.00015276832,0.00053642615,0.00019315822,0.000032416458,0.0009901159,0.000003013586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7046345,0.0039941445,0.27452624,0.000017938575,0.0006919641,0.000053783413,0.00011735095,0.00004047768,0.00004472344,0.0002108815,0.00007032388,0.015597681],"study_design_scores_gemma":[0.68707013,0.02381932,0.28743312,0.000045267516,0.00013290452,0.000017307579,0.000015793403,0.0006213141,0.000023522214,0.000103505095,0.00061565253,0.00010216321],"about_ca_topic_score_codex":0.00006753057,"about_ca_topic_score_gemma":0.00006389172,"teacher_disagreement_score":0.019825175,"about_ca_system_score_codex":0.00018191776,"about_ca_system_score_gemma":0.0007541121,"threshold_uncertainty_score":0.7477722},"labels":[],"label_agreement":null},{"id":"W2533275266","doi":"10.1200/jco.2007.25.18_suppl.19553","title":"What can physicians do to promote patient involvement in decision making (DM) in the oncology consultation?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Coding (social sciences); Empathy; Focus group; Patient satisfaction; Family medicine; Qualitative research; Nursing; Psychiatry","score_opus":0.40091165517506766,"score_gpt":0.6007361091511069,"score_spread":0.1998244539760392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533275266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456394,0.00082759553,0.00029236678,0.044971563,0.0051189107,0.0018674973,0.000003935655,0.00000879365,0.0012699403],"genre_scores_gemma":[0.94631004,0.0005765423,0.010386984,0.042165235,0.00044020455,0.000087791996,0.0000029654348,0.000017635142,0.00001258264],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98615956,0.0057948935,0.006462472,0.00028392722,0.00065940496,0.000639768],"domain_scores_gemma":[0.9628382,0.03153423,0.0037779764,0.00055657356,0.0010498438,0.00024318017],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013042542,0.00016709672,0.0010917102,0.00044155278,0.000248279,0.00001561493,0.00080834795,0.00059440196,0.00005031192],"category_scores_gemma":[0.013449763,0.00011837104,0.00016707723,0.000725497,0.00013753472,0.00026592758,0.00028331642,0.0032847035,0.00004289238],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022753454,0.0016491164,0.11570473,0.000041971372,0.000025069183,0.00019100201,0.11421962,0.00021345115,0.000015608523,0.0004501815,0.0025035015,0.7627104],"study_design_scores_gemma":[0.0076216897,0.010311082,0.4557121,0.0029665534,0.000036767906,0.000021477916,0.27603906,0.00015980215,0.0000067259675,0.007131645,0.2397748,0.00021829775],"about_ca_topic_score_codex":0.00022062162,"about_ca_topic_score_gemma":0.025083318,"teacher_disagreement_score":0.7624921,"about_ca_system_score_codex":0.0018017391,"about_ca_system_score_gemma":0.0031838384,"threshold_uncertainty_score":0.99901474},"labels":[],"label_agreement":null},{"id":"W2534115301","doi":"10.1200/jco.2015.33.3_suppl.351","title":"Do recurrent and de novo metastatic biliary tract cancer patients have the same outcome on treatment?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Ampulla of Vater; Gallbladder cancer; Hazard ratio; Internal medicine; Gallbladder; Biliary tract; Biliary tract cancer; Gastroenterology; Chemotherapy; Cancer; Pancreatic cancer; Proportional hazards model; Oncology; Confidence interval; Surgery; Carcinoma","score_opus":0.33834714802369886,"score_gpt":0.5224813683388702,"score_spread":0.1841342203151713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534115301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97485626,0.0037833839,0.0000040508658,0.01870775,0.0012838531,0.00020191762,0.00001123964,0.0000038745275,0.0011476598],"genre_scores_gemma":[0.99278355,0.0018973069,0.00026009273,0.004021173,0.0007848582,0.000010376307,0.000001179724,0.000010590533,0.00023085227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794966,0.00031548602,0.0011257678,0.00014426246,0.00027810433,0.00018674375],"domain_scores_gemma":[0.996892,0.001659581,0.0006963352,0.00013303489,0.00026893633,0.00035015447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014323433,0.00013726759,0.0010352362,0.000060231927,0.00003873342,0.000009690822,0.000081172104,0.000095769814,0.00002763368],"category_scores_gemma":[0.0020666996,0.00006308696,0.00030625492,0.00005231929,0.00016671904,0.000048616646,0.000029317986,0.00050126994,0.000005630272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021579934,0.0017180329,0.80364656,0.0000094784755,0.0004233307,0.00021365896,0.0008633393,0.0000024826984,0.0000012152352,0.000008701274,0.0045748767,0.18638031],"study_design_scores_gemma":[0.011058006,0.024413336,0.9041256,0.00005522937,0.0009565463,0.00016707515,0.00051867083,0.000014067375,0.0000066339176,0.00020865235,0.05841217,0.00006403265],"about_ca_topic_score_codex":0.00007753615,"about_ca_topic_score_gemma":0.00018242355,"teacher_disagreement_score":0.18631628,"about_ca_system_score_codex":0.00042937804,"about_ca_system_score_gemma":0.00086348114,"threshold_uncertainty_score":0.25726116},"labels":[],"label_agreement":null},{"id":"W2534121364","doi":"10.1200/jco.2006.24.18_suppl.13015","title":"A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metal-Catalyzed Oxygenation Mechanisms","field":"Chemistry","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Neutropenia; Tolerability; Prostate cancer; Internal medicine; Chemotherapy; Oncology; Ribonucleotide reductase; Pharmacology; Cabazitaxel; Cancer; Gastroenterology; Adverse effect; Androgen deprivation therapy; Biology; Protein subunit","score_opus":0.0692760631176686,"score_gpt":0.4176388006762158,"score_spread":0.3483627375585472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534121364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543524,0.0015225037,0.000006309469,0.0014900255,0.00036817775,0.0003904304,0.000042731495,0.00000952121,0.000735086],"genre_scores_gemma":[0.99477947,0.0028228662,0.000310904,0.00011372678,0.00047307764,0.000025238394,0.0000041195603,0.000027032811,0.0014435491],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956815,0.0003153751,0.002970218,0.00030714806,0.00045651017,0.00026922737],"domain_scores_gemma":[0.9952215,0.00092047,0.0030315318,0.00036495872,0.0002749639,0.00018655366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015267052,0.00023731487,0.0014100267,0.0001163282,0.000105974694,0.000014271807,0.00027513952,0.00029284993,0.00015819751],"category_scores_gemma":[0.0010209878,0.00015248817,0.0002716856,0.00019537266,0.00018155485,0.00014246796,0.0001518085,0.0006627439,0.0000029965624],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043933343,0.24117315,0.037551817,0.00034163674,0.0033492506,0.004568811,0.010371138,0.004597808,0.25892308,0.00029563598,0.0035142894,0.39138004],"study_design_scores_gemma":[0.4646443,0.16732264,0.1346326,0.0007209769,0.0036653923,0.0011133885,0.004532195,0.003265525,0.07675192,0.003458715,0.1384464,0.0014459413],"about_ca_topic_score_codex":0.0010014112,"about_ca_topic_score_gemma":0.002825445,"teacher_disagreement_score":0.42071095,"about_ca_system_score_codex":0.00038994374,"about_ca_system_score_gemma":0.000986267,"threshold_uncertainty_score":0.6218287},"labels":[],"label_agreement":null},{"id":"W2534204981","doi":"10.1200/jco.2009.27.15_suppl.e15059","title":"Extent of resection for curable colorectal cancer in young patients: A 27-year experience at a tertiary care centre","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Colectomy; Rectum; Surgery; Cancer; Family history; Resection margin; Disease; Internal medicine; General surgery; Resection","score_opus":0.0481603184710013,"score_gpt":0.434797689499083,"score_spread":0.3866373710280817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534204981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416864,0.0007251307,0.000015319436,0.001185399,0.0026278407,0.0005221876,0.000013159299,0.0000044770713,0.0007378232],"genre_scores_gemma":[0.99731886,0.0004908494,0.001258653,0.00037429982,0.00041216647,0.000014551869,0.0000031297423,0.000011651173,0.00011581572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724346,0.00017931854,0.0017331255,0.00021310784,0.00036876835,0.00026222557],"domain_scores_gemma":[0.9971531,0.0005779059,0.0010796776,0.00012052321,0.00086786854,0.00020092937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006367022,0.00012326348,0.0009016768,0.00012415806,0.000028313996,0.0000033173753,0.00013513012,0.00031801529,0.00020192051],"category_scores_gemma":[0.0024506464,0.00009444521,0.00032957774,0.00015003851,0.00012896242,0.00007949863,0.000037466525,0.00045952352,0.0000016612581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015290273,0.001031557,0.9464255,0.000056153385,0.000053443047,0.00002893306,0.0019316439,0.000077604745,0.002923249,0.0000047272056,0.0021800688,0.02999685],"study_design_scores_gemma":[0.009348906,0.020911584,0.9586128,0.00027501205,0.0001030595,0.00003257475,0.0010215361,0.000082872495,0.006045887,0.000069193506,0.0034087931,0.000087798704],"about_ca_topic_score_codex":0.00006256069,"about_ca_topic_score_gemma":0.0013322681,"teacher_disagreement_score":0.029909052,"about_ca_system_score_codex":0.0009835829,"about_ca_system_score_gemma":0.000876811,"threshold_uncertainty_score":0.3851364},"labels":[],"label_agreement":null},{"id":"W2534225621","doi":"10.1200/jco.2007.25.18_suppl.547","title":"Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Queen's University","funders":"","keywords":"Medicine; Hazard ratio; Breast cancer; Internal medicine; Interim analysis; Adjuvant; Gynecology; Tamoxifen; Placebo; Randomized controlled trial; Gastroenterology; Cancer; Oncology; Confidence interval; Pathology","score_opus":0.03774385119763941,"score_gpt":0.3955393887054389,"score_spread":0.3577955375077995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534225621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957736,0.00038637687,0.00013530788,0.0024167525,0.00042365995,0.0002526433,0.000079674326,0.00000376236,0.00052822905],"genre_scores_gemma":[0.99623895,0.00027541557,0.0013621832,0.0011952164,0.0007340441,0.000032386677,0.0000038656613,0.000028062088,0.0001299088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968718,0.00020387139,0.0018668511,0.00033821285,0.00028308644,0.0004361505],"domain_scores_gemma":[0.9976638,0.00025494836,0.0011722377,0.00026313783,0.00034396147,0.00030192887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020056358,0.0002332778,0.0011290843,0.000113695845,0.000020856149,0.00000722055,0.00028948244,0.0001897992,0.00006075419],"category_scores_gemma":[0.00020912329,0.00016764904,0.00012807814,0.00013658541,0.00023985183,0.000012730473,0.000121599944,0.00035529866,0.0000032612681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4155286,0.0026285576,0.48000944,0.00003599793,0.001417893,0.00050727,0.0015221535,0.00014601336,0.012867386,0.0000031580526,0.0037261292,0.0816074],"study_design_scores_gemma":[0.017287172,0.009121475,0.95275545,0.00014350213,0.000064247186,0.00017514837,0.00026352998,0.000001713404,0.0028971804,0.000015384896,0.01709153,0.0001836411],"about_ca_topic_score_codex":0.0003028717,"about_ca_topic_score_gemma":0.0036593932,"teacher_disagreement_score":0.47274604,"about_ca_system_score_codex":0.00027855576,"about_ca_system_score_gemma":0.00064404967,"threshold_uncertainty_score":0.68365294},"labels":[],"label_agreement":null},{"id":"W2534490732","doi":"10.1200/jco.2009.27.15_suppl.5511","title":"What is the optimal strategy to confirm the diagnosis of epithelial ovarian carcinoma (EOC) prior to neoadjuvant chemotherapy (NAC)?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cytology; Histology; Biopsy; Radiology; Serous fluid; Chemotherapy; Internal medicine; Pathology","score_opus":0.09716349933024788,"score_gpt":0.4434798229453422,"score_spread":0.34631632361509435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534490732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65543073,0.00089641404,0.000058125886,0.34132907,0.0011181966,0.000637241,0.000012094108,0.000004402511,0.00051373814],"genre_scores_gemma":[0.9351473,0.0027491292,0.0018002412,0.058143716,0.0019258694,0.000027320497,8.757119e-7,0.000018407385,0.00018717156],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99641997,0.000346364,0.0020860708,0.00028612846,0.0005180167,0.0003434353],"domain_scores_gemma":[0.9950286,0.002356574,0.0010977404,0.0005064699,0.0004862072,0.00052439247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025165146,0.00022628257,0.0015079224,0.00009367937,0.000086815286,0.00004924955,0.000426251,0.0002758712,0.00058117637],"category_scores_gemma":[0.00059319887,0.00010875178,0.00073389907,0.00024077001,0.00016957571,0.00011856405,0.00004560093,0.0006891376,0.00003457547],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060450705,0.00330263,0.025291303,0.000009603224,0.00059820624,0.0003914463,0.0016968773,0.00012100319,0.00015688773,0.00053651497,0.022654377,0.9391961],"study_design_scores_gemma":[0.0090438705,0.04772858,0.72713214,0.00018292354,0.0006038623,0.00020166353,0.0007384036,0.00002885813,0.0021685897,0.00027101798,0.21177651,0.00012357136],"about_ca_topic_score_codex":0.00010708473,"about_ca_topic_score_gemma":0.00005266684,"teacher_disagreement_score":0.9390725,"about_ca_system_score_codex":0.00018725405,"about_ca_system_score_gemma":0.0014385647,"threshold_uncertainty_score":0.63634735},"labels":[],"label_agreement":null},{"id":"W2534535679","doi":"10.1200/jco.2006.24.18_suppl.8521","title":"What role do cancer patients want to play in treatment decision making: A pooled-analysis","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Concordance; Preference; Demographics; Cancer; Internal medicine; Patient participation; Family medicine; Demography; MEDLINE","score_opus":0.3072776863677467,"score_gpt":0.5953807641825214,"score_spread":0.2881030778147747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534535679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796147,0.003147629,0.00009165823,0.011777493,0.003606175,0.00080049946,0.000019478672,0.000011972965,0.00093042274],"genre_scores_gemma":[0.99006206,0.0013366694,0.003891912,0.0037894708,0.00059111335,0.00012821358,0.000008018118,0.00002066276,0.00017186924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98968625,0.003255353,0.0056752767,0.00031868898,0.0005607279,0.00050368946],"domain_scores_gemma":[0.9843204,0.010143419,0.0035040325,0.0005882355,0.001074276,0.00036963398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020553225,0.00019487037,0.0017975129,0.00064276764,0.00022156668,0.000018306255,0.0005490504,0.00059854414,0.0004275183],"category_scores_gemma":[0.0029820923,0.00013922033,0.00053937477,0.0007911755,0.000058250138,0.000311995,0.0002317486,0.0012786,0.00009656981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016344526,0.0016504219,0.83413,0.000010826162,0.0002994267,0.000020717407,0.0027177318,0.0015798394,0.0000031572274,0.000074057665,0.0022044217,0.15567498],"study_design_scores_gemma":[0.005218818,0.0036144524,0.9139464,0.0005788953,0.0006130562,0.0000010886727,0.0032354377,0.000326939,0.000002912523,0.0023436272,0.06997527,0.00014310869],"about_ca_topic_score_codex":0.001468953,"about_ca_topic_score_gemma":0.01889928,"teacher_disagreement_score":0.15553187,"about_ca_system_score_codex":0.0021408862,"about_ca_system_score_gemma":0.0023797106,"threshold_uncertainty_score":0.99900323},"labels":[],"label_agreement":null},{"id":"W2534574534","doi":"10.1200/jco.2007.25.18_suppl.10049","title":"Verification of imatiNib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; GiST; Imatinib; Stromal tumor; Internal medicine; Imatinib mesylate; Progression-free survival; Cost effectiveness; Retrospective cohort study; Surgery; Survival analysis; Cohort; Oncology; Overall survival; Stromal cell","score_opus":0.10596699956929244,"score_gpt":0.47797711302434975,"score_spread":0.3720101134550573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534574534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977705,0.000081963444,0.00063738355,0.00020638983,0.00013134224,0.0006192863,0.0000056080785,0.0000049996274,0.00054253265],"genre_scores_gemma":[0.97736484,0.000026113306,0.022371123,0.000059350437,0.00012300954,0.000010726322,0.0000043467435,0.00001259842,0.000027898688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960012,0.0005091016,0.0024627007,0.00020799764,0.00042036225,0.00039864864],"domain_scores_gemma":[0.99446994,0.0032265985,0.0012396995,0.0001424427,0.000546921,0.00037441417],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006962908,0.00009531359,0.0012503082,0.00016092115,0.000017612469,0.000012560379,0.000143462,0.0000701735,0.000081808146],"category_scores_gemma":[0.011169612,0.0001111674,0.00023915592,0.0002869245,0.00024822992,0.00011037912,0.000037849208,0.0010261614,0.0000044835097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006187739,0.0036189302,0.8744745,0.00007331634,0.000022823571,0.0111198295,0.000009016082,0.000028599197,0.0020964467,0.000007678216,0.000036835194,0.10232425],"study_design_scores_gemma":[0.014429621,0.025365802,0.9489691,0.0014186262,0.000032635515,0.008946813,0.00020661514,0.00010928025,0.00017864766,0.00014651232,0.00014021495,0.000056088906],"about_ca_topic_score_codex":0.0018406609,"about_ca_topic_score_gemma":0.02103655,"teacher_disagreement_score":0.10226815,"about_ca_system_score_codex":0.00049310765,"about_ca_system_score_gemma":0.0013698703,"threshold_uncertainty_score":0.9971597},"labels":[],"label_agreement":null},{"id":"W2535419004","doi":"10.1200/jco.2006.24.18_suppl.4555","title":"Predictors of clinical outcome in patients with bone metastases from prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Waterloo","funders":"","keywords":"Medicine; Zoledronic acid; Internal medicine; Prostate cancer; Hazard ratio; Proportional hazards model; Creatinine; Relative risk; Urology; Bone remodeling; Cancer; Surgery; Oncology; Confidence interval","score_opus":0.10516677011166983,"score_gpt":0.49077199760279394,"score_spread":0.38560522749112414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535419004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953642,0.0005298868,0.0000059817257,0.0021052437,0.0012307231,0.0003596385,0.0000826444,0.0000053764584,0.0003163037],"genre_scores_gemma":[0.99544793,0.00026260925,0.0025539321,0.001029971,0.0004915819,0.0000062208965,0.000024553456,0.000016654505,0.00016655568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99302495,0.0004957132,0.00553705,0.00020673955,0.00047574128,0.0002598147],"domain_scores_gemma":[0.9937392,0.0019077954,0.0033341153,0.00017838851,0.00043475864,0.00040574503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022416194,0.00014687097,0.0025737158,0.00012398652,0.000016044205,0.0000024337953,0.00008020554,0.00031516617,0.000102628546],"category_scores_gemma":[0.0014520176,0.00008555506,0.00036070912,0.00014755086,0.00023411182,0.00009378628,0.00002711194,0.00089954096,0.0000058818596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016697306,0.0068790107,0.93435705,0.00002527368,0.00037716664,0.00036013883,0.000016511975,0.000012204803,5.081412e-7,0.0000051041916,0.0013410887,0.03992866],"study_design_scores_gemma":[0.03584207,0.01730719,0.9365263,0.00013870736,0.00065031793,0.000007742538,0.000011586538,0.000008529334,0.000006014269,0.000081543956,0.009359159,0.00006081979],"about_ca_topic_score_codex":0.0015638362,"about_ca_topic_score_gemma":0.0010915677,"teacher_disagreement_score":0.039867837,"about_ca_system_score_codex":0.000107520435,"about_ca_system_score_gemma":0.0017686463,"threshold_uncertainty_score":0.3908108},"labels":[],"label_agreement":null},{"id":"W2535743794","doi":"10.1200/jco.2009.27.15_suppl.e20713","title":"The effects of a brief relaxation program on heart rate variability in cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heart Rate Variability and Autonomic Control","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Heart rate variability; Medicine; Anxiety; Heart rate; Supine position; Relaxation (psychology); Cardiology; Physical therapy; Internal medicine; Blood pressure; Psychiatry","score_opus":0.04319512948230641,"score_gpt":0.44501068471645006,"score_spread":0.40181555523414364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535743794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97632414,0.00005540722,0.0000135868295,0.021565836,0.0009192059,0.00065788935,7.5159437e-7,0.0000053843924,0.00045782293],"genre_scores_gemma":[0.99648947,0.00015315285,0.00028795347,0.0027087189,0.0003027688,0.000010061478,5.15921e-7,0.0000038417315,0.000043499982],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99585843,0.0016650769,0.0019909486,0.00013652364,0.00017817756,0.00017084842],"domain_scores_gemma":[0.98756546,0.0108023165,0.0009782392,0.00017312093,0.0003342923,0.0001465472],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010058926,0.00008007538,0.00091754954,0.00004820542,0.000029599705,0.00000529578,0.00008121577,0.00024818679,0.0000148048675],"category_scores_gemma":[0.02974702,0.00004634142,0.0002652269,0.00012887926,0.00012669383,0.000055119875,0.000010959878,0.0008203394,0.0000024902763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027325093,0.008848757,0.09212228,0.000038574584,0.00006380674,0.000016141521,0.000076388016,0.000020576215,0.0009304674,0.00024453673,0.0004966841,0.8944093],"study_design_scores_gemma":[0.0064261546,0.02494798,0.9119793,0.00014196629,0.000069403795,0.0000028246056,0.0000040346417,0.00031793574,0.00022207125,0.0010397221,0.05481295,0.00003564765],"about_ca_topic_score_codex":0.000032509055,"about_ca_topic_score_gemma":0.000029675759,"teacher_disagreement_score":0.89437366,"about_ca_system_score_codex":0.00021113445,"about_ca_system_score_gemma":0.0013641141,"threshold_uncertainty_score":0.97842586},"labels":[],"label_agreement":null},{"id":"W2535794650","doi":"10.1200/jco.2007.25.18_suppl.19612","title":"The variations in symptom clusters related to well-being in palliative care patients during the final weeks of life","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Wellbeing Research","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Capital District Health Authority","funders":"","keywords":"Medicine; Palliative care; LISREL; Depression (economics); Anxiety; Goodness of fit; Structural equation modeling; Death anxiety; Psychiatry; Statistics","score_opus":0.11782139672730131,"score_gpt":0.5624418280792584,"score_spread":0.44462043135195706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535794650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719424,0.00008902774,0.00005560641,0.018933374,0.0013712961,0.00064526807,0.0000017412929,0.0000032969806,0.0069579748],"genre_scores_gemma":[0.99683213,0.00027115128,0.00017583599,0.0021616057,0.00028675704,0.000011531697,9.735347e-7,0.000011145076,0.000248864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911629,0.0032447416,0.0043431493,0.00014519138,0.00046488497,0.00063915155],"domain_scores_gemma":[0.9674277,0.02958215,0.0016607492,0.00019424169,0.00071137137,0.0004238399],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.017068025,0.00009356057,0.0006665442,0.00024147333,0.00041423558,0.000004353131,0.0004123916,0.0004523242,0.00005039663],"category_scores_gemma":[0.023387056,0.000052849533,0.00014237556,0.0005304195,0.00012206628,0.00006596632,0.00015929781,0.0035226182,0.000037180016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00207609,0.00023224803,0.97589916,0.000065876106,0.00002934983,0.000025735191,0.010363819,0.00021818712,0.0000019447614,0.00039725302,0.00044216347,0.010248201],"study_design_scores_gemma":[0.004827287,0.0013085031,0.9790936,0.00030736421,0.00000964279,4.5288223e-7,0.0047993,0.00008791052,0.000001308256,0.00060292095,0.00891397,0.000047746777],"about_ca_topic_score_codex":0.0003070998,"about_ca_topic_score_gemma":0.0040268027,"teacher_disagreement_score":0.02633741,"about_ca_system_score_codex":0.00061486266,"about_ca_system_score_gemma":0.0031907065,"threshold_uncertainty_score":0.9987763},"labels":[],"label_agreement":null},{"id":"W2536138290","doi":"10.1200/jco.2006.24.18_suppl.10034","title":"A comparison of BRCA1 and BRCA2 risk assessment models","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Proband; Internal medicine; Ovarian cancer; Cancer; Oncology; Mutation; Gynecology; Demography; Genetics; Biology","score_opus":0.10141562261453158,"score_gpt":0.5037484647076051,"score_spread":0.4023328420930736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536138290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782568,0.0019097672,0.0133357495,0.0007698339,0.00053843023,0.000069524445,0.000009347376,0.0000016092841,0.005108906],"genre_scores_gemma":[0.9741863,0.00067130395,0.024157675,0.0001848882,0.0007021426,0.0000019748873,0.000004296801,0.000009363289,0.000082073675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976502,0.00032170603,0.001588545,0.00015515336,0.00016832551,0.00011604141],"domain_scores_gemma":[0.9973302,0.00028930206,0.0017791714,0.00016127684,0.00035734609,0.00008269852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017070749,0.00008447934,0.00062852795,0.000044999153,0.000030280155,0.000006631098,0.00015588268,0.0003032806,0.000015163105],"category_scores_gemma":[0.00041108392,0.00006957902,0.00020073245,0.00005037181,0.0002155773,0.000006767099,0.00007342808,0.00035349771,6.418353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015109107,0.0034262168,0.6499398,0.00004412871,0.00090823765,0.00002880885,0.00013362918,0.030902192,0.031659313,0.002130555,0.04842102,0.2308952],"study_design_scores_gemma":[0.009953496,0.017209714,0.7109639,0.000049187976,0.00060103665,0.0001790479,0.00040258153,0.011903389,0.01607632,0.018099213,0.21418516,0.00037693421],"about_ca_topic_score_codex":0.000030248142,"about_ca_topic_score_gemma":0.00008031581,"teacher_disagreement_score":0.23051827,"about_ca_system_score_codex":0.000050007693,"about_ca_system_score_gemma":0.0009701569,"threshold_uncertainty_score":0.283735},"labels":[],"label_agreement":null},{"id":"W2537692172","doi":"10.1200/jco.2013.31.6_suppl.lba8","title":"Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Docetaxel; Dasatinib; Clinical endpoint; Internal medicine; Prostate cancer; Hazard ratio; Urology; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Gastroenterology; Cancer; Tyrosine kinase; Clinical trial; Chemotherapy; Confidence interval","score_opus":0.13517631676059172,"score_gpt":0.46769107226991663,"score_spread":0.3325147555093249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537692172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861,0.0007230732,0.000006897977,0.006363852,0.0006859779,0.0027292417,0.00020972629,0.000003905188,0.0006672967],"genre_scores_gemma":[0.9954656,0.002743476,0.0008384622,0.00020820364,0.00029735206,0.00006793933,0.00008296457,0.00001763089,0.00027840096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937593,0.0015310512,0.0034203082,0.0002733154,0.00072158675,0.0002944734],"domain_scores_gemma":[0.9842337,0.011712826,0.0026008287,0.00025741587,0.000903634,0.00029159384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052896263,0.00020587641,0.0024611126,0.000098042816,0.000058705224,0.00002409224,0.00015192867,0.00014714312,0.00015842897],"category_scores_gemma":[0.0051513137,0.00009649874,0.00025105948,0.00016221723,0.00061748753,0.00021685977,0.000044539735,0.0007897443,0.0000026613443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9709086,0.002703419,0.0056945817,0.000021927926,0.001574189,0.00008484391,0.0005164479,0.000017081262,0.000044299344,0.000040889234,0.00072695164,0.017666787],"study_design_scores_gemma":[0.88884985,0.016431449,0.0920782,0.0001963882,0.00087977736,0.0000021407398,0.00024667196,0.000093850926,0.000024676325,0.00019118248,0.0009150727,0.0000907553],"about_ca_topic_score_codex":0.0022357826,"about_ca_topic_score_gemma":0.0007400162,"teacher_disagreement_score":0.08638362,"about_ca_system_score_codex":0.0001728964,"about_ca_system_score_gemma":0.0020626704,"threshold_uncertainty_score":0.61669755},"labels":[],"label_agreement":null},{"id":"W2538206848","doi":"10.1200/jco.2006.24.18_suppl.10686","title":"Breast cancer wait times: Use of breast screening clinics affect presenting stage","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Breast cancer; Biopsy; Cancer; Mammography; Stage (stratigraphy); Presentation (obstetrics); Retrospective cohort study; Surgery; General surgery; Radiology; Internal medicine","score_opus":0.2421185712595953,"score_gpt":0.503371381445016,"score_spread":0.26125281018542074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538206848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920703,0.0006109547,0.0008636307,0.0032295857,0.0008797043,0.00020931188,0.00007227997,0.000017896999,0.0020463236],"genre_scores_gemma":[0.985797,0.00042379685,0.008349171,0.0010950618,0.003042052,0.0000024117587,0.0000050254544,0.000027499509,0.0012579765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460214,0.00046495593,0.0034844517,0.0002647813,0.00076619507,0.00041748126],"domain_scores_gemma":[0.99197495,0.00276966,0.0035048674,0.00026997732,0.0011146795,0.0003658686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004068558,0.00020188736,0.0018859479,0.00015896105,0.000061063154,0.000024202589,0.0002515924,0.00045887043,0.0004791158],"category_scores_gemma":[0.0015178196,0.00015109731,0.0008812617,0.00027817377,0.0002956077,0.0004292098,0.000115061965,0.0012741947,0.000007727538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004905879,0.0006903018,0.8807371,0.00007357696,0.00038777565,0.0007724164,0.00002807152,0.0009563009,0.00023080753,0.00016038596,0.012931893,0.09812549],"study_design_scores_gemma":[0.004871046,0.0023130334,0.9586768,0.0006876532,0.00061296247,0.0022984347,0.00013191313,0.0016664526,0.00006188095,0.000082977465,0.02844533,0.00015150488],"about_ca_topic_score_codex":0.0011712505,"about_ca_topic_score_gemma":0.00023533746,"teacher_disagreement_score":0.09797399,"about_ca_system_score_codex":0.0001395865,"about_ca_system_score_gemma":0.0015347782,"threshold_uncertainty_score":0.61615694},"labels":[],"label_agreement":null},{"id":"W2538251152","doi":"10.1200/jco.2009.27.15_suppl.3023","title":"Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sorafenib; Temsirolimus; Sunitinib; Internal medicine; Oncology; Bevacizumab; Everolimus; Adverse effect; Phases of clinical research; Vascular endothelial growth factor; Progression-free survival; Renal cell carcinoma; Gastroenterology; Clinical trial; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; VEGF receptors","score_opus":0.27611046466165373,"score_gpt":0.5126640576467328,"score_spread":0.2365535929850791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538251152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864456,0.0014248085,0.00008840077,0.007603258,0.001594336,0.0017505131,0.000051960735,0.000013222698,0.0010279213],"genre_scores_gemma":[0.9809166,0.0014969759,0.0046677445,0.0021772713,0.0010929661,0.00004161856,0.000016229218,0.000036382047,0.009554217],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9921605,0.0008118642,0.0052808844,0.0004982528,0.0007433036,0.00050520664],"domain_scores_gemma":[0.99000216,0.0034130726,0.004400041,0.000489419,0.001082545,0.0006127585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004870223,0.0003966572,0.0034472786,0.00027489208,0.0001212133,0.000012335315,0.00035587212,0.00033807335,0.0004872747],"category_scores_gemma":[0.0020515807,0.00023458633,0.0009794304,0.0002772196,0.00016700459,0.00013852997,0.00005350567,0.0011577522,0.000010813013],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5177401,0.11452562,0.00031822678,0.00012115222,0.0024939291,0.01199463,0.0020513507,0.00019265506,0.0050896737,0.000027547407,0.03390909,0.31153607],"study_design_scores_gemma":[0.23995402,0.69302374,0.0068267146,0.00019649557,0.0019692993,0.0011480944,0.00065714365,0.0002418571,0.0077666882,0.0006957834,0.047265355,0.0002547917],"about_ca_topic_score_codex":0.0000670806,"about_ca_topic_score_gemma":0.00020849798,"teacher_disagreement_score":0.5784981,"about_ca_system_score_codex":0.0004293895,"about_ca_system_score_gemma":0.004678515,"threshold_uncertainty_score":0.95661527},"labels":[],"label_agreement":null},{"id":"W2538621833","doi":"10.1200/jco.2007.25.18_suppl.17041","title":"20-year epidemiology and treatment experience with lung cancer in Manitoba, Canada","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Radiation therapy; Epidemiology; Chemotherapy; Cancer registry; Cancer; Proportional hazards model; Surveillance, Epidemiology, and End Results; Oncology; Surgery","score_opus":0.11716392257767029,"score_gpt":0.5240651159084065,"score_spread":0.40690119333073627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538621833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766524,0.0018708176,0.00008145532,0.0072797188,0.000528543,0.00017039903,0.000004064033,0.0000020791758,0.0023976865],"genre_scores_gemma":[0.9935629,0.0013888685,0.0022084424,0.0021027927,0.00044521454,0.000008871301,0.0000010999678,0.0000069940015,0.00027482017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983293,0.000113639886,0.0010989682,0.00013323722,0.00010924272,0.00021560992],"domain_scores_gemma":[0.99736494,0.0015672958,0.00055982766,0.00008204912,0.0001229858,0.00030289864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009378006,0.00008882431,0.0008576406,0.000059967933,0.000025292902,0.0000014028112,0.000039434824,0.00011834076,0.00006567146],"category_scores_gemma":[0.00047249708,0.000050576913,0.000062592706,0.00007569538,0.00012252778,0.00004238087,0.0000090000985,0.00024915626,3.5788472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014712261,0.0003065153,0.9053778,0.0000057069105,0.00023241455,0.001207766,0.00022264764,0.000030463634,0.0000059801177,0.000053735745,0.0006624655,0.09042329],"study_design_scores_gemma":[0.007013219,0.0047112224,0.94759893,0.00007018491,0.0002830035,0.00027968877,0.0008857874,0.000034203647,0.000014512922,0.000026626574,0.039031908,0.000050708284],"about_ca_topic_score_codex":0.14845768,"about_ca_topic_score_gemma":0.8497873,"teacher_disagreement_score":0.70132965,"about_ca_system_score_codex":0.0010805867,"about_ca_system_score_gemma":0.0037570884,"threshold_uncertainty_score":0.85721284},"labels":[],"label_agreement":null},{"id":"W2539438153","doi":"10.1200/jco.2006.24.18_suppl.9017","title":"A phase I study of bevacizumab in children with refractory solid tumors: A Children’s Oncology Group study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Bevacizumab; Mucositis; Rash; Pharmacokinetics; Refractory (planetary science); Internal medicine; Toxicity; Gastroenterology; Vascular endothelial growth factor; Proteinuria; Phases of clinical research; Chemotherapy; Surgery; VEGF receptors","score_opus":0.04757449360193812,"score_gpt":0.43454754442815624,"score_spread":0.38697305082621813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539438153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970752,0.00033084085,0.000022492977,0.00048603924,0.00019401651,0.0013610818,0.000003895532,0.000013334795,0.0005130987],"genre_scores_gemma":[0.9977182,0.000045008055,0.00059872767,0.00029053004,0.0012438878,0.00001705912,0.000007718107,0.0000379764,0.000040877716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297184,0.0013375801,0.0041841785,0.00039823033,0.0007103006,0.00039785384],"domain_scores_gemma":[0.9953298,0.00066986016,0.0029102154,0.00042365366,0.00035035363,0.00031614373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042244024,0.00028086398,0.0033761142,0.0004561508,0.00004788337,0.00000821371,0.00032799967,0.00031233314,0.00007206338],"category_scores_gemma":[0.0007705215,0.00018643406,0.0005381768,0.00037011364,0.00023758897,0.00014975615,0.00010112732,0.0017270003,0.0000056124695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073296693,0.16834873,0.7884151,0.000007209793,0.0010440475,0.0027541798,0.00046187566,0.000021097083,0.00007302899,0.000010673009,0.00029900394,0.03123538],"study_design_scores_gemma":[0.08048643,0.23808919,0.67665184,0.00007656197,0.0007869304,0.0020415504,0.0013557929,0.000010837654,0.000009706544,0.00003099201,0.00033829644,0.0001218471],"about_ca_topic_score_codex":0.00063127966,"about_ca_topic_score_gemma":0.0011518039,"teacher_disagreement_score":0.11176324,"about_ca_system_score_codex":0.00026701417,"about_ca_system_score_gemma":0.0013631054,"threshold_uncertainty_score":0.76025605},"labels":[],"label_agreement":null},{"id":"W2540579743","doi":"10.1200/jco.2006.24.18_suppl.18012","title":"Correlation between hemodynamic parameters and response to high-dose interleukin-2 in metastatic melanoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Blood pressure; Statistical significance; Internal medicine; Diastole; Heart rate; Cardiology; Hemodynamics","score_opus":0.057171383634080024,"score_gpt":0.408721084138593,"score_spread":0.35154970050451295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540579743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889793,0.00041929877,0.00056651497,0.009134419,0.0005299123,0.00024200513,0.0000031982445,0.0000069891944,0.00011836726],"genre_scores_gemma":[0.99376476,0.00012978168,0.004472835,0.0008618372,0.00039443115,0.000004165966,0.0000039440074,0.000017071054,0.00035116397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960287,0.0011714769,0.0021353457,0.00019013464,0.00024982783,0.00022450957],"domain_scores_gemma":[0.99208015,0.0064915353,0.0008868916,0.00016834415,0.00013757842,0.00023547297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004300517,0.00014224267,0.0014065868,0.00040338442,0.000024219375,0.000012668556,0.000092347684,0.00021480695,0.000024412648],"category_scores_gemma":[0.0037474434,0.00011166861,0.00023470663,0.00020267112,0.0001750199,0.00010674219,0.000033750734,0.00068839005,0.000014839086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16698565,0.001516213,0.46643248,0.000055712022,0.00035400898,0.0033495703,0.0005029744,0.0007216524,0.0011596633,0.00007491832,0.002842465,0.3560047],"study_design_scores_gemma":[0.008981428,0.011675617,0.9606036,0.00017711133,0.00026631352,0.00080973184,0.00015636321,0.00035651424,0.000046058045,0.00040666308,0.016415633,0.000104942934],"about_ca_topic_score_codex":0.00030292736,"about_ca_topic_score_gemma":0.00019234222,"teacher_disagreement_score":0.49417114,"about_ca_system_score_codex":0.0003047766,"about_ca_system_score_gemma":0.0008950089,"threshold_uncertainty_score":0.45537138},"labels":[],"label_agreement":null},{"id":"W2540641331","doi":"10.1200/jco.2009.27.15_suppl.e11510","title":"A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Regimen; Internal medicine; Breast cancer; Tolerability; Cohort; Chemotherapy; Gastroenterology; Oncology; Paclitaxel; Cancer; Surgery; Adverse effect","score_opus":0.04071021150147342,"score_gpt":0.41119027017082327,"score_spread":0.37048005866934985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540641331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926928,0.0010073549,0.002066188,0.0031796014,0.0004948324,0.00046192022,0.00004468007,0.000004405234,0.00004816631],"genre_scores_gemma":[0.9955082,0.0006628024,0.002939284,0.00039085222,0.00040114662,0.000024804629,0.000012704769,0.000012696223,0.00004750284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99784553,0.00029278602,0.0012174417,0.00027584907,0.00015421545,0.00021416247],"domain_scores_gemma":[0.99683297,0.00058494735,0.0018542822,0.00015522391,0.00043674686,0.00013583574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014855276,0.00018014433,0.00092209294,0.000066749926,0.00008755688,0.0000057939346,0.00012434131,0.00029655712,0.00000408432],"category_scores_gemma":[0.0009631398,0.00012622646,0.0002476857,0.00007637311,0.00022484436,0.000015642583,0.000046091125,0.00018622215,1.04888294e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62555534,0.0013396007,0.008414247,0.0000068871877,0.000461774,0.00007154862,0.00009173335,0.00003911739,0.005417723,0.000006578916,0.00015958036,0.35843587],"study_design_scores_gemma":[0.4682298,0.29160994,0.23566753,0.000264752,0.0006997013,0.0007511911,0.00021062183,0.00006653598,0.0010349448,0.00013424267,0.0010608222,0.00026992956],"about_ca_topic_score_codex":0.000005651447,"about_ca_topic_score_gemma":0.000057089594,"teacher_disagreement_score":0.35816592,"about_ca_system_score_codex":0.00006411846,"about_ca_system_score_gemma":0.00086557434,"threshold_uncertainty_score":0.51473653},"labels":[],"label_agreement":null},{"id":"W2541318692","doi":"10.1200/jco.2009.27.15_suppl.e16529","title":"Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Ontario Clinical Oncology Group; BC Cancer Agency","funders":"","keywords":"Medicine; Randomized controlled trial; Ovarian cancer; Low molecular weight heparin; Chemotherapy; Heparin; Surgery; Internal medicine; Taxane; Cancer; Gastroenterology; Breast cancer","score_opus":0.08121915640578144,"score_gpt":0.5341580470062968,"score_spread":0.45293889060051534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2541318692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664441,0.001557357,0.00008591895,0.025146611,0.0017055406,0.0011195684,0.0000024520414,0.000011193605,0.0039273086],"genre_scores_gemma":[0.9902233,0.0013588868,0.000676888,0.005774321,0.0013068083,0.00003601409,0.0000031003176,0.0000152404255,0.00060544757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942937,0.0014449456,0.0032558525,0.00029207423,0.00035990382,0.00035352568],"domain_scores_gemma":[0.99613374,0.0014255833,0.0015122637,0.00021472295,0.00024582204,0.00046789178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005158073,0.00022735151,0.0036363308,0.000290162,0.0000519196,0.0000073564324,0.00020672627,0.00033890005,0.0006833649],"category_scores_gemma":[0.0012713701,0.00015888868,0.00077646534,0.000286887,0.0001696417,0.00009275907,0.0000506115,0.0012599303,0.000008944953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65441835,0.07859825,0.025543077,0.000016931175,0.0019465317,0.012001441,0.00076516054,0.0000629527,0.0018584625,0.00023990766,0.006912743,0.21763621],"study_design_scores_gemma":[0.8698382,0.072031364,0.029886603,0.00009336479,0.00218914,0.00026741592,0.00006580756,0.0003306415,0.0003782604,0.0009803425,0.023767196,0.00017166579],"about_ca_topic_score_codex":0.00020855472,"about_ca_topic_score_gemma":0.00028352393,"teacher_disagreement_score":0.21746454,"about_ca_system_score_codex":0.00034651693,"about_ca_system_score_gemma":0.002002619,"threshold_uncertainty_score":0.74823666},"labels":[],"label_agreement":null},{"id":"W2543488039","doi":"10.1200/jco.2015.33.15_suppl.e14019","title":"ZW38, a bispecific CD3 x CD19 azymetric antibody to deplete human leukemic B cells by the “controlled” activation of T cells.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD19; Antibody; Blinatumomab; Antigen; T cell; Cancer research; Cytokine; Immune system; CD3; B cell; Cytotoxic T cell; Immunology; Molecular biology; Medicine; Biology; In vitro; CD8; Biochemistry","score_opus":0.2066256439881135,"score_gpt":0.5094023533349838,"score_spread":0.30277670934687034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2543488039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402894,0.000438928,0.0005330484,0.0063513075,0.0012171009,0.00079035974,0.0000051896204,0.000010246273,0.006624868],"genre_scores_gemma":[0.989466,0.0005188214,0.0005988616,0.0019917262,0.001698397,0.000007288147,0.0000042403876,0.000038377697,0.005676257],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940528,0.0011647806,0.0029720915,0.00026641125,0.0011386607,0.00040520445],"domain_scores_gemma":[0.9907475,0.0049682707,0.0018739399,0.00047857186,0.001216945,0.0007147762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010261479,0.00019646916,0.0021320812,0.0005523365,0.000063316904,0.000021595422,0.0005232233,0.0004380334,0.00062152126],"category_scores_gemma":[0.004213495,0.000117799515,0.0007558114,0.00082347146,0.00029149724,0.000107019165,0.00011103083,0.0016362682,0.00007401484],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01568578,0.0015053359,0.004159195,0.000022750924,0.0004755669,0.00009272942,0.00021727404,0.00006825182,0.83942944,0.000029595514,0.09716125,0.041152857],"study_design_scores_gemma":[0.07088437,0.05111451,0.01934249,0.00018168041,0.0006118133,0.00024068548,0.00072296493,0.00034106494,0.12943467,0.00037158522,0.72644037,0.00031381045],"about_ca_topic_score_codex":0.000097779,"about_ca_topic_score_gemma":0.000015340423,"teacher_disagreement_score":0.70999473,"about_ca_system_score_codex":0.00052342395,"about_ca_system_score_gemma":0.0020414633,"threshold_uncertainty_score":0.71088624},"labels":[],"label_agreement":null},{"id":"W2543554890","doi":"10.1200/jco.2009.27.15_suppl.5075","title":"Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Oncology; Internal medicine; Chemotherapy; Hazard ratio; Cancer; Proportional hazards model; Cohort; Stage (stratigraphy); Urology; Confidence interval","score_opus":0.05733589957730952,"score_gpt":0.39925409083762553,"score_spread":0.34191819126031603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2543554890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9390331,0.0010009803,0.00030616162,0.053531516,0.002931938,0.0012926415,0.00078232714,0.000025628513,0.001095704],"genre_scores_gemma":[0.973047,0.00093597383,0.0032186492,0.011765408,0.010275071,0.000022689856,0.000084464955,0.000056842604,0.0005939006],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944166,0.0007201509,0.003178518,0.00051928393,0.0006724376,0.0004930125],"domain_scores_gemma":[0.99209094,0.0037670687,0.0023308457,0.00053756725,0.0008050818,0.00046852214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027026741,0.00039790763,0.001979454,0.000114280105,0.00020491515,0.000049776227,0.0003874233,0.00073086406,0.00019588055],"category_scores_gemma":[0.002945547,0.00023617894,0.0010163974,0.00021896148,0.00021277182,0.00024330102,0.000018463912,0.001301196,0.000025196092],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13115701,0.011347911,0.2962507,0.000020985139,0.0011775629,0.00074393034,0.00361706,0.000040263378,0.0022583958,0.00026663914,0.05792882,0.4951907],"study_design_scores_gemma":[0.057708837,0.030048812,0.78854585,0.000054963508,0.001327406,0.000173829,0.00034058472,0.000083049265,0.0014717401,0.0015659396,0.11845726,0.00022174527],"about_ca_topic_score_codex":0.0005142217,"about_ca_topic_score_gemma":0.00008823976,"teacher_disagreement_score":0.49496898,"about_ca_system_score_codex":0.0003516591,"about_ca_system_score_gemma":0.0036101849,"threshold_uncertainty_score":0.9631098},"labels":[],"label_agreement":null},{"id":"W2544767777","doi":"10.1200/jco.2007.25.18_suppl.2507","title":"Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Toronto General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"CLOCK; Timeless; Circadian rhythm; Gene; Microarray analysis techniques; Microarray; Gene expression; Biology; Circadian clock; Rhythm; Medicine; Genetics; Internal medicine","score_opus":0.2881406927419542,"score_gpt":0.4780038080840144,"score_spread":0.18986311534206018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544767777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734956,0.000415233,0.00080262014,0.00093416305,0.00022938268,0.0002073333,0.0000070945334,0.0000026604619,0.0000519795],"genre_scores_gemma":[0.99676937,0.0006075627,0.0022705079,0.00019440347,0.00013036362,0.0000045514175,3.687142e-7,0.000009426061,0.000013429627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967772,0.0007881427,0.0017516818,0.00024657237,0.00015245442,0.00028396057],"domain_scores_gemma":[0.99333835,0.005533761,0.0007891089,0.00009873027,0.00006373546,0.0001763152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00608569,0.000114369774,0.0007830673,0.0003583514,0.00005129303,0.000011723639,0.00014049969,0.00027072057,0.000010675503],"category_scores_gemma":[0.0026821997,0.00009001,0.00009663117,0.00020329373,0.00026375896,0.00015699297,0.000060875336,0.00057468883,1.1795606e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004883365,0.00065800914,0.5004106,0.0000070412234,0.0000058001406,0.00011333615,0.0005055,0.00002453056,0.4839814,0.00050592556,0.000015071628,0.008889427],"study_design_scores_gemma":[0.0055154334,0.001722124,0.942913,0.000037436006,0.0000052214655,0.00013352474,0.00013148735,0.00016318611,0.04833602,0.0008146558,0.00014110463,0.00008682667],"about_ca_topic_score_codex":0.000009755143,"about_ca_topic_score_gemma":0.00010832739,"teacher_disagreement_score":0.44250238,"about_ca_system_score_codex":0.00005982634,"about_ca_system_score_gemma":0.00025943923,"threshold_uncertainty_score":0.36705014},"labels":[],"label_agreement":null},{"id":"W2544829765","doi":"10.1200/jco.2009.27.15_suppl.e15027","title":"Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Oxaliplatin; Bevacizumab; Colorectal cancer; Perioperative; Chemotherapy; Internal medicine; Hepatectomy; Surgery; Oncology; Cancer","score_opus":0.1393635826127538,"score_gpt":0.4516437712909993,"score_spread":0.3122801886782455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544829765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923141,0.00053426536,0.000016717946,0.0051317317,0.00021757993,0.0008540478,0.00004805831,0.0000074108225,0.0008760617],"genre_scores_gemma":[0.99557793,0.0014306427,0.0012654373,0.0011389595,0.0002467332,0.000008755745,0.0000013229882,0.000009983515,0.0003202539],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99831057,0.0002466874,0.0007794493,0.00023119843,0.00021970176,0.0002123872],"domain_scores_gemma":[0.9979262,0.0007671417,0.00056551874,0.000075151824,0.0004973038,0.00016868947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077377236,0.00017021748,0.0014605188,0.0001147967,0.00010038558,0.0000039299443,0.000098983226,0.000080346654,0.00010298458],"category_scores_gemma":[0.0002865535,0.00010621063,0.00020028639,0.0001809056,0.00012359834,0.000109213666,0.000019485657,0.00040258624,0.0000010651479],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38758844,0.037869353,0.17513573,0.000030073896,0.0042725415,0.00444756,0.0023201874,0.000072892806,0.00042795998,0.00014404232,0.0026908757,0.38500035],"study_design_scores_gemma":[0.0377654,0.2757853,0.6611345,0.000051343133,0.0006959146,0.0000848386,0.0017757125,0.00002988761,0.00012343742,0.000018362738,0.022424312,0.000111038746],"about_ca_topic_score_codex":0.00027197992,"about_ca_topic_score_gemma":0.0055353404,"teacher_disagreement_score":0.48599875,"about_ca_system_score_codex":0.0007413258,"about_ca_system_score_gemma":0.00085441046,"threshold_uncertainty_score":0.43311438},"labels":[],"label_agreement":null},{"id":"W2544972614","doi":"10.1200/jco.2006.24.18_suppl.1502","title":"Significance of necrosis in grading of anaplastic oligodendroglial tumors: A clinicopathological and genetic study of 916 high-grade gliomas","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Oligodendroglial Tumor; Medicine; Anaplastic astrocytoma; Grading (engineering); Oligodendroglioma; Proportional hazards model; Astrocytoma; Multivariate analysis; Pathology; Internal medicine; Necrosis; Glioma; Oncology; Log-rank test; Gastroenterology; Cancer research; Biology","score_opus":0.07967090490122503,"score_gpt":0.4092913660148544,"score_spread":0.32962046111362936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544972614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981784,0.00066653127,0.000013370921,0.00039615427,0.0002907974,0.0003888504,0.000008110893,0.000003187238,0.000054580956],"genre_scores_gemma":[0.9972323,0.00024385897,0.0022114725,0.000043094857,0.00024252,0.0000096447075,8.734309e-7,0.000012481014,0.0000037091738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421436,0.00059708883,0.0043073245,0.0002545657,0.000406389,0.00022026236],"domain_scores_gemma":[0.99279535,0.0036945972,0.0028923363,0.00019540002,0.00024438775,0.00017795582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015461049,0.00016983246,0.0026110052,0.000341286,0.000016248883,0.0000033295244,0.00014450058,0.00026782602,0.000018260438],"category_scores_gemma":[0.0016962256,0.00011876983,0.00033098523,0.00029774822,0.00040774402,0.000044501605,0.00006223934,0.0004439528,5.7249923e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025791242,0.022134574,0.95969284,0.000071454,0.00015618255,0.0035821144,0.00013938347,0.00021346049,0.004793118,0.0000869614,0.00006995544,0.006480847],"study_design_scores_gemma":[0.017629607,0.049988918,0.9267,0.00023589331,0.00059079425,0.0003078597,0.0003038724,0.000053657386,0.0034927374,0.0005941888,0.000026659347,0.000075821205],"about_ca_topic_score_codex":0.0002831774,"about_ca_topic_score_gemma":0.00029714193,"teacher_disagreement_score":0.032992832,"about_ca_system_score_codex":0.000064997315,"about_ca_system_score_gemma":0.00035278045,"threshold_uncertainty_score":0.4843293},"labels":[],"label_agreement":null},{"id":"W2545179883","doi":"10.1200/jco.2009.27.15_suppl.e17547","title":"Assessment of barriers to patient participation in clinical trials among oncology outpatients at a community teaching hospital in Toronto","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto East General Hospital; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Likert scale; Family medicine; Alternative medicine; Internal medicine; Pathology; Psychology","score_opus":0.6296418078345738,"score_gpt":0.7381948751499177,"score_spread":0.10855306731534387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545179883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978055,0.000060789785,0.000097320764,0.00995648,0.0017690458,0.0010320003,0.000005617674,0.0000068204868,0.009016916],"genre_scores_gemma":[0.98838943,0.00037023993,0.0064582475,0.0042600753,0.0004298368,0.000019340008,0.000005383183,0.000017249276,0.000050216007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9436093,0.034501884,0.019000102,0.0004545794,0.0017595262,0.00067459326],"domain_scores_gemma":[0.8164061,0.16993771,0.008416569,0.00094354653,0.0016353996,0.0026607036],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.20345223,0.00021787734,0.004594279,0.00027439438,0.000089119705,0.00001009611,0.0005449411,0.0018235784,0.00024639518],"category_scores_gemma":[0.5714135,0.00016811653,0.0009822237,0.00021798894,0.0005250994,0.00022373405,0.0003663532,0.011130032,0.0000051839775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059657125,0.013150508,0.79262805,0.0000311331,0.00013290838,0.00024169665,0.0017328825,0.000069551425,0.000047116664,0.0004928082,0.000502131,0.18500549],"study_design_scores_gemma":[0.0117930705,0.11128159,0.87042534,0.0004925757,0.00012963108,0.0000066470657,0.002261126,0.0002860836,0.00001722925,0.001740101,0.0014471016,0.000119493365],"about_ca_topic_score_codex":0.0013493362,"about_ca_topic_score_gemma":0.019543096,"teacher_disagreement_score":0.3679613,"about_ca_system_score_codex":0.0035185788,"about_ca_system_score_gemma":0.0056921146,"threshold_uncertainty_score":0.9999447},"labels":[],"label_agreement":null},{"id":"W2546392269","doi":"10.1200/jco.2006.24.18_suppl.539","title":"Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"FOXO transcription factor regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"FOXA1; GATA3; Breast cancer; Estrogen receptor; Medicine; Immunohistochemistry; Transcription factor; Cancer research; Estrogen; Estrogen receptor alpha; Internal medicine; Cancer; Oncology; Biology; Gene; Genetics","score_opus":0.08140289924343928,"score_gpt":0.4128757887329539,"score_spread":0.3314728894895146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546392269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979177,0.00026764726,0.0010533246,0.00009540718,0.00050302094,0.000088003784,0.00005944161,9.503774e-7,0.000014506791],"genre_scores_gemma":[0.9986303,0.00014673712,0.0009144623,0.000010037431,0.0002700764,0.0000010746501,0.000007050606,0.000009230069,0.000011071613],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997074,0.0006060436,0.0018695703,0.0001278466,0.00021008564,0.00011242197],"domain_scores_gemma":[0.99748504,0.00017883396,0.0018184936,0.00014110252,0.000320242,0.000056312765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016214907,0.000086885586,0.0005860962,0.00010955827,0.000010677256,0.000001446567,0.0001246713,0.0003417074,0.000015658045],"category_scores_gemma":[0.0002177791,0.00007188037,0.00026994248,0.00008224657,0.00019689409,0.000012467459,0.000029435694,0.00015583451,7.255818e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067112558,0.00038089225,0.4009034,0.00002110676,0.00002440781,0.000009181047,0.000012664731,0.00056972494,0.5895671,0.0000027041415,0.000014356156,0.0017831548],"study_design_scores_gemma":[0.0022846372,0.0015692693,0.80374306,0.00012804968,0.0000559749,0.00006118567,0.000014068197,0.000074915435,0.19190435,0.000017712036,0.00010513805,0.0000416132],"about_ca_topic_score_codex":0.00008203211,"about_ca_topic_score_gemma":0.00012707576,"teacher_disagreement_score":0.4028397,"about_ca_system_score_codex":0.000049109844,"about_ca_system_score_gemma":0.0005566593,"threshold_uncertainty_score":0.29311964},"labels":[],"label_agreement":null},{"id":"W2548991426","doi":"10.1200/jco.2015.33.15_suppl.6053","title":"Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Horizon Health Network; Thunder Bay Regional Health Sciences Centre; Saint John Regional Hospital; McGill University; Centre Hospitalier Universitaire de Sherbrooke; Juravinski Cancer Centre; Queen's University; London Health Sciences Centre; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Chemoradiotherapy; Quality of life (healthcare); Gastroenterology; Surgery; Urology; Oncology","score_opus":0.21889621646866742,"score_gpt":0.5159881544397257,"score_spread":0.29709193797105826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548991426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922541,0.0010169096,0.0018487232,0.0011325208,0.0009580828,0.0025982214,0.00002664181,0.0000055268033,0.00015927239],"genre_scores_gemma":[0.99598503,0.001218412,0.0021283643,0.00022381713,0.00033962197,0.000054682252,0.000013392197,0.000027077973,0.000009586718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9858903,0.0056418786,0.0066381856,0.00035045645,0.0012610849,0.00021809393],"domain_scores_gemma":[0.9715385,0.017028758,0.00905119,0.00024475792,0.0018564977,0.00028028397],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017787613,0.0002903709,0.0057913894,0.00027859298,0.000040007133,0.000008570824,0.00015541121,0.00039809514,0.000028838891],"category_scores_gemma":[0.010296031,0.00015790986,0.0004377421,0.0004784899,0.0007324029,0.0002580423,0.000021994496,0.0010815939,9.350935e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8522091,0.007538894,0.095601976,0.00007151809,0.00052145805,0.000014055749,0.0005479931,0.00019041382,0.00006056249,0.000060131864,0.00013042314,0.043053493],"study_design_scores_gemma":[0.7640757,0.08921017,0.14453468,0.00025282393,0.00028152074,0.000008716591,0.0003054553,0.0004093612,0.000045748468,0.00002838398,0.00071940344,0.00012805258],"about_ca_topic_score_codex":0.00017855855,"about_ca_topic_score_gemma":0.000654236,"teacher_disagreement_score":0.088133395,"about_ca_system_score_codex":0.00049147324,"about_ca_system_score_gemma":0.0044517517,"threshold_uncertainty_score":0.9980407},"labels":[],"label_agreement":null},{"id":"W2549545156","doi":"10.1200/jco.2016.69.6203","title":"Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Androgen deprivation therapy; Dementia; Hazard ratio; Prostate cancer; Proportional hazards model; Cumulative incidence; Internal medicine; Incidence (geometry); Cohort; Cohort study; Cancer; Cancer registry; Oncology; Disease; Confidence interval","score_opus":0.06520635983712432,"score_gpt":0.4284426023133785,"score_spread":0.3632362424762542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549545156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298334,0.0010577295,0.000008890418,0.005056343,0.00022842178,0.00038805685,0.0000038290414,0.0000010828815,0.0002723134],"genre_scores_gemma":[0.9874146,0.011832396,0.00016933636,0.0004288211,0.00012372503,0.0000073276915,3.8688614e-7,0.000005500163,0.000017891447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857324,0.0002147415,0.00084704126,0.000081123384,0.00019384244,0.000090008994],"domain_scores_gemma":[0.99633276,0.00071244757,0.002350723,0.000113969814,0.00043787714,0.000052226227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017890695,0.00006461829,0.00065687933,0.000042396245,0.0000702052,0.0000055451314,0.000073719195,0.00007749076,0.00001732843],"category_scores_gemma":[0.0020682837,0.00003045612,0.00008668297,0.0000333876,0.00053095387,0.00008509175,0.000037972197,0.00038516277,3.2419308e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02610301,0.0003560257,0.8250164,0.0000060365105,0.0008074462,0.0000061846617,0.00019559912,0.0000038809676,0.0000015447179,0.0000063589437,0.00011960731,0.1473779],"study_design_scores_gemma":[0.047295626,0.0056901136,0.944741,0.00012165522,0.0004350718,0.0000034191278,0.000049083184,0.00001632573,0.000024027315,0.00021000416,0.0013830907,0.00003057622],"about_ca_topic_score_codex":0.00011315234,"about_ca_topic_score_gemma":0.00020575819,"teacher_disagreement_score":0.14734732,"about_ca_system_score_codex":0.000038857295,"about_ca_system_score_gemma":0.0002948304,"threshold_uncertainty_score":0.24760781},"labels":[],"label_agreement":null},{"id":"W2552235514","doi":"10.1200/jco.2016.68.4480","title":"Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":400,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Obesity; Overweight; Oncology; Cancer; Internal medicine; Psychological intervention; Estrogen receptor","score_opus":0.6184352284105114,"score_gpt":0.566566294170403,"score_spread":0.0518689342401083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552235514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044512987,0.9852793,8.99154e-7,0.012399318,0.0010643011,0.0003246136,0.000034912315,0.0000068157105,0.000444667],"genre_scores_gemma":[0.00043680376,0.99543273,0.00005437893,0.00048206866,0.0032417509,0.000018680903,7.458304e-7,0.000026685095,0.00030614747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996251,0.00051674293,0.0024556129,0.00027554552,0.00028270768,0.00021838062],"domain_scores_gemma":[0.9932321,0.0027566787,0.0028591112,0.0001583194,0.00034247802,0.0006513541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028626246,0.00027194005,0.0051240767,0.00016997378,0.000032852597,0.000011431141,0.00012886312,0.00084496546,0.00015108332],"category_scores_gemma":[0.00077443535,0.00014121036,0.0006656956,0.000037696787,0.00045016682,0.00014969136,0.00010604821,0.0011881501,0.0000033516399],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029004406,0.00023477511,0.0011918037,0.005342207,0.000654553,0.0003721745,0.000029551533,9.961157e-10,1.8770592e-8,0.00008737473,0.0021573848,0.9896401],"study_design_scores_gemma":[0.0010676092,0.002582343,0.021090299,0.052646406,0.0029294486,0.00302412,0.000034256605,1.2969498e-7,1.3386172e-8,0.000046717367,0.9164424,0.0001362711],"about_ca_topic_score_codex":0.00002590916,"about_ca_topic_score_gemma":0.000046416895,"teacher_disagreement_score":0.98950386,"about_ca_system_score_codex":0.00017522131,"about_ca_system_score_gemma":0.004375699,"threshold_uncertainty_score":0.7762302},"labels":[],"label_agreement":null},{"id":"W2552299662","doi":"10.1200/jco.2016.69.2855","title":"National Cancer Data Base: An Important Research Tool, but Not Population-Based","year":2017,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Cancer; Population; Base (topology); Environmental health; Internal medicine","score_opus":0.7596819512929659,"score_gpt":0.6551424435805348,"score_spread":0.10453950771243115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552299662","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052465808,0.00079112034,0.00004518173,0.939736,0.0043377574,0.00034380145,0.00055123185,0.000013446025,0.0017156589],"genre_scores_gemma":[0.08100619,0.00075208,0.006335746,0.8278141,0.080724135,0.000015527929,0.0013304721,0.000068013,0.0019537248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903636,0.0011794214,0.0038387908,0.00062656763,0.0034395233,0.00055209844],"domain_scores_gemma":[0.9852213,0.004817218,0.0044746757,0.0013085984,0.0037728697,0.00040532945],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.02287504,0.0002548347,0.0021329566,0.0003601374,0.00023691119,0.00008167588,0.0016875196,0.0020510145,0.0009504705],"category_scores_gemma":[0.030253375,0.0001909023,0.0004764459,0.00013105037,0.00038224037,0.0005265549,0.00024056941,0.009099046,0.000024870988],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020512906,0.00022109068,0.06024054,0.000067728804,0.000260056,0.0075002937,0.0000047334865,0.000023345914,0.000010316123,0.000017075274,0.91064507,0.018958444],"study_design_scores_gemma":[0.0028750827,0.0038623796,0.13931063,0.000558384,0.00036527784,0.00039551992,0.000011676944,0.0011558431,0.0000050520107,0.00037239984,0.8509025,0.00018523294],"about_ca_topic_score_codex":0.0022375921,"about_ca_topic_score_gemma":0.0008640169,"teacher_disagreement_score":0.111921884,"about_ca_system_score_codex":0.000875992,"about_ca_system_score_gemma":0.025885144,"threshold_uncertainty_score":0.9999628},"labels":[],"label_agreement":null},{"id":"W2558960477","doi":"10.1200/jco.2016.69.6187","title":"Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Obesity; Adipokine; Cancer; Disease; Risk factor; Diabetes mellitus; Type 2 diabetes; Internal medicine; Oncology; Bioinformatics; Insulin resistance; Endocrinology; Biology","score_opus":0.07091216823901572,"score_gpt":0.4629293540692169,"score_spread":0.3920171858302012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558960477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006899833,0.9911736,0.00005336953,0.00006551269,0.0012685915,0.00018192733,0.00016111926,0.0000021253009,0.00019389177],"genre_scores_gemma":[0.00031622668,0.99695337,0.0002297374,0.000115904244,0.0013520801,0.000014557792,0.00001068345,0.000029495957,0.0009779372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99527234,0.0012083995,0.0027777397,0.00026448275,0.0002507208,0.00022630423],"domain_scores_gemma":[0.9907879,0.0007018168,0.0076037943,0.00023065454,0.00046896847,0.00020684567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033051071,0.00024548118,0.0035057473,0.000100571895,0.00003920483,0.000008010792,0.0002464869,0.0011715066,0.00011681031],"category_scores_gemma":[0.0022391523,0.00013703223,0.0009065839,0.00011843112,0.0001733268,0.0000083682335,0.00007616444,0.0007769543,0.0000054397874],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007110404,0.00018167324,0.013699955,0.00035054065,0.0020708991,0.000003863709,0.0000064089045,8.436817e-7,0.0000024409621,0.000037069334,0.0010057174,0.98256946],"study_design_scores_gemma":[0.001606968,0.0009509186,0.0036546225,0.0007769065,0.0041179876,0.00002006732,0.000004443965,2.3702616e-7,0.000005746092,0.0000652259,0.98863256,0.00016433056],"about_ca_topic_score_codex":0.000015481983,"about_ca_topic_score_gemma":0.00009721144,"teacher_disagreement_score":0.98762685,"about_ca_system_score_codex":0.000061624334,"about_ca_system_score_gemma":0.0015522905,"threshold_uncertainty_score":0.90357316},"labels":[],"label_agreement":null},{"id":"W2559591136","doi":"10.1200/jco.2016.69.0958","title":"Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Universitätsklinikum Köln; Rigshospitalet; Universitätsklinikum Tübingen; Monash University; University College Dublin; University of Warwick; Universitätsklinikum Hamburg-Eppendorf; Univerzita Komenského v Bratislave","keywords":"Medicine; Carboplatin; Seminoma; Stage (stratigraphy); Surgery; Orchiectomy; Retrospective cohort study; Chemotherapy; Radiation therapy; Internal medicine; Cisplatin","score_opus":0.22137653877916064,"score_gpt":0.5470195915661841,"score_spread":0.32564305278702343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559591136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994002,0.00083767535,0.00013133854,0.0021629604,0.0005768055,0.0003679687,0.00003144797,0.0000051101647,0.001884701],"genre_scores_gemma":[0.98943,0.00019969793,0.008015378,0.00048596683,0.00068004604,0.000009820982,0.0000026179318,0.000021098655,0.0011553867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642485,0.00016745093,0.0027189746,0.00020247769,0.00029721163,0.00018902078],"domain_scores_gemma":[0.9927362,0.0020403326,0.0037464479,0.00050096883,0.00045833504,0.0005176878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002186389,0.00014360202,0.0019007166,0.000048139358,0.000051000276,0.000010013385,0.00019620529,0.00031520028,0.00007692586],"category_scores_gemma":[0.0073506283,0.00008280013,0.00085605565,0.000020837755,0.00036917432,0.000093565206,0.00006549201,0.0005020848,0.000006157863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012436631,0.0022939143,0.9389463,0.00006924628,0.00081945607,0.0020045345,0.000023743884,0.0000013279245,0.0000046038595,0.000033232645,0.0007991509,0.042567827],"study_design_scores_gemma":[0.02099882,0.021826407,0.94661325,0.0001706684,0.0018318744,0.0001418752,0.000058865135,0.0000810686,0.000011990489,0.00007832596,0.008108218,0.000078655445],"about_ca_topic_score_codex":0.00002203485,"about_ca_topic_score_gemma":0.000031721214,"teacher_disagreement_score":0.04248917,"about_ca_system_score_codex":0.00005502962,"about_ca_system_score_gemma":0.0009625266,"threshold_uncertainty_score":0.87999195},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2559783268","doi":"10.1200/jco.2011.29.7_suppl.131","title":"Intermittent androgen-deprivation therapy in the management of castrate-resistant prostate cancer (CRPCa): Results of a multi-institutional randomized prospective clinical trial.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Randomized controlled trial; Prostate cancer; Quality of life (healthcare); Androgen suppression; Internal medicine; Testosterone (patch); Androgen; Cancer; Urology; Surgery; Hormone","score_opus":0.3080507567097401,"score_gpt":0.5188036444834452,"score_spread":0.2107528877737051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559783268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917327,0.001318192,0.00006626849,0.0016055705,0.0007122471,0.0028454415,0.000020343048,0.0000033322497,0.0016958931],"genre_scores_gemma":[0.98090905,0.016097873,0.002313155,0.0001610981,0.00021897313,0.000109475404,0.000004511628,0.000008823309,0.00017701487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99316174,0.001393114,0.0044724066,0.00023276864,0.00053705345,0.00020290562],"domain_scores_gemma":[0.9948213,0.0015480872,0.002554975,0.00022650509,0.00072097714,0.00012814459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01294635,0.00015050583,0.0019136491,0.0001525812,0.000030745807,0.00000473656,0.00023558999,0.00021099213,0.000041701824],"category_scores_gemma":[0.00124595,0.00007023654,0.00075311644,0.0002304401,0.0009380814,0.000086074906,0.000047529807,0.0007271514,0.0000013845143],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89544016,0.00794892,0.019509949,0.00006259754,0.0017715859,0.00060357415,0.0010067722,0.0000053176195,0.000060499977,0.00037699507,0.00011218073,0.07310147],"study_design_scores_gemma":[0.71408707,0.017239744,0.26576132,0.00036282558,0.00034294513,0.000026795815,0.00047676836,0.000058043213,0.00044866034,0.0004937475,0.00064461835,0.000057493937],"about_ca_topic_score_codex":0.00015468728,"about_ca_topic_score_gemma":0.00007924035,"teacher_disagreement_score":0.24625137,"about_ca_system_score_codex":0.00016177208,"about_ca_system_score_gemma":0.0016110651,"threshold_uncertainty_score":0.44869724},"labels":[],"label_agreement":null},{"id":"W2559811762","doi":"10.1200/jco.2012.30.5_suppl.58","title":"Use of zoledronic acid therapy–associated severe hypophosphatemia to identify poor-prognosis patients with metastatic castration-resistant prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hypophosphatemia; Medicine; Zoledronic acid; Prostate cancer; Internal medicine; Concomitant; Oncology; Urology; Cancer","score_opus":0.1656908690974706,"score_gpt":0.4743631614571913,"score_spread":0.3086722923597207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559811762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459046,0.0013182487,0.0000040458112,0.0025491966,0.0006743187,0.00076733937,0.00005474969,0.0000078804205,0.000033749384],"genre_scores_gemma":[0.99473566,0.0008382454,0.002265771,0.0018549891,0.000093991475,0.000028860186,0.000015678635,0.000025938103,0.00014084674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618477,0.00042016653,0.002235017,0.00016127819,0.00056148553,0.00043728316],"domain_scores_gemma":[0.9947908,0.0008313025,0.0024351205,0.00014154924,0.0009915098,0.00080970686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001448595,0.000183665,0.0013958301,0.00010966127,0.00005615061,0.000010360155,0.00008795942,0.00018762847,0.00010176398],"category_scores_gemma":[0.0013111547,0.00011407062,0.0002491135,0.00026792425,0.00009406186,0.00032250362,0.000022013313,0.00051276357,0.000012756449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013469523,0.004439837,0.93333364,0.00004714573,0.0012979783,0.000078916695,0.0002318604,0.000012344614,0.00020540132,0.0000052916357,0.0012600372,0.045618016],"study_design_scores_gemma":[0.014222704,0.016236588,0.96470577,0.00023558673,0.0007636639,0.000026500524,0.000048547176,0.000004106353,0.00045376827,0.00001651207,0.0031881402,0.0000981262],"about_ca_topic_score_codex":0.00035400968,"about_ca_topic_score_gemma":0.00034235875,"teacher_disagreement_score":0.045519892,"about_ca_system_score_codex":0.00036275428,"about_ca_system_score_gemma":0.0020865584,"threshold_uncertainty_score":0.4651665},"labels":[],"label_agreement":null},{"id":"W2559816502","doi":"10.1200/jco.2012.30.5_suppl.80","title":"Effect of open versus robot-assisted laparoscopic radical prostatectomy on cancer control in patients with clinically localized prostate cancer: Prospective analysis of 1,014 consecutive patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Laparoscopic radical prostatectomy; Urology; Prospective cohort study; Surgical margin; Cancer; Stage (stratigraphy); Surgery; Internal medicine","score_opus":0.041259996157956697,"score_gpt":0.44908084930471265,"score_spread":0.407820853146756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559816502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427325,0.000447496,0.000009700982,0.0006001307,0.0008212808,0.0033089381,0.00022865162,0.00000561587,0.00030491783],"genre_scores_gemma":[0.9979512,0.00077791524,0.00024170493,0.0005280722,0.00010757012,0.00031649513,0.000033772892,0.000029276243,0.000014005186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99329925,0.001487935,0.003605829,0.00039344263,0.00073931477,0.00047421159],"domain_scores_gemma":[0.9876709,0.005647694,0.004567331,0.0002997186,0.0012855907,0.0005287687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003192358,0.00033231053,0.004852842,0.0003660305,0.00003497234,0.000011130294,0.00026924096,0.00033844452,0.00011163712],"category_scores_gemma":[0.002382061,0.00019670873,0.0006210841,0.00083005556,0.0006506036,0.00020825015,0.00008720197,0.0008556387,0.0000016039394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23486236,0.009685598,0.70597327,0.00008904575,0.007160088,0.000027225848,0.00017541664,0.0001738483,0.00000401468,0.00001574247,0.000105951214,0.041727442],"study_design_scores_gemma":[0.14752708,0.113172986,0.7313433,0.0006098068,0.006510812,5.319867e-7,0.000021581616,0.000036175992,0.0002789676,0.000004647618,0.0003692486,0.00012484688],"about_ca_topic_score_codex":0.00040914785,"about_ca_topic_score_gemma":0.00020757724,"teacher_disagreement_score":0.10348739,"about_ca_system_score_codex":0.00096780615,"about_ca_system_score_gemma":0.0019979926,"threshold_uncertainty_score":0.80215496},"labels":[],"label_agreement":null},{"id":"W2559823317","doi":"10.1200/jco.2011.29.7_suppl.147","title":"Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Internal medicine; Androgen deprivation therapy; Randomization; Oncology; Cancer; Clinical trial; Urology; Adverse effect","score_opus":0.15198837334142098,"score_gpt":0.4516235399127012,"score_spread":0.2996351665712802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559823317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951809,0.0009071662,0.000015418567,0.00021330474,0.00017746114,0.0034369342,0.000020833737,0.000005064089,0.000042886593],"genre_scores_gemma":[0.99661547,0.0022339968,0.000971228,0.000027534374,0.00005421458,0.000038749193,0.000020289024,0.000018990007,0.00001950298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568385,0.0011108342,0.0021827456,0.00034462195,0.00042425093,0.0002536826],"domain_scores_gemma":[0.9958363,0.0011508124,0.0019892065,0.00020407113,0.0005473941,0.00027218147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003703358,0.00021190944,0.002493783,0.00020535896,0.00008751241,0.000017967071,0.00013422866,0.00014575805,0.000042420805],"category_scores_gemma":[0.0011111264,0.00012992501,0.00012754776,0.00022680739,0.00037832203,0.00031591253,0.00014203422,0.00052684644,5.356305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36514664,0.008215938,0.5982743,0.00003603576,0.0008715958,0.00011134716,0.0007351023,0.000013321566,0.000013971066,0.000005781269,0.000014086631,0.0265619],"study_design_scores_gemma":[0.42883518,0.02861675,0.54107535,0.00007566901,0.00091412466,0.000008056159,0.000113871734,0.00015091206,0.000045134988,0.000068532965,0.000020381627,0.00007604768],"about_ca_topic_score_codex":0.0008387874,"about_ca_topic_score_gemma":0.000178799,"teacher_disagreement_score":0.06368856,"about_ca_system_score_codex":0.00013818513,"about_ca_system_score_gemma":0.000576705,"threshold_uncertainty_score":0.52981883},"labels":[],"label_agreement":null},{"id":"W2559825321","doi":"10.1200/jco.2011.29.7_suppl.190","title":"Association of baseline risk factors with cardiovascular (CV) events during long-term degarelix therapy in men with prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Prospective cohort study; Proportional hazards model; Cumulative incidence; Regimen; Incidence (geometry); Cancer; Confidence interval; Cohort","score_opus":0.0977173856996109,"score_gpt":0.4240858204945931,"score_spread":0.3263684347949822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559825321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674916,0.0019493153,0.000021133428,0.0004030344,0.0001277592,0.00045785916,0.000010216496,0.0000051138422,0.00027638904],"genre_scores_gemma":[0.9752502,0.023701513,0.00030232494,0.000030223784,0.00019232705,0.000013727053,0.0000042538204,0.000020585305,0.00048486935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971317,0.0006080916,0.0011478525,0.00018166282,0.0006589505,0.00027172983],"domain_scores_gemma":[0.9970763,0.00045235528,0.0014475517,0.00017807333,0.00063003023,0.0002157126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031983315,0.00014134291,0.0012964413,0.00015440166,0.0000317368,0.000002865835,0.000108803586,0.0002087953,0.000089501154],"category_scores_gemma":[0.0004589912,0.000073633666,0.00033640277,0.00020487465,0.0000936106,0.00011847177,0.000021062415,0.0007950211,0.0000010708501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028749391,0.0011973314,0.94716585,0.000046063622,0.0037496914,0.00051405275,0.0006011516,0.000059157497,0.000040125546,2.2691374e-7,0.000043339565,0.017833622],"study_design_scores_gemma":[0.025456708,0.013352629,0.95858157,0.00028739986,0.00058156176,0.000030297988,0.000119672186,0.000010929115,0.0013301319,0.000011713383,0.0001604181,0.0000769963],"about_ca_topic_score_codex":0.0005820204,"about_ca_topic_score_gemma":0.00035582104,"teacher_disagreement_score":0.021752197,"about_ca_system_score_codex":0.00050229987,"about_ca_system_score_gemma":0.0013229226,"threshold_uncertainty_score":0.34540153},"labels":[],"label_agreement":null},{"id":"W2559827739","doi":"10.1200/jco.2012.30.5_suppl.193","title":"Impact of androgen deprivation therapy (ADT) on bone mineral density (BMD) over 3 years in men with nonmetastatic prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Femoral neck; Bone mineral; Osteoporosis; Urology; Osteopenia; Vitamin D and neurology; Internal medicine; Cancer; Oncology","score_opus":0.1003161194509372,"score_gpt":0.4895979066042036,"score_spread":0.3892817871532664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559827739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982151,0.00047442026,0.000003889052,0.0006525998,0.00013351423,0.00029224064,0.0000046308164,0.0000022279974,0.00022137073],"genre_scores_gemma":[0.99716544,0.001023104,0.0009393499,0.00061958,0.0001607746,0.0000046796317,0.000003221911,0.000011321361,0.00007251041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810815,0.00022283502,0.0010975037,0.000089875495,0.00024555708,0.00023606732],"domain_scores_gemma":[0.99790955,0.00044844003,0.0010809976,0.00010742802,0.000127462,0.00032612507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012896869,0.00009797149,0.00094903074,0.00011104833,0.000011176861,0.000001712682,0.00003513945,0.00013311011,0.00006288163],"category_scores_gemma":[0.0002802903,0.000056823566,0.0001751866,0.00012565312,0.00007133876,0.000102156264,0.000008568672,0.00040349437,0.000003958232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017310746,0.0025173377,0.90798324,0.000011964316,0.00031892594,0.00019787048,0.00020790288,0.000019229998,0.00011661032,0.000004188655,0.0005824489,0.07072953],"study_design_scores_gemma":[0.01754711,0.016881013,0.9645085,0.000072773975,0.00011369336,0.00014880327,0.000012920918,0.0000294907,0.00006476253,0.000033957855,0.0005424349,0.000044579476],"about_ca_topic_score_codex":0.0004889943,"about_ca_topic_score_gemma":0.00012061187,"teacher_disagreement_score":0.070684955,"about_ca_system_score_codex":0.00025125116,"about_ca_system_score_gemma":0.0012477584,"threshold_uncertainty_score":0.23171978},"labels":[],"label_agreement":null},{"id":"W2559850178","doi":"10.1200/jco.2011.29.7_suppl.124","title":"Can MRI accurately define tumor boundaries to guide focal salvage after radiotherapy?","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Biopsy; Radiology; Radiation therapy; Prostate cancer; Magnetic resonance imaging; Nuclear medicine; Cancer; Internal medicine","score_opus":0.10212067452287345,"score_gpt":0.4585404308136208,"score_spread":0.35641975629074735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559850178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89105177,0.0015417102,0.012414756,0.08054523,0.0041208086,0.00028552618,0.000004177161,0.000035299898,0.010000717],"genre_scores_gemma":[0.81687874,0.0002562338,0.119054355,0.06017978,0.002769849,0.000006875793,0.0000013580132,0.00004560896,0.00080721214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961901,0.00036417352,0.0023978946,0.0002446559,0.00041544123,0.00038773924],"domain_scores_gemma":[0.9965706,0.00088604883,0.0009500256,0.0002634004,0.00035120637,0.0009787286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004040553,0.00019007691,0.0015404079,0.00018041176,0.0000760465,0.000037407346,0.00028159583,0.00023404445,0.00109648],"category_scores_gemma":[0.007820253,0.0001300665,0.0004925697,0.00015976436,0.0005678522,0.00009397967,0.00007145344,0.001663307,0.000033684282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020774907,0.0028371578,0.255275,0.00010430248,0.0013383148,0.021926576,0.0030458434,0.000023203373,0.0009340375,0.0014351957,0.19702399,0.4952815],"study_design_scores_gemma":[0.0050779204,0.009916216,0.23031609,0.0001366127,0.00024244556,0.002471187,0.000100146164,0.00022162458,0.000086060834,0.00072394224,0.7505474,0.00016037162],"about_ca_topic_score_codex":0.00013773447,"about_ca_topic_score_gemma":0.000055424014,"teacher_disagreement_score":0.5535234,"about_ca_system_score_codex":0.00019283904,"about_ca_system_score_gemma":0.0024599081,"threshold_uncertainty_score":0.99981666},"labels":[],"label_agreement":null},{"id":"W2559857122","doi":"10.1200/jco.2012.30.5_suppl.316","title":"Urothelial cancer: Impact of gender on stage at diagnosis and survival.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Stage (stratigraphy); Carboplatin; Internal medicine; Chemotherapy; Cancer; Radiation therapy; Disease; Oncology; Cisplatin","score_opus":0.24006407378325242,"score_gpt":0.5268482598088098,"score_spread":0.28678418602555733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559857122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997295,0.0023116255,0.0000074756995,0.0009932523,0.0014166206,0.00016463523,0.00004887914,0.0000039186243,0.005080673],"genre_scores_gemma":[0.990422,0.006235437,0.00018219386,0.0008385357,0.0018246574,0.000007369419,0.0000010055563,0.000017896935,0.00047089692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979306,0.00027190777,0.0011346762,0.00011286788,0.00030731887,0.00024263558],"domain_scores_gemma":[0.99691105,0.0013383431,0.0009152691,0.00013809899,0.00017382899,0.00052340154],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001331647,0.00013270727,0.001200471,0.000077705066,0.000027130345,0.0000024693552,0.00006933692,0.00023780456,0.0012669365],"category_scores_gemma":[0.0007272353,0.000079871184,0.00050236715,0.00006387471,0.00015055457,0.00007875926,0.00003839855,0.000412858,0.00001165325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005680894,0.0018223491,0.9397447,0.00002724946,0.00088815106,0.00005530285,0.00015544769,0.000006488936,0.00015510108,0.00003786607,0.0035745895,0.047851823],"study_design_scores_gemma":[0.008329206,0.014531551,0.9450607,0.00005032817,0.0005285491,0.00006595758,0.000032551827,0.0000029768041,0.00050562184,0.000036274832,0.030788895,0.000067442175],"about_ca_topic_score_codex":0.0002139279,"about_ca_topic_score_gemma":0.000035868088,"teacher_disagreement_score":0.04778438,"about_ca_system_score_codex":0.00030125948,"about_ca_system_score_gemma":0.00089641486,"threshold_uncertainty_score":0.99964607},"labels":[],"label_agreement":null},{"id":"W2559885493","doi":"10.1200/jco.2011.29.7_suppl.117","title":"Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Placebo; Internal medicine; Hazard ratio; Bone pain; Population; Bone metastasis; Cancer; Urology; Oncology; Confidence interval; Surgery; Randomized controlled trial; Pathology","score_opus":0.1240587776185652,"score_gpt":0.4656068067404579,"score_spread":0.3415480291218927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559885493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814785,0.00016318914,0.0000019205281,0.00039489852,0.00018333062,0.0009842576,0.000012547201,0.0000011393303,0.000110895395],"genre_scores_gemma":[0.99914885,0.0001180006,0.0005062731,0.00015871151,0.000019322766,0.000006640958,0.0000011074325,0.000008012779,0.000033066313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968552,0.00035383878,0.0022152916,0.00011971267,0.00031107423,0.00014487965],"domain_scores_gemma":[0.9968374,0.0004363092,0.0020543789,0.0001476403,0.00032452017,0.00019977396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010279313,0.00009935921,0.0011356592,0.00007438376,0.000028204993,0.0000011711782,0.000059188358,0.00006644509,0.00003318123],"category_scores_gemma":[0.00033599182,0.000049953727,0.00007967906,0.00014434957,0.00017108713,0.000057746605,0.00002272415,0.00037125917,2.367702e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08487847,0.032848652,0.8432155,0.000051266892,0.00046611938,0.00015339402,0.0014976815,0.0000029373,0.000022707625,0.0000071212867,0.000022461662,0.036833655],"study_design_scores_gemma":[0.11656627,0.054271083,0.8278449,0.00015094827,0.00063490536,0.000014857407,0.00037086877,0.0000045690913,0.000025070734,0.00001866205,0.000065655804,0.000032188535],"about_ca_topic_score_codex":0.0006754467,"about_ca_topic_score_gemma":0.001834991,"teacher_disagreement_score":0.036801465,"about_ca_system_score_codex":0.0000716583,"about_ca_system_score_gemma":0.0009852233,"threshold_uncertainty_score":0.20370539},"labels":[],"label_agreement":null},{"id":"W2559888887","doi":"10.1200/jco.2011.29.7_suppl.108","title":"Long-term results of salvage cryotherapy for prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Cryotherapy; Prostate cancer; Perioperative; Surgery; Salvage therapy; Cancer; Radiation therapy; Retrospective cohort study; Prostate; Internal medicine; Chemotherapy","score_opus":0.2856062605475759,"score_gpt":0.5464977228279001,"score_spread":0.2608914622803242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559888887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875185,0.002673864,0.00009723383,0.0050486103,0.0010138563,0.0006090357,0.000041196505,0.000006706509,0.0029910002],"genre_scores_gemma":[0.98043114,0.011398848,0.003368004,0.00069448515,0.0009780724,0.0000220671,0.000006090031,0.000022588327,0.003078701],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973251,0.00015386145,0.0018779312,0.0001495635,0.0002532544,0.00024025953],"domain_scores_gemma":[0.99640435,0.0009485645,0.00145939,0.00016408923,0.0007409266,0.0002826901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023832393,0.00010081381,0.0010957712,0.000107062915,0.00002504037,0.0000027416356,0.00014555316,0.00022839388,0.00014607029],"category_scores_gemma":[0.0009758657,0.000060606497,0.00044793595,0.00009730163,0.00028274365,0.00007134809,0.000022174045,0.00044281376,0.0000031975069],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13023704,0.003048111,0.41735026,0.0001757446,0.001092048,0.00058332516,0.00085207797,8.832305e-7,0.0011212593,0.000051527666,0.008890541,0.4365972],"study_design_scores_gemma":[0.047365192,0.04971048,0.8702793,0.00031501282,0.0003792967,0.000082591556,0.00006851975,0.00001125703,0.0067485613,0.00061598636,0.024329698,0.00009411094],"about_ca_topic_score_codex":0.000043007512,"about_ca_topic_score_gemma":0.000054201,"teacher_disagreement_score":0.45292905,"about_ca_system_score_codex":0.00011069061,"about_ca_system_score_gemma":0.0019700543,"threshold_uncertainty_score":0.34947917},"labels":[],"label_agreement":null},{"id":"W2559889112","doi":"10.1200/jco.2011.29.7_suppl.114","title":"Use of a surgically derived nomogram to predict high likelihood of Gleason score upgrading for favorable-risk prostate cancer treated with permanent seed brachytherapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Nomogram; Medicine; Prostate cancer; Urology; Prostatectomy; Brachytherapy; High-grade prostatic intraepithelial neoplasia; Cohort; Prostate; Cancer; Gynecology; Oncology; Intraepithelial neoplasia; Internal medicine; Radiation therapy","score_opus":0.1185130998232101,"score_gpt":0.38728169541850893,"score_spread":0.26876859559529886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559889112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957195,0.0008707426,0.00021515467,0.0012709264,0.00027799414,0.0014325446,0.00015610516,0.000012296675,0.000044736404],"genre_scores_gemma":[0.9758538,0.007151775,0.01610702,0.00044504987,0.00021975812,0.00011896654,0.000013803237,0.00003882501,0.000051002502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964399,0.00025038625,0.002323424,0.00028989746,0.00034091977,0.00035550643],"domain_scores_gemma":[0.9934591,0.0014466064,0.0028639832,0.00023992799,0.0014449597,0.0005454444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011748801,0.00023619771,0.0020562073,0.00016048487,0.000038835027,0.000007743929,0.00012954189,0.000235219,0.000060010534],"category_scores_gemma":[0.0008360945,0.00014350619,0.00045758506,0.00026650372,0.00020129408,0.00013300423,0.000029652472,0.00040137678,8.1729814e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041599896,0.0042225765,0.8501051,0.00012701632,0.0019274073,0.00022206186,0.0007713322,0.00007947191,0.0009868571,0.00001832396,0.0003353691,0.09960459],"study_design_scores_gemma":[0.019713206,0.08846989,0.8753836,0.001129599,0.001922836,0.00009475009,0.0001051679,0.00009124041,0.007966128,0.00009691097,0.004873173,0.00015348355],"about_ca_topic_score_codex":0.0009433712,"about_ca_topic_score_gemma":0.0003139399,"teacher_disagreement_score":0.09945111,"about_ca_system_score_codex":0.00021661176,"about_ca_system_score_gemma":0.0015733886,"threshold_uncertainty_score":0.58520126},"labels":[],"label_agreement":null},{"id":"W2559909514","doi":"10.1200/jco.2012.30.5_suppl.61","title":"Inhibition of Src and insulin/insulin-like growth factor-1 receptor (IR/IGF-1R) on tumors and bone turnover in prostate cancer (PCa) models in vivo compared with inhibition of either kinase alone.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Dasatinib; Proto-oncogene tyrosine-protein kinase Src; Medicine; Protein kinase B; Prostate cancer; Cancer research; Endocrinology; Internal medicine; Insulin-like growth factor; Bone remodeling; Phosphorylation; Growth factor; Cancer; Receptor; Chemistry; Tyrosine kinase; Biochemistry","score_opus":0.07637249769221782,"score_gpt":0.38715438254372675,"score_spread":0.3107818848515089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559909514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996261,0.0014417701,0.0000071554355,0.0012954823,0.00020771398,0.0005117956,0.000046896508,0.000004009837,0.00022415932],"genre_scores_gemma":[0.9957443,0.0024252262,0.0007292442,0.00092231226,0.000114838964,0.000013473889,0.000006723367,0.000020595266,0.000023317729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996828,0.00032743195,0.0020291442,0.00019561457,0.00032717784,0.00029263593],"domain_scores_gemma":[0.99703103,0.0005632962,0.0016052736,0.00010375716,0.00028748537,0.00040916097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011837899,0.00018328213,0.0014925728,0.0002893002,0.000019409428,0.0000031509355,0.000026375807,0.00025806628,0.00003283594],"category_scores_gemma":[0.0002560244,0.00012639628,0.00008510573,0.00020732157,0.00024463263,0.00027459915,0.000021902879,0.00070320367,0.0000010404705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040355526,0.0071148095,0.93502724,0.00042340174,0.00015576356,0.00031619644,0.0023235697,0.00005730696,0.002487661,0.00008820489,0.00030732935,0.011343017],"study_design_scores_gemma":[0.041519295,0.013432247,0.9379249,0.0019510867,0.00015144049,0.00013701816,0.00025148,0.00017026543,0.0035630013,0.0003988259,0.0003392803,0.00016111144],"about_ca_topic_score_codex":0.0005635999,"about_ca_topic_score_gemma":0.0009320331,"teacher_disagreement_score":0.011181906,"about_ca_system_score_codex":0.00022213819,"about_ca_system_score_gemma":0.0006161124,"threshold_uncertainty_score":0.5154291},"labels":[],"label_agreement":null},{"id":"W2559923310","doi":"10.1200/jco.2011.29.7_suppl.151","title":"A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Clinical endpoint; Internal medicine; Adverse effect; Sunitinib; Chemotherapy; Phases of clinical research; Clinical trial; Oncology; Urology; Cancer","score_opus":0.31119724182316544,"score_gpt":0.5511332515752233,"score_spread":0.23993600975205787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559923310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322605,0.00066755863,0.000021245281,0.0036860562,0.00029436836,0.0019350718,0.000048816168,0.0000036342958,0.00011720229],"genre_scores_gemma":[0.99503636,0.000761792,0.0021965278,0.00064970745,0.0001358439,0.00028803834,0.0000015595485,0.000020158124,0.0009100283],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962541,0.0007000393,0.0021429635,0.00021833151,0.00035297452,0.00033163073],"domain_scores_gemma":[0.9962912,0.0013524194,0.00091113395,0.00019783978,0.0009187173,0.0003286476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049761077,0.00015203809,0.0012827603,0.0002937353,0.000039478808,0.000006278937,0.00014679795,0.000100006015,0.00018591387],"category_scores_gemma":[0.001487183,0.00009329238,0.00025023962,0.00026569588,0.00015458438,0.00010497139,0.000029536362,0.00046278816,0.0000017941614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8230099,0.036425464,0.021505862,0.000065184526,0.0008715955,0.0025376987,0.0114174085,0.000006613205,0.005036361,0.000017353439,0.00076377543,0.0983428],"study_design_scores_gemma":[0.17076099,0.49879363,0.30403128,0.0003819738,0.0004219468,0.000070310336,0.004711484,0.00002997256,0.0018000118,0.00038756648,0.018431887,0.00017894148],"about_ca_topic_score_codex":0.00020237411,"about_ca_topic_score_gemma":0.0007752735,"teacher_disagreement_score":0.6522489,"about_ca_system_score_codex":0.0001909276,"about_ca_system_score_gemma":0.002872334,"threshold_uncertainty_score":0.5095397},"labels":[],"label_agreement":null},{"id":"W2559925257","doi":"10.1200/jco.2011.29.27_suppl.207","title":"Improvement in the quality of care for patients with locally advanced breast cancer through implementation of an integrated electronic care pathway.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Referral; Multidisciplinary approach; Radiation oncologist; Cancer; Surgery; Internal medicine; Radiation therapy; Family medicine","score_opus":0.04361392035502858,"score_gpt":0.44121804530570774,"score_spread":0.39760412495067915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559925257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983041,0.00055999355,0.00022245212,0.00011661665,0.00012624443,0.00041548346,0.00021338715,8.894574e-7,0.000040775412],"genre_scores_gemma":[0.9976918,0.00028989394,0.0015974836,0.00021554377,0.000081664286,0.000049247268,0.000064208434,0.000009350847,7.742942e-7],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99809945,0.00024202859,0.0011586663,0.0001612008,0.00016551628,0.00017313698],"domain_scores_gemma":[0.99710727,0.000100646444,0.0014672204,0.0001573782,0.00113374,0.00003374733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004987867,0.00011427878,0.00055455294,0.000021587011,0.000024127708,0.0000014743276,0.00019087178,0.00012007613,0.000009839537],"category_scores_gemma":[0.00007562251,0.00006601161,0.00015988409,0.0000647576,0.00012189992,0.000013704243,0.00002874678,0.00014881765,3.902322e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022923637,0.0017354884,0.43417335,0.000113906994,0.00054455164,0.0000019254637,0.004545098,0.000027124031,0.001342437,0.00010536887,0.000022252087,0.53446484],"study_design_scores_gemma":[0.012428552,0.031696063,0.9258636,0.00004423148,0.00013594265,0.0000026242174,0.019562032,4.4199305e-7,0.008879092,0.00007923233,0.0012123864,0.00009575643],"about_ca_topic_score_codex":0.0008202996,"about_ca_topic_score_gemma":0.014116931,"teacher_disagreement_score":0.5343691,"about_ca_system_score_codex":0.00011938061,"about_ca_system_score_gemma":0.0011819795,"threshold_uncertainty_score":0.7877579},"labels":[],"label_agreement":null},{"id":"W2559964267","doi":"10.1200/jco.2011.29.27_suppl.286","title":"The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Trastuzumab; Cohort; Internal medicine; Oncology; Cancer; Gynecology","score_opus":0.12100030117918352,"score_gpt":0.5276321636059318,"score_spread":0.40663186242674826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559964267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978356,0.0006665996,0.00003044803,0.0077266297,0.0011453034,0.0004827882,0.000010067205,0.000004910639,0.011577234],"genre_scores_gemma":[0.9965762,0.0018342511,0.0002569215,0.0006374,0.00049821637,0.000017775736,3.5421468e-7,0.000020755784,0.0001581456],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99545074,0.0013807742,0.0020182743,0.00018960742,0.0006062831,0.00035429906],"domain_scores_gemma":[0.9909728,0.006920099,0.0010719964,0.0002446275,0.00046017344,0.00033028558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006749764,0.00014392716,0.0014366426,0.00011922847,0.0000375143,0.0000037807686,0.00033664415,0.0003131009,0.00023708983],"category_scores_gemma":[0.003392391,0.00007783572,0.0003949796,0.00023163234,0.00055591244,0.000057941714,0.00005277445,0.0019113196,0.00001659311],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05706421,0.0010519462,0.14130612,0.000057856072,0.00026407032,0.0008213698,0.00020910548,0.000024445646,0.0002442481,0.00007133037,0.0012187179,0.7976666],"study_design_scores_gemma":[0.013251209,0.09324263,0.88207996,0.00091577746,0.00013854308,0.00038722053,0.00013235945,0.00005673307,0.0026830083,0.00014884873,0.0068755364,0.00008814781],"about_ca_topic_score_codex":0.00025056332,"about_ca_topic_score_gemma":0.00047365346,"teacher_disagreement_score":0.79757845,"about_ca_system_score_codex":0.0005251306,"about_ca_system_score_gemma":0.0023764374,"threshold_uncertainty_score":0.8303839},"labels":[],"label_agreement":null},{"id":"W2560003588","doi":"10.1200/jco.2012.30.5_suppl.140","title":"Patterns of referral for adjuvant radiotherapy after radical prostatectomy in men with prostate cancer: A population-based analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Perineural invasion; Cancer; Internal medicine; Stage (stratigraphy); Randomized controlled trial; Urology; Gynecology; Surgery","score_opus":0.08933078052148417,"score_gpt":0.4870944906100888,"score_spread":0.3977637100886046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560003588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221075,0.0023433052,0.00037540018,0.0039945687,0.0001426919,0.0008405155,0.000037553036,0.0000044895614,0.00005070049],"genre_scores_gemma":[0.99449444,0.00091073493,0.0033314382,0.0004759956,0.0004267006,0.00012198454,0.000026094105,0.000020242393,0.00019236335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971457,0.00029606276,0.0016154211,0.00016385595,0.00040189418,0.0003770363],"domain_scores_gemma":[0.99739605,0.0007797001,0.0009792611,0.00015126559,0.00033121576,0.0003624932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022774804,0.00013922961,0.0016660829,0.00037505003,0.00001817968,0.000004884681,0.000087641936,0.00020191736,0.00014473153],"category_scores_gemma":[0.00023466385,0.00007843326,0.00042830277,0.00033958192,0.00010485944,0.000121271485,0.000010859086,0.0004982092,3.6877614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060973566,0.0016113179,0.9128114,0.00011316286,0.0013307515,0.00009616598,0.00022823748,0.00013126555,0.00004435506,0.0000074052164,0.00011648195,0.022535883],"study_design_scores_gemma":[0.025370233,0.008778333,0.96009105,0.00018888556,0.0009421839,0.000015990712,0.000061424165,0.0006961742,0.00016726303,0.000024167864,0.0035791309,0.00008515633],"about_ca_topic_score_codex":0.00023621242,"about_ca_topic_score_gemma":0.00026652613,"teacher_disagreement_score":0.04727965,"about_ca_system_score_codex":0.0003978264,"about_ca_system_score_gemma":0.0014688584,"threshold_uncertainty_score":0.31984153},"labels":[],"label_agreement":null},{"id":"W2560022202","doi":"10.1200/jco.2011.29.27_suppl.155","title":"Physician experience and challenges obtaining unfunded oral chemotherapy across Canada.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Family medicine; Psychosocial","score_opus":0.3376887119468509,"score_gpt":0.41123988313451276,"score_spread":0.07355117118766186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560022202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95281243,0.00562915,0.0001880938,0.0037955912,0.0017272448,0.000061421124,0.000012836879,0.0000053219846,0.03576793],"genre_scores_gemma":[0.98287547,0.010097301,0.0013650388,0.0049169855,0.0006022572,0.0000021013798,2.018652e-7,0.00001527065,0.00012538256],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975813,0.000038893344,0.0018119103,0.00021961641,0.000040508312,0.0003077979],"domain_scores_gemma":[0.9971612,0.0002538106,0.0020945182,0.00014958033,0.00008992456,0.00025097147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020329272,0.00012556666,0.0011998059,0.000031375246,0.000062509265,0.000016720789,0.0002879132,0.00021449242,0.00011032567],"category_scores_gemma":[0.000676681,0.00012082221,0.00015355571,0.00005233179,0.000218232,0.0003279385,0.000048740538,0.00039306335,0.000010652633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081609393,0.00042566433,0.1300948,0.000019761546,0.00024405103,0.000090620626,0.0070695183,0.000004208916,0.0000025998722,0.03634329,0.0017451075,0.8231443],"study_design_scores_gemma":[0.0020598017,0.001302515,0.5554429,0.000014886329,0.0000065587346,0.000019990357,0.0010748355,0.000044939203,0.000022419004,0.0132013345,0.4266361,0.00017368008],"about_ca_topic_score_codex":0.01827624,"about_ca_topic_score_gemma":0.04243751,"teacher_disagreement_score":0.8229706,"about_ca_system_score_codex":0.00015604775,"about_ca_system_score_gemma":0.00045704472,"threshold_uncertainty_score":0.98826116},"labels":[],"label_agreement":null},{"id":"W2560029553","doi":"10.1200/jco.2011.29.7_suppl.118","title":"Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Proportional hazards model; Mitoxantrone; Chemotherapy; Oncology; Cancer; Post-hoc analysis","score_opus":0.14391705938219349,"score_gpt":0.45291083745730354,"score_spread":0.3089937780751101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560029553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990617,0.0007436326,0.000007870684,0.0074953893,0.000103908635,0.0003195942,0.00000738417,0.00000477813,0.0007004766],"genre_scores_gemma":[0.9928082,0.0044328794,0.0014930011,0.00018402869,0.00018250407,0.0000115984685,0.000002128042,0.0000152425855,0.00087039097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972408,0.0008785302,0.0010989094,0.00015983367,0.0003833917,0.00023857078],"domain_scores_gemma":[0.9964327,0.001967926,0.0009718598,0.000086296415,0.00031301435,0.00022815455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006440747,0.00011046561,0.00092844135,0.00021684833,0.000034068573,0.000011308577,0.000061803854,0.00014218927,0.00007379252],"category_scores_gemma":[0.00088338205,0.00006879068,0.00011595368,0.00021401145,0.00011880809,0.00014356937,0.000012921434,0.0006242177,7.8178533e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049931444,0.00039840935,0.93068874,0.000028628157,0.0010782891,0.00043615545,0.00092793023,0.0000014507066,0.000423008,0.000006240383,0.00028166868,0.015798038],"study_design_scores_gemma":[0.016258214,0.008816363,0.97232556,0.00015323216,0.00036034547,0.000023819468,0.00020531176,0.00001331706,0.00015435906,0.00024373013,0.0013760217,0.00006974308],"about_ca_topic_score_codex":0.00027621302,"about_ca_topic_score_gemma":0.0004136953,"teacher_disagreement_score":0.041636806,"about_ca_system_score_codex":0.00036542836,"about_ca_system_score_gemma":0.0015271328,"threshold_uncertainty_score":0.28052026},"labels":[],"label_agreement":null},{"id":"W2560051574","doi":"10.1200/jco.2012.30.4_suppl.21","title":"Metabolomic signature of esophageal cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Metabolomics; Esophageal cancer; Medicine; Metabolome; Urinary system; Cancer; Malignancy; Internal medicine; Urine; Oncology; Metabolite; Bioinformatics; Biology","score_opus":0.06797155818574838,"score_gpt":0.44160634948464184,"score_spread":0.37363479129889343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560051574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956689,0.03744374,0.00025321404,0.00079497666,0.0027778982,0.000063303705,0.000012013835,0.000001571147,0.0019643053],"genre_scores_gemma":[0.98226583,0.009957766,0.00377045,0.00063729414,0.0030168404,0.0000022090499,0.0000023666908,0.0000118118105,0.00033540555],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781173,0.00027947294,0.001369343,0.00012254204,0.00016645077,0.00025048002],"domain_scores_gemma":[0.9975366,0.00022100443,0.0015816222,0.0001619176,0.0002944717,0.00020439175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025694396,0.00012041119,0.0009993279,0.00006634255,0.00002662456,0.0000025465986,0.0002463063,0.0003897051,0.00008147168],"category_scores_gemma":[0.001602312,0.00008570539,0.00048076137,0.00009379367,0.00016945829,0.000008031443,0.00011125135,0.0004284506,0.0000027001565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041719587,0.002987787,0.29870367,0.000061800885,0.003726372,0.000032428794,0.00016073564,0.00006759666,0.48926595,0.004072434,0.06755268,0.1291966],"study_design_scores_gemma":[0.0029834337,0.0038364234,0.29053774,0.00001270126,0.00044967563,0.00006583056,0.00010818057,0.000003937306,0.06351437,0.00030416637,0.6380037,0.0001798244],"about_ca_topic_score_codex":0.000007664643,"about_ca_topic_score_gemma":0.0000071123295,"teacher_disagreement_score":0.570451,"about_ca_system_score_codex":0.00001551772,"about_ca_system_score_gemma":0.00048968126,"threshold_uncertainty_score":0.34949642},"labels":[],"label_agreement":null},{"id":"W2560060872","doi":"10.1200/jco.2016.70.5327","title":"Obesity and Cancer: Insights for Clinicians","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; Breast Cancer Research Foundation; American Institute for Cancer Research; U.S. Department of Health and Human Services","keywords":"Medicine; Cancer; Obesity; Internal medicine","score_opus":0.19443516478766215,"score_gpt":0.5321156970189881,"score_spread":0.33768053223132594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560060872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746659,0.00156129,0.00072595436,0.020331565,0.0019443219,0.00015566038,0.000008046135,0.0000053326867,0.00060197606],"genre_scores_gemma":[0.98039573,0.012327648,0.0010113595,0.0031019177,0.0026112443,0.000003523506,2.0666391e-7,0.000009667992,0.0005387038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981977,0.000084818756,0.0013301386,0.00012463577,0.00012827823,0.0001344655],"domain_scores_gemma":[0.99580246,0.002551678,0.00093504734,0.000094140356,0.0003031757,0.00031348807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011735902,0.00007386026,0.001005183,0.00005385413,0.000028993172,0.0000030056256,0.00006436103,0.00026609068,0.0000782185],"category_scores_gemma":[0.0020467031,0.000036515605,0.00033051113,0.00003733773,0.0001827915,0.00006844856,0.000021246418,0.00028151297,0.0000033250726],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027742898,0.00039517455,0.2796681,0.000016408709,0.00016318542,0.000050370443,0.000049805643,1.5179364e-7,0.0001998335,0.00019932985,0.010828237,0.7056551],"study_design_scores_gemma":[0.007093889,0.0071847755,0.38923582,0.00010135085,0.00021870807,0.000051006245,0.000025171405,0.000006134192,0.00007386701,0.0010726404,0.5948911,0.000045521298],"about_ca_topic_score_codex":0.000034628047,"about_ca_topic_score_gemma":0.00019462554,"teacher_disagreement_score":0.7056096,"about_ca_system_score_codex":0.00009198494,"about_ca_system_score_gemma":0.0010951229,"threshold_uncertainty_score":0.24502428},"labels":[],"label_agreement":null},{"id":"W2560077513","doi":"10.1200/jco.2011.29.7_suppl.78","title":"Long-term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2C-T3B).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Prostate cancer; Cryoablation; Prostate; Radiation therapy; Hormonal therapy; External beam radiotherapy; Randomized controlled trial; Urology; Surgery; Cancer; Internal medicine; Ablation","score_opus":0.23414840016786878,"score_gpt":0.534109479044825,"score_spread":0.2999610788769562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560077513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910075,0.0036092312,0.0010745979,0.0009854331,0.00082751823,0.00233331,0.000012951259,0.0000057639513,0.0001436806],"genre_scores_gemma":[0.98416597,0.010616243,0.0031167632,0.0002532265,0.0011894322,0.000093062685,0.0000056341914,0.000020443162,0.00053922855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961226,0.0003646871,0.0027544932,0.00018453381,0.00033397155,0.00023969005],"domain_scores_gemma":[0.9940998,0.0026908966,0.0020830845,0.0001233931,0.00071564683,0.00028716945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004781854,0.00014689745,0.002519742,0.00013348939,0.000036811787,0.000006589202,0.00011672325,0.0002646461,0.0001116078],"category_scores_gemma":[0.0016016713,0.000084515406,0.00065302127,0.000072148374,0.00044120898,0.000136346,0.000028932971,0.00047357669,8.898584e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5707039,0.0005445968,0.28581554,0.000046363486,0.00056563906,0.000032410906,0.00015524693,9.380714e-7,0.00017697233,0.000008527058,0.00002617631,0.14192365],"study_design_scores_gemma":[0.70430326,0.01964446,0.27329156,0.00015024211,0.0004784025,0.000013436144,0.000016475926,0.000013166067,0.001140053,0.00060521404,0.00027709405,0.000066639754],"about_ca_topic_score_codex":0.000025093597,"about_ca_topic_score_gemma":0.000007695472,"teacher_disagreement_score":0.141857,"about_ca_system_score_codex":0.00009177226,"about_ca_system_score_gemma":0.0010344572,"threshold_uncertainty_score":0.34464383},"labels":[],"label_agreement":null},{"id":"W2560088324","doi":"10.1200/jco.2012.30.4_suppl.292","title":"Associations between county-level general surgeon (GS) and gastroenterologist (GA) density and outcomes for hepatobiliary cancer (HBC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Incidence (geometry); Demography; Logistic regression; Socioeconomic status; Mortality rate; Cancer; Bayesian multivariate linear regression; Internal medicine; Linear regression; Surgery; Population; Environmental health; Statistics","score_opus":0.22078057026601539,"score_gpt":0.47210771294320825,"score_spread":0.25132714267719286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560088324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98248214,0.0017845761,0.0001630208,0.01417708,0.0010228957,0.00017594361,0.00010620837,0.00000617925,0.00008197667],"genre_scores_gemma":[0.9913521,0.0013411437,0.001787009,0.003275659,0.0020777062,0.000007344926,0.000008030839,0.000010667316,0.00014033476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808794,0.00016289165,0.0011238559,0.00014030415,0.0001895383,0.000295443],"domain_scores_gemma":[0.99627817,0.0021075539,0.0008536251,0.00008747212,0.00033456663,0.0003386069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002449179,0.00012633084,0.0014451188,0.000056024877,0.000091912334,0.000008303695,0.00005199944,0.000219342,0.000009191395],"category_scores_gemma":[0.0018264711,0.00008863303,0.00028579473,0.000036684414,0.00021309467,0.000114115515,0.00006636546,0.0004278646,5.3139075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045850978,0.00022868977,0.9763657,0.00001796746,0.000684863,0.000012467906,0.00009067055,1.9315026e-7,0.000016121317,0.000022419192,0.009193091,0.012909316],"study_design_scores_gemma":[0.0041480665,0.0015832123,0.9833963,0.000019533516,0.0008542588,0.00005281667,0.000049178845,0.0000068832946,0.000011713057,0.00007281326,0.009740439,0.00006476521],"about_ca_topic_score_codex":0.00018757736,"about_ca_topic_score_gemma":0.00048969453,"teacher_disagreement_score":0.012844551,"about_ca_system_score_codex":0.00014399976,"about_ca_system_score_gemma":0.00029068795,"threshold_uncertainty_score":0.361435},"labels":[],"label_agreement":null},{"id":"W2560098259","doi":"10.1200/jco.2012.30.5_suppl.292","title":"Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; GLUT1; Bladder cancer; Hypoxia (environmental); Biomarker; Immunohistochemistry; Radiation therapy; Oncology; Internal medicine; Univariate analysis; Biopsy; Pathology; Urology; Cancer; Multivariate analysis; Glucose transporter","score_opus":0.037331208602838464,"score_gpt":0.3826690726315741,"score_spread":0.3453378640287357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560098259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98361635,0.0069350135,0.0008641779,0.0010555715,0.0070532155,0.00019186745,0.000034020468,0.000002076902,0.00024771248],"genre_scores_gemma":[0.9709328,0.0062189978,0.0037742208,0.0017489202,0.016300874,0.000031309777,0.000005063417,0.000032634263,0.00095522637],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980441,0.00025164257,0.0010228979,0.00015279838,0.00022864786,0.00029992644],"domain_scores_gemma":[0.99680644,0.00047546122,0.001741828,0.0001539459,0.00061204424,0.00021026854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002072106,0.00013431361,0.0008078601,0.000040710365,0.000023646218,0.0000054820534,0.00015204448,0.00033689078,0.000099915465],"category_scores_gemma":[0.00115778,0.000097701886,0.0004416014,0.00005806321,0.00010374773,0.000015082536,0.000023797385,0.0002443678,9.367481e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04139984,0.0052306424,0.45463482,0.00014904393,0.007820681,0.000022756598,0.00052178657,0.0001839274,0.21610864,0.00011377798,0.11253333,0.16128077],"study_design_scores_gemma":[0.0058905478,0.0049819686,0.19314536,0.000023225932,0.0003901146,0.000020328665,0.00005637454,0.0000034264162,0.0040255804,0.000025170295,0.7912844,0.00015353116],"about_ca_topic_score_codex":0.00001627377,"about_ca_topic_score_gemma":0.00028169187,"teacher_disagreement_score":0.67875105,"about_ca_system_score_codex":0.00007214651,"about_ca_system_score_gemma":0.0010822704,"threshold_uncertainty_score":0.39841673},"labels":[],"label_agreement":null},{"id":"W2560099152","doi":"10.1200/jco.2011.29.7_suppl.90","title":"Predicting intrafraction displacement of the prostate during a five-fraction radiotherapy regimen: Implications for stereotactic body radiotherapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate; Nuclear medicine; Radiation therapy; Fiducial marker; Prostate cancer; Dose fractionation; Displacement (psychology); Regimen; Stereotactic radiotherapy; Radiosurgery; Radiology; Surgery; Internal medicine; Cancer","score_opus":0.05216064959258825,"score_gpt":0.42096607874490893,"score_spread":0.3688054291523207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560099152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77908564,0.0002511557,0.21665697,0.0018642753,0.0008127953,0.0008979482,0.000015830496,0.000020769385,0.00039460062],"genre_scores_gemma":[0.95379174,0.00046462513,0.044048782,0.00017632928,0.0011935569,0.00007226661,0.000001603313,0.000036046997,0.00021507459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975546,0.00029514046,0.0016324524,0.00017903224,0.0001380294,0.00020075502],"domain_scores_gemma":[0.9947589,0.00081585447,0.0037591618,0.00028608853,0.00028622898,0.000093762654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012036093,0.00014375846,0.00066299556,0.0000765162,0.00012868263,0.000009793608,0.00027015214,0.00012466492,0.00009574914],"category_scores_gemma":[0.00013246857,0.00009835034,0.00044883965,0.00011948007,0.0001356782,0.00034821246,0.000019788744,0.0005363558,1.4189008e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057028993,0.002578676,0.7895292,0.000051246505,0.0017990592,0.0000017936065,0.0014006493,0.00014213655,0.03496066,0.0023080683,0.0007504512,0.16077518],"study_design_scores_gemma":[0.012956029,0.010503489,0.8905191,0.00021709828,0.0004477442,0.00009455422,0.00049050135,0.0018156327,0.016155325,0.0089336345,0.057468414,0.0003984901],"about_ca_topic_score_codex":0.000037360103,"about_ca_topic_score_gemma":0.0000029257271,"teacher_disagreement_score":0.17470606,"about_ca_system_score_codex":0.00022249344,"about_ca_system_score_gemma":0.00031667744,"threshold_uncertainty_score":0.40106106},"labels":[],"label_agreement":null},{"id":"W2560125212","doi":"10.1200/jco.2012.30.4_suppl.277","title":"Endoscopic or percutaneous biliary drainage for Klatskin tumors? A large retrospective study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network; St. Michael's Hospital; Mount Sinai Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Klatskin tumor; Biliary drainage; Surgery; Retrospective cohort study; Chemotherapy; Percutaneous; Therapeutic effect; Radiation therapy; Multivariate analysis; Decompression; Internal medicine; Resection","score_opus":0.12861001269050146,"score_gpt":0.4689760652550469,"score_spread":0.34036605256454544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560125212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875775,0.0016390337,0.00013816358,0.0034233904,0.0022621907,0.00078636815,0.00001144979,0.000017579701,0.004144329],"genre_scores_gemma":[0.9901903,0.0001307262,0.0019830968,0.0020501972,0.004570809,0.000018306826,0.0000013042895,0.000026359565,0.0010288601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969242,0.00029476814,0.001737596,0.00021331756,0.00035009658,0.00048000773],"domain_scores_gemma":[0.99597216,0.0019519756,0.0009688923,0.00022582142,0.0004592035,0.000421962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003513455,0.00018236949,0.0019008641,0.00012654564,0.000098709155,0.00000849738,0.00015239387,0.00022528296,0.00021280543],"category_scores_gemma":[0.006533163,0.000112379625,0.0006248083,0.00015182715,0.00013132193,0.0001343343,0.00009075958,0.00086233154,0.00001557028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007077092,0.006250765,0.95965254,0.000060362858,0.0010444077,0.00238872,0.0025935292,1.9402309e-7,0.00009508786,0.00018453696,0.010468201,0.010184559],"study_design_scores_gemma":[0.01018252,0.03531998,0.9072669,0.00006892985,0.00089054124,0.0022820777,0.0030359859,0.000007583818,0.000015828178,0.00022741694,0.040599883,0.00010235022],"about_ca_topic_score_codex":0.000012606369,"about_ca_topic_score_gemma":0.00011692811,"teacher_disagreement_score":0.05238564,"about_ca_system_score_codex":0.00030632477,"about_ca_system_score_gemma":0.000911181,"threshold_uncertainty_score":0.78212786},"labels":[],"label_agreement":null},{"id":"W2560133080","doi":"10.1200/jco.2012.30.4_suppl.289","title":"Fear of cancer recurrence and quality of life among survivors of pancreatic and periampullary neoplasms.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Adenocarcinoma; Pancreatic cancer; Gastroenterology; Psychosocial; Hospital Anxiety and Depression Scale; Periampullary cancer; Distress; Incidence (geometry); Cancer; Oncology; Anxiety","score_opus":0.14294581319959163,"score_gpt":0.47211104008120064,"score_spread":0.329165226881609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560133080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865382,0.011173511,0.00001878846,0.00048878015,0.0011196272,0.00009954942,0.000014311459,0.0000017628646,0.0005454895],"genre_scores_gemma":[0.99129903,0.007673068,0.00035198775,0.00020443028,0.000418986,0.000001495917,7.529267e-7,0.000007939606,0.00004232136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966196,0.00059410115,0.002215259,0.00010667374,0.00030717865,0.00015723392],"domain_scores_gemma":[0.99394226,0.002693722,0.0024122258,0.00014648815,0.0004137091,0.00039159413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004248602,0.00009974029,0.0018904342,0.000075295175,0.000013073224,0.0000016043341,0.000078809004,0.00026407524,0.00009535655],"category_scores_gemma":[0.0033988655,0.000073031464,0.0002233533,0.000117587006,0.0006017848,0.00010034479,0.000054825625,0.00043737947,1.9118887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023504691,0.0003714976,0.9724025,0.00047403658,0.00023335824,0.0000036321842,0.00094242377,0.000001235736,0.0002669587,0.000085244355,0.00012820776,0.022740424],"study_design_scores_gemma":[0.002320994,0.0024995608,0.99184966,0.00029799927,0.00035423302,0.000022358776,0.0009380494,0.000011070638,0.00021691281,0.000051849205,0.0013752576,0.0000620686],"about_ca_topic_score_codex":0.0040287483,"about_ca_topic_score_gemma":0.004447127,"teacher_disagreement_score":0.022678357,"about_ca_system_score_codex":0.000028872513,"about_ca_system_score_gemma":0.0007417881,"threshold_uncertainty_score":0.60902894},"labels":[],"label_agreement":null},{"id":"W2560154122","doi":"10.1200/jco.2011.29.7_suppl.104","title":"A review of radical prostatectomy outcomes in active surveillance patients—The Sunnybrook experience.","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Guideline; Cancer; Biochemical recurrence; Internal medicine; Biopsy; Radiation therapy; Salvage therapy; Retrospective cohort study; Surgery; Urology; Gynecology; Oncology; Pathology; Chemotherapy","score_opus":0.27411762407888474,"score_gpt":0.568808687517933,"score_spread":0.2946910634390483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560154122","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007438185,0.9942217,9.939702e-7,0.00061463757,0.00075574656,0.0018509388,0.00002475859,0.0000036477454,0.0017837936],"genre_scores_gemma":[0.00015801427,0.9984485,0.00012970029,0.0006436314,0.00025249057,0.00009544268,0.000015314201,0.000024316567,0.0002325968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917097,0.0019392008,0.005143547,0.00029247548,0.00054904807,0.00036599935],"domain_scores_gemma":[0.9897226,0.0042757457,0.004533008,0.00039663425,0.0007397006,0.00033229767],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044722334,0.00032058495,0.008055777,0.000226116,0.000026364598,0.0000038748753,0.00049566734,0.0005806608,0.00024586514],"category_scores_gemma":[0.00818603,0.00014132795,0.0018421107,0.00041767888,0.0008196412,0.00007920709,0.00010376336,0.002423913,0.000014001332],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011775433,0.0019749184,0.016006608,0.021682194,0.0006582937,0.00022381406,0.00010058712,4.37625e-9,1.4282472e-8,0.000013628505,0.0017907933,0.9563716],"study_design_scores_gemma":[0.004486372,0.005659358,0.019263048,0.057199974,0.00062199996,0.00009829185,0.000021661126,9.875544e-8,4.8336074e-7,0.000030957202,0.91250324,0.00011454069],"about_ca_topic_score_codex":0.00002041967,"about_ca_topic_score_gemma":0.000011215514,"teacher_disagreement_score":0.95625705,"about_ca_system_score_codex":0.0004507147,"about_ca_system_score_gemma":0.0057057734,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W2560158104","doi":"10.1200/jco.2012.30.15_suppl.e14621","title":"Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Everolimus; Placebo; Hazard ratio; Sunitinib; Internal medicine; Progression-free survival; Neuroendocrine tumors; Randomized controlled trial; Oncology; Urology; Chemotherapy; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.21156457713355445,"score_gpt":0.5061926296216926,"score_spread":0.29462805248813817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560158104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923541,0.001214177,0.00034179896,0.0028498173,0.0006701638,0.00201237,0.000017378294,0.000020159638,0.00052006333],"genre_scores_gemma":[0.98673314,0.0010001668,0.010621006,0.00041820778,0.0009636809,0.000056670644,0.000006888938,0.000047917336,0.00015233584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9885137,0.0047337105,0.0051258532,0.00025100893,0.00074675446,0.00062894804],"domain_scores_gemma":[0.93911594,0.05409431,0.005060215,0.00024145938,0.00070230983,0.00078575057],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01146701,0.0002903402,0.009141358,0.00030526213,0.00005368727,0.00001253417,0.00020175015,0.000043403757,0.0000620646],"category_scores_gemma":[0.068013154,0.00017694104,0.000843385,0.00017809465,0.00056117715,0.00032190589,0.00008410966,0.0012405716,0.0000031597217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90124726,0.0027346124,0.07761365,0.0004340572,0.001273394,0.00094200775,0.0001630843,0.000058761892,0.0011280227,0.00025071777,0.00074193225,0.013412479],"study_design_scores_gemma":[0.8778415,0.04368353,0.049972046,0.00080437266,0.0037399565,0.006320987,0.00087616243,0.00028894257,0.003631918,0.00075458473,0.011759724,0.00032627734],"about_ca_topic_score_codex":0.000019960822,"about_ca_topic_score_gemma":0.000032663036,"teacher_disagreement_score":0.056546144,"about_ca_system_score_codex":0.00006169749,"about_ca_system_score_gemma":0.000800683,"threshold_uncertainty_score":0.9398374},"labels":[],"label_agreement":null},{"id":"W2560162499","doi":"10.1200/jco.2012.30.4_suppl.180","title":"The metabolomic signature of pancreatic cancer in urine.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pancreatic cancer; Metabolomics; Medicine; Urine; Cancer; Internal medicine; Oncology; Bioinformatics; Biology","score_opus":0.04972547131091927,"score_gpt":0.41868958054692407,"score_spread":0.3689641092360048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560162499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9419773,0.05371261,0.00004871229,0.0014298309,0.0015390046,0.000071789014,0.000004520952,6.949492e-7,0.0012155414],"genre_scores_gemma":[0.9629417,0.034442663,0.0008023484,0.00029164742,0.0012209871,0.000004214742,6.536902e-7,0.000007954951,0.00028779925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979189,0.00034626434,0.0012748864,0.000093514784,0.00012886836,0.00023753363],"domain_scores_gemma":[0.99790615,0.00052950816,0.0011321406,0.00015719338,0.00016986993,0.000105126084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033553133,0.00009502583,0.00074095913,0.000048611873,0.000030827596,0.0000031251147,0.0002405694,0.00024563135,0.00002420437],"category_scores_gemma":[0.0022970655,0.000053777294,0.00028828726,0.00010086058,0.00017162126,0.0000054711954,0.000093306626,0.00040616977,0.0000011545911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045840456,0.0019289396,0.5776008,0.000042646425,0.0023867523,0.00001916273,0.00016545969,0.00010683299,0.21920781,0.0037217392,0.018788297,0.17144756],"study_design_scores_gemma":[0.0020256515,0.0016927265,0.5195708,0.000015418507,0.00021025649,0.000025163634,0.00014425577,0.0000064598808,0.011839961,0.0005274482,0.4638346,0.000107226166],"about_ca_topic_score_codex":0.000014579634,"about_ca_topic_score_gemma":0.00006611528,"teacher_disagreement_score":0.44504634,"about_ca_system_score_codex":0.00001784424,"about_ca_system_score_gemma":0.00037331428,"threshold_uncertainty_score":0.2749968},"labels":[],"label_agreement":null},{"id":"W2560181204","doi":"10.1200/jco.2012.30.4_suppl.163","title":"A population-based analysis of prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Oncology; Multivariate analysis; Ascites; Population","score_opus":0.09462465649844944,"score_gpt":0.35435430674611684,"score_spread":0.2597296502476674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560181204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989221,0.00017729349,0.00006381226,0.0001223733,0.00007530921,0.00054457673,0.000009524754,0.0000080168165,0.00007697541],"genre_scores_gemma":[0.9977605,0.0000070915953,0.0019141112,0.000081791724,0.00006441908,0.000009582521,0.00012739071,0.000023694452,0.000011449106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996753,0.00040390313,0.001826263,0.00018915211,0.00050649105,0.00032120734],"domain_scores_gemma":[0.99581116,0.0012784968,0.0017362394,0.000221619,0.00053457584,0.00041793182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009344673,0.00022098335,0.0021905378,0.00065847154,0.000024856303,0.000004089815,0.00009189045,0.00026849093,0.000087076296],"category_scores_gemma":[0.00068129355,0.0001266663,0.00050585036,0.0010450092,0.00010073923,0.00016055926,0.000011729911,0.00041605497,0.000001465103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070890333,0.0047630933,0.9831912,0.000033393255,0.0016518723,0.00015462747,0.00009204988,0.00006158856,0.000010351816,0.000004834812,0.000003738307,0.0029442445],"study_design_scores_gemma":[0.012639611,0.015570928,0.9635459,0.00009072247,0.0065598707,0.000003965371,0.000043184955,0.0011495709,0.00020317707,0.000001694141,0.00006563305,0.00012573205],"about_ca_topic_score_codex":0.00015773227,"about_ca_topic_score_gemma":0.00007793298,"teacher_disagreement_score":0.019645263,"about_ca_system_score_codex":0.0001883098,"about_ca_system_score_gemma":0.00055712624,"threshold_uncertainty_score":0.51653016},"labels":[],"label_agreement":null},{"id":"W2560209468","doi":"10.1200/jco.2011.29.7_suppl.23","title":"Capsaicin, a novel radiosensitizer, acts via a TRPV6 mediated phenomenon.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"TRPV; Capsaicin; TRPV1; DU145; Pharmacology; Transient receptor potential channel; Radiosensitizer; LNCaP; Clonogenic assay; Apoptosis; Medicine; Cancer research; Chemistry; Internal medicine; Receptor; Cancer; Cancer cell; Biochemistry; Radiation therapy","score_opus":0.3451429682934103,"score_gpt":0.4330849101325511,"score_spread":0.08794194183914084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560209468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95540655,0.00014463784,0.0023779487,0.0035034455,0.013443392,0.0002118556,0.000008415431,0.000037405167,0.02486636],"genre_scores_gemma":[0.98971164,0.0004003633,0.0018147867,0.0058646565,0.0017260265,0.00000105013,4.2646968e-7,0.000023293687,0.0004577603],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613005,0.00060017564,0.0021860877,0.00027593152,0.00042681867,0.00038095991],"domain_scores_gemma":[0.9942437,0.002770504,0.002026574,0.00014690791,0.0002501813,0.0005621791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002746687,0.00017374495,0.0011557426,0.00016354841,0.000071435374,0.000009899642,0.00042057782,0.0004395977,0.00055509125],"category_scores_gemma":[0.0081845205,0.00011630946,0.00044889448,0.00025350563,0.00040325572,0.00019328369,0.00007598641,0.0010714314,0.00018941137],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008443902,0.01401207,0.0007689495,0.000044486147,0.00037081985,0.0042204224,0.005289293,0.00006358056,0.77881825,0.0029954743,0.03057776,0.15439498],"study_design_scores_gemma":[0.04332756,0.048940536,0.015731156,0.00021986084,0.0005939113,0.0073485933,0.00086958596,0.0046808627,0.26755586,0.006482556,0.60272646,0.0015230275],"about_ca_topic_score_codex":0.0000154689,"about_ca_topic_score_gemma":0.000008905392,"teacher_disagreement_score":0.57214874,"about_ca_system_score_codex":0.00007949685,"about_ca_system_score_gemma":0.000691226,"threshold_uncertainty_score":0.9798227},"labels":[],"label_agreement":null},{"id":"W2560228393","doi":"10.1200/jco.2011.29.27_suppl.89","title":"Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Proportional hazards model; Cancer; Stage (stratigraphy); Oncology; Cohort; Asymptomatic; Surgery","score_opus":0.06591164866574813,"score_gpt":0.3760716735748223,"score_spread":0.3101600249090742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560228393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444526,0.00038035444,0.000011094747,0.0036291522,0.0005933338,0.00032143577,0.0003595369,0.000001911948,0.00025793278],"genre_scores_gemma":[0.99566483,0.0007406715,0.00058429694,0.0014007717,0.000506703,0.0002504343,0.0000039681395,0.000020467101,0.0008278342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984159,0.00011592272,0.0008465796,0.00021319678,0.0001621179,0.00024626747],"domain_scores_gemma":[0.9975879,0.00030568385,0.001426262,0.00023167745,0.00030332545,0.00014512277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031145028,0.00018211502,0.0008590848,0.00002311906,0.00006257667,0.0000023235066,0.00021116597,0.0001374291,0.00004718853],"category_scores_gemma":[0.00009990324,0.00008941107,0.0003755629,0.000038233626,0.00038521254,0.0000048630636,0.00009243147,0.000094664254,5.202151e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009648523,0.0018912414,0.9575913,0.000022894923,0.0016980645,0.000021659418,0.00023988103,0.000005638514,0.0005135051,0.000018143135,0.00084977923,0.02749938],"study_design_scores_gemma":[0.0075319274,0.009332762,0.95382994,0.000016765145,0.0002410681,0.00007397422,0.00013497283,5.482802e-7,0.0027575118,0.000071385344,0.025905408,0.000103727485],"about_ca_topic_score_codex":0.00014092367,"about_ca_topic_score_gemma":0.001101089,"teacher_disagreement_score":0.027395653,"about_ca_system_score_codex":0.0004020735,"about_ca_system_score_gemma":0.0011743588,"threshold_uncertainty_score":0.36460775},"labels":[],"label_agreement":null},{"id":"W2560233749","doi":"10.1200/jco.2012.30.15_suppl.4109","title":"Biliary tract cancer: A large institutional experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Gallbladder cancer; Klatskin tumor; Biliary tract cancer; Ampulla of Vater; Internal medicine; Cancer; Stage (stratigraphy); Gallbladder; Adenocarcinoma; Gastroenterology; Carcinoma; Gemcitabine; Oncology; Surgery; Resection","score_opus":0.1982081002031606,"score_gpt":0.5087362799872497,"score_spread":0.3105281797840891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560233749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688276,0.01124181,0.000081138576,0.0076174,0.0041170428,0.00008913229,0.0000063075527,0.000008581721,0.00801099],"genre_scores_gemma":[0.98680204,0.002061453,0.00074311544,0.0045975526,0.005552573,0.000008027573,0.0000011892787,0.0000073855854,0.00022668146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978869,0.000120954646,0.0012740969,0.00010423196,0.00031816034,0.00029563427],"domain_scores_gemma":[0.9980066,0.0005569183,0.00064468035,0.000111367866,0.00024825888,0.00043216578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016732601,0.00010051397,0.00092811405,0.00007766444,0.00006883239,0.0000037264067,0.00009995613,0.00020547527,0.00048967154],"category_scores_gemma":[0.0013657676,0.00006601657,0.0004616088,0.000111562505,0.00021628378,0.00022599449,0.000046376044,0.00069628033,0.000022400734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008384535,0.0020353466,0.92842156,0.000015258905,0.00021706706,0.0002310883,0.0008998529,7.6400374e-7,0.000067971,0.0002451104,0.015062095,0.05196541],"study_design_scores_gemma":[0.0027235006,0.0011619235,0.6143245,0.00003507775,0.00015049482,0.0004974066,0.00029324435,0.000004455739,0.000031777978,0.000022038781,0.38070977,0.000045809844],"about_ca_topic_score_codex":0.000024796942,"about_ca_topic_score_gemma":0.000021720969,"teacher_disagreement_score":0.36564767,"about_ca_system_score_codex":0.00017102668,"about_ca_system_score_gemma":0.0014314023,"threshold_uncertainty_score":0.536156},"labels":[],"label_agreement":null},{"id":"W2560249597","doi":"10.1200/jco.2012.30.5_suppl.303","title":"The neoadjuvant management of muscle-invasive bladder cancer (MIBC) in Canada: A national survey of urologists.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Referral; Internal medicine; Cancer; Cystoscopy; General surgery; Oncology; Family medicine; Urinary system","score_opus":0.19055156153014477,"score_gpt":0.4646989688525063,"score_spread":0.27414740732236154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560249597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581594,0.0038384134,0.000012942667,0.0045719915,0.0016706003,0.0002430807,0.000043865588,0.0000012920168,0.0038018976],"genre_scores_gemma":[0.99351513,0.0045288512,0.00024204535,0.0013181781,0.00027105975,0.000008518198,0.0000022788315,0.000008434664,0.00010548698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996808,0.00044753277,0.0018283441,0.00009658227,0.000581523,0.00023800206],"domain_scores_gemma":[0.9950336,0.0025920707,0.0013918972,0.0001265332,0.0006718076,0.00018404408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035500627,0.00009856875,0.0008835205,0.0000569332,0.000020858313,0.000001370413,0.00016559116,0.00012234796,0.00009987287],"category_scores_gemma":[0.0012443444,0.000057417572,0.00017032122,0.00015865109,0.00017630821,0.00005017375,0.00004697257,0.0004041497,0.0000012858021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025707132,0.0010823056,0.89238244,0.00003645704,0.0011005087,0.00011649037,0.00007577531,0.00005815457,0.000017779468,0.00014916646,0.006430638,0.09597956],"study_design_scores_gemma":[0.0046869065,0.0015709897,0.98231626,0.00007172884,0.00022893972,0.000025830868,0.00015378873,0.000011516409,0.0000830607,0.00008208688,0.01072449,0.000044407276],"about_ca_topic_score_codex":0.2985072,"about_ca_topic_score_gemma":0.6804605,"teacher_disagreement_score":0.38195327,"about_ca_system_score_codex":0.00056802615,"about_ca_system_score_gemma":0.009078779,"threshold_uncertainty_score":0.9965388},"labels":[],"label_agreement":null},{"id":"W2560259678","doi":"10.1200/jco.2011.29.7_suppl.285","title":"The neoadjuvant management of bladder cancer in Canada: A survey of genitourinary medical oncologists.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Bladder cancer; Stage (stratigraphy); Genitourinary system; Cystoscopy; Gemcitabine; Cystectomy; Cancer; Gynecology; General surgery; Oncology; Internal medicine; Urinary system","score_opus":0.22134077731878132,"score_gpt":0.4657628962123015,"score_spread":0.24442211889352017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560259678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798612,0.0035335566,0.000018857734,0.003520964,0.0020583554,0.00029474462,0.000023071712,0.0000020860357,0.010687157],"genre_scores_gemma":[0.98970526,0.008750049,0.00040911735,0.0007516542,0.00018278143,0.000008568376,8.552644e-7,0.000010882428,0.00018084171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956704,0.00062732067,0.0026335863,0.00013822493,0.000688481,0.00024202077],"domain_scores_gemma":[0.99596727,0.0015881744,0.0014966369,0.00021526926,0.00043302606,0.00029964297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003949174,0.000119182805,0.001312455,0.00005970104,0.000020844891,9.460567e-7,0.00032462654,0.00021636355,0.0007518002],"category_scores_gemma":[0.00088679226,0.00006642949,0.0002151534,0.00017951889,0.00032822095,0.000030000818,0.00009114013,0.00066190574,0.0000016519758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008286208,0.0018271167,0.6902764,0.000052676492,0.0013604226,0.0030209227,0.0000877271,0.0000047669964,0.000003866604,0.000046498204,0.0059722955,0.2890611],"study_design_scores_gemma":[0.006640484,0.0055161137,0.98117614,0.00017983976,0.00032313305,0.00011514722,0.00024041889,0.00002330933,0.0000700958,0.00009939374,0.0055621318,0.00005379046],"about_ca_topic_score_codex":0.6153971,"about_ca_topic_score_gemma":0.84114414,"teacher_disagreement_score":0.29089972,"about_ca_system_score_codex":0.0004895844,"about_ca_system_score_gemma":0.015537263,"threshold_uncertainty_score":0.9900437},"labels":[],"label_agreement":null},{"id":"W2560287004","doi":"10.1200/jco.2012.30.5_suppl.312","title":"Small cell carcinoma of the genitourinary tract: A 10-year single institution experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Genitourinary system; Chemotherapy; Radiation therapy; Stage (stratigraphy); Urinary system; Small-cell carcinoma; Cancer; Surgery; Chemotherapy regimen; Internal medicine","score_opus":0.20979491479810378,"score_gpt":0.45824200198930054,"score_spread":0.24844708719119676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560287004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820429,0.0005604769,0.0000144265705,0.0018184051,0.0013191941,0.00017837655,0.0000012871852,0.0000041485123,0.014060753],"genre_scores_gemma":[0.99542964,0.000090739966,0.0016397365,0.0003713325,0.0016028766,0.0000029865175,2.5376565e-7,0.000010716981,0.000851749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732167,0.0004226512,0.0013995469,0.000110317196,0.00042882192,0.00031698757],"domain_scores_gemma":[0.9968815,0.00096519146,0.001148198,0.00024603057,0.0003580253,0.00040107095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011108955,0.00009780813,0.00071175466,0.000088596105,0.000042514934,0.00000393286,0.0002708572,0.000052361418,0.00030907936],"category_scores_gemma":[0.004634252,0.000057168534,0.00041255436,0.00015815886,0.00045163417,0.00021799405,0.00011373324,0.0008743122,0.000020453566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039273524,0.010252994,0.9464335,0.00010381139,0.00004290602,0.0023950858,0.00037787505,0.000007535961,0.01619787,0.00008644546,0.0042091617,0.01596546],"study_design_scores_gemma":[0.0055795214,0.017282028,0.78700155,0.00006184874,0.00014355809,0.005097039,0.0007262389,0.000009021251,0.032771494,0.00008370724,0.15115534,0.00008863693],"about_ca_topic_score_codex":0.000010710641,"about_ca_topic_score_gemma":0.000004830971,"teacher_disagreement_score":0.15943193,"about_ca_system_score_codex":0.00010216316,"about_ca_system_score_gemma":0.00089226675,"threshold_uncertainty_score":0.5547967},"labels":[],"label_agreement":null},{"id":"W2560289362","doi":"10.1200/jco.2011.29.18_suppl.lba504","title":"Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Tamoxifen; Raloxifene; Internal medicine; Gynecology; Oncology; Randomized controlled trial; Cancer","score_opus":0.05053709135694542,"score_gpt":0.4167283492334085,"score_spread":0.3661912578764631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560289362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919485,0.0023772533,0.00030048043,0.00041629566,0.0023770244,0.0017916254,0.000013447878,0.0000033359886,0.00077202567],"genre_scores_gemma":[0.98982334,0.004607622,0.0026716725,0.00048804676,0.0015250681,0.00020216823,0.000011282429,0.000030974214,0.0006398428],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924585,0.00229834,0.0044304244,0.00028543503,0.00020073525,0.00032655703],"domain_scores_gemma":[0.993966,0.0018217659,0.0033657954,0.00020856573,0.00038328572,0.00025463087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014963006,0.0001974198,0.0028898348,0.00010884394,0.000024392843,0.00000459814,0.00028175264,0.0009953096,0.00007697626],"category_scores_gemma":[0.0029548488,0.00013437714,0.0012325697,0.00007387867,0.000346191,0.000012822439,0.000070379465,0.00064376,0.0000024672743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94564736,0.003431044,0.0010051463,0.00003811169,0.0012915153,0.0000420903,0.00004774248,0.000009370683,0.0028300008,0.000053431308,0.00049700134,0.04510716],"study_design_scores_gemma":[0.9532113,0.037451282,0.005360266,0.000080639154,0.0005624682,0.00008659821,0.000053800806,0.000034912828,0.00042868248,0.0007369277,0.0018286908,0.00016444467],"about_ca_topic_score_codex":0.000009386804,"about_ca_topic_score_gemma":0.000011201945,"teacher_disagreement_score":0.044942714,"about_ca_system_score_codex":0.00007445247,"about_ca_system_score_gemma":0.0018301335,"threshold_uncertainty_score":0.76767385},"labels":[],"label_agreement":null},{"id":"W2560304542","doi":"10.1200/jco.2011.29.7_suppl.326","title":"Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brain metastasis; Radiosurgery; Sunitinib; Temsirolimus; Sorafenib; Bevacizumab; Renal cell carcinoma; Targeted therapy; Internal medicine; Radiation therapy; Oncology; Neurosurgery; Metastasis; Cancer; Chemotherapy; Radiology; Discovery and development of mTOR inhibitors","score_opus":0.14039510267600167,"score_gpt":0.4085960071780156,"score_spread":0.26820090450201395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560304542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966632,0.00051867304,0.0002731283,0.0009812233,0.000190514,0.0007826688,0.000041300093,0.000007026762,0.00054225576],"genre_scores_gemma":[0.963937,0.00007748943,0.033629462,0.0019842898,0.0001383483,0.00002448058,0.000037621176,0.000030547882,0.00014076201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996352,0.0007773302,0.0019854608,0.00024994707,0.00030936295,0.00032587425],"domain_scores_gemma":[0.99555236,0.0019311219,0.001455793,0.0002159337,0.0004743091,0.00037047075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026769529,0.00022671519,0.0017545262,0.00022584671,0.000032862456,0.0000055603955,0.00013056591,0.00014935576,0.00027227888],"category_scores_gemma":[0.0009111789,0.00012717063,0.0005226589,0.00020327473,0.00014921064,0.000104950275,0.000017380597,0.00045609762,0.000005756361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058443606,0.021165807,0.8182186,0.00005015042,0.001470011,0.0018172782,0.00031252665,0.0000069148073,0.00008654197,0.00007401822,0.005626492,0.09272808],"study_design_scores_gemma":[0.066834226,0.11437651,0.8038648,0.00004416012,0.0009377977,0.00008730977,0.000117771546,0.000022383892,0.001709215,0.00017154095,0.011693361,0.00014092689],"about_ca_topic_score_codex":0.000089004534,"about_ca_topic_score_gemma":0.000053619147,"teacher_disagreement_score":0.093210705,"about_ca_system_score_codex":0.00010765177,"about_ca_system_score_gemma":0.0008404121,"threshold_uncertainty_score":0.51858675},"labels":[],"label_agreement":null},{"id":"W2560325158","doi":"10.1200/jco.2012.30.4_suppl.117","title":"Incorporation of laparoscopic D2 dissection into the management of gastric adenocarcinoma (GCa) in a community-based setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Humber River Regional Hospital; University of Toronto; North York General Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Dissection (medical); Surgery; Lymphadenectomy; Stage (stratigraphy); Regimen; Lymph node; Gastrectomy; Resection margin; General surgery; Laparoscopy; Radiation therapy; Cancer; Internal medicine; Resection","score_opus":0.10010475127070079,"score_gpt":0.4362712211534659,"score_spread":0.3361664698827651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560325158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346423,0.00028386887,0.00058813015,0.0037061246,0.0006666887,0.00023586355,4.4378388e-7,0.0000032696607,0.0010513524],"genre_scores_gemma":[0.9948965,0.00015429336,0.004009505,0.0006009956,0.00025247698,0.0000043774185,0.0000035860453,0.0000066664097,0.0000716211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971131,0.0006757035,0.0017113872,0.00005813655,0.0002985022,0.00014314783],"domain_scores_gemma":[0.9967113,0.0010078006,0.0018251552,0.00021246253,0.00015341066,0.00008987136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005014579,0.00008326785,0.00074187113,0.00022626865,0.000034235563,0.000002777453,0.00017075837,0.00011475398,0.000026343987],"category_scores_gemma":[0.00036640692,0.000053700252,0.00022229222,0.00037722202,0.0001401575,0.00009488125,0.000070218804,0.0007068394,0.0000016527143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012375178,0.0012438194,0.9573023,0.00029627283,0.00020255568,0.000018759161,0.00039901538,0.00005565405,0.0000550341,0.00019003595,0.0005211388,0.03847793],"study_design_scores_gemma":[0.00518391,0.0038092665,0.986801,0.0001941881,0.000480083,0.000016078086,0.0011898007,0.00007763356,0.0001030558,0.00021705737,0.0018927839,0.000035120054],"about_ca_topic_score_codex":0.00010156699,"about_ca_topic_score_gemma":0.000097740856,"teacher_disagreement_score":0.03844281,"about_ca_system_score_codex":0.00013794942,"about_ca_system_score_gemma":0.00020047642,"threshold_uncertainty_score":0.30709046},"labels":[],"label_agreement":null},{"id":"W2560329402","doi":"10.1200/jco.2011.29.7_suppl.312","title":"Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Everolimus; Medicine; Sorafenib; Sunitinib; Internal medicine; Placebo; Renal cell carcinoma; Subgroup analysis; Oncology; Tyrosine-kinase inhibitor; Adverse effect; Gastroenterology; Urology; Hepatocellular carcinoma; Confidence interval; Cancer; Pathology","score_opus":0.049749145513324655,"score_gpt":0.3362646173618153,"score_spread":0.28651547184849063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560329402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503475,0.00043005063,0.000058309764,0.000018881641,0.00034843417,0.003957404,0.00006695869,0.0000047294193,0.00008044802],"genre_scores_gemma":[0.99826807,0.00015664319,0.0012748487,0.000055546254,0.00009959093,0.00005988233,0.000028303017,0.000042871787,0.0000142680965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9870925,0.0031333084,0.007480051,0.00045758515,0.0014506713,0.00038587285],"domain_scores_gemma":[0.98527765,0.0036397986,0.008085736,0.0005168642,0.0020579954,0.0004219675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004198284,0.0004842862,0.009495421,0.0012331612,0.0000310139,0.0000049602836,0.00032958842,0.0002759111,0.00028850895],"category_scores_gemma":[0.0021400137,0.00028343181,0.0021379683,0.0007682065,0.00037836397,0.00016638324,0.00007216176,0.00073427154,0.0000011248195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5507808,0.060480002,0.37572172,0.00006209521,0.0073433095,0.000119756485,0.0019072426,0.000017771004,0.0005633245,0.0000014692758,0.000008077404,0.0029944254],"study_design_scores_gemma":[0.54951614,0.0725849,0.36441004,0.00006994267,0.008691717,0.0000013584935,0.00018667668,0.00006166562,0.0043404386,0.000006174266,0.0000049175696,0.00012600415],"about_ca_topic_score_codex":0.0004984478,"about_ca_topic_score_gemma":0.00010531655,"teacher_disagreement_score":0.012104896,"about_ca_system_score_codex":0.0002611201,"about_ca_system_score_gemma":0.0008177384,"threshold_uncertainty_score":0.9999618},"labels":[],"label_agreement":null},{"id":"W2560340269","doi":"10.1200/jco.2011.29.7_suppl.98","title":"Is it possible to get adequate dose coverage of a clinical target volume (CTV) to account for the possible extra capsular extension in early-stage prostate cancer by low dose rate (LDR) brachytherapy?","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Prostate; Nuclear medicine; Implant; Prostate brachytherapy; Univariate analysis; Dosimetry; Rectum; Stage (stratigraphy); Radiation therapy; Cancer; Urology; Radiology; Surgery; Multivariate analysis; Internal medicine","score_opus":0.14465812022679178,"score_gpt":0.4580543743001751,"score_spread":0.31339625407338334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560340269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679494,0.0028502094,0.0004884188,0.023989901,0.0018684599,0.0023889614,0.00030010022,0.000009140988,0.00015540449],"genre_scores_gemma":[0.9570188,0.012689331,0.003468935,0.023033673,0.0007322132,0.00030318226,0.000009969158,0.00006850335,0.0026753815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930807,0.00057811296,0.00453465,0.00062090706,0.00051064685,0.0006750194],"domain_scores_gemma":[0.99309796,0.002099473,0.0023501127,0.0005915546,0.0009966574,0.0008642338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072314576,0.000362238,0.002516733,0.00019204778,0.000084436644,0.000031934767,0.00039726566,0.00047680177,0.00071969675],"category_scores_gemma":[0.0017446489,0.00022536368,0.00087492843,0.00036942336,0.00022232707,0.00027261509,0.00012261582,0.0010333831,0.000041274783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06331005,0.010861843,0.62513757,0.00018314933,0.0017403277,0.0012224216,0.006405868,0.0007114238,0.0009898772,0.000046853722,0.07552152,0.21386907],"study_design_scores_gemma":[0.024416357,0.03707148,0.80476964,0.0006514812,0.0005171803,0.000026326476,0.00029729382,0.0009206107,0.001866713,0.000397792,0.12874876,0.00031633777],"about_ca_topic_score_codex":0.0011183762,"about_ca_topic_score_gemma":0.0003293172,"teacher_disagreement_score":0.21355273,"about_ca_system_score_codex":0.00032801944,"about_ca_system_score_gemma":0.0023379205,"threshold_uncertainty_score":0.9190064},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2560348793","doi":"10.1200/jco.2011.29.7_suppl.66","title":"High dose rate brachytherapy as a single 15 Gy fraction combined with hypofractionated external beam radiotherapy for intermediate-risk prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; External beam radiotherapy; Urology; Prostate; Radiation therapy; Urinary system; Androgen deprivation therapy; Cancer; Surgery; Internal medicine","score_opus":0.07704621653107536,"score_gpt":0.41296072578990417,"score_spread":0.3359145092588288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560348793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907379,0.0015656549,0.000970698,0.0031274082,0.0024401401,0.0009987613,0.000029852827,0.000026521426,0.00010302787],"genre_scores_gemma":[0.96566117,0.019067157,0.009110526,0.0041279006,0.0015207023,0.00018062307,0.000013980686,0.000057645168,0.0002603132],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99685156,0.0003167782,0.0019033416,0.00031598483,0.0002845712,0.00032778337],"domain_scores_gemma":[0.99320424,0.0019300273,0.003400634,0.000203681,0.0008336885,0.0004277182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016088415,0.00025520351,0.0015099345,0.00014680636,0.00008542363,0.000019665391,0.00012527614,0.00029447634,0.0004901526],"category_scores_gemma":[0.00076313375,0.00016343924,0.00041540453,0.00014269774,0.00023560181,0.0003564109,0.000013241541,0.00080273737,0.000008717723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19660668,0.010043844,0.27063927,0.000045968023,0.0030211597,0.00080328004,0.0003922325,0.000080668135,0.0021952563,0.00006399641,0.0022470034,0.51386064],"study_design_scores_gemma":[0.06427029,0.20435447,0.67935497,0.00038354425,0.0011086105,0.00039640724,0.000113893686,0.00013508069,0.008410808,0.0019409457,0.039273035,0.00025792595],"about_ca_topic_score_codex":0.00059291825,"about_ca_topic_score_gemma":0.0001618763,"teacher_disagreement_score":0.51360273,"about_ca_system_score_codex":0.0006879895,"about_ca_system_score_gemma":0.0016171376,"threshold_uncertainty_score":0.66648585},"labels":[],"label_agreement":null},{"id":"W2560357662","doi":"10.1200/jco.2011.29.7_suppl.91","title":"Dose to regions within the prostate during the learning curve phase in low dose rate (LDR) brachytherapy: Sector analysis of 71 consecutive patients at Princess Margaret Hospital.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate; Brachytherapy; Prostate brachytherapy; Nuclear medicine; Dosimetry; Univariate analysis; Prostate cancer; Wilcoxon signed-rank test; Implant; Urology; Radiation therapy; Surgery; Internal medicine; Mann–Whitney U test; Multivariate analysis; Cancer","score_opus":0.04379183998516917,"score_gpt":0.4003239581282403,"score_spread":0.3565321181430711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560357662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552095,0.00006017223,0.0028294597,0.0005922559,0.00024286192,0.0005254851,0.000019640658,0.0000093442295,0.00019984409],"genre_scores_gemma":[0.99773294,0.00010810959,0.0015549491,0.00027732368,0.0001450227,0.000028713615,0.000003795886,0.000022335811,0.0001268326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961995,0.00128737,0.0018193865,0.00023323485,0.00021066156,0.00024988415],"domain_scores_gemma":[0.99458456,0.0014960282,0.0031388002,0.00028178928,0.00035867488,0.00014015149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002324661,0.00018349134,0.0010238825,0.0001860385,0.00012560528,0.000012369813,0.00043096195,0.00010761535,0.00015168118],"category_scores_gemma":[0.00037516357,0.00010259076,0.00045909674,0.0005828417,0.00035270373,0.0001699149,0.0001042747,0.0009946737,0.0000011738316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004098092,0.002159785,0.9760447,0.0000068986483,0.0016499707,0.000031332984,0.0067801373,0.0015646723,0.00021039043,0.00047472276,0.000071932875,0.0069073513],"study_design_scores_gemma":[0.007397906,0.0067994613,0.9787261,0.00009850853,0.00037816618,0.0000026748032,0.0007541556,0.0006857184,0.0013396689,0.001353323,0.0022312407,0.00023309997],"about_ca_topic_score_codex":0.0000973119,"about_ca_topic_score_gemma":0.00011057712,"teacher_disagreement_score":0.0066742515,"about_ca_system_score_codex":0.00013289141,"about_ca_system_score_gemma":0.0002658113,"threshold_uncertainty_score":0.43214175},"labels":[],"label_agreement":null},{"id":"W2560383530","doi":"10.1200/jco.2011.29.27_suppl.81","title":"Impact of internal mammary node inclusion in the radiation treatment volume on the outcomes of patients with breast cancer treated with locoregional radiation after six years of follow-up.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Univariate analysis; Confounding; Inclusion and exclusion criteria; Internal medicine; Lymph node; Cancer; Oncology; Multivariate analysis; Pathology","score_opus":0.029257389776804896,"score_gpt":0.3485430198192942,"score_spread":0.3192856300424893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560383530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989465,0.0001254335,0.000026955602,0.00051492837,0.000081852595,0.00018155693,0.00006877873,6.774519e-7,0.000053318625],"genre_scores_gemma":[0.99932516,0.0002862249,0.0000870308,0.00018410958,0.00007108566,0.000014803067,0.000012253068,0.000009065193,0.000010299476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985284,0.0002737914,0.0007247279,0.00012226198,0.0002456784,0.00010510563],"domain_scores_gemma":[0.99795705,0.00023591843,0.0013136903,0.00017531092,0.0002785517,0.00003947287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003562447,0.00012744844,0.00052314595,0.000061921724,0.000021080657,0.0000018728008,0.00019161003,0.00012096916,0.00002484352],"category_scores_gemma":[0.000097645185,0.000054950862,0.00024025148,0.00009410877,0.00017674766,0.00001226275,0.00007761939,0.00011743326,2.657519e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0150655955,0.0016417973,0.93626225,0.0000030754704,0.0010530063,0.000009879403,0.00046645067,0.00005384361,0.00004388692,0.0000043799873,0.000098797216,0.04529703],"study_design_scores_gemma":[0.0072016907,0.009337643,0.98270035,0.000039142597,0.00019863939,0.000010719239,0.000035898316,0.0000056052454,0.0003199459,0.000013716693,0.000084094674,0.000052544856],"about_ca_topic_score_codex":0.0007012003,"about_ca_topic_score_gemma":0.00031863118,"teacher_disagreement_score":0.0464381,"about_ca_system_score_codex":0.00013419059,"about_ca_system_score_gemma":0.0003944831,"threshold_uncertainty_score":0.22408311},"labels":[],"label_agreement":null},{"id":"W2560419359","doi":"10.1200/jco.2012.30.5_suppl.304","title":"Neoadjuvant cisplatin/gemcitabine (CG) chemotherapy for muscle-invasive transitional cell carcinoma of the bladder (TCCB): A single-institution experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Chemotherapy; Gemcitabine; Neoadjuvant therapy; Retrospective cohort study; Cystectomy; Contraindication; Medical record; Cisplatin; Bladder cancer; Surgery; Internal medicine; Oncology; Cancer; Pathology; Breast cancer","score_opus":0.1114895497710876,"score_gpt":0.4129933114946542,"score_spread":0.3015037617235666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560419359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885371,0.0006685209,0.0013789955,0.0043724193,0.0020357342,0.0005058343,0.000026735746,0.000005167454,0.002469518],"genre_scores_gemma":[0.992003,0.000110947476,0.0029345253,0.002762199,0.0019983407,0.000018460996,0.000003982775,0.00001863888,0.00014991044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750537,0.00016225863,0.0015270371,0.00014876031,0.00037603267,0.0002805299],"domain_scores_gemma":[0.997057,0.00090713194,0.0011178072,0.00019047868,0.0004498147,0.0002777495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082581304,0.00015985765,0.00093197846,0.000064652595,0.00007174601,0.000004159938,0.00015102916,0.0002857943,0.00024534846],"category_scores_gemma":[0.00055117183,0.00009496156,0.0007577653,0.00012261748,0.0003314711,0.00016398677,0.000017383923,0.00037810748,0.000003486679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029531797,0.03126779,0.5218855,0.0004378206,0.0016498849,0.00017454528,0.01299321,0.0000854579,0.08564085,0.0009322756,0.009434965,0.30596587],"study_design_scores_gemma":[0.034786895,0.016727388,0.8703233,0.00017928338,0.0010714782,0.0004440882,0.0009316125,0.00005260709,0.038504023,0.00045371745,0.036324687,0.00020091432],"about_ca_topic_score_codex":0.000018870936,"about_ca_topic_score_gemma":0.000015391257,"teacher_disagreement_score":0.3484378,"about_ca_system_score_codex":0.00015733794,"about_ca_system_score_gemma":0.0013792436,"threshold_uncertainty_score":0.387242},"labels":[],"label_agreement":null},{"id":"W2560425847","doi":"10.1200/jco.2011.29.7_suppl.175","title":"ECF chemotherapy for liver metastases due to castration-resistant prostate cancer (mCRPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Gastroenterology; Epirubicin; Chemotherapy; Cancer; Urology; Anemia; Oncology; Breast cancer","score_opus":0.2742572706579442,"score_gpt":0.5203774591856515,"score_spread":0.24612018852770728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560425847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770065,0.0026475166,0.00032169235,0.015616969,0.0010598196,0.0012410376,0.00006972833,0.000012792604,0.0020239383],"genre_scores_gemma":[0.95807254,0.004251741,0.026842358,0.005192083,0.0016602258,0.000110600864,0.000008541025,0.00003984462,0.0038220745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978619,0.0001507622,0.0012448754,0.00018215844,0.00027546065,0.00028482074],"domain_scores_gemma":[0.99729294,0.0006915251,0.00061650184,0.00013907971,0.0007783455,0.00048162902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018061752,0.00012555679,0.0009927455,0.000118936114,0.000051005525,0.000009022375,0.00012323831,0.00015978106,0.000631517],"category_scores_gemma":[0.0007398914,0.0000770574,0.00037890492,0.00012333257,0.00013644333,0.000097998345,0.000021167265,0.00036169746,0.000015926438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121925965,0.005098181,0.022602217,0.00020757526,0.002619846,0.0037117626,0.0021816937,0.000008617491,0.0046622837,0.00041330367,0.060200427,0.77636814],"study_design_scores_gemma":[0.037792787,0.07141106,0.34475747,0.0003163229,0.0011720138,0.0004360609,0.0005432981,0.000059819387,0.017709328,0.0013500162,0.52415323,0.00029862358],"about_ca_topic_score_codex":0.00011737686,"about_ca_topic_score_gemma":0.00019974522,"teacher_disagreement_score":0.7760695,"about_ca_system_score_codex":0.0001834247,"about_ca_system_score_gemma":0.002351273,"threshold_uncertainty_score":0.6914668},"labels":[],"label_agreement":null},{"id":"W2560448574","doi":"10.1200/jco.2011.29.7_suppl.218","title":"Development of leptomeningeal carcinomatosis (LC) in advanced prostate cancer patients: Characteristics of six cases in a single institution.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Prostate cancer; Zoledronic acid; Docetaxel; Internal medicine; Cancer; Dexamethasone; Oncology; Surgery","score_opus":0.16401226665325028,"score_gpt":0.42542879876132794,"score_spread":0.2614165321080777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560448574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99881595,0.00021653644,0.000012792264,0.0001353468,0.0003701082,0.00023397127,0.000015128821,0.0000016509216,0.00019849131],"genre_scores_gemma":[0.98108053,0.0002222812,0.018505843,0.000114897666,0.000043326123,0.000011261657,0.000004853709,0.0000074789764,0.00000953666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658865,0.00015690787,0.0027633866,0.000119169876,0.0002107637,0.00016114455],"domain_scores_gemma":[0.99721175,0.0003983184,0.0018233202,0.00008806539,0.00034868685,0.00012983227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010233277,0.00010450954,0.0012262663,0.00019472676,0.000011412144,0.0000010076911,0.000067751775,0.00012396855,0.00005632821],"category_scores_gemma":[0.0012246864,0.00007571538,0.00013945681,0.00016151808,0.0001390878,0.00007861108,0.000036184818,0.00028476998,8.941521e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037869671,0.006444293,0.8254963,0.00008373144,0.00012736424,0.00036002678,0.0014883144,0.00000377138,0.0001687732,0.000021675041,0.0000117006,0.16200705],"study_design_scores_gemma":[0.009133012,0.007570026,0.97886395,0.0004381388,0.00011986783,0.00003216939,0.00025004952,0.0000048199704,0.0014288885,0.000013164999,0.0020860587,0.000059875103],"about_ca_topic_score_codex":0.00012575054,"about_ca_topic_score_gemma":0.00045623182,"teacher_disagreement_score":0.16194718,"about_ca_system_score_codex":0.00028279494,"about_ca_system_score_gemma":0.0015104992,"threshold_uncertainty_score":0.30875838},"labels":[],"label_agreement":null},{"id":"W2560468865","doi":"10.1200/jco.2011.29.7_suppl.57","title":"Three-dimensional ultrasound-based spectroscopic imaging for detection of prostate cancer in men.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Prostatectomy; Histopathology; Medicine; Ultrasound; Prostate; Nuclear medicine; Urology; Radiology; Cancer; Pathology; Internal medicine","score_opus":0.052076281973706735,"score_gpt":0.36266139560859784,"score_spread":0.3105851136348911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560468865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985182,0.00047854046,0.012542704,0.00023321767,0.0006141394,0.00021125088,0.000009222782,0.000015713005,0.00071324175],"genre_scores_gemma":[0.9929512,0.00009269349,0.0066107423,0.00008749349,0.0002108612,0.000023487723,7.0758387e-7,0.000014753338,0.000008075085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985995,0.000033466225,0.0010470441,0.00008292641,0.00009322927,0.00014380975],"domain_scores_gemma":[0.99836975,0.0009648581,0.00037950694,0.00007951996,0.00013560825,0.00007074142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075058924,0.00007735297,0.0004482994,0.00009037308,0.000019033521,0.0000028789786,0.00010264685,0.00010233521,0.00008022058],"category_scores_gemma":[0.0002251128,0.00006347764,0.00015849827,0.0000938763,0.00007440976,0.000071229006,0.000004477107,0.00030907444,0.0000021483102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019789094,0.0016965157,0.43635643,0.00015351597,0.0003476284,0.00002654492,0.00046318193,0.011904271,0.37172064,0.000462213,0.0010745073,0.17381564],"study_design_scores_gemma":[0.010187015,0.0026277385,0.8540727,0.00017660722,0.00026461662,0.000069220005,0.000114116796,0.035322584,0.07573229,0.011182742,0.009915934,0.00033444376],"about_ca_topic_score_codex":0.000060760343,"about_ca_topic_score_gemma":0.000529899,"teacher_disagreement_score":0.41771626,"about_ca_system_score_codex":0.00008620601,"about_ca_system_score_gemma":0.0002596587,"threshold_uncertainty_score":0.25885427},"labels":[],"label_agreement":null},{"id":"W2560470830","doi":"10.1200/jco.2011.29.7_suppl.387","title":"Neoadjuvant temsirolimus in high-risk renal cell carcinoma: Results from a single-center prospective study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Temsirolimus; Nephrectomy; Renal cell carcinoma; Surgery; Urology; Internal medicine; Kidney; Discovery and development of mTOR inhibitors","score_opus":0.1387588322372436,"score_gpt":0.3726228569516508,"score_spread":0.2338640247144072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560470830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98684824,0.0003279924,0.00001977431,0.00046968137,0.0012610374,0.00086579466,0.000034218552,0.000013298096,0.010159972],"genre_scores_gemma":[0.9931386,0.000074393494,0.00493258,0.0003031603,0.0012607112,0.000013634657,0.0000075414637,0.00003636167,0.00023301308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297327,0.0012316464,0.004229711,0.0005384516,0.0006007237,0.0004262203],"domain_scores_gemma":[0.99339116,0.0019693382,0.0030769687,0.00049218774,0.00049192936,0.000578414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003128724,0.00030545332,0.0023147925,0.00028447295,0.00004137989,0.000010319075,0.0002712865,0.00045400762,0.000118941505],"category_scores_gemma":[0.002241612,0.00020606382,0.0005786073,0.000222091,0.00019670812,0.00013061517,0.00012764882,0.0019067308,0.00006106137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0403796,0.027733965,0.8961062,0.000007140162,0.0003459704,0.015450213,0.0024164505,0.000004635125,0.00031486858,0.0000033571948,0.00073619164,0.016501427],"study_design_scores_gemma":[0.060315505,0.07259784,0.8629647,0.000068664565,0.00075181865,0.00027084284,0.00070042704,0.000018778599,0.001129057,0.00032912064,0.0007044375,0.00014883644],"about_ca_topic_score_codex":0.0020668246,"about_ca_topic_score_gemma":0.0009464862,"teacher_disagreement_score":0.044863876,"about_ca_system_score_codex":0.0007433698,"about_ca_system_score_gemma":0.0010245325,"threshold_uncertainty_score":0.8403039},"labels":[],"label_agreement":null},{"id":"W2560485866","doi":"10.1200/jco.2011.29.27_suppl.201","title":"The potential economic impact of the 21-gene recurrence score: Guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Cohort; Oncology; Internal medicine; Population; Stage (stratigraphy); Cancer; Gynecology; Disease","score_opus":0.03596350288879635,"score_gpt":0.37345482368638083,"score_spread":0.3374913207975845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560485866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790484,0.00023101951,0.000039774746,0.0011755156,0.0002394969,0.00020731468,0.000094031624,0.0000010668417,0.000106939384],"genre_scores_gemma":[0.99830765,0.0008113813,0.00041405158,0.00023301462,0.00019402042,0.000012041494,0.0000029990317,0.000011937908,0.00001292546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984147,0.00028433296,0.0008183893,0.00019982214,0.000112206,0.00017054894],"domain_scores_gemma":[0.99798906,0.00024345229,0.001276601,0.00019160456,0.00022220114,0.00007706886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068352075,0.00014847227,0.0005237743,0.000026624592,0.00007518934,0.0000073411634,0.00021509262,0.00015410593,0.000017910394],"category_scores_gemma":[0.00013742156,0.000075341326,0.00023437658,0.000060537706,0.00043085442,0.000009963045,0.00005304866,0.00023283067,2.8918095e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058599263,0.00017910308,0.9878003,0.0000027215208,0.00061623706,0.0000065382055,0.00007668285,0.00045291753,0.0004035123,0.0000068525446,0.00007537464,0.0045198486],"study_design_scores_gemma":[0.0037958017,0.0014535219,0.99235594,0.00004678974,0.000101379796,0.000051337367,0.000024944306,0.00007176867,0.0019289436,0.000066366854,0.00001935167,0.000083845305],"about_ca_topic_score_codex":0.0041715126,"about_ca_topic_score_gemma":0.0017514165,"teacher_disagreement_score":0.0045556636,"about_ca_system_score_codex":0.00020204525,"about_ca_system_score_gemma":0.001280859,"threshold_uncertainty_score":0.6306107},"labels":[],"label_agreement":null},{"id":"W2560522321","doi":"10.1200/jco.2011.29.7_suppl.116","title":"Robotic-assisted radical prostatectomy in a system of universal health care with limited access to high-tech resources.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Prostatectomy; Urology; Grading (engineering); Prostate cancer; Surgical margin; Pathological; Stage (stratigraphy); Surgery; Internal medicine; Cancer; Resection","score_opus":0.12665555604073506,"score_gpt":0.42653799153245786,"score_spread":0.2998824354917228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560522321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919765,0.00065151183,0.00017246146,0.005000174,0.00036134227,0.0008123586,0.000009135621,0.00001577192,0.001000745],"genre_scores_gemma":[0.9908643,0.00024723657,0.007578235,0.0010959033,0.00015785628,0.000015531117,0.000004607491,0.000020670288,0.000015663234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658793,0.00044347826,0.002053621,0.00024638037,0.00037034557,0.00029825792],"domain_scores_gemma":[0.99645656,0.0005355727,0.0016224483,0.00023142218,0.0005223543,0.0006316202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011943214,0.00015821328,0.0019448105,0.00031857056,0.000026669339,0.0000070982987,0.00022424765,0.00023390663,0.000025019546],"category_scores_gemma":[0.00030035438,0.000100934274,0.00020052781,0.0004381629,0.00017999382,0.00009638154,0.00007253579,0.0006399993,0.0000027695658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052159,0.0076172254,0.806705,0.0011216629,0.0011734477,0.008635594,0.0053385263,0.00015711872,0.000028226877,0.00047205703,0.0019858982,0.114606224],"study_design_scores_gemma":[0.02039178,0.05255936,0.9165962,0.0021444836,0.00033124842,0.00035955638,0.00192342,0.00001254331,0.00028096535,0.000010028499,0.0052805534,0.00010987772],"about_ca_topic_score_codex":0.0005972688,"about_ca_topic_score_gemma":0.00049841724,"teacher_disagreement_score":0.11449634,"about_ca_system_score_codex":0.0011090196,"about_ca_system_score_gemma":0.0027495248,"threshold_uncertainty_score":0.4877539},"labels":[],"label_agreement":null},{"id":"W2560526418","doi":"10.1200/jco.2011.29.7_suppl.304","title":"Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Everolimus; Medicine; Hazard ratio; Sorafenib; Sunitinib; Internal medicine; Placebo; Renal cell carcinoma; Oncology; Gastroenterology; Urology; Confidence interval; Hepatocellular carcinoma; Pathology","score_opus":0.11169553886781514,"score_gpt":0.37803803422792326,"score_spread":0.2663424953601081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560526418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971215,0.0004185586,0.000028992445,0.0001795338,0.0004971464,0.0014746211,0.000036142203,0.0000065921554,0.00023687426],"genre_scores_gemma":[0.99678105,0.00019775493,0.0024356453,0.00017560877,0.0002780647,0.00004952347,0.000019217572,0.000039935123,0.000023188193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913959,0.002620512,0.003888651,0.0004810355,0.0011533076,0.0004606194],"domain_scores_gemma":[0.9922292,0.0033206672,0.0028493172,0.00054850033,0.0007140666,0.0003382481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037179936,0.00041612604,0.0035758158,0.0009854762,0.000051179406,0.000013024392,0.00042903307,0.00021131692,0.00038404646],"category_scores_gemma":[0.0013102801,0.00023949887,0.0010299934,0.001180802,0.0002815074,0.00018723922,0.000072496216,0.0011439787,0.000006068174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14559072,0.052092914,0.7740233,0.000055858716,0.0052407836,0.001606726,0.0068775993,0.0000111758145,0.001306716,0.0000080695145,0.000038035534,0.013148128],"study_design_scores_gemma":[0.16646995,0.0868045,0.7364462,0.00006191301,0.006750053,0.000007952652,0.0014135481,0.000035648485,0.0016814402,0.00001644527,0.00012249178,0.00018986786],"about_ca_topic_score_codex":0.0009765087,"about_ca_topic_score_gemma":0.0017328816,"teacher_disagreement_score":0.037577078,"about_ca_system_score_codex":0.00047820763,"about_ca_system_score_gemma":0.00089200126,"threshold_uncertainty_score":0.97664803},"labels":[],"label_agreement":null},{"id":"W2560583067","doi":"10.1200/jco.2012.30.4_suppl.36","title":"The urinary metabolomic signature of Barrett's esophagus.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Metabolomics; Esophagus; Medicine; Urinary system; Barrett's esophagus; Internal medicine; Urine; Gastroenterology; Cancer; Bioinformatics; Adenocarcinoma; Biology","score_opus":0.11144776946956748,"score_gpt":0.4965283075681142,"score_spread":0.38508053809854675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560583067","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42393997,0.55529827,0.000028188022,0.015756235,0.0023981517,0.00030809818,0.000005126351,0.000007238688,0.0022587525],"genre_scores_gemma":[0.9918442,0.0038339675,0.0010435097,0.0007710366,0.0020124975,0.0000036181684,8.675318e-7,0.0000107108535,0.00047962484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972182,0.00050202676,0.0014097639,0.000084244006,0.00046328406,0.0003225014],"domain_scores_gemma":[0.9948852,0.0029664882,0.00101493,0.00020929097,0.00034765125,0.00057645567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045264787,0.000099451194,0.0009973322,0.0000621057,0.00005378772,0.000003825179,0.00019631702,0.00025515386,0.00018169159],"category_scores_gemma":[0.0028414812,0.000048208298,0.0005654578,0.000111312984,0.0003155423,0.00010791889,0.00005994739,0.00118388,0.000023608154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015416498,0.0049196514,0.7558836,0.00005313791,0.0017757702,0.0013138647,0.00014747494,0.000002803891,0.00006221439,0.0015184643,0.024336565,0.19456998],"study_design_scores_gemma":[0.0057767387,0.017248757,0.9398305,0.000036235855,0.0004750047,0.00076460175,0.00010278695,0.0000051033053,0.00095682946,0.000527522,0.03422869,0.00004724217],"about_ca_topic_score_codex":0.0000061156916,"about_ca_topic_score_gemma":0.0000020126542,"teacher_disagreement_score":0.5679042,"about_ca_system_score_codex":0.00010626634,"about_ca_system_score_gemma":0.0012318578,"threshold_uncertainty_score":0.51434356},"labels":[],"label_agreement":null},{"id":"W2560629381","doi":"10.1200/jco.2011.29.7_suppl.75","title":"Quality of life after pelvic radiotherapy with hypofractionated IMRT boost and long-term hormone therapy for locally advanced prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Urology; Hormonal therapy; Radiation therapy; Sexual function; Quality of life (healthcare); Concomitant; Prostate; Urinary system; Hormone therapy; Internal medicine; Cancer; Oncology; Gynecology; Breast cancer","score_opus":0.11413504341226367,"score_gpt":0.4552362708511676,"score_spread":0.3411012274389039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560629381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675983,0.027085496,0.0003082366,0.0037562754,0.0003026368,0.000843329,0.000028619805,0.000007138494,0.00006995749],"genre_scores_gemma":[0.923746,0.06859351,0.004378842,0.0027873444,0.0002739833,0.0001205652,0.000003948776,0.000025279342,0.000070558606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745363,0.00017204868,0.001703977,0.0002230324,0.00023864342,0.00020868178],"domain_scores_gemma":[0.99596447,0.0008974917,0.0018719388,0.00016233601,0.000745424,0.00035836807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011496949,0.00017180447,0.0014718947,0.000070912545,0.00002843739,0.0000050144504,0.00007173964,0.0001860007,0.00010365858],"category_scores_gemma":[0.00027279966,0.0001028771,0.0002607359,0.00008335226,0.00029020425,0.00017876075,0.00001166475,0.0003342751,4.9992855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12454012,0.0023901518,0.5908129,0.00006278916,0.0011597467,0.000100975994,0.00026903616,0.0000032214793,0.00048360555,0.000013088693,0.00022186489,0.27994248],"study_design_scores_gemma":[0.036238797,0.043683328,0.91512805,0.00014793966,0.00017471594,0.000050102604,0.000040734132,0.0000067840883,0.00048099377,0.000082054685,0.003862258,0.000104254104],"about_ca_topic_score_codex":0.00005329854,"about_ca_topic_score_gemma":0.00008111307,"teacher_disagreement_score":0.32431513,"about_ca_system_score_codex":0.00015699906,"about_ca_system_score_gemma":0.0016180287,"threshold_uncertainty_score":0.41952065},"labels":[],"label_agreement":null},{"id":"W2560682371","doi":"10.1200/jco.2011.29.27_suppl.249","title":"The experience of young women diagnosed with breast cancer who undergo fertility preservation (FP) consultation.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Referral; Breast cancer; Family medicine; Fertility preservation; Cancer; Fertility; Systemic therapy; Gynecology; Demographics; Pediatrics; Population; Internal medicine; Demography","score_opus":0.14083541339728656,"score_gpt":0.43674485113685974,"score_spread":0.2959094377395732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560682371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954813,0.00029297938,0.00017039976,0.0022687926,0.0004900192,0.00020656904,0.000004008292,0.0000044582844,0.0010814545],"genre_scores_gemma":[0.9983629,0.00046930666,0.0003434796,0.0003520275,0.00020868967,0.000022804299,4.823386e-7,0.0000047585518,0.00023557931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975765,0.00052180554,0.0013527615,0.0001786698,0.00020332253,0.00016699059],"domain_scores_gemma":[0.994941,0.0019166281,0.0013790951,0.00026191314,0.0013450807,0.0001562696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031134603,0.000084056395,0.0006928606,0.00002622085,0.00006929465,0.0000026946102,0.00016433037,0.00019723085,0.00015693206],"category_scores_gemma":[0.0064539206,0.000041478997,0.00011038397,0.00012217322,0.0010719227,0.0001789772,0.00002979175,0.00047316754,0.000001343248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06043427,0.00086454995,0.91615814,0.00001558608,0.00025133742,0.000029134639,0.004002968,0.000001451266,0.00019083658,0.00008834767,0.00016099414,0.017802365],"study_design_scores_gemma":[0.0029532714,0.0034610804,0.9891006,0.000038217582,0.00007570515,0.00007331756,0.0017641261,0.000017399749,0.00022665979,0.0007159638,0.0015320233,0.000041682724],"about_ca_topic_score_codex":0.00015743263,"about_ca_topic_score_gemma":0.0001864477,"teacher_disagreement_score":0.07294239,"about_ca_system_score_codex":0.00011601765,"about_ca_system_score_gemma":0.0011141555,"threshold_uncertainty_score":0.7726412},"labels":[],"label_agreement":null},{"id":"W2560691627","doi":"10.1200/jco.2011.29.7_suppl.83","title":"Single fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer: Long-term results.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Toxicity; Prostate; Radiation therapy; Urology; Acute toxicity; Biopsy; Surgery; Cancer; Internal medicine","score_opus":0.10776572351883232,"score_gpt":0.42000241160182816,"score_spread":0.3122366880829959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560691627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99024504,0.006559463,0.000015661639,0.0015518814,0.0009567763,0.00057805364,0.00002868281,0.0000057983925,0.00005862693],"genre_scores_gemma":[0.7638123,0.23501545,0.00016767092,0.0004689894,0.00045391495,0.0000398572,0.000009909129,0.000011716984,0.000020171741],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969557,0.00054002565,0.0018944102,0.0002121626,0.0002210572,0.00017664884],"domain_scores_gemma":[0.99506855,0.0016118755,0.002754527,0.00017097213,0.00025712018,0.00013695448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016066651,0.00016671854,0.00091369025,0.00014253308,0.000040434305,0.0000108822205,0.00007913713,0.00019627235,0.000053808886],"category_scores_gemma":[0.00032621267,0.00009281957,0.00022219156,0.00013129099,0.00016992178,0.00023351217,0.000006578853,0.00039790064,0.0000018276689],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014490618,0.004974296,0.47728202,0.0000057186026,0.00028206513,0.0001753044,0.0007865212,0.0000055344026,0.0003023471,0.0000033862807,0.000042027674,0.50165015],"study_design_scores_gemma":[0.023614066,0.056501422,0.9119833,0.000104929444,0.00023859213,0.00006765585,0.00007646184,0.000015568012,0.003417596,0.00024935897,0.0036621636,0.00006889038],"about_ca_topic_score_codex":0.0008073231,"about_ca_topic_score_gemma":0.0002478102,"teacher_disagreement_score":0.5015813,"about_ca_system_score_codex":0.00044423668,"about_ca_system_score_gemma":0.0004652222,"threshold_uncertainty_score":0.37850723},"labels":[],"label_agreement":null},{"id":"W2560712876","doi":"10.1200/jco.2011.29.7_suppl.93","title":"Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Prostate; Urology; Androgen deprivation therapy; Radiation therapy; Cancer; Stage (stratigraphy); Surgery; Internal medicine; Nuclear medicine","score_opus":0.12285335101792888,"score_gpt":0.47119865293363894,"score_spread":0.34834530191571006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560712876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931027,0.0030355037,0.00017226538,0.0012350671,0.000798729,0.0002920824,0.00000780584,0.000015726691,0.0013400831],"genre_scores_gemma":[0.96812516,0.020827414,0.007062214,0.00085886737,0.0013753744,0.000022429233,0.0000029305647,0.00003396245,0.0016916174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736786,0.0002685525,0.0014592075,0.00020189451,0.0003972836,0.000305227],"domain_scores_gemma":[0.99627584,0.00084382965,0.0017070523,0.0001461814,0.00058266765,0.000444401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016595896,0.00015844846,0.00106077,0.00015891063,0.000064161184,0.000009764818,0.00013328872,0.00022265733,0.00071637874],"category_scores_gemma":[0.0006520329,0.000087058645,0.00027964066,0.00015726917,0.00033293932,0.00022970475,0.00002147009,0.0012363642,0.000010832181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029610574,0.0013143368,0.65767205,0.000017819422,0.0009859324,0.0014749906,0.00055462535,0.000008526018,0.00046363988,0.000003949615,0.00083656824,0.30705696],"study_design_scores_gemma":[0.02742063,0.033183534,0.918024,0.00035412642,0.00057119475,0.0007646285,0.00023668706,0.00013656555,0.002211094,0.00017978047,0.016773151,0.00014459662],"about_ca_topic_score_codex":0.00037987522,"about_ca_topic_score_gemma":0.00007586577,"teacher_disagreement_score":0.30691236,"about_ca_system_score_codex":0.00032422083,"about_ca_system_score_gemma":0.0021394913,"threshold_uncertainty_score":0.7843845},"labels":[],"label_agreement":null},{"id":"W2560724357","doi":"10.1200/jco.2011.29.27_suppl.200","title":"Results of a pilot study of a web-based care plan to meet the communication needs of breast cancer survivors and their primary care physicians.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Focus group; Medicine; Feeling; Information needs; Needs assessment; Breast cancer; Stakeholder; Qualitative research; Medical education; Nursing; Cancer; Psychology; World Wide Web; Computer science; Internal medicine","score_opus":0.15156313411469172,"score_gpt":0.4131411255300197,"score_spread":0.261577991415328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560724357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895961,0.00036864972,0.000004234366,0.0014062849,0.00045209823,0.00036706144,0.00013680085,0.0000040379878,0.0076647103],"genre_scores_gemma":[0.9991748,0.00016341945,0.00016223376,0.00035748052,0.000115375246,0.000007806804,0.0000017488136,0.000008903242,0.000008234544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553007,0.0020961035,0.0017358136,0.00010172271,0.00038147107,0.00015483216],"domain_scores_gemma":[0.9927035,0.003150423,0.0024738512,0.000350583,0.0012083777,0.00011324341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038320906,0.00010262589,0.00096017093,0.000121262536,0.00010182418,0.0000044459493,0.00075022446,0.0001328841,0.0000123705195],"category_scores_gemma":[0.00069413125,0.00006503453,0.00013908546,0.00036899766,0.0007839327,0.00009116198,0.00011848736,0.00031113025,1.8075389e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010298936,0.0040969807,0.4645631,0.00012347428,0.00030035802,0.000005983252,0.44928592,0.000066153014,0.00016636684,0.0003325586,0.0010844946,0.06967568],"study_design_scores_gemma":[0.0035069673,0.009830481,0.6056675,0.00018647376,0.00013175687,0.0000013308762,0.3790299,0.0000040073387,0.000060663708,0.00011014536,0.0013912995,0.000079532125],"about_ca_topic_score_codex":0.02634268,"about_ca_topic_score_gemma":0.12112604,"teacher_disagreement_score":0.14110436,"about_ca_system_score_codex":0.00011175849,"about_ca_system_score_gemma":0.0017924296,"threshold_uncertainty_score":0.980141},"labels":[],"label_agreement":null},{"id":"W2560726134","doi":"10.1200/jco.2012.30.5_suppl.155","title":"Promoting consultation recording practice in oncology: Identification of critical implementation factors and determination of patient benefit.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Active listening; Anxiety; Family medicine; Breast cancer; Cancer; Internal medicine; Psychology; Psychiatry","score_opus":0.40521257597432025,"score_gpt":0.6327372177729476,"score_spread":0.2275246417986273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560726134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902695,0.00059202546,0.00026856645,0.006266336,0.0016918747,0.00066510704,0.0000111314985,0.0000056857098,0.00022976387],"genre_scores_gemma":[0.9881984,0.0003610182,0.01095242,0.00029227635,0.00014052808,0.000030460866,0.000011089268,0.000011517346,0.0000022930253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9884053,0.004549813,0.0062901396,0.00013790217,0.0003432171,0.00027365086],"domain_scores_gemma":[0.9502014,0.037895683,0.009331922,0.00018770859,0.0021891668,0.00019413748],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007364702,0.00010350554,0.0008022455,0.0002799634,0.00013665947,0.000002903821,0.00015055414,0.00042714673,0.000033818986],"category_scores_gemma":[0.067410745,0.00009001906,0.000091662965,0.00023320269,0.00018794888,0.00090027996,0.00010476597,0.0010122281,0.0000020235145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004931936,0.001085789,0.6377602,0.0003095673,0.00002469982,0.0000016624086,0.05992446,0.0000018029373,0.00085045595,0.0012968726,0.000033372562,0.2982179],"study_design_scores_gemma":[0.0045280317,0.0054135234,0.80845267,0.0004744935,0.00022768513,0.000023151424,0.17252028,0.0005405299,0.0011988693,0.0024263347,0.004043124,0.00015128682],"about_ca_topic_score_codex":0.00023687685,"about_ca_topic_score_gemma":0.00021677163,"teacher_disagreement_score":0.2980666,"about_ca_system_score_codex":0.00043997352,"about_ca_system_score_gemma":0.0010827013,"threshold_uncertainty_score":0.9404448},"labels":[],"label_agreement":null},{"id":"W2560729232","doi":"10.1200/jco.2011.29.7_suppl.42","title":"Use of genetic instability to predict biochemical recurrence in intermediate-risk prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Internal medicine; Cancer; Hormonal therapy; Oncology; Radiation therapy; Prostate; Cohort; Urology; Prostatectomy","score_opus":0.23790406165585926,"score_gpt":0.49077265823531163,"score_spread":0.2528685965794524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560729232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687856,0.0008622944,0.000021392018,0.00092868035,0.00065972266,0.00044531925,0.0000300113,0.000004259567,0.00016973905],"genre_scores_gemma":[0.98846155,0.0072068833,0.0038182368,0.00020435231,0.00022032489,0.000018454908,0.0000015910496,0.000010107857,0.000058474692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642855,0.00041518116,0.0023434,0.00021982582,0.00031955302,0.00027348264],"domain_scores_gemma":[0.99661285,0.0011529181,0.0010036939,0.0002135618,0.00052906456,0.00048789338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021237298,0.000115524854,0.001073655,0.00018127041,0.000012154785,0.0000033107194,0.00017968562,0.00024438364,0.00013617011],"category_scores_gemma":[0.007800721,0.00007523874,0.00023383409,0.00027105107,0.0004295658,0.00009348938,0.00010361659,0.00098871,0.0000054383345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0130989915,0.0016153839,0.82247066,0.000054541204,0.000112107286,0.00023924865,0.00059160223,0.000003941439,0.00030125765,0.0000019290555,0.001038353,0.160472],"study_design_scores_gemma":[0.004560981,0.014561566,0.97404337,0.00031852053,0.00012613417,0.000027940707,0.00007176793,0.000047459464,0.002478873,0.00020522659,0.0034931956,0.00006497719],"about_ca_topic_score_codex":0.00031233556,"about_ca_topic_score_gemma":0.00016291732,"teacher_disagreement_score":0.16040702,"about_ca_system_score_codex":0.00024663302,"about_ca_system_score_gemma":0.0023180675,"threshold_uncertainty_score":0.93387556},"labels":[],"label_agreement":null},{"id":"W2560741749","doi":"10.1200/jco.2011.29.7_suppl.295","title":"CD151 as a prognostic indicator in malignancy of the bladder and prostate.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Prostatectomy; Cystectomy; Malignancy; Prostate; Stage (stratigraphy); Cohort; Pathology; Urology; Oncology; Internal medicine; Bladder cancer; Cancer; Biology","score_opus":0.1492005816146881,"score_gpt":0.4662809874682588,"score_spread":0.31708040585357067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560741749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059427,0.00039098551,0.000004842312,0.002977356,0.00018002263,0.0003489257,6.8651804e-7,0.0000017969508,0.00550113],"genre_scores_gemma":[0.9968405,0.0005114816,0.0013345494,0.00079961127,0.00009985613,0.0000042491324,1.5607671e-7,0.000010304449,0.00039928945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728006,0.00047192574,0.001566886,0.00012494485,0.00037580245,0.00018035651],"domain_scores_gemma":[0.9973578,0.0010574908,0.0009424649,0.00016857083,0.0002226007,0.0002510965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025002572,0.00007418676,0.0007274777,0.00014259834,0.0000141767605,0.0000023506777,0.00017751622,0.00023531748,0.0003594805],"category_scores_gemma":[0.007826753,0.000040377385,0.00018438173,0.0001790783,0.00042342875,0.00003748993,0.00012865131,0.00095603656,0.000017658293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024994193,0.0019479505,0.9517213,0.000059344657,0.00010803357,0.0009721759,0.0005309626,1.5524913e-7,0.001261553,0.00016335314,0.00076594995,0.039969813],"study_design_scores_gemma":[0.004055444,0.00852274,0.97954535,0.00016783572,0.00009385922,0.00047376085,0.0001467044,0.0000108581,0.0009585376,0.0009598258,0.00502591,0.000039148304],"about_ca_topic_score_codex":0.00002332009,"about_ca_topic_score_gemma":0.00001621945,"teacher_disagreement_score":0.039930664,"about_ca_system_score_codex":0.00003563837,"about_ca_system_score_gemma":0.0017191097,"threshold_uncertainty_score":0.93699193},"labels":[],"label_agreement":null},{"id":"W2560743903","doi":"10.1200/jco.2011.29.7_suppl.249","title":"Prognostic factors of cancer recurrence and progression in non-muscle-invasive urothelial carcinoma: A multicenter study of over 4,300 patients.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Proportional hazards model; Oncology; Cancer; Disease; Tumor progression; Stage (stratigraphy); Population; Carcinoma in situ; Chemotherapy; Urology","score_opus":0.11276722229075488,"score_gpt":0.4469037268728961,"score_spread":0.3341365045821412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560743903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979039,0.00026859314,0.0000019706686,0.00004411434,0.00065944245,0.0009044615,0.00001417928,0.0000017864119,0.00020155132],"genre_scores_gemma":[0.99929065,0.00023128708,0.0002451977,0.000071884344,0.00012178205,0.000017360242,9.1701145e-7,0.000012631457,0.000008278507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973237,0.0002556254,0.0017346969,0.00019005704,0.0003280449,0.00016789071],"domain_scores_gemma":[0.99707186,0.000659166,0.0015208791,0.00012816908,0.00042801673,0.00019188388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049697387,0.00014223105,0.0011537522,0.00013956454,0.000014240887,0.0000016610367,0.00010522064,0.00018154172,0.00008502028],"category_scores_gemma":[0.0011778494,0.00008887107,0.00016018796,0.00011416646,0.00017352687,0.00008824552,0.0000572333,0.00043204715,4.92363e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050844857,0.012835709,0.9429332,0.000086525295,0.0001875805,0.000097202326,0.003925813,3.3564035e-7,0.00006885844,6.484417e-7,0.00003475154,0.034744885],"study_design_scores_gemma":[0.020649815,0.038743924,0.9385285,0.00043936042,0.00048418477,0.0000030695726,0.00059535215,0.0000080244035,0.00043397487,0.000014672879,0.000036460347,0.000062697756],"about_ca_topic_score_codex":0.00089232053,"about_ca_topic_score_gemma":0.00065979536,"teacher_disagreement_score":0.03468219,"about_ca_system_score_codex":0.000078586665,"about_ca_system_score_gemma":0.0007745256,"threshold_uncertainty_score":0.36240572},"labels":[],"label_agreement":null},{"id":"W2560750372","doi":"10.1200/jco.2011.29.7_suppl.241","title":"Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Nausea; Tolerability; Docetaxel; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Progressive disease; Refractory (planetary science); Gastroenterology; Adverse effect; Phases of clinical research; Chemotherapy; Metastatic Urothelial Carcinoma; Oncology; Performance status; Surgery; Cancer; Bladder cancer; Urothelial carcinoma","score_opus":0.27510356231521305,"score_gpt":0.4665840911058216,"score_spread":0.19148052879060856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560750372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994092,0.0003681518,0.000024310759,0.0002423036,0.000844409,0.0006248015,0.00007782428,0.0000048866323,0.0037213515],"genre_scores_gemma":[0.9972669,0.00005395112,0.0016413329,0.0003090039,0.0003734811,0.0000080078,0.000003561827,0.00002510523,0.00031865257],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99340147,0.0007438494,0.0048002214,0.00026613133,0.00050344534,0.0002848798],"domain_scores_gemma":[0.99445474,0.0012281904,0.0031756419,0.00032468155,0.00049057737,0.00032616706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030183797,0.00021698658,0.0023935954,0.0003136463,0.0000278014,0.0000019371485,0.00021434849,0.00022103198,0.0004919288],"category_scores_gemma":[0.0023278063,0.00015405127,0.0004573071,0.0002132293,0.00021752031,0.00011443778,0.00008314065,0.0007669805,0.0000045947827],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25537497,0.36020243,0.11905445,0.00033948198,0.004322809,0.0066426313,0.02658981,0.000016265485,0.017972494,0.000038215243,0.002014769,0.20743167],"study_design_scores_gemma":[0.20965257,0.571211,0.20276456,0.0002393841,0.0020534978,0.00026912495,0.0033772842,0.00003788878,0.0056689605,0.0003251517,0.0041946988,0.00020588377],"about_ca_topic_score_codex":0.00041298967,"about_ca_topic_score_gemma":0.0006171095,"teacher_disagreement_score":0.21100856,"about_ca_system_score_codex":0.00016421612,"about_ca_system_score_gemma":0.001639482,"threshold_uncertainty_score":0.62820286},"labels":[],"label_agreement":null},{"id":"W2560763809","doi":"10.1200/jco.2011.29.27_suppl.152","title":"An international perspective: The role of nurse involvement in improving breast cancer control.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Latin Americans; Family medicine; Cancer; Low and middle income countries; Developing country; Economic growth; Political science; Internal medicine","score_opus":0.052671942833737904,"score_gpt":0.5059121701533579,"score_spread":0.45324022731962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560763809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97218364,0.0019807694,0.00071448775,0.01079626,0.003584813,0.00026312502,0.000011326162,0.000005548748,0.010460043],"genre_scores_gemma":[0.9924241,0.0010409461,0.0022059483,0.002602097,0.0016767953,0.000005455991,2.6698885e-7,0.000007744138,0.000036664722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980813,0.00031526282,0.0011814048,0.00011585093,0.00018095883,0.00012516837],"domain_scores_gemma":[0.9973891,0.0006771904,0.001193909,0.00013675596,0.00049175794,0.000111296584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021764536,0.00007520986,0.00068414194,0.00008598049,0.000020566196,0.0000014857758,0.00026419054,0.00020889782,0.00046817603],"category_scores_gemma":[0.00053058687,0.000042370695,0.00019335106,0.000063832646,0.00042048344,0.00015119264,0.00001168114,0.00074988423,0.000001121677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008633073,0.0027752141,0.73297876,0.0000035844182,0.00035713814,0.000112732916,0.0013949391,0.000030137187,0.0009163353,0.003668177,0.00006682184,0.2490631],"study_design_scores_gemma":[0.010245188,0.007072862,0.9636566,0.00005433767,0.00015935607,0.00036304176,0.004273973,0.0006830846,0.00010318032,0.0043040006,0.009024863,0.00005949529],"about_ca_topic_score_codex":0.0001861921,"about_ca_topic_score_gemma":0.00022114736,"teacher_disagreement_score":0.24900362,"about_ca_system_score_codex":0.00031437678,"about_ca_system_score_gemma":0.0010294034,"threshold_uncertainty_score":0.5126199},"labels":[],"label_agreement":null},{"id":"W2560768786","doi":"10.1200/jco.2011.29.7_suppl.89","title":"Utilizing metformin as a radiosensitizing agent in the treatment of prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Metformin; DU145; Hyperinsulinemia; Medicine; Prostate cancer; LNCaP; Radioresistance; Cancer research; Cancer; Internal medicine; In vivo; Endocrinology; Oncology; Clonogenic assay; Insulin; Radiation therapy; Pharmacology; Insulin resistance; Biology","score_opus":0.16169124196268306,"score_gpt":0.44447069507475834,"score_spread":0.2827794531120753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560768786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8982497,0.0991179,0.0000063530906,0.00008958954,0.0006900076,0.00013314719,0.0000035524624,8.4108547e-7,0.0017089281],"genre_scores_gemma":[0.7948094,0.20303,0.00071649754,0.0007717457,0.0005960494,0.000010285016,0.0000013716424,0.00000834843,0.000056288405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787176,0.00043116897,0.0012143629,0.00014105487,0.00014733212,0.00019431474],"domain_scores_gemma":[0.9984659,0.00016742597,0.00095192314,0.00017814222,0.00014220839,0.00009443176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018310158,0.00010811321,0.0006638882,0.000047033354,0.000021344225,0.00000368667,0.00018594594,0.00018936757,0.00004026301],"category_scores_gemma":[0.00034967042,0.00006355381,0.00034542903,0.00007317747,0.00013156337,0.0000057109755,0.00001961073,0.00017142,0.0000018207596],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013818062,0.0011282797,0.01153438,0.00000942256,0.00025101632,0.00013924846,0.001667339,0.000009309881,0.0022566365,0.00011126776,0.00049926294,0.98101205],"study_design_scores_gemma":[0.0048938063,0.014993732,0.023582093,0.00004190384,0.0002513447,0.00012412155,0.0012410376,0.000015811553,0.036276978,0.00044993652,0.91799307,0.000136173],"about_ca_topic_score_codex":0.00012527157,"about_ca_topic_score_gemma":0.00021289325,"teacher_disagreement_score":0.98087585,"about_ca_system_score_codex":0.00004084855,"about_ca_system_score_gemma":0.00066780753,"threshold_uncertainty_score":0.25916493},"labels":[],"label_agreement":null},{"id":"W2560778965","doi":"10.1200/jco.2011.29.7_suppl.2","title":"Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University Health Network","funders":"","keywords":"Dutasteride; Medicine; Prostate cancer; Urology; Placebo; Clinical endpoint; Prostatectomy; Prostate; Internal medicine; Biopsy; Cancer; Oncology; Clinical trial; Pathology","score_opus":0.15748958612359235,"score_gpt":0.5466624502100026,"score_spread":0.3891728640864103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560778965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926481,0.0012344813,1.0733743e-7,0.0037669386,0.0004103863,0.0010706044,0.000014098619,0.000002779778,0.00085250736],"genre_scores_gemma":[0.99096394,0.008137292,0.000026058546,0.00030691098,0.00024947108,0.00023473552,8.3016073e-7,0.0000113265205,0.00006944785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996691,0.001522001,0.00095833634,0.00020181348,0.00041671772,0.00021016976],"domain_scores_gemma":[0.9955089,0.0031234403,0.0008791415,0.00016302573,0.00018797565,0.00013750451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043061343,0.00013661796,0.0010309488,0.00011601858,0.000033960598,0.0000047023896,0.00013013871,0.00014336893,0.000073982184],"category_scores_gemma":[0.0011338823,0.000060515842,0.00013937306,0.00017022403,0.0002374243,0.000052371528,0.000039456212,0.00082612736,0.0000011761834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04971653,0.001977115,0.5959903,0.000046818066,0.00017373331,0.0005083048,0.0012098722,0.0000011743057,0.000031170555,0.0000018563449,0.0003448691,0.34999827],"study_design_scores_gemma":[0.011943478,0.10259354,0.88051,0.0005668964,0.000121511875,0.000022782135,0.00030037187,0.0000056998865,0.0025737144,0.00001964492,0.0012889411,0.000053443084],"about_ca_topic_score_codex":0.00019619349,"about_ca_topic_score_gemma":0.0002540734,"teacher_disagreement_score":0.34994483,"about_ca_system_score_codex":0.0001625167,"about_ca_system_score_gemma":0.00047905528,"threshold_uncertainty_score":0.35891584},"labels":[],"label_agreement":null},{"id":"W2560790621","doi":"10.1200/jco.2011.29.7_suppl.196","title":"Got central prostate pathology review? A cross-sectional audit of 2009 versus 2003 outcomes.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Perineural invasion; Grading (engineering); Genitourinary system; Prostatectomy; Prostate; Prostate biopsy; Audit; Gynecology; Cancer; Internal medicine","score_opus":0.22550273343141505,"score_gpt":0.4976828030939326,"score_spread":0.2721800696625175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560790621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96504056,0.0133412415,0.000028580294,0.0043608043,0.007979473,0.00069229084,0.00005872267,0.000012256804,0.008486075],"genre_scores_gemma":[0.92599845,0.06107563,0.0052776816,0.005940546,0.0008833644,0.000030455642,0.000015071479,0.0000286386,0.0007501463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958035,0.00029154483,0.0029948554,0.00022901912,0.0003407709,0.00034030588],"domain_scores_gemma":[0.9949618,0.0007170083,0.0024889945,0.00023624462,0.0011670685,0.00042888155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022413419,0.00016723963,0.0018361611,0.00008206134,0.00002848956,0.000003310066,0.00014811802,0.00030029606,0.0008951223],"category_scores_gemma":[0.004580187,0.00010930724,0.0006519596,0.00016853426,0.00036313062,0.00009992014,0.000047329304,0.00070146535,0.00003609085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006802308,0.0029712243,0.94957983,0.00014270424,0.0006542793,0.0014263962,0.000057469293,0.0000012934136,0.000009675461,0.00014626142,0.015744595,0.022463987],"study_design_scores_gemma":[0.013362754,0.01947607,0.9157855,0.0002548584,0.0004987222,0.00037987376,0.000010010123,0.0000015860531,0.00008239672,0.00014952623,0.049920116,0.000078567406],"about_ca_topic_score_codex":0.00002354033,"about_ca_topic_score_gemma":0.000021683392,"teacher_disagreement_score":0.04773439,"about_ca_system_score_codex":0.00024496342,"about_ca_system_score_gemma":0.0022559774,"threshold_uncertainty_score":0.98009616},"labels":[],"label_agreement":null},{"id":"W2560795972","doi":"10.1200/jco.2011.29.7_suppl.20","title":"Prostate cancer hypoxia as a predictor of early biochemical and local failure after radiotherapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Hypoxia (environmental); Radiation therapy; Radioresistance; Tumor hypoxia; Urology; Prostate; Internal medicine; Multivariate analysis; Hormonal therapy; Proportional hazards model; Oncology; Cancer; Oxygen","score_opus":0.029063079678971048,"score_gpt":0.3528279837093242,"score_spread":0.3237649040303532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560795972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803359,0.017219549,0.00026353204,0.00041062353,0.0013966984,0.00013053449,0.00002089264,0.000002711352,0.00021957213],"genre_scores_gemma":[0.98214036,0.011046372,0.0028973399,0.00082722266,0.002788141,0.000012647898,0.0000017396732,0.000021693842,0.00026450242],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979987,0.0001842568,0.0011787529,0.00023699123,0.00017887933,0.00022241927],"domain_scores_gemma":[0.99830014,0.00007828368,0.0008394641,0.00018315105,0.0002931926,0.0003057716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007813348,0.00015179727,0.0007669559,0.000053107364,0.000016237656,0.00000541838,0.00019173815,0.0005196163,0.00013347177],"category_scores_gemma":[0.00031933418,0.00011459022,0.0003129785,0.000060056893,0.0005645399,0.000010599176,0.00005782445,0.00038555718,0.0000015100239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042287156,0.0020944464,0.14227974,0.000129453,0.002033333,0.00011591794,0.0015698231,0.0000063711605,0.44673005,0.000111626905,0.03352445,0.32911766],"study_design_scores_gemma":[0.009387545,0.014395707,0.32079798,0.00008772152,0.00038140005,0.00032306058,0.00014831741,0.000009565368,0.04043279,0.00044620494,0.6132666,0.00032308247],"about_ca_topic_score_codex":0.000074002426,"about_ca_topic_score_gemma":0.00005992402,"teacher_disagreement_score":0.5797422,"about_ca_system_score_codex":0.000018393139,"about_ca_system_score_gemma":0.000917697,"threshold_uncertainty_score":0.46728536},"labels":[],"label_agreement":null},{"id":"W2560827114","doi":"10.1200/jco.2012.30.4_suppl.303","title":"The introduction of bevacizumab for the treatment of metastatic colorectal cancer (CRC) in Ontario and its effect on hepatic metastectomy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Bevacizumab; Irinotecan; FOLFIRI; Colorectal cancer; Oxaliplatin; Internal medicine; Perioperative; FOLFOX; Oncology; Regimen; Chemotherapy; Surgery; Cancer","score_opus":0.11080890636783311,"score_gpt":0.4572792523599977,"score_spread":0.34647034599216464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560827114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813298,0.012484205,0.0000032715384,0.004298291,0.0010006177,0.0007728373,0.0000047651356,0.0000011651481,0.00010507225],"genre_scores_gemma":[0.99252653,0.0066387537,0.00010454078,0.00005490323,0.00045252626,0.00009523136,7.424231e-7,0.0000069080993,0.000119844924],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981432,0.0003035964,0.0011016852,0.00009568599,0.00018573871,0.00017007193],"domain_scores_gemma":[0.9918171,0.006882925,0.0009220932,0.000085725434,0.00021385924,0.00007827103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001837339,0.00011924962,0.0012346819,0.000057280617,0.00006078386,0.0000024534086,0.000051926552,0.00006414912,0.00003550534],"category_scores_gemma":[0.0012515261,0.00004777957,0.00029376466,0.000085385735,0.00016311332,0.00004181871,0.000013145333,0.00021731028,3.9414005e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05420681,0.004112556,0.24830715,0.00007595561,0.0048592426,0.000016147984,0.0021126228,0.000042471667,0.00032417884,0.00015515173,0.00032367013,0.685464],"study_design_scores_gemma":[0.015578706,0.12574121,0.7958577,0.000048555758,0.0033401335,0.00006857668,0.0002508989,0.00007874159,0.0027000203,0.00007103531,0.056207,0.000057387584],"about_ca_topic_score_codex":0.0012881276,"about_ca_topic_score_gemma":0.036574174,"teacher_disagreement_score":0.6854066,"about_ca_system_score_codex":0.0005176928,"about_ca_system_score_gemma":0.0005140793,"threshold_uncertainty_score":0.98100585},"labels":[],"label_agreement":null},{"id":"W2560907445","doi":"10.1200/jco.2011.29.15_suppl.tps226","title":"PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Bortezomib; Vincristine; Internal medicine; Rituximab; Oncology; International Prognostic Index; Lymphoma; Cyclophosphamide; Chemotherapy; Multiple myeloma","score_opus":0.08384203089736851,"score_gpt":0.41520540604603934,"score_spread":0.3313633751486708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560907445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150807,0.0054105753,0.00007180166,0.00051051204,0.0005817411,0.0015179917,0.000015841757,0.000014062962,0.00036943037],"genre_scores_gemma":[0.9810669,0.014583221,0.0030539217,0.00066963973,0.0002312726,0.00010803714,0.000009583331,0.000046784782,0.00023068397],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945412,0.0006181085,0.0034684653,0.00046792632,0.00047042148,0.00043383223],"domain_scores_gemma":[0.9923166,0.0025783824,0.0035374705,0.0003658849,0.00086117233,0.00034047934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036107555,0.00040734973,0.0040342775,0.00033443936,0.00012953223,0.000015740585,0.00021562401,0.00034800175,0.00008275137],"category_scores_gemma":[0.0013433285,0.00023667322,0.00053866685,0.00030421026,0.00076492125,0.00024138311,0.00012351832,0.00038788316,0.00000458808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49927682,0.15504226,0.3124114,0.000177767,0.0029957031,0.0020919552,0.008028353,4.1103007e-7,0.0015432177,0.000027073746,0.00054497534,0.017860053],"study_design_scores_gemma":[0.8195368,0.024013089,0.14533451,0.00039352986,0.0013620723,0.0002668756,0.0013364074,0.00016435157,0.006769563,0.00007650448,0.00051049277,0.00023577335],"about_ca_topic_score_codex":0.00009055516,"about_ca_topic_score_gemma":0.00011542582,"teacher_disagreement_score":0.32026002,"about_ca_system_score_codex":0.00039361612,"about_ca_system_score_gemma":0.0013111997,"threshold_uncertainty_score":0.9651254},"labels":[],"label_agreement":null},{"id":"W2561134547","doi":"10.1200/jco.2012.30.5_suppl.428","title":"Pleotrophic action of renal cell carcinoma: Dysregulated microRNAs on hypoxia-related signaling pathways.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"microRNA; Clear cell renal cell carcinoma; Cancer research; Biology; Transfection; Signal transduction; Downregulation and upregulation; Western blot; Cell culture; Medicine; Gene; Cell biology; Renal cell carcinoma; Internal medicine; Genetics","score_opus":0.07582178712659277,"score_gpt":0.36330928878328606,"score_spread":0.2874875016566933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561134547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887751,0.0044698296,0.00014244166,0.00021144397,0.005359606,0.000106483,0.000009086494,0.000004348771,0.0009216986],"genre_scores_gemma":[0.99222976,0.0010211408,0.0007009751,0.0003764336,0.005341982,0.0000018655861,0.000013721511,0.000026847545,0.00028725297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99671435,0.0005325198,0.0019256403,0.0002141785,0.00025892316,0.00035440328],"domain_scores_gemma":[0.99659085,0.00024454057,0.0022092469,0.00025372603,0.00036550782,0.00033613874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002188947,0.00019051641,0.0009015833,0.000115620474,0.000048246486,0.0000055886467,0.00024123355,0.00076492305,0.00006623189],"category_scores_gemma":[0.0006808166,0.00015482986,0.0006240496,0.0001214883,0.00018381633,0.000014620347,0.000063956235,0.0006952893,0.000011338217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018694578,0.0010629371,0.0021401537,0.00001869662,0.00017805715,0.000009436161,0.00006690101,0.00027876376,0.97149754,0.000042473785,0.0035249798,0.019310618],"study_design_scores_gemma":[0.008009233,0.008994074,0.075608045,0.000043727436,0.0004490503,0.00023595119,0.00012074382,0.0000250067,0.6763179,0.00013892671,0.22974937,0.00030801442],"about_ca_topic_score_codex":0.000012873588,"about_ca_topic_score_gemma":0.000006646575,"teacher_disagreement_score":0.29517967,"about_ca_system_score_codex":0.000046303765,"about_ca_system_score_gemma":0.00071303424,"threshold_uncertainty_score":0.6313778},"labels":[],"label_agreement":null},{"id":"W2561336955","doi":"10.1200/jco.2011.29.15_suppl.e19713","title":"Invasive pulmonary aspergillosis in neutropenic patients: Early diagnosis by thoracic high-resolution CT scan.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Halo sign; Radiology; Aspergillosis; High-resolution computed tomography; Lung; Pleural effusion; Computed tomography; Internal medicine","score_opus":0.10714419559798315,"score_gpt":0.40765998619511956,"score_spread":0.3005157905971364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561336955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937249,0.0006525422,0.000018964101,0.001239494,0.0007228733,0.00027223353,0.000010290301,0.00000839265,0.0033503447],"genre_scores_gemma":[0.9944006,0.0029659607,0.00075572886,0.0013731268,0.00029230403,0.000011295773,0.0000072610956,0.00001916362,0.00017456345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567825,0.00077494857,0.0024851684,0.00029941733,0.00042945155,0.00033276962],"domain_scores_gemma":[0.9958796,0.0015910811,0.0013332706,0.0002675535,0.0005243111,0.0004042202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024178948,0.00017295672,0.0014138615,0.00015665019,0.000045883353,0.0000066989955,0.00023918148,0.00031047597,0.00045261453],"category_scores_gemma":[0.005117651,0.0001267938,0.0004902715,0.00025397274,0.000290792,0.0003183059,0.00007294237,0.0011761183,0.00006136525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004797782,0.0045296247,0.93000484,0.000030101532,0.00011167331,0.0007046328,0.00006992481,6.601861e-7,0.000114823364,0.000032118158,0.003766604,0.055837233],"study_design_scores_gemma":[0.0027906948,0.0095991595,0.98346025,0.00019350329,0.00022723865,0.00003069776,0.000094552095,0.000005310863,0.00036479897,0.00034993657,0.0027675657,0.00011626946],"about_ca_topic_score_codex":0.00043607745,"about_ca_topic_score_gemma":0.00042995706,"teacher_disagreement_score":0.055720963,"about_ca_system_score_codex":0.00035074455,"about_ca_system_score_gemma":0.00086312543,"threshold_uncertainty_score":0.6126676},"labels":[],"label_agreement":null},{"id":"W2561617804","doi":"10.1200/jco.2016.71.0038","title":"Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; American Society of Clinical Oncology","keywords":"Medicine; Trastuzumab; Ejection fraction; Internal medicine; Epirubicin; Docetaxel; Breast cancer; Context (archaeology); Cardiology; Oncology; Cancer; Heart failure","score_opus":0.2981843192828471,"score_gpt":0.5143215649261138,"score_spread":0.2161372456432667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561617804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031628036,0.98938274,0.00062770996,0.0019393116,0.0015156749,0.0012460871,0.000004418874,0.0000115009425,0.002109755],"genre_scores_gemma":[0.0009670304,0.9921953,0.00040460404,0.001004137,0.0040042466,0.000016246691,0.000029654328,0.000045357818,0.0013334259],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954447,0.0009044263,0.002506826,0.00029372142,0.00063729106,0.00021301972],"domain_scores_gemma":[0.99216676,0.0009352611,0.0056729005,0.00053128425,0.00048543984,0.00020832733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041214246,0.00031599076,0.0039160377,0.00015264087,0.00016966909,0.000041155825,0.00032021603,0.0011127448,0.00010053633],"category_scores_gemma":[0.0005577325,0.00015784011,0.0024290548,0.00011109759,0.0002629979,0.0001791121,0.00002915032,0.002237146,0.00003388277],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071099895,0.0010045987,0.000059252547,0.00080701546,0.002015252,0.00024231857,0.000035179582,7.4675046e-7,0.0000049057385,0.000010573995,0.00097326364,0.9941359],"study_design_scores_gemma":[0.004427891,0.011379833,0.00069437135,0.006088184,0.0042994246,0.0049987817,0.00003400302,0.0000012182205,0.000019146519,0.00010592076,0.96779877,0.00015246854],"about_ca_topic_score_codex":0.0000040333875,"about_ca_topic_score_gemma":0.0000037453274,"teacher_disagreement_score":0.99398345,"about_ca_system_score_codex":0.0005105577,"about_ca_system_score_gemma":0.004886508,"threshold_uncertainty_score":0.97194105},"labels":[],"label_agreement":null},{"id":"W2561651629","doi":"10.1200/jco.2015.33.7_suppl.424","title":"The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Dalhousie University; University of Toronto; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Cohort; Internal medicine; Hazard ratio; Population; Cancer; Proportional hazards model; Kidney cancer; Prospective cohort study; Surgery; Oncology; Gastroenterology; Confidence interval","score_opus":0.06635071013552195,"score_gpt":0.34558572398363874,"score_spread":0.2792350138481168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561651629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719805,0.00022209749,0.00006411139,0.0007408457,0.00007851908,0.0014391507,0.00014205217,0.000006836968,0.00010832414],"genre_scores_gemma":[0.9980324,0.0003088111,0.00073705585,0.00015323845,0.0001296527,0.000031528307,0.00018640915,0.000026489173,0.00039440603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966929,0.00055033393,0.0016660036,0.00029015652,0.00058314885,0.00021744483],"domain_scores_gemma":[0.9937657,0.0006299285,0.0034795508,0.00024581162,0.0015375211,0.00034147955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009834758,0.00024052201,0.0013840428,0.000079733305,0.00006337596,0.000014087181,0.00006972017,0.00014878613,0.000011735028],"category_scores_gemma":[0.0003246312,0.00009514958,0.00013526458,0.00014317266,0.00020028581,0.00016464516,0.000017981947,0.00028893535,0.0000010930884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16648836,0.0032549722,0.8221959,0.000006337818,0.001225137,0.0005326526,0.00060374616,0.000002712123,0.00023680425,0.0000011663082,0.00007413556,0.005378101],"study_design_scores_gemma":[0.05276868,0.09345361,0.84727913,0.0000648161,0.0012668422,0.000043686498,0.0002681151,0.000083382816,0.0038150835,0.000012862067,0.000853629,0.00009013853],"about_ca_topic_score_codex":0.0001649357,"about_ca_topic_score_gemma":0.00020858116,"teacher_disagreement_score":0.113719694,"about_ca_system_score_codex":0.00040146813,"about_ca_system_score_gemma":0.0012636953,"threshold_uncertainty_score":0.38800874},"labels":[],"label_agreement":null},{"id":"W2561804778","doi":"10.1200/jco.2009.27.15_suppl.e15590","title":"Elucidating genetic events in human hepatocellular carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Hepatocellular carcinoma; Carcinogenesis; Hepatoblastoma; Cancer research; Biology; Pathology; Medicine; Liver cancer; Cancer; HCCS; Internal medicine; Genetics","score_opus":0.10278098342693731,"score_gpt":0.4404498349673203,"score_spread":0.337668851540383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561804778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303806,0.0007788807,0.00054408103,0.0023730192,0.0006108278,0.00019347604,4.09419e-7,0.000007698518,0.002453557],"genre_scores_gemma":[0.9936287,0.0001129402,0.0032846946,0.0019899001,0.00088375685,0.0000011791111,0.0000016576195,0.000015052237,0.000082135884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963044,0.00036777765,0.0025269964,0.00018824282,0.00035000462,0.0002625825],"domain_scores_gemma":[0.9977429,0.00028416608,0.0012243867,0.00022054436,0.00020400589,0.00032400878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021203244,0.0001241387,0.0011513428,0.00019698936,0.000027866758,0.0000027039098,0.00016325913,0.00041785074,0.00008933218],"category_scores_gemma":[0.0017281297,0.000104902545,0.00042430512,0.00018426395,0.00005989521,0.0000476806,0.000028982566,0.0013662522,0.000015447273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012939249,0.0021972223,0.82122535,0.000023779354,0.00012502936,0.0076240115,0.00013570958,0.00010706024,0.028335841,0.00009245546,0.00090644334,0.13793315],"study_design_scores_gemma":[0.009660471,0.013287413,0.96662974,0.00017441521,0.00018375028,0.0010098907,0.000031307958,0.0005607012,0.0015587324,0.0010007673,0.005794706,0.000108097745],"about_ca_topic_score_codex":0.000023005332,"about_ca_topic_score_gemma":0.000016464839,"teacher_disagreement_score":0.14540438,"about_ca_system_score_codex":0.00026704956,"about_ca_system_score_gemma":0.0010307471,"threshold_uncertainty_score":0.5935762},"labels":[],"label_agreement":null},{"id":"W2561862303","doi":"10.1200/jco.2011.29.4_suppl.2","title":"Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative study (SWOG 0356).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ERCC1; Medicine; Esophageal cancer; Internal medicine; XRCC1; Univariate analysis; Cancer research; Oncology; XRCC3; DNA repair; Cancer; Nucleotide excision repair; Biology; Gene; Genotype; Single-nucleotide polymorphism","score_opus":0.06319772777475113,"score_gpt":0.4053542874503229,"score_spread":0.3421565596755718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561862303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834937,0.00005691445,0.00046876958,0.000031392356,0.00012896625,0.0008305757,0.000062129344,0.0000040343775,0.000067860565],"genre_scores_gemma":[0.9965688,0.00003407293,0.002859,0.00014306206,0.00012448546,0.000035386678,0.00014801938,0.000021042106,0.00006611947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963759,0.00051537063,0.0021676477,0.00036960538,0.00034930816,0.00022214296],"domain_scores_gemma":[0.99622434,0.00032750747,0.0023943265,0.00020323889,0.0007303911,0.000120179175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017512067,0.00021464354,0.00087128906,0.00015634287,0.000088833774,0.000012349795,0.0001586352,0.00029355893,0.000041077015],"category_scores_gemma":[0.0008636645,0.00016063309,0.00013157594,0.00020231475,0.000090314534,0.000042668464,0.0000849419,0.00035439752,3.5927977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018436689,0.008759178,0.96335787,0.000009385343,0.00014363091,0.00006613809,0.0013274351,0.0010950725,0.006078558,0.0000031175684,0.00007233025,0.00065058673],"study_design_scores_gemma":[0.047023233,0.08080919,0.848462,0.00004138228,0.00010027131,0.0000020741134,0.00037220237,0.000469595,0.022515109,0.000004159315,0.000039999726,0.00016080766],"about_ca_topic_score_codex":0.00019901742,"about_ca_topic_score_gemma":0.0018104276,"teacher_disagreement_score":0.1148959,"about_ca_system_score_codex":0.00031635695,"about_ca_system_score_gemma":0.0005714649,"threshold_uncertainty_score":0.65504277},"labels":[],"label_agreement":null},{"id":"W2561952745","doi":"10.1200/jco.2004.22.90140.8161","title":"Frequency of axillary node dissection and chemotherapy in breast cancer patients over 60 years of age compared with those younger than 60 years of age","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Axillary Lymph Node Dissection; Chemotherapy; Surgery; Retrospective cohort study; Stage (stratigraphy); Cancer; Internal medicine; Sentinel lymph node","score_opus":0.028061977479366285,"score_gpt":0.36757570546543383,"score_spread":0.33951372798606755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561952745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99877477,0.0005387523,0.0000100868,0.00027141732,0.00018246591,0.00009375245,0.000043191852,9.988023e-7,0.00008459472],"genre_scores_gemma":[0.9972301,0.0018665367,0.00059743435,0.00016182456,0.00011448168,0.0000029675148,0.000007623859,0.000012653966,0.000006387614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986491,0.000093451716,0.0008267461,0.00014983655,0.00016223249,0.000118586235],"domain_scores_gemma":[0.9986219,0.00007262987,0.00096302293,0.00011987624,0.00016089523,0.000061682884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026671635,0.000101183774,0.0006815452,0.00005572898,0.000008975184,0.0000018364714,0.0000976246,0.00018548834,0.000009814109],"category_scores_gemma":[0.000066231194,0.00008185417,0.00013419286,0.00008395944,0.0003003809,0.000011125438,0.000036468977,0.00015733017,1.162736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003406281,0.0016966761,0.97027,0.00003224724,0.00052519,0.00017375173,0.00036499716,0.00010123147,0.012208032,0.0000075317234,0.00007154954,0.011142536],"study_design_scores_gemma":[0.007694839,0.0016795469,0.9890343,0.0001294451,0.00008032079,0.000027590377,0.00006223573,7.338416e-7,0.0009948858,0.00009513113,0.00012855457,0.00007243088],"about_ca_topic_score_codex":0.0006855027,"about_ca_topic_score_gemma":0.0008736532,"teacher_disagreement_score":0.018764311,"about_ca_system_score_codex":0.000060063787,"about_ca_system_score_gemma":0.00026452518,"threshold_uncertainty_score":0.3337916},"labels":[],"label_agreement":null},{"id":"W2562181424","doi":"10.1200/jco.2011.29.15_suppl.9115","title":"Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Multiple myeloma; Oncology; Prostate cancer; Breast cancer; Internal medicine; Prostate; Osteoporosis; Cancer","score_opus":0.08033359347406338,"score_gpt":0.41248791927863676,"score_spread":0.3321543258045734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562181424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982186,0.00013437332,0.000012649205,0.00058031495,0.00021623113,0.00043833553,0.000090386166,0.000008483501,0.00030060488],"genre_scores_gemma":[0.99528,0.00006806963,0.0032469144,0.0011442505,0.00009338717,0.0000175657,0.00001621258,0.000026097592,0.00010744748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705774,0.0003015906,0.0016313614,0.00029846016,0.00031128558,0.00039954888],"domain_scores_gemma":[0.99702793,0.0006721852,0.0010440956,0.00020954794,0.00023629094,0.00080995396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059827894,0.00022240072,0.0020121257,0.00023291708,0.000041628984,0.0000076164556,0.000082558916,0.00018137759,0.000305271],"category_scores_gemma":[0.0004636382,0.00012846837,0.00022573041,0.0003966502,0.00014150703,0.00013378508,0.00003777622,0.0004612173,0.00002128405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12253169,0.0020236059,0.8510826,0.0000134364145,0.0016324982,0.00078591425,0.00047989967,0.000005677624,0.0000029269502,9.599345e-7,0.00017253897,0.021268222],"study_design_scores_gemma":[0.054934762,0.015632173,0.92568135,0.000102563165,0.00269351,0.000079433485,0.00031660713,0.000025502153,0.000050040937,0.000010617508,0.00035326378,0.00012016521],"about_ca_topic_score_codex":0.00822252,"about_ca_topic_score_gemma":0.025820421,"teacher_disagreement_score":0.07459873,"about_ca_system_score_codex":0.00042065917,"about_ca_system_score_gemma":0.0015709938,"threshold_uncertainty_score":0.9983818},"labels":[],"label_agreement":null},{"id":"W2562322739","doi":"10.1200/jco.2016.68.8283","title":"Predictors of and Trends in High-Intensity End-of-Life Care Among Children With Cancer: A Population-Based Study Using Health Services Data","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; American Society of Clinical Oncology","keywords":"Medicine; Cancer; Population; Gerontology; Demography; Environmental health; Internal medicine","score_opus":0.17005830406114275,"score_gpt":0.504867765374546,"score_spread":0.3348094613134033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562322739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528116,0.0005616802,0.000010739691,0.003195083,0.00054003135,0.0002969396,0.000098223805,0.00000480743,0.000011350444],"genre_scores_gemma":[0.99726295,0.00008915025,0.0012054474,0.0007251208,0.00066206796,9.962973e-7,0.00003651984,0.000015870713,0.0000018811623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995844,0.00053817686,0.002573794,0.0002984082,0.0005589388,0.00018665944],"domain_scores_gemma":[0.99218154,0.00053816044,0.0057634464,0.0007483353,0.00040310292,0.0003654101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033148902,0.00015144981,0.0024341915,0.00022769229,0.00008479854,0.00001065345,0.00044442996,0.00017760316,0.000019068237],"category_scores_gemma":[0.0008332993,0.00011185975,0.00011482302,0.00011866858,0.00026907667,0.00022904672,0.00017566467,0.00063037546,4.787332e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029690654,0.001039588,0.9785053,0.00016460431,0.00049522374,0.000021421753,0.0013249737,0.00014839985,7.013702e-7,0.0000012174696,0.000035845424,0.015293667],"study_design_scores_gemma":[0.011942736,0.0076608425,0.9771791,0.00083385163,0.00044185205,0.000014137698,0.001477381,0.0003383478,0.000002016854,0.0000043260666,0.000025172245,0.00008021924],"about_ca_topic_score_codex":0.09077172,"about_ca_topic_score_gemma":0.15261663,"teacher_disagreement_score":0.061844915,"about_ca_system_score_codex":0.00015972904,"about_ca_system_score_gemma":0.002354591,"threshold_uncertainty_score":0.9152829},"labels":[],"label_agreement":null},{"id":"W2562830036","doi":"10.1200/jco.2016.69.4182","title":"Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Internal medicine; Clinical trial; Accrual; Odds ratio; Adjuvant therapy; Oncology; Hormonal therapy; Randomized controlled trial; Cancer","score_opus":0.63463900394665,"score_gpt":0.7116586127095029,"score_spread":0.07701960876285296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562830036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483175,0.000059351645,0.000051530493,0.018315371,0.0009137533,0.031054853,0.000046654393,0.000008134884,0.0012328371],"genre_scores_gemma":[0.9821596,0.00072306243,0.0025355192,0.004400849,0.0035634781,0.0040065185,0.0000013281751,0.00006658775,0.0025430685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911751,0.0013475227,0.004965921,0.00034998474,0.0017937567,0.00036767314],"domain_scores_gemma":[0.96357083,0.023073114,0.007230838,0.00088892423,0.004464588,0.00077169196],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029999547,0.00020156297,0.0033424858,0.00009020679,0.00009595595,0.000034286655,0.000919489,0.0009558368,0.0012784832],"category_scores_gemma":[0.07370335,0.00010972693,0.000623344,0.000102447106,0.0006748793,0.00019675477,0.0001860149,0.0029092277,0.00004491142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06829319,0.0041349577,0.75763345,0.00029111974,0.0010233589,0.00013681766,0.0000993088,0.000010608156,0.00044857824,0.00008268537,0.007682091,0.16016385],"study_design_scores_gemma":[0.032614253,0.016713662,0.93710023,0.0023510803,0.00014476007,0.000046078974,0.00001164017,0.000009816408,0.00011599016,0.00031126678,0.010464737,0.00011649824],"about_ca_topic_score_codex":0.00006563922,"about_ca_topic_score_gemma":0.000055097586,"teacher_disagreement_score":0.17946678,"about_ca_system_score_codex":0.00020127642,"about_ca_system_score_gemma":0.005622386,"threshold_uncertainty_score":0.9996345},"labels":[],"label_agreement":null},{"id":"W2563125910","doi":"10.1200/jco.2012.30.5_suppl.234","title":"Three-dimensional ultrasound-based spectroscopic imaging for the detection of prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Prostatectomy; Histopathology; Medicine; Ultrasound; Prostate; Nuclear medicine; Urology; Radiology; Cancer; Pathology; Internal medicine","score_opus":0.09530806100121551,"score_gpt":0.4706581124804022,"score_spread":0.37535005147918665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563125910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9233437,0.008564145,0.009019357,0.05109928,0.006989531,0.0007833813,0.000012751822,0.000011827125,0.00017602227],"genre_scores_gemma":[0.9884749,0.00086480065,0.004972696,0.0027540042,0.0028537824,0.000034716373,8.167195e-7,0.000016867907,0.000027403463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977915,0.00011395304,0.0014177558,0.000105419786,0.00031462804,0.0002567296],"domain_scores_gemma":[0.9888498,0.008727391,0.0015715027,0.00016031812,0.0004949344,0.00019601834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033659132,0.00009890683,0.000769261,0.000068742585,0.000054578984,0.000003954534,0.000115525756,0.00012910062,0.00018402837],"category_scores_gemma":[0.0019711454,0.000058583155,0.00041728342,0.00011017287,0.0002425696,0.00009187122,0.000015569736,0.0005705012,0.000003286669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039267237,0.0009194818,0.8727566,0.00007366129,0.00027921496,0.000008885913,0.00004644817,0.00014046271,0.0070762956,0.00003330382,0.008224088,0.10651481],"study_design_scores_gemma":[0.009762309,0.00635925,0.85265297,0.00025668927,0.0011816921,0.00015756156,0.00005285535,0.0013213959,0.020742781,0.0004595404,0.10694756,0.000105396706],"about_ca_topic_score_codex":0.00009356997,"about_ca_topic_score_gemma":0.00021001762,"teacher_disagreement_score":0.106409416,"about_ca_system_score_codex":0.0002417626,"about_ca_system_score_gemma":0.0013643964,"threshold_uncertainty_score":0.24785756},"labels":[],"label_agreement":null},{"id":"W2563182326","doi":"10.1200/jco.2009.27.15_suppl.9594","title":"Association between inflammatory markers, symptom burden, hypogonadism, and survival in cancer patients with cachexia","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare and Venom Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cachexia; Internal medicine; Wasting Syndrome; Anorexia; Gastroenterology; Wasting; Cancer; Weight loss; Testosterone (patch); Obesity","score_opus":0.10754951772222619,"score_gpt":0.49073685227346153,"score_spread":0.3831873345512353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563182326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97381836,0.00022753088,0.000002979402,0.024807228,0.00021544445,0.00017943101,0.0000039067954,0.0000035623,0.00074158324],"genre_scores_gemma":[0.9968,0.00067568093,0.00013539835,0.00092324975,0.0012268452,0.0000014814686,0.000003457933,0.00000803869,0.00022583971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971556,0.0005900963,0.0013323387,0.00013217003,0.0005162039,0.000273605],"domain_scores_gemma":[0.99621207,0.0019297139,0.0008168719,0.00007886013,0.00052296085,0.0004395173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00464267,0.0000861368,0.00094041676,0.00014106478,0.000026234882,0.000006887605,0.000074994794,0.00039419072,0.000042037285],"category_scores_gemma":[0.0024224687,0.0000599862,0.00008773556,0.000127433,0.000055282322,0.00009668446,0.00001753286,0.001225672,0.0000031496588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013866595,0.00024796717,0.83570606,0.000018100707,0.00014115425,0.00009914989,0.00007307053,0.0000010558529,0.000003002119,0.000007744566,0.0008543142,0.16146173],"study_design_scores_gemma":[0.0065409844,0.009089396,0.9662959,0.00012991276,0.00010928934,0.0000053948247,0.00004505892,0.000008701589,0.0000015460512,0.000076198,0.017641746,0.000055857206],"about_ca_topic_score_codex":0.00019275415,"about_ca_topic_score_gemma":0.0003616891,"teacher_disagreement_score":0.16140588,"about_ca_system_score_codex":0.00056292786,"about_ca_system_score_gemma":0.0021001413,"threshold_uncertainty_score":0.5325003},"labels":[],"label_agreement":null},{"id":"W2563832576","doi":"10.1200/jco.2009.27.15_suppl.6505","title":"The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer registry; Stage (stratigraphy); Population; Cancer; Breast cancer; Socioeconomic status; Disease; Colorectal cancer; Demography; Internal medicine; Environmental health","score_opus":0.12597289437251505,"score_gpt":0.49204406068491446,"score_spread":0.36607116631239944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563832576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979826,0.00029360267,4.368938e-7,0.0010578638,0.00016696165,0.0002336267,0.0000189476,8.25041e-7,0.00024513967],"genre_scores_gemma":[0.99908555,0.0000860263,0.000046910303,0.00058841397,0.00007380827,0.0000029591724,0.0000014952295,0.0000045997126,0.000110222274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996909,0.00024312576,0.0022136287,0.00010419714,0.00033563745,0.00019437318],"domain_scores_gemma":[0.99481493,0.0022340873,0.0023728493,0.00016060975,0.00025457854,0.00016292313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016811637,0.000096543954,0.0012248064,0.00007037774,0.00002301322,0.0000017799401,0.00013959623,0.00011505938,0.000576109],"category_scores_gemma":[0.00097381725,0.00005919084,0.0003197586,0.0000690024,0.00005873241,0.00004042258,0.000014892297,0.0004909699,6.0600865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006302919,0.0008356378,0.97504246,0.0000055127007,0.00020058143,0.000063268766,0.00014671715,0.006536487,0.000022576442,0.0000036190652,0.0015269659,0.009313263],"study_design_scores_gemma":[0.004619118,0.019127022,0.97500485,0.00012395534,0.00011107122,0.0000019350346,0.00021923761,0.000111981215,0.00004504277,0.000028336337,0.0005638719,0.000043560518],"about_ca_topic_score_codex":0.9350019,"about_ca_topic_score_gemma":0.9858387,"teacher_disagreement_score":0.05083677,"about_ca_system_score_codex":0.0028615338,"about_ca_system_score_gemma":0.011806583,"threshold_uncertainty_score":0.9937956},"labels":[],"label_agreement":null},{"id":"W2564048036","doi":"10.1200/jco.2009.27.15_suppl.10557","title":"Analysis of an observational registry of gastrointestinal stromal tumor (GIST) patients (pts) in the United States: reGISTry","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; GiST; Internal medicine; Observational study; Sunitinib; Imatinib mesylate; PDGFRA; Clinical trial; Cancer; Oncology; Gastroenterology; Surgery; Imatinib; Stromal cell","score_opus":0.20538526462903806,"score_gpt":0.4839378534896514,"score_spread":0.27855258886061335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564048036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960938,0.000019381321,0.00010913841,0.003164172,0.00004037037,0.00017724295,0.00004873406,0.000003536676,0.00034361918],"genre_scores_gemma":[0.9864699,0.000015526113,0.012344334,0.0007706768,0.00013530577,0.0000018102165,0.00022333942,0.00000681028,0.000032277378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99494636,0.00070553087,0.002904859,0.0001991727,0.0009460165,0.00029805585],"domain_scores_gemma":[0.99282664,0.0020366276,0.003000145,0.00040145556,0.0013805823,0.00035457689],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031885451,0.00015692295,0.0014700642,0.00049086224,0.000026549058,0.000008533507,0.00040855864,0.000071703515,0.000060680683],"category_scores_gemma":[0.0098851435,0.00009746378,0.0005696833,0.0010135416,0.000350935,0.00010203011,0.00002908779,0.00096938736,0.0000010887754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006684574,0.009023749,0.9773607,0.000027374226,0.000367399,0.002033036,0.00005773569,0.00068093906,0.00007041533,0.00011878531,0.0005801041,0.0029951602],"study_design_scores_gemma":[0.0059492895,0.04826941,0.9408634,0.00022162522,0.000796693,0.000829231,0.0004540544,0.0019701822,0.00001660269,0.00024932303,0.0003288305,0.000051363324],"about_ca_topic_score_codex":0.00018321387,"about_ca_topic_score_gemma":0.0000825386,"teacher_disagreement_score":0.03924566,"about_ca_system_score_codex":0.00015696393,"about_ca_system_score_gemma":0.0013113979,"threshold_uncertainty_score":0.998455},"labels":[],"label_agreement":null},{"id":"W2564069001","doi":"10.1200/jco.2004.22.14_suppl.5","title":"Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"DPYD; Medicine; Irinotecan; Internal medicine; Quality of life (healthcare); Oncology; Pharmacogenetics; Oxaliplatin; Methylenetetrahydrofolate reductase; Genotype; Genotyping; Colorectal cancer; Cancer; Bioinformatics; Genetics; Gene; Biology","score_opus":0.42787189452201346,"score_gpt":0.5655701213931008,"score_spread":0.13769822687108735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564069001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989316,0.0023798048,0.000113687296,0.0072415755,0.00019692622,0.00022170164,0.000002821746,0.0000026508487,0.0005248734],"genre_scores_gemma":[0.99138045,0.0011450794,0.006806279,0.0003470826,0.0002729122,0.0000017504647,8.5201634e-7,0.000008696229,0.00003691754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943905,0.0011762527,0.003555595,0.00016466623,0.0005229407,0.00019007863],"domain_scores_gemma":[0.98132634,0.014943791,0.0023448402,0.00022155381,0.0006960759,0.00046738965],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058560236,0.000096735566,0.0015536539,0.00017990023,0.000027895892,0.0000021283468,0.00014887599,0.00048719806,0.00004090142],"category_scores_gemma":[0.03126086,0.00007078035,0.00031003304,0.00018432993,0.0006111345,0.00009603659,0.0001039925,0.0009982404,0.000004450825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010625475,0.0010683298,0.91102064,0.00024170743,0.0002024194,0.00011874439,0.00023881259,0.000029845427,0.0002915439,0.000058934394,0.0003379758,0.07576556],"study_design_scores_gemma":[0.0046162927,0.0625747,0.9301975,0.00032545207,0.00024259764,0.00009029667,0.00021783278,0.000007993993,0.000097923075,0.00073688023,0.0008395685,0.000052986914],"about_ca_topic_score_codex":0.00009553855,"about_ca_topic_score_gemma":0.000022358301,"teacher_disagreement_score":0.07571257,"about_ca_system_score_codex":0.00016775531,"about_ca_system_score_gemma":0.003554759,"threshold_uncertainty_score":0.97689927},"labels":[],"label_agreement":null},{"id":"W2564310149","doi":"10.1200/jco.2013.31.18_suppl.lba2009","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated <i>O<sup>6</sup>-methylguanine-DNA methyltransferase</i> (<i>MGMT</i>) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Temozolomide; Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Progression-free survival; Concomitant; Population; Radiation therapy; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval","score_opus":0.03613921631583751,"score_gpt":0.36769985141308775,"score_spread":0.33156063509725026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564310149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97641337,0.00050993747,0.00019453335,0.0031967184,0.0002585238,0.019136325,0.0002143197,0.000015577623,0.000060667808],"genre_scores_gemma":[0.9920642,0.00074127177,0.005752205,0.00050181744,0.00013487502,0.0006760753,0.000027442344,0.00006272651,0.00003941839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99143904,0.002195194,0.004426021,0.0005859416,0.0008316256,0.0005221772],"domain_scores_gemma":[0.9808867,0.012362035,0.0032860932,0.0005554695,0.0022186807,0.00069101376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037900878,0.00058386195,0.006314929,0.00024043085,0.00016600818,0.00007363881,0.00038570975,0.00028859626,0.0000347742],"category_scores_gemma":[0.0038130528,0.0002575649,0.00065101363,0.00039073604,0.00048059752,0.00027079417,0.00009770996,0.00049663853,0.0000015320298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87306994,0.06877042,0.016394127,0.00003371396,0.009919693,0.00035167488,0.00093174184,0.00006900551,0.00024343791,0.000008975074,0.0004504193,0.029756855],"study_design_scores_gemma":[0.7648194,0.21875915,0.004004102,0.00024495294,0.007641139,0.000035117908,0.00032483294,0.0006759141,0.0026768039,0.000030017763,0.0005918,0.00019680939],"about_ca_topic_score_codex":0.00022938375,"about_ca_topic_score_gemma":0.00016886421,"teacher_disagreement_score":0.14998873,"about_ca_system_score_codex":0.00030770697,"about_ca_system_score_gemma":0.0010294515,"threshold_uncertainty_score":0.99998766},"labels":[],"label_agreement":null},{"id":"W2564383306","doi":"10.1200/jco.2016.67.1503","title":"Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Harvard T.H. Chan School of Public Health; National Human Genome Research Institute; Brigham and Women's Hospital; University of Minnesota; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Personal genomics; Prostate cancer; Breast cancer; Cancer; Colorectal cancer; Odds ratio; Genetic testing; Family history; Internal medicine; Oncology; Gerontology; Genomics; Genetics","score_opus":0.1669977163892583,"score_gpt":0.4927667877426991,"score_spread":0.3257690713534408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564383306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613345,0.0007434964,0.00015264191,0.00095241686,0.0010053073,0.00026019683,0.0005621106,0.0000011769191,0.000189192],"genre_scores_gemma":[0.9916024,0.00029994434,0.0037410879,0.00013405806,0.0041181236,0.0000106846965,0.0000087973185,0.000019405172,0.00006546379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976695,0.00032071755,0.0014101907,0.00025615704,0.0001540019,0.00018941799],"domain_scores_gemma":[0.9929991,0.00181009,0.004056651,0.00035784813,0.0006646732,0.00011168823],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035091026,0.00013400351,0.00059665943,0.000022038364,0.00025861023,0.00002856926,0.0006587004,0.0002528384,0.000020639705],"category_scores_gemma":[0.011800118,0.000085698615,0.0005938735,0.00002517942,0.0003255915,0.000008172688,0.00015979414,0.0004418062,0.0000011684906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080975555,0.0008603965,0.81571865,0.0000037658165,0.0021867007,0.000011457669,0.001441742,0.0013014236,0.023863913,9.082831e-7,0.0101004075,0.13641307],"study_design_scores_gemma":[0.0066942945,0.008933066,0.9743397,0.000014492906,0.000316015,0.000016967355,0.0006624705,0.001103567,0.00039962397,0.00010963975,0.007299369,0.00011074971],"about_ca_topic_score_codex":0.0011700399,"about_ca_topic_score_gemma":0.0008581158,"teacher_disagreement_score":0.15862109,"about_ca_system_score_codex":0.00020472206,"about_ca_system_score_gemma":0.0041449536,"threshold_uncertainty_score":0.9965239},"labels":[],"label_agreement":null},{"id":"W2564571185","doi":"10.1200/jco.2016.68.5826","title":"Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":392,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Cancer Institute; University of Rochester","keywords":"Medicine; Breast cancer; Longitudinal study; Internal medicine; Cancer; Anxiety; Cog; Prospective cohort study; Depression (economics); Anthracycline; Cognition; Generalizability theory; Oncology; Psychiatry; Psychology; Pathology","score_opus":0.09411119688927093,"score_gpt":0.47263582243380714,"score_spread":0.3785246255445362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564571185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961261,0.00012522748,0.00028102737,0.0017059501,0.00033227965,0.0010995897,0.00014191946,0.000007383084,0.00018050957],"genre_scores_gemma":[0.99862444,0.00014645158,0.0003216061,0.00041540305,0.00037508085,0.00006462521,0.00000750398,0.000020799402,0.00002410406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604875,0.0006471204,0.00207005,0.00038717344,0.00059055997,0.00025632727],"domain_scores_gemma":[0.9918285,0.0019410375,0.0034833474,0.00026930057,0.0022320822,0.00024572818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017977799,0.00024777092,0.0031540992,0.0003282467,0.00009610391,0.00002677854,0.00022117572,0.00018076599,0.0002651616],"category_scores_gemma":[0.0012858387,0.00017343178,0.00040202308,0.0002519268,0.00079187285,0.00027552462,0.00006480917,0.00082811946,0.0000021070168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086109884,0.010266161,0.8840575,0.000011440021,0.012736043,0.00089468685,0.0020153485,0.000036984366,0.000013627407,7.097067e-7,0.000009165553,0.0038484358],"study_design_scores_gemma":[0.06173521,0.008583625,0.91918766,0.0004124196,0.005470527,0.00002281773,0.0038873649,0.0005011408,0.000011276119,0.000032213942,0.000008849857,0.00014691216],"about_ca_topic_score_codex":0.0057350867,"about_ca_topic_score_gemma":0.09786476,"teacher_disagreement_score":0.09212967,"about_ca_system_score_codex":0.0003261435,"about_ca_system_score_gemma":0.00054590264,"threshold_uncertainty_score":0.91859686},"labels":[],"label_agreement":null},{"id":"W2564667489","doi":"10.1200/jco.2012.30.5_suppl.69","title":"Comparison of acute toxicity in patients treated with a 4-field box or IMRT to deliver elective pelvic nodal irradiation for localized high-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Prostate cancer; Proctitis; Prostate; Toxicity; Urology; Nuclear medicine; Cancer; Radiology; Oncology; Internal medicine; Disease","score_opus":0.06465563903656465,"score_gpt":0.45941448081083847,"score_spread":0.3947588417742738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564667489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964296,0.00020733847,0.00022297747,0.0015689596,0.0003482053,0.0011148544,0.000068021545,0.0000046459563,0.000035360492],"genre_scores_gemma":[0.99518085,0.0007055265,0.0027852678,0.00092759664,0.0002426474,0.0000948533,0.000013098298,0.00001637589,0.000033771343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738,0.00021508816,0.0016725168,0.00017124547,0.00025788482,0.0003032216],"domain_scores_gemma":[0.9956574,0.0014888117,0.001717316,0.000109474,0.0006780045,0.00034900554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084419805,0.00015199305,0.0015171578,0.00013021684,0.000029051605,0.0000040069413,0.00006951733,0.00020588236,0.000045801666],"category_scores_gemma":[0.0009990577,0.00008982937,0.00018462558,0.00022178612,0.00005310494,0.00012833653,0.000019371311,0.00038703287,0.0000019976042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06633754,0.0051285257,0.83746195,0.000025727184,0.00082295417,0.000017381395,0.0005032017,0.00006183389,0.00003241553,0.0000059959057,0.0015164657,0.08808599],"study_design_scores_gemma":[0.026239557,0.08422217,0.8830138,0.00016972896,0.0012031773,0.0000057198454,0.000064359556,0.000098063756,0.0032634907,0.000015722164,0.0016151934,0.00008903416],"about_ca_topic_score_codex":0.0005282399,"about_ca_topic_score_gemma":0.00068494375,"teacher_disagreement_score":0.08799695,"about_ca_system_score_codex":0.0006197494,"about_ca_system_score_gemma":0.00068326487,"threshold_uncertainty_score":0.36631355},"labels":[],"label_agreement":null},{"id":"W2564750478","doi":"10.1200/jco.2009.27.15_suppl.9589","title":"Characteristics of patients who refuse medically appropriate do not resuscitate orders (DNR) upon admission to a palliative care (PC) unit in a comprehensive cancer center","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Cardiopulmonary resuscitation; Cancer; Do not resuscitate; Retrospective cohort study; Internal medicine; Intensive care unit; Multivariate analysis; Emergency medicine; Pediatrics; Resuscitation; Intensive care medicine","score_opus":0.27459928249389837,"score_gpt":0.5421010583732876,"score_spread":0.2675017758793892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564750478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912275,0.0003638975,0.00004785132,0.0069015413,0.0007327508,0.00033516393,0.00006509922,0.0000045713473,0.00032163644],"genre_scores_gemma":[0.98743266,0.0051235105,0.0023209725,0.004683532,0.00036613515,0.0000034634368,0.000019878154,0.000015521362,0.000034323053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537486,0.00053494726,0.0029097951,0.00024339287,0.00064978504,0.00028722282],"domain_scores_gemma":[0.993132,0.0012252936,0.0023014725,0.00019829672,0.0025866358,0.0005562944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081466814,0.0002004844,0.0020956413,0.00026664848,0.00002100151,0.0000039940423,0.00022743661,0.0003891111,0.000056178014],"category_scores_gemma":[0.0077142017,0.00014178359,0.00031419098,0.0003030898,0.00012774538,0.00007185988,0.000067454486,0.0010149291,0.0000037741725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024982497,0.001965872,0.8299932,0.00020289024,0.00026557516,0.00034462084,0.00735729,0.000016176135,0.00034819436,0.000023390969,0.0013541143,0.13314617],"study_design_scores_gemma":[0.011688202,0.012419097,0.8895717,0.0035860373,0.00017588379,0.0000018958889,0.0013268226,0.000025478617,0.00030235242,0.000060575752,0.080715604,0.00012632739],"about_ca_topic_score_codex":0.0000710027,"about_ca_topic_score_gemma":0.00010481946,"teacher_disagreement_score":0.13301983,"about_ca_system_score_codex":0.00019493859,"about_ca_system_score_gemma":0.0012459178,"threshold_uncertainty_score":0.9235177},"labels":[],"label_agreement":null},{"id":"W2564840852","doi":"10.1200/jco.2007.13.1839","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Family medicine","score_opus":0.18145885832219863,"score_gpt":0.5408156734800993,"score_spread":0.35935681515790063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564840852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589883,0.0007899523,0.00003239091,0.026379734,0.0009700338,0.00006692211,1.4436863e-7,0.000002384131,0.012770108],"genre_scores_gemma":[0.9787841,0.0004240677,0.00394689,0.015635328,0.0010231258,5.719837e-7,1.8590536e-7,0.000005197256,0.00018054496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997751,0.00009075667,0.0017706607,0.000078900994,0.00017026148,0.00013842358],"domain_scores_gemma":[0.996388,0.0025018745,0.00064965483,0.00010144335,0.00013313539,0.0002258591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047387467,0.00005120521,0.0007776623,0.00011330445,0.0000070414067,0.000001548874,0.000050783237,0.00015179583,0.0001609084],"category_scores_gemma":[0.0029401882,0.000032587137,0.00028251854,0.000093800845,0.00005565457,0.000042957272,0.00001388598,0.00048027126,0.000033457516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016582407,0.003475014,0.7310809,0.0000032758112,0.0000856956,0.011246331,0.000030498612,5.195865e-7,0.000020221672,0.00021447122,0.010161989,0.24202289],"study_design_scores_gemma":[0.0052347817,0.0043130973,0.7083896,0.000029902285,0.00006714685,0.00069918134,0.000038860013,0.0000016832907,0.00009773291,0.00035599922,0.28075105,0.00002101199],"about_ca_topic_score_codex":0.000018356752,"about_ca_topic_score_gemma":0.00004825695,"teacher_disagreement_score":0.27058905,"about_ca_system_score_codex":0.000120652105,"about_ca_system_score_gemma":0.00043137895,"threshold_uncertainty_score":0.3519892},"labels":[],"label_agreement":null},{"id":"W2564858174","doi":"10.1200/jco.2011.29.4_suppl.88","title":"A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Lapatinib; Capecitabine; Medicine; Internal medicine; Cancer; Gastroenterology; Oncology; Progressive disease; Tyrosine-kinase inhibitor; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Chemotherapy; Clinical trial; Trastuzumab; Breast cancer; Colorectal cancer","score_opus":0.19257453198829422,"score_gpt":0.49483963677413534,"score_spread":0.3022651047858411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564858174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882516,0.0003039491,0.000117314245,0.002273587,0.0026374632,0.00041550602,0.0000070807805,0.000005297886,0.0059881983],"genre_scores_gemma":[0.99336016,0.0008851563,0.003287084,0.0010508008,0.001090731,0.000007944195,0.0000012814602,0.0000083008035,0.0003085476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962917,0.00019351172,0.002789622,0.00015200466,0.0003345437,0.00023863834],"domain_scores_gemma":[0.9969935,0.00039858613,0.0019395222,0.00016486662,0.00026599388,0.00023753538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018388059,0.00012520325,0.0016232501,0.0001881465,0.000016058908,0.000002171987,0.00019113405,0.00019099866,0.0007741764],"category_scores_gemma":[0.0019642673,0.00008971705,0.00046412315,0.00034864288,0.00013537546,0.00008881586,0.00008852887,0.0004549567,0.0000036541192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38835984,0.011792502,0.2158649,0.000058733865,0.00044045819,0.00070848333,0.0002577674,0.0000091867,0.000015285972,0.000070000686,0.009003287,0.37341955],"study_design_scores_gemma":[0.53982085,0.09407476,0.3336862,0.00015528998,0.0007473797,0.000051624567,0.0002302044,0.00016391475,0.000013189933,0.00009976583,0.030859439,0.00009739468],"about_ca_topic_score_codex":0.00033610288,"about_ca_topic_score_gemma":0.00045168973,"teacher_disagreement_score":0.37332216,"about_ca_system_score_codex":0.0002911333,"about_ca_system_score_gemma":0.0011286122,"threshold_uncertainty_score":0.8476689},"labels":[],"label_agreement":null},{"id":"W2564864626","doi":"10.1200/jco.2012.30.5_suppl.392","title":"Tumor suppressor effects for miR-215 identified through use of miRNA profiling in metastatic renal cell carcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"microRNA; Renal cell carcinoma; Metastasis; Gene expression profiling; Medicine; Cancer research; Microarray; Microarray analysis techniques; Oncology; Cancer; Gene expression; Gene; Internal medicine; Biology; Genetics","score_opus":0.13486726168803626,"score_gpt":0.4525949585665189,"score_spread":0.3177276968784826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564864626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97897583,0.002126826,0.016580587,0.00016080287,0.0013559574,0.0006287548,0.000019926494,0.0000019621862,0.00014935438],"genre_scores_gemma":[0.97265375,0.00009612863,0.026072932,0.00030867115,0.0005438811,0.000037287722,0.000016293954,0.000033968867,0.0002371147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633676,0.0008210244,0.0017865318,0.00025073916,0.0003178977,0.00048704006],"domain_scores_gemma":[0.9965661,0.0011933967,0.0012815136,0.00029018024,0.00042492003,0.00024389007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030358646,0.00016846882,0.00091872265,0.00011518837,0.000028580002,0.000012354443,0.00030604337,0.00033421107,0.0000267832],"category_scores_gemma":[0.0042161695,0.00014258003,0.00054257875,0.0001295224,0.00014391623,0.00003128186,0.0001410261,0.0005882393,0.000003066859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043872236,0.0015216657,0.0017641758,0.00021342555,0.00026731286,0.00012390323,0.00009926067,0.00017708146,0.9858208,0.00013701133,0.0029252344,0.0025629378],"study_design_scores_gemma":[0.0066991714,0.006151156,0.005602172,0.000052163912,0.0002241686,0.0000947202,0.00007209477,0.00010554786,0.96278125,0.00019201598,0.017864268,0.00016124305],"about_ca_topic_score_codex":0.000035114146,"about_ca_topic_score_gemma":0.000030620493,"teacher_disagreement_score":0.02303949,"about_ca_system_score_codex":0.000061760984,"about_ca_system_score_gemma":0.0009003742,"threshold_uncertainty_score":0.5814245},"labels":[],"label_agreement":null},{"id":"W2565262280","doi":"10.1200/jco.2011.29.15_suppl.tps238","title":"A randomized placebo-controlled trial of testosterone replacement for fatigue in male hypogonadic patients with advanced cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Internal medicine; Prostate cancer; Testosterone (patch); Hospital Anxiety and Depression Scale; Libido; Cancer; Cachexia; Physical therapy; Anxiety; Psychiatry","score_opus":0.14726862867831486,"score_gpt":0.441493116868591,"score_spread":0.29422448819027613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565262280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092746,0.00055855844,0.00011583323,0.0012182334,0.0009242859,0.0039902236,0.0000037941873,0.000002579953,0.002259021],"genre_scores_gemma":[0.9937061,0.00047679702,0.004477592,0.00017792307,0.00044935293,0.00028517144,0.0000012098074,0.000011774198,0.00041406517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959976,0.00046966324,0.0028436973,0.00020483349,0.0002957972,0.00018841292],"domain_scores_gemma":[0.9930858,0.0031542992,0.0026463878,0.0001398443,0.0008339147,0.00013975553],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047120163,0.00013845671,0.0037994382,0.00012548962,0.000022369948,9.607161e-7,0.000086512126,0.00014019026,0.00006492857],"category_scores_gemma":[0.009436948,0.00007078165,0.0004999243,0.000086955384,0.000351043,0.000059143043,0.000026317257,0.0003618782,5.9254336e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94611454,0.0041229366,0.02545032,0.000036819085,0.0011092067,0.000022472648,0.00031267895,0.000008272292,0.000019834408,0.000022554703,0.00012934845,0.022650996],"study_design_scores_gemma":[0.8992127,0.05806308,0.040883906,0.00015533826,0.00072841434,0.000008286237,0.00013172798,0.000012591941,0.000055308254,0.00015095712,0.0005298124,0.00006786997],"about_ca_topic_score_codex":0.000029191586,"about_ca_topic_score_gemma":0.0000752692,"teacher_disagreement_score":0.05394014,"about_ca_system_score_codex":0.00009262328,"about_ca_system_score_gemma":0.00079112337,"threshold_uncertainty_score":0.99890697},"labels":[],"label_agreement":null},{"id":"W2565812816","doi":"10.1200/jco.2015.33.15_suppl.9073","title":"Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Radiological weapon; Hazard ratio; Nuclear medicine; Response Evaluation Criteria in Solid Tumors; Pembrolizumab; Oncology; Radiology; Progressive disease; Cancer; Chemotherapy; Confidence interval; Immunotherapy","score_opus":0.14473248165729216,"score_gpt":0.49835399092426463,"score_spread":0.35362150926697244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565812816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494964,0.00012545082,0.00017185637,0.0036556495,0.00067915133,0.00031024925,0.000009955515,0.0000041118597,0.000093912495],"genre_scores_gemma":[0.9974724,0.000041762847,0.0018208346,0.0004799481,0.0001393473,0.0000028641705,0.0000033887916,0.000014705311,0.000024721558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922377,0.0046036113,0.0022740443,0.00022137635,0.00043508454,0.00022821761],"domain_scores_gemma":[0.98485327,0.013030042,0.0011687175,0.00019814273,0.00021713931,0.00053268654],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012242479,0.00017827652,0.0026365686,0.00028541958,0.000015475798,0.0000060376174,0.00014889971,0.00020080402,0.000030410696],"category_scores_gemma":[0.031305905,0.000110943976,0.00026014927,0.00010714702,0.00016377866,0.000047185396,0.000060441285,0.00070103916,0.000002713252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13255002,0.0022987283,0.82438284,0.00003109075,0.00018435236,0.00043102814,0.0003665119,0.00007342133,0.0009861668,0.000013614537,0.00023934936,0.038442872],"study_design_scores_gemma":[0.021909352,0.11667836,0.85730445,0.00021816696,0.00020225346,0.00006634334,0.00005734253,0.00081542216,0.00012585711,0.00006670032,0.0024801127,0.00007561246],"about_ca_topic_score_codex":0.000059697762,"about_ca_topic_score_gemma":0.000018646731,"teacher_disagreement_score":0.11437963,"about_ca_system_score_codex":0.00016960125,"about_ca_system_score_gemma":0.00046128116,"threshold_uncertainty_score":0.9768538},"labels":[],"label_agreement":null},{"id":"W2566155228","doi":"10.1200/jco.2014.32.31_suppl.173","title":"Developing a decision support tool for responding to patients’ reported levels of information needs, family anxiety, depression, and breathlessness.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Psychological intervention; Anxiety; Nice; MEDLINE; Guideline; Delphi method; Coping (psychology); Palliative care; Family medicine; Systematic review; Psychiatry; Nursing","score_opus":0.26815427553603727,"score_gpt":0.5216087581752985,"score_spread":0.25345448263926124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566155228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9209606,0.000076550146,0.077232555,0.000508946,0.0005033558,0.00023384289,0.000009264816,0.000004213135,0.00047064797],"genre_scores_gemma":[0.9119305,0.00044338193,0.08609544,0.0012950321,0.00019156374,0.0000036379372,0.000007662243,0.000007819532,0.000024957339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963198,0.00013265443,0.0029738764,0.00008831741,0.0003437378,0.00014165409],"domain_scores_gemma":[0.99218255,0.0034660688,0.0023246505,0.00014056254,0.0017058073,0.00018038334],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040049287,0.00010097075,0.0011363887,0.0004902063,0.000029877667,0.0000059824706,0.00009900469,0.0002616653,0.000009027423],"category_scores_gemma":[0.028390523,0.00007172394,0.00019512209,0.00028853535,0.00006142838,0.00024924226,0.00007096577,0.000213059,0.000001321621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037482302,0.00010657971,0.4997543,0.00007347692,0.00007932062,0.0000038339276,0.0007422702,0.0000064186197,0.0003109452,0.00015757211,0.0011799696,0.49383706],"study_design_scores_gemma":[0.0062092994,0.0044891164,0.81437874,0.0010682362,0.00016479453,0.000036838082,0.00045424508,0.00004618844,0.001183046,0.0005891659,0.17129837,0.00008196529],"about_ca_topic_score_codex":0.0000060762727,"about_ca_topic_score_gemma":0.0000027780095,"teacher_disagreement_score":0.4937551,"about_ca_system_score_codex":0.000068668705,"about_ca_system_score_gemma":0.00071847835,"threshold_uncertainty_score":0.9797937},"labels":[],"label_agreement":null},{"id":"W2566698805","doi":"10.1200/jco.2011.29.4_suppl.425","title":"The significance of HPV status in patients with anal cancer: A comparative technical analysis.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; CISH; Anal cancer; Oncology; Internal medicine; Immunohistochemistry; Subtyping; Cancer; In situ hybridization","score_opus":0.14703932211596163,"score_gpt":0.44484180175318017,"score_spread":0.2978024796372185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566698805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941992,0.00027111865,0.00003748951,0.00045879828,0.00013381346,0.00018062431,0.00000548387,0.000002497381,0.0047109374],"genre_scores_gemma":[0.99874264,0.00016247347,0.00072881806,0.00020484385,0.000107824264,0.0000052526743,0.0000012041068,0.0000043923305,0.00004255504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729,0.00030729763,0.0017028082,0.00013472588,0.00035387633,0.00021126923],"domain_scores_gemma":[0.9963369,0.0011823389,0.0014933489,0.00013608893,0.0006171869,0.00023416638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013453966,0.00009787661,0.0014906015,0.00015371491,0.000026753123,0.0000024604094,0.00015367068,0.0001373184,0.00015021669],"category_scores_gemma":[0.000535382,0.000048063237,0.0003790658,0.0006080947,0.0004983214,0.00005035729,0.000034323435,0.00075568934,0.0000011838181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01658045,0.0015439319,0.96051013,0.0000063690322,0.0006937265,0.00007079251,0.0001780286,0.0000183635,0.000013257632,0.0000901933,0.0002068302,0.020087933],"study_design_scores_gemma":[0.004225827,0.016210346,0.97649777,0.000021286762,0.0008638524,0.0000054747447,0.00016793863,0.00005840699,0.000041740448,0.00009568766,0.0017585732,0.00005312165],"about_ca_topic_score_codex":0.00022356809,"about_ca_topic_score_gemma":0.003097517,"teacher_disagreement_score":0.020034812,"about_ca_system_score_codex":0.00012361728,"about_ca_system_score_gemma":0.0011470439,"threshold_uncertainty_score":0.32831362},"labels":[],"label_agreement":null},{"id":"W2566831570","doi":"10.1200/jco.2011.29.15_suppl.2012","title":"A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: Have we improved outcome?","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Temozolomide; Cohort; Internal medicine; Population; Log-rank test; Glioblastoma; Proportional hazards model; Radiation therapy; Oncology; Clinical trial; Survival analysis","score_opus":0.19723109303733466,"score_gpt":0.46878959652122504,"score_spread":0.2715585034838904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566831570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314517,0.00011728026,0.000020390904,0.0054666284,0.00040017176,0.0006410714,0.0000015265099,0.0000041925673,0.00020357713],"genre_scores_gemma":[0.9977415,0.00002351451,0.0010333871,0.0009120839,0.00024624952,0.0000120805025,8.796843e-7,0.000011763069,0.000018506702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959461,0.00046860988,0.0028743364,0.00015893846,0.0003567133,0.00019529437],"domain_scores_gemma":[0.9951981,0.0023224181,0.0018115185,0.00029018073,0.00014598157,0.0002318497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00217428,0.00014693501,0.0014392942,0.00020946041,0.000025491627,0.000004992218,0.0002085945,0.00021323831,0.00011187418],"category_scores_gemma":[0.001715733,0.00007768066,0.00043392033,0.00016328906,0.00004776776,0.000060890143,0.000024723819,0.00057439896,0.000006138289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034988532,0.018284693,0.95016164,0.000011853251,0.00025991446,0.0006559267,0.0011216833,0.000015361813,0.000017793425,0.00003644968,0.00027607064,0.02565977],"study_design_scores_gemma":[0.025352161,0.03720327,0.93434376,0.000050578496,0.00049468427,0.000055343284,0.0010958248,0.00022967136,0.000049103743,0.00023708124,0.0008266028,0.000061920706],"about_ca_topic_score_codex":0.0005032679,"about_ca_topic_score_gemma":0.0024366959,"teacher_disagreement_score":0.02559785,"about_ca_system_score_codex":0.00010936187,"about_ca_system_score_gemma":0.00055016263,"threshold_uncertainty_score":0.31677255},"labels":[],"label_agreement":null},{"id":"W2566922698","doi":"10.1200/jco.2009.27.15_suppl.e16118","title":"Skeletal related events in patients with metastatic renal cell carcinoma: A retrospective review","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Spinal cord compression; Renal cell carcinoma; Sunitinib; Bone metastasis; Retrospective cohort study; Pathologic fracture; Radiation therapy; Cancer; Surgery; Metastasis; Radiology; Oncology; Internal medicine; Spinal cord","score_opus":0.10161634186021425,"score_gpt":0.4768969768265106,"score_spread":0.3752806349662964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566922698","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033620796,0.99223745,0.0000011582032,0.000487116,0.00050912675,0.0019564999,0.0000137945035,0.000006294611,0.0014265015],"genre_scores_gemma":[0.0026842596,0.9946255,0.0009976289,0.0010288453,0.00014128881,0.000018870429,0.00007034814,0.000047958238,0.00038526722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98981065,0.0018228758,0.0067310203,0.0004290917,0.0007447856,0.00046158963],"domain_scores_gemma":[0.9896697,0.0010407541,0.007621925,0.00036385536,0.00055718864,0.00074660126],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0034672264,0.00047735198,0.010738223,0.000342662,0.000031537304,0.0000022914537,0.00020758963,0.00071103784,0.0001060905],"category_scores_gemma":[0.002043002,0.00026845827,0.0015756828,0.0005899707,0.00010122998,0.0000954425,0.000036893907,0.0036432636,0.00006972491],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010197405,0.006845636,0.039058313,0.0133635765,0.0007382765,0.0023842433,0.000008713868,5.4852354e-8,1.1367933e-9,0.0000046310543,0.0015202018,0.9350566],"study_design_scores_gemma":[0.021879839,0.04356059,0.30802265,0.060480192,0.012188354,0.00066549884,0.000001459371,2.46707e-7,1.0718827e-8,0.00007327411,0.5528926,0.00023524367],"about_ca_topic_score_codex":0.000017284357,"about_ca_topic_score_gemma":0.00001647325,"teacher_disagreement_score":0.93482137,"about_ca_system_score_codex":0.0011066754,"about_ca_system_score_gemma":0.006501473,"threshold_uncertainty_score":0.99997675},"labels":[],"label_agreement":null},{"id":"W2566958034","doi":"10.1200/jco.2005.23.16_suppl.4603","title":"Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Nausea; Discontinuation; Internal medicine; Renal cell carcinoma; Gastroenterology; Constipation; Ileus; Adjuvant therapy; Carcinoma; Surgery; Chemotherapy","score_opus":0.07917845952725919,"score_gpt":0.42234288424944494,"score_spread":0.3431644247221858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566958034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834849,0.0013057183,0.000024831219,0.0033102361,0.00024175529,0.00036173058,0.000007798727,0.0000065411145,0.0112564685],"genre_scores_gemma":[0.98497844,0.000252823,0.012980394,0.00047840807,0.0007175312,0.000005425802,0.000008186603,0.00002585806,0.0005529227],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9949363,0.00043494828,0.0034368325,0.00030363616,0.0005442713,0.0003440416],"domain_scores_gemma":[0.9941551,0.0019811813,0.0025544087,0.00036063156,0.00046942398,0.00047922542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002293178,0.0002238625,0.0018830149,0.0002859337,0.00001978983,0.0000033121717,0.00019446714,0.00034940572,0.000053804855],"category_scores_gemma":[0.0011822206,0.0001463004,0.00041798322,0.00024747726,0.00024363997,0.00015146624,0.00004912368,0.0010903601,0.000013131621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42682275,0.028522683,0.080362715,0.00021220384,0.0003608247,0.020093607,0.0009839499,0.0010805699,0.012825418,0.000025476545,0.0053185965,0.42339122],"study_design_scores_gemma":[0.13495544,0.25395146,0.5449029,0.000376951,0.0006947614,0.0019274107,0.00024824918,0.00021916405,0.04079055,0.00003734832,0.021678733,0.00021700912],"about_ca_topic_score_codex":0.00002921253,"about_ca_topic_score_gemma":0.00008628466,"teacher_disagreement_score":0.4645402,"about_ca_system_score_codex":0.00035158222,"about_ca_system_score_gemma":0.001987466,"threshold_uncertainty_score":0.5965957},"labels":[],"label_agreement":null},{"id":"W2567267008","doi":"10.1200/jco.2012.30.4_suppl.504","title":"Colorectal cancer (CRC) KRAS mutational status and response to chemotherapy in absence of influence of epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) therapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"KRAS; Medicine; Cetuximab; Internal medicine; Irinotecan; Colorectal cancer; Chemotherapy; Oncology; Bevacizumab; Gastroenterology; Oxaliplatin; Performance status; Cancer","score_opus":0.07232275358412463,"score_gpt":0.4677301832482577,"score_spread":0.3954074296641331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567267008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348354,0.0024164906,0.0000058053097,0.0033108806,0.00036559135,0.00029062442,0.00004098624,0.0000031227607,0.000082954124],"genre_scores_gemma":[0.9921837,0.0052024606,0.0014465749,0.00085706764,0.00026265476,0.00001190421,0.0000015757145,0.000012436733,0.000021647056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971649,0.00036913133,0.001640511,0.00016181571,0.000365162,0.0002984933],"domain_scores_gemma":[0.9949784,0.0029441337,0.0010886719,0.00007380083,0.0005825379,0.00033241438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015012058,0.00015777936,0.001315594,0.00018223199,0.000026642932,0.0000028889197,0.00008885359,0.00018393144,0.00020637873],"category_scores_gemma":[0.0023211874,0.000109992725,0.00019228789,0.00022126148,0.00029650755,0.00016131977,0.000040442934,0.0003733409,0.0000014283637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05541869,0.0013492339,0.8832235,0.000024002566,0.0003647326,0.00002856864,0.0020257058,0.000025730656,0.027700154,0.000028320655,0.0001081971,0.029703174],"study_design_scores_gemma":[0.007448278,0.01142008,0.9746421,0.00011653275,0.00004080264,0.000043936725,0.00020272183,0.000007393127,0.0039303186,0.000052119736,0.0020067361,0.00008896592],"about_ca_topic_score_codex":0.00028453342,"about_ca_topic_score_gemma":0.00007587541,"teacher_disagreement_score":0.091418624,"about_ca_system_score_codex":0.0002514307,"about_ca_system_score_gemma":0.0014171108,"threshold_uncertainty_score":0.4485373},"labels":[],"label_agreement":null},{"id":"W2567319931","doi":"10.1200/jco.2009.27.15_suppl.e20674","title":"Phase III randomized anastrozole exercise (RAE) trial: First planned interim analysis","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Interim analysis; Anastrozole; Physical therapy; Quality of life (healthcare); Clinical endpoint; Randomized controlled trial; Visual analogue scale; Internal medicine; Breast cancer; Cancer","score_opus":0.12916344628643567,"score_gpt":0.5220366772905242,"score_spread":0.3928732310040885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567319931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705222,0.00076296326,0.000817189,0.022944875,0.0014132278,0.00096015993,0.0000047482295,0.000020650241,0.0025539345],"genre_scores_gemma":[0.9910797,0.001666184,0.0020242538,0.004034985,0.00062995136,0.000009606817,0.000013489492,0.0000094386705,0.0005324047],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942124,0.0005709227,0.0043430435,0.00020887094,0.00034630098,0.00031845146],"domain_scores_gemma":[0.9936122,0.002236422,0.002687477,0.00025302792,0.0002986039,0.000912278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004832283,0.00018095427,0.0054434557,0.00036808915,0.000060778235,0.000009939503,0.00013570984,0.00038469426,0.00033468165],"category_scores_gemma":[0.003036135,0.000113935006,0.0020267947,0.00035754955,0.0001533499,0.00009368614,0.00001768926,0.0007760038,0.000027145146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8367826,0.010813308,0.0009497149,0.000007591523,0.0019394329,0.0008963306,0.000060360948,0.0000053026843,0.0000022451,0.000014358201,0.0043250024,0.14420377],"study_design_scores_gemma":[0.9124956,0.05468545,0.0058048004,0.00008871036,0.008924633,0.000076945085,0.00002994618,0.00029287563,0.00001360688,0.00020226787,0.017307848,0.00007729841],"about_ca_topic_score_codex":0.000062248444,"about_ca_topic_score_gemma":0.00008001776,"teacher_disagreement_score":0.14412646,"about_ca_system_score_codex":0.00012229553,"about_ca_system_score_gemma":0.0009145135,"threshold_uncertainty_score":0.4646135},"labels":[],"label_agreement":null},{"id":"W2567395185","doi":"10.1200/jco.2016.69.9538","title":"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Takeda Oncology; Genentech; National Cancer Institute; Onyx Pharmaceuticals; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ovarian cancer; Internal medicine; Fallopian tube; Adverse effect; Gastroenterology; Fallopian tube cancer; Response Evaluation Criteria in Solid Tumors; Population; Nausea; Phases of clinical research; Folate receptor; Oncology; Cancer; Surgery; Chemotherapy; Cancer cell","score_opus":0.08803792109366386,"score_gpt":0.47507233083841643,"score_spread":0.38703440974475256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567395185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98831475,0.0009521262,0.00003520773,0.008361102,0.0010426019,0.00085194677,0.00007486308,0.000008485305,0.00035894103],"genre_scores_gemma":[0.99146914,0.004810836,0.0025399383,0.000326804,0.0006725379,0.0000136947065,0.000008247813,0.00003172661,0.0001270583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950939,0.00066966907,0.002914726,0.0004606125,0.00049709785,0.00036402303],"domain_scores_gemma":[0.993843,0.0015054578,0.0033688904,0.00042093187,0.00043474376,0.00042694734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041718916,0.00030095258,0.0030185806,0.00016537601,0.0001982842,0.00003699555,0.0002370891,0.00030177555,0.00017560797],"category_scores_gemma":[0.0019315397,0.00020451903,0.00029952047,0.00012365983,0.00033539423,0.00032501615,0.00016083132,0.000994596,0.0000013508115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16197023,0.027796235,0.48426947,0.00026677488,0.0017318925,0.0043067983,0.0012457779,0.000009855173,0.017016042,0.00002953638,0.00084092905,0.30051646],"study_design_scores_gemma":[0.07905639,0.034786154,0.87533766,0.0008980281,0.00077880436,0.000106443564,0.0003261355,0.0001987863,0.0005817953,0.000025595546,0.00769026,0.00021394012],"about_ca_topic_score_codex":0.0014021442,"about_ca_topic_score_gemma":0.0020486051,"teacher_disagreement_score":0.3910682,"about_ca_system_score_codex":0.00042424133,"about_ca_system_score_gemma":0.002627015,"threshold_uncertainty_score":0.8340044},"labels":[],"label_agreement":null},{"id":"W2568080812","doi":"10.1200/jco.2011.29.15_suppl.3601","title":"The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Magnesium in Health and Disease","field":"Nursing","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Toronto East General Hospital; Moncton Hospital; University of Toronto; University of the Fraser Valley; University of Ottawa; Mount Sinai Hospital","funders":"","keywords":"Medicine; Hypomagnesemia; Cetuximab; Internal medicine; Randomized controlled trial; Oncology; Cancer; Colorectal cancer","score_opus":0.1511114257041537,"score_gpt":0.48990883681583586,"score_spread":0.33879741111168216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568080812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98755854,0.0005480706,0.0000028980976,0.00048790863,0.0029490637,0.0014195844,0.000025208124,0.000009601903,0.0069991415],"genre_scores_gemma":[0.9987776,0.00009901098,0.00011012211,0.0004774778,0.00042091432,0.000033740813,0.0000034801176,0.000026686233,0.000050960272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98787284,0.004080294,0.0061939806,0.0003716908,0.00089085905,0.0005903257],"domain_scores_gemma":[0.9743135,0.017872188,0.0054326733,0.0005422275,0.0011810928,0.000658312],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007816664,0.00032175056,0.0035362204,0.0002730877,0.00012632739,0.000013848242,0.00073617423,0.0004398877,0.00021208724],"category_scores_gemma":[0.019908018,0.00021474024,0.0007201881,0.0002748514,0.00083361135,0.00022232124,0.00010163225,0.0014133413,0.000011899182],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95588094,0.011188318,0.014897512,0.00017096514,0.00014576364,0.00049221393,0.005462404,0.0002037053,0.00004170702,0.00008284241,0.0004742744,0.010959374],"study_design_scores_gemma":[0.8236375,0.088233724,0.07698344,0.0001228706,0.0010357545,0.000020886333,0.008277894,0.00015528502,0.0001089137,0.000511139,0.00063330826,0.000279276],"about_ca_topic_score_codex":0.0014061268,"about_ca_topic_score_gemma":0.0011546628,"teacher_disagreement_score":0.13224341,"about_ca_system_score_codex":0.00035645574,"about_ca_system_score_gemma":0.0023224347,"threshold_uncertainty_score":0.9883477},"labels":[],"label_agreement":null},{"id":"W2569288066","doi":"10.1200/jco.2015.33.7_suppl.157","title":"Genomic analysis of circulating cell-free DNA (cfDNA) to investigate mechanisms of resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Androgen receptor; Abiraterone acetate; Oncology; Progression-free survival; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.1701778719691283,"score_gpt":0.45910992064103445,"score_spread":0.28893204867190614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569288066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944925,0.0004724303,0.00016146421,0.003431258,0.00028041462,0.00068101264,0.00009159827,0.000003946293,0.00038541664],"genre_scores_gemma":[0.98608583,0.00013380704,0.012654047,0.00065831776,0.00007286756,0.000026409354,0.000012315662,0.000021613872,0.00033478456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99474376,0.00055497757,0.003171855,0.00030348313,0.0008604838,0.0003654498],"domain_scores_gemma":[0.9946655,0.0008378772,0.0019527652,0.0003594983,0.001363309,0.0008210593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003819352,0.00018664899,0.0020530084,0.0008140897,0.000027390877,0.0000093325125,0.00029869625,0.00014346317,0.000041276755],"category_scores_gemma":[0.003971585,0.00014022626,0.0003807428,0.0012664539,0.00014822796,0.00010588031,0.00011742963,0.00045437156,0.0000035483333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043466683,0.0052148015,0.7650545,0.0006599202,0.005688841,0.0011965632,0.0064598923,0.016733814,0.1383905,0.0003385752,0.003630502,0.013165395],"study_design_scores_gemma":[0.025071919,0.01609741,0.92863345,0.0006715497,0.0038480873,0.000006168978,0.0013157362,0.0004860579,0.01900276,0.003236445,0.0013345795,0.00029582204],"about_ca_topic_score_codex":0.00036796456,"about_ca_topic_score_gemma":0.0029205463,"teacher_disagreement_score":0.16357894,"about_ca_system_score_codex":0.00075641094,"about_ca_system_score_gemma":0.003592124,"threshold_uncertainty_score":0.63722736},"labels":[],"label_agreement":null},{"id":"W2569859240","doi":"10.1200/jco.2004.22.90140.6042","title":"Renal safety with pamidronate (PAM) 1-hour infusion for metastatic breast cancer (MBC) and multiple myeloma (MM): A multi-centre, population-based analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Metastatic breast cancer; Urology; Renal function; Population; Creatinine; Randomized controlled trial; Breast cancer; Surgery; Cancer; Internal medicine","score_opus":0.08170321424602131,"score_gpt":0.44240929573447013,"score_spread":0.36070608148844885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569859240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798224,0.00028203343,0.0062218006,0.012804594,0.00020454726,0.00054649235,0.00009225977,0.000012002366,0.000013866526],"genre_scores_gemma":[0.9503199,0.00023203656,0.047163174,0.0020042676,0.00014738434,0.00000896252,0.000040193194,0.000019353825,0.000064725726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971602,0.00020617805,0.001784769,0.00024393029,0.00030769358,0.00029724365],"domain_scores_gemma":[0.99583554,0.0013807574,0.0015212295,0.00014432793,0.0004862226,0.00063192943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011504142,0.00017857309,0.0015781849,0.00023762185,0.00010580854,0.000007907,0.000058829395,0.00019414298,0.000056519882],"category_scores_gemma":[0.0007340253,0.000110385015,0.00040986444,0.00030669363,0.00009247954,0.0000932004,0.0000151522245,0.00041870985,0.0000021399057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018904954,0.0027425676,0.8884123,0.000070033166,0.0020632949,0.00027657047,0.00005163837,0.003472837,0.00001658743,0.000012332922,0.000035773934,0.08394111],"study_design_scores_gemma":[0.053190354,0.004263073,0.9310445,0.00017073109,0.0043066223,0.00015779943,0.000030934225,0.005522185,0.000013526686,0.00005390723,0.0011470917,0.00009927283],"about_ca_topic_score_codex":0.0014119779,"about_ca_topic_score_gemma":0.008110615,"teacher_disagreement_score":0.08384184,"about_ca_system_score_codex":0.00037714367,"about_ca_system_score_gemma":0.0018681062,"threshold_uncertainty_score":0.4525914},"labels":[],"label_agreement":null},{"id":"W2572288598","doi":"10.1200/jco.2009.27.15_suppl.1025","title":"α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Brain metastasis; Tissue microarray; Cancer; Metastasis; Oncology; Pathology; Cytokeratin; Internal medicine; Metastatic breast cancer; Immunohistochemistry","score_opus":0.0316419144826284,"score_gpt":0.40583684310943163,"score_spread":0.37419492862680326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572288598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771082,0.0008125614,0.0018244084,0.019739114,0.00008302993,0.00014513975,0.000017870672,0.000004297436,0.00026539262],"genre_scores_gemma":[0.9890861,0.0018533677,0.00368368,0.0048942845,0.00028108747,0.000009859754,0.000008950238,0.000008649996,0.00017400342],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845517,0.00028124003,0.0007686463,0.00020677119,0.00012424581,0.0001639297],"domain_scores_gemma":[0.99853027,0.00014323051,0.0008750247,0.000115716735,0.00021393491,0.00012183065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641828,0.000106113606,0.00044343778,0.00005278375,0.000029738432,0.000007267933,0.00013752538,0.00042900883,0.00001711346],"category_scores_gemma":[0.00033614345,0.00007592395,0.00011447413,0.00008336239,0.000041244708,0.000007734528,0.000036010762,0.00035780855,6.2791094e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027281796,0.0014556478,0.07379511,0.000013666354,0.00026210595,0.00008546354,0.00003714912,0.000107460175,0.74930286,0.00032328104,0.027404532,0.14448452],"study_design_scores_gemma":[0.008735734,0.013705695,0.58634645,0.00016997862,0.0002364359,0.00036350952,0.000073147516,0.00013737507,0.09003623,0.0014621059,0.29819167,0.0005416844],"about_ca_topic_score_codex":0.0000058315886,"about_ca_topic_score_gemma":0.000063805586,"teacher_disagreement_score":0.65926665,"about_ca_system_score_codex":0.000044864228,"about_ca_system_score_gemma":0.0002956396,"threshold_uncertainty_score":0.3308909},"labels":[],"label_agreement":null},{"id":"W2572922053","doi":"10.1200/jco.2016.69.9645","title":"Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":376,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; National Cancer Coalition","keywords":"Medicine; Guideline; Nephrology; Kidney disease; Nephrectomy; Internal medicine; Intensive care medicine; Renal function; Observational study; Clinical trial; Surgery; Kidney; Pathology","score_opus":0.34390507024286443,"score_gpt":0.5798912535917476,"score_spread":0.23598618334888322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572922053","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8737334,0.0008348509,0.00284301,0.061446704,0.004360936,0.00086157327,0.000015473363,0.000020471802,0.055883553],"genre_scores_gemma":[0.46292078,0.0123011125,0.5141166,0.0061134286,0.0035959415,0.000007477962,0.000008185541,0.000049171227,0.0008873414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97729343,0.0028262767,0.017508358,0.0006797626,0.001150396,0.0005417968],"domain_scores_gemma":[0.9506422,0.013313798,0.03042176,0.0015503641,0.0029210902,0.0011507807],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037711363,0.00039014794,0.0068522124,0.00012879558,0.00011538664,0.000017759596,0.0011003352,0.0011289968,0.00016369675],"category_scores_gemma":[0.021977188,0.00027709611,0.004229175,0.00017420277,0.003129579,0.00023944369,0.00063741056,0.0030257662,0.000031218475],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020634707,0.014403449,0.19593,0.0001657107,0.0067656045,0.0047514047,0.0000613025,0.000019929243,0.00006371084,0.00025317835,0.04729542,0.7096556],"study_design_scores_gemma":[0.015970029,0.05112273,0.3876174,0.00024744804,0.0037964934,0.0005851174,0.0006877047,0.00019128951,0.00007120501,0.00016358148,0.5393919,0.00015511033],"about_ca_topic_score_codex":0.00019604337,"about_ca_topic_score_gemma":0.00004979422,"teacher_disagreement_score":0.7095005,"about_ca_system_score_codex":0.0003239331,"about_ca_system_score_gemma":0.0047517484,"threshold_uncertainty_score":0.9999681},"labels":[],"label_agreement":null},{"id":"W2573011907","doi":"10.1200/jco.2006.24.18_suppl.10068","title":"Use of denaturing high performance liquid chromatography (dHPLC) for detection of EGFR mutations in patients with NSCLC","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Denaturing high performance liquid chromatography; Exon; genomic DNA; Epidermal growth factor receptor; Missense mutation; Molecular biology; DNA sequencing; Gene; Mutation; Lung cancer; Biology; Genetics; Cancer research; Medicine; Cancer; Pathology","score_opus":0.037885809764650766,"score_gpt":0.39847104845873427,"score_spread":0.3605852386940835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573011907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857765,0.00006511408,0.0005070537,0.00020582607,0.00024279534,0.0002876834,0.000009159203,0.000003042055,0.00010169592],"genre_scores_gemma":[0.9937634,0.000040307557,0.005968129,0.000063714004,0.00011997397,0.000008375907,0.000009751817,0.00000916,0.00001720189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983662,0.00005008283,0.0012303289,0.00008204497,0.00017066362,0.00010067541],"domain_scores_gemma":[0.9975569,0.0005784079,0.0011795639,0.00007937381,0.0005487407,0.000056972593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030538495,0.00006798846,0.0005783782,0.00021839859,0.00002262242,0.0000020990558,0.00003857703,0.00012793406,0.0000056074273],"category_scores_gemma":[0.0002587197,0.00004603487,0.00015972038,0.00018340092,0.00010018164,0.00015462785,0.0000067165392,0.0001939252,2.4255206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011369059,0.0036736415,0.94615674,0.00011775556,0.00043772455,0.000012368794,0.00008986373,0.0011694112,0.0007298555,0.00007136495,0.000059448033,0.036112785],"study_design_scores_gemma":[0.010613018,0.020259708,0.96451104,0.00019095346,0.00046166603,0.000010355566,0.000021469958,0.00007638496,0.0029593897,0.000043897573,0.00081143196,0.000040688516],"about_ca_topic_score_codex":0.00011365123,"about_ca_topic_score_gemma":0.00013444513,"teacher_disagreement_score":0.036072098,"about_ca_system_score_codex":0.00009171564,"about_ca_system_score_gemma":0.00040395514,"threshold_uncertainty_score":0.18772475},"labels":[],"label_agreement":null},{"id":"W2574119868","doi":"10.1200/jco.2016.71.6712","title":"Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Internal medicine; Autologous stem-cell transplantation; Oncology; Lymphoma; Transplantation; Hematopoietic stem cell transplantation; Cumulative incidence; Myeloid; Cohort","score_opus":0.08473478358565387,"score_gpt":0.44151671627837075,"score_spread":0.35678193269271685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574119868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868283,0.000061889354,0.0006073297,0.009753506,0.0005500423,0.00037614233,0.000026825865,0.000013180875,0.0017827334],"genre_scores_gemma":[0.9913665,0.00016782962,0.004252513,0.0015993584,0.00037702915,0.000022245084,0.0000070861015,0.000027974027,0.0021794538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970432,0.00028546678,0.0016178146,0.00020952139,0.0004996458,0.00034435643],"domain_scores_gemma":[0.99232185,0.004020585,0.0022174218,0.00031121372,0.0007506254,0.00037829246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032418924,0.00016665127,0.0016039655,0.00012127637,0.00014501633,0.000018618424,0.00031935872,0.00054569467,0.00008025422],"category_scores_gemma":[0.0025711278,0.00010391519,0.00060455047,0.000044921737,0.00039792238,0.00020886454,0.000036517766,0.0005764851,0.000018612292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045582157,0.0027320797,0.84688026,0.00020436398,0.0016356269,0.0076910774,0.00031106925,0.000008672637,0.000103387065,0.00007788358,0.004880278,0.089893155],"study_design_scores_gemma":[0.02826858,0.007597965,0.9562903,0.0001342143,0.00089238014,0.000667292,0.00010850091,0.00011894804,0.00017051079,0.00010363868,0.0055331346,0.000114522496],"about_ca_topic_score_codex":0.000014550459,"about_ca_topic_score_gemma":0.00009285449,"teacher_disagreement_score":0.10941006,"about_ca_system_score_codex":0.00040816233,"about_ca_system_score_gemma":0.0029967236,"threshold_uncertainty_score":0.5316059},"labels":[],"label_agreement":null},{"id":"W2574220585","doi":"10.1200/jco.2016.68.8895","title":"Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Discontinuation; Breast cancer; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.2931763235209957,"score_gpt":0.5308697601492762,"score_spread":0.23769343662828052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574220585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617493,0.00004276454,0.000020657464,0.0022056852,0.0005638457,0.0007639036,0.0000073250817,0.000002080263,0.00021883097],"genre_scores_gemma":[0.99910486,0.000111424415,0.000014808398,0.00003140104,0.00043607486,0.000017321967,0.0000027879207,0.0000067207093,0.00027457488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976415,0.00046768965,0.001326483,0.00011615086,0.00033923407,0.000108942186],"domain_scores_gemma":[0.9959074,0.0005329396,0.003038158,0.00023797214,0.00021031444,0.00007319226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022939832,0.000101288744,0.0009775426,0.00006468274,0.0000562088,0.000019682184,0.00017886511,0.00014741985,0.00004223061],"category_scores_gemma":[0.00075460214,0.00004735269,0.00035686273,0.000060275917,0.0000983355,0.00019728177,0.00001887505,0.00034068443,2.2844017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018907515,0.009406987,0.8861216,0.000002776139,0.000547147,0.000037688715,0.0007131804,0.0000021275428,0.00000863487,0.000006448558,0.00005598615,0.084189914],"study_design_scores_gemma":[0.07184833,0.031531453,0.89522547,0.00010844608,0.0005954872,0.000005493542,0.00040786405,0.0000055763353,0.000009299056,0.00005741421,0.00016446979,0.00004069429],"about_ca_topic_score_codex":0.00081370154,"about_ca_topic_score_gemma":0.004221914,"teacher_disagreement_score":0.08414922,"about_ca_system_score_codex":0.00024381738,"about_ca_system_score_gemma":0.00095660903,"threshold_uncertainty_score":0.23559271},"labels":[],"label_agreement":null},{"id":"W2576883525","doi":"10.1200/jco.2014.32.4_suppl.477","title":"Neutrophil to lymphocyte ratio and response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Renal cell carcinoma; Sorafenib; Gastroenterology; Oncology; Tyrosine-kinase inhibitor; Neutrophil to lymphocyte ratio; Lymphocyte; Response Evaluation Criteria in Solid Tumors; Progressive disease; Cancer; Disease; Hepatocellular carcinoma","score_opus":0.08616720757808899,"score_gpt":0.4004625786739059,"score_spread":0.3142953710958169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576883525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98304105,0.0008030203,0.00020890262,0.014619961,0.00047838417,0.00047408507,0.0000022889303,0.000005950351,0.00036634918],"genre_scores_gemma":[0.9829329,0.00016894453,0.00907482,0.0066564265,0.00077931513,0.000013330114,0.0000012388463,0.000027248085,0.00034576564],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995396,0.0015132313,0.0020802398,0.00031066642,0.00039050728,0.00030931432],"domain_scores_gemma":[0.99501526,0.0027516123,0.00065364526,0.0002931697,0.00032271806,0.00096360856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050864806,0.00021583209,0.0015558081,0.00040296733,0.00003324812,0.000016628235,0.00013488054,0.000177961,0.000042572392],"category_scores_gemma":[0.0028707986,0.00014839279,0.00026592438,0.00027727254,0.000097843105,0.00007538288,0.00006900889,0.00050386554,0.000036141653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28580058,0.0056275576,0.107825324,0.00007989844,0.00024727397,0.00936178,0.001399752,0.00044736368,0.28463873,0.00006265655,0.006424944,0.29808414],"study_design_scores_gemma":[0.030137375,0.09391247,0.8008659,0.00010172662,0.0002124859,0.0005956163,0.00008726855,0.00013815357,0.026126448,0.000083602084,0.047549933,0.00018903564],"about_ca_topic_score_codex":0.00005035129,"about_ca_topic_score_gemma":0.000040182815,"teacher_disagreement_score":0.69304055,"about_ca_system_score_codex":0.00046185797,"about_ca_system_score_gemma":0.0014429789,"threshold_uncertainty_score":0.6051282},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2577047889","doi":"10.1200/jco.2011.29.4_suppl.380","title":"Causes of suboptimal colorectal cancer screening (CRCS) in U.S. immigrants.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sigmoidoscopy; Colonoscopy; Immigration; Colorectal cancer; Fecal occult blood; Residence; Health care; Logistic regression; Odds ratio; Demography; Family medicine; Internal medicine; Gerontology; Cancer","score_opus":0.19867034395780966,"score_gpt":0.45472669460090004,"score_spread":0.2560563506430904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577047889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939968,0.00097240595,0.00043575783,0.0005247838,0.0010377197,0.00012522422,0.000002921153,0.000010004424,0.0028943666],"genre_scores_gemma":[0.991528,0.0005997287,0.0068809446,0.0003418035,0.0005635095,0.000005279814,4.8572423e-7,0.0000141965775,0.00006608631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701774,0.00023564209,0.0020640527,0.00016365509,0.0002992222,0.00021966164],"domain_scores_gemma":[0.99725384,0.00054065767,0.0014631028,0.00010013258,0.00041190715,0.00023036916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021690768,0.000119128075,0.0013398182,0.00025582736,0.000020403544,0.0000023782136,0.00012477279,0.00035140003,0.000269911],"category_scores_gemma":[0.0012964777,0.00009152467,0.00042949565,0.00028602427,0.00021626458,0.00011413715,0.000040981748,0.00095626235,0.0000029252362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061603528,0.0009732191,0.7135023,0.00003303876,0.00027757956,0.0004687092,0.00047496255,0.000038678805,0.001282342,0.000024754914,0.00053552486,0.22078538],"study_design_scores_gemma":[0.0058468287,0.029491132,0.9549785,0.00022328793,0.00022720135,0.0003413272,0.00022836839,0.00030029254,0.0051597375,0.000056516288,0.0030551786,0.00009158239],"about_ca_topic_score_codex":0.002110328,"about_ca_topic_score_gemma":0.0023346266,"teacher_disagreement_score":0.24147627,"about_ca_system_score_codex":0.000104391394,"about_ca_system_score_gemma":0.0010310173,"threshold_uncertainty_score":0.41545373},"labels":[],"label_agreement":null},{"id":"W2577999923","doi":"10.1200/jco.2012.30.4_suppl.338","title":"Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Regimen; Internal medicine; Gallbladder cancer; Chemotherapy; Oncology; Bile duct cancer; Gastroenterology; Univariate analysis; Gemcitabine; Biliary tract; Population; Ampulla of Vater; Chemotherapy regimen; Gallbladder; Cancer; Surgery; Carcinoma; Multivariate analysis","score_opus":0.07894480036505948,"score_gpt":0.4134499826407875,"score_spread":0.334505182275728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577999923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919063,0.0055935634,0.0000041155245,0.001581167,0.0005089751,0.00021435086,0.000011135927,0.0000024914614,0.00017789047],"genre_scores_gemma":[0.9964142,0.0015539147,0.0006923702,0.0007967635,0.000507538,0.0000023367545,0.0000015098426,0.000010260616,0.000021144695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981482,0.0001060586,0.0011991436,0.00012926,0.0002257277,0.00019161851],"domain_scores_gemma":[0.99813837,0.00035218312,0.00087990705,0.00011596216,0.00030428573,0.00020928174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010508244,0.00010977264,0.0011492328,0.0000734123,0.000015150671,0.0000015698062,0.00005864152,0.00015744123,0.000097426135],"category_scores_gemma":[0.00031884972,0.00006971155,0.00015767789,0.000096933385,0.00016996256,0.00014990281,0.000023722136,0.00047638908,3.3308936e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0095806895,0.0024040814,0.8608123,0.0000421243,0.00014025276,0.000009278383,0.00017919815,0.000007213615,0.000039734925,0.0000025983898,0.00013580374,0.1266467],"study_design_scores_gemma":[0.02018196,0.00878673,0.96950173,0.00009583093,0.00015285284,0.000027056745,0.00006913538,0.0000026106677,0.000077139135,0.000016107353,0.0010244802,0.000064369786],"about_ca_topic_score_codex":0.000016472819,"about_ca_topic_score_gemma":0.00010863914,"teacher_disagreement_score":0.12658232,"about_ca_system_score_codex":0.00010058801,"about_ca_system_score_gemma":0.00035307242,"threshold_uncertainty_score":0.28427544},"labels":[],"label_agreement":null},{"id":"W2578420050","doi":"10.1200/jco.2006.24.18_suppl.20001","title":"Distress and breast cancer anxiety (BCA) among BRCA mutation carriers participating in MRI-based screening","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anxiety; BRCA mutation; Breast cancer; Mammography; Hospital Anxiety and Depression Scale; Internal medicine; Cancer; Distress; Oncology; Depression (economics); Psychiatry; Clinical psychology","score_opus":0.039657153331884125,"score_gpt":0.4086722355618575,"score_spread":0.36901508222997337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578420050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938609,0.00056123413,0.0031582126,0.0017029035,0.0003900889,0.00008192543,0.00002885436,0.0000028705663,0.00021301588],"genre_scores_gemma":[0.9942366,0.00013627141,0.004308628,0.00038690332,0.0008514468,0.000027487256,0.00001454029,0.000014510756,0.000023622615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979691,0.00030652492,0.0011529158,0.00021309171,0.00015648831,0.00020190034],"domain_scores_gemma":[0.9984236,0.00020991983,0.0009042814,0.00011320035,0.00022937631,0.000119638746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013153959,0.00010772231,0.00039142094,0.000058419788,0.000054228207,0.000015993832,0.00011485602,0.00029394915,0.000033282322],"category_scores_gemma":[0.00044143997,0.000096913485,0.00013682997,0.00010839708,0.0002747866,0.000012923754,0.00003835415,0.0003332892,2.682566e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048948,0.00015142304,0.87750804,0.000012732679,0.000062540516,0.000037030608,0.00003974049,0.028451558,0.0015413671,0.000008900634,0.001305085,0.090392075],"study_design_scores_gemma":[0.0031789246,0.00057460566,0.9835442,0.00005708872,0.00007520513,0.00006069084,0.0001480888,0.0042883134,0.0019363584,0.00009028492,0.0059092185,0.000137039],"about_ca_topic_score_codex":0.00034306644,"about_ca_topic_score_gemma":0.0025691972,"teacher_disagreement_score":0.10603611,"about_ca_system_score_codex":0.00009425683,"about_ca_system_score_gemma":0.0006884952,"threshold_uncertainty_score":0.3952017},"labels":[],"label_agreement":null},{"id":"W2580323927","doi":"10.1200/jco.2012.30.5_suppl.287","title":"Extended lymphadenectomy and adjuvant chemotherapy in muscle-invasive bladder cancer treated by radical cystectomy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Lymphadenectomy; Lymph node; Urology; Dissection (medical); Proportional hazards model; Adjuvant; Cisplatin; Cohort; Chemotherapy; Oncology; Stage (stratigraphy); Internal medicine; Cancer; Surgery","score_opus":0.06565529934703658,"score_gpt":0.43626167899297397,"score_spread":0.3706063796459374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580323927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97880596,0.012498623,0.000015848638,0.0062483745,0.0007156089,0.00029749083,0.000009398866,0.000012238021,0.0013964674],"genre_scores_gemma":[0.9838487,0.009126281,0.00042272196,0.0049105324,0.0013119418,0.0000189742,0.0000031692648,0.00003087113,0.00032680164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971419,0.0003662128,0.001540123,0.00021605987,0.00032258232,0.00041309703],"domain_scores_gemma":[0.99730396,0.0009735203,0.00072955695,0.00014907481,0.00015303606,0.0006908248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001147598,0.00021054054,0.0015913129,0.0001327163,0.000029650291,0.000006998672,0.00010308123,0.0004684725,0.0005296158],"category_scores_gemma":[0.0005823057,0.00014129994,0.00028813837,0.00016797628,0.000257333,0.00016223364,0.000025579984,0.00059504376,0.000009110874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051022638,0.003937185,0.6727909,0.000029913195,0.0008693995,0.00046790953,0.00039483377,4.4021843e-7,0.002092197,0.000012570328,0.008905368,0.30539703],"study_design_scores_gemma":[0.036960877,0.005740888,0.88686275,0.00014834413,0.00050848856,0.00056211423,0.000108834916,0.000010965004,0.0016148386,0.00006300148,0.067270465,0.00014844033],"about_ca_topic_score_codex":0.00024583805,"about_ca_topic_score_gemma":0.000090691334,"teacher_disagreement_score":0.3052486,"about_ca_system_score_codex":0.00031863016,"about_ca_system_score_gemma":0.0012353517,"threshold_uncertainty_score":0.57989216},"labels":[],"label_agreement":null},{"id":"W2580880090","doi":"10.1200/jco.2012.30.5_suppl.328","title":"Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Gastroenterology; Kidney disease; Pneumonitis; Surgery; Chemotherapy; Lung","score_opus":0.04360169391427558,"score_gpt":0.39130825181259726,"score_spread":0.34770655789832167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580880090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821067,0.00006897783,0.0000066760704,0.00027648127,0.00017276929,0.0006343709,0.000015149876,0.000009576158,0.0006053479],"genre_scores_gemma":[0.9989702,0.00013634955,0.00021165262,0.00029047037,0.00029860938,0.00000925491,0.0000041491476,0.000039449365,0.00003985721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971339,0.00035870887,0.001423535,0.00026062343,0.00040213467,0.00042111694],"domain_scores_gemma":[0.9963917,0.00084138045,0.0016032058,0.00018565642,0.0004202138,0.0005578192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008556136,0.00029083152,0.0017095155,0.00018987223,0.00006442818,0.000016752734,0.00008295619,0.00019969614,0.00009792494],"category_scores_gemma":[0.00014987757,0.00017538157,0.0002035641,0.00022868348,0.00017643793,0.00020508899,0.000031224834,0.00086379127,0.0000015494406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021218237,0.0031721294,0.9656498,0.000047118705,0.00033973754,0.000106199295,0.00018477606,0.000057924422,0.003909709,0.0000020773216,0.000078247234,0.005234033],"study_design_scores_gemma":[0.030999728,0.06416294,0.9020805,0.00022026157,0.0002981834,0.0002109786,0.000040165138,0.00004875767,0.0016374754,0.00000184498,0.00013470721,0.00016445556],"about_ca_topic_score_codex":0.000326286,"about_ca_topic_score_gemma":0.0001276733,"teacher_disagreement_score":0.06356931,"about_ca_system_score_codex":0.00040390514,"about_ca_system_score_gemma":0.00092112686,"threshold_uncertainty_score":0.7151853},"labels":[],"label_agreement":null},{"id":"W2581661112","doi":"10.1200/jco.2012.30.4_suppl.605","title":"Gender differences in outcomes for early-stage colon cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Proportional hazards model; Colorectal cancer; Hazard ratio; Internal medicine; Stage (stratigraphy); Cancer; Cohort; Disease; Multivariate analysis; Population; Oncology; Cohort study; Retrospective cohort study; Gynecology; Confidence interval","score_opus":0.3616483812846959,"score_gpt":0.5381500724485542,"score_spread":0.17650169116385828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581661112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894853,0.00087588636,0.00010874161,0.0032088694,0.004708736,0.0003092999,0.0000066091998,0.0000052110604,0.0012912934],"genre_scores_gemma":[0.99209136,0.0004351501,0.0035446077,0.0019353286,0.001294854,0.000025848567,4.6688476e-7,0.000014941586,0.0006574417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736655,0.0002103621,0.0016538887,0.00012502419,0.00029110405,0.00035309434],"domain_scores_gemma":[0.9952909,0.0030186402,0.0009747956,0.00011992697,0.00023492196,0.00036082193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024586592,0.00012410287,0.0014130834,0.0001089994,0.000020761447,0.000004582125,0.00015017115,0.0003888997,0.00036725926],"category_scores_gemma":[0.003578925,0.000081025304,0.0003869158,0.00009308433,0.00014580337,0.00008130289,0.000038672322,0.00068845757,0.0000064046135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020081208,0.00074260565,0.9759489,0.00003395051,0.00016855399,0.000021594185,0.0002459178,0.0000033544843,0.000116043855,0.000056412402,0.0015111184,0.01914341],"study_design_scores_gemma":[0.0050867293,0.0053882087,0.9576185,0.000032529017,0.0001574548,0.000021303886,0.00010882606,0.000020865156,0.0001307156,0.0001644417,0.031191,0.000079442296],"about_ca_topic_score_codex":0.00005696535,"about_ca_topic_score_gemma":0.00015952755,"teacher_disagreement_score":0.029679881,"about_ca_system_score_codex":0.00026268876,"about_ca_system_score_gemma":0.0011857705,"threshold_uncertainty_score":0.4284566},"labels":[],"label_agreement":null},{"id":"W2581835979","doi":"10.1200/jco.2009.27.15_suppl.8011","title":"Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Gefitinib; Internal medicine; Tolerability; Oncology; Lung cancer; Randomized controlled trial; Population; Meta-analysis; Chemotherapy; Cancer; Adverse effect; Epidermal growth factor receptor","score_opus":0.2585591461781658,"score_gpt":0.5740744277265593,"score_spread":0.3155152815483935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581835979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279404,0.0033396445,0.00036157682,0.0018400749,0.00024340101,0.0006497504,0.00007006931,0.0000046469545,0.00069677195],"genre_scores_gemma":[0.98833877,0.0005859569,0.009904192,0.0008070195,0.00020206247,0.000011232002,0.000023696435,0.000011919504,0.000115140945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925948,0.0011548211,0.0053522564,0.00032003463,0.0003719016,0.00020618924],"domain_scores_gemma":[0.98912513,0.004579929,0.0050114365,0.00023909037,0.00067660154,0.00036781703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037791007,0.00020957194,0.006847561,0.00023992422,0.00002656946,0.000008956475,0.0001196498,0.00035747906,0.00021090994],"category_scores_gemma":[0.0019329811,0.00011789903,0.0015577395,0.00036640317,0.00011330022,0.00010399053,0.000019881893,0.00073915755,8.510452e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007507989,0.004606745,0.90082425,0.000014487964,0.048398882,0.000054146625,0.00018339611,0.0003325037,0.0000107794585,0.0000022538375,0.00027951266,0.03778507],"study_design_scores_gemma":[0.02678448,0.010054034,0.76350313,0.000046251505,0.19874474,0.0000011897781,0.00006608591,0.00030272052,0.000037099293,0.000027234395,0.00034805032,0.00008495554],"about_ca_topic_score_codex":0.0001459853,"about_ca_topic_score_gemma":0.0002914782,"teacher_disagreement_score":0.15034586,"about_ca_system_score_codex":0.00011336745,"about_ca_system_score_gemma":0.0011120678,"threshold_uncertainty_score":0.48077828},"labels":[],"label_agreement":null},{"id":"W2581928354","doi":"10.1200/jco.2015.33.7_suppl.475","title":"Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Everolimus; Medicine; Internal medicine; Oncology; Clinical endpoint; Biomarker; Urology; Randomized controlled trial","score_opus":0.2568634252205198,"score_gpt":0.5349604265872128,"score_spread":0.27809700136669296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581928354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828404,0.0003030033,0.000064298016,0.015312218,0.000244993,0.00041780423,0.0000033867916,0.00000323,0.0008106287],"genre_scores_gemma":[0.99467945,0.0006969625,0.0017290591,0.0016059631,0.0010007304,0.000003989755,0.0000015757157,0.000013700301,0.00026855725],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99388975,0.00194696,0.0027985638,0.00020203477,0.0009129523,0.0002497648],"domain_scores_gemma":[0.98296714,0.013927471,0.0018021276,0.00021903784,0.0006618062,0.00042241268],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031037664,0.00012439003,0.0016546428,0.000104287596,0.000018078676,0.000012333567,0.00015375706,0.00039632744,0.00001493783],"category_scores_gemma":[0.02629534,0.000060048915,0.00013948674,0.00018555662,0.00042613363,0.00010191899,0.000060207953,0.0013228693,0.000002294313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17383552,0.0022464225,0.7949034,0.00006109994,0.00040611567,0.0011946489,0.00026049773,0.000010378409,0.000002811079,0.00006548157,0.0055124857,0.021501126],"study_design_scores_gemma":[0.564414,0.07387101,0.33255205,0.00019461967,0.00070635224,0.00160468,0.000890551,0.0011476757,0.0000040565546,0.0001910366,0.024300033,0.00012390608],"about_ca_topic_score_codex":0.00010994022,"about_ca_topic_score_gemma":0.00042364496,"teacher_disagreement_score":0.46235138,"about_ca_system_score_codex":0.0014640506,"about_ca_system_score_gemma":0.009632935,"threshold_uncertainty_score":0.99775064},"labels":[],"label_agreement":null},{"id":"W2582197961","doi":"10.1200/jco.2012.30.5_suppl.175","title":"Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Internal medicine; Concordance; Logistic regression; Cohort; Oncology; Proportional hazards model; Population; Biochemical recurrence; Cancer","score_opus":0.18252013667788702,"score_gpt":0.505684934508733,"score_spread":0.32316479783084595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582197961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995846,0.00044888808,0.0010865977,0.0005696529,0.00092334655,0.0009749394,0.00010683058,0.0000041820435,0.000039583738],"genre_scores_gemma":[0.98593384,0.0021665979,0.0110046,0.00009901232,0.0006179983,0.000030564217,0.000032994834,0.000021609123,0.000092769915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327326,0.0008489159,0.0048320317,0.00023469175,0.00047480772,0.00033629365],"domain_scores_gemma":[0.99056387,0.0033956133,0.00432,0.00019734823,0.0011465341,0.00037664318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008763728,0.0001465969,0.0018797902,0.000163479,0.00003058662,0.0000036651822,0.0001399531,0.00043751037,0.000032899952],"category_scores_gemma":[0.005178864,0.000091854214,0.0004327154,0.00017394395,0.0003528599,0.0002178143,0.000054262055,0.0010121915,9.734963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03206491,0.0037336133,0.87827176,0.000094089606,0.00038199034,0.000003685819,0.00017619097,0.0005936456,0.0000058044657,0.000021747343,0.00019863872,0.08445393],"study_design_scores_gemma":[0.031445846,0.011024609,0.94671917,0.00030725737,0.0005862978,0.000002289016,0.000044092456,0.00900358,0.00003141761,0.0003011427,0.00045150076,0.00008279637],"about_ca_topic_score_codex":0.00008724941,"about_ca_topic_score_gemma":0.000053708543,"teacher_disagreement_score":0.084371135,"about_ca_system_score_codex":0.00020368793,"about_ca_system_score_gemma":0.0019852424,"threshold_uncertainty_score":0.61999583},"labels":[],"label_agreement":null},{"id":"W2582375203","doi":"10.1200/jco.2014.32.18_suppl.lba9514","title":"Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Deprescribing; Polypharmacy; Quality of life (healthcare); Statin; Randomized controlled trial; Life expectancy; Internal medicine; Randomization; Physical therapy; Population","score_opus":0.34162717238602586,"score_gpt":0.5167210937620845,"score_spread":0.17509392137605867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582375203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96527624,0.0007620216,0.0019596743,0.02252497,0.0028722566,0.0018099984,0.000012970501,0.000005181674,0.0047766957],"genre_scores_gemma":[0.99311095,0.0005020211,0.0035331096,0.0017858949,0.00094523124,0.00007949754,0.0000024836572,0.000019248151,0.00002153698],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9610115,0.011618706,0.02640068,0.000311214,0.00023788451,0.00042000084],"domain_scores_gemma":[0.782461,0.17728077,0.039449006,0.00035617637,0.00028083273,0.00017225306],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2468284,0.00020413201,0.009769632,0.0006367687,0.000057711244,0.000028657149,0.0005167891,0.00035554776,0.000037993414],"category_scores_gemma":[0.21905528,0.0001670601,0.0009609188,0.00022559843,0.00036161198,0.0003550751,0.000077825374,0.0010155097,0.0000075823846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86835784,0.0014546255,0.04965862,0.00029572283,0.0006872987,0.00001910197,0.023750369,0.0023222838,0.0000037610862,0.028483415,0.00044699412,0.024519954],"study_design_scores_gemma":[0.9453832,0.0021888241,0.008611322,0.00040305007,0.000089022076,0.0000050504805,0.013947316,0.021305192,0.0000011172543,0.005882765,0.0020019666,0.00018116353],"about_ca_topic_score_codex":0.0006607741,"about_ca_topic_score_gemma":0.0013863739,"teacher_disagreement_score":0.17855054,"about_ca_system_score_codex":0.00030050793,"about_ca_system_score_gemma":0.000512846,"threshold_uncertainty_score":0.787523},"labels":[],"label_agreement":null},{"id":"W2582500594","doi":"10.1200/jco.2005.23.16_suppl.6070","title":"Patterns of trastuzumab use and cost in a single Canadian cancer institute","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Pharmacy; Metastatic breast cancer; Cancer; Breast cancer; Chemotherapy; Internal medicine; Family medicine","score_opus":0.4083267166461031,"score_gpt":0.5638005249704544,"score_spread":0.15547380832435131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582500594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97789866,0.00042414467,0.000027272625,0.020062579,0.00053523097,0.00019253528,0.000016708143,0.0000016759335,0.00084118237],"genre_scores_gemma":[0.9935569,0.0017581823,0.0010410583,0.0025753486,0.00085830275,0.0000045272186,9.0522684e-7,0.000011004067,0.00019375741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976081,0.00020589487,0.0015006639,0.0001271736,0.0002825098,0.0002756553],"domain_scores_gemma":[0.9975873,0.00080253225,0.00048234494,0.000121210855,0.00032056312,0.0006860174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019138913,0.00007912408,0.0009106212,0.0002700304,0.000015762893,0.000008053719,0.00011455581,0.0002635196,0.0002537956],"category_scores_gemma":[0.0030300096,0.000061976665,0.00011946763,0.00013035338,0.00018036508,0.00017224473,0.000026552949,0.0009826735,0.0000035546793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006165936,0.0005196952,0.6404718,0.000030082689,0.00006551943,0.0005799245,0.00015117816,0.000039598162,0.00013813264,0.00002329271,0.0019273071,0.35543683],"study_design_scores_gemma":[0.004232125,0.0031125008,0.6133567,0.00025474836,0.000047510635,0.00018517488,0.00005258856,0.00007766839,0.00008952374,0.000013540711,0.378532,0.00004593754],"about_ca_topic_score_codex":0.06454043,"about_ca_topic_score_gemma":0.7029676,"teacher_disagreement_score":0.6384272,"about_ca_system_score_codex":0.000972045,"about_ca_system_score_gemma":0.0070790243,"threshold_uncertainty_score":0.99854994},"labels":[],"label_agreement":null},{"id":"W2582574187","doi":"10.1200/jco.2012.30.4_suppl.355","title":"Liver resection for multifocal hepatocellular carcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cirrhosis; Liver cancer; Gastroenterology; Stage (stratigraphy); Hepatectomy; Internal medicine; Liver disease; Etiology; Hepatitis C; Cancer; Surgery; Resection","score_opus":0.3315555599175756,"score_gpt":0.43944874778331533,"score_spread":0.1078931878657397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582574187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019897,0.0030764733,0.0012984667,0.0016521562,0.001992538,0.00046773575,0.000003014356,0.000011516946,0.0012991341],"genre_scores_gemma":[0.9841163,0.00028425074,0.00987492,0.00066922035,0.0045413487,0.000016575385,0.0000079573065,0.000023529958,0.00046588422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972781,0.00034328562,0.0016040765,0.00014182519,0.00028007643,0.00035264526],"domain_scores_gemma":[0.9962075,0.0016323116,0.0008733603,0.0001650369,0.0004815634,0.0006402402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004042031,0.00014055836,0.0010932902,0.00013254255,0.00005872144,0.0000062766167,0.00009029487,0.0004933755,0.00015662456],"category_scores_gemma":[0.0022084685,0.00009900753,0.00094784505,0.00010345752,0.00010977066,0.0001756057,0.000028662982,0.0005849485,0.000050407038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005316594,0.0018335602,0.9224066,0.000051431365,0.00026727837,0.00031846765,0.000117918935,1.4937156e-7,0.0002694093,0.0001071759,0.004641818,0.06466957],"study_design_scores_gemma":[0.013379747,0.02785587,0.6014707,0.00005839004,0.0015346424,0.0009973173,0.000104065795,0.0042152745,0.003713401,0.00010333452,0.34639913,0.00016812386],"about_ca_topic_score_codex":0.000018750508,"about_ca_topic_score_gemma":0.000005619709,"teacher_disagreement_score":0.3417573,"about_ca_system_score_codex":0.00016331422,"about_ca_system_score_gemma":0.0005841168,"threshold_uncertainty_score":0.40374097},"labels":[],"label_agreement":null},{"id":"W2583154960","doi":"10.1200/jco.2012.30.5_suppl.281","title":"Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Lymph node; Urology; Cancer; Retrospective cohort study; Oncology; Cohort; Lymphovascular invasion; Cutoff; Metastasis","score_opus":0.06613269030895551,"score_gpt":0.3862691484980403,"score_spread":0.32013645818908476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583154960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99788105,0.00039687142,0.00003970745,0.0003907804,0.00045714993,0.00029792127,0.000007742642,0.0000030134688,0.00052574265],"genre_scores_gemma":[0.99514693,0.000040900293,0.0032734852,0.0012067348,0.0002834259,0.0000035943197,0.00000123924,0.000022031487,0.000021663749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978345,0.0002675479,0.0011912357,0.00014273691,0.00031894405,0.0002450274],"domain_scores_gemma":[0.9980013,0.0007279978,0.00067656237,0.00012964997,0.0001609417,0.00030355377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009724938,0.00013767053,0.0009987084,0.00011209479,0.000015036712,0.0000029313521,0.000060833405,0.00022322545,0.0000411428],"category_scores_gemma":[0.00061750674,0.00008261678,0.00017214868,0.0000789452,0.00018934566,0.00011541791,0.000015698086,0.0003514508,0.0000028853256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010001667,0.004168546,0.9686434,0.000028694516,0.00013359492,0.000054069245,0.00019877478,0.0000067108817,0.00003844885,0.000015434833,0.00003085595,0.016679764],"study_design_scores_gemma":[0.019940218,0.009063793,0.9692246,0.00014799325,0.00047747206,0.0001311151,0.000042797597,0.000016995973,0.00009562755,0.000034199442,0.000749195,0.00007600765],"about_ca_topic_score_codex":0.00007119933,"about_ca_topic_score_gemma":0.0000033434596,"teacher_disagreement_score":0.016603755,"about_ca_system_score_codex":0.00008051986,"about_ca_system_score_gemma":0.00054623664,"threshold_uncertainty_score":0.33690146},"labels":[],"label_agreement":null},{"id":"W2583230376","doi":"10.1200/jco.2012.30.5_suppl.121","title":"A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Tolerability; Internal medicine; Clinical endpoint; Urology; Chemotherapy; Oncology; Cancer; Gastroenterology; Randomized controlled trial; Adverse effect","score_opus":0.08482545155794204,"score_gpt":0.4649350255997086,"score_spread":0.3801095740417666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583230376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963247,0.0006962514,0.000102658436,0.00038116792,0.00031116407,0.0020607295,0.000028404773,0.000002520429,0.00009241057],"genre_scores_gemma":[0.99756,0.00033232966,0.0015218297,0.00006726448,0.00026336114,0.000111696565,0.00001538517,0.000028814164,0.00009927084],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945427,0.0017374204,0.0024053808,0.00026742733,0.00061180897,0.00043521592],"domain_scores_gemma":[0.9963978,0.00063264533,0.0016401546,0.0002906034,0.00071232696,0.00032649428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004834776,0.00021691325,0.0018046864,0.0001349144,0.000060716506,0.000009491905,0.00027304358,0.00021950348,0.000054567507],"category_scores_gemma":[0.002451911,0.00014955706,0.00023701633,0.00020567844,0.0003132524,0.00003088613,0.00010996767,0.00052631996,0.0000011130013],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9364233,0.020899879,0.015162831,0.000043515807,0.0017940274,0.000036315214,0.0015082689,0.0002591333,0.0066503617,0.0000050911067,0.00015486672,0.017062437],"study_design_scores_gemma":[0.87020224,0.10617676,0.016534854,0.00006307133,0.0003585369,0.0000067919705,0.0006221518,0.00007136287,0.0046681156,0.000011102242,0.0010812536,0.00020373627],"about_ca_topic_score_codex":0.00021541209,"about_ca_topic_score_gemma":0.00040566068,"teacher_disagreement_score":0.08527688,"about_ca_system_score_codex":0.00014415986,"about_ca_system_score_gemma":0.0018209803,"threshold_uncertainty_score":0.609876},"labels":[],"label_agreement":null},{"id":"W2583240333","doi":"10.1200/jco.2012.30.5_suppl.358","title":"Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Surgery; Oncology; Urology","score_opus":0.10404273790826808,"score_gpt":0.3658012201547133,"score_spread":0.2617584822464452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583240333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924701,0.0003566329,0.0005019557,0.0016003943,0.00086487667,0.0010074604,0.0026519417,0.000014708533,0.00053196074],"genre_scores_gemma":[0.98919487,0.0001414028,0.0061033657,0.0009583359,0.0017521303,0.000037685597,0.0016418314,0.000053983593,0.000116372066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99487025,0.0008164778,0.0022069323,0.00040494592,0.0012310846,0.00047029147],"domain_scores_gemma":[0.98642224,0.008778714,0.002336672,0.00040386975,0.0014559164,0.00060257426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019029776,0.00038309555,0.0014816184,0.00012952046,0.00012078758,0.000028002973,0.00037130143,0.00020167316,0.0003330059],"category_scores_gemma":[0.0020544056,0.00018812793,0.00059788936,0.0001382908,0.0003912667,0.00031919297,0.000052611103,0.0007939902,0.000016038612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08289911,0.0074589276,0.8988907,0.000017756753,0.0036732291,0.0003594924,0.00024555394,0.000013194325,0.0010516708,0.00007669572,0.0030724427,0.0022412767],"study_design_scores_gemma":[0.07536749,0.01822162,0.8881908,0.000056769044,0.0013878882,0.00008517743,0.00015458441,0.000039122,0.0040361295,0.000050649338,0.012187461,0.00022231418],"about_ca_topic_score_codex":0.00020305492,"about_ca_topic_score_gemma":0.000051593164,"teacher_disagreement_score":0.010762692,"about_ca_system_score_codex":0.00029950563,"about_ca_system_score_gemma":0.0013308987,"threshold_uncertainty_score":0.76716346},"labels":[],"label_agreement":null},{"id":"W2584972501","doi":"10.1200/jco.2012.30.5_suppl.336","title":"Consolidative high-dose chemotherapy (HDCT) after conventional-dose chemotherapy (CDCT) as first salvage treatment for male patients (pts) with metastatic germ cell tumors (mGCTs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Etoposide; Salvage therapy; Cisplatin; Germ cell tumors; Oncology; Internal medicine; Testicular cancer; Surgery","score_opus":0.054148237731736805,"score_gpt":0.40720097606775246,"score_spread":0.35305273833601564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584972501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407506,0.001175307,0.00017523616,0.0022226411,0.00049304205,0.0013356997,0.000082766506,0.000015135283,0.0004251233],"genre_scores_gemma":[0.98466223,0.0005260647,0.009184769,0.0034578987,0.00060504023,0.00012785646,0.00006850699,0.000065802036,0.0013018552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684465,0.00025559773,0.0016482127,0.00030799393,0.00045841213,0.00048512904],"domain_scores_gemma":[0.9944144,0.0018154894,0.0020625626,0.00027881595,0.00056178047,0.00086693297],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068418984,0.0003734791,0.0017026607,0.00011838625,0.00008153406,0.000017854381,0.000120306715,0.00018919275,0.0012436552],"category_scores_gemma":[0.0005298154,0.00022791115,0.0008219567,0.000116639945,0.00026972208,0.00020383761,0.00002054063,0.00028550279,0.00009239598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05150814,0.05196906,0.8344927,0.00018413564,0.004698199,0.0010896071,0.0005487418,0.000008796018,0.000029335386,0.000118408636,0.0028218534,0.052531034],"study_design_scores_gemma":[0.1017962,0.043502897,0.8035409,0.00019781647,0.0025430487,0.00034781516,0.00014026994,0.00002163954,0.00044739357,0.00021607484,0.046981093,0.0002648757],"about_ca_topic_score_codex":0.00004081815,"about_ca_topic_score_gemma":0.000016730603,"teacher_disagreement_score":0.05226616,"about_ca_system_score_codex":0.00046312707,"about_ca_system_score_gemma":0.0012060094,"threshold_uncertainty_score":0.9996694},"labels":[],"label_agreement":null},{"id":"W2585634112","doi":"10.1200/jco.2012.30.4_suppl.104","title":"Processes of care in curative therapy for gastric cancer: A RAND/UCLA appropriateness study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Dalhousie University","funders":"","keywords":"Medicine; Cancer; Perforation; Gastrectomy; Disease; Dissection (medical); Surgery; Lymph node; General surgery; Resection margin; Radiology; Internal medicine; Resection","score_opus":0.16074239073423,"score_gpt":0.51018397070266,"score_spread":0.34944157996842995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585634112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890069,0.00631822,0.00026235962,0.001958635,0.0010540585,0.0009927701,0.000003222412,0.000003925989,0.00039992415],"genre_scores_gemma":[0.99395,0.0031954765,0.0012886444,0.00045212772,0.0009755624,0.000034842447,0.0000011529055,0.000011142544,0.000091057445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766296,0.00018789724,0.0015669808,0.00010966344,0.0002536935,0.00021883145],"domain_scores_gemma":[0.99645,0.0012354105,0.0013822732,0.00009544625,0.0006985242,0.0001383169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018875535,0.0001093116,0.0014256669,0.00018867379,0.000017594488,0.0000033367307,0.0001318146,0.0001268502,0.000041774434],"category_scores_gemma":[0.0014854054,0.00006829592,0.00025707466,0.00033681435,0.00007064108,0.00013040022,0.000026566991,0.00033552636,5.473647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014007656,0.0022708673,0.7851733,0.00016838506,0.00033986717,0.000017480575,0.0021464836,0.000011323514,0.000009367639,0.0000114718505,0.00046217447,0.19538166],"study_design_scores_gemma":[0.036141086,0.024972359,0.9044452,0.00012569976,0.0004668514,0.000016470814,0.0076553286,0.000006848495,0.00006928186,0.00004818803,0.02597527,0.00007746332],"about_ca_topic_score_codex":0.000041101415,"about_ca_topic_score_gemma":0.00016466585,"teacher_disagreement_score":0.19530419,"about_ca_system_score_codex":0.0001273164,"about_ca_system_score_gemma":0.0013329173,"threshold_uncertainty_score":0.2785027},"labels":[],"label_agreement":null},{"id":"W2586110468","doi":"10.1200/jco.2012.30.15_suppl.6027","title":"Patterns of diagnostic imaging and cumulative radiation exposure among long-term young adult cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; St. Michael's Hospital; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Cancer registry; Poisson regression; Malignancy; Cancer; Radiological weapon; Population; Young adult; Retrospective cohort study; Radiation therapy; Nuclear medicine; Surgery; Internal medicine; Environmental health","score_opus":0.05325579342325829,"score_gpt":0.43856748325592676,"score_spread":0.38531168983266845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586110468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924841,0.0031525807,0.0005522841,0.001811326,0.0015741406,0.00013589131,0.0000044842172,0.0000050993763,0.00028010926],"genre_scores_gemma":[0.99253523,0.004591551,0.00012805527,0.0007746317,0.0018919882,0.000003240795,0.0000035739256,0.0000138382275,0.000057878253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975809,0.0003040567,0.0015492153,0.00010668998,0.00025683668,0.00020231002],"domain_scores_gemma":[0.99441063,0.0030768514,0.0017323497,0.000101175574,0.0003658972,0.00031307718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015891786,0.000104913146,0.0008307069,0.00012759458,0.000029200753,0.00000793225,0.00006611149,0.00013264436,0.000109165696],"category_scores_gemma":[0.0060646865,0.000080202895,0.00018466344,0.00007859327,0.00010250576,0.00048425264,0.000026330694,0.00049475336,0.000002147368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016738666,0.00028705676,0.841172,0.000037209367,0.00013886578,0.000047526915,0.00058936,0.0000104575,0.000042743563,0.000015757507,0.0001778317,0.15731384],"study_design_scores_gemma":[0.0032105611,0.0006656279,0.9944338,0.0002331018,0.00035308348,0.00014716963,0.00017164259,0.0002882353,0.00018574996,0.000014376449,0.00022393063,0.00007271447],"about_ca_topic_score_codex":0.0003903751,"about_ca_topic_score_gemma":0.00024184742,"teacher_disagreement_score":0.15724112,"about_ca_system_score_codex":0.00008504031,"about_ca_system_score_gemma":0.00025404818,"threshold_uncertainty_score":0.72604346},"labels":[],"label_agreement":null},{"id":"W2586194686","doi":"10.1200/jco.2016.34.3_suppl.103","title":"Integrating primary care and cancer care in survivorship: A collaborative approach.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; BC Cancer Agency; Cancer Care Ontario; University of Manitoba; Juravinski Cancer Centre","funders":"","keywords":"Survivorship curve; Referral; Medicine; Family medicine; Nursing; Curriculum; Cancer; Medical education; Psychology","score_opus":0.06637959283437213,"score_gpt":0.4287514634207598,"score_spread":0.3623718705863877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586194686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94850343,0.023883697,0.000084368105,0.0027102646,0.0014951612,0.00025839,0.000025815049,0.000009395201,0.0230295],"genre_scores_gemma":[0.9895381,0.005445855,0.0021808909,0.0014405121,0.0011970487,0.000015852227,0.0000035839169,0.000018471967,0.00015969637],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972873,0.0005847471,0.0013969655,0.00022819357,0.00028792003,0.00021488468],"domain_scores_gemma":[0.9962161,0.0015432647,0.0008327447,0.00013684119,0.0009816174,0.00028939167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013651219,0.0001469277,0.0013176397,0.0001391054,0.000028329512,0.000008833983,0.00011274144,0.00037653698,0.000038066577],"category_scores_gemma":[0.0012948705,0.000082555875,0.0002115852,0.0002421346,0.0002307806,0.00012515855,0.00005679568,0.00074820884,0.0000014193025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002499737,0.00012805553,0.32231054,0.00016550574,0.00007618732,0.00014407239,0.0058361553,4.876289e-7,0.00010573635,0.00006654447,0.00020208767,0.6684649],"study_design_scores_gemma":[0.022612482,0.02114074,0.5264196,0.003375178,0.0005540869,0.00028614447,0.092039526,0.000007793862,0.00036269327,0.00016629465,0.33257183,0.0004636264],"about_ca_topic_score_codex":0.00043871463,"about_ca_topic_score_gemma":0.01388986,"teacher_disagreement_score":0.66800123,"about_ca_system_score_codex":0.00062720664,"about_ca_system_score_gemma":0.0032843282,"threshold_uncertainty_score":0.7750868},"labels":[],"label_agreement":null},{"id":"W2586282482","doi":"10.1200/jco.2012.30.27_suppl.68","title":"Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Breast cancer; Letrozole; Exemestane; Tamoxifen; Hazard ratio; Cohort; Cancer; Gynecology; Surgery; Confidence interval","score_opus":0.13186213766408375,"score_gpt":0.44166050313310734,"score_spread":0.3097983654690236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586282482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930324,0.00094069255,0.000063006424,0.0046217493,0.0007746955,0.00024474607,0.000008539032,0.000005012935,0.0003091862],"genre_scores_gemma":[0.99195147,0.0038966604,0.0010132693,0.00120129,0.0018727651,0.000007982084,0.0000018934817,0.000013417261,0.00004124459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698234,0.00041462888,0.0019025222,0.00010630982,0.00032304224,0.00027115084],"domain_scores_gemma":[0.99729866,0.0011140878,0.0010384966,0.00013387877,0.0002477804,0.00016711622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037847096,0.00011200589,0.0011817673,0.00022224631,0.00001821904,0.0000044793587,0.00010370826,0.0002336368,0.00008041051],"category_scores_gemma":[0.00093505403,0.00008989032,0.00043040386,0.00024565117,0.00010702368,0.00024945693,0.000019213905,0.00083569775,8.3835425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021655546,0.0012177638,0.8969464,0.000027699256,0.00023468357,0.00006605731,0.0013696281,0.000096178985,0.021006668,0.000100577905,0.00009855325,0.07667029],"study_design_scores_gemma":[0.014448668,0.0012606051,0.9707679,0.00022669532,0.000053516953,0.00011177786,0.0004386789,0.000063268264,0.0062192036,0.00009597323,0.0062314374,0.00008226159],"about_ca_topic_score_codex":0.00042126852,"about_ca_topic_score_gemma":0.00020145073,"teacher_disagreement_score":0.07658803,"about_ca_system_score_codex":0.00023340156,"about_ca_system_score_gemma":0.0008830243,"threshold_uncertainty_score":0.36656213},"labels":[],"label_agreement":null},{"id":"W2586291419","doi":"10.1200/jco.2013.31.15_suppl.9571","title":"Taking control of cancer: Why women are choosing mastectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Grounded theory; Mastectomy; Nonprobability sampling; Cancer; Qualitative research; Lumpectomy; Surgery; Internal medicine; Population","score_opus":0.056134363518623054,"score_gpt":0.4233137366226022,"score_spread":0.36717937310397913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586291419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899715,0.0020886238,0.0024304874,0.003247564,0.0012995873,0.000128952,0.000008648909,0.0000024231967,0.0008222054],"genre_scores_gemma":[0.993361,0.00058094756,0.0019167083,0.0025625357,0.0014540507,0.000021414258,9.492249e-7,0.00001596935,0.000086405715],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977244,0.000280561,0.0014438833,0.000160151,0.00017234156,0.00021865322],"domain_scores_gemma":[0.99571055,0.00027041713,0.002976128,0.00018503204,0.0006955213,0.00016232018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012448805,0.000103342885,0.000697706,0.000059984868,0.000030381652,0.000010124811,0.00026864753,0.00033285044,0.00043390557],"category_scores_gemma":[0.0017284876,0.00008326236,0.0002507578,0.000080778824,0.00017908459,0.000010063741,0.00005486146,0.00034749755,0.000005612627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014834994,0.0007012625,0.3001399,0.00006077829,0.0014221583,0.000031635056,0.00021525938,0.0021911687,0.14059483,0.000033026863,0.02173832,0.53138816],"study_design_scores_gemma":[0.013691733,0.006873768,0.57609475,0.00017351563,0.00026301306,0.00012674465,0.0010689667,0.00038915925,0.021999184,0.00083424634,0.37809226,0.00039264272],"about_ca_topic_score_codex":0.00005963773,"about_ca_topic_score_gemma":0.00006420709,"teacher_disagreement_score":0.53099555,"about_ca_system_score_codex":0.00014604391,"about_ca_system_score_gemma":0.0010984866,"threshold_uncertainty_score":0.4750962},"labels":[],"label_agreement":null},{"id":"W2586304582","doi":"10.1200/jco.2012.30.4_suppl.645","title":"The management of patients with T1 adenocarcinoma of the low rectum: An updated decision analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital","funders":"","keywords":"Medicine; Rectum; Adenocarcinoma; Life expectancy; Markov model; Decision analysis; Decision model; Markov chain; General surgery; Surgery; Statistics; Cancer; Computer science; Internal medicine; Population; Machine learning; Mathematics","score_opus":0.06399550615066427,"score_gpt":0.4318814697294132,"score_spread":0.3678859635787489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586304582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968532,0.00033416768,0.00006276415,0.000511087,0.0006516845,0.00027478547,0.0000039716256,0.00000254208,0.0013058474],"genre_scores_gemma":[0.99774396,0.00015571527,0.0016712681,0.00019482677,0.00013425457,0.0000026729447,0.0000037289512,0.0000095059995,0.000084058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996706,0.00047864515,0.0017837859,0.00012625712,0.0006941862,0.00021109932],"domain_scores_gemma":[0.99553555,0.0011925846,0.0020443844,0.00041261906,0.0005508952,0.0002639575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022865175,0.00011473957,0.0011378757,0.00008782747,0.00004777672,0.000003415276,0.00029288352,0.00015157592,0.00014042182],"category_scores_gemma":[0.00031739418,0.000046061836,0.0005567144,0.0006083218,0.00027510058,0.00009118738,0.000106115265,0.0004023285,0.0000026662033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011824055,0.0026002815,0.8991683,0.000009596089,0.003066179,0.000025341878,0.0000444599,0.000019729727,0.0000021131066,0.000043340027,0.00027654064,0.08292006],"study_design_scores_gemma":[0.005938281,0.008042053,0.97752035,0.00006489544,0.0036273438,0.000011194303,0.00006414353,0.000024683059,0.00006565588,0.00008363821,0.0045145755,0.00004320501],"about_ca_topic_score_codex":0.000009758327,"about_ca_topic_score_gemma":0.000036137928,"teacher_disagreement_score":0.08287685,"about_ca_system_score_codex":0.00014207288,"about_ca_system_score_gemma":0.0002233881,"threshold_uncertainty_score":0.18783471},"labels":[],"label_agreement":null},{"id":"W2586386913","doi":"10.1200/jco.2016.34.4_suppl.333","title":"Outcome of second-line treatment (2L Tx) following <i>nab</i>-paclitaxel (<i>nab</i>-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Gemcitabine; Nab-paclitaxel; Internal medicine; Population; Capecitabine; Regimen; Gastroenterology; Cancer; Post-hoc analysis; Urology; Nuclear medicine; Colorectal cancer","score_opus":0.12568024052969995,"score_gpt":0.45915274417775,"score_spread":0.33347250364805003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586386913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643273,0.0037042624,0.0039312495,0.0028801414,0.0020740726,0.0004466442,0.00033645227,0.0000043672794,0.00019008522],"genre_scores_gemma":[0.978638,0.005756719,0.009756598,0.0016669141,0.0016415964,0.000063435924,0.000016493845,0.000050266157,0.0024099771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99587697,0.00021863396,0.0029330738,0.00035467482,0.00021454591,0.00040212617],"domain_scores_gemma":[0.9942525,0.0026233161,0.0019796076,0.0003782192,0.00043012417,0.00033623434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018499634,0.0002833944,0.0019160917,0.0000868558,0.000052018055,0.000011284965,0.0003170885,0.00031212997,0.00017903601],"category_scores_gemma":[0.004379012,0.00016263673,0.0011702927,0.000089119094,0.00017859599,0.000015138749,0.000092324946,0.000164,0.000004374239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027887082,0.0071134088,0.22626768,0.00041407262,0.010300924,0.00052041025,0.00019071423,0.00038430165,0.26828405,0.00040369853,0.024997234,0.43323642],"study_design_scores_gemma":[0.051702414,0.069072045,0.026009286,0.00027805823,0.0036596756,0.00018272309,0.00018478894,0.00006796455,0.041430816,0.0015461498,0.8050892,0.00077687926],"about_ca_topic_score_codex":0.000064413565,"about_ca_topic_score_gemma":0.0011645255,"teacher_disagreement_score":0.78009194,"about_ca_system_score_codex":0.00017262038,"about_ca_system_score_gemma":0.0015880804,"threshold_uncertainty_score":0.6632133},"labels":[],"label_agreement":null},{"id":"W2586412306","doi":"10.1200/jco.2012.30.5_suppl.30","title":"Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Prospective cohort study; Radiology; Cohort; Magnetic resonance imaging; Cancer; Multiparametric MRI; Univariate analysis; Multivariate analysis; Internal medicine","score_opus":0.04596130864443774,"score_gpt":0.4580879608079175,"score_spread":0.41212665216347977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586412306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627507,0.00013425304,0.00014137028,0.0006658357,0.0007871791,0.0009431029,0.0000113737415,0.000012024265,0.0010298225],"genre_scores_gemma":[0.99816096,0.00028537904,0.000500141,0.00011850075,0.00078295456,0.000020969446,0.000008187696,0.000023919429,0.00009897291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961611,0.0009228742,0.0017553078,0.00024289165,0.00058900414,0.00032879997],"domain_scores_gemma":[0.9925416,0.0032356929,0.0024980356,0.00024737744,0.0005947541,0.0008825134],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005599236,0.00018117392,0.001494957,0.00028048147,0.000049071376,0.0000091261845,0.0001474625,0.00015905328,0.000050759558],"category_scores_gemma":[0.024287662,0.000115630726,0.00051094,0.00038501117,0.0003637698,0.00017337018,0.00003676684,0.0015613653,0.000007712402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011865884,0.006212381,0.9434031,0.00001772506,0.00084944424,0.0001192619,0.00040940542,0.00009409877,0.000042055635,0.000008072329,0.0005708359,0.036407705],"study_design_scores_gemma":[0.0067284536,0.0122128315,0.9779713,0.000078634985,0.0003356066,0.000053380754,0.00013316979,0.0020652087,0.000018487359,0.000025983803,0.00027574244,0.00010117644],"about_ca_topic_score_codex":0.00019943708,"about_ca_topic_score_gemma":0.000013920374,"teacher_disagreement_score":0.03630653,"about_ca_system_score_codex":0.0005154155,"about_ca_system_score_gemma":0.0011843663,"threshold_uncertainty_score":0.9839312},"labels":[],"label_agreement":null},{"id":"W2586441648","doi":"10.1200/jco.2006.24.18_suppl.7139","title":"Phase II trial with carboplatin/gemcitabine induction chemotherapy followed by radiotherapy concomitantly with paclitaxel/gemcitabine in stage III non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Regimen; Internal medicine; Concomitant; Radiation therapy; Gastroenterology; Stage (stratigraphy); Chemotherapy; Lung cancer; Induction chemotherapy; Surgery; Cisplatin","score_opus":0.03219122899623298,"score_gpt":0.4019354239487124,"score_spread":0.3697441949524794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586441648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982417,0.0031744952,0.00038832688,0.0097451275,0.001015384,0.0016172648,0.000031261618,0.000019098843,0.0015920607],"genre_scores_gemma":[0.9886311,0.0028261852,0.0026465044,0.0016907252,0.002387357,0.00012487563,0.000022495984,0.00007509262,0.0015956409],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956662,0.0002927294,0.0025318356,0.0004710322,0.0005534957,0.00048469927],"domain_scores_gemma":[0.99582314,0.0007529278,0.002345863,0.00031792323,0.00038922258,0.00037090192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016990689,0.00040774763,0.0025463135,0.00021202122,0.00008411335,0.00002137105,0.0001684376,0.00047513063,0.00026308905],"category_scores_gemma":[0.00007909995,0.00025090398,0.00039398347,0.00040169584,0.00022612845,0.00018109826,0.000018219536,0.0010919996,8.0776977e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5901867,0.05091217,0.27396256,0.00015223656,0.0024975163,0.0018223244,0.0006779342,0.0002873141,0.004537291,0.00003930064,0.039916217,0.035008427],"study_design_scores_gemma":[0.76761293,0.16106658,0.025743267,0.0005311031,0.0010923141,0.000099602265,0.00017296452,0.00028644767,0.0021422596,0.000009185848,0.04086953,0.00037382974],"about_ca_topic_score_codex":0.0013602717,"about_ca_topic_score_gemma":0.001742763,"teacher_disagreement_score":0.24821928,"about_ca_system_score_codex":0.0013395417,"about_ca_system_score_gemma":0.0031481588,"threshold_uncertainty_score":0.99999434},"labels":[],"label_agreement":null},{"id":"W2586463909","doi":"10.1200/jco.2014.32.30_suppl.288","title":"The impact of physician use of electronic medical records on colorectal cancer screening.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Cancer Care Ontario; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Sigmoidoscopy; Colonoscopy; Family medicine; Logistic regression; Medical record; Colorectal cancer; Cohort; Population; Electronic medical record; Propensity score matching; Primary care physician; Cancer; Primary care; Internal medicine; Environmental health","score_opus":0.09185485558923423,"score_gpt":0.47028918674594616,"score_spread":0.37843433115671193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586463909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945114,0.00025795287,0.00059560995,0.0024048954,0.0008111803,0.00012190019,0.0000027973063,0.000007817782,0.0012864415],"genre_scores_gemma":[0.9967679,0.00078902656,0.00024853303,0.00052813435,0.00157073,0.0000037523046,7.0328963e-7,0.000015272375,0.00007598145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964446,0.00065173936,0.0018032161,0.00014718478,0.000668163,0.00028512574],"domain_scores_gemma":[0.99054545,0.0061806045,0.0021840872,0.00017678703,0.0006114123,0.00030163545],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042988798,0.00013141394,0.0012827883,0.000105695006,0.0000518861,0.000005811805,0.0001924913,0.00036246196,0.00007785265],"category_scores_gemma":[0.0096872505,0.00007183106,0.00093082467,0.00024027974,0.0003684698,0.00006870435,0.000037457743,0.0014212998,0.0000018322424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06335611,0.0007407216,0.047517598,0.000012061636,0.0007622878,0.000015783538,0.000038244118,0.00030830648,0.00038291092,0.000110844994,0.004410347,0.8823448],"study_design_scores_gemma":[0.0066841366,0.20328026,0.7471262,0.00037247705,0.00035268546,0.00016600196,0.000038235277,0.0081745805,0.0015928267,0.00034627135,0.0317484,0.00011793004],"about_ca_topic_score_codex":0.0006360548,"about_ca_topic_score_gemma":0.00060330465,"teacher_disagreement_score":0.8822269,"about_ca_system_score_codex":0.00023039483,"about_ca_system_score_gemma":0.0027374942,"threshold_uncertainty_score":0.9986546},"labels":[],"label_agreement":null},{"id":"W2586513663","doi":"10.1200/jco.2016.34.3_suppl.210","title":"Predicting patterns of distress in adult survivors of childhood cancer: A latent profile analysis from the Childhood Cancer Survivor Study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Distress; Somatization; Anxiety; Comorbidity; Asymptomatic; Depression (economics); Psychiatry; Internal medicine; Clinical psychology","score_opus":0.06364808727896869,"score_gpt":0.4239089118787962,"score_spread":0.3602608245998275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586513663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820284,0.0009334907,0.000083606225,0.013788743,0.0014313064,0.0008019046,0.0008497905,0.000013879717,0.00006882555],"genre_scores_gemma":[0.9947906,0.002511195,0.00014601924,0.0008453649,0.0015662931,0.00004389948,0.000011752184,0.000038926104,0.000045912777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892727,0.0022704736,0.006165507,0.00052174134,0.0013169445,0.0004526289],"domain_scores_gemma":[0.9840538,0.007613435,0.0061620665,0.0007206583,0.001062461,0.00038759742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006049141,0.0003385526,0.0039130016,0.00030900785,0.000052609113,0.000009172533,0.0007244112,0.0003953067,0.000542386],"category_scores_gemma":[0.0058234083,0.00018410267,0.0012757694,0.0008174018,0.0002973991,0.00016129913,0.00021598849,0.0011701243,0.0000022437264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016940361,0.0069550094,0.935903,0.000057178746,0.00579813,0.000056249493,0.0050117415,0.000074663236,0.000048635906,0.0000072000685,0.00012766277,0.044266455],"study_design_scores_gemma":[0.012141989,0.004159559,0.9756573,0.0013911984,0.0033802248,0.000008387976,0.0026502584,0.000044479293,0.00019687208,0.000039679635,0.00014849227,0.00018157053],"about_ca_topic_score_codex":0.06991175,"about_ca_topic_score_gemma":0.23834044,"teacher_disagreement_score":0.16842869,"about_ca_system_score_codex":0.00026191326,"about_ca_system_score_gemma":0.0019493772,"threshold_uncertainty_score":0.9362818},"labels":[],"label_agreement":null},{"id":"W2586527205","doi":"10.1200/jco.2013.31.15_suppl.tps4144","title":"Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with <i>BRCA or PALB2</i>-mutated pancreas adenocarcinoma (PC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Veliparib; Medicine; Clinical endpoint; Internal medicine; Gemcitabine; Carboplatin; Phases of clinical research; BRCA mutation; Oncology; Urology; Surgery; Cisplatin; Cancer; Randomized controlled trial; Clinical trial; Chemotherapy; Ovarian cancer; Poly ADP ribose polymerase","score_opus":0.05941126104619237,"score_gpt":0.3713309865635099,"score_spread":0.3119197255173175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586527205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964275,0.0003515737,0.000109195236,0.00014327666,0.0002833076,0.0026007139,0.00003402567,0.000004477059,0.000045924513],"genre_scores_gemma":[0.9978887,0.00017539428,0.0012898402,0.0002182452,0.00022609351,0.00007432285,0.000028684542,0.00005142472,0.00004731814],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99416107,0.000816229,0.0035483239,0.0005534968,0.0005119512,0.0004089068],"domain_scores_gemma":[0.9934654,0.0011440828,0.0034446383,0.00046103608,0.0010897047,0.000395132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001880503,0.00042069762,0.003020523,0.00020045972,0.00009386412,0.000025124216,0.00035691742,0.00033038924,0.00008434445],"category_scores_gemma":[0.0024318625,0.00024882288,0.00018905484,0.00029097003,0.00043768622,0.000029304712,0.00031085534,0.000497312,6.004836e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6191164,0.18008831,0.17275697,0.0000483594,0.001849251,0.0001538605,0.0025648158,0.00019880332,0.003610519,0.0000014709482,0.00022431582,0.019386917],"study_design_scores_gemma":[0.53413635,0.44015157,0.020957353,0.000098595,0.0010025701,0.00004106515,0.0021601971,0.00015067832,0.0007404467,0.00000959791,0.00027779175,0.0002737777],"about_ca_topic_score_codex":0.00047756307,"about_ca_topic_score_gemma":0.0019699365,"teacher_disagreement_score":0.26006326,"about_ca_system_score_codex":0.00007735788,"about_ca_system_score_gemma":0.000899951,"threshold_uncertainty_score":0.9999964},"labels":[],"label_agreement":null},{"id":"W2586565784","doi":"10.1200/jco.2016.34.3_suppl.31","title":"Successful implementation of a disease-specific survivorship program for men with prostate cancer (PC) and their partners.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Family medicine; Population; Prostate cancer; Quality of life (healthcare); Androgen deprivation therapy; Survivorship curve; Physical therapy; Cancer; Internal medicine; Nursing","score_opus":0.11742309981568005,"score_gpt":0.4842678651193373,"score_spread":0.3668447653036572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586565784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98320955,0.0011312313,0.00026850638,0.013933694,0.0003805339,0.00076860405,0.000058933274,0.0000097015845,0.0002392431],"genre_scores_gemma":[0.9959683,0.0025138154,0.00030841478,0.0002941794,0.00063469616,0.00009675131,0.0000039451747,0.00001795378,0.00016193872],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980415,0.00019963327,0.0011602383,0.00017714524,0.00021192776,0.00020954171],"domain_scores_gemma":[0.9964768,0.0012477726,0.0011635019,0.00012956916,0.00062463334,0.00035771166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016459147,0.0001207604,0.00085489405,0.00006786642,0.000026098927,0.000007983834,0.00008211805,0.00010597459,0.000097813514],"category_scores_gemma":[0.00017736459,0.000057132784,0.00021652847,0.000095654126,0.00025201027,0.00011415144,0.000020924208,0.00017386742,3.776863e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015791928,0.00030323464,0.46833846,0.00009414917,0.00020865454,0.00001695631,0.0004013596,2.9049517e-7,0.000101374215,0.000090842215,0.0014339269,0.5132188],"study_design_scores_gemma":[0.017819421,0.024161143,0.7337544,0.00040896388,0.00044045382,0.000032191023,0.0032169921,0.000009987595,0.00075191865,0.0007112165,0.21853614,0.00015719353],"about_ca_topic_score_codex":0.00016970784,"about_ca_topic_score_gemma":0.0034758323,"teacher_disagreement_score":0.51306164,"about_ca_system_score_codex":0.00008302949,"about_ca_system_score_gemma":0.0011879883,"threshold_uncertainty_score":0.23298073},"labels":[],"label_agreement":null},{"id":"W2586602836","doi":"10.1200/jco.2015.33.15_suppl.9561","title":"The price of survival: Breast cancer patient preferences about fertility.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Assisted Reproductive Technology and Twin Pregnancy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital; University of Toronto; University Health Network; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fertility; Breast cancer; Fertility preservation; Logistic regression; Demography; Cancer; Tamoxifen; Marital status; Gynecology; Population; Internal medicine; Environmental health","score_opus":0.18202157983227682,"score_gpt":0.4710308242566642,"score_spread":0.28900924442438736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586602836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96235985,0.006408874,0.00005661257,0.018593868,0.002987976,0.00017572183,0.000004473832,0.000013435851,0.00939922],"genre_scores_gemma":[0.997372,0.0012625768,0.0004485222,0.00023381547,0.0003867492,0.0000051117745,2.948096e-7,0.000007039679,0.00028393217],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99699014,0.00050959765,0.0017978406,0.00016479776,0.00036143805,0.0001761936],"domain_scores_gemma":[0.994665,0.0013284975,0.0019877835,0.0003090885,0.0014918805,0.00021770348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036740734,0.00009508978,0.000971834,0.00005163035,0.00004473713,0.0000028230008,0.00023746281,0.0003649158,0.000045555673],"category_scores_gemma":[0.006256472,0.000047279194,0.00025567962,0.00015688705,0.0007568532,0.00006439657,0.000082035935,0.0010086321,0.000005089758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005451317,0.001301784,0.46722606,0.000022887833,0.00048813465,0.00006223647,0.00017625389,0.000004243918,0.00003719981,0.0003566062,0.0025785472,0.52229476],"study_design_scores_gemma":[0.0022573988,0.005190416,0.94887614,0.00017177548,0.00023127378,0.00021284951,0.0005086584,0.0000065988193,0.00016975295,0.002784592,0.039539415,0.00005109849],"about_ca_topic_score_codex":0.000026570397,"about_ca_topic_score_gemma":0.000041050047,"teacher_disagreement_score":0.5222436,"about_ca_system_score_codex":0.00008944175,"about_ca_system_score_gemma":0.002118575,"threshold_uncertainty_score":0.7490033},"labels":[],"label_agreement":null},{"id":"W2586609652","doi":"10.1200/jco.2012.30.15_suppl.e14537","title":"Comparison of adjuvant chemoradiation to peri-operative chemotherapy for the treatment of resected gastric and gastroesophageal junction adenocarincoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Chemotherapy; Gastroesophageal Junction; Cancer; Surgery; Adenocarcinoma; Internal medicine; Oncology","score_opus":0.1483966751148379,"score_gpt":0.5031317150333158,"score_spread":0.3547350399184779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586609652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901031,0.0015283163,0.0024302637,0.0045307446,0.00070705195,0.0005607125,0.0000025713466,0.000003034526,0.00013418852],"genre_scores_gemma":[0.9931237,0.00074325845,0.004661053,0.00029168045,0.0009694175,0.000010538205,0.0000025364498,0.000008149507,0.00018966873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824405,0.00010521583,0.0012145843,0.000085265005,0.00019755599,0.0001533575],"domain_scores_gemma":[0.99738455,0.0010681269,0.0010331229,0.00010843274,0.00024783637,0.00015792562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097383244,0.00009470611,0.0010644748,0.00014275472,0.00003063407,0.0000033920137,0.000060446488,0.00009315145,0.00004149903],"category_scores_gemma":[0.00047080728,0.0000533779,0.00024299885,0.00017676379,0.000087652385,0.000063102,0.000012649006,0.00014129016,5.791284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063407896,0.0016361335,0.64536774,0.000026117144,0.0004314875,0.0000020327564,0.0009674085,0.000038380025,0.0003937223,0.000032838754,0.0018575384,0.3429058],"study_design_scores_gemma":[0.009695165,0.033946715,0.93596166,0.000019300398,0.00059576414,0.00002031102,0.000674153,0.00031651536,0.0010686531,0.000007290805,0.017662667,0.00003182507],"about_ca_topic_score_codex":0.000017514812,"about_ca_topic_score_gemma":0.000014071546,"teacher_disagreement_score":0.34287396,"about_ca_system_score_codex":0.0001484314,"about_ca_system_score_gemma":0.00017674435,"threshold_uncertainty_score":0.21766876},"labels":[],"label_agreement":null},{"id":"W2586653554","doi":"10.1200/jco.2016.34.3_suppl.179","title":"Weight control strategies in breast cancer patients: A systematic review.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Waist; Randomized controlled trial; Cancer; Internal medicine; Psychological intervention; Weight loss; Systematic review; Meta-analysis; Obesity; Weight change; Weight management; Physical therapy; MEDLINE; Oncology","score_opus":0.05202700030204108,"score_gpt":0.4588571780005761,"score_spread":0.406830177698535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586653554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8622871,0.028443558,0.00028573332,0.10114762,0.0038989573,0.0017004391,0.00006868744,0.000016028145,0.0021518976],"genre_scores_gemma":[0.9634527,0.030088361,0.00003251141,0.0057039685,0.00060302124,0.000015132376,2.7294175e-7,0.000009453762,0.00009458987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626094,0.00038227058,0.0027917642,0.00011246004,0.00028361994,0.00016895345],"domain_scores_gemma":[0.99597776,0.0013252333,0.0018599376,0.00013568492,0.00047678745,0.00022457924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019946198,0.00010311497,0.0022792253,0.000080520134,0.000009779552,0.000004382152,0.00011265886,0.00017704439,0.00037251596],"category_scores_gemma":[0.0016874053,0.00004591665,0.00038782074,0.000091903414,0.000100338,0.00014977019,0.000012802973,0.00039154716,0.000017187711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041627777,0.0023799841,0.92182744,0.024411658,0.0007437753,0.0003740211,0.000058584894,0.0000010012919,0.00005978761,0.00022174563,0.01814954,0.027609708],"study_design_scores_gemma":[0.021210462,0.0044205096,0.8634392,0.101703376,0.0013963433,0.00021038426,0.000057469006,0.0000059687736,0.0000022564145,0.0002133989,0.007220317,0.00012032572],"about_ca_topic_score_codex":0.000051835876,"about_ca_topic_score_gemma":0.000099417906,"teacher_disagreement_score":0.10116561,"about_ca_system_score_codex":0.00027504432,"about_ca_system_score_gemma":0.0014110134,"threshold_uncertainty_score":0.40787885},"labels":[],"label_agreement":null},{"id":"W2586658211","doi":"10.1200/jco.2012.30.4_suppl.620","title":"Cohort study evaluating the impact of a discharge letter (DL) compared with usual care on adherence to surveillance following treatment for stage II/III colorectal cancer (CRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Colorectal cancer; Stage (stratigraphy); Cancer registry; Internal medicine; Cancer; Oxaliplatin; Adjuvant therapy; Surgery","score_opus":0.21230876583448435,"score_gpt":0.5464166120459163,"score_spread":0.33410784621143197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586658211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529046,0.00017932063,0.0000780656,0.0010266746,0.0009561331,0.0020927906,0.000020744323,0.000006227429,0.00034957484],"genre_scores_gemma":[0.9975125,0.000024396366,0.00039215034,0.0005002488,0.001085218,0.000121339406,0.0000042545,0.000017835286,0.0003420279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972995,0.00033673533,0.0012976897,0.00019320882,0.0005162159,0.0003566648],"domain_scores_gemma":[0.9963059,0.0017523145,0.0011865693,0.00019627727,0.00030971042,0.00024921892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028374216,0.00019907914,0.0016104209,0.00008355446,0.00010186701,0.000009238021,0.00016355139,0.00007835959,0.000110471345],"category_scores_gemma":[0.00063390937,0.000094084,0.0006420323,0.00016431617,0.000062365645,0.00009150257,0.00005611718,0.00030741,0.000001319224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013679572,0.0016953193,0.96239674,0.000012487365,0.001993663,0.000022113565,0.0022920982,0.0004565849,0.000085337706,0.0000024933602,0.0012832745,0.016080324],"study_design_scores_gemma":[0.015387356,0.12606966,0.8551303,0.000065425345,0.0007227265,0.000005863433,0.0014989947,0.000075493204,0.000023046498,6.2883817e-7,0.0009356399,0.000084817446],"about_ca_topic_score_codex":0.0006536026,"about_ca_topic_score_gemma":0.00094326463,"teacher_disagreement_score":0.124374345,"about_ca_system_score_codex":0.00064908207,"about_ca_system_score_gemma":0.00079640007,"threshold_uncertainty_score":0.38366342},"labels":[],"label_agreement":null},{"id":"W2586669759","doi":"10.1200/jco.2012.30.34_suppl.12","title":"Doctor, what are my options? A prospective cohort study of an individualized care plan for patients with gastrointestinal cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anxiety; Cohort; Depression (economics); Cancer; Prospective cohort study; Intervention (counseling); Family medicine; Physical therapy; Internal medicine; Psychiatry","score_opus":0.0867710478965519,"score_gpt":0.45220449404201846,"score_spread":0.3654334461454666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586669759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965546,0.00045503004,0.0000392206,0.00021989136,0.0012754006,0.0012849265,0.000042326894,0.0000076929255,0.00012087198],"genre_scores_gemma":[0.99646574,0.00007276085,0.0019579502,0.00024539427,0.0011065353,0.00008498023,0.000018567285,0.000020210358,0.000027850328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974072,0.00032344792,0.0013144696,0.00018494616,0.0005114159,0.00025854982],"domain_scores_gemma":[0.99506736,0.0006979479,0.0018733161,0.00018797125,0.0017417334,0.00043168772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012994568,0.00014992728,0.0013667812,0.00010311006,0.000049421287,0.000013477262,0.00013597438,0.00012974831,0.00006616315],"category_scores_gemma":[0.00076695374,0.000099588506,0.00021786241,0.00012723093,0.00012602152,0.0003816302,0.000031684278,0.0005457808,7.266991e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013833193,0.0062481393,0.96458876,0.000058885696,0.0003980056,0.000024639623,0.003116703,0.000006816701,0.0000015989061,0.000010057258,0.00013829816,0.0115749],"study_design_scores_gemma":[0.01814601,0.059324987,0.89945114,0.00037172248,0.0009284511,0.000071902854,0.019934885,0.0000021016524,0.0000064573806,0.000010822352,0.0016632099,0.00008830389],"about_ca_topic_score_codex":0.00016939008,"about_ca_topic_score_gemma":0.0025361478,"teacher_disagreement_score":0.06513762,"about_ca_system_score_codex":0.0002718783,"about_ca_system_score_gemma":0.00082995923,"threshold_uncertainty_score":0.40611014},"labels":[],"label_agreement":null},{"id":"W2586707082","doi":"10.1200/jco.2016.34.3_suppl.32","title":"Prevalence of cognitive impairment in patients with hematologic cancers preceding stem cell transplantation: Program for healthy aging.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Medicine; Montreal Cognitive Assessment; Depression (economics); Transplantation; Internal medicine; Cognition; Disease; Pediatrics; Gerontology; Psychiatry","score_opus":0.06547915556953075,"score_gpt":0.43559767454657217,"score_spread":0.3701185189770414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586707082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410176,0.0003110165,0.00052711845,0.0023194156,0.00045233063,0.0019665381,0.00003630977,0.000010992897,0.00027448987],"genre_scores_gemma":[0.9963117,0.0016461485,0.0012742176,0.00042308375,0.00014778152,0.00010225633,0.0000018358998,0.000013796075,0.00007918513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971149,0.00021948836,0.0018222819,0.0002181433,0.0003389091,0.0002863078],"domain_scores_gemma":[0.99324036,0.003579217,0.0019487733,0.00006722894,0.0009777119,0.00018669335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013599629,0.00014648844,0.0011148187,0.000123651,0.00004629563,0.0000034752056,0.00008083934,0.00016956218,0.000022989952],"category_scores_gemma":[0.00044620153,0.00008211061,0.0002098606,0.00014221287,0.00027981846,0.000114550734,0.000016130158,0.00032938848,0.0000011706712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034400225,0.0027675554,0.85159665,0.0009111601,0.0002743579,0.000041958432,0.0003917672,0.0000040204627,0.0000063333555,0.0000028990448,0.0002193283,0.109383725],"study_design_scores_gemma":[0.04402993,0.099279195,0.8513913,0.0035701704,0.0006902103,0.00003863779,0.00035616822,0.0000071335676,0.00031229496,0.000022796301,0.00020180234,0.000100338875],"about_ca_topic_score_codex":0.000008488279,"about_ca_topic_score_gemma":0.000036490237,"teacher_disagreement_score":0.10928339,"about_ca_system_score_codex":0.00047819386,"about_ca_system_score_gemma":0.0013527109,"threshold_uncertainty_score":0.33483735},"labels":[],"label_agreement":null},{"id":"W2586724517","doi":"10.1200/jco.2012.30.34_suppl.314","title":"How to integrate vital interdisciplinary information in a non-closed-loop system?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmacy and Medical Practices","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Documentation; Medicine; Vital signs; Workaround; Discontinuation; Medical emergency; Medical record; Surgery; Computer science","score_opus":0.2861169807668377,"score_gpt":0.598766480081021,"score_spread":0.31264949931418323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586724517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93606645,0.00034339083,0.0014484499,0.030691985,0.015157963,0.00039163258,0.000012432991,0.000022514829,0.015865209],"genre_scores_gemma":[0.9859399,0.00017416239,0.00078728516,0.010111205,0.0026701672,0.000018305696,0.000004079207,0.000011501981,0.00028338472],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946157,0.0018373431,0.0025195966,0.00013540001,0.00031701947,0.0005749914],"domain_scores_gemma":[0.99198186,0.004342039,0.0019773918,0.00013498105,0.00029185353,0.001271842],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01384346,0.00020664289,0.0011100108,0.00035012735,0.000091951675,0.000029970231,0.0004847136,0.00074805244,0.00021565192],"category_scores_gemma":[0.005689748,0.0001518194,0.00033507947,0.00029735224,0.00021062426,0.0022798802,0.00030296718,0.003730331,0.00031457937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013124866,0.004320265,0.04655657,0.00024071538,0.00063817453,0.00065515336,0.0047726524,0.00015424877,0.0022602142,0.0008186183,0.08307175,0.84338677],"study_design_scores_gemma":[0.008067327,0.0036846278,0.02989937,0.00014702807,0.0003415797,0.0005964623,0.0048312605,0.0010107385,0.0011365169,0.00013886002,0.9498834,0.00026284196],"about_ca_topic_score_codex":0.000009261507,"about_ca_topic_score_gemma":0.000016072463,"teacher_disagreement_score":0.86681163,"about_ca_system_score_codex":0.00030627492,"about_ca_system_score_gemma":0.0005857079,"threshold_uncertainty_score":0.9985681},"labels":[],"label_agreement":null},{"id":"W2586740931","doi":"10.1200/jco.2012.30.30_suppl.80","title":"Identification of multifunctional cytotoxic T-cell subsets as immune correlates with clinical outcomes in a phase II study of AGS-003, an autologous dendritic cell-based therapy administered to patients with newly diagnosed, metastatic RCC.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"CTL*; Medicine; Cluster of differentiation; Cytotoxic T cell; Immune system; CD8; T cell; Immunology; Cell; Biology","score_opus":0.06275273621190049,"score_gpt":0.40619252469951256,"score_spread":0.3434397884876121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586740931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963661,0.00027654055,0.00029660686,0.000110195906,0.0016734641,0.0011981733,0.000049835744,0.0000119106035,0.000017181002],"genre_scores_gemma":[0.9987438,0.000023163175,0.00067715626,0.00027369874,0.00005360701,0.000048304046,0.000046074914,0.00003174308,0.00010245335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906282,0.0030781562,0.0052918675,0.00036143974,0.00025968524,0.00038069353],"domain_scores_gemma":[0.98864573,0.005220813,0.0047627557,0.00043777347,0.00072564045,0.00020726403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034929882,0.0003120743,0.0021533072,0.00037145725,0.000099359735,0.000009219427,0.0003980415,0.00043319463,0.00031552874],"category_scores_gemma":[0.0018301579,0.00021002004,0.00033126678,0.00026171736,0.0004450614,0.00028811436,0.000054081967,0.000960481,0.000037225178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024878629,0.09777647,0.8581859,0.000023239363,0.0005869676,0.0000673381,0.0014268468,0.00022707744,0.012607834,0.0000056317226,0.00009809363,0.0041159634],"study_design_scores_gemma":[0.07400363,0.11548273,0.8009342,0.000044215194,0.000396775,0.000030701038,0.0010875101,0.000019548921,0.0074839224,0.0000060131492,0.00029226847,0.00021849561],"about_ca_topic_score_codex":0.00008626959,"about_ca_topic_score_gemma":0.00028897598,"teacher_disagreement_score":0.057251714,"about_ca_system_score_codex":0.00008251585,"about_ca_system_score_gemma":0.0009439601,"threshold_uncertainty_score":0.85643685},"labels":[],"label_agreement":null},{"id":"W2586747250","doi":"10.1200/jco.2016.34.3_suppl.139","title":"Feasibility and acceptability of integrated cardiac rehabilitation in outpatients referred for autologous bone marrow transplantation.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diabetic Foot Ulcer Assessment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"","keywords":"Medicine; Rehabilitation; Transplantation; Dyslipidemia; Adverse effect; Internal medicine; Physical therapy; Surgery; Obesity","score_opus":0.09380544947223556,"score_gpt":0.45045945255868375,"score_spread":0.3566540030864482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586747250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990684,0.00012056918,0.0008581349,0.0063954364,0.00067032035,0.0007091051,0.000023906687,0.000005447755,0.00053313404],"genre_scores_gemma":[0.9863835,0.0003172097,0.013035164,0.00011432343,0.00005962236,0.000014800655,0.00000616427,0.000006444696,0.00006277426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969022,0.0004648373,0.0021062829,0.00018748148,0.00020111234,0.00013806757],"domain_scores_gemma":[0.99504507,0.003330234,0.00089658104,0.00015223047,0.00044943806,0.00012643384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005197306,0.00009080778,0.0011485667,0.00013700526,0.0000110313285,0.000002566466,0.00006435561,0.00019534252,0.0000677962],"category_scores_gemma":[0.0059323865,0.000054538243,0.00027676203,0.00009875523,0.0002524667,0.00011981527,0.00001795718,0.0001896769,6.1408525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070586875,0.0011670922,0.6603551,0.00017654152,0.00009314258,0.000007721908,0.00013723905,6.4838036e-7,0.0002017339,0.00015276359,0.00040902125,0.3302403],"study_design_scores_gemma":[0.011521424,0.011142507,0.96960306,0.000109861925,0.00026646032,0.000004389818,0.0002245827,0.000020238213,0.00007162622,0.0018993609,0.0050838,0.000052694395],"about_ca_topic_score_codex":0.000017920283,"about_ca_topic_score_gemma":0.000056629906,"teacher_disagreement_score":0.3301876,"about_ca_system_score_codex":0.00021051221,"about_ca_system_score_gemma":0.0004656237,"threshold_uncertainty_score":0.7102049},"labels":[],"label_agreement":null},{"id":"W2586804150","doi":"10.1200/jco.2006.24.18_suppl.3506","title":"A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Irinotecan; Capecitabine; Clinical endpoint; Bevacizumab; FOLFIRI; Celecoxib; Nausea; Placebo; Gastroenterology; Internal medicine; Bolus (digestion); Colorectal cancer; Tolerability; Vomiting; Randomized controlled trial; Chemotherapy; Adverse effect; Cancer","score_opus":0.1089623824251588,"score_gpt":0.4604463677779143,"score_spread":0.3514839853527555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586804150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885226,0.0008842142,0.00011188974,0.0061810147,0.00063067226,0.0013685243,0.000010906716,0.00000803248,0.002282177],"genre_scores_gemma":[0.99500185,0.0015984664,0.0020385263,0.00018733769,0.0004739718,0.00013397109,0.000003817403,0.000018595047,0.0005434454],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99564993,0.00050467864,0.0029838756,0.00019350313,0.00042782066,0.00024017048],"domain_scores_gemma":[0.9927977,0.00418057,0.002114054,0.00011074398,0.0006532082,0.00014377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024072179,0.00020197466,0.003985707,0.00022943055,0.000046166875,0.000005760177,0.0001047731,0.00015330352,0.0002130563],"category_scores_gemma":[0.0023955007,0.000105283325,0.00051778747,0.0003543854,0.00049705955,0.00007450872,0.00003414245,0.0005478209,0.0000011889592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95064193,0.010340888,0.02565956,0.00004792569,0.0011303895,0.0004008084,0.00011096313,0.000103496706,0.000017171998,0.000085267566,0.00045746198,0.011004115],"study_design_scores_gemma":[0.9187906,0.05330685,0.021854416,0.00018740018,0.0017527986,0.00013798571,0.000080107995,0.00043706442,0.0001469264,0.00032860148,0.0028697124,0.00010758323],"about_ca_topic_score_codex":0.0012741814,"about_ca_topic_score_gemma":0.020550974,"teacher_disagreement_score":0.042965963,"about_ca_system_score_codex":0.0003048559,"about_ca_system_score_gemma":0.0018838563,"threshold_uncertainty_score":0.9973214},"labels":[],"label_agreement":null},{"id":"W2586892955","doi":"10.1200/jco.2013.31.15_suppl.4059","title":"Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Multivariate analysis; Univariate analysis; Proportional hazards model; Gastroenterology; Performance status; Randomized controlled trial; Oncology; Overall survival; Survival analysis; Cancer","score_opus":0.13358753057059836,"score_gpt":0.47310876143921426,"score_spread":0.3395212308686159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586892955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919357,0.00059326296,0.00014014625,0.0012430146,0.00094176596,0.0041727116,0.000026235557,0.0000074518553,0.00093974505],"genre_scores_gemma":[0.996508,0.0009424825,0.0017165677,0.00012955113,0.00027338398,0.00017988436,0.000018891975,0.00004096447,0.00019029497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98729014,0.0033209012,0.006983935,0.00039722223,0.0012853786,0.00072243356],"domain_scores_gemma":[0.96738267,0.025495324,0.004660044,0.00040164494,0.0013896571,0.00067064737],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0094350185,0.0004123962,0.01034311,0.00073112646,0.000032898784,0.000010171264,0.0003680645,0.00047981672,0.00068443455],"category_scores_gemma":[0.027491288,0.0002531841,0.0008079007,0.0007183002,0.0012585458,0.0002858378,0.000092643575,0.0015944006,0.000007836095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6447229,0.009090956,0.34001172,0.00018376445,0.0016905424,0.00016076065,0.00053645053,0.000029564708,0.00004719948,0.000026696576,0.00019895827,0.0033005495],"study_design_scores_gemma":[0.7550296,0.047700234,0.19234583,0.00056509156,0.0025496585,0.000011902424,0.00068179547,0.0006819175,0.000022730537,0.00018004961,0.00006266677,0.00016851991],"about_ca_topic_score_codex":0.0030120858,"about_ca_topic_score_gemma":0.00094817946,"teacher_disagreement_score":0.14766587,"about_ca_system_score_codex":0.0005769698,"about_ca_system_score_gemma":0.005667744,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W2586977270","doi":"10.1200/jco.2012.30.34_suppl.69","title":"Rates of diagnostic imaging in long-term survivors of young adult malignancies.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; St. Michael's Hospital; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Confidence interval; Poisson regression; Cancer; Malignancy; Cancer registry; Population; Young adult; Retrospective cohort study; Pediatrics; Surgery; Internal medicine","score_opus":0.06688152567163082,"score_gpt":0.44921854140228507,"score_spread":0.38233701573065426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586977270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929895,0.0021237403,0.00016422114,0.0019559588,0.0012717351,0.0000982916,0.0000013867575,0.0000025145664,0.0013926534],"genre_scores_gemma":[0.99651414,0.0015608976,0.0005033868,0.00070991024,0.0006502995,0.0000011428336,0.0000014582706,0.000010678764,0.000048087222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665344,0.00029676972,0.002485058,0.00008143403,0.00025916286,0.00022415794],"domain_scores_gemma":[0.9924892,0.0048588696,0.0018889204,0.00012975329,0.00041947485,0.00021375353],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032140028,0.000088730565,0.0010991304,0.00020699788,0.0000100312145,0.0000027006329,0.000117888994,0.00012079597,0.00010892675],"category_scores_gemma":[0.017619597,0.00006705641,0.00027375578,0.00016904825,0.00018831185,0.00026153692,0.000030499743,0.00045392034,0.0000060646194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030822144,0.000903977,0.9506573,0.000058263086,0.00005973368,0.00012731063,0.0002527765,0.000006812489,0.0006824257,0.00006166403,0.000379562,0.04650194],"study_design_scores_gemma":[0.0033205831,0.00080872717,0.9928139,0.00035894106,0.00014486264,0.0002373697,0.0001668815,0.0000645565,0.0017219294,0.000040273106,0.0002673532,0.000054642973],"about_ca_topic_score_codex":0.00009624785,"about_ca_topic_score_gemma":0.000067472,"teacher_disagreement_score":0.046447296,"about_ca_system_score_codex":0.00006358736,"about_ca_system_score_gemma":0.0005041284,"threshold_uncertainty_score":0.9906554},"labels":[],"label_agreement":null},{"id":"W2586986791","doi":"10.1200/jco.2012.30.30_suppl.87","title":"Biopsy-driven study to identify biomarkers of drug resistance in patients with triple-negative breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Hôtel-Dieu de Montréal; Hôpital du Saint-Sacrement; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Triple-negative breast cancer; Chemotherapy; Drug resistance; Liquid biopsy; Oncology; Paclitaxel; Biopsy; Internal medicine; Cancer; Cancer research; Pathology; Biology","score_opus":0.07309021360902741,"score_gpt":0.4978080930385941,"score_spread":0.4247178794295667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586986791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933346,0.00021182283,0.000004396119,0.0037768444,0.0014131322,0.0006993332,0.000025163175,0.0000036481565,0.00053106237],"genre_scores_gemma":[0.9975222,0.00007271148,0.0011533371,0.000478282,0.00046593643,0.000014612316,0.0000016337889,0.000014339457,0.00027695973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969214,0.000571645,0.0017021251,0.00016576661,0.00036335975,0.00027569663],"domain_scores_gemma":[0.9964769,0.0010217818,0.0014495305,0.00013858601,0.0005017831,0.00041145278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017309608,0.00014331413,0.0013763041,0.00024410311,0.00002232665,0.0000027633953,0.00014259256,0.00010893002,0.00023354404],"category_scores_gemma":[0.0003974481,0.000094865296,0.00018851708,0.00040812005,0.00016251783,0.00014513695,0.000043697193,0.00045532998,0.0000060931898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0455118,0.0147400005,0.9267166,0.000021877351,0.0010194341,0.00009247838,0.0014845029,0.0000027461538,0.00004979737,0.0000042762654,0.005150011,0.0052064685],"study_design_scores_gemma":[0.030272013,0.008404465,0.95860106,0.0001405376,0.0006450495,0.000016030363,0.00049869245,7.0903775e-7,0.000038421145,0.000013547966,0.0012867863,0.00008270811],"about_ca_topic_score_codex":0.00022524878,"about_ca_topic_score_gemma":0.001375829,"teacher_disagreement_score":0.03188443,"about_ca_system_score_codex":0.0003782778,"about_ca_system_score_gemma":0.00079338346,"threshold_uncertainty_score":0.38684946},"labels":[],"label_agreement":null},{"id":"W2586988489","doi":"10.1200/jco.2014.32.31_suppl.44","title":"A preliminary study of attitudes toward the assessment and management of cancer cachexia among medical oncologists and nurses.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Psychological intervention; Anorexia; Family medicine; Clinical trial; Cachexia; Cancer; Weight management; Weight loss; MEDLINE; Depression (economics); Intensive care medicine; Internal medicine; Nursing; Obesity","score_opus":0.16508494697492077,"score_gpt":0.558454833682434,"score_spread":0.3933698867075132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586988489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851015,0.0017459461,0.000027526896,0.010582664,0.00059974036,0.00036222953,8.225247e-7,0.0000029762691,0.0015765667],"genre_scores_gemma":[0.99097174,0.007534556,0.0006156789,0.0005126709,0.00029113868,0.000017168502,1.3111557e-7,0.0000068213208,0.000050081635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970709,0.00047257822,0.0016096575,0.00016011528,0.00054422556,0.00014254038],"domain_scores_gemma":[0.9963842,0.0019107922,0.001108151,0.00014484266,0.00023037473,0.00022163383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041248184,0.00010850086,0.0015096121,0.000051371637,0.00003547128,0.0000028402521,0.00014400519,0.00017722008,0.000038489754],"category_scores_gemma":[0.0006749456,0.00005756676,0.00012236624,0.000073797826,0.0007556013,0.000035750025,0.00018327041,0.0005744508,1.4783468e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012177029,0.002670918,0.77424586,0.00023559369,0.0009964958,0.00015476618,0.00086864183,0.0000031292761,0.000004609011,0.00008026731,0.0010466332,0.21847536],"study_design_scores_gemma":[0.007173035,0.036050525,0.9498074,0.00046990247,0.0008985095,0.000038550133,0.002192496,0.00009675069,0.000004462535,0.000040696214,0.0031804254,0.000047247722],"about_ca_topic_score_codex":0.00016881818,"about_ca_topic_score_gemma":0.0004553918,"teacher_disagreement_score":0.21842812,"about_ca_system_score_codex":0.00007354308,"about_ca_system_score_gemma":0.0005235098,"threshold_uncertainty_score":0.27840444},"labels":[],"label_agreement":null},{"id":"W2587043031","doi":"10.1200/jco.2012.30.34_suppl.170","title":"Bridging efforts to longitudinally improve and evaluate venous thromboembolism prophylaxis uptake in hospitalized cancer patients through interprofessional teamwork (BELIEVE IT): A study by Princess Margaret Cancer Centre.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Audit; Venous thromboembolism; Psychological intervention; Teamwork; Population; Emergency medicine; Family medicine; Intensive care medicine; Nursing; Surgery; Thrombosis","score_opus":0.05262491034680572,"score_gpt":0.44523938128813356,"score_spread":0.39261447094132784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587043031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98440886,0.0016753465,0.000038405044,0.0063773603,0.0050270697,0.0021561831,0.000019378393,0.0000130326425,0.00028437056],"genre_scores_gemma":[0.99150383,0.0018180456,0.00062634767,0.004540094,0.001191542,0.0001364867,0.000004717163,0.000047678666,0.00013122777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99469966,0.0005206784,0.0026773417,0.00047471529,0.00088704505,0.0007405745],"domain_scores_gemma":[0.99660766,0.00039667138,0.0015958588,0.00025727975,0.0005224165,0.00062012044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033805172,0.00034839747,0.002790973,0.00015787172,0.00009917169,0.000027451902,0.00026843115,0.000314175,0.00023244235],"category_scores_gemma":[0.0010626616,0.00024820046,0.00026888578,0.00027617204,0.00013641326,0.0003470563,0.00037902666,0.0010718621,0.000009357194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002137566,0.020730413,0.8311091,0.00010893692,0.0009586569,0.00011006386,0.0046896026,0.000015248376,0.00003553185,0.000017624536,0.012173156,0.12791407],"study_design_scores_gemma":[0.00944407,0.014354561,0.96310085,0.00091449753,0.00081038754,0.000008983475,0.0006996906,0.000021122676,0.000026969334,0.00006306673,0.010302753,0.0002530434],"about_ca_topic_score_codex":0.001051409,"about_ca_topic_score_gemma":0.0008185105,"teacher_disagreement_score":0.13199173,"about_ca_system_score_codex":0.0006211784,"about_ca_system_score_gemma":0.000965876,"threshold_uncertainty_score":0.999997},"labels":[],"label_agreement":null},{"id":"W2587049046","doi":"10.1200/jco.2007.25.18_suppl.9056","title":"A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Thalidomide; Randomized controlled trial; Warfarin; Multiple myeloma; Chemoprophylaxis; Surgery","score_opus":0.08647644461623892,"score_gpt":0.46032977444641243,"score_spread":0.3738533298301735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587049046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1466175,0.84895104,0.0000067979545,0.0000151979175,0.00018265501,0.0041508637,0.000016860773,0.0000015652333,0.000057521385],"genre_scores_gemma":[0.1882003,0.81129044,0.00037099628,0.000024174937,0.000047888192,0.000032423726,0.0000038026087,0.000025899524,0.000004057351],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9880318,0.0046925503,0.005734816,0.00026432637,0.0010041277,0.00027234963],"domain_scores_gemma":[0.9726684,0.016749455,0.0086889,0.0005188044,0.0011498486,0.00022459084],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011710119,0.00031333853,0.012263887,0.00030315036,0.000022263195,0.0000028290717,0.00039761246,0.0005089249,0.000007852752],"category_scores_gemma":[0.031789754,0.00014396587,0.0009854925,0.0005533328,0.0004972484,0.000071032555,0.00016586561,0.0012826769,0.0000010075408],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016037596,0.0023617216,0.065479696,0.76244193,0.0014394849,0.00014270362,0.000037252918,2.1057312e-7,8.909359e-7,0.0000035979504,0.0000025873853,0.16648616],"study_design_scores_gemma":[0.004998507,0.010336398,0.29624096,0.6852023,0.0026737764,0.00016212491,0.000009173289,9.839792e-7,0.0000064071705,0.00000949625,0.0002802233,0.00007961915],"about_ca_topic_score_codex":0.000066419234,"about_ca_topic_score_gemma":0.00003307503,"teacher_disagreement_score":0.23076126,"about_ca_system_score_codex":0.00028471265,"about_ca_system_score_gemma":0.0024921244,"threshold_uncertainty_score":0.97636586},"labels":[],"label_agreement":null},{"id":"W2587092249","doi":"10.1200/jco.2012.30.30_suppl.90","title":"Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Biochemical recurrence; Prostate cancer; breakpoint cluster region; Prostatectomy; Internal medicine; Oncology; Disease; Confounding; Cancer; Localized disease; Stage (stratigraphy)","score_opus":0.261240829825691,"score_gpt":0.5795278070506483,"score_spread":0.3182869772249573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587092249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899298,0.008442765,0.000020582747,0.0010331364,0.00024184509,0.00017989893,0.000008508199,0.0000012463425,0.00014220201],"genre_scores_gemma":[0.9921134,0.004804357,0.00274465,0.00008473183,0.00021164425,0.000003143651,0.000007022706,0.000006046113,0.000024978217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996032,0.00063165545,0.0026571546,0.00014213406,0.00032224695,0.00021483019],"domain_scores_gemma":[0.9953685,0.0022733961,0.001316202,0.00015417355,0.00025654552,0.00063118816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055465726,0.000092434166,0.0018401385,0.0003481716,0.000009551787,0.0000022053264,0.00009805746,0.00014163702,0.000077692086],"category_scores_gemma":[0.0020331957,0.000055980294,0.0005594571,0.00042566741,0.0006807217,0.00008276188,0.000072701645,0.00059484306,0.0000013991456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007917419,0.0045108525,0.92707455,0.000097092496,0.0014673319,0.000115439594,0.000055585304,0.0000011403099,0.0002389214,0.000040596384,0.00022389785,0.05825717],"study_design_scores_gemma":[0.0063136443,0.0039742747,0.9847469,0.00018938992,0.0033072734,0.000019179164,0.00012431382,0.00018589047,0.00009865678,0.00012995029,0.0008628128,0.000047713012],"about_ca_topic_score_codex":0.0000068616387,"about_ca_topic_score_gemma":0.000005193189,"teacher_disagreement_score":0.058209457,"about_ca_system_score_codex":0.00006280764,"about_ca_system_score_gemma":0.0010492356,"threshold_uncertainty_score":0.258433},"labels":[],"label_agreement":null},{"id":"W2587098043","doi":"10.1200/jco.2016.34.3_suppl.13","title":"Bridging the gap: The design of a survivorship curriculum for interspecialty collaboration.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Curriculum; Medicine; Medical education; Survivorship curve; Specialty; Family medicine; Focus group; Nursing; Psychology; Cancer; Pedagogy","score_opus":0.48833200777586233,"score_gpt":0.5772095215411791,"score_spread":0.08887751376531677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587098043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66865385,0.0031979317,0.17483608,0.1463952,0.004056125,0.00091054215,0.000020476202,0.000008832186,0.001920933],"genre_scores_gemma":[0.9884219,0.0017918093,0.005740234,0.0012936204,0.0025013087,0.000006500269,4.0997682e-7,0.000009204226,0.00023497849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972179,0.0007783913,0.0015495889,0.00008526245,0.00023898203,0.00012990554],"domain_scores_gemma":[0.9811372,0.015272107,0.0018583835,0.00016477959,0.0014742846,0.00009322887],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006274659,0.00007682231,0.0008292987,0.000047999216,0.000034157452,0.000003894861,0.00021877713,0.00014198908,0.00004469196],"category_scores_gemma":[0.02477138,0.0000284646,0.0003373791,0.00014834382,0.0003641347,0.000064359534,0.000027796445,0.00025387615,0.0000028873626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014782039,0.002446741,0.36389506,0.00015251202,0.001968554,0.00009630025,0.004746071,0.00006951709,0.0034640613,0.009554675,0.22273037,0.3760941],"study_design_scores_gemma":[0.02312636,0.034048278,0.08552403,0.0032199528,0.0017546283,0.0001549796,0.0096295895,0.000859559,0.0061431634,0.009106109,0.8261545,0.0002788645],"about_ca_topic_score_codex":0.000020677106,"about_ca_topic_score_gemma":0.00007587866,"teacher_disagreement_score":0.60342413,"about_ca_system_score_codex":0.00007130451,"about_ca_system_score_gemma":0.0010105071,"threshold_uncertainty_score":0.9834434},"labels":[],"label_agreement":null},{"id":"W2587114112","doi":"10.1200/jco.2012.30.34_suppl.68","title":"Use of a community of practice (CoP) platform as a model in regional quality improvements in cancer surgery: The Ottawa model.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Quality management; Audit; Outreach; Health care; Standardization; Multidisciplinary approach; Population; Population health; Operations management; Environmental health; Business","score_opus":0.8363987176705352,"score_gpt":0.6782605655290821,"score_spread":0.1581381521414531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587114112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703302,0.00015686663,0.00057292817,0.027947044,0.0003777246,0.0003532201,0.000013762304,0.0000024907592,0.00024576415],"genre_scores_gemma":[0.97755927,0.001138885,0.0072105117,0.0137864165,0.00024108957,0.000010939789,0.000006157393,0.0000147935325,0.00003194917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9873076,0.0028136175,0.008687974,0.00011176867,0.00077000965,0.00030902692],"domain_scores_gemma":[0.9213933,0.06777351,0.00888863,0.000434549,0.0012513496,0.00025870657],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.048355687,0.00013917885,0.0016741091,0.00019119962,0.000032279986,0.0000041890107,0.00022982439,0.00035679594,0.000051682968],"category_scores_gemma":[0.11979626,0.00009414419,0.00042987254,0.00028812868,0.00029032832,0.0011137784,0.00013861072,0.0025270013,0.0000013804541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03309592,0.022942586,0.6797962,0.00019126893,0.0006965022,0.0000318057,0.003310511,0.010512531,0.0010264415,0.0014865745,0.01308029,0.23382935],"study_design_scores_gemma":[0.014765211,0.0039640255,0.9139994,0.0003767243,0.00088440604,0.00014283771,0.0041937777,0.041408423,0.00012596502,0.0045322995,0.015388953,0.00021797096],"about_ca_topic_score_codex":0.01572639,"about_ca_topic_score_gemma":0.004664387,"teacher_disagreement_score":0.23420319,"about_ca_system_score_codex":0.0003487676,"about_ca_system_score_gemma":0.0041885464,"threshold_uncertainty_score":0.9997742},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"low"}],"label_agreement":"split"},{"id":"W2587114148","doi":"10.1200/jco.2012.30.34_suppl.225","title":"Impact on mortality of increasing surgical volumes within hospitals after regionalization of thoracic surgery in Ontario, Canada.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University Health Network; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Logistic regression; Mortality rate; Surgery; Confidence interval; Emergency medicine; Internal medicine","score_opus":0.08834853911484873,"score_gpt":0.4635246543955147,"score_spread":0.37517611528066597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587114148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752116,0.0005830838,0.000002140419,0.0007761618,0.00064533367,0.00011645641,0.0000052043224,0.0000012433642,0.00034920123],"genre_scores_gemma":[0.99903876,0.00019811152,0.0001826756,0.00024451982,0.00029143135,0.0000034580971,0.0000053354192,0.000008539296,0.000027200356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965251,0.00054084056,0.0021963264,0.00010301297,0.00045350377,0.0001811875],"domain_scores_gemma":[0.99433506,0.0031089506,0.001844518,0.00014896602,0.00028022088,0.0002822984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042216335,0.000112003225,0.0015113243,0.00010931545,0.000008378993,0.0000018120194,0.000048500708,0.00019712534,0.00021830326],"category_scores_gemma":[0.0013947051,0.000070446054,0.00041063453,0.00011645658,0.000100700185,0.00009928641,0.00001653377,0.00039362948,4.9989467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006226588,0.0023423913,0.98545796,0.000044183962,0.00040331218,0.00040947355,0.000117791635,0.000034371456,0.000001744472,0.000020901747,0.0011889855,0.0037522807],"study_design_scores_gemma":[0.001177304,0.0021674207,0.99473053,0.0005195118,0.00030473262,0.00013716622,0.000024841796,0.0000073313804,0.00009909431,0.000042146632,0.00073429337,0.0000556108],"about_ca_topic_score_codex":0.55181473,"about_ca_topic_score_gemma":0.669469,"teacher_disagreement_score":0.11765425,"about_ca_system_score_codex":0.0013270888,"about_ca_system_score_gemma":0.0067225085,"threshold_uncertainty_score":0.99890846},"labels":[],"label_agreement":null},{"id":"W2587183463","doi":"10.1200/jco.2016.34.3_suppl.129","title":"Cardiovascular disease (CVD) risk factors and health behaviors following cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Waist; Internal medicine; Overweight; Odds ratio; Logistic regression; Cancer; Population; National Health and Nutrition Examination Survey; Obesity; Environmental health","score_opus":0.12849369161398924,"score_gpt":0.4547227779162002,"score_spread":0.3262290863022109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587183463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175346,0.003251222,0.0014417793,0.0014446893,0.0015533057,0.00048956845,0.000041490835,0.000012845443,0.000011622373],"genre_scores_gemma":[0.99761987,0.0010289081,0.00047489928,0.00043268767,0.00037643156,0.000014240092,0.0000024947842,0.000026206915,0.000024247565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960225,0.00064786494,0.0019152017,0.0003354869,0.00080436986,0.00027455878],"domain_scores_gemma":[0.995797,0.0012952202,0.0013721912,0.0003447563,0.00039237033,0.00079847826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037044878,0.00024280639,0.002105777,0.00015277673,0.000096362484,0.0000064023516,0.00014367906,0.00020999851,0.00007015702],"category_scores_gemma":[0.0017668944,0.00013578407,0.0013539382,0.00018231197,0.0002470801,0.000088644025,0.000033327833,0.00053441164,9.878662e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012402708,0.0026488816,0.924503,0.000047674996,0.0015474764,0.0002792227,0.00034499465,0.00013759584,0.00004755809,0.0000021912326,0.000048691807,0.069152415],"study_design_scores_gemma":[0.01943473,0.005970561,0.9685221,0.0003207222,0.0019943337,0.000014024187,0.0003963951,0.00010179477,0.000055077926,0.000007812825,0.0030314764,0.00015098907],"about_ca_topic_score_codex":0.0072494736,"about_ca_topic_score_gemma":0.0037319176,"teacher_disagreement_score":0.06900142,"about_ca_system_score_codex":0.00032360584,"about_ca_system_score_gemma":0.0032424957,"threshold_uncertainty_score":0.99936134},"labels":[],"label_agreement":null},{"id":"W2587198085","doi":"10.1200/jco.2012.30.34_suppl.305","title":"The power of knowledge: Sharing patient test results electronically to improve quality of care.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Test (biology); Patient portal; Health care; Patient experience; Medical emergency; Nursing","score_opus":0.3205428268251228,"score_gpt":0.6103963722081367,"score_spread":0.2898535453830139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587198085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761445,0.00093427114,0.00017760188,0.01586769,0.0020615438,0.00042258223,0.000021579835,0.000005310131,0.004364943],"genre_scores_gemma":[0.9934592,0.00023448806,0.0038620026,0.0014439555,0.0009035509,0.000003422869,0.0000032529492,0.000014693287,0.0000753818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9884395,0.00074248936,0.009724217,0.00018534804,0.0005510491,0.0003574185],"domain_scores_gemma":[0.9404693,0.04759576,0.007682541,0.0005548014,0.0031164596,0.00058110536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020419193,0.00012444201,0.0013723006,0.000073717165,0.00004283626,0.000005020634,0.0002871911,0.00026991582,0.000040081504],"category_scores_gemma":[0.23776773,0.00007595934,0.00056797854,0.00019433832,0.00019738995,0.00015161588,0.00020654233,0.0010939975,0.000015020675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040289897,0.008291007,0.24653465,0.00012784587,0.00063893135,0.000013655646,0.0024385715,0.000012048492,0.010413709,0.0009142009,0.013079347,0.67724615],"study_design_scores_gemma":[0.011475728,0.06123715,0.71339905,0.00012712387,0.00053533394,0.000049033046,0.002555217,0.000019929445,0.0024981697,0.00026556864,0.2076987,0.00013895993],"about_ca_topic_score_codex":0.000045663128,"about_ca_topic_score_gemma":0.00017159284,"teacher_disagreement_score":0.67710716,"about_ca_system_score_codex":0.00023537164,"about_ca_system_score_gemma":0.00198116,"threshold_uncertainty_score":0.76865286},"labels":[],"label_agreement":null},{"id":"W2587326061","doi":"10.1200/jco.2016.34.3_suppl.120","title":"Partner’s survivorship care needs: Multivariable analysis in head and neck cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Survivorship curve; Needs assessment; Head and neck cancer; Family medicine; Cancer; Cancer survivor; Gerontology; Internal medicine","score_opus":0.1287184633547006,"score_gpt":0.4763958668747995,"score_spread":0.3476774035200989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587326061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98557895,0.000314957,0.000030209845,0.00461117,0.0017807431,0.00010805754,0.000010252143,0.000006632558,0.007558997],"genre_scores_gemma":[0.99687034,0.0009885563,0.0003592978,0.0006862711,0.00055234693,0.000005324874,8.529187e-7,0.000008003176,0.0005289841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593204,0.0014359005,0.0016728659,0.00017961826,0.00042923496,0.0003503321],"domain_scores_gemma":[0.9931208,0.0046514524,0.0011615814,0.00012318805,0.0005818823,0.00036109364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004698624,0.00010476393,0.0010741095,0.00030115782,0.00009645046,0.000018536524,0.00029678957,0.0004341411,0.00034087084],"category_scores_gemma":[0.0070150285,0.000066630244,0.00027864767,0.00074553007,0.0004541984,0.00030130715,0.00006259491,0.00039720236,0.0000070615397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024069211,0.00029199125,0.9283207,0.0000043484156,0.00015752521,0.000022019787,0.0035005475,0.000014601075,0.0000019676118,0.00048004652,0.0006495611,0.066316],"study_design_scores_gemma":[0.0026677034,0.00065804156,0.85711825,0.000053670883,0.00019965426,3.667514e-7,0.0032376647,0.0000055629343,0.0000028190068,0.00045682202,0.13549155,0.00010791802],"about_ca_topic_score_codex":0.010010182,"about_ca_topic_score_gemma":0.085700646,"teacher_disagreement_score":0.134842,"about_ca_system_score_codex":0.00034423516,"about_ca_system_score_gemma":0.0014166483,"threshold_uncertainty_score":0.99658227},"labels":[],"label_agreement":null},{"id":"W2587328392","doi":"10.1200/jco.2016.34.3_suppl.50","title":"Moving forward after cancer: Implementation of transition appointments and follow-up care plans in Manitoba.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Cancer; Breast cancer; Colorectal cancer; Nursing; Internal medicine","score_opus":0.0595401702200909,"score_gpt":0.4393303119064111,"score_spread":0.3797901416863202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587328392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459165,0.00063763664,0.00019714385,0.0032461903,0.0010214399,0.00014050161,0.000037888196,0.0000022068946,0.00012531322],"genre_scores_gemma":[0.9974584,0.0013358635,0.00012932609,0.00066686264,0.00036809043,0.000014612475,0.0000020647897,0.000007334407,0.00001747228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983417,0.00013936062,0.0011076721,0.000103813414,0.00018877571,0.000118689895],"domain_scores_gemma":[0.998812,0.00030567902,0.0005065522,0.00006373375,0.00019435515,0.00011767739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065102,0.00006990478,0.0006096406,0.00009748862,0.00000916222,0.0000021725816,0.000039880026,0.0001453846,0.00014276117],"category_scores_gemma":[0.00008632133,0.00004485441,0.00017544546,0.000053822052,0.00005536307,0.00009731467,0.0000131463485,0.00018149418,8.5373864e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034648778,0.00007206315,0.5406323,0.000070615024,0.00008549135,0.00008735913,0.0017207363,4.4995448e-7,0.00028455866,0.0000063460416,0.0001618466,0.45341334],"study_design_scores_gemma":[0.016053926,0.0052859564,0.9604435,0.00045823393,0.00030342097,0.00005091297,0.00962827,0.0000023174182,0.00066206645,0.00015113324,0.0068891956,0.00007107114],"about_ca_topic_score_codex":0.00077524583,"about_ca_topic_score_gemma":0.042555463,"teacher_disagreement_score":0.45334226,"about_ca_system_score_codex":0.0002135699,"about_ca_system_score_gemma":0.00047118534,"threshold_uncertainty_score":0.9749154},"labels":[],"label_agreement":null},{"id":"W2587345106","doi":"10.1200/jco.2012.30.34_suppl.47","title":"Creation of On-PROST: The Ontario patient-reported outcomes of symptoms and toxicity applied clinical research unit.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Health care; Geriatric oncology; Cancer; Family medicine; Nursing","score_opus":0.34402031228455626,"score_gpt":0.5624965136413584,"score_spread":0.21847620135680218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587345106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98173106,0.00022344769,0.0000069170187,0.00372034,0.0007712537,0.00028597977,0.0000016624755,0.000002787059,0.013256564],"genre_scores_gemma":[0.9975758,0.00038784585,0.00037084532,0.0010034326,0.00044390824,0.0000043947243,7.936539e-7,0.000008065484,0.00020490434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504346,0.0007039747,0.0032353469,0.00013325008,0.00063659344,0.00024740075],"domain_scores_gemma":[0.98758185,0.009205729,0.0018824087,0.00025209849,0.0007883239,0.0002895785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01169279,0.00010227722,0.0017880508,0.00010807338,0.000062770785,0.0000025344823,0.000110406814,0.00031169472,0.000064223066],"category_scores_gemma":[0.008219617,0.000053139916,0.00030559604,0.00014466517,0.0008573446,0.000050592575,0.00009827275,0.0013973524,0.0000028007569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003974055,0.002319345,0.9023858,0.000020387177,0.0005726605,0.000014003313,0.0009768947,6.599198e-7,0.00013097133,0.00036264566,0.0010961863,0.08814643],"study_design_scores_gemma":[0.004450637,0.016556242,0.9578289,0.00008248401,0.00026588325,0.000034617187,0.00036844224,0.0000028156269,0.00039133916,0.00018211524,0.019793341,0.00004323004],"about_ca_topic_score_codex":0.00032323715,"about_ca_topic_score_gemma":0.0006708143,"teacher_disagreement_score":0.088103205,"about_ca_system_score_codex":0.00009983509,"about_ca_system_score_gemma":0.0011988798,"threshold_uncertainty_score":0.9840243},"labels":[],"label_agreement":null},{"id":"W2587373959","doi":"10.1200/jco.2012.30.34_suppl.103","title":"Quality oversight for specialized cancer services.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Transparency (behavior); Stakeholder engagement; Stakeholder; Equity (law); Referral; Service (business); Best practice; Business; Process management; Public relations; Nursing; Marketing; Computer science; Management","score_opus":0.6788373647160237,"score_gpt":0.7020614761068085,"score_spread":0.02322411139078473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587373959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9181078,0.0009768221,0.0025848188,0.062285677,0.010785973,0.0006372821,0.000024744922,0.00001593975,0.004580954],"genre_scores_gemma":[0.912456,0.0011227457,0.030417006,0.03376737,0.021644432,0.000011331497,0.000013834462,0.000025837184,0.0005414451],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99363804,0.0005674531,0.0049677063,0.00013004612,0.00041192133,0.00028480712],"domain_scores_gemma":[0.98096853,0.012903777,0.0043435073,0.00018021748,0.0010320719,0.0005718786],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014910074,0.00010852277,0.0013899077,0.0000672371,0.00003951931,0.000006871149,0.00013030457,0.00034044808,0.0011495672],"category_scores_gemma":[0.019671537,0.00007864405,0.00071044726,0.000100026344,0.000087512024,0.00039006342,0.00004512022,0.0006577705,0.000029412136],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019084666,0.0032296712,0.5065244,0.00015343042,0.00077496754,0.000024920868,0.00021668302,0.000004190239,0.00059478224,0.0009565887,0.063103534,0.4053322],"study_design_scores_gemma":[0.012099618,0.0020235593,0.32891747,0.000031391493,0.00057820353,0.000046594472,0.00024758946,0.000024199779,0.000053185537,0.0004075914,0.65550613,0.000064477026],"about_ca_topic_score_codex":0.00012916375,"about_ca_topic_score_gemma":0.00015961121,"teacher_disagreement_score":0.5924026,"about_ca_system_score_codex":0.00021928162,"about_ca_system_score_gemma":0.0014442934,"threshold_uncertainty_score":0.9997635},"labels":[],"label_agreement":null},{"id":"W2587409548","doi":"10.1200/jco.2016.34.26_suppl.219","title":"Palliative whole brain radiotherapy: Predictors of prescribing 5 versus 10 fractions.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Radiation therapy; Logistic regression; Lung cancer; Palliative care; Internal medicine; Radiosurgery; Confidence interval; Odds ratio; Performance status; Multivariate analysis; Nuclear medicine; Cancer","score_opus":0.1660650711885163,"score_gpt":0.48017442657701986,"score_spread":0.3141093553885036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587409548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91396326,0.0013061314,0.0028367366,0.07614151,0.0031583982,0.00027639265,0.000027609623,0.000013002006,0.002276941],"genre_scores_gemma":[0.98363185,0.000832827,0.010005682,0.0012067027,0.0019215692,0.0000039103147,0.0000022664333,0.000020833091,0.0023743461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99735206,0.0004707977,0.0015741541,0.00013795402,0.00030392912,0.00016107343],"domain_scores_gemma":[0.99037147,0.0072392365,0.0015924613,0.00018239598,0.00033999133,0.00027445133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002172478,0.00010677897,0.0010637804,0.00009347493,0.000025354457,0.000002872332,0.000095870586,0.00022498629,0.0008272056],"category_scores_gemma":[0.0060716085,0.000056155295,0.00052849605,0.000087058834,0.00021940586,0.000103430604,0.000020727835,0.00034163235,0.000017939501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03764482,0.005612483,0.1435031,0.000041936426,0.006271455,0.00065038796,0.00027873792,0.000019089735,0.0033673674,0.00041336665,0.14646427,0.655733],"study_design_scores_gemma":[0.032387465,0.03643678,0.18431228,0.00020791541,0.0006462208,0.000063505046,0.000119116565,0.00001842588,0.00041190494,0.00016901425,0.7451531,0.00007424074],"about_ca_topic_score_codex":0.00000860491,"about_ca_topic_score_gemma":0.000009416459,"teacher_disagreement_score":0.6556587,"about_ca_system_score_codex":0.00018821724,"about_ca_system_score_gemma":0.00084644783,"threshold_uncertainty_score":0.9057321},"labels":[],"label_agreement":null},{"id":"W2587537833","doi":"10.1200/jco.2014.32.30_suppl.192","title":"Examining health beliefs: Why mastectomies are on the rise.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Mastectomy; Breast cancer; Nonprobability sampling; Grounded theory; Family medicine; Population; Qualitative research; General surgery; Cancer; Internal medicine","score_opus":0.14713905978799835,"score_gpt":0.44100768253228045,"score_spread":0.2938686227442821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587537833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.931214,0.0015292781,0.0031235286,0.05608247,0.0024529577,0.00013685352,0.0000048877123,0.000005761713,0.005450313],"genre_scores_gemma":[0.97366405,0.0005950355,0.0020347976,0.02060013,0.002838531,0.00000526932,0.0000013065444,0.000016513162,0.00024436807],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972647,0.0010160359,0.0011550022,0.00018232742,0.00019383714,0.000188126],"domain_scores_gemma":[0.9966163,0.0010664111,0.0016639343,0.00029465894,0.00022077869,0.00013793113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004896128,0.000105505766,0.0005048148,0.00004258504,0.00009403534,0.000012892289,0.00033759206,0.0002486244,0.000043452255],"category_scores_gemma":[0.004734198,0.00006608731,0.00020198149,0.00006707186,0.00020861416,0.0000034188952,0.00007677876,0.00052584865,0.000016370906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015603967,0.0011300314,0.028200502,0.000033302607,0.00064013165,0.000024356174,0.00029372168,0.0012659396,0.0028890546,0.0015082886,0.48331994,0.47913432],"study_design_scores_gemma":[0.0017558477,0.009680668,0.03744492,0.000049680886,0.000025924735,0.000055817756,0.00034450673,0.000042396707,0.001148045,0.00071079505,0.9486447,0.000096678945],"about_ca_topic_score_codex":0.000004220626,"about_ca_topic_score_gemma":0.000056542634,"teacher_disagreement_score":0.47903764,"about_ca_system_score_codex":0.00007546652,"about_ca_system_score_gemma":0.00084035785,"threshold_uncertainty_score":0.5667619},"labels":[],"label_agreement":null},{"id":"W2587683233","doi":"10.1200/jco.2009.27.15_suppl.10570","title":"Dermatofibrosarcoma protuberans (DFSP) in six patients with ADA-SCID","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Dermatofibrosarcoma protuberans; PDGFB; Medicine; CD34; Pathology; Dermis; Biopsy; Dermatopathology; Lesion; Dermatofibrosarcoma; Internal medicine; Biology","score_opus":0.06289141141419652,"score_gpt":0.42237613264530666,"score_spread":0.35948472123111014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587683233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834877,0.00034513726,0.000015198003,0.013191257,0.00022486344,0.00041123695,0.000001818388,0.000007051022,0.0023157],"genre_scores_gemma":[0.99033564,0.00012756206,0.004264146,0.0049385475,0.00028238192,0.0000062442637,0.0000031520385,0.0000105270165,0.00003181722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997276,0.00022153402,0.0017088745,0.00016261118,0.00038853733,0.00024243387],"domain_scores_gemma":[0.99761546,0.00080263114,0.0007942349,0.00016774893,0.00029235182,0.0003275915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007837917,0.00013970559,0.0012327158,0.00013911378,0.000023378903,0.0000074003688,0.00010717017,0.00022440945,0.00007154354],"category_scores_gemma":[0.0006285012,0.00008167913,0.00027820686,0.00015554871,0.00008302115,0.00011283554,0.000013861792,0.00061341014,0.000018104776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031497376,0.009178529,0.8213198,0.0000070484984,0.000102750084,0.0014899869,0.00004407539,0.0000041314643,0.000007810762,0.000056664318,0.0011087124,0.16353077],"study_design_scores_gemma":[0.020736067,0.021244204,0.938378,0.00016861978,0.00016965026,0.0002706822,0.000021529384,0.000011043668,0.000069581365,0.00020250618,0.018650873,0.00007727513],"about_ca_topic_score_codex":0.000008544154,"about_ca_topic_score_gemma":0.00004145481,"teacher_disagreement_score":0.16345349,"about_ca_system_score_codex":0.00014587399,"about_ca_system_score_gemma":0.0006514744,"threshold_uncertainty_score":0.33307782},"labels":[],"label_agreement":null},{"id":"W2587744318","doi":"10.1200/jco.2012.30.34_suppl.315","title":"Combining web-based educational tools and mobile apps.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Formulary; Medicine; World Wide Web; Point of care; Usability; The Internet; Internet privacy; Mobile device; Mobile apps; User interface; Family medicine; Nursing; Computer science","score_opus":0.2722225180509899,"score_gpt":0.6087811320144154,"score_spread":0.3365586139634255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587744318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92365307,0.003708952,0.00045875393,0.036183923,0.0076325275,0.0018580855,0.00002756958,0.000029141938,0.026447995],"genre_scores_gemma":[0.9672952,0.0012860592,0.0067766854,0.019027691,0.0042957566,0.0008415329,0.00001105913,0.000017885204,0.00044812384],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944402,0.0013831226,0.0032342216,0.00013950825,0.00023905345,0.0005638915],"domain_scores_gemma":[0.97845435,0.01699718,0.002577299,0.00019134123,0.00045633153,0.0013234953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009818795,0.00010981571,0.00086558505,0.00011590412,0.0003802265,0.000004198468,0.00017148638,0.0005156459,0.0008760569],"category_scores_gemma":[0.0047053616,0.000085664265,0.00014712835,0.00013850501,0.00016158576,0.00020314517,0.00005198052,0.0018108411,0.00019402339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000537926,0.0015728271,0.610529,0.00018478018,0.000033337998,0.0000019761628,0.00030415726,0.000007742088,0.00002024918,0.012006604,0.07915472,0.29564667],"study_design_scores_gemma":[0.0036883873,0.0009214991,0.25670666,0.000065274886,0.000036278598,0.000011995083,0.00023464856,0.000052071842,9.331754e-7,0.000534208,0.73769265,0.00005538921],"about_ca_topic_score_codex":0.000013913177,"about_ca_topic_score_gemma":0.000016952323,"teacher_disagreement_score":0.6585379,"about_ca_system_score_codex":0.0001672795,"about_ca_system_score_gemma":0.008565872,"threshold_uncertainty_score":0.99705464},"labels":[],"label_agreement":null},{"id":"W2587781858","doi":"10.1200/jco.2012.30.15_suppl.4536","title":"An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Renal cell carcinoma; Clinical trial; Gastroenterology; Population; Surgery; Confidence interval","score_opus":0.34731477682087525,"score_gpt":0.55479961950805,"score_spread":0.20748484268717476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587781858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973146,0.00015199526,0.0004823279,0.00031347934,0.00058467034,0.0009802761,0.00012381,0.0000041115773,0.00004473312],"genre_scores_gemma":[0.97746915,0.000018931532,0.021822356,0.00035940795,0.00018533411,0.000012883317,0.000101324775,0.00002499227,0.0000056103527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98639095,0.004306762,0.007834879,0.00035177806,0.00075902266,0.0003566234],"domain_scores_gemma":[0.9737069,0.016703837,0.0073602614,0.00058285514,0.0010067939,0.00063933857],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020639382,0.000280504,0.006327579,0.0005921783,0.000023326087,0.000007651341,0.00023099077,0.00034297313,0.00010646515],"category_scores_gemma":[0.010284099,0.00016657854,0.002218422,0.0003520417,0.00020932472,0.00020297046,0.0000310672,0.00045751708,6.521181e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033182684,0.014916478,0.94433147,0.00012039536,0.0022967802,0.00002474866,0.00011412288,0.00010775048,0.000094245835,0.000006051683,0.000053719104,0.0047515365],"study_design_scores_gemma":[0.03272459,0.017782582,0.9342008,0.000045516506,0.013462971,0.000001990489,0.000089245164,0.000828875,0.00067109836,0.000019129446,0.000049777893,0.00012342208],"about_ca_topic_score_codex":0.00015259864,"about_ca_topic_score_gemma":0.00026773682,"teacher_disagreement_score":0.02134003,"about_ca_system_score_codex":0.00024165798,"about_ca_system_score_gemma":0.00075863174,"threshold_uncertainty_score":0.9980527},"labels":[],"label_agreement":null},{"id":"W2587806722","doi":"10.1200/jco.2015.33.29_suppl.40","title":"Exploring the preferences for place of death among cancer patients and their family caregivers.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Place of death; Palliative care; Psychosocial; Cancer; Delirium; Distress; Terminally ill; Family medicine; Gerontology; Psychiatry; Internal medicine; Nursing; Clinical psychology","score_opus":0.7084401344986521,"score_gpt":0.551332582925933,"score_spread":0.15710755157271905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587806722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954413,0.0018890069,0.000055248856,0.000757008,0.00079578714,0.00013585734,0.000011818934,0.0000017479299,0.0009122321],"genre_scores_gemma":[0.99450487,0.004281251,0.00060625275,0.00020077234,0.0003617153,0.0000067325664,9.939994e-7,0.000005078,0.00003235428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986881,0.00014501305,0.0008274736,0.00007732117,0.00016510847,0.00009695814],"domain_scores_gemma":[0.99526155,0.0027411242,0.0009517762,0.00006696047,0.0008272774,0.00015130505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011222046,0.00007090745,0.00076800195,0.00003993769,0.00001412069,0.0000019450715,0.00010251694,0.00008995107,0.0000027305828],"category_scores_gemma":[0.0031848068,0.00003500079,0.00015960292,0.000045007975,0.00019510757,0.00009943766,0.00003210731,0.00024025611,1.6075575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002068714,0.00022344835,0.9219802,0.00004157164,0.00026989152,0.0000042172205,0.005509778,0.00001369763,0.000017960818,0.000020824991,0.0018889111,0.06796079],"study_design_scores_gemma":[0.007791593,0.01267201,0.90097696,0.00061966927,0.0003245091,0.0000029049406,0.013919588,0.00005470743,0.0006199475,0.0003570399,0.06259298,0.00006808548],"about_ca_topic_score_codex":0.0001739344,"about_ca_topic_score_gemma":0.000098541204,"teacher_disagreement_score":0.06789271,"about_ca_system_score_codex":0.00004975787,"about_ca_system_score_gemma":0.00057080726,"threshold_uncertainty_score":0.38127413},"labels":[],"label_agreement":null},{"id":"W2587903738","doi":"10.1200/jco.2011.29.4_suppl.68","title":"Sites of gastric cancer recurrence after adjuvant chemoradiotherapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Chemoradiotherapy; Cancer; Radiation therapy; Cancer recurrence; Adjuvant radiotherapy; Lymph node; Surgery; Internal medicine","score_opus":0.1845634543694164,"score_gpt":0.46292993597891946,"score_spread":0.27836648160950306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587903738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856997,0.0042174105,0.00020545482,0.002210926,0.0014638418,0.00013939598,0.0000027285803,0.0000059660447,0.0060545797],"genre_scores_gemma":[0.9841916,0.0052287555,0.007143791,0.0019214427,0.00088692666,0.0000044564435,4.1544072e-7,0.000008869734,0.00061373005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774855,0.00009847852,0.0015765837,0.00012074416,0.00028584298,0.00016977741],"domain_scores_gemma":[0.99755704,0.0003413508,0.0014123152,0.00015182857,0.00034189166,0.00019559577],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013015668,0.00010037472,0.0013104987,0.00014900125,0.000008988388,0.0000020782372,0.00015216961,0.00015970957,0.0019378292],"category_scores_gemma":[0.0006414951,0.000067109984,0.00042080533,0.00019962514,0.00016248348,0.000078716446,0.000034409422,0.0004916,0.0000074629725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003585886,0.00060764357,0.7279193,0.00004633455,0.00025685047,0.00023026203,0.00015217597,6.2697274e-7,0.000065784676,0.00002275207,0.006734716,0.26037768],"study_design_scores_gemma":[0.0044901352,0.006449998,0.9543185,0.00010814678,0.00043219607,0.00010764869,0.000058223963,0.000014657148,0.0001506196,0.00013414658,0.03367435,0.0000613428],"about_ca_topic_score_codex":0.000049726445,"about_ca_topic_score_gemma":0.000036564565,"teacher_disagreement_score":0.2603163,"about_ca_system_score_codex":0.00007538875,"about_ca_system_score_gemma":0.0006211167,"threshold_uncertainty_score":0.99897456},"labels":[],"label_agreement":null},{"id":"W2587925277","doi":"10.1200/jco.2011.29.4_suppl.45","title":"Establishment of primary human esophageal xenografts: Rationale for selection and cancer model.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Esophageal cancer; Esophagus; Cancer; Transplantation; Pathology; Adenosquamous carcinoma; Primary tumor; Oncology; Internal medicine; Cancer research; Adenocarcinoma; Metastasis","score_opus":0.16586525264511262,"score_gpt":0.4684338520153443,"score_spread":0.30256859937023173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587925277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956919,0.001278339,0.0017654891,0.00016966557,0.00016830977,0.0001845331,0.000020275398,0.0000010545599,0.00072046224],"genre_scores_gemma":[0.9912056,0.001367054,0.0064825355,0.00021732869,0.00046035132,0.000022598502,0.000012805778,0.00000723512,0.00022450117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989846,0.000071948714,0.00061359216,0.00011221571,0.000108421795,0.00010924663],"domain_scores_gemma":[0.9989764,0.00006333553,0.00048299017,0.000056590936,0.00030707926,0.00011358615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067546795,0.000058000773,0.0003140356,0.0000378148,0.000034130313,0.0000034527754,0.00007563724,0.00013778369,0.000023748573],"category_scores_gemma":[0.00016959626,0.00004553921,0.00014026914,0.000028531906,0.00008492804,0.000008710344,0.00003454749,0.0001127209,1.2004621e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026495608,0.008012867,0.23757274,0.00027406565,0.0033240526,0.000046656813,0.000518088,0.0007741661,0.23277727,0.0014334006,0.03991224,0.44885886],"study_design_scores_gemma":[0.056790557,0.13129456,0.35006323,0.00015782012,0.0011511949,0.0002282357,0.00020241429,0.001936871,0.27127716,0.012601049,0.17357807,0.00071881874],"about_ca_topic_score_codex":0.000065837135,"about_ca_topic_score_gemma":0.00028246606,"teacher_disagreement_score":0.44814003,"about_ca_system_score_codex":0.000040581766,"about_ca_system_score_gemma":0.00076782325,"threshold_uncertainty_score":0.18570352},"labels":[],"label_agreement":null},{"id":"W2587946539","doi":"10.1200/jco.2004.22.90140.878","title":"Local accrual pattern of a breast cancer adjuvant chemotherapy clinical trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Cancer; Internal medicine; Chemotherapy; Oncology; Surgery","score_opus":0.6418777691918434,"score_gpt":0.701061109990532,"score_spread":0.05918334079868859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587946539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.913165,0.00044201623,0.003946641,0.076282874,0.004512904,0.0005410429,0.00002371965,0.000014753468,0.0010710591],"genre_scores_gemma":[0.970339,0.0088151675,0.0024172321,0.011132086,0.006979312,0.000008174501,0.000001702134,0.00004614178,0.0002612003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98644114,0.0012087439,0.00939758,0.00047691335,0.0019455329,0.00053006597],"domain_scores_gemma":[0.95813775,0.033042006,0.0043692593,0.0006319698,0.0025381378,0.001280901],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.033985358,0.0002455662,0.0038720074,0.00017925687,0.000043332406,0.000011285236,0.00072231446,0.0023373973,0.0010084799],"category_scores_gemma":[0.03370409,0.00016662822,0.0020616946,0.00028333577,0.0022738276,0.00012334582,0.0001999858,0.008737703,0.00004812243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2173987,0.01218015,0.065613866,0.000117396216,0.0010860575,0.0008233495,0.00011769245,0.000040878724,0.00006430577,0.00037446243,0.0019490581,0.7002341],"study_design_scores_gemma":[0.39446786,0.07853093,0.49728116,0.0011138564,0.00064829737,0.00076119223,0.00028284165,0.00007643569,0.00018675097,0.010546073,0.015842374,0.00026222397],"about_ca_topic_score_codex":0.00022212634,"about_ca_topic_score_gemma":0.00043145136,"teacher_disagreement_score":0.69997185,"about_ca_system_score_codex":0.00035586004,"about_ca_system_score_gemma":0.0144477375,"threshold_uncertainty_score":0.99990475},"labels":[],"label_agreement":null},{"id":"W2588013730","doi":"10.1200/jco.2015.33.28_suppl.55","title":"The association of clinical-pathologic factors and Oncotype Dx recurrence score (RS) in the outcome of early stage breast cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Internal medicine; Mastectomy; Context (archaeology); Cancer; Oncology; Incidence (geometry); Retrospective cohort study; BRCA mutation; Disease","score_opus":0.2226265295013898,"score_gpt":0.4972993864930111,"score_spread":0.27467285699162125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588013730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944696,0.0011549309,0.000008395685,0.0030262186,0.0009509239,0.000112366375,0.00003855341,0.0000010647549,0.00023794886],"genre_scores_gemma":[0.99563813,0.0035836098,0.00012579652,0.0002591985,0.0003359184,0.0000039203046,0.0000020035798,0.000005874409,0.00004557045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962302,0.0011070202,0.0020402616,0.00016764847,0.0002867163,0.00016814657],"domain_scores_gemma":[0.993986,0.002042475,0.0031337636,0.00019866531,0.0005466402,0.000092418755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071181813,0.00011884555,0.0008681324,0.00002717939,0.00003743941,0.000007992923,0.00032838067,0.00034504448,0.000003002681],"category_scores_gemma":[0.0059051327,0.00005809359,0.00026165365,0.00010007038,0.00037702784,0.000011363413,0.00011054372,0.00048638388,4.5561208e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011957199,0.00034857987,0.9809928,0.00000674906,0.00016909615,0.000009458384,0.0002018432,0.000007295558,0.000046402933,0.000024487646,0.00041492475,0.016582668],"study_design_scores_gemma":[0.0022833215,0.0031952555,0.98977226,0.000022601462,0.000101410464,0.000015050093,0.000628098,0.0000018729401,0.00004795859,0.00008227826,0.0037948622,0.000055045955],"about_ca_topic_score_codex":0.00027265184,"about_ca_topic_score_gemma":0.0014537432,"teacher_disagreement_score":0.016527623,"about_ca_system_score_codex":0.0000640994,"about_ca_system_score_gemma":0.0006616729,"threshold_uncertainty_score":0.7069422},"labels":[],"label_agreement":null},{"id":"W2588249879","doi":"10.1200/jco.2013.31.15_suppl.10066","title":"Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; SickKids Foundation; University of Toronto; Children's Hospital of Eastern Ontario; McGill University; University of British Columbia; Hospital for Sick Children; Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Genetic testing; Pediatric cancer; Cancer; Genetic counseling; Childhood cancer; Family medicine; Internal medicine; Genetics","score_opus":0.07057089367614136,"score_gpt":0.458841115571388,"score_spread":0.3882702218952466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588249879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959659,0.0013167507,0.000027903256,0.0017322244,0.00062826584,0.00029014514,0.000019271882,0.0000016334003,0.000017927658],"genre_scores_gemma":[0.99371034,0.0018788367,0.0029544437,0.00029556404,0.0010845589,0.000034484987,0.000009393421,0.000015075248,0.000017322522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972315,0.0009654563,0.0011147895,0.00023098194,0.00023562675,0.00022168654],"domain_scores_gemma":[0.9978237,0.00063474476,0.0006197656,0.00019266842,0.0005742414,0.00015485995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029667357,0.00009642246,0.00037136546,0.00017202509,0.00006865947,0.000018410381,0.00030364993,0.00030431728,0.00006851489],"category_scores_gemma":[0.0024696381,0.00007278809,0.00008267772,0.00025344535,0.00021613199,0.000014051409,0.00015843454,0.0005982399,0.000004430199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021607287,0.00035650565,0.9078772,0.000023864852,0.00022489755,0.00001769468,0.00047556352,0.0010822746,0.05518328,0.000007041906,0.007414339,0.025176596],"study_design_scores_gemma":[0.0029521952,0.0048823217,0.9885777,0.000010972273,0.000059986643,0.000016054826,0.0002904565,0.00012419876,0.0013222906,0.0001366639,0.0015433535,0.00008378065],"about_ca_topic_score_codex":0.0005964323,"about_ca_topic_score_gemma":0.0017777857,"teacher_disagreement_score":0.08070051,"about_ca_system_score_codex":0.00017110765,"about_ca_system_score_gemma":0.001120059,"threshold_uncertainty_score":0.2968212},"labels":[],"label_agreement":null},{"id":"W2588309151","doi":"10.1200/jco.2004.22.90140.3137","title":"A phase II clinical trial involving the use of low-dose daily oral cyclophosphamide, weekly vinblastine and rofecoxib in patients with advanced solid tumors","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Cyclophosphamide; Neutropenia; Regimen; Nausea; Internal medicine; Vinblastine; Gastroenterology; Surgery; Chemotherapy; Vomiting; Phases of clinical research","score_opus":0.08175405395946261,"score_gpt":0.4277055078039231,"score_spread":0.34595145384446047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588309151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970995,0.00043039527,0.00019239113,0.00059726776,0.0012236574,0.00042108257,0.000012170009,0.0000035096828,0.000019987172],"genre_scores_gemma":[0.9934812,0.00048395162,0.004149565,0.0010953931,0.0007155686,0.000008119708,0.000008701605,0.000028457303,0.000029030007],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950746,0.000599691,0.0033020638,0.0003684106,0.00033294465,0.00032226715],"domain_scores_gemma":[0.9953532,0.0008485555,0.0027181706,0.0003290012,0.0004915638,0.00025947133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029710608,0.00022608327,0.0013164962,0.000073538205,0.00006763951,0.000014894188,0.00035743346,0.00045351498,0.000012288989],"category_scores_gemma":[0.0069499267,0.00014543245,0.00032080407,0.00016020701,0.00063681474,0.000035061854,0.00021793367,0.00091611396,8.18791e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5929439,0.026913054,0.20915708,0.000062399246,0.0007753992,0.00028747425,0.00020167202,0.0063285134,0.008231346,0.000047235113,0.0017144214,0.1533375],"study_design_scores_gemma":[0.5140416,0.26792184,0.19837429,0.0004672711,0.0002599317,0.000046459245,0.00007391624,0.000120507844,0.0024260045,0.00023985498,0.015568514,0.00045982498],"about_ca_topic_score_codex":0.000019108533,"about_ca_topic_score_gemma":0.00014024414,"teacher_disagreement_score":0.24100877,"about_ca_system_score_codex":0.00006554704,"about_ca_system_score_gemma":0.0015583384,"threshold_uncertainty_score":0.83202136},"labels":[],"label_agreement":null},{"id":"W2588546205","doi":"10.1200/jco.2009.27.15_suppl.594","title":"Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Bone resorption; Breast cancer; Bone remodeling; Oncology; Gastroenterology; Cancer; Endocrinology","score_opus":0.04575873752947568,"score_gpt":0.4596898129724428,"score_spread":0.41393107544296714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588546205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839398,0.00032327458,0.000003094321,0.011853229,0.00039230552,0.00037020887,0.0000017660032,0.000006130396,0.0031101874],"genre_scores_gemma":[0.9917435,0.00093530095,0.00068939227,0.005970883,0.00028378726,0.0000044717335,0.000002948816,0.000013218735,0.0003564677],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99611455,0.0007625153,0.0022742066,0.0001738455,0.00034942437,0.00032548452],"domain_scores_gemma":[0.99610436,0.0018263012,0.001323169,0.00018850571,0.00013012305,0.00042756554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005454744,0.00015628462,0.0019141344,0.00022458345,0.000016820699,0.0000023517803,0.000079381476,0.00037243098,0.000128058],"category_scores_gemma":[0.0012437653,0.0001001405,0.00022796374,0.00016321483,0.00007970849,0.000061037834,0.000010048479,0.0008552998,0.000024780682],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07211789,0.003905783,0.13678281,0.000047063928,0.00014946122,0.0010659214,0.000085985055,0.0000018071835,0.0006330856,0.000019746989,0.001293942,0.7838965],"study_design_scores_gemma":[0.024893597,0.15843996,0.80674964,0.00020639725,0.00009164455,0.00022295323,0.000010557231,0.000008764028,0.0005773644,0.00022963606,0.008511355,0.000058110778],"about_ca_topic_score_codex":0.000021184178,"about_ca_topic_score_gemma":0.0000119791675,"teacher_disagreement_score":0.7838384,"about_ca_system_score_codex":0.00035960402,"about_ca_system_score_gemma":0.00064895395,"threshold_uncertainty_score":0.40836114},"labels":[],"label_agreement":null},{"id":"W2588549428","doi":"10.1200/jco.2013.31.15_suppl.4061","title":"Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Gemcitabine; Erlotinib; Placebo; Cancer; Oncology; Gastroenterology; Confidence interval; Pathology; Epidermal growth factor receptor","score_opus":0.0701668271814474,"score_gpt":0.4796537983267765,"score_spread":0.4094869711453291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588549428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917126,0.000027565598,0.000014697066,0.0040616416,0.00009525737,0.0031345,0.000010307134,0.0000039658694,0.000939409],"genre_scores_gemma":[0.99742573,0.00011978439,0.00093780976,0.0005537547,0.00008568588,0.00019407354,0.000002745419,0.000023740005,0.0006566918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99451774,0.0013805164,0.002215354,0.00024404413,0.0012593465,0.00038300842],"domain_scores_gemma":[0.988528,0.0059087113,0.003870318,0.00046609508,0.0010800393,0.00014679958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033003364,0.00025699654,0.0026706718,0.00011799687,0.000067766145,0.000011608197,0.00041236932,0.00026343408,0.00010466088],"category_scores_gemma":[0.0027223907,0.00007907614,0.00016743703,0.0007034559,0.00059162406,0.00015288714,0.00004175005,0.0013211315,7.235026e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079960614,0.0075826766,0.908957,0.000050629984,0.0006571337,0.00003972455,0.00029944087,0.000039879134,0.000033622047,0.000008321618,0.000081146376,0.002289773],"study_design_scores_gemma":[0.18168299,0.059424784,0.7563846,0.00056734425,0.0009914407,0.00002924182,0.00059879705,0.00013967174,0.000020578056,0.000008002948,0.00006999306,0.00008256762],"about_ca_topic_score_codex":0.0006930045,"about_ca_topic_score_gemma":0.005241863,"teacher_disagreement_score":0.15257244,"about_ca_system_score_codex":0.0005764292,"about_ca_system_score_gemma":0.004652663,"threshold_uncertainty_score":0.82536244},"labels":[],"label_agreement":null},{"id":"W2588758512","doi":"10.1200/jco.2011.29.4_suppl.91","title":"Incidence and distribution of HER2-positive gastric and gastroesophageal junction (GEJ) adenocarinomas in British Columbia (BC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Immunohistochemistry; Adenocarcinoma; Internal medicine; Cancer; Incidence (geometry); Gastroenterology; Gastroesophageal Junction; Pathology; Breast cancer","score_opus":0.05290725849595658,"score_gpt":0.35733767355830376,"score_spread":0.3044304150623472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588758512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978063,0.00042265072,0.00039126587,0.00028616562,0.00035448748,0.00015709632,0.0000037972418,0.0000036054212,0.0005746246],"genre_scores_gemma":[0.9971176,0.0009856474,0.0012900644,0.00019873661,0.00020350321,0.0000016886776,0.0000037676712,0.0000054330894,0.00019358988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808735,0.00016512092,0.0012475408,0.00014990987,0.0001931396,0.0001569201],"domain_scores_gemma":[0.99836785,0.00034668104,0.0008635968,0.00006895716,0.00017660306,0.00017632535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013684948,0.000066272645,0.0008002176,0.00008595165,0.0000234515,0.000014206408,0.00005875221,0.00015596816,0.00007340048],"category_scores_gemma":[0.0008707689,0.000077655255,0.000115219256,0.0001980883,0.0002458871,0.00014346672,0.00006835893,0.0004595707,6.64374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000638204,0.00032412214,0.87065315,0.000029959014,0.000062613806,0.00059973,0.00004784029,3.946642e-7,0.000005445485,0.000013762854,0.00089921337,0.12672554],"study_design_scores_gemma":[0.0044619455,0.007826783,0.9856984,0.00013193321,0.00021991546,0.00082721194,0.00016983655,0.00002148851,0.0000053662193,0.00018860969,0.0004065039,0.00004203318],"about_ca_topic_score_codex":0.0041971253,"about_ca_topic_score_gemma":0.006694699,"teacher_disagreement_score":0.1266835,"about_ca_system_score_codex":0.00010202605,"about_ca_system_score_gemma":0.00023031385,"threshold_uncertainty_score":0.63448256},"labels":[],"label_agreement":null},{"id":"W2588927753","doi":"10.1200/jco.2009.27.15_suppl.11100","title":"Mechanisms of Plk4 haploinsufficiency in hepatocellular carcinogenesis","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Carcinogenesis; Biology; Loss of heterozygosity; Cell culture; Cancer research; Molecular biology; Genetics; Gene; Allele","score_opus":0.10079826091989798,"score_gpt":0.41910861210143996,"score_spread":0.318310351181542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588927753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986116,0.0012475973,0.005067445,0.0033195103,0.00090777996,0.00020334646,0.0000016759295,0.000007865711,0.003128816],"genre_scores_gemma":[0.99309736,0.00047776106,0.0046227993,0.0015125313,0.00023255718,9.3894516e-7,8.8811794e-7,0.0000133954945,0.000041740444],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960147,0.00029205094,0.0027998085,0.00018446233,0.00046534554,0.00024360722],"domain_scores_gemma":[0.9971411,0.00043406882,0.001505274,0.00024351911,0.0003819432,0.00029406828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029726466,0.00012832179,0.0015756116,0.00029359217,0.000014340007,0.0000022801883,0.00019203861,0.0004936445,0.000088307024],"category_scores_gemma":[0.002428119,0.000102358215,0.0005939995,0.00033587497,0.00011030539,0.000049298105,0.000027435806,0.0008945923,0.000009611141],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01157497,0.017309507,0.06154732,0.00012097418,0.0005197113,0.013256752,0.0006235352,0.0007415185,0.5094161,0.008706984,0.0017592127,0.3744234],"study_design_scores_gemma":[0.039607268,0.12698914,0.6869699,0.0009301262,0.0014472193,0.0027900524,0.00040856804,0.0038036595,0.095012896,0.021203911,0.020299371,0.000537925],"about_ca_topic_score_codex":0.000024339473,"about_ca_topic_score_gemma":0.000016351647,"teacher_disagreement_score":0.62542254,"about_ca_system_score_codex":0.00019079643,"about_ca_system_score_gemma":0.0019905071,"threshold_uncertainty_score":0.41740468},"labels":[],"label_agreement":null},{"id":"W2588936898","doi":"10.1200/jco.2005.23.16_suppl.7018","title":"Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCIC CTG BR.21 trial","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Clinical endpoint; Quality of life (healthcare); Internal medicine; Placebo; Lung cancer; Palliative care; Discontinuation; Randomized controlled trial; Cancer; Pathology; Epidermal growth factor receptor","score_opus":0.06928640520948959,"score_gpt":0.48546743199420195,"score_spread":0.41618102678471236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588936898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958153,0.000250148,0.000025802605,0.0023319896,0.0003080755,0.0005964656,0.000038418973,0.000003077371,0.0006307739],"genre_scores_gemma":[0.9979992,0.00015712497,0.00048251223,0.0007312063,0.00026116075,0.000014776298,0.000005395071,0.0000134543825,0.0003351949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948866,0.0011874068,0.0031020981,0.00019062836,0.00044327634,0.00019000101],"domain_scores_gemma":[0.99256873,0.0027991855,0.0034127196,0.000290118,0.0006987471,0.00023049329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028132095,0.0001456053,0.0019587125,0.0002967824,0.000029346902,0.0000035888547,0.00017867617,0.00025221522,0.00012941023],"category_scores_gemma":[0.0021128252,0.00007875239,0.0007189239,0.0007605391,0.00017192162,0.000064266,0.00003087473,0.0004820164,9.1477096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19506054,0.005036831,0.79019326,0.00002918657,0.0027578874,0.000010581693,0.0005592102,0.0009802028,0.00008255773,0.0000028115926,0.0002479892,0.005038943],"study_design_scores_gemma":[0.10000849,0.008718612,0.8838888,0.00012968731,0.0060471045,0.0000012183467,0.000119933735,0.0002737255,0.00010042145,0.0000017449076,0.0006442952,0.00006599592],"about_ca_topic_score_codex":0.0006355946,"about_ca_topic_score_gemma":0.0015441782,"teacher_disagreement_score":0.09505205,"about_ca_system_score_codex":0.00043098387,"about_ca_system_score_gemma":0.0038169562,"threshold_uncertainty_score":0.6771116},"labels":[],"label_agreement":null},{"id":"W2588998411","doi":"10.1200/jco.2009.27.15_suppl.5577","title":"Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Endometrial cancer; Internal medicine; Clinical endpoint; Ovarian cancer; Cancer; Adverse effect; Oncology; Phases of clinical research; PTEN; Gastroenterology; Toxicity; Urology; Clinical trial; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.13055940009060127,"score_gpt":0.5050653213768045,"score_spread":0.3745059212862032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588998411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339753,0.0003565792,0.00001088262,0.003850087,0.0010970723,0.0011156985,0.00005915922,0.0000047001713,0.0001082688],"genre_scores_gemma":[0.9951505,0.00086211634,0.0022939853,0.0008595905,0.00062991737,0.00004618811,0.000002386844,0.00001843578,0.00013688182],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953518,0.0004536956,0.002934698,0.00029666745,0.0006682714,0.00029488237],"domain_scores_gemma":[0.99486893,0.0015820287,0.0023997093,0.0002454734,0.00056993036,0.0003339195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015146523,0.0002188894,0.0025234108,0.00032576662,0.000045781082,0.0000062324193,0.0001597404,0.00013715241,0.000671074],"category_scores_gemma":[0.0020883307,0.000110769106,0.0002362972,0.0005923488,0.00009202799,0.00012950628,0.000028811117,0.00058120233,9.872338e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3435781,0.0854365,0.08915438,0.000023952025,0.0013887949,0.0015146696,0.0003948821,0.00009230042,0.000036829784,0.000012535773,0.00034616265,0.4780209],"study_design_scores_gemma":[0.24585962,0.3368673,0.4102484,0.0002998568,0.0013887442,0.000009842411,0.00018466666,0.0000061577207,0.00006276568,0.0000235667,0.0049538915,0.0000952081],"about_ca_topic_score_codex":0.0003270192,"about_ca_topic_score_gemma":0.002766828,"teacher_disagreement_score":0.4779257,"about_ca_system_score_codex":0.0005094079,"about_ca_system_score_gemma":0.0034724684,"threshold_uncertainty_score":0.734779},"labels":[],"label_agreement":null},{"id":"W2589132724","doi":"10.1200/jco.2014.32.3_suppl.393","title":"Incidence of diabetes among patients with colorectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Women's College Hospital; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Colorectal cancer; Incidence (geometry); Hazard ratio; Internal medicine; Cancer registry; Proportional hazards model; Population; Cancer; Diabetes mellitus; Oncology; Cohort; Confidence interval; Endocrinology; Environmental health","score_opus":0.039527369821087475,"score_gpt":0.4136380056470342,"score_spread":0.3741106358259467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589132724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969949,0.00018596942,0.000009869039,0.0012853962,0.000532289,0.00013236068,0.0000032307244,0.0000028044894,0.0008531551],"genre_scores_gemma":[0.9980954,0.00022225677,0.0006334989,0.000593489,0.00041887022,0.000007829405,0.0000011591014,0.000008370198,0.000019122908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981755,0.0001407691,0.0011418085,0.000106946674,0.00030067092,0.00013430139],"domain_scores_gemma":[0.9960598,0.0015592858,0.0015272939,0.000091825874,0.0005361455,0.00022566676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087601895,0.000082963954,0.0010930245,0.000052213698,0.000015925034,0.0000025225547,0.00007930518,0.000135719,0.00010838848],"category_scores_gemma":[0.0012627183,0.000048065536,0.00021498042,0.000082284554,0.00024699816,0.00006403354,0.000023938728,0.00030847802,0.0000022459665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009846537,0.0015462844,0.9129219,0.000018824669,0.00028727937,0.000013863253,0.000027436414,0.000014647606,0.000014440336,0.000017866414,0.00095932744,0.08319347],"study_design_scores_gemma":[0.0072238166,0.027696138,0.9606248,0.00025235245,0.00041755015,0.0000029430382,0.00000834019,0.00003543184,0.00038982084,0.000045415673,0.003258565,0.000044822413],"about_ca_topic_score_codex":0.00006954193,"about_ca_topic_score_gemma":0.000290105,"teacher_disagreement_score":0.08314865,"about_ca_system_score_codex":0.00012228067,"about_ca_system_score_gemma":0.0006117996,"threshold_uncertainty_score":0.19600557},"labels":[],"label_agreement":null},{"id":"W2589145609","doi":"10.1200/jco.2012.30.34_suppl.306","title":"SAGE directory of cancer guidelines.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Guideline; Medicine; SAGE; Audit; Process management; Business; Pathology; Accounting","score_opus":0.6920104574565268,"score_gpt":0.7024700808348142,"score_spread":0.01045962337828743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589145609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95434105,0.0063360576,0.0010160289,0.0296297,0.0058559706,0.00020517659,0.0000074279656,0.000010742687,0.0025978547],"genre_scores_gemma":[0.9553308,0.004765566,0.021053009,0.011266228,0.0071876138,0.000002932114,0.0000024937763,0.000020645213,0.0003707002],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99140626,0.0004988831,0.007213796,0.000111514724,0.0005240963,0.00024547745],"domain_scores_gemma":[0.9851898,0.007464344,0.0050823865,0.00021015681,0.0015413228,0.00051197404],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013532584,0.00011239399,0.0014820748,0.000114941024,0.000017834636,0.0000022860813,0.00013389096,0.00029782785,0.0013820586],"category_scores_gemma":[0.06343082,0.000079090474,0.0006011708,0.00016016382,0.00017224817,0.00027174686,0.000059219314,0.00087110454,0.000021958738],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016542324,0.0012114596,0.43418455,0.000026230464,0.00031047588,0.000030453919,0.00004010077,0.0000067960787,0.0010120241,0.000047503567,0.03494874,0.5265274],"study_design_scores_gemma":[0.0048271823,0.002288137,0.51470923,0.000106326515,0.0008518421,0.00010929827,0.00013910072,0.000040030747,0.00032392077,0.0000897437,0.4764487,0.0000664887],"about_ca_topic_score_codex":0.00017686147,"about_ca_topic_score_gemma":0.00006861947,"teacher_disagreement_score":0.52646095,"about_ca_system_score_codex":0.00013559585,"about_ca_system_score_gemma":0.0020218682,"threshold_uncertainty_score":0.9995308},"labels":[],"label_agreement":null},{"id":"W2589148784","doi":"10.1200/jco.2013.31.6_suppl.396","title":"Metastatic non–clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clear cell renal cell carcinoma; Hazard ratio; Renal cell carcinoma; Internal medicine; Clear cell; Cohort; Chromophobe cell; Oncology; Targeted therapy; Urology; Cancer; Database; Confidence interval","score_opus":0.12270829399509908,"score_gpt":0.3778673700901337,"score_spread":0.25515907609503463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589148784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851765,0.0004854997,0.0024220634,0.0037723603,0.00057010824,0.0038748886,0.00008740602,0.000034504414,0.003576693],"genre_scores_gemma":[0.9698552,0.0001377775,0.022399385,0.0042435112,0.0003975024,0.0004596705,0.00010489985,0.00012113936,0.0022809415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916714,0.0010008919,0.0038982802,0.00081594504,0.0017381407,0.0008753473],"domain_scores_gemma":[0.9904305,0.00307998,0.0028537838,0.00092204625,0.0013631667,0.0013505684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027211031,0.0007440886,0.0026756383,0.00046990998,0.00017942429,0.0000974456,0.00095488364,0.0002434091,0.0007627529],"category_scores_gemma":[0.00084842293,0.00040635373,0.0009387606,0.00044096514,0.00040812846,0.00039315195,0.0002447411,0.0017865828,0.00018346027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026295869,0.018390488,0.8311518,0.00040538586,0.0039694686,0.0118463,0.0014270837,0.008433642,0.043808796,0.00001973142,0.042938642,0.011312826],"study_design_scores_gemma":[0.070579395,0.060439494,0.76235354,0.00027016414,0.007512446,0.0012118588,0.0017825244,0.057166725,0.029466962,0.000109841494,0.007937301,0.0011697764],"about_ca_topic_score_codex":0.00031796476,"about_ca_topic_score_gemma":0.00003523627,"teacher_disagreement_score":0.06879826,"about_ca_system_score_codex":0.0005469066,"about_ca_system_score_gemma":0.0026086003,"threshold_uncertainty_score":0.9998388},"labels":[],"label_agreement":null},{"id":"W2589151049","doi":"10.1200/jco.2012.30.4_suppl.519","title":"Growth patterns of liver metastases as compared to resected tumors of the same colorectal cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Colorectal cancer; Metastasis; Cancer; Oncology; Haematoxylin; Pathology; Internal medicine; Immunohistochemistry","score_opus":0.053928981862503216,"score_gpt":0.39224156176392216,"score_spread":0.33831257990141894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589151049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480563,0.001519206,0.000025655601,0.0002948667,0.002881804,0.00017158869,0.00010373651,0.0000012341455,0.00019629167],"genre_scores_gemma":[0.99585444,0.0009980046,0.00026034028,0.00088394596,0.001897565,0.00000585506,0.0000072178195,0.000012827158,0.00007983342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745774,0.00054125255,0.0013492928,0.00013343185,0.00028315527,0.00023513906],"domain_scores_gemma":[0.99707174,0.00026869692,0.0015035718,0.00016608833,0.0007418809,0.00024802302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010963503,0.0001208692,0.00083585584,0.000054790875,0.000026370994,0.000002739704,0.00035214543,0.00020251363,0.00009543834],"category_scores_gemma":[0.0024659038,0.000078271274,0.00045545542,0.00011526371,0.000168985,0.0000093731,0.00017531661,0.00028111317,0.0000019806882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005904928,0.0030147387,0.8083014,0.00006167354,0.00082377804,0.0000035969556,0.00042611506,0.000045990055,0.14178622,0.00012963745,0.021027304,0.018474652],"study_design_scores_gemma":[0.0022628123,0.0030079861,0.82400626,0.000042798987,0.00021218411,0.000017354016,0.00007195363,0.0000012821929,0.09599472,0.000019870085,0.07426785,0.00009492014],"about_ca_topic_score_codex":0.0004544021,"about_ca_topic_score_gemma":0.0005203449,"teacher_disagreement_score":0.05324054,"about_ca_system_score_codex":0.000028776261,"about_ca_system_score_gemma":0.0006801523,"threshold_uncertainty_score":0.319181},"labels":[],"label_agreement":null},{"id":"W2589157935","doi":"10.1200/jco.2005.23.16_suppl.5569","title":"A phase I study of VB4–845 in patients with advanced, recurrent head and neck cancer on a weekly dosing scheme","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada)","funders":"","keywords":"Medicine; Head and neck cancer; Internal medicine; Dosing; Clinical trial; Immunogenicity; Cancer; Phases of clinical research; Oncology; Gastroenterology; Immunology; Antibody","score_opus":0.13618745554376835,"score_gpt":0.5385583200023969,"score_spread":0.4023708644586286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589157935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474233,0.0007917384,0.000002655626,0.003536657,0.00019647289,0.00033587837,0.0000045277043,0.000001828404,0.00038793497],"genre_scores_gemma":[0.99700195,0.00042907384,0.0015997437,0.00046450036,0.000379889,0.000004365513,0.0000012522289,0.000009420752,0.0001098042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755305,0.0002072978,0.00139267,0.00017362968,0.00045964422,0.00021372341],"domain_scores_gemma":[0.997868,0.0006748908,0.0007241623,0.00010362239,0.0003363598,0.0002929618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008636619,0.00011679224,0.0010524516,0.00014712344,0.000030225836,0.0000045098436,0.000089778296,0.00011068133,0.00007581556],"category_scores_gemma":[0.00061380526,0.00007017015,0.000102295686,0.00014404621,0.00017814031,0.00008525843,0.000037375426,0.0009232225,0.0000024033095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03735542,0.01638692,0.58022684,0.000025640935,0.00011276861,0.00009479601,0.00025909272,0.000020451305,0.000024041665,0.000008045814,0.00013424677,0.36535174],"study_design_scores_gemma":[0.051901866,0.13763551,0.7965116,0.00045450346,0.00006375873,0.000015731172,0.00013020159,0.00013080944,0.0000225917,0.000010699392,0.013056024,0.00006669153],"about_ca_topic_score_codex":0.000040502753,"about_ca_topic_score_gemma":0.00027996727,"teacher_disagreement_score":0.36528507,"about_ca_system_score_codex":0.0000854661,"about_ca_system_score_gemma":0.0005331577,"threshold_uncertainty_score":0.40109935},"labels":[],"label_agreement":null},{"id":"W2589161095","doi":"10.1200/jco.2014.32.30_suppl.69","title":"Using the experience-based design (EBD) approach to strengthen patients’ impact.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Phone; Medicine; Agency (philosophy); Health care; Resource (disambiguation); Medical education; Nursing","score_opus":0.7120120871949063,"score_gpt":0.6236276035902385,"score_spread":0.08838448360466777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589161095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79036534,0.000013280383,0.2016155,0.005756538,0.0008848103,0.00044361918,0.0000015973881,0.000008330407,0.0009109616],"genre_scores_gemma":[0.85188824,0.000008908439,0.13502477,0.011573055,0.0014633241,0.0000049106275,0.0000032386583,0.000017889508,0.000015669644],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931748,0.0018666909,0.0038640988,0.00021067618,0.00061466487,0.000269066],"domain_scores_gemma":[0.9794349,0.01594831,0.0026611094,0.00035823623,0.0010422842,0.0005551327],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0115858875,0.00015054803,0.00102819,0.0001093376,0.000077843404,0.000021371736,0.00028565095,0.00024200285,0.00012961874],"category_scores_gemma":[0.06543649,0.00008169467,0.00050532375,0.00022596189,0.00017102444,0.00016264933,0.0000611648,0.00091056526,0.0000154366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018442253,0.009558154,0.28624523,0.000029027771,0.0005287181,0.000035137982,0.0014290457,0.024240874,0.00038086053,0.00016167777,0.023820184,0.63512886],"study_design_scores_gemma":[0.036532335,0.06394878,0.61030394,0.00015776255,0.0017743844,0.00023653344,0.0027460156,0.14222579,0.0001778797,0.0005808005,0.14084953,0.0004662271],"about_ca_topic_score_codex":0.00005911841,"about_ca_topic_score_gemma":0.0000049413125,"teacher_disagreement_score":0.6346626,"about_ca_system_score_codex":0.00021017561,"about_ca_system_score_gemma":0.0017052559,"threshold_uncertainty_score":0.94243574},"labels":[],"label_agreement":null},{"id":"W2589166085","doi":"10.1200/jco.2014.32.4_suppl.159","title":"Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Abiraterone acetate; Prostate cancer; Discontinuation; Internal medicine; Cabazitaxel; Oncology; Urology; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.1344995534570567,"score_gpt":0.4956395757429001,"score_spread":0.3611400222858434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589166085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936072,0.00019952799,0.000011567692,0.004061717,0.00057881477,0.00093844195,0.000019108998,0.000005168354,0.0005784418],"genre_scores_gemma":[0.9972081,0.001121427,0.00034633485,0.0006742045,0.00028979284,0.000062309104,0.000005919546,0.000021506163,0.0002703973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993857,0.0017809661,0.0028008565,0.00032931782,0.00083011744,0.00040173397],"domain_scores_gemma":[0.993843,0.0024853416,0.0023028597,0.00032452328,0.0007102404,0.0003340371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005303357,0.0002162754,0.0017220691,0.0001397639,0.00006803629,0.000020408781,0.00029123772,0.00022459442,0.00004776398],"category_scores_gemma":[0.0027802244,0.00011428568,0.0003542934,0.00021073953,0.0008291634,0.00017822404,0.000074745956,0.0012995895,0.000003160169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026472302,0.0042000823,0.739687,0.00009847243,0.00035023622,0.0001565392,0.00060784654,0.000076044074,0.000245088,0.000024319981,0.00038093963,0.2277011],"study_design_scores_gemma":[0.017989026,0.017484024,0.95766526,0.00043407723,0.00015832509,0.0000046408,0.00021739402,0.00036876777,0.0015074282,0.00009193816,0.003969038,0.00011007724],"about_ca_topic_score_codex":0.00006852983,"about_ca_topic_score_gemma":0.00033034917,"teacher_disagreement_score":0.22759102,"about_ca_system_score_codex":0.0002758839,"about_ca_system_score_gemma":0.0017754429,"threshold_uncertainty_score":0.56461424},"labels":[],"label_agreement":null},{"id":"W2589166122","doi":"10.1200/jco.2014.32.3_suppl.350","title":"Prognostic factors in advanced biliary tract cancer treated with first-line chemotherapy with cisplatin and gemcitabine.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Performance status; Oncology; Chemotherapy; Univariate analysis; Proportional hazards model; Gallbladder cancer; Gastroenterology; Pancreatic cancer; Cancer; Multivariate analysis","score_opus":0.06172937564604881,"score_gpt":0.39661645671242696,"score_spread":0.33488708106637816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589166122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055445,0.000982902,0.00006791577,0.0075001423,0.00012299784,0.000277425,0.0000023643563,0.000009854003,0.00048193545],"genre_scores_gemma":[0.9957156,0.0017678932,0.0010533626,0.0009684359,0.00036719322,0.000011806946,0.000001901019,0.00002258757,0.00009118221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982488,0.000112037924,0.0009818696,0.0002189874,0.0002211093,0.0002171722],"domain_scores_gemma":[0.9966663,0.002062208,0.0007041558,0.000121145546,0.00022374667,0.00022241188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006424248,0.00018329246,0.0013504771,0.00011566484,0.000033089687,0.0000061264263,0.00006645925,0.00016623692,0.00004215783],"category_scores_gemma":[0.00082265993,0.000096081254,0.00011201874,0.00018320997,0.00021209923,0.000096920936,0.000013668323,0.0006103062,5.867311e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066872723,0.0007044948,0.93239164,0.00005098452,0.00023023268,0.00020668271,0.00024092986,0.000040448664,0.000040233135,0.0000029493926,0.00017585712,0.05922825],"study_design_scores_gemma":[0.017628452,0.021748645,0.9536384,0.00037859115,0.00030387696,0.00018582771,0.00012514101,0.00009274555,0.00006797222,0.000020037483,0.0056959894,0.00011432679],"about_ca_topic_score_codex":0.0000939579,"about_ca_topic_score_gemma":0.00167581,"teacher_disagreement_score":0.059113923,"about_ca_system_score_codex":0.00009032364,"about_ca_system_score_gemma":0.0004696751,"threshold_uncertainty_score":0.39180797},"labels":[],"label_agreement":null},{"id":"W2589168267","doi":"10.1200/jco.2013.31.4_suppl.196","title":"Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Clonogenic assay; In vivo; Flow cytometry; Cancer research; Cell cycle; Medicine; Cancer; Oncology; Pharmacology; Internal medicine; Biology; Immunology","score_opus":0.16420466324073527,"score_gpt":0.453761276110114,"score_spread":0.2895566128693787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589168267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878403,0.0023963985,0.00009153103,0.008118381,0.0005788342,0.0005761135,0.000015007267,0.000004659926,0.0003787779],"genre_scores_gemma":[0.99190855,0.0018628547,0.0049669296,0.00037735427,0.0005830996,0.000048537127,0.0000017505033,0.000013350276,0.00023758045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997535,0.00009521488,0.0017294516,0.00016669201,0.00028347585,0.00019018124],"domain_scores_gemma":[0.9952629,0.0015943247,0.0016173059,0.00018153262,0.0011368452,0.00020708116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055336545,0.000144041,0.0018217283,0.00008532929,0.000024108083,0.0000025818597,0.00011415839,0.00016065965,0.00008478777],"category_scores_gemma":[0.0006285267,0.00008230084,0.00040748683,0.00012113029,0.00036913776,0.00010063635,0.000024320629,0.00016358827,0.000001618498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020026552,0.0041239383,0.782682,0.00033661156,0.0022410234,0.00019377621,0.00069183524,0.000026933669,0.01021739,0.00010370005,0.006277497,0.17307873],"study_design_scores_gemma":[0.031528775,0.18683687,0.76112765,0.0004847247,0.0016199432,0.00022629218,0.000587547,0.00012530299,0.009619226,0.00043098629,0.0072403345,0.00017234076],"about_ca_topic_score_codex":0.00033802888,"about_ca_topic_score_gemma":0.0002792348,"teacher_disagreement_score":0.18271293,"about_ca_system_score_codex":0.00017038929,"about_ca_system_score_gemma":0.0015477331,"threshold_uncertainty_score":0.33561307},"labels":[],"label_agreement":null},{"id":"W2589176960","doi":"10.1200/jco.2014.32.30_suppl.46","title":"Enhancing the delivery of take-home cancer therapies in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Reimbursement; Multidisciplinary approach; Cancer; Socioeconomic status; Family medicine; Health care; Nursing; Environmental health; Population; Economic growth; Political science","score_opus":0.12427074360155413,"score_gpt":0.36668966666092223,"score_spread":0.2424189230593681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589176960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97924006,0.002985108,0.00041694296,0.00319453,0.0022514844,0.00006894939,0.000005383971,0.00000203531,0.011835478],"genre_scores_gemma":[0.9944812,0.0019385378,0.00052930356,0.0019718972,0.00063000823,0.0000033992449,2.0743484e-7,0.0000109953635,0.0004344422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630356,0.00009346093,0.0031976479,0.00014956133,0.000040380717,0.000215398],"domain_scores_gemma":[0.9950234,0.0013043291,0.003285119,0.00017899706,0.00011584235,0.000092287206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055715106,0.000103491715,0.0013812617,0.0001372369,0.000030767686,0.00001226552,0.00036371744,0.00024009903,0.0005431092],"category_scores_gemma":[0.0010375465,0.000077643555,0.0003498336,0.00008692332,0.00019811712,0.00023700093,0.00004214437,0.0007301186,0.000029105422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053245894,0.00031831415,0.89510286,0.000011937129,0.0001844162,0.0000071776763,0.0012330539,0.00028033607,0.00003208514,0.026948655,0.0011790246,0.07416971],"study_design_scores_gemma":[0.0015069294,0.000965859,0.7194939,0.000034948625,0.000011916111,0.000004187981,0.00008077912,0.000057403497,0.000031732416,0.02434714,0.25337625,0.00008896879],"about_ca_topic_score_codex":0.017569339,"about_ca_topic_score_gemma":0.1311152,"teacher_disagreement_score":0.2521972,"about_ca_system_score_codex":0.00028704156,"about_ca_system_score_gemma":0.0007782561,"threshold_uncertainty_score":0.9889727},"labels":[],"label_agreement":null},{"id":"W2589189560","doi":"10.1200/jco.2013.31.15_suppl.e14715","title":"Efficacy and safety of single agent (SA) or combination (CO) adjuvant chemotherapy (AC) in elderly patients with colon cancer: A Canadian Cancer Institute experience.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Discontinuation; Cancer; Internal medicine; Colorectal cancer; Toxicity; Surgery","score_opus":0.10120572763960713,"score_gpt":0.457852425946238,"score_spread":0.35664669830663087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589189560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040574,0.0004534828,0.0000042903894,0.007207122,0.0008473449,0.000686689,0.000010040472,0.0000030530375,0.00038222593],"genre_scores_gemma":[0.9947853,0.0025374615,0.00023885777,0.0020240687,0.00019440302,0.000042632804,0.0000059190124,0.000011493808,0.00015986567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814004,0.00012825927,0.0011452698,0.00016069398,0.00019879035,0.00022696727],"domain_scores_gemma":[0.997941,0.00033863974,0.00088410074,0.00008271231,0.00035754035,0.00039600048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033461076,0.00012773805,0.000975242,0.00016612353,0.00003535538,0.0000056852514,0.000085113745,0.00020462296,0.0007802225],"category_scores_gemma":[0.00017446373,0.00008165544,0.00007586213,0.0001643139,0.0002866199,0.00015676173,0.000010560095,0.00034702668,0.000001632018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013259031,0.0033014969,0.624049,0.000027426888,0.00026486424,0.00008314452,0.0011188126,0.000022076441,0.0002804117,0.0000074426152,0.0019521476,0.35563415],"study_design_scores_gemma":[0.03952431,0.024536463,0.8888916,0.00019324964,0.0001528146,0.000017924458,0.00008821352,0.00003078484,0.00019274911,0.000014147907,0.046272825,0.00008491617],"about_ca_topic_score_codex":0.034737494,"about_ca_topic_score_gemma":0.13693848,"teacher_disagreement_score":0.35554925,"about_ca_system_score_codex":0.0007327107,"about_ca_system_score_gemma":0.0028627212,"threshold_uncertainty_score":0.9716903},"labels":[],"label_agreement":null},{"id":"W2589192293","doi":"10.1200/jco.2015.33.7_suppl.196","title":"Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Cabozantinib; Prostate cancer; Oncology; Cohort; Discontinuation; Biomarker; Response Evaluation Criteria in Solid Tumors; Cancer; Randomized controlled trial; Clinical trial; Phases of clinical research","score_opus":0.03943750518335649,"score_gpt":0.3809152647121456,"score_spread":0.3414777595287891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589192293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574095,0.0010013252,0.00005520353,0.0010596138,0.0007698126,0.0012738495,0.000052963263,6.996691e-7,0.000045580236],"genre_scores_gemma":[0.9958773,0.0028585368,0.0006191196,0.000048180955,0.00034717342,0.00009931185,0.000025459702,0.000009485835,0.00011538914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99517673,0.0018793872,0.0022168714,0.00018430287,0.00039724482,0.00014546156],"domain_scores_gemma":[0.9931655,0.0008779896,0.004811227,0.00017508086,0.00089636026,0.00007385498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069715935,0.00014414042,0.0025823112,0.000246074,0.000011458358,0.000005057613,0.00010942808,0.00015630967,0.000008146256],"category_scores_gemma":[0.0021563303,0.00007464678,0.00048682452,0.00045801912,0.00016962216,0.000014028345,0.000017962218,0.00012208607,2.977687e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92600423,0.0013317656,0.03996018,0.000015402391,0.0055952044,0.0000013143376,0.0006324217,0.000814454,0.020384792,0.000006363811,0.00006735843,0.0051865266],"study_design_scores_gemma":[0.9083655,0.015412169,0.061129756,0.00013970894,0.007400542,0.0000030664405,0.00087831623,0.00024248236,0.0048080967,0.000011288137,0.0014821952,0.00012691792],"about_ca_topic_score_codex":0.0017905209,"about_ca_topic_score_gemma":0.07178074,"teacher_disagreement_score":0.06999022,"about_ca_system_score_codex":0.00011152917,"about_ca_system_score_gemma":0.0022213366,"threshold_uncertainty_score":0.9451568},"labels":[],"label_agreement":null},{"id":"W2589193077","doi":"10.1200/jco.2016.34.2_suppl.368","title":"Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bladder cancer; Multidisciplinary approach; Modalities; Family medicine; Community practice; Pharmacy; Cancer; Internal medicine","score_opus":0.20252220958062464,"score_gpt":0.4767857431331576,"score_spread":0.27426353355253297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589193077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482978,0.0005795993,0.0000072681637,0.049666293,0.00056396116,0.0002592058,0.0000125725255,9.0582574e-7,0.00061241124],"genre_scores_gemma":[0.98461676,0.012984455,0.00014098182,0.0018771009,0.0002677318,0.000035847715,2.4032116e-7,0.000008044368,0.00006886658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792147,0.0003832298,0.0010520048,0.0001326868,0.0003133647,0.0001972424],"domain_scores_gemma":[0.9958964,0.003051504,0.0006649344,0.00016934164,0.00012812117,0.00008967721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002105985,0.00009349687,0.00051743485,0.000031356645,0.00003208659,0.0000041772264,0.00016641017,0.00007073142,0.00003566945],"category_scores_gemma":[0.00043557913,0.000038855884,0.00008368818,0.000082981926,0.00012239949,0.00017489899,0.00009081262,0.0004011382,9.28568e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029628277,0.0013143787,0.6717804,0.0000882385,0.0007194359,0.003111889,0.0035306925,0.000016249916,0.000055686116,0.00003837021,0.0014719826,0.31490985],"study_design_scores_gemma":[0.0069362037,0.0012938133,0.9701152,0.00039106008,0.00021127403,0.00009007403,0.008043024,0.0000015481564,0.000049234397,0.000045535588,0.012776019,0.000047055848],"about_ca_topic_score_codex":0.09218956,"about_ca_topic_score_gemma":0.5071469,"teacher_disagreement_score":0.41495737,"about_ca_system_score_codex":0.00022342359,"about_ca_system_score_gemma":0.0011410686,"threshold_uncertainty_score":0.9138556},"labels":[],"label_agreement":null},{"id":"W2589193621","doi":"10.1200/jco.2014.32.30_suppl.58","title":"Transition of breast cancer (BC) survivors to primary care: Results of a Cancer Care Ontario (CCO) pilot project.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Survivorship curve; Medicine; Referral; Family medicine; Breast cancer; Documentation; Cancer; Health care; Nursing; Internal medicine","score_opus":0.07895543369716965,"score_gpt":0.42547217604232784,"score_spread":0.34651674234515817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589193621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838152,0.0010279341,0.00007883886,0.0048730182,0.0030209888,0.00043967494,0.00022702091,0.000009313603,0.0065080035],"genre_scores_gemma":[0.9952313,0.00055685744,0.00043466495,0.0020129366,0.0014606839,0.000019536546,0.000020419062,0.00002604293,0.00023761448],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956727,0.0004606824,0.0026681917,0.00028629208,0.0006394717,0.00027264282],"domain_scores_gemma":[0.9948284,0.0007168373,0.0017065185,0.00029686478,0.002113127,0.00033825697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016330606,0.00019663783,0.0019872044,0.00021249714,0.000029288656,0.000004446291,0.00021837447,0.000344729,0.00012517691],"category_scores_gemma":[0.0003333587,0.00015039524,0.00056446966,0.0002924321,0.00018912928,0.00008650741,0.00004159388,0.00087069016,0.0000017516955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1137741,0.0021335578,0.30668586,0.002079067,0.0009913151,0.00012637084,0.043321252,0.00040603755,0.001806969,0.000040931493,0.005947577,0.52268696],"study_design_scores_gemma":[0.013888084,0.024224712,0.85316336,0.001387217,0.0010185145,0.000080595484,0.0030522384,0.000006832337,0.0005739852,0.000018134899,0.10237339,0.00021293978],"about_ca_topic_score_codex":0.3682178,"about_ca_topic_score_gemma":0.8324557,"teacher_disagreement_score":0.5464775,"about_ca_system_score_codex":0.0010841965,"about_ca_system_score_gemma":0.00766691,"threshold_uncertainty_score":0.9979587},"labels":[],"label_agreement":null},{"id":"W2589193981","doi":"10.1200/jco.2016.34.26_suppl.209","title":"Effects of high-dose Asian ginseng (Panax ginseng) to improve cancer-related fatigue: Results of a double-blind, placebo-controlled randomized controlled trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer-related fatigue; Placebo; Ginseng; Internal medicine; Quality of life (healthcare); Anxiety; Hospital Anxiety and Depression Scale; Randomized controlled trial; Cancer; Physical therapy; Clinical endpoint; Depression (economics); Visual analogue scale; Psychiatry; Alternative medicine","score_opus":0.054814152436753194,"score_gpt":0.41709633076238983,"score_spread":0.36228217832563664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589193981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488014,0.0011720528,0.00035000645,0.02480399,0.010706268,0.011286901,0.000027036569,0.00003122472,0.0028211363],"genre_scores_gemma":[0.99360895,0.0012937341,0.00041290422,0.000606715,0.0017303985,0.000488532,0.00000221064,0.00004575447,0.0018107772],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9847846,0.0035280504,0.00975303,0.00046129327,0.0009779703,0.00049502397],"domain_scores_gemma":[0.95342207,0.034537554,0.009008518,0.00048871187,0.0017350258,0.00080814713],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016723156,0.00041910412,0.013689399,0.0005662689,0.00004163464,0.000010186263,0.00038207564,0.00095903873,0.00012976595],"category_scores_gemma":[0.035379246,0.00021913239,0.003496296,0.00040472756,0.00040970359,0.000121225305,0.00007500164,0.0010382775,0.0000082343095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9478064,0.0023401922,0.000046873432,0.00015517404,0.006172995,0.00023327602,0.00056087854,0.000015609981,0.0035217507,0.00023003216,0.0010702614,0.037846517],"study_design_scores_gemma":[0.9660456,0.021973068,0.00034970307,0.0009525802,0.0058954996,0.000027108537,0.000092891925,0.000045047895,0.0022926473,0.00023233824,0.001881503,0.00021196593],"about_ca_topic_score_codex":0.00086492376,"about_ca_topic_score_gemma":0.00094480516,"teacher_disagreement_score":0.04480759,"about_ca_system_score_codex":0.00035044187,"about_ca_system_score_gemma":0.0039958935,"threshold_uncertainty_score":0.9727462},"labels":[],"label_agreement":null},{"id":"W2589210877","doi":"10.1200/jco.2014.32.4_suppl.479","title":"Pharmacist-led monitoring program for patients on sunitinib for metastatic renal-cell carcinoma: A Canadian experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dr. H. Bliss Murphy Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Discontinuation; Renal cell carcinoma; Population; Pharmacist; Internal medicine; Cohort; Cancer; Oncology; Pharmacy; Family medicine","score_opus":0.19155723390402837,"score_gpt":0.4350749123014374,"score_spread":0.24351767839740904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589210877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821812,0.00019291055,0.0011681225,0.00089284976,0.004685951,0.0007108091,0.000121015015,0.000007251689,0.010039891],"genre_scores_gemma":[0.98880714,0.00009297237,0.007992048,0.0010138705,0.0016231313,0.00012394729,0.0000069267226,0.000029163723,0.00031080504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671215,0.0000544985,0.0024619254,0.00026485758,0.000042774773,0.00046378953],"domain_scores_gemma":[0.9951038,0.0014770819,0.0023897989,0.00016487196,0.0003125256,0.000551924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002639711,0.00016444463,0.0012744197,0.00023942803,0.0001173657,0.000040552135,0.00032040285,0.00019788084,0.000054334167],"category_scores_gemma":[0.0040766997,0.00015969695,0.00053823204,0.00007567338,0.000094648174,0.00023112091,0.000016738644,0.0003376325,0.00003381379],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003500978,0.0036861359,0.4733342,0.00011870736,0.0002784562,0.00001859477,0.0008535458,0.00014269231,0.0000066891585,0.015196057,0.015880547,0.4869834],"study_design_scores_gemma":[0.011524546,0.014487007,0.07787085,0.00002017906,0.000054546934,0.0000031870384,0.00006406915,0.00083259493,0.000104495826,0.007074903,0.88771194,0.00025166373],"about_ca_topic_score_codex":0.0008198888,"about_ca_topic_score_gemma":0.0006555916,"teacher_disagreement_score":0.8718314,"about_ca_system_score_codex":0.00033122578,"about_ca_system_score_gemma":0.0005242015,"threshold_uncertainty_score":0.65122527},"labels":[],"label_agreement":null},{"id":"W2589214874","doi":"10.1200/jco.2013.31.15_suppl.e14603","title":"Causes of urban-rural disparities in adjuvant chemotherapy (AC) for rectal cancer (RC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Quartile; Cancer; Logistic regression; Rural area; Demography; Internal medicine; Confidence interval; Pathology","score_opus":0.11501469267710429,"score_gpt":0.4710199071701964,"score_spread":0.3560052144930921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589214874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98089826,0.0025499791,0.000041947857,0.013909565,0.0013548332,0.00036603442,0.000012546624,0.0000043025416,0.00086254766],"genre_scores_gemma":[0.9853664,0.004338128,0.0017874104,0.0063594985,0.0012571545,0.000028608363,0.000003258507,0.000017968707,0.0008415518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973336,0.00012829168,0.0020015056,0.000116744486,0.00018948928,0.00023035324],"domain_scores_gemma":[0.9967835,0.001431504,0.0010817661,0.00012105847,0.00037994815,0.00020220589],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010210831,0.00011624398,0.0015895026,0.0001111846,0.000015887337,0.000004676738,0.0001313609,0.00027130512,0.0009393566],"category_scores_gemma":[0.0010799404,0.00008121686,0.0004349307,0.00007487333,0.00022654566,0.00016685354,0.000018560566,0.0005622482,0.0000030329645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069729653,0.00094090955,0.63427764,0.00016344192,0.0004310345,0.00004912694,0.00035568362,0.000019644895,0.002066522,0.00006918123,0.08434323,0.27031064],"study_design_scores_gemma":[0.016427252,0.008295999,0.8811586,0.00023393723,0.00014541835,0.00006537007,0.00034076138,0.00023327889,0.0010758433,0.00035678796,0.09154556,0.00012120678],"about_ca_topic_score_codex":0.00061276794,"about_ca_topic_score_gemma":0.0003496086,"teacher_disagreement_score":0.27018943,"about_ca_system_score_codex":0.00019662961,"about_ca_system_score_gemma":0.0017653925,"threshold_uncertainty_score":0.9999739},"labels":[],"label_agreement":null},{"id":"W2589215978","doi":"10.1200/jco.2013.31.6_suppl.301","title":"Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Progression-free survival; Anemia; Overall survival; Oncology; Chemotherapy; Confidence interval","score_opus":0.07199907428177772,"score_gpt":0.43668257297948737,"score_spread":0.36468349869770966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589215978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962769,0.000347101,0.00001317102,0.0009568275,0.00062399916,0.0016010893,0.0000734876,0.0000066545635,0.00010075551],"genre_scores_gemma":[0.9980673,0.00020247317,0.00095537957,0.00026539966,0.00031389034,0.000041038304,0.000010731147,0.00003474747,0.00010903784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996403,0.0007382674,0.0018803491,0.00026466828,0.0003852705,0.0003284451],"domain_scores_gemma":[0.99089986,0.006599182,0.0012792571,0.00026149035,0.0005869534,0.00037323037],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002317565,0.00023631782,0.0014794006,0.00019169356,0.00004338876,0.0000068832883,0.00015548276,0.0003004705,0.00026312852],"category_scores_gemma":[0.0095124515,0.00013953769,0.0004490465,0.00011351998,0.00014373918,0.00013132316,0.00005828455,0.00046980404,0.000002258641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11633465,0.0029409132,0.771365,0.00002356331,0.0002025349,0.000024596251,0.00016407145,0.000007766909,0.00060297706,7.0171427e-7,0.00034047585,0.107992776],"study_design_scores_gemma":[0.040044066,0.111495264,0.8471437,0.00016550308,0.00008543801,0.000009262514,0.000037379676,0.0000600156,0.00044590197,0.000086077685,0.0003303356,0.00009707135],"about_ca_topic_score_codex":0.00005042976,"about_ca_topic_score_gemma":0.00005834268,"teacher_disagreement_score":0.108554356,"about_ca_system_score_codex":0.0003144296,"about_ca_system_score_gemma":0.0011501511,"threshold_uncertainty_score":0.99883085},"labels":[],"label_agreement":null},{"id":"W2589217865","doi":"10.1200/jco.2013.31.15_suppl.557","title":"Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Everolimus; Internal medicine; Clinical endpoint; Metastatic breast cancer; Oncology; Cancer; Aromatase inhibitor; Chemotherapy; Randomized controlled trial; Aromatase","score_opus":0.04429092118661206,"score_gpt":0.42472936744359124,"score_spread":0.3804384462569792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589217865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880395,0.00010437122,0.00059623754,0.009634042,0.0007755409,0.0007557942,0.000028446018,0.0000057596785,0.000060291102],"genre_scores_gemma":[0.99000835,0.0010837045,0.004737734,0.0031438586,0.000715915,0.000060137067,0.000010142611,0.000033813994,0.00020632373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971418,0.00012553977,0.0021011368,0.00017326802,0.00023530847,0.00022298316],"domain_scores_gemma":[0.9954904,0.00051233947,0.002407067,0.0001479392,0.0012632961,0.0001789881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544994,0.00013836168,0.0014023843,0.00013015677,0.0000184585,0.000003831788,0.00013663904,0.00025706185,0.00032516665],"category_scores_gemma":[0.00056551874,0.00010379239,0.00026373388,0.00014978033,0.00014512952,0.0003178047,0.0000166035,0.0003949231,0.0000027469846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011562173,0.0011922674,0.20473467,0.000057014047,0.00014092412,0.0000027609922,0.00019459179,0.000013877772,0.02424683,0.0000072178623,0.00008098314,0.7577667],"study_design_scores_gemma":[0.02305687,0.0034841516,0.9543131,0.00031300905,0.000055570035,0.000015057208,0.000047545473,0.00007949194,0.001849501,0.00021267809,0.016483044,0.000089978676],"about_ca_topic_score_codex":0.00001744472,"about_ca_topic_score_gemma":0.000016138232,"teacher_disagreement_score":0.7576767,"about_ca_system_score_codex":0.00023008214,"about_ca_system_score_gemma":0.00068692496,"threshold_uncertainty_score":0.42325306},"labels":[],"label_agreement":null},{"id":"W2589226049","doi":"10.1200/jco.2013.31.6_suppl.335","title":"Use of radiotherapy for seminoma patients with low-volume infradiaphragmatic nodal disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Radiation therapy; Chemotherapy; Hilum (anatomy); Stage (stratigraphy); Surgery; Radiology","score_opus":0.054569322173793074,"score_gpt":0.3929318724527277,"score_spread":0.33836255027893464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589226049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661374,0.00055930676,0.0005250153,0.0012831194,0.00028217607,0.00068516785,0.000020808347,0.000005556605,0.000025131667],"genre_scores_gemma":[0.982489,0.00009547169,0.015807834,0.0011055414,0.00028050743,0.000017968763,0.000012960801,0.000021815953,0.0001688949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979815,0.000109390756,0.0013276053,0.00012732837,0.0002801063,0.00017407436],"domain_scores_gemma":[0.99569786,0.0013644932,0.0014421565,0.00019834863,0.00066063256,0.00063651864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002416638,0.00012484909,0.0010230431,0.00007775871,0.000021232214,0.000009859437,0.000083532475,0.00012837176,0.00020983042],"category_scores_gemma":[0.0021758259,0.000074491894,0.00047024607,0.00006869999,0.00015615945,0.00017776643,0.000012425186,0.00018644669,0.000008830156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038057524,0.0046657696,0.9210517,0.00010156233,0.0007864418,0.00007795019,0.000017586057,0.000027013535,0.000007043352,0.000015039471,0.003765416,0.06567872],"study_design_scores_gemma":[0.013082139,0.012755331,0.9670465,0.00020345922,0.00087760075,0.00001798762,0.0000069762054,0.0006929197,0.0000025653378,0.0001327419,0.005111439,0.000070340204],"about_ca_topic_score_codex":0.000015205061,"about_ca_topic_score_gemma":0.0000015549334,"teacher_disagreement_score":0.06560838,"about_ca_system_score_codex":0.00008345236,"about_ca_system_score_gemma":0.00087905483,"threshold_uncertainty_score":0.30376914},"labels":[],"label_agreement":null},{"id":"W2589230655","doi":"10.1200/jco.2012.30.4_suppl.390","title":"Survival analysis of PETCAM: A multicenter randomized controlled trial of PET/CT versus no PET/CT for patients with resectable liver colorectal adenocarcinoma metastases.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Hazard ratio; Colorectal cancer; Confidence interval; Randomized controlled trial; Occult; Radiology; PET-CT; Internal medicine; Nuclear medicine; Cancer; Positron emission tomography; Pathology","score_opus":0.12588039348988433,"score_gpt":0.39408570596695247,"score_spread":0.26820531247706814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589230655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233806,0.000774304,0.000044436634,0.00014575273,0.0019291033,0.003920631,0.00006151886,0.0000060860484,0.000780118],"genre_scores_gemma":[0.9950815,0.00023442565,0.003710416,0.000047917514,0.00056919345,0.00013004965,0.000067652494,0.000028945364,0.00012993871],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99187315,0.0025110566,0.0040989146,0.00025348752,0.00081660086,0.00044678626],"domain_scores_gemma":[0.9713904,0.02156176,0.004498275,0.0002663834,0.0017968597,0.00048627277],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009636024,0.00030220384,0.008536535,0.0004993657,0.000046729438,0.000008230343,0.00018868285,0.000039834897,0.0005190087],"category_scores_gemma":[0.013781233,0.00017366749,0.0043394314,0.0003845693,0.00040426137,0.00018372247,0.00005197369,0.0004731373,0.0000063567636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5938462,0.0066380515,0.37827742,0.00004226027,0.02014368,0.0005975027,0.000030717354,0.0000018174162,0.000006377013,0.000015708354,0.00011117658,0.00028907933],"study_design_scores_gemma":[0.86397976,0.03798151,0.03630047,0.000047029098,0.05912316,0.00007579389,0.00006818094,0.0016685302,0.00008807365,0.000002121031,0.0005332327,0.00013214155],"about_ca_topic_score_codex":0.0000935025,"about_ca_topic_score_gemma":0.000055700562,"teacher_disagreement_score":0.34197697,"about_ca_system_score_codex":0.00014098064,"about_ca_system_score_gemma":0.00088275236,"threshold_uncertainty_score":0.9945261},"labels":[],"label_agreement":null},{"id":"W2589230750","doi":"10.1200/jco.2013.31.15_suppl.3624","title":"Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Ottawa; University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Hazard ratio; Proportional hazards model; Clinical endpoint; Cohort; Oncology; Multivariate analysis; Univariate analysis; Cancer; Population; Primary tumor; Quartile; Surgery; Confidence interval; Randomized controlled trial; Metastasis","score_opus":0.053169390733071635,"score_gpt":0.37283235200375325,"score_spread":0.3196629612706816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589230750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934353,0.0010516272,0.0000029832443,0.002382508,0.00056374737,0.0011527911,0.000027005392,0.000015851896,0.0013681736],"genre_scores_gemma":[0.9945203,0.0025988123,0.00021902323,0.0010915246,0.0004265137,0.00020446672,0.0000051291204,0.000043067845,0.00089115225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659806,0.00038847319,0.0015707323,0.00034487355,0.00063934526,0.0004584853],"domain_scores_gemma":[0.9963789,0.000966547,0.0014048045,0.00015414726,0.0008131631,0.00028244613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008379939,0.00023889843,0.001797433,0.000052087493,0.00021727684,0.000114396,0.00018828375,0.000115049,0.0011880886],"category_scores_gemma":[0.0003803541,0.00015589026,0.0002529389,0.0003108283,0.0004035447,0.0002068604,0.00004576899,0.0008703573,0.0000034198922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004635443,0.0017947046,0.8554149,0.000025782241,0.0016082965,0.00040061842,0.00020867896,0.00003545831,0.000008785991,6.08891e-7,0.0031226499,0.13274407],"study_design_scores_gemma":[0.025282856,0.019924488,0.95067203,0.0004425311,0.0007096086,0.00013206406,0.00016915615,0.00009651814,0.000009023341,0.00003541637,0.0023597775,0.00016650115],"about_ca_topic_score_codex":0.09623892,"about_ca_topic_score_gemma":0.3593281,"teacher_disagreement_score":0.26308918,"about_ca_system_score_codex":0.00066609634,"about_ca_system_score_gemma":0.0015467339,"threshold_uncertainty_score":0.999725},"labels":[],"label_agreement":null},{"id":"W2589230933","doi":"10.1200/jco.2016.34.2_suppl.534","title":"Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Oncology; Targeted therapy; Cancer","score_opus":0.22719711655302252,"score_gpt":0.472124269521861,"score_spread":0.24492715296883846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589230933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752119,0.0012713698,0.00021128652,0.021835513,0.00054860435,0.00065974396,0.00006285457,0.000004379056,0.0001943471],"genre_scores_gemma":[0.9944965,0.0015323192,0.0022386229,0.00093039434,0.0006101765,0.00004323368,0.000020189173,0.00001299223,0.00011552688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773574,0.00015859093,0.0016412461,0.00017745476,0.00013537458,0.00015161393],"domain_scores_gemma":[0.99344873,0.0045870934,0.0011212056,0.00017194853,0.00046383333,0.0002071986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014446329,0.00010559509,0.0008096363,0.0001741857,0.000013648445,0.0000027393269,0.00012170328,0.00016095629,0.00016976114],"category_scores_gemma":[0.0032878004,0.00006036141,0.00020720321,0.00007156821,0.00017740706,0.000104016646,0.00003957445,0.00022758366,0.0000025504314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00813901,0.0035869807,0.67670715,0.000046982463,0.0004514401,0.000119361466,0.00013632703,4.8155283e-7,0.018106433,0.00034328384,0.001185137,0.29117742],"study_design_scores_gemma":[0.018132811,0.007839515,0.96005553,0.00010424786,0.00013380407,0.00020448893,0.000020877183,0.00001731986,0.001224129,0.00033399375,0.011874574,0.000058697744],"about_ca_topic_score_codex":0.000014658065,"about_ca_topic_score_gemma":0.00006021286,"teacher_disagreement_score":0.2911187,"about_ca_system_score_codex":0.00009748952,"about_ca_system_score_gemma":0.0005920511,"threshold_uncertainty_score":0.39360416},"labels":[],"label_agreement":null},{"id":"W2589233229","doi":"10.1200/jco.2012.30.15_suppl.tps658","title":"HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Metastatic breast cancer; Internal medicine; Discontinuation; Oncology; Clinical endpoint; Breast cancer; Chemotherapy; Blockade; Cancer; Adverse effect; Clinical trial; Receptor","score_opus":0.1545185930237691,"score_gpt":0.5411181389432805,"score_spread":0.3865995459195114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589233229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526122,0.0004537161,0.00025387283,0.043249648,0.0006875102,0.0006202057,0.00009662822,0.0000048052198,0.0020214142],"genre_scores_gemma":[0.9938547,0.00030215265,0.002087041,0.0023835988,0.0010958912,0.00004190095,0.000004598318,0.000024898949,0.00020521398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99556434,0.0013230015,0.0016758256,0.00017387472,0.00082519965,0.0004377466],"domain_scores_gemma":[0.99456435,0.0028693348,0.0010872493,0.0002273591,0.00070859294,0.0005431118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052810735,0.00015262494,0.0012860369,0.0001757941,0.00003868515,0.0000070306287,0.00023459348,0.00019080903,0.0014847164],"category_scores_gemma":[0.001440268,0.00008119261,0.00022474887,0.00036652214,0.0003135378,0.0001742024,0.000064389984,0.0014307357,0.000024680032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035405166,0.009842263,0.27275577,0.00029761778,0.001072721,0.0007036737,0.004215984,0.0002946949,0.0023994897,0.00014758202,0.084792204,0.58807284],"study_design_scores_gemma":[0.007381929,0.01517101,0.93719935,0.0012150506,0.00038259482,0.0008540798,0.0012131884,0.00006741636,0.0012017239,0.00005181009,0.03513112,0.00013072116],"about_ca_topic_score_codex":0.0003659826,"about_ca_topic_score_gemma":0.0007374395,"teacher_disagreement_score":0.66444355,"about_ca_system_score_codex":0.000462597,"about_ca_system_score_gemma":0.001909368,"threshold_uncertainty_score":0.99942803},"labels":[],"label_agreement":null},{"id":"W2589234634","doi":"10.1200/jco.2016.34.2_suppl.616","title":"The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"BAP1; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Immunohistochemistry; Clear cell renal cell carcinoma; Pathological; Gastroenterology; Cancer","score_opus":0.0691629640922425,"score_gpt":0.39484717094715505,"score_spread":0.32568420685491256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589234634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981879,0.00040386917,0.00002016709,0.000499763,0.00006447105,0.00039620133,0.000014570212,0.0000034894392,0.0004095758],"genre_scores_gemma":[0.998626,0.00029647167,0.00079387816,0.00006360955,0.00005698378,0.00000481834,0.0000027200256,0.000024398963,0.0001311315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682,0.00058494176,0.0016249141,0.0001950789,0.00054036704,0.00023469905],"domain_scores_gemma":[0.9924166,0.0038305814,0.002518353,0.00031469713,0.0006133541,0.00030641875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009402815,0.00023668387,0.0016711897,0.00012900881,0.00004423428,0.000004390536,0.00013590683,0.00013649832,0.000051879964],"category_scores_gemma":[0.00049912144,0.00007204435,0.0004111966,0.00010820587,0.00038483317,0.00007779682,0.000024880317,0.00030972506,0.0000014364946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04103435,0.0025893447,0.93106645,0.000016801398,0.00080347306,0.0001635865,0.00007346739,0.00000642027,0.0046944604,0.0000029778016,0.000243099,0.019305553],"study_design_scores_gemma":[0.027548995,0.10359565,0.8520479,0.00015403572,0.00037057555,0.00003315601,0.00004243797,0.000003205537,0.016007604,0.00002714221,0.00009739343,0.000071874376],"about_ca_topic_score_codex":0.00004056532,"about_ca_topic_score_gemma":0.0000089944915,"teacher_disagreement_score":0.10100631,"about_ca_system_score_codex":0.0001429713,"about_ca_system_score_gemma":0.00080604723,"threshold_uncertainty_score":0.29378834},"labels":[],"label_agreement":null},{"id":"W2589243237","doi":"10.1200/jco.2016.34.4_suppl.708","title":"Does the dose of leucovorin (LV) matter with 5-fluorouracil (5FU) in colorectal cancer (CRC)?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; McMaster University","funders":"","keywords":"Medicine; Colorectal cancer; Fluorouracil; Internal medicine; Bevacizumab; Dose; Adverse effect; Randomized controlled trial; Cancer; Oncology; Chemotherapy; Surgery","score_opus":0.07037168958697851,"score_gpt":0.4364155926024026,"score_spread":0.3660439030154241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589243237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951059,0.0005805591,0.000008289506,0.043212377,0.0007937464,0.00020878612,0.0000075922926,0.00000319134,0.0041264887],"genre_scores_gemma":[0.9948978,0.0018853626,0.00023978118,0.0010854062,0.000630687,0.00002206219,1.7512626e-7,0.000011809198,0.0012269269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771845,0.00022820645,0.0013757336,0.00015680365,0.00030564654,0.00021513483],"domain_scores_gemma":[0.9963616,0.0020216461,0.0010301159,0.0001239382,0.00033591135,0.00012676777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011237966,0.00013643914,0.001236959,0.00006979924,0.000031372383,0.0000036424058,0.0001365857,0.00015439086,0.0005596366],"category_scores_gemma":[0.0005233981,0.00003956189,0.00026265968,0.00012806508,0.0004406845,0.00008243831,0.00005634861,0.00041208367,0.000010759798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0146709485,0.0008168446,0.8183214,0.000017698694,0.00055639225,0.0003127027,0.00026387998,0.0000019773652,0.00051039906,0.000029637726,0.002203207,0.1622949],"study_design_scores_gemma":[0.01005029,0.01061473,0.9467593,0.0002645768,0.00029495722,0.0001255394,0.00024609608,0.0000017503171,0.0006792586,0.0001691732,0.03072449,0.00006987686],"about_ca_topic_score_codex":0.00024197299,"about_ca_topic_score_gemma":0.0029498064,"teacher_disagreement_score":0.16222501,"about_ca_system_score_codex":0.00027518178,"about_ca_system_score_gemma":0.001008771,"threshold_uncertainty_score":0.61276287},"labels":[],"label_agreement":null},{"id":"W2589249052","doi":"10.1200/jco.2015.33.3_suppl.186","title":"Quality of life (QOL) in patients with esophageal cancer treated with radiation (RT) in the radical setting.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Southlake Regional Health Center","funders":"","keywords":"Medicine; Nausea; Vomiting; Quality of life (healthcare); Internal medicine; Esophageal cancer; Gastroenterology; Radiation therapy; Cohort; Cancer; Prospective cohort study; Surgery","score_opus":0.13179018074885535,"score_gpt":0.4914331193730917,"score_spread":0.35964293862423635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589249052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924661,0.0012520486,0.000008478916,0.0054303897,0.00007044637,0.00038990323,0.000006538641,0.0000024722526,0.00037365675],"genre_scores_gemma":[0.9980683,0.00013448732,0.00043189616,0.0010609059,0.00025250783,0.000013484574,0.0000072633447,0.000008981182,0.000022174683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601257,0.0012336434,0.0015522968,0.00014400003,0.0008354322,0.00022204596],"domain_scores_gemma":[0.99651957,0.0014377981,0.0010704654,0.00015316148,0.000414262,0.00040477174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004566879,0.00010829921,0.0010649259,0.00013072774,0.000013515481,0.0000045700313,0.00013553625,0.0001657003,0.000035349705],"category_scores_gemma":[0.002605026,0.000050651677,0.00010681597,0.0002991532,0.00023787434,0.00009209942,0.000015775615,0.00083192566,0.0000018402527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03170227,0.0028989476,0.93087465,0.00002219729,0.00016825924,0.0004064741,0.00025518925,0.000078900586,3.1486985e-7,0.000019662588,0.0006372591,0.032935858],"study_design_scores_gemma":[0.040785722,0.02445602,0.93399686,0.00007505176,0.00007263099,0.000012713449,0.00010957308,0.000026723741,0.000009020406,0.000039198836,0.0003749211,0.00004155128],"about_ca_topic_score_codex":0.0007058571,"about_ca_topic_score_gemma":0.00090761593,"teacher_disagreement_score":0.032894306,"about_ca_system_score_codex":0.00041444568,"about_ca_system_score_gemma":0.0038196184,"threshold_uncertainty_score":0.67758393},"labels":[],"label_agreement":null},{"id":"W2589250691","doi":"10.1200/jco.2016.34.2_suppl.409","title":"Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cystectomy; Contouring; Bladder cancer; Adjuvant radiotherapy; Radiation therapy; Clinical trial; Cancer; Surgery; Nuclear medicine; Urology; Radiology; Internal medicine","score_opus":0.21738115833288513,"score_gpt":0.505035433597135,"score_spread":0.28765427526424986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589250691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894512,0.001363329,0.001277287,0.006882412,0.00056607125,0.00026336257,0.000015096712,0.000002747433,0.00017848301],"genre_scores_gemma":[0.98405385,0.0010841156,0.013549533,0.00050414907,0.0006334943,0.000010144702,0.0000016975853,0.0000092469845,0.00015375645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997678,0.00006853878,0.001883457,0.00009421908,0.00018263108,0.00009319365],"domain_scores_gemma":[0.99607754,0.0007630608,0.0015450424,0.000066968496,0.001434492,0.0001129236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012040348,0.000074670534,0.0008255666,0.00007495231,0.000015041045,0.0000013253346,0.000046626585,0.00013619025,0.000059108395],"category_scores_gemma":[0.0021704715,0.00004143846,0.00015279693,0.00003520715,0.000067870526,0.000071440634,0.000013744957,0.000073928066,6.113136e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004383256,0.0003723182,0.05365318,0.00009303919,0.0007027157,0.000009192082,0.0001879844,0.0000041799117,0.012586457,0.000031142947,0.0012409635,0.9267356],"study_design_scores_gemma":[0.05724612,0.019105313,0.5566285,0.0012090906,0.001563513,0.0001247402,0.0002956897,0.000040328054,0.22716483,0.00033732472,0.136101,0.00018349684],"about_ca_topic_score_codex":0.00003079579,"about_ca_topic_score_gemma":0.00002669174,"teacher_disagreement_score":0.92655206,"about_ca_system_score_codex":0.00008742318,"about_ca_system_score_gemma":0.0014940499,"threshold_uncertainty_score":0.26503804},"labels":[],"label_agreement":null},{"id":"W2589251389","doi":"10.1200/jco.2014.32.3_suppl.353","title":"Cost-effectiveness of <i>nab</i>-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Erlotinib; Internal medicine; Nab-paclitaxel; Taxane; Oncology; Clinical trial; Adverse effect; Deoxycytidine; Paclitaxel; Cancer; Breast cancer","score_opus":0.28546473600347544,"score_gpt":0.5416867612353754,"score_spread":0.25622202523189996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589251389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829959,0.0016235408,0.0016382203,0.0028365632,0.0017305358,0.0013352889,0.000016456352,0.0000150099495,0.0078084464],"genre_scores_gemma":[0.9902566,0.002052855,0.005808375,0.000534156,0.00081986416,0.00010332916,0.0000105366535,0.00004304577,0.00037121313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98996234,0.0038772717,0.0041616876,0.00041287445,0.000882646,0.00070318003],"domain_scores_gemma":[0.9670981,0.028261635,0.0023271202,0.0004739536,0.0011118274,0.0007273352],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018221477,0.0003301424,0.005725338,0.00046778106,0.000054852986,0.00000904461,0.0004285215,0.00053044845,0.00038950215],"category_scores_gemma":[0.025891801,0.00024161101,0.00068353105,0.00058323686,0.0008639005,0.00017011208,0.00013834916,0.0018755612,0.00003176848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16854323,0.0057297586,0.7194171,0.0019928347,0.003956752,0.0016606298,0.0005518581,0.0010124862,0.0012571851,0.002497383,0.0021865126,0.09119426],"study_design_scores_gemma":[0.11853097,0.042719718,0.8109356,0.0013807188,0.003130885,0.00035779702,0.0005153241,0.0065962435,0.00019425062,0.0012460947,0.014069225,0.0003231557],"about_ca_topic_score_codex":0.00060495053,"about_ca_topic_score_gemma":0.0004567175,"teacher_disagreement_score":0.09151851,"about_ca_system_score_codex":0.0010927527,"about_ca_system_score_gemma":0.007864198,"threshold_uncertainty_score":0.9977603},"labels":[],"label_agreement":null},{"id":"W2589254732","doi":"10.1200/jco.2016.34.3_suppl.199","title":"Neurocognitive function and psychological distress in young adults (YA) with cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Ontario Clinical Oncology Group; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Neurocognitive; Medicine; Anxiety; Breast cancer; Prospective cohort study; Internal medicine; Cohort; Cancer; Cognition; Psychiatry","score_opus":0.09540269029005828,"score_gpt":0.46111967968886763,"score_spread":0.36571698939880937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589254732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98294973,0.00032508757,0.00024747074,0.012778956,0.0009388033,0.00024740185,0.000009315024,0.000008886626,0.0024943205],"genre_scores_gemma":[0.9943441,0.003364631,0.000103070786,0.0012455956,0.00075085997,0.000016970396,6.09612e-7,0.000010645752,0.0001635314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800295,0.0002539131,0.0010628455,0.00023745006,0.00023678415,0.0002060845],"domain_scores_gemma":[0.9968864,0.0015722326,0.00080432394,0.00006891499,0.00045235828,0.00021581266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000721211,0.00012753435,0.0008878615,0.000098379904,0.00002898,0.0000037430943,0.00004929501,0.00021912888,0.000112114765],"category_scores_gemma":[0.0020866306,0.000063070125,0.00011867252,0.00013075536,0.0004450465,0.000112535105,0.00003468245,0.00066163694,0.0000058057467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03410048,0.0010404582,0.6114113,0.000012410663,0.0001889215,0.0003819266,0.000044531433,3.632508e-7,0.00007367628,0.000011383873,0.0006611547,0.35207343],"study_design_scores_gemma":[0.02372155,0.035338562,0.9376365,0.00080409413,0.00029948063,0.00049087964,0.0001856499,0.0000040053296,0.000012176118,0.00016846895,0.0012584691,0.00008019113],"about_ca_topic_score_codex":0.00002977001,"about_ca_topic_score_gemma":0.00054005755,"teacher_disagreement_score":0.35199323,"about_ca_system_score_codex":0.00013015838,"about_ca_system_score_gemma":0.00017184064,"threshold_uncertainty_score":0.287452},"labels":[],"label_agreement":null},{"id":"W2589265581","doi":"10.1200/jco.2015.33.28_suppl.38","title":"Implantable marker to facilitate use of hypofractionated radiation in early breast cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Mastectomy; Radiation treatment planning; Dose fractionation; Cancer; Surgery; Radiology; Internal medicine","score_opus":0.18298049468540675,"score_gpt":0.43130497781143373,"score_spread":0.24832448312602698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589265581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952158,0.00035082022,0.00007739282,0.0032179055,0.000718799,0.00008456011,0.000084003004,0.0000015480816,0.00024921232],"genre_scores_gemma":[0.99742633,0.0005816853,0.0008015807,0.00060190086,0.0004016047,0.000006596253,0.000006959144,0.0000076227384,0.00016574093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833554,0.00024758145,0.0009794636,0.00014009711,0.00015159487,0.00014574456],"domain_scores_gemma":[0.99836326,0.00025616394,0.00064580684,0.00010575957,0.0004496568,0.00017933804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091889827,0.000088700035,0.00052586733,0.00007297085,0.00001221825,0.0000045975044,0.000095173695,0.00018514617,0.000011771334],"category_scores_gemma":[0.00076977664,0.00007080972,0.00012397218,0.00010718798,0.000066436056,0.000022208427,0.000052843836,0.00017090488,0.0000051679385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010049282,0.00061912683,0.8454646,0.000006181004,0.00039056735,0.000028172331,0.00013073777,0.001146555,0.0019419595,0.0000069659213,0.02898755,0.11122829],"study_design_scores_gemma":[0.0031043792,0.0016110414,0.8972301,0.000017662198,0.00004579426,0.00009469343,0.000055588174,0.000010944033,0.00041876687,0.000037721824,0.09730697,0.00006633958],"about_ca_topic_score_codex":0.0012583013,"about_ca_topic_score_gemma":0.00041963506,"teacher_disagreement_score":0.11116195,"about_ca_system_score_codex":0.00011820902,"about_ca_system_score_gemma":0.0007424273,"threshold_uncertainty_score":0.28875366},"labels":[],"label_agreement":null},{"id":"W2589267164","doi":"10.1200/jco.2015.33.3_suppl.381","title":"Investigating autophagy and glutamine metabolism as therapeutic targets for pancreatic cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); Simon Fraser University; BC Cancer Agency","funders":"","keywords":"Glutamine; Autophagy; Pancreatic cancer; Cancer research; Glutaminase; Asparagine; Cancer cell; Cancer; Medicine; Downregulation and upregulation; Chemistry; Enzyme; Biochemistry; Internal medicine; Apoptosis; Amino acid; Gene","score_opus":0.10852114491460807,"score_gpt":0.44004125979814096,"score_spread":0.3315201148835329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589267164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91399646,0.07724132,0.0008789227,0.002059787,0.005112012,0.00021955822,0.000011859194,0.0000055510777,0.00047452244],"genre_scores_gemma":[0.9513722,0.012742691,0.012040246,0.007580147,0.015217243,0.000036500784,0.000011874772,0.000043840933,0.000955234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979097,0.00026470938,0.0011605964,0.0002307073,0.00017926081,0.0002550273],"domain_scores_gemma":[0.9977165,0.00025086128,0.0010497542,0.00015612169,0.00041204345,0.00041475266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023067507,0.00015667625,0.0009297385,0.000047404083,0.000047941743,0.000015464488,0.00019079543,0.00035737205,0.000012549449],"category_scores_gemma":[0.0035103369,0.00012016426,0.00026655177,0.00006198619,0.0002331038,0.0000119631895,0.000069816706,0.00029054438,0.0000016143595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024519404,0.00056386105,0.0066972068,0.00007297568,0.0013710951,0.000014690405,0.00042458705,0.00015223963,0.09355411,0.001133512,0.03775215,0.85581166],"study_design_scores_gemma":[0.0061848485,0.003505277,0.012431564,0.000020381576,0.00044980165,0.00014171003,0.00014635247,0.00014856533,0.005925534,0.002938754,0.9679373,0.00016989461],"about_ca_topic_score_codex":0.00004222233,"about_ca_topic_score_gemma":0.000053620963,"teacher_disagreement_score":0.93018514,"about_ca_system_score_codex":0.000024335377,"about_ca_system_score_gemma":0.0016056915,"threshold_uncertainty_score":0.49001563},"labels":[],"label_agreement":null},{"id":"W2589267254","doi":"10.1200/jco.2016.34.26_suppl.216","title":"Patterns of symptom control and palliative care-focused original research articles in major radiation oncology journals.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Radiation oncology; Oncology; Clinical Oncology; Family medicine; Cancer; Internal medicine; Radiation therapy; Nursing","score_opus":0.15004643867753528,"score_gpt":0.57775127645295,"score_spread":0.4277048377754147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589267254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96931493,0.004695571,0.0024980486,0.021804268,0.00088229607,0.0002914076,0.000009197708,0.000004322478,0.0004999827],"genre_scores_gemma":[0.980716,0.013246633,0.0033996727,0.0010353356,0.0014887322,0.0000067862766,4.196049e-7,0.000014402203,0.000092025286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994553,0.0020276874,0.0024091385,0.00021255802,0.00044612476,0.00035144697],"domain_scores_gemma":[0.98254603,0.014297864,0.0017286415,0.00015604068,0.0009389329,0.00033247905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007617955,0.00012787686,0.001665327,0.0004422518,0.000051964773,0.0000044243975,0.00017732095,0.0006235745,0.00022930444],"category_scores_gemma":[0.006014201,0.000073050294,0.00022101612,0.00020082435,0.0006591497,0.00017669104,0.000029619945,0.0013203202,0.0000068458035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008099485,0.0006946456,0.56943727,0.00002222453,0.00021192731,0.00045657693,0.0005490063,0.0000031505074,0.002149648,0.00026731877,0.00027689364,0.4178319],"study_design_scores_gemma":[0.043340303,0.027387498,0.85289735,0.00039923264,0.00016023302,0.00027250007,0.00064279104,0.000032280932,0.0006703485,0.0022751791,0.071829155,0.00009314662],"about_ca_topic_score_codex":0.000018941606,"about_ca_topic_score_gemma":0.00013508614,"teacher_disagreement_score":0.41773874,"about_ca_system_score_codex":0.00067741476,"about_ca_system_score_gemma":0.0021719655,"threshold_uncertainty_score":0.7199995},"labels":[],"label_agreement":null},{"id":"W2589269013","doi":"10.1200/jco.2016.34.7_suppl.89","title":"Engagement in a statewide oral oncolytic collaborative and practice impact.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Documentation; Concordance; Best practice; Workflow; Scale (ratio); Quality management; Software deployment; Oncolytic virus; Medical education; Management system; Internal medicine; Cancer; Database; Operations management","score_opus":0.1888759014741328,"score_gpt":0.4700143463514238,"score_spread":0.281138444877291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589269013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9098481,0.0036693935,0.0029781882,0.035050385,0.0018924106,0.00029591972,0.00007562973,0.000007161511,0.046182826],"genre_scores_gemma":[0.98687774,0.00656593,0.0038259448,0.002018452,0.00038682032,0.0000042741367,2.5130552e-7,0.0000139383055,0.00030666575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963258,0.00030223583,0.0028299398,0.00021962723,0.00004413334,0.0002782539],"domain_scores_gemma":[0.99123174,0.004866171,0.003278238,0.00013601754,0.0002170569,0.00027080218],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010992479,0.00012966762,0.0013770094,0.00021519547,0.000030278305,0.000027993723,0.00017306456,0.00023792217,0.00025952002],"category_scores_gemma":[0.019987207,0.000092062684,0.00018134569,0.00015414291,0.0002005899,0.0009254557,0.000063984284,0.00045540812,0.00009406965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008755978,0.002029922,0.42872638,0.000020133955,0.00076176046,0.0005359259,0.0015136062,0.00015843984,0.000035036865,0.07973799,0.020126183,0.45759866],"study_design_scores_gemma":[0.007623335,0.005945706,0.3483125,0.00004964586,0.000027206699,0.00006238154,0.0002880997,0.00004629596,0.0000046674795,0.032030754,0.6054273,0.00018208999],"about_ca_topic_score_codex":0.00013949494,"about_ca_topic_score_gemma":0.00017392616,"teacher_disagreement_score":0.58530116,"about_ca_system_score_codex":0.00057083275,"about_ca_system_score_gemma":0.0010953203,"threshold_uncertainty_score":0.98826784},"labels":[],"label_agreement":null},{"id":"W2589270712","doi":"10.1200/jco.2014.32.3_suppl.420","title":"Predicting the risk of gastrointestinal (GI) toxicity in early colon cancer (CC) patients (pts) treated with adjuvant chemotherapy: Developing a GI toxicity scoring system.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Nausea; Vomiting; FOLFOX; Internal medicine; Toxicity; Gastroenterology; Chemotherapy; Diarrhea; Cancer; Colorectal cancer; Surgery; Oxaliplatin","score_opus":0.05110750467787921,"score_gpt":0.3672165670919757,"score_spread":0.3161090624140965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589270712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962876,0.00005183645,0.0011312185,0.0012388885,0.00035101094,0.00040756084,0.0000041486314,0.000015195694,0.0005125815],"genre_scores_gemma":[0.9960598,0.00012557389,0.0026969332,0.0005133352,0.0005320305,0.0000090596,9.560266e-7,0.000018500696,0.00004383691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964451,0.00052668375,0.0020177935,0.00021552142,0.00047890004,0.00031600008],"domain_scores_gemma":[0.994787,0.0015684175,0.0028354246,0.00018311423,0.0004650352,0.00016101985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034571395,0.0001831739,0.0014298322,0.00015209733,0.0000642153,0.000011543942,0.00022180656,0.00012456947,0.000012469821],"category_scores_gemma":[0.0021703627,0.00010405249,0.00023907844,0.00031798074,0.00016404536,0.0001023557,0.0000646493,0.0008803299,0.000001158669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003943205,0.00070241676,0.96548367,0.00011771939,0.00022761663,0.000046653153,0.00016216359,0.000095004056,0.00003784211,0.000020518883,0.000097107164,0.029066097],"study_design_scores_gemma":[0.018250551,0.009773794,0.96795,0.0016114936,0.00039004034,0.000061298786,0.00022571305,0.0011522132,0.000103744635,0.000010465885,0.00038545812,0.0000852264],"about_ca_topic_score_codex":0.0007906344,"about_ca_topic_score_gemma":0.0008900047,"teacher_disagreement_score":0.028980872,"about_ca_system_score_codex":0.0005214091,"about_ca_system_score_gemma":0.0006372957,"threshold_uncertainty_score":0.42431372},"labels":[],"label_agreement":null},{"id":"W2589270983","doi":"10.1200/jco.2014.32.30_suppl.185","title":"Can we accurately identify chemotherapy-related acute care visits in administrative data?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Neutropenia; Febrile neutropenia; Breast cancer; Emergency department; Internal medicine; Population; Chemotherapy; Cancer; Diagnosis code; Algorithm; Environmental health","score_opus":0.24598069381810936,"score_gpt":0.561255816255799,"score_spread":0.3152751224376896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589270983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94898325,0.0003901951,0.00007086994,0.03873682,0.002090995,0.00025350793,0.000018746197,0.000013963208,0.009441646],"genre_scores_gemma":[0.9940017,0.0014155762,0.0005172444,0.0028436186,0.0008373425,0.0000028954028,0.0000144740625,0.000016393058,0.00035078867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970719,0.00042183604,0.0018354377,0.00023327192,0.00023623135,0.00020128177],"domain_scores_gemma":[0.99697196,0.00090748776,0.001129447,0.00034008347,0.00034843618,0.0003025541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014699202,0.00012755301,0.0011515996,0.00012169482,0.000038224014,0.000014768738,0.0003060769,0.0003543344,0.00026261152],"category_scores_gemma":[0.00096509885,0.00009354831,0.00023091219,0.00022274147,0.00012129461,0.00016800869,0.00006435072,0.0012995681,0.000029664528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008142778,0.0025118163,0.19175659,0.00008750072,0.0020799257,0.0024633838,0.0019884435,0.000025375697,0.0019233733,0.0010103472,0.019608416,0.76840204],"study_design_scores_gemma":[0.02046292,0.016573504,0.5969597,0.00029043254,0.00084814377,0.0013474224,0.00085247227,0.00006851591,0.0005858826,0.0009752203,0.36083367,0.00020208587],"about_ca_topic_score_codex":0.000034477158,"about_ca_topic_score_gemma":0.00073482096,"teacher_disagreement_score":0.7682,"about_ca_system_score_codex":0.00012600646,"about_ca_system_score_gemma":0.0019287539,"threshold_uncertainty_score":0.5646049},"labels":[],"label_agreement":null},{"id":"W2589273581","doi":"10.1200/jco.2011.29.4_suppl.264","title":"Significance and reliability of pathologic marker Ki-67 in patients with neuroendocrine cancers.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; York University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ki-67; Internal medicine; Neuroendocrine tumors; Log-rank test; Cohen's kappa; Kappa; Exact test; Cancer; Gastroenterology; Oncology; Survival analysis; Immunohistochemistry; Statistics","score_opus":0.08523944955156366,"score_gpt":0.4213750308125786,"score_spread":0.33613558126101495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589273581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656373,0.000096840515,0.000006323683,0.0011284796,0.00024135136,0.00033922464,0.000003897938,0.0000049254522,0.0016152107],"genre_scores_gemma":[0.9939805,0.0005138422,0.0047887866,0.00053430087,0.00008688252,0.0000052960477,4.9723354e-7,0.0000131112565,0.00007673455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671555,0.0006023555,0.0017267619,0.00025461963,0.00040655144,0.00029418227],"domain_scores_gemma":[0.9964681,0.0012518035,0.0011800858,0.00024348812,0.00053683703,0.0003196397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011345493,0.00012871364,0.0012223709,0.0001393119,0.000013211514,0.000002007839,0.00016257157,0.000024918303,0.000120534874],"category_scores_gemma":[0.0066351998,0.000079550366,0.00012430798,0.00018583013,0.00065622164,0.00015145326,0.000081147475,0.0010393119,0.0000016584728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017431414,0.0015738189,0.9628058,0.00006558449,0.000023724422,0.0071040182,0.000021004771,0.0000045256143,0.000035491696,0.000010961945,0.00022170518,0.010701931],"study_design_scores_gemma":[0.008455329,0.029458703,0.95858353,0.00006853372,0.00005467637,0.00047244545,0.000036866335,0.000007069931,0.00016695511,0.00030227946,0.0023331917,0.000060441595],"about_ca_topic_score_codex":0.00007379279,"about_ca_topic_score_gemma":0.00006115505,"teacher_disagreement_score":0.027884884,"about_ca_system_score_codex":0.00009688993,"about_ca_system_score_gemma":0.0007808944,"threshold_uncertainty_score":0.79434335},"labels":[],"label_agreement":null},{"id":"W2589275553","doi":"10.1200/jco.2012.30.4_suppl.571","title":"Reasons for and outcomes of adjuvant chemotherapy choices in elderly patients with resected stage III colon cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Capecitabine; Internal medicine; Regimen; Colorectal cancer; Cancer; Oncology; Chemotherapy; Stage (stratigraphy); Adjuvant; Multivariate analysis; Logistic regression; Adjuvant chemotherapy; Oxaliplatin; Surgery; Breast cancer","score_opus":0.08213693468628189,"score_gpt":0.47014696436070275,"score_spread":0.3880100296744209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589275553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947471,0.00172498,0.000006506534,0.0024018437,0.00032309216,0.00039945482,0.00001881869,0.0000024674564,0.00037570874],"genre_scores_gemma":[0.99676955,0.0013593154,0.00095139665,0.00043601988,0.00017393804,0.000020338535,0.0000017282307,0.000009307654,0.000278397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855,0.0000796911,0.00091313885,0.00009468962,0.00017828603,0.00018416779],"domain_scores_gemma":[0.9972002,0.0013083633,0.00094820914,0.000069516915,0.00032135684,0.0001523916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073722634,0.0000983625,0.0013255713,0.00006980972,0.000024735886,0.000002041223,0.000045877314,0.00012741977,0.000033548633],"category_scores_gemma":[0.00067942403,0.000054133772,0.00012369423,0.000080142694,0.00013759203,0.00007979852,0.000016294143,0.0002290684,1.0232218e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014801999,0.001704599,0.88996106,0.000031062104,0.0005085642,0.0000069509742,0.0003017983,4.798039e-7,0.000013645138,0.000014549132,0.00034767078,0.092307635],"study_design_scores_gemma":[0.02556694,0.02526881,0.9318057,0.00008885499,0.0002217993,0.0000032608625,0.00012871425,0.0000029863886,0.000034419438,0.000013415079,0.016816072,0.00004905638],"about_ca_topic_score_codex":0.00019759157,"about_ca_topic_score_gemma":0.0015627582,"teacher_disagreement_score":0.09225858,"about_ca_system_score_codex":0.000115856616,"about_ca_system_score_gemma":0.00036046703,"threshold_uncertainty_score":0.22075112},"labels":[],"label_agreement":null},{"id":"W2589278117","doi":"10.1200/jco.2016.34.7_suppl.18","title":"Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Oncology; Anaplastic large-cell lymphoma; Adverse effect; Chemotherapy; Lymphoma; Hodgkin lymphoma","score_opus":0.1165858313692119,"score_gpt":0.4453076312071934,"score_spread":0.3287217998379815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589278117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600124,0.0008765985,0.00010418815,0.0004701823,0.0012863472,0.00045636378,0.000014358823,0.000006926879,0.00078380917],"genre_scores_gemma":[0.99789613,0.0011968734,0.00024194043,0.00019549395,0.00027411486,0.000020400086,0.0000016502737,0.000018798364,0.00015460498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953558,0.001246682,0.0025272882,0.00023044385,0.00034533857,0.00029448068],"domain_scores_gemma":[0.9838182,0.01340566,0.0018840617,0.00024051222,0.00034491217,0.0003066709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041999873,0.00017011055,0.0020659808,0.0002079579,0.000018113551,0.0000030065794,0.00014887453,0.00042183412,0.00011042591],"category_scores_gemma":[0.0045564305,0.00008482952,0.00044405766,0.0001699672,0.000129459,0.000075252465,0.00005012043,0.00023071062,0.000043503856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058301907,0.043009456,0.67752343,0.000544352,0.0005787133,0.0057207947,0.00009565833,0.000006305156,0.0025818523,0.00014366512,0.0012364754,0.21025737],"study_design_scores_gemma":[0.13789372,0.029284455,0.8169445,0.002562635,0.00044126005,0.0007889329,0.00009289946,0.000019012201,0.0013697941,0.000056947552,0.010435085,0.00011075955],"about_ca_topic_score_codex":0.000018497034,"about_ca_topic_score_gemma":0.000046948007,"teacher_disagreement_score":0.2101466,"about_ca_system_score_codex":0.00095271505,"about_ca_system_score_gemma":0.0026129195,"threshold_uncertainty_score":0.54548025},"labels":[],"label_agreement":null},{"id":"W2589279080","doi":"10.1200/jco.2016.34.2_suppl.606","title":"Accuracy of kidney cancer diagnosis and histological subtype within cancer registry data.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Cancer registry; Chromophobe cell; Kidney cancer; Not Otherwise Specified; Cancer; Nomogram; Population; Medical diagnosis; Pathology; Pathological; Nephrectomy; Cohort; Renal cell carcinoma; Clear cell; Internal medicine; Kidney","score_opus":0.27390759338646015,"score_gpt":0.509607140652033,"score_spread":0.2356995472655729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589279080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9061231,0.0089981835,0.000080000944,0.08047021,0.002716076,0.00017816786,0.00019069125,0.000008532649,0.0012350542],"genre_scores_gemma":[0.9004332,0.07600421,0.002931281,0.017771183,0.0019336537,0.000019702682,0.0000073131578,0.000019587407,0.00087989995],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969789,0.00026085268,0.0020147762,0.00027525326,0.00027848044,0.0001917865],"domain_scores_gemma":[0.9917069,0.0037188812,0.0030285881,0.0004248969,0.0003625204,0.0007582339],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019632925,0.0001303361,0.0014542366,0.00006793175,0.0000273158,0.0000036662898,0.00033159566,0.0003849965,0.0020893742],"category_scores_gemma":[0.022889897,0.000069747926,0.00018924961,0.00007923341,0.00058950536,0.00022744856,0.00014472667,0.00063216296,0.0000032903858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003443321,0.00033475473,0.5071581,0.0000680629,0.00032653476,0.00021323624,0.00004264539,7.8011857e-7,0.00069408567,0.00004527377,0.15488152,0.33279166],"study_design_scores_gemma":[0.008325334,0.0032848634,0.25951537,0.00046429218,0.00053847296,0.00019121631,0.000033615197,0.000029010665,0.00038263726,0.00014130416,0.7269824,0.00011147144],"about_ca_topic_score_codex":0.00027323994,"about_ca_topic_score_gemma":0.00022416943,"teacher_disagreement_score":0.5721009,"about_ca_system_score_codex":0.0002214978,"about_ca_system_score_gemma":0.008153606,"threshold_uncertainty_score":0.99882287},"labels":[],"label_agreement":null},{"id":"W2589283019","doi":"10.1200/jco.2016.34.3_suppl.133","title":"New conditions identified through a comprehensive geriatric assessment in cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Polypharmacy; Dementia; Geriatric oncology; Cohort; Gerontology; Geriatrics; Comorbidity; Malnutrition; Montreal Cognitive Assessment; Mood; Physical therapy; Osteoporosis; Cancer; Prostate cancer; Internal medicine; Pediatrics; Psychiatry; Disease","score_opus":0.15617705221997938,"score_gpt":0.5248704217743216,"score_spread":0.3686933695543423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589283019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516018,0.00031321534,0.0009968509,0.037553005,0.0051467237,0.00033765472,0.000016587439,0.000009994038,0.0040241554],"genre_scores_gemma":[0.98557925,0.0010569372,0.005312964,0.0035256327,0.0014579662,0.000010064797,0.0000037849368,0.000016591173,0.003036804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656975,0.0003211262,0.0023063344,0.00018408369,0.00038482563,0.00023387543],"domain_scores_gemma":[0.9946055,0.002764432,0.0014588519,0.00017292942,0.00068182603,0.0003164902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005678369,0.00011867218,0.0011414144,0.00013655756,0.000021766533,0.0000060863877,0.00014935581,0.0002839396,0.0016895692],"category_scores_gemma":[0.0016029042,0.00007185751,0.00032975525,0.00019163168,0.00013336919,0.0002159381,0.000053263404,0.00070030143,0.000054932014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015190613,0.0035184692,0.53205967,0.0000309505,0.00053320243,0.00066445593,0.00027684012,0.000008270265,0.0005103827,0.00060102186,0.2432496,0.21702808],"study_design_scores_gemma":[0.019128436,0.004892499,0.88164943,0.0002454671,0.00020087435,0.000059636455,0.00006870117,0.000002843088,0.000029744251,0.0014422749,0.09220175,0.000078355064],"about_ca_topic_score_codex":0.00017714809,"about_ca_topic_score_gemma":0.00019400704,"teacher_disagreement_score":0.34958974,"about_ca_system_score_codex":0.00046004186,"about_ca_system_score_gemma":0.0028794492,"threshold_uncertainty_score":0.999223},"labels":[],"label_agreement":null},{"id":"W2589283742","doi":"10.1200/jco.2015.33.29_suppl.1","title":"Symptoms associated with circadian rest-activity rhythm disruption in 237 patients with metastatic colorectal cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Circadian rhythm; Medicine; Actigraphy; Internal medicine; Colorectal cancer; Cancer; Endocrinology; Gastroenterology","score_opus":0.09294871647811138,"score_gpt":0.425740994733562,"score_spread":0.3327922782554506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589283742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958654,0.00012818872,0.000053031068,0.0018257304,0.0010014137,0.00026146937,0.000015782167,0.000009688115,0.00083931786],"genre_scores_gemma":[0.9988281,0.000048321937,0.00011248334,0.00058188057,0.0003150931,0.00001330389,0.000010555862,0.000020812064,0.00006940906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973301,0.0006224271,0.0009878278,0.0001902814,0.000604917,0.00026442946],"domain_scores_gemma":[0.9962341,0.000908937,0.0013645376,0.00011248242,0.00083340204,0.0005465481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021158524,0.00014643496,0.0012760977,0.00014049461,0.000022784308,0.000009753134,0.00008176238,0.00022162197,0.000038204635],"category_scores_gemma":[0.0021278125,0.00009288146,0.0001464973,0.00036415644,0.00019657695,0.00018645734,0.000019679994,0.0009860275,0.0000033648196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015763119,0.0016663043,0.9280327,0.000014943428,0.00038948713,0.00063339586,0.00049270963,0.00006314318,0.000007185315,0.000009433309,0.00026597295,0.052661616],"study_design_scores_gemma":[0.016516093,0.025104191,0.95483553,0.0002740456,0.00038277995,0.00008312781,0.00021196858,0.000080694634,0.0000114377035,0.000034929228,0.0023491236,0.00011604896],"about_ca_topic_score_codex":0.0006096293,"about_ca_topic_score_gemma":0.028276866,"teacher_disagreement_score":0.05254557,"about_ca_system_score_codex":0.0009094738,"about_ca_system_score_gemma":0.003123523,"threshold_uncertainty_score":0.98945457},"labels":[],"label_agreement":null},{"id":"W2589285052","doi":"10.1200/jco.2013.31.6_suppl.141","title":"Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Prostate; Genitourinary system; Toxicity; Hormonal therapy; Urology; Surgery; Cancer; Internal medicine","score_opus":0.13186805803046636,"score_gpt":0.5112920681895393,"score_spread":0.37942401015907296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589285052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95325637,0.0035927666,0.0003752064,0.03869636,0.0021886255,0.0012565766,0.000023589086,0.00002231274,0.00058821414],"genre_scores_gemma":[0.8902575,0.060979612,0.0057185176,0.006972919,0.0031517898,0.00032642815,0.000042211082,0.000093713665,0.032457337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654806,0.00031539524,0.0019608275,0.00027859482,0.00045984407,0.00043725577],"domain_scores_gemma":[0.99295557,0.0031156763,0.0018913081,0.0002188005,0.0012592588,0.000559419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017252051,0.00020611183,0.0015407897,0.00018162672,0.00016235068,0.000025587562,0.00015330433,0.00042041193,0.0028749425],"category_scores_gemma":[0.0014796825,0.00012576928,0.000710307,0.00012882114,0.00023757364,0.00040730965,0.000034431796,0.0011132644,0.00010556277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00675449,0.0011853313,0.6686349,0.00004063261,0.0012872802,0.00009333433,0.000046368128,0.000018653218,0.00034507515,0.0000059931976,0.017193103,0.30439484],"study_design_scores_gemma":[0.019731043,0.007953185,0.76318073,0.000053253752,0.00035867334,0.00016413436,0.000037234444,0.00014231578,0.00018099455,0.00021952183,0.20785876,0.00012015458],"about_ca_topic_score_codex":0.00023358816,"about_ca_topic_score_gemma":0.00007854097,"teacher_disagreement_score":0.30427468,"about_ca_system_score_codex":0.0012330569,"about_ca_system_score_gemma":0.0020546257,"threshold_uncertainty_score":0.99803656},"labels":[],"label_agreement":null},{"id":"W2589286168","doi":"10.1200/jco.2016.34.2_suppl.168","title":"Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Cabazitaxel; Internal medicine; Prostate cancer; Docetaxel; Prednisone; Taxane; Post-hoc analysis; Discontinuation; Oncology; Chemotherapy; Placebo; Androgen deprivation therapy; Gastroenterology; Urology; Cancer; Androgen receptor; Breast cancer; Pathology","score_opus":0.08113460230896853,"score_gpt":0.45225686761719075,"score_spread":0.37112226530822223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589286168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418104,0.000463583,0.000019730274,0.004290458,0.00016631771,0.0005562771,0.00026526718,0.000003839545,0.000053461536],"genre_scores_gemma":[0.9958575,0.0027127822,0.00036760583,0.0002121763,0.0000836554,0.00006260818,0.000023150906,0.000020287758,0.00066027005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996344,0.00040085957,0.0020566385,0.00027464068,0.0005707087,0.00035315874],"domain_scores_gemma":[0.99640566,0.000685161,0.0013740571,0.00023149652,0.0009677953,0.00033584802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008227405,0.00021659974,0.0018769474,0.00046979653,0.000023085186,0.000010203041,0.0001032353,0.00012431003,0.00041453989],"category_scores_gemma":[0.00018215652,0.000097484575,0.00040401265,0.00040700502,0.0002499742,0.00017571093,0.000025805717,0.000256842,0.0000061060377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06913686,0.0034622613,0.8242419,0.00005260062,0.005284336,0.0011703129,0.00042691763,0.000031850483,0.00046711517,0.0000026318555,0.000033342152,0.09568989],"study_design_scores_gemma":[0.036807206,0.048452485,0.90953726,0.00028203498,0.0035322134,0.000011712248,0.00012463398,0.000023368264,0.00038112278,0.000011613229,0.0007313021,0.00010505361],"about_ca_topic_score_codex":0.00033486224,"about_ca_topic_score_gemma":0.0038218957,"teacher_disagreement_score":0.09558483,"about_ca_system_score_codex":0.000771862,"about_ca_system_score_gemma":0.0018286057,"threshold_uncertainty_score":0.45389208},"labels":[],"label_agreement":null},{"id":"W2589298233","doi":"10.1200/jco.2016.34.3_suppl.161","title":"Development and evaluation of the TrueNTH-Prostate Cancer Canada electronic Library for Improved (urinary and bowel) Function post Treatment (TrueNTH-PCC-eLIFT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Brachytherapy; Prostate cancer; Prostatectomy; Quality of life (healthcare); Cancer; Family medicine; Radiation therapy; Internal medicine; Nursing","score_opus":0.06707393764000007,"score_gpt":0.39232577570213784,"score_spread":0.32525183806213775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589298233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784569,0.003038096,0.000009141961,0.016826576,0.0008517358,0.00056913815,0.00003134391,0.0000029069222,0.00021413402],"genre_scores_gemma":[0.99214286,0.0042621796,0.0004277323,0.0024332695,0.00030779603,0.000033583,0.000004986322,0.000014062758,0.00037352764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979939,0.00020098065,0.0011010322,0.00016809734,0.0003385277,0.00019749407],"domain_scores_gemma":[0.9976408,0.00066671753,0.00092893926,0.000112023736,0.0004787447,0.0001727794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001667126,0.000117399664,0.0005955555,0.000044890076,0.00006082045,0.000004254881,0.000060214257,0.00012142459,0.00015330547],"category_scores_gemma":[0.00048961735,0.000057985424,0.000127724,0.000041858566,0.000106397754,0.00014311854,0.0000319163,0.00017413861,1.5005249e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010145247,0.0002851446,0.024192961,0.00004172882,0.0005733981,0.0000062100135,0.00012375631,0.0000030227532,0.00293799,0.000028456425,0.0024388798,0.9592232],"study_design_scores_gemma":[0.019438602,0.011439136,0.45233902,0.000115328534,0.0008401261,0.0000814628,0.00014810845,0.00022699682,0.002373923,0.0001747676,0.51272297,0.0000995457],"about_ca_topic_score_codex":0.001547578,"about_ca_topic_score_gemma":0.031265974,"teacher_disagreement_score":0.9591237,"about_ca_system_score_codex":0.0012518251,"about_ca_system_score_gemma":0.023998098,"threshold_uncertainty_score":0.9864109},"labels":[],"label_agreement":null},{"id":"W2589298977","doi":"10.1200/jco.2014.32.4_suppl.396","title":"Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Pazopanib; Temsirolimus; Sunitinib; Renal cell carcinoma; Sorafenib; Nephrectomy; Bevacizumab; Internal medicine; Urology; Oncology; Surgery; Gastroenterology; Kidney; Chemotherapy; Discovery and development of mTOR inhibitors; Hepatocellular carcinoma","score_opus":0.0559746623152129,"score_gpt":0.3418407938285052,"score_spread":0.28586613151329227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589298977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917616,0.00053816615,0.00027005916,0.0025782583,0.001284032,0.0006436347,0.0008538228,0.000011820627,0.0020585952],"genre_scores_gemma":[0.98110265,0.0000439223,0.014956866,0.0014040489,0.0016184078,0.000017209104,0.00070224603,0.000051266452,0.000103412225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919158,0.001906884,0.0036488296,0.0007566533,0.001261798,0.00051000994],"domain_scores_gemma":[0.98511726,0.00914171,0.003435614,0.0008072761,0.00086847064,0.0006297019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030451752,0.00048122628,0.002180397,0.00024965362,0.00008842585,0.000044118187,0.0006849437,0.00024922288,0.000276433],"category_scores_gemma":[0.002875229,0.00027959817,0.00056346046,0.00024290792,0.00052667677,0.0003162712,0.00022678236,0.0017541687,0.00005023156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0779542,0.010782753,0.8738442,0.000033998233,0.0014986714,0.0041779215,0.0009120181,0.0002748823,0.0017481456,0.000022953722,0.01688456,0.011865694],"study_design_scores_gemma":[0.055438135,0.015322442,0.9081,0.00012898685,0.0023490482,0.00008867993,0.0003972389,0.00023032867,0.005852335,0.00012160295,0.011673159,0.00029804336],"about_ca_topic_score_codex":0.0022222823,"about_ca_topic_score_gemma":0.0005585886,"teacher_disagreement_score":0.034255803,"about_ca_system_score_codex":0.0006963637,"about_ca_system_score_gemma":0.0022622966,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W2589300439","doi":"10.1200/jco.2012.30.4_suppl.361","title":"Predicting survival in resected pancreatic cancer: A Canadian provincial experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Pancreatic cancer; Internal medicine; Cancer; Adenocarcinoma; Adjuvant therapy; Pancreaticoduodenectomy; Surgery; Gastroenterology; Pancreas","score_opus":0.1967810230760642,"score_gpt":0.519809743403157,"score_spread":0.3230287203270928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589300439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777229,0.000781902,0.000013080818,0.0039503663,0.0015622329,0.00031737206,0.00000441923,0.0000072302723,0.015640521],"genre_scores_gemma":[0.99415404,0.0006755363,0.0010263384,0.0007947291,0.002844513,0.000026186404,0.000001622776,0.000014660743,0.00046236286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562377,0.00083640206,0.0021639313,0.00015363785,0.00048692076,0.00073536165],"domain_scores_gemma":[0.9944873,0.0026866475,0.000784853,0.0001704727,0.0004198936,0.0014508736],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0069069825,0.00012882728,0.0018020627,0.0003426323,0.00006709258,0.000006386247,0.00019485077,0.00053259707,0.000692002],"category_scores_gemma":[0.015149367,0.00009294771,0.00022197106,0.0003255719,0.00030839082,0.00018011214,0.00004501695,0.0015595016,0.000015979113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001983726,0.000695335,0.97901183,0.000023044235,0.00015873347,0.000551477,0.0013284384,0.0000013418397,0.00008445851,0.000049881295,0.00088459114,0.015227163],"study_design_scores_gemma":[0.005001864,0.0035469518,0.9774866,0.0001506896,0.00021829217,0.00028523747,0.0009342891,0.00034081048,0.00001509053,0.00004508094,0.0118949795,0.000080091224],"about_ca_topic_score_codex":0.07448814,"about_ca_topic_score_gemma":0.21523151,"teacher_disagreement_score":0.14074336,"about_ca_system_score_codex":0.0009168906,"about_ca_system_score_gemma":0.01250728,"threshold_uncertainty_score":0.9931464},"labels":[],"label_agreement":null},{"id":"W2589306946","doi":"10.1200/jco.2016.34.2_suppl.475","title":"Optimization of an imaging protocol for stage I seminoma surveillance based on variations in relapse location over time.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Stage (stratigraphy); Pelvis; Radiology; Radiation therapy; Surgery; Chemotherapy","score_opus":0.06618603313955984,"score_gpt":0.47550333119328647,"score_spread":0.40931729805372663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589306946","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38904655,0.00008265245,0.46870786,0.018832317,0.00092330185,0.12045882,0.00015027334,0.000058981837,0.0017392494],"genre_scores_gemma":[0.9739548,0.0000022951772,0.02311478,0.00038433014,0.00018679234,0.0022258484,0.0000092399405,0.00001358023,0.00010835465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984098,0.00021960371,0.0010191719,0.00011131784,0.0001532745,0.00008682767],"domain_scores_gemma":[0.99660766,0.0016010834,0.0011410068,0.00013716021,0.00038701377,0.00012606608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011581231,0.00006455395,0.00043034702,0.00009737873,0.000013310274,0.0000028128236,0.00004750781,0.000092295515,0.00011621576],"category_scores_gemma":[0.0044111586,0.000039113915,0.00012912854,0.00008733002,0.000041956693,0.000098675075,0.0000060777015,0.00008908338,0.000002030998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010944901,0.0077373376,0.87609506,0.00009622571,0.00008702717,0.0001149996,0.000014340789,0.016098768,0.00017227644,0.00011270236,0.00039332043,0.088133045],"study_design_scores_gemma":[0.023729071,0.0067368727,0.8448195,0.0002913183,0.000066507,0.00000915607,0.0000029962857,0.123284146,0.000035485482,0.00010513302,0.0008724679,0.000047387744],"about_ca_topic_score_codex":0.0000060558796,"about_ca_topic_score_gemma":0.0000058804853,"teacher_disagreement_score":0.58490825,"about_ca_system_score_codex":0.00013035856,"about_ca_system_score_gemma":0.000945259,"threshold_uncertainty_score":0.52808875},"labels":[],"label_agreement":null},{"id":"W2589310309","doi":"10.1200/jco.2016.34.2_suppl.49","title":"Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Cohesin; Prostate cancer; Biochemical recurrence; Medicine; Prostate; Prostatectomy; Oncology; Cancer; Cancer research; Internal medicine; Radiation therapy; Biology; Chromosome; Genetics; Gene","score_opus":0.11107115885498087,"score_gpt":0.47017768866776877,"score_spread":0.3591065298127879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589310309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914765,0.00018135639,0.000053253953,0.005182206,0.0020570448,0.0004279582,0.00003504789,0.0000024112883,0.00058424415],"genre_scores_gemma":[0.99649066,0.0012587236,0.0014503719,0.00035482744,0.00031247793,0.0000152071125,5.865209e-7,0.000011504499,0.000105623345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583286,0.0007378462,0.0027127815,0.00014914127,0.0003787607,0.00018863712],"domain_scores_gemma":[0.9917859,0.0044741426,0.002724827,0.00020791992,0.0006655704,0.00014168496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021707562,0.00011315634,0.0010817244,0.000074381234,0.00001794086,0.0000023200569,0.00024047201,0.00020651706,0.0004387704],"category_scores_gemma":[0.012577507,0.00005554479,0.0002973498,0.00020964848,0.0007081703,0.000049958147,0.00008056695,0.0006161838,0.0000056157746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016058494,0.00061479514,0.92868656,0.00004229869,0.000112973765,0.000013965568,0.00023935967,0.00004062232,0.0015567521,0.000036063815,0.0034223231,0.06362845],"study_design_scores_gemma":[0.0045522116,0.0044275923,0.98188263,0.0008010725,0.00022844484,0.000054597145,0.000044118904,0.000078386496,0.0021634928,0.00085324264,0.004852081,0.0000621387],"about_ca_topic_score_codex":0.00008248706,"about_ca_topic_score_gemma":0.000518638,"teacher_disagreement_score":0.06356631,"about_ca_system_score_codex":0.00019667987,"about_ca_system_score_gemma":0.0026761952,"threshold_uncertainty_score":0.99574},"labels":[],"label_agreement":null},{"id":"W2589310540","doi":"10.1200/jco.2014.32.3_suppl.404","title":"Impact of colonoscopically missed cancers on patient outcomes.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Institute for Clinical Evaluative Sciences; Mount Sinai Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Colonoscopy; Proportional hazards model; Cancer; Internal medicine; Hazard ratio; Retrospective cohort study; Colorectal cancer; Population; Logistic regression; Comorbidity; Cohort; Surgery; Confidence interval","score_opus":0.10535328306562776,"score_gpt":0.48329725855898115,"score_spread":0.3779439754933534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589310540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071085,0.000039531194,0.00023771948,0.0026987048,0.0012273259,0.00010718236,0.0000014451003,0.0000076139568,0.0049696146],"genre_scores_gemma":[0.9961537,0.00003614771,0.0011397952,0.0022287027,0.00036743243,0.0000016751534,4.5797532e-7,0.000008751582,0.00006331644],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975966,0.00026797917,0.0015605015,0.00011893626,0.00031001857,0.00014591397],"domain_scores_gemma":[0.9956959,0.0019496796,0.0014865047,0.00015095931,0.00039868205,0.00031827472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012078853,0.00009890564,0.0012539071,0.000108062464,0.00001897303,0.0000027389344,0.000082100065,0.00025144455,0.00009861213],"category_scores_gemma":[0.0057796254,0.00006117087,0.00073368516,0.00010633281,0.000107219144,0.000029442079,0.000017015831,0.00065294566,0.0000065208333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06980052,0.0014005171,0.41603857,0.000021085081,0.00064627005,0.00007267064,0.000104612765,0.00055050955,0.00044447015,0.000037288548,0.007920188,0.5029633],"study_design_scores_gemma":[0.005093963,0.21730362,0.76229584,0.00007727325,0.00012448076,0.000056477627,0.000012942109,0.00024385453,0.00021530912,0.00006692619,0.014459574,0.000049768056],"about_ca_topic_score_codex":0.00016836298,"about_ca_topic_score_gemma":0.000050851308,"teacher_disagreement_score":0.50291353,"about_ca_system_score_codex":0.0004260494,"about_ca_system_score_gemma":0.0017240023,"threshold_uncertainty_score":0.69191694},"labels":[],"label_agreement":null},{"id":"W2589310911","doi":"10.1200/jco.2014.32.3_suppl.416","title":"Pretreatment rectal tumors quantitative dynamic contrast-enhanced MRI characterization and predictability of outcome: Pilot study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Dynamic contrast-enhanced MRI; Colorectal cancer; Dynamic contrast; Perfusion; Imaging biomarker; Radiology; Flip angle; Magnetic resonance imaging; Nuclear medicine; Oncology; Internal medicine; Cancer","score_opus":0.12070389454352778,"score_gpt":0.4841613137394097,"score_spread":0.3634574191958819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589310911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891034,0.00006211491,0.004836256,0.0041755782,0.00084491115,0.00072196743,0.00001372073,0.000009777557,0.00023230129],"genre_scores_gemma":[0.99599856,0.00054098706,0.0028470105,0.00033106413,0.00019806427,0.000017660674,0.000004826866,0.000014545083,0.000047297966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954265,0.0009405352,0.0028611221,0.0002448918,0.00036340457,0.00016356239],"domain_scores_gemma":[0.9921311,0.0042860736,0.0025322398,0.00020790282,0.00058529485,0.0002573764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004078751,0.00014777885,0.0018688338,0.00010171996,0.000023700022,0.000005238286,0.00010256561,0.00013070318,0.00008067012],"category_scores_gemma":[0.005353853,0.00010547897,0.00017396697,0.0001173098,0.00030552124,0.00011497657,0.000042940952,0.00052298047,0.0000026095224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008629522,0.007517083,0.9486305,0.00008186474,0.0004458096,0.00003194969,0.00047441048,0.00000808371,0.0032088123,0.000041026,0.000055473683,0.030875446],"study_design_scores_gemma":[0.009012363,0.12685993,0.8620123,0.000119815806,0.000501166,0.00003486306,0.00020473033,0.0004795226,0.00028984426,0.000067049274,0.00035313732,0.000065273576],"about_ca_topic_score_codex":0.000027941735,"about_ca_topic_score_gemma":0.0001773505,"teacher_disagreement_score":0.11934285,"about_ca_system_score_codex":0.0002198841,"about_ca_system_score_gemma":0.00042877207,"threshold_uncertainty_score":0.6409449},"labels":[],"label_agreement":null},{"id":"W2589314330","doi":"10.1200/jco.2013.31.31_suppl.39","title":"Patterns of referral to palliative care in clinical practice in patients with stage IV non-small cell lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Referral; Internal medicine; Lung cancer; Stage (stratigraphy); Cohort; Population; Palliative care; Proportional hazards model; Performance status; Cancer; Family medicine","score_opus":0.2242920015848983,"score_gpt":0.5562161358366517,"score_spread":0.3319241342517535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589314330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459994,0.00067746313,0.000088909655,0.001792649,0.00058772374,0.00060578616,0.00002157224,0.0000024091312,0.0016235198],"genre_scores_gemma":[0.9866523,0.0018528244,0.008909813,0.0020796522,0.00035285935,0.000014005979,0.0000058364826,0.000019368776,0.00011333065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947247,0.0006978271,0.0035941254,0.00025077973,0.00045064508,0.00028193658],"domain_scores_gemma":[0.9898148,0.0048677013,0.0028537598,0.00021772347,0.0018798602,0.00036615838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018556061,0.00017337708,0.0020006315,0.0001971815,0.000009722962,0.000004035059,0.00021824069,0.00039590138,0.00010811126],"category_scores_gemma":[0.0066393344,0.000119197335,0.00026106657,0.0002245239,0.00009165434,0.00017341156,0.00007906874,0.0013608454,0.000007075011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065700235,0.0021839216,0.9672971,0.00018262076,0.00017396742,0.00016220074,0.0038307575,0.00007193697,0.000008342511,0.000002867995,0.0005653579,0.018950947],"study_design_scores_gemma":[0.014657626,0.019359916,0.948822,0.0015674271,0.00020079013,8.507567e-7,0.0049314024,0.000031886102,0.00007487001,0.000004204738,0.010237226,0.00011176086],"about_ca_topic_score_codex":0.0011987102,"about_ca_topic_score_gemma":0.0018187073,"teacher_disagreement_score":0.018839186,"about_ca_system_score_codex":0.0002760217,"about_ca_system_score_gemma":0.0014905912,"threshold_uncertainty_score":0.7948383},"labels":[],"label_agreement":null},{"id":"W2589320867","doi":"10.1200/jco.2005.23.16_suppl.3588","title":"Conformal therapy improves the therapeutic index in patients treated with radiation therapy and concurrent chemotherapy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Bolus (digestion); Cancer; Internal medicine; Surgery; Urology","score_opus":0.06420769399215841,"score_gpt":0.3866131618159838,"score_spread":0.3224054678238254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589320867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899162,0.0019594254,0.0000074030113,0.007172157,0.00014361266,0.00035227445,7.305827e-7,0.000005546438,0.00044264866],"genre_scores_gemma":[0.9880496,0.004695395,0.000027363709,0.006621475,0.00052964775,0.000004766476,0.0000019307154,0.000011634572,0.000058136728],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982176,0.00020351492,0.0010273413,0.00012256137,0.0002526547,0.00017635923],"domain_scores_gemma":[0.99825436,0.00054492254,0.00074904715,0.00009266461,0.00021652976,0.00014248726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010410672,0.00013804155,0.0007252209,0.00008666339,0.000035240348,0.000012608289,0.00009415314,0.00017943786,0.00005145559],"category_scores_gemma":[0.00008221713,0.0000629089,0.00015913387,0.0001279927,0.00022243144,0.00012706405,0.0000097642205,0.00063428393,0.0000016340417],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072615775,0.0006857281,0.41070324,0.0000017442798,0.00011055086,0.0000066468333,0.00017584936,0.0000012940242,0.000059567137,0.000018826779,0.00005398112,0.580921],"study_design_scores_gemma":[0.026149934,0.02213198,0.9115276,0.000018903453,0.000030827505,0.000043630695,0.000059408536,0.0003169578,0.00015910869,0.000025628884,0.039465044,0.0000710151],"about_ca_topic_score_codex":0.000016690821,"about_ca_topic_score_gemma":0.000030628766,"teacher_disagreement_score":0.58085,"about_ca_system_score_codex":0.00007465092,"about_ca_system_score_gemma":0.00039164166,"threshold_uncertainty_score":0.27556834},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2589324897","doi":"10.1200/jco.2014.32.30_suppl.22","title":"Cost of treatment failure in patients with chronic lymphocytic leukemia: Results of a large U.S. observational study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Observational study; Hematologic malignancy; Malignancy; Internal medicine; Incidence (geometry); Retrospective cohort study; Leukemia","score_opus":0.15912669978009505,"score_gpt":0.46339520996889483,"score_spread":0.30426851018879975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589324897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798816,0.000057279885,0.000047215945,0.00041659863,0.00019295797,0.0008051301,0.000018202649,0.0000040877667,0.00047039182],"genre_scores_gemma":[0.9982658,0.00007889595,0.0009510037,0.00015641242,0.00036060158,0.00001147631,0.000016560778,0.000019891444,0.00013937676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432445,0.00065753167,0.0034981067,0.0002625783,0.0009024519,0.0003548832],"domain_scores_gemma":[0.99229723,0.003608589,0.002321113,0.00040609567,0.0010784302,0.0002885152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004282927,0.00018154722,0.002062896,0.0002478589,0.000021295897,0.0000034802124,0.00024186134,0.00033970032,0.000057223897],"category_scores_gemma":[0.005206822,0.00011313627,0.00029054147,0.00035569232,0.00027078594,0.00010272314,0.00007901848,0.00054523424,0.0000070026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.057932477,0.00986218,0.8907945,0.00021110725,0.0011846112,0.00034773676,0.00064937153,0.0032752804,0.000039618222,0.00012821928,0.0018480129,0.033726852],"study_design_scores_gemma":[0.27782804,0.098186195,0.6110327,0.00027625315,0.0002673063,0.000045118326,0.00012178816,0.0041407687,0.00005404093,0.00002856894,0.007937155,0.000082060986],"about_ca_topic_score_codex":0.0005588081,"about_ca_topic_score_gemma":0.0023005814,"teacher_disagreement_score":0.27976185,"about_ca_system_score_codex":0.057490345,"about_ca_system_score_gemma":0.09610898,"threshold_uncertainty_score":0.9461278},"labels":[],"label_agreement":null},{"id":"W2589328609","doi":"10.1200/jco.2014.32.30_suppl.75","title":"Quality care and patient involvement in their care: Preferences for transitioning cancer follow-up care to the community.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Referral; Psychosocial; Survivorship curve; Family medicine; Population; Anxiety; Cancer; Specialty; Breast cancer; Internal medicine; Psychiatry","score_opus":0.18558919122045822,"score_gpt":0.4703344764592948,"score_spread":0.2847452852388366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589328609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868331,0.0045770044,0.00017207832,0.005395098,0.00172749,0.00043460247,0.000037147704,0.000004454889,0.00081899913],"genre_scores_gemma":[0.99326974,0.00038339957,0.00025542796,0.0055423127,0.00046535008,0.00005679603,0.00001034404,0.00000921973,0.0000074287577],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99717504,0.0011435089,0.0011660353,0.00012515554,0.00022166948,0.00016859367],"domain_scores_gemma":[0.9963091,0.0020865293,0.00046867755,0.0001936511,0.00075096404,0.00019107136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017734019,0.00011106392,0.0008247966,0.000057437668,0.00012308445,0.000012622376,0.00015409676,0.00018036581,0.000014966499],"category_scores_gemma":[0.0007816309,0.00006526262,0.00026486893,0.000088101784,0.00009028655,0.000041708576,0.0000464877,0.00079955254,3.4456818e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023001332,0.00011730668,0.09942322,0.0002618484,0.000083366875,0.0000025864817,0.1522531,0.000049190738,0.00001981259,0.00004141925,0.0004550029,0.74499303],"study_design_scores_gemma":[0.007866548,0.020386925,0.28069237,0.0005653826,0.00022055778,0.000007061815,0.44179004,0.000010594956,0.00018484966,0.00025890462,0.24786514,0.00015162301],"about_ca_topic_score_codex":0.0028288977,"about_ca_topic_score_gemma":0.18164313,"teacher_disagreement_score":0.7448414,"about_ca_system_score_codex":0.0002598107,"about_ca_system_score_gemma":0.0006695251,"threshold_uncertainty_score":0.83328974},"labels":[],"label_agreement":null},{"id":"W2589329894","doi":"10.1200/jco.2012.30.5_suppl.422","title":"Improving outcomes through the development of quality indicators in renal cell cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Delphi method; Disease; Multidisciplinary approach; Intensive care medicine; Cancer; Quality (philosophy); Family medicine; Medical physics; Internal medicine","score_opus":0.20895726177201457,"score_gpt":0.520540339531365,"score_spread":0.31158307775935046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589329894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889456,0.0009990501,0.00019377023,0.0036714054,0.0011495462,0.00013305554,0.000002035702,0.000002531376,0.0049029733],"genre_scores_gemma":[0.98590624,0.00022224255,0.009512833,0.0036825289,0.000493659,0.000004173676,8.8070055e-7,0.000008128056,0.00016931687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958125,0.0004179112,0.003085869,0.000097710246,0.0003376933,0.00024832296],"domain_scores_gemma":[0.99512184,0.0019994308,0.002425361,0.0001545613,0.000106505264,0.00019229871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059494604,0.0001015142,0.0012124275,0.00011023825,0.000033855926,0.0000021168132,0.00018781479,0.00022734451,0.0002489867],"category_scores_gemma":[0.00138357,0.000055581084,0.00029866403,0.00017270994,0.00017776666,0.00015005603,0.00006229616,0.0009543425,0.000003137701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096490607,0.0007286981,0.7613408,0.000057290203,0.00014423858,0.000010199919,0.002170269,0.0000057806647,0.0005718732,0.000050132352,0.00049336144,0.23346244],"study_design_scores_gemma":[0.004346304,0.0007235573,0.9105421,0.000036649668,0.00008977721,0.000009994335,0.00063844037,0.000004001907,0.0015513931,0.000025528107,0.08196859,0.00006369493],"about_ca_topic_score_codex":0.00011973613,"about_ca_topic_score_gemma":0.00020405548,"teacher_disagreement_score":0.23339875,"about_ca_system_score_codex":0.00030653097,"about_ca_system_score_gemma":0.0040485365,"threshold_uncertainty_score":0.718193},"labels":[],"label_agreement":null},{"id":"W2589330644","doi":"10.1200/jco.2016.34.7_suppl.238","title":"“It looks good”: How a provincial radiation oncology program benefits from implementing peer review across cancer centers.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Canadian Partnership Against Cancer; Princess Margaret Cancer Centre; University Health Network; Regional Municipality of Durham","funders":"","keywords":"Medicine; Radiation oncology; Thematic analysis; Medical education; Documentation; Family medicine; Quality assurance; Qualitative research; Oncology; Radiation therapy; Internal medicine; Pathology; Computer science; External quality assessment","score_opus":0.12509574454730832,"score_gpt":0.5757427779154524,"score_spread":0.45064703336814405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589330644","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27740833,0.034669854,0.0012710056,0.67083895,0.010007298,0.0018606824,0.00017787896,0.000067504225,0.0036984892],"genre_scores_gemma":[0.27778244,0.4404834,0.0586858,0.15724905,0.053283446,0.00037535853,0.00008660264,0.0001927875,0.0118611185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494034,0.00076832785,0.0026302675,0.00038124816,0.0006488167,0.0006310283],"domain_scores_gemma":[0.9907544,0.003411966,0.0038435792,0.00026798277,0.001273672,0.0004483449],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006611617,0.0002430369,0.002282241,0.00006685975,0.00012995431,0.000012483691,0.0003250029,0.00079243747,0.0009976159],"category_scores_gemma":[0.007514839,0.00014025609,0.0006843063,0.00013394628,0.00046438532,0.0002825997,0.0000967816,0.0011515524,0.00002592259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002181877,0.0012534425,0.086204045,0.000073231546,0.00056863984,0.00027939177,0.00016401213,6.6224067e-7,0.00015776826,0.000032737178,0.06965272,0.83943146],"study_design_scores_gemma":[0.0128133595,0.0124920225,0.062021215,0.0011553125,0.00052047113,0.0002696783,0.00008334796,0.000009651627,0.000057915477,0.00011439744,0.91031283,0.00014978378],"about_ca_topic_score_codex":0.000024394281,"about_ca_topic_score_gemma":0.00069250894,"teacher_disagreement_score":0.8406601,"about_ca_system_score_codex":0.0009545487,"about_ca_system_score_gemma":0.003059694,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W2589339251","doi":"10.1200/jco.2015.33.7_suppl.438","title":"Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Stage (stratigraphy); Systemic therapy; Institutional review board; Retrospective cohort study; Surgery; Internal medicine; Cancer; Kidney","score_opus":0.07012396852517819,"score_gpt":0.38628301924040775,"score_spread":0.31615905071522954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589339251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969973,0.00010696794,0.000009827886,0.00025539182,0.00033788203,0.00083986373,0.000006785295,0.0000030428293,0.0014429421],"genre_scores_gemma":[0.997192,0.000030029589,0.002405246,0.0001719991,0.00007221055,0.0000055341,0.000004245073,0.000017323688,0.000101403144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961342,0.0003795134,0.0021633462,0.00022987029,0.00091340096,0.00017967162],"domain_scores_gemma":[0.9952962,0.00037836653,0.002263058,0.00026622255,0.0013961989,0.00039994504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011355708,0.00018491688,0.0018406162,0.00019447271,0.000016647988,0.0000030416497,0.00012449831,0.00014109476,0.000018865325],"category_scores_gemma":[0.00073382776,0.00010683099,0.0002168521,0.00012088319,0.00020242327,0.000085360356,0.0001283968,0.00040322996,0.0000014464982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012798012,0.016154071,0.96121055,0.00004161051,0.0014985477,0.00043700953,0.00066428096,0.00000387377,0.0000012312069,0.000008222309,0.0002848665,0.0068977117],"study_design_scores_gemma":[0.046882473,0.08251295,0.8679981,0.000059990816,0.001345818,0.000009780149,0.00077226973,0.0000055537653,0.000018441839,0.000030019006,0.0002928901,0.00007166841],"about_ca_topic_score_codex":0.00003932784,"about_ca_topic_score_gemma":0.00003855766,"teacher_disagreement_score":0.09321242,"about_ca_system_score_codex":0.00025582412,"about_ca_system_score_gemma":0.0002545874,"threshold_uncertainty_score":0.43564412},"labels":[],"label_agreement":null},{"id":"W2589343245","doi":"10.1200/jco.2015.33.7_suppl.224","title":"Dose escalation of five-fraction SABR for prostate cancer: Biochemical outcome and toxicity comparison of two prospective trials.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; SABR volatility model; Urology; Radiation therapy; Prostate; Toxicity; Nuclear medicine; Cancer; Internal medicine; Surgery","score_opus":0.3731556804267076,"score_gpt":0.6109997615838767,"score_spread":0.2378440811571691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589343245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929509,0.0015391881,0.0002651625,0.0037245064,0.000487853,0.0008256774,0.000024987605,0.0000037373734,0.00017795604],"genre_scores_gemma":[0.9956631,0.0005448494,0.0029924838,0.000069224,0.0005462976,0.00001816929,0.000006621989,0.000008513077,0.00015071615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650055,0.00034509835,0.0025303555,0.00014470977,0.00033564825,0.00014365611],"domain_scores_gemma":[0.99358535,0.0022721945,0.00252649,0.000088650806,0.0012461672,0.00028113945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005314713,0.000095905954,0.0020071035,0.00010761622,0.000019509924,0.000003883855,0.000059186546,0.000225749,0.000013212126],"category_scores_gemma":[0.0077097286,0.000059969276,0.00030351328,0.000111923844,0.00027741905,0.00009614612,0.000031274743,0.0004551811,4.5460158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050351568,0.002209836,0.8663955,0.0001424356,0.00048026745,0.000009530358,0.0003881975,0.00003121905,0.009626254,0.000047897545,0.0025188737,0.06779846],"study_design_scores_gemma":[0.122126885,0.05822013,0.70395243,0.00041573375,0.001962322,0.00005753676,0.0010018563,0.0028804268,0.09978401,0.004773182,0.0046243593,0.00020109965],"about_ca_topic_score_codex":0.00006541018,"about_ca_topic_score_gemma":0.000022455826,"teacher_disagreement_score":0.16244301,"about_ca_system_score_codex":0.00028254636,"about_ca_system_score_gemma":0.0013015021,"threshold_uncertainty_score":0.9229822},"labels":[],"label_agreement":null},{"id":"W2589344089","doi":"10.1200/jco.2014.32.4_suppl.265","title":"Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Docetaxel; Prostate cancer; Prednisone; Internal medicine; Corticosteroid; Cancer; Clinical trial; Urology; Gastroenterology; Androgen deprivation therapy","score_opus":0.19438999630608111,"score_gpt":0.5148497195759574,"score_spread":0.32045972326987626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589344089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932661,0.00011404589,0.000014745344,0.0028348141,0.00033410985,0.00040066076,0.0000028661666,0.000008521846,0.0030241567],"genre_scores_gemma":[0.99272823,0.0018014959,0.00039184056,0.00079080864,0.00035416379,0.000008521897,0.00001997995,0.000020524252,0.0038844172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974193,0.00035784137,0.0013728419,0.0001841151,0.00038726832,0.00027866254],"domain_scores_gemma":[0.997724,0.00036952712,0.00088455324,0.00012472908,0.0004637523,0.0004334233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000981535,0.00012876731,0.00095372734,0.00021568051,0.000025098925,0.000010652641,0.00008911515,0.00010050619,0.00017162162],"category_scores_gemma":[0.0004972535,0.000074809235,0.000120528566,0.00033829876,0.00012577772,0.00012752345,0.000027267277,0.0005483209,0.000010012049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01049467,0.001181862,0.8118322,0.000016004988,0.00013485162,0.0001830612,0.00007770931,0.000023606222,0.000020531066,0.00001118024,0.0024525712,0.17357175],"study_design_scores_gemma":[0.034188833,0.014844432,0.92419475,0.00021637377,0.00020112496,0.0000134809015,0.00001470672,0.00028308574,0.00015696722,0.000078211924,0.02573315,0.00007485812],"about_ca_topic_score_codex":0.00072934816,"about_ca_topic_score_gemma":0.0025820332,"teacher_disagreement_score":0.1734969,"about_ca_system_score_codex":0.00039231655,"about_ca_system_score_gemma":0.001589148,"threshold_uncertainty_score":0.30506322},"labels":[],"label_agreement":null},{"id":"W2589352431","doi":"10.1200/jco.2014.32.4_suppl.39","title":"Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) .","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Proportional hazards model; Prostate-specific antigen; Hazard ratio; Urology; Oncology; Internal medicine; Chemotherapy; Docetaxel; Prostate; Cancer; Survival analysis; Androgen deprivation therapy; Confidence interval","score_opus":0.1576559576015668,"score_gpt":0.432733376269414,"score_spread":0.2750774186678472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589352431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511963,0.0007442808,0.0000335866,0.002811574,0.0003047451,0.00069430756,0.000035358196,0.000007610783,0.00024891103],"genre_scores_gemma":[0.9969211,0.0006077748,0.0016241192,0.00012947795,0.000343206,0.00001638035,0.0000428719,0.000029183506,0.00028585762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617106,0.00069875474,0.0018503527,0.00029363506,0.00061497174,0.00037123784],"domain_scores_gemma":[0.99606043,0.0017249378,0.0010156865,0.00018472296,0.0006126619,0.0004015656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023497513,0.00020355228,0.001229041,0.00020624939,0.000063486754,0.000034551475,0.00010205986,0.00017479701,0.00004197259],"category_scores_gemma":[0.0007875879,0.00012917366,0.00010539797,0.00019670345,0.00031950168,0.00020821259,0.000036405116,0.0008220508,0.0000050533786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012011716,0.0009130065,0.97094744,0.00007601388,0.00019618424,0.00011438377,0.00023378378,0.000030838197,0.0001003391,0.000070643546,0.00022784127,0.0150778135],"study_design_scores_gemma":[0.02476741,0.020657487,0.94916236,0.00017347654,0.00017767813,0.0000058597752,0.000059607242,0.000009933048,0.000057272013,0.00040971732,0.004390508,0.00012868411],"about_ca_topic_score_codex":0.00007019036,"about_ca_topic_score_gemma":0.00025583195,"teacher_disagreement_score":0.02178507,"about_ca_system_score_codex":0.00024041285,"about_ca_system_score_gemma":0.000799333,"threshold_uncertainty_score":0.52675486},"labels":[],"label_agreement":null},{"id":"W2589353141","doi":"10.1200/jco.2016.34.2_suppl.99","title":"Early salvage versus adjuvant post-prostatectomy radiation therapy: Long-term results of a large institutional experience.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Androgen deprivation therapy; Salvage therapy; Adverse effect; Prostate cancer; Retrospective cohort study; Radiation therapy; Surgery; Urology; Cancer; Internal medicine; Chemotherapy","score_opus":0.10355559623764192,"score_gpt":0.4567732285528066,"score_spread":0.3532176323151647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589353141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896138,0.0015474171,0.00006811544,0.006149636,0.0017841344,0.00027754446,0.000087959605,0.000008032143,0.00046336112],"genre_scores_gemma":[0.9912575,0.007002891,0.00026840984,0.0007059251,0.00066488486,0.000014251819,0.000011782632,0.000010388235,0.00006396954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971152,0.00019482545,0.001879834,0.00019682542,0.00038714055,0.00022616859],"domain_scores_gemma":[0.9958552,0.0015055661,0.0015577564,0.00019205542,0.00060604856,0.0002833626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012753452,0.0001293363,0.0009212488,0.000111103946,0.000040186915,0.0000051735983,0.000117580166,0.0002142855,0.00014917438],"category_scores_gemma":[0.0021313685,0.000069101574,0.00038509903,0.000101877726,0.0003186273,0.00021141542,0.000032789758,0.0002704869,0.000017357072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053103972,0.003054979,0.50489223,0.0000145493195,0.0005338079,0.0008655103,0.00069358206,0.0000010107619,0.0014752116,0.00015846484,0.0005388046,0.4346679],"study_design_scores_gemma":[0.06266432,0.027806325,0.88913894,0.00019971887,0.00011020054,0.000041375097,0.000044149623,0.0000014194206,0.0024796892,0.00003398192,0.017408526,0.000071331175],"about_ca_topic_score_codex":0.000020986403,"about_ca_topic_score_gemma":0.00002073059,"teacher_disagreement_score":0.43459657,"about_ca_system_score_codex":0.00029018908,"about_ca_system_score_gemma":0.0016170178,"threshold_uncertainty_score":0.286852},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2589353607","doi":"10.1200/jco.2016.34.26_suppl.211","title":"Patterns of radiation therapy technology use in the treatment of bone metastases.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Tomotherapy; Logistic regression; Radiosurgery; Lung cancer; Nuclear medicine; Cancer; Internal medicine","score_opus":0.1674958282562613,"score_gpt":0.47672034799182916,"score_spread":0.30922451973556786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589353607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790853,0.002560806,0.000040000064,0.017816607,0.00022325927,0.00022202548,0.000015001358,0.0000017258701,0.000035261455],"genre_scores_gemma":[0.9552904,0.043876927,0.00026217915,0.0003543837,0.00017254293,0.0000122097335,0.00000102665,0.000005239441,0.000025105726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978376,0.00024915684,0.0015434976,0.000090477486,0.00017868189,0.00010057157],"domain_scores_gemma":[0.9956206,0.002637683,0.0013468263,0.00019804493,0.00014184749,0.000054982982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009583559,0.00007877446,0.001086779,0.00018413925,0.0000065916265,0.0000013143982,0.00006453123,0.0001584167,0.00008674632],"category_scores_gemma":[0.0005299271,0.00003137732,0.00036723085,0.00011332588,0.00009972275,0.000046810812,0.0000060188418,0.000109871966,0.00000152438],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011022043,0.005021778,0.48853773,0.0000030462395,0.00025157398,0.00014072344,0.00006461679,5.9622374e-7,0.00019545287,0.00011807426,0.00016768683,0.5043965],"study_design_scores_gemma":[0.019619025,0.04204926,0.85104316,0.00009178619,0.00028233902,0.000107777356,0.00007581505,8.09079e-7,0.0051103374,0.00020208786,0.0813867,0.00003088874],"about_ca_topic_score_codex":0.00010725961,"about_ca_topic_score_gemma":0.00017993622,"teacher_disagreement_score":0.5043656,"about_ca_system_score_codex":0.00015475255,"about_ca_system_score_gemma":0.00035454787,"threshold_uncertainty_score":0.127953},"labels":[],"label_agreement":null},{"id":"W2589357477","doi":"10.1200/jco.2012.30.34_suppl.266","title":"The Canadian partnership for quality radiotherapy: A model for radiation treatment quality and safety.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Canadian Partnership Against Cancer; Kingston Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"General partnership; Quality assurance; Medicine; Accreditation; Government (linguistics); Alliance; Quality (philosophy); Public relations; Medical education; Business; Political science; Finance","score_opus":0.35022657149718783,"score_gpt":0.6168679655353292,"score_spread":0.26664139403814135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589357477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36979663,0.051766206,0.21942881,0.3403455,0.008315671,0.0051977183,0.000101687685,0.000040133298,0.005007623],"genre_scores_gemma":[0.9088282,0.015083861,0.046853505,0.01883171,0.008081623,0.00009936887,0.000012074115,0.00003519777,0.0021744827],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710697,0.00057932077,0.0016936412,0.00012678606,0.00012781426,0.00036544073],"domain_scores_gemma":[0.9853992,0.012338343,0.0012382377,0.00016665287,0.00024399499,0.000613569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010871066,0.00012140936,0.0010525938,0.000051028237,0.00031757672,0.000007823733,0.000089222915,0.0004509149,0.000009449302],"category_scores_gemma":[0.0041643986,0.000067791705,0.00041349107,0.00004039536,0.00035826737,0.0001103462,0.000003913055,0.00030149904,4.5384783e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022767404,0.0008524512,0.106378324,0.000030760297,0.0008544358,0.0000034924012,0.00086508936,0.00010988337,0.000029402489,0.01710484,0.0053622993,0.8456416],"study_design_scores_gemma":[0.014686664,0.0061421366,0.1348099,0.000009868338,0.00021667952,0.000068749476,0.00009303725,0.0034572363,0.000008899159,0.0035537307,0.8368606,0.00009249671],"about_ca_topic_score_codex":0.0002902555,"about_ca_topic_score_gemma":0.010430358,"teacher_disagreement_score":0.8455491,"about_ca_system_score_codex":0.0010140345,"about_ca_system_score_gemma":0.0030059908,"threshold_uncertainty_score":0.58203846},"labels":[],"label_agreement":null},{"id":"W2589361578","doi":"10.1200/jco.2016.34.26_suppl.251","title":"Differences in perceptions of smoking and second-hand smoke (SHS) in palliative and nonpalliative patients with cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Palliative care; Cancer; Logistic regression; Quality of life (healthcare); Odds ratio; Smoking cessation; Internal medicine; Pathology; Nursing","score_opus":0.09336418960427867,"score_gpt":0.43056492149967923,"score_spread":0.33720073189540056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589361578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747133,0.00039463857,0.000025716181,0.001428504,0.00024085605,0.000116827185,0.000017425808,9.920906e-7,0.00030372976],"genre_scores_gemma":[0.9977111,0.0017632105,0.000080759666,0.00028124024,0.000106275686,0.0000048289244,4.462065e-7,0.0000055625255,0.000046538524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984296,0.00020358527,0.0009221284,0.0001375059,0.00018318243,0.0001239754],"domain_scores_gemma":[0.99736035,0.0014971073,0.00069933385,0.000056939523,0.0002525568,0.00013373018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066569383,0.00008787492,0.000902624,0.00012250751,0.000015250431,0.0000037453383,0.000048233724,0.00016625233,0.00016974802],"category_scores_gemma":[0.00050269964,0.000046686404,0.00005913434,0.00010252307,0.00036729814,0.000088481494,0.000027865002,0.0003822459,1.3637202e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018891471,0.00029132763,0.94952005,0.000030919604,0.00008310913,0.000022683236,0.0015737052,1.7427467e-7,0.000031731695,0.000022793784,0.000016300603,0.04651804],"study_design_scores_gemma":[0.009270513,0.005164178,0.9832299,0.00073942705,0.00007703682,0.000003194708,0.0009943483,0.0000035211303,0.000019122615,0.00015087095,0.00028907918,0.000058805508],"about_ca_topic_score_codex":0.00037546808,"about_ca_topic_score_gemma":0.023593193,"teacher_disagreement_score":0.046459235,"about_ca_system_score_codex":0.000111496156,"about_ca_system_score_gemma":0.0005177346,"threshold_uncertainty_score":0.9942237},"labels":[],"label_agreement":null},{"id":"W2589363967","doi":"10.1200/jco.2016.34.2_suppl.27","title":"Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; McMaster University","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Urinary system; EPIC; Cyberknife; Internal medicine; Quality of life (healthcare); Colorectal cancer; Urology; Cancer; Radiation therapy; Randomized controlled trial; Oncology; Radiosurgery","score_opus":0.2779095632377782,"score_gpt":0.5904249112582566,"score_spread":0.31251534802047837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589363967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401674,0.00065051054,0.000048720623,0.054863926,0.0019321782,0.0011971893,0.000021377757,0.000017415274,0.0011012531],"genre_scores_gemma":[0.9863193,0.0026198963,0.00373015,0.0020806734,0.00074127474,0.00019516799,0.000008743571,0.00003843738,0.004266372],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944761,0.0006511844,0.0033841252,0.0003694113,0.00061057816,0.00050863315],"domain_scores_gemma":[0.98857456,0.006307228,0.0028712612,0.0002504099,0.0015753865,0.00042115926],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0057120193,0.00020364167,0.0017665897,0.00027514997,0.00007044484,0.000008367997,0.00012602624,0.0003876202,0.00022183405],"category_scores_gemma":[0.011858649,0.000106710024,0.00050578057,0.00021996185,0.00026984827,0.00018566436,0.000047849477,0.00085547153,0.000012068375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022149542,0.0024177814,0.401512,0.00003235034,0.00093319255,0.0010930495,0.00025938766,0.000024181094,0.004628363,0.000021186504,0.00533966,0.5615893],"study_design_scores_gemma":[0.12578875,0.064955935,0.57625705,0.0009279613,0.0010818529,0.0007447423,0.00060868525,0.00027229372,0.0029057849,0.0026257655,0.22345886,0.0003723126],"about_ca_topic_score_codex":0.00012975564,"about_ca_topic_score_gemma":0.00021750516,"teacher_disagreement_score":0.561217,"about_ca_system_score_codex":0.0015175327,"about_ca_system_score_gemma":0.0062410384,"threshold_uncertainty_score":0.9993926},"labels":[],"label_agreement":null},{"id":"W2589368456","doi":"10.1200/jco.2016.34.4_suppl.164","title":"Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Vomiting; Chemoradiotherapy; Radiation therapy; Internal medicine; Quality of life (healthcare); Cisplatin; Cancer; Chemotherapy; Fluorouracil; Phases of clinical research; Prospective cohort study; Surgery; Gastroenterology","score_opus":0.24971247968799667,"score_gpt":0.545678619985781,"score_spread":0.29596614029778434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589368456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925365,0.00030361523,0.0021235796,0.0027508046,0.00031079078,0.0019087883,0.00001886992,0.0000061170604,0.000040932715],"genre_scores_gemma":[0.993709,0.000517869,0.0051017217,0.00012674602,0.0004239235,0.000036075853,0.0000012284438,0.000020085832,0.00006330808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99445486,0.0007027116,0.0033498732,0.00024257533,0.0010612159,0.00018877808],"domain_scores_gemma":[0.989352,0.0020524277,0.0051563075,0.0002871417,0.0029964545,0.00015567987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006815793,0.00015867969,0.002383618,0.00027617393,0.000036788337,0.0000025335316,0.0001977391,0.000122287,0.00020014949],"category_scores_gemma":[0.004303952,0.00008853934,0.00033454737,0.00035279465,0.00021135561,0.00011753972,0.00003687907,0.0002263245,1.1970455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18387455,0.015640177,0.4427846,0.00026503275,0.00359749,0.000013723713,0.00092656346,0.0001054937,0.0547627,0.00003000189,0.0014500526,0.2965496],"study_design_scores_gemma":[0.16010451,0.078542426,0.7578753,0.00021903618,0.00072303205,0.000007736962,0.00031291327,0.00013059353,0.001788674,0.00012650205,0.000098618075,0.00007060487],"about_ca_topic_score_codex":0.0001986838,"about_ca_topic_score_gemma":0.00015601546,"teacher_disagreement_score":0.31509075,"about_ca_system_score_codex":0.00038632035,"about_ca_system_score_gemma":0.0013944558,"threshold_uncertainty_score":0.5152544},"labels":[],"label_agreement":null},{"id":"W2589370503","doi":"10.1200/jco.2014.32.4_suppl.222","title":"Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Taxane; Placebo; Cabazitaxel; Internal medicine; Prostate cancer; Regimen; Oncology; Phases of clinical research; Surgery; Clinical trial; Cancer; Breast cancer; Androgen deprivation therapy","score_opus":0.31248239554376095,"score_gpt":0.599375163075988,"score_spread":0.2868927675322271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589370503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94877124,0.00014936997,0.00058204256,0.042623587,0.0010574041,0.00026720008,0.0000010707047,0.000016425922,0.0065316823],"genre_scores_gemma":[0.98273593,0.00069074536,0.005586322,0.008848467,0.0013668154,0.000019897774,0.000032982676,0.000017614228,0.0007012379],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949552,0.001898275,0.0023326657,0.00025720632,0.00027204197,0.0002846215],"domain_scores_gemma":[0.9941141,0.0031341636,0.0018169333,0.00015980516,0.00029638008,0.00047862166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009710211,0.00015630186,0.0013750074,0.00027452759,0.00006129537,0.0000073811198,0.00017899337,0.00061407214,0.0006275432],"category_scores_gemma":[0.0033624552,0.00012444452,0.00015746639,0.00022296415,0.00016459082,0.00013962711,0.000035822522,0.0010741717,0.00006900749],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008946075,0.011816453,0.02764896,0.000017556076,0.0002608945,0.00036710367,0.00078627374,0.0000112579755,0.00064175273,0.0005515048,0.0040755346,0.9448766],"study_design_scores_gemma":[0.07615974,0.047972254,0.08402041,0.00006669946,0.0004093996,0.00019699335,0.000250715,0.00085928926,0.00021863874,0.0019166946,0.7877617,0.0001674882],"about_ca_topic_score_codex":0.000035170822,"about_ca_topic_score_gemma":0.00047346964,"teacher_disagreement_score":0.9447091,"about_ca_system_score_codex":0.00058528315,"about_ca_system_score_gemma":0.0043346076,"threshold_uncertainty_score":0.7689408},"labels":[],"label_agreement":null},{"id":"W2589373985","doi":"10.1200/jco.2014.32.3_suppl.434","title":"Retrospective review of FOLFIRI with or without bevacizumab (bev) for patients (pts) with metastatic colorectal cancer (mCRC): Reviewing a single-center standard clinical practice.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"FOLFIRI; Medicine; Bevacizumab; Colorectal cancer; Internal medicine; Oncology; Surgery; Irinotecan; Cancer; Chemotherapy","score_opus":0.138338448823182,"score_gpt":0.49956616417844557,"score_spread":0.36122771535526355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589373985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342515,0.028686574,0.002026983,0.018371372,0.0026492772,0.006665007,0.00018166125,0.00003566572,0.007131967],"genre_scores_gemma":[0.88918453,0.055080876,0.047530413,0.0067847213,0.0009924948,0.00018131874,0.000011837805,0.0000699843,0.00016382274],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935457,0.0009218222,0.0038525602,0.00043165675,0.00088978454,0.0003584492],"domain_scores_gemma":[0.9844958,0.0046985596,0.0056916485,0.00025282585,0.004485704,0.0003754411],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055228868,0.00032817732,0.004976656,0.000085936685,0.00008740498,0.000011928796,0.00016685908,0.00017500632,0.000112584894],"category_scores_gemma":[0.022813005,0.00016132959,0.00072062586,0.00027914968,0.00046781194,0.00023116823,0.00006251974,0.0007772747,0.0000017716345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16521397,0.007995961,0.4786483,0.0026708704,0.005578656,0.00015927774,0.00019931159,8.7720395e-7,0.000002821708,0.000035190078,0.007112519,0.33238223],"study_design_scores_gemma":[0.06226609,0.38913986,0.08394518,0.019501405,0.011008953,0.0005096119,0.00018903746,0.00002351035,0.000017329676,0.000050499064,0.4330412,0.00030733945],"about_ca_topic_score_codex":0.000017892975,"about_ca_topic_score_gemma":0.00039333652,"teacher_disagreement_score":0.42592868,"about_ca_system_score_codex":0.0007115251,"about_ca_system_score_gemma":0.002347197,"threshold_uncertainty_score":0.98541826},"labels":[],"label_agreement":null},{"id":"W2589375307","doi":"10.1200/jco.2012.30.4_suppl.70","title":"What care is appropriate and necessary for metastatic gastric cancer patients? Results of a RAND/UCLA expert panel.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Dalhousie University","funders":"","keywords":"Medicine; Cancer; Disease; Stage (stratigraphy); Surgery; General surgery; Internal medicine","score_opus":0.16612214346001414,"score_gpt":0.4670250445238959,"score_spread":0.3009029010638818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589375307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97330403,0.012562844,0.00021905226,0.008817573,0.004012198,0.00065445,0.000025563735,0.0000057867665,0.00039851692],"genre_scores_gemma":[0.9780176,0.0121414885,0.00488699,0.0033615627,0.0011928268,0.000017398199,0.000008100644,0.00001633454,0.00035767324],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99728906,0.00015429448,0.0018508194,0.00014267002,0.00030587002,0.00025727565],"domain_scores_gemma":[0.99603933,0.0013378211,0.0017131373,0.00012922034,0.00049414166,0.00028635078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015215742,0.00012911807,0.0013244863,0.00014522762,0.000027205051,0.000010950312,0.0001037017,0.00013147315,0.000052679705],"category_scores_gemma":[0.0013833416,0.00008448503,0.0003716057,0.0001319957,0.00010965596,0.00032315828,0.000056492423,0.0002972632,0.0000010680463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015694184,0.0012542602,0.1982856,0.00034572757,0.000862973,0.000019126346,0.0027321687,0.000002760115,0.00002400628,0.000013248712,0.02256669,0.7581993],"study_design_scores_gemma":[0.08721131,0.018749114,0.586413,0.00051893503,0.0029078964,0.00005048069,0.00744621,0.000065269014,0.00017903323,0.00017324605,0.29606134,0.00022413344],"about_ca_topic_score_codex":0.000038210208,"about_ca_topic_score_gemma":0.000013386069,"teacher_disagreement_score":0.7579751,"about_ca_system_score_codex":0.00008823936,"about_ca_system_score_gemma":0.00032043012,"threshold_uncertainty_score":0.34451994},"labels":[],"label_agreement":null},{"id":"W2589376012","doi":"10.1200/jco.2015.33.7_suppl.212","title":"The impact of time to metastasis on survival in treatment-naïve prostate cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Metastasis; Prostate cancer; Docetaxel; Oncology; Internal medicine; Cancer; Overall survival","score_opus":0.23055821605102628,"score_gpt":0.5569435287405887,"score_spread":0.32638531268956245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589376012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98912674,0.0005716127,4.1675318e-7,0.0063080383,0.00037413382,0.00045688808,0.000031324795,0.0000025041488,0.003128354],"genre_scores_gemma":[0.9949691,0.0017795011,0.00009112989,0.00015833967,0.00031608585,0.000018282024,0.000004955379,0.000015123404,0.0026474453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734694,0.0005123109,0.0012952611,0.00013219447,0.00043425852,0.0002790578],"domain_scores_gemma":[0.99634457,0.0015902878,0.000678103,0.00015629463,0.00070708786,0.000523642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024903135,0.00012664429,0.0011224753,0.00014356182,0.000023569082,0.000006942829,0.00012554233,0.00012045427,0.00011113341],"category_scores_gemma":[0.0021234793,0.000054202057,0.00042427596,0.00022933705,0.00014394867,0.00005411636,0.00003410402,0.00037307854,0.000053739877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04454531,0.004893521,0.5446721,0.000006100397,0.0011678193,0.00021746312,0.00041384733,0.00021816649,0.000048324397,0.0000061851338,0.011809884,0.3920013],"study_design_scores_gemma":[0.0344674,0.16284463,0.7601197,0.00012460577,0.0002916723,0.000013086908,0.00016930181,0.00006156238,0.00040017773,0.00018608927,0.04122024,0.00010154583],"about_ca_topic_score_codex":0.00040376972,"about_ca_topic_score_gemma":0.00012542555,"teacher_disagreement_score":0.39189976,"about_ca_system_score_codex":0.0010888238,"about_ca_system_score_gemma":0.0036308644,"threshold_uncertainty_score":0.6440998},"labels":[],"label_agreement":null},{"id":"W2589381099","doi":"10.1200/jco.2016.34.26_suppl.144","title":"Characteristics of patients with unscheduled versus scheduled visits to outpatient supportive care center (SCC) at a comprehensive cancer center.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Anxiety; Depression (economics); Center for Epidemiologic Studies Depression Scale; Palliative care; Distress; Emergency medicine; Internal medicine; Physical therapy; Psychiatry; Depressive symptoms","score_opus":0.21809383145510977,"score_gpt":0.5143449460754678,"score_spread":0.296251114620358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589381099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576855,0.00021234491,0.000093026414,0.0013086867,0.00174388,0.0003404126,0.00027041658,0.000004846726,0.00025782498],"genre_scores_gemma":[0.99563247,0.00061954174,0.0024035638,0.0008243295,0.0004006107,0.000005686228,0.000026989528,0.00002195717,0.00006482348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659616,0.00026465557,0.0020988479,0.00022684417,0.00053641613,0.00027705033],"domain_scores_gemma":[0.99156857,0.0015038888,0.0025694035,0.00021081757,0.0036747248,0.00047259772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002708192,0.0002017621,0.0018696061,0.00013248244,0.000023394769,0.0000022357979,0.00016177219,0.00025215634,0.0002142091],"category_scores_gemma":[0.0021424473,0.00011204749,0.00037144456,0.00011564319,0.00021046157,0.0000785868,0.00011429942,0.00034092506,0.000015807753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050825365,0.0015144836,0.918316,0.000105376144,0.0007834445,0.00008873808,0.0011169596,0.000001368509,0.00018047834,0.000009379978,0.0005618431,0.02649658],"study_design_scores_gemma":[0.032264173,0.028446406,0.88192683,0.0017314929,0.0004218122,0.0000037673346,0.00048442592,0.0000012179439,0.0011313114,0.0000020770524,0.05346044,0.00012603469],"about_ca_topic_score_codex":0.000013410051,"about_ca_topic_score_gemma":0.00006730256,"teacher_disagreement_score":0.052898597,"about_ca_system_score_codex":0.0004445178,"about_ca_system_score_gemma":0.0007284867,"threshold_uncertainty_score":0.4569164},"labels":[],"label_agreement":null},{"id":"W2589385382","doi":"10.1200/jco.2016.34.2_suppl.456","title":"Predictive models for improved prognostication and selection of neoadjuvant and adjuvant systemic chemotherapy in upper tract urothelial cell carcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nomogram; Lymphadenectomy; Oncology; Internal medicine; Chemotherapy; Cancer","score_opus":0.05183069055577775,"score_gpt":0.3833531651343911,"score_spread":0.33152247457861334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589385382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98978555,0.00084382057,0.006006969,0.0020939475,0.00020668902,0.00087265094,0.00002028076,0.000004281893,0.00016582856],"genre_scores_gemma":[0.99617887,0.001389656,0.00173725,0.00022122978,0.00035915055,0.000025300626,9.360252e-7,0.000015432737,0.00007217503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828154,0.00012717277,0.001168309,0.00017484624,0.00010866418,0.00013949262],"domain_scores_gemma":[0.99779946,0.000910343,0.0007838229,0.000059823917,0.00030067202,0.00014590507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008965118,0.00010625919,0.00086680404,0.00009756275,0.000015589181,0.0000028392976,0.00004062237,0.00023592204,0.000008045701],"category_scores_gemma":[0.00036608856,0.00006116754,0.00012995019,0.00004792608,0.00010758323,0.00012189777,0.000009027315,0.00018695746,2.0803881e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031702213,0.002878782,0.45375827,0.00022108227,0.00024365401,0.000020247608,0.0006261646,0.000009616107,0.06426862,0.000060421477,0.00015658535,0.44605434],"study_design_scores_gemma":[0.06380611,0.057003446,0.858021,0.0004897125,0.0007484884,0.00061900564,0.00017355263,0.006509321,0.009904017,0.0018099673,0.00076731056,0.00014803302],"about_ca_topic_score_codex":0.000023217623,"about_ca_topic_score_gemma":0.000008326502,"teacher_disagreement_score":0.4459063,"about_ca_system_score_codex":0.0001131926,"about_ca_system_score_gemma":0.000759741,"threshold_uncertainty_score":0.24943401},"labels":[],"label_agreement":null},{"id":"W2589397571","doi":"10.1200/jco.2016.34.2_suppl.223","title":"Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Circulating tumor cell; Internal medicine; Docetaxel; Oncology; Cancer; TMPRSS2; Androgen receptor; Clinical endpoint; Urology; Clinical trial; Metastasis; Disease","score_opus":0.12199367474308939,"score_gpt":0.42064032115494554,"score_spread":0.2986466464118561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589397571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661875,0.00021134676,0.00023352636,0.0019696285,0.00013350842,0.0006561021,0.000042125925,0.000007728056,0.00012726268],"genre_scores_gemma":[0.9965578,0.00031538357,0.0020891216,0.000063236934,0.000057211175,0.00003893109,0.000009697351,0.000027339329,0.00084128435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965005,0.00038430968,0.0018053745,0.0002590042,0.0007302044,0.0003205978],"domain_scores_gemma":[0.9957678,0.0010077365,0.0017885591,0.00017887534,0.0009894073,0.00026765137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016292752,0.00021074124,0.0013642954,0.0003653218,0.000043077896,0.000010882069,0.00010414522,0.00014394049,0.000042424595],"category_scores_gemma":[0.00071693637,0.00009215766,0.00014096606,0.00036381814,0.00026741854,0.00030549243,0.000027455557,0.00045159145,0.000002406536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027004104,0.0042528817,0.9249232,0.000077854726,0.0007372288,0.00033010982,0.00024082593,0.00018866165,0.026313972,0.0000029898008,0.00003684275,0.01589132],"study_design_scores_gemma":[0.07055585,0.018605663,0.8979244,0.0017936513,0.00070049585,0.000039974682,0.00013259126,0.000075088254,0.00986371,0.000015044607,0.00015791292,0.00013561502],"about_ca_topic_score_codex":0.00013284748,"about_ca_topic_score_gemma":0.0005357005,"teacher_disagreement_score":0.043551747,"about_ca_system_score_codex":0.00028759977,"about_ca_system_score_gemma":0.0015668505,"threshold_uncertainty_score":0.37580803},"labels":[],"label_agreement":null},{"id":"W2589397635","doi":"10.1200/jco.2015.33.29_suppl.227","title":"Caregiver symptom burden assessment using the Edmonton Symptom Assessment System (ESAS): A preliminary report.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Caregiver burden; Referral; Depression (economics); Distress; Anxiety; Quality of life (healthcare); Family medicine; Physical therapy; Psychiatry; Clinical psychology; Nursing; Internal medicine","score_opus":0.15873571725846303,"score_gpt":0.5022275075827867,"score_spread":0.34349179032432364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589397635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456536,0.001447457,0.0029916614,0.01364832,0.010432198,0.00056048145,0.0000051933794,0.000040431773,0.025220634],"genre_scores_gemma":[0.9902632,0.0001063584,0.0026146222,0.00089742173,0.0053602518,0.0000121978865,0.000005501795,0.00003388577,0.00070656504],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938131,0.0011886971,0.00304031,0.00033358874,0.0012624569,0.00036184836],"domain_scores_gemma":[0.9922336,0.0017486069,0.003093253,0.00061649503,0.001559685,0.00074841577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008884123,0.0002399083,0.001775427,0.00012469439,0.000096986914,0.00003820268,0.00035531123,0.0004994046,0.000047165504],"category_scores_gemma":[0.0009830277,0.00014453886,0.00076768326,0.00020705751,0.0002286102,0.00016762108,0.00017983066,0.0016170637,0.0000056848503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017868223,0.0051546735,0.60753644,0.0010488126,0.006140934,0.08658376,0.011692894,0.0026766602,0.0006555301,0.0035147,0.0858987,0.17122868],"study_design_scores_gemma":[0.019801857,0.03728686,0.41272035,0.002019584,0.0056841336,0.04098048,0.047106154,0.009801217,0.000032438635,0.00026199193,0.4236755,0.0006294153],"about_ca_topic_score_codex":0.0007594729,"about_ca_topic_score_gemma":0.00012659976,"teacher_disagreement_score":0.3377768,"about_ca_system_score_codex":0.0019960976,"about_ca_system_score_gemma":0.008922817,"threshold_uncertainty_score":0.9966957},"labels":[],"label_agreement":null},{"id":"W2589411513","doi":"10.1200/jco.2016.34.4_suppl.702","title":"Utilization and effectiveness of adjuvant chemotherapy (ACT) for colon cancer (CC) in the general population.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Cancer registry; Population; Stage (stratigraphy); Lymphovascular invasion; Internal medicine; Cancer; Colorectal cancer; Proportional hazards model; Logistic regression; Oncology; Surgery; Metastasis; Environmental health","score_opus":0.1607948348665474,"score_gpt":0.5248115717890024,"score_spread":0.364016736922455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589411513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928471,0.0015982664,0.00012275117,0.0046728,0.00031522044,0.00032217224,0.000004608458,0.0000011557217,0.00011591761],"genre_scores_gemma":[0.99523664,0.0037434062,0.00025318292,0.00044154172,0.00026722412,0.000021757125,7.960145e-7,0.0000046187656,0.000030842548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988798,0.00023066743,0.0006365116,0.00007601738,0.00010279121,0.000074237425],"domain_scores_gemma":[0.99692243,0.0023410167,0.0004732119,0.00004736005,0.00018036382,0.000035603956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015554511,0.000055603283,0.000647631,0.000038522598,0.000018839239,0.0000014648199,0.00003664375,0.00009127915,0.000010207776],"category_scores_gemma":[0.0007058929,0.000023633158,0.000119554,0.000053229192,0.00007979459,0.0000365452,0.00000783797,0.00008152233,8.284258e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00889655,0.0008606774,0.57684016,0.00003919874,0.00015516978,0.0000085646325,0.00010943455,0.0000015179995,0.00023375657,0.00015885704,0.00020833555,0.4124878],"study_design_scores_gemma":[0.018321974,0.0072416845,0.9661915,0.00014917424,0.00012614121,0.000017384866,0.0000315907,0.000028019856,0.00019320962,0.000635692,0.007037431,0.00002622761],"about_ca_topic_score_codex":0.0000754554,"about_ca_topic_score_gemma":0.00025761657,"teacher_disagreement_score":0.41246158,"about_ca_system_score_codex":0.00011143048,"about_ca_system_score_gemma":0.00021087517,"threshold_uncertainty_score":0.09637322},"labels":[],"label_agreement":null},{"id":"W2589412640","doi":"10.1200/jco.2016.34.7_suppl.285","title":"The impact of immigration status on cancer outcomes in Ontario, Canada.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Immigration; Demography; Proportional hazards model; Cancer; Cohort; Disadvantaged; Cohort study; Gerontology; Internal medicine","score_opus":0.20241204982325375,"score_gpt":0.5262445612701931,"score_spread":0.32383251144693936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589412640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855391,0.00017685616,0.000009852206,0.012307604,0.00063615927,0.00006893111,0.000004192034,8.4317094e-7,0.0012564992],"genre_scores_gemma":[0.9978792,0.0005297279,0.00006791369,0.0008691261,0.00016478103,0.0000014879954,2.0474883e-7,0.000003565353,0.00048396023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978793,0.00015039282,0.0013617146,0.00007293815,0.00033934735,0.00019625125],"domain_scores_gemma":[0.9961746,0.0022174774,0.0010237313,0.00011062806,0.00028772815,0.00018583715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014840305,0.000070187656,0.00072968344,0.000040108138,0.00001930295,0.0000023661996,0.000097339165,0.000110758854,0.00018026754],"category_scores_gemma":[0.0024124978,0.000027105069,0.00025546277,0.00005823396,0.000078637924,0.00005878875,0.000013327093,0.00044555895,0.0000010513206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031781024,0.00010976597,0.90149325,9.786099e-7,0.0001279621,0.00008880096,0.000041638057,0.00004050095,0.00007515366,0.000031134616,0.008631275,0.08618146],"study_design_scores_gemma":[0.0027637572,0.00553917,0.97362465,0.00012292492,0.000039696846,0.000017052998,0.00007642243,0.000006195716,0.00003817548,0.00012596643,0.017614948,0.000031066727],"about_ca_topic_score_codex":0.9460214,"about_ca_topic_score_gemma":0.9965934,"teacher_disagreement_score":0.0861504,"about_ca_system_score_codex":0.0020013466,"about_ca_system_score_gemma":0.017081967,"threshold_uncertainty_score":0.9884903},"labels":[],"label_agreement":null},{"id":"W2589412941","doi":"10.1200/jco.2016.34.4_suppl.244","title":"Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Olaparib; Germline mutation; Internal medicine; Germline; Oncology; Breast cancer; Cancer; Somatic cell; Mutation; Genetics; Gene","score_opus":0.13143995446246645,"score_gpt":0.4480112141650352,"score_spread":0.3165712597025687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589412941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849457,0.0011540945,0.0001313179,0.009224531,0.0023063074,0.00015655196,0.00001359528,0.000010326036,0.0020575556],"genre_scores_gemma":[0.9909868,0.0036075904,0.0011969605,0.0009566095,0.0028287107,0.0000015398683,0.000001406865,0.000022623368,0.00039772812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945909,0.0004728968,0.0039816233,0.00025796038,0.0004203586,0.00027628732],"domain_scores_gemma":[0.99139374,0.004752395,0.0024399725,0.000300333,0.00063850626,0.00047506925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037469543,0.00019624889,0.0027031782,0.0001250534,0.000033875025,0.000007365078,0.00018274636,0.00041128683,0.000116879375],"category_scores_gemma":[0.006570612,0.0001120221,0.00084669,0.00008255224,0.0005753239,0.00012325872,0.000134529,0.00066483783,0.000015096243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023033512,0.0007937673,0.84782475,0.000068486705,0.0006591734,0.00035434848,0.00005481895,1.6746437e-8,0.0003225078,0.00015083078,0.0023410674,0.14512686],"study_design_scores_gemma":[0.011174146,0.00853561,0.96241105,0.0002734745,0.0007441256,0.00036100962,0.00005115838,0.00000741177,0.000034781664,0.00025414108,0.016034098,0.00011898354],"about_ca_topic_score_codex":0.000012193827,"about_ca_topic_score_gemma":0.000016997235,"teacher_disagreement_score":0.14500788,"about_ca_system_score_codex":0.000075332995,"about_ca_system_score_gemma":0.0008502652,"threshold_uncertainty_score":0.78661114},"labels":[],"label_agreement":null},{"id":"W2589414539","doi":"10.1200/jco.2016.34.2_suppl.e628","title":"Changes in prostate volume during neo-adjuvant hormone therapy and definitive radiotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Radiation therapy; Nuclear medicine; Urology; Radiation oncologist; Context (archaeology); Internal medicine; Cancer","score_opus":0.09752674451489718,"score_gpt":0.41320341723861703,"score_spread":0.31567667272371985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589414539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9463012,0.014043837,0.00001047267,0.03886042,0.0002855206,0.0002786968,0.000006946754,0.00000588138,0.00020700376],"genre_scores_gemma":[0.80700254,0.19005617,0.00071579183,0.0015310051,0.0004470855,0.000017448618,4.5585446e-7,0.000014852829,0.00021462618],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982109,0.00020339864,0.0010067197,0.00018113789,0.00016696149,0.00023085396],"domain_scores_gemma":[0.99790484,0.00085434335,0.0007223586,0.0001055055,0.00015875782,0.00025420185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011321995,0.00012766937,0.0010934288,0.000120310135,0.000022847053,0.000006219902,0.00005427371,0.00014258349,0.00007051312],"category_scores_gemma":[0.00043376232,0.00006606311,0.00014515972,0.000075184485,0.00019166373,0.00008815777,0.000021237422,0.00029995147,0.000004755566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069795605,0.0009216375,0.42181313,0.000009725692,0.00025081262,0.0018208964,0.0002484533,2.9872717e-7,0.0022267604,0.000021599182,0.00044812862,0.565259],"study_design_scores_gemma":[0.026716113,0.022866633,0.9189698,0.00022362926,0.000055154997,0.00048254177,0.0000613228,0.000003846805,0.00079085195,0.00022424343,0.029526139,0.00007973978],"about_ca_topic_score_codex":0.000014718385,"about_ca_topic_score_gemma":0.00005739774,"teacher_disagreement_score":0.5651792,"about_ca_system_score_codex":0.00024011068,"about_ca_system_score_gemma":0.0004200986,"threshold_uncertainty_score":0.26939756},"labels":[],"label_agreement":null},{"id":"W2589426936","doi":"10.1200/jco.2016.34.26_suppl.116","title":"Referral patterns and characteristics of uninsured versus insured patients referred to the outpatient supportive care center (SCC) at a comprehensive cancer center.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Medicaid; Cancer; Palliative care; Internal medicine; Family medicine; Health care; Nursing","score_opus":0.3526135497108783,"score_gpt":0.5316066675536056,"score_spread":0.1789931178427273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589426936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308157,0.000290167,0.000013846282,0.0028256504,0.002755096,0.0002693763,0.0005626521,0.0000034582888,0.00019819404],"genre_scores_gemma":[0.9962897,0.0021575848,0.00016763357,0.0008704212,0.0003971824,0.0000051730453,0.000030488496,0.000015666563,0.00006615596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687845,0.00040423425,0.0018952409,0.00019105372,0.00040740595,0.00022360876],"domain_scores_gemma":[0.9939048,0.0016246687,0.00200009,0.00021048062,0.0019499852,0.00030995256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033719183,0.00016571922,0.0013499373,0.00008728886,0.00002990678,0.0000026375658,0.00015779234,0.00023042035,0.000067101224],"category_scores_gemma":[0.0025103546,0.00008471759,0.00028072242,0.00007188725,0.00021314534,0.000055589415,0.00015777395,0.00033805502,0.0000040762247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018949471,0.0006652312,0.92170715,0.000070010195,0.00045898007,0.000044800014,0.002886624,2.6001663e-7,0.00011546704,0.0000034150635,0.0019881113,0.053110484],"study_design_scores_gemma":[0.014884691,0.012992334,0.84752524,0.0009009049,0.00021476691,0.0000050122394,0.00082132703,7.784439e-7,0.0002698861,0.0000017536344,0.12230588,0.00007740987],"about_ca_topic_score_codex":0.00006261139,"about_ca_topic_score_gemma":0.00031937636,"teacher_disagreement_score":0.120317765,"about_ca_system_score_codex":0.00029264204,"about_ca_system_score_gemma":0.00032926802,"threshold_uncertainty_score":0.3454683},"labels":[],"label_agreement":null},{"id":"W2589427803","doi":"10.1200/jco.2016.72.0003","title":"The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non–Small-Cell Lung Cancer?","year":2017,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; Vrije Universiteit Amsterdam","keywords":"Medicine; Stage (stratigraphy); Radiation therapy; Lung cancer; Lead (geology); Surgery; Oncology; Cancer; Internal medicine","score_opus":0.06324216222387943,"score_gpt":0.4554325500907654,"score_spread":0.392190387866886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589427803","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65353596,0.0019202165,0.00007252454,0.3392147,0.0020257612,0.0029232702,0.0001382148,0.0000063334905,0.00016298605],"genre_scores_gemma":[0.4544187,0.04205594,0.0012030412,0.4735813,0.01653577,0.0015558203,0.00019065425,0.00027633214,0.010182458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644995,0.00064935023,0.0015244832,0.0004945457,0.0004064222,0.00047524928],"domain_scores_gemma":[0.9912621,0.0047850674,0.0023169124,0.0005419596,0.000777908,0.0003160592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027533458,0.0004284696,0.0024802592,0.000073647876,0.0003190946,0.0001262722,0.000300373,0.00075139134,0.000021155896],"category_scores_gemma":[0.00044844917,0.00021387366,0.00046076425,0.00005135219,0.00018357702,0.00018570878,0.00005193873,0.0020425797,0.0000012866232],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07286145,0.0022808728,0.3488926,0.0007216805,0.032085996,0.004255586,0.0008354123,0.000022778046,0.0004667237,0.0000057256884,0.44541436,0.09215681],"study_design_scores_gemma":[0.04628745,0.13390028,0.12194974,0.0005538923,0.0069638826,0.00012651911,0.000039450253,0.00040504607,0.0005121499,0.000007447351,0.6887994,0.0004547711],"about_ca_topic_score_codex":0.000778139,"about_ca_topic_score_gemma":0.0016358456,"teacher_disagreement_score":0.243385,"about_ca_system_score_codex":0.00085796777,"about_ca_system_score_gemma":0.0032536965,"threshold_uncertainty_score":0.8874106},"labels":[],"label_agreement":null},{"id":"W2589428111","doi":"10.1200/jco.2005.23.16_suppl.5566","title":"A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Progressive disease; Cancer; KRAS; Head and neck cancer; Chemotherapy; Cancer research","score_opus":0.054887103285731785,"score_gpt":0.3927872439765381,"score_spread":0.3379001406908063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589428111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974009,0.0018512543,0.0000058688597,0.0001738031,0.0001745002,0.0002902294,0.000017226683,9.548207e-7,0.00008531178],"genre_scores_gemma":[0.998506,0.00031133695,0.00069205865,0.00021733613,0.00020863194,0.0000074947043,0.0000042449105,0.000011049526,0.000041866744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807465,0.00028376654,0.0010735902,0.0002406266,0.00015166965,0.00017572544],"domain_scores_gemma":[0.9986043,0.00017350953,0.000739102,0.000117034935,0.00014923936,0.00021678886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065515854,0.0001452809,0.0007494103,0.0000680229,0.000036101734,0.0000056372774,0.00009045064,0.00013817931,0.000013487379],"category_scores_gemma":[0.00021667109,0.00009516155,0.00005612388,0.000053542066,0.000120131765,0.000011787722,0.000105181134,0.00028040833,1.6605911e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019814402,0.020388346,0.82613397,0.00008715585,0.0001561518,0.0001118426,0.0006429134,0.000014067348,0.0016426147,0.0000044135454,0.0004908031,0.1305133],"study_design_scores_gemma":[0.07044181,0.25501317,0.66619897,0.000035344434,0.00029433417,0.000044887234,0.0002541544,0.00006766581,0.00061376556,0.000010163767,0.0068431995,0.00018255567],"about_ca_topic_score_codex":0.000050560775,"about_ca_topic_score_gemma":0.0015095156,"teacher_disagreement_score":0.23462482,"about_ca_system_score_codex":0.000020994117,"about_ca_system_score_gemma":0.0003476191,"threshold_uncertainty_score":0.38805753},"labels":[],"label_agreement":null},{"id":"W2589445072","doi":"10.1200/jco.2016.34.26_suppl.83","title":"Effect of Edmonton Symptom Assessment Scale (ESAS) on symptom data collection in a radiation oncology department.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Intervention (counseling); Family medicine; Radiation oncology; Scale (ratio); Nursing; Radiation therapy; Internal medicine","score_opus":0.059924984365045335,"score_gpt":0.5581579033081051,"score_spread":0.49823291894305977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589445072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763783,0.0005786887,0.0023654196,0.010079513,0.004112028,0.0006558256,0.000011567451,0.000014014454,0.005804648],"genre_scores_gemma":[0.9820011,0.007296458,0.0068078754,0.0015783155,0.0018515287,0.000020390384,0.000016256881,0.00002564658,0.000402408],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994065,0.0023570477,0.002543642,0.00035236255,0.0003957735,0.00028621673],"domain_scores_gemma":[0.9815715,0.015109983,0.002409678,0.00047085914,0.00019313455,0.00024482596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0090426365,0.00019159139,0.0021060212,0.00031206018,0.000046877387,0.0000027864817,0.00034293273,0.00080354034,0.0001585563],"category_scores_gemma":[0.003810346,0.000109155204,0.00028760463,0.0002447246,0.00038080392,0.00019330291,0.00006932566,0.00088110456,0.0000104227],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017811224,0.0027342252,0.29275608,0.00003202626,0.00034564364,0.00025446992,0.000043171833,0.000019045117,0.0011235442,0.00007990567,0.005084646,0.67971605],"study_design_scores_gemma":[0.04777294,0.16642605,0.5352311,0.0004248318,0.0005641965,0.0006251244,0.000027982822,0.00059640507,0.0010984256,0.0003177343,0.24674046,0.00017473417],"about_ca_topic_score_codex":0.000009663004,"about_ca_topic_score_gemma":0.00011371588,"teacher_disagreement_score":0.6795413,"about_ca_system_score_codex":0.0014454487,"about_ca_system_score_gemma":0.0023853164,"threshold_uncertainty_score":0.6197639},"labels":[],"label_agreement":null},{"id":"W2589446870","doi":"10.1200/jco.2014.32.30_suppl.122","title":"Enabling quality data reporting: National implementation of standardization pathology reporting.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"General partnership; Standardization; Medicine; Vendor; Medical education; Family medicine; Political science","score_opus":0.7814616540568575,"score_gpt":0.7209403295212471,"score_spread":0.06052132453561043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589446870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9109487,0.00005941023,0.06885412,0.01659247,0.0016984475,0.00031397532,0.000029034753,0.00001709378,0.0014867461],"genre_scores_gemma":[0.9499047,0.00014488804,0.045012806,0.0027416567,0.0019658492,0.0000018010558,0.00018482862,0.000017184057,0.000026310776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9617957,0.0017728808,0.034523822,0.00039685523,0.0012886125,0.00022213109],"domain_scores_gemma":[0.8234606,0.016219698,0.15156752,0.0009090434,0.007461676,0.00038150852],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.12730029,0.00012756229,0.0018842596,0.00018633429,0.000053049855,0.0000114922905,0.00024294696,0.00031344342,0.0002453965],"category_scores_gemma":[0.5656924,0.00010411673,0.0003754488,0.00023183259,0.00016568853,0.00045629602,0.00018335503,0.0007954973,0.0000038093967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018010595,0.000802282,0.49462137,0.000083266685,0.0003008781,0.00013369169,0.00010377139,0.0000851677,0.002230999,0.0007352051,0.00749854,0.49160376],"study_design_scores_gemma":[0.010229592,0.006687042,0.8453096,0.00008142295,0.0007438649,0.0012249214,0.0014216028,0.00080801605,0.0006863126,0.0034485043,0.12920754,0.00015156042],"about_ca_topic_score_codex":0.00009484845,"about_ca_topic_score_gemma":0.00015809755,"teacher_disagreement_score":0.4914522,"about_ca_system_score_codex":0.00017150366,"about_ca_system_score_gemma":0.0047220853,"threshold_uncertainty_score":0.898628},"labels":[],"label_agreement":null},{"id":"W2589454492","doi":"10.1200/jco.2016.34.7_suppl.121","title":"Optimizing the collection and reporting of wait time data.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiology practices and education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Data collection; Medicine; Medical physics; Timeline; Consistency (knowledge bases); Workflow; Automatic identification and data capture; Computer science; Data science; Data mining; Database; Artificial intelligence","score_opus":0.4012725870529192,"score_gpt":0.5620485553062461,"score_spread":0.1607759682533269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589454492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372063,0.00033736622,0.00035249264,0.058953363,0.0008391378,0.00006906143,5.1041764e-7,0.0000023910234,0.002239352],"genre_scores_gemma":[0.9845898,0.0014871822,0.011149125,0.000751732,0.0012296813,5.0675794e-7,8.140673e-7,0.0000051589304,0.0007860074],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99697304,0.00028925322,0.0024706956,0.00009184643,0.00009984758,0.00007529938],"domain_scores_gemma":[0.987503,0.004570433,0.007383486,0.00020498844,0.00025013168,0.00008795853],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010837225,0.00003874266,0.00062086387,0.000039341703,0.000037379315,0.0000026661794,0.000089124755,0.00014667575,0.00008055638],"category_scores_gemma":[0.036689125,0.000016712092,0.00008003987,0.000056584697,0.00017127789,0.00015645413,0.000041696207,0.00029948947,0.0000039364304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004081234,0.0007932558,0.33937177,0.000029302511,0.00067497254,0.00015081967,0.00039404482,0.0000058462138,0.0060459604,0.000105367624,0.06211075,0.5862367],"study_design_scores_gemma":[0.0064285104,0.011987837,0.6708814,0.00029157216,0.0012754258,0.008394251,0.00074283447,0.0011346518,0.00028232165,0.0012388177,0.2972447,0.00009771013],"about_ca_topic_score_codex":0.000009741802,"about_ca_topic_score_gemma":0.0000034459076,"teacher_disagreement_score":0.58613896,"about_ca_system_score_codex":0.00003694196,"about_ca_system_score_gemma":0.00076267554,"threshold_uncertainty_score":0.97142524},"labels":[],"label_agreement":null},{"id":"W2589457235","doi":"10.1200/jco.2016.34.26_suppl.7","title":"Patient, family member, and clinician perspectives on advance care planning (ACP) in hematology and hematopoietic stem cell transplantation (HSCT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Advance care planning; Hematopoietic stem cell transplantation; Psychological intervention; Transplantation; Disease; Hematopoietic cell; Family medicine; Internal medicine; Palliative care; Nursing; Haematopoiesis; Stem cell","score_opus":0.19650191360698913,"score_gpt":0.5117386985735223,"score_spread":0.3152367849665332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589457235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97653604,0.01928253,0.00017650054,0.001043307,0.00031542158,0.00012581584,0.000006300535,0.000004813063,0.0025092957],"genre_scores_gemma":[0.97929394,0.018490722,0.0015594857,0.0004858727,0.00012971344,0.0000021931608,7.5881997e-7,0.000010735429,0.000026572587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766284,0.00032931106,0.0014599179,0.00021261147,0.00017295005,0.00016235298],"domain_scores_gemma":[0.9944915,0.0040450613,0.00096305914,0.00009545399,0.00023557113,0.00016935355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006367433,0.0001266902,0.0011924068,0.00014844546,0.000019546702,0.0000024138526,0.000053677606,0.00026735282,0.0000070422243],"category_scores_gemma":[0.0005681913,0.00007963171,0.00013391883,0.00006754467,0.00024572216,0.000092003254,0.000016031336,0.00040967696,0.0000019155398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007668528,0.0007527251,0.79908043,0.0004267627,0.000127735,0.001445453,0.034491975,0.000009435384,0.0007465626,0.00063554506,0.00018262338,0.15443219],"study_design_scores_gemma":[0.039220296,0.05078782,0.6667048,0.011270338,0.0006769804,0.0010192,0.19430105,0.000027146783,0.0051940815,0.0010447907,0.029267631,0.00048587457],"about_ca_topic_score_codex":0.0000058668415,"about_ca_topic_score_gemma":0.000017376677,"teacher_disagreement_score":0.15980908,"about_ca_system_score_codex":0.0000646898,"about_ca_system_score_gemma":0.00022077304,"threshold_uncertainty_score":0.3247287},"labels":[],"label_agreement":null},{"id":"W2589457793","doi":"10.1200/jco.2005.23.16_suppl.8106","title":"Quality of life findings from a multicenter, multinational, observational study of patients with metatstatic hormone-refractory prostate cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Observational study; Prostate cancer; Clinical trial; Physical therapy; Cancer; Palliative care; Internal medicine","score_opus":0.308537723253256,"score_gpt":0.5346520422855282,"score_spread":0.2261143190322722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589457793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960567,0.00095053227,0.000014000376,0.0020178598,0.00016710395,0.0006505212,0.000102559396,0.0000032548742,0.00003750933],"genre_scores_gemma":[0.9951195,0.00060487934,0.0035069236,0.0003806853,0.00019450171,0.000019130595,0.00003327442,0.000013294259,0.00012778271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954771,0.0004729441,0.0026902386,0.00017910209,0.0010124218,0.00016819683],"domain_scores_gemma":[0.99226016,0.0028371653,0.002470212,0.0001418483,0.0020297363,0.0002608605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017500423,0.0001284948,0.0013436659,0.00013085258,0.000031153588,0.000004044114,0.00013783628,0.00012068765,0.0001614191],"category_scores_gemma":[0.0028862336,0.00007780423,0.00020414828,0.00015404879,0.00021639894,0.00021493724,0.000043152246,0.00051997375,0.000002130923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031041007,0.018669879,0.9288972,0.000044560667,0.0014990903,0.000013731458,0.001209408,0.00008117138,0.0002211768,0.0000049322653,0.00054575125,0.017772075],"study_design_scores_gemma":[0.04826394,0.014077054,0.93493545,0.00007037863,0.00032894546,3.5587556e-7,0.000522139,0.00012347825,0.000046344187,0.000022548638,0.001544436,0.00006493642],"about_ca_topic_score_codex":0.00026718693,"about_ca_topic_score_gemma":0.00022322501,"teacher_disagreement_score":0.01770714,"about_ca_system_score_codex":0.00021463205,"about_ca_system_score_gemma":0.0020406463,"threshold_uncertainty_score":0.3620019},"labels":[],"label_agreement":null},{"id":"W2589459531","doi":"10.1200/jco.2016.34.7_suppl.219","title":"Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; McMaster University; Population Health Research Institute; C17 Council; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Consistency (knowledge bases); Medical education; Pathology","score_opus":0.9274298487565293,"score_gpt":0.7784471207702949,"score_spread":0.14898272798623446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589459531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58779556,0.00065994187,0.012357849,0.38991266,0.005630058,0.0017755934,0.00009582073,0.000040736664,0.0017317792],"genre_scores_gemma":[0.82332426,0.009346557,0.07673393,0.06443859,0.021054551,0.00008564815,0.000004056259,0.000108585955,0.004903841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96562994,0.010583399,0.020244831,0.0008482844,0.0018331193,0.0008604026],"domain_scores_gemma":[0.1562248,0.81964386,0.010839673,0.0011048559,0.007272409,0.004914414],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.27173838,0.0003152541,0.005729595,0.0003517525,0.000083345454,0.000014806002,0.000997346,0.0034535385,0.00036551306],"category_scores_gemma":[0.9086342,0.00017218245,0.0024328085,0.0003833946,0.0017057065,0.00023007208,0.00034387683,0.00770504,0.00022157522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0561271,0.0031829844,0.26404157,0.00018245606,0.0017213622,0.00068482326,0.00014209864,0.0000037127793,0.0018052163,0.0134482905,0.17455347,0.48410693],"study_design_scores_gemma":[0.04412625,0.083538555,0.22216053,0.003114385,0.0011413719,0.0002562421,0.0001655869,0.00003836363,0.0015657014,0.12181423,0.5216282,0.00045057564],"about_ca_topic_score_codex":0.0000038951275,"about_ca_topic_score_gemma":0.000037357782,"teacher_disagreement_score":0.80940515,"about_ca_system_score_codex":0.00033922266,"about_ca_system_score_gemma":0.014295676,"threshold_uncertainty_score":0.99784017},"labels":[],"label_agreement":null},{"id":"W2589459789","doi":"10.1200/jco.2014.32.30_suppl.153","title":"Mobile solution for clinical research documentation.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electronic Health Records Systems","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Electronic data capture; Documentation; Medicine; Usability; Clinical trial; Audit; Focus group; Informed consent; Consolidated Standards of Reporting Trials; Electronic data; Medical emergency; Computer science; Alternative medicine","score_opus":0.6694103159742466,"score_gpt":0.7606800889346792,"score_spread":0.0912697729604326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589459789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7290042,0.0030713098,0.090966105,0.046290148,0.06326247,0.007812553,0.000015194282,0.00010112156,0.059476875],"genre_scores_gemma":[0.92049223,0.0044267764,0.023125725,0.008927883,0.03369636,0.00049901305,0.000008053163,0.00006898262,0.008755003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96794254,0.02139771,0.00870498,0.00031211443,0.0006561307,0.0009865436],"domain_scores_gemma":[0.91873306,0.07299751,0.004414138,0.00034205976,0.0027821702,0.00073105586],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15477574,0.000119902375,0.0016854068,0.00020782741,0.0005811336,0.000008232932,0.00045520472,0.001236767,0.0003073125],"category_scores_gemma":[0.048232123,0.00008959088,0.0005372733,0.00022371813,0.00029022273,0.0002137433,0.00010013622,0.0049078516,0.00046387213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021549664,0.00080373563,0.068574935,0.00019766693,0.00010953639,0.000005559866,0.00037296422,0.0000036995525,0.00002508285,0.0040366435,0.441236,0.4824792],"study_design_scores_gemma":[0.0068875626,0.026515791,0.019620024,0.0001456027,0.000042906435,0.000011342951,0.00045847314,0.0007921174,0.0000016754989,0.0072281994,0.9382188,0.00007752938],"about_ca_topic_score_codex":0.00009353123,"about_ca_topic_score_gemma":0.0002695124,"teacher_disagreement_score":0.49698278,"about_ca_system_score_codex":0.0007287294,"about_ca_system_score_gemma":0.009201387,"threshold_uncertainty_score":0.9973879},"labels":[],"label_agreement":null},{"id":"W2589461905","doi":"10.1200/jco.2015.33.29_suppl.104","title":"Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Constipation; Anxiety; Cervical cancer; Psychological intervention; Nausea; Physical therapy; Internal medicine; Cancer; Psychiatry","score_opus":0.11779655644690977,"score_gpt":0.49806590535785406,"score_spread":0.38026934891094427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589461905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241065,0.06808587,0.000036082296,0.004909374,0.00057008915,0.00023906677,0.0000112850375,0.0000036037234,0.0020381648],"genre_scores_gemma":[0.9687188,0.029018685,0.00031758918,0.0016577306,0.00021669717,0.000018178112,0.0000010911075,0.000008617437,0.00004259186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777675,0.00026789642,0.0013943088,0.00013670267,0.00028498302,0.00013934697],"domain_scores_gemma":[0.99700797,0.00028512432,0.0011228436,0.00011027486,0.0011469559,0.00032681174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014213444,0.000090221925,0.0014629961,0.00007289623,0.000008152411,0.0000019086592,0.000080121215,0.00013704812,0.000085170905],"category_scores_gemma":[0.0015215975,0.000059328857,0.0001878486,0.00021605555,0.00017922834,0.00006712426,0.00003795563,0.0006441901,6.554437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009712529,0.0006472119,0.73213184,0.003390128,0.000376334,0.00022316877,0.0045407694,0.000005285721,0.0000050443655,0.00011710699,0.0005585819,0.24829198],"study_design_scores_gemma":[0.0088910675,0.029742986,0.9235367,0.019033486,0.00030289058,0.00004313315,0.005196747,0.0000028445656,0.000008389732,0.00021930093,0.012934981,0.000087474284],"about_ca_topic_score_codex":0.00010555199,"about_ca_topic_score_gemma":0.001931601,"teacher_disagreement_score":0.2482045,"about_ca_system_score_codex":0.00064982264,"about_ca_system_score_gemma":0.0014333973,"threshold_uncertainty_score":0.27987212},"labels":[],"label_agreement":null},{"id":"W2589471851","doi":"10.1200/jco.2016.34.2_suppl.503","title":"Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Discontinuation; Toxicity; Internal medicine; Renal cell carcinoma; Gastroenterology; Oncology; Urology","score_opus":0.15214884365136852,"score_gpt":0.45839115816830117,"score_spread":0.3062423145169326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589471851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908164,0.0031214808,0.00016172546,0.0039554015,0.0008471177,0.00079723384,0.000020358675,0.000009113722,0.0002711634],"genre_scores_gemma":[0.99143374,0.0004396934,0.0071673905,0.00027870346,0.00038370333,0.000023967616,0.0000045973125,0.000037809536,0.00023042277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949865,0.0006478643,0.0031252105,0.00030476224,0.00048351102,0.00045219425],"domain_scores_gemma":[0.9906492,0.0053815315,0.0028012884,0.0003161628,0.0004704288,0.0003813725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00324044,0.00030539336,0.0025635816,0.0002744325,0.000033834738,0.00000881094,0.00023378071,0.00028998544,0.00017697515],"category_scores_gemma":[0.002161137,0.00014882791,0.0010184025,0.00015036225,0.0002515248,0.00020021157,0.000051937623,0.0004964448,0.0000033260549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059448473,0.00628141,0.5118562,0.00018047166,0.0014007926,0.00080992654,0.00096367445,0.0000041087515,0.15168017,0.00003762486,0.0005726993,0.26676443],"study_design_scores_gemma":[0.05981566,0.055222332,0.79389775,0.0002676341,0.0004095313,0.000063182684,0.00025275798,0.000019605095,0.08791102,0.0003529004,0.0016136465,0.00017399182],"about_ca_topic_score_codex":0.000015164356,"about_ca_topic_score_gemma":0.00013996741,"teacher_disagreement_score":0.28204152,"about_ca_system_score_codex":0.0003181497,"about_ca_system_score_gemma":0.0011403944,"threshold_uncertainty_score":0.6069026},"labels":[],"label_agreement":null},{"id":"W2589475321","doi":"10.1200/jco.2016.34.2_suppl.12","title":"Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Internal medicine; Oncology; Radiation therapy; Clinical endpoint; Clinical trial; Proportional hazards model; Cohort; Metastasis; Retrospective cohort study; Cancer; Surgery","score_opus":0.10732402568670935,"score_gpt":0.49120371076822966,"score_spread":0.3838796850815203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589475321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952217,0.0011487256,0.00012141478,0.0024089864,0.0002296246,0.0007955987,0.000014097785,0.000003149365,0.00005675037],"genre_scores_gemma":[0.9852649,0.012901795,0.0012621226,0.00009014937,0.00033705187,0.000009265121,0.0000018743948,0.000011008536,0.000121842364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713206,0.00041286284,0.0019387607,0.00018036833,0.00015577358,0.00018017572],"domain_scores_gemma":[0.99137366,0.006845993,0.0011389661,0.00009775549,0.00027109575,0.00027250455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004669636,0.00008529046,0.0010698078,0.00013797659,0.000019677469,0.000003936433,0.000056566063,0.0002872199,0.000012007345],"category_scores_gemma":[0.005539798,0.00004607586,0.00019618537,0.00007600854,0.00036913413,0.00007237162,0.000032797296,0.00041645224,0.0000013225249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026209448,0.00052910135,0.6612335,0.000017247246,0.00031261906,0.000043328535,0.00004654815,2.1174563e-7,0.0002473998,0.000009521224,0.00014258467,0.3112085],"study_design_scores_gemma":[0.050065737,0.024385873,0.92172,0.00009916606,0.0003619551,0.00004304843,0.00001706571,0.000054342818,0.00006772551,0.00022963338,0.0029092524,0.00004618229],"about_ca_topic_score_codex":0.000039349146,"about_ca_topic_score_gemma":0.00003902388,"teacher_disagreement_score":0.3111623,"about_ca_system_score_codex":0.00010382919,"about_ca_system_score_gemma":0.00096940895,"threshold_uncertainty_score":0.6632056},"labels":[],"label_agreement":null},{"id":"W2589476242","doi":"10.1200/jco.2016.34.26_suppl.98","title":"Symptom burden to predict health care utilization in hospitalized patients with incurable cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anxiety; Mood; Nausea; Depression (economics); Comorbidity; Population; Marital status; Cancer; Physical therapy; Patient Health Questionnaire; Internal medicine; Psychiatry; Depressive symptoms","score_opus":0.06284529110637824,"score_gpt":0.4484517642753427,"score_spread":0.38560647316896446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589476242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97582555,0.00072211,0.00020468853,0.020789701,0.0014270872,0.00036615436,0.00001941934,0.000009355699,0.0006359265],"genre_scores_gemma":[0.9953552,0.00082080933,0.00023583675,0.0027023,0.00070027815,0.0000122346,0.000004697794,0.000016702483,0.00015197568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975211,0.00026780122,0.0013869578,0.00018004426,0.00040627245,0.00023782493],"domain_scores_gemma":[0.9973906,0.00041000027,0.0008726581,0.00015305309,0.00072610413,0.00044758298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009129626,0.00010786215,0.0010247027,0.00013580496,0.000023430575,0.0000046737223,0.000118083895,0.00018624649,0.000132798],"category_scores_gemma":[0.0009340598,0.000058920963,0.00013437023,0.00022449139,0.000065616965,0.00010557633,0.000031087966,0.0003077425,0.000005529506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004006931,0.00024210424,0.7304517,0.000036980084,0.000060184575,0.000028483515,0.0009568953,0.000009297154,0.000002384039,0.000013004922,0.0026474055,0.26154464],"study_design_scores_gemma":[0.012899664,0.019048396,0.8635737,0.000830079,0.00006700994,0.000006933825,0.0004676675,0.0000031216593,0.000009103652,0.00002028696,0.10299364,0.00008041144],"about_ca_topic_score_codex":0.00066975807,"about_ca_topic_score_gemma":0.003987789,"teacher_disagreement_score":0.26146424,"about_ca_system_score_codex":0.0007340038,"about_ca_system_score_gemma":0.0028524932,"threshold_uncertainty_score":0.50602007},"labels":[],"label_agreement":null},{"id":"W2589476940","doi":"10.1200/jco.2014.32.30_suppl.43","title":"Moving toward patient-based funding through quality-based procedures (QBPs) for GI endoscopy and colposcopy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Best practice; Workload; Accountability; Quality (philosophy); Quality management; Colposcopy; Health care; Operations management; Process management; Business; Management system","score_opus":0.5006549889950059,"score_gpt":0.6199025470076805,"score_spread":0.11924755801267461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589476940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8235669,0.00017199013,0.12071959,0.052195847,0.0018644371,0.00091328565,0.000013019494,0.00003104373,0.0005238805],"genre_scores_gemma":[0.7839724,0.00005828631,0.18685974,0.02777236,0.0012634051,0.000018595862,0.000012815859,0.000027993949,0.000014430466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99227405,0.001021558,0.005495301,0.00032964887,0.0005281191,0.00035133597],"domain_scores_gemma":[0.9552203,0.038412403,0.0046477565,0.00022872313,0.0010570738,0.0004337537],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010993524,0.00020066737,0.0016269101,0.00012340897,0.0000988463,0.000030034318,0.00014685286,0.0003921139,0.00008422929],"category_scores_gemma":[0.13592595,0.00015606139,0.0004930558,0.00013556743,0.00023394225,0.00027255653,0.00004402036,0.0008516719,0.000005508684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07564526,0.0072699618,0.33056578,0.002273897,0.0009908123,0.00014369046,0.0007297068,0.0006954788,0.0074050133,0.0029914165,0.032160785,0.5391282],"study_design_scores_gemma":[0.12568542,0.14800127,0.11025598,0.0015380225,0.0036493742,0.00023938296,0.0033135714,0.020187326,0.0056486106,0.008722818,0.571831,0.0009272591],"about_ca_topic_score_codex":0.000056800865,"about_ca_topic_score_gemma":0.00008095239,"teacher_disagreement_score":0.53967017,"about_ca_system_score_codex":0.00015607472,"about_ca_system_score_gemma":0.003542458,"threshold_uncertainty_score":0.8713525},"labels":[],"label_agreement":null},{"id":"W2589481545","doi":"10.1200/jco.2015.33.7_suppl.336","title":"Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Gemcitabine; Bladder cancer; Cystectomy; Dosing; Cisplatin; Urology; Internal medicine; Chemotherapy; Cohort; Cancer; Neoadjuvant therapy; Oncology; Gastroenterology; Surgery","score_opus":0.16153477344881828,"score_gpt":0.4737695148506772,"score_spread":0.3122347414018589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589481545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98345804,0.0007429602,0.00044144454,0.013667472,0.00087932084,0.00040682455,0.000011858479,0.000011093208,0.00038101355],"genre_scores_gemma":[0.9855294,0.00017881561,0.009742432,0.0031848885,0.0011080537,0.000008830715,0.0000014510782,0.000029554323,0.00021656681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975413,0.00033683563,0.0013893277,0.00022722388,0.00027219317,0.00023313843],"domain_scores_gemma":[0.99391514,0.004016421,0.00093127426,0.00013395895,0.000434354,0.0005688712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037278517,0.00017205764,0.0013160327,0.000105603016,0.00006153104,0.000024329258,0.00007063531,0.00028633064,0.000013530999],"category_scores_gemma":[0.0073933126,0.00011625475,0.00023002517,0.00006078031,0.00019090548,0.00016364641,0.000038532733,0.0004601013,0.0000010324162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024222128,0.0006859669,0.7988028,0.000047945436,0.00038636653,0.0004093853,0.0007849428,0.000002150314,0.001019452,0.000015282141,0.0011761131,0.17244747],"study_design_scores_gemma":[0.04580562,0.01810375,0.92324233,0.00009866862,0.0005179833,0.00059013494,0.0005285947,0.00016476527,0.00019046527,0.00040699737,0.010241271,0.00010944876],"about_ca_topic_score_codex":0.000029502826,"about_ca_topic_score_gemma":0.000016002912,"teacher_disagreement_score":0.17233802,"about_ca_system_score_codex":0.00013619714,"about_ca_system_score_gemma":0.0023283141,"threshold_uncertainty_score":0.885102},"labels":[],"label_agreement":null},{"id":"W2589489210","doi":"10.1200/jco.2016.34.7_suppl.163","title":"Cervical screening reminder calls pilot: Utilizing EMRs to improve cancer screening.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Family medicine; Cervical cancer screening; Primary care; Cervical cancer; Pap test; Outreach; Cancer screening; Medical record; Electronic medical record; Pilot program; Test (biology); Health care; Cancer; Medical education; Internal medicine","score_opus":0.5419734872651147,"score_gpt":0.612059880649653,"score_spread":0.07008639338453826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589489210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63661706,0.00024408371,0.07744725,0.27877885,0.004494661,0.000663219,0.00002262527,0.00004344391,0.0016888077],"genre_scores_gemma":[0.8855941,0.00040523813,0.07558403,0.032061104,0.005662299,0.000011541958,0.000001992304,0.00005013077,0.00062953454],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9909493,0.0006931167,0.0064719976,0.00045536045,0.0008962451,0.000534005],"domain_scores_gemma":[0.97782075,0.0156522,0.0033100215,0.0003985289,0.001521781,0.0012967422],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011002084,0.00024099289,0.0017758077,0.00021803056,0.00007422343,0.000019266614,0.00032539878,0.00046243897,0.0013443755],"category_scores_gemma":[0.062085975,0.00014840014,0.0006264904,0.0002687008,0.00020531859,0.00038886236,0.00022223065,0.0014378561,0.00008514137],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010822979,0.00074161764,0.09139576,0.000017982653,0.00042957536,0.00031744922,0.000040812643,0.000011530507,0.0051430343,0.000053567688,0.021628933,0.86939675],"study_design_scores_gemma":[0.023596844,0.025593888,0.53975195,0.00071904634,0.0011420455,0.00042579797,0.00043462258,0.0002383197,0.00065904926,0.00032495637,0.4067869,0.00032656934],"about_ca_topic_score_codex":0.00024253961,"about_ca_topic_score_gemma":0.00030879505,"teacher_disagreement_score":0.8690702,"about_ca_system_score_codex":0.00027631156,"about_ca_system_score_gemma":0.0019968324,"threshold_uncertainty_score":0.9995685},"labels":[],"label_agreement":null},{"id":"W2589489743","doi":"10.1200/jco.2005.23.16_suppl.4127","title":"Preliminary results of a phase I study of stereotactic radiotherapy for unresectable primary and metastatic liver cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Toxicity; Hepatocellular carcinoma; Cancer; Radiation therapy; Primary tumor; Phases of clinical research; Nuclear medicine; Internal medicine; Oncology; Gastroenterology; Radiology; Surgery; Metastasis","score_opus":0.2761979206675339,"score_gpt":0.48255950196073855,"score_spread":0.20636158129320464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589489743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985547,0.007353891,0.000094478244,0.0015672824,0.00014773315,0.0008408252,0.000017437354,0.0000024482324,0.000120460056],"genre_scores_gemma":[0.98746336,0.002270587,0.009421695,0.00028306738,0.00034497338,0.000019608999,0.0000025565375,0.000013520622,0.00018061325],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971167,0.0003888705,0.00198221,0.0001445922,0.00022879583,0.0001388536],"domain_scores_gemma":[0.994579,0.0031005326,0.0016493633,0.00014090729,0.0003530425,0.00017714943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022411663,0.00010861214,0.0014782036,0.00012745279,0.000020648971,0.000002707158,0.00007498009,0.000110416884,0.00005175882],"category_scores_gemma":[0.00077488937,0.000072906834,0.0002737111,0.000089863206,0.000108760374,0.000101390586,0.000019804324,0.0002521922,2.9494586e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1839486,0.03624051,0.25886044,0.0004073626,0.004252915,0.0006417035,0.0026198048,0.000007772615,0.001971482,0.0000045687443,0.0013961447,0.5096487],"study_design_scores_gemma":[0.22875421,0.5577296,0.1705119,0.00034145924,0.007152076,0.00041807158,0.00065215345,0.0036206758,0.0030257183,0.000032691427,0.027579451,0.0001819764],"about_ca_topic_score_codex":0.00006030783,"about_ca_topic_score_gemma":0.000033992263,"teacher_disagreement_score":0.52148914,"about_ca_system_score_codex":0.00008869747,"about_ca_system_score_gemma":0.00073195953,"threshold_uncertainty_score":0.29730543},"labels":[],"label_agreement":null},{"id":"W2589496493","doi":"10.1200/jco.2015.33.18_suppl.lba500","title":"Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Anastrozole; Lumpectomy; Tamoxifen; Clinical endpoint; Breast cancer; Internal medicine; Oncology; Randomization; Gynecology; Cancer; Randomized controlled trial; Mastectomy","score_opus":0.08197520445746322,"score_gpt":0.42798407401753497,"score_spread":0.34600886956007176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589496493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923929,0.0010097316,0.00010644368,0.0006924275,0.0027447043,0.00051444967,0.00001682768,0.000006658281,0.002515867],"genre_scores_gemma":[0.9894379,0.0014982625,0.0064812927,0.0006007261,0.0017947964,0.000007253955,0.000066498964,0.000041878837,0.0000714205],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930902,0.001941567,0.00360677,0.00044197903,0.00049705827,0.00042243494],"domain_scores_gemma":[0.99358493,0.0018950984,0.0030796423,0.0003839793,0.000511461,0.0005448853],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0059857713,0.0002762229,0.001798764,0.00015378457,0.000035081386,0.000011115889,0.00045885038,0.0013182821,0.0000054878446],"category_scores_gemma":[0.004282389,0.00020117288,0.00044736324,0.00021659597,0.0005104408,0.000025387058,0.0001457619,0.0013360978,0.0000037665216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90734315,0.006412661,0.026094355,0.000019671135,0.0013178422,0.0003516921,0.000106527965,0.0003948406,0.0010571271,0.000016414337,0.0067296736,0.050156057],"study_design_scores_gemma":[0.5887207,0.31308487,0.044227656,0.0001058039,0.00035786466,0.00007348556,0.00017637313,0.00006923886,0.0003181483,0.000036591522,0.052480396,0.00034890004],"about_ca_topic_score_codex":0.000022213437,"about_ca_topic_score_gemma":0.00008367916,"teacher_disagreement_score":0.31862244,"about_ca_system_score_codex":0.00033900957,"about_ca_system_score_gemma":0.0061830124,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W2589497668","doi":"10.1200/jco.2016.34.7_suppl.105","title":"Feasibility, acceptability, and efficacy of a proactive telephone intervention to improve toxicity management during chemotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Cancer Care Ontario; Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ambulatory; Docetaxel; Intervention (counseling); Telephone counseling; Emergency department; Emergency medicine; Breast cancer; Chemotherapy; Cancer; Internal medicine; Randomized controlled trial; Nursing","score_opus":0.06758130981555961,"score_gpt":0.44997938347871275,"score_spread":0.38239807366315315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589497668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928177,0.00008879585,0.00078979565,0.0042238617,0.0006893151,0.0005044981,0.0000039220536,0.000006585937,0.0008755513],"genre_scores_gemma":[0.9977884,0.00023200116,0.000965226,0.00031536358,0.00038550684,0.0000059467793,1.6553008e-7,0.000009997267,0.00029738495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99757296,0.00028635163,0.0014941868,0.00022871414,0.00026260756,0.0001551829],"domain_scores_gemma":[0.9977006,0.0006732974,0.0008190944,0.00021950892,0.00031125484,0.00027627693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029399337,0.00010259025,0.0009254109,0.00010156746,0.000016119291,0.0000043952673,0.000115659284,0.00016475584,0.00022077073],"category_scores_gemma":[0.0013793734,0.0000619536,0.00042459634,0.00011077521,0.00016159489,0.00008946143,0.00013356132,0.0002691966,0.0000027150559],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012972305,0.00244552,0.14654037,0.00015018816,0.00045750898,0.000035232057,0.00033535343,1.6142343e-7,0.005486612,0.000020188982,0.000068371635,0.8314882],"study_design_scores_gemma":[0.014590946,0.008189673,0.96610796,0.00016390978,0.00019408113,0.00004289997,0.00034602275,8.468203e-7,0.008802539,0.00027227393,0.0012230224,0.00006581181],"about_ca_topic_score_codex":0.000038088474,"about_ca_topic_score_gemma":0.00020270917,"teacher_disagreement_score":0.8314224,"about_ca_system_score_codex":0.00025725132,"about_ca_system_score_gemma":0.00014891238,"threshold_uncertainty_score":0.25263944},"labels":[],"label_agreement":null},{"id":"W2589498315","doi":"10.1200/jco.2014.32.30_suppl.130","title":"Development of an evidence-based clinical pathway for patients undergoing pancreaticoduodenectomy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital","funders":"","keywords":"Medicine; Perioperative; Pancreaticoduodenectomy; Internal medicine; Surgery; Pancreas","score_opus":0.5494231232252323,"score_gpt":0.6041019100319357,"score_spread":0.05467878680670335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589498315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658904,0.000046922803,0.028060889,0.0034424192,0.0017974818,0.00056389795,0.000003336689,0.000012781503,0.00018187142],"genre_scores_gemma":[0.68364054,0.00009728379,0.3107821,0.0041118586,0.0013038934,0.0000076626475,0.000015635642,0.000022672317,0.000018337434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9858551,0.0016405786,0.011182279,0.00033062196,0.0007093048,0.00028211906],"domain_scores_gemma":[0.9078665,0.07940059,0.00876076,0.0004305388,0.0028287394,0.00071286876],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029631961,0.00018452617,0.0023018774,0.0001509334,0.000065028944,0.000011305111,0.00027089327,0.00047786633,0.00008011638],"category_scores_gemma":[0.23881742,0.00013816607,0.00076423096,0.00013968008,0.00019409205,0.00039447396,0.00006016551,0.00077498564,0.000010995231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010404142,0.005042981,0.25196934,0.00012797286,0.00027808108,0.000009963435,0.000044615903,0.000027253265,0.00011627003,0.00008498097,0.000741102,0.7311533],"study_design_scores_gemma":[0.045426358,0.08190324,0.74521494,0.0010104848,0.0012453342,0.000025195352,0.0002272589,0.004114946,0.0006835231,0.00076054194,0.11912696,0.0002612275],"about_ca_topic_score_codex":0.000006665062,"about_ca_topic_score_gemma":0.00010225372,"teacher_disagreement_score":0.73089206,"about_ca_system_score_codex":0.00016792407,"about_ca_system_score_gemma":0.007414186,"threshold_uncertainty_score":0.9991981},"labels":[],"label_agreement":null},{"id":"W2589500480","doi":"10.1200/jco.2014.32.4_suppl.127","title":"Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; PTEN; Prostatectomy; Prostate cancer; Biopsy; Cancer; Prostate; Prostate-specific antigen; Prostate biopsy; Oncology; Internal medicine; Urology; Pathology; Biology","score_opus":0.06205925677674814,"score_gpt":0.4518105693286346,"score_spread":0.3897513125518865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589500480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430336,0.00024261478,0.00011841325,0.013919408,0.00023932934,0.00066280714,0.000027047194,0.0000061948926,0.00048082587],"genre_scores_gemma":[0.99292475,0.00028423924,0.0049826982,0.00022006118,0.00055698387,0.000026316478,0.0000052969554,0.00001893022,0.0009807379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967555,0.00040767112,0.0016780127,0.00018928615,0.00069354585,0.00027603147],"domain_scores_gemma":[0.9954387,0.0010555827,0.0020195849,0.00015426989,0.0009536605,0.00037817948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002874656,0.00012563897,0.0014245403,0.0001601322,0.000025225681,0.000005788816,0.00013981064,0.00026266254,0.00009702537],"category_scores_gemma":[0.0024733155,0.00007382732,0.0002251443,0.0002698969,0.00022461762,0.00008170059,0.000041144114,0.00066276325,0.0000044598987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030675534,0.0018864613,0.8594561,0.00017994919,0.0015054919,0.00023468514,0.0005247426,0.000027255817,0.015848847,0.00007300404,0.0014427451,0.08814518],"study_design_scores_gemma":[0.05427177,0.06467992,0.76234126,0.0026852926,0.0013804176,0.00010007163,0.00026840437,0.00025077135,0.06097991,0.0015586795,0.051165137,0.0003183568],"about_ca_topic_score_codex":0.00018232036,"about_ca_topic_score_gemma":0.000049357546,"teacher_disagreement_score":0.09711484,"about_ca_system_score_codex":0.00035700042,"about_ca_system_score_gemma":0.0017857456,"threshold_uncertainty_score":0.3167836},"labels":[],"label_agreement":null},{"id":"W2589504456","doi":"10.1200/jco.2013.31.26_suppl.69","title":"Do locoregional recurrence and survival outcomes differ in women with node-negative, HER2-positive breast cancer treated with breast-conserving therapy versus mastectomy?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Proportional hazards model; Oncology; Mastectomy; Population; Cancer; Gynecology","score_opus":0.04310730892741215,"score_gpt":0.36696815193255006,"score_spread":0.3238608430051379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589504456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927266,0.00039532516,0.000021305195,0.006181327,0.0002004663,0.00022441566,0.000050253482,0.00000402002,0.00019625596],"genre_scores_gemma":[0.9971339,0.0014261449,0.00047390812,0.0005842099,0.0002497554,0.00007588553,0.0000034441798,0.000022793078,0.000029964196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801034,0.00037860675,0.0006931953,0.0003530659,0.00022941691,0.00033536795],"domain_scores_gemma":[0.99763525,0.00075477373,0.0007098446,0.00016170218,0.00052608334,0.00021234178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040762688,0.0002731616,0.00096542516,0.00006622325,0.00005630466,0.000022887029,0.00017505945,0.00021805486,0.00007964589],"category_scores_gemma":[0.00010324602,0.00015518973,0.00009365916,0.00013080379,0.00050621247,0.000027939117,0.00007905627,0.00037507477,0.0000018784261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029455056,0.00063597225,0.8957308,0.0000065802988,0.00115404,0.000063480154,0.00016540072,0.000016861257,0.00017160668,0.0000044202766,0.00011872537,0.07247704],"study_design_scores_gemma":[0.01817943,0.0039626714,0.97639674,0.00011310631,0.00006194022,0.00028357198,0.0004888086,0.0000051960674,0.00009587593,0.000031683776,0.0001876569,0.00019331883],"about_ca_topic_score_codex":0.0006340635,"about_ca_topic_score_gemma":0.0007718537,"teacher_disagreement_score":0.08066592,"about_ca_system_score_codex":0.00014859188,"about_ca_system_score_gemma":0.0005366412,"threshold_uncertainty_score":0.63284534},"labels":[],"label_agreement":null},{"id":"W2589509227","doi":"10.1200/jco.2014.32.3_suppl.410","title":"Patient-reported sleep disruption as an independent prognostic factor for overall survival in metastatic colorectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Chemotherapy; Cancer; Oncology; Proportional hazards model; Multivariate analysis; Sleep (system call); Performance status; Sleep disorder; Metastatic breast cancer; Breast cancer; Insomnia","score_opus":0.10397865064584312,"score_gpt":0.45793854612749235,"score_spread":0.35395989548164924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589509227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927095,0.00012084432,0.00061816775,0.0014120452,0.0042160554,0.0005641235,0.000016037737,0.0000112496555,0.00033194813],"genre_scores_gemma":[0.99747366,0.000090430745,0.00045451542,0.00094300974,0.0009212009,0.000041781346,0.00001248199,0.000023185634,0.00003972322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605846,0.00066207745,0.0022436506,0.000254102,0.0004969531,0.0002847761],"domain_scores_gemma":[0.9948649,0.0023268582,0.0016579869,0.00014017214,0.00057526433,0.00043481012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002445275,0.00015902681,0.0013682095,0.00013961131,0.000030148005,0.000013884663,0.00011000411,0.00027437982,0.0001806176],"category_scores_gemma":[0.0058485414,0.00011901092,0.00040957748,0.00011589333,0.00008528769,0.00015975906,0.000029088698,0.00073739287,0.0000036291121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011328912,0.0020743052,0.67273104,0.00007583176,0.0003756414,0.00029950758,0.00083219673,0.00006826154,0.0003315633,0.00017127533,0.00008779231,0.3116237],"study_design_scores_gemma":[0.010836691,0.034023184,0.94084084,0.00011012572,0.00051708706,0.00020323813,0.00041405606,0.0010089648,0.000119286255,0.00095543975,0.010812711,0.0001583842],"about_ca_topic_score_codex":0.0005056262,"about_ca_topic_score_gemma":0.008028458,"teacher_disagreement_score":0.3114653,"about_ca_system_score_codex":0.00029676087,"about_ca_system_score_gemma":0.0012912019,"threshold_uncertainty_score":0.70016724},"labels":[],"label_agreement":null},{"id":"W2589514784","doi":"10.1200/jco.2014.32.3_suppl.85","title":"Open versus minimally invasive management of gastric GIST: An international multi-institutional analysis of short- and long-term outcomes.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; GiST; Surgery; Propensity score matching; Stromal tumor; Stomach; Stromal cell; Gastroenterology; Internal medicine","score_opus":0.28667826109378775,"score_gpt":0.5356126589115887,"score_spread":0.24893439781780097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589514784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619216,0.000046520003,0.0008840526,0.00092858076,0.0002476407,0.00021719902,0.00001336159,0.000002035668,0.0014684476],"genre_scores_gemma":[0.96778053,0.0002568203,0.031640522,0.00012376772,0.00008236274,0.000003691891,0.000023522038,0.000005520055,0.00008325291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973066,0.000218691,0.0016132797,0.00019653213,0.0005075066,0.00015742879],"domain_scores_gemma":[0.9966029,0.0012465857,0.0009557606,0.00019351424,0.00060435,0.0003969145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001974681,0.00011895656,0.0013252093,0.00037906232,0.000023964118,0.000012177593,0.00038712594,0.00007067251,0.0001530696],"category_scores_gemma":[0.002242022,0.00007865888,0.00042167955,0.00021700907,0.00033622046,0.00015542579,0.0002597264,0.00029686585,0.0000020591692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006877935,0.0036715565,0.94496006,0.000044855937,0.0062816013,0.0011443967,0.000012940319,0.000054036747,0.000080546415,0.0004137609,0.000021082062,0.036437254],"study_design_scores_gemma":[0.012411055,0.01590519,0.96811736,0.00011883626,0.0025898672,0.00017794706,0.000042672345,0.00039976693,0.000028638327,0.000017385944,0.00014579669,0.00004548648],"about_ca_topic_score_codex":0.000022076078,"about_ca_topic_score_gemma":0.00016014348,"teacher_disagreement_score":0.03639177,"about_ca_system_score_codex":0.00012524541,"about_ca_system_score_gemma":0.0005201467,"threshold_uncertainty_score":0.32076162},"labels":[],"label_agreement":null},{"id":"W2589516461","doi":"10.1200/jco.2013.31.4_suppl.456","title":"Survival impact of surgical resection of primary tumor (SRPT) in metastatic colorectal cancer (mCRC): A population-based cohort study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Internal medicine; Cohort; Proportional hazards model; Colorectal cancer; Performance status; Surgery; Quartile; Retrospective cohort study; Chemotherapy; Population; Randomization; Log-rank test; Cancer; Oncology; Randomized controlled trial; Confidence interval","score_opus":0.08959748010332952,"score_gpt":0.47844417295032293,"score_spread":0.3888466928469934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589516461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681056,0.00035823215,0.0000027410092,0.00048690633,0.00055112183,0.0008779976,0.000010707294,0.000003909643,0.00089784997],"genre_scores_gemma":[0.9992535,0.00017941052,0.00020473733,0.000047971986,0.00021596269,0.000046410714,0.000004839016,0.0000125627175,0.000034584926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957457,0.00070652843,0.0026325695,0.00018352068,0.0005306248,0.00020104917],"domain_scores_gemma":[0.9944227,0.0027229458,0.0018358642,0.000116456744,0.00072227017,0.00017977331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024655084,0.00015671997,0.002562611,0.00023192307,0.000024112473,0.000003811353,0.00008859764,0.000110492925,0.00044382442],"category_scores_gemma":[0.0011752414,0.00009724511,0.0006187952,0.00031898177,0.00014991737,0.000092859045,0.00003464815,0.0004923769,0.0000014829693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014036501,0.005158053,0.971005,0.000048601658,0.0013310048,0.0002803688,0.00009539442,0.00023479166,0.000113581744,0.0000030950262,0.0002272,0.007466365],"study_design_scores_gemma":[0.012743495,0.04070613,0.9453073,0.00009140821,0.00055928243,0.000050123926,0.00015273398,0.00018966672,0.00003134463,0.000043387776,0.00005679332,0.00006829084],"about_ca_topic_score_codex":0.010955056,"about_ca_topic_score_gemma":0.0034019132,"teacher_disagreement_score":0.035548076,"about_ca_system_score_codex":0.0008211388,"about_ca_system_score_gemma":0.0021887457,"threshold_uncertainty_score":0.9956311},"labels":[],"label_agreement":null},{"id":"W2589522228","doi":"10.1200/jco.2016.34.7_suppl.271","title":"Diffuse large B-cell lymphoma: A single-institution experience of patient outcomes.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Toronto","funders":"","keywords":"Medicine; International Prognostic Index; Diffuse large B-cell lymphoma; Internal medicine; Cancer; Lymphoma; Population; Performance status; Retrospective cohort study; Cohort; Oncology","score_opus":0.07884245237558474,"score_gpt":0.4154093438504994,"score_spread":0.33656689147491464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589522228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920154,0.00029063504,0.00017394616,0.0038548633,0.0011899892,0.00013936844,0.0000057184275,0.0000067936244,0.002323286],"genre_scores_gemma":[0.99655044,0.0004157276,0.0011498258,0.0015523216,0.0001732615,0.000006252515,5.247909e-7,0.000007923017,0.00014374376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704796,0.00016372903,0.0020544636,0.00015666848,0.0003687696,0.0002083858],"domain_scores_gemma":[0.9960695,0.0013912731,0.0016840267,0.00021653881,0.0003189579,0.00031971722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065199303,0.00012466015,0.0012051754,0.00008493694,0.000027001282,0.0000031268064,0.00010369024,0.00023160386,0.00007817751],"category_scores_gemma":[0.0022079595,0.000059876278,0.0005751734,0.00007337454,0.00020665131,0.00011159227,0.00005474765,0.000091677626,0.000027371112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017874211,0.07577287,0.62689495,0.000017056971,0.00022247684,0.0009994084,0.00034728347,2.393528e-7,0.0008902418,0.00044282502,0.0012321996,0.291393],"study_design_scores_gemma":[0.109388925,0.024299458,0.68744403,0.00029872073,0.00041621912,0.00035491015,0.000262363,0.0000052391842,0.00892459,0.0001397902,0.1683333,0.00013246271],"about_ca_topic_score_codex":0.000012658727,"about_ca_topic_score_gemma":0.000009546037,"teacher_disagreement_score":0.29126054,"about_ca_system_score_codex":0.00036693073,"about_ca_system_score_gemma":0.0008206884,"threshold_uncertainty_score":0.26432934},"labels":[],"label_agreement":null},{"id":"W2589527742","doi":"10.1200/jco.2015.33.29_suppl.100","title":"Symptom burden in hospitalized patients with advanced cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Depression (economics); Anxiety; Anorexia; Cancer; Population; Breast cancer; Internal medicine; Physical therapy; Pediatrics; Psychiatry","score_opus":0.07135924983879985,"score_gpt":0.45067245221298646,"score_spread":0.37931320237418664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589527742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858047,0.0006768921,0.0000196507,0.0047924337,0.0021890714,0.0001679949,0.0000029155503,0.0000065102286,0.0035640944],"genre_scores_gemma":[0.9966395,0.000317989,0.0005474341,0.0014259778,0.00084423536,0.000006550218,0.0000023920172,0.000014505119,0.00020143343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778926,0.00019079703,0.0012615576,0.00013834402,0.00043278767,0.00018725965],"domain_scores_gemma":[0.9973404,0.00036630544,0.00089527684,0.00013854857,0.0008047532,0.00045471187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012121103,0.00010278149,0.0011313842,0.000091408256,0.000009059299,0.0000043602454,0.000120423036,0.00021450946,0.000074552256],"category_scores_gemma":[0.0013121202,0.000065880224,0.00017233632,0.0001783455,0.00010335304,0.0001111707,0.00002768192,0.0006418133,0.0000064054657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009843563,0.00056391227,0.84679836,0.000013003158,0.00010273526,0.00022191851,0.00043385004,0.000053030697,0.0000020395996,0.0000141938635,0.0015933991,0.14035997],"study_design_scores_gemma":[0.02837604,0.018654656,0.840448,0.00022540084,0.00015086055,0.000022002176,0.0003886099,0.000015605427,0.00000594733,0.00012031262,0.11149544,0.000097106764],"about_ca_topic_score_codex":0.00029352657,"about_ca_topic_score_gemma":0.00095965224,"teacher_disagreement_score":0.14026287,"about_ca_system_score_codex":0.0003163603,"about_ca_system_score_gemma":0.0022000647,"threshold_uncertainty_score":0.39028203},"labels":[],"label_agreement":null},{"id":"W2589537108","doi":"10.1200/jco.2015.33.7_suppl.173","title":"Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Cohort; Biochemical recurrence; Internal medicine; Oncology; Adjuvant therapy; Cumulative incidence; Androgen deprivation therapy; Cancer; Metastasis; Biomarker; Urology","score_opus":0.10952880917681386,"score_gpt":0.4525458447130599,"score_spread":0.3430170355362461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589537108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190414,0.0002695092,0.000015847729,0.0057325517,0.00032004772,0.0009756979,0.00015353932,0.0000075449248,0.0006211167],"genre_scores_gemma":[0.996056,0.0012550273,0.00066930876,0.00037557737,0.0005033985,0.00011404567,0.00002881695,0.000026087546,0.0009717012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963628,0.00086526223,0.0014607031,0.00023600232,0.0007723442,0.0003028962],"domain_scores_gemma":[0.9964377,0.000782196,0.0012074222,0.00020074706,0.0008850946,0.00048679035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022509699,0.00017556331,0.0010421671,0.00018172589,0.000038562324,0.000011801484,0.00019726472,0.0002464836,0.00043206164],"category_scores_gemma":[0.0012266386,0.000082606675,0.00018951912,0.00037979914,0.0004020596,0.00013502516,0.00005314583,0.001000471,0.000009023395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06480932,0.0016905494,0.8537526,0.000018801524,0.00059737574,0.00022247434,0.0004917829,0.00017271745,0.0003765188,0.000012420743,0.012800025,0.06505541],"study_design_scores_gemma":[0.041842345,0.018773673,0.90429044,0.00049243186,0.00023417313,0.0000725192,0.000286073,0.0001441726,0.0053416756,0.00043258147,0.02795304,0.00013686574],"about_ca_topic_score_codex":0.00025408296,"about_ca_topic_score_gemma":0.00015830487,"teacher_disagreement_score":0.06491854,"about_ca_system_score_codex":0.0005194208,"about_ca_system_score_gemma":0.004045915,"threshold_uncertainty_score":0.7177279},"labels":[],"label_agreement":null},{"id":"W2589540729","doi":"10.1200/jco.2016.34.3_suppl.242","title":"Psychotropic and stimulant medication (PSM) use among testicular cancer survivors (TCS): A multi-institutional clinical study of 680 patients given cisplatin-based chemotherapy (CHEM) (NCI 1R01 CA157823-02).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Testicular cancer; Internal medicine; Cancer; Medical prescription; Gynecology; Pharmacology","score_opus":0.1432455578281274,"score_gpt":0.47645644457953745,"score_spread":0.3332108867514101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589540729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203527,0.00019987838,0.0021445309,0.0029134927,0.0016265393,0.0009960965,0.00003779828,0.000016511838,0.000029875519],"genre_scores_gemma":[0.99522626,0.0014341829,0.0014275727,0.0011018936,0.000675045,0.00003232441,0.000005339783,0.00002710952,0.000070263835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940916,0.00077125645,0.003583667,0.00042937853,0.00082477,0.0002993317],"domain_scores_gemma":[0.98857623,0.0059379963,0.0030529408,0.0002602289,0.0016857303,0.00048685033],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025232194,0.00028156838,0.0019361879,0.00019871017,0.00009069633,0.000007733127,0.00016884736,0.0004395746,0.000132328],"category_scores_gemma":[0.009980224,0.00016530753,0.00036628117,0.00020560797,0.0010938826,0.00017174726,0.00005563064,0.0007994829,0.000004741252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054632574,0.009590199,0.9096565,0.000035661786,0.0011767099,0.00009134202,0.0001277053,0.000034252018,0.00007613529,0.0000023171901,0.00086134847,0.07288452],"study_design_scores_gemma":[0.055186428,0.022170804,0.91817904,0.00063047156,0.0009406033,0.000016184373,0.00008362343,0.00051407755,0.000033621225,0.000017130318,0.0020705792,0.0001574479],"about_ca_topic_score_codex":0.00045671855,"about_ca_topic_score_gemma":0.000970346,"teacher_disagreement_score":0.07272708,"about_ca_system_score_codex":0.00031500516,"about_ca_system_score_gemma":0.0014781288,"threshold_uncertainty_score":0.99835914},"labels":[],"label_agreement":null},{"id":"W2589545520","doi":"10.1200/jco.2016.34.7_suppl.122","title":"Communities of practice: A jurisdictional approach to improving the quality of care in radiation medicine in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Regional Municipality of Durham; Princess Margaret Cancer Centre; University Health Network; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Best practice; Patient safety; Medical education; Radiation Therapist; Quality management; Quality (philosophy); Medical physics; Radiation therapy; Health care; Operations management; Surgery; Management; Political science","score_opus":0.43549084052700043,"score_gpt":0.6074317264975685,"score_spread":0.17194088597056806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589545520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519997,0.00017150823,0.0018130944,0.04257733,0.0005489858,0.00039372928,0.0000043301925,0.000002200784,0.002489084],"genre_scores_gemma":[0.9879852,0.00022222051,0.008813862,0.002552553,0.00038005234,0.000006461475,0.000005295591,0.000007520656,0.000026839283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99012846,0.0023086697,0.0067009,0.00011205243,0.00061191595,0.00013797685],"domain_scores_gemma":[0.95752406,0.036060028,0.0048007974,0.00025886248,0.0012346529,0.000121595105],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02372319,0.00009152734,0.0012450836,0.00023514446,0.00001894726,0.0000018375752,0.00019364954,0.00021451688,0.00009107867],"category_scores_gemma":[0.067453064,0.000048476457,0.00019026572,0.00021288994,0.00028969807,0.00026503392,0.00007362972,0.0010457732,0.0000012269384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018650357,0.0024101317,0.61872226,0.00009239119,0.00017424725,0.00001517526,0.012874861,0.0001650812,0.0005971159,0.0007391223,0.00072847644,0.34483078],"study_design_scores_gemma":[0.013019814,0.009397735,0.93862236,0.00023523183,0.00020254999,0.0000591566,0.02489157,0.0000635403,0.000025136414,0.00031908412,0.013110916,0.000052880052],"about_ca_topic_score_codex":0.042870943,"about_ca_topic_score_gemma":0.11953865,"teacher_disagreement_score":0.34477788,"about_ca_system_score_codex":0.00055856316,"about_ca_system_score_gemma":0.003428798,"threshold_uncertainty_score":0.96350265},"labels":[],"label_agreement":null},{"id":"W2589548433","doi":"10.1200/jco.2013.31.6_suppl.88","title":"Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Tumor progression; Internal medicine; Oncology; Prostate biopsy; Cancer; Biopsy","score_opus":0.07824628479789668,"score_gpt":0.5009006886177039,"score_spread":0.4226544038198072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589548433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918155,0.00052291667,0.0000018636404,0.0061427,0.00023019224,0.00094608724,0.000008277141,0.0000021790643,0.0003303046],"genre_scores_gemma":[0.99719256,0.0019514732,0.00025148122,0.00010570967,0.00019991897,0.000046549776,0.0000014512591,0.00000905242,0.00024181811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961978,0.0014917077,0.0012931256,0.0001362113,0.00067502167,0.00020613408],"domain_scores_gemma":[0.9926256,0.003118751,0.0028699148,0.0001365579,0.0011429735,0.00010623758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060367873,0.00009741211,0.0010159806,0.000104359664,0.00003183687,0.0000053631575,0.00013519356,0.00016025096,0.00005998838],"category_scores_gemma":[0.0026688536,0.00004427116,0.00014682476,0.00025857685,0.00015632714,0.000114413735,0.00003117561,0.00092175073,0.0000011180122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009275573,0.0029777368,0.92689043,0.000026475182,0.0007540028,0.00012310526,0.0017605203,0.000024718489,0.000039032013,4.956933e-7,0.001178207,0.0569497],"study_design_scores_gemma":[0.010104863,0.025520913,0.9607564,0.00023656746,0.00024111367,0.000009295454,0.0025050049,0.000073371215,0.0000695536,0.000079997815,0.00035956962,0.00004331361],"about_ca_topic_score_codex":0.0012115673,"about_ca_topic_score_gemma":0.0021766592,"teacher_disagreement_score":0.05690639,"about_ca_system_score_codex":0.00028806966,"about_ca_system_score_gemma":0.0018636667,"threshold_uncertainty_score":0.40045998},"labels":[],"label_agreement":null},{"id":"W2589549609","doi":"10.1200/jco.2005.23.16_suppl.695","title":"Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Chemotherapy; Cyclophosphamide; Gastroenterology; Regimen; Breast cancer; Chemotherapy regimen; Progression-free survival; Phases of clinical research; Cancer; Surgery","score_opus":0.15506704465995005,"score_gpt":0.5456303374866971,"score_spread":0.39056329282674707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589549609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780429,0.0055327024,0.00004131804,0.014493983,0.0005823476,0.001030696,0.000055172357,0.000008093402,0.00021276262],"genre_scores_gemma":[0.97908676,0.011952312,0.0050837155,0.0021080922,0.000976287,0.000060994236,0.000005015051,0.000028691613,0.0006981299],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99658877,0.0004771678,0.0020866615,0.00030941097,0.00025625195,0.00028172834],"domain_scores_gemma":[0.99502087,0.0022964212,0.0016947218,0.00016184745,0.00038999814,0.00043613015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00242195,0.00023461421,0.0020817143,0.0001634308,0.00009278671,0.000008415903,0.000120787125,0.00017879467,0.00033424495],"category_scores_gemma":[0.00035132328,0.00016079715,0.0002741148,0.00015058643,0.0002631544,0.00014991369,0.00006426854,0.00048044274,0.000001074848],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067599155,0.04947258,0.041820582,0.00008004594,0.004180653,0.0002477613,0.0015489359,0.000027816284,0.0030413028,0.000039648272,0.005395122,0.8265464],"study_design_scores_gemma":[0.2895896,0.36355364,0.19169158,0.000121806,0.006133969,0.0015450448,0.0009956344,0.00049506954,0.0012175675,0.000742135,0.14358695,0.0003269828],"about_ca_topic_score_codex":0.00028373534,"about_ca_topic_score_gemma":0.0003974039,"teacher_disagreement_score":0.82621944,"about_ca_system_score_codex":0.0001148997,"about_ca_system_score_gemma":0.0011520929,"threshold_uncertainty_score":0.65571177},"labels":[],"label_agreement":null},{"id":"W2589549853","doi":"10.1200/jco.2016.34.3_suppl.186","title":"Exploring correlates of quality of life in older family caregivers to cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Anxiety; Psychological intervention; Depression (economics); Cancer; Gerontology; Colorectal cancer; Family caregivers; Descriptive statistics; Internal medicine; Psychiatry","score_opus":0.33703314687913644,"score_gpt":0.49132728099014195,"score_spread":0.1542941341110055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589549853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989875,0.00009356765,0.000033712487,0.0032320176,0.0039703436,0.00013111271,0.0000107524,0.0000033405581,0.002650139],"genre_scores_gemma":[0.9979438,0.0009982354,0.00019408707,0.0004917134,0.00027526612,0.0000053917784,1.2624685e-7,0.000006960154,0.00008437621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952338,0.0010512486,0.0027544086,0.00014125378,0.0005820435,0.00023724983],"domain_scores_gemma":[0.99082434,0.005655555,0.002282928,0.00011887804,0.0008032528,0.00031501954],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005932718,0.000080446654,0.0011330931,0.00014569623,0.000031666477,0.000002683963,0.00038913285,0.00023825011,0.00014173615],"category_scores_gemma":[0.016311238,0.00005482505,0.00026487888,0.00026378702,0.00047155237,0.00031803938,0.000072808616,0.00028893916,0.000005919821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005863258,0.00050281343,0.9299516,0.000011467875,0.000046055902,0.0000048766747,0.0052875495,0.000023450993,0.000057062738,0.00056707347,0.0012628869,0.061698828],"study_design_scores_gemma":[0.0025623778,0.00089231436,0.9782763,0.00016482997,0.000020033041,6.7899244e-8,0.0069384556,3.5858838e-7,0.000028501607,0.0002499482,0.010788975,0.000077823075],"about_ca_topic_score_codex":0.0047162045,"about_ca_topic_score_gemma":0.0039277,"teacher_disagreement_score":0.061621003,"about_ca_system_score_codex":0.00026304927,"about_ca_system_score_gemma":0.0021493782,"threshold_uncertainty_score":0.9919748},"labels":[],"label_agreement":null},{"id":"W2589551387","doi":"10.1200/jco.2011.29.27_suppl.35","title":"Pathologic characteristics of breast cancer with special emphasis on prevalence of triple-negative breast cancer from Kenya: A 4-year experience.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Progesterone receptor; Estrogen receptor; Cancer; Triple-negative breast cancer; Internal medicine; Oncology; Invasive ductal carcinoma; Gynecology; Pathological; Ductal carcinoma; Stage (stratigraphy); Pathology","score_opus":0.0702407780447447,"score_gpt":0.38912659910359165,"score_spread":0.31888582105884694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589551387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602556,0.0003113317,0.00003054092,0.00042532294,0.0010985899,0.00014626945,0.0013446164,0.0000025733734,0.0006151823],"genre_scores_gemma":[0.9914992,0.004697919,0.0010948943,0.0002659947,0.002335613,0.00002534661,0.0000041253784,0.00001767543,0.00005922461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747545,0.00028869428,0.0013968897,0.00032859546,0.00028524414,0.00022514212],"domain_scores_gemma":[0.9960903,0.00023285682,0.0025403078,0.00025353118,0.0007330921,0.00014989063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003983772,0.00022454478,0.0011506744,0.00005518658,0.000037787137,0.0000030566216,0.00032951837,0.00030835456,0.00068697345],"category_scores_gemma":[0.00031959926,0.0001489938,0.00030163376,0.000106626794,0.0007651919,0.000014246687,0.00009913552,0.00029354592,0.0000019743368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025619445,0.0020734195,0.9005623,0.00003800991,0.00096789264,0.0001088397,0.0014325193,0.0000030750653,0.0019430674,0.000016822038,0.00064807467,0.06658657],"study_design_scores_gemma":[0.004332309,0.0042259838,0.9850968,0.00019078891,0.00037078545,0.000112365284,0.00048806224,9.1034235e-7,0.0045978585,0.000052967505,0.00038228673,0.00014889464],"about_ca_topic_score_codex":0.000400221,"about_ca_topic_score_gemma":0.00019479387,"teacher_disagreement_score":0.08453452,"about_ca_system_score_codex":0.0000805437,"about_ca_system_score_gemma":0.000826029,"threshold_uncertainty_score":0.7521877},"labels":[],"label_agreement":null},{"id":"W2589552038","doi":"10.1200/jco.2013.31.31_suppl.157","title":"Patients’ and caregivers’ views on the timing and benefits of early palliative care: A qualitative study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Referral; Medicine; Palliative care; Quality of life (healthcare); Family medicine; Qualitative research; Grounded theory; Nursing; Intervention (counseling); Randomized controlled trial; Patient satisfaction; Advance care planning; Internal medicine","score_opus":0.5120880134381346,"score_gpt":0.5738530000198397,"score_spread":0.06176498658170515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589552038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945285,0.0018474668,0.0000069557477,0.0018398958,0.00018901401,0.0003935284,0.0000069916455,0.0000016538971,0.0011860045],"genre_scores_gemma":[0.99716216,0.0014179536,0.000714125,0.00052152557,0.00013238828,0.0000051766915,8.1111443e-7,0.0000074065906,0.0000384747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973782,0.000782349,0.0012789075,0.00013485363,0.00030997806,0.00011572055],"domain_scores_gemma":[0.98982614,0.0072138915,0.0015320296,0.00010797545,0.0011644757,0.00015548796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303397,0.00011484944,0.001156542,0.000074797084,0.000032654763,0.0000047659614,0.00008971545,0.0001386634,0.000032279466],"category_scores_gemma":[0.0045108916,0.000062594365,0.00016203772,0.000086154214,0.0003198731,0.00007623803,0.00005381568,0.00045854872,0.000003137944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013860451,0.00094486575,0.6383105,0.000059557362,0.00056309515,0.000015317777,0.29294908,0.0000017961738,0.0000140696375,0.00021521427,0.0011661416,0.06437435],"study_design_scores_gemma":[0.0053195506,0.031906746,0.8132353,0.00047458077,0.00028980308,0.0000014009844,0.14577496,0.0000031965017,0.00006773459,0.00017494,0.0026876167,0.00006419754],"about_ca_topic_score_codex":0.00015657698,"about_ca_topic_score_gemma":0.000048581805,"teacher_disagreement_score":0.1749248,"about_ca_system_score_codex":0.000045992205,"about_ca_system_score_gemma":0.00017765755,"threshold_uncertainty_score":0.54002845},"labels":[],"label_agreement":null},{"id":"W2589557101","doi":"10.1200/jco.2016.34.2_suppl.385","title":"Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Salvage therapy; Oncology; Proportional hazards model; Immunotherapy; Chemotherapy; Cancer","score_opus":0.10481926618742168,"score_gpt":0.45382248907565464,"score_spread":0.34900322288823293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589557101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934629,0.00024823652,0.0002395497,0.003348442,0.0015833286,0.000444821,0.000012337405,0.0000078443845,0.00065251626],"genre_scores_gemma":[0.9951806,0.00015467973,0.0030661118,0.0002649109,0.00064086687,0.000010448662,0.0000013143224,0.000022465862,0.0006586111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962378,0.00022438171,0.0026415368,0.0001871726,0.00047540246,0.00023369532],"domain_scores_gemma":[0.9955696,0.0015407179,0.0020372395,0.0002082786,0.00038806756,0.00025611842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013510624,0.00017026326,0.0019291771,0.00012426655,0.000023263809,0.0000033933272,0.00014062549,0.00026859788,0.00006217527],"category_scores_gemma":[0.0033712396,0.00008129944,0.0008495982,0.00011495895,0.00016691431,0.00016594,0.000038794264,0.0002615974,0.000003847505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008866345,0.001675527,0.72638786,0.000027070455,0.00051837333,0.00016898391,0.0001227593,4.4621572e-7,0.004903071,0.000031656098,0.00015172017,0.2571462],"study_design_scores_gemma":[0.038305294,0.029189643,0.9029183,0.00040376908,0.0011499552,0.000056847817,0.00016746197,0.0000021752749,0.020989314,0.0002919778,0.006403412,0.000121872086],"about_ca_topic_score_codex":0.00004058519,"about_ca_topic_score_gemma":0.00006352703,"teacher_disagreement_score":0.25702435,"about_ca_system_score_codex":0.00011714112,"about_ca_system_score_gemma":0.0016508009,"threshold_uncertainty_score":0.4035932},"labels":[],"label_agreement":null},{"id":"W2589561739","doi":"10.1200/jco.2014.32.4_suppl.61","title":"Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Cancer; Progression-free survival; Chemotherapy; Oncology; Urology; Androgen deprivation therapy","score_opus":0.1297104336152411,"score_gpt":0.47866846514905964,"score_spread":0.34895803153381855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589561739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9571364,0.0012708337,0.000028158198,0.038520858,0.0004088713,0.0007720591,0.000013384656,0.000009173294,0.0018402473],"genre_scores_gemma":[0.9921252,0.0032299878,0.00049604394,0.0008867819,0.00045049694,0.00010963225,0.0000050013364,0.000026383785,0.0026704727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961327,0.00074445934,0.0016503095,0.00030731162,0.0006746325,0.0004905967],"domain_scores_gemma":[0.9969392,0.00077011413,0.0011578714,0.0002536034,0.00051352207,0.00036570433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002478074,0.00022110755,0.0012257572,0.000118081734,0.000095624186,0.000037365153,0.00026890368,0.00013758618,0.00025400537],"category_scores_gemma":[0.00038526402,0.00010503505,0.00016741705,0.0002983986,0.00052927085,0.00019838254,0.000053873147,0.00094173267,0.0000057128277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10147564,0.0041515646,0.57214344,0.00047372334,0.002730332,0.003743756,0.012845394,0.002607769,0.0048189084,0.00054190453,0.00818552,0.28628203],"study_design_scores_gemma":[0.05076291,0.011715632,0.8683192,0.00093945494,0.0008373631,0.00016510922,0.0036379558,0.0019248087,0.0020533348,0.0005271835,0.058735464,0.00038154054],"about_ca_topic_score_codex":0.00070511823,"about_ca_topic_score_gemma":0.003868643,"teacher_disagreement_score":0.29617578,"about_ca_system_score_codex":0.0004288984,"about_ca_system_score_gemma":0.0027851174,"threshold_uncertainty_score":0.49406785},"labels":[],"label_agreement":null},{"id":"W2589565253","doi":"10.1200/jco.2014.32.30_suppl.161","title":"Moving to secondary use of IT solutions: A provincial “near miss indicator” for chemotherapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacy; Regimen; Emergency medicine; Medical emergency; Family medicine; Surgery","score_opus":0.44601731176226633,"score_gpt":0.5804088669541518,"score_spread":0.1343915551918855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589565253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8717969,0.000047652095,0.03386997,0.09172612,0.0013357039,0.0008782678,0.00001996201,0.00001173473,0.00031370446],"genre_scores_gemma":[0.75597906,0.0000990966,0.1911042,0.049451794,0.0031721382,0.000014494625,0.000009019357,0.000031447133,0.00013871622],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99359196,0.00048425206,0.005067294,0.00020891738,0.0003890073,0.0002585685],"domain_scores_gemma":[0.9775261,0.01699091,0.00376665,0.00025406518,0.0009944267,0.0004678076],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011560908,0.00012338615,0.0013302567,0.00014445875,0.000062672305,0.000015422129,0.00017318563,0.0003599041,0.0002406457],"category_scores_gemma":[0.10220396,0.000099141944,0.0005602814,0.00012991854,0.00017628293,0.00026495775,0.000069859445,0.00079368835,0.000015671827],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0109629305,0.0019714066,0.017845936,0.00009932706,0.00038421486,0.000019160532,0.000224234,0.00003969744,0.0011527436,0.00021393632,0.08535782,0.8817286],"study_design_scores_gemma":[0.012291343,0.019917514,0.077177756,0.00010834594,0.0004931189,0.00011264129,0.00017872403,0.0012822113,0.00015644715,0.00060349965,0.8875657,0.000112753],"about_ca_topic_score_codex":0.00005976101,"about_ca_topic_score_gemma":0.00012700015,"teacher_disagreement_score":0.8816158,"about_ca_system_score_codex":0.00013152239,"about_ca_system_score_gemma":0.0036375215,"threshold_uncertainty_score":0.90535855},"labels":[],"label_agreement":null},{"id":"W2589567505","doi":"10.1200/jco.2014.32.31_suppl.190","title":"The McGill University Health Centre interdisciplinary approach to cancer pain management: Description of treatments and outcomes.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Palliative care; Medical prescription; Opioid; Psychosocial; Brief Pain Inventory; Cancer pain; Morphine; McGill Pain Questionnaire; Cancer; Internal medicine; Physical therapy; Chronic pain; Visual analogue scale; Nursing; Psychiatry","score_opus":0.12629462847540376,"score_gpt":0.47474995244364865,"score_spread":0.34845532396824486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589567505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8858639,0.0006253078,0.00073225977,0.10237818,0.001466577,0.0007230042,0.000043197728,0.000010173027,0.008157392],"genre_scores_gemma":[0.9856239,0.002786297,0.0023673535,0.004043637,0.0002016789,0.0000019612169,0.0000027232704,0.0000083980485,0.0049640457],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99821913,0.00065791176,0.0007201113,0.0001262625,0.00012553958,0.00015105553],"domain_scores_gemma":[0.9980895,0.0007722026,0.00068887486,0.00009593054,0.000093805036,0.00025970564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022318447,0.00008487421,0.00073024386,0.000076665565,0.00009453433,0.0000013387961,0.00008902419,0.00008611235,0.0000151306285],"category_scores_gemma":[0.000102444945,0.000049950828,0.00018594335,0.00008415078,0.00009332753,0.00003865556,0.00010070501,0.00021548283,0.000001426304],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005230659,0.002688835,0.15479463,0.00007742258,0.0013759787,0.000045634166,0.00033529548,0.000016723825,0.000012179935,0.00038247588,0.037627228,0.79741293],"study_design_scores_gemma":[0.011192094,0.011013075,0.6327483,0.000081536586,0.0007608492,0.00002433728,0.0007968767,0.00018935453,0.0000043936047,0.00028630465,0.34284216,0.000060753202],"about_ca_topic_score_codex":0.00008344282,"about_ca_topic_score_gemma":0.00019101617,"teacher_disagreement_score":0.7973522,"about_ca_system_score_codex":0.0003947066,"about_ca_system_score_gemma":0.00014753125,"threshold_uncertainty_score":0.20369357},"labels":[],"label_agreement":null},{"id":"W2589575011","doi":"10.1200/jco.2012.30.4_suppl.448","title":"Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Cetuximab; Irinotecan; Internal medicine; Gastroenterology; Colorectal cancer; Rash; Nausea; Phases of clinical research; Adverse effect; Oxaliplatin; Cancer; Toxicity","score_opus":0.12753577347245432,"score_gpt":0.49634762269404736,"score_spread":0.36881184922159305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589575011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712235,0.00042509416,0.0000064864944,0.00047823935,0.00048660298,0.0009333443,0.0000120984905,0.0000060176303,0.00052974536],"genre_scores_gemma":[0.9981829,0.00014372643,0.00092190097,0.00026571716,0.00028409404,0.000049075396,0.0000020316493,0.000024979507,0.00012559697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667996,0.00033063136,0.0018052013,0.0002043863,0.0006163901,0.00036345175],"domain_scores_gemma":[0.99683505,0.0007373437,0.0013375577,0.00014672086,0.00061205484,0.00033126623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011215155,0.0002376193,0.002545241,0.00017105293,0.00006319816,0.0000031065363,0.00011573876,0.00010785214,0.00016622226],"category_scores_gemma":[0.00051684293,0.00011299701,0.00015408659,0.00031017314,0.00021397923,0.00018318064,0.00006904287,0.0006167141,0.0000015152496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10839536,0.06472815,0.78398144,0.000028600034,0.0018386559,0.00016509634,0.0019425482,0.000006269333,0.0000061735677,0.0000019479278,0.00015966939,0.03874606],"study_design_scores_gemma":[0.09572107,0.28909338,0.6110973,0.00011723624,0.0014177343,0.000044957214,0.001280893,0.000008308032,0.000021165286,0.000002596698,0.0010999021,0.00009550413],"about_ca_topic_score_codex":0.00024066109,"about_ca_topic_score_gemma":0.003369489,"teacher_disagreement_score":0.22436522,"about_ca_system_score_codex":0.00031758472,"about_ca_system_score_gemma":0.0012025547,"threshold_uncertainty_score":0.46078843},"labels":[],"label_agreement":null},{"id":"W2589575991","doi":"10.1200/jco.2015.33.29_suppl.196","title":"Efficacy of acupuncture (ACU) therapy for cancer-related pain management in oncology patients (pts).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acupuncture Treatment Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neuropathic pain; Cancer pain; Internal medicine; Acupuncture; Physical therapy; Population; Odds ratio; Performance status; Cancer; Logistic regression; Oncology; Anesthesia; Alternative medicine; Pathology","score_opus":0.20572391337438595,"score_gpt":0.5490373332429328,"score_spread":0.34331341986854685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589575991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96655947,0.0025128308,0.00011413859,0.023129221,0.0014921259,0.0023846272,0.000008268267,0.00001616893,0.0037831215],"genre_scores_gemma":[0.9801234,0.0065052733,0.009296435,0.0027552913,0.00058757537,0.00008896812,0.000015572461,0.00003158781,0.0005958939],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521637,0.0010438894,0.0025347362,0.00024791624,0.0005809058,0.00037620618],"domain_scores_gemma":[0.98977363,0.006806768,0.0017062254,0.000215435,0.0010933679,0.00040455424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073027737,0.00029806307,0.0028644688,0.00028087304,0.000025662996,0.0000032986566,0.00024341414,0.0005145885,0.00006333326],"category_scores_gemma":[0.007853988,0.00012433025,0.0007226193,0.00025999884,0.0002445199,0.000067744855,0.000091903,0.00083680527,0.0000045283646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027473222,0.011734756,0.19655006,0.00008144238,0.0033998494,0.0004420018,0.00073656917,0.000043979588,0.000014302019,0.00007727125,0.046131827,0.7133147],"study_design_scores_gemma":[0.080658235,0.061224952,0.40171272,0.00015427568,0.0006984171,0.000020610063,0.00033936097,0.00006865746,0.00003899919,0.0007818192,0.45418444,0.00011753418],"about_ca_topic_score_codex":0.000029134995,"about_ca_topic_score_gemma":0.000078924546,"teacher_disagreement_score":0.7131972,"about_ca_system_score_codex":0.00097178266,"about_ca_system_score_gemma":0.0016018146,"threshold_uncertainty_score":0.9402524},"labels":[],"label_agreement":null},{"id":"W2589576240","doi":"10.1200/jco.2008.26.15_suppl.6536","title":"Uptake of aromatase inhibitors (AI) and trastuzumab (T) during the first 5 years after market introduction. A North American and European comparison","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Letrozole; Anastrozole; Trastuzumab; Breast cancer; Exemestane; Metastatic breast cancer; Aromatase; Tamoxifen; Per capita; Cancer; Oncology; Internal medicine; Demography; Population; Environmental health","score_opus":0.01444105795071814,"score_gpt":0.3120123038069161,"score_spread":0.29757124585619793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589576240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747115,0.0011903094,0.000007738405,0.0009454288,0.00023043485,0.00006309308,0.000004229135,0.0000017954281,0.00008579887],"genre_scores_gemma":[0.99658865,0.0019337853,0.0002608466,0.00020327124,0.00096339657,0.0000010228755,0.0000020921514,0.000010682327,0.00003624555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849474,0.00029765745,0.0008449729,0.00014685554,0.00009910147,0.0001166635],"domain_scores_gemma":[0.9989268,0.000096110714,0.0006657472,0.00012665654,0.00006391192,0.000120740435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072855357,0.000089598245,0.0004253228,0.000035326484,0.000054820026,0.000005118215,0.00009113561,0.00008949454,0.0000049756527],"category_scores_gemma":[0.0003231327,0.000059131802,0.00012675322,0.00006741336,0.0006112149,0.0000059791355,0.00007991604,0.00041006802,0.0000010428582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059389365,0.0009470531,0.8901257,0.000037149777,0.00060382305,0.0005425471,0.00036696187,0.000061260005,0.0039117634,0.0000017534511,0.028369812,0.06909325],"study_design_scores_gemma":[0.0012759782,0.0033387467,0.9379252,0.000008398128,0.00006309128,0.000742545,0.00005335819,0.000015360696,0.000544989,0.0000010782987,0.05596861,0.00006264212],"about_ca_topic_score_codex":0.0000049732607,"about_ca_topic_score_gemma":0.000029574747,"teacher_disagreement_score":0.06903061,"about_ca_system_score_codex":0.000009683502,"about_ca_system_score_gemma":0.000090234935,"threshold_uncertainty_score":0.24113248},"labels":[],"label_agreement":null},{"id":"W2589576668","doi":"10.1200/jco.2013.31.4_suppl.436","title":"Impact of KRAS mutational status on clinical outcomes in patients receiving capecitabine based chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"KRAS; Medicine; Hazard ratio; Internal medicine; Capecitabine; Oncology; Chemotherapy; Colorectal cancer; Chemotherapy regimen; Regimen; Predictive marker; Cancer; Confidence interval","score_opus":0.09455600784857054,"score_gpt":0.496841165983194,"score_spread":0.40228515813462346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589576668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944359,0.00006164782,0.0000066337116,0.002581582,0.0006610308,0.00030436486,0.000007631814,0.0000037318541,0.0019374652],"genre_scores_gemma":[0.9966933,0.00019822731,0.001320182,0.0014255857,0.0002535127,0.000006696393,0.0000046526384,0.0000131083525,0.000084707615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961218,0.0003150515,0.0027662239,0.0001666054,0.00039470973,0.0002355759],"domain_scores_gemma":[0.9929195,0.0044712257,0.0015367236,0.000129465,0.0006694195,0.0002736889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012709183,0.00015093244,0.0018274949,0.00015983824,0.000019456384,0.000004506027,0.00008072897,0.00022160991,0.00069178134],"category_scores_gemma":[0.005420163,0.00008755363,0.0008541125,0.00012622177,0.00017003283,0.0000785421,0.000020434063,0.0006146438,0.00001355936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005120494,0.0062991255,0.8175695,0.0000062122076,0.0006229845,0.000031391857,0.000053328647,0.000027146492,0.0000027840645,0.0000026930886,0.0012886951,0.16897567],"study_design_scores_gemma":[0.0243072,0.05168935,0.9230044,0.00006363436,0.000098470504,0.000003357726,0.000029483272,0.0000602516,0.0000026277007,0.000086672124,0.0005909115,0.00006364854],"about_ca_topic_score_codex":0.00017998414,"about_ca_topic_score_gemma":0.000083185565,"teacher_disagreement_score":0.16891202,"about_ca_system_score_codex":0.0003825013,"about_ca_system_score_gemma":0.001312436,"threshold_uncertainty_score":0.7574521},"labels":[],"label_agreement":null},{"id":"W2589580027","doi":"10.1200/jco.2014.32.4_suppl.404","title":"Professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC) among oncologists in the United States.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Sunitinib; Thematic analysis; Family medicine; Renal cell carcinoma; Temsirolimus; Kidney cancer; Cancer; Qualitative research; Internal medicine","score_opus":0.06505440544012524,"score_gpt":0.382661489316703,"score_spread":0.31760708387657777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589580027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805867,0.00084578426,0.00033632357,0.006072499,0.00094279123,0.00018151996,0.000026471005,0.000002092685,0.01100581],"genre_scores_gemma":[0.9914003,0.00048067374,0.0019194251,0.005673808,0.00041375353,0.000005777444,0.0000037546297,0.000012036118,0.000090442976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965643,0.00036158244,0.002501455,0.00022589133,0.00007353511,0.00027319705],"domain_scores_gemma":[0.9934614,0.0028019606,0.002913347,0.00019119304,0.00026655418,0.00036559333],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0069481796,0.00013297083,0.0011041752,0.00027549049,0.00006046116,0.000020779953,0.00038670242,0.00033858532,0.000075751836],"category_scores_gemma":[0.009571399,0.00010298675,0.00018189524,0.00020686761,0.0002992275,0.0002931185,0.00008668421,0.00085314875,0.000010934117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039191893,0.00089640066,0.9267392,0.00009141958,0.00010853698,0.00013895302,0.013256386,0.0066432017,0.000009341966,0.014243232,0.016189571,0.017764563],"study_design_scores_gemma":[0.0033039898,0.0061675347,0.5731803,0.000035589535,0.000033094155,0.000023079832,0.0044220393,0.000554658,0.000018689387,0.001478158,0.4106244,0.00015843393],"about_ca_topic_score_codex":0.00043720883,"about_ca_topic_score_gemma":0.00019573013,"teacher_disagreement_score":0.39443484,"about_ca_system_score_codex":0.000180397,"about_ca_system_score_gemma":0.00062325335,"threshold_uncertainty_score":0.9987714},"labels":[],"label_agreement":null},{"id":"W2589581539","doi":"10.1200/jco.2015.33.3_suppl.287","title":"Overall survival and clinical characteristics in <i>BRCA</i> mutation carriers with stage I/II pancreatic cancer (PC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; BRCA mutation; Oncology; Breast cancer; Ovarian cancer; Pancreatic cancer; Carboplatin; Exact test; Stage (stratigraphy); Lymphovascular invasion; Cancer; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.0663149098773968,"score_gpt":0.4129896549761734,"score_spread":0.3466747450987766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589581539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957881,0.00079530437,0.0002388876,0.0009948509,0.0014112589,0.00011557937,0.000034006323,0.0000018691159,0.0006201687],"genre_scores_gemma":[0.9905816,0.0053646127,0.0010982334,0.0012230972,0.0014712543,0.000004094642,0.000015997573,0.000019183026,0.00022197887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974522,0.00033165707,0.0015918645,0.00023375022,0.00018748351,0.00020303798],"domain_scores_gemma":[0.99736685,0.00052589877,0.0011740035,0.00015855857,0.00036899548,0.00040566878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026960184,0.00013686062,0.0008554625,0.000043918186,0.00002843574,0.00001605443,0.00014195264,0.0003654278,0.000008585765],"category_scores_gemma":[0.0030669293,0.00010733283,0.00013414712,0.0000543356,0.00023641548,0.0000098770615,0.00009769888,0.00046467702,0.0000013193974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005941552,0.0006598423,0.9502629,0.000019653611,0.0003360544,0.00035427485,0.00011897112,0.00023223502,0.00040106583,0.0001244914,0.0030531692,0.038495794],"study_design_scores_gemma":[0.01764549,0.02554182,0.6826458,0.000082842176,0.00034349982,0.00012617292,0.00039713987,0.00034237714,0.00021340592,0.00024803294,0.2720428,0.0003705977],"about_ca_topic_score_codex":0.00013344182,"about_ca_topic_score_gemma":0.0013810993,"teacher_disagreement_score":0.26898965,"about_ca_system_score_codex":0.00007744312,"about_ca_system_score_gemma":0.0023734425,"threshold_uncertainty_score":0.4376906},"labels":[],"label_agreement":null},{"id":"W2589585238","doi":"10.1200/jco.2016.34.7_suppl.263","title":"Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; University of Toronto; Institute for Clinical Evaluative Sciences; Health Sciences Centre; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decile; Systemic therapy; Breast cancer; Stage (stratigraphy); Benchmark (surveying); Quality management; Health care; Population; Cancer; Internal medicine; Operations management; Statistics","score_opus":0.08308209218728892,"score_gpt":0.4580980536149824,"score_spread":0.3750159614276935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589585238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889823,0.0011399129,0.0019127504,0.005860623,0.0012231381,0.00051574316,0.0002653508,0.0000026395314,0.00009753074],"genre_scores_gemma":[0.99330306,0.00302362,0.001045888,0.00066907064,0.0015763541,0.00015444502,0.000008300403,0.00001859921,0.0002006611],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99748343,0.00021363262,0.0015634075,0.00028803467,0.00013845495,0.0003130267],"domain_scores_gemma":[0.99661607,0.0012630611,0.001372646,0.00019158974,0.0004335239,0.0001231332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030973998,0.00015670748,0.000829426,0.000045932644,0.000053337943,0.000012946449,0.00025229575,0.0003141676,0.000022149141],"category_scores_gemma":[0.001060967,0.0000944771,0.0004126292,0.000044809112,0.000103789025,0.000019454708,0.00006353252,0.00014564926,3.6990107e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019048152,0.0010986015,0.41459885,0.00007867694,0.0008360747,0.0000072267476,0.000082263796,0.000027558508,0.045011073,0.00012732735,0.003765735,0.51531845],"study_design_scores_gemma":[0.045539387,0.015447559,0.82465357,0.00032360727,0.00015892621,0.000056971396,0.00039453607,0.000010035632,0.009907692,0.00064008153,0.10243253,0.00043510398],"about_ca_topic_score_codex":0.00022357386,"about_ca_topic_score_gemma":0.00051512657,"teacher_disagreement_score":0.51488334,"about_ca_system_score_codex":0.00019148618,"about_ca_system_score_gemma":0.00078975334,"threshold_uncertainty_score":0.38526642},"labels":[],"label_agreement":null},{"id":"W2589592541","doi":"10.1200/jco.2013.31.6_suppl.77","title":"Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Hazard ratio; Internal medicine; Cohort; Population; Oncology; Radiation therapy; Confidence interval; Cancer; Surgery","score_opus":0.10817203860025536,"score_gpt":0.5104333920947581,"score_spread":0.40226135349450276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589592541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639553,0.0006909682,0.00005244866,0.033395454,0.00061457395,0.0011648347,0.000049907416,0.0000041669537,0.00007237318],"genre_scores_gemma":[0.9962517,0.00092819094,0.0006519911,0.0006038711,0.001085455,0.00009821219,0.000024281515,0.000017514734,0.00033876026],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99727464,0.00045775122,0.0013518876,0.00016603369,0.000527834,0.0002218479],"domain_scores_gemma":[0.99598354,0.0014625445,0.0011137298,0.00018234263,0.0010870425,0.00017079336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024453097,0.0001393097,0.00090480037,0.00010927859,0.000054145083,0.000021083182,0.000083640356,0.0001111652,0.0006372891],"category_scores_gemma":[0.00095372484,0.000064197106,0.00045129517,0.000109211025,0.00013389369,0.00013856537,0.000007581278,0.00043551618,0.000004241072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5102644,0.00332635,0.25719988,0.00020959358,0.0027232664,0.000104034465,0.00039475478,0.001995714,0.0045222784,0.0002390222,0.017223164,0.20179754],"study_design_scores_gemma":[0.021104302,0.043481644,0.9234673,0.00009708678,0.00032578578,0.000019761983,0.00009119935,0.00028750146,0.0011891598,0.002207143,0.0076343636,0.000094782976],"about_ca_topic_score_codex":0.00048878015,"about_ca_topic_score_gemma":0.000108381064,"teacher_disagreement_score":0.6662674,"about_ca_system_score_codex":0.0003880172,"about_ca_system_score_gemma":0.0022539473,"threshold_uncertainty_score":0.69778687},"labels":[],"label_agreement":null},{"id":"W2589597960","doi":"10.1200/jco.2016.34.2_suppl.101","title":"Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Biopsy; Univariate analysis; Cancer; Prostate; Oncology; Urology; Genitourinary system; Internal medicine; Carcinoma; Metastasis; Multivariate analysis; Radiology","score_opus":0.0330986083319683,"score_gpt":0.35659454319049494,"score_spread":0.3234959348585266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589597960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936473,0.00048394434,0.000016154441,0.004850711,0.00013480271,0.00076610176,0.000030677187,0.000009502968,0.000060829494],"genre_scores_gemma":[0.9978572,0.0008478937,0.0006101745,0.00041735914,0.00015288773,0.000024157172,0.000006506275,0.00003102613,0.000052784606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980294,0.00009390098,0.001009331,0.00026992944,0.0002942674,0.0003031543],"domain_scores_gemma":[0.9976564,0.0007072383,0.00080364966,0.00012510885,0.00031163197,0.00039597988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028900412,0.000230955,0.0011565798,0.00014453373,0.0000264479,0.0000102422755,0.0000666147,0.00019145478,0.00005167019],"category_scores_gemma":[0.00027614532,0.00009469555,0.00010136928,0.00016790444,0.0002960928,0.00012200096,0.000015385662,0.00044769485,6.801221e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020411357,0.0019488735,0.84824723,0.000024027731,0.0004810564,0.00030944,0.00024140651,0.000005773829,0.00009854539,0.0000042248594,0.00003806703,0.12818998],"study_design_scores_gemma":[0.03807272,0.046556734,0.9127989,0.00054857734,0.00031027495,0.00013488553,0.00002964669,0.0000038273765,0.00025814137,0.000022229096,0.0011378042,0.00012628578],"about_ca_topic_score_codex":0.00015183163,"about_ca_topic_score_gemma":0.0001772635,"teacher_disagreement_score":0.1280637,"about_ca_system_score_codex":0.0003746292,"about_ca_system_score_gemma":0.0011011487,"threshold_uncertainty_score":0.38615724},"labels":[],"label_agreement":null},{"id":"W2589605691","doi":"10.1200/jco.2015.33.3_suppl.551","title":"Treatment and outcomes of goblet cell adenocarcinomas (GCAs) of the appendix.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Population; Appendix; Univariate analysis; Cancer; Lymph node; Adenocarcinoma; Oxaliplatin; Gastroenterology; Surgery; Oncology; Multivariate analysis; Colorectal cancer","score_opus":0.14429874415670182,"score_gpt":0.43235947343264675,"score_spread":0.28806072927594495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589605691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846462,0.0009716464,0.000004524171,0.0066699414,0.0006667348,0.00013710928,0.0000056251133,0.0000018156297,0.006896384],"genre_scores_gemma":[0.99729383,0.0002843444,0.00079393835,0.00054046593,0.0002677602,8.621014e-7,5.617364e-7,0.0000067451697,0.00081151695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775416,0.00021213056,0.001555953,0.00009136723,0.00025110654,0.00013526704],"domain_scores_gemma":[0.9971513,0.0007984651,0.0014073827,0.00015517668,0.0002489384,0.00023873008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010013183,0.00010301395,0.0013404379,0.000045291323,0.000017358554,0.0000019923343,0.00012430639,0.00018954593,0.00005978427],"category_scores_gemma":[0.00064530433,0.000048198897,0.00038488655,0.000065114305,0.0003615788,0.000038629805,0.0000553334,0.0002876549,0.000007907684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019615926,0.0020297219,0.9743457,0.00006811232,0.00030594564,0.00021463372,0.00048724285,0.0000040211885,0.0015150268,0.000663869,0.0023190656,0.01608509],"study_design_scores_gemma":[0.012312904,0.03226996,0.88171995,0.000089493245,0.0008038726,0.0007263841,0.0009592066,0.000019226862,0.0066061327,0.000666054,0.063742936,0.00008386665],"about_ca_topic_score_codex":0.00006127614,"about_ca_topic_score_gemma":0.000014919401,"teacher_disagreement_score":0.09262572,"about_ca_system_score_codex":0.0000534592,"about_ca_system_score_gemma":0.00086576975,"threshold_uncertainty_score":0.1965494},"labels":[],"label_agreement":null},{"id":"W2589606547","doi":"10.1200/jco.2013.31.4_suppl.46","title":"The role of miRNA-145 in esophageal adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; St Joseph's Health Centre; University Health Network","funders":"","keywords":"microRNA; Apoptosis; Cancer research; Medicine; Cell growth; Adenocarcinoma; Cell culture; Downregulation and upregulation; Cell; Cancer; Biology; Internal medicine; Gene; Genetics","score_opus":0.03505984720267826,"score_gpt":0.40528719825028886,"score_spread":0.3702273510476106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589606547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98260504,0.0105968015,0.00049001334,0.0020201055,0.00069180655,0.0002685867,0.0000021556673,0.000001756573,0.0033237434],"genre_scores_gemma":[0.99640316,0.0016905587,0.00074129854,0.00029449095,0.0005277469,0.00000895324,0.0000016177547,0.000015230712,0.00031692407],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717015,0.00057515234,0.0015182651,0.00016800291,0.00029029214,0.0002781578],"domain_scores_gemma":[0.9978624,0.00041853808,0.0008234488,0.00027969258,0.00043240402,0.00018349696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002485141,0.00009971733,0.00049872516,0.00007135175,0.000034292465,0.0000121738085,0.00050620665,0.0004535776,0.00007403331],"category_scores_gemma":[0.0022006382,0.00006731035,0.00033091573,0.00011644255,0.0002382661,0.0000066552725,0.00016556482,0.0007270199,0.00001887118],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002798683,0.0011648961,0.0214984,0.000019078652,0.0005810647,0.00017278174,0.000091567985,0.00027471536,0.48837304,0.001157424,0.008860953,0.47500739],"study_design_scores_gemma":[0.010898397,0.023152318,0.26090312,0.00008080258,0.00013206062,0.00047301067,0.0008101139,0.0008828817,0.28493282,0.011225029,0.40610358,0.00040586505],"about_ca_topic_score_codex":0.00007435803,"about_ca_topic_score_gemma":0.00011554881,"teacher_disagreement_score":0.47460154,"about_ca_system_score_codex":0.000042530493,"about_ca_system_score_gemma":0.0010089859,"threshold_uncertainty_score":0.34984058},"labels":[],"label_agreement":null},{"id":"W2589609144","doi":"10.1200/jco.2016.34.2_suppl.417","title":"Are we systemically under treating cisplatin-eligible patients with muscle invasive bladder cancer (MIBC) who are undergoing bladder preservation by chemoradiotherapy?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; University Health Network; Lakeridge Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Gemcitabine; Cisplatin; Chemoradiotherapy; Neutropenia; Urology; Radiation therapy; Febrile neutropenia; Chemotherapy; Oncology; Cystoscopy; Internal medicine; Cancer; Surgery; Urinary system","score_opus":0.08324105154999831,"score_gpt":0.39913078654151457,"score_spread":0.3158897349915163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589609144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755751,0.0017454068,0.0010296445,0.01924117,0.00061962527,0.0006027643,0.00004577424,0.000029808696,0.0011107442],"genre_scores_gemma":[0.9879088,0.003427457,0.0008654982,0.00460485,0.0011598693,0.00003582103,0.000005370674,0.000076032935,0.0019163263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961945,0.00034660043,0.0019219874,0.0004104421,0.0007131729,0.0004133051],"domain_scores_gemma":[0.99201035,0.0023900769,0.0038105377,0.00030364294,0.0010313115,0.00045405925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006277121,0.00032085966,0.0018499123,0.00012114375,0.00009971617,0.000026768314,0.00020819622,0.0004655543,0.00039178648],"category_scores_gemma":[0.0011334788,0.00017498326,0.00033604307,0.00020909203,0.00019163509,0.00043990018,0.000042820953,0.00052157027,0.000011083994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049418625,0.0020426165,0.9214209,0.0002141981,0.002532886,0.0001391565,0.00022705589,0.000057263962,0.0012299294,0.000017741213,0.026630174,0.040546227],"study_design_scores_gemma":[0.059895415,0.013301209,0.8993297,0.006797894,0.0018375596,0.00008084394,0.00072231033,0.00003926431,0.0014073668,0.00043385432,0.015645579,0.00050895754],"about_ca_topic_score_codex":0.00007294564,"about_ca_topic_score_gemma":0.00046012565,"teacher_disagreement_score":0.05495355,"about_ca_system_score_codex":0.0006501872,"about_ca_system_score_gemma":0.0017885405,"threshold_uncertainty_score":0.71356106},"labels":[],"label_agreement":null},{"id":"W2589616310","doi":"10.1200/jco.2012.30.34_suppl.248","title":"Development of quality indicators for treatment of ductal carcinoma in situ (DCIS) of the breast using a multidisciplinary Delphi process.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Medicine; Delphi method; Ductal carcinoma; Multidisciplinary approach; Likert scale; Breast cancer; Medical diagnosis; Medical physics; Family medicine; Cancer; Internal medicine; Pathology; Psychology","score_opus":0.5030551334098053,"score_gpt":0.6324420316247569,"score_spread":0.12938689821495153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589616310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997342,0.00014268597,0.00011109508,0.001141475,0.00031160418,0.00047269982,0.000008071975,0.000002366137,0.00046801343],"genre_scores_gemma":[0.98562866,0.00003768411,0.014077447,0.00001107114,0.00021851968,0.000011006514,3.3075622e-7,0.0000074505883,0.000007810843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504775,0.0010340088,0.0028258134,0.00011354155,0.000669069,0.0003098483],"domain_scores_gemma":[0.9934822,0.0026336254,0.0030506107,0.00014488699,0.0005025138,0.00018618305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012481395,0.000092186776,0.0009769768,0.00020787548,0.000089118985,0.0000024799963,0.00046260876,0.00031189952,0.000016473326],"category_scores_gemma":[0.0028412049,0.000059272996,0.00034686897,0.00042128025,0.0008472779,0.00014557796,0.000104748164,0.00022225257,2.2131759e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012067495,0.0044589834,0.92813563,0.000075149765,0.000096878415,0.0000066970197,0.02252283,0.00001285135,0.0020782943,0.0004284927,0.000019009194,0.040958412],"study_design_scores_gemma":[0.0020509635,0.0012870218,0.97738457,0.000083424886,0.000057218545,0.000026712476,0.012190469,0.000021452106,0.0055335118,0.000710571,0.00057282764,0.000081231636],"about_ca_topic_score_codex":0.00023945271,"about_ca_topic_score_gemma":0.00094766926,"teacher_disagreement_score":0.049248945,"about_ca_system_score_codex":0.0004588427,"about_ca_system_score_gemma":0.0051535717,"threshold_uncertainty_score":0.91422147},"labels":[],"label_agreement":null},{"id":"W2589616340","doi":"10.1200/jco.2006.24.18_suppl.6028","title":"Timely access to care for colorectal cancer (CRC): A description and analysis of associated factors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Dartmouth General Hospital; Dalhousie University","funders":"","keywords":"Medicine; Interquartile range; Colorectal cancer; Confidence interval; Cohort; Multivariate analysis; Prospective cohort study; Internal medicine; Cancer; Cohort study","score_opus":0.13808693095068666,"score_gpt":0.47575856909933084,"score_spread":0.3376716381486442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589616340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967018,0.00037847343,0.0011124378,0.00061075593,0.00061829865,0.00024153871,0.000034581943,0.000008972679,0.00029315133],"genre_scores_gemma":[0.9986352,0.00005982363,0.0006568066,0.0002007166,0.00035330883,0.000009853117,0.0000137143725,0.000008485337,0.0000621136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981731,0.00012825243,0.001201317,0.00014647986,0.00021473946,0.00013611604],"domain_scores_gemma":[0.9967514,0.00096419395,0.0011428755,0.000055782974,0.00091865426,0.00016707472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083309005,0.000089470115,0.0012740839,0.00034948727,0.000042534484,0.000012773247,0.00007247309,0.00027046524,0.000032251188],"category_scores_gemma":[0.001904035,0.00006746014,0.0004919982,0.0005414858,0.000062509265,0.000095715826,0.000027254322,0.000266515,1.8214487e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017205896,0.0004186623,0.92857003,0.000030809002,0.0015704242,0.000010395249,0.00027365139,0.0005024733,0.0016758356,0.0000054661205,0.0013089771,0.048427407],"study_design_scores_gemma":[0.0026067279,0.019443316,0.9697517,0.000048913054,0.0032857251,0.0000059912327,0.00015724945,0.0007921263,0.0010558763,0.00003361849,0.0027554203,0.00006334519],"about_ca_topic_score_codex":0.0009367312,"about_ca_topic_score_gemma":0.006757807,"teacher_disagreement_score":0.04836406,"about_ca_system_score_codex":0.00029019144,"about_ca_system_score_gemma":0.0005131289,"threshold_uncertainty_score":0.37710148},"labels":[],"label_agreement":null},{"id":"W2589626476","doi":"10.1200/jco.2013.31.31_suppl.166","title":"Feasibility and utility of influenza vaccination in hematology/oncology clinics.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Vaccination; Hematology; Internal medicine; Cancer; Influenza vaccine; Family medicine; Pediatrics; Immunology","score_opus":0.32140882517648145,"score_gpt":0.5862310452701984,"score_spread":0.264822220093717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589626476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768098,0.0014797018,0.00004349066,0.0059134695,0.0003725433,0.0004213842,0.000001534799,0.000004337069,0.014953716],"genre_scores_gemma":[0.99559957,0.0010203896,0.0012006802,0.0018909018,0.00024192994,0.0000062215354,7.65622e-7,0.0000071507056,0.000032372518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947079,0.00093954965,0.003554916,0.00022683346,0.0003208055,0.0002500338],"domain_scores_gemma":[0.99156654,0.005068049,0.0013491944,0.00023575564,0.0013519616,0.0004284869],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00822595,0.000104895385,0.0019728718,0.00019301951,0.000018124658,0.000004480167,0.00015669357,0.00068683946,0.0032719288],"category_scores_gemma":[0.0145104015,0.000075471515,0.00028819643,0.0002133841,0.00034951928,0.0001513044,0.000118094234,0.0015479256,0.000016042828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030543013,0.0014497119,0.6157379,0.00009293772,0.000045648816,0.00004577363,0.00005782944,3.6394167e-7,0.000012294372,0.0001388085,0.00087104243,0.3784934],"study_design_scores_gemma":[0.011085201,0.0080913305,0.963072,0.000019994199,0.00006638495,0.00015429637,0.00015148189,0.00034788199,0.00003940908,0.0063330815,0.010586828,0.000052082116],"about_ca_topic_score_codex":0.00011381324,"about_ca_topic_score_gemma":0.00026056767,"teacher_disagreement_score":0.3784413,"about_ca_system_score_codex":0.00017678364,"about_ca_system_score_gemma":0.0019294953,"threshold_uncertainty_score":0.99763924},"labels":[],"label_agreement":null},{"id":"W2589629201","doi":"10.1200/jco.2014.32.4_suppl.334","title":"Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Hazard ratio; Confidence interval; Proportional hazards model; Radiation therapy; Chemotherapy; Retrospective cohort study; Stage (stratigraphy); Population; Oncology; Cohort; Confounding; Internal medicine; Urology; Surgery; Cancer","score_opus":0.1539236396010719,"score_gpt":0.46470202795964544,"score_spread":0.3107783883585735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589629201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209857,0.00015158144,0.0029468308,0.00053112954,0.001764424,0.00094373006,0.000016607033,0.000012011591,0.001535095],"genre_scores_gemma":[0.9950129,0.000017298606,0.003471606,0.00013631997,0.001221482,0.000054226268,0.000024381052,0.000023270763,0.00003852258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623466,0.0008570856,0.0020217185,0.00029306833,0.00035006853,0.0002434042],"domain_scores_gemma":[0.9847054,0.012298607,0.0018311028,0.0002613387,0.0005642401,0.00033930433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020449169,0.00022323462,0.0024346355,0.00012160726,0.00009546139,0.000010221858,0.000111177,0.0003201348,0.000028885166],"category_scores_gemma":[0.0033678438,0.00015469042,0.00091802725,0.000110246576,0.00018405124,0.00006065051,0.000016795624,0.0003140746,0.0000031085565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22088984,0.012832014,0.68965495,0.0008007401,0.0059703537,0.0017219316,0.00042245392,0.0011205759,0.003507694,0.0004704679,0.0004398428,0.06216915],"study_design_scores_gemma":[0.10896903,0.08599394,0.78534704,0.00031450455,0.0031367796,0.00027195626,0.000073446776,0.0006211412,0.008062873,0.0003260452,0.006692658,0.00019060657],"about_ca_topic_score_codex":0.00037020328,"about_ca_topic_score_gemma":0.00016946747,"teacher_disagreement_score":0.111920804,"about_ca_system_score_codex":0.000484612,"about_ca_system_score_gemma":0.0027276187,"threshold_uncertainty_score":0.63080925},"labels":[],"label_agreement":null},{"id":"W2589639638","doi":"10.1200/jco.2013.31.31_suppl.245","title":"Concordance with best-practice guidelines for systemic treatment computerized prescriber order entry systems.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Concordance; Audit; Usability; Likert scale; Descriptive statistics; Family medicine; Order entry; Medical emergency; Nursing; Internal medicine","score_opus":0.4732749545152524,"score_gpt":0.5988048136187624,"score_spread":0.12552985910350994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589639638","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.590408,0.0035133697,0.09690573,0.29242805,0.0075551826,0.006852807,0.000024208786,0.00007649056,0.002236182],"genre_scores_gemma":[0.3192471,0.0051100748,0.6177812,0.04243265,0.011747441,0.00033759125,0.00004509082,0.00012091201,0.0031779045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900376,0.0008779072,0.0078053446,0.0003504103,0.0005782177,0.0003505271],"domain_scores_gemma":[0.95368683,0.021445153,0.006965282,0.00042408964,0.016897786,0.00058087124],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005408404,0.00027682027,0.0023425363,0.00010194911,0.00006526601,0.00005613323,0.0002028958,0.0003746197,0.00014474956],"category_scores_gemma":[0.058768462,0.00016685973,0.0004442286,0.00017147335,0.0001605001,0.00066447177,0.00004149133,0.00058470055,0.00009166561],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04470866,0.011219262,0.011536441,0.0005527619,0.0056828344,0.001232568,0.00022231248,0.0016801364,0.001022646,0.00039248087,0.47906768,0.4426822],"study_design_scores_gemma":[0.048169587,0.06389471,0.0020251952,0.0007237698,0.003900038,0.010912532,0.0028583135,0.0075032287,0.00002976577,0.00006718893,0.8596503,0.0002653406],"about_ca_topic_score_codex":0.0005528669,"about_ca_topic_score_gemma":0.000023168344,"teacher_disagreement_score":0.5208755,"about_ca_system_score_codex":0.00037041405,"about_ca_system_score_gemma":0.0035868715,"threshold_uncertainty_score":0.9491599},"labels":[],"label_agreement":null},{"id":"W2589639915","doi":"10.1200/jco.2014.32.30_suppl.148","title":"A national strategy for quality and safety in radiotherapy: A comprehensive quality improvement approach.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CBC (Canada); Canadian Association of Nurses in Oncology; BC Cancer Agency; Canadian Association of Physicists; Canadian Partnership Against Cancer","funders":"","keywords":"Accreditation; Medicine; General partnership; Quality management; Patient safety; Quality (philosophy); Hospital accreditation; Quality assurance; Health care; Business; Medical education; Marketing","score_opus":0.23814483138459933,"score_gpt":0.5799786512937175,"score_spread":0.3418338199091182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589639915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8191382,0.0027463462,0.1498085,0.018704519,0.0018026114,0.0012155304,0.000025031311,0.000017237246,0.0065420168],"genre_scores_gemma":[0.83551806,0.0032241836,0.13477135,0.02278482,0.003421611,0.000026006677,0.000010641177,0.000023778546,0.00021953885],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956508,0.0009574785,0.0026781843,0.00023232224,0.00028075548,0.0002004031],"domain_scores_gemma":[0.98940104,0.008096299,0.0016564144,0.00012116936,0.0005213676,0.00020368844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009361223,0.00013193912,0.0016926606,0.00009691123,0.000048718324,0.0000045486363,0.00010800636,0.00043422868,0.000027663005],"category_scores_gemma":[0.0031215418,0.00009339841,0.00029689222,0.000078088764,0.0004302032,0.000089238754,0.000016694923,0.0007430291,4.2386944e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03462071,0.003860978,0.042493265,0.00021029159,0.00067845586,0.000018840503,0.0002478326,0.0006216416,0.001061584,0.021033395,0.001508467,0.8936445],"study_design_scores_gemma":[0.040750347,0.023215387,0.62439835,0.000043358385,0.00007165617,0.00020256938,0.00030195678,0.0024529952,0.000014046849,0.0140360305,0.29434058,0.00017268874],"about_ca_topic_score_codex":0.00001153876,"about_ca_topic_score_gemma":0.00002662171,"teacher_disagreement_score":0.89347184,"about_ca_system_score_codex":0.00029833443,"about_ca_system_score_gemma":0.0011380492,"threshold_uncertainty_score":0.38086766},"labels":[],"label_agreement":null},{"id":"W2589640014","doi":"10.1200/jco.2011.29.15_suppl.6059","title":"Screening for hepatitis B virus (HBV) prior to chemotherapy: A cost-effectiveness analysis.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hepatitis B virus; HBsAg; Lamivudine; Hepatitis B; Internal medicine; Chemotherapy; Lymphoma; CHOP; Intensive care medicine; Oncology; Immunology; Virus","score_opus":0.28382253133015234,"score_gpt":0.5090080340334768,"score_spread":0.2251855027033245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589640014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9221482,0.00022299365,0.07183751,0.0021319587,0.0008404213,0.0011832981,0.00001926907,0.0000212986,0.0015950258],"genre_scores_gemma":[0.9219772,0.0006507094,0.07003027,0.006182253,0.0009039612,0.00007229009,0.0000022146953,0.000031100975,0.00014998692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965112,0.00048291194,0.0020866457,0.0002651941,0.00031732582,0.0003366735],"domain_scores_gemma":[0.99372363,0.0034019372,0.001215412,0.00023356923,0.00091493875,0.00051052857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005251873,0.00017910867,0.0026580477,0.00034886334,0.00008023218,0.0000073666884,0.00018719163,0.00031098962,0.00025572564],"category_scores_gemma":[0.0074123666,0.00013511672,0.001155293,0.000457278,0.00015092139,0.000096374766,0.00006325629,0.00053832453,0.00002132474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007833012,0.0009888207,0.7124634,0.000029735816,0.0039249873,0.00020251477,0.00034607833,0.000008828957,0.00020407134,0.000056190947,0.0016151521,0.27232724],"study_design_scores_gemma":[0.005986119,0.013260272,0.9039508,0.00009352859,0.0022485636,0.000048667196,0.00002084235,0.00013672294,0.0007035927,0.00014610797,0.07328,0.00012478029],"about_ca_topic_score_codex":0.0012731736,"about_ca_topic_score_gemma":0.0046625086,"teacher_disagreement_score":0.27220246,"about_ca_system_score_codex":0.00018197608,"about_ca_system_score_gemma":0.0006141358,"threshold_uncertainty_score":0.88738304},"labels":[],"label_agreement":null},{"id":"W2589647670","doi":"10.1200/jco.2016.34.3_suppl.243","title":"Androgen deprivation therapy educational program: A Canadian true nth initiative.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of British Columbia; University Health Network; Prostate Cancer Canada","funders":"","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Quality of life (healthcare); Session (web analytics); Family medicine; Physical therapy; Gerontology; Cancer; Internal medicine; Nursing","score_opus":0.18550121573969075,"score_gpt":0.49011934717253486,"score_spread":0.3046181314328441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589647670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89510506,0.0004906441,0.00007518321,0.09276654,0.0017781284,0.00022134629,0.000007243491,0.000007634728,0.009548233],"genre_scores_gemma":[0.9901841,0.0007419945,0.0006654658,0.005925112,0.002133872,0.000012269897,0.000003813027,0.000010901333,0.00032246372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826473,0.00022933002,0.0009845743,0.00011746312,0.00022553006,0.00017835447],"domain_scores_gemma":[0.99699986,0.0011261299,0.0006166462,0.000119479126,0.0005970261,0.0005408305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013319699,0.000079851525,0.00053952413,0.00013837755,0.000034127414,0.000006635421,0.000105004496,0.00023528829,0.0008047197],"category_scores_gemma":[0.0018432066,0.000045628905,0.0002571658,0.00012880529,0.0001264474,0.00010524546,0.000008716451,0.00031281222,0.00002690963],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010869731,0.00046848497,0.25263584,0.00000371507,0.0001456194,0.000056728135,0.00014916832,7.440952e-8,0.000041226085,0.0003536067,0.005191144,0.73986745],"study_design_scores_gemma":[0.0035469078,0.004486196,0.48221844,0.000055654582,0.00004509394,0.00016387465,0.00006623339,0.0000013728762,0.00010069344,0.0012984611,0.5079633,0.00005377587],"about_ca_topic_score_codex":0.0017179679,"about_ca_topic_score_gemma":0.045281656,"teacher_disagreement_score":0.7398136,"about_ca_system_score_codex":0.0002980306,"about_ca_system_score_gemma":0.008150448,"threshold_uncertainty_score":0.9974724},"labels":[],"label_agreement":null},{"id":"W2589648232","doi":"10.1200/jco.2016.34.2_suppl.115","title":"Expanded criteria in men on active surveillance monitored by MRI-TRUS fusion biopsy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Multiparametric MRI; Prostate; Prostate biopsy; Radiology; Urology; Cancer; Internal medicine","score_opus":0.08215054503825324,"score_gpt":0.46998917375732163,"score_spread":0.3878386287190684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589648232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96950364,0.00040069938,0.00001964684,0.026325112,0.0011592674,0.0002055516,0.000024913435,0.0000066664784,0.00235451],"genre_scores_gemma":[0.9919279,0.0060151266,0.00030853646,0.00083044905,0.0006697934,0.000012787889,0.0000029027906,0.000013040245,0.0002194545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99759966,0.0003818732,0.0013385824,0.0002086703,0.00025178312,0.00021941599],"domain_scores_gemma":[0.99631405,0.0021518667,0.00088235235,0.0001637183,0.00020196363,0.0002860619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012831807,0.00013098307,0.0011134485,0.00009269386,0.000019783287,0.0000049652767,0.00009649088,0.00025983906,0.00016641151],"category_scores_gemma":[0.0012216298,0.00006866579,0.00022558743,0.00008596274,0.00011372592,0.000080820995,0.00003076007,0.0003386029,0.000024207042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01747415,0.0037074857,0.44328925,0.0000110494975,0.00025346462,0.0011118806,0.00009514686,5.302846e-7,0.006517874,0.000018984663,0.033805605,0.49371457],"study_design_scores_gemma":[0.020281391,0.017232941,0.9215691,0.000325453,0.000055648226,0.00010204666,0.0000731151,0.0000060242664,0.0044284547,0.00032049548,0.03550818,0.000097140306],"about_ca_topic_score_codex":0.000029293187,"about_ca_topic_score_gemma":0.000013407827,"teacher_disagreement_score":0.49361745,"about_ca_system_score_codex":0.0004740918,"about_ca_system_score_gemma":0.00047861694,"threshold_uncertainty_score":0.28001097},"labels":[],"label_agreement":null},{"id":"W2589657590","doi":"10.1200/jco.2005.23.16_suppl.8156","title":"The development of a prediciton index for patients at high risk of severe chemotherapy induced nausea and vomiting","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Nausea; Antiemetic; Vomiting; Chemotherapy; Internal medicine; Incidence (geometry); Prospective cohort study; Logistic regression; Surgery","score_opus":0.07302689306932589,"score_gpt":0.42420402087565723,"score_spread":0.35117712780633137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589657590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677366,0.00006383916,0.00014707436,0.002023755,0.0002966535,0.00035750674,0.0000025430127,0.0000032017053,0.0003317454],"genre_scores_gemma":[0.98863626,0.00024969058,0.010081423,0.00039639135,0.0005077434,0.0000041605063,0.0000012326374,0.000011707294,0.00011138947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703586,0.000155369,0.0022214,0.00011448787,0.00031003015,0.00016285948],"domain_scores_gemma":[0.9936257,0.002883106,0.002789875,0.000116363284,0.0004518395,0.00013312072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036893957,0.00009415962,0.0008142497,0.000070039176,0.00007836811,0.000003248263,0.000114896124,0.00019267209,0.000011372087],"category_scores_gemma":[0.003112088,0.000056090714,0.00017702255,0.00006145338,0.00010990053,0.000042113537,0.000069572794,0.0003470469,5.7015467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054330532,0.00078515476,0.56125367,0.00006120616,0.000546527,0.0000017071093,0.00027843015,0.0000048264533,0.000106407744,0.000025546047,0.0008341395,0.43066934],"study_design_scores_gemma":[0.018505448,0.006498265,0.94449496,0.00014531043,0.00023606907,0.000007711389,0.00010361225,0.000106096784,0.0012708124,0.00015238194,0.028421458,0.000057847712],"about_ca_topic_score_codex":0.0000045705588,"about_ca_topic_score_gemma":0.000044456327,"teacher_disagreement_score":0.4306115,"about_ca_system_score_codex":0.00011914837,"about_ca_system_score_gemma":0.00041585625,"threshold_uncertainty_score":0.3725685},"labels":[],"label_agreement":null},{"id":"W2589667993","doi":"10.1200/jco.2013.31.31_suppl.279","title":"Development of a capital investment strategy for radiation (RT) equipment in Ontario.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Procurement; Medicine; Pace; Investment (military); Capital expenditure; Cancer incidence; Operations management; Capital investment; Finance; Business; Cancer; Engineering; Marketing","score_opus":0.2012743496092989,"score_gpt":0.3849851176192834,"score_spread":0.18371076800998448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589667993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844676,0.0005738421,0.001013225,0.00065677497,0.0010108678,0.00029957487,0.000005657525,0.0000015771539,0.011970861],"genre_scores_gemma":[0.984451,0.00013126212,0.013967149,0.00078976527,0.00020601467,0.000026532738,0.0000026982593,0.000009296813,0.0004162746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570835,0.000022909095,0.0038641365,0.00015252721,0.000036038353,0.00021601513],"domain_scores_gemma":[0.99632937,0.0003011631,0.0030020738,0.00009529166,0.000113773836,0.00015835272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024957152,0.00009871327,0.0010991592,0.00017639848,0.000020304193,0.000013939202,0.00017526891,0.00022959693,0.00044382768],"category_scores_gemma":[0.0005743672,0.00009565332,0.00022749731,0.000046315603,0.00006164655,0.00031910613,0.000028154076,0.00029651457,0.000054426084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091694616,0.0027185131,0.44226754,0.00006140268,0.00051642203,0.000012090292,0.0049949163,0.0008800249,0.00005146585,0.13514334,0.0072290767,0.4052083],"study_design_scores_gemma":[0.0037850912,0.00207256,0.7611427,0.000020777314,0.000008400786,0.0000029769337,0.00015332786,0.00014465701,0.00004517505,0.04564592,0.18685423,0.00012424213],"about_ca_topic_score_codex":0.003218158,"about_ca_topic_score_gemma":0.015120013,"teacher_disagreement_score":0.40508404,"about_ca_system_score_codex":0.00083351205,"about_ca_system_score_gemma":0.001824967,"threshold_uncertainty_score":0.84373224},"labels":[],"label_agreement":null},{"id":"W2589669942","doi":"10.1200/jco.2005.23.16_suppl.7253","title":"Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Neutropenia; Internal medicine; Febrile neutropenia; Lung cancer; Oncology; Cancer; Chemotherapy; Performance status; Regimen; Gastroenterology","score_opus":0.05050418528996949,"score_gpt":0.4415250837430545,"score_spread":0.391020898453085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589669942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494565,0.0028680784,0.000053535874,0.00056382903,0.00035084283,0.00032520387,0.000023066239,0.0000011487552,0.00086864486],"genre_scores_gemma":[0.9936463,0.003266928,0.0005024313,0.0009855313,0.0012461524,0.000014806584,0.0000023959292,0.000020234087,0.0003151711],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9976733,0.00013423171,0.001612991,0.00024786405,0.00011340635,0.0002182299],"domain_scores_gemma":[0.9981149,0.00023792098,0.0010980514,0.0001920157,0.00014965229,0.00020747306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007650999,0.00017069076,0.0009507112,0.00007612861,0.00003339189,0.000007660269,0.00017256927,0.0002456689,0.00004507053],"category_scores_gemma":[0.0002611263,0.00013412684,0.00019537339,0.000059002406,0.000093710405,0.0000047717695,0.00010883797,0.0002478155,0.0000010746161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027686663,0.11154313,0.20725189,0.00013692153,0.002313773,0.00090056413,0.0053813006,0.022147795,0.092839666,0.000050540028,0.0065152906,0.52323246],"study_design_scores_gemma":[0.21597473,0.40705442,0.03251989,0.00024053804,0.0015580907,0.00023735923,0.0024190948,0.004166367,0.06415809,0.00011931291,0.27052602,0.0010260752],"about_ca_topic_score_codex":0.00047356638,"about_ca_topic_score_gemma":0.0041854396,"teacher_disagreement_score":0.5222064,"about_ca_system_score_codex":0.00012748865,"about_ca_system_score_gemma":0.0013377203,"threshold_uncertainty_score":0.5469534},"labels":[],"label_agreement":null},{"id":"W2589671106","doi":"10.1200/jco.2014.32.4_suppl.320","title":"Concurrent cisplatin and radiotherapy: Decision making, tolerability, and outcomes for patients treated in a multidisciplinary bladder clinic.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cystectomy; Tolerability; Bladder cancer; Cystoscopy; External beam radiotherapy; Cisplatin; Urology; Radiation therapy; Surgery; Urinary system; Chemotherapy; Internal medicine; Cancer; Adverse effect; Brachytherapy","score_opus":0.0813056010773686,"score_gpt":0.4859404120487397,"score_spread":0.4046348109713711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589671106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961766,0.0005115274,0.00044975852,0.0013656258,0.0006975185,0.00054729957,0.000008909133,0.0000054092447,0.00023732222],"genre_scores_gemma":[0.9924295,0.00051720825,0.005778654,0.0009309643,0.00025116233,0.000011724901,0.0000025199433,0.000017112507,0.0000611671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709547,0.00028697262,0.001980385,0.00025411896,0.00019761283,0.00018543102],"domain_scores_gemma":[0.99314183,0.0054641324,0.00082558964,0.00012939675,0.00020763176,0.00023140234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019529968,0.00015980995,0.0015600577,0.000113293514,0.00003383545,0.000009313029,0.00006676185,0.00029806318,0.00006271111],"category_scores_gemma":[0.0027975417,0.000101846344,0.00024659256,0.000058267535,0.00017452918,0.000074791154,0.000046628265,0.00038241685,0.0000013800199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027229192,0.0013892663,0.6086205,0.000017367838,0.00011939678,0.000009427469,0.0000922313,7.006188e-7,0.0000023035536,0.0000064988953,0.0002932747,0.38672608],"study_design_scores_gemma":[0.03375968,0.022622036,0.93794626,0.00015341211,0.00023321305,0.000029442572,0.000024607709,0.00062938064,0.0000023667722,0.0006457218,0.0038681687,0.00008570774],"about_ca_topic_score_codex":0.00001156054,"about_ca_topic_score_gemma":0.000056576235,"teacher_disagreement_score":0.38664037,"about_ca_system_score_codex":0.000093826144,"about_ca_system_score_gemma":0.00020624085,"threshold_uncertainty_score":0.41531733},"labels":[],"label_agreement":null},{"id":"W2589675870","doi":"10.1200/jco.2014.32.4_suppl.162","title":"Incidence, distribution, and outcomes of node positive patients at radical prostatectomy: Manitoba Prostate Center experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Dissection (medical); Prostatectomy; Lymph node; Prostate; Lymphadenectomy; Laparoscopic radical prostatectomy; Pelvis; Surgery; Urology; Cancer; Internal medicine","score_opus":0.03575664186617927,"score_gpt":0.39852414622612975,"score_spread":0.3627675043599505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589675870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545634,0.00013244318,0.000056786586,0.0030863252,0.0005524533,0.00038128134,0.00007422005,0.000005181352,0.00025494324],"genre_scores_gemma":[0.997029,0.00073793356,0.0006053204,0.0013749242,0.00014865478,0.000015842606,0.000037791528,0.000010693232,0.000039845025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720156,0.0002542149,0.0017432107,0.00020748713,0.0003687465,0.0002247782],"domain_scores_gemma":[0.99649566,0.0010070935,0.0013700943,0.00014173592,0.0006041128,0.0003813077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008876694,0.0001494281,0.0012611172,0.000052643514,0.000052156793,0.0000071137238,0.000083751635,0.0001731238,0.00003167153],"category_scores_gemma":[0.0019299018,0.000092853916,0.0002488507,0.00007541537,0.00048451824,0.00011865799,0.00009989497,0.00033572802,0.0000053016465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025615038,0.0021833833,0.96114945,0.00002879151,0.00021609195,0.00008839759,0.00024679184,6.8945496e-7,0.00001554987,0.00007128334,0.0011519807,0.032286085],"study_design_scores_gemma":[0.012450959,0.011160519,0.9598009,0.00016847912,0.00018565608,0.000076557655,0.0000728184,0.000014584199,0.0006081068,0.00018192647,0.015201432,0.00007803383],"about_ca_topic_score_codex":0.000023783947,"about_ca_topic_score_gemma":0.000025343397,"teacher_disagreement_score":0.03220805,"about_ca_system_score_codex":0.00032540568,"about_ca_system_score_gemma":0.00030729757,"threshold_uncertainty_score":0.37864727},"labels":[],"label_agreement":null},{"id":"W2589682239","doi":"10.1200/jco.2012.30.27_suppl.131","title":"Neoadjuvant therapy (NAT) for breast cancer at the Odette Cancer Centre: What have we been doing and how do we compare?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Taxane; Internal medicine; Trastuzumab; Oncology; Anthracycline; Nat; Cancer; Regimen; Chemotherapy; Estrogen receptor; Gynecology","score_opus":0.07985488167322953,"score_gpt":0.42530106255853567,"score_spread":0.34544618088530615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589682239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55103034,0.21697766,0.000074142445,0.22899711,0.0024281258,0.0003048219,0.00012354965,0.0000038904395,0.00006033755],"genre_scores_gemma":[0.7571379,0.23561138,0.0003108737,0.002925749,0.003643422,0.000033371492,0.0000037282841,0.000023213042,0.000310351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982678,0.0002687201,0.00063239346,0.00024047341,0.00018220114,0.00040838987],"domain_scores_gemma":[0.9976801,0.00062695047,0.0009768539,0.0001923286,0.0002920749,0.00023168417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093651377,0.00021618075,0.00076205103,0.000025959307,0.00016691508,0.000039699768,0.00020590723,0.00023225597,0.000073151066],"category_scores_gemma":[0.000085033025,0.00012408178,0.00034606783,0.000037324557,0.00033759864,0.000033521133,0.0001592728,0.00028417908,0.0000013814299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030699333,0.00034191005,0.17858686,0.00001629448,0.0012104266,0.000006448104,0.00042344345,0.000023884215,0.0012603656,0.000014995862,0.039220102,0.7758253],"study_design_scores_gemma":[0.0055143787,0.00057422626,0.13512367,0.00012655597,0.00024191309,0.00016617108,0.0008388321,0.000010065662,0.0014627514,0.000045267672,0.85572624,0.00016994117],"about_ca_topic_score_codex":0.000051044004,"about_ca_topic_score_gemma":0.001066558,"teacher_disagreement_score":0.81650615,"about_ca_system_score_codex":0.00014126606,"about_ca_system_score_gemma":0.00032137046,"threshold_uncertainty_score":0.5059908},"labels":[],"label_agreement":null},{"id":"W2589683331","doi":"10.1200/jco.2014.32.3_suppl.254","title":"Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nuclear medicine; Positron emission tomography; Progressive disease; Response Evaluation Criteria in Solid Tumors; Internal medicine; Chemotherapy","score_opus":0.032710831983711136,"score_gpt":0.37477120889568666,"score_spread":0.34206037691197555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589683331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896698,0.0011778703,0.0053636413,0.001942431,0.00053171464,0.0010923819,0.0001768041,0.000018430139,0.000026945454],"genre_scores_gemma":[0.990672,0.000039064067,0.008051781,0.0008259924,0.00018499869,0.000020151147,0.00013297169,0.00005214314,0.000020905536],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898797,0.0040601874,0.003769697,0.00053627393,0.0012310622,0.0005230672],"domain_scores_gemma":[0.97781473,0.014292409,0.0054805544,0.0006765372,0.00092079234,0.0008150019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008354138,0.00045354344,0.005342952,0.0007926417,0.00015117998,0.00003006508,0.00063753995,0.00012156242,0.000026465465],"category_scores_gemma":[0.0070542977,0.00026637132,0.0015362735,0.0016228234,0.00088967377,0.0001618898,0.000109691355,0.0013218519,2.9481365e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8239821,0.0054230774,0.15178043,0.000045385525,0.008505724,0.00007055147,0.0002219482,0.00037350718,0.0037947928,0.000005837503,0.0035144195,0.0022822253],"study_design_scores_gemma":[0.57797605,0.0626733,0.27777204,0.00052148855,0.026165951,0.00008705987,0.00026726726,0.043996446,0.00084427913,0.000027294387,0.009261553,0.00040726515],"about_ca_topic_score_codex":0.00035944546,"about_ca_topic_score_gemma":0.000031219315,"teacher_disagreement_score":0.24600606,"about_ca_system_score_codex":0.000117049436,"about_ca_system_score_gemma":0.00093677634,"threshold_uncertainty_score":0.99997884},"labels":[],"label_agreement":null},{"id":"W2589683484","doi":"10.1200/jco.2011.29.4_suppl.597","title":"Role of trimodality therapy versus dual-modality in T3N0 rectal cancer patients.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Total mesorectal excision; Colorectal cancer; Cohort; Cancer; Chemotherapy; Surgery; Population; Univariate analysis; Radiation therapy; Multivariate analysis; Oncology; Internal medicine","score_opus":0.26281103486968166,"score_gpt":0.49576028757616375,"score_spread":0.2329492527064821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589683484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98087347,0.0006213016,0.0000012608288,0.00050254975,0.0015152183,0.0002851707,0.000010477541,0.0000064932333,0.016184041],"genre_scores_gemma":[0.9977534,0.0012145996,0.00036001578,0.0002714086,0.0003380529,0.000011748814,0.0000019301817,0.000013581597,0.000035285328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599683,0.00064582424,0.0024624984,0.00021754284,0.00043266176,0.00024462098],"domain_scores_gemma":[0.9957743,0.0014859831,0.0016904213,0.00019561192,0.00053593155,0.00031770175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021676235,0.00015391562,0.0017161812,0.00011200959,0.000015285734,0.0000018457956,0.00013895113,0.00038795127,0.00071152014],"category_scores_gemma":[0.0020620949,0.00010629819,0.0005897887,0.00024337506,0.00024280528,0.00010742107,0.000052287596,0.0007820431,0.0000058120822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069899075,0.0067524537,0.74964255,0.000008441914,0.0003781523,0.00012013244,0.0002797407,7.9498835e-7,0.00009331038,0.00006728559,0.00006817718,0.17268986],"study_design_scores_gemma":[0.03161337,0.026137587,0.9365484,0.000052328636,0.00013894933,0.000010701112,0.00006340523,0.000008593891,0.00097357616,0.00087375625,0.0034976534,0.000081644175],"about_ca_topic_score_codex":0.000783865,"about_ca_topic_score_gemma":0.00037372648,"teacher_disagreement_score":0.18690586,"about_ca_system_score_codex":0.0004338596,"about_ca_system_score_gemma":0.0016051822,"threshold_uncertainty_score":0.77906466},"labels":[],"label_agreement":null},{"id":"W2589684073","doi":"10.1200/jco.2013.31.4_suppl.39","title":"Results from Ion AmpiSeq Cancer Panel in 200 cases of gastric and gastroesophageal junction cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ion semiconductor sequencing; KRAS; Amplicon; Cancer; Cancer research; Medicine; IDH1; Gene; Pathology; Mutant; DNA sequencing; Biology; Genetics; Polymerase chain reaction; Internal medicine; Colorectal cancer","score_opus":0.08377077993540238,"score_gpt":0.3980812610514126,"score_spread":0.31431048111601023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589684073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941311,0.0034115876,0.000077915676,0.000945526,0.0011092175,0.00010081581,0.000088526474,9.349168e-7,0.00013435839],"genre_scores_gemma":[0.9803576,0.016684653,0.00087099615,0.00048043937,0.001494289,0.000007903345,0.000014825328,0.000009195626,0.000080109385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980529,0.00014407904,0.0013377968,0.00019353566,0.000109376066,0.00016231865],"domain_scores_gemma":[0.99781936,0.0005693702,0.0010966813,0.0001236873,0.00023219328,0.00015869382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058746483,0.00010096843,0.00052991667,0.00007640641,0.000016764388,0.0000084007615,0.00011166995,0.000260875,0.000050529525],"category_scores_gemma":[0.0014598578,0.00008380192,0.00012450128,0.00008242725,0.00012393571,0.000008448872,0.00006463931,0.00026802396,0.0000012274405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071386974,0.0009342033,0.4427955,0.000021997595,0.00029224038,0.00016295383,0.00008614756,0.0023824936,0.05601305,0.000011903603,0.035415635,0.4547452],"study_design_scores_gemma":[0.0077631734,0.006255362,0.9581511,0.00007914262,0.00012302592,0.00006576587,0.00011028957,0.00019379082,0.0044876854,0.0001904149,0.02244201,0.00013825181],"about_ca_topic_score_codex":0.003952292,"about_ca_topic_score_gemma":0.0021476336,"teacher_disagreement_score":0.5153556,"about_ca_system_score_codex":0.000056648976,"about_ca_system_score_gemma":0.000750229,"threshold_uncertainty_score":0.59747094},"labels":[],"label_agreement":null},{"id":"W2589691088","doi":"10.1200/jco.2016.34.7_suppl.193","title":"Standardizing architecture and governance of radiology clinical checklist development.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Checklist; Medicine; White paper; Clinical governance; Medical physics; Documentation; Health care; Population; Radiology; Medical education; Computer science","score_opus":0.2953127586449733,"score_gpt":0.5716929478476335,"score_spread":0.27638018920266016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589691088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501314,0.0005944534,0.010316031,0.036078718,0.0016129644,0.00019498746,0.00000996862,0.0000086342225,0.0010528455],"genre_scores_gemma":[0.92605233,0.0030076047,0.065556176,0.0033725079,0.0017514345,0.0000014876812,0.0000015682451,0.000018863282,0.00023800696],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9902665,0.0009777664,0.007801857,0.0002696592,0.0004457905,0.00023843782],"domain_scores_gemma":[0.97228485,0.020436289,0.0058029243,0.00022921353,0.00081319857,0.00043350688],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01635315,0.00014734747,0.0020288783,0.00007135692,0.000033088636,0.0000041667695,0.0001712871,0.00047986186,0.00019738816],"category_scores_gemma":[0.084919035,0.00008438166,0.0004252141,0.00009896401,0.00068670267,0.00015127027,0.00011648222,0.0010112711,0.000008263358],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058530597,0.00049524807,0.24262233,0.000028284681,0.00037113423,0.00014334172,0.000043097454,7.9792744e-7,0.0006554473,0.00019077778,0.007016471,0.74258],"study_design_scores_gemma":[0.012752108,0.007090994,0.5695386,0.0001940168,0.00028717375,0.0010406211,0.00006036978,0.0000046840673,0.00019727116,0.0005943202,0.40815097,0.0000888753],"about_ca_topic_score_codex":0.000007695409,"about_ca_topic_score_gemma":0.000048688627,"teacher_disagreement_score":0.7424911,"about_ca_system_score_codex":0.00012332074,"about_ca_system_score_gemma":0.0032289615,"threshold_uncertainty_score":0.9227891},"labels":[],"label_agreement":null},{"id":"W2589693254","doi":"10.1200/jco.2014.32.4_suppl.383","title":"Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Kinome; Exome sequencing; Exome; Cancer research; Computational biology; Kinase; Medicine; Biology; Genetics; Gene; Mutation","score_opus":0.07111603529556897,"score_gpt":0.421560107367877,"score_spread":0.35044407207230804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589693254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891314,0.0007658646,0.0029575895,0.0047746743,0.001296017,0.00014395316,0.0000038872113,0.0000112332145,0.00091536716],"genre_scores_gemma":[0.96537983,0.0003205398,0.030448854,0.0026065449,0.0010636037,0.0000018154379,0.0000048400734,0.000024829002,0.00014915752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680656,0.00042660694,0.0020164081,0.00021947727,0.0002848351,0.0002461228],"domain_scores_gemma":[0.9945013,0.0025302134,0.001834881,0.00016450386,0.0005994668,0.00036966763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002294726,0.00015779989,0.0016326875,0.00012702041,0.00004727088,0.00001119748,0.00015689508,0.0002962998,0.000055378307],"category_scores_gemma":[0.00380376,0.000113165785,0.00023613239,0.00011708849,0.00041166064,0.00008837266,0.000076034325,0.0017539463,0.0000037633909],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067968788,0.0023916413,0.28845,0.0015481882,0.00058450253,0.0012242249,0.001547426,0.0060008643,0.21596348,0.0015407882,0.009586252,0.46436575],"study_design_scores_gemma":[0.072138794,0.043323737,0.22135767,0.001406703,0.0035067843,0.0029980002,0.003269643,0.20757696,0.015934743,0.004257335,0.4230891,0.0011405292],"about_ca_topic_score_codex":0.0002467764,"about_ca_topic_score_gemma":0.0000120205195,"teacher_disagreement_score":0.46322522,"about_ca_system_score_codex":0.00016755315,"about_ca_system_score_gemma":0.0012385707,"threshold_uncertainty_score":0.7620121},"labels":[],"label_agreement":null},{"id":"W2589696161","doi":"10.1200/jco.2014.32.4_suppl.484","title":"Association of partial nephrectomy and presence of robotic surgery for kidney cancer in the United States.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Kidney cancer; Logistic regression; Odds ratio; Cohort; Surgery; Cancer; Internal medicine; Population; Urology; Kidney","score_opus":0.1208028169277016,"score_gpt":0.43629647491804563,"score_spread":0.315493657990344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589696161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854489,0.00017291092,0.00022311862,0.013442413,0.00040022662,0.00023367419,0.000004162686,0.0000010548607,0.0000735675],"genre_scores_gemma":[0.9972559,0.0007760388,0.00047118784,0.0011189267,0.0003056364,0.000010602256,0.000004234861,0.000005212459,0.000052248568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973764,0.000709335,0.0014615507,0.000076768505,0.0002516493,0.00012431346],"domain_scores_gemma":[0.9832179,0.0143454075,0.0018220627,0.00009026937,0.00039923977,0.00012513445],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056146993,0.00006164173,0.00095730455,0.00011097079,0.000009856355,0.0000022680763,0.00006380414,0.00015271694,0.000018118504],"category_scores_gemma":[0.012394135,0.00003542633,0.00020738422,0.0001366139,0.00008903758,0.000035209967,0.000012924976,0.00027056955,2.1244662e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002718531,0.000765832,0.9676713,0.00011821057,0.0002878412,0.000023907194,0.00022040076,0.00059949805,0.0001538401,0.0000404654,0.009333711,0.018066498],"study_design_scores_gemma":[0.0061802417,0.0058341054,0.9446731,0.00022123443,0.0007155231,0.00002986205,0.00009120935,0.004119947,0.00057344587,0.00038357888,0.03712884,0.000048886475],"about_ca_topic_score_codex":0.00017934229,"about_ca_topic_score_gemma":0.00006668903,"teacher_disagreement_score":0.027795127,"about_ca_system_score_codex":0.000099483164,"about_ca_system_score_gemma":0.00072389044,"threshold_uncertainty_score":0.9959249},"labels":[],"label_agreement":null},{"id":"W2589700874","doi":"10.1200/jco.2005.23.16_suppl.3614","title":"Population-based analysis of patients with advanced colorectal cancer: The impact of age on treatment and outcomes","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Group B; Colorectal cancer; Population; Cancer; Cancer registry; Systemic therapy; Gastroenterology; Group A; Overall survival; Surgery; Breast cancer","score_opus":0.05370676821428514,"score_gpt":0.4711404641330553,"score_spread":0.41743369591877016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589700874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99797225,0.00026073577,0.0000022052275,0.0012358295,0.00006913879,0.00021409034,0.00003857312,0.0000018127298,0.00020534264],"genre_scores_gemma":[0.9991556,0.00030994587,0.00027849924,0.00015497675,0.000057211568,0.0000073595374,0.0000072820135,0.000005469888,0.000023651852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985117,0.000107363834,0.00097632885,0.00010231271,0.00020291687,0.00009940534],"domain_scores_gemma":[0.9967068,0.0015796733,0.0012633752,0.00009361621,0.0002607532,0.00009582158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026882227,0.00012102311,0.0016681803,0.00013618382,0.000030421877,0.0000018176521,0.00004313284,0.000071476374,0.00005658295],"category_scores_gemma":[0.0003150511,0.000046907007,0.0005923691,0.00020269972,0.000128824,0.000029115818,0.00000891898,0.00012844191,1.2822636e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010841553,0.002082261,0.84318316,0.0000033335225,0.005987376,0.000008557097,0.00011215864,0.0029548525,0.0000043504688,0.0000032310977,0.000020472882,0.13479869],"study_design_scores_gemma":[0.009131608,0.04358783,0.9434543,0.000024116473,0.0033636934,7.621682e-7,0.000028479155,0.00016733975,0.000022961476,0.000004674276,0.00017655747,0.000037634665],"about_ca_topic_score_codex":0.00047668364,"about_ca_topic_score_gemma":0.0019485478,"teacher_disagreement_score":0.13476105,"about_ca_system_score_codex":0.00040961962,"about_ca_system_score_gemma":0.00040321023,"threshold_uncertainty_score":0.19128123},"labels":[],"label_agreement":null},{"id":"W2589701123","doi":"10.1200/jco.2011.29.4_suppl.381","title":"The impact of Asian race on colorectal cancer screening (CRCS).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Demography; Logistic regression; Confounding; Multivariate analysis; Population; Ethnic group; Health equity; Gerontology; Public health; Environmental health; Internal medicine","score_opus":0.17896220860012838,"score_gpt":0.4922459873316115,"score_spread":0.31328377873148316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589701123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787591,0.0004459367,0.00030650536,0.0014594361,0.0012044036,0.0001408471,0.0000024611302,0.000010844718,0.017670427],"genre_scores_gemma":[0.9969914,0.00044800082,0.0011291236,0.0001928722,0.0010500589,0.000004286641,2.6802078e-7,0.00001399325,0.00017001775],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975094,0.00034244012,0.0014810271,0.00013250913,0.00031769276,0.00021691978],"domain_scores_gemma":[0.9957863,0.001544131,0.0017581341,0.00014667638,0.0004792672,0.0002854729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002708398,0.00011981496,0.0009560743,0.00010052688,0.00007793805,0.000005481422,0.00016468274,0.0002794082,0.00018920923],"category_scores_gemma":[0.002851757,0.00006369266,0.00083064975,0.00018971117,0.00025180468,0.00006534488,0.000034055087,0.001089312,0.000005341341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11598524,0.0007242806,0.1321743,0.000007934956,0.0008469999,0.00013403763,0.0003532933,0.000062154126,0.00042937155,0.000047325484,0.004023703,0.74521136],"study_design_scores_gemma":[0.003971393,0.098139614,0.8900969,0.00013032783,0.00021697587,0.0003009473,0.00019827383,0.0003870324,0.0014334985,0.00017786265,0.004873677,0.00007350722],"about_ca_topic_score_codex":0.0004847234,"about_ca_topic_score_gemma":0.00020688894,"teacher_disagreement_score":0.7579226,"about_ca_system_score_codex":0.00018549396,"about_ca_system_score_gemma":0.0013315663,"threshold_uncertainty_score":0.4732579},"labels":[],"label_agreement":null},{"id":"W2589703775","doi":"10.1200/jco.2013.31.31_suppl.140","title":"Avoidable and unavoidable visits to the emergency department among advanced cancer patients (AdCa) followed by the supportive care (SCPC) outpatient clinic.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Emergency department; Depression (economics); Referral; Nausea; Anxiety; Outpatient clinic; Palliative care; DASS; Emergency medicine; Family medicine; Internal medicine; Psychiatry","score_opus":0.12348447596025752,"score_gpt":0.5014678385373905,"score_spread":0.377983362577133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589703775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839377,0.0049669202,0.00003274594,0.006407714,0.0019712974,0.001132765,0.00003600723,0.00000587701,0.0015089657],"genre_scores_gemma":[0.99041563,0.0047767656,0.0005033009,0.0024252383,0.0003829384,0.00010264461,0.000011104664,0.00002034249,0.0013620293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960847,0.00049366977,0.0023199837,0.00024865777,0.0005142069,0.00033878794],"domain_scores_gemma":[0.99427456,0.0016201034,0.0018696035,0.00025046448,0.0015447172,0.00044057498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012394439,0.00019613528,0.0011684686,0.00005410769,0.000117598705,0.000009782528,0.00025881044,0.0002419919,0.00045454616],"category_scores_gemma":[0.0036208956,0.000097806194,0.00037493944,0.00017924898,0.0001594668,0.00016066317,0.00012435572,0.00071991084,0.00003327625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010654835,0.0007087417,0.8242963,0.000035507623,0.00033781957,0.000011459607,0.0021878232,0.000028274155,0.000047069432,0.000003156925,0.123628154,0.047650237],"study_design_scores_gemma":[0.004903902,0.015977997,0.6350609,0.00029819028,0.0004416381,0.000002615927,0.004101852,0.000018281495,0.00054517563,0.00004694474,0.33846575,0.00013677361],"about_ca_topic_score_codex":0.00024569966,"about_ca_topic_score_gemma":0.00039256632,"teacher_disagreement_score":0.21483758,"about_ca_system_score_codex":0.00019161368,"about_ca_system_score_gemma":0.0005027599,"threshold_uncertainty_score":0.49769616},"labels":[],"label_agreement":null},{"id":"W2589703875","doi":"10.1200/jco.2014.32.30_suppl.174","title":"Driving action through data: Delivering online cancer screening reports to primary care providers.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Primary care; eHealth; Cancer screening; Family medicine; Health care; Cancer; Medical emergency; Internal medicine","score_opus":0.6023129102117756,"score_gpt":0.6361281723374387,"score_spread":0.033815262125663104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589703875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90967447,0.00032227914,0.04806898,0.037270088,0.0035881558,0.00043459903,0.000009318727,0.000031844564,0.0006002687],"genre_scores_gemma":[0.770441,0.00072858983,0.1994999,0.021735132,0.007386391,0.0000046755076,0.00010793511,0.000037808764,0.000058586254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928656,0.0005371881,0.005243381,0.0004342399,0.0006427597,0.0002768112],"domain_scores_gemma":[0.98842317,0.005144305,0.004142478,0.0006113001,0.0012452762,0.00043347522],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006882362,0.00016356916,0.0013303903,0.00010602111,0.00007865191,0.000023556282,0.0002483091,0.00030438893,0.00008884732],"category_scores_gemma":[0.045740057,0.00013271003,0.00027538952,0.0001835474,0.00007770629,0.0009688157,0.0003378863,0.00137219,0.000006357655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014404634,0.00032319053,0.1585771,0.00009305008,0.00023907414,0.00034536698,0.0001693262,0.000450973,0.00063675083,0.0000036925412,0.008278934,0.8294421],"study_design_scores_gemma":[0.0044610235,0.0054958095,0.43815738,0.00055834843,0.0010990205,0.0008665877,0.0013395577,0.00096761354,0.00007326972,0.00007343998,0.5467278,0.00018015712],"about_ca_topic_score_codex":0.0006011515,"about_ca_topic_score_gemma":0.001876232,"teacher_disagreement_score":0.82926196,"about_ca_system_score_codex":0.0003776919,"about_ca_system_score_gemma":0.0020605025,"threshold_uncertainty_score":0.9622981},"labels":[],"label_agreement":null},{"id":"W2589704839","doi":"10.1200/jco.2013.31.31_suppl.116","title":"Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate, and rectum in Alberta, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Rectum; Prostate; Cervix; Prostate cancer; Gynecology; Radiation therapy; Lung; Cancer; Internal medicine; Oncology","score_opus":0.034892059541760126,"score_gpt":0.4292018333792226,"score_spread":0.39430977383746246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589704839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439634,0.0013373048,0.000024846877,0.013121886,0.00052917405,0.00031403685,0.0000014029439,5.652591e-7,0.00027445052],"genre_scores_gemma":[0.9931526,0.0035828098,0.00065004063,0.0023348392,0.0001524779,0.000004180147,2.5532782e-7,0.000007609083,0.000115157956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809855,0.0003823335,0.001177344,0.00009093029,0.00012804325,0.00012277148],"domain_scores_gemma":[0.9960149,0.0026434322,0.00102466,0.00010490069,0.00014432559,0.000067783105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010303007,0.00007683677,0.00073598407,0.00005809958,0.00002178613,0.0000016334222,0.00010551193,0.00017515283,0.000035346748],"category_scores_gemma":[0.00086025347,0.000038864822,0.000054328248,0.00015025657,0.0004449104,0.00007079039,0.000017816066,0.00048703657,2.114452e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008173906,0.00011534298,0.88324916,0.000025982765,0.00005929037,0.000008117822,0.000587238,0.00006582766,0.00006866724,0.000020691876,0.00089529424,0.11408698],"study_design_scores_gemma":[0.0054247673,0.0013565051,0.9851634,0.00013693332,0.000034694815,0.00020226669,0.00023256204,0.0013069154,0.000030298808,0.00019489629,0.005878392,0.000038407296],"about_ca_topic_score_codex":0.038955126,"about_ca_topic_score_gemma":0.2634109,"teacher_disagreement_score":0.22445576,"about_ca_system_score_codex":0.00022986953,"about_ca_system_score_gemma":0.0021753665,"threshold_uncertainty_score":0.96744454},"labels":[],"label_agreement":null},{"id":"W2589709223","doi":"10.1200/jco.2016.34.3_suppl.66","title":"Physician needs and preferences for information about long-term follow-up and care of survivors of childhood cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Thematic analysis; Childhood cancer; Cancer; Health care; Information needs; Disease; Qualitative research; Internal medicine","score_opus":0.07417446919996883,"score_gpt":0.42780113083807975,"score_spread":0.3536266616381109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589709223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251753,0.0019239765,0.00023117456,0.0035127387,0.0010031911,0.00032601366,0.00006063342,0.000005079029,0.00041969147],"genre_scores_gemma":[0.99501795,0.0030035865,0.00046805872,0.0008418933,0.0006239734,0.000005862347,0.000003946711,0.0000094787865,0.000025279378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969011,0.00019803534,0.0022880072,0.000109608176,0.00033853168,0.00016470937],"domain_scores_gemma":[0.99388736,0.002155601,0.0027698183,0.00014769909,0.0008123064,0.00022718606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016434521,0.00013299905,0.001497595,0.00016635605,0.000028634384,0.0000058676155,0.00012893481,0.00025891676,0.000014424139],"category_scores_gemma":[0.001961764,0.000083284736,0.00028552327,0.00010828097,0.00034474093,0.00032381425,0.000050391376,0.000248251,4.4099937e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002126806,0.00023503663,0.48805448,0.0004748625,0.0003596478,0.0000012724172,0.004338243,5.1201414e-7,0.00010212103,0.00011551614,0.00025336957,0.50393814],"study_design_scores_gemma":[0.01177283,0.008930792,0.97206014,0.0011237225,0.00042279626,0.000018498318,0.0016634407,0.0000016134,0.0005852677,0.00027167023,0.0030531094,0.00009613478],"about_ca_topic_score_codex":0.00016443562,"about_ca_topic_score_gemma":0.0010482543,"teacher_disagreement_score":0.503842,"about_ca_system_score_codex":0.00004925234,"about_ca_system_score_gemma":0.0010555917,"threshold_uncertainty_score":0.3396253},"labels":[],"label_agreement":null},{"id":"W2589713800","doi":"10.1200/jco.2016.34.4_suppl.755","title":"Pre-treatment serum folate levels and toxicity in colorectal cancer patients treated with 5-fluorouracil and folinic acid.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Ottawa Hospital; London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Folinic acid; Medicine; Toxicity; Internal medicine; Quartile; Fluorouracil; Colorectal cancer; Gastroenterology; Prospective cohort study; Cohort; Cancer; Confidence interval","score_opus":0.07311141722690827,"score_gpt":0.4187422562135352,"score_spread":0.34563083898662694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589713800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527246,0.0012772172,0.0000030170822,0.0024495067,0.00019047645,0.000354776,0.000031491552,0.000007116414,0.00041393674],"genre_scores_gemma":[0.9953619,0.0037570568,0.00018470308,0.00024750008,0.00017049014,0.00002309716,5.5984526e-7,0.00001286792,0.00024179474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805117,0.00017784968,0.0010827293,0.00024864086,0.00019432769,0.00024528825],"domain_scores_gemma":[0.997805,0.0008965949,0.00069406285,0.00007013044,0.00025600768,0.00027821725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004734421,0.00019568087,0.001369454,0.00008429923,0.00004662088,0.000006894532,0.000042919823,0.00020677326,0.00006697056],"category_scores_gemma":[0.00041708982,0.00008880525,0.00013033855,0.00009106573,0.00023757762,0.00012299872,0.00004660497,0.00020644322,0.0000012453545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008950621,0.0010749797,0.68331665,0.0000080996015,0.00051769754,0.00018420813,0.00015532774,1.5059263e-7,0.00026591518,0.0000024888525,0.00004573161,0.3054781],"study_design_scores_gemma":[0.023686381,0.0660268,0.9073238,0.00019352509,0.00042345742,0.000093054994,0.000029772298,0.000005065388,0.0011258748,0.000057413,0.00093922945,0.000095670825],"about_ca_topic_score_codex":0.00013696685,"about_ca_topic_score_gemma":0.0024837179,"teacher_disagreement_score":0.30538243,"about_ca_system_score_codex":0.00047340785,"about_ca_system_score_gemma":0.00058089476,"threshold_uncertainty_score":0.36213732},"labels":[],"label_agreement":null},{"id":"W2589716546","doi":"10.1200/jco.2012.30.4_suppl.648","title":"Should lymph node retrieval be a surgical quality indicator in colon cancer?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Lymph node; Logistic regression; Univariate analysis; Multivariate analysis; Univariate; Lymph; Stage (stratigraphy); Surgery; Dissection (medical); Cancer; Oncology; Multivariate statistics; Internal medicine; Pathology; Statistics","score_opus":0.34932097668203593,"score_gpt":0.5711252046142489,"score_spread":0.22180422793221294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589716546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743906,0.0017595416,0.0000041625144,0.014907972,0.002316587,0.00024620752,0.000012188363,0.000015385816,0.0063473224],"genre_scores_gemma":[0.99201274,0.0013672806,0.0005596514,0.0033690708,0.002374108,0.000010747505,0.000003305752,0.000022678832,0.00028040915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938358,0.0012054205,0.0032953308,0.0002544137,0.0008377905,0.000571212],"domain_scores_gemma":[0.9922517,0.0043296586,0.0018060005,0.00023413781,0.00023632453,0.0011422095],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007927937,0.0002119067,0.0024425313,0.0001950528,0.00003438364,0.0000070156198,0.00020817209,0.0008543202,0.0013266238],"category_scores_gemma":[0.0047127246,0.00014936291,0.0007212772,0.00040802956,0.00031543899,0.0001797416,0.00010687132,0.0015209735,0.00003360659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026831156,0.0042942315,0.92925316,0.000031864234,0.0003007255,0.0014217963,0.0001247232,0.0000028387203,0.00006486409,0.00010980842,0.0007910391,0.036773775],"study_design_scores_gemma":[0.016296614,0.003463851,0.837203,0.000083395294,0.0002463581,0.0005265634,0.00004936768,0.000011242429,0.00013007436,0.000054660533,0.14181018,0.00012470085],"about_ca_topic_score_codex":0.00017344052,"about_ca_topic_score_gemma":0.000055146622,"teacher_disagreement_score":0.14101914,"about_ca_system_score_codex":0.0013715082,"about_ca_system_score_gemma":0.0025795992,"threshold_uncertainty_score":0.9995863},"labels":[],"label_agreement":null},{"id":"W2589723661","doi":"10.1200/jco.2014.32.3_suppl.412","title":"Predicting toxicities from adjuvant treatment in a population-based cohort of early colon cancer (CC) patients (pts): A strategy to improve use of curative chemotherapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Chemotherapy; Cancer; Colorectal cancer; Population; Cohort; Oncology; Gastroenterology; Surgery; Oxaliplatin","score_opus":0.0842648507245775,"score_gpt":0.4319219805264959,"score_spread":0.3476571298019184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589723661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979662,0.00015388719,0.000017889937,0.0006401747,0.00038545334,0.0006033351,0.00008587284,0.0000035367186,0.00014368478],"genre_scores_gemma":[0.99851537,0.00018087435,0.0005942035,0.00039944955,0.00019988624,0.0000385059,0.000007790105,0.000012029353,0.0000518937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973255,0.00023581191,0.0018178929,0.00018138987,0.00028337,0.00015607933],"domain_scores_gemma":[0.9958229,0.0018914636,0.0015303402,0.000116850344,0.0004948018,0.00014365902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004119602,0.00015129565,0.001676527,0.00011386097,0.000021495287,0.000004483691,0.000057782785,0.00016224332,0.000037739825],"category_scores_gemma":[0.0009649547,0.000099139936,0.00026003818,0.00011419128,0.000085867214,0.00007877841,0.00001695662,0.00020251995,3.7875506e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009947215,0.0036210197,0.84864116,0.000013246128,0.00056777213,0.000010476532,0.0006238164,0.00012473053,0.00011795909,0.000004260285,0.000036574034,0.13629176],"study_design_scores_gemma":[0.018153287,0.0628111,0.91705936,0.00021158898,0.0003168082,5.268444e-7,0.0001094394,0.00039514445,0.0004539157,0.00004685552,0.0003777667,0.00006420329],"about_ca_topic_score_codex":0.012313682,"about_ca_topic_score_gemma":0.006976267,"teacher_disagreement_score":0.13622756,"about_ca_system_score_codex":0.0005237848,"about_ca_system_score_gemma":0.0007395725,"threshold_uncertainty_score":0.9942634},"labels":[],"label_agreement":null},{"id":"W2589726725","doi":"10.1200/jco.2016.34.4_suppl.540","title":"Thrombocytosis as a predictor of poor prognosis in colorectal cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Nova Scotia Cancer Centre; Dalhousie University","funders":"","keywords":"Thrombocytosis; Medicine; Internal medicine; Colorectal cancer; Gastroenterology; Proportional hazards model; Cancer; Univariate analysis; Population; Pathological; Lymph node; Multivariate analysis; Stage (stratigraphy); Oncology; Platelet","score_opus":0.06256989866454961,"score_gpt":0.4306314186736072,"score_spread":0.3680615200090576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589726725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914705,0.0002462748,0.000004294311,0.005325822,0.0011879295,0.0004563343,0.000025459753,0.0000103564225,0.0012730142],"genre_scores_gemma":[0.9971826,0.00066688337,0.0009112227,0.00063115265,0.00050813024,0.00004100319,0.0000010673779,0.000021918087,0.000035998346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954116,0.0004510532,0.0030623563,0.00021947594,0.0005698334,0.0002857265],"domain_scores_gemma":[0.99442965,0.0019020409,0.0022432432,0.00010436521,0.0009088594,0.00041184667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021041173,0.00015936053,0.0015868027,0.00023878951,0.000017610313,0.0000031969416,0.0002268336,0.00047229862,0.000616249],"category_scores_gemma":[0.008040515,0.00009291231,0.00059963844,0.00022134425,0.00047691315,0.00015354394,0.000086323904,0.00041272692,0.00001741468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010655318,0.0036860064,0.9046208,0.00006769653,0.00055525993,0.00018393689,0.00006601312,1.6501524e-7,0.0025999763,0.000028214132,0.003362479,0.0741741],"study_design_scores_gemma":[0.014369632,0.012822339,0.9577803,0.0007029226,0.0004846582,0.000033287066,0.000035494406,0.000006739631,0.010172829,0.00019108356,0.0033009774,0.00009971328],"about_ca_topic_score_codex":0.000019551097,"about_ca_topic_score_gemma":0.000033032156,"teacher_disagreement_score":0.07407438,"about_ca_system_score_codex":0.00035291963,"about_ca_system_score_gemma":0.0025095842,"threshold_uncertainty_score":0.9625828},"labels":[],"label_agreement":null},{"id":"W2589731098","doi":"10.1200/jco.2014.32.30_suppl.311","title":"Examining the use of PET scans in the diagnosis and management of non-small cell lung cancer patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Radiology; Nuclear medicine; Internal medicine","score_opus":0.10073290450612446,"score_gpt":0.4264560150479975,"score_spread":0.3257231105418731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589731098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921083,0.00023859822,0.0004115103,0.0058856388,0.0003592701,0.00018842338,8.8597824e-7,9.094375e-7,0.0008064627],"genre_scores_gemma":[0.98911375,0.0042288294,0.003663454,0.0027436707,0.00019736921,0.0000070863384,4.9797114e-7,0.00000764904,0.00003767091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978136,0.00046759905,0.0012460125,0.000096131254,0.00025138666,0.00012531785],"domain_scores_gemma":[0.99418795,0.0043484364,0.0011104097,0.00014008283,0.00012544522,0.00008770235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004087304,0.000071733615,0.00064867834,0.00006359362,0.000022733586,0.0000058945993,0.00017842017,0.000065467255,0.000017986185],"category_scores_gemma":[0.0016585813,0.000035256326,0.000117592324,0.00009592674,0.00021810338,0.000036518413,0.00006280401,0.0007263275,1.8407196e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015978755,0.00056262285,0.85704017,0.00014001201,0.000094952746,0.00004597754,0.00035831897,0.00023872427,0.000009659852,0.000036714122,0.0023083375,0.13900472],"study_design_scores_gemma":[0.0037874617,0.0021968614,0.9637795,0.00044440757,0.00040086353,0.000015772242,0.00020190295,0.0077639343,0.000008964247,0.000020235922,0.021343546,0.00003654551],"about_ca_topic_score_codex":0.00011316689,"about_ca_topic_score_gemma":0.000027077473,"teacher_disagreement_score":0.13896817,"about_ca_system_score_codex":0.000026518264,"about_ca_system_score_gemma":0.00011228866,"threshold_uncertainty_score":0.31555718},"labels":[],"label_agreement":null},{"id":"W2589733809","doi":"10.1200/jco.2012.30.4_suppl.199","title":"Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"FOLFIRINOX; Irinotecan; Medicine; Oxaliplatin; Gemcitabine; Pancreatic cancer; Oncology; Internal medicine; Cancer; Colorectal cancer","score_opus":0.37317607931413216,"score_gpt":0.4805248293951181,"score_spread":0.10734875008098593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589733809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97049654,0.0146023985,0.008800774,0.0005826753,0.0025542022,0.0006324519,0.00024080943,0.000002935035,0.0020872052],"genre_scores_gemma":[0.9891393,0.0074471845,0.0024306965,0.00010253599,0.0006980704,0.000055537435,0.0000025874363,0.00001869638,0.00010540251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623084,0.00009743821,0.0031992039,0.00014429438,0.000037727274,0.0002905165],"domain_scores_gemma":[0.9907636,0.0039551156,0.0046635987,0.0001771971,0.00021876453,0.00022174788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038023598,0.00014619807,0.0026771182,0.00014815648,0.000027764945,0.0000042491442,0.00017707628,0.00018305861,0.00014699271],"category_scores_gemma":[0.0020411685,0.00012402094,0.00073616684,0.00009349318,0.00016585334,0.00026613893,0.000019036983,0.00013080306,0.000010102972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053006653,0.0049776733,0.76184535,0.00041613224,0.0019167443,0.0000058407218,0.00040334903,0.0009351564,0.000026236125,0.039830554,0.00052537426,0.1838169],"study_design_scores_gemma":[0.016689593,0.022439986,0.6995652,0.0001774471,0.0005690288,0.000020983403,0.00006685308,0.00036097827,0.0010132906,0.027563581,0.23124896,0.00028409564],"about_ca_topic_score_codex":0.00021973449,"about_ca_topic_score_gemma":0.00008015979,"teacher_disagreement_score":0.23072359,"about_ca_system_score_codex":0.00035292507,"about_ca_system_score_gemma":0.0003841996,"threshold_uncertainty_score":0.50574267},"labels":[],"label_agreement":null},{"id":"W2589737363","doi":"10.1200/jco.2014.32.4_suppl.30","title":"Using adjuvant radiotherapy to improve cancer-specific survival in patients with highly aggressive prostate cancer: Examining recently released criteria.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Internal medicine; Radiation therapy; Cancer; Adverse effect; Lymph node; Population; Proportional hazards model; Oncology","score_opus":0.13332308207713617,"score_gpt":0.4743767950744137,"score_spread":0.34105371299727755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589737363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902267,0.002388333,0.00010277233,0.004049557,0.0023427214,0.0007221621,0.000024103656,0.000009237568,0.00013445244],"genre_scores_gemma":[0.98527056,0.0075867972,0.0040974133,0.0011264114,0.0016332875,0.000033344928,0.0000074469845,0.00005212612,0.00019260359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961627,0.00067019084,0.0016673653,0.00037554034,0.0006178111,0.0005063534],"domain_scores_gemma":[0.99580765,0.00082229736,0.0016694542,0.00023087845,0.0008798371,0.0005898993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020099909,0.00022424076,0.0016841392,0.00025809454,0.000059484846,0.000023186849,0.00018206243,0.00023668437,0.00011689027],"category_scores_gemma":[0.0007446317,0.0001405958,0.0001438703,0.00033099653,0.00018785155,0.0001507829,0.000043428936,0.00089213107,0.0000025200197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037760705,0.0009684432,0.6102933,0.000042173386,0.00025770353,0.0003077352,0.00031951992,0.0000870793,0.0013155747,0.0000036605131,0.00065570703,0.3479884],"study_design_scores_gemma":[0.046472084,0.03173653,0.8837501,0.0012856919,0.00015463588,0.00001533318,0.00011762594,0.0003061687,0.0004682914,0.000023584704,0.035442628,0.00022735029],"about_ca_topic_score_codex":0.00024075159,"about_ca_topic_score_gemma":0.00015295608,"teacher_disagreement_score":0.34776103,"about_ca_system_score_codex":0.0011457668,"about_ca_system_score_gemma":0.0023096935,"threshold_uncertainty_score":0.5733331},"labels":[],"label_agreement":null},{"id":"W2589740788","doi":"10.1200/jco.2013.31.26_suppl.65","title":"Propensity-score matched pair comparison of brachytherapy-based accelerated partial breast irradiation versus whole breast Canadian hypofractionation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cosmesis; Breast cancer; Brachytherapy; Internal medicine; Oncology; Stage (stratigraphy); Nuclear medicine; Urology; Radiation therapy; Cancer; Surgery","score_opus":0.1563430058535578,"score_gpt":0.41117944695404296,"score_spread":0.2548364411004852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589740788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985386,0.00019621332,0.00013133847,0.01262038,0.0010946939,0.00022829762,0.000055632514,0.000005561848,0.00028189493],"genre_scores_gemma":[0.9975746,0.000034925495,0.00067655,0.00064370217,0.0009101515,0.000015674894,0.00008977137,0.000017774386,0.000036798065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976455,0.0003435294,0.0013232054,0.00021634773,0.00023126206,0.00024014263],"domain_scores_gemma":[0.9966714,0.00027359603,0.0014775088,0.00018765086,0.001093838,0.00029605508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006083576,0.0001649205,0.000772772,0.00009826619,0.00009103972,0.00001901145,0.00018557497,0.00036912496,0.00015989516],"category_scores_gemma":[0.0003498591,0.00013424111,0.0002562265,0.00012908372,0.00017647303,0.000029128967,0.000027937454,0.00032232705,0.000025161786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006280699,0.0018371883,0.8082074,0.000017346307,0.0010617381,0.000017469365,0.0000844762,0.0011890236,0.0093071805,0.0000217201,0.01841353,0.15356225],"study_design_scores_gemma":[0.006718874,0.002297406,0.97167057,0.000017065504,0.0001150883,0.000070988484,0.00011512346,0.0003108428,0.0015698731,0.000025207726,0.016948644,0.00014029528],"about_ca_topic_score_codex":0.005122322,"about_ca_topic_score_gemma":0.011672228,"teacher_disagreement_score":0.1634632,"about_ca_system_score_codex":0.0001717543,"about_ca_system_score_gemma":0.0021196606,"threshold_uncertainty_score":0.7743453},"labels":[],"label_agreement":null},{"id":"W2589743022","doi":"10.1200/jco.2014.32.4_suppl.26","title":"Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Image-guided radiation therapy; Oncology; Cohort; Prostatectomy; Proportional hazards model; Internal medicine; Hazard ratio; Cancer; Radiation therapy; Prostate","score_opus":0.05087398432345788,"score_gpt":0.43084622001509815,"score_spread":0.3799722356916403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589743022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97143537,0.0013610271,0.021454955,0.0010614038,0.0041631795,0.00036325637,0.00006082307,0.000005404516,0.00009459742],"genre_scores_gemma":[0.91631824,0.004578818,0.066294335,0.004037773,0.008522774,0.000035386223,0.000020280735,0.00007258073,0.00011981006],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969801,0.00025154406,0.0018624517,0.0003597058,0.00018018446,0.00036604216],"domain_scores_gemma":[0.9965134,0.0009732866,0.0013026498,0.0002789316,0.00049596874,0.000435763],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028113958,0.00020504699,0.00090360345,0.00007640497,0.0000698288,0.00003009209,0.00035362874,0.00045386335,0.000014118628],"category_scores_gemma":[0.01325021,0.00017261246,0.00073028513,0.00008018102,0.00013935012,0.000009796509,0.000117486816,0.0004090873,0.0000020809177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015962297,0.0010846229,0.07483444,0.00008464695,0.001761951,0.000058150934,0.00030207323,0.002965871,0.58291245,0.000051989828,0.19091058,0.12907091],"study_design_scores_gemma":[0.01768442,0.018645147,0.010451929,0.00017523837,0.0006964442,0.00006735793,0.000077070785,0.0033309055,0.043189015,0.0006770866,0.904388,0.00061734737],"about_ca_topic_score_codex":0.000040870716,"about_ca_topic_score_gemma":0.000053874377,"teacher_disagreement_score":0.71347743,"about_ca_system_score_codex":0.00014693252,"about_ca_system_score_gemma":0.0012215812,"threshold_uncertainty_score":0.9950616},"labels":[],"label_agreement":null},{"id":"W2589745289","doi":"10.1200/jco.2013.31.31_suppl.141","title":"Transition care clinic: Evidence-based survivorship care.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Survivorship curve; Specialty; Cancer; Family medicine; Colorectal cancer; Depression (economics); Health care; Emergency medicine; Internal medicine","score_opus":0.1992687415531618,"score_gpt":0.4724070921283274,"score_spread":0.27313835057516556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589745289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95996207,0.007772303,0.00057117565,0.019782633,0.0053442474,0.00043338534,0.0000054990187,0.000029359288,0.006099348],"genre_scores_gemma":[0.98543686,0.00089404144,0.0010210939,0.009664138,0.0027542557,0.000013783765,0.0000087989,0.000026369842,0.0001806538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99526405,0.0009947713,0.002573216,0.0002601286,0.00060402934,0.00030382],"domain_scores_gemma":[0.99156845,0.003994161,0.0012398182,0.0003219319,0.0022427896,0.00063288206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002470587,0.00018764733,0.0015669387,0.00015976798,0.00005277365,0.000022221391,0.00022932295,0.0006740931,0.0018028923],"category_scores_gemma":[0.002854408,0.00013782656,0.0011593562,0.0002107599,0.00022670113,0.00028775408,0.000020709283,0.0013955071,0.00021067995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009777661,0.0011912951,0.23664063,0.0008178484,0.00040887203,0.00078656786,0.0064789224,0.000050631326,0.0002843819,0.000034385946,0.015323962,0.72820485],"study_design_scores_gemma":[0.017687714,0.051971555,0.7192246,0.0024940914,0.0018678096,0.00030468803,0.026102787,0.000116388954,0.00067983824,0.0003255658,0.1786604,0.00056461786],"about_ca_topic_score_codex":0.00080259173,"about_ca_topic_score_gemma":0.0012954427,"teacher_disagreement_score":0.7276402,"about_ca_system_score_codex":0.00030228522,"about_ca_system_score_gemma":0.0030598831,"threshold_uncertainty_score":0.99910957},"labels":[],"label_agreement":null},{"id":"W2589745415","doi":"10.1200/jco.2012.30.4_suppl.591","title":"Clinical research in surgical oncology: An analysis of clinicaltrials.gov.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Blinding; Randomized controlled trial; Observational study; Internal medicine; Surgery; Oncology","score_opus":0.8549687409635847,"score_gpt":0.7748279222412143,"score_spread":0.08014081872237033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589745415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9495137,0.001165839,0.000045448316,0.03146913,0.0023136805,0.00050223485,0.000007998919,0.000009799298,0.014972198],"genre_scores_gemma":[0.97167,0.012343816,0.003275115,0.0053038932,0.007198277,0.0000071588884,0.000010605288,0.000024883782,0.00016630063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9600377,0.02086281,0.01358544,0.00047546576,0.0028478445,0.002190709],"domain_scores_gemma":[0.66564405,0.26103458,0.009665363,0.002307444,0.0067891874,0.054559406],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.30283192,0.00021110613,0.0067026126,0.0018393268,0.000060726405,0.000008537812,0.0006069953,0.0023304732,0.00087554305],"category_scores_gemma":[0.36228135,0.00014060597,0.0019056229,0.0025735376,0.00200145,0.00032980516,0.00020909296,0.008464494,0.00006759177],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016648486,0.014285722,0.47348914,0.00005044063,0.00085700065,0.0014256912,0.00011203331,0.00000376346,0.0000125460165,0.0002467647,0.005032748,0.48783568],"study_design_scores_gemma":[0.011520269,0.037322063,0.43086708,0.00011909393,0.0008872927,0.00016337747,0.00029625717,0.00022691287,0.0000069464895,0.0001467174,0.51836085,0.000083165316],"about_ca_topic_score_codex":0.00016532575,"about_ca_topic_score_gemma":0.0001851018,"teacher_disagreement_score":0.5133281,"about_ca_system_score_codex":0.0007367686,"about_ca_system_score_gemma":0.037182283,"threshold_uncertainty_score":0.9989647},"labels":[],"label_agreement":null},{"id":"W2589747494","doi":"10.1200/jco.2012.30.34_suppl.8","title":"Follow-up of long-term young breast cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Cancer; Cancer registry; Survivorship curve; Population; Internal medicine; Retrospective cohort study; Cohort; Pediatrics","score_opus":0.12287294610470878,"score_gpt":0.46474890756644216,"score_spread":0.3418759614617334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589747494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98214656,0.0019781727,0.000081208,0.0027585218,0.00751246,0.00011424771,0.00001694446,0.0000056300937,0.0053862343],"genre_scores_gemma":[0.9907926,0.0023554282,0.00039933986,0.0020462926,0.0034375975,0.0000021526698,0.0000032799003,0.000017635803,0.00094568636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967975,0.00027158932,0.0021461176,0.000117785006,0.00035814845,0.00030884938],"domain_scores_gemma":[0.99624366,0.00085944106,0.0016912321,0.00019383554,0.00045676925,0.00055508444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027046357,0.00012828938,0.0016056256,0.000105001476,0.000024431023,0.0000031097045,0.0001679282,0.00034178692,0.0021890332],"category_scores_gemma":[0.0006300024,0.00009036429,0.00065660867,0.00010966636,0.00021139099,0.00023681314,0.000046864876,0.00082983414,0.000014750128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003947842,0.0006710523,0.8126848,0.000062792016,0.00041435962,0.00010433177,0.00016192332,0.0000013933306,0.0003678556,0.000018583392,0.0031915861,0.17837347],"study_design_scores_gemma":[0.008127812,0.0018712811,0.9744136,0.00010486858,0.00045495175,0.0010120173,0.000057669822,0.0000081705275,0.00015482857,0.000009165679,0.013700772,0.00008487307],"about_ca_topic_score_codex":0.00021460759,"about_ca_topic_score_gemma":0.00051224313,"teacher_disagreement_score":0.17828861,"about_ca_system_score_codex":0.00020352226,"about_ca_system_score_gemma":0.0018765015,"threshold_uncertainty_score":0.9987231},"labels":[],"label_agreement":null},{"id":"W2589748065","doi":"10.1200/jco.2012.30.34_suppl.249","title":"Quality of systemic cancer therapy in routine care: What are we measuring?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Population; MEDLINE; Clinical trial; Family medicine; Internal medicine; Cancer registry; Breast cancer; Intensive care medicine; Oncology","score_opus":0.4384824179354035,"score_gpt":0.5850279326458419,"score_spread":0.14654551471043836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589748065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90288794,0.085616075,0.000004811276,0.007304505,0.0035094197,0.00020540404,0.0000030814588,0.000004217857,0.00046453063],"genre_scores_gemma":[0.9250671,0.07139473,0.000105327825,0.0012809739,0.0020174382,0.000009483825,8.500383e-7,0.000011085629,0.000112964284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962173,0.00083080854,0.002304906,0.00011204997,0.00028683624,0.0002480978],"domain_scores_gemma":[0.9955422,0.0013666555,0.00227204,0.00013507715,0.00041429148,0.0002696995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034679258,0.000121007615,0.0018228374,0.00011430865,0.000013794579,0.0000032366454,0.00011221003,0.00031599842,0.000264695],"category_scores_gemma":[0.00042875382,0.000081332226,0.00041839047,0.00013251368,0.00011835769,0.00019276072,0.000023803535,0.0006700773,0.0000039976408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070665553,0.0022262493,0.8562862,0.00012749582,0.00038402824,0.000057168225,0.0013381641,0.00001079021,0.0011190221,0.000018534516,0.0010322214,0.13033357],"study_design_scores_gemma":[0.022305563,0.006066973,0.9386306,0.0007343615,0.0002584951,0.00016071876,0.002406487,0.0000024903595,0.0008935239,0.000034091987,0.028409608,0.000097081545],"about_ca_topic_score_codex":0.00017845098,"about_ca_topic_score_gemma":0.0002553537,"teacher_disagreement_score":0.13023649,"about_ca_system_score_codex":0.00046902962,"about_ca_system_score_gemma":0.0010648043,"threshold_uncertainty_score":0.3316632},"labels":[],"label_agreement":null},{"id":"W2589748500","doi":"10.1200/jco.2013.31.4_suppl.130","title":"A prospective comparison of the FACT-e and EORTC-QLQC30 and OG25 questionnaires for evaluating changes in health-related quality of life in patients with esophageal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Prospective cohort study; Cancer; Esophageal cancer; Esophagectomy; Chemoradiotherapy; Disease; Surgery; Internal medicine; Physical therapy","score_opus":0.20567023049482927,"score_gpt":0.5526338736587859,"score_spread":0.34696364316395667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589748500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877891,0.0049614375,0.000004063326,0.0059541026,0.00007871138,0.0011901016,0.0000073521314,0.0000011913443,0.000013969214],"genre_scores_gemma":[0.99897546,0.00022768076,0.0005238447,0.00017373874,0.00003801913,0.00004298404,9.331884e-7,0.0000054905145,0.000011874495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970494,0.00065195083,0.0016987119,0.00012585173,0.00031922752,0.0001548649],"domain_scores_gemma":[0.99582803,0.0015911923,0.0018455104,0.000077256176,0.00047688527,0.00018109841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026857283,0.000078756304,0.0012247685,0.00008029512,0.000024924047,0.0000028622565,0.000052602318,0.00010803656,0.000015646734],"category_scores_gemma":[0.003755842,0.000042718468,0.0000610533,0.00011769922,0.0002503172,0.00005604956,0.000031877025,0.00043160262,8.6335284e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005642362,0.0011456332,0.94611144,0.0002165717,0.00012568609,0.0000018847765,0.000646772,0.000020077776,0.0000046584114,0.00004049312,0.000033176737,0.046011217],"study_design_scores_gemma":[0.016884852,0.025519196,0.9562169,0.00045329236,0.00003576311,0.0000015000029,0.0001862125,0.00021369805,0.00003662529,0.00042111645,0.0000031110712,0.000027740172],"about_ca_topic_score_codex":0.0031753564,"about_ca_topic_score_gemma":0.005522817,"teacher_disagreement_score":0.04598348,"about_ca_system_score_codex":0.00020218777,"about_ca_system_score_gemma":0.0013101328,"threshold_uncertainty_score":0.480021},"labels":[],"label_agreement":null},{"id":"W2589751217","doi":"10.1200/jco.2012.30.15_suppl.4058","title":"Benefits of platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations:  A translational case series.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Oncology; Chemotherapy; Internal medicine; Loss of heterozygosity; Cisplatin; Germline; Cancer; Cancer research; Allele; Gene; Genetics; Biology","score_opus":0.05191792434046027,"score_gpt":0.35976980999443053,"score_spread":0.30785188565397026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589751217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633765,0.0018333235,0.0003601623,0.00083139027,0.00019948858,0.00013586134,0.000042896514,0.0000017054156,0.00025754867],"genre_scores_gemma":[0.99514985,0.00026193867,0.0034263637,0.0006430508,0.00043212026,0.0000059886024,0.000037721886,0.000018797882,0.00002415787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804765,0.00017778002,0.0012667212,0.0001329671,0.00016449731,0.00021039859],"domain_scores_gemma":[0.99740005,0.00091455557,0.0010926181,0.00013166558,0.00030112005,0.00015997574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001273842,0.00012754842,0.0006260149,0.00007523863,0.00002643233,0.0000054093166,0.000108960856,0.00033698694,0.000040720897],"category_scores_gemma":[0.0014180655,0.000106119216,0.0001910954,0.00012823536,0.00015883312,0.00001304951,0.000013348285,0.0002649493,7.2403856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004077153,0.002207673,0.96767443,0.000026626052,0.00043688674,0.000204147,0.0003032869,0.0049528237,0.0018943513,0.0001829519,0.00041643862,0.01762323],"study_design_scores_gemma":[0.01637188,0.009775563,0.96134233,0.00012279945,0.00028474221,0.0016106839,0.00021973457,0.00026374438,0.0062615355,0.0002190663,0.0032400333,0.00028788953],"about_ca_topic_score_codex":0.000028256361,"about_ca_topic_score_gemma":0.0005318738,"teacher_disagreement_score":0.01733534,"about_ca_system_score_codex":0.000052455674,"about_ca_system_score_gemma":0.0011081807,"threshold_uncertainty_score":0.4327416},"labels":[],"label_agreement":null},{"id":"W2589753046","doi":"10.1200/jco.2016.34.4_suppl.296","title":"PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Randomization; Colorectal cancer; Confidence interval; Liver cancer; Christian ministry; Radiology; Nuclear medicine; Surgery; Cancer; Internal medicine","score_opus":0.04920606098488949,"score_gpt":0.44246365701602264,"score_spread":0.39325759603113314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589753046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93722653,0.00059314125,0.0010895341,0.051925603,0.0010019138,0.0034212836,0.000010033156,0.000004429292,0.004727497],"genre_scores_gemma":[0.9918446,0.0024547128,0.002927767,0.0019077868,0.00036869897,0.00017011096,0.0000013915795,0.000012585845,0.00031237118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99255747,0.0029625143,0.0034938897,0.00017866949,0.0005655004,0.00024194094],"domain_scores_gemma":[0.9815242,0.014811302,0.0026163957,0.00028653452,0.00057303486,0.00018851421],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02133437,0.0001403057,0.0033427656,0.00015611971,0.000051391195,0.000010459758,0.00050128024,0.00002013605,0.00026580825],"category_scores_gemma":[0.012061666,0.000054168057,0.0010399086,0.00023201031,0.00048752988,0.00004934879,0.000086571374,0.0006597539,0.0000060292364],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95433396,0.0019115604,0.0012995427,0.000048135422,0.002843893,0.0011398494,0.0000803934,0.00008828417,0.00056059164,0.0011277018,0.007489063,0.029077016],"study_design_scores_gemma":[0.96890557,0.003043305,0.009604244,0.00048904587,0.0025363602,0.0007108327,0.00019561559,0.0007459253,0.000029199218,0.00024562926,0.013415872,0.000078398436],"about_ca_topic_score_codex":0.0002399929,"about_ca_topic_score_gemma":0.00008592374,"teacher_disagreement_score":0.054618012,"about_ca_system_score_codex":0.0001292564,"about_ca_system_score_gemma":0.00078677176,"threshold_uncertainty_score":0.99626017},"labels":[],"label_agreement":null},{"id":"W2589756810","doi":"10.1200/jco.2016.34.2_suppl.386","title":"Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Taxane; Medicine; Carboplatin; Salvage therapy; Chemotherapy; Oncology; Cisplatin; Internal medicine; Gemcitabine; Surgery; Urology; Cancer; Breast cancer","score_opus":0.08306237165049717,"score_gpt":0.45369411177645275,"score_spread":0.37063174012595557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589756810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959846,0.00022062137,0.00019930757,0.0006397634,0.0013058872,0.0007578671,0.000053285847,0.000007929937,0.00083069765],"genre_scores_gemma":[0.9970551,0.0004267198,0.0008271508,0.00041644764,0.001004222,0.000015303985,0.0000018736265,0.000033369473,0.00021981096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699366,0.0002484477,0.0019435463,0.0002034075,0.00032899354,0.00028194283],"domain_scores_gemma":[0.9943642,0.002624203,0.0019063007,0.00022378472,0.0006086173,0.00027290886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010966457,0.00018123465,0.0014816952,0.000115528084,0.000035543144,0.0000032873063,0.00015028178,0.0002829285,0.00010371353],"category_scores_gemma":[0.0023473208,0.00008937599,0.00092581403,0.000068854344,0.00009925956,0.000095724805,0.000018428907,0.0002823184,0.000008902152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033075985,0.001714268,0.49817932,0.000026637403,0.0004627948,0.000027280841,0.00008676458,0.000002661588,0.0041119754,0.000008645843,0.0007615845,0.4615421],"study_design_scores_gemma":[0.055640787,0.09442615,0.84621066,0.00045718809,0.00018255989,0.000056823188,0.000017105336,0.000003520111,0.0011895362,0.00011239534,0.0016114922,0.00009180912],"about_ca_topic_score_codex":0.000013523143,"about_ca_topic_score_gemma":0.0000039647657,"teacher_disagreement_score":0.46145028,"about_ca_system_score_codex":0.0003716479,"about_ca_system_score_gemma":0.0016576461,"threshold_uncertainty_score":0.36446473},"labels":[],"label_agreement":null},{"id":"W2589758423","doi":"10.1200/jco.2016.34.7_suppl.31","title":"Influencing antiemetic prescribing practices and funding changes through evidence-based guidelines.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Aprepitant; Medicine; Antiemetic; Ondansetron; Formulary; Medical prescription; Family medicine; Pharmacology; Chemotherapy; Internal medicine; Vomiting","score_opus":0.6934237566061516,"score_gpt":0.5887943556294042,"score_spread":0.10462940097674744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589758423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85676175,0.0029051588,0.00298586,0.13540402,0.0009517166,0.00018305477,4.3148302e-7,0.000017195265,0.0007908074],"genre_scores_gemma":[0.9542436,0.0051685935,0.0282599,0.009945536,0.0021129616,0.0000023416806,1.1358713e-7,0.000014701374,0.00025223408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969624,0.00040132616,0.0017922057,0.00020948928,0.00038939418,0.00024513528],"domain_scores_gemma":[0.98691064,0.008241506,0.0037384017,0.00018355912,0.00069566636,0.00023023474],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00811147,0.0001201924,0.0009134931,0.00013689412,0.00005582392,0.000021876507,0.00013464094,0.0001923299,0.000069088004],"category_scores_gemma":[0.06984477,0.00006613326,0.00017223411,0.00011714597,0.00016466461,0.00045767182,0.00008752912,0.00040311195,0.000007706394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029866642,0.0004086412,0.3785511,0.000250072,0.00042818242,0.000780501,0.000118821335,0.00000572996,0.008902305,0.00027607486,0.010150482,0.59714144],"study_design_scores_gemma":[0.019801904,0.02529956,0.35166356,0.012488337,0.0025767945,0.00068827503,0.0006856038,0.00030921568,0.0044569857,0.0013286432,0.5803052,0.00039590962],"about_ca_topic_score_codex":0.000028802006,"about_ca_topic_score_gemma":0.000017213806,"teacher_disagreement_score":0.5967455,"about_ca_system_score_codex":0.00010667181,"about_ca_system_score_gemma":0.00069774693,"threshold_uncertainty_score":0.9379903},"labels":[],"label_agreement":null},{"id":"W2589758764","doi":"10.1200/jco.2016.34.7_suppl.208","title":"Preoperative triage and multidisciplinary consultation for patients with breast cancer: A pilot study between surgery and medical oncology.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Waterloo; BC Cancer Agency","funders":"","keywords":"Medicine; Triage; Breast cancer; Referral; Radiation oncologist; Multidisciplinary approach; Cancer; General surgery; Medical emergency; Surgery; Family medicine; Radiation therapy; Internal medicine","score_opus":0.36065880087955626,"score_gpt":0.5822831535548416,"score_spread":0.22162435267528535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589758764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523822,0.00005769608,0.00070414256,0.045039114,0.0004509561,0.0012652744,0.00007350141,0.000007870393,0.000019230873],"genre_scores_gemma":[0.99486345,0.00062256056,0.0023267136,0.0009444057,0.0011401514,0.000043106407,0.00000980699,0.000018951981,0.000030873685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99414647,0.0011279911,0.0036953369,0.00030049204,0.0005246457,0.0002050661],"domain_scores_gemma":[0.9213405,0.073683076,0.0026758949,0.00011544996,0.0015883648,0.0005967069],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010208559,0.00015740658,0.0016741572,0.00011996683,0.00008158917,0.000009300615,0.00007224663,0.00022625465,0.00009405484],"category_scores_gemma":[0.051736835,0.00008116767,0.00010481143,0.000097945085,0.00043007074,0.0003316976,0.00008067705,0.00052472076,0.0000015012131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026420502,0.0035277663,0.6304971,0.000016842052,0.0004128787,0.000054312277,0.00013371941,1.09900796e-7,0.000006678625,0.0000031267932,0.00079349976,0.33813345],"study_design_scores_gemma":[0.052527737,0.07842385,0.8656281,0.00018996566,0.0010588756,0.00011185977,0.0005745235,0.000021410697,0.0000018106448,0.00006983024,0.0012996355,0.00009238079],"about_ca_topic_score_codex":0.000058566166,"about_ca_topic_score_gemma":0.00035125387,"teacher_disagreement_score":0.3380411,"about_ca_system_score_codex":0.00016934382,"about_ca_system_score_gemma":0.0032914598,"threshold_uncertainty_score":0.9562508},"labels":[],"label_agreement":null},{"id":"W2589766713","doi":"10.1200/jco.2016.34.2_suppl.506","title":"FGFR2 expression to predict survival outcome in patients with metastatic papillary renal cell carcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immunohistochemistry; Papillary renal cell carcinomas; Renal cell carcinoma; Internal medicine; Fibroblast growth factor receptor 2; Oncology; Pathology; Receptor; Fibroblast growth factor","score_opus":0.06661912753880815,"score_gpt":0.4007569702760367,"score_spread":0.3341378427372285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589766713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976223,0.000050844385,0.0006879824,0.00065853447,0.00038336255,0.00020394492,0.00001663212,0.0000022399122,0.00037417535],"genre_scores_gemma":[0.99680895,0.000024421679,0.0023161639,0.00024374455,0.0003226425,0.0000045006786,0.0000053662957,0.000023788845,0.00025043925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650735,0.0008246827,0.0015263867,0.0002909763,0.0004986172,0.0003520181],"domain_scores_gemma":[0.9976609,0.00059753587,0.0006764821,0.00028131562,0.00035981135,0.00042397308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021394978,0.000158334,0.0007223485,0.00012993392,0.000023653594,0.0000076285833,0.00037820087,0.00024764182,0.00006085913],"category_scores_gemma":[0.0022158301,0.000085049825,0.00019409611,0.000107622174,0.00012970678,0.000014724375,0.00021629958,0.00040431076,0.000018345589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055317674,0.00072110887,0.937083,0.000015540141,0.000041183586,0.00007805783,0.000011841404,0.000017034357,0.049596235,0.00000193728,0.0018577186,0.0050445697],"study_design_scores_gemma":[0.008618922,0.021158127,0.9423837,0.00005879754,0.000025215988,0.000007467133,0.000016071584,0.0000012558442,0.015570677,0.000018407327,0.012002324,0.00013901002],"about_ca_topic_score_codex":0.0000060697457,"about_ca_topic_score_gemma":0.000028037684,"teacher_disagreement_score":0.03402556,"about_ca_system_score_codex":0.000068417285,"about_ca_system_score_gemma":0.00061747717,"threshold_uncertainty_score":0.34682313},"labels":[],"label_agreement":null},{"id":"W2589768468","doi":"10.1200/jco.2016.34.4_suppl.722","title":"Capecitabine dosing using skeletal muscle index (SMI) compared to body surface area (BSA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; CancerCare Manitoba","funders":"","keywords":"Capecitabine; Medicine; Body surface area; Internal medicine; Colorectal cancer; Dosing; Sarcopenia; Cancer; Toxicity; Urology; Gastroenterology","score_opus":0.15376926690425885,"score_gpt":0.46404909861811966,"score_spread":0.3102798317138608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589768468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98389167,0.0004898322,0.0009554436,0.0104754595,0.0015257362,0.00020736454,0.0000066086664,0.0000129100745,0.0024350083],"genre_scores_gemma":[0.9938492,0.00023003029,0.003168999,0.0012903573,0.0010665036,0.0000014808589,5.1127756e-7,0.000018400873,0.00037447645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718803,0.00018854659,0.0016949513,0.00022531171,0.00037776039,0.00032540673],"domain_scores_gemma":[0.99649334,0.0014699734,0.0008610116,0.00017556132,0.00050907995,0.00049103406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011950536,0.00017680776,0.0016082837,0.00009751199,0.0000818612,0.0000096740905,0.00012362387,0.0001971424,0.00029055256],"category_scores_gemma":[0.0017379748,0.000097320066,0.00042712362,0.00016290319,0.00018213861,0.0001091197,0.00010083864,0.00038055432,0.000020805353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010090635,0.0037183259,0.54923826,0.000036401005,0.001765008,0.0020089748,0.00040094522,0.00017940534,0.017039433,0.000039844545,0.010455087,0.40502766],"study_design_scores_gemma":[0.013106156,0.01054005,0.86521435,0.00030884144,0.00046805327,0.00033676132,0.00020964212,0.00024259673,0.00015143793,0.00009808408,0.10915676,0.00016724918],"about_ca_topic_score_codex":0.00006845801,"about_ca_topic_score_gemma":0.00013255715,"teacher_disagreement_score":0.40486044,"about_ca_system_score_codex":0.0005072249,"about_ca_system_score_gemma":0.0008430051,"threshold_uncertainty_score":0.3968597},"labels":[],"label_agreement":null},{"id":"W2589771270","doi":"10.1200/jco.2013.31.31_suppl.128","title":"Outcomes of cancer patients who do not satisfy conventional clinical trial eligibility criteria (CTEC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cancer; Chemotherapy; Clinical trial; Performance status; Surgery","score_opus":0.1896973943953612,"score_gpt":0.5694258325789664,"score_spread":0.3797284381836052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589771270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543733,0.00040246182,0.000004934945,0.00661065,0.0053135226,0.0006600818,0.000031486405,0.000005907076,0.0015335961],"genre_scores_gemma":[0.99425614,0.0012160708,0.0007662445,0.001977378,0.0013536948,0.000032280466,0.0000043040877,0.0000123155,0.0003815493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935273,0.00055872137,0.004852685,0.0002688863,0.0005640545,0.00022835562],"domain_scores_gemma":[0.9917147,0.003375158,0.0027832442,0.00020915296,0.0015691059,0.000348628],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025628144,0.00018180348,0.002916968,0.00007886622,0.00004579505,0.000010844202,0.00015433067,0.0003844993,0.0019887814],"category_scores_gemma":[0.0073019406,0.00011088662,0.0012599812,0.000088235916,0.00048541988,0.00012211123,0.000102434344,0.00068538205,0.000021738831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044518318,0.0044141933,0.8170744,0.000023219474,0.001247289,0.0000174432,0.000037819435,1.8127594e-7,0.0000047704325,0.000039903887,0.012444712,0.12017776],"study_design_scores_gemma":[0.08990572,0.026310364,0.868029,0.00006584347,0.00054907973,0.00000448987,0.00003101003,0.0000074765376,0.000009468537,0.00044651073,0.014561254,0.000079814556],"about_ca_topic_score_codex":0.0003527304,"about_ca_topic_score_gemma":0.00016298477,"teacher_disagreement_score":0.12009795,"about_ca_system_score_codex":0.00018671568,"about_ca_system_score_gemma":0.0010491819,"threshold_uncertainty_score":0.99892354},"labels":[],"label_agreement":null},{"id":"W2589776278","doi":"10.1200/jco.2016.34.4_suppl.496","title":"Outcomes of perioperative systemic therapy (ST) in patients with R0 resection of metastatic colorectal cancer (mCRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Interquartile range; Colorectal cancer; Internal medicine; Bevacizumab; Oxaliplatin; Perioperative; Cohort; Irinotecan; Oncology; Population; Proportional hazards model; Surgery; Cancer; Chemotherapy","score_opus":0.08518857444679839,"score_gpt":0.45397855179327984,"score_spread":0.36878997734648145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589776278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692184,0.0006318417,0.0000101072565,0.0011141819,0.00044409384,0.00036037833,0.0000189879,0.0000019768281,0.00049659604],"genre_scores_gemma":[0.9978906,0.0015880904,0.00020683468,0.000103285405,0.00007303536,0.000017713788,5.658425e-7,0.000009110475,0.00011075382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975638,0.00030544956,0.0015556121,0.00012605682,0.00032030226,0.00012877832],"domain_scores_gemma":[0.99640423,0.0012137172,0.0014217582,0.000078965015,0.0007992933,0.00008204687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080616487,0.000116706186,0.0017192912,0.000122772,0.000017614318,0.0000013544466,0.00006439057,0.00009343989,0.00013235812],"category_scores_gemma":[0.0008113758,0.000049318147,0.00021729997,0.00013144233,0.00024064015,0.0000794721,0.000019071153,0.00020628981,6.1431456e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027896421,0.0015855636,0.91528475,0.0000274951,0.0013282525,0.0000304335,0.0004057124,0.0000046843165,0.00036151937,0.00001735545,0.000045502446,0.053012293],"study_design_scores_gemma":[0.024066951,0.050319392,0.9238756,0.0002865252,0.00021590322,0.000014832807,0.0002615162,0.0000019503284,0.00045090335,0.000013348174,0.00044414581,0.000048944796],"about_ca_topic_score_codex":0.00012054613,"about_ca_topic_score_gemma":0.00073499186,"teacher_disagreement_score":0.05296335,"about_ca_system_score_codex":0.00029575394,"about_ca_system_score_gemma":0.0008608255,"threshold_uncertainty_score":0.20111357},"labels":[],"label_agreement":null},{"id":"W2589777133","doi":"10.1200/jco.2013.31.6_suppl.5","title":"Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Abiraterone acetate; Internal medicine; Prostate cancer; Interim analysis; Hazard ratio; Clinical endpoint; Prednisone; Placebo; Progression-free survival; Gastroenterology; Asymptomatic; Urology; Chemotherapy; Androgen deprivation therapy; Oncology; Population; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.08645765738220536,"score_gpt":0.4905051951186309,"score_spread":0.40404753773642554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589777133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949112,0.00024528085,0.00006360433,0.0009425765,0.00012041703,0.0036269159,0.00002239512,0.0000046429095,0.00006295252],"genre_scores_gemma":[0.9977916,0.00038944243,0.0010817068,0.0001479534,0.000044177832,0.00018509311,0.000020218751,0.000025313628,0.0003145051],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936103,0.0012112213,0.003825784,0.0002897031,0.00074937317,0.00031359165],"domain_scores_gemma":[0.9936492,0.0006269754,0.003487386,0.00026607464,0.0016822293,0.00028817082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00321367,0.000245814,0.004254531,0.00052683376,0.0000302063,0.000015378917,0.0001829142,0.00012404978,0.00053275283],"category_scores_gemma":[0.00042314976,0.0001364268,0.00042221305,0.00071898574,0.00048322915,0.00020890897,0.00003765364,0.0005804069,0.0000021932701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7376649,0.024198376,0.1937487,0.00012723323,0.015107906,0.00019545882,0.0029563955,0.00018764264,0.0028582145,0.0000011962715,0.00014748907,0.022806514],"study_design_scores_gemma":[0.763641,0.041791253,0.18586175,0.00023357221,0.0051822215,0.0000075762473,0.0012344123,0.0007382163,0.001083268,0.00002346258,0.00006753142,0.00013574118],"about_ca_topic_score_codex":0.0010419482,"about_ca_topic_score_gemma":0.00097061205,"teacher_disagreement_score":0.025976118,"about_ca_system_score_codex":0.00023782792,"about_ca_system_score_gemma":0.0015061867,"threshold_uncertainty_score":0.583327},"labels":[],"label_agreement":null},{"id":"W2589784053","doi":"10.1200/jco.2005.23.16_suppl.7007","title":"Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Immunohistochemistry; Epidermal growth factor receptor; Gefitinib; Erlotinib Hydrochloride; KRAS; Internal medicine; Cancer; Oncology; Polysomy; Copy-number variation; Exon; Fluorescence in situ hybridization; EGFR inhibitors; Chromogenic in situ hybridization; Cancer research; Pathology; Gene expression; In situ hybridization; Gene; Biology; Genetics","score_opus":0.09834642691559599,"score_gpt":0.4801009994690773,"score_spread":0.38175457255348133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589784053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958847,0.00017126527,0.000021470703,0.0023870035,0.00041140718,0.00095649064,0.00007957079,0.0000014389517,0.000086643835],"genre_scores_gemma":[0.99777645,0.00012069166,0.0012696971,0.0004303231,0.00030225102,0.0000311259,0.0000181477,0.000009312454,0.000041976582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99363375,0.0014174065,0.0039600893,0.00021087434,0.00061453023,0.00016335798],"domain_scores_gemma":[0.9946349,0.0013820888,0.0030722246,0.00012345806,0.0005945806,0.00019269742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033786602,0.00013875015,0.0020992511,0.0002471518,0.000024683848,0.0000033333974,0.00011703743,0.0002468017,0.00007160039],"category_scores_gemma":[0.0068349284,0.000075384996,0.00038880832,0.00049586257,0.00018397612,0.00011527351,0.00003049349,0.000480832,9.51108e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056395944,0.0029902477,0.92260325,0.000023534385,0.002229581,0.000033457283,0.00010010967,0.00048219683,0.00079650834,0.000024044364,0.00032939514,0.0139917545],"study_design_scores_gemma":[0.090809755,0.0045463135,0.9001417,0.00021332987,0.0014360298,0.000002489397,0.00001947223,0.000112189584,0.001229522,0.000012045386,0.0014017847,0.00007533787],"about_ca_topic_score_codex":0.009749236,"about_ca_topic_score_gemma":0.06844038,"teacher_disagreement_score":0.058691144,"about_ca_system_score_codex":0.0005340078,"about_ca_system_score_gemma":0.0055960375,"threshold_uncertainty_score":0.99684495},"labels":[],"label_agreement":null},{"id":"W2589788766","doi":"10.1200/jco.2012.30.4_suppl.16","title":"A RAND/UCLA appropriateness study of the management of familial gastric cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Queen's University; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Cancer; Family history; Breast cancer; Internal medicine; Genetic testing; Family medicine; Pediatrics; General surgery","score_opus":0.16227522787819065,"score_gpt":0.4782980597739555,"score_spread":0.31602283189576486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589788766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921376,0.0006834908,0.00006012365,0.00054744695,0.004546786,0.0005249678,0.0000020287619,0.000002339309,0.0014951865],"genre_scores_gemma":[0.99689686,0.0004940033,0.001435116,0.00020160817,0.0008067809,0.000007961196,1.09269365e-7,0.000011920658,0.00014562694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646515,0.00047574998,0.0021195794,0.0001116284,0.0006124582,0.00021542737],"domain_scores_gemma":[0.9965685,0.0005797235,0.0020204822,0.00026426325,0.00038235763,0.0001846729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029605364,0.00011121189,0.0012919158,0.00007304589,0.000021593505,0.0000013024636,0.00029443848,0.00019022575,0.00012108219],"category_scores_gemma":[0.00048140128,0.000060955903,0.00038184153,0.00026544192,0.0001957055,0.000035781446,0.00014682369,0.00057748705,0.0000015053519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008819281,0.0075982297,0.84958863,0.00019202089,0.001521493,0.000035208854,0.0007717159,0.000108535554,0.0007530214,0.000025060404,0.00073994324,0.12984684],"study_design_scores_gemma":[0.012706035,0.011129927,0.969717,0.00014048445,0.0013434466,0.000057838184,0.0014535295,0.000013674331,0.00043634858,0.000042993983,0.0029039262,0.00005475432],"about_ca_topic_score_codex":0.000056379522,"about_ca_topic_score_gemma":0.000029891145,"teacher_disagreement_score":0.1297921,"about_ca_system_score_codex":0.00014575626,"about_ca_system_score_gemma":0.0006484306,"threshold_uncertainty_score":0.25089258},"labels":[],"label_agreement":null},{"id":"W2589792859","doi":"10.1200/jco.2014.32.30_suppl.189","title":"Equity of access: Consent interpretation program at Princess Margaret Cancer Centre (PM) in Canada.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Access Alliance Multicultural Health and Community Services; Princess Margaret Cancer Centre","funders":"","keywords":"Interpreter; Medicine; Clinical trial; Informed consent; Limited English proficiency; Family medicine; Medical education; Equity (law); Accreditation; Health care; Alternative medicine; Political science; Pathology","score_opus":0.3575286409017279,"score_gpt":0.6368228865474213,"score_spread":0.27929424564569333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589792859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95270675,0.00029842285,0.00009564303,0.027448267,0.0036994503,0.00050457724,0.0000119904735,0.0000107547785,0.015224151],"genre_scores_gemma":[0.9941259,0.00065357116,0.00069330545,0.0039540837,0.0003389084,0.000033951157,0.0000034564525,0.00001077869,0.00018604813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903972,0.004868126,0.00389799,0.00014800565,0.000345442,0.00034322805],"domain_scores_gemma":[0.9830344,0.0110432645,0.004365267,0.00029263677,0.0010171921,0.0002472788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059817135,0.00010340803,0.0009857053,0.000080629434,0.00011293402,0.0000037805517,0.00069660257,0.00032320042,0.00043076082],"category_scores_gemma":[0.008201057,0.000079982296,0.00013148854,0.00013562304,0.00012842542,0.000083556755,0.0004883045,0.0016802383,0.0000054494476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015988784,0.00022866843,0.80779153,0.00027398698,0.00004033322,0.00000645253,0.0010027897,0.0000815861,0.0000027514823,0.0002849827,0.008445639,0.18024239],"study_design_scores_gemma":[0.0030175892,0.0013571583,0.8419867,0.0025884737,0.000058512724,0.000006538255,0.002317545,0.0042448277,0.000019370023,0.0010241685,0.14323553,0.00014356151],"about_ca_topic_score_codex":0.3949405,"about_ca_topic_score_gemma":0.9588127,"teacher_disagreement_score":0.5638722,"about_ca_system_score_codex":0.0019725522,"about_ca_system_score_gemma":0.016116109,"threshold_uncertainty_score":0.9894616},"labels":[],"label_agreement":null},{"id":"W2589794075","doi":"10.1200/jco.2014.32.3_suppl.222","title":"Functional BRM promoter polymorphisms, pancreatic adenocarcinoma risk, and survival.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Odds ratio; Pancreatic cancer; Proportional hazards model; Lung cancer; Adenocarcinoma; Population; Cancer; Confidence interval","score_opus":0.05560423289796568,"score_gpt":0.36278709892889544,"score_spread":0.30718286603092976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589794075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861414,0.0016873514,0.0061312784,0.0008892182,0.0010735833,0.000049870036,0.0000030410433,0.0000035202156,0.0015479943],"genre_scores_gemma":[0.9930303,0.0008789524,0.002271267,0.00073715276,0.002579507,0.000001603731,0.0000048482675,0.000011896281,0.00048446123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979766,0.00051346776,0.0009723543,0.00019578256,0.00018951579,0.00015226651],"domain_scores_gemma":[0.99825126,0.00033729142,0.0008377397,0.0001675003,0.00021432365,0.00019189429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027346842,0.00010851512,0.00053157634,0.00003206399,0.000052212738,0.000010353577,0.00011874989,0.00034909724,0.000056078483],"category_scores_gemma":[0.0019001159,0.00008107702,0.00022441318,0.000032460066,0.00014939434,0.000004803166,0.00006042043,0.00042006015,0.000007855232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027109378,0.0007588708,0.5095471,0.00004156748,0.000654959,0.00003139448,0.000058544047,0.0002297209,0.017037025,0.0002459693,0.02003861,0.4486453],"study_design_scores_gemma":[0.0059736073,0.009586992,0.81690127,0.00004396605,0.00033184426,0.00044698166,0.000047939055,0.00096692896,0.0015096619,0.0014307924,0.16250294,0.0002571001],"about_ca_topic_score_codex":0.00002104179,"about_ca_topic_score_gemma":0.00002619043,"teacher_disagreement_score":0.4483882,"about_ca_system_score_codex":0.000016314933,"about_ca_system_score_gemma":0.00036880947,"threshold_uncertainty_score":0.3306225},"labels":[],"label_agreement":null},{"id":"W2589794374","doi":"10.1200/jco.2012.30.34_suppl.230","title":"Claims/utilization-based intensity of end-of-life (EOL) cancer care in integrated health systems (IHS).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Cancer; End-of-life care; Cause of death; Emergency department; Regimen; Quality of life (healthcare); Internal medicine; Emergency medicine; Palliative care; Nursing","score_opus":0.48926431606684845,"score_gpt":0.5936498781281471,"score_spread":0.10438556206129862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589794374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96715987,0.026866283,0.0005714434,0.002223266,0.0024035685,0.00024510865,0.00003393405,0.000005796706,0.0004907487],"genre_scores_gemma":[0.9933051,0.0034882794,0.0013130984,0.0012459111,0.00059216714,0.0000032046614,0.000015275835,0.000013594872,0.000023364619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994927,0.0007319454,0.0035663778,0.00012492671,0.0003890786,0.00026068147],"domain_scores_gemma":[0.9916377,0.0023245665,0.0034026327,0.00018176039,0.0020304818,0.00042283794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002989607,0.00014181786,0.0026196567,0.00025647008,0.00001496983,0.000001476513,0.00014800862,0.00037091275,0.00009008719],"category_scores_gemma":[0.005989418,0.00010086014,0.00035789437,0.00033664447,0.00030301962,0.000079528785,0.000027215243,0.00075182563,0.0000017511447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00353274,0.00092565716,0.970959,0.0006078504,0.00021663727,0.00001886256,0.0015767112,0.00020631064,0.00009167706,0.00011233907,0.001979563,0.019772626],"study_design_scores_gemma":[0.013926232,0.0130731175,0.8215811,0.0071783415,0.00041372288,0.000027289163,0.011987452,0.0009359011,0.0018899685,0.00003086601,0.12875172,0.00020426838],"about_ca_topic_score_codex":0.0016671942,"about_ca_topic_score_gemma":0.0011159736,"teacher_disagreement_score":0.14937791,"about_ca_system_score_codex":0.00038755743,"about_ca_system_score_gemma":0.0059145223,"threshold_uncertainty_score":0.999721},"labels":[],"label_agreement":null},{"id":"W2589795422","doi":"10.1200/jco.2012.30.4_suppl.677","title":"Assessment of safety of bevacizumab (bev) use for metastatic colorectal cancer (mCRC) in elderly patients treated at the Centre Hospitalier de l’Université de Montréal (CHUM): A retrospective study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Bevacizumab; FOLFIRI; Discontinuation; Febrile neutropenia; Neutropenia; FOLFOX; Internal medicine; Population; Retrospective cohort study; Colorectal cancer; Surgery; Adverse effect; Irinotecan; Cancer; Chemotherapy; Oxaliplatin","score_opus":0.04743115592918729,"score_gpt":0.4020109863831496,"score_spread":0.3545798304539623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589795422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968759,0.00063956936,0.000007985292,0.00082818966,0.00026428793,0.0009339446,0.000098123244,0.000002587232,0.00034943054],"genre_scores_gemma":[0.99807906,0.00088657934,0.00055533624,0.0000862447,0.00008586686,0.000021693644,0.0000044738244,0.000012863621,0.00026785885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974511,0.00043882508,0.0013175674,0.00014732066,0.00033030024,0.00031487757],"domain_scores_gemma":[0.9962144,0.0014828272,0.0014500542,0.00011443117,0.0005537058,0.00018458265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013386877,0.00015431138,0.0014088426,0.00008399805,0.00008096387,0.000002478737,0.000098625416,0.00012033199,0.00012550803],"category_scores_gemma":[0.00090277824,0.00009213218,0.0004136716,0.00015596159,0.00017884416,0.00009553261,0.00009802871,0.00030653473,3.3873573e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017839419,0.006374885,0.9573518,0.0000205673,0.0019754549,0.00005683701,0.0028675334,0.000021106516,0.000071586706,0.000013986532,0.00087160023,0.012535228],"study_design_scores_gemma":[0.020701898,0.02632733,0.94801354,0.000054925902,0.0016203136,0.000017051825,0.0015806628,0.00005223876,0.00008916327,0.00001644259,0.001457225,0.00006917676],"about_ca_topic_score_codex":0.0011511344,"about_ca_topic_score_gemma":0.017649911,"teacher_disagreement_score":0.019952446,"about_ca_system_score_codex":0.0035542902,"about_ca_system_score_gemma":0.00064498483,"threshold_uncertainty_score":0.9849065},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2589796679","doi":"10.1200/jco.2015.33.28_suppl.75","title":"A misperceived threat: Understanding the increasing mastectomy rates.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Nonprobability sampling; Population; Family medicine; Cancer; Internal medicine; Environmental health","score_opus":0.25833431200985546,"score_gpt":0.47268891728249207,"score_spread":0.2143546052726366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589796679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704941,0.0014380255,0.009313304,0.0067894855,0.001864319,0.0001143527,0.0000020609643,0.0000040413083,0.009980313],"genre_scores_gemma":[0.99263644,0.00024487366,0.0034833266,0.0016872867,0.0017636055,0.0000023354582,0.000002137533,0.000014553324,0.00016545429],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977784,0.0007178803,0.0009807291,0.0001488446,0.00020663225,0.00016748042],"domain_scores_gemma":[0.99788606,0.00055315334,0.00079659984,0.00021233293,0.0003570342,0.00019480102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048439237,0.00009805886,0.00039539678,0.000039022503,0.000062818064,0.000019734773,0.00030749541,0.00028560046,0.00002666496],"category_scores_gemma":[0.004126679,0.00006133357,0.00023414262,0.0000945785,0.00028494562,0.000007369891,0.00008977071,0.00041631615,0.000009365721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02997067,0.0029186548,0.31386507,0.000060596503,0.005102677,0.0008189619,0.004295791,0.007344504,0.08229865,0.0036204108,0.32772183,0.2219822],"study_design_scores_gemma":[0.02181693,0.016278517,0.085480146,0.00011156278,0.0006618575,0.003151901,0.012387896,0.00070008676,0.005971156,0.01882655,0.83394873,0.00066468987],"about_ca_topic_score_codex":0.000014056345,"about_ca_topic_score_gemma":0.000058096764,"teacher_disagreement_score":0.5062269,"about_ca_system_score_codex":0.00025492063,"about_ca_system_score_gemma":0.002397853,"threshold_uncertainty_score":0.49403188},"labels":[],"label_agreement":null},{"id":"W2589800501","doi":"10.1200/jco.2016.34.3_suppl.163","title":"Utilization of sexual health and pelvic floor physiotherapy services in Vancouver’s Prostate Cancer Supportive Care (PCSC) Program.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Attendance; Physical therapy; Prostate cancer; Reproductive health; Cancer; Family medicine; Population; Internal medicine","score_opus":0.10013327676985104,"score_gpt":0.534068287496846,"score_spread":0.4339350107269949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589800501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990566,0.0048972135,0.0000054701973,0.0040456187,0.00049766846,0.0005233655,0.000022064782,0.0000063900625,0.00009653476],"genre_scores_gemma":[0.99410385,0.0021142215,0.0004999162,0.0028188012,0.00031346086,0.000012908039,0.0000037469842,0.000011181163,0.00012190738],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99756354,0.00023654039,0.0015858527,0.00015795592,0.00022546582,0.0002306432],"domain_scores_gemma":[0.9971417,0.00025200564,0.0013810511,0.00009194364,0.0004939089,0.00063938595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069811294,0.00009680363,0.00088871643,0.000097460455,0.000019837738,0.0000022223935,0.000056413857,0.00014239935,0.000053872947],"category_scores_gemma":[0.00028095813,0.00005580727,0.00008056868,0.00011951081,0.00012274199,0.00010848739,0.000017395929,0.00022036482,0.0000015394749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006921402,0.00094984163,0.33353502,0.0011207109,0.00002515179,0.000044455723,0.0012296141,0.0000012966711,0.000052956362,0.000002547549,0.0005413485,0.65557563],"study_design_scores_gemma":[0.017045274,0.039295655,0.9274212,0.00046940395,0.000080428435,0.000019460243,0.0043915603,0.000046582743,0.000056879526,0.00015727636,0.010933555,0.000082682905],"about_ca_topic_score_codex":0.0003169043,"about_ca_topic_score_gemma":0.0032939264,"teacher_disagreement_score":0.65549296,"about_ca_system_score_codex":0.00014759655,"about_ca_system_score_gemma":0.0045501995,"threshold_uncertainty_score":0.8071859},"labels":[],"label_agreement":null},{"id":"W2589804174","doi":"10.1200/jco.2014.32.30_suppl.221","title":"Peer review in radiotherapy (RT): A national quality improvement initiative.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Trillium Health Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"","keywords":"General partnership; Medicine; Baseline (sea); Quality (philosophy); Inclusion (mineral); Quality management; Medical education; Process management; Business; Political science; Psychology; Finance; Marketing","score_opus":0.21130972145961247,"score_gpt":0.6074747712635633,"score_spread":0.39616504980395084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589804174","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13818483,0.04516985,0.022609932,0.7062578,0.009072413,0.0014195865,0.000012054819,0.00003775068,0.07723576],"genre_scores_gemma":[0.26976666,0.14341924,0.08306976,0.48636076,0.012375311,0.00003619033,0.00001428241,0.000056731173,0.00490109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946939,0.0011648667,0.0029551543,0.00018087531,0.0008116805,0.00019353161],"domain_scores_gemma":[0.99001294,0.005651516,0.0022494385,0.0001699767,0.0016786681,0.00023745176],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022231674,0.00012659715,0.001811567,0.00011454149,0.000028449453,0.0000026436467,0.000173476,0.000358907,0.00043623624],"category_scores_gemma":[0.023310812,0.000085534906,0.00041001942,0.000158447,0.00028684275,0.000119811164,0.000017129942,0.0012296374,0.000010301395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046453653,0.003938078,0.03368936,0.00022889007,0.0004252167,0.00014811888,0.00013897086,0.000016921425,0.00020425113,0.002786469,0.08120217,0.8725762],"study_design_scores_gemma":[0.012242163,0.0110263545,0.08266864,0.0003680229,0.00005846716,0.00020747747,0.00002418257,0.00006443266,0.000016979588,0.0032814066,0.8899511,0.00009078792],"about_ca_topic_score_codex":0.0000029937573,"about_ca_topic_score_gemma":0.000016206679,"teacher_disagreement_score":0.8724854,"about_ca_system_score_codex":0.000458783,"about_ca_system_score_gemma":0.001765125,"threshold_uncertainty_score":0.98491627},"labels":[],"label_agreement":null},{"id":"W2589806920","doi":"10.1200/jco.2016.34.7_suppl.41","title":"Financial risk-sharing agreements: Using options to make marginal benefits cost effective.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Pazopanib; Medicine; Actuarial science; Revenue; Renal cell carcinoma; Finance; Oncology; Business; Sunitinib","score_opus":0.1700036024836161,"score_gpt":0.41015412757761427,"score_spread":0.24015052509399817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589806920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662338,0.0011117723,0.019465044,0.0020876667,0.004262872,0.0004343149,0.00017249705,0.000009609156,0.0062224087],"genre_scores_gemma":[0.986453,0.0019368328,0.0061939713,0.0018447092,0.0029143267,0.00001946091,6.9627345e-7,0.00003096098,0.00060602004],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961243,0.00007918799,0.0029327504,0.00036730646,0.00006290177,0.00043352885],"domain_scores_gemma":[0.994919,0.00084391295,0.0033680333,0.00026049704,0.0002203156,0.00038823747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045549716,0.00018408426,0.0014407478,0.00030207442,0.00012148671,0.00003564847,0.00044447093,0.00036321918,0.00041869006],"category_scores_gemma":[0.0070129596,0.00015246094,0.00050171843,0.00016778462,0.00012510753,0.00041914216,0.00014862673,0.0005238633,0.0005275551],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008885789,0.00042399956,0.4458585,0.000007771226,0.0001595146,0.000034168694,0.0000603405,0.00072216074,0.000028202163,0.050646406,0.0020552413,0.4991151],"study_design_scores_gemma":[0.0035898017,0.0021324002,0.6789697,0.00010012003,0.000043108532,0.000031380656,0.000009090785,0.0001252432,0.000018165554,0.01711562,0.29763955,0.00022582027],"about_ca_topic_score_codex":0.00010700091,"about_ca_topic_score_gemma":0.00013151212,"teacher_disagreement_score":0.4988893,"about_ca_system_score_codex":0.0006121477,"about_ca_system_score_gemma":0.00035876164,"threshold_uncertainty_score":0.8395674},"labels":[],"label_agreement":null},{"id":"W2589826075","doi":"10.1200/jco.2005.23.16_suppl.712","title":"Why so late? Presentation delay in locally advanced breast cancer (LABC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Presentation (obstetrics); Cancer; Family history; Breast pain; Gynecology; Pediatrics; Internal medicine; Surgery","score_opus":0.0357725768891484,"score_gpt":0.4293621773067943,"score_spread":0.3935896004176459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589826075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597192,0.002689047,0.00035330484,0.03559428,0.0007716272,0.00012047289,0.000016939242,0.000004186807,0.0007309571],"genre_scores_gemma":[0.98454046,0.0040489305,0.0023592934,0.0068111867,0.0020809183,0.000013598498,0.00000583818,0.00001575178,0.00012400746],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979937,0.00023468598,0.0011714431,0.00020931089,0.00016472208,0.00022615364],"domain_scores_gemma":[0.99847674,0.0001836614,0.0007699959,0.00013846575,0.00029980813,0.00013130013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006863959,0.00013119004,0.0006010054,0.00005431147,0.000035691355,0.000008551827,0.00018233332,0.00027619436,0.000070950766],"category_scores_gemma":[0.00031809058,0.000102811806,0.00020990352,0.00008463383,0.00016519212,0.000017461349,0.000074855714,0.00032563892,0.000006781507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068522105,0.001488819,0.20275635,0.000012589992,0.0005325002,0.00010444708,0.00012498604,0.00538815,0.003425771,0.000025614565,0.024195315,0.7550932],"study_design_scores_gemma":[0.0099693015,0.001597913,0.61286134,0.00005555189,0.000109425935,0.00019187301,0.00007313439,0.00008944076,0.001091405,0.000091411166,0.37370425,0.00016492112],"about_ca_topic_score_codex":0.000102627375,"about_ca_topic_score_gemma":0.0034333721,"teacher_disagreement_score":0.75492835,"about_ca_system_score_codex":0.00011608662,"about_ca_system_score_gemma":0.0007216996,"threshold_uncertainty_score":0.41925436},"labels":[],"label_agreement":null},{"id":"W2589831226","doi":"10.1200/jco.2012.30.34_suppl.190","title":"Does a quality-of-care problem exist? Cancer Care Ontario practice pattern data and the recommendations of two lung cancer practice guidelines.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Referral; Family medicine; Quality (philosophy); Data collection; Best practice; Clinical Practice; Nursing","score_opus":0.588791430040011,"score_gpt":0.6958034802357941,"score_spread":0.10701205019578308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589831226","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12786551,0.020316668,0.0027908003,0.8350881,0.0074631614,0.0020854098,0.0003636243,0.00001642873,0.0040103244],"genre_scores_gemma":[0.7465987,0.023577033,0.17513163,0.04805451,0.0060994024,0.00006588138,0.00014156173,0.000058368285,0.00027288584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868223,0.0029829673,0.008797303,0.00031232438,0.00079315517,0.00029193674],"domain_scores_gemma":[0.9354944,0.041146003,0.013600613,0.00075274927,0.008671276,0.00033495846],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024818197,0.00019945131,0.0017457644,0.00008804871,0.00008884176,0.000018101524,0.00044080557,0.00026305133,0.0002889443],"category_scores_gemma":[0.13925448,0.0001044208,0.00030504316,0.00018170832,0.00038130826,0.0015126881,0.00042243602,0.0016663239,0.0000018391022],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012842396,0.0014661339,0.30048823,0.00044893695,0.001938358,0.00002049238,0.010080835,0.000030271614,0.00003024219,0.00030257192,0.03236644,0.6399851],"study_design_scores_gemma":[0.022869216,0.0016730455,0.032007504,0.00061221886,0.0076435613,0.00016343346,0.03591856,0.000113923124,0.000021656648,0.000115266404,0.898682,0.00017963638],"about_ca_topic_score_codex":0.0654016,"about_ca_topic_score_gemma":0.092204005,"teacher_disagreement_score":0.86631554,"about_ca_system_score_codex":0.00046759375,"about_ca_system_score_gemma":0.005936624,"threshold_uncertainty_score":0.9996988},"labels":[],"label_agreement":null},{"id":"W2589833818","doi":"10.1200/jco.2016.34.3_suppl.140","title":"Cognitive rehabilitation for brain tumor survivors: A pilot study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Psychoeducation; Medicine; Mood; Cognitive rehabilitation therapy; Cognition; Mindfulness; Cognitive training; Executive functions; Executive dysfunction; Psychological intervention; Rehabilitation; Physical therapy; Coping (psychology); Acquired brain injury; Clinical psychology; Psychiatry; Neuropsychology","score_opus":0.15646420254453242,"score_gpt":0.5042767044645334,"score_spread":0.347812501920001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589833818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94000995,0.00010033651,0.0018952889,0.054058094,0.0015506012,0.0013656142,0.000017393131,0.000016826676,0.0009858905],"genre_scores_gemma":[0.9933314,0.000055148314,0.0011188342,0.00310971,0.001644787,0.000063823936,8.554844e-7,0.000022261196,0.00065319485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961147,0.00079078344,0.0022495524,0.0002413284,0.0003537165,0.00024996177],"domain_scores_gemma":[0.95296234,0.04294502,0.0016639798,0.00011058481,0.0020574713,0.00026057992],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006936675,0.00014753386,0.0014019024,0.00016851527,0.000058797672,0.0000046722726,0.000085223895,0.00009956871,0.00012282508],"category_scores_gemma":[0.08797311,0.00008484914,0.00039294158,0.00014169447,0.00038212858,0.00013802105,0.000045991914,0.0004188716,0.000031214386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10389044,0.021438278,0.4969379,0.00008486862,0.002679026,0.0003464682,0.0007963693,4.778336e-7,0.0007358906,0.00010472491,0.040906355,0.3320792],"study_design_scores_gemma":[0.037184644,0.33184165,0.6079093,0.00047158878,0.0007804968,0.000108212495,0.0020220573,0.0000035002226,0.000032814398,0.0009867519,0.01855503,0.00010391719],"about_ca_topic_score_codex":0.000020450343,"about_ca_topic_score_gemma":0.00024739248,"teacher_disagreement_score":0.33197528,"about_ca_system_score_codex":0.000253842,"about_ca_system_score_gemma":0.0010531301,"threshold_uncertainty_score":0.91970927},"labels":[],"label_agreement":null},{"id":"W2589838993","doi":"10.1200/jco.2012.30.34_suppl.113","title":"The association between the transfer of emergency department boarders to inpatient hallways or off-service beds and the quality of oncology care.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Emergency department; Crowding; Patient satisfaction; Emergency medicine; Medical emergency; Surgery; Nursing","score_opus":0.1833596032126019,"score_gpt":0.5083235530410355,"score_spread":0.3249639498284336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589838993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94108236,0.00089326367,0.00009206257,0.05292462,0.0017373142,0.00049998576,0.000011520758,0.0000025618012,0.0027563386],"genre_scores_gemma":[0.994086,0.0027299866,0.000083843064,0.002186865,0.00081630796,0.000021203343,0.0000012952097,0.0000075809926,0.00006686585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99524516,0.0016682296,0.00236266,0.00008861333,0.00042205869,0.00021327479],"domain_scores_gemma":[0.9905962,0.006870112,0.0013322276,0.00020087781,0.00080847414,0.00019210431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008183784,0.00009487168,0.0010396326,0.000034528603,0.00012295862,0.0000030745011,0.00018570505,0.00022229948,0.000070768074],"category_scores_gemma":[0.0022492665,0.000038179944,0.00036187292,0.00018197816,0.00017270005,0.000053662727,0.000052186162,0.00060169963,0.000002856387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010227862,0.0010201533,0.8271059,0.00006659168,0.0015751091,0.000002035976,0.0051587024,0.000016134754,0.00012823238,0.0012876267,0.0048134737,0.1485982],"study_design_scores_gemma":[0.0050949743,0.006210736,0.7201185,0.000017737684,0.0009955189,0.000008472232,0.0015360748,0.0000010867218,0.00013218456,0.00011340436,0.2657303,0.000041018087],"about_ca_topic_score_codex":0.00015375864,"about_ca_topic_score_gemma":0.0019741883,"teacher_disagreement_score":0.26091683,"about_ca_system_score_codex":0.00025487048,"about_ca_system_score_gemma":0.00088435033,"threshold_uncertainty_score":0.28363523},"labels":[],"label_agreement":null},{"id":"W2589842982","doi":"10.1200/jco.2016.34.2_suppl.234","title":"Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"PI3K/AKT/mTOR pathway; LNCaP; Cancer research; Protein kinase B; In vivo; Apoptosis; Medicine; Prostate cancer; Oncogene; PTEN; Flow cytometry; Cell growth; Cancer; Biology; Internal medicine; Cell cycle; Immunology","score_opus":0.15111351480082363,"score_gpt":0.5444075210011432,"score_spread":0.39329400620031957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589842982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573653,0.0008893275,0.00022529908,0.039965514,0.000584439,0.000735105,0.000012137866,0.000004695133,0.0002182086],"genre_scores_gemma":[0.9854805,0.009656559,0.0014404217,0.00073225005,0.0005453527,0.00006407676,0.00000728457,0.0000108444965,0.002062726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975646,0.00024936307,0.0016265764,0.00017255622,0.0002144508,0.00017242227],"domain_scores_gemma":[0.9955466,0.002869172,0.0007736925,0.00007109263,0.00053120306,0.00020824815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031312604,0.0000785778,0.00072843937,0.00010433086,0.00002920529,0.000005553118,0.00003400552,0.0002146826,0.000049064463],"category_scores_gemma":[0.0032489246,0.000044105644,0.00016256687,0.00008009271,0.00022428308,0.00019280403,0.000023353876,0.00032857174,0.0000025810364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022870792,0.0016722799,0.32454976,0.00006287529,0.00012775509,0.00011329679,0.000110041205,0.0000033075892,0.001246601,0.00028925834,0.0033234672,0.64563054],"study_design_scores_gemma":[0.06449042,0.024237435,0.8650188,0.0005240556,0.00011249128,0.00006798337,0.00006133527,0.00010820734,0.0008239317,0.006344951,0.03812077,0.00008963981],"about_ca_topic_score_codex":0.0000062329996,"about_ca_topic_score_gemma":0.00007047643,"teacher_disagreement_score":0.6455409,"about_ca_system_score_codex":0.00020131099,"about_ca_system_score_gemma":0.0014412144,"threshold_uncertainty_score":0.38895008},"labels":[],"label_agreement":null},{"id":"W2589845673","doi":"10.1200/jco.2016.34.2_suppl.558","title":"Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Targeted therapy; Axitinib; Sorafenib; Renal cell carcinoma; Everolimus; Internal medicine; Oncology; Surgery; Cancer","score_opus":0.1513470616238918,"score_gpt":0.45103699635048816,"score_spread":0.29968993472659633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589845673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95487297,0.010900155,0.000005168479,0.031878475,0.0002417528,0.00056582503,0.0000059057165,0.000002081516,0.0015276603],"genre_scores_gemma":[0.9849264,0.009007471,0.0005616202,0.005122829,0.00015361734,0.000015614805,9.829423e-7,0.000012510354,0.00019895236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99459445,0.0014650706,0.0030296352,0.00019562089,0.00048061897,0.00023462002],"domain_scores_gemma":[0.9939084,0.003487567,0.0018231265,0.00031143377,0.00032639687,0.00014304725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006938403,0.00016992592,0.002626312,0.00019013004,0.000011000506,0.0000021641413,0.0002339468,0.00014145349,0.00054651423],"category_scores_gemma":[0.003734495,0.00006855239,0.0006445908,0.000273031,0.0002053861,0.00008647673,0.000026835129,0.0007082279,0.000011206884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022425272,0.0021425555,0.96249163,0.00011007853,0.0003929186,0.002130466,0.00025886888,1.7890108e-7,0.00089465146,0.000116676485,0.0030461682,0.026173279],"study_design_scores_gemma":[0.012274725,0.01266126,0.9662767,0.00059107994,0.00021114465,0.00036294726,0.00007178181,9.977272e-7,0.00031595473,0.00043229442,0.006736221,0.00006491069],"about_ca_topic_score_codex":0.000027862445,"about_ca_topic_score_gemma":0.00015013957,"teacher_disagreement_score":0.030053424,"about_ca_system_score_codex":0.0002996775,"about_ca_system_score_gemma":0.00092971965,"threshold_uncertainty_score":0.59839475},"labels":[],"label_agreement":null},{"id":"W2589852050","doi":"10.1200/jco.2013.31.31_suppl.239","title":"Use of electronic medical record queries to support clinical decision quality assurance.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Radiation oncologist; Medicine; Medical physics; Quality assurance; Medical record; Radiation oncology; Rework; Radiation treatment planning; Demographics; Radiation therapy; Internal medicine; Computer science; Pathology","score_opus":0.12672967050444175,"score_gpt":0.5302965581161327,"score_spread":0.403566887611691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589852050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74693656,0.000042728334,0.24783744,0.0030994015,0.0011218681,0.00024609113,0.0000056963577,0.000017046086,0.0006931468],"genre_scores_gemma":[0.8097311,0.0006000435,0.18513219,0.0023544638,0.001913295,0.000014386733,0.000002135498,0.000029361227,0.00022299009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919954,0.0011048786,0.0056262463,0.00027113172,0.00061547256,0.00038689116],"domain_scores_gemma":[0.98296076,0.012301814,0.0030100283,0.00036856573,0.000749537,0.00060929783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0076896395,0.00018020293,0.0020101406,0.000096694035,0.000035240257,0.000017806427,0.0005319674,0.00043052543,0.0038525765],"category_scores_gemma":[0.0063660922,0.00013106673,0.0008341945,0.00016397738,0.00033945052,0.0004433008,0.000103427454,0.0015410519,0.000028448225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000730506,0.00079528533,0.33624703,0.0000033483825,0.00017554346,0.000007557969,0.000015728594,0.0000071238396,0.000059810212,0.0018164188,0.021768054,0.6383736],"study_design_scores_gemma":[0.0024944572,0.014796682,0.26596013,0.00009182323,0.000058229627,0.000018242861,0.0000398011,0.00007155101,0.00024300077,0.021015089,0.69497406,0.00023690164],"about_ca_topic_score_codex":0.0001785241,"about_ca_topic_score_gemma":0.000075875345,"teacher_disagreement_score":0.67320603,"about_ca_system_score_codex":0.000081955965,"about_ca_system_score_gemma":0.002377167,"threshold_uncertainty_score":0.99705803},"labels":[],"label_agreement":null},{"id":"W2589855920","doi":"10.1200/jco.2016.34.2_suppl.121","title":"13-year oncologic and functional outcomes and morbidity in men &lt;/= 55 years treated with I-125 brachytherapy +/- external beam radiation and/or androgen deprivation.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Urology; Androgen deprivation therapy; External beam radiotherapy; Urinary system; Surgery; Radiation therapy; Internal medicine; Cancer","score_opus":0.08403308029583048,"score_gpt":0.40093907387728467,"score_spread":0.3169059935814542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589855920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352235,0.001058936,0.0000648242,0.004908764,0.00010423503,0.00022882162,0.000006387553,0.000005887012,0.00009978874],"genre_scores_gemma":[0.98594445,0.011948122,0.0008452412,0.0008913049,0.00022331084,0.000013229118,0.0000019761142,0.000009228764,0.00012316041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985863,0.00014267411,0.00076732645,0.00018939389,0.00018010724,0.00013422949],"domain_scores_gemma":[0.997699,0.0013575789,0.000550149,0.00007601196,0.00010513676,0.00021212477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089097663,0.00011198361,0.00073679455,0.000101204125,0.000026797416,0.00001031852,0.0000287037,0.00017368798,0.00008852326],"category_scores_gemma":[0.0004479824,0.000054995577,0.00006288525,0.00006753368,0.00017432714,0.00015277747,0.000021318427,0.0001974842,0.0000020569105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004437067,0.00049942004,0.8358131,0.0000054885713,0.00017788344,0.00026490676,0.000034034696,0.0000020918587,0.0001266552,0.000029436274,0.00039261012,0.15821728],"study_design_scores_gemma":[0.022491077,0.008392721,0.9652881,0.00008274973,0.00014413385,0.0003279225,0.00002861245,0.000016608803,0.00010499922,0.00028086995,0.0027755557,0.00006664168],"about_ca_topic_score_codex":0.000035279503,"about_ca_topic_score_gemma":0.000085674146,"teacher_disagreement_score":0.15815064,"about_ca_system_score_codex":0.00017409986,"about_ca_system_score_gemma":0.00038213632,"threshold_uncertainty_score":0.22426546},"labels":[],"label_agreement":null},{"id":"W2589858858","doi":"10.1200/jco.2014.32.4_suppl.336","title":"Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; Pazopanib; Docetaxel; Regimen; Gemcitabine; Chemotherapy regimen; Chemotherapy; Urology; Cisplatin; Sunitinib; Cancer","score_opus":0.04430694764260752,"score_gpt":0.3876285428344488,"score_spread":0.3433215951918413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589858858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998245,0.0002602368,0.000033342774,0.00014533546,0.00017228822,0.0003095348,0.000013565424,0.0000024398903,0.0008182785],"genre_scores_gemma":[0.99784714,0.00023967955,0.0014485444,0.00024327796,0.00017378389,0.0000018551207,0.000003143069,0.000017682425,0.000024870531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977226,0.00022538203,0.0014325547,0.00014787314,0.0002952693,0.00017627049],"domain_scores_gemma":[0.9972026,0.0008004264,0.0013973741,0.00015551153,0.00026216637,0.00018193258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089587265,0.00013568036,0.0013870565,0.00011802369,0.000014394741,0.0000028968261,0.00007054978,0.00016466655,0.00004735988],"category_scores_gemma":[0.00057422236,0.00008010227,0.00023935328,0.000097510274,0.00012708087,0.000102300524,0.000029373772,0.00038621674,8.176836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016607193,0.0013894134,0.75170827,0.0000278822,0.0001664161,0.00001884626,0.00021332974,0.000009900165,0.000458572,0.0000010842333,0.000029591205,0.22936949],"study_design_scores_gemma":[0.03209247,0.050642088,0.9164201,0.00015781244,0.00011152773,0.000016607099,0.000012110237,0.000010253613,0.000101923135,0.000028803164,0.0003455894,0.00006072459],"about_ca_topic_score_codex":0.00004855526,"about_ca_topic_score_gemma":0.00001632656,"teacher_disagreement_score":0.22930877,"about_ca_system_score_codex":0.00013503584,"about_ca_system_score_gemma":0.0008404184,"threshold_uncertainty_score":0.32664758},"labels":[],"label_agreement":null},{"id":"W2589862549","doi":"10.1200/jco.2014.32.30_suppl.173","title":"Meaningful reporting in primary care: An evaluation of the screening activity report.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Primary care; Fecal occult blood; Colorectal cancer; Family medicine; Population; Colorectal cancer screening; Test (biology); Cancer; Internal medicine; Colonoscopy; Environmental health","score_opus":0.24713139407208906,"score_gpt":0.5048802613612787,"score_spread":0.25774886728918966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589862549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882686,0.00009737328,0.0014522418,0.0009043591,0.0010274234,0.00016602747,1.5339276e-7,0.0000068465533,0.008076971],"genre_scores_gemma":[0.99550444,0.000007755693,0.0034246987,0.00023419928,0.0007965045,0.000002584106,9.000309e-7,0.000008385909,0.000020559033],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99434006,0.0013486443,0.0032235936,0.00016962596,0.000797234,0.00012082944],"domain_scores_gemma":[0.9884994,0.00093990465,0.009045469,0.00027933778,0.0011178354,0.00011803768],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029533714,0.00007514414,0.0009143263,0.00009790802,0.000038465896,0.0000044308845,0.00009455204,0.0002405887,0.000011059012],"category_scores_gemma":[0.038650926,0.000049205093,0.00034563334,0.00020740168,0.00009068212,0.00012771168,0.000046271944,0.00093583064,2.2119646e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043314486,0.00021673428,0.26752985,0.000026557113,0.00004082804,0.00006402008,0.0001789584,0.00053130096,0.001079678,0.000003287917,0.000027343789,0.72597],"study_design_scores_gemma":[0.0033421754,0.008915515,0.97907454,0.0002153084,0.00030371652,0.0011467516,0.00014812841,0.004310372,0.0011255677,0.00014132365,0.0012281715,0.000048431782],"about_ca_topic_score_codex":0.00013130355,"about_ca_topic_score_gemma":0.00034022666,"teacher_disagreement_score":0.7259216,"about_ca_system_score_codex":0.00032274053,"about_ca_system_score_gemma":0.0017791714,"threshold_uncertainty_score":0.9992993},"labels":[],"label_agreement":null},{"id":"W2589867709","doi":"10.1200/jco.2013.31.6_suppl.166","title":"Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Dasatinib; Medicine; Docetaxel; Prostate cancer; Insulin-like growth factor; Internal medicine; Growth factor; Bone metastasis; Cancer research; Oncology; Cancer; Endocrinology; Receptor; Tyrosine kinase","score_opus":0.156928292636308,"score_gpt":0.49003514343175303,"score_spread":0.333106850795445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589867709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354331,0.0003169441,0.0000108341455,0.062426995,0.00073168636,0.0009315201,0.000021743186,0.00000844528,0.00011875058],"genre_scores_gemma":[0.9791514,0.00020330222,0.00486695,0.015099068,0.00010296211,0.000060808838,0.0000017031451,0.000024489242,0.000489299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99427056,0.0014136982,0.0031498992,0.00026972493,0.00038314023,0.00051299966],"domain_scores_gemma":[0.9934734,0.0037633248,0.0012312976,0.00021464842,0.00041603224,0.0009012938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038065338,0.0001956176,0.0017130579,0.0004642788,0.00002779872,0.000009545623,0.00012182223,0.00027271867,0.0002540448],"category_scores_gemma":[0.0066247946,0.0001414742,0.00020348984,0.0004331851,0.00009941008,0.00014645689,0.000035541103,0.0012029057,0.000094045994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021786528,0.0027299684,0.8876368,0.000085534506,0.00009785824,0.0025792867,0.0005322519,0.000040631752,0.00023206403,0.0000067804103,0.0019456667,0.08232664],"study_design_scores_gemma":[0.02526662,0.012950417,0.9540717,0.0003272989,0.00005871008,0.000085120555,0.00009557576,0.00007931381,0.000052031693,0.0002094938,0.0066952575,0.00010848666],"about_ca_topic_score_codex":0.0010045833,"about_ca_topic_score_gemma":0.0012935768,"teacher_disagreement_score":0.082218155,"about_ca_system_score_codex":0.0006237516,"about_ca_system_score_gemma":0.0054038907,"threshold_uncertainty_score":0.958627},"labels":[],"label_agreement":null},{"id":"W2589873828","doi":"10.1200/jco.2014.32.30_suppl.11","title":"HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost-effectiveness analysis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Hepatitis B virus; Breast cancer; Internal medicine; Chemotherapy; Cost effectiveness; Cohort; Hepatitis B; Cancer; Oncology; Immunology; Virus","score_opus":0.05631618160073768,"score_gpt":0.36442847646147486,"score_spread":0.30811229486073716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589873828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990389,0.00022810358,0.005728763,0.001245592,0.0005545984,0.00022117356,0.000060246635,0.0000051381908,0.0015673739],"genre_scores_gemma":[0.9974094,0.00017360666,0.0007038947,0.0011291612,0.00050839764,0.000010573524,0.0000028895288,0.000022127684,0.00003994243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969337,0.00013749079,0.0022457456,0.00029281952,0.00006663805,0.00032357796],"domain_scores_gemma":[0.99587595,0.00049281766,0.002970962,0.00020117732,0.00022074742,0.00023831682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039543365,0.00016905542,0.0023301165,0.00039621428,0.0000388344,0.000028134033,0.00028616813,0.00029622688,0.00017395371],"category_scores_gemma":[0.00044477254,0.00014149159,0.0004432958,0.000388425,0.00014173785,0.00040367633,0.00003047985,0.0006116847,0.00001736946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019886375,0.00038520622,0.81609195,0.000005797858,0.0004919671,0.0000042194297,0.000064032625,0.0007938853,6.583474e-8,0.001452267,0.000055099285,0.17866687],"study_design_scores_gemma":[0.009177369,0.00283176,0.9702983,0.000045767643,0.00008955489,0.0000023796515,0.0000067242563,0.00057187723,6.2419684e-7,0.0017743043,0.015041612,0.00015975746],"about_ca_topic_score_codex":0.0006311351,"about_ca_topic_score_gemma":0.0006815125,"teacher_disagreement_score":0.17850712,"about_ca_system_score_codex":0.00028717978,"about_ca_system_score_gemma":0.000212808,"threshold_uncertainty_score":0.57698596},"labels":[],"label_agreement":null},{"id":"W2589875684","doi":"10.1200/jco.2014.32.30_suppl.56","title":"Population-based standardized symptom screening: Cancer Care Ontario’s Edmonton Symptom Assessment System and performance status initiatives.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; Élisabeth Bruyère Hospital; Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Family medicine; Population; Feeling; Health care; Cancer; Intervention (counseling); Physical therapy; Nursing; Environmental health","score_opus":0.201034555021466,"score_gpt":0.5504518428528278,"score_spread":0.3494172878313618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589875684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857852,0.00023469323,0.006551354,0.0034372327,0.0013862422,0.0004379883,0.000019116962,0.000026336273,0.0021218325],"genre_scores_gemma":[0.9722319,0.00027363424,0.02382863,0.002392983,0.001151214,0.00001357691,0.000046112615,0.000027410488,0.000034491033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99303305,0.0010448204,0.004445032,0.00031074093,0.0008289032,0.0003374814],"domain_scores_gemma":[0.98652893,0.0071960785,0.0038711338,0.00024574125,0.001566904,0.00059122336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006282449,0.00021905359,0.0017909138,0.00016328531,0.00012379407,0.000032234955,0.00011631036,0.00034990208,0.00018639395],"category_scores_gemma":[0.006010079,0.00016890933,0.00033278126,0.00012491683,0.00011887562,0.00040737953,0.00005566099,0.0013216372,0.0000024245512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037235196,0.00021479113,0.8386845,0.00014886972,0.0002627493,0.000029114726,0.00019138551,0.00032742988,0.000010006295,0.00008343734,0.00026660386,0.15605757],"study_design_scores_gemma":[0.017415324,0.0091303885,0.933254,0.0005039938,0.000813253,0.00004544755,0.0009031324,0.005285823,0.000009994942,0.000011867082,0.032474693,0.00015206562],"about_ca_topic_score_codex":0.0058310907,"about_ca_topic_score_gemma":0.009701706,"teacher_disagreement_score":0.1559055,"about_ca_system_score_codex":0.0017265939,"about_ca_system_score_gemma":0.00590047,"threshold_uncertainty_score":0.9997352},"labels":[],"label_agreement":null},{"id":"W2589877446","doi":"10.1200/jco.2015.33.7_suppl.89","title":"Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Lymph node; Prostate cancer; Dissection (medical); Lymph; Urology; Cancer; Population; Cohort; Cancer registry; Surgery; Database; Internal medicine; Pathology","score_opus":0.2115491250514839,"score_gpt":0.4866860268586406,"score_spread":0.27513690180715666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589877446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98813576,0.00036549463,0.00009998846,0.010438917,0.00052529376,0.00020802491,0.000120006465,0.000011058722,0.00009545377],"genre_scores_gemma":[0.99704593,0.00059319084,0.0008738012,0.00048409426,0.0007381672,0.00001869103,0.000047862486,0.00001155959,0.00018667872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972014,0.00025094737,0.0014327981,0.00021978386,0.0006931901,0.00020187123],"domain_scores_gemma":[0.9955991,0.001532364,0.0015186416,0.000090543654,0.0007274777,0.0005318672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022116257,0.00014574784,0.0013795965,0.00022273904,0.00005309446,0.000019818708,0.00005935727,0.00023722164,0.00003295853],"category_scores_gemma":[0.005307979,0.000092622606,0.00034854858,0.00024700852,0.00007452641,0.00022582265,0.000042821815,0.00043408043,0.000002177812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006461222,0.0006496646,0.9894579,0.000028964701,0.0047529857,0.00007431822,0.00010932687,0.000027450975,0.00001808017,0.000009043191,0.00064662757,0.0035795162],"study_design_scores_gemma":[0.009303302,0.000988406,0.9835699,0.000055682038,0.0034320208,0.000018543127,0.00007298945,0.00005492538,0.0001793195,0.00011477436,0.0021252937,0.000084821375],"about_ca_topic_score_codex":0.00018010597,"about_ca_topic_score_gemma":0.00013245796,"teacher_disagreement_score":0.009954823,"about_ca_system_score_codex":0.0017936054,"about_ca_system_score_gemma":0.00222022,"threshold_uncertainty_score":0.63545305},"labels":[],"label_agreement":null},{"id":"W2589882411","doi":"10.1200/jco.2012.30.34_suppl.254","title":"Measuring and reporting on system performance across the Canadian cancer control continuum.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Concordance; General partnership; Family medicine; Business","score_opus":0.638366452294361,"score_gpt":0.6169176228133815,"score_spread":0.02144882948097948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589882411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96928453,0.00040944453,0.000049889244,0.025467917,0.002612078,0.00025595998,0.0000033224073,0.000006884641,0.0019099995],"genre_scores_gemma":[0.987221,0.00016217676,0.00034368673,0.008309028,0.0038740577,0.000006379176,5.5906656e-7,0.000012936469,0.00007016009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930208,0.0004943177,0.005605309,0.0001179497,0.0003835922,0.00037808108],"domain_scores_gemma":[0.9847485,0.005770896,0.007945517,0.00017313132,0.0006994265,0.00066255097],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03265884,0.00010191893,0.001021001,0.000046703266,0.00019445077,0.000020025891,0.00009368338,0.00022842061,0.000028596687],"category_scores_gemma":[0.044827167,0.000058705475,0.00020841719,0.0000744629,0.00014912858,0.0002121613,0.000024001889,0.0012371715,0.000011080687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010062945,0.000107549706,0.80352265,0.000034264773,0.00019465522,0.00008300606,0.00017317025,0.000014237336,0.000031205887,0.00004449945,0.0016871794,0.19310129],"study_design_scores_gemma":[0.0049567595,0.0017507465,0.91011333,0.00020264702,0.0003945871,0.0010812478,0.001020606,0.00032724932,0.000024037103,0.0000043949167,0.080060594,0.00006381389],"about_ca_topic_score_codex":0.0077238255,"about_ca_topic_score_gemma":0.052501548,"teacher_disagreement_score":0.19303748,"about_ca_system_score_codex":0.00046492668,"about_ca_system_score_gemma":0.0020699927,"threshold_uncertainty_score":0.99888384},"labels":[],"label_agreement":null},{"id":"W2589884212","doi":"10.1200/jco.2016.34.3_suppl.137","title":"Cardio-oncology interventions in outpatients referred for autologous bone marrow transplantation.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Population; Transplantation; Cardiology; Surgery","score_opus":0.18922930187300266,"score_gpt":0.48389191651735847,"score_spread":0.29466261464435584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589884212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678229,0.0002733586,0.008929105,0.01830651,0.0019565553,0.00050022965,0.000022984252,0.000014214539,0.0021741139],"genre_scores_gemma":[0.99195707,0.00097205845,0.0047020116,0.0011545698,0.0007269471,0.00002351454,0.000008757741,0.000015979043,0.00043909354],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99648404,0.00046742734,0.002431953,0.00018625977,0.00020832644,0.00022199277],"domain_scores_gemma":[0.99596363,0.002101152,0.0011830333,0.00014234193,0.00039422087,0.00021560298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032522539,0.00011416495,0.0014275203,0.00021901223,0.00002922824,0.000003515539,0.00010179314,0.0005708884,0.00006133674],"category_scores_gemma":[0.0026410474,0.00007579972,0.0011036424,0.00010678106,0.00015245377,0.00012742978,0.000011691045,0.00045807642,0.000009550804],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015620742,0.0025471174,0.02028111,0.00021776752,0.0007154895,0.00080105796,0.00049565773,0.000011614524,0.038555987,0.00041177968,0.0044711917,0.9158705],"study_design_scores_gemma":[0.12725362,0.06188338,0.55396116,0.0024264094,0.0020413082,0.0048041036,0.0005095507,0.000060723596,0.020505436,0.006182647,0.21989879,0.00047288736],"about_ca_topic_score_codex":0.0000071312497,"about_ca_topic_score_gemma":0.00009892688,"teacher_disagreement_score":0.9153976,"about_ca_system_score_codex":0.0004035465,"about_ca_system_score_gemma":0.0009276911,"threshold_uncertainty_score":0.44032142},"labels":[],"label_agreement":null},{"id":"W2589893537","doi":"10.1200/jco.2014.32.30_suppl.136","title":"Improving the quality of care for patients receiving radiation therapy: Increasing the proportion of radiation treatment plans undergoing peer review in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Regional Municipality of Durham; Princess Margaret Cancer Centre; Queen's University; Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Quality assurance; Peer review; Radiation therapy; Radiation Therapist; Family medicine; Surgery; Business","score_opus":0.120082279546346,"score_gpt":0.4630954874136218,"score_spread":0.3430132078672758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589893537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036074,0.00172339,0.0005046528,0.0059800087,0.0003815263,0.00076782395,0.0000019881759,0.0000023142006,0.00027756012],"genre_scores_gemma":[0.9949573,0.0034842305,0.00042611905,0.00080468145,0.000265827,0.000009898269,0.000018892368,0.000007930112,0.000025105644],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99599487,0.0010286258,0.002344327,0.00010336215,0.00042201803,0.00010678026],"domain_scores_gemma":[0.99039006,0.004711052,0.00391544,0.00016602394,0.0007656966,0.000051732302],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010081457,0.00008378477,0.00082901755,0.00006940842,0.000053965025,0.000006008609,0.00008928291,0.00010438013,0.00000912505],"category_scores_gemma":[0.018285712,0.000043149932,0.00029582242,0.00009300823,0.00005553131,0.00013796738,0.000009257489,0.00029062797,2.4131512e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006741796,0.00022268588,0.45939237,0.00011414029,0.000052451665,2.2606689e-7,0.0007545296,0.000024697181,0.0000631135,0.000020932443,0.000053074447,0.5386276],"study_design_scores_gemma":[0.005919861,0.0048920554,0.9758422,0.0005062906,0.00018269375,0.0000050172657,0.0002327858,0.00023252763,0.00030176505,0.00006204108,0.0117811635,0.00004164505],"about_ca_topic_score_codex":0.0024829877,"about_ca_topic_score_gemma":0.0062248795,"teacher_disagreement_score":0.53858596,"about_ca_system_score_codex":0.0004913703,"about_ca_system_score_gemma":0.0013939912,"threshold_uncertainty_score":0.9899837},"labels":[],"label_agreement":null},{"id":"W2589894444","doi":"10.1200/jco.2013.31.31_suppl.158","title":"Screening for hepatitis B virus prior to chemotherapy: A quality improvement project.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Hepatitis B virus; HBsAg; Context (archaeology); Chemotherapy; Psychological intervention; Hepatitis B; Population; Internal medicine; Immunology; Virus; Nursing","score_opus":0.2246783235142395,"score_gpt":0.5256199568162029,"score_spread":0.3009416333019634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589894444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626816,0.000119030236,0.007524992,0.026012197,0.0008615206,0.0018174768,0.000012531155,0.000019712828,0.0009509726],"genre_scores_gemma":[0.8076021,0.00113651,0.15247312,0.034793723,0.002694012,0.00020477742,0.0000021660078,0.000044201475,0.0010493691],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99585295,0.0002310816,0.0029336594,0.00023307794,0.00039655712,0.00035268266],"domain_scores_gemma":[0.9947379,0.0021178694,0.0014798862,0.00021634523,0.0010549483,0.00039304496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038970516,0.00016235998,0.0017399671,0.00013036406,0.00007539733,0.000016635866,0.00016461396,0.00026266827,0.00021570708],"category_scores_gemma":[0.008864279,0.000115697156,0.00056647666,0.00013239562,0.00011265438,0.00012426528,0.00007824788,0.0005262304,0.00004104425],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020469115,0.0009677018,0.1712438,0.00006072071,0.00053473277,0.000030011826,0.000340917,7.997461e-7,0.002940141,0.00004827046,0.040583007,0.781203],"study_design_scores_gemma":[0.007809223,0.026097493,0.6947954,0.000116994765,0.00016220582,0.0000326623,0.00009404127,0.000077132005,0.0008244045,0.0002807502,0.26956454,0.00014513513],"about_ca_topic_score_codex":0.004314935,"about_ca_topic_score_gemma":0.002630145,"teacher_disagreement_score":0.78105783,"about_ca_system_score_codex":0.00019838045,"about_ca_system_score_gemma":0.0010167994,"threshold_uncertainty_score":0.9994845},"labels":[],"label_agreement":null},{"id":"W2589905095","doi":"10.1200/jco.2013.31.6_suppl.183","title":"Wait time intervals for patients with prostate cancer in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Health Sciences Centre; North York General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Referral; Cohort; Prostate cancer; Cancer; Watchful waiting; Cohort study; Pediatrics; Emergency medicine; Internal medicine; Family medicine","score_opus":0.14303411219777656,"score_gpt":0.3946502635152667,"score_spread":0.25161615131749016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589905095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912573,0.0001792039,0.0006712663,0.0050783004,0.0006805285,0.000923447,0.00025335277,0.0000069167277,0.00094969943],"genre_scores_gemma":[0.9944828,0.000096612996,0.0015266998,0.0033108403,0.0002304574,0.00014159817,0.00001715629,0.00003206214,0.00016174618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636465,0.00019359966,0.0027984737,0.00021567386,0.000048757593,0.00037886697],"domain_scores_gemma":[0.9937763,0.0030814516,0.0022144155,0.00024571686,0.0003583133,0.0003237721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024301219,0.00018895823,0.0016453348,0.0002821951,0.000075932585,0.00003904305,0.00042969338,0.00022023407,0.0004964059],"category_scores_gemma":[0.0023752095,0.00016200362,0.00025063276,0.00014637265,0.00013118163,0.0004551447,0.00008977525,0.000772081,0.00017704492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023873174,0.0019069184,0.9180659,0.000047556663,0.00012171933,0.0000072739936,0.00058123464,0.0011280251,0.0000012455492,0.00007045952,0.0035606374,0.07212171],"study_design_scores_gemma":[0.009413799,0.008224048,0.9516757,0.00019808472,0.00002161129,0.0000010856731,0.000055458477,0.0014674382,0.0000022293239,0.0024977839,0.026211562,0.00023117097],"about_ca_topic_score_codex":0.00085659587,"about_ca_topic_score_gemma":0.00075596874,"teacher_disagreement_score":0.07189054,"about_ca_system_score_codex":0.0002962528,"about_ca_system_score_gemma":0.0003736087,"threshold_uncertainty_score":0.6606316},"labels":[],"label_agreement":null},{"id":"W2589908657","doi":"10.1200/jco.2012.30.34_suppl.228","title":"Quality of adjuvant chemotherapy in stage III colon cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Oxaliplatin; Colorectal cancer; Internal medicine; Chemotherapy; Guideline; Capecitabine; Cancer; Stage (stratigraphy); Oncology; Cancer registry; Referral; Medical record; Family medicine; Pathology","score_opus":0.2939690586038478,"score_gpt":0.585308747368643,"score_spread":0.2913396887647952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589908657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876074,0.0021256772,0.000014668332,0.0032376824,0.0012544027,0.00021604862,0.0000063109937,0.0000046313676,0.0055331346],"genre_scores_gemma":[0.99471015,0.0019970897,0.00073350896,0.0013509243,0.00072061975,0.0000072318335,9.0689775e-7,0.000011944897,0.00046760726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99595433,0.0005264554,0.002729717,0.00012031561,0.00039331045,0.0002758808],"domain_scores_gemma":[0.9950499,0.002125882,0.0020234606,0.0001553799,0.00025427595,0.00039110926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004767209,0.00011741929,0.0021707944,0.00009449124,0.00001095896,0.0000014544505,0.00011517529,0.00032271296,0.0008457267],"category_scores_gemma":[0.0015627783,0.00008064007,0.00046119795,0.00019634358,0.00018366221,0.0001032756,0.000034944103,0.00069715694,0.0000054412426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01699589,0.0037768318,0.8377817,0.000039003407,0.0002463549,0.00009943377,0.0002025759,0.0000047293092,0.0004987057,0.00008844625,0.00046940605,0.13979688],"study_design_scores_gemma":[0.018463377,0.0067798314,0.9258901,0.000082730236,0.000078694444,0.00003132044,0.00008827806,0.000009343034,0.0005566799,0.000060853396,0.04789374,0.000065066044],"about_ca_topic_score_codex":0.00031238885,"about_ca_topic_score_gemma":0.00026741222,"teacher_disagreement_score":0.13973182,"about_ca_system_score_codex":0.00046436026,"about_ca_system_score_gemma":0.0011434485,"threshold_uncertainty_score":0.92601144},"labels":[],"label_agreement":null},{"id":"W2589913055","doi":"10.1200/jco.2013.31.4_suppl.167","title":"Outcomes following stereotactic body radiotherapy for patients with Child-Pugh B/C hepatocellular carcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Liver function; Univariate analysis; Internal medicine; Gastroenterology; Portal vein thrombosis; Milan criteria; Liver cancer; Liver function tests; Liver transplantation; Thrombosis; Multivariate analysis; Transplantation","score_opus":0.09031533649146176,"score_gpt":0.37234594667418924,"score_spread":0.28203061018272746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589913055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912218,0.0006038673,0.0002477653,0.0047869612,0.0010605409,0.0014595389,0.000003444937,0.000016240116,0.0005998344],"genre_scores_gemma":[0.98971826,0.00006167939,0.0073130913,0.0018686458,0.0005945105,0.000053564392,0.00001567006,0.000050559713,0.0003240447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967297,0.00026623296,0.0018999478,0.00026548462,0.00045564873,0.0003829951],"domain_scores_gemma":[0.99575216,0.0016135026,0.0012790939,0.0002813054,0.000552146,0.0005217868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011146927,0.00026614204,0.0020615668,0.0001570627,0.00009138289,0.000027101041,0.000174542,0.0003516356,0.00020516483],"category_scores_gemma":[0.0008343538,0.00015764711,0.0012540467,0.000121841134,0.00009270045,0.00026973037,0.000022393926,0.0005771679,0.00002313963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013817601,0.0024140836,0.9762755,0.000033021646,0.0018129695,0.00034352217,0.000074986136,1.4190448e-7,0.000015070606,0.000016739885,0.00077888154,0.016853314],"study_design_scores_gemma":[0.02479856,0.02279263,0.9313726,0.0000701388,0.0011971573,0.00005835863,0.000031113643,0.00036508607,0.000044995264,0.000063344945,0.019038403,0.0001676262],"about_ca_topic_score_codex":0.000033513326,"about_ca_topic_score_gemma":0.0000024830829,"teacher_disagreement_score":0.044902924,"about_ca_system_score_codex":0.00017497681,"about_ca_system_score_gemma":0.0005587214,"threshold_uncertainty_score":0.64286625},"labels":[],"label_agreement":null},{"id":"W2589913138","doi":"10.1200/jco.2016.34.3_suppl.74","title":"Continuum of care: Establishment of a comprehensive cardio-oncology program.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Cardiotoxicity; Cancer; Internal medicine; Breast cancer; Population; Oncology; Intensive care medicine; Chemotherapy","score_opus":0.09532607232402943,"score_gpt":0.46182756737616076,"score_spread":0.36650149505213137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589913138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868469,0.00084434537,0.00026901942,0.004916958,0.0012753438,0.00047490135,0.000009205885,0.00001031795,0.0053529665],"genre_scores_gemma":[0.99200815,0.0011099279,0.005075176,0.000699253,0.000993069,0.0000070641267,0.0000020399748,0.000014322146,0.00009100804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996143,0.00052727276,0.0025418724,0.00016861955,0.0004126415,0.00020661054],"domain_scores_gemma":[0.99261445,0.002336305,0.0026381467,0.0002373377,0.0019086314,0.0002651332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016425811,0.00013078832,0.0024949694,0.00013320272,0.00001553864,0.0000022527986,0.00014933286,0.00055541564,0.00005479237],"category_scores_gemma":[0.0015283175,0.00008039978,0.0009997525,0.00013785633,0.0005393363,0.00008679693,0.000044760734,0.00048449152,0.0000031218817],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055741617,0.0016217788,0.012335096,0.00014649006,0.0010651527,0.00019324862,0.00045472744,0.0000016143725,0.18526174,0.00012241756,0.003811832,0.7894117],"study_design_scores_gemma":[0.032291804,0.069063626,0.103035815,0.0007014801,0.0011351648,0.00080577313,0.0018320058,0.000002636814,0.24625127,0.0004079357,0.54429984,0.000172667],"about_ca_topic_score_codex":0.000012874121,"about_ca_topic_score_gemma":0.000020738546,"teacher_disagreement_score":0.78923905,"about_ca_system_score_codex":0.00025995282,"about_ca_system_score_gemma":0.0019522439,"threshold_uncertainty_score":0.4283874},"labels":[],"label_agreement":null},{"id":"W2589914723","doi":"10.1200/jco.2016.34.4_suppl.668","title":"Loco-regional outcomes of a population-based cohort of rectal neuroendocrine tumors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Neuroendocrine tumors; Cohort; Capecitabine; Colorectal cancer; Univariate analysis; Lymphovascular invasion; Population; Surgery; Resection margin; Internal medicine; Oncology; Gastroenterology; Metastasis; Cancer; Multivariate analysis; Resection","score_opus":0.10093870003965771,"score_gpt":0.4799869027177462,"score_spread":0.3790482026780885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589914723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772728,0.000077152785,0.00007022693,0.021401895,0.00044677444,0.00028512234,0.000009804606,0.00000936997,0.00042687048],"genre_scores_gemma":[0.9959125,0.00015136419,0.00220211,0.0009637217,0.00036304354,0.000004418032,0.0000023452092,0.000021901242,0.00037861522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946813,0.00052742177,0.0033685449,0.00021207886,0.000910429,0.00030020048],"domain_scores_gemma":[0.98881644,0.006936717,0.0027164475,0.00029325765,0.0008288926,0.0004082189],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011600243,0.00015451013,0.002176329,0.00029619993,0.000017439343,0.0000019206911,0.00026173142,0.000027960392,0.00029543997],"category_scores_gemma":[0.017972272,0.00008586537,0.00072874693,0.00018793956,0.00043786105,0.00012797129,0.00006131282,0.00056626793,0.000008387079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046838094,0.0013974967,0.9710682,0.00005495314,0.00019566492,0.003141888,0.0000018143918,0.000014539887,0.0018302405,0.00012018238,0.0016215668,0.015869642],"study_design_scores_gemma":[0.008657381,0.0123084495,0.9661721,0.00017544557,0.00014622099,0.0017392687,0.000008085239,0.000021939815,0.0020393513,0.00041171157,0.0082503585,0.00006971312],"about_ca_topic_score_codex":0.000060452294,"about_ca_topic_score_gemma":0.000033018092,"teacher_disagreement_score":0.020438174,"about_ca_system_score_codex":0.00008879674,"about_ca_system_score_gemma":0.0013460508,"threshold_uncertainty_score":0.99029976},"labels":[],"label_agreement":null},{"id":"W2589922325","doi":"10.1200/jco.2014.32.3_suppl.398","title":"Outcomes of adjuvant chemotherapy (AC) in young (YP) and elderly patients (EP) with high-risk stage II colon cancer (CC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Perineural invasion; Lymphovascular invasion; Proportional hazards model; Cancer; Chemotherapy; Perforation; Oncology; Gastroenterology; Surgery; Metastasis","score_opus":0.034235567354582754,"score_gpt":0.3855618394201513,"score_spread":0.35132627206556855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589922325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956726,0.00018220638,0.000014871572,0.0029885967,0.0004344913,0.00016671745,0.00000850252,0.0000038060523,0.00052823155],"genre_scores_gemma":[0.99723727,0.0006972266,0.0005153425,0.00089613145,0.00024432407,0.0000030922972,0.0000013729856,0.0000134915235,0.00039177318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771124,0.00023894984,0.0014012967,0.00016237456,0.0003002087,0.00018593491],"domain_scores_gemma":[0.99706614,0.000837453,0.0014519936,0.00010887426,0.00031422832,0.0002213139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013026267,0.00013405239,0.0015614056,0.00011283198,0.000031088344,0.000003359336,0.000093666815,0.0002183486,0.00006722935],"category_scores_gemma":[0.0008640569,0.000079015765,0.00017809325,0.00010904815,0.0002039002,0.00006917019,0.000040466122,0.00068658986,8.070421e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051834295,0.0020481402,0.9010529,0.000029590943,0.00015614668,0.000043597323,0.00020673705,0.0000041232734,0.00006158586,0.000030649357,0.00017115247,0.09101195],"study_design_scores_gemma":[0.027040184,0.041894346,0.92647624,0.00010010125,0.00018016947,0.000017607066,0.00007571901,0.00006434192,0.000094024355,0.000112781454,0.0038647277,0.000079772326],"about_ca_topic_score_codex":0.0006695283,"about_ca_topic_score_gemma":0.003419554,"teacher_disagreement_score":0.09093218,"about_ca_system_score_codex":0.00008374864,"about_ca_system_score_gemma":0.00036876992,"threshold_uncertainty_score":0.32221693},"labels":[],"label_agreement":null},{"id":"W2589928042","doi":"10.1200/jco.2013.31.4_suppl.509","title":"The impact of palliative resection (PR) of the primary tumor on overall survival (OS) in metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Hazard ratio; Proportional hazards model; Oncology; Primary tumor; Cancer; Population; Multivariate analysis; Gastroenterology; Surgery; Confidence interval; Metastasis","score_opus":0.11005070732565882,"score_gpt":0.48138517791641405,"score_spread":0.37133447059075525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589928042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910475,0.0007368236,0.0000010753377,0.0034140141,0.00087498233,0.000444946,0.000009666738,0.0000015680328,0.0034694024],"genre_scores_gemma":[0.9979024,0.0014024673,0.00005743722,0.00023463211,0.00022694626,0.000024201283,4.3260113e-7,0.000008520769,0.00014297714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971103,0.0006331355,0.0015678165,0.00011613539,0.0003864497,0.00018617796],"domain_scores_gemma":[0.9931091,0.0043614735,0.0018021511,0.00012447611,0.0005105898,0.00009220594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016100603,0.00012528854,0.001255681,0.00006311058,0.00005161054,0.0000045403995,0.00014441258,0.00008181753,0.0001313543],"category_scores_gemma":[0.002436414,0.000050834216,0.0006214656,0.00017629321,0.0003314369,0.00005765872,0.000059626655,0.00064782205,0.0000019141344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02716033,0.0027042248,0.91610444,0.000047138128,0.0023767974,0.000060332255,0.00055356143,0.0002474868,0.0012172278,0.00009080313,0.004190318,0.045247324],"study_design_scores_gemma":[0.0055056135,0.02111747,0.97141355,0.00013914738,0.0001990758,0.000012657477,0.00020853266,0.000069571535,0.00024472375,0.00057695276,0.00047067818,0.00004200957],"about_ca_topic_score_codex":0.0017690792,"about_ca_topic_score_gemma":0.0021040721,"teacher_disagreement_score":0.055309113,"about_ca_system_score_codex":0.00065550744,"about_ca_system_score_gemma":0.0016401258,"threshold_uncertainty_score":0.2916791},"labels":[],"label_agreement":null},{"id":"W2589931311","doi":"10.1200/jco.2010.28.15_suppl.8073","title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma (FL) treated with radiotherapy.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Lymphoma; Incidence (geometry); Cohort; Stage (stratigraphy); Radiation therapy; Gastroenterology; Aggressive lymphoma; Cancer; Surgery; Oncology; Rituximab","score_opus":0.041357263025294445,"score_gpt":0.398741871788049,"score_spread":0.3573846087627545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589931311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942645,0.00043076617,0.00011884487,0.0035614192,0.00027960035,0.00042710936,0.0000058639566,0.000008316691,0.0009036155],"genre_scores_gemma":[0.9927186,0.00088130013,0.0046630125,0.0014013973,0.00023153532,0.000016957305,0.000003908838,0.000017779394,0.000065537664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685866,0.00022235644,0.002065402,0.00019104095,0.00042784505,0.00023472676],"domain_scores_gemma":[0.99593747,0.0011391864,0.0018362339,0.00024503603,0.0004404696,0.00040159066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00135115,0.0001839861,0.0015080897,0.0003004695,0.00002560297,0.00000860512,0.00016262764,0.0003891126,0.00008481566],"category_scores_gemma":[0.0010690652,0.00011304341,0.0003574858,0.00035443163,0.00015656957,0.00017246237,0.000014243253,0.00023095089,0.0000072498756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010123344,0.005745193,0.4921874,0.0000367471,0.00050734787,0.0036156252,0.0006623416,0.00006969334,0.0020800228,0.00026239222,0.00022541918,0.48448446],"study_design_scores_gemma":[0.03352686,0.02086777,0.91595477,0.00037906662,0.00029537125,0.0012479833,0.00014495784,0.00021135288,0.005385362,0.000025872409,0.021836618,0.00012401237],"about_ca_topic_score_codex":0.00018028263,"about_ca_topic_score_gemma":0.00045376667,"teacher_disagreement_score":0.48436046,"about_ca_system_score_codex":0.0003130559,"about_ca_system_score_gemma":0.0014259737,"threshold_uncertainty_score":0.46097764},"labels":[],"label_agreement":null},{"id":"W2589934757","doi":"10.1200/jco.2015.33.7_suppl.387","title":"Is the International Germ Cell Consensus Classification (IGCCC) sufficiently predictive in 2015?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Sherbrooke","funders":"","keywords":"Medicine; Germ cell tumors; Clinical trial; Oncology; Internal medicine; Disease; Chemotherapy","score_opus":0.24003665706409383,"score_gpt":0.5027538065309096,"score_spread":0.2627171494668158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589934757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94986314,0.0009070124,0.00008049852,0.04018669,0.0015023903,0.00018637945,0.0000096651975,0.0000055188784,0.0072587105],"genre_scores_gemma":[0.995962,0.00012578015,0.00061928947,0.0023753308,0.0005245295,0.0000032064215,0.000004048306,0.0000067691785,0.00037904613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979616,0.0002328259,0.0011532342,0.00012626487,0.00041003004,0.00011607933],"domain_scores_gemma":[0.9965452,0.0012572977,0.0011557182,0.00014749364,0.0005960081,0.00029831214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018288468,0.000076843295,0.00044275165,0.000077100274,0.000015910591,0.000008774954,0.00014489626,0.00015407575,0.00005734953],"category_scores_gemma":[0.0041765147,0.000043382403,0.00024222364,0.00008875879,0.00015892067,0.000034403536,0.000035123074,0.00044959688,0.00004622997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043051355,0.0056688306,0.91386044,0.000007714759,0.00031834346,0.00091926166,0.00036010842,0.00006334764,0.000042277563,0.00013690421,0.05493214,0.019385483],"study_design_scores_gemma":[0.009658204,0.00444532,0.93784046,0.000042541502,0.0003273982,0.00024105501,0.00063296297,0.0026751175,0.000023353108,0.0004891139,0.043580838,0.000043641838],"about_ca_topic_score_codex":0.000022219036,"about_ca_topic_score_gemma":0.000012651881,"teacher_disagreement_score":0.046098866,"about_ca_system_score_codex":0.00026133555,"about_ca_system_score_gemma":0.0020838308,"threshold_uncertainty_score":0.49999797},"labels":[],"label_agreement":null},{"id":"W2589940972","doi":"10.1200/jco.2014.32.30_suppl.57","title":"Quality indicators of end-of-life cancer care: What rate is right?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Alberta; Institute of Health Services and Policy Research; Institute for Clinical Evaluative Sciences; Dalhousie University; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Decile; Funnel plot; Medicine; Confidence interval; Demography; Emergency medicine; Emergency department; Intensive care unit; Statistics; Publication bias; Internal medicine; Nursing","score_opus":0.5666575041784615,"score_gpt":0.5963210506833848,"score_spread":0.02966354650492331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589940972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92994094,0.0070458357,0.00087872247,0.053053275,0.004946721,0.00023546348,0.00010138747,0.0000060996595,0.0037915595],"genre_scores_gemma":[0.9708369,0.0037300447,0.0020274988,0.021889465,0.0013823663,0.000007987053,0.000002959739,0.000019792298,0.000102994265],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9778075,0.0025690377,0.018813701,0.00032872878,0.00018673549,0.00029427276],"domain_scores_gemma":[0.95843005,0.011673872,0.028593713,0.00043561694,0.0003998755,0.00046686048],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07383206,0.00016309366,0.0041319407,0.00041048208,0.000058031863,0.00002106724,0.0005271353,0.000535899,0.0013721146],"category_scores_gemma":[0.028531825,0.00016049122,0.0006696551,0.00021425764,0.00038004736,0.00057403045,0.000067235014,0.0006239995,0.000138304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065389095,0.0009742454,0.82873374,0.000895028,0.0008790448,0.000003150956,0.0040668026,0.00020413905,0.0000075310345,0.07538764,0.033393186,0.054801624],"study_design_scores_gemma":[0.0042454456,0.0017015933,0.44065228,0.00018344117,0.000046774123,0.0000029287924,0.0014678013,0.00016121814,0.000046450565,0.014327819,0.5369226,0.00024164362],"about_ca_topic_score_codex":0.000659676,"about_ca_topic_score_gemma":0.00034021898,"teacher_disagreement_score":0.5035294,"about_ca_system_score_codex":0.00037317318,"about_ca_system_score_gemma":0.0022680974,"threshold_uncertainty_score":0.99954075},"labels":[],"label_agreement":null},{"id":"W2589942403","doi":"10.1200/jco.2012.30.34_suppl.95","title":"The use of a palliative care tool in a community private practice.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Population; Palliative care; Veterans Affairs; Family medicine; Internal medicine; Nursing","score_opus":0.3385702127751342,"score_gpt":0.5349882192956705,"score_spread":0.19641800652053631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589942403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904256,0.0015538963,0.000047515758,0.0054351403,0.0012615969,0.00014521298,0.0000034658929,0.0000023272123,0.0011252634],"genre_scores_gemma":[0.99433386,0.0014446039,0.0012186592,0.0024437378,0.0004956434,0.0000028962459,0.0000010294611,0.0000072703783,0.000052277905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593353,0.00201868,0.0015521473,0.00004457964,0.00026904314,0.00018203458],"domain_scores_gemma":[0.9817541,0.015599282,0.0016080968,0.00024147249,0.0006644253,0.00013257208],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005139954,0.00007173927,0.00076299044,0.000047424623,0.000046501475,0.000005922848,0.00014732414,0.00021360029,0.000020135636],"category_scores_gemma":[0.02261474,0.000041201234,0.00027699262,0.00013589462,0.00020422344,0.00020529827,0.00007342145,0.0018573946,0.0000030996835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082190335,0.0017319656,0.82150763,0.000059758117,0.00026179373,0.00007448614,0.01083048,0.000005623729,0.000031328425,0.0006665691,0.0016397785,0.15497153],"study_design_scores_gemma":[0.0022380694,0.0035484086,0.5129965,0.00010369849,0.00016195198,0.00003610511,0.005946811,0.000004024298,0.000024807594,0.000076704935,0.47482738,0.00003555451],"about_ca_topic_score_codex":0.00045033346,"about_ca_topic_score_gemma":0.0020884473,"teacher_disagreement_score":0.4731876,"about_ca_system_score_codex":0.00017654532,"about_ca_system_score_gemma":0.0007626979,"threshold_uncertainty_score":0.9856182},"labels":[],"label_agreement":null},{"id":"W2589949871","doi":"10.1200/jco.2005.23.16_suppl.6040","title":"Economic evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: Tamoxifen vs tamoxifen then exemestane vs anastrazole","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Tamoxifen; Exemestane; Breast cancer; Hazard ratio; Oncology; Gynecology; Internal medicine; Cancer; Confidence interval","score_opus":0.028510096377125954,"score_gpt":0.38637271853043703,"score_spread":0.3578626221533111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589949871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952936,0.0014308102,0.000015472537,0.0020508762,0.00024037132,0.00022278304,0.000034904293,0.0000026978303,0.00070845085],"genre_scores_gemma":[0.996255,0.0016854927,0.0008823576,0.00026521593,0.0007985807,0.000018966279,0.000015166162,0.000019111412,0.000060129503],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972996,0.00051688263,0.001373512,0.00023380139,0.00028355976,0.0002926472],"domain_scores_gemma":[0.997945,0.00013391626,0.0011707746,0.00018743292,0.00032358186,0.0002392643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033841026,0.00016411662,0.0007508964,0.00010151882,0.000030583917,0.0000076010538,0.00024412521,0.00042778783,0.000115982526],"category_scores_gemma":[0.00012388344,0.00011897814,0.00013953766,0.00007544287,0.00020212417,0.000023405531,0.00005685934,0.00049685495,0.0000068583226],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058084287,0.005715777,0.117887154,0.000050452934,0.002881256,0.0001871996,0.0007673636,0.05948598,0.15095773,0.0003048785,0.004597447,0.5990805],"study_design_scores_gemma":[0.01762496,0.033488475,0.9288666,0.00011140396,0.0005685356,0.0010003103,0.0002737128,0.0023305344,0.0035706758,0.00024787497,0.011524569,0.0003923078],"about_ca_topic_score_codex":0.000040197043,"about_ca_topic_score_gemma":0.00021253806,"teacher_disagreement_score":0.8109795,"about_ca_system_score_codex":0.00028849114,"about_ca_system_score_gemma":0.0024426149,"threshold_uncertainty_score":0.48517877},"labels":[],"label_agreement":null},{"id":"W2589956154","doi":"10.1200/jco.2016.34.2_suppl.3","title":"NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Urology; Bicalutamide; Prostate cancer; Prostatectomy; Internal medicine; Placebo; Hazard ratio; Salvage therapy; Clinical endpoint; Prostate; Androgen suppression; Radiation therapy; Randomized controlled trial; Oncology; Cancer; Chemotherapy; Confidence interval; Androgen receptor; Pathology","score_opus":0.05486591700445969,"score_gpt":0.45553566449555205,"score_spread":0.40066974749109235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589956154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907966,0.0031291174,0.000007817772,0.0036468278,0.00036320894,0.0019893236,0.000017678554,0.00001870654,0.000030699062],"genre_scores_gemma":[0.9709897,0.027350549,0.0001950603,0.0005938818,0.0005905064,0.00015281905,0.000009161156,0.000041227948,0.00007711044],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958533,0.0008630195,0.0017891991,0.00046136664,0.00051241694,0.0005207],"domain_scores_gemma":[0.997156,0.0008929103,0.0008935914,0.00017579312,0.0002768352,0.00060486054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023774898,0.00028008167,0.0016329841,0.00030702743,0.00008549045,0.000028970113,0.0001098169,0.00038228554,0.00007826059],"category_scores_gemma":[0.0004501274,0.0001406564,0.00020523336,0.00026162318,0.0004911705,0.00044431124,0.000040463918,0.0007806525,0.0000013586747],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36331472,0.0035000825,0.40888903,0.000016493626,0.00052210636,0.0011185522,0.00042054444,5.4743333e-7,0.0029998543,0.0000013129699,0.00003307616,0.2191837],"study_design_scores_gemma":[0.57799226,0.055085495,0.3586178,0.00028518014,0.00015372098,0.000086305845,0.00006171966,0.000026335461,0.002030894,0.00007660022,0.005392163,0.00019151579],"about_ca_topic_score_codex":0.000048762988,"about_ca_topic_score_gemma":0.000066999324,"teacher_disagreement_score":0.21899219,"about_ca_system_score_codex":0.0004816255,"about_ca_system_score_gemma":0.0019017896,"threshold_uncertainty_score":0.57358015},"labels":[],"label_agreement":null},{"id":"W2589956845","doi":"10.1200/jco.2015.33.15_suppl.tps7586","title":"Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Tumor-infiltrating lymphocytes; Oncology; Internal medicine; Interim analysis; Chemotherapy regimen; Melanoma; Chemotherapy; Surgery; Immunotherapy; Urology; Cancer; Clinical trial; Cancer research","score_opus":0.053856422459383685,"score_gpt":0.4045336414614896,"score_spread":0.3506772190021059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589956845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99897075,0.00013349256,0.0000026314683,0.00013405799,0.00023443036,0.00032436513,0.000009355147,0.0000038691114,0.00018707941],"genre_scores_gemma":[0.9988462,0.00003259406,0.000592769,0.00038908873,0.0000985289,0.0000036671206,0.0000059128593,0.000012527762,0.000018718945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972147,0.0002238738,0.0017740321,0.00016993097,0.0004667214,0.0001507574],"domain_scores_gemma":[0.997689,0.0003794561,0.001275985,0.00011920504,0.00017616087,0.00036019078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008903143,0.00013623961,0.0009143078,0.00013641379,0.000026695334,0.000003934744,0.00008900602,0.00007772522,0.000028187307],"category_scores_gemma":[0.0009523942,0.00008621254,0.000096218406,0.000113550355,0.00015553502,0.00017097518,0.00009355165,0.00026650206,0.00000218045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04453408,0.020927664,0.8244348,0.000024254732,0.00008582981,0.00039312942,0.00039655025,0.00007162732,0.0003308797,0.0000029097155,0.000045852248,0.108752415],"study_design_scores_gemma":[0.075198,0.13790989,0.78485835,0.00025152927,0.0001500768,0.00008091641,0.0009534707,0.00015123372,0.0000867319,0.000035605444,0.00024305796,0.00008113114],"about_ca_topic_score_codex":0.00002115827,"about_ca_topic_score_gemma":0.000031894866,"teacher_disagreement_score":0.11698222,"about_ca_system_score_codex":0.00017359124,"about_ca_system_score_gemma":0.00045560813,"threshold_uncertainty_score":0.35156453},"labels":[],"label_agreement":null},{"id":"W2589960962","doi":"10.1200/jco.2016.34.7_suppl.214","title":"Implementation of a new patient health questionnaire into standard practice in outpatient cancer clinics to improve patient care and quality of treatment.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Cancer; Outpatient clinic; Health care; Medical record; Population; Cohort; Surgery; Internal medicine","score_opus":0.2081831220079029,"score_gpt":0.6022067597361491,"score_spread":0.3940236377282462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589960962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856643,0.0029960226,0.00034674632,0.009861412,0.0005632147,0.0004834212,0.000035067027,0.0000022628908,0.00004753018],"genre_scores_gemma":[0.9864138,0.0036737756,0.007733438,0.0020056076,0.00015195325,0.0000086341215,0.0000011551284,0.0000066867124,0.000004957909],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951555,0.000589938,0.0034792759,0.00018509118,0.00042044578,0.00016973571],"domain_scores_gemma":[0.99358594,0.0010428429,0.0037420236,0.0001433609,0.0010905898,0.0003952613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018893658,0.000108612025,0.001215715,0.00009994278,0.000019211222,0.000002600865,0.00005469718,0.0001403837,0.00002141229],"category_scores_gemma":[0.004189639,0.00006649244,0.00018231041,0.000115252915,0.00007538311,0.00015156722,0.000043671276,0.00020143342,4.3396258e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061791316,0.00023439141,0.3031157,0.0000490833,0.00007441667,0.000009020938,0.0061691715,0.000009124888,0.00007511999,0.000031399024,0.0002385038,0.68381494],"study_design_scores_gemma":[0.019896995,0.39105105,0.51353604,0.0017531872,0.000275131,0.000021638572,0.026513208,0.0000026946448,0.0012107926,0.00023264057,0.045363966,0.00014266485],"about_ca_topic_score_codex":0.011735101,"about_ca_topic_score_gemma":0.011685023,"teacher_disagreement_score":0.6836723,"about_ca_system_score_codex":0.0014664758,"about_ca_system_score_gemma":0.006160764,"threshold_uncertainty_score":0.9994734},"labels":[],"label_agreement":null},{"id":"W2589963701","doi":"10.1200/jco.2016.34.3_suppl.17","title":"Financial toxicity in thyroid cancer: An analysis from the North American Thyroid Cancer Survivorship study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Thyroid cancer; Cancer; Survivorship curve; Internal medicine; Cohort; Quality of life (healthcare); Thyroid; Oncology; Nursing","score_opus":0.11088261068754438,"score_gpt":0.39360936527119256,"score_spread":0.28272675458364815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589963701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866254,0.0019324096,0.00057197886,0.007860962,0.0018428026,0.00021542692,0.0004022968,0.000008887974,0.0005398753],"genre_scores_gemma":[0.98785347,0.005947718,0.00013291724,0.003246237,0.0026499343,0.000025667156,0.0000021652181,0.000024022183,0.00011789894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945144,0.00043805927,0.003891172,0.00053656014,0.00011357834,0.0005062307],"domain_scores_gemma":[0.99189943,0.002255186,0.0048407833,0.00050244597,0.0001944543,0.0003076718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049518044,0.00025733988,0.0027670043,0.00030605125,0.000097670585,0.000044800625,0.0009679781,0.00024159241,0.0004780266],"category_scores_gemma":[0.0031011128,0.00016717565,0.0007024714,0.000800856,0.00042582478,0.0005680756,0.00010623511,0.0008227302,0.000045356686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008748734,0.0008762168,0.9255663,0.0000011077133,0.0005080882,0.000029860777,0.00040212905,0.00028449728,0.00000312049,0.0007562186,0.0009033093,0.06979428],"study_design_scores_gemma":[0.002778321,0.0030182835,0.97592133,0.000012505854,0.00018782007,9.694093e-7,0.00014693108,0.000096708194,0.0000035406342,0.003471651,0.014112781,0.00024916092],"about_ca_topic_score_codex":0.049882762,"about_ca_topic_score_gemma":0.5472307,"teacher_disagreement_score":0.49734798,"about_ca_system_score_codex":0.00064118556,"about_ca_system_score_gemma":0.0009798008,"threshold_uncertainty_score":0.95644414},"labels":[],"label_agreement":null},{"id":"W2589963973","doi":"10.1200/jco.2014.32.3_suppl.558","title":"Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prospective cohort study; Colorectal cancer; Internal medicine; Odds ratio; Cancer; Cohort; Incidence (geometry); Confidence interval; Surgery; Cohort study","score_opus":0.05898138209424245,"score_gpt":0.44053931211598657,"score_spread":0.3815579300217441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589963973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876156,0.00018192352,0.000015812153,0.0013843552,0.0019526088,0.00085394434,0.00006261604,0.0000110247165,0.007922107],"genre_scores_gemma":[0.997098,0.000674522,0.0005887498,0.00019137323,0.001368921,0.000032118198,0.0000029547184,0.000011844824,0.000031499356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99322814,0.00057594135,0.0049204347,0.00040493245,0.00060088135,0.00026969454],"domain_scores_gemma":[0.99173135,0.004073154,0.0030217334,0.00016374736,0.00070757867,0.00030242593],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005676688,0.00020287393,0.0028601673,0.00008848912,0.000037212933,0.0000065234008,0.00019177044,0.00030985073,0.00004097421],"category_scores_gemma":[0.011312504,0.00013602592,0.00046223582,0.0002957874,0.00034435056,0.00007034209,0.00010595571,0.000797756,0.0000025561278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04089042,0.004923081,0.927878,0.000008076274,0.0019394057,0.0002419851,0.0005340385,0.000024310888,0.000049527793,0.000019131672,0.0004652682,0.023026725],"study_design_scores_gemma":[0.02280782,0.051588457,0.92268133,0.00015002818,0.0009950312,0.000014226343,0.0006234564,0.00008462339,0.000033937646,0.00029729583,0.00062676443,0.00009704521],"about_ca_topic_score_codex":0.001407302,"about_ca_topic_score_gemma":0.0019898918,"teacher_disagreement_score":0.046665374,"about_ca_system_score_codex":0.0006913856,"about_ca_system_score_gemma":0.0016067773,"threshold_uncertainty_score":0.99701566},"labels":[],"label_agreement":null},{"id":"W2589967630","doi":"10.1200/jco.2013.31.6_suppl.113","title":"A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Internal medicine; Prostate cancer; Population; Surgery; Cancer; Gastroenterology; Androgen deprivation therapy","score_opus":0.08306378935611403,"score_gpt":0.45138472523179707,"score_spread":0.36832093587568304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589967630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951219,0.00011151404,0.000025525504,0.0036248895,0.00013824878,0.0009023004,0.000006017338,0.000005535993,0.00006408425],"genre_scores_gemma":[0.99529856,0.00006285288,0.003692127,0.0005044865,0.00006766654,0.00008729937,0.000016169517,0.000018142147,0.00025269674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749047,0.00026850012,0.0012423053,0.00020242977,0.0005131897,0.00028309866],"domain_scores_gemma":[0.99767214,0.0002859606,0.00088783767,0.00013987508,0.0007427892,0.00027140704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005860813,0.00014470573,0.0007856959,0.00014700505,0.000037602345,0.000022745013,0.000079480684,0.00008241539,0.0001949229],"category_scores_gemma":[0.00023156535,0.00007509827,0.00007823774,0.00019481551,0.00016272868,0.0002985037,0.000012484864,0.00046956056,0.0000075761636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025677446,0.0015227692,0.95689255,0.00005190355,0.00016015813,0.0002390844,0.00035244992,0.00024981025,0.00013696976,0.0000016118552,0.000091018956,0.0146242175],"study_design_scores_gemma":[0.02993195,0.012376383,0.95623195,0.0003056049,0.00012855181,0.0000060073353,0.00018531558,0.00034404837,0.000137633,0.000014411409,0.0002521089,0.000086051776],"about_ca_topic_score_codex":0.0005705537,"about_ca_topic_score_gemma":0.00076602586,"teacher_disagreement_score":0.014538166,"about_ca_system_score_codex":0.0003415564,"about_ca_system_score_gemma":0.0012020434,"threshold_uncertainty_score":0.30624187},"labels":[],"label_agreement":null},{"id":"W2589971577","doi":"10.1200/jco.2015.33.7_suppl.145","title":"The association between statin use and outcomes in patients initiating androgen deprivation therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Statin; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Radiation therapy; Cohort; Randomized controlled trial; Cancer; Urology","score_opus":0.11079284231776086,"score_gpt":0.41844461095121155,"score_spread":0.3076517686334507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589971577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616694,0.0003750326,0.00005025036,0.00062584714,0.0026069996,0.0000877779,0.0000054499374,0.000001136996,0.000080559505],"genre_scores_gemma":[0.9935199,0.0015446418,0.0004910226,0.0006508511,0.0037154215,0.000002146894,0.000008971706,0.0000073259757,0.00005972067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816436,0.00048267926,0.00095169817,0.000094972,0.00018099083,0.00012527594],"domain_scores_gemma":[0.99743545,0.00090107,0.0011055269,0.000080869366,0.00037278666,0.00010429082],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032829524,0.00006566716,0.0003694756,0.000028342285,0.000033999135,0.000022758895,0.00009267708,0.0002196757,6.899386e-7],"category_scores_gemma":[0.009343869,0.000042514293,0.00008766554,0.00004049889,0.000034671168,0.000017155526,0.00004335722,0.0002306055,5.9784935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002866798,0.00009352318,0.91607475,6.228161e-7,0.00009167968,9.381701e-8,0.000059931186,0.0000043280693,0.00005395729,0.00000907617,0.0024725704,0.08085279],"study_design_scores_gemma":[0.0036407073,0.0011648578,0.7736662,0.0000027585772,0.000018806959,5.8861514e-7,0.000044834578,0.0000025657553,0.000056599492,0.0001471801,0.22121532,0.00003955917],"about_ca_topic_score_codex":0.00002207012,"about_ca_topic_score_gemma":0.00011698225,"teacher_disagreement_score":0.21874274,"about_ca_system_score_codex":0.000048340662,"about_ca_system_score_gemma":0.0003560214,"threshold_uncertainty_score":0.99900085},"labels":[],"label_agreement":null},{"id":"W2589973169","doi":"10.1200/jco.2010.28.15_suppl.e11030","title":"Review of cost-effectiveness studies on aromatase inhibitors for the treatment of early-stage breast cancer.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exemestane; Letrozole; Medicine; Aromatase; Breast cancer; Oncology; Internal medicine; Gynecology; Cancer; Stage (stratigraphy); Cost effectiveness","score_opus":0.7164988618912492,"score_gpt":0.6381067556953143,"score_spread":0.07839210619593495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589973169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90379703,0.04270379,0.00010638171,0.04399317,0.0063301865,0.0018700552,0.0010632304,0.000003881552,0.0001322931],"genre_scores_gemma":[0.82460904,0.161743,0.0010794356,0.009293768,0.002795165,0.00034015163,0.0000061472892,0.00003241309,0.000100897065],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99000645,0.0007353225,0.008802075,0.00020173915,0.000085860906,0.00016854629],"domain_scores_gemma":[0.96148586,0.024638308,0.013010129,0.00031651236,0.0004132686,0.00013590985],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.040579528,0.00013162049,0.0030063703,0.00011299356,0.00006250623,0.0000048979814,0.0002393115,0.00018811694,0.000092420356],"category_scores_gemma":[0.015014949,0.00009231737,0.0006211416,0.00009404711,0.00026557062,0.000116797026,0.000019010513,0.00028711956,0.00001977169],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007976236,0.014581367,0.5617866,0.027170643,0.008732427,0.00002157232,0.0034957565,0.0010418284,0.000053052136,0.06975342,0.1013217,0.20406543],"study_design_scores_gemma":[0.008679421,0.016594032,0.3429157,0.004311922,0.00031199938,0.000026423255,0.0006376764,0.00023937138,0.000112501075,0.003464935,0.6224398,0.00026622595],"about_ca_topic_score_codex":0.00024391567,"about_ca_topic_score_gemma":0.00023476976,"teacher_disagreement_score":0.5211181,"about_ca_system_score_codex":0.0003385972,"about_ca_system_score_gemma":0.00071808277,"threshold_uncertainty_score":0.993282},"labels":[],"label_agreement":null},{"id":"W2589974889","doi":"10.1200/jco.2012.30.34_suppl.88","title":"Enabling quality improvement in systemic cancer treatment through a collaborative approach.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Stroke Network; University Health Network; Cancer Care Ontario","funders":"","keywords":"Medicine; Collaborative network; Quality management; Systemic therapy; Quality (philosophy); Scale (ratio); Nursing; Medical education; Knowledge management; Cancer; Operations management; Internal medicine","score_opus":0.5955320633422864,"score_gpt":0.6526455129085001,"score_spread":0.05711344956621378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589974889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293847,0.0025299534,0.001243649,0.008750148,0.0020568268,0.0007860718,0.000010802808,0.0000094700845,0.0016746036],"genre_scores_gemma":[0.97638416,0.0040045716,0.012673433,0.0038304832,0.0029235762,0.00004709057,0.00000660019,0.00001749745,0.000112561145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.991117,0.0013017014,0.0065435544,0.00021270901,0.00046135805,0.00036367204],"domain_scores_gemma":[0.9880121,0.00626286,0.004389429,0.00021817203,0.0007581076,0.00035935437],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011916831,0.00017332379,0.0018591874,0.00009909214,0.00003289912,0.000009064307,0.00010268085,0.0003328362,0.00012071845],"category_scores_gemma":[0.013244299,0.00011591207,0.00037806312,0.00030252658,0.00010664712,0.00046805103,0.000045372813,0.0007815169,0.000012081532],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009478567,0.0114673395,0.46729985,0.00014254072,0.0010409898,0.00009729836,0.0026532444,0.00013600092,0.0020328483,0.0004764734,0.0017780098,0.50339687],"study_design_scores_gemma":[0.09079195,0.04943031,0.49103117,0.00061790075,0.0031321717,0.0007696582,0.03939681,0.00043690955,0.0012663954,0.00059895037,0.321892,0.0006358041],"about_ca_topic_score_codex":0.00075899874,"about_ca_topic_score_gemma":0.00023668107,"teacher_disagreement_score":0.50276107,"about_ca_system_score_codex":0.0013475246,"about_ca_system_score_gemma":0.0033178073,"threshold_uncertainty_score":0.99506754},"labels":[],"label_agreement":null},{"id":"W2589975200","doi":"10.1200/jco.2015.33.7_suppl.314","title":"Correlation of the clinical frailty scale with long-term survival after radical cystectomy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cystectomy; Perioperative; Frailty Index; Cohort; Interquartile range; Comorbidity; Internal medicine; Bladder cancer; Surgery; Cancer","score_opus":0.15390579951562225,"score_gpt":0.46710887733237144,"score_spread":0.31320307781674916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589975200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881017,0.00040365322,0.00075278996,0.0036770578,0.0032764405,0.00027982504,0.0000053722238,0.0000070887577,0.0034960664],"genre_scores_gemma":[0.995311,0.00010682769,0.0010897678,0.0011859008,0.001773267,0.0000041132707,0.0000014734183,0.000018441564,0.0005091887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568015,0.0009053457,0.0023420437,0.00018770632,0.0006945211,0.00019021229],"domain_scores_gemma":[0.9957896,0.0012232643,0.0015234337,0.00030982037,0.0006107678,0.0005431209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032615243,0.00014251714,0.0014461306,0.00005072863,0.000024136905,0.000005462607,0.00019861272,0.00047636358,0.00014697199],"category_scores_gemma":[0.0016927823,0.00007023952,0.00060500123,0.00015138827,0.00069228036,0.00009145613,0.000062238054,0.0011725967,0.000020188689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01619299,0.0017767302,0.94878584,0.000016288544,0.00042705785,0.0002923805,0.00008088876,0.0000075373455,0.0000041286876,0.000007627043,0.00083624385,0.03157226],"study_design_scores_gemma":[0.019425338,0.015942601,0.9554678,0.00017735867,0.0009433141,0.0005190366,0.000039158178,0.0000191615,0.00003459117,0.00009960343,0.007261955,0.00007007564],"about_ca_topic_score_codex":0.000022164197,"about_ca_topic_score_gemma":0.00015355712,"teacher_disagreement_score":0.031502184,"about_ca_system_score_codex":0.00012147388,"about_ca_system_score_gemma":0.0032915645,"threshold_uncertainty_score":0.5839094},"labels":[],"label_agreement":null},{"id":"W2589977168","doi":"10.1200/jco.2012.30.5_suppl.332","title":"Large retroperitoneal lymph nodes (RPLN) as a predictor for venous thromboembolism (VTE) in patients (pts) with germ cell tumor (GCT) receiving first-line chemotherapy (chemo).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Univariate analysis; Chemotherapy; Surgery; Oncology; Multivariate analysis","score_opus":0.03840937310965369,"score_gpt":0.3847834702101736,"score_spread":0.3463740971005199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589977168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598294,0.0011065624,0.000119651246,0.000911121,0.000790527,0.0005922638,0.00002673476,0.000017933711,0.00045223528],"genre_scores_gemma":[0.9925554,0.00031362972,0.0033757964,0.0020174324,0.0015436972,0.000022004602,0.000019181665,0.000059164297,0.00009371318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698025,0.00017005447,0.0015974413,0.00025135526,0.00043660874,0.0005642892],"domain_scores_gemma":[0.99619406,0.00095025165,0.0015453502,0.00024858446,0.00039573794,0.000665991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012205377,0.00025037013,0.0017107609,0.0001070534,0.00007139092,0.000012418677,0.00015590884,0.000288361,0.00012922382],"category_scores_gemma":[0.0021045997,0.00016352169,0.0004386483,0.00013449803,0.00011112887,0.00018508559,0.000042316955,0.00046311284,0.000018494735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008273339,0.02404958,0.95283633,0.00012904736,0.000410526,0.00023375567,0.00030785293,0.000005467461,0.000019140216,0.000014322529,0.000362315,0.013358303],"study_design_scores_gemma":[0.04239652,0.015020737,0.9338023,0.00030034545,0.0006599421,0.00015087456,0.000080686885,0.00008932361,0.00007360129,0.00007166274,0.0072008376,0.0001531911],"about_ca_topic_score_codex":0.000030284886,"about_ca_topic_score_gemma":0.00001576061,"teacher_disagreement_score":0.034123182,"about_ca_system_score_codex":0.000386135,"about_ca_system_score_gemma":0.0010762871,"threshold_uncertainty_score":0.6668221},"labels":[],"label_agreement":null},{"id":"W2589985730","doi":"10.1200/jco.2014.32.3_suppl.42","title":"Genomic determinants of prognosis in esophageal adenocarcinoma: Using computational methods to account for gene-gene interactions.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Genome-wide association study; Single-nucleotide polymorphism; Population; Survival analysis; Population stratification; Candidate gene; Medicine; SNP; Esophageal adenocarcinoma; Gene; Oncology; Computational biology; Biology; Genetics; Bioinformatics; Internal medicine; Adenocarcinoma; Cancer; Genotype","score_opus":0.2426813497708459,"score_gpt":0.5756671265876132,"score_spread":0.33298577681676733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589985730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806963,0.0008470991,0.016475698,0.0009386821,0.00051513547,0.00048420808,0.000009626524,0.000002647056,0.00003060319],"genre_scores_gemma":[0.6851449,0.000024203026,0.31394008,0.00036760204,0.00048037324,0.000014708222,0.0000021108203,0.000010990981,0.000015032307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688923,0.0005037827,0.0019275921,0.00018851289,0.0002556683,0.00023520601],"domain_scores_gemma":[0.99505436,0.003025538,0.0009388075,0.00010638862,0.00053821015,0.00033670565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003994159,0.000110257366,0.0011864502,0.00028882618,0.000031617532,0.0000066747143,0.00013622978,0.00013666089,0.000032256914],"category_scores_gemma":[0.002392268,0.000084370986,0.0003530676,0.00014275523,0.00008614894,0.00007808835,0.000057654663,0.00038439463,0.0000036528827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055254,0.0015387732,0.7922353,0.00007183807,0.00023856231,0.00027867875,0.00011138596,0.0012675282,0.0011102301,0.000023901492,0.00012048875,0.19747789],"study_design_scores_gemma":[0.0076273815,0.013730479,0.961186,0.00008330113,0.0002404493,0.0005720563,0.000029601004,0.009932281,0.005336438,0.00062647695,0.00056910014,0.00006644036],"about_ca_topic_score_codex":0.000046543333,"about_ca_topic_score_gemma":0.000049437716,"teacher_disagreement_score":0.2974644,"about_ca_system_score_codex":0.00041620567,"about_ca_system_score_gemma":0.0014400685,"threshold_uncertainty_score":0.34405488},"labels":[],"label_agreement":null},{"id":"W2589985846","doi":"10.1200/jco.2012.30.34_suppl.318","title":"Use of online resources by patients with cancer: The Canadian experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; The Internet; Logistic regression; Family medicine; Demographics; Descriptive statistics; Cancer; Disease; Interim; Demography; Internal medicine; World Wide Web","score_opus":0.2855716101014195,"score_gpt":0.5926232575112275,"score_spread":0.30705164740980795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589985846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904083,0.0001572622,0.000017708102,0.0064244997,0.0016629441,0.0002536495,0.00009023025,0.0000028846496,0.0009825125],"genre_scores_gemma":[0.9767546,0.00014098205,0.0009342526,0.021298304,0.0006504213,0.00000887293,0.000007803436,0.0000056442987,0.00019912033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939813,0.0014597229,0.0038008487,0.00006248055,0.00031498919,0.0003806471],"domain_scores_gemma":[0.9902967,0.0036795808,0.004083803,0.00018696317,0.0010651379,0.00068778836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051218485,0.00007590886,0.0005791894,0.00006406484,0.0003472268,0.0000055863234,0.0002570626,0.00030424967,0.0007440083],"category_scores_gemma":[0.004742508,0.000035850542,0.000084903266,0.00014609616,0.00023724255,0.0009498109,0.000036822737,0.0013600055,0.000009644728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004354213,0.00031370824,0.9310202,0.000022429826,0.000020033198,2.8665542e-7,0.0049934713,0.000002288042,1.8574379e-7,0.00003285468,0.0274186,0.03574049],"study_design_scores_gemma":[0.00060656044,0.00036777838,0.5070576,0.00004317437,0.000010261354,3.2335302e-7,0.00055702694,0.000015343083,4.6310498e-7,0.0000048883244,0.49131382,0.000022769458],"about_ca_topic_score_codex":0.036591183,"about_ca_topic_score_gemma":0.080949396,"teacher_disagreement_score":0.4638952,"about_ca_system_score_codex":0.00027043856,"about_ca_system_score_gemma":0.00374747,"threshold_uncertainty_score":0.96982425},"labels":[],"label_agreement":null},{"id":"W2589986680","doi":"10.1200/jco.2014.32.30_suppl.5","title":"The Choosing Wisely Canada cancer initiative.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Ontario Institute for Cancer Research; Canadian Medical Association; Canadian Association of Nurses in Oncology; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Best practice; General partnership; Harm; Population; Family medicine; Psychology; Environmental health; Management","score_opus":0.7173012975134447,"score_gpt":0.5937465477979921,"score_spread":0.12355474971545266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589986680","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36088043,0.00557066,0.0026696112,0.5921007,0.013897058,0.0002877284,0.000047431655,0.000010474538,0.024535954],"genre_scores_gemma":[0.9153935,0.001201019,0.001186574,0.07765251,0.0040989057,0.0000103178145,9.1685297e-7,0.000019233923,0.00043704952],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880389,0.0014276312,0.009894435,0.00019735553,0.00013606285,0.00030560835],"domain_scores_gemma":[0.96749973,0.019368524,0.012235814,0.00025036867,0.00030502857,0.00034055745],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05974402,0.000108403205,0.0016697538,0.000072274655,0.00021990707,0.0000359818,0.00041739517,0.00019635697,0.00018847904],"category_scores_gemma":[0.052158307,0.00008902132,0.0002252385,0.00009435331,0.00014800845,0.00022885855,0.000039576666,0.0006718551,0.000099272176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029202417,0.00024943726,0.22598949,0.000066668406,0.0004927605,0.000012155308,0.00049004727,0.0005250382,6.3912245e-7,0.0846046,0.6355333,0.051743872],"study_design_scores_gemma":[0.0011023547,0.00039041735,0.13750914,0.000033916287,0.000011991705,0.000009318888,0.0002410662,0.0010823306,0.0000010016935,0.012541251,0.8469803,0.00009691838],"about_ca_topic_score_codex":0.053022206,"about_ca_topic_score_gemma":0.27075937,"teacher_disagreement_score":0.55451304,"about_ca_system_score_codex":0.0008806125,"about_ca_system_score_gemma":0.0044330284,"threshold_uncertainty_score":0.9681914},"labels":[],"label_agreement":null},{"id":"W2589990295","doi":"10.1200/jco.2005.23.16_suppl.6076","title":"Economic evaluation of two adjuvant chemotherapy regimens in lung cancer: Vinorelbine and cisplatin versus paclitaxel and carboplatin","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Vinorelbine; Medicine; Regimen; Carboplatin; Chemotherapy; Oncology; Internal medicine; Indirect costs; Lung cancer; Chemotherapy regimen; Cost effectiveness; Surgery; Cisplatin","score_opus":0.1276439273426363,"score_gpt":0.4493628165912208,"score_spread":0.3217188892485845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589990295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738263,0.015013643,0.000038092643,0.003961413,0.00092907605,0.00016836317,0.00002971212,0.0000021518242,0.0060312822],"genre_scores_gemma":[0.98790514,0.009763489,0.001167763,0.00036685137,0.00072776305,0.000005613192,9.0802814e-7,0.00001419048,0.000048270223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681324,0.000087641376,0.0026183664,0.00023322595,0.000050956987,0.00019656892],"domain_scores_gemma":[0.99611676,0.000689285,0.00281296,0.00013383642,0.00009761669,0.00014957164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057150377,0.00012895469,0.0013397741,0.0001959752,0.000022415092,0.000012694083,0.00011853969,0.00022903444,0.00025381922],"category_scores_gemma":[0.00081275014,0.00013146717,0.00013680587,0.000054478878,0.00016669979,0.00031971073,0.000033751363,0.00036785443,0.000005057033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016799407,0.0002278064,0.60757864,0.000022278624,0.0002312088,0.000004140426,0.00049383234,0.0023913921,0.000019159725,0.010426127,0.0011322577,0.37579325],"study_design_scores_gemma":[0.032083467,0.0021249163,0.9005342,0.0000714789,0.00011264205,0.000014233129,0.00006855757,0.039718017,0.000045835885,0.008306995,0.016667133,0.0002524843],"about_ca_topic_score_codex":0.00051475724,"about_ca_topic_score_gemma":0.0016985056,"teacher_disagreement_score":0.37554076,"about_ca_system_score_codex":0.0005103947,"about_ca_system_score_gemma":0.00053613656,"threshold_uncertainty_score":0.53610754},"labels":[],"label_agreement":null},{"id":"W2590000420","doi":"10.1200/jco.2016.34.4_suppl.211","title":"The prognostic value of stroma desmoplasia in pancreatic ductal adenocarcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Stroma; Medicine; Desmoplasia; Pathology; Gemcitabine; Oncology; Perineural invasion; Pancreatic cancer; Internal medicine; Immunohistochemistry; Chemotherapy; Cancer","score_opus":0.12028817457649814,"score_gpt":0.475293011257086,"score_spread":0.35500483668058785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590000420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842193,0.0013253392,0.00013276753,0.010886261,0.00043689902,0.00031393702,0.0000019029145,0.0000039753845,0.0026795778],"genre_scores_gemma":[0.99459606,0.0017936783,0.0022294237,0.0002001097,0.00052479433,0.000008902966,3.2860945e-7,0.000012825181,0.0006338679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511474,0.001105176,0.0027570648,0.00016300121,0.00048521065,0.0003748279],"domain_scores_gemma":[0.979156,0.018472504,0.0013405489,0.00026389826,0.00043683464,0.0003302209],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006770827,0.00012232135,0.0017488472,0.0001429516,0.0000445419,0.0000039789506,0.00028497982,0.00036356942,0.00011206772],"category_scores_gemma":[0.023315547,0.000054179338,0.00035078128,0.0001779255,0.0009221608,0.00007603718,0.00007179241,0.0007782599,0.000027182883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040065646,0.00088684715,0.97839653,0.000028493607,0.00039470202,0.0010558832,0.00006006731,4.1351043e-7,0.00053821463,0.0011290546,0.0008460244,0.012657198],"study_design_scores_gemma":[0.008156514,0.014153374,0.97162634,0.00029943133,0.00049121014,0.0012277015,0.0001538583,0.000062961924,0.00003984468,0.0018285583,0.0019068666,0.00005334827],"about_ca_topic_score_codex":0.000021707574,"about_ca_topic_score_gemma":0.000044232434,"teacher_disagreement_score":0.01736733,"about_ca_system_score_codex":0.0001823824,"about_ca_system_score_gemma":0.0034327405,"threshold_uncertainty_score":0.9849115},"labels":[],"label_agreement":null},{"id":"W2590001458","doi":"10.1200/jco.2014.32.30_suppl.240","title":"Improving the patient experience for cancer patients in Ontario through real-time measurement.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Patient experience; Cancer; Government (linguistics); Focus group; Data collection; Patient satisfaction; Agency (philosophy); Health care; Family medicine; Ambulatory; Nursing; Surgery; Internal medicine","score_opus":0.419305167876886,"score_gpt":0.5547413359843477,"score_spread":0.13543616810746173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590001458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743474,0.000026359237,0.0011557869,0.0080667855,0.0018344816,0.0006304673,0.0000016758698,0.000005276061,0.00084443507],"genre_scores_gemma":[0.9816419,0.00011684549,0.009890297,0.0074935737,0.00073483854,0.00004014716,0.0000032136022,0.000016442837,0.00006277679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99392635,0.0005565971,0.004380691,0.00021253072,0.000672527,0.00025128378],"domain_scores_gemma":[0.9883677,0.0063549415,0.0034139962,0.00021656045,0.0014822104,0.00016460287],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008309359,0.00012212605,0.00091394945,0.000044581917,0.000055722732,0.000011267849,0.00017813452,0.0001989392,0.00020571418],"category_scores_gemma":[0.044902194,0.000074154996,0.00032479197,0.000087425906,0.00012039401,0.00025635565,0.000061945306,0.00081416307,0.0000074371906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060476945,0.0023877379,0.51081014,0.000021384205,0.00014003763,0.00001256933,0.001932615,0.000044486394,0.0006981204,0.00004784909,0.007661189,0.47019616],"study_design_scores_gemma":[0.014636793,0.017876947,0.74349284,0.00013186174,0.00037472948,0.000016187403,0.00047168275,0.0007271926,0.00014808863,0.00054640864,0.22144485,0.00013243864],"about_ca_topic_score_codex":0.02531905,"about_ca_topic_score_gemma":0.07175008,"teacher_disagreement_score":0.47006372,"about_ca_system_score_codex":0.00080147514,"about_ca_system_score_gemma":0.0025170106,"threshold_uncertainty_score":0.9811714},"labels":[],"label_agreement":null},{"id":"W2590001533","doi":"10.1200/jco.2016.34.3_suppl.20","title":"Impact of health care costs on utilization of needed health care in the Childhood Cancer Survivor Study (CCSS).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Health care; Medical Expenditure Panel Survey; Medical prescription; Logistic regression; Poisson regression; Odds ratio; Odds; Family medicine; Stratified sampling; Demography; Environmental health; Health insurance; Population; Nursing","score_opus":0.19426855074815585,"score_gpt":0.5691509392010622,"score_spread":0.37488238845290633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590001533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519295,0.008094742,0.000026158643,0.03761177,0.0009318161,0.0010914733,0.0000680409,0.0000070016404,0.00023949605],"genre_scores_gemma":[0.987602,0.0026806488,0.00007568284,0.00889012,0.00070356834,0.000008177463,0.000006013857,0.000025391852,0.00000837587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98894006,0.0045597316,0.0048712385,0.00027711288,0.0009845532,0.000367306],"domain_scores_gemma":[0.9894742,0.003639113,0.0052141612,0.00047960423,0.0008588514,0.00033409087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0087365545,0.00021784347,0.0028241475,0.0002717106,0.0000540323,0.000004301001,0.00036098386,0.00024076209,0.00008659169],"category_scores_gemma":[0.0037398124,0.000112352915,0.0006462614,0.0004002468,0.0001849261,0.00009937995,0.000047908045,0.0008164195,0.0000021418336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00542723,0.006745216,0.6503929,0.0001908243,0.00048248257,0.000022963348,0.039222006,0.000027003298,0.00000628051,0.000026122103,0.006141918,0.29131505],"study_design_scores_gemma":[0.0139429495,0.07142168,0.8857217,0.0008920037,0.000092109054,0.000021492515,0.02580937,9.65766e-7,0.000012965919,0.0000103775865,0.0019908056,0.00008361149],"about_ca_topic_score_codex":0.009906564,"about_ca_topic_score_gemma":0.021025449,"teacher_disagreement_score":0.29123142,"about_ca_system_score_codex":0.001424023,"about_ca_system_score_gemma":0.011013656,"threshold_uncertainty_score":0.9968383},"labels":[],"label_agreement":null},{"id":"W2590003096","doi":"10.1200/jco.2014.32.30_suppl.90","title":"Understanding the interaction between physicians and pharmacists as a method of quality improvement.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Medical prescription; Pharmacy; Audit; Pharmacist; Family medicine; Callback; Electronic prescribing; Medical emergency; Nursing","score_opus":0.674384855001879,"score_gpt":0.6579374901300125,"score_spread":0.016447364871866488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590003096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9156137,0.0000505288,0.051605094,0.02224072,0.0011362582,0.00019258558,0.000002338647,0.0000048987035,0.009153879],"genre_scores_gemma":[0.9909347,0.00018476738,0.0021711288,0.005882524,0.0007479512,5.9913117e-7,5.6043103e-7,0.0000057423986,0.000072016934],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99693036,0.0010875384,0.0015076513,0.000095943775,0.00026723035,0.00011125791],"domain_scores_gemma":[0.983364,0.014100674,0.0021466704,0.00009570334,0.00013937648,0.00015360389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076402244,0.00007315675,0.0008466295,0.00004308256,0.00003845225,0.0000066042417,0.00008264155,0.00010503106,0.000053823987],"category_scores_gemma":[0.0045587006,0.00004165537,0.00025559647,0.0000640526,0.00014663131,0.00014064954,0.000042839856,0.0008605963,0.000002727429],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004303585,0.00075128354,0.16222239,0.00010832924,0.0008560233,0.000014906917,0.00038324695,0.0000062155677,0.0036934717,0.0018486944,0.00060940057,0.82520247],"study_design_scores_gemma":[0.055992343,0.07195497,0.44330394,0.0005512338,0.0089783035,0.00079390424,0.006222251,0.008654024,0.009592566,0.06303411,0.3303613,0.00056104636],"about_ca_topic_score_codex":0.00001013085,"about_ca_topic_score_gemma":0.0000015352962,"teacher_disagreement_score":0.8246414,"about_ca_system_score_codex":0.00006959178,"about_ca_system_score_gemma":0.00013182385,"threshold_uncertainty_score":0.545752},"labels":[],"label_agreement":null},{"id":"W2590003273","doi":"10.1200/jco.2014.32.3_suppl.543","title":"A comparison of biologics in first-line advanced colorectal cancer: A Bayesian network meta-analysis of EGFR inhibitors and bevacizumab.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Meta-analysis; Oncology; Hazard ratio; Randomized controlled trial; Colorectal cancer; Chemotherapy; Cancer; Confidence interval","score_opus":0.18706401304630532,"score_gpt":0.49892306327876534,"score_spread":0.31185905023246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590003273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98476493,0.010656491,0.00011611502,0.0033535133,0.00035806396,0.00021631752,0.000013084799,0.000003527784,0.00051797595],"genre_scores_gemma":[0.9944679,0.002963053,0.0020386246,0.00024846572,0.00023901192,0.000013278553,0.000002923356,0.000007507376,0.000019224524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959348,0.00039367058,0.0030020096,0.0002107842,0.0002504667,0.00020828785],"domain_scores_gemma":[0.9934085,0.003241317,0.002677656,0.00012255592,0.00038374445,0.00016621512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002103059,0.0001713511,0.005940883,0.00023643475,0.00003381709,0.0000022747176,0.000097686134,0.00026461278,0.00008886638],"category_scores_gemma":[0.0017188817,0.00010340088,0.0012660015,0.0006024257,0.00034005716,0.00004084607,0.000072969924,0.00045978563,1.8187856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00843174,0.0016002939,0.859776,0.000046399473,0.053250805,0.000029714658,0.0003512813,0.0042187283,0.000049381757,0.00006172076,0.00027130172,0.07191261],"study_design_scores_gemma":[0.008800834,0.03994284,0.81457454,0.000067781635,0.123583995,0.000015915612,0.00028659275,0.0039992617,0.00020101202,0.00034062177,0.008037988,0.00014860598],"about_ca_topic_score_codex":0.00018172793,"about_ca_topic_score_gemma":0.007237398,"teacher_disagreement_score":0.071764,"about_ca_system_score_codex":0.00012620736,"about_ca_system_score_gemma":0.00029630985,"threshold_uncertainty_score":0.42165655},"labels":[],"label_agreement":null},{"id":"W2590006625","doi":"10.1200/jco.2012.30.34_suppl.246","title":"Using quality indicators to monitor changes in adherence to clinical practice guidelines for treatment of ductal carcinoma in situ (DCIS) of the breast.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lumpectomy; Ductal carcinoma; Sentinel lymph node; Breast cancer; Referral; Population; Sentinel node; Mastectomy; Radiation therapy; Cohort; Medical physics; Cancer; General surgery; Surgery; Internal medicine; Family medicine","score_opus":0.38204194447482753,"score_gpt":0.5899671167116705,"score_spread":0.20792517223684293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590006625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898113,0.0009477427,0.000066489854,0.0074866693,0.0012279744,0.0003739282,0.00003438203,7.76106e-7,0.000050722774],"genre_scores_gemma":[0.98239815,0.00030808186,0.014748298,0.0009170247,0.0015872447,0.000020389674,0.0000014243352,0.000010953273,0.000008439562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613947,0.000697409,0.0025003068,0.00020880355,0.00020137,0.00025265303],"domain_scores_gemma":[0.9957277,0.0012537338,0.0018439434,0.0002484733,0.0007332828,0.00019283373],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034655135,0.00014794996,0.0010749125,0.00010016044,0.000021147247,0.000002199251,0.00023418489,0.00028600692,0.0000032274083],"category_scores_gemma":[0.009922247,0.00009508017,0.00034467745,0.00019946978,0.00014690145,0.000012025919,0.00014023604,0.00012527482,5.6835216e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049712188,0.0027910916,0.91998726,0.000015080891,0.0002236946,0.000007256704,0.00032684722,0.00004045038,0.0051473244,0.0000121700305,0.0003187378,0.06615885],"study_design_scores_gemma":[0.0036902523,0.007329538,0.97401506,0.000052266336,0.00015861125,0.00009194343,0.0008621414,0.0000022660272,0.007977033,0.000013965048,0.0057107764,0.00009613018],"about_ca_topic_score_codex":0.00031547976,"about_ca_topic_score_gemma":0.001201991,"teacher_disagreement_score":0.06606272,"about_ca_system_score_codex":0.00011581457,"about_ca_system_score_gemma":0.0005735242,"threshold_uncertainty_score":0.9984176},"labels":[],"label_agreement":null},{"id":"W2590008492","doi":"10.1200/jco.2016.34.2_suppl.79","title":"Predictive parameters of symptomatic haematochezia following 5-fraction gantry-based SABR in prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; SABR volatility model; Prostate cancer; Prostate; Nuclear medicine; Radiation therapy; Univariate analysis; Prospective cohort study; Internal medicine; Urology; Multivariate analysis; Surgery; Cancer","score_opus":0.07463536626681674,"score_gpt":0.44933684485289793,"score_spread":0.37470147858608116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590008492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98877543,0.0006754532,0.00029041848,0.008748385,0.0008933155,0.00044093517,0.000011619684,0.000007267179,0.00015717777],"genre_scores_gemma":[0.99524844,0.001431877,0.00240492,0.00068398425,0.00014421748,0.000047001486,0.0000011782198,0.000014390357,0.000023976216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969038,0.0002788058,0.0021134734,0.0001717448,0.00032088722,0.00021129935],"domain_scores_gemma":[0.9946629,0.002827888,0.0019010995,0.00015004455,0.00023314642,0.0002249489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016421499,0.00012811477,0.0014806229,0.00015357471,0.000015194877,0.000003392049,0.00007840294,0.00017541197,0.000044535405],"category_scores_gemma":[0.002111542,0.00007179663,0.0004823367,0.00014535067,0.00013971949,0.00013928166,0.00001618184,0.0003235129,0.000004138522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048291264,0.0018389797,0.8643671,0.00009614608,0.000625532,0.00077258406,0.00009848133,0.00008521545,0.00065216783,0.000008924053,0.0005250462,0.12610064],"study_design_scores_gemma":[0.031006347,0.022811566,0.9303556,0.0045135557,0.0010442813,0.00008631286,0.00016529099,0.00035372257,0.0075923903,0.0007326795,0.0012033562,0.00013490728],"about_ca_topic_score_codex":0.000056009776,"about_ca_topic_score_gemma":0.000039329138,"teacher_disagreement_score":0.12596574,"about_ca_system_score_codex":0.0006293219,"about_ca_system_score_gemma":0.0019230321,"threshold_uncertainty_score":0.34113765},"labels":[],"label_agreement":null},{"id":"W2590020101","doi":"10.1200/jco.2015.33.29_suppl.183","title":"Survival among cancer patients undergoing opioid rotation to methadone as compared to other opioids.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Methadone; Opioid; Cancer pain; Anesthesia; Cancer; Internal medicine; Morphine; Methadone maintenance","score_opus":0.16471991102100983,"score_gpt":0.4782319792829399,"score_spread":0.3135120682619301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590020101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798588,0.000072445546,0.0014425156,0.0069652153,0.0032097588,0.00047498624,0.0000021433755,0.00001569648,0.007958439],"genre_scores_gemma":[0.97862333,0.000074862524,0.006414547,0.011713776,0.0016172929,0.000012011509,0.00000366875,0.000026544878,0.0015139687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968076,0.00045786877,0.0016236468,0.00020912431,0.0006293584,0.00027244329],"domain_scores_gemma":[0.99599034,0.0011728837,0.0008652123,0.0001751842,0.00079263194,0.0010037685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036362137,0.00014436562,0.0011080964,0.0002279654,0.00003225572,0.000017690383,0.0002137646,0.00019057048,0.0001823508],"category_scores_gemma":[0.0076192357,0.000111481386,0.0002276425,0.00026732066,0.000059360467,0.00013304515,0.00009928437,0.0004601314,0.0001466838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032970551,0.00091971917,0.93186224,0.000023660823,0.0002915283,0.000064609245,0.00065891905,0.00046033633,0.000026737744,0.00008631814,0.03279748,0.02951143],"study_design_scores_gemma":[0.008533289,0.007106987,0.8609957,0.00013767858,0.0002317235,0.0000012367931,0.00047456956,0.0001389524,0.00003865871,0.00031431045,0.12190239,0.0001244631],"about_ca_topic_score_codex":0.00025658106,"about_ca_topic_score_gemma":0.000677891,"teacher_disagreement_score":0.08910491,"about_ca_system_score_codex":0.00032436612,"about_ca_system_score_gemma":0.0010699132,"threshold_uncertainty_score":0.9121487},"labels":[],"label_agreement":null},{"id":"W2590021364","doi":"10.1200/jco.2012.30.5_suppl.66","title":"The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-cre PTEN knockout mice.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"PTEN; Endocrinology; Prostate; Cancer research; Growth factor; Internal medicine; Prostate cancer; Dysplasia; Insulin-like growth factor; Medicine; Biology; PI3K/AKT/mTOR pathway; Signal transduction; Cancer; Receptor; Cell biology","score_opus":0.08181889710047036,"score_gpt":0.4420071836591098,"score_spread":0.36018828655863944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590021364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883267,0.0038713145,0.0000039936076,0.005204581,0.00055765733,0.0004307461,0.00000816419,0.00000601921,0.0015907878],"genre_scores_gemma":[0.9916307,0.0068089752,0.00032065788,0.0006174556,0.00034834092,0.000011106977,0.0000019353356,0.000018081051,0.0002427989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959926,0.0005495604,0.0020900047,0.0001778282,0.00064656243,0.0005434262],"domain_scores_gemma":[0.99332494,0.0041500805,0.0012161859,0.00020030132,0.0006552459,0.00045324926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032392214,0.00017869943,0.0010705226,0.00019909833,0.00007556261,0.000009581056,0.0003159473,0.00030381334,0.000020472824],"category_scores_gemma":[0.0049252254,0.00009334737,0.00029484776,0.00031443394,0.0006080061,0.00017498317,0.00007345472,0.0013536421,0.000032894968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028069448,0.00749916,0.9162357,0.0002532334,0.0005012941,0.00058675464,0.0023323237,0.000021877946,0.004859747,0.0016629887,0.002584494,0.03539297],"study_design_scores_gemma":[0.009225904,0.013760467,0.97200626,0.00019833459,0.00014318383,0.00013998998,0.00045159555,0.000022593358,0.0006014396,0.00092151196,0.002419289,0.000109459404],"about_ca_topic_score_codex":0.000042855267,"about_ca_topic_score_gemma":0.000017703489,"teacher_disagreement_score":0.05577052,"about_ca_system_score_codex":0.00030307414,"about_ca_system_score_gemma":0.0015768759,"threshold_uncertainty_score":0.589631},"labels":[],"label_agreement":null},{"id":"W2590024561","doi":"10.1200/jco.2014.32.4_suppl.351","title":"Evaluation of the neutrophil-lymphocyte ratio (NLR) during neoadjuvant chemotherapy (NC) for muscle-invasive bladder cancer (MIBC) and correlation with pathologic response to treatment.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Neutrophil to lymphocyte ratio; Internal medicine; Gastroenterology; Univariate analysis; Receiver operating characteristic; Cystectomy; Pathological; Logistic regression; Urology; Stage (stratigraphy); Oncology; Cancer; Multivariate analysis; Lymphocyte","score_opus":0.09948004143879045,"score_gpt":0.43744735700544785,"score_spread":0.3379673155666574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590024561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898989,0.00042651815,0.00049823767,0.00753278,0.000493642,0.0009780674,0.000009626293,0.000004945102,0.00015728358],"genre_scores_gemma":[0.99634165,0.0005234609,0.0009008736,0.0014005621,0.00056829484,0.00006629284,0.0000011729645,0.000019119081,0.00017855594],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974332,0.00087830715,0.000923688,0.00019855113,0.0004136241,0.00015264208],"domain_scores_gemma":[0.99642086,0.001346938,0.0010319903,0.00017586668,0.000863763,0.00016060648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028195942,0.00014553174,0.0007847522,0.00007625321,0.00007398756,0.000006399331,0.00006910979,0.00018253163,0.000043634245],"category_scores_gemma":[0.0017434219,0.00007527725,0.00021756651,0.0001041036,0.00012624438,0.00006708485,0.000014728212,0.0001607201,0.0000011088495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09744069,0.0017472265,0.079253435,0.000046946887,0.0012606913,0.00005232113,0.0017681327,0.0029938996,0.023833146,0.000023653913,0.00021742503,0.7913624],"study_design_scores_gemma":[0.045029655,0.032677058,0.9109427,0.00014254985,0.0021469023,0.00017395793,0.00011145362,0.0010294854,0.004302562,0.00019988076,0.0031514482,0.00009239985],"about_ca_topic_score_codex":0.00003658801,"about_ca_topic_score_gemma":0.00013749658,"teacher_disagreement_score":0.83168924,"about_ca_system_score_codex":0.00049441244,"about_ca_system_score_gemma":0.002477861,"threshold_uncertainty_score":0.43956193},"labels":[],"label_agreement":null},{"id":"W2590029130","doi":"10.1200/jco.2016.34.2_suppl.544","title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Regional Cancer Foundation; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Renal cell carcinoma; Hazard ratio; Internal medicine; Oncology; Population; Urology; Overall survival; Gastroenterology; Confidence interval","score_opus":0.18944983327741965,"score_gpt":0.40771099974216746,"score_spread":0.2182611664647478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590029130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656481,0.0009193367,0.00029744612,0.024645723,0.0027272499,0.0006189961,0.0006819835,0.000016314352,0.0044448497],"genre_scores_gemma":[0.98770934,0.00058325706,0.0068901177,0.00166116,0.0018212685,0.000023534074,0.00017883895,0.00006139076,0.0010710929],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9899047,0.0017211868,0.005559574,0.00075876457,0.0013524404,0.0007033458],"domain_scores_gemma":[0.9686227,0.025120562,0.003644647,0.0009558537,0.0008300079,0.0008262439],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0061924057,0.0005280671,0.0022924608,0.00035170664,0.00010371191,0.000039879236,0.0009400246,0.00028036447,0.0008626148],"category_scores_gemma":[0.008483659,0.00028582677,0.00093714916,0.0003199888,0.0005954703,0.00032825125,0.00033215882,0.001660785,0.00016274226],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39650297,0.026112214,0.23252703,0.0003204542,0.004523762,0.10643244,0.002431018,0.0005148641,0.036575515,0.00039215657,0.12311927,0.07054829],"study_design_scores_gemma":[0.246823,0.042200062,0.55828166,0.0007478265,0.0061426503,0.0015750256,0.0011676698,0.00081740355,0.03163163,0.0009952015,0.10864657,0.0009713189],"about_ca_topic_score_codex":0.0008347789,"about_ca_topic_score_gemma":0.0014376306,"teacher_disagreement_score":0.3257546,"about_ca_system_score_codex":0.0007985365,"about_ca_system_score_gemma":0.003063268,"threshold_uncertainty_score":0.9999594},"labels":[],"label_agreement":null},{"id":"W2590030891","doi":"10.1200/jco.2015.33.29_suppl.182","title":"The Opioid Rotation Ratio (ORR) from transdermal fentanyl (TDF) to strong opioids in cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fentanyl; Opioid; Cancer pain; Cancer; Transdermal; Morphine; Anesthesia; Internal medicine; Pharmacology","score_opus":0.17791441831879826,"score_gpt":0.5153400393633385,"score_spread":0.3374256210445402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590030891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778073,0.0008035483,0.000109512825,0.01587376,0.003931059,0.00037622458,0.0000119514425,0.00000489277,0.0010817533],"genre_scores_gemma":[0.9930909,0.00060456706,0.00044635803,0.0035884487,0.0018826209,0.0000279422,0.00001146774,0.000011947517,0.0003357318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974122,0.0003628953,0.0015400819,0.00014987164,0.00030807004,0.00022685555],"domain_scores_gemma":[0.99728054,0.0012076214,0.0006033452,0.0000972266,0.00037396012,0.00043729323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012103297,0.00011396017,0.00074712245,0.00007751884,0.00003954767,0.000011016198,0.00014226353,0.00019668821,0.00015625726],"category_scores_gemma":[0.00065662706,0.00007152467,0.00020052951,0.00013170883,0.00009164939,0.00010943643,0.000023293525,0.00062464323,0.000019171675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0146845905,0.0032214688,0.6401669,0.0000069347957,0.00037813178,0.00016848146,0.001543303,0.0002779568,0.00027771696,0.000055842927,0.033883497,0.30533522],"study_design_scores_gemma":[0.025989763,0.016868796,0.72614926,0.000055435412,0.00040027857,0.000011371205,0.00042967507,0.00025711948,0.00026282037,0.00025815782,0.22921626,0.00010104654],"about_ca_topic_score_codex":0.00034857716,"about_ca_topic_score_gemma":0.0016208845,"teacher_disagreement_score":0.30523416,"about_ca_system_score_codex":0.0005122432,"about_ca_system_score_gemma":0.0023144195,"threshold_uncertainty_score":0.4105681},"labels":[],"label_agreement":null},{"id":"W2590031993","doi":"10.1200/jco.2013.31.31_suppl.73","title":"Quality assurance governance and implementation in cancer pathology: A national survey of Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; London Health Sciences Centre; Trillium Health Centre; Hôtel-Dieu de Québec; Saskatchewan Health Authority; Canadian Partnership Against Cancer","funders":"","keywords":"Accreditation; Quality assurance; Medicine; Corporate governance; Quality (philosophy); Medical education; Pathology; External quality assessment; Business","score_opus":0.18160156780954165,"score_gpt":0.4579743952731692,"score_spread":0.27637282746362757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590031993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879446,0.002319448,0.0000845211,0.0042079906,0.00086684275,0.00010519986,0.00023560703,8.698021e-7,0.004234939],"genre_scores_gemma":[0.9952304,0.0027839039,0.00044599405,0.0012890474,0.0001509509,0.0000075257794,0.0000018364908,0.000006084041,0.00008429261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964648,0.00014287268,0.002988052,0.00015858436,0.00006601553,0.00017966582],"domain_scores_gemma":[0.99425936,0.0012666456,0.0039147544,0.00007353563,0.000377419,0.00010827443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00596091,0.00007983288,0.0010572666,0.000058424674,0.00001856741,0.0000082757615,0.00014811794,0.00015439349,0.00037031568],"category_scores_gemma":[0.0044520916,0.00008009962,0.000074577765,0.000104197476,0.00010226079,0.00031828962,0.000028288969,0.000295033,0.0000040763966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010130152,0.0000949672,0.9569628,0.000011437134,0.000037095193,0.0000036513272,0.00004534823,0.000045959056,0.0000049046457,0.008879893,0.008797947,0.025014672],"study_design_scores_gemma":[0.0017176433,0.00027419112,0.9776033,0.000010966201,0.0000020874136,0.000004257881,0.000024256984,0.000062629406,0.0000062127497,0.011305469,0.008908267,0.00008071536],"about_ca_topic_score_codex":0.46692798,"about_ca_topic_score_gemma":0.7966763,"teacher_disagreement_score":0.32974833,"about_ca_system_score_codex":0.00038622555,"about_ca_system_score_gemma":0.002534365,"threshold_uncertainty_score":0.5366218},"labels":[],"label_agreement":null},{"id":"W2590033156","doi":"10.1200/jco.2016.34.4_suppl.511","title":"Objective sleep duration (SD) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Hazard ratio; Colorectal cancer; Proportional hazards model; FOLFOX; Chemotherapy; Population; Cancer; Oncology; Gastroenterology; Surgery; Confidence interval","score_opus":0.05263798441090075,"score_gpt":0.4116451530406331,"score_spread":0.35900716862973236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590033156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918916,0.0001653673,0.00013179361,0.0055260262,0.00091741234,0.00038142563,0.000011174955,0.0000062203244,0.0009689359],"genre_scores_gemma":[0.9976317,0.00084977044,0.0002963633,0.0007070976,0.00036110432,0.000015766358,0.0000011521546,0.0000150511605,0.00012195299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973637,0.00043772743,0.0013893064,0.0002071913,0.00037582061,0.00022629654],"domain_scores_gemma":[0.9954563,0.0023583402,0.0012116554,0.000060881528,0.00071497064,0.00019788917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013253894,0.00014982691,0.0011727262,0.00014516935,0.000035198842,0.000005268532,0.000050729435,0.0001454265,0.0001275301],"category_scores_gemma":[0.0029402822,0.00008090374,0.00012851936,0.0001250069,0.000301084,0.00019710514,0.000041623647,0.0005073887,0.000006265206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020113809,0.0011795524,0.86368936,0.000016544991,0.00084339955,0.00014404356,0.00023049707,0.0000048665443,0.00009113437,0.000026963517,0.0004973175,0.113162525],"study_design_scores_gemma":[0.03308018,0.021396337,0.9429972,0.00028402242,0.0004905202,0.00004725103,0.00013003573,0.000021667867,0.000097101256,0.00019338199,0.0011604623,0.00010181733],"about_ca_topic_score_codex":0.00006670414,"about_ca_topic_score_gemma":0.00094889523,"teacher_disagreement_score":0.113060705,"about_ca_system_score_codex":0.00044783016,"about_ca_system_score_gemma":0.00073648087,"threshold_uncertainty_score":0.35200047},"labels":[],"label_agreement":null},{"id":"W2590038753","doi":"10.1200/jco.2016.34.2_suppl.191","title":"Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Bone metastasis; Proportional hazards model; Metastasis; Oncology; Clinical endpoint; Internal medicine; Cancer; Radiology; Urology; Clinical trial","score_opus":0.18147378967777789,"score_gpt":0.5010028006530577,"score_spread":0.3195290109752798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590038753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98755723,0.00062563707,0.00029089153,0.010548979,0.00026906215,0.0005602571,0.000049643935,0.0000061411215,0.00009213527],"genre_scores_gemma":[0.98509675,0.001873306,0.012284413,0.0004164404,0.0001278255,0.000030573854,0.0000073680817,0.000016300812,0.00014702327],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99622416,0.00057487295,0.0021763786,0.00027010817,0.00047094177,0.00028355457],"domain_scores_gemma":[0.9967632,0.0010922775,0.0009190335,0.00016501339,0.0005608404,0.00049959496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035363247,0.00017153377,0.001549394,0.0005469822,0.000035716595,0.000020676458,0.00009502258,0.000086186024,0.00012879382],"category_scores_gemma":[0.0010258529,0.000095437674,0.00024472334,0.00037063257,0.00026537888,0.0002812404,0.00004860852,0.0003903084,0.000002109429],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039515506,0.0031358958,0.05696728,0.00019241024,0.0010440339,0.0027386055,0.0010016329,0.000009151781,0.26088545,0.00042052474,0.00066305033,0.6334264],"study_design_scores_gemma":[0.037456542,0.041149583,0.8804381,0.0014729754,0.00095558626,0.0005897608,0.0011607859,0.00011975105,0.027686292,0.0019376588,0.0067227613,0.0003102064],"about_ca_topic_score_codex":0.00031868787,"about_ca_topic_score_gemma":0.0009788993,"teacher_disagreement_score":0.82347083,"about_ca_system_score_codex":0.00025991525,"about_ca_system_score_gemma":0.0015803309,"threshold_uncertainty_score":0.38918352},"labels":[],"label_agreement":null},{"id":"W2590040832","doi":"10.1200/jco.2016.34.7_suppl.50","title":"Lung cancer diagnosis transformation: Aligning the people, processes, and technology sides of the learning system.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Referral; Population; Workflow; Lung cancer; Cancer; Cancer registry; Operations management; Family medicine; Internal medicine","score_opus":0.18483421971976224,"score_gpt":0.539496675519561,"score_spread":0.3546624557997988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590040832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7572978,0.0014606192,0.0012927534,0.23860773,0.00067653146,0.00034350867,0.0000035529408,0.000012491461,0.0003050201],"genre_scores_gemma":[0.99433565,0.0037499722,0.00039438196,0.00090004626,0.00053108926,0.00003294746,2.974941e-7,0.000010242543,0.000045390447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957215,0.0005456598,0.0031339475,0.00011698154,0.00033495296,0.00014692174],"domain_scores_gemma":[0.9807163,0.014717718,0.0032036246,0.0001470273,0.0011239555,0.00009137892],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054094503,0.00009190315,0.00078891247,0.00008258469,0.000096853524,0.0000067516967,0.00018454998,0.00024506173,0.00006461926],"category_scores_gemma":[0.04076131,0.000037036047,0.00016743169,0.0003627262,0.00029835541,0.0002110219,0.00006011106,0.0007005581,0.0000012936208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005692213,0.00016931673,0.76787674,0.0002896159,0.00029093554,0.000011437494,0.0003509465,0.00001699211,0.00026821188,0.0003953738,0.00200246,0.22775877],"study_design_scores_gemma":[0.027582586,0.011704166,0.70462507,0.005875294,0.0060138926,0.002340831,0.017647315,0.0010850474,0.003720641,0.001030738,0.2180225,0.00035194893],"about_ca_topic_score_codex":0.00006347897,"about_ca_topic_score_gemma":0.0003819934,"teacher_disagreement_score":0.23770769,"about_ca_system_score_codex":0.000106883825,"about_ca_system_score_gemma":0.0017026647,"threshold_uncertainty_score":0.9673188},"labels":[],"label_agreement":null},{"id":"W2590044882","doi":"10.1200/jco.2014.32.3_suppl.365","title":"Resection of isolated metastases to the pancreas: An institutional retrospective review.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pancreas; Pancreatectomy; Pancreatic cancer; Retrospective cohort study; Clinical endpoint; Surgery; Presentation (obstetrics); Resection; Cancer; General surgery; Internal medicine; Randomized controlled trial","score_opus":0.16015910806928194,"score_gpt":0.5305799242385605,"score_spread":0.3704208161692786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590044882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553566,0.0020196042,0.0041659363,0.02721968,0.0008045393,0.0005249155,0.000008036946,0.000008169657,0.009892545],"genre_scores_gemma":[0.98380655,0.004666048,0.004346905,0.0055528474,0.001364529,0.000007963028,0.000004411004,0.000007962081,0.00024276818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954325,0.0017528028,0.0019455301,0.0001586439,0.0005267231,0.00018378603],"domain_scores_gemma":[0.99433887,0.0023748444,0.0011590539,0.00029719758,0.0014358107,0.0003942251],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013830729,0.00009374996,0.0017272948,0.00012350483,0.00007573335,0.0000033807,0.00021690232,0.00021874016,0.00027832398],"category_scores_gemma":[0.030746372,0.000050402185,0.00032295636,0.00030138553,0.00037096484,0.00009942154,0.00005131888,0.0009423526,0.00003060107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027577586,0.0055428925,0.7226331,0.00045556267,0.0023613642,0.0002879044,0.00026316682,0.000036435613,0.0011787065,0.0073764306,0.07987766,0.15240914],"study_design_scores_gemma":[0.0042274287,0.064255536,0.75914085,0.00078069017,0.0012275262,0.0008937765,0.000074058175,0.00053968997,0.000050053288,0.0010192973,0.16771638,0.00007468338],"about_ca_topic_score_codex":0.000060071467,"about_ca_topic_score_gemma":0.0000950426,"teacher_disagreement_score":0.15233447,"about_ca_system_score_codex":0.00015332668,"about_ca_system_score_gemma":0.0017837099,"threshold_uncertainty_score":0.97741807},"labels":[],"label_agreement":null},{"id":"W2590047023","doi":"10.1200/jco.2015.33.28_suppl.102","title":"Ethnodrama: An innovative knowledge translation tool in the management of lymphedema.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal University Hospital; University of Ottawa; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Lymphedema; Medicine; Knowledge translation; Family medicine; Quality of life (healthcare); Breast cancer; Health professionals; Medical education; Nursing; Physical therapy; Health care; Cancer; Knowledge management; Internal medicine","score_opus":0.46473612250934093,"score_gpt":0.5572127446076168,"score_spread":0.0924766220982759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590047023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680833,0.000825584,0.00031464975,0.0024372756,0.00058041996,0.0002622065,0.0000010377973,0.0000033857589,0.027492115],"genre_scores_gemma":[0.9960259,0.00006352093,0.002596107,0.0007754703,0.00045647222,0.0000038871985,0.0000020013003,0.0000053879253,0.00007124257],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967854,0.00070052623,0.0019914843,0.00009005892,0.00032909267,0.00010344036],"domain_scores_gemma":[0.9969604,0.0012295835,0.00092289154,0.00016206854,0.00061246793,0.000112571935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006741446,0.00007248136,0.00074663997,0.00010306826,0.000010148204,0.000004014682,0.00015401962,0.00015944778,0.00002216464],"category_scores_gemma":[0.001058437,0.00003985117,0.00014444048,0.00035276994,0.00011215718,0.00011271267,0.000014650614,0.000059669175,0.000008495855],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007526249,0.010455482,0.13590503,0.00034589012,0.0006560305,0.00097171357,0.009903838,0.000028511684,0.000045970268,0.0053040776,0.0039456403,0.8249116],"study_design_scores_gemma":[0.03939694,0.016239993,0.87963873,0.00064378354,0.000826155,0.00036383222,0.01727158,0.0003784306,0.000046540143,0.003939337,0.041109815,0.00014487862],"about_ca_topic_score_codex":0.0000071630143,"about_ca_topic_score_gemma":0.000011593131,"teacher_disagreement_score":0.8247667,"about_ca_system_score_codex":0.000090532216,"about_ca_system_score_gemma":0.001278888,"threshold_uncertainty_score":0.23364641},"labels":[],"label_agreement":null},{"id":"W2590047371","doi":"10.1200/jco.2012.30.34_suppl.187","title":"Categorization of measures of quality in radiation treatment.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Categorization; Medicine; Quality assurance; Kappa; Statement (logic); Quality (philosophy); Delphi method; Cohen's kappa; Documentation; Computer science; Artificial intelligence; External quality assessment; Mathematics; Machine learning; Linguistics; Pathology","score_opus":0.23216755222197732,"score_gpt":0.589529995523891,"score_spread":0.35736244330191363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590047371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878727,0.0031542324,0.0034482777,0.0017583495,0.0016558564,0.00012972573,0.0000015928863,0.0000022300003,0.0019770097],"genre_scores_gemma":[0.9901326,0.004469398,0.0039964314,0.000325825,0.000994454,0.0000011083907,0.0000018295619,0.0000049299333,0.00007345697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970672,0.000627111,0.001986706,0.000054743745,0.00015887764,0.0001053201],"domain_scores_gemma":[0.9953794,0.0021229943,0.0020951307,0.00009245641,0.00020709183,0.00010293876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036247238,0.000059253955,0.0011093053,0.000109078384,0.000008376025,3.027329e-7,0.000051273062,0.0003090912,0.000056183493],"category_scores_gemma":[0.0030542396,0.00003885037,0.00020745597,0.00011311934,0.00018583031,0.000114305345,0.000004503716,0.00024362472,0.0000010319459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026762353,0.0024382418,0.657458,0.000015205804,0.00013935,0.0000070946007,0.00031627467,0.000042905973,0.0011530116,0.0007704315,0.000104649625,0.33487862],"study_design_scores_gemma":[0.008366581,0.009664979,0.94122803,0.000025004234,0.00013604618,0.00005639644,0.0001107842,0.00001679039,0.0018841266,0.00064449804,0.03782937,0.000037404898],"about_ca_topic_score_codex":0.000021060028,"about_ca_topic_score_gemma":0.000022206743,"teacher_disagreement_score":0.3348412,"about_ca_system_score_codex":0.00019754341,"about_ca_system_score_gemma":0.0006890473,"threshold_uncertainty_score":0.36564308},"labels":[],"label_agreement":null},{"id":"W2590047801","doi":"10.1200/jco.2014.32.4_suppl.443","title":"Dovitinib in first-line renal cell carcinoma: An investigation into tumour gene status and correlation with efficacy: A phase II clinical trial.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Renal cell carcinoma; Gastroenterology; Adverse effect; Phases of clinical research; Performance status; Progression-free survival; Surgery; Abdominal pain; Oncology; Clinical trial; Cancer; Chemotherapy","score_opus":0.12657641956834362,"score_gpt":0.434838953061354,"score_spread":0.30826253349301036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590047801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492764,0.00030349384,0.00038461524,0.0026963016,0.00064935547,0.0007570142,0.000001892222,0.000013271078,0.00026643887],"genre_scores_gemma":[0.98682886,0.00023679835,0.00994358,0.0008135265,0.002015487,0.0000109085995,0.000035209632,0.00003245449,0.00008317287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930558,0.0016191709,0.004022223,0.00045931427,0.00049812114,0.00034534172],"domain_scores_gemma":[0.99172693,0.0037518179,0.0026384308,0.0003094682,0.00042709857,0.0011462386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007212035,0.00026361007,0.0019604168,0.0002706692,0.000092225135,0.000017045544,0.00012550222,0.0005494978,0.000031421976],"category_scores_gemma":[0.003523295,0.00017960262,0.00029944564,0.00022729767,0.00042072844,0.00021796682,0.00006616829,0.001462303,0.0000067188116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26434708,0.0192004,0.5929346,0.000076420496,0.00018071152,0.0014218139,0.0009683713,0.0004236245,0.0012023823,0.00007306125,0.00034124436,0.118830286],"study_design_scores_gemma":[0.2970123,0.23055188,0.46552736,0.000087894645,0.0006259202,0.00025943812,0.00006390279,0.0029045702,0.0005496716,0.00029414,0.0019655786,0.0001573324],"about_ca_topic_score_codex":0.00014974724,"about_ca_topic_score_gemma":0.0004849992,"teacher_disagreement_score":0.21135148,"about_ca_system_score_codex":0.00025590503,"about_ca_system_score_gemma":0.001712436,"threshold_uncertainty_score":0.7323983},"labels":[],"label_agreement":null},{"id":"W2590051582","doi":"10.1200/jco.2012.30.15_suppl.e19547","title":"Treatment patterns and outcomes of acneiform skin eruptions from anti-epidermal growth factor receptor (EGFR) therapies for metastatic colorectal cancer (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Cetuximab; Panitumumab; Colorectal cancer; Internal medicine; Epidermal growth factor receptor; Proportional hazards model; EGFR inhibitors; Dermatology; Cancer; Oncology","score_opus":0.13876797762857074,"score_gpt":0.47071587352402966,"score_spread":0.3319478958954589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590051582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887558,0.003167249,0.00007419431,0.005709001,0.0012795839,0.00045306978,0.00046072935,0.000006794583,0.00009355476],"genre_scores_gemma":[0.9883972,0.0075440225,0.0027471916,0.00038876355,0.00073671114,0.000062603875,0.000011863591,0.000018044066,0.00009359939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774814,0.00015759519,0.0014520839,0.00015548029,0.00020714827,0.0002795595],"domain_scores_gemma":[0.9949679,0.0032196539,0.0011439277,0.000086469845,0.0003066885,0.0002753921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042626724,0.00021166641,0.0020771206,0.00008770371,0.000070224596,0.000006503281,0.00006722128,0.0001468024,0.00028700527],"category_scores_gemma":[0.00062964985,0.00011803354,0.00060675974,0.00005516292,0.00018738919,0.00015196747,0.00003403843,0.00020475422,0.000001933731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022002147,0.0022303245,0.87852454,0.00002901407,0.0043705455,0.000011312493,0.0014469684,3.6282185e-7,0.00026152257,0.000038423983,0.00025414108,0.11063261],"study_design_scores_gemma":[0.009409247,0.012323283,0.9648585,0.00004190778,0.0015332431,0.000026825866,0.00076058524,0.000007724081,0.00090882543,0.00007525283,0.009954957,0.00009969033],"about_ca_topic_score_codex":0.000655952,"about_ca_topic_score_gemma":0.0006629512,"teacher_disagreement_score":0.110532925,"about_ca_system_score_codex":0.00027613185,"about_ca_system_score_gemma":0.0004030625,"threshold_uncertainty_score":0.48132682},"labels":[],"label_agreement":null},{"id":"W2590055499","doi":"10.1200/jco.2011.29.7_suppl.356","title":"Effect of an individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Toxicity; Urology; Internal medicine; Oncology; Nuclear medicine; Cancer","score_opus":0.18349031932270524,"score_gpt":0.4801632282143826,"score_spread":0.2966729088916774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590055499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643415,0.00037275898,0.00026512967,0.00015413019,0.0004575376,0.0011709948,0.000118423166,0.000008092757,0.0010188023],"genre_scores_gemma":[0.9731032,0.00013201687,0.026120316,0.000105158884,0.00018345918,0.000038704795,0.00018934635,0.000040234132,0.0000875606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946919,0.0017408943,0.0022520823,0.00038880252,0.0005810905,0.00034522137],"domain_scores_gemma":[0.98982495,0.0062469603,0.002575229,0.0006267654,0.0003736749,0.00035240618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007099233,0.00028289406,0.001960941,0.00025308982,0.000040692878,0.000011026395,0.00046646583,0.00030456678,0.00017101444],"category_scores_gemma":[0.0017894877,0.00017114435,0.00025752385,0.00021348751,0.0002627949,0.00024362345,0.00006456613,0.0009130165,0.000004001128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29098836,0.023441741,0.4830988,0.001351959,0.0029813112,0.003254001,0.0009362953,0.0020275237,0.010257759,0.00013117539,0.0008549239,0.18067615],"study_design_scores_gemma":[0.09816814,0.27882004,0.59568435,0.0011480337,0.004360286,0.00062140956,0.00034367727,0.0017455621,0.01765805,0.00037048024,0.000691432,0.00038853186],"about_ca_topic_score_codex":0.0001928402,"about_ca_topic_score_gemma":0.00097115955,"teacher_disagreement_score":0.2553783,"about_ca_system_score_codex":0.0002212983,"about_ca_system_score_gemma":0.0017987563,"threshold_uncertainty_score":0.69790643},"labels":[],"label_agreement":null},{"id":"W2590057071","doi":"10.1200/jco.2016.34.4_suppl.64","title":"Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; VEGF receptors; Ramucirumab; Interleukin 8; Oncology; Bevacizumab; Gastroenterology; Placebo; Vascular endothelial growth factor; Refractory (planetary science); Proportional hazards model; Biomarker; Cancer; Pathology; Cytokine; Chemotherapy; Biology","score_opus":0.2280426544723023,"score_gpt":0.5213034478385022,"score_spread":0.2932607933661999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590057071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889242,0.00041048107,0.00026880112,0.0020843984,0.0005936393,0.0075686513,0.000004670992,0.0000061811184,0.0001389466],"genre_scores_gemma":[0.9989251,0.0000664779,0.0003889507,0.00006729643,0.00022786018,0.00025246525,0.00000225787,0.000020284886,0.000049329235],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9791261,0.0099521745,0.0085836435,0.00039804162,0.0015745905,0.00036542665],"domain_scores_gemma":[0.97513896,0.014906952,0.008391195,0.0003402817,0.0010460437,0.00017656175],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08004111,0.00029728073,0.0054539265,0.0008502256,0.00004208949,0.000009338202,0.00032331693,0.00015883577,0.00024607917],"category_scores_gemma":[0.03443831,0.00014827099,0.0008271176,0.0007454128,0.00026693946,0.00019115878,0.00006396696,0.00078190526,4.456235e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7621843,0.015093325,0.08217025,0.00002217694,0.0014541793,0.00011919473,0.00036215447,0.00034053207,0.0010134294,0.0000015536093,0.00013810433,0.13710079],"study_design_scores_gemma":[0.9191166,0.033003245,0.037267406,0.0005575601,0.0043974677,0.00001955037,0.0038936846,0.0015588204,0.000030050944,0.000031209063,0.00002748663,0.00009689223],"about_ca_topic_score_codex":0.0004469761,"about_ca_topic_score_gemma":0.001284792,"teacher_disagreement_score":0.15693231,"about_ca_system_score_codex":0.00070830906,"about_ca_system_score_gemma":0.0019508543,"threshold_uncertainty_score":0.97369504},"labels":[],"label_agreement":null},{"id":"W2590061441","doi":"10.1200/jco.2016.34.2_suppl.200","title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Leuprorelin; Prostate cancer; Clinical endpoint; Urology; Gonadotropin-releasing hormone antagonist; Internal medicine; Interim analysis; Hormone antagonist; Prostate-specific antigen; Testosterone (patch); Prostate; Pharmacokinetics; Antagonist; Gastroenterology; Cancer; Randomized controlled trial; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","score_opus":0.18046994721721318,"score_gpt":0.5432057560749756,"score_spread":0.36273580885776235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590061441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325645,0.00019968324,0.00001016645,0.0040664184,0.00089458853,0.00048672938,0.0006264169,0.000005019465,0.0004545221],"genre_scores_gemma":[0.9961113,0.0013828556,0.00031737474,0.00029650948,0.00068427797,0.000014068296,0.0000752307,0.000015621808,0.0011028157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99472386,0.0007054908,0.0034078318,0.00033638807,0.00049437786,0.00033207663],"domain_scores_gemma":[0.9952548,0.0011901059,0.0021264227,0.0002814774,0.00067979447,0.0004673808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027713762,0.00017187568,0.0020778184,0.0004075906,0.0000374617,0.0000087749595,0.00022223692,0.00027588077,0.0008334969],"category_scores_gemma":[0.0020668628,0.00009191028,0.0005732307,0.00041376648,0.0003544929,0.00023230189,0.00009377106,0.000598174,0.000004306396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61432827,0.018513598,0.0984608,0.000014535417,0.002038322,0.000524691,0.0005763507,0.0000026283735,0.0011584294,0.0000023418431,0.0019474921,0.26243252],"study_design_scores_gemma":[0.67982364,0.14871573,0.13777235,0.00026474087,0.0015320914,0.0000061714604,0.00012690248,0.00009486132,0.0016030916,0.00020659706,0.02969211,0.00016173815],"about_ca_topic_score_codex":0.00036506323,"about_ca_topic_score_gemma":0.0017421381,"teacher_disagreement_score":0.26227078,"about_ca_system_score_codex":0.00039766365,"about_ca_system_score_gemma":0.002011295,"threshold_uncertainty_score":0.91262066},"labels":[],"label_agreement":null},{"id":"W2590066672","doi":"10.1200/jco.2014.32.4_suppl.425","title":"Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis.","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Temsirolimus; Clear cell renal cell carcinoma; Oncology; Internal medicine; Sorafenib; Renal cell carcinoma; Clinical endpoint; Progression-free survival; Everolimus; Meta-analysis; Clinical trial; Chemotherapy; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway","score_opus":0.2410394227245558,"score_gpt":0.48326098857595884,"score_spread":0.24222156585140303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590066672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010817497,0.9919563,0.000031600415,0.0012116666,0.00017966237,0.005077712,0.000013157618,0.000007887919,0.00044025943],"genre_scores_gemma":[0.0035511628,0.98958707,0.0008336166,0.0034155266,0.00021955444,0.0002444623,0.0000073475812,0.000086879816,0.0020543565],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9724962,0.013042107,0.012336118,0.0007703726,0.0008693967,0.00048579817],"domain_scores_gemma":[0.9758723,0.011217458,0.00995164,0.0012477709,0.0006317904,0.0010790707],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.02844121,0.0008514551,0.048622597,0.001334015,0.000034958182,0.000027332931,0.0006071973,0.0011167146,0.00015562927],"category_scores_gemma":[0.0036978547,0.00044789477,0.011017038,0.0011167404,0.00011827272,0.00006034301,0.00014242301,0.002235588,0.00014766493],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002726434,0.0013855072,0.000045938777,0.8734879,0.1112514,0.003788928,0.000083511346,0.0000042501906,0.000005699142,0.0000011384252,0.0017335592,0.0054857363],"study_design_scores_gemma":[0.0025723043,0.01740947,0.000118207296,0.052587043,0.8277394,0.0015800917,0.000020606347,0.0000028462925,0.0000013484987,0.0000016786815,0.097639754,0.0003272181],"about_ca_topic_score_codex":0.000022493225,"about_ca_topic_score_gemma":0.000012240257,"teacher_disagreement_score":0.82090086,"about_ca_system_score_codex":0.00075273024,"about_ca_system_score_gemma":0.002604903,"threshold_uncertainty_score":0.9997973},"labels":[],"label_agreement":null},{"id":"W2590066918","doi":"10.1200/jco.2015.33.3_suppl.682","title":"Impact of duration of neoadjuvant radiation on rectal cancer survival.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Proportional hazards model; Cohort; Confounding; Radiation therapy; Gastroenterology; Stage (stratigraphy); Oncology; Population; Survival analysis; Logistic regression; Cancer; Surgery","score_opus":0.29276159092686144,"score_gpt":0.5403374432531786,"score_spread":0.24757585232631713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590066918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929786,0.00035111548,0.000022543592,0.0020353582,0.0011257096,0.00008546195,0.0000055591613,0.000002516099,0.0033931513],"genre_scores_gemma":[0.9982158,0.0003053781,0.00013229872,0.00013620812,0.001091938,7.7889894e-7,0.0000024568694,0.000006433785,0.000108720786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749506,0.0002757304,0.001695446,0.000082746985,0.0003515417,0.00009946714],"domain_scores_gemma":[0.9961202,0.0008138114,0.0019382971,0.00008485234,0.00077863334,0.0002641973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021988803,0.000076651726,0.0010437485,0.000113502036,0.000007939445,0.000001484423,0.000065172884,0.00019274307,0.00009257811],"category_scores_gemma":[0.004064472,0.00004750541,0.0005219404,0.00013603391,0.000091424095,0.00006684511,0.00001505589,0.00039770376,0.0000034461343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02377269,0.0019299145,0.66843146,0.000031080843,0.00044313006,0.00013241616,0.00026528546,0.00028741994,0.0050744815,0.000108560154,0.0055584796,0.29396507],"study_design_scores_gemma":[0.005648738,0.047581963,0.9430882,0.00008593078,0.00019530518,0.000072810624,0.00007285364,0.00032400136,0.00091411965,0.00019882096,0.0017707116,0.00004657238],"about_ca_topic_score_codex":0.00018716224,"about_ca_topic_score_gemma":0.00007391858,"teacher_disagreement_score":0.2939185,"about_ca_system_score_codex":0.00021582597,"about_ca_system_score_gemma":0.0022768464,"threshold_uncertainty_score":0.4865846},"labels":[],"label_agreement":null},{"id":"W2590067227","doi":"10.1200/jco.2012.30.4_suppl.184","title":"Epidemiology and survival of neuroendocrine tumors in Ontario: A 15-year population-based study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Incidence (geometry); Epidemiology; Neuroendocrine tumors; Cancer registry; Population; Internal medicine; Relative survival; Colorectal cancer; Cancer; Database","score_opus":0.18863713005527488,"score_gpt":0.5059467539401763,"score_spread":0.3173096238849014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590067227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951041,0.00020268552,0.000012802477,0.0032996228,0.0006983772,0.00033785572,0.0000011496974,0.000005193654,0.00033822644],"genre_scores_gemma":[0.9968862,0.000037969192,0.0018651237,0.0006835409,0.00035381294,0.000004439438,0.0000015623076,0.000015965188,0.000151401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937746,0.0020714542,0.0031196477,0.00019420414,0.00036044468,0.0004796788],"domain_scores_gemma":[0.9884573,0.009049317,0.0014990661,0.00021079184,0.00021720328,0.00056630117],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047422056,0.00014206997,0.0022278593,0.00030900564,0.000018908388,0.00000138395,0.00014675324,0.000028303864,0.00018436932],"category_scores_gemma":[0.02236834,0.0001039301,0.00023819588,0.0001700756,0.00017629791,0.00014811034,0.00008426128,0.0015309445,0.0000040841096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004050148,0.003055104,0.9877202,0.000028602783,0.00005709573,0.0025675015,0.00002751201,0.000040444673,0.00002214641,0.00010225289,0.00010085522,0.0022281334],"study_design_scores_gemma":[0.008459688,0.014829084,0.9724557,0.000043629763,0.000079601916,0.0008667949,0.0001546044,0.000023053542,0.000014939009,0.00015269699,0.0028585976,0.00006165356],"about_ca_topic_score_codex":0.0055925674,"about_ca_topic_score_gemma":0.032637663,"teacher_disagreement_score":0.027045097,"about_ca_system_score_codex":0.00014858117,"about_ca_system_score_gemma":0.0009930873,"threshold_uncertainty_score":0.98586667},"labels":[],"label_agreement":null},{"id":"W2590067244","doi":"10.1200/jco.2012.30.4_suppl.640","title":"Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cetuximab; Irinotecan; KRAS; Colorectal cancer; Internal medicine; Oxaliplatin; Panitumumab; Oncology; Regimen; Cancer","score_opus":0.13047441644321178,"score_gpt":0.44829292518614255,"score_spread":0.31781850874293077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590067244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877742,0.003328764,0.00000837221,0.001199918,0.0041198446,0.00052878464,0.000014027928,0.000021267755,0.0030048469],"genre_scores_gemma":[0.9943305,0.0024814436,0.0007867842,0.0008111804,0.0013343602,0.000028949371,0.000008231431,0.00004363585,0.00017489196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964144,0.00037428061,0.0016491064,0.00026945616,0.00070068956,0.00059203705],"domain_scores_gemma":[0.9950927,0.0014987927,0.0016408284,0.00020172297,0.00095159037,0.0006143953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010913245,0.00033807036,0.0020957731,0.00014078074,0.00013312051,0.000016048716,0.00018236852,0.00023869678,0.00049864873],"category_scores_gemma":[0.0009990868,0.00019805558,0.0004591053,0.0003038163,0.00047570618,0.00029250066,0.000071673116,0.00096640957,0.000020727699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05535089,0.00600877,0.7615583,0.000017947777,0.0035554585,0.00015412456,0.0004467776,0.0000071683385,0.000017072762,0.000015501337,0.0022269336,0.1706411],"study_design_scores_gemma":[0.03861289,0.060203403,0.8529745,0.00007768483,0.0013571552,0.000039537743,0.0002159906,0.000009115389,0.00008481749,0.00001704435,0.046209216,0.0001986391],"about_ca_topic_score_codex":0.0002386623,"about_ca_topic_score_gemma":0.00072597095,"teacher_disagreement_score":0.17044245,"about_ca_system_score_codex":0.00066070596,"about_ca_system_score_gemma":0.0014021663,"threshold_uncertainty_score":0.8076472},"labels":[],"label_agreement":null},{"id":"W2590075723","doi":"10.1200/jco.2014.32.4_suppl.151","title":"Effect of a genomic classifier on adjuvant radiation recommendations after prostate cancer surgery.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Adverse effect; Radiation therapy; Concordance; Internal medicine; Surgery; General surgery; Cancer","score_opus":0.06953365191050184,"score_gpt":0.4580520801148689,"score_spread":0.3885184282043671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590075723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790046,0.00097351696,0.000017969716,0.017459009,0.0017267389,0.00029704277,0.000015913545,0.000004390065,0.00050082646],"genre_scores_gemma":[0.9897535,0.007047467,0.00018243882,0.0020269104,0.0007902506,0.00005989118,0.000007767396,0.000014607149,0.000117198324],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972048,0.0006948829,0.001610799,0.0001465428,0.0001854287,0.00015757613],"domain_scores_gemma":[0.9927102,0.0051828227,0.0015360313,0.00014756118,0.00020267705,0.00022075573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033700918,0.000115716684,0.0013181334,0.00012832503,0.000020297328,0.000004420757,0.000048156297,0.00016381744,0.00028705035],"category_scores_gemma":[0.0014643981,0.00007153303,0.00046933908,0.00007109662,0.000081244405,0.000057839003,0.000015182727,0.00038575867,0.000019959549],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006092309,0.0006044903,0.3376557,0.000045498597,0.00024219824,0.000040224004,0.000046494926,0.000016227043,0.00005085831,0.000011722308,0.008516851,0.64667743],"study_design_scores_gemma":[0.006754249,0.022502027,0.7659075,0.0003406414,0.00059871,0.000026784744,0.000006436655,0.00008165894,0.0010865037,0.000062844716,0.20256333,0.00006926405],"about_ca_topic_score_codex":0.000018711056,"about_ca_topic_score_gemma":0.000020511452,"teacher_disagreement_score":0.6466082,"about_ca_system_score_codex":0.00029158435,"about_ca_system_score_gemma":0.00074759335,"threshold_uncertainty_score":0.3143},"labels":[],"label_agreement":null},{"id":"W2590077137","doi":"10.1200/jco.2016.34.7_suppl.174","title":"Validation of a real-time patient-reported experience measurement tool for cancer patients in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Cronbach's alpha; Medicine; Patient experience; General partnership; Reliability (semiconductor); Cancer; Patient satisfaction; Exploratory factor analysis; Health care; Family medicine; Nursing; Psychometrics; Internal medicine; Clinical psychology","score_opus":0.3805285323544158,"score_gpt":0.5624000509084592,"score_spread":0.18187151855404343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590077137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931556,0.000013068242,0.00014999665,0.0011651012,0.0040760925,0.0010519524,0.0000164414,0.00000742912,0.00036430475],"genre_scores_gemma":[0.99770874,0.00013243196,0.0012457746,0.00036257357,0.00019173454,0.00019387886,0.0000023563778,0.000014104426,0.0001484164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913661,0.0014156501,0.0059651355,0.00021398977,0.00070363306,0.0003355311],"domain_scores_gemma":[0.98549676,0.003941001,0.0070612524,0.00019906696,0.0031043084,0.00019758698],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0044129123,0.00012047012,0.0010223716,0.00016054862,0.00009191759,0.0000011697323,0.00015025078,0.00043460366,0.0007121519],"category_scores_gemma":[0.012189886,0.00007824785,0.00021165877,0.00011198013,0.00008575522,0.0002475972,0.00004786855,0.00056702207,0.000012456147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002060075,0.000381546,0.9558895,0.000040157138,0.000050984738,0.0000034065868,0.001959127,0.0000063972316,0.00065455347,0.000017667602,0.001391593,0.03754495],"study_design_scores_gemma":[0.0063930717,0.003991012,0.9784264,0.0006716933,0.000039116945,8.2372713e-7,0.00017932657,0.000004617351,0.00028055595,0.00028186385,0.009644486,0.00008703246],"about_ca_topic_score_codex":0.013657102,"about_ca_topic_score_gemma":0.027300444,"teacher_disagreement_score":0.03745792,"about_ca_system_score_codex":0.0023865516,"about_ca_system_score_gemma":0.0062109814,"threshold_uncertainty_score":0.9994229},"labels":[],"label_agreement":null},{"id":"W2590083393","doi":"10.1200/jco.2016.34.26_suppl.123","title":"Palliative Care Always as a massive open online course (MOOC) to build primary palliative care in a global audience.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palliative care; Psychosocial; Medicine; Massive open online course; Target audience; Medical education; Nursing; Psychology","score_opus":0.296211462154624,"score_gpt":0.5914102060298227,"score_spread":0.29519874387519873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590083393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502455,0.005562934,0.00031861363,0.027120432,0.0011684225,0.00092672824,0.0002808886,0.000012706694,0.014363753],"genre_scores_gemma":[0.96688414,0.00403181,0.020179847,0.0074773594,0.0010853892,0.000022502963,0.000019428313,0.000026157197,0.0002733708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950133,0.00061989855,0.0027271577,0.00046622098,0.0006898614,0.00048358302],"domain_scores_gemma":[0.99097306,0.003271866,0.0022191226,0.00033580177,0.0024397357,0.00076039997],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011883539,0.0003121168,0.002756176,0.00014852917,0.000044311193,0.000012211579,0.0007442811,0.0005324163,0.00016438725],"category_scores_gemma":[0.010257775,0.00019161648,0.00054066745,0.00046472644,0.0004496115,0.00021737402,0.00042977618,0.0007979738,0.00005255677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010651174,0.0019418212,0.7857143,0.00012456492,0.0005418618,0.0021415146,0.007598073,0.00002085531,0.00014084044,0.00036562537,0.004061922,0.1866974],"study_design_scores_gemma":[0.01728454,0.026209518,0.8146506,0.004028483,0.00046228908,0.000021364267,0.019637205,0.000004124362,0.00025171586,0.00090597785,0.11626157,0.00028263294],"about_ca_topic_score_codex":0.0002243052,"about_ca_topic_score_gemma":0.0016573363,"teacher_disagreement_score":0.18641476,"about_ca_system_score_codex":0.0016951613,"about_ca_system_score_gemma":0.006036708,"threshold_uncertainty_score":0.99959815},"labels":[],"label_agreement":null},{"id":"W2590085384","doi":"10.1200/jco.2013.31.4_suppl.450","title":"A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant <i>KRAS-</i>mutant metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Neutropenia; FOLFIRI; Internal medicine; Irinotecan; Gastroenterology; KRAS; Febrile neutropenia; Phases of clinical research; Colorectal cancer; Leukopenia; Toxicity; Cancer","score_opus":0.04136524051435573,"score_gpt":0.41281433500156495,"score_spread":0.3714490944872092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590085384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867433,0.00008196977,0.00005210695,0.0001212536,0.0000959027,0.00091478485,0.000018927338,0.0000011791357,0.000039517286],"genre_scores_gemma":[0.99928737,0.000118564116,0.000411172,0.000035950852,0.00004314635,0.000060719798,0.000020411837,0.000014895633,0.000007776186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968525,0.0005362902,0.0016926802,0.0002467623,0.0004365221,0.00023519865],"domain_scores_gemma":[0.9972164,0.00022175004,0.0016114608,0.00015786325,0.0006397089,0.00015280722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076081784,0.00016987184,0.0008747034,0.00015503283,0.000018922134,0.00000993134,0.00016838513,0.00013503098,0.000040630082],"category_scores_gemma":[0.0003482457,0.0001151213,0.00009487404,0.00019128976,0.00015103907,0.000034892084,0.000040839255,0.00037530376,8.87459e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07764939,0.08495816,0.6509717,0.000074682255,0.0011380453,0.00032461292,0.0009410708,0.00036363964,0.025082346,0.0000034746542,0.000043250173,0.15844959],"study_design_scores_gemma":[0.074074365,0.2541,0.65176684,0.00015147476,0.00019258184,0.000024989411,0.00068710075,0.00018687267,0.01846039,0.000017506032,0.00016601368,0.00017186099],"about_ca_topic_score_codex":0.001781436,"about_ca_topic_score_gemma":0.014242409,"teacher_disagreement_score":0.16914184,"about_ca_system_score_codex":0.00016079078,"about_ca_system_score_gemma":0.001037261,"threshold_uncertainty_score":0.79475987},"labels":[],"label_agreement":null},{"id":"W2590088447","doi":"10.1200/jco.2016.34.7_suppl.107","title":"Bringing provincial improvements to oral chemotherapy prescribing through co-ordinated regional initiatives.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Medical prescription; Quality management; Government (linguistics); Agency (philosophy); Family medicine; Nursing; Business; Service (business); Accounting","score_opus":0.45775776559705644,"score_gpt":0.6000433079581186,"score_spread":0.1422855423610621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590088447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88649595,0.000038266167,0.014729556,0.0935968,0.0013839875,0.0006610474,0.0000096325575,0.000030054714,0.0030547292],"genre_scores_gemma":[0.93130445,0.00026676437,0.028240658,0.036956254,0.0028873798,0.000007719857,0.000004817334,0.000037818132,0.00029414945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99360925,0.000530736,0.0045377575,0.00031216373,0.0006505623,0.0003595263],"domain_scores_gemma":[0.98978555,0.005608186,0.0029073388,0.00022060677,0.001031596,0.00044669164],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065707816,0.00018270202,0.0012516922,0.00013352299,0.00006106991,0.000015108813,0.00021562703,0.000300004,0.00049739005],"category_scores_gemma":[0.028844232,0.00011590314,0.00043751657,0.00017888626,0.00017276836,0.000712668,0.00008152501,0.0007339263,0.00005901271],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014958389,0.0019893537,0.080458716,0.000025758416,0.0006721577,0.00031063403,0.00028068543,0.0000026364646,0.011937274,0.00025593015,0.053787924,0.83532053],"study_design_scores_gemma":[0.04438445,0.027949648,0.37819698,0.00048146967,0.00049519143,0.00038936766,0.00048275435,0.00008035108,0.0029206146,0.0016547338,0.542634,0.0003304385],"about_ca_topic_score_codex":0.00008685598,"about_ca_topic_score_gemma":0.000040296523,"teacher_disagreement_score":0.8349901,"about_ca_system_score_codex":0.00038210265,"about_ca_system_score_gemma":0.0022589269,"threshold_uncertainty_score":0.9793362},"labels":[],"label_agreement":null},{"id":"W2590097386","doi":"10.1200/jco.2012.30.34_suppl.166","title":"Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bone and Joint Health Institute; Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; University of Calgary; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Cohort; Breast cancer; Odds ratio; Population; Cancer; Cancer registry; Medical record; Exact test","score_opus":0.5359880732810848,"score_gpt":0.5793496880569081,"score_spread":0.04336161477582334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590097386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634194,0.0006806875,0.000015977552,0.0013769676,0.00045811044,0.00031269138,0.0000031495663,0.000004980769,0.0008054714],"genre_scores_gemma":[0.9825226,0.0003155839,0.016011147,0.00028130694,0.00069319195,0.000006037674,9.943899e-7,0.000016086882,0.0001530397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929201,0.0003630002,0.005494822,0.00022218085,0.00039579533,0.000604101],"domain_scores_gemma":[0.9927968,0.0023368166,0.0030617684,0.00014004186,0.0006603435,0.0010042745],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047283135,0.00016224608,0.0017610195,0.0001562555,0.000038258815,0.000008559643,0.00007958373,0.00022488323,0.00021801902],"category_scores_gemma":[0.034812596,0.0001137029,0.00014762777,0.00013708699,0.00017456667,0.00013364782,0.00007761494,0.0008379876,0.000001356496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005869779,0.0005201565,0.7689328,0.000034231096,0.000067751724,0.00014761201,0.000854731,0.0000022079007,0.0012670376,0.00000731766,0.00022982304,0.22734931],"study_design_scores_gemma":[0.0037609916,0.022300927,0.9678252,0.00032554867,0.00007678514,0.00029529372,0.00029077608,0.00001548352,0.0005088043,0.00005287967,0.0044562276,0.00009112421],"about_ca_topic_score_codex":0.029533094,"about_ca_topic_score_gemma":0.02402384,"teacher_disagreement_score":0.22725819,"about_ca_system_score_codex":0.00091986614,"about_ca_system_score_gemma":0.0029855885,"threshold_uncertainty_score":0.9937852},"labels":[],"label_agreement":null},{"id":"W2590100781","doi":"10.1200/jco.2014.32.30_suppl.169","title":"An electronic prompt to improve hepatitis B virus screening prior to cancer treatment.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Hepatitis B virus; HBsAg; Hepatitis B; Cancer; Pediatrics; Emergency medicine; Internal medicine; Virus; Virology","score_opus":0.08331433426089732,"score_gpt":0.479931039372907,"score_spread":0.39661670511200964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590100781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930735,0.00025984785,0.0023490097,0.015672063,0.0010007725,0.0005696268,0.000010356199,0.000024185287,0.0008067724],"genre_scores_gemma":[0.97219175,0.0016797299,0.011693664,0.010440911,0.0034010063,0.000056580164,0.0000012871964,0.000035954898,0.0004991402],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965152,0.0004374397,0.001826393,0.00032013358,0.0003593895,0.0005414476],"domain_scores_gemma":[0.9965245,0.0009548092,0.00079354603,0.0002898297,0.00049391994,0.0009433677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002178803,0.00020497253,0.0017759878,0.00016922866,0.00008809753,0.0000143705,0.00019256161,0.000255685,0.00019277849],"category_scores_gemma":[0.0040012617,0.00014515147,0.00034599632,0.00018096677,0.00007839895,0.00011819013,0.000058172245,0.0006230803,0.000083437175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020575745,0.00090627844,0.2884176,0.000009332777,0.00042278,0.00010385411,0.00027567026,0.000026444819,0.0033446094,0.000057359626,0.0024025317,0.70197594],"study_design_scores_gemma":[0.004307868,0.08627327,0.5425975,0.000099110875,0.00040015506,0.000060233997,0.000015679667,0.00020694452,0.0014696242,0.000084481384,0.36433554,0.00014961054],"about_ca_topic_score_codex":0.004633589,"about_ca_topic_score_gemma":0.039151836,"teacher_disagreement_score":0.70182633,"about_ca_system_score_codex":0.00067599583,"about_ca_system_score_gemma":0.0016382579,"threshold_uncertainty_score":0.97838116},"labels":[],"label_agreement":null},{"id":"W2590105108","doi":"10.1200/jco.2016.34.7_suppl.98","title":"Has venous thromboembolism (VTE) prophylaxis made any difference for solid tumor inpatients at Princess Margaret Cancer Center (PM)?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Venous thromboembolism; Odds ratio; Internal medicine; Cancer; Retrospective cohort study; Emergency medicine; Pediatrics; Thrombosis","score_opus":0.12673661228608457,"score_gpt":0.4380154078996178,"score_spread":0.3112787956135332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590105108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773967,0.0003419905,0.0005190635,0.015686955,0.0041239094,0.0010304311,0.000051134622,0.00002211263,0.00082769844],"genre_scores_gemma":[0.988251,0.0018605724,0.0012179092,0.005383771,0.0022147486,0.00009600351,0.0000043773266,0.00004952354,0.0009220951],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955705,0.00027215725,0.0024977804,0.0004332075,0.00059571746,0.000630652],"domain_scores_gemma":[0.9949852,0.0011481006,0.0022378785,0.00037279248,0.00066906936,0.000586942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015216103,0.00028869012,0.002801114,0.00015523072,0.00014603251,0.000023064056,0.00041862327,0.0003487483,0.0004831698],"category_scores_gemma":[0.0017564163,0.00016414482,0.00066269457,0.00010789829,0.0004200235,0.0001411471,0.0002674161,0.00051121716,0.000042282536],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076861973,0.023705555,0.3951172,0.00061723,0.002535899,0.00076931546,0.00077556906,0.000007999987,0.0043821596,0.00054533844,0.0633499,0.50050765],"study_design_scores_gemma":[0.010866312,0.020624293,0.80010444,0.00068935717,0.00053625385,0.00009880658,0.0000375017,0.000015227942,0.0007553015,0.0007287936,0.16533059,0.00021312888],"about_ca_topic_score_codex":0.00004560634,"about_ca_topic_score_gemma":0.0001479114,"teacher_disagreement_score":0.5002945,"about_ca_system_score_codex":0.000604956,"about_ca_system_score_gemma":0.0011337039,"threshold_uncertainty_score":0.66936314},"labels":[],"label_agreement":null},{"id":"W2590110225","doi":"10.1200/jco.2016.34.7_suppl.158","title":"Using information technology (IT) to improve communication between the emergency room and cancer clinic.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Regimen; Cancer; Internal medicine; Palliative care; Emergency department; Family medicine; Emergency medicine; Nursing","score_opus":0.3141837724695761,"score_gpt":0.5526826807675025,"score_spread":0.23849890829792642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590110225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87435883,0.00081169466,0.0027600157,0.12005692,0.0006868905,0.00020591193,0.0000051653083,0.000008398747,0.0011061771],"genre_scores_gemma":[0.9862191,0.0031364916,0.0060314583,0.003804253,0.00070473365,0.0000051736615,4.5768456e-7,0.0000055231094,0.0000927811],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973668,0.0001530577,0.0019965384,0.00008814473,0.00022776905,0.00016771158],"domain_scores_gemma":[0.996718,0.00076533546,0.0014561253,0.00024898237,0.00061854854,0.000193008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033319008,0.000082338614,0.0006326215,0.00011967167,0.00007851932,0.000006487045,0.0002487048,0.00032271192,0.00014672357],"category_scores_gemma":[0.0038727622,0.00004108092,0.00013885177,0.0001946437,0.00012530264,0.0003273651,0.00013518406,0.00055659976,0.000017899662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005183458,0.000029343724,0.392413,0.000006362973,0.00009922882,0.000004103976,0.00007150694,0.0000027308674,0.00017822492,0.00008756738,0.0054817325,0.60110784],"study_design_scores_gemma":[0.0041264715,0.006184437,0.6071949,0.00043684812,0.0005253879,0.00013180067,0.00064026675,0.000057085574,0.00018737203,0.0036716107,0.3767121,0.00013170564],"about_ca_topic_score_codex":0.00007125824,"about_ca_topic_score_gemma":0.000057439105,"teacher_disagreement_score":0.60097617,"about_ca_system_score_codex":0.00014949207,"about_ca_system_score_gemma":0.0006920689,"threshold_uncertainty_score":0.46363378},"labels":[],"label_agreement":null},{"id":"W2590115326","doi":"10.1200/jco.2010.28.15_suppl.6096","title":"Quality and consistency in breast cancer clinical guidelines internationally: Are we globally consistent?","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; CLARITY; Consistency (knowledge bases); Guideline; Breast cancer; Nice; Family medicine; Quality (philosophy); Health care; Nursing; Cancer; Internal medicine; Pathology","score_opus":0.629778333039432,"score_gpt":0.6755276325570057,"score_spread":0.04574929951757367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590115326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63888484,0.0003555662,0.00009317655,0.35573402,0.0039271866,0.00020108068,0.00003283774,0.000009848486,0.00076139864],"genre_scores_gemma":[0.9226687,0.008645224,0.019815901,0.044495437,0.004201025,0.0000061196215,0.0000063267225,0.00002233801,0.00013894083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9843682,0.0011743939,0.01306543,0.00039305983,0.00073532516,0.00026360404],"domain_scores_gemma":[0.9719237,0.01571273,0.0073942114,0.00033270355,0.003955413,0.00068123033],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.026507137,0.00020092436,0.0021832646,0.00016033977,0.000039542087,0.000026939175,0.00026459867,0.00067472487,0.00056898623],"category_scores_gemma":[0.09237359,0.00015171965,0.0006134609,0.00017653739,0.0006825145,0.00028906667,0.00017070178,0.0026669148,0.000014203647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032964114,0.0012791412,0.7299949,0.000027109469,0.0002502653,0.00026695168,0.000012711892,0.0000024724618,0.00010034214,0.000516978,0.017936261,0.24631645],"study_design_scores_gemma":[0.011846705,0.0011780801,0.8750571,0.0002034874,0.00031456514,0.0013034734,0.00035216927,0.0002016417,0.0000017251024,0.0017381171,0.10767289,0.00013002663],"about_ca_topic_score_codex":0.00033443264,"about_ca_topic_score_gemma":0.0046381466,"teacher_disagreement_score":0.3112386,"about_ca_system_score_codex":0.00012176464,"about_ca_system_score_gemma":0.004080183,"threshold_uncertainty_score":0.99963397},"labels":[],"label_agreement":null},{"id":"W2590117034","doi":"10.1200/jco.2013.31.4_suppl.395","title":"Association of tissue factor pathway inhibitor gene polymorphism -33T→C with disease-free survival in colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Genotype; Tissue factor pathway inhibitor; Colorectal cancer; Internal medicine; Single-nucleotide polymorphism; Gastroenterology; Proportional hazards model; Hazard ratio; Factor V; Factor V Leiden; Oncology; Cancer; Tissue factor; Gene; Biology; Thrombosis; Venous thrombosis; Genetics; Coagulation","score_opus":0.04433500510912326,"score_gpt":0.42100574124322204,"score_spread":0.3766707361340988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590117034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98323053,0.00047032032,0.000023531375,0.014049292,0.001088751,0.00035993863,0.000059909107,0.000005619636,0.0007121227],"genre_scores_gemma":[0.9967058,0.0002738486,0.0009417727,0.00036068875,0.00093033037,0.000023496812,0.000006942576,0.000015111858,0.0007420607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772006,0.00021436336,0.0013182962,0.00013541606,0.0004230469,0.00018881015],"domain_scores_gemma":[0.99656785,0.0009153921,0.0015249786,0.000115754505,0.0005392736,0.0003367646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056197966,0.00011119655,0.00096060097,0.000102153645,0.000021174043,0.000006379649,0.00010393096,0.00021216231,0.0003789734],"category_scores_gemma":[0.001471975,0.00007178854,0.00016705166,0.00014106336,0.00007869954,0.00013778337,0.000026987816,0.00039705445,0.00000885015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022952026,0.0018202387,0.944074,0.000028794237,0.00071496965,0.0002591459,0.00022107083,0.000019707524,0.0037852726,0.000029967767,0.002764018,0.043987628],"study_design_scores_gemma":[0.011274854,0.0062522255,0.9746183,0.00009907159,0.00035820535,0.000017529062,0.000073649855,0.000018084786,0.0015984268,0.00013748529,0.005478455,0.00007370888],"about_ca_topic_score_codex":0.00052223995,"about_ca_topic_score_gemma":0.0006832043,"teacher_disagreement_score":0.04391392,"about_ca_system_score_codex":0.00063891284,"about_ca_system_score_gemma":0.0028687739,"threshold_uncertainty_score":0.50890815},"labels":[],"label_agreement":null},{"id":"W2590119712","doi":"10.1200/jco.2016.34.4_suppl.686","title":"Clinical effectiveness of adjuvant chemotherapy (AC) with or without oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) in stage II rectal cancer (RC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; BC Cancer Agency; University of Calgary; St. John’s Health Sciences Centre; University of Alberta","funders":"","keywords":"Medicine; Oxaliplatin; Perineural invasion; Internal medicine; Colorectal cancer; Regimen; Capecitabine; Oncology; Lymphovascular invasion; Stage (stratigraphy); Chemotherapy; Neoadjuvant therapy; Surgery; Cancer; Breast cancer; Metastasis","score_opus":0.1094039896813433,"score_gpt":0.5049432445026044,"score_spread":0.3955392548212611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590119712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935357,0.00086531637,0.0002123291,0.0020422782,0.0015575431,0.0008295564,0.000012712505,0.000020921858,0.0009236208],"genre_scores_gemma":[0.99121636,0.0027536456,0.0036540946,0.0007222429,0.0007894121,0.000040768067,0.0000013269545,0.0000693495,0.0007528058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928883,0.0015335041,0.0038057535,0.0005376347,0.0007443729,0.0004904624],"domain_scores_gemma":[0.9880137,0.008110629,0.0025303548,0.00038127814,0.00040983083,0.0005541971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075341905,0.00037829226,0.0051349797,0.00021026559,0.00004425833,0.00000631502,0.0002957095,0.0006463027,0.00071034447],"category_scores_gemma":[0.002366261,0.00018258381,0.0010795039,0.00042629061,0.0005033064,0.00020603043,0.00007146591,0.0010524772,0.000004227692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08822865,0.0027502312,0.6964991,0.000071455936,0.0011620981,0.0014456993,0.00010863257,0.0000067933565,0.0017444061,0.00000881105,0.000068728375,0.20790538],"study_design_scores_gemma":[0.0825206,0.05854207,0.84088296,0.0027930725,0.00040896953,0.00027035642,0.000062136576,0.000056532383,0.002773431,0.00007275177,0.011342362,0.00027477014],"about_ca_topic_score_codex":0.00015168371,"about_ca_topic_score_gemma":0.00042581814,"teacher_disagreement_score":0.20763062,"about_ca_system_score_codex":0.0008083197,"about_ca_system_score_gemma":0.0035909081,"threshold_uncertainty_score":0.7777774},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2590120672","doi":"10.1200/jco.2016.34.4_suppl.721","title":"Prognostic significance of regional lymph nodes status in stage IV colorectal cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Stage (stratigraphy); Lymph node; Multivariate analysis; Metastasectomy; Oncology; Chemotherapy; Retrospective cohort study; Proportional hazards model; Cancer; Gastroenterology","score_opus":0.13906028898158396,"score_gpt":0.4653311451056485,"score_spread":0.32627085612406453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590120672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914188,0.0009119471,0.000047044112,0.0044809086,0.0008107063,0.00034534637,0.00002860717,0.0000091909415,0.001947467],"genre_scores_gemma":[0.9948318,0.0025686559,0.0011873612,0.0004143988,0.0004786968,0.000032157,0.0000012119281,0.00001964276,0.0004660996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579,0.00048268185,0.0025030712,0.00026839628,0.0005580105,0.0003978329],"domain_scores_gemma":[0.99065536,0.006301505,0.0018803426,0.00014798145,0.0005411044,0.00047369133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016442542,0.00017607225,0.0017714476,0.00016898174,0.000017505783,0.000003259678,0.00017327972,0.0003316982,0.0005436806],"category_scores_gemma":[0.0050031994,0.00010182589,0.00044664077,0.0002841943,0.00054402853,0.000124876,0.000055607867,0.0004333241,0.0000113030555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015887167,0.0018833979,0.859328,0.000043365428,0.00026322313,0.00090668886,0.00005223891,0.000010894453,0.0022681882,0.00008521955,0.00027029938,0.11900136],"study_design_scores_gemma":[0.015516741,0.008709494,0.96089184,0.0004655099,0.00016592765,0.000103848055,0.00005188144,0.00002261341,0.0007047164,0.00026128307,0.013001478,0.000104673905],"about_ca_topic_score_codex":0.00018682129,"about_ca_topic_score_gemma":0.0002225816,"teacher_disagreement_score":0.118896686,"about_ca_system_score_codex":0.0008705662,"about_ca_system_score_gemma":0.0045377193,"threshold_uncertainty_score":0.80497193},"labels":[],"label_agreement":null},{"id":"W2590120987","doi":"10.1200/jco.2014.32.3_suppl.547","title":"A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Ottawa Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Colorectal cancer; Health Utilities Index; Regression; Scale (ratio); Cancer; Algorithm; Statistics; Internal medicine; Mathematics; Health related quality of life; Disease; Cartography; Nursing","score_opus":0.5405777147736457,"score_gpt":0.567730266492366,"score_spread":0.02715255171872033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590120987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8915815,0.003013537,0.018643035,0.08219014,0.0028656756,0.0006717039,0.00022276846,0.000010580249,0.00080107717],"genre_scores_gemma":[0.9489597,0.0013115455,0.027556248,0.021219531,0.000848581,0.000034326673,0.000008752741,0.000020549502,0.000040748226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9760159,0.0035415192,0.01911139,0.000555023,0.00021265906,0.0005634866],"domain_scores_gemma":[0.9728376,0.007696447,0.018281888,0.0003201859,0.00022644096,0.0006373958],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08496958,0.00020576915,0.0049427,0.00047720966,0.00009156643,0.000017602097,0.0005236368,0.00036792722,0.00030201714],"category_scores_gemma":[0.01745204,0.00022150623,0.00032685336,0.00034980054,0.00014924533,0.0003028383,0.000098623976,0.0008818477,0.00006698641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035332039,0.00064920745,0.5875196,0.00016486987,0.00012354543,0.0000015826674,0.0017711228,0.00032344152,8.195667e-7,0.0005612617,0.005781593,0.40274966],"study_design_scores_gemma":[0.0030760353,0.0033198644,0.90874803,0.00034260558,0.0000036690637,0.0000034758218,0.0011816156,0.005547573,0.0000012678507,0.011882944,0.06571191,0.00018098888],"about_ca_topic_score_codex":0.009707712,"about_ca_topic_score_gemma":0.0071134004,"teacher_disagreement_score":0.40256867,"about_ca_system_score_codex":0.0012031404,"about_ca_system_score_gemma":0.0039327713,"threshold_uncertainty_score":0.99688673},"labels":[],"label_agreement":null},{"id":"W2590121544","doi":"10.1200/jco.2014.32.4_suppl.191","title":"The role of FSH in castration-induced adipogenesis and cardiovascular diseases: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Orchiectomy; Medicine; Endocrinology; Internal medicine; Testosterone (patch); Castration; Androgen deprivation therapy; Hormone; Agonist; Weight gain; Receptor; Body weight; Prostate cancer; Cancer","score_opus":0.022555891171157142,"score_gpt":0.3314289626054169,"score_spread":0.30887307143425974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590121544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869268,0.0122599825,0.000027640754,0.00031862422,0.00016240543,0.00008720173,0.0000030723334,0.0000015688712,0.00021270383],"genre_scores_gemma":[0.99485207,0.004375883,0.00020570567,0.000032953583,0.00051267666,0.0000022620418,0.000003176855,0.000008573612,0.0000067193473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782234,0.0007314065,0.0009371603,0.000185575,0.000161353,0.00016218348],"domain_scores_gemma":[0.998205,0.0008124794,0.00055399816,0.00016255125,0.0000979106,0.00016808389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019626722,0.00011381465,0.00071664446,0.000038397204,0.00012218666,0.000016592076,0.0001649948,0.00032405523,6.7647676e-7],"category_scores_gemma":[0.0009905397,0.000070302376,0.00026444142,0.000055821354,0.00025346104,0.0000065787967,0.00013170521,0.0002948996,2.612072e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004325195,0.00013766525,0.65326965,0.000020916554,0.0008551179,0.000018438068,0.00006087035,0.000009328473,0.026563779,0.00016642491,0.000023733386,0.31844154],"study_design_scores_gemma":[0.0040132334,0.00762109,0.9459965,0.00006930185,0.00071332697,0.00017059223,0.0002489263,0.00012908477,0.016508734,0.0010027688,0.023297483,0.00022892785],"about_ca_topic_score_codex":0.000033256947,"about_ca_topic_score_gemma":0.00002998441,"teacher_disagreement_score":0.3182126,"about_ca_system_score_codex":0.000007964361,"about_ca_system_score_gemma":0.00024550888,"threshold_uncertainty_score":0.28668478},"labels":[],"label_agreement":null},{"id":"W2590121969","doi":"10.1200/jco.2015.33.3_suppl.706","title":"The association of baseline anxiety and depression with overall survival (OS) in colorectal cancer (CRC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Anxiety; Depression (economics); Psychosocial; Internal medicine; Proportional hazards model; Cohort; Population; Colorectal cancer; Cancer; Quality of life (healthcare); Psychiatry","score_opus":0.06654072671219842,"score_gpt":0.4246213734589067,"score_spread":0.3580806467467083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590121969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076945,0.001170852,0.000031790725,0.004895883,0.0014424436,0.00009817505,0.000003884241,0.0000024957005,0.001585037],"genre_scores_gemma":[0.9960786,0.0023916734,0.0001291788,0.0004418931,0.00080082717,0.0000029554,0.0000010584116,0.0000072013677,0.00014658342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997788,0.00056897296,0.0009912043,0.00009938573,0.0004172871,0.00013511548],"domain_scores_gemma":[0.9956029,0.0022548859,0.0011455751,0.00006857113,0.0007259663,0.0002021039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065577137,0.00007096261,0.00071814965,0.000038677274,0.00001853881,0.000005162285,0.000069161106,0.0002315373,0.000015517926],"category_scores_gemma":[0.0038202368,0.000037816302,0.000106854706,0.00009921892,0.00008511986,0.00006319255,0.000030958246,0.00061010476,4.5749226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009511584,0.00022202928,0.9329811,0.0000107172045,0.000095589756,0.000031594183,0.00023920102,0.000026223488,0.000087993634,0.00001770932,0.0024204142,0.054355882],"study_design_scores_gemma":[0.009959313,0.0032628353,0.9364673,0.00011772076,0.00016765179,0.000050276325,0.00053400267,0.00021005579,0.00015947378,0.00010539453,0.04890955,0.0000564326],"about_ca_topic_score_codex":0.0005251783,"about_ca_topic_score_gemma":0.01720193,"teacher_disagreement_score":0.054299448,"about_ca_system_score_codex":0.00025846818,"about_ca_system_score_gemma":0.0014413744,"threshold_uncertainty_score":0.95990807},"labels":[],"label_agreement":null},{"id":"W2590122590","doi":"10.1200/jco.2014.32.30_suppl.267","title":"Unplanned visits to hospital emergency for oropharynx patients undergoing radiation therapy in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Radiation therapy; Emergency department; Cancer; Population; Head and neck cancer; Emergency medicine; Health care; Family medicine; Internal medicine; Nursing","score_opus":0.08447968420011086,"score_gpt":0.4455514840238153,"score_spread":0.3610717998237044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590122590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863604,0.0001629172,0.00020192239,0.008788313,0.0030712513,0.00032674137,9.930314e-7,0.0000039961815,0.0010835121],"genre_scores_gemma":[0.99467534,0.00073286536,0.0011539672,0.002374651,0.0008379656,0.0000082389515,0.000002563582,0.00001064448,0.00020379106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979068,0.00013368423,0.0014486918,0.00013671702,0.00018488197,0.0001892486],"domain_scores_gemma":[0.99776983,0.001016279,0.00059962814,0.000080246835,0.00031744095,0.00021655133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014257145,0.0000910604,0.0009653639,0.000101677186,0.000033234195,0.0000026206076,0.000077231496,0.00015718254,0.00007345562],"category_scores_gemma":[0.0033601944,0.00006568838,0.00022582988,0.00008397293,0.000015376101,0.000073888,0.000017965102,0.0003538659,0.000008797736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029620705,0.000988654,0.74001884,0.000009514664,0.00009070269,0.000008925713,0.00041162694,0.000007896187,0.000013260082,0.000026119122,0.007369742,0.24809262],"study_design_scores_gemma":[0.012248811,0.05424876,0.8314753,0.00005928794,0.000033289027,0.0000020968193,0.000024002567,0.000019417816,0.000015317299,0.00023987482,0.101572335,0.00006150676],"about_ca_topic_score_codex":0.0002464008,"about_ca_topic_score_gemma":0.011856674,"teacher_disagreement_score":0.24803111,"about_ca_system_score_codex":0.0002664863,"about_ca_system_score_gemma":0.00092777034,"threshold_uncertainty_score":0.6616303},"labels":[],"label_agreement":null},{"id":"W2590126529","doi":"10.1200/jco.2011.29.15_suppl.4031","title":"Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemcitabine; Neutropenia; Internal medicine; Clinical endpoint; Population; Gastroenterology; Immunohistochemistry; Phases of clinical research; Pancreatic cancer; Adverse effect; Cancer; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy","score_opus":0.29606206603478313,"score_gpt":0.5318115390963654,"score_spread":0.23574947306158223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590126529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869033,0.00035736576,0.0005740252,0.00088283845,0.00064596103,0.0034619542,0.000010293245,0.000011658275,0.0071525993],"genre_scores_gemma":[0.9759672,0.00073058956,0.021553878,0.0009473581,0.00031904952,0.00013206486,0.000010167337,0.000031789466,0.00030784876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99183583,0.0022020058,0.0040664957,0.000423746,0.00083310006,0.0006388144],"domain_scores_gemma":[0.991659,0.0032828718,0.0029167419,0.0003801052,0.0009831941,0.00077812455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007869612,0.0003508566,0.0070466897,0.0002347684,0.00011515305,0.000023986884,0.0005773827,0.00030295324,0.0007062677],"category_scores_gemma":[0.005466766,0.000199399,0.00026839157,0.0004334189,0.00095992227,0.0003253672,0.0002568168,0.0012257878,0.000013386544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7202802,0.025149137,0.24115549,0.00005606315,0.0021986128,0.0009420361,0.0003721343,0.000006641032,0.0000020449015,0.00006138066,0.0004407593,0.009335493],"study_design_scores_gemma":[0.8361518,0.09884496,0.057602905,0.0005002219,0.003912396,0.00010518563,0.0001773111,0.0018966565,0.0000030372787,0.000107197564,0.00051531056,0.00018301445],"about_ca_topic_score_codex":0.0010886618,"about_ca_topic_score_gemma":0.0012187929,"teacher_disagreement_score":0.1835526,"about_ca_system_score_codex":0.00074314274,"about_ca_system_score_gemma":0.004698886,"threshold_uncertainty_score":0.8335622},"labels":[],"label_agreement":null},{"id":"W2590127461","doi":"10.1200/jco.2015.33.29_suppl.79","title":"Are palliative patients less accepting to self-report symptom measures for clinical management than curative patients?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prom; Palliative care; Curative treatment; Cancer; Palliative treatment; Surgery; Internal medicine; Nursing; Disease","score_opus":0.6787595424019568,"score_gpt":0.6463149088124457,"score_spread":0.03244463358951111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590127461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698233,0.000030553278,0.005513013,0.015272422,0.0055616884,0.002072151,0.000023190669,0.000035644433,0.0016680524],"genre_scores_gemma":[0.93220806,0.00023208598,0.050346117,0.01395682,0.0029224737,0.000053542473,0.000054128297,0.000054695076,0.00017207924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9862324,0.0014149693,0.0100085605,0.0005556783,0.0013451264,0.00044324732],"domain_scores_gemma":[0.96083176,0.01548953,0.013373559,0.0004456506,0.008385501,0.0014739924],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01843402,0.00029767395,0.0022845245,0.0002041698,0.000086545355,0.000033040043,0.00035839304,0.00048472098,0.000025831137],"category_scores_gemma":[0.16346373,0.00022410913,0.00093104545,0.000268704,0.00013538309,0.00041744203,0.0002603715,0.0011921152,0.000043403754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068116854,0.005284565,0.7517607,0.000031068426,0.0010815426,0.00021458528,0.00024432974,0.000015474901,2.6687047e-7,0.000028453418,0.05535972,0.17916757],"study_design_scores_gemma":[0.023036461,0.016697595,0.7671271,0.00015391105,0.0012585697,0.000019661371,0.0022971083,0.000060507737,0.0000035681946,0.00034337805,0.18881568,0.00018648572],"about_ca_topic_score_codex":0.000016042393,"about_ca_topic_score_gemma":0.00009971274,"teacher_disagreement_score":0.17898108,"about_ca_system_score_codex":0.0005762733,"about_ca_system_score_gemma":0.0013902469,"threshold_uncertainty_score":0.91389054},"labels":[],"label_agreement":null},{"id":"W2590128314","doi":"10.1200/jco.2016.34.2_suppl.192","title":"Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Protein kinase B; LNCaP; Prostate cancer; Cancer research; Enzalutamide; PTEN; Medicine; Androgen receptor; PI3K/AKT/mTOR pathway; Growth inhibition; Apoptosis; Cell growth; Cancer; Internal medicine; Chemistry; Biochemistry","score_opus":0.1586946210047408,"score_gpt":0.4948424818601984,"score_spread":0.3361478608554576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590128314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801315,0.0029608577,0.000029414106,0.015221567,0.00052534364,0.00044813476,0.00002724158,0.0000065031295,0.00064943597],"genre_scores_gemma":[0.9794668,0.017461697,0.00069209526,0.0003493019,0.000379975,0.000015303458,0.0000011725672,0.000019633797,0.0016140209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948038,0.000693026,0.0033969441,0.0002782777,0.00047033664,0.00035761515],"domain_scores_gemma":[0.9935674,0.0037020275,0.0014749689,0.00021444468,0.0005190608,0.0005220642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049620443,0.00016317973,0.0019370224,0.00017565252,0.00002450029,0.0000054371294,0.00016738202,0.00039985383,0.00008681918],"category_scores_gemma":[0.0023506812,0.00008450343,0.00035159453,0.00015891851,0.0007235496,0.00014863884,0.00009837726,0.0007962391,0.000002685725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09374927,0.0059383023,0.5403091,0.00020489353,0.0009625931,0.0017109435,0.00052896026,0.000023846214,0.007243783,0.0003650111,0.0018248707,0.34713846],"study_design_scores_gemma":[0.09035021,0.07350333,0.8028467,0.0019299457,0.00049827783,0.000114630064,0.00015653328,0.00041588832,0.004846151,0.0116391415,0.013425918,0.00027325208],"about_ca_topic_score_codex":0.000098192024,"about_ca_topic_score_gemma":0.00016758744,"teacher_disagreement_score":0.3468652,"about_ca_system_score_codex":0.00020155167,"about_ca_system_score_gemma":0.0032737649,"threshold_uncertainty_score":0.58075184},"labels":[],"label_agreement":null},{"id":"W2590128943","doi":"10.1200/jco.2015.33.7_suppl.404","title":"Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Oncology; Neutrophil to lymphocyte ratio; Proportional hazards model; Surrogate endpoint; Predictive marker; Cohort; Targeted therapy; Progression-free survival; Prospective cohort study; Lymphocyte; Overall survival; Cancer","score_opus":0.12707490393632198,"score_gpt":0.43442931255427614,"score_spread":0.30735440861795416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590128943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572695,0.0011884533,0.00009575597,0.010031025,0.00047485548,0.0023677885,0.000016554231,0.0000066005346,0.00009202001],"genre_scores_gemma":[0.9857384,0.000088338515,0.0073645627,0.005989286,0.00041475813,0.00032613927,0.0000034450327,0.000028037748,0.000047034366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958971,0.0012166264,0.0018757033,0.0003031512,0.00036096887,0.00034645453],"domain_scores_gemma":[0.99438053,0.003265675,0.00062957004,0.00017719087,0.0005817338,0.00096529507],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008236829,0.00018889781,0.0011940048,0.00056048104,0.000020606514,0.000012377554,0.00015311663,0.00022568922,0.000022623568],"category_scores_gemma":[0.012886365,0.00014626728,0.00019583936,0.00036129847,0.00011055643,0.0001323491,0.000072039904,0.00037966215,0.000008599577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4259982,0.001885983,0.54207385,0.000057368376,0.00016451348,0.0025604342,0.0022080156,0.000033044576,0.0016348151,0.0000056788444,0.0019830652,0.021394996],"study_design_scores_gemma":[0.028186388,0.034733612,0.9276657,0.00014872644,0.000184525,0.00014050417,0.00031705384,0.0006966592,0.00037996084,0.00017672186,0.0072350707,0.00013506226],"about_ca_topic_score_codex":0.000024918798,"about_ca_topic_score_gemma":0.00004281673,"teacher_disagreement_score":0.39781183,"about_ca_system_score_codex":0.00049081916,"about_ca_system_score_gemma":0.0032670961,"threshold_uncertainty_score":0.9954285},"labels":[],"label_agreement":null},{"id":"W2590129025","doi":"10.1200/jco.2014.32.30_suppl.257","title":"Improving the safe delivery of systemic treatment by assessing concordance with labeling guidelines.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Concordance; Medicine; Guideline; Quality management; Internal medicine; Operations management; Pathology","score_opus":0.3632528676379009,"score_gpt":0.5685413941854774,"score_spread":0.20528852654757657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590129025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96343184,0.0011895072,0.01916169,0.014503091,0.0009910612,0.00033830456,0.0000040185673,0.00001067668,0.00036979103],"genre_scores_gemma":[0.95542186,0.0010171508,0.036819175,0.0050454237,0.0015647877,0.00000439497,0.000004913518,0.000024882987,0.00009740152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99137974,0.0010079573,0.00653988,0.00023108548,0.00060801726,0.00023332004],"domain_scores_gemma":[0.9729134,0.01613482,0.0077599566,0.00036304738,0.002577306,0.0002515093],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01319359,0.00018266309,0.001658706,0.00006807743,0.000072104485,0.000019685584,0.00020870629,0.00025899624,0.00003993259],"category_scores_gemma":[0.028903171,0.00009465543,0.00037134753,0.00015848824,0.00025200378,0.00026949478,0.000049732076,0.0007980682,0.000006552225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034032492,0.0009196149,0.067335,0.000083052095,0.0005717277,0.000078395584,0.00007933855,0.00027125012,0.012985518,0.00004789826,0.005992611,0.90823233],"study_design_scores_gemma":[0.14818795,0.18626201,0.099323615,0.00610949,0.017000023,0.011033596,0.013024803,0.055640496,0.006412557,0.00050845393,0.45516303,0.001333993],"about_ca_topic_score_codex":0.00038650964,"about_ca_topic_score_gemma":0.0000915668,"teacher_disagreement_score":0.9068983,"about_ca_system_score_codex":0.00026468848,"about_ca_system_score_gemma":0.0029748678,"threshold_uncertainty_score":0.9792768},"labels":[],"label_agreement":null},{"id":"W2590130898","doi":"10.1200/jco.2012.30.5_suppl.11","title":"TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erg; TMPRSS2; Medicine; Prostate cancer; Tissue microarray; Prostate; Oncology; Immunohistochemistry; Radiation therapy; Internal medicine; Cancer; Ophthalmology","score_opus":0.11334181556799748,"score_gpt":0.5202996541605988,"score_spread":0.40695783859260126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590130898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586335,0.035404865,0.00010987145,0.00295937,0.002321317,0.00044180613,0.000021237855,0.000007771582,0.00010025629],"genre_scores_gemma":[0.9345632,0.058525674,0.0039937124,0.00045576438,0.0021294323,0.00003440898,0.000006232241,0.000020832682,0.00027069618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757034,0.00021304884,0.0012708715,0.00016948114,0.0002600262,0.00051624473],"domain_scores_gemma":[0.99584895,0.0021731528,0.000851748,0.00011211263,0.00023634864,0.0007777128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029078862,0.00013705202,0.0010277523,0.00009640245,0.000056156157,0.00001109962,0.00009105804,0.0002591745,0.00003846953],"category_scores_gemma":[0.003022151,0.00008624162,0.00039572554,0.000102382146,0.00025898663,0.00016373266,0.000037025013,0.0007886446,0.0000018147829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008385697,0.00069481344,0.6503942,0.00005655084,0.0006677202,0.00004551465,0.00046971376,5.6329054e-7,0.0007091019,0.000012291382,0.0055045765,0.33305928],"study_design_scores_gemma":[0.046828132,0.030572204,0.52959985,0.0005444706,0.0012129782,0.00015372696,0.00046153358,0.0002267105,0.0026204484,0.00048523987,0.38697982,0.00031488022],"about_ca_topic_score_codex":0.000021557522,"about_ca_topic_score_gemma":0.000005097425,"teacher_disagreement_score":0.38147524,"about_ca_system_score_codex":0.00027392257,"about_ca_system_score_gemma":0.0013286036,"threshold_uncertainty_score":0.36180153},"labels":[],"label_agreement":null},{"id":"W2590141003","doi":"10.1200/jco.2011.29.4_suppl.16","title":"Surgical density and its effect on esophageal cancer (EC) and gastric (GC) mortality.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Incidence (geometry); Socioeconomic status; Population; Demography; Mortality rate; Cancer; Esophageal cancer; Cardiothoracic surgery; Surgery; Internal medicine; Environmental health","score_opus":0.17653020075444528,"score_gpt":0.4959115474922093,"score_spread":0.31938134673776397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590141003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925734,0.007405929,0.0000021798983,0.0009581385,0.00036436896,0.00023366924,0.0000035099238,0.0000068780555,0.0017680165],"genre_scores_gemma":[0.9943908,0.0039213332,0.00015621114,0.0005402002,0.0007883474,0.0000068136756,7.2762407e-7,0.000010875208,0.00018473435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976617,0.0005358897,0.0009156764,0.00022590603,0.00038986036,0.00027094665],"domain_scores_gemma":[0.9967115,0.0016421383,0.00046233044,0.000117209245,0.00020115757,0.0008656488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024858087,0.00014520189,0.001199204,0.00010363941,0.00004680609,0.00000656246,0.00007042181,0.00024532934,0.00024105073],"category_scores_gemma":[0.0011481943,0.00008858919,0.00022301322,0.00009311281,0.00020081303,0.00006965543,0.00005996089,0.00093396823,0.000012519697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010814515,0.0009846607,0.8774434,0.000062620646,0.00054885127,0.016280364,0.00005022855,2.6761876e-7,0.0000113922115,0.00017984377,0.0003415175,0.09328239],"study_design_scores_gemma":[0.010737792,0.0484265,0.9372463,0.000073694755,0.00042366004,0.0015162473,0.000006820451,0.00001871566,0.00047832634,0.00015217054,0.00086232414,0.000057427394],"about_ca_topic_score_codex":0.00008239576,"about_ca_topic_score_gemma":0.000049546303,"teacher_disagreement_score":0.09322496,"about_ca_system_score_codex":0.000115217044,"about_ca_system_score_gemma":0.000650599,"threshold_uncertainty_score":0.40576792},"labels":[],"label_agreement":null},{"id":"W2590145253","doi":"10.1200/jco.2013.31.31_suppl.80","title":"Bidirectional consultative process as a novel methodology to develop a pan-Canadian cancer quality initiative.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Stakeholder; Quality (philosophy); Relevance (law); Enthusiasm; Stakeholder engagement; Process (computing); Focus group; Medicine; Public relations; Medical education; Computer science; Business; Psychology; Political science; Marketing","score_opus":0.8167217640693439,"score_gpt":0.7086509886297792,"score_spread":0.10807077543956478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590145253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8152338,0.00007544692,0.0077838367,0.17052469,0.0020215795,0.00081076357,0.000031173324,0.000014381175,0.003504311],"genre_scores_gemma":[0.7607877,0.00016502407,0.14072248,0.096202664,0.0016826086,0.00008962896,0.000011105726,0.000026646676,0.00031211355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914511,0.0019722665,0.0053732856,0.0003198821,0.00050562585,0.00037787008],"domain_scores_gemma":[0.9344007,0.04695808,0.0045943153,0.00020632024,0.012112843,0.0017277469],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014397208,0.00018103329,0.0016543268,0.00032171098,0.00007971187,0.00001701393,0.00019337266,0.00045519482,0.0024708726],"category_scores_gemma":[0.33115867,0.00013986405,0.00023961194,0.0007307038,0.000254007,0.0003516029,0.00005206376,0.0013995186,0.00030997212],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009473972,0.0024342048,0.13208365,0.000069615955,0.0018806108,0.00021277237,0.0025600852,0.00004918457,0.0017325463,0.0009795415,0.04179152,0.8067323],"study_design_scores_gemma":[0.010156838,0.0075875903,0.83498186,0.00010671627,0.00046541973,0.0005875148,0.004315747,0.000074207266,0.0003308672,0.0043765977,0.13677521,0.00024142588],"about_ca_topic_score_codex":0.03997658,"about_ca_topic_score_gemma":0.05072385,"teacher_disagreement_score":0.80649084,"about_ca_system_score_codex":0.0005486491,"about_ca_system_score_gemma":0.028468026,"threshold_uncertainty_score":0.998441},"labels":[],"label_agreement":null},{"id":"W2590145929","doi":"10.1200/jco.2016.34.4_suppl.247","title":"Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Pancreas Centre (Canada); Simon Fraser University; BC Cancer Agency","funders":"","keywords":"KRAS; Medicine; Biomarker; Liquid biopsy; Internal medicine; Circulating tumor DNA; Oncology; Multiplex; Minimal residual disease; Digital polymerase chain reaction; Pancreatic cancer; Mutation; Cancer research; Cancer; Bioinformatics; Gene; Polymerase chain reaction; Colorectal cancer; Biology; Genetics","score_opus":0.08693141935859376,"score_gpt":0.4201993912716209,"score_spread":0.33326797191302715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590145929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946034,0.0013643965,0.0003590466,0.0008248558,0.0011676656,0.00012540714,0.000017566083,0.0000019684937,0.0015356801],"genre_scores_gemma":[0.9945971,0.0013319327,0.0019845888,0.00042435856,0.0015656152,0.0000027800681,0.000002654591,0.000018295223,0.00007271524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951735,0.00065633043,0.0033125486,0.00032993773,0.00021991742,0.0003077415],"domain_scores_gemma":[0.99476755,0.0022779102,0.0019471301,0.00037276695,0.0003693594,0.0002652878],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0053653633,0.00014835627,0.0011937337,0.000075095864,0.000024865827,0.000006325198,0.00035611138,0.00043495605,0.00009174003],"category_scores_gemma":[0.01556205,0.00010489015,0.00055136066,0.00010131383,0.00038581775,0.000010276825,0.00018980405,0.0004360192,0.0000056455688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018846324,0.0007414076,0.94953704,0.000021446618,0.0001507467,0.00020954569,0.000015036081,0.0000073125125,0.02028672,0.00007794206,0.002198877,0.024869276],"study_design_scores_gemma":[0.005786024,0.006304226,0.9688337,0.00010976533,0.00010553603,0.00020731454,0.000060793,0.000060581064,0.0030817154,0.0010124063,0.014275548,0.0001624234],"about_ca_topic_score_codex":0.000043609733,"about_ca_topic_score_gemma":0.00019439956,"teacher_disagreement_score":0.024706852,"about_ca_system_score_codex":0.000048009504,"about_ca_system_score_gemma":0.0017736059,"threshold_uncertainty_score":0.99273026},"labels":[],"label_agreement":null},{"id":"W2590149856","doi":"10.1200/jco.2005.23.16_suppl.5539","title":"A phase I open-label study to evaluate safety, tolerability and pharmacokinetic (PK) profile of VB4–845, an anti-EpCAM immunotoxin, in subjects with SCCHN","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada)","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Immunogenicity; Epithelial cell adhesion molecule; Internal medicine; Pharmacodynamics; Lesion; Cancer; Pharmacology; Oncology; Pathology; Antibody; Adverse effect; Immunology","score_opus":0.10482104516264341,"score_gpt":0.47240523173144855,"score_spread":0.36758418656880515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590149856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947861,0.0010791869,0.00012517114,0.0009395842,0.0008551727,0.0017553817,0.000030369407,0.000011466427,0.00041757795],"genre_scores_gemma":[0.9953555,0.00018859486,0.0034825392,0.00057021744,0.000121514335,0.000028231292,0.0000071671516,0.000029693023,0.00021655238],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9926697,0.0025948891,0.0035640579,0.00051754055,0.000149943,0.000503872],"domain_scores_gemma":[0.9959627,0.0010484847,0.001798507,0.0004934463,0.0005120131,0.00018489745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009504183,0.0003174734,0.0024071955,0.0002629135,0.00013300315,0.000032043496,0.00092331116,0.0003892203,0.0006889896],"category_scores_gemma":[0.0012237785,0.00022982046,0.00012418219,0.00033859027,0.0004944594,0.00047594844,0.00035663255,0.0013931497,0.000040305018],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046265084,0.11204976,0.030316126,0.000039198778,0.0010065774,0.00021088718,0.0035915375,0.00013512658,0.44386068,0.00014482753,0.00043148635,0.36194873],"study_design_scores_gemma":[0.26853555,0.3069874,0.3484087,0.0003359105,0.00084943476,0.0007636103,0.0031326097,0.00019601255,0.052582223,0.00027013288,0.017080426,0.0008579846],"about_ca_topic_score_codex":0.00009616684,"about_ca_topic_score_gemma":0.00034364327,"teacher_disagreement_score":0.39127845,"about_ca_system_score_codex":0.000104741506,"about_ca_system_score_gemma":0.0012750516,"threshold_uncertainty_score":0.93718064},"labels":[],"label_agreement":null},{"id":"W2590154604","doi":"10.1200/jco.2005.23.16_suppl.649","title":"Mortality reduction of breast cancer in Canada: Beneficial impact of cancer care infrastructure","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Statistics Canada","funders":"","keywords":"Medicine; Breast cancer; Relative survival; Demography; Population; Outreach; Psychological intervention; Cancer; Mortality rate; Mammography; Cancer registry; Gerontology; Environmental health; Surgery; Internal medicine; Economic growth","score_opus":0.11722235194970676,"score_gpt":0.5158835511881686,"score_spread":0.3986611992384619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590154604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461764,0.002277842,0.0000028400345,0.0017854277,0.0008141978,0.000091879345,0.00010537725,0.0000012456356,0.00030357123],"genre_scores_gemma":[0.9966471,0.0010774157,0.00024656576,0.00023872225,0.0017748995,0.0000015222627,0.0000015161648,0.000006751361,0.0000054826855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705446,0.0001193188,0.0020545435,0.00012267884,0.00045604317,0.000192939],"domain_scores_gemma":[0.9968083,0.0001295556,0.001839812,0.00012229009,0.00088669744,0.00021338138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006615888,0.00010772344,0.0012764194,0.00008671748,0.000012718593,0.0000013564696,0.00012914522,0.00023178864,0.00050548883],"category_scores_gemma":[0.00031796726,0.00007665072,0.0003515862,0.00020446222,0.000106179315,0.00010937767,0.000024190103,0.00071830774,1.4409265e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023016525,0.00008025608,0.77608633,0.000033685792,0.00020655598,0.00004189893,0.00013675907,0.014748024,0.00041597348,0.0000045597367,0.0010785585,0.20486574],"study_design_scores_gemma":[0.002321496,0.001298048,0.9940977,0.00026240846,0.0002558335,0.00015973947,0.0005934199,0.00011422447,0.0002083026,0.000024461138,0.0006060747,0.0000582567],"about_ca_topic_score_codex":0.8230088,"about_ca_topic_score_gemma":0.9065573,"teacher_disagreement_score":0.21801141,"about_ca_system_score_codex":0.0027360094,"about_ca_system_score_gemma":0.024479527,"threshold_uncertainty_score":0.9810508},"labels":[],"label_agreement":null},{"id":"W2590157633","doi":"10.1200/jco.2013.31.15_suppl.e16068","title":"Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) refractory to docetaxel (D).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Abiraterone acetate; Ketoconazole; Oncology; Refractory (planetary science); Progression-free survival; Urology; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.18282704748474443,"score_gpt":0.5120465585913472,"score_spread":0.32921951110660275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590157633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382675,0.00045086225,0.000007942199,0.003408921,0.0004596451,0.001215201,0.0000144254755,0.0000050402086,0.0006112178],"genre_scores_gemma":[0.9969669,0.00040674084,0.0017563928,0.00021584466,0.00012589326,0.000073178126,0.000010743404,0.000021001335,0.00042333058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961128,0.00040193947,0.0022682573,0.00023090112,0.0006316347,0.00035443073],"domain_scores_gemma":[0.9961142,0.0007028615,0.0014888266,0.00019238409,0.0010779948,0.00042371775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012815079,0.00017794385,0.0015520852,0.0002383474,0.000032100397,0.00001514749,0.0001412494,0.00014219058,0.00025106015],"category_scores_gemma":[0.00051838986,0.00010890221,0.00014846094,0.0002687835,0.00021143236,0.00025861876,0.00003380537,0.000773474,0.000025387275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13189028,0.007345071,0.6941115,0.00023959515,0.001039778,0.00026205435,0.0014651483,0.00034107052,0.0038778458,0.000013959766,0.0037855443,0.15562816],"study_design_scores_gemma":[0.049096253,0.054705065,0.88808507,0.00034831106,0.00032790808,0.0000058366986,0.0005647029,0.000093612114,0.0014967121,0.000038509515,0.0051051374,0.00013288314],"about_ca_topic_score_codex":0.00036977537,"about_ca_topic_score_gemma":0.00073990837,"teacher_disagreement_score":0.19397357,"about_ca_system_score_codex":0.00051549403,"about_ca_system_score_gemma":0.0019775669,"threshold_uncertainty_score":0.4440903},"labels":[],"label_agreement":null},{"id":"W2590158182","doi":"10.1200/jco.2014.32.3_suppl.594","title":"Treatment and outcomes of neuroendocrine malignancies (NEMs) of the rectum.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rectum; Neuroendocrine tumors; Colorectal cancer; Stage (stratigraphy); Univariate analysis; Radiation therapy; Multimodal therapy; Internal medicine; Oncology; Cancer; Gastroenterology; Multivariate analysis; Biology","score_opus":0.10226569313811577,"score_gpt":0.4756421537502647,"score_spread":0.3733764606121489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590158182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772533,0.00023596146,0.000007311147,0.020087188,0.0005385626,0.00017732826,0.0000024854908,0.0000033491895,0.001694473],"genre_scores_gemma":[0.99632305,0.001237207,0.00079294574,0.0006229472,0.00022225414,0.0000019621834,1.3213783e-7,0.00001056135,0.00078892347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997095,0.0005780998,0.0016715621,0.00012503522,0.0003392259,0.00019110946],"domain_scores_gemma":[0.9939365,0.0038532016,0.0014275084,0.00026793667,0.00031085746,0.00020401865],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006695749,0.00011037757,0.0015065372,0.00008822388,0.000020856065,0.0000023185853,0.00017564835,0.00001580823,0.00003289764],"category_scores_gemma":[0.011740668,0.000052757045,0.0004286316,0.00010270155,0.0005116838,0.00005182685,0.000096168485,0.00039326015,0.000001394257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023620485,0.0015590612,0.90524924,0.00008910692,0.00029760096,0.00094608846,0.00002818848,0.000010978828,0.0040383018,0.00048569893,0.0010928609,0.08384084],"study_design_scores_gemma":[0.008392049,0.034513067,0.8300799,0.00007066005,0.00028809535,0.003985294,0.000059508813,0.00002587678,0.010352204,0.0007119916,0.11146817,0.00005318842],"about_ca_topic_score_codex":0.00002142071,"about_ca_topic_score_gemma":0.00002779892,"teacher_disagreement_score":0.110375315,"about_ca_system_score_codex":0.000033239576,"about_ca_system_score_gemma":0.00043464347,"threshold_uncertainty_score":0.9965839},"labels":[],"label_agreement":null},{"id":"W2590163563","doi":"10.1200/jco.2016.34.26_suppl.39","title":"Attitude and support to inform clinical predictions of survival in patients with advanced cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Psychosocial; Lung cancer; Palliative care; Disease; Cancer; Performance status; Internal medicine","score_opus":0.19489885747082966,"score_gpt":0.5272027095218715,"score_spread":0.33230385205104185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590163563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921564,0.000050189,0.00024294115,0.0050187665,0.00079698407,0.00018702321,0.000011789829,0.0000037618017,0.0015321441],"genre_scores_gemma":[0.99518704,0.00048274995,0.002570377,0.0012921575,0.00033480182,0.000003542591,7.1185656e-7,0.000006881143,0.000121749756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968456,0.000115343384,0.0022701554,0.00014673827,0.0004335256,0.00018860579],"domain_scores_gemma":[0.9966279,0.0010994129,0.0010279319,0.00013247435,0.0006840411,0.00042823478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024625435,0.000089592155,0.0011706959,0.00009929766,0.000017748493,0.00000221059,0.00011000222,0.00020306661,0.0001058126],"category_scores_gemma":[0.0033271285,0.000048587914,0.00014606483,0.00016843266,0.00021798952,0.00018233513,0.00005396048,0.00042138615,0.0000034771992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008252322,0.0003752801,0.7775264,0.000008288663,0.00008693679,0.000034485518,0.000028417444,0.000012852333,0.0000053357294,0.00002817016,0.0006238482,0.21301766],"study_design_scores_gemma":[0.01207212,0.030605536,0.93452996,0.0003426762,0.00010898909,0.000016301361,0.000043569413,0.0000027750727,0.000006210098,0.000024933111,0.02219284,0.000054066877],"about_ca_topic_score_codex":0.00002870555,"about_ca_topic_score_gemma":0.000422258,"teacher_disagreement_score":0.2129636,"about_ca_system_score_codex":0.00012499522,"about_ca_system_score_gemma":0.0014089751,"threshold_uncertainty_score":0.3983124},"labels":[],"label_agreement":null},{"id":"W2590164171","doi":"10.1200/jco.2014.32.30_suppl.181","title":"Understanding disparities and organisational variation in cancer patient experience: Lessons from the English National Cancer Patient Experience survey.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Patient experience; Cancer; Family medicine; Logistic regression; Specialty; Odds ratio; Ethnic group; Breast cancer; Demography; Health care; Internal medicine","score_opus":0.5680045811713331,"score_gpt":0.5944364614529504,"score_spread":0.026431880281617248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590164171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798666,0.00025356747,0.001018861,0.009709738,0.008371873,0.00034137385,0.00014536345,0.000010605658,0.00028196708],"genre_scores_gemma":[0.992267,0.0007658988,0.00033713927,0.0052028676,0.0012351492,0.00015357543,0.000011181804,0.00001436226,0.000012830665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99167055,0.0042381887,0.0026820828,0.00027741626,0.00080891466,0.00032286445],"domain_scores_gemma":[0.9750766,0.020806562,0.0025540227,0.00013501894,0.0012069169,0.00022086721],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034815508,0.00014662558,0.00063635135,0.000097215474,0.0005293506,0.000015623637,0.00018919221,0.00040365756,0.0006425703],"category_scores_gemma":[0.016111704,0.00010404291,0.00007494172,0.00021603394,0.00026945485,0.00034567318,0.00011137663,0.0013878447,0.0000033610277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003241065,0.00009197762,0.9519258,0.000011529283,0.000030250238,0.0000014868036,0.038498178,0.00031821884,0.0000071655086,0.0022110895,0.0020268585,0.004553336],"study_design_scores_gemma":[0.0013823083,0.00046394326,0.97663635,0.00019134647,0.00001371876,0.0000010066236,0.010515728,0.00065312797,0.000002811497,0.003317228,0.0067137727,0.00010865485],"about_ca_topic_score_codex":0.009315153,"about_ca_topic_score_gemma":0.01549911,"teacher_disagreement_score":0.02798245,"about_ca_system_score_codex":0.0017008611,"about_ca_system_score_gemma":0.0028017622,"threshold_uncertainty_score":0.9972819},"labels":[],"label_agreement":null},{"id":"W2590164673","doi":"10.1200/jco.2015.33.7_suppl.464","title":"Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Sunitinib; Mucositis; Renal cell carcinoma; Internal medicine; Adverse effect; Sorafenib; Toxicity; Oncology; Surgery; Urology; Hepatocellular carcinoma","score_opus":0.10954902848682431,"score_gpt":0.36216653307392144,"score_spread":0.25261750458709714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590164673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635756,0.00022242215,0.00015866992,0.00145563,0.00012443661,0.0010640204,0.00043695036,0.000009692378,0.00017061167],"genre_scores_gemma":[0.99386805,0.00010661587,0.005184663,0.00028366232,0.00006673282,0.000021029578,0.0003530394,0.000028670598,0.00008750849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956772,0.0008869365,0.0020382146,0.00040658106,0.0007399834,0.00025108914],"domain_scores_gemma":[0.9943281,0.002365634,0.0018660919,0.00033441462,0.0005461839,0.0005596217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001631167,0.0003213633,0.001352026,0.00019762825,0.0000435487,0.000026269408,0.00017391965,0.000103097715,0.000015325239],"category_scores_gemma":[0.0014238721,0.00014145563,0.00016934494,0.00021880181,0.0001759675,0.00020487723,0.000045218665,0.0005314176,0.000003060429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053818215,0.004653247,0.93039495,0.0000022487015,0.0014718189,0.00044622476,0.0019386112,0.001778005,0.00010571665,0.0000019754943,0.00031703518,0.0050719324],"study_design_scores_gemma":[0.071243994,0.052338134,0.8679582,0.00008618475,0.0016534358,0.000024959709,0.0005728558,0.0047100973,0.0010997175,0.00003576718,0.00012839137,0.00014825077],"about_ca_topic_score_codex":0.001127598,"about_ca_topic_score_gemma":0.00064705126,"teacher_disagreement_score":0.06243676,"about_ca_system_score_codex":0.000539192,"about_ca_system_score_gemma":0.0012644283,"threshold_uncertainty_score":0.5768393},"labels":[],"label_agreement":null},{"id":"W2590172935","doi":"10.1200/jco.2015.33.3_suppl.22","title":"Urinary metabolomics of gastric cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Metabolomics; Medicine; Receiver operating characteristic; Metabolite; Cancer; Urine; Biomarker; Internal medicine; Area under the curve; Univariate analysis; Multivariate analysis; Gastroenterology; Chromatography; Biology; Chemistry","score_opus":0.1341551739639363,"score_gpt":0.4505411803043417,"score_spread":0.31638600634040537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590172935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789411,0.013567935,0.00059646094,0.0011910734,0.0019872147,0.00006070069,0.000009903698,0.0000016457977,0.003643975],"genre_scores_gemma":[0.9753021,0.013240033,0.009010413,0.00047056956,0.0015596944,0.0000022561248,0.000002380547,0.000011940733,0.00040064094],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977313,0.00026424677,0.001489598,0.00014994145,0.0001897494,0.00017511887],"domain_scores_gemma":[0.997157,0.00015433015,0.0016510469,0.00017774465,0.0006179299,0.00024198659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002669982,0.000109594585,0.0009834871,0.00008567428,0.000017357712,0.0000031583663,0.0002767547,0.00025550043,0.000018135488],"category_scores_gemma":[0.0028830396,0.00008144942,0.0003718535,0.00012951539,0.00018099783,0.000005039603,0.00015354318,0.00029837093,0.0000022317993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0156781,0.007519556,0.2988285,0.000085818225,0.006036739,0.00031037396,0.00020182709,0.000672857,0.1798101,0.0031733708,0.21896796,0.2687148],"study_design_scores_gemma":[0.0061090817,0.021892963,0.054395832,0.000014772145,0.00042935042,0.00027630397,0.00026209585,0.000026406515,0.010981074,0.0012758345,0.9041375,0.00019877327],"about_ca_topic_score_codex":0.000013108374,"about_ca_topic_score_gemma":0.0000098134,"teacher_disagreement_score":0.6851696,"about_ca_system_score_codex":0.000023452232,"about_ca_system_score_gemma":0.0014623131,"threshold_uncertainty_score":0.3451476},"labels":[],"label_agreement":null},{"id":"W2590175277","doi":"10.1200/jco.2016.34.7_suppl.295","title":"Choosing Wisely in oncology: Screening for a new primary cancer in patients with metastatic disease.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer; Breast cancer; Population; Lung cancer; Colorectal cancer; Internal medicine; Prostate cancer; Disease; Oncology; Metastatic breast cancer; Incidence (geometry); Cohort; Gynecology; Environmental health","score_opus":0.6200285364892965,"score_gpt":0.5728676873117792,"score_spread":0.04716084917751728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590175277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8509553,0.0016327852,0.015122182,0.1293936,0.0013580224,0.00095763156,0.00013637038,0.0000074277323,0.00043668138],"genre_scores_gemma":[0.9249779,0.0005872243,0.04752807,0.025055164,0.0013562544,0.000080767255,0.0000068265626,0.000053423864,0.00035436198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98937494,0.00076027657,0.009013002,0.00034359813,0.000120754295,0.00038743566],"domain_scores_gemma":[0.98152226,0.009543092,0.008083242,0.00019183337,0.00017899886,0.00048058166],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027170159,0.00014979887,0.0025135027,0.00043505587,0.000037914735,0.000014733387,0.00026879171,0.00016959308,0.00015276203],"category_scores_gemma":[0.017648838,0.00011814109,0.00023229404,0.00016518432,0.00010635262,0.0005835343,0.00003753061,0.000385288,0.000032473643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002308483,0.0006877353,0.919834,0.000071796865,0.00012086204,0.000011973718,0.00015524165,0.00025212127,2.2978479e-7,0.0011200305,0.0051188115,0.07031867],"study_design_scores_gemma":[0.016723698,0.0019835802,0.9107382,0.00040600233,0.00003078151,0.0000017376109,0.00005955558,0.00022074976,1.2350513e-7,0.0073781027,0.06230166,0.00015579748],"about_ca_topic_score_codex":0.00021756001,"about_ca_topic_score_gemma":0.00088436145,"teacher_disagreement_score":0.104338445,"about_ca_system_score_codex":0.0015841874,"about_ca_system_score_gemma":0.0034823613,"threshold_uncertainty_score":0.9906259},"labels":[],"label_agreement":null},{"id":"W2590180332","doi":"10.1200/jco.2013.31.31_suppl.71","title":"Use of pharmacist integration in oncology clinics to identify and resolve moderate to major drug-drug interactions.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pharmacist; Drug; Ambulatory; Adverse effect; Clinical pharmacy; Outpatient clinic; Internal medicine; Emergency medicine; Pharmacy; Family medicine; Pharmacology","score_opus":0.46286397721886513,"score_gpt":0.6137721017180139,"score_spread":0.15090812449914875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590180332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517882,0.00009472747,0.0007093938,0.043762393,0.0022032643,0.00060124934,0.000004534169,0.000005895485,0.00083037827],"genre_scores_gemma":[0.9652821,0.0006338614,0.014702521,0.018213456,0.00042500655,0.000013881205,0.0000024934886,0.000015098932,0.0007116012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950405,0.0009198788,0.003290673,0.00022980003,0.0002872007,0.00023195369],"domain_scores_gemma":[0.98786545,0.009017781,0.0015150477,0.00016522798,0.00072507653,0.00071141747],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034764903,0.00014818083,0.0013898347,0.00034931267,0.000030802083,0.000028393044,0.00013974802,0.0001589246,0.00027155553],"category_scores_gemma":[0.010429646,0.000108636785,0.0002524951,0.00024268117,0.000115521565,0.0006411811,0.00012396713,0.0015559386,0.00009561224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029363016,0.00491756,0.27956748,0.00009191169,0.00041459515,0.00039839177,0.0018916125,0.00022757727,0.005159588,0.00014310231,0.05535771,0.62246746],"study_design_scores_gemma":[0.016234918,0.009834957,0.37040457,0.00048077948,0.00079240673,0.00043245187,0.0010745632,0.014986214,0.0016673736,0.0009094921,0.5828804,0.0003019046],"about_ca_topic_score_codex":0.00016241484,"about_ca_topic_score_gemma":0.0002728286,"teacher_disagreement_score":0.62216556,"about_ca_system_score_codex":0.0001805849,"about_ca_system_score_gemma":0.00048000566,"threshold_uncertainty_score":0.9979059},"labels":[],"label_agreement":null},{"id":"W2590191068","doi":"10.1200/jco.2016.34.2_suppl.106","title":"Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Cohort; Gene signature; Adjuvant; Enzalutamide; Logistic regression; Metastasis; Cancer; Adjuvant therapy; Androgen receptor; Gene expression; Gene; Biology","score_opus":0.1027191597097351,"score_gpt":0.45533432049334854,"score_spread":0.35261516078361343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590191068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865895,0.0011851608,0.00013498018,0.011178698,0.00017327041,0.00028443718,0.000008447104,0.000004941222,0.0004405724],"genre_scores_gemma":[0.977505,0.0015640119,0.018486982,0.00018131884,0.0004122473,0.000009671704,0.0000043579957,0.000009960488,0.0018264501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979571,0.00018560908,0.0011731895,0.0001690823,0.00034128618,0.0001737355],"domain_scores_gemma":[0.9978447,0.0005958254,0.00057595456,0.00013842757,0.00038093087,0.0004641445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013460811,0.0001056032,0.0008275774,0.000117429976,0.000029223947,0.0000040529835,0.000077673765,0.00021207651,0.00004101987],"category_scores_gemma":[0.0006766219,0.000050253297,0.000112659196,0.000089304456,0.000116680305,0.0001050106,0.000027321823,0.00019005725,0.000005421327],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031713597,0.0031887747,0.028820666,0.000053102303,0.0009023533,0.0007899421,0.00084226835,0.00000220553,0.03285868,0.00008373993,0.0069762664,0.8937684],"study_design_scores_gemma":[0.030292954,0.051292967,0.41601202,0.0005091474,0.00038524988,0.00011940951,0.00026904192,0.0000036735114,0.058053665,0.00030334463,0.44260576,0.0001527513],"about_ca_topic_score_codex":0.0000022388542,"about_ca_topic_score_gemma":0.00005448352,"teacher_disagreement_score":0.89361566,"about_ca_system_score_codex":0.0003007665,"about_ca_system_score_gemma":0.0014500805,"threshold_uncertainty_score":0.25723806},"labels":[],"label_agreement":null},{"id":"W2590191086","doi":"10.1200/jco.2015.33.29_suppl.56","title":"Increased symptom expression among patients (PTS) with delirium admitted to an acute palliative care unit (APCU).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Delirium; Medicine; Depression (economics); Internal medicine; Intensive care medicine","score_opus":0.10234029151417677,"score_gpt":0.45233031944069696,"score_spread":0.3499900279265202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590191086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925745,0.00004571651,0.0005000779,0.0028014854,0.00078973244,0.0005294357,0.000023245479,0.000020673335,0.0027151485],"genre_scores_gemma":[0.950076,0.000022630427,0.0028121695,0.046393868,0.00047628485,0.000009515324,0.00008166247,0.00004185788,0.0000860177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614125,0.0009000372,0.0015725357,0.00030649255,0.00073872175,0.00034096529],"domain_scores_gemma":[0.9437977,0.0010989354,0.0013612764,0.0002632821,0.05183646,0.0016423262],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009922268,0.00025192782,0.0014059911,0.0002881326,0.00005214083,0.000013249983,0.00024204818,0.00045594797,0.00007313732],"category_scores_gemma":[0.035521973,0.00016728569,0.00027201598,0.00029265438,0.00027968007,0.00023660064,0.00009248712,0.0012053682,0.00003568683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022299197,0.0014478453,0.94843894,0.000016286001,0.0005345912,0.0010099259,0.0019431983,0.000016635173,0.00019910325,0.000006785323,0.012058553,0.01202893],"study_design_scores_gemma":[0.023413034,0.06969581,0.87671155,0.0005329073,0.0009102984,0.00003864533,0.017532336,0.00003445566,0.00063417497,0.000034027635,0.010229208,0.0002335392],"about_ca_topic_score_codex":0.00006697923,"about_ca_topic_score_gemma":0.00015582953,"teacher_disagreement_score":0.07172739,"about_ca_system_score_codex":0.00029944742,"about_ca_system_score_gemma":0.002353831,"threshold_uncertainty_score":0.97260225},"labels":[],"label_agreement":null},{"id":"W2590194247","doi":"10.1200/jco.2014.32.30_suppl.263","title":"Measuring quality of life in chronic hematologic malignancy: The QUALMS-1.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Ottawa","funders":"","keywords":"Quality of life (healthcare); Medicine; Disease; Hematologic malignancy; Cancer; Gerontology; Internal medicine","score_opus":0.3484975847992349,"score_gpt":0.4953015845341096,"score_spread":0.14680399973487468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590194247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98224837,0.0018208423,0.00022199604,0.008159456,0.00072411523,0.0001380564,9.082562e-7,0.0000045485435,0.0066817035],"genre_scores_gemma":[0.9938527,0.0006485426,0.00068480003,0.0039875344,0.00075113657,0.0000022119873,5.652269e-7,0.000008247877,0.00006429944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99436426,0.0014087276,0.003529371,0.00014171515,0.00034928476,0.00020661874],"domain_scores_gemma":[0.9921132,0.0048584426,0.0023164502,0.00027211668,0.00022383161,0.00021599529],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012053464,0.00010333539,0.0018957215,0.00008653751,0.000024051762,0.0000029693551,0.00024956287,0.00028592852,0.00023331378],"category_scores_gemma":[0.010707795,0.00005875941,0.00049579225,0.000111564,0.0002728567,0.00007164783,0.000049980757,0.0010236125,0.000009652285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007834508,0.0013639958,0.8063406,0.00057734933,0.00050882075,0.00015738248,0.00044513287,0.00034851578,0.002995411,0.0030482917,0.0036418184,0.1727382],"study_design_scores_gemma":[0.012664219,0.006559622,0.9357658,0.00022215665,0.00010782302,0.000121943594,0.00020469636,0.00038544316,0.00027007674,0.0010009846,0.042591132,0.00010612878],"about_ca_topic_score_codex":0.00008180595,"about_ca_topic_score_gemma":0.0002969293,"teacher_disagreement_score":0.17263207,"about_ca_system_score_codex":0.0002639444,"about_ca_system_score_gemma":0.0034634257,"threshold_uncertainty_score":0.9976254},"labels":[],"label_agreement":null},{"id":"W2590196392","doi":"10.1200/jco.2011.29.4_suppl.239","title":"Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Oxaliplatin; Regimen; Pancreatic cancer; Internal medicine; Adverse effect; Capecitabine; Chemotherapy; Surgery; Cancer; Gastroenterology; Colorectal cancer","score_opus":0.13648240388366595,"score_gpt":0.47282984481761453,"score_spread":0.3363474409339486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590196392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994388,0.0006524103,0.000055286593,0.0008719867,0.00037685025,0.0010615292,0.000014739145,0.0000067611127,0.002572439],"genre_scores_gemma":[0.9898154,0.0027570815,0.005641909,0.00023832815,0.0005855531,0.000035892415,0.000011253203,0.00002629688,0.0008882431],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99477535,0.0007717729,0.0030831825,0.00028975206,0.0006327999,0.00044714968],"domain_scores_gemma":[0.9937335,0.0024608492,0.0020860026,0.00028638996,0.0009636464,0.0004695698],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0046777665,0.0002056203,0.0027055035,0.00035613333,0.00008006319,0.0000055187825,0.00018396745,0.00046763173,0.00084228127],"category_scores_gemma":[0.008528981,0.0001244691,0.0001554121,0.0004372898,0.00043053163,0.00022171435,0.00008831783,0.0010989619,0.0000028917611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51454705,0.012914796,0.41957182,0.000088981535,0.0004193346,0.00020572418,0.00041657823,0.0000033987392,0.00008680935,0.00003124299,0.0010460364,0.050668217],"study_design_scores_gemma":[0.3785293,0.25791025,0.3591904,0.00033444967,0.0006984941,0.000057312074,0.00016968901,0.00051770994,0.000046282155,0.00017576371,0.0022473664,0.00012298948],"about_ca_topic_score_codex":0.00051678,"about_ca_topic_score_gemma":0.0005842883,"teacher_disagreement_score":0.24499545,"about_ca_system_score_codex":0.00020675691,"about_ca_system_score_gemma":0.0038497804,"threshold_uncertainty_score":0.9998226},"labels":[],"label_agreement":null},{"id":"W2590202114","doi":"10.1200/jco.2016.34.3_suppl.144","title":"Patient preferences for research access to administrative data in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Robarts Clinical Trials; Princess Margaret Cancer Centre; Kingston General Hospital; Southlake Regional Health Center; University Health Network","funders":"","keywords":"Medicine; Confidentiality; Clinical trial; Family medicine; Health care; Cancer registry; Cancer; Cohort; Internal medicine","score_opus":0.9718091279493919,"score_gpt":0.8068438334806901,"score_spread":0.16496529446870178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590202114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8795088,0.00004951615,0.00037186855,0.10862377,0.0010013389,0.0009078721,0.00002342092,0.0000037280154,0.00950967],"genre_scores_gemma":[0.983797,0.00040400916,0.010661673,0.0025401313,0.0007213238,0.00003041906,0.000002885816,0.000013635934,0.001828929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99233407,0.0013403555,0.003631933,0.0005092949,0.0016602982,0.00052404485],"domain_scores_gemma":[0.66166186,0.32640615,0.0017107512,0.0016289465,0.0067732497,0.001819022],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.056402475,0.00010656127,0.0012596096,0.00030409862,0.000047329846,0.000030406234,0.0014818009,0.000784402,0.00045941529],"category_scores_gemma":[0.37259972,0.000056783683,0.00019968569,0.0002601274,0.0006249377,0.00031013,0.0010636016,0.004649909,0.000039613016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02493041,0.0037449908,0.54705507,0.000062337494,0.00022171592,0.000499432,0.00041108954,7.669503e-7,0.00013373766,0.0018416505,0.028229324,0.39286947],"study_design_scores_gemma":[0.006252332,0.061693422,0.6381969,0.00093319925,0.00004333346,0.000035562018,0.00028243623,0.0000050182402,0.00017777267,0.059306424,0.23297992,0.00009372468],"about_ca_topic_score_codex":0.0013437156,"about_ca_topic_score_gemma":0.25194737,"teacher_disagreement_score":0.39277574,"about_ca_system_score_codex":0.00059758587,"about_ca_system_score_gemma":0.024990482,"threshold_uncertainty_score":0.9976464},"labels":[],"label_agreement":null},{"id":"W2590205902","doi":"10.1200/jco.2016.34.4_suppl.394","title":"Intention to treat analysis of neoadjuvant chemoradiation and liver transplantation for perihilar cholangiocarcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; St. Michael's Hospital; Toronto General Hospital","funders":"","keywords":"Medicine; Capecitabine; Gemcitabine; Liver transplantation; Surgery; Cohort; Chemotherapy; Transplantation; Radiology; Cancer; Internal medicine; Colorectal cancer","score_opus":0.09601694580545998,"score_gpt":0.4268444350168147,"score_spread":0.3308274892113547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590205902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888812,0.00085000566,0.0040661413,0.00548143,0.0002151487,0.0001788975,0.000017554037,0.000003521105,0.00030610873],"genre_scores_gemma":[0.9951882,0.0021583904,0.0016994978,0.00055772834,0.00026065923,0.000005855889,0.0000057350194,0.0000065510358,0.00011742982],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985185,0.00007563184,0.0010163912,0.00013526535,0.00015003141,0.00010413633],"domain_scores_gemma":[0.9979065,0.00083415816,0.0005905791,0.00008323211,0.00042635336,0.0001591955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009156916,0.00007904327,0.0009782485,0.00028556614,0.000021104188,0.0000032286198,0.000044935397,0.00012483318,0.000027675453],"category_scores_gemma":[0.0007783612,0.000046904843,0.0005003852,0.00017550086,0.00007306161,0.000087483204,0.000009964112,0.00009081846,0.000001206824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007822115,0.00037979998,0.45778584,0.00012605939,0.001738375,0.00010278055,0.0010370179,0.0000039775705,0.007572468,0.00012008119,0.00077599037,0.5225355],"study_design_scores_gemma":[0.0057847397,0.0060873157,0.97875637,0.00007307946,0.005581438,0.00007676086,0.00013478684,0.00007426314,0.0010421976,0.000040123145,0.002294948,0.000053998952],"about_ca_topic_score_codex":0.000027905353,"about_ca_topic_score_gemma":0.00007484085,"teacher_disagreement_score":0.5224815,"about_ca_system_score_codex":0.00007283942,"about_ca_system_score_gemma":0.0001418984,"threshold_uncertainty_score":0.19127241},"labels":[],"label_agreement":null},{"id":"W2590210026","doi":"10.1200/jco.2013.31.15_suppl.e20700","title":"Effect of intervention on a quality measure of pain management at Medstar Washington Cancer Institute (MWCI).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Documentation; Physical therapy; Pain management; Quarter (Canadian coin); Family medicine; Nursing","score_opus":0.10463334702926294,"score_gpt":0.4860257003477578,"score_spread":0.38139235331849486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590210026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899089,0.00028683612,0.0004634081,0.0038070355,0.0011891342,0.0005407415,0.000001381559,0.000007183113,0.0037954357],"genre_scores_gemma":[0.99639976,0.00063446217,0.0006741072,0.0009669752,0.00035129944,0.0000143953785,0.0000029081612,0.000010591557,0.00094549544],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994407,0.0021530325,0.0025381774,0.0001599078,0.00057174976,0.0001701566],"domain_scores_gemma":[0.9946421,0.0021357222,0.0024891004,0.00024531485,0.00031113948,0.00017662579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019872094,0.00013578398,0.001436374,0.0001830812,0.00002184126,0.000003853793,0.00020432269,0.00022119776,0.0003469239],"category_scores_gemma":[0.0044673565,0.00008845355,0.0007328857,0.00012868481,0.00017918204,0.00011753857,0.00009882767,0.00048996886,0.00001682932],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009856606,0.0018784957,0.29067582,0.001667393,0.001555462,0.00009934994,0.00011963993,0.000056215427,0.0005359431,0.0004147289,0.018537117,0.6746032],"study_design_scores_gemma":[0.017818999,0.03348608,0.8885573,0.0020764263,0.0012376596,0.0000034008235,0.00012589245,0.00029029968,0.0012627556,0.00035710106,0.05464133,0.00014273444],"about_ca_topic_score_codex":0.00016648264,"about_ca_topic_score_gemma":0.0001246552,"teacher_disagreement_score":0.6744605,"about_ca_system_score_codex":0.00022628957,"about_ca_system_score_gemma":0.00010201766,"threshold_uncertainty_score":0.6887311},"labels":[],"label_agreement":null},{"id":"W2590225297","doi":"10.1200/jco.2015.33.7_suppl.463","title":"Exploring the effect of medication features in renal cell carcinoma: A patient preference study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dosing; Tolerability; Renal cell carcinoma; Toxicity; Interim; Internal medicine; Interim analysis; Adverse effect; Progression-free survival; Oncology; Clinical trial; Chemotherapy","score_opus":0.777707235576729,"score_gpt":0.547498420390651,"score_spread":0.23020881518607805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590225297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98557293,0.0010104007,0.000079459416,0.009345,0.0017712478,0.00047197353,0.000005833966,0.0000028108766,0.0017403607],"genre_scores_gemma":[0.99810904,0.00008052447,0.0003964404,0.00083033077,0.0005042919,0.000039905124,9.1596064e-7,0.000008791933,0.000029765693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9879479,0.0028716996,0.008583851,0.00021375586,0.00019345763,0.00018937675],"domain_scores_gemma":[0.9821158,0.008749073,0.008465313,0.000290351,0.00015251017,0.00022696536],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.070942335,0.000106607855,0.0017405438,0.00022568187,0.00003258404,0.000010192908,0.00036746528,0.00014403989,0.000022777998],"category_scores_gemma":[0.026881397,0.00007890345,0.00018462005,0.00014735083,0.00009805995,0.00029607728,0.00006575428,0.0006640917,0.000047555033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008898378,0.0010613233,0.96603817,0.000095173345,0.0000819592,0.000016571226,0.008081987,0.0005430741,0.0000022849124,0.00071830634,0.010718116,0.011753174],"study_design_scores_gemma":[0.005488704,0.013663328,0.96679205,0.000051809897,0.00002923206,0.000012627105,0.0027789695,0.00018272613,0.000033982258,0.0011172275,0.009745916,0.000103437],"about_ca_topic_score_codex":0.00047824834,"about_ca_topic_score_gemma":0.00027811827,"teacher_disagreement_score":0.044060938,"about_ca_system_score_codex":0.00036573783,"about_ca_system_score_gemma":0.0006731829,"threshold_uncertainty_score":0.9813156},"labels":[],"label_agreement":null},{"id":"W2590234373","doi":"10.1200/jco.2014.32.3_suppl.429","title":"Are the cardiovascular side effects of bevacizumab caused by autonomic nervous system toxicity?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Cancer Care South East; University of Manitoba; Queen's University","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Adverse effect; Cardiology; Heart rate variability; Toxicity; Heart rate; Vascular endothelial growth factor; Aldosterone; Autonomic nervous system; Analysis of variance; Heart failure; Sinus rhythm; Plasma renin activity; Hormone; Blood pressure; Endocrinology; Renin–angiotensin system; Chemotherapy; VEGF receptors","score_opus":0.051790235838715636,"score_gpt":0.4022700080996506,"score_spread":0.35047977226093496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590234373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98659366,0.0039174454,0.00023939488,0.003977341,0.002783894,0.00035447255,0.0000034965342,0.00001433381,0.0021159751],"genre_scores_gemma":[0.99591887,0.00032938807,0.00010126826,0.0017509673,0.0016622694,0.000009048694,0.0000013127138,0.000017857114,0.0002090429],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643886,0.0012090342,0.0016648262,0.00017125635,0.0002968491,0.00021917037],"domain_scores_gemma":[0.99282676,0.004278327,0.0020882213,0.00031281085,0.00024103481,0.0002528315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029531254,0.00015145431,0.002251611,0.00006838064,0.000046039364,0.0000044251597,0.00020679335,0.00033497607,0.000017671604],"category_scores_gemma":[0.0015054984,0.000087923276,0.001283396,0.00009027361,0.00021363574,0.000041923075,0.000044712535,0.0006982831,0.00001626278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015972247,0.010236756,0.099485494,0.0024959429,0.03628134,0.005195042,0.00071397336,0.0013238159,0.018168513,0.00063842454,0.119857304,0.68963116],"study_design_scores_gemma":[0.049594734,0.03723815,0.36624908,0.00057449896,0.01269305,0.0013806459,0.00032261497,0.00072527456,0.009372935,0.00011927206,0.5214465,0.0002832395],"about_ca_topic_score_codex":0.00004504314,"about_ca_topic_score_gemma":0.000022910239,"teacher_disagreement_score":0.6893479,"about_ca_system_score_codex":0.0003218176,"about_ca_system_score_gemma":0.0005970979,"threshold_uncertainty_score":0.3585407},"labels":[],"label_agreement":null},{"id":"W2590238499","doi":"10.1200/jco.2012.30.34_suppl.211","title":"Peer-review of radiation treatment planning in a provincial radiation oncology program: A survey of current practice.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Cancer Care Ontario; Princess Margaret Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Peer review; Radiation oncology; Likert scale; Family medicine; Radiation Therapist; Radiation therapy; Surgery; Psychology","score_opus":0.25752779027225564,"score_gpt":0.6351456929939162,"score_spread":0.37761790272166057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590238499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59596014,0.34568393,0.0020268422,0.033648532,0.01319957,0.0037117812,0.000039700506,0.000025122583,0.0057044094],"genre_scores_gemma":[0.80323756,0.16989125,0.019734811,0.0023821273,0.0044151177,0.000070561706,0.00008029892,0.00003336955,0.00015488984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932558,0.0024788477,0.0033689996,0.000142266,0.00048994645,0.00026416514],"domain_scores_gemma":[0.98457634,0.008132451,0.005635132,0.00015948399,0.00125762,0.00023893962],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015474037,0.0001464303,0.0021880476,0.0001960111,0.000020294658,0.0000012962016,0.000116712166,0.00045276227,0.00005556983],"category_scores_gemma":[0.034901425,0.00010124682,0.00031979577,0.00028553835,0.0002487065,0.00027021518,0.000017705488,0.0008039328,0.0000025504294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005084637,0.011184342,0.26506844,0.00026306984,0.00021724415,0.000045143104,0.0004136338,0.000011694265,0.0000139216045,0.000047771486,0.002577849,0.7150723],"study_design_scores_gemma":[0.007593317,0.031506415,0.39150417,0.00063916604,0.00036109833,0.00024372172,0.000057729332,0.000033717188,0.000043089065,0.000019645895,0.56793743,0.000060492017],"about_ca_topic_score_codex":0.00005740589,"about_ca_topic_score_gemma":0.00005265023,"teacher_disagreement_score":0.7150118,"about_ca_system_score_codex":0.0008810219,"about_ca_system_score_gemma":0.004439549,"threshold_uncertainty_score":0.97322804},"labels":[],"label_agreement":null},{"id":"W2590244275","doi":"10.1200/jco.2013.31.6_suppl.16","title":"Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Prostate cancer; Internal medicine; Tolerability; Oncology; Placebo; Androgen receptor; Cancer; Adverse effect; Alternative medicine","score_opus":0.09677433790762337,"score_gpt":0.4403547263729814,"score_spread":0.34358038846535804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590244275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661481,0.00041967572,0.0000019476718,0.030404415,0.00027096958,0.0025009832,0.0001522682,0.0000076272454,0.0000940359],"genre_scores_gemma":[0.9971942,0.00041832597,0.0003528383,0.0007248566,0.00037574995,0.00017057608,0.00005833682,0.000024409706,0.00068070594],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959369,0.0007862508,0.0019448913,0.0002762511,0.00070684205,0.00034890193],"domain_scores_gemma":[0.99318427,0.003882818,0.0015643568,0.00028780743,0.0007982479,0.00028247983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017790423,0.0002275766,0.0012792267,0.0000658045,0.00010980415,0.00004873207,0.00020456495,0.00013837902,0.00018128013],"category_scores_gemma":[0.0010454829,0.00007903407,0.0001934672,0.00029423164,0.00040596433,0.00021489328,0.000028273098,0.0009821318,0.000011525844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6918141,0.006821102,0.18011448,0.0000149407215,0.0022862449,0.00039156774,0.001463376,0.000025199737,0.00020299242,0.0000035305534,0.009065063,0.10779736],"study_design_scores_gemma":[0.62679064,0.07060729,0.2873681,0.00031114207,0.0009607846,0.000010865718,0.0012935412,0.000029226001,0.0003708317,0.000040800398,0.012036266,0.00018053259],"about_ca_topic_score_codex":0.0015949137,"about_ca_topic_score_gemma":0.0023314948,"teacher_disagreement_score":0.10761683,"about_ca_system_score_codex":0.0002793889,"about_ca_system_score_gemma":0.0020565917,"threshold_uncertainty_score":0.42669287},"labels":[],"label_agreement":null},{"id":"W2590248786","doi":"10.1200/jco.2016.34.7_suppl.215","title":"Patients as partners in managing cancer treatment-related toxicity.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Cancer Care Ontario","funders":"","keywords":"Stakeholder engagement; Medicine; Government (linguistics); Stakeholder; Agency (philosophy); Quality management; Quality (philosophy); Public relations; Nursing; Business; Marketing; Political science; Service (business)","score_opus":0.37014061669287696,"score_gpt":0.6348419365875267,"score_spread":0.2647013198946498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590248786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.933242,0.00009226443,0.000049660517,0.061990835,0.0014839958,0.00023184913,0.0000027553,0.000008319287,0.00289829],"genre_scores_gemma":[0.9901866,0.0024847512,0.0007145802,0.0051672314,0.00057405536,0.000006099539,0.0000024934038,0.000016192398,0.0008480061],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942421,0.00054888445,0.0044387383,0.0001968612,0.0003318088,0.00024162323],"domain_scores_gemma":[0.9898956,0.006768855,0.0024262161,0.00015661436,0.00042027349,0.00033246833],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003261195,0.00012455921,0.0010749613,0.00016329843,0.000019683535,0.0000047231206,0.00009972438,0.00027898134,0.0009220116],"category_scores_gemma":[0.019981116,0.00006963244,0.00034852943,0.00016038172,0.00012129543,0.00025467237,0.00003532156,0.0004352638,0.000091588816],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024624448,0.0013994419,0.44821504,0.0000034752563,0.0001813702,0.00020776057,0.000040484294,0.000005309575,0.000106527536,0.000043376593,0.0018012865,0.5455335],"study_design_scores_gemma":[0.048525926,0.020570645,0.77705526,0.0002671969,0.0005727959,0.00008204659,0.00017181224,0.00006140712,0.00012620521,0.0018581622,0.150576,0.00013256741],"about_ca_topic_score_codex":0.00019852235,"about_ca_topic_score_gemma":0.00040013512,"teacher_disagreement_score":0.5454009,"about_ca_system_score_codex":0.00064672367,"about_ca_system_score_gemma":0.001630067,"threshold_uncertainty_score":0.9999913},"labels":[],"label_agreement":null},{"id":"W2590257863","doi":"10.1200/jco.2016.34.2_suppl.493","title":"Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Seminoma; Stage (stratigraphy); Medicine; Gene expression; Pathological; Oncology; Cancer; Gene; RNA extraction; Internal medicine; Pathology; Biology; Genetics; Chemotherapy","score_opus":0.060870106467872144,"score_gpt":0.4357108508593129,"score_spread":0.3748407443914407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590257863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419653,0.0020768095,0.00039418365,0.0019581558,0.00047339473,0.0005628087,0.0000138205905,0.000012763353,0.00031153994],"genre_scores_gemma":[0.9887304,0.0002303826,0.009118117,0.0007405078,0.0004947508,0.000020137268,0.0000038300946,0.000025490117,0.0006364115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972891,0.00025675027,0.001614917,0.00024146581,0.0003173981,0.0002803317],"domain_scores_gemma":[0.99237084,0.005175838,0.0014006784,0.00020521402,0.00032064613,0.00052679057],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011970216,0.00016257609,0.0010153974,0.00012357067,0.000030557603,0.0000066320817,0.00012984293,0.00033594042,0.00010616824],"category_scores_gemma":[0.018613338,0.00008419454,0.0005194842,0.000083226005,0.000118756136,0.00008589265,0.00004219817,0.00039913386,0.00002785215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071450844,0.008681428,0.9016823,0.0001541217,0.0002265962,0.011261273,0.000038766313,0.000045592147,0.015909676,0.00009544403,0.002141575,0.052618146],"study_design_scores_gemma":[0.032380395,0.02672699,0.91705066,0.0010881132,0.00090025656,0.00036153154,0.000045985376,0.000060864393,0.0069931657,0.001961352,0.012228466,0.00020219205],"about_ca_topic_score_codex":0.0000064228757,"about_ca_topic_score_gemma":0.0000039915426,"teacher_disagreement_score":0.052415956,"about_ca_system_score_codex":0.00013890403,"about_ca_system_score_gemma":0.001574326,"threshold_uncertainty_score":0.9896533},"labels":[],"label_agreement":null},{"id":"W2590261072","doi":"10.1200/jco.2014.32.30_suppl.155","title":"Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prom; Patient-reported outcome; Family medicine; Population; Quality of life (healthcare); Nursing; Obstetrics","score_opus":0.19249936967091802,"score_gpt":0.5264312757515429,"score_spread":0.3339319060806249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590261072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98489356,0.00028469428,0.0019295337,0.006561,0.0046511204,0.0005211229,0.000016885793,0.000022674745,0.0011194006],"genre_scores_gemma":[0.99430376,0.000029605093,0.0029201808,0.0022356072,0.00044742227,0.00002174848,0.0000033903573,0.000025726538,0.000012559848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911149,0.0022506628,0.004982722,0.00047155202,0.00073248585,0.00044764133],"domain_scores_gemma":[0.99316466,0.0011709532,0.0028272804,0.0005628233,0.0017854702,0.0004888331],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011485837,0.00024406149,0.0024710814,0.00030912433,0.000050234987,0.000012860822,0.00022305775,0.0007256755,0.00024346565],"category_scores_gemma":[0.010837939,0.00018870941,0.0004914446,0.000554521,0.00017631265,0.000110275825,0.00017447605,0.0017600589,0.0000023999303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083059864,0.00055961806,0.6697488,0.00004569193,0.00011177021,0.00006918972,0.00026057125,0.000058859863,0.0005208191,0.00003764303,0.000036237096,0.32772022],"study_design_scores_gemma":[0.006004422,0.008511314,0.9682552,0.000104432744,0.00028023098,0.000058987524,0.0017361069,0.00008898597,0.00031477035,0.0002611074,0.014149334,0.00023506947],"about_ca_topic_score_codex":0.004225861,"about_ca_topic_score_gemma":0.012212275,"teacher_disagreement_score":0.32748514,"about_ca_system_score_codex":0.001289956,"about_ca_system_score_gemma":0.0022702024,"threshold_uncertainty_score":0.9974942},"labels":[],"label_agreement":null},{"id":"W2590263484","doi":"10.1200/jco.2014.32.30_suppl.104","title":"Quality of febrile neutropenia management in a regional cancer center emergency department.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Credit Valley Hospital; University of Toronto","funders":"","keywords":"Medicine; Febrile neutropenia; Emergency department; Triage; Medical record; Emergency medicine; Neutropenia; Cancer; Adverse effect; Pediatrics; Internal medicine; Chemotherapy","score_opus":0.19733068806748352,"score_gpt":0.5305023715186883,"score_spread":0.33317168345120474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590263484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699678,0.00025226455,0.00011064347,0.008351293,0.0018591362,0.00019774656,0.0000038849594,0.0000042564757,0.019253008],"genre_scores_gemma":[0.9925139,0.0033137712,0.00079854944,0.0018441357,0.0008417043,0.00001483759,0.0000019119566,0.000010080639,0.0006611221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964962,0.00047144655,0.0024123692,0.00015075142,0.00029398294,0.00017527347],"domain_scores_gemma":[0.99774075,0.0002890738,0.0013499282,0.00017391662,0.0002500322,0.00019630486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021541156,0.00009303939,0.0010490951,0.000116716845,0.000019803989,0.0000019903525,0.00012778003,0.00013288495,0.00078995526],"category_scores_gemma":[0.00022468991,0.0000687666,0.00042267446,0.00015499961,0.00009040926,0.00006980918,0.00004815419,0.00047092984,0.000012513558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038309705,0.002660124,0.8664704,0.000083887404,0.00041690763,0.000073359726,0.000034771332,0.00004083267,0.00026533566,0.0022210935,0.033199854,0.090702474],"study_design_scores_gemma":[0.005758102,0.0018646104,0.68220687,0.000053358875,0.0001081598,0.00003951407,0.000021742479,0.0000073799542,0.000025475676,0.0003770028,0.30949116,0.00004659152],"about_ca_topic_score_codex":0.00011229672,"about_ca_topic_score_gemma":0.0006447546,"teacher_disagreement_score":0.2762913,"about_ca_system_score_codex":0.00013751848,"about_ca_system_score_gemma":0.00032763003,"threshold_uncertainty_score":0.86494565},"labels":[],"label_agreement":null},{"id":"W2590267628","doi":"10.1200/jco.2016.34.7_suppl.277","title":"Psychosocial oncology quality indicators prioritization exercise.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Psychosocial; Medicine; Performance indicator; Worksheet; Delphi method; Quality (philosophy); Prioritization; Scale (ratio); Relevance (law); Process management; Operations management; Family medicine; Psychology; Statistics; Marketing; Psychiatry; Business","score_opus":0.4686772326585329,"score_gpt":0.6608217481033887,"score_spread":0.19214451544485578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590267628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8219714,0.00019012322,0.0071516545,0.15747683,0.0060754544,0.00048893195,0.000009482449,0.00003429246,0.006601825],"genre_scores_gemma":[0.97111744,0.0025951776,0.012695139,0.008410447,0.004750089,0.000005923729,0.000005253782,0.000026446649,0.00039405806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989583,0.0014875648,0.007684074,0.0002767571,0.0006835338,0.00028503535],"domain_scores_gemma":[0.9733682,0.017291607,0.0072537134,0.00028679147,0.0011468711,0.00065276405],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017032864,0.0001515202,0.0018375812,0.00024127083,0.00005573446,0.000007985105,0.00021544113,0.0008003436,0.00082362816],"category_scores_gemma":[0.07348822,0.0000935565,0.00064926164,0.0002893521,0.00036176707,0.00034163045,0.00006705816,0.0009601324,0.00012076353],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00617429,0.0017952645,0.12637076,0.00001599465,0.00018161742,0.00011705399,0.000062501524,2.5613437e-7,0.00051423616,0.00045781274,0.02551437,0.83879584],"study_design_scores_gemma":[0.01654199,0.00940976,0.47026664,0.00012666247,0.00055668066,0.00015872551,0.00021566353,0.000002918234,0.000096379925,0.0025793524,0.49992847,0.00011675706],"about_ca_topic_score_codex":0.000020927318,"about_ca_topic_score_gemma":0.000048842943,"teacher_disagreement_score":0.8386791,"about_ca_system_score_codex":0.00052758213,"about_ca_system_score_gemma":0.0051725423,"threshold_uncertainty_score":0.93431616},"labels":[],"label_agreement":null},{"id":"W2590275090","doi":"10.1200/jco.2014.32.30_suppl.39","title":"Automating a program for the evidence-based reimbursement of oncology drugs across a complex network: Benefits and challenges.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Software deployment; Workflow; Reimbursement; Medicine; Early adopter; Adjudication; Process management; Health care; Computer science; Business; Software engineering","score_opus":0.724174703092473,"score_gpt":0.6355368481969429,"score_spread":0.08863785489553011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590275090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65900654,0.007351624,0.005004004,0.3239564,0.0019028606,0.0023890783,0.0000070738374,0.000037294583,0.00034510402],"genre_scores_gemma":[0.8973906,0.007343128,0.0839894,0.008249379,0.0029297879,0.000060671115,0.000004490841,0.000023268145,0.0000092966775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99225086,0.001190253,0.0054211332,0.00026214984,0.00048283825,0.00039278116],"domain_scores_gemma":[0.916689,0.075749464,0.005650901,0.00029463443,0.0013262402,0.00028978748],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.034872934,0.00016072895,0.0016745797,0.000047466165,0.00011902757,0.000014133882,0.00023816533,0.00036013895,0.000040852003],"category_scores_gemma":[0.05662858,0.00010019573,0.0004962083,0.0001228037,0.00043660076,0.0001498419,0.000121529454,0.0008063432,0.0000018032089],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044492697,0.0012735865,0.009146826,0.000164632,0.0003226982,0.000007728136,0.00019639083,0.00040874476,0.000023348188,0.00038686724,0.0021960994,0.9814238],"study_design_scores_gemma":[0.022984546,0.081664234,0.3757378,0.000984941,0.0016715394,0.00016796478,0.0015115344,0.051214084,0.000017476348,0.00058221276,0.46330008,0.00016360192],"about_ca_topic_score_codex":0.000027962393,"about_ca_topic_score_gemma":0.00017555666,"teacher_disagreement_score":0.9812602,"about_ca_system_score_codex":0.00012987359,"about_ca_system_score_gemma":0.0013548643,"threshold_uncertainty_score":0.9938014},"labels":[],"label_agreement":null},{"id":"W2590280289","doi":"10.1200/jco.2016.34.4_suppl.665","title":"Patterns in<i> KRAS</i> testing and EGFRi therapy across lines of treatment for metastatic colorectal cancer in Canada: A retrospective analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Amgen (Canada); BC Cancer Agency; Centre hospitalier universitaire de Québec; McGill University; University of Ottawa","funders":"","keywords":"Medicine; KRAS; Colorectal cancer; Internal medicine; Cancer; Systemic therapy; Oncology; Breast cancer","score_opus":0.14882071512693382,"score_gpt":0.4810794416672257,"score_spread":0.33225872654029187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590280289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957965,0.0013542962,0.000019873241,0.0021257978,0.00022280625,0.0003231521,0.000114483984,0.0000013883962,0.000041677056],"genre_scores_gemma":[0.995218,0.0039351503,0.00041729526,0.00019681605,0.00014929939,0.000047652156,5.3679526e-7,0.000007645477,0.00002763138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979309,0.0001238389,0.0014022121,0.00018074196,0.00014600938,0.00021629522],"domain_scores_gemma":[0.9948158,0.0037042075,0.0009471176,0.00006297326,0.00035801338,0.00011185049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007795142,0.00013090426,0.0019722783,0.000102922386,0.000022035798,0.000002363154,0.00004727077,0.00006601795,0.000018750587],"category_scores_gemma":[0.001455472,0.000065761684,0.00024038799,0.00026337348,0.0000865335,0.00004164383,0.000019630736,0.0001325293,4.129006e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034601495,0.00048758602,0.82614636,0.000010229386,0.0018269164,0.00012645511,0.00023011705,0.000017901944,0.00024285339,0.0000016821101,0.000017253391,0.16743247],"study_design_scores_gemma":[0.0144768935,0.015589219,0.9680964,0.00011012889,0.0006261401,0.000017931818,0.00031291353,0.00009355841,0.00023712835,0.00007016407,0.0003097926,0.000059726222],"about_ca_topic_score_codex":0.2737298,"about_ca_topic_score_gemma":0.95080984,"teacher_disagreement_score":0.67708004,"about_ca_system_score_codex":0.0018321783,"about_ca_system_score_gemma":0.0031985014,"threshold_uncertainty_score":0.73110646},"labels":[],"label_agreement":null},{"id":"W2590282482","doi":"10.1200/jco.2014.32.4_suppl.230","title":"Transurethral (TURP) biopsy of suspected anterior prostate cancers identified by MRI: Pilot study of a novel technique.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Biopsy; Prostate; Prostate cancer; Radiology; Prostate biopsy; Magnetic resonance imaging; Cancer; Internal medicine","score_opus":0.09917786022845647,"score_gpt":0.4479231714725311,"score_spread":0.3487453112440746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590282482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492043,0.00022609864,0.0013408517,0.0009858293,0.0007785136,0.0008874939,0.000035362194,0.00001191171,0.0008134904],"genre_scores_gemma":[0.9970054,0.00020863439,0.0020460254,0.00023516812,0.00026878965,0.000019537809,0.0000022075549,0.000024137651,0.00019010364],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959606,0.0003616024,0.0027866107,0.00021976222,0.00045545312,0.00021596653],"domain_scores_gemma":[0.99634546,0.00052507326,0.002054778,0.00024026577,0.0005929142,0.00024151476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002064377,0.00017362341,0.0019907071,0.00014883808,0.000024447643,0.0000042285633,0.00019839522,0.00018196915,0.00009228826],"category_scores_gemma":[0.000603955,0.000121011006,0.000311147,0.00021656048,0.00027457403,0.00007304268,0.000025463693,0.0006099873,0.0000010211803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.099509805,0.06626838,0.30485776,0.00043698706,0.004646826,0.000401732,0.002198775,0.00002149677,0.47185427,0.000038012513,0.0058281305,0.043937843],"study_design_scores_gemma":[0.09612323,0.40149325,0.47364652,0.0006928744,0.0025718575,0.00055955566,0.0008546226,0.000067978945,0.019718613,0.00017227598,0.0038097724,0.00028945375],"about_ca_topic_score_codex":0.0005977701,"about_ca_topic_score_gemma":0.00024212072,"teacher_disagreement_score":0.45213565,"about_ca_system_score_codex":0.0001432433,"about_ca_system_score_gemma":0.0010900605,"threshold_uncertainty_score":0.49346855},"labels":[],"label_agreement":null},{"id":"W2590286012","doi":"10.1200/jco.2016.34.4_suppl.208","title":"Age barrier in clinical trials: Are we truly moving forward?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Age limit; Inclusion and exclusion criteria; Internal medicine; Pediatrics; Gastroenterology; Pathology; Demography; Alternative medicine","score_opus":0.18426665808806608,"score_gpt":0.499842697177366,"score_spread":0.31557603908929993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590286012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97634506,0.0023527138,0.0038800659,0.011068923,0.004595429,0.00019087429,0.00003518797,0.0000035938601,0.0015281218],"genre_scores_gemma":[0.9686216,0.02041308,0.0018932754,0.0027686527,0.005756207,0.0000049012733,0.000002267445,0.000024844929,0.0005151311],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927907,0.001700458,0.0047280057,0.00030939616,0.00018251607,0.00028892257],"domain_scores_gemma":[0.99007684,0.0060740476,0.002908579,0.00030413986,0.00023300987,0.00040336399],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018143838,0.00015660748,0.0016813517,0.000085388456,0.000025503816,0.000014859699,0.00036925956,0.00080015813,0.000083691135],"category_scores_gemma":[0.05751623,0.00009792368,0.0010664547,0.00006358358,0.00030373165,0.000008371332,0.00016051004,0.00053050305,0.000013701293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051981076,0.001084514,0.1474546,0.00001488137,0.00040691436,0.00074197387,0.000024261319,0.00003656799,0.010516685,0.00028385522,0.054530293,0.7797073],"study_design_scores_gemma":[0.01104103,0.0062177842,0.07344502,0.00012848421,0.00012957361,0.00006509853,0.00007637087,0.000014269643,0.0010628006,0.002173614,0.9054279,0.0002180617],"about_ca_topic_score_codex":0.000005377098,"about_ca_topic_score_gemma":0.00023123425,"teacher_disagreement_score":0.8508976,"about_ca_system_score_codex":0.000064528846,"about_ca_system_score_gemma":0.0013436804,"threshold_uncertainty_score":0.9504227},"labels":[],"label_agreement":null},{"id":"W2590287407","doi":"10.1200/jco.2008.26.15_suppl.6573","title":"Accounting for improved outcomes in budget impact analyses: Adjuvant trastuzumab in HER2/neu-positive breast cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Population; Internal medicine; Oncology; Cancer; Demography; Environmental health","score_opus":0.5671595169594689,"score_gpt":0.6141098846666126,"score_spread":0.04695036770714378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590287407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95574254,0.00095373165,0.0007642212,0.03995507,0.0013202558,0.0005533347,0.00040456222,0.0000061829896,0.00030007798],"genre_scores_gemma":[0.98690283,0.0007099023,0.0022624978,0.009029903,0.00093390804,0.000042770378,0.0000064692877,0.000028361552,0.00008337721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9849749,0.00072839734,0.013286071,0.00039933983,0.0000976766,0.0005135813],"domain_scores_gemma":[0.98205477,0.007437075,0.009747632,0.00022138478,0.0002621169,0.00027703398],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.030819612,0.0002202054,0.004298993,0.0006383832,0.00007849589,0.00002266519,0.00035962023,0.00044593154,0.00019065996],"category_scores_gemma":[0.01330822,0.00020561731,0.000793593,0.0002647843,0.00013294036,0.00064252387,0.000042177995,0.00080500834,0.000040408417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006408044,0.0009591445,0.9892264,0.00004296512,0.00030890436,0.000025480897,0.00079338154,0.00092282647,0.0000055919463,0.00020753514,0.0026453605,0.004221613],"study_design_scores_gemma":[0.0064618634,0.0012608562,0.98196983,0.0000814378,0.000023677396,0.00007721612,0.00046302375,0.005872154,0.0000011470455,0.0017425566,0.0018391232,0.00020713033],"about_ca_topic_score_codex":0.0040219054,"about_ca_topic_score_gemma":0.0036306407,"teacher_disagreement_score":0.031160245,"about_ca_system_score_codex":0.0020396593,"about_ca_system_score_gemma":0.0023048173,"threshold_uncertainty_score":0.9979752},"labels":[],"label_agreement":null},{"id":"W2590291539","doi":"10.1200/jco.2016.34.26_suppl.158","title":"The evolving radiation therapist role in a multidisciplinary palliative radiotherapy clinic.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Staffing; Medicine; Radiation Therapist; Multidisciplinary approach; Palliative care; Autonomy; Workload; Nursing; Family medicine; Medical education; Radiation therapy; Management","score_opus":0.06608671017827515,"score_gpt":0.5199612722916248,"score_spread":0.45387456211334964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590291539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8107757,0.04822696,0.008276959,0.11716108,0.007935915,0.0008559407,0.0000049355963,0.000033256118,0.00672926],"genre_scores_gemma":[0.8681109,0.103327125,0.016349688,0.004085171,0.005538193,0.00001868334,8.214187e-7,0.000042966316,0.002526465],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995633,0.0010860746,0.002489602,0.00021375652,0.00027468186,0.0003028833],"domain_scores_gemma":[0.97970986,0.017470531,0.0020812217,0.00025639212,0.00027154948,0.0002104265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065611405,0.00015453804,0.0011860336,0.000113160066,0.00012603718,0.000006926683,0.0002785932,0.00051594584,0.00028122877],"category_scores_gemma":[0.004743916,0.00006818893,0.00046181417,0.00016411637,0.0006963623,0.00020169497,0.000026563124,0.0009869284,0.000020251944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077565713,0.0008288459,0.32117227,0.0000039689958,0.0003031862,0.00018109544,0.00036917644,0.000007667627,0.00068916054,0.00015024282,0.0020672104,0.6664706],"study_design_scores_gemma":[0.017469764,0.0112986425,0.6905917,0.00015733141,0.00005517163,0.00015034183,0.00030748502,0.0002676311,0.00004379963,0.004082167,0.27546614,0.00010981238],"about_ca_topic_score_codex":0.0000033733531,"about_ca_topic_score_gemma":0.00004197084,"teacher_disagreement_score":0.6663608,"about_ca_system_score_codex":0.00055794825,"about_ca_system_score_gemma":0.0014092014,"threshold_uncertainty_score":0.56792533},"labels":[],"label_agreement":null},{"id":"W2590291877","doi":"10.1200/jco.2012.30.4_suppl.686","title":"Pathologic complete response to standard preoperative chemoradiation in patients with locally advanced rectal cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Chemoradiotherapy; Radiation therapy; Continuous variable; Retrospective cohort study; Cancer; Surgery; Chemotherapy; Gastroenterology","score_opus":0.08194850977251857,"score_gpt":0.45075727211691485,"score_spread":0.3688087623443963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590291877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948612,0.00020342534,0.00008155172,0.002733614,0.0007192313,0.00065074675,0.00002149508,0.000009038387,0.0007197316],"genre_scores_gemma":[0.9923392,0.000066701636,0.005524343,0.0016541971,0.00030010473,0.000031799176,0.0000039511833,0.000016390251,0.000063294945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968174,0.00080534216,0.0013730705,0.00019488946,0.0004771453,0.00033211365],"domain_scores_gemma":[0.9963627,0.0015082803,0.00080766756,0.00013731755,0.0006250521,0.0005589762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002606441,0.0001607815,0.0013411215,0.00013761538,0.000028800478,0.000005582371,0.00009669598,0.00021097974,0.00014573842],"category_scores_gemma":[0.003921829,0.00010161564,0.00016003851,0.00031352983,0.000111571295,0.00020412661,0.000044661207,0.0006460147,0.000014661497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20645836,0.0013272578,0.7116917,0.0000062011086,0.000090821355,0.00020962523,0.0003142835,0.000097959164,0.000061064624,0.0000028233437,0.00012862736,0.07961129],"study_design_scores_gemma":[0.021893952,0.055342037,0.91473114,0.00013517596,0.0000979904,0.00004038394,0.000066243345,0.000008697983,0.00007886659,0.000011430594,0.007492686,0.00010138149],"about_ca_topic_score_codex":0.000010447789,"about_ca_topic_score_gemma":0.00005628485,"teacher_disagreement_score":0.20303947,"about_ca_system_score_codex":0.0011630018,"about_ca_system_score_gemma":0.001261755,"threshold_uncertainty_score":0.4695079},"labels":[],"label_agreement":null},{"id":"W2590292924","doi":"10.1200/jco.2013.31.4_suppl.356","title":"Temporal trends in colorectal cancer screening (CRCS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Sigmoidoscopy; Demography; Confounding; Residence; Colonoscopy; Colorectal cancer; Cohort; Logistic regression; Odds ratio; Gerontology; Colorectal cancer screening; Cancer; Internal medicine","score_opus":0.13848495625083604,"score_gpt":0.47577557156652034,"score_spread":0.3372906153156843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590292924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837756,0.00044576448,0.00023641602,0.00781586,0.0013800383,0.00011346643,0.000001004306,0.00001732729,0.0062145335],"genre_scores_gemma":[0.99263185,0.00013404174,0.003968357,0.0010639771,0.0016420156,0.000015070024,0.0000015151447,0.000014850153,0.0005283373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99717975,0.00025908035,0.0018183955,0.0001778157,0.00031347485,0.00025146137],"domain_scores_gemma":[0.9975311,0.0006535989,0.0010324139,0.00008613112,0.00034883682,0.00034792133],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017480708,0.00012235467,0.0011476682,0.0003665974,0.000029955918,0.000012428191,0.000109106804,0.00038053372,0.0010894681],"category_scores_gemma":[0.001049831,0.00009042458,0.00042789066,0.00041724354,0.00012502712,0.00018713623,0.000038699956,0.0012679755,0.000018074998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072413157,0.00031599816,0.34191638,0.0000055365604,0.00009369449,0.00015227891,0.00005490931,0.00003926879,0.0003228391,0.0000044106973,0.0053822915,0.64447105],"study_design_scores_gemma":[0.006356635,0.021318818,0.94699335,0.0001044851,0.000097357246,0.0003552537,0.00011978303,0.0017698135,0.0002583975,0.000088729495,0.022437857,0.00009950551],"about_ca_topic_score_codex":0.0013246834,"about_ca_topic_score_gemma":0.000990991,"teacher_disagreement_score":0.64437157,"about_ca_system_score_codex":0.00020715527,"about_ca_system_score_gemma":0.0006613099,"threshold_uncertainty_score":0.9998237},"labels":[],"label_agreement":null},{"id":"W2590303665","doi":"10.1200/jco.2013.31.4_suppl.32","title":"MicroRNA polymorphisms and esophageal cancer outcome.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Memorial University of Newfoundland; University of Alberta; Princess Margaret Cancer Centre; BC Cancer Agency; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Esophageal cancer; Oncology; microRNA; Proportional hazards model; Confidence interval; Carcinogenesis; Esophagectomy; Cancer; Gene; Biology; Genetics","score_opus":0.055774390618474244,"score_gpt":0.4193964485002146,"score_spread":0.3636220578817404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590303665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880804,0.003924779,0.0002370759,0.005931544,0.001306324,0.00010220905,0.000002690921,0.0000025617135,0.00041243585],"genre_scores_gemma":[0.99245,0.0014052573,0.0014977802,0.0015041444,0.0020518554,0.00000471153,0.0000027820333,0.000014093977,0.0010693668],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99817085,0.00016283467,0.0012197462,0.00016577548,0.000119549906,0.00016124136],"domain_scores_gemma":[0.99836403,0.000114611146,0.000939811,0.0001324892,0.00023921442,0.0002098323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007422281,0.00010198829,0.0004835384,0.000044305973,0.00003039766,0.000011973014,0.00013570943,0.00043802758,0.00017066307],"category_scores_gemma":[0.00045310287,0.00008009612,0.00021131481,0.000047341815,0.00016056691,0.000009155417,0.00006947074,0.00031853246,0.000014573557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007475777,0.00032667286,0.23007238,0.000013827481,0.00047222947,0.000030239731,0.00003578877,0.0001754871,0.1954026,0.000050988925,0.043338988,0.52933323],"study_design_scores_gemma":[0.004439842,0.0039653196,0.7803826,0.000021791046,0.00015832346,0.0002982662,0.000028077924,0.00012545391,0.011948823,0.00033904,0.19808239,0.00021011954],"about_ca_topic_score_codex":0.00006568791,"about_ca_topic_score_gemma":0.00005914164,"teacher_disagreement_score":0.5503102,"about_ca_system_score_codex":0.000036431295,"about_ca_system_score_gemma":0.00042361126,"threshold_uncertainty_score":0.337847},"labels":[],"label_agreement":null},{"id":"W2590305498","doi":"10.1200/jco.2015.33.29_suppl.35","title":"Does expected survival influence palliative radiotherapy treatment recommendations?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Life expectancy; Radiation therapy; Logistic regression; Lung cancer; Proportional hazards model; Performance status; Multivariate analysis; Internal medicine; Cancer; Survival analysis; Population","score_opus":0.1994908098916481,"score_gpt":0.5713722593753758,"score_spread":0.3718814494837277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590305498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90203565,0.002855046,0.0068963924,0.069496,0.013464573,0.00046493244,0.000008130345,0.00004382582,0.0047354177],"genre_scores_gemma":[0.6587277,0.04765654,0.25350764,0.01934861,0.0150765395,0.000034762506,0.000016696005,0.000075562,0.0055559496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967063,0.0008352751,0.001808068,0.00018820784,0.00025510532,0.00020702922],"domain_scores_gemma":[0.99342805,0.0036040274,0.0015838139,0.00020616042,0.0006858009,0.0004921656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021478168,0.00015931786,0.001517918,0.000107800355,0.00005000106,0.000005771653,0.00015464448,0.00040498067,0.00023939904],"category_scores_gemma":[0.0033219978,0.000076468954,0.00035097724,0.00015357626,0.00038345176,0.00017700272,0.000013270412,0.00063345337,0.000013086892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014654435,0.0046055783,0.33287105,0.0000074853174,0.0016629415,0.00077787624,0.0016066667,0.00016760099,0.00021466626,0.00036857274,0.008535172,0.6345279],"study_design_scores_gemma":[0.017863024,0.032213375,0.08713265,0.00004749784,0.00016898401,0.00018556677,0.00064719236,0.00005895485,0.0000824705,0.0013078764,0.8601782,0.00011422139],"about_ca_topic_score_codex":0.000011584754,"about_ca_topic_score_gemma":0.00003802135,"teacher_disagreement_score":0.851643,"about_ca_system_score_codex":0.00084423885,"about_ca_system_score_gemma":0.002460823,"threshold_uncertainty_score":0.4365394},"labels":[],"label_agreement":null},{"id":"W2590307037","doi":"10.1200/jco.2015.33.7_suppl.335","title":"Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; University of British Columbia","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Cisplatin; Regimen; Oncology; Proportional hazards model; Chemotherapy regimen; Progression-free survival; Perioperative; Neutropenia; Surgery","score_opus":0.06260395794880635,"score_gpt":0.417628241629942,"score_spread":0.35502428368113564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590307037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523306,0.000060145536,0.00019738472,0.001156815,0.00030824184,0.0017002065,0.000062880354,0.000016818107,0.0012644316],"genre_scores_gemma":[0.99232566,0.000028782064,0.0065631606,0.00051035604,0.00033669546,0.000044413722,0.00003978542,0.00009345393,0.000057684887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952373,0.0004921928,0.0021228325,0.00049036107,0.0011569656,0.00050033064],"domain_scores_gemma":[0.9939529,0.0015154375,0.0020558184,0.00057645136,0.0012263753,0.000673063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013634086,0.00054399465,0.002577297,0.00028866663,0.000057046655,0.000015922038,0.00031676036,0.00044072734,0.00025012143],"category_scores_gemma":[0.0011297084,0.0003065504,0.00047288294,0.00047736955,0.00032905806,0.00017040891,0.000025244262,0.0009406366,0.0000041892895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30076608,0.0062219338,0.6573836,0.000033473225,0.0004776544,0.00019147019,0.0002692456,0.0011793042,0.000033650842,0.000001032463,0.00012417116,0.033318404],"study_design_scores_gemma":[0.20692395,0.18720579,0.60287046,0.0005152608,0.00027152363,0.000008714669,0.00004229517,0.0012777623,0.00048940757,0.0000040321797,0.00018023918,0.00021056109],"about_ca_topic_score_codex":0.00018167148,"about_ca_topic_score_gemma":0.00029064683,"teacher_disagreement_score":0.18098386,"about_ca_system_score_codex":0.00074626924,"about_ca_system_score_gemma":0.0047110813,"threshold_uncertainty_score":0.99993867},"labels":[],"label_agreement":null},{"id":"W2590307370","doi":"10.1200/jco.2016.34.7_suppl.157","title":"Defining user needs for an electronic tool to improve chemotherapy-related toxicity management.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University Health Network; University of Toronto; Sunnybrook Health Science Centre; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Focus group; Thematic analysis; Feeling; Participatory design; Health care; Nursing; Qualitative research; Psychology","score_opus":0.07234324366116814,"score_gpt":0.4524830754771584,"score_spread":0.38013983181599026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590307370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9316508,0.00012886687,0.028868776,0.03201291,0.0008967979,0.00056458364,0.0000020432121,0.000021481466,0.0058537195],"genre_scores_gemma":[0.9536867,0.00048807473,0.013151364,0.019252514,0.0006617197,0.000030011104,0.0000013169075,0.000021227408,0.012707029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976893,0.00012468244,0.0014884461,0.00016823689,0.00022569294,0.00030364154],"domain_scores_gemma":[0.9975461,0.00073835795,0.00083909737,0.00023420138,0.00029013498,0.0003521076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032506494,0.00010005643,0.0007113597,0.00011362998,0.000030218866,0.0000057908337,0.00021674493,0.00023092456,0.0006276298],"category_scores_gemma":[0.0014411341,0.000059912643,0.00025143079,0.0001566955,0.000067514215,0.000118943986,0.000023670247,0.00034307616,0.00020520181],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027522838,0.0007936533,0.0064368392,0.000020170595,0.00034554463,0.000017449102,0.000046323417,8.8742394e-7,0.0035951645,0.0091612125,0.02239703,0.95443344],"study_design_scores_gemma":[0.020412255,0.034696784,0.06712219,0.0002532564,0.00030372757,0.000112459566,0.00017891073,0.0000763748,0.001227267,0.005884896,0.8695438,0.00018810773],"about_ca_topic_score_codex":9.983887e-7,"about_ca_topic_score_gemma":0.0000023428981,"teacher_disagreement_score":0.9542453,"about_ca_system_score_codex":0.00013836988,"about_ca_system_score_gemma":0.0007005601,"threshold_uncertainty_score":0.6872106},"labels":[],"label_agreement":null},{"id":"W2590316303","doi":"10.1200/jco.2013.31.6_suppl.60","title":"A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Capra; Medicine; Concordance; Cohort; Prostate cancer; Hazard ratio; Prostatectomy; Oncology; Internal medicine; Proportional hazards model; Cancer; Confidence interval","score_opus":0.09709191774009196,"score_gpt":0.45492588546957213,"score_spread":0.3578339677294802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590316303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919789,0.0018456978,0.000003604277,0.0037233904,0.00051344204,0.0009296371,0.0000108494405,0.0000053346484,0.0009891887],"genre_scores_gemma":[0.9888327,0.0088152755,0.00049428915,0.0001720896,0.0005014659,0.00006923358,0.000003936384,0.000019555673,0.001091435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996002,0.000560042,0.0023188512,0.0002292162,0.00050992175,0.00037995545],"domain_scores_gemma":[0.9956271,0.0016754279,0.0014525296,0.0001694059,0.00063569855,0.0004398188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026246426,0.0001496389,0.0015931744,0.00023589948,0.000024494248,0.000010302959,0.00016810911,0.00039184437,0.0006228286],"category_scores_gemma":[0.0012816022,0.000091336406,0.00033477653,0.0002048907,0.0002748154,0.000121019155,0.00007561308,0.0014947752,0.000034041124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046253917,0.0015997704,0.9381304,0.000048053127,0.0005057899,0.0013396387,0.000093086004,0.000018193703,0.00008163256,0.000039458744,0.00078411464,0.0527345],"study_design_scores_gemma":[0.017180309,0.0077275946,0.96917427,0.00018002396,0.0003292406,0.00018224357,0.00006289165,0.00011784674,0.00008173355,0.00074602215,0.004136333,0.00008147898],"about_ca_topic_score_codex":0.0011350099,"about_ca_topic_score_gemma":0.00019993963,"teacher_disagreement_score":0.052653026,"about_ca_system_score_codex":0.00038005225,"about_ca_system_score_gemma":0.0033205352,"threshold_uncertainty_score":0.6819536},"labels":[],"label_agreement":null},{"id":"W2590318564","doi":"10.1200/jco.2013.31.15_suppl.561","title":"Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Incidence (geometry); Pneumonitis; Surgery; Internal medicine; Lung","score_opus":0.042537317156580504,"score_gpt":0.40128574826440677,"score_spread":0.3587484311078263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590318564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411976,0.0009862399,0.00039633017,0.00039819328,0.0005391944,0.00010900247,0.0000012414297,0.0000016762249,0.0034483871],"genre_scores_gemma":[0.9946507,0.0021476354,0.0022512015,0.00039431307,0.000355578,0.0000058771325,0.0000011830908,0.000008544995,0.00018495512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814475,0.00024602,0.0011743815,0.00015280434,0.00013282486,0.00014919497],"domain_scores_gemma":[0.99847627,0.00018598046,0.0008951871,0.0001328162,0.0002102351,0.00009951407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013428323,0.00008152492,0.00044626993,0.00009360799,0.000016307802,0.0000066688103,0.00015130453,0.00028897755,0.000033776923],"category_scores_gemma":[0.0006143582,0.00007075665,0.0001242832,0.00008467544,0.00018501193,0.000011564705,0.00009970661,0.00029316527,0.0000045552947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010043014,0.0009338673,0.7251416,0.0000850061,0.00040431778,0.00017775354,0.00006783597,0.00041390868,0.0840383,0.00024382082,0.013831969,0.17365736],"study_design_scores_gemma":[0.0046752356,0.009770176,0.92211264,0.00014732506,0.00009225141,0.00028012786,0.00008991368,0.00017478413,0.005188955,0.0016673432,0.05560431,0.00019695492],"about_ca_topic_score_codex":0.000058116104,"about_ca_topic_score_gemma":0.000074550415,"teacher_disagreement_score":0.19697106,"about_ca_system_score_codex":0.000033607346,"about_ca_system_score_gemma":0.00019283606,"threshold_uncertainty_score":0.28853726},"labels":[],"label_agreement":null},{"id":"W2590320673","doi":"10.1200/jco.2016.34.2_suppl.96","title":"Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"MSH2; MSH6; MLH1; PMS2; Medicine; Lynch syndrome; Oncology; Cohort; Prostate cancer; Internal medicine; DNA mismatch repair; Cancer research; Cancer","score_opus":0.08022135410154034,"score_gpt":0.4505735313364065,"score_spread":0.37035217723486613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590320673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98549056,0.0004159419,0.00016734879,0.009825158,0.0018365873,0.00053603,0.00001868756,0.000013624784,0.0016960328],"genre_scores_gemma":[0.9886482,0.0013145145,0.0071746493,0.0013492501,0.00059152127,0.00003871276,0.0000013351275,0.00002797998,0.00085384015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577916,0.00033712978,0.002834563,0.0002673207,0.00047236332,0.00030947963],"domain_scores_gemma":[0.99403733,0.0030289341,0.0015252125,0.00024274953,0.0008271131,0.0003386608],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022031155,0.00017565773,0.0013283555,0.00012221314,0.000022623293,0.0000048951624,0.00017356013,0.00038509438,0.001152076],"category_scores_gemma":[0.0059954715,0.00010838115,0.00042859113,0.00022566362,0.00041981135,0.00009237287,0.00005709957,0.00052150723,0.000026688256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007973773,0.0015203268,0.9230506,0.00010052408,0.00037123504,0.00021734103,0.0001784935,0.0000582326,0.011006756,0.000036322155,0.008705837,0.04678057],"study_design_scores_gemma":[0.026208734,0.015945798,0.86748767,0.0016184399,0.000678947,0.0006637581,0.00021592014,0.00023957998,0.011376588,0.00074382377,0.07449255,0.0003282084],"about_ca_topic_score_codex":0.000120474244,"about_ca_topic_score_gemma":0.00036911672,"teacher_disagreement_score":0.06578672,"about_ca_system_score_codex":0.00035571874,"about_ca_system_score_gemma":0.0039886404,"threshold_uncertainty_score":0.999761},"labels":[],"label_agreement":null},{"id":"W2590321819","doi":"10.1200/jco.2016.34.7_suppl.108","title":"Pathway map development as an approach to identifying priority areas for quality improvement in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Trillium Health Centre; Juravinski Cancer Centre; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multidisciplinary approach; Specialty; Quality management; Cervical cancer; Stakeholder; Survivorship curve; Reimbursement; Health care; Nursing; Knowledge translation; Family medicine; MEDLINE; Process management; Cancer; Knowledge management; Public relations; Operations management; Business","score_opus":0.5967053015558434,"score_gpt":0.6142961221569955,"score_spread":0.017590820601152024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590321819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95715755,0.000012818018,0.02620893,0.013554577,0.0015125439,0.00095165457,0.0000031633883,0.0000099364925,0.00058884965],"genre_scores_gemma":[0.857324,0.000014626996,0.13459753,0.006530847,0.00082209246,0.000042027288,0.000009603577,0.00001940802,0.0006398612],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9908787,0.00058232894,0.007180382,0.0003971757,0.0006080429,0.00035336305],"domain_scores_gemma":[0.98911595,0.0060751154,0.0028258252,0.00031016298,0.00095837173,0.0007145982],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024875982,0.00016822889,0.0013795679,0.00016405409,0.00004802495,0.000016678032,0.00023319488,0.00032869584,0.00014453456],"category_scores_gemma":[0.029836802,0.00010867672,0.00033987974,0.00009327793,0.00006564007,0.000370465,0.00011564678,0.00074511924,0.000033647448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009536516,0.0050301463,0.20153135,0.00005987795,0.00019309009,0.000053476466,0.0005978147,0.0000026608927,0.002176247,0.00039259414,0.0008692362,0.779557],"study_design_scores_gemma":[0.016357072,0.009988366,0.78713703,0.00013724205,0.00012790655,0.00004746367,0.00076506723,0.000009951612,0.00052430836,0.0022496097,0.18248425,0.00017175125],"about_ca_topic_score_codex":0.0027405291,"about_ca_topic_score_gemma":0.040127046,"teacher_disagreement_score":0.7793852,"about_ca_system_score_codex":0.0014204836,"about_ca_system_score_gemma":0.008954254,"threshold_uncertainty_score":0.99666405},"labels":[],"label_agreement":null},{"id":"W2590328801","doi":"10.1200/jco.2015.33.7_suppl.9","title":"Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Prostatectomy; Medicine; Subtyping; Biochemical recurrence; Random forest; Gene expression profiling; Erg; Gene expression; Oncology; Computational biology; Gene; Internal medicine; Cancer; Biology; Genetics; Artificial intelligence","score_opus":0.18887667025605195,"score_gpt":0.4957003258065545,"score_spread":0.3068236555505025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590328801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871229,0.0020776393,0.000081514576,0.009062093,0.0008528754,0.000570698,0.000010060197,0.000008722972,0.00021351973],"genre_scores_gemma":[0.9838005,0.0099782245,0.0020858033,0.0029354095,0.00095630466,0.000010058943,0.000016015863,0.000020348125,0.00019734749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948309,0.0007459557,0.0033272274,0.00039469288,0.00043387417,0.0002673571],"domain_scores_gemma":[0.9950061,0.0011234145,0.0013322025,0.00017717083,0.0011156156,0.0012455202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053210896,0.00018606297,0.0020123634,0.00015788023,0.000033661927,0.0000120656,0.00014839698,0.0005767373,0.000012242042],"category_scores_gemma":[0.004989782,0.0001147711,0.00027335732,0.0002132849,0.0007770562,0.00013801073,0.00021445102,0.0010797527,0.0000051929305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019094145,0.002368984,0.8460243,0.00009700383,0.00049739535,0.0006196259,0.00029215394,0.0000017601692,0.010308059,0.00008809627,0.000535161,0.12007332],"study_design_scores_gemma":[0.014103023,0.025151536,0.94335693,0.00025344617,0.00025356302,0.00012586954,0.000055930137,0.00005972617,0.000601726,0.0002146593,0.01568948,0.0001341382],"about_ca_topic_score_codex":0.000017873293,"about_ca_topic_score_gemma":0.000010312265,"teacher_disagreement_score":0.119939186,"about_ca_system_score_codex":0.00011961041,"about_ca_system_score_gemma":0.0027895174,"threshold_uncertainty_score":0.59735954},"labels":[],"label_agreement":null},{"id":"W2590333824","doi":"10.1200/jco.2013.31.26_suppl.133","title":"Group medical appointments: A novel approach in patient education for adjuvant endocrine therapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Pharmacist; Population; Medical prescription; Family medicine; Guideline; Patient satisfaction; Patient education; Physical therapy; Nursing; Pharmacy","score_opus":0.3197123828094086,"score_gpt":0.5540309275015405,"score_spread":0.23431854469213187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590333824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523526,0.0011471929,0.0019033998,0.035362016,0.00246819,0.0014719507,0.0000023384669,0.000008488776,0.0052838637],"genre_scores_gemma":[0.9570148,0.0011173261,0.016672669,0.024071502,0.00094714505,0.00008544242,0.00001049944,0.00001569588,0.0000649419],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965378,0.00026985095,0.0022841017,0.00017444922,0.00048805904,0.0002457294],"domain_scores_gemma":[0.9949885,0.0028988596,0.0011894322,0.00012947297,0.00022814977,0.0005655627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021483528,0.0001243914,0.0010232221,0.00012193854,0.000020818918,0.0000085967185,0.00014653824,0.00023854303,0.00042842588],"category_scores_gemma":[0.004820176,0.000076780096,0.0003626677,0.00010851293,0.00008289901,0.0002218079,0.000041056042,0.00095047004,0.000013709864],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034214845,0.019092226,0.05137474,0.000055128003,0.00019628683,0.00003426631,0.00009216678,0.0000020114935,0.00012982596,0.00048352635,0.006089314,0.919029],"study_design_scores_gemma":[0.034082446,0.033922445,0.23002644,0.00021640047,0.0002532659,0.0010768672,0.0005981713,0.0050054854,0.0000560446,0.0016952808,0.6928449,0.00022223988],"about_ca_topic_score_codex":0.00003121352,"about_ca_topic_score_gemma":0.0000033566498,"teacher_disagreement_score":0.9188068,"about_ca_system_score_codex":0.000115397735,"about_ca_system_score_gemma":0.001252596,"threshold_uncertainty_score":0.5770549},"labels":[],"label_agreement":null},{"id":"W2590334405","doi":"10.1200/jco.2012.30.34_suppl.188","title":"Primary care providers’ evaluation of survivorship care plans.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Survivorship curve; Psychosocial; Respondent; Family medicine; Reimbursement; Cancer survivorship; Health care; Cancer; Cancer survivor; Nursing; Internal medicine; Psychiatry","score_opus":0.20692037319152373,"score_gpt":0.4836404729786007,"score_spread":0.27672009978707696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590334405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95584005,0.0120857265,0.00003382639,0.0009343051,0.0047347443,0.0003173174,0.000013172202,0.00000814337,0.026032723],"genre_scores_gemma":[0.99578077,0.0002319931,0.00039382695,0.0010039088,0.0024849337,0.0000059460444,0.000024582567,0.000017714308,0.000056356013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566686,0.001052471,0.0018576429,0.00013148422,0.0010380141,0.00025350036],"domain_scores_gemma":[0.9942665,0.0011768042,0.0015099617,0.00023662813,0.0024113848,0.00039873723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064404975,0.00012724703,0.0012473805,0.00012673716,0.000026093001,0.0000041748667,0.00014597982,0.00044764497,0.00016834543],"category_scores_gemma":[0.002321715,0.00009438008,0.0005472063,0.00013951873,0.00014524625,0.00017929943,0.000039268936,0.0007739993,0.000009475731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002403891,0.0005036796,0.6424303,0.00045396495,0.0002094455,0.000025073856,0.007942698,0.000009016631,0.00008875471,0.00004769713,0.0011844723,0.344701],"study_design_scores_gemma":[0.007770985,0.0065041473,0.9004848,0.00030098745,0.0018420878,0.00015694428,0.01664622,0.000007665376,0.00034678305,0.000073307536,0.065727286,0.00013880467],"about_ca_topic_score_codex":0.00019542135,"about_ca_topic_score_gemma":0.0012937228,"teacher_disagreement_score":0.3445622,"about_ca_system_score_codex":0.0005220514,"about_ca_system_score_gemma":0.0037215028,"threshold_uncertainty_score":0.6601786},"labels":[],"label_agreement":null},{"id":"W2590336836","doi":"10.1200/jco.2013.31.4_suppl.242","title":"A retrospective review of chemotherapy for patients with small bowel adenocarcinoma in British Columbia.","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Proportional hazards model; Stage (stratigraphy); Cancer; Adenocarcinoma; Cancer registry; Gastroenterology; Epidemiology; Retrospective cohort study; Oncology; Surgery","score_opus":0.13852112307382486,"score_gpt":0.4610594199189624,"score_spread":0.3225382968451375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590336836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004835417,0.99080604,0.000010798473,0.00033679386,0.00014882884,0.0036170003,0.00004389587,0.0000033736699,0.00019782243],"genre_scores_gemma":[0.00017771173,0.9880678,0.010501313,0.0003830216,0.0003629718,0.00012271116,0.00003249034,0.000048837668,0.0003031256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944172,0.0005097472,0.003917392,0.0003175037,0.00048012266,0.00035803698],"domain_scores_gemma":[0.9915253,0.0015795137,0.004441187,0.00025821722,0.0017420735,0.00045373826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023993396,0.0002200763,0.007244933,0.000115572046,0.00001817772,0.000017148981,0.00025374294,0.00030576694,0.00022379438],"category_scores_gemma":[0.0070189033,0.00018204993,0.0014557256,0.0002360915,0.000229069,0.00004825845,0.000042420117,0.0013906311,0.000006110425],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004634186,0.0034976038,0.18213287,0.03503407,0.0006304905,0.00071049127,0.0000022187708,4.2011563e-9,6.1421814e-9,0.0000010005664,0.005093368,0.7724345],"study_design_scores_gemma":[0.0122495545,0.06969238,0.28556752,0.2328676,0.0017821188,0.0014105708,0.000005241335,3.1078417e-7,2.0295966e-8,0.000049977378,0.39624214,0.00013256272],"about_ca_topic_score_codex":0.00042726818,"about_ca_topic_score_gemma":0.00122826,"teacher_disagreement_score":0.7723019,"about_ca_system_score_codex":0.00057150505,"about_ca_system_score_gemma":0.0038871674,"threshold_uncertainty_score":0.840279},"labels":[],"label_agreement":null},{"id":"W2590337884","doi":"10.1200/jco.2005.23.16_suppl.4157","title":"Toxicity and outcomes of adjuvant chemoradiotherapy in patients with resected gastric adenocarcinoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Toxicity; Chemoradiotherapy; Chemotherapy; Gastroenterology; Surgery; Adenocarcinoma; Cancer; Internal medicine; Stage (stratigraphy); Stomach; Radiation therapy","score_opus":0.050861836350405226,"score_gpt":0.3976281425812701,"score_spread":0.3467663062308649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590337884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939645,0.00032293046,0.000038091137,0.0049378136,0.0001508863,0.00018411591,0.0000011549729,0.0000034873703,0.00039702636],"genre_scores_gemma":[0.99350244,0.0002488365,0.004501616,0.0013693338,0.00021990764,9.0405837e-7,9.004566e-7,0.00000890677,0.00014717135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978645,0.00011233014,0.001420915,0.0001223774,0.00031885205,0.00016105738],"domain_scores_gemma":[0.9979631,0.000545748,0.0010017934,0.0001241711,0.00020482106,0.00016041905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009933216,0.00010168093,0.0014830362,0.00023380907,0.000009815542,0.0000031273103,0.000094861985,0.00012775588,0.00007422741],"category_scores_gemma":[0.00070120895,0.0000620703,0.00014542922,0.00021247097,0.00012488438,0.00009008391,0.000029146495,0.00043301604,9.0234505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003944557,0.0012675325,0.8909443,0.000017976594,0.00016752578,0.00004562128,0.000046879384,0.0000049755217,0.000006836045,0.000009187478,0.00057806773,0.102966525],"study_design_scores_gemma":[0.025794547,0.0108128125,0.96091557,0.000040064126,0.00014427492,0.000019908748,0.00003354017,0.000024303166,0.000017735152,0.000014149932,0.0021336323,0.000049464805],"about_ca_topic_score_codex":0.000013895863,"about_ca_topic_score_gemma":0.00006421873,"teacher_disagreement_score":0.10291706,"about_ca_system_score_codex":0.00011450454,"about_ca_system_score_gemma":0.00027318887,"threshold_uncertainty_score":0.25311536},"labels":[],"label_agreement":null},{"id":"W2590339222","doi":"10.1200/jco.2014.32.30_suppl.68","title":"Involving clinic patients in systematic symptom reporting to improve cancer care: Exploring prevalence of sleep disturbances (SD) and fatigue (FAT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Physical therapy; Internal medicine","score_opus":0.14731952296307643,"score_gpt":0.4448971661843534,"score_spread":0.29757764322127694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590339222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911142,0.0045150504,0.000083078005,0.00038538966,0.0031515402,0.0004373827,0.0000031869567,0.000006161442,0.0003040069],"genre_scores_gemma":[0.9965303,0.0018766483,0.00035631843,0.00044098185,0.0006869097,0.00004504189,5.929647e-7,0.000016091648,0.000047096313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927727,0.0005230925,0.00575484,0.00027591843,0.00044149015,0.00023193269],"domain_scores_gemma":[0.98979026,0.0025975388,0.00634548,0.00024790742,0.00071759097,0.0003012369],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004947056,0.00014936815,0.0021115607,0.00014763184,0.000028120063,0.000009336684,0.00016239907,0.00019979605,0.000016981161],"category_scores_gemma":[0.020692782,0.00010913904,0.0002825889,0.00019997462,0.00009901224,0.00016432589,0.0000926123,0.0006225088,0.0000011041479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055472035,0.0001932613,0.9439667,0.012244016,0.00008969601,0.000027937187,0.0023802437,0.00002071613,0.000057619603,0.000011792156,0.000036978054,0.040416326],"study_design_scores_gemma":[0.0035304227,0.0069475025,0.9707781,0.015047851,0.0005073647,0.000015155433,0.0023391251,0.00010710201,0.0002084423,0.000059453934,0.00030374565,0.00015571628],"about_ca_topic_score_codex":0.00034508624,"about_ca_topic_score_gemma":0.0013256167,"teacher_disagreement_score":0.04026061,"about_ca_system_score_codex":0.00022032442,"about_ca_system_score_gemma":0.00036192764,"threshold_uncertainty_score":0.98755634},"labels":[],"label_agreement":null},{"id":"W2590346812","doi":"10.1200/jco.2014.32.30_suppl.18","title":"Quantifying the psychosocial needs of cancer patients and associated provider workload to build PSO services into the funding model for systemic treatment in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Psychosocial; Medicine; Workload; Documentation; Family medicine; Social work; Needs assessment; Nursing; Psychiatry","score_opus":0.38837579662075394,"score_gpt":0.5779125875991922,"score_spread":0.18953679097843823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590346812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623148,0.0001595009,0.0006417982,0.03522235,0.00072134647,0.0009044394,0.0000021831854,0.0000031199959,0.00003048255],"genre_scores_gemma":[0.992133,0.00020017399,0.0013175731,0.0057982015,0.00041955413,0.00004391311,0.0000026544608,0.000013387934,0.00007153695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956332,0.0005457094,0.0031980197,0.00013449304,0.00029152923,0.00019704216],"domain_scores_gemma":[0.98689646,0.0094219865,0.0027811655,0.00013240844,0.0006260353,0.00014196828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068623214,0.00012201503,0.0009637584,0.00009511005,0.00008084009,0.000015913483,0.00015579222,0.00022168065,0.000009498874],"category_scores_gemma":[0.0067244447,0.00006327833,0.00023825675,0.00016098544,0.00007062241,0.000116892625,0.000043315937,0.0005172219,7.592519e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003907601,0.0008805909,0.8653677,0.00004950964,0.0003439184,0.0000013380835,0.00710052,0.00062913814,0.00007976423,0.000038614337,0.00039022588,0.1212111],"study_design_scores_gemma":[0.024700886,0.014396997,0.9164048,0.0010363766,0.0016876362,0.000013350778,0.005449737,0.024143001,0.000013914521,0.0008848587,0.011108182,0.0001602691],"about_ca_topic_score_codex":0.019110452,"about_ca_topic_score_gemma":0.33094114,"teacher_disagreement_score":0.3118307,"about_ca_system_score_codex":0.00066243205,"about_ca_system_score_gemma":0.0012565954,"threshold_uncertainty_score":0.9874214},"labels":[],"label_agreement":null},{"id":"W2590350652","doi":"10.1200/jco.2016.34.3_suppl.92","title":"What is the role of comorbidity, frailty, and functional status in the decision-making process for older adults with cancer and their family members, oncologists, and family physician?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Family medicine; Comorbidity; Population; Geriatric oncology; Geriatrics; Gerontology; Family caregivers; Cancer; Psychiatry; Internal medicine","score_opus":0.36563506080165337,"score_gpt":0.5153567614988109,"score_spread":0.14972170069715757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590350652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94741786,0.015038537,0.0007213843,0.035413116,0.00053671614,0.00050910906,0.00011332702,0.000002045956,0.0002478811],"genre_scores_gemma":[0.9679261,0.009983199,0.00048477,0.02112844,0.00041323173,0.000043559197,7.71338e-7,0.0000112031175,0.000008755778],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957283,0.0003763338,0.003282969,0.00027824135,0.0001110291,0.00022309694],"domain_scores_gemma":[0.97516006,0.020392593,0.0039673294,0.00016185293,0.00021956387,0.00009861418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01539328,0.00013114596,0.0012083879,0.00010052058,0.00009678306,0.000042675823,0.00017249386,0.00019271273,0.000016241585],"category_scores_gemma":[0.002654247,0.00006711375,0.00009733922,0.0000866108,0.00039563669,0.00049664394,0.00005139193,0.00028402897,0.0000014532153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025936156,0.0006394484,0.28853148,0.00019310178,0.00033315553,0.000002996786,0.011742029,0.00007021101,0.0000043495575,0.004430103,0.0074708196,0.6839887],"study_design_scores_gemma":[0.0060430844,0.0017890432,0.8401465,0.0008482988,0.000032942495,0.000018043436,0.0321958,0.0011202553,0.0000018692008,0.05420628,0.063438736,0.00015917997],"about_ca_topic_score_codex":0.00016913842,"about_ca_topic_score_gemma":0.00067804195,"teacher_disagreement_score":0.6838295,"about_ca_system_score_codex":0.00012727601,"about_ca_system_score_gemma":0.00057365693,"threshold_uncertainty_score":0.5335035},"labels":[],"label_agreement":null},{"id":"W2590354601","doi":"10.1200/jco.2011.29.4_suppl.545","title":"SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Sunitinib; Irinotecan; Capecitabine; Oxaliplatin; Internal medicine; Colorectal cancer; Refractory (planetary science); Oncology; KRAS; Phases of clinical research; Toxicity; Gastroenterology; Cancer","score_opus":0.11490542516467939,"score_gpt":0.43438141456296364,"score_spread":0.31947598939828425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590354601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962273,0.00040198167,0.0000061382634,0.00052844454,0.00013948641,0.0016912966,0.000021407743,0.000009882707,0.0009740556],"genre_scores_gemma":[0.9970978,0.00035662786,0.0017559979,0.0003416075,0.00012505383,0.00015250569,0.000003481644,0.000031689153,0.0001352264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997296,0.000279372,0.0012922586,0.00035998496,0.00043908105,0.00033330027],"domain_scores_gemma":[0.9973458,0.00052271,0.00095151213,0.00016847206,0.0005528465,0.0004586354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057882624,0.00032694667,0.002042848,0.00020210225,0.00009326988,0.000007903532,0.000082713224,0.00008910822,0.00014539037],"category_scores_gemma":[0.000179624,0.00015995259,0.00009782758,0.0002732565,0.0002339306,0.00012172774,0.000054022523,0.00043487377,0.0000012508121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123670876,0.035298664,0.69443977,0.000017868011,0.002245025,0.0016302358,0.004646762,0.0000042150427,0.000003745101,0.0000022852926,0.000048708265,0.13799186],"study_design_scores_gemma":[0.055004757,0.42037207,0.5200811,0.00012372428,0.001258139,0.00006863893,0.00088373356,0.0000023586238,0.000011798904,0.0000022861723,0.0020760417,0.00011533173],"about_ca_topic_score_codex":0.0009141563,"about_ca_topic_score_gemma":0.01844968,"teacher_disagreement_score":0.3850734,"about_ca_system_score_codex":0.00052863156,"about_ca_system_score_gemma":0.0012431019,"threshold_uncertainty_score":0.99946105},"labels":[],"label_agreement":null},{"id":"W2590363383","doi":"10.1200/jco.2012.30.34_suppl.13","title":"Cancer patients’ and physicians’ preferences for decision making regarding pharmacogenomic testing (PGT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Conjoint analysis; Pharmacogenomics; Cancer; Family medicine; Willingness to pay; Genetic testing; Pharmacogenetics; Internal medicine; Preference; Pharmacology","score_opus":0.7288844181195036,"score_gpt":0.6857004196612614,"score_spread":0.04318399845824217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590363383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197274,0.0012425317,0.0007081146,0.0018113854,0.0022745866,0.00029914713,0.0000053203416,0.0000070991546,0.0016790952],"genre_scores_gemma":[0.9545597,0.0015616099,0.03765587,0.0024310537,0.0036811493,0.00000954893,4.781968e-7,0.000020101013,0.000080494836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963122,0.00028754506,0.002203821,0.00020211808,0.00060290913,0.00039140892],"domain_scores_gemma":[0.86949384,0.12600559,0.0019889122,0.0001410382,0.0019139984,0.00045663884],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014762034,0.00011620866,0.0010720514,0.00010114107,0.00009456322,0.000015598896,0.00019663453,0.0004748344,0.00005114315],"category_scores_gemma":[0.14766379,0.00008149647,0.0002909763,0.00012315257,0.0002715454,0.00020152789,0.00014247191,0.0022541925,0.0000045813345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020030583,0.0005691809,0.50257355,0.00006796577,0.00012646632,0.000005587645,0.00007842056,0.0000030371596,0.00023505895,0.00007691271,0.0009125693,0.49334818],"study_design_scores_gemma":[0.011598308,0.01173637,0.9359342,0.0024012355,0.00073011895,0.000047689693,0.00020292311,0.00044777954,0.00024662126,0.014189079,0.022269214,0.00019650011],"about_ca_topic_score_codex":0.000005882256,"about_ca_topic_score_gemma":0.00001510361,"teacher_disagreement_score":0.4931517,"about_ca_system_score_codex":0.00016068388,"about_ca_system_score_gemma":0.0011152847,"threshold_uncertainty_score":0.97934705},"labels":[],"label_agreement":null},{"id":"W2590364524","doi":"10.1200/jco.2013.31.15_suppl.553","title":"Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cambridge Memorial Hospital","funders":"","keywords":"Medicine; Exemestane; Discontinuation; Quality of life (healthcare); Breast cancer; Internal medicine; Adverse effect; Cancer; Clinical endpoint; Aromatase inhibitor; Oncology; Randomized controlled trial; Tamoxifen","score_opus":0.05542602667405326,"score_gpt":0.4080886539194081,"score_spread":0.3526626272453548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590364524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98833245,0.0006724506,0.00010129142,0.009597497,0.0008715365,0.00018559945,0.0000062485265,0.000012556383,0.0002203476],"genre_scores_gemma":[0.99405605,0.00019919744,0.0015496656,0.002193587,0.0019247115,0.000016243674,0.000004223422,0.000019089055,0.000037229234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975172,0.0001882102,0.0015547066,0.00022751009,0.00031860496,0.00019372796],"domain_scores_gemma":[0.99683946,0.000736209,0.001569497,0.000102891776,0.0005454183,0.00020650218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020679149,0.00014813339,0.0011878113,0.00010885613,0.00006130996,0.000011341282,0.00006290063,0.00021252948,0.00023851446],"category_scores_gemma":[0.0003000582,0.000110881665,0.00021027023,0.00014058374,0.00025079973,0.000379697,0.00004148119,0.000856585,0.000009177782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003347323,0.0013192348,0.115905434,0.000014990159,0.00040707283,0.00014172817,0.0008803825,0.000096036165,0.003909369,0.000053046948,0.0004083394,0.87351704],"study_design_scores_gemma":[0.008911243,0.0017514757,0.9733382,0.00016720252,0.00012810867,0.00021053046,0.0006875794,0.00018669432,0.0000517125,0.0030342056,0.011422179,0.00011090269],"about_ca_topic_score_codex":0.0001654941,"about_ca_topic_score_gemma":0.000052940413,"teacher_disagreement_score":0.8734061,"about_ca_system_score_codex":0.00022257741,"about_ca_system_score_gemma":0.0007041218,"threshold_uncertainty_score":0.4521623},"labels":[],"label_agreement":null},{"id":"W2590366964","doi":"10.1200/jco.2012.30.4_suppl.15","title":"What studies are appropriate and necessary for staging gastric cancer? Results of a RAND/UCLA expert panel.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Endoscopic ultrasound; Esophagogastroduodenoscopy; Radiology; Cancer; Radiological weapon; Cancer staging; Esophageal cancer; Nuclear medicine; Endoscopy; Internal medicine","score_opus":0.3155210312802703,"score_gpt":0.5149941087389714,"score_spread":0.19947307745870113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590366964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9266148,0.038171336,0.00033767286,0.028845392,0.00533356,0.00045796248,0.000006998837,0.000009313966,0.000222922],"genre_scores_gemma":[0.92769355,0.06311387,0.0036272553,0.0022562912,0.002742986,0.000014508891,0.0000013334401,0.000014185176,0.0005360478],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973624,0.00015418544,0.0018224458,0.00013855686,0.0002541442,0.00026827265],"domain_scores_gemma":[0.99475956,0.0023386606,0.0021579878,0.00012309404,0.00038877098,0.00023194008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033934559,0.00012544394,0.0015995856,0.00015133411,0.00003592114,0.000009817751,0.00009651117,0.00013640881,0.000011220121],"category_scores_gemma":[0.0028380232,0.0000814144,0.00030111466,0.00013080025,0.00016418914,0.00032256256,0.000080635626,0.0003398602,4.6479784e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018916247,0.00082609645,0.26501343,0.00041885432,0.0016726408,0.000069822076,0.001694889,0.000009891701,0.00008598274,0.000039277274,0.021525484,0.6897274],"study_design_scores_gemma":[0.06908872,0.010814517,0.7018601,0.0014989985,0.0021984973,0.00014728018,0.02477256,0.000109296176,0.0001709089,0.00060900365,0.18847786,0.0002523125],"about_ca_topic_score_codex":0.000017503024,"about_ca_topic_score_gemma":0.000015553062,"teacher_disagreement_score":0.68947506,"about_ca_system_score_codex":0.000095751166,"about_ca_system_score_gemma":0.00024473923,"threshold_uncertainty_score":0.3397584},"labels":[],"label_agreement":null},{"id":"W2590367359","doi":"10.1200/jco.2014.32.3_suppl.107","title":"A province-wide retrospective comparison of pathologic response and progression-free survival in locally advanced esophagus cancer patients treated with either cisplatin-5FU (CF) or carboplatin-paclitaxel (CP) concurrent with radiation (XRT) with or without surgery.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Esophageal cancer; Radiation therapy; Chemotherapy; Cisplatin; Internal medicine; Esophagus; Cancer; Paclitaxel; Surgery; Gastroenterology","score_opus":0.0774229373696001,"score_gpt":0.4556703368345948,"score_spread":0.3782473994649947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590367359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577004,0.0016620004,0.00013446838,0.0008187637,0.00012530612,0.0013713776,0.000026911743,0.000015069868,0.000076091106],"genre_scores_gemma":[0.997125,0.0002682243,0.0021049778,0.0001401788,0.000116456715,0.00008901402,0.000009180281,0.000040218674,0.00010672127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99471384,0.0014836576,0.0018650598,0.00045536354,0.0010485067,0.00043356148],"domain_scores_gemma":[0.9902548,0.005203619,0.0027051482,0.0003038349,0.0010291077,0.00050345017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028653543,0.00033369375,0.0026646073,0.00024914116,0.000060870578,0.000014854714,0.00015006406,0.0002574057,0.000046951394],"category_scores_gemma":[0.005659451,0.00015160232,0.000117516305,0.00040396367,0.00060827244,0.0001732528,0.000052777752,0.00092469953,7.0527403e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24895352,0.0022698957,0.6811666,0.0000779665,0.00027105314,0.00097181555,0.00018525454,0.00003854831,0.000007747126,0.0000043470413,0.000055687357,0.06599757],"study_design_scores_gemma":[0.039543543,0.13439782,0.82365054,0.0010757527,0.0002900035,0.00010209793,0.00013860669,0.0003241654,0.00023722401,0.000011953138,0.00007558941,0.00015269234],"about_ca_topic_score_codex":0.00016108659,"about_ca_topic_score_gemma":0.0046245777,"teacher_disagreement_score":0.20940997,"about_ca_system_score_codex":0.00061978714,"about_ca_system_score_gemma":0.0042032385,"threshold_uncertainty_score":0.7456364},"labels":[],"label_agreement":null},{"id":"W2590368828","doi":"10.1200/jco.2014.32.31_suppl.76","title":"Advance-care planning quality improvement plan: A Cancer Care Ontario toolkit to support primary care teams to implement advance care plans in practice.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Advance care planning; Medicine; Quality management; Quality (philosophy); Health care; Nursing; Process management; Plan (archaeology); PDCA; Best practice; Process (computing); Christian ministry; Palliative care; Operations management; Business; Computer science; Engineering","score_opus":0.24830430641154283,"score_gpt":0.6029922644922815,"score_spread":0.35468795808073866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590368828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656456,0.0014080257,0.0016185482,0.016876925,0.004420074,0.0026472223,0.0002739259,0.00003930878,0.0070703826],"genre_scores_gemma":[0.9093346,0.00025492127,0.041768763,0.04534973,0.0026053598,0.000153253,0.0003489266,0.00006627291,0.000118186115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98818153,0.0009591226,0.007853622,0.00083168934,0.0013617998,0.0008122343],"domain_scores_gemma":[0.98463565,0.0066674943,0.0038910683,0.0006826062,0.0029887615,0.0011344108],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0050534946,0.00044845862,0.00252664,0.00029778594,0.00012230202,0.000039698116,0.0004897521,0.00047441796,0.00029076837],"category_scores_gemma":[0.01696682,0.00038835124,0.0005242383,0.0002927491,0.00006655124,0.00060330285,0.000375458,0.0024149243,0.00003834157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013309584,0.00048746853,0.36542147,0.0004181956,0.00020424956,0.00039676536,0.024638101,0.0012025307,0.0001666696,0.00002336822,0.0030959162,0.59063566],"study_design_scores_gemma":[0.01149989,0.027330466,0.23650038,0.00048446518,0.0005459324,0.00006492697,0.09741325,0.000002590588,0.0000834797,0.000014426964,0.62573504,0.00032516668],"about_ca_topic_score_codex":0.008382273,"about_ca_topic_score_gemma":0.21282463,"teacher_disagreement_score":0.6226391,"about_ca_system_score_codex":0.0073635518,"about_ca_system_score_gemma":0.0095743835,"threshold_uncertainty_score":0.9998866},"labels":[],"label_agreement":null},{"id":"W2590371371","doi":"10.1200/jco.2013.31.31_suppl.247","title":"eOutcomes-H&amp;N: Development of an electronic point-of-care outcomes collection system for head and neck cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Head and neck cancer; Data collection; Schedule; Cancer; Usability; Radiation therapy; Population; Family medicine; Medical physics; Medical emergency; Surgery; Internal medicine","score_opus":0.31926945088715153,"score_gpt":0.5904079996329705,"score_spread":0.271138548745819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590371371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887031,0.00033573917,0.0016800791,0.0073170653,0.0010010563,0.0008259402,0.0000046883733,0.000009041387,0.00012329296],"genre_scores_gemma":[0.93897843,0.00017852399,0.059503574,0.0008411166,0.0003496481,0.000030708034,0.000010121998,0.000017919232,0.00008993423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993404,0.00033752192,0.0054929657,0.00018764198,0.00033870412,0.0002391878],"domain_scores_gemma":[0.98849523,0.005259168,0.0040762527,0.00017113412,0.0017321663,0.0002660391],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039273696,0.00013883019,0.0017693465,0.00014710244,0.000053062264,0.0000070926003,0.00011453964,0.00027875046,0.00008087626],"category_scores_gemma":[0.009191033,0.00010019968,0.00034311722,0.00013475525,0.00009363093,0.00024723116,0.0000391402,0.00049977924,0.0000032622845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007974994,0.0014553533,0.5226152,0.0008632806,0.0011707317,0.000008466522,0.0007747864,0.000024372865,0.0009668924,0.00015369529,0.0026646736,0.46132755],"study_design_scores_gemma":[0.022153243,0.023820562,0.91350526,0.00035007848,0.001003745,0.00017747289,0.0033207445,0.00029542527,0.0006092792,0.00023542687,0.034366205,0.00016255499],"about_ca_topic_score_codex":0.00020716843,"about_ca_topic_score_gemma":0.0014300224,"teacher_disagreement_score":0.461165,"about_ca_system_score_codex":0.0004704712,"about_ca_system_score_gemma":0.0039102198,"threshold_uncertainty_score":0.999155},"labels":[],"label_agreement":null},{"id":"W2590373457","doi":"10.1200/jco.2016.34.4_suppl.601","title":"Oxaliplatin associated neurotoxicity outcomes among older adults with colorectal cancer: A population-based study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Women's College Hospital; Queen's University; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Oxaliplatin; Medicine; Hazard ratio; Internal medicine; Colorectal cancer; Cohort; Regimen; Cancer registry; Population; Incidence (geometry); Cancer; Surgery; Oncology; Confidence interval","score_opus":0.06502031611701335,"score_gpt":0.46263581986832353,"score_spread":0.39761550375131016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590373457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187547,0.000029392519,0.000015754245,0.006011635,0.001015045,0.000820965,0.00001320311,0.00002350458,0.00019504367],"genre_scores_gemma":[0.99742705,0.000030239597,0.00012756011,0.0015600811,0.0004810711,0.000046646455,0.0000033148797,0.000022291015,0.00030173396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968237,0.0006379139,0.0016353633,0.00023748183,0.00040653095,0.00025897485],"domain_scores_gemma":[0.99351025,0.0036047031,0.0019694383,0.000114060334,0.00045175554,0.00034979775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011829784,0.00018840474,0.0015889793,0.00012456399,0.000054643806,0.0000056879426,0.000117501346,0.0002802596,0.0007023737],"category_scores_gemma":[0.0015755651,0.0000938737,0.00036435542,0.00016415934,0.000121530065,0.00009912281,0.000021868353,0.0005402873,0.000005748842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011377881,0.0072074602,0.96131533,0.000008760347,0.000892087,0.0005712863,0.00010089726,0.000013035617,0.000053977106,0.0000014310898,0.0008328414,0.017624985],"study_design_scores_gemma":[0.04676094,0.028153602,0.9235077,0.00017992753,0.0008691511,0.000018929184,0.000045526045,0.000042945194,0.00006169949,0.000008817648,0.00024730034,0.000103500504],"about_ca_topic_score_codex":0.0004724913,"about_ca_topic_score_gemma":0.004809037,"teacher_disagreement_score":0.037807696,"about_ca_system_score_codex":0.00042700965,"about_ca_system_score_gemma":0.0012963334,"threshold_uncertainty_score":0.76904994},"labels":[],"label_agreement":null},{"id":"W2590378396","doi":"10.1200/jco.2014.32.30_suppl.7","title":"Canadian cancer site-specific health utility values: Creating the basis for measuring value and costs of therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Breast cancer; Prostate cancer; Internal medicine; Lung cancer; Multiple myeloma; Colorectal cancer; Disease; Health care; Oncology","score_opus":0.6816396279038215,"score_gpt":0.558258745065782,"score_spread":0.1233808828380395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590378396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8151365,0.014499207,0.004019523,0.16035159,0.0022436413,0.0008119824,0.0001863814,0.0000066339535,0.002744575],"genre_scores_gemma":[0.96948874,0.004296712,0.0050003766,0.019714229,0.0013999688,0.000021334425,0.0000017054523,0.000019649882,0.000057309036],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895243,0.0017313381,0.00802181,0.00027388002,0.00010450565,0.00034417445],"domain_scores_gemma":[0.9734172,0.016671525,0.0088483235,0.00028623544,0.00029283957,0.00048385444],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.10197711,0.00012326337,0.0020494268,0.0001772769,0.00024483228,0.000026646723,0.00027907485,0.00022612592,0.00011610904],"category_scores_gemma":[0.022138804,0.000104844374,0.00029820096,0.00009005317,0.000142733,0.00014024238,0.000023590504,0.00041367862,0.000011904963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050916994,0.00041605777,0.64835,0.00027757342,0.00044546978,0.0000011378821,0.004803736,0.00058177166,0.0000031801953,0.05343953,0.03735962,0.25381273],"study_design_scores_gemma":[0.0038224317,0.002616556,0.46068493,0.00030903405,0.000023276492,0.000012880116,0.0012561338,0.009558853,0.0000049158166,0.015337319,0.506141,0.00023268262],"about_ca_topic_score_codex":0.052291427,"about_ca_topic_score_gemma":0.048162203,"teacher_disagreement_score":0.46878138,"about_ca_system_score_codex":0.0010016542,"about_ca_system_score_gemma":0.0022916314,"threshold_uncertainty_score":0.9860981},"labels":[],"label_agreement":null},{"id":"W2590379099","doi":"10.1200/jco.2015.33.28_suppl.155","title":"Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- <i>BRCA</i>-associated locally advanced or metastatic breast cancer (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Veliparib; Medicine; PARP inhibitor; Carboplatin; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; BRCA mutation; Cancer; Placebo; Chemotherapy; Phases of clinical research; Olaparib; Pathology; Cisplatin; Poly ADP ribose polymerase","score_opus":0.10079719884237634,"score_gpt":0.4784896302964782,"score_spread":0.3776924314541018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590379099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666835,0.0012082045,0.000553769,0.0058317953,0.0013528299,0.0033931572,0.00003667323,0.000015871781,0.00093937095],"genre_scores_gemma":[0.99222094,0.0015340847,0.0030971118,0.0018413452,0.0006504033,0.00025653216,0.0000047988983,0.00004158075,0.00035319687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99042696,0.002625612,0.0054200757,0.00032277685,0.00081854477,0.00038601324],"domain_scores_gemma":[0.9857341,0.0067729168,0.0053503867,0.00022863236,0.0012446526,0.00066928606],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012906557,0.00032233255,0.0070538013,0.00026563223,0.000030207537,0.000011912284,0.00016309496,0.0003925674,0.000179344],"category_scores_gemma":[0.009066971,0.0001899614,0.00056289934,0.0003387042,0.0007326777,0.00019265829,0.00003266955,0.0012124494,0.000002096892],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9641,0.006056215,0.0009945902,0.0000366417,0.0019050658,0.00041686013,0.00039839215,0.00024354881,0.00015111583,0.000020948428,0.00070210575,0.024974523],"study_design_scores_gemma":[0.9624398,0.031336624,0.00048899406,0.0006678613,0.0016057984,0.00036493107,0.0003580821,0.0011982183,0.00005752329,0.0003077503,0.0009843269,0.00019009478],"about_ca_topic_score_codex":0.00036888587,"about_ca_topic_score_gemma":0.001201267,"teacher_disagreement_score":0.025280409,"about_ca_system_score_codex":0.00049693725,"about_ca_system_score_gemma":0.00667892,"threshold_uncertainty_score":0.9992801},"labels":[],"label_agreement":null},{"id":"W2590393130","doi":"10.1200/jco.2015.33.29_suppl.170","title":"Concordance with the ASCO Provisional Clinical Opinion on the integration of palliative care into standard oncology care in Ontario.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Cancer Care Ontario","funders":"","keywords":"Medicine; Concordance; Palliative care; Cohort; Population; Family medicine; Cancer; Psychosocial; Cancer registry; Oncology; Internal medicine; Nursing","score_opus":0.4392881194784103,"score_gpt":0.5900681212304948,"score_spread":0.1507800017520845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590393130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975759,0.0023888014,0.0003885402,0.01451608,0.0013194234,0.0005101349,0.000009529166,0.000004052036,0.00510443],"genre_scores_gemma":[0.99061084,0.0010745041,0.0055617583,0.0019725328,0.00069009536,0.000010931625,0.000011914447,0.000013147191,0.000054291257],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947908,0.0015465063,0.0025379767,0.0002240579,0.0007196589,0.000181006],"domain_scores_gemma":[0.98521996,0.00883008,0.0026609928,0.00026814066,0.0027995068,0.0002213447],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045961956,0.00017757482,0.00177227,0.000095145275,0.000036815505,0.0000051254046,0.0003117518,0.00042905766,0.000036934154],"category_scores_gemma":[0.009159093,0.000078999175,0.00037725962,0.00018197307,0.0008618982,0.00008007434,0.00006784038,0.0021367203,0.0000038264966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04164483,0.0008756914,0.7727492,0.00004999637,0.00036037696,0.00014221153,0.032400604,0.00009759537,0.000022263448,0.0010665507,0.0059602084,0.14463049],"study_design_scores_gemma":[0.013351491,0.104527146,0.3948726,0.0017991452,0.00018304982,0.00001633383,0.05809581,0.000030536994,0.00030546507,0.00054920925,0.426148,0.000121198675],"about_ca_topic_score_codex":0.0017989901,"about_ca_topic_score_gemma":0.06522169,"teacher_disagreement_score":0.4201878,"about_ca_system_score_codex":0.0010618449,"about_ca_system_score_gemma":0.01115234,"threshold_uncertainty_score":0.9991872},"labels":[],"label_agreement":null},{"id":"W2590412859","doi":"10.1200/jco.2014.32.31_suppl.17","title":"Developing pathways for cancer rehabilitation in tertiary oncology centers: Initial observations at the McGill University Health Centre.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Concordia University; McGill University","funders":"","keywords":"Medicine; Rehabilitation; Cancer; Quality of life (healthcare); Breast cancer; Psychological intervention; Cachexia; Physical therapy; Cohort; Disease; Internal medicine; Nursing","score_opus":0.21256790997210614,"score_gpt":0.466801904137026,"score_spread":0.2542339941649199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590412859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6946711,0.00015044466,0.0009080263,0.3010973,0.002462181,0.00036332486,0.00007992218,0.0000075103485,0.00026019991],"genre_scores_gemma":[0.9600795,0.00077960064,0.0051116124,0.032698408,0.0010954974,0.0000065666077,0.000018379431,0.000015381369,0.0001950744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972148,0.0010115679,0.0012336131,0.00015933135,0.00016140606,0.00021927673],"domain_scores_gemma":[0.9923452,0.0059059346,0.00102964,0.00012278504,0.0004176581,0.00017876364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036477393,0.00008497779,0.00072809594,0.00009121548,0.00011346202,0.0000015239806,0.00012833314,0.00022451831,0.000035071014],"category_scores_gemma":[0.0026670091,0.00006104971,0.00028235282,0.00014260862,0.00012715302,0.000087978326,0.000055599656,0.000482796,0.0000020318405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007807967,0.0009765814,0.34314588,0.00019148776,0.00019259941,0.000060970633,0.0027103624,0.000084170584,0.00006809307,0.0039333417,0.024805447,0.6160231],"study_design_scores_gemma":[0.0044944803,0.003499575,0.31368372,0.00014712654,0.000061329236,0.000019329847,0.0013531023,0.00010499366,0.000010015581,0.00061365106,0.6759601,0.00005255039],"about_ca_topic_score_codex":0.0008667751,"about_ca_topic_score_gemma":0.063096315,"teacher_disagreement_score":0.6511547,"about_ca_system_score_codex":0.0024410381,"about_ca_system_score_gemma":0.0026013944,"threshold_uncertainty_score":0.95399976},"labels":[],"label_agreement":null},{"id":"W2590413398","doi":"10.1200/jco.2013.31.6_suppl.153","title":"Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Medicine Hat College; BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Docetaxel; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Sunitinib; Oncology; Phases of clinical research; Progression-free survival; Urology; Clinical trial; Cancer; Chemotherapy","score_opus":0.1578829523383898,"score_gpt":0.5247198377054069,"score_spread":0.3668368853670171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590413398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871266,0.0004116474,0.0000034172044,0.010495137,0.00022366409,0.0014526171,0.000072704046,0.0000028796096,0.0002113307],"genre_scores_gemma":[0.99646133,0.00038505252,0.0010095765,0.00033752274,0.00010514932,0.00012164348,0.000002431606,0.000015341222,0.001561957],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943078,0.0010715667,0.0034885933,0.00023275979,0.0005699608,0.00032931395],"domain_scores_gemma":[0.9943384,0.0020389257,0.0015564228,0.000262704,0.0014174897,0.00038607747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051699756,0.00015612566,0.0015690944,0.0003771708,0.000027051643,0.000008199127,0.00016268334,0.0001103412,0.00019507114],"category_scores_gemma":[0.00413253,0.000097738164,0.00021486645,0.00042903333,0.0002270837,0.0001479299,0.000060400314,0.0006303357,0.000005709403],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81483,0.03765571,0.027095398,0.00018948918,0.001193164,0.0043371315,0.009739073,0.00009579057,0.027123041,0.000010268322,0.004396567,0.073334344],"study_design_scores_gemma":[0.14553039,0.24178341,0.5936834,0.0008826369,0.00053621223,0.00008029929,0.006059794,0.000074333984,0.001688853,0.00017073871,0.009333178,0.00017675823],"about_ca_topic_score_codex":0.00084147917,"about_ca_topic_score_gemma":0.0011458986,"teacher_disagreement_score":0.66929966,"about_ca_system_score_codex":0.00022356994,"about_ca_system_score_gemma":0.0030666108,"threshold_uncertainty_score":0.5440036},"labels":[],"label_agreement":null},{"id":"W2590414680","doi":"10.1200/jco.2016.34.2_suppl.521","title":"Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mucositis; Sunitinib; Discontinuation; Stomatitis; Adverse effect; Internal medicine; Pazopanib; Regimen; Diarrhea; Dysgeusia; Sorafenib; Incidence (geometry); Renal cell carcinoma; Surgery; Chemotherapy","score_opus":0.09808525899197854,"score_gpt":0.41966320398896223,"score_spread":0.32157794499698367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590414680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98602617,0.008455963,0.00008702265,0.0023721377,0.00053537934,0.0014558698,0.000032734282,0.000003982118,0.0010307725],"genre_scores_gemma":[0.9707865,0.023920733,0.0037028193,0.0007506799,0.00024014789,0.000031683056,0.000016711801,0.000028716497,0.00052197656],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936029,0.00051669544,0.0046556704,0.00028502374,0.0006299404,0.00030978848],"domain_scores_gemma":[0.9924389,0.0012966992,0.004993427,0.00032891246,0.0006446705,0.00029735384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034992495,0.00024871438,0.0022888426,0.0003298464,0.000016803575,0.0000011568754,0.00019629835,0.00012401002,0.00015659434],"category_scores_gemma":[0.0007371592,0.00014428234,0.00088362035,0.0002725127,0.00015924854,0.000093899405,0.000065510794,0.00031222234,0.000003976545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030782335,0.023922838,0.34880444,0.0074825445,0.0014101497,0.0009083748,0.00014109166,0.000010772757,0.0075590936,0.00009790295,0.020682637,0.5581978],"study_design_scores_gemma":[0.09149499,0.07697105,0.7200506,0.0143187,0.002510323,0.000030415209,0.00007992486,0.000020266642,0.038984288,0.00014021856,0.055019192,0.00038005036],"about_ca_topic_score_codex":0.000036599202,"about_ca_topic_score_gemma":0.00001936423,"teacher_disagreement_score":0.55781776,"about_ca_system_score_codex":0.00039933593,"about_ca_system_score_gemma":0.00045456173,"threshold_uncertainty_score":0.5883663},"labels":[],"label_agreement":null},{"id":"W2590424286","doi":"10.1200/jco.2012.30.34_suppl.220","title":"Monitoring acute care utilization (ACU) during adjuvant chemotherapy for early breast cancer (EBC) as a measure of quality.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Health Sciences Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Cancer; Breast cancer; Anthracycline; Toxicity; Oncology; Taxane; Cancer registry; Adjuvant","score_opus":0.20062423864101492,"score_gpt":0.5401553750017236,"score_spread":0.3395311363607087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590424286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919042,0.0019010338,0.00018382327,0.0026279562,0.002455812,0.00026157318,0.000017504964,0.0000097996835,0.00063831],"genre_scores_gemma":[0.99313855,0.0019572694,0.0005431864,0.00035703953,0.003798766,0.000018687528,9.4966725e-7,0.00002287645,0.00016270144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977447,0.00016413696,0.0014479575,0.00011477364,0.00029598124,0.00023246638],"domain_scores_gemma":[0.99688524,0.0003536055,0.0012884405,0.00013831937,0.0010394099,0.00029501403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010949003,0.000112301685,0.0010417554,0.000084791325,0.00005647229,0.0000052104415,0.00009490405,0.00025544694,0.0000989576],"category_scores_gemma":[0.00032114206,0.00008383454,0.00048733567,0.00012514074,0.00007881431,0.00018883368,0.000017779754,0.00045767718,0.000002785682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007153892,0.00065817573,0.82914704,0.00013413155,0.00075317855,0.000011992257,0.0010806068,0.0000066564503,0.010372324,0.000050595667,0.00014790165,0.15048352],"study_design_scores_gemma":[0.008184069,0.0024553828,0.97058237,0.0002911891,0.0006803956,0.0002860897,0.00039889515,0.0000011521865,0.009018927,0.000024263936,0.007995395,0.00008185921],"about_ca_topic_score_codex":0.000106476786,"about_ca_topic_score_gemma":0.000021182444,"teacher_disagreement_score":0.15040167,"about_ca_system_score_codex":0.00025065205,"about_ca_system_score_gemma":0.0009075165,"threshold_uncertainty_score":0.34186733},"labels":[],"label_agreement":null},{"id":"W2590425344","doi":"10.1200/jco.2014.32.30_suppl.64","title":"Involving patients to improve their care through real-time patient reported outcome (PRO)-CTCAE chemotoxicity surveys in an outpatient chemodaycare (DC) setting: Evaluating patient acceptability.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dysgeusia; Nausea; Feeling; Patient-reported outcome; Quality of life (healthcare); Family medicine; Constipation; Physical therapy; Vomiting; Nursing; Adverse effect; Surgery; Psychology; Internal medicine","score_opus":0.16592804291243962,"score_gpt":0.49369897234723903,"score_spread":0.3277709294347994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590425344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929381,0.00008027615,0.00003905573,0.0010538527,0.0022904815,0.0018524702,0.000028885754,0.00003958674,0.0016772626],"genre_scores_gemma":[0.9915371,0.000035269582,0.0049002552,0.0026072864,0.00068989996,0.000065959895,0.00007809553,0.000058582336,0.000027564816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9874754,0.0041673244,0.0059942952,0.00079907296,0.0008795303,0.0006843551],"domain_scores_gemma":[0.98955166,0.0025703404,0.0041022985,0.00066856155,0.0023255928,0.0007815598],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008363489,0.00047061677,0.002726375,0.0002696897,0.00011479197,0.000025167294,0.00031341042,0.0006779686,0.00029569492],"category_scores_gemma":[0.010773391,0.00035080177,0.0007023824,0.00043064318,0.00015754146,0.00031528593,0.00028923652,0.0014471785,0.000014563681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021114533,0.0045757922,0.6418937,0.00007962482,0.00014585107,0.000061216946,0.0069421562,0.00009928253,0.0018083751,0.0000013245539,0.0001835188,0.3420977],"study_design_scores_gemma":[0.013046327,0.08327127,0.89523816,0.00013288429,0.00037991838,0.00002360578,0.001797256,0.0005595616,0.003096526,0.00010418775,0.0019951917,0.00035510943],"about_ca_topic_score_codex":0.0003150541,"about_ca_topic_score_gemma":0.0003406552,"teacher_disagreement_score":0.3417426,"about_ca_system_score_codex":0.0017157563,"about_ca_system_score_gemma":0.0012906237,"threshold_uncertainty_score":0.9998944},"labels":[],"label_agreement":null},{"id":"W2590432301","doi":"10.1200/jco.2013.31.15_suppl.5033","title":"Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; breakpoint cluster region; Internal medicine; Proportional hazards model; Metastasis; Cohort; Oncology; Context (archaeology); Urology; Cancer","score_opus":0.11569438920027351,"score_gpt":0.4629404359793572,"score_spread":0.34724604677908366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590432301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960996,0.0008932434,0.000031898868,0.007923311,0.00011696702,0.0009954388,0.000008156425,0.0000057590105,0.00041528195],"genre_scores_gemma":[0.9963616,0.00071481505,0.0024467648,0.00014443489,0.00014103102,0.000047415466,0.000022090877,0.0000142098725,0.00010762806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971215,0.00044621763,0.001364815,0.00021422068,0.0005838426,0.0002693908],"domain_scores_gemma":[0.99692255,0.00081592525,0.0009851704,0.00016548492,0.00051155005,0.0005993018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015701699,0.00013451492,0.00094830757,0.00019250678,0.000020301728,0.0000109917655,0.0001430468,0.0001348238,0.00016960272],"category_scores_gemma":[0.0013680703,0.000072552626,0.00017740083,0.00017374025,0.00052759814,0.0001878126,0.000053746786,0.00078241335,0.000012712037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014676,0.008594826,0.7897411,0.00059042434,0.0007142961,0.0022297525,0.00036164845,0.000013045935,0.016086247,0.000038909817,0.0060977577,0.11538523],"study_design_scores_gemma":[0.02475869,0.019525629,0.94266135,0.0012022421,0.0004599241,0.00022602211,0.00022991924,0.00056484994,0.00840213,0.0005569645,0.0012731188,0.00013918514],"about_ca_topic_score_codex":0.00001381764,"about_ca_topic_score_gemma":0.0000013403417,"teacher_disagreement_score":0.15292022,"about_ca_system_score_codex":0.00020537105,"about_ca_system_score_gemma":0.002845639,"threshold_uncertainty_score":0.5048041},"labels":[],"label_agreement":null},{"id":"W2590440658","doi":"10.1200/jco.2014.32.4_suppl.lba287","title":"The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Cystectomy; Trastuzumab; Internal medicine; Paclitaxel; Clinical endpoint; Oncology; Radiation therapy; Population; Gastroenterology; Urology; Chemotherapy; Surgery; Bladder cancer; Cancer; Randomized controlled trial; Breast cancer","score_opus":0.07959428162180378,"score_gpt":0.4301499064487896,"score_spread":0.3505556248269858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590440658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940354,0.00037598595,0.0013732677,0.002194559,0.00054396945,0.0012648493,0.00006453422,0.000006888732,0.00014050154],"genre_scores_gemma":[0.9975601,0.00041140366,0.0012183359,0.0001277751,0.0004951473,0.000080745915,0.000030283063,0.00003436655,0.00004188188],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957214,0.00047846447,0.002596587,0.00027584817,0.0006702718,0.00025745525],"domain_scores_gemma":[0.98888975,0.005668267,0.004034005,0.0002359087,0.0009596495,0.00021239335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003340851,0.00024043536,0.002052961,0.00017067566,0.000121893245,0.000010298742,0.00009936896,0.0002636721,0.000011225549],"category_scores_gemma":[0.0020535048,0.0001254968,0.00036736194,0.00024821656,0.0004281009,0.00024348816,0.000010080122,0.00034995071,6.262239e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7468896,0.0077844886,0.0807,0.0004977563,0.0056861215,0.00037825573,0.0026468753,0.00004810391,0.0009475611,0.00006310423,0.00045886307,0.15389927],"study_design_scores_gemma":[0.48052943,0.31613576,0.1895236,0.00123366,0.0067336326,0.000622382,0.0011938815,0.00033342367,0.0018790743,0.0002619043,0.0012376338,0.00031561722],"about_ca_topic_score_codex":0.00042550263,"about_ca_topic_score_gemma":0.001849819,"teacher_disagreement_score":0.30835128,"about_ca_system_score_codex":0.00013606368,"about_ca_system_score_gemma":0.00450588,"threshold_uncertainty_score":0.7993238},"labels":[],"label_agreement":null},{"id":"W2590445558","doi":"10.1200/jco.2012.30.30_suppl.40","title":"Development and validation of a digital Gleason score biomarker signature for risk stratification of patients with prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Internal medicine; Receiver operating characteristic; Biomarker; Biochemical recurrence; Cutoff; Grading (engineering); Cancer","score_opus":0.059444363605281415,"score_gpt":0.4194303748471161,"score_spread":0.35998601124183466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590445558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966556,0.00036416188,0.0016928742,0.0007367266,0.00021977235,0.00025015115,0.000012398511,0.0000017534423,0.000066577144],"genre_scores_gemma":[0.9829864,0.00011566531,0.016652135,0.000059561444,0.00012862823,0.0000037482305,0.000022041966,0.00000795638,0.000023852213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851173,0.00006770395,0.0010216199,0.00007569809,0.00022053007,0.00010268882],"domain_scores_gemma":[0.99687576,0.00056182634,0.0018994752,0.000054827706,0.0004502497,0.00015783218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015070365,0.00006439006,0.0005061885,0.00005644578,0.000020003545,0.0000045002002,0.00003851308,0.00011526507,0.000008810422],"category_scores_gemma":[0.0022826733,0.00003933051,0.000070678434,0.000061149556,0.00012999686,0.00013774823,0.000011145929,0.00031463563,1.267856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024526126,0.0005318169,0.64696705,0.0000732989,0.000141475,7.311067e-7,0.0002047769,0.000011837047,0.00019410612,0.000012097171,0.00018105347,0.34922916],"study_design_scores_gemma":[0.005181291,0.002476175,0.9821611,0.00020236986,0.00026315995,0.000006930641,0.00007730819,0.00020965119,0.00092478335,0.0000536892,0.008394866,0.000048695336],"about_ca_topic_score_codex":0.000003369015,"about_ca_topic_score_gemma":0.0000013343214,"teacher_disagreement_score":0.34918046,"about_ca_system_score_codex":0.000036693447,"about_ca_system_score_gemma":0.000497978,"threshold_uncertainty_score":0.2732738},"labels":[],"label_agreement":null},{"id":"W2590445943","doi":"10.1200/jco.2015.33.28_suppl.133","title":"Next-generation sequencing (NGS) in metastatic breast cancer (mBC) patients: Translation from sequence data into clinical practice.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; PTEN; Internal medicine; Oncology; Metastatic breast cancer; Targeted therapy; Breast cancer; Disease; Cancer; Bioinformatics; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.4487766294507804,"score_gpt":0.5118462957027257,"score_spread":0.06306966625194527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590445943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849266,0.0032976775,0.0042327745,0.0040961066,0.002942592,0.00018029688,0.00015497475,0.0000027096582,0.0001662927],"genre_scores_gemma":[0.9432018,0.0076845307,0.041535884,0.0037460597,0.0034414127,0.0000052467976,0.00035752027,0.000020877795,0.0000067048595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957467,0.0008676336,0.0025149677,0.00039341298,0.0002975902,0.00017972538],"domain_scores_gemma":[0.99556416,0.0011685318,0.0017244049,0.00040995394,0.0008175495,0.00031538232],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043420405,0.0001441504,0.0006764366,0.000056395485,0.000028629851,0.000035882866,0.00045766204,0.0003448116,0.000017482595],"category_scores_gemma":[0.010742786,0.00012534903,0.00015389809,0.00010547733,0.0001382636,0.00008823626,0.0001483767,0.0005460814,0.0000048288503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038559511,0.0021256437,0.09703458,0.000014269833,0.0005616708,0.00016721124,0.0003855294,0.0030885069,0.013992817,0.000042897373,0.017231535,0.86149937],"study_design_scores_gemma":[0.03243172,0.016473185,0.08033256,0.00021348032,0.0016292918,0.00020247368,0.0017273902,0.037676714,0.0012457762,0.0021394892,0.8248339,0.0010940003],"about_ca_topic_score_codex":0.001002924,"about_ca_topic_score_gemma":0.0033374624,"teacher_disagreement_score":0.8604054,"about_ca_system_score_codex":0.00022422128,"about_ca_system_score_gemma":0.0042828904,"threshold_uncertainty_score":0.9975901},"labels":[],"label_agreement":null},{"id":"W2590451180","doi":"10.1200/jco.2014.32.30_suppl.170","title":"The use of IT to improve practice quality within a radiation oncology program.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Rework; Workload; Workgroup; Workflow; Quality (philosophy); Process (computing); Computer science; Database","score_opus":0.20615993851569375,"score_gpt":0.6261315075394013,"score_spread":0.4199715690237075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590451180","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45109037,0.0013167836,0.03201776,0.47276893,0.027438156,0.00265832,0.000008228331,0.00006037826,0.012641075],"genre_scores_gemma":[0.30351934,0.005313764,0.57603306,0.10137512,0.011625012,0.000060092538,0.0000037018865,0.000055265577,0.002014631],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99272454,0.0029398317,0.0035082565,0.00020601737,0.00036879978,0.00025253708],"domain_scores_gemma":[0.9512313,0.04119074,0.005416981,0.00037446435,0.00140024,0.0003862561],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016107386,0.00013148216,0.0015113303,0.000080087906,0.00009541351,0.000009645045,0.00024387032,0.0006370347,0.000026693273],"category_scores_gemma":[0.115443915,0.00007448068,0.00037518414,0.00018420815,0.0006339491,0.0002455904,0.000045495195,0.0014005634,0.000011815663],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019419413,0.0028123674,0.0050930823,0.000018143915,0.0004628137,0.00006195027,0.0003928362,0.00013889631,0.00029518074,0.0022972345,0.017834568,0.9511735],"study_design_scores_gemma":[0.005683323,0.053100314,0.01732496,0.000029517458,0.000268049,0.00029475958,0.00023083415,0.00032900248,0.00007719105,0.0006015946,0.9219874,0.00007303197],"about_ca_topic_score_codex":0.000021155496,"about_ca_topic_score_gemma":0.000090084264,"teacher_disagreement_score":0.95110047,"about_ca_system_score_codex":0.00029975033,"about_ca_system_score_gemma":0.0024361112,"threshold_uncertainty_score":0.89200705},"labels":[],"label_agreement":null},{"id":"W2590456362","doi":"10.1200/jco.2014.32.30_suppl.236","title":"Assessing the utility of a patient-reported screener question to detect fatigue symptoms: Improving the quality of systematic symptom measurement in clinical practice.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer-related fatigue; Quality of life (healthcare); Physical therapy; Intervention (counseling); Clinical Practice; Disease; Cancer; Psychiatry; Internal medicine","score_opus":0.2958733223473227,"score_gpt":0.538813356578045,"score_spread":0.24294003423072225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590456362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98237205,0.00055083947,0.00963935,0.004146576,0.001674955,0.000822094,0.0000010465508,0.0000068507347,0.00078623707],"genre_scores_gemma":[0.996689,0.000040931143,0.0012154689,0.0015946716,0.00042822794,0.00001580548,4.2490547e-7,0.000012186668,0.0000032566018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97609085,0.012032185,0.0097936215,0.0002685744,0.0015789404,0.00023584376],"domain_scores_gemma":[0.9624701,0.022073451,0.011156056,0.0008063019,0.003223383,0.0002706642],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0919407,0.00015653486,0.0022759796,0.000104462226,0.000047002246,0.00001924532,0.00029577408,0.0003470899,0.000014160999],"category_scores_gemma":[0.17249227,0.00007873082,0.0007174527,0.00030693517,0.0002929794,0.0001801272,0.00009609414,0.001219583,8.248588e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006678567,0.0027611507,0.49527505,0.004813216,0.0013129542,0.00005798793,0.0015824598,0.000069263566,0.0007960626,0.0002760894,0.00023903855,0.48613816],"study_design_scores_gemma":[0.0035976146,0.007922794,0.9759068,0.0052517178,0.0013849682,0.00011282988,0.0035856788,0.000952089,0.0002250383,0.00020433238,0.0007364543,0.00011971176],"about_ca_topic_score_codex":0.001077656,"about_ca_topic_score_gemma":0.0015594763,"teacher_disagreement_score":0.48601845,"about_ca_system_score_codex":0.0002111268,"about_ca_system_score_gemma":0.0018230438,"threshold_uncertainty_score":0.93503815},"labels":[],"label_agreement":null},{"id":"W2590456563","doi":"10.1200/jco.2012.30.34_suppl.70","title":"Effect of intervention on quality measures of symptom management in the Michigan Oncology Quality Consortium (MOQC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Psychological intervention; Intervention (counseling); Quality management; Quality (philosophy); Scale (ratio); Nursing; Best practice; Oncology; Family medicine","score_opus":0.5339994093975494,"score_gpt":0.6538548991603399,"score_spread":0.11985548976279048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590456563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878608,0.0013218692,0.00013549074,0.0017707974,0.00089253194,0.00030185096,0.000004840459,0.0000028772238,0.0077089155],"genre_scores_gemma":[0.9974202,0.0009400515,0.0005793016,0.00065047026,0.0003525717,0.000005276608,0.0000026962807,0.000006947415,0.000042492877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881629,0.006946165,0.003987289,0.00012835626,0.00056151394,0.00021382359],"domain_scores_gemma":[0.9818784,0.013589741,0.0037735032,0.00027202012,0.00034553945,0.00014076916],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032124795,0.00013370036,0.0021375217,0.00016836716,0.000012628517,0.0000014082676,0.00024281387,0.0003194558,0.000048132253],"category_scores_gemma":[0.009836567,0.00007699206,0.0007894801,0.00015187044,0.0003818099,0.00006460249,0.00005335267,0.00072570646,0.000004355237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016869456,0.0060076043,0.7971357,0.000741871,0.0010397026,0.000054770866,0.0019641519,0.0000070454216,0.00069915684,0.0022209375,0.00070126186,0.17255835],"study_design_scores_gemma":[0.011560243,0.031237112,0.91914856,0.00091399706,0.0007196736,0.000023306595,0.0021427185,0.0000034892132,0.0048414264,0.00026761153,0.029059842,0.00008201291],"about_ca_topic_score_codex":0.00010548723,"about_ca_topic_score_gemma":0.00012696348,"teacher_disagreement_score":0.17247634,"about_ca_system_score_codex":0.000107312386,"about_ca_system_score_gemma":0.00018671811,"threshold_uncertainty_score":0.998504},"labels":[],"label_agreement":null},{"id":"W2590458383","doi":"10.1200/jco.2012.30.4_suppl.95","title":"Perioperative chemotherapy for upper gastrointestinal cancer: Correlation between response to treatment and outcome.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Ottawa Hospital; Montreal General Hospital","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Chemotherapy; Perioperative; Cancer; Gastroenterology; Esophagus; Surgery; Oncology","score_opus":0.16560611554526644,"score_gpt":0.5043341566558412,"score_spread":0.3387280411105748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590458383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565746,0.00022361829,0.003537762,0.03841439,0.0005779627,0.00043087677,0.000005398593,0.000005786257,0.00022958298],"genre_scores_gemma":[0.9739715,0.00013951655,0.01844327,0.003032964,0.0021343967,0.000017373308,0.000001693266,0.0000130280505,0.0022462877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836063,0.00015377249,0.0010480983,0.0001050509,0.00012330124,0.00020915836],"domain_scores_gemma":[0.99684715,0.0019926026,0.00052242476,0.00007704888,0.00018419078,0.0003766086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002065275,0.00011044269,0.00090685615,0.000111946516,0.00003973472,0.0000075928388,0.00003838581,0.00008171864,0.000108872846],"category_scores_gemma":[0.0016237926,0.00007159104,0.00025408642,0.000068367655,0.00005724238,0.00009180717,0.00001690915,0.00019771772,0.0000049420696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0110186245,0.00023284915,0.84744096,0.0000072033727,0.00016553162,0.000008488174,0.00027249535,0.000005567791,0.00005323396,0.000024294375,0.001193321,0.1395774],"study_design_scores_gemma":[0.008400027,0.016087921,0.80139256,0.000035187222,0.00036766875,0.000089551635,0.00016996957,0.000023378334,0.000016841377,0.0000071956147,0.17336196,0.00004776836],"about_ca_topic_score_codex":0.0000152169,"about_ca_topic_score_gemma":0.000008635991,"teacher_disagreement_score":0.17216864,"about_ca_system_score_codex":0.000316758,"about_ca_system_score_gemma":0.00035431207,"threshold_uncertainty_score":0.2919398},"labels":[],"label_agreement":null},{"id":"W2590463106","doi":"10.1200/jco.2012.30.34_suppl.93","title":"Using a disease pathway management (DPM) approach to improve the quality of lung cancer care in Ontario.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Audit; Multidisciplinary approach; Quality management; Lung cancer; Health care; Palliative care; Leverage (statistics); Family medicine; Nursing; Oncology; Operations management; Management","score_opus":0.5922212068602525,"score_gpt":0.644608197688865,"score_spread":0.052386990828612534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590463106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890869,0.00056098367,0.0014399104,0.0045922645,0.0016072822,0.0007889002,0.00000852048,0.000003010506,0.0019121998],"genre_scores_gemma":[0.97909236,0.0000784237,0.015241399,0.0045423075,0.0009239941,0.000017070946,0.0000035257383,0.000012884314,0.000088005676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99351996,0.0009221153,0.0045755142,0.0001722233,0.00053603505,0.0002741602],"domain_scores_gemma":[0.9933161,0.002824675,0.00255862,0.00029850705,0.00050570065,0.0004963546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011222955,0.00011910981,0.001027377,0.0001023276,0.000029523291,0.000005544398,0.00018190879,0.0001473419,0.000100009274],"category_scores_gemma":[0.0076929936,0.000074801676,0.00039121846,0.00016747818,0.00008886971,0.0001877,0.0001428636,0.00097377034,0.0000018909691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007452342,0.0023927537,0.901433,0.00019083181,0.00030731052,0.00003210044,0.0013229948,0.00026234903,0.00010702217,0.00028661496,0.0005445286,0.08566814],"study_design_scores_gemma":[0.005841346,0.0010263183,0.96801126,0.00010715757,0.00076628476,0.000010724623,0.0023029833,0.00025930462,0.000011868479,0.00006306026,0.021514913,0.00008480668],"about_ca_topic_score_codex":0.009870575,"about_ca_topic_score_gemma":0.013970733,"teacher_disagreement_score":0.08558333,"about_ca_system_score_codex":0.0010210833,"about_ca_system_score_gemma":0.0025903883,"threshold_uncertainty_score":0.99672276},"labels":[],"label_agreement":null},{"id":"W2590465622","doi":"10.1200/jco.2005.23.16_suppl.6082","title":"Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta analysis of the literature","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Meta-analysis; Odds ratio; CINAHL; MEDLINE; Systematic review; Cancer; Relative risk; Cochrane Library; Confidence interval; Internal medicine; Intensive care medicine; Psychological intervention; Psychiatry","score_opus":0.18733643821120216,"score_gpt":0.5652478966558772,"score_spread":0.377911458444675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590465622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002174114,0.98922205,0.000012934262,0.0034245418,0.00048981095,0.005973175,0.00063253444,0.000008775385,0.000018765018],"genre_scores_gemma":[0.000110412264,0.9914871,0.0007958905,0.006126124,0.00051866315,0.00045794286,0.000030125502,0.000060951534,0.00041278597],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9765929,0.013562657,0.008269922,0.000493411,0.00059343834,0.0004876717],"domain_scores_gemma":[0.9381452,0.019254234,0.039915506,0.00076098565,0.0014162392,0.0005077954],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012026784,0.00053775153,0.022531798,0.00036355958,0.00039858618,0.000010659906,0.00072919915,0.0010078182,0.000084119834],"category_scores_gemma":[0.0105084125,0.00023635579,0.004079685,0.0013337053,0.00017162385,0.000119133925,0.00017268902,0.0029883988,0.0000018919943],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000439487,0.0002392588,0.001691922,0.8944751,0.08092662,0.0000093744475,0.0013475575,0.0000074576087,7.2288775e-10,0.0000058938917,0.0033025108,0.017554838],"study_design_scores_gemma":[0.0010558164,0.00078235456,0.00077507464,0.32432926,0.5386283,0.000015009097,0.00039060408,0.0000023216921,2.2487738e-9,0.0000031865313,0.13385113,0.0001670002],"about_ca_topic_score_codex":0.00010050008,"about_ca_topic_score_gemma":0.0023801157,"teacher_disagreement_score":0.57014585,"about_ca_system_score_codex":0.0006995483,"about_ca_system_score_gemma":0.010718447,"threshold_uncertainty_score":0.99931175},"labels":[],"label_agreement":null},{"id":"W2590468527","doi":"10.1200/jco.2016.34.7_suppl.205","title":"Toward quality peer review: Outcomes of peer review across provincial radiation oncology programs.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; University Health Network; Regional Municipality of Durham; Canadian Partnership Against Cancer; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Radiation oncologist; Breast cancer; Radiation oncology; Radiation treatment planning; Rectum; Internal medicine; Cancer; Family medicine; General surgery; Oncology","score_opus":0.2602186077910313,"score_gpt":0.6309848413958701,"score_spread":0.3707662336048388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590468527","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04631635,0.08887307,0.0022507773,0.8483544,0.007129924,0.0018417169,0.00004124705,0.000037573875,0.00515495],"genre_scores_gemma":[0.07176992,0.75402915,0.027199512,0.1191652,0.007638056,0.000083259314,0.000034973003,0.0000770484,0.020002907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900813,0.0019576768,0.0057771415,0.00032307737,0.0014412004,0.00041958975],"domain_scores_gemma":[0.9797688,0.0064133313,0.0072054975,0.00047402043,0.0056722956,0.00046601778],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03170596,0.00024545114,0.004680649,0.00006480934,0.000054362405,0.0000030210103,0.00040186875,0.00088380015,0.00043530064],"category_scores_gemma":[0.08147222,0.00012635642,0.0012535615,0.00019670674,0.00097095215,0.0002292772,0.00007427509,0.0011962946,0.00003551934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020315317,0.0021020647,0.10618027,0.0011105952,0.00047991428,0.00018899847,0.00010670438,1.3065826e-7,0.00003756494,0.00017452253,0.10730915,0.78027856],"study_design_scores_gemma":[0.008043389,0.013007064,0.13116556,0.0022492702,0.0005397285,0.00048034242,0.000033430526,5.1620395e-7,0.00001880892,0.00039540633,0.8439362,0.0001302806],"about_ca_topic_score_codex":0.000010187613,"about_ca_topic_score_gemma":0.000037738446,"teacher_disagreement_score":0.78014827,"about_ca_system_score_codex":0.00059573137,"about_ca_system_score_gemma":0.0035806121,"threshold_uncertainty_score":0.9970625},"labels":[],"label_agreement":null},{"id":"W2590468732","doi":"10.1200/jco.2005.23.16_suppl.898","title":"Informing women about letrozole after tamoxifen. Is there an easier way?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Letrozole; Medicine; Tamoxifen; Breast cancer; Medical prescription; Family medicine; Oncology; Gynecology; Internal medicine; Cancer; Randomized controlled trial; Nursing","score_opus":0.040672381376959055,"score_gpt":0.4075862630124993,"score_spread":0.36691388163554023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590468732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045926,0.0022354831,0.00006316493,0.0037905003,0.0005478061,0.00006307618,0.000008319432,0.000004436979,0.0028279496],"genre_scores_gemma":[0.98610103,0.0010467995,0.0021080398,0.006934779,0.0032799866,0.000014818408,0.000003049702,0.000018869072,0.0004926186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793816,0.00015249295,0.0011910126,0.00020609872,0.00019144405,0.00032081152],"domain_scores_gemma":[0.9983296,0.00010923586,0.0007816287,0.00025299512,0.00024306723,0.0002834783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001032648,0.00016345488,0.00063662056,0.000044291744,0.000050681243,0.000013635246,0.00020928857,0.00036467946,0.00029559163],"category_scores_gemma":[0.00033804387,0.00011929127,0.0003010228,0.000050867588,0.00017634183,0.000025694679,0.000112359616,0.0003450357,0.00003090072],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051846975,0.0017767969,0.2126977,0.00001724242,0.001213638,0.0002249719,0.0012558533,0.000048189653,0.001325689,0.000024286865,0.012925827,0.7633051],"study_design_scores_gemma":[0.0024646034,0.003369901,0.2947768,0.000016649741,0.00006752755,0.00017073311,0.00023510418,0.000006663893,0.0012017677,0.00010595997,0.69744533,0.00013898103],"about_ca_topic_score_codex":0.000008166573,"about_ca_topic_score_gemma":0.00007665127,"teacher_disagreement_score":0.7631661,"about_ca_system_score_codex":0.00011615665,"about_ca_system_score_gemma":0.00043067482,"threshold_uncertainty_score":0.48645568},"labels":[],"label_agreement":null},{"id":"W2590469459","doi":"10.1200/jco.2014.32.30_suppl.102","title":"Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dysphagia; Choking; Swallowing; Physical therapy; Esophageal cancer; Cancer; Pediatrics; Surgery; Internal medicine","score_opus":0.18829004985453157,"score_gpt":0.553122236973032,"score_spread":0.3648321871185004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590469459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8244236,0.0006505715,0.15197346,0.018193658,0.0024360588,0.0011239033,0.000028181448,0.000016240227,0.0011543129],"genre_scores_gemma":[0.7378412,0.00006741004,0.25725812,0.0035405748,0.0011742557,0.000014254968,0.000009597066,0.000015805232,0.00007877614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99419385,0.0011626314,0.0039279144,0.00024259785,0.00020924323,0.00026373996],"domain_scores_gemma":[0.9697396,0.025707826,0.0027071203,0.00022080938,0.0013323945,0.0002922179],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010280414,0.00013167565,0.0017177763,0.00015320827,0.000035968336,0.000006935125,0.00014326985,0.0005777162,0.000014479025],"category_scores_gemma":[0.05711941,0.000098125616,0.00069634325,0.00008919593,0.0002236469,0.00019536726,0.000053124233,0.00095833634,9.946413e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004020114,0.004014519,0.84601086,0.00012668765,0.00025107813,0.00018113147,0.000094483534,0.00006238908,0.00026793964,0.0010184373,0.0010777869,0.14287457],"study_design_scores_gemma":[0.016946489,0.03576129,0.90179026,0.00023076597,0.00077889743,0.00027197474,0.00023848648,0.0014547615,0.00003819314,0.00038487153,0.042016562,0.000087426975],"about_ca_topic_score_codex":0.000019610914,"about_ca_topic_score_gemma":0.00008850189,"teacher_disagreement_score":0.14278714,"about_ca_system_score_codex":0.00008789154,"about_ca_system_score_gemma":0.000969812,"threshold_uncertainty_score":0.9508229},"labels":[],"label_agreement":null},{"id":"W2590473298","doi":"10.1200/jco.2012.30.4_suppl.673","title":"Predicting acute small-bowel toxicity in patients with rectal cancer treated with neoadjuvant chemoradiation: A comparison of peritoneal space versus small-bowel loop contouring techniques.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Contouring; Toxicity; Colorectal cancer; Radiation therapy; Internal medicine; Urology; Gastroenterology; Radiology; Nuclear medicine; Cancer","score_opus":0.0765273415441216,"score_gpt":0.3952583194350143,"score_spread":0.3187309778908927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590473298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661684,0.0002515696,0.000030094552,0.0011201629,0.0003938605,0.00037979658,0.0000069644557,0.000020255233,0.0011804707],"genre_scores_gemma":[0.99616706,0.000058391528,0.0026170155,0.00015250623,0.0008954846,0.000011537523,0.0000062316167,0.00002446618,0.00006732609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971258,0.00021654491,0.0016479692,0.00021879595,0.000401367,0.000389539],"domain_scores_gemma":[0.99632305,0.0006489056,0.0018812855,0.0001495307,0.00056793046,0.0004293266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011262819,0.00022462112,0.0016654844,0.00016548556,0.00004509865,0.0000074521686,0.0001385494,0.0003427353,0.000034542158],"category_scores_gemma":[0.0005565521,0.00014720303,0.00022444713,0.00026406455,0.0002194709,0.00015795107,0.000057552454,0.0011437796,7.3575876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046694558,0.0024012795,0.924078,0.000046947087,0.0004283235,0.00016704421,0.00036140071,0.000027758671,0.00031139486,0.0000056407675,0.000046552617,0.0254311],"study_design_scores_gemma":[0.017596737,0.029680964,0.9460278,0.00040678075,0.0007347088,0.00007315014,0.00034399075,0.0003932536,0.004315674,0.0000012855327,0.00026506287,0.00016059354],"about_ca_topic_score_codex":0.0003433948,"about_ca_topic_score_gemma":0.0014148488,"teacher_disagreement_score":0.029097822,"about_ca_system_score_codex":0.00041767952,"about_ca_system_score_gemma":0.0007718657,"threshold_uncertainty_score":0.6002765},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2590484520","doi":"10.1200/jco.2013.31.6_suppl.378","title":"Contrasting the vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Sunitinib; Nuclear medicine; Magnetic resonance imaging; Dynamic contrast; Radiology; Renal cell carcinoma; Internal medicine","score_opus":0.1152200069225144,"score_gpt":0.46132715443151884,"score_spread":0.34610714750900445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590484520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82092863,0.0012993992,0.00020959594,0.17383946,0.001031917,0.00058849214,0.000004721904,0.000016098638,0.0020817008],"genre_scores_gemma":[0.95017177,0.0030301008,0.0040706396,0.04002832,0.0018929669,0.000050564682,0.000001433567,0.00004775474,0.00070643565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940769,0.002051973,0.0024015822,0.00030343796,0.0007306431,0.00043545902],"domain_scores_gemma":[0.9778942,0.018256841,0.001349891,0.00043766867,0.0010324988,0.0010288965],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012768822,0.00021830885,0.0016123031,0.0001308258,0.0001164439,0.0000445547,0.00034115597,0.00029784552,0.00096275756],"category_scores_gemma":[0.026019564,0.00013647522,0.0004573894,0.0002240346,0.00038528317,0.00014604034,0.00011326602,0.001547624,0.00014550077],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011830304,0.0014604451,0.14333583,0.000058316116,0.0012990906,0.000965493,0.00051008444,0.000049776234,0.004503303,0.000064565975,0.6672038,0.16871901],"study_design_scores_gemma":[0.008220377,0.009704828,0.256816,0.00026052576,0.00056924723,0.0009609316,0.00040116065,0.00006625618,0.00037909896,0.00030658446,0.7221521,0.00016289318],"about_ca_topic_score_codex":0.00019480808,"about_ca_topic_score_gemma":0.00006532878,"teacher_disagreement_score":0.16855612,"about_ca_system_score_codex":0.00022008056,"about_ca_system_score_gemma":0.0014411231,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W2590495164","doi":"10.1200/jco.2014.32.30_suppl.54","title":"Evaluating the implementation of computerized prescriber order entry (CPOE) for systemic treatment (ST) in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Workload; Medicine; CLARITY; Workflow; Patient safety; Multidisciplinary team; Nursing; Medical education; Medical emergency; Health care; Computer science","score_opus":0.5520222324696515,"score_gpt":0.6486270182007524,"score_spread":0.09660478573110087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590495164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757273,0.00004635653,0.007253379,0.014747399,0.0009750855,0.0011270066,0.000003412809,0.000004184621,0.000115851915],"genre_scores_gemma":[0.9602642,0.00007909618,0.035825003,0.0027675268,0.0008638831,0.000032377946,0.000021366572,0.000015148796,0.0001313675],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99213415,0.0012952866,0.00580472,0.0001827173,0.0003860018,0.00019714903],"domain_scores_gemma":[0.9789701,0.015519386,0.004183997,0.00022203391,0.0009788959,0.00012554879],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013428419,0.00012626966,0.0012647501,0.00008624806,0.000034610697,0.0000088703855,0.000133864,0.00017903732,0.00024247072],"category_scores_gemma":[0.009391256,0.00007561625,0.00038993976,0.000101738195,0.00007679897,0.00012554057,0.000035536792,0.00045921787,0.0000029796824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013254536,0.0021092796,0.23957634,0.000094872245,0.0007287548,0.000024604682,0.001205376,0.00050377793,0.0015779865,0.00024707356,0.0039047645,0.73677266],"study_design_scores_gemma":[0.1068116,0.096793644,0.66694444,0.00038275134,0.002704613,0.00066830154,0.0027769448,0.011046032,0.00024871976,0.001284103,0.11013155,0.00020728986],"about_ca_topic_score_codex":0.0065685096,"about_ca_topic_score_gemma":0.025255203,"teacher_disagreement_score":0.73656535,"about_ca_system_score_codex":0.0005239725,"about_ca_system_score_gemma":0.0033939518,"threshold_uncertainty_score":0.99895304},"labels":[],"label_agreement":null},{"id":"W2590497273","doi":"10.1200/jco.2016.34.7_suppl.289","title":"Prostate cancer care in Canada: Informed decision-making, patterns of care, and treatment trends.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Thematic analysis; Focus group; Prostate cancer; Family medicine; Cancer registry; Descriptive statistics; Cancer; Qualitative research; Internal medicine","score_opus":0.04943230589485171,"score_gpt":0.44034840134821146,"score_spread":0.39091609545335976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590497273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891243,0.0072478186,0.0000022103077,0.0022723593,0.0005686782,0.00018269502,0.00011270568,0.0000015823898,0.00048768168],"genre_scores_gemma":[0.9629672,0.03604401,0.00035525148,0.0003955899,0.00016344545,0.000022446491,0.0000019740694,0.00000954802,0.000040549246],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977647,0.00007184642,0.0015690286,0.00014979127,0.00024566558,0.00019893788],"domain_scores_gemma":[0.9965394,0.0017657381,0.001000336,0.00013131702,0.00032273092,0.00024044566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001978957,0.0001318128,0.0012036463,0.00013090052,0.000013837939,0.000002508646,0.000060631763,0.00011258483,0.00010622268],"category_scores_gemma":[0.00044749363,0.00006571804,0.000179629,0.00007485837,0.000061332,0.00006412716,0.000028981014,0.00014768605,4.5105952e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017677442,0.00014137934,0.48944578,0.0000243322,0.00011270727,0.0003301145,0.00037480393,0.0000030873812,0.0000015270699,0.000002765163,0.00022303405,0.50757277],"study_design_scores_gemma":[0.013909256,0.016614433,0.91464466,0.0013931468,0.00022793372,0.000042915806,0.00088469626,0.0000012558717,0.00014607444,0.000018843875,0.052049898,0.00006689728],"about_ca_topic_score_codex":0.10246188,"about_ca_topic_score_gemma":0.8930933,"teacher_disagreement_score":0.7906314,"about_ca_system_score_codex":0.0031874299,"about_ca_system_score_gemma":0.010528724,"threshold_uncertainty_score":0.99508065},"labels":[],"label_agreement":null},{"id":"W2590498238","doi":"10.1200/jco.2016.34.2_suppl.352","title":"Examination of current Algoma District cancer program practices and local referral processes for patients with prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group Health Centre; Essar Steel Algoma (Canada)","funders":"","keywords":"Medicine; Referral; Prostate cancer; Cancer; Radiation oncologist; Medical record; Family medicine; Internal medicine; General surgery; Radiation therapy","score_opus":0.42059483015869964,"score_gpt":0.6269786833465727,"score_spread":0.20638385318787306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590498238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827206,0.0007778135,0.0016884947,0.012935716,0.000632693,0.0011504163,0.000056824603,0.000008941453,0.000028509916],"genre_scores_gemma":[0.9895356,0.004713336,0.004722267,0.00024706827,0.0006131594,0.00010493701,0.0000125674915,0.000016571044,0.00003447689],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99618113,0.00028391372,0.0027359854,0.00021797669,0.00039728786,0.00018369411],"domain_scores_gemma":[0.9802595,0.007966021,0.008146657,0.00010055041,0.0033058994,0.00022137289],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028245153,0.00012485591,0.00083930825,0.0000759487,0.000031760785,0.000008816104,0.00008379876,0.00014438028,0.000028376135],"category_scores_gemma":[0.035221927,0.00006450113,0.00010207937,0.00015776756,0.00029821243,0.0004932062,0.000033312674,0.0003269021,3.9788097e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009656082,0.0020416416,0.32959145,0.0002332159,0.00014429378,0.0000032880164,0.000040765433,0.0000011281857,0.000014805891,0.0000071647996,0.0006564064,0.65760976],"study_design_scores_gemma":[0.017011352,0.032651316,0.87473446,0.00058100704,0.0009635235,0.000016134836,0.0001264563,0.000051486204,0.00006973189,0.00007978096,0.073623456,0.000091270515],"about_ca_topic_score_codex":0.00004713503,"about_ca_topic_score_gemma":0.00031410955,"teacher_disagreement_score":0.6575185,"about_ca_system_score_codex":0.00016202575,"about_ca_system_score_gemma":0.0027789285,"threshold_uncertainty_score":0.9729048},"labels":[],"label_agreement":null},{"id":"W2590500502","doi":"10.1200/jco.2015.33.7_suppl.158","title":"Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FANCA; Medicine; Prostate cancer; Exome sequencing; Cancer research; Germline; Cancer; Exome; Oncology; Internal medicine; Gene; Mutation; Genetics; DNA repair; Biology; Fanconi anemia","score_opus":0.10880677586214689,"score_gpt":0.4577888700019991,"score_spread":0.3489820941398522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590500502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892146,0.0014138567,0.0005999367,0.00593059,0.0016245038,0.00073885126,0.000018196948,0.000005508787,0.0004539577],"genre_scores_gemma":[0.9854121,0.0013843662,0.0080878,0.0019037635,0.002787488,0.000038202987,0.000023041352,0.000028206041,0.00033499798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99757427,0.00019733068,0.0014354115,0.00030183,0.00022042888,0.00027073204],"domain_scores_gemma":[0.99685144,0.00092907465,0.0011328732,0.00018998921,0.0005122439,0.0003843578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027157564,0.0001686516,0.00080535706,0.00008423702,0.000027225877,0.000012531558,0.000143616,0.00035520547,0.000004085309],"category_scores_gemma":[0.00833869,0.00012485597,0.00017414066,0.000099871475,0.00012854014,0.000013535628,0.00007573001,0.00041854798,0.000001737479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015552438,0.00070662407,0.020831794,0.000036326353,0.00012284449,0.00014830676,0.0004191774,0.007438699,0.028165968,0.000056232413,0.020193554,0.906328],"study_design_scores_gemma":[0.019168766,0.04965348,0.024972247,0.00038820927,0.00010823143,0.000082763574,0.0003078684,0.0009807212,0.006482305,0.0019957633,0.89553785,0.0003217942],"about_ca_topic_score_codex":0.0001057995,"about_ca_topic_score_gemma":0.0021406033,"teacher_disagreement_score":0.9060062,"about_ca_system_score_codex":0.00024541665,"about_ca_system_score_gemma":0.0037476018,"threshold_uncertainty_score":0.9982793},"labels":[],"label_agreement":null},{"id":"W2590502787","doi":"10.1200/jco.2016.34.4_suppl.752","title":"Impact of relative dose intensity and G-CSF use in the adjuvant treatment of resected colon cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; FOLFOX; Capecitabine; Oxaliplatin; Colorectal cancer; Internal medicine; Regimen; Oncology; Fluorouracil; Stage (stratigraphy); Adjuvant; Chemotherapy; Cancer; Gastroenterology","score_opus":0.24664590899302374,"score_gpt":0.5330798669304161,"score_spread":0.28643395793739235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590502787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928088,0.0016814834,0.000002195636,0.0048033395,0.00018028039,0.00023094004,0.000018783194,0.0000012550356,0.00027292874],"genre_scores_gemma":[0.991053,0.008511064,0.00011177684,0.00009450447,0.00011925826,0.0000054115612,3.391354e-7,0.0000041985995,0.00010045469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815494,0.0003216589,0.001135092,0.00010506063,0.00016406568,0.00011918439],"domain_scores_gemma":[0.9944512,0.0037825522,0.0010552334,0.00011286772,0.00050724077,0.0000909102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074959954,0.00009804555,0.0013758785,0.0000754558,0.000017631319,0.0000015610276,0.00004916108,0.00013076638,0.00003350597],"category_scores_gemma":[0.00246957,0.000035677764,0.00032345613,0.000111300746,0.00035750036,0.00007815497,0.00002477307,0.00017777157,3.2802353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02750003,0.0019736474,0.83926797,0.000006488549,0.0009889697,0.00026537722,0.0009546488,8.8971404e-7,0.00060203654,0.00001682939,0.0004576331,0.12796547],"study_design_scores_gemma":[0.011534863,0.072234645,0.9142989,0.00015566402,0.0003883267,0.00008136226,0.00014317516,0.0000041917174,0.000104660205,0.00014587156,0.0008780673,0.000030282283],"about_ca_topic_score_codex":0.0011735992,"about_ca_topic_score_gemma":0.0021099134,"teacher_disagreement_score":0.12793519,"about_ca_system_score_codex":0.0004242914,"about_ca_system_score_gemma":0.0007464606,"threshold_uncertainty_score":0.29564843},"labels":[],"label_agreement":null},{"id":"W2590504398","doi":"10.1200/jco.2012.30.34_suppl.316","title":"Patient identification and tracking for chemotherapy delivery: Use of RFID or barcode technologies for automated self check-in.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telecommunications and Broadcasting Technologies","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Interactive kiosk; Medicine; Barcode; Chemotherapy; Identification (biology); Medical emergency; Emergency medicine; Internal medicine; World Wide Web; Computer science","score_opus":0.14430276401882214,"score_gpt":0.41267003682114617,"score_spread":0.26836727280232403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590504398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206614,0.00082055415,0.0053647533,0.000822475,0.0002878672,0.00029927655,0.000009671736,0.00032296864,0.0000062597906],"genre_scores_gemma":[0.82698673,0.001845788,0.17107487,0.000022549191,0.00003219274,0.000022596336,0.0000012705165,0.00001162594,0.0000023906407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982573,0.000043938584,0.0013818452,0.000072792056,0.00006415871,0.00017999568],"domain_scores_gemma":[0.9965122,0.0023649703,0.00069536245,0.00018555489,0.00020991864,0.000032009673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010410234,0.000088119974,0.0005293925,0.00017237847,0.000029575782,0.000012125321,0.00019565418,0.00033687282,0.000001449279],"category_scores_gemma":[0.003016449,0.00006646601,0.0001118832,0.00013928908,0.00009711831,0.00025894862,0.00003749001,0.0002678046,2.0551404e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035113702,0.00054549077,0.009820679,0.00009420948,0.00013865964,0.0000010356985,0.00027162847,0.00064041815,0.004505641,0.00021136951,0.0015815157,0.9818382],"study_design_scores_gemma":[0.010941704,0.009445305,0.29775605,0.00047409005,0.0003731038,0.00017625224,0.0036589436,0.26661336,0.051425632,0.002604716,0.35583204,0.00069880555],"about_ca_topic_score_codex":0.0000022590957,"about_ca_topic_score_gemma":0.000011414068,"teacher_disagreement_score":0.9811394,"about_ca_system_score_codex":0.00006834577,"about_ca_system_score_gemma":0.00006834039,"threshold_uncertainty_score":0.3611189},"labels":[],"label_agreement":null},{"id":"W2590508760","doi":"10.1200/jco.2013.31.4_suppl.342","title":"Classification of a VUS in <i>MLH1</i> using a combination of family segregation studies and protein biochemistry.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McMaster University; Mount Sinai Hospital; Juravinski Cancer Centre","funders":"","keywords":"MLH1; Genetics; Microsatellite instability; DNA mismatch repair; Point mutation; Mutation; Lynch syndrome; Computational biology; Mutagenesis; Gene; Medicine; Biology; Microsatellite; DNA repair; Allele","score_opus":0.24783615303494338,"score_gpt":0.49477044271139503,"score_spread":0.24693428967645165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590508760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629337,0.00089644,0.0000563076,0.0019417093,0.00020498039,0.00032332845,5.8428157e-7,0.0000015871075,0.000281668],"genre_scores_gemma":[0.9928002,0.0001906661,0.0068052793,0.00009507966,0.00006777553,0.0000067244328,4.688427e-7,0.000005461066,0.000028349728],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977827,0.00017497447,0.0016405884,0.00009851996,0.00022618673,0.00007700383],"domain_scores_gemma":[0.99654365,0.0005541226,0.0018072089,0.00008847861,0.0009403054,0.00006624146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013748398,0.000067450776,0.0007701582,0.000102896454,0.000008302236,0.0000019424454,0.00005285845,0.00021473071,0.000009133332],"category_scores_gemma":[0.003919242,0.000051220133,0.00008615,0.00014455842,0.00022188,0.000063343316,0.000026995347,0.0002901561,3.9213182e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009895896,0.0007513076,0.10386343,0.00034037582,0.00014167279,0.000006815863,0.00029521142,0.000013616615,0.83402824,0.000055532153,0.000268456,0.05924573],"study_design_scores_gemma":[0.00709866,0.008406042,0.9239451,0.0007918616,0.00017974235,0.00005877144,0.001389006,0.0013400975,0.053083163,0.0034072297,0.00021841229,0.000081903585],"about_ca_topic_score_codex":0.000033876266,"about_ca_topic_score_gemma":0.00001018315,"teacher_disagreement_score":0.82008165,"about_ca_system_score_codex":0.00015880459,"about_ca_system_score_gemma":0.0006362917,"threshold_uncertainty_score":0.46919817},"labels":[],"label_agreement":null},{"id":"W2590508915","doi":"10.1200/jco.2012.30.30_suppl.16","title":"The lipid metabolome of kidney cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kidney cancer; False discovery rate; Metabolomics; Liquid chromatography–mass spectrometry; Medicine; Cancer; Metabolome; Multiple comparisons problem; Bonferroni correction; Kidney; Mass spectrometry; Internal medicine; Cancer research; Computational biology; Bioinformatics; Chromatography; Biology; Chemistry; Biochemistry; Statistics; Gene","score_opus":0.06660497525809382,"score_gpt":0.4384453172750612,"score_spread":0.37184034201696736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590508915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7649017,0.061716776,0.00041868168,0.012945164,0.15210296,0.00023293454,0.000041321913,0.0000054849606,0.007634979],"genre_scores_gemma":[0.7569424,0.062754005,0.0014397935,0.006184224,0.17031622,0.000011535769,0.000004783169,0.000030656636,0.0023163802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974895,0.000411919,0.0014943437,0.00011059332,0.00020176054,0.00029187556],"domain_scores_gemma":[0.9969716,0.00036335216,0.0015356696,0.00024467066,0.00035487473,0.00052982854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003805661,0.000108819186,0.00073197996,0.000030280487,0.00005469717,0.0000054162697,0.00035301366,0.0003249134,0.000054953092],"category_scores_gemma":[0.0053400146,0.00006514705,0.00052452646,0.00007226909,0.00031088735,0.000009389996,0.00009352848,0.0003792582,0.00000459037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020623114,0.0007098898,0.032000292,0.000018659095,0.0007499779,3.1415564e-7,0.000086450746,0.000013772276,0.055120222,0.0008793823,0.6716941,0.23666465],"study_design_scores_gemma":[0.0014877968,0.0010697943,0.02370017,0.000009620597,0.00016850025,0.00003138484,0.000055128512,0.0000015480699,0.0036767367,0.000056385335,0.96966934,0.000073582436],"about_ca_topic_score_codex":0.000024081095,"about_ca_topic_score_gemma":0.00003628321,"teacher_disagreement_score":0.29797527,"about_ca_system_score_codex":0.000017326818,"about_ca_system_score_gemma":0.0017802949,"threshold_uncertainty_score":0.63928825},"labels":[],"label_agreement":null},{"id":"W2590509160","doi":"10.1200/jco.2013.31.31_suppl.230","title":"Developing a culture of safety in systemic cancer treatment at the system level.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Multidisciplinary approach; Agency (philosophy); Patient safety; Quality management; Guideline; Quality (philosophy); Health care; Work (physics); Safety culture; Systemic therapy; Business; Process management; Nursing; Service (business); Cancer; Political science; Marketing; Breast cancer","score_opus":0.5710822285061773,"score_gpt":0.6138298690846965,"score_spread":0.04274764057851921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590509160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96537036,0.0009871151,0.00051137933,0.030297905,0.0013522975,0.00074684684,0.000009243125,0.000005901381,0.0007189384],"genre_scores_gemma":[0.99107045,0.0022426269,0.0034936047,0.0017965902,0.000842914,0.000025482585,0.0000036147555,0.00001214893,0.00051259337],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.992612,0.00087711716,0.0058237785,0.0001534539,0.00034920036,0.00018443775],"domain_scores_gemma":[0.98868793,0.0062030996,0.0038787809,0.0002008928,0.00087015337,0.0001591275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049920264,0.0001259779,0.0014465067,0.000070997325,0.0000401814,0.000005310281,0.00014214353,0.000291521,0.00021688186],"category_scores_gemma":[0.0069681844,0.000062923944,0.00036355352,0.00017116412,0.0001142445,0.00012679586,0.000061864535,0.0005506728,0.000036958958],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074791973,0.0011346601,0.3918587,0.00044590732,0.0014158582,0.00033570235,0.001906164,0.0003034302,0.002000611,0.0005343845,0.014800712,0.57778466],"study_design_scores_gemma":[0.0330474,0.012631016,0.80901724,0.002441828,0.0015740284,0.0029484571,0.01514253,0.0008976687,0.00044006293,0.00016549487,0.121453054,0.00024121908],"about_ca_topic_score_codex":0.0012601654,"about_ca_topic_score_gemma":0.0013954461,"teacher_disagreement_score":0.57754344,"about_ca_system_score_codex":0.001984224,"about_ca_system_score_gemma":0.0027783469,"threshold_uncertainty_score":0.8342071},"labels":[],"label_agreement":null},{"id":"W2590515244","doi":"10.1200/jco.2013.31.6_suppl.385","title":"Supression of tumor progression and metastasis in renal cell carcinoma by miR-192, miR-194, and miR-215.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"microRNA; Clear cell renal cell carcinoma; Renal cell carcinoma; Cancer research; Metastasis; Medicine; Tumor progression; Cell; Mdm2; Cell culture; Cancer; Biology; Oncology; Internal medicine; Gene","score_opus":0.037235268163283895,"score_gpt":0.40386780088284857,"score_spread":0.3666325327195647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590515244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918704,0.00614134,0.00027807715,0.000898133,0.00019489936,0.00030436026,0.000011093161,0.00000176358,0.00029995738],"genre_scores_gemma":[0.9943211,0.0011415235,0.003934607,0.00027064868,0.00015224086,0.000014105021,0.000010862215,0.000022579963,0.00013233238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672425,0.0008381459,0.0014567401,0.00034032913,0.0003290004,0.00031155924],"domain_scores_gemma":[0.9978397,0.00029751426,0.0009768985,0.0002165583,0.00031237738,0.00035693456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021439898,0.00017372318,0.00080003,0.00012660444,0.000036403475,0.000016905216,0.00023293511,0.0004924573,0.000072453964],"category_scores_gemma":[0.0010216415,0.0001327538,0.00018941742,0.00010542454,0.00028512167,0.000016991697,0.00026883543,0.0006871285,0.0000021217656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014651609,0.0006106151,0.0038807974,0.000055876662,0.000064977816,0.00008028767,0.00003085585,0.0000051460743,0.9487039,0.000004853444,0.008226342,0.03687121],"study_design_scores_gemma":[0.008995225,0.014199675,0.029672902,0.00013772251,0.00012210743,0.0003311896,0.00013792192,0.0002067598,0.8942252,0.00020126405,0.051498212,0.00027183632],"about_ca_topic_score_codex":0.000093253555,"about_ca_topic_score_gemma":0.000049430677,"teacher_disagreement_score":0.05447869,"about_ca_system_score_codex":0.00003250636,"about_ca_system_score_gemma":0.0005169984,"threshold_uncertainty_score":0.5413543},"labels":[],"label_agreement":null},{"id":"W2590516903","doi":"10.1200/jco.2012.30.34_suppl.177","title":"Use of a Pan-Canadian indicator to measure treatment rates relative to evidence-based guidelines for rectal cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Referral; Colorectal cancer; Cancer; Retrospective cohort study; Stage (stratigraphy); Cancer registry; General surgery; Surgery; Family medicine; Internal medicine","score_opus":0.8692273456714583,"score_gpt":0.6786525626966591,"score_spread":0.19057478297479924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590516903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.725398,0.00088488933,0.0035431434,0.2664846,0.0019943113,0.0015745623,0.00007378991,0.000007713237,0.000039014536],"genre_scores_gemma":[0.8430021,0.000471067,0.11978646,0.033418506,0.003063932,0.00007860787,0.0000074843692,0.000029622568,0.00014226386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930091,0.0006947356,0.0051883804,0.00022985098,0.0004674302,0.00041052012],"domain_scores_gemma":[0.96708596,0.024555806,0.002833703,0.0002582098,0.0035052176,0.0017611366],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008226193,0.00019032153,0.0015634592,0.00036041942,0.000052957083,0.0000107328715,0.00015147978,0.00035794725,0.00021612583],"category_scores_gemma":[0.23082587,0.00013269256,0.0006096471,0.00030580943,0.00008809795,0.00053351454,0.000027813436,0.00042792095,0.0000305737],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015329413,0.001429049,0.32633093,0.000033048083,0.0008422491,0.000034457433,0.000341609,0.00014604942,0.0014800838,0.000053277905,0.0842172,0.56976265],"study_design_scores_gemma":[0.008162328,0.043598924,0.35158312,0.00081535726,0.002184228,0.00005404834,0.00037492823,0.0001879398,0.0018087937,0.000064440275,0.5909504,0.00021548633],"about_ca_topic_score_codex":0.011629844,"about_ca_topic_score_gemma":0.026210401,"teacher_disagreement_score":0.5695472,"about_ca_system_score_codex":0.0010164655,"about_ca_system_score_gemma":0.0099438615,"threshold_uncertainty_score":0.9956688},"labels":[],"label_agreement":null},{"id":"W2590523296","doi":"10.1200/jco.2015.33.3_suppl.692","title":"Trends in the design and interpretation of metastatic colorectal cancer phase III clinical trials.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Clinical endpoint; Colorectal cancer; Clinical trial; Internal medicine; Randomized controlled trial; Oncology; Clinical study design; Sample size determination; Surrogate endpoint; Cancer; Statistics","score_opus":0.8732730454891728,"score_gpt":0.6872476713250579,"score_spread":0.1860253741641149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590523296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9245603,0.0036979094,0.022281503,0.04502314,0.002926341,0.00050527096,0.00004014717,0.0000039549877,0.0009614062],"genre_scores_gemma":[0.98511356,0.0007672571,0.0074006626,0.0059024277,0.0007394064,0.000023140881,0.0000027432186,0.000010304526,0.000040517883],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9616938,0.014613208,0.023067022,0.00026059194,0.00015736559,0.00020799568],"domain_scores_gemma":[0.9355758,0.045463637,0.018261472,0.00017159998,0.00023028215,0.0002972454],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3617064,0.00011794541,0.0039513567,0.00038870864,0.00002672026,0.000021016547,0.00030129118,0.00026349648,0.00012903669],"category_scores_gemma":[0.09995389,0.00009000597,0.00044118558,0.00021589757,0.0002537353,0.00030966126,0.000030352376,0.0006738827,0.000018991255],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01879829,0.0070176576,0.12864287,0.00014688598,0.0016940464,0.00007097932,0.01603061,0.0030134383,0.0000041467765,0.019838257,0.14136021,0.66338265],"study_design_scores_gemma":[0.14748408,0.053220194,0.2505157,0.0004527838,0.000867224,0.0002525118,0.013068758,0.29324716,0.000010780753,0.09952642,0.14047772,0.00087667187],"about_ca_topic_score_codex":0.0002068496,"about_ca_topic_score_gemma":0.00021462621,"teacher_disagreement_score":0.6625059,"about_ca_system_score_codex":0.00021495698,"about_ca_system_score_gemma":0.0011764609,"threshold_uncertainty_score":0.9076276},"labels":[],"label_agreement":null},{"id":"W2590523665","doi":"10.1200/jco.2007.25.18_suppl.4077","title":"Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer (MCRC): A population- based study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Irinotecan; Oxaliplatin; Colorectal cancer; Internal medicine; Oncology; Population; Chemotherapy; Cohort; Cancer; Surgery","score_opus":0.0801530001300504,"score_gpt":0.4753695371595514,"score_spread":0.395216537029501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590523665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998832,0.000058504385,0.000005840011,0.00019634055,0.00022212755,0.0004506382,0.0000111130885,0.0000025059603,0.00022091936],"genre_scores_gemma":[0.99946415,0.000016143522,0.0003000018,0.000102157406,0.0000906426,0.0000042498973,0.0000026461817,0.000010372953,0.000009637843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977079,0.00021577536,0.0013601212,0.00015025762,0.00038956763,0.00017634565],"domain_scores_gemma":[0.9967814,0.0016675326,0.0010123991,0.00007314776,0.0002959435,0.00016955237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014494954,0.00013951465,0.0013495384,0.00017686714,0.000024566567,0.0000032916953,0.000043424403,0.00007765458,0.000054777567],"category_scores_gemma":[0.00071161374,0.00007862508,0.00017787341,0.00014791286,0.00006568416,0.000047927977,0.000018178236,0.00036944766,2.3538333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041150793,0.007336504,0.9228921,0.000011060522,0.00073427643,0.0001379764,0.00016492164,0.00013278678,0.0000034894128,0.0000038931735,0.000016177746,0.027416054],"study_design_scores_gemma":[0.024360642,0.106289774,0.86876893,0.00007011134,0.0003137559,0.0000031090358,0.00007427458,0.000024824816,0.0000031061968,0.00001279511,0.00001870785,0.0000599761],"about_ca_topic_score_codex":0.0012935376,"about_ca_topic_score_gemma":0.006836284,"teacher_disagreement_score":0.09895327,"about_ca_system_score_codex":0.00042580554,"about_ca_system_score_gemma":0.000625096,"threshold_uncertainty_score":0.3814807},"labels":[],"label_agreement":null},{"id":"W2590523801","doi":"10.1200/jco.2015.33.7_suppl.121","title":"Association of neutrophil count with overall survival in localized prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Univariate analysis; Internal medicine; Neutrophil to lymphocyte ratio; Mean corpuscular volume; Complete blood count; Absolute neutrophil count; Proportional hazards model; Red blood cell distribution width; Oncology; Comorbidity; Multivariate analysis; Cancer; Gastroenterology; Urology; Hemoglobin; Lymphocyte; Neutropenia; Chemotherapy","score_opus":0.0864611375232482,"score_gpt":0.43306087084737965,"score_spread":0.34659973332413146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590523801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987383,0.00037181712,0.000013591719,0.009462495,0.0010249852,0.00023864643,0.00000651239,0.0000058323335,0.0014930838],"genre_scores_gemma":[0.9963529,0.0005203519,0.0014731399,0.00090742094,0.00052330707,0.0000080156615,0.0000019440993,0.000015158617,0.00019776066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963257,0.00061769044,0.0020377836,0.00012755668,0.00068776426,0.0002035591],"domain_scores_gemma":[0.9946297,0.00092283584,0.0026711863,0.0001217621,0.0013099489,0.00034458953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060317917,0.00010583222,0.0013038956,0.00011260042,0.00000951551,0.000004597187,0.000110043045,0.00030035505,0.00004663982],"category_scores_gemma":[0.00361194,0.00007248403,0.000204394,0.00015316231,0.000139338,0.000102647944,0.000030661326,0.00058862986,0.000003354909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028596496,0.0010451517,0.95669144,0.00005506407,0.00050410524,0.00066096283,0.000117585805,0.00010040846,0.00005387471,0.00003675652,0.005636302,0.0065018767],"study_design_scores_gemma":[0.031278983,0.008501782,0.9202487,0.00028248373,0.0005591134,0.000054432337,0.00013476925,0.00021898052,0.00008124583,0.00033397743,0.038204413,0.000101130056],"about_ca_topic_score_codex":0.00007142015,"about_ca_topic_score_gemma":0.0001891242,"teacher_disagreement_score":0.036442727,"about_ca_system_score_codex":0.00079749635,"about_ca_system_score_gemma":0.0043164934,"threshold_uncertainty_score":0.7657274},"labels":[],"label_agreement":null},{"id":"W2590525661","doi":"10.1200/jco.2015.33.7_suppl.405","title":"The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Renal cell carcinoma; Internal medicine; Underweight; Oncology; Body mass index; Overweight; Cancer; Odds ratio; Cohort; Targeted therapy; Clear cell renal cell carcinoma; Confidence interval","score_opus":0.3065606119022541,"score_gpt":0.48059280297045665,"score_spread":0.17403219106820256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590525661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99803466,0.0008930231,0.000119045646,0.0002442262,0.00004552954,0.0002990606,0.00033776925,0.000001749042,0.00002496478],"genre_scores_gemma":[0.9983857,0.000240257,0.0010164225,0.00006241964,0.000045012464,0.0000030137778,0.00022570998,0.000014338136,0.0000071011314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649674,0.0011117549,0.0015591219,0.00024286269,0.00042269527,0.00016683561],"domain_scores_gemma":[0.9925097,0.0028091753,0.003133918,0.00059717096,0.0007321508,0.00021784722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018483406,0.00018840384,0.0017023577,0.0001565437,0.00003517883,0.000007462908,0.00034385792,0.0001073746,0.00003439707],"category_scores_gemma":[0.00034816,0.00006825127,0.00025887182,0.00030275533,0.00038955346,0.000099852434,0.000054450542,0.00031791546,2.0406597e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016195813,0.0010663437,0.9693092,0.000004849144,0.0064219823,0.00002538885,0.00030658508,0.00074370543,0.0010326771,0.0000018446067,0.00002175116,0.004869841],"study_design_scores_gemma":[0.010205247,0.036210395,0.9473012,0.00002266481,0.004803425,0.000005568296,0.0002147691,0.00048524453,0.0006305826,0.00003995528,0.000019370307,0.000061568164],"about_ca_topic_score_codex":0.0025544825,"about_ca_topic_score_gemma":0.00033432565,"teacher_disagreement_score":0.035144053,"about_ca_system_score_codex":0.00014399315,"about_ca_system_score_gemma":0.0010105208,"threshold_uncertainty_score":0.38616306},"labels":[],"label_agreement":null},{"id":"W2590539404","doi":"10.1200/jco.2016.34.7_suppl.78","title":"Use of alkylating chemotherapy in high-grade neuroendocrine tumours: Evaluation of real-world data.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Discontinuation; Regimen; Internal medicine; Dacarbazine; Chemotherapy; Streptozotocin; Chemotherapy regimen; Gastroenterology; Progressive disease; Diabetes mellitus; Surgery; Endocrinology","score_opus":0.38187183037234335,"score_gpt":0.5576972129274532,"score_spread":0.17582538255510988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590539404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783159,0.000094452604,0.00002524558,0.020624183,0.0003774816,0.00033569022,0.000012817611,0.000005803709,0.00020841321],"genre_scores_gemma":[0.990573,0.0023067787,0.0060018436,0.00038991004,0.0005301304,0.000002780297,0.0000032244404,0.000024522864,0.00016781777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934332,0.0014851049,0.0032953997,0.00027621983,0.0011950206,0.0003150857],"domain_scores_gemma":[0.98759985,0.0074919825,0.0031462745,0.0005763896,0.000933204,0.00025231254],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048620766,0.00013491263,0.0016481335,0.00044573133,0.000010893164,0.000003913696,0.00039005902,0.00001810545,0.00013758837],"category_scores_gemma":[0.02761805,0.00008282059,0.00019990446,0.0004016855,0.00042660572,0.00044581442,0.00014777132,0.0006718808,0.00000297422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006433426,0.0023942292,0.6182712,0.000059089823,0.00014475988,0.002133255,0.00001232633,0.000068972884,0.015501594,0.0001679961,0.002582517,0.35223064],"study_design_scores_gemma":[0.0205471,0.011265079,0.94362736,0.00047314996,0.0002515165,0.00073213235,0.000031846106,0.00061194546,0.01082052,0.0010587643,0.01048529,0.00009530341],"about_ca_topic_score_codex":0.00023725312,"about_ca_topic_score_gemma":0.000795996,"teacher_disagreement_score":0.35213533,"about_ca_system_score_codex":0.00014346102,"about_ca_system_score_gemma":0.0014530005,"threshold_uncertainty_score":0.98057276},"labels":[],"label_agreement":null},{"id":"W2590540865","doi":"10.1200/jco.2016.34.2_suppl.44","title":"Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Randomized controlled trial; Prostate; Androgen deprivation therapy; Urology; Toxicity; International Prostate Symptom Score; Radiation therapy; Surgery; Internal medicine; Lower urinary tract symptoms; Cancer","score_opus":0.04752467215323587,"score_gpt":0.4318506478091085,"score_spread":0.3843259756558726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590540865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849944,0.0015390059,0.00010350268,0.01000004,0.0011596439,0.0021247086,0.0000416729,0.00000512856,0.000031904143],"genre_scores_gemma":[0.9200554,0.07722695,0.0005478714,0.0010550768,0.0007434044,0.00024060061,0.0000010526022,0.000020858577,0.000108776745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99541223,0.0008489122,0.0030613944,0.00024055975,0.00019138757,0.00024550458],"domain_scores_gemma":[0.9864463,0.00976481,0.003049628,0.00015015248,0.0003344666,0.00025463908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059849676,0.0001778729,0.003091028,0.00013860759,0.000020781565,0.000007938292,0.00009366409,0.00026746996,0.00006438127],"category_scores_gemma":[0.00435896,0.000090986156,0.00061186065,0.00008286497,0.00039016845,0.00012277834,0.000019386569,0.00033391468,0.0000014997487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6878863,0.0015690139,0.024621055,0.000028055767,0.0006308594,0.00006347682,0.00024617158,0.0000020880536,0.00021260377,0.0000617213,0.00013411883,0.28454453],"study_design_scores_gemma":[0.86093295,0.045708746,0.08399446,0.0005423974,0.00034163913,0.000011883383,0.000017927672,0.000016780345,0.001505383,0.0052036056,0.0016349488,0.00008931074],"about_ca_topic_score_codex":0.00031547228,"about_ca_topic_score_gemma":0.00016518842,"teacher_disagreement_score":0.28445524,"about_ca_system_score_codex":0.00019390234,"about_ca_system_score_gemma":0.0013253172,"threshold_uncertainty_score":0.5218397},"labels":[],"label_agreement":null},{"id":"W2590545034","doi":"10.1200/jco.2016.34.7_suppl.90","title":"Standardization of oral chemotherapy delivery to improve patient safety: A pilot study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Trillium Health Centre; University of Toronto","funders":"","keywords":"Medicine; Psychological intervention; Pharmacist; Pharmacy; Medical prescription; Patient education; Chemotherapy; Intensive care medicine; Internal medicine; Family medicine; Nursing","score_opus":0.1527263620593356,"score_gpt":0.47837312169207774,"score_spread":0.32564675963274214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590545034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546357,0.000055978813,0.026586404,0.016185947,0.00079621153,0.00042386257,0.000004505422,0.0000058350347,0.0013055602],"genre_scores_gemma":[0.9905861,0.0003028973,0.0039019017,0.0044172686,0.00027662888,0.000004543096,3.0350128e-7,0.000007946479,0.0005024188],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99720484,0.00022338411,0.0019025442,0.00013021572,0.00042343116,0.00011556757],"domain_scores_gemma":[0.9967075,0.0006088118,0.0013336509,0.00019008212,0.0008730683,0.00028687756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019513363,0.00007518456,0.00085907854,0.000075335156,0.000015782469,0.0000019219028,0.00011872959,0.00007528701,0.0007026494],"category_scores_gemma":[0.0023507609,0.000041404997,0.00012745966,0.00012038387,0.00008386884,0.00006160038,0.000026840631,0.00019862803,0.00006047022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016225955,0.0038964152,0.033244055,0.000010362916,0.00021644971,0.00004428676,0.00012587027,0.000004073784,0.0058683073,0.000043843123,0.009852468,0.9304679],"study_design_scores_gemma":[0.025258327,0.29120523,0.34332982,0.00034506753,0.00022236585,0.000056925637,0.00041971655,0.000017618893,0.0018620228,0.00035759725,0.33679894,0.00012637282],"about_ca_topic_score_codex":0.000007243054,"about_ca_topic_score_gemma":0.0000073402643,"teacher_disagreement_score":0.93034154,"about_ca_system_score_codex":0.00010626511,"about_ca_system_score_gemma":0.001128862,"threshold_uncertainty_score":0.76935184},"labels":[],"label_agreement":null},{"id":"W2590545625","doi":"10.1200/jco.2012.30.34_suppl.109","title":"Improving the quality of abstract reporting for economic analyses in oncology.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Likert scale; Psychological intervention; Quality Score; Family medicine; Quality (philosophy); Medical physics; Operations management; Statistics; Nursing","score_opus":0.9066848443192708,"score_gpt":0.70834686035124,"score_spread":0.19833798396803082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590545625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676697,0.0022055844,0.0013541057,0.02174685,0.0031417168,0.000408551,0.000037251222,0.0000048442566,0.0034313549],"genre_scores_gemma":[0.98573816,0.0001581244,0.008030365,0.0038230023,0.0021602788,0.000018272249,0.000002264694,0.000016069254,0.00005347616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9613724,0.0011755467,0.036692075,0.0002484691,0.00009030828,0.00042120853],"domain_scores_gemma":[0.87880355,0.03354155,0.08680104,0.00040247972,0.0001758507,0.00027555248],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24355552,0.00013289783,0.0035959457,0.00025962558,0.000071723676,0.00001421062,0.0003860192,0.0004359395,0.00018245206],"category_scores_gemma":[0.12036908,0.00011304509,0.0007851378,0.00007796108,0.00018260523,0.000527774,0.00005759443,0.0006645002,0.00006892303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006182443,0.0013668473,0.9323397,0.0003205627,0.00046639564,0.00000435843,0.0015854895,0.00090025406,0.00007743728,0.025646495,0.008672207,0.028001968],"study_design_scores_gemma":[0.0029237145,0.0011054575,0.92309093,0.000040522755,0.000042058167,0.000027427403,0.0022885602,0.0010949332,0.000022379458,0.00765697,0.06152829,0.00017876702],"about_ca_topic_score_codex":0.0011185359,"about_ca_topic_score_gemma":0.0005947734,"teacher_disagreement_score":0.12318645,"about_ca_system_score_codex":0.0009416714,"about_ca_system_score_gemma":0.0016205907,"threshold_uncertainty_score":0.88704044},"labels":[],"label_agreement":null},{"id":"W2590565136","doi":"10.1200/jco.2014.32.4_suppl.398","title":"The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Thrombocytosis; Neutrophilia; Gastroenterology; Anemia; Carcinoma; Concordance; Interquartile range; Oncology; Urology","score_opus":0.07833004758076212,"score_gpt":0.36076151513493276,"score_spread":0.28243146755417065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590565136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921502,0.0009852088,0.0007595327,0.002481817,0.00039333073,0.0016989058,0.00004551488,0.000019918229,0.0014655719],"genre_scores_gemma":[0.988935,0.0005744079,0.007902003,0.0012528121,0.00033283347,0.00011198178,0.00015312547,0.00008092685,0.00065694435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915862,0.0014468477,0.0041391654,0.000675896,0.0013867908,0.0007650757],"domain_scores_gemma":[0.98798144,0.0062086163,0.0031904103,0.0007158846,0.0012808051,0.00062282727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040925276,0.0005937733,0.0022317946,0.00037513944,0.00016546136,0.00006189739,0.0006686382,0.00022634462,0.00014323337],"category_scores_gemma":[0.0035902949,0.00033271287,0.00065019284,0.0003684624,0.00044435303,0.00028174074,0.00014596869,0.0014925373,0.000039897615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05214289,0.017477944,0.8935593,0.00026109882,0.0014247986,0.005613524,0.0005957063,0.003882472,0.0015677217,0.00010345548,0.004944281,0.018426806],"study_design_scores_gemma":[0.115414605,0.10437143,0.7067847,0.00048005886,0.0041336403,0.0012610916,0.00026588907,0.045886748,0.010301523,0.0007060794,0.0094450675,0.0009491735],"about_ca_topic_score_codex":0.0001944635,"about_ca_topic_score_gemma":0.00035827764,"teacher_disagreement_score":0.1867746,"about_ca_system_score_codex":0.0004960871,"about_ca_system_score_gemma":0.0032026991,"threshold_uncertainty_score":0.9999125},"labels":[],"label_agreement":null},{"id":"W2590578211","doi":"10.1200/jco.2012.30.34_suppl.36","title":"Barriers to patient accrual in Ontario oncology clinical trials: Attitudes of oncologists and clinical research personnel.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Clinical trial; Accrual; Specialty; Family medicine; Population; Test (biology); Protocol (science); Internal medicine; Alternative medicine; Pathology","score_opus":0.9221766539476144,"score_gpt":0.7788884790441656,"score_spread":0.1432881749034488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590578211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649098,0.00079779694,0.00003986075,0.020845812,0.0057533314,0.0012861341,0.0000072313496,0.000011879106,0.0063481806],"genre_scores_gemma":[0.9708866,0.004711634,0.014746635,0.00536791,0.0036810515,0.000025477088,0.0000021173119,0.000048063474,0.00053053634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9081818,0.052753754,0.031243445,0.0013519827,0.004283572,0.0021854464],"domain_scores_gemma":[0.25605163,0.7138689,0.009403805,0.0016283544,0.0073166327,0.011730672],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.47314242,0.00037087087,0.008350422,0.0008851261,0.00014504678,0.000026456208,0.0009737678,0.0052601076,0.0010983574],"category_scores_gemma":[0.7803318,0.00026572865,0.002049105,0.00068368664,0.0045590918,0.00028837833,0.0012088731,0.026377222,0.000081490485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024796342,0.009803299,0.79848576,0.00007790358,0.0007114544,0.0007108594,0.0014889964,0.0000035253267,0.000030909196,0.00084996154,0.0050523668,0.15798865],"study_design_scores_gemma":[0.013447962,0.08284943,0.7938176,0.00048292242,0.000351357,0.00022692009,0.002988028,0.000014667194,0.000018803483,0.0010109014,0.10458821,0.00020325149],"about_ca_topic_score_codex":0.003268268,"about_ca_topic_score_gemma":0.0725124,"teacher_disagreement_score":0.66111517,"about_ca_system_score_codex":0.001865741,"about_ca_system_score_gemma":0.038478322,"threshold_uncertainty_score":0.9999795},"labels":[],"label_agreement":null},{"id":"W2590581990","doi":"10.1200/jco.2016.34.3_suppl.113","title":"Perspective of young breast cancer survivors (BCS) on fertility preservation (FP) referral.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; CReATe Fertility Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Oncofertility; Medicine; Fertility preservation; Fertility; Referral; Family medicine; Breast cancer; Gynecology; Cancer; Population; Internal medicine","score_opus":0.18302317551101085,"score_gpt":0.48963167927457935,"score_spread":0.3066085037635685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590581990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95580965,0.00023449374,0.00010677624,0.03704286,0.0015612522,0.0001812722,0.000019873527,0.000007636587,0.0050361636],"genre_scores_gemma":[0.9971102,0.00038198725,0.00016002535,0.000527324,0.001002326,0.0000036996896,6.4799104e-7,0.000008174679,0.00080564496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662244,0.0008848949,0.0017189262,0.00031053805,0.00028193227,0.00018126785],"domain_scores_gemma":[0.9944663,0.0015236291,0.001496218,0.0003536739,0.0019630499,0.00019712577],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004769456,0.00012129101,0.0011738823,0.000082102306,0.0000308766,0.0000014239498,0.00015942805,0.0004323314,0.00038930806],"category_scores_gemma":[0.009981845,0.00006251564,0.0004012564,0.0001152574,0.000560775,0.00017575179,0.00004182305,0.0006438643,0.000009736083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080694534,0.0019945402,0.86464155,0.000020271267,0.0004081179,0.000029668661,0.00014255197,0.0000013280958,0.0034055135,0.00039160336,0.00105854,0.047211785],"study_design_scores_gemma":[0.0031019805,0.0056869406,0.9837825,0.000105762054,0.00015138235,0.00007192382,0.00011665216,0.000004285842,0.0007569046,0.0029942999,0.0031669796,0.000060413957],"about_ca_topic_score_codex":0.00040954494,"about_ca_topic_score_gemma":0.00035281928,"teacher_disagreement_score":0.11914093,"about_ca_system_score_codex":0.00038092118,"about_ca_system_score_gemma":0.0009782854,"threshold_uncertainty_score":0.9983575},"labels":[],"label_agreement":null},{"id":"W2590585543","doi":"10.1200/jco.2011.29.15_suppl.6131","title":"Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Interquartile range; Informed consent; Ethics committee; Internal medicine; Alternative medicine","score_opus":0.9256589636532153,"score_gpt":0.7350031336866057,"score_spread":0.19065582996660957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590585543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91057587,0.00011937485,0.00070207566,0.047363743,0.000309365,0.001153565,0.0000048693746,0.000028204702,0.039742917],"genre_scores_gemma":[0.9796769,0.0023585006,0.010985708,0.0048902896,0.00046979898,0.000026038038,0.0000035912751,0.00003540158,0.0015537658],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9826107,0.009872739,0.004041018,0.0004172111,0.002473847,0.00058447657],"domain_scores_gemma":[0.649744,0.3375983,0.001428933,0.0017664446,0.0072244112,0.0022379404],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.10736752,0.00019456996,0.0014580839,0.00052251416,0.00030748275,0.000043007036,0.0011301158,0.0012418973,0.00058698363],"category_scores_gemma":[0.35934913,0.00015028976,0.00020278295,0.00051061244,0.003653143,0.0002662474,0.0009281644,0.017068634,0.00026924166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17001402,0.11806124,0.15308882,0.0009046927,0.0031069503,0.002004375,0.031692237,0.000018809194,0.0025084629,0.046457447,0.020815741,0.4513272],"study_design_scores_gemma":[0.010923942,0.19884722,0.72143465,0.00078621705,0.00027486056,0.0003113152,0.0047958326,0.00024408895,0.00014448015,0.013353831,0.048620667,0.0002628807],"about_ca_topic_score_codex":0.0002806777,"about_ca_topic_score_gemma":0.0020241612,"teacher_disagreement_score":0.56834584,"about_ca_system_score_codex":0.00043137188,"about_ca_system_score_gemma":0.020597374,"threshold_uncertainty_score":0.99905837},"labels":[],"label_agreement":null},{"id":"W2590586032","doi":"10.1200/jco.2013.31.6_suppl.394","title":"Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Lymph node; Internal medicine; Proportional hazards model; Oncology; Urology; Surgery; Gastroenterology","score_opus":0.06672928261054789,"score_gpt":0.3562116065377301,"score_spread":0.2894823239271822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590586032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973339,0.00050928857,0.00004549631,0.0006368169,0.00009389284,0.0007020235,0.00044208713,0.000004497038,0.00023200667],"genre_scores_gemma":[0.993681,0.000111910354,0.0052917334,0.00039629295,0.00009393427,0.000010711017,0.0003323861,0.000027472752,0.00005454738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531716,0.0008203266,0.002411738,0.0003660693,0.000794371,0.00029034837],"domain_scores_gemma":[0.9933313,0.0023774374,0.0025286963,0.0004013844,0.00093282573,0.00042832457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012818968,0.00029996797,0.0015955247,0.00022050236,0.000031591047,0.000024992474,0.00020736453,0.00012871208,0.00028255372],"category_scores_gemma":[0.0012967002,0.0001436868,0.00032184037,0.0002147439,0.00037951005,0.00027203385,0.000096690404,0.0007011877,0.000009497935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036560632,0.0044484925,0.9460631,0.000019355164,0.0019473355,0.003101154,0.00018398474,0.000062789986,0.0012956362,0.0000017465317,0.0029930833,0.003322666],"study_design_scores_gemma":[0.04010436,0.024195055,0.9319111,0.0001410426,0.0014536995,0.00013622109,0.000098125296,0.00022904537,0.0014315788,0.000009936871,0.00015984272,0.00013000962],"about_ca_topic_score_codex":0.0032368547,"about_ca_topic_score_gemma":0.00019269521,"teacher_disagreement_score":0.019746562,"about_ca_system_score_codex":0.00024663567,"about_ca_system_score_gemma":0.0009619195,"threshold_uncertainty_score":0.5859378},"labels":[],"label_agreement":null},{"id":"W2590586313","doi":"10.1200/jco.2016.34.7_suppl.153","title":"Meeting patient and provider eTechnology needs: A provincial approach.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Benchmarking; Medicine; Standardization; Usability; Health care; Quality management; Process management; Agency (philosophy); Knowledge management; Nursing; Business; Service (business); Marketing","score_opus":0.30090325597952833,"score_gpt":0.5337032523946855,"score_spread":0.2327999964151572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590586313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92884445,0.00020156096,0.0031497625,0.06415858,0.0008593876,0.00042692933,0.0000026543307,0.000025169886,0.0023315037],"genre_scores_gemma":[0.9599733,0.0003363374,0.03262537,0.0055375546,0.0014070021,0.000007855145,8.766575e-7,0.000019294164,0.00009244574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99420625,0.00052907044,0.004434382,0.000212941,0.00037112515,0.00024622306],"domain_scores_gemma":[0.9883743,0.007086982,0.003344461,0.00019386904,0.00066772895,0.00033265594],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00599724,0.00013128153,0.0011345964,0.0001989362,0.000039022016,0.000007947838,0.00011339601,0.000491809,0.00005590429],"category_scores_gemma":[0.07205686,0.000072344665,0.00026767736,0.00014356719,0.0003529789,0.00023951994,0.0001365031,0.0008176924,0.0000135238815],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031368076,0.0012439394,0.044733573,0.000029522842,0.00018523954,0.0001406276,0.00011007602,6.720748e-7,0.00094617147,0.00033238454,0.004209065,0.9449319],"study_design_scores_gemma":[0.045162152,0.07609666,0.093700826,0.00050303835,0.0018388352,0.00564406,0.0042616003,0.00034237266,0.0007147862,0.0050260704,0.76624584,0.0004637622],"about_ca_topic_score_codex":0.0000281371,"about_ca_topic_score_gemma":0.000023476838,"teacher_disagreement_score":0.94446814,"about_ca_system_score_codex":0.00013082987,"about_ca_system_score_gemma":0.0015964872,"threshold_uncertainty_score":0.9357596},"labels":[],"label_agreement":null},{"id":"W2590588847","doi":"10.1200/jco.2014.32.3_suppl.339","title":"A qualitative study of patient and clinician attitudes regarding surveillance following resection of pancreatic and periampullary cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Pancreatic cancer; Disease; Qualitative research; Nonprobability sampling; Family medicine; Cancer; General surgery; Surgery; Internal medicine; Population","score_opus":0.1701989713434178,"score_gpt":0.5615548209427227,"score_spread":0.3913558495993049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590588847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966911,0.0012388281,0.00005567231,0.0006574787,0.00037689385,0.00031926946,0.0000015777839,0.0000029693415,0.0006562305],"genre_scores_gemma":[0.99645394,0.0016124313,0.001494955,0.00012315543,0.0002590072,0.000006913582,4.7716725e-7,0.000009959346,0.00003913822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940927,0.0026773955,0.0024585302,0.00019497544,0.00040550224,0.0001708687],"domain_scores_gemma":[0.98764384,0.0096120685,0.001902479,0.0001564962,0.0004656414,0.00021945976],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010400327,0.00010965497,0.0025279333,0.00014769068,0.00005343161,0.000003910351,0.000073860065,0.00022981827,0.00001485158],"category_scores_gemma":[0.010528428,0.00007708348,0.00019729017,0.00013329071,0.00034626792,0.000068610876,0.00007487976,0.0005632098,2.6615263e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050888965,0.0014284417,0.95762604,0.00016289177,0.0010727749,0.0000577073,0.008734128,0.0000037052034,0.00021664116,0.000034166293,0.00007340118,0.025501199],"study_design_scores_gemma":[0.010734597,0.07243558,0.893553,0.00045183755,0.00072942104,0.000077605386,0.021031069,0.00018339472,0.000021771786,0.0003027424,0.0004021158,0.000076860815],"about_ca_topic_score_codex":0.00028801503,"about_ca_topic_score_gemma":0.00048564715,"teacher_disagreement_score":0.07100714,"about_ca_system_score_codex":0.000065163505,"about_ca_system_score_gemma":0.0005918672,"threshold_uncertainty_score":0.9978063},"labels":[],"label_agreement":null},{"id":"W2590593093","doi":"10.1200/jco.2014.32.3_suppl.397","title":"Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: A multicenter study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; Memorial University of Newfoundland; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Cancer; Oncology; Neoadjuvant therapy; Univariate analysis; Population; Breast cancer; Retrospective cohort study; Gastroenterology; Surgery; Multivariate analysis","score_opus":0.1501787171209598,"score_gpt":0.48259497295403275,"score_spread":0.332416255833073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590593093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360305,0.0007984826,0.000048343994,0.002964694,0.0014988405,0.00082079304,0.000043637927,0.0000076633105,0.0002145123],"genre_scores_gemma":[0.99655926,0.0005349623,0.0011924258,0.00053840433,0.0007914727,0.0001242734,0.000001316396,0.000014429712,0.00024347947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681675,0.000703466,0.0018112372,0.00021465837,0.00023527385,0.00021859322],"domain_scores_gemma":[0.9945555,0.0033962952,0.0012012937,0.00017134649,0.00046798505,0.00020759212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022380045,0.00017537126,0.0019065272,0.000098345015,0.000041629555,0.000003698083,0.00008547133,0.00015732419,0.000064213586],"category_scores_gemma":[0.0024196736,0.00009809495,0.00066388544,0.00006740026,0.00018969862,0.000037069276,0.00004341053,0.00022765374,0.000002083153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17858186,0.0066388417,0.685386,0.000021999229,0.0015672343,0.00044787014,0.0012489368,0.0000072303337,0.00019458031,0.0000020263533,0.0005857976,0.12531762],"study_design_scores_gemma":[0.023625394,0.15886825,0.76730824,0.000074186755,0.0012163214,0.00004693313,0.00040902838,0.00007256652,0.000044113134,0.00001828364,0.04824938,0.00006733097],"about_ca_topic_score_codex":0.000050325016,"about_ca_topic_score_gemma":0.00027789053,"teacher_disagreement_score":0.15495647,"about_ca_system_score_codex":0.00032746847,"about_ca_system_score_gemma":0.00054701616,"threshold_uncertainty_score":0.40001962},"labels":[],"label_agreement":null},{"id":"W2590593538","doi":"10.1200/jco.2014.32.3_suppl.432","title":"A case series of Lynch syndrome-associated breast cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Mount Sinai Hospital; Juravinski Cancer Centre","funders":"","keywords":"Lynch syndrome; Medicine; MSH2; MLH1; PMS2; Pedigree chart; Breast cancer; MSH6; Cancer; Internal medicine; Oncology; Genetics; Colorectal cancer; Biology; Gene; DNA mismatch repair","score_opus":0.09749784449332176,"score_gpt":0.44525529450487816,"score_spread":0.3477574500115564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590593538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899448,0.0002031984,0.000032702515,0.0060430127,0.0020738093,0.00011884876,0.000016912176,0.000008411314,0.0015583128],"genre_scores_gemma":[0.9965862,0.00027892637,0.0013370735,0.00093057565,0.0005431925,0.0000035302899,7.460005e-7,0.000018248016,0.00030147887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660945,0.00048023486,0.002167155,0.00015017064,0.00036960986,0.00022339023],"domain_scores_gemma":[0.9947961,0.0016953802,0.0020733112,0.00018534732,0.0008985221,0.00035133315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028966572,0.00012913861,0.0017249078,0.00009862984,0.000029138788,0.0000037603015,0.00014345201,0.0004513704,0.00059596065],"category_scores_gemma":[0.004988384,0.0000934626,0.00043455925,0.00018708155,0.00033631554,0.00006429447,0.000054443823,0.0007964524,0.0000065945496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011046588,0.003614095,0.7237855,0.00022109551,0.0019725466,0.01964516,0.00034109544,0.000113036134,0.0017178421,0.00013243272,0.016075926,0.22133467],"study_design_scores_gemma":[0.009531651,0.034810174,0.7390317,0.000331298,0.0009482966,0.20056814,0.00015640048,0.0001635965,0.00034620243,0.00047007337,0.013469704,0.00017278543],"about_ca_topic_score_codex":0.000097762764,"about_ca_topic_score_gemma":0.00030369934,"teacher_disagreement_score":0.22116189,"about_ca_system_score_codex":0.00025430814,"about_ca_system_score_gemma":0.0017932397,"threshold_uncertainty_score":0.6525351},"labels":[],"label_agreement":null},{"id":"W2590601363","doi":"10.1200/jco.2014.32.3_suppl.426","title":"Targeted analysis of progressive metabolic perturbations in colorectal cancer in colorectal adenoma: Potential for a serum metabolomics-based colorectal cancer screening test.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Colorectal cancer; Metabolome; Metabolomics; Medicine; Adenoma; Colorectal adenoma; Internal medicine; Progressive disease; Colonoscopy; Cancer; Stage (stratigraphy); Gastroenterology; Oncology; Disease; Metabolite; Endocrinology; Bioinformatics; Biology","score_opus":0.026295192393411753,"score_gpt":0.3803053627739888,"score_spread":0.354010170380577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590601363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98506993,0.0070116003,0.0016924202,0.0009086784,0.0043159993,0.00055518025,0.00039809712,0.0000057046454,0.00004238428],"genre_scores_gemma":[0.9886467,0.0012381412,0.0033738944,0.00039508726,0.0060103214,0.00020574957,0.00006451274,0.000035567173,0.000030014113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955141,0.000700939,0.0025176757,0.0004479838,0.0003025593,0.00051674317],"domain_scores_gemma":[0.9953419,0.0010461503,0.0023483792,0.00015492793,0.00084735104,0.00026130592],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026070396,0.00029937777,0.0023895218,0.0006242325,0.00006653271,0.00001786763,0.00041772702,0.0007205778,0.00009408402],"category_scores_gemma":[0.004149364,0.00025964715,0.0011524621,0.0008494389,0.00037350302,0.000026162117,0.000089936984,0.0006114806,3.5036408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016764214,0.0028847223,0.47778872,0.00005522033,0.004677736,0.0000071813233,0.0003635457,0.04783229,0.3780334,0.00010974697,0.001939877,0.06954333],"study_design_scores_gemma":[0.012479147,0.004188385,0.9031853,0.000050431157,0.0029685434,0.000014141152,0.00017943965,0.025340505,0.027172247,0.000048194146,0.024000281,0.00037339702],"about_ca_topic_score_codex":0.00033430636,"about_ca_topic_score_gemma":0.008886402,"teacher_disagreement_score":0.42539656,"about_ca_system_score_codex":0.00009866599,"about_ca_system_score_gemma":0.0025135954,"threshold_uncertainty_score":0.9999856},"labels":[],"label_agreement":null},{"id":"W2590603177","doi":"10.1200/jco.2011.29.4_suppl.295","title":"Biliary tract cancer (BTC) in the older adult: Complex decisions for complex patients.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Stage (stratigraphy); Internal medicine; Malignancy; Chemotherapy; Cancer; Radiation therapy; Biliary tract cancer; Performance status; Geriatric oncology; Adenocarcinoma; Pathological; Surgery","score_opus":0.41565965357934886,"score_gpt":0.5012867562171416,"score_spread":0.08562710263779272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590603177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776385,0.00059480994,0.00015623357,0.013774513,0.0012220062,0.0005915536,0.000029702014,0.0000058891246,0.005986792],"genre_scores_gemma":[0.98164624,0.0006952536,0.0032870069,0.013381303,0.0008930897,0.000029054749,0.000006584885,0.000013447843,0.0000480256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972062,0.00025343962,0.0018147426,0.00017295059,0.00030362976,0.00024903656],"domain_scores_gemma":[0.9945174,0.0035741776,0.0008389316,0.00020054572,0.0006990512,0.00016989044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001573226,0.00013246074,0.0011254722,0.00010609507,0.000067226356,0.0000052442447,0.00026136497,0.00018699559,0.00030277052],"category_scores_gemma":[0.0028909454,0.0000719115,0.0005739576,0.00014283635,0.0002140323,0.000070471746,0.00004153313,0.00065391074,0.0000063680895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024879533,0.003350853,0.77462363,0.000016912194,0.00019610449,0.00010908791,0.0016726906,4.7792827e-7,0.000010738351,0.000096797725,0.09391203,0.12352275],"study_design_scores_gemma":[0.009515061,0.005334347,0.90628654,0.00007606249,0.0002947394,0.000058227946,0.0006248152,0.000035786226,0.000002987156,0.00043443785,0.07726466,0.00007235546],"about_ca_topic_score_codex":0.00014278143,"about_ca_topic_score_gemma":0.0006771199,"teacher_disagreement_score":0.13166292,"about_ca_system_score_codex":0.000098897406,"about_ca_system_score_gemma":0.0005522966,"threshold_uncertainty_score":0.34609407},"labels":[],"label_agreement":null},{"id":"W2590605599","doi":"10.1200/jco.2016.34.2_suppl.213","title":"Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Placebo; Docetaxel; Internal medicine; Prostate cancer; Prednisone; Oncology; Enzalutamide; Clinical trial; Hypoalbuminemia; Cancer; Surgery; Pathology","score_opus":0.23265920659390768,"score_gpt":0.5383989148074215,"score_spread":0.3057397082135138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590605599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677056,0.00066626765,0.000028206287,0.0015572339,0.0000713682,0.00044310826,0.00023938778,0.000002409632,0.00022145367],"genre_scores_gemma":[0.99750787,0.0017582999,0.00031622956,0.000035537272,0.00009283481,0.000010920554,0.000013173529,0.000011943207,0.00025318688],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99554574,0.0010275883,0.0024729818,0.00020225505,0.00051857845,0.00023286698],"domain_scores_gemma":[0.99408996,0.0025841931,0.0021304097,0.00017445175,0.00069875637,0.00032223467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004636686,0.0001589036,0.0027176666,0.0005002838,0.000021803638,0.000008738375,0.000088632616,0.0001044592,0.00019663615],"category_scores_gemma":[0.00149278,0.000071415765,0.00043111405,0.00034728998,0.00038981292,0.00016866124,0.000018990577,0.00024093139,2.2931245e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43016428,0.018952709,0.18454182,0.00014014865,0.023928631,0.0011079549,0.0021437916,0.00040568959,0.16048706,0.00006271322,0.0001871709,0.17787802],"study_design_scores_gemma":[0.105087586,0.17223996,0.7080608,0.0004515453,0.00707995,0.000028539176,0.0016285799,0.00028533646,0.0048359185,0.000077375786,0.00007888761,0.00014549983],"about_ca_topic_score_codex":0.0006648202,"about_ca_topic_score_gemma":0.0014949852,"teacher_disagreement_score":0.523519,"about_ca_system_score_codex":0.0003555582,"about_ca_system_score_gemma":0.0026022152,"threshold_uncertainty_score":0.4616218},"labels":[],"label_agreement":null},{"id":"W2590612794","doi":"10.1200/jco.2016.34.2_suppl.266","title":"Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Placebo; Prostate-specific antigen; Urology; Internal medicine; Proportional hazards model; Post-hoc analysis; Statistical significance; Oncology; Gynecology; Cancer; Confidence interval; Androgen receptor; Pathology","score_opus":0.1386197241547089,"score_gpt":0.4735383301453112,"score_spread":0.3349186059906023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590612794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834388,0.00069516647,0.00048557573,0.014090576,0.00037017514,0.00058931584,0.00005071235,0.0000066799125,0.00027298598],"genre_scores_gemma":[0.990307,0.004940767,0.0033851345,0.00029158912,0.00044805795,0.0000137634715,0.00001656382,0.000024572422,0.0005725797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961159,0.0003458654,0.0023809022,0.00029834957,0.00043583725,0.00042311146],"domain_scores_gemma":[0.99248445,0.004371549,0.0015100922,0.00027303078,0.0010002739,0.00036062291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046758205,0.00017945009,0.0023799317,0.0005494772,0.000027488384,0.00000858732,0.00021002139,0.00028681481,0.00015057612],"category_scores_gemma":[0.001742087,0.00008889413,0.000713051,0.00054653996,0.00035278834,0.00015266627,0.00006324679,0.00043254855,0.000003043475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09753368,0.0030131552,0.7914619,0.00005382416,0.0040293387,0.00039009535,0.000119360055,0.000029007679,0.010818538,0.00012750435,0.0008962442,0.09152738],"study_design_scores_gemma":[0.049595542,0.024517527,0.8770723,0.00021881882,0.0013583133,0.000023421291,0.000099038734,0.0002008832,0.0017531735,0.00039964588,0.04460099,0.00016037514],"about_ca_topic_score_codex":0.000048664693,"about_ca_topic_score_gemma":0.000540434,"teacher_disagreement_score":0.09136701,"about_ca_system_score_codex":0.000274327,"about_ca_system_score_gemma":0.0018975236,"threshold_uncertainty_score":0.36249974},"labels":[],"label_agreement":null},{"id":"W2590617369","doi":"10.1200/jco.2015.33.28_suppl.5","title":"Assessing the value of hepatic arterial phase CT imaging in patients with breast cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Breast cancer; Radiology; Cancer; Liver cancer; Population; Metastasis; Internal medicine","score_opus":0.05838805657013771,"score_gpt":0.4940796037270539,"score_spread":0.43569154715691616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590617369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836589,0.0000963357,0.0004931385,0.013987998,0.001221526,0.000114390736,0.0000015835082,0.0000032281716,0.00042289705],"genre_scores_gemma":[0.99532056,0.000030432318,0.002013224,0.0017331279,0.0008792508,0.000001239917,0.0000014096971,0.00001307444,0.00000768886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724156,0.0005053634,0.0015186685,0.00011037006,0.00044777142,0.00017628325],"domain_scores_gemma":[0.99682504,0.00090434944,0.0014632844,0.00012813367,0.0003989579,0.0002802482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042993585,0.00009309627,0.0009165678,0.000089169494,0.000023124188,0.00001602829,0.00015069383,0.00005063232,0.00002959144],"category_scores_gemma":[0.0031617347,0.000047952195,0.00013622016,0.0001293615,0.0003012071,0.00017276079,0.00003327829,0.000988154,8.8736385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018683004,0.0012901106,0.75725037,0.000013140866,0.000064803746,0.00021695011,0.00009943416,0.00013196947,0.000033534172,0.000013762717,0.0005602313,0.23845737],"study_design_scores_gemma":[0.029563814,0.0026664662,0.95563537,0.00038081512,0.00025405074,0.00035229232,0.00017099646,0.008449202,0.0000060198877,0.00013317638,0.0023259614,0.00006181282],"about_ca_topic_score_codex":0.00012788828,"about_ca_topic_score_gemma":0.0000063665448,"teacher_disagreement_score":0.23839556,"about_ca_system_score_codex":0.0001345861,"about_ca_system_score_gemma":0.0017787585,"threshold_uncertainty_score":0.42930922},"labels":[],"label_agreement":null},{"id":"W2590619154","doi":"10.1200/jco.2015.33.7_suppl.412","title":"Renal nephrometry score and predictors of pathologic upstaging in patients undergoing partial and radical nephrectomies.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Nephrectomy; Malignancy; Renal sinus; Exact test; Radiology; Renal capsule; Adipose capsule of kidney; Surgery; Urology; Kidney; Internal medicine","score_opus":0.12409944290767404,"score_gpt":0.39380111749688407,"score_spread":0.26970167458921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590619154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970176,0.0010770602,0.00003192134,0.0008384283,0.00044521713,0.00017477572,0.0000015545913,0.0000049276514,0.00040851414],"genre_scores_gemma":[0.9964169,0.00044245474,0.002389646,0.000333728,0.00038786652,9.72039e-7,0.00000192263,0.000011323065,0.000015174784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968834,0.0004927764,0.0018184233,0.00019393499,0.00039970293,0.00021175397],"domain_scores_gemma":[0.9965016,0.0015914211,0.0010423567,0.00012013586,0.00021029508,0.00053417066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002764082,0.00013637175,0.0012878196,0.00024062209,0.00001671381,0.0000064627843,0.00007298955,0.00029868612,0.00001254305],"category_scores_gemma":[0.0047295103,0.00009211315,0.00018433714,0.00015234506,0.0004364956,0.00010566439,0.00009494105,0.0006801053,9.891264e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041568563,0.00069667294,0.972837,0.00003436008,0.00013329911,0.0008729316,0.00020638763,0.000012816145,0.000048479753,0.00001693753,0.00029692418,0.02068734],"study_design_scores_gemma":[0.018146686,0.021389877,0.95798784,0.0001766158,0.0002877836,0.0003890351,0.00014355667,0.00006368576,0.00009478805,0.0002906602,0.0009596016,0.000069884576],"about_ca_topic_score_codex":0.000010604666,"about_ca_topic_score_gemma":0.00001178735,"teacher_disagreement_score":0.020693203,"about_ca_system_score_codex":0.00017492086,"about_ca_system_score_gemma":0.0009343204,"threshold_uncertainty_score":0.5662007},"labels":[],"label_agreement":null},{"id":"W2590621732","doi":"10.1200/jco.2011.29.7_suppl.59","title":"Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"TMPRSS2; Prostate cancer; Medicine; Docetaxel; PCA3; Oncology; Internal medicine; Cytarabine; Cancer; Prostate; Mitoxantrone; Cancer research; Leukemia; Chemotherapy","score_opus":0.4058045400873943,"score_gpt":0.5760165026994505,"score_spread":0.17021196261205618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590621732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938072,0.0010953306,0.0000044950248,0.0031656285,0.00053760695,0.0012115747,0.000120465345,0.0000038023254,0.000053912325],"genre_scores_gemma":[0.98836243,0.009137691,0.0015546528,0.00036822935,0.00019811996,0.00005935862,0.00001010722,0.000016773603,0.00029261893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934254,0.0010350613,0.0044992245,0.00037637862,0.00029634574,0.00036758074],"domain_scores_gemma":[0.9952987,0.0011798425,0.002094744,0.00024314248,0.0006415593,0.0005420102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004687501,0.00020619907,0.0026347875,0.00083972345,0.000024968358,0.0000053513613,0.00014299645,0.00044385658,0.0002240534],"category_scores_gemma":[0.0026274624,0.00013955282,0.00034173785,0.0009889981,0.0007574417,0.00020828756,0.000103245075,0.0008751166,9.2833767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1711747,0.005650754,0.6421304,0.0000608198,0.0013775678,0.0003294689,0.0013255253,0.000024737936,0.0032689688,0.0000067432056,0.00017156042,0.17447878],"study_design_scores_gemma":[0.14892296,0.059184134,0.78500116,0.0003088542,0.0012197489,0.000012409454,0.00014926266,0.00024187689,0.0018232751,0.00015684382,0.0028211349,0.00015831736],"about_ca_topic_score_codex":0.0020301477,"about_ca_topic_score_gemma":0.004489597,"teacher_disagreement_score":0.17432047,"about_ca_system_score_codex":0.00017846243,"about_ca_system_score_gemma":0.0034250559,"threshold_uncertainty_score":0.6075902},"labels":[],"label_agreement":null},{"id":"W2590623229","doi":"10.1200/jco.2013.31.31_suppl.103","title":"Coordinating cancer care: Measurement and intervention approaches across the cancer continuum.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Psychological intervention; CINAHL; MEDLINE; Health care; Cochrane Library; Family medicine; PsycINFO; Nursing; Meta-analysis; Pathology","score_opus":0.3068526267094702,"score_gpt":0.423112632168434,"score_spread":0.11626000545896376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590623229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9316108,0.04006144,0.000810063,0.015084504,0.0033416098,0.00029056857,0.000028810573,0.0000065428326,0.00876562],"genre_scores_gemma":[0.9939857,0.0029407514,0.0003036257,0.0012099401,0.0012302368,0.000046862846,3.5564344e-7,0.00001495271,0.00026754718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99698687,0.00009000577,0.0023594238,0.00022378674,0.00006351747,0.00027639838],"domain_scores_gemma":[0.9958879,0.00031923046,0.0031256797,0.00014814048,0.000362156,0.00015693116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004988188,0.00012727798,0.0009993176,0.00004724893,0.00011321306,0.00008731109,0.00030168655,0.00022684131,0.00030138897],"category_scores_gemma":[0.0016832398,0.00009359396,0.00033145692,0.000069316884,0.0002504757,0.000410302,0.00009491213,0.00057157554,0.000030470657],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111219364,0.00016131747,0.26029176,0.000037254096,0.0002842706,0.0000025945965,0.0011514097,0.00005585974,0.0000043779696,0.0034431422,0.00842568,0.7260311],"study_design_scores_gemma":[0.003220377,0.0009721872,0.69949585,0.000095537325,0.00004615527,0.000009991956,0.0014851065,0.0003793708,0.000025242873,0.006996365,0.28708205,0.00019172532],"about_ca_topic_score_codex":0.0019803895,"about_ca_topic_score_gemma":0.0019427813,"teacher_disagreement_score":0.7258394,"about_ca_system_score_codex":0.00035289864,"about_ca_system_score_gemma":0.00020916968,"threshold_uncertainty_score":0.38166508},"labels":[],"label_agreement":null},{"id":"W2590624293","doi":"10.1200/jco.2013.31.26_suppl.34","title":"Transglutaminase II expression in invasive ductal carcinomas.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Stromal cell; Stroma; Medicine; Ductal carcinoma; Breast cancer; Tissue transglutaminase; Immunohistochemistry; Oncology; Hazard ratio; Proportional hazards model; Cancer; Pathology; Metastasis; Internal medicine; Cancer research; Pathological; Biology; Enzyme; Confidence interval","score_opus":0.08682712326099494,"score_gpt":0.41587286121636224,"score_spread":0.3290457379553673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590624293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840286,0.000940604,0.000033444507,0.008556751,0.0014178955,0.00022827041,9.1464545e-7,0.0000053492117,0.0047882227],"genre_scores_gemma":[0.99214864,0.0007929529,0.0026941546,0.002771211,0.0012216427,0.000005687662,0.0000015164296,0.0000117900645,0.00035241892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715585,0.00030156647,0.0018947329,0.0001527909,0.00026697226,0.00022807343],"domain_scores_gemma":[0.9974497,0.0009798454,0.0007142617,0.00015685511,0.00026545525,0.00043385886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001361931,0.00011402317,0.0012153817,0.00016984425,0.000029312887,0.0000047804,0.00013595368,0.00034727322,0.00064240897],"category_scores_gemma":[0.0038311523,0.00007511592,0.00037578697,0.00012926795,0.00016660252,0.00023565326,0.00004423774,0.00086131494,0.0000446068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005490964,0.00913436,0.6451988,0.00013943441,0.00019245167,0.0028092214,0.0025154187,0.000019562458,0.04245506,0.00020384025,0.054250713,0.23759016],"study_design_scores_gemma":[0.015161813,0.006568246,0.9346959,0.00012078731,0.00014677273,0.00039308923,0.00095612695,0.000018257422,0.0016523526,0.00075896335,0.039419364,0.00010830619],"about_ca_topic_score_codex":0.00005397823,"about_ca_topic_score_gemma":0.00004187596,"teacher_disagreement_score":0.2894971,"about_ca_system_score_codex":0.000044076718,"about_ca_system_score_gemma":0.0013046814,"threshold_uncertainty_score":0.70339274},"labels":[],"label_agreement":null},{"id":"W2590626129","doi":"10.1200/jco.2016.34.2_suppl.306","title":"Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Aspirin; Prostate cancer; Prostate; Hazard ratio; Incidence (geometry); Internal medicine; Cancer; Proportional hazards model; Population; Oncology; Prospective cohort study; Confidence interval","score_opus":0.05379459073905654,"score_gpt":0.42328020216635576,"score_spread":0.3694856114272992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590626129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98282284,0.0037576559,0.000053387408,0.01046524,0.002547346,0.00029197696,0.000018496765,6.937901e-7,0.00004238588],"genre_scores_gemma":[0.9713765,0.020747712,0.0000939796,0.0017662878,0.0058531966,0.000011114758,3.884176e-7,0.000007984443,0.00014285589],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964261,0.0019451834,0.0011356882,0.00015249947,0.00017572353,0.0001648298],"domain_scores_gemma":[0.9972851,0.00080262014,0.0014514955,0.00023443406,0.00016461745,0.000061708306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006286621,0.00009017206,0.0006798842,0.000026885322,0.000038085524,0.0000074828554,0.00023161054,0.00011792116,0.000004136363],"category_scores_gemma":[0.0014149684,0.00003692929,0.00021680104,0.000061669896,0.00046745007,0.00000911857,0.00006327859,0.00031554248,3.2606818e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084743155,0.0014086294,0.29430637,0.000019778028,0.0005385123,0.0000036071501,0.0017687853,0.00004364543,0.0038227672,0.00026138205,0.02111731,0.6682349],"study_design_scores_gemma":[0.0111962035,0.004258502,0.57199615,0.000048402595,0.00011921661,0.000021920134,0.0006588591,0.0000030738609,0.00014756153,0.00035001468,0.4111319,0.00006816915],"about_ca_topic_score_codex":0.00036287063,"about_ca_topic_score_gemma":0.0016790727,"teacher_disagreement_score":0.6681667,"about_ca_system_score_codex":0.000016887143,"about_ca_system_score_gemma":0.0006406848,"threshold_uncertainty_score":0.217883},"labels":[],"label_agreement":null},{"id":"W2590627534","doi":"10.1200/jco.2013.31.26_suppl.128","title":"Impact of physician and center case volume on the adequacy of cardiac monitoring during adjuvant trastuzumab in breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Kingston General Hospital; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto; University Health Network; St. Michael's Hospital","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Internal medicine; Breast cancer; Cohort; Heart failure; Cancer; Logistic regression; Adjuvant; Oncology; Chemotherapy","score_opus":0.03950603007809151,"score_gpt":0.4049740595912906,"score_spread":0.3654680295131991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590627534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758303,0.00092901464,9.604489e-7,0.0009597093,0.0002900007,0.000104323575,0.00004507468,7.196498e-7,0.00008715091],"genre_scores_gemma":[0.99741113,0.0018431474,0.000043458895,0.00004442007,0.000629898,0.000008656966,6.4419544e-7,0.000009740202,0.0000088951265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852777,0.00023531592,0.0008335606,0.0001330849,0.00010771176,0.00016256474],"domain_scores_gemma":[0.9985386,0.0002539828,0.0007978488,0.0001377543,0.0001909898,0.00008078397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035987314,0.00011832022,0.0007071458,0.000038063663,0.000027152786,0.0000035870041,0.00010114058,0.00012542984,0.0000129548735],"category_scores_gemma":[0.00013561927,0.000070173504,0.00033427268,0.000053201395,0.00017642142,0.000009214764,0.00006790065,0.00023676569,6.8800233e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010271285,0.00063091004,0.9240868,0.00001784843,0.0006637473,0.000052095096,0.00012687499,0.00006449645,0.01042888,0.0000015798743,0.00024411442,0.0626555],"study_design_scores_gemma":[0.0018319632,0.001767337,0.9936445,0.00009657096,0.00006900911,0.0002352595,0.00029179477,0.000006167494,0.0019215,0.000011555495,0.00006504898,0.0000592945],"about_ca_topic_score_codex":0.0007197278,"about_ca_topic_score_gemma":0.000051906627,"teacher_disagreement_score":0.069557674,"about_ca_system_score_codex":0.00008883515,"about_ca_system_score_gemma":0.000265973,"threshold_uncertainty_score":0.28615925},"labels":[],"label_agreement":null},{"id":"W2590629622","doi":"10.1200/jco.2016.34.7_suppl.124","title":"Clinical specialist radiation therapists (CSRT): Creating capacity while improving quality of care.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ministry of Health and Long Term Care; Cancer Care Ontario","funders":"","keywords":"Radiation Therapist; Medicine; Referral; Accreditation; Health care; Quality (philosophy); Population; Quality management; Nursing; Radiation therapy; Family medicine; Medical emergency; Medical education; Service (business); Environmental health; Business; Surgery","score_opus":0.16524291769392002,"score_gpt":0.5529957947020743,"score_spread":0.38775287700815425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590629622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97026056,0.001901026,0.007919595,0.004667946,0.0059269513,0.00026130295,0.000014103937,0.000017435039,0.00903106],"genre_scores_gemma":[0.9605015,0.0037189086,0.024038995,0.0019105317,0.009550646,0.000002255108,0.0000016315348,0.000021049504,0.00025451678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.992243,0.0018619049,0.00497931,0.00027006722,0.00039045772,0.00025523847],"domain_scores_gemma":[0.9793467,0.013659678,0.005513533,0.00032967728,0.000817048,0.00033339488],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0096336715,0.00016362332,0.0023797792,0.000096401294,0.000078248406,0.0000039517035,0.00023977937,0.0008173232,0.00032926176],"category_scores_gemma":[0.016975364,0.00009414298,0.00091912807,0.00011578817,0.0010422205,0.00019609512,0.000035976645,0.001007401,0.000008502513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005195822,0.00086817966,0.35374436,0.000051978925,0.0002784134,0.000047990186,0.00023046689,0.0000018256834,0.0016342242,0.0006248357,0.0006400285,0.6366819],"study_design_scores_gemma":[0.01714828,0.0186604,0.8419583,0.0002262549,0.00022511298,0.00015862766,0.00025689078,0.000012712234,0.000506264,0.0011590517,0.119524926,0.0001631735],"about_ca_topic_score_codex":0.000026448994,"about_ca_topic_score_gemma":0.00006807473,"teacher_disagreement_score":0.6365187,"about_ca_system_score_codex":0.00037737231,"about_ca_system_score_gemma":0.001768417,"threshold_uncertainty_score":0.99130505},"labels":[],"label_agreement":null},{"id":"W2590630896","doi":"10.1200/jco.2016.34.26_suppl.95","title":"Evaluating the prognostic effect of a pain classification system in patients with advanced cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer pain; Referral; Cancer; Palliative care; Distress; Internal medicine; Morphine; Opioid; Pain control; Physical therapy; Anesthesia; Family medicine; Clinical psychology","score_opus":0.10677873606685097,"score_gpt":0.48605928103322993,"score_spread":0.379280544966379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590630896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962981,0.00009308003,0.00027222902,0.0022171426,0.00027280865,0.0005966199,5.8192416e-7,0.000004388586,0.00024504602],"genre_scores_gemma":[0.99893856,0.00005512321,0.0005680326,0.00018870365,0.00018081888,0.000021342135,4.6540907e-7,0.000007201828,0.000039729734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644357,0.0017229363,0.0012590021,0.000101673875,0.00035171089,0.000121114324],"domain_scores_gemma":[0.98915875,0.008698443,0.0016364986,0.00014029926,0.00029616442,0.00006981958],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01234672,0.00007285334,0.00070095266,0.00007044087,0.000016186379,0.0000019392653,0.00011263693,0.00009331424,0.000010225772],"category_scores_gemma":[0.012250685,0.000027526685,0.00011306593,0.00012741925,0.000098180586,0.000054584652,0.000017473321,0.00024778573,0.0000020448445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052048094,0.00018162327,0.65929246,0.000087763605,0.00006744333,0.000006395417,0.000018229459,0.000010888779,0.000080012804,0.000024724972,0.00007639308,0.33494925],"study_design_scores_gemma":[0.012629716,0.033569828,0.9509626,0.0013077243,0.0002555638,8.410376e-7,0.0000559472,0.0007211452,0.000014608779,0.000009928774,0.00043913638,0.000032965276],"about_ca_topic_score_codex":0.0000036602833,"about_ca_topic_score_gemma":0.000011086743,"teacher_disagreement_score":0.3349163,"about_ca_system_score_codex":0.00016523708,"about_ca_system_score_gemma":0.00034604332,"threshold_uncertainty_score":0.99606955},"labels":[],"label_agreement":null},{"id":"W2590632696","doi":"10.1200/jco.2013.31.6_suppl.299","title":"Using micro-RNA expression to predict response to neoadjuvant chemotherapy in urothelial carcinoma of the bladder.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"microRNA; Medicine; Chemotherapy; Bladder cancer; Oncology; Pathological; Gene expression; Cancer research; Carcinoma; Internal medicine; Gene; Cancer; Biology; Genetics","score_opus":0.10354131106993009,"score_gpt":0.442964800491746,"score_spread":0.33942348942181594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590632696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98162055,0.00013228197,0.00012997052,0.015846241,0.0009836251,0.00077613106,0.000007018661,0.0000038779895,0.00050027866],"genre_scores_gemma":[0.9857085,0.000039330745,0.0059521776,0.007218281,0.00074028684,0.000010337934,1.8362145e-7,0.000024795367,0.00030614308],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99664885,0.0006747123,0.0018276647,0.00019949807,0.00038808715,0.0002612076],"domain_scores_gemma":[0.99740237,0.00080481067,0.00073510065,0.00031815513,0.00032399318,0.0004155765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017336115,0.00015478733,0.001104257,0.0001714521,0.000032210544,0.000007271975,0.00027619366,0.00026961885,0.00030281738],"category_scores_gemma":[0.001677532,0.00008852896,0.00038241723,0.00024065381,0.00010761897,0.00007553087,0.00008747467,0.00055850577,0.000016677073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049711447,0.0022980687,0.26178545,0.00002336006,0.00020401152,0.00019466171,0.0013017426,0.00010939749,0.6030101,0.0000025556203,0.009153016,0.072206184],"study_design_scores_gemma":[0.014226691,0.012722364,0.8979188,0.00035680956,0.00012397599,0.00016792153,0.0001785885,0.000048039186,0.06198522,0.00008867602,0.012084072,0.00009880188],"about_ca_topic_score_codex":0.00022577423,"about_ca_topic_score_gemma":0.000021303555,"teacher_disagreement_score":0.6361334,"about_ca_system_score_codex":0.0002310319,"about_ca_system_score_gemma":0.0018526558,"threshold_uncertainty_score":0.36101064},"labels":[],"label_agreement":null},{"id":"W2590634444","doi":"10.1200/jco.2012.30.4_suppl.17","title":"The impact of HER2 positivity on survival in metastatic gastric and GEJ cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cancer; Gastroenterology; Adenocarcinoma; Oncology","score_opus":0.162857628749293,"score_gpt":0.526177269544465,"score_spread":0.363319640795172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590634444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243563,0.0010479849,0.000028375844,0.003904821,0.00073752785,0.000118295786,0.0000019694635,0.0000015358036,0.0017238517],"genre_scores_gemma":[0.99700856,0.0018914208,0.00020227414,0.00027269978,0.00048431868,0.0000014465626,2.412828e-7,0.00000559836,0.0001334665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804246,0.0003902382,0.0010594154,0.00006501411,0.00022617495,0.0002166947],"domain_scores_gemma":[0.99533176,0.0033870698,0.00089751225,0.000095528805,0.000093288225,0.00019486102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043405932,0.000082380815,0.00090731325,0.000103967686,0.000020427315,0.0000043014265,0.00007717864,0.00006423413,0.000047457474],"category_scores_gemma":[0.001618198,0.000041736235,0.00029311597,0.00016422904,0.00012743406,0.0000749344,0.00003510264,0.000498404,0.000001683741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023007875,0.0006293843,0.86133146,0.0000130015005,0.00030769224,0.000048193822,0.000042782984,0.00002201366,0.000016145728,0.00009468833,0.0013637783,0.13383006],"study_design_scores_gemma":[0.0039793365,0.006310492,0.9870784,0.000040521052,0.00022689068,0.000056316636,0.00009168987,0.000038405895,0.000005485458,0.000091419584,0.0020497816,0.000031230287],"about_ca_topic_score_codex":0.00031542053,"about_ca_topic_score_gemma":0.00015753257,"teacher_disagreement_score":0.13379882,"about_ca_system_score_codex":0.00016308784,"about_ca_system_score_gemma":0.0004468547,"threshold_uncertainty_score":0.21653451},"labels":[],"label_agreement":null},{"id":"W2590634522","doi":"10.1200/jco.2014.32.31_suppl.209","title":"PROMs from hospital to hospice.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Constipation; Palliative care; Anorexia; Quality of life (healthcare); Psychological intervention; Prospective cohort study; Physical therapy; Internal medicine; Nursing","score_opus":0.0704040609320153,"score_gpt":0.45368784730590017,"score_spread":0.3832837863738849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590634522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517902,0.00016123096,0.0009524021,0.03116498,0.0061981506,0.00012896213,0.0000027317496,0.0000108362165,0.00959049],"genre_scores_gemma":[0.9812493,0.00006411082,0.002541835,0.009953976,0.005716056,0.000002751602,0.0000016053378,0.000013522753,0.00045685956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778277,0.00021504531,0.0013496046,0.00015874207,0.00032190798,0.00017192407],"domain_scores_gemma":[0.99695545,0.0011859854,0.00068451086,0.00020590052,0.00037743474,0.0005906952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018437804,0.00009392902,0.0010870516,0.000060829763,0.000018335248,0.000007906971,0.00016613938,0.00028492525,0.00032216363],"category_scores_gemma":[0.0040932707,0.00006578219,0.0004237767,0.000099427874,0.000073488154,0.000055907356,0.000046877096,0.00071465084,0.00011636869],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025709358,0.0013302838,0.2413039,0.000015711194,0.00028722483,0.00029048804,0.0007070371,0.000003207413,0.00018529485,0.00024303033,0.040381256,0.7126816],"study_design_scores_gemma":[0.002659982,0.019002069,0.4024303,0.000064436754,0.00016182497,0.000026081028,0.000144994,0.000010360195,0.00008859159,0.00059477706,0.5747444,0.00007215868],"about_ca_topic_score_codex":0.00013829784,"about_ca_topic_score_gemma":0.0002434151,"teacher_disagreement_score":0.71260947,"about_ca_system_score_codex":0.000078992525,"about_ca_system_score_gemma":0.0005759776,"threshold_uncertainty_score":0.4900323},"labels":[],"label_agreement":null},{"id":"W2590639172","doi":"10.1200/jco.2014.32.4_suppl.21","title":"Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Post-hoc analysis; Prostate cancer; Internal medicine; Discontinuation; Prednisone; Population; Oncology; Androgen deprivation therapy; Cancer; Gastroenterology; Urology; Androgen receptor","score_opus":0.07136008729815171,"score_gpt":0.44600169250982996,"score_spread":0.3746416052116782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590639172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957459,0.00040760665,0.000009379693,0.0021307361,0.000071393064,0.0015485086,0.000053679083,0.000008972827,0.000023815528],"genre_scores_gemma":[0.99778664,0.0003564733,0.00091631454,0.00040369033,0.000050030918,0.0001450101,0.000017200491,0.000030779924,0.00029386958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516124,0.0015465899,0.0017975988,0.00036343685,0.0007668482,0.0003643136],"domain_scores_gemma":[0.99581885,0.0010183052,0.001119654,0.0002778645,0.001343374,0.00042194332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026372725,0.00027364588,0.0020994488,0.00066219096,0.000047547644,0.000021989625,0.00011338105,0.00009877509,0.00014834279],"category_scores_gemma":[0.00027838894,0.0001421495,0.0002416039,0.00094648503,0.00016966663,0.00012267908,0.000021987324,0.00033046797,0.0000035987136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45054254,0.0067407466,0.50278383,0.00001691567,0.0068023703,0.0008734965,0.002521387,0.0005640646,0.0016242499,3.3024295e-7,0.000014184136,0.02751586],"study_design_scores_gemma":[0.050913785,0.22836633,0.7154357,0.00015711618,0.0027221157,0.000010740532,0.00064989715,0.00009711168,0.00084014697,0.000004065508,0.0006644513,0.0001385377],"about_ca_topic_score_codex":0.00040949465,"about_ca_topic_score_gemma":0.0031222238,"teacher_disagreement_score":0.39962876,"about_ca_system_score_codex":0.00055130647,"about_ca_system_score_gemma":0.0021124284,"threshold_uncertainty_score":0.5796688},"labels":[],"label_agreement":null},{"id":"W2590652784","doi":"10.1200/jco.2005.23.16_suppl.3645","title":"Impact of obesity on presentation of colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Body mass index; Colorectal cancer; Underweight; Overweight; Cancer; Obesity; Internal medicine; Cohort; Prospective cohort study; Incidence (geometry)","score_opus":0.14191550682188928,"score_gpt":0.5644302286771337,"score_spread":0.4225147218552444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590652784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643004,0.00019041203,0.000018096931,0.0013326252,0.00047197,0.00009953807,0.000010257627,0.0000018409577,0.001445206],"genre_scores_gemma":[0.99772376,0.0007484228,0.00041051165,0.00017941918,0.00086351915,7.825253e-7,8.3209e-7,0.000005749244,0.00006702004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980442,0.00012065967,0.0014123803,0.000072430565,0.0002526255,0.00009769268],"domain_scores_gemma":[0.9969123,0.00081103586,0.0016759166,0.000073726274,0.00036025775,0.0001667798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008411001,0.00006511556,0.00095937296,0.00008320112,0.000008516567,0.0000010230858,0.00006770929,0.0001862741,0.00047885667],"category_scores_gemma":[0.0009144371,0.000041109623,0.00057390303,0.00008272179,0.00013002608,0.000056795525,0.000013046942,0.00042602784,0.0000027253022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008966595,0.002031479,0.84630126,0.000016026488,0.0003479536,0.000018057497,0.00012917639,0.0004158418,0.0019197714,0.000019492272,0.004695002,0.13513938],"study_design_scores_gemma":[0.0042968607,0.020444075,0.9699501,0.000063836356,0.0001891693,0.000027359336,0.000023497234,0.00012546909,0.0016977896,0.000032320273,0.003117852,0.000031704887],"about_ca_topic_score_codex":0.00040977504,"about_ca_topic_score_gemma":0.0002062976,"teacher_disagreement_score":0.13510767,"about_ca_system_score_codex":0.00022280081,"about_ca_system_score_gemma":0.0014494859,"threshold_uncertainty_score":0.52431446},"labels":[],"label_agreement":null},{"id":"W2590656741","doi":"10.1200/jco.2015.33.7_suppl.281","title":"A retrospective analysis of clinical factors influencing response to treatment with cabazitaxel in patients with metastatic castration resistant prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; London Health Sciences Centre; Grand River Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Taxane; Prostate-specific antigen; Cancer; Urology; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.17530298368492458,"score_gpt":0.5108860198869127,"score_spread":0.33558303620198815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590656741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975491,0.0001310506,0.000012753111,0.0013017725,0.0001344368,0.00072435575,0.000055701075,0.0000042880242,0.000086512686],"genre_scores_gemma":[0.9976477,0.00013655161,0.0018147404,0.00010856214,0.00006683943,0.000020339106,0.000012573431,0.00001616645,0.00017652517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948832,0.0011052594,0.002587106,0.00030406102,0.0008330817,0.00028733784],"domain_scores_gemma":[0.994182,0.0012997655,0.0018429813,0.00023114787,0.0017498615,0.0006942399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044406937,0.00019148734,0.0025163414,0.0006309556,0.000026442873,0.000009894919,0.00009534463,0.0001437883,0.000019818315],"category_scores_gemma":[0.0028538306,0.00009735675,0.00032527873,0.0011429499,0.00023539961,0.000147309,0.000024050298,0.0005335641,0.0000011016831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2019964,0.002326371,0.78411597,0.000010408945,0.0034984683,0.00044305305,0.0015457899,0.00037179323,0.0000353108,0.0000019551078,0.000030311083,0.0056241457],"study_design_scores_gemma":[0.026228053,0.12572561,0.8436918,0.0001491192,0.0026286205,0.000004072412,0.0010523953,0.000040004277,0.00006113848,0.000010969067,0.0003254441,0.00008272504],"about_ca_topic_score_codex":0.00064785284,"about_ca_topic_score_gemma":0.0036346642,"teacher_disagreement_score":0.17576836,"about_ca_system_score_codex":0.0016138338,"about_ca_system_score_gemma":0.0071275653,"threshold_uncertainty_score":0.9985011},"labels":[],"label_agreement":null},{"id":"W2590658581","doi":"10.1200/jco.2015.33.3_suppl.600","title":"Dual role of <i>TGFBR1 </i>as a modifier of colorectal cancer risk.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Genotype; Single-nucleotide polymorphism; Internal medicine; Oncology; Haplotype; Case-control study; Stage (stratigraphy); Cancer; Gastroenterology; Gene; Genetics; Biology","score_opus":0.06732602064900257,"score_gpt":0.4378752797040927,"score_spread":0.3705492590550901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590658581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422115,0.0033128322,0.00006402193,0.00015157199,0.0006854203,0.000076615645,0.000032573807,0.000002343719,0.0014534796],"genre_scores_gemma":[0.9970374,0.00043893818,0.0013622636,0.00019179781,0.0008454778,0.0000036225208,0.00000473375,0.00001559791,0.00010018658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971677,0.00045901022,0.0017178145,0.0001699292,0.00031096378,0.00017458177],"domain_scores_gemma":[0.99589115,0.00036255652,0.0024033934,0.00017430009,0.0008371007,0.00033146603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018940896,0.00011983976,0.0008098072,0.000052510473,0.000016784856,0.000003148557,0.00027996104,0.00042024508,0.000053672444],"category_scores_gemma":[0.004917313,0.00009552523,0.0004151886,0.000072765375,0.0003417808,0.0000064576266,0.00011782278,0.00033900986,0.0000047237363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024378758,0.00532403,0.39859486,0.000056919536,0.0019988474,0.0001218323,0.0005424797,0.005128269,0.45475996,0.00015084501,0.020477183,0.08846602],"study_design_scores_gemma":[0.014625072,0.035847746,0.096366554,0.00012305721,0.00092940393,0.00020874261,0.0009070877,0.00030874836,0.6015987,0.0024559742,0.24616393,0.00046499443],"about_ca_topic_score_codex":0.000097057164,"about_ca_topic_score_gemma":0.00007158204,"teacher_disagreement_score":0.3022283,"about_ca_system_score_codex":0.000028227485,"about_ca_system_score_gemma":0.003003271,"threshold_uncertainty_score":0.5886838},"labels":[],"label_agreement":null},{"id":"W2590660342","doi":"10.1200/jco.2013.31.6_suppl.42","title":"Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Myocardial infarction; Prostate cancer; Proportional hazards model; Hazard ratio; Cancer; Confidence interval","score_opus":0.07728898096749841,"score_gpt":0.40521253656954564,"score_spread":0.3279235556020472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590660342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980474,0.00082231744,0.000012410028,0.00027353113,0.000059868966,0.00047353248,0.0000044277867,0.0000014664812,0.00030502962],"genre_scores_gemma":[0.99837035,0.0009867472,0.0005215344,0.00003366056,0.00003295981,0.0000042458673,0.0000027569363,0.000008625832,0.000039092363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767584,0.00050533225,0.001049744,0.00012237177,0.00049918686,0.00014755577],"domain_scores_gemma":[0.9975445,0.00046999464,0.00095920614,0.00020700834,0.0006613334,0.00015795146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000990814,0.0001003312,0.0013420541,0.00008411424,0.000026421087,0.0000026089479,0.000109777946,0.00012789045,0.000015914748],"category_scores_gemma":[0.00029432296,0.00004187296,0.00024720942,0.00016238842,0.00023856295,0.000057828835,0.000043234417,0.0005090621,8.892961e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007224623,0.0014800808,0.97999996,0.000033799843,0.0013735726,0.000027935563,0.00006877347,0.000107403335,0.000006152124,0.0000016293686,0.00013580563,0.0095402645],"study_design_scores_gemma":[0.0243309,0.0134477075,0.9602844,0.00031188148,0.0007030239,0.000022033548,0.000059014314,0.000096604475,0.00015615179,0.00003362105,0.00051351055,0.0000411639],"about_ca_topic_score_codex":0.0006022454,"about_ca_topic_score_gemma":0.00005331148,"teacher_disagreement_score":0.019715572,"about_ca_system_score_codex":0.00008995099,"about_ca_system_score_gemma":0.00049295864,"threshold_uncertainty_score":0.22116497},"labels":[],"label_agreement":null},{"id":"W2590660749","doi":"10.1200/jco.2013.31.26_suppl.174","title":"Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Eribulin; Medicine; Metastatic breast cancer; Anthracycline; Discontinuation; Internal medicine; Oncology; Breast cancer; Toxicity; Cancer; Surgery","score_opus":0.11903135798488274,"score_gpt":0.5668154112911684,"score_spread":0.4477840533062857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590660749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815689,0.00006791869,0.000011616821,0.015869591,0.00018184815,0.0006185415,0.00006897892,0.0000048567244,0.0016078044],"genre_scores_gemma":[0.9908587,0.0005685281,0.0068355617,0.0010864105,0.00016866464,0.00007488532,0.000032327396,0.000016705395,0.00035824376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927034,0.0029718995,0.0034923702,0.00021799345,0.00028582613,0.0003285039],"domain_scores_gemma":[0.992708,0.0037495361,0.0022600845,0.00032296107,0.0005181779,0.00044122493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036782385,0.0002249932,0.003904334,0.0012163139,0.000025613685,0.0000043327072,0.00024281212,0.00025151006,0.004452164],"category_scores_gemma":[0.0002486002,0.0001629733,0.0005884451,0.0012380636,0.00021462658,0.00012631652,0.00007367981,0.0010131502,0.000010617501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004574214,0.029221727,0.8165567,0.00006204432,0.0058977692,0.00035002286,0.001334531,0.0023804626,0.0038837222,0.00001831331,0.0019545231,0.13376598],"study_design_scores_gemma":[0.012467541,0.030649278,0.94536424,0.00010147632,0.004671334,0.000048450944,0.00045160932,0.0019907583,0.000092068854,0.000058848516,0.003994764,0.00010962231],"about_ca_topic_score_codex":0.018582378,"about_ca_topic_score_gemma":0.09178293,"teacher_disagreement_score":0.13365635,"about_ca_system_score_codex":0.0018987393,"about_ca_system_score_gemma":0.0034075973,"threshold_uncertainty_score":0.9964579},"labels":[],"label_agreement":null},{"id":"W2590661078","doi":"10.1200/jco.2014.32.4_suppl.12","title":"Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Prostate cancer; Placebo; Internal medicine; Clinical endpoint; Androgen deprivation therapy; Oncology; Brief Pain Inventory; Quality of life (healthcare); Cancer; Urology; Osteoporosis; Randomized controlled trial; Physical therapy; Pathology","score_opus":0.1448658092322055,"score_gpt":0.44536533747876084,"score_spread":0.30049952824655535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590661078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993751,0.0028618649,0.00011105624,0.0024870536,0.00017854055,0.0004979053,0.000042688993,0.0000049793707,0.00006492497],"genre_scores_gemma":[0.9924679,0.0047730342,0.00087926566,0.001694367,0.00009394695,0.00001873913,0.000003994587,0.000019360232,0.000049434137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948668,0.00171073,0.0023347037,0.00030564397,0.0005178535,0.00026427594],"domain_scores_gemma":[0.9949726,0.0019125302,0.0020985403,0.00023277312,0.00036224144,0.00042134558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00600246,0.00021629703,0.0018082364,0.00017537667,0.000028566501,0.000016361557,0.000121361336,0.00010984763,0.00019166553],"category_scores_gemma":[0.0024242802,0.00012827832,0.00011591603,0.00015201293,0.00039909547,0.00011339501,0.000047818674,0.000554953,7.596231e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12957874,0.003382961,0.49041647,0.00037185458,0.0005926375,0.000117211806,0.00027552136,0.000023763067,0.00013957817,0.00012115982,0.0007106926,0.37426943],"study_design_scores_gemma":[0.031366497,0.031962708,0.9311107,0.0005548855,0.00024851118,0.0000035921978,0.00026668955,0.000069886075,0.000054348617,0.00011500647,0.004094532,0.00015269192],"about_ca_topic_score_codex":0.00021951429,"about_ca_topic_score_gemma":0.001115717,"teacher_disagreement_score":0.44069418,"about_ca_system_score_codex":0.00011456045,"about_ca_system_score_gemma":0.001013856,"threshold_uncertainty_score":0.5231038},"labels":[],"label_agreement":null},{"id":"W2590661131","doi":"10.1200/jco.2016.34.3_suppl.249","title":"Impact of yoga on quality of life for young adult noncurative cancer patients: A pilot study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University","funders":"","keywords":"Medicine; Hatha yoga; Quality of life (healthcare); Cancer; Physical therapy; Palliative care; Nursing; Internal medicine","score_opus":0.5415243966296345,"score_gpt":0.6459725372849764,"score_spread":0.10444814065534191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590661131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670106,0.00019974571,0.00017056802,0.0010898737,0.00068002153,0.00039026464,0.00011689654,0.0000024089293,0.0006491639],"genre_scores_gemma":[0.99763197,0.0008497133,0.0005444315,0.000330227,0.00054957933,0.000014005845,0.0000013090435,0.000010982738,0.000067797446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955654,0.00058366696,0.0031243816,0.00014585353,0.00041740478,0.00016328883],"domain_scores_gemma":[0.9839811,0.007904028,0.0043738508,0.0001644312,0.0033261168,0.00025047993],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020661126,0.00013267114,0.0021724459,0.00010357072,0.0000136284625,9.5139717e-7,0.00014294108,0.00014516492,0.00014590203],"category_scores_gemma":[0.032544084,0.00006687614,0.0006281787,0.00009978584,0.0002421391,0.00008477666,0.000028414044,0.00028298356,0.0000016880286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040070355,0.009537091,0.9302664,0.0000609906,0.0013098543,0.0000056152717,0.00078191713,0.0000026640037,0.00042091956,0.00007042579,0.0031955102,0.014278279],"study_design_scores_gemma":[0.02089007,0.17553638,0.80122125,0.00065535173,0.00026316431,7.445323e-7,0.0004150454,0.0000025811837,0.00027911644,0.00010842785,0.00056819397,0.000059671445],"about_ca_topic_score_codex":0.0005010908,"about_ca_topic_score_gemma":0.0003649574,"teacher_disagreement_score":0.1659993,"about_ca_system_score_codex":0.00020573685,"about_ca_system_score_gemma":0.0016064355,"threshold_uncertainty_score":0.9756052},"labels":[],"label_agreement":null},{"id":"W2590661915","doi":"10.1200/jco.2014.32.30_suppl.129","title":"CANES family health team EMR optimization pilot.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Workflow; Medicine; Health care; Best practice; Leverage (statistics); Standardization; Teamwork; Medical education; Nursing; Computer science; Artificial intelligence","score_opus":0.501833181321445,"score_gpt":0.6245548490820877,"score_spread":0.12272166776064264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590661915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47241724,0.0006638961,0.1953578,0.30217433,0.0093474565,0.00094823475,0.0000070969527,0.000075316224,0.019008629],"genre_scores_gemma":[0.80444413,0.0022264922,0.11833653,0.06971731,0.0049470607,0.0000028967243,0.00001702785,0.000031712447,0.00027682993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917134,0.0013372786,0.0059831953,0.00020306061,0.0005108226,0.0002522592],"domain_scores_gemma":[0.98440266,0.008714178,0.005020631,0.00025056797,0.0009860724,0.00062586507],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016223473,0.00012851121,0.0014631551,0.00013325924,0.000060375853,0.000012155821,0.00015093278,0.00022379133,0.00020540094],"category_scores_gemma":[0.05251897,0.00009632188,0.0003249705,0.00016483945,0.00013362816,0.00021913112,0.00004660156,0.0010632133,0.00004258368],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064146155,0.0032606116,0.034318715,0.00007288953,0.00025963105,0.00008416859,0.000085218984,0.0041540973,0.00008089487,0.00030235416,0.16732493,0.7836419],"study_design_scores_gemma":[0.020821834,0.0761779,0.20001684,0.00014797572,0.00055412314,0.00083601725,0.0004217148,0.013409123,0.000009641872,0.000647938,0.6867735,0.00018338724],"about_ca_topic_score_codex":0.00020206941,"about_ca_topic_score_gemma":0.00011389448,"teacher_disagreement_score":0.7834585,"about_ca_system_score_codex":0.00021091293,"about_ca_system_score_gemma":0.0033968363,"threshold_uncertainty_score":0.95546204},"labels":[],"label_agreement":null},{"id":"W2590664248","doi":"10.1200/jco.2015.33.3_suppl.531","title":"Measuring compliance to capecitabine in colon cancer: A comparison of administrative data and medical records.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Concordance; Colorectal cancer; Medical record; Internal medicine; Cohort; Medical prescription; Cancer; Pharmacy; Cancer registry; Population; Stage (stratigraphy); Surgery; Family medicine","score_opus":0.6944398190100649,"score_gpt":0.5311920557953064,"score_spread":0.16324776321475853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590664248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97269845,0.0049574184,0.0007283621,0.0100390585,0.0018879484,0.00015197623,0.00010780764,0.0000029052123,0.009426082],"genre_scores_gemma":[0.994413,0.0013616763,0.0027994805,0.0007764379,0.00055252353,0.0000035122232,0.0000018207234,0.000010135611,0.00008138303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957506,0.00009245255,0.0035632956,0.00027676512,0.00009871343,0.00021814414],"domain_scores_gemma":[0.99557364,0.00079279,0.0026135517,0.00025022912,0.00019870728,0.0005710562],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00656342,0.00011236469,0.0019652406,0.00015550927,0.000017353237,0.000012162688,0.0005969263,0.00028591722,0.00013324514],"category_scores_gemma":[0.010659884,0.00011111629,0.00008386515,0.00015323827,0.0002000744,0.00029257414,0.00019763596,0.0006195051,0.00001899741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013948289,0.0006323858,0.83506083,0.000022670212,0.000092494316,0.00003955633,0.0005868334,0.00007634451,0.000002162008,0.002357787,0.00920794,0.15052614],"study_design_scores_gemma":[0.008623891,0.009246158,0.566525,0.00035308106,0.000032788448,0.000043441843,0.0006691539,0.005934449,0.000024675839,0.0071963803,0.40103322,0.00031780038],"about_ca_topic_score_codex":0.00056425115,"about_ca_topic_score_gemma":0.004337789,"teacher_disagreement_score":0.3918253,"about_ca_system_score_codex":0.00022598635,"about_ca_system_score_gemma":0.0013836148,"threshold_uncertainty_score":0.99767375},"labels":[],"label_agreement":null},{"id":"W2590667525","doi":"10.1200/jco.2015.33.3_suppl.358","title":"Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Gastroenterology; Clinical endpoint; Veliparib; Hazard ratio; Surgery; Oncology; Confidence interval; Clinical trial; Adverse effect; Poly ADP ribose polymerase","score_opus":0.08617428512118895,"score_gpt":0.41329595975195843,"score_spread":0.32712167463076947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590667525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765193,0.00051741244,0.000046830482,0.0002593922,0.00065200083,0.00039922123,0.000028766313,0.0000024785727,0.00044198977],"genre_scores_gemma":[0.9973901,0.00068406627,0.00062552345,0.00035852866,0.0007493974,0.000008635755,0.000050006118,0.00002357784,0.00011016781],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99672,0.00038050723,0.0020902245,0.0002652194,0.00026594257,0.000278098],"domain_scores_gemma":[0.99648774,0.0003653788,0.0017479921,0.00027995784,0.0007224908,0.00039642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016661779,0.0001856307,0.0011364412,0.00009647766,0.000024955836,0.000008710307,0.00029410192,0.00044990136,0.000023410132],"category_scores_gemma":[0.004289056,0.00012734358,0.00023143631,0.00016465552,0.00018609645,0.000009253916,0.00012194174,0.0003642122,0.0000024086685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6708446,0.025655465,0.207995,0.000028881735,0.00072036113,0.0003214591,0.000239293,0.00021441984,0.0007164831,0.000019524947,0.013554177,0.07969031],"study_design_scores_gemma":[0.49754143,0.41361377,0.03420591,0.00008636021,0.00042946334,0.00007491013,0.0001021017,0.0000541862,0.0020523407,0.00008244576,0.05145115,0.0003059293],"about_ca_topic_score_codex":0.000104826206,"about_ca_topic_score_gemma":0.00039862058,"teacher_disagreement_score":0.3879583,"about_ca_system_score_codex":0.00009826443,"about_ca_system_score_gemma":0.0028152666,"threshold_uncertainty_score":0.519292},"labels":[],"label_agreement":null},{"id":"W2590667995","doi":"10.1200/jco.2012.30.15_suppl.e14176","title":"Clinical benefit rate (CBR) of panitumumab monotherapy among patients with KRAS wild-type metastatic colorectal cancer (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Irinotecan; Oxaliplatin; Panitumumab; Bevacizumab; Internal medicine; Clinical endpoint; KRAS; Colorectal cancer; Capecitabine; Oncology; Response Evaluation Criteria in Solid Tumors; Cetuximab; Tolerability; Phases of clinical research; Gastroenterology; Cancer; Clinical trial; Chemotherapy; Adverse effect","score_opus":0.09966892773303992,"score_gpt":0.4553142123894501,"score_spread":0.35564528465641015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590667995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328756,0.0021837605,0.000017258611,0.0008217851,0.0022797866,0.0004346831,0.00001569721,0.0000096089525,0.00094986235],"genre_scores_gemma":[0.99304587,0.0033689097,0.0014729231,0.0009097298,0.0009412875,0.000014695565,0.000004994736,0.000033501678,0.00020807532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957886,0.0004736818,0.002631956,0.0002304019,0.0004714841,0.00040389292],"domain_scores_gemma":[0.9929644,0.0023623402,0.0027914394,0.00017953775,0.0011851807,0.0005170886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024831707,0.00025690132,0.0026697072,0.00011487669,0.000064097796,0.000006435581,0.00015188265,0.00025423666,0.00033562887],"category_scores_gemma":[0.0012987035,0.000149306,0.00058683206,0.00024552253,0.00055609643,0.00021255962,0.00005526096,0.0008075887,0.000008103015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02140808,0.0045696488,0.8661273,0.00002419298,0.0030997542,0.000056095752,0.00021003444,0.000011037632,0.000017333577,0.000022821465,0.0009553085,0.10349836],"study_design_scores_gemma":[0.017410666,0.036659006,0.9301932,0.00013185543,0.0017261,0.000021187683,0.000114508824,0.000015365194,0.00006418885,0.000054409917,0.013471223,0.00013827576],"about_ca_topic_score_codex":0.00012503199,"about_ca_topic_score_gemma":0.0004192911,"teacher_disagreement_score":0.10336009,"about_ca_system_score_codex":0.00022789327,"about_ca_system_score_gemma":0.0010040728,"threshold_uncertainty_score":0.6088522},"labels":[],"label_agreement":null},{"id":"W2590668491","doi":"10.1200/jco.2016.34.26_suppl.65","title":"Association between tobacco use, pain expression, and maladaptive coping among patients with advanced cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Smoking cessation; Breast cancer; Cancer; Substance abuse; Coping (psychology); Psychiatry; Pathology","score_opus":0.059139017027921646,"score_gpt":0.39525715914875365,"score_spread":0.336118142120832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590668491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419045,0.00015946424,0.0006010403,0.004129964,0.0005879438,0.00015052049,0.000013094536,0.0000070760725,0.0001604678],"genre_scores_gemma":[0.99671775,0.00058576814,0.0005331408,0.001047588,0.0007192455,0.0000055257096,0.0000014696298,0.000012685827,0.00037683212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789023,0.00048098955,0.0009534064,0.00015003834,0.0003513,0.00017405256],"domain_scores_gemma":[0.99272937,0.004500734,0.0016536133,0.0000900703,0.0007587012,0.00026752023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019234762,0.00009754741,0.0008283854,0.000052330794,0.000034519257,0.0000080544805,0.00005933113,0.00026743094,0.00006112848],"category_scores_gemma":[0.004065059,0.00005205867,0.00011700877,0.00007345547,0.00008797549,0.00027812063,0.000030128924,0.00038546577,0.0000010446569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001285738,0.00008271017,0.7614322,0.0000069586486,0.00016921714,0.000012713213,0.000074121046,6.555778e-7,0.000023305427,0.0000020158561,0.0012889002,0.23562147],"study_design_scores_gemma":[0.0068195113,0.0050148265,0.95826,0.00066090917,0.00021467537,0.0000013173201,0.00008940991,5.984868e-7,0.00005335398,0.000027465963,0.02878407,0.00007385168],"about_ca_topic_score_codex":0.00006495344,"about_ca_topic_score_gemma":0.00047941096,"teacher_disagreement_score":0.23554762,"about_ca_system_score_codex":0.00034964373,"about_ca_system_score_gemma":0.00044494186,"threshold_uncertainty_score":0.4866549},"labels":[],"label_agreement":null},{"id":"W2590670927","doi":"10.1200/jco.2014.32.30_suppl.109","title":"The toxicity gap: Do real-life patients get hospitalized more during chemotherapy compared to trial patients?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Observational study; Chemotherapy; Clinical trial; Internal medicine; Lung cancer; Surgery; Intensive care medicine","score_opus":0.06978940608941775,"score_gpt":0.4461089882026998,"score_spread":0.37631958211328204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590670927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98466223,0.000014376143,0.00003626361,0.0075278566,0.0035319205,0.00061622483,0.0000033704555,0.000014227132,0.003593516],"genre_scores_gemma":[0.992017,0.00029052087,0.00019227836,0.00497256,0.0023327654,0.000015736476,0.0000022937852,0.000020596673,0.00015626237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996508,0.00047620284,0.0020752638,0.00019299485,0.00047516846,0.00027238944],"domain_scores_gemma":[0.995888,0.0011435017,0.0013823749,0.00029027282,0.0007018838,0.00059396983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016740101,0.00014698482,0.0011980566,0.00006908608,0.00016610132,0.000025395424,0.00023229532,0.00021693442,0.000095734234],"category_scores_gemma":[0.0038533972,0.00008737757,0.000510656,0.00014168778,0.000149469,0.000077344295,0.000057141897,0.00066589296,0.000023428709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11738817,0.00340534,0.843162,0.000012315693,0.00032024807,0.000010157454,0.00016113289,0.000016374162,0.000051066032,0.000100740166,0.01442917,0.020943297],"study_design_scores_gemma":[0.110030286,0.015024457,0.80713147,0.00003644874,0.00012671282,0.00000532058,0.000028427241,0.0000061219016,0.000041517746,0.000100080426,0.067385234,0.00008392676],"about_ca_topic_score_codex":0.00001723892,"about_ca_topic_score_gemma":0.000025628176,"teacher_disagreement_score":0.052956067,"about_ca_system_score_codex":0.00019450727,"about_ca_system_score_gemma":0.00048214363,"threshold_uncertainty_score":0.46131545},"labels":[],"label_agreement":null},{"id":"W2590672938","doi":"10.1200/jco.2011.29.4_suppl.412","title":"EGFR expression in invasive anal carcinoma.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Cetuximab; Immunohistochemistry; Medicine; Tissue microarray; Pathology; Staining; Anal cancer; Carcinoma; Cancer; Epidermal growth factor receptor; H&E stain; Head and neck squamous-cell carcinoma; Head and neck cancer; Colorectal cancer; Internal medicine","score_opus":0.2540177689320197,"score_gpt":0.4464426776282388,"score_spread":0.1924249086962191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590672938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745005,0.00028856072,0.000018351528,0.0013939633,0.0006867129,0.00008570398,6.36599e-7,0.0000042892834,0.023021286],"genre_scores_gemma":[0.99527246,0.0001578423,0.0020026057,0.0014153173,0.0008346372,0.0000014691867,7.246589e-7,0.0000086060645,0.000306365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974353,0.00028136684,0.0017066129,0.00014525313,0.00023648259,0.00019502259],"domain_scores_gemma":[0.9975766,0.0008368946,0.00084048294,0.000119718265,0.00025482656,0.00037146546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016759344,0.000100512334,0.0010671257,0.00018805788,0.000017507704,0.0000023475855,0.00014037658,0.000297229,0.00049122336],"category_scores_gemma":[0.0025603964,0.000058557678,0.0004222769,0.00015685687,0.00014471976,0.00009899251,0.000066796565,0.0009806772,0.000026062198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006217068,0.0014625634,0.9484068,0.000023834473,0.00004434221,0.0054261833,0.00044905915,5.815051e-7,0.002373617,0.000065938424,0.0022377132,0.0332923],"study_design_scores_gemma":[0.00481586,0.012029239,0.97315127,0.000114670205,0.000092119495,0.00059523154,0.00033847758,0.000014891866,0.002249635,0.0007856472,0.0057430603,0.00006991443],"about_ca_topic_score_codex":0.000046179404,"about_ca_topic_score_gemma":0.0001825114,"teacher_disagreement_score":0.033222385,"about_ca_system_score_codex":0.00010529821,"about_ca_system_score_gemma":0.001278073,"threshold_uncertainty_score":0.53785515},"labels":[],"label_agreement":null},{"id":"W2590684839","doi":"10.1200/jco.2016.34.26_suppl.255","title":"Symptom burden and distress in patients with cancer in Africa.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Worry; Medicine; Palliative care; Distress; Public health; Cancer; Family medicine; Psychiatry; Health care; Anxiety; Nursing; Clinical psychology","score_opus":0.20975589670623354,"score_gpt":0.5245549763231564,"score_spread":0.3147990796169229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590684839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933226,0.00090747036,0.000014492091,0.0045587313,0.00018967294,0.00006546519,0.000006871728,0.0000011227718,0.0009335595],"genre_scores_gemma":[0.9968116,0.0022797773,0.00037175938,0.00012443356,0.0002827688,0.0000015765203,3.5489666e-7,0.0000049861587,0.00012272625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858,0.00012991628,0.000912438,0.000088512796,0.00016815266,0.00012100735],"domain_scores_gemma":[0.99760264,0.001468719,0.0005465495,0.0000633742,0.0001932705,0.00012542012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060602365,0.000061357656,0.00077812135,0.00008437453,0.0000038741496,0.0000010762519,0.00005672506,0.00013265335,0.00005605372],"category_scores_gemma":[0.0015794705,0.000029896151,0.00005728206,0.00007987561,0.00014927,0.000058443708,0.000021321915,0.0002426468,0.0000012046097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002274214,0.00024983255,0.8463816,0.000013169144,0.000051589086,0.00008635418,0.0002505996,0.0000016339768,0.000014730856,0.000011762445,0.00022471717,0.15043981],"study_design_scores_gemma":[0.011744851,0.0038495539,0.9519008,0.001298946,0.00005000365,0.0000025493428,0.00008824653,0.0000029538805,0.00001714261,0.00007625781,0.030929117,0.000039605642],"about_ca_topic_score_codex":0.00005621275,"about_ca_topic_score_gemma":0.00018501074,"teacher_disagreement_score":0.1504002,"about_ca_system_score_codex":0.00009087694,"about_ca_system_score_gemma":0.0002792007,"threshold_uncertainty_score":0.18908878},"labels":[],"label_agreement":null},{"id":"W2590693960","doi":"10.1200/jco.2014.32.4_suppl.473","title":"Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Biomarker; Oncology; Hazard ratio; Internal medicine; Proportional hazards model; Renal cell carcinoma; Progression-free survival; Cohort; Overall survival; Confidence interval; Hepatocellular carcinoma","score_opus":0.09803582891267835,"score_gpt":0.3702265866734542,"score_spread":0.27219075776077584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590693960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996056,0.0013589765,0.00007766543,0.00046021916,0.00051086367,0.001347902,0.00006121606,0.000009269138,0.00011788735],"genre_scores_gemma":[0.9903281,0.00031144777,0.008231302,0.00031497385,0.00063195324,0.000041485942,0.00005973938,0.000049580565,0.000031440853],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99253523,0.0016305994,0.0037781664,0.00057267933,0.001041396,0.00044189786],"domain_scores_gemma":[0.9916303,0.003364831,0.0032322,0.0005082251,0.000656357,0.00060808525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026755617,0.00043420948,0.0038273048,0.0006946289,0.000038619342,0.000021735194,0.00020813064,0.00041271272,0.00034120426],"category_scores_gemma":[0.00075776456,0.000284175,0.0008927089,0.00063325034,0.00032796434,0.00016824264,0.000060592403,0.00083126436,0.0000041749686],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73490006,0.020244936,0.12907387,0.000030101255,0.004285268,0.00034075894,0.00040330426,0.0000023994685,0.003613362,0.0000019009071,0.0000385375,0.10706548],"study_design_scores_gemma":[0.40188032,0.07741071,0.51462555,0.000069301626,0.002517335,0.000003931123,0.000049538547,0.00006788346,0.002644785,0.000021984128,0.0005254736,0.00018316964],"about_ca_topic_score_codex":0.00019141243,"about_ca_topic_score_gemma":0.0001759088,"teacher_disagreement_score":0.3855517,"about_ca_system_score_codex":0.00022752493,"about_ca_system_score_gemma":0.0012396149,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W2590694856","doi":"10.1200/jco.2015.33.29_suppl.15","title":"Barriers to goals of care discussions with patients with advanced cancer and their families: A multicenter survey of oncologists.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Respondent; Referral; Family medicine; Palliative care; Cancer; Documentation; Descriptive statistics; Scale (ratio); Nursing; Internal medicine","score_opus":0.2507642625586505,"score_gpt":0.5382729457013274,"score_spread":0.28750868314267697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590694856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707425,0.0010990212,0.00008898313,0.0007254432,0.00025694125,0.00026184047,0.00010306306,0.0000021647345,0.0003882892],"genre_scores_gemma":[0.9942913,0.00092916493,0.0042036413,0.00046815627,0.000060316786,0.0000047983212,0.00000556591,0.000011521725,0.00002555054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778944,0.00036123183,0.0012698078,0.00014255717,0.00028910587,0.00014782538],"domain_scores_gemma":[0.99345905,0.0018881878,0.0014226888,0.00015194577,0.0024689387,0.0006092205],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009918377,0.00012960385,0.0016286466,0.00009342438,0.000014227414,0.0000012977414,0.00011562023,0.00015665003,0.000016638905],"category_scores_gemma":[0.008604473,0.00005916982,0.00011089147,0.00016647218,0.00042653238,0.00006855297,0.000049013237,0.0003031222,2.8056974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01841674,0.00040409504,0.94755113,0.00006990783,0.00031065886,0.000014104572,0.004268867,0.0000915245,0.000031424985,0.0000017845759,0.0004216807,0.028418068],"study_design_scores_gemma":[0.013361228,0.03479007,0.9290823,0.0012398413,0.00019739637,0.0000023144555,0.011217098,0.000007629804,0.00033433276,0.0000042266474,0.009686217,0.00007734435],"about_ca_topic_score_codex":0.0003366231,"about_ca_topic_score_gemma":0.0023485827,"teacher_disagreement_score":0.034385975,"about_ca_system_score_codex":0.00011046556,"about_ca_system_score_gemma":0.0017461167,"threshold_uncertainty_score":0.9997465},"labels":[],"label_agreement":null},{"id":"W2590697598","doi":"10.1200/jco.2015.33.7_suppl.4","title":"A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; McGill University Health Centre; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Randomized controlled trial; Urology; Surgery; Cancer; Internal medicine; Confidence interval","score_opus":0.3147061067878082,"score_gpt":0.570950177722728,"score_spread":0.25624407093491985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590697598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597672,0.008707985,0.00027070538,0.019688934,0.006402758,0.0037179703,0.000020154452,0.000012473992,0.0014117772],"genre_scores_gemma":[0.9402362,0.04895845,0.0022994953,0.00095507514,0.005267653,0.00034119622,0.000029787347,0.00004681907,0.0018653204],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956223,0.000981071,0.0024322346,0.00017251194,0.00051904336,0.0002728901],"domain_scores_gemma":[0.99082184,0.0052994485,0.0020522818,0.00015722238,0.0012149132,0.00045430582],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008426009,0.00014340502,0.0026363176,0.00014528033,0.000028977985,0.000008178078,0.00013664416,0.00032401184,0.00007658203],"category_scores_gemma":[0.008428132,0.00008332241,0.0008849707,0.00015437926,0.00040316847,0.000096645395,0.000021819964,0.0004655967,0.0000033152803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8037469,0.0012300613,0.0004158753,0.000024886409,0.0011054686,0.00004515847,0.00023536752,0.00001683162,0.000049534192,0.000056654022,0.0060314736,0.18704182],"study_design_scores_gemma":[0.8393191,0.04983853,0.0001475822,0.00004846261,0.00044442574,0.00001123027,0.00008706722,0.0002850234,0.00048418512,0.0007474761,0.1085223,0.00006460526],"about_ca_topic_score_codex":0.00007526276,"about_ca_topic_score_gemma":0.000016644562,"teacher_disagreement_score":0.18697721,"about_ca_system_score_codex":0.00033224627,"about_ca_system_score_gemma":0.0064371247,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W2590701245","doi":"10.1200/jco.2016.34.4_suppl.242","title":"Systemic treatment patterns in small bowel and appendiceal adenocarcinomas (SBA and AA): A population-based study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; Health Sciences Centre; Mount Sinai Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Oxaliplatin; Bevacizumab; Internal medicine; Capecitabine; Cetuximab; Colorectal cancer; Irinotecan; Raltitrexed; Panitumumab; Cancer registry; KRAS; Cohort; Population; Cancer; Oncology; Chemotherapy","score_opus":0.09305890704151408,"score_gpt":0.4045528877442892,"score_spread":0.3114939807027751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590701245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941175,0.000499497,0.000033409964,0.0045460896,0.00032363794,0.00038079105,0.0000060447887,0.00000693075,0.00008607473],"genre_scores_gemma":[0.9984213,0.00026722485,0.00021923574,0.0005106968,0.00046174796,0.000007633138,0.0000013145545,0.000011911657,0.00009890378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745965,0.00035274104,0.0015953653,0.00021360851,0.00016265752,0.00021600662],"domain_scores_gemma":[0.99743754,0.0013454541,0.0007242727,0.00011414895,0.00008371432,0.00029489247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011922673,0.00015085033,0.0011537484,0.00014435718,0.000034867906,0.000008920297,0.00006406042,0.00021164253,0.00003997495],"category_scores_gemma":[0.00033635882,0.000079645106,0.00014050271,0.00005152964,0.00008121537,0.000059091275,0.000027134784,0.00025667687,0.0000044005415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018656839,0.0012092154,0.93348527,0.00005012007,0.000101604564,0.001621734,0.00015070269,8.7197304e-7,0.00016479686,0.00004960992,0.000009612717,0.061290767],"study_design_scores_gemma":[0.013622744,0.020265741,0.96372473,0.00042975857,0.0002334494,0.00071468466,0.0004272838,0.000027637172,0.000022999498,0.00007123451,0.00037517902,0.00008453209],"about_ca_topic_score_codex":0.0004449621,"about_ca_topic_score_gemma":0.0008697413,"teacher_disagreement_score":0.061206236,"about_ca_system_score_codex":0.00017843116,"about_ca_system_score_gemma":0.00039922184,"threshold_uncertainty_score":0.3247833},"labels":[],"label_agreement":null},{"id":"W2590701695","doi":"10.1200/jco.2012.30.4_suppl.426","title":"Bevacizumab in combination with FOLFIRI in metastatic colorectal cancer: A retrospective study of adverse events and their correlation with clinical outcome.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Bevacizumab; FOLFIRI; Adverse effect; Internal medicine; Colorectal cancer; Common Terminology Criteria for Adverse Events; Surgery; Retrospective cohort study; Proteinuria; Oncology; Cancer; Irinotecan; Chemotherapy","score_opus":0.10697282954763022,"score_gpt":0.46832408927647506,"score_spread":0.36135125972884485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590701695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774796,0.00034824922,0.000031793556,0.00053416565,0.00038258315,0.0007332124,0.0000032921616,0.0000028865663,0.00021587861],"genre_scores_gemma":[0.9991014,0.0002831644,0.00038524385,0.00008214733,0.00009020728,0.00002688659,0.0000010913798,0.000010567773,0.000019311225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684244,0.0005519781,0.0019705805,0.00016816813,0.00028367582,0.00018317993],"domain_scores_gemma":[0.9966278,0.0012712997,0.0015618274,0.000079163416,0.00031054218,0.00014935489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026575807,0.00014678543,0.0018036987,0.0001732869,0.000025061236,9.980946e-7,0.00005053076,0.00011777939,0.000013820625],"category_scores_gemma":[0.00096103246,0.00007982485,0.00011578022,0.00026454774,0.00016482019,0.00016561517,0.00003488485,0.00066863914,4.1663776e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022371085,0.010287155,0.9484529,0.000014652224,0.0007087517,0.00009924893,0.0025377015,0.000030872663,0.0000013390005,0.000015929078,0.00000854813,0.015471809],"study_design_scores_gemma":[0.03766505,0.0635479,0.8938653,0.00011951575,0.0004867632,0.00007463215,0.003956478,0.00011535766,0.0000023251932,0.000056037446,0.000043599975,0.00006702732],"about_ca_topic_score_codex":0.00023132106,"about_ca_topic_score_gemma":0.006795626,"teacher_disagreement_score":0.0545876,"about_ca_system_score_codex":0.00042569436,"about_ca_system_score_gemma":0.00048532765,"threshold_uncertainty_score":0.3792119},"labels":[],"label_agreement":null},{"id":"W2590702803","doi":"10.1200/jco.2013.31.31_suppl.192","title":"Managing chemotherapy drug shortages in Ontario.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Economic shortage; Chemotherapy; Drug; Intensive care medicine; Surgery; Pharmacology","score_opus":0.191689334561121,"score_gpt":0.43035365550137833,"score_spread":0.23866432094025733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590702803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8669481,0.00046579842,0.000067712834,0.034798585,0.0012547225,0.00010454345,0.000002011168,0.0000037518448,0.096354745],"genre_scores_gemma":[0.98058885,0.0013947533,0.0011685138,0.014831438,0.00047692852,0.0000041968947,5.250364e-7,0.000014218116,0.0015205776],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658483,0.000054141517,0.0028929396,0.00017687376,0.000026677675,0.0002645146],"domain_scores_gemma":[0.99755585,0.0005802579,0.001423437,0.00014056626,0.000054864133,0.00024502614],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030017192,0.00010388753,0.0011400183,0.00020967853,0.000019564153,0.00003260422,0.00031537234,0.00017973267,0.003539822],"category_scores_gemma":[0.0003619749,0.000099708974,0.00028562348,0.000095053176,0.00008558298,0.00029268864,0.00004375821,0.0009431731,0.00054077624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015435429,0.0007648441,0.85308695,0.000008333474,0.00017241285,0.000049278893,0.00046095488,0.000112567584,0.0000054013367,0.031510934,0.027767463,0.08590649],"study_design_scores_gemma":[0.0018629385,0.00027411175,0.43448883,0.000007822058,0.000004213582,0.000009904151,0.000025940892,0.0007310332,0.0000052025566,0.11242482,0.4500627,0.00010248632],"about_ca_topic_score_codex":0.008776841,"about_ca_topic_score_gemma":0.010467284,"teacher_disagreement_score":0.42229524,"about_ca_system_score_codex":0.00028068654,"about_ca_system_score_gemma":0.0003083064,"threshold_uncertainty_score":0.9978238},"labels":[],"label_agreement":null},{"id":"W2590703406","doi":"10.1200/jco.2013.31.31_suppl.98","title":"Examination of differences in quality of life and use of support services in urban versus rural breast cancer patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Pharmacist; Quality of life (healthcare); Phone; Rural area; Support group; Gerontology; Cancer; Demography; Pharmacy; Nursing; Internal medicine","score_opus":0.16538710653544064,"score_gpt":0.3823553176913088,"score_spread":0.21696821115586817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590703406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979966,0.00035123786,0.0000045068937,0.00035160704,0.0005561508,0.00009723425,0.00008571223,6.163652e-7,0.00055633223],"genre_scores_gemma":[0.9977339,0.001935545,0.00010375101,0.0001172036,0.000082885905,0.0000026316711,0.0000014970436,0.00000483946,0.000017742192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960848,0.000098021694,0.003534141,0.000108425644,0.000047728397,0.00012687116],"domain_scores_gemma":[0.993995,0.0010874352,0.004514571,0.000086187436,0.00022124883,0.00009554508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016863936,0.00008011319,0.0014242674,0.00021011356,0.0000060832226,0.0000066828825,0.00014566691,0.00021139778,0.00018443077],"category_scores_gemma":[0.0011115565,0.00007362852,0.00012240821,0.00009797225,0.00017321591,0.0005707311,0.000040861134,0.00021322609,0.0000019719687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006979858,0.0005120901,0.9760851,0.00005960948,0.00004393045,3.2995973e-7,0.00035237652,0.000010129507,0.0000040785776,0.0012833189,0.00005645482,0.020894587],"study_design_scores_gemma":[0.0042135054,0.0014745847,0.9930634,0.000045331686,0.0000064987767,2.7503168e-7,0.00016727037,0.000093327624,0.0000051002494,0.000657786,0.00020704686,0.000065875145],"about_ca_topic_score_codex":0.0043667736,"about_ca_topic_score_gemma":0.0020754165,"teacher_disagreement_score":0.02082871,"about_ca_system_score_codex":0.00007970317,"about_ca_system_score_gemma":0.00022763383,"threshold_uncertainty_score":0.6601285},"labels":[],"label_agreement":null},{"id":"W2590707171","doi":"10.1200/jco.2005.23.16_suppl.8154","title":"Dying with breast cancer: An audit","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Referral; Palliative care; Audit; Breast cancer; End-of-life care; Cancer; Family medicine; Cause of death; Disease; Emergency medicine; Internal medicine; Nursing","score_opus":0.36408300101621416,"score_gpt":0.5920841320077366,"score_spread":0.22800113099152242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590707171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972209,0.0013278283,0.00022295203,0.02131158,0.0004341796,0.00005809283,0.000004499652,0.0000070982333,0.0044248165],"genre_scores_gemma":[0.9743221,0.0033176693,0.014889666,0.0032768676,0.0039256634,0.0000011899417,0.0000010793963,0.000012069846,0.00025370382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981138,0.00015703906,0.0012095565,0.00010604047,0.00026197472,0.00015156338],"domain_scores_gemma":[0.9970137,0.00081991084,0.0011559913,0.00011905265,0.0005739457,0.00031742532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011848322,0.00008566415,0.0010493296,0.000069606554,0.0000188581,0.0000028027653,0.00011078344,0.00018492546,0.00032319207],"category_scores_gemma":[0.00059580203,0.00005177271,0.00018281459,0.00009010388,0.00016429857,0.00014619403,0.000016055232,0.0005836099,0.000009633734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043463474,0.0009759124,0.55255955,0.000024948255,0.0003735191,0.00032395328,0.00031540083,0.00009041076,0.00021687655,0.000042150525,0.0049825152,0.4357484],"study_design_scores_gemma":[0.008299399,0.012053798,0.5372861,0.00079119834,0.0005132958,0.001085215,0.00040061827,0.00013126893,0.00029875856,0.000048595593,0.43898496,0.000106804066],"about_ca_topic_score_codex":0.00004317415,"about_ca_topic_score_gemma":0.00016602925,"teacher_disagreement_score":0.4356416,"about_ca_system_score_codex":0.000115063594,"about_ca_system_score_gemma":0.0013163903,"threshold_uncertainty_score":0.35387266},"labels":[],"label_agreement":null},{"id":"W2590710144","doi":"10.1200/jco.2013.31.6_suppl.196","title":"Evaluation of a genomic-based prognostic test for metastasis in high-risk post-prostatectomy patients: Does it impact physician decision making?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Internal medicine; Prostate cancer; Radiation oncologist; Clinical endpoint; Oncology; Referral; Nomogram; Confidence interval; Clinical trial; Cancer; Radiation therapy; Family medicine","score_opus":0.09944651828228353,"score_gpt":0.5001001007031128,"score_spread":0.4006535824208293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590710144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527,0.00024720075,0.00013998005,0.0017988086,0.00032806746,0.0020613363,0.00009424438,0.0000037269353,0.000056651097],"genre_scores_gemma":[0.993069,0.0001289017,0.005946249,0.00048219156,0.0002336593,0.00008759283,0.000024116644,0.0000204698,0.000007813213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960425,0.0006405364,0.001989245,0.00020514266,0.0008307583,0.00029180112],"domain_scores_gemma":[0.9848376,0.008379637,0.00187363,0.0001820753,0.00452767,0.00019939298],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0064721396,0.00015234378,0.0011862683,0.0003186899,0.000035355028,0.000013769552,0.0001397493,0.0001971138,0.00020412922],"category_scores_gemma":[0.02218106,0.00007968058,0.00049971405,0.00019893727,0.0001457405,0.00016330786,0.000032751035,0.00048574744,0.000013115115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005527864,0.003408071,0.50662637,0.000038353308,0.00032121906,0.000011920049,0.00006638632,0.00016178834,0.00028842446,8.5033685e-7,0.00039090024,0.48315784],"study_design_scores_gemma":[0.031669486,0.033715505,0.9270435,0.00031369543,0.0012482824,0.0000021574062,0.00012130622,0.003231765,0.00029805407,0.0020481031,0.0002283594,0.000079811936],"about_ca_topic_score_codex":0.00012564538,"about_ca_topic_score_gemma":0.00012885917,"teacher_disagreement_score":0.48307803,"about_ca_system_score_codex":0.00065894716,"about_ca_system_score_gemma":0.0032428727,"threshold_uncertainty_score":0.9860555},"labels":[],"label_agreement":null},{"id":"W2590714628","doi":"10.1200/jco.2014.32.4_suppl.284","title":"Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Urology; Cumulative incidence; Surgery; Internal medicine; Oncology; Cohort; Cancer","score_opus":0.15992891190645198,"score_gpt":0.46372382415040536,"score_spread":0.3037949122439534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590714628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393016,0.00021637749,0.000357759,0.0039235894,0.00043506332,0.0008606281,0.00022948344,0.0000065183067,0.00004042465],"genre_scores_gemma":[0.9969516,0.0006419663,0.00036085834,0.0016085249,0.00024305959,0.000057271518,0.000019542596,0.000026466967,0.0000907515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99544364,0.0011198126,0.0023817362,0.00031331048,0.00046437423,0.00027712164],"domain_scores_gemma":[0.9903405,0.0053833243,0.0025659301,0.00042748067,0.0010310563,0.00025175393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001986102,0.00025969712,0.0025568816,0.00022758212,0.00010765236,0.000019065219,0.00025990696,0.00028809492,0.00025222692],"category_scores_gemma":[0.0024050558,0.00014312449,0.0009052412,0.0003383158,0.00065582374,0.00016238332,0.00008598096,0.00047151142,4.6766928e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06922473,0.0025044451,0.8754225,0.00006937297,0.010699738,0.000015999847,0.00061177363,0.000033288477,0.00024333512,0.000006412717,0.00014683495,0.041021597],"study_design_scores_gemma":[0.030926608,0.021091465,0.93953973,0.000119227756,0.0067634746,0.0000052600903,0.00008196499,0.00075530424,0.00012246438,0.00022126322,0.00025229176,0.00012096887],"about_ca_topic_score_codex":0.00047067736,"about_ca_topic_score_gemma":0.0012868448,"teacher_disagreement_score":0.06411724,"about_ca_system_score_codex":0.000089430825,"about_ca_system_score_gemma":0.00072545744,"threshold_uncertainty_score":0.58364475},"labels":[],"label_agreement":null},{"id":"W2590720397","doi":"10.1200/jco.2014.32.3_suppl.15","title":"Association between polymorphisms of the FOXF1 and MHC locus genes and gastroesophageal reflux disease (GERD).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"","keywords":"GERD; Medicine; Gastroenterology; Internal medicine; Odds ratio; Esophagus; Allele; Reflux; Disease; Genetics; Biology; Gene","score_opus":0.05261020332484738,"score_gpt":0.3828317758316197,"score_spread":0.3302215725067723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590720397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649647,0.0006407494,0.00008318356,0.033423815,0.00061481434,0.00011306599,0.000007537128,0.000005323416,0.00014680844],"genre_scores_gemma":[0.9956522,0.00051820406,0.00052298594,0.0018707585,0.0012056981,0.0000013558158,0.0000010470936,0.000011313698,0.00021643487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970006,0.0007489017,0.0015597115,0.00016134666,0.0002979946,0.00023144626],"domain_scores_gemma":[0.9953595,0.0019260448,0.0018640511,0.0001646583,0.00031410647,0.00037163304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029350284,0.00012682595,0.0011782141,0.000092471586,0.000060805687,0.0000052033074,0.00011304078,0.00028814163,0.000011615127],"category_scores_gemma":[0.0057951338,0.000076745324,0.00022509386,0.000090038346,0.00039286367,0.00006830745,0.00013312201,0.00078768673,0.0000018618771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007914112,0.00016889306,0.9541197,0.000016720678,0.0007379575,0.00003936515,0.000047906382,8.9262267e-7,0.00015179726,0.000014287808,0.0010381682,0.04287292],"study_design_scores_gemma":[0.0045683067,0.004357719,0.98378104,0.000057967874,0.0013648749,0.00007349383,0.000014442036,0.000012713877,0.00005318937,0.00021564681,0.0054639457,0.00003663391],"about_ca_topic_score_codex":0.000005121596,"about_ca_topic_score_gemma":0.000008910651,"teacher_disagreement_score":0.042836286,"about_ca_system_score_codex":0.00007978754,"about_ca_system_score_gemma":0.00022818678,"threshold_uncertainty_score":0.6937735},"labels":[],"label_agreement":null},{"id":"W2590722941","doi":"10.1200/jco.2013.31.4_suppl.226","title":"Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oxaliplatin; Internal medicine; Pancreatic cancer; Neoadjuvant therapy; Adenocarcinoma; Radiation therapy; Chemotherapy; Clinical endpoint; Pancreatectomy; Quality of life (healthcare); Oncology; Surgery; Clinical trial; Gastroenterology; Cancer; Pancreas; Colorectal cancer","score_opus":0.1157003720393044,"score_gpt":0.47432286964216025,"score_spread":0.35862249760285586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590722941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587643,0.0005244386,0.00003372754,0.0014456935,0.00016943194,0.001590172,0.0000097704315,0.0000030734393,0.00034727706],"genre_scores_gemma":[0.9944408,0.0005741685,0.004302056,0.00020319945,0.00022848915,0.00003277828,0.00001086154,0.000016732667,0.00019094233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924508,0.0015114299,0.0047294158,0.00026309412,0.0006604853,0.00038481283],"domain_scores_gemma":[0.9898651,0.0056568086,0.0026946052,0.0002967187,0.001060517,0.0004262249],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065979837,0.00017853944,0.003241736,0.00042949393,0.00003436661,0.000005954133,0.0001629599,0.00042183537,0.0003637815],"category_scores_gemma":[0.02406674,0.000110359186,0.00015034,0.00042089357,0.0004085977,0.00025292602,0.00009403469,0.0009866733,0.0000023742318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34499115,0.009436666,0.6342983,0.00014329473,0.00018894611,0.000035069992,0.00023147589,0.000005563411,0.00014137171,0.000008989653,0.00028508488,0.0102340905],"study_design_scores_gemma":[0.2800244,0.0894815,0.62868357,0.00020666882,0.0001381942,0.000007393121,0.00023065788,0.0010108157,0.000009202069,0.000046353536,0.00009458902,0.00006663155],"about_ca_topic_score_codex":0.0012562447,"about_ca_topic_score_gemma":0.0007219103,"teacher_disagreement_score":0.080044836,"about_ca_system_score_codex":0.00015786622,"about_ca_system_score_gemma":0.0024594634,"threshold_uncertainty_score":0.984154},"labels":[],"label_agreement":null},{"id":"W2590722959","doi":"10.1200/jco.2016.34.2_suppl.303","title":"Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Prostate; DECIPHER; Medicine; Metastasis; Adenocarcinoma; Carcinoma; Microarray; Cancer; Cancer research; Androgen deprivation therapy; Gene expression profiling; Androgen receptor; Oncology; Gene; Gene expression; Pathology; Internal medicine; Biology; Bioinformatics; Genetics","score_opus":0.14371395706064038,"score_gpt":0.47120583379404035,"score_spread":0.32749187673339997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590722959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344773,0.0014030148,0.0004368461,0.012540828,0.0008452503,0.00034918237,0.000006736825,0.0000056866174,0.00096470217],"genre_scores_gemma":[0.9872344,0.007934766,0.0019688439,0.00043922022,0.0010248715,0.000009053739,4.0668957e-7,0.00001926568,0.0013691827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639255,0.000499221,0.002213813,0.00022055265,0.00036203567,0.00031184405],"domain_scores_gemma":[0.9951038,0.0021471174,0.0015202224,0.00027813803,0.0006025103,0.00034825125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004469202,0.00013362417,0.0011634422,0.000055529323,0.000045493187,0.000006691719,0.00025745935,0.00024242907,0.00025721863],"category_scores_gemma":[0.00079874473,0.000051051422,0.0004952681,0.0000942407,0.0007531815,0.000054415286,0.000115176306,0.0008441371,0.000011024482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022517297,0.0013305653,0.5337723,0.000050712937,0.0006044421,0.0005253556,0.00011157609,0.000017903214,0.0020697806,0.000009320217,0.00075053144,0.43824026],"study_design_scores_gemma":[0.020796312,0.016204702,0.91855687,0.00035501682,0.00059654383,0.00016377555,0.00013307361,0.000078481484,0.0016178582,0.00021912142,0.041172847,0.00010541038],"about_ca_topic_score_codex":0.00004104051,"about_ca_topic_score_gemma":0.0000731187,"teacher_disagreement_score":0.43813485,"about_ca_system_score_codex":0.00014249684,"about_ca_system_score_gemma":0.0036091139,"threshold_uncertainty_score":0.6402413},"labels":[],"label_agreement":null},{"id":"W2590724612","doi":"10.1200/jco.2013.31.31_suppl.70","title":"Using RFID technology to drive quality improvement.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare Systems and Technology","field":"Business, Management and Accounting","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Interactive kiosk; Medicine; Medical emergency; Ambulatory; Service (business); Quality management; Patient satisfaction; Emergency medicine; Operations management; Management system; Nursing; Surgery; Computer science; World Wide Web","score_opus":0.20555350187139132,"score_gpt":0.5088057008853029,"score_spread":0.30325219901391154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590724612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484225,0.00006444832,0.0017902837,0.04156106,0.0029377658,0.0003950869,6.2933424e-7,0.000062690524,0.0047655357],"genre_scores_gemma":[0.97890186,0.000013856899,0.0060659833,0.0116342995,0.0032533326,0.000011626193,4.468371e-7,0.000021147936,0.000097450495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955438,0.00009187663,0.0033588007,0.00026727575,0.00029188042,0.0004464107],"domain_scores_gemma":[0.99473286,0.0003808807,0.0030999328,0.00032220478,0.0013761561,0.00008796947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004087711,0.0001684617,0.0013663156,0.0006850267,0.00009800478,0.000053578104,0.0005565217,0.0007699349,0.00031161585],"category_scores_gemma":[0.0052088313,0.00012838302,0.00028350254,0.0006625152,0.00017255817,0.00058185897,0.00033335653,0.0009766676,0.0005020316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001178114,0.00047689778,0.095174596,0.00008358196,0.00013784088,0.000083369516,0.000014634405,0.000012991145,0.0034381982,0.03180248,0.009835467,0.8588221],"study_design_scores_gemma":[0.0024449867,0.0017617554,0.064838715,0.00008788008,0.000078766476,0.00006391765,0.0008919724,0.00030380755,0.00008740584,0.034796447,0.8943471,0.00029730212],"about_ca_topic_score_codex":0.0022499445,"about_ca_topic_score_gemma":0.00034894265,"teacher_disagreement_score":0.8845116,"about_ca_system_score_codex":0.00013340096,"about_ca_system_score_gemma":0.000408046,"threshold_uncertainty_score":0.6452768},"labels":[],"label_agreement":null},{"id":"W2590741945","doi":"10.1200/jco.2011.29.15_suppl.e16541","title":"Canadian cancer risk management model: A new health policy tool useful in policy decisions related to lung cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Health care; Population; Environmental health; Economic growth","score_opus":0.3005639665499549,"score_gpt":0.5643587949970218,"score_spread":0.2637948284470669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590741945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8221665,0.0024125152,0.0011197868,0.15716934,0.0010665376,0.00073706364,0.000039627706,0.000018094393,0.015270507],"genre_scores_gemma":[0.91428494,0.01694646,0.01843095,0.04739562,0.0012592602,0.000018032868,0.0000012820989,0.000030364827,0.0016330816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956031,0.00028632092,0.0026657844,0.000292873,0.0004428808,0.00070902886],"domain_scores_gemma":[0.9956543,0.000288138,0.0012013172,0.00029327915,0.00028149757,0.0022815072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002947878,0.00018073931,0.0013263833,0.000944236,0.00008402939,0.000010201002,0.00035856717,0.00033542508,0.00024966107],"category_scores_gemma":[0.0031537248,0.00014615917,0.0003286618,0.00100106,0.000057185363,0.00014812966,0.00008853915,0.001240352,0.000016940712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020841488,0.00021969588,0.42226422,0.000015614673,0.00034121267,0.0007830362,0.0012886876,0.0063153314,8.745409e-7,0.002199408,0.054221913,0.5102659],"study_design_scores_gemma":[0.006651613,0.003912329,0.9125289,0.0010761955,0.00032107392,0.00015714623,0.0002627003,0.0032681131,0.0000019997979,0.0062189023,0.065382734,0.00021829564],"about_ca_topic_score_codex":0.78037745,"about_ca_topic_score_gemma":0.6555368,"teacher_disagreement_score":0.51004755,"about_ca_system_score_codex":0.0049992064,"about_ca_system_score_gemma":0.041583255,"threshold_uncertainty_score":0.9988204},"labels":[],"label_agreement":null},{"id":"W2590743877","doi":"10.1200/jco.2005.23.16_suppl.4617","title":"Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Paclitaxel; LNCaP; Prostate cancer; Clusterin; Chemotherapy; Internal medicine; Androgen; Oncology; Bicalutamide; Cancer; Endocrinology; Cancer research; Androgen receptor; Apoptosis; Hormone; Biology","score_opus":0.2351972301471544,"score_gpt":0.5300675690633291,"score_spread":0.29487033891617465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590743877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6925908,0.002534092,0.000048499176,0.30239776,0.0009269131,0.00085527694,0.00002219589,0.00001670113,0.00060777133],"genre_scores_gemma":[0.8419477,0.0063885814,0.0056909937,0.12199501,0.008953346,0.0001514676,0.00000894248,0.00009977729,0.014764238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99586785,0.00060511316,0.0022173468,0.00037622603,0.0005159483,0.0004174949],"domain_scores_gemma":[0.98750985,0.00879227,0.002282877,0.00043342097,0.00044856797,0.00053299783],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0050074398,0.00022478892,0.0015847977,0.00006403838,0.00009622648,0.00001482696,0.00040631,0.00056135724,0.0020922164],"category_scores_gemma":[0.008651663,0.00013220846,0.0008734442,0.00009371002,0.00072630047,0.00015275656,0.0001650157,0.0010316857,0.000090626985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07353454,0.0025003313,0.24513078,0.000103271326,0.0012024355,0.00048315828,0.00092895987,0.00016137722,0.0011403252,0.000017304805,0.1943775,0.48042002],"study_design_scores_gemma":[0.014906949,0.01630205,0.14632484,0.00033310484,0.0010103137,0.0019186746,0.00006771474,0.00061397866,0.000897032,0.00033564388,0.81707096,0.00021874439],"about_ca_topic_score_codex":0.000023724082,"about_ca_topic_score_gemma":0.00017023798,"teacher_disagreement_score":0.6226935,"about_ca_system_score_codex":0.0004285017,"about_ca_system_score_gemma":0.0020288832,"threshold_uncertainty_score":0.9996989},"labels":[],"label_agreement":null},{"id":"W2590746369","doi":"10.1200/jco.2012.30.34_suppl.290","title":"The use of technology to improve the delivery process of ambulatory chemotherapy at the Odette Cancer Centre (OCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Staffing; Ambulatory; Cancer; Intensive care medicine; Medical emergency; Emergency medicine; Nursing; Internal medicine","score_opus":0.11123374671555956,"score_gpt":0.4987429479297216,"score_spread":0.38750920121416205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590746369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8803078,0.0040817987,0.000005490001,0.11347565,0.0015639438,0.00040807528,0.000008936881,0.0000046748273,0.00014361713],"genre_scores_gemma":[0.98170173,0.00428476,0.00013722655,0.01138198,0.0012346039,0.000018203225,4.7571234e-7,0.000017407641,0.0012236111],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762577,0.00027047622,0.0014012603,0.00011881473,0.00026959507,0.00031406857],"domain_scores_gemma":[0.99432224,0.0029783614,0.0016698875,0.00029809977,0.0005595583,0.00017182752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001675087,0.0001334562,0.0008707266,0.00006709466,0.00009326937,0.0000032599985,0.0003119158,0.00029372776,0.00024627338],"category_scores_gemma":[0.0007073452,0.00005421288,0.00036375356,0.00021966474,0.00073494186,0.00007092099,0.00008950238,0.0007049922,0.000006589091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018015977,0.0027358783,0.38948786,0.000061316685,0.0024797025,0.000030311796,0.0015225097,0.000086140695,0.013298142,0.00016042964,0.11567395,0.45644778],"study_design_scores_gemma":[0.0058039436,0.004787669,0.09667664,0.000059926122,0.0009414242,0.0001014538,0.00038244456,0.0000325847,0.014506806,0.00009525662,0.8765318,0.00008009369],"about_ca_topic_score_codex":0.00006542132,"about_ca_topic_score_gemma":0.0002896049,"teacher_disagreement_score":0.7608578,"about_ca_system_score_codex":0.00019559928,"about_ca_system_score_gemma":0.0009424699,"threshold_uncertainty_score":0.30628797},"labels":[],"label_agreement":null},{"id":"W2590749769","doi":"10.1200/jco.2013.31.15_suppl.4542","title":"Development of a genomic-clinical classifier for predicting progression after radical cystectomy in patients with muscle invasive bladder cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Receiver operating characteristic; Logistic regression; Classifier (UML); Oncology; Internal medicine; Cancer; Artificial intelligence","score_opus":0.0819361119725455,"score_gpt":0.4297834293374855,"score_spread":0.34784731736494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590749769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964605,0.00022362599,0.00010518117,0.0009964742,0.0006439936,0.0012588181,0.000007659022,0.0000057862494,0.00029796292],"genre_scores_gemma":[0.9683707,0.00007963035,0.029810727,0.0008363778,0.0006244751,0.00018552502,0.0000044204617,0.000027469941,0.0000607004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562335,0.00024338094,0.003151546,0.00026825533,0.00041384497,0.00029961768],"domain_scores_gemma":[0.99585426,0.0012078926,0.0017017965,0.00015461836,0.0006870221,0.00039442402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014431403,0.00017588622,0.0014703381,0.00011878379,0.00003251499,0.0000069475027,0.00013610185,0.00041959164,0.00028857612],"category_scores_gemma":[0.0010165406,0.00010548174,0.00030783337,0.00009862899,0.00025121032,0.0001310383,0.000058034384,0.0006938715,0.000007820858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009101822,0.0028113255,0.7726489,0.00006513485,0.0005028609,0.000036254027,0.0002772627,0.0000014468654,0.000052181204,0.0000010771623,0.0004489994,0.2140528],"study_design_scores_gemma":[0.03037609,0.013334852,0.9464272,0.00050115585,0.0003399723,0.000009752762,0.00010484194,0.000025872789,0.00009322722,0.000027101554,0.008659671,0.000100210025],"about_ca_topic_score_codex":0.000023080249,"about_ca_topic_score_gemma":0.00014918036,"teacher_disagreement_score":0.21395259,"about_ca_system_score_codex":0.00025297859,"about_ca_system_score_gemma":0.00424967,"threshold_uncertainty_score":0.75387317},"labels":[],"label_agreement":null},{"id":"W2590750405","doi":"10.1200/jco.2013.31.31_suppl.47","title":"Identifying knowledge-translation opportunities in the treatment of locally advanced breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Jewish General Hospital; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Expert opinion; Knowledge translation; Lumpectomy; Guideline; Breast cancer; Psychological intervention; Systematic review; Medical physics; MEDLINE; Cancer; Mastectomy; Intensive care medicine; Pathology; Nursing; Knowledge management","score_opus":0.22916769041500257,"score_gpt":0.47326431167370664,"score_spread":0.24409662125870407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590750405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98280364,0.009620522,0.00012678266,0.0056976588,0.0006002993,0.00020744183,0.000011916292,0.0000017083264,0.00093003],"genre_scores_gemma":[0.9786407,0.01978209,0.0006495446,0.00027172215,0.00054652704,0.000035060326,0.0000046286304,0.00000834242,0.000061387625],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99819916,0.00032013643,0.0010895104,0.00012584719,0.000121630525,0.00014372065],"domain_scores_gemma":[0.9983067,0.00042652205,0.00075091765,0.00013908278,0.00031337075,0.000063444815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005397344,0.00011561866,0.0005478646,0.000049347902,0.000036868005,0.000008601462,0.00016791587,0.00015783674,0.000034925903],"category_scores_gemma":[0.00008429917,0.00006901947,0.00025690123,0.00006489657,0.00022637518,0.000013434391,0.000017133876,0.00011653776,0.0000026467862],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008329115,0.00165521,0.032390364,0.00001434496,0.00031317575,0.00001825803,0.0007794497,0.00006071165,0.0013862165,0.000028850855,0.00058064424,0.9619399],"study_design_scores_gemma":[0.009175707,0.007813361,0.9013782,0.0001160077,0.00026087515,0.00016404224,0.0032813093,0.000026834032,0.0012611868,0.00039645497,0.07595857,0.0001674181],"about_ca_topic_score_codex":0.00013067435,"about_ca_topic_score_gemma":0.0008816042,"teacher_disagreement_score":0.96177244,"about_ca_system_score_codex":0.00006482537,"about_ca_system_score_gemma":0.00064658356,"threshold_uncertainty_score":0.28145322},"labels":[],"label_agreement":null},{"id":"W2590754613","doi":"10.1200/jco.2014.32.3_suppl.482","title":"Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Pharmacodynamics; Adverse effect; Internal medicine; Vomiting; Pharmacokinetics; Gastroenterology; Cohort; Anemia; Cancer; Anorexia; Dysgeusia; Colorectal cancer; Pharmacology; Oncology","score_opus":0.024888420442325,"score_gpt":0.37649671423982467,"score_spread":0.3516082937974997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590754613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998755,0.00007209611,0.0001063582,0.00029964434,0.00032292964,0.00027032325,0.000009214579,0.0000022124832,0.00016221417],"genre_scores_gemma":[0.99866766,0.00030150832,0.00043937445,0.00015112631,0.0003978379,0.0000030494275,0.00000183964,0.000016699018,0.000020913005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979726,0.0003820095,0.0010690065,0.00024179847,0.00018421274,0.00015038443],"domain_scores_gemma":[0.99771684,0.00017568601,0.0014686192,0.00015762277,0.00036082364,0.00012039536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014511322,0.00013657486,0.0009920655,0.000066494256,0.00003519692,0.000004398768,0.00010953698,0.00026987662,0.000022541835],"category_scores_gemma":[0.0006360532,0.00009858583,0.00013023244,0.00011211595,0.00021624808,0.0000145150225,0.00005921179,0.00037812238,2.7788434e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08793543,0.0074996324,0.71170336,0.00009133399,0.0012804508,0.000069950314,0.00048395834,0.00015184545,0.12783128,0.00003053371,0.001987855,0.06093433],"study_design_scores_gemma":[0.027299585,0.08799269,0.84189785,0.000085619766,0.00046772917,0.000117878386,0.00034435085,0.00039425687,0.0117099695,0.000036422265,0.029410623,0.00024302474],"about_ca_topic_score_codex":0.00009283385,"about_ca_topic_score_gemma":0.0010596191,"teacher_disagreement_score":0.13019447,"about_ca_system_score_codex":0.000035433943,"about_ca_system_score_gemma":0.00039647627,"threshold_uncertainty_score":0.40202132},"labels":[],"label_agreement":null},{"id":"W2590756575","doi":"10.1200/jco.2012.30.34_suppl.169","title":"Adherence to guidelines for adjuvant chemotherapy (AC) use in stage II colon cancer (CC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Perineural invasion; Internal medicine; Stage (stratigraphy); Lymphovascular invasion; Oncology; Population; Proportional hazards model; Cancer; Guideline; Concordance; Pathology; Metastasis","score_opus":0.4949904166151402,"score_gpt":0.5999877267104501,"score_spread":0.10499731009530988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590756575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737417,0.0030486383,0.0000815083,0.02030824,0.0019390943,0.00050676626,0.000017802598,0.000005874971,0.0003503557],"genre_scores_gemma":[0.9651607,0.0038769513,0.010367845,0.015011072,0.0022450062,0.00007771764,0.0000012742198,0.000019175846,0.003240208],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975284,0.00008584937,0.0017263478,0.00014427851,0.00020433885,0.00031082795],"domain_scores_gemma":[0.9968881,0.0011087331,0.00073458365,0.00011225324,0.00081851956,0.0003377995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017617112,0.00013486444,0.001356303,0.00009016842,0.000045712113,0.0000050095937,0.00009320872,0.00018567676,0.00014776851],"category_scores_gemma":[0.0042818454,0.00008564658,0.00030763887,0.00012408273,0.00006928519,0.00012908691,0.000050683047,0.0003124826,0.0000038777894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016228862,0.005399429,0.46301106,0.00003446355,0.00046772324,0.00007163028,0.00076500454,0.000014190781,0.00024768483,0.00005120538,0.06654178,0.44716695],"study_design_scores_gemma":[0.01634954,0.023364121,0.369013,0.0001371771,0.00015364875,0.000020814348,0.00019603506,0.000028539074,0.000127917,0.000028999777,0.5904928,0.00008740458],"about_ca_topic_score_codex":0.00029046126,"about_ca_topic_score_gemma":0.0020960309,"teacher_disagreement_score":0.523951,"about_ca_system_score_codex":0.00032959634,"about_ca_system_score_gemma":0.00078045577,"threshold_uncertainty_score":0.5126078},"labels":[],"label_agreement":null},{"id":"W2590760113","doi":"10.1200/jco.2016.34.2_suppl.135","title":"High-intensity focused ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: Predictors of disease response.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; High-intensity focused ultrasound; Prostate; Biochemical recurrence; Prostate-specific antigen; Biopsy; Salvage therapy; Cancer; Surgery; Urology; Oncology; Radiology; Internal medicine; Ultrasound; Prostatectomy; Clinical trial; Chemotherapy","score_opus":0.06974584846966742,"score_gpt":0.4310563232643238,"score_spread":0.3613104747946564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590760113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95568997,0.0037457326,0.00006662532,0.03601888,0.0032789593,0.00093197107,0.00023674415,0.000012818424,0.000018311577],"genre_scores_gemma":[0.96753883,0.028815184,0.0006292038,0.001379443,0.0012617145,0.000084922445,0.000006004944,0.000028447826,0.00025624706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965514,0.0004153343,0.0020487374,0.00028213565,0.00039167478,0.00031071395],"domain_scores_gemma":[0.9896497,0.006421286,0.0019595728,0.00027973927,0.0009530481,0.0007366465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025591415,0.00020470229,0.0017382996,0.00011239215,0.00004289844,0.0000064146657,0.0001550704,0.00019445876,0.00013877297],"category_scores_gemma":[0.0056041544,0.00010693858,0.00077739736,0.00009609732,0.0003599704,0.00010722481,0.000025253214,0.00029848007,0.000005253033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2777818,0.0038207846,0.4427159,0.000055190758,0.0014672077,0.00025469155,0.00015262251,0.0000037831646,0.0018661054,0.00006759232,0.023426827,0.24838747],"study_design_scores_gemma":[0.03183495,0.057134856,0.79291576,0.0005618616,0.0007138014,0.00003836673,0.000024134346,0.000002116132,0.004769326,0.00097162306,0.11090997,0.00012321275],"about_ca_topic_score_codex":0.00003546977,"about_ca_topic_score_gemma":0.000017093118,"teacher_disagreement_score":0.35019988,"about_ca_system_score_codex":0.000481704,"about_ca_system_score_gemma":0.0034166316,"threshold_uncertainty_score":0.6709101},"labels":[],"label_agreement":null},{"id":"W2590765858","doi":"10.1200/jco.2012.30.34_suppl.223","title":"Use of performance data to drive process change and improve patient wait time for chemotherapy treatment.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pharmacy; Performance indicator; Turnaround time; Quality management; Workload; Staffing; Workflow; Operations management; Medical emergency; Process management; Nursing; Computer science; Database; Business; Management system; Engineering","score_opus":0.6722592022322286,"score_gpt":0.585383917682816,"score_spread":0.08687528454941262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590765858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211216,0.00025065098,0.000035759826,0.0062449686,0.00053027424,0.0006700146,0.000032830263,0.0000029670075,0.000120385266],"genre_scores_gemma":[0.98772836,0.0010577921,0.004593953,0.0055930205,0.0008927625,0.000010826481,0.000007931464,0.00001057337,0.00010476807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841046,0.00008623524,0.0010175772,0.00012286966,0.00016614777,0.00019670479],"domain_scores_gemma":[0.99603975,0.0021482138,0.0009828755,0.00018475905,0.00022311404,0.00042128412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010174069,0.00009831974,0.0008263795,0.00005118535,0.000020954285,0.000004310703,0.00009824532,0.00013453669,0.000057085992],"category_scores_gemma":[0.0016141969,0.0000593976,0.00011477086,0.00005332617,0.000068162386,0.0005584857,0.000049218754,0.00021511463,0.000005785444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009772489,0.0026426706,0.24547371,0.000094494244,0.0003493057,0.0000056758377,0.00073422113,6.831372e-7,0.0004718073,0.000006919252,0.00079401303,0.739654],"study_design_scores_gemma":[0.008906242,0.05167968,0.11512526,0.00009184339,0.00077782985,0.00007714649,0.00008070163,0.003037888,0.001487539,0.00001090665,0.8186105,0.00011445692],"about_ca_topic_score_codex":0.0000041437265,"about_ca_topic_score_gemma":0.0000011029339,"teacher_disagreement_score":0.8178165,"about_ca_system_score_codex":0.000044425753,"about_ca_system_score_gemma":0.00018726477,"threshold_uncertainty_score":0.2422164},"labels":[],"label_agreement":null},{"id":"W2590769060","doi":"10.1200/jco.2013.31.4_suppl.330","title":"Adjuvant chemotherapy in the management of cholangiocarcinoma: A 10-year cohort analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Internal medicine; Cohort; Surgery; Radiation therapy; Retrospective cohort study; Gastroenterology; Incidence (geometry); Adenocarcinoma; Cancer","score_opus":0.07645872858245246,"score_gpt":0.42459657852886323,"score_spread":0.3481378499464108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590769060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97009856,0.0018412155,0.000035945628,0.010282456,0.00021473735,0.0003601884,0.0000010657179,0.0000034186712,0.017162407],"genre_scores_gemma":[0.99387133,0.0014816767,0.0015270485,0.0023376436,0.00034706388,0.000014496433,0.0000018862394,0.00000837069,0.0004104575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720836,0.0002361998,0.0017743667,0.00016095625,0.00042622862,0.0001938972],"domain_scores_gemma":[0.9978254,0.0005507775,0.00092044316,0.00029268005,0.00029508505,0.00011561668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027500906,0.00011791337,0.0015818026,0.00021138937,0.000019559046,0.0000074295267,0.0002564963,0.00014568583,0.0005101211],"category_scores_gemma":[0.00015412351,0.00006540063,0.00082317804,0.00051172165,0.00016002773,0.000067015135,0.000045518776,0.00049045775,0.000024823492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082040654,0.0009767277,0.9486813,0.000038165348,0.004425118,0.00027929724,0.00033334867,0.0000047549343,0.000011423539,0.000093913,0.014409237,0.029926311],"study_design_scores_gemma":[0.0057101864,0.0023946604,0.97498256,0.00004770015,0.002120349,0.000048239293,0.0009353576,0.000028821414,0.000008521966,0.00012434738,0.0135418875,0.00005739866],"about_ca_topic_score_codex":0.000082105056,"about_ca_topic_score_gemma":0.000030135454,"teacher_disagreement_score":0.029868912,"about_ca_system_score_codex":0.0000732986,"about_ca_system_score_gemma":0.00017454462,"threshold_uncertainty_score":0.55854684},"labels":[],"label_agreement":null},{"id":"W2590780582","doi":"10.1200/jco.2012.30.34_suppl.183","title":"Safe chemotherapy: Clinicians driving technology and not the other way around.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electronic Health Records Systems","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Cancer Care Ontario","funders":"","keywords":"Guideline; Usability; Medicine; Clinical decision support system; Audit; Vendor; Computerized physician order entry; Patient safety; Quality management; MEDLINE; Quality (philosophy); Health information technology; Nursing; Decision support system; Process management; Health care; Management system; Computer science; Operations management","score_opus":0.22334130434404817,"score_gpt":0.5833460777426843,"score_spread":0.3600047733986361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590780582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8324309,0.002015253,0.00056524266,0.14378181,0.007691912,0.000611109,0.000001750131,0.00003573565,0.012866295],"genre_scores_gemma":[0.95642126,0.0015912113,0.0013075165,0.029720185,0.008949006,0.000016536349,1.8044719e-7,0.000046547826,0.0019475606],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9896512,0.0039553596,0.0047944696,0.00020460674,0.00032220202,0.0010721696],"domain_scores_gemma":[0.97791547,0.016400818,0.004436484,0.000402142,0.000360589,0.00048450512],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.02960713,0.00019114156,0.0016337627,0.00022555757,0.00046021765,0.0000058448977,0.0004852399,0.0014364687,0.00033807106],"category_scores_gemma":[0.007460106,0.0001103285,0.00026560234,0.0003204909,0.00042902847,0.00018462139,0.00012568428,0.0049461564,0.0002134413],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043931123,0.00033450237,0.72481006,0.000056278368,0.00018528278,0.000008631098,0.0009759839,6.558265e-7,0.00006905717,0.006455048,0.0112075815,0.25545758],"study_design_scores_gemma":[0.0026821466,0.0020208156,0.14360428,0.00015699671,0.0000622778,0.00010838823,0.0019061002,0.000039850038,0.000006998447,0.0012277571,0.84807956,0.00010485229],"about_ca_topic_score_codex":0.00008264458,"about_ca_topic_score_gemma":0.00042887844,"teacher_disagreement_score":0.836872,"about_ca_system_score_codex":0.00037791274,"about_ca_system_score_gemma":0.002557743,"threshold_uncertainty_score":0.99985987},"labels":[],"label_agreement":null},{"id":"W2590783949","doi":"10.1200/jco.2015.33.3_suppl.235","title":"Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Multivariate analysis; Univariate analysis; Biliary tract cancer; Prognostic model; Oncology; Cancer; Overall survival; Gemcitabine","score_opus":0.3576095081168085,"score_gpt":0.5228105478692894,"score_spread":0.16520103975248085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590783949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930068,0.00027334783,0.00035319547,0.0018727022,0.0006890987,0.0024131166,0.000005151933,0.000005282149,0.0013812819],"genre_scores_gemma":[0.9940582,0.00010810187,0.00422845,0.00040980693,0.00051532005,0.0000795795,0.000001730133,0.00002171009,0.00057713856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396485,0.0016180774,0.002976289,0.0002604051,0.0007854738,0.00039487408],"domain_scores_gemma":[0.9925187,0.0037805156,0.0014576212,0.00040267906,0.0013240229,0.0005164667],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012436612,0.00016601695,0.0027311798,0.00014324699,0.000044465654,0.000006061202,0.00041033077,0.00041026206,0.0000173498],"category_scores_gemma":[0.013288455,0.000098037235,0.00036222604,0.00021163182,0.00026319252,0.00015030557,0.00011574337,0.000964108,0.0000020990972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15930508,0.014449634,0.81875086,0.00006209824,0.0003040295,0.00014470126,0.0007509156,0.0009990769,0.00004216134,0.00008215318,0.0010186884,0.0040905923],"study_design_scores_gemma":[0.3025744,0.12887292,0.517083,0.0001326731,0.0009934899,0.00005982525,0.0025542774,0.044978596,0.000013092505,0.0017791556,0.00082029606,0.0001382922],"about_ca_topic_score_codex":0.00019086525,"about_ca_topic_score_gemma":0.0009019427,"teacher_disagreement_score":0.3016679,"about_ca_system_score_codex":0.00030934735,"about_ca_system_score_gemma":0.0079809,"threshold_uncertainty_score":0.99764293},"labels":[],"label_agreement":null},{"id":"W2590785206","doi":"10.1200/jco.2013.31.4_suppl.486","title":"Adjuvant treatment and outcomes in patients with stage III colon cancer (CC) who do not fit clinical trial eligibility criteria (CTEC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; FOLFOX; Population; Cohort; Cancer; Colorectal cancer; Surgery; Stage (stratigraphy); Clinical trial; Oxaliplatin","score_opus":0.16531933474985305,"score_gpt":0.5340303772850059,"score_spread":0.36871104253515286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590785206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910676,0.00048741009,0.00000101951,0.005196047,0.0013963057,0.0013586475,0.000029392359,0.000007714902,0.0004558784],"genre_scores_gemma":[0.99475944,0.002287564,0.0003190547,0.0013224304,0.0005410896,0.00008267288,0.000002952479,0.000016043752,0.00066874485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955104,0.0004848266,0.0029771973,0.00038351034,0.00033369267,0.00031037134],"domain_scores_gemma":[0.99519795,0.0022502816,0.001411294,0.00023111912,0.0004998878,0.0004094581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015117001,0.0002604509,0.0032986272,0.00009328263,0.00005680238,0.000022477187,0.0000950938,0.0003369995,0.00028845877],"category_scores_gemma":[0.0015073621,0.00013595144,0.0004130193,0.00009123427,0.0003634761,0.00014241897,0.00007634351,0.0005874415,0.000005384163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13199124,0.010755855,0.7169555,0.00001244932,0.0006917623,0.00008046565,0.00013950588,5.474489e-7,8.882941e-7,0.0000031277689,0.0007482921,0.13862038],"study_design_scores_gemma":[0.22852571,0.075006105,0.68501455,0.00006283825,0.0003661269,0.0000035605951,0.000071345195,0.000009774016,0.000002150356,0.000023532742,0.01082319,0.00009110748],"about_ca_topic_score_codex":0.00084199104,"about_ca_topic_score_gemma":0.0018607347,"teacher_disagreement_score":0.13852926,"about_ca_system_score_codex":0.0005230884,"about_ca_system_score_gemma":0.0008586088,"threshold_uncertainty_score":0.55439395},"labels":[],"label_agreement":null},{"id":"W2590790023","doi":"10.1200/jco.2016.34.2_suppl.458","title":"The impact of histological variants on bladder cancer survival: A population-based analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Oncology; Proportional hazards model; Surveillance, Epidemiology, and End Results; Population; Cohort; Adenocarcinoma; Cancer; Pathology; Cancer registry","score_opus":0.1849036059960199,"score_gpt":0.5213591067956634,"score_spread":0.33645550079964354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590790023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98373103,0.0004425059,0.00034333696,0.012521369,0.0009108908,0.00015060687,0.000024042367,0.0000066067255,0.0018696233],"genre_scores_gemma":[0.99785495,0.00042369455,0.00015185836,0.00068070914,0.0005338159,0.000004454548,0.0000014209749,0.000009755296,0.00033933195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971289,0.00052773784,0.001618507,0.00015289464,0.00037636925,0.00019556917],"domain_scores_gemma":[0.9929908,0.004552078,0.0015144685,0.00024036325,0.0004465233,0.00025578114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017040323,0.00012599786,0.0014226348,0.00012467407,0.0000494256,0.000003937737,0.00015402868,0.00024980292,0.00076204847],"category_scores_gemma":[0.0028031168,0.0000460252,0.0012963502,0.00024009628,0.00017817164,0.000036751415,0.000013878584,0.00031940787,0.00000743357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008331024,0.0013562039,0.898404,0.0000026230184,0.0049119517,0.000086547174,0.000009843738,0.0001540369,0.000077134944,0.00011366602,0.0020482014,0.08450476],"study_design_scores_gemma":[0.0067014527,0.010852597,0.9775335,0.000038909133,0.0019945109,0.00001087178,0.0000053295958,0.00008185648,0.000019981862,0.0003828877,0.002326359,0.000051706036],"about_ca_topic_score_codex":0.0006675872,"about_ca_topic_score_gemma":0.00027829545,"teacher_disagreement_score":0.08445306,"about_ca_system_score_codex":0.00035574762,"about_ca_system_score_gemma":0.0023765366,"threshold_uncertainty_score":0.8343896},"labels":[],"label_agreement":null},{"id":"W2590791596","doi":"10.1200/jco.2015.33.29_suppl.67","title":"Inclusion criteria for cancer cachexia clinical trials: CT-defined skeletal muscle loss versus body weight loss.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cachexia; Weight loss; Sarcopenia; Cancer; Internal medicine; Skeletal muscle; Wasting; Gastroenterology; Obesity","score_opus":0.5607317782436527,"score_gpt":0.641536855030548,"score_spread":0.0808050767868953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590791596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.773725,0.0035069634,0.0010493842,0.18198398,0.036261976,0.0010247121,0.000048606104,0.000048187205,0.002351203],"genre_scores_gemma":[0.9356143,0.005235057,0.017263966,0.016606605,0.024774663,0.000032678945,0.000022265203,0.000053222284,0.00039728312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886824,0.0026480493,0.007223953,0.00034879002,0.0006235485,0.00047326935],"domain_scores_gemma":[0.9784534,0.01414152,0.0039003866,0.00029398463,0.0014873073,0.0017234291],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04311409,0.00022465007,0.0035608453,0.00018641358,0.00016338886,0.000015332247,0.0002805487,0.0006231935,0.0005037557],"category_scores_gemma":[0.04756479,0.00016070608,0.0013398452,0.00016600621,0.0003803274,0.00016183629,0.00024897692,0.0017383179,0.000035565878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08311154,0.007242617,0.043449465,0.00036316513,0.0009824384,0.0022085654,0.00029590869,0.0000031008167,0.00023074796,0.0009956699,0.42627078,0.434846],"study_design_scores_gemma":[0.07076888,0.016521769,0.025159856,0.00023682113,0.00078313163,0.0002439339,0.00007173486,0.0004881716,0.000026107089,0.0023219392,0.883221,0.00015670042],"about_ca_topic_score_codex":0.000052174684,"about_ca_topic_score_gemma":0.00005891203,"teacher_disagreement_score":0.4569502,"about_ca_system_score_codex":0.00045989125,"about_ca_system_score_gemma":0.0052153436,"threshold_uncertainty_score":0.98531544},"labels":[],"label_agreement":null},{"id":"W2590792234","doi":"10.1200/jco.2012.30.34_suppl.233","title":"Patient-centered wait time measurement in Ontario.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Referral; Colorectal cancer; Cohort; Stage (stratigraphy); Cancer; Internal medicine; Chemotherapy; Lung cancer; Oncology; Surgery; Family medicine","score_opus":0.5829692135386074,"score_gpt":0.5649596914009644,"score_spread":0.018009522137643064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590792234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806347,0.00017793223,0.00011398983,0.011837296,0.0024262858,0.0002819394,8.545695e-7,0.0000065170248,0.004520476],"genre_scores_gemma":[0.98539263,0.000055261316,0.006265548,0.007042638,0.0010596326,0.0000026998837,0.0000037206837,0.000014365458,0.00016352821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224037,0.00073255785,0.005750657,0.00013745239,0.00080557814,0.00033336726],"domain_scores_gemma":[0.9930466,0.0026668592,0.0027563048,0.00019336573,0.0007867377,0.0005501228],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01449214,0.0001222389,0.0011954961,0.00013797828,0.00001801915,0.000005705529,0.00010095545,0.00028253824,0.0017262726],"category_scores_gemma":[0.027313888,0.00009170825,0.0004089276,0.00010528769,0.00007070723,0.0003454492,0.00006273277,0.0014629939,0.00020972469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051281396,0.0057692365,0.7451096,0.0000094087045,0.00022968857,0.00016642342,0.00030827834,0.0000042044644,0.0004404519,0.00001903527,0.019834163,0.22298135],"study_design_scores_gemma":[0.009074415,0.0067982306,0.67265815,0.00008215766,0.00027290266,0.00024102937,0.00015734088,0.000027307877,0.000038379927,0.00009053731,0.31048506,0.00007451913],"about_ca_topic_score_codex":0.0016743272,"about_ca_topic_score_gemma":0.009951181,"teacher_disagreement_score":0.2906509,"about_ca_system_score_codex":0.0010448088,"about_ca_system_score_gemma":0.002956667,"threshold_uncertainty_score":0.9991863},"labels":[],"label_agreement":null},{"id":"W2590795949","doi":"10.1200/jco.2016.34.4_suppl.256","title":"Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Cetuximab; Internal medicine; Oncology; Colorectal cancer; Proportional hazards model; Multivariate analysis; Univariate analysis; Progression-free survival; Refractory (planetary science); Chemotherapy; Cancer","score_opus":0.10265635139880135,"score_gpt":0.456099759367497,"score_spread":0.35344340796869567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590795949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043405,0.0005369855,0.000041323347,0.008259885,0.00023622268,0.00022366547,0.000025021098,0.000005583983,0.00023728143],"genre_scores_gemma":[0.9956176,0.0015775064,0.00046371666,0.00066218304,0.00033246694,0.000004123002,8.276323e-7,0.000013555901,0.0013279724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594593,0.0007694132,0.002439592,0.00023029787,0.0004168853,0.00019789254],"domain_scores_gemma":[0.9917189,0.0052014193,0.0017028571,0.000331627,0.00066546863,0.0003797496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030427775,0.00016131699,0.0030593257,0.0005920331,0.000024187386,0.0000029016894,0.00010958712,0.0002866439,0.00017655299],"category_scores_gemma":[0.010542307,0.000087243825,0.0009044085,0.00036834512,0.0003642391,0.000061524544,0.000032745203,0.00021939367,0.000005395269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19177568,0.002248004,0.73955,0.000016251051,0.003235207,0.00055117003,0.0003425589,0.0000031482914,0.015402183,0.000012758686,0.0012110601,0.045652002],"study_design_scores_gemma":[0.01188916,0.052304022,0.9075594,0.00016199058,0.0034383922,0.00036215247,0.00014222432,0.00001896428,0.0007238984,0.000020817077,0.023303427,0.000075537064],"about_ca_topic_score_codex":0.00007162609,"about_ca_topic_score_gemma":0.00005776226,"teacher_disagreement_score":0.17988652,"about_ca_system_score_codex":0.00038741843,"about_ca_system_score_gemma":0.0011429916,"threshold_uncertainty_score":0.9977923},"labels":[],"label_agreement":null},{"id":"W2590797467","doi":"10.1200/jco.2005.23.16_suppl.8045","title":"Patient controlled methyphenidate [PCM] for cancer-related fatigue [CRF]: A randomized controlled trial","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Somnolence; Nausea; Cancer-related fatigue; Internal medicine; Cancer; Physical therapy; Adverse effect","score_opus":0.12855012789128675,"score_gpt":0.5252281053468183,"score_spread":0.39667797745553157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590797467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8969641,0.0077432534,0.00044362544,0.05899669,0.011085135,0.01686244,0.000016171158,0.000049643426,0.007838982],"genre_scores_gemma":[0.9670198,0.0058882996,0.0069103497,0.008074396,0.0069859223,0.0019129779,0.000010503491,0.000046205878,0.0031515548],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98935294,0.0024062821,0.007140868,0.00027894147,0.0004177982,0.00040318543],"domain_scores_gemma":[0.96858954,0.023872185,0.0058949133,0.00016649123,0.0009589901,0.00051786145],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007764966,0.00030575533,0.011205423,0.00022511557,0.0000709761,0.000012354083,0.00015121467,0.000636446,0.001254069],"category_scores_gemma":[0.010178971,0.00017368866,0.0046247966,0.00012987872,0.0002552193,0.00010676128,0.000028299339,0.0009272983,0.000013008461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9100471,0.006911832,0.000081465114,0.000014287978,0.011431091,0.00009542461,0.00023829905,0.00010726272,0.00014040853,0.000159145,0.011291522,0.05948214],"study_design_scores_gemma":[0.8471893,0.029085401,0.000049172093,0.00004738502,0.011765825,0.00006235706,0.000027281816,0.0022136143,0.00009195421,0.0003759729,0.10896289,0.00012883906],"about_ca_topic_score_codex":0.000022466917,"about_ca_topic_score_gemma":0.00007189764,"teacher_disagreement_score":0.09767137,"about_ca_system_score_codex":0.0004049805,"about_ca_system_score_gemma":0.0032407488,"threshold_uncertainty_score":0.99965894},"labels":[],"label_agreement":null},{"id":"W2590798347","doi":"10.1200/jco.2016.34.26_suppl.103","title":"Randomized trial of inpatient palliative care in patients hospitalized for hematopoietic stem cell transplantation (HCT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hospital Anxiety and Depression Scale; Anxiety; Quality of life (healthcare); Mood; Palliative care; Randomized controlled trial; Depression (economics); Transplantation; Patient Health Questionnaire; Physical therapy; Intervention (counseling); Internal medicine; Psychiatry; Depressive symptoms; Nursing","score_opus":0.18632593368181818,"score_gpt":0.5038120584836043,"score_spread":0.3174861248017862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590798347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505883,0.0004799443,0.0011249668,0.0005257053,0.0010138163,0.0012618841,0.00003077762,0.0000027656647,0.0005013022],"genre_scores_gemma":[0.9944746,0.00314066,0.0019688515,0.00012835344,0.00019970478,0.000026729165,0.000008325468,0.0000118612825,0.000040941883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952432,0.0007016488,0.0033989646,0.00014088146,0.00036346365,0.00015184343],"domain_scores_gemma":[0.98866296,0.0070770537,0.0029740748,0.000108544016,0.0010436352,0.00013372261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019920368,0.00012818049,0.0026515613,0.00014914255,0.000009790925,0.0000013094922,0.00010417819,0.0002843695,0.000021379961],"category_scores_gemma":[0.002446912,0.00007135222,0.00081977947,0.0000869799,0.00019774136,0.00006887862,0.000011367215,0.00019991165,0.0000013967218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8983435,0.0016328157,0.07218009,0.00030113547,0.00020456118,0.000016189679,0.0041917134,0.0000021380624,0.000037236197,0.00005044332,0.000107300446,0.022932867],"study_design_scores_gemma":[0.9442847,0.02921073,0.020372674,0.0012749054,0.0005865151,6.872234e-7,0.00054056034,0.000004746696,0.0021148166,0.00028741683,0.0012439981,0.00007825777],"about_ca_topic_score_codex":0.000007930241,"about_ca_topic_score_gemma":0.0000073468314,"teacher_disagreement_score":0.051807422,"about_ca_system_score_codex":0.00012597306,"about_ca_system_score_gemma":0.0005781329,"threshold_uncertainty_score":0.2929359},"labels":[],"label_agreement":null},{"id":"W2590799755","doi":"10.1200/jco.2016.34.4_suppl.750","title":"Effects of adjuvant 5FU/oxaliplatin chemotherapy in individuals treated for colon cancer on cognitive and mobility function.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Oxaliplatin; Stroop effect; Neuropsychological test; Colorectal cancer; Physical therapy; Chemotherapy; Neuropsychology; Verbal learning; Internal medicine; Cognition; Oncology; Cancer; Psychiatry","score_opus":0.07079276472626138,"score_gpt":0.45996081112289383,"score_spread":0.38916804639663244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590799755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222285,0.0009582798,0.00019050129,0.0047682314,0.0005272499,0.0010808861,0.00002960161,0.0000060460043,0.0002163378],"genre_scores_gemma":[0.99424785,0.00320183,0.000100954676,0.0018350924,0.00037590982,0.00007697524,0.0000011021816,0.000014252214,0.00014602102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761075,0.0003248816,0.001449383,0.00020866553,0.0002144972,0.00019184603],"domain_scores_gemma":[0.9846161,0.0132920705,0.0012959145,0.000060302005,0.0005894126,0.00014618541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017903484,0.0001433354,0.001468209,0.0001545733,0.000025636678,0.0000018236419,0.00004192614,0.00030103792,0.000075669115],"category_scores_gemma":[0.0065223775,0.00008323322,0.00023171479,0.00012605815,0.00035846513,0.000060959595,0.00002067103,0.0003600516,0.000001701387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037387826,0.0031450547,0.48555067,0.00015574448,0.0012134155,0.000030269508,0.00019084828,0.000001218647,0.0017187049,0.00001404225,0.0011542115,0.46943802],"study_design_scores_gemma":[0.050828584,0.03998827,0.90096664,0.0013940316,0.00072570564,0.000012995217,0.00009669016,0.0000095602945,0.0035519875,0.00035212204,0.0019936047,0.000079781916],"about_ca_topic_score_codex":0.000025782896,"about_ca_topic_score_gemma":0.000077426994,"teacher_disagreement_score":0.46935824,"about_ca_system_score_codex":0.00022088682,"about_ca_system_score_gemma":0.00046297043,"threshold_uncertainty_score":0.7808366},"labels":[],"label_agreement":null},{"id":"W2590801142","doi":"10.1200/jco.2016.34.26_suppl.168","title":"Integrating palliative care services in oncology clinics: An application of the Edmonton Symptom Assessment System (ESAS).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Palliative care; Quality of life (healthcare); Cancer; Ambulatory care; Family medicine; Emergency medicine; Internal medicine; Health care; Nursing","score_opus":0.21034733472333933,"score_gpt":0.5808101150700281,"score_spread":0.3704627803466888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590801142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892627,0.0009996494,0.0016074502,0.002754389,0.0009152234,0.0003744007,0.000012175627,0.000008599366,0.0040654195],"genre_scores_gemma":[0.98919284,0.0010295504,0.008333998,0.0006955393,0.00069676625,0.000012828997,0.000003195819,0.000013602319,0.000021669372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945185,0.0012292074,0.0034339984,0.00022467162,0.00040124505,0.00019237079],"domain_scores_gemma":[0.98827356,0.005306861,0.0045989836,0.00032749327,0.0013127631,0.00018036233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033614696,0.00015365046,0.0017953536,0.00012203721,0.000028612742,0.0000030661602,0.00038276264,0.0004604277,0.000012933834],"category_scores_gemma":[0.0016408623,0.000075599935,0.00042279725,0.00019021092,0.00024446854,0.00013094366,0.000085703614,0.0007173483,0.0000029009502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009122488,0.00065811997,0.7928305,0.00024253,0.00017774808,0.000029733064,0.0021123483,0.00001148182,0.0009182482,0.0009160103,0.00003062785,0.20116039],"study_design_scores_gemma":[0.008529143,0.012850627,0.9069016,0.004358669,0.0004065974,0.000021821706,0.025529126,0.00053526426,0.0007603867,0.0003061931,0.039680086,0.00012047257],"about_ca_topic_score_codex":0.00016018454,"about_ca_topic_score_gemma":0.0008021823,"teacher_disagreement_score":0.20103991,"about_ca_system_score_codex":0.00073899335,"about_ca_system_score_gemma":0.001817998,"threshold_uncertainty_score":0.355124},"labels":[],"label_agreement":null},{"id":"W2590807365","doi":"10.1200/jco.2013.31.6_suppl.337","title":"Survivorship care in Canadian genitourinary oncology: Toward a multidisciplinary perspective.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Survivorship curve; Population; Multidisciplinary approach; Cancer; Nursing; Internal medicine","score_opus":0.07698477424584199,"score_gpt":0.4478940540089777,"score_spread":0.3709092797631357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590807365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97135884,0.0031766123,0.000037346726,0.010555036,0.001901545,0.00025783703,0.000009475189,0.000003478938,0.01269982],"genre_scores_gemma":[0.9920285,0.0005455684,0.004479442,0.00096801546,0.0017087256,0.000025088728,0.000009510715,0.000024600544,0.0002105727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969588,0.00077026413,0.0013630453,0.00031057678,0.00016811273,0.00042923362],"domain_scores_gemma":[0.99721384,0.00033502287,0.0006786426,0.00025560308,0.00094853074,0.0005683762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018095945,0.00016261204,0.0006762208,0.00022152171,0.000059396974,0.000013462005,0.0004362903,0.0008004965,0.00016732296],"category_scores_gemma":[0.001975648,0.00014342935,0.00032666372,0.00016206545,0.00025259465,0.000016142138,0.00013356324,0.0008270673,0.000048749065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028831079,0.0020778999,0.737823,0.000067061796,0.00076400937,0.0018041945,0.0069726263,0.0011753353,0.007860037,0.0003416595,0.034697156,0.20353393],"study_design_scores_gemma":[0.00509496,0.015259912,0.68796223,0.000038243954,0.00008879179,0.00049393426,0.017537951,0.00008921981,0.00086949323,0.001406083,0.27076104,0.00039811566],"about_ca_topic_score_codex":0.045903016,"about_ca_topic_score_gemma":0.3522695,"teacher_disagreement_score":0.30636647,"about_ca_system_score_codex":0.0014495071,"about_ca_system_score_gemma":0.011858545,"threshold_uncertainty_score":0.9937433},"labels":[],"label_agreement":null},{"id":"W2590808165","doi":"10.1200/jco.2013.31.6_suppl.256","title":"Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Nomogram; Proportional hazards model; Docetaxel; Internal medicine; Oncology; Discontinuation; Chemotherapy; Hazard ratio; Concordance; Prognostic variable; Survival analysis; Cancer; Confidence interval","score_opus":0.08535991598127514,"score_gpt":0.4134286707482571,"score_spread":0.328068754766982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590808165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605293,0.00022814353,0.001913699,0.0084319785,0.00024937038,0.0026456413,0.000092770875,0.00002128475,0.00036418624],"genre_scores_gemma":[0.97963405,0.00087883783,0.013975114,0.0028183667,0.0005692561,0.000449984,0.000023254202,0.00007301733,0.0015781194],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975006,0.00010118168,0.0013404777,0.000299646,0.0003906641,0.00036742183],"domain_scores_gemma":[0.99573904,0.0010116529,0.0011176108,0.00021056585,0.001446883,0.0004742357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002711405,0.00031862862,0.001641813,0.000102333455,0.00007131196,0.000017379625,0.000119862234,0.00017704349,0.00028145337],"category_scores_gemma":[0.00035055637,0.00015821247,0.0003606832,0.000117396296,0.00017195466,0.00015828235,0.000011189154,0.00028065423,0.00001526503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062363233,0.022795368,0.58616304,0.0001707232,0.007031852,0.0002181495,0.00056735484,0.0011429095,0.00006746243,0.000017863573,0.001236779,0.31822523],"study_design_scores_gemma":[0.21403064,0.44549963,0.300962,0.00067050505,0.009348067,0.0002508631,0.00013864625,0.0107275285,0.0003994807,0.00037006068,0.017010752,0.0005918028],"about_ca_topic_score_codex":0.00037673116,"about_ca_topic_score_gemma":0.00075968646,"teacher_disagreement_score":0.42270428,"about_ca_system_score_codex":0.0003899257,"about_ca_system_score_gemma":0.002711979,"threshold_uncertainty_score":0.64517176},"labels":[],"label_agreement":null},{"id":"W2590818354","doi":"10.1200/jco.2013.31.6_suppl.36","title":"Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Internal medicine; Cohort; Population; Prostatectomy; Cumulative incidence; Prostate cancer; Oncology; Incidence (geometry); Clinical endpoint; Pathology; Clinical trial; Cancer","score_opus":0.09002796308985557,"score_gpt":0.4412508873607713,"score_spread":0.3512229242709157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590818354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292845,0.0011904397,0.000024969338,0.004297835,0.00014754011,0.0009572809,0.0000131787665,0.000007817738,0.0004325216],"genre_scores_gemma":[0.99419725,0.0019137869,0.003228526,0.0001544673,0.00013719393,0.00004353586,0.0000185519,0.00001654097,0.00029016266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970591,0.0007699344,0.0011987975,0.00020765778,0.0005013848,0.00026308946],"domain_scores_gemma":[0.9965733,0.0008956343,0.0015060024,0.00018710403,0.00042677787,0.00041116227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019462436,0.00014616022,0.0010499082,0.00022343203,0.00003079723,0.000013204384,0.00012841125,0.00014121571,0.00013129771],"category_scores_gemma":[0.0010092265,0.00007285596,0.00018380214,0.00015461419,0.00031452216,0.00018929696,0.00005156661,0.0008492745,0.000010806926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023750726,0.0025118608,0.89031,0.00013850306,0.00040374676,0.0026790162,0.00022851497,0.000054054915,0.0013043788,0.00001620097,0.0015310743,0.077071905],"study_design_scores_gemma":[0.015114114,0.01688255,0.9642925,0.00028543585,0.00045581104,0.00014920124,0.00021849884,0.00008115176,0.0011341195,0.0010849652,0.00022813653,0.00007350025],"about_ca_topic_score_codex":0.00006212376,"about_ca_topic_score_gemma":0.000010154173,"teacher_disagreement_score":0.076998405,"about_ca_system_score_codex":0.00017453553,"about_ca_system_score_gemma":0.0014788697,"threshold_uncertainty_score":0.36897224},"labels":[],"label_agreement":null},{"id":"W2590820075","doi":"10.1200/jco.2008.26.15_suppl.6633","title":"Generalizability of results from oncology clinical trials: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Irinotecan; FOLFIRI; Internal medicine; Colorectal cancer; Oncology; Clinical trial; Population; Clinical endpoint; Cancer","score_opus":0.3097883033506736,"score_gpt":0.5251583597246001,"score_spread":0.21537005637392653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590820075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945636,0.0004903946,0.00003660031,0.0026158327,0.00094732817,0.0006481653,0.00021625221,0.0000053747344,0.00047647144],"genre_scores_gemma":[0.9929839,0.0008560284,0.005133872,0.00061205425,0.00034672776,0.000015301459,0.000015411257,0.00001548435,0.000021216909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9866924,0.004052646,0.007991402,0.00038472872,0.0006047802,0.00027401422],"domain_scores_gemma":[0.9739992,0.0173112,0.0068401913,0.00027467526,0.0012444655,0.00033029297],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010704699,0.00023443055,0.005796156,0.0001678183,0.00003700145,0.0000014792417,0.00017880758,0.00042877003,0.00011119787],"category_scores_gemma":[0.021644747,0.00014107951,0.00090120203,0.0002835468,0.0011323693,0.00006271835,0.000058604368,0.0009477367,9.369051e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13898706,0.014032975,0.8023112,0.000027404367,0.0015184504,0.0002825509,0.000260323,0.00015295127,0.000054747354,0.0000036084796,0.0011099769,0.041258737],"study_design_scores_gemma":[0.061940685,0.075025536,0.85902274,0.00013217799,0.0010501352,0.000009817804,0.00006787486,0.00009316259,0.00055899157,0.00004644671,0.0019499772,0.00010243488],"about_ca_topic_score_codex":0.0010558924,"about_ca_topic_score_gemma":0.002552097,"teacher_disagreement_score":0.07704638,"about_ca_system_score_codex":0.00055895303,"about_ca_system_score_gemma":0.005618743,"threshold_uncertainty_score":0.99674094},"labels":[],"label_agreement":null},{"id":"W2590822106","doi":"10.1200/jco.2011.29.15_suppl.542","title":"Long-term results of the Toronto magnetic resonance imaging (MRI) breast surveillance study of women with <i>BRCA1</i> or <i>BRCA2</i> mutations.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mammography; Breast cancer; BRCA mutation; Magnetic resonance imaging; Cancer; Oncology; Internal medicine; Breast MRI; Stage (stratigraphy); Confidence interval; Prospective cohort study; Radiology; Gynecology","score_opus":0.037617051019016606,"score_gpt":0.3615496029328665,"score_spread":0.32393255191384984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590822106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995496,0.0019023223,0.00009513944,0.00035630763,0.00062129926,0.0002795661,0.000035633842,0.0000026928772,0.0012110842],"genre_scores_gemma":[0.99735767,0.00038550637,0.0013885859,0.00028764005,0.000297544,0.000014998045,0.0000021583255,0.000021204005,0.00024472654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996505,0.00065051275,0.0019827343,0.00028293548,0.00032285135,0.0002559324],"domain_scores_gemma":[0.9959591,0.00034892702,0.0021887792,0.00055378,0.00081712264,0.00013228835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024516848,0.00015573813,0.00070713076,0.000030231815,0.00004852408,0.0000056616027,0.00059878675,0.00015956559,0.00006735746],"category_scores_gemma":[0.00084851694,0.00009405336,0.00014955288,0.0001614522,0.00047143205,0.000017236594,0.00014755236,0.00026903235,7.5992887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028376795,0.0041632093,0.80943346,0.000038481245,0.00037246503,0.000097548065,0.0028214876,0.00012207545,0.0031170154,0.00000943923,0.0025920866,0.14885594],"study_design_scores_gemma":[0.008195956,0.012844097,0.97044086,0.000049998485,0.00008574387,0.00033166696,0.0013403563,0.0000067897913,0.0014127208,0.000024973033,0.005134205,0.00013261952],"about_ca_topic_score_codex":0.00013443678,"about_ca_topic_score_gemma":0.003863046,"teacher_disagreement_score":0.16100742,"about_ca_system_score_codex":0.00018475794,"about_ca_system_score_gemma":0.0017010736,"threshold_uncertainty_score":0.38353845},"labels":[],"label_agreement":null},{"id":"W2590827642","doi":"10.1200/jco.2013.31.4_suppl.444","title":"A case of the utilization of genomic information in the management of metastatic colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Bevacizumab; Colorectal cancer; KRAS; Metastasis; Medicine; Loss of heterozygosity; Cancer research; Somatic cell; Copy-number variation; Cancer; Gene; Genome; Biology; Internal medicine; Allele; Genetics; Chemotherapy","score_opus":0.14165361652772104,"score_gpt":0.46436384505741357,"score_spread":0.32271022852969256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590827642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543923,0.0004015515,0.000020191255,0.0018576729,0.00024673087,0.00043719966,0.000005133229,5.754553e-7,0.0015917235],"genre_scores_gemma":[0.9982601,0.0009913148,0.00043536746,0.0002508243,0.00002985779,0.000016344988,5.328062e-7,0.0000020776004,0.000013585133],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980346,0.00018686835,0.001496675,0.00003768781,0.00017583162,0.00006832634],"domain_scores_gemma":[0.9975206,0.000493257,0.0015828796,0.00008121204,0.0002955853,0.000026446298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010010401,0.000054701988,0.0005996999,0.000057209836,0.000016560996,0.0000016595629,0.00009089168,0.000045725978,0.00006816629],"category_scores_gemma":[0.00020656142,0.000025006686,0.00018707973,0.00014413676,0.00015182704,0.00007947902,0.000039244944,0.00015943519,8.158479e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051548467,0.0030055186,0.14878228,0.00074110716,0.00298245,0.00038351916,0.0073001133,0.00046281246,0.00033010877,0.00097347266,0.001982915,0.8279008],"study_design_scores_gemma":[0.004601692,0.005217371,0.982898,0.00012746673,0.00065944926,0.00035484755,0.0038018806,0.00035147526,0.00018272182,0.00029476223,0.0014819356,0.00002842722],"about_ca_topic_score_codex":0.00034889753,"about_ca_topic_score_gemma":0.00030341977,"teacher_disagreement_score":0.8341157,"about_ca_system_score_codex":0.00008611359,"about_ca_system_score_gemma":0.00028396214,"threshold_uncertainty_score":0.1019743},"labels":[],"label_agreement":null},{"id":"W2590831645","doi":"10.1200/jco.2015.33.29_suppl.13","title":"Timeliness of end-of-life (EOL) discussions for blood cancers: A national survey of hematologic oncologists.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Family medicine; Do not resuscitate; Internal medicine; Emergency medicine; Intensive care medicine","score_opus":0.6994849106915128,"score_gpt":0.6225453393031799,"score_spread":0.07693957138833285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590831645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987887,0.0032983758,0.001166131,0.0036629431,0.0012381324,0.0003221563,0.00021141763,0.0000055778655,0.0022082462],"genre_scores_gemma":[0.98105484,0.0009917059,0.016989836,0.00037899485,0.00043554278,0.0000067709175,0.000025059819,0.000011941218,0.00010532786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945599,0.0006638802,0.0038009945,0.00016292997,0.00062499795,0.00018734175],"domain_scores_gemma":[0.97842026,0.011313743,0.0046619573,0.00016938032,0.005077574,0.0003570962],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007202239,0.0001432077,0.0027779483,0.00017991968,0.000014796426,0.0000011906652,0.0002711781,0.00043720275,0.000080236],"category_scores_gemma":[0.07558479,0.00008807818,0.00056142843,0.00026915607,0.0007046717,0.000071025206,0.00006860365,0.00041594618,0.0000013994758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015165552,0.006012695,0.93631727,0.0005128629,0.0018688082,0.000067954345,0.0006402444,0.0003014605,0.00065344194,0.0011210411,0.025303889,0.012034759],"study_design_scores_gemma":[0.07152969,0.08053544,0.7284138,0.0036471607,0.0031592394,0.0002723692,0.0033409337,0.001173078,0.009700974,0.007024753,0.09065999,0.0005425672],"about_ca_topic_score_codex":0.00034111383,"about_ca_topic_score_gemma":0.00047827387,"teacher_disagreement_score":0.20790347,"about_ca_system_score_codex":0.0001360125,"about_ca_system_score_gemma":0.009229611,"threshold_uncertainty_score":0.9963871},"labels":[],"label_agreement":null},{"id":"W2590837522","doi":"10.1200/jco.2009.27.15_suppl.e11613","title":"Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Anastrozole; Breast cancer; Tamoxifen; Cancer; Male breast cancer; Gynecology; Rash; Population; Estrogen receptor; Gastroenterology; Oncology","score_opus":0.07277460185859241,"score_gpt":0.4555349011277054,"score_spread":0.382760299269113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590837522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990134,0.0043290136,2.2023303e-7,0.0044631152,0.00015722525,0.0002648356,0.00004119625,0.000003020066,0.0006073518],"genre_scores_gemma":[0.99239635,0.0060387296,0.00013656201,0.0009623889,0.00021250092,0.000006748834,0.0000038909047,0.0000062446434,0.00023656532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976711,0.00019285323,0.001601425,0.00014670278,0.00017969368,0.00020820365],"domain_scores_gemma":[0.99798137,0.00042829572,0.00090452377,0.00008739637,0.00038012298,0.00021828165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028939277,0.00013638155,0.0012366694,0.00010742321,0.000025817637,0.0000019102454,0.000052481057,0.00017806148,0.00007525319],"category_scores_gemma":[0.00019516492,0.0000863878,0.00015136568,0.00007249206,0.00016205694,0.00005606595,0.000030777297,0.00023850244,0.0000016986605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005458208,0.0018060156,0.90175515,0.000044734872,0.00008655344,0.00016243872,0.00062151504,6.585713e-7,0.00008562736,0.0000013607015,0.0007506241,0.08922709],"study_design_scores_gemma":[0.013303527,0.017143693,0.96767706,0.00021877722,0.00013518897,0.00027038626,0.00027241977,0.00000753138,0.000072726405,0.000008253906,0.0008316884,0.000058775386],"about_ca_topic_score_codex":0.00026157248,"about_ca_topic_score_gemma":0.0005369964,"teacher_disagreement_score":0.08916832,"about_ca_system_score_codex":0.00040313916,"about_ca_system_score_gemma":0.00043544348,"threshold_uncertainty_score":0.35227922},"labels":[],"label_agreement":null},{"id":"W2590842281","doi":"10.1200/jco.2014.32.4_suppl.7","title":"Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prednisone; Abiraterone acetate; Placebo; Prostate cancer; Internal medicine; Adverse effect; Population; Ketoconazole; Urology; Randomized controlled trial; Cancer; Oncology; Gastroenterology; Androgen deprivation therapy; Dermatology; Pathology","score_opus":0.18533527850798012,"score_gpt":0.4686484202466603,"score_spread":0.28331314173868016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590842281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800764,0.0005679585,0.00008251451,0.0019965302,0.0011780867,0.01596514,0.000074743635,0.0000149229145,0.000043703963],"genre_scores_gemma":[0.99624884,0.0004425348,0.0013854002,0.0001198483,0.0004942389,0.0009872519,0.000084559804,0.000048416667,0.00018891878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902145,0.002398248,0.005071103,0.00050914014,0.0012656297,0.0005413255],"domain_scores_gemma":[0.98671037,0.0069310465,0.004854114,0.00038021477,0.0006809968,0.00044327535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007476345,0.00041115988,0.005301778,0.0003846537,0.000107996384,0.00006498039,0.00025529877,0.0002869745,0.00006996055],"category_scores_gemma":[0.00351509,0.00021132923,0.0009905146,0.00028628274,0.0004473528,0.00027561781,0.00003180972,0.0009042467,0.0000014304973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96640766,0.019348813,0.0017441589,0.00008338091,0.004179155,0.0005049826,0.0007098384,0.00025888285,0.00017189313,7.1113425e-7,0.00002444402,0.006566108],"study_design_scores_gemma":[0.9351259,0.058391947,0.0012782259,0.00077970116,0.0019681787,0.0000024183284,0.00011235861,0.0013691915,0.00061876094,0.000012342572,0.00014899134,0.0001919809],"about_ca_topic_score_codex":0.0003149679,"about_ca_topic_score_gemma":0.0005116258,"teacher_disagreement_score":0.039043136,"about_ca_system_score_codex":0.0004432751,"about_ca_system_score_gemma":0.0051356778,"threshold_uncertainty_score":0.91104716},"labels":[],"label_agreement":null},{"id":"W2590854912","doi":"10.1200/jco.2012.30.27_suppl.56","title":"Determination of breast density by bioimpedance.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Body Composition Measurement Techniques","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Breast density; Correlation; Pearson product-moment correlation coefficient; Breast imaging; Mammography; Nuclear medicine; Internal medicine; Cancer; Statistics; Mathematics","score_opus":0.14011768833105304,"score_gpt":0.48467475598015347,"score_spread":0.34455706764910043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590854912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159504,0.00031579638,0.011421825,0.0035955,0.0007860701,0.0001250127,0.000002953181,0.000016183478,0.0021415928],"genre_scores_gemma":[0.9709729,0.00013156162,0.027204525,0.00088662136,0.00074924994,7.5535496e-7,0.0000014848583,0.0000070294186,0.00004585352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976516,0.00029139975,0.0015145242,0.00006307894,0.0003451014,0.00013431451],"domain_scores_gemma":[0.99687165,0.00051126536,0.0015743205,0.00011748983,0.0006806804,0.00024457768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042842627,0.00006792235,0.0007636041,0.00008267593,0.00001535669,0.0000017812342,0.00008508044,0.0002412818,0.00008169289],"category_scores_gemma":[0.0011678307,0.000050831175,0.0002598308,0.000076789474,0.00013950089,0.00015327396,0.000023214023,0.00044702686,0.000007041223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019175871,0.0036397972,0.52472264,0.00004796946,0.00012120638,0.000035994806,0.00005312128,5.9155706e-8,0.09239866,0.00016042768,0.027372653,0.3495299],"study_design_scores_gemma":[0.00373252,0.006816693,0.92679495,0.00016284279,0.0004289173,0.0018953431,0.000028049195,0.00003736078,0.033093296,0.00030823844,0.02660926,0.0000925428],"about_ca_topic_score_codex":0.0000036775289,"about_ca_topic_score_gemma":0.0000012796582,"teacher_disagreement_score":0.4020723,"about_ca_system_score_codex":0.000099584904,"about_ca_system_score_gemma":0.00029972786,"threshold_uncertainty_score":0.20728351},"labels":[],"label_agreement":null},{"id":"W2590859698","doi":"10.1200/jco.2013.31.4_suppl.579","title":"Treatment and outcomes of patients with metastatic colorectal cancer (mCRC) with epidermal growth factor receptor (EGFR) therapy in the third-line setting.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; KRAS; Panitumumab; Cetuximab; Internal medicine; Colorectal cancer; Oncology; Irinotecan; Targeted therapy; Epidermal growth factor receptor; FOLFIRI; Oxaliplatin; Systemic therapy; Cancer; Breast cancer","score_opus":0.07045413628106793,"score_gpt":0.41166262760217376,"score_spread":0.3412084913211058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590859698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864201,0.00070041994,0.0000033765693,0.011688438,0.00015908932,0.0007503338,0.000025382009,0.0000037249085,0.00024914218],"genre_scores_gemma":[0.99565196,0.0019583036,0.0011063331,0.0010536597,0.00010570253,0.000057843754,0.0000035254109,0.000013615005,0.000049061717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978696,0.00032651683,0.0011334463,0.00016569904,0.00030188408,0.00020284372],"domain_scores_gemma":[0.99610806,0.0021424827,0.0010701091,0.00009250864,0.00045596375,0.00013090024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004221099,0.00020137143,0.001544298,0.00007661581,0.000045410976,0.000008699221,0.00008522271,0.00008487771,0.00013238683],"category_scores_gemma":[0.00036449655,0.00007440457,0.0001717525,0.0001190764,0.00028578634,0.00010531514,0.000018631792,0.000314405,0.0000013776472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072511076,0.0025086512,0.88154423,0.000013034629,0.0014398615,0.00004311251,0.0009920201,0.0000020745606,0.000013856844,0.0000063026637,0.00021913585,0.105966605],"study_design_scores_gemma":[0.018467993,0.062206242,0.9170025,0.000042921256,0.00033263487,0.000027707078,0.00044187147,0.000007631583,0.00006848493,0.000026677762,0.0013016777,0.000073647716],"about_ca_topic_score_codex":0.00050292927,"about_ca_topic_score_gemma":0.0006120625,"teacher_disagreement_score":0.105892956,"about_ca_system_score_codex":0.00017494046,"about_ca_system_score_gemma":0.0004914357,"threshold_uncertainty_score":0.30341303},"labels":[],"label_agreement":null},{"id":"W2590864636","doi":"10.1200/jco.2013.31.6_suppl.54","title":"Evaluation of the UCSF cancer of the prostate risk assessment for prediction of biochemical recurrence (CAPRA) to predict which patients need dose escalation in intermediate-risk disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Capra; Prostate cancer; Prostatectomy; Biochemical recurrence; Urology; Pathological; Proportional hazards model; Internal medicine; Oncology; Cancer","score_opus":0.10330693925102917,"score_gpt":0.4863514896427835,"score_spread":0.38304455039175433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590864636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275845,0.00019639147,0.000059471266,0.0032074377,0.0010265288,0.0024586192,0.0002413579,0.0000016528329,0.000050113737],"genre_scores_gemma":[0.9985725,0.00079973217,0.00021376417,0.000044125612,0.00017456755,0.00015782157,0.000014777021,0.000008069384,0.000014595002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579054,0.0010596584,0.0017909339,0.00015566836,0.0010465325,0.00015666732],"domain_scores_gemma":[0.99281186,0.00096034043,0.0023130057,0.00021740267,0.0035312204,0.00016619168],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050704074,0.00009452601,0.0005803627,0.00010497755,0.000029597164,0.0000036827355,0.00018881256,0.00015918072,0.000038996553],"category_scores_gemma":[0.011173463,0.00004691062,0.00025100046,0.00033967994,0.00020573809,0.00011103718,0.00008425313,0.00054303044,3.706479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003345789,0.0014416589,0.9077994,0.00007477383,0.00016778965,1.8583304e-7,0.00020307794,0.0003799804,0.0005500425,0.0000014440652,0.0013858007,0.08465006],"study_design_scores_gemma":[0.010705138,0.004659816,0.96881396,0.00056310644,0.0008023263,4.1866986e-7,0.00008232469,0.012228027,0.0013851542,0.0006634016,0.00006399077,0.000032339485],"about_ca_topic_score_codex":0.00010654285,"about_ca_topic_score_gemma":0.00006809754,"teacher_disagreement_score":0.08461773,"about_ca_system_score_codex":0.00042008463,"about_ca_system_score_gemma":0.0030992727,"threshold_uncertainty_score":0.99715585},"labels":[],"label_agreement":null},{"id":"W2590868182","doi":"10.1200/jco.2015.33.7_suppl.430","title":"Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Sorafenib; Internal medicine; Hazard ratio; Targeted therapy; Oncology; Renal cell carcinoma; Temsirolimus; Salvage therapy; Everolimus; Proportional hazards model; Surgery; Cancer; Chemotherapy; Confidence interval; Hepatocellular carcinoma","score_opus":0.29668788690280007,"score_gpt":0.4566390676937862,"score_spread":0.15995118079098614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590868182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96365017,0.0018471716,0.00006624396,0.025427964,0.0016710964,0.0002836466,0.00007508325,0.000006723138,0.006971924],"genre_scores_gemma":[0.9864022,0.0006904176,0.0062472117,0.0044177067,0.0016876153,0.0000052692426,0.00007459681,0.000018355577,0.00045658983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945586,0.00093122653,0.0031770938,0.00029313535,0.0007995334,0.00024045222],"domain_scores_gemma":[0.9904878,0.0060109915,0.0019223244,0.00044665407,0.0006470702,0.000485118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069734906,0.0001932053,0.0012414124,0.0001262477,0.000023923123,0.000017373126,0.00044565627,0.00017816032,0.000110946945],"category_scores_gemma":[0.006501958,0.00010355567,0.00040581074,0.00015248568,0.00023570844,0.00013869425,0.00011146374,0.0012964214,0.000055089164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15272784,0.015883084,0.48938778,0.00002086813,0.0018843198,0.0317641,0.0024627573,0.00039008827,0.005279894,0.0001581127,0.21063797,0.089403205],"study_design_scores_gemma":[0.119025946,0.030807994,0.6569199,0.00015803633,0.0008837856,0.0011628575,0.0014388125,0.0009495784,0.006197927,0.0011786569,0.180985,0.00029149262],"about_ca_topic_score_codex":0.0004478451,"about_ca_topic_score_gemma":0.00021830256,"teacher_disagreement_score":0.16753213,"about_ca_system_score_codex":0.00033325632,"about_ca_system_score_gemma":0.0029718333,"threshold_uncertainty_score":0.7783921},"labels":[],"label_agreement":null},{"id":"W2590871047","doi":"10.1200/jco.2014.32.30_suppl.258","title":"Identifying targets for outpatient palliative care wait times in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Palliative care; Medicine; Triage; Health care; Family medicine; Nursing; Medical emergency","score_opus":0.42470204315731025,"score_gpt":0.5675452090949973,"score_spread":0.14284316593768703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590871047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98625386,0.0017957554,0.0020241437,0.0014432546,0.0017372865,0.00028943658,0.0000042466518,0.0000049740465,0.0064470675],"genre_scores_gemma":[0.9767113,0.00034604603,0.020957164,0.0009628685,0.000584188,0.00000609625,0.000007899304,0.000012329356,0.0004121392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715966,0.00024081604,0.0019854836,0.00015217636,0.00026242918,0.00019945251],"domain_scores_gemma":[0.9941061,0.0033370107,0.0014392744,0.00011757081,0.0008071551,0.00019289847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017589829,0.00011502351,0.0014626909,0.00013381508,0.000020412246,0.000003752568,0.00012727489,0.0002972615,0.00010525231],"category_scores_gemma":[0.007183034,0.00008370837,0.00048527934,0.00006594445,0.00010285378,0.000071866896,0.00003603111,0.00071320933,0.000007556283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026901027,0.0006604503,0.9428204,0.00012492086,0.0002483174,0.00007068364,0.0074209175,0.00002306095,0.000053819324,0.00041164155,0.0025485246,0.042927153],"study_design_scores_gemma":[0.009672097,0.014191111,0.5990742,0.0009597688,0.00026838196,0.000005604651,0.0023748055,0.00010948456,0.00047202597,0.0015735135,0.37118855,0.0001104583],"about_ca_topic_score_codex":0.00084434374,"about_ca_topic_score_gemma":0.01245687,"teacher_disagreement_score":0.36864004,"about_ca_system_score_codex":0.00035132313,"about_ca_system_score_gemma":0.0010476387,"threshold_uncertainty_score":0.85992813},"labels":[],"label_agreement":null},{"id":"W2590872269","doi":"10.1200/jco.2014.32.4_suppl.420","title":"Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Toronto; Western University; University of British Columbia; University of Manitoba; St. Joseph's Hospital; Ottawa Hospital; University of Alberta; Dalhousie University; McMaster University; University of Calgary; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Kidney cancer; Demographics; Pathological; Logistic regression; Surgical margin; Cancer; Multivariate analysis; Database; Internal medicine; Kidney; Surgery; Urology","score_opus":0.051584954986938075,"score_gpt":0.36107427225146294,"score_spread":0.3094893172645249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590872269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800654,0.00019283213,0.00038558335,0.007118136,0.0021527815,0.0007271225,0.0014276212,0.000010978483,0.007919529],"genre_scores_gemma":[0.9897006,0.0000396124,0.0031915687,0.0026641255,0.0038057189,0.00006452588,0.0003592979,0.00001986895,0.0001546636],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561304,0.0005437291,0.0027147634,0.00026044578,0.00042618247,0.0004418297],"domain_scores_gemma":[0.9933265,0.002236146,0.001552472,0.00031560237,0.0007294877,0.0018397828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024912464,0.00022759064,0.0013976379,0.00021929514,0.00007187007,0.000025459576,0.0001679895,0.00045614218,0.00010731603],"category_scores_gemma":[0.0016855294,0.00016264293,0.0005727185,0.000111189205,0.00011419167,0.0002874231,0.000042524825,0.00072891184,0.00004934104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26795173,0.0024300877,0.42622846,0.0006980545,0.0022491782,0.011848791,0.0017468891,0.00017178258,0.00048767874,0.0005385617,0.19559333,0.09005546],"study_design_scores_gemma":[0.03357686,0.008033306,0.3366353,0.0003255458,0.0012408263,0.00036306193,0.00012705551,0.0011565441,0.0016409426,0.0000121103385,0.6166763,0.00021219061],"about_ca_topic_score_codex":0.026460122,"about_ca_topic_score_gemma":0.008657959,"teacher_disagreement_score":0.42108294,"about_ca_system_score_codex":0.0011338438,"about_ca_system_score_gemma":0.0047424817,"threshold_uncertainty_score":0.9800228},"labels":[],"label_agreement":null},{"id":"W2590874416","doi":"10.1200/jco.2015.33.29_suppl.190","title":"Personalized symptom goals in symptom assessment: A prospective multicenter study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Logistic regression; Palliative care; Nausea; Prospective cohort study; Depression (economics); Anxiety; Internal medicine; Odds ratio; Hospital Anxiety and Depression Scale; Visual analogue scale; Quality of life (healthcare); Observational study; Physical therapy; Psychiatry","score_opus":0.1455018079728112,"score_gpt":0.519163790529745,"score_spread":0.37366198255693384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590874416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98174036,0.00042243936,0.00007276204,0.003799394,0.002486149,0.00055977143,0.0000025066279,0.0000116433375,0.010904999],"genre_scores_gemma":[0.9955567,0.00009279599,0.000622298,0.0018387554,0.0011979291,0.000017998123,0.0000012129311,0.000019079313,0.0006531942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579334,0.00094018935,0.0020914169,0.00024709673,0.0006658257,0.00026214556],"domain_scores_gemma":[0.9959906,0.0012933612,0.0010825983,0.00019927196,0.00087360863,0.0005606109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005734684,0.00015792486,0.0017227315,0.00018077207,0.000019511424,0.000015073939,0.00017855244,0.0002858013,0.0001726889],"category_scores_gemma":[0.0026724327,0.00011230511,0.0004261217,0.00023065503,0.00016060908,0.00014382538,0.000070918344,0.0013233633,0.000021201153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061799595,0.0050776517,0.97289973,0.000015759875,0.0003785165,0.001229779,0.003727466,0.000004543178,0.00001007855,0.000093856,0.0014001018,0.008982531],"study_design_scores_gemma":[0.036626913,0.017526364,0.9093728,0.00013440741,0.0003648734,0.00011434447,0.009734398,0.00008254187,0.0000055204523,0.00022502709,0.02569779,0.00011499827],"about_ca_topic_score_codex":0.00017696027,"about_ca_topic_score_gemma":0.0010509576,"teacher_disagreement_score":0.063526936,"about_ca_system_score_codex":0.0007190973,"about_ca_system_score_gemma":0.0028434475,"threshold_uncertainty_score":0.5749429},"labels":[],"label_agreement":null},{"id":"W2590886987","doi":"10.1200/jco.2016.34.2_suppl.98","title":"The frequency of druggable targets in localized prostate cancer: Initial analysis from the Decipher GRID.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Druggability; Medicine; Computational biology; Prostate cancer; Population; Gene expression profiling; Bioinformatics; Cancer; Gene; Gene expression; Biology; Genetics; Internal medicine","score_opus":0.09692976115524495,"score_gpt":0.49111820894542224,"score_spread":0.3941884477901773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590886987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93606806,0.009287547,0.00009545162,0.052037463,0.001011307,0.00032546604,0.000052733718,0.000003844856,0.0011181375],"genre_scores_gemma":[0.9787527,0.018446188,0.00039893863,0.00070151145,0.000994783,0.000020134834,0.000003660921,0.00001110967,0.0006709978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963489,0.0007850705,0.0019390642,0.00016211679,0.0004670414,0.00029778745],"domain_scores_gemma":[0.9907727,0.0071024047,0.0011456594,0.0002581876,0.00052409526,0.00019693666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037332892,0.00011002559,0.0011697205,0.000097022195,0.00006816087,0.000008580779,0.00029356912,0.00019453198,0.00050133414],"category_scores_gemma":[0.0026610058,0.000037490176,0.00053318613,0.00043893105,0.0006261855,0.00008565131,0.000060917107,0.00059551274,0.000008294262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008904478,0.00061914197,0.8026068,0.0000063744124,0.0026621504,0.00034483045,0.0002580835,0.000013174431,0.00039415076,0.000055251643,0.006144846,0.1779907],"study_design_scores_gemma":[0.027239457,0.004727622,0.85149986,0.00029243765,0.0021040328,0.000016149694,0.00040392595,0.00008798996,0.0012728095,0.005996833,0.106235564,0.00012331657],"about_ca_topic_score_codex":0.0011143227,"about_ca_topic_score_gemma":0.0030262328,"teacher_disagreement_score":0.17786738,"about_ca_system_score_codex":0.00024657874,"about_ca_system_score_gemma":0.0025067586,"threshold_uncertainty_score":0.54892576},"labels":[],"label_agreement":null},{"id":"W2590890526","doi":"10.1200/jco.2012.30.34_suppl.5","title":"Patient navigation in cancer diagnostics: Providing information and support for more effective care.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Stroke Network; Cancer Care Ontario","funders":"","keywords":"Medicine; Anxiety; Patient satisfaction; Multidisciplinary approach; Patient care; Multidisciplinary team; Patient experience; Medical emergency; Family medicine; Nursing; Health care; Psychiatry","score_opus":0.27907644749661376,"score_gpt":0.5825527939350822,"score_spread":0.30347634643846844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590890526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98306084,0.0038222456,0.00019297971,0.0054737283,0.0043192673,0.002598561,0.00003661009,0.000011871596,0.00048390205],"genre_scores_gemma":[0.99202615,0.0009419673,0.002963016,0.00288535,0.0005730945,0.00056891196,0.000025869034,0.00001026529,0.000005359397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99512213,0.0013773,0.002884125,0.00008063467,0.00020738355,0.00032844135],"domain_scores_gemma":[0.98281115,0.012431682,0.0030953626,0.00015260768,0.0012390887,0.00027011175],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022248598,0.00009744134,0.00061291864,0.00013929747,0.00018826786,0.0000039830725,0.00012237874,0.00042146456,0.00001773121],"category_scores_gemma":[0.012769107,0.0000784764,0.00009545243,0.00010442111,0.00008743164,0.0007818574,0.00010589414,0.0011817485,0.000008120584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005565974,0.00014576592,0.697024,0.00039781793,0.000021878004,9.914061e-7,0.031824127,0.000017768389,0.0000026140992,0.00023664966,0.0011267561,0.26864502],"study_design_scores_gemma":[0.0049959905,0.0042082877,0.772533,0.00073113973,0.00007511224,0.0000066001376,0.030436795,0.00021564757,0.00002116854,0.0003119441,0.18633743,0.00012686398],"about_ca_topic_score_codex":0.00018327498,"about_ca_topic_score_gemma":0.00011591413,"teacher_disagreement_score":0.26851815,"about_ca_system_score_codex":0.0007282157,"about_ca_system_score_gemma":0.0016424699,"threshold_uncertainty_score":0.99554676},"labels":[],"label_agreement":null},{"id":"W2590892234","doi":"10.1200/jco.2013.31.31_suppl.11","title":"Taking control of cancer: Women’s choice for mastectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Nonprobability sampling; Thematic analysis; Qualitative research; Grounded theory; Cancer; Surgery; Gynecology; Internal medicine; Population","score_opus":0.06558042886622016,"score_gpt":0.4520614110015011,"score_spread":0.3864809821352809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590892234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879058,0.0017455085,0.0058835214,0.0022059288,0.0015116653,0.0002453851,0.000015590607,0.0000018593677,0.00048473972],"genre_scores_gemma":[0.9919394,0.00038669896,0.004026851,0.0014671326,0.0018870331,0.00009289456,0.000001450795,0.000014880953,0.00018362483],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980194,0.00015726914,0.0013575627,0.0001440471,0.000121676596,0.00020003931],"domain_scores_gemma":[0.9960663,0.00066658127,0.0021565987,0.00015600516,0.0008207533,0.0001337604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012785026,0.00008798843,0.00061175344,0.000045456556,0.000025158006,0.0000063685206,0.00025119277,0.00030497226,0.0002748056],"category_scores_gemma":[0.003258388,0.00007007792,0.00028761505,0.000050967443,0.00014245747,0.0000072148055,0.000035001794,0.00021412758,0.0000028909617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001964358,0.00067282707,0.1060866,0.00007434678,0.0014196036,0.0000045237007,0.00013769617,0.0014521852,0.12569447,0.000093240065,0.018610619,0.74378955],"study_design_scores_gemma":[0.014534004,0.009931822,0.17082179,0.00004672037,0.00021051023,0.000034910296,0.00028359873,0.0004187919,0.016127937,0.00077566353,0.78658396,0.00023031331],"about_ca_topic_score_codex":0.000044544242,"about_ca_topic_score_gemma":0.000068210786,"teacher_disagreement_score":0.7679733,"about_ca_system_score_codex":0.00012267382,"about_ca_system_score_gemma":0.0013868859,"threshold_uncertainty_score":0.39008301},"labels":[],"label_agreement":null},{"id":"W2590893780","doi":"10.1200/jco.2012.30.5_suppl.451","title":"Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Toxicity; Vascular endothelial growth factor; Gastroenterology; Oncology; VEGF receptors","score_opus":0.10394098664119455,"score_gpt":0.37933308281242534,"score_spread":0.2753920961712308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590893780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493,0.00085300027,0.00004263852,0.0011572484,0.0005784985,0.0004389266,0.000013505421,0.000005494344,0.0019806388],"genre_scores_gemma":[0.9961418,0.0006066622,0.0016251034,0.00034808196,0.0011755326,0.000008121881,0.0000075749763,0.000030061447,0.000057096968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955659,0.00084327534,0.00222574,0.0002637497,0.00059756526,0.0005037506],"domain_scores_gemma":[0.9959022,0.0015181439,0.0012757019,0.00021524739,0.00024172498,0.00084699935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015819289,0.00029664524,0.0021131076,0.00027287533,0.000044163877,0.000014699819,0.00018923766,0.00031371485,0.00010847628],"category_scores_gemma":[0.000736794,0.00018605714,0.0005704572,0.0001476581,0.00022230184,0.00021263912,0.00005838667,0.0010211978,0.000013342379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009779774,0.0022022896,0.92625064,0.000038226528,0.0002951188,0.00021977969,0.00069924886,7.008731e-8,0.00021683864,0.0000066823945,0.000084788044,0.06900837],"study_design_scores_gemma":[0.015993683,0.019068018,0.9612323,0.000046333716,0.00043637998,0.00005246612,0.00016962364,0.0000026262862,0.0011447758,0.00010631151,0.0015943473,0.00015312512],"about_ca_topic_score_codex":0.00007064903,"about_ca_topic_score_gemma":0.000019683477,"teacher_disagreement_score":0.06885524,"about_ca_system_score_codex":0.00021101319,"about_ca_system_score_gemma":0.0005815413,"threshold_uncertainty_score":0.75871897},"labels":[],"label_agreement":null},{"id":"W2590900349","doi":"10.1200/jco.2013.31.6_suppl.125","title":"From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Discontinuation; Prednisone; Prostate cancer; Internal medicine; Cabazitaxel; Clinical endpoint; Proportional hazards model; Oncology; Chemotherapy; Clinical trial; Cancer; Androgen deprivation therapy","score_opus":0.09837554427195687,"score_gpt":0.49831209920109476,"score_spread":0.3999365549291379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590900349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93339634,0.00061694015,0.00027165154,0.06198592,0.00027518827,0.0031149003,0.000021836968,0.00000555206,0.00031169353],"genre_scores_gemma":[0.97813195,0.00089299557,0.01766922,0.0008037756,0.00083209947,0.00068696117,0.000006491927,0.000022116665,0.0009544173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99770224,0.00028836768,0.0009883282,0.00025306057,0.0005034251,0.00026454794],"domain_scores_gemma":[0.9954113,0.002107078,0.0010299592,0.00017357747,0.0009225408,0.00035555515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001381956,0.00014527449,0.0007815344,0.00004783161,0.00009822417,0.00006549964,0.00013075973,0.00008747546,0.000064754284],"category_scores_gemma":[0.0014359031,0.00006247949,0.000082489176,0.00012523207,0.00032451967,0.00038357943,0.00003563006,0.00043654063,0.0000020718292],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8682802,0.003054849,0.017349327,0.00009371824,0.0023736977,0.00063285267,0.009164825,0.000034406614,0.0006860081,0.00007153547,0.0106294565,0.08762914],"study_design_scores_gemma":[0.3758936,0.29011026,0.19027339,0.0007279176,0.0030327258,0.00032820576,0.024636768,0.0003711949,0.0010759963,0.0007942249,0.11229986,0.00045586983],"about_ca_topic_score_codex":0.0005147192,"about_ca_topic_score_gemma":0.00019979142,"teacher_disagreement_score":0.49238658,"about_ca_system_score_codex":0.00015479434,"about_ca_system_score_gemma":0.0019703829,"threshold_uncertainty_score":0.34953743},"labels":[],"label_agreement":null},{"id":"W2590900969","doi":"10.1200/jco.2016.34.26_suppl.99","title":"Differences in the symptom distress between young adult and adult patients with advanced cancer admitted to acute palliative care unit.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Young adult; Palliative care; Distress; Cancer; Nausea; Sleep disorder; Feeling; Pediatrics; Internal medicine; Psychiatry; Insomnia; Nursing; Clinical psychology","score_opus":0.18140353005814994,"score_gpt":0.5194350759826721,"score_spread":0.3380315459245222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590900969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992678,0.0004066755,0.00008473019,0.0060581644,0.00021402915,0.00025017254,0.00010476011,0.0000034122318,0.00020006207],"genre_scores_gemma":[0.99475205,0.0031325452,0.0007443779,0.0010120486,0.00029660537,0.000012367262,0.0000073333763,0.000009268714,0.000033390315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785167,0.00032337417,0.0010753864,0.000174419,0.0003793657,0.00019577045],"domain_scores_gemma":[0.99444747,0.0028486864,0.0009065951,0.00013257412,0.0014333496,0.00023129834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002860687,0.00014639761,0.0011268385,0.0000814619,0.00002688137,0.000004734272,0.00019034454,0.00017072233,0.000014489195],"category_scores_gemma":[0.002424705,0.000060946975,0.00011113802,0.00016969597,0.00022120873,0.00008959509,0.000038934602,0.00039647173,0.0000012713575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025116112,0.0001859332,0.9069599,0.00002562038,0.0003062157,0.00005159512,0.0025661436,2.716853e-7,0.000010538298,0.00002122468,0.00010063229,0.08726033],"study_design_scores_gemma":[0.008966405,0.009000827,0.9757493,0.0018472805,0.000360269,0.0000018129105,0.0023527672,8.705519e-7,0.00007095395,0.000034203316,0.0015272213,0.00008805293],"about_ca_topic_score_codex":0.00009323632,"about_ca_topic_score_gemma":0.0010154468,"teacher_disagreement_score":0.08717228,"about_ca_system_score_codex":0.000089121124,"about_ca_system_score_gemma":0.00032110696,"threshold_uncertainty_score":0.29027736},"labels":[],"label_agreement":null},{"id":"W2590902670","doi":"10.1200/jco.2014.32.30_suppl.106","title":"Socioeconomic status and recurrent emergency visits amongst chemotherapy patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Credit Valley Hospital; University of Toronto","funders":"","keywords":"Medicine; Emergency department; Incidence (geometry); Socioeconomic status; Chemotherapy; Demography; Internal medicine; Pediatrics; Population; Environmental health","score_opus":0.052089029054098845,"score_gpt":0.4376092522072241,"score_spread":0.38552022315312523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590902670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888302,0.00023082863,0.000054880566,0.004068531,0.0026512106,0.00010161154,0.0000013480567,0.0000057845623,0.004055623],"genre_scores_gemma":[0.99188536,0.004403582,0.0002693876,0.0019351637,0.0012848192,0.0000020451323,0.0000013910236,0.000011473509,0.00020678843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981562,0.00016223412,0.0012870762,0.00012405096,0.000107771375,0.00016269989],"domain_scores_gemma":[0.9980897,0.0003034274,0.0009307178,0.00009719558,0.000236779,0.00034222228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090779975,0.00008336964,0.0007413468,0.00005666094,0.000039515406,0.000004442194,0.00005353194,0.00016213328,0.0006343511],"category_scores_gemma":[0.00043733185,0.00006123097,0.0002457294,0.000034101573,0.000078312325,0.00007586503,0.000019841122,0.0005320171,0.00003356119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006628007,0.0005726237,0.64669776,0.000009199324,0.00009985142,0.0000025325514,0.000048608043,5.984844e-7,0.00002141854,0.00009189611,0.0091992505,0.3425935],"study_design_scores_gemma":[0.004728441,0.0084280465,0.6954078,0.000011242752,0.00008462854,0.000014997636,0.000012577525,0.0000095814585,0.000012993248,0.00046508075,0.29077947,0.000045138957],"about_ca_topic_score_codex":0.000007778591,"about_ca_topic_score_gemma":0.000026535277,"teacher_disagreement_score":0.34254834,"about_ca_system_score_codex":0.00009659109,"about_ca_system_score_gemma":0.00031760952,"threshold_uncertainty_score":0.69456995},"labels":[],"label_agreement":null},{"id":"W2590905635","doi":"10.1200/jco.2016.34.4_suppl.tps477","title":"LAPACT: An open-label, multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Discontinuation; Nab-paclitaxel; Performance status; Oncology; Cancer; Progressive disease; Gastroenterology; Surgery; Clinical trial; Urology; Chemotherapy","score_opus":0.05381307791062821,"score_gpt":0.4241843371871553,"score_spread":0.3703712592765271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590905635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956532,0.00046593297,0.00039554175,0.0010526653,0.0011850469,0.00077076536,0.00011744268,0.0000027239964,0.00035665988],"genre_scores_gemma":[0.9916571,0.002979691,0.0027907484,0.0014330262,0.0008285883,0.000039775896,0.000020361407,0.000042469197,0.00020826155],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961116,0.00035741873,0.0023736898,0.00043704774,0.00031528057,0.00040496554],"domain_scores_gemma":[0.9956751,0.00055402116,0.0021702063,0.0004616167,0.0007369996,0.0004020866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015629665,0.00026718358,0.0014208294,0.00009107013,0.000051107556,0.00001844574,0.0006876493,0.00040432604,0.000061342595],"category_scores_gemma":[0.0022900116,0.00017156401,0.0001601344,0.000120573226,0.0003074157,0.000050040704,0.0003272048,0.0003457995,0.000002424972],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56727755,0.024237415,0.023319827,0.000038474478,0.00048824403,0.00007563707,0.00008698418,0.00017022049,0.026671458,0.000050215654,0.002666994,0.354917],"study_design_scores_gemma":[0.6519894,0.25919747,0.010876928,0.00033347966,0.00030945725,0.000010506498,0.000060554532,0.00006234992,0.0033069134,0.00012624566,0.073300466,0.0004262139],"about_ca_topic_score_codex":0.00009597492,"about_ca_topic_score_gemma":0.0009715368,"teacher_disagreement_score":0.35449076,"about_ca_system_score_codex":0.00018314699,"about_ca_system_score_gemma":0.0019304673,"threshold_uncertainty_score":0.6996177},"labels":[],"label_agreement":null},{"id":"W2590905913","doi":"10.1200/jco.2015.33.7_suppl.29","title":"Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of Alberta","funders":"","keywords":"AXIN2; Prostate cancer; Gene knockdown; Cancer research; Biochemical recurrence; DU145; Medicine; Cancer; Biology; Oncology; Pathology; Wnt signaling pathway; Internal medicine; Prostatectomy; Gene; Genetics; LNCaP","score_opus":0.08530551974317657,"score_gpt":0.4700689290950268,"score_spread":0.3847634093518502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590905913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964967,0.0019648776,0.000045659024,0.00026152833,0.00065804843,0.00010771191,0.0000064101037,0.0000012684873,0.0004578166],"genre_scores_gemma":[0.9958328,0.002902496,0.00035303787,0.00018830829,0.0005999742,0.000008586824,0.0000034037419,0.000008051187,0.00010336031],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998352,0.0005236052,0.0007084385,0.00016662231,0.00014349534,0.000105845254],"domain_scores_gemma":[0.9982384,0.00021679957,0.0008496948,0.00017366993,0.00030009268,0.00022136183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019214287,0.00008740028,0.00042181558,0.000032099473,0.000021339383,0.0000052601563,0.00015609908,0.00018011026,0.00001024497],"category_scores_gemma":[0.0014040442,0.000057840218,0.00009761323,0.000044819317,0.00014248761,0.000009562124,0.000042538104,0.00022777636,0.0000014785364],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016771518,0.0010340951,0.08606648,0.000083875835,0.00017048833,0.000031679476,0.0002509716,0.00042560665,0.31394058,0.00008621146,0.012768386,0.5683701],"study_design_scores_gemma":[0.016370498,0.17220287,0.10029863,0.0004335515,0.00030997084,0.000104834086,0.00024619343,0.000108317196,0.57158,0.0007740535,0.137074,0.00049706775],"about_ca_topic_score_codex":0.000014794813,"about_ca_topic_score_gemma":0.000028762128,"teacher_disagreement_score":0.56787306,"about_ca_system_score_codex":0.000021779097,"about_ca_system_score_gemma":0.0008127095,"threshold_uncertainty_score":0.23586556},"labels":[],"label_agreement":null},{"id":"W2590909925","doi":"10.1200/jco.2012.30.34_suppl.46","title":"A multicenter, phase IV study of the effectiveness of palliative gemcitabine in patients with advanced pancreatic cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Internal medicine; Cancer registry; Clinical trial; Cancer; Population; Stage (stratigraphy); Palliative care; Randomized controlled trial; Surgery","score_opus":0.09880175982412148,"score_gpt":0.520384232018217,"score_spread":0.42158247219409556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590909925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745387,0.00030037048,0.000028073451,0.00014692775,0.00037080204,0.0013478098,0.000005933409,0.0000016491952,0.00034454145],"genre_scores_gemma":[0.99903977,0.00015626337,0.00055009534,0.00007273178,0.00011566977,0.000032063643,9.42959e-7,0.000011711816,0.000020726575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948112,0.002349485,0.0018933081,0.00013042882,0.00053976866,0.00027585658],"domain_scores_gemma":[0.9902544,0.0065622283,0.0019083904,0.0002377253,0.00081705156,0.00022020892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051049343,0.0001311108,0.0022625378,0.000121666235,0.000023108325,9.966149e-7,0.00019323555,0.00017030493,0.00004993547],"category_scores_gemma":[0.005651928,0.00006637102,0.00018750443,0.00029542818,0.00033961242,0.00009904129,0.000070316135,0.00075741747,9.168536e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07781647,0.032401323,0.87805426,0.00015321793,0.0007461695,0.000018729323,0.00049304945,0.00001334996,0.0001173037,0.000012082286,0.000011263206,0.010162786],"study_design_scores_gemma":[0.08105754,0.055684965,0.8610421,0.0006232172,0.00081763335,0.0000026658497,0.0005177043,0.00004284897,0.000086534266,0.000014388773,0.000061430306,0.000049013805],"about_ca_topic_score_codex":0.00012412923,"about_ca_topic_score_gemma":0.00010278635,"teacher_disagreement_score":0.023283642,"about_ca_system_score_codex":0.00023015497,"about_ca_system_score_gemma":0.0011794623,"threshold_uncertainty_score":0.67662936},"labels":[],"label_agreement":null},{"id":"W2590912943","doi":"10.1200/jco.2016.34.7_suppl.73","title":"Identifying tools for capturing the overall experience of dyspnea in a lung cancer population: The patient’s perspective.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Lung cancer; Distress; Stage (stratigraphy); Population; Physical therapy; Quality of life (healthcare); Cancer; Internal medicine; Nursing","score_opus":0.1510066383485367,"score_gpt":0.5038855643535174,"score_spread":0.3528789260049807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590912943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783058,0.0020670344,0.0002313394,0.017715024,0.0007415608,0.00055385986,0.000010075239,0.0000027646554,0.00037251992],"genre_scores_gemma":[0.9979779,0.00040408166,0.00026083994,0.00045229177,0.0007114337,0.00004308525,3.8994588e-7,0.000011825246,0.0001381533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973634,0.00036300675,0.0013987297,0.00017853882,0.00045267603,0.00024366732],"domain_scores_gemma":[0.9936478,0.0043945224,0.0009969262,0.00022389706,0.00060036045,0.00013646136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016613246,0.00009445197,0.0006369583,0.00008001373,0.000063301806,0.000012496992,0.0002583303,0.00012294877,0.00019348876],"category_scores_gemma":[0.0064568594,0.000041390398,0.00036055793,0.00012005296,0.00032830838,0.00027012682,0.00009541537,0.00046863858,8.912356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061195483,0.0008298514,0.73992664,0.00015468143,0.00038388098,0.00020096131,0.004464109,0.00007721439,0.001230214,0.0029008142,0.00087896327,0.24283315],"study_design_scores_gemma":[0.0041751806,0.0007179479,0.98673326,0.0003357898,0.000112277296,0.00006368254,0.003182457,0.0002842905,0.00011316106,0.0016684639,0.0025537107,0.00005975213],"about_ca_topic_score_codex":0.0003325832,"about_ca_topic_score_gemma":0.00020318806,"teacher_disagreement_score":0.24680668,"about_ca_system_score_codex":0.00089009735,"about_ca_system_score_gemma":0.0010341387,"threshold_uncertainty_score":0.772993},"labels":[],"label_agreement":null},{"id":"W2590915266","doi":"10.1200/jco.2013.31.26_suppl.111","title":"Assessing the need for a nurse-led breast cancer telephone follow-up clinic in Alberta, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Medicine; Concordance; Family medicine; Psychosocial; Breast cancer; Pharmacy; Health care; Cancer; Psychiatry; Internal medicine","score_opus":0.06347790707151683,"score_gpt":0.44769873706645685,"score_spread":0.38422082999494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590915266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86552984,0.0003555819,0.000046298115,0.12334373,0.007797525,0.00046145837,0.0000070999777,0.000003929322,0.002454571],"genre_scores_gemma":[0.9810299,0.00017240358,0.00018664713,0.013307637,0.0023661335,0.00005435826,0.0000021792987,0.000024813571,0.0028558937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637246,0.00039528523,0.0022989197,0.00019573476,0.00036710693,0.0003704996],"domain_scores_gemma":[0.9908586,0.0064531234,0.0013535935,0.00022530585,0.00074291416,0.00036643964],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00252123,0.00015830193,0.0014488214,0.00008023756,0.000058321024,0.000029606865,0.00024822238,0.00034049037,0.0009324559],"category_scores_gemma":[0.0025672808,0.00009390678,0.00050572876,0.00023560804,0.00013995764,0.00018121662,0.000024923746,0.0011270996,0.000010240482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003813119,0.0007048781,0.5010629,0.00006786067,0.00052778097,0.00013458898,0.0006068481,0.00001094478,0.0001113456,0.000030188949,0.14319117,0.34973836],"study_design_scores_gemma":[0.011963623,0.0013477331,0.86389345,0.00023697075,0.0003710069,0.00025116192,0.0029179086,0.00021141805,0.000013759013,0.0002169905,0.1184424,0.00013357738],"about_ca_topic_score_codex":0.59205604,"about_ca_topic_score_gemma":0.94419867,"teacher_disagreement_score":0.36283055,"about_ca_system_score_codex":0.00052350917,"about_ca_system_score_gemma":0.010755349,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W2590920587","doi":"10.1200/jco.2016.34.26_suppl.79","title":"Oncology massage impact on patient with cancer and caregiver self-reported symptoms as part of an integrative oncology program at a comprehensive cancer center.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Massage; Distress; Physical therapy; Sadness; Anxiety; Cancer; Internal medicine; Psychiatry; Alternative medicine; Clinical psychology; Anger","score_opus":0.10745256737320621,"score_gpt":0.52051999158328,"score_spread":0.4130674242100738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590920587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98859406,0.0006090946,0.000009084992,0.006476864,0.0012374928,0.0007883015,0.00007362676,0.000018427709,0.002193077],"genre_scores_gemma":[0.99253714,0.004015297,0.0005786988,0.0016368418,0.00094975886,0.000071343835,0.000008876713,0.000022546219,0.00017948277],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99589765,0.00078882504,0.0020625019,0.00039190293,0.00047669912,0.00038244273],"domain_scores_gemma":[0.99192184,0.002885148,0.0031855362,0.00021195896,0.0012252803,0.00057024753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006816633,0.00032894808,0.0025574781,0.00016469562,0.00007338092,0.0000030795773,0.00013890814,0.000156605,0.000624795],"category_scores_gemma":[0.0004730294,0.00014552548,0.0003297398,0.00013130996,0.000977006,0.00011400613,0.0001385756,0.0007191079,0.0000026109956],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023527803,0.0048452346,0.3085609,0.000032736956,0.0055790683,0.0029713153,0.0020620096,0.0000053386757,0.00026352826,0.00002352771,0.0025700233,0.6495585],"study_design_scores_gemma":[0.02671783,0.34462342,0.27725548,0.0011203967,0.0016008088,0.0018049055,0.0022703197,0.000023875147,0.00052061776,0.00004872152,0.3438166,0.0001970234],"about_ca_topic_score_codex":0.00041923075,"about_ca_topic_score_gemma":0.0016332427,"teacher_disagreement_score":0.6493615,"about_ca_system_score_codex":0.0014014752,"about_ca_system_score_gemma":0.0022061241,"threshold_uncertainty_score":0.6841067},"labels":[],"label_agreement":null},{"id":"W2590921469","doi":"10.1200/jco.2014.32.30_suppl.265","title":"Reporting on quality indicators in renal cell carcinoma: Proportion of metastatic patients who initially commence on full-dose targeted therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Juravinski Cancer Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University; Centre Hospitalier de l’Université de Montréal; University of Calgary; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Sorafenib; Renal cell carcinoma; Temsirolimus; Everolimus; Internal medicine; Oncology; Kidney cancer; Cohort; Urology; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; Hepatocellular carcinoma","score_opus":0.1825192556823884,"score_gpt":0.46168308318022716,"score_spread":0.27916382749783875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590921469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529606,0.00007033238,0.000037099016,0.0007998676,0.00035841292,0.0004941012,0.0000030855997,0.0000056876083,0.0029353802],"genre_scores_gemma":[0.9969244,0.000059198846,0.0014778426,0.001250003,0.00021487878,0.000008027068,0.000011735466,0.000020705864,0.000033179305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98883045,0.0019915008,0.007680769,0.00030030202,0.00092506787,0.0002719394],"domain_scores_gemma":[0.98165476,0.0025745488,0.014584115,0.00030168807,0.00055213895,0.00033277355],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010856363,0.00021746688,0.0021685746,0.00048228938,0.000033941524,0.000005377158,0.00016596564,0.00025568524,0.00004619314],"category_scores_gemma":[0.011862233,0.00014336464,0.0004883909,0.00033336168,0.00016768508,0.00007800562,0.000036777736,0.0011448653,0.00000659178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016041722,0.010212739,0.8964685,0.00010014438,0.00014811213,0.0008523286,0.00031348888,0.000070287046,0.0016834385,0.00007376543,0.0002315716,0.073803894],"study_design_scores_gemma":[0.013811636,0.061837886,0.91701144,0.00016493491,0.00013514943,0.000049195893,0.000059957983,0.000045139634,0.006124516,0.0001368171,0.0005180448,0.00010527466],"about_ca_topic_score_codex":0.000046041925,"about_ca_topic_score_gemma":0.00001219094,"teacher_disagreement_score":0.07369862,"about_ca_system_score_codex":0.0003259847,"about_ca_system_score_gemma":0.0010000751,"threshold_uncertainty_score":0.9964613},"labels":[],"label_agreement":null},{"id":"W2590926364","doi":"10.1200/jco.2008.26.15_suppl.5045","title":"Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sorafenib; Expanded access; Internal medicine; Renal cell carcinoma; Adverse effect; Oncology; Clinical trial; Hepatocellular carcinoma","score_opus":0.07165830181736565,"score_gpt":0.39756561600240575,"score_spread":0.3259073141850401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590926364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762547,0.00065387075,0.000022084196,0.0005829655,0.00014404571,0.00074259704,0.000028123171,0.000007091009,0.00019376825],"genre_scores_gemma":[0.9963742,0.0010156023,0.0020233623,0.00028916536,0.00016725557,0.000015373173,0.00007166529,0.000020610814,0.000022780425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454355,0.0008914561,0.0031931591,0.00040175495,0.0006012296,0.00036884958],"domain_scores_gemma":[0.99364245,0.0030539357,0.0022121207,0.00041060182,0.00033586327,0.00034505082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008923988,0.00025163035,0.002429096,0.000389702,0.000039208753,0.000011347295,0.00038304977,0.00027765374,0.000059782637],"category_scores_gemma":[0.0011088657,0.0001642776,0.0006521042,0.0011457031,0.00046475162,0.00017280644,0.00013389431,0.0010797664,0.000003651874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011964265,0.0048731733,0.82422656,0.000012074572,0.00037769583,0.0011258995,0.00081347727,0.00026409057,0.000033571763,3.2186028e-7,0.000077327146,0.15623152],"study_design_scores_gemma":[0.027480561,0.013151396,0.9562659,0.000047022215,0.00093435345,0.000024506771,0.0001619265,0.00012722609,0.00007729157,0.000013709705,0.0015863618,0.00012972625],"about_ca_topic_score_codex":0.0006371637,"about_ca_topic_score_gemma":0.0022775608,"teacher_disagreement_score":0.1561018,"about_ca_system_score_codex":0.00024731,"about_ca_system_score_gemma":0.0008684612,"threshold_uncertainty_score":0.66990465},"labels":[],"label_agreement":null},{"id":"W2590933795","doi":"10.1200/jco.2013.31.6_suppl.231","title":"Utilization of local salvage therapy after primary radiotherapy for prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Prostatectomy; Biochemical recurrence; Salvage therapy; Brachytherapy; Cryotherapy; Cancer; Androgen deprivation therapy; Surgery; Internal medicine; Chemotherapy","score_opus":0.10956458401806028,"score_gpt":0.4661305859081321,"score_spread":0.3565660018900718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590933795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612328,0.020867508,0.0026777552,0.01284272,0.00093085325,0.001189744,0.00001754973,0.000006836799,0.00023426178],"genre_scores_gemma":[0.93625873,0.051541585,0.004621059,0.00644329,0.0007300191,0.00020456994,0.000006268901,0.00002367019,0.00017077672],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99781704,0.00012706172,0.0015422694,0.00013948469,0.00020100192,0.00017316292],"domain_scores_gemma":[0.99705106,0.0008117442,0.0011707034,0.00012953338,0.0006369184,0.00020002323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008186495,0.00011526754,0.0011254133,0.00006533725,0.000015859203,0.000005629099,0.000071405804,0.00019325409,0.0003502813],"category_scores_gemma":[0.00012968354,0.00007114947,0.0004073227,0.00007695169,0.00018956287,0.00011481268,0.000009987249,0.00022751746,0.0000023947644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074164625,0.001711463,0.12512359,0.00006727093,0.00054780283,0.000034351087,0.00013954508,0.000017713808,0.00034375678,0.000019082332,0.007542793,0.8570362],"study_design_scores_gemma":[0.020602323,0.030777315,0.78960264,0.00020950777,0.00021480261,0.000036821617,0.00006838337,0.00016752089,0.002544502,0.00042237635,0.15525995,0.000093859984],"about_ca_topic_score_codex":0.00004696448,"about_ca_topic_score_gemma":0.000011444962,"teacher_disagreement_score":0.8569423,"about_ca_system_score_codex":0.00026305986,"about_ca_system_score_gemma":0.0012440532,"threshold_uncertainty_score":0.38353348},"labels":[],"label_agreement":null},{"id":"W2590933850","doi":"10.1200/jco.2013.31.4_suppl.482","title":"A phase II multicenter study of metastasectomy for intra- and extra-hepatic metastases from colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Metastasectomy; Medicine; Colorectal cancer; Contraindication; Perioperative; Hepatectomy; Internal medicine; Overall survival; Oncology; Surgery; Cancer; Resection; Pathology","score_opus":0.12255408225291071,"score_gpt":0.46470805216932715,"score_spread":0.34215396991641644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590933850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257106,0.0035323757,0.00008091594,0.0019706937,0.00071284146,0.0009943916,0.00007229245,0.000005302827,0.000060150094],"genre_scores_gemma":[0.9951558,0.00047057317,0.0029652088,0.0006299983,0.00065179536,0.0000832759,0.0000044691415,0.000015080298,0.000023813776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971493,0.0002775312,0.001913244,0.00021202932,0.0002486024,0.00019929327],"domain_scores_gemma":[0.99508053,0.0026460532,0.0012800591,0.0001234398,0.00059519167,0.00027471423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009775673,0.00016178709,0.0019294698,0.00010343568,0.00006023488,0.000008459771,0.00010633983,0.000115144205,0.0002101088],"category_scores_gemma":[0.0016766887,0.00010651279,0.00036123957,0.000085212,0.0001990025,0.00012771029,0.000074554,0.00038559057,0.0000012402278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023838526,0.040738013,0.48533642,0.0001647511,0.010364116,0.0003029964,0.0049749273,0.0000035553128,0.007479715,0.000015211796,0.014409797,0.41237196],"study_design_scores_gemma":[0.12135039,0.17819872,0.67515117,0.0001706738,0.007395232,0.000058894795,0.0051180846,0.0004518621,0.0018487448,0.00018234254,0.009855808,0.00021807903],"about_ca_topic_score_codex":0.0008089372,"about_ca_topic_score_gemma":0.00077154784,"teacher_disagreement_score":0.4121539,"about_ca_system_score_codex":0.00005935311,"about_ca_system_score_gemma":0.00040810343,"threshold_uncertainty_score":0.43434653},"labels":[],"label_agreement":null},{"id":"W2590936583","doi":"10.1200/jco.2016.34.2_suppl.340","title":"Metformin (Met): A cost-effective adjunct therapy with enzalutamide (Enza) for metastatic castrate-resistant prostate cancer (mCRPC)?","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Quality-adjusted life year; Enzalutamide; Cancer; Actuarial science; Cost effectiveness; Internal medicine; Risk analysis (engineering); Economics","score_opus":0.1878538938582237,"score_gpt":0.5275029001028327,"score_spread":0.33964900624460903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590936583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98120785,0.0034489315,0.00071903225,0.009001045,0.0012845612,0.0037110213,0.00010112233,0.000015198943,0.00051123125],"genre_scores_gemma":[0.9828854,0.005333429,0.005350835,0.0025103688,0.0012561777,0.0009983589,0.000004558598,0.000053079795,0.0016077843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967863,0.00048758992,0.0016646228,0.00030048296,0.0003195916,0.00044140278],"domain_scores_gemma":[0.9910998,0.0057160575,0.0017755355,0.00016713256,0.00077416335,0.00046734314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025233815,0.00027076225,0.001994927,0.00016072547,0.000059774608,0.000009223045,0.00013947768,0.00019339952,0.00041713775],"category_scores_gemma":[0.00072111835,0.00012413187,0.0005816585,0.00017472779,0.00034536168,0.00017818343,0.000019002784,0.00046684887,0.000009193918],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13571672,0.002841779,0.010271254,0.000056038676,0.0037916773,0.0011156813,0.00018080509,0.000010357155,0.015449319,0.00010321647,0.0038681985,0.82659495],"study_design_scores_gemma":[0.12106207,0.20267871,0.040615458,0.00043280676,0.0038253802,0.0009974648,0.00020720779,0.000022123972,0.019215828,0.00092098,0.60969484,0.00032711803],"about_ca_topic_score_codex":0.00006974318,"about_ca_topic_score_gemma":0.00047635962,"teacher_disagreement_score":0.82626784,"about_ca_system_score_codex":0.0005133442,"about_ca_system_score_gemma":0.0032014332,"threshold_uncertainty_score":0.5679205},"labels":[],"label_agreement":null},{"id":"W2590938463","doi":"10.1200/jco.2011.29.4_suppl.452","title":"Evaluation of the association of matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-2 (MMP-2) expression with KRAS and BRAF mutational status or survival outcomes in colorectal cancer (CRC) patients.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"KRAS; Medicine; Colorectal cancer; Hazard ratio; Oncology; Exact test; Tissue microarray; Internal medicine; Cancer; Immunohistochemistry; Metastasis; Stage (stratigraphy); Cancer research; Proportional hazards model; Pathology; Biology; Confidence interval","score_opus":0.06715035259336344,"score_gpt":0.3982176997064601,"score_spread":0.33106734711309665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590938463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825436,0.00053171854,0.0000610613,0.00012562837,0.00031946928,0.0005520386,0.00003792952,0.0000014186144,0.0001163635],"genre_scores_gemma":[0.9972485,0.0002232177,0.0022730154,0.000046226618,0.00009323984,0.000032444896,0.0000074810737,0.000012889293,0.00006299034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647415,0.0011384948,0.0012658659,0.00020835802,0.00073547533,0.0001776346],"domain_scores_gemma":[0.99618185,0.00026203057,0.0023233164,0.00011260979,0.0010151817,0.000104988416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044409027,0.00014553516,0.0007212447,0.000073147705,0.000038008,0.0000058434043,0.00013321609,0.00034749584,0.000057675697],"category_scores_gemma":[0.0031963359,0.00008372389,0.00015846315,0.00010024984,0.00013991098,0.000031906497,0.000105463514,0.00027453245,2.2575362e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073015452,0.0016421297,0.7178663,0.00006544006,0.00078797445,0.00001134389,0.00024170555,0.00006171548,0.26034147,0.00012220419,0.000065498425,0.011492646],"study_design_scores_gemma":[0.009457136,0.007431061,0.61179084,0.00008968174,0.00058880454,0.000011123598,0.00017657407,0.00008105161,0.36922288,0.00073582114,0.00026330657,0.0001517099],"about_ca_topic_score_codex":0.00017000586,"about_ca_topic_score_gemma":0.0007071381,"teacher_disagreement_score":0.108881414,"about_ca_system_score_codex":0.00008816389,"about_ca_system_score_gemma":0.0011995819,"threshold_uncertainty_score":0.38265434},"labels":[],"label_agreement":null},{"id":"W2590938812","doi":"10.1200/jco.2011.29.15_suppl.7012","title":"Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer registry; Carboplatin; Population; Lung cancer; Internal medicine; Cancer; Medical record; Cisplatin; Surgery; Chemotherapy","score_opus":0.11364106727940122,"score_gpt":0.462761861775072,"score_spread":0.3491207944956708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590938812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357027,0.00031817,0.00015335935,0.004072567,0.0005621433,0.0010324046,0.0000039611364,0.000002666556,0.00028447495],"genre_scores_gemma":[0.9950171,0.0003068827,0.0023936254,0.0018846662,0.00026683963,0.00008439708,0.0000025684733,0.000013326211,0.000030564548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977449,0.00019658273,0.0015596536,0.00013743917,0.00021554694,0.00014584025],"domain_scores_gemma":[0.9964516,0.0017100781,0.0013285164,0.00017894531,0.00024158375,0.00008927341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001892768,0.00011573022,0.0010965313,0.000092576935,0.000021315442,0.0000032080695,0.00013531369,0.00015820858,0.00007534628],"category_scores_gemma":[0.0002501376,0.00006154262,0.00044447003,0.00008887925,0.00003315768,0.000038347684,0.000007618153,0.0003011061,7.340065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002506071,0.0078068683,0.9444372,0.00006438235,0.00027487756,0.000041034644,0.0007787831,0.00002152243,0.0000050124786,0.0000092162845,0.0005211327,0.04353391],"study_design_scores_gemma":[0.02041157,0.018575322,0.9589429,0.00015289568,0.00070830504,0.0000035438734,0.00034213794,0.0001601043,0.00005973393,0.00004788396,0.00054095197,0.00005463933],"about_ca_topic_score_codex":0.00055595377,"about_ca_topic_score_gemma":0.0011226903,"teacher_disagreement_score":0.043479268,"about_ca_system_score_codex":0.0002500213,"about_ca_system_score_gemma":0.000947535,"threshold_uncertainty_score":0.2509635},"labels":[],"label_agreement":null},{"id":"W2590941790","doi":"10.1200/jco.2012.30.34_suppl.258","title":"From evidence to impact: Determining the vital few indicators for systemic treatment computerized prescriber order entry systems (ST CPOE).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electronic Health Records Systems","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Delphi method; Usability; Health informatics; Process management; Quality (philosophy); Quality management; Guideline; Performance indicator; Knowledge management; Operations management; Nursing; Computer science; Management system; Business","score_opus":0.35660694565127,"score_gpt":0.6171754067682979,"score_spread":0.26056846111702786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590941790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687042,0.003623547,0.0034790968,0.0051410776,0.01517931,0.0035816773,0.000051377254,0.000032045544,0.00020766578],"genre_scores_gemma":[0.9809159,0.00041601053,0.0014932654,0.0019680003,0.014347482,0.00036240477,0.000007092014,0.00005452879,0.00043529982],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98589957,0.006224347,0.005742504,0.0003197997,0.00050025654,0.001313526],"domain_scores_gemma":[0.95421255,0.038048413,0.0052355085,0.0004903202,0.0007241354,0.0012891061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013424122,0.00032349082,0.002469364,0.00018706989,0.00044986376,0.000025779484,0.0006475462,0.0008819417,0.00011147563],"category_scores_gemma":[0.0072205104,0.00017493808,0.0005687493,0.00028435802,0.00008850995,0.00034378387,0.0001308893,0.0015433902,0.00015724897],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00540037,0.0016187078,0.80072874,0.00060960685,0.0013913978,0.000043807715,0.009065421,0.00008546825,0.00017491334,0.00012976775,0.09279604,0.08795579],"study_design_scores_gemma":[0.018287947,0.027914621,0.2827371,0.0056365784,0.000956581,0.00036333853,0.0042406293,0.0007889821,0.000011014292,0.000051187948,0.65841824,0.00059379864],"about_ca_topic_score_codex":0.00064086856,"about_ca_topic_score_gemma":0.00010738907,"teacher_disagreement_score":0.5656222,"about_ca_system_score_codex":0.0026098543,"about_ca_system_score_gemma":0.0072898264,"threshold_uncertainty_score":0.9983379},"labels":[],"label_agreement":null},{"id":"W2590945765","doi":"10.1200/jco.2016.34.26_suppl.240","title":"Family Camp: A multi-disciplinary intervention for brain tumor patients and families.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Mental Health & Substance Use Services","funders":"","keywords":"Respite care; Medicine; Psychological intervention; Anxiety; Attendance; Coping (psychology); Intervention (counseling); Psychiatry; Nursing","score_opus":0.14850435476136134,"score_gpt":0.4953159135270214,"score_spread":0.34681155876566006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590945765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653054,0.00033659948,0.0054479036,0.026561173,0.0017894413,0.00040189349,0.000022297949,0.000012037478,0.00012327889],"genre_scores_gemma":[0.98104703,0.00018609852,0.009738156,0.0076651224,0.0010363526,0.000010117928,0.000003464777,0.00002379759,0.00028983486],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963209,0.0003890029,0.0025370854,0.0002305346,0.00030446053,0.00021802873],"domain_scores_gemma":[0.99337023,0.0037804828,0.0017824142,0.0001563458,0.0005160227,0.00039448743],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004492689,0.00013841323,0.0012259021,0.00012392129,0.000043477663,0.0000065910676,0.00013152591,0.00022800441,0.000026966796],"category_scores_gemma":[0.011586418,0.00008411754,0.0005899332,0.00006202927,0.00026981538,0.00015672093,0.00010011113,0.00037748498,0.000010386613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01616622,0.00854164,0.37613392,0.0004023558,0.0007146371,0.00016117316,0.0011013282,0.0000010246,0.0007555997,0.00017364949,0.02452931,0.57131916],"study_design_scores_gemma":[0.04543061,0.023950292,0.89794743,0.0008267248,0.00019840643,0.00008373686,0.00045004254,0.000016918344,0.000041337873,0.0010476103,0.029885063,0.00012184283],"about_ca_topic_score_codex":0.00003250971,"about_ca_topic_score_gemma":0.0001228493,"teacher_disagreement_score":0.5711973,"about_ca_system_score_codex":0.0001897656,"about_ca_system_score_gemma":0.0007509127,"threshold_uncertainty_score":0.9967394},"labels":[],"label_agreement":null},{"id":"W2590956383","doi":"10.1200/jco.2014.32.3_suppl.343","title":"Outcomes of patients treated with capecitabine and temozolamide (CapTem) for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Neuroendocrine tumors; Internal medicine; Gastroenterology; Retrospective cohort study; Cohort; Progression-free survival; Chemotherapy; Pancreas; Cancer; Oncology; Colorectal cancer","score_opus":0.0382298732085299,"score_gpt":0.4036787613566976,"score_spread":0.3654488881481677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590956383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958216,0.00013758606,0.00007672334,0.0027376504,0.00014070333,0.0007108284,0.000010651072,0.000009709671,0.00035454458],"genre_scores_gemma":[0.9931262,0.00054596184,0.0051349076,0.0007105499,0.00013479214,0.000013219995,0.0000051837615,0.00003633821,0.00029285456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966645,0.0002566534,0.0019692304,0.00030196406,0.00042345905,0.00038415287],"domain_scores_gemma":[0.99343836,0.003614578,0.0015072543,0.0002330587,0.0006838832,0.0005228791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006522348,0.00023258636,0.0022772178,0.0002066113,0.000039736165,0.000007805611,0.000138453,0.000024583213,0.000017045317],"category_scores_gemma":[0.0083483625,0.00014259064,0.00018889483,0.0001336957,0.000429361,0.00017632612,0.00007505806,0.0005325245,0.0000010919723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010016374,0.00093861803,0.94605356,0.00020524241,0.00021650716,0.00065782655,0.000010087323,0.0000102162,0.0005025722,0.000030382475,0.00023375165,0.041124884],"study_design_scores_gemma":[0.027811626,0.053334042,0.9071901,0.00013134643,0.00035030217,0.00078362797,0.000040882256,0.00023638028,0.00066910003,0.00014676241,0.009187331,0.00011850474],"about_ca_topic_score_codex":0.000020387733,"about_ca_topic_score_gemma":0.00004440349,"teacher_disagreement_score":0.052395426,"about_ca_system_score_codex":0.000035269466,"about_ca_system_score_gemma":0.00022246018,"threshold_uncertainty_score":0.9994373},"labels":[],"label_agreement":null},{"id":"W2590969311","doi":"10.1200/jco.2012.30.4_suppl.656","title":"The prognostic signficance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Leukocytosis; Medicine; Chemoradiotherapy; Internal medicine; Gastroenterology; Proportional hazards model; White blood cell; Anal cancer; Radiation therapy; Cancer; Stage (stratigraphy); Surgery","score_opus":0.062264088635557775,"score_gpt":0.40301522638303916,"score_spread":0.3407511377474814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590969311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953566,0.0019955877,0.000024890765,0.0019070483,0.00013440965,0.00042947108,0.0000031661748,0.0000045620723,0.00014422505],"genre_scores_gemma":[0.99676305,0.0011072115,0.0010435722,0.00043537767,0.00047126834,0.000019819381,0.0000013089254,0.00001956241,0.000138833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976295,0.0002811754,0.0012018259,0.00013956732,0.0004380903,0.00030981353],"domain_scores_gemma":[0.99664354,0.0015285946,0.001077031,0.00013949424,0.00028631257,0.00032502928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095355156,0.00016547402,0.0013147593,0.0000819022,0.000038005746,0.0000052169567,0.0001275393,0.00016319234,0.000120223594],"category_scores_gemma":[0.00035622786,0.000065604654,0.00019145566,0.00032418733,0.00045329396,0.000087370136,0.000009894042,0.0005044782,4.9798723e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05827391,0.0029858458,0.8669617,0.000019120145,0.000588735,0.00008144118,0.0001207968,0.000012344849,0.000050074264,0.000007245934,0.0001723782,0.07072637],"study_design_scores_gemma":[0.017602963,0.04591654,0.93146044,0.00018254342,0.00033132738,0.000078263736,0.000047675996,0.00004906284,0.00020775919,0.0000024138446,0.0040375893,0.000083433704],"about_ca_topic_score_codex":0.000072789124,"about_ca_topic_score_gemma":0.00027206336,"teacher_disagreement_score":0.07064294,"about_ca_system_score_codex":0.0003817085,"about_ca_system_score_gemma":0.0012751236,"threshold_uncertainty_score":0.267528},"labels":[],"label_agreement":null},{"id":"W2590972835","doi":"10.1200/jco.2014.32.30_suppl.201","title":"Effect of physical activity (PA) perceptions in cancer survivors on PA behaviors: Helping health care providers improve patient communication.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Logistic regression; Breast cancer; Disease; Internal medicine; Lung cancer; Survivorship curve; Gerontology; Physical therapy; Nursing","score_opus":0.05276344475973225,"score_gpt":0.4761371305943676,"score_spread":0.4233736858346353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590972835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925264,0.000299147,0.00003095526,0.0053747613,0.00088916946,0.000447982,0.000013342171,0.000008161263,0.00041006913],"genre_scores_gemma":[0.9982032,0.00029715706,0.00007790819,0.00091440626,0.0004383166,0.000032576758,0.0000045002757,0.000018307574,0.000013631263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99565476,0.0023114255,0.0011972965,0.00020103838,0.00040150885,0.0002339931],"domain_scores_gemma":[0.99414694,0.0033645972,0.0015114624,0.0003608446,0.00033846614,0.00027768553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025476934,0.0001574616,0.0015762913,0.0001409867,0.000055723285,0.000006381503,0.0001707852,0.0002342958,0.000024145489],"category_scores_gemma":[0.0012636862,0.00011452994,0.0005276581,0.00016359478,0.00021010134,0.00010125585,0.000059954273,0.0013769123,0.0000025479321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003691103,0.001895794,0.120776094,0.00026910115,0.000071150396,0.000009605724,0.0052178707,0.00008695751,0.00040198115,0.000024120838,0.00024150399,0.8673147],"study_design_scores_gemma":[0.013158357,0.1707395,0.7908868,0.0018110294,0.00059743685,0.000027280093,0.006054002,0.0005627148,0.0019362703,0.00003435713,0.013848069,0.00034415326],"about_ca_topic_score_codex":0.006439097,"about_ca_topic_score_gemma":0.019604256,"teacher_disagreement_score":0.86697054,"about_ca_system_score_codex":0.0006637702,"about_ca_system_score_gemma":0.0012346846,"threshold_uncertainty_score":0.9982854},"labels":[],"label_agreement":null},{"id":"W2590980860","doi":"10.1200/jco.2014.32.3_suppl.606","title":"Retrospective cohort study of patients with anal cancer treated over a 12-year period at a large Canadian cancer center.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Anal cancer; Chemoradiotherapy; Cancer; Population; Internal medicine; Retrospective cohort study; Surgery; Colostomy; Cohort","score_opus":0.03377930683162758,"score_gpt":0.38232663107217346,"score_spread":0.3485473242405459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590980860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962441,0.00004276872,0.0000010600513,0.0006526408,0.00042362415,0.0003798041,0.00006910751,0.0000038544977,0.002183092],"genre_scores_gemma":[0.99830973,0.00005178509,0.000024838662,0.0006723403,0.0005346778,0.000010447104,0.0000065001395,0.000016698485,0.00037298285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762064,0.0002632418,0.001114767,0.00022478175,0.00048002813,0.00029651972],"domain_scores_gemma":[0.99730426,0.00013161388,0.001033079,0.00014573288,0.00078680034,0.00059854],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008621069,0.00014756843,0.0014741471,0.00014776122,0.000063785374,0.000004513396,0.00010805519,0.0001861994,0.001029812],"category_scores_gemma":[0.00048918615,0.00009229494,0.0002470815,0.000174149,0.00011656,0.00005457023,0.000041912663,0.0005845586,0.0000029766982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00809364,0.0025049173,0.9852566,0.000010817129,0.0007091554,0.00016188766,0.00027120847,0.000003269323,0.000005491603,0.000007228544,0.0013685094,0.0016072848],"study_design_scores_gemma":[0.017605092,0.027112672,0.945841,0.00007177892,0.0006078233,0.000016030446,0.00012853146,0.000062257524,0.000003110359,0.0000047940534,0.008456957,0.00008991045],"about_ca_topic_score_codex":0.031217735,"about_ca_topic_score_gemma":0.58836234,"teacher_disagreement_score":0.5571446,"about_ca_system_score_codex":0.0010337078,"about_ca_system_score_gemma":0.0013419979,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W2590997329","doi":"10.1200/jco.2016.34.26_suppl.67","title":"Edmonton Symptom Assessment Scale (ESAS): Time duration of self-completion versus assisted-completion in palliative care patients—A randomized controlled trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Physical therapy; Health literacy; Health care; Internal medicine","score_opus":0.05783596086952225,"score_gpt":0.43270614460542967,"score_spread":0.3748701837359074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590997329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865976,0.0001810975,0.0005772309,0.0026072224,0.0034564948,0.0021638414,0.0000104083165,0.000013954051,0.0043921736],"genre_scores_gemma":[0.9975629,0.0004220721,0.00083025143,0.00017831194,0.00080551126,0.000076412834,0.000022759747,0.000014798345,0.000086970256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917147,0.0026778819,0.004436133,0.0002249435,0.0007484644,0.00019783761],"domain_scores_gemma":[0.9845554,0.008927829,0.00442226,0.00018341767,0.0017208048,0.00019025989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005870332,0.0001820825,0.0042195837,0.00022537039,0.00003176283,0.000008071461,0.00011958421,0.00040180812,0.00024569975],"category_scores_gemma":[0.0049054944,0.000104820945,0.0012126076,0.00015067008,0.0001562775,0.00014023407,0.000028435901,0.00045825125,0.000010094565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9531741,0.0021162147,0.024298528,0.000035153906,0.000564887,0.000015275442,0.00041018132,0.0000026507157,0.00024985132,0.00008217431,0.00021996237,0.018830994],"study_design_scores_gemma":[0.76684463,0.011886666,0.21838427,0.00024981107,0.0008376742,0.0000020878397,0.00018203983,0.000101514896,0.000028318404,0.00006141978,0.0013350483,0.00008650145],"about_ca_topic_score_codex":0.000071905066,"about_ca_topic_score_gemma":0.000460654,"teacher_disagreement_score":0.19408573,"about_ca_system_score_codex":0.0009620414,"about_ca_system_score_gemma":0.0012502071,"threshold_uncertainty_score":0.58726895},"labels":[],"label_agreement":null},{"id":"W2590997938","doi":"10.1200/jco.2013.31.31_suppl.53","title":"Using a statewide collaborative approach to improve primary palliative care performance.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Quality management; Primary care; Psychological intervention; Best practice; Scale (ratio); Nursing; Family medicine","score_opus":0.36999812722704145,"score_gpt":0.5506561339513426,"score_spread":0.18065800672430116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590997938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745278,0.0015008512,0.0011556646,0.0008831792,0.0007098362,0.00053833105,0.00001278837,0.000007055432,0.02066454],"genre_scores_gemma":[0.84926665,0.0013105752,0.14590274,0.0023183546,0.000974017,0.0000133965095,0.0000068771046,0.000021368098,0.00018600833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968294,0.00030072147,0.001991882,0.0002049655,0.0004080512,0.00026500245],"domain_scores_gemma":[0.9936535,0.0012911643,0.0016154962,0.00017243126,0.0028186042,0.00044884405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001010429,0.00017064008,0.001757299,0.00015456279,0.000038747425,0.000009236457,0.00016488867,0.000293117,0.000051301653],"category_scores_gemma":[0.0026510898,0.00011666567,0.00030150657,0.00031355247,0.0002021147,0.00021185323,0.000074996045,0.00073325285,0.000022619217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007352129,0.0025387737,0.66806865,0.00078934693,0.0017172111,0.00015774228,0.020434272,0.0004956365,0.007067608,0.000102499704,0.010783869,0.28049228],"study_design_scores_gemma":[0.0194551,0.048141677,0.723848,0.0018940148,0.0012188248,0.00006460401,0.032956805,0.001487459,0.006612635,0.00026005023,0.16350663,0.00055420026],"about_ca_topic_score_codex":0.000045130357,"about_ca_topic_score_gemma":0.0000050011245,"teacher_disagreement_score":0.27993807,"about_ca_system_score_codex":0.00039421825,"about_ca_system_score_gemma":0.0026120425,"threshold_uncertainty_score":0.4757488},"labels":[],"label_agreement":null},{"id":"W2590999537","doi":"10.1200/jco.2014.32.30_suppl.15","title":"Measuring alignment with evidence-informed practice in Ontario’s systemic treatment funding model.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Reimbursement; Family medicine; Baseline (sea); Palliative care; Health care; Nursing","score_opus":0.6707966750586397,"score_gpt":0.5965454953352355,"score_spread":0.07425117972340423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590999537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657562,0.0002008442,0.007565787,0.019675922,0.00089494325,0.0006477296,4.4571627e-7,0.000013676094,0.0052444465],"genre_scores_gemma":[0.9586659,0.00082225696,0.035951715,0.003622743,0.0006207538,0.00001434578,0.0000018232912,0.000019489074,0.0002809878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99215454,0.0008771037,0.005570588,0.0002607802,0.00080631586,0.0003306755],"domain_scores_gemma":[0.96567696,0.027781423,0.004870627,0.00032415413,0.0008443609,0.0005024664],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015424157,0.00019364619,0.0015990188,0.00018862021,0.00004126044,0.00002069079,0.0001473198,0.00027228074,0.00007453622],"category_scores_gemma":[0.06453397,0.00012522184,0.00030736078,0.00013412956,0.00008149057,0.00080941425,0.000045074416,0.0010840702,0.00001928818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04534622,0.005152765,0.49657142,0.00014196546,0.001374518,0.0013219143,0.0025604032,0.016798614,0.00034362913,0.0003466678,0.0011989286,0.42884296],"study_design_scores_gemma":[0.115651354,0.20140004,0.32432252,0.008294634,0.009155116,0.0154444305,0.009467918,0.035972927,0.00025164927,0.000931709,0.2781008,0.0010069138],"about_ca_topic_score_codex":0.004921922,"about_ca_topic_score_gemma":0.03823467,"teacher_disagreement_score":0.42783606,"about_ca_system_score_codex":0.003305101,"about_ca_system_score_gemma":0.009101532,"threshold_uncertainty_score":0.9965159},"labels":[],"label_agreement":null},{"id":"W2591000248","doi":"10.1200/jco.2013.31.31_suppl.228","title":"Hepatitis B reactivation in patients with lymphoma: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; HBsAg; Hepatitis B virus; Rituximab; Internal medicine; Hepatitis B; Meta-analysis; Lymphoma; Relative risk; Immunology; Gastroenterology; Virology; Virus; Confidence interval","score_opus":0.15530715425617045,"score_gpt":0.4330132477314909,"score_spread":0.2777060934753205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591000248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915325,0.00015502243,0.0001087935,0.0054853414,0.00015533484,0.00027782988,0.0000021685942,0.0000055508954,0.0022774441],"genre_scores_gemma":[0.9926258,0.00020208787,0.004197082,0.002619053,0.00015932981,0.00001638208,0.0000038689127,0.0000111271975,0.00016527192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647075,0.00043187742,0.0022530432,0.00016791982,0.00048720746,0.00018920933],"domain_scores_gemma":[0.9952811,0.001481437,0.001734294,0.00019030205,0.0011030192,0.0002098393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016780292,0.00012819083,0.0031134833,0.00032985208,0.000023170538,0.0000078377725,0.00009074103,0.00020995359,0.0005630918],"category_scores_gemma":[0.0036326323,0.000073082854,0.00092797,0.00047528913,0.0001244236,0.00024211784,0.00003318997,0.0003921372,0.000047717756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053972367,0.0017605203,0.93716735,0.0000051251177,0.042127106,0.000076370416,0.00005760693,0.000007777248,0.0000017519474,0.000020083848,0.001731754,0.016504806],"study_design_scores_gemma":[0.005261318,0.005432713,0.9392331,0.000007076818,0.04593798,0.000007793515,0.000010724223,0.00003128551,0.000004461575,0.00011841079,0.003889029,0.00006609612],"about_ca_topic_score_codex":0.0022582724,"about_ca_topic_score_gemma":0.003315168,"teacher_disagreement_score":0.01643871,"about_ca_system_score_codex":0.00020126512,"about_ca_system_score_gemma":0.00051582546,"threshold_uncertainty_score":0.61654603},"labels":[],"label_agreement":null},{"id":"W2591002464","doi":"10.1200/jco.2016.34.26_suppl.96","title":"Use of the Edmonton Symptom Assessment Scale in patients with advanced cancer referred to an embedded palliative care clinician.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Referral; Distress; Quality of life (healthcare); Anxiety; Cancer; Hospital Anxiety and Depression Scale; Breast cancer; Lung cancer; Physical therapy; Internal medicine; Family medicine; Nursing; Psychiatry; Clinical psychology","score_opus":0.12069461445746532,"score_gpt":0.49715371213395776,"score_spread":0.37645909767649244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591002464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940966,0.000086891785,0.00005234398,0.0034127473,0.0015472982,0.00043180515,0.00003315627,0.000004327718,0.00033487772],"genre_scores_gemma":[0.996116,0.0001680402,0.0011964312,0.002028736,0.00033090843,0.000015073939,0.0000019787394,0.000018749877,0.00012409611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670357,0.000555856,0.0017403143,0.00023357931,0.00054524635,0.00022143807],"domain_scores_gemma":[0.99554753,0.0010302004,0.001496409,0.00035113547,0.0012576396,0.00031708615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082408165,0.00014247796,0.0012024966,0.00008930537,0.000023471492,0.000004970026,0.000213549,0.00024606512,0.00006592755],"category_scores_gemma":[0.0009247906,0.00006587832,0.00026394875,0.00021941357,0.00014491896,0.00018052397,0.000062871455,0.0005481132,0.0000011544752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075161024,0.0007406609,0.7952608,0.000016068465,0.000090437796,0.000009320153,0.0008388727,0.000033374152,0.00006358901,0.000006948699,0.00018586658,0.19523796],"study_design_scores_gemma":[0.009420247,0.014672251,0.96478087,0.0008386376,0.0001674821,9.2863723e-7,0.00077686814,0.0000038201792,0.00012956561,0.000018946579,0.009097849,0.000092530434],"about_ca_topic_score_codex":0.00022944441,"about_ca_topic_score_gemma":0.018048868,"teacher_disagreement_score":0.19514544,"about_ca_system_score_codex":0.00057168887,"about_ca_system_score_gemma":0.0018745661,"threshold_uncertainty_score":0.99986917},"labels":[],"label_agreement":null},{"id":"W2591006056","doi":"10.1200/jco.2012.30.4_suppl.257","title":"RTOG 0438: A phase I trial of highly conformal radiation therapy for patients with liver metastases.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nuclear medicine; Radiation therapy; Hepatocellular carcinoma; Toxicity; Radiology; Internal medicine","score_opus":0.06463265827077302,"score_gpt":0.45577151358593154,"score_spread":0.3911388553151585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591006056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89961296,0.0002537574,0.09827209,0.00011319042,0.0006910746,0.00069612917,0.00005118612,0.00000678489,0.0003028258],"genre_scores_gemma":[0.9636046,0.00017235892,0.03409435,0.00019145205,0.0018685485,0.000019244562,0.000015243974,0.000015607648,0.000018568187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979819,0.0001957106,0.0013624391,0.00007663091,0.00018922724,0.00019409682],"domain_scores_gemma":[0.9957028,0.001204655,0.0024894364,0.0001097964,0.00034178296,0.00015153881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014942937,0.00011236236,0.0008212324,0.000067348636,0.000029030813,0.0000048015786,0.00013615955,0.00010265676,0.00013586547],"category_scores_gemma":[0.00011917289,0.000071879236,0.0003505154,0.000058672653,0.00010780499,0.00041515083,0.000009366044,0.00026290392,5.3622915e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10992954,0.008659912,0.036392193,0.0000043825507,0.000596973,7.7278946e-7,0.00011123246,0.000007205651,0.000050523384,0.0018020995,0.001297806,0.84114736],"study_design_scores_gemma":[0.42895478,0.095889606,0.014861865,0.000025040983,0.00029232018,0.0000024287103,0.000034273864,0.00009147814,0.0025291012,0.00064789725,0.45643827,0.00023291573],"about_ca_topic_score_codex":0.0000070846036,"about_ca_topic_score_gemma":2.829423e-7,"teacher_disagreement_score":0.8409144,"about_ca_system_score_codex":0.000034013756,"about_ca_system_score_gemma":0.00031619248,"threshold_uncertainty_score":0.29311502},"labels":[],"label_agreement":null},{"id":"W2591009946","doi":"10.1200/jco.2016.34.26_suppl.64","title":"Caregivers' accuracy in reporting patients' symptom: A preliminary report.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Depression (economics); Palliative care; Anxiety; Nausea; Cancer; Lung cancer; Anorexia; Quality of life (healthcare); Hospital Anxiety and Depression Scale; Physical therapy; Internal medicine; Psychiatry","score_opus":0.33538268715461483,"score_gpt":0.5710442162692788,"score_spread":0.23566152911466398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591009946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98794514,0.000512322,0.00012448442,0.004765231,0.0011104265,0.00013028987,0.000001660581,0.000006462212,0.005403997],"genre_scores_gemma":[0.9944605,0.0012052216,0.0028093094,0.00041915406,0.00064840016,0.0000018975669,0.000001791667,0.000011174921,0.0004425201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99311244,0.00027070526,0.005858147,0.00018655063,0.00037172815,0.00020043939],"domain_scores_gemma":[0.97562504,0.010637154,0.012064266,0.00027223848,0.0011273971,0.00027389423],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003927192,0.000109294284,0.0015502371,0.0001609656,0.000013544592,0.000001983465,0.0001237007,0.00030798532,0.00009152597],"category_scores_gemma":[0.14215283,0.00006286386,0.00046942706,0.00013020712,0.00017084995,0.00016162462,0.000066787106,0.0004884571,0.000007689458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024021103,0.0007677628,0.8645002,0.000031901218,0.00012694002,0.006553792,0.00045223744,7.8280567e-7,0.000102368875,0.000017353337,0.0041993097,0.12084522],"study_design_scores_gemma":[0.008752581,0.010766075,0.848758,0.002031016,0.00020387383,0.00068198977,0.0005484893,0.0000039084657,0.00034743626,0.00023384146,0.1275794,0.00009341308],"about_ca_topic_score_codex":0.000039589522,"about_ca_topic_score_gemma":0.000015571806,"teacher_disagreement_score":0.13822563,"about_ca_system_score_codex":0.00018644947,"about_ca_system_score_gemma":0.0012521935,"threshold_uncertainty_score":0.8650732},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"methods","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2591011509","doi":"10.1200/jco.2016.34.4_suppl.418","title":"The use of stereotactic body radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Liver transplantation; Radiation therapy; Milan criteria; Liver disease; Transplantation; Radiology; Internal medicine","score_opus":0.2808413951478221,"score_gpt":0.41711480668640255,"score_spread":0.13627341153858047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591011509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838467,0.00075158395,0.0038529679,0.010272938,0.000493399,0.00071074907,0.000010834181,0.000005275642,0.000055542358],"genre_scores_gemma":[0.9909222,0.0038637542,0.00303853,0.0010872023,0.00056105835,0.00001901298,0.0000021814262,0.000021315675,0.00048475456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974074,0.00039047142,0.0015605333,0.0001556446,0.00026948802,0.00021647925],"domain_scores_gemma":[0.99196625,0.006148238,0.00089663145,0.00020490919,0.0004678324,0.0003161518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017229221,0.00012876917,0.00088817114,0.0000954422,0.000052098254,0.000011066509,0.00012886588,0.0002156699,0.000056338657],"category_scores_gemma":[0.0014488595,0.00006223995,0.0006621857,0.000087135966,0.00012328412,0.00012799333,0.000009679092,0.0001909176,0.000012119406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01615073,0.00067150476,0.83058035,0.000058876805,0.00057375093,0.0011213423,0.00022055123,2.2468667e-7,0.0035231744,0.00014773392,0.0021430838,0.14480866],"study_design_scores_gemma":[0.014816247,0.034750815,0.6382329,0.00018581346,0.0013788688,0.0009942551,0.000013992954,0.00057090155,0.0061636865,0.0001126349,0.30264533,0.0001345888],"about_ca_topic_score_codex":0.000046189627,"about_ca_topic_score_gemma":0.000014623302,"teacher_disagreement_score":0.30050224,"about_ca_system_score_codex":0.0001117869,"about_ca_system_score_gemma":0.00073148333,"threshold_uncertainty_score":0.2538072},"labels":[],"label_agreement":null},{"id":"W2591012698","doi":"10.1200/jco.2016.34.2_suppl.178","title":"The RADICAL-PC trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Queen's University; University of Waterloo; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Prostatectomy; Population; Cohort; Prospective cohort study; Disease; Internal medicine; Cancer; Clinical trial; Oncology; Physical therapy; Gynecology; Environmental health","score_opus":0.07473852122511906,"score_gpt":0.439373951409078,"score_spread":0.36463543018395894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591012698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7491574,0.011814558,0.004355715,0.05198895,0.16925213,0.00046634997,0.000011575825,0.000010617414,0.012942697],"genre_scores_gemma":[0.61907643,0.05645818,0.0012513578,0.006782915,0.30207527,0.000017629342,0.0000019720562,0.00004446041,0.014291804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748933,0.0005107678,0.0014383189,0.00015232313,0.00019167773,0.00021760099],"domain_scores_gemma":[0.99722993,0.0010192033,0.0010222828,0.0002641295,0.00022672754,0.00023773365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004060891,0.0000922495,0.00053651724,0.000021554022,0.00006766277,0.000009738313,0.00037484645,0.0003591388,0.000050312156],"category_scores_gemma":[0.006805648,0.00004095684,0.00053237175,0.0000383576,0.00041808726,0.0000045051015,0.00007481411,0.00026740227,0.00002011398],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031080006,0.00032613188,0.00037978144,0.0000016090913,0.00020694714,0.0000015622823,0.0000065320305,9.696583e-7,0.013436276,0.0005059565,0.4113594,0.54269487],"study_design_scores_gemma":[0.030149128,0.0047035175,0.0020177653,0.000008571664,0.000054347765,0.00004767278,0.000012338365,4.68255e-7,0.00049413694,0.000562251,0.9618837,0.00006605775],"about_ca_topic_score_codex":0.0000027163126,"about_ca_topic_score_gemma":0.000032610544,"teacher_disagreement_score":0.55052435,"about_ca_system_score_codex":0.000020283895,"about_ca_system_score_gemma":0.0011678945,"threshold_uncertainty_score":0.8147488},"labels":[],"label_agreement":null},{"id":"W2591014697","doi":"10.1200/jco.2011.29.4_suppl.600","title":"Characteristics and treatment effect of senior patients with metastatic colorectal cancer (mCRC): A retrospective analysis.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Comorbidity; Colorectal cancer; Proportional hazards model; Hazard ratio; Medical record; Anemia; Multivariate analysis; Bleed; Retrospective cohort study; Cancer; Surgery; Confidence interval","score_opus":0.05799446116139687,"score_gpt":0.4133573705314313,"score_spread":0.3553629093700344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591014697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983497,0.0002846241,0.000009185635,0.00012596344,0.0002396932,0.00033148224,0.000038398888,0.000003541122,0.0006174116],"genre_scores_gemma":[0.99809676,0.0009698872,0.00067925284,0.000062682935,0.00011191894,0.00001845922,0.0000037321895,0.000009624249,0.000047695183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998094,0.00024396037,0.0011018696,0.00017074941,0.00024157183,0.00014782163],"domain_scores_gemma":[0.99695915,0.0007836271,0.0014835421,0.000086455344,0.0004921318,0.00019507839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005750196,0.00017371897,0.0026707225,0.0001419437,0.000032371623,0.000002755151,0.00004106806,0.00008974303,0.0001100165],"category_scores_gemma":[0.0005248191,0.00008312414,0.00040804234,0.00022267926,0.0002592953,0.000047134334,0.000023049359,0.00021085239,6.514246e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021146176,0.0017353509,0.90830344,0.000019258645,0.011593127,0.0001806675,0.0004852097,2.9712376e-7,0.000008432823,0.0000048615225,0.00002270742,0.056500442],"study_design_scores_gemma":[0.010995014,0.11270322,0.86164963,0.000035294983,0.014102652,0.000018797347,0.000036422225,0.000011693991,0.00015147956,0.000008234993,0.00022809919,0.00005945756],"about_ca_topic_score_codex":0.00016864686,"about_ca_topic_score_gemma":0.00049839675,"teacher_disagreement_score":0.11096787,"about_ca_system_score_codex":0.0002986159,"about_ca_system_score_gemma":0.0003731662,"threshold_uncertainty_score":0.33897042},"labels":[],"label_agreement":null},{"id":"W2591016102","doi":"10.1200/jco.2008.26.15_suppl.20645","title":"Impact of a community-based pediatric oncology nursing model","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Nursing; Pediatric oncology; Coding (social sciences); Family medicine; Schema (genetic algorithms); Oncology nursing; Cancer; Nurse education","score_opus":0.3448042357321802,"score_gpt":0.5672234600976682,"score_spread":0.222419224365488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591016102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98228323,0.00039333163,0.0024541274,0.009967,0.00078118395,0.00017562979,0.000009058749,0.000016847194,0.003919586],"genre_scores_gemma":[0.9805919,0.0005430684,0.012157878,0.0049285283,0.0016956741,0.00000148235,0.0000047969042,0.000028439348,0.000048263984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99208325,0.0026484577,0.0041607623,0.00013713213,0.00063008256,0.0003403353],"domain_scores_gemma":[0.9863824,0.007579128,0.00395531,0.00045802954,0.0009411211,0.00068401475],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008106535,0.00020331187,0.0029538616,0.0003575354,0.00011256549,0.0000025835504,0.00037622164,0.00069043506,0.00009356432],"category_scores_gemma":[0.006401987,0.00015584975,0.0016017728,0.00032468195,0.00069662224,0.00011175265,0.000048829894,0.0031939165,0.000008843547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031823605,0.050492413,0.7177131,0.0003583905,0.0015257242,0.0011875272,0.009908616,0.008914343,0.0003635009,0.00012797644,0.096980415,0.08060438],"study_design_scores_gemma":[0.027614808,0.08465293,0.87522954,0.00026211079,0.0013026276,0.0021070482,0.00045077907,0.0030317085,0.000049374048,0.0013430521,0.0036929832,0.00026305523],"about_ca_topic_score_codex":0.00016108641,"about_ca_topic_score_gemma":0.000032924858,"teacher_disagreement_score":0.15751642,"about_ca_system_score_codex":0.00084453466,"about_ca_system_score_gemma":0.018501898,"threshold_uncertainty_score":0.99910575},"labels":[],"label_agreement":null},{"id":"W2591020155","doi":"10.1200/jco.2016.34.2_suppl.e631","title":"MRI response to focal salvage HDR prostate brachytherapy for locally recurrent prostate cancer after external-beam radiotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiotherapy; Prostate; Radiology; Radiation therapy; Cryotherapy; Nuclear medicine; Cancer; Internal medicine","score_opus":0.055477868897645985,"score_gpt":0.45227622594596795,"score_spread":0.39679835704832195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591020155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8816594,0.009868809,0.0047376794,0.0991374,0.002513193,0.0019167517,0.00011529499,0.00002130453,0.00003016002],"genre_scores_gemma":[0.9088579,0.04105563,0.018008567,0.024641374,0.0035472051,0.0011109316,0.0000028436152,0.00012617352,0.0026494071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99545413,0.00049282226,0.0025170597,0.000476013,0.0004778112,0.00058214203],"domain_scores_gemma":[0.99359953,0.0029617206,0.001333412,0.0003470003,0.0008124092,0.00094590866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038926804,0.00031781493,0.0017439763,0.00019025484,0.000051978743,0.00002474162,0.00019718276,0.00030028733,0.00029252667],"category_scores_gemma":[0.0011977978,0.00017423595,0.0007747745,0.00015193663,0.00021506632,0.00018005107,0.000043376953,0.0004611646,0.00002217866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2255542,0.001975743,0.080948696,0.00004516794,0.0006529271,0.0008731389,0.00040109738,0.000014230528,0.0043430137,0.000011811437,0.013375153,0.67180485],"study_design_scores_gemma":[0.033397485,0.078810565,0.26807454,0.0014982445,0.0003331537,0.0002137784,0.000030226154,0.000018716975,0.002950614,0.00031707247,0.6140846,0.00027096842],"about_ca_topic_score_codex":0.00001299818,"about_ca_topic_score_gemma":0.00005999366,"teacher_disagreement_score":0.6715339,"about_ca_system_score_codex":0.0010271968,"about_ca_system_score_gemma":0.002853961,"threshold_uncertainty_score":0.7105136},"labels":[],"label_agreement":null},{"id":"W2591022134","doi":"10.1200/jco.2009.27.15_suppl.1033","title":"Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Taxane; Vinorelbine; Metastatic breast cancer; Internal medicine; Docetaxel; Capecitabine; Bevacizumab; Clinical endpoint; Population; Oncology; Trastuzumab; Surgery; Chemotherapy; Gastroenterology; Breast cancer; Cancer; Clinical trial; Colorectal cancer","score_opus":0.12530062789995866,"score_gpt":0.5168701766002968,"score_spread":0.3915695487003381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591022134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691266,0.0014895969,0.0024665054,0.025390489,0.00060245674,0.0007113251,0.00011912019,0.0000062977465,0.00008761448],"genre_scores_gemma":[0.987717,0.0060069496,0.0034512584,0.0021309394,0.0005204606,0.000009147501,0.00001009356,0.000015256569,0.00013894645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99637794,0.00017856505,0.002668824,0.00025008302,0.00026906782,0.00025552572],"domain_scores_gemma":[0.99364734,0.0033308547,0.001902564,0.00017000812,0.00057029136,0.00037893382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015836601,0.0001985602,0.0031000762,0.00037334612,0.000038472037,0.0000040261193,0.0001549926,0.000086719694,0.00044573421],"category_scores_gemma":[0.00079601206,0.00013027477,0.00081061525,0.0005822272,0.00013330783,0.00006148231,0.000028092563,0.00035609913,5.702097e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14494984,0.0047732987,0.017771406,0.000114138915,0.008955531,0.00019264055,0.00022596242,0.0020875202,0.00030401975,0.000026347254,0.0014896366,0.8191097],"study_design_scores_gemma":[0.17035282,0.13318634,0.5730497,0.0008314012,0.049777668,0.0011101014,0.00040612067,0.010513984,0.0012356205,0.00021012759,0.058816344,0.00050973817],"about_ca_topic_score_codex":0.00009133756,"about_ca_topic_score_gemma":0.00048064018,"teacher_disagreement_score":0.81859994,"about_ca_system_score_codex":0.00035705144,"about_ca_system_score_gemma":0.0012648907,"threshold_uncertainty_score":0.53124505},"labels":[],"label_agreement":null},{"id":"W2591024218","doi":"10.1200/jco.2016.34.7_suppl.251","title":"Publication of quality improvement in medical oncology: A descriptive numerical summary from a scoping review.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Psychological intervention; MEDLINE; Publishing; Descriptive statistics; Family medicine; Alternative medicine; Quality (philosophy); Internal medicine; Medical education; Oncology; Nursing; Pathology","score_opus":0.20705607298631545,"score_gpt":0.4655112676117857,"score_spread":0.25845519462547023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591024218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6533582,0.07009366,0.025115827,0.18857916,0.0068993918,0.001406045,0.0002675163,0.00002316417,0.054256987],"genre_scores_gemma":[0.9042045,0.076845296,0.0030104173,0.0145947635,0.0011273905,0.000025996122,0.0000043011105,0.000021673166,0.00016566737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9916602,0.00028376476,0.0073602027,0.0003059144,0.000117947806,0.0002719847],"domain_scores_gemma":[0.98899126,0.002825114,0.00727503,0.0002585418,0.00030268286,0.00034735605],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012567106,0.00013176547,0.0026106474,0.00017567932,0.000017853496,0.000007553423,0.00045604722,0.00052180514,0.0012282559],"category_scores_gemma":[0.026375642,0.00010022209,0.00044303146,0.00016164582,0.0002595175,0.00045953775,0.000110680674,0.000566844,0.00007399222],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010628243,0.0015639933,0.13083002,0.00018924735,0.00019474562,0.000039583883,0.00014388791,8.1918245e-7,0.000039180843,0.014798077,0.010378883,0.84075874],"study_design_scores_gemma":[0.021356786,0.013194657,0.581004,0.020523785,0.00010234906,0.000030148047,0.00015462829,0.000114875715,0.00013543188,0.08503779,0.27761206,0.0007334368],"about_ca_topic_score_codex":0.0004781642,"about_ca_topic_score_gemma":0.0003080591,"teacher_disagreement_score":0.8400253,"about_ca_system_score_codex":0.0006689384,"about_ca_system_score_gemma":0.0022155216,"threshold_uncertainty_score":0.99968475},"labels":[],"label_agreement":null},{"id":"W2591025245","doi":"10.1200/jco.2015.33.7_suppl.311","title":"Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Hypoalbuminemia; Thrombocytosis; Internal medicine; Gastroenterology; Proportional hazards model; Univariate analysis; Neutrophilia; Performance status; Oncology; Platelet; Chemotherapy; Multivariate analysis","score_opus":0.12895214116770118,"score_gpt":0.4319379404089743,"score_spread":0.3029857992412731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591025245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443996,0.00054006855,0.0005745904,0.0006688401,0.00198252,0.0013543529,0.00001274303,0.000013565716,0.00041333569],"genre_scores_gemma":[0.9920354,0.00010283637,0.0066856127,0.000314884,0.0007336859,0.000053616117,0.000009516033,0.000028866278,0.00003561874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959917,0.00046057865,0.0027567726,0.00020084438,0.00037356792,0.00021655892],"domain_scores_gemma":[0.9920028,0.0018688958,0.0032163449,0.0002359735,0.0022746786,0.00040131697],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037662822,0.00014454496,0.0011677125,0.00013541676,0.00002719929,0.0000058611718,0.00020322241,0.00035214797,0.000012002032],"category_scores_gemma":[0.015129105,0.00010606041,0.00048504732,0.00011580002,0.00017417662,0.00012568549,0.00002948142,0.00035686494,0.000002722399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023939746,0.0015830246,0.7834308,0.00016292093,0.00025542348,0.000017719447,0.00012710284,0.000001823541,0.0046758256,0.00001968878,0.0009979615,0.18478796],"study_design_scores_gemma":[0.028803296,0.017773539,0.94658875,0.00024425337,0.00040116938,0.000035003515,0.0002233446,0.0005516786,0.0008799893,0.00013773433,0.004244625,0.000116638446],"about_ca_topic_score_codex":0.0000013897172,"about_ca_topic_score_gemma":0.0000015308337,"teacher_disagreement_score":0.18467133,"about_ca_system_score_codex":0.00023252705,"about_ca_system_score_gemma":0.0023444118,"threshold_uncertainty_score":0.99316686},"labels":[],"label_agreement":null},{"id":"W2591026775","doi":"10.1200/jco.2014.32.30_suppl.159","title":"A strategic roadmap for oncology electronic medical records (EMRs) in Ontario’s complex multiregional health care system.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Interoperability; Vendor; Medicine; eHealth; Health care; Work (physics); Information system; Knowledge management; Process management; Business; Computer science; Engineering; World Wide Web; Political science","score_opus":0.5417378515304927,"score_gpt":0.6220346110552446,"score_spread":0.0802967595247519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591026775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8362265,0.00047921334,0.0067140316,0.14310193,0.004955475,0.0018886067,0.000010716349,0.000044225806,0.006579299],"genre_scores_gemma":[0.96131575,0.00021697384,0.016280316,0.019145828,0.002793793,0.000032037755,0.000076888704,0.00003406109,0.00010437363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9865949,0.002465576,0.008886421,0.00043522706,0.0009035247,0.00071436213],"domain_scores_gemma":[0.9748139,0.017569548,0.005146153,0.0003023119,0.0011461218,0.0010219946],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024117533,0.00024536767,0.003027771,0.00025674055,0.00008035376,0.000012036226,0.00034830568,0.00089806406,0.00050526863],"category_scores_gemma":[0.022243142,0.00019470323,0.00074549235,0.0001684575,0.00023119013,0.0001439693,0.000073942676,0.0031859837,0.000023056791],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030551925,0.006386327,0.1149894,0.00057879736,0.0008140863,0.0006211095,0.0010419688,0.00009665104,0.00003418285,0.012057419,0.03799837,0.7948298],"study_design_scores_gemma":[0.04173514,0.073951885,0.12905104,0.0003647799,0.00037470678,0.0017313585,0.004121326,0.0053068763,0.0000013119427,0.0011874151,0.74194705,0.00022709128],"about_ca_topic_score_codex":0.012571164,"about_ca_topic_score_gemma":0.4124442,"teacher_disagreement_score":0.7946027,"about_ca_system_score_codex":0.0051802825,"about_ca_system_score_gemma":0.046084214,"threshold_uncertainty_score":0.9991137},"labels":[],"label_agreement":null},{"id":"W2591029157","doi":"10.1200/jco.2011.29.15_suppl.6038","title":"The development of a value-based pricing index for new drugs in metastatic colorectal cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Per capita; Colorectal cancer; Gini coefficient; Index (typography); Cancer; Price index; Oncology; Internal medicine; Economics; Population; Econometrics; Environmental health; Inequality; Economic inequality","score_opus":0.20546643528314176,"score_gpt":0.4060473888066174,"score_spread":0.20058095352347563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591029157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97601086,0.0017841646,0.013985657,0.0013391806,0.0017170939,0.00027623112,0.000010701215,0.0000027457631,0.0048733493],"genre_scores_gemma":[0.97819453,0.00027830226,0.02074489,0.00039271938,0.00024675886,0.000014299791,3.363462e-7,0.000013477795,0.00011468082],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99575174,0.000050900653,0.0037484134,0.00015040103,0.000041421907,0.000257131],"domain_scores_gemma":[0.99417853,0.0015969523,0.0038555267,0.00009669693,0.00011926021,0.00015301973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005572091,0.000105380175,0.0011845635,0.00015484283,0.000053173477,0.000009671754,0.00033081044,0.00015402945,0.00006788734],"category_scores_gemma":[0.0022469694,0.000083008454,0.00030232908,0.00012218316,0.00012876981,0.00014188749,0.000029860026,0.00033638522,0.000006757522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005753096,0.0009481413,0.45389593,0.000055172302,0.00051696505,0.0000071320333,0.004318994,0.0005817876,0.000009769093,0.03569745,0.0016881155,0.49652743],"study_design_scores_gemma":[0.008752533,0.002913839,0.8353536,0.00008312502,0.000044738903,0.0000031190393,0.00032333125,0.0020811209,0.00034144052,0.053729493,0.09614723,0.00022644502],"about_ca_topic_score_codex":0.000333197,"about_ca_topic_score_gemma":0.0009949385,"teacher_disagreement_score":0.496301,"about_ca_system_score_codex":0.00028691484,"about_ca_system_score_gemma":0.0030009684,"threshold_uncertainty_score":0.5323589},"labels":[],"label_agreement":null},{"id":"W2591034403","doi":"10.1200/jco.2014.32.3_suppl.459","title":"Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; Medicine; PTEN; HRAS; Colorectal cancer; Oncology; Internal medicine; Concordance; Cancer; Amplicon; Cancer research; Gene; Genetics; Biology; Polymerase chain reaction","score_opus":0.039664607587355696,"score_gpt":0.42349445609216585,"score_spread":0.38382984850481017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591034403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433655,0.0009336975,0.0000604487,0.0015027896,0.0009504874,0.00038383188,0.0000126732475,0.000008273011,0.0018112416],"genre_scores_gemma":[0.9958952,0.0011721876,0.0019539197,0.0005569999,0.00030693528,0.000038539994,0.0000029646203,0.000020355757,0.000052919448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973473,0.00018869147,0.0014274305,0.0002530436,0.0005018143,0.00028172066],"domain_scores_gemma":[0.996447,0.00044327375,0.0016683844,0.00012931191,0.001047676,0.0002643018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004634922,0.00019227077,0.0015273608,0.00007093018,0.00004967715,0.0000047444773,0.00014749888,0.00017823272,0.00014236948],"category_scores_gemma":[0.0007704419,0.000116198906,0.00027227696,0.000170939,0.0003115678,0.00009702832,0.0000636495,0.00043415712,9.623683e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102688195,0.001295731,0.8239307,0.000060768863,0.0005684546,0.0000786591,0.00045653956,0.0001312217,0.00040980362,0.000050520994,0.00012733621,0.16262148],"study_design_scores_gemma":[0.017245064,0.023568643,0.92876416,0.00044788828,0.00067310256,0.000018238043,0.0005449163,0.00012950477,0.009359233,0.000048501504,0.018996427,0.00020429661],"about_ca_topic_score_codex":0.000091083166,"about_ca_topic_score_gemma":0.00038237742,"teacher_disagreement_score":0.16241719,"about_ca_system_score_codex":0.00029493382,"about_ca_system_score_gemma":0.0010026109,"threshold_uncertainty_score":0.4738454},"labels":[],"label_agreement":null},{"id":"W2591034534","doi":"10.1200/jco.2016.34.3_suppl.208","title":"Young cancer survivors’ expectations of physicians for issues of mental health, interpersonal relationships, and reintegration to society.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Survivorship curve; Mental health; Cancer; Breast cancer; Interpersonal communication; Cancer survivorship; Colorectal cancer; Interpersonal relationship; Family medicine; Psychiatry; Gerontology; Internal medicine; Psychology","score_opus":0.16264577911626266,"score_gpt":0.5117165583072057,"score_spread":0.3490707791909431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591034534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86783147,0.0004696402,0.0042952206,0.124294594,0.0021276905,0.0003052768,0.0000714935,0.0000052234286,0.0005994178],"genre_scores_gemma":[0.9891303,0.0011665091,0.008017927,0.0005446516,0.00056879065,0.000009785814,0.0000014740784,0.0000067442306,0.00055378396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767673,0.0005330109,0.0012778746,0.00010645356,0.00026747768,0.0001384783],"domain_scores_gemma":[0.99502367,0.0028457348,0.0014480463,0.000057658537,0.00051867013,0.00010621554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035254892,0.00005786011,0.00054430414,0.000052483847,0.00014822258,0.0000050572653,0.00013507996,0.0001487647,0.000035976194],"category_scores_gemma":[0.0028318719,0.000040918978,0.00024230027,0.0001201447,0.000402616,0.00020185445,0.000018547551,0.00016372053,7.826302e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011157966,0.0008867412,0.33619368,0.000054384825,0.00037031356,0.0000013466133,0.20662566,0.000009446082,0.0017098758,0.014594389,0.099317275,0.33912107],"study_design_scores_gemma":[0.0055482164,0.009600769,0.28355023,0.001205301,0.00019451631,0.000007917149,0.33355728,0.0001391803,0.0007171659,0.009397132,0.355708,0.00037429968],"about_ca_topic_score_codex":0.0014023837,"about_ca_topic_score_gemma":0.025761578,"teacher_disagreement_score":0.3387468,"about_ca_system_score_codex":0.00017965313,"about_ca_system_score_gemma":0.001109236,"threshold_uncertainty_score":0.9920157},"labels":[],"label_agreement":null},{"id":"W2591044260","doi":"10.1200/jco.2013.31.15_suppl.4032","title":"Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Everolimus; Bevacizumab; Sunitinib; Clinical endpoint; Phases of clinical research; Progression-free survival; Oncology; Interim analysis; Progressive disease; Response Evaluation Criteria in Solid Tumors; Leukopenia; Gastroenterology; Chemotherapy; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.0922024343955625,"score_gpt":0.47898035470000794,"score_spread":0.38677792030444547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591044260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898536,0.0003297307,0.0000040472846,0.008170066,0.00067717757,0.001078175,0.000003718871,0.000008603059,0.00074310956],"genre_scores_gemma":[0.9951963,0.0010201293,0.0014025046,0.0010985482,0.00080580916,0.000023825884,0.0000011943329,0.00002655986,0.00042512297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943392,0.0007970099,0.0035329896,0.0002804958,0.000572701,0.0004775945],"domain_scores_gemma":[0.9935961,0.0033515382,0.0016900742,0.0002852185,0.00043538888,0.00064169],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011008312,0.0002007549,0.0022163948,0.0003556564,0.000032513006,0.000010948728,0.00022759229,0.00002525505,0.00029171462],"category_scores_gemma":[0.013416025,0.00014057037,0.00033518203,0.00020383245,0.00042936185,0.0002782408,0.00018303447,0.0013990708,0.000014837752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60711163,0.037298262,0.063546136,0.00046444836,0.0004751779,0.062257435,0.0000902721,0.000011655272,0.009106319,0.000086752014,0.006832292,0.21271962],"study_design_scores_gemma":[0.6123872,0.2687645,0.062202867,0.00028810193,0.00034923124,0.009866594,0.0002131502,0.00077826355,0.0012616083,0.0005501741,0.043136787,0.00020152367],"about_ca_topic_score_codex":0.00008763134,"about_ca_topic_score_gemma":0.000035179735,"teacher_disagreement_score":0.23146625,"about_ca_system_score_codex":0.00007644408,"about_ca_system_score_gemma":0.0006358575,"threshold_uncertainty_score":0.9948944},"labels":[],"label_agreement":null},{"id":"W2591045952","doi":"10.1200/jco.2014.32.3_suppl.289","title":"Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Gastroenterology; Liver cancer; Context (archaeology); Population; Hepatitis C; Hepatitis B; Milan criteria; Liver disease; Liver transplantation; Transplantation","score_opus":0.1956236094031757,"score_gpt":0.396342878072195,"score_spread":0.2007192686690193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591045952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945482,0.00048188138,0.000046351317,0.00369167,0.0003035282,0.0003628856,0.000004743014,0.000004835621,0.00055592903],"genre_scores_gemma":[0.9959153,0.0017592772,0.0009254329,0.00030815584,0.0009966536,0.000008861873,0.000007107247,0.000017561535,0.000061670886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952438,0.0009125272,0.0030155494,0.00032222056,0.00020709792,0.00029881924],"domain_scores_gemma":[0.9954149,0.002850456,0.00092128443,0.00018091865,0.00009314306,0.0005393122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035709946,0.00023068541,0.0026617418,0.00023059042,0.000029082805,0.000016249816,0.00009547143,0.0005966714,0.00002074254],"category_scores_gemma":[0.0012524772,0.00015798565,0.0003164991,0.00012381123,0.0003010715,0.00007705913,0.000047502162,0.0007983004,0.0000057847396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060491293,0.0009527659,0.75329536,0.000023301045,0.00011073529,0.0012382633,0.00017508055,5.709748e-9,0.0000073937063,0.000011376193,0.00001625612,0.24356453],"study_design_scores_gemma":[0.01073974,0.018255552,0.9653853,0.00011903222,0.00042170813,0.00011745518,0.00008104345,0.0013102005,0.000020151969,0.00009270133,0.003331559,0.00012554562],"about_ca_topic_score_codex":0.00011808776,"about_ca_topic_score_gemma":0.00011916493,"teacher_disagreement_score":0.24343899,"about_ca_system_score_codex":0.00011460447,"about_ca_system_score_gemma":0.00052241405,"threshold_uncertainty_score":0.64424676},"labels":[],"label_agreement":null},{"id":"W2591046237","doi":"10.1200/jco.2015.33.7_suppl.226","title":"Current era clinical outcomes of castration-resistant prostate cancer in real-life population study in Quebec, Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Abiraterone acetate; Proportional hazards model; Oncology; Internal medicine; Hazard ratio; Cohort; Population; Androgen deprivation therapy; Enzalutamide; Chemotherapy; Survival analysis; Cancer; Androgen receptor; Confidence interval","score_opus":0.27694533253567555,"score_gpt":0.5697048201899734,"score_spread":0.2927594876542978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885838,0.00094353314,8.268317e-7,0.008217533,0.0014750796,0.00063223945,0.000010941528,0.000002530896,0.00013349808],"genre_scores_gemma":[0.99746495,0.001662034,0.000072623116,0.0001692445,0.00033690868,0.000015112454,0.0000068158083,0.000010442298,0.00026186323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397254,0.0009278862,0.003950382,0.00019995356,0.00070281286,0.00024643025],"domain_scores_gemma":[0.9960777,0.0012273869,0.0014151939,0.00016055586,0.00060997513,0.00050915394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049118646,0.00012715325,0.0016854114,0.00019395213,0.000013974036,0.0000062512872,0.00011950144,0.0001685453,0.000030424982],"category_scores_gemma":[0.0038097682,0.00008235641,0.0001753436,0.00025244875,0.00010650126,0.00011557537,0.000038463746,0.0011701905,8.631904e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00865914,0.003565445,0.9488143,0.000026846472,0.0001823072,0.00061323366,0.00032435165,0.00011039355,0.0000037236139,0.000014145429,0.001487156,0.036198974],"study_design_scores_gemma":[0.018834036,0.0046158847,0.973893,0.00012355458,0.00011462321,0.0000032719656,0.0008221587,0.000054775905,0.0000021643277,0.00006178111,0.0014085481,0.000066195826],"about_ca_topic_score_codex":0.700962,"about_ca_topic_score_gemma":0.9846678,"teacher_disagreement_score":0.2837058,"about_ca_system_score_codex":0.0011747282,"about_ca_system_score_gemma":0.024906376,"threshold_uncertainty_score":0.9806215},"labels":[],"label_agreement":null},{"id":"W2591046281","doi":"10.1200/jco.2005.23.16_suppl.8559","title":"High local recurrence of Wilms tumor: A single institutional experience at western region of Saudi Arabia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Wilms' tumor; Stage (stratigraphy); Chemotherapy; Nephrectomy; Surgery; Clear-cell sarcoma; Histology; Retrospective cohort study; Internal medicine; Kidney","score_opus":0.058054926062910496,"score_gpt":0.37782784672323827,"score_spread":0.31977292066032775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468637,0.0013099844,0.0017900795,0.00078204076,0.0007896941,0.000048487404,0.0000033192791,0.000001393678,0.00058865413],"genre_scores_gemma":[0.9961694,0.0013964424,0.0011610592,0.00045530844,0.00061262556,0.0000014136012,0.0000032890573,0.0000054286884,0.00019506385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978008,0.00015095186,0.0015098075,0.00017097687,0.00022152353,0.0001459254],"domain_scores_gemma":[0.9976608,0.00012038147,0.0016306731,0.00014891083,0.00029551596,0.00014372313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005266888,0.000100713165,0.0005801146,0.00004090687,0.000029057448,0.0000020120472,0.00024760835,0.00031699552,0.000020897556],"category_scores_gemma":[0.00048583825,0.00007347676,0.00029586762,0.00007606275,0.00085712713,0.0000117361415,0.00008861887,0.00030288022,0.0000028044115],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017196156,0.004917348,0.086829156,0.00013896154,0.00081874995,0.0005242353,0.0005048747,0.018380264,0.32577616,0.00044248134,0.014049366,0.5304223],"study_design_scores_gemma":[0.009943548,0.029774703,0.05093411,0.0006979273,0.00022650663,0.0035171332,0.0002127945,0.000185749,0.35525426,0.00033039166,0.5484332,0.0004896668],"about_ca_topic_score_codex":0.000013851843,"about_ca_topic_score_gemma":0.000046840345,"teacher_disagreement_score":0.53438383,"about_ca_system_score_codex":0.00007674146,"about_ca_system_score_gemma":0.00064756843,"threshold_uncertainty_score":0.31581205},"labels":[],"label_agreement":null},{"id":"W2591047932","doi":"10.1200/jco.2014.32.4_suppl.43","title":"Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Internal medicine; Hazard ratio; Confidence interval; Oncology; Docetaxel; C-reactive protein; Clinical endpoint; Proportional hazards model; Cancer; Randomized controlled trial; Urology; Inflammation","score_opus":0.15531502120245025,"score_gpt":0.5207476835636471,"score_spread":0.36543266236119687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591047932","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021080494,0.99565804,0.000038192065,0.00013132501,0.0005576283,0.003235004,0.0001254551,0.0000016981882,0.000041857733],"genre_scores_gemma":[0.0003555497,0.9969846,0.00034556512,0.000244276,0.001179817,0.00053761876,0.000026814307,0.00004064989,0.0002851348],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98808676,0.0041018277,0.006663551,0.00048769347,0.00033218515,0.00032799752],"domain_scores_gemma":[0.986437,0.0010426048,0.011081407,0.00051323336,0.0006256854,0.00030006206],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.007996912,0.0005289192,0.022823405,0.00034051973,0.000018456583,0.000014051071,0.00043748211,0.0005434522,0.00005743563],"category_scores_gemma":[0.0072885067,0.00029038385,0.0076926365,0.0004997527,0.00023323126,0.000012174593,0.0001227151,0.0009225586,0.00000216059],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026687133,0.00082561735,0.00007949511,0.5998558,0.36983144,0.000009622298,0.000032645494,0.00001773419,0.000012411109,0.000016950402,0.0017408053,0.02731063],"study_design_scores_gemma":[0.0007795619,0.0024392933,0.000065806875,0.015937636,0.7414869,0.0001091593,0.0000067835617,0.0000019273486,0.0000010956455,0.00002430928,0.23888221,0.00026530505],"about_ca_topic_score_codex":0.000119459226,"about_ca_topic_score_gemma":0.00027792767,"teacher_disagreement_score":0.58391815,"about_ca_system_score_codex":0.00010297252,"about_ca_system_score_gemma":0.0038378104,"threshold_uncertainty_score":0.9999548},"labels":[],"label_agreement":null},{"id":"W2591049751","doi":"10.1200/jco.2013.31.4_suppl.448","title":"Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; KRAS; Internal medicine; Population; FOLFOX; Oncology; Colorectal cancer; FOLFIRI; Gastroenterology; Cancer; Chemotherapy; Oxaliplatin; Epidermal growth factor receptor","score_opus":0.1051107122822753,"score_gpt":0.46173558544623156,"score_spread":0.35662487316395625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591049751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390405,0.00027728121,0.0000343136,0.002464595,0.00032070803,0.0025376515,0.000011219481,0.000008547593,0.00044160296],"genre_scores_gemma":[0.99462456,0.0009717485,0.0007842863,0.0026668084,0.0002181423,0.00058333966,0.0000048179577,0.000029036746,0.00011727956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954651,0.00075487944,0.0021272274,0.00039803918,0.0007015981,0.00055318355],"domain_scores_gemma":[0.9952864,0.0018808475,0.0014748005,0.00024179155,0.00075246807,0.00036370626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019409352,0.00032669056,0.0028315834,0.0004427552,0.000081315804,0.000036398,0.00024184003,0.00013061156,0.00026121954],"category_scores_gemma":[0.0011491124,0.00014095286,0.00032302842,0.0013124214,0.00023993631,0.0002704097,0.00004920419,0.00082595996,0.000008113435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4279131,0.0066232467,0.4433646,0.000010093156,0.0028970689,0.00046652884,0.0029190355,0.00006751114,0.000008717848,0.0000034832865,0.00040963953,0.115317],"study_design_scores_gemma":[0.3539351,0.17895573,0.45182818,0.00020935076,0.0020635887,0.000044859557,0.009845091,0.000084064246,0.000020440226,0.000026780743,0.0027401329,0.00024668835],"about_ca_topic_score_codex":0.0016887282,"about_ca_topic_score_gemma":0.016592976,"teacher_disagreement_score":0.1723325,"about_ca_system_score_codex":0.0007056648,"about_ca_system_score_gemma":0.0022909255,"threshold_uncertainty_score":0.925927},"labels":[],"label_agreement":null},{"id":"W2591060404","doi":"10.1200/jco.2012.30.27_suppl.26","title":"Can excisional biopsy be avoided for papillary breast lesions with typical benign sonographic features and concordant core needle biopsy (CNB)?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Lesions and Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Benignity; Medicine; Atypia; Radiology; Malignancy; Biopsy; Concordance; Echogenicity; Ultrasound; Pathology; Internal medicine","score_opus":0.12857749889689088,"score_gpt":0.41442029524271723,"score_spread":0.2858427963458263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591060404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97600394,0.0010395932,0.00017829191,0.021412557,0.00073165237,0.00030491772,0.00006915986,0.000013280397,0.00024660144],"genre_scores_gemma":[0.98440945,0.00022890436,0.010062267,0.0030902766,0.0019957917,0.000008651857,0.000022313518,0.00003160534,0.00015074607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973396,0.00020522212,0.0013675214,0.00023922631,0.00038853276,0.00045991942],"domain_scores_gemma":[0.99495703,0.0021129958,0.0008676984,0.00022773062,0.00065490045,0.0011796384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019354337,0.00023348891,0.0014356133,0.0002097512,0.00016141971,0.0000143633615,0.00014971015,0.00053358387,0.00010290512],"category_scores_gemma":[0.00082196615,0.00013775178,0.0004888774,0.00021324477,0.00060705777,0.000117950236,0.00007331634,0.0010663929,0.0000023480923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02646347,0.0033171345,0.8927083,0.00006861458,0.00056493306,0.00038629203,0.00018848541,0.0000012349778,0.00105014,0.003322635,0.022145344,0.0497834],"study_design_scores_gemma":[0.009169876,0.0065570297,0.9464977,0.00013829673,0.0006050694,0.021968566,0.00050901267,0.000017359367,0.000010991638,0.00033561816,0.014025549,0.00016492639],"about_ca_topic_score_codex":0.000021777674,"about_ca_topic_score_gemma":0.00003108183,"teacher_disagreement_score":0.05378939,"about_ca_system_score_codex":0.000062280465,"about_ca_system_score_gemma":0.001116071,"threshold_uncertainty_score":0.56173545},"labels":[],"label_agreement":null},{"id":"W2591074898","doi":"10.1200/jco.2015.33.7_suppl.186","title":"Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Docetaxel; Internal medicine; Proportional hazards model; Response Evaluation Criteria in Solid Tumors; Oncology; Progressive disease; Cancer; Confidence interval; Disease","score_opus":0.22080835571266436,"score_gpt":0.4928362006397185,"score_spread":0.2720278449270541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591074898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973491,0.002155515,0.0000038488297,0.022950731,0.00038621778,0.00036100007,0.00003850803,0.0000024187743,0.0006107552],"genre_scores_gemma":[0.9945253,0.0021547612,0.00035155422,0.0001598818,0.00013423986,0.00002507759,0.000011293963,0.000011445471,0.0026264042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971172,0.0006133873,0.001169653,0.00013399712,0.00073888036,0.00022684097],"domain_scores_gemma":[0.9967394,0.00088157784,0.0011041671,0.000088548884,0.0008185278,0.0003678099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005557705,0.00009376948,0.00096048147,0.00014902154,0.000011797962,0.0000070122433,0.00007104261,0.000103227714,0.000038074304],"category_scores_gemma":[0.002834679,0.000058458067,0.00007883448,0.0002770013,0.0000943843,0.000107174856,0.0000133105195,0.00053515506,0.0000014194937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03570807,0.0019748618,0.94052637,0.00009128693,0.00033881314,0.0009052135,0.00033443814,0.000106412175,0.000521623,0.000009284177,0.004815351,0.01466828],"study_design_scores_gemma":[0.04936721,0.017489227,0.9072254,0.0007301714,0.00061068137,0.000018420844,0.0011603214,0.00017350324,0.0006661983,0.00050443865,0.021882664,0.00017180006],"about_ca_topic_score_codex":0.0006610714,"about_ca_topic_score_gemma":0.01146,"teacher_disagreement_score":0.033301003,"about_ca_system_score_codex":0.00092677487,"about_ca_system_score_gemma":0.0048026675,"threshold_uncertainty_score":0.8519726},"labels":[],"label_agreement":null},{"id":"W2591077493","doi":"10.1200/jco.2008.26.15_suppl.15016","title":"Effect of surgical resection (SR) of primary tumor in advanced colorectal cancer (CRC) on outcome: A Canadian province’s experience","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Primary tumor; Colorectal cancer; Surgery; Proportional hazards model; Internal medicine; Multivariate analysis; Medical record; Cancer; Metastasis","score_opus":0.07760539765816171,"score_gpt":0.46391890408695713,"score_spread":0.3863135064287954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591077493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179244,0.00078310986,4.235945e-7,0.001097946,0.00084208255,0.0004258124,0.000006999327,0.0000034051593,0.00504779],"genre_scores_gemma":[0.9977867,0.0014709173,0.000092971684,0.00022596758,0.00023718317,0.000030759544,0.0000010250451,0.00001053784,0.00014395798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686646,0.00039082242,0.0019156868,0.000195365,0.00037885283,0.00025279564],"domain_scores_gemma":[0.996247,0.001974027,0.0011102754,0.00010864985,0.00026821037,0.00029184003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001272331,0.00015099518,0.0020165555,0.00023602344,0.00004345312,0.0000011322863,0.00010698027,0.0001831533,0.00007370354],"category_scores_gemma":[0.0016149671,0.000097213815,0.00037086065,0.00023132165,0.00038809804,0.00006903693,0.00003043415,0.00062444224,0.0000011788796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04835932,0.00090471626,0.895268,0.000093853174,0.0001574981,0.003011831,0.0003345515,0.0000414564,0.0002453361,0.000010465315,0.0002871551,0.051285792],"study_design_scores_gemma":[0.013150293,0.07234501,0.90496373,0.00022906395,0.0001085662,0.00046011942,0.00007631988,0.000016696227,0.0021020484,0.0000048064867,0.006461996,0.00008133985],"about_ca_topic_score_codex":0.007458349,"about_ca_topic_score_gemma":0.0537234,"teacher_disagreement_score":0.071440294,"about_ca_system_score_codex":0.001067434,"about_ca_system_score_gemma":0.0033491056,"threshold_uncertainty_score":0.99915105},"labels":[],"label_agreement":null},{"id":"W2591087106","doi":"10.1200/jco.2014.32.3_suppl.259","title":"Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Regimen; Performance status; Chemotherapy; Chemotherapy regimen; Cancer; Surgery; Irinotecan","score_opus":0.2640040517692418,"score_gpt":0.5254704340481197,"score_spread":0.26146638227887786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591087106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322284,0.000707147,0.007224072,0.004351802,0.0013869535,0.0012708317,0.00003777461,0.000012939479,0.0017856648],"genre_scores_gemma":[0.98232335,0.0007261226,0.015117876,0.0006803275,0.0007866508,0.000053107702,0.000024859251,0.000035412086,0.00025231557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992266,0.0010961064,0.0046991045,0.00044438126,0.0008788209,0.00061557285],"domain_scores_gemma":[0.9681463,0.023954168,0.0034496912,0.0005887028,0.0030128348,0.0008483023],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008274772,0.00032426097,0.004501536,0.0002675006,0.00009659082,0.000008839461,0.00041760626,0.00047054057,0.00017211893],"category_scores_gemma":[0.057278592,0.00022590924,0.0011032114,0.00026029904,0.0007935449,0.00013161181,0.00015721633,0.0011141037,0.00002697505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059620906,0.0060428726,0.8951331,0.00074140925,0.0030149363,0.00006998543,0.00043060392,0.000037112546,0.000029262435,0.0008166238,0.0047566043,0.029306602],"study_design_scores_gemma":[0.06511987,0.095863275,0.8185507,0.00032171165,0.0031496407,0.000033598622,0.0003033442,0.0039479695,0.00005805379,0.004246388,0.008199893,0.00020554078],"about_ca_topic_score_codex":0.000065788954,"about_ca_topic_score_gemma":0.00013621242,"teacher_disagreement_score":0.0898204,"about_ca_system_score_codex":0.000630643,"about_ca_system_score_gemma":0.0024126112,"threshold_uncertainty_score":0.9506624},"labels":[],"label_agreement":null},{"id":"W2591092403","doi":"10.1200/jco.2016.34.7_suppl.106","title":"Recommendations for the delivery of focal tumor ablation services.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; McMaster University; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Microwave ablation; Radiofrequency ablation; Multidisciplinary approach; Workflow; Medical physics; Intensive care medicine; Ablation; Internal medicine","score_opus":0.29816438245716476,"score_gpt":0.44239475826561275,"score_spread":0.144230375808448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591092403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9234941,0.00052394386,0.0026085966,0.071655825,0.000843619,0.0003307343,0.000010863855,0.0000046278774,0.0005276688],"genre_scores_gemma":[0.992545,0.0005352553,0.004651566,0.0013693884,0.0007029121,0.000008018922,0.0000027256524,0.0000072555345,0.00017786335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982771,0.00015720885,0.0012621199,0.000073661526,0.00013154016,0.0000983312],"domain_scores_gemma":[0.99296147,0.005303999,0.0010359375,0.00011199984,0.00047619743,0.000110396235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019651656,0.0000596899,0.00053291494,0.000051261944,0.000034657765,0.0000024209019,0.000090955786,0.00012081623,0.00017470964],"category_scores_gemma":[0.0006828549,0.00002623334,0.00043705394,0.000057275396,0.00008213811,0.00007745443,0.000017610897,0.00014900658,0.000009079882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002092295,0.0006256576,0.45306703,0.000029172816,0.0004046495,0.00003313018,0.000054615193,2.843662e-7,0.0004287855,0.00020178745,0.0053711715,0.5376914],"study_design_scores_gemma":[0.015452394,0.016363734,0.3416224,0.00030383575,0.0018569961,0.00020014937,0.00018780286,0.0011897385,0.0018021802,0.0014073548,0.61952055,0.000092847964],"about_ca_topic_score_codex":0.000011328253,"about_ca_topic_score_gemma":0.000019269208,"teacher_disagreement_score":0.6141494,"about_ca_system_score_codex":0.00005107919,"about_ca_system_score_gemma":0.00047284545,"threshold_uncertainty_score":0.1912948},"labels":[],"label_agreement":null},{"id":"W2591096460","doi":"10.1200/jco.2014.32.4_suppl.51","title":"Population-based comparison of surgical margin status for robotic versus open radical prostatectomy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Confidence interval; Odds ratio; Incidence (geometry); Prostate cancer; Surgical margin; Urology; Population; Open Prostatectomy; Surgery; Gynecology; Internal medicine; Cancer","score_opus":0.19741290796979058,"score_gpt":0.5273551040825138,"score_spread":0.32994219611272324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591096460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979564,0.0006527305,0.0016418513,0.0130067915,0.0023404944,0.0013942713,0.000016944445,0.000010076263,0.0013728095],"genre_scores_gemma":[0.9854734,0.00018785807,0.013322124,0.0003709718,0.00052309723,0.000029716628,0.00003923389,0.000017604665,0.00003598723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963956,0.00038696438,0.0024205241,0.0001980994,0.00032168033,0.0002771584],"domain_scores_gemma":[0.98965484,0.0074758707,0.0017955585,0.0001884132,0.00041044308,0.0004748525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00231113,0.00013455833,0.0021546758,0.000087734574,0.000039367154,0.0000133139365,0.00017928571,0.0002519133,0.0001263044],"category_scores_gemma":[0.0026768346,0.00009181123,0.00047224556,0.00010253436,0.00014852031,0.00007305844,0.000046320092,0.00042796382,0.000003875537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050272513,0.0062755104,0.7898156,0.00013841689,0.00053839455,0.00010151474,0.000035465357,0.0015575407,0.000008980034,0.0013236754,0.0053767464,0.14455563],"study_design_scores_gemma":[0.108573,0.08105817,0.59614307,0.000326615,0.0010837477,0.000033632066,0.00005139144,0.007507713,0.00031858627,0.0006966168,0.20404318,0.00016426951],"about_ca_topic_score_codex":0.00006906339,"about_ca_topic_score_gemma":0.00004086654,"teacher_disagreement_score":0.19866644,"about_ca_system_score_codex":0.00028059995,"about_ca_system_score_gemma":0.0015583703,"threshold_uncertainty_score":0.3743953},"labels":[],"label_agreement":null},{"id":"W2591113678","doi":"10.1200/jco.2016.34.2_suppl.59","title":"Validation of the Decipher prostate cancer classifier for predicting 10-year postoperative metastasis from analysis of diagnostic needle biopsy specimens.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; DECIPHER; Prostatectomy; Prostate cancer; Biopsy; Cohort; Metastasis; Prostate; Prostate biopsy; Cancer; Oncology; Internal medicine; Pathology; Radiology; Bioinformatics","score_opus":0.14712856599949414,"score_gpt":0.47976550028385356,"score_spread":0.3326369342843594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591113678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886784,0.0005824615,0.00020229818,0.009035415,0.00046022626,0.00043097505,0.00030761203,0.000002468866,0.0003001279],"genre_scores_gemma":[0.99558276,0.0012262447,0.0015157143,0.00014399449,0.00034107285,0.000021536154,0.000010098735,0.000012535019,0.0011460403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726003,0.0003865655,0.0016110359,0.00016951363,0.00039485327,0.00017799533],"domain_scores_gemma":[0.98812824,0.008656303,0.0016676107,0.00019725312,0.0012037555,0.0001468482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016895444,0.00010577432,0.0012165353,0.0001647431,0.000041341547,0.0000047327912,0.00014582464,0.00016494584,0.0008648835],"category_scores_gemma":[0.008163274,0.000045802706,0.00071056536,0.00040569893,0.0003163138,0.00009827636,0.000051828287,0.00022178466,0.0000021528708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009540407,0.0010419711,0.8979254,0.000026366406,0.010437709,0.000024989864,0.00057903264,0.000076984616,0.016243637,0.00004024563,0.002753865,0.061309405],"study_design_scores_gemma":[0.015113223,0.0066983374,0.91102636,0.00042164876,0.011017898,0.000006584244,0.00062156067,0.00016324692,0.046160396,0.0003614601,0.008307408,0.00010185751],"about_ca_topic_score_codex":0.00008478676,"about_ca_topic_score_gemma":0.00005236148,"teacher_disagreement_score":0.061207548,"about_ca_system_score_codex":0.00018906628,"about_ca_system_score_gemma":0.0011739014,"threshold_uncertainty_score":0.97727907},"labels":[],"label_agreement":null},{"id":"W2591114737","doi":"10.1200/jco.2016.34.26_suppl.185","title":"Symptom distress and patterns of palliative-care referral among oncology outpatients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Referral; Distress; Ambulatory care; Family medicine; Psychological intervention; Internal medicine; Health care; Nursing","score_opus":0.35245130874216846,"score_gpt":0.5570038909407915,"score_spread":0.20455258219862305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591114737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931037,0.0011418663,0.00030395138,0.001968415,0.000870297,0.00012864181,0.00004818828,0.0000050351105,0.0024299205],"genre_scores_gemma":[0.9928124,0.0046090186,0.0015035059,0.00034273395,0.00052502705,0.0000024030162,0.0000053111776,0.000013604002,0.00018603056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965214,0.00044631868,0.002302788,0.00018952659,0.00032967297,0.00021026703],"domain_scores_gemma":[0.99236965,0.0036031133,0.0025782047,0.00018186758,0.0009218713,0.00034528968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008874986,0.00014975271,0.0018663718,0.000117341864,0.00001835275,0.0000019632903,0.00016383745,0.00045926604,0.00014127763],"category_scores_gemma":[0.0043333448,0.00008460145,0.0003854714,0.00006639838,0.0005085394,0.00009882209,0.000088703884,0.00047725145,0.0000035974633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018535629,0.00053343334,0.8355831,0.000101957354,0.00030780694,0.00013880579,0.00097200647,3.3799944e-7,0.00014429502,0.00011109735,0.00042015122,0.15983343],"study_design_scores_gemma":[0.00908302,0.016216552,0.92897266,0.001566659,0.00034210543,0.00001196364,0.0014031128,0.0000028903867,0.0006214233,0.00014752867,0.041542716,0.000089350455],"about_ca_topic_score_codex":0.000045127963,"about_ca_topic_score_gemma":0.000094094394,"teacher_disagreement_score":0.15974408,"about_ca_system_score_codex":0.00016511978,"about_ca_system_score_gemma":0.00044755303,"threshold_uncertainty_score":0.51877314},"labels":[],"label_agreement":null},{"id":"W2591114740","doi":"10.1200/jco.2015.33.29_suppl.117","title":"Development of provincial clinical standards for the province of Ontario.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Palliative care; Medicine; Stakeholder; Declaration; Context (archaeology); Stakeholder engagement; General partnership; Nursing; Best practice; Health care; Public relations; Business; Political science","score_opus":0.5834127224071559,"score_gpt":0.6381986634460823,"score_spread":0.05478594103892642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591114740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597082,0.00016889106,0.022261214,0.011925162,0.0035818026,0.0011985416,0.00002364686,0.0000063262855,0.0011261773],"genre_scores_gemma":[0.713885,0.0000905731,0.27976575,0.0026420613,0.0029714906,0.000013363474,0.000008288794,0.000028447788,0.0005949694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.987011,0.0004980612,0.011016415,0.00018978285,0.0010825647,0.00020218849],"domain_scores_gemma":[0.96860725,0.016584337,0.008836709,0.0003081578,0.0052265236,0.00043700062],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.048691228,0.00012872987,0.0018105996,0.00006924021,0.000036897538,0.0000048778147,0.0002953816,0.0003622585,0.000079130325],"category_scores_gemma":[0.110953845,0.00007556299,0.00067890726,0.00009483836,0.00040242847,0.00014618253,0.00011493778,0.0010311768,0.0000025438808],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037722897,0.0037569324,0.09466102,0.00009846512,0.00090618077,0.00005529556,0.00065232575,0.000025030693,0.000053772197,0.00022235503,0.039469995,0.8223757],"study_design_scores_gemma":[0.018143727,0.021480195,0.102284245,0.00009932448,0.0009604707,0.0000715741,0.00054992805,0.00011293349,0.00017998168,0.00040434068,0.85563034,0.00008292423],"about_ca_topic_score_codex":0.00039948281,"about_ca_topic_score_gemma":0.017635968,"teacher_disagreement_score":0.8222928,"about_ca_system_score_codex":0.00068207044,"about_ca_system_score_gemma":0.10537835,"threshold_uncertainty_score":0.98412836},"labels":[],"label_agreement":null},{"id":"W2591117952","doi":"10.1200/jco.2016.70.7950","title":"Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Medicine; Interquartile range; Population; Quality management; Receipt; Health care; Breast cancer; Ranking (information retrieval); Cohort; Cancer; Emergency medicine; Intensive care medicine; Family medicine; Internal medicine; Environmental health; Operations management","score_opus":0.6387516887229594,"score_gpt":0.6191365839411577,"score_spread":0.01961510478180173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591117952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036264,0.00037590787,0.0027518743,0.0036531407,0.0011414466,0.0007155108,0.0009274928,0.000006450922,0.000065524466],"genre_scores_gemma":[0.9877189,0.0003362317,0.008541195,0.00097388757,0.002022335,0.000032384858,0.000015133146,0.000017945513,0.00034198372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667835,0.0001750569,0.0021637513,0.00029116755,0.00034736822,0.0003443012],"domain_scores_gemma":[0.99259794,0.0016577533,0.004252457,0.00046612558,0.0007696191,0.00025613184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007965449,0.00014805,0.0012111806,0.000036027024,0.00032728844,0.00007557258,0.0004905724,0.00024688971,0.000026574528],"category_scores_gemma":[0.0043975604,0.00011302737,0.00023533641,0.000026254498,0.00012206521,0.0005341371,0.000100093115,0.00040219096,2.1910544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009528937,0.00018920918,0.6578266,0.00021931039,0.0005690552,0.000016648168,0.00036670265,0.000012347012,0.0015214714,0.000046832996,0.0013534133,0.3283495],"study_design_scores_gemma":[0.010986009,0.0071450323,0.9691003,0.0008257792,0.00019565155,0.00012053444,0.0023249616,0.0010511872,0.00009966711,0.00034261873,0.0075964206,0.0002118379],"about_ca_topic_score_codex":0.0012020812,"about_ca_topic_score_gemma":0.00026159958,"teacher_disagreement_score":0.32813767,"about_ca_system_score_codex":0.00058494974,"about_ca_system_score_gemma":0.0021247524,"threshold_uncertainty_score":0.5264608},"labels":[],"label_agreement":null},{"id":"W2591118628","doi":"10.1200/jco.2016.34.3_suppl.207","title":"Psychosocial well-being assessment in women with breast cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Anxiety; Breast cancer; Depression (economics); Quality of life (healthcare); Population; Psychological intervention; Referral; Distress; Psychiatry; Cancer; Internal medicine; Clinical psychology; Family medicine","score_opus":0.04443899140986696,"score_gpt":0.46420614991566844,"score_spread":0.4197671585058015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591118628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215091,0.00007467623,0.00013457207,0.06353162,0.0018215106,0.00008862103,0.0000029627834,0.00000577413,0.012831161],"genre_scores_gemma":[0.99190867,0.00092619826,0.00025759664,0.0041454365,0.002356885,0.000010633079,1.2312822e-7,0.00001348991,0.00038096894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977821,0.00025035063,0.0012118678,0.00014878753,0.0003446202,0.00026225764],"domain_scores_gemma":[0.99773264,0.00074898056,0.00079019746,0.00011576945,0.00028127484,0.0003311268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021654768,0.00009774922,0.000989253,0.000092286624,0.000018696102,0.0000050440735,0.00011483541,0.00022419206,0.00085686625],"category_scores_gemma":[0.0001547889,0.000050351577,0.000151999,0.00014470596,0.00013915506,0.000096551244,0.000021551525,0.0006992443,0.000007843146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010379705,0.0005892127,0.50840586,0.000016145174,0.00017399558,0.0004482895,0.00036705242,0.0000010274127,0.00009979012,0.00012187151,0.0021181817,0.47727886],"study_design_scores_gemma":[0.0103692515,0.005943959,0.8978434,0.0004046558,0.00007371017,0.00027386512,0.00049231556,0.0000016278382,0.0000069438224,0.0004790782,0.0840329,0.00007828499],"about_ca_topic_score_codex":0.000134433,"about_ca_topic_score_gemma":0.0014880166,"teacher_disagreement_score":0.4772006,"about_ca_system_score_codex":0.00077639014,"about_ca_system_score_gemma":0.0027928345,"threshold_uncertainty_score":0.93820846},"labels":[],"label_agreement":null},{"id":"W2591131471","doi":"10.1200/jco.2012.30.34_suppl.179","title":"Chemotherapy safe handling and safe labeling guideline concordance evaluation: A Canadian experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Cancer Care Ontario; University of Toronto","funders":"","keywords":"Concordance; Medicine; Guideline; Baseline (sea); Family medicine; Intensive care medicine; Medical emergency; Emergency medicine; Internal medicine; Pathology","score_opus":0.48529387579503014,"score_gpt":0.6256200424269078,"score_spread":0.1403261666318777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591131471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93174803,0.0024387701,0.0015045902,0.058065675,0.0029135281,0.0004208374,0.0000034146026,0.000008042006,0.0028971334],"genre_scores_gemma":[0.9069467,0.0013065559,0.0555443,0.03140195,0.004664988,0.0000066295015,0.000008651172,0.000020827585,0.000099384626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99286884,0.00060870603,0.0052752756,0.0002055786,0.00063483533,0.00040674236],"domain_scores_gemma":[0.98968107,0.004550744,0.002525757,0.00022659647,0.0017724556,0.00124337],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.022877162,0.00015817964,0.0011413778,0.0001551891,0.00010036291,0.000017563536,0.0001290303,0.00032864517,0.0015177807],"category_scores_gemma":[0.044411305,0.00012567417,0.00023192346,0.00018123227,0.00020255172,0.00046999127,0.00003529767,0.0008957337,0.000026326197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001714074,0.0004909748,0.28057587,0.00001386356,0.00022627786,0.000060317834,0.0006859535,0.000025660656,0.00053485495,0.000087147026,0.015621106,0.6999639],"study_design_scores_gemma":[0.01688898,0.0036780066,0.14375675,0.00012649632,0.00071553205,0.0010227237,0.0019767997,0.0025720801,0.00015250231,0.00033882487,0.8285639,0.00020738589],"about_ca_topic_score_codex":0.0030028205,"about_ca_topic_score_gemma":0.005329557,"teacher_disagreement_score":0.8129428,"about_ca_system_score_codex":0.00038815392,"about_ca_system_score_gemma":0.0048093684,"threshold_uncertainty_score":0.99939495},"labels":[],"label_agreement":null},{"id":"W2591137227","doi":"10.1200/jco.2015.33.7_suppl.23","title":"Association of baseline perineural invasion with shorter time to progression in men with prostate cancer undergoing active surveillance: Results from the REDEEM study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Perineural invasion; Prostatectomy; Prostate cancer; Prostate-specific antigen; Prostate; Internal medicine; Pathological; Cancer; Tumor progression; Biopsy; Oncology; Proportional hazards model; Dutasteride; Urology","score_opus":0.11224477025903523,"score_gpt":0.47127888059595635,"score_spread":0.3590341103369211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591137227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96776134,0.0001256057,0.0000034084796,0.030440459,0.00008935742,0.000853127,0.000024516788,0.000004469472,0.000697725],"genre_scores_gemma":[0.9973424,0.00024998383,0.00041910994,0.00024253315,0.00037623016,0.000020892781,0.000015133384,0.000013726763,0.0013199699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676526,0.0009517738,0.0011252834,0.00020374595,0.0007522462,0.00020170657],"domain_scores_gemma":[0.99474376,0.0027566229,0.0011616156,0.00015213448,0.000952847,0.00023298697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005458504,0.00011352418,0.0008388715,0.00007566046,0.000028018887,0.000009601724,0.00011060304,0.00012069219,0.00003225311],"category_scores_gemma":[0.003114054,0.00004893104,0.00006315771,0.00026158415,0.00007377125,0.00010614682,0.000057557292,0.00062866503,0.0000039567826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14648972,0.0013273549,0.8073263,0.000007192075,0.0004259935,0.000314448,0.0020753352,0.00016469895,0.00012688887,8.8370555e-8,0.006131264,0.035610713],"study_design_scores_gemma":[0.03475434,0.03697073,0.92238194,0.0005118842,0.00016255499,0.000015466261,0.0021902851,0.0002721993,0.00025641025,0.000012039719,0.0023945286,0.000077599296],"about_ca_topic_score_codex":0.0002562335,"about_ca_topic_score_gemma":0.0028879677,"teacher_disagreement_score":0.11505567,"about_ca_system_score_codex":0.00063520746,"about_ca_system_score_gemma":0.002712455,"threshold_uncertainty_score":0.4811779},"labels":[],"label_agreement":null},{"id":"W2591139416","doi":"10.1200/jco.2014.32.4_suppl.18","title":"The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Internal medicine; Confounding; Oncology; Logistic regression; Gynecology; Cancer; Androgen receptor","score_opus":0.10970715604217106,"score_gpt":0.475957179631135,"score_spread":0.3662500235889639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591139416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876855,0.00011903635,0.000013700752,0.010026323,0.00013558715,0.0003833689,0.0000014299195,0.0000018870711,0.0016331415],"genre_scores_gemma":[0.9987662,0.00039679644,0.000074056086,0.0001759431,0.00018675931,0.000007565203,2.596663e-7,0.0000098685105,0.00038254703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966458,0.0016711279,0.0009498729,0.00011044365,0.00042557198,0.00019715619],"domain_scores_gemma":[0.98262835,0.015768059,0.0010340562,0.00025234293,0.00019614951,0.00012104261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007581533,0.00010309875,0.0010317242,0.00006853093,0.000039853912,0.0000059337144,0.00018114419,0.00016199677,0.00001901178],"category_scores_gemma":[0.004696214,0.000035791774,0.00020315358,0.00012870501,0.00053308136,0.00006311948,0.000040668107,0.000902532,0.0000028825068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12814571,0.0017580058,0.57328767,0.000107783555,0.00086090155,0.00018487204,0.00023287514,0.000045691977,0.005974901,0.00023177925,0.001873799,0.287296],"study_design_scores_gemma":[0.018971043,0.08963801,0.8569593,0.00033114624,0.0002456521,0.00004331576,0.000057233403,0.00017611006,0.025613757,0.00012786315,0.007780419,0.000056182922],"about_ca_topic_score_codex":0.000047486225,"about_ca_topic_score_gemma":0.00008885208,"teacher_disagreement_score":0.28723982,"about_ca_system_score_codex":0.00011511596,"about_ca_system_score_gemma":0.0005407787,"threshold_uncertainty_score":0.5622146},"labels":[],"label_agreement":null},{"id":"W2591142941","doi":"10.1200/jco.2016.34.7_suppl.220","title":"Improving anti-emetics in chemotherapy induced nausea and vomiting.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Credit Valley Hospital; Trillium Health Centre; University of Toronto","funders":"","keywords":"Medicine; Concordance; Chemotherapy-induced nausea and vomiting; Chemotherapy; Nausea; Vomiting; Guideline; Internal medicine; Oncology; Antiemetic; Pathology","score_opus":0.13993195176374396,"score_gpt":0.47278159162751454,"score_spread":0.3328496398637706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591142941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97824776,0.000095233045,0.0002740163,0.019488443,0.00048047886,0.0001240744,3.2835493e-7,0.000007382054,0.0012822814],"genre_scores_gemma":[0.99192244,0.0006329114,0.0033708366,0.0029897776,0.0008785201,8.446327e-7,9.398265e-8,0.000013823894,0.0001907694],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99769175,0.0001895415,0.0015623253,0.0001498645,0.00020199917,0.0002045086],"domain_scores_gemma":[0.996793,0.001685657,0.0010152427,0.00012727184,0.000163648,0.0002152259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004036472,0.000093952585,0.00092306966,0.00016661565,0.000017472874,0.0000072234716,0.00009296112,0.0002422101,0.000043617954],"category_scores_gemma":[0.0047786357,0.000054397387,0.00015119113,0.00009575844,0.00010313191,0.00007922519,0.000053709784,0.00049079687,0.0000058735327],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008734044,0.00051475747,0.37427813,0.00002928729,0.00009983481,0.0003593277,0.000036202506,1.01110686e-7,0.0076012295,0.0001253406,0.000586409,0.615496],"study_design_scores_gemma":[0.021356594,0.0067669544,0.9464566,0.00027756972,0.00012777529,0.00016950659,0.00007351445,0.00004768161,0.0015539571,0.00038659974,0.022679362,0.00010385127],"about_ca_topic_score_codex":0.00000894152,"about_ca_topic_score_gemma":0.000011087215,"teacher_disagreement_score":0.61539215,"about_ca_system_score_codex":0.00008443666,"about_ca_system_score_gemma":0.0003790741,"threshold_uncertainty_score":0.57208186},"labels":[],"label_agreement":null},{"id":"W2591143777","doi":"10.1200/jco.2016.34.4_suppl.196","title":"A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; St Mary's Hospital Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Gemcitabine; Taxane; Irinotecan; Paclitaxel; Pancreatic cancer; Capecitabine; Gastroenterology; Oncology; Performance status; Cancer; Nausea; Neutropenia; Chemotherapy; Adverse effect; Breast cancer; Colorectal cancer","score_opus":0.12730128512111996,"score_gpt":0.5383634431411422,"score_spread":0.4110621580200222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591143777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696315,0.0004974119,0.000014593285,0.010492742,0.00066572556,0.000607957,0.000007457539,0.0000070712026,0.0007438684],"genre_scores_gemma":[0.9964506,0.0010994198,0.00040296445,0.0006555953,0.00039056028,0.000037876835,7.4958973e-7,0.000017495244,0.00094474613],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9966134,0.00045607175,0.0021682656,0.00020993502,0.00029734062,0.00025499772],"domain_scores_gemma":[0.99519,0.0022188707,0.0017485537,0.00018894605,0.0003583379,0.00029524896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013081091,0.0001670186,0.0021515652,0.00018002732,0.00002769982,0.0000015144992,0.00013959061,0.00018157151,0.000397864],"category_scores_gemma":[0.0007000338,0.00008583207,0.00021632688,0.00022611879,0.00021803606,0.00010652606,0.000040852294,0.0004737489,0.0000034913517],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15621784,0.07370953,0.49599978,0.000047307625,0.0015648536,0.0017837081,0.0007837121,0.000010333191,0.00432057,0.000029814075,0.0025023906,0.26303014],"study_design_scores_gemma":[0.25127783,0.50625634,0.22948526,0.00040497526,0.0014125757,0.00012705749,0.00064562354,0.000011797681,0.00035158687,0.00013446365,0.009771744,0.00012074996],"about_ca_topic_score_codex":0.00012210592,"about_ca_topic_score_gemma":0.0010105232,"teacher_disagreement_score":0.43254682,"about_ca_system_score_codex":0.00027685834,"about_ca_system_score_gemma":0.0015841728,"threshold_uncertainty_score":0.43563318},"labels":[],"label_agreement":null},{"id":"W2591149691","doi":"10.1200/jco.2015.33.3_suppl.552","title":"Improving the prediction of colon cancer survival after curative resection.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Colorectal cancer; Proportional hazards model; Internal medicine; Cancer; Oncology; Stage (stratigraphy); Hazard ratio; Cancer registry; Multivariate analysis; TNM staging system; Lymph node; Survival analysis; Cancer staging; Adenocarcinoma; AJCC staging system; Surgery; Staging system; Confidence interval","score_opus":0.26591966162757147,"score_gpt":0.4942673907991435,"score_spread":0.22834772917157203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591149691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840611,0.000940365,0.00032523277,0.0048945094,0.0077396748,0.00021900446,0.000009593064,0.000005224464,0.0018052954],"genre_scores_gemma":[0.9958044,0.0002766126,0.0009170158,0.00063648546,0.0020600662,0.00001547329,4.9531695e-7,0.0000111963445,0.000278226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971431,0.00054040336,0.001534191,0.0001259107,0.00051127124,0.00014511608],"domain_scores_gemma":[0.9953517,0.0014059619,0.0014571347,0.00015619272,0.0013952958,0.00023376748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003366032,0.00008997466,0.000766602,0.00006519822,0.000023546667,0.000004396867,0.00012534013,0.00029069628,0.0001504581],"category_scores_gemma":[0.005753482,0.000050767732,0.00025196758,0.0001570436,0.00032551205,0.00007746195,0.00005590465,0.0009043787,0.0000035433563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05943886,0.001467327,0.75002384,0.00008896723,0.0010515241,0.00019147295,0.0017099662,0.0003658575,0.0056724693,0.0000472555,0.032074213,0.14786828],"study_design_scores_gemma":[0.012715637,0.05693967,0.8203416,0.00021103356,0.0009332158,0.00032132893,0.0015000674,0.0009066724,0.004587349,0.00054878305,0.10086428,0.00013035507],"about_ca_topic_score_codex":0.00012552249,"about_ca_topic_score_gemma":0.00031399736,"teacher_disagreement_score":0.14773792,"about_ca_system_score_codex":0.00035761727,"about_ca_system_score_gemma":0.003234546,"threshold_uncertainty_score":0.68878716},"labels":[],"label_agreement":null},{"id":"W2591150335","doi":"10.1200/jco.2014.32.3_suppl.580","title":"Predictors of treatment interruption/dose reduction of neoadjuvant chemotherapy for rectal cancer: A multicenter study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; Memorial University of Newfoundland; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Chemotherapy; Cancer; Breast cancer; Internal medicine; Oncology; Univariate analysis; Surgery; Retrospective cohort study; Multivariate analysis","score_opus":0.12814543158620867,"score_gpt":0.47516278852399807,"score_spread":0.3470173569377894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591150335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955087,0.00014322627,0.000096637705,0.0020599712,0.0015062992,0.000462098,0.000005378538,0.0000043383466,0.00021338035],"genre_scores_gemma":[0.99699295,0.00037326769,0.00069209235,0.00012618882,0.0015532945,0.000013564219,0.0000015335675,0.000011146756,0.00023595005],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975909,0.00020955034,0.001775832,0.00013533595,0.00017019674,0.0001181888],"domain_scores_gemma":[0.9970856,0.00060187734,0.0015626857,0.000111973466,0.00048326427,0.00015464076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012547573,0.0001060334,0.0012637023,0.00010665335,0.000015808393,0.0000016117708,0.00007636282,0.00014713412,0.00006096578],"category_scores_gemma":[0.00074336387,0.00006593706,0.0006032924,0.000072782525,0.00013554758,0.00004584443,0.000015728585,0.00021302598,6.157305e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044899687,0.009974825,0.38637108,0.000083395964,0.0014221924,0.000017213255,0.0019264495,0.000033585915,0.009739929,0.0000142393665,0.0008134677,0.54470396],"study_design_scores_gemma":[0.036497913,0.23593426,0.70260864,0.00022636645,0.0012480752,0.00008859882,0.0012785821,0.0010144641,0.0036397723,0.0000743853,0.017292736,0.000096202646],"about_ca_topic_score_codex":0.00008887575,"about_ca_topic_score_gemma":0.00008887486,"teacher_disagreement_score":0.54460776,"about_ca_system_score_codex":0.00020231013,"about_ca_system_score_gemma":0.00050163997,"threshold_uncertainty_score":0.26888353},"labels":[],"label_agreement":null},{"id":"W2591158495","doi":"10.1200/jco.2014.32.4_suppl.242","title":"Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cabazitaxel; Medicine; Cohort; Mitoxantrone; Prostate cancer; Population; Interim analysis; Internal medicine; Prednisone; Cancer; Clinical trial; Androgen deprivation therapy; Chemotherapy","score_opus":0.10024579945243786,"score_gpt":0.4656482243335842,"score_spread":0.3654024248811464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591158495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956519,0.00026962618,0.000024323423,0.0009772084,0.000064926695,0.0028416477,0.00003390124,0.000024588533,0.00011189291],"genre_scores_gemma":[0.9930231,0.0004356142,0.0055679884,0.0002157847,0.000081023325,0.00038766357,0.00006681586,0.000035584293,0.0001864076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995609,0.0006028291,0.00212918,0.00047922583,0.00074567157,0.00043409012],"domain_scores_gemma":[0.99420476,0.0009593894,0.0028129967,0.00024237554,0.0012701736,0.0005103304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010842494,0.00036122787,0.0028657606,0.00050993444,0.00006430973,0.00005231981,0.00017696586,0.00019396743,0.00005591285],"category_scores_gemma":[0.00017712612,0.00019929999,0.0002439695,0.0010349373,0.00066821097,0.00039203593,0.000040425824,0.00068402017,4.481618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06597844,0.009728292,0.87269,0.00013356328,0.009080224,0.00036272992,0.0002932076,0.00079879956,0.000016218812,0.000011009825,0.00020247849,0.040705033],"study_design_scores_gemma":[0.03791686,0.07780869,0.8670352,0.00038272282,0.013399619,0.00008307354,0.00004594586,0.0012357023,0.000014183521,0.0000070744313,0.0018774577,0.00019343256],"about_ca_topic_score_codex":0.0020314115,"about_ca_topic_score_gemma":0.010191107,"teacher_disagreement_score":0.0680804,"about_ca_system_score_codex":0.00036548983,"about_ca_system_score_gemma":0.0019621605,"threshold_uncertainty_score":0.8127217},"labels":[],"label_agreement":null},{"id":"W2591161534","doi":"10.1200/jco.2016.34.2_suppl.467","title":"Molecular tumor grading of non muscle invasive bladder cancer based on whole transcriptome analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Grading (engineering); Bladder cancer; Transcriptome; Medicine; Pathological; Correlation; Pathology; Oncology; Computational biology; Internal medicine; Bioinformatics; Cancer; Gene; Gene expression; Biology; Genetics","score_opus":0.07414910570578977,"score_gpt":0.4336104160529946,"score_spread":0.35946131034720485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591161534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484963,0.00023732161,0.0018034859,0.010057549,0.00062034605,0.00018500733,0.000029273175,0.000005958644,0.0022114043],"genre_scores_gemma":[0.9933681,0.00018345336,0.0006811483,0.005169539,0.00043016745,0.000008382892,0.0000014019353,0.000019282628,0.00013854369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972899,0.00026089264,0.0015744483,0.00021389418,0.00044042978,0.0002204675],"domain_scores_gemma":[0.99686533,0.0011015575,0.0011196764,0.00023045493,0.00034714577,0.00033585934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009735883,0.00015395069,0.0016541578,0.0003085309,0.000021700353,0.0000033682943,0.00014836952,0.00019001347,0.0004890837],"category_scores_gemma":[0.00066905224,0.0000865483,0.0010954739,0.000284042,0.00017543534,0.00007053014,0.000010981433,0.00035744547,0.000010778485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016048413,0.009092245,0.32973993,0.00015609848,0.015294817,0.004085135,0.00034329703,0.0009811395,0.31554815,0.00006693984,0.0058289156,0.3028149],"study_design_scores_gemma":[0.033923507,0.031646494,0.8493319,0.00065304537,0.011466352,0.00004113059,0.00008888821,0.00037446475,0.05448801,0.00026850856,0.0174659,0.0002517617],"about_ca_topic_score_codex":0.00006905636,"about_ca_topic_score_gemma":0.000070624454,"teacher_disagreement_score":0.519592,"about_ca_system_score_codex":0.00018934085,"about_ca_system_score_gemma":0.0018021599,"threshold_uncertainty_score":0.5355124},"labels":[],"label_agreement":null},{"id":"W2591163415","doi":"10.1200/jco.2016.34.7_suppl.274","title":"Quality assurance metrics in clinical trial conduct.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Quality assurance; Documentation; Quality (philosophy); Process management; Process (computing); Medicine; Protocol (science); Quality management; Best practice; Computer science; Operations management; Business","score_opus":0.9235605989743348,"score_gpt":0.7844270008124985,"score_spread":0.13913359816183635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591163415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8991753,0.00034991585,0.00071767665,0.081671916,0.0069900663,0.00046130543,0.00000527627,0.000013335821,0.01061525],"genre_scores_gemma":[0.9683445,0.008438361,0.009720078,0.0055759544,0.0055008642,0.0000059496174,5.219263e-7,0.000027003205,0.002386751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9729401,0.0072474,0.0161763,0.00060838135,0.002400629,0.0006271913],"domain_scores_gemma":[0.25009254,0.73229814,0.008866462,0.0014123026,0.0050913873,0.0022391619],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.19018313,0.00018981232,0.003928416,0.00036013173,0.000033164968,0.000012932084,0.0007138832,0.002651336,0.00049124035],"category_scores_gemma":[0.7777964,0.00010409897,0.0016480745,0.0006143305,0.0014986924,0.00020186474,0.00022611664,0.008517177,0.00016854377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16702093,0.006700449,0.45280412,0.00006279405,0.0003214908,0.0010982965,0.000017374632,4.012168e-7,0.000110562825,0.0056920466,0.0073676123,0.35880393],"study_design_scores_gemma":[0.22511466,0.037665006,0.5854765,0.0003888312,0.000120970406,0.000093457296,0.000049939437,0.000005786705,0.00004002875,0.031847373,0.11903442,0.00016304324],"about_ca_topic_score_codex":0.000024013381,"about_ca_topic_score_gemma":0.00030869825,"teacher_disagreement_score":0.72505075,"about_ca_system_score_codex":0.00033698868,"about_ca_system_score_gemma":0.011617802,"threshold_uncertainty_score":0.99864346},"labels":[],"label_agreement":null},{"id":"W2591165110","doi":"10.1200/jco.2014.32.30_suppl.131","title":"A new model of care: An advanced practice radiation therapy role.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health and Long Term Care; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Radiation Therapist; Medicine; Certification; Palliative care; Health care; Nursing; Family medicine; Medical education; Radiation therapy; Management","score_opus":0.3437513112969116,"score_gpt":0.6196689098131248,"score_spread":0.2759175985162132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591165110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85125333,0.0013203983,0.08202108,0.05659502,0.0020206168,0.00060974597,0.0000040273794,0.000025155932,0.0061506378],"genre_scores_gemma":[0.7890189,0.0021305415,0.19579168,0.010947889,0.0020224843,0.0000015841015,0.00000813949,0.00002046854,0.00005828819],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935941,0.0010654295,0.004457219,0.00018835104,0.000534393,0.00016047568],"domain_scores_gemma":[0.9806267,0.011091193,0.0057856455,0.00030901315,0.0017038618,0.0004835672],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007913163,0.00011845383,0.0011992264,0.00010266988,0.000024987305,0.000007132742,0.00016782987,0.00032266695,0.000084416],"category_scores_gemma":[0.0669008,0.00009067583,0.00036945785,0.00012514819,0.000069094596,0.00072782143,0.000026108459,0.0008771853,0.000008606353],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014488365,0.0009923454,0.0030029044,0.000010993856,0.00014937464,0.000009899128,0.00035560067,0.001591361,0.0016964191,0.0003189864,0.0016332649,0.9757505],"study_design_scores_gemma":[0.061799716,0.1126731,0.04196292,0.00009977569,0.0016131051,0.00033679302,0.0030556612,0.044367507,0.0010600837,0.0058325864,0.72691226,0.0002865111],"about_ca_topic_score_codex":0.00006611268,"about_ca_topic_score_gemma":0.000039487444,"teacher_disagreement_score":0.975464,"about_ca_system_score_codex":0.00011537083,"about_ca_system_score_gemma":0.0033470807,"threshold_uncertainty_score":0.9409591},"labels":[],"label_agreement":null},{"id":"W2591165175","doi":"10.1200/jco.2014.32.4_suppl.70","title":"A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Internal medicine; Prostate cancer; Proportional hazards model; Hazard ratio; Oncology; Lymph node; Cancer; Gastroenterology; Urology; Androgen deprivation therapy; Confidence interval","score_opus":0.08463559250725394,"score_gpt":0.43584952964092244,"score_spread":0.3512139371336685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591165175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923442,0.00020860272,0.00011720316,0.0054935534,0.00012147813,0.0015476284,0.00003989335,0.000011808196,0.00011562334],"genre_scores_gemma":[0.9939165,0.00024369085,0.0039745546,0.0007972543,0.0002419451,0.00011072747,0.000045198565,0.000042572166,0.00062756904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975619,0.00021887948,0.00116717,0.00024668174,0.00044690873,0.00035849397],"domain_scores_gemma":[0.99554133,0.0009331563,0.0011480704,0.00015506473,0.0018461936,0.00037616343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001024277,0.00020702965,0.0011972686,0.00011795194,0.00007352874,0.000024325609,0.0001006598,0.00010807774,0.00005660036],"category_scores_gemma":[0.0005779126,0.00010089323,0.00016907619,0.00017852864,0.00029144244,0.0001449537,0.000010971244,0.00040315124,0.0000033026822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1419896,0.003832451,0.7496652,0.00027521688,0.0020816862,0.00025226868,0.00025975896,0.000041492814,0.0005718789,0.000022454686,0.00052375183,0.100484245],"study_design_scores_gemma":[0.06466573,0.12005614,0.8077202,0.00050761976,0.0012814874,0.00005947751,0.000076692864,0.00012663225,0.00038694727,0.000077066485,0.0048784404,0.00016358514],"about_ca_topic_score_codex":0.00003694038,"about_ca_topic_score_gemma":0.00019197271,"teacher_disagreement_score":0.116223685,"about_ca_system_score_codex":0.00017674774,"about_ca_system_score_gemma":0.0019848535,"threshold_uncertainty_score":0.41143066},"labels":[],"label_agreement":null},{"id":"W2591173804","doi":"10.1200/jco.2015.33.29_suppl.171","title":"End-of-life cancer care: Health service delivery in the last 12 months of life in Calgary, Alberta, Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Palliative care; Psychosocial; Cancer; End-of-life care; Intensive care unit; Multivariate analysis; Retrospective cohort study; Emergency medicine; Family medicine; Internal medicine; Nursing","score_opus":0.2979200142520399,"score_gpt":0.5125129827203562,"score_spread":0.21459296846831627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591173804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957482,0.013621425,0.000009792449,0.025190251,0.0008935833,0.00020663037,0.000015807333,0.0000012058701,0.0025793144],"genre_scores_gemma":[0.9789246,0.0044515477,0.00065089576,0.015407582,0.00051505177,0.0000045165107,0.00000476801,0.000011776764,0.000029279166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950724,0.0008713493,0.003048966,0.00014330882,0.0005987761,0.00026519026],"domain_scores_gemma":[0.9918916,0.0044024056,0.002118894,0.00020474351,0.000879874,0.00050247385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026818675,0.00013756641,0.0020423636,0.00013312226,0.000011750119,0.0000015064684,0.00030589057,0.00024741967,0.000042290245],"category_scores_gemma":[0.005810053,0.0000901312,0.00018596232,0.00029622912,0.00014945299,0.000062294144,0.00005306053,0.000859613,0.0000010398032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024109827,0.00060903624,0.948182,0.00021931656,0.00018357497,0.00013450504,0.0058846367,0.000253467,0.000006796871,0.000037628222,0.01897798,0.023100067],"study_design_scores_gemma":[0.014331998,0.005747563,0.68633,0.0014475696,0.00016861157,0.000024250206,0.01430492,0.00027893056,0.000048783855,0.000039119088,0.27713662,0.00014157261],"about_ca_topic_score_codex":0.8244958,"about_ca_topic_score_gemma":0.98236907,"teacher_disagreement_score":0.26185197,"about_ca_system_score_codex":0.0004941161,"about_ca_system_score_gemma":0.029788394,"threshold_uncertainty_score":0.9757118},"labels":[],"label_agreement":null},{"id":"W2591193595","doi":"10.1200/jco.2016.34.2_suppl.393","title":"Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; University of British Columbia; McMaster University","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Cumulative incidence; Chemotherapy; Pulmonary embolism; Incidence (geometry); Urology; Thrombosis; Surgery; Internal medicine; Cancer; Cohort","score_opus":0.038275387806383177,"score_gpt":0.3691996249696561,"score_spread":0.3309242371632729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591193595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539787,0.00006726208,0.00005241493,0.0036527084,0.00023624244,0.00028928075,0.00001921761,0.0000015530826,0.00028344506],"genre_scores_gemma":[0.9985567,0.00030990472,0.00026769796,0.00063835894,0.00016086859,0.000003144918,6.107036e-7,0.000013583866,0.00004913312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979808,0.00016749484,0.0013333354,0.00013082077,0.0002488016,0.00013875635],"domain_scores_gemma":[0.9972474,0.00069338665,0.0013927633,0.00021038101,0.00033974956,0.000116298674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005064258,0.00010645099,0.0009110391,0.00007653911,0.00002058189,0.00000117429,0.00013765835,0.00014400715,0.000049126545],"category_scores_gemma":[0.0005886975,0.000048661892,0.00015063045,0.000109251196,0.00026844503,0.000072948926,0.00004071688,0.00022219351,9.632897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019691507,0.0010524495,0.95158273,0.000017925657,0.00018726128,0.0000032688802,0.00010505437,1.5868099e-7,0.00032311777,0.0000470727,0.000051392948,0.044660434],"study_design_scores_gemma":[0.015145208,0.0056633973,0.9776096,0.00028852667,0.00019247041,0.000023102362,0.000019609275,8.227693e-7,0.000299459,0.00045339463,0.0002556103,0.000048815225],"about_ca_topic_score_codex":0.000037833328,"about_ca_topic_score_gemma":0.00006528522,"teacher_disagreement_score":0.044611618,"about_ca_system_score_codex":0.00008381728,"about_ca_system_score_gemma":0.0012747729,"threshold_uncertainty_score":0.22613923},"labels":[],"label_agreement":null},{"id":"W2591193600","doi":"10.1200/jco.2016.34.2_suppl.e629","title":"Modified Kegel exercise regimen following definitive and adjuvant prostate cancer radiotherapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Regimen; Radiation therapy; Prostate cancer; Urinary incontinence; Sphincter; Fecal incontinence; Urology; Surgery; Internal medicine; Cancer","score_opus":0.09662600454421257,"score_gpt":0.4455468232256739,"score_spread":0.34892081868146135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591193600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94995606,0.022213139,0.000094385745,0.025306122,0.0010888694,0.0003879584,0.000011694552,0.000010344258,0.0009314283],"genre_scores_gemma":[0.9016673,0.09355205,0.0018193456,0.0018467001,0.00050116616,0.000038489423,7.210164e-7,0.00002168425,0.0005525594],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99784696,0.00015773377,0.0012869843,0.00022182851,0.00023952543,0.00024696303],"domain_scores_gemma":[0.9969354,0.0013309482,0.00095341215,0.00013996604,0.00022237854,0.00041788307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012586928,0.00015003307,0.001420867,0.00007896647,0.000038734725,0.000008123012,0.00006947664,0.00019606904,0.00006423187],"category_scores_gemma":[0.0005456358,0.00007709797,0.00039308128,0.000065072425,0.00016820557,0.0001347169,0.000029342062,0.0002904273,0.0000034844763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005339488,0.0007854749,0.16899778,0.000018675673,0.00083432446,0.0012078079,0.0002716218,0.0000031340617,0.00035386757,0.00008553152,0.0027990965,0.8193032],"study_design_scores_gemma":[0.09312301,0.03669988,0.7355885,0.0044864337,0.0030216612,0.00050121284,0.00030122884,0.000075444485,0.0020003263,0.002500438,0.12124669,0.00045515964],"about_ca_topic_score_codex":0.000029640138,"about_ca_topic_score_gemma":0.000014813907,"teacher_disagreement_score":0.8188481,"about_ca_system_score_codex":0.00029948747,"about_ca_system_score_gemma":0.0011258853,"threshold_uncertainty_score":0.31439638},"labels":[],"label_agreement":null},{"id":"W2591193722","doi":"10.1200/jco.2014.32.4_suppl.391","title":"Influence of social demographics and African-American race on outcomes in testicular cancer: Analysis of 75,902 patients in the National Cancer database.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Ethnic group; Cancer; Demography; Population; Testicular cancer; Demographics; Multivariate analysis; Incidence (geometry); Presentation (obstetrics); Family medicine; Internal medicine; Surgery; Environmental health","score_opus":0.06538038478225681,"score_gpt":0.4820857824577889,"score_spread":0.41670539767553205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591193722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972752,0.0001653109,0.0000065204545,0.0022893616,0.000043084852,0.00011403644,0.000058718055,9.981231e-7,0.000046771827],"genre_scores_gemma":[0.9979352,0.0003916019,0.00028266272,0.0013155435,0.00005518513,0.000007580486,0.000005726316,0.0000044011504,0.000002099195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976665,0.0003989841,0.0011819326,0.00012863464,0.0005098075,0.00011413668],"domain_scores_gemma":[0.9946949,0.0031372046,0.0015756089,0.00008747297,0.00041111026,0.000093743016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012298356,0.0000904731,0.001163843,0.00032471612,0.000017652903,0.0000021706244,0.00011284065,0.000075943324,0.0000089089335],"category_scores_gemma":[0.005854691,0.000053387255,0.00026169175,0.00070282235,0.0003231093,0.000042858996,0.000025228084,0.0003099643,1.5326866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057993893,0.0023972183,0.98431665,0.00001796397,0.0008525436,0.000019330022,0.00011021455,0.0013005484,0.0000067526034,0.00009396624,0.000032796335,0.01027209],"study_design_scores_gemma":[0.0038089526,0.0021246301,0.991397,0.00006757546,0.0017254896,0.0000013886815,0.00006113893,0.00049134495,0.000001777524,0.000062045365,0.00021647074,0.00004218421],"about_ca_topic_score_codex":0.0007259486,"about_ca_topic_score_gemma":0.0009833226,"teacher_disagreement_score":0.010229906,"about_ca_system_score_codex":0.00008223365,"about_ca_system_score_gemma":0.00043600437,"threshold_uncertainty_score":0.7009035},"labels":[],"label_agreement":null},{"id":"W2591194257","doi":"10.1200/jco.2016.34.2_suppl.258","title":"Effect of anti-GRP78 autoantibodies on prostate cancer progression through tissue factor procoagulant activity.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Autoantibody; DU145; Tissue factor; Medicine; Prostate cancer; Cancer research; Gene knockdown; Antibody; Cancer; Immunology; Cell culture; Internal medicine; LNCaP; Biology","score_opus":0.04166223888841537,"score_gpt":0.4760352870639848,"score_spread":0.43437304817556943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591194257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634725,0.0007057557,0.0000874319,0.0012392296,0.00072331436,0.00027964936,0.00003941875,0.0000044774156,0.0005734486],"genre_scores_gemma":[0.99477124,0.004053969,0.00020694407,0.00011716742,0.0005450599,0.000014051877,0.000002061997,0.00001609836,0.0002734302],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978339,0.0005289123,0.00091145234,0.00024385836,0.00025686302,0.00022498822],"domain_scores_gemma":[0.9974439,0.0005538577,0.0014171891,0.00019970379,0.00021364709,0.00017167091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072611007,0.00017346334,0.00085845304,0.000034407116,0.00003229842,0.0000061619826,0.00019149874,0.0003033335,0.000035575315],"category_scores_gemma":[0.0017357385,0.00008380478,0.00031337,0.000040134335,0.00026714735,0.000013658011,0.00008134692,0.0002112517,0.0000055346186],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008437979,0.0008516276,0.12220162,0.00014185467,0.00024079371,0.00010123862,0.000031082265,0.000014551146,0.38632864,0.000024570629,0.0018887926,0.47973725],"study_design_scores_gemma":[0.0053713773,0.030165952,0.08120843,0.00041755833,0.00012612544,0.000029482786,0.000005101575,0.000004947796,0.8333425,0.00004388522,0.049130943,0.00015370626],"about_ca_topic_score_codex":0.0000072544904,"about_ca_topic_score_gemma":0.000008854449,"teacher_disagreement_score":0.47958353,"about_ca_system_score_codex":0.000023685436,"about_ca_system_score_gemma":0.0005068315,"threshold_uncertainty_score":0.34174597},"labels":[],"label_agreement":null},{"id":"W2591197031","doi":"10.1200/jco.2014.32.4_suppl.434","title":"Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Alberta; University of British Columbia; Dalhousie University; University of Toronto; McMaster University; University of Calgary; McGill University; University of Manitoba","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Histopathology; Pathological; Pathological staging; Urology; Lymph; Kidney cancer; Surgery; Kidney; Internal medicine; Pathology","score_opus":0.18659174630362937,"score_gpt":0.42943832872924786,"score_spread":0.2428465824256185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591197031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727242,0.00055279164,0.00026042777,0.0027322564,0.0010870488,0.00019641328,0.000007342139,0.0000049685436,0.022434566],"genre_scores_gemma":[0.99072653,0.000030647745,0.006478358,0.0016732629,0.0005165238,0.0000046761947,0.000005397218,0.000013647917,0.00055098475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617964,0.0003824885,0.0024995592,0.00020956043,0.00045384344,0.0002748995],"domain_scores_gemma":[0.99548465,0.0012073856,0.0014570096,0.0002668274,0.0005397205,0.001044386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019023732,0.00019148683,0.0018317341,0.0002545868,0.000056730216,0.0000050645767,0.00021475989,0.0003571104,0.00016183691],"category_scores_gemma":[0.0022159494,0.00012035509,0.00076166604,0.000110812754,0.00045921083,0.000104155166,0.000038001686,0.00066865596,0.000025609057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010448634,0.0015464823,0.98380566,0.00003166601,0.00018844093,0.001724216,0.00023433441,0.000017247943,0.0007375355,0.0001285795,0.004365908,0.0061750547],"study_design_scores_gemma":[0.010915229,0.00806178,0.93195784,0.000039877275,0.0001972586,0.0004255484,0.00015946037,0.0001275699,0.0016599849,0.000029658397,0.04632121,0.000104581246],"about_ca_topic_score_codex":0.006548641,"about_ca_topic_score_gemma":0.0024182869,"teacher_disagreement_score":0.051847827,"about_ca_system_score_codex":0.00036333923,"about_ca_system_score_gemma":0.006879507,"threshold_uncertainty_score":0.99875057},"labels":[],"label_agreement":null},{"id":"W2591198891","doi":"10.1200/jco.2014.32.3_suppl.532","title":"Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Odds ratio; Prospective cohort study; Regimen; Body mass index; Chemotherapy regimen; Cohort; Cancer; Surgery; Oncology","score_opus":0.16165640916721996,"score_gpt":0.5372519779546603,"score_spread":0.3755955687874403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591198891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950181,0.000015416173,0.00006511816,0.0014902919,0.0015865779,0.0009784778,0.00005476236,0.0000084995145,0.0007827126],"genre_scores_gemma":[0.9972788,0.000109128705,0.0008018986,0.0007369037,0.0010294507,0.0000107767855,0.000012243223,0.000013790998,0.0000069744387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912933,0.0011397799,0.006255604,0.0003345261,0.0007719393,0.00020483318],"domain_scores_gemma":[0.98460305,0.008867956,0.0050197477,0.00019719708,0.0010557995,0.0002562414],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00874926,0.00015372904,0.0017099879,0.00007038795,0.000021287577,0.000007289396,0.00016937005,0.0003031355,0.00006337712],"category_scores_gemma":[0.048365965,0.00011927644,0.0002990962,0.00025843125,0.000174925,0.00020139491,0.00006706968,0.0008270603,0.0000033257243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020126032,0.0061033946,0.9571881,0.00000786799,0.0009921443,0.000028776063,0.00029913185,0.000024832021,0.000018083729,0.000006573508,0.00041475348,0.014790306],"study_design_scores_gemma":[0.038381737,0.026431566,0.9333054,0.00008871109,0.0006849321,0.0000031139054,0.00023964212,0.00011541414,0.000025436908,0.0004282869,0.00021326747,0.00008251245],"about_ca_topic_score_codex":0.0035564844,"about_ca_topic_score_gemma":0.00939231,"teacher_disagreement_score":0.039616704,"about_ca_system_score_codex":0.000577256,"about_ca_system_score_gemma":0.0019919765,"threshold_uncertainty_score":0.95965004},"labels":[],"label_agreement":null},{"id":"W2591204291","doi":"10.1200/jco.2014.32.3_suppl.311","title":"Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Proportional hazards model; Cirrhosis; Hepatitis C; Gastroenterology; Univariate analysis; Population; Multivariate analysis; Hepatitis B; Oncology","score_opus":0.11367448055993387,"score_gpt":0.3507066768715217,"score_spread":0.2370321963115878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591204291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702126,0.00017990702,0.000028201397,0.001230649,0.00043544552,0.0005750759,0.000017230648,0.000002644263,0.000509583],"genre_scores_gemma":[0.9982559,0.000060776263,0.0009477933,0.00041000583,0.00015073502,0.00001267018,0.000018750045,0.000018105029,0.00012528356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965256,0.0006796627,0.0019726707,0.00023349076,0.00033277972,0.0002557821],"domain_scores_gemma":[0.995438,0.002882833,0.0009494593,0.00014697199,0.00030493768,0.0002778185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025470604,0.000112611175,0.0014226012,0.000098842174,0.00003399061,0.000010279967,0.00009809335,0.00035000884,0.000025470763],"category_scores_gemma":[0.0050753197,0.00013378944,0.00022052767,0.00013370729,0.000096961456,0.00007663202,0.000026673993,0.00066208316,5.3023933e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012079921,0.0011302512,0.94868076,0.00006931145,0.000036273872,0.0003016169,0.000053301494,0.0000028194052,0.0000082771385,0.00002083889,0.00029747054,0.048191093],"study_design_scores_gemma":[0.018824406,0.007176483,0.96919656,0.00018241264,0.00010908957,0.00002198232,0.00004827432,0.0006053891,0.000018227085,0.00051510154,0.003199081,0.000103022394],"about_ca_topic_score_codex":0.12140843,"about_ca_topic_score_gemma":0.81279635,"teacher_disagreement_score":0.69138795,"about_ca_system_score_codex":0.00030483966,"about_ca_system_score_gemma":0.001371895,"threshold_uncertainty_score":0.8844422},"labels":[],"label_agreement":null},{"id":"W2591211152","doi":"10.1200/jco.2013.31.6_suppl.194","title":"Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; St. Michael's Hospital","funders":"","keywords":"Prostate cancer; Medicine; microRNA; Prostatectomy; Logistic regression; Oncology; Cancer; Proportional hazards model; Biomarker; Biochemical recurrence; Internal medicine; Computational biology; Bioinformatics; Gene; Biology","score_opus":0.048400166149728384,"score_gpt":0.3994887254896084,"score_spread":0.35108855933988004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591211152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994601,0.0006980044,0.0003528476,0.0034220587,0.0004836463,0.00033639735,0.00004860753,0.0000025141687,0.000054885793],"genre_scores_gemma":[0.9911606,0.00052127696,0.0063665407,0.0010047497,0.0006122638,0.000018043595,0.00001609257,0.000027670383,0.00027280618],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712926,0.000359469,0.001541856,0.00033354558,0.00029726775,0.0003385915],"domain_scores_gemma":[0.9974422,0.0003021307,0.00085352594,0.000278339,0.0007581093,0.00036572554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077682873,0.00016566238,0.000770565,0.00011033008,0.000018064631,0.000024628498,0.0003970944,0.00068570644,0.00010980847],"category_scores_gemma":[0.0036954395,0.00013928647,0.00030435802,0.00020814931,0.0001463402,0.000013307049,0.00023013141,0.0010465201,0.000013471318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013593477,0.00029613415,0.004470488,0.000011268314,0.00018548044,0.00008677709,0.00006620078,0.0002692517,0.9600444,0.000004763424,0.016467659,0.01673827],"study_design_scores_gemma":[0.0058327243,0.008921589,0.07894374,0.000337976,0.00011923305,0.000038180962,0.000082866674,0.00014690094,0.7565472,0.0005677318,0.1479886,0.0004732666],"about_ca_topic_score_codex":0.000887416,"about_ca_topic_score_gemma":0.0004574224,"teacher_disagreement_score":0.20349717,"about_ca_system_score_codex":0.0000752208,"about_ca_system_score_gemma":0.0008845572,"threshold_uncertainty_score":0.5679937},"labels":[],"label_agreement":null},{"id":"W2591213878","doi":"10.1200/jco.2012.30.34_suppl.75","title":"Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Spouse; Hazard ratio; Proportional hazards model; Multivariate analysis; Logistic regression; Depression (economics); Demography; Internal medicine; Varenicline; Cancer; Confidence interval","score_opus":0.0820662134839534,"score_gpt":0.4418075708763139,"score_spread":0.35974135739236046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591213878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956818,0.00025846195,0.000050764567,0.0012209957,0.0009992446,0.00029194797,0.0000017140715,0.000004494649,0.0014905769],"genre_scores_gemma":[0.9981463,0.000104613435,0.00072529656,0.00037091973,0.000621339,0.000013634745,0.0000013399327,0.000009189584,0.0000073652855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967237,0.00094251474,0.0012563509,0.00009697537,0.0006515505,0.0003289099],"domain_scores_gemma":[0.99624217,0.0012751613,0.0021334162,0.00006414892,0.00018995616,0.00009514639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031690819,0.000089101515,0.0005625689,0.000069014764,0.00019930761,0.000012709645,0.00028800586,0.00025448308,0.00004716486],"category_scores_gemma":[0.00055444083,0.00005962112,0.00011641434,0.0002193054,0.0004870951,0.00034628095,0.00006360203,0.0005832905,4.438214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016680587,0.00040745878,0.82671773,0.00000501042,0.00008994658,0.0000015304405,0.0061650565,0.000023005536,0.0000011746968,0.0010717048,0.00004671048,0.16530384],"study_design_scores_gemma":[0.0014249289,0.00028763045,0.9069315,0.000048308648,0.00007478625,3.9768503e-7,0.0052570105,0.0000111278805,0.0000076462675,0.00022780024,0.085655004,0.00007382488],"about_ca_topic_score_codex":0.00038290975,"about_ca_topic_score_gemma":0.00038186493,"teacher_disagreement_score":0.16523002,"about_ca_system_score_codex":0.0005226383,"about_ca_system_score_gemma":0.00091501774,"threshold_uncertainty_score":0.25341392},"labels":[],"label_agreement":null},{"id":"W2591214434","doi":"10.1200/jco.2014.32.3_suppl.299","title":"Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Neuroendocrine tumors; Octreotide; Chromogranin A; Bloating; Abdominal pain; Diarrhea; Biomarker; Somatostatin","score_opus":0.030273293247562248,"score_gpt":0.41029952720383994,"score_spread":0.3800262339562777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591214434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692833,0.00005263001,0.0000707414,0.0013891979,0.00039062882,0.0005803881,0.0000027017334,0.0000132957275,0.0005720978],"genre_scores_gemma":[0.9986573,0.00007060801,0.00061785924,0.0002935724,0.0002216184,0.0000067673423,0.0000048035026,0.000034539637,0.00009293454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936328,0.0017421844,0.0030719233,0.00026686912,0.00091848726,0.0003677141],"domain_scores_gemma":[0.9877321,0.0065701823,0.0035388225,0.00045337804,0.0012334838,0.00047202752],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022630172,0.00022500328,0.0023783445,0.00033435112,0.000025633826,0.0000054369793,0.0003266312,0.000030188747,0.000059580405],"category_scores_gemma":[0.024584569,0.00013869203,0.00041233172,0.00030428308,0.00069967663,0.0002076972,0.00009657851,0.0010799633,0.000011498331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011627995,0.0018699865,0.94532734,0.00046780938,0.0002261038,0.0012888107,0.000015040695,0.00007708067,0.0008227847,0.000039674014,0.00084718165,0.037390165],"study_design_scores_gemma":[0.016153308,0.11043108,0.8626702,0.0005350293,0.00041748476,0.0008497381,0.000019296675,0.00050673756,0.006495342,0.00007152415,0.0017432492,0.00010704991],"about_ca_topic_score_codex":0.000021092797,"about_ca_topic_score_gemma":0.000014312927,"teacher_disagreement_score":0.1085611,"about_ca_system_score_codex":0.00006482637,"about_ca_system_score_gemma":0.00038426116,"threshold_uncertainty_score":0.9836318},"labels":[],"label_agreement":null},{"id":"W2591225160","doi":"10.1200/jco.2016.34.3_suppl.2","title":"Survivorship workshop delivery to primary care providers.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; University Health Network; McGill University; McGill University Health Centre","funders":"","keywords":"Survivorship curve; Medicine; Cancer survivorship; Family medicine; Accreditation; Population; Likert scale; Gerontology; Nursing; Medical education; Psychology; Environmental health","score_opus":0.11390420852838033,"score_gpt":0.4309644819259243,"score_spread":0.31706027339754395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591225160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9413053,0.0016128736,0.0006376229,0.03838091,0.0049413084,0.00026622077,0.0000065685545,0.000023467888,0.012825729],"genre_scores_gemma":[0.98009735,0.00054953346,0.0011407663,0.013329058,0.0030221564,0.0000056724716,0.0000017688768,0.000025662954,0.0018280175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967502,0.00043162107,0.0017780534,0.00024150644,0.00048958755,0.00030907788],"domain_scores_gemma":[0.99387634,0.0032824038,0.00078472076,0.00029682097,0.0009815716,0.0007781562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022893033,0.00015207897,0.0013406205,0.000157484,0.00003183059,0.000010170947,0.00024035512,0.00045215912,0.00022593932],"category_scores_gemma":[0.0033029884,0.000086969325,0.00063980493,0.00019066207,0.00014672127,0.0001468939,0.0000914058,0.0006754319,0.0000919203],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007614556,0.0003720368,0.11702436,0.000097171134,0.00019699923,0.0007445138,0.0007515636,0.0000012617081,0.00038289945,0.00005606507,0.018605558,0.85415304],"study_design_scores_gemma":[0.0071695778,0.010736972,0.26879045,0.0008081619,0.0003720739,0.00030839816,0.0018095272,5.356588e-7,0.00020328502,0.0001851858,0.70939726,0.0002186015],"about_ca_topic_score_codex":0.00008808987,"about_ca_topic_score_gemma":0.0018072454,"teacher_disagreement_score":0.8539344,"about_ca_system_score_codex":0.00047614495,"about_ca_system_score_gemma":0.002688384,"threshold_uncertainty_score":0.47690776},"labels":[],"label_agreement":null},{"id":"W2591225238","doi":"10.1200/jco.2011.29.15_suppl.e11082","title":"Cognitive function and predictors for mild cognitive impairment in women receiving adjuvant hormone therapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cognition; Montreal Cognitive Assessment; Breast cancer; Cancer; Tamoxifen; Cognitive test; Internal medicine; Cognitive impairment; Psychiatry","score_opus":0.13114519690599405,"score_gpt":0.42139378529587784,"score_spread":0.29024858838988377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591225238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214554,0.0030383214,0.00039113298,0.0010131493,0.00095662725,0.0011700373,0.000018812665,0.000014954301,0.001251431],"genre_scores_gemma":[0.9886296,0.007551216,0.00028390734,0.0025769714,0.0007121739,0.00011463627,0.0000033481774,0.000025593774,0.00010259098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688894,0.00033863244,0.0018362685,0.00027810104,0.000269315,0.00038873844],"domain_scores_gemma":[0.9940019,0.003437838,0.0012936316,0.00006242693,0.0008575412,0.00034665523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034406674,0.00020563911,0.0014252727,0.00026014267,0.000063536674,0.0000055115415,0.000055360717,0.00033311322,0.00011206633],"category_scores_gemma":[0.0036851123,0.00015241592,0.00026903767,0.00017365435,0.00031985732,0.00016778734,0.00005261598,0.0008615831,0.000004508545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19545291,0.0052925465,0.41782302,0.000054073615,0.0031426551,0.0001788342,0.005557859,3.2245345e-7,0.000086404325,0.000009444018,0.0020053873,0.37039655],"study_design_scores_gemma":[0.041327607,0.08177608,0.86860263,0.00055905804,0.00064112054,0.00008503331,0.0051382883,0.000013738861,0.00005290464,0.0006385577,0.0010372006,0.00012779405],"about_ca_topic_score_codex":0.000018496068,"about_ca_topic_score_gemma":0.00002463044,"teacher_disagreement_score":0.45077962,"about_ca_system_score_codex":0.00028248597,"about_ca_system_score_gemma":0.0006583535,"threshold_uncertainty_score":0.62153405},"labels":[],"label_agreement":null},{"id":"W2591230159","doi":"10.1200/jco.2016.34.4_suppl.648","title":"Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Baker Hughes (Canada); Western University; Juravinski Hospital; Alberta Health Services; Queen's University; University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Cardiorespiratory fitness; Physical therapy; Randomized controlled trial; Colorectal cancer; Metabolic equivalent; Psychological intervention; Physical activity; Internal medicine; Cancer","score_opus":0.14565774882309115,"score_gpt":0.4838932285964171,"score_spread":0.3382354797733259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591230159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97458124,0.00069390313,0.0000027084884,0.021749267,0.0013371931,0.0014927594,0.0000568368,0.000011775059,0.000074287775],"genre_scores_gemma":[0.9968411,0.0020638856,0.000039324375,0.00020536243,0.0007588443,0.000033103373,0.0000025605007,0.000016040303,0.00003978855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957611,0.0016105003,0.0015550262,0.00034413612,0.0004712061,0.00025802222],"domain_scores_gemma":[0.98978937,0.007535868,0.0018312377,0.00031029384,0.00023983329,0.00029341597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003867284,0.00017401429,0.0020851933,0.00006262283,0.00003302253,0.0000058816386,0.00016720127,0.00043090316,0.00002295581],"category_scores_gemma":[0.0031885924,0.00009139525,0.00033934053,0.0001787453,0.00034197507,0.0000674543,0.000047243273,0.001052008,0.0000015759741],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3176494,0.007920724,0.015481951,0.00013810952,0.00023654602,0.00006394294,0.0012432608,0.0000016138466,0.00040443902,0.000017806577,0.00035701203,0.6564852],"study_design_scores_gemma":[0.1065843,0.025198504,0.86427575,0.0013393451,0.00023887266,0.0000034368268,0.00013876004,0.000014988891,0.0007107167,0.0006041972,0.00078576006,0.00010535973],"about_ca_topic_score_codex":0.0048023025,"about_ca_topic_score_gemma":0.018916935,"teacher_disagreement_score":0.8487938,"about_ca_system_score_codex":0.00034421356,"about_ca_system_score_gemma":0.0013907581,"threshold_uncertainty_score":0.9989853},"labels":[],"label_agreement":null},{"id":"W2591236790","doi":"10.1200/jco.2014.32.3_suppl.460","title":"Predictors of radiotherapy-related gastrointestinal toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Radiation therapy; Supine position; Adverse effect; Acute toxicity; Internal medicine; Colorectal cancer; Proportional hazards model; Logistic regression; Cancer; Oncology; Gastroenterology; Urology; Nuclear medicine; Toxicity","score_opus":0.04831937755960083,"score_gpt":0.40083398258414454,"score_spread":0.35251460502454374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591236790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478865,0.0007224181,0.00049407117,0.0016527012,0.0006163525,0.00008739654,0.000059488062,0.000007912325,0.0015710287],"genre_scores_gemma":[0.99587536,0.00024034092,0.0020449022,0.00066200027,0.0010028624,0.0000010948257,0.000012727998,0.00001384802,0.00014687718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952996,0.00054975995,0.003207777,0.00023227226,0.0004804356,0.00023016425],"domain_scores_gemma":[0.9932578,0.0024685147,0.0029960708,0.00021571231,0.0006343403,0.00042754112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022960624,0.00017629344,0.0028629424,0.0003914085,0.000024817467,0.0000034503178,0.00023028703,0.00028666612,0.0021057343],"category_scores_gemma":[0.002087387,0.00012487365,0.0014925236,0.0006058714,0.00045099927,0.00007534584,0.000048207366,0.0011029242,0.0000016218864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005215125,0.001178547,0.94268304,0.00003212417,0.0046393527,0.00012797426,0.00014021993,0.0002751192,0.00966446,0.000034972687,0.0012424699,0.034766622],"study_design_scores_gemma":[0.0055840053,0.015223215,0.96609956,0.00017785655,0.004573136,0.00011773489,0.00006594354,0.0046462542,0.0006274332,0.0001496771,0.002639987,0.00009517941],"about_ca_topic_score_codex":0.0003272218,"about_ca_topic_score_gemma":0.00048860343,"teacher_disagreement_score":0.03467144,"about_ca_system_score_codex":0.00013524183,"about_ca_system_score_gemma":0.0012625322,"threshold_uncertainty_score":0.9988065},"labels":[],"label_agreement":null},{"id":"W2591237872","doi":"10.1200/jco.2011.29.4_suppl.364","title":"The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis.","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Hazard ratio; Colorectal cancer; Internal medicine; Oncology; Systematic review; Proportional hazards model; Survival analysis; Cancer; Surgery; Confidence interval; MEDLINE","score_opus":0.29764185013394173,"score_gpt":0.5589222168684334,"score_spread":0.2612803667344916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591237872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022908887,0.99530554,4.972001e-7,0.0011778917,0.00012873979,0.0022113714,0.00004693849,0.0000026537741,0.0008972807],"genre_scores_gemma":[0.00030014836,0.99819857,0.00003092413,0.00052342453,0.000121130484,0.00019296471,0.0000021455755,0.000025787916,0.00060493045],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99222124,0.0017356898,0.0051439665,0.00029546503,0.0003454163,0.0002582341],"domain_scores_gemma":[0.988613,0.005333818,0.0050364095,0.00030019705,0.00043158347,0.0002849699],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0059921755,0.00043420185,0.027836606,0.00026962187,0.000035873974,0.000007520157,0.00027452837,0.00033766835,0.00060416193],"category_scores_gemma":[0.0025644575,0.00016259584,0.007581254,0.00061179197,0.00017513573,0.000025849584,0.00007008665,0.00085637503,0.000016383874],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023279332,0.0015720901,0.00020852988,0.11149087,0.7115892,0.00018151362,0.000113852424,0.0000017077436,8.298162e-8,0.000009217092,0.0026194865,0.16988553],"study_design_scores_gemma":[0.0014163575,0.017003464,0.0023770512,0.023820104,0.8971423,0.000103691265,0.000010509604,0.0000014939142,8.717884e-8,0.000010374879,0.0579444,0.00017016439],"about_ca_topic_score_codex":0.00019824415,"about_ca_topic_score_gemma":0.00040710848,"teacher_disagreement_score":0.18555312,"about_ca_system_score_codex":0.00052727736,"about_ca_system_score_gemma":0.0018530118,"threshold_uncertainty_score":0.98659617},"labels":[],"label_agreement":null},{"id":"W2591241287","doi":"10.1200/jco.2013.31.26_suppl.64","title":"Impact of endocrine therapy in early-stage breast cancer on time to locoregional recurrence.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Statistics Canada; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Lumpectomy; Tamoxifen; Cancer; Lymph node; Internal medicine; Stage (stratigraphy); Oncology; Univariate analysis; Median follow-up; Gynecology; Surgery; Chemotherapy; Mastectomy; Multivariate analysis","score_opus":0.13539720691474938,"score_gpt":0.5325383420881753,"score_spread":0.3971411351734259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591241287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98333395,0.00019826757,0.000002090632,0.013460277,0.00045686492,0.0003662063,0.000015220273,0.000003307622,0.0021638442],"genre_scores_gemma":[0.9941306,0.0013382685,0.00015654706,0.0020760223,0.0010158435,0.000020873485,0.000001969834,0.000011771541,0.0012481086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978422,0.00022607394,0.0013194383,0.00014856103,0.00022882418,0.00023492867],"domain_scores_gemma":[0.9973299,0.0010212425,0.00078870263,0.000115366514,0.00037161866,0.00037319295],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005835228,0.00013408775,0.0011767723,0.00021068064,0.000010205016,0.0000033074996,0.00013034775,0.00015328881,0.012151527],"category_scores_gemma":[0.00018727838,0.00008218344,0.00046214528,0.00018711168,0.00011918582,0.000075697426,0.000022317028,0.000619701,0.00017932683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016423743,0.004784027,0.61066484,0.0000071131285,0.0005091957,0.00025312518,0.00010876203,0.000105649226,0.0010671638,0.000009381715,0.03007228,0.33599472],"study_design_scores_gemma":[0.010620476,0.039104175,0.9368701,0.000078176265,0.00005618996,0.00014865382,0.0000060669704,0.000047028934,0.00006863377,0.000054839875,0.012881552,0.00006411956],"about_ca_topic_score_codex":0.0007461918,"about_ca_topic_score_gemma":0.000059092294,"teacher_disagreement_score":0.3359306,"about_ca_system_score_codex":0.00031524926,"about_ca_system_score_gemma":0.0013139648,"threshold_uncertainty_score":0.9887515},"labels":[],"label_agreement":null},{"id":"W2591246871","doi":"10.1200/jco.2016.34.2_suppl.455","title":"Impact of multidisciplinary bladder cancer care for muscle invasive bladder cancer: A propensity score matched analysis of survival outcomes.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Propensity score matching; Radiation therapy; Comorbidity; Proportional hazards model; Cancer; Cohort; Internal medicine; Urology; Surgery; Oncology","score_opus":0.20110187636747193,"score_gpt":0.5000804061531497,"score_spread":0.29897852978567785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591246871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942206,0.0009481569,0.00013908504,0.0023891993,0.00085606874,0.00069212605,0.00051606627,0.0000070489536,0.00023161771],"genre_scores_gemma":[0.9967102,0.0016721213,0.0005951865,0.00020523157,0.00046757894,0.000040208924,0.0000091110205,0.00003217173,0.00026819986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996063,0.00028856855,0.0024908348,0.00032696902,0.00048970344,0.00034095556],"domain_scores_gemma":[0.99209684,0.0022150627,0.0027636716,0.00036709197,0.0021528364,0.00040450224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010134599,0.0002667207,0.0040686387,0.0003084696,0.00004662811,0.0000037662764,0.00024161531,0.00040002604,0.0006869198],"category_scores_gemma":[0.0014083022,0.00013542594,0.002541443,0.000400314,0.00036758438,0.00013064123,0.00009767464,0.000340489,0.0000018140892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070118182,0.0015592565,0.9184066,0.000102076076,0.018769618,0.000068329864,0.0007604436,0.00009355892,0.0023468465,0.00000411028,0.00047269717,0.05040465],"study_design_scores_gemma":[0.015585892,0.010271705,0.96036595,0.00022946732,0.012062199,0.000007903197,0.00030192165,0.000020848014,0.00072926236,0.000051354524,0.00023409876,0.0001394066],"about_ca_topic_score_codex":0.0020503404,"about_ca_topic_score_gemma":0.005452364,"teacher_disagreement_score":0.050265245,"about_ca_system_score_codex":0.00056084775,"about_ca_system_score_gemma":0.006149406,"threshold_uncertainty_score":0.9994848},"labels":[],"label_agreement":null},{"id":"W2591251711","doi":"10.1200/jco.2016.34.7_suppl.203","title":"Quality improvement strategies in medical oncology: A qualitative analysis from a scoping review.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Inclusion (mineral); MEDLINE; Telehealth; Quality management; Health care; Quality (philosophy); Medical education; Qualitative research; Telemedicine; Psychology","score_opus":0.2551898100796035,"score_gpt":0.5495223371144882,"score_spread":0.29433252703488466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591251711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.864373,0.030707462,0.021256855,0.05158058,0.0023343551,0.00047368216,0.00014756412,0.000013035263,0.029113436],"genre_scores_gemma":[0.93776137,0.052076146,0.0017653458,0.0075018024,0.00076019805,0.000015831863,0.0000025453303,0.000012963299,0.00010379638],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.990922,0.0005904282,0.007644183,0.0003790587,0.00012970745,0.00033464478],"domain_scores_gemma":[0.986538,0.006052276,0.006557174,0.0002747081,0.00019125997,0.00038659864],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.02213427,0.00016727162,0.003805249,0.00031979228,0.000027848419,0.000018632274,0.0004676973,0.0005447088,0.0022544896],"category_scores_gemma":[0.01553061,0.0001222695,0.0008707837,0.0003271181,0.00031284458,0.0005531506,0.00009214065,0.0006454925,0.000118768614],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001799559,0.0022385234,0.16508414,0.0003332627,0.003189347,0.0002788409,0.0023376634,0.000019688343,0.00002059057,0.07457247,0.0039972696,0.7461286],"study_design_scores_gemma":[0.021650422,0.011226184,0.5145829,0.01024876,0.0005598062,0.000015102311,0.0031194957,0.00011235543,0.000019287167,0.34527367,0.09213687,0.001055161],"about_ca_topic_score_codex":0.0008629411,"about_ca_topic_score_gemma":0.0040890826,"teacher_disagreement_score":0.7450735,"about_ca_system_score_codex":0.0006025695,"about_ca_system_score_gemma":0.0026268095,"threshold_uncertainty_score":0.9986576},"labels":[],"label_agreement":null},{"id":"W2591256239","doi":"10.1200/jco.2013.31.15_suppl.e20639","title":"Patients’ perceptions of early palliative oncology care: A qualitative analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palliative care; Referral; Family medicine; Qualitative research; Focus group; Oncology; Intervention (counseling); Grounded theory; Internal medicine; Nursing","score_opus":0.35479636619545246,"score_gpt":0.6218203949452622,"score_spread":0.26702402874980974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591256239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897374,0.0006629026,0.0006995084,0.002027412,0.0004534823,0.0002505015,0.000022895902,0.0000051372303,0.006140757],"genre_scores_gemma":[0.98208743,0.0011938467,0.015427651,0.00074332854,0.00035031672,0.00000858588,0.000015912903,0.000011565894,0.00016135153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432653,0.0014581996,0.003326204,0.00019375463,0.00047262586,0.00022268484],"domain_scores_gemma":[0.9846487,0.0068608252,0.0036317308,0.00021125676,0.0042847595,0.00036273673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001731805,0.00015968346,0.0029554972,0.00038526527,0.000028391143,0.0000034644033,0.00019683327,0.000474573,0.000666046],"category_scores_gemma":[0.0076568173,0.00011199168,0.0012757239,0.00053107395,0.0006048504,0.00014555207,0.000055409004,0.00082061713,0.00004387534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014187297,0.0022046703,0.9086484,0.00005789991,0.0037934526,0.00003065333,0.045992732,0.000015904332,0.00013028625,0.00018505703,0.0028956821,0.034626536],"study_design_scores_gemma":[0.0056745512,0.027811581,0.91530496,0.00016791101,0.0026803166,0.00000248515,0.033738915,0.000021049504,0.00006443822,0.00045776833,0.013975709,0.000100296136],"about_ca_topic_score_codex":0.0003493261,"about_ca_topic_score_gemma":0.00012048892,"teacher_disagreement_score":0.03452624,"about_ca_system_score_codex":0.00026478324,"about_ca_system_score_gemma":0.0012710994,"threshold_uncertainty_score":0.91664785},"labels":[],"label_agreement":null},{"id":"W2591265870","doi":"10.1200/jco.2016.34.3_suppl.115","title":"Patterns of health care-related multimorbidity among breast cancer survivors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Cancer; Cancer registry; Cohort; Medical diagnosis; Health care; Disease; Population; Pediatrics; Diagnosis code; Family medicine; Internal medicine; Environmental health; Pathology","score_opus":0.10108717304348415,"score_gpt":0.46089851566326395,"score_spread":0.3598113426197798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591265870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828122,0.0009519974,0.00017405346,0.012549255,0.002533476,0.00017055019,0.00008854199,0.000008780231,0.0007110985],"genre_scores_gemma":[0.9930685,0.0037110758,0.00028013988,0.0019632878,0.0006697544,0.0000021884882,0.0000034389977,0.000017337416,0.0002842819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545354,0.0006303104,0.0031273742,0.00018786301,0.00033712146,0.00026380332],"domain_scores_gemma":[0.9945585,0.0012254281,0.002970998,0.00021940569,0.0005923901,0.00043329305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026184556,0.00013402064,0.0019055528,0.00011220411,0.00003119566,0.0000021085052,0.00016890107,0.000335462,0.0017422149],"category_scores_gemma":[0.0006622739,0.00007639195,0.00055974163,0.0000830564,0.00021566922,0.00014101717,0.000043720072,0.00065464,0.0000072346584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010561832,0.00029881793,0.62265617,0.00006213374,0.0002406736,0.00006604138,0.00017193191,0.0000034266875,0.00011611335,0.0000074486325,0.0013041967,0.37401685],"study_design_scores_gemma":[0.009406936,0.0033125032,0.9642565,0.0003503973,0.00012702965,0.00012897955,0.00016039904,0.000013671767,0.00008303967,0.000012801934,0.022067612,0.00008011186],"about_ca_topic_score_codex":0.0023356953,"about_ca_topic_score_gemma":0.0019337335,"teacher_disagreement_score":0.37393674,"about_ca_system_score_codex":0.00046341802,"about_ca_system_score_gemma":0.0038885141,"threshold_uncertainty_score":0.9991703},"labels":[],"label_agreement":null},{"id":"W2591267069","doi":"10.1200/jco.2015.33.3_suppl.670","title":"Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Oxaliplatin; Bevacizumab; Internal medicine; Regimen; Folinic acid; Gastroenterology; Colorectal cancer; Surgery; Chemotherapy; Cancer","score_opus":0.19443641690474334,"score_gpt":0.4799617446662262,"score_spread":0.28552532776148287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591267069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154365,0.0010879869,0.000042464373,0.0030795983,0.0018184155,0.0019855143,0.000030335827,0.000004508877,0.0004075193],"genre_scores_gemma":[0.9984698,0.00081175583,0.00016599872,0.00011403988,0.00029482672,0.00006780886,0.0000017685346,0.000015749394,0.000058202266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99487275,0.0011041075,0.0029518055,0.000230158,0.00062508805,0.00021610527],"domain_scores_gemma":[0.9920277,0.0032734133,0.003517322,0.00024067266,0.00078746094,0.00015340382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004791746,0.00022312044,0.0027468617,0.00010576472,0.000081412785,0.0000052178525,0.00023110159,0.000139214,0.000018926643],"category_scores_gemma":[0.004504675,0.00009288548,0.0005854797,0.00039383728,0.000582044,0.00009795965,0.000086677544,0.0007183168,1.9252207e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86810434,0.010890702,0.0020420693,0.000015845293,0.0024163313,0.00005975259,0.0029440275,0.00038548035,0.00020073113,0.000007978097,0.00010132489,0.11283143],"study_design_scores_gemma":[0.9221417,0.05901236,0.012467851,0.00013230024,0.0020290806,0.00004411875,0.0020802051,0.00072798436,0.00071802794,0.000055060224,0.00049217325,0.00009916888],"about_ca_topic_score_codex":0.0017817663,"about_ca_topic_score_gemma":0.006470361,"teacher_disagreement_score":0.11273226,"about_ca_system_score_codex":0.00044832667,"about_ca_system_score_gemma":0.0024610055,"threshold_uncertainty_score":0.5392842},"labels":[],"label_agreement":null},{"id":"W2591267078","doi":"10.1200/jco.2016.34.7_suppl.95","title":"Electronic operative reports to support quality improvement and patient-centered care.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Imaging in Medicine","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Quality assurance; Patient care; Medical physics; General surgery; Medical emergency; Family medicine; Surgery; Nursing","score_opus":0.09110466044957982,"score_gpt":0.5065715237356023,"score_spread":0.4154668632860225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591267078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695956,0.00021420734,0.0002865955,0.023352213,0.001223415,0.0003171879,0.0000028806865,0.000009907568,0.0049979663],"genre_scores_gemma":[0.98638403,0.00016905558,0.0011731794,0.0113208955,0.000456408,0.000004598235,0.0000014058113,0.000014038855,0.0004763695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960622,0.00018667588,0.0027560685,0.000253928,0.00042932088,0.00031179923],"domain_scores_gemma":[0.996294,0.0007760747,0.0013095025,0.00024404773,0.00075887336,0.0006174962],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023848738,0.00013023405,0.0011918844,0.000093171664,0.0000208852,0.000009608365,0.00007908661,0.00013503295,0.00011839394],"category_scores_gemma":[0.008438133,0.000069665315,0.00020091812,0.00006846512,0.0002008335,0.00015458844,0.00009376177,0.0004445972,0.00001241613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020451655,0.00071963127,0.07536632,0.000021610978,0.00021941055,0.0013450403,0.00038834353,1.7117003e-7,0.005418652,0.00006337913,0.010161968,0.9042503],"study_design_scores_gemma":[0.014421331,0.1583288,0.1973222,0.00045266433,0.0003455893,0.0029170436,0.0013305511,0.0000011441149,0.0035491632,0.00063478836,0.6204645,0.00023221952],"about_ca_topic_score_codex":0.000008804341,"about_ca_topic_score_gemma":0.000016691773,"teacher_disagreement_score":0.9040181,"about_ca_system_score_codex":0.00034329144,"about_ca_system_score_gemma":0.0016210321,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W2591276039","doi":"10.1200/jco.2015.33.29_suppl.95","title":"Correlations between functional Interleukin-1 and changes in fatigue and quality of life in children and adolescents with cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Cancer-related fatigue; Confounding; Cancer; Quality of life (healthcare); Correlation; Immune system; Internal medicine; Population; Interleukin; Oncology; Cytokine; Immunology; Environmental health","score_opus":0.28384200884063776,"score_gpt":0.4883261246266858,"score_spread":0.20448411578604803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591276039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98796606,0.0013204708,0.00008048496,0.010197806,0.00018987754,0.00017722714,0.000012304825,0.0000026235261,0.0000531152],"genre_scores_gemma":[0.99740773,0.00057355367,0.00036968646,0.0010991744,0.0005259577,0.0000022191646,0.0000031727268,0.0000075880253,0.000010912612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972944,0.0005332543,0.0015846888,0.0001661618,0.00030100686,0.00012048391],"domain_scores_gemma":[0.9972487,0.00093805924,0.0011376272,0.000083058854,0.0002002055,0.00039235348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038271255,0.000099793986,0.0012550673,0.00016605781,0.000012356787,0.000004609156,0.000049671024,0.00020604514,0.000007694538],"category_scores_gemma":[0.002715823,0.00007580375,0.00004264011,0.00012193396,0.0003267816,0.00009096563,0.00005452615,0.0007009582,1.8297821e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025207975,0.0003175426,0.98624545,0.00005750745,0.00010931215,0.0000049490172,0.00063822203,0.000009054621,0.0000031317861,0.000020486932,0.00015513774,0.009918397],"study_design_scores_gemma":[0.013507999,0.0032924695,0.98168546,0.00064591574,0.00009091376,0.00004264604,0.00042378454,0.000013744456,0.0000029344394,0.000110187095,0.00011458797,0.00006933432],"about_ca_topic_score_codex":0.0014842332,"about_ca_topic_score_gemma":0.011278461,"teacher_disagreement_score":0.010987202,"about_ca_system_score_codex":0.0000816615,"about_ca_system_score_gemma":0.0009923766,"threshold_uncertainty_score":0.6293646},"labels":[],"label_agreement":null},{"id":"W2591280060","doi":"10.1200/jco.2009.27.15_suppl.e17505","title":"Interobserver and interlaboratory variability of mismatch repair protein expression in ovarian tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health","funders":"","keywords":"Concordance; MSH6; MSH2; Medicine; Immunohistochemistry; MLH1; Tissue microarray; Pathology; Ovarian cancer; Oncology; DNA mismatch repair; Internal medicine; Cancer; Colorectal cancer","score_opus":0.07407134858911846,"score_gpt":0.42865771314893564,"score_spread":0.3545863645598172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591280060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953498,0.00016399342,0.00012998507,0.0025854162,0.00049675064,0.0002804481,0.0000011680921,0.0000068816603,0.0009855058],"genre_scores_gemma":[0.9802243,0.000028275397,0.018478159,0.0009730749,0.00024304377,0.0000026634186,3.225565e-7,0.000007538059,0.000042619096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608755,0.00076154876,0.0025451302,0.000203649,0.0002480438,0.00015406041],"domain_scores_gemma":[0.9970163,0.0008048323,0.0012192203,0.00022833742,0.000500241,0.00023103869],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048946696,0.000114592876,0.0012743558,0.00011055477,0.0000083086015,0.0000027523915,0.00012851048,0.0003678074,0.00010760034],"category_scores_gemma":[0.0093512405,0.00008224371,0.00022946262,0.0001510247,0.00019868644,0.00007605056,0.00005677103,0.0009144379,9.3769853e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018722937,0.005708574,0.677971,0.0002510722,0.00013439388,0.00062890636,0.00075774733,0.000011670644,0.23886245,0.00007644948,0.0031035477,0.05377126],"study_design_scores_gemma":[0.004762702,0.021706495,0.95303047,0.00071640447,0.000056957007,0.00010728021,0.00013365793,0.000038972794,0.015797105,0.0014875323,0.002081169,0.000081273814],"about_ca_topic_score_codex":0.000007890724,"about_ca_topic_score_gemma":0.000019843048,"teacher_disagreement_score":0.27505946,"about_ca_system_score_codex":0.00017833184,"about_ca_system_score_gemma":0.0008665288,"threshold_uncertainty_score":0.9989934},"labels":[],"label_agreement":null},{"id":"W2591291913","doi":"10.1200/jco.2012.30.34_suppl.300","title":"Developing an IT infrastructure for the National Radiation Oncology Registry.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Varian Medical Systems (Canada)","funders":"","keywords":"Interoperability; Medicine; Data collection; Usability; Electronic data capture; Computer science; Data science; World Wide Web; Clinical trial; Internal medicine","score_opus":0.17472451626305782,"score_gpt":0.5182119112359214,"score_spread":0.3434873949728635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591291913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5573956,0.0019840843,0.04307137,0.33098283,0.013108856,0.0011003133,0.000041783645,0.000048646332,0.052266523],"genre_scores_gemma":[0.9520272,0.0001637341,0.025299892,0.015624177,0.0067410055,0.0000058707637,0.000011655894,0.000011235543,0.000115232986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792165,0.00016028079,0.0012793367,0.000096457625,0.00030893198,0.0002333564],"domain_scores_gemma":[0.9945587,0.003099853,0.0013350473,0.00008854726,0.00063350034,0.00028435036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046062293,0.00009290797,0.0006022258,0.00011255265,0.00007712749,0.00001571091,0.00017227458,0.00027671424,0.000042005366],"category_scores_gemma":[0.0055873096,0.00005508304,0.00037273622,0.00015281876,0.00018543782,0.0004341647,0.000021770928,0.0006076024,0.0000035483808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001595059,0.00053273863,0.05559433,0.000017555662,0.00034091392,0.000013472226,0.0001801994,0.00002836264,0.00002830751,0.004829591,0.04070172,0.8961378],"study_design_scores_gemma":[0.0024731827,0.0021743902,0.32089347,0.000022402617,0.00015727527,0.0013527116,0.00020172147,0.00014554332,0.000015391748,0.0020815134,0.67043,0.000052394833],"about_ca_topic_score_codex":0.0000018241553,"about_ca_topic_score_gemma":0.0000030860901,"teacher_disagreement_score":0.8960854,"about_ca_system_score_codex":0.0002410668,"about_ca_system_score_gemma":0.0023691948,"threshold_uncertainty_score":0.6688935},"labels":[],"label_agreement":null},{"id":"W2591292174","doi":"10.1200/jco.2014.32.4_suppl.5","title":"Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Randomized controlled trial; Quality of life (healthcare); Prostate cancer; Androgen deprivation therapy; Radiation therapy; Randomization; Physical therapy; Hormonal therapy; Internal medicine; Cancer","score_opus":0.5028771619613998,"score_gpt":0.585498264006893,"score_spread":0.08262110204549322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591292174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745221,0.0014747328,0.0013509231,0.0179028,0.0026215112,0.0012101287,0.00023870543,0.000005299412,0.0006738061],"genre_scores_gemma":[0.9906558,0.0039335154,0.0016185448,0.0024369091,0.0011607697,0.000043414184,0.000007715759,0.000018061342,0.00012526175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.94378775,0.008873595,0.046391945,0.00039885592,0.00021650337,0.00033136795],"domain_scores_gemma":[0.8821469,0.047596324,0.06886576,0.0005074342,0.0004661442,0.0004174562],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.26768285,0.00018464726,0.009797892,0.00045160792,0.000038055747,0.000011725563,0.00043377114,0.00047563956,0.000151932],"category_scores_gemma":[0.2441429,0.00017360714,0.0008978772,0.00020958543,0.00042123027,0.00027600676,0.00005894824,0.0007764913,0.000029151644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85141325,0.0031004753,0.122712046,0.00030358759,0.0005422844,0.0000029281025,0.00092027267,0.00034870332,0.0000017957209,0.008590952,0.0024002448,0.009663471],"study_design_scores_gemma":[0.91266197,0.004058436,0.06831794,0.00016053453,0.000065084394,0.0000013804456,0.00008939628,0.0008048371,0.0000034209338,0.011044335,0.0026299094,0.00016277476],"about_ca_topic_score_codex":0.005055026,"about_ca_topic_score_gemma":0.0016610353,"teacher_disagreement_score":0.061640855,"about_ca_system_score_codex":0.00030267626,"about_ca_system_score_gemma":0.0018395677,"threshold_uncertainty_score":0.76417214},"labels":[],"label_agreement":null},{"id":"W2591296020","doi":"10.1200/jco.2016.34.2_suppl.209","title":"BPS-001, a complex biologic agent extracted from the medicinal leech (<i>Huridinaria manillensis</i>) for treatment of metastatic castration-resistant prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Leech Biology and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"LNCaP; Prostate cancer; Medicine; Angiogenesis; Tramp; Docetaxel; In vivo; CD31; Cancer research; Androgen receptor; Pharmacology; Cancer; Internal medicine; Biology","score_opus":0.32177407924986484,"score_gpt":0.5057638083041082,"score_spread":0.18398972905424332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591296020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90642214,0.0013493921,0.00056163047,0.08976191,0.0005337217,0.0009072379,0.00031036406,0.00000981297,0.00014375953],"genre_scores_gemma":[0.98959255,0.0027081429,0.0049359277,0.0014599222,0.0008366754,0.000086079985,0.000039849834,0.00001067003,0.00033018508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969232,0.00042733017,0.0020365363,0.00021775068,0.000174535,0.00022065912],"domain_scores_gemma":[0.98993367,0.0071146195,0.0019673773,0.00024151357,0.0005573281,0.00018548575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014044811,0.00016003959,0.001293642,0.000045437948,0.000091281574,0.0000034728369,0.00016507633,0.00021340874,0.00034607656],"category_scores_gemma":[0.0013568719,0.000064228334,0.00037078396,0.00008814692,0.0005164621,0.00004073957,0.000018603307,0.00017632227,0.00000828697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029448956,0.008683981,0.04530449,0.00005215623,0.004304068,0.0003617104,0.0004893455,0.000006799038,0.31221718,0.0022333143,0.023935597,0.5729624],"study_design_scores_gemma":[0.027111152,0.04004379,0.5097458,0.00019083348,0.0027630988,0.00024810995,0.00041994135,0.00004560383,0.0029987087,0.0041646217,0.41210952,0.00015883044],"about_ca_topic_score_codex":0.00016395084,"about_ca_topic_score_gemma":0.00035476926,"teacher_disagreement_score":0.5728036,"about_ca_system_score_codex":0.0001817748,"about_ca_system_score_gemma":0.0012598374,"threshold_uncertainty_score":0.37892956},"labels":[],"label_agreement":null},{"id":"W2591301926","doi":"10.1200/jco.2013.31.31_suppl.280","title":"Consensus development: Within general oncology practice, what constitutes high-quality palliative care delivery?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Palliative care; Psychosocial; Delphi method; Referral; Scope (computer science); Scale (ratio); Scope of practice; Nursing; Multidisciplinary approach; Family medicine; Quality of life (healthcare); Oncology; Health care","score_opus":0.42010627858335886,"score_gpt":0.5854569823283318,"score_spread":0.1653507037449729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591301926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96977127,0.0074794167,0.0001608465,0.01212705,0.0031431594,0.00037108563,0.000006368683,0.000015848687,0.006924983],"genre_scores_gemma":[0.7848774,0.008039621,0.1969089,0.008597753,0.0012568118,0.000012207222,0.000017042661,0.000020730828,0.0002695246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931395,0.0014974527,0.004181342,0.00029037675,0.0005580951,0.00033323414],"domain_scores_gemma":[0.97497797,0.013864174,0.0052959966,0.0002500394,0.005004296,0.0006075128],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003277892,0.0002466924,0.0025021483,0.00015796267,0.00007339537,0.00002408292,0.00022549806,0.0007116105,0.00026254848],"category_scores_gemma":[0.020452352,0.00017801096,0.00041119178,0.00016839354,0.00089886633,0.00041866198,0.00010060596,0.0012940372,0.00010254679],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011946995,0.004395721,0.31129158,0.00037833911,0.005105634,0.0033072657,0.016455043,0.00013212462,0.0018048348,0.005155576,0.019453611,0.6205733],"study_design_scores_gemma":[0.015913341,0.012074159,0.16650863,0.0011569978,0.0009430221,0.0003079389,0.030835537,0.00002977598,0.0043020397,0.00066567754,0.7669003,0.00036261027],"about_ca_topic_score_codex":0.00028277346,"about_ca_topic_score_gemma":0.00016186977,"teacher_disagreement_score":0.74744666,"about_ca_system_score_codex":0.00050449604,"about_ca_system_score_gemma":0.007325942,"threshold_uncertainty_score":0.9983016},"labels":[],"label_agreement":null},{"id":"W2591302822","doi":"10.1200/jco.2012.30.15_suppl.9076","title":"Paucity of core palliative care elements available to children with cancer at end-of-life: Perspectives of bereaved parents and clinicians.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Palliative care; Family medicine; Pediatric oncology; Sibling; Childhood cancer; Quality of life (healthcare); Cancer; Pediatric cancer; Nursing; Psychology; Internal medicine","score_opus":0.18580949426459664,"score_gpt":0.49414867940792195,"score_spread":0.3083391851433253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591302822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915086,0.005462245,0.000022101358,0.0013765243,0.00048261526,0.00044026517,0.00013109787,0.0000041333883,0.00057240896],"genre_scores_gemma":[0.99208915,0.0022626691,0.0037654724,0.0010053426,0.0007593264,0.0000054827233,0.000007068901,0.000021891821,0.000083595136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99514526,0.00042913237,0.0031526624,0.00025455075,0.0007085435,0.0003098461],"domain_scores_gemma":[0.9920517,0.0015779414,0.0042828675,0.00027832366,0.0011544591,0.00065468595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002626238,0.00020036717,0.0024580692,0.00012397589,0.00003583502,0.0000019584443,0.00019514549,0.00027527125,0.00045136],"category_scores_gemma":[0.003387205,0.00014466842,0.00032575664,0.00018448065,0.00052439014,0.000109982735,0.0001389915,0.000588271,0.0000039526076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007199869,0.0016700095,0.9704941,0.00016461739,0.0015722207,0.000004244718,0.010184851,0.000004083126,0.00008015443,0.000024300209,0.001854812,0.006746757],"study_design_scores_gemma":[0.008653318,0.010707396,0.9704392,0.000597492,0.0007500971,0.000011978461,0.0055346154,0.0000017527498,0.0005733815,0.00001636373,0.0025902793,0.00012411845],"about_ca_topic_score_codex":0.0013500445,"about_ca_topic_score_gemma":0.0030663079,"teacher_disagreement_score":0.009037387,"about_ca_system_score_codex":0.00024604073,"about_ca_system_score_gemma":0.0017974044,"threshold_uncertainty_score":0.58994067},"labels":[],"label_agreement":null},{"id":"W2591302983","doi":"10.1200/jco.2014.32.30_suppl.165","title":"Improving quality of care by obtaining patient-reported outcomes (PRO)-CTCAE chemotoxicities using tablet technology in daycare (DC) waiting rooms.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Adverse effect; Quality of life (healthcare); Cancer; Population; Emergency medicine; Physical therapy; Surgery; Internal medicine","score_opus":0.09529714560442472,"score_gpt":0.4497269563688385,"score_spread":0.3544298107644138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591302983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945642,0.00079695886,0.0006888991,0.0022215636,0.0006787732,0.000337104,0.0000063452208,0.00004020164,0.0006659565],"genre_scores_gemma":[0.9878119,0.000058438723,0.010769586,0.0010418858,0.00023822571,0.0000034543905,0.000006124175,0.00004819116,0.000022173208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991601,0.00070667325,0.00614659,0.00040573027,0.000620005,0.000520028],"domain_scores_gemma":[0.98845625,0.0029841638,0.006819763,0.00046122048,0.0010207149,0.00025786314],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005236956,0.00030636907,0.0033920233,0.00047101398,0.00007136368,0.000010838153,0.00029921802,0.0012676609,0.000050289815],"category_scores_gemma":[0.023687223,0.00025115712,0.00059487676,0.00047774953,0.0004491903,0.00017164566,0.00015515451,0.0023036168,0.0000010100632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016555085,0.00093885587,0.75583404,0.00030564202,0.0004668483,0.00018942151,0.0011712223,0.00014589338,0.072271526,0.000077507786,0.000103973725,0.16683955],"study_design_scores_gemma":[0.12124175,0.052032895,0.3614125,0.0060627176,0.00273397,0.0027292753,0.06387229,0.01944786,0.34993413,0.0051913955,0.012556808,0.002784423],"about_ca_topic_score_codex":0.00027474767,"about_ca_topic_score_gemma":0.00008685659,"teacher_disagreement_score":0.39442155,"about_ca_system_score_codex":0.0005780657,"about_ca_system_score_gemma":0.0012167748,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W2591310062","doi":"10.1200/jco.2016.34.26_suppl.21","title":"Systematic review of interventions to facilitate advance care planning (ACP) in cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Psychological intervention; Medicine; CINAHL; Checklist; Documentation; PsycINFO; MEDLINE; Advance care planning; Family medicine; Health care; Nursing; Palliative care; Psychology","score_opus":0.5130200227907241,"score_gpt":0.6252369539624244,"score_spread":0.11221693117170028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591310062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73051375,0.25957975,0.0009849909,0.005160483,0.0013123237,0.0008813479,0.000058994563,0.0000051853854,0.0015031897],"genre_scores_gemma":[0.9253282,0.068889536,0.003123862,0.002055926,0.000183817,0.00002984756,0.0000025797824,0.0000124202315,0.00037384374],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.99592716,0.0003799143,0.0032569582,0.00009555695,0.00022766412,0.00011277688],"domain_scores_gemma":[0.9947262,0.002154236,0.001879457,0.00012836963,0.00096707675,0.00014468227],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015046699,0.000078289624,0.0019621544,0.00011345459,0.0000059344943,5.9545465e-7,0.00012319235,0.00009101727,0.00006510695],"category_scores_gemma":[0.018982882,0.00004298577,0.00050160976,0.00012630424,0.000068188514,0.00006474097,0.0000340402,0.0002152496,0.0000066367047],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00117746,0.0011204595,0.5361276,0.4196882,0.0004458341,0.00012071012,0.0026922764,0.00001230044,0.00008257775,0.000041829146,0.003199577,0.03529115],"study_design_scores_gemma":[0.0032177009,0.006646802,0.0467699,0.9317107,0.0004889713,0.0000051273214,0.0007305861,6.202942e-7,0.000076439894,0.000034140627,0.010256846,0.00006216535],"about_ca_topic_score_codex":0.000016782022,"about_ca_topic_score_gemma":0.00004366594,"teacher_disagreement_score":0.5120225,"about_ca_system_score_codex":0.00017475714,"about_ca_system_score_gemma":0.00031409782,"threshold_uncertainty_score":0.98928064},"labels":[],"label_agreement":null},{"id":"W2591314150","doi":"10.1200/jco.2014.32.3_suppl.318","title":"Prognostic factors and long-term outcomes of resected pancreatic adenocarcinoma: A comparison between two decades.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Adenocarcinoma; Adjuvant therapy; Proportional hazards model; Perioperative; Multivariate analysis; Cohort; Univariate analysis; Retrospective cohort study; Confidence interval; Oncology; Lymph node; Survival analysis; Resection margin; Survival rate; Surgery; Cancer; Resection","score_opus":0.24998810360167098,"score_gpt":0.5320947783980153,"score_spread":0.2821066747963443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591314150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954908,0.00071492087,0.0006319779,0.001649222,0.00022671779,0.00037855547,0.0000032616088,0.00001079009,0.00089373597],"genre_scores_gemma":[0.9967299,0.0001987064,0.0022721924,0.00017963466,0.0004490775,0.0000041322073,0.0000058161727,0.000018658833,0.00014187071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945614,0.0011154748,0.0031581114,0.00023480733,0.00056364544,0.00036656272],"domain_scores_gemma":[0.9771155,0.019401917,0.00195751,0.00026666312,0.0005802789,0.0006781463],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004494607,0.00020345996,0.0042957403,0.0002718402,0.000053989614,0.000008417022,0.0002352451,0.0004884116,0.00011068403],"category_scores_gemma":[0.020949764,0.00012383919,0.00038911577,0.00018479531,0.00076281815,0.00007779861,0.00010722127,0.0013293131,0.000007227042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011248467,0.00093195215,0.98446125,0.000117160555,0.0010529333,0.000113794085,0.0001734747,4.2279612e-7,0.000063136205,0.000053000564,0.0002530317,0.011655016],"study_design_scores_gemma":[0.010001033,0.016596774,0.9699408,0.00019127649,0.0023412935,0.0001321726,0.00008482125,0.00015576991,0.000050069197,0.00023597214,0.0001738982,0.00009613779],"about_ca_topic_score_codex":0.00004462947,"about_ca_topic_score_gemma":0.000056378904,"teacher_disagreement_score":0.018286442,"about_ca_system_score_codex":0.000095688905,"about_ca_system_score_gemma":0.0011416764,"threshold_uncertainty_score":0.9872972},"labels":[],"label_agreement":null},{"id":"W2591325514","doi":"10.1200/jco.2013.31.4_suppl.485","title":"Natural history and outcomes in a population-based cohort of synchronous and metachronous colorectal cancers (CRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Cohort; Stage (stratigraphy); Proportional hazards model; Natural history; Cancer; Gastroenterology","score_opus":0.03902261487461094,"score_gpt":0.3799765414398598,"score_spread":0.34095392656524887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591325514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391145,0.0030007607,0.000007331455,0.001377562,0.00085704296,0.00029364435,0.0000021367027,0.0000037253253,0.00054638035],"genre_scores_gemma":[0.9957696,0.00035999308,0.0017061398,0.0019305154,0.00013276546,0.0000067394044,0.0000041387825,0.000009319869,0.00008074951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780774,0.00019372535,0.001508062,0.0001515632,0.00018814311,0.0001507711],"domain_scores_gemma":[0.9970305,0.0015499333,0.00094850216,0.00008906448,0.00017035884,0.00021163335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009499497,0.0001123504,0.0015054232,0.00015898784,0.000014399704,0.0000029296593,0.000062535735,0.00020397831,0.00027522448],"category_scores_gemma":[0.0010656592,0.000081697246,0.00018179652,0.00004524731,0.00025723086,0.00013309985,0.000020065103,0.0006055344,9.1236626e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010371045,0.00019660946,0.95560575,0.000050176106,0.00023304095,0.0000678475,0.000080180886,0.000027846198,0.00021911804,0.000008171794,0.00061082526,0.041863356],"study_design_scores_gemma":[0.006464266,0.0034751028,0.98559445,0.000038270588,0.00018832392,0.000078161764,0.00004532215,0.001439999,0.000012646223,0.000023430055,0.0025661672,0.000073859825],"about_ca_topic_score_codex":0.002045909,"about_ca_topic_score_gemma":0.00078789116,"teacher_disagreement_score":0.0417895,"about_ca_system_score_codex":0.0010873493,"about_ca_system_score_gemma":0.0026270174,"threshold_uncertainty_score":0.46602163},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2591327090","doi":"10.1200/jco.2013.31.15_suppl.e15518","title":"First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Temsirolimus; Everolimus; Renal cell carcinoma; Internal medicine; Refractory (planetary science); Discovery and development of mTOR inhibitors; Oncology; Clinical trial; Nephrectomy; Gastroenterology; Surgery; PI3K/AKT/mTOR pathway; Kidney","score_opus":0.11154676364097064,"score_gpt":0.401862091780227,"score_spread":0.29031532813925637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591327090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981163,0.00027161546,0.00055493176,0.016178988,0.0006503611,0.00039447102,0.00007807526,0.000009496865,0.0006990156],"genre_scores_gemma":[0.98884106,0.00015609806,0.005761681,0.003460916,0.0009970249,0.000017426759,0.0005580721,0.000020948175,0.00018674952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99455476,0.00090400985,0.0031701068,0.00038151536,0.0006976484,0.00029196026],"domain_scores_gemma":[0.9938601,0.0024708554,0.0019664548,0.00049781415,0.0007002715,0.0005044656],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002678474,0.00023927195,0.0015627426,0.00037600537,0.00005320162,0.000039663562,0.00029606547,0.00022308393,0.0034014047],"category_scores_gemma":[0.0011900939,0.00014404823,0.0006800321,0.00046774966,0.00023085033,0.0003785127,0.000119938406,0.001127964,0.0001062543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008128202,0.010439523,0.9147751,0.000027454156,0.0043967115,0.008514933,0.00049060496,0.0014186645,0.0077564013,0.000059713868,0.031654663,0.012338045],"study_design_scores_gemma":[0.013291874,0.006086932,0.9579406,0.000048817325,0.0042604585,0.00023164136,0.00036676327,0.0074333795,0.0024057378,0.00037404636,0.007385499,0.00017426597],"about_ca_topic_score_codex":0.0016706779,"about_ca_topic_score_gemma":0.002016265,"teacher_disagreement_score":0.0431655,"about_ca_system_score_codex":0.00038210137,"about_ca_system_score_gemma":0.00090938003,"threshold_uncertainty_score":0.9975096},"labels":[],"label_agreement":null},{"id":"W2591330406","doi":"10.1200/jco.2016.34.7_suppl.38","title":"Ontario’s approach to tackling drug funding sustainability.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Cancer Care Ontario","funders":"","keywords":"Sustainability; Reimbursement; Medicine; Transparency (behavior); Context (archaeology); Disinvestment; Health care; Economic growth; Political science; Incentive; Economics","score_opus":0.599075217660759,"score_gpt":0.5620457472849504,"score_spread":0.037029470375808615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591330406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.731192,0.00038439475,0.033572543,0.19106522,0.0039570206,0.0005671736,0.00001764408,0.00001796474,0.039226055],"genre_scores_gemma":[0.9479592,0.00006825082,0.022225533,0.018114563,0.0024460598,0.000020356616,9.4296246e-7,0.000027514752,0.009137566],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9842357,0.001044065,0.013606207,0.0004539559,0.00015151026,0.0005085825],"domain_scores_gemma":[0.979459,0.009841838,0.009016642,0.00043413,0.0004701874,0.0007782258],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09547776,0.00016709065,0.0027199127,0.0003871886,0.000107690284,0.00003602264,0.0005336077,0.00033301485,0.00046951376],"category_scores_gemma":[0.06398131,0.00013940631,0.0005221643,0.0001555753,0.00013265845,0.0005550752,0.00011037635,0.0006030405,0.00073058734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058834534,0.0017096176,0.7221653,0.0001927624,0.00038568105,0.000023712577,0.004588301,0.00032866243,0.0000023566806,0.12103954,0.10698171,0.041994035],"study_design_scores_gemma":[0.0025261883,0.0010034969,0.11845374,0.00007230369,0.000018073277,0.000033113643,0.0011911758,0.00009855981,0.0000010159723,0.04680783,0.8295619,0.00023261244],"about_ca_topic_score_codex":0.0015124084,"about_ca_topic_score_gemma":0.002369846,"teacher_disagreement_score":0.7225802,"about_ca_system_score_codex":0.0038532468,"about_ca_system_score_gemma":0.003043181,"threshold_uncertainty_score":0.9999708},"labels":[],"label_agreement":null},{"id":"W2591332831","doi":"10.1200/jco.2014.32.30_suppl.48","title":"Improving radiotherapy utilization rates in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario","funders":"","keywords":"Medicine; Christian ministry; Staffing; Population; Cancer incidence; Cancer; Health care; Emergency medicine; Environmental health; Internal medicine; Nursing","score_opus":0.12029618007629625,"score_gpt":0.5235256132414079,"score_spread":0.4032294331651116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591332831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92691356,0.0014342099,0.05375089,0.0063868007,0.004531497,0.00021202762,2.085162e-7,0.000013008863,0.0067577926],"genre_scores_gemma":[0.90465796,0.0020202794,0.07587937,0.012861303,0.0031287174,0.0000031043128,0.0000018769382,0.000025034318,0.0014223524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734485,0.00045833006,0.0017175976,0.00014264732,0.00015784462,0.00017874007],"domain_scores_gemma":[0.9959146,0.0023861441,0.0012176929,0.00013730992,0.0001763243,0.00016793158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039326255,0.000100215526,0.0011751376,0.00013704751,0.000027802875,0.000003661936,0.00012110207,0.00045205426,0.00034496284],"category_scores_gemma":[0.0027635556,0.00006962479,0.00023389212,0.00010321698,0.0002104742,0.00012850399,0.000010649446,0.001169747,0.000004460638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031212694,0.00081624434,0.47420716,0.000009144281,0.00008769387,0.00013416194,0.00015396481,0.00007954667,0.0004271738,0.000376415,0.00077803066,0.5198092],"study_design_scores_gemma":[0.011637964,0.012938307,0.46374202,0.00005510054,0.000058259884,0.000418453,0.00003757344,0.001462915,0.0000808887,0.0011470183,0.50833994,0.00008157804],"about_ca_topic_score_codex":0.00031705204,"about_ca_topic_score_gemma":0.0063227573,"teacher_disagreement_score":0.51972765,"about_ca_system_score_codex":0.0004613749,"about_ca_system_score_gemma":0.0018008637,"threshold_uncertainty_score":0.5082034},"labels":[],"label_agreement":null},{"id":"W2591334128","doi":"10.1200/jco.2016.34.7_suppl.93","title":"Successful completion of EGFR/ALK testing in non-squamous non-small cell lung cancer (non-sq NSCLC) with the implementation of reflex testing (RT) by pathologists.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; North York General Hospital; University of Toronto; Health Sciences Centre; Pediatric Oncology Group","funders":"","keywords":"Medicine; Biomarker; Lung cancer; Oncology; Internal medicine; Stage (stratigraphy); Adenocarcinoma; Cancer","score_opus":0.06081244894910432,"score_gpt":0.4514777850534587,"score_spread":0.3906653361043544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591334128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98241836,0.00020481904,0.006783768,0.008407296,0.00029838743,0.00033695722,0.0000065938693,0.0000064331066,0.0015373896],"genre_scores_gemma":[0.9857198,0.00015632232,0.012624191,0.0009614481,0.00045293785,0.000009886063,0.000002738418,0.000025325417,0.000047367346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99619466,0.00041247442,0.002411436,0.0002368754,0.0004217157,0.00032282315],"domain_scores_gemma":[0.9888932,0.0063705635,0.0036474047,0.00019921904,0.0007015414,0.00018804763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005656045,0.00017268852,0.0012550656,0.00014187887,0.000054402764,0.0000075226217,0.00028409497,0.00019871163,0.000049872273],"category_scores_gemma":[0.0039766394,0.00008895222,0.00016401452,0.00031139486,0.00042910458,0.0000959072,0.00007418834,0.0010710881,9.0271595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006234085,0.00037499543,0.7484892,0.00013659621,0.000052830554,0.00013351803,0.00025031908,0.000100878955,0.038207226,0.000003199918,0.0015096781,0.21011816],"study_design_scores_gemma":[0.014094875,0.0077098506,0.9690002,0.0011418277,0.00038157252,0.00018389105,0.0007214677,0.003968332,0.0015456671,0.00003988642,0.0010615188,0.00015090875],"about_ca_topic_score_codex":0.0010597679,"about_ca_topic_score_gemma":0.00017470129,"teacher_disagreement_score":0.220511,"about_ca_system_score_codex":0.00019961208,"about_ca_system_score_gemma":0.0012164676,"threshold_uncertainty_score":0.47606963},"labels":[],"label_agreement":null},{"id":"W2591334624","doi":"10.1200/jco.2011.29.15_suppl.9005","title":"Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Survivorship curve; Breast cancer; Cancer survivorship; Randomized controlled trial; Cancer; Oncology; Internal medicine","score_opus":0.23192832680726744,"score_gpt":0.4948753511217446,"score_spread":0.26294702431447714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591334624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795704,0.00046682506,0.00024606942,0.0065611387,0.006202573,0.0035650798,0.0002986948,0.000013002936,0.0030762015],"genre_scores_gemma":[0.9939939,0.00052772375,0.001662889,0.0013086917,0.0020863742,0.00013433144,0.0000050630515,0.000027691989,0.0002533602],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99343556,0.001371694,0.004090284,0.00027482386,0.00049175054,0.00033588373],"domain_scores_gemma":[0.98559386,0.008053126,0.0028555337,0.00019298297,0.0028882583,0.00041624153],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009907703,0.00021278659,0.0035869172,0.0002234886,0.000041129737,0.000003827384,0.00018004616,0.0003466471,0.00018893897],"category_scores_gemma":[0.018653495,0.00013914276,0.001260481,0.0001621249,0.0003471598,0.00006882658,0.000070392045,0.00062013546,0.0000075135945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94763577,0.0014734511,0.007774941,0.00008904638,0.0018116933,0.000045517747,0.0028250755,0.0000038600024,0.000018440509,0.000008956852,0.0020007635,0.036312457],"study_design_scores_gemma":[0.9166533,0.021100478,0.054074388,0.0004872274,0.0027057556,0.000044255416,0.0009484845,0.000045009725,0.00010512044,0.00007585717,0.0036271187,0.00013300846],"about_ca_topic_score_codex":0.0015315319,"about_ca_topic_score_gemma":0.0038964264,"teacher_disagreement_score":0.046299446,"about_ca_system_score_codex":0.00022555233,"about_ca_system_score_gemma":0.0014863317,"threshold_uncertainty_score":0.9896128},"labels":[],"label_agreement":null},{"id":"W2591339568","doi":"10.1200/jco.2013.31.4_suppl.461","title":"Association of time to adjuvant chemotherapy (TTAC) and overall survival among patients with rectal cancer treated with preoperative radiation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Internal medicine; Stage (stratigraphy); Oxaliplatin; Multivariate analysis; Univariate analysis; Chemotherapy; Cancer; Proportional hazards model; Surgery; Oncology","score_opus":0.02139309269698076,"score_gpt":0.33724979936359795,"score_spread":0.3158567066666172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591339568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477226,0.00005331404,0.0000070115175,0.0035952881,0.00007560884,0.00035760415,0.0000063815505,0.000004241394,0.0011283244],"genre_scores_gemma":[0.9965996,0.00008594984,0.0002676065,0.00062842167,0.00025347405,0.000007895391,0.0000040304144,0.000011425913,0.002141552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846756,0.00019101094,0.0007643796,0.0001279962,0.00031712567,0.00013192906],"domain_scores_gemma":[0.9971823,0.0005858084,0.0009953679,0.00005578444,0.00094155694,0.00023915444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005242513,0.00010504366,0.0009155813,0.00006594042,0.000021874015,0.000007734094,0.00004376223,0.0001517716,0.0004985562],"category_scores_gemma":[0.00048579747,0.000058382833,0.000092154005,0.00011242043,0.00007119585,0.00014422667,0.00001276718,0.00029981558,0.000007149638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004816294,0.0005293023,0.9659844,0.000007957331,0.00043957087,0.000010757064,0.00016937661,0.000015654598,0.00013863796,0.000001079237,0.00228148,0.025605513],"study_design_scores_gemma":[0.009278837,0.02187644,0.96719825,0.000080561185,0.00021466469,0.000005687816,0.000024853563,0.00012027662,0.0001471119,0.0000071286236,0.00097509666,0.000071118906],"about_ca_topic_score_codex":0.00023261658,"about_ca_topic_score_gemma":0.00017343884,"teacher_disagreement_score":0.025534395,"about_ca_system_score_codex":0.00018885189,"about_ca_system_score_gemma":0.0003912399,"threshold_uncertainty_score":0.5458841},"labels":[],"label_agreement":null},{"id":"W2591339827","doi":"10.1200/jco.2012.30.34_suppl.319","title":"Use of iPad technology to determine cancer patient-reported preferences for and understanding of pharmacogenetic testing (PGT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Malignancy; Internal medicine; Interim; Oncology; Breast cancer; Test (biology); Family medicine","score_opus":0.5311195014013987,"score_gpt":0.5382484923085379,"score_spread":0.007128990907139143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591339827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179703,0.0016401664,0.004175872,0.0014676235,0.0005691263,0.0003049987,0.000007940178,0.000006399245,0.000030818184],"genre_scores_gemma":[0.9464369,0.00021766289,0.05265099,0.00038295734,0.00027441687,0.000011553125,2.8574294e-7,0.000013083156,0.00001215593],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976176,0.00007765374,0.0017934332,0.000116877985,0.00017174456,0.00022268441],"domain_scores_gemma":[0.99430245,0.0025088463,0.0022859797,0.00010510579,0.0005701337,0.00022750608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078444555,0.000103555496,0.0010546127,0.00021264654,0.000021459715,0.0000017471689,0.00007230307,0.0001783464,0.000021781409],"category_scores_gemma":[0.0038860098,0.000075565724,0.00011354406,0.00021206486,0.0002846446,0.00012106427,0.00004853254,0.00026601722,1.2356672e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027950422,0.0003690722,0.45767486,0.00007866275,0.0003465262,0.0000113813085,0.00017955195,0.000035853438,0.032171648,0.000025217549,0.000047805774,0.5062644],"study_design_scores_gemma":[0.0334415,0.08053268,0.69481486,0.0030158383,0.004709248,0.0027067135,0.0028435846,0.00060725084,0.1098908,0.007930417,0.05882342,0.00068368175],"about_ca_topic_score_codex":0.00001047766,"about_ca_topic_score_gemma":0.000013195022,"teacher_disagreement_score":0.5055807,"about_ca_system_score_codex":0.00011473225,"about_ca_system_score_gemma":0.0005211334,"threshold_uncertainty_score":0.46521974},"labels":[],"label_agreement":null},{"id":"W2591342011","doi":"10.1200/jco.2015.33.28_suppl.117","title":"Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Placebo; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Population; Breast cancer; Trastuzumab; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.14825902496273938,"score_gpt":0.4963269494320232,"score_spread":0.3480679244692838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591342011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94610095,0.0036306747,0.0000376453,0.03592451,0.00534146,0.0068797185,0.00004140106,0.000025596619,0.002018063],"genre_scores_gemma":[0.9822364,0.007600511,0.00019836884,0.0034417599,0.004054964,0.00061095215,0.000008737528,0.00007647939,0.0017718333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9843545,0.0061878394,0.005788076,0.00056941935,0.0021407215,0.0009594725],"domain_scores_gemma":[0.9735736,0.019306777,0.0029505289,0.00090368866,0.0011706313,0.002094744],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.030537385,0.00047300494,0.0067379046,0.0002825398,0.00012004125,0.00008731245,0.001073975,0.0005434579,0.0009482005],"category_scores_gemma":[0.03446165,0.0002643938,0.002310342,0.00039301356,0.000658227,0.00025300565,0.00018008695,0.002684424,0.000019413177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9415326,0.003691396,0.0035918609,0.00001872321,0.0018136048,0.0037946638,0.00064909377,0.00012617782,0.000069307804,0.00019880118,0.002105543,0.042408235],"study_design_scores_gemma":[0.96921855,0.012559374,0.008869652,0.0003068335,0.00076131255,0.000095978,0.00054890354,0.000526028,0.000030128516,0.001586208,0.005238852,0.00025817897],"about_ca_topic_score_codex":0.0015452408,"about_ca_topic_score_gemma":0.0015996865,"teacher_disagreement_score":0.042150058,"about_ca_system_score_codex":0.00073713926,"about_ca_system_score_gemma":0.017659858,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W2591342859","doi":"10.1200/jco.2014.32.4_suppl.97","title":"Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Exact test; Internal medicine; Cancer; Oncology; Urology; Androgen deprivation therapy","score_opus":0.14492034401977447,"score_gpt":0.516104788827655,"score_spread":0.3711844448078805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591342859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590117,0.00011461573,0.000011538221,0.0028093962,0.00026606434,0.00070772506,0.000054451742,0.000002966461,0.00013210335],"genre_scores_gemma":[0.9986181,0.00031334645,0.0005737448,0.00013752327,0.00008382093,0.000019161374,0.000003255389,0.000018474086,0.00023257599],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99542356,0.0013415923,0.0020364232,0.00022592272,0.0006368485,0.00033563876],"domain_scores_gemma":[0.99489355,0.0018940938,0.0017120031,0.00023930539,0.0008405038,0.00042052908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046588485,0.00018229328,0.001663704,0.00035850715,0.00002428046,0.0000068606328,0.00014679886,0.00013986227,0.00008683325],"category_scores_gemma":[0.0034248107,0.000110977984,0.00040009854,0.00030106504,0.00020941971,0.0001229364,0.000041403906,0.00061746594,0.0000058766273],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38930959,0.009638974,0.37036163,0.00021629332,0.0010489795,0.00031595884,0.0008786017,0.00079153245,0.07680914,0.000013682128,0.00045070663,0.1501649],"study_design_scores_gemma":[0.020300448,0.058444817,0.91341054,0.00032909517,0.00018194746,0.0000086538985,0.000029470473,0.0000579756,0.006586121,0.000056923913,0.00051102735,0.00008294927],"about_ca_topic_score_codex":0.00034874387,"about_ca_topic_score_gemma":0.00032131988,"teacher_disagreement_score":0.5430489,"about_ca_system_score_codex":0.0007380706,"about_ca_system_score_gemma":0.003744296,"threshold_uncertainty_score":0.66422206},"labels":[],"label_agreement":null},{"id":"W2591348809","doi":"10.1200/jco.2015.33.29_suppl.152","title":"Changing focus: Living with advanced cancer—Development of a palliative care transition project.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Referral; Palliative care; Advance care planning; Focus group; Cancer; Nursing; Family medicine; Health care","score_opus":0.3953067276428939,"score_gpt":0.5696025047436539,"score_spread":0.17429577710076005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591348809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98692477,0.0054194853,0.004458742,0.00094888615,0.00039001022,0.00024535102,0.00000553483,0.000007330537,0.0015998756],"genre_scores_gemma":[0.9521653,0.0011392039,0.045943953,0.00026047116,0.0004262194,0.000009738044,0.0000023933562,0.000012906635,0.000039788774],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9976904,0.00018138185,0.0014307055,0.00012543307,0.00039073656,0.00018133939],"domain_scores_gemma":[0.995754,0.0009488766,0.001544938,0.00008202764,0.0014870575,0.0001830739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012215875,0.000114206894,0.0012229333,0.0001768646,0.00002092602,0.0000017121549,0.00008481578,0.00016666182,0.000014542761],"category_scores_gemma":[0.0016846055,0.00007543208,0.00017832713,0.00022295011,0.000118434094,0.00009071494,0.000021256728,0.0003874068,7.903325e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009579143,0.001434496,0.18727387,0.000658432,0.0014652769,0.0002914827,0.20492858,0.0002994557,0.0006803131,0.000039665705,0.0005589674,0.5927903],"study_design_scores_gemma":[0.048159055,0.08799494,0.2570007,0.04034685,0.0024877691,0.00009830585,0.36993283,0.00039489503,0.025205836,0.00019642625,0.16738184,0.0008005311],"about_ca_topic_score_codex":0.000026797845,"about_ca_topic_score_gemma":0.00016234981,"teacher_disagreement_score":0.59198976,"about_ca_system_score_codex":0.00026956803,"about_ca_system_score_gemma":0.0038649181,"threshold_uncertainty_score":0.6856199},"labels":[],"label_agreement":null},{"id":"W2591351015","doi":"10.1200/jco.2016.34.2_suppl.561","title":"Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and/or PBRM1 mutations.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"BAP1; Medicine; Sunitinib; ARID1A; Germline; Exon; Gene; Oncology; Internal medicine; Cancer; Cancer research; Mutation; Molecular biology; Genetics; Biology","score_opus":0.06155275534997289,"score_gpt":0.3851219480862011,"score_spread":0.3235691927362282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591351015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203825,0.00006434908,0.003324822,0.0026310275,0.0011282328,0.0002274764,0.00007865041,0.000003013602,0.0005041908],"genre_scores_gemma":[0.99813676,0.00023701755,0.0003441597,0.00054013234,0.0005873942,0.000008827184,0.00002111775,0.000022003616,0.000102609316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698395,0.0004907381,0.0016576382,0.00037930283,0.00024106141,0.00024732208],"domain_scores_gemma":[0.996461,0.0019458049,0.0009028834,0.00028566705,0.00016942494,0.00023522362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001430265,0.0001859564,0.00071291806,0.00007757055,0.00003761872,0.000021259595,0.00024367821,0.00035100494,0.00004409847],"category_scores_gemma":[0.0049588024,0.00011874727,0.00021195218,0.00006139493,0.00015369963,0.000006625431,0.00009975039,0.00034100257,0.000003390336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07463516,0.011662543,0.5667049,0.000025303932,0.00057682884,0.0011197693,0.00006284393,0.00016933032,0.054081406,0.00024676012,0.016023973,0.27469113],"study_design_scores_gemma":[0.04950802,0.047383737,0.85131514,0.000094066476,0.0002134546,0.000024845052,0.00007574859,0.00045844645,0.0020345936,0.0007649953,0.04763273,0.0004941975],"about_ca_topic_score_codex":0.000054705026,"about_ca_topic_score_gemma":0.0022157049,"teacher_disagreement_score":0.2846102,"about_ca_system_score_codex":0.00007371412,"about_ca_system_score_gemma":0.0006173003,"threshold_uncertainty_score":0.59365076},"labels":[],"label_agreement":null},{"id":"W2591351447","doi":"10.1200/jco.2008.26.15_suppl.6615","title":"Review of utilization of trastuzumab in the adjuvant treatment of breast cancer in four university-teaching hospitals in Quebec, Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Adjuvant; Taxane; Regimen; Anthracycline; Metastatic breast cancer; Cancer","score_opus":0.20308625434264685,"score_gpt":0.4986246580019878,"score_spread":0.2955384036593409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591351447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97243506,0.012969407,0.0000061721307,0.013453337,0.00014870787,0.00034898435,0.000016864324,5.370961e-7,0.0006209049],"genre_scores_gemma":[0.89069784,0.108730756,0.000083145336,0.00033873718,0.00007300366,0.0000015001161,9.5020016e-7,0.0000051575435,0.000068891095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616885,0.0012521872,0.0018806707,0.00010568111,0.0004339473,0.0001586627],"domain_scores_gemma":[0.99694914,0.0014598077,0.0010837169,0.00014812902,0.00026957245,0.000089608024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002790149,0.00008046842,0.001424284,0.00018015545,0.000010229266,4.6167176e-7,0.00018264218,0.000121098325,0.000097276505],"category_scores_gemma":[0.001182155,0.0000525445,0.00016816483,0.0003304609,0.00015694975,0.000054784672,0.000018610122,0.0005407262,1.3143284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016007842,0.0019230436,0.73850876,0.00091179257,0.00009727053,0.0015617122,0.0008993417,0.00010109682,0.000047744157,0.00002533381,0.0026316391,0.2516915],"study_design_scores_gemma":[0.004887543,0.0029998694,0.97439235,0.004719051,0.00007277583,0.00013040371,0.00055196084,0.000048023834,0.000028291994,0.000007896149,0.012122574,0.00003926642],"about_ca_topic_score_codex":0.56951755,"about_ca_topic_score_gemma":0.86593956,"teacher_disagreement_score":0.29642195,"about_ca_system_score_codex":0.0016652767,"about_ca_system_score_gemma":0.010708551,"threshold_uncertainty_score":0.9948998},"labels":[],"label_agreement":null},{"id":"W2591353062","doi":"10.1200/jco.2015.33.3_suppl.195","title":"A systematic review of post first-line treatments for advanced gastrointestinal stromal tumor (GIST): Direct pairwise meta-analyses and indirect comparisons.","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Regorafenib; Placebo; GiST; Internal medicine; Sunitinib; Imatinib; Meta-analysis; Hazard ratio; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer; Stromal cell; Pathology","score_opus":0.5464839162125237,"score_gpt":0.5909117235331975,"score_spread":0.04442780732067386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591353062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010796953,0.9939832,0.00010092179,0.00063056324,0.00013023031,0.0045155617,0.00029240432,0.000014604036,0.00022452566],"genre_scores_gemma":[0.0001938702,0.9708804,0.027693313,0.00019420864,0.0002577687,0.00034396115,0.00010962459,0.00006865041,0.00025823104],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9863543,0.002359561,0.009166832,0.00053977204,0.0010228817,0.000556659],"domain_scores_gemma":[0.97046864,0.012360216,0.012578504,0.0006070759,0.002651768,0.0013337801],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00848446,0.00078617065,0.028146887,0.00042881217,0.00006068775,0.000017116765,0.0003900916,0.00017635239,0.000072580595],"category_scores_gemma":[0.04854001,0.0004043336,0.006475116,0.00033751212,0.00036987668,0.000092849,0.00013508055,0.0011957888,0.0000117782565],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028028737,0.0050631976,0.00029743885,0.89165527,0.038960896,0.004220572,0.000005445211,0.0000011626795,7.4787715e-7,0.0000038317185,0.002328651,0.054659907],"study_design_scores_gemma":[0.006152952,0.077174574,0.00009341635,0.55236185,0.29772705,0.022906473,0.000024828027,0.00001408894,0.0000013098785,0.000012381328,0.043313112,0.00021800038],"about_ca_topic_score_codex":0.000025600591,"about_ca_topic_score_gemma":0.000030554227,"teacher_disagreement_score":0.33929345,"about_ca_system_score_codex":0.00053519686,"about_ca_system_score_gemma":0.0048980573,"threshold_uncertainty_score":0.99984086},"labels":[],"label_agreement":null},{"id":"W2591359904","doi":"10.1200/jco.2015.33.29_suppl.66","title":"Agreement between physician and patient performance status ratings in an outpatient setting.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Performance status; Feeling; Physical therapy; Internal medicine; Cancer","score_opus":0.4221117804708975,"score_gpt":0.5763398205115738,"score_spread":0.15422804004067636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591359904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923504,0.000097484735,0.0000656667,0.009079642,0.0006296717,0.00030032813,0.0000034304312,0.000005366113,0.00058338407],"genre_scores_gemma":[0.9816322,0.00012707218,0.009884056,0.007421202,0.0008988286,0.0000031906202,0.000010823805,0.000012115974,0.00001051138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99386144,0.0006845052,0.004426225,0.00020297932,0.00055475044,0.00027011658],"domain_scores_gemma":[0.9929259,0.002568491,0.0028574716,0.00016526981,0.0007714658,0.0007114024],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006582425,0.00012514407,0.0010096026,0.000117885684,0.000025919557,0.0000125579745,0.00008129615,0.00019436337,0.000018097237],"category_scores_gemma":[0.012538783,0.000095324074,0.00011769747,0.00012245768,0.000114722694,0.000407612,0.000083254876,0.0010247632,0.000010784048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012175092,0.00076264056,0.49922913,0.000010099603,0.000035347603,0.00004049589,0.00061724795,0.000024114563,0.000014486994,0.0000032913758,0.0010908104,0.4969548],"study_design_scores_gemma":[0.011228072,0.056573454,0.8785383,0.00010476806,0.0002161329,0.000031700467,0.0032030074,0.000916504,0.000042712243,0.00015541981,0.048878234,0.00011169672],"about_ca_topic_score_codex":0.00006110332,"about_ca_topic_score_gemma":0.00008148908,"teacher_disagreement_score":0.4968431,"about_ca_system_score_codex":0.0002680905,"about_ca_system_score_gemma":0.0014957543,"threshold_uncertainty_score":0.99577904},"labels":[],"label_agreement":null},{"id":"W2591364804","doi":"10.1200/jco.2014.32.4_suppl.353","title":"Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Docetaxel; Chemotherapy; Pazopanib; Sunitinib; Paclitaxel; Urology; Cancer","score_opus":0.04561009356560923,"score_gpt":0.43272369703405417,"score_spread":0.3871136034684449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591364804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978473,0.00013374965,0.000047259942,0.0002737839,0.00025876367,0.0003237509,0.000009486429,0.0000029575097,0.0011029398],"genre_scores_gemma":[0.99616224,0.0004899105,0.0027038069,0.00025804204,0.00031036942,0.0000028578406,0.0000015980172,0.000028749933,0.000042425254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968067,0.0003137826,0.002127554,0.00016255,0.00037979882,0.00020960656],"domain_scores_gemma":[0.99573916,0.0008741978,0.002346078,0.00023462548,0.00064456486,0.00016139814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011492156,0.00017370978,0.001916712,0.00012103172,0.000011407168,0.0000015875501,0.00015594819,0.00023992985,0.00019149687],"category_scores_gemma":[0.00076929235,0.00010267404,0.00049773685,0.00018110652,0.00018357173,0.00008909123,0.00001876129,0.00040570335,0.0000013489413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025451815,0.0034233169,0.7703598,0.000036946483,0.00034776566,0.000009681293,0.00023863974,0.000014837072,0.0009709158,0.0000038612657,0.00005163812,0.19909073],"study_design_scores_gemma":[0.042444255,0.046266362,0.9083352,0.00023547698,0.00011779252,0.00002160691,0.000023569522,0.00001485879,0.001938606,0.000068486166,0.0004600623,0.00007372419],"about_ca_topic_score_codex":0.0001579245,"about_ca_topic_score_gemma":0.00002933021,"teacher_disagreement_score":0.19901702,"about_ca_system_score_codex":0.000110790774,"about_ca_system_score_gemma":0.0011274464,"threshold_uncertainty_score":0.4186926},"labels":[],"label_agreement":null},{"id":"W2591365257","doi":"10.1200/jco.2012.30.34_suppl.17","title":"Robotic radiosurgery for the treatment of one to three brain metastases: A pragmatic application of cost-benefit analysis using willingness to pay.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Radiosurgery; Medicine; Medical physics; Cost–benefit analysis; Cost effectiveness; Radiation therapy; Surgery; Risk analysis (engineering)","score_opus":0.11099733115965786,"score_gpt":0.4712357488821758,"score_spread":0.3602384177225179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591365257","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18488596,0.00023630078,0.81295204,0.0010477841,0.0001332532,0.00071209663,0.000020191153,0.0000031501856,0.0000092156515],"genre_scores_gemma":[0.76123804,0.000037580638,0.2378747,0.00018321586,0.0005639623,0.00007502672,0.000003597583,0.0000143374655,0.000009521926],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975764,0.00016776625,0.0017634045,0.000119344426,0.00017286344,0.0002001882],"domain_scores_gemma":[0.9914113,0.005754061,0.0020779322,0.00028089955,0.000297698,0.0001781022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022921085,0.00012321457,0.0014635338,0.00014754733,0.000039262617,0.000004882296,0.00019088584,0.0000716181,0.000032777218],"category_scores_gemma":[0.00022673132,0.000071774964,0.00074538344,0.00041310553,0.000067496025,0.00010042525,0.00001563229,0.00011360692,3.497373e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008562126,0.0039164564,0.20004088,0.000021160628,0.005315804,4.956904e-7,0.00040155443,0.076574676,0.0020038434,0.0028716233,0.00008425024,0.70791304],"study_design_scores_gemma":[0.0197808,0.050026096,0.48899108,0.0004632089,0.04251266,0.000032365537,0.0013624886,0.13019966,0.022255076,0.032464724,0.2102408,0.0016710539],"about_ca_topic_score_codex":0.00007025232,"about_ca_topic_score_gemma":0.000023148474,"teacher_disagreement_score":0.706242,"about_ca_system_score_codex":0.00012279935,"about_ca_system_score_gemma":0.00016738412,"threshold_uncertainty_score":0.2926898},"labels":[],"label_agreement":null},{"id":"W2591372505","doi":"10.1200/jco.2011.29.15_suppl.6082","title":"Cost-effectiveness of a survivorship care plan for breast cancer survivors.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Breast cancer; Survivorship curve; Economic evaluation; Cost effectiveness; Health care; Cost–benefit analysis; Family medicine; Physical therapy; Cancer; Surgery; Internal medicine","score_opus":0.3705697753469716,"score_gpt":0.49916763132004505,"score_spread":0.12859785597307344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591372505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989602,0.0009186509,0.0005057151,0.00042216823,0.0028586816,0.0007077101,0.00018787773,0.0000076695915,0.004789473],"genre_scores_gemma":[0.9965671,0.00048871746,0.0013754759,0.0006725098,0.000784011,0.000026392037,0.000008287656,0.000021188347,0.000056318037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970802,0.00063234975,0.001655934,0.00017743629,0.00022437083,0.00022971912],"domain_scores_gemma":[0.9936227,0.0034732588,0.0013375077,0.00017889109,0.0010560419,0.00033156175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036517011,0.00013637569,0.0017757701,0.00011343004,0.000027315013,0.0000022208399,0.00018734067,0.00036524853,0.0005004311],"category_scores_gemma":[0.0009227772,0.000098211654,0.00063710415,0.00009758734,0.00021523162,0.00010069337,0.000029320976,0.000574567,0.0000021842568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049533684,0.000892289,0.68511564,0.00076716277,0.00069997687,0.00012866352,0.00095360656,0.0000098054325,0.00030913114,0.00013802518,0.00047892888,0.26097307],"study_design_scores_gemma":[0.011661931,0.008303567,0.95848817,0.00028234892,0.00046272567,0.00021128241,0.00062473735,0.000022654294,0.00080584065,0.00014294797,0.018880807,0.00011297338],"about_ca_topic_score_codex":0.0010971976,"about_ca_topic_score_gemma":0.001954153,"teacher_disagreement_score":0.27337253,"about_ca_system_score_codex":0.00022392806,"about_ca_system_score_gemma":0.0028293994,"threshold_uncertainty_score":0.547937},"labels":[],"label_agreement":null},{"id":"W2591372913","doi":"10.1200/jco.2014.32.4_suppl.264","title":"Pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiotherapy; Prostate; Cryotherapy; Radiation therapy; Urology; Radiology; Surgery; Cancer; Internal medicine","score_opus":0.04684941702956927,"score_gpt":0.38398923521057976,"score_spread":0.33713981818101046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591372913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630475,0.00065137126,0.0005855361,0.0006578559,0.00072204456,0.0010002962,0.00001076283,0.000006251416,0.0000611038],"genre_scores_gemma":[0.9950861,0.0011832848,0.0013950976,0.0019028462,0.0003125281,0.000064316926,0.000003625865,0.00003371187,0.000018488958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995531,0.0009833778,0.0023179732,0.00034901395,0.0004894482,0.00032914634],"domain_scores_gemma":[0.99506706,0.0019432134,0.0018078515,0.00027614506,0.0005685315,0.00033720533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023711286,0.0002601695,0.0019069304,0.00017640225,0.000024947816,0.000010635036,0.0001506183,0.00012533739,0.00007005342],"category_scores_gemma":[0.00046430196,0.00016264338,0.00017279222,0.00020159646,0.00031738455,0.0001603152,0.00003239598,0.0008884273,0.000004786664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07002188,0.02417438,0.758844,0.00002456652,0.00039146375,0.0004640009,0.00039880813,0.000059264534,0.000015570467,0.000016567545,0.00011778915,0.14547172],"study_design_scores_gemma":[0.049453918,0.25105157,0.69798577,0.00037212807,0.00016596758,0.000016618273,0.00006611379,0.00002098767,0.0000816213,0.00013815552,0.00053763436,0.00010953472],"about_ca_topic_score_codex":0.00014247443,"about_ca_topic_score_gemma":0.00028414387,"teacher_disagreement_score":0.2268772,"about_ca_system_score_codex":0.00031903473,"about_ca_system_score_gemma":0.000688024,"threshold_uncertainty_score":0.6632405},"labels":[],"label_agreement":null},{"id":"W2591377132","doi":"10.1200/jco.2014.32.15_suppl.7025","title":"Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"Medicine; Imatinib; Nilotinib; Imatinib mesylate; Internal medicine; Gastroenterology; Nuclear medicine; Myeloid leukemia","score_opus":0.02489342773528545,"score_gpt":0.4009312724431337,"score_spread":0.37603784470784823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591377132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976027,0.00017264816,0.000045185134,0.0004116899,0.0003448211,0.0007049218,0.000005152712,0.000010192025,0.00070268527],"genre_scores_gemma":[0.9972842,0.000036094443,0.001395969,0.0008964596,0.00024156412,0.000030432066,0.0000031846812,0.00004078195,0.00007136438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936526,0.003039765,0.002006119,0.0003533217,0.00062173087,0.0003264712],"domain_scores_gemma":[0.9876789,0.009891676,0.0014773788,0.00050810375,0.00015691212,0.0002870445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048171314,0.0002697886,0.0023830119,0.00024497404,0.00001785496,0.000009013904,0.0002150901,0.00034213896,0.00012478654],"category_scores_gemma":[0.006712542,0.00017458964,0.00032220825,0.00017560166,0.00016719509,0.000064169784,0.000054254084,0.0010441949,0.000048150683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3115728,0.00811303,0.4953722,0.00006211632,0.00143944,0.011606657,0.00041643967,0.00019929766,0.0023225304,0.000009183861,0.00020636243,0.16867995],"study_design_scores_gemma":[0.06393733,0.16378056,0.76292694,0.00065731636,0.0008321846,0.00008748461,0.000084087354,0.00016113442,0.0055748625,0.000049294697,0.0017490687,0.00015974017],"about_ca_topic_score_codex":0.00010783189,"about_ca_topic_score_gemma":0.00024001545,"teacher_disagreement_score":0.26755473,"about_ca_system_score_codex":0.00048520314,"about_ca_system_score_gemma":0.0007599493,"threshold_uncertainty_score":0.80360246},"labels":[],"label_agreement":null},{"id":"W2591381806","doi":"10.1200/jco.2013.31.31_suppl.115","title":"Identifying opportunities to improve quality of cancer care: An evaluation of the use of routine surveillance imaging scans in women with early breast cancer (EBC) treated in Ontario, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Credit Valley Hospital","funders":"","keywords":"Medicine; Cancer registry; Medical imaging; Population; Logistic regression; Cancer; Radiology; Breast cancer; Medical record; Comorbidity; Internal medicine","score_opus":0.173157473253014,"score_gpt":0.426891105385611,"score_spread":0.253733632132597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591381806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978094,0.000349433,0.0000038047335,0.0012209631,0.00022818141,0.00025537363,0.00010423461,5.6801997e-7,0.000028048285],"genre_scores_gemma":[0.9993866,0.00012925679,0.00009208326,0.0002447049,0.00006279437,0.000047931066,0.000003468025,0.000009498733,0.000023649596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717695,0.00068026676,0.0014006965,0.00017934233,0.0003690699,0.00019370209],"domain_scores_gemma":[0.99655545,0.00016496965,0.0015338315,0.00021155979,0.0014381111,0.00009609813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014142204,0.00012287765,0.0007638535,0.000058228725,0.00001776716,0.000005252514,0.000177998,0.000091018235,0.000042838645],"category_scores_gemma":[0.00027732796,0.00008191642,0.000072431205,0.000108427885,0.00016991707,0.000026176927,0.00007026124,0.00019495154,2.3018632e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018493042,0.00019400532,0.95485324,0.000020461854,0.00020002083,0.0000025179008,0.00090059463,0.0010791457,0.0036222104,9.4506925e-7,0.00006189317,0.037215658],"study_design_scores_gemma":[0.0032582104,0.0005356707,0.993403,0.00010892933,0.000062725114,0.0000038421394,0.0012292034,0.00002149515,0.0011943609,0.0000065264494,0.000095606854,0.000080398764],"about_ca_topic_score_codex":0.975337,"about_ca_topic_score_gemma":0.99673915,"teacher_disagreement_score":0.03854979,"about_ca_system_score_codex":0.0010002228,"about_ca_system_score_gemma":0.006232229,"threshold_uncertainty_score":0.9994015},"labels":[],"label_agreement":null},{"id":"W2591382503","doi":"10.1200/jco.2013.31.6_suppl.322","title":"Preoperative intensity modulated radiation therapy for retroperitoneal sarcoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Radiation therapy; Toxicity; Retrospective cohort study; Radiology; Surgery; Nuclear medicine; Urology; Internal medicine","score_opus":0.13046562097384717,"score_gpt":0.45396162194751527,"score_spread":0.3234960009736681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591382503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790029,0.0011331077,0.00010781834,0.017818224,0.00086092355,0.00067217037,0.0000020640462,0.000008636891,0.00039418234],"genre_scores_gemma":[0.98853314,0.001343795,0.004711918,0.0042102854,0.0010384625,0.000030010255,0.0000063603193,0.000012929357,0.00011310294],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979736,0.00020350484,0.0013475204,0.00014208778,0.00017471665,0.00015855805],"domain_scores_gemma":[0.9965801,0.0012130506,0.000775166,0.00013379789,0.0010491408,0.00024873688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009853934,0.00010740631,0.0010854593,0.000065212094,0.000042033967,0.000012312285,0.00007369952,0.00025537662,0.00019778562],"category_scores_gemma":[0.0016912177,0.00006352441,0.00044900883,0.00006827618,0.00009326273,0.00012386811,0.000015201791,0.0003743317,0.000029321161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004060174,0.004018821,0.42117122,0.000006246371,0.0007618177,0.00010514166,0.00013404257,0.000007005666,0.000531618,0.000047423346,0.020513784,0.5486427],"study_design_scores_gemma":[0.012178333,0.01951113,0.9407608,0.00002792993,0.00015358809,0.00017041952,0.00006236435,0.00071121444,0.00089893705,0.00038869865,0.025074376,0.00006222913],"about_ca_topic_score_codex":0.00004475508,"about_ca_topic_score_gemma":0.000004444435,"teacher_disagreement_score":0.54858047,"about_ca_system_score_codex":0.00014777892,"about_ca_system_score_gemma":0.00046901192,"threshold_uncertainty_score":0.25904503},"labels":[],"label_agreement":null},{"id":"W2591382683","doi":"10.1200/jco.2005.23.16_suppl.8017","title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dexamethasone; Nausea; Vomiting; Chemotherapy; Anesthesia; Internal medicine","score_opus":0.1516139322622105,"score_gpt":0.4284672326651524,"score_spread":0.27685330040294187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591382683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889636,0.00023125486,0.0041240994,0.005818981,0.00012689242,0.0006440708,0.00000420488,0.000005665823,0.00008122245],"genre_scores_gemma":[0.9748881,0.00013598619,0.021430746,0.0028323769,0.00035146243,0.000016709299,0.0000011407728,0.00002336887,0.00032012584],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99728537,0.00038602116,0.0016244432,0.00014232042,0.00035628027,0.00020555564],"domain_scores_gemma":[0.9890619,0.007667586,0.002158164,0.0002077941,0.0007759987,0.00012856332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033018168,0.00013311466,0.0013675196,0.00010475589,0.000024952516,0.0000058065325,0.00013426223,0.0002513352,0.000025324853],"category_scores_gemma":[0.0054444564,0.00007051132,0.000521222,0.00017806458,0.00019603333,0.00008146263,0.000025988773,0.0004378774,9.716846e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11182668,0.008866644,0.046935163,0.00037638933,0.010774275,0.0002273284,0.0005922963,0.0008280654,0.00536816,0.0001000647,0.009351058,0.8047539],"study_design_scores_gemma":[0.05599879,0.13016428,0.74922955,0.00070526276,0.0049481858,0.000089052555,0.000112329566,0.003188538,0.01930775,0.00041536434,0.035502255,0.00033861314],"about_ca_topic_score_codex":0.000009363848,"about_ca_topic_score_gemma":0.000063877356,"teacher_disagreement_score":0.8044153,"about_ca_system_score_codex":0.00008908145,"about_ca_system_score_gemma":0.00046926053,"threshold_uncertainty_score":0.65179163},"labels":[],"label_agreement":null},{"id":"W2591383126","doi":"10.1200/jco.2013.31.31_suppl.187","title":"Collaborating with Ontario cancer centers to ensure coordinated access to safe, evidence-based, high-quality IMRT treatment.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Quality assurance; Coaching; Radiation Therapist; Medical physics; Radiation therapy; Health care; Medical education; Radiology; Pathology; Psychology","score_opus":0.615407570406539,"score_gpt":0.6413850375045523,"score_spread":0.025977467098013296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591383126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81442344,0.000047143687,0.0010696367,0.18180312,0.0011901213,0.0011682227,0.000012126623,0.000014028434,0.00027212495],"genre_scores_gemma":[0.9304657,0.000100081954,0.022973737,0.044639368,0.0011000414,0.00007234034,0.0000092397795,0.000028265184,0.0006112222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99263024,0.0010150586,0.0049045617,0.0004027746,0.0006551032,0.0003922864],"domain_scores_gemma":[0.9797645,0.011763883,0.0032607904,0.00036681135,0.0036587098,0.0011852846],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004992745,0.00025324983,0.0018627218,0.00018751534,0.00007907424,0.00008051821,0.0002980492,0.00029270086,0.0022188784],"category_scores_gemma":[0.025171839,0.00016437925,0.0002825375,0.00057428045,0.000101779384,0.0007627515,0.00008912749,0.0008515516,0.00008817408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016999608,0.0015375812,0.77410024,0.000026868625,0.00056497136,0.00021617238,0.00015853622,0.0009636787,0.0008213124,0.000010412789,0.036196224,0.1684044],"study_design_scores_gemma":[0.0127018625,0.031179955,0.89257455,0.00054424535,0.00077283307,0.000045733,0.0002990779,0.00004197993,0.00034293986,0.000027516824,0.061278105,0.0001911838],"about_ca_topic_score_codex":0.08320887,"about_ca_topic_score_gemma":0.15503196,"teacher_disagreement_score":0.16821322,"about_ca_system_score_codex":0.0020507178,"about_ca_system_score_gemma":0.010141952,"threshold_uncertainty_score":0.9986932},"labels":[],"label_agreement":null},{"id":"W2591384018","doi":"10.1200/jco.2013.31.4_suppl.278","title":"Chemosensitivity and clinical characteristics of pancreatic malignancies in <i>BRCA </i>mutation carriers.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; Chemotherapy; Pancreatic cancer; BRCA mutation; Carboplatin; Gemcitabine; Ovarian cancer; Malignancy; Family history; Cancer; Gastroenterology; Cisplatin","score_opus":0.03539213264191323,"score_gpt":0.37333085092627877,"score_spread":0.33793871828436556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591384018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976837,0.00041113867,0.00017811742,0.00071213476,0.0005902576,0.00011475593,0.0000107342175,9.2806926e-7,0.00029820498],"genre_scores_gemma":[0.9931227,0.003657719,0.0017323273,0.0008207652,0.0006173779,0.0000020508448,0.000006981637,0.000009460881,0.000030593685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742573,0.00027242224,0.0018938615,0.0001598499,0.00010507849,0.00014305336],"domain_scores_gemma":[0.9970149,0.0009760941,0.0013308657,0.00014063099,0.00037301172,0.00016450376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019522305,0.00009657451,0.0008324585,0.000041713,0.000014558305,0.000009238913,0.00009919618,0.0003600388,0.000012340515],"category_scores_gemma":[0.005790369,0.00008258811,0.00020138806,0.00004947336,0.00028506175,0.000008332788,0.00007636246,0.0002954478,0.0000021493217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008523703,0.0007426017,0.7862842,0.000042634107,0.00021798171,0.00009936518,0.000068421345,0.000011147728,0.017690131,0.00009544602,0.0023047184,0.19159095],"study_design_scores_gemma":[0.002410128,0.0041588102,0.983602,0.000038328388,0.00009654372,0.00008161486,0.00010268989,0.00010241692,0.0019279761,0.0003851732,0.006989261,0.000105099185],"about_ca_topic_score_codex":0.00006562212,"about_ca_topic_score_gemma":0.000094293995,"teacher_disagreement_score":0.19731773,"about_ca_system_score_codex":0.000021539732,"about_ca_system_score_gemma":0.0006168929,"threshold_uncertainty_score":0.6932031},"labels":[],"label_agreement":null},{"id":"W2591388724","doi":"10.1200/jco.2014.32.30_suppl.306","title":"Outcomes in stage I non-small cell lung cancer following the introduction of stereotactic body radiotherapy in Alberta, Canada.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Red Deer Polytechnic; University of Alberta","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Cancer registry; Radiation therapy; Comorbidity; Population; Proportional hazards model; Internal medicine; Cancer; Surgery","score_opus":0.027449140592058295,"score_gpt":0.40459478704923024,"score_spread":0.37714564645717197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591388724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95326686,0.0005487337,0.000018307133,0.043639224,0.0019060767,0.00025038267,0.0000010384017,8.5214066e-7,0.00036849937],"genre_scores_gemma":[0.9954558,0.0008743234,0.0002100553,0.0020622525,0.00083708944,0.000012849257,6.7440664e-7,0.000012211573,0.00053476304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975418,0.00034475798,0.0015485114,0.0001470415,0.00023434033,0.00018355952],"domain_scores_gemma":[0.9960104,0.0026065637,0.0009963921,0.00018865538,0.00008513917,0.000112818896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018219983,0.000110475085,0.0012367265,0.00008717652,0.000015580375,0.000003942377,0.00011707881,0.00012835774,0.000074144555],"category_scores_gemma":[0.00068748073,0.00006266882,0.00025416721,0.00011412229,0.000037805195,0.00005127946,0.000014989698,0.0005555156,3.234755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059758476,0.00095705834,0.9891887,0.000050356197,0.00036323833,0.00010102634,0.00021914374,0.0001978443,0.00004103968,0.000016252541,0.0022982256,0.00596953],"study_design_scores_gemma":[0.01017365,0.002094427,0.960678,0.000107047,0.00028305285,0.000010241146,0.00008136021,0.0004168085,0.00015756759,0.0000091891625,0.025930036,0.000058647816],"about_ca_topic_score_codex":0.27253807,"about_ca_topic_score_gemma":0.74311584,"teacher_disagreement_score":0.47057778,"about_ca_system_score_codex":0.0011309986,"about_ca_system_score_gemma":0.0024683853,"threshold_uncertainty_score":0.7323062},"labels":[],"label_agreement":null},{"id":"W2591390419","doi":"10.1200/jco.2014.32.30_suppl.140","title":"An assessment of neoadjuvant therapy for breast cancer and treatment wait times at the BC Cancer Agency Vancouver.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Nat; Internal medicine; Cancer; Oncology; Chemotherapy; Stage (stratigraphy); Population; Hormonal therapy; Neoadjuvant therapy; Gynecology","score_opus":0.05330749195230813,"score_gpt":0.4693218679644994,"score_spread":0.41601437601219127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591390419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929846,0.0036765123,0.00019833406,0.0049152793,0.001133937,0.00027261418,0.00013812562,0.0000024486562,0.00036426142],"genre_scores_gemma":[0.97644424,0.020000257,0.0008439501,0.0008158043,0.0014266837,0.00007365406,0.0000056442937,0.000017634318,0.00037210243],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983516,0.00025071483,0.00083784724,0.00023329887,0.00013889452,0.0001876604],"domain_scores_gemma":[0.9978989,0.00040918743,0.0010368609,0.00022404984,0.00030347437,0.00012757331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000792191,0.00016906062,0.00073884835,0.000021660795,0.000096525626,0.000005600184,0.000166642,0.00018280312,0.000100124365],"category_scores_gemma":[0.00006522456,0.000089679525,0.00029726347,0.00003162224,0.00026016746,0.000007642193,0.0000528665,0.00010554327,2.7768573e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027014022,0.0010363528,0.16183414,0.000009269922,0.0012362341,0.0000030613085,0.00009140789,0.00014423311,0.004088259,0.000050989293,0.0069963047,0.82180834],"study_design_scores_gemma":[0.008873724,0.0121022295,0.8184503,0.000028093387,0.00036054442,0.00003166048,0.000076152915,0.0001693146,0.0022615376,0.00017820552,0.15732688,0.00014140469],"about_ca_topic_score_codex":0.00030865977,"about_ca_topic_score_gemma":0.0034095352,"teacher_disagreement_score":0.82166696,"about_ca_system_score_codex":0.00013630543,"about_ca_system_score_gemma":0.0007140372,"threshold_uncertainty_score":0.36570248},"labels":[],"label_agreement":null},{"id":"W2591393981","doi":"10.1200/jco.2016.34.4_suppl.724","title":"Time to first-line chemotherapy and travel distance to the cancer center and their relationship to subsequent-line therapies in stage IV CRC.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Bevacizumab; FOLFIRI; Internal medicine; Stage (stratigraphy); Colorectal cancer; Chemotherapy; Performance status; Cohort; Metastasectomy; Logistic regression; Multivariate analysis; Cancer; Irinotecan; Oncology; Surgery","score_opus":0.11212500421246642,"score_gpt":0.43499239358170233,"score_spread":0.3228673893692359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591393981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75463814,0.0012076369,0.00033581082,0.24303861,0.00016326264,0.00033941751,0.000031169886,0.0000031466673,0.00024281784],"genre_scores_gemma":[0.9839264,0.00294219,0.0003600174,0.009470434,0.00046222899,0.000028901502,4.719255e-7,0.000013370341,0.002796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852294,0.000120583616,0.0008355309,0.00019956192,0.00013274529,0.00018861234],"domain_scores_gemma":[0.9976593,0.0015556511,0.00024768498,0.00013207602,0.00014725018,0.00025798636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010754459,0.0001363102,0.00077614514,0.00007614187,0.000059615882,0.000008817134,0.00009217892,0.00009536113,0.00016674808],"category_scores_gemma":[0.0007986957,0.000057661087,0.000095776006,0.00013051993,0.00012638273,0.000049282247,0.000047432022,0.00022170677,0.000011305324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015311951,0.0007886262,0.57627195,0.000018651308,0.0004136919,0.000068881345,0.0044884076,0.000018824647,0.0003896566,0.00007930669,0.0048819184,0.39726812],"study_design_scores_gemma":[0.005299746,0.0059745954,0.7804576,0.00017450086,0.000032230615,0.000019143681,0.000199544,0.000011503499,0.00003973016,0.0001331288,0.20758842,0.000069849906],"about_ca_topic_score_codex":0.00003513987,"about_ca_topic_score_gemma":0.0028280863,"teacher_disagreement_score":0.39719826,"about_ca_system_score_codex":0.00019077904,"about_ca_system_score_gemma":0.00016513551,"threshold_uncertainty_score":0.23513508},"labels":[],"label_agreement":null},{"id":"W2591394521","doi":"10.1200/jco.2014.32.3_suppl.303","title":"Effects of statin, aspirin, or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Metformin; Gastroenterology; Aspirin; Statin; Cohort; Proportional hazards model; Atorvastatin; Cancer; Surgery; Insulin","score_opus":0.03931580923160858,"score_gpt":0.37614929941578923,"score_spread":0.33683349018418063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591394521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950236,0.0004382821,0.00009987875,0.00013979104,0.004025771,0.00016458973,0.000021289381,0.0000011865721,0.000085600914],"genre_scores_gemma":[0.9895503,0.0038343319,0.0017492505,0.001064008,0.003648079,0.000008041132,0.0000069838406,0.000019915848,0.00011906991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979288,0.0004557099,0.0009986159,0.00021325871,0.00022079736,0.00018284275],"domain_scores_gemma":[0.99718285,0.0012307406,0.0009801439,0.00019017099,0.00025163044,0.00016447828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013316473,0.00013712587,0.00081209984,0.0000658196,0.000015025676,0.000006466275,0.00018267696,0.00025277748,0.0000096008835],"category_scores_gemma":[0.0039821174,0.00008599604,0.0001200079,0.000059684946,0.00015580925,0.000017705865,0.00006016824,0.00037293683,3.303082e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020908806,0.0027384115,0.6338956,0.00014333415,0.00023006446,0.000005372682,0.00007913278,0.000078369485,0.0017502685,0.00009000354,0.009999102,0.33008158],"study_design_scores_gemma":[0.010694638,0.014939537,0.7903947,0.000108627915,0.000083158564,0.0000046009204,0.000007347353,0.000008093414,0.0008934306,0.00007550732,0.18267252,0.000117838164],"about_ca_topic_score_codex":0.00011688317,"about_ca_topic_score_gemma":0.0006391446,"teacher_disagreement_score":0.32996374,"about_ca_system_score_codex":0.000023169345,"about_ca_system_score_gemma":0.00054994924,"threshold_uncertainty_score":0.4767254},"labels":[],"label_agreement":null},{"id":"W2591394585","doi":"10.1200/jco.2013.31.6_suppl.244","title":"The risk of debilitating falls in Manitobans living with prostate cancer (pc).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Winnipeg Regional Health Authority; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cancer; Hazard ratio; Cohort; Incidence (geometry); Population; Prostate cancer; Internal medicine; Retrospective cohort study; Cancer registry; Poison control; Cumulative incidence; Emergency medicine; Confidence interval","score_opus":0.2585505711471284,"score_gpt":0.6143436777343625,"score_spread":0.35579310658723406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591394585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97811925,0.00088975695,0.00002676701,0.015339209,0.0015658207,0.000611525,0.0000032539037,0.000004074283,0.003440344],"genre_scores_gemma":[0.9933024,0.003059882,0.0014666171,0.00085028313,0.0008142601,0.000058562575,7.5564806e-8,0.000013706575,0.00043418282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9852401,0.010104141,0.0038762933,0.00012355132,0.000280348,0.00037553598],"domain_scores_gemma":[0.9168876,0.075183526,0.0065403283,0.00017225089,0.0010057987,0.00021048298],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024602333,0.00009379934,0.0009115007,0.00006121783,0.00026830845,0.000007666842,0.00022238816,0.00031163864,0.00017711226],"category_scores_gemma":[0.025223488,0.00004493172,0.00012167394,0.00014993607,0.00014366406,0.00027156025,0.00005567947,0.0026740606,0.000028882934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032671663,0.000120134355,0.8514384,0.00011484109,0.00008330646,0.000009863361,0.005150635,0.000027745979,0.0000075861844,0.00008257675,0.0013220693,0.14131612],"study_design_scores_gemma":[0.0011133966,0.0024417562,0.9002055,0.0009983785,0.00003923371,0.0000070667447,0.022662023,0.00010153896,5.021545e-7,0.0003808525,0.07199524,0.00005452723],"about_ca_topic_score_codex":0.0122346645,"about_ca_topic_score_gemma":0.046925757,"teacher_disagreement_score":0.14126159,"about_ca_system_score_codex":0.00015872704,"about_ca_system_score_gemma":0.003461125,"threshold_uncertainty_score":0.9996268},"labels":[],"label_agreement":null},{"id":"W2591397831","doi":"10.1200/jco.2016.34.2_suppl.499","title":"Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cabozantinib; Medicine; Clinical endpoint; Everolimus; Internal medicine; Interim analysis; Population; Oncology; Renal cell carcinoma; Randomized controlled trial; Pazopanib; Progression-free survival; Sunitinib; Urology; Overall survival","score_opus":0.13154582464890424,"score_gpt":0.4595782746031576,"score_spread":0.32803244995425335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591397831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958465,0.00038959362,0.00011147506,0.00034232772,0.0008312325,0.0010148005,0.000014165678,0.0000039710344,0.0014459107],"genre_scores_gemma":[0.9961562,0.0003001275,0.0030576591,0.00006119845,0.00029490024,0.000014812476,0.0000055518663,0.000024928539,0.000084635525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921515,0.0015666586,0.004829762,0.00030147642,0.0008263753,0.00032424208],"domain_scores_gemma":[0.9841886,0.008795603,0.0052966783,0.00037425413,0.0009673136,0.00037752086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038311088,0.00027025264,0.0048407866,0.0004260836,0.0000152083685,0.000002465104,0.00021632377,0.00032689978,0.00011982847],"category_scores_gemma":[0.0055900076,0.0001342082,0.0012064852,0.00029887535,0.00054212037,0.00014095717,0.00005065215,0.00048662277,0.0000037057232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9286801,0.010314003,0.020267483,0.00004513429,0.0008097063,0.00046766398,0.000072237955,0.000010123332,0.0046008797,0.0000094542265,0.00008161364,0.034641586],"study_design_scores_gemma":[0.8072052,0.13747337,0.036071967,0.00016749682,0.0020898704,0.000019033481,0.00003815601,0.000009750137,0.016548721,0.000023424982,0.00024728038,0.00010571166],"about_ca_topic_score_codex":0.000077426,"about_ca_topic_score_gemma":0.000037835518,"teacher_disagreement_score":0.12715937,"about_ca_system_score_codex":0.00022185103,"about_ca_system_score_gemma":0.0014926911,"threshold_uncertainty_score":0.6692165},"labels":[],"label_agreement":null},{"id":"W2591404024","doi":"10.1200/jco.2015.33.3_suppl.393","title":"Quality of life in RCT of pasireotide to reduce pancreatic complications following resection.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pasireotide; Quality of life (healthcare); Nausea; Population; Placebo; Randomized controlled trial; Constipation; Randomization; Clinical endpoint; Pancreatic cancer; Internal medicine; Surgery; Cancer","score_opus":0.46878629426466367,"score_gpt":0.598055966251194,"score_spread":0.12926967198653028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591404024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975316,0.00032095402,0.000715164,0.010224973,0.00037848658,0.00031457766,0.000002680409,0.0000037575785,0.012723391],"genre_scores_gemma":[0.9854068,0.00012790313,0.013270944,0.0006313993,0.00029008646,0.000008950392,0.0000014116943,0.000009025293,0.00025345793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99355996,0.0014234463,0.0040687686,0.00015714926,0.0005750542,0.00021564474],"domain_scores_gemma":[0.98952013,0.0066771153,0.00171114,0.0003212578,0.0010364082,0.000733972],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01391064,0.00009140725,0.0025897245,0.00029578482,0.000019647448,0.0000020046264,0.00021577427,0.00026917612,0.000038643808],"category_scores_gemma":[0.059402682,0.000069180365,0.00040800034,0.0004222823,0.0002453231,0.00006684272,0.000069513706,0.00072860846,0.000013012608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062139924,0.0019299781,0.98095703,0.00006752369,0.0003707702,0.00005907475,0.00027777234,0.000028056425,0.000988945,0.00036034256,0.0037649013,0.0049815844],"study_design_scores_gemma":[0.0084993495,0.009466845,0.9769798,0.00021849292,0.0001976965,0.000053524018,0.00072383875,0.00007439627,0.00008236521,0.0013230011,0.0023261749,0.000054520187],"about_ca_topic_score_codex":0.00043852834,"about_ca_topic_score_gemma":0.00021991477,"teacher_disagreement_score":0.04549204,"about_ca_system_score_codex":0.00022479914,"about_ca_system_score_gemma":0.0050615105,"threshold_uncertainty_score":0.94852036},"labels":[],"label_agreement":null},{"id":"W2591404122","doi":"10.1200/jco.2016.34.7_suppl.286","title":"Quality of radiation therapy referral and utilization post-prostatectomy: A population-based study of time trends.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Referral; Radiation therapy; Population; Cohort; Cancer registry; Cancer; Internal medicine; Family medicine","score_opus":0.18950854003682954,"score_gpt":0.5598677161914019,"score_spread":0.3703591761545723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591404122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957512,0.0004458761,0.0005325046,0.002515377,0.00040118885,0.0001981675,0.000006959501,0.0000058488627,0.00014285548],"genre_scores_gemma":[0.99705654,0.00077597,0.0011479303,0.00058031746,0.00029075285,0.0000019628596,0.000004861712,0.000009491011,0.00013215489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651587,0.0008953205,0.0021235356,0.00013160752,0.00023823543,0.000095422605],"domain_scores_gemma":[0.9934972,0.0031671787,0.0026429372,0.00014885506,0.00044301216,0.00010081972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026735829,0.00009049535,0.0011901648,0.0001799526,0.000024758374,0.0000010589599,0.00007111017,0.0002669498,0.00019004908],"category_scores_gemma":[0.0023389917,0.00005013497,0.00016860875,0.00013582349,0.00016218021,0.00010746056,0.000007942136,0.0002171552,7.2985216e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010087256,0.0018669122,0.52433765,0.000008221791,0.00014214925,0.0000067597707,0.00014507305,0.000008766968,0.001428634,0.000022049595,0.000049392063,0.46189713],"study_design_scores_gemma":[0.022800008,0.03204366,0.9425886,0.000034917877,0.000068886264,0.000009942911,0.000062215404,0.000049907572,0.00019644662,0.00027821434,0.0018166311,0.00005055781],"about_ca_topic_score_codex":0.0000253764,"about_ca_topic_score_gemma":0.000033466957,"teacher_disagreement_score":0.4618466,"about_ca_system_score_codex":0.00009092296,"about_ca_system_score_gemma":0.0004730407,"threshold_uncertainty_score":0.28001606},"labels":[],"label_agreement":null},{"id":"W2591410678","doi":"10.1200/jco.2014.32.4_suppl.85","title":"Transcriptome-wide analysis of matched biopsy and prostatectomy to measure genomic classifiers of prostate cancer progression and field effect.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Biopsy; Prostate cancer; Prostatectomy; Medicine; Prostate; Pathology; Cancer; Prostate biopsy; Metastasis; RNA extraction; RNA; Internal medicine; Biology; Gene","score_opus":0.026139410474751813,"score_gpt":0.4058772504086056,"score_spread":0.3797378399338538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591410678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926432,0.00060257583,0.0045958427,0.001706113,0.00006114185,0.00028180247,0.000011045303,0.0000025086306,0.00009581662],"genre_scores_gemma":[0.9938295,0.0007529178,0.0048567723,0.0004497138,0.000052778083,0.000024465178,0.0000056815725,0.00000823469,0.000019957142],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983622,0.00029741478,0.00091835426,0.0002051255,0.00009375932,0.00012315431],"domain_scores_gemma":[0.9984695,0.00022685368,0.00078596745,0.0001645865,0.00020499292,0.00014810881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015781806,0.00010546152,0.0007868408,0.00011638435,0.00002269426,0.0000037980735,0.00012666134,0.00033454146,0.0000054429256],"category_scores_gemma":[0.0005693971,0.00007459786,0.00021588687,0.0001577853,0.00018821289,0.000003042259,0.00005511092,0.00019518827,8.9884836e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014871978,0.0001272315,0.20479988,0.000038987007,0.0006605518,0.0000028799554,0.00005458223,0.000015320784,0.70638347,0.000037812388,0.000260895,0.086131185],"study_design_scores_gemma":[0.0048318333,0.02820279,0.46497747,0.0001556782,0.0025139067,0.000057368765,0.00007237653,0.00022090544,0.44909406,0.0002635968,0.04926716,0.00034284068],"about_ca_topic_score_codex":0.000015770023,"about_ca_topic_score_gemma":0.00003265498,"teacher_disagreement_score":0.2601776,"about_ca_system_score_codex":0.000008063464,"about_ca_system_score_gemma":0.00013117345,"threshold_uncertainty_score":0.30420125},"labels":[],"label_agreement":null},{"id":"W2591414525","doi":"10.1200/jco.2014.32.30_suppl.70","title":"Assessing person-centered care readiness at a cancer system level through a provincial environmental scan in Ontario.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Psychosocial; Psychological intervention; Government (linguistics); Nursing; Agency (philosophy); Focus group; Family medicine; Business; Psychiatry","score_opus":0.6023538795043089,"score_gpt":0.5728025790492429,"score_spread":0.029551300455065932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591414525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940176,0.00013952446,0.00053982105,0.004876259,0.0023421007,0.00039452623,0.00001219003,0.000010450006,0.0022833871],"genre_scores_gemma":[0.9885599,0.00005015168,0.006779887,0.0024153178,0.0019042898,0.000011617294,0.000021573764,0.000028132183,0.00022914102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937958,0.0009167004,0.0040476467,0.00032883714,0.0005900604,0.00032095934],"domain_scores_gemma":[0.9931752,0.002867502,0.0032081602,0.00022165022,0.00023009603,0.00029736906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042380267,0.00019492688,0.0015880527,0.000101489415,0.000075405536,0.000024416453,0.00017491198,0.00040844554,0.0003168713],"category_scores_gemma":[0.005020897,0.00015358554,0.00043123,0.00008669639,0.00017059463,0.0005125032,0.000099404024,0.0014160844,0.000020459898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004195351,0.00088669313,0.86235696,0.00009748602,0.0001585451,0.0003653423,0.0014394693,0.00002537086,0.00048213778,0.000020360701,0.0011212584,0.12885101],"study_design_scores_gemma":[0.01669239,0.004027681,0.90877545,0.000482465,0.0005758849,0.0005613313,0.00848432,0.00034319508,0.000048590042,0.00001318958,0.059834808,0.00016068023],"about_ca_topic_score_codex":0.02475096,"about_ca_topic_score_gemma":0.23348734,"teacher_disagreement_score":0.20873637,"about_ca_system_score_codex":0.0052258917,"about_ca_system_score_gemma":0.0038886361,"threshold_uncertainty_score":0.99859285},"labels":[],"label_agreement":null},{"id":"W2591415331","doi":"10.1200/jco.2015.33.28_suppl.121","title":"Early breast cancer response to neoadjuvant chemotherapy: Defining the optimal timing and response rate using clinical tumor measurement.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Breast cancer; Complete response; Internal medicine; Neoadjuvant therapy; Cancer; Oncology; Cutoff; Chemotherapy; Receiver operating characteristic; Nat; Gastroenterology","score_opus":0.17304147651534227,"score_gpt":0.46042241168168335,"score_spread":0.2873809351663411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591415331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97680795,0.0017014007,0.00034972795,0.01990898,0.0010236172,0.00015830327,0.000017666433,0.000005140458,0.000027227079],"genre_scores_gemma":[0.9876569,0.00029689385,0.0054132584,0.005307217,0.0012463456,0.000009081883,4.7063347e-7,0.00003272953,0.000037122416],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9936435,0.0036506937,0.0016455913,0.0003555274,0.00036781275,0.00033684308],"domain_scores_gemma":[0.9956251,0.0016050311,0.0011400051,0.00027617917,0.00087974936,0.00047394302],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025094336,0.00022018861,0.0008925971,0.0000648626,0.00012345563,0.00003198637,0.00028728705,0.0002499282,0.000009602823],"category_scores_gemma":[0.008601121,0.00014319217,0.00030073986,0.00011583384,0.0003615724,0.000014969375,0.00022111852,0.0004972933,0.000005596192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60665846,0.0010935302,0.22762673,0.000009501378,0.0021769337,0.0004291025,0.0010862859,0.0009138062,0.02769682,0.000010472052,0.008561562,0.12373682],"study_design_scores_gemma":[0.011109794,0.0075401706,0.9338248,0.00011365627,0.00032941188,0.0008108535,0.00062702695,0.00008497638,0.0008678508,0.000019579778,0.04442109,0.00025082898],"about_ca_topic_score_codex":0.000079510195,"about_ca_topic_score_gemma":0.000050820356,"teacher_disagreement_score":0.70619804,"about_ca_system_score_codex":0.00020430266,"about_ca_system_score_gemma":0.0029291578,"threshold_uncertainty_score":0.99974984},"labels":[],"label_agreement":null},{"id":"W2591420086","doi":"10.1200/jco.2016.34.2_suppl.264","title":"Phase I/II study of stereotactic ablative radiotherapy including regional lymph node irradiation for patients with high-risk prostate cancer (SATURN): Early results.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Common Terminology Criteria for Adverse Events; Radiation therapy; Context (archaeology); Cyberknife; SABR volatility model; Androgen deprivation therapy; Urology; Cancer; Radiology; Internal medicine; Radiosurgery","score_opus":0.09137467345605657,"score_gpt":0.44864508255509955,"score_spread":0.35727040909904295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591420086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928313,0.00033267678,0.000080204874,0.0048461496,0.0005657254,0.0011640759,0.00015582288,0.000005807306,0.000018270452],"genre_scores_gemma":[0.99427027,0.0029085882,0.0017363973,0.0004139213,0.0004818012,0.00007793885,0.0000075589573,0.000025449888,0.00007806045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966969,0.00031807533,0.002074086,0.00026673693,0.00042494334,0.00021924183],"domain_scores_gemma":[0.9911573,0.0030440928,0.0043217163,0.00018315419,0.0010578984,0.00023583554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013459164,0.00017225744,0.001223693,0.00013109505,0.000086478736,0.00000618308,0.000093253344,0.00014732518,0.000016387423],"category_scores_gemma":[0.0011986615,0.000087667206,0.00020220944,0.00012202531,0.00013098684,0.00022194831,0.00002234347,0.00024363735,5.2007266e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08364886,0.019285088,0.6768649,0.000016670498,0.0022603741,0.000038963448,0.0015236206,0.000018949895,0.00003963526,0.000010627975,0.0006326469,0.21565962],"study_design_scores_gemma":[0.16139686,0.1622037,0.67165935,0.00028767163,0.0007263216,0.0000052546143,0.0000844501,0.000013473083,0.000054827546,0.00008720668,0.0033981013,0.00008281267],"about_ca_topic_score_codex":0.00018631355,"about_ca_topic_score_gemma":0.000052205007,"teacher_disagreement_score":0.2155768,"about_ca_system_score_codex":0.0007021594,"about_ca_system_score_gemma":0.0010686304,"threshold_uncertainty_score":0.35749647},"labels":[],"label_agreement":null},{"id":"W2591428992","doi":"10.1200/jco.2016.34.7_suppl.118","title":"The Canadian True NTH Initiative: A multisite intervention to improve the lives of men with prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Prostate Cancer Canada; Cancer Care Ontario","funders":"","keywords":"Psychological intervention; Medicine; Prostate cancer; Medical education; Narrative; Intervention (counseling); Program evaluation; Plan (archaeology); Public relations; Nursing; Political science; Cancer; Public administration","score_opus":0.24856286727339377,"score_gpt":0.5762888402728389,"score_spread":0.3277259729994451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591428992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74559116,0.00025817505,0.00060189003,0.24990112,0.0009629571,0.0009681727,0.000037454884,0.0000050306835,0.0016740084],"genre_scores_gemma":[0.9924279,0.0007727772,0.0013065718,0.0043087923,0.00067878596,0.000023176566,0.0000010249569,0.000013722352,0.00046726217],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954398,0.0008270847,0.0029991842,0.00014777074,0.00035894685,0.00022718299],"domain_scores_gemma":[0.9832996,0.011743952,0.003005062,0.00022552494,0.001328644,0.0003972055],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008381113,0.00010249847,0.00064633234,0.00007811955,0.00010609478,0.000014632345,0.00021232381,0.000112546324,0.000105924846],"category_scores_gemma":[0.027250962,0.00003816056,0.0002504514,0.000144422,0.0003428416,0.00018136462,0.0000516206,0.0005689194,0.000010465722],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011174447,0.00029841828,0.06378911,0.000013603573,0.0005083112,0.000071187314,0.00064308255,0.000004857259,0.00035837022,0.000057125624,0.005377128,0.91770434],"study_design_scores_gemma":[0.019974887,0.03687384,0.7940833,0.0007400626,0.00092322147,0.00016824692,0.004408062,0.00012846998,0.00059625204,0.00062674534,0.14133345,0.00014347908],"about_ca_topic_score_codex":0.020083234,"about_ca_topic_score_gemma":0.37412065,"teacher_disagreement_score":0.9175609,"about_ca_system_score_codex":0.00032589163,"about_ca_system_score_gemma":0.0031248175,"threshold_uncertainty_score":0.9864421},"labels":[],"label_agreement":null},{"id":"W2591438633","doi":"10.1200/jco.2012.30.15_suppl.3560","title":"Impact of body mass index (BMI) and weight changes on recurrence and survival in stage III colon cancer (CC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Overweight; Body mass index; Confounding; Internal medicine; Proportional hazards model; Cancer; Obesity; Weight loss; Stage (stratigraphy); Gastroenterology; Colorectal cancer","score_opus":0.06394326303538458,"score_gpt":0.44672089493620104,"score_spread":0.3827776319008165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591438633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987599,0.0055847773,0.000027487536,0.00034713373,0.00589914,0.00009156272,0.000025363015,9.3466144e-7,0.0004246082],"genre_scores_gemma":[0.9664718,0.025059903,0.00008787209,0.00018485397,0.008027942,0.000003883057,0.000002286731,0.000009257927,0.00015220536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984027,0.00030972247,0.00074780436,0.00015843034,0.00013832592,0.00024298384],"domain_scores_gemma":[0.99844706,0.0002618136,0.00079949654,0.0001181176,0.00012813993,0.000245346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018095527,0.00012453835,0.00076491525,0.00007712403,0.00001808376,0.0000047076396,0.000109505556,0.00035981415,0.000025604682],"category_scores_gemma":[0.00053643854,0.000091383496,0.00013462213,0.00006083367,0.00019990926,0.000008988844,0.00006065489,0.00038437586,2.8154298e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00465693,0.0012187712,0.88903534,0.000030089666,0.0002098764,0.0000019601353,0.000082078426,0.000011753133,0.022760626,0.000075277734,0.003615609,0.07830166],"study_design_scores_gemma":[0.007091015,0.0047812234,0.76657546,0.000040832867,0.00005141481,0.000015299127,0.00005157446,0.00001472577,0.0007737283,0.000030032677,0.22046015,0.000114545874],"about_ca_topic_score_codex":0.00018153046,"about_ca_topic_score_gemma":0.0007823731,"teacher_disagreement_score":0.21684454,"about_ca_system_score_codex":0.000037696725,"about_ca_system_score_gemma":0.00048326296,"threshold_uncertainty_score":0.37265107},"labels":[],"label_agreement":null},{"id":"W2591440427","doi":"10.1200/jco.2005.23.16_suppl.6094","title":"A systematic approach to adaptation of clinical practice guidelines (CPGs)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Guideline; Medicine; Adaptation (eye); Context (archaeology); Credibility; Multidisciplinary approach; Quality (philosophy); Process (computing); Process management; Systematic review; MEDLINE; Computer science; Psychology; Pathology; Engineering","score_opus":0.7029968161426422,"score_gpt":0.6773461285402052,"score_spread":0.02565068760243705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591440427","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41285256,0.0023067424,0.21457042,0.33501926,0.007779623,0.004301746,0.00001584247,0.00007721345,0.023076618],"genre_scores_gemma":[0.33755782,0.0006713283,0.62599933,0.02980602,0.0056780153,0.000013849319,0.0000064839346,0.000032117674,0.00023503647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96738315,0.0029883555,0.027537856,0.0003954319,0.0013889717,0.00030624535],"domain_scores_gemma":[0.9305832,0.041052863,0.016659394,0.0005952354,0.010201201,0.0009081298],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0624481,0.00022639027,0.003772537,0.00026305905,0.000039144725,0.000015722906,0.00035813285,0.0006176391,0.00008371457],"category_scores_gemma":[0.5974474,0.00016217427,0.0011957529,0.0003943501,0.00016617106,0.0006485493,0.00011639248,0.0015338038,0.00011650937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021036789,0.017270757,0.00779226,0.0028616132,0.0027617416,0.00022066338,0.0007054116,0.0043392703,0.00010595674,0.0010868781,0.10835141,0.83346725],"study_design_scores_gemma":[0.037582695,0.045653604,0.04405523,0.004439594,0.011243255,0.0042255768,0.013654821,0.048889108,0.00004826873,0.00036274106,0.7892708,0.000574259],"about_ca_topic_score_codex":0.00006967514,"about_ca_topic_score_gemma":0.000050616574,"teacher_disagreement_score":0.832893,"about_ca_system_score_codex":0.00015959184,"about_ca_system_score_gemma":0.003872379,"threshold_uncertainty_score":0.96540695},"labels":[],"label_agreement":null},{"id":"W2591446975","doi":"10.1200/jco.2016.34.7_suppl.2","title":"Assessing the quality of chemotherapy in an episode-based funding model in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Regimen; Anthracycline; Adjuvant; Internal medicine; Adjuvant therapy; Chemotherapy; Cancer; Oncology; Breast cancer","score_opus":0.40682692932771863,"score_gpt":0.49615287679589026,"score_spread":0.08932594746817163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591446975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825484,0.0001758991,0.008194199,0.0041483343,0.0005009611,0.00007555856,0.000004778603,0.0000019599477,0.004349872],"genre_scores_gemma":[0.9958495,0.00014505876,0.0022298526,0.0014964954,0.0001583807,0.0000020578452,2.0714471e-7,0.000010716144,0.00010776182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955342,0.00015542509,0.003854904,0.00018011128,0.000043378288,0.0002320247],"domain_scores_gemma":[0.9945166,0.0015874942,0.0035055578,0.00020912295,0.000076900906,0.00010428518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012017069,0.000097187105,0.0013275516,0.00018862089,0.00002003901,0.000019652101,0.000340999,0.00027754917,0.00015195657],"category_scores_gemma":[0.0017997588,0.000065246604,0.00026906605,0.0000889002,0.00018033404,0.0006811893,0.000021532098,0.0005317452,0.000006434676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039834555,0.0004276415,0.9485503,0.0000039123124,0.000016475145,0.0000036121671,0.0001449105,0.0010962085,0.00003138496,0.0089492565,0.000043141026,0.040334847],"study_design_scores_gemma":[0.004211807,0.0006180039,0.94500947,0.00004427096,0.0000028939023,0.0000012438272,0.000033382534,0.0019433422,0.000012768405,0.044571724,0.003457705,0.00009339024],"about_ca_topic_score_codex":0.0053840713,"about_ca_topic_score_gemma":0.07565165,"teacher_disagreement_score":0.07026759,"about_ca_system_score_codex":0.00065611536,"about_ca_system_score_gemma":0.0010784108,"threshold_uncertainty_score":0.9412153},"labels":[],"label_agreement":null},{"id":"W2591450482","doi":"10.1200/jco.2009.27.15_suppl.1032","title":"Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Tolerability; Taxane; Bevacizumab; Internal medicine; Population; Clinical trial; Breast cancer; Cohort; Randomized controlled trial; Oncology; Adverse effect; Cancer; Chemotherapy","score_opus":0.05015774311574187,"score_gpt":0.45404138520252485,"score_spread":0.40388364208678296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591450482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484694,0.00021121532,0.000009305586,0.004124249,0.00017758601,0.0005850372,0.000012877253,0.0000021910218,0.000030626652],"genre_scores_gemma":[0.9992132,0.00028463494,0.00009211802,0.0002886426,0.000094537376,0.000003988716,0.0000032727291,0.0000058487635,0.0000137615925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974354,0.00027251767,0.0017058267,0.00017570618,0.00028414282,0.00012639507],"domain_scores_gemma":[0.9969214,0.00071360875,0.0016659566,0.00018170991,0.00041435615,0.0001029674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007757966,0.00012207942,0.0016671411,0.00016156724,0.00002448503,0.0000017440427,0.000099501,0.00009404007,0.000112169524],"category_scores_gemma":[0.00020858292,0.000068672794,0.00027376495,0.0005335392,0.0001429818,0.00006724962,0.000015257939,0.0003617588,6.4112186e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023613127,0.008988264,0.8062071,0.000011067598,0.0010206684,0.000012179716,0.00028222983,0.0017789855,0.000021322714,0.0000010490294,0.00001618066,0.1580478],"study_design_scores_gemma":[0.042905707,0.022578767,0.9313983,0.00005132669,0.0024257652,0.000008360611,0.000051731953,0.0003782611,0.000020280318,0.000025779276,0.00010390768,0.00005182821],"about_ca_topic_score_codex":0.00030293223,"about_ca_topic_score_gemma":0.0035424412,"teacher_disagreement_score":0.15799597,"about_ca_system_score_codex":0.00023954557,"about_ca_system_score_gemma":0.00040056976,"threshold_uncertainty_score":0.28003952},"labels":[],"label_agreement":null},{"id":"W2591451639","doi":"10.1200/jco.2014.32.3_suppl.475","title":"Correlation of peripheral blood lymphocyte counts with outcome and histopathologic features of lymphocytic inflammation in patients with stage II colorectal carcinoma.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital; University of British Columbia","funders":"","keywords":"Medicine; Lymph; Lymph node; Lymphocyte; Colorectal cancer; Internal medicine; Hazard ratio; Stage (stratigraphy); Gastroenterology; Pathology; Inflammation; Confidence interval; Oncology; Cancer","score_opus":0.022325632501490025,"score_gpt":0.3256643621595902,"score_spread":0.3033387296581002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591451639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820584,0.00011986652,0.000036092246,0.00006115096,0.00020665576,0.00021598727,0.0000037838256,0.000003946082,0.001146702],"genre_scores_gemma":[0.9980221,0.000018149774,0.0017339545,0.0000782831,0.00007510033,0.0000027035005,0.000004629328,0.000009971591,0.00005512273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797463,0.00024626826,0.0012402001,0.00011766025,0.0003118835,0.00010933823],"domain_scores_gemma":[0.9974153,0.00035454784,0.0016196339,0.00010422507,0.0004031955,0.000103071914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011642706,0.00010481959,0.0008143409,0.00013447371,0.000020802338,0.0000023029006,0.000067215646,0.00021583296,0.000024780671],"category_scores_gemma":[0.00096020073,0.00006794328,0.00008506831,0.000095401985,0.00030403043,0.00008004709,0.00002833625,0.00021428426,6.288023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011314876,0.00039935895,0.9795902,0.00010179528,0.00008085292,0.000066355715,0.00011172267,0.0000438952,0.000053990225,0.00004909591,0.000022308524,0.008165594],"study_design_scores_gemma":[0.016812183,0.011533846,0.97040886,0.00011067753,0.00033242596,0.00006135429,0.000030256777,0.00029419202,0.00009351123,0.000014991869,0.00024249364,0.00006522971],"about_ca_topic_score_codex":0.0000068321874,"about_ca_topic_score_gemma":0.000015751953,"teacher_disagreement_score":0.011134488,"about_ca_system_score_codex":0.00027392618,"about_ca_system_score_gemma":0.0008098265,"threshold_uncertainty_score":0.27706462},"labels":[],"label_agreement":null},{"id":"W2591452996","doi":"10.1200/jco.2005.23.16_suppl.8019","title":"The characteristics and correlates of dyspnea (D) in advanced cancer patients (ACP)","year":2005,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Anxiety; Depression (economics); Hospital Anxiety and Depression Scale; Univariate analysis; Cancer; Gastroenterology; Multivariate analysis; Psychiatry","score_opus":0.04911176665465096,"score_gpt":0.4461173378771145,"score_spread":0.39700557122246355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591452996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93020564,0.048802514,0.0000060761067,0.0146134505,0.0051996503,0.000312678,0.00005157794,0.0000018126507,0.0008066115],"genre_scores_gemma":[0.941811,0.05386283,0.00027802296,0.00038609112,0.0022701558,0.0000057069265,0.0000030630868,0.000021817536,0.0013612737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99454397,0.0008369704,0.0033650636,0.000217467,0.00053266104,0.0005038719],"domain_scores_gemma":[0.98951197,0.0065098777,0.0023070902,0.00020111543,0.00092427584,0.00054569833],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031699,0.00017932209,0.0014858181,0.00011815166,0.000059529793,0.000009759186,0.0002678768,0.0004472922,0.00040787802],"category_scores_gemma":[0.008869399,0.00012332857,0.00028089405,0.00019381715,0.0013211329,0.00020135051,0.00015956543,0.0019339533,0.000019147572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002924966,0.0015424776,0.4806626,0.00010930811,0.00015453467,0.00013187261,0.00009059546,0.000023204075,0.000015543299,0.00015109935,0.00045526607,0.5137385],"study_design_scores_gemma":[0.008225415,0.0036222888,0.87138563,0.00066882523,0.00026480507,0.000043088003,0.00020963264,0.0017049963,0.000011666999,0.00024172782,0.113532655,0.000089254725],"about_ca_topic_score_codex":0.00004248678,"about_ca_topic_score_gemma":0.00019950159,"teacher_disagreement_score":0.5136493,"about_ca_system_score_codex":0.00081644277,"about_ca_system_score_gemma":0.0027727967,"threshold_uncertainty_score":0.9994793},"labels":[],"label_agreement":null},{"id":"W2591457709","doi":"10.1200/jco.2013.31.6_suppl.13","title":"Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Aflibercept; Medicine; Docetaxel; Prednisone; Internal medicine; Bevacizumab; Hazard ratio; Clinical endpoint; Prostate cancer; Gastroenterology; Placebo; Oncology; Surgery; Randomized controlled trial; Urology; Cancer; Chemotherapy; Confidence interval; Pathology","score_opus":0.17351494744900267,"score_gpt":0.4880195139565482,"score_spread":0.31450456650754555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591457709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747865,0.00044383047,0.00008307202,0.020136302,0.00026194326,0.0037942706,0.00021789165,0.0000051513603,0.00027102523],"genre_scores_gemma":[0.9939321,0.0010288428,0.0032453774,0.00006974811,0.00039993352,0.00045150323,0.00015592272,0.000019468578,0.00069707626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967409,0.0003109822,0.0019171153,0.0002442031,0.00054229534,0.00024450934],"domain_scores_gemma":[0.9903569,0.0066042193,0.0017305689,0.00017868531,0.00094204355,0.00018755822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013499196,0.0001837859,0.0011300695,0.00010661303,0.0000769534,0.000018650671,0.00011485399,0.000118280856,0.00010745019],"category_scores_gemma":[0.00086370256,0.000086804466,0.0001954397,0.00018690036,0.0002889248,0.00018564683,0.000013465242,0.00029312895,0.0000018675046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92839754,0.008945464,0.00091494544,0.00002367573,0.0014492797,0.00010761713,0.0013683245,0.00039248329,0.00017841852,0.000030516061,0.0009114599,0.057280257],"study_design_scores_gemma":[0.845046,0.1306316,0.015722828,0.00018225811,0.0009554055,0.000011372121,0.00085106277,0.002390332,0.00042027375,0.0001722825,0.0035171097,0.00009947083],"about_ca_topic_score_codex":0.0011487168,"about_ca_topic_score_gemma":0.003333711,"teacher_disagreement_score":0.12168614,"about_ca_system_score_codex":0.0005259108,"about_ca_system_score_gemma":0.0025305287,"threshold_uncertainty_score":0.4489049},"labels":[],"label_agreement":null},{"id":"W2591460777","doi":"10.1200/jco.2014.32.3_suppl.471","title":"Immune response and its correlation with the disease activity in patients with advanced colorectal cancer (aCRC): Results from a prospective observational study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Cancer; Antibody; Immune system; Gastroenterology; Titer; Oncology; Immunology","score_opus":0.09019225142709718,"score_gpt":0.4448637149123492,"score_spread":0.354671463485252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591460777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98668754,0.00010864058,0.000014626996,0.012266855,0.00013364691,0.00067332946,0.000035766407,0.0000032006988,0.0000764229],"genre_scores_gemma":[0.99906445,0.00005468564,0.00017742126,0.00027788346,0.00021946795,0.00002046803,0.0000073586816,0.000009238588,0.0001690327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972798,0.0010172068,0.0007630472,0.000212506,0.0005693764,0.00015804045],"domain_scores_gemma":[0.9922559,0.0059487107,0.00081263663,0.000098834156,0.0006588164,0.00022505494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025671585,0.000115785864,0.0006587786,0.00006170006,0.00007478839,0.000008541102,0.00009384717,0.00008791141,0.000018533217],"category_scores_gemma":[0.003973579,0.00005569684,0.000069369606,0.000162451,0.00019217841,0.0001557231,0.000050783747,0.0008539256,0.0000017302851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38652125,0.0013905546,0.60279673,0.0000038412622,0.00012690017,0.000054569155,0.00021667314,0.00010323362,0.000058313326,0.000009556376,0.000032244876,0.00868613],"study_design_scores_gemma":[0.022750452,0.026680628,0.94860274,0.00010927382,0.00011523255,0.000004398114,0.0000784196,0.00088443875,0.000015559786,0.00003931859,0.0006512794,0.00006823419],"about_ca_topic_score_codex":0.00009945764,"about_ca_topic_score_gemma":0.00033674255,"teacher_disagreement_score":0.3637708,"about_ca_system_score_codex":0.00012712514,"about_ca_system_score_gemma":0.0010435093,"threshold_uncertainty_score":0.47570327},"labels":[],"label_agreement":null},{"id":"W2591462114","doi":"10.1200/jco.2016.34.4_suppl.322","title":"Stereotactic body radiotherapy for unresectable hepatocellular carcinoma: A population based analysis of tumors up to 15 cm.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cyberknife; Radiosurgery; Radiofrequency ablation; Percutaneous ethanol injection; Population; Liver cancer; Retrospective cohort study; Percutaneous; Radiation therapy; Nuclear medicine; Radiology; Surgery; Ablation; Internal medicine","score_opus":0.16187744370322352,"score_gpt":0.41676094236129235,"score_spread":0.2548834986580688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591462114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874768,0.00040391705,0.0062660533,0.00461651,0.00047570778,0.0006553867,0.000021133395,0.000009222965,0.00007522462],"genre_scores_gemma":[0.9937382,0.00005364239,0.0045618033,0.00074649946,0.00046075415,0.000023858134,0.000017063714,0.000028012506,0.0003701686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961135,0.00048181645,0.00242461,0.00027022575,0.00040758794,0.00030229887],"domain_scores_gemma":[0.9937235,0.0032078982,0.0016030684,0.00032112593,0.0006477279,0.00049668626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002891662,0.00018829781,0.0023250137,0.0007096626,0.00003944279,0.0000079665,0.00016173949,0.00030344955,0.00037237347],"category_scores_gemma":[0.0022164097,0.000113857524,0.0015146913,0.0006024035,0.000060851435,0.00011172158,0.00001830828,0.00021635422,0.000004869196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007355409,0.00080647005,0.9727211,0.00004287235,0.0026080492,0.00021185339,0.00005892678,0.000006217074,0.0028860823,0.000036210808,0.00055679673,0.012710032],"study_design_scores_gemma":[0.014313958,0.019337736,0.9394426,0.00011842228,0.006356089,0.00003886605,0.000025318752,0.009123089,0.0025965045,0.000069182664,0.00842138,0.00015690367],"about_ca_topic_score_codex":0.00012727885,"about_ca_topic_score_gemma":0.000041406896,"teacher_disagreement_score":0.03327853,"about_ca_system_score_codex":0.00032206907,"about_ca_system_score_gemma":0.0009490076,"threshold_uncertainty_score":0.46429753},"labels":[],"label_agreement":null},{"id":"W2591465097","doi":"10.1200/jco.2016.34.26_suppl.84","title":"Integrative oncology consultation and symptom palliation: Analysis of patient-reported outcomes at a comprehensive cancer center.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Nausea; Anxiety; Physical therapy; Distress; Palliative care; Cancer; Breast cancer; Patient satisfaction; Internal medicine; Family medicine; Psychiatry; Nursing; Clinical psychology","score_opus":0.10260783753442763,"score_gpt":0.4810872973820467,"score_spread":0.37847945984761905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591465097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98854333,0.00051727984,0.00018283844,0.008645927,0.0012469036,0.00016080424,0.00003624648,0.0000053720373,0.00066130195],"genre_scores_gemma":[0.9949873,0.0023126558,0.000255438,0.002009686,0.00014067332,0.0000073344386,0.000007823666,0.000007437523,0.00027165894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996593,0.00046311942,0.0023058576,0.00018883296,0.00030958385,0.00013959812],"domain_scores_gemma":[0.9893512,0.005173058,0.003300554,0.00013715781,0.001797479,0.00024052746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006098176,0.00013032516,0.0020324641,0.0002487665,0.000027266451,0.0000027200572,0.000063707674,0.00029439564,0.00031046686],"category_scores_gemma":[0.0024246832,0.00006948037,0.0005433949,0.000303032,0.0003404705,0.0000736105,0.000048892674,0.00028302812,0.0000017869957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037853685,0.00047855763,0.8681208,0.000015538697,0.005225362,0.000119901844,0.0016238841,0.000004628127,0.0004803837,0.00006225889,0.0006960644,0.11938724],"study_design_scores_gemma":[0.00899541,0.0055426713,0.9360882,0.00013752138,0.0038224035,0.000063112544,0.0014340151,0.000036028738,0.00016459325,0.00006282151,0.04357256,0.00008068761],"about_ca_topic_score_codex":0.00019819463,"about_ca_topic_score_gemma":0.0032648512,"teacher_disagreement_score":0.11930656,"about_ca_system_score_codex":0.00042762607,"about_ca_system_score_gemma":0.0008262613,"threshold_uncertainty_score":0.33993942},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2591465484","doi":"10.1200/jco.2014.32.4_suppl.512","title":"Renal nephrometry score and predictors of complications in partial nephrectomies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Nephrectomy; Surgery; Univariate analysis; Multivariate analysis; Kidney; Internal medicine","score_opus":0.12399645738417438,"score_gpt":0.42329001034311803,"score_spread":0.29929355295894366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591465484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307835,0.00044115577,0.00017659346,0.0030503483,0.0003182304,0.00014671405,0.0000017128515,0.0000041743333,0.0027826973],"genre_scores_gemma":[0.9955119,0.00026622196,0.0029747412,0.00054743665,0.00064740307,0.0000019658298,0.0000020857779,0.000008971666,0.000039282877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715716,0.00035047188,0.0019502136,0.00014094375,0.00025286322,0.00014836987],"domain_scores_gemma":[0.99608016,0.002091298,0.0011264124,0.00018131488,0.0002190273,0.0003017951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020232196,0.00009718684,0.0011667788,0.00021249389,0.000016006328,0.0000032746516,0.0000943322,0.00022712526,0.000043488562],"category_scores_gemma":[0.002435756,0.00006795961,0.00029214314,0.00017210316,0.0003129327,0.00005572936,0.000043632946,0.00055803935,0.000004161433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016593576,0.0008499433,0.94885147,0.000031399835,0.00022532877,0.000091843496,0.00007066457,0.00002624165,0.0009139149,0.00022739446,0.0010219729,0.046030473],"study_design_scores_gemma":[0.0058317436,0.009140204,0.9654267,0.000105178566,0.00027853512,0.0003147723,0.000025436184,0.00017930697,0.00036605855,0.0002940952,0.017991219,0.00004674641],"about_ca_topic_score_codex":0.000020646967,"about_ca_topic_score_gemma":0.000026979747,"teacher_disagreement_score":0.045983728,"about_ca_system_score_codex":0.00008867816,"about_ca_system_score_gemma":0.00051483576,"threshold_uncertainty_score":0.29160032},"labels":[],"label_agreement":null},{"id":"W2591469525","doi":"10.1200/jco.2016.34.2_suppl.552","title":"The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Targeted therapy; Oncology; Cancer; Smoking cessation; Carcinoma; Gastroenterology; Pathology","score_opus":0.1336050188865711,"score_gpt":0.43381586510572606,"score_spread":0.30021084621915495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591469525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734086,0.00014444187,0.000007877577,0.0006045639,0.00019824287,0.0003623607,0.0000109377115,0.0000034981688,0.0013271967],"genre_scores_gemma":[0.9993473,0.00014452351,0.00013151241,0.00008320111,0.00012230832,0.0000052114074,0.0000024505525,0.000024182422,0.00013926269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569494,0.0010906802,0.0021548623,0.00019804243,0.0005494408,0.0003120094],"domain_scores_gemma":[0.9910175,0.005594707,0.002301023,0.00026790236,0.0005471224,0.0002717133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019446678,0.00022482351,0.0016133081,0.00018155675,0.00003458393,0.000004856232,0.00017671908,0.00016151431,0.00006659577],"category_scores_gemma":[0.0012151389,0.000078834535,0.0006457854,0.00019651522,0.00020427584,0.00007981477,0.000024624336,0.0006032628,0.0000043420914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03428556,0.0027912771,0.9002421,0.00000538995,0.000613047,0.0005374763,0.0000835813,0.00001618282,0.00073787663,0.0000039235397,0.00008172176,0.060601845],"study_design_scores_gemma":[0.026336443,0.069061965,0.90017796,0.00007192417,0.00022178373,0.000034892386,0.000057038917,0.0000064751034,0.0037980394,0.000034975255,0.00012159176,0.00007689906],"about_ca_topic_score_codex":0.0001780255,"about_ca_topic_score_gemma":0.000042304266,"teacher_disagreement_score":0.06627069,"about_ca_system_score_codex":0.0006435665,"about_ca_system_score_gemma":0.0010167605,"threshold_uncertainty_score":0.32147792},"labels":[],"label_agreement":null},{"id":"W2591471662","doi":"10.1200/jco.2014.32.3_suppl.423","title":"Dose intensity and survival outcomes with adjuvant FOLFOX for colon cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FOLFOX; Medicine; Oxaliplatin; Colorectal cancer; Internal medicine; Neutropenia; Oncology; Proportional hazards model; Chemotherapy; Cancer; Surgery","score_opus":0.18572815130798548,"score_gpt":0.5404889401147074,"score_spread":0.3547607888067219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591471662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96820843,0.0003715336,0.00020696578,0.027849983,0.0021881256,0.0002634841,0.000005379051,0.000007541606,0.0008985303],"genre_scores_gemma":[0.9898916,0.00065363094,0.0020035736,0.0054922607,0.0012973576,0.0000121828025,0.0000019239344,0.000012828944,0.0006346509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842817,0.00016588862,0.00092218403,0.00015183167,0.00014690107,0.00018505649],"domain_scores_gemma":[0.9955557,0.0027799553,0.0008287897,0.00008799162,0.00044270387,0.0003048572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017254502,0.000118504446,0.001696385,0.00005584598,0.000039910392,0.000004370623,0.000065032444,0.00020438187,0.00006827116],"category_scores_gemma":[0.0009673024,0.00006823584,0.00024037946,0.000046949142,0.00021694023,0.000047621175,0.000026951684,0.00042462,0.000001824961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030791676,0.0014153348,0.8154528,0.000045220924,0.00096165907,0.00014089496,0.000084893516,0.000004008778,0.00018303559,0.00015550698,0.009300172,0.14146478],"study_design_scores_gemma":[0.028866401,0.04521607,0.7457584,0.000046108154,0.0013617825,0.00019727409,0.000046558795,0.00010905196,0.00008654735,0.00024592542,0.17798272,0.00008316959],"about_ca_topic_score_codex":0.00006743682,"about_ca_topic_score_gemma":0.0005583566,"teacher_disagreement_score":0.16868255,"about_ca_system_score_codex":0.00009878222,"about_ca_system_score_gemma":0.0007339405,"threshold_uncertainty_score":0.27825767},"labels":[],"label_agreement":null},{"id":"W2591473726","doi":"10.1200/jco.2005.23.16_suppl.5157","title":"Adjuvant pelvic radiation therapy and high dose rate brachytherapy for pathologic stage III endometrial cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Brachytherapy; Endometrial cancer; Stage (stratigraphy); Radiation therapy; External beam radiotherapy; Pelvis; Surgery; Vaginal vault; Radiology; Hysterectomy; Cancer; Internal medicine","score_opus":0.16002388246163068,"score_gpt":0.4771538184966236,"score_spread":0.3171299360349929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591473726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708563,0.013113677,0.00021696684,0.012816305,0.0020767378,0.0006701149,0.000028789134,0.00001295606,0.00020816599],"genre_scores_gemma":[0.9365898,0.047252223,0.0025413865,0.0065026465,0.006476597,0.00003919589,0.000007836158,0.000020005535,0.00057031884],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969806,0.00043034673,0.0018136981,0.00024223745,0.00026670052,0.00026643008],"domain_scores_gemma":[0.99340826,0.0042468444,0.0015246167,0.00013222506,0.00032537244,0.0003626627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032292223,0.00017610146,0.0016551235,0.00022163759,0.000060982286,0.0000143233465,0.00010257585,0.00035247422,0.0005645531],"category_scores_gemma":[0.002251499,0.00010679431,0.0004733812,0.0002576173,0.00012593708,0.00015021295,0.000018683304,0.00050914753,0.000005218249],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045349963,0.0012381813,0.014223152,0.000013787853,0.00044690914,0.00012884573,0.000060391656,0.000021079979,0.00065104617,0.000115119365,0.0004877466,0.9372638],"study_design_scores_gemma":[0.19742659,0.04854258,0.4667567,0.000042792886,0.000465852,0.000113114096,0.000042593303,0.000117730226,0.00078293856,0.0007392291,0.2847884,0.00018148507],"about_ca_topic_score_codex":0.000054261167,"about_ca_topic_score_gemma":0.00003804403,"teacher_disagreement_score":0.9370823,"about_ca_system_score_codex":0.00022440184,"about_ca_system_score_gemma":0.0007385644,"threshold_uncertainty_score":0.61814606},"labels":[],"label_agreement":null},{"id":"W2591479741","doi":"10.1200/jco.2015.33.29_suppl.137","title":"Impact of integrated palliative care model on end-of-life (EOL) quality metrics for patients with kidney cancer (RCC) and melanoma (M).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Palliative care; Quality of life (healthcare); Cancer; Cohort; Internal medicine; Retrospective cohort study; Demographics; Family medicine; Nursing","score_opus":0.49349607600035084,"score_gpt":0.60079989177996,"score_spread":0.10730381577960912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591479741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563044,0.0014402792,0.0009457208,0.00047485833,0.00028827717,0.00029119497,0.00041503255,0.0000032008472,0.00051100046],"genre_scores_gemma":[0.98916686,0.0010284245,0.009093265,0.00046917453,0.00016502813,0.0000049703017,0.000030797062,0.000015806847,0.000025675596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677646,0.0003175934,0.0020530326,0.00017161248,0.00050158845,0.00017968177],"domain_scores_gemma":[0.98868454,0.003187092,0.003029024,0.00015777179,0.0042534717,0.00068808143],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014684867,0.00017466578,0.002147351,0.00020615199,0.000013757477,0.0000022429347,0.00012859992,0.00031483613,0.000019472232],"category_scores_gemma":[0.023521312,0.000100540296,0.00041176146,0.00024892302,0.0002986328,0.0000750299,0.000030654533,0.0004672721,2.9407025e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021669459,0.0012116577,0.95233965,0.0001517975,0.0010407837,0.000006190638,0.0016641145,0.00025585288,0.000016488015,0.00007291408,0.0020411317,0.019529974],"study_design_scores_gemma":[0.037492972,0.086568125,0.8627335,0.0013807225,0.001036487,0.0000015616216,0.0021335126,0.0012987183,0.00039817527,0.00035608304,0.0063891476,0.00021103589],"about_ca_topic_score_codex":0.00046631735,"about_ca_topic_score_gemma":0.00010165522,"teacher_disagreement_score":0.08960618,"about_ca_system_score_codex":0.00035269762,"about_ca_system_score_gemma":0.0062876395,"threshold_uncertainty_score":0.9993458},"labels":[],"label_agreement":null},{"id":"W2591484293","doi":"10.1200/jco.2014.32.4_suppl.306","title":"Neoadjuvant gemcitabine-cisplatin (GC) for muscle-invasive bladder cancer (MIBC): Does midway CT staging predict for pathologic complete response (pCR)?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Radiological weapon; Gemcitabine; Cisplatin; Neoadjuvant therapy; Internal medicine; Radiation therapy; Chemotherapy; Progressive disease; Cancer; Urology; Oncology; Surgery","score_opus":0.1305535509564767,"score_gpt":0.4537866521078087,"score_spread":0.323233101151332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591484293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960967,0.0006434495,0.010407347,0.021233104,0.0042408383,0.0016246282,0.00036727314,0.000040120478,0.0004762289],"genre_scores_gemma":[0.96753484,0.00058285915,0.018480958,0.008183316,0.003949999,0.00019482739,0.000019845314,0.000066861474,0.0009864853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952169,0.00082768145,0.0025341564,0.00045081542,0.00040556843,0.00056489545],"domain_scores_gemma":[0.9839028,0.012506503,0.0018833852,0.0003343485,0.00085464056,0.0005183356],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055910414,0.00031939265,0.0021298456,0.00017260047,0.00015406424,0.000021256405,0.00027382144,0.00032174902,0.00020457117],"category_scores_gemma":[0.010209229,0.00019135904,0.0010115686,0.00011246267,0.00029138697,0.00014216985,0.00006149753,0.00071152195,0.000008361696],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14307742,0.004303437,0.09517687,0.000587113,0.0034018226,0.0016194457,0.0009923478,0.00030789047,0.011621388,0.00032551415,0.03572208,0.7028647],"study_design_scores_gemma":[0.068309285,0.069125265,0.32004756,0.0006662314,0.0033098396,0.0005063752,0.00046957083,0.0015162693,0.0012409998,0.005260632,0.52903944,0.0005085067],"about_ca_topic_score_codex":0.000039564376,"about_ca_topic_score_gemma":0.0001221686,"teacher_disagreement_score":0.70235616,"about_ca_system_score_codex":0.00028392675,"about_ca_system_score_gemma":0.002177589,"threshold_uncertainty_score":0.9981282},"labels":[],"label_agreement":null},{"id":"W2591486309","doi":"10.1200/jco.2014.32.3_suppl.644","title":"Patterns of systemic therapy in metastatic colorectal cancer (mCRC): Use of intermittent and stop-and-go strategies in a population-based setting.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Bevacizumab; FOLFIRI; Internal medicine; Capecitabine; Population; Colorectal cancer; Systemic therapy; Cancer; Cohort; Oncology; Chemotherapy; Irinotecan; Breast cancer; Oxaliplatin","score_opus":0.12366162210276459,"score_gpt":0.480810905861421,"score_spread":0.3571492837586564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591486309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976212,0.00069319963,0.000032435826,0.001113284,0.00028508055,0.00023251852,0.000008045031,0.0000016659775,0.00001259174],"genre_scores_gemma":[0.9978843,0.0012715851,0.00029708046,0.00042618165,0.00009238282,0.000009461869,0.0000024702679,0.0000071991117,0.000009381929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997508,0.0005749607,0.0015738902,0.000110652225,0.00012231492,0.000110172165],"domain_scores_gemma":[0.9958743,0.00268591,0.0011764623,0.000053407548,0.00012508352,0.00008482623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012620428,0.00009361118,0.0011899386,0.00019091708,0.000006353656,0.0000037079712,0.000044121316,0.00011633675,0.00003941453],"category_scores_gemma":[0.00035646762,0.00006510682,0.000115811345,0.00007125346,0.00007728324,0.00007289907,0.000013799699,0.00032316367,1.0699449e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004264803,0.00079653034,0.93935084,0.00013345256,0.00017195195,0.000057729998,0.00041818654,0.00018734518,0.0013571986,0.000029459969,0.000024010616,0.053208463],"study_design_scores_gemma":[0.012777683,0.009413087,0.97539634,0.00045818658,0.00018571511,0.00006835718,0.0002571241,0.0010007012,0.00016973708,0.00006734002,0.00015802398,0.000047735273],"about_ca_topic_score_codex":0.0011889099,"about_ca_topic_score_gemma":0.0020739739,"teacher_disagreement_score":0.053160727,"about_ca_system_score_codex":0.000097820695,"about_ca_system_score_gemma":0.0006005113,"threshold_uncertainty_score":0.2654979},"labels":[],"label_agreement":null},{"id":"W2591492785","doi":"10.1200/jco.2012.30.4_suppl.638","title":"Prevalence of bowel dysfunction in colorectal cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Odds ratio; Logistic regression; Cancer; Population; Gastroenterology; Multivariate analysis","score_opus":0.09434937146815457,"score_gpt":0.4413463837246723,"score_spread":0.3469970122565177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591492785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913671,0.0018183732,0.00017311757,0.00071740313,0.0033469463,0.000114657116,0.0000018806185,0.0000067584037,0.0024537344],"genre_scores_gemma":[0.9964691,0.001152656,0.00054629706,0.00021608877,0.0014153242,0.000005403687,2.8057374e-7,0.000008268119,0.00018657747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975797,0.00031115106,0.0015296338,0.000099384444,0.00028612537,0.00019400404],"domain_scores_gemma":[0.99727076,0.0009308332,0.0011952359,0.00007374706,0.00030663493,0.00022277096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003611075,0.00008145212,0.000799328,0.00015091257,0.000014345342,0.0000016492598,0.00007059818,0.00029495015,0.00019881326],"category_scores_gemma":[0.002289281,0.00006164428,0.0002643647,0.00020003215,0.00011917612,0.00015762303,0.000025469697,0.0007369845,0.0000044713597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017879657,0.0007698832,0.87932414,0.00008808282,0.000067279456,0.000016879103,0.00014068103,0.000028795237,0.0009946377,0.0000147074525,0.00028964833,0.10038559],"study_design_scores_gemma":[0.0031315873,0.014795146,0.9746796,0.00014380174,0.00016646946,0.00017006022,0.0000704923,0.00014249852,0.0021821938,0.000024371302,0.004439748,0.00005406601],"about_ca_topic_score_codex":0.00042038938,"about_ca_topic_score_gemma":0.0005683807,"teacher_disagreement_score":0.10033153,"about_ca_system_score_codex":0.00020870805,"about_ca_system_score_gemma":0.00071227853,"threshold_uncertainty_score":0.32018718},"labels":[],"label_agreement":null},{"id":"W2591492929","doi":"10.1200/jco.2005.23.16_suppl.1557","title":"Chemoradiation or standard radiation followed by adjuvant temozolomide (TMZ) and 13-cis-retinoic acid (CRA) for high grade glioma in adults - a regional cancer centre study","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Temozolomide; Anaplastic astrocytoma; Glioma; Internal medicine; Clinical endpoint; Radiation therapy; Phases of clinical research; Cancer; Oncology; Gastroenterology; Surgery; Chemotherapy; Astrocytoma; Clinical trial; Cancer research","score_opus":0.05848166812880944,"score_gpt":0.42715236225333136,"score_spread":0.3686706941245219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591492929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94993687,0.0023840058,0.000017209815,0.04611938,0.0004725597,0.0010035551,0.00004387297,0.000009161246,0.000013366876],"genre_scores_gemma":[0.99509805,0.0015025894,0.0011056028,0.0011213481,0.0010185724,0.00006412808,0.000025202891,0.000022026274,0.00004249885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967876,0.00027366515,0.0019345897,0.00030594243,0.00041636586,0.0002818355],"domain_scores_gemma":[0.99641186,0.0014153818,0.0014094614,0.00013540198,0.00028791526,0.000339995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014784456,0.00019481975,0.0014263266,0.00019183761,0.0000529471,0.000014205714,0.00008935088,0.00029789322,0.00008784185],"category_scores_gemma":[0.0015459267,0.00013183587,0.00024098862,0.00017930291,0.00007589126,0.00015345254,0.000022230255,0.0003725467,0.0000024975602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041115005,0.009280567,0.6111762,0.0000523731,0.00061671325,0.00061298086,0.0006057956,0.00003636186,0.0006432447,0.00002780258,0.047745746,0.28808722],"study_design_scores_gemma":[0.13735686,0.028320685,0.7951189,0.00033319532,0.0010144709,0.00017892428,0.00064078055,0.0003939317,0.0024604446,0.00009990831,0.033846475,0.00023538902],"about_ca_topic_score_codex":0.00011481524,"about_ca_topic_score_gemma":0.001713041,"teacher_disagreement_score":0.2878518,"about_ca_system_score_codex":0.0005784276,"about_ca_system_score_gemma":0.00078709784,"threshold_uncertainty_score":0.53761107},"labels":[],"label_agreement":null},{"id":"W2591496615","doi":"10.1200/jco.2014.32.4_suppl.267","title":"Prostate cancer patients' adherence to medication while on abiraterone acetate (AA) therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Abiraterone acetate; Dosing; Prostate cancer; Medical prescription; Chemotherapy; Cancer; Internal medicine; Pharmacy; Oncology; Androgen deprivation therapy; Pharmacology; Family medicine","score_opus":0.16638427038625161,"score_gpt":0.5057545212422049,"score_spread":0.3393702508559533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591496615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97480875,0.00037537888,0.000033939312,0.020525979,0.0013057906,0.00045740156,0.0000055159967,0.0000101562455,0.0024770985],"genre_scores_gemma":[0.9873064,0.0039005012,0.0004636316,0.0055339895,0.00095244084,0.00003604989,0.0000069321222,0.000017812241,0.001782211],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974137,0.00036464454,0.0012099504,0.00020585253,0.00054100016,0.00026485327],"domain_scores_gemma":[0.9971374,0.0006806899,0.00078733684,0.00017942967,0.00068602356,0.0005290865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021110189,0.00012393734,0.0008161957,0.0001203876,0.000045425855,0.000010333797,0.00016136271,0.00018356368,0.0003237185],"category_scores_gemma":[0.0011626199,0.00007189219,0.00017531688,0.00014492053,0.00011761853,0.00008178222,0.00003278241,0.00063747226,0.00011224608],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01190069,0.0019884084,0.1305156,0.000021287738,0.00021651888,0.000035126995,0.00032199206,0.000014666819,0.00044151818,0.000029499066,0.01773075,0.83678395],"study_design_scores_gemma":[0.020010892,0.08058242,0.59723735,0.00025337838,0.00009486309,0.000009637166,0.00003775371,0.00005117916,0.001579429,0.0002682437,0.29975918,0.00011568013],"about_ca_topic_score_codex":0.000027643553,"about_ca_topic_score_gemma":0.000023146715,"teacher_disagreement_score":0.83666825,"about_ca_system_score_codex":0.00019402946,"about_ca_system_score_gemma":0.0009785856,"threshold_uncertainty_score":0.35444906},"labels":[],"label_agreement":null},{"id":"W2591501973","doi":"10.1200/jco.2016.34.2_suppl.34","title":"Causes of death in intermediate- and high-risk prostate cancer treated with radiotherapy with or without androgen deprivation therapy: Analysis from two phase III trials.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Population; Cancer; Radiation therapy; Urology; Cause of death; Androgen deprivation therapy; Prostate; Oncology; Gastroenterology; Disease","score_opus":0.13076893971685674,"score_gpt":0.5009969256653771,"score_spread":0.37022798594852036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591501973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946345,0.0027721592,0.00037186063,0.0015098191,0.00006115346,0.00057503587,0.000060986764,0.000006277727,0.000008222936],"genre_scores_gemma":[0.9376315,0.060570903,0.001186469,0.00012660719,0.00027926668,0.000024178507,0.000009620696,0.000018962832,0.00015251689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965798,0.00083218765,0.0018083844,0.00024955414,0.00032537887,0.00020466911],"domain_scores_gemma":[0.9945762,0.002461189,0.0021507037,0.00017077163,0.0003919278,0.0002492189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024981424,0.00017380768,0.0025799999,0.00036184292,0.000024437817,0.000009121736,0.0000876447,0.0001596182,0.00019371675],"category_scores_gemma":[0.0006371089,0.00006366988,0.00018461881,0.00041171358,0.0003327999,0.00013915314,0.00001318499,0.0003287018,2.5080007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17410219,0.00069399946,0.6053535,0.000005032239,0.004871806,0.00024187975,0.00022944063,0.000008834005,0.0008022589,8.03851e-7,0.000017008924,0.21367326],"study_design_scores_gemma":[0.2522786,0.04125535,0.6951632,0.00036522528,0.003247753,0.00003236904,0.00010203479,0.0001599404,0.006226731,0.000063512016,0.0009766833,0.00012864462],"about_ca_topic_score_codex":0.00195688,"about_ca_topic_score_gemma":0.003130768,"teacher_disagreement_score":0.2135446,"about_ca_system_score_codex":0.00020797433,"about_ca_system_score_gemma":0.0014671963,"threshold_uncertainty_score":0.29582304},"labels":[],"label_agreement":null},{"id":"W2591502620","doi":"10.1200/jco.2016.34.4_suppl.690","title":"A national survey on the management of liver metastases from colorectal cancer (CRC): Comparison of perspectives and expectations among medical oncologists and hepatobiliary surgeons across Canada.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Colorectal cancer; General surgery; Hepatectomy; Cancer; Resection; Internal medicine; Surgery","score_opus":0.23902671424218347,"score_gpt":0.45545682745134225,"score_spread":0.21643011320915878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591502620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931006,0.0017614106,0.000016110685,0.004340735,0.00016850546,0.0002172135,0.0002548063,0.0000022171614,0.00013842424],"genre_scores_gemma":[0.9974627,0.0020632704,0.00023420693,0.000109343106,0.00008379899,0.000013044203,0.000007314878,0.0000066394095,0.000019683966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970704,0.0008280237,0.0011709677,0.00017088975,0.0006205859,0.00013917303],"domain_scores_gemma":[0.9863978,0.011824464,0.0009451783,0.0000781928,0.00053088646,0.000223469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002451035,0.00011180612,0.0009635387,0.00003699357,0.00005537041,0.000003667456,0.00009785592,0.0001603036,0.00027208708],"category_scores_gemma":[0.0025137407,0.000056380784,0.00015139881,0.000097203905,0.00077576144,0.000045097404,0.000065294575,0.00026634548,3.863534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016134172,0.0010338529,0.97141874,0.000015287744,0.0013403142,0.00022399885,0.0005568221,4.1497316e-7,0.000023605522,0.00010595532,0.0017656748,0.021901889],"study_design_scores_gemma":[0.0028375601,0.002079598,0.9918569,0.0001667055,0.00033617645,0.000013820119,0.0017728191,0.00017191556,0.0003236297,0.000042505046,0.0003435074,0.000054865413],"about_ca_topic_score_codex":0.071814604,"about_ca_topic_score_gemma":0.4479341,"teacher_disagreement_score":0.3761195,"about_ca_system_score_codex":0.0001866495,"about_ca_system_score_gemma":0.0016152051,"threshold_uncertainty_score":0.9343663},"labels":[],"label_agreement":null},{"id":"W2591502998","doi":"10.1200/jco.2014.32.3_suppl.367","title":"FOLFIRINOX in the real-world setting: The multicentric experience of six Canadian institutions.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Saint-Luc; Hôpital Notre-Dame; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; FOLFIRINOX; Febrile neutropenia; Regimen; Irinotecan; Internal medicine; Neutropenia; Performance status; Surgery; Pancreatic cancer; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.2139384082753749,"score_gpt":0.5351824105261934,"score_spread":0.3212440022508185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591502998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9116539,0.000119863595,0.000060193062,0.032535233,0.00042347552,0.0002618877,9.755107e-7,0.0000019071044,0.05494259],"genre_scores_gemma":[0.99324006,0.00045574285,0.0011411713,0.0043136864,0.0005584254,0.00000811968,6.7158976e-7,0.0000045425586,0.00027757068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961805,0.0012973108,0.0017289956,0.000112434485,0.0003806231,0.0003001333],"domain_scores_gemma":[0.9891037,0.009135989,0.00080793025,0.00029535027,0.00033384803,0.00032319996],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009412652,0.00008088425,0.0009123008,0.00023497606,0.00009266518,0.000005893685,0.0004253781,0.00019769037,0.00011436181],"category_scores_gemma":[0.015627056,0.00003848248,0.00020315622,0.00040724105,0.0007400009,0.000053569212,0.00003649295,0.0011358503,0.000014818627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046271036,0.00053164037,0.9653763,0.000013855047,0.0000710484,0.00024699728,0.0012461289,0.0000136594535,0.000014427034,0.003689361,0.0030999137,0.025233919],"study_design_scores_gemma":[0.0027277588,0.0018684202,0.830653,0.000053849155,0.00013589735,0.00013455664,0.0008462559,0.00057719933,0.000006325981,0.00021237081,0.16274999,0.000034381057],"about_ca_topic_score_codex":0.016422905,"about_ca_topic_score_gemma":0.10209222,"teacher_disagreement_score":0.15965007,"about_ca_system_score_codex":0.00020643577,"about_ca_system_score_gemma":0.0053328597,"threshold_uncertainty_score":0.99266475},"labels":[],"label_agreement":null},{"id":"W2591506614","doi":"10.1200/jco.2015.33.7_suppl.480","title":"The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Hôtel-Dieu de Québec; University of Calgary; University of Alberta; University of British Columbia; Dalhousie University; University of Toronto; Montreal General Hospital; Juravinski Cancer Centre; Ottawa Hospital; University of Manitoba","funders":"","keywords":"Chromophobe cell; Medicine; Histopathology; Histology; Clear cell; Renal cell carcinoma; Internal medicine; Pathological; Pathology; Stage (stratigraphy); Clear cell renal cell carcinoma; Carcinoma; Clear cell carcinoma; Kidney cancer; Kidney disease; Oncology; Gastroenterology","score_opus":0.20426369534707145,"score_gpt":0.4453578029397895,"score_spread":0.24109410759271804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591506614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221796,0.0014012107,0.000051476494,0.002768462,0.0004075288,0.00026542746,0.000019136747,0.0000047680437,0.0028640463],"genre_scores_gemma":[0.9979508,0.000074563126,0.0008658721,0.0003571421,0.00046632622,0.000007897385,0.000011799697,0.000010228853,0.0002553919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625903,0.0007060254,0.0018817115,0.00023565796,0.0005732267,0.00034437294],"domain_scores_gemma":[0.99403656,0.0010526315,0.0013720433,0.00032066257,0.00094342703,0.0022747086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032791414,0.00020428514,0.0014469322,0.0003256082,0.000088489905,0.000010265087,0.00025197072,0.00026678143,0.000054788372],"category_scores_gemma":[0.0043027583,0.00009517467,0.0017441709,0.0003607708,0.0005045938,0.000052371208,0.000035528516,0.0008062406,0.000023660485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010933888,0.003229213,0.9674946,0.000009068529,0.00086984417,0.0071517476,0.000069561356,0.0015017749,0.000050174545,0.00008514854,0.0040665497,0.0045384173],"study_design_scores_gemma":[0.005272431,0.018818036,0.969014,0.0000198716,0.0021995746,0.00020399202,0.000036402107,0.00076875824,0.000052841973,0.00006463914,0.00346602,0.00008343045],"about_ca_topic_score_codex":0.0037628596,"about_ca_topic_score_gemma":0.0036884213,"teacher_disagreement_score":0.015588822,"about_ca_system_score_codex":0.0015294413,"about_ca_system_score_gemma":0.014787961,"threshold_uncertainty_score":0.9907973},"labels":[],"label_agreement":null},{"id":"W2591507192","doi":"10.1200/jco.2016.34.26_suppl.222","title":"Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Nausea; Chemotherapy-induced nausea and vomiting; Internal medicine; Vomiting; Aprepitant; Gastroenterology; Antiemetic; Oncology; Anesthesia","score_opus":0.06142842681044062,"score_gpt":0.41112340866106833,"score_spread":0.3496949818506277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591507192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828506,0.000028695975,0.00023831017,0.0009245495,0.000066444525,0.00038127328,0.0000019272618,0.0000019360057,0.000071835966],"genre_scores_gemma":[0.99329436,0.000042252308,0.006434584,0.00007906742,0.00012136576,0.0000022956215,4.477888e-7,0.000008882457,0.000016738937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831945,0.00010155858,0.0011737421,0.000118755255,0.00015792831,0.00012857019],"domain_scores_gemma":[0.9966244,0.0015172241,0.0014150909,0.000057859546,0.00028175875,0.000103635524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014429099,0.00007676213,0.00077324494,0.00009790402,0.0000111234785,0.0000018066922,0.00004364871,0.000072603594,0.000007397499],"category_scores_gemma":[0.0019979938,0.00004425945,0.00009189622,0.00005408283,0.00012137807,0.00005516088,0.000021444233,0.00016066855,7.101557e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025065685,0.000841963,0.8608468,0.00008680757,0.00013179047,0.000010850443,0.000047791982,6.240871e-7,0.00261635,0.000046687142,0.000039821058,0.11026483],"study_design_scores_gemma":[0.04100343,0.038324267,0.9183965,0.00091589167,0.00014080029,0.00002642785,0.000039604987,0.000022128152,0.00092383625,0.00009135054,0.000074911935,0.00004090512],"about_ca_topic_score_codex":0.000008960525,"about_ca_topic_score_gemma":0.000030889474,"teacher_disagreement_score":0.11022393,"about_ca_system_score_codex":0.00007774123,"about_ca_system_score_gemma":0.00029511706,"threshold_uncertainty_score":0.23919296},"labels":[],"label_agreement":null},{"id":"W2591511288","doi":"10.1200/jco.2016.34.7_suppl.63","title":"Quality of life (QoL) by response: An interim analysis of patients (pts) with squamous (SCC) NSCLC treated with <i>nab</i>-paclitaxel/carboplatin (<i>nab</i>-P/C) induction therapy in the phase III ABOUND.sqm study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Induction chemotherapy; Interim analysis; Quality of life (healthcare); Carboplatin; Response Evaluation Criteria in Solid Tumors; Maintenance therapy; Oncology; Surgery; Phases of clinical research; Randomized controlled trial; Gastroenterology; Chemotherapy","score_opus":0.15138756162189743,"score_gpt":0.515527758474879,"score_spread":0.36414019685298155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591511288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626327,0.00021129883,0.000050130304,0.0022470409,0.00019434672,0.0008261671,0.000058524165,0.000008601653,0.0001406047],"genre_scores_gemma":[0.9983985,0.00020878315,0.000094681825,0.0009502935,0.0001881088,0.00002817585,0.00001996166,0.000022605564,0.00008890523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908233,0.0044671674,0.0033714706,0.0003544527,0.00070220575,0.00028139446],"domain_scores_gemma":[0.9897787,0.004749182,0.0038930473,0.0004434537,0.00084143516,0.00029419782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064827646,0.0002798461,0.002771857,0.0004815154,0.00004231509,0.000008246151,0.0002953503,0.00030468195,0.00024431577],"category_scores_gemma":[0.0010929789,0.00012544863,0.0004203289,0.0010180444,0.0005716711,0.00021940842,0.00002600924,0.00063853903,8.1219747e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32354432,0.035293914,0.58037966,0.000009178695,0.0035835363,0.000077994984,0.001622153,0.000011358813,0.004572772,0.0000030483823,0.00046789972,0.05043416],"study_design_scores_gemma":[0.100705184,0.18436666,0.70945436,0.000043326017,0.002291754,0.0000122537695,0.0011647759,0.000011056076,0.0003702976,0.000010856346,0.00144171,0.00012773919],"about_ca_topic_score_codex":0.0007130864,"about_ca_topic_score_gemma":0.0012019271,"teacher_disagreement_score":0.22283913,"about_ca_system_score_codex":0.00025567942,"about_ca_system_score_gemma":0.0012019394,"threshold_uncertainty_score":0.5115647},"labels":[],"label_agreement":null},{"id":"W2591513328","doi":"10.1200/jco.2013.31.6_suppl.463","title":"Involvement of miRNAs in the formation and maintenance of self-renewing kidney cancer spheres with stem cell properties.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"CD44; Cancer stem cell; Cancer research; Clonogenic assay; Progenitor cell; microRNA; Mesenchymal stem cell; Stem cell; Cancer cell; Stem cell marker; Cancer; Biology; Cell culture; Cell; Cell biology; Medicine; Genetics","score_opus":0.10852602870475564,"score_gpt":0.37385480551511757,"score_spread":0.26532877681036193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591513328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305844,0.0015992733,0.00006327405,0.003988853,0.00015502892,0.00028555503,0.000001470523,0.0000012159038,0.00084686856],"genre_scores_gemma":[0.99327165,0.002834785,0.0019542503,0.001715358,0.000121922385,0.0000096625945,2.4342154e-7,0.000005204047,0.00008689712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981673,0.00016349406,0.0012598531,0.00006826832,0.00022938843,0.00011173066],"domain_scores_gemma":[0.99798405,0.00022774607,0.0012505921,0.00009544336,0.00032815637,0.00011401656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012511343,0.00006699508,0.00066993973,0.000043312048,0.000010367795,0.0000038817057,0.00008352554,0.00007614915,0.00006215579],"category_scores_gemma":[0.00010454038,0.000030865933,0.00009473163,0.00008651824,0.00010635586,0.000114989576,0.00002046778,0.00027685935,5.307245e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068515665,0.0043129134,0.3408827,0.002730536,0.0007500134,0.00010665879,0.009414998,0.00019295739,0.01925218,0.00008600592,0.03243665,0.58298284],"study_design_scores_gemma":[0.063979596,0.054438308,0.422994,0.0069145733,0.0026394357,0.00048045456,0.038613338,0.0015068931,0.07236328,0.0003179247,0.33526906,0.00048316817],"about_ca_topic_score_codex":0.0005977737,"about_ca_topic_score_gemma":0.0005316778,"teacher_disagreement_score":0.5824997,"about_ca_system_score_codex":0.00007219942,"about_ca_system_score_gemma":0.00082954345,"threshold_uncertainty_score":0.14715745},"labels":[],"label_agreement":null},{"id":"W2591514632","doi":"10.1200/jco.2013.31.4_suppl.338","title":"Use of adjuvant chemotherapy (AC) and outcomes in stage II colon cancer (CC) with versus without poor prognostic features.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Perineural invasion; Internal medicine; Lymphovascular invasion; Stage (stratigraphy); Proportional hazards model; Oncology; Perforation; Cancer; Gastroenterology; Surgery; Metastasis","score_opus":0.12481395547180521,"score_gpt":0.46125368985692194,"score_spread":0.33643973438511676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591514632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856625,0.0013218151,0.0000015997866,0.011802528,0.00040431757,0.0004910006,0.0000065146814,0.000004280127,0.0003054384],"genre_scores_gemma":[0.9936905,0.0026038168,0.0013284896,0.0011338213,0.00013044862,0.000027460143,6.4428207e-7,0.000013510232,0.001071343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983784,0.00009934594,0.0009540098,0.00015232668,0.00023359501,0.00018229801],"domain_scores_gemma":[0.99720687,0.0013646657,0.0008458195,0.00009161846,0.00032149634,0.00016952251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037541,0.00014414403,0.0015717023,0.00008466718,0.00003083427,0.00000692772,0.00005654079,0.0001653442,0.00008505021],"category_scores_gemma":[0.00094384555,0.00007668479,0.00013830338,0.00009237176,0.0002664324,0.00011097378,0.000040255596,0.0004538385,6.8731254e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01676505,0.0026084576,0.90971935,0.00003126443,0.000887613,0.00017908897,0.00032823626,0.0000037707746,0.00005278657,0.000009907557,0.001098188,0.068316296],"study_design_scores_gemma":[0.033042364,0.031390168,0.9263215,0.00014269233,0.0003176864,0.000037338046,0.00019340668,0.000020433532,0.0000478534,0.000011916074,0.008402149,0.00007251035],"about_ca_topic_score_codex":0.000759694,"about_ca_topic_score_gemma":0.0031374267,"teacher_disagreement_score":0.06824379,"about_ca_system_score_codex":0.00015220993,"about_ca_system_score_gemma":0.0006388737,"threshold_uncertainty_score":0.3127115},"labels":[],"label_agreement":null},{"id":"W2591526365","doi":"10.1200/jco.2016.34.26_suppl.130","title":"Disparities in access to palliative care services among cancer patients in south Texas.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Referral; Family medicine; Cancer; Nursing; Emergency medicine; Internal medicine","score_opus":0.3086586317174963,"score_gpt":0.573331365558345,"score_spread":0.26467273384084866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591526365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948732,0.00089548994,0.000012120757,0.0026643581,0.000641491,0.00017999214,0.000022574679,0.0000028783938,0.0007078926],"genre_scores_gemma":[0.99545133,0.0020859232,0.0002991671,0.0017090974,0.0003651547,0.000007283478,0.0000016746407,0.000010314082,0.0000700662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974,0.00023645647,0.001691766,0.00016213137,0.0002919163,0.00021775438],"domain_scores_gemma":[0.996465,0.0015378724,0.0010181476,0.0001023352,0.0006451109,0.00023147785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006187103,0.00011778561,0.0012407613,0.00022011307,0.0000091688935,0.000005789548,0.00023969461,0.00024767467,0.000072949675],"category_scores_gemma":[0.002107102,0.00006820189,0.00017878275,0.00019383267,0.00013264084,0.00020348423,0.00009654019,0.00039630456,0.0000062379186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015434135,0.000368848,0.97117203,0.0000994678,0.00007100776,0.00008162933,0.0034730579,0.000010569313,0.000008504554,0.000006715861,0.00021241956,0.022952322],"study_design_scores_gemma":[0.0064939633,0.0024044465,0.9805424,0.0031725643,0.000059283764,2.6686152e-7,0.0012389795,0.0000029206835,0.00023292548,0.000085172454,0.0056875795,0.00007950319],"about_ca_topic_score_codex":0.0010664358,"about_ca_topic_score_gemma":0.007896508,"teacher_disagreement_score":0.022872819,"about_ca_system_score_codex":0.0002796455,"about_ca_system_score_gemma":0.0005181451,"threshold_uncertainty_score":0.4406437},"labels":[],"label_agreement":null},{"id":"W2591529322","doi":"10.1200/jco.2016.34.4_suppl.285","title":"Comprehensive genomic analysis in metastatic pancreatic ductal adenocarcinoma (PDAC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Pancreas Centre (Canada); BC Cancer Agency","funders":"","keywords":"KRAS; CDKN2A; Medicine; Transcriptome; Cancer; Subtyping; Oncology; Cancer research; Biopsy; Internal medicine; Gene; Pathology; Gene expression; Colorectal cancer; Biology; Genetics","score_opus":0.07063469562858105,"score_gpt":0.4039139450292059,"score_spread":0.33327924940062487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591529322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930397,0.003207236,0.001588522,0.0012374185,0.00055796234,0.000089574176,0.0000195004,0.0000014424561,0.0002586115],"genre_scores_gemma":[0.9913414,0.0039176843,0.0029841214,0.00091790967,0.00070133834,0.0000032552498,0.000006081646,0.000014354537,0.000113843904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972939,0.0003622469,0.0017124938,0.00025019908,0.0001422064,0.00023899358],"domain_scores_gemma":[0.9971168,0.0011023444,0.0010463031,0.00025999738,0.00025741168,0.00021713808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010427524,0.00014026598,0.0010757862,0.00018734322,0.000020373325,0.000008758593,0.00027374644,0.00020620802,0.00007964235],"category_scores_gemma":[0.0016267917,0.00009394995,0.000610685,0.00018331326,0.00018311184,0.0000060432376,0.00011211831,0.00021719551,0.0000164486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022014396,0.00074514863,0.9071024,0.000015111113,0.0032378077,0.00061037694,0.000050287555,0.0004630306,0.055889297,0.0001507383,0.002791414,0.02674292],"study_design_scores_gemma":[0.0047387723,0.0042902674,0.9435036,0.000017047676,0.0011327448,0.00015105978,0.000082729304,0.000045821496,0.0007581587,0.0005550474,0.044545777,0.00017893348],"about_ca_topic_score_codex":0.00003641457,"about_ca_topic_score_gemma":0.00026188692,"teacher_disagreement_score":0.055131137,"about_ca_system_score_codex":0.00008415875,"about_ca_system_score_gemma":0.0008472302,"threshold_uncertainty_score":0.38311678},"labels":[],"label_agreement":null},{"id":"W2591530513","doi":"10.1200/jco.2014.32.3_suppl.10","title":"Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Underweight; Proportional hazards model; Hazard ratio; Gastroenterology; Adenocarcinoma; Cumulative incidence; Obesity; Survival analysis; Stage (stratigraphy); Cancer; Cohort; Overweight; Confidence interval","score_opus":0.08676429191619581,"score_gpt":0.45327528678249057,"score_spread":0.3665109948662948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591530513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880471,0.0030923313,0.00044103485,0.0036858618,0.0006805836,0.0002408885,0.0000038143353,0.000012627764,0.0037957444],"genre_scores_gemma":[0.9954339,0.00041192948,0.0011853781,0.0008547201,0.0017059307,0.000004775039,0.000002029393,0.000021842521,0.00037949247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632275,0.0008412916,0.001539785,0.0002607798,0.0006732502,0.00036217092],"domain_scores_gemma":[0.995013,0.0023958925,0.00097369443,0.00021127795,0.0004898358,0.00091627997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00373859,0.00017443135,0.0014399227,0.00015440915,0.000062698695,0.000018713441,0.00015075623,0.00036800076,0.00013934163],"category_scores_gemma":[0.0032986265,0.00011968052,0.00034419153,0.00012416214,0.00028347163,0.00013526116,0.00006911251,0.0013927496,0.000018237872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038177737,0.0006112731,0.93419373,0.000030771145,0.0005533913,0.0017849708,0.000096797965,0.0000026429955,0.000007823573,0.00045261448,0.00043427985,0.05801392],"study_design_scores_gemma":[0.013999584,0.029907957,0.9512868,0.00006591369,0.00029657743,0.00026460137,0.000050190913,0.00023116714,0.00004148961,0.0014969903,0.0022785757,0.00008014259],"about_ca_topic_score_codex":0.00007960637,"about_ca_topic_score_gemma":0.000017475837,"teacher_disagreement_score":0.057933778,"about_ca_system_score_codex":0.000167079,"about_ca_system_score_gemma":0.00088802044,"threshold_uncertainty_score":0.6050882},"labels":[],"label_agreement":null},{"id":"W2591535929","doi":"10.1200/jco.2012.30.5_suppl.186","title":"Biochemical, pathologic, toxicity, and quality-of-life outcomes in a five-fraction hypofractionated accelerated radiotherapy treatment using standard linear accelerators and gold seed fiducials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Image-guided radiation therapy; Cohort; Prospective cohort study; Quality of life (healthcare); Prostate; Cancer; Urology; Nuclear medicine; Surgery; Internal medicine","score_opus":0.353239664599931,"score_gpt":0.551250282577846,"score_spread":0.19801061797791503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591535929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992892,0.003849709,0.000041945746,0.0024813262,0.0003331965,0.00032228525,0.000014536647,0.0000078983185,0.00005709982],"genre_scores_gemma":[0.9828583,0.012101886,0.0039463136,0.00056712347,0.00041726232,0.000004734311,0.000005745736,0.0000143897505,0.00008422372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694073,0.0006126864,0.0017087553,0.00018107891,0.00029212862,0.0002645933],"domain_scores_gemma":[0.9962706,0.0017996154,0.0010982215,0.00010895,0.00032648453,0.0003961052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021536867,0.00016954158,0.0017682619,0.00022425318,0.000041797495,0.000011795778,0.000053074982,0.00041781567,0.000049500035],"category_scores_gemma":[0.0021423332,0.000105746745,0.00018869832,0.00019580248,0.00025163905,0.00028279726,0.00003334867,0.00053453393,6.014401e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012479096,0.002966152,0.9261783,0.000041905023,0.0005034096,0.00007037478,0.00021219396,0.0000043266855,0.037338946,0.0000127400235,0.00009733727,0.020095266],"study_design_scores_gemma":[0.02826226,0.00955617,0.9503118,0.00007619611,0.00019680244,0.00011553638,0.0003976867,0.00017916155,0.0068882247,0.000050713283,0.0038228845,0.00014259094],"about_ca_topic_score_codex":0.00014319182,"about_ca_topic_score_gemma":0.000013852436,"teacher_disagreement_score":0.03045072,"about_ca_system_score_codex":0.0005206966,"about_ca_system_score_gemma":0.00093937677,"threshold_uncertainty_score":0.4312227},"labels":[],"label_agreement":null},{"id":"W2591539479","doi":"10.1200/jco.2012.30.5_suppl.16","title":"Impact of 36 months of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) in men with nonmetastatic prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Grip strength; Quality of life (healthcare); Analysis of variance; Internal medicine; Physical therapy; Cancer","score_opus":0.09242753582723225,"score_gpt":0.4768567205650392,"score_spread":0.38442918473780696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591539479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987601,0.0006881916,0.000054057746,0.00011378835,0.000058256326,0.00018277261,0.000014696524,6.134011e-7,0.00012753725],"genre_scores_gemma":[0.99869967,0.0008464532,0.00017699631,0.000033163764,0.00020868199,0.000005075207,0.000004309815,0.00000997623,0.000015671081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976201,0.00063202,0.0012000041,0.00012103026,0.00027110075,0.00015572905],"domain_scores_gemma":[0.99750507,0.0004039013,0.0014888345,0.00014463453,0.00030664334,0.00015089527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022948368,0.00009613449,0.00077974104,0.000078666526,0.000010988102,0.0000015449576,0.00008387921,0.00015464381,0.0000080848],"category_scores_gemma":[0.0009834126,0.00006324224,0.00018765092,0.00011037815,0.000259197,0.000014865854,0.000028314744,0.00027263848,2.8082053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033376284,0.003204983,0.5970113,0.000055770342,0.00048392502,0.0000017156156,0.00029608983,0.00041894428,0.33732724,0.000022950768,0.0002615552,0.027539227],"study_design_scores_gemma":[0.0068937363,0.023794234,0.909344,0.000043853255,0.000035907415,0.0000041327658,0.00009009581,0.00006920677,0.05934039,0.000041981206,0.00026306903,0.00007937904],"about_ca_topic_score_codex":0.0001986014,"about_ca_topic_score_gemma":0.00005231579,"teacher_disagreement_score":0.3123327,"about_ca_system_score_codex":0.00004952505,"about_ca_system_score_gemma":0.0008669917,"threshold_uncertainty_score":0.25789437},"labels":[],"label_agreement":null},{"id":"W2591550658","doi":"10.1200/jco.2016.34.3_suppl.183","title":"Elimination of second-hand smoke (SHS) exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient smoking cessation.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Smoking cessation; Cohort; Cancer; Logistic regression; Pathology","score_opus":0.10905238162864958,"score_gpt":0.44472635658404114,"score_spread":0.33567397495539153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591550658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793798,0.007408392,0.000018243007,0.012210023,0.00061112345,0.00016011912,0.00001588951,0.0000029620733,0.00019347414],"genre_scores_gemma":[0.9829729,0.01471512,0.00025242654,0.0015196573,0.00041567156,0.000046538113,3.3299327e-7,0.000009739418,0.000067605004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978922,0.00016479235,0.0013822109,0.00016126625,0.0002444315,0.00015512141],"domain_scores_gemma":[0.9966772,0.0016731143,0.00092708285,0.0000850336,0.00043483404,0.00020271273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008832652,0.00011007311,0.0009928902,0.00009653015,0.00004176215,0.000006844699,0.000037887465,0.00020070931,0.00041201216],"category_scores_gemma":[0.0014433276,0.000058140817,0.00012156402,0.00006894785,0.00024164484,0.00013955744,0.000046984947,0.000244939,2.7375535e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002790178,0.0002901719,0.73292303,0.000099684476,0.00022023931,0.000101252066,0.0006112187,2.3742048e-7,0.00012432391,0.000014429711,0.0013860941,0.26143914],"study_design_scores_gemma":[0.0073798373,0.010699331,0.95302355,0.0011146606,0.00029790102,0.00006959673,0.00012943282,0.000005583823,0.00056739984,0.000066376146,0.026572173,0.000074126256],"about_ca_topic_score_codex":0.00004818637,"about_ca_topic_score_gemma":0.0007962428,"teacher_disagreement_score":0.26136503,"about_ca_system_score_codex":0.00013838634,"about_ca_system_score_gemma":0.0006096703,"threshold_uncertainty_score":0.45112443},"labels":[],"label_agreement":null},{"id":"W2591551400","doi":"10.1200/jco.2013.31.15_suppl.e14553","title":"Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Multivariate analysis; Cancer; Referral; Chemotherapy; Colorectal cancer; Adjuvant; Surgery; Gastroenterology","score_opus":0.11323082520081915,"score_gpt":0.49191821179634154,"score_spread":0.37868738659552237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591551400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696394,0.0005827907,0.00017570115,0.027300041,0.00038120578,0.0011155037,0.000020600408,0.0000030866934,0.0007816407],"genre_scores_gemma":[0.98712486,0.00076819694,0.0062069064,0.0042262506,0.00063405064,0.00025644098,0.0000035447915,0.000015125607,0.00076464843],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983845,0.000057874888,0.0011675563,0.00010930028,0.00013056546,0.0001502505],"domain_scores_gemma":[0.99677557,0.0016905764,0.0007204465,0.000066054345,0.000614992,0.00013236496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092112215,0.000082112034,0.001115922,0.00008440771,0.000019312023,0.00000298513,0.00006887248,0.00015806743,0.00020210359],"category_scores_gemma":[0.0015207428,0.000055227887,0.00027297746,0.00008399687,0.000050775794,0.00005174807,0.000015070342,0.0001480188,0.0000064463215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02717792,0.006628308,0.09282807,0.00009846267,0.0009879794,0.000024496423,0.00064908125,0.00002316685,0.0011207229,0.00004868014,0.11259866,0.75781447],"study_design_scores_gemma":[0.046680655,0.052208133,0.6617262,0.00028451087,0.00044127335,0.000028534989,0.00012659583,0.00036445426,0.0004966315,0.00072817167,0.23679204,0.0001228504],"about_ca_topic_score_codex":0.00008535472,"about_ca_topic_score_gemma":0.00030748165,"teacher_disagreement_score":0.7576916,"about_ca_system_score_codex":0.000226011,"about_ca_system_score_gemma":0.00062518386,"threshold_uncertainty_score":0.22521278},"labels":[],"label_agreement":null},{"id":"W2591556663","doi":"10.1200/jco.2012.30.4_suppl.240","title":"Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Gemcitabine; Clonogenic assay; Cancer research; In vivo; Cancer; Medicine; Cell cycle; Cancer cell; Cell growth; Pharmacology; Internal medicine; Biology; Biochemistry","score_opus":0.22405367776398985,"score_gpt":0.5011278258308577,"score_spread":0.2770741480668678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591556663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907274,0.0036023585,0.00002130348,0.003012999,0.0013766163,0.00091212674,0.0000131360275,0.000005661746,0.00032836615],"genre_scores_gemma":[0.9951662,0.0008581513,0.0013844647,0.00021378834,0.0021229046,0.000049272407,0.0000018515835,0.000020709002,0.00018268483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621356,0.00024722284,0.0027309847,0.00017735356,0.0003656856,0.00026517347],"domain_scores_gemma":[0.9934529,0.0030852356,0.002118455,0.00024630627,0.0007691398,0.0003279837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016425105,0.00018203756,0.0027365924,0.00010870546,0.00003070607,0.0000017787296,0.00011170646,0.00021279158,0.00004454949],"category_scores_gemma":[0.0010608085,0.000103308,0.00056388846,0.00014046015,0.00026408097,0.00008799442,0.00003918369,0.000235399,7.997464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036225345,0.023560941,0.8937427,0.00009697393,0.0024952954,0.000036471098,0.0012504301,0.0000049118507,0.00015776239,0.000015990065,0.0022933302,0.04011986],"study_design_scores_gemma":[0.037695896,0.23650843,0.71285945,0.00010895242,0.0024510936,0.00004515868,0.0010862252,0.000008203324,0.00048116312,0.000018504368,0.00865376,0.0000831453],"about_ca_topic_score_codex":0.00008489508,"about_ca_topic_score_gemma":0.0002539242,"teacher_disagreement_score":0.21294749,"about_ca_system_score_codex":0.00015622788,"about_ca_system_score_gemma":0.0009860061,"threshold_uncertainty_score":0.42127776},"labels":[],"label_agreement":null},{"id":"W2591566448","doi":"10.1200/jco.2015.33.29_suppl.181","title":"The Opioid Rotation Ratio (ORR) to transdermal fentanyl (TDF) in cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Opioid; Cancer pain; Fentanyl; Cancer; Palliative care; Constipation; Anesthesia; Internal medicine","score_opus":0.1952582740294113,"score_gpt":0.5363013727625947,"score_spread":0.3410430987331834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591566448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658537,0.00061462383,0.00004504256,0.02785429,0.0034824247,0.0003584688,0.000002985737,0.000003975295,0.0017844844],"genre_scores_gemma":[0.990911,0.0006869917,0.00028942112,0.0061578904,0.0013262164,0.000025684514,0.0000032194855,0.000009376319,0.0005902067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774486,0.0003081302,0.0013820989,0.00011057861,0.00025935267,0.00019499016],"domain_scores_gemma":[0.9976717,0.00091808446,0.00053351006,0.0000739211,0.00041232322,0.00039042285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015881936,0.00008865326,0.0006260665,0.00007896325,0.000033110275,0.0000072542366,0.00010824996,0.00015901246,0.00009457468],"category_scores_gemma":[0.00082408066,0.000053192256,0.00017842714,0.00014538194,0.00008110018,0.00008323092,0.00001603616,0.00051279966,0.000020463065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016723521,0.00399784,0.5200084,0.000011146931,0.0002677474,0.00021260566,0.0014943746,0.00019148852,0.00018957526,0.00007178858,0.06927378,0.38755774],"study_design_scores_gemma":[0.020884981,0.019232722,0.51526654,0.00003604943,0.00025515343,0.00003218191,0.00021017661,0.00009883886,0.00018986156,0.00018610762,0.44353622,0.00007114685],"about_ca_topic_score_codex":0.000089956244,"about_ca_topic_score_gemma":0.0008119304,"teacher_disagreement_score":0.3874866,"about_ca_system_score_codex":0.00041739387,"about_ca_system_score_gemma":0.0022540535,"threshold_uncertainty_score":0.3998594},"labels":[],"label_agreement":null},{"id":"W2591571462","doi":"10.1200/jco.2012.30.4_suppl.203","title":"Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Gemcitabine; Medicine; Cetuximab; Internal medicine; Oncology; KRAS; Single-nucleotide polymorphism; Pancreatic cancer; Population; Hazard ratio; Genotype; Regimen; Colorectal cancer; Cancer; Confidence interval; Biology","score_opus":0.17878624473719235,"score_gpt":0.4646909342786344,"score_spread":0.28590468954144205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591571462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959983,0.00026782852,0.00020138662,0.00048639954,0.00058262853,0.0022264603,0.000024113586,0.000007256438,0.00020559793],"genre_scores_gemma":[0.9930102,0.00012968954,0.0061537293,0.00023082258,0.00022356531,0.00004631862,0.000011024233,0.000041852025,0.00015279067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910256,0.0015844475,0.004961387,0.00036779584,0.0012745119,0.0007862259],"domain_scores_gemma":[0.9881104,0.007336399,0.0022726003,0.0005142016,0.00089986215,0.0008664956],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049391296,0.0003523642,0.0052497066,0.0007820275,0.00002971832,0.0000060515395,0.00034955036,0.0003077152,0.00022508028],"category_scores_gemma":[0.00980101,0.00022922,0.000256948,0.00073846057,0.00037357176,0.0004084174,0.00017968204,0.0012596402,0.0000057871707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2464365,0.029033778,0.71556383,0.00009999566,0.0009733077,0.0004922491,0.00094614015,0.00009768464,0.000041199663,0.000021585483,0.000092297625,0.006201409],"study_design_scores_gemma":[0.19651489,0.1294953,0.6711921,0.00030009713,0.0011163693,0.000035350997,0.0007929411,0.0002800736,0.000008907282,0.000008054466,0.00012081707,0.00013509912],"about_ca_topic_score_codex":0.00063872914,"about_ca_topic_score_gemma":0.0009889579,"teacher_disagreement_score":0.10046151,"about_ca_system_score_codex":0.000594415,"about_ca_system_score_gemma":0.0034102749,"threshold_uncertainty_score":0.99853987},"labels":[],"label_agreement":null},{"id":"W2591573325","doi":"10.1200/jco.2014.32.4_suppl.506","title":"Are regional funding decisions resticting pharmaceutical research and development in metastatic renal cell carcinoma (mRCC)?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Axitinib; Medicine; Nice; Sunitinib; Sorafenib; Everolimus; Clinical trial; Formulary; Oncology; Renal cell carcinoma; Internal medicine; Intensive care medicine; Family medicine","score_opus":0.6379986424506716,"score_gpt":0.5200150632302218,"score_spread":0.11798357922044977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591573325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841508,0.0017436165,0.0023123291,0.0026926433,0.00070711254,0.00009830948,0.000003825541,0.0000031709665,0.008288163],"genre_scores_gemma":[0.9874233,0.00041356843,0.010434643,0.0008988959,0.0006242709,0.000004177743,6.207911e-7,0.000016321384,0.00018417137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566984,0.0002530173,0.0031896397,0.00031509294,0.0001089842,0.00046343912],"domain_scores_gemma":[0.9907281,0.006219256,0.0022511084,0.00014938545,0.00021264465,0.0004395372],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016511638,0.000126622,0.0012280793,0.0004926532,0.00012966983,0.000042300504,0.00028750574,0.00022324124,0.00009693858],"category_scores_gemma":[0.011963036,0.000121918616,0.00012965233,0.00018635075,0.00028087056,0.00025268854,0.00013002884,0.0013569515,0.00007763454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009383724,0.00084868947,0.8858612,0.000031202148,0.00006644763,0.00019800443,0.00039836718,0.00013446633,0.000013908637,0.02720541,0.0041237418,0.08018016],"study_design_scores_gemma":[0.003330121,0.0010782158,0.61213714,0.000067659945,0.000008990041,0.000050764025,0.00017738894,0.0006449883,0.000022703007,0.023134239,0.35920042,0.00014736725],"about_ca_topic_score_codex":0.00003547903,"about_ca_topic_score_gemma":0.00011997198,"teacher_disagreement_score":0.35507667,"about_ca_system_score_codex":0.00032228956,"about_ca_system_score_gemma":0.00054369716,"threshold_uncertainty_score":0.99635965},"labels":[],"label_agreement":null},{"id":"W2591925750","doi":"10.1200/jco.2013.31.15_suppl.1055","title":"Quality of life (QoL) and content validity in objective tumor response.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Capecitabine; Quality of life (healthcare); Eribulin; Internal medicine; Breast cancer; Metastatic breast cancer; Multivariate analysis; Health related quality of life; Oncology; Cancer; Physical therapy; Disease; Colorectal cancer","score_opus":0.5428370661455958,"score_gpt":0.5661834348095452,"score_spread":0.023346368663949457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591925750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865022,0.00045778663,0.000009261958,0.011142549,0.00066708773,0.00026988762,0.0000031918282,0.0000028220586,0.000945268],"genre_scores_gemma":[0.9954784,0.00034512504,0.00054460147,0.0030259888,0.0003680625,0.000006990814,4.3643033e-7,0.0000057367542,0.0002246413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956762,0.0016878454,0.0021835067,0.00012753539,0.00017959438,0.00014527942],"domain_scores_gemma":[0.98995584,0.007670825,0.0015038142,0.00009555649,0.00044374523,0.00033023205],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054033636,0.00008914585,0.0015822477,0.000110048735,0.000012476762,0.0000024744227,0.00006573727,0.00018178589,0.00038171312],"category_scores_gemma":[0.008725867,0.000060982515,0.00025570605,0.000085328975,0.000276399,0.00007711159,0.000037703903,0.0006087354,0.000008239286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04818563,0.003217381,0.92263865,0.000036434787,0.0003096483,0.00017971426,0.00024458184,0.00000120074,0.004841828,0.00005002448,0.004084843,0.016210075],"study_design_scores_gemma":[0.015828248,0.017060354,0.96212894,0.00003320584,0.00011668629,0.00008763008,0.0003410679,0.000012006763,0.00026212688,0.0003784991,0.0037029467,0.000048276896],"about_ca_topic_score_codex":0.0003914311,"about_ca_topic_score_gemma":0.00013799322,"teacher_disagreement_score":0.039490316,"about_ca_system_score_codex":0.00014654154,"about_ca_system_score_gemma":0.0015162427,"threshold_uncertainty_score":0.9996241},"labels":[],"label_agreement":null},{"id":"W2591942151","doi":"10.1200/jco.2014.32.15_suppl.6602","title":"Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Clinical trial; Medicine; Accrual; Cancer; Family medicine; Internal medicine; Finance; Business","score_opus":0.8147524529295846,"score_gpt":0.7129527457560362,"score_spread":0.10179970717354847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591942151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94096196,0.00026925714,0.00019681214,0.03130149,0.02339691,0.0011282671,0.0000060974126,0.000011755767,0.0027274762],"genre_scores_gemma":[0.9572569,0.0018119001,0.0022685714,0.018352773,0.018640459,0.000042766624,0.0000027944075,0.000049315684,0.0015745364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9468396,0.020651251,0.02709249,0.0010700428,0.0032251708,0.0011214521],"domain_scores_gemma":[0.32066256,0.65064013,0.018790776,0.0023053794,0.004020909,0.0035802575],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.25561154,0.0003999974,0.0068764174,0.0001787213,0.00016800936,0.00006500961,0.0015664472,0.0035039731,0.002043753],"category_scores_gemma":[0.63477945,0.00022639151,0.002350484,0.00037507847,0.0021018814,0.00020811717,0.0005595173,0.027376931,0.000012777043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.110644184,0.0016261428,0.5178491,0.000032405067,0.00051821873,0.00043304366,0.00020547604,0.000028616532,0.000010616311,0.00053156464,0.018884199,0.34923643],"study_design_scores_gemma":[0.09897658,0.018653821,0.6135033,0.00022252055,0.00045940134,0.0000946722,0.0004931042,0.00025304398,0.00000704093,0.0032045073,0.26390234,0.00022966792],"about_ca_topic_score_codex":0.47669455,"about_ca_topic_score_gemma":0.97753817,"teacher_disagreement_score":0.62998885,"about_ca_system_score_codex":0.0014502639,"about_ca_system_score_gemma":0.09219942,"threshold_uncertainty_score":0.9988685},"labels":[],"label_agreement":null},{"id":"W2591951146","doi":"10.1200/jco.2012.30.15_suppl.2572","title":"Does the addition of molecular targeted therapy to standard treatments lead to better or worse outcomes overall? A systematic review of EGFR-targeted therapies used in combination with standard treatments.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Statistics Canada; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Erlotinib; Cetuximab; Targeted therapy; Progression-free survival; Rash; Lapatinib; Combination therapy; Pemetrexed; Gefitinib; Cancer; Trastuzumab; Breast cancer; Chemotherapy; Colorectal cancer; Epidermal growth factor receptor","score_opus":0.0988626422243408,"score_gpt":0.4955390530168683,"score_spread":0.39667641079252747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591951146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009196218,0.9765166,0.00015963247,0.004973074,0.00049754564,0.008136562,0.00044791208,0.000010528242,0.00006192392],"genre_scores_gemma":[0.0031630597,0.9909362,0.0025215214,0.002287817,0.000094648036,0.0004858624,0.00013428151,0.00006256407,0.00031404747],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9922574,0.0016696573,0.004606214,0.00028143806,0.00089738466,0.00028790813],"domain_scores_gemma":[0.9916087,0.0020921007,0.0047351923,0.00050691253,0.00080702227,0.0002501202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021527747,0.00048887444,0.008381665,0.00038327716,0.00004131222,0.000011804018,0.0002498828,0.00033647596,0.00023930472],"category_scores_gemma":[0.0010610998,0.00016481815,0.0011782103,0.0004980519,0.00011149049,0.00012777049,0.000028855657,0.0004593126,0.0000055776513],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009955746,0.0059693987,0.0045029577,0.16990477,0.029550612,0.00040851417,0.0016929888,0.0000029329913,0.0000066309963,0.00004610754,0.0006945937,0.7772648],"study_design_scores_gemma":[0.033355407,0.0643721,0.0071167448,0.5836351,0.051093623,0.00013798427,0.00037897745,5.635379e-7,0.00004358012,0.000105699255,0.25924402,0.00051619124],"about_ca_topic_score_codex":0.000032308286,"about_ca_topic_score_gemma":0.00005021916,"teacher_disagreement_score":0.77674854,"about_ca_system_score_codex":0.0013610673,"about_ca_system_score_gemma":0.0022469568,"threshold_uncertainty_score":0.6721089},"labels":[],"label_agreement":null},{"id":"W2592052797","doi":"10.1200/jco.2013.31.15_suppl.1605","title":"Identification of the occult tumor in cancer of unknown primary (CUP): A priority based on histology.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Cancer; Cancer registry; Metastasis; Primary tumor; Histology; Adenocarcinoma; Occult; Internal medicine; Log-rank test; Pathological; Oncology; Proportional hazards model; Pathology","score_opus":0.08698840864132013,"score_gpt":0.4622327738910285,"score_spread":0.3752443652497084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592052797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808263,0.00046733892,0.00000956924,0.0166781,0.0009213199,0.00034410277,0.000004869189,0.000001596505,0.00074676075],"genre_scores_gemma":[0.99686545,0.00030977448,0.00023356896,0.0022928065,0.00017764498,0.000023376791,7.099802e-7,0.0000056865865,0.00009097802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971456,0.00030166967,0.0020560343,0.00012057456,0.00026974312,0.00010639119],"domain_scores_gemma":[0.9956595,0.0012872183,0.0023213616,0.0002229202,0.00041670477,0.00009233797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001308086,0.000078315454,0.0010072474,0.0000896128,0.000012705567,0.0000016770165,0.00013152609,0.00014965831,0.00016944631],"category_scores_gemma":[0.0013848719,0.00004403084,0.00036412422,0.00013928565,0.00022421828,0.000040419163,0.000022984412,0.00044459742,0.000004137489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016637194,0.006392874,0.9139221,0.00010347589,0.00014268949,0.000042958003,0.000068556365,0.00011098858,0.0017079337,0.00010081296,0.00502491,0.070719026],"study_design_scores_gemma":[0.005377792,0.0033390778,0.9820543,0.0002209335,0.00021788423,0.000016178361,0.000014898735,0.00017766631,0.0011703911,0.00012025673,0.0072572203,0.000033387267],"about_ca_topic_score_codex":0.00037381952,"about_ca_topic_score_gemma":0.00033766776,"teacher_disagreement_score":0.07068564,"about_ca_system_score_codex":0.00047121037,"about_ca_system_score_gemma":0.0018852302,"threshold_uncertainty_score":0.33443174},"labels":[],"label_agreement":null},{"id":"W2592092676","doi":"10.1200/jco.2009.27.15_suppl.1133","title":"A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pazopanib; Clinical endpoint; Metastatic breast cancer; Adverse effect; Progressive disease; Internal medicine; Phases of clinical research; Progression-free survival; Capecitabine; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Breast cancer; Stage (stratigraphy); Surgery; Oncology; Cancer; Gastroenterology; Clinical trial; Colorectal cancer","score_opus":0.056495212553391114,"score_gpt":0.40247910464472453,"score_spread":0.3459838920913334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592092676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762356,0.00010803295,0.000008810422,0.00052953354,0.00036202677,0.0009971973,0.0003447128,9.924149e-7,0.000025102046],"genre_scores_gemma":[0.9995234,0.000045897832,0.00018668966,0.000068563226,0.00011793958,0.000017543269,0.000018925111,0.000008877853,0.000012149552],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99602246,0.0006879507,0.00244655,0.00026335818,0.00039792567,0.00018177807],"domain_scores_gemma":[0.9951632,0.00029871488,0.0034618871,0.00029920248,0.00068692956,0.00009006528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096651935,0.00019169001,0.0012712103,0.00007812145,0.00004313693,0.0000025138404,0.00026111896,0.00011868833,0.000008646229],"category_scores_gemma":[0.0010784636,0.000107668464,0.0002440326,0.00016349545,0.0003204199,0.00001356656,0.0001677303,0.00026912658,6.523441e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72450864,0.13867822,0.11834885,0.000039217553,0.00083310314,0.000068986104,0.0011622909,0.00001647022,0.00025007263,0.0000039699166,0.00020722757,0.015882952],"study_design_scores_gemma":[0.26161668,0.2804808,0.45641595,0.00008089008,0.0003611026,0.000009072729,0.00041015216,0.0000019041083,0.0004102227,0.0000071869085,0.00012434433,0.00008170641],"about_ca_topic_score_codex":0.00006594029,"about_ca_topic_score_gemma":0.0006311659,"teacher_disagreement_score":0.46289197,"about_ca_system_score_codex":0.00006130393,"about_ca_system_score_gemma":0.000914903,"threshold_uncertainty_score":0.43905926},"labels":[],"label_agreement":null},{"id":"W2592222179","doi":"10.1200/jco.2013.31.15_suppl.6639","title":"Do clinical trial acronyms affect patients’ interest in clinical trials? A randomized survey.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Text Mining and Ontologies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Acronym; Clinical trial; Likert scale; Randomized controlled trial; Respondent; Family medicine; Internal medicine; Psychology","score_opus":0.4403399898659247,"score_gpt":0.5692918533877555,"score_spread":0.12895186352183075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592222179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537403,0.00080541195,0.00050329766,0.001575654,0.010070562,0.0010964314,0.000010890596,0.000009703466,0.00055401464],"genre_scores_gemma":[0.98690903,0.0031133704,0.0030685177,0.001721505,0.0049048862,0.000040819654,0.000032623786,0.000029593895,0.00017964013],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9424086,0.04139688,0.014659653,0.0006513701,0.00035672987,0.0005267627],"domain_scores_gemma":[0.93627095,0.05342091,0.007921142,0.0006324985,0.000902321,0.0008521859],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.15540029,0.0003312233,0.0062321457,0.00014793903,0.000042199226,0.00005484157,0.0008606084,0.002538812,0.0002232445],"category_scores_gemma":[0.40907922,0.00020579826,0.0032760908,0.0001771343,0.001692503,0.000017269562,0.00034906532,0.002557389,0.00007618405],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.390831,0.003306539,0.12514806,0.000006434089,0.00052661845,0.00002757054,0.000011735787,6.077321e-7,0.00001240553,0.000014525533,0.02747049,0.45264402],"study_design_scores_gemma":[0.59998524,0.026772324,0.31732503,0.00005713091,0.00017146322,0.000013508495,0.00004772655,0.00003737302,0.000012121147,0.0004546804,0.054892864,0.00023054177],"about_ca_topic_score_codex":0.000080078746,"about_ca_topic_score_gemma":0.0003003547,"teacher_disagreement_score":0.4524135,"about_ca_system_score_codex":0.000038812275,"about_ca_system_score_gemma":0.0014310295,"threshold_uncertainty_score":0.99974376},"labels":[],"label_agreement":null},{"id":"W2592299719","doi":"10.1200/jco.2013.31.15_suppl.4031","title":"A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Pasireotide; Lanreotide; Octreotide; Gastroenterology; Internal medicine; Neuroendocrine tumors; Somatostatin; Interim analysis; Phases of clinical research; Abdominal pain; Mallinckrodt; Clinical endpoint; Tolerability; Adverse effect; Randomized controlled trial; Clinical trial; Acromegaly; Hormone","score_opus":0.0411544532521575,"score_gpt":0.4069491457250471,"score_spread":0.3657946924728896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592299719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914129,0.00027743186,0.000027506596,0.0015981444,0.0002554219,0.0063079875,0.000022280947,0.00002223059,0.00007610242],"genre_scores_gemma":[0.99853694,0.00016772813,0.00053867506,0.00034540525,0.00005375259,0.00017661882,0.00002303294,0.000066224544,0.00009162886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98779714,0.0038151457,0.005564505,0.0005276403,0.0015262616,0.00076933164],"domain_scores_gemma":[0.9835617,0.009189414,0.004427335,0.00045076752,0.0012117369,0.0011590437],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001862277,0.00048299928,0.0058810804,0.000602367,0.0000548745,0.000028070497,0.0004065034,0.000024265784,0.00016279315],"category_scores_gemma":[0.012580522,0.00027755936,0.0005130603,0.000601534,0.0007629201,0.000480137,0.00010804475,0.0017010254,0.000012286357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76548916,0.031938095,0.17755,0.00007438809,0.002292049,0.019242028,0.00007928494,0.00021057643,0.000016543145,0.000011779586,0.00033192278,0.0027641528],"study_design_scores_gemma":[0.8648543,0.08589001,0.044746816,0.00024176239,0.0019298173,0.00021690843,0.00057420775,0.0011566678,0.00003065702,0.000055702738,0.00010033324,0.00020286127],"about_ca_topic_score_codex":0.00027497372,"about_ca_topic_score_gemma":0.00021248302,"teacher_disagreement_score":0.13280319,"about_ca_system_score_codex":0.00014674281,"about_ca_system_score_gemma":0.0010881294,"threshold_uncertainty_score":0.99996763},"labels":[],"label_agreement":null},{"id":"W2592440964","doi":"10.1200/jco.2013.31.15_suppl.e12549","title":"Evaluating the hidden biology of cancer of unknown primary (CUP) in comparison to known metastatic disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Winnipeg Regional Health Authority; Western University","funders":"","keywords":"Medicine; Cohort; Cancer; Autopsy; Primary tumor; Disease; Internal medicine; Cancer registry; Oncology; Pathology; Metastasis","score_opus":0.31581250644265435,"score_gpt":0.5925599009541039,"score_spread":0.2767473945114496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592440964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716596,0.00640935,0.000020450776,0.02037796,0.0005623321,0.00049609796,0.000007292836,0.0000016562652,0.00046523786],"genre_scores_gemma":[0.99354553,0.0011227593,0.0032764457,0.0016346584,0.00029602763,0.000053295997,0.0000021268447,0.000008857292,0.000060280716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962776,0.00058571924,0.002555604,0.000141895,0.0002656829,0.0001735151],"domain_scores_gemma":[0.9934286,0.0039125225,0.0017271797,0.00019907541,0.00048002653,0.0002525938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022141892,0.00010467247,0.0016826678,0.000116370036,0.0000144438845,0.0000026812468,0.00016053172,0.000077963196,0.00040449188],"category_scores_gemma":[0.0022559979,0.000055744124,0.00034484305,0.00017685034,0.00019573793,0.000040347735,0.000068471934,0.0003890275,0.0000087656135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016338301,0.0023986625,0.56103456,0.0000684695,0.00048363677,0.000021228405,0.00014272628,0.00024035825,0.00035788325,0.00012835168,0.002492808,0.43099746],"study_design_scores_gemma":[0.005358584,0.012836843,0.9714555,0.00031588846,0.0009211027,0.000008778943,0.00009190042,0.00038405217,0.00016175007,0.00065406755,0.0077587804,0.000052751737],"about_ca_topic_score_codex":0.0007611418,"about_ca_topic_score_gemma":0.0004583807,"teacher_disagreement_score":0.4309447,"about_ca_system_score_codex":0.00021994689,"about_ca_system_score_gemma":0.0017492307,"threshold_uncertainty_score":0.44289026},"labels":[],"label_agreement":null},{"id":"W2592499472","doi":"10.1200/jco.2009.27.15_suppl.e13524","title":"Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada); Institute of Cancer Research","funders":"","keywords":"Medicine; Neutropenia; Docetaxel; Toxicity; Pharmacokinetics; Pharmacology; In vivo; Internal medicine; Leukopenia; Chemotherapy; Gastroenterology","score_opus":0.06983978760561946,"score_gpt":0.46684746424441287,"score_spread":0.39700767663879344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592499472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983084,0.00019345027,0.000075702825,0.0004192186,0.000052252526,0.0008734024,0.00002467595,8.5836297e-7,0.000051989682],"genre_scores_gemma":[0.9987353,0.00028711715,0.00077655463,0.00013500352,0.00004500864,0.0000029959442,0.0000066502857,0.000004455952,0.000006891347],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978513,0.00045027194,0.0010416332,0.00021009853,0.00029919928,0.00014746236],"domain_scores_gemma":[0.9978072,0.00035528475,0.0007063488,0.00022995197,0.0007266638,0.00017453908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013300026,0.00011176935,0.00066686573,0.000044758235,0.00002570913,0.0000036829188,0.00016837759,0.0000873413,0.0000015151642],"category_scores_gemma":[0.002349172,0.000055985853,0.0000761754,0.0001447215,0.00018290356,0.000006637916,0.000057718495,0.00014042703,2.1300285e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59238297,0.026873294,0.15283975,0.00005799957,0.000881479,0.00012440886,0.0005189135,0.00012755023,0.045568224,0.000012618214,0.00011783382,0.18049496],"study_design_scores_gemma":[0.018629417,0.43117854,0.5354225,0.000057102076,0.00010870192,0.000014088182,0.00006908396,8.118678e-7,0.014209577,0.000037704398,0.0002168421,0.000055631972],"about_ca_topic_score_codex":0.000027721033,"about_ca_topic_score_gemma":0.00025063122,"teacher_disagreement_score":0.57375354,"about_ca_system_score_codex":0.000025094838,"about_ca_system_score_gemma":0.0005666655,"threshold_uncertainty_score":0.2812348},"labels":[],"label_agreement":null},{"id":"W2592511344","doi":"10.1200/jco.2015.33.15_suppl.e17696","title":"A comparison of prognostic systems in hepatocellular carcinoma treated with sorafenib.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Manitoba; BC Cancer Agency; University of Toronto; CancerCare Manitoba; University of British Columbia","funders":"","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Cohort; Oncology; Cirrhosis","score_opus":0.35487947614299703,"score_gpt":0.44059796537662044,"score_spread":0.08571848923362341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592511344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349093,0.0034981128,0.00006375928,0.00065102073,0.00029920932,0.0006098845,0.0000022041022,0.000009820503,0.0013750299],"genre_scores_gemma":[0.99836636,0.000042071122,0.0010875884,0.000061385224,0.00030336718,0.000013657917,0.000007845331,0.000022908042,0.00009479826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954061,0.00071170344,0.002898969,0.00019641922,0.00052228454,0.00026451543],"domain_scores_gemma":[0.99547327,0.0010527121,0.0018699237,0.00021452077,0.0008200029,0.0005695501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027477292,0.00018951966,0.0026204837,0.0002691622,0.000014050922,0.000007881192,0.00013993257,0.00039823877,0.000016777962],"category_scores_gemma":[0.0013960514,0.00011931626,0.00032476088,0.0003487443,0.00019654268,0.000086920794,0.000027611442,0.0006893734,0.00001232401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005594499,0.003584715,0.98093116,0.00009246742,0.00029549093,0.0042923535,0.00028478494,0.000018077408,0.00009314114,0.000036738482,0.00049478916,0.0042818044],"study_design_scores_gemma":[0.025108306,0.06095532,0.88803947,0.00049767277,0.0014486886,0.0009609775,0.0009856118,0.01431788,0.00095675327,0.000032822958,0.006507911,0.00018861616],"about_ca_topic_score_codex":0.00023595359,"about_ca_topic_score_gemma":0.00003376634,"teacher_disagreement_score":0.0928917,"about_ca_system_score_codex":0.00019438965,"about_ca_system_score_gemma":0.0021044258,"threshold_uncertainty_score":0.4865576},"labels":[],"label_agreement":null},{"id":"W2592578668","doi":"10.1200/jco.2009.27.15_suppl.e12019","title":"An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Pfizer (Canada); Montreal General Hospital","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Sunitinib; Exemestane; Bevacizumab; Letrozole; Regimen; Oncology; Palbociclib; Pharmacology; Progression-free survival; Breast cancer; Aromatase inhibitor; Pharmacokinetics; Gastroenterology; Cancer; Tamoxifen; Chemotherapy","score_opus":0.08892945395639623,"score_gpt":0.459016489290721,"score_spread":0.37008703533432474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592578668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478334,0.0024051827,0.000023096436,0.0017468341,0.00018168737,0.0006230536,0.000034332486,0.000001374857,0.00020111213],"genre_scores_gemma":[0.99389386,0.004745945,0.0006125526,0.00040837753,0.00026267738,0.000012930106,0.000016976092,0.000012442082,0.00003423696],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99659175,0.0010510036,0.0017015771,0.0002221795,0.000226254,0.00020723225],"domain_scores_gemma":[0.9973325,0.0004240274,0.0014750798,0.00028880098,0.0003378231,0.00014175901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017474078,0.00018381141,0.0011397061,0.00007200818,0.00004314628,0.000011629741,0.00051593035,0.00026393254,0.000011253526],"category_scores_gemma":[0.00018995523,0.00010756355,0.00015667376,0.00017820732,0.00015159376,0.000016399576,0.000046760153,0.0003413066,8.908071e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07734878,0.23642637,0.012001675,0.00003510409,0.0044072717,0.0014327733,0.0053293603,0.001436228,0.20219482,0.00019225125,0.0031001568,0.45609522],"study_design_scores_gemma":[0.08614381,0.7041136,0.18736154,0.00012529393,0.0015820955,0.00063192705,0.0028886201,0.00025109784,0.01155417,0.00021442224,0.0047043636,0.00042907137],"about_ca_topic_score_codex":0.00019694507,"about_ca_topic_score_gemma":0.0002245319,"teacher_disagreement_score":0.46768722,"about_ca_system_score_codex":0.0000749346,"about_ca_system_score_gemma":0.0006664614,"threshold_uncertainty_score":0.43863142},"labels":[],"label_agreement":null},{"id":"W2592703227","doi":"10.1200/jco.2013.31.15_suppl.2033","title":"Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Temozolomide; Procarbazine; Primary central nervous system lymphoma; Phases of clinical research; Dacarbazine; Lomustine; Clinical endpoint; Vincristine; Radiation therapy; Regimen; Internal medicine; Chemotherapy; Surgery; Gastroenterology; Clinical trial; Cyclophosphamide","score_opus":0.04520119841995056,"score_gpt":0.392990256553215,"score_spread":0.34778905813326444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592703227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98836905,0.0007517343,0.0000899135,0.007940832,0.00037300366,0.0022116958,0.000025544443,0.00002412957,0.00021408682],"genre_scores_gemma":[0.991039,0.00033521134,0.006616821,0.0012006459,0.0006077003,0.00009121152,0.000025469077,0.000032882093,0.000051099956],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99641526,0.00044116084,0.0021205759,0.00037717546,0.00031094707,0.00033488552],"domain_scores_gemma":[0.9944929,0.0021922528,0.0019658601,0.0002207239,0.0006053969,0.0005228606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022064091,0.0002518825,0.0017210399,0.00018318335,0.00014570802,0.00003998059,0.000089314475,0.0002981848,0.0000090647645],"category_scores_gemma":[0.0010477044,0.0001607719,0.00020757169,0.00012375314,0.00013721724,0.00029278736,0.000033570308,0.00025668743,0.0000022577203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026110342,0.021503314,0.076452345,0.00015877635,0.0017301795,0.0003477619,0.0008821155,0.000017764576,0.0011362892,0.00005904673,0.0021920193,0.86941004],"study_design_scores_gemma":[0.122477144,0.074568786,0.79710835,0.000090704634,0.0010287631,0.000621676,0.0007266783,0.00066981115,0.00010722589,0.000040324776,0.0024207544,0.00013978385],"about_ca_topic_score_codex":0.00013382036,"about_ca_topic_score_gemma":0.000038614282,"teacher_disagreement_score":0.86927027,"about_ca_system_score_codex":0.00037553217,"about_ca_system_score_gemma":0.0006022878,"threshold_uncertainty_score":0.65560883},"labels":[],"label_agreement":null},{"id":"W2592759196","doi":"10.1200/jco.2016.70.3108","title":"Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada); Gilead Sciences (Canada)","funders":"University of South Florida; University of Rochester; Astellas Pharma; University of Pennsylvania; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Wayne State University; Brigham and Women's Hospital","keywords":"Medicine; Bleomycin; Testicular cancer; Internal medicine; Etoposide; Chemotherapy; Adverse effect; Cumulative dose; Odds ratio; Cumulative incidence; Cancer; Cisplatin; Gastroenterology; Cohort","score_opus":0.09885228117281308,"score_gpt":0.5109043898356658,"score_spread":0.4120521086628527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592759196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930866,0.00020716191,0.0027855316,0.0030675547,0.00048321826,0.00027162718,0.000039217743,0.0000072982807,0.00005182406],"genre_scores_gemma":[0.972625,0.00019041623,0.024869878,0.0020592627,0.00018191074,0.000013984925,0.0000062813524,0.000016407676,0.000036863283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738693,0.00018365394,0.0015298665,0.00020301262,0.00047218375,0.0002243309],"domain_scores_gemma":[0.99423593,0.00060290674,0.0038321135,0.0003656867,0.00041521073,0.00054813427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000737602,0.00018269976,0.0016327548,0.00007963098,0.00010665134,0.0000061937417,0.00017341168,0.00009434929,0.00008355632],"category_scores_gemma":[0.0014547653,0.000114520146,0.0007013936,0.00005477541,0.00071722944,0.000090128284,0.00003198246,0.0004023702,0.0000016587327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007886414,0.0035109704,0.9290229,0.00004080693,0.00069737126,0.00056142634,0.000015582607,0.0010331464,0.000002722123,0.0000031593609,0.000015511692,0.06430774],"study_design_scores_gemma":[0.011388471,0.0034355654,0.97485447,0.00014706822,0.00047393542,0.000015766982,0.000011333328,0.009280103,0.0000017345274,0.0000079441115,0.00029595348,0.000087647604],"about_ca_topic_score_codex":0.0020687894,"about_ca_topic_score_gemma":0.005935029,"teacher_disagreement_score":0.06422009,"about_ca_system_score_codex":0.00026947176,"about_ca_system_score_gemma":0.0044373753,"threshold_uncertainty_score":0.7871713},"labels":[],"label_agreement":null},{"id":"W2592854110","doi":"10.1200/jco.2013.31.15_suppl.8108","title":"Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced <i>ALK</i>+ non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Docetaxel; Pemetrexed; ALK inhibitor; Internal medicine; Clinical endpoint; Chemotherapy; Oncology; Quality of life (healthcare); Performance status; Randomization; Clinical trial; Cisplatin","score_opus":0.08649349253772255,"score_gpt":0.49274907376296934,"score_spread":0.4062555812252468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592854110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974827,0.00034262252,0.00003590694,0.00026089585,0.00017458171,0.0012742798,0.000012574187,0.00000320129,0.00041322256],"genre_scores_gemma":[0.99887437,0.00016365445,0.00056570675,0.00026467518,0.000063036896,0.000026274252,0.0000032020257,0.000017031414,0.000022037828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957769,0.00026572373,0.0032410307,0.0002013101,0.0003383867,0.00017665503],"domain_scores_gemma":[0.99341816,0.00084316154,0.0044652433,0.00022484161,0.000758149,0.00029047253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006482615,0.00017367455,0.0021094834,0.0001460417,0.000016772121,0.0000033003869,0.00008128971,0.00012615752,0.0000879202],"category_scores_gemma":[0.00031415923,0.00010599412,0.00024633374,0.00018196131,0.00014534242,0.000078670826,0.000018967565,0.00032867532,1.7907666e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02919088,0.04327815,0.8739445,0.00012257473,0.0022352783,0.000043597858,0.0040210453,0.00061545015,0.006361507,9.972218e-7,0.00014843246,0.040037546],"study_design_scores_gemma":[0.11649499,0.0855348,0.79443944,0.00035239026,0.00068602816,0.000008702907,0.0015195842,0.0001397305,0.0006863129,0.0000038074004,0.00004252645,0.00009171518],"about_ca_topic_score_codex":0.0017152282,"about_ca_topic_score_gemma":0.00029851386,"teacher_disagreement_score":0.08730411,"about_ca_system_score_codex":0.00022140745,"about_ca_system_score_gemma":0.0017023549,"threshold_uncertainty_score":0.4322315},"labels":[],"label_agreement":null},{"id":"W2592987956","doi":"10.1200/jco.2013.31.15_suppl.2008","title":"A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario","funders":"","keywords":"Medicine; Temozolomide; Regimen; Internal medicine; Chemoradiotherapy; Radiation therapy; Population; Clinical endpoint; Phases of clinical research; Glioma; Surgery; Gastroenterology; Oncology; Toxicity; Randomized controlled trial","score_opus":0.07644452246564526,"score_gpt":0.4421761580022757,"score_spread":0.36573163553663046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592987956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989323,0.0005951318,0.00005307626,0.0076270867,0.00046764466,0.001823563,0.000037214613,0.000010055427,0.00006319219],"genre_scores_gemma":[0.9928398,0.0002287992,0.005805983,0.00043067397,0.0005162069,0.000093473136,0.00000831884,0.00003131798,0.000045427114],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99442536,0.0004925792,0.004044708,0.00030330225,0.00045644943,0.00027758913],"domain_scores_gemma":[0.9882107,0.005014207,0.005032037,0.00047723323,0.00089398597,0.00037185932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026747012,0.0002297787,0.002779853,0.00030041006,0.00005577575,0.000005580314,0.00023968515,0.00037147815,0.00006375188],"category_scores_gemma":[0.0035292981,0.00015157189,0.0007208194,0.00024990545,0.00021974638,0.000093857445,0.000041429554,0.00045546275,0.0000027171877],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17843214,0.3875543,0.0459613,0.0002605485,0.0052195266,0.000998567,0.0013567522,0.00014724971,0.008081756,0.00004219786,0.039643683,0.332302],"study_design_scores_gemma":[0.29495135,0.6043714,0.079348214,0.0003041807,0.0019498914,0.00007970732,0.0005137437,0.00047372075,0.014899911,0.00033054454,0.0026276123,0.00014967362],"about_ca_topic_score_codex":0.00025835237,"about_ca_topic_score_gemma":0.000028044453,"teacher_disagreement_score":0.33215234,"about_ca_system_score_codex":0.00012740545,"about_ca_system_score_gemma":0.0008224387,"threshold_uncertainty_score":0.61809224},"labels":[],"label_agreement":null},{"id":"W2593147789","doi":"10.1200/jco.2016.71.8478","title":"Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Guideline; Survivorship curve; Family medicine; Referral; Health care; Promotion (chess); MEDLINE; Cancer; Nursing; Internal medicine; Pathology","score_opus":0.4366951522681437,"score_gpt":0.6547638548574098,"score_spread":0.21806870258926614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593147789","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042560315,0.92627054,0.00009631435,0.0576334,0.008279463,0.0016032769,0.0003626197,0.000022905753,0.0014754239],"genre_scores_gemma":[0.00034985348,0.9054587,0.05487826,0.02623132,0.012528513,0.00007317432,0.000034651275,0.00013355359,0.00031199987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9551245,0.006457851,0.034256987,0.0013378902,0.0018185765,0.0010042151],"domain_scores_gemma":[0.9090102,0.018362232,0.06123314,0.0017027336,0.0084508825,0.0012408315],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.038110986,0.0011181197,0.028025795,0.00014372778,0.0002959285,0.000022660524,0.0016599434,0.002017927,0.00013793452],"category_scores_gemma":[0.03824454,0.0006636293,0.011747715,0.00068977685,0.007351635,0.0001895687,0.0012615777,0.0075197457,0.000004329434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001560718,0.0017680326,0.018873908,0.0019584266,0.006090928,0.000069616486,0.0001895176,0.0000045203064,7.1631274e-7,0.000006124549,0.28944743,0.68003005],"study_design_scores_gemma":[0.008298684,0.020936513,0.008584729,0.0072174016,0.014468115,0.00022490342,0.0016121388,0.0000637542,9.874709e-7,0.0000103896555,0.93807715,0.00050525717],"about_ca_topic_score_codex":0.009724365,"about_ca_topic_score_gemma":0.0052262563,"teacher_disagreement_score":0.6795248,"about_ca_system_score_codex":0.0011178675,"about_ca_system_score_gemma":0.03937995,"threshold_uncertainty_score":0.9995815},"labels":[],"label_agreement":null},{"id":"W2593246085","doi":"10.1200/jco.2013.31.15_suppl.9518","title":"Intensity of palliative care and its impact on the aggressiveness of end-of-life care in patients with advanced pancreatic cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Cancer; Retrospective cohort study; Pancreatic cancer; Population; Emergency department; Emergency medicine; Comorbidity; Intensive care unit; Logistic regression; Cohort; Internal medicine; Nursing","score_opus":0.15409837553933303,"score_gpt":0.5116054124043474,"score_spread":0.3575070368650144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593246085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918677,0.006918985,0.0000029534165,0.00039146064,0.0001700969,0.00035695097,0.000039943374,0.0000011880295,0.0002506755],"genre_scores_gemma":[0.995527,0.0038449615,0.00033137642,0.00020252811,0.00007160254,0.00000573203,0.0000039197707,0.00000962425,0.000003203343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975709,0.000316272,0.0014895892,0.00012637078,0.00035130983,0.00014559488],"domain_scores_gemma":[0.9907808,0.0031031456,0.002933962,0.0001487676,0.0028732342,0.00016011581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038916888,0.00014380123,0.0019375574,0.000100408135,0.000013005306,0.0000011548202,0.0001305481,0.00017370553,0.000059181508],"category_scores_gemma":[0.004728895,0.000071356706,0.0002256438,0.00015500572,0.00032518856,0.00006905382,0.000040723357,0.00046364934,4.4775734e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009846312,0.00037542914,0.95537627,0.00029766635,0.0003936608,0.000013074992,0.0033221494,0.00009658355,0.00011055257,0.00001344297,0.000043986984,0.030110857],"study_design_scores_gemma":[0.006957357,0.02122296,0.96020615,0.0043399855,0.00023167126,7.661628e-7,0.0050149704,0.000016800019,0.001794831,0.00003402393,0.000118810465,0.00006168955],"about_ca_topic_score_codex":0.00029921523,"about_ca_topic_score_gemma":0.00013983877,"teacher_disagreement_score":0.030049168,"about_ca_system_score_codex":0.0001389288,"about_ca_system_score_gemma":0.00112372,"threshold_uncertainty_score":0.56612706},"labels":[],"label_agreement":null},{"id":"W2593287697","doi":"10.1200/jco.2013.31.15_suppl.tps2622","title":"Phase II, multicenter, open-label, proof of concept study of tasquinimod in patients with advanced/metastatic hepatocellular (HCC), ovarian (OC), renal cell (RCC) and gastric (GC) carcinomas.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Combination therapy; Progression-free survival; Clinical endpoint; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.1109235187220886,"score_gpt":0.4580474076056311,"score_spread":0.3471238888835425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593287697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526364,0.00087917666,0.000062876934,0.0004751132,0.00017850536,0.0029248404,0.000015284993,0.0000027874983,0.00019779059],"genre_scores_gemma":[0.994522,0.0001235328,0.0049684094,0.00013953152,0.00008047226,0.000048730144,0.0000040750956,0.000023897968,0.00008937348],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947063,0.0007625587,0.0030081556,0.0003401832,0.00079709874,0.0003857182],"domain_scores_gemma":[0.9942255,0.0011409578,0.0025747612,0.00032043245,0.0013191148,0.00041925893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019802859,0.00023072935,0.0025259876,0.00028449117,0.000049568123,0.000010676233,0.00037643523,0.00011776902,0.000085663254],"category_scores_gemma":[0.001788994,0.0001505198,0.00009551054,0.0003555507,0.00051358907,0.00032439386,0.00040869287,0.0009395732,9.071982e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026000554,0.10366193,0.7899014,0.00027969183,0.00087545085,0.00041925145,0.001854201,0.00003360739,0.0005314604,0.0000032037658,0.0010663966,0.075372905],"study_design_scores_gemma":[0.26925063,0.38868752,0.33770546,0.00046849204,0.0006374455,0.000021647797,0.0015616661,0.00046219426,0.00056331273,0.000038322552,0.00044305215,0.00016027458],"about_ca_topic_score_codex":0.0002059678,"about_ca_topic_score_gemma":0.00006661654,"teacher_disagreement_score":0.45219588,"about_ca_system_score_codex":0.00017051294,"about_ca_system_score_gemma":0.0010862488,"threshold_uncertainty_score":0.6138019},"labels":[],"label_agreement":null},{"id":"W2593338225","doi":"10.1200/jco.2012.30.15_suppl.9138","title":"Prospective cohort study of chemotherapy-induced alopecia with or without scalp cooling.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Saint-Sacrement; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Scalp; Hair loss; Prospective cohort study; Chemotherapy; Breast cancer; Internal medicine; Cancer; Surgery; Dermatology","score_opus":0.08993041830116778,"score_gpt":0.46101197015767326,"score_spread":0.3710815518565055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593338225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908653,0.00009112593,0.0000854978,0.00063663436,0.0005017887,0.00085149455,4.6274144e-7,0.000010112467,0.0069576073],"genre_scores_gemma":[0.9959031,0.000064668915,0.0013509145,0.0012246108,0.0011662602,0.000009463074,4.2726717e-7,0.000024980249,0.00025559904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969517,0.0002842188,0.0017960788,0.00016272946,0.000512171,0.00029310482],"domain_scores_gemma":[0.996373,0.0007666201,0.0014657759,0.00021423654,0.000643827,0.00053656864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030609746,0.00015614922,0.001965184,0.000115472925,0.00003295561,0.0000038277326,0.00013552343,0.00026931328,0.00021626249],"category_scores_gemma":[0.0019903833,0.0000846373,0.00020673816,0.00023226682,0.00017339602,0.00013456075,0.000024546152,0.0008120824,0.000011392649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029768193,0.010087221,0.9424771,0.00001784289,0.0008304708,0.00008617667,0.0011235715,0.0000012925079,0.000060955164,0.0000130596145,0.0005344088,0.014999704],"study_design_scores_gemma":[0.02330359,0.049304157,0.9204305,0.00005759353,0.00058437034,0.00028197904,0.0024886893,0.000013186042,0.00014071041,0.0000138905225,0.0032859761,0.00009540261],"about_ca_topic_score_codex":0.0000442966,"about_ca_topic_score_gemma":0.00021324576,"teacher_disagreement_score":0.039216936,"about_ca_system_score_codex":0.00008607236,"about_ca_system_score_gemma":0.0013857451,"threshold_uncertainty_score":0.3528139},"labels":[],"label_agreement":null},{"id":"W2593653865","doi":"10.1200/jco.2014.32.15_suppl.e16023","title":"The FRAX score as a tool for estimating fracture risk in patients with advanced prostate cancer on androgen-deprivation therapy compared to the conventional T-score.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"FRAX; Medicine; Prostate cancer; Androgen deprivation therapy; Osteoporosis; Internal medicine; Cohort; Hip fracture; Trabecular bone score; Framingham Risk Score; Osteoporotic fracture; Bone mineral; Cancer","score_opus":0.06397775839621317,"score_gpt":0.45005220545478986,"score_spread":0.3860744470585767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593653865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982131,0.00013283952,0.0009498215,0.0148285,0.00058049517,0.0013278315,0.0000080413465,0.0000041532658,0.00003733618],"genre_scores_gemma":[0.98503095,0.00017523998,0.0056047216,0.008744679,0.00029281856,0.00009671579,0.000010169082,0.0000134827405,0.00003119999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797904,0.00027756585,0.0010787761,0.00014596783,0.00031514675,0.00020347623],"domain_scores_gemma":[0.9953261,0.0026037337,0.0013382145,0.00014970402,0.00042321146,0.00015900866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017230721,0.000109707056,0.0005603795,0.000040835628,0.00015660324,0.000010412462,0.000095705545,0.00011445255,0.000015729967],"category_scores_gemma":[0.0025460403,0.00004692888,0.00012623674,0.000090871785,0.000067426925,0.00005342891,0.000010481553,0.0005685051,0.0000047956873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023454228,0.00062282407,0.63964844,0.0000069717303,0.00010443992,0.000003279352,0.00009284944,0.001260589,4.706531e-7,0.000026557973,0.00049097516,0.33428836],"study_design_scores_gemma":[0.023965346,0.016416026,0.9185974,0.00017667408,0.000064515705,0.0000060278835,0.000018012157,0.0013199159,0.000007677833,0.00061464345,0.03876367,0.000050103416],"about_ca_topic_score_codex":0.000037881826,"about_ca_topic_score_gemma":0.00019482692,"teacher_disagreement_score":0.33423826,"about_ca_system_score_codex":0.00012123076,"about_ca_system_score_gemma":0.0006322254,"threshold_uncertainty_score":0.3048032},"labels":[],"label_agreement":null},{"id":"W2593918819","doi":"10.1200/jco.2012.30.15_suppl.3610","title":"A population-based study of the effect of FDG PET/CT in the management of liver-limited colorectal adenocarcinoma (CRC) metastases.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Concordance; Colorectal cancer; Radiology; Liver disease; Nuclear medicine; Cancer; Internal medicine","score_opus":0.14482511296064773,"score_gpt":0.4018377242558669,"score_spread":0.25701261129521913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593918819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700475,0.0008972993,0.0000034565528,0.0004132978,0.00029186576,0.0011648063,0.000005346936,0.0000021769547,0.00021700768],"genre_scores_gemma":[0.9993827,0.00003644392,0.00033801302,0.000091520924,0.00010813399,0.000018491352,0.000004423338,0.000010748033,0.000009570224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944385,0.0026211103,0.0020600804,0.0001165293,0.0005709836,0.0001927677],"domain_scores_gemma":[0.9942897,0.0032863847,0.0018821334,0.00028732573,0.00014579372,0.00010863791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005933274,0.00014827248,0.0014468343,0.00015625349,0.000026882228,0.0000022173058,0.00026426223,0.000050748382,0.000064054395],"category_scores_gemma":[0.00067032385,0.000070979884,0.000680233,0.00037393565,0.00010945164,0.000054626576,0.000058519876,0.00045653997,0.0000015852537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032335178,0.005513535,0.98224235,0.00017274839,0.0009526567,0.0008709725,0.0002082417,0.000011191461,0.00003235814,0.00002234786,0.00005703442,0.006683044],"study_design_scores_gemma":[0.011160645,0.026097223,0.9577591,0.00013469621,0.0032762578,0.00015449437,0.00039462483,0.00019131938,0.00067761965,0.00000588815,0.00009849133,0.000049646205],"about_ca_topic_score_codex":0.0002139044,"about_ca_topic_score_gemma":0.0000751539,"teacher_disagreement_score":0.024483256,"about_ca_system_score_codex":0.000082250845,"about_ca_system_score_gemma":0.00016507412,"threshold_uncertainty_score":0.28944758},"labels":[],"label_agreement":null},{"id":"W2594044276","doi":"10.1200/jco.2012.30.15_suppl.1019","title":"Metformin in early breast cancer (BC): A prospective, open-label, neoadjuvant “window of opportunity” study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Statistics Canada; Ontario Institute for Cancer Research; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Metformin; Internal medicine; Breast cancer; Cancer; Clinical endpoint; Prospective cohort study; Gastroenterology; Insulin; Oncology; Clinical trial","score_opus":0.14234684148065163,"score_gpt":0.4722731821919143,"score_spread":0.32992634071126264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594044276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696697,0.02723393,0.000014882321,0.00015729309,0.0013641536,0.00039731132,0.000025368845,0.000001546821,0.0011358245],"genre_scores_gemma":[0.981008,0.016054785,0.00056445313,0.00068316783,0.0014459473,0.000032400014,0.000002274843,0.000020873977,0.0001880983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650747,0.00063259545,0.0019818784,0.00022515944,0.00027232556,0.00038058287],"domain_scores_gemma":[0.99698627,0.00017194546,0.00167104,0.00027620263,0.00045990982,0.00043461996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004854689,0.00017451445,0.0013159794,0.00009573948,0.00002978763,0.000012969459,0.0005850083,0.0003583652,0.0001747351],"category_scores_gemma":[0.0009514567,0.00013114474,0.00018634269,0.00016354655,0.00017178367,0.00004451173,0.00027252562,0.00056773133,0.0000038851877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024399436,0.006403781,0.5975106,0.000014758616,0.0003826862,0.000029685623,0.00020789164,0.0000043625487,0.0017064693,0.000063562904,0.001513264,0.38972303],"study_design_scores_gemma":[0.013554178,0.008075584,0.8576432,0.000048570386,0.00021714572,0.000065945715,0.0003643167,0.0000032279386,0.0022392685,0.0001463734,0.11743301,0.00020919177],"about_ca_topic_score_codex":0.0003593099,"about_ca_topic_score_gemma":0.0005371844,"teacher_disagreement_score":0.38951382,"about_ca_system_score_codex":0.00006254137,"about_ca_system_score_gemma":0.0016843277,"threshold_uncertainty_score":0.5347927},"labels":[],"label_agreement":null},{"id":"W2594191163","doi":"10.1200/jco.2013.31.15_suppl.5530","title":"Locally advanced adenocarcinoma and adenosquamous carcinoma of the cervix compared to squamous cell carcinoma of the cervix in Gynecologic Oncology Group trials of chemoradiation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Adenosquamous carcinoma; Medicine; Cervix; Oncology; Adenocarcinoma; Internal medicine; Squamous carcinoma; Carcinoma; Cancer","score_opus":0.09928428275840427,"score_gpt":0.39985096544748266,"score_spread":0.3005666826890784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594191163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98087114,0.0040331413,0.0000100967445,0.011396263,0.0011404527,0.0017613973,0.000026297,0.0000033042388,0.0007579007],"genre_scores_gemma":[0.99671406,0.00027590094,0.001011844,0.0015542416,0.00029578703,0.00006418822,0.0000023012344,0.000023378834,0.000058284568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915573,0.0017452898,0.0054648654,0.0003423828,0.0005313028,0.0003588861],"domain_scores_gemma":[0.98394936,0.008778362,0.0055823238,0.0005751316,0.00076735066,0.0003474824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036586348,0.00027531225,0.003933338,0.00021598511,0.00004768256,0.000006092694,0.000538524,0.0005226301,0.0002728311],"category_scores_gemma":[0.0054984423,0.00015105506,0.0009516383,0.00046056218,0.00050789287,0.00008926986,0.00026829034,0.0007619071,0.000004133411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003352047,0.0047610425,0.9506949,0.00021292659,0.00013980734,0.00007641563,0.0007073778,0.0002961467,0.0018305667,0.00007731782,0.0022565266,0.0355949],"study_design_scores_gemma":[0.021679275,0.018479262,0.9520715,0.000109387474,0.0006599656,0.00010466029,0.00070917344,0.000116702315,0.0041995677,0.0002527554,0.0015013579,0.000116418414],"about_ca_topic_score_codex":0.0011146467,"about_ca_topic_score_gemma":0.0011768298,"teacher_disagreement_score":0.03547848,"about_ca_system_score_codex":0.000560522,"about_ca_system_score_gemma":0.0020398677,"threshold_uncertainty_score":0.6582546},"labels":[],"label_agreement":null},{"id":"W2594251315","doi":"10.1200/jco.2009.27.15_suppl.556","title":"Patterns of use of tamoxifen and aromatase inhibitors: A population-based observational study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Tamoxifen; Exemestane; Letrozole; Breast cancer; Population; Medical prescription; Internal medicine; Oncology; Cancer; Gynecology; Pharmacology","score_opus":0.1262870634327675,"score_gpt":0.42992075205433017,"score_spread":0.3036336886215627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594251315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990018,0.00016494212,0.00007803276,0.00044120883,0.00016148888,0.00012725798,0.0000129382015,0.0000011628416,0.000011169203],"genre_scores_gemma":[0.99802774,0.00006867514,0.0013133333,0.00031474768,0.00023315017,6.92462e-7,0.000025594925,0.0000050590324,0.000010987866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980128,0.0003164575,0.0013107137,0.00011429711,0.00016372564,0.0000820448],"domain_scores_gemma":[0.9979221,0.00040824982,0.0012336778,0.00012482663,0.00020714472,0.0001039815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094352936,0.00008088686,0.00050304586,0.000052319083,0.000015393121,0.000003831571,0.0000859157,0.00026822713,0.000004623682],"category_scores_gemma":[0.0013079561,0.000060670478,0.00018279064,0.00004918967,0.00003896618,0.000008991858,0.000023542221,0.00021018196,2.1453823e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013242346,0.0020606203,0.9635251,0.000011081047,0.00015790858,0.000033172717,0.00002103085,0.00024091495,0.023264645,0.000017675718,0.0004899509,0.008853638],"study_design_scores_gemma":[0.0029111279,0.016148191,0.9742435,0.000037250444,0.00010671423,0.000019802512,0.000019088811,0.00007568272,0.005731013,0.00008556887,0.0005587042,0.00006335451],"about_ca_topic_score_codex":0.000025861149,"about_ca_topic_score_gemma":0.000006557539,"teacher_disagreement_score":0.017533632,"about_ca_system_score_codex":0.000008206037,"about_ca_system_score_gemma":0.0002681193,"threshold_uncertainty_score":0.24740703},"labels":[],"label_agreement":null},{"id":"W2594354048","doi":"10.1200/jco.2015.33.15_suppl.6583","title":"Frequency and predictors of hospitalization during chemotherapy: a systematic review.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Observational study; Internal medicine; Chemotherapy; Randomized controlled trial; Lung cancer; Cancer; Breast cancer; Clinical trial","score_opus":0.0772614104984543,"score_gpt":0.44597960670865744,"score_spread":0.36871819621020313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594354048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98514825,0.009377446,0.000074312746,0.0027577379,0.0006927054,0.0003595281,7.612513e-7,0.000005881746,0.0015833675],"genre_scores_gemma":[0.986164,0.011783638,0.0003662524,0.0011154738,0.00043578906,0.0000052043265,4.4226823e-7,0.000008815688,0.00012039401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776596,0.00020032993,0.0016987916,0.00006808707,0.00019926012,0.00006754803],"domain_scores_gemma":[0.99751186,0.00020985217,0.0014797972,0.00010973174,0.00047566567,0.0002130736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017151714,0.000059035494,0.0012472466,0.00005549363,0.0000113172455,0.00000216751,0.00005155688,0.000109702465,0.000023757426],"category_scores_gemma":[0.0029070913,0.000038228074,0.00017359006,0.000102982354,0.000081972285,0.00007757069,0.000011541399,0.00023060631,0.0000019880517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076356623,0.0013066882,0.9120521,0.07738804,0.0010542099,0.0001778706,0.00038076082,0.000003743716,0.0008464908,0.00030244014,0.0048216907,0.00090241415],"study_design_scores_gemma":[0.024832223,0.031697348,0.8260295,0.100903325,0.0069015524,0.0041588508,0.0004025348,0.000020322805,0.0007914997,0.0012721478,0.0027274522,0.00026324546],"about_ca_topic_score_codex":0.0000048548172,"about_ca_topic_score_gemma":0.0000028024597,"teacher_disagreement_score":0.086022586,"about_ca_system_score_codex":0.00007223537,"about_ca_system_score_gemma":0.0005903191,"threshold_uncertainty_score":0.34802696},"labels":[],"label_agreement":null},{"id":"W2594363918","doi":"10.1200/jco.2013.31.15_suppl.e17569","title":"A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Calgary; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Incremental cost-effectiveness ratio; Willingness to pay; Cost effectiveness; Cohort; Pancreatic cancer; Oncology; Nab-paclitaxel; Internal medicine; Quality-adjusted life year; Emergency medicine; Cancer","score_opus":0.29292352458669585,"score_gpt":0.5587329015568046,"score_spread":0.2658093769701087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594363918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98747855,0.0013779349,0.00053946214,0.0062422073,0.0002564666,0.00070518156,0.000013456065,0.00000539037,0.0033813696],"genre_scores_gemma":[0.9895687,0.0020099352,0.0065410617,0.000957401,0.0001982459,0.00005900372,0.000005577699,0.000012711742,0.000647373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929539,0.0013693777,0.004346058,0.0002570738,0.00063317956,0.0004403975],"domain_scores_gemma":[0.9877314,0.007988526,0.0021263415,0.00037230112,0.0011894987,0.0005919276],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007690117,0.00017946269,0.0053035463,0.0007612358,0.000028073891,0.0000066621806,0.0002699665,0.00035130777,0.0034171569],"category_scores_gemma":[0.013060043,0.0001214853,0.0009056855,0.0012023869,0.0006291491,0.00014917851,0.0000779279,0.0012573231,0.000029595989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00291001,0.0020614688,0.94252485,0.000115097275,0.005928995,0.0003277051,0.000288437,0.000074482894,0.00010657823,0.00006435381,0.0018309486,0.04376707],"study_design_scores_gemma":[0.009348704,0.0053727548,0.9571559,0.0001237515,0.0082715405,0.000062047475,0.0005588503,0.016803319,0.000012072234,0.000572292,0.0016306726,0.00008811391],"about_ca_topic_score_codex":0.0021603685,"about_ca_topic_score_gemma":0.0010628358,"teacher_disagreement_score":0.043678958,"about_ca_system_score_codex":0.00044437932,"about_ca_system_score_gemma":0.004572527,"threshold_uncertainty_score":0.99749386},"labels":[],"label_agreement":null},{"id":"W2594599346","doi":"10.1200/jco.2012.30.15_suppl.e14588","title":"Defining eligibility of FOLFIRINOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the province of British Columbia: A population-based retrospective study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Internal medicine; Pancreatic cancer; Population; Retrospective cohort study; Oncology; Cancer; Irinotecan; Surgery","score_opus":0.12067942059154554,"score_gpt":0.4794628654135561,"score_spread":0.3587834448220105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594599346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554014,0.0010905543,0.00044714267,0.0007920181,0.00018904168,0.0016356473,0.000032444503,0.0000035588914,0.0002694636],"genre_scores_gemma":[0.99258566,0.000078054574,0.006700595,0.0002568736,0.00022600233,0.00005634914,0.000006032149,0.00001430084,0.000076106764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940673,0.0013071029,0.003433877,0.00020714404,0.00062318123,0.00036136855],"domain_scores_gemma":[0.9837735,0.012635862,0.0022975835,0.0003048028,0.00078291947,0.00020532451],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015187549,0.000111921894,0.0027111247,0.00011134594,0.000055495246,0.000008352673,0.00025508238,0.00022049191,0.00006806914],"category_scores_gemma":[0.022715392,0.00009728366,0.0004523225,0.00029147865,0.00031882332,0.00010616021,0.000042461594,0.0007675499,0.0000012204403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024187875,0.007836811,0.9838249,0.00024753337,0.00040558598,0.00013263963,0.00023159392,0.000012521088,0.0000033089214,0.000053009528,0.0005538618,0.0042794663],"study_design_scores_gemma":[0.011724042,0.024511198,0.9597279,0.00022162186,0.0014053364,0.00014740275,0.0007122531,0.0004077943,0.000002500655,0.0009955958,0.00007583134,0.00006855779],"about_ca_topic_score_codex":0.0043001426,"about_ca_topic_score_gemma":0.026486875,"teacher_disagreement_score":0.024097016,"about_ca_system_score_codex":0.00028116346,"about_ca_system_score_gemma":0.0022248332,"threshold_uncertainty_score":0.9912772},"labels":[],"label_agreement":null},{"id":"W2594798307","doi":"10.1200/jco.2012.30.15_suppl.e15020","title":"Urothelial cancer: Gender discrepancies and impact on overall survival.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Cancer; Oncology; Chemotherapy; Urothelial carcinoma; Bladder cancer","score_opus":0.19096560195336396,"score_gpt":0.5116201035681026,"score_spread":0.32065450161473863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594798307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815055,0.0024999985,0.000027024942,0.0038118472,0.002524456,0.00014735364,0.00001793692,0.000008340021,0.009457506],"genre_scores_gemma":[0.9893727,0.0026519704,0.00035000313,0.002760433,0.004425739,0.0000038633266,9.877507e-7,0.000018877578,0.00041546387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980461,0.00024556875,0.0009705259,0.00012183128,0.0003208075,0.00029518377],"domain_scores_gemma":[0.9976845,0.0008261524,0.00060006743,0.00013265498,0.00014505353,0.0006116199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013971749,0.00015233965,0.0011089093,0.00006719395,0.000036063626,0.0000075088124,0.00006829832,0.00022592592,0.00045595827],"category_scores_gemma":[0.00059114577,0.00008461853,0.00042894948,0.000048611866,0.00013492913,0.00013549125,0.0000281363,0.0005704345,0.00001745815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009447636,0.0019892089,0.8980833,0.000023343535,0.0010897259,0.000112732116,0.00025242296,0.000005734523,0.00016524456,0.0004961593,0.006082714,0.082251735],"study_design_scores_gemma":[0.007858203,0.009120749,0.90798086,0.000040975865,0.00050853024,0.0002226966,0.000049996484,0.000005883399,0.00008004775,0.0002664398,0.073781446,0.00008419008],"about_ca_topic_score_codex":0.00015360992,"about_ca_topic_score_gemma":0.000016662982,"teacher_disagreement_score":0.08216754,"about_ca_system_score_codex":0.00018149383,"about_ca_system_score_gemma":0.0010231033,"threshold_uncertainty_score":0.49924234},"labels":[],"label_agreement":null},{"id":"W2594826311","doi":"10.1200/jco.2009.27.15_suppl.e16109","title":"Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Chemotherapy; Germ cell tumors; Incidence (geometry); Cancer; Testicular cancer; Internal medicine; Retrospective cohort study; Cisplatin; Surgery","score_opus":0.08483301536177637,"score_gpt":0.46246818487871977,"score_spread":0.3776351695169434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594826311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946093,0.00022827428,0.000051966683,0.0037360087,0.00064451084,0.0004960933,0.0000073493247,0.0000049043906,0.0002215884],"genre_scores_gemma":[0.9923549,0.0026780881,0.0020514724,0.0023575185,0.00049977336,0.000014014386,0.0000041983326,0.000012779367,0.000027222139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754006,0.0002194344,0.0015800728,0.00018266065,0.00024951066,0.00022827329],"domain_scores_gemma":[0.9959882,0.0019948464,0.0012904702,0.00010483,0.00037852602,0.00024312019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011117717,0.000150895,0.0014072527,0.0001037722,0.000037380483,0.0000034632803,0.00008439508,0.00025694957,0.00007697869],"category_scores_gemma":[0.005021512,0.00009504672,0.000407008,0.00010939716,0.000037174923,0.00007367867,0.000008268807,0.0004929242,0.0000028184247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008154513,0.0050113504,0.87930644,0.0000068317513,0.0001940096,0.000018442724,0.00015705095,0.000025380805,0.000018294893,0.000014397821,0.00076037075,0.113671996],"study_design_scores_gemma":[0.014748687,0.016096516,0.96319765,0.00015618087,0.00025501673,0.0000063332277,0.000024423187,0.00006274669,0.00019932992,0.0007374198,0.004436697,0.00007901179],"about_ca_topic_score_codex":0.00003678512,"about_ca_topic_score_gemma":0.00006463171,"teacher_disagreement_score":0.11359299,"about_ca_system_score_codex":0.00027346963,"about_ca_system_score_gemma":0.00056919164,"threshold_uncertainty_score":0.60115814},"labels":[],"label_agreement":null},{"id":"W2594936753","doi":"10.1200/jco.2012.30.15_suppl.3101","title":"A phase I study of the gamma-secretase inhibitor RO4929097 and capecitabine in refractory solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cmax; Medicine; Capecitabine; Refractory (planetary science); Pharmacokinetics; Colorectal cancer; Toxicity; Internal medicine; Pharmacology; Cancer; Gastroenterology; Urology; Oncology","score_opus":0.1239627432334588,"score_gpt":0.4833545288141249,"score_spread":0.3593917855806661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594936753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461627,0.001927754,0.000005734659,0.0012891125,0.0012848364,0.00029565502,0.00000424715,0.0000019940592,0.00057440146],"genre_scores_gemma":[0.99695224,0.00043520753,0.00025812158,0.0006926684,0.0015488303,0.0000034563136,4.504479e-7,0.0000119055085,0.00009711753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964822,0.000514833,0.0023240994,0.00012004387,0.00033218216,0.0002266703],"domain_scores_gemma":[0.9967527,0.00086916494,0.0015919365,0.0002180563,0.00019025366,0.00037790267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040609976,0.000113825154,0.0014775821,0.00011685772,0.00002190125,0.0000030175138,0.000109534776,0.00015359253,0.00012521999],"category_scores_gemma":[0.0024081457,0.00006479532,0.00025678886,0.0001670833,0.00018076053,0.0001095797,0.00008127642,0.00094101694,0.000002031412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01504426,0.073201254,0.5145852,0.00013178901,0.000561799,0.0007161549,0.0031880054,0.0000047977187,0.00817562,0.000028232029,0.0053322827,0.37903062],"study_design_scores_gemma":[0.087068334,0.062637076,0.7095309,0.00030544712,0.0012510953,0.00074731436,0.004380434,0.000025405818,0.0014578163,0.000045478377,0.13236977,0.00018092614],"about_ca_topic_score_codex":0.000055491255,"about_ca_topic_score_gemma":0.00014753263,"teacher_disagreement_score":0.3788497,"about_ca_system_score_codex":0.00009600322,"about_ca_system_score_gemma":0.00070586737,"threshold_uncertainty_score":0.40883029},"labels":[],"label_agreement":null},{"id":"W2595045540","doi":"10.1200/jco.2013.31.15_suppl.tps8126","title":"GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Ottawa Hospital","funders":"","keywords":"Docetaxel; Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Response Evaluation Criteria in Solid Tumors; Neutropenia; Adverse effect; Phases of clinical research; Gastroenterology; Randomized controlled trial; Cancer; Chemotherapy","score_opus":0.038339304608726046,"score_gpt":0.39161698482110757,"score_spread":0.35327768021238154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595045540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947201,0.00023119384,0.00018450971,0.0001542506,0.00021388291,0.004212921,0.000001909386,0.0000021639714,0.0002790457],"genre_scores_gemma":[0.997943,0.00011623521,0.0015286171,0.000050929095,0.000111053785,0.00015939598,0.000012903472,0.000027606375,0.000050263465],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99448663,0.0016015399,0.0026446998,0.00036817451,0.0005206847,0.00037827692],"domain_scores_gemma":[0.9959231,0.0009569791,0.0016674921,0.00034245334,0.0008689528,0.00024100576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038980958,0.00022821772,0.0019890515,0.0002742431,0.00002656257,0.000014449831,0.00038098515,0.00036455516,0.00003262674],"category_scores_gemma":[0.0020662118,0.0001534838,0.00019399115,0.000290275,0.00021555641,0.00003039968,0.000110737245,0.00081681635,0.0000024413418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8969375,0.01677252,0.078755096,0.00003374338,0.00028615896,0.000066454624,0.00017842358,0.00020048967,0.0014739339,0.0000012801411,0.00006367233,0.00523073],"study_design_scores_gemma":[0.83035934,0.10289725,0.064719744,0.000051816784,0.000111837966,0.000003022735,0.00025661054,0.00018414474,0.0012019213,0.000010068067,0.00005046706,0.00015378412],"about_ca_topic_score_codex":0.00017863829,"about_ca_topic_score_gemma":0.00038599066,"teacher_disagreement_score":0.086124726,"about_ca_system_score_codex":0.000095419826,"about_ca_system_score_gemma":0.0010572192,"threshold_uncertainty_score":0.62588876},"labels":[],"label_agreement":null},{"id":"W2595062990","doi":"10.1200/jco.2009.27.15_suppl.e19503","title":"Current treatment (Tx) patterns in relapsed or refractory multiple myeloma (MM): A retrospective chart review study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Refractory (planetary science); Internal medicine; Prednisone; Bortezomib; Multiple myeloma; Surgery; Cyclophosphamide; Oncology; Chemotherapy","score_opus":0.21476384551059627,"score_gpt":0.5339815459925386,"score_spread":0.3192177004819423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595062990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828283,0.0076495325,0.00000913716,0.0065582315,0.0006633593,0.0018080781,0.0000124722865,0.000015920987,0.0004549398],"genre_scores_gemma":[0.9579676,0.039377514,0.000329482,0.0012217439,0.00078592385,0.000036271555,0.0000082166725,0.000018473962,0.000254803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942044,0.0011859451,0.0030022594,0.00040588112,0.00073766225,0.00046382291],"domain_scores_gemma":[0.9953161,0.0016570104,0.001425394,0.00042404022,0.0004581051,0.0007193896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029592358,0.0002837912,0.0026948957,0.00026099643,0.00004846554,0.00000904772,0.0001992195,0.00022960317,0.00036892437],"category_scores_gemma":[0.008027275,0.00016126441,0.0006352811,0.00028157688,0.00007658616,0.00010679258,0.00004080248,0.001375266,0.000062153966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008668836,0.021456422,0.540019,0.00005468594,0.00031079727,0.005552421,0.00013107255,2.5023533e-7,0.000012509526,0.0000016223646,0.0011307218,0.42266166],"study_design_scores_gemma":[0.034205053,0.11221449,0.8307977,0.0013854015,0.00035767446,0.00023624975,0.00012437567,0.00003096893,0.0000113475035,0.000026334908,0.020501036,0.000109421744],"about_ca_topic_score_codex":0.000047497822,"about_ca_topic_score_gemma":0.00048141475,"teacher_disagreement_score":0.42255223,"about_ca_system_score_codex":0.0013644579,"about_ca_system_score_gemma":0.0017219532,"threshold_uncertainty_score":0.96099776},"labels":[],"label_agreement":null},{"id":"W2595066197","doi":"10.1200/jco.2009.27.15_suppl.3539","title":"Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"IGFBP3; Medicine; Internal medicine; Endocrinology; Autophosphorylation; IC50; Insulin-like growth factor; Tolerability; Carboplatin; Growth factor; Receptor; In vitro; Chemistry; Chemotherapy; Kinase; Cisplatin; Biochemistry; Adverse effect; Protein kinase A","score_opus":0.08628617516748581,"score_gpt":0.3857199257859726,"score_spread":0.29943375061848676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595066197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920461,0.00049838447,0.00011756498,0.0033134269,0.0022629192,0.00035512907,0.00007445559,0.000009134727,0.0013228926],"genre_scores_gemma":[0.9955037,0.0009453693,0.0016404015,0.0009323719,0.0008329651,8.118892e-7,0.0000031992624,0.000022621567,0.000118563374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913015,0.00051789935,0.006726948,0.0003118459,0.00083478313,0.0003070478],"domain_scores_gemma":[0.9870495,0.0046605146,0.005900384,0.0005249856,0.001417786,0.00044683646],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028097704,0.00028403327,0.0028331557,0.0002479847,0.000051343173,0.000006377596,0.00049745786,0.0010707278,0.000079636724],"category_scores_gemma":[0.014026316,0.00018152785,0.0011515656,0.0003674414,0.00076409854,0.00025460264,0.00016703185,0.0017604609,0.0000036615072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011524229,0.0061200834,0.830458,0.00019592386,0.0009966578,0.00008017254,0.00056867016,0.000023532679,0.005033998,0.00118427,0.00612247,0.13769202],"study_design_scores_gemma":[0.013644054,0.021977138,0.9552641,0.00032748934,0.0006097621,0.00012306414,0.000095019874,0.00017824378,0.003467214,0.00215979,0.0020051345,0.00014897325],"about_ca_topic_score_codex":0.000027624017,"about_ca_topic_score_gemma":0.000023762132,"teacher_disagreement_score":0.13754304,"about_ca_system_score_codex":0.00008983509,"about_ca_system_score_gemma":0.0014279332,"threshold_uncertainty_score":0.99427897},"labels":[],"label_agreement":null},{"id":"W2595074665","doi":"10.1200/jco.2014.32.15_suppl.1096","title":"Evaluation of cardiac dose reduction with deep inspiration breath hold in patients with left-sided breast cancer receiving adjuvant radiotherapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Adjuvant radiotherapy; Lung cancer; Nuclear medicine; Radiology; Cancer; Internal medicine","score_opus":0.03566779341551087,"score_gpt":0.37650114054467393,"score_spread":0.3408333471291631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595074665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755055,0.000866579,0.00014701395,0.0006101466,0.00042422264,0.00022299484,0.000008142028,0.0000020886976,0.00016828426],"genre_scores_gemma":[0.99762964,0.0006598941,0.00089887873,0.00013801272,0.0006256494,0.0000126731,0.000012714915,0.000016733859,0.0000058181777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752563,0.00077558873,0.0008739184,0.00021904324,0.0004629933,0.00014284866],"domain_scores_gemma":[0.9971563,0.000108284694,0.0012982497,0.00016957292,0.001193616,0.00007398184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002582113,0.00013753341,0.00067714776,0.0000732241,0.000031202828,0.0000051796947,0.00008887657,0.00019629311,0.000012332926],"category_scores_gemma":[0.0003330578,0.000091257585,0.00011620374,0.00009146536,0.00013909796,0.000021570024,0.000019489207,0.00019621714,2.5472613e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046694013,0.0006119573,0.6216322,0.000007028208,0.000516999,6.492892e-7,0.000110216344,0.0018847155,0.0011430521,0.0000019909182,0.000073753436,0.36934805],"study_design_scores_gemma":[0.009027546,0.0050520403,0.9840706,0.00010705459,0.0004351233,0.00001941417,0.000053618427,0.00015157727,0.0005423019,0.000019374058,0.0004170768,0.00010429452],"about_ca_topic_score_codex":0.00009287148,"about_ca_topic_score_gemma":0.00045126554,"teacher_disagreement_score":0.36924374,"about_ca_system_score_codex":0.00022218289,"about_ca_system_score_gemma":0.00073026156,"threshold_uncertainty_score":0.37213764},"labels":[],"label_agreement":null},{"id":"W2595109760","doi":"10.1200/jco.2012.30.15_suppl.8035","title":"Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Bortezomib; Internal medicine; Clinical endpoint; Thalidomide; Lenalidomide; Gastroenterology; Multiple myeloma; Proteasome inhibitor; Progressive disease; Clinical trial; Phases of clinical research; Surgery; Oncology; Disease","score_opus":0.18607810554596838,"score_gpt":0.5003545129570304,"score_spread":0.314276407411062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595109760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945478,0.00024676105,0.000007450768,0.0027940192,0.0012592352,0.0010315907,0.0000060411,0.0000048804977,0.00010223877],"genre_scores_gemma":[0.9958668,0.00011989143,0.0017821186,0.0014988375,0.0005225335,0.000021809352,0.0000032550645,0.000023495328,0.00016129886],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9945734,0.001587877,0.0024927973,0.00025352108,0.00050994207,0.0005824216],"domain_scores_gemma":[0.9944445,0.0032017394,0.00061175774,0.00024689638,0.00020397459,0.0012911259],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065340614,0.00020303969,0.0015647019,0.000579691,0.00003275342,0.000015516121,0.00015150897,0.00032562125,0.00010009406],"category_scores_gemma":[0.017799,0.00013205923,0.00019664886,0.00031543965,0.00009106192,0.0001884323,0.0001290179,0.0008743036,0.000031409396],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48138165,0.006422255,0.4390783,0.000009205608,0.00012281815,0.0005135353,0.0005069759,0.000003047874,0.00045780375,0.0000011236307,0.00070387614,0.07079941],"study_design_scores_gemma":[0.11166956,0.049179353,0.8145486,0.00013847541,0.000048264792,0.00003539607,0.00014106181,0.000010112255,0.00012767976,0.0000065665554,0.023990043,0.00010487894],"about_ca_topic_score_codex":0.00013492553,"about_ca_topic_score_gemma":0.00020856857,"teacher_disagreement_score":0.3754703,"about_ca_system_score_codex":0.0008330815,"about_ca_system_score_gemma":0.0011585908,"threshold_uncertainty_score":0.9904745},"labels":[],"label_agreement":null},{"id":"W2595146624","doi":"10.1200/jco.2013.31.15_suppl.3569","title":"Adjuvant chemotherapy (AC) outcomes in young (YP) and elderly patients (EP) with high-risk stage II colon cancer (CC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Perineural invasion; Stage (stratigraphy); Lymphovascular invasion; Proportional hazards model; Cancer; Perforation; Chemotherapy; Oncology; Surgery; Gastroenterology; Metastasis","score_opus":0.042107816571412326,"score_gpt":0.4094753634515956,"score_spread":0.36736754688018325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595146624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992421,0.00032761227,0.0000054216325,0.0050043925,0.0008123219,0.00061823823,0.000013725753,0.000010486715,0.00078683055],"genre_scores_gemma":[0.99424267,0.002028754,0.001117278,0.0013149471,0.0002256585,0.000041110372,0.0000024063256,0.00002673571,0.0010004163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997025,0.00029311766,0.0016447314,0.000274393,0.00043920867,0.00032353934],"domain_scores_gemma":[0.9964166,0.0011272146,0.0014399878,0.00016783846,0.00041330178,0.000435037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007867027,0.00022137086,0.0019035699,0.00012836415,0.00005288136,0.000013038859,0.00012101093,0.00033139868,0.0004964996],"category_scores_gemma":[0.0007058685,0.00012968975,0.000212175,0.00016022973,0.0002199859,0.00018730704,0.000059938928,0.0009547591,0.00000949582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004832016,0.0042649866,0.84410834,0.000014388033,0.00040245,0.00017643388,0.00016405963,0.0000035878963,0.000008781517,0.000005446369,0.0003920101,0.1456275],"study_design_scores_gemma":[0.049547344,0.04039863,0.90404767,0.00010253143,0.00020579775,0.000029509934,0.00006215919,0.000026959826,0.00002913118,0.00010024742,0.005329902,0.000120125645],"about_ca_topic_score_codex":0.0022528206,"about_ca_topic_score_gemma":0.003017475,"teacher_disagreement_score":0.14550737,"about_ca_system_score_codex":0.00041471198,"about_ca_system_score_gemma":0.0006147125,"threshold_uncertainty_score":0.54363227},"labels":[],"label_agreement":null},{"id":"W2595191687","doi":"10.1200/jco.2015.33.15_suppl.e17547","title":"Establishment of a baseline to measure academic clinical trial activity in Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Ontario Institute for Cancer Research","funders":"","keywords":"Clinical trial; Medicine; Receipt; Portfolio; Family medicine; Patient recruitment; Internal medicine; Accounting; Finance","score_opus":0.694728486465098,"score_gpt":0.6376722686330413,"score_spread":0.05705621783205672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595191687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9310205,0.00009638847,0.0009833627,0.06194454,0.0047664572,0.0007467323,0.000010099174,0.0000045277056,0.00042740302],"genre_scores_gemma":[0.97927064,0.00022945556,0.007062305,0.00999721,0.0033642228,0.000006501459,0.0000035162675,0.000018695859,0.00004745381],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9824005,0.0034667223,0.012014856,0.00033548256,0.0014363207,0.00034616294],"domain_scores_gemma":[0.9650143,0.024860512,0.0060185483,0.00038945538,0.0020943948,0.0016228313],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0635561,0.00017441204,0.0027427957,0.00020946182,0.000012453914,0.0000043820773,0.00031519326,0.0005595147,0.00010028438],"category_scores_gemma":[0.31058598,0.00013476158,0.0004634229,0.0004317321,0.00011576493,0.0002491128,0.00013951799,0.0032278488,0.0000105822955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27344415,0.0027945042,0.20666778,0.000017666931,0.00019557566,0.00038180026,0.000053901287,0.000113068265,0.0000703281,0.000010481069,0.066676825,0.4495739],"study_design_scores_gemma":[0.31484064,0.05320836,0.41896755,0.000295785,0.0009720782,0.0002113757,0.0011194127,0.000866587,0.00012919275,0.00030024294,0.20881902,0.0002697856],"about_ca_topic_score_codex":0.120053425,"about_ca_topic_score_gemma":0.44617495,"teacher_disagreement_score":0.44930413,"about_ca_system_score_codex":0.001218083,"about_ca_system_score_gemma":0.051631812,"threshold_uncertainty_score":0.9990717},"labels":[],"label_agreement":null},{"id":"W2595209185","doi":"10.1200/jco.2014.32.15_suppl.5062","title":"Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sanofi (Canada); CancerCare Manitoba; Hôtel-Dieu de Québec; Sunnybrook Health Science Centre; University Health Network; Moncton Hospital; University of Toronto; London Health Sciences Centre; Grand River Hospital; Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Cabazitaxel; Prostate cancer; Internal medicine; Discontinuation; Adverse effect; Neutropenia; Febrile neutropenia; Enzalutamide; Oncology; Surgery; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.16610965670482203,"score_gpt":0.4860665985901908,"score_spread":0.3199569418853688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595209185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962853,0.0004807347,0.000008836433,0.0020856527,0.00014644656,0.000779495,0.000044145632,0.0000029093276,0.00016648306],"genre_scores_gemma":[0.9971038,0.00066557864,0.0016288289,0.00024099112,0.00008397932,0.000015263842,0.000008107391,0.000020128648,0.00023329473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554175,0.0008268268,0.002499457,0.00023606638,0.00051834265,0.00037758372],"domain_scores_gemma":[0.9953258,0.0009515527,0.0019201835,0.00019037271,0.0008657754,0.00074630475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037874908,0.00017261991,0.0018874437,0.00038502048,0.000040262297,0.00000924057,0.000110144545,0.00015499382,0.000050373783],"category_scores_gemma":[0.0029284493,0.00009925112,0.000101913676,0.00037276163,0.0004786158,0.00013976808,0.000027580758,0.0005280272,0.000001004079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07731759,0.0016735358,0.86740875,0.00047631186,0.0005577649,0.000088742396,0.0009866403,0.00004570515,0.0010377239,0.000022006287,0.00008440309,0.050300833],"study_design_scores_gemma":[0.04634314,0.024031265,0.9268426,0.00046771197,0.00031246422,0.000012422309,0.00024022847,0.00011125289,0.00035331948,0.000026888163,0.0011504423,0.00010832369],"about_ca_topic_score_codex":0.037571754,"about_ca_topic_score_gemma":0.30540958,"teacher_disagreement_score":0.26783785,"about_ca_system_score_codex":0.0003589962,"about_ca_system_score_gemma":0.0066756997,"threshold_uncertainty_score":0.99895555},"labels":[],"label_agreement":null},{"id":"W2595289574","doi":"10.1200/jco.2015.33.15_suppl.e20509","title":"Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Palliative care; Lung cancer; Cancer; Chemotherapy; Internal medicine; Medical record; Family medicine; Emergency medicine; Oncology; Nursing","score_opus":0.30018776310577716,"score_gpt":0.5509756005475396,"score_spread":0.2507878374417624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595289574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820203,0.01416128,0.00000649479,0.002253166,0.0004576542,0.00028498043,0.000017157981,0.0000028046088,0.00079615874],"genre_scores_gemma":[0.9719133,0.02502514,0.0021299447,0.00028414596,0.0004885728,0.000012992498,0.000005496271,0.000012667318,0.00012775569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975301,0.00019697692,0.00151081,0.00018268585,0.0003926759,0.00018674137],"domain_scores_gemma":[0.99537504,0.0009369724,0.0018547012,0.00013571061,0.0012701877,0.00042740532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006238935,0.00016548776,0.001880729,0.00008613078,0.000017649434,0.0000094317775,0.00010359666,0.00025757356,0.0000129027385],"category_scores_gemma":[0.00094221206,0.00008740935,0.00022919677,0.0000741398,0.0004203979,0.00017954802,0.000042579464,0.00028087472,7.109111e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045605153,0.001171515,0.7019214,0.00005947026,0.00031911166,0.0001598974,0.0017374598,0.000008275005,0.0000032881092,0.000008971675,0.00039854506,0.2896515],"study_design_scores_gemma":[0.021529622,0.12797482,0.75033945,0.0029533063,0.0012152309,0.00007428914,0.0069456743,0.000012571641,0.00087302807,0.00008435804,0.087850414,0.00014724744],"about_ca_topic_score_codex":0.00013431121,"about_ca_topic_score_gemma":0.00044447303,"teacher_disagreement_score":0.2895043,"about_ca_system_score_codex":0.00034951358,"about_ca_system_score_gemma":0.0013704504,"threshold_uncertainty_score":0.35644498},"labels":[],"label_agreement":null},{"id":"W2595403935","doi":"10.1200/jco.2012.30.15_suppl.9131","title":"Prevalence of cancer-related fatigue in a population-based sample of colorectal, breast, and prostate cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer; Breast cancer; Survivorship curve; Population; Quality of life (healthcare); Internal medicine; Prostate cancer; Depression (economics); Colorectal cancer; Physical therapy; Disease; Oncology","score_opus":0.10282846162688326,"score_gpt":0.4932229183544065,"score_spread":0.39039445672752326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595403935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222356,0.0043598865,0.000004228334,0.0021088363,0.00083739765,0.0003078716,0.00007192453,0.000004027346,0.000082255865],"genre_scores_gemma":[0.9954004,0.0033946936,0.00073682243,0.00019566252,0.00019058178,0.000016398022,0.0000041349604,0.000010024117,0.000051279214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738103,0.00034568543,0.0017710859,0.00011186501,0.00019116032,0.00019920067],"domain_scores_gemma":[0.995364,0.0023243898,0.0017408858,0.000072490526,0.00028532156,0.00021291125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014898191,0.00010682089,0.0011310616,0.00014544201,0.000013194132,0.0000010885335,0.00006634751,0.0002272192,0.0004530992],"category_scores_gemma":[0.0004870827,0.000079436395,0.00016459447,0.00019245264,0.00015934324,0.00009083782,0.000019256246,0.00038827516,3.0082194e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048364596,0.0023601577,0.9698836,0.00028682657,0.00027584026,0.00001202055,0.0003644209,0.00012602475,0.00040292245,0.00001738791,0.00013633909,0.021297969],"study_design_scores_gemma":[0.008454742,0.00384149,0.9854022,0.00025419588,0.000620154,0.00003315294,0.000021028958,0.0002802014,0.00034597385,0.0000613483,0.00062430324,0.00006118675],"about_ca_topic_score_codex":0.007679241,"about_ca_topic_score_gemma":0.002784977,"teacher_disagreement_score":0.021236781,"about_ca_system_score_codex":0.00018632262,"about_ca_system_score_gemma":0.0012505064,"threshold_uncertainty_score":0.9989287},"labels":[],"label_agreement":null},{"id":"W2595416856","doi":"10.1200/jco.2007.25.18_suppl.7522","title":"Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Niagara Health System; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Vandetanib; Gastroenterology; Hazard ratio; Asymptomatic; Progressive disease; Rash; Maintenance therapy; Performance status; Progression-free survival; Surgery; Chemotherapy; Confidence interval; Sorafenib","score_opus":0.19794544748806914,"score_gpt":0.5368576189100606,"score_spread":0.3389121714219914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595416856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914394,0.0006650064,0.0002302262,0.0037827722,0.0010322223,0.002638422,0.000011307057,0.000007005143,0.00019362026],"genre_scores_gemma":[0.9956244,0.0011765044,0.00038832639,0.0012859447,0.00073840894,0.00006666078,0.0000011024638,0.00002699266,0.00069163117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9918267,0.0026377498,0.0039029743,0.0003448027,0.0007506687,0.0005370955],"domain_scores_gemma":[0.98937863,0.006504321,0.0020327484,0.00027429595,0.0013321188,0.000477892],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018176006,0.0002336838,0.0032404352,0.00042816778,0.00008407966,0.000007700549,0.00025923722,0.00024794563,0.00012607989],"category_scores_gemma":[0.012502202,0.00014148102,0.00042250942,0.00040303936,0.00032118562,0.000099522294,0.00015349254,0.0012954473,0.0000018557271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8659206,0.011789318,0.07819413,0.00004319346,0.000717424,0.0006465126,0.004121094,0.00005616137,0.0008913939,0.000001183664,0.0023797173,0.035239276],"study_design_scores_gemma":[0.6857319,0.079696074,0.22057393,0.00034703492,0.0003736808,0.000020127025,0.001478733,0.0002486999,0.00029234224,0.000018678254,0.011066608,0.0001522082],"about_ca_topic_score_codex":0.0003336916,"about_ca_topic_score_gemma":0.0028903568,"teacher_disagreement_score":0.18018872,"about_ca_system_score_codex":0.00074451254,"about_ca_system_score_gemma":0.0018879906,"threshold_uncertainty_score":0.99581593},"labels":[],"label_agreement":null},{"id":"W2595420534","doi":"10.1200/jco.2015.33.15_suppl.e11502","title":"Treatment patterns and characteristics of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Metastatic breast cancer; Exemestane; Internal medicine; Breast cancer; Everolimus; Oncology; Odds ratio; Cancer; Anastrozole; Gynecology; Tamoxifen","score_opus":0.08902011211839758,"score_gpt":0.43607617497690004,"score_spread":0.34705606285850243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595420534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928728,0.0003558637,0.00021274122,0.0058159516,0.00042366848,0.00016824093,0.000071813956,0.000007054649,0.00007188101],"genre_scores_gemma":[0.9944063,0.0008766451,0.0028772242,0.0009988388,0.00068370544,0.000012703919,0.0000022104584,0.00002758548,0.000114805945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99753976,0.00024600068,0.0014456537,0.00017185474,0.0003339597,0.00026277348],"domain_scores_gemma":[0.9959104,0.0006921882,0.0018162547,0.00016192274,0.00084211334,0.00057712826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010064646,0.00018013432,0.0017212111,0.00009206013,0.000019000163,0.000006180329,0.00008823923,0.00011459127,0.00013609265],"category_scores_gemma":[0.00039066313,0.00010878028,0.00006464581,0.00008242804,0.0002397524,0.00014085959,0.00003106852,0.0003760547,0.0000019264132],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027407927,0.0014604719,0.34839404,0.00007613026,0.0015391806,0.00062758056,0.0014728688,0.000012839339,0.00060582324,0.0000075859634,0.000024502833,0.61837107],"study_design_scores_gemma":[0.013688861,0.04858762,0.92668307,0.00023991446,0.0006606524,0.003300351,0.0010263649,0.000015216691,0.000044897362,0.00007335588,0.0055695716,0.000110146604],"about_ca_topic_score_codex":0.0001584308,"about_ca_topic_score_gemma":0.00009425726,"teacher_disagreement_score":0.6182609,"about_ca_system_score_codex":0.00059805537,"about_ca_system_score_gemma":0.0019673284,"threshold_uncertainty_score":0.4435931},"labels":[],"label_agreement":null},{"id":"W2595518715","doi":"10.1200/jco.2012.30.15_suppl.2588","title":"Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immune system; Adjuvant; Immunogenicity; Prostate cancer; Breast cancer; Cancer; Cancer vaccine; Antigen; Ovarian cancer; Immunology; Prostate; Oncology; Adverse effect; Internal medicine; Immunotherapy","score_opus":0.039302261890883164,"score_gpt":0.3870292660413478,"score_spread":0.34772700415046465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595518715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882986,0.007099959,0.000011633106,0.0012582679,0.0029226912,0.0003156454,0.000031016403,0.0000029597632,0.00005921423],"genre_scores_gemma":[0.99738294,0.0011339694,0.00001851652,0.00061911484,0.00013568267,0.000017361941,0.0000028849126,0.000013796208,0.00067575916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629205,0.0018911097,0.0013416617,0.00012479816,0.00008300724,0.0002673624],"domain_scores_gemma":[0.9933557,0.0049302513,0.0013507081,0.00013768813,0.00019467635,0.000031001182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034346948,0.00016074454,0.0007540661,0.00013530049,0.00008256537,0.0000037753534,0.00016177456,0.0003864829,0.00018965191],"category_scores_gemma":[0.000720893,0.00008831647,0.00023040801,0.00013203816,0.0001464616,0.00016720677,0.000047853224,0.00078528083,0.0000053170925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08030206,0.0019393613,0.67907685,0.000025838208,0.00034119794,8.332436e-7,0.00029185615,0.000038826904,0.10583202,0.000054169166,0.0002515764,0.13184541],"study_design_scores_gemma":[0.016438814,0.006032813,0.93475884,0.00011024702,0.0001317569,0.00004392452,0.000020042547,0.000005587255,0.025441816,0.000014435531,0.01691244,0.000089259374],"about_ca_topic_score_codex":0.00013015051,"about_ca_topic_score_gemma":0.000031900097,"teacher_disagreement_score":0.25568202,"about_ca_system_score_codex":0.000109187626,"about_ca_system_score_gemma":0.00040660298,"threshold_uncertainty_score":0.3601441},"labels":[],"label_agreement":null},{"id":"W2595553254","doi":"10.1200/jco.2013.31.15_suppl.2601","title":"Copper transporter CTR1 expression and tissue platinum concentration in NSCLC.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Immunohistochemistry; Medicine; Lung cancer; Staining; Chemotherapy; Internal medicine; Oncology; Pathology","score_opus":0.05629332091230673,"score_gpt":0.40632644647275934,"score_spread":0.35003312556045263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595553254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896636,0.0003875146,0.0005566098,0.0050410116,0.0006436605,0.0002400168,8.5251327e-7,0.0000054815587,0.0034612294],"genre_scores_gemma":[0.9936763,0.00048043442,0.0038996513,0.0011073083,0.0004102732,0.0000033202193,0.0000030903652,0.0000091245065,0.00041048942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787664,0.0001010018,0.0015249238,0.00012578553,0.00020991445,0.00016173489],"domain_scores_gemma":[0.99872065,0.00029798454,0.0005083986,0.00007937163,0.00014363133,0.00024994623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009595153,0.00009065228,0.00081363675,0.000050076207,0.000017843302,0.000005913136,0.00005437169,0.0003299174,0.0004578157],"category_scores_gemma":[0.00013441227,0.000058289064,0.00011569848,0.000054940476,0.00010608847,0.00015850374,0.0000043235814,0.00056576665,0.000013408158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057207183,0.002484642,0.44585386,0.00015571075,0.000142702,0.0019816002,0.0013316651,0.000013564436,0.18465662,0.00041695518,0.009202437,0.34803954],"study_design_scores_gemma":[0.014213601,0.004901496,0.9315329,0.00045794377,0.00014264362,0.00018785073,0.00035074435,0.00008274627,0.006681228,0.0009327976,0.040381532,0.00013450721],"about_ca_topic_score_codex":0.000010577328,"about_ca_topic_score_gemma":0.000035601297,"teacher_disagreement_score":0.48567906,"about_ca_system_score_codex":0.00003115782,"about_ca_system_score_gemma":0.0003151152,"threshold_uncertainty_score":0.5012761},"labels":[],"label_agreement":null},{"id":"W2595581805","doi":"10.1200/jco.2012.30.15_suppl.e11000","title":"The value of personalizing medicine: Medical oncologists’ and patients’ perspectives on genomic testing of breast tumors in chemotherapy treatment decisions.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McMaster University; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Qualitative research; Personalized medicine; Oncology; Adjuvant chemotherapy; Test (biology); Internal medicine; Cancer; Bioinformatics","score_opus":0.08154253313855395,"score_gpt":0.43588455286514427,"score_spread":0.3543420197265903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595581805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934704,0.0030149927,0.000044616114,0.0024169504,0.0003427616,0.00010430851,0.0000035414696,8.305581e-7,0.0006016403],"genre_scores_gemma":[0.99341327,0.0032846748,0.0023101307,0.00029063062,0.00067240885,0.0000036444533,0.0000011657692,0.000010188397,0.000013894894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764746,0.00043637597,0.0013275658,0.00014195645,0.00027799828,0.00016865954],"domain_scores_gemma":[0.99509895,0.0031171322,0.0011918007,0.0001444911,0.000299158,0.00014848047],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031798505,0.00010627731,0.000573109,0.00006378485,0.000041218278,0.0000020097748,0.00019912585,0.00023787394,0.000019195253],"category_scores_gemma":[0.008381823,0.00006132967,0.00013689864,0.00009267083,0.00071094173,0.0000052335317,0.00005147622,0.0002475935,3.491598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001979155,0.0018041328,0.5984476,0.0000071003424,0.00025429437,0.000007564709,0.0015809358,0.000068249996,0.0032968707,0.00035533338,0.0005119236,0.3916868],"study_design_scores_gemma":[0.0053676395,0.011642109,0.9718474,0.00011160911,0.000053027532,0.0001278593,0.0030052993,0.00006149844,0.0006707253,0.00015603636,0.0068787583,0.00007802821],"about_ca_topic_score_codex":0.000034663914,"about_ca_topic_score_gemma":0.000031619955,"teacher_disagreement_score":0.39160877,"about_ca_system_score_codex":0.00021189365,"about_ca_system_score_gemma":0.0013149404,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W2595594504","doi":"10.1200/jco.2012.30.15_suppl.tps8113","title":"ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Internal medicine; Phases of clinical research; Urology; Gastroenterology; Combination therapy; Oncology; Surgery; Chemotherapy","score_opus":0.20673582234737273,"score_gpt":0.5079667286859392,"score_spread":0.3012309063385664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595594504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032605,0.00078891317,0.00027373765,0.0007225187,0.00032925553,0.0054597557,0.000010838939,0.000016461434,0.0020724845],"genre_scores_gemma":[0.98134017,0.0007788417,0.015706135,0.00029277193,0.0005962119,0.0002011968,0.000017061946,0.000063964806,0.001003671],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99026614,0.0029506222,0.0043367026,0.0004262029,0.0010713458,0.00094900606],"domain_scores_gemma":[0.9833183,0.010201887,0.003769274,0.0005310721,0.0008323779,0.0013470479],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0117055895,0.00045014036,0.0066487673,0.00046758878,0.00006578619,0.000032640204,0.00047328844,0.00048843306,0.0003810959],"category_scores_gemma":[0.01173964,0.00022311856,0.0004068553,0.0006337294,0.00086427864,0.00049897644,0.00014746113,0.0013723361,0.000015680898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82905126,0.031025585,0.0732131,0.00007747637,0.0029409283,0.0022125186,0.00043895526,0.0000034234258,0.00012683118,0.000027018752,0.00015295568,0.06072995],"study_design_scores_gemma":[0.8915758,0.095585234,0.0068473513,0.0007472288,0.0015008737,0.0012879609,0.0002945315,0.0003089543,0.0004950284,0.00001548241,0.0011195292,0.00022200175],"about_ca_topic_score_codex":0.0010147623,"about_ca_topic_score_gemma":0.0012320915,"teacher_disagreement_score":0.06636575,"about_ca_system_score_codex":0.00042886563,"about_ca_system_score_gemma":0.0049732625,"threshold_uncertainty_score":0.9965849},"labels":[],"label_agreement":null},{"id":"W2595604151","doi":"10.1200/jco.2014.32.15_suppl.tps6638","title":"Simone-simulation in medical oncology education: Part I—Pilot feasibility study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Ottawa Skills and Simulation Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Debriefing; Medicine; Curriculum; Medical education; Medical physics; Oncology; Psychology","score_opus":0.20278987093510364,"score_gpt":0.6170593071314155,"score_spread":0.4142694361963119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595604151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95296824,0.00050283025,0.0021573398,0.02195953,0.00844497,0.00059810746,5.048807e-7,0.000016897451,0.013351579],"genre_scores_gemma":[0.97592527,0.0005032879,0.00417409,0.0122712655,0.006759173,0.000010897737,0.0000021203207,0.000016007798,0.00033789538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99278957,0.00259994,0.0034714164,0.00031097056,0.0005607082,0.0002674163],"domain_scores_gemma":[0.98514163,0.011487364,0.0018609592,0.00035806466,0.0005428472,0.00060910656],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01443349,0.00016153295,0.0019938322,0.00018688726,0.00005461638,0.0000037218101,0.00027801245,0.0007851411,0.00087291625],"category_scores_gemma":[0.023446122,0.000115400646,0.0002738177,0.00023594209,0.00051279337,0.00014511113,0.00004819725,0.0020569982,0.000028704668],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007934034,0.023196805,0.4603502,0.000014090933,0.00012199154,0.0002989382,0.00015776987,0.00033280105,0.0000049164196,0.00021831923,0.0025577792,0.50481236],"study_design_scores_gemma":[0.015607818,0.064029284,0.46013483,0.00007100422,0.00013474081,0.00037886528,0.00029824715,0.0012323295,0.0000016242498,0.0019286771,0.45608103,0.00010156157],"about_ca_topic_score_codex":0.00001054931,"about_ca_topic_score_gemma":0.0002887293,"teacher_disagreement_score":0.5047108,"about_ca_system_score_codex":0.0006344778,"about_ca_system_score_gemma":0.00698957,"threshold_uncertainty_score":0.9986399},"labels":[],"label_agreement":null},{"id":"W2595780838","doi":"10.1200/jco.2013.31.15_suppl.2006","title":"Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Donepezil; Placebo; Internal medicine; Clinical endpoint; Verbal learning; Montreal Cognitive Assessment; Cognitive decline; Randomized controlled trial; Cognition; Dementia; Psychiatry; Pathology","score_opus":0.09044039737832517,"score_gpt":0.4548232936847564,"score_spread":0.3643828963064312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595780838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630011,0.00042973246,0.000062963634,0.020999778,0.0031017724,0.0069228187,0.0000030537274,0.000014879899,0.0054639233],"genre_scores_gemma":[0.99396515,0.0006849122,0.00025609822,0.0022553974,0.0016588464,0.0003157868,0.000003834732,0.000028602553,0.00083138276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9893869,0.0022438176,0.0070373765,0.00028269796,0.0006264599,0.0004227426],"domain_scores_gemma":[0.9726509,0.020040546,0.005429873,0.00022294857,0.0012006622,0.00045511365],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015501268,0.0002918262,0.008026245,0.0005585539,0.00004028798,0.000011555778,0.00020876185,0.00047813254,0.000699588],"category_scores_gemma":[0.021885911,0.00019241015,0.0016325788,0.00039266082,0.0007106989,0.00019771593,0.000070453156,0.0016997011,0.000043629632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96845734,0.009945965,0.00047257537,0.00002775841,0.0023430558,0.00029904087,0.00017870992,0.000015635369,0.00011074293,0.000034034467,0.006747216,0.01136792],"study_design_scores_gemma":[0.96537787,0.028439786,0.0009363568,0.00021115137,0.0013950863,0.0001151538,0.00022851022,0.00037556398,0.000032434946,0.0002530113,0.002480476,0.00015463187],"about_ca_topic_score_codex":0.0004622581,"about_ca_topic_score_gemma":0.00028468642,"teacher_disagreement_score":0.03096406,"about_ca_system_score_codex":0.00024227463,"about_ca_system_score_gemma":0.0019838326,"threshold_uncertainty_score":0.98635316},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2595885360","doi":"10.1200/jco.2015.33.15_suppl.1033","title":"Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CARE Canada; Queen's University","funders":"","keywords":"Medicine; Epirubicin; Internal medicine; Febrile neutropenia; Granulocyte colony-stimulating factor; Breast cancer; Chemotherapy; Anthracycline; Neutropenia; Gastroenterology; Surgery; Cancer","score_opus":0.045792394959544395,"score_gpt":0.38709130512691725,"score_spread":0.34129891016737285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595885360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761367,0.0000924403,0.000016786506,0.000533259,0.00034093915,0.0012421279,0.00010940559,0.000008110308,0.000043238128],"genre_scores_gemma":[0.9991387,0.00007590102,0.0002919993,0.00021625824,0.00017516363,0.000020099335,0.0000048966167,0.000037693197,0.000039250135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927843,0.0012234888,0.0042863535,0.00039055804,0.0009997833,0.00031551113],"domain_scores_gemma":[0.99025476,0.0014263813,0.004865104,0.00053839415,0.0024964905,0.00041887714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024771555,0.000312114,0.0038139871,0.00037155324,0.000040938372,0.0000057837783,0.00029662825,0.00038626164,0.000106176594],"category_scores_gemma":[0.0010811676,0.00016179412,0.00074373756,0.0016582796,0.00070666097,0.00014315294,0.000068353394,0.001221038,5.4468836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048793856,0.008906468,0.92890954,0.00005056528,0.0045754206,0.00005617228,0.0005981738,0.0010942074,0.00009282328,0.0000012413807,0.00009611932,0.0068253987],"study_design_scores_gemma":[0.03455678,0.043487854,0.9163084,0.00029225953,0.0043829884,0.000017501889,0.00050749886,0.00008956417,0.00010781248,0.000003880376,0.00010553352,0.00013991303],"about_ca_topic_score_codex":0.0014626674,"about_ca_topic_score_gemma":0.0054244213,"teacher_disagreement_score":0.034581386,"about_ca_system_score_codex":0.00039030815,"about_ca_system_score_gemma":0.002496071,"threshold_uncertainty_score":0.6597772},"labels":[],"label_agreement":null},{"id":"W2595926616","doi":"10.1200/jco.2006.24.18_suppl.10077","title":"Nuclear localization of NF-kappaB p65 in primary prostate tumors is predictive of pelvic lymph node metastases","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Metastasis; Univariate analysis; Oncology; Biochemical recurrence; Immunohistochemistry; Primary tumor; Prostate; Proportional hazards model; Pathology; Urology; Internal medicine; Cancer; Multivariate analysis","score_opus":0.05636035180279126,"score_gpt":0.42078726662258253,"score_spread":0.3644269148197913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595926616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918944,0.0012607524,0.0001659124,0.0020537977,0.00019602625,0.00034374875,0.000040826337,0.0000058009714,0.0040387046],"genre_scores_gemma":[0.99655086,0.001318127,0.0010851743,0.0005130715,0.00022596096,0.0000033334964,0.000020092108,0.000019091825,0.0002642993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638253,0.00037684324,0.002346639,0.00016745197,0.0005072662,0.00021928098],"domain_scores_gemma":[0.9967336,0.0007517174,0.0015841611,0.00014965773,0.0006308333,0.00015000088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018665919,0.00011992371,0.00140023,0.0002679603,0.000019402094,0.0000033038004,0.0001202047,0.00019633614,0.000121056975],"category_scores_gemma":[0.000614305,0.00008150481,0.00031546512,0.0003024192,0.0004428989,0.00012362254,0.000054208827,0.00041356575,0.0000043938353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027195632,0.006907613,0.9281503,0.000509919,0.00058652135,0.0009838002,0.0005303529,0.00074459304,0.0015924037,0.00012871812,0.0063626794,0.02630749],"study_design_scores_gemma":[0.025498835,0.014068957,0.94535446,0.00073240564,0.00054277526,0.00016417318,0.000442501,0.0013377975,0.0038674632,0.0011581443,0.0067118416,0.000120627934],"about_ca_topic_score_codex":0.00010506978,"about_ca_topic_score_gemma":0.000008543283,"teacher_disagreement_score":0.026186863,"about_ca_system_score_codex":0.00028828604,"about_ca_system_score_gemma":0.0019096929,"threshold_uncertainty_score":0.3387713},"labels":[],"label_agreement":null},{"id":"W2595933696","doi":"10.1200/jco.2013.31.15_suppl.6045","title":"A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Gastroenterology; Phases of clinical research; Adenoid cystic carcinoma; Clinical endpoint; Chemotherapy; Progression-free survival; Surgery; Carcinoma; Clinical trial","score_opus":0.06270060775462792,"score_gpt":0.43513113785035357,"score_spread":0.37243053009572563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595933696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742854,0.0008394525,0.00017484356,0.00023553659,0.00034022692,0.0008051503,0.000007299318,0.0000034822751,0.0001654553],"genre_scores_gemma":[0.9974628,0.0001599064,0.0016892006,0.00012653346,0.0002562764,0.000043815297,0.000007994082,0.000035307938,0.00021813068],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9948011,0.0012691555,0.0025336593,0.0004190608,0.00053043285,0.00044657305],"domain_scores_gemma":[0.9963439,0.0006511908,0.0014981517,0.00042662708,0.0007072146,0.00037287676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023569048,0.00025133812,0.0013834528,0.00024511424,0.000054605203,0.00001115548,0.00051417336,0.00027253467,0.00008756232],"category_scores_gemma":[0.004082811,0.00017220936,0.00022519058,0.00032495242,0.00031176387,0.000027706546,0.00019661957,0.00097254786,0.000013402277],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08153626,0.071709,0.023768818,0.00027603834,0.0012632413,0.004549944,0.0014011377,0.00076687336,0.5827105,0.000008356441,0.004709219,0.22730063],"study_design_scores_gemma":[0.111447565,0.76981074,0.020124875,0.00032502666,0.00046450723,0.0014987808,0.0033225338,0.0006749351,0.08501528,0.00007678554,0.0064991214,0.00073982176],"about_ca_topic_score_codex":0.00010933952,"about_ca_topic_score_gemma":0.0020368143,"teacher_disagreement_score":0.69810176,"about_ca_system_score_codex":0.00012075817,"about_ca_system_score_gemma":0.0021260863,"threshold_uncertainty_score":0.7022494},"labels":[],"label_agreement":null},{"id":"W2595948223","doi":"10.1200/jco.2012.30.15_suppl.e14073","title":"Predictors of pathologic complete response (pCR) after neoadjuvant chemoradiation (Neo CRT) for rectal cancer: A multicenter population-based study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Dr. H. Bliss Murphy Cancer Centre; University of Calgary; Baker Hughes (Canada); Memorial University of Newfoundland","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Internal medicine; Oxaliplatin; Cancer; Population; Oncology; Stage (stratigraphy); Gastroenterology; Surgery","score_opus":0.13747619931840963,"score_gpt":0.47414803545590134,"score_spread":0.33667183613749174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595948223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444664,0.00048185233,0.00006780591,0.0016484391,0.0022222686,0.0010172942,0.00004748276,0.000012844262,0.000055374334],"genre_scores_gemma":[0.99549395,0.000034969176,0.0023890298,0.0007760622,0.0011147173,0.000109370856,0.000010850905,0.000022409658,0.00004863858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958509,0.00093818863,0.0022793266,0.00020170116,0.0004204502,0.00030941085],"domain_scores_gemma":[0.9922675,0.0047292537,0.0018919625,0.00019375207,0.00051688787,0.0004006826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003790693,0.00017924981,0.0015495823,0.00016091249,0.00003458317,0.000004668593,0.00010915138,0.0002902803,0.00019821512],"category_scores_gemma":[0.005471831,0.00012372722,0.0006219248,0.00015834738,0.00009155761,0.00012381692,0.000034345016,0.00043183586,0.0000043931104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10917839,0.0046554715,0.8685684,0.000031922613,0.00032607137,0.00015657715,0.00024674958,0.00004750754,0.00015839697,0.0000011805589,0.00011852162,0.016510773],"study_design_scores_gemma":[0.019732717,0.025148094,0.94915587,0.00008875216,0.0007875069,0.00003785032,0.000084948966,0.00032914558,0.00007385694,0.000012285859,0.0044539482,0.000095024785],"about_ca_topic_score_codex":0.0000605041,"about_ca_topic_score_gemma":0.000066945344,"teacher_disagreement_score":0.08944567,"about_ca_system_score_codex":0.0005738673,"about_ca_system_score_gemma":0.00072610035,"threshold_uncertainty_score":0.6550688},"labels":[],"label_agreement":null},{"id":"W2595986426","doi":"10.1200/jco.2004.22.90140.3033","title":"A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to <i>clusterin</i>, in patients with prostate cancer prior to radical prostatectomy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Clusterin; Medicine; Prostate cancer; Flutamide; Prostate; Urology; Prostatectomy; Pharmacokinetics; Pharmacodynamics; LNCaP; Internal medicine; Peripheral blood mononuclear cell; Oncology; Cancer; Endocrinology; Androgen receptor; Apoptosis; Biology; In vitro","score_opus":0.04688705222068034,"score_gpt":0.4775213126929641,"score_spread":0.43063426047228376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595986426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912971,0.00022318315,0.00012455146,0.0034602045,0.0007058105,0.0040819016,0.00004614022,0.000016676728,0.00004439391],"genre_scores_gemma":[0.99074197,0.00018431585,0.0053536426,0.0033059649,0.0001967131,0.00012533972,0.000002589458,0.000058230056,0.000031245483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944463,0.0007147951,0.0030743754,0.0005657462,0.0006666746,0.0005321192],"domain_scores_gemma":[0.99592316,0.00062151876,0.0013574813,0.000301225,0.0006471687,0.0011494632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022034724,0.00034636087,0.0022916899,0.00049493025,0.00004003726,0.0000117754125,0.00024271668,0.00021115638,0.00007364941],"category_scores_gemma":[0.0013038839,0.00025671354,0.00017286552,0.0006006362,0.0003318314,0.00011989531,0.00026505216,0.0011036595,0.00000590939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29832143,0.053741414,0.38344026,0.00038890677,0.00079223263,0.007631301,0.0053894715,0.0016391417,0.009247668,0.0000017629019,0.00022875512,0.23917769],"study_design_scores_gemma":[0.21460974,0.10581512,0.6742519,0.0006549237,0.00093406875,0.00035514255,0.00031255253,0.00011920918,0.0009803666,0.00002687779,0.0016240425,0.00031603186],"about_ca_topic_score_codex":0.00010674341,"about_ca_topic_score_gemma":0.00012811414,"teacher_disagreement_score":0.2908117,"about_ca_system_score_codex":0.00035388148,"about_ca_system_score_gemma":0.0014201443,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W2596012784","doi":"10.1200/jco.2015.33.15_suppl.e12614","title":"Canadian National Breast Screening Study (CNBSS): Mortality (MOR), survival (SUR), and mammographic screening (MS).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Overdiagnosis; Breast cancer; Internal medicine; Incidence (geometry); Randomization; Gynecology; Relative risk; Randomized controlled trial; Cancer; Demography; Confidence interval","score_opus":0.4317250341247496,"score_gpt":0.518055887192503,"score_spread":0.08633085306775334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596012784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861969,0.000493973,0.00040078085,0.0060982835,0.0009404673,0.00025648263,0.000018266479,0.000015312948,0.0055795475],"genre_scores_gemma":[0.9917565,0.00005622398,0.003768882,0.0023927991,0.0019145085,0.000003085847,0.0000058963483,0.000018999952,0.000083099716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951248,0.0005571087,0.0021575694,0.0003204227,0.0013946901,0.00044536902],"domain_scores_gemma":[0.9939242,0.0007628807,0.0011200589,0.00019624109,0.001936032,0.0020605705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013042817,0.00020869572,0.0014252771,0.00036372073,0.000119403914,0.00004170363,0.00025173975,0.00034797855,0.00007000504],"category_scores_gemma":[0.0038797434,0.00016979384,0.00034677758,0.0003938761,0.00023315907,0.0003480708,0.00009082582,0.0013245513,0.000006169701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016363903,0.00038015324,0.9525877,0.000007057267,0.0005169798,0.0013899194,0.00011842043,0.00007542438,0.0000028601903,0.00006965009,0.0032684559,0.03994698],"study_design_scores_gemma":[0.0075777797,0.005685478,0.9690247,0.00010565487,0.00040940873,0.0018628014,0.0015900997,0.00039438583,8.6855675e-7,0.0002649629,0.012926288,0.00015755359],"about_ca_topic_score_codex":0.05059831,"about_ca_topic_score_gemma":0.14930525,"teacher_disagreement_score":0.09870694,"about_ca_system_score_codex":0.00030333555,"about_ca_system_score_gemma":0.005341255,"threshold_uncertainty_score":0.9557238},"labels":[],"label_agreement":null},{"id":"W2596210945","doi":"10.1200/jco.2012.30.15_suppl.e11061","title":"Development of preclinical models of human BT474 and MDA-MB-361 breast cancer that endogenously overexpress HER2 and that respond to trastuzumab.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Trastuzumab; Medicine; Bioluminescence imaging; In vivo; Breast cancer; Cancer research; Cancer; Lymph node; Chemotherapy; Metastatic breast cancer; Metastasis; Oncology; Internal medicine; Pathology; Cell culture; Luciferase; Biology; Transfection","score_opus":0.47719018676011143,"score_gpt":0.5664286975740835,"score_spread":0.0892385108139721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596210945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321735,0.0021393052,0.00014251904,0.0023035791,0.0004523493,0.00043875922,0.00003296244,0.0000056717427,0.0012674901],"genre_scores_gemma":[0.98847663,0.0014900668,0.008375157,0.00064913684,0.00074689847,0.00001605718,0.0000012520647,0.000033870714,0.00021093432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948512,0.00064089324,0.002726938,0.00029694007,0.0009639916,0.00052006263],"domain_scores_gemma":[0.99402505,0.0025959301,0.0014347745,0.00029778673,0.00051291805,0.00113354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007758732,0.0002142204,0.0020992926,0.00022621306,0.000066637745,0.000010021352,0.00027983024,0.00049827644,0.0002960208],"category_scores_gemma":[0.00097456755,0.00015786916,0.00025127598,0.00013914447,0.00053478015,0.00022643567,0.0002695488,0.0011200085,0.0000022915285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017243747,0.0038481066,0.6603331,0.00060734665,0.001057477,0.00012333826,0.0064599426,0.000021480217,0.012586014,0.00020176504,0.002968888,0.2945488],"study_design_scores_gemma":[0.008924099,0.008132606,0.9495722,0.0010654764,0.0003455861,0.0007881401,0.0009280176,0.000042882013,0.005923901,0.0002687423,0.023774648,0.00023369756],"about_ca_topic_score_codex":0.00012915434,"about_ca_topic_score_gemma":0.00021309257,"teacher_disagreement_score":0.2943151,"about_ca_system_score_codex":0.00027613202,"about_ca_system_score_gemma":0.0026238726,"threshold_uncertainty_score":0.64377177},"labels":[],"label_agreement":null},{"id":"W2596227191","doi":"10.1200/jco.2012.30.15_suppl.tps4675","title":"Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Paclitaxel; Oncology; Vascular endothelial growth factor; Internal medicine; Cancer research; Cancer; VEGF receptors","score_opus":0.09876581949273502,"score_gpt":0.439622911102911,"score_spread":0.34085709161017597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596227191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486697,0.00019725825,0.00017382429,0.00058791996,0.0005244516,0.0032596667,0.000024412739,0.000014094182,0.00035141],"genre_scores_gemma":[0.9962373,0.000031462478,0.0021877557,0.0006566295,0.00058609,0.00010177439,0.000017679362,0.000063792526,0.00011756324],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99420476,0.0010246544,0.0027467278,0.00035681078,0.0012014358,0.0004656147],"domain_scores_gemma":[0.9948584,0.0019473053,0.0020174326,0.000300545,0.00041539175,0.00046091704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025308614,0.0004236266,0.003423948,0.00029512797,0.00013744923,0.000010164968,0.00018991544,0.00032220344,0.0003068617],"category_scores_gemma":[0.0004485014,0.00019641893,0.00052949897,0.0003057714,0.00020962082,0.00024735602,0.000022354287,0.00091987284,0.0000027867538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6620442,0.06718982,0.25073528,0.00003647223,0.0006346803,0.00032019755,0.0010797671,0.000059372203,0.000014468125,0.0000010864865,0.000033680422,0.017850945],"study_design_scores_gemma":[0.70910007,0.23352487,0.05461687,0.00041505994,0.0011367155,0.000034841138,0.0001883261,0.00010375444,0.0002928337,0.0000050763665,0.00039638253,0.00018518347],"about_ca_topic_score_codex":0.000056468885,"about_ca_topic_score_gemma":0.00017335951,"teacher_disagreement_score":0.19611841,"about_ca_system_score_codex":0.00020806382,"about_ca_system_score_gemma":0.0019952913,"threshold_uncertainty_score":0.8009732},"labels":[],"label_agreement":null},{"id":"W2596260927","doi":"10.1200/jco.2004.22.90140.3104","title":"The BC Cancer Agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Lung cancer; Adenocarcinoma; Oncology; Population; Cancer; Gastroenterology; Pathology; Epidermal growth factor receptor","score_opus":0.053792637891429566,"score_gpt":0.4935900234301468,"score_spread":0.4397973855387172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596260927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864854,0.00453986,0.00021891609,0.009076192,0.0011737437,0.00038080002,0.00000353441,0.000005777221,0.0059526362],"genre_scores_gemma":[0.9861612,0.0078853145,0.002481149,0.0018468321,0.00060355186,0.000107522916,7.7709495e-7,0.000017739412,0.0008959457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997953,0.00007802843,0.0012479752,0.00018794132,0.00024601995,0.0002870129],"domain_scores_gemma":[0.9977627,0.00055449083,0.0009432343,0.00017209939,0.00031737852,0.00025009437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005390274,0.00013468096,0.00070045097,0.000056746154,0.0000896185,0.000010390274,0.00016355001,0.00014923624,0.00009825763],"category_scores_gemma":[0.00022969849,0.000070003516,0.00018265645,0.00018896304,0.00017560727,0.00010949605,0.000023352974,0.0006410636,0.0000037175573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049515194,0.0023355873,0.68592703,0.00006736479,0.0005251642,0.0016255305,0.0061735883,0.0036426946,0.00046560337,0.0001312249,0.00075279275,0.29340187],"study_design_scores_gemma":[0.03234413,0.0074889227,0.904401,0.00087519124,0.00079784537,0.00013146142,0.0017218133,0.00007222527,0.00061981566,0.00019503575,0.05115122,0.00020134862],"about_ca_topic_score_codex":0.0006678367,"about_ca_topic_score_gemma":0.0023887255,"teacher_disagreement_score":0.29320052,"about_ca_system_score_codex":0.0005908823,"about_ca_system_score_gemma":0.0057338667,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W2596276146","doi":"10.1200/jco.2006.24.18_suppl.1534","title":"Primary intraocular lymphoma (PIOL): An International Primary CNS Lymphoma Collaborative group report","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Lymphoma; Surgery; Methotrexate; Intraocular lymphoma; Primary central nervous system lymphoma; Vitrectomy; Internal medicine; Visual acuity","score_opus":0.042331250397591696,"score_gpt":0.40518832215815476,"score_spread":0.36285707176056303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596276146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569756,0.0009919547,0.00018739502,0.0067157857,0.0028627783,0.0003526967,0.000019897869,0.000032687032,0.031861246],"genre_scores_gemma":[0.97185117,0.0013659156,0.015700296,0.0051820814,0.005043497,0.000026086534,0.00023689422,0.00004787803,0.00054617756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99418956,0.0004564143,0.003708593,0.00044344258,0.00086481543,0.0003371804],"domain_scores_gemma":[0.99385536,0.0012705359,0.0028146084,0.00043644535,0.0011055483,0.00051753304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027850096,0.00028710504,0.0019573562,0.00024035503,0.000079667814,0.000040350038,0.000301067,0.0005366773,0.00016841108],"category_scores_gemma":[0.0011818766,0.00021309916,0.0007303515,0.00026620625,0.00032787502,0.00042180254,0.00010453355,0.0002731873,0.000031193165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050560804,0.021125294,0.37154967,0.000026178688,0.0012245552,0.03596596,0.000052154755,0.000014528918,0.00044588558,0.0010473485,0.016559869,0.5469325],"study_design_scores_gemma":[0.014380853,0.0065136664,0.67825603,0.00007140056,0.0004330723,0.007141772,0.000046603178,0.000020812418,0.00012019543,0.00044043118,0.29244015,0.00013500679],"about_ca_topic_score_codex":0.00013132211,"about_ca_topic_score_gemma":0.00007708448,"teacher_disagreement_score":0.54679745,"about_ca_system_score_codex":0.0016620196,"about_ca_system_score_gemma":0.004156454,"threshold_uncertainty_score":0.86899316},"labels":[],"label_agreement":null},{"id":"W2596280960","doi":"10.1200/jco.2007.25.18_suppl.15620","title":"The effect of surgical volume on the rate of secondary therapy after radical prostatectomy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Pathological; Stage (stratigraphy); Lymph node; Logistic regression; Biopsy; Biochemical recurrence; Surgery; Internal medicine; Cancer; Gynecology","score_opus":0.04091197885159453,"score_gpt":0.4261132139271554,"score_spread":0.38520123507556087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596280960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97719014,0.0030927574,0.0000072021576,0.016790504,0.0006952364,0.0005195093,0.0000057039924,0.0000031433356,0.001695831],"genre_scores_gemma":[0.9923489,0.005708872,0.000056313973,0.0011531455,0.0005646589,0.000017449305,8.7088614e-7,0.000013333757,0.00013645635],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962733,0.0009881015,0.0020304727,0.00013506376,0.00032839447,0.0002446831],"domain_scores_gemma":[0.9812929,0.01663644,0.0013674425,0.0002463056,0.00024202338,0.00021489224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011667045,0.00014197276,0.001239734,0.00005329958,0.00004400127,0.000005358254,0.000165031,0.00022254621,0.000250545],"category_scores_gemma":[0.0011763939,0.000052988747,0.0007008127,0.000118698976,0.0007423535,0.000032985798,0.000030659558,0.0009741252,0.00000809569],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10933177,0.0019413666,0.293385,0.000052536772,0.0012561948,0.0021124815,0.000107200976,0.0000029644725,0.00013171573,0.00027918172,0.0077729085,0.5836267],"study_design_scores_gemma":[0.018875783,0.078866586,0.5403419,0.000184871,0.00022214437,0.00020976123,0.00003217371,0.000007722929,0.009845253,0.00025735117,0.35109532,0.00006109478],"about_ca_topic_score_codex":0.000007131018,"about_ca_topic_score_gemma":0.0000060425605,"teacher_disagreement_score":0.5835656,"about_ca_system_score_codex":0.00009471769,"about_ca_system_score_gemma":0.00067156926,"threshold_uncertainty_score":0.42321438},"labels":[],"label_agreement":null},{"id":"W2596296337","doi":"10.1200/jco.2013.31.15_suppl.7073","title":"Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Pancytopenia; Febrile neutropenia; Anemia; Sepsis; Dosing; Gastroenterology; Toxicity; Bone marrow","score_opus":0.05854109868732343,"score_gpt":0.4407336791632391,"score_spread":0.38219258047591564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596296337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862449,0.006488103,0.00006496362,0.0040864204,0.0006710224,0.00069372903,0.00002345057,0.000020332724,0.0017070565],"genre_scores_gemma":[0.99073887,0.0047860914,0.0017446367,0.00076790224,0.0011230864,0.00002830709,0.00004596058,0.00004769692,0.0007174519],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99122936,0.0008313275,0.0057675582,0.0005468159,0.0008830829,0.0007418765],"domain_scores_gemma":[0.99073815,0.0025221594,0.0040627993,0.0007792833,0.0010738613,0.00082374056],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031676705,0.00043432467,0.004715107,0.0013340587,0.000051876235,0.000016149414,0.00053683674,0.0008891321,0.0049631856],"category_scores_gemma":[0.0029159284,0.00030915882,0.0017875631,0.0014682851,0.00042981052,0.00037800233,0.00018476098,0.0020271528,0.00013119738],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012717309,0.007977208,0.03244743,0.00042218808,0.015765985,0.0037722352,0.00046123168,0.0024773625,0.048185334,0.00010057261,0.007985611,0.8676875],"study_design_scores_gemma":[0.15338936,0.09466783,0.6607495,0.001152549,0.0140916705,0.00089820597,0.00027740764,0.02462621,0.0042953487,0.00023147109,0.044943415,0.0006770529],"about_ca_topic_score_codex":0.0005697232,"about_ca_topic_score_gemma":0.00088059856,"teacher_disagreement_score":0.8670105,"about_ca_system_score_codex":0.009672709,"about_ca_system_score_gemma":0.016394248,"threshold_uncertainty_score":0.99993604},"labels":[],"label_agreement":null},{"id":"W2596303874","doi":"10.1200/jco.2012.30.15_suppl.6624","title":"Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Discontinuation; Ruxolitinib; Myelofibrosis; Internal medicine; Adverse effect; Surgery; Gastroenterology; Bone marrow","score_opus":0.10272816596117287,"score_gpt":0.446228553385707,"score_spread":0.34350038742453415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596303874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361306,0.0011613573,0.000030875668,0.0036707295,0.00063177256,0.0004010824,0.00000799056,0.0000030525089,0.0004800944],"genre_scores_gemma":[0.9960408,0.002319612,0.0005751302,0.0004520584,0.00036518395,0.00001975584,0.0000043558875,0.000011881935,0.00021120631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964578,0.00072947284,0.002218353,0.00011725928,0.00030653825,0.00017055616],"domain_scores_gemma":[0.9947387,0.0024440428,0.0021127118,0.00015767483,0.00036141512,0.0001854834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027713818,0.00013847284,0.0012693484,0.00008912547,0.000024076762,0.0000019770732,0.00007459419,0.00026378478,0.00034721836],"category_scores_gemma":[0.0015978571,0.00006345232,0.00043671473,0.00009927578,0.00030068212,0.0001658636,0.000039726718,0.0003911806,0.0000050538824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028202612,0.0029548004,0.877016,0.000029480141,0.0010983836,0.000016639246,0.0017307537,0.000001018246,0.00014496096,0.00033477013,0.0001561787,0.08831441],"study_design_scores_gemma":[0.022108836,0.01052478,0.96198213,0.00038510552,0.00068191445,0.00013624557,0.00050120545,0.000045051216,0.0006617067,0.00021628902,0.002690375,0.00006638486],"about_ca_topic_score_codex":0.000012962462,"about_ca_topic_score_gemma":0.000010864939,"teacher_disagreement_score":0.08824802,"about_ca_system_score_codex":0.000060199167,"about_ca_system_score_gemma":0.00024371421,"threshold_uncertainty_score":0.38017976},"labels":[],"label_agreement":null},{"id":"W2596339699","doi":"10.1200/jco.2014.32.15_suppl.e16029","title":"Canadian cost comparison of different forms of androgen ablative therapies prior and during the castration-resistant prostate cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Cabazitaxel; Castration; Goserelin; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Cancer; Androgen; Urology; Gynecology; Hormone","score_opus":0.10019757478991576,"score_gpt":0.4733046291161632,"score_spread":0.37310705432624747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596339699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915121,0.0017256481,0.0000031639252,0.0058322544,0.00012270472,0.0003681473,0.00001729039,0.0000011928253,0.0004174644],"genre_scores_gemma":[0.99778354,0.0017406557,0.0000690136,0.000074801224,0.00012484376,0.000008087865,0.0000017309501,0.000006491641,0.00019085391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982508,0.00018915767,0.0010813174,0.00008497638,0.00022367461,0.0001700923],"domain_scores_gemma":[0.9976028,0.0008025056,0.00091092783,0.00009409216,0.00034345893,0.00024621098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091810443,0.00008223444,0.0008463129,0.00007704385,0.00006882385,0.0000057286766,0.00007991466,0.00010122013,0.000033573782],"category_scores_gemma":[0.00032236957,0.000038322436,0.00012401528,0.00006579328,0.00032030753,0.000046403035,0.000018914834,0.00035863934,2.5121042e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060792635,0.00040603767,0.8999997,0.00011904981,0.0006778249,0.00002752448,0.002052779,0.000011990174,0.0023968357,0.00016049271,0.00013019211,0.08793833],"study_design_scores_gemma":[0.006453252,0.007184232,0.9761017,0.0001714163,0.00017967775,0.000022569327,0.0010042773,0.00011912679,0.004669073,0.00031388827,0.0037344706,0.000046319205],"about_ca_topic_score_codex":0.002606665,"about_ca_topic_score_gemma":0.036598,"teacher_disagreement_score":0.08789201,"about_ca_system_score_codex":0.00019018292,"about_ca_system_score_gemma":0.0014938673,"threshold_uncertainty_score":0.9809816},"labels":[],"label_agreement":null},{"id":"W2596356909","doi":"10.1200/jco.2014.32.15_suppl.8013","title":"Pan-Canadian rash trial with EGFR inhibitors.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbott (Canada); Princess Margaret Cancer Centre; Baker Hughes (Canada); Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Erlotinib; Rash; Medicine; Erlotinib Hydrochloride; Internal medicine; Minocycline; Dermatology; Surgery; Cancer; Epidermal growth factor receptor; Antibiotics","score_opus":0.07618340137758299,"score_gpt":0.49099512744974955,"score_spread":0.41481172607216654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596356909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90740335,0.00017769614,0.00020348837,0.030801713,0.0030812114,0.000361439,0.0000025653178,0.000008784777,0.057959743],"genre_scores_gemma":[0.9869762,0.00006864803,0.0025603091,0.0055189533,0.0040143398,0.000004095229,0.000002683614,0.000012009933,0.0008427809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982399,0.00017925477,0.0010894176,0.000107216736,0.00020840137,0.00017580738],"domain_scores_gemma":[0.99753207,0.00074904907,0.0006944536,0.00012524595,0.0002867535,0.0006124024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013497905,0.00008207769,0.00080178643,0.00011030365,0.00004425689,0.000008253988,0.000068610716,0.00021257329,0.00016267768],"category_scores_gemma":[0.0014577657,0.000047368358,0.00023696787,0.00008783885,0.00011118922,0.00006592859,0.000007534705,0.0004728954,0.000040476607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048074547,0.0025118336,0.09539311,0.0000197339,0.0013945109,0.00093323266,0.00022123252,0.000012265795,0.000020630781,0.0009430489,0.0707654,0.7797105],"study_design_scores_gemma":[0.10502363,0.029567933,0.070667885,0.000059845817,0.00079434033,0.00023087922,0.000058694175,0.000011916076,0.0000126680325,0.00025154828,0.79325974,0.0000609121],"about_ca_topic_score_codex":0.0012525212,"about_ca_topic_score_gemma":0.007142025,"teacher_disagreement_score":0.77964956,"about_ca_system_score_codex":0.00024552067,"about_ca_system_score_gemma":0.0046534957,"threshold_uncertainty_score":0.8255102},"labels":[],"label_agreement":null},{"id":"W2596411967","doi":"10.1200/jco.2014.32.15_suppl.1123","title":"Outcomes of patients with triple-negative breast cancer compared to non-triple negative breast cancer: A single-center study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Clinical Research; University of Windsor; Windsor Regional Hospital","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Stage (stratigraphy); Oncology; Internal medicine; Single Center; Cancer; Estrogen receptor; Progesterone receptor","score_opus":0.02651746259364981,"score_gpt":0.3706201939806801,"score_spread":0.3441027313870303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596411967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996436,0.0000467809,0.00011128092,0.0012804827,0.0010342741,0.00066246465,0.00016655646,0.000003706162,0.0002584546],"genre_scores_gemma":[0.9978569,0.00006841028,0.0005652085,0.0008354766,0.00048885786,0.000024799729,0.00000807186,0.000027803175,0.00012444834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688494,0.0006452542,0.0014751811,0.00033079847,0.00035212818,0.00031168884],"domain_scores_gemma":[0.9961989,0.00042336833,0.0017460833,0.00023989237,0.0010111717,0.00038057734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086052116,0.00025734122,0.0013947185,0.00009551319,0.00006065508,0.000011591376,0.00033649526,0.00034799083,0.000044570115],"category_scores_gemma":[0.00053200434,0.0001636677,0.0003469879,0.00018231192,0.00022232633,0.000015399348,0.00013094496,0.0005270641,0.0000043494374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013690615,0.0055313036,0.9560903,0.00001321134,0.0016250436,0.00001465113,0.00023766125,0.00018108494,0.0010049723,0.0000018360804,0.0025216544,0.01908769],"study_design_scores_gemma":[0.020667708,0.01502387,0.9609765,0.00008589772,0.0003062111,0.00003184172,0.00017086907,0.000039612885,0.001113089,0.000008916522,0.001364973,0.00021052583],"about_ca_topic_score_codex":0.0002191083,"about_ca_topic_score_gemma":0.00039473566,"teacher_disagreement_score":0.018877165,"about_ca_system_score_codex":0.0000997477,"about_ca_system_score_gemma":0.0005802061,"threshold_uncertainty_score":0.6674175},"labels":[],"label_agreement":null},{"id":"W2596458707","doi":"10.1200/jco.2009.27.15_suppl.3580","title":"Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Pharmacodynamics; Pharmacokinetics; Internal medicine; Myeloid leukemia; Refractory (planetary science); Bone marrow; Gastroenterology; Myeloid; Toxicity; Pharmacology","score_opus":0.056220188537247785,"score_gpt":0.4726576236598117,"score_spread":0.41643743512256387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596458707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956399,0.00016283544,0.000028927761,0.0016756646,0.0010910532,0.00096240785,0.000050795563,0.000016348056,0.0003720743],"genre_scores_gemma":[0.9891836,0.0019843308,0.0040210555,0.002489874,0.0021301783,0.0000059404933,0.000046064513,0.000043206666,0.00009576123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912124,0.0014100008,0.005252369,0.0005693689,0.0010218275,0.00053400366],"domain_scores_gemma":[0.99190235,0.0032333347,0.0026396946,0.0003995034,0.00071843975,0.0011066714],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0056644664,0.0003491741,0.003076033,0.00049526425,0.000047980888,0.000017863316,0.0004474179,0.00076883944,0.00021251391],"category_scores_gemma":[0.0028516697,0.00024888286,0.00046352,0.0004061679,0.00066660653,0.00047879983,0.000105530584,0.0038173771,0.000009309069],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49343246,0.0132014435,0.042566195,0.000022977627,0.0007285608,0.0013308525,0.00013610306,0.000005367212,0.0044518723,0.0000026070625,0.0017900333,0.44233152],"study_design_scores_gemma":[0.51480085,0.14602692,0.32671908,0.00023007735,0.0011754892,0.000070442766,0.000051036102,0.00071513903,0.000413354,0.0000791452,0.009477251,0.0002412218],"about_ca_topic_score_codex":0.000045908255,"about_ca_topic_score_gemma":0.000015762982,"teacher_disagreement_score":0.4420903,"about_ca_system_score_codex":0.000799722,"about_ca_system_score_gemma":0.0042215115,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2596486877","doi":"10.1200/jco.2004.22.90140.630","title":"A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Metastatic breast cancer; Anthracycline; Trastuzumab; Ejection fraction; Cardiotoxicity; Doxorubicin; Internal medicine; Breast cancer; Cancer; Heart failure; Oncology; Chemotherapy","score_opus":0.1422473115020502,"score_gpt":0.5265052184546788,"score_spread":0.3842579069526286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596486877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043995,0.0012552956,0.00003178978,0.006603307,0.0010958283,0.00044681967,0.000029049279,0.0000064063356,0.00009152367],"genre_scores_gemma":[0.99503076,0.0011781995,0.0022427726,0.0006525,0.0007700377,0.000006375863,0.0000033531153,0.000017583736,0.000098392804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965832,0.0003786921,0.0022874288,0.00021734096,0.00025516588,0.00027817077],"domain_scores_gemma":[0.9970823,0.0007838467,0.0014980165,0.000102932805,0.00019922701,0.00033369518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011025096,0.00018500272,0.0018800473,0.00020264446,0.000039781335,0.000005319939,0.000091832124,0.00025145325,0.00033776846],"category_scores_gemma":[0.00037533362,0.00013405642,0.00035133923,0.00019095534,0.00025266412,0.00012990047,0.000045029385,0.0008000253,0.0000011227272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5181255,0.10322281,0.021914313,0.00016414956,0.0022832528,0.003680516,0.0023287917,0.00025314078,0.050818797,0.00002169203,0.00076142274,0.29642567],"study_design_scores_gemma":[0.86726236,0.06480657,0.059053693,0.0005383471,0.002188121,0.00093372347,0.000259558,0.00035530803,0.0015711962,0.00010655754,0.0027525981,0.00017193721],"about_ca_topic_score_codex":0.00043846926,"about_ca_topic_score_gemma":0.00062989676,"teacher_disagreement_score":0.34913695,"about_ca_system_score_codex":0.00037963895,"about_ca_system_score_gemma":0.002233856,"threshold_uncertainty_score":0.5466662},"labels":[],"label_agreement":null},{"id":"W2596557105","doi":"10.1200/jco.2012.30.15_suppl.e16558","title":"Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Curriculum; Medical education; Family medicine; MEDLINE; Psychology","score_opus":0.0974903356597005,"score_gpt":0.5422559766492706,"score_spread":0.4447656409895701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596557105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628417,0.0055939015,0.000022269805,0.027198404,0.002315942,0.00020634127,0.0000014459113,0.0000030574217,0.0018169553],"genre_scores_gemma":[0.98286617,0.009032447,0.0033742227,0.0037552647,0.00078926294,0.0000036360138,0.000005536466,0.000013676481,0.00015978953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963904,0.0012086652,0.0016388904,0.00015256669,0.0002238538,0.00038562098],"domain_scores_gemma":[0.9943566,0.0028675832,0.000998058,0.000114816765,0.00028033578,0.0013826482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009079974,0.00012502745,0.0013188325,0.00030492543,0.000033516262,0.0000027470862,0.00010943469,0.0007287984,0.00004460656],"category_scores_gemma":[0.008080494,0.00009158077,0.00009633425,0.00020758605,0.0009337319,0.00013541603,0.000027130844,0.0011949587,0.0000022001436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070169,0.0012827866,0.5742418,0.000018178293,0.00008326315,0.000051553263,0.00018916024,1.681648e-7,0.0000029072119,0.00028267605,0.0006075848,0.42253822],"study_design_scores_gemma":[0.0033557822,0.0067738704,0.880507,0.00010199693,0.00008840056,0.0019595718,0.00040192305,0.00001978449,0.000002696882,0.00049064204,0.10622118,0.00007719135],"about_ca_topic_score_codex":0.021569772,"about_ca_topic_score_gemma":0.13858454,"teacher_disagreement_score":0.42246103,"about_ca_system_score_codex":0.0003993765,"about_ca_system_score_gemma":0.021477751,"threshold_uncertainty_score":0.98494565},"labels":[],"label_agreement":null},{"id":"W2596564154","doi":"10.1200/jco.2006.24.18_suppl.7608","title":"Update of melphalan 280 mg/m<sup>2 </sup>plus amifostine cytoprotection before autologous stem cell transplantation as part of initial therapy in multiple myeloma patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Regimen; Internal medicine; Transplantation; Autologous stem-cell transplantation; Amifostine; Urology; Surgery; Clinical endpoint; AL amyloidosis; Gastroenterology; Toxicity; Clinical trial; Immunology","score_opus":0.07193456100702537,"score_gpt":0.41084819333757455,"score_spread":0.33891363233054916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596564154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975595,0.00013174307,0.00010562433,0.00044003048,0.00026655456,0.0006753839,0.000046996975,0.00000974493,0.0007644308],"genre_scores_gemma":[0.99788487,0.00054346264,0.00092279835,0.00010985058,0.0003669809,0.000013841742,0.00008132159,0.000020893292,0.000056001914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953225,0.0006995959,0.0028247647,0.00022325858,0.0006139529,0.00031589394],"domain_scores_gemma":[0.99631643,0.0009804341,0.0017272199,0.00017783919,0.000577567,0.00022052083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013798638,0.00018907378,0.0014307934,0.00031879116,0.00003716268,0.000004502136,0.00014876176,0.0004286319,0.000088128945],"category_scores_gemma":[0.00040189657,0.00013624835,0.0003760842,0.00022914805,0.00021767094,0.00013382005,0.000022030134,0.00070831284,0.000012001615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029078424,0.004713341,0.5639208,0.00012984182,0.00021904078,0.0008863816,0.00027967762,0.00034679472,0.0006184404,0.000012754705,0.00009228594,0.39970222],"study_design_scores_gemma":[0.045981996,0.029791093,0.9133377,0.00016762018,0.00014545706,0.00017434836,0.00009592498,0.001448144,0.0073651955,0.00018384625,0.00121267,0.000095971096],"about_ca_topic_score_codex":0.00046770027,"about_ca_topic_score_gemma":0.00030594663,"teacher_disagreement_score":0.39960623,"about_ca_system_score_codex":0.00018591246,"about_ca_system_score_gemma":0.00082282705,"threshold_uncertainty_score":0.55560464},"labels":[],"label_agreement":null},{"id":"W2596571349","doi":"10.1200/jco.2004.22.14_suppl.522","title":"An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Lymphovascular invasion; Internal medicine; Cancer; Tamoxifen; Population; Stage (stratigraphy); Proportional hazards model; Oncology; Gynecology; Adjuvant therapy; Metastasis","score_opus":0.05224858097771272,"score_gpt":0.443099204210998,"score_spread":0.3908506232332853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596571349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920196,0.00021331114,0.0031157637,0.003358656,0.0009809185,0.00017112902,0.00012003595,0.000001796778,0.000018765575],"genre_scores_gemma":[0.99499553,0.00010270403,0.003566908,0.0006061642,0.0006720879,0.000012589323,0.000015856003,0.0000116396695,0.00001652488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982902,0.00013579201,0.0010564763,0.00016712365,0.0002244001,0.00012605207],"domain_scores_gemma":[0.9977062,0.00022869249,0.0013071148,0.00021903591,0.0004477906,0.00009121366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008721506,0.00010331427,0.0004660737,0.000032975047,0.000089995454,0.000004464244,0.00023612031,0.00022352427,0.000023220735],"category_scores_gemma":[0.0005358621,0.00006332471,0.0003509559,0.000058450605,0.00008581945,0.0000091199,0.00005396919,0.00014853996,3.1077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006362165,0.0020852387,0.86359525,0.00001894844,0.0004266558,0.0000049207856,0.000058341564,0.027917698,0.003266771,0.00011072019,0.00038453608,0.09576877],"study_design_scores_gemma":[0.00928004,0.0030409482,0.9734743,0.00006010277,0.0001863404,0.000022826991,0.00004998651,0.00003550646,0.008214151,0.0006899141,0.004851926,0.000093926465],"about_ca_topic_score_codex":0.00017350973,"about_ca_topic_score_gemma":0.000585711,"teacher_disagreement_score":0.1098791,"about_ca_system_score_codex":0.00011392635,"about_ca_system_score_gemma":0.0011410975,"threshold_uncertainty_score":0.2582307},"labels":[],"label_agreement":null},{"id":"W2596631689","doi":"10.1200/jco.2004.22.90140.716","title":"Adherence to clinical practice guidelines for adjuvant therapy of breast cance","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Guideline; Breast cancer; Adjuvant therapy; Internal medicine; Hormone therapy; Radiation therapy; Chemotherapy; Disease; Cancer; Adjuvant; Hormonal therapy; Oncology; Pathology","score_opus":0.5777969794367662,"score_gpt":0.6539647543003372,"score_spread":0.07616777486357096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596631689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52854913,0.004395044,0.040601067,0.41334993,0.0068743294,0.0014674241,0.000024033448,0.000025360041,0.0047136787],"genre_scores_gemma":[0.4944019,0.008316309,0.37804204,0.112029225,0.0061172014,0.000037045626,0.0000029743808,0.000027572674,0.0010257071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939546,0.00022925537,0.00488135,0.00023333415,0.00049287785,0.00020858373],"domain_scores_gemma":[0.985343,0.0033697698,0.0035473725,0.0003246087,0.006800533,0.0006147493],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0075071384,0.00012587906,0.0015814105,0.00006755848,0.000027329306,0.0000045217407,0.00033304584,0.00030140392,0.00020817325],"category_scores_gemma":[0.051506557,0.000084907886,0.0005284924,0.00019222115,0.00021608642,0.00013001228,0.000032123557,0.00065425254,0.000088685025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01162901,0.002844336,0.010920431,0.000031672196,0.0002890942,0.00009838279,0.000071272414,0.00004553943,0.00031895953,0.0005215487,0.080999956,0.8922298],"study_design_scores_gemma":[0.016607907,0.041207217,0.14618358,0.0006035203,0.00018418033,0.0010659276,0.0003877945,0.000040230156,0.00018615597,0.0013988937,0.7920051,0.00012945359],"about_ca_topic_score_codex":0.00004665722,"about_ca_topic_score_gemma":0.000014859196,"teacher_disagreement_score":0.89210033,"about_ca_system_score_codex":0.000070647606,"about_ca_system_score_gemma":0.0054367464,"threshold_uncertainty_score":0.9644554},"labels":[],"label_agreement":null},{"id":"W2596651967","doi":"10.1200/jco.2013.31.15_suppl.e14575","title":"Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil (5FU)-based regimens in adjuvant treatment of colon cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oxaliplatin; Capecitabine; Internal medicine; Colorectal cancer; Oncology; Fluorouracil; Retrospective cohort study; Toxicity; Gastroenterology; Cancer","score_opus":0.11918104528298487,"score_gpt":0.48614637961138146,"score_spread":0.3669653343283966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596651967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252933,0.00093532656,0.0000035789808,0.0053935954,0.00034045114,0.0004189231,0.000016521493,0.0000029803812,0.00035931755],"genre_scores_gemma":[0.9943592,0.004463553,0.0005569936,0.00041889652,0.00008894101,0.000017457542,0.000001937003,0.000008119424,0.000084902786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955857,0.00037966872,0.0032479772,0.0002659061,0.00030773197,0.00021303158],"domain_scores_gemma":[0.994591,0.0022874142,0.0020188338,0.00019084748,0.0007071623,0.00020474406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014437041,0.00018688447,0.004782078,0.00044959626,0.00001713231,0.0000036336266,0.00008453162,0.00030001774,0.00009749127],"category_scores_gemma":[0.0017354203,0.00011620801,0.0008795423,0.00049889926,0.00043916403,0.00006533192,0.00006104041,0.00041833043,8.0845865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051845103,0.007778825,0.92689896,0.000014776755,0.0040472047,0.0002333448,0.00026165482,0.000028799515,0.000039897048,0.000009407472,0.0001000918,0.05540253],"study_design_scores_gemma":[0.016396657,0.038524996,0.9410665,0.00009449709,0.0028662842,0.000008803401,0.00027941787,0.00041119687,0.00007488867,0.000091349284,0.00010774883,0.00007765891],"about_ca_topic_score_codex":0.003105456,"about_ca_topic_score_gemma":0.017615814,"teacher_disagreement_score":0.055324867,"about_ca_system_score_codex":0.0007950691,"about_ca_system_score_gemma":0.0008303549,"threshold_uncertainty_score":0.9830038},"labels":[],"label_agreement":null},{"id":"W2596681760","doi":"10.1200/jco.2013.31.15_suppl.e20568","title":"Differences in pain, symptom burden, and opioid use among cancer pain patients with active versus non-active disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Opioid; Anxiety; Cancer pain; Depression (economics); Cancer; Internal medicine; Physical therapy; Psychiatry","score_opus":0.0815141294209158,"score_gpt":0.42356041457200744,"score_spread":0.34204628515109164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596681760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949881,0.00016984707,0.000014425498,0.0034009921,0.000771219,0.00050965976,0.000012580824,0.000004734482,0.00012846249],"genre_scores_gemma":[0.99675673,0.00095316494,0.0001296339,0.0011780707,0.00076889124,0.000056242636,0.0000065766817,0.000013536014,0.00013717297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977626,0.0006964563,0.0008426594,0.00021632561,0.0002361641,0.00024576715],"domain_scores_gemma":[0.9928044,0.005314431,0.0008548508,0.00009197053,0.00040970606,0.00052463287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072200847,0.0001690375,0.0010475486,0.00011741652,0.000034031804,0.0000134791935,0.000083430525,0.0002019841,0.0003958226],"category_scores_gemma":[0.0014669606,0.000104935796,0.00013712297,0.00010958105,0.000337642,0.00028436113,0.0000358272,0.00066339964,0.0000031161542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018476339,0.0009789142,0.7659187,0.000016634558,0.0005063172,0.00011842796,0.00028576795,0.000002710583,0.0000059265894,0.0000013011608,0.0013196991,0.21236928],"study_design_scores_gemma":[0.020831,0.016924623,0.9585646,0.00016705094,0.00045436085,0.0000013405388,0.00024086414,0.00020893614,0.000006472956,0.000037965758,0.0024573423,0.000105492494],"about_ca_topic_score_codex":0.0009996569,"about_ca_topic_score_gemma":0.00066513394,"teacher_disagreement_score":0.2122638,"about_ca_system_score_codex":0.0002849421,"about_ca_system_score_gemma":0.0008663376,"threshold_uncertainty_score":0.433398},"labels":[],"label_agreement":null},{"id":"W2596694419","doi":"10.1200/jco.2012.30.15_suppl.1036","title":"A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; University of Toronto; Kingston General Hospital; Interior Health; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Baker Hughes (Canada); London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Rash; Clinical endpoint; Progressive disease; Adverse effect; Interim analysis; Nausea; Gastroenterology; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.2071610312700796,"score_gpt":0.5449791943742308,"score_spread":0.33781816310415125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596694419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045473,0.0009789249,0.00006180862,0.0018792512,0.005088531,0.0012060719,0.00003244242,0.000005833121,0.00029237484],"genre_scores_gemma":[0.9949161,0.000992703,0.00073396397,0.00061553664,0.0025592765,0.000041431846,0.0000018171089,0.000024383287,0.00011481886],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940959,0.00093339494,0.0037870808,0.00020874248,0.000574667,0.0004001734],"domain_scores_gemma":[0.9942509,0.0015139115,0.0030845352,0.0002292733,0.00042518796,0.0004961953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060356124,0.0002096057,0.0025901664,0.0003182901,0.000045461624,0.000004850036,0.00020393095,0.00023914527,0.0008961982],"category_scores_gemma":[0.001771025,0.00014768534,0.00052189984,0.0003978706,0.00014975098,0.00018787636,0.000063184,0.0012834402,0.0000037117964],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38944414,0.0733861,0.010273037,0.000040486364,0.0007378658,0.0001583883,0.002642685,0.0000022348372,0.00015296035,0.00013695382,0.0016001277,0.521425],"study_design_scores_gemma":[0.66842353,0.2827759,0.033232715,0.000333227,0.00098968,0.0002880433,0.002272948,0.00006604545,0.00011287342,0.0009022135,0.010408523,0.00019427501],"about_ca_topic_score_codex":0.00015960002,"about_ca_topic_score_gemma":0.00047365358,"teacher_disagreement_score":0.5212307,"about_ca_system_score_codex":0.00026383632,"about_ca_system_score_gemma":0.0018917801,"threshold_uncertainty_score":0.9812742},"labels":[],"label_agreement":null},{"id":"W2596828685","doi":"10.1200/jco.2015.33.15_suppl.e20558","title":"Trends toward declining aggressive care at end of life among older cancer patients in the Deep South.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; End-of-life care; Population; Cancer; Health care; Quarter (Canadian coin); Gerontology; Descriptive statistics; Emergency medicine; Family medicine; Demography; Internal medicine; Nursing; Environmental health","score_opus":0.36156271056484485,"score_gpt":0.5502608959683503,"score_spread":0.18869818540350541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596828685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933494,0.0056300005,0.000013765676,0.001336451,0.0010134012,0.00008732992,0.0000098040755,0.0000022851466,0.0025720487],"genre_scores_gemma":[0.99620295,0.0011752191,0.0005683454,0.0012314698,0.0007479377,0.000004166187,0.0000057794396,0.000011199261,0.00005295168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646086,0.0005268816,0.0021436112,0.00013907213,0.00053726946,0.00019229446],"domain_scores_gemma":[0.9928239,0.0022784772,0.0033661118,0.0001472589,0.0010728443,0.00031141596],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015509339,0.00012437908,0.0014083512,0.00016484079,0.000015854792,0.0000026100977,0.00021923159,0.0003228268,0.0001112009],"category_scores_gemma":[0.011262854,0.00007210331,0.00040031993,0.00019597019,0.00032703282,0.00006851455,0.00006879655,0.0006716054,0.0000028574748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015127852,0.00040008075,0.9129405,0.000035875593,0.00017801349,0.00014479946,0.023836922,0.000040021434,0.0000017798158,0.0000031555762,0.0020350767,0.05887097],"study_design_scores_gemma":[0.010484665,0.005233391,0.9587514,0.00079353724,0.00030906842,0.0000072398198,0.011599411,0.000029146326,0.000060572966,0.000025536234,0.012631054,0.00007499772],"about_ca_topic_score_codex":0.0001549023,"about_ca_topic_score_gemma":0.0007418137,"teacher_disagreement_score":0.058795974,"about_ca_system_score_codex":0.00018255044,"about_ca_system_score_gemma":0.0010129012,"threshold_uncertainty_score":0.9970657},"labels":[],"label_agreement":null},{"id":"W2596835303","doi":"10.1200/jco.2013.31.15_suppl.2542","title":"A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Juravinski Cancer Centre; McGill University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Discontinuation; Cancer; Internal medicine; Nausea; Oncology; Gastroenterology","score_opus":0.06318784046783296,"score_gpt":0.428759684470128,"score_spread":0.36557184400229503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596835303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971361,0.00018780642,0.000011818379,0.0009404468,0.00065089803,0.0009024021,0.0000036215163,0.0000023858495,0.00016448539],"genre_scores_gemma":[0.9988582,0.00016170593,0.00042031473,0.00024390698,0.00021355117,0.00003936213,0.0000011727891,0.000013476761,0.000048290785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968042,0.00020493173,0.0022092278,0.00017652712,0.0004088247,0.00019633512],"domain_scores_gemma":[0.9969706,0.00049424125,0.0015661976,0.00015134393,0.0006266595,0.00019094528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010086452,0.000120806144,0.001416127,0.00019944411,0.000012888687,0.000004153816,0.00008802178,0.00014958582,0.00019024266],"category_scores_gemma":[0.00047977403,0.00007865756,0.00013154978,0.00030788704,0.0000780349,0.00017960224,0.000027822518,0.00050126034,0.0000022529196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009972506,0.014976729,0.7997725,0.000059221555,0.00010468521,0.00007368211,0.00041612945,0.00016924387,0.000071472336,0.0000012607355,0.00026919623,0.17411336],"study_design_scores_gemma":[0.07607122,0.034977347,0.8845168,0.0003732767,0.00016210717,0.000004270298,0.00068409275,0.00006209467,0.000056833385,0.00000912099,0.003006997,0.00007587142],"about_ca_topic_score_codex":0.00045664344,"about_ca_topic_score_gemma":0.0028045843,"teacher_disagreement_score":0.17403749,"about_ca_system_score_codex":0.0002572953,"about_ca_system_score_gemma":0.0007734959,"threshold_uncertainty_score":0.32075623},"labels":[],"label_agreement":null},{"id":"W2596883961","doi":"10.1200/jco.2016.70.7257","title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Breast cancer; Guideline; Internal medicine; Oncology; Adjuvant; Adjuvant therapy; Cancer; Clinical trial; Osteonecrosis of the jaw; Bisphosphonate; Osteoporosis; Pathology","score_opus":0.5669481703085816,"score_gpt":0.6544656793088844,"score_spread":0.08751750900030286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596883961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030791301,0.9576439,0.0000034110358,0.007566633,0.0023232703,0.0011441131,0.00028041893,0.000006806388,0.000240123],"genre_scores_gemma":[0.0012970429,0.9764488,0.014268331,0.006812967,0.00085550005,0.000035771263,0.000016995553,0.00007067161,0.00019396878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97968173,0.0024941762,0.015852127,0.00078420335,0.00062421476,0.000563573],"domain_scores_gemma":[0.95800245,0.012028646,0.026435705,0.0005900133,0.001738167,0.0012050429],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010588784,0.0005752499,0.016173992,0.00020311335,0.00008069821,0.00001564138,0.00031445062,0.0022108594,0.00010904011],"category_scores_gemma":[0.008545395,0.00038811454,0.002168728,0.000213423,0.0018940412,0.00022886173,0.00030436285,0.0047609424,0.0000020444622],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004369791,0.0022813496,0.30589715,0.001905048,0.0020476468,0.0004930947,0.00017801758,6.743794e-7,3.4483904e-8,0.0000018590913,0.0048970883,0.67792827],"study_design_scores_gemma":[0.010277229,0.007978973,0.1534792,0.00722331,0.0065026623,0.00095110334,0.00018117392,0.000018689965,5.662565e-8,0.0000053468543,0.81317174,0.00021049505],"about_ca_topic_score_codex":0.101934396,"about_ca_topic_score_gemma":0.066499956,"teacher_disagreement_score":0.8082747,"about_ca_system_score_codex":0.0010459422,"about_ca_system_score_gemma":0.03314182,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W2596908787","doi":"10.1200/jco.2012.30.15_suppl.e15180","title":"Severe zoledronic acid (ZOL)-associated hypophosphatemia and prognosis in patients with castration-resistant prostate cancer (CRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hypophosphatemia; Medicine; Internal medicine; Concomitant; Nomogram; Prostate cancer; Gastroenterology; Oncology; Urology; Cancer","score_opus":0.05713958397664065,"score_gpt":0.4162039337105179,"score_spread":0.35906434973387724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596908787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947128,0.0018045238,2.8943117e-7,0.0023651859,0.00040636677,0.00048040075,0.000011471527,0.0000057851476,0.00021316025],"genre_scores_gemma":[0.9977662,0.0006760941,0.0005153853,0.00075953524,0.00011358724,0.00001663921,0.000007642537,0.00001549955,0.0001293921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752694,0.0002171107,0.0014401808,0.00013390764,0.0002990821,0.00038279995],"domain_scores_gemma":[0.9974617,0.00032915644,0.0012456368,0.000073641386,0.0003245328,0.0005653681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011617176,0.00013424609,0.0009368501,0.00007339633,0.000039190458,0.000006096965,0.000041355237,0.00026844916,0.000044739118],"category_scores_gemma":[0.0005811966,0.00008450506,0.00008705705,0.00014453665,0.00009043029,0.00020047768,0.000016861259,0.00063822954,0.0000058004775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007782055,0.003077819,0.9524171,0.00003739424,0.00024212623,0.0001016378,0.00015312027,0.0000013283493,0.0000059174945,0.0000053116637,0.00032842974,0.035847794],"study_design_scores_gemma":[0.021570224,0.010693072,0.9654094,0.0002151291,0.00029953656,0.000037998223,0.000037168305,0.0000041681005,0.000024721287,0.000018554285,0.0016109894,0.000079032725],"about_ca_topic_score_codex":0.00015190827,"about_ca_topic_score_gemma":0.00066890207,"teacher_disagreement_score":0.035768762,"about_ca_system_score_codex":0.0003936303,"about_ca_system_score_gemma":0.0016360066,"threshold_uncertainty_score":0.34460163},"labels":[],"label_agreement":null},{"id":"W2596950809","doi":"10.1200/jco.2012.30.15_suppl.10522","title":"The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Malignancy; Lung cancer; Cancer research; Oncology; Internal medicine; Odds ratio; Carcinogenesis; Cancer","score_opus":0.04208426404780629,"score_gpt":0.41774783470958304,"score_spread":0.37566357066177675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596950809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995378,0.001109672,0.0000777771,0.0007863775,0.000911456,0.00015038108,0.000016149,0.0000011278916,0.001569048],"genre_scores_gemma":[0.99724895,0.001097338,0.00018630184,0.00026055754,0.00093869603,0.0000039259016,0.0000010759281,0.000010167276,0.00025296907],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99726003,0.0010974517,0.0010858335,0.00011427191,0.00023397025,0.00020843688],"domain_scores_gemma":[0.9958511,0.0017618621,0.0017729696,0.00027200324,0.00022058019,0.00012150855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006288103,0.000118197895,0.0005513303,0.000017089149,0.000093124,0.0000040216373,0.0002916502,0.00024433236,0.000041403404],"category_scores_gemma":[0.0042015156,0.00005300695,0.00043216813,0.000045133635,0.00028322113,0.000005763452,0.000068409834,0.0005777343,0.0000018605292],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02092324,0.0030482472,0.39209387,0.0001222012,0.0040741293,0.000026413145,0.0010786455,0.003371436,0.11944544,0.00073083106,0.018320128,0.43676543],"study_design_scores_gemma":[0.01598182,0.09676747,0.4120496,0.00033416826,0.0013728904,0.00016563274,0.0003388177,0.0006808381,0.27235273,0.0004340823,0.19902267,0.0004992847],"about_ca_topic_score_codex":0.00006207329,"about_ca_topic_score_gemma":0.000030889383,"teacher_disagreement_score":0.43626615,"about_ca_system_score_codex":0.000038520335,"about_ca_system_score_gemma":0.00066549686,"threshold_uncertainty_score":0.502991},"labels":[],"label_agreement":null},{"id":"W2596957725","doi":"10.1200/jco.2012.30.15_suppl.7592","title":"Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Histology; Paclitaxel; Carboplatin; Gastroenterology; Lung cancer; Neutropenia; Clinical endpoint; Cancer; Randomized controlled trial; Urology; Oncology; Chemotherapy; Cisplatin","score_opus":0.02133934613977678,"score_gpt":0.405305727424815,"score_spread":0.38396638128503824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596957725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944072,0.0020682449,0.00023007863,0.0018858291,0.00015975919,0.00047875888,0.000010288271,0.0000025817092,0.0007572757],"genre_scores_gemma":[0.9961466,0.0019694066,0.001277896,0.00037479386,0.000053602274,0.000014214898,0.000020675181,0.000014606525,0.00012816516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783236,0.00019135777,0.0013632991,0.00017393233,0.00021740643,0.00022166864],"domain_scores_gemma":[0.9970984,0.0008657031,0.0013822503,0.00012820694,0.00032676186,0.00019870374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070848776,0.00014744475,0.0013181142,0.0002735433,0.00002595205,0.0000023379614,0.000065731685,0.00019813511,0.000042310705],"category_scores_gemma":[0.0001965055,0.00009335314,0.000117784766,0.00040575428,0.00012888253,0.00011908865,0.000013810067,0.0004251783,3.9290694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011676762,0.0058568856,0.936419,0.000029679706,0.0008319057,0.000023933397,0.00093798304,0.0004442055,0.000022460748,0.000009639313,0.000067751345,0.043679796],"study_design_scores_gemma":[0.05380377,0.019465055,0.9232196,0.00012690984,0.0012702013,0.0000071900877,0.000128633,0.00017795856,0.000040598206,0.00000655628,0.0016648768,0.000088652894],"about_ca_topic_score_codex":0.00049774017,"about_ca_topic_score_gemma":0.0011486857,"teacher_disagreement_score":0.043591145,"about_ca_system_score_codex":0.00042385815,"about_ca_system_score_gemma":0.000719521,"threshold_uncertainty_score":0.38068306},"labels":[],"label_agreement":null},{"id":"W2597035387","doi":"10.1200/jco.2012.30.15_suppl.8007","title":"A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Clinical endpoint; Gastroenterology; Randomized controlled trial; Lymphoma; Progression-free survival; Neutropenia; Dosing; Chemotherapy; Oncology; Surgery","score_opus":0.10232580207271426,"score_gpt":0.45872859381288655,"score_spread":0.3564027917401723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597035387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649481,0.0003936581,0.0015007658,0.00031486075,0.00027062968,0.0323168,0.0000078922385,0.000008332065,0.00023893703],"genre_scores_gemma":[0.98611856,0.00006618136,0.0012548171,0.00043289896,0.00060494867,0.011473289,0.000011127239,0.000028414079,0.0000097648945],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99061275,0.0029135223,0.004782555,0.00044819363,0.00060519885,0.00063778786],"domain_scores_gemma":[0.9866763,0.008582986,0.003470106,0.00036872047,0.00044925665,0.00045264885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008556535,0.0004925544,0.007187854,0.00064078346,0.00011355871,0.00006499832,0.00033490444,0.00026163217,0.00002946156],"category_scores_gemma":[0.00083303184,0.00027514843,0.0012000917,0.0005098073,0.0005712805,0.0002360943,0.00015272475,0.00037428387,0.0000017422952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5228963,0.0896145,0.30051342,0.00020197681,0.011098148,0.0011836397,0.009495823,0.00033092147,0.000074578544,0.00033222145,0.000033970508,0.06422455],"study_design_scores_gemma":[0.781492,0.029441908,0.14238583,0.00032674853,0.01058374,0.00040732426,0.007931311,0.026804674,0.000037513168,0.000046871446,0.0003136925,0.00022838241],"about_ca_topic_score_codex":0.0010660947,"about_ca_topic_score_gemma":0.0019095854,"teacher_disagreement_score":0.25859573,"about_ca_system_score_codex":0.0013640708,"about_ca_system_score_gemma":0.0023795182,"threshold_uncertainty_score":0.9999701},"labels":[],"label_agreement":null},{"id":"W2597067106","doi":"10.1200/jco.2013.31.15_suppl.5547","title":"Benefit in progression-free survival (PFS) to expect based on CA125 reduction at week 6 in recurrent ovarian cancer (ROC) patients: CALYPSO phase III trial data (a GINECO-GCIG study).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Progression-free survival; Oncology; Ovarian cancer; Internal medicine; Receiver operating characteristic; Clinical trial; Cancer; Overall survival","score_opus":0.20946949223040787,"score_gpt":0.514383490258674,"score_spread":0.30491399802826613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597067106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713457,0.00020802753,0.000008655768,0.019371698,0.005886118,0.0028024674,0.000059681264,0.000009275546,0.00030836105],"genre_scores_gemma":[0.99535155,0.00020112829,0.0008672246,0.0006507698,0.0023766875,0.00035746075,0.00007191203,0.000030414589,0.00009286615],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941508,0.00069156446,0.0032881622,0.0006385677,0.0008328265,0.0003980506],"domain_scores_gemma":[0.9954087,0.0013566458,0.0014497704,0.0008686153,0.00039525828,0.00052101334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030591853,0.00027439155,0.001884006,0.00039832477,0.000052303734,0.000022111486,0.00044651647,0.00030214046,0.0008236534],"category_scores_gemma":[0.0025550872,0.00019142083,0.00023979366,0.00037967498,0.00006866117,0.00019547627,0.00022967104,0.00087780063,0.000021105818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17204294,0.08678107,0.2513741,0.000020973726,0.00026806197,0.00045733378,0.00022011522,0.00022254536,0.0000065950335,0.000009974974,0.038113557,0.45048276],"study_design_scores_gemma":[0.39135858,0.07903156,0.51165956,0.0005132664,0.00033518352,0.000007427494,0.00016958467,0.0005856283,0.000011257814,0.000047020072,0.016093785,0.00018715659],"about_ca_topic_score_codex":0.0018724157,"about_ca_topic_score_gemma":0.0060738507,"teacher_disagreement_score":0.4502956,"about_ca_system_score_codex":0.001707723,"about_ca_system_score_gemma":0.0014310082,"threshold_uncertainty_score":0.9018427},"labels":[],"label_agreement":null},{"id":"W2597070782","doi":"10.1200/jco.2013.31.15_suppl.5561","title":"Does aggressive primary debulking surgery influence survival in ovarian cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Debulking; Surgery; Ovarian cancer; Stage (stratigraphy); Serous fluid; Retrospective cohort study; Medical record; Cancer; Internal medicine","score_opus":0.08658466243258553,"score_gpt":0.4361711961414098,"score_spread":0.3495865337088243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597070782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617116,0.001019991,0.000011512689,0.032797523,0.0029843375,0.00023574334,0.0000025515994,0.0000062480167,0.0012305053],"genre_scores_gemma":[0.9872418,0.0053980793,0.00110388,0.004635507,0.0014609476,0.00003478921,0.0000015054159,0.000016214695,0.00010727672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964533,0.0003862378,0.0022974939,0.0002188918,0.00034912355,0.00029496473],"domain_scores_gemma":[0.9915792,0.004990449,0.0023966648,0.00018999074,0.0004687179,0.0003750079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021309562,0.0001486506,0.0017769234,0.00017400914,0.0000284991,0.00001664843,0.00012548687,0.000307721,0.00047827497],"category_scores_gemma":[0.0031298723,0.00007843201,0.00041861672,0.00018314864,0.00014606239,0.00022688894,0.000049641265,0.0007894707,0.000026410964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005679763,0.000984054,0.76083624,0.000033099095,0.0002512719,0.001670884,0.0000517869,0.000022898155,0.000057500467,0.000028861248,0.0018067885,0.23368862],"study_design_scores_gemma":[0.004236459,0.0012558337,0.9818421,0.00066528417,0.00017399294,0.00010630162,0.000048097954,0.000010162855,0.00007373948,0.00045647717,0.011039079,0.00009245587],"about_ca_topic_score_codex":0.0009027916,"about_ca_topic_score_gemma":0.0003511706,"teacher_disagreement_score":0.23359616,"about_ca_system_score_codex":0.00047945406,"about_ca_system_score_gemma":0.0031229637,"threshold_uncertainty_score":0.5540003},"labels":[],"label_agreement":null},{"id":"W2597077431","doi":"10.1200/jco.2013.31.15_suppl.2093","title":"Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Temozolomide; Medicine; Radiation therapy; Glioma; Oncology; Bevacizumab; Brain tumor; Internal medicine; Chemotherapy; Pathology; Cancer research","score_opus":0.05672199724298657,"score_gpt":0.4328534423043013,"score_spread":0.3761314450613147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597077431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955753,0.00015192253,5.1052507e-7,0.002256383,0.00044882114,0.0013709727,0.000005710281,0.0000044029407,0.00018594078],"genre_scores_gemma":[0.99899876,0.000014637065,0.00032126767,0.00038330615,0.00019142653,0.00005793034,0.0000037108716,0.000016910946,0.000012032295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962518,0.00042353664,0.002365549,0.00022884354,0.00047998346,0.00025024073],"domain_scores_gemma":[0.9952665,0.0011853917,0.0023281362,0.00022184323,0.0006191089,0.00037904494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009268157,0.00018062879,0.0016484739,0.00029419755,0.000032739285,0.000007917333,0.00013471681,0.00014286595,0.00053122954],"category_scores_gemma":[0.0013804121,0.000093775874,0.00020636113,0.00028217322,0.00012937945,0.00016332339,0.00006671568,0.0006192042,0.000009758246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0130551765,0.1641357,0.60612804,0.00003385858,0.00063429464,0.0045464397,0.00042020887,0.0000017213935,0.000039481733,0.0000035127396,0.002760664,0.20824088],"study_design_scores_gemma":[0.08778385,0.29115558,0.6184915,0.00026534838,0.0002776861,0.000122024234,0.0004621476,0.00001150055,0.00012520162,0.000015425627,0.0012129372,0.00007683152],"about_ca_topic_score_codex":0.00004623453,"about_ca_topic_score_gemma":0.000120643104,"teacher_disagreement_score":0.20816405,"about_ca_system_score_codex":0.0001396199,"about_ca_system_score_gemma":0.0009648066,"threshold_uncertainty_score":0.5816591},"labels":[],"label_agreement":null},{"id":"W2597218142","doi":"10.1200/jco.2013.31.15_suppl.9628","title":"Hypocalcemia in patients with metastatic bone disease receiving denosumab.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Adverse effect; Internal medicine; Multiple myeloma; Clinical trial; Urology; Gastroenterology; Osteoporosis","score_opus":0.0824289461526568,"score_gpt":0.441146050599753,"score_spread":0.35871710444709615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597218142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933519,0.00026204553,0.000023197335,0.0050138533,0.00035181618,0.00039262368,0.0000013815662,0.0000051818474,0.0005980111],"genre_scores_gemma":[0.99072313,0.00010282872,0.005834452,0.003004754,0.00010310387,0.000009915605,0.000003698918,0.000014331309,0.00020378988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711245,0.00030513896,0.0018287482,0.00014356569,0.0003392429,0.0002708402],"domain_scores_gemma":[0.9963343,0.0011536665,0.0010536562,0.00015515495,0.00035255586,0.0009506538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009887797,0.00011408245,0.0011345486,0.0001297549,0.000024279983,0.0000060690854,0.00006330906,0.00011518883,0.00022319282],"category_scores_gemma":[0.003015391,0.00006693778,0.00016710082,0.0001348782,0.00009794948,0.0001584614,0.000020617512,0.00068416883,0.0000871024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046778796,0.0031150633,0.87880623,0.000030241632,0.00011898996,0.00059871736,0.000020006877,0.000002903386,4.835305e-7,0.0000074475015,0.0012445641,0.11137748],"study_design_scores_gemma":[0.02042603,0.009465869,0.9667873,0.00015683353,0.00029235583,0.000037461767,0.000016885517,0.000028527886,6.083198e-7,0.0003151867,0.0024155832,0.00005736835],"about_ca_topic_score_codex":0.000073610274,"about_ca_topic_score_gemma":0.00004727644,"teacher_disagreement_score":0.11132011,"about_ca_system_score_codex":0.00018170875,"about_ca_system_score_gemma":0.0014203874,"threshold_uncertainty_score":0.36099225},"labels":[],"label_agreement":null},{"id":"W2597223639","doi":"10.1200/jco.2007.25.18_suppl.1099","title":"Randomized phase II study of biweekly gemcitabine (gem)-paclitaxel (pac), gem-carboplatin (carb) and gem-cisplatin (cis) as first-line treatments in metastatic breast cancer (MBC) after anthracycline failure","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Metastatic breast cancer; Interim analysis; Internal medicine; Carboplatin; Gemcitabine; Anthracycline; Breast cancer; Phases of clinical research; Surgery; Performance status; Chemotherapy; Oncology; Urology; Cancer; Randomized controlled trial; Gastroenterology; Cisplatin","score_opus":0.09059287299246062,"score_gpt":0.5155515087569532,"score_spread":0.4249586357644926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597223639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98404956,0.0028142359,0.00007634363,0.009640361,0.0009981575,0.0020028544,0.000084924126,0.000014983033,0.00031858997],"genre_scores_gemma":[0.9922102,0.0033531126,0.0015705072,0.0010502622,0.0010292698,0.00009645179,0.000016860486,0.000051708306,0.00062161736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99163806,0.0010585121,0.005525913,0.0005364032,0.00064612087,0.000595013],"domain_scores_gemma":[0.9891904,0.0061301943,0.0031487958,0.00032155952,0.0005359807,0.0006730451],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0063300417,0.0005159233,0.005292076,0.0006628984,0.00008629977,0.000011935303,0.00018962371,0.00042039168,0.0013873888],"category_scores_gemma":[0.0014757706,0.0003504001,0.00074348436,0.0005138485,0.00055568496,0.0002420939,0.00014039206,0.0012094023,0.0000068435925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7342618,0.061567247,0.10182502,0.00012866045,0.0055462955,0.005908987,0.0018486015,0.000068413574,0.000784821,0.000011657004,0.0007901361,0.08725835],"study_design_scores_gemma":[0.7625472,0.07442766,0.15033181,0.00029773053,0.0078345435,0.0008566406,0.0007114634,0.0003991197,0.00012462572,0.00023717126,0.0019453826,0.0002866741],"about_ca_topic_score_codex":0.0012388753,"about_ca_topic_score_gemma":0.005645954,"teacher_disagreement_score":0.08697168,"about_ca_system_score_codex":0.00038571662,"about_ca_system_score_gemma":0.00084966514,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W2597233393","doi":"10.1200/jco.2012.30.15_suppl.e13604","title":"MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Docetaxel; Medicine; Pharmacodynamics; Pharmacokinetics; Internal medicine; Pharmacology; Tolerability; Tyrosine-kinase inhibitor; Adverse effect; Gastroenterology; Urology; Oncology; Chemotherapy; Cancer","score_opus":0.09008837123463677,"score_gpt":0.43806726456931677,"score_spread":0.34797889333468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597233393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931949,0.00279983,0.000009510611,0.0029111903,0.0005239057,0.00017634346,0.0000034323446,0.0000031577733,0.00037775084],"genre_scores_gemma":[0.9929495,0.00071221555,0.005723483,0.0002493561,0.00028977974,0.000004748135,0.0000022382253,0.000007884551,0.00006078059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832934,0.00017833048,0.0010479148,0.00008988286,0.0001978829,0.00015664737],"domain_scores_gemma":[0.9980807,0.00062214,0.0007450621,0.000063207415,0.00030420156,0.00018473022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013257326,0.000096976226,0.0010766957,0.0000862621,0.000018532603,0.000002272329,0.000033641547,0.00014072248,0.000050207273],"category_scores_gemma":[0.001263985,0.0000576807,0.00010728768,0.00014180173,0.00018118345,0.00012299104,0.000029203347,0.0003707562,0.0000016615868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013004744,0.00531844,0.8762486,0.000053770094,0.00038249977,0.000084261366,0.0005131709,0.0000010937649,0.00087389804,0.000106208325,0.0010613538,0.10235195],"study_design_scores_gemma":[0.022978239,0.03375248,0.92793274,0.00019150364,0.00033186623,0.0000795144,0.00032912032,0.000019427815,0.00070737273,0.000050151662,0.013554734,0.000072841336],"about_ca_topic_score_codex":0.000046001023,"about_ca_topic_score_gemma":0.00011948298,"teacher_disagreement_score":0.10227911,"about_ca_system_score_codex":0.000118182084,"about_ca_system_score_gemma":0.00023317224,"threshold_uncertainty_score":0.23521507},"labels":[],"label_agreement":null},{"id":"W2597256494","doi":"10.1200/jco.2007.25.18_suppl.21178","title":"A novel case of Silver Russell Syndrome (SRS) and male breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic Syndromes and Imprinting","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Breast cancer; Cancer; Biopsy; Oncology; Pathology; Internal medicine","score_opus":0.046802345447217196,"score_gpt":0.40222441366332434,"score_spread":0.35542206821610717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597256494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962542,0.00086805155,0.0010931765,0.00042418644,0.0005603471,0.00005894871,0.000011216425,0.0000010035534,0.00072886725],"genre_scores_gemma":[0.9925926,0.00062341715,0.00570507,0.0003637181,0.000418843,5.5951654e-7,6.9064095e-7,0.000011797066,0.00028332046],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981354,0.00006603164,0.0013134206,0.00016814073,0.00010853102,0.00020850725],"domain_scores_gemma":[0.9981804,0.00020029576,0.0010024927,0.00014240421,0.000250577,0.00022384267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021623971,0.000101379126,0.00056958024,0.000052972373,0.000026379868,0.000004925356,0.00012894216,0.00033214872,0.00011271823],"category_scores_gemma":[0.00036853243,0.000081419064,0.00022065055,0.00006027478,0.00017497667,0.000004652213,0.00010863393,0.00025931373,0.0000014089708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091674173,0.0016173887,0.34558082,0.00010465539,0.00068460737,0.0034839672,0.00010497626,0.00006822475,0.3629683,0.00009015269,0.0015334055,0.28284675],"study_design_scores_gemma":[0.003396523,0.0042298576,0.80122566,0.000048062586,0.00015178716,0.17207675,0.0002312899,0.000031141284,0.0026518863,0.00003295174,0.015767522,0.0001565539],"about_ca_topic_score_codex":0.00009066045,"about_ca_topic_score_gemma":0.00011729661,"teacher_disagreement_score":0.45564485,"about_ca_system_score_codex":0.000013168829,"about_ca_system_score_gemma":0.0003315647,"threshold_uncertainty_score":0.3320173},"labels":[],"label_agreement":null},{"id":"W2597259535","doi":"10.1200/jco.2009.27.15_suppl.e20528","title":"Single- versus multiple-item assessment of quality of life in patients with advanced cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Spearman's rank correlation coefficient; Correlation; Palliative care; Cancer; Physical therapy; Internal medicine; Statistics; Nursing","score_opus":0.1712967563599531,"score_gpt":0.5217193562319288,"score_spread":0.35042259987197566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597259535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554664,0.0002459678,0.000052569943,0.0016809233,0.0011198805,0.00015689131,0.000008261558,0.0000026409386,0.0011862027],"genre_scores_gemma":[0.99738795,0.00013455225,0.0014120492,0.0008326816,0.00020983507,0.0000015585977,0.000002258441,0.0000067837077,0.000012353524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643373,0.00034353993,0.0024467176,0.00012866927,0.00050007855,0.00014725522],"domain_scores_gemma":[0.9941151,0.002234793,0.0024875484,0.00016283842,0.0007832171,0.00021648222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015508692,0.00009810556,0.0016515824,0.00009647661,0.000007647918,0.0000013609639,0.0001070385,0.00019532656,0.00005184745],"category_scores_gemma":[0.0030919274,0.00006782865,0.0002534955,0.00017477649,0.00011444641,0.00007516184,0.000016327096,0.00055277586,1.8768336e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032025497,0.002827973,0.82829463,0.00004548057,0.00013028631,0.000011370023,0.00009918253,0.00007477773,0.00012125839,0.00002897676,0.00005206823,0.1362885],"study_design_scores_gemma":[0.030911269,0.031029107,0.9361143,0.00021093564,0.00010433567,6.965744e-7,0.00019294086,0.000021314681,0.000055315366,0.000017064298,0.0012814853,0.0000612536],"about_ca_topic_score_codex":0.00019070333,"about_ca_topic_score_gemma":0.0021715667,"teacher_disagreement_score":0.13622724,"about_ca_system_score_codex":0.0002443165,"about_ca_system_score_gemma":0.0016213902,"threshold_uncertainty_score":0.37015492},"labels":[],"label_agreement":null},{"id":"W2597260458","doi":"10.1200/jco.2006.24.18_suppl.1005","title":"Detection of colorectal neoplasia associated K-Ras mutations in human urine","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Urine; Colorectal cancer; Molecular biology; Urinary system; Medicine; Cancer; Amplicon; DNA; Biology; Polymerase chain reaction; Gene; Internal medicine; Genetics","score_opus":0.06052792296127009,"score_gpt":0.43920077754887676,"score_spread":0.3786728545876067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597260458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918789,0.00022671794,0.000016744903,0.0008687,0.00044338897,0.00017185353,0.0000030235633,0.0000060014286,0.006384627],"genre_scores_gemma":[0.9991068,0.000066281085,0.0002499808,0.00007826172,0.0002729266,0.0000069243733,0.000003984776,0.000007144517,0.00020765544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977022,0.0001738713,0.0016995462,0.000096279444,0.00019714229,0.00013095723],"domain_scores_gemma":[0.99750614,0.0008508483,0.001182689,0.00005057665,0.00033803747,0.00007172219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092193484,0.00008328186,0.0010172769,0.00015239272,0.00003787318,0.000002382479,0.000044276894,0.00019805177,0.000049029346],"category_scores_gemma":[0.0013068068,0.00006159716,0.0002836399,0.00020859533,0.00014443629,0.000046393707,0.000018943723,0.00041725312,0.0000017776822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003857001,0.0058539757,0.9320492,0.000018892997,0.00056111964,0.00061105366,0.00015685475,0.00009031343,0.0072354777,0.00009857227,0.0005488662,0.048918642],"study_design_scores_gemma":[0.008055839,0.015298762,0.9722467,0.00004507175,0.0002689486,0.000089827976,0.000084177205,0.00004277519,0.0010417916,0.00070133177,0.0020797644,0.000045020304],"about_ca_topic_score_codex":0.00030517037,"about_ca_topic_score_gemma":0.0053219926,"teacher_disagreement_score":0.048873622,"about_ca_system_score_codex":0.00030297867,"about_ca_system_score_gemma":0.00039516232,"threshold_uncertainty_score":0.29697967},"labels":[],"label_agreement":null},{"id":"W2597266194","doi":"10.1200/jco.2013.31.15_suppl.2546","title":"Effects of gefitinib and vandetanib on human equilibrative nucleoside transporter 1 and on gemcitabine cytotoxicity.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Vandetanib; Gemcitabine; Gefitinib; Pharmacology; Medicine; Cytidine; Tyrosine kinase; Tyrosine-kinase inhibitor; Nucleoside; Cancer research; Epidermal growth factor receptor; Chemistry; Internal medicine; Biochemistry; Cancer; Receptor; Enzyme","score_opus":0.04916109599232144,"score_gpt":0.38953187917297083,"score_spread":0.3403707831806494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597266194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971011,0.0006008086,0.00012519308,0.00067128794,0.0001224368,0.0001479161,0.0000021188546,0.0000019376946,0.0012271799],"genre_scores_gemma":[0.9970999,0.00035729728,0.0004705159,0.0014122794,0.0005368253,0.0000031354375,0.000002384149,0.000012653129,0.00010505424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99843276,0.00020771475,0.00091596507,0.00018104908,0.00012366577,0.00013887727],"domain_scores_gemma":[0.99831414,0.0006520408,0.0006467108,0.00009673822,0.000121966914,0.00016841636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000530234,0.00012858708,0.0006143091,0.000049038415,0.00003247449,0.000007592502,0.00009970433,0.00029082297,0.000046323115],"category_scores_gemma":[0.00041177985,0.00009115856,0.0001543565,0.00003047461,0.00019356214,0.000010183386,0.000032994554,0.00031920924,0.0000018474545],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025888886,0.0015346167,0.01961345,0.000117458956,0.0005477395,0.0001706613,0.00017875829,0.00003485596,0.9506404,0.0010461947,0.008394334,0.015132658],"study_design_scores_gemma":[0.014921386,0.0780922,0.5457482,0.00029546313,0.00033132642,0.00016660485,0.00015152579,0.000053933596,0.34803927,0.002857935,0.00890287,0.00043927645],"about_ca_topic_score_codex":0.0000067357105,"about_ca_topic_score_gemma":0.0000029654436,"teacher_disagreement_score":0.6026011,"about_ca_system_score_codex":0.0000056151375,"about_ca_system_score_gemma":0.00007539212,"threshold_uncertainty_score":0.3717338},"labels":[],"label_agreement":null},{"id":"W2597269601","doi":"10.1200/jco.2016.70.7901","title":"New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Mantle cell lymphoma; Medicine; Concordance; Lymphoma; Vincristine; Gene expression profiling; Oncology; Pathology; Biopsy; Cancer research; Internal medicine; Cyclophosphamide; Gene expression; Chemotherapy; Biology; Gene","score_opus":0.07130655620119355,"score_gpt":0.4386988255223168,"score_spread":0.36739226932112323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597269601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90481895,0.0013083348,0.008486452,0.079231344,0.0013752405,0.0019229451,0.0000073856568,0.000012144181,0.002837211],"genre_scores_gemma":[0.97863686,0.0002178472,0.01568483,0.0039982013,0.00084000884,0.000068687616,0.0000030702051,0.000015562035,0.0005349364],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979472,0.000120041805,0.0012338897,0.00018563519,0.00025969435,0.0002535467],"domain_scores_gemma":[0.9963455,0.0016180614,0.0011132114,0.00037609454,0.00023942406,0.00030771448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002189986,0.00014421361,0.0009219484,0.000071323775,0.00012874887,0.00005151079,0.00029635537,0.00036169088,0.000025683445],"category_scores_gemma":[0.0018935045,0.000080523496,0.0004034832,0.000056757803,0.0000582448,0.00011328056,0.00006575902,0.00023488316,0.000020656633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014419458,0.008594385,0.08494603,0.00010198402,0.00085089944,0.0013676449,0.00044324537,0.0006442033,0.0055317334,0.003555764,0.0703938,0.8091509],"study_design_scores_gemma":[0.07504993,0.020343078,0.48412368,0.00025808578,0.0013167356,0.00035123146,0.00025296406,0.0021122866,0.058718257,0.002877558,0.3542354,0.00036079332],"about_ca_topic_score_codex":0.00004208934,"about_ca_topic_score_gemma":0.00008948623,"teacher_disagreement_score":0.8087901,"about_ca_system_score_codex":0.00017081792,"about_ca_system_score_gemma":0.0012934883,"threshold_uncertainty_score":0.3283653},"labels":[],"label_agreement":null},{"id":"W2597308635","doi":"10.1200/jco.2009.27.15_suppl.10007","title":"Expression of CD133 and poor outcome in neuroblastoma associated with chemoresistance mediated by AKT pathway","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Neuroblastoma; Medicine; Oncology; Vincristine; Stage (stratigraphy); Cisplatin; Population; Internal medicine; Univariate analysis; Chemotherapy; Cancer research; Multivariate analysis; Cyclophosphamide; Cell culture; Biology","score_opus":0.06811724481356199,"score_gpt":0.4244851194950184,"score_spread":0.35636787468145636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597308635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526685,0.00017026528,0.000008170277,0.0037726015,0.00007252265,0.00016356543,0.0000088353045,0.0000070647443,0.0005300934],"genre_scores_gemma":[0.9980083,0.00015184264,0.00041194755,0.0011538279,0.000055145847,0.0000013773653,0.0000037782265,0.00001140618,0.00020233897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970889,0.00039762424,0.0016000435,0.00018189696,0.00047779447,0.0002537284],"domain_scores_gemma":[0.99599564,0.0019826028,0.0012354826,0.000120153316,0.00025688185,0.00040923172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012076364,0.00013302798,0.0012856426,0.00014142362,0.000018370783,0.0000044837698,0.00010581849,0.0002280747,0.000025216503],"category_scores_gemma":[0.005785414,0.00008173054,0.0001372812,0.00020875287,0.0001788093,0.00009511027,0.000025284244,0.00079981424,0.000002136328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051007323,0.014706626,0.6909049,0.00007072933,0.00031867548,0.011332183,0.00010420004,0.0000050754325,0.17875896,0.000019015753,0.006670123,0.046102192],"study_design_scores_gemma":[0.019950902,0.033428054,0.9317619,0.00029295418,0.000068204055,0.0001619692,0.000021626793,0.000027440892,0.01313703,0.00006333992,0.0010121271,0.000074436866],"about_ca_topic_score_codex":0.0000037777513,"about_ca_topic_score_gemma":0.000027000751,"teacher_disagreement_score":0.24085702,"about_ca_system_score_codex":0.00007929132,"about_ca_system_score_gemma":0.00047180883,"threshold_uncertainty_score":0.69260985},"labels":[],"label_agreement":null},{"id":"W2597345820","doi":"10.1200/jco.2013.31.15_suppl.e19066","title":"Survival versus intrinsic and acquired resistance in advanced non-small cell lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Gastroenterology; Internal medicine; Nuclear medicine; Tumor progression; Cancer","score_opus":0.03543982923533742,"score_gpt":0.37754573225170074,"score_spread":0.34210590301636334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597345820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883358,0.0056482176,0.00009482715,0.0011674252,0.0021008002,0.0001605809,0.0000055929027,0.0000012982485,0.002485464],"genre_scores_gemma":[0.98338795,0.011795588,0.0030751794,0.00054393336,0.00094225473,0.000012605789,0.000002881833,0.0000149717725,0.00022463914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829745,0.00012839891,0.0010414021,0.00021721987,0.00009464133,0.00022088006],"domain_scores_gemma":[0.9980603,0.000623701,0.0007145443,0.0001637658,0.0002359131,0.00020176522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000761022,0.000118969125,0.00057229295,0.00004543628,0.00002461965,0.0000152041075,0.00019731229,0.00029598075,0.000026636126],"category_scores_gemma":[0.0010455252,0.0001059464,0.00013448294,0.00006732796,0.00010992802,0.00000815688,0.00011515784,0.0002464981,0.0000025240352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021537721,0.0019128512,0.46870103,0.00022272654,0.0005685215,0.00031717375,0.00033955285,0.0007226804,0.0829354,0.00034857812,0.039769962,0.3826238],"study_design_scores_gemma":[0.029090399,0.008071009,0.7669873,0.00011689225,0.00016912304,0.000012195633,0.00031555895,0.00013216397,0.0053019077,0.00046463747,0.18884109,0.00049769116],"about_ca_topic_score_codex":0.00007879758,"about_ca_topic_score_gemma":0.002298029,"teacher_disagreement_score":0.38212612,"about_ca_system_score_codex":0.000065633016,"about_ca_system_score_gemma":0.000878116,"threshold_uncertainty_score":0.43203688},"labels":[],"label_agreement":null},{"id":"W2597369096","doi":"10.1200/jco.2007.25.18_suppl.4076","title":"Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients &gt;65 years compared with those ≤65: The BICC-C study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; FOLFIRI; Irinotecan; Bevacizumab; Internal medicine; Regimen; Placebo; Surgery; Gastroenterology; Colorectal cancer; Chemotherapy; Cancer","score_opus":0.07233552466216654,"score_gpt":0.4737691966828702,"score_spread":0.4014336720207037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597369096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467933,0.000194114,0.00012976048,0.0028575286,0.00028578067,0.00062009116,0.0000071840627,0.000004447353,0.0012217861],"genre_scores_gemma":[0.99857086,0.00023511543,0.00066532684,0.0002837656,0.00012605725,0.0000030049189,0.0000057752172,0.00001096626,0.000099106845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975731,0.00018415008,0.0016346704,0.0001335326,0.0003183854,0.00015616055],"domain_scores_gemma":[0.9959436,0.0023225439,0.0009667449,0.00017149486,0.0004242794,0.00017131455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018519082,0.00010353725,0.00085052714,0.00014609286,0.000055179706,0.00000456485,0.00010392602,0.0001037402,0.000034188724],"category_scores_gemma":[0.001007625,0.000057655434,0.00011005251,0.00025942113,0.00021703403,0.00005784971,0.00003970568,0.0004557029,0.000001534882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007091207,0.021008477,0.87441194,0.000012856006,0.00054116984,0.00021584032,0.0013146643,0.0001225435,0.0000033486212,0.0000927587,0.00023743384,0.09494775],"study_design_scores_gemma":[0.039594393,0.020505385,0.93001974,0.00009655506,0.0005828698,0.000028509518,0.0004929129,0.000045672805,0.000004540748,0.00004538643,0.008533091,0.000050959843],"about_ca_topic_score_codex":0.00009589669,"about_ca_topic_score_gemma":0.0011299079,"teacher_disagreement_score":0.094896786,"about_ca_system_score_codex":0.00015652488,"about_ca_system_score_gemma":0.00042831947,"threshold_uncertainty_score":0.23511203},"labels":[],"label_agreement":null},{"id":"W2597369162","doi":"10.1200/jco.2013.31.15_suppl.9046","title":"Open-label, multicenter safety study of vemurafenib in patients with <i>BRAF<sup>V600</sup></i> mutation–positive metastatic melanoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Vemurafenib; Rash; Internal medicine; Adverse effect; Metastatic melanoma; Population; Melanoma; Oncology; Surgery; Gastroenterology; Cancer; Cancer research","score_opus":0.05019999233793844,"score_gpt":0.37571206789341166,"score_spread":0.32551207555547323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597369162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973546,0.0000651768,0.00011134613,0.00023895761,0.00022888469,0.0009764396,0.000017718628,0.0000016796272,0.0010051938],"genre_scores_gemma":[0.9958709,0.000029922605,0.0031509215,0.00062779296,0.0001383563,0.000020969588,0.000032194264,0.000020576372,0.00010837651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960971,0.0009445378,0.002126321,0.00029769534,0.000289995,0.00024436467],"domain_scores_gemma":[0.99671817,0.00047836278,0.0015989229,0.00026951692,0.0007266013,0.000208434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013697554,0.00018857158,0.0010380911,0.00008968043,0.000039692393,0.00002104863,0.00051471405,0.0002029685,0.00006728877],"category_scores_gemma":[0.000774519,0.00013089398,0.000105664134,0.00012028784,0.000131337,0.000041166146,0.00023444681,0.00039832256,0.000013994663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018599605,0.042057462,0.8698488,0.000044867767,0.0019194977,0.00034322715,0.0015322323,0.0007141401,0.0020808019,0.000060959235,0.0020168999,0.060781535],"study_design_scores_gemma":[0.060257792,0.080819175,0.8525517,0.00007066781,0.00028616533,0.000033799763,0.0011909152,0.00015641536,0.0007510906,0.000061792314,0.00355413,0.00026637514],"about_ca_topic_score_codex":0.0001013796,"about_ca_topic_score_gemma":0.00017292847,"teacher_disagreement_score":0.060515158,"about_ca_system_score_codex":0.00003785978,"about_ca_system_score_gemma":0.00045085658,"threshold_uncertainty_score":0.5337702},"labels":[],"label_agreement":null},{"id":"W2597397084","doi":"10.1200/jco.2013.31.15_suppl.e22020","title":"Practical application of whole genome and transcriptome tumour analysis to guide chemotherapy decision-making for patients with advanced cancers.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Cancer; Amplicon; Crizotinib; Lung cancer; Internal medicine; Transcriptome; Colorectal cancer; Bioinformatics; Gene; Biology; Gene expression; Genetics","score_opus":0.020843503637799108,"score_gpt":0.4093971434680795,"score_spread":0.38855363983028035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597397084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86192876,0.00012793849,0.13624021,0.0011939615,0.0001005199,0.0003274449,0.000027953689,8.8058755e-7,0.000052306314],"genre_scores_gemma":[0.8903951,0.0003325828,0.107771896,0.0012379984,0.00020855421,0.000021988475,0.000010766102,0.000011654714,0.000009476973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851424,0.000040059214,0.0009807396,0.00019890869,0.00013113552,0.0001349332],"domain_scores_gemma":[0.9975539,0.00060950883,0.0008239236,0.00015104997,0.0006989293,0.00016268673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053440634,0.000092189446,0.00057237985,0.00007701311,0.000024555025,0.000007860471,0.00012351,0.00015148889,0.000010350536],"category_scores_gemma":[0.0011622865,0.00007046397,0.00019339906,0.00012366383,0.00006789491,0.000009881394,0.000026004676,0.00010785409,7.973817e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013199758,0.0018116091,0.1397944,0.000041038875,0.0024151944,0.000005274109,0.0001798733,0.0054689376,0.12240721,0.00011833003,0.005465478,0.7090929],"study_design_scores_gemma":[0.007906117,0.019705324,0.7168515,0.000029398116,0.0008125767,0.00000941314,0.00013189924,0.0006047229,0.00092311663,0.0004883193,0.2522754,0.00026220348],"about_ca_topic_score_codex":0.000018326436,"about_ca_topic_score_gemma":0.00010724195,"teacher_disagreement_score":0.7088307,"about_ca_system_score_codex":0.000053763557,"about_ca_system_score_gemma":0.0004558134,"threshold_uncertainty_score":0.2873437},"labels":[],"label_agreement":null},{"id":"W2597411510","doi":"10.1200/jco.2015.33.15_suppl.6020","title":"Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (−) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Stage (stratigraphy); Head and neck cancer; Radiation therapy","score_opus":0.1386178202417946,"score_gpt":0.4594465956711609,"score_spread":0.32082877542936633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597411510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380904,0.0013140615,0.0000049172795,0.0011163291,0.00061123294,0.0002586112,0.000009251572,0.00001220003,0.0028643664],"genre_scores_gemma":[0.99843025,0.00036089995,0.00024288622,0.00043741977,0.00030944525,0.0000018961815,0.000005894193,0.000023512883,0.00018776373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996491,0.00031094343,0.0021992254,0.00029183697,0.00039642275,0.0003105339],"domain_scores_gemma":[0.9956247,0.0011079566,0.0015426785,0.00019923449,0.00074998953,0.000775434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010383055,0.00026689834,0.0024773087,0.00017052334,0.000073496674,0.00000715098,0.000105612606,0.00050366536,0.0000918108],"category_scores_gemma":[0.0015839456,0.00017680359,0.00043399647,0.00013682469,0.00051524147,0.00009105307,0.00010834937,0.0012918197,0.000004866476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0527282,0.004439834,0.849172,0.00013118563,0.0007271429,0.0017866358,0.0013233332,0.000041167175,0.0074053565,0.00009540809,0.0060408297,0.076108925],"study_design_scores_gemma":[0.033301312,0.06468722,0.89951456,0.00012442961,0.00038960294,0.00039619816,0.00011940218,0.00012483579,0.0002324409,0.00030108276,0.0006614618,0.00014743372],"about_ca_topic_score_codex":0.00014374823,"about_ca_topic_score_gemma":0.000065871296,"teacher_disagreement_score":0.07596149,"about_ca_system_score_codex":0.00020158748,"about_ca_system_score_gemma":0.00090185873,"threshold_uncertainty_score":0.7209841},"labels":[],"label_agreement":null},{"id":"W2597425187","doi":"10.1200/jco.2013.31.15_suppl.tps4594","title":"A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Cancer Care Ontario; Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Ozmosis Research (Canada); Lakeridge Health; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Toxicity; Sunitinib; Internal medicine; Phases of clinical research; Urology; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.17033965749960592,"score_gpt":0.48658810486254805,"score_spread":0.3162484473629421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597425187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939562,0.0003465195,0.000016363008,0.0030908037,0.0002523954,0.0021534387,0.000026276812,0.000002774927,0.00015521196],"genre_scores_gemma":[0.99643636,0.00045643,0.0020316653,0.00066533673,0.00022758909,0.000043550837,0.0000039336132,0.000019811721,0.00011534977],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962155,0.00080830697,0.00219333,0.00019568397,0.00040216852,0.00018497708],"domain_scores_gemma":[0.99283177,0.0036686445,0.0023326906,0.00028892362,0.00060444785,0.00027352353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019063501,0.0001740486,0.0015283764,0.00010165991,0.000076382756,0.000005253474,0.00020230439,0.00012859487,0.00023257257],"category_scores_gemma":[0.0012906053,0.00009071892,0.00035022022,0.00010319145,0.00021438736,0.0000751638,0.00006199191,0.00047488033,0.0000013054845],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22607736,0.3150481,0.06412298,0.00030857738,0.006125006,0.00023099374,0.009994343,0.00034871532,0.012373489,0.000040504354,0.0014854766,0.36384445],"study_design_scores_gemma":[0.2661724,0.45325735,0.26159212,0.00026052803,0.0018882162,0.0000419594,0.0012427464,0.00026889116,0.010578804,0.00010266203,0.004471649,0.00012267314],"about_ca_topic_score_codex":0.00012859433,"about_ca_topic_score_gemma":0.00008101331,"teacher_disagreement_score":0.3637218,"about_ca_system_score_codex":0.00007053015,"about_ca_system_score_gemma":0.0005745248,"threshold_uncertainty_score":0.369941},"labels":[],"label_agreement":null},{"id":"W2597431707","doi":"10.1200/jco.2012.30.15_suppl.3027","title":"Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Neutropenia; Febrile neutropenia; Adverse effect; Internal medicine; Leukopenia; Pharmacology; Oncology; Toxicity; Gastroenterology","score_opus":0.06951995384007696,"score_gpt":0.45923291073914174,"score_spread":0.38971295689906477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597431707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675907,0.00017597975,0.0002162142,0.008966163,0.0008132068,0.0029319767,0.000019114987,0.0000082745155,0.000109977875],"genre_scores_gemma":[0.9974597,0.00006958717,0.000645302,0.0010400721,0.0005327633,0.00009547573,0.000049550836,0.000042462023,0.00006508586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99208784,0.0025217428,0.0028889363,0.0002885836,0.0016904668,0.00052240724],"domain_scores_gemma":[0.99260324,0.0027568978,0.002618257,0.00048391125,0.0012801649,0.000257553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060578506,0.00028329183,0.0015321526,0.00028570453,0.00014908468,0.00003499997,0.0005381301,0.00028145133,0.00011147705],"category_scores_gemma":[0.005063606,0.00011692585,0.0002735905,0.00094048656,0.0007493527,0.00042184963,0.00013686705,0.0019431501,0.000004500702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63984305,0.076372795,0.24977173,0.00020831198,0.00093620055,0.00047797104,0.0027336897,0.00037229335,0.004012206,0.00066047464,0.002315678,0.02229563],"study_design_scores_gemma":[0.48995855,0.07261138,0.430179,0.00070415233,0.00031530377,0.000106522595,0.00060212635,0.00062620983,0.0007886547,0.00016232478,0.0036692603,0.00027651543],"about_ca_topic_score_codex":0.000031773296,"about_ca_topic_score_gemma":0.0001570302,"teacher_disagreement_score":0.18040726,"about_ca_system_score_codex":0.00048245693,"about_ca_system_score_gemma":0.003665246,"threshold_uncertainty_score":0.84421283},"labels":[],"label_agreement":null},{"id":"W2597439582","doi":"10.1200/jco.2012.30.15_suppl.5022","title":"Use of chemotherapy (CT) in <i>BRCA1/2</i>-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Taxane; Internal medicine; Oncology; Proportional hazards model; Population; PARP inhibitor; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Gastroenterology; Cancer; Surgery; Phases of clinical research; Breast cancer; Poly ADP ribose polymerase","score_opus":0.14114276139837664,"score_gpt":0.4457801977001478,"score_spread":0.3046374363017712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597439582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910608,0.0020960947,0.0002470245,0.0033816006,0.0021355308,0.00078154186,0.000060033035,0.00001374539,0.00022365683],"genre_scores_gemma":[0.98894125,0.0005315482,0.005023542,0.0033592586,0.00182875,0.00004330129,0.000007089882,0.000040991974,0.000224288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942671,0.0006324098,0.003251414,0.00033098474,0.0009984792,0.00051958166],"domain_scores_gemma":[0.9947809,0.00096473226,0.0025210795,0.00036888637,0.00078337686,0.0005809991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021449926,0.0003142745,0.0018696946,0.00034870775,0.00007508281,0.000012134812,0.00020390039,0.00025496518,0.00033831227],"category_scores_gemma":[0.00083370093,0.00021707935,0.00038231927,0.000500482,0.00053507497,0.00045409685,0.000045645356,0.0011469611,0.000007721057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030194206,0.02905584,0.8967087,0.000052086656,0.0006006905,0.00030036017,0.0008392211,0.000072423456,0.000634995,0.000095971765,0.0035996872,0.037845783],"study_design_scores_gemma":[0.06200561,0.007495388,0.83332825,0.00058927934,0.00026342826,0.0001014865,0.00027157448,0.000026405265,0.0016240306,0.000013079989,0.09402387,0.00025760077],"about_ca_topic_score_codex":0.0002974667,"about_ca_topic_score_gemma":0.00051752414,"teacher_disagreement_score":0.09042418,"about_ca_system_score_codex":0.0008051831,"about_ca_system_score_gemma":0.0025959846,"threshold_uncertainty_score":0.88522387},"labels":[],"label_agreement":null},{"id":"W2597463500","doi":"10.1200/jco.2012.30.15_suppl.4535","title":"Large retroperitoneal lymph nodes (RPLN) as a novel risk factor for venous thromboembolism (VTE) in germ cell tumor (GCT) patients (pts) receiving first-line chemotherapy (chemo).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre; University of Toronto; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Venous thromboembolism; Internal medicine; Cancer; Retrospective cohort study; Incidence (geometry); Surgery; Thrombosis","score_opus":0.06538234753893979,"score_gpt":0.4057966986002745,"score_spread":0.3404143510613347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597463500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430645,0.0007065123,0.00011724753,0.0014916948,0.0018629322,0.00060709525,0.000101371326,0.00001547105,0.00079124636],"genre_scores_gemma":[0.98883486,0.0019971076,0.0036424468,0.0031013202,0.0022391106,0.000029562481,0.000011407438,0.0000594697,0.00008472859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957869,0.00022291776,0.0025114303,0.00031423266,0.0004575856,0.0007069049],"domain_scores_gemma":[0.9936014,0.0026860407,0.002382124,0.00028866285,0.00042886546,0.00061295356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022321218,0.00031653763,0.0023815385,0.00015334415,0.0001062363,0.000017813412,0.00021030597,0.0004899945,0.00027221986],"category_scores_gemma":[0.0037911024,0.000219996,0.0007694596,0.00014991844,0.000104195606,0.0002187587,0.000068603695,0.0006004417,0.00004199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034341982,0.041098528,0.874789,0.0000782011,0.0003918221,0.00009325067,0.0009636044,0.0000039737697,0.00015037261,0.000022431022,0.00056758896,0.07840703],"study_design_scores_gemma":[0.045435697,0.008915343,0.912907,0.00017963405,0.00038273513,0.00011579411,0.000116251846,0.00008101092,0.0011587047,0.000059231017,0.03044998,0.00019859304],"about_ca_topic_score_codex":0.00010157361,"about_ca_topic_score_gemma":0.000051178722,"teacher_disagreement_score":0.07820844,"about_ca_system_score_codex":0.0008992443,"about_ca_system_score_gemma":0.0009832522,"threshold_uncertainty_score":0.8971176},"labels":[],"label_agreement":null},{"id":"W2597472111","doi":"10.1200/jco.2012.30.15_suppl.524","title":"Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Queen's University","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Hazard ratio; Breast cancer; Oncology; Placebo; Proportional hazards model; Tamoxifen; Cancer; Confidence interval; Pathology","score_opus":0.04552238003045397,"score_gpt":0.42183939020238753,"score_spread":0.3763170101719336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597472111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924261,0.0057716626,0.000051138493,0.00076705625,0.0004603068,0.00010892828,0.000006562199,0.000004644889,0.00040362778],"genre_scores_gemma":[0.99458116,0.0027458912,0.00069852377,0.00084274216,0.00085930026,0.0000030482954,0.000011288787,0.000017313554,0.00024072856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981104,0.00048028206,0.00071500073,0.00019851103,0.00023932417,0.00025644363],"domain_scores_gemma":[0.9978266,0.0006739185,0.0009513432,0.00014483284,0.00011604791,0.00028728554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00131699,0.00017596257,0.00074389443,0.00005540116,0.000055958404,0.000015140557,0.00010104997,0.0005870345,0.000018128741],"category_scores_gemma":[0.0006470557,0.00010474553,0.000262449,0.000047849488,0.00011636836,0.00001724626,0.00004814736,0.00052902964,0.0000039394677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002940353,0.0013113462,0.84615123,0.000007652692,0.0028090605,0.000044355405,0.00006927179,0.000010614537,0.046335228,0.000023824614,0.0017528468,0.098544225],"study_design_scores_gemma":[0.0061319396,0.013873482,0.95504165,0.000024824732,0.00042490795,0.00005554112,0.000056000492,0.000017165457,0.005834858,0.000049035403,0.018297873,0.00019271679],"about_ca_topic_score_codex":0.0000124714825,"about_ca_topic_score_gemma":0.0000073323604,"teacher_disagreement_score":0.10889044,"about_ca_system_score_codex":0.000040383,"about_ca_system_score_gemma":0.000153849,"threshold_uncertainty_score":0.45277476},"labels":[],"label_agreement":null},{"id":"W2597498551","doi":"10.1200/jco.2012.30.15_suppl.e15540","title":"Small cell carcinoma of the female genital tract: A single institution experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Chemotherapy; Small-cell carcinoma; Cancer; Radiation therapy; Surgery; Stage (stratigraphy); Cervix; Cohort; Internal medicine; Gynecology","score_opus":0.12733779721982766,"score_gpt":0.38946454493248106,"score_spread":0.26212674771265343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597498551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934405,0.0012956985,0.00047261445,0.00013059223,0.0014741147,0.000052044874,0.0000020954178,0.0000010290189,0.0031313216],"genre_scores_gemma":[0.9970894,0.00007311725,0.0011552805,0.0002906475,0.0012229804,0.0000014002377,8.967333e-7,0.0000063145294,0.00015998608],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856937,0.00016391692,0.0009029036,0.0000863936,0.00012615781,0.00015127494],"domain_scores_gemma":[0.9986015,0.00008151392,0.0008757859,0.0001664649,0.00015813975,0.00011662732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085328874,0.00007308529,0.0003100825,0.000016551312,0.00003488485,0.0000033261583,0.00021159675,0.0002583741,0.00001971567],"category_scores_gemma":[0.0005769598,0.000046558438,0.00034156188,0.00004524049,0.00018206247,0.0000071116538,0.00006464767,0.00023456606,0.0000018973241],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067696755,0.0038128127,0.49168164,0.00004177935,0.00006583316,0.000011708935,0.0010295965,0.0002792692,0.4529257,0.000047504178,0.0011212742,0.048305914],"study_design_scores_gemma":[0.0045080334,0.0071607884,0.41050625,0.000044975142,0.00019346185,0.0004469615,0.001224343,0.00010784421,0.46470445,0.0000616364,0.11078021,0.00026105272],"about_ca_topic_score_codex":0.000010570227,"about_ca_topic_score_gemma":0.0000105499175,"teacher_disagreement_score":0.109658934,"about_ca_system_score_codex":0.000029056222,"about_ca_system_score_gemma":0.0005030979,"threshold_uncertainty_score":0.19928177},"labels":[],"label_agreement":null},{"id":"W2597509495","doi":"10.1200/jco.2012.30.15_suppl.4113","title":"SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Sorafenib; Erlotinib; Gallbladder cancer; Clinical endpoint; Gastroenterology; Oncology; Progressive disease; Gallbladder; Phases of clinical research; Cancer; Progression-free survival; Performance status; Surgery; Epidermal growth factor receptor; Toxicity; Chemotherapy; Clinical trial; Hepatocellular carcinoma","score_opus":0.11930459616539715,"score_gpt":0.4677784698520907,"score_spread":0.3484738736866936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597509495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473125,0.0025539212,0.0000038613384,0.0008679599,0.0006613746,0.0006697462,0.000007469434,0.0000067526785,0.0004976485],"genre_scores_gemma":[0.9974869,0.00047459372,0.0005024559,0.00070836215,0.00063762633,0.000023180046,0.0000017874846,0.000026332329,0.00013875283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966126,0.00026278736,0.0020220755,0.00024112711,0.00047422596,0.0003871791],"domain_scores_gemma":[0.99677354,0.00063923973,0.0014608158,0.00021828184,0.0004994593,0.00040865573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013658395,0.00022538236,0.0019866796,0.00021724857,0.00005703845,0.000004692618,0.00013329869,0.00019372416,0.00010456075],"category_scores_gemma":[0.0008677231,0.00013428865,0.00018278172,0.0002769843,0.00020098858,0.0002570722,0.000116963776,0.000775643,0.0000013731849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02624462,0.017325876,0.85452163,0.0000421751,0.00060158246,0.00013651793,0.0035356332,0.0000033368692,0.000030654486,0.0000030624994,0.0008935808,0.096661314],"study_design_scores_gemma":[0.068225786,0.08606323,0.8391508,0.00015083348,0.0006208615,0.000058797268,0.0019687752,0.000004174239,0.000024603763,0.00000366779,0.0036012165,0.00012726065],"about_ca_topic_score_codex":0.000100843994,"about_ca_topic_score_gemma":0.0006139874,"teacher_disagreement_score":0.09653405,"about_ca_system_score_codex":0.00013269648,"about_ca_system_score_gemma":0.00066055474,"threshold_uncertainty_score":0.54761326},"labels":[],"label_agreement":null},{"id":"W2597525360","doi":"10.1200/jco.2017.35.6_suppl.378","title":"Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"PTEN; CDKN2A; Cancer research; Liquid biopsy; BAP1; ARID1A; Bladder cancer; Cancer; Medicine; Colorectal cancer; Biology; Gene; Mutation; Genetics; PI3K/AKT/mTOR pathway; Melanoma; Internal medicine","score_opus":0.1324159974081884,"score_gpt":0.46724956828793063,"score_spread":0.3348335708797422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597525360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953632,0.0014219217,0.00030173568,0.00055401336,0.0015747502,0.00007769439,0.000010619405,7.443428e-7,0.0006953389],"genre_scores_gemma":[0.9955664,0.00052098924,0.0014695538,0.00042067628,0.0019681181,0.0000016484364,0.0000011576531,0.000015717458,0.00003569897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824923,0.000121504876,0.0011925342,0.00014343523,0.00012314766,0.00017013043],"domain_scores_gemma":[0.99570817,0.0005322338,0.0029725481,0.00032888807,0.00035664384,0.00010153028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018080642,0.00009923236,0.0005555168,0.000025162068,0.00016703307,0.000029632047,0.0004260936,0.00010543592,0.000031791005],"category_scores_gemma":[0.005014499,0.000066701876,0.00032828547,0.000022738652,0.00020759414,0.000006803934,0.00017866114,0.0002823944,7.226304e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015740104,0.0007449858,0.46869603,0.00008303492,0.0024071517,0.00023861676,0.00030240318,0.013147125,0.4408888,0.00035542337,0.0022574596,0.069304965],"study_design_scores_gemma":[0.011892402,0.007284051,0.86200833,0.0002767379,0.002356434,0.00095723895,0.0016765109,0.009362874,0.033263616,0.0023183227,0.06781578,0.00078768964],"about_ca_topic_score_codex":0.00010713552,"about_ca_topic_score_gemma":0.00023551878,"teacher_disagreement_score":0.40762517,"about_ca_system_score_codex":0.000026799575,"about_ca_system_score_gemma":0.0009988408,"threshold_uncertainty_score":0.6003186},"labels":[],"label_agreement":null},{"id":"W2597532271","doi":"10.1200/jco.2017.35.6_suppl.140","title":"Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; PALB2; Medicine; Germline; DNA repair; Androgen deprivation therapy; Oncology; Internal medicine; Germline mutation; Cancer; Cancer research; Androgen receptor; Mutation; Gene; Biology; Genetics","score_opus":0.20046546095766327,"score_gpt":0.5339502792579713,"score_spread":0.3334848183003081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597532271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905476,0.0010694392,0.000006944661,0.007493401,0.00013540087,0.00055823487,0.000020959318,0.000005603478,0.00016240543],"genre_scores_gemma":[0.9964732,0.0010340251,0.0020331908,0.00014539083,0.00013714113,0.000030163765,0.0000024867138,0.0000108860195,0.0001335293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967861,0.00061840314,0.0018922825,0.00020079382,0.0003061044,0.00019631271],"domain_scores_gemma":[0.9948533,0.0023660313,0.0017782132,0.00028892205,0.00049158954,0.00022193277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006061248,0.00010925332,0.001053181,0.00012135026,0.00010809924,0.00001529865,0.00011265415,0.00008925694,0.000040821247],"category_scores_gemma":[0.0049621686,0.000072613475,0.00023807249,0.00009050312,0.00058482244,0.00013759725,0.000036745525,0.00050910574,6.663735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09087948,0.0031122784,0.7571555,0.0002586126,0.00080390886,0.0026794383,0.0014095225,0.000081819664,0.045552325,0.00006926548,0.00015181926,0.09784606],"study_design_scores_gemma":[0.012951924,0.0059635574,0.97706187,0.0001669731,0.00013976797,0.00011654399,0.0003955627,0.0003115368,0.0011247445,0.0005989066,0.0011035396,0.00006506718],"about_ca_topic_score_codex":0.00015874446,"about_ca_topic_score_gemma":0.00026257377,"teacher_disagreement_score":0.2199064,"about_ca_system_score_codex":0.00017762318,"about_ca_system_score_gemma":0.0030165925,"threshold_uncertainty_score":0.59405375},"labels":[],"label_agreement":null},{"id":"W2597532593","doi":"10.1200/jco.2013.31.15_suppl.e19077","title":"Clinical impact of <i>EGFR</i> mutation fraction and tumor cellularity in <i>EGFR</i> mutation positive NSCLC.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Grand River Hospital; Trillium Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; York Central Hospital; Toronto East General Hospital; University of Toronto; Ottawa Hospital; Health Sciences Centre; University Health Network; Royal Columbian Hospital; Princess Margaret Cancer Centre; Mount Sinai Hospital; Credit Valley Hospital","funders":"","keywords":"Medicine; Mutation; Internal medicine; Exon; Oncology; Biopsy; Pathology; Gastroenterology; Gene; Genetics; Biology","score_opus":0.053940914662725235,"score_gpt":0.5001591688104652,"score_spread":0.44621825414773997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597532593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932238,0.0003678745,0.0006677969,0.0024558145,0.00057548215,0.00048672946,0.000009565982,0.0000067188726,0.0022062398],"genre_scores_gemma":[0.9944884,0.00029021397,0.0035849775,0.0010496777,0.00047908386,0.000008828517,0.00002011658,0.000014512909,0.0000641658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960138,0.00056794094,0.002741008,0.00021227874,0.00028002137,0.0001849559],"domain_scores_gemma":[0.9942415,0.0022699048,0.0022403004,0.00013114332,0.0007921664,0.00032500664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020491509,0.00014491905,0.0012624665,0.00017931148,0.000035412286,0.000013320512,0.000063814296,0.00031578258,0.00012462545],"category_scores_gemma":[0.0021112696,0.0001026098,0.0004902786,0.00018660983,0.00022094167,0.00040258295,0.000022454173,0.0008304702,0.000015853546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030863308,0.004415954,0.7059333,0.00004653351,0.0008618102,0.0007637523,0.00038960253,0.00008648393,0.000888335,0.000076852775,0.0018374817,0.2816136],"study_design_scores_gemma":[0.011124812,0.014140982,0.97062606,0.00014689214,0.0006293602,0.0005264447,0.0003158046,0.0006030215,0.00014861743,0.0012065179,0.0004450565,0.00008644161],"about_ca_topic_score_codex":0.0008364603,"about_ca_topic_score_gemma":0.00006870473,"teacher_disagreement_score":0.28152716,"about_ca_system_score_codex":0.00040063693,"about_ca_system_score_gemma":0.0016071236,"threshold_uncertainty_score":0.41843066},"labels":[],"label_agreement":null},{"id":"W2597539313","doi":"10.1200/jco.2013.31.15_suppl.7088","title":"Predictive factors associated with achievement of major cytogenetic response (MCyR) to omacetaxine mepesuccinate among patients with chronic phase chronic myeloid leukemia (CML-CP).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Logistic regression; Internal medicine; Blast Crisis; Myeloid leukemia; Oncology; Gastroenterology","score_opus":0.04249160936299737,"score_gpt":0.36757103020577675,"score_spread":0.3250794208427794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597539313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543536,0.00029202164,0.00022140986,0.0011459643,0.00040525227,0.002188622,0.00006496693,0.00003241348,0.00021400492],"genre_scores_gemma":[0.9977443,0.000096119045,0.0007016213,0.00033038273,0.00036991527,0.000065440196,0.00005359196,0.00008935948,0.0005492473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927294,0.0011811332,0.003340352,0.0005929044,0.0013397764,0.00081640715],"domain_scores_gemma":[0.98982066,0.0026925406,0.003990083,0.0006156608,0.0016841614,0.0011968771],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024254606,0.0005627474,0.0028663303,0.0004305988,0.000098084434,0.000018758896,0.00043036605,0.0006029903,0.00083245506],"category_scores_gemma":[0.0034434376,0.0003450945,0.0004878631,0.0005663296,0.00053376803,0.00029482326,0.00014808319,0.0014283065,0.000035593286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06164357,0.009806373,0.8858603,0.0001257495,0.0074146134,0.0005598396,0.00049360545,0.0011198239,0.0040159733,0.000004130298,0.0020275847,0.02692839],"study_design_scores_gemma":[0.07637214,0.14982645,0.7671674,0.00073476153,0.0015595827,0.000027871496,0.00008752642,0.00023117833,0.0027638355,0.000009554634,0.00096520304,0.00025450496],"about_ca_topic_score_codex":0.0002171422,"about_ca_topic_score_gemma":0.00052968855,"teacher_disagreement_score":0.14002007,"about_ca_system_score_codex":0.010548516,"about_ca_system_score_gemma":0.012954816,"threshold_uncertainty_score":0.9999001},"labels":[],"label_agreement":null},{"id":"W2597542696","doi":"10.1200/jco.2015.33.15_suppl.6594","title":"PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian rectal cancer consortium.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; St. John’s Health Sciences Centre; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency; Ottawa Hospital","funders":"","keywords":"Medicine; FOLFOX; Colorectal cancer; Internal medicine; Proportional hazards model; Oncology; Stage (stratigraphy); Neoadjuvant therapy; Cancer; Surgery; Oxaliplatin; Breast cancer","score_opus":0.28889417944950807,"score_gpt":0.5425290152778174,"score_spread":0.2536348358283093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597542696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94698405,0.0010914833,0.0000024659375,0.04072759,0.0032626665,0.00046288982,0.00009454838,0.000013202492,0.0073611173],"genre_scores_gemma":[0.9888563,0.0014527666,0.0008139536,0.0065941093,0.0018930149,0.0000089246405,0.000006053323,0.000017289576,0.00035757996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99392766,0.0010989987,0.0036684726,0.00042817375,0.00052155653,0.00035516478],"domain_scores_gemma":[0.982982,0.012443299,0.0016364073,0.0004270766,0.00073584606,0.0017754094],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008413571,0.00020830012,0.0020826145,0.000056355962,0.00006307523,0.00002178175,0.00024154923,0.00056380447,0.00012465891],"category_scores_gemma":[0.03824915,0.000109255925,0.0006873253,0.00016856856,0.0007255393,0.00010063699,0.00009520149,0.0016378167,0.000037807513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010409791,0.0006665692,0.88086957,0.000002242123,0.000754351,0.00073372625,0.00010899637,7.3181826e-7,6.868329e-7,0.000013580692,0.011786082,0.094653696],"study_design_scores_gemma":[0.015743544,0.0072425446,0.8563918,0.000055474764,0.0005799875,0.00012388712,0.00010931406,0.000022765924,0.0000032252678,0.00068951264,0.118942775,0.00009515893],"about_ca_topic_score_codex":0.03402917,"about_ca_topic_score_gemma":0.115884624,"teacher_disagreement_score":0.107156694,"about_ca_system_score_codex":0.00071065745,"about_ca_system_score_gemma":0.008055083,"threshold_uncertainty_score":0.9975683},"labels":[],"label_agreement":null},{"id":"W2597556088","doi":"10.1200/jco.2013.31.15_suppl.tps1608","title":"Change in mammographic density with metformin use: A companion study to NCIC study MA.32.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Metformin; Breast cancer; Internal medicine; Oncology; Placebo; Cancer; Gynecology; Insulin; Pathology","score_opus":0.2559064000256187,"score_gpt":0.5037873218244326,"score_spread":0.24788092179881394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597556088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514526,0.00007108204,0.000025083358,0.0022302452,0.0006026472,0.0018597111,9.4305113e-7,0.000008946104,0.000056095527],"genre_scores_gemma":[0.9968382,0.00006979895,0.0006497718,0.0017585203,0.0005786587,0.000032186545,5.052943e-7,0.000017345214,0.00005498059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673635,0.0004935128,0.0017782581,0.00023725255,0.00048269905,0.00027192244],"domain_scores_gemma":[0.9971443,0.00082006195,0.0008220551,0.00025405287,0.00044959804,0.000509938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029952498,0.00016316694,0.0017237144,0.0003880027,0.000030825937,0.000020125504,0.00015362182,0.00014418593,0.00014636859],"category_scores_gemma":[0.0006951443,0.00009952067,0.00020730104,0.00046683892,0.00010109955,0.00024491147,0.00007930252,0.0010514257,0.000026668564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030788586,0.010495496,0.9362499,0.000006963569,0.0002478707,0.001018541,0.0016478684,0.000002670232,0.0000076125543,0.000003390873,0.00051109435,0.046729736],"study_design_scores_gemma":[0.010011298,0.06281688,0.9197918,0.00006204357,0.0003042239,0.00018724926,0.0040837466,0.000021895123,0.0000016736165,0.000013599338,0.0026066878,0.00009887614],"about_ca_topic_score_codex":0.0062795714,"about_ca_topic_score_gemma":0.021303056,"teacher_disagreement_score":0.052321386,"about_ca_system_score_codex":0.00017041425,"about_ca_system_score_gemma":0.00037251232,"threshold_uncertainty_score":0.9965556},"labels":[],"label_agreement":null},{"id":"W2597559961","doi":"10.1200/jco.2013.31.15_suppl.tps652","title":"A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Letrozole; Internal medicine; Adverse effect; Oncology; Regimen; Progression-free survival; Neutropenia; Placebo; Clinical endpoint; Fulvestrant; Breast cancer; Phases of clinical research; Metastatic breast cancer; Clinical trial; Cancer; Tamoxifen; Chemotherapy","score_opus":0.11242801869707363,"score_gpt":0.46402493767064373,"score_spread":0.3515969189735701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597559961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777557,0.0028468396,0.00062121195,0.0024083075,0.0012508186,0.014792606,0.00028803517,0.000022815884,0.00001362202],"genre_scores_gemma":[0.98907983,0.0025010614,0.0014652093,0.00026502437,0.0013376292,0.004925261,0.000019306404,0.00010625047,0.0003004022],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99351853,0.0007002747,0.0036316798,0.00064514106,0.00071659725,0.00078774657],"domain_scores_gemma":[0.98692024,0.005527679,0.004279453,0.00066069444,0.0017752852,0.0008366449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015623702,0.0006479161,0.005289396,0.00021480052,0.00017345384,0.000030285266,0.00035194916,0.0002687221,0.00010294222],"category_scores_gemma":[0.00032730564,0.0003532574,0.0007465121,0.0001899483,0.00079379877,0.0004538206,0.000042039937,0.00036937345,0.0000012949995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83080167,0.015929285,0.0015333407,0.00015456682,0.0065648123,0.000055034438,0.0037985458,0.0019168841,0.00086831144,0.0000071505438,0.000023303113,0.13834712],"study_design_scores_gemma":[0.8426484,0.135306,0.004013411,0.00044830012,0.0044935844,0.00006590013,0.0074810274,0.0028263293,0.000521268,0.000010912571,0.0018966314,0.00028824],"about_ca_topic_score_codex":0.0008043702,"about_ca_topic_score_gemma":0.00086965674,"teacher_disagreement_score":0.13805887,"about_ca_system_score_codex":0.0031358209,"about_ca_system_score_gemma":0.0031640937,"threshold_uncertainty_score":0.99989194},"labels":[],"label_agreement":null},{"id":"W2597562859","doi":"10.1200/jco.2017.35.5_suppl.219","title":"A preliminary evaluation of the TrueNTH androgen deprivation therapy educational program.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network; Baker Hughes (Canada); Prostate Cancer Canada; University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Quality of life (healthcare); Adverse effect; Internal medicine; Oncology; Cancer; Physical therapy; Nursing","score_opus":0.3617694813062418,"score_gpt":0.6086548668789356,"score_spread":0.24688538557269374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597562859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626657,0.0007652368,0.0000027869746,0.029848196,0.0016480335,0.00054343964,0.0000012803979,0.000002054793,0.004523318],"genre_scores_gemma":[0.99698937,0.00046311656,0.0006358709,0.00052063336,0.0011730707,0.000025043246,0.000002152138,0.000005616034,0.00018510192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99798155,0.00039252493,0.00094181445,0.000088493536,0.00051197817,0.000083643594],"domain_scores_gemma":[0.9956652,0.0006010874,0.002303889,0.00023024036,0.0011123278,0.000087284905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003825829,0.00006317838,0.00046596114,0.0000402998,0.00008788219,0.0000064790015,0.00019865723,0.00015381006,0.00034622304],"category_scores_gemma":[0.0029644913,0.000035441222,0.00032189785,0.000039019134,0.00023634147,0.00008852396,0.000032571017,0.00028846267,0.000002766788],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003609181,0.0040035504,0.3338095,0.000006943536,0.00035329998,0.0000040633113,0.00009687014,0.000007036373,0.0002688687,0.00006463353,0.0040103043,0.65376574],"study_design_scores_gemma":[0.010852973,0.010597314,0.9417555,0.000036935482,0.0006860425,0.00010139822,0.00001507156,0.0001856529,0.0006228656,0.0014556402,0.03366138,0.00002922345],"about_ca_topic_score_codex":0.000014101577,"about_ca_topic_score_gemma":0.000019956493,"teacher_disagreement_score":0.65373653,"about_ca_system_score_codex":0.00015669364,"about_ca_system_score_gemma":0.0037846216,"threshold_uncertainty_score":0.67137563},"labels":[],"label_agreement":null},{"id":"W2597591782","doi":"10.1200/jco.2013.31.15_suppl.6552","title":"Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; KRAS; Cetuximab; Colorectal cancer; Internal medicine; Oncology; Irinotecan; Bevacizumab; Cohort; Capecitabine; Oxaliplatin; Cancer; Family medicine; Chemotherapy","score_opus":0.23975910142225917,"score_gpt":0.42313102664918356,"score_spread":0.1833719252269244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597591782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194896,0.0012717247,0.0008958048,0.0013909509,0.0026287374,0.0010063162,0.00019640333,0.000002715642,0.0006583705],"genre_scores_gemma":[0.99619144,0.00086610415,0.0014944128,0.00070392434,0.00033302273,0.00007032722,0.000002516631,0.000019152742,0.00031909745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958033,0.00015412677,0.0034512556,0.00023066333,0.00007131261,0.0002893197],"domain_scores_gemma":[0.9889323,0.0037605928,0.0061518205,0.00022781968,0.0007556865,0.00017178312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024423932,0.00015883295,0.0025384678,0.00035753133,0.000052470426,0.000023953487,0.0003710061,0.0002665028,0.00049185404],"category_scores_gemma":[0.007416314,0.00011973102,0.0012170656,0.0006411482,0.0003518611,0.0005245298,0.00007730635,0.00043244622,0.000011768374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022308128,0.0012891619,0.82510656,0.00007805556,0.009161386,0.0000038512057,0.0004967857,0.014978879,0.00022206985,0.0069107274,0.024784265,0.11473742],"study_design_scores_gemma":[0.0036778161,0.004180008,0.7463193,0.000054880493,0.0013993892,0.0000038805474,0.000086442116,0.0056929374,0.00065894943,0.005760326,0.2319317,0.00023436079],"about_ca_topic_score_codex":0.0019091547,"about_ca_topic_score_gemma":0.0011336139,"teacher_disagreement_score":0.20714743,"about_ca_system_score_codex":0.0003091339,"about_ca_system_score_gemma":0.0006118206,"threshold_uncertainty_score":0.88785565},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2597593796","doi":"10.1200/jco.2017.35.4_suppl.358","title":"Interim results of a multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Neutropenia; Internal medicine; Discontinuation; Interim analysis; Adverse effect; Gastroenterology; Clinical endpoint; Phases of clinical research; Febrile neutropenia; Surgery; Cancer; Clinical trial; Chemotherapy","score_opus":0.1414387291662786,"score_gpt":0.5281105214175,"score_spread":0.38667179225122145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597593796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925376,0.00024941485,0.00079556706,0.0038404968,0.0012998006,0.0021428852,0.00012244756,0.0000068978784,0.0022887203],"genre_scores_gemma":[0.98424757,0.0011922013,0.011943425,0.00048479147,0.0009252532,0.000093425704,0.00001609913,0.000038634465,0.0010586308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930282,0.00045447692,0.0048173405,0.0003922554,0.00078506157,0.0005226651],"domain_scores_gemma":[0.9844827,0.0040058917,0.007349861,0.00076999166,0.0028178776,0.0005736806],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045152945,0.0002953639,0.0042728134,0.00020072173,0.00016887441,0.00001128944,0.000612088,0.0005200186,0.000088719105],"category_scores_gemma":[0.022738958,0.00018985131,0.000731327,0.00010020107,0.0012864345,0.00025711954,0.00021084571,0.00092477584,0.0000026864548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8190339,0.016729377,0.044745345,0.00031524157,0.0015174621,0.00011645859,0.0003171641,0.000009040949,0.00051871035,0.000023695458,0.0026888116,0.113984786],"study_design_scores_gemma":[0.62327236,0.31047103,0.04565763,0.001217699,0.0020856867,0.000028071423,0.00016996743,0.000844398,0.00027284987,0.000106171516,0.015700577,0.00017358093],"about_ca_topic_score_codex":0.00014936706,"about_ca_topic_score_gemma":0.00018587789,"teacher_disagreement_score":0.29374164,"about_ca_system_score_codex":0.00029305433,"about_ca_system_score_gemma":0.0038646809,"threshold_uncertainty_score":0.98549294},"labels":[],"label_agreement":null},{"id":"W2597606909","doi":"10.1200/jco.2013.31.15_suppl.1507","title":"MRI volumetric analysis of fibroglandular tissue to assess risk of the spared nipple in <i>BRCA 1/2</i> patients who are considering prophylactic nipple-sparing mastectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Nuclear medicine; Univariate analysis; Breast MRI; Multivariate analysis; Mammography; Internal medicine; Cancer","score_opus":0.07838119253515374,"score_gpt":0.3798817129876335,"score_spread":0.30150052045247977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597606909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794686,0.00007977858,0.00020725577,0.0005124599,0.00067203323,0.00041377658,0.000013732479,0.0000035545997,0.00015054374],"genre_scores_gemma":[0.9972708,0.00004496172,0.0023506475,0.00006533184,0.00018604947,0.0000042682086,0.0000022850895,0.000011364145,0.00006424168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624306,0.00054607756,0.0024051755,0.00017808499,0.00041301287,0.00021458443],"domain_scores_gemma":[0.9940834,0.0014794093,0.0032896285,0.0002464589,0.0006824043,0.00021869379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014954191,0.0001333664,0.0020173679,0.000695254,0.000032355954,0.000008962438,0.00018231425,0.00030242448,0.00017386446],"category_scores_gemma":[0.0027901668,0.00008235349,0.000440779,0.0013054127,0.0001366274,0.0001282088,0.00009303992,0.0007577176,0.000007130442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060157967,0.00045563397,0.9152503,0.00006394607,0.0007579423,0.000017776923,0.00005933671,0.000547191,0.00029652737,0.0000010341089,0.00021279986,0.08173593],"study_design_scores_gemma":[0.0036993562,0.0017148877,0.9898022,0.00023769455,0.0016589253,0.0004918363,0.0001316583,0.0011442999,0.0006936908,0.00003375878,0.00031052288,0.00008120642],"about_ca_topic_score_codex":0.0002975937,"about_ca_topic_score_gemma":0.0002928591,"teacher_disagreement_score":0.08165473,"about_ca_system_score_codex":0.000108674765,"about_ca_system_score_gemma":0.00036048426,"threshold_uncertainty_score":0.33582777},"labels":[],"label_agreement":null},{"id":"W2597630242","doi":"10.1200/jco.2013.31.15_suppl.8532","title":"Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Tolerability; Lenalidomide; Adverse effect; Regimen; Bortezomib; Population; Internal medicine; Multiple myeloma; Surgery","score_opus":0.07793697440587355,"score_gpt":0.42683275227097156,"score_spread":0.348895777865098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597630242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971987,0.0001708547,0.00018464438,0.00084769225,0.00012420927,0.0011317881,0.000012219318,0.000018392742,0.0003114925],"genre_scores_gemma":[0.98332036,0.00024296131,0.014517438,0.0006943094,0.00023143625,0.00004423573,0.000038627724,0.000050749975,0.0008599048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432224,0.0009691525,0.0024917522,0.0005577078,0.00097535603,0.00068379997],"domain_scores_gemma":[0.9923608,0.0031806235,0.0018136777,0.0005000756,0.0007996561,0.0013451879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021847766,0.00039814276,0.0031758295,0.0007148393,0.000116267925,0.00003741124,0.00024361705,0.00047794127,0.00036863153],"category_scores_gemma":[0.0044919807,0.00021491753,0.00035825456,0.00078968774,0.0005984275,0.00045141886,0.00012039118,0.0016240211,0.000024544817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0844324,0.013736734,0.7842155,0.000044493736,0.0027212424,0.0038634639,0.00021049184,0.000013177615,0.0002492489,0.0000017374836,0.00025554153,0.11025596],"study_design_scores_gemma":[0.13687025,0.080751106,0.77792156,0.00019294217,0.001272307,0.00015708912,0.00014869298,0.001015059,0.00008065808,0.000011679206,0.0013670955,0.00021158294],"about_ca_topic_score_codex":0.0004785579,"about_ca_topic_score_gemma":0.002145555,"teacher_disagreement_score":0.11004437,"about_ca_system_score_codex":0.00034766257,"about_ca_system_score_gemma":0.0011589442,"threshold_uncertainty_score":0.8764082},"labels":[],"label_agreement":null},{"id":"W2597637166","doi":"10.1200/jco.2012.30.15_suppl.e13011","title":"Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Internal medicine; Cohort; Maximum tolerated dose; Toxicity; Gastroenterology; Cancer; Oncology; Surgery; Epidermal growth factor receptor","score_opus":0.07679519443808776,"score_gpt":0.5008483345529107,"score_spread":0.4240531401148229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597637166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512273,0.000095062234,0.00014509355,0.0013269557,0.0007353374,0.0009102325,0.000005298298,0.000011803348,0.0016475017],"genre_scores_gemma":[0.9909395,0.00004407361,0.0075855167,0.00068840326,0.0005070005,0.00003082073,0.000027499284,0.000024241488,0.00015296221],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99693716,0.00030989255,0.0018053254,0.0001732239,0.000455411,0.0003189995],"domain_scores_gemma":[0.9964801,0.00059639366,0.0017956209,0.00017475663,0.0005031329,0.00044998404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012625267,0.0001782423,0.0013936501,0.00017765137,0.000040495685,0.000008387209,0.000084552055,0.0001725169,0.00009761697],"category_scores_gemma":[0.0011306012,0.00010290948,0.00017291884,0.0003059099,0.0001347015,0.00039607682,0.000016807488,0.00057713006,0.000009726998],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40440413,0.027738359,0.33525008,0.000021317148,0.0004307488,0.00016136348,0.00050274865,0.000050945342,0.000017146367,0.00004204952,0.00046612666,0.23091497],"study_design_scores_gemma":[0.414696,0.13077569,0.4501362,0.00019623045,0.0006365911,0.000026702917,0.00017335551,0.000046025398,0.000021356098,0.00002582171,0.0031619049,0.00010408303],"about_ca_topic_score_codex":0.000015732006,"about_ca_topic_score_gemma":0.00005870737,"teacher_disagreement_score":0.23081088,"about_ca_system_score_codex":0.00036246088,"about_ca_system_score_gemma":0.0013674143,"threshold_uncertainty_score":0.41965267},"labels":[],"label_agreement":null},{"id":"W2597637268","doi":"10.1200/jco.2017.35.4_suppl.478","title":"Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Asymptomatic; Incidence (geometry); Surgery; Abdominal surgery; Colorectal cancer; Prospective cohort study; Cohort; Cancer; Laparoscopic surgery; Confidence interval; Laparoscopy; Internal medicine","score_opus":0.1357251611535018,"score_gpt":0.4868250536657298,"score_spread":0.351099892512228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597637268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98877937,0.0014799186,0.00014776931,0.006106534,0.0026277949,0.00034616457,0.0000043905748,0.0000039766237,0.0005040759],"genre_scores_gemma":[0.9921948,0.0036017196,0.002074723,0.0009679691,0.0010607697,0.000015394187,7.7216635e-7,0.00001826184,0.000065598484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971942,0.00012869918,0.0018931532,0.00019357026,0.0003257914,0.00026460187],"domain_scores_gemma":[0.9941921,0.0018520639,0.0030633176,0.00030694305,0.00030952133,0.00027601843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043947888,0.00013458937,0.0027196717,0.00011630072,0.00016034761,0.000014187314,0.00025014175,0.00022484243,0.00004113264],"category_scores_gemma":[0.0058577373,0.00010311048,0.00078990223,0.000036990707,0.00020455188,0.00018193362,0.00012301045,0.000346538,0.000002237819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018717635,0.004025624,0.5498146,0.0004458242,0.0016381064,0.0005043426,0.00025061276,0.0000057571206,0.00047428644,0.00025918797,0.008357771,0.43235216],"study_design_scores_gemma":[0.004194998,0.005127275,0.97643507,0.000602855,0.0015507216,0.00008225151,0.00009233102,0.000046333782,0.00011358805,0.0010580405,0.010600908,0.0000956593],"about_ca_topic_score_codex":0.00021840511,"about_ca_topic_score_gemma":0.00017094791,"teacher_disagreement_score":0.4322565,"about_ca_system_score_codex":0.00008144953,"about_ca_system_score_gemma":0.0011348858,"threshold_uncertainty_score":0.7012682},"labels":[],"label_agreement":null},{"id":"W2597648644","doi":"10.1200/jco.2017.35.6_suppl.146","title":"PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Abiraterone acetate; Androgen deprivation therapy; Oncology; Urology; Progression-free survival; Cancer; Phases of clinical research; Randomized controlled trial; Clinical trial; Gastroenterology; Chemotherapy","score_opus":0.08849816467571489,"score_gpt":0.470523404404511,"score_spread":0.3820252397287961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597648644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996165,0.00025006846,0.000023063845,0.0004984054,0.00019841795,0.0027420335,0.000017033546,0.0000020887205,0.00010388374],"genre_scores_gemma":[0.9983451,0.00041839946,0.0006674375,0.000024066872,0.00017213615,0.0001749875,0.0000071348045,0.000027424032,0.00016335757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99413854,0.0020392048,0.0025759537,0.0003951341,0.0005180814,0.0003331163],"domain_scores_gemma":[0.9954615,0.00031259647,0.002803003,0.00043300242,0.00073060027,0.00025926053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067608487,0.00022317965,0.0018580408,0.00021143802,0.00020463752,0.00006140688,0.0003105228,0.00023400209,0.000018056631],"category_scores_gemma":[0.0034292424,0.00014327535,0.00015294932,0.00009931195,0.0005248923,0.0000465979,0.00020412893,0.0005425066,4.1724002e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8450379,0.010498874,0.04835107,0.000076076976,0.0006053315,0.00012333914,0.00082559604,0.000025306837,0.0118063,0.0000015198669,0.00012742185,0.08252127],"study_design_scores_gemma":[0.8365201,0.1183976,0.03896638,0.00031065685,0.00021942642,0.000009041205,0.00052277284,0.00012511558,0.003924374,0.000023682282,0.00076862366,0.00021224395],"about_ca_topic_score_codex":0.00020630183,"about_ca_topic_score_gemma":0.0012253189,"teacher_disagreement_score":0.10789873,"about_ca_system_score_codex":0.00006795354,"about_ca_system_score_gemma":0.0010688767,"threshold_uncertainty_score":0.5842599},"labels":[],"label_agreement":null},{"id":"W2597654933","doi":"10.1200/jco.2012.30.15_suppl.6084","title":"Does drug cost drive drug adherence? The designer drug phenomenon.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Southlake Regional Health Center; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Drug; Context (archaeology); Descriptive statistics; Family medicine; Cohort; Emergency medicine; Internal medicine; Pharmacology","score_opus":0.1785352794428429,"score_gpt":0.47700121457800965,"score_spread":0.2984659351351667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597654933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79191715,0.002884081,0.0013255312,0.13271658,0.011755969,0.0010992297,0.000005046484,0.000041144613,0.058255263],"genre_scores_gemma":[0.9488158,0.0011567768,0.0025655278,0.015061435,0.0049992604,0.000026407864,0.0000019990796,0.000017377633,0.027355377],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99586874,0.00082980254,0.0021244555,0.00017956669,0.000586795,0.0004106461],"domain_scores_gemma":[0.99266523,0.0035902874,0.0020431462,0.00039022393,0.0005181524,0.000792963],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0068518193,0.00016947283,0.0011023787,0.00006657385,0.00010813865,0.000014361568,0.00047375064,0.00016582927,0.004009681],"category_scores_gemma":[0.0026531573,0.00007171406,0.00039295675,0.00018378046,0.0004994272,0.00022698843,0.00007299599,0.0014626667,0.0013169579],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001271491,0.0024487546,0.15827875,0.00003823663,0.0003862755,0.0000997655,0.0022209818,0.000002954914,0.00014721874,0.0011225668,0.63284755,0.20113549],"study_design_scores_gemma":[0.0040406864,0.0010347379,0.11703416,0.00016356666,0.00036139204,0.00017115804,0.002667168,0.00004026755,0.00018501437,0.0015920589,0.8725656,0.00014418678],"about_ca_topic_score_codex":0.00001927577,"about_ca_topic_score_gemma":0.000017203714,"teacher_disagreement_score":0.23971808,"about_ca_system_score_codex":0.00011719341,"about_ca_system_score_gemma":0.0014171875,"threshold_uncertainty_score":0.99946064},"labels":[],"label_agreement":null},{"id":"W2597667990","doi":"10.1200/jco.2017.35.6_suppl.60","title":"Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; SABR volatility model; Common Terminology Criteria for Adverse Events; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Prostate; Urology; Radiation therapy; Quality of life (healthcare); Adverse effect; Surgery; Cancer; Internal medicine","score_opus":0.11784654119546613,"score_gpt":0.4655993004877078,"score_spread":0.3477527592922417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597667990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895825,0.0016078801,0.0000059442723,0.0077564055,0.00046429405,0.00033852638,0.000039121474,0.0000036265396,0.00020172684],"genre_scores_gemma":[0.98159766,0.01657091,0.00056526973,0.0009332905,0.00018805853,0.000017547534,0.0000012387633,0.000014894824,0.000111126625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970485,0.00028210794,0.0019093878,0.00024499814,0.0002743184,0.00024069013],"domain_scores_gemma":[0.99430466,0.00158828,0.0031370975,0.00026900347,0.00025132063,0.0004496279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024301463,0.00017065633,0.0019865087,0.00008882567,0.00007574858,0.000028776503,0.00012646354,0.00020034469,0.000028658564],"category_scores_gemma":[0.0033965732,0.00010229991,0.00013155113,0.000041880085,0.00055618474,0.00020864788,0.000098511926,0.00071679585,0.0000014059273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048864074,0.0010330934,0.94393045,0.00008859421,0.00040765104,0.00019855333,0.00033244677,0.0000041106505,0.000014499363,0.00004956596,0.00016661781,0.04888799],"study_design_scores_gemma":[0.022147063,0.010334025,0.9649668,0.00036862172,0.00028681816,0.0000151041095,0.000121729456,0.000008769239,0.00009670237,0.00023497758,0.0013190559,0.00010034208],"about_ca_topic_score_codex":0.00319967,"about_ca_topic_score_gemma":0.0045910394,"teacher_disagreement_score":0.04878765,"about_ca_system_score_codex":0.00015015206,"about_ca_system_score_gemma":0.0011376959,"threshold_uncertainty_score":0.48369652},"labels":[],"label_agreement":null},{"id":"W2597687769","doi":"10.1200/jco.2017.35.6_suppl.96","title":"Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cancer; Urology; Interquartile range; Univariate analysis; Tumor progression; Brachytherapy; Radiation therapy; Oncology; Prostate; Biopsy; Prostate-specific antigen; Multivariate analysis","score_opus":0.14036715576169392,"score_gpt":0.5532531567504972,"score_spread":0.41288600098880335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597687769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878534,0.00068806496,0.000013081715,0.0061711916,0.0012248245,0.003963798,0.000042654858,0.0000071331974,0.00003586485],"genre_scores_gemma":[0.99058306,0.0010378599,0.0065184557,0.00026421333,0.0010103203,0.00019439303,0.0000061528444,0.000034502867,0.00035101996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712783,0.00023347295,0.001463955,0.0003151508,0.00042303198,0.0004365572],"domain_scores_gemma":[0.99601877,0.0007917974,0.0016467787,0.00026102774,0.0006911921,0.00059044035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085096393,0.00022123432,0.0012754143,0.00019359993,0.00019117657,0.000045134024,0.00019664863,0.0002507537,0.000036278732],"category_scores_gemma":[0.0037083116,0.00013074024,0.00033203367,0.00009569049,0.00023170134,0.00022180655,0.000057809342,0.00042442745,0.0000025667919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025872901,0.0031567828,0.5981322,0.00004522182,0.00033437213,0.00016936728,0.00090314844,0.000010019764,0.00043680592,0.0000011297499,0.000241742,0.37069634],"study_design_scores_gemma":[0.044126634,0.082716994,0.85939527,0.0010954317,0.00025576414,0.000023010807,0.00009665885,0.00015769724,0.0043021934,0.00010803234,0.00755662,0.00016572441],"about_ca_topic_score_codex":0.00019970287,"about_ca_topic_score_gemma":0.00008829369,"teacher_disagreement_score":0.3705306,"about_ca_system_score_codex":0.0014327033,"about_ca_system_score_gemma":0.0039779358,"threshold_uncertainty_score":0.70566875},"labels":[],"label_agreement":null},{"id":"W2597747698","doi":"10.1200/jco.2015.33.15_suppl.5564","title":"Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Ascites; Performance status; Cancer; Ovarian cancer; Progression-free survival; Thrombocytosis; Gastroenterology; Chemotherapy; Univariate analysis; Oncology; Surgery; Confidence interval; Multivariate analysis; Platelet","score_opus":0.045707615327933604,"score_gpt":0.36437930156863124,"score_spread":0.31867168624069764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597747698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358994,0.00061418983,0.000016973758,0.0035004176,0.0010381704,0.0010770858,0.00008695814,0.000006774653,0.00006947027],"genre_scores_gemma":[0.9971162,0.0012041539,0.00073323183,0.0002252902,0.00058395456,0.000047612884,0.00000802484,0.00003094827,0.000050592356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957109,0.000604165,0.00243602,0.00037428088,0.00059683766,0.00027779583],"domain_scores_gemma":[0.9935835,0.0018608988,0.0028429483,0.00027562655,0.0011352912,0.00030171432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019332431,0.00031626978,0.0019669938,0.00018326764,0.000042771597,0.000012122846,0.00014800264,0.00028886687,0.00009666324],"category_scores_gemma":[0.0007343745,0.00016929701,0.0002107344,0.0002463346,0.00024103171,0.0001238377,0.000063987594,0.00058511645,4.1550777e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018580973,0.007858455,0.8541248,0.000029555535,0.002060613,0.00011585345,0.0025162292,0.00013447525,0.000016623777,0.000004944011,0.000236918,0.11432056],"study_design_scores_gemma":[0.031593107,0.07207073,0.8924869,0.00053724484,0.001129158,0.000007261803,0.0010244816,0.00004342022,0.000041838826,0.000020748239,0.00091898633,0.00012614856],"about_ca_topic_score_codex":0.00095332606,"about_ca_topic_score_gemma":0.009502738,"teacher_disagreement_score":0.11419441,"about_ca_system_score_codex":0.00085331604,"about_ca_system_score_gemma":0.0017526848,"threshold_uncertainty_score":0.6903732},"labels":[],"label_agreement":null},{"id":"W2597765860","doi":"10.1200/jco.2013.31.15_suppl.e14573","title":"Quality of life in a multicenter phase II trial of metastasectomy for intra- and extra-hepatic metastases from colorectal adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Metastasectomy; Contraindication; Colorectal cancer; Quality of life (healthcare); Perioperative; Internal medicine; Surgery; Oncology; Cancer","score_opus":0.18044799514336224,"score_gpt":0.4899702401558237,"score_spread":0.30952224501246145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597765860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939887,0.0027741794,0.00007047257,0.0013104256,0.0005010434,0.001128015,0.00012665884,0.0000025166264,0.000097977114],"genre_scores_gemma":[0.9935372,0.00047444072,0.005313207,0.00027642839,0.00031273073,0.000056119927,0.000008390327,0.000009877574,0.000011602966],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995425,0.0005614064,0.0033808837,0.00019125822,0.00026046173,0.00018097543],"domain_scores_gemma":[0.9910818,0.005956777,0.002142369,0.00012013863,0.00045248002,0.00024648203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021971012,0.00015362464,0.0028518045,0.00013165941,0.00002683101,0.00000392195,0.000087037835,0.00016196187,0.00016715586],"category_scores_gemma":[0.007738708,0.0000996441,0.00052296446,0.00009695906,0.00031170103,0.000104367755,0.00006073823,0.00031121736,5.7290464e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6152034,0.022452885,0.21070156,0.00019261881,0.0037825473,0.00006457702,0.00082745514,0.000001365082,0.0023208966,0.00006356692,0.00095147215,0.14343768],"study_design_scores_gemma":[0.38191825,0.13708954,0.47630188,0.00010410589,0.0014521596,0.000010189565,0.0007026775,0.00015215749,0.0006781557,0.00045566354,0.0010233077,0.00011189257],"about_ca_topic_score_codex":0.00082808017,"about_ca_topic_score_gemma":0.0006054119,"teacher_disagreement_score":0.26560035,"about_ca_system_score_codex":0.00007449308,"about_ca_system_score_gemma":0.00066615525,"threshold_uncertainty_score":0.9264515},"labels":[],"label_agreement":null},{"id":"W2597802438","doi":"10.1200/jco.2013.31.15_suppl.4539","title":"Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Oncology; Pazopanib; Internal medicine; Docetaxel; Metastatic Urothelial Carcinoma; Chemotherapy; Progression-free survival; Gemcitabine; Response Evaluation Criteria in Solid Tumors; Progressive disease; Cancer; Sunitinib; Urothelial carcinoma; Bladder cancer","score_opus":0.18920341546983926,"score_gpt":0.5262245445798065,"score_spread":0.33702112910996723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597802438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742412,0.00008209695,0.0021740333,0.0176268,0.00054862484,0.0051919324,0.00007860541,0.0000066592934,0.000050077037],"genre_scores_gemma":[0.9798574,0.00011570052,0.014643496,0.0037207983,0.00071990566,0.00048045348,0.0000030037854,0.000040455187,0.00041882956],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.996834,0.00035210987,0.0020941037,0.00023920176,0.00016362203,0.0003169807],"domain_scores_gemma":[0.9907893,0.006974223,0.0010445758,0.00028706054,0.0005783131,0.00032650586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002377471,0.00020269869,0.0017614063,0.00023650365,0.00003663479,0.000007304967,0.00019552343,0.00028829038,0.00020911256],"category_scores_gemma":[0.0026828365,0.0001264109,0.0010283659,0.00013137488,0.000070532624,0.00008492206,0.0000093897825,0.000295379,0.0000052343344],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7750943,0.004528097,0.036071245,0.000010479726,0.00048176493,0.0000041923995,0.00017100153,0.000034676923,0.011190303,0.000012790496,0.0019201395,0.17048101],"study_design_scores_gemma":[0.20689626,0.18168288,0.6056714,0.000024344836,0.00007284658,0.000011490935,0.000015956926,0.00001534923,0.0014941851,0.0006677911,0.0033658363,0.00008162609],"about_ca_topic_score_codex":0.000026555506,"about_ca_topic_score_gemma":0.0000145492895,"teacher_disagreement_score":0.56960016,"about_ca_system_score_codex":0.00030778954,"about_ca_system_score_gemma":0.002596735,"threshold_uncertainty_score":0.51548874},"labels":[],"label_agreement":null},{"id":"W2597805329","doi":"10.1200/jco.2013.31.15_suppl.4586","title":"First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Context (archaeology); Renal cell carcinoma; Internal medicine; Proportional hazards model; Oncology; Clinical trial; Population; Overall survival; Surgery","score_opus":0.3180546292660904,"score_gpt":0.45724678382809447,"score_spread":0.13919215456200407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597805329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9150489,0.0033038452,0.027908549,0.043307535,0.0039973278,0.005052211,0.00046141585,0.000014412114,0.0009057841],"genre_scores_gemma":[0.88022405,0.0007723996,0.104071885,0.008902572,0.004494311,0.00036365885,0.00026995645,0.000051340376,0.0008497998],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.992684,0.0013047758,0.0046062237,0.00042508473,0.00057348993,0.00040644762],"domain_scores_gemma":[0.9394904,0.054360077,0.003885246,0.00049891457,0.0012773761,0.00048799362],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012161685,0.00033625367,0.0026222405,0.00012946692,0.00012339257,0.00005690004,0.00060286943,0.00031604286,0.0033394552],"category_scores_gemma":[0.0108052725,0.0001793883,0.0015956274,0.00008588836,0.00024753495,0.00023532314,0.00007906719,0.00080712594,0.000029377563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06683035,0.0070180222,0.015186493,0.00012774902,0.005664642,0.0005725453,0.00049526204,0.00020950705,0.013296279,0.00020383744,0.82837677,0.062018532],"study_design_scores_gemma":[0.15056917,0.08473667,0.119242914,0.00028501937,0.006243817,0.0006382926,0.0009291276,0.008605941,0.044792566,0.010406835,0.572823,0.00072668504],"about_ca_topic_score_codex":0.0000991273,"about_ca_topic_score_gemma":0.00007075229,"teacher_disagreement_score":0.2555538,"about_ca_system_score_codex":0.00024130844,"about_ca_system_score_gemma":0.0021006109,"threshold_uncertainty_score":0.99757165},"labels":[],"label_agreement":null},{"id":"W2597837743","doi":"10.1200/jco.2013.31.15_suppl.e13503","title":"Development of a new equation to estimate GFR in cancer patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Carboplatin; Medicine; Renal function; Body surface area; Urology; Dosing; Lung cancer; Creatinine; Pharmacokinetics; Lean body mass; Internal medicine; Oncology; Nuclear medicine; Chemotherapy; Cisplatin; Body weight","score_opus":0.2701873512720473,"score_gpt":0.5754353173007194,"score_spread":0.3052479660286721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597837743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908862,0.000120493314,0.0001279392,0.0068617486,0.0008834053,0.0002787363,5.0642825e-7,0.0000022631118,0.0008386836],"genre_scores_gemma":[0.9711263,0.0000902595,0.025893005,0.0019708404,0.00038759143,0.000015912787,0.0000021247108,0.0000072571597,0.0005067066],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978403,0.00007546866,0.0016884779,0.00008815736,0.00017314321,0.00013445303],"domain_scores_gemma":[0.99819076,0.00038458442,0.0007917936,0.00004950465,0.0003000361,0.00028330905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064116914,0.000070175636,0.00075127266,0.00012786535,0.000008997078,0.000001852054,0.00006523577,0.00013513354,0.00087760127],"category_scores_gemma":[0.00057170296,0.000049972965,0.000108085645,0.000121336416,0.00002760418,0.00006275286,0.000026052196,0.00025524708,0.00003824649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001616596,0.0025489104,0.33584803,0.000017812448,0.00015421877,0.000018385492,0.00075689174,0.00005606145,0.000649294,0.000013582544,0.013033093,0.6452871],"study_design_scores_gemma":[0.0096062,0.006754829,0.91211337,0.000090786816,0.00011810421,0.000005115921,0.000024947582,0.00006795839,0.00061079056,0.00013286284,0.070426434,0.000048583912],"about_ca_topic_score_codex":0.00020815573,"about_ca_topic_score_gemma":0.00045365508,"teacher_disagreement_score":0.6452385,"about_ca_system_score_codex":0.00028370405,"about_ca_system_score_gemma":0.0024894844,"threshold_uncertainty_score":0.9609118},"labels":[],"label_agreement":null},{"id":"W2597838921","doi":"10.1200/jco.2004.22.90140.7226","title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Zoledronic acid; Medicine; Placebo; Internal medicine; Hazard ratio; Lung cancer; Pathologic fracture; Surgery; Spinal cord compression; Urology; Oncology; Confidence interval; Pathology","score_opus":0.06257154037284854,"score_gpt":0.4562930126003374,"score_spread":0.3937214722274889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597838921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968156,0.0005722393,0.000067359026,0.0016602913,0.00015942643,0.00025667145,0.000014585621,0.000002491991,0.00045130483],"genre_scores_gemma":[0.9958918,0.00011631652,0.002168661,0.0017121248,0.000058246966,0.000006471326,0.0000040824443,0.000011322207,0.000030978543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665076,0.00015328485,0.0025564611,0.00018163188,0.00029052206,0.00016733652],"domain_scores_gemma":[0.99621695,0.0006883942,0.002240635,0.00021009016,0.00033736878,0.00030658266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010979476,0.00010987406,0.0017024283,0.00026812858,0.000013521265,7.807481e-7,0.000078207995,0.00021166187,0.00006406298],"category_scores_gemma":[0.0004307443,0.00007410436,0.00033934842,0.00019717912,0.00028962467,0.00003710429,0.0000137614015,0.0005478024,9.857803e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003953182,0.0059450846,0.9694828,0.000052110125,0.0006935265,0.000020859414,0.000040890955,0.0003710164,0.0000018830015,0.000032611766,0.000051851846,0.019354232],"study_design_scores_gemma":[0.022150304,0.012115811,0.96271276,0.0002838233,0.0013829875,0.0000040179048,0.000006520423,0.00033627442,0.0000043715563,0.00002728874,0.0009239072,0.000051903295],"about_ca_topic_score_codex":0.00020899969,"about_ca_topic_score_gemma":0.0007707523,"teacher_disagreement_score":0.019302329,"about_ca_system_score_codex":0.0005781294,"about_ca_system_score_gemma":0.0030038327,"threshold_uncertainty_score":0.532867},"labels":[],"label_agreement":null},{"id":"W2597839935","doi":"10.1200/jco.2013.31.15_suppl.e11613","title":"Fulvestrant for advanced breast cancer: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Fulvestrant; Medicine; Discontinuation; Internal medicine; Oncology; Adverse effect; Breast cancer; Hazard ratio; Aromatase inhibitor; Cancer; Metastatic breast cancer; Anastrozole; Population; Tamoxifen; Confidence interval","score_opus":0.08903876053986022,"score_gpt":0.45073519568837245,"score_spread":0.36169643514851224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597839935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97897,0.00883681,0.0016932809,0.008861104,0.00070939324,0.0003863755,0.000033925622,0.0000047685453,0.0005043724],"genre_scores_gemma":[0.990211,0.0015082044,0.0054564164,0.0015000359,0.0007356799,0.000047847516,0.000009593653,0.000015589412,0.0005156238],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99781775,0.0002710308,0.0013423591,0.00021015023,0.00013539493,0.00022330899],"domain_scores_gemma":[0.99752706,0.00034752258,0.0011640771,0.00018927842,0.0005008189,0.00027121638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013120458,0.00013936017,0.0015428978,0.0000672561,0.000037626538,0.000011281762,0.00023594913,0.00046686205,0.00018515147],"category_scores_gemma":[0.00037836636,0.00008578914,0.00295742,0.00012043852,0.00011151757,0.000009374814,0.000035461417,0.00034781903,0.00000886784],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005996763,0.002578505,0.007198991,0.000048653717,0.58012885,0.000085884116,0.000043285036,0.0042400905,0.14365113,0.0002493669,0.040542044,0.21523647],"study_design_scores_gemma":[0.020490188,0.037123676,0.074942715,0.000017111826,0.52561766,0.00091778004,0.0001839595,0.0009832447,0.023433521,0.0016884056,0.3134855,0.0011162467],"about_ca_topic_score_codex":0.000019223568,"about_ca_topic_score_gemma":0.000018336119,"teacher_disagreement_score":0.27294344,"about_ca_system_score_codex":0.000015352098,"about_ca_system_score_gemma":0.0004901335,"threshold_uncertainty_score":0.36008677},"labels":[],"label_agreement":null},{"id":"W2597847903","doi":"10.1200/jco.2013.31.15_suppl.e17509","title":"A discrete choice experiment to examine preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors (G-CSF) in previously treated breast cancer patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Willingness to pay; Context (archaeology); Febrile neutropenia; Schedule; Logistic regression; Breast cancer; Neutropenia; Granulocyte colony-stimulating factor; Incidence (geometry); Intensive care medicine; Internal medicine; Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.3503556131395722,"score_gpt":0.5479328216880263,"score_spread":0.19757720854845406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597847903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98392636,0.0002562558,0.00005717292,0.009717531,0.0011082434,0.0048125787,0.000036628415,0.000017330694,0.00006789652],"genre_scores_gemma":[0.99379796,0.00009410509,0.0023864899,0.001903952,0.00033023447,0.0013459042,0.00000936409,0.000030514922,0.00010146308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99305004,0.0020704414,0.0036202115,0.000358018,0.00033033645,0.0005709623],"domain_scores_gemma":[0.98534805,0.009622389,0.002321649,0.0003176782,0.0016289445,0.00076127204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012398034,0.00023389273,0.0013289483,0.00017884297,0.00029240083,0.000017835446,0.00041252462,0.00039428726,0.000106686275],"category_scores_gemma":[0.007719599,0.00014690986,0.00012227855,0.00028274598,0.00007848645,0.0003283251,0.00023312612,0.001104478,0.000010554201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001140313,0.0004431788,0.9638346,0.00019809457,0.000038174956,9.2776594e-7,0.005962245,0.00008443992,0.000055652785,0.000006266779,0.00032979794,0.027906353],"study_design_scores_gemma":[0.0044029774,0.0073578404,0.98201406,0.00062205753,0.000050091316,9.485232e-7,0.0017074234,0.00035498655,0.000015013256,0.000091071954,0.0032073355,0.00017619641],"about_ca_topic_score_codex":0.0043203197,"about_ca_topic_score_gemma":0.0029277483,"teacher_disagreement_score":0.027730156,"about_ca_system_score_codex":0.00065897324,"about_ca_system_score_gemma":0.0011979124,"threshold_uncertainty_score":0.9241639},"labels":[],"label_agreement":null},{"id":"W2597850117","doi":"10.1200/jco.2013.31.15_suppl.10528","title":"Discordance of oncologic surgical classifications in COG studies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Cog; Surgery; Radical surgery; Resection; Resection margin; General surgery; Cancer; Internal medicine","score_opus":0.3937819821831515,"score_gpt":0.5854029967110247,"score_spread":0.19162101452787317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597850117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613761,0.00391015,0.000007441271,0.030182075,0.00071041967,0.00026160575,0.0000014410862,0.0000031356121,0.0035476778],"genre_scores_gemma":[0.98709995,0.009960096,0.0015651009,0.00066755177,0.00043025942,0.000030658164,8.717113e-7,0.000005892367,0.00023959659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996924,0.00024925778,0.002324533,0.00013479617,0.00021618824,0.00015122381],"domain_scores_gemma":[0.9939194,0.0038563847,0.0013825309,0.00015814506,0.00048515177,0.00019839169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013567272,0.000088620676,0.0015638068,0.00009571452,0.00001483304,0.0000026926496,0.00009813165,0.00017797035,0.0002585574],"category_scores_gemma":[0.002072517,0.0000532249,0.00036718987,0.00017007928,0.0003300658,0.00006970565,0.000036576123,0.00051217264,0.000026979009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010968975,0.00924711,0.7850052,0.000044212687,0.0006433353,0.0009106906,0.00015430614,0.000019064824,0.00006360506,0.0008800055,0.02064882,0.18128671],"study_design_scores_gemma":[0.0082624415,0.010201096,0.9252982,0.00016895737,0.00025662227,0.00019701208,0.0004477605,0.000026441234,0.00004414084,0.000907072,0.05413955,0.000050701386],"about_ca_topic_score_codex":0.000060211303,"about_ca_topic_score_gemma":0.0001219361,"teacher_disagreement_score":0.18123601,"about_ca_system_score_codex":0.00026496281,"about_ca_system_score_gemma":0.0009421412,"threshold_uncertainty_score":0.2831022},"labels":[],"label_agreement":null},{"id":"W2597889290","doi":"10.1200/jco.2017.35.4_suppl.674","title":"Primary tumor location and survival in general population with metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Primary tumor; Oncology; Cohort; Chemotherapy; Population; Proportional hazards model; Multivariate analysis; Gastroenterology; Cancer; Metastasis","score_opus":0.10478725132042753,"score_gpt":0.4691968319345005,"score_spread":0.36440958061407297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597889290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934687,0.0007084388,0.000017876657,0.0035565253,0.0005782232,0.00017766976,0.0000021926494,0.000002744894,0.0014876082],"genre_scores_gemma":[0.9969206,0.00072358694,0.0014081006,0.0003752042,0.0004392926,0.000010726095,0.0000021064754,0.000007966645,0.000112406124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985869,0.0001313741,0.00082108757,0.00013055743,0.00020586884,0.00012423158],"domain_scores_gemma":[0.99811006,0.0003434915,0.0011014213,0.00008720612,0.0002372786,0.00012052544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009780328,0.000093336515,0.0009855346,0.000061593775,0.00008247832,0.000014435363,0.000059524544,0.00006145736,0.00001977369],"category_scores_gemma":[0.0007587815,0.000056705223,0.000077635115,0.000044199416,0.00017169249,0.00013877977,0.000035309,0.00030185567,6.492848e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006100933,0.0004326477,0.89360744,0.00003184678,0.00026174812,0.0003943277,0.00007030999,0.000020261334,0.00004477646,0.000050420975,0.0000837717,0.09890153],"study_design_scores_gemma":[0.0076635224,0.0067888936,0.98374414,0.0000965598,0.00031799433,0.0001582814,0.00005383117,0.00012617902,0.000013848696,0.00011298655,0.0008667409,0.00005702916],"about_ca_topic_score_codex":0.00080623763,"about_ca_topic_score_gemma":0.0054217563,"teacher_disagreement_score":0.098844506,"about_ca_system_score_codex":0.00025311502,"about_ca_system_score_gemma":0.000726646,"threshold_uncertainty_score":0.3025467},"labels":[],"label_agreement":null},{"id":"W2597889315","doi":"10.1200/jco.2009.27.15_suppl.4609","title":"Phase II trial of erlotinib in advanced pancreatic cancer (PC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Rash; Gemcitabine; Internal medicine; Adverse effect; Gastroenterology; Epidermal growth factor receptor; Erlotinib Hydrochloride; Oncology; Cancer","score_opus":0.20255830559391272,"score_gpt":0.5849707875033292,"score_spread":0.38241248190941646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597889315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979057,0.0007989888,0.000047438625,0.010366139,0.0007248053,0.0005831241,0.0000030703725,0.0000053381946,0.008414081],"genre_scores_gemma":[0.98958135,0.0032489307,0.0037094117,0.0014603913,0.001137071,0.000011139475,0.0000014351757,0.000009558571,0.0008406945],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948334,0.0006142045,0.0035599628,0.00018243537,0.00047590816,0.00033405115],"domain_scores_gemma":[0.99422675,0.0028657757,0.0018205285,0.00022191137,0.0004711869,0.0003938447],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005221319,0.00013579585,0.0031040169,0.00025019902,0.00003241913,0.000002089243,0.00020070275,0.00045467826,0.0004120306],"category_scores_gemma":[0.0093339365,0.00009420664,0.00045212032,0.00027299864,0.00027604494,0.00009264723,0.000033989265,0.0012247814,0.0000061296414],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.381008,0.028114317,0.053968962,0.000040869785,0.00034860655,0.00083031284,0.00025198126,0.0000101181,0.0013541827,0.0002048482,0.002129615,0.5317382],"study_design_scores_gemma":[0.5131253,0.3122632,0.15348808,0.00040214605,0.000772288,0.00016589052,0.00015975513,0.0002605904,0.0001779585,0.0013261414,0.01774251,0.00011618112],"about_ca_topic_score_codex":0.000035957008,"about_ca_topic_score_gemma":0.00004727988,"teacher_disagreement_score":0.531622,"about_ca_system_score_codex":0.00018968775,"about_ca_system_score_gemma":0.004090159,"threshold_uncertainty_score":0.99901086},"labels":[],"label_agreement":null},{"id":"W2597896213","doi":"10.1200/jco.2014.32.15_suppl.2097","title":"Neurocognitive functions in adults treated with radiation for primary brain tumors: A longitudinal study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neurocognitive; Medicine; Cognition; Cohort; Population; Executive functions; Effects of sleep deprivation on cognitive performance; Pediatrics; Internal medicine; Psychiatry","score_opus":0.07629892438433158,"score_gpt":0.42336033971382353,"score_spread":0.347061415329492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597896213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258363,0.0000519387,0.00027501496,0.0054241265,0.00016694053,0.00079022005,0.0000039519423,0.000007129476,0.0006970465],"genre_scores_gemma":[0.99750715,0.000016366295,0.0005024867,0.001267567,0.0005803824,0.00006386067,0.000011102343,0.000013515932,0.000037546433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978299,0.00037337406,0.0012438438,0.00019452459,0.000196638,0.00016171474],"domain_scores_gemma":[0.99419963,0.0042170356,0.00088150427,0.00010099811,0.00039981105,0.00020100528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015157884,0.00011597376,0.0010206786,0.00019600014,0.00003351385,0.000006592749,0.000048493876,0.00011922077,0.000020115831],"category_scores_gemma":[0.0031605929,0.00007249176,0.00021901952,0.00017637327,0.0000635001,0.00008374078,0.000011665601,0.00035344542,0.000006418807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011692295,0.009144566,0.8733965,0.000017629674,0.00027249023,0.0005107296,0.000073371346,0.000015478177,0.000009387155,0.000015485855,0.0010288901,0.103823155],"study_design_scores_gemma":[0.038197715,0.07310099,0.8852631,0.00016495404,0.00044678836,0.00017878684,0.00016727563,0.00009291022,0.000013090092,0.000039358754,0.002278414,0.000056638277],"about_ca_topic_score_codex":0.000029264063,"about_ca_topic_score_gemma":0.00022936708,"teacher_disagreement_score":0.103766516,"about_ca_system_score_codex":0.00013714985,"about_ca_system_score_gemma":0.00044316158,"threshold_uncertainty_score":0.37837532},"labels":[],"label_agreement":null},{"id":"W2597924473","doi":"10.1200/jco.2014.32.15_suppl.9504","title":"Long-term risk of heart failure associated with adjuvant trastuzumab in breast cancer patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Trastuzumab; Breast cancer; Anthracycline; Proportional hazards model; Population; Cohort; Oncology; Cancer; Retrospective cohort study; Surgery","score_opus":0.03156497776054292,"score_gpt":0.3798128040625056,"score_spread":0.3482478263019627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597924473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509263,0.00004746617,0.00007191144,0.0041813985,0.00027039828,0.00016038124,0.000013686494,0.000004647264,0.00015750695],"genre_scores_gemma":[0.99802494,0.00019238671,0.0002661026,0.0010438636,0.00043086952,0.0000024054968,0.0000055121054,0.000013872414,0.000020024407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742216,0.0005240989,0.0014053342,0.00013218458,0.00034973217,0.0001664656],"domain_scores_gemma":[0.9966082,0.0009511235,0.0016166292,0.0001103252,0.0005282031,0.00018553258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002107748,0.00010694098,0.0013737015,0.000100444784,0.000017700646,0.0000030604854,0.00007683803,0.00036294572,0.000073998395],"category_scores_gemma":[0.0012869883,0.00007195475,0.00032042808,0.0001540443,0.00014554942,0.000080784004,0.000011424353,0.00092090387,0.0000014853102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021343867,0.0016799079,0.9453531,0.000018974752,0.00034105362,0.000018147986,0.00009403131,0.000026308782,0.0011438042,0.0000035971507,0.0006315408,0.048555147],"study_design_scores_gemma":[0.014930181,0.0069247023,0.9753312,0.00043532616,0.0003151915,0.00007389005,0.00002799264,0.000028044353,0.0012350163,0.000033976,0.00059452414,0.000069949936],"about_ca_topic_score_codex":0.0000441917,"about_ca_topic_score_gemma":0.0004953347,"teacher_disagreement_score":0.048485197,"about_ca_system_score_codex":0.0002402441,"about_ca_system_score_gemma":0.000746983,"threshold_uncertainty_score":0.40009204},"labels":[],"label_agreement":null},{"id":"W2597943206","doi":"10.1200/jco.2017.35.6_suppl.e560","title":"Integrated somatic subtypes of localized intermediate-risk prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Biomarker; Prostate cancer; Medicine; Oncology; Biomarker discovery; TMPRSS2; Cancer; Prostate; Internal medicine; Bioinformatics; Disease; Biology; Gene; Genetics; Proteomics; Coronavirus disease 2019 (COVID-19)","score_opus":0.13373867607831488,"score_gpt":0.5165692708157237,"score_spread":0.38283059473740877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597943206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011,0.0016774894,0.000035461453,0.004996158,0.0014000607,0.0002789985,0.000018733408,0.0000068326526,0.001476285],"genre_scores_gemma":[0.9832887,0.013774984,0.0009938959,0.00017083068,0.0005218327,0.000008152694,0.0000035707546,0.000015775879,0.0012222411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967607,0.00035305636,0.0021252297,0.00014918348,0.00036586373,0.00024591645],"domain_scores_gemma":[0.9935354,0.0011626293,0.0037466073,0.00033655346,0.000868092,0.00035072758],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029184902,0.00012947552,0.0015975081,0.000119592005,0.00008776728,0.000017780685,0.00032749763,0.0002631096,0.00025181912],"category_scores_gemma":[0.009149801,0.00007301666,0.00043412118,0.00006786577,0.0008187901,0.00013982804,0.000088860135,0.0010120192,0.000015296233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012851482,0.00095733133,0.643385,0.000112611015,0.00082512555,0.00053243747,0.00021037128,0.0000035200821,0.0003239775,0.000015912938,0.0025876458,0.3381946],"study_design_scores_gemma":[0.031273272,0.02156734,0.8957801,0.0010406775,0.0010439432,0.00010788641,0.0003672517,0.00052976754,0.003297298,0.0015628644,0.043289296,0.00014031424],"about_ca_topic_score_codex":0.00026641646,"about_ca_topic_score_gemma":0.00016075629,"teacher_disagreement_score":0.3380543,"about_ca_system_score_codex":0.00016511344,"about_ca_system_score_gemma":0.0034248324,"threshold_uncertainty_score":0.9991965},"labels":[],"label_agreement":null},{"id":"W2597980213","doi":"10.1200/jco.2014.32.15_suppl.e19080","title":"Population-based evaluation of second-line palliative chemotherapy (SCT) versus erlotinib (E) in advanced non-small cell lung cancer (NSCLC) patients (pts).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Erlotinib; Internal medicine; Vinorelbine; Lung cancer; Pemetrexed; Oncology; Population; Cancer; Performance status; Proportional hazards model; Hazard ratio; Chemotherapy; Epidermal growth factor receptor; Confidence interval; Cisplatin","score_opus":0.07575034353656812,"score_gpt":0.5097801773952608,"score_spread":0.4340298338586927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597980213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427986,0.0002676506,0.0002632338,0.001074637,0.0013961119,0.0006987343,0.000012660137,0.000004201566,0.0020029142],"genre_scores_gemma":[0.9952328,0.000121987396,0.0032076961,0.00090456236,0.00036518127,0.00003006264,0.000036196405,0.000019383962,0.00008209247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698246,0.0003757537,0.0018142184,0.00018995652,0.00046666517,0.00017096073],"domain_scores_gemma":[0.99486005,0.0014621454,0.0021044991,0.00015591687,0.0012530504,0.00016434139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019825846,0.00013994557,0.0009950328,0.00015081375,0.000026198399,0.0000035009466,0.00009281823,0.00022345659,0.0003934293],"category_scores_gemma":[0.0013338958,0.00010551879,0.0002623612,0.00016946202,0.000044271725,0.00008291135,0.000009674107,0.0003817315,0.0000022385946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058081974,0.0023827928,0.8269405,0.00006936824,0.0002618456,0.0000037170735,0.00031344948,0.0045248982,0.000081626895,0.000008672646,0.00017903066,0.15942591],"study_design_scores_gemma":[0.074161045,0.008009183,0.9063409,0.00023330619,0.00083237316,3.511107e-7,0.00006120192,0.0087790545,0.00029162338,0.00006484741,0.0011387101,0.00008739299],"about_ca_topic_score_codex":0.00012531834,"about_ca_topic_score_gemma":0.00080602133,"teacher_disagreement_score":0.15933852,"about_ca_system_score_codex":0.0007091126,"about_ca_system_score_gemma":0.0025348242,"threshold_uncertainty_score":0.44966692},"labels":[],"label_agreement":null},{"id":"W2597980661","doi":"10.1200/jco.2017.35.4_suppl.tps814","title":"Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Neoadjuvant therapy; Clinical endpoint; Total mesorectal excision; Oncology; FOLFOX; Population; Internal medicine; Chemoradiotherapy; Radiation therapy; Randomized controlled trial; Cancer; Surgery; Oxaliplatin; Breast cancer","score_opus":0.4656506032312347,"score_gpt":0.609232623020844,"score_spread":0.14358201978960933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597980661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97288615,0.0014097629,0.000006428042,0.0068350644,0.009220126,0.0009231763,0.000008770571,0.000020596455,0.008689907],"genre_scores_gemma":[0.9848511,0.006369027,0.0007756427,0.0013402454,0.0061090956,0.000038085807,0.0000031244404,0.000038593596,0.0004750875],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920253,0.000652809,0.005479296,0.00052086957,0.00072793924,0.0005937884],"domain_scores_gemma":[0.99015903,0.0035317193,0.004370479,0.000626361,0.00039573634,0.0009166523],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007648827,0.00033888526,0.0037434069,0.00019003445,0.00025052478,0.000044307886,0.00053773506,0.00096895674,0.00070068194],"category_scores_gemma":[0.010631551,0.00023239502,0.0017206741,0.0001416695,0.000644067,0.00040465096,0.00026168214,0.0027575374,0.00002249084],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3306026,0.010068067,0.05817371,0.000007084063,0.0005090171,0.0031885249,0.000085022875,0.0000021070146,0.000040789175,0.000024267072,0.0009831712,0.5963156],"study_design_scores_gemma":[0.5008278,0.1552199,0.26085213,0.0002978019,0.0003213876,0.0006064701,0.000075316944,0.0002549607,0.00008928154,0.00031715995,0.08089521,0.00024260122],"about_ca_topic_score_codex":0.00023458624,"about_ca_topic_score_gemma":0.00036053188,"teacher_disagreement_score":0.59607303,"about_ca_system_score_codex":0.0005708797,"about_ca_system_score_gemma":0.0039711683,"threshold_uncertainty_score":0.99954313},"labels":[],"label_agreement":null},{"id":"W2597981368","doi":"10.1200/jco.2014.32.15_suppl.8519","title":"Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Gastroenterology; Rituximab; Adverse effect; Febrile neutropenia; Refractory (planetary science); Nausea; Diarrhea; Lymphoma; Surgery; Toxicity","score_opus":0.041500481084312306,"score_gpt":0.3980693829016003,"score_spread":0.356568901817288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597981368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436,0.00039384008,0.00004572027,0.0008264337,0.00083071116,0.0021302649,0.000025894207,0.000014651944,0.001372461],"genre_scores_gemma":[0.9962148,0.00039557053,0.0024015894,0.0003437427,0.00034920764,0.000056804536,0.000019681522,0.000057434376,0.00016118916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98776245,0.002532933,0.0073652235,0.0006138039,0.0011929523,0.0005326647],"domain_scores_gemma":[0.9809256,0.009605538,0.0070245345,0.0007585402,0.0011367016,0.0005490854],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007470956,0.0005117632,0.006833244,0.0006148516,0.000088720684,0.000009723842,0.00044773717,0.00066240143,0.000065200285],"category_scores_gemma":[0.012801016,0.00030545352,0.0009548947,0.0004848481,0.00062960084,0.00021607743,0.00022497773,0.0008376425,0.000010919646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7367303,0.13806233,0.020073608,0.000094883486,0.0012258113,0.0009552132,0.0014277381,0.000039878614,0.000019760027,0.000019455343,0.0011039545,0.10024706],"study_design_scores_gemma":[0.57584125,0.25630954,0.16323602,0.0006833201,0.0012091533,0.000088917455,0.00032919494,0.0005473916,0.00011787614,0.000033197684,0.0014300335,0.00017413145],"about_ca_topic_score_codex":0.00043556278,"about_ca_topic_score_gemma":0.00018528686,"teacher_disagreement_score":0.16088907,"about_ca_system_score_codex":0.0010337398,"about_ca_system_score_gemma":0.0041599427,"threshold_uncertainty_score":0.99993974},"labels":[],"label_agreement":null},{"id":"W2598038468","doi":"10.1200/jco.2012.30.15_suppl.6627","title":"Post hoc analysis of association between treatment response and various indicators of efficacy and safety in a randomized phase III trial of decitabine in older patients with acute myeloid leukemia.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Cytarabine; Myeloid leukemia; Post-hoc analysis; Gastroenterology; Azacitidine; Neutropenia; Surgery; Chemotherapy","score_opus":0.030669062270419694,"score_gpt":0.4196863267027829,"score_spread":0.3890172644323632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598038468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997734,0.00020238655,0.000040155453,0.000717391,0.000068823596,0.0011492132,0.000049236114,0.0000016010044,0.000037169248],"genre_scores_gemma":[0.9976067,0.0012484856,0.000911693,0.000056502726,0.000104330706,0.000008380745,0.000024476034,0.0000122064275,0.000027220369],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9920162,0.0028687224,0.0040245806,0.00018075717,0.00062944187,0.00028029882],"domain_scores_gemma":[0.9727597,0.022050263,0.004226935,0.00018024692,0.00045059167,0.0003322669],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015860066,0.00016607619,0.00496846,0.001556914,0.00001551697,0.0000026442572,0.00009998502,0.0004697048,0.000024394176],"category_scores_gemma":[0.012754152,0.00010391286,0.0004025159,0.0009482152,0.00035175346,0.000122053265,0.000058594145,0.0006355662,1.8318836e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59835815,0.003535053,0.3716165,0.000010772919,0.005014642,0.000029018016,0.0008422013,0.000004403708,0.00008854901,0.0000021134078,0.000006204465,0.020492353],"study_design_scores_gemma":[0.48485094,0.01976904,0.49079093,0.000047750516,0.004322756,0.0000032522942,0.000048136684,0.000026223197,0.00006170731,0.0000027752224,0.000036939146,0.000039548402],"about_ca_topic_score_codex":0.00014938739,"about_ca_topic_score_gemma":0.00007065828,"teacher_disagreement_score":0.1191744,"about_ca_system_score_codex":0.001382508,"about_ca_system_score_gemma":0.0023963717,"threshold_uncertainty_score":0.99556184},"labels":[],"label_agreement":null},{"id":"W2598049994","doi":"10.1200/jco.2014.32.15_suppl.e14504","title":"Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Queen's University; Cancer Care Ontario; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Essar Steel Algoma (Canada); Group Health Centre; St. Michael's Hospital; Health Sciences Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Cancer; Colorectal cancer; Internal medicine; Cohort; Chemotherapy; Surgery","score_opus":0.1441770359254079,"score_gpt":0.510190790814212,"score_spread":0.36601375488880417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598049994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897204,0.00008673576,0.0032101641,0.0045361645,0.0004875583,0.0017291702,0.000015574491,0.0000057825364,0.00020842893],"genre_scores_gemma":[0.9883276,0.00008196142,0.009621287,0.0012185833,0.00044558445,0.0001604083,0.000003605479,0.000013337231,0.00012763949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99768674,0.00022145455,0.0015449924,0.00016887437,0.00021288582,0.00016506568],"domain_scores_gemma":[0.995778,0.0024097676,0.0009822034,0.00010637106,0.0005231948,0.00020046391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002987839,0.00010236837,0.0013087312,0.00013397324,0.00002180319,0.0000030081937,0.00010208229,0.00021155289,0.00005396117],"category_scores_gemma":[0.004551942,0.000076047945,0.00031102472,0.00015270745,0.000056145218,0.000056994795,0.000018119052,0.00021223447,0.0000044039534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072353795,0.012881126,0.39515114,0.00007749106,0.0005620256,0.0000527292,0.0004264118,0.00026095827,0.00078529207,0.000051246123,0.002321956,0.5150758],"study_design_scores_gemma":[0.060085494,0.07978255,0.78557026,0.00023671731,0.00043137235,0.000031092553,0.000043815668,0.0024222324,0.00036805696,0.0001241797,0.07079674,0.000107479165],"about_ca_topic_score_codex":0.000047340232,"about_ca_topic_score_gemma":0.0004853307,"teacher_disagreement_score":0.51496834,"about_ca_system_score_codex":0.00040276613,"about_ca_system_score_gemma":0.0008567193,"threshold_uncertainty_score":0.54494286},"labels":[],"label_agreement":null},{"id":"W2598060115","doi":"10.1200/jco.2013.31.15_suppl.3521","title":"Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Capecitabine; Medicine; Bevacizumab; Hazard ratio; Internal medicine; Colorectal cancer; Population; Clinical endpoint; Confidence interval; Oncology; Phases of clinical research; Randomized controlled trial; Cancer; Clinical trial; Surgery; Chemotherapy","score_opus":0.058861511105318495,"score_gpt":0.4165541518441126,"score_spread":0.3576926407387941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598060115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990937,0.00047532303,0.00016496664,0.002953963,0.00018640544,0.005227705,0.000012474021,0.0000017281338,0.000040414525],"genre_scores_gemma":[0.9975699,0.0010532448,0.000799466,0.00007063093,0.000076099015,0.00040039638,0.000005647471,0.00001071094,0.000013867665],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973238,0.0002137022,0.00190011,0.00015642945,0.00024088321,0.0001650615],"domain_scores_gemma":[0.99172336,0.0064108125,0.0012782331,0.00008206378,0.00040581753,0.00009971403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010719574,0.00016008654,0.002633807,0.00015292369,0.000036832505,0.0000050325257,0.000059365073,0.00006971786,0.000016782784],"category_scores_gemma":[0.0009870923,0.000072605326,0.00019297555,0.00020403595,0.00022100002,0.00007008012,0.000017674118,0.00015361342,9.706512e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76856464,0.008473596,0.015504605,0.000026470583,0.0009946774,0.000027170592,0.00088769157,0.0000638601,0.000008151901,0.00001084141,0.000009168832,0.2054291],"study_design_scores_gemma":[0.72836185,0.14985426,0.119945645,0.00015054847,0.0009519265,0.000005542231,0.00027285842,0.0002012324,0.00002344455,0.000035591143,0.00014494268,0.00005216006],"about_ca_topic_score_codex":0.00076941523,"about_ca_topic_score_gemma":0.0047167283,"teacher_disagreement_score":0.20537695,"about_ca_system_score_codex":0.00030907686,"about_ca_system_score_gemma":0.0003968928,"threshold_uncertainty_score":0.2960759},"labels":[],"label_agreement":null},{"id":"W2598071611","doi":"10.1200/jco.2017.35.6_suppl.492","title":"Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta; Université de Montréal; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Avelumab; Pembrolizumab; Atezolizumab; Renal cell carcinoma; Internal medicine; Oncology; Population; Cancer; Immunotherapy","score_opus":0.2582689320801057,"score_gpt":0.4875456563478964,"score_spread":0.22927672426779067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598071611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97189754,0.00045492983,0.00000767137,0.0065031755,0.001341131,0.00032305068,0.000021071954,0.0000034564828,0.019447945],"genre_scores_gemma":[0.9935657,0.0005507961,0.0037776898,0.0005959725,0.0007119542,0.000009092597,0.000007867093,0.000019506771,0.0007614267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99325156,0.0011968203,0.004267268,0.00034095132,0.00058016187,0.00036325393],"domain_scores_gemma":[0.9861142,0.0064118775,0.0057490245,0.0009974599,0.00038991214,0.00033751325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004594345,0.00022588669,0.0022241161,0.0001563013,0.00013245558,0.000022854327,0.0008362674,0.0002668493,0.00014157957],"category_scores_gemma":[0.005081497,0.00013179821,0.00065516966,0.00012490423,0.0009929134,0.00016000569,0.00024283875,0.0011956829,0.00001759134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049075164,0.007262225,0.8351361,0.00004311167,0.00072061416,0.016516067,0.0059697093,0.000044756853,0.007453245,0.000068469264,0.011845617,0.06586493],"study_design_scores_gemma":[0.021418126,0.009519099,0.94585073,0.00011242343,0.00053711503,0.00015212383,0.00067153206,0.00006126935,0.0034507583,0.00023304427,0.017891346,0.000102457954],"about_ca_topic_score_codex":0.0035739192,"about_ca_topic_score_gemma":0.0020140267,"teacher_disagreement_score":0.11071461,"about_ca_system_score_codex":0.00048395598,"about_ca_system_score_gemma":0.0027149657,"threshold_uncertainty_score":0.60833937},"labels":[],"label_agreement":null},{"id":"W2598094694","doi":"10.1200/jco.2012.30.15_suppl.tps7613","title":"The GALAXY Trial(NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Oncology; KRAS; Lung cancer; Population; Cancer; Clinical endpoint; Adverse effect; Gastroenterology; Clinical trial; Colorectal cancer","score_opus":0.09510765718728818,"score_gpt":0.4441843038017148,"score_spread":0.3490766466144266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598094694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945494,0.00064605626,0.00013575371,0.0007758603,0.00043204668,0.0026516628,0.000002548581,0.000003444613,0.00080322963],"genre_scores_gemma":[0.9977088,0.0006868292,0.0005526082,0.00008747764,0.0003766946,0.00012590637,0.0000049779787,0.000032031065,0.00042466633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911941,0.0041090883,0.002930179,0.00033000266,0.00080200814,0.000634592],"domain_scores_gemma":[0.99264216,0.0041713696,0.0018020627,0.00048130788,0.00059112196,0.00031197222],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018007776,0.00026396086,0.0020538636,0.00023603623,0.00007629622,0.00002674832,0.0005417919,0.00045930143,0.000035864166],"category_scores_gemma":[0.0096595455,0.00013636898,0.00024565883,0.00044869195,0.000534353,0.000038390233,0.00015997904,0.0011630337,0.0000029876776],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9730216,0.006584892,0.012237074,0.000022198901,0.0005598991,0.0001595377,0.0003181732,0.00007933616,0.0010951627,0.0000425372,0.00013597053,0.00574361],"study_design_scores_gemma":[0.9072687,0.0728998,0.012509405,0.00006053253,0.00015050541,0.00004424854,0.0013043963,0.00006658515,0.0014950442,0.000022639219,0.003970744,0.0002073721],"about_ca_topic_score_codex":0.0002351673,"about_ca_topic_score_gemma":0.004604225,"teacher_disagreement_score":0.06631491,"about_ca_system_score_codex":0.0001271796,"about_ca_system_score_gemma":0.0021034486,"threshold_uncertainty_score":0.9986825},"labels":[],"label_agreement":null},{"id":"W2598103319","doi":"10.1200/jco.2012.30.15_suppl.6604","title":"Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Adverse effect; Tolerability; Rash; Gastroenterology; Nausea; Febrile neutropenia; Anemia; Surgery; Toxicity","score_opus":0.03072465755673829,"score_gpt":0.36816574566352855,"score_spread":0.33744108810679024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598103319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954198,0.0009413876,0.000061842824,0.0014653549,0.00061560137,0.0005516146,0.000030393825,0.000011220805,0.0009027919],"genre_scores_gemma":[0.99555516,0.000254574,0.0026188775,0.0006255727,0.00064367516,0.0000074473965,0.00003478725,0.00003893901,0.00022096452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931316,0.0006154016,0.0042972076,0.00035640705,0.0009269328,0.0006724773],"domain_scores_gemma":[0.993711,0.0013214895,0.0027230044,0.0005484253,0.0007401366,0.0009559645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040236833,0.00034023993,0.003439299,0.0010369188,0.000043278214,0.000006449217,0.0002643991,0.00048522043,0.00037793157],"category_scores_gemma":[0.0026501205,0.0002290864,0.0007811404,0.0017103996,0.00019558484,0.00023432223,0.000118847995,0.0011120035,0.00002197136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027930927,0.003937957,0.9086611,0.00007771452,0.004751306,0.00029018187,0.0002163345,0.00071413873,0.00060741196,0.00003927348,0.0008362324,0.05193739],"study_design_scores_gemma":[0.03159613,0.016431231,0.9327131,0.0003209033,0.005510978,0.000019704354,0.000047056194,0.00011814375,0.0005983704,0.0000059204485,0.012442283,0.00019620241],"about_ca_topic_score_codex":0.00022679736,"about_ca_topic_score_gemma":0.00082465674,"teacher_disagreement_score":0.051741187,"about_ca_system_score_codex":0.0067407396,"about_ca_system_score_gemma":0.0044154106,"threshold_uncertainty_score":0.9970722},"labels":[],"label_agreement":null},{"id":"W2598106009","doi":"10.1200/jco.2017.35.5_suppl.213","title":"Couples symptom burden in oncology care: Perception of self and the other.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Anxiety; Distress; Nausea; Massage; Physical therapy; Depression (economics); Breast cancer; Rating scale; Cancer; Internal medicine; Psychiatry; Clinical psychology; Alternative medicine","score_opus":0.08031024428780027,"score_gpt":0.46844776960058254,"score_spread":0.3881375253127823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598106009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654383,0.001563653,0.000013396487,0.023482088,0.0012893507,0.00015274592,0.000002118089,0.0000032521439,0.008055087],"genre_scores_gemma":[0.993254,0.0038172344,0.00027879767,0.0011293804,0.0014165606,0.0000029677617,4.2970757e-7,0.000008407668,0.00009222704],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978173,0.00045529724,0.0012792186,0.0001138736,0.00020879284,0.00012551829],"domain_scores_gemma":[0.9958563,0.0018490847,0.00158061,0.00025449105,0.00033360213,0.00012594354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036424908,0.000080693135,0.0012161596,0.0000600453,0.000056651308,0.00000929868,0.00021789676,0.0003591769,0.0000809534],"category_scores_gemma":[0.0020191523,0.000046409612,0.00026766106,0.00003181113,0.0006854486,0.00006513348,0.00006883078,0.0007116794,0.0000029863083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010766005,0.00049028726,0.35181057,0.00010633275,0.00029253613,0.00021623017,0.011138106,0.000006981887,0.00020142533,0.0007818561,0.00084289996,0.62334675],"study_design_scores_gemma":[0.018920846,0.006660395,0.7119286,0.00014965585,0.0003906149,0.00025806527,0.007824036,0.00010536067,0.000010927657,0.00037689265,0.2533073,0.00006731603],"about_ca_topic_score_codex":0.0011850352,"about_ca_topic_score_gemma":0.0034088804,"teacher_disagreement_score":0.62327945,"about_ca_system_score_codex":0.00015428146,"about_ca_system_score_gemma":0.001026792,"threshold_uncertainty_score":0.30919325},"labels":[],"label_agreement":null},{"id":"W2598127994","doi":"10.1200/jco.2013.31.15_suppl.10062","title":"Predictors of declining levels of physical activity among adult survivors of childhood cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Confidence interval; Demography; Physical activity; Cancer; Relative risk; Obesity; Poisson regression; Childhood cancer; Gerontology; Population; Physical therapy; Internal medicine; Environmental health","score_opus":0.10164654603550043,"score_gpt":0.4533942580595001,"score_spread":0.3517477120239997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598127994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993657,0.00017006531,0.00011464849,0.0031729364,0.0015130348,0.00039882478,0.000045389916,0.0000116603305,0.00091646746],"genre_scores_gemma":[0.99633646,0.00026074832,0.0010407246,0.0004259733,0.0018476908,0.0000065488593,0.0000011643518,0.000033712764,0.000046953322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99287444,0.0010756198,0.0043213973,0.00029516913,0.00109659,0.00033679875],"domain_scores_gemma":[0.9821417,0.006958789,0.007978974,0.00043640693,0.001943817,0.0005403249],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039897314,0.0002571421,0.004084177,0.00021412845,0.000027444414,0.0000038423846,0.00041210305,0.00052710704,0.00024071588],"category_scores_gemma":[0.011777766,0.00019812869,0.0013193934,0.00033736165,0.0009853999,0.00030262538,0.0001316732,0.0014553514,0.0000036861288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015035393,0.0066248486,0.91067606,0.0003322238,0.0016161302,0.000016477221,0.0023614136,0.000075941105,0.001780786,0.000068872076,0.00080073386,0.07414295],"study_design_scores_gemma":[0.0061983657,0.011134151,0.9737367,0.0008716538,0.0006458086,0.000022330276,0.000587492,0.0001690672,0.0060555753,0.00023820339,0.00020060659,0.00014004202],"about_ca_topic_score_codex":0.003078637,"about_ca_topic_score_gemma":0.0008565474,"teacher_disagreement_score":0.07400291,"about_ca_system_score_codex":0.00010487823,"about_ca_system_score_gemma":0.0026587723,"threshold_uncertainty_score":0.99654645},"labels":[],"label_agreement":null},{"id":"W2598128017","doi":"10.1200/jco.2013.31.15_suppl.e14556","title":"Are XELOX and FOLFOX equivalent in colorectal cancer? Dose intensity, toxicity, and treatment duration in clinical practice.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"FOLFOX; Oxaliplatin; Medicine; Capecitabine; Internal medicine; Nausea; Colorectal cancer; Cumulative dose; Gastroenterology; Surgery; Oncology; Cancer","score_opus":0.20942390221721394,"score_gpt":0.5424612950939143,"score_spread":0.3330373928767003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598128017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95394546,0.0013752757,0.0000023589857,0.04235302,0.0011602518,0.00055786356,0.0000024261653,0.0000051598645,0.0005981584],"genre_scores_gemma":[0.97994316,0.014298771,0.0007182378,0.003935898,0.00096305786,0.00003292056,0.0000016442373,0.000010787534,0.00009550739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961928,0.0006323572,0.0024903645,0.000264161,0.00018136433,0.00023895767],"domain_scores_gemma":[0.99408054,0.0032909417,0.0018541504,0.00007747176,0.00032932175,0.00036754488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022749046,0.00016478903,0.0016154296,0.00017398236,0.000024927114,0.000014994538,0.000057703146,0.00041921771,0.00014021959],"category_scores_gemma":[0.0027705284,0.00011594033,0.00018903746,0.00012305474,0.00026495894,0.00024170196,0.00008079748,0.000809158,0.00000739375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008960657,0.0062723956,0.7877497,0.000015810383,0.00029228296,0.0011824423,0.00021182034,0.0000025995048,0.0003798109,0.000015603264,0.0018716701,0.19304523],"study_design_scores_gemma":[0.024402052,0.023172697,0.9418922,0.000102276186,0.0004032648,0.0005631663,0.00033536783,0.00021435936,0.00010627256,0.00021551421,0.008501733,0.00009106266],"about_ca_topic_score_codex":0.000611422,"about_ca_topic_score_gemma":0.004050855,"teacher_disagreement_score":0.19295417,"about_ca_system_score_codex":0.0005179731,"about_ca_system_score_gemma":0.00080222276,"threshold_uncertainty_score":0.47279096},"labels":[],"label_agreement":null},{"id":"W2598143957","doi":"10.1200/jco.2013.31.15_suppl.6595","title":"Patient perceptions about potential side effects and benefits from chemotherapy agents.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Nausea; Medicine; Mucositis; Side effect (computer science); Vomiting; Quality of life (healthcare); Chemotherapy; Internal medicine; Surgery","score_opus":0.06326017516239979,"score_gpt":0.4419449892995883,"score_spread":0.3786848141371885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598143957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98517704,0.0013549882,0.000029623008,0.010067396,0.0016819296,0.00029511558,0.0000044379626,0.000008004929,0.0013814701],"genre_scores_gemma":[0.9825305,0.003866775,0.0017491232,0.009976095,0.0016421048,0.000010765098,0.0000056911786,0.000013426228,0.00020553655],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982678,0.00020695818,0.0010267261,0.00015244672,0.00017470487,0.000171341],"domain_scores_gemma":[0.99773884,0.00093951344,0.00062574906,0.00009583864,0.0002049304,0.00039510202],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002771441,0.000117631345,0.0008816583,0.00006591389,0.00004143728,0.000009603114,0.000056382545,0.0002704471,0.002019325],"category_scores_gemma":[0.00023188746,0.00008171839,0.00030358764,0.000045928497,0.00013845981,0.00008775182,0.000029427705,0.00049791986,0.000071716895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017774432,0.0028911096,0.07543372,0.000017353628,0.0008469724,0.00030271814,0.000398747,0.000014464439,0.0029010028,0.000010353053,0.03246213,0.882944],"study_design_scores_gemma":[0.011398586,0.013034549,0.94743437,0.000051675626,0.00054528576,0.00016199099,0.000068198635,0.000085420266,0.00013508757,0.0003040246,0.026710479,0.00007031762],"about_ca_topic_score_codex":0.00016793954,"about_ca_topic_score_gemma":0.000020950889,"teacher_disagreement_score":0.88287365,"about_ca_system_score_codex":0.000085901294,"about_ca_system_score_gemma":0.00028298996,"threshold_uncertainty_score":0.99889296},"labels":[],"label_agreement":null},{"id":"W2598145223","doi":"10.1200/jco.2013.31.15_suppl.558","title":"Clinical management and resolution of stomatitis in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Memorial Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Stomatitis; Exemestane; Internal medicine; Everolimus; Surgery; Placebo; Breast cancer; Cancer; Tamoxifen","score_opus":0.10342428957402121,"score_gpt":0.48924493115082496,"score_spread":0.38582064157680374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598145223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892418,0.0015455976,0.00069579383,0.005263756,0.0006258806,0.00023332196,7.255194e-7,0.0000049498935,0.0023882184],"genre_scores_gemma":[0.96042275,0.0027792137,0.03466777,0.0014225546,0.00045513647,0.0000045972997,4.0762853e-7,0.000009428091,0.00023812788],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99653006,0.0003292524,0.0026490511,0.00012832279,0.00021808053,0.00014524942],"domain_scores_gemma":[0.99701524,0.0010703052,0.0013396664,0.000141781,0.00023745406,0.00019553292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025851298,0.00007742159,0.0011382034,0.00012928068,0.000009049208,0.0000022786458,0.00008656465,0.00022172938,0.0001398368],"category_scores_gemma":[0.0009213222,0.000057169495,0.00019223017,0.00009858198,0.0003198782,0.00013312123,0.00005407069,0.0005902931,0.000010666293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012799519,0.0007461868,0.23539126,0.000049173294,0.00017025511,0.00013274254,0.00004560337,0.000009593931,0.000052224485,0.00026293856,0.001067382,0.7607927],"study_design_scores_gemma":[0.00830365,0.0049709175,0.95403206,0.00023165994,0.000092113645,0.0001673085,0.00016602594,0.00013364303,0.00001274617,0.002441167,0.029402288,0.000046392608],"about_ca_topic_score_codex":0.000024484725,"about_ca_topic_score_gemma":0.000021176307,"teacher_disagreement_score":0.7607463,"about_ca_system_score_codex":0.00007444468,"about_ca_system_score_gemma":0.00020622637,"threshold_uncertainty_score":0.25645626},"labels":[],"label_agreement":null},{"id":"W2598147971","doi":"10.1200/jco.2017.35.4_suppl.tps503","title":"KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Hepatocellular carcinoma; Internal medicine; Adverse effect; Placebo; Milan criteria; Liver disease; Transplantation; Response Evaluation Criteria in Solid Tumors; Liver transplantation; Oncology; Surgery; Phases of clinical research; Clinical trial; Cancer; Immunotherapy; Pathology","score_opus":0.2289387289289545,"score_gpt":0.47014669670842907,"score_spread":0.24120796777947456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598147971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905073,0.0015174935,0.00016490615,0.0007612103,0.002121178,0.0032263915,0.000041460244,0.000010137087,0.0016498906],"genre_scores_gemma":[0.9967191,0.00022725957,0.0013355485,0.00010999052,0.0010224909,0.00010463972,0.00003596546,0.000044564476,0.00040044036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99388874,0.00071183016,0.0040856143,0.00040315968,0.00050762563,0.00040304425],"domain_scores_gemma":[0.987482,0.003899,0.0056263832,0.0007068624,0.001718937,0.0005668271],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003416696,0.00034411924,0.0051836646,0.00019930107,0.00023132999,0.00002239065,0.00042983118,0.0004857684,0.0002649242],"category_scores_gemma":[0.0064553604,0.00024605778,0.0019461875,0.0000711039,0.0004829951,0.00021784178,0.00011223897,0.0007691849,0.000008045727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7409378,0.009411889,0.20114098,0.0001587862,0.0019954701,0.0021366875,0.0012879465,0.0000016194178,0.00026397346,0.0000225505,0.00018294045,0.042459324],"study_design_scores_gemma":[0.87603843,0.10043139,0.0051834946,0.000100925376,0.0061745523,0.000079048186,0.002692086,0.00090819184,0.0026733354,0.000059146918,0.005452064,0.00020733959],"about_ca_topic_score_codex":0.00007858271,"about_ca_topic_score_gemma":0.00012536427,"teacher_disagreement_score":0.1959575,"about_ca_system_score_codex":0.00018566489,"about_ca_system_score_gemma":0.0017751051,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W2598181800","doi":"10.1200/jco.2012.30.15_suppl.5019","title":"A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University of Toronto; University Health Network; Cancer Care Ontario; Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Progression-free survival; Cancer; Oncology; Progressive disease; Adverse effect; Serous fluid; Chemotherapy; Gastroenterology","score_opus":0.09066157760645395,"score_gpt":0.46517900892513414,"score_spread":0.3745174313186802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598181800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271744,0.0019983025,0.0000041989474,0.0024220347,0.00088057306,0.0017308587,0.00010635503,0.000005545282,0.00013469718],"genre_scores_gemma":[0.99821913,0.00036550636,0.00026150505,0.0004290947,0.0005653872,0.00009143872,0.000002393261,0.000026945017,0.000038607603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99382025,0.00090773625,0.0038880315,0.00033443025,0.00064444,0.0004051116],"domain_scores_gemma":[0.9942217,0.001274272,0.00316417,0.00045931686,0.00035648423,0.0005240507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030285616,0.00029412194,0.0025359273,0.00019850151,0.00012498733,0.000005856429,0.00020359262,0.00025829024,0.00022253409],"category_scores_gemma":[0.0016361156,0.00017637001,0.00033635745,0.00036594959,0.00027310516,0.00012888586,0.00021814376,0.00097590155,9.395673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035839994,0.30216333,0.5563003,0.00008671115,0.0020015598,0.00058110495,0.0067966296,0.000027791237,0.0014453222,0.00004416063,0.0007465038,0.093966596],"study_design_scores_gemma":[0.2903851,0.27239302,0.41688064,0.00056652975,0.003151222,0.000115417366,0.0055642175,0.00006663529,0.00052233454,0.0000532508,0.010074591,0.00022704838],"about_ca_topic_score_codex":0.00061469997,"about_ca_topic_score_gemma":0.0027983093,"teacher_disagreement_score":0.2545451,"about_ca_system_score_codex":0.00026365666,"about_ca_system_score_gemma":0.0014609719,"threshold_uncertainty_score":0.71921605},"labels":[],"label_agreement":null},{"id":"W2598212995","doi":"10.1200/jco.2014.32.15_suppl.1586","title":"Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and subanalysis of the NCIC clinical trials group HN.6 clinical trial.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Southlake Regional Health Center; BC Cancer Agency; Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epidemiology; Clinical trial; Context (archaeology); Family medicine; Cancer; Randomized controlled trial; Surgery; Internal medicine","score_opus":0.8636786661117098,"score_gpt":0.6623241713887889,"score_spread":0.201354494722921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598212995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782319,0.0005591026,0.001005001,0.0064678257,0.010396969,0.0031600646,0.000074671065,0.000012536594,0.000091915266],"genre_scores_gemma":[0.98701423,0.0005631046,0.0045338213,0.0045857425,0.0031537109,0.00009922511,0.0000058826117,0.000033316835,0.000010961767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.72536856,0.1502071,0.12177686,0.0015559132,0.0005147007,0.00057690585],"domain_scores_gemma":[0.49537203,0.2750715,0.22267915,0.00271813,0.0024347238,0.0017244824],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.627086,0.00039175057,0.014985929,0.00031158072,0.0001741186,0.000027669957,0.0011282514,0.0015089675,0.00016506744],"category_scores_gemma":[0.7029863,0.00029167085,0.002765477,0.00040350916,0.0016150149,0.0005124498,0.0003645879,0.0024390307,0.000011713465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05014123,0.011821186,0.8717267,0.0000784729,0.0008366477,6.6634465e-7,0.0004016441,0.00006734655,5.5919312e-8,0.0019901795,0.00056030456,0.06237557],"study_design_scores_gemma":[0.120382,0.051449515,0.8107805,0.00010117135,0.00049179175,0.0000016271997,0.0005409058,0.0027391773,2.0343766e-7,0.012205067,0.0010782023,0.00022981275],"about_ca_topic_score_codex":0.0010117933,"about_ca_topic_score_gemma":0.0025520055,"teacher_disagreement_score":0.2299965,"about_ca_system_score_codex":0.00030165314,"about_ca_system_score_gemma":0.0024642807,"threshold_uncertainty_score":0.99995357},"labels":[],"label_agreement":null},{"id":"W2598231003","doi":"10.1200/jco.2013.31.15_suppl.3580","title":"Survival benefit and complications of primary tumor resection (PTR) in patients with stage IV colorectal cancer (CRC) in the era of modern chemotherapy: A systematic review and meta-analysis.","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Meta-analysis; Population; Surgery; Internal medicine; Stage (stratigraphy); Cancer; Chemotherapy; Retrospective cohort study; Oncology","score_opus":0.1922228379859563,"score_gpt":0.45850491544683286,"score_spread":0.26628207746087657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598231003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011508158,0.9842095,0.000014791471,0.0012089665,0.00004038026,0.0028732517,0.000027688176,0.000001310072,0.00011596586],"genre_scores_gemma":[0.0053785476,0.99334663,0.00023214828,0.00078017486,0.000030056786,0.00014294646,0.000011567279,0.0000142079725,0.0000637113],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945176,0.0009056249,0.0038145704,0.00020826247,0.00042804002,0.00012588532],"domain_scores_gemma":[0.99190634,0.001986609,0.0054217805,0.00025958684,0.00035109842,0.000074600626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003845654,0.00021321354,0.01131591,0.00030009245,0.000013499471,0.0000067112687,0.00020045738,0.00015130948,0.00004969933],"category_scores_gemma":[0.0004376871,0.00009958293,0.0009572353,0.00062073517,0.0001458197,0.000065692795,0.000046881403,0.0007938202,2.478055e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009838367,0.0022214216,0.080000974,0.71884155,0.10686239,0.000025908,0.00017742743,0.00001537827,8.340397e-8,0.000057698613,0.00021242247,0.09060092],"study_design_scores_gemma":[0.004488289,0.0038654294,0.38179076,0.023719024,0.58106023,0.000023098359,0.000036691647,0.000021699228,2.3767477e-8,0.00003275309,0.004806787,0.0001552062],"about_ca_topic_score_codex":0.00014047328,"about_ca_topic_score_gemma":0.00074294576,"teacher_disagreement_score":0.69512254,"about_ca_system_score_codex":0.00015282142,"about_ca_system_score_gemma":0.00045356122,"threshold_uncertainty_score":0.773533},"labels":[],"label_agreement":null},{"id":"W2598236349","doi":"10.1200/jco.2015.33.15_suppl.7540","title":"Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA <i>EGFR</i> positive (IHC/FISH) non-small cell lung cancer (NSCLC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Clinical endpoint; Placebo; Oncology; Subgroup analysis; Randomized controlled trial; Adjuvant; Surgery; Gastroenterology; Confidence interval; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.12479863557113825,"score_gpt":0.4557257503106037,"score_spread":0.33092711473946546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598236349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868686,0.00022511982,0.00013720944,0.001002595,0.0051293196,0.0032862958,0.000346732,0.000009288586,0.0029948074],"genre_scores_gemma":[0.9964031,0.000109816996,0.0014809706,0.00037016242,0.0009400599,0.00009024165,0.00017205857,0.00003887449,0.00039469352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941704,0.0008754147,0.00341397,0.00042370238,0.00072828116,0.0003882135],"domain_scores_gemma":[0.9910213,0.0039020104,0.0033737826,0.0002661865,0.0008495213,0.00058723026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034357135,0.00030039056,0.0029780562,0.00028533567,0.0000737272,0.000021953534,0.00018733305,0.00028684048,0.00003288513],"category_scores_gemma":[0.0021103064,0.0002081661,0.0007723195,0.000302932,0.00018972844,0.0002345735,0.000048806767,0.0009421645,0.0000038815697],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98104274,0.0053240517,0.004728412,0.000026164342,0.0017619347,0.0006859954,0.0022055495,0.00023628847,0.000039184342,0.0000026164496,0.0015479882,0.002399089],"study_design_scores_gemma":[0.9470094,0.04228211,0.003149129,0.0006080474,0.0038510005,0.000007617658,0.0005270714,0.0006625275,0.00017458716,0.000010344139,0.0015314366,0.00018673792],"about_ca_topic_score_codex":0.0027078104,"about_ca_topic_score_gemma":0.0026392885,"teacher_disagreement_score":0.036958057,"about_ca_system_score_codex":0.00091297185,"about_ca_system_score_gemma":0.0051015057,"threshold_uncertainty_score":0.90498525},"labels":[],"label_agreement":null},{"id":"W2598237493","doi":"10.1200/jco.2012.30.15_suppl.tps665","title":"OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Population; Gynecology; Cancer","score_opus":0.1291823621215415,"score_gpt":0.4729301048396774,"score_spread":0.3437477427181359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598237493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380875,0.0046460526,0.00031619985,0.00030090698,0.00058133097,0.000240198,0.00005310967,0.0000031896957,0.000050290593],"genre_scores_gemma":[0.9904372,0.0007605746,0.0073113744,0.000099298566,0.0012672895,0.000023201326,0.000005363348,0.000021451411,0.000074219315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702847,0.0005392337,0.0015549955,0.00026579408,0.00026977755,0.00034172548],"domain_scores_gemma":[0.9970524,0.00031446043,0.0016682755,0.00027048914,0.00043104173,0.0002633749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084744155,0.00024744438,0.0015228785,0.0001328637,0.000056799323,0.0000071339073,0.00019017867,0.0002892223,0.00007050274],"category_scores_gemma":[0.00015924398,0.00017319077,0.0010167517,0.00019305434,0.00027381547,0.000020733054,0.00009848844,0.00016678154,0.0000018296705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013510372,0.009247591,0.93721455,0.000007536961,0.014084639,0.0000339321,0.0008884365,0.0016510014,0.00080203585,0.0000017481821,0.00011981887,0.022438362],"study_design_scores_gemma":[0.008043954,0.017073523,0.96480304,0.000017355389,0.0072029205,0.00013460997,0.00065389456,0.00017164256,0.00048999226,0.0000013345167,0.001239202,0.00016850949],"about_ca_topic_score_codex":0.00037230275,"about_ca_topic_score_gemma":0.00005037532,"teacher_disagreement_score":0.027588537,"about_ca_system_score_codex":0.00015990864,"about_ca_system_score_gemma":0.00044589874,"threshold_uncertainty_score":0.7062515},"labels":[],"label_agreement":null},{"id":"W2598238437","doi":"10.1200/jco.2013.31.15_suppl.3528","title":"Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; University of Toronto; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; KRAS; Colorectal cancer; Cetuximab; Oncology; Proportional hazards model; Splenic flexure; Multivariate analysis; Hazard ratio; Cancer; Univariate analysis; Gastroenterology; Colonoscopy; Confidence interval","score_opus":0.09176001116513371,"score_gpt":0.4539326422381781,"score_spread":0.36217263107304437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598238437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435515,0.0038989957,0.00001551888,0.004606832,0.0018281657,0.0004962407,0.00003100828,0.000010801767,0.0047573014],"genre_scores_gemma":[0.9949497,0.0020837348,0.00072392443,0.0006174139,0.0009668015,0.000026582304,0.000011080578,0.000020305766,0.0006004456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612975,0.00018606213,0.0026023432,0.00025573347,0.00056243385,0.00026367162],"domain_scores_gemma":[0.99162614,0.0033633811,0.0026339202,0.00025110197,0.0018200036,0.00030546018],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067438354,0.00021432545,0.002236991,0.00013297905,0.000049790833,0.0000065553136,0.00019056404,0.0004053397,0.0018926781],"category_scores_gemma":[0.0029638123,0.00014645886,0.0004472304,0.00018744235,0.00037245837,0.00014286104,0.00006490703,0.0005555722,0.000024601432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14713967,0.015021474,0.4854413,0.000494261,0.015582389,0.0005958171,0.0030325975,0.00021893541,0.008365642,0.00044076468,0.08953029,0.23413686],"study_design_scores_gemma":[0.03837117,0.0438548,0.89703727,0.0008158648,0.0021849538,0.00004714928,0.00050611666,0.00019621589,0.003381225,0.0013279048,0.012089216,0.00018814215],"about_ca_topic_score_codex":0.002338634,"about_ca_topic_score_gemma":0.0017719732,"teacher_disagreement_score":0.41159594,"about_ca_system_score_codex":0.00046958402,"about_ca_system_score_gemma":0.0021030346,"threshold_uncertainty_score":0.99901974},"labels":[],"label_agreement":null},{"id":"W2598242242","doi":"10.1200/jco.2012.30.15_suppl.9020","title":"Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Conventional PCI; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Chemotherapy; Breast cancer; Hormonal therapy; Physical therapy; Cancer; Oncology; Myocardial infarction","score_opus":0.11130930453111895,"score_gpt":0.4356347418920276,"score_spread":0.3243254373609087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598242242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775541,0.0016528328,0.0002455127,0.0118527515,0.002131354,0.0053300085,0.00097365514,0.000039968287,0.00021984043],"genre_scores_gemma":[0.9859485,0.004448073,0.00069782283,0.003762069,0.0032119993,0.0015237981,0.00014842828,0.00008867401,0.00017061291],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930871,0.0010912743,0.0032098019,0.0005576796,0.0011043637,0.0009497405],"domain_scores_gemma":[0.98347163,0.010237537,0.003833653,0.0002877965,0.0012649727,0.00090438605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037299425,0.0006032202,0.0027098998,0.00017707006,0.00037075253,0.00005155593,0.0002206515,0.00049123995,0.00028467897],"category_scores_gemma":[0.0017383428,0.0003326743,0.00082964305,0.00038746794,0.0004921596,0.00035061373,0.000050365546,0.0007166712,0.000005828979],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76694757,0.0069098873,0.029994158,0.0000018380033,0.015398287,0.00005818416,0.0038970853,0.000005153311,0.000501869,4.4866135e-7,0.0143422345,0.16194332],"study_design_scores_gemma":[0.5306593,0.09998483,0.35208327,0.00015017299,0.0012771873,0.000051322946,0.0017813916,0.00000775552,0.00024070386,0.000014022303,0.013461757,0.00028824576],"about_ca_topic_score_codex":0.00026270314,"about_ca_topic_score_gemma":0.00007118953,"teacher_disagreement_score":0.3220891,"about_ca_system_score_codex":0.0013242378,"about_ca_system_score_gemma":0.001983854,"threshold_uncertainty_score":0.9999125},"labels":[],"label_agreement":null},{"id":"W2598244667","doi":"10.1200/jco.2014.32.15_suppl.647","title":"Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Breast cancer; Adjuvant; Oncology; Internal medicine; Quality of life (healthcare); Cancer","score_opus":0.20429124569115753,"score_gpt":0.5118660664074929,"score_spread":0.30757482071633535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598244667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944242,0.00010569373,0.000024363411,0.003608401,0.00015027654,0.0009684292,0.000020640708,0.0000069485714,0.00069103664],"genre_scores_gemma":[0.99722207,0.00047229836,0.00033376936,0.0012210775,0.00053257216,0.000054000615,0.0000025828563,0.000031581283,0.00013006182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923808,0.0028032653,0.002765813,0.00036497333,0.0012738061,0.00041135892],"domain_scores_gemma":[0.9914305,0.0045968387,0.0020710616,0.00042052317,0.0009812537,0.0004997963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007941048,0.00024122503,0.0022712655,0.0001057508,0.0000531593,0.00001526039,0.00038788308,0.00025812996,0.00013030472],"category_scores_gemma":[0.0034895584,0.00011200258,0.0001498659,0.00040522072,0.0006918498,0.000111742746,0.000059814964,0.0015536115,0.0000032988403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02370337,0.006226272,0.8646332,0.0001082932,0.00033912947,0.00014315838,0.00076630036,0.000028448074,0.000003882133,0.0000045951006,0.00068993797,0.10335344],"study_design_scores_gemma":[0.027182708,0.04647066,0.92223436,0.00045917797,0.00019299301,0.00005648818,0.0012585011,0.000073114476,0.000005028865,0.000009518214,0.0019317998,0.0001256661],"about_ca_topic_score_codex":0.004187406,"about_ca_topic_score_gemma":0.029507577,"teacher_disagreement_score":0.10322777,"about_ca_system_score_codex":0.00026956078,"about_ca_system_score_gemma":0.0029424403,"threshold_uncertainty_score":0.9882014},"labels":[],"label_agreement":null},{"id":"W2598272769","doi":"10.1200/jco.2013.31.15_suppl.9536","title":"The role of social exposure to smoking on smoking cessation in adult cancer survivors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Public Health Ontario; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Logistic regression; Odds ratio; Cancer; Multivariate analysis; Breast cancer; Genitourinary system; Demography; Internal medicine; Pathology","score_opus":0.06328345347547781,"score_gpt":0.424789194692041,"score_spread":0.3615057412165632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598272769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975916,0.00024159164,0.000008500086,0.012755209,0.001076835,0.00017819816,0.0000019887373,0.0000029175837,0.0059756185],"genre_scores_gemma":[0.99383056,0.00041261842,0.00011179143,0.0044221166,0.0011048869,0.000011112919,8.9246896e-7,0.00001001793,0.00009600892],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997361,0.00032791818,0.0016642585,0.00011585874,0.00034291027,0.00018806936],"domain_scores_gemma":[0.9966135,0.0015754731,0.0010843304,0.000103909486,0.0004842889,0.00013849177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001998918,0.00008613255,0.0007674879,0.000102129394,0.000054757038,0.000008683944,0.00015442146,0.000250938,0.00029991433],"category_scores_gemma":[0.0016163744,0.000054077336,0.00022505742,0.00013519975,0.000088697416,0.00010020896,0.000029161218,0.00082803454,0.000003651562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015644433,0.00022145064,0.43355545,0.000012849219,0.00012752411,0.0000144034875,0.0008002224,0.00010668994,0.0004332993,0.00022137322,0.0017613013,0.561181],"study_design_scores_gemma":[0.003822258,0.0035894495,0.9385166,0.000100658974,0.00006729244,0.000009546297,0.0010761332,0.000115891766,0.0003037374,0.00034575086,0.051988184,0.00006450528],"about_ca_topic_score_codex":0.0010234412,"about_ca_topic_score_gemma":0.0022696797,"teacher_disagreement_score":0.5611165,"about_ca_system_score_codex":0.00025968166,"about_ca_system_score_gemma":0.00091059535,"threshold_uncertainty_score":0.3597444},"labels":[],"label_agreement":null},{"id":"W2598321200","doi":"10.1200/jco.2012.30.15_suppl.561","title":"Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Toronto; Sunnybrook Health Science Centre; McGill University; Queen's University","funders":"","keywords":"Medicine; Hazard ratio; Breast cancer; Internal medicine; Proportional hazards model; Oncology; Univariate analysis; Cancer; Multivariate analysis; Confidence interval","score_opus":0.06066536096971585,"score_gpt":0.45369125065632604,"score_spread":0.3930258896866102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598321200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967716,0.00065549574,0.0000387152,0.0010097352,0.00088037783,0.00029379284,0.00006286407,9.474594e-7,0.00028648935],"genre_scores_gemma":[0.99896884,0.00020353514,0.00007977331,0.0001888332,0.0005195997,0.000013512509,7.583943e-7,0.000007727976,0.000017430373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976963,0.00079791126,0.0009220903,0.00015102368,0.0002656325,0.00016708543],"domain_scores_gemma":[0.9975848,0.00029673104,0.0013442878,0.00028252578,0.00038273208,0.00010889132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015569784,0.00011880577,0.0005737631,0.000016387474,0.00005907274,0.0000026756586,0.0002709955,0.00018093684,0.000019956959],"category_scores_gemma":[0.0005049792,0.00005913764,0.00021865233,0.00007701414,0.00051463675,0.00001133307,0.0002817425,0.000329587,7.617375e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084772985,0.0025379374,0.9858898,0.000013013731,0.000635843,9.935292e-7,0.00013630734,0.000013174196,0.00023591181,0.0000072277044,0.000222349,0.009459716],"study_design_scores_gemma":[0.002103632,0.0021646302,0.99392766,0.000031314255,0.00045194846,0.000054762648,0.0004115337,0.000025045518,0.00019154702,0.000041829007,0.0005453654,0.00005074046],"about_ca_topic_score_codex":0.00007480217,"about_ca_topic_score_gemma":0.00027191022,"teacher_disagreement_score":0.009408976,"about_ca_system_score_codex":0.00004243771,"about_ca_system_score_gemma":0.0007703864,"threshold_uncertainty_score":0.2411563},"labels":[],"label_agreement":null},{"id":"W2598322637","doi":"10.1200/jco.2015.33.15_suppl.tps5071","title":"A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Placebo; Androgen receptor; Internal medicine; Population; Cancer; Clinical endpoint; Chemotherapy; Oncology; Pharmacology; Urology; Randomized controlled trial; Androgen deprivation therapy; Pathology","score_opus":0.2629922469881669,"score_gpt":0.5399140988926265,"score_spread":0.2769218519044596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598322637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845402,0.0026044147,0.000025837704,0.0063209673,0.00063794287,0.005258284,0.000010731879,0.000008350775,0.000593224],"genre_scores_gemma":[0.9950215,0.0016961134,0.0005755932,0.0002788109,0.00035467002,0.00033568018,0.000006676102,0.000033406297,0.0016975433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922498,0.0016669879,0.004426912,0.00032014918,0.00090747443,0.00042871654],"domain_scores_gemma":[0.99321824,0.0018922677,0.0028426924,0.00025518573,0.0011994018,0.00059218693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011547915,0.0002884984,0.005018831,0.00041410833,0.00003774148,0.000025420528,0.00020816499,0.00020057267,0.00013430322],"category_scores_gemma":[0.0015126659,0.00016887671,0.000547614,0.00036008825,0.0004146705,0.00020579982,0.00004310803,0.0010167682,0.000007267705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9593622,0.014029077,0.0013493175,0.000072922645,0.0032755649,0.0016696306,0.004038395,0.00041104978,0.0005412824,0.00001086891,0.00051633385,0.014723322],"study_design_scores_gemma":[0.958792,0.0338029,0.0008110489,0.00016521158,0.0015385116,0.00006675476,0.0027424525,0.00078189763,0.0003976665,0.00020041238,0.0005669002,0.0001342926],"about_ca_topic_score_codex":0.000455239,"about_ca_topic_score_gemma":0.0009773908,"teacher_disagreement_score":0.01977382,"about_ca_system_score_codex":0.0005823926,"about_ca_system_score_gemma":0.0065835374,"threshold_uncertainty_score":0.99904823},"labels":[],"label_agreement":null},{"id":"W2598334582","doi":"10.1200/jco.2013.31.15_suppl.tps10593","title":"A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Response Evaluation Criteria in Solid Tumors; Internal medicine; Population; Phases of clinical research; Sarcoma; Oncology; Soft tissue sarcoma; Surgery; Clinical trial; Pathology","score_opus":0.04098936322154361,"score_gpt":0.41955294812783767,"score_spread":0.37856358490629405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598334582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978212,0.000073514224,0.0004964229,0.00035332554,0.0004035812,0.0005888994,0.000009702249,0.000002884128,0.00025043718],"genre_scores_gemma":[0.99423987,0.00006742269,0.0042179623,0.0009251126,0.00022761781,0.000017139851,0.000011462937,0.000023025297,0.00027041498],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972665,0.00028543634,0.0016874792,0.00027608805,0.00023189955,0.00025264802],"domain_scores_gemma":[0.9972086,0.00012132893,0.001282911,0.00032447212,0.0007225997,0.00034007276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060530246,0.000181264,0.00092174916,0.00007353475,0.000049308255,0.000008579508,0.00037269774,0.00028465185,0.000069549395],"category_scores_gemma":[0.0007467669,0.0001309721,0.00017226579,0.00009496387,0.00009910802,0.000014081059,0.00020308555,0.0003116949,0.000011535297],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010591877,0.047576662,0.04429252,0.000025428168,0.00072888285,0.00007029565,0.00044568194,0.00006783857,0.13974181,0.000007317559,0.0070524137,0.74939924],"study_design_scores_gemma":[0.055068363,0.66855204,0.045338444,0.00006432829,0.0003032298,0.000077395176,0.0006382075,0.000032047898,0.013051154,0.00004108587,0.21641214,0.00042155807],"about_ca_topic_score_codex":0.00003314003,"about_ca_topic_score_gemma":0.00025946868,"teacher_disagreement_score":0.7489777,"about_ca_system_score_codex":0.000026111873,"about_ca_system_score_gemma":0.00041185642,"threshold_uncertainty_score":0.53408873},"labels":[],"label_agreement":null},{"id":"W2598337878","doi":"10.1200/jco.2012.30.15_suppl.9111","title":"Continued suppression of bone turnover following a single dose of zoledronic acid: Time to re-think dosing intervals in the management of bone metastases?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Mount Sinai Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Zoledronic acid; Dosing; Bone remodeling; Bisphosphonate; Breast cancer; Bone pain; Population; Internal medicine; Bone metastasis; Phases of clinical research; Cancer; Surgery; Urology; Osteoporosis; Toxicity","score_opus":0.10826488945048816,"score_gpt":0.46041824690081157,"score_spread":0.3521533574503234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598337878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925321,0.002353929,0.000044885033,0.0028830613,0.00046583364,0.00045533848,0.0000059518575,0.0000029167963,0.0012559914],"genre_scores_gemma":[0.99157447,0.00008657697,0.0072097876,0.0008420403,0.00011544317,0.0000036126332,0.000003242577,0.000013133745,0.00015172234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99494284,0.00071562093,0.0033995342,0.00012704982,0.0004942025,0.0003207581],"domain_scores_gemma":[0.99554366,0.0013107108,0.0024473488,0.0002712974,0.0001512897,0.00027567236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072974036,0.00013711769,0.0019751713,0.00020043553,0.000018743309,0.0000028243956,0.0001311871,0.00020209652,0.00014279803],"category_scores_gemma":[0.00097122637,0.00008126373,0.0006026524,0.00022435244,0.00008899832,0.00013954644,0.00009811961,0.00050214655,0.000011830251],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061658006,0.060931094,0.23533969,0.002369219,0.0068556136,0.0039912444,0.0078813,0.000030617055,0.06854035,0.00025517278,0.013932903,0.5382148],"study_design_scores_gemma":[0.05633107,0.034243498,0.85486645,0.0066158525,0.0051590987,0.00048327137,0.0013712287,0.000043885182,0.01272336,0.00031142565,0.027592055,0.00025882674],"about_ca_topic_score_codex":0.00003981213,"about_ca_topic_score_gemma":0.00001788122,"teacher_disagreement_score":0.61952674,"about_ca_system_score_codex":0.00012706722,"about_ca_system_score_gemma":0.00022936451,"threshold_uncertainty_score":0.33138388},"labels":[],"label_agreement":null},{"id":"W2598343706","doi":"10.1200/jco.2017.35.4_suppl.730","title":"Ten-year survival data following resection of locally recurrent rectal cancer (LRRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Sunnybrook Health Science Centre; Health Sciences Centre; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Cohort; Surgery; Colorectal cancer; Retrospective cohort study; Overall survival; Multivariate analysis; Cancer; Survival analysis; Metastasis; Internal medicine","score_opus":0.3274595006335174,"score_gpt":0.5586011867035788,"score_spread":0.23114168607006141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598343706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716458,0.00086950534,0.000058040307,0.0047890167,0.009947982,0.00022943282,0.000023468056,0.000008910832,0.012427896],"genre_scores_gemma":[0.99419284,0.0017803673,0.0013756469,0.00014005277,0.00214141,0.000004149584,0.000006837616,0.000020080875,0.00033863913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99620146,0.000422284,0.002106562,0.00032191974,0.00069178396,0.00025602322],"domain_scores_gemma":[0.9940232,0.0014959072,0.0027367542,0.00083554734,0.0005169601,0.00039161168],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0046458887,0.00015333717,0.0017552476,0.00009283993,0.000106134044,0.000018072184,0.00065809226,0.0003686837,0.00022010428],"category_scores_gemma":[0.011827429,0.00010782587,0.000625774,0.00009220822,0.00027214462,0.0002960835,0.0003783584,0.0010300074,0.000011839021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021145642,0.0016457252,0.618682,0.000044499862,0.0013370174,0.0009972869,0.000037539547,0.000003807127,0.0001517859,0.000029812765,0.0031314732,0.35279337],"study_design_scores_gemma":[0.014568645,0.023147758,0.9125354,0.00055992906,0.0010100647,0.00013216892,0.00007282007,0.00016002053,0.00018776146,0.00019332865,0.047299854,0.0001322044],"about_ca_topic_score_codex":0.0002687966,"about_ca_topic_score_gemma":0.00084548123,"teacher_disagreement_score":0.35266116,"about_ca_system_score_codex":0.00031386875,"about_ca_system_score_gemma":0.002150517,"threshold_uncertainty_score":0.9964964},"labels":[],"label_agreement":null},{"id":"W2598366105","doi":"10.1200/jco.2014.32.15_suppl.e12530","title":"Triple-negative breast cancer: A population-based description of clinical-pathologic correlates and survival outcomes as a function of age at diagnosis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Cohort; Population; Internal medicine; Lymph node; Cancer; Triple-negative breast cancer; Pathological; Sentinel lymph node; Oncology","score_opus":0.12195619415490133,"score_gpt":0.45864133994610723,"score_spread":0.3366851457912059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598366105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915036,0.00041278312,0.0015588651,0.0036649434,0.002399781,0.00026980505,0.000022949565,0.000012515756,0.00015473417],"genre_scores_gemma":[0.99512553,0.000603384,0.0021991744,0.0013530708,0.0005579118,0.000014353978,0.000006415388,0.000019850933,0.00012028525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943318,0.0011767923,0.0036430722,0.00025690228,0.0004026775,0.00018875387],"domain_scores_gemma":[0.9850663,0.008780156,0.0049644317,0.00020805295,0.00071725156,0.00026379246],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043119458,0.00018831657,0.002742572,0.00015946211,0.000044538712,0.0000038661005,0.00011050523,0.00047042643,0.00019764226],"category_scores_gemma":[0.0092349965,0.0001299663,0.00061174313,0.00016535807,0.00052862626,0.00014879611,0.000045356115,0.0007043374,0.0000030167664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014087669,0.000844048,0.7941861,0.000052761752,0.00029410227,0.00003851328,0.000050355102,0.0001240204,0.000087363675,0.00008619018,0.000054646964,0.19009425],"study_design_scores_gemma":[0.0151519,0.010745796,0.9692544,0.00022524071,0.00068551284,0.00010732465,0.00008718474,0.00027174462,0.000027362763,0.0024226145,0.0009189126,0.0001020182],"about_ca_topic_score_codex":0.00022839935,"about_ca_topic_score_gemma":0.00033735484,"teacher_disagreement_score":0.18999222,"about_ca_system_score_codex":0.0001680512,"about_ca_system_score_gemma":0.00047694778,"threshold_uncertainty_score":0.99911064},"labels":[],"label_agreement":null},{"id":"W2598367752","doi":"10.1200/jco.2015.33.15_suppl.5536","title":"Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Chemotherapy; Adverse effect; Clinical trial; Progression-free survival; Anorexia; Surgery","score_opus":0.13420773932320723,"score_gpt":0.4486649365407507,"score_spread":0.31445719721754345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598367752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95071566,0.0009964869,0.0000035622622,0.04528025,0.0007300382,0.002150843,0.000050973722,0.000004348481,0.0000678528],"genre_scores_gemma":[0.9915564,0.0025373271,0.0003439798,0.0045213625,0.0007949241,0.00013057081,0.000004233818,0.000030255867,0.00008092369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99156356,0.0022975157,0.004693781,0.0005102403,0.00058271835,0.00035216677],"domain_scores_gemma":[0.9854559,0.010463478,0.0029650433,0.00029894925,0.0004988621,0.00031777794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014093219,0.0003354523,0.0034998711,0.00026900202,0.000041852956,0.000026409953,0.00021279439,0.00037335826,0.00012998718],"category_scores_gemma":[0.0047817286,0.00017220151,0.00024300355,0.00029280028,0.00021431009,0.00014420651,0.00017312932,0.0010390589,0.0000017594301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016914003,0.0029671276,0.7552511,0.000024029563,0.0007595216,0.00011386799,0.0044380245,0.00002257048,0.000004297695,0.0000017880304,0.0004781851,0.2190255],"study_design_scores_gemma":[0.031916454,0.021338204,0.94189894,0.0009105844,0.0004662811,0.000006378513,0.0010978839,0.000060951792,0.0000036729502,0.000038708113,0.0020980968,0.00016381484],"about_ca_topic_score_codex":0.0007637854,"about_ca_topic_score_gemma":0.009534254,"teacher_disagreement_score":0.21886168,"about_ca_system_score_codex":0.00075446913,"about_ca_system_score_gemma":0.0010843534,"threshold_uncertainty_score":0.7022174},"labels":[],"label_agreement":null},{"id":"W2598375808","doi":"10.1200/jco.2017.35.6_suppl.e558","title":"Three year results of a prospective study on focal salvage HDR prostate brachytherapy for local recurrence after external beam radiotherapy (XRT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiotherapy; Cryotherapy; Radiation therapy; Prostate; Biopsy; Radiology; Urology; Surgery; Cancer; Internal medicine","score_opus":0.09784960012197569,"score_gpt":0.4726977938127939,"score_spread":0.37484819369081823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598375808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98859364,0.0010089474,0.0028747213,0.003858018,0.0013080167,0.0020205656,0.000069988266,0.000007462603,0.00025862528],"genre_scores_gemma":[0.9924991,0.0012431382,0.004095352,0.0006611442,0.0012611444,0.00013668544,0.0000016614382,0.000030169225,0.000071565206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966442,0.00015178807,0.0020756794,0.00038014146,0.00045698803,0.00029118248],"domain_scores_gemma":[0.9945055,0.0013170162,0.0027338464,0.00053801487,0.00060596655,0.0002996306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002726672,0.00022043084,0.00165694,0.00009088609,0.00008871175,0.000026820737,0.0002721367,0.00022832987,0.0000268733],"category_scores_gemma":[0.0013905042,0.0001431251,0.0005737862,0.00004748182,0.0004591295,0.00014819005,0.000041993484,0.0006896063,0.0000044486733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12271609,0.010095443,0.6033192,0.000029888779,0.0009380078,0.0007170103,0.0005702225,0.00001023908,0.00006211969,0.000052136096,0.0014834728,0.26000616],"study_design_scores_gemma":[0.04796885,0.13674796,0.8083449,0.00039761106,0.00027345002,0.00005297516,0.00011064339,0.000045002813,0.00059179764,0.00084415264,0.004509938,0.00011275254],"about_ca_topic_score_codex":0.000031146883,"about_ca_topic_score_gemma":0.00010457503,"teacher_disagreement_score":0.2598934,"about_ca_system_score_codex":0.00031940348,"about_ca_system_score_gemma":0.0009580394,"threshold_uncertainty_score":0.5836472},"labels":[],"label_agreement":null},{"id":"W2598377309","doi":"10.1200/jco.2012.30.15_suppl.6069","title":"Effectiveness of a screening intervention to identify clinical-trial-eligible patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Randomized controlled trial; Accrual","score_opus":0.7007071687452561,"score_gpt":0.7340689180405807,"score_spread":0.03336174929532465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598377309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500043,0.00028289255,0.0045088255,0.0015074,0.0058054444,0.00082604564,0.0000034300363,0.000010355897,0.0020551668],"genre_scores_gemma":[0.9862981,0.0005088246,0.009858132,0.0008113544,0.0022535853,0.00001087626,0.000003669911,0.000029820578,0.0002256432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9839815,0.0053076902,0.008296665,0.0003241924,0.0015868326,0.0005031531],"domain_scores_gemma":[0.8422008,0.14454493,0.005347645,0.0007479437,0.0051984284,0.001960241],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.13744052,0.00016798897,0.0026656878,0.000325528,0.00004315203,0.000012762886,0.00048948516,0.0013355581,0.0001824101],"category_scores_gemma":[0.33575344,0.00012450645,0.0019161047,0.00040463943,0.0004744517,0.00025865296,0.0004136613,0.0046532876,0.00009965395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14880967,0.012652812,0.6762801,0.0004556773,0.0006826743,0.00003767544,0.000054039727,0.000004470592,0.00014160149,0.0008055915,0.0013062248,0.15876952],"study_design_scores_gemma":[0.07456139,0.05137863,0.8608966,0.001609204,0.0003949167,0.000016860513,0.000067628316,0.000006202913,0.0003159622,0.0022684461,0.0083819525,0.0001022009],"about_ca_topic_score_codex":0.000039825765,"about_ca_topic_score_gemma":0.000014524062,"teacher_disagreement_score":0.19831292,"about_ca_system_score_codex":0.00014794644,"about_ca_system_score_gemma":0.0011896921,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W2598407279","doi":"10.1200/jco.2013.31.15_suppl.tps2618","title":"A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid tumor malignancies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Aflibercept; Placental growth factor; Angiogenesis; Blockade; Bevacizumab; Oncology; Angiopoietin receptor; Cohort; Internal medicine; Cancer; Cancer research; Pharmacology; Vascular endothelial growth factor; Receptor; Chemotherapy; VEGF receptors","score_opus":0.019815380373440678,"score_gpt":0.36526728340916703,"score_spread":0.34545190303572637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598407279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833,0.0005083747,0.000057953555,0.0001713838,0.00012612846,0.000677963,0.000015547776,0.0000040036402,0.00010864704],"genre_scores_gemma":[0.9972174,0.0002512334,0.0017451762,0.0004738592,0.00018382826,0.000033419037,0.000018625462,0.000038051963,0.000038372655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969858,0.00036006083,0.0015337899,0.0004245079,0.00033893943,0.00035693235],"domain_scores_gemma":[0.99674714,0.00018018515,0.0016572081,0.00026239085,0.0009019938,0.000251096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067563757,0.00028224863,0.0012220556,0.00014042154,0.00005551187,0.0000134534475,0.0002543054,0.00024976203,0.00002201623],"category_scores_gemma":[0.00024405017,0.00019366234,0.00023167097,0.00022650544,0.00030886236,0.000028704097,0.00010705397,0.00027460326,0.0000013138304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020319276,0.018309314,0.88598883,0.000040306997,0.0010889772,0.00014125653,0.0005326224,0.00030249156,0.042973556,0.0000033622443,0.000857335,0.029442698],"study_design_scores_gemma":[0.044332113,0.10720123,0.8392074,0.00012516583,0.00027320886,0.0000394697,0.0009109304,0.000048571317,0.006618792,0.000016972052,0.00085957535,0.0003665357],"about_ca_topic_score_codex":0.000053463,"about_ca_topic_score_gemma":0.00013374262,"teacher_disagreement_score":0.08889192,"about_ca_system_score_codex":0.00004983203,"about_ca_system_score_gemma":0.0006029421,"threshold_uncertainty_score":0.7897321},"labels":[],"label_agreement":null},{"id":"W2598407941","doi":"10.1200/jco.2017.35.4_suppl.tps215","title":"Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Cancer; Breast cancer; Internal medicine; Oncology; Antibody; Lapatinib; Cancer research; Immunology","score_opus":0.14309171806447504,"score_gpt":0.5409719488933747,"score_spread":0.3978802308288997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598407941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956516,0.00017081558,0.00000859041,0.0013082115,0.00055140146,0.00041393525,0.00000756421,0.000003236519,0.0018846216],"genre_scores_gemma":[0.9976678,0.00042607647,0.0010859137,0.00016466559,0.00044366202,0.0000025862632,0.0000034420548,0.000018281218,0.0001876037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625516,0.00034185383,0.0020353445,0.0002541396,0.00078386784,0.00032966398],"domain_scores_gemma":[0.9953732,0.0007225473,0.0024267896,0.00041152487,0.00072610925,0.0003398271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017567576,0.00016947594,0.001865905,0.00019668022,0.00012063845,0.000020036361,0.00041314776,0.0001928348,0.00011722889],"category_scores_gemma":[0.0014894578,0.00010530416,0.00022985866,0.00011482022,0.0004884274,0.00022828249,0.0001342265,0.0011396009,0.0000046852633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02398374,0.015897678,0.8542057,0.000049075585,0.00026177877,0.0008813981,0.0002161167,0.000018978875,0.0005096276,0.000005659166,0.0002571952,0.103713006],"study_design_scores_gemma":[0.046241637,0.059125766,0.88557285,0.00039047317,0.00010296525,0.000025119654,0.00029443746,0.000041724234,0.00010927565,0.00001691319,0.007980473,0.00009838346],"about_ca_topic_score_codex":0.0003424594,"about_ca_topic_score_gemma":0.00022593855,"teacher_disagreement_score":0.10361462,"about_ca_system_score_codex":0.00011955413,"about_ca_system_score_gemma":0.0011535996,"threshold_uncertainty_score":0.49510622},"labels":[],"label_agreement":null},{"id":"W2598411993","doi":"10.1200/jco.2013.31.15_suppl.e16074","title":"Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: Are we changing outcomes?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Overall survival; Oncology; Cancer","score_opus":0.13981528806071503,"score_gpt":0.4941348214930954,"score_spread":0.3543195334323804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598411993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94739145,0.0024843502,0.000036642152,0.047329087,0.0014249551,0.0012163804,0.000017299093,0.000013236379,0.00008659238],"genre_scores_gemma":[0.9848786,0.0037122676,0.0035584404,0.0045561134,0.00014512237,0.00008388306,0.000008884914,0.000031523254,0.0030251443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966023,0.0002342678,0.0022274444,0.00020877497,0.00026804578,0.00045917986],"domain_scores_gemma":[0.9954499,0.0010440084,0.0022442443,0.00013022247,0.00040216127,0.0007294848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015047897,0.00018361173,0.0017701974,0.00020140872,0.00008504383,0.000007715572,0.000067967965,0.00022931113,0.00017651898],"category_scores_gemma":[0.001411647,0.00011886513,0.00040038404,0.00014538174,0.000080755024,0.00015301724,0.00003671358,0.00056198955,0.000027725826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014473756,0.0019840559,0.7512009,0.00032246913,0.0019082301,0.0004395127,0.00034801953,0.0000059693475,0.000020698284,0.00003841555,0.005979121,0.2363052],"study_design_scores_gemma":[0.03125057,0.0068350416,0.9162251,0.00037857587,0.0012251458,0.00027165792,0.00021207427,0.00046345423,0.000011623671,0.0019753848,0.04101046,0.0001409306],"about_ca_topic_score_codex":0.000066534994,"about_ca_topic_score_gemma":0.000033847864,"teacher_disagreement_score":0.23616427,"about_ca_system_score_codex":0.00014893922,"about_ca_system_score_gemma":0.0006850435,"threshold_uncertainty_score":0.48471794},"labels":[],"label_agreement":null},{"id":"W2598436660","doi":"10.1200/jco.2014.32.15_suppl.542","title":"Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital du Saint-Sacrement; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Vitamin B12; Gastroenterology; Internal medicine; Placebo; Breast cancer; Cancer; Type 2 diabetes; Methylmalonic acid; Diabetes mellitus; Gynecology; Endocrinology; Pathology","score_opus":0.07422636074314128,"score_gpt":0.4604588196536638,"score_spread":0.38623245891052255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598436660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198925,0.00013601356,0.00016757817,0.0021873787,0.0020378958,0.001894535,0.00001249509,0.0000138284995,0.0015610034],"genre_scores_gemma":[0.9954534,0.00023985519,0.0007379993,0.0016550926,0.0014879084,0.00008811856,0.000012612981,0.000044018594,0.00028097496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910756,0.0015616618,0.0046340534,0.00056974345,0.0012537505,0.00090518594],"domain_scores_gemma":[0.9893214,0.00695648,0.0015217697,0.00042490565,0.0006386497,0.0011367898],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012593273,0.0003947203,0.004944547,0.0007751647,0.000081332786,0.000032222437,0.0005230679,0.00067663816,0.00045538504],"category_scores_gemma":[0.011507178,0.00026741676,0.0010038012,0.00060209766,0.0004127572,0.00015949001,0.0002057267,0.0022824763,0.0001376861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86639154,0.009979879,0.010151715,0.00007336126,0.00026965383,0.00023388768,0.0001623462,0.000041473282,0.0009025672,0.000020646292,0.0047032298,0.10706968],"study_design_scores_gemma":[0.93310666,0.029349295,0.02875576,0.0006037333,0.00057357346,0.00009752604,0.000072026356,0.003022888,0.00063640013,0.00006349361,0.003403712,0.00031491756],"about_ca_topic_score_codex":0.0004343266,"about_ca_topic_score_gemma":0.00017563997,"teacher_disagreement_score":0.106754765,"about_ca_system_score_codex":0.0006591561,"about_ca_system_score_gemma":0.0013321252,"threshold_uncertainty_score":0.9999778},"labels":[],"label_agreement":null},{"id":"W2598488323","doi":"10.1200/jco.2012.30.15_suppl.2051","title":"Phase II study of PX-866 in recurrent glioblastoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Dalhousie University; Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre; BC Cancer Agency; University of Manitoba; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Temozolomide; Internal medicine; PTEN; Oncology; Phases of clinical research; Clinical endpoint; Interim analysis; Clinical trial; Gastroenterology; Surgery; Chemotherapy; PI3K/AKT/mTOR pathway; Signal transduction","score_opus":0.1707776804509126,"score_gpt":0.5325706223306893,"score_spread":0.36179294187977673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598488323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949317,0.00085831265,0.0000019580916,0.002016301,0.0013922029,0.0002790392,0.0000015071535,0.0000029896855,0.00051601307],"genre_scores_gemma":[0.9984944,0.00022285998,0.00026184838,0.00024662347,0.00073853915,0.000006798265,4.9477745e-7,0.000008814059,0.0000196451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965588,0.00038354416,0.0024014576,0.000107050684,0.00032490492,0.00022425354],"domain_scores_gemma":[0.9966707,0.0011511231,0.001408684,0.00016722843,0.00021817257,0.00038405153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028042838,0.000108038985,0.0014390261,0.00021774133,0.000020139396,0.0000016479457,0.000093793635,0.00017948562,0.00014504931],"category_scores_gemma":[0.001837573,0.00006265037,0.00031365824,0.00018554727,0.00006770732,0.00008604146,0.000060217215,0.0005597974,0.000010359892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007487695,0.23855525,0.43302035,0.000013288393,0.000400897,0.0006180735,0.0007473665,0.0000029857001,0.00011896507,0.000034331846,0.0026762588,0.31632453],"study_design_scores_gemma":[0.077902354,0.3790082,0.5077917,0.00014059366,0.0007229519,0.00019957001,0.0009037693,0.000018387238,0.00039476412,0.000048455022,0.032791007,0.00007822857],"about_ca_topic_score_codex":0.000012817905,"about_ca_topic_score_gemma":0.00009349321,"teacher_disagreement_score":0.3162463,"about_ca_system_score_codex":0.00011995775,"about_ca_system_score_gemma":0.0003187021,"threshold_uncertainty_score":0.2554808},"labels":[],"label_agreement":null},{"id":"W2598494804","doi":"10.1200/jco.2012.30.15_suppl.10050","title":"Does combined dose intensification radiotherapy improve disease control in resectable retroperitoneal sarcoma? Long-term results of a phase I/II trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lakeridge Health; Princess Margaret Cancer Centre; University of Toronto; Pediatric Oncology Group","funders":"","keywords":"Medicine; Radiation therapy; External beam radiotherapy; Abdomen; Stage (stratigraphy); Cohort; Surgery; Log-rank test; Prospective cohort study; Survival analysis; Brachytherapy; Internal medicine","score_opus":0.09638035741177713,"score_gpt":0.4636944831425686,"score_spread":0.3673141257307915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598494804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809656,0.0023892417,0.00003384332,0.013553762,0.0020327268,0.0008906926,0.000028308315,0.0000073391934,0.00009848109],"genre_scores_gemma":[0.99534696,0.0012495832,0.0006980263,0.0011777441,0.0013526588,0.000031576197,0.000016213367,0.000020239058,0.00010697032],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9950082,0.000784303,0.0032996302,0.00021278046,0.00036600124,0.00032912957],"domain_scores_gemma":[0.9937027,0.0026306536,0.002161223,0.00038164202,0.00047660503,0.0006471878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004307299,0.00017064168,0.0018414586,0.00020220982,0.00003671076,0.000007288782,0.00015240586,0.0002675839,0.00008022125],"category_scores_gemma":[0.0062800855,0.00009147477,0.00055129,0.0001591294,0.0002195086,0.00017800098,0.000031146115,0.00062275934,0.0000035516532],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53764623,0.049031224,0.34764376,0.000031072756,0.00047008606,0.00052202394,0.00015744445,9.3538796e-7,0.0023425403,0.000029327219,0.0010788614,0.061046463],"study_design_scores_gemma":[0.401663,0.047577016,0.54700387,0.00015059128,0.00047228867,0.000030477231,0.000039505205,0.000103600454,0.00032013652,0.00003839786,0.002518779,0.00008231261],"about_ca_topic_score_codex":0.000047636786,"about_ca_topic_score_gemma":0.000029813724,"teacher_disagreement_score":0.19936012,"about_ca_system_score_codex":0.0002969548,"about_ca_system_score_gemma":0.00087414624,"threshold_uncertainty_score":0.7518303},"labels":[],"label_agreement":null},{"id":"W2598500814","doi":"10.1200/jco.2013.31.15_suppl.e15084","title":"Chemoembolization with super absorbent polymer microspheres (SAP-MS) loaded with doxorubicin (D) using escalating doses and adverse events (AE) in resectable hepatocellular carcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Adverse effect; Toxicity; Nausea; Embolization; Liver function; Surgery; Internal medicine; Nuclear medicine; Gastroenterology; Urology","score_opus":0.10765798791282115,"score_gpt":0.3519448223960642,"score_spread":0.24428683448324306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598500814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656373,0.0012971405,0.00014549066,0.00075735146,0.00012457083,0.0006936016,0.0000012450504,0.000008929063,0.0004079466],"genre_scores_gemma":[0.99438906,0.00011921211,0.004550247,0.000385416,0.00025159118,0.000009510925,0.000006549446,0.000040394192,0.00024803594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970982,0.00032165123,0.0014934193,0.00031129163,0.00039417343,0.000381283],"domain_scores_gemma":[0.9977323,0.0005279644,0.00084723183,0.00019729529,0.0003500441,0.00034520222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009157415,0.00024891595,0.001346968,0.0001645927,0.000057944362,0.000014325301,0.00009612651,0.0003386944,0.0003176265],"category_scores_gemma":[0.00022604571,0.00015754956,0.0001768985,0.00028642296,0.00015439163,0.00031628276,0.00005021493,0.0006356627,0.000012962877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023506093,0.00072763895,0.9771439,0.00008305072,0.0002254625,0.0006724054,0.00021938128,0.000027152219,0.01606686,0.000006599922,0.000048684476,0.002428261],"study_design_scores_gemma":[0.017042493,0.007280203,0.93618244,0.00056794944,0.0006152695,0.0006759208,0.0006169805,0.009427822,0.027055927,0.000026934531,0.00026442698,0.00024365517],"about_ca_topic_score_codex":0.0010544985,"about_ca_topic_score_gemma":0.00010258256,"teacher_disagreement_score":0.040961478,"about_ca_system_score_codex":0.00018469567,"about_ca_system_score_gemma":0.0008406973,"threshold_uncertainty_score":0.6424684},"labels":[],"label_agreement":null},{"id":"W2598514911","doi":"10.1200/jco.2017.35.6_suppl.129","title":"A combination of both testosterone and white blood count as predictive factors of overall survival in localized prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Internal medicine; Proportional hazards model; Prospective cohort study; Cancer; Population; Urology; Hazard ratio; Oncology; Gastroenterology; Confidence interval","score_opus":0.06633724405845183,"score_gpt":0.42643132660570193,"score_spread":0.3600940825472501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598514911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961925,0.00041500223,0.000008654823,0.0015226749,0.00060575514,0.0003712425,0.000026190552,0.0000033945455,0.00085454376],"genre_scores_gemma":[0.9982606,0.0011003652,0.0003506342,0.000118132564,0.00010040811,0.00000605782,0.0000021456176,0.000012291741,0.000049323655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968767,0.0003658805,0.0020157543,0.00015706173,0.00042514852,0.0001594672],"domain_scores_gemma":[0.994224,0.0009673295,0.0037631684,0.00021656981,0.0006106187,0.00021832847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026504507,0.00012583437,0.0014080747,0.00013188481,0.000035722536,0.000008235005,0.00017045575,0.00028136637,0.00004509463],"category_scores_gemma":[0.0050729257,0.00009477047,0.00019117963,0.000046203673,0.0006638803,0.00017543396,0.000090957474,0.00044364185,3.0987613e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014115545,0.0019376992,0.97669315,0.00017651738,0.0005378646,0.00017380915,0.00033692888,0.000004451121,0.00052476407,0.00004475474,0.00011605581,0.0053384476],"study_design_scores_gemma":[0.020179447,0.01217154,0.9647471,0.0005440147,0.0006044946,0.00002727242,0.00013501587,0.00013255823,0.00056749844,0.00043367,0.00038784757,0.00006958513],"about_ca_topic_score_codex":0.00012643368,"about_ca_topic_score_gemma":0.000116824776,"teacher_disagreement_score":0.011946107,"about_ca_system_score_codex":0.000102833445,"about_ca_system_score_gemma":0.0013812212,"threshold_uncertainty_score":0.6073132},"labels":[],"label_agreement":null},{"id":"W2598516659","doi":"10.1200/jco.2012.30.15_suppl.1008","title":"Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; BC Cancer Agency","funders":"","keywords":"Medicine; Immunohistochemistry; Progesterone receptor; Estrogen receptor; Breast cancer; Internal medicine; Oncology; Triple-negative breast cancer; Hormone receptor; Estrogen; Cancer","score_opus":0.04360156841696243,"score_gpt":0.4028711193306463,"score_spread":0.35926955091368384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598516659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98287636,0.011068999,0.000083638566,0.0036710403,0.0014937225,0.00023400754,0.00009861034,0.0000021723572,0.0004714259],"genre_scores_gemma":[0.99243104,0.0046462277,0.0014915022,0.0006668535,0.0006537167,0.000017464296,0.0000030243514,0.000017578663,0.00007258734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977157,0.00053959293,0.001061627,0.00019328916,0.00023652628,0.00025325108],"domain_scores_gemma":[0.99678385,0.00044481282,0.0016050643,0.0001815955,0.00080255535,0.0001821036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011780938,0.00019059397,0.000860101,0.000045284407,0.000072254974,0.0000052699083,0.00019923599,0.00029679041,0.000014526737],"category_scores_gemma":[0.0012681556,0.00011661691,0.00028908756,0.00022230296,0.0006971943,0.000015737118,0.00015783598,0.00033104993,0.0000013515163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031778947,0.0042374968,0.78046674,0.00007664871,0.009060669,0.00005288312,0.0036398508,0.000048461538,0.053006787,0.0013359772,0.029386504,0.086909026],"study_design_scores_gemma":[0.0074137016,0.0053826147,0.94465744,0.0000791974,0.0006131829,0.00014053869,0.0016809823,0.000003938547,0.016084284,0.00023591581,0.023473943,0.0002342349],"about_ca_topic_score_codex":0.00008556982,"about_ca_topic_score_gemma":0.00016308964,"teacher_disagreement_score":0.16419071,"about_ca_system_score_codex":0.000079272,"about_ca_system_score_gemma":0.0010570046,"threshold_uncertainty_score":0.47554997},"labels":[],"label_agreement":null},{"id":"W2598548323","doi":"10.1200/jco.2017.35.6_suppl.287","title":"Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Bladder cancer; Cystectomy; Medicine; Transcriptome; Oncology; Basal (medicine); Microarray; Subtyping; Gene expression profiling; Chemotherapy; Internal medicine; Tissue microarray; Cancer; Pathology; Gene; Gene expression; Biology","score_opus":0.4174777389471016,"score_gpt":0.5841523085155853,"score_spread":0.1666745695684837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598548323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9272188,0.00034337142,0.00029693707,0.06484215,0.004654382,0.00059068075,0.000015302205,0.000014735511,0.0020236184],"genre_scores_gemma":[0.9662866,0.0013914371,0.0021852783,0.024674682,0.0045090523,0.000026842856,6.2261836e-7,0.000036573852,0.0008889256],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941545,0.0015033458,0.0029390124,0.0004396051,0.00054389547,0.00041961428],"domain_scores_gemma":[0.9894587,0.0050303843,0.0020565267,0.0008152741,0.0012174385,0.0014216944],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009915794,0.0002408906,0.0022142646,0.00013840938,0.00020861554,0.000053567786,0.00058708235,0.00056356686,0.00039441965],"category_scores_gemma":[0.02694218,0.0001666321,0.0008597652,0.00012710874,0.00022116138,0.00018295326,0.00016116851,0.0012057592,0.000095523166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09752521,0.003271585,0.43074962,0.00001773127,0.0016225046,0.0014125587,0.00031684578,0.000013878992,0.0012671163,0.00003164595,0.01946685,0.44430444],"study_design_scores_gemma":[0.012656105,0.019121977,0.8127582,0.00018904345,0.0003386749,0.000062933876,0.00007091963,0.0000029753712,0.00033792792,0.00012676654,0.15419202,0.00014242795],"about_ca_topic_score_codex":0.00022898329,"about_ca_topic_score_gemma":0.00031446145,"teacher_disagreement_score":0.444162,"about_ca_system_score_codex":0.00029963936,"about_ca_system_score_gemma":0.008318711,"threshold_uncertainty_score":0.9973032},"labels":[],"label_agreement":null},{"id":"W2598606084","doi":"10.1200/jco.2012.30.15_suppl.9032","title":"Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Recidivism; Odds ratio; Quality of life (healthcare); Confidence interval; Tobacco smoke; Smoke; Internal medicine; Psychiatry; Environmental health","score_opus":0.09313236666916781,"score_gpt":0.4531655128129706,"score_spread":0.3600331461438028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598606084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913317,0.0028507437,0.000050336435,0.003109787,0.001324176,0.00009723193,0.0000030317976,0.0000022585527,0.0012307282],"genre_scores_gemma":[0.9952775,0.0022716238,0.000076396915,0.0005144434,0.0017706875,0.000004582305,0.0000011074651,0.000008870011,0.00007479163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789536,0.00031458208,0.0012275707,0.00008821311,0.0003095429,0.00016475898],"domain_scores_gemma":[0.9980841,0.00063237926,0.00096481194,0.000061283674,0.00007663598,0.00018076686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029340554,0.00007494516,0.0007982131,0.0000872002,0.000017929886,0.0000022809422,0.00005361964,0.00028275218,0.00021117713],"category_scores_gemma":[0.00051249634,0.000059158494,0.00015885638,0.00006843535,0.0001220831,0.00010974996,0.000036406796,0.0005428227,6.2457906e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092017924,0.0004004012,0.9401655,0.000058549922,0.00011534413,0.000017822356,0.0019125944,0.0000025706722,0.00007900056,0.00009389552,0.00039116302,0.05584295],"study_design_scores_gemma":[0.0031711496,0.001084601,0.96822315,0.00010253714,0.00024341552,0.00002922669,0.0003718233,0.000025719237,0.00006786246,0.00013610952,0.026491491,0.00005292517],"about_ca_topic_score_codex":0.0007726322,"about_ca_topic_score_gemma":0.0007671501,"teacher_disagreement_score":0.055790026,"about_ca_system_score_codex":0.00020494628,"about_ca_system_score_gemma":0.00040138964,"threshold_uncertainty_score":0.24124134},"labels":[],"label_agreement":null},{"id":"W2598673240","doi":"10.1200/jco.2013.31.15_suppl.1584","title":"U.S. Preventive Services Task Force (USPSTF) recommendations on breast cancer screening (BCS): Are they justified?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomization; Task force; Population; Randomized controlled trial; Confounding; Internal medicine; Gynecology; Demography; Environmental health","score_opus":0.10441696889043495,"score_gpt":0.4695971175844514,"score_spread":0.36518014869401644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598673240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90134794,0.0003144236,0.00024682938,0.09233485,0.0024016313,0.00039412596,0.00008302343,0.000018611212,0.0028585426],"genre_scores_gemma":[0.9863708,0.0016343476,0.001094677,0.007248411,0.002354781,0.000017255266,0.000008920918,0.00002207001,0.0012487478],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974594,0.00024602434,0.0015532427,0.00020354838,0.00028972203,0.00024806848],"domain_scores_gemma":[0.99565804,0.0011083437,0.00202614,0.00019031532,0.0006147923,0.0004023746],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010440669,0.00015221314,0.001053878,0.00011907968,0.00008268353,0.000021702423,0.00018438548,0.000287789,0.0014660344],"category_scores_gemma":[0.0002710637,0.00010200816,0.00045261046,0.00010493443,0.00008307919,0.00023272586,0.000053906762,0.0011014036,0.000054092092],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025827573,0.0012431093,0.26655224,0.00007438067,0.000792795,0.00007971972,0.0003815042,0.000114233386,0.0001341465,0.00006270793,0.0423455,0.68563694],"study_design_scores_gemma":[0.0039139017,0.0026903173,0.88604623,0.0006928928,0.00044051209,0.00016304135,0.0009590354,0.00023160632,0.00001579317,0.0004238606,0.104303405,0.0001194286],"about_ca_topic_score_codex":0.0010022267,"about_ca_topic_score_gemma":0.00073862367,"teacher_disagreement_score":0.6855175,"about_ca_system_score_codex":0.0001707545,"about_ca_system_score_gemma":0.0005124401,"threshold_uncertainty_score":0.99944675},"labels":[],"label_agreement":null},{"id":"W2598701304","doi":"10.1200/jco.2012.30.15_suppl.6103","title":"Development of a disease-specific measure of quality of life in myelodysplastic syndromes (MDS): The “QUALMS-1”.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Laurentian University","funders":"","keywords":"Medicine; Quality of life (healthcare); Cohort; Debriefing; Disease; Focus group; Gerontology; Family medicine; Clinical psychology; Nursing; Pathology; Medical education","score_opus":0.33621499780270037,"score_gpt":0.49580175825931116,"score_spread":0.1595867604566108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598701304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265856,0.0022103854,0.00026648364,0.0034898394,0.00048142008,0.00027249003,0.000006098395,0.0000027654255,0.0006119364],"genre_scores_gemma":[0.9932487,0.00051165913,0.0054985285,0.00026831205,0.00039002983,0.0000048259703,0.0000015671916,0.00001609929,0.000060294733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99119776,0.0015464586,0.005560264,0.00014831423,0.0011816737,0.00036555415],"domain_scores_gemma":[0.9857982,0.008868099,0.0033643886,0.00037582597,0.00090046925,0.0006930471],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018262306,0.000149663,0.002297432,0.0002506082,0.000025316527,0.0000019930412,0.0004090591,0.00031195124,0.00019269844],"category_scores_gemma":[0.020247439,0.00008778158,0.00047980214,0.00037152055,0.00064949994,0.00010342233,0.00014596949,0.0012667399,0.000010704081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030393213,0.009177886,0.87815094,0.0008599656,0.0012249287,0.00011846713,0.0023999254,0.00003303157,0.003926632,0.001353819,0.003451573,0.06890962],"study_design_scores_gemma":[0.0064910008,0.0021392654,0.97861034,0.00033161938,0.00013610243,0.000046385416,0.000865898,0.000018846882,0.0002518259,0.000098684315,0.010929949,0.00008009237],"about_ca_topic_score_codex":0.000017412356,"about_ca_topic_score_gemma":0.000025039788,"teacher_disagreement_score":0.1004594,"about_ca_system_score_codex":0.0003139453,"about_ca_system_score_gemma":0.0074108336,"threshold_uncertainty_score":0.9982162},"labels":[],"label_agreement":null},{"id":"W2598709449","doi":"10.1200/jco.2017.35.6_suppl.66","title":"Permanent seed brachytherapy for low risk prostate cancer, long term outcome, and urinary toxicity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interquartile range; Brachytherapy; Prostate cancer; Urology; Urinary system; Median follow-up; Cancer; Surgery; Internal medicine; Radiation therapy; Overall survival","score_opus":0.1557918007465678,"score_gpt":0.5367211438602499,"score_spread":0.38092934311368215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598709449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791513,0.0031869505,0.000030507734,0.015554937,0.0010632707,0.0006181056,0.000026949001,0.0000067173773,0.0003612414],"genre_scores_gemma":[0.9667869,0.02703812,0.000727457,0.00083902077,0.0014581013,0.000027837736,0.000004011545,0.000021168758,0.0030973805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765956,0.00015973454,0.0014076876,0.00020936097,0.0002595188,0.00030414597],"domain_scores_gemma":[0.99592656,0.0010008791,0.0019144148,0.00026706618,0.0004565077,0.00043454728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024013575,0.00014180518,0.0011568312,0.000078432946,0.00025318048,0.00003839614,0.00019175817,0.00024132017,0.000042966985],"category_scores_gemma":[0.0019852577,0.00008741032,0.00033000528,0.00002917532,0.0004089931,0.00017002819,0.000078067606,0.000780006,0.0000032362898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010723874,0.00101076,0.77762944,0.00010638878,0.00040519747,0.00069234456,0.000091601345,0.0000011901216,0.000155429,0.0000062535787,0.00057222205,0.20860532],"study_design_scores_gemma":[0.019986551,0.015546571,0.9524474,0.00015057134,0.0003038246,0.00026826715,0.000027963812,0.00006406755,0.00018510499,0.00017008146,0.01076108,0.000088484885],"about_ca_topic_score_codex":0.000028329318,"about_ca_topic_score_gemma":0.000053887277,"teacher_disagreement_score":0.20851684,"about_ca_system_score_codex":0.00016404048,"about_ca_system_score_gemma":0.0010795242,"threshold_uncertainty_score":0.35644895},"labels":[],"label_agreement":null},{"id":"W2598715439","doi":"10.1200/jco.2017.35.6_suppl.346","title":"Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Oncology; Nomogram; Internal medicine; Docetaxel; Pazopanib; Sunitinib; Salvage therapy; Atezolizumab; Carboplatin; Progression-free survival; Urology; Cancer; Chemotherapy; Overall survival; Pembrolizumab; Cisplatin; Immunotherapy","score_opus":0.3327630428131123,"score_gpt":0.5385285176088863,"score_spread":0.205765474795774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598715439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894238,0.0002860673,0.00030397082,0.0023219578,0.0032337264,0.0026514179,0.000031347376,0.0000042247016,0.0017434832],"genre_scores_gemma":[0.9956704,0.0004516186,0.0014317223,0.0005141547,0.0011774639,0.00008807785,0.0000029162682,0.000041567073,0.00062209065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99289834,0.001742818,0.004089863,0.0003088056,0.0006435449,0.00031663856],"domain_scores_gemma":[0.9769607,0.017538493,0.004205092,0.0004971364,0.00030075677,0.0004978281],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012780848,0.000302068,0.007559682,0.00026601148,0.000050021372,0.000014002532,0.00041847565,0.00033502013,0.00017528198],"category_scores_gemma":[0.02771371,0.00018281356,0.0021511829,0.00008061801,0.00017320336,0.00009483999,0.00004914666,0.00053011783,0.000004712481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7383772,0.0032153127,0.05393684,0.00009969517,0.0018968955,0.00025733883,0.00020831467,0.000020610636,0.00032449802,0.000041405507,0.0031051238,0.19851676],"study_design_scores_gemma":[0.5912831,0.09094603,0.30299345,0.00030769792,0.0023051216,0.000026618905,0.000016929102,0.000067412715,0.0024767998,0.0005976454,0.008810033,0.00016915839],"about_ca_topic_score_codex":0.002413671,"about_ca_topic_score_gemma":0.00024936587,"teacher_disagreement_score":0.24905662,"about_ca_system_score_codex":0.00047929265,"about_ca_system_score_gemma":0.0017012515,"threshold_uncertainty_score":0.98047626},"labels":[],"label_agreement":null},{"id":"W2598740988","doi":"10.1200/jco.2004.22.90140.3764","title":"Prognostication using serum levels of components of the folate metabolic pathway in patients (PTS) treated with capecitabine for advanced colorectal cancer (ACRC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Thymidylate synthase; Homocysteine; Internal medicine; Gastroenterology; Vitamin B12; Cancer; Colorectal cancer; Fluorouracil","score_opus":0.10361903941469253,"score_gpt":0.41828595469522534,"score_spread":0.3146669152805328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598740988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975166,0.00051339803,0.00003748319,0.0005980399,0.00033911483,0.00085344893,0.000071642724,0.0000024737221,0.000067814915],"genre_scores_gemma":[0.9978447,0.00014685359,0.0017854734,0.000089656605,0.000083821884,0.000021569194,0.0000021737508,0.000013248661,0.000012494592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780935,0.000117969445,0.0014854817,0.00014180798,0.00026994915,0.00017543482],"domain_scores_gemma":[0.9967613,0.0004672354,0.0017660713,0.000095674615,0.0008263541,0.00008336957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048321966,0.00013208047,0.0013232229,0.00008474969,0.00003634765,0.0000016422459,0.00009582754,0.0001245285,0.000011248727],"category_scores_gemma":[0.00074925437,0.000070318194,0.000254664,0.00023934929,0.0001961869,0.00007411864,0.00003370343,0.00023331087,1.2162103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015955571,0.0033788397,0.880341,0.000056439436,0.0007632602,0.0000115278945,0.00030979805,0.00047369784,0.0036530048,0.00005183398,0.0000027625954,0.09500225],"study_design_scores_gemma":[0.027783886,0.01458174,0.9498303,0.00031518814,0.0005031632,0.00001042091,0.00006518937,0.000056332632,0.0064588855,0.00010936837,0.00022428688,0.000061254155],"about_ca_topic_score_codex":0.00013338558,"about_ca_topic_score_gemma":0.000486483,"teacher_disagreement_score":0.094941,"about_ca_system_score_codex":0.0002733538,"about_ca_system_score_gemma":0.00088700943,"threshold_uncertainty_score":0.28674927},"labels":[],"label_agreement":null},{"id":"W2598741724","doi":"10.1200/jco.2017.35.6_suppl.388","title":"The impact of peri-operative chemotherapy for patients with lymph node-positive urothelial cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Chemotherapy; Cystectomy; Stage (stratigraphy); Bladder cancer; Urothelial cancer; Internal medicine; Lymph node; Proportional hazards model; Cancer; Oncology; Surgery; Urology","score_opus":0.06450535148327566,"score_gpt":0.4889928042519054,"score_spread":0.42448745276862976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598741724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914194,0.00021078778,0.00011706848,0.004819686,0.0006710549,0.0005848364,0.00009536223,0.0000026250243,0.0020792028],"genre_scores_gemma":[0.9964743,0.00076802797,0.00077134586,0.0006287882,0.0010108107,0.000021506346,0.000002176508,0.000022788994,0.0003002236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827754,0.00012846636,0.0009828758,0.00014243911,0.00026112158,0.00020757449],"domain_scores_gemma":[0.99545485,0.00096319953,0.0019663095,0.00026826857,0.0011427498,0.00020464053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007122959,0.00015186777,0.001078181,0.000028431657,0.00023806072,0.000022586915,0.00024657528,0.00017255844,0.00007393469],"category_scores_gemma":[0.00092690537,0.0000670996,0.0005865727,0.000027056338,0.0004942918,0.00011820211,0.000022239019,0.000276599,0.0000015352874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05104856,0.0020946465,0.758834,0.000010293715,0.002474126,0.000020792058,0.00029717627,0.0000117268755,0.00007839768,0.000029143257,0.0011467582,0.18395436],"study_design_scores_gemma":[0.032618586,0.033147898,0.93076205,0.00011243423,0.00038760196,0.00001716751,0.00004436753,0.00003473566,0.00032226226,0.00011118411,0.0023705608,0.00007113149],"about_ca_topic_score_codex":0.00027867607,"about_ca_topic_score_gemma":0.000037128862,"teacher_disagreement_score":0.18388322,"about_ca_system_score_codex":0.00026123127,"about_ca_system_score_gemma":0.0031513257,"threshold_uncertainty_score":0.55903167},"labels":[],"label_agreement":null},{"id":"W2598746040","doi":"10.1200/jco.2014.32.15_suppl.6588","title":"The risks of debilitating falls (DFs) in patients (pts) with cancer: The Manitoba experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cancer; Hazard ratio; Cancer registry; Cohort; Retrospective cohort study; Population; Confidence interval; Internal medicine; Demography; Environmental health","score_opus":0.1653868627355819,"score_gpt":0.49432904876565775,"score_spread":0.32894218603007586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598746040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054563,0.00019985515,0.000051474817,0.0067471405,0.00091133727,0.00023056757,0.0000010885337,0.0000029772168,0.0013099319],"genre_scores_gemma":[0.9966626,0.0003528189,0.0010367779,0.0013822102,0.0004906667,0.000010091718,3.0429553e-7,0.000011056616,0.000053461612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646485,0.0007072531,0.0019952888,0.00013134987,0.0004775157,0.00022373865],"domain_scores_gemma":[0.98847044,0.008797426,0.0017423294,0.0002780024,0.0005684562,0.00014334252],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037871206,0.00010274962,0.000810785,0.000044122247,0.00006223637,0.0000068253685,0.00033347044,0.00016389658,0.000026220387],"category_scores_gemma":[0.011758104,0.000043684762,0.00017422435,0.00014116328,0.0005748153,0.00007100066,0.00005364755,0.0009534409,0.0000037806133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015736063,0.0004700948,0.69544905,0.000011744175,0.000069922884,0.000011773296,0.0010750826,0.000041291078,0.000009202778,0.000041020834,0.0008107522,0.30043644],"study_design_scores_gemma":[0.007726585,0.011520186,0.9512019,0.00026060076,0.000092653136,0.000026614094,0.0031969894,0.00022928667,0.000041831045,0.00021231508,0.025432993,0.00005805215],"about_ca_topic_score_codex":0.00040203033,"about_ca_topic_score_gemma":0.0035390693,"teacher_disagreement_score":0.30037838,"about_ca_system_score_codex":0.00013581556,"about_ca_system_score_gemma":0.00053499645,"threshold_uncertainty_score":0.9965663},"labels":[],"label_agreement":null},{"id":"W2598754923","doi":"10.1200/jco.2004.22.90140.1556","title":"Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Immunostaining; Vascular endothelial growth factor; Pathology; Chemotherapy; Immunohistochemistry; Angiogenesis; Glioma; Radiation therapy; Internal medicine; VEGF receptors; Cancer research","score_opus":0.09444963013180507,"score_gpt":0.39969091682876323,"score_spread":0.30524128669695816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598754923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453175,0.0010151973,0.000030500369,0.0017145908,0.0011697292,0.00037039616,0.0000020120212,0.000013492869,0.0011523037],"genre_scores_gemma":[0.99102247,0.0005973413,0.00637391,0.00051042816,0.0013435547,0.000007670175,0.0000027865692,0.000025418967,0.00011641953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959325,0.00028290716,0.0026753943,0.00027647926,0.0004723587,0.00036036537],"domain_scores_gemma":[0.9964833,0.0009471119,0.0013925383,0.00027240513,0.00035927058,0.00054534426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020664767,0.00020702844,0.0016127246,0.00037755538,0.000027540647,0.000008314892,0.00019082992,0.0005336138,0.000030993513],"category_scores_gemma":[0.001901276,0.00015312569,0.0006204339,0.00031474134,0.00014895195,0.000118135256,0.00006938707,0.0012662194,0.000049331495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002864775,0.008509451,0.9179663,0.000075085256,0.00014249393,0.049300686,0.000119335564,0.000045423967,0.004322365,0.0000735302,0.00027263482,0.016307905],"study_design_scores_gemma":[0.015224658,0.01516904,0.95986855,0.00006109543,0.0008349305,0.005594393,0.000040319384,0.0000050425997,0.0024092996,0.00030463366,0.00037291666,0.000115140196],"about_ca_topic_score_codex":0.000047347727,"about_ca_topic_score_gemma":0.00006936388,"teacher_disagreement_score":0.04370629,"about_ca_system_score_codex":0.000713231,"about_ca_system_score_gemma":0.0032592718,"threshold_uncertainty_score":0.62442845},"labels":[],"label_agreement":null},{"id":"W2598763057","doi":"10.1200/jco.2012.30.15_suppl.3039","title":"MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Pharmacodynamics; Pharmacokinetics; Internal medicine; Gastroenterology; Pharmacology; Urology","score_opus":0.09979410875692372,"score_gpt":0.47105458380067167,"score_spread":0.37126047504374793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598763057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509513,0.0021674787,0.00028540578,0.00034345625,0.0018273549,0.00019665742,0.000016549368,0.000003949328,0.00006403977],"genre_scores_gemma":[0.99078554,0.00024245464,0.0064126616,0.00025539522,0.0022219785,0.0000048236034,0.000012451907,0.000020491554,0.000044198096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970357,0.0006245788,0.0016535518,0.00020005998,0.00024345246,0.00024267004],"domain_scores_gemma":[0.99731445,0.00034087838,0.0014218305,0.00019766887,0.00041516477,0.0003100291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033535599,0.0001555739,0.0007953397,0.00005965393,0.000035627436,0.0000071726195,0.00016721804,0.0004112605,0.00007258546],"category_scores_gemma":[0.0027711196,0.00012389554,0.00023758177,0.00010132398,0.0002044665,0.000022156633,0.00010035165,0.00042479878,0.000004275827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008191782,0.009347393,0.16335641,0.000035533474,0.00064154534,0.00002240536,0.00028643227,0.000030105657,0.69700336,0.000019572744,0.006692281,0.11437314],"study_design_scores_gemma":[0.07532722,0.15688573,0.22272667,0.00021029646,0.0013080253,0.00017707265,0.0009944078,0.0002811034,0.276379,0.0001292859,0.2646547,0.0009265134],"about_ca_topic_score_codex":0.000011706969,"about_ca_topic_score_gemma":0.000013502056,"teacher_disagreement_score":0.4206244,"about_ca_system_score_codex":0.000042975193,"about_ca_system_score_gemma":0.00032416167,"threshold_uncertainty_score":0.5052314},"labels":[],"label_agreement":null},{"id":"W2598769704","doi":"10.1200/jco.2004.22.90140.6000","title":"Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Regimen; Oncology","score_opus":0.4378834278044212,"score_gpt":0.5387757457056198,"score_spread":0.10089231790119862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598769704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96357495,0.0085838055,0.020810883,0.003574076,0.0020164724,0.0006332499,0.00007119844,0.0000038722737,0.0007314929],"genre_scores_gemma":[0.99487084,0.0017721847,0.0021482015,0.00066654634,0.00048345173,0.0000044774815,8.520887e-7,0.000017819979,0.00003560758],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9823345,0.0010922601,0.01594299,0.00024757857,0.00010229326,0.00028038907],"domain_scores_gemma":[0.96556365,0.012834956,0.02083955,0.0002316192,0.00027169308,0.0002585502],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.052344695,0.00021525151,0.0137588605,0.00029884587,0.000056924207,0.000020067306,0.0002682946,0.00047476313,0.00017732228],"category_scores_gemma":[0.044149265,0.00016307249,0.0020112342,0.000096036056,0.0006846932,0.000277606,0.000048998776,0.00049450085,0.0000050751487],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33019617,0.013688725,0.1442354,0.00015077551,0.011637518,0.000053472246,0.0016652854,0.0021880465,0.0010122303,0.43420812,0.00049954467,0.06046472],"study_design_scores_gemma":[0.7911609,0.010464689,0.015839957,0.000119548306,0.0016643566,0.00003002755,0.00015562096,0.0013413646,0.00050690834,0.1723236,0.0060630087,0.0003300341],"about_ca_topic_score_codex":0.000126186,"about_ca_topic_score_gemma":0.000017302742,"teacher_disagreement_score":0.46096474,"about_ca_system_score_codex":0.00017338959,"about_ca_system_score_gemma":0.00065668207,"threshold_uncertainty_score":0.9758106},"labels":[],"label_agreement":null},{"id":"W2598786376","doi":"10.1200/jco.2013.31.15_suppl.5072","title":"Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Cell-free fetal DNA; Prostate cancer; Medicine; Copy-number variation; Copy number analysis; Cancer; Oncology; Prostate; Population; Biomarker; Malignancy; Internal medicine; Biology; Genetics; Genome; Gene","score_opus":0.0714029852786465,"score_gpt":0.4428962011028492,"score_spread":0.3714932158242027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598786376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878244,0.0005753327,0.0048172567,0.0026168474,0.0029886405,0.00049378455,0.0002857686,0.0000029566538,0.0003950515],"genre_scores_gemma":[0.9831348,0.004370081,0.008085686,0.0018282409,0.0023406663,0.00005381178,0.000055072775,0.00002186779,0.00010976352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963538,0.00036751459,0.0024495467,0.00034582947,0.00015927326,0.0003240053],"domain_scores_gemma":[0.9961645,0.0012937072,0.0013840232,0.0003410289,0.0005551911,0.00026153307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029925553,0.0001470165,0.00084790133,0.000031954893,0.000056777666,0.000030467492,0.00035161062,0.0006050603,0.0003066385],"category_scores_gemma":[0.0036158918,0.0001282298,0.00051857554,0.00006199767,0.00012276965,0.000013308745,0.0001899805,0.00052784674,0.000015584874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013655521,0.0015077358,0.9317254,0.000012218796,0.0002295717,0.000017941753,0.00002824636,0.000052607396,0.001673411,0.000068982,0.05207355,0.011244788],"study_design_scores_gemma":[0.011979294,0.0020678635,0.82487017,0.000026538954,0.00023427753,0.000008646762,0.00007007708,0.0012906078,0.0007392418,0.0025573405,0.15593071,0.00022524237],"about_ca_topic_score_codex":0.0005328469,"about_ca_topic_score_gemma":0.0013718319,"teacher_disagreement_score":0.10685524,"about_ca_system_score_codex":0.00005037189,"about_ca_system_score_gemma":0.0015539359,"threshold_uncertainty_score":0.52290595},"labels":[],"label_agreement":null},{"id":"W2598788278","doi":"10.1200/jco.2017.35.5_suppl.96","title":"Comparative study of the perceptions of continuity of care of CRC survivors transitioned to primary care.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Survivorship curve; Quality of life (healthcare); Family medicine; Colorectal cancer; Cancer; Continuity of care; Stage (stratigraphy); Disease; Health care; Internal medicine; Nursing","score_opus":0.12485792105743444,"score_gpt":0.48240988907915167,"score_spread":0.35755196802171724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598788278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539,0.00011109072,0.00012970658,0.00039617767,0.00060601166,0.0003694773,0.000020411191,0.000001943509,0.0029751689],"genre_scores_gemma":[0.999346,0.000024296358,0.00039696382,0.000049649534,0.00015223605,0.0000025926718,8.445353e-7,0.000004506834,0.000022905868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733883,0.00047722203,0.0016417004,0.0001022341,0.000363187,0.00007680809],"domain_scores_gemma":[0.99475086,0.0007160101,0.0024362516,0.00030342225,0.0016942043,0.00009922492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010771453,0.0000758265,0.0015702136,0.0000816861,0.000063280975,0.0000018527974,0.00021249561,0.00014961968,0.000023133744],"category_scores_gemma":[0.0008598388,0.00004957077,0.00045267618,0.00009378739,0.0003523083,0.00004766648,0.00005404249,0.00042069398,2.8999418e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05814145,0.0045523583,0.81251776,0.000413742,0.0008208376,0.000015896863,0.05553177,0.00029841857,0.011277916,0.000018024619,0.0002179067,0.056193896],"study_design_scores_gemma":[0.0047279517,0.052228637,0.9187096,0.00020392275,0.00046036197,0.000012784238,0.021637725,0.0000065305812,0.0018294656,0.000011763233,0.00013645049,0.00003483507],"about_ca_topic_score_codex":0.0006154489,"about_ca_topic_score_gemma":0.0060817753,"teacher_disagreement_score":0.10619179,"about_ca_system_score_codex":0.0000899211,"about_ca_system_score_gemma":0.000708267,"threshold_uncertainty_score":0.33937734},"labels":[],"label_agreement":null},{"id":"W2598794769","doi":"10.1200/jco.2012.30.15_suppl.582","title":"Relationship between body mass index (BMI) at diagnosis of ER+ node negative breast cancer (BC) and Oncotype DX recurrence score.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health; BC Cancer Agency","funders":"","keywords":"Medicine; Overweight; Body mass index; Breast cancer; Internal medicine; Cancer; Obesity; Oncology; Stage (stratigraphy); Gynecology","score_opus":0.21510511625604758,"score_gpt":0.49085710677849564,"score_spread":0.27575199052244803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598794769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251026,0.000777444,0.00007538106,0.0046604658,0.0011683822,0.00015983495,0.000044149892,0.000004862795,0.0005992165],"genre_scores_gemma":[0.9952601,0.0018339106,0.00055467687,0.00038842828,0.0018587514,0.000007034653,0.0000027982385,0.000015148916,0.00007914745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724865,0.00030697847,0.0016857921,0.00015663498,0.0003418345,0.00026011516],"domain_scores_gemma":[0.99143595,0.005598595,0.0018746752,0.00015421023,0.00038101114,0.00055556744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018138755,0.00014048199,0.0012607509,0.0001239858,0.000052878924,0.0000054729576,0.00011223918,0.00041747556,0.00034760492],"category_scores_gemma":[0.002853001,0.000101306905,0.00026617502,0.00018673093,0.00038436634,0.00024312899,0.00006596858,0.0010869823,0.000007452933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016397691,0.00033838474,0.9692721,0.000039983326,0.00017213855,0.000013141861,0.00015913116,0.0000035934975,0.000012914806,0.00002804764,0.0022283464,0.02609245],"study_design_scores_gemma":[0.0032310889,0.0019211391,0.98824763,0.00024422878,0.00053551357,0.0000700109,0.00008880021,0.000010860489,0.00007135312,0.00016471763,0.005318401,0.000096271884],"about_ca_topic_score_codex":0.00077939534,"about_ca_topic_score_gemma":0.00032432156,"teacher_disagreement_score":0.025996177,"about_ca_system_score_codex":0.00032829016,"about_ca_system_score_gemma":0.0008365716,"threshold_uncertainty_score":0.47224575},"labels":[],"label_agreement":null},{"id":"W2598811272","doi":"10.1200/jco.2014.32.15_suppl.6622","title":"Permanent stoma use in rectal cancer surgery in Canada: A population-based analysis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Colorectal cancer; Colostomy; Stoma (medicine); Population; Abdominoperineal resection; Rectum; Surgery; Ileostomy; Demography; Cancer; General surgery; Internal medicine; Environmental health","score_opus":0.14314066022187666,"score_gpt":0.44879210913899664,"score_spread":0.30565144891712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598811272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522775,0.0001439639,0.0000090748135,0.003444706,0.0008178957,0.00012372372,0.0000046064984,0.000003415578,0.00022487389],"genre_scores_gemma":[0.9972189,0.00009782109,0.00021204163,0.0021259089,0.00027646453,0.000009984888,0.00000889551,0.000010372333,0.000039629518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995921,0.000781165,0.0023797783,0.00020725,0.00045218912,0.00025858163],"domain_scores_gemma":[0.9906323,0.007649118,0.0010395817,0.00015298423,0.00018780348,0.00033820822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023069365,0.00012910101,0.0021650724,0.00045890216,0.000012917499,0.0000051786105,0.00007972582,0.00019165626,0.0002496557],"category_scores_gemma":[0.0044342307,0.00009668166,0.0005282399,0.0007179855,0.000037257803,0.00007810774,0.000018736357,0.0006856107,0.0000017257651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030964315,0.0005930025,0.957565,0.000010039119,0.00030932555,0.0012523744,0.000009641558,0.0022741985,0.0000016516268,0.0000035971,0.00035631694,0.0345284],"study_design_scores_gemma":[0.0038090046,0.000791615,0.9879602,0.00008762116,0.0004383203,0.000025028057,0.00000997967,0.0033466879,0.000004048715,0.000016119293,0.003428861,0.00008248361],"about_ca_topic_score_codex":0.74318755,"about_ca_topic_score_gemma":0.98442495,"teacher_disagreement_score":0.24123734,"about_ca_system_score_codex":0.0031103564,"about_ca_system_score_gemma":0.008085078,"threshold_uncertainty_score":0.99753815},"labels":[],"label_agreement":null},{"id":"W2598812260","doi":"10.1200/jco.2017.35.5_suppl.102","title":"Metabolic syndrome (MetS) after platinum-based chemotherapy (CHEM): A multicenter study of North American testicular cancer survivors (TCS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Metabolic syndrome; Internal medicine; Abdominal obesity; Waist; Obesity; Cancer; Endocrinology; Gynecology","score_opus":0.038688651628835016,"score_gpt":0.4005895840081175,"score_spread":0.3619009323792825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598812260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922692,0.0009311043,0.00012772874,0.0004704334,0.005796991,0.00030616618,0.000028410564,0.0000037722434,0.00006617049],"genre_scores_gemma":[0.9903518,0.0012981978,0.0011378741,0.0011338426,0.0059030806,0.00003127448,0.0000035154533,0.00003721686,0.00010318656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674547,0.0004239571,0.0017794038,0.0003661598,0.00035992297,0.0003250695],"domain_scores_gemma":[0.9948427,0.00024258364,0.003363206,0.0007134044,0.00052976375,0.00030831317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013733523,0.00025503727,0.0017066333,0.000091353904,0.000084127634,0.000023798766,0.00064685935,0.00020100437,0.000056991255],"category_scores_gemma":[0.0015495201,0.00019661742,0.0005840248,0.00009028809,0.0005234372,0.000016345075,0.0001219692,0.00047314068,0.0000029594987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003622123,0.002863501,0.9211662,0.000017513035,0.00085938215,0.000020054385,0.000095489384,0.00014782713,0.0017007873,7.685803e-7,0.0008460807,0.06866029],"study_design_scores_gemma":[0.007716164,0.0048424075,0.8373926,0.000018836236,0.0003654383,0.000019027542,0.000067617046,0.000043901713,0.0005793444,0.000002239433,0.14877154,0.00018083454],"about_ca_topic_score_codex":0.0011100775,"about_ca_topic_score_gemma":0.011088181,"teacher_disagreement_score":0.14792545,"about_ca_system_score_codex":0.000026165257,"about_ca_system_score_gemma":0.0008317995,"threshold_uncertainty_score":0.80178255},"labels":[],"label_agreement":null},{"id":"W2598814209","doi":"10.1200/jco.2013.31.15_suppl.2534","title":"Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Mucositis; Peripheral edema; Internal medicine; Nausea; Tolerability; Rash; Temsirolimus; Gastroenterology; Pharmacology; Toxicity; PI3K/AKT/mTOR pathway","score_opus":0.08051871756361849,"score_gpt":0.4348607984110177,"score_spread":0.3543420808473992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598814209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370676,0.00016273998,0.000022241764,0.0011572217,0.00094823196,0.0013526372,0.000005287028,0.0000098634,0.0026349912],"genre_scores_gemma":[0.9963778,0.00014705939,0.0017872372,0.00056571624,0.0007556687,0.00003099743,0.000009285712,0.000040256302,0.00028592552],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99323505,0.0007312763,0.0044019436,0.0003409263,0.00082651083,0.00046430557],"domain_scores_gemma":[0.99269956,0.0018822819,0.0035246748,0.00040366902,0.00082271,0.00066708634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019770574,0.00030917948,0.0032443793,0.00032537378,0.000034084434,0.000008866068,0.00025923716,0.00039822285,0.00023871774],"category_scores_gemma":[0.002513694,0.00019408653,0.0006103463,0.00027468143,0.00031283312,0.00023348528,0.00005897815,0.0012521321,0.000045886914],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5587406,0.04372878,0.075976156,0.0001085491,0.0008347723,0.002518749,0.00046659954,0.00017836665,0.00089703506,0.00002852219,0.0022971532,0.3142247],"study_design_scores_gemma":[0.5339956,0.24664718,0.21503764,0.0002863543,0.0005134399,0.00016770982,0.00020689749,0.00012340698,0.00064887333,0.00015442794,0.0020241577,0.0001942658],"about_ca_topic_score_codex":0.00012616404,"about_ca_topic_score_gemma":0.00007255079,"teacher_disagreement_score":0.31403044,"about_ca_system_score_codex":0.000660984,"about_ca_system_score_gemma":0.0023799532,"threshold_uncertainty_score":0.79146194},"labels":[],"label_agreement":null},{"id":"W2598832696","doi":"10.1200/jco.2017.35.6_suppl.522","title":"Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lesion; Target lesion; Cabozantinib; Renal cell carcinoma; Urology; Internal medicine; Nuclear medicine; Surgery","score_opus":0.2587199908589407,"score_gpt":0.4938968465033816,"score_spread":0.2351768556444409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598832696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383694,0.00017030878,0.000012240145,0.0016772053,0.0011302507,0.00073668343,0.00003507314,0.0000024949916,0.0023987836],"genre_scores_gemma":[0.99800545,0.00010311207,0.00077111245,0.00043089688,0.0006034652,0.00001843306,0.000020616491,0.000020030822,0.00002686818],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99320966,0.0017036627,0.003391696,0.00035484778,0.0009755712,0.00036455094],"domain_scores_gemma":[0.98846614,0.005328795,0.004788816,0.0008273338,0.0003414099,0.00024747243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070916764,0.0002728474,0.0032821167,0.0007411606,0.00005088786,0.000009902614,0.00056707585,0.0003226816,0.00016339176],"category_scores_gemma":[0.004384451,0.00017159298,0.0013377948,0.0003678411,0.00026484605,0.00014795233,0.00007177767,0.0010350073,0.0000025257757],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7388015,0.015790831,0.22540712,0.0000775807,0.0006609631,0.0037985449,0.00029984498,0.0005522818,0.002158913,0.000024043922,0.00012722009,0.012301147],"study_design_scores_gemma":[0.28338864,0.05163943,0.6577479,0.00009150256,0.00193159,0.000008879254,0.000083245475,0.0022562807,0.0020758705,0.000014824688,0.0006482378,0.00011356877],"about_ca_topic_score_codex":0.00046482933,"about_ca_topic_score_gemma":0.00050056604,"teacher_disagreement_score":0.45541286,"about_ca_system_score_codex":0.00024087995,"about_ca_system_score_gemma":0.0011177069,"threshold_uncertainty_score":0.6997359},"labels":[],"label_agreement":null},{"id":"W2598833272","doi":"10.1200/jco.2012.30.15_suppl.2013","title":"Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Veliparib; Medicine; Internal medicine; Adverse effect; Oncology; Nausea; PARP inhibitor; Radiation therapy; Surgery","score_opus":0.08408595961704525,"score_gpt":0.4750247566108158,"score_spread":0.39093879699377054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598833272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932365,0.0004737881,0.000162809,0.0050074696,0.00022468055,0.0007618791,0.00000736815,0.000003848923,0.00012164837],"genre_scores_gemma":[0.9970929,0.00025532377,0.00037118574,0.0020409906,0.00017918581,0.000012362331,0.000011517599,0.00001693751,0.000019623545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628925,0.0011042111,0.0018065906,0.00015402598,0.00044271947,0.00020317783],"domain_scores_gemma":[0.9961969,0.0016373448,0.0015592413,0.00012357855,0.00027965076,0.00020324031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003961272,0.00013943184,0.001080842,0.0003148488,0.000019474901,0.0000043549635,0.00007432813,0.00012582357,0.00005751819],"category_scores_gemma":[0.0005456325,0.000093955,0.00006075025,0.00036322957,0.0001385279,0.00027121702,0.0000129322425,0.00061215035,0.0000010919259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04396466,0.03769878,0.6459948,0.000017702483,0.00025757198,0.000043428077,0.0015644754,0.00008880887,0.0002903429,0.00001765586,0.0008103257,0.26925144],"study_design_scores_gemma":[0.21736033,0.07440953,0.6953997,0.00008681325,0.00009928703,0.00003008252,0.00030370947,0.000088028966,0.00015559576,0.000022587894,0.011959862,0.00008447917],"about_ca_topic_score_codex":0.000030741034,"about_ca_topic_score_gemma":0.000053181735,"teacher_disagreement_score":0.26916698,"about_ca_system_score_codex":0.00022127533,"about_ca_system_score_gemma":0.0003785835,"threshold_uncertainty_score":0.38313738},"labels":[],"label_agreement":null},{"id":"W2598843411","doi":"10.1200/jco.2009.27.15_suppl.e20631","title":"Phase II study of AVR118 in the management of cancer related anorexia/cachexia","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Anorexia; Cachexia; Weight loss; Lean body mass; Quality of life (healthcare); Internal medicine; Appetite; Cancer; Performance status; Weight gain; Physical therapy; Body weight; Obesity","score_opus":0.15654360748112028,"score_gpt":0.5673518325129696,"score_spread":0.41080822503184933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598843411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98495835,0.0006775858,0.000004262973,0.00813758,0.00017080929,0.00053427217,0.000001413591,0.0000033637687,0.0055123856],"genre_scores_gemma":[0.99709606,0.0012889198,0.0007984235,0.00059648545,0.00006335103,0.0000074790687,0.0000012150267,0.000004571871,0.00014346301],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965439,0.00033199124,0.002597762,0.00011361445,0.00027903094,0.00013371305],"domain_scores_gemma":[0.9974001,0.00040139025,0.0016113912,0.00024690173,0.00023064825,0.00010953476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020804727,0.00008107216,0.0008963925,0.00013132663,0.000037686692,0.0000010224492,0.00016979154,0.00016207209,0.00006956401],"category_scores_gemma":[0.000105443556,0.000046825986,0.0001681277,0.00032790282,0.000055760243,0.000032710715,0.00002165042,0.00061139854,0.0000032468126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059501072,0.19750695,0.15520579,0.00008754389,0.002150913,0.001210155,0.00452855,0.000089446934,0.00003850801,0.0010249113,0.0022768287,0.6299303],"study_design_scores_gemma":[0.043040037,0.10686278,0.8401497,0.0002746199,0.0012114097,0.00006399314,0.00097177,0.00012569368,0.0000048493207,0.0006369909,0.006612495,0.000045640205],"about_ca_topic_score_codex":0.000049846065,"about_ca_topic_score_gemma":0.0000306494,"teacher_disagreement_score":0.6849439,"about_ca_system_score_codex":0.000098687065,"about_ca_system_score_gemma":0.00035829633,"threshold_uncertainty_score":0.26562563},"labels":[],"label_agreement":null},{"id":"W2598860788","doi":"10.1200/jco.2013.31.15_suppl.6543","title":"Willingness of patients to provide biologic samples for pharmacogenomic testing.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Biopsy; Blood sampling; Blood cancer; Sampling (signal processing); Cancer; Internal medicine; Likert scale; Genetic testing; Blood test; Oncology","score_opus":0.13241217331651356,"score_gpt":0.4300233084624255,"score_spread":0.2976111351459119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598860788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958452,0.00024595726,0.0017739548,0.0005637718,0.0009660177,0.00039411048,0.000051012175,0.0000015419465,0.00015842298],"genre_scores_gemma":[0.9731175,0.00022200549,0.023690943,0.0018468332,0.0010411177,0.000020011432,0.000014502706,0.000013711759,0.000033381624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981155,0.000087578424,0.0013647521,0.00017219382,0.00007711442,0.00018286299],"domain_scores_gemma":[0.9963675,0.0011538005,0.0011582032,0.00013075751,0.000989092,0.00020065579],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00087087956,0.00010196069,0.0005550195,0.00003693011,0.000025744186,0.000007643618,0.00026731673,0.00020829233,0.000019820913],"category_scores_gemma":[0.008740018,0.00007833809,0.00024611846,0.000054382617,0.00009092779,0.000004177237,0.00009718168,0.00012542582,0.0000052143546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023437056,0.0015646066,0.34487635,0.00005681693,0.00031124006,0.0000033263161,0.000036306603,0.0006012413,0.18910721,0.00005293392,0.042917665,0.4181286],"study_design_scores_gemma":[0.0067302957,0.033545353,0.28196803,0.00003466928,0.00017860683,0.000011410251,0.00004814584,0.00010794666,0.030022202,0.0013183643,0.6457429,0.00029207105],"about_ca_topic_score_codex":0.000025079493,"about_ca_topic_score_gemma":0.000011838578,"teacher_disagreement_score":0.6028252,"about_ca_system_score_codex":0.000025969015,"about_ca_system_score_gemma":0.00062000006,"threshold_uncertainty_score":0.99960977},"labels":[],"label_agreement":null},{"id":"W2598864615","doi":"10.1200/jco.2012.30.15_suppl.e13598","title":"Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Wee1; Pharmacodynamics; Pharmacology; Oncology; Chemotherapy; Cisplatin; Biomarker; Tolerability; Internal medicine; Urology; Pharmacokinetics; Cancer; Cyclin-dependent kinase 1; Adverse effect","score_opus":0.39022315236694166,"score_gpt":0.585126215296599,"score_spread":0.19490306292965737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598864615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256737,0.0010052248,0.00012395423,0.009198581,0.0032154045,0.0006361096,0.000011414444,0.000004666471,0.0032372454],"genre_scores_gemma":[0.9959815,0.00029919224,0.0008520537,0.0013151813,0.001374755,0.000022159846,0.0000038160333,0.00001462315,0.00013668869],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950837,0.0021273608,0.0016297827,0.00014296664,0.00075688487,0.00025932194],"domain_scores_gemma":[0.99421936,0.002485862,0.0018201787,0.00018983726,0.00094245933,0.00034231134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014309386,0.00015146783,0.0011454769,0.00016359695,0.00004173502,0.000003051676,0.00016085444,0.00020913953,0.0012897744],"category_scores_gemma":[0.002245727,0.000093413444,0.00043109266,0.00025014085,0.00019520136,0.00014582586,0.00008963667,0.0006697937,0.0000150421265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025922459,0.022881955,0.12025208,0.000148443,0.003014915,0.00008191609,0.00088767544,0.0001444092,0.3520206,0.00010202515,0.029748898,0.44479463],"study_design_scores_gemma":[0.02703834,0.017595991,0.77372825,0.00015472976,0.0059932787,0.00015806191,0.00020879244,0.0010975308,0.06999875,0.0001881868,0.10366192,0.00017616306],"about_ca_topic_score_codex":0.000048791906,"about_ca_topic_score_gemma":0.000014448986,"teacher_disagreement_score":0.6534762,"about_ca_system_score_codex":0.0003563054,"about_ca_system_score_gemma":0.0017236761,"threshold_uncertainty_score":0.9996232},"labels":[],"label_agreement":null},{"id":"W2598873759","doi":"10.1200/jco.2015.33.15_suppl.1037","title":"Tumor infiltrating lymphocytes (TILs) in HER2 positive breast cancer: Evaluation according to the new recommendations by the international TILs working group 2014.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Tumor-infiltrating lymphocytes; Oncology; Trastuzumab; Kappa; Cancer; Pathology; Immunotherapy","score_opus":0.15832878338563722,"score_gpt":0.4891784860668536,"score_spread":0.3308497026812164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598873759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5769491,0.002080283,0.000560849,0.4117219,0.0053891772,0.00058167224,0.000016379172,0.000008681363,0.002691953],"genre_scores_gemma":[0.97917897,0.0005428434,0.0008903944,0.016725237,0.0025184888,0.000018415223,0.000008622055,0.000011417699,0.00010561697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971956,0.0005704879,0.0014342705,0.00014471529,0.0004848706,0.00017002915],"domain_scores_gemma":[0.99644846,0.001686721,0.001115831,0.00012716845,0.00044147423,0.00018036409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009024062,0.00010278764,0.00044680721,0.00009304762,0.00006918538,0.00004448619,0.0003074047,0.000103941995,0.00023500311],"category_scores_gemma":[0.0020377673,0.000057177866,0.00019402633,0.00023256466,0.000072666735,0.00015996167,0.00005614129,0.00055931066,0.000008514309],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005641299,0.00022805862,0.051913634,0.0000013692539,0.00026387963,0.000012096581,0.00067364477,0.00010257332,0.00051007245,0.000018187979,0.1430101,0.79762506],"study_design_scores_gemma":[0.02572139,0.0043040426,0.42811826,0.0012082001,0.0004993018,0.0017016847,0.009452273,0.003838042,0.00029039232,0.0005123487,0.5240872,0.00026688125],"about_ca_topic_score_codex":0.0010461751,"about_ca_topic_score_gemma":0.0014184096,"teacher_disagreement_score":0.7973582,"about_ca_system_score_codex":0.001170669,"about_ca_system_score_gemma":0.0028013135,"threshold_uncertainty_score":0.496941},"labels":[],"label_agreement":null},{"id":"W2598875489","doi":"10.1200/jco.2009.27.15_suppl.9054","title":"Long-term survival of patients with metastatic melanoma (MM) treated with dacarbazine (DTIC) or temozolomide (TMZ)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Dacarbazine; Medicine; Temozolomide; Internal medicine; Chemotherapy; Melanoma; Oncology; Cancer; Surgery; Gastroenterology; Cancer research","score_opus":0.06095066757354006,"score_gpt":0.3711432739701306,"score_spread":0.3101926063965905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598875489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741846,0.00015774414,0.0005618559,0.00023172484,0.00022627779,0.00020332902,0.000020116706,0.0000042220568,0.0011762821],"genre_scores_gemma":[0.99610156,0.00014464303,0.0026652117,0.00037791277,0.0003348356,0.0000020549908,0.00005051841,0.000019831565,0.00030343528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713445,0.00042438,0.0015738736,0.0002654092,0.00032589037,0.00027598222],"domain_scores_gemma":[0.9967755,0.00032490943,0.0017488308,0.00030227358,0.00056628475,0.00028218774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009727804,0.0002236046,0.0012348798,0.00007811335,0.00003233045,0.000008216295,0.0002989614,0.00027148364,0.00006370084],"category_scores_gemma":[0.0007031809,0.00012210768,0.00023283307,0.0001293998,0.0002064309,0.000012556053,0.000040302246,0.0003335893,0.00000347409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033668056,0.003581771,0.9122835,0.00003974505,0.0011267761,0.00075630995,0.000027175267,0.000030911313,0.0073133814,0.00005543023,0.0006906823,0.040426277],"study_design_scores_gemma":[0.012397885,0.08290789,0.8944136,0.000058783222,0.00049314287,0.00016047293,0.000022496119,0.0000044052294,0.0056850603,0.000025232648,0.0036251706,0.00020586916],"about_ca_topic_score_codex":0.0000044808853,"about_ca_topic_score_gemma":0.00009896835,"teacher_disagreement_score":0.07932612,"about_ca_system_score_codex":0.000024262145,"about_ca_system_score_gemma":0.00077600946,"threshold_uncertainty_score":0.4979407},"labels":[],"label_agreement":null},{"id":"W2598880209","doi":"10.1200/jco.2013.31.15_suppl.11016","title":"Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Cancer Care Ontario; London Health Sciences Centre; Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Precision oncology; Clinical trial; Oncology; Sanger sequencing; Internal medicine; DNA sequencing; Bioinformatics; Medical physics; Computational biology; Cancer; Gene","score_opus":0.11521682335451679,"score_gpt":0.4257415105624504,"score_spread":0.31052468720793364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598880209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959371,0.0001467343,0.0009640775,0.0009872898,0.00076063676,0.00035470052,0.000029445353,0.0000046653568,0.0008153382],"genre_scores_gemma":[0.960039,0.0022155289,0.033311445,0.00060444453,0.0036099565,0.000016298874,0.00011830891,0.00001694814,0.00006804686],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960522,0.0003373616,0.0029972808,0.00028501844,0.0001614071,0.00016673809],"domain_scores_gemma":[0.9953972,0.0009028764,0.0024650595,0.00032108638,0.0006916856,0.00022207233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020501863,0.0001189466,0.0006767527,0.000035367033,0.000026607884,0.000021777338,0.00024714688,0.00051948323,0.000028157692],"category_scores_gemma":[0.0041457857,0.000098514094,0.0003839077,0.00005346685,0.00017041704,0.000014164668,0.00009226629,0.0003140289,0.000031041727],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017905608,0.0013145237,0.01142981,0.000007432753,0.00028459437,0.00001044797,0.000050388702,0.00021187923,0.51881737,0.000025949521,0.018944109,0.44711292],"study_design_scores_gemma":[0.040400032,0.052749306,0.2718031,0.00017033966,0.0010639438,0.00007615762,0.00041147257,0.07240996,0.076060854,0.001485312,0.482229,0.001140509],"about_ca_topic_score_codex":0.00044306155,"about_ca_topic_score_gemma":0.0001269563,"teacher_disagreement_score":0.4632849,"about_ca_system_score_codex":0.00005271056,"about_ca_system_score_gemma":0.00082757114,"threshold_uncertainty_score":0.4963192},"labels":[],"label_agreement":null},{"id":"W2598893135","doi":"10.1200/jco.2015.33.15_suppl.10070","title":"Long-term outcomes by race/ethnicity in the Childhood Cancer Survivor Study (CCSS) cohort.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cohort; Relative risk; Demography; Poisson regression; Cancer; Confidence interval; Dyslipidemia; Internal medicine; Ethnic group; Incidence (geometry); Disease; Population; Environmental health","score_opus":0.22064347306068355,"score_gpt":0.5301338009141244,"score_spread":0.3094903278534409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598893135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9346719,0.0017101896,0.000035865352,0.058817692,0.0028754182,0.0009918907,0.000012065306,0.000018010156,0.0008669621],"genre_scores_gemma":[0.9773181,0.00060359185,0.00012835796,0.019950863,0.0016740081,0.000026810181,0.0000043537198,0.000033250206,0.00026068566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.989388,0.0037863157,0.0043896586,0.00039921934,0.0015804302,0.00045636523],"domain_scores_gemma":[0.9905875,0.005488628,0.0019864426,0.000619281,0.0006131075,0.0007050855],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.025223654,0.00030251272,0.0031259253,0.00015393861,0.000056217024,0.000027017626,0.00074192137,0.0004474376,0.00015269144],"category_scores_gemma":[0.011211308,0.00017935317,0.0006458445,0.00035717283,0.0002960787,0.00019716012,0.00014054267,0.0026376806,0.000031355223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015581343,0.01132789,0.94611734,0.000016559972,0.00077296945,0.0005057318,0.0035431783,0.000007805439,0.0000027395674,0.000006955406,0.025525955,0.010614762],"study_design_scores_gemma":[0.017440379,0.009602508,0.96083283,0.00009562331,0.00059211516,0.00017138914,0.0021634714,0.0000040297386,0.0000054638795,0.00007834167,0.008835775,0.00017807761],"about_ca_topic_score_codex":0.0019511915,"about_ca_topic_score_gemma":0.012552765,"teacher_disagreement_score":0.042646173,"about_ca_system_score_codex":0.00036722998,"about_ca_system_score_gemma":0.0030224738,"threshold_uncertainty_score":0.9996633},"labels":[],"label_agreement":null},{"id":"W2598900011","doi":"10.1200/jco.2014.32.15_suppl.6567","title":"Asian and non-Asian disparities in outcomes of head and neck cancer (HNC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Head and neck cancer; Internal medicine; Cancer; Confounding; Cohort; Proportional hazards model; Demography; Oncology","score_opus":0.09295739453404164,"score_gpt":0.4896196884698372,"score_spread":0.39666229393579555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598900011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94740915,0.00115039,0.0000106893085,0.044438288,0.00052412803,0.000077000346,0.0000019585689,0.000001985349,0.0063863867],"genre_scores_gemma":[0.99232614,0.003756796,0.00086255686,0.0024434074,0.00038575567,0.000002689625,1.6501623e-7,0.000007387069,0.0002150954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981155,0.00013604172,0.0013140311,0.000116512536,0.00015352154,0.00016439475],"domain_scores_gemma":[0.9981882,0.0008579589,0.0005362626,0.000082878934,0.000117974,0.00021670313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012961425,0.00009580577,0.0018195708,0.00008991002,0.000022173117,0.0000034678137,0.000051966126,0.00018701187,0.000019017332],"category_scores_gemma":[0.0015487422,0.00006233369,0.0001242941,0.00005755147,0.0003071948,0.00005895395,0.000045654084,0.00049472164,5.5060707e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005985893,0.00024989952,0.8389155,0.00007091305,0.000108184584,0.000037892638,0.0002517129,3.1705454e-7,0.00001770732,0.00009945518,0.0010153884,0.15863444],"study_design_scores_gemma":[0.006586146,0.0062808725,0.96313006,0.00027533548,0.000106794345,0.00004427045,0.00018236456,0.00002382422,0.000012430088,0.00033444862,0.022969496,0.0000539553],"about_ca_topic_score_codex":0.00024884034,"about_ca_topic_score_gemma":0.0027878615,"teacher_disagreement_score":0.15858048,"about_ca_system_score_codex":0.00003969456,"about_ca_system_score_gemma":0.00035207183,"threshold_uncertainty_score":0.2541894},"labels":[],"label_agreement":null},{"id":"W2598916155","doi":"10.1200/jco.2004.22.90140.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Epitope; Cancer; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","score_opus":0.18380388789095847,"score_gpt":0.5762637421299914,"score_spread":0.39245985423903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598916155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393661,0.0016878415,0.00031632674,0.054018542,0.0014406288,0.00038268228,0.000013390329,0.0000146613,0.0027598378],"genre_scores_gemma":[0.9863661,0.0027280967,0.0025635879,0.005414544,0.0027121515,0.000013231006,0.0000023170123,0.000038827162,0.00016113755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948683,0.0007288536,0.0026810865,0.00032396193,0.00080652646,0.00059131376],"domain_scores_gemma":[0.99558836,0.0016953927,0.0011891604,0.00020992177,0.0007324998,0.0005846338],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005358683,0.00021150864,0.0017031835,0.0002552645,0.000053752345,0.000017287382,0.00033028977,0.0004932882,0.0009476503],"category_scores_gemma":[0.0023477008,0.00015439065,0.00049270596,0.00046536932,0.00044196303,0.00016851531,0.00008297834,0.0030321013,0.000043176093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01275529,0.004804071,0.6852301,0.00014841942,0.00087409955,0.0044901855,0.0008684942,0.0008250019,0.0045863865,0.00038788226,0.0029884805,0.28204164],"study_design_scores_gemma":[0.021582188,0.009439007,0.93448555,0.0009440861,0.00022198119,0.0015859054,0.0006428962,0.00016375571,0.0006023139,0.0044919923,0.025569187,0.0002711543],"about_ca_topic_score_codex":0.0011260009,"about_ca_topic_score_gemma":0.0006424463,"teacher_disagreement_score":0.28177047,"about_ca_system_score_codex":0.0014418387,"about_ca_system_score_gemma":0.007918887,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W2598922717","doi":"10.1200/jco.2013.31.15_suppl.tps5613","title":"A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ovarian cancer; Placebo; Internal medicine; Chemotherapy; Gastroenterology; Cancer; Oncology; Performance status; Phases of clinical research; Urology; Pathology","score_opus":0.13559782063363848,"score_gpt":0.444828116016042,"score_spread":0.30923029538240354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598922717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581463,0.00036274397,0.00004254339,0.00394084,0.0026053586,0.004606994,0.000007950414,0.000022842843,0.00259611],"genre_scores_gemma":[0.99612933,0.00021778134,0.0009799205,0.0005309776,0.0015730232,0.0003575922,0.00002106466,0.000051260962,0.00013903272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928373,0.0005916731,0.0045937262,0.00051205856,0.0008492405,0.0006160027],"domain_scores_gemma":[0.99108243,0.0036316197,0.0033732767,0.00031491928,0.0008136605,0.00078411156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026589055,0.00044818252,0.005129446,0.00036140112,0.0000923727,0.00006380689,0.00026489986,0.00057194475,0.0008887175],"category_scores_gemma":[0.0011055657,0.00028494842,0.00062724797,0.00035798558,0.00031814023,0.00030946732,0.00008638092,0.001540537,0.000028281418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9706035,0.0064799828,0.008995839,0.000037193808,0.003114246,0.00045035727,0.00037278005,0.00037088554,0.000011699197,0.00010316446,0.0009464355,0.008513869],"study_design_scores_gemma":[0.94257015,0.03210939,0.019571925,0.0005333566,0.0024891526,0.000023479708,0.00012475063,0.001240969,0.00004599797,0.000038316728,0.0009793222,0.00027320985],"about_ca_topic_score_codex":0.0023370993,"about_ca_topic_score_gemma":0.0014291994,"teacher_disagreement_score":0.028033419,"about_ca_system_score_codex":0.0016119684,"about_ca_system_score_gemma":0.0041636294,"threshold_uncertainty_score":0.99996024},"labels":[],"label_agreement":null},{"id":"W2598945839","doi":"10.1200/jco.2006.24.18_suppl.3007","title":"Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Nausea; Pharmacokinetics; Internal medicine; Gastroenterology; Vomiting; Pharmacodynamics; Cancer; Leukocytopenia; Pharmacology; Adverse effect; Oncology; Chemotherapy","score_opus":0.028592920474669412,"score_gpt":0.425812251157462,"score_spread":0.3972193306827926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598945839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972102,0.00028633833,0.000041134757,0.0002571822,0.000360698,0.00066521566,0.000013151224,0.000005790837,0.0011602978],"genre_scores_gemma":[0.9980248,0.000033774817,0.00085833366,0.000106177664,0.000506278,0.00001995839,0.000022055707,0.00004685089,0.0003817777],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9948423,0.0008401853,0.0026672725,0.00049411564,0.00068008574,0.00047603718],"domain_scores_gemma":[0.9959197,0.00033478392,0.0019740104,0.00036950552,0.0011102783,0.0002917307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018673271,0.00029790658,0.0015340019,0.00028511113,0.00006904983,0.000010494412,0.00041399416,0.00044497717,0.000047944428],"category_scores_gemma":[0.0018442275,0.00023845096,0.00030091513,0.00034997228,0.00044450816,0.00003207956,0.00015909849,0.001016818,0.000014788615],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18674326,0.22679025,0.22032984,0.00014886669,0.0016473207,0.002661706,0.0009435395,0.0027088327,0.15147512,0.00004797421,0.04123227,0.16527101],"study_design_scores_gemma":[0.1661835,0.536074,0.14349923,0.00025623068,0.00034853464,0.00016155331,0.0010559045,0.00013078081,0.1329375,0.0003205608,0.018032255,0.0009999678],"about_ca_topic_score_codex":0.0002849248,"about_ca_topic_score_gemma":0.0021776555,"teacher_disagreement_score":0.30928373,"about_ca_system_score_codex":0.00028363234,"about_ca_system_score_gemma":0.0017764685,"threshold_uncertainty_score":0.9723748},"labels":[],"label_agreement":null},{"id":"W2598951077","doi":"10.1200/jco.2017.35.6_suppl.423","title":"Impact of modern treatment strategies on second cancer incidence for patients with early stage seminoma: A population-based study in British Columbia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Seminoma; Incidence (geometry); Cancer registry; Cumulative incidence; Stage (stratigraphy); Radiation therapy; Confidence interval; Population; Cancer; Internal medicine; Chemotherapy; Testicular cancer; Surgery; Cohort","score_opus":0.0836556280595282,"score_gpt":0.4783434009340612,"score_spread":0.394687772874533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598951077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99875623,0.00011253125,0.0000083765035,0.000036082263,0.00010678091,0.0008282896,0.00012212747,0.0000024426718,0.00002714678],"genre_scores_gemma":[0.99948674,0.0000115856465,0.00025936408,0.000029966837,0.00007658551,0.000031495463,0.000007916862,0.000012493685,0.00008382846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984524,0.000092285074,0.0009160085,0.00016413776,0.00023254994,0.00014257203],"domain_scores_gemma":[0.9968875,0.00059108355,0.0017646609,0.00021776182,0.00034645008,0.00019253761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026819995,0.00009386017,0.00094115804,0.000041261006,0.000060936738,0.000054806987,0.00009438225,0.00010230165,0.000070850125],"category_scores_gemma":[0.00067181326,0.0000779829,0.0002921381,0.00002681105,0.00005736321,0.00014106328,0.000010807322,0.00014581466,2.7750772e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037630973,0.013896398,0.93042606,0.000021410442,0.000524485,0.00041003307,0.000044235145,0.00029357043,7.2335285e-7,3.380151e-7,0.000011942667,0.050607722],"study_design_scores_gemma":[0.028868854,0.08513563,0.8850785,0.00020195337,0.00040986345,0.0000034141224,0.000034290435,0.00014210794,3.3949846e-7,0.00006271258,0.0000061842143,0.00005614123],"about_ca_topic_score_codex":0.029196765,"about_ca_topic_score_gemma":0.17124487,"teacher_disagreement_score":0.1420481,"about_ca_system_score_codex":0.00041918465,"about_ca_system_score_gemma":0.0022624305,"threshold_uncertainty_score":0.9772679},"labels":[],"label_agreement":null},{"id":"W2598960636","doi":"10.1200/jco.2013.31.15_suppl.5070","title":"Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University Health Network; Jewish General Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metformin; Prostate cancer; Tolerability; Internal medicine; Prostatectomy; Diabetes mellitus; Urology; Adverse effect; Prostate; Cancer; Oncology; Gastroenterology; Insulin; Endocrinology","score_opus":0.10536647974518354,"score_gpt":0.4498500145487333,"score_spread":0.34448353480354976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598960636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98811114,0.010738512,0.00001422298,0.000094198374,0.00042875315,0.00031496928,0.00001180129,7.045678e-7,0.00028571146],"genre_scores_gemma":[0.99571794,0.0028583903,0.0007724659,0.00018792713,0.00033968675,0.000011911182,0.000004156282,0.000009105921,0.00009840641],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961329,0.00044702206,0.0028130605,0.0001845806,0.00022611777,0.00019632863],"domain_scores_gemma":[0.99685436,0.00025481975,0.002050002,0.00024037337,0.00045960597,0.00014083032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025503552,0.00011642127,0.0010994815,0.00009793876,0.000016278993,0.0000029004314,0.00026105653,0.00023222255,0.000043823547],"category_scores_gemma":[0.0022299087,0.00008455418,0.00023374654,0.00011091699,0.00013994912,0.000010844187,0.00009833903,0.0003224218,0.0000015318174],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006695374,0.01359369,0.014398198,0.00003901786,0.00026578116,0.000056039717,0.000752125,0.000053607626,0.017827064,0.00001305908,0.0050213556,0.9412847],"study_design_scores_gemma":[0.16272514,0.35386747,0.19697486,0.00016767175,0.000676149,0.00009081782,0.004294841,0.00035120244,0.0471256,0.0008539688,0.23231837,0.0005539243],"about_ca_topic_score_codex":0.00012762558,"about_ca_topic_score_gemma":0.0001902967,"teacher_disagreement_score":0.94073075,"about_ca_system_score_codex":0.000016813889,"about_ca_system_score_gemma":0.00077561097,"threshold_uncertainty_score":0.34480193},"labels":[],"label_agreement":null},{"id":"W2598968435","doi":"10.1200/jco.2017.35.5_suppl.225","title":"The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neurocognitive; Internal medicine; Quality of life (healthcare); Lung cancer; Asymptomatic; Cancer; Oncology; Stage (stratigraphy); Disease; Gastroenterology; Cognition","score_opus":0.16405613200716299,"score_gpt":0.5830119411110996,"score_spread":0.4189558091039366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598968435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886842,0.0009030745,0.000016344158,0.008949679,0.0002602268,0.0005647513,0.000043515916,0.0000025450358,0.0005756783],"genre_scores_gemma":[0.9962468,0.0026606843,0.000038960738,0.0007368787,0.0002063778,0.000011294548,0.0000011906047,0.000009542438,0.00008825426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700356,0.0008726012,0.001139554,0.00019214557,0.00051429,0.00027782467],"domain_scores_gemma":[0.99364203,0.0028955017,0.0022551885,0.00023346084,0.0007018721,0.0002719417],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004284138,0.00013163249,0.0011683141,0.00009226505,0.00019384094,0.00001959674,0.00014593652,0.000086846,0.000029552857],"category_scores_gemma":[0.01121269,0.00006181426,0.00017765247,0.00006550952,0.0008063226,0.00015151466,0.00008774118,0.0009931164,4.7254161e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024682282,0.0008146132,0.8472783,0.000060066515,0.0005992612,0.00002685662,0.00012338863,0.000007036456,0.0000048739685,0.000008991502,0.0036004316,0.12279388],"study_design_scores_gemma":[0.010649821,0.039845094,0.9471102,0.0003784192,0.0001245199,0.0000069215926,0.00011588673,0.000095913674,0.000010108411,0.00005047389,0.0015668562,0.00004582301],"about_ca_topic_score_codex":0.0019561995,"about_ca_topic_score_gemma":0.004385646,"teacher_disagreement_score":0.122748055,"about_ca_system_score_codex":0.00031435638,"about_ca_system_score_gemma":0.0026213382,"threshold_uncertainty_score":0.99711627},"labels":[],"label_agreement":null},{"id":"W2598974724","doi":"10.1200/jco.2009.27.15_suppl.3055","title":"Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Population; Gastroenterology; Lung cancer; Vaccination; Phases of clinical research; Cancer; Surgery; Clinical trial; Immunology","score_opus":0.023771877857839546,"score_gpt":0.3548341963689943,"score_spread":0.33106231851115475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598974724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883248,0.007959307,0.0001454696,0.00087881484,0.0015659587,0.00040338273,0.000019732803,0.000009559968,0.0006929819],"genre_scores_gemma":[0.9911919,0.0050692037,0.00020470958,0.0010781279,0.0001447625,0.0000045776537,0.000013646035,0.000025783842,0.0022672869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945796,0.0011624031,0.0033133633,0.00029734144,0.00011585056,0.0005313985],"domain_scores_gemma":[0.99460924,0.0015600353,0.0029213552,0.00036590456,0.00046463238,0.00007885725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021943524,0.00031018438,0.0020459287,0.00031247493,0.00008136798,0.000008096157,0.0005953428,0.0008457331,0.00064327405],"category_scores_gemma":[0.00039324083,0.00021909697,0.00044593902,0.00025635073,0.0002139834,0.0002115882,0.00007170839,0.0016567551,0.000023481472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0857036,0.0064958585,0.756828,0.00006537191,0.0008546216,0.00014584369,0.0005293289,0.00008193109,0.019820515,0.000020939777,0.00088305667,0.1285709],"study_design_scores_gemma":[0.03389395,0.02032693,0.92985713,0.00036733836,0.00020447873,0.00004027846,0.00006864796,0.0000035410856,0.0063700574,0.000009582555,0.008617537,0.00024053219],"about_ca_topic_score_codex":0.00006422679,"about_ca_topic_score_gemma":0.0001301032,"teacher_disagreement_score":0.1730291,"about_ca_system_score_codex":0.00019345192,"about_ca_system_score_gemma":0.0013857711,"threshold_uncertainty_score":0.8934515},"labels":[],"label_agreement":null},{"id":"W2599008969","doi":"10.1200/jco.2013.31.15_suppl.5079","title":"Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Prostate cancer; Internal medicine; Urology; Oncology; Genitourinary system; Adverse effect; Cancer; Surgery; Osteoporosis","score_opus":0.057207506295108373,"score_gpt":0.4152286010436675,"score_spread":0.35802109474855914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599008969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943276,0.0025669483,0.0000015265632,0.002279672,0.00015551256,0.00041071244,0.0000031746865,0.0000030166093,0.00025185331],"genre_scores_gemma":[0.9954716,0.0015707985,0.001964149,0.00078741764,0.0000873137,0.000014111016,0.0000029543853,0.000010371935,0.00009126563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982865,0.00017027359,0.0010108117,0.00014766718,0.0001624813,0.00022229219],"domain_scores_gemma":[0.9983423,0.0003393021,0.0005740858,0.0000955638,0.00013210103,0.0005166882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038195332,0.00012317346,0.0010281145,0.00010419992,0.000028795632,0.0000053427275,0.000025213187,0.00014571697,0.00005404885],"category_scores_gemma":[0.00015828424,0.000070407645,0.0000741328,0.0000612428,0.00013680608,0.000113107395,0.000018498336,0.0003250191,0.00000724625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032816688,0.0014703828,0.7599285,0.000016621996,0.00023155873,0.00042412104,0.0000441238,7.130756e-7,0.000001754527,0.0000030992232,0.00015552156,0.23444194],"study_design_scores_gemma":[0.032010093,0.04075822,0.92308724,0.0000502191,0.00034585633,0.00027596616,0.000039056184,0.000008662431,0.000006213343,0.000054676882,0.0033102846,0.000053488417],"about_ca_topic_score_codex":0.0006301647,"about_ca_topic_score_gemma":0.00043526554,"teacher_disagreement_score":0.23438844,"about_ca_system_score_codex":0.0003865795,"about_ca_system_score_gemma":0.0012485258,"threshold_uncertainty_score":0.28711402},"labels":[],"label_agreement":null},{"id":"W2599028185","doi":"10.1200/jco.2013.31.15_suppl.e15087","title":"Factors affecting the administration of adjuvant therapy in patients with pancreatic adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Pancreatic cancer; Pancreatectomy; Adjuvant therapy; Univariate analysis; Adenocarcinoma; Pancreaticoduodenectomy; Internal medicine; Multivariate analysis; Surgery; Cancer; Pancreas","score_opus":0.15317739692842533,"score_gpt":0.46001278132131573,"score_spread":0.3068353843928904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599028185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963231,0.00023472098,0.000027592,0.0016367867,0.00015248364,0.0005969858,7.8157365e-7,0.0000027655021,0.0010247746],"genre_scores_gemma":[0.99866605,0.00017263624,0.00060473604,0.00029183092,0.00017391227,0.0000059289882,0.000002227186,0.000010113291,0.00007259264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969102,0.0006857813,0.0016527958,0.00011832389,0.0004222138,0.00021066706],"domain_scores_gemma":[0.99299216,0.004718782,0.0013463943,0.00018437169,0.0005725131,0.00018578081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024010683,0.00011325124,0.0014456231,0.00011168508,0.000032820626,0.0000056762347,0.00015225027,0.00023663737,0.00023580424],"category_scores_gemma":[0.0029573939,0.000049644128,0.0001861393,0.00016538642,0.00031417763,0.00010484686,0.000021712493,0.0008311278,0.000006390419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004142385,0.0014472165,0.97446233,0.000017628941,0.00024385034,0.000029825427,0.00030494123,0.0000012276527,0.000021685248,0.000010233452,0.00019720974,0.01912149],"study_design_scores_gemma":[0.008149422,0.036563396,0.954044,0.000097672906,0.00016253846,0.000023541694,0.0006297133,0.000042359683,0.00004875959,0.000086502965,0.00010699704,0.00004509459],"about_ca_topic_score_codex":0.00007482672,"about_ca_topic_score_gemma":0.000038102833,"teacher_disagreement_score":0.03511618,"about_ca_system_score_codex":0.00008929365,"about_ca_system_score_gemma":0.001484792,"threshold_uncertainty_score":0.3610883},"labels":[],"label_agreement":null},{"id":"W2599044204","doi":"10.1200/jco.2013.31.15_suppl.10029","title":"Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; Centre hospitalier universitaire de Québec; Alberta Children's Hospital; McGill University; Alberta Hospital Edmonton; Centre Hospitalier Universitaire Sainte-Justine; Hamilton Health Sciences; BC Children's Hospital; Children's Hospital of Western Ontario; McMaster University; McMaster Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Vinblastine; Chemotherapy; Neutropenia; Pilocytic astrocytoma; Internal medicine; Gastroenterology; Surgery; Febrile neutropenia; Glioma; Astrocytoma","score_opus":0.0537330875033347,"score_gpt":0.4078009861275729,"score_spread":0.35406789862423815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599044204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808157,0.0002571827,0.000002287658,0.016718375,0.00018256204,0.0016262386,0.0000050951558,0.000006988394,0.00038555852],"genre_scores_gemma":[0.9969854,0.000060699236,0.00070069905,0.0015399575,0.00047484835,0.000094781695,0.000003985706,0.000027506043,0.00011214746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706185,0.00037950787,0.0014680759,0.00027994148,0.00037801795,0.00043259253],"domain_scores_gemma":[0.996477,0.00090061,0.00089342124,0.00019819745,0.0006942657,0.00083648646],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00090763194,0.00023015893,0.0015742205,0.00035959738,0.00006164693,0.00003261359,0.00018600606,0.00024698878,0.0009397126],"category_scores_gemma":[0.001132349,0.00012017355,0.0001713614,0.0005002095,0.00019842721,0.00016479749,0.000028923352,0.0007998004,0.000036669422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002946475,0.013149378,0.95459616,0.0000073255537,0.001426192,0.007655558,0.0004177904,0.000030047482,0.000053434258,0.000009707272,0.0056026196,0.014105296],"study_design_scores_gemma":[0.032386843,0.051087588,0.91329676,0.0001955405,0.00025833273,0.0010048727,0.0006300639,0.000049382295,0.0002440284,0.000021198723,0.0006986537,0.00012673753],"about_ca_topic_score_codex":0.014076281,"about_ca_topic_score_gemma":0.071919695,"teacher_disagreement_score":0.057843417,"about_ca_system_score_codex":0.00040596302,"about_ca_system_score_gemma":0.0037753743,"threshold_uncertainty_score":0.99997354},"labels":[],"label_agreement":null},{"id":"W2599055371","doi":"10.1200/jco.2013.31.15_suppl.5541","title":"Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Bevacizumab; Ovarian cancer; Carboplatin; Surgery; Debulking; Internal medicine; Ovarian carcinoma; Perforation; Chemotherapy; Oncology; Cancer; Cisplatin","score_opus":0.11580552362747036,"score_gpt":0.45036663206945615,"score_spread":0.3345611084419858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599055371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95345974,0.007915923,0.00043500809,0.035995234,0.00081252435,0.0011958978,0.000017454118,0.0000060812463,0.00016216512],"genre_scores_gemma":[0.9814237,0.009133085,0.003252684,0.0049274974,0.00093496795,0.00020405518,0.0000017227378,0.000022943448,0.00009937711],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99696934,0.00023561437,0.0019563334,0.00028585608,0.00027433137,0.00027851044],"domain_scores_gemma":[0.9958189,0.001712178,0.0013562206,0.0003257279,0.0005025658,0.00028438595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001770532,0.00020054592,0.0015229101,0.000047880083,0.000070619564,0.000017067974,0.00016346911,0.00019071708,0.0011039678],"category_scores_gemma":[0.00045659774,0.00010624417,0.00051143096,0.000067007364,0.0003509151,0.00013849167,0.000032865224,0.00045047826,0.0000022364502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018673642,0.0014913382,0.40411294,0.000023214661,0.00066667114,0.00004298743,0.0010997849,0.000005956114,0.00012068432,0.000082383645,0.0010064746,0.5726739],"study_design_scores_gemma":[0.031866413,0.011536072,0.91281897,0.00015912579,0.00024190759,0.00009582673,0.00048401245,0.0001897148,0.00038758465,0.0005880598,0.041521415,0.00011092536],"about_ca_topic_score_codex":0.00038324125,"about_ca_topic_score_gemma":0.00016998351,"teacher_disagreement_score":0.572563,"about_ca_system_score_codex":0.00027293214,"about_ca_system_score_gemma":0.00096234673,"threshold_uncertainty_score":0.99980915},"labels":[],"label_agreement":null},{"id":"W2599056240","doi":"10.1200/jco.2012.30.15_suppl.e14171","title":"Optimizing the sequence of biological agents in advanced colorectal cancer: A decision analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Irinotecan; Oncology; Hazard ratio; Colorectal cancer; Oxaliplatin; KRAS; Clinical trial; Cancer; Clinical endpoint; Confidence interval; Chemotherapy","score_opus":0.2774692413286158,"score_gpt":0.5402567154990208,"score_spread":0.262787474170405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599056240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921963,0.004503096,0.00007423158,0.0014771865,0.0007202215,0.00016977679,0.0000050837616,0.0000028737068,0.00085121463],"genre_scores_gemma":[0.9896324,0.005838889,0.0037012743,0.00050866266,0.0002845729,0.000011157199,0.000001038644,0.000004570643,0.000017387963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741554,0.00028850583,0.001663324,0.00012543617,0.00026644333,0.00024075722],"domain_scores_gemma":[0.99568605,0.0026238444,0.0011672155,0.00010440362,0.00024427174,0.0001741984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024201362,0.00010983711,0.0015919253,0.00014179014,0.00003685697,0.0000024400376,0.00014135678,0.00018363427,0.00012186289],"category_scores_gemma":[0.0023594473,0.0000529338,0.00057895656,0.00049881614,0.00025452854,0.00008160567,0.000077333396,0.00049142644,0.0000016737702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056948066,0.0010230007,0.81904554,0.00000435623,0.0010637203,0.000079503974,0.00036304683,0.00030816815,0.0002626742,0.000022809336,0.00013417665,0.17199817],"study_design_scores_gemma":[0.0035989126,0.0056063402,0.9836167,0.00006173003,0.00086178485,0.000044577155,0.00030416477,0.00017567129,0.00011187214,0.0000611852,0.0055047492,0.000052282503],"about_ca_topic_score_codex":0.00006573821,"about_ca_topic_score_gemma":0.0002725274,"teacher_disagreement_score":0.17194588,"about_ca_system_score_codex":0.0002631757,"about_ca_system_score_gemma":0.00042016353,"threshold_uncertainty_score":0.28246492},"labels":[],"label_agreement":null},{"id":"W2599058564","doi":"10.1200/jco.2013.31.15_suppl.7516","title":"Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Adenocarcinoma; Histology; Internal medicine; Oncology; Cancer; Progressive disease; Epidermal growth factor receptor; Pathology; Chemotherapy","score_opus":0.07637053929550952,"score_gpt":0.46607542450189837,"score_spread":0.38970488520638885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599058564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901366,0.00039742887,0.0012117667,0.0027059212,0.00089614885,0.0023142465,0.000009152367,0.000008387178,0.0023203539],"genre_scores_gemma":[0.9923805,0.0001070577,0.0029403141,0.0008842818,0.0005315101,0.00031189085,0.0000036852107,0.000028035412,0.0028127292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763906,0.00023802373,0.0014271138,0.00022380601,0.00021414379,0.0002578688],"domain_scores_gemma":[0.9933301,0.0035117802,0.0013090565,0.0001290668,0.0013937177,0.00032627632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009725281,0.00017051486,0.0012933256,0.00012084781,0.00007847653,0.000019506453,0.00007958993,0.00018740748,0.00024902856],"category_scores_gemma":[0.00058782636,0.00009747428,0.0003457417,0.00017577082,0.00010885423,0.0001743845,0.000017802671,0.00046844722,0.000011264286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035898692,0.003736759,0.9510497,0.00003984839,0.0024218273,0.00014875851,0.002198151,0.000021977196,0.000033381846,0.0000039205083,0.016362466,0.020393375],"study_design_scores_gemma":[0.0133440355,0.02007312,0.96010303,0.00015622811,0.002359895,0.00004868706,0.0009645979,0.0003941254,0.00004713194,0.000020419488,0.002369648,0.000119081655],"about_ca_topic_score_codex":0.00036035295,"about_ca_topic_score_gemma":0.00023169302,"teacher_disagreement_score":0.020274295,"about_ca_system_score_codex":0.0002345851,"about_ca_system_score_gemma":0.004102089,"threshold_uncertainty_score":0.727693},"labels":[],"label_agreement":null},{"id":"W2599063392","doi":"10.1200/jco.2017.35.4_suppl.789","title":"ECOG performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Capecitabine; Nausea; Performance status; FOLFOX; Cohort; Anemia; Cancer; Adjuvant therapy; Vomiting; Univariate analysis; Colorectal cancer; Gastroenterology; Oncology; Surgery; Oxaliplatin; Multivariate analysis","score_opus":0.08958946198783549,"score_gpt":0.48544376314409,"score_spread":0.39585430115625453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599063392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890223,0.0006510764,0.0000011226234,0.0017703874,0.0022055644,0.0003473274,0.000038839215,0.0000054718234,0.0059579154],"genre_scores_gemma":[0.9837169,0.013147773,0.00015542406,0.0010935547,0.000809816,0.000016643235,0.0000047992107,0.000018082426,0.0010369914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971685,0.00015177108,0.0018520954,0.00017968328,0.0003155841,0.00033240052],"domain_scores_gemma":[0.9959268,0.0005982907,0.002600714,0.00018619694,0.0003859556,0.00030207308],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009249876,0.00016570943,0.0016374089,0.00013640436,0.000063340536,0.000007936286,0.00023034887,0.00031369168,0.0013204365],"category_scores_gemma":[0.0006393688,0.00011995226,0.0003217848,0.000054881944,0.0004685379,0.0002324228,0.000060520357,0.00073373877,0.0000056791123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021274282,0.003109576,0.8880686,0.00006189277,0.0004319079,0.00012727086,0.00061333115,0.000012860668,0.00038358214,0.00001574336,0.0016636659,0.08423729],"study_design_scores_gemma":[0.034962606,0.027637558,0.9008269,0.000152618,0.00021966182,0.00001729182,0.00010349742,0.00010901314,0.0018810859,0.000030747928,0.033966884,0.00009218805],"about_ca_topic_score_codex":0.00046333132,"about_ca_topic_score_gemma":0.00063461706,"teacher_disagreement_score":0.08414511,"about_ca_system_score_codex":0.000387534,"about_ca_system_score_gemma":0.0025132373,"threshold_uncertainty_score":0.9995925},"labels":[],"label_agreement":null},{"id":"W2599110122","doi":"10.1200/jco.2012.30.15_suppl.2019","title":"IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; IDH1; Anaplastic astrocytoma; Astrocytoma; Glioma; Oncology; Internal medicine; Brain tumor; Pathology; Cancer research; Mutant; Gene; Biology","score_opus":0.07162402908018344,"score_gpt":0.4180734097358771,"score_spread":0.34644938065569364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599110122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539304,0.0031051598,0.000016569862,0.0005096038,0.0005893507,0.00010552342,0.0000036887564,0.000002722987,0.00027436134],"genre_scores_gemma":[0.9968839,0.0011008098,0.0012469569,0.00007105252,0.0006768842,0.000002409361,0.0000018623706,0.0000097805705,0.000006315061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740434,0.00023290708,0.0016766685,0.0001461997,0.00025636973,0.00028352867],"domain_scores_gemma":[0.9957706,0.002652919,0.0009046781,0.00009135133,0.00014312782,0.00043735217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024709022,0.00011179425,0.0012711926,0.00014703983,0.000022004864,0.0000054811035,0.00003310128,0.00018325738,0.000051942432],"category_scores_gemma":[0.0010256715,0.00007786638,0.00014623767,0.00009464309,0.00010131238,0.0001258905,0.0000529546,0.0004387366,0.000001467816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027976597,0.001397349,0.967748,0.000023120276,0.00016285373,0.0005480787,0.00016729477,0.0000028778418,0.0056621907,0.000108748834,0.00002040629,0.021361427],"study_design_scores_gemma":[0.01055287,0.006152908,0.9720441,0.0002819916,0.00023882686,0.0003200042,0.00033256586,0.000031408435,0.008583845,0.00011119684,0.0012863055,0.00006396354],"about_ca_topic_score_codex":0.0002523329,"about_ca_topic_score_gemma":0.0006874437,"teacher_disagreement_score":0.021297464,"about_ca_system_score_codex":0.000113734226,"about_ca_system_score_gemma":0.00021773115,"threshold_uncertainty_score":0.3175299},"labels":[],"label_agreement":null},{"id":"W2599122764","doi":"10.1200/jco.2014.32.15_suppl.4027","title":"Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Population; Gastroenterology; Neutropenia; Post-hoc analysis; Toxicity; Phases of clinical research; Surgery; Urology; Chemotherapy; Randomized controlled trial","score_opus":0.13443488009011875,"score_gpt":0.5035536575445521,"score_spread":0.36911877745443333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599122764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995037,0.0007936574,0.00054419285,0.00060277723,0.0003139866,0.002474117,0.0001202726,0.0000054214584,0.00010855624],"genre_scores_gemma":[0.99754566,0.00050142466,0.0012961754,0.0002207682,0.0002667003,0.00006926939,0.000029135008,0.000031794752,0.000039082162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99334556,0.0022399176,0.002853775,0.00038823072,0.0007732131,0.0003992922],"domain_scores_gemma":[0.9710884,0.024240447,0.0026540742,0.0004069551,0.0010772161,0.0005328846],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047105975,0.00033642404,0.0044681816,0.00021283046,0.00009136323,0.000012532689,0.00026851022,0.00020297022,0.00006968644],"category_scores_gemma":[0.009931188,0.0001814804,0.00028792262,0.00030577419,0.0006685836,0.00012466054,0.00011782014,0.0005249469,8.2979267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20260213,0.0055598463,0.7742105,0.00040484802,0.0058904793,0.000069176895,0.00090175244,0.00022013497,0.0011756882,0.000019261752,0.0008516996,0.008094491],"study_design_scores_gemma":[0.22999401,0.22311923,0.5254662,0.00029923033,0.015504743,0.000023133245,0.0005686445,0.00409412,0.00023435017,0.000066422406,0.00043481137,0.00019511861],"about_ca_topic_score_codex":0.0021351387,"about_ca_topic_score_gemma":0.00059775345,"teacher_disagreement_score":0.24874431,"about_ca_system_score_codex":0.00018287211,"about_ca_system_score_gemma":0.0015719263,"threshold_uncertainty_score":0.99840856},"labels":[],"label_agreement":null},{"id":"W2599125050","doi":"10.1200/jco.2013.31.15_suppl.e18559","title":"Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel (PC) or cisplatin/etoposide (PE) in stage III non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Carboplatin; Neutropenia; Internal medicine; Radiation therapy; Chemoradiotherapy; Regimen; Pneumonitis; Etoposide; Lung cancer; Febrile neutropenia; Gastroenterology; Toxicity; Esophagitis; Chemotherapy; Surgery; Oncology; Cisplatin; Lung; Disease","score_opus":0.07717377376130297,"score_gpt":0.4753629626389688,"score_spread":0.39818918887766586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599125050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258214,0.0032744766,0.0001553622,0.0023453229,0.0004189809,0.000707459,0.000013048347,0.0000031744376,0.00050004444],"genre_scores_gemma":[0.9935208,0.002744458,0.0028084377,0.0005256648,0.00015783576,0.000026783022,0.0000012883376,0.000018319026,0.00019641269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639904,0.00020886092,0.0026096797,0.00021602405,0.00033061297,0.00023579446],"domain_scores_gemma":[0.994153,0.002467746,0.002549022,0.0001893639,0.0003511992,0.0002896628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000887129,0.00020664991,0.002808115,0.0001253451,0.000019173762,0.000006501205,0.000116488365,0.0002470799,0.00028071867],"category_scores_gemma":[0.00020934499,0.000115226205,0.00024704053,0.0001213519,0.0002373811,0.00008288126,0.000033671033,0.0005855951,4.6986375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023218894,0.0039586048,0.9711015,0.00026892324,0.0007180328,0.00007515475,0.000861785,0.00010454341,0.00040188205,0.000022156093,0.0009578643,0.01920765],"study_design_scores_gemma":[0.030008813,0.016584791,0.9473634,0.0006680701,0.00057699456,0.000017688082,0.0004081397,0.0012585558,0.002369534,0.0000067760866,0.00061569625,0.00012155131],"about_ca_topic_score_codex":0.0013536713,"about_ca_topic_score_gemma":0.002127131,"teacher_disagreement_score":0.027686924,"about_ca_system_score_codex":0.00035305973,"about_ca_system_score_gemma":0.0014063083,"threshold_uncertainty_score":0.46987882},"labels":[],"label_agreement":null},{"id":"W2599130567","doi":"10.1200/jco.2009.27.15_suppl.e21500","title":"Systematic review of response evaluation in gastrointestinal stromal tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Imatinib; GiST; Rank correlation; Radiology; Log-rank test; Correlation; Internal medicine; Clinical trial; Nuclear medicine; Oncology; Survival analysis; Progressive disease; Disease; Stromal cell; Statistics","score_opus":0.15803752623191697,"score_gpt":0.5271780189821204,"score_spread":0.3691404927502034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599130567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98312545,0.0047655045,0.0000691783,0.01005611,0.000056622583,0.0010497931,0.0000015533118,0.000004493685,0.0008713032],"genre_scores_gemma":[0.98942065,0.00042440105,0.0091559235,0.00082705176,0.00011174975,0.0000070118463,0.0000017885002,0.0000061401875,0.000045304725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99219584,0.0025730012,0.003936177,0.00013422365,0.0009229487,0.00023782399],"domain_scores_gemma":[0.99267817,0.0031610157,0.002359118,0.00021525114,0.0012153814,0.00037107267],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021786088,0.00011742351,0.0022271383,0.0002208924,0.000011104625,0.000003136472,0.00014177518,0.000048455513,0.00010354294],"category_scores_gemma":[0.08930176,0.00007547046,0.00046675306,0.0002208286,0.00010137842,0.00006724998,0.000017803011,0.00071582757,0.000011976958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18626283,0.038566753,0.380217,0.27981824,0.0010082506,0.06408886,0.00016624002,0.00008497558,0.006428778,0.0005437026,0.004442641,0.038371764],"study_design_scores_gemma":[0.007269666,0.08183091,0.57365096,0.31918687,0.0006488785,0.01678252,0.00007193323,0.00021122253,0.000041180167,0.00024653104,0.000010168594,0.00004914852],"about_ca_topic_score_codex":0.000004298806,"about_ca_topic_score_gemma":0.0000030840738,"teacher_disagreement_score":0.193434,"about_ca_system_score_codex":0.00032170216,"about_ca_system_score_gemma":0.003000419,"threshold_uncertainty_score":0.9183694},"labels":[],"label_agreement":null},{"id":"W2599139414","doi":"10.1200/jco.2017.35.4_suppl.400","title":"The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Proportional hazards model; Survival analysis; Internal medicine; Hazard ratio; Intensity (physics); Gastroenterology; Nuclear medicine; Confidence interval","score_opus":0.09490646127285561,"score_gpt":0.3770551873831609,"score_spread":0.2821487261103053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599139414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678975,0.00023686734,0.0000023041791,0.001549898,0.0004784536,0.0005026265,0.0000020425994,0.0000034132001,0.00043463212],"genre_scores_gemma":[0.9993881,0.00010600283,0.00019296259,0.00010048126,0.00016252635,0.0000046090927,0.0000020697175,0.00001585902,0.000027386175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972157,0.0005896088,0.0013658548,0.00019910223,0.00038052027,0.00024923048],"domain_scores_gemma":[0.9945174,0.0025538676,0.0019495753,0.00038361675,0.00034800504,0.00024754778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003999934,0.00017899036,0.0015482536,0.00007581796,0.00015509373,0.000018906392,0.00018543539,0.00021460163,0.0000053606655],"category_scores_gemma":[0.004051778,0.00009049617,0.00026691952,0.00005255208,0.00039982665,0.000114598166,0.00008095995,0.00075229694,0.0000024207009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03275657,0.0005014073,0.86828667,0.000033698932,0.0001590736,0.00057691545,0.000053388067,6.768807e-7,0.000040073417,0.000014702926,0.000022621649,0.09755421],"study_design_scores_gemma":[0.023533436,0.046023346,0.92834365,0.0001651295,0.00028272183,0.0000113924725,0.000030011443,0.0002438318,0.0007648696,0.00003701244,0.0004871643,0.00007742128],"about_ca_topic_score_codex":0.000044365297,"about_ca_topic_score_gemma":0.00004493333,"teacher_disagreement_score":0.09747678,"about_ca_system_score_codex":0.00007892132,"about_ca_system_score_gemma":0.00026951905,"threshold_uncertainty_score":0.48506495},"labels":[],"label_agreement":null},{"id":"W2599150135","doi":"10.1200/jco.2017.35.4_suppl.224","title":"Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; Sunnybrook Hospital; Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Specialty; Neuroendocrine tumors; Stage (stratigraphy); Family medicine; Demographics; Cohort; Commonwealth; Internal medicine; General surgery; Oncology; Demography","score_opus":0.16722174322402855,"score_gpt":0.4776548349446512,"score_spread":0.31043309172062267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599150135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96388257,0.00007948507,0.0003666358,0.03272081,0.00095309137,0.0017217903,0.00014666753,0.000026806047,0.0001021714],"genre_scores_gemma":[0.9651789,0.0012317916,0.031520363,0.0014136148,0.00023226181,0.00006611926,0.0001727978,0.000096001684,0.00008811549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98906493,0.0023128134,0.005713428,0.0007036185,0.0011936725,0.0010115564],"domain_scores_gemma":[0.97677517,0.00659542,0.011159006,0.0008685449,0.0038536286,0.0007482062],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025653508,0.00052759115,0.0036780643,0.00050192163,0.00034192382,0.00006458789,0.0008917365,0.00001884026,0.00002502528],"category_scores_gemma":[0.025272511,0.000438635,0.0004607638,0.00086525135,0.0010227157,0.0008245636,0.00032550716,0.001924208,0.0000026347864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07316251,0.0059215054,0.87903196,0.00047264976,0.00068725884,0.0042642034,0.00013773802,0.00033369096,0.0025542884,0.00002985608,0.016052742,0.017351607],"study_design_scores_gemma":[0.023524614,0.03566765,0.9119161,0.00027549473,0.0003692016,0.00485395,0.0006235127,0.00082234805,0.0017400088,0.000009464416,0.019955711,0.00024194871],"about_ca_topic_score_codex":0.0013724399,"about_ca_topic_score_gemma":0.03615309,"teacher_disagreement_score":0.0496379,"about_ca_system_score_codex":0.00035575984,"about_ca_system_score_gemma":0.00379889,"threshold_uncertainty_score":0.9998065},"labels":[],"label_agreement":null},{"id":"W2599150633","doi":"10.1200/jco.2017.35.6_suppl.286","title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Durvalumab; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Tolerability; Oncology; Population; Urology; Gastroenterology; Surgery; Immunotherapy; Clinical trial; Adverse effect; Bladder cancer; Urothelial carcinoma; Cancer; Nivolumab","score_opus":0.15712397564556346,"score_gpt":0.4943208089412711,"score_spread":0.33719683329570765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599150633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427104,0.00026219775,0.000044414355,0.0028127872,0.0005608919,0.00037140603,0.000009280376,0.0000033598378,0.001664596],"genre_scores_gemma":[0.99568194,0.00028332046,0.0030948326,0.00049768196,0.00021701267,0.0000035279293,0.0000011256908,0.00001259562,0.00020795404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691993,0.00034402622,0.0020951193,0.00019671381,0.00025996566,0.0001842656],"domain_scores_gemma":[0.99644667,0.0009700146,0.0016544946,0.0003511837,0.00030671537,0.00027093422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019572966,0.0001324405,0.0018045414,0.00007978383,0.000046267443,0.000008937936,0.00019434578,0.00016937207,0.00018439553],"category_scores_gemma":[0.005074588,0.000082523846,0.00020960822,0.0000531916,0.00043799725,0.00013501078,0.000063107946,0.00054877356,0.0000035651688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06687346,0.004732342,0.46657553,0.00010635307,0.0004860562,0.0015707671,0.00021517904,0.000018467372,0.0005310729,0.00004329753,0.00025688866,0.45859057],"study_design_scores_gemma":[0.047341004,0.020465825,0.9266308,0.00012410819,0.0004480448,0.0002486932,0.00006011814,0.00006354874,0.0003114266,0.00028302995,0.003948985,0.00007439605],"about_ca_topic_score_codex":0.0001631884,"about_ca_topic_score_gemma":0.0002526568,"teacher_disagreement_score":0.46005526,"about_ca_system_score_codex":0.00009342009,"about_ca_system_score_gemma":0.0023009654,"threshold_uncertainty_score":0.60751224},"labels":[],"label_agreement":null},{"id":"W2599152652","doi":"10.1200/jco.2013.31.15_suppl.e20589","title":"Patterns of follow-up in oncologic care across Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Prostate cancer; Cancer; Radiation therapy; Internal medicine","score_opus":0.07377032510265663,"score_gpt":0.5134210432791859,"score_spread":0.4396507181765293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599152652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866394,0.0012335188,0.00015465762,0.0057407236,0.0043875584,0.00023674346,0.0000075145967,0.0000038017774,0.001596087],"genre_scores_gemma":[0.98882496,0.0012032527,0.0028957175,0.0055684973,0.0010367185,0.0000061330325,0.000002153903,0.000012247273,0.0004503413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648607,0.00037532425,0.0023951596,0.00015740871,0.00028126824,0.00030476318],"domain_scores_gemma":[0.99449325,0.0028354481,0.0016450471,0.000187459,0.0005737219,0.000265054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013590553,0.00012772027,0.0017919657,0.000048335496,0.000029538849,0.0000021499982,0.00023927192,0.00055637606,0.00045824618],"category_scores_gemma":[0.0025635948,0.00008514704,0.00030613347,0.00011836311,0.00020144555,0.000099402234,0.00004173678,0.0011980048,0.0000052690516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014429202,0.00055011304,0.7207863,0.00004459747,0.00014424154,0.00077698374,0.00046449728,0.000033157965,0.00007769878,0.000022687698,0.0042460854,0.27141073],"study_design_scores_gemma":[0.012464664,0.010493729,0.8306701,0.00011082589,0.00006792612,0.00034136002,0.002556218,0.000017388116,0.000081396334,0.00018919451,0.14291504,0.000092130045],"about_ca_topic_score_codex":0.020452892,"about_ca_topic_score_gemma":0.27165416,"teacher_disagreement_score":0.2713186,"about_ca_system_score_codex":0.0006392901,"about_ca_system_score_gemma":0.0040887413,"threshold_uncertainty_score":0.98607},"labels":[],"label_agreement":null},{"id":"W2599153150","doi":"10.1200/jco.2009.27.15_suppl.8537","title":"PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Multiple myeloma; Clinical endpoint; Internal medicine; Phases of clinical research; Proteasome inhibitor; Adverse effect; Gastroenterology; Oncology; Chemotherapy; Clinical trial","score_opus":0.08971307137979027,"score_gpt":0.48656278221239757,"score_spread":0.3968497108326073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599153150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742943,0.000047456397,0.000008163249,0.000952242,0.00018354379,0.0010349705,0.0000054960515,0.00000817705,0.00033053328],"genre_scores_gemma":[0.99745333,0.000043415093,0.0016850207,0.0004811516,0.00021523396,0.0000046881564,0.000014792252,0.000017970196,0.00008440129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952528,0.0007956524,0.0024651515,0.0002995151,0.0007618579,0.00042504954],"domain_scores_gemma":[0.9961234,0.00067842816,0.0013735244,0.00037180664,0.0007454875,0.0007073701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001820104,0.00020815399,0.0017779828,0.0002663432,0.0000576119,0.00000791302,0.00023894971,0.00024056339,0.00009889587],"category_scores_gemma":[0.0023441985,0.00012824009,0.00024133814,0.00026592813,0.00013755108,0.00022668178,0.00006297099,0.0010669947,0.000009563197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11400838,0.14185038,0.5358757,0.00001111057,0.0004971214,0.002334408,0.000457011,0.000010520982,0.00003830682,0.000005583559,0.00020350136,0.20470798],"study_design_scores_gemma":[0.16583231,0.22519529,0.60761863,0.000065065906,0.00022008843,0.000013267971,0.0001975697,0.0000574529,0.000022122316,0.000009369141,0.0007034103,0.00006543923],"about_ca_topic_score_codex":0.000054129472,"about_ca_topic_score_gemma":0.00012069832,"teacher_disagreement_score":0.20464255,"about_ca_system_score_codex":0.00017194341,"about_ca_system_score_gemma":0.00064329244,"threshold_uncertainty_score":0.5229479},"labels":[],"label_agreement":null},{"id":"W2599154108","doi":"10.1200/jco.2013.31.15_suppl.1585","title":"Breast cancer subtype variation by ethnicity in a population-based cohort in British Columbia.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Ethnic group; Mammography; Cohort; Population; Gynecology; Demography; Cancer; Internal medicine; Oncology","score_opus":0.025529829677405094,"score_gpt":0.37069346689931026,"score_spread":0.3451636372219052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599154108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652326,0.000462693,0.000051916402,0.0022604268,0.00040892503,0.00017747264,0.00003056896,0.000002110831,0.00008262853],"genre_scores_gemma":[0.9976643,0.0005473019,0.00028273178,0.0010341429,0.00033473715,0.000035341673,0.000024382902,0.000010461466,0.00006663985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980231,0.0003312119,0.0011283684,0.00019889459,0.0001429718,0.00017544602],"domain_scores_gemma":[0.99862474,0.00022348078,0.000708162,0.00009998347,0.00025168582,0.00009195899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009028117,0.00007462065,0.00055285636,0.000030693263,0.000024204974,0.000021825152,0.00011791913,0.00033052207,0.00019109341],"category_scores_gemma":[0.00049560657,0.00009166324,0.00012705276,0.00011222306,0.0000620445,0.00001203185,0.000032139542,0.00029514031,0.0000030730846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017421119,0.0006235524,0.96239513,0.000004557018,0.0000784164,0.0000145143,0.00000717364,0.000121835146,0.00021518728,3.841368e-7,0.0055610454,0.030803975],"study_design_scores_gemma":[0.003217304,0.0004111083,0.99513334,0.00003680039,0.000034141467,0.000038234248,0.00001152842,0.000082201426,0.000010492009,0.000083743515,0.00085395976,0.00008711791],"about_ca_topic_score_codex":0.12994596,"about_ca_topic_score_gemma":0.2954977,"teacher_disagreement_score":0.16555172,"about_ca_system_score_codex":0.00019062712,"about_ca_system_score_gemma":0.00059582124,"threshold_uncertainty_score":0.8758478},"labels":[],"label_agreement":null},{"id":"W2599175392","doi":"10.1200/jco.2015.33.15_suppl.8025","title":"First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Rash; Lung cancer; Pneumonitis; Tolerability; Neutropenia; Adverse effect; Oncology; Cancer; Gastroenterology; Chemotherapy; Immunotherapy; Lung","score_opus":0.05510212609985535,"score_gpt":0.4032218573776451,"score_spread":0.3481197312777897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599175392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98864245,0.0039683515,0.0025496082,0.003248249,0.0005178227,0.00076674967,0.0000054402226,0.00001193218,0.000289415],"genre_scores_gemma":[0.98475283,0.0058408584,0.008114396,0.0007477625,0.00025394355,0.000016265472,0.0000041056337,0.000040575906,0.00022923926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966308,0.00020249224,0.0021145884,0.00031074992,0.00042430573,0.00031709333],"domain_scores_gemma":[0.9955288,0.0012525968,0.0021214813,0.00026042626,0.00047684566,0.00035982454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017141312,0.00027240397,0.0018525354,0.00020077586,0.000048258757,0.000012194312,0.0001708784,0.00039497347,0.0000308751],"category_scores_gemma":[0.0003031789,0.00016399268,0.00021552756,0.00027021932,0.00027143376,0.00016998572,0.00003520668,0.0007718921,6.648703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12852837,0.0018931864,0.8064829,0.00010238595,0.00037161692,0.0002011912,0.0006869587,0.0013853633,0.0013005981,0.0000020633402,0.00024446438,0.058800872],"study_design_scores_gemma":[0.114679575,0.023204064,0.85038555,0.0014796475,0.0004156267,0.00011392674,0.0003744215,0.0009519504,0.0015235258,0.000017705197,0.0066024344,0.00025155293],"about_ca_topic_score_codex":0.00024169385,"about_ca_topic_score_gemma":0.0008249541,"teacher_disagreement_score":0.058549322,"about_ca_system_score_codex":0.0002497416,"about_ca_system_score_gemma":0.0017639088,"threshold_uncertainty_score":0.6687428},"labels":[],"label_agreement":null},{"id":"W2599197862","doi":"10.1200/jco.2015.33.15_suppl.tps10081","title":"A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pazopanib; Medicine; Sarcoma; Hepatoblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Trabectedin; Response Evaluation Criteria in Solid Tumors; Cancer; Pharmacodynamics; Chemotherapy; Pharmacokinetics; Pathology; Sunitinib","score_opus":0.08232619701603851,"score_gpt":0.44583973875402316,"score_spread":0.36351354173798467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599197862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977481,0.0010193685,0.0000014872534,0.00048101236,0.0001815376,0.00041832853,0.0000020200364,0.000003501048,0.00014464206],"genre_scores_gemma":[0.99880975,0.00032428885,0.00025390167,0.00029007986,0.0002933195,0.000005741655,0.0000013250105,0.000012044373,0.000009521451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726355,0.00029129355,0.0017663518,0.00017362543,0.0003476873,0.00015751517],"domain_scores_gemma":[0.9976088,0.00024049057,0.0012812145,0.00015842021,0.00031542632,0.00039564737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001508895,0.00012497317,0.0014739264,0.00013700641,0.00001794652,0.0000030957392,0.000080061,0.00013437837,0.000008673289],"category_scores_gemma":[0.0009887121,0.000075511125,0.00010669672,0.0001065562,0.000112164096,0.000073155454,0.000052637643,0.0005712866,0.0000013205978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012718994,0.07536857,0.83748084,0.000010797949,0.00025508952,0.0013175694,0.0008208963,0.00000124538,0.0000050229187,0.00000196218,0.00029202344,0.07172699],"study_design_scores_gemma":[0.0844861,0.1608615,0.7514964,0.0003889276,0.00032883818,0.0007791559,0.0013710732,0.000010605975,0.0000131675715,0.000009507599,0.00020223334,0.000052520452],"about_ca_topic_score_codex":0.000115271774,"about_ca_topic_score_gemma":0.00025484402,"teacher_disagreement_score":0.085984476,"about_ca_system_score_codex":0.000098681805,"about_ca_system_score_gemma":0.0006695702,"threshold_uncertainty_score":0.30792543},"labels":[],"label_agreement":null},{"id":"W2599206489","doi":"10.1200/jco.2017.35.4_suppl.566","title":"Impact of CEA alone or as part of a high intensity surveillance strategy in detecting curative colorectal cancer recurrence: A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Carcinoembryonic antigen; Meta-analysis; Colorectal cancer; Internal medicine; Relative risk; Cohort; Cohort study; Randomized controlled trial; Study heterogeneity; Stage (stratigraphy); Oncology; Cancer; Surgery; Confidence interval","score_opus":0.4644229917313989,"score_gpt":0.5958446078022904,"score_spread":0.13142161607089153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599206489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049315346,0.99260676,0.0000012744214,0.00028455534,0.000198329,0.001686181,0.00014874176,0.0000023237556,0.00014028605],"genre_scores_gemma":[0.059510183,0.9400416,0.000039965624,0.000058004574,0.000094515395,0.00010612822,0.0000058923074,0.000015120552,0.0001285714],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9897319,0.0021030547,0.0071214726,0.00037591573,0.00041599898,0.00025164778],"domain_scores_gemma":[0.9750628,0.0056821713,0.017194642,0.00034813405,0.0014902464,0.00022201217],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0061834725,0.00046005365,0.04006296,0.00030033354,0.00004489625,0.000009408713,0.0002535724,0.00045161034,0.00023961699],"category_scores_gemma":[0.01696432,0.00020992673,0.005348806,0.00055154186,0.00040755776,0.000081947415,0.00011952607,0.0012017394,9.050311e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030184104,0.0013486947,0.0033637898,0.32719272,0.5774249,0.00060594955,0.00012315442,0.000003490953,1.2026946e-7,0.0000026916966,0.00040219614,0.08651387],"study_design_scores_gemma":[0.0019389399,0.023816984,0.009354928,0.060622755,0.90099114,0.00086037547,0.000056254114,0.0000043513037,3.8087728e-7,0.000019916602,0.0021105283,0.0002234274],"about_ca_topic_score_codex":0.0013833878,"about_ca_topic_score_gemma":0.0044481815,"teacher_disagreement_score":0.32356626,"about_ca_system_score_codex":0.00046646397,"about_ca_system_score_gemma":0.004628396,"threshold_uncertainty_score":0.9913162},"labels":[],"label_agreement":null},{"id":"W2599211667","doi":"10.1200/jco.2013.31.15_suppl.7500","title":"START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Cancer; Stage (stratigraphy); Phases of clinical research; Population; Lung cancer; Placebo; Hazard ratio; Chemotherapy; Surgery; Oncology; Urology; Clinical trial; Confidence interval; Pathology","score_opus":0.07376836886841615,"score_gpt":0.47372670980950465,"score_spread":0.3999583409410885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599211667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933313,0.0018180931,0.0017916418,0.00057747966,0.00058732997,0.0014345745,0.00002681707,0.0000035368805,0.0004291948],"genre_scores_gemma":[0.99191296,0.0021443095,0.00078360114,0.0004180925,0.00071199733,0.00020971388,0.0000062373706,0.00003455293,0.0037785529],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697185,0.0003258975,0.0017952048,0.00026814066,0.0002860121,0.00035291424],"domain_scores_gemma":[0.99654865,0.0003155994,0.0014390217,0.00029891328,0.0011532928,0.0002445242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018752079,0.00016480946,0.00091412844,0.00010028697,0.00006643251,0.000020157531,0.00042482655,0.00034405096,0.0005442013],"category_scores_gemma":[0.00032769502,0.00012701453,0.00034730684,0.0001241798,0.00010685513,0.000015794323,0.00009627848,0.00046173052,0.0000015807649],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028137898,0.0152020315,0.038876284,0.0002042774,0.0018148328,0.00004293092,0.00087769376,0.0015450938,0.71868414,0.00001290095,0.035183035,0.15941888],"study_design_scores_gemma":[0.23191646,0.12065919,0.022495773,0.00014420984,0.00037832456,0.000016008426,0.0043694265,0.0061218953,0.18530211,0.00008624842,0.42772093,0.00078943145],"about_ca_topic_score_codex":0.0016344531,"about_ca_topic_score_gemma":0.0013226729,"teacher_disagreement_score":0.53338206,"about_ca_system_score_codex":0.00006432993,"about_ca_system_score_gemma":0.0018579996,"threshold_uncertainty_score":0.59586227},"labels":[],"label_agreement":null},{"id":"W2599229094","doi":"10.1200/jco.2017.35.6_suppl.458","title":"Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Toxicity; Internal medicine; Progression-free survival; Tumor progression; Clear cell renal cell carcinoma; Oncology; Retrospective cohort study; Surgery; Urology; Cancer; Overall survival","score_opus":0.15509539644251874,"score_gpt":0.47761155820560264,"score_spread":0.3225161617630839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599229094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896836,0.00081010745,0.000027854874,0.004651462,0.00058169273,0.00035384388,0.0000033316367,0.0000046255363,0.0038834536],"genre_scores_gemma":[0.9946802,0.000119798555,0.0036661555,0.00042056295,0.00068598863,0.000016266744,0.0000055176733,0.000019381103,0.00038609654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647367,0.00054787146,0.002012925,0.0002247757,0.0004800623,0.0002606721],"domain_scores_gemma":[0.9955266,0.00079434935,0.0021840853,0.00045745232,0.00031059943,0.0007269249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024725394,0.00016847128,0.0011498119,0.00017565087,0.00006800543,0.000027861619,0.00020121159,0.0001810446,0.00017615012],"category_scores_gemma":[0.002594596,0.00010971746,0.00049635646,0.00005416522,0.00024407009,0.00022876752,0.00008934687,0.0008343393,0.000033445387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017492713,0.0031931398,0.87294644,0.000082831546,0.000067744964,0.018133614,0.00008149511,0.000008899592,0.00024931724,0.000013787477,0.00038868372,0.08734133],"study_design_scores_gemma":[0.012028455,0.0069322577,0.9757997,0.00020726814,0.0005839116,0.00015483092,0.000029199893,0.00014599609,0.00034392579,0.00030597698,0.0033751454,0.00009333259],"about_ca_topic_score_codex":0.000020045942,"about_ca_topic_score_gemma":0.000034389905,"teacher_disagreement_score":0.10285326,"about_ca_system_score_codex":0.00021450648,"about_ca_system_score_gemma":0.0015000615,"threshold_uncertainty_score":0.44741482},"labels":[],"label_agreement":null},{"id":"W2599230368","doi":"10.1200/jco.2013.31.15_suppl.4536","title":"Stomach cancer risk following radiotherapy for testicular cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Stomach; Radiation therapy; Stomach cancer; Cancer; Internal medicine; Odds ratio; Seminoma; Gastroenterology; Testicular cancer; Chemotherapy; Surgery","score_opus":0.09580369153341523,"score_gpt":0.5173677876201173,"score_spread":0.42156409608670203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599230368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683168,0.022058886,0.0011834623,0.0059967902,0.0017490324,0.0005738124,0.000013416909,0.000013782565,0.00009400543],"genre_scores_gemma":[0.97455233,0.0037360939,0.01714528,0.0023867975,0.0018075715,0.000094305775,0.0000020264695,0.000028205208,0.000247387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980024,0.0001573441,0.0011951245,0.00016613558,0.0002432789,0.00023570198],"domain_scores_gemma":[0.9959358,0.0017505493,0.0012639,0.00014865096,0.00039932234,0.0005017703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072197797,0.00013159732,0.0011332146,0.000056840145,0.000056982164,0.000011747924,0.00010149797,0.00021063104,0.00035048992],"category_scores_gemma":[0.0030118253,0.00008391181,0.0010061159,0.00008121794,0.000069089,0.00009065658,0.000012647812,0.00037228482,0.000009091645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065278367,0.0011366727,0.60716677,0.000023084205,0.002034679,0.00023558717,0.000019712928,0.00007313625,0.00013897606,0.000009449441,0.0053681033,0.38314104],"study_design_scores_gemma":[0.017577484,0.008383303,0.92855567,0.00017726124,0.0030607884,0.000083834275,0.000029407183,0.0016293129,0.000030190207,0.00049431564,0.039869282,0.00010913925],"about_ca_topic_score_codex":0.0005029887,"about_ca_topic_score_gemma":0.000032989446,"teacher_disagreement_score":0.3830319,"about_ca_system_score_codex":0.00023947458,"about_ca_system_score_gemma":0.0015825541,"threshold_uncertainty_score":0.38376188},"labels":[],"label_agreement":null},{"id":"W2599238962","doi":"10.1200/jco.2015.33.15_suppl.5034","title":"Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Enzalutamide; Internal medicine; Docetaxel; Asymptomatic; Bone pain; Urology; Cancer; Surgery; Gastroenterology","score_opus":0.19529464890392434,"score_gpt":0.5424210881110837,"score_spread":0.34712643920715935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599238962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394673,0.00027638368,0.0000040084647,0.002849591,0.0014293881,0.0009766738,0.000013817985,0.000005704736,0.0004977033],"genre_scores_gemma":[0.99815273,0.00073366135,0.00046525183,0.00021413936,0.00025167703,0.00006965459,0.00003217956,0.000014209742,0.00006649043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960744,0.00072025403,0.001894036,0.00021311783,0.0008565593,0.00024167565],"domain_scores_gemma":[0.99625385,0.0011895768,0.0012076978,0.00014321334,0.00081525475,0.0003904323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026558856,0.00013654877,0.0009906705,0.00031049515,0.000012979489,0.000021180036,0.00025315833,0.00015603805,0.000025940904],"category_scores_gemma":[0.0024334593,0.000092012495,0.00015893804,0.00020878836,0.00019470186,0.00039902795,0.000042033345,0.00070400164,0.0000020825346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022225045,0.008974578,0.862261,0.000099339166,0.0003020675,0.0006528131,0.0006210698,0.00006812882,0.00015341617,0.00009985637,0.00021423664,0.104328446],"study_design_scores_gemma":[0.037083555,0.025323307,0.9347827,0.00036962674,0.00011177623,0.000005458523,0.0000796182,0.00023200439,0.00028208844,0.000346298,0.0013055023,0.00007805753],"about_ca_topic_score_codex":0.00047801374,"about_ca_topic_score_gemma":0.0009892911,"teacher_disagreement_score":0.10425039,"about_ca_system_score_codex":0.0006953123,"about_ca_system_score_gemma":0.002804383,"threshold_uncertainty_score":0.49748552},"labels":[],"label_agreement":null},{"id":"W2599263426","doi":"10.1200/jco.2017.35.4_suppl.694","title":"Impact of primary tumor sidedness on survival after resection of colorectal liver metastases (CRLM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Internal medicine; Oncology; Colorectal cancer; Splenic flexure; Primary tumor; Proportional hazards model; Resection; Gastroenterology; Cancer; Surgery; Metastasis; Colonoscopy","score_opus":0.15940742115327974,"score_gpt":0.4930833905577216,"score_spread":0.3336759694044419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599263426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907817,0.00065535714,0.000003917953,0.00042783716,0.0012521708,0.00018189411,0.00003789684,0.000002787713,0.0066563906],"genre_scores_gemma":[0.9982158,0.000691195,0.0003350736,0.00010251673,0.00051699457,0.000005391823,0.0000017263301,0.00001162505,0.00011967594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974463,0.00030353945,0.0015239061,0.00015544119,0.0004004818,0.0001703466],"domain_scores_gemma":[0.99462795,0.0016233402,0.0026325728,0.00024264907,0.0006933316,0.00018015564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016268514,0.00014623384,0.0020031568,0.00011581557,0.00006530946,0.000006853474,0.00014798493,0.0001482614,0.00020179225],"category_scores_gemma":[0.0037485934,0.00008664637,0.00096321834,0.0000533879,0.0004853178,0.000118365104,0.0000920591,0.00045654905,0.0000035287974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12287634,0.0048669963,0.8065064,0.00010047703,0.0030376771,0.0015104486,0.00015048015,0.000009956346,0.0006133129,0.000022785463,0.0015096599,0.05879547],"study_design_scores_gemma":[0.006602488,0.07648802,0.91445285,0.00014593432,0.0007184176,0.00014032597,0.000049056285,0.0000066245416,0.0004524024,0.000056301422,0.00082656933,0.00006101784],"about_ca_topic_score_codex":0.0003714968,"about_ca_topic_score_gemma":0.00042567408,"teacher_disagreement_score":0.11627385,"about_ca_system_score_codex":0.00029817628,"about_ca_system_score_gemma":0.0012792957,"threshold_uncertainty_score":0.44876873},"labels":[],"label_agreement":null},{"id":"W2599264445","doi":"10.1200/jco.2006.24.18_suppl.13079","title":"Mechanisms of resistance to low-dose metronomic cyclophosphamide","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"In vivo; Medicine; Cyclophosphamide; Cancer research; Pharmacology; Hypoxia (environmental); Chemotherapy; Internal medicine; Biology; Chemistry","score_opus":0.03227263018614897,"score_gpt":0.383128575661956,"score_spread":0.35085594547580706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599264445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98230433,0.0018173839,0.010728134,0.0010918883,0.0010283967,0.000088573426,0.000009602282,0.0000020051327,0.002929689],"genre_scores_gemma":[0.98269576,0.00033784204,0.013687602,0.0011902596,0.00091885414,0.000002949922,0.000003195016,0.000015666537,0.0011479007],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977357,0.00015601197,0.0015851923,0.0001871321,0.00015490394,0.00018110077],"domain_scores_gemma":[0.99803334,0.00016571285,0.0011611169,0.00021213273,0.0002813096,0.00014638418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015756969,0.00010838287,0.00066951656,0.000053795018,0.000022549135,0.0000041025446,0.00028147496,0.00029062774,0.00004455518],"category_scores_gemma":[0.00051960826,0.00008807454,0.0004859581,0.00008400045,0.000090990034,0.0000040040827,0.0000742659,0.00014838987,0.000008662318],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0107267415,0.00241147,0.025124336,0.00006571676,0.00074688246,0.00012334503,0.000024730934,0.0018937722,0.743532,0.0062578283,0.1605597,0.04853345],"study_design_scores_gemma":[0.00390215,0.006624862,0.17263643,0.00006701848,0.00015695141,0.000029292818,0.00006512249,0.000008442179,0.21677415,0.004116936,0.5953307,0.0002879183],"about_ca_topic_score_codex":0.000022268936,"about_ca_topic_score_gemma":0.00012411653,"teacher_disagreement_score":0.5267579,"about_ca_system_score_codex":0.000041831965,"about_ca_system_score_gemma":0.00058003026,"threshold_uncertainty_score":0.35915756},"labels":[],"label_agreement":null},{"id":"W2599267926","doi":"10.1200/jco.2017.35.6_suppl.e551","title":"Comparison of conventionally fractionated and hypofractionated schedule for post-prostatectomy salvage radiotherapy: Early results from non-randomized observational study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Concomitant; Urology; Hormonal therapy; Prostate; Salvage therapy; Genitourinary system; Surgery; Internal medicine; Cancer; Chemotherapy","score_opus":0.27141294636571583,"score_gpt":0.5376987085970281,"score_spread":0.26628576223131223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599267926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832117,0.00055483595,0.00047595522,0.013033796,0.0010940818,0.0013015622,0.00019437399,0.0000066666903,0.00012705589],"genre_scores_gemma":[0.987714,0.00048406035,0.010412098,0.0006003502,0.000519106,0.000051393727,0.00009912442,0.000017339524,0.00010255191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960025,0.0003023237,0.0029004328,0.00025583617,0.00039663265,0.00014227153],"domain_scores_gemma":[0.9844502,0.008014977,0.0052007735,0.00024772706,0.0018785627,0.00020775551],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003170766,0.00015514086,0.0022520274,0.00010132714,0.00015818306,0.000030663738,0.00014140175,0.00024298993,0.000073070645],"category_scores_gemma":[0.008716755,0.00011108562,0.0004997082,0.00004270732,0.00041753575,0.00033622573,0.000032967127,0.00047790617,0.0000019772383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34438467,0.0075008953,0.6248666,0.000023995024,0.0039062055,0.00006783071,0.00033776756,0.000045191202,0.0008829884,0.00010537934,0.0010246737,0.0168538],"study_design_scores_gemma":[0.26731873,0.010052056,0.71655595,0.00009616822,0.00064231345,0.000007151838,0.00015277472,0.0009945873,0.00029082922,0.00043731247,0.0033840202,0.00006814625],"about_ca_topic_score_codex":0.00034141395,"about_ca_topic_score_gemma":0.00004922172,"teacher_disagreement_score":0.091689326,"about_ca_system_score_codex":0.0001407083,"about_ca_system_score_gemma":0.001138487,"threshold_uncertainty_score":0.99963325},"labels":[],"label_agreement":null},{"id":"W2599273184","doi":"10.1200/jco.2017.35.4_suppl.781","title":"Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; KRAS; Capecitabine; Internal medicine; Erlotinib; Clinical endpoint; Colorectal cancer; Oncology; Gastroenterology; Cancer; Phases of clinical research; Chemotherapy; Randomized controlled trial; Epidermal growth factor receptor","score_opus":0.0557468869161804,"score_gpt":0.4607185790415015,"score_spread":0.4049716921253211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599273184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992885,0.00096440164,0.0000044593444,0.0023447818,0.00052694534,0.00048348398,0.000024959136,0.0000037024965,0.0027622462],"genre_scores_gemma":[0.9966384,0.0015756739,0.00088589883,0.00022827665,0.00050299487,0.000021980344,0.0000025951138,0.00001063133,0.0001335374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743104,0.00013852552,0.0016294402,0.00025713287,0.00033858896,0.00020527716],"domain_scores_gemma":[0.9956356,0.00060821866,0.00286833,0.0001951769,0.00048625638,0.00020637417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013048677,0.00016769093,0.002987561,0.00019256634,0.00012756126,0.000008400579,0.000119219316,0.00013180819,0.00005342566],"category_scores_gemma":[0.0018744715,0.00010436349,0.00037603837,0.00019276392,0.0005407281,0.00014352336,0.000100092926,0.0005736934,2.8805408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38748828,0.00713991,0.5416767,0.000021961283,0.00270915,0.0007288896,0.00032077052,0.000007547659,0.00040886088,0.000014123992,0.00010814235,0.059375677],"study_design_scores_gemma":[0.1999905,0.11671041,0.6800346,0.00007294619,0.0018957201,0.00004236396,0.00007339513,0.000025588324,0.000085371335,0.00003215837,0.0009656879,0.00007128406],"about_ca_topic_score_codex":0.00024387357,"about_ca_topic_score_gemma":0.0042516873,"teacher_disagreement_score":0.18749776,"about_ca_system_score_codex":0.0003319643,"about_ca_system_score_gemma":0.0011200112,"threshold_uncertainty_score":0.42558196},"labels":[],"label_agreement":null},{"id":"W2599322403","doi":"10.1200/jco.2017.35.4_suppl.tps504","title":"KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Hepatocellular carcinoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Oncology; Progressive disease; Liver disease; Cancer; Surgery; Gastroenterology; Disease; Immunotherapy","score_opus":0.1418710922414108,"score_gpt":0.41516858503769366,"score_spread":0.27329749279628285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599322403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700874,0.0002579347,0.000005573219,0.000417578,0.00027013398,0.0013553605,0.0000047558547,0.000007893195,0.00067203515],"genre_scores_gemma":[0.99902135,0.00007740922,0.00044121713,0.00008943935,0.00017898201,0.000017866028,0.000009777361,0.000031745007,0.00013223493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567103,0.00048275842,0.0026200425,0.0003210795,0.0005631502,0.00034194355],"domain_scores_gemma":[0.99447507,0.00042382014,0.0032973934,0.0006665944,0.00071606674,0.00042105827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015479497,0.00026332357,0.002444546,0.00023024325,0.00013722018,0.000012908595,0.0003510811,0.00032230723,0.000074491465],"category_scores_gemma":[0.0014163838,0.00017226177,0.00040876563,0.0001271965,0.00022114496,0.00023447307,0.000110090725,0.00075402646,0.000004518543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034835912,0.032083042,0.8679299,0.000035611734,0.0004411153,0.0022690839,0.00039142015,0.0000013693466,0.000032087908,0.000002513271,0.00005814598,0.061919816],"study_design_scores_gemma":[0.11980443,0.1700734,0.7077539,0.00012584783,0.0008715317,0.000027362878,0.00009556963,0.00018355931,0.0001766572,0.000010282556,0.00076472486,0.00011275057],"about_ca_topic_score_codex":0.00012877463,"about_ca_topic_score_gemma":0.0000849749,"teacher_disagreement_score":0.16017601,"about_ca_system_score_codex":0.00017045972,"about_ca_system_score_gemma":0.000851868,"threshold_uncertainty_score":0.70246315},"labels":[],"label_agreement":null},{"id":"W2599344293","doi":"10.1200/jco.2012.30.15_suppl.tps4695","title":"A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Dutasteride; Bicalutamide; Urology; Androgen receptor; Prostatectomy; Internal medicine; Clinical endpoint; Oncology; Antiandrogen; Androgen; Endocrinology; Cancer; Cancer research; Hormone; Randomized controlled trial","score_opus":0.1287908155528639,"score_gpt":0.5162259652658956,"score_spread":0.3874351497130317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599344293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901959,0.0018991822,0.000004906464,0.0035766198,0.00019595155,0.0040842416,0.00000926794,0.0000031928635,0.000030789553],"genre_scores_gemma":[0.985737,0.012868647,0.00046673903,0.0003945138,0.000100948724,0.00023250961,0.000002770107,0.000019095514,0.00017773117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959776,0.001110488,0.0020339184,0.00022428544,0.0003277817,0.0003259627],"domain_scores_gemma":[0.996336,0.001610347,0.0012585265,0.00012573822,0.00027993115,0.000389469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006735069,0.00017631725,0.002270089,0.00032429743,0.00004113958,0.000018510085,0.00012401197,0.000118393895,0.0000268792],"category_scores_gemma":[0.0015323905,0.000091236114,0.000038626196,0.00029056513,0.0002926801,0.00031001872,0.00016424421,0.0006875077,6.6678854e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5960157,0.01416733,0.16900231,0.000032244814,0.0003156851,0.00047666565,0.0049876277,0.0000030068807,0.00016079076,0.000003155367,0.0000414446,0.21479404],"study_design_scores_gemma":[0.7458112,0.15338452,0.09798306,0.0003914749,0.00017071595,0.000121187455,0.0011117095,0.000056725214,0.00032140614,0.000105337785,0.00044985994,0.00009275059],"about_ca_topic_score_codex":0.0014140166,"about_ca_topic_score_gemma":0.001442456,"teacher_disagreement_score":0.2147013,"about_ca_system_score_codex":0.00015603544,"about_ca_system_score_gemma":0.0009842846,"threshold_uncertainty_score":0.37205008},"labels":[],"label_agreement":null},{"id":"W2599371299","doi":"10.1200/jco.2013.31.15_suppl.e11597","title":"Bevacizumab for advanced breast cancer: Hope, hype, and hundreds of headlines.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Bevacizumab; Breast cancer; Newspaper; Headline; Food and drug administration; Family medicine; Clinical trial; Cancer; Oncology; Internal medicine; Advertising; Pharmacology; Chemotherapy","score_opus":0.10516201181284197,"score_gpt":0.5141664109434135,"score_spread":0.40900439913057157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599371299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655775,0.0028269922,0.000045662615,0.02900522,0.0012247503,0.00046341747,0.000025676478,0.000005565765,0.00082523096],"genre_scores_gemma":[0.9852323,0.0062379357,0.0038290115,0.0024174198,0.0015434021,0.00003553233,0.0000032244611,0.000016917522,0.0006842551],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978589,0.00009958507,0.0015603761,0.00014329224,0.00014275814,0.00019509287],"domain_scores_gemma":[0.9961723,0.0013941881,0.0012136636,0.00009946353,0.00080485945,0.00031554507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066488975,0.00011563627,0.001419522,0.000095477284,0.000026007096,0.00000351186,0.00008667614,0.0002441953,0.00047015937],"category_scores_gemma":[0.0003783687,0.000081839535,0.00031806072,0.00009382373,0.0002218057,0.00011922101,0.000029299687,0.0003654028,0.0000041308153],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011099513,0.002045567,0.054441158,0.00011305334,0.00070984976,0.000046930196,0.00007627606,0.0000125966635,0.0026739445,0.000060617436,0.025917301,0.9028032],"study_design_scores_gemma":[0.074511446,0.045637045,0.6357581,0.00025425674,0.0022962561,0.0019001167,0.00019900061,0.00033816256,0.0010711544,0.001519709,0.23627742,0.00023731306],"about_ca_topic_score_codex":0.00010221549,"about_ca_topic_score_gemma":0.00006739268,"teacher_disagreement_score":0.9025659,"about_ca_system_score_codex":0.00010122053,"about_ca_system_score_gemma":0.0011370344,"threshold_uncertainty_score":0.51479155},"labels":[],"label_agreement":null},{"id":"W2599386056","doi":"10.1200/jco.2017.35.6_suppl.4","title":"Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; DECIPHER; Oncology; Prostate; Metastasis; Biopsy; Internal medicine; Prostatectomy; Prostate biopsy; Cancer; Biochemical recurrence; Pathology; Bioinformatics","score_opus":0.30499408326372374,"score_gpt":0.5165378263537546,"score_spread":0.21154374309003082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599386056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753476,0.004526109,0.0000152243365,0.005818635,0.0006149449,0.000874183,0.00037667615,0.0000023089792,0.00023716781],"genre_scores_gemma":[0.9943709,0.004628856,0.00032496406,0.00013932717,0.00032132302,0.000035202425,0.000011115993,0.000014256556,0.00015408399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958425,0.000745178,0.0017526249,0.00028666563,0.0011482451,0.00022476699],"domain_scores_gemma":[0.99338156,0.0016690308,0.0022984578,0.0006409491,0.0014686711,0.0005413301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005410493,0.00015263788,0.0014347973,0.00018585271,0.00013074196,0.00002961051,0.00028768324,0.00013250775,0.00035764824],"category_scores_gemma":[0.008159076,0.00008505357,0.0005663174,0.0002632396,0.0007624094,0.00012192211,0.00017128234,0.00038942668,0.0000020687864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038178342,0.0007473524,0.9159532,0.000025632613,0.0065185004,0.0000630717,0.00036593733,0.00028296502,0.0012453885,0.000008882141,0.0009160522,0.07005517],"study_design_scores_gemma":[0.0057395473,0.0011264633,0.9719293,0.00015002342,0.016778896,0.0000027442077,0.00011985223,0.0008629499,0.0003397292,0.0005592688,0.002318716,0.00007247021],"about_ca_topic_score_codex":0.00033058765,"about_ca_topic_score_gemma":0.00030041987,"teacher_disagreement_score":0.06998271,"about_ca_system_score_codex":0.00030613202,"about_ca_system_score_gemma":0.0030893532,"threshold_uncertainty_score":0.9767766},"labels":[],"label_agreement":null},{"id":"W2599407426","doi":"10.1200/jco.2014.32.15_suppl.2549","title":"Correlation between phase 2 clinical trial design and subsequent phase 3 outcome.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Queen's University; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Clinical trial; Outcome (game theory); Discontinuation; Clinical endpoint; Internal medicine; Randomized controlled trial; Surrogate endpoint","score_opus":0.8939519433398854,"score_gpt":0.736351741187874,"score_spread":0.15760020215201131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599407426","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23707935,0.000032063024,0.7526297,0.0020637517,0.0068368814,0.00075675023,0.000014923797,0.00002944988,0.00055713125],"genre_scores_gemma":[0.2576253,0.00014602559,0.73214775,0.0009499893,0.008984288,0.000009326732,0.000001524661,0.000043311844,0.00009249841],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9625444,0.020086622,0.01563567,0.00050979276,0.0007838036,0.00043974578],"domain_scores_gemma":[0.46586755,0.5227184,0.009071609,0.00052700244,0.0006593037,0.0011561274],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.1264511,0.0003141023,0.0050567216,0.00015105311,0.000094503994,0.000043407796,0.00043905314,0.0014030499,0.00027777013],"category_scores_gemma":[0.6664466,0.00022581773,0.001116644,0.00017702222,0.0008591521,0.00017411615,0.00014472683,0.0027076288,0.00004199888],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10573394,0.008038549,0.006447926,0.00003904384,0.0005554908,0.00019110237,0.000030372437,0.000008015029,0.0000075426747,0.0157619,0.007164452,0.85602164],"study_design_scores_gemma":[0.29822525,0.08455633,0.002040201,0.00006614982,0.0015728301,0.00006736892,0.000015796024,0.002821232,0.000012737422,0.58487415,0.025471998,0.00027595923],"about_ca_topic_score_codex":0.0000017951409,"about_ca_topic_score_gemma":0.0000011482622,"teacher_disagreement_score":0.85574573,"about_ca_system_score_codex":0.00009518699,"about_ca_system_score_gemma":0.0007155255,"threshold_uncertainty_score":0.99989337},"labels":[],"label_agreement":null},{"id":"W2599412706","doi":"10.1200/jco.2017.35.5_suppl.100","title":"Barriers to care in two differing models of follow-up for long-term childhood cancer survivors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Vignette; Family medicine; Scale (ratio); Primary care; Quality of life (healthcare); Cancer; Demography; Gerontology; Nursing; Internal medicine","score_opus":0.1334494530458558,"score_gpt":0.5027659129032778,"score_spread":0.369316459857422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599412706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98244673,0.0009364468,0.00072561536,0.009813076,0.0046635354,0.0006896805,0.000034840003,0.00000888286,0.0006812115],"genre_scores_gemma":[0.9929537,0.00047913866,0.001639856,0.0026455908,0.0021141039,0.000026151034,0.0000025232787,0.00004339039,0.00009555145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951398,0.0003334155,0.0032070612,0.00034547126,0.00055268843,0.0004215905],"domain_scores_gemma":[0.9932984,0.0015756399,0.0027360558,0.0006381428,0.00071973784,0.0010319861],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003818583,0.00023294217,0.0028090067,0.00021517619,0.00012634187,0.0000212816,0.0006565738,0.0003184058,0.00007324783],"category_scores_gemma":[0.01009823,0.00019496269,0.00089695357,0.000086512555,0.00022009811,0.00024705962,0.00018215772,0.0009033967,0.0000018024322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061278823,0.00047501334,0.9110573,0.00026753292,0.00044602403,0.00010586996,0.0048373663,0.00032799618,0.00007110165,0.000084252606,0.0003236607,0.07587599],"study_design_scores_gemma":[0.022461561,0.0057609114,0.9670389,0.0010932978,0.0003689978,0.000037853864,0.0007811234,0.000099044555,0.00026085135,0.0004800904,0.0014047937,0.00021255923],"about_ca_topic_score_codex":0.0016081904,"about_ca_topic_score_gemma":0.04082358,"teacher_disagreement_score":0.07566343,"about_ca_system_score_codex":0.00031314843,"about_ca_system_score_gemma":0.0032469654,"threshold_uncertainty_score":0.9982401},"labels":[],"label_agreement":null},{"id":"W2599444544","doi":"10.1200/jco.2017.35.6_suppl.450","title":"Combined inhibition of autophagy with mTOR inhibitor to enhance cell death in renal cell carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Autophagy; PI3K/AKT/mTOR pathway; Clonogenic assay; Programmed cell death; Protein kinase B; Cancer research; Cell biology; Autophagosome; Lysosome; Biology; Viability assay; RPTOR; Cancer cell; Cell; Signal transduction; Cancer; Apoptosis; Biochemistry","score_opus":0.0554562812717667,"score_gpt":0.4235569135971827,"score_spread":0.368100632325416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599444544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249846,0.00018199284,0.00017601656,0.0021094163,0.00054010324,0.00026181308,0.0000044220933,0.0000052731907,0.0042225197],"genre_scores_gemma":[0.994548,0.0000974496,0.0025769158,0.0014070367,0.00080051634,0.000005298656,0.000001849955,0.0000191306,0.00054378825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719673,0.00021395719,0.0017822839,0.0002111586,0.00036050167,0.00023533743],"domain_scores_gemma":[0.99613583,0.00048127992,0.0021988535,0.0003934257,0.00037952344,0.00041111384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014606459,0.00015235646,0.0012985066,0.00015657535,0.000054950982,0.000010371021,0.00021758337,0.00030307137,0.00010763769],"category_scores_gemma":[0.0005450601,0.00010755496,0.00028047562,0.000075984244,0.00018471021,0.00014784618,0.000060180562,0.0007103181,0.000020872498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07396888,0.017999453,0.7051378,0.00035664372,0.00031790344,0.009732393,0.0008546627,0.000077492456,0.15531053,0.00018342288,0.0057320567,0.030328758],"study_design_scores_gemma":[0.013080166,0.027062561,0.71486187,0.00023811545,0.00018929364,0.000040242554,0.00004191806,0.000031003634,0.24186146,0.00023351656,0.0022444923,0.00011535679],"about_ca_topic_score_codex":0.000041254872,"about_ca_topic_score_gemma":0.000028800045,"teacher_disagreement_score":0.08655095,"about_ca_system_score_codex":0.00011322982,"about_ca_system_score_gemma":0.0014722816,"threshold_uncertainty_score":0.4385964},"labels":[],"label_agreement":null},{"id":"W2599451377","doi":"10.1200/jco.2013.31.15_suppl.1552","title":"Genome sequencing of multiple primary tumors to reveal underlying germline cancer susceptibility.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"PALB2; Sanger sequencing; Germline; Genetics; Ovarian cancer; Germline mutation; Biology; Breast cancer; Cancer; Medicine; DNA sequencing; Mutation; Gene","score_opus":0.12310611672530512,"score_gpt":0.4392346748890833,"score_spread":0.31612855816377816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599451377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943583,0.0006813755,0.0014383475,0.0019753142,0.0007476713,0.00024119653,0.000010928469,0.0000031917484,0.0005436705],"genre_scores_gemma":[0.97786456,0.00023042172,0.018505314,0.002019006,0.0010299953,0.000016203167,0.0000068904064,0.000020786281,0.00030683065],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970249,0.0002925705,0.0019954536,0.00025993513,0.00019012488,0.00023699248],"domain_scores_gemma":[0.9969834,0.00038654552,0.0012842818,0.00029051618,0.00080597925,0.00024925254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018767419,0.00012959365,0.0007438766,0.000081807826,0.00003685881,0.00000828326,0.00033683662,0.00030717204,0.00014439881],"category_scores_gemma":[0.002112635,0.00010962004,0.00031185045,0.00012845472,0.00018122986,0.000012697489,0.00014481955,0.00038264386,0.00001117718],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004139888,0.00022273068,0.043722592,0.000044515054,0.00021069004,0.000013644362,0.000121716985,0.0030607036,0.90830433,0.0000056536182,0.0025825396,0.04129689],"study_design_scores_gemma":[0.004371068,0.008768529,0.9088435,0.00012533605,0.00016632589,0.00014752251,0.00057436666,0.00014636818,0.03383495,0.00064612314,0.04195582,0.00042008364],"about_ca_topic_score_codex":0.00014730226,"about_ca_topic_score_gemma":0.0002966171,"teacher_disagreement_score":0.8744694,"about_ca_system_score_codex":0.0003807076,"about_ca_system_score_gemma":0.0031023298,"threshold_uncertainty_score":0.55034},"labels":[],"label_agreement":null},{"id":"W2599455091","doi":"10.1200/jco.2013.31.15_suppl.7078","title":"The role of salvage induction chemotherapy after azacitidine (AZA) treatment failure.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Azacitidine; Chemotherapy; Salvage therapy; Induction chemotherapy; Surgery; Oncology","score_opus":0.056182440377792194,"score_gpt":0.42690926001585827,"score_spread":0.3707268196380661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599455091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504169,0.000619592,0.000030610827,0.046236932,0.0003530707,0.0003447137,0.0000012595079,0.000006010419,0.0019908852],"genre_scores_gemma":[0.99126285,0.0024405827,0.0024200755,0.0010461211,0.0017475656,0.000023939141,0.0000010824895,0.000019918105,0.0010378708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971426,0.00038334672,0.001689888,0.00013512814,0.00039036205,0.00025867345],"domain_scores_gemma":[0.9962598,0.0015201116,0.0010098933,0.00027127733,0.00063694245,0.00030195297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019727026,0.00012462444,0.0009808743,0.00009941155,0.00004156176,0.000011577377,0.00017371988,0.00035616304,0.0006159153],"category_scores_gemma":[0.0012570875,0.00006242883,0.00047345902,0.00013592321,0.00037099782,0.00012483656,0.000035004065,0.00084412895,0.00007724148],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053120577,0.001446441,0.043299753,0.000010629116,0.00080862,0.00012120623,0.00019063374,0.0000017222828,0.012443161,0.00010290695,0.013570008,0.92269284],"study_design_scores_gemma":[0.01091465,0.023152433,0.3492891,0.000050886454,0.0002092406,0.0005095176,0.0006844038,0.00013657747,0.007980524,0.0017186459,0.6052628,0.000091218986],"about_ca_topic_score_codex":0.00006787358,"about_ca_topic_score_gemma":0.000039997984,"teacher_disagreement_score":0.92260164,"about_ca_system_score_codex":0.00042089738,"about_ca_system_score_gemma":0.0013790868,"threshold_uncertainty_score":0.674384},"labels":[],"label_agreement":null},{"id":"W2599456777","doi":"10.1200/jco.2006.24.18_suppl.14513","title":"Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Clinical endpoint; Capecitabine; Internal medicine; Prostate cancer; Urology; Refractory (planetary science); Gastroenterology; Phases of clinical research; Chemotherapy; Randomized controlled trial; Surgery; Oncology; Cancer","score_opus":0.07944983119989771,"score_gpt":0.4741449583049285,"score_spread":0.39469512710503074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599456777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540914,0.004498625,0.000010563308,0.003986046,0.0026699672,0.0022383947,0.00008245807,0.000019036468,0.0010857729],"genre_scores_gemma":[0.98183435,0.011635375,0.0005364783,0.0005348386,0.0025400005,0.00011879973,0.00007067904,0.00004751969,0.0026819557],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908928,0.0014302112,0.006040892,0.00041614904,0.0006650098,0.0005548815],"domain_scores_gemma":[0.9904366,0.0034239509,0.0047072363,0.00028713632,0.0007421297,0.00040291942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003405782,0.0004032891,0.0053793364,0.00045953772,0.00006591644,0.000007819259,0.00024412558,0.00056986004,0.0010658506],"category_scores_gemma":[0.0023967181,0.00025920908,0.001063445,0.00044899643,0.00059062126,0.00021293992,0.00009285713,0.0012659286,0.000008427448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87562376,0.050129697,0.0068124975,0.000051419695,0.0010077155,0.0006928103,0.00019482817,0.000020099815,0.0026218737,0.000005865413,0.01249444,0.05034501],"study_design_scores_gemma":[0.8671007,0.089233354,0.013081408,0.00015022226,0.002301267,0.000044206037,0.000031935866,0.00010288891,0.00041747067,0.00011189233,0.027221167,0.00020348644],"about_ca_topic_score_codex":0.0006185713,"about_ca_topic_score_gemma":0.0004535688,"teacher_disagreement_score":0.050141525,"about_ca_system_score_codex":0.00061647885,"about_ca_system_score_gemma":0.0022515582,"threshold_uncertainty_score":0.999986},"labels":[],"label_agreement":null},{"id":"W2599463965","doi":"10.1200/jco.2012.30.15_suppl.tps2615","title":"A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Carboplatin; Gemcitabine; Lung cancer; Tolerability; Internal medicine; Oncology; Cisplatin; Bevacizumab; Chemotherapy; Paclitaxel; non-small cell lung cancer (NSCLC); Adverse effect","score_opus":0.04032783369128001,"score_gpt":0.3947619390814295,"score_spread":0.35443410539014947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599463965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978133,0.00042093705,0.00012823251,0.000067625915,0.0003667359,0.00084780494,0.00005427571,0.0000018053499,0.00029928776],"genre_scores_gemma":[0.9976997,0.00040212335,0.0012954918,0.00011789235,0.0002604027,0.00003843605,0.00003026932,0.000033887085,0.00012184832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969461,0.00028263617,0.0018168394,0.00029652903,0.0002812413,0.00037666826],"domain_scores_gemma":[0.99643445,0.00063191546,0.001970226,0.00027669588,0.00044153657,0.0002451883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010247375,0.00026759424,0.0011183564,0.00019833099,0.000034336703,0.000011175899,0.00020700015,0.00029261984,0.000030519543],"category_scores_gemma":[0.0004568114,0.00018104924,0.00012488697,0.00027123492,0.000099016164,0.00002564791,0.00007602377,0.00037548773,5.448777e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0151224295,0.025166702,0.94765043,0.000039182385,0.00026869547,0.00005845062,0.00058576715,0.00082880596,0.00039863383,0.000005596932,0.0001416227,0.009733679],"study_design_scores_gemma":[0.11439177,0.12155502,0.75987744,0.000108803986,0.0003867357,0.0000070563024,0.0011203742,0.0004499738,0.00078024884,0.0000036602587,0.0010125219,0.00030639707],"about_ca_topic_score_codex":0.00054704025,"about_ca_topic_score_gemma":0.005287672,"teacher_disagreement_score":0.18777299,"about_ca_system_score_codex":0.00024082513,"about_ca_system_score_gemma":0.0011892606,"threshold_uncertainty_score":0.7382974},"labels":[],"label_agreement":null},{"id":"W2599466693","doi":"10.1200/jco.2007.25.18_suppl.17022","title":"The use of the internet for medical information and a needs assessment for a web based educational resource: A survey of Canadian medical oncology trainees and training program directors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Sciences Research and Education","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"The Internet; Oncology; Medicine; Resource (disambiguation); Internal medicine; Medical education; Educational resources; Work (physics); Family medicine; Psychology; World Wide Web; Computer science","score_opus":0.46467297075880537,"score_gpt":0.6384637901665955,"score_spread":0.17379081940779012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599466693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8860851,0.00006116631,0.00053883455,0.11003829,0.0015994038,0.0011917982,0.000034793087,0.0000023965688,0.00044823406],"genre_scores_gemma":[0.98640573,0.00017254976,0.006716701,0.005945277,0.00057582697,0.000101196296,0.000013797381,0.000005698696,0.000063194486],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9940911,0.0019603162,0.0027381585,0.00008246454,0.0006882577,0.00043972506],"domain_scores_gemma":[0.9198511,0.076104805,0.0016065569,0.00009250852,0.00115466,0.0011903316],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05821816,0.00006949185,0.0005201389,0.00035353575,0.00028348505,0.000010375869,0.00029720465,0.00052288134,0.000084183106],"category_scores_gemma":[0.11934671,0.00003662776,0.00009910789,0.00041748345,0.0007547275,0.00013095324,0.000041197298,0.0010200398,1.8573307e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001230554,0.00032050983,0.18642305,0.00013935921,0.000051358817,6.609007e-7,0.0036599727,0.0000018234336,0.0000013156365,0.0010248434,0.05683618,0.75031036],"study_design_scores_gemma":[0.0015259562,0.0022197377,0.50972694,0.00009569622,0.000010744055,0.000007201083,0.001974601,0.004420469,2.800346e-7,0.000058483758,0.47993767,0.000022218119],"about_ca_topic_score_codex":0.010291634,"about_ca_topic_score_gemma":0.24039781,"teacher_disagreement_score":0.7502881,"about_ca_system_score_codex":0.0002287648,"about_ca_system_score_gemma":0.07406467,"threshold_uncertainty_score":0.9962989},"labels":[],"label_agreement":null},{"id":"W2599470944","doi":"10.1200/jco.2012.30.15_suppl.e16528","title":"Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Modalities; Population; Chemotherapy; Cancer; Anesthesia; Surgery; Internal medicine","score_opus":0.16767519239022002,"score_gpt":0.4003670981371267,"score_spread":0.23269190574690665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599470944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924434,0.0055660782,0.0013695804,0.0015088957,0.0006967307,0.00023161998,0.00030527127,0.0000041695725,0.0010733298],"genre_scores_gemma":[0.9907599,0.00613669,0.0024048975,0.00027292335,0.00024925286,0.0000068007475,0.00000471266,0.000011115109,0.00015372643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99738467,0.000066425564,0.0021346784,0.00011759144,0.000027770373,0.0002688911],"domain_scores_gemma":[0.9945713,0.0011719507,0.0037602475,0.000090048416,0.00012619779,0.00028020816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020311482,0.00010624253,0.0016645372,0.00014287184,0.0000675553,0.000009683203,0.00006232122,0.0001314382,0.000039303086],"category_scores_gemma":[0.0011474497,0.00008282263,0.00019556389,0.000079480706,0.00016100373,0.00019786421,0.00001309785,0.00013108777,0.000002855497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002956914,0.0062890993,0.36797836,0.000042552987,0.0015756311,0.000017116727,0.0024047634,0.00016929494,0.000005195914,0.016518155,0.0016095018,0.6004334],"study_design_scores_gemma":[0.008299523,0.07687826,0.6968257,0.00006429979,0.00017790639,0.00021930847,0.0002446845,0.0000771196,0.00001634876,0.01766487,0.19926009,0.0002719274],"about_ca_topic_score_codex":0.00029445943,"about_ca_topic_score_gemma":0.0007676947,"teacher_disagreement_score":0.6001615,"about_ca_system_score_codex":0.00023641197,"about_ca_system_score_gemma":0.0005613074,"threshold_uncertainty_score":0.3377409},"labels":[],"label_agreement":null},{"id":"W2599484388","doi":"10.1200/jco.2017.35.4_suppl.735","title":"Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Regorafenib; Medicine; Colorectal cancer; Placebo; Internal medicine; Meta-analysis; Oncology; Randomized controlled trial; Randomization; Cancer; Pathology; Alternative medicine","score_opus":0.4970990250534385,"score_gpt":0.583730368497327,"score_spread":0.08663134344388845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599484388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020581268,0.9918285,0.000043991364,0.001805262,0.00031795222,0.0056595276,0.00018496127,0.000004225938,0.0001350163],"genre_scores_gemma":[0.00023128868,0.9959324,0.0022935013,0.00059531926,0.0002897318,0.0003701617,0.000016987044,0.000029007075,0.00024162428],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99079263,0.0013109222,0.0068061743,0.00042871042,0.00036111518,0.00030042144],"domain_scores_gemma":[0.9780085,0.009797984,0.010546483,0.00040927235,0.0007636475,0.00047413053],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.006803903,0.0004884406,0.044886105,0.00021548409,0.0001251069,0.000018016448,0.00027784117,0.000280594,0.000057751087],"category_scores_gemma":[0.00732633,0.00025301435,0.005484358,0.00033875147,0.0002927939,0.000047414604,0.00015710216,0.0006017764,0.0000011850541],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019080422,0.00046247052,0.000029439605,0.39963916,0.5070539,0.000097793716,0.00003785999,0.000003940909,1.1505153e-8,0.000024776757,0.0036954964,0.08704708],"study_design_scores_gemma":[0.002179631,0.004757305,0.00015996891,0.039104138,0.65199107,0.00016732766,0.000007540515,0.0000035995292,1.4097175e-8,0.00001220808,0.30148992,0.00012726303],"about_ca_topic_score_codex":0.000029331437,"about_ca_topic_score_gemma":0.00030211342,"teacher_disagreement_score":0.36053503,"about_ca_system_score_codex":0.00020100798,"about_ca_system_score_gemma":0.0015122293,"threshold_uncertainty_score":0.9999922},"labels":[],"label_agreement":null},{"id":"W2599485233","doi":"10.1200/jco.2017.35.5_suppl.108","title":"Development of a decision aid for young canadians diagnosed with breast cancer who are at risk of infertility following cancer treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Health and Technologies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Canadian Partnership Against Cancer; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Fertility preservation; Medicine; Fertility; Breast cancer; Family medicine; Gynecology; Cancer; Health care; Infertility; Inclusion (mineral); Qualitative research; Population; Environmental health; Psychology; Social psychology; Internal medicine; Pregnancy","score_opus":0.13668455534800952,"score_gpt":0.49562627704480944,"score_spread":0.35894172169679994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599485233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939927,0.0010115339,0.00013636673,0.0035134803,0.0006858302,0.0004694679,0.000068271394,0.000005299873,0.000117043055],"genre_scores_gemma":[0.98619294,0.0023267325,0.010974666,0.0001097103,0.00024766222,0.00005262439,8.753394e-7,0.000012379798,0.00008243035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749315,0.00007761878,0.0016909511,0.00023300838,0.00025543323,0.0002498378],"domain_scores_gemma":[0.99370444,0.0010982101,0.003811623,0.00040868975,0.00070225116,0.00027480864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016094537,0.00013527044,0.0017148627,0.00010130846,0.00018181332,0.000003987773,0.0001874691,0.0002765328,0.000026841679],"category_scores_gemma":[0.005896927,0.00007914312,0.00033658624,0.000057294517,0.0002726362,0.000092590315,0.000047281632,0.00030918547,3.4768888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071430686,0.00039788795,0.7093176,0.000053428907,0.0005177651,0.00008766299,0.0001871237,0.000006298369,0.00004089841,0.0000022946651,0.0002542493,0.28199172],"study_design_scores_gemma":[0.010935327,0.0035276327,0.97057295,0.0006690799,0.0005237224,0.000048225214,0.00022805308,0.000011316348,0.0006628635,0.00007237963,0.012681222,0.00006725714],"about_ca_topic_score_codex":0.008333906,"about_ca_topic_score_gemma":0.13734923,"teacher_disagreement_score":0.28192446,"about_ca_system_score_codex":0.000847419,"about_ca_system_score_gemma":0.0054339874,"threshold_uncertainty_score":0.9982697},"labels":[],"label_agreement":null},{"id":"W2599490173","doi":"10.1200/jco.2013.31.15_suppl.7551","title":"Reducing futile thoracotomy rates in PET-CT staged non small cell lung cancer: Clinical risk factors from a population-based review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Thoracotomy; Univariate analysis; Surgery; Population; Odds ratio; Internal medicine; Multivariate analysis","score_opus":0.07896302473405785,"score_gpt":0.47905264951964555,"score_spread":0.4000896247855877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599490173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833173,0.007479901,0.0000148914,0.005972779,0.0018376865,0.0010305753,0.000026098538,0.000012321728,0.00030841303],"genre_scores_gemma":[0.9587394,0.03462187,0.002720134,0.002571513,0.0011459998,0.00006152805,0.000032300908,0.00003070271,0.00007654206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933397,0.0012953391,0.004276654,0.00040931115,0.00035090966,0.00032809208],"domain_scores_gemma":[0.9881472,0.007072339,0.0035064644,0.00035038783,0.00037724635,0.0005463474],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035130836,0.00025476865,0.0025821677,0.00012824214,0.000056766967,0.0000193426,0.00019948867,0.00016805604,0.001143856],"category_scores_gemma":[0.0032111024,0.0001675099,0.0008896747,0.0001966293,0.00007806588,0.00013051415,0.000040530416,0.0016685625,0.00002482318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044052614,0.0023421799,0.9607497,0.00020728081,0.00031285948,0.0004685224,0.000031638097,0.0001293247,0.000008324175,6.418074e-7,0.010345826,0.024963163],"study_design_scores_gemma":[0.008488186,0.0031002022,0.979242,0.0027154156,0.0015262183,0.000011976233,0.000075762546,0.0012451685,0.00011692249,0.000044117503,0.0032788583,0.00015515955],"about_ca_topic_score_codex":0.01143374,"about_ca_topic_score_gemma":0.0008684076,"teacher_disagreement_score":0.027141968,"about_ca_system_score_codex":0.0007688644,"about_ca_system_score_gemma":0.0023258913,"threshold_uncertainty_score":0.9997692},"labels":[],"label_agreement":null},{"id":"W2599496750","doi":"10.1200/jco.2017.35.4_suppl.188","title":"Iron deficiency anemia in gastric cancer: A single site retrospective cohort study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Interquartile range; Cancer; Internal medicine; Anemia; Retrospective cohort study; Gastroenterology; Ferritin; Iron-deficiency anemia; Population; Surgery","score_opus":0.07435782336433361,"score_gpt":0.45126026353856474,"score_spread":0.37690244017423113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599496750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98194724,0.0008357074,0.000021234951,0.0023401473,0.0015398633,0.00033403095,0.0000022954498,0.0000052896667,0.012974198],"genre_scores_gemma":[0.9967384,0.0010166682,0.0005147045,0.00059386005,0.0008307421,0.000004852771,5.555769e-7,0.000012135915,0.00028810394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971357,0.00027238185,0.0016373283,0.00023682624,0.00044359657,0.00027416032],"domain_scores_gemma":[0.9967305,0.0003497672,0.0019939733,0.00036168867,0.0003109998,0.00025309017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036798855,0.000125862,0.0014534491,0.00016597274,0.000097647106,0.000019758434,0.0002618138,0.0002514677,0.00017798124],"category_scores_gemma":[0.0068722456,0.00009226023,0.00024145894,0.00011637745,0.0002566308,0.0001615925,0.00007796053,0.0010418227,0.000018015207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014330413,0.0037063598,0.9588202,0.000017793558,0.000013135399,0.00063088146,0.00017069258,0.000010119279,0.00011885128,0.000020800784,0.0011334497,0.03392466],"study_design_scores_gemma":[0.009521847,0.009346614,0.97865146,0.000033974928,0.00036396013,0.00009252913,0.00026380917,0.0000066401644,0.0000053118342,0.000115467905,0.001518834,0.00007952989],"about_ca_topic_score_codex":0.00044768062,"about_ca_topic_score_gemma":0.00090242334,"teacher_disagreement_score":0.03384513,"about_ca_system_score_codex":0.00027159337,"about_ca_system_score_gemma":0.0010892585,"threshold_uncertainty_score":0.8227216},"labels":[],"label_agreement":null},{"id":"W2599497396","doi":"10.1200/jco.2012.30.15_suppl.616","title":"Can MRI accurately identify which patients with operable breast cancer will have a pathologic complete response after neoadjuvant therapy?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Neoadjuvant therapy; Chemotherapy; Breast MRI; Oncology; Complete response; Cancer; Internal medicine; Radiology; Stage (stratigraphy); Magnetic resonance imaging; Mammography","score_opus":0.16257617054287915,"score_gpt":0.47807405625405125,"score_spread":0.3154978857111721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599497396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94148356,0.0013859153,0.000027265713,0.054451797,0.0018345059,0.00046281822,0.00011439301,0.000014036111,0.0002257324],"genre_scores_gemma":[0.98119324,0.003987289,0.001316703,0.01162705,0.0015753928,0.00006596482,0.00000550079,0.000045470126,0.00018340077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490875,0.0014000029,0.0020770216,0.00030622756,0.0006866399,0.0006213481],"domain_scores_gemma":[0.9931479,0.0023056148,0.0017096316,0.0003936655,0.0016364494,0.0008067243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004519769,0.0002823527,0.0017477415,0.00016441823,0.00007165579,0.000026222313,0.0002901751,0.00046148902,0.001603324],"category_scores_gemma":[0.00088206783,0.00016817707,0.00032915545,0.0002470557,0.00024037863,0.00042160583,0.00009115213,0.0014165905,0.00002798252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055036604,0.0025323522,0.9127002,0.000018152843,0.00038214034,0.00050837477,0.00047584696,0.00002705934,0.00007332434,0.0000023454497,0.00882101,0.019422632],"study_design_scores_gemma":[0.012281155,0.008723496,0.88318896,0.00026031106,0.00030666098,0.00060165464,0.00009405369,0.0000095269215,0.000030816125,0.00002317916,0.09429764,0.00018254197],"about_ca_topic_score_codex":0.00015664836,"about_ca_topic_score_gemma":0.0005027581,"teacher_disagreement_score":0.08547663,"about_ca_system_score_codex":0.00050404755,"about_ca_system_score_gemma":0.0019142821,"threshold_uncertainty_score":0.99930936},"labels":[],"label_agreement":null},{"id":"W2599498906","doi":"10.1200/jco.2014.32.15_suppl.10032","title":"A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children’s Oncology Group AREN0321 study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Medicine; Irinotecan; Vincristine; Internal medicine; Wilms' tumor; Progressive disease; Regimen; Etoposide; Carboplatin; Oncology; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Chemotherapy regimen; Phases of clinical research; Cancer; Surgery; Cyclophosphamide; Colorectal cancer; Cisplatin","score_opus":0.041173532945791444,"score_gpt":0.3979814739871093,"score_spread":0.35680794104131786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599498906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99785954,0.00044743728,0.00007482889,0.0005988891,0.0005204638,0.00037324987,0.000024753554,0.0000023044768,0.00009854097],"genre_scores_gemma":[0.998388,0.00037467916,0.00020427855,0.00043593062,0.00054949085,0.000007639367,0.000012136812,0.000014440604,0.000013439832],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947732,0.0019292462,0.002477712,0.00035589,0.00024312736,0.00022082767],"domain_scores_gemma":[0.9953598,0.0020229223,0.0019656867,0.00031104867,0.00014536334,0.00019521573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00327865,0.00018995689,0.0011937637,0.00007908908,0.000051269264,0.000009444711,0.0003776205,0.00021044021,0.0000062156278],"category_scores_gemma":[0.004186974,0.0001109868,0.00018055587,0.00013028515,0.00030411943,0.0000073489814,0.00016567046,0.00082172843,0.0000010540077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08910805,0.1364816,0.3602563,0.0000299406,0.005333592,0.0012223301,0.0033989362,0.0013934494,0.0099027045,0.000029691882,0.004364957,0.38847843],"study_design_scores_gemma":[0.12029825,0.32153258,0.5438811,0.00007889149,0.0010504808,0.0002408174,0.0031539358,0.00046977113,0.00023192055,0.00019075105,0.008577487,0.00029403123],"about_ca_topic_score_codex":0.00051908725,"about_ca_topic_score_gemma":0.0032875587,"teacher_disagreement_score":0.3881844,"about_ca_system_score_codex":0.000043057324,"about_ca_system_score_gemma":0.00035667737,"threshold_uncertainty_score":0.50125015},"labels":[],"label_agreement":null},{"id":"W2599505216","doi":"10.1200/jco.2017.35.6_suppl.87","title":"Risk prediction-modeling approach to identify best predictive parameters for urethral strictures after prostate brachytherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Urethra; Prostate brachytherapy; Prostate; Brachytherapy; Urology; Urethral stricture; Cohort; Radiation therapy; Surgery; Internal medicine","score_opus":0.13505549488868607,"score_gpt":0.4826120925047521,"score_spread":0.34755659761606605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599505216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754908,0.0010879707,0.015110036,0.004006273,0.0021298951,0.0014029036,0.00020630054,0.0000131415845,0.0005526702],"genre_scores_gemma":[0.97238743,0.002817903,0.021611966,0.001228794,0.001575971,0.00023893299,0.000010101737,0.000031058957,0.00009785054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695164,0.00018723765,0.0018055659,0.0003606548,0.00036527275,0.0003296397],"domain_scores_gemma":[0.9955439,0.00089730957,0.0018945907,0.00040999052,0.0006895895,0.0005646017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022164753,0.0002069329,0.0012645607,0.0001235598,0.00021128678,0.000070441594,0.0002323114,0.000343896,0.0000119305805],"category_scores_gemma":[0.0035937415,0.00013915141,0.0006926789,0.000049806975,0.00017671278,0.0002692973,0.00006320471,0.00078678306,0.0000054236193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03234033,0.005289466,0.7202658,0.000092622344,0.002841464,0.00023013775,0.0011299425,0.00543432,0.000021049103,0.000028866903,0.0051399344,0.22718604],"study_design_scores_gemma":[0.02144733,0.055482358,0.8880708,0.00039302977,0.0027656597,0.00017341445,0.00037443428,0.012489327,0.00010991826,0.002902221,0.015548294,0.00024321646],"about_ca_topic_score_codex":0.000050190672,"about_ca_topic_score_gemma":0.000017001117,"teacher_disagreement_score":0.22694282,"about_ca_system_score_codex":0.00025106894,"about_ca_system_score_gemma":0.00078417326,"threshold_uncertainty_score":0.56744295},"labels":[],"label_agreement":null},{"id":"W2599524623","doi":"10.1200/jco.2012.30.15_suppl.587","title":"Endocrine therapy in early breast cancer: Encouraging observations in a nontrial setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Letrozole; Exemestane; Tamoxifen; Breast cancer; Internal medicine; Cancer; Aromatase inhibitor; Metastatic breast cancer; Surgery; Oncology; Gynecology","score_opus":0.20944872204652545,"score_gpt":0.5267936544192303,"score_spread":0.3173449323727049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599524623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666317,0.0015564187,0.000004178515,0.028412107,0.002551725,0.00022957235,0.000006116028,0.0000053333565,0.00060284423],"genre_scores_gemma":[0.98822415,0.0033060599,0.00062250806,0.0031261947,0.0045613986,0.000017564007,0.0000017558181,0.000011628963,0.0001287663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728996,0.0003945265,0.0016741861,0.00010937312,0.00018229132,0.00034964815],"domain_scores_gemma":[0.9970739,0.0016183752,0.00080491946,0.000082915314,0.00015970148,0.00026020422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023006187,0.00011130955,0.0010258993,0.0002102768,0.000019417064,0.0000041881485,0.00009713548,0.00017492515,0.00033651697],"category_scores_gemma":[0.00043069775,0.00008149909,0.0002471969,0.0002422987,0.0000729084,0.00019892778,0.000022934699,0.0009464094,0.0000059814674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060954853,0.002850697,0.8684906,0.000005274908,0.00013901647,0.00029495676,0.0004380601,0.000012166999,0.0003644609,0.0000232467,0.0016664001,0.11961965],"study_design_scores_gemma":[0.02601448,0.0030839732,0.9347832,0.000066300774,0.000104509956,0.0003537725,0.000052791507,0.000034848348,0.000034700417,0.00006381114,0.035344314,0.00006326363],"about_ca_topic_score_codex":0.00065586047,"about_ca_topic_score_gemma":0.0005988662,"teacher_disagreement_score":0.11955639,"about_ca_system_score_codex":0.00037505027,"about_ca_system_score_gemma":0.0012708894,"threshold_uncertainty_score":0.41117308},"labels":[],"label_agreement":null},{"id":"W2599526286","doi":"10.1200/jco.2017.35.6_suppl.33","title":"Prostate cancer in 671 hypogonadal men with and without long-term testosterone treatment: Results from a controlled registry study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Incidence (geometry); Testosterone (patch); Rectal examination; Prostate; Internal medicine; Gastroenterology; Urology; Gynecology; Prostate-specific antigen; Cancer","score_opus":0.11730441501579736,"score_gpt":0.46622823847976214,"score_spread":0.3489238234639648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599526286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801129,0.0017027687,7.224482e-7,0.014349471,0.000249066,0.00076492515,0.000020578766,0.0000041360067,0.0027954204],"genre_scores_gemma":[0.9936409,0.0024115213,0.0001815885,0.00010241625,0.0011990779,0.000024408148,0.0000012973373,0.000012543715,0.002426258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973814,0.00025537828,0.0015478092,0.0003473717,0.00027115998,0.00019691906],"domain_scores_gemma":[0.9960802,0.0008006894,0.0022321874,0.00034280855,0.00032081924,0.00022324879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015463306,0.00018080798,0.0023548463,0.000057543246,0.00011845148,0.000020609003,0.000121847246,0.00013728937,0.000008013476],"category_scores_gemma":[0.0028748799,0.00008797188,0.00013087351,0.000029918487,0.00055418885,0.0001103643,0.00007179003,0.0005296634,0.0000013825356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11091,0.0023453136,0.82238847,0.0000069807784,0.0014413951,0.0018062769,0.0008776893,0.0000016890282,0.000098625744,6.505524e-7,0.00007925349,0.060043648],"study_design_scores_gemma":[0.1151199,0.026105588,0.8565922,0.0001853278,0.0007400618,0.0001179854,0.00051579886,0.000007002779,0.000018042763,0.000031806187,0.00048443323,0.000081875085],"about_ca_topic_score_codex":0.0008688986,"about_ca_topic_score_gemma":0.0050137066,"teacher_disagreement_score":0.059961773,"about_ca_system_score_codex":0.00013750148,"about_ca_system_score_gemma":0.00087530696,"threshold_uncertainty_score":0.3587389},"labels":[],"label_agreement":null},{"id":"W2599530196","doi":"10.1200/jco.2017.35.4_suppl.464","title":"FDG PET/CT in pancreatic cancer staging and management: A retrospective study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Pancreas; Radiology; Stage (stratigraphy); Pancreatic mass; Adenocarcinoma; Positron emission tomography; Cancer; Cancer staging; Prospective cohort study; Retrospective cohort study; PET-CT; Nuclear medicine; Internal medicine","score_opus":0.1714438452246863,"score_gpt":0.5502946536046834,"score_spread":0.37885080837999713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599530196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97094613,0.00038377318,0.000011890769,0.0058784005,0.00038366628,0.0004896657,0.0000012727739,0.0000041229314,0.02190109],"genre_scores_gemma":[0.9900531,0.006066493,0.0014347205,0.00043268813,0.00041400787,0.000019577918,1.9146735e-7,0.000011674909,0.0015674992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972217,0.00043399492,0.0014534837,0.00023007378,0.00037678852,0.00028395737],"domain_scores_gemma":[0.997055,0.0008273632,0.0012580841,0.0003304538,0.00023080315,0.00029832963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056788195,0.00011894585,0.0019131438,0.00018754616,0.00013217759,0.000024571591,0.00023733974,0.00004643815,0.00016068917],"category_scores_gemma":[0.0037498774,0.00008373065,0.00014830618,0.00007008692,0.00041675012,0.00014060011,0.00017444402,0.0010674567,0.000007893069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018874352,0.0014210034,0.9513977,0.000055105975,0.00070753816,0.020397471,0.00015012568,4.589097e-7,0.0000043573787,0.00016097895,0.0004636006,0.02335422],"study_design_scores_gemma":[0.013436818,0.006695715,0.97430086,0.00025024917,0.00074771646,0.00066438946,0.00083221606,0.00015529298,9.4805733e-7,0.0006758143,0.0021710438,0.00006894281],"about_ca_topic_score_codex":0.0003413406,"about_ca_topic_score_gemma":0.0005585659,"teacher_disagreement_score":0.023285275,"about_ca_system_score_codex":0.0002928377,"about_ca_system_score_gemma":0.000783627,"threshold_uncertainty_score":0.46376273},"labels":[],"label_agreement":null},{"id":"W2599559428","doi":"10.1200/jco.2013.31.15_suppl.10039","title":"Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Bone marrow; Pathology; TaqMan; Concordance; Correlation; Internal medicine; Gene; Real-time polymerase chain reaction; Biology; Genetics","score_opus":0.1184212511553015,"score_gpt":0.40299843361847204,"score_spread":0.28457718246317054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599559428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473464,0.00017365946,0.0002774425,0.0015049184,0.00010084797,0.0031814803,0.000014276572,0.0000064618985,0.0000062481577],"genre_scores_gemma":[0.9937308,0.000040103292,0.005725394,0.0002937277,0.00005479474,0.000092366354,0.0000066848493,0.000031929543,0.000024230234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965093,0.00068251643,0.0015040931,0.00049442594,0.00044085263,0.00036877007],"domain_scores_gemma":[0.99574757,0.0018682866,0.0011855909,0.00019318814,0.00031295858,0.00069239567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014204542,0.00028200992,0.0016249579,0.00039039183,0.0000564207,0.00002766222,0.000095740186,0.00008385673,0.0000039991087],"category_scores_gemma":[0.00068411615,0.00018719841,0.000095957184,0.00016319384,0.00021404096,0.00022331493,0.00006306121,0.00055795367,2.5977542e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019270135,0.011653123,0.91197723,0.00013930115,0.00012253695,0.0002831188,0.00018844423,0.00001204854,0.0014929159,0.0000016113776,0.000074799376,0.054784752],"study_design_scores_gemma":[0.03523885,0.065452725,0.8976914,0.00013439891,0.000210834,0.000044714117,0.00013956845,0.0006164905,0.00026102463,0.000031056443,0.000038378297,0.00014053046],"about_ca_topic_score_codex":0.00002581879,"about_ca_topic_score_gemma":0.00017431477,"teacher_disagreement_score":0.05464422,"about_ca_system_score_codex":0.00011938583,"about_ca_system_score_gemma":0.0004597792,"threshold_uncertainty_score":0.76337296},"labels":[],"label_agreement":null},{"id":"W2599564927","doi":"10.1200/jco.2015.33.15_suppl.6525","title":"Utilization of palliative chemotherapy for advanced bladder cancer: Patterns of care in routine clinical practice.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"","keywords":"Medicine; Bladder cancer; Cancer registry; Comorbidity; Cancer; Internal medicine; Poisson regression; Referral; Population; Chemotherapy; Lung cancer; Medical record; Cohort; Palliative care; Family medicine","score_opus":0.22860531872505893,"score_gpt":0.5640090565918715,"score_spread":0.33540373786681255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599564927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98227257,0.0038626557,0.0018925803,0.007945439,0.0017467499,0.0008146424,0.000054027132,0.0000052714477,0.0014060409],"genre_scores_gemma":[0.9831443,0.0064934664,0.0075957915,0.0018855266,0.00076692493,0.000014804336,0.000008613417,0.000020341142,0.00007025185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959334,0.00038338348,0.0030057996,0.00017674679,0.00034086208,0.00015981194],"domain_scores_gemma":[0.9923711,0.0021889354,0.003022871,0.00015746347,0.0020234184,0.00023622118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022487382,0.000124817,0.0016986184,0.00008854735,0.000008727606,0.0000017253147,0.00011553643,0.00033642427,0.00005453623],"category_scores_gemma":[0.0057638674,0.00008986375,0.00042167408,0.00012564172,0.00011245647,0.000118008014,0.000019854344,0.0004345346,7.0617466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036392063,0.002692748,0.62241584,0.00009749924,0.00061775267,0.000036147063,0.0011291379,0.000053573505,0.000023289329,0.000057331963,0.0005988729,0.33588573],"study_design_scores_gemma":[0.09684492,0.07722076,0.7399705,0.00054315606,0.0012133463,0.000023345074,0.004551156,0.00013559232,0.0017886539,0.00043353334,0.077121004,0.00015405177],"about_ca_topic_score_codex":0.00010438644,"about_ca_topic_score_gemma":0.00025490994,"teacher_disagreement_score":0.3357317,"about_ca_system_score_codex":0.00020810752,"about_ca_system_score_gemma":0.0031676993,"threshold_uncertainty_score":0.6900304},"labels":[],"label_agreement":null},{"id":"W2599582001","doi":"10.1200/jco.2017.35.4_suppl.285","title":"Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Gastroenterology; Placebo; Discontinuation; Rectum; Pathology","score_opus":0.16517999758322105,"score_gpt":0.5245528463895766,"score_spread":0.3593728488063555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599582001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848959,0.00012349957,0.000005637218,0.013438191,0.00026973625,0.0009904117,0.000009787771,0.0000036503316,0.0002631804],"genre_scores_gemma":[0.9977677,0.00015401938,0.0013152706,0.0005553229,0.00015033077,0.000007695096,0.0000030473268,0.00001795057,0.00002864995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906767,0.0022266326,0.0054595885,0.00026094614,0.00089191325,0.00048419123],"domain_scores_gemma":[0.9869063,0.0041843606,0.007342867,0.00059449434,0.0005026512,0.00046935133],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0044671395,0.00018581195,0.0028036719,0.00029033466,0.000048362832,0.0000083826535,0.0006524462,0.000018839262,0.000038627877],"category_scores_gemma":[0.04552844,0.00011043603,0.00029272918,0.00024062504,0.00074516505,0.00024864214,0.00008285719,0.0018884508,0.0000017294927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2946768,0.009172139,0.6724402,0.00012320658,0.000043826098,0.0042345882,0.00003323481,0.000056017423,0.000042076088,0.00006311307,0.00028226525,0.018832544],"study_design_scores_gemma":[0.21564616,0.08388914,0.698484,0.0003703009,0.000023221915,0.00059740135,0.00007836824,0.00002273753,0.00002055019,0.000112722344,0.00069629523,0.000059071695],"about_ca_topic_score_codex":0.00031764762,"about_ca_topic_score_gemma":0.00044998145,"teacher_disagreement_score":0.07903065,"about_ca_system_score_codex":0.00010917963,"about_ca_system_score_gemma":0.0028556597,"threshold_uncertainty_score":0.9625115},"labels":[],"label_agreement":null},{"id":"W2599582945","doi":"10.1200/jco.2013.31.15_suppl.7099","title":"Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bosutinib; Internal medicine; Dasatinib; Discontinuation; Rash; Nilotinib; Gastroenterology; Cohort; Neutropenia; Adverse effect; Imatinib; Mucositis; Toxicity; Incidence (geometry); Febrile neutropenia; Myeloid leukemia","score_opus":0.0351583267820405,"score_gpt":0.3684158386602952,"score_spread":0.3332575118782547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599582945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950859,0.00043824347,0.000058105135,0.0016590912,0.0003895064,0.00074913603,0.0000043683494,0.000006802087,0.001608865],"genre_scores_gemma":[0.99342716,0.00015298203,0.004262303,0.0013007756,0.00034706848,0.000030153058,0.0000016916148,0.000021935248,0.0004559281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961158,0.00031767462,0.0023984527,0.00027330237,0.0005663889,0.0003283979],"domain_scores_gemma":[0.9963738,0.0006797502,0.0014797351,0.00033283673,0.00076729065,0.0003666373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012240174,0.00019442565,0.0015134029,0.00018199031,0.00002060607,0.0000055944342,0.00018910089,0.0003510359,0.0004099344],"category_scores_gemma":[0.0012756678,0.00012732817,0.00026062975,0.00028247942,0.00015570872,0.00018597725,0.000035251913,0.00076351385,0.00004727216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025936315,0.0029878018,0.89864755,0.00004810519,0.00023648648,0.00013477441,0.0002625988,0.000042816333,0.00031571367,0.000016542388,0.0028492627,0.06852201],"study_design_scores_gemma":[0.027898205,0.014623857,0.946714,0.00044343897,0.00008262515,0.000019753576,0.000046734982,0.000025662179,0.00032999882,0.00011406917,0.009592321,0.00010934855],"about_ca_topic_score_codex":0.00016091838,"about_ca_topic_score_gemma":0.00048654678,"teacher_disagreement_score":0.06841266,"about_ca_system_score_codex":0.003239883,"about_ca_system_score_gemma":0.003330017,"threshold_uncertainty_score":0.84721816},"labels":[],"label_agreement":null},{"id":"W2599594081","doi":"10.1200/jco.2007.25.18_suppl.10059","title":"Perifosine (P) as an active agent in the treatment of patients with advanced sarcoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Vomiting; Sarcoma; Internal medicine; Clinical trial; Gastroenterology; Tolerability; Phases of clinical research; Diarrhea; Cancer; Surgery; Adverse effect; Pathology","score_opus":0.04983501330670995,"score_gpt":0.4408266056891376,"score_spread":0.39099159238242764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599594081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982009,0.00032736216,0.00011509148,0.00023013234,0.00034648657,0.00016027149,0.0000058205305,9.4439935e-7,0.0006129686],"genre_scores_gemma":[0.99716944,0.00037067782,0.0014039514,0.0005790476,0.00042999844,0.0000033336446,0.000009568298,0.000010429364,0.00002352937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982715,0.00021933677,0.00095509685,0.00015906375,0.00022130618,0.00017365174],"domain_scores_gemma":[0.9981368,0.00032510335,0.0009424366,0.00020951251,0.00027644748,0.00010967121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011110038,0.00011066211,0.00047441828,0.000044050492,0.000020164274,0.0000031618183,0.00022482025,0.00020869258,0.00002198873],"category_scores_gemma":[0.000329401,0.00006171422,0.00016782117,0.000074980075,0.00016215378,0.0000074259196,0.00001528732,0.0001952588,0.0000010530985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038386803,0.014226173,0.25910342,0.000009160668,0.0004661436,0.00022903594,0.0008165042,0.00019833111,0.015404776,0.000058319667,0.00024382287,0.6708575],"study_design_scores_gemma":[0.010685101,0.1314747,0.72300595,0.000022461156,0.000093896146,0.000032541702,0.00037296876,0.0000042961724,0.024553351,0.00008524844,0.10954368,0.00012581525],"about_ca_topic_score_codex":0.000010493745,"about_ca_topic_score_gemma":0.00016679187,"teacher_disagreement_score":0.6707317,"about_ca_system_score_codex":0.00008882405,"about_ca_system_score_gemma":0.000424201,"threshold_uncertainty_score":0.25166327},"labels":[],"label_agreement":null},{"id":"W2599642625","doi":"10.1200/jco.2013.31.15_suppl.3590","title":"Impact of M1a and M1b staging in patients (pts) with metastatic colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Oncology; Proportional hazards model; Univariate analysis; Cancer; Hazard ratio; Stage (stratigraphy); Cohort; Primary tumor; Cancer staging; Metastasis; Multivariate analysis; Confidence interval","score_opus":0.07423104464943296,"score_gpt":0.4710823155217089,"score_spread":0.39685127087227595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599642625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975827,0.0005031248,0.0000031107572,0.00076209835,0.00015895606,0.00027624556,0.0000062887293,0.0000019595814,0.0007055505],"genre_scores_gemma":[0.9984655,0.00060725113,0.00066218374,0.00013501049,0.00007799793,0.000010243429,8.4622314e-7,0.000008126267,0.00003287619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982861,0.00012777276,0.0010965102,0.000112334696,0.0002112818,0.0001659646],"domain_scores_gemma":[0.99772793,0.0007210501,0.00089386926,0.000054217973,0.00042244678,0.00018051198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048487945,0.00011007935,0.0012918381,0.000102743725,0.000017853314,0.000004412728,0.00004548047,0.00006688716,0.00015470246],"category_scores_gemma":[0.00051882287,0.00005819554,0.00017437612,0.00012091798,0.00018672776,0.00010263482,0.00003105755,0.0003353381,0.0000011909949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00466654,0.0012807214,0.87077004,0.000019066172,0.0007502565,0.000060494007,0.00022076303,0.000011309771,0.000022333663,0.0000024671394,0.00037795273,0.12181803],"study_design_scores_gemma":[0.012482841,0.04548391,0.9411788,0.000104733226,0.00028569417,0.000023468509,0.00014079703,0.000040526804,0.000012553847,0.000050286366,0.00014633311,0.00005007888],"about_ca_topic_score_codex":0.0009724682,"about_ca_topic_score_gemma":0.0004264294,"teacher_disagreement_score":0.12176795,"about_ca_system_score_codex":0.0002707539,"about_ca_system_score_gemma":0.0008245333,"threshold_uncertainty_score":0.23731452},"labels":[],"label_agreement":null},{"id":"W2599647662","doi":"10.1200/jco.2004.22.90140.7041","title":"Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Toxicity; Univariate analysis; Vincristine; Etoposide; Chemotherapy; Performance status; Cyclophosphamide; Oncology; Multivariate analysis","score_opus":0.22601284712966604,"score_gpt":0.5548682603600174,"score_spread":0.3288554132303513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599647662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911433,0.0016392613,0.000008811922,0.0056363097,0.00016141329,0.00023439892,0.000003165663,0.0000026415105,0.0011707363],"genre_scores_gemma":[0.9925005,0.005215591,0.0006256101,0.0012899763,0.00024432165,0.000007435845,1.313519e-7,0.0000076130955,0.0001088552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977936,0.0001574262,0.0014538121,0.00014972177,0.00023872257,0.00020667861],"domain_scores_gemma":[0.99762005,0.0011158114,0.00068131136,0.00012266455,0.00022900802,0.00023113514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012855602,0.000111476635,0.0012268102,0.00012709702,0.000017427,0.0000022902032,0.00008555158,0.00016635527,0.00001894771],"category_scores_gemma":[0.0014581849,0.00006654827,0.00018478438,0.00010043747,0.0002120206,0.000043455773,0.00004870862,0.0005785402,0.0000015626789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002545789,0.0017819671,0.98404604,0.0001319925,0.00025215198,0.0005091241,0.00042876258,0.0021348211,0.0007738618,0.000042464515,0.000091166316,0.0072618416],"study_design_scores_gemma":[0.013213137,0.012367657,0.9714258,0.00017316495,0.00018240928,0.000031918808,0.00007037331,0.000014572616,0.0012670298,0.0001780895,0.0010195822,0.000056321507],"about_ca_topic_score_codex":0.00033953338,"about_ca_topic_score_gemma":0.00057620514,"teacher_disagreement_score":0.012620314,"about_ca_system_score_codex":0.00090728793,"about_ca_system_score_gemma":0.0017207762,"threshold_uncertainty_score":0.3052583},"labels":[],"label_agreement":null},{"id":"W2599648636","doi":"10.1200/jco.2012.30.15_suppl.519","title":"Dual effects of metformin on breast cancer proliferation in a randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Metformin; Medicine; Placebo; Internal medicine; Breast cancer; Clinical endpoint; IGFBP3; Quartile; Gastroenterology; Cancer; Oncology; Randomized controlled trial; Insulin; Pathology; Confidence interval","score_opus":0.042899363627923036,"score_gpt":0.4276541422637088,"score_spread":0.3847547786357858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599648636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95200205,0.044240035,0.000060604918,0.00018579498,0.0027787827,0.0004202433,0.0000043920522,0.0000010452416,0.00030707542],"genre_scores_gemma":[0.96102554,0.033583056,0.00026359913,0.000987252,0.0040200893,0.000048610236,0.0000027432272,0.000010718011,0.0000583738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996605,0.001179587,0.0016966136,0.00011567742,0.00019552847,0.00020763252],"domain_scores_gemma":[0.9972006,0.0009173831,0.00141334,0.00012394412,0.00018886004,0.0001558392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060047302,0.00011057099,0.0014395085,0.00007799292,0.000012120537,0.0000034990417,0.00010638783,0.00036106296,0.000042630214],"category_scores_gemma":[0.0037726487,0.00007360007,0.0004787086,0.000067542576,0.00012392497,0.000011927429,0.000027056256,0.00030304163,0.0000020683067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6441926,0.0017725407,0.0022993006,0.000040830044,0.00032457677,0.0000068241416,0.00006504019,0.000024653587,0.0026269208,0.00018881883,0.0016169944,0.34684092],"study_design_scores_gemma":[0.89258146,0.0050481637,0.0071112206,0.00008835147,0.00032592067,0.00003114376,0.000019254961,0.000018639812,0.024546374,0.00019190834,0.069891326,0.00014621428],"about_ca_topic_score_codex":0.000011808047,"about_ca_topic_score_gemma":0.000024013721,"teacher_disagreement_score":0.3466947,"about_ca_system_score_codex":0.000029522129,"about_ca_system_score_gemma":0.00064545695,"threshold_uncertainty_score":0.45164853},"labels":[],"label_agreement":null},{"id":"W2599666249","doi":"10.1200/jco.2017.35.6_suppl.527","title":"CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Usability; Likert scale; Renal cell carcinoma; Visualization; Cohort; Medical decision making; Internal medicine; Medical physics; Oncology; Family medicine; Data mining; Computer science; Statistics","score_opus":0.23361126024498824,"score_gpt":0.5369498648941909,"score_spread":0.3033386046492027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599666249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356264,0.00019583302,0.0019097427,0.00094708946,0.0022087113,0.00063668913,0.000012420928,0.0000060611046,0.00052079646],"genre_scores_gemma":[0.9722346,0.000109144465,0.02647173,0.00070428307,0.00037786353,0.000009123517,0.000006726641,0.000039386185,0.000047165428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921993,0.0007800343,0.0058606896,0.00033337716,0.0005237699,0.000302842],"domain_scores_gemma":[0.98648804,0.005743672,0.0060633123,0.0005782039,0.0008050077,0.00032176424],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050256485,0.00022732036,0.0027258948,0.0002633304,0.000059079786,0.000023669096,0.00035537605,0.0003703953,0.000070900154],"category_scores_gemma":[0.012864078,0.00015555766,0.0012930703,0.00006951906,0.00028157674,0.00018805261,0.00014271273,0.0005277923,0.000005209016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015882298,0.004427541,0.87285,0.000119420365,0.00020532617,0.00089161115,0.00011004211,0.000006356117,0.00023691216,0.000041420502,0.0015775424,0.10365153],"study_design_scores_gemma":[0.02348733,0.028160043,0.94226366,0.00023417415,0.00076820643,0.00014027288,0.00007601282,0.0004197793,0.000721126,0.0006771449,0.0029330377,0.00011921103],"about_ca_topic_score_codex":0.00002112087,"about_ca_topic_score_gemma":0.000051108836,"teacher_disagreement_score":0.10353232,"about_ca_system_score_codex":0.00019250833,"about_ca_system_score_gemma":0.0010309765,"threshold_uncertainty_score":0.995451},"labels":[],"label_agreement":null},{"id":"W2599671602","doi":"10.1200/jco.2017.35.6_suppl.487","title":"Health-related quality of life (HRQoL), treatment satisfaction, and work productivity for patients (Pts) with advanced renal cell carcinoma (aRCC) in a chart review across six countries.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Observational study; Physical therapy; Internal medicine","score_opus":0.25896900466850975,"score_gpt":0.4721688174133084,"score_spread":0.21319981274479866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599671602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04046054,0.9546615,0.00002102556,0.0012640506,0.0009364544,0.0016242334,0.0008370692,0.0000029631437,0.00019219556],"genre_scores_gemma":[0.029163398,0.96971923,0.000270861,0.0002711724,0.00026370562,0.00007418841,0.00003315391,0.00003776614,0.0001665226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99031,0.00030996217,0.008317651,0.00056133926,0.00007582878,0.00042522547],"domain_scores_gemma":[0.97339934,0.0013643121,0.024153978,0.00044895624,0.00028910505,0.00034430012],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007086204,0.00038568492,0.010301744,0.00012918626,0.000109077424,0.000024765159,0.0002665773,0.00058748835,0.00002683528],"category_scores_gemma":[0.003951358,0.00030573923,0.0007839016,0.00012820831,0.00033532575,0.0003577079,0.00005231902,0.000720472,0.000008435808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010485613,0.0007220703,0.12676518,0.0071878918,0.00022220016,0.0000024697667,0.00006891111,0.0000012818258,2.4972708e-9,0.000107896725,0.0021823384,0.8616912],"study_design_scores_gemma":[0.005522196,0.006487944,0.13751373,0.004151983,0.000110448505,0.0000051767506,0.0000036314539,3.453839e-7,4.556919e-8,0.00015834274,0.8457938,0.00025239005],"about_ca_topic_score_codex":0.000565729,"about_ca_topic_score_gemma":0.0006844945,"teacher_disagreement_score":0.8614388,"about_ca_system_score_codex":0.0009401743,"about_ca_system_score_gemma":0.0024199586,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W2599694538","doi":"10.1200/jco.2017.35.6_suppl.38","title":"Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Prospective cohort study; Internal medicine; Androgen deprivation therapy; Cohort; Cancer; Androgen; Oncology; Retrospective cohort study; Endocrinology; Hormone","score_opus":0.23544384171287003,"score_gpt":0.5102009271200337,"score_spread":0.2747570854071637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599694538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703345,0.0037076215,0.000002679804,0.024618844,0.00041721607,0.00050144386,0.00002562199,0.000008060474,0.0003840297],"genre_scores_gemma":[0.9898233,0.005307755,0.001859922,0.00017436301,0.001297766,0.000027387456,0.000013937727,0.0000205402,0.0014750435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973141,0.0005353703,0.001253787,0.00026206733,0.00035127753,0.0002833921],"domain_scores_gemma":[0.9968788,0.00072038954,0.0011980882,0.00022394944,0.00038462976,0.0005941689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032151805,0.0001425974,0.0010521585,0.00013992417,0.00020706821,0.0000429531,0.00021442454,0.0005703995,0.00007780839],"category_scores_gemma":[0.0027713184,0.00009023973,0.00013765087,0.00007081519,0.00037014918,0.0003736592,0.000090553025,0.0017898553,0.000006619533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002477599,0.000506993,0.89653784,0.00003806199,0.00013746435,0.00030950183,0.0004340884,0.0000012049977,0.0003339696,0.0000055691703,0.004323238,0.094894476],"study_design_scores_gemma":[0.009625377,0.0050309654,0.9295381,0.00045297752,0.00018771818,0.00003565404,0.00019858633,0.000015238447,0.0017402179,0.00041228265,0.052653674,0.0001092538],"about_ca_topic_score_codex":0.000052192834,"about_ca_topic_score_gemma":0.000106586434,"teacher_disagreement_score":0.09478522,"about_ca_system_score_codex":0.00015350133,"about_ca_system_score_gemma":0.0011830444,"threshold_uncertainty_score":0.77761304},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2599723835","doi":"10.1200/jco.2013.31.15_suppl.8565","title":"Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Dalhousie University","funders":"","keywords":"Medicine; Bendamustine; Mantle cell lymphoma; Internal medicine; Rituximab; Gastroenterology; Tolerability; CHOP; Rash; Adverse effect; Surgery; Lymphoma","score_opus":0.07524653254316141,"score_gpt":0.4107670444412533,"score_spread":0.33552051189809184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599723835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99115884,0.0010515423,0.0000065334925,0.0017990317,0.00034973494,0.0053201676,0.000011825099,0.000004953805,0.00029738527],"genre_scores_gemma":[0.996839,0.0019803373,0.00042820352,0.0002614387,0.00017572106,0.00022310903,0.0000040543187,0.00002843008,0.000059706283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925414,0.0017022184,0.0044231205,0.0004442096,0.0005690699,0.0003200215],"domain_scores_gemma":[0.9903452,0.0055693146,0.002764284,0.00047787957,0.00049958075,0.0003437751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004158143,0.00036460304,0.0044940314,0.00021246381,0.00009891973,0.000040808416,0.00042543982,0.00027839246,0.00011595515],"category_scores_gemma":[0.0009929929,0.0001854523,0.00020756389,0.00018117297,0.0004626267,0.0002145292,0.00045299545,0.00029543083,0.0000028029958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104489736,0.17750353,0.5382443,0.00011414772,0.0009878516,0.00034934087,0.0019343083,0.000004336778,0.000101507736,0.000018958897,0.00022014468,0.17603183],"study_design_scores_gemma":[0.4264095,0.030112365,0.5402056,0.00013562413,0.00082708633,0.000083411745,0.0014608757,0.00027178793,0.00014507268,0.00007978317,0.00016903253,0.000099855424],"about_ca_topic_score_codex":0.0011131916,"about_ca_topic_score_gemma":0.0010777051,"teacher_disagreement_score":0.32191977,"about_ca_system_score_codex":0.00018952042,"about_ca_system_score_gemma":0.0004991861,"threshold_uncertainty_score":0.7562525},"labels":[],"label_agreement":null},{"id":"W2599728916","doi":"10.1200/jco.2006.24.18_suppl.6123","title":"A prospective evaluation of the attitudes of patients, physicians and nurses using a computer-assisted quality of life instrument (LCSS-QL) in a multicenter clinical trial in non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Health professionals; Lung cancer; Clinical trial; Docetaxel; Physical therapy; Health care; Family medicine; Medical physics; Cancer; Internal medicine","score_opus":0.19399514146164282,"score_gpt":0.5165202914252974,"score_spread":0.3225251499636546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599728916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959125,0.00029134526,0.00006810823,0.00063908985,0.0014247291,0.0015837154,0.000017778699,0.0000018884675,0.00006082761],"genre_scores_gemma":[0.99680436,0.00007476097,0.0019835639,0.00039641396,0.00071356504,0.000010881846,0.0000015918682,0.000012447537,0.0000024074632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98902524,0.0032341443,0.006387118,0.00027357353,0.00089317886,0.0001867734],"domain_scores_gemma":[0.9892393,0.002877232,0.0064693163,0.0002139949,0.0010968503,0.00010332828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010796263,0.00016095831,0.0023764877,0.00014333602,0.000018707919,0.0000042160395,0.00018072437,0.00030105084,0.000009147807],"category_scores_gemma":[0.0033262507,0.00011645856,0.0005320096,0.00025650012,0.00043265402,0.00008736808,0.000102056416,0.00076470076,6.6009875e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034515955,0.0163815,0.93060327,0.00028539865,0.00023366281,0.0000017167803,0.0010513527,0.0004646509,0.00008647175,0.000007448524,0.000038984526,0.01632961],"study_design_scores_gemma":[0.12524785,0.0043775183,0.86407965,0.0011794937,0.00047567568,8.2699904e-7,0.00025369256,0.0041694283,0.00008799103,0.000038887476,0.000009448441,0.00007953993],"about_ca_topic_score_codex":0.0028069103,"about_ca_topic_score_gemma":0.006376526,"teacher_disagreement_score":0.09073189,"about_ca_system_score_codex":0.0003851321,"about_ca_system_score_gemma":0.0025526676,"threshold_uncertainty_score":0.4749042},"labels":[],"label_agreement":null},{"id":"W2599757594","doi":"10.1200/jco.2014.32.15_suppl.3561","title":"Impact of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oxaliplatin; Capecitabine; Internal medicine; Colorectal cancer; Stage (stratigraphy); Chemotherapy; Oncology; Proportional hazards model; Cancer; Gastroenterology; Population; Surgery","score_opus":0.1278696055926564,"score_gpt":0.533839260970177,"score_spread":0.4059696553775206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599757594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543804,0.00022460935,0.00028353676,0.0021531659,0.0005552127,0.0004567,0.000017957822,0.0000055865025,0.00086518115],"genre_scores_gemma":[0.99585545,0.00020713836,0.0022476346,0.001031352,0.0004694375,0.00002161047,0.0000032305556,0.000020449039,0.00014370725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682534,0.00029166695,0.0021629785,0.00017856441,0.00028334136,0.00025813203],"domain_scores_gemma":[0.99281746,0.0044313166,0.0018574721,0.000163151,0.00041919615,0.00031141008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002585379,0.00015349458,0.002143772,0.00013761403,0.000016075013,0.0000028630182,0.00013121069,0.00034215645,0.00039250596],"category_scores_gemma":[0.0020682528,0.000100006546,0.00090117636,0.00017752174,0.00014997151,0.000045142464,0.000015202887,0.0004989621,0.0000015007429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05801208,0.0030377991,0.75492793,0.000057007623,0.00051227305,0.00012714596,0.00006779632,0.0008547796,0.0007862874,0.000025956626,0.000995926,0.18059501],"study_design_scores_gemma":[0.052998256,0.06089504,0.8641222,0.00017939245,0.00020320319,0.000026294367,0.0000121629055,0.003114577,0.0004500107,0.0001128021,0.017788926,0.00009714067],"about_ca_topic_score_codex":0.0002918424,"about_ca_topic_score_gemma":0.00043704014,"teacher_disagreement_score":0.18049787,"about_ca_system_score_codex":0.0006123751,"about_ca_system_score_gemma":0.00243595,"threshold_uncertainty_score":0.4321271},"labels":[],"label_agreement":null},{"id":"W2599783394","doi":"10.1200/jco.2017.35.5_suppl.5","title":"Reducing the burden of patient reporting of physical function in the chronic care of cancer survivors through a branching logic electronic symptom survey (BLESS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Physical therapy; Head and neck cancer; Cancer; Quality of life (healthcare); Internal medicine","score_opus":0.10247459831065611,"score_gpt":0.46579153812033813,"score_spread":0.36331693980968205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599783394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918348,0.0040142867,0.000041240528,0.0018869383,0.0011915423,0.0002527026,0.0000059775903,0.000002360776,0.00077013345],"genre_scores_gemma":[0.99775815,0.0007997341,0.000016064821,0.0001429423,0.0012490818,0.0000070641513,0.000002695316,0.000013824112,0.000010458636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99400693,0.0011729357,0.0037639106,0.0001994687,0.0005763488,0.00028039527],"domain_scores_gemma":[0.9834927,0.0027249902,0.012342138,0.00055415346,0.0008314256,0.000054595064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075331135,0.00014180684,0.0016766977,0.000058407863,0.00009320141,0.0000088808,0.00040917675,0.00021777659,0.000021425181],"category_scores_gemma":[0.006654837,0.00007539657,0.0006202082,0.00017136273,0.0003883802,0.000113993265,0.00008639974,0.001256283,2.4570627e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005796393,0.0010248775,0.6857911,0.00063053763,0.0008576047,0.000083083,0.034321632,0.004719298,0.0026398464,0.00051015825,0.00015140162,0.2634741],"study_design_scores_gemma":[0.0035897626,0.015310836,0.9624063,0.0012673013,0.00074631715,0.000068761954,0.011129792,0.00033616833,0.0013591078,0.00077780907,0.0028656006,0.0001422757],"about_ca_topic_score_codex":0.03665452,"about_ca_topic_score_gemma":0.044971645,"teacher_disagreement_score":0.2766152,"about_ca_system_score_codex":0.00029171797,"about_ca_system_score_gemma":0.0027329947,"threshold_uncertainty_score":0.97245514},"labels":[],"label_agreement":null},{"id":"W2599784226","doi":"10.1200/jco.2013.31.15_suppl.9551","title":"Comparing elderly and non-elderly adult cancer survivors: Differences in modifiable behaviours of smoking and alcohol cessation and physical activity.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Centre for Addiction and Mental Health; Public Health Ontario; Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Binge drinking; Survivorship curve; Logistic regression; Smoking cessation; Quality of life (healthcare); Head and neck cancer; Gerontology; Internal medicine; Environmental health; Poison control","score_opus":0.12171869284462905,"score_gpt":0.42552712045866614,"score_spread":0.3038084276140371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599784226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973354,0.00037281265,0.000039917675,0.0014716781,0.0003583989,0.00016482503,0.000002478706,0.0000031493712,0.00025139094],"genre_scores_gemma":[0.9987271,0.0007903799,0.00007408354,0.00009383676,0.00027072942,0.00000853728,5.6565653e-7,0.0000083716795,0.00002642393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985383,0.00017616682,0.0007063566,0.00017809289,0.00023686966,0.00016419953],"domain_scores_gemma":[0.9978021,0.00091859425,0.00072238065,0.00007988021,0.0002747459,0.00020232609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006637971,0.00011752417,0.0011762866,0.000109308276,0.000028130733,0.000019981248,0.000060050086,0.00021304071,0.000015055726],"category_scores_gemma":[0.00024020915,0.00008830447,0.000085903404,0.000094708346,0.00023734316,0.00024236398,0.000044662163,0.0006398483,1.3927358e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040284873,0.00036614586,0.8382272,0.00006484249,0.00006195755,0.000013274077,0.0009147715,0.000004341295,0.00035913193,0.000016188755,0.00003252232,0.15953673],"study_design_scores_gemma":[0.0036743334,0.0035848394,0.98866147,0.0003373193,0.00019796628,0.000032568318,0.0009892392,0.002020462,0.00016129216,0.00023225181,0.000023501456,0.000084739346],"about_ca_topic_score_codex":0.02302659,"about_ca_topic_score_gemma":0.011276543,"teacher_disagreement_score":0.15945199,"about_ca_system_score_codex":0.00004596206,"about_ca_system_score_gemma":0.00020678168,"threshold_uncertainty_score":0.98347914},"labels":[],"label_agreement":null},{"id":"W2599786871","doi":"10.1200/jco.2012.30.15_suppl.9533","title":"Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children’s Oncology Group trials P9641 and A3961.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Medicine; Internal medicine; Univariate analysis; Stage (stratigraphy); Oncology; Loss of heterozygosity; Proportional hazards model; Neuroblastoma; Histology; Population; Clinical endpoint; Clinical trial; Allele; Multivariate analysis; Biology; Genetics; Gene","score_opus":0.12914847006534208,"score_gpt":0.5053090221149062,"score_spread":0.37616055204956417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599786871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968403,0.00008770765,0.00006497086,0.0009103944,0.001016111,0.0005811182,0.00005230823,0.000007977772,0.0004391032],"genre_scores_gemma":[0.9964617,0.0005313753,0.0010654205,0.0010523575,0.00076471514,0.000008553971,0.000015744074,0.000026125563,0.00007401298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9900522,0.0036864239,0.0046825544,0.000302867,0.0007626758,0.0005132685],"domain_scores_gemma":[0.98206896,0.011519321,0.0045203553,0.00033713886,0.0004260801,0.0011281237],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008605798,0.00026954256,0.0051822257,0.000928544,0.00006641962,0.0000082238885,0.00020315927,0.000494301,0.00019206312],"category_scores_gemma":[0.017940935,0.0001687756,0.0014993313,0.0005047955,0.00030053125,0.00015085019,0.00012166262,0.0013983255,0.000026464684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013566171,0.01263754,0.8457623,0.000011333705,0.006815702,0.00017224671,0.00006240707,0.000013650456,0.00009819755,0.00001963419,0.0007165154,0.12012429],"study_design_scores_gemma":[0.03472444,0.06798163,0.8890543,0.000024150933,0.0070272763,0.00006732543,0.000013299433,0.000043683358,0.0001273749,0.000025930582,0.0008172721,0.00009333045],"about_ca_topic_score_codex":0.00006079758,"about_ca_topic_score_gemma":0.000037897345,"teacher_disagreement_score":0.120030954,"about_ca_system_score_codex":0.00017680808,"about_ca_system_score_gemma":0.0003960992,"threshold_uncertainty_score":0.99033135},"labels":[],"label_agreement":null},{"id":"W2599804073","doi":"10.1200/jco.2017.35.5_suppl.169","title":"Implementation of an exercise behavior change clinic for men with prostate cancer: Baseline results.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Overweight; Physical therapy; Prostate cancer; Survivorship curve; Waist; Cancer; Body mass index; Family medicine; Internal medicine","score_opus":0.22428754427270375,"score_gpt":0.556916882548345,"score_spread":0.3326293382756413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599804073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824686,0.00036736066,0.00004293223,0.008007737,0.001306492,0.0013298957,0.00020965996,0.000006491131,0.0004825763],"genre_scores_gemma":[0.99274075,0.0024846534,0.0016587806,0.0006074995,0.0018311952,0.00020891552,0.000028325834,0.000022039554,0.00041786412],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971216,0.00015294067,0.0020466812,0.00019328402,0.00029479945,0.00019070326],"domain_scores_gemma":[0.9939627,0.0004930334,0.0038891835,0.00036276208,0.00099426,0.00029802675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046964595,0.00011306596,0.0011791941,0.00007315709,0.00007554912,0.000011892227,0.00020760369,0.00019222498,0.00012330928],"category_scores_gemma":[0.0006276115,0.000076095756,0.00028886937,0.000040010076,0.00018121816,0.00024798792,0.000032553315,0.00036244513,0.0000012267799],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036569703,0.00077559345,0.16230758,0.00007668716,0.000116849405,0.00010772074,0.0006346258,4.5873284e-7,0.00004864003,0.0000038080943,0.002289221,0.79706913],"study_design_scores_gemma":[0.030649442,0.03730981,0.8725505,0.00034371778,0.0018382762,0.00005168281,0.0021539233,0.000043677323,0.00078894035,0.0000464367,0.054094546,0.00012903122],"about_ca_topic_score_codex":0.0016929818,"about_ca_topic_score_gemma":0.010317841,"teacher_disagreement_score":0.7969401,"about_ca_system_score_codex":0.000081095524,"about_ca_system_score_gemma":0.0013779401,"threshold_uncertainty_score":0.5757597},"labels":[],"label_agreement":null},{"id":"W2599844614","doi":"10.1200/jco.2017.35.4_suppl.373","title":"Adjuvant therapy (AT) following resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Pancreatic cancer; Logistic regression; Internal medicine; Pancreatectomy; Proportional hazards model; Residence; Rural area; Socioeconomic status; Disadvantaged; Univariate analysis; Multivariate analysis; Cancer; Oncology; Demography; Pancreas; Population; Environmental health; Pathology","score_opus":0.14132658462421227,"score_gpt":0.48680562998621807,"score_spread":0.3454790453620058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599844614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091804,0.0018665186,0.000061839746,0.0027188708,0.001850355,0.00041366168,0.000016349068,0.000008800061,0.0021455875],"genre_scores_gemma":[0.99170256,0.0038468821,0.002126151,0.00034674062,0.0013408622,0.0000032536843,0.000014621854,0.000029855839,0.0005890603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949548,0.0008219751,0.0026982438,0.00028360306,0.00084755215,0.00039382852],"domain_scores_gemma":[0.9906173,0.0030739522,0.0043599186,0.0007258583,0.00068758073,0.0005354333],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030427848,0.00022477476,0.0030210172,0.0001578283,0.00029415506,0.000018060413,0.00048029347,0.0005916443,0.00030552497],"category_scores_gemma":[0.013257123,0.00015358203,0.0009429856,0.00007466642,0.0005930319,0.00025272393,0.00019176635,0.0012151923,0.000031736476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015211997,0.0013726437,0.95223176,0.000028134755,0.0013089175,0.0010413753,0.00016803188,4.243242e-7,0.00088637305,0.0000058174355,0.001529889,0.026214616],"study_design_scores_gemma":[0.020087933,0.017047158,0.95830876,0.0004935954,0.00091668544,0.00014427153,0.00035497537,0.000100205965,0.00022219021,0.00075234624,0.0014476224,0.00012427074],"about_ca_topic_score_codex":0.00041505124,"about_ca_topic_score_gemma":0.00016773418,"teacher_disagreement_score":0.026090344,"about_ca_system_score_codex":0.00035185335,"about_ca_system_score_gemma":0.0010536835,"threshold_uncertainty_score":0.9950546},"labels":[],"label_agreement":null},{"id":"W2599893246","doi":"10.1200/jco.2017.35.6_suppl.436","title":"A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Oncology; Cancer; Biomarker; Clinical trial","score_opus":0.14825006570547877,"score_gpt":0.45561138248292093,"score_spread":0.30736131677744216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599893246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312913,0.00028924085,0.0000123369155,0.0017996308,0.00097147113,0.0006886857,0.000018024595,0.0000047035414,0.0030867641],"genre_scores_gemma":[0.9963924,0.00012367043,0.0024465153,0.00039026162,0.0004976198,0.000013206783,0.000008709014,0.000026212445,0.00010138013],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957071,0.00038347061,0.002684342,0.00027409886,0.0006287294,0.00032224832],"domain_scores_gemma":[0.99256635,0.0010880708,0.004752299,0.00050159934,0.00066578476,0.0004259165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016626434,0.00022321728,0.0019905227,0.00019764985,0.00008342808,0.000009165954,0.00027465547,0.00033591426,0.00015953132],"category_scores_gemma":[0.002084764,0.00014315391,0.00050332426,0.000090410875,0.0004029895,0.00013894429,0.000070371076,0.0006684236,0.0000021624985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5365107,0.051577047,0.11948546,0.00007352687,0.00031518308,0.0010880078,0.000050387167,0.000021208458,0.0017410559,0.000002753534,0.00044792844,0.28868675],"study_design_scores_gemma":[0.42087132,0.2802578,0.28732306,0.00040213796,0.0005113977,0.000013150432,0.000018017992,0.00003117981,0.003684981,0.00002745432,0.006731369,0.00012815715],"about_ca_topic_score_codex":0.00005340174,"about_ca_topic_score_gemma":0.000070457274,"teacher_disagreement_score":0.2885586,"about_ca_system_score_codex":0.00037006912,"about_ca_system_score_gemma":0.0024420489,"threshold_uncertainty_score":0.58376473},"labels":[],"label_agreement":null},{"id":"W2599896351","doi":"10.1200/jco.2013.31.15_suppl.4583","title":"Contrasting vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US in renal cell carcinoma (RCC) patients (pts).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Nuclear medicine; Renal cell carcinoma; Perfusion; Magnetic resonance imaging; Radiology; Urology; Internal medicine","score_opus":0.07114056189426408,"score_gpt":0.40173378586331504,"score_spread":0.33059322396905094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599896351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788531,0.00073464046,0.000056874593,0.016964454,0.0009270699,0.00076030317,0.000011256204,0.000012150035,0.0016801503],"genre_scores_gemma":[0.98728806,0.00062114466,0.003086957,0.007993349,0.0006711581,0.000038555314,0.000004543889,0.00004441933,0.00025181484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930957,0.0019368419,0.003152483,0.000429725,0.0008192646,0.0005659665],"domain_scores_gemma":[0.988048,0.0078519145,0.0014781958,0.00035429496,0.0010590941,0.0012085004],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071609267,0.00028060627,0.0019549278,0.00032355182,0.00006369699,0.000030915686,0.00028668885,0.00040330805,0.000572026],"category_scores_gemma":[0.012592944,0.00023018257,0.0003868752,0.00029031417,0.00022425626,0.00019187025,0.00012450988,0.0015833233,0.000088215966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009879838,0.0023328417,0.85289264,0.000060199556,0.00016630544,0.00085960294,0.0002978693,0.000034404617,0.0022553427,0.0000031694692,0.08928559,0.04193222],"study_design_scores_gemma":[0.022295043,0.018323079,0.82571054,0.00029818487,0.0002979221,0.00017469763,0.00018315956,0.00006267964,0.0009248857,0.000080032245,0.13141946,0.00023033796],"about_ca_topic_score_codex":0.00049769424,"about_ca_topic_score_gemma":0.00016004418,"teacher_disagreement_score":0.04213387,"about_ca_system_score_codex":0.00050458097,"about_ca_system_score_gemma":0.0014971799,"threshold_uncertainty_score":0.9957244},"labels":[],"label_agreement":null},{"id":"W2599909104","doi":"10.1200/jco.2017.35.6_suppl.158","title":"Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Asymptomatic; Internal medicine; Prostate cancer; Adverse effect; Clinical endpoint; Surgery; Gastroenterology; Cancer; Clinical trial","score_opus":0.2218471606640261,"score_gpt":0.57124287542136,"score_spread":0.3493957147573339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599909104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930045,0.00017324204,0.0000011494386,0.0038132276,0.0008288984,0.0010807973,0.000024273539,0.000010936276,0.0010629992],"genre_scores_gemma":[0.99747294,0.00086091977,0.000652063,0.0001769271,0.00030051643,0.00011348385,0.000030796025,0.000022428567,0.0003699342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601984,0.00045423093,0.0021964225,0.00029221707,0.0006433177,0.00039396694],"domain_scores_gemma":[0.9963657,0.00045228036,0.001785423,0.00030187485,0.00069111236,0.00040359242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019065961,0.00019166633,0.0011594964,0.00034407538,0.00008585232,0.0001597033,0.0005602537,0.00019834183,0.00013592222],"category_scores_gemma":[0.0016525221,0.00012966388,0.00021219296,0.00016577194,0.00029322112,0.0010216942,0.000092172406,0.0008690256,0.000008009014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069505945,0.0066012614,0.80311227,0.000042442,0.00027366754,0.0011843176,0.00024075713,0.000012177145,0.0000482832,0.000009986782,0.0001156329,0.1814086],"study_design_scores_gemma":[0.030885184,0.009981447,0.95642203,0.0003367116,0.0001503914,0.000018193921,0.000049806655,0.00044271923,0.00008580728,0.00018247367,0.0013328339,0.00011242356],"about_ca_topic_score_codex":0.001133502,"about_ca_topic_score_gemma":0.004165318,"teacher_disagreement_score":0.18129617,"about_ca_system_score_codex":0.0006841229,"about_ca_system_score_gemma":0.0016786188,"threshold_uncertainty_score":0.52875394},"labels":[],"label_agreement":null},{"id":"W2599912442","doi":"10.1200/jco.2012.30.15_suppl.1583","title":"Factors associated with referral to medical oncology (MO) and subsequent use of adjuvant chemotherapy (ACT) among patients with resected non-small cell lung cancer (NSCLC): A population-based study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Referral; Cancer registry; Lung cancer; Population; Internal medicine; Stage (stratigraphy); Cancer; Comorbidity; Logistic regression; Multivariate analysis; Surgery; Family medicine; Environmental health","score_opus":0.1252188058244334,"score_gpt":0.419122485886459,"score_spread":0.2939036800620256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599912442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976226,0.000091883296,0.000059997532,0.00078488805,0.00045386437,0.0008498521,0.000018168843,0.000009715446,0.00010903128],"genre_scores_gemma":[0.99636286,0.00004251839,0.00055585854,0.0026531199,0.0002519724,0.000015381405,0.00003073714,0.00003774468,0.000049790462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958195,0.0006770081,0.0020355298,0.00026093467,0.0007921771,0.00041481925],"domain_scores_gemma":[0.9931774,0.0025220914,0.0021668873,0.00018812151,0.0007488051,0.0011966615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020206922,0.00024754152,0.001928111,0.00021346885,0.000047421374,0.000008131574,0.00015535772,0.0005123247,0.00046075694],"category_scores_gemma":[0.0023626122,0.00014763177,0.00018081733,0.00024343796,0.00017239308,0.00020255847,0.000038799706,0.0011007215,2.9461657e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011704543,0.004567444,0.9723417,0.00003691086,0.00074201805,0.00005729823,0.0008326507,0.000062324485,0.00003560153,4.0274693e-7,0.0005372109,0.009081889],"study_design_scores_gemma":[0.026291117,0.023823382,0.947659,0.00027981156,0.000576528,0.0000034627192,0.00017133179,0.00023825372,0.0000638264,3.4377254e-7,0.0007349823,0.0001579351],"about_ca_topic_score_codex":0.0007431437,"about_ca_topic_score_gemma":0.0034769862,"teacher_disagreement_score":0.024682682,"about_ca_system_score_codex":0.0008099903,"about_ca_system_score_gemma":0.0039248154,"threshold_uncertainty_score":0.6962454},"labels":[],"label_agreement":null},{"id":"W2599933157","doi":"10.1200/jco.2012.30.15_suppl.4105","title":"Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; Sorafenib; XIAP; Hepatocellular carcinoma; Clinical endpoint; Internal medicine; Combination therapy; Gastroenterology; Oncology; Apoptosis; Surgery; Randomized controlled trial; Urology; Caspase; Programmed cell death","score_opus":0.038020035446615766,"score_gpt":0.3482368006178546,"score_spread":0.31021676517123886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599933157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824625,0.00017369584,0.00003668711,0.00011301044,0.00028553308,0.0010679492,0.0000054603306,0.0000011173937,0.00007029273],"genre_scores_gemma":[0.9992896,0.000042143736,0.000447338,0.00006792684,0.000101913545,0.000017257998,0.0000064164938,0.0000148441495,0.000012558584],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99610054,0.0014104557,0.0018128734,0.00016256575,0.00030644384,0.0002071046],"domain_scores_gemma":[0.9967883,0.00032504485,0.002146375,0.00023223646,0.00040330764,0.00010469003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030172449,0.00015025312,0.0012803893,0.00010281603,0.000029602454,0.0000023918114,0.00020272697,0.00024172361,0.000007606151],"category_scores_gemma":[0.0010992939,0.00008661511,0.00020028095,0.0001891061,0.00024088011,0.000018299444,0.00009310735,0.00039537574,2.3918045e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20928636,0.020030864,0.7452217,0.00002928625,0.00017309078,0.0000058418755,0.00060780975,0.00003646127,0.018877406,0.000015109549,0.000019872932,0.0056962203],"study_design_scores_gemma":[0.6625048,0.056585677,0.16647501,0.0001267579,0.00020155958,0.0000073268307,0.00042519366,0.000057790665,0.11317451,0.0000322225,0.00023270774,0.00017645911],"about_ca_topic_score_codex":0.0000208256,"about_ca_topic_score_gemma":0.000036179572,"teacher_disagreement_score":0.5787467,"about_ca_system_score_codex":0.000028564185,"about_ca_system_score_gemma":0.0003193642,"threshold_uncertainty_score":0.35320616},"labels":[],"label_agreement":null},{"id":"W2599942611","doi":"10.1200/jco.2014.32.15_suppl.3529","title":"A comparison of survival by site of metastatic resection (MR) in metastatic colorectal cancer (mCRC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Proportional hazards model; Internal medicine; Oncology; Metastasis; Gastroenterology; Cancer","score_opus":0.17132168048260266,"score_gpt":0.527812375025674,"score_spread":0.35649069454307136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599942611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937469,0.0020473492,0.00011244278,0.0013688817,0.0008898302,0.00021473475,0.00001839154,0.000003003714,0.0015985066],"genre_scores_gemma":[0.9977951,0.0007411009,0.0010598304,0.00012126794,0.00015698928,0.000010513276,0.0000034064187,0.000011242625,0.000100517034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957277,0.00076202117,0.0027332813,0.00015776581,0.00042873944,0.0001904514],"domain_scores_gemma":[0.9938491,0.0031760016,0.0022532186,0.000098663884,0.00047355218,0.0001494842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029004284,0.00013745105,0.0028357066,0.00016758018,0.000022384012,0.0000025033235,0.00008307522,0.000108340464,0.00011944413],"category_scores_gemma":[0.0028343785,0.00009348752,0.00037947847,0.00025817804,0.00026425306,0.00006238525,0.000040619267,0.00053259986,0.0000018372904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019441733,0.005405842,0.88103104,0.00020731705,0.0016984897,0.00006377668,0.0009505758,0.00013774335,0.0045752362,0.00006739467,0.0033025977,0.08311825],"study_design_scores_gemma":[0.021744631,0.06828176,0.8827214,0.0003453626,0.0021254322,0.000060251154,0.0010972694,0.001468947,0.0046304204,0.0003378537,0.017024843,0.00016182811],"about_ca_topic_score_codex":0.00057165464,"about_ca_topic_score_gemma":0.004066965,"teacher_disagreement_score":0.082956426,"about_ca_system_score_codex":0.00019515169,"about_ca_system_score_gemma":0.00063839724,"threshold_uncertainty_score":0.38123104},"labels":[],"label_agreement":null},{"id":"W2599952659","doi":"10.1200/jco.2017.35.4_suppl.332","title":"A preclinical trial to evaluate therapies for <i>BRCA</i>-associated pancreatic cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research; McGill University Health Centre; McGill University","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; PARP inhibitor; Pancreatic cancer; BRCA mutation; Internal medicine; Oncology; Cancer research; Combination therapy; Olaparib; Chemotherapy; Cancer; Pharmacology; Poly ADP ribose polymerase; Breast cancer; Polymerase; Biology; DNA","score_opus":0.2565038096556995,"score_gpt":0.5824217293881295,"score_spread":0.32591791973243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599952659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883799,0.0010243448,0.00014987726,0.007178594,0.0018264524,0.00068788364,0.000043191907,0.000002948437,0.0007068223],"genre_scores_gemma":[0.9915216,0.0021336263,0.0010628045,0.0013163915,0.0029418014,0.00012169105,0.000008329058,0.000020466485,0.00087328866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737585,0.00044014966,0.001319986,0.00026318626,0.00028028782,0.0003205647],"domain_scores_gemma":[0.99627537,0.0007559181,0.0015939153,0.00039048947,0.0005896289,0.00039469588],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004165587,0.0001356644,0.00089938816,0.00003504794,0.00018220709,0.000049308317,0.0005561129,0.00036421217,0.000044401288],"category_scores_gemma":[0.018262532,0.000096599666,0.0006626926,0.000025605837,0.00018990505,0.000009996563,0.00013529688,0.00029325087,0.0000069791154],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4066118,0.00393259,0.05816515,0.000022681135,0.004842273,0.00007258004,0.000079628175,0.0000297793,0.005288007,0.000038403883,0.055958595,0.46495852],"study_design_scores_gemma":[0.24968341,0.12105981,0.13328318,0.000118309974,0.0007614407,0.000020701855,0.000041229006,0.00005249741,0.0025621841,0.001526249,0.49055734,0.0003336381],"about_ca_topic_score_codex":0.00013574385,"about_ca_topic_score_gemma":0.0012742527,"teacher_disagreement_score":0.46462488,"about_ca_system_score_codex":0.00007927743,"about_ca_system_score_gemma":0.0020452759,"threshold_uncertainty_score":0.99000704},"labels":[],"label_agreement":null},{"id":"W2599973137","doi":"10.1200/jco.2004.22.90140.5572","title":"Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Feeding tube; Regimen; Radiation therapy; Chemoradiotherapy; Surgery; Weight change; Internal medicine; Head and neck cancer; Weight loss; Adverse effect","score_opus":0.05051975656579242,"score_gpt":0.42152142878661497,"score_spread":0.37100167222082253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599973137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108774,0.0005245418,0.000019606512,0.015854277,0.00058948464,0.0002736506,0.000010569049,0.0000028408977,0.0016372808],"genre_scores_gemma":[0.99592096,0.00068765524,0.0008854136,0.0021851026,0.0002753581,0.000012758292,6.6344643e-7,0.000008528864,0.000023564997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974968,0.00019822932,0.0015178253,0.00016278228,0.0004107655,0.00021363096],"domain_scores_gemma":[0.99748135,0.00078302785,0.0009174124,0.00015099558,0.0004941122,0.0001731259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007777353,0.00011197404,0.001217125,0.000060946928,0.000026096865,0.0000016822596,0.000119235905,0.00014546873,0.000038138358],"category_scores_gemma":[0.001150231,0.000059318547,0.00024009444,0.0001670292,0.0003242285,0.00006520651,0.000042297444,0.00085468125,0.0000010952496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043185532,0.008158041,0.8121131,0.00008004677,0.00028101564,0.00013104215,0.00044222796,0.0002986396,0.0000854253,0.000336602,0.0006570986,0.13423122],"study_design_scores_gemma":[0.030102544,0.031182474,0.93099827,0.0010917266,0.000078713696,0.000017772145,0.00009717338,0.0000035140154,0.00023646627,0.0011973386,0.004930154,0.00006386824],"about_ca_topic_score_codex":0.00011131206,"about_ca_topic_score_gemma":0.0010591208,"teacher_disagreement_score":0.13416734,"about_ca_system_score_codex":0.00056153187,"about_ca_system_score_gemma":0.0022671516,"threshold_uncertainty_score":0.40218294},"labels":[],"label_agreement":null},{"id":"W2599979212","doi":"10.1200/jco.2012.30.15_suppl.e14003","title":"Serious adverse events among a population-based cohort of patients receiving first-line chemotherapy for metastatic colorectal cancer (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Emergency department; Colorectal cancer; Chemotherapy; Cohort; Population; Cancer; Internal medicine; Bevacizumab; Emergency medicine","score_opus":0.06015244145068638,"score_gpt":0.434245575171116,"score_spread":0.3740931337204296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599979212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609,0.00036685896,0.000117081334,0.0009928053,0.0014218618,0.0008328504,0.00003157409,0.000006630907,0.0001403566],"genre_scores_gemma":[0.99594015,0.00042983607,0.0023947165,0.0005479369,0.000506401,0.000067955494,0.000017736224,0.000022574384,0.00007271614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732447,0.00014744453,0.0017815835,0.00014258623,0.00033613289,0.00026778918],"domain_scores_gemma":[0.9953974,0.0016641166,0.0019709151,0.00009504412,0.00061701366,0.00025550456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013801006,0.00016289827,0.001540714,0.00009755173,0.00006473763,0.0000013168225,0.00007906788,0.00016475495,0.00014460934],"category_scores_gemma":[0.001917155,0.00011245157,0.00056595623,0.00012672399,0.00009093204,0.00011743108,0.000019733023,0.00027523586,0.0000010316654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008336703,0.002814326,0.9416677,0.00007253979,0.0012259512,0.0000062314316,0.00014611483,0.00010336994,0.0000068544073,0.0000018886163,0.00030590262,0.045312423],"study_design_scores_gemma":[0.015119232,0.0095835,0.9705532,0.00013531097,0.0010776917,0.0000046635373,0.00003846111,0.0002148058,0.000068385874,0.000033125452,0.0030806272,0.0000909553],"about_ca_topic_score_codex":0.00021075377,"about_ca_topic_score_gemma":0.0008074835,"teacher_disagreement_score":0.045221467,"about_ca_system_score_codex":0.0004135924,"about_ca_system_score_gemma":0.00050517864,"threshold_uncertainty_score":0.4585642},"labels":[],"label_agreement":null},{"id":"W2599986538","doi":"10.1200/jco.2013.31.15_suppl.2523","title":"A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Afatinib; Internal medicine; Maximum tolerated dose; Gastroenterology; Pharmacology; Urology; Nuclear medicine; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.04642476607821685,"score_gpt":0.45680400366740986,"score_spread":0.41037923758919304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599986538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972144,0.00004894658,0.0001334598,0.000961449,0.00015172514,0.0009485597,0.000006383664,0.000004812247,0.00053029193],"genre_scores_gemma":[0.9962892,0.00004761991,0.003161721,0.00022177788,0.00012506115,0.000028382283,0.000026906133,0.000012153221,0.00008717311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971249,0.00022672852,0.0019063804,0.00019510179,0.00036588454,0.00018100112],"domain_scores_gemma":[0.99601775,0.0007319836,0.0021037296,0.00015103033,0.0007485726,0.00024695808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069549633,0.0001482856,0.0018249925,0.000304501,0.000025819834,0.000009409887,0.00006510372,0.00013576225,0.00009049457],"category_scores_gemma":[0.00082619936,0.00008702495,0.00019548464,0.00044920974,0.00018008058,0.00020855988,0.000015187608,0.00037113501,0.0000015425908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3240968,0.021535708,0.41126487,0.000031116124,0.0023845364,0.00014100659,0.0003060272,0.00017484082,0.00005268886,0.00001562717,0.00013454481,0.23986225],"study_design_scores_gemma":[0.32974175,0.12874092,0.5388779,0.000096620046,0.0018537156,0.0000098184,0.000117513104,0.0003453063,0.000015582415,0.00003713746,0.00010109286,0.00006265477],"about_ca_topic_score_codex":0.00006146733,"about_ca_topic_score_gemma":0.00012226944,"teacher_disagreement_score":0.2397996,"about_ca_system_score_codex":0.00011360001,"about_ca_system_score_gemma":0.00077715743,"threshold_uncertainty_score":0.35487744},"labels":[],"label_agreement":null},{"id":"W2600008150","doi":"10.1200/jco.2012.30.15_suppl.8020","title":"A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Thalidomide; Multiple myeloma; Refractory (planetary science); Bortezomib; Internal medicine; Phases of clinical research; Progressive disease; Gastroenterology; Toxicity; Urology; Surgery; Chemotherapy","score_opus":0.08419696088202684,"score_gpt":0.44069445114764233,"score_spread":0.3564974902656155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600008150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742043,0.0004075282,0.000032266977,0.00020188978,0.00013784942,0.0016084394,0.0000048725356,0.0000057427937,0.00018095609],"genre_scores_gemma":[0.9963444,0.00015791557,0.0030957437,0.00011685094,0.0001646324,0.000028794253,0.000005421538,0.000027691882,0.00005858299],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946296,0.0016184247,0.0023218195,0.00022972078,0.000772399,0.00042799543],"domain_scores_gemma":[0.9903924,0.006139893,0.0018906515,0.00026556008,0.0005553287,0.0007561807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00518457,0.00023136473,0.0030496267,0.00032608391,0.0000534883,0.0000055171176,0.00011896991,0.00022494403,0.00005397059],"category_scores_gemma":[0.007682673,0.00012252739,0.00021100741,0.00022235718,0.00045489313,0.00027646637,0.000081360755,0.0010202593,0.0000027239287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46558276,0.037875067,0.4605108,0.00002451745,0.0009501607,0.00026316365,0.00048482735,0.000003244618,0.00002192962,0.0000018654459,0.000020902835,0.034260765],"study_design_scores_gemma":[0.5067334,0.06883399,0.4233057,0.00013202174,0.00041701246,0.00004129393,0.00025411544,0.00004228735,0.000024035842,0.0000039471674,0.00014630007,0.000065908105],"about_ca_topic_score_codex":0.00010860571,"about_ca_topic_score_gemma":0.00015259761,"teacher_disagreement_score":0.041150633,"about_ca_system_score_codex":0.00016858353,"about_ca_system_score_gemma":0.0008170378,"threshold_uncertainty_score":0.91974324},"labels":[],"label_agreement":null},{"id":"W2600014321","doi":"10.1200/jco.2013.31.15_suppl.5009","title":"Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Abiraterone acetate; Tolerability; Prostate cancer; Internal medicine; Interim analysis; Post-hoc analysis; Urology; Placebo; Adverse effect; Prednisone; Chemotherapy; Incidence (geometry); Oncology; Gastroenterology; Cancer; Randomized controlled trial; Androgen deprivation therapy; Pathology","score_opus":0.10376297802675932,"score_gpt":0.47752228994048673,"score_spread":0.3737593119137274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600014321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072057,0.002386888,0.00007402251,0.0054212576,0.00016434677,0.0010841623,0.000025178839,0.0000069395032,0.00011665593],"genre_scores_gemma":[0.98779726,0.009174454,0.0015403511,0.00039317357,0.0001354502,0.000034054487,0.0000134233005,0.00002562958,0.0008862028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561507,0.00045075864,0.0027157709,0.00031448036,0.00051819655,0.00038571545],"domain_scores_gemma":[0.9961062,0.0009283654,0.0016685718,0.0002423504,0.00063853693,0.00041594138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020706914,0.00022671213,0.0025210534,0.0004387017,0.000047551137,0.000026435917,0.00015048197,0.00019503891,0.0004997417],"category_scores_gemma":[0.0004357213,0.00014509277,0.0003712228,0.000566972,0.0004494836,0.00022197813,0.00004416507,0.0006777059,0.0000051042143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044026095,0.0027635116,0.7353498,0.00029060582,0.00845145,0.0005886298,0.0016038987,0.00048338843,0.007279605,0.000009706508,0.00014834882,0.19900498],"study_design_scores_gemma":[0.033181045,0.0057563744,0.95630425,0.00023001217,0.0022886493,0.00003733805,0.00013162757,0.0010660792,0.0005419334,0.00003150963,0.00030709693,0.00012411177],"about_ca_topic_score_codex":0.00035726535,"about_ca_topic_score_gemma":0.0010423909,"teacher_disagreement_score":0.22095445,"about_ca_system_score_codex":0.00039925397,"about_ca_system_score_gemma":0.0021015154,"threshold_uncertainty_score":0.59167117},"labels":[],"label_agreement":null},{"id":"W2600015683","doi":"10.1200/jco.2013.31.15_suppl.e17020","title":"Significance of plasma osteopontin (OPN) as a biomarker in squamous cell carcinoma of tongue.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone and Dental Protein Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osteopontin; Medicine; Internal medicine; Urology; Radiation therapy; Biomarker; Cancer; Gastroenterology; Oncology","score_opus":0.08538399638549739,"score_gpt":0.41001980010325056,"score_spread":0.3246358037177532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600015683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975157,0.00090179464,0.0000075955436,0.0020484442,0.00047062492,0.0003640063,0.0000017909355,0.0000025899842,0.021046137],"genre_scores_gemma":[0.9973358,0.00010809877,0.0012072357,0.00041456093,0.00016011295,0.000007561651,4.2903312e-7,0.000011444164,0.0007547532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612767,0.00030376235,0.0028812601,0.00015081889,0.00033119108,0.00020528793],"domain_scores_gemma":[0.99512535,0.0020619188,0.0019657356,0.00017699637,0.0004781385,0.00019183413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017072306,0.00012372977,0.0017191633,0.00016091045,0.000012774339,0.0000024029982,0.00014502894,0.00031338178,0.00030691986],"category_scores_gemma":[0.0024670656,0.000087380795,0.00041116562,0.00018350189,0.00035946793,0.00008852995,0.000081089136,0.0005780931,0.000044010787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010495462,0.0067311474,0.82582235,0.00044554702,0.00021283644,0.0013688869,0.00062430464,0.000005816476,0.03930908,0.000073230236,0.019412829,0.095498495],"study_design_scores_gemma":[0.011342435,0.016360307,0.95660895,0.00010527931,0.00015806072,0.00020172163,0.00097081665,0.00007666862,0.009740181,0.0003504566,0.0039894106,0.00009571216],"about_ca_topic_score_codex":0.00072725175,"about_ca_topic_score_gemma":0.00013309086,"teacher_disagreement_score":0.1307866,"about_ca_system_score_codex":0.000056154277,"about_ca_system_score_gemma":0.0006509269,"threshold_uncertainty_score":0.35632855},"labels":[],"label_agreement":null},{"id":"W2600031158","doi":"10.1200/jco.2012.30.15_suppl.7007","title":"Prognostic and predictive effects of<i> KRAS</i> mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Hazard ratio; Colorectal cancer; Oncology; Internal medicine; Mutation; Cancer; Chemotherapy; Lung cancer; Cancer research; Genetics; Gene; Confidence interval; Biology","score_opus":0.05092843085666312,"score_gpt":0.45615974207965954,"score_spread":0.40523131122299644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600031158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375796,0.0027963382,0.0001690015,0.00050571485,0.00083789654,0.0011659582,0.0000064335377,0.000004862826,0.0007558597],"genre_scores_gemma":[0.99812996,0.00034440306,0.00070131477,0.00024088225,0.00045053643,0.000043487453,0.0000043610985,0.0000141064265,0.000070950635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781543,0.0004577581,0.001165605,0.00013659468,0.00021305002,0.00021156452],"domain_scores_gemma":[0.995286,0.0029996512,0.0009941785,0.00009462648,0.00037118146,0.0002543485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012090489,0.00011636602,0.00091328536,0.00014531854,0.00003190254,0.000004327938,0.000058943057,0.00017182411,0.000015378746],"category_scores_gemma":[0.0015584152,0.000082033264,0.00011663565,0.00019680834,0.00009621083,0.000109899906,0.000029953235,0.0005653848,0.0000014076322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002437732,0.004723178,0.9791923,0.0002136178,0.0005216302,0.00026728993,0.0030536696,0.00002368151,0.00032599168,0.000004123432,0.00043749818,0.0087993],"study_design_scores_gemma":[0.015217519,0.015411139,0.9654683,0.00033774745,0.002147411,0.000053937943,0.00049916893,0.0002322088,0.00019345192,0.000016556021,0.0003593458,0.000063237916],"about_ca_topic_score_codex":0.00015159344,"about_ca_topic_score_gemma":0.00018986507,"teacher_disagreement_score":0.013724011,"about_ca_system_score_codex":0.00020827547,"about_ca_system_score_gemma":0.0011754523,"threshold_uncertainty_score":0.33452195},"labels":[],"label_agreement":null},{"id":"W2600041910","doi":"10.1200/jco.2017.35.6_suppl.65","title":"A systematic review and meta-analysis to evaluate the influence of surgical method on specimen margins and biochemical recurrence after radical prostatectomy for high-risk prostate cancer.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostatectomy; Medicine; Biochemical recurrence; Prostate cancer; Meta-analysis; Open Prostatectomy; Systematic review; Urology; Cancer; MEDLINE; Internal medicine; Gynecology","score_opus":0.24627594489357774,"score_gpt":0.5635585275528668,"score_spread":0.3172825826592891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600041910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014110958,0.98326164,0.00001526601,0.00705498,0.000113244925,0.007571082,0.0005582944,0.0000035527307,0.000010828883],"genre_scores_gemma":[0.00058429065,0.99301314,0.0024931498,0.0008797993,0.00017404305,0.0027268222,0.00001135994,0.000032574397,0.00008483529],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98974204,0.0027254585,0.0058734748,0.0006706255,0.00064178696,0.0003466362],"domain_scores_gemma":[0.9784559,0.012452195,0.006867071,0.00077654445,0.0008353471,0.00061293645],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.013978093,0.000548141,0.019850092,0.00023555034,0.00007931597,0.000035040666,0.00038901911,0.0004487136,0.000055548993],"category_scores_gemma":[0.008819026,0.00023527976,0.0035471658,0.00033189723,0.00048663895,0.000065962726,0.00017428314,0.0012272776,0.0000029128817],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00305032,0.0012105015,0.00021243872,0.49635756,0.32926702,0.00054003904,0.00008511264,0.000006001236,1.5861629e-7,0.00006530359,0.0012520738,0.16795346],"study_design_scores_gemma":[0.002255991,0.006606537,0.0005098493,0.053792175,0.7942099,0.0002522898,0.0000031951915,0.0000025575944,0.0000022661006,0.0000941901,0.14207084,0.00020020356],"about_ca_topic_score_codex":0.000041146617,"about_ca_topic_score_gemma":0.000013325306,"teacher_disagreement_score":0.46494287,"about_ca_system_score_codex":0.00025890465,"about_ca_system_score_gemma":0.001763862,"threshold_uncertainty_score":0.99953014},"labels":[],"label_agreement":null},{"id":"W2600063748","doi":"10.1200/jco.2013.31.15_suppl.2561","title":"Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Pharmacokinetics; Gastroenterology; Rash; Neutropenia; Nausea; Mucositis; Oncology; Toxicity","score_opus":0.09889875574028306,"score_gpt":0.4869222895295139,"score_spread":0.3880235337892308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600063748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750817,0.000036666068,0.00010973543,0.0004995322,0.00015873014,0.0012660961,0.0000062807967,0.0000016298338,0.00041316997],"genre_scores_gemma":[0.9958984,0.00006516768,0.0033108008,0.00037800334,0.00012434543,0.00005028712,0.00001098401,0.000021499043,0.0001404769],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959508,0.0007241287,0.0023060653,0.0002986433,0.00041836724,0.00030198024],"domain_scores_gemma":[0.9958454,0.00021653851,0.0012663325,0.00035696258,0.0020281845,0.00028659837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015597839,0.00015657976,0.0009502569,0.00010359331,0.000035390847,0.000022681521,0.00066663657,0.00031627287,0.00006356504],"category_scores_gemma":[0.0032505072,0.000111879766,0.000078664954,0.000185621,0.00015542803,0.000038827635,0.00030402528,0.00048265856,0.00000874171],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03452351,0.14564434,0.32744363,0.00007077588,0.00067840505,0.00020150807,0.0004253321,0.000090656526,0.09230914,0.000020106541,0.002331536,0.39626107],"study_design_scores_gemma":[0.20081206,0.36422145,0.4228912,0.00015716125,0.000074497104,0.000024142702,0.0007033109,0.00016241855,0.006352817,0.00009417506,0.0041266973,0.00038005778],"about_ca_topic_score_codex":0.000061742205,"about_ca_topic_score_gemma":0.0002980591,"teacher_disagreement_score":0.395881,"about_ca_system_score_codex":0.000049000664,"about_ca_system_score_gemma":0.0013313264,"threshold_uncertainty_score":0.45623246},"labels":[],"label_agreement":null},{"id":"W2600084901","doi":"10.1200/jco.2015.33.15_suppl.e14641","title":"An updated meta-analysis of randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; University of Toronto; Queen's University; McMaster University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Randomized controlled trial; Oncology; Clinical trial; Induction chemotherapy; Meta-analysis; Confidence interval; Chemotherapy; Cancer","score_opus":0.4405944159264322,"score_gpt":0.5349451926152108,"score_spread":0.09435077668877856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600084901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98092437,0.014120349,0.00035227076,0.0004075565,0.00093350786,0.002715611,0.00016317847,0.000012755229,0.00037040745],"genre_scores_gemma":[0.9964729,0.0016149594,0.0011296526,0.00010008728,0.00018404218,0.00035873087,0.0000316369,0.000022141765,0.000085880005],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98702365,0.00358346,0.008234024,0.0003312359,0.0005424005,0.00028520933],"domain_scores_gemma":[0.96970415,0.017317137,0.009784509,0.00022678969,0.002618714,0.00034871013],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01450984,0.00040048454,0.03078602,0.0005265947,0.000040271207,0.000020746778,0.00017103365,0.0002258658,0.00032848443],"category_scores_gemma":[0.007842129,0.00019834419,0.007891926,0.0003400702,0.00034666987,0.00014292003,0.00003278386,0.00021901385,5.8402134e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5184588,0.0013813548,0.0007453883,0.000028325663,0.4710253,0.00008981172,0.0008368186,0.0008857601,0.0004424458,0.000032816006,0.000064107386,0.0060090953],"study_design_scores_gemma":[0.41196948,0.03493758,0.00076115184,0.000039117913,0.5461861,0.000023120523,0.0030709405,0.0023204966,0.00044873467,0.000027432456,0.000111247406,0.00010461109],"about_ca_topic_score_codex":0.00069896097,"about_ca_topic_score_gemma":0.00072480424,"teacher_disagreement_score":0.10648931,"about_ca_system_score_codex":0.0005114324,"about_ca_system_score_gemma":0.0023115152,"threshold_uncertainty_score":0.983603},"labels":[],"label_agreement":null},{"id":"W2600099876","doi":"10.1200/jco.2014.32.15_suppl.10056","title":"Complete radiographic responses in pediatric patients with <i>BRAF</i><sup>V600</sup>-positive tumors including high-grade gliomas: Preliminary results of an ongoing phase 1/2a safety and pharmacokinetics (PK) study of dabrafenib.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Dabrafenib; Trametinib; Internal medicine; Phases of clinical research; Pharmacokinetics; Anaplastic astrocytoma; Progressive disease; Anaplastic thyroid cancer; Oncology; Cancer; Gastroenterology; Glioma; Chemotherapy; Astrocytoma; Cancer research; Kinase; Thyroid cancer; Vemurafenib","score_opus":0.06140223544629098,"score_gpt":0.4056580172350463,"score_spread":0.3442557817887553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600099876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783474,0.00029516537,0.000012241522,0.0007583104,0.00014566912,0.00081640534,0.000078868194,0.000008010795,0.00005057968],"genre_scores_gemma":[0.99773633,0.0004127576,0.0012898225,0.00019018083,0.00030738328,0.0000074794493,0.000024821458,0.000029712446,0.000001511009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931187,0.0018861577,0.0036380799,0.00039022224,0.0006610079,0.0003058568],"domain_scores_gemma":[0.9888899,0.006717739,0.0031036588,0.000299089,0.0005539064,0.00043573132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032187614,0.0002807831,0.0022275317,0.0009927945,0.0000717437,0.000008576228,0.00020197016,0.00020013796,0.0000047025337],"category_scores_gemma":[0.0021531049,0.00019704827,0.00021962017,0.0007374528,0.00029111764,0.0001802346,0.00012026875,0.00069721893,3.1858116e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.124096245,0.047170438,0.80605084,0.000089252586,0.00064495736,0.0012209283,0.0016673077,0.0008694481,0.00018404578,0.00001280591,0.00006109007,0.017932616],"study_design_scores_gemma":[0.114722736,0.15157121,0.7305125,0.00025913407,0.0013815582,0.00008889038,0.00038698618,0.00057046436,0.00022540058,0.00001913146,0.00013232615,0.0001296758],"about_ca_topic_score_codex":0.00007555234,"about_ca_topic_score_gemma":0.000056928555,"teacher_disagreement_score":0.10440078,"about_ca_system_score_codex":0.00008706122,"about_ca_system_score_gemma":0.00030734728,"threshold_uncertainty_score":0.8035395},"labels":[],"label_agreement":null},{"id":"W2600101994","doi":"10.1200/jco.2013.31.15_suppl.5007","title":"Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Interquartile range; Metformin; Proportional hazards model; Internal medicine; Cancer; Cohort; Retrospective cohort study; Oncology; Population; Prostate; Cumulative dose; Confidence interval","score_opus":0.12453402013052564,"score_gpt":0.41676120170644626,"score_spread":0.29222718157592065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600101994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9135087,0.0853035,0.000019316272,0.00021898244,0.0005482821,0.0002010301,0.000008517503,0.0000028819952,0.00018875425],"genre_scores_gemma":[0.69782877,0.2998955,0.0005543761,0.00078391616,0.00074405724,0.000020867657,0.0000039871634,0.000015748921,0.0001527643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977,0.0003289387,0.0012325257,0.00028129062,0.00017720518,0.0002800395],"domain_scores_gemma":[0.99792814,0.0002682606,0.0008818,0.00021529554,0.00030651537,0.0003999888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015249075,0.00016479689,0.0007675617,0.00004281616,0.000039902585,0.000054996355,0.00014953387,0.00037006376,0.00010745831],"category_scores_gemma":[0.00069367886,0.00012070978,0.00016326332,0.000048536825,0.00043650685,0.000046182715,0.000113542,0.00037633788,0.0000038512853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031812774,0.00037989664,0.45299965,0.00003442861,0.0012544824,0.000030973308,0.00009062694,0.000006640873,0.007236103,0.00008451341,0.027379232,0.5101853],"study_design_scores_gemma":[0.002532943,0.0016993535,0.5728408,0.000022418642,0.00033062452,0.000026246164,0.000098696575,0.000031001055,0.0026433186,0.0005130511,0.41907278,0.00018874618],"about_ca_topic_score_codex":0.00005694706,"about_ca_topic_score_gemma":0.00006418183,"teacher_disagreement_score":0.5099966,"about_ca_system_score_codex":0.000018254697,"about_ca_system_score_gemma":0.00022735806,"threshold_uncertainty_score":0.4922402},"labels":[],"label_agreement":null},{"id":"W2600110340","doi":"10.1200/jco.2013.31.15_suppl.7067","title":"Do quality of life and physical function at diagnosis predict short-term outcomes during intensive chemotherapy in acute myeloid leukemia patients?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Univariate analysis; Quality of life (healthcare); Internal medicine; Intensive care unit; Logistic regression; Comorbidity; Performance status; Prospective cohort study; Myeloid leukemia; Multivariate analysis; Chemotherapy","score_opus":0.09308544646276525,"score_gpt":0.4433040097069141,"score_spread":0.35021856324414885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600110340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384123,0.000100323494,0.000011531189,0.004984008,0.00038324826,0.000502446,0.000006710918,0.000008923437,0.00016158924],"genre_scores_gemma":[0.99542254,0.001627369,0.00023811126,0.0020135357,0.00052656856,0.000026017735,0.0000047699414,0.000025533926,0.000115554576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542135,0.0005780906,0.0027249665,0.0002984421,0.0006402653,0.0003368622],"domain_scores_gemma":[0.9928718,0.0036851938,0.0012993377,0.0002749573,0.0013074141,0.00056129636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001810275,0.00020514936,0.0023280676,0.00022463333,0.00003738507,0.000010900974,0.0001849907,0.00043846146,0.00017712703],"category_scores_gemma":[0.007857629,0.000139343,0.0004867362,0.00017359156,0.00044109713,0.0002529837,0.00020132663,0.0014267414,0.000015409332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007483068,0.0009972345,0.94953585,0.00007451467,0.0007136414,0.0000528081,0.00033192703,0.000002790679,0.0014621963,0.000006490456,0.002015253,0.03732424],"study_design_scores_gemma":[0.01553716,0.0067762113,0.976237,0.00008867719,0.00015924318,0.000028773724,0.00024111246,0.00008482708,0.00034079378,0.00010409312,0.00029436316,0.0001077324],"about_ca_topic_score_codex":0.00007729211,"about_ca_topic_score_gemma":0.000025239322,"teacher_disagreement_score":0.037216507,"about_ca_system_score_codex":0.001014238,"about_ca_system_score_gemma":0.0009738106,"threshold_uncertainty_score":0.9406884},"labels":[],"label_agreement":null},{"id":"W2600127539","doi":"10.1200/jco.2015.33.15_suppl.3590","title":"Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; KRAS; Internal medicine; FOLFOX; Oncology; Gastroenterology; Colorectal cancer; Proportional hazards model; Biomarker; Stage (stratigraphy); Cetuximab; Cancer; Oxaliplatin","score_opus":0.18423516385328695,"score_gpt":0.49365461627551255,"score_spread":0.30941945242222557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600127539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946893,0.002613023,0.0000061655023,0.0051287236,0.0010268859,0.0006486321,0.000009083132,0.0000060131106,0.0010925585],"genre_scores_gemma":[0.99543107,0.0019501625,0.0005131441,0.0013377903,0.00042511267,0.00004721416,0.000002083023,0.000012415571,0.00028103034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968779,0.00041398752,0.001738802,0.0002443656,0.00050045707,0.00022447406],"domain_scores_gemma":[0.9968717,0.0011220985,0.00084510574,0.00018886448,0.000672072,0.000300151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017076395,0.00015454294,0.0014272409,0.00013201246,0.00003244889,0.000007786399,0.0001529507,0.00018493178,0.000050610728],"category_scores_gemma":[0.003307727,0.000109371154,0.0003071558,0.00035530629,0.00009830714,0.000076541466,0.00004070942,0.0005690766,0.000027230688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6011878,0.016387817,0.040806733,0.00002946095,0.0011793764,0.0027423291,0.0023906543,0.006926592,0.015384705,0.00007114327,0.026101293,0.28679204],"study_design_scores_gemma":[0.33006105,0.20576075,0.2811921,0.0014287033,0.00031732203,0.00003541823,0.00013752369,0.00016121879,0.0031249751,0.00029851662,0.17707264,0.00040979838],"about_ca_topic_score_codex":0.000074984586,"about_ca_topic_score_gemma":0.00023965926,"teacher_disagreement_score":0.28638226,"about_ca_system_score_codex":0.00042802308,"about_ca_system_score_gemma":0.0014311277,"threshold_uncertainty_score":0.44600263},"labels":[],"label_agreement":null},{"id":"W2600193304","doi":"10.1200/jco.2007.25.18_suppl.7611","title":"A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T790M; Internal medicine; Lapatinib; Clinical endpoint; KRAS; Population; Lung cancer; non-small cell lung cancer (NSCLC); Gastroenterology; Phases of clinical research; Oncology; Cancer; Chemotherapy; Surgery; Clinical trial; Breast cancer; Trastuzumab; Colorectal cancer","score_opus":0.0857046195069171,"score_gpt":0.4627108171647395,"score_spread":0.3770061976578224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600193304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945841,0.0013894615,0.0006535863,0.00025616187,0.0009221522,0.0012909467,0.000010645531,0.000009276084,0.00088366494],"genre_scores_gemma":[0.97404313,0.00029723305,0.022744494,0.0009987775,0.0005780091,0.000051530264,0.0000058401915,0.000054662567,0.0012263075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965266,0.00020050455,0.0022328007,0.00032311064,0.00032866868,0.0003883455],"domain_scores_gemma":[0.99466616,0.0019183692,0.0023482079,0.00023017601,0.00050313404,0.00033397757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013596872,0.00029508866,0.0019735922,0.00024964398,0.000067175715,0.0000065686104,0.00016428383,0.00016481213,0.0009819276],"category_scores_gemma":[0.0004270447,0.00015263827,0.00023024227,0.00019962237,0.0002031918,0.000170916,0.000029659343,0.0008106529,0.0000015051015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8253336,0.013235308,0.13250303,0.0003316793,0.0017541286,0.0023593185,0.0030860384,0.00046759393,0.0004091225,0.0000038352355,0.00015350475,0.020362837],"study_design_scores_gemma":[0.7557422,0.19109416,0.028666519,0.0015869156,0.0027040432,0.00018149425,0.0009651353,0.0016536217,0.0011618146,0.0000025852135,0.015918605,0.00032291707],"about_ca_topic_score_codex":0.00043835145,"about_ca_topic_score_gemma":0.021103894,"teacher_disagreement_score":0.17785886,"about_ca_system_score_codex":0.0008842991,"about_ca_system_score_gemma":0.0053130197,"threshold_uncertainty_score":0.99993134},"labels":[],"label_agreement":null},{"id":"W2600197643","doi":"10.1200/jco.2015.33.15_suppl.4537","title":"Clinical outcomes of late relapse in stage I seminoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Radiation therapy; Stage (stratigraphy); Chemotherapy; Internal medicine; Surgery; Oncology","score_opus":0.24946918523774905,"score_gpt":0.545264842070876,"score_spread":0.2957956568331269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600197643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367654,0.001193838,0.000015569201,0.0022339555,0.0010907056,0.00013102866,0.0000048772504,0.0000054750276,0.0016479848],"genre_scores_gemma":[0.99354595,0.00032243622,0.0038746349,0.0010451133,0.00028280195,0.0000010734111,0.0000019901156,0.000011744912,0.00091426086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99558085,0.00046385912,0.0033023984,0.00014773355,0.00033982133,0.00016531588],"domain_scores_gemma":[0.9943381,0.0024149495,0.0019651684,0.00022602692,0.0003558259,0.00069991953],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038710036,0.00010911224,0.0018638351,0.00010471383,0.0000067781075,0.0000024692317,0.00012106749,0.0003400441,0.000060944614],"category_scores_gemma":[0.015087249,0.00006925206,0.00073126715,0.000104636194,0.00018910991,0.00006874039,0.000055497858,0.00069374195,0.000027692782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002246829,0.004766108,0.95240784,0.00001618209,0.00043051035,0.0030756,0.000034730085,0.00001433805,0.0000026372156,0.00005756034,0.0011063252,0.03584132],"study_design_scores_gemma":[0.017812688,0.010229317,0.958943,0.000080584025,0.00049616094,0.00008176082,0.00007396403,0.000049392293,0.0000028394038,0.00035385424,0.011823358,0.000053072472],"about_ca_topic_score_codex":0.00003668857,"about_ca_topic_score_gemma":0.000030799376,"teacher_disagreement_score":0.035788245,"about_ca_system_score_codex":0.00009285593,"about_ca_system_score_gemma":0.0020066947,"threshold_uncertainty_score":0.99320906},"labels":[],"label_agreement":null},{"id":"W2600209860","doi":"10.1200/jco.2004.22.90140.4063","title":"A phase II study to assess the efficacy of combined preoperative irinotecan (I)/cisplatin (C) chemotherapy and conformal radiotherapy (RT) followed by surgery for potentially resectable esophageal cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Surgery; Esophageal cancer; Esophagus; Adenocarcinoma; Chemotherapy; Febrile neutropenia; Neutropenia; Irinotecan; Cancer; Internal medicine; Colorectal cancer","score_opus":0.11921696576726887,"score_gpt":0.5026467028786833,"score_spread":0.3834297371114144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600209860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825413,0.0022103863,0.0009834993,0.011615603,0.00035679602,0.002205354,0.00003554238,0.000007109908,0.000044411252],"genre_scores_gemma":[0.9950749,0.00078382576,0.001609704,0.0016845191,0.00047040326,0.00008083876,0.000005364111,0.000026602265,0.00026384252],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99667937,0.0003884678,0.001781232,0.0002453334,0.00053538685,0.00037023067],"domain_scores_gemma":[0.994488,0.003251725,0.00093261374,0.00021855457,0.00061121606,0.00049787835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037389493,0.00020102359,0.0017155142,0.00012788891,0.00015912078,0.000021656446,0.00019537137,0.00014749887,0.00009670753],"category_scores_gemma":[0.0014167796,0.000117271535,0.00042930184,0.00020442468,0.00022591413,0.000122892,0.000047967664,0.0005712664,4.899897e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.407318,0.106789514,0.124864295,0.00017769556,0.008937761,0.0012188018,0.0060415627,0.0004322164,0.0042522135,0.00016099763,0.018500187,0.32130677],"study_design_scores_gemma":[0.27876338,0.55808073,0.14815374,0.00022793509,0.00080914167,0.00013293883,0.00064651464,0.00014281133,0.00846642,0.000095441064,0.004240408,0.00024054627],"about_ca_topic_score_codex":0.0002558177,"about_ca_topic_score_gemma":0.00017797461,"teacher_disagreement_score":0.4512912,"about_ca_system_score_codex":0.00028869766,"about_ca_system_score_gemma":0.0034039542,"threshold_uncertainty_score":0.60384685},"labels":[],"label_agreement":null},{"id":"W2600223414","doi":"10.1200/jco.2012.30.15_suppl.4010","title":"Assessment of <i>HER2</i> gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Immunohistochemistry; Gastroenterology; Internal medicine; Fluorescence in situ hybridization; Cancer; Stomach; Gastroesophageal Junction; Adenocarcinoma; Oncology; Pathology; Breast cancer; Gene; Biology","score_opus":0.2626046725639303,"score_gpt":0.524102490977539,"score_spread":0.26149781841360875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600223414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903036,0.0002979445,0.00030439429,0.0056343344,0.002777437,0.000687555,0.0000012844952,0.000002641618,0.0012640615],"genre_scores_gemma":[0.9942371,0.0005753798,0.001908821,0.0015025042,0.0016105906,0.000011694498,0.0000017999878,0.000009767976,0.0001422995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297655,0.0017309781,0.0042778864,0.00015332145,0.0006106529,0.00025063567],"domain_scores_gemma":[0.9931874,0.0030110502,0.0031103075,0.00036805833,0.00020001346,0.00012312533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015843065,0.0001246685,0.0013626766,0.00018060736,0.000020994436,0.0000047089006,0.00036935465,0.0002681042,0.000097183],"category_scores_gemma":[0.0031192238,0.000061256185,0.00056899025,0.0004423194,0.00024936267,0.0001229124,0.00008680979,0.0012516829,0.0000018815342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01578796,0.0035564657,0.94788945,0.000033955544,0.0001183889,0.000024473771,0.0001284707,0.000015271924,0.000028598155,0.00023056583,0.0031280795,0.029058328],"study_design_scores_gemma":[0.037405364,0.008111007,0.9466401,0.000050224106,0.00034874777,0.000054830136,0.00038410482,0.000047533253,0.000013974419,0.000048786223,0.006856144,0.000039204453],"about_ca_topic_score_codex":0.000054068045,"about_ca_topic_score_gemma":0.00012708142,"teacher_disagreement_score":0.029019123,"about_ca_system_score_codex":0.00019785567,"about_ca_system_score_gemma":0.0010662954,"threshold_uncertainty_score":0.5490922},"labels":[],"label_agreement":null},{"id":"W2600232782","doi":"10.1200/jco.2012.30.15_suppl.9021","title":"Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Depression (economics); Anxiety; Colorectal cancer; Verbal memory; Cognition; Visual memory; Gastroenterology; Cancer; Psychiatry","score_opus":0.11377010248787453,"score_gpt":0.4720022894392879,"score_spread":0.35823218695141334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600232782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927422,0.0012510968,0.000055508764,0.00082379143,0.0018895937,0.0017923323,0.0000065209815,0.000008705073,0.0014302614],"genre_scores_gemma":[0.997586,0.00042047596,0.00003803113,0.0005670391,0.0011956252,0.00012610674,0.0000014240445,0.000015280692,0.00004997562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669546,0.00055901904,0.0018261628,0.00021183942,0.00038515445,0.00032235513],"domain_scores_gemma":[0.99426734,0.0027349098,0.0014398677,0.000043690925,0.0012164087,0.0002977705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024234853,0.00018644487,0.0019278612,0.00021189601,0.00006055643,0.0000069195717,0.000040672443,0.0002320622,0.00012244341],"category_scores_gemma":[0.0072212536,0.0001298821,0.00024695645,0.00022240568,0.00028867336,0.0002547253,0.000061445804,0.0010888189,0.0000058021164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07711262,0.008965899,0.88737494,0.000012423059,0.0018908343,0.000053182463,0.00069667306,0.0000011437928,0.000009467754,0.000009787912,0.0002880703,0.023584954],"study_design_scores_gemma":[0.105089165,0.037661973,0.8528853,0.00019332608,0.0019638531,0.000035367415,0.0018667036,0.000011689922,0.000009113587,0.000057924026,0.000124723,0.00010083373],"about_ca_topic_score_codex":0.00006367821,"about_ca_topic_score_gemma":0.0003776902,"teacher_disagreement_score":0.034489617,"about_ca_system_score_codex":0.00041042757,"about_ca_system_score_gemma":0.0005623552,"threshold_uncertainty_score":0.8645037},"labels":[],"label_agreement":null},{"id":"W2600242980","doi":"10.1200/jco.2012.30.15_suppl.1099","title":"Phase II trial of sorafenib (S) and vinorelbine (V) in metastatic breast cancer (mBC) with pharmacokinetics (PK) analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Metastatic breast cancer; Vinorelbine; Internal medicine; Toxicity; Gastroenterology; Neutropenia; Urology; Pharmacology; Cancer; Breast cancer; Oncology; Chemotherapy; Adverse effect","score_opus":0.15162748440593077,"score_gpt":0.5508904711779373,"score_spread":0.39926298677200656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600242980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127096,0.0018768214,0.000052203286,0.005325854,0.0007818445,0.00031681612,0.000033250453,0.000003321646,0.0003389304],"genre_scores_gemma":[0.9936383,0.002881127,0.0011002214,0.0009166497,0.0012901849,0.00001031626,0.000005676325,0.000012559872,0.0001450141],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969498,0.0003899482,0.0019672336,0.00014410577,0.0002760437,0.00027285866],"domain_scores_gemma":[0.99656314,0.0010102192,0.001627549,0.00011164001,0.00025911277,0.0004283636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002118713,0.00015783482,0.0022489761,0.0003551172,0.000022720675,0.000002436441,0.00008610429,0.00014210251,0.0006658548],"category_scores_gemma":[0.00017807336,0.00009926077,0.00034574035,0.00048467316,0.0002719987,0.00011925228,0.000040712315,0.0006131186,9.971125e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5385034,0.07547046,0.20232365,0.00008315123,0.0119513655,0.0005630925,0.000569301,0.00013302334,0.001940933,0.00004675779,0.002999798,0.16541508],"study_design_scores_gemma":[0.68414444,0.1108754,0.1504473,0.00007766618,0.03154917,0.0006340493,0.0000999152,0.00039068703,0.00070987357,0.000041097323,0.020839246,0.0001911962],"about_ca_topic_score_codex":0.000110798406,"about_ca_topic_score_gemma":0.00018895473,"teacher_disagreement_score":0.1652239,"about_ca_system_score_codex":0.00012304951,"about_ca_system_score_gemma":0.00087138655,"threshold_uncertainty_score":0.7290643},"labels":[],"label_agreement":null},{"id":"W2600299187","doi":"10.1200/jco.2016.70.6226","title":"Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universiteit van Amsterdam; American Society of Clinical Oncology","keywords":"Medicine; Survivorship curve; Sarcoma; Observational study; Quality of life (healthcare); Anxiety; Cohort; Physical therapy; Depression (economics); Somatization; Mental health; Internal medicine; Cancer; Psychiatry; Pathology","score_opus":0.48705762905163036,"score_gpt":0.5642762646421993,"score_spread":0.07721863559056891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600299187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981673,0.00008676764,0.0000054347183,0.00088804145,0.00035217762,0.00043855017,0.000020302095,0.00000196188,0.000039483915],"genre_scores_gemma":[0.9995188,0.000060136008,0.000114092945,0.000056918023,0.00021601576,0.000010579981,0.000005792491,0.000010449506,0.000007219335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99453497,0.0014552643,0.0029073264,0.00027122707,0.00066742784,0.00016379406],"domain_scores_gemma":[0.98840535,0.0068289614,0.0036200578,0.0004274467,0.00045458786,0.00026357346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006720384,0.0001556456,0.0025540534,0.00016182111,0.000036574635,0.000006753014,0.0002166296,0.00018738116,0.000023409937],"category_scores_gemma":[0.006797945,0.000117336436,0.00039278506,0.00009833176,0.00035902337,0.00025883864,0.00011306045,0.0005956704,2.905115e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007959825,0.04314181,0.9328472,0.00011696642,0.00030919866,0.00023628234,0.000152499,0.000012608477,0.00004470242,0.00007857859,0.0000026839325,0.0150976665],"study_design_scores_gemma":[0.012369397,0.0059564486,0.9807585,0.00014946295,0.00026104416,0.0000073959936,0.00014204867,0.0000791822,0.000016214593,0.00017831042,0.0000027526494,0.0000792525],"about_ca_topic_score_codex":0.00095929595,"about_ca_topic_score_gemma":0.006711787,"teacher_disagreement_score":0.04791131,"about_ca_system_score_codex":0.00010004858,"about_ca_system_score_gemma":0.0006450444,"threshold_uncertainty_score":0.8138266},"labels":[],"label_agreement":null},{"id":"W2600306685","doi":"10.1200/jco.2017.35.6_suppl.498","title":"Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Sorafenib; Sunitinib; Pazopanib; Everolimus; Targeted therapy; Axitinib; Internal medicine; Temsirolimus; Oncology; Renal cell carcinoma; Nivolumab; Cancer; Hepatocellular carcinoma; Immunotherapy; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway","score_opus":0.2193807385605218,"score_gpt":0.4479544508668474,"score_spread":0.2285737123063256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600306685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954026,0.0009674381,0.00008745382,0.03821578,0.0022298666,0.00037979078,0.00015899741,0.000006844522,0.003927822],"genre_scores_gemma":[0.98574984,0.0011945148,0.007112867,0.0032039015,0.0020747439,0.000007707042,0.000099577286,0.000026814292,0.00053003785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942618,0.00080728513,0.0034206735,0.0004023805,0.0007755285,0.0003323507],"domain_scores_gemma":[0.98829186,0.00578083,0.003968366,0.0009874575,0.00056335604,0.00040810663],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005443657,0.0002614838,0.0015205746,0.00013716373,0.00012430869,0.000056474844,0.00093216816,0.00023693543,0.000346274],"category_scores_gemma":[0.008703218,0.00014821353,0.0006096422,0.00007241615,0.00043818203,0.0002390357,0.00020775551,0.0015711836,0.00004943895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10827729,0.010607247,0.6265619,0.000029575305,0.0024490994,0.037260283,0.0010144768,0.00017785966,0.017101567,0.00010239364,0.06064427,0.13577408],"study_design_scores_gemma":[0.047930878,0.009637648,0.88701767,0.000115682604,0.00048605117,0.00039521963,0.00022569786,0.00075179397,0.006271747,0.00035690353,0.046635587,0.00017512208],"about_ca_topic_score_codex":0.00081520906,"about_ca_topic_score_gemma":0.00055091263,"teacher_disagreement_score":0.26045582,"about_ca_system_score_codex":0.0002632635,"about_ca_system_score_gemma":0.0019183259,"threshold_uncertainty_score":0.9996469},"labels":[],"label_agreement":null},{"id":"W2600310070","doi":"10.1200/jco.2014.32.15_suppl.e19568","title":"Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexamethasone (CyBor-P/D): Updated experience at Princess Margaret Cancer Centre (PMCC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Regimen; Prednisone; Discontinuation; Internal medicine; Dexamethasone; Multiple myeloma; Surgery; Gastroenterology; Cyclophosphamide; Urology; Chemotherapy","score_opus":0.08999254252035456,"score_gpt":0.42933988416640345,"score_spread":0.3393473416460489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600310070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935209,0.0011541866,0.00025661403,0.0025205405,0.0006689111,0.00095041515,0.00004813522,0.00003142709,0.0008488647],"genre_scores_gemma":[0.9827615,0.004029817,0.008386717,0.0002932788,0.00060925697,0.000058031128,0.00003768232,0.00006099482,0.0037626994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940058,0.00084095413,0.0027547881,0.0005884829,0.0010564369,0.00075355644],"domain_scores_gemma":[0.9908268,0.0036489232,0.002731621,0.00063238223,0.00088597037,0.0012743355],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010174718,0.00045171072,0.0030089524,0.00019429346,0.00013002938,0.000015232466,0.00036524786,0.00056138024,0.00094832666],"category_scores_gemma":[0.0029430815,0.00025655617,0.00049879396,0.0003385831,0.00073530845,0.00022843086,0.00012930633,0.00070242136,0.000027576578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13162686,0.0051359045,0.7034977,0.00009461474,0.0019301286,0.003207753,0.0009948352,0.00017365745,0.000737345,0.00001322377,0.001211416,0.15137653],"study_design_scores_gemma":[0.09357417,0.05036883,0.7302137,0.00039050315,0.0007986752,0.0006596736,0.0005624579,0.0022284305,0.004026056,0.000011154078,0.11684565,0.00032068207],"about_ca_topic_score_codex":0.00076976727,"about_ca_topic_score_gemma":0.0024633498,"teacher_disagreement_score":0.15105584,"about_ca_system_score_codex":0.0021211796,"about_ca_system_score_gemma":0.004135858,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W2600317547","doi":"10.1200/jco.2012.30.15_suppl.6026","title":"Is care coordination associated with improved care quality for comorbid conditions in cancer survivors?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Comorbidity; Logistic regression; Survivorship curve; Cancer; Colorectal cancer; Quality of life (healthcare); Cancer registry; Prostate cancer; Internal medicine; Nursing","score_opus":0.20215787967630178,"score_gpt":0.5344449377528168,"score_spread":0.332287058076515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600317547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916479,0.0012463417,0.000067167544,0.003931193,0.0011995075,0.0004008139,0.00014176156,0.0000070278315,0.0013582786],"genre_scores_gemma":[0.99447805,0.00014428902,0.0004566583,0.0039659743,0.00067351555,0.000027007569,0.00008419286,0.000014576258,0.00015572231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767375,0.00034578567,0.0014039131,0.00012547834,0.00019917262,0.00025191877],"domain_scores_gemma":[0.9953169,0.001931109,0.0012956352,0.0001131527,0.0010807062,0.0002624613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017326826,0.00010835958,0.0011061702,0.00009554814,0.00004806488,0.0000046690166,0.00008127174,0.0003319777,0.00025953562],"category_scores_gemma":[0.0018664042,0.00007956387,0.0002867434,0.00012337125,0.000118446966,0.00018553043,0.000014249928,0.0006265562,0.0000012447591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031058395,0.00070837565,0.96231973,0.00012544215,0.00035400662,0.000014334955,0.0029040526,0.000011534608,0.0002749072,0.000048055506,0.0024830217,0.02765071],"study_design_scores_gemma":[0.014892531,0.0046250327,0.9350953,0.00011400287,0.00031317392,0.000012004942,0.004320229,0.00005527383,0.00016898058,0.000020782834,0.040271625,0.000111023415],"about_ca_topic_score_codex":0.00052859396,"about_ca_topic_score_gemma":0.0068528973,"teacher_disagreement_score":0.037788603,"about_ca_system_score_codex":0.00088238774,"about_ca_system_score_gemma":0.0021202483,"threshold_uncertainty_score":0.38240775},"labels":[],"label_agreement":null},{"id":"W2600340656","doi":"10.1200/jco.2013.31.15_suppl.e16052","title":"International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Incidence (geometry); Demography; Population; Prostate-specific antigen; Cancer; Disease; Oncology; Gynecology; Internal medicine; Environmental health","score_opus":0.1487583170269903,"score_gpt":0.5172608125796673,"score_spread":0.368502495552677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600340656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97940755,0.0012087828,0.000025957514,0.014205047,0.0010072892,0.00040795206,0.00002432633,0.000004106206,0.003708985],"genre_scores_gemma":[0.9848608,0.0064896652,0.0034212451,0.0003613027,0.00050744443,0.00002397443,0.0000033753952,0.000010425024,0.0043218085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972625,0.00018196425,0.0017195635,0.00013594546,0.0005173335,0.00018270638],"domain_scores_gemma":[0.996477,0.0007520066,0.0012453564,0.00012397642,0.0011399423,0.00026170275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012272211,0.00009456833,0.0007176189,0.00011769034,0.000022299893,0.000010414329,0.00016871984,0.00011863206,0.0021841985],"category_scores_gemma":[0.0010894024,0.000058791033,0.0002556697,0.000102239035,0.00026707893,0.00019692797,0.000038409682,0.00048757065,0.000028464106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01232165,0.004133956,0.50512135,0.00075129943,0.0022498607,0.00077915296,0.00068575435,0.00007022474,0.02426004,0.00017978123,0.020053558,0.42939338],"study_design_scores_gemma":[0.011675735,0.011570102,0.9415698,0.00044320713,0.0004734929,0.00015077885,0.0002443976,0.00026582615,0.002140534,0.0006487093,0.030710341,0.000107094835],"about_ca_topic_score_codex":0.00009908044,"about_ca_topic_score_gemma":0.00001770421,"teacher_disagreement_score":0.43644845,"about_ca_system_score_codex":0.0001690696,"about_ca_system_score_gemma":0.001974296,"threshold_uncertainty_score":0.9987279},"labels":[],"label_agreement":null},{"id":"W2600343376","doi":"10.1200/jco.2017.35.4_suppl.126","title":"Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Esophageal cancer; Internal medicine; Chemoradiotherapy; Gastroenterology; Regimen; Cancer; Cisplatin; Chemotherapy regimen; Surgery; Chemotherapy; Urology; Oncology","score_opus":0.3075880622488101,"score_gpt":0.5819538745376933,"score_spread":0.27436581228888324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600343376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741545,0.008754852,0.00022483022,0.013492564,0.0020468873,0.00074122066,0.000145501,0.000008158757,0.0004315395],"genre_scores_gemma":[0.99019694,0.0024725473,0.0037692806,0.00050894095,0.0025122366,0.00007704373,0.000008957942,0.000026594831,0.00042743524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968965,0.00019307653,0.0014683852,0.00030749198,0.0007686116,0.0003659354],"domain_scores_gemma":[0.99210715,0.003654228,0.0026498933,0.00045631817,0.00071256835,0.00041983186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008944785,0.00021631339,0.0016817739,0.000042108397,0.0002578091,0.000034256624,0.0005161117,0.00023570254,0.0008037178],"category_scores_gemma":[0.0015841814,0.000109614426,0.00035877875,0.000076719596,0.00076768204,0.0001702302,0.00006349463,0.00074714114,0.0000016016744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085086085,0.001095165,0.80821645,0.00005183597,0.0013007397,0.00028526454,0.0006388055,0.000060821698,0.000049263956,0.000068852714,0.00432425,0.09882246],"study_design_scores_gemma":[0.037735246,0.018357653,0.92362183,0.00029660668,0.00059921894,0.00003606206,0.0004762165,0.00070484093,0.0015899927,0.000053925745,0.016391201,0.00013717487],"about_ca_topic_score_codex":0.002102154,"about_ca_topic_score_gemma":0.005913562,"teacher_disagreement_score":0.1154054,"about_ca_system_score_codex":0.00045139555,"about_ca_system_score_gemma":0.0038272669,"threshold_uncertainty_score":0.88001466},"labels":[],"label_agreement":null},{"id":"W2600362622","doi":"10.1200/jco.2017.35.4_suppl.312","title":"Germline mutations in seemingly sporadic pancreatic cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital; McGill University Health Centre","funders":"","keywords":"MSH6; PALB2; Germline mutation; Genetics; Germline; CDKN2A; PMS2; MSH2; MLH1; Medicine; Cancer; Lynch syndrome; Mutation; Cancer research; Biology; Gene; Colorectal cancer; DNA mismatch repair","score_opus":0.0785753204947561,"score_gpt":0.4609350087067625,"score_spread":0.3823596882120064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600362622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920036,0.001346899,0.00014429499,0.003107526,0.0013244685,0.00006707391,0.00001239632,9.878731e-7,0.0019927216],"genre_scores_gemma":[0.990698,0.004849399,0.0014963218,0.0008112935,0.0018752074,0.0000043262376,0.000005941914,0.000011150511,0.00024840655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983863,0.00008259253,0.001131373,0.00014587329,0.00009716367,0.00015669217],"domain_scores_gemma":[0.9975589,0.0002955137,0.0015150172,0.00028384355,0.00018878104,0.00015797789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012719303,0.000085249616,0.0005370875,0.000044888475,0.0000702733,0.00002217239,0.00034206832,0.00025333336,0.00003375583],"category_scores_gemma":[0.0044426704,0.00007362771,0.00020890223,0.000025437317,0.00019551376,0.0000066291877,0.00008494607,0.00030462243,0.000004065734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014717104,0.00093553023,0.7993848,0.000022286675,0.00026863348,0.00046671304,0.000081023114,0.0009201437,0.008561852,0.0002787,0.009513598,0.17809503],"study_design_scores_gemma":[0.004984366,0.0034428183,0.7832773,0.00006675974,0.00014212704,0.00008911302,0.000060952174,0.0001630503,0.0011593474,0.001065379,0.20537737,0.00017145133],"about_ca_topic_score_codex":0.00015256136,"about_ca_topic_score_gemma":0.0011672189,"teacher_disagreement_score":0.19586377,"about_ca_system_score_codex":0.00004848396,"about_ca_system_score_gemma":0.0013736701,"threshold_uncertainty_score":0.53186125},"labels":[],"label_agreement":null},{"id":"W2600365723","doi":"10.1200/jco.2017.35.6_suppl.252","title":"Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Cabazitaxel; Enzalutamide; Docetaxel; Medicine; Prostate cancer; Hazard ratio; Toxicity; Population; Internal medicine; Proportional hazards model; Oncology; Cohort; Chemotherapy; Cancer; Confidence interval; Androgen deprivation therapy","score_opus":0.14593400711687557,"score_gpt":0.5120480420107019,"score_spread":0.3661140348938263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600365723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938732,0.0001784426,0.000016707485,0.003642951,0.00010422609,0.00030018052,0.000032478667,0.0000036089864,0.0018482388],"genre_scores_gemma":[0.99760467,0.0004648261,0.000660521,0.00006666296,0.00019152093,0.00001380721,0.000018627727,0.000008845802,0.0009705272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783635,0.00017050043,0.0012828782,0.0001641449,0.00036632418,0.00017978545],"domain_scores_gemma":[0.99583256,0.0005560671,0.0024081888,0.0003141866,0.0006032163,0.0002857969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010278843,0.000119461874,0.0014678484,0.00020575881,0.0001261154,0.00001952002,0.00012941669,0.00014723802,0.00014393868],"category_scores_gemma":[0.00049345545,0.00006449791,0.00045466574,0.00016047715,0.00029404252,0.00011925564,0.000014161213,0.0002474545,6.482786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011450773,0.0010224098,0.96292496,0.000021740927,0.0041255523,0.00028787673,0.00007341156,0.0008395809,0.0003023014,0.00001456431,0.00009223908,0.01884462],"study_design_scores_gemma":[0.009154631,0.016523771,0.96754205,0.00008953556,0.003898262,0.000003981843,0.0000600102,0.0014487545,0.0007279972,0.000024667157,0.00046795525,0.000058411315],"about_ca_topic_score_codex":0.0027150966,"about_ca_topic_score_gemma":0.005400061,"teacher_disagreement_score":0.018786209,"about_ca_system_score_codex":0.000572957,"about_ca_system_score_gemma":0.003051343,"threshold_uncertainty_score":0.5412951},"labels":[],"label_agreement":null},{"id":"W2600450780","doi":"10.1200/jco.2012.30.15_suppl.e19643","title":"Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: A preliminary double-blind placebo-controlled trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Testosterone (patch); Placebo; Internal medicine; Cancer; Quality of life (healthcare); Randomized controlled trial","score_opus":0.17299694056297935,"score_gpt":0.46745664718079155,"score_spread":0.2944597066178122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600450780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858001,0.0024192513,0.000049426195,0.004632629,0.0016648924,0.0040884903,0.000003859894,0.000005009647,0.0013363711],"genre_scores_gemma":[0.99345565,0.00044104838,0.002296106,0.0004080303,0.0018827143,0.0004657777,0.0000038940448,0.000019632087,0.0010271305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99661356,0.00022487495,0.0021789977,0.0002448358,0.00036524297,0.00037248875],"domain_scores_gemma":[0.9952003,0.0019192991,0.0017522506,0.00017554166,0.0006401009,0.00031251134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033469417,0.00018320381,0.0021441993,0.00014819606,0.00005281568,0.0000032161806,0.00009777105,0.000200289,0.00005154654],"category_scores_gemma":[0.0024136764,0.00010214011,0.00031156302,0.00012376437,0.00017349901,0.00016726246,0.000045662695,0.00058506813,0.0000028559327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80974025,0.0056835623,0.15203233,0.000038033424,0.0006134524,0.000019686588,0.00018794341,0.00003015072,0.00001649949,0.00001033559,0.0007174823,0.030910261],"study_design_scores_gemma":[0.7327518,0.079409264,0.17765273,0.00014627514,0.0005670255,0.000028905983,0.00017606674,0.0000069276625,0.000027627146,0.00001758252,0.009114328,0.0001014573],"about_ca_topic_score_codex":0.000010726351,"about_ca_topic_score_gemma":0.00003791357,"teacher_disagreement_score":0.07698845,"about_ca_system_score_codex":0.00023225114,"about_ca_system_score_gemma":0.00079368695,"threshold_uncertainty_score":0.41651526},"labels":[],"label_agreement":null},{"id":"W2600452842","doi":"10.1200/jco.2013.31.15_suppl.4015","title":"A Bayesian network meta-analysis of systemic regimens for advanced pancreatic cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Internal medicine; Oncology; Oxaliplatin; Pancreatic cancer; Erlotinib; Randomized controlled trial; Hazard ratio; Meta-analysis; Cancer; Colorectal cancer; Confidence interval","score_opus":0.1056410187381098,"score_gpt":0.4334366861743924,"score_spread":0.32779566743628263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600452842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93262595,0.036537614,0.024515301,0.0032090114,0.0015418436,0.00079482887,0.00012433698,0.0000038764606,0.0006472417],"genre_scores_gemma":[0.9829871,0.0049781273,0.009466573,0.001248485,0.0009307163,0.00007018586,0.000014733683,0.000017044427,0.00028705483],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972025,0.00021797094,0.002010278,0.00021090906,0.00013116366,0.00022717848],"domain_scores_gemma":[0.9950909,0.0012558864,0.0024567698,0.00029459206,0.00070717593,0.00019467877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001489718,0.00013586774,0.0022948554,0.00007193882,0.000030179071,0.000008666476,0.00025590236,0.00029821123,0.00011694795],"category_scores_gemma":[0.0015123484,0.00009958528,0.0022042412,0.00017742583,0.00009971611,0.0000053385315,0.000054403474,0.0001659991,0.0000012608896],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004928111,0.001422789,0.029441921,0.00021002647,0.58950007,0.000031593787,0.00014128824,0.16271628,0.04306116,0.0010316698,0.104564354,0.06295072],"study_design_scores_gemma":[0.012262106,0.031299,0.022072816,0.000102250226,0.7225529,0.000115370756,0.0004897721,0.00655882,0.004663193,0.003637879,0.1952519,0.0009940113],"about_ca_topic_score_codex":0.000084273684,"about_ca_topic_score_gemma":0.00026217612,"teacher_disagreement_score":0.15615746,"about_ca_system_score_codex":0.00003751553,"about_ca_system_score_gemma":0.0007585463,"threshold_uncertainty_score":0.406097},"labels":[],"label_agreement":null},{"id":"W2600462870","doi":"10.1200/jco.2012.30.15_suppl.531","title":"A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Clinical endpoint; Cohort; Placebo; Population; Randomized controlled trial; Pazopanib; Surgery; Cancer; Toxicity; Pathology","score_opus":0.1521543493657456,"score_gpt":0.5263324141883701,"score_spread":0.3741780648226245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600462870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368036,0.0005613408,0.000012302198,0.0012168081,0.0020163048,0.001789165,0.000043789998,0.0000122040365,0.0006677254],"genre_scores_gemma":[0.9974038,0.00034952955,0.00031360894,0.0003215081,0.0013967471,0.000068250934,0.000005611594,0.000052359395,0.00008856304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911304,0.002134812,0.004181354,0.00031153238,0.0015416195,0.00070026424],"domain_scores_gemma":[0.99057037,0.004083374,0.002614294,0.00047950554,0.0013640164,0.0008884229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012559292,0.00030375615,0.004005727,0.00037838196,0.000059954797,0.000009134063,0.00042061447,0.0004221371,0.0007683317],"category_scores_gemma":[0.005121302,0.0001975572,0.00049109204,0.00044824192,0.0006294779,0.00033862708,0.00020460594,0.002055637,0.000014911761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5478909,0.0135716535,0.4103056,0.00007162976,0.0008838458,0.00022422985,0.001093286,0.0000118409625,0.00001584672,0.000023276481,0.0006984783,0.025209406],"study_design_scores_gemma":[0.6384742,0.030876847,0.32552347,0.0003012354,0.0007455149,0.000042357897,0.00066906644,0.00003403543,0.000014218885,0.000009298231,0.0031532226,0.0001565365],"about_ca_topic_score_codex":0.0002263935,"about_ca_topic_score_gemma":0.00049117696,"teacher_disagreement_score":0.09058327,"about_ca_system_score_codex":0.0009349018,"about_ca_system_score_gemma":0.004615228,"threshold_uncertainty_score":0.89308345},"labels":[],"label_agreement":null},{"id":"W2600483330","doi":"10.1200/jco.2013.31.15_suppl.2517","title":"A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Pharmacodynamics; Cancer; Peripheral edema; Gastroenterology; Oncology","score_opus":0.03159889900067862,"score_gpt":0.4230644155060121,"score_spread":0.39146551650533346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600483330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975756,0.00021039638,0.0000061915134,0.00042789258,0.00020987344,0.0010982867,0.000003879782,0.0000065014788,0.00046138294],"genre_scores_gemma":[0.9985404,0.000057669586,0.00065936946,0.00044763822,0.00020692279,0.00002111112,0.000005932092,0.000024212075,0.00003675808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597484,0.0003546703,0.0025111197,0.00032777665,0.00045979634,0.0003717988],"domain_scores_gemma":[0.996489,0.00052368164,0.0017307193,0.00022110932,0.000712495,0.0003229964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012981532,0.0002295171,0.002079735,0.00037021248,0.000055013697,0.000009869807,0.00017084769,0.00018550231,0.00009704092],"category_scores_gemma":[0.0012290906,0.00016091109,0.00017861994,0.00029485862,0.0002858406,0.00027860756,0.000072601055,0.00081763836,0.0000026254534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067040618,0.032134876,0.9508876,0.000062454186,0.00021340212,0.00022775211,0.001776767,0.000021056652,0.0009468226,0.000028496492,0.00045809842,0.006538616],"study_design_scores_gemma":[0.08338936,0.0636753,0.85006183,0.00020090619,0.00020363934,0.000030200305,0.0016325167,0.000020398616,0.00006230166,0.00021196793,0.00036979647,0.00014180658],"about_ca_topic_score_codex":0.00022466986,"about_ca_topic_score_gemma":0.000588179,"teacher_disagreement_score":0.10082579,"about_ca_system_score_codex":0.000080560894,"about_ca_system_score_gemma":0.000501081,"threshold_uncertainty_score":0.6561764},"labels":[],"label_agreement":null},{"id":"W2600486674","doi":"10.1200/jco.2012.30.15_suppl.4644","title":"Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Prostate cancer; Oncology; Proportional hazards model; Clinical endpoint; Chemotherapy; Gastroenterology; Randomized controlled trial; Cancer","score_opus":0.19932598669651053,"score_gpt":0.5331515742694648,"score_spread":0.3338255875729543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600486674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632073,0.0050558117,0.00014892191,0.0044874204,0.0010265748,0.0024284865,0.00007665003,0.000007711394,0.00044768522],"genre_scores_gemma":[0.9931454,0.0023952175,0.002674539,0.00020661391,0.00095193664,0.00012083926,0.00007281973,0.00001723968,0.00041537144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939538,0.0013368033,0.0036128955,0.00017774849,0.00060900016,0.00030973981],"domain_scores_gemma":[0.99070024,0.0042363787,0.0032412633,0.00019480231,0.0011807956,0.0004465025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006828479,0.00016543793,0.0024155923,0.00016364489,0.0000453041,0.000013678969,0.000112206784,0.00018202724,0.00037821362],"category_scores_gemma":[0.0063931625,0.000098678865,0.0005909967,0.00018697703,0.0003875199,0.0002779816,0.000019482855,0.00062458124,0.000006600529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93832386,0.005515187,0.001256769,0.00007167728,0.0015135101,0.00010399932,0.0006569806,0.0000042498896,0.008403485,0.000119475306,0.00044040117,0.043590393],"study_design_scores_gemma":[0.9691912,0.01605711,0.0065888916,0.0002177447,0.0031084777,0.000033267796,0.00042964297,0.00015701432,0.0021197505,0.0005469353,0.0014521284,0.00009782913],"about_ca_topic_score_codex":0.00025516475,"about_ca_topic_score_gemma":0.000060829985,"teacher_disagreement_score":0.043492563,"about_ca_system_score_codex":0.00023204865,"about_ca_system_score_gemma":0.0042175953,"threshold_uncertainty_score":0.76536745},"labels":[],"label_agreement":null},{"id":"W2600488379","doi":"10.1200/jco.2012.30.15_suppl.6596","title":"Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Internal medicine; Adverse effect; Imatinib; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Bosutinib; Tyrosine kinase","score_opus":0.07203863384198393,"score_gpt":0.4499658444050667,"score_spread":0.37792721056308276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600488379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055636,0.0025182557,0.000023676617,0.0028823037,0.0020344,0.0012958057,0.000024950346,0.000030185478,0.00063405716],"genre_scores_gemma":[0.9903655,0.0010970144,0.0020945116,0.001967947,0.0034245562,0.000045390054,0.000025974035,0.000099547375,0.0008795678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99036556,0.00089451723,0.0057140025,0.0006340393,0.0009926726,0.0013992046],"domain_scores_gemma":[0.99318224,0.0018821143,0.0022851757,0.0007018743,0.00040471816,0.0015438555],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0048407535,0.0006166505,0.0034072173,0.0009134155,0.00007639928,0.00002303932,0.0004910404,0.00079621136,0.0008805993],"category_scores_gemma":[0.0057654036,0.00040935507,0.0005608901,0.0011651975,0.0002851481,0.0005403681,0.00025922834,0.0025372875,0.0001083946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13637267,0.01765013,0.29776022,0.00054017646,0.00082269276,0.010197333,0.0013522219,0.0005349762,0.0036086522,0.00005704085,0.015972283,0.5151316],"study_design_scores_gemma":[0.21575865,0.06627998,0.5799628,0.0021757723,0.00059929525,0.00047859465,0.00020862908,0.00058738963,0.0019242539,0.000022245782,0.13132228,0.00068010995],"about_ca_topic_score_codex":0.0005010654,"about_ca_topic_score_gemma":0.004639606,"teacher_disagreement_score":0.5144515,"about_ca_system_score_codex":0.025459193,"about_ca_system_score_gemma":0.017275045,"threshold_uncertainty_score":0.99983585},"labels":[],"label_agreement":null},{"id":"W2600505527","doi":"10.1200/jco.2015.33.15_suppl.e13025","title":"Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Temozolomide; Cancer registry; Glioblastoma; Cancer; Radiation therapy; Incidence (geometry); Population; Glioma; Epidemiology; Internal medicine; Clinical trial; Proportional hazards model; Hazard ratio; Oncology; Confidence interval","score_opus":0.11713035326659864,"score_gpt":0.45257834105138584,"score_spread":0.3354479877847872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600505527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808123,0.001960479,0.0000073415595,0.013722981,0.00043756867,0.00017898486,0.0000029345615,0.0000026874307,0.0028746873],"genre_scores_gemma":[0.9964561,0.00056586455,0.00045100384,0.0018799854,0.0005999276,0.00000310733,0.0000012703487,0.0000075451917,0.000035213616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967146,0.0005954105,0.001964179,0.00010923757,0.00042563374,0.00019094668],"domain_scores_gemma":[0.9957871,0.0019892845,0.0013004477,0.000209365,0.0004157477,0.00029807232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00573994,0.00009994038,0.001200089,0.00017321945,0.000011411516,0.0000046351947,0.00016552188,0.00022325559,0.00004963788],"category_scores_gemma":[0.0045871404,0.000050497405,0.0003134066,0.00024749516,0.00010418628,0.000049697246,0.000025316327,0.0005326949,0.000015960546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006615768,0.008230893,0.8211032,0.000039285012,0.00042664038,0.00498328,0.00046219502,0.000028198565,0.00015561651,0.00030201115,0.095186055,0.062466837],"study_design_scores_gemma":[0.02732509,0.034601945,0.6571247,0.00033136067,0.00072561874,0.0014891052,0.0008531676,0.000067669826,0.00039016866,0.00059328316,0.27639335,0.000104540675],"about_ca_topic_score_codex":0.000054223492,"about_ca_topic_score_gemma":0.00022917362,"teacher_disagreement_score":0.18120731,"about_ca_system_score_codex":0.00011818316,"about_ca_system_score_gemma":0.0010558828,"threshold_uncertainty_score":0.5491567},"labels":[],"label_agreement":null},{"id":"W2600507120","doi":"10.1200/jco.2009.27.15_suppl.11023","title":"TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Erlotinib; Amphiregulin; Gastroenterology; Hazard ratio; Lung cancer; Placebo; Biomarker; non-small cell lung cancer (NSCLC); Oncology; Cancer; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.1284308504461082,"score_gpt":0.49728029437540094,"score_spread":0.36884944392929275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600507120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884463,0.00070985116,0.000024679428,0.0074551604,0.00077852793,0.0009871464,0.00005969064,0.0000027430588,0.0015359042],"genre_scores_gemma":[0.99314564,0.00090707705,0.00062053656,0.0043654377,0.0006759522,0.00003934492,0.000011309576,0.000012770604,0.00022190504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99428254,0.00097491295,0.0036001287,0.00027763293,0.0005834834,0.00028130334],"domain_scores_gemma":[0.99349576,0.003144129,0.002346223,0.00012654121,0.00062074966,0.00026656708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060139755,0.00020485937,0.0018801716,0.00016694116,0.00004837332,0.000010360236,0.0001774418,0.00030064612,0.000061388026],"category_scores_gemma":[0.0023804063,0.00011568429,0.00022622959,0.0003173796,0.00018722928,0.00013399155,0.000018048275,0.00082596374,3.3972066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076069273,0.0033470578,0.9204471,0.0000457269,0.0005348141,0.0002287597,0.00044184033,0.00038721488,0.00002740535,0.000039043407,0.005572381,0.06132173],"study_design_scores_gemma":[0.03927158,0.0047320863,0.9480906,0.00042622027,0.0007910062,0.000023180934,0.000112502436,0.00021573913,0.000017302737,0.00004269626,0.0061636763,0.00011336856],"about_ca_topic_score_codex":0.02725459,"about_ca_topic_score_gemma":0.26872334,"teacher_disagreement_score":0.24146874,"about_ca_system_score_codex":0.0007747434,"about_ca_system_score_gemma":0.010527758,"threshold_uncertainty_score":0.9950816},"labels":[],"label_agreement":null},{"id":"W2600538636","doi":"10.1200/jco.2017.35.6_suppl.238","title":"Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Sherbrooke; Dalhousie University; Hôtel-Dieu de Québec; University of Calgary; University of Manitoba; University of Alberta; Trillium Health Centre","funders":"","keywords":"Abiraterone acetate; Medicine; Observational study; Prostate cancer; Clinical trial; Randomized controlled trial; Androgen deprivation therapy; Clinical Practice; Family medicine; Internal medicine; Oncology; Cancer","score_opus":0.3810844143040263,"score_gpt":0.5612095128641381,"score_spread":0.18012509856011183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600538636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897757,0.00009147621,0.0000023300533,0.008371901,0.00016290124,0.0011497495,0.000046856392,0.0000013165289,0.00039777954],"genre_scores_gemma":[0.9977551,0.00048936054,0.0011608375,0.0001855086,0.00007219624,0.00004843551,0.0000030607093,0.000009539058,0.0002759387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714243,0.0004874355,0.0014766196,0.00021013952,0.00047070943,0.00021266108],"domain_scores_gemma":[0.995787,0.0008513141,0.0022638212,0.0003367187,0.0005260015,0.00023509162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002430051,0.000119710916,0.0011341025,0.00012039945,0.00007639939,0.000014940687,0.00023993223,0.000059074297,0.000012288544],"category_scores_gemma":[0.00086726295,0.000055197168,0.00007036162,0.00014286986,0.00071427244,0.00012853598,0.0000567442,0.0004985342,7.8874045e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09888259,0.0010412983,0.8956084,0.000016629125,0.00046435907,0.00044875726,0.00091402297,0.00005576068,0.0000675953,0.000013190999,0.000042369822,0.002444985],"study_design_scores_gemma":[0.09957244,0.017525971,0.8815238,0.00018591569,0.00024641934,0.000008463213,0.0004502819,0.000112520145,0.000052500516,0.00006821096,0.00020516124,0.000048350354],"about_ca_topic_score_codex":0.10125573,"about_ca_topic_score_gemma":0.50337434,"teacher_disagreement_score":0.40211862,"about_ca_system_score_codex":0.00024901156,"about_ca_system_score_gemma":0.0075444537,"threshold_uncertainty_score":0.99808186},"labels":[],"label_agreement":null},{"id":"W2600545212","doi":"10.1200/jco.2014.32.15_suppl.7030","title":"First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Clinical endpoint; Internal medicine; Neutropenia; Refractory (planetary science); Phases of clinical research; Gastroenterology; Surgery; Decitabine; Clinical trial; Chemotherapy","score_opus":0.1540066286250848,"score_gpt":0.46430109972436145,"score_spread":0.31029447109927666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600545212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925753,0.00038730603,0.001004091,0.0029416617,0.0008264928,0.0017322965,0.00006363902,0.0000069975827,0.00046224982],"genre_scores_gemma":[0.9912372,0.0007954011,0.0057611284,0.00018916761,0.0010660011,0.000019132844,0.0000033779763,0.000050791605,0.00087774923],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.991938,0.0012070665,0.004948988,0.00038443552,0.001046818,0.00047469878],"domain_scores_gemma":[0.96496326,0.025386212,0.006857457,0.0010204382,0.0014369161,0.00033573376],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0104153715,0.00031166052,0.002690404,0.0002508659,0.00014908674,0.0000086987375,0.00071231904,0.00047553008,0.000039322113],"category_scores_gemma":[0.016081812,0.00015908707,0.0012553518,0.00044917187,0.00078298006,0.00008712747,0.00017912453,0.0010617345,0.0000019661352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24498859,0.06448259,0.0078126555,0.00046352175,0.018145423,0.0011061042,0.01475071,0.0034108309,0.13385685,0.000100978075,0.008822514,0.5020592],"study_design_scores_gemma":[0.2392869,0.47717363,0.02925964,0.00097363914,0.011021198,0.0016613848,0.003999274,0.031324394,0.01475321,0.00019277199,0.1898339,0.0005200823],"about_ca_topic_score_codex":0.00023401152,"about_ca_topic_score_gemma":0.0001115432,"teacher_disagreement_score":0.5015392,"about_ca_system_score_codex":0.001610866,"about_ca_system_score_gemma":0.004173626,"threshold_uncertainty_score":0.99220616},"labels":[],"label_agreement":null},{"id":"W2600554485","doi":"10.1200/jco.2017.35.4_suppl.594","title":"Tumor budding is a strong predictor of disease-free survival in stage II colorectal cancer: Validation study based on the International Tumor Budding Consensus Conference (ITBCC) recommendations.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Tumor budding; Budding; Colorectal cancer; Medicine; Oncology; Univariate analysis; Stage (stratigraphy); Internal medicine; Pathology; Cancer; Cancer research; Multivariate analysis; Biology; Metastasis","score_opus":0.2113354990228978,"score_gpt":0.47840790367398606,"score_spread":0.2670724046510883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600554485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642171,0.000023082377,0.000019318539,0.029996086,0.0024486717,0.00072322506,0.00020542495,0.000009834823,0.002357226],"genre_scores_gemma":[0.99834514,0.000047612415,0.00031394503,0.0005789971,0.00050440157,0.000040646395,0.000007917658,0.000019217065,0.00014214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956589,0.00072604395,0.0021447556,0.00033029402,0.00088556524,0.00025447184],"domain_scores_gemma":[0.9902684,0.004954908,0.003268858,0.0004627617,0.00072803395,0.00031700544],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040286398,0.00021104694,0.0012202123,0.00019270874,0.00021141209,0.000047131387,0.00070360163,0.00010449695,0.0011839842],"category_scores_gemma":[0.014611617,0.00014404704,0.00035808148,0.00011717792,0.00033513736,0.00014018871,0.0002790242,0.00088254496,0.000002630943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019739453,0.0043411567,0.9671185,0.000022749076,0.0004767495,0.0006124688,0.0002320451,0.00019863473,0.000096765885,0.00022518159,0.0012206011,0.005715675],"study_design_scores_gemma":[0.018846178,0.0121951215,0.95555633,0.00052802666,0.00036724057,0.000016019956,0.0008024798,0.008804927,0.00039298597,0.00017732754,0.0021737579,0.0001395911],"about_ca_topic_score_codex":0.0002777281,"about_ca_topic_score_gemma":0.00047074747,"teacher_disagreement_score":0.03412799,"about_ca_system_score_codex":0.00066354655,"about_ca_system_score_gemma":0.0026016664,"threshold_uncertainty_score":0.9997291},"labels":[],"label_agreement":null},{"id":"W2600571906","doi":"10.1200/jco.2013.31.15_suppl.e17523","title":"Febrile neutropenia with adjuvant docetaxel and cyclophosphamide (TC) chemotherapy for breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Febrile neutropenia; Cyclophosphamide; Internal medicine; Chemotherapy; Neutropenia; Breast cancer; Cancer; Cardiotoxicity; Oncology; Surgery","score_opus":0.05185915919306907,"score_gpt":0.4244904939645825,"score_spread":0.37263133477151344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600571906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537014,0.00085461256,0.00020290686,0.042163312,0.00082035986,0.00057105464,0.000013510121,0.00001244236,0.0016604272],"genre_scores_gemma":[0.9813184,0.0036737386,0.0030842058,0.008935285,0.0019574733,0.000062822764,9.598972e-7,0.00003148307,0.00093563594],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99820644,0.00007450024,0.0011124717,0.0001902901,0.0001761209,0.00024018623],"domain_scores_gemma":[0.99731416,0.00056501466,0.0009037237,0.00014427735,0.00064144866,0.00043135823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005997616,0.00014266065,0.00120716,0.000058657464,0.00006717687,0.000020873778,0.00009903252,0.00018588747,0.0007299182],"category_scores_gemma":[0.000118590084,0.00008598063,0.00024764566,0.00010395773,0.00022403426,0.00018217615,0.000020495729,0.00054111256,0.000012107863],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010477557,0.0011869555,0.30775866,0.00007799764,0.0007960452,0.00010871789,0.000072796116,0.000024831952,0.0018332613,0.00017844314,0.045184482,0.63230026],"study_design_scores_gemma":[0.015530653,0.009233853,0.8284487,0.0001132505,0.00037570647,0.001981466,0.0000599077,0.000034286568,0.00018983471,0.0002325454,0.14368898,0.000110818735],"about_ca_topic_score_codex":0.00019268408,"about_ca_topic_score_gemma":0.00011172347,"teacher_disagreement_score":0.63218945,"about_ca_system_score_codex":0.00010124038,"about_ca_system_score_gemma":0.0011612064,"threshold_uncertainty_score":0.7992092},"labels":[],"label_agreement":null},{"id":"W2600576686","doi":"10.1200/jco.2013.31.15_suppl.542","title":"Predictors of patient-reported toxicities from endocrine therapy: Importance of illness perceptions, treatment beliefs, and fear of recurrence.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Psychological intervention; Breast cancer; Univariate analysis; Disease; Quality of life (healthcare); Multivariate analysis; Cancer; Psychiatry","score_opus":0.0431604093421079,"score_gpt":0.3801254725037597,"score_spread":0.3369650631616518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600576686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954801,0.0031991457,0.000043963864,0.00036094926,0.0005420379,0.00016469258,0.00004261334,0.0000012265373,0.00016523547],"genre_scores_gemma":[0.9869773,0.010090741,0.002480009,0.000087773624,0.00028842143,0.000010647549,0.000016735112,0.000008804293,0.000039602266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975593,0.00019435528,0.0018301719,0.00015508106,0.00015985266,0.000101205864],"domain_scores_gemma":[0.9967151,0.00026004252,0.0022047579,0.00021527009,0.000520929,0.00008388487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032471906,0.00010537867,0.0006647733,0.000050148377,0.00001793065,0.0000023873185,0.00012058284,0.00018633966,0.00014251469],"category_scores_gemma":[0.0005511015,0.0000769105,0.00020855352,0.000056162477,0.0003964545,0.000009840778,0.000042597694,0.00012119377,3.6956587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008533472,0.001321486,0.70345545,0.000018480978,0.0011377356,0.000008258573,0.00088179787,0.000067173314,0.08411775,0.000015140787,0.0023975736,0.20572582],"study_design_scores_gemma":[0.005336795,0.022412717,0.82704735,0.0000755253,0.0002194448,0.00006284819,0.0023338434,0.000021189564,0.1209257,0.00067020516,0.020711888,0.00018249091],"about_ca_topic_score_codex":0.00010992171,"about_ca_topic_score_gemma":0.000061356455,"teacher_disagreement_score":0.20554332,"about_ca_system_score_codex":0.000039551192,"about_ca_system_score_gemma":0.0006821386,"threshold_uncertainty_score":0.31363192},"labels":[],"label_agreement":null},{"id":"W2600577610","doi":"10.1200/jco.2013.31.15_suppl.3515","title":"Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Bevacizumab; Medicine; Erlotinib; FOLFOX; KRAS; Internal medicine; Oncology; Clinical endpoint; FOLFIRI; Colorectal cancer; Population; Maintenance therapy; Panitumumab; Randomized controlled trial; Cancer; Chemotherapy; Oxaliplatin; Epidermal growth factor receptor","score_opus":0.13805510414188202,"score_gpt":0.48231684683101644,"score_spread":0.34426174268913445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600577610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871696,0.00030044522,0.00002595004,0.008521137,0.0005886331,0.0022904964,0.000014399628,0.000007120789,0.0010822],"genre_scores_gemma":[0.99473554,0.0008298453,0.0018729634,0.0013676888,0.00034656626,0.00021163333,7.7311046e-7,0.000025597335,0.0006093867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962366,0.00037623412,0.0022526798,0.00029234702,0.00049115345,0.0003509616],"domain_scores_gemma":[0.99482226,0.0019067528,0.0020399075,0.00022662013,0.00074826845,0.00025621644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016182704,0.00024702112,0.0024057736,0.00013065973,0.0000645652,0.000013361534,0.0002346587,0.00011991532,0.000105597544],"category_scores_gemma":[0.0017008911,0.000096550306,0.0002751029,0.00047466136,0.00033798555,0.00013572385,0.000057923153,0.0006650407,0.0000024801857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7959451,0.0041045616,0.042937394,0.000019495146,0.0013018093,0.00024694751,0.0011561761,0.000038465703,0.0002412751,0.00000613785,0.0013414925,0.15266111],"study_design_scores_gemma":[0.6259519,0.21103476,0.14740196,0.0009446069,0.00081850775,0.00038274034,0.0036797908,0.00008910713,0.0006582037,0.00004443844,0.008758807,0.0002351726],"about_ca_topic_score_codex":0.0009972984,"about_ca_topic_score_gemma":0.0056156344,"teacher_disagreement_score":0.20693019,"about_ca_system_score_codex":0.00033995823,"about_ca_system_score_gemma":0.0026606512,"threshold_uncertainty_score":0.47198808},"labels":[],"label_agreement":null},{"id":"W2600578171","doi":"10.1200/jco.2012.30.15_suppl.5087","title":"How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Endometrial cancer; Dissection (medical); Lymph node; General surgery; Gynecology; Grading (engineering); Cancer; Family medicine; Surgery; Internal medicine","score_opus":0.2760761207281901,"score_gpt":0.5328990008697259,"score_spread":0.25682288014153576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600578171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611202,0.004386826,0.00016521865,0.020538965,0.011706996,0.0006379941,0.00013038816,0.000007236568,0.0013061974],"genre_scores_gemma":[0.97990257,0.01236904,0.0006418241,0.0027280177,0.0038168167,0.000024906309,0.000024042254,0.000017680208,0.00047509873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923479,0.0023317223,0.0036067164,0.0002928133,0.0009965902,0.00042425463],"domain_scores_gemma":[0.9845408,0.0097936895,0.0039264774,0.00040059918,0.0008187865,0.0005196156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010543751,0.00023966086,0.0020839542,0.00009989888,0.00006909989,0.000015400861,0.0008200667,0.00038586918,0.00064319576],"category_scores_gemma":[0.002534187,0.00011343155,0.0014966727,0.0005133498,0.00084555766,0.0002091935,0.0002962402,0.0016709102,0.000008000054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047376063,0.0048005204,0.5213753,0.000025578747,0.0018224898,0.000012222714,0.000095062474,0.0000012254345,0.0000028434206,0.000040103052,0.008502301,0.45858476],"study_design_scores_gemma":[0.012873842,0.0070260223,0.7300758,0.00003344286,0.000888354,0.000021879228,0.00011658335,0.000035878584,0.000016661217,0.00005657728,0.2487745,0.00008051373],"about_ca_topic_score_codex":0.00008773074,"about_ca_topic_score_gemma":0.00013506996,"teacher_disagreement_score":0.45850423,"about_ca_system_score_codex":0.00035142875,"about_ca_system_score_gemma":0.0007703613,"threshold_uncertainty_score":0.7259366},"labels":[],"label_agreement":null},{"id":"W2600593406","doi":"10.1200/jco.2007.25.18_suppl.2549","title":"Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Celator Pharmaceuticals (Canada); Jewish General Hospital","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Vomiting; Adverse effect; Nausea; Gastroenterology; Phases of clinical research; Febrile neutropenia; Chemotherapy; Pharmacology","score_opus":0.1267529900258266,"score_gpt":0.477922118907667,"score_spread":0.3511691288818404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600593406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83703464,0.00034968433,0.16154851,0.00044056887,0.00025490098,0.00029338186,0.0000016689804,5.7927815e-7,0.00007609103],"genre_scores_gemma":[0.9938952,0.0005511554,0.0048538623,0.00023091145,0.00042239024,0.00000255379,0.0000019865076,0.000008661824,0.0000333155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983973,0.00012977129,0.00111197,0.000122021134,0.00011983738,0.00011913169],"domain_scores_gemma":[0.997818,0.0005422453,0.0012858716,0.000113428236,0.00017064172,0.0000698332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053672306,0.00007475654,0.00054630724,0.00013945291,0.000018903978,0.0000043496134,0.000118847034,0.00021428817,0.0000030811186],"category_scores_gemma":[0.00081987464,0.000053585125,0.00018716906,0.00019707227,0.000078754165,0.0000060283633,0.000024231445,0.0001809121,1.9585906e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036508933,0.0015357911,0.00007056357,0.000020296251,0.00010418426,8.418049e-7,0.0000862919,0.000015240782,0.5586805,0.00012298906,0.00005205354,0.40280232],"study_design_scores_gemma":[0.11306628,0.03033639,0.0019531648,0.000025836402,0.00011364874,0.000021310372,0.0001344774,0.0006398677,0.8431593,0.0008062706,0.0096335,0.00010993035],"about_ca_topic_score_codex":0.000021712043,"about_ca_topic_score_gemma":0.00008652109,"teacher_disagreement_score":0.40269238,"about_ca_system_score_codex":0.00002825019,"about_ca_system_score_gemma":0.00051712594,"threshold_uncertainty_score":0.2185138},"labels":[],"label_agreement":null},{"id":"W2600594844","doi":"10.1200/jco.2017.35.6_suppl.208","title":"Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Enzalutamide; LNCaP; Prostate cancer; Clonogenic assay; Medicine; Cancer research; Androgen receptor; Cancer; Oncology; Internal medicine; Cell; Biology; Genetics","score_opus":0.0661779758453938,"score_gpt":0.48988665169817464,"score_spread":0.4237086758527808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600594844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476606,0.00022955352,0.000003761493,0.0033387793,0.0004005464,0.0005558018,0.000027703258,0.0000032157498,0.0006745702],"genre_scores_gemma":[0.9980656,0.001248839,0.000065440254,0.00014602498,0.0002230502,0.000007650215,0.000004111477,0.0000090483545,0.00023025235],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771553,0.0004494781,0.0011654296,0.00015251008,0.00034258215,0.00017448023],"domain_scores_gemma":[0.99679446,0.0012559486,0.0012940526,0.00019420128,0.00025888893,0.00020243322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051783053,0.0000984356,0.0010849538,0.0001313202,0.00003397897,0.000005572351,0.000054569802,0.00018057553,0.000023033903],"category_scores_gemma":[0.00092171156,0.00006464466,0.00026214324,0.00006974402,0.00017825802,0.00010825319,0.000028221175,0.0004781765,0.0000027621445],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14678921,0.0025433986,0.39086238,0.00048803096,0.00043976153,0.0010003473,0.00035154307,0.00020450201,0.20346446,0.000013463803,0.0072976598,0.24654524],"study_design_scores_gemma":[0.031978022,0.036972895,0.30264148,0.00067942037,0.0002023335,0.000022285341,0.000019954274,0.00006634723,0.62523663,0.000032996653,0.0020757364,0.00007186326],"about_ca_topic_score_codex":0.00039947126,"about_ca_topic_score_gemma":0.00024326026,"teacher_disagreement_score":0.42177218,"about_ca_system_score_codex":0.00023631094,"about_ca_system_score_gemma":0.00070437137,"threshold_uncertainty_score":0.26361328},"labels":[],"label_agreement":null},{"id":"W2600606817","doi":"10.1200/jco.2013.31.15_suppl.e17557","title":"Time from surgery to first adjuvant chemotherapy: Experiences at two Toronto hospitals.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Regimen; Colorectal cancer; Referral; Surgery; FOLFOX; Chemotherapy regimen; Cancer; Stage (stratigraphy); Chemotherapy; Population; Internal medicine; Oxaliplatin; Nursing","score_opus":0.06587122538995897,"score_gpt":0.4293495503634163,"score_spread":0.36347832497345733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600606817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97874093,0.001494745,0.000005757109,0.012771848,0.0018940576,0.0003356882,0.000003310172,0.00001893571,0.0047347103],"genre_scores_gemma":[0.9892181,0.0006749386,0.0014853199,0.0056286263,0.001718812,0.00005100927,0.000003343836,0.000023991346,0.0011958615],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966658,0.00020486784,0.0019917092,0.00029059208,0.00047903607,0.00036803784],"domain_scores_gemma":[0.99301356,0.004396087,0.000952924,0.00025260908,0.00033279497,0.0010520028],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011591258,0.00019420173,0.0020448123,0.000048136015,0.000050289276,0.000014526347,0.00019088721,0.00025883233,0.022308977],"category_scores_gemma":[0.002193198,0.00012701048,0.00073109695,0.00010232855,0.00019231258,0.0002220336,0.000099955105,0.00030019297,0.00082078285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084430855,0.0025056556,0.39953354,0.000011009052,0.0010116475,0.0010831574,0.002676074,0.00000467111,0.00028924245,0.000002133779,0.15507072,0.42936906],"study_design_scores_gemma":[0.005579751,0.009890662,0.81391734,0.00012332838,0.00015097964,0.00012537897,0.00052416703,0.000046745277,0.0003474918,0.00008655128,0.16902764,0.00017997778],"about_ca_topic_score_codex":0.00094066985,"about_ca_topic_score_gemma":0.00053748966,"teacher_disagreement_score":0.4291891,"about_ca_system_score_codex":0.0009722024,"about_ca_system_score_gemma":0.00063491584,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W2600624233","doi":"10.1200/jco.2007.25.18_suppl.19522","title":"Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis (DVT) in cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Cancer; Deep vein; Malignancy; D-dimer; Thrombosis; Pre- and post-test probability; Internal medicine; Population; Prospective cohort study; Surgery","score_opus":0.2565900811932768,"score_gpt":0.50344897635074,"score_spread":0.24685889515746323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600624233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966944,0.0005149743,0.000066143686,0.00083191437,0.00093339226,0.00029581418,0.0000018879491,0.0000046954497,0.00065681065],"genre_scores_gemma":[0.99419564,0.0026470032,0.001854076,0.0007950815,0.00048254916,0.000005801721,0.0000010166648,0.000013540765,0.000005284668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516535,0.00031835277,0.00372542,0.0002378991,0.00029365477,0.0002593365],"domain_scores_gemma":[0.99174756,0.0056931046,0.0018998954,0.000109463515,0.0003023635,0.00024760806],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008428478,0.00012491892,0.0018024475,0.0002603737,0.000028118317,0.000006889387,0.00008523922,0.0003460718,0.000029551882],"category_scores_gemma":[0.011784201,0.00009815174,0.00013700029,0.00025007938,0.00019905226,0.00018342526,0.000114221766,0.0008512538,6.6996677e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004699987,0.002879638,0.76547575,0.000058813865,0.00010674574,0.000051378316,0.00022632327,0.000018290133,0.00003920724,0.000027464195,0.00016067382,0.23048572],"study_design_scores_gemma":[0.008603694,0.004982833,0.98322254,0.00056482456,0.00025344937,0.000011642637,0.00023177454,0.00032797555,0.000035129022,0.00016004486,0.0015312508,0.000074835785],"about_ca_topic_score_codex":0.0003082675,"about_ca_topic_score_gemma":0.00063049054,"teacher_disagreement_score":0.23041089,"about_ca_system_score_codex":0.000110951696,"about_ca_system_score_gemma":0.00032929436,"threshold_uncertainty_score":0.99653995},"labels":[],"label_agreement":null},{"id":"W2600627787","doi":"10.1200/jco.2013.31.15_suppl.e19131","title":"Less toxic chemotherapy on the uptake of all lines of chemotherapy in advanced non-small cell lung cancer: A 10-year retrospective population-based review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Erlotinib; Docetaxel; Lung cancer; Chemotherapy; Internal medicine; Retrospective cohort study; Population; Oncology; Cancer; Surgery; Cisplatin; Epidermal growth factor receptor","score_opus":0.0500419783845666,"score_gpt":0.45640071460609166,"score_spread":0.4063587362215251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600627787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752673,0.0021424885,0.000029754463,0.019984152,0.00026843883,0.00088794203,0.000008660296,0.0000034122531,0.0014078651],"genre_scores_gemma":[0.97913855,0.010541373,0.0025579755,0.007083736,0.00027224934,0.000043438722,0.0000052713704,0.000022002425,0.0003353792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974592,0.00013518325,0.0018479939,0.00015721931,0.0002518058,0.00014864994],"domain_scores_gemma":[0.9963332,0.0007744879,0.001969158,0.00022547353,0.000593198,0.00010447393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094913214,0.00013610591,0.0012753446,0.00008897072,0.000017068984,0.0000027557278,0.00014610431,0.0001669617,0.00037787654],"category_scores_gemma":[0.0005106591,0.00007876426,0.0003699046,0.00019894358,0.00006985486,0.000050344664,0.0000075533185,0.00038795103,0.000003694665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044074855,0.005501923,0.82632023,0.00073596317,0.0009848943,0.000027043021,0.00050896214,0.0005043578,0.0024329035,0.00012219402,0.010665527,0.14778852],"study_design_scores_gemma":[0.013190784,0.0055392412,0.9734098,0.0017295533,0.00035307088,0.000003488435,0.0001835173,0.0003395397,0.0012960094,0.00014366045,0.003726034,0.000085318134],"about_ca_topic_score_codex":0.00033562555,"about_ca_topic_score_gemma":0.00011832153,"teacher_disagreement_score":0.14770322,"about_ca_system_score_codex":0.0002986128,"about_ca_system_score_gemma":0.0010802557,"threshold_uncertainty_score":0.4137483},"labels":[],"label_agreement":null},{"id":"W2600669512","doi":"10.1200/jco.2017.35.6_suppl.281","title":"Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of Alberta; University of British Columbia","funders":"","keywords":"Subtyping; Bladder cancer; Medicine; Cystectomy; Concordance; Cisplatin; Oncology; Transcriptome; Internal medicine; Chemotherapy; Basal (medicine); Neoadjuvant therapy; Regimen; Pathology; Cancer; Gene expression; Gene; Biology","score_opus":0.08460426618305014,"score_gpt":0.47344365460566734,"score_spread":0.3888393884226172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600669512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934529,0.0011572366,0.00005030769,0.061397117,0.0008881959,0.0002176041,0.0000065224167,0.0000061332053,0.0017478956],"genre_scores_gemma":[0.9824493,0.0025191505,0.001818967,0.011679697,0.0008750691,0.0000072552066,2.953828e-7,0.00002286786,0.0006274272],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981589,0.00023354054,0.0009274037,0.00021059657,0.00025956903,0.0002100432],"domain_scores_gemma":[0.99710655,0.00075829244,0.0009047145,0.0003476675,0.00033388543,0.00054891116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015180205,0.00014031376,0.001050092,0.000079648766,0.00009851107,0.000025519372,0.00019789701,0.00024726326,0.00018820529],"category_scores_gemma":[0.0034009244,0.00009720238,0.00027469586,0.00003558487,0.00021395237,0.00008920164,0.000063229534,0.00044181675,0.000015819416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043932166,0.0011362716,0.10054035,0.000027366363,0.001367192,0.003662082,0.0005892419,0.000005970695,0.01634297,0.000037543177,0.007045042,0.8253138],"study_design_scores_gemma":[0.013303481,0.015207563,0.8488354,0.00015014259,0.00046685737,0.00024703343,0.00008209966,0.000004631778,0.0029136506,0.00029407445,0.11838075,0.00011429447],"about_ca_topic_score_codex":0.00011753872,"about_ca_topic_score_gemma":0.000101736725,"teacher_disagreement_score":0.8251995,"about_ca_system_score_codex":0.00011514413,"about_ca_system_score_gemma":0.002132404,"threshold_uncertainty_score":0.407147},"labels":[],"label_agreement":null},{"id":"W2600681548","doi":"10.1200/jco.2004.22.90140.4576","title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Medicine; Placebo; Zoledronic acid; Prostate cancer; Hazard ratio; Internal medicine; Surgery; Urology; Cancer; Pathology; Confidence interval","score_opus":0.1011746862801276,"score_gpt":0.4642173471630571,"score_spread":0.3630426608829295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600681548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908025,0.00048830017,0.000681939,0.005965572,0.00037800474,0.0012792866,0.000057647212,0.000003329002,0.00034341664],"genre_scores_gemma":[0.994968,0.0001975874,0.0039741057,0.0006435196,0.00005593506,0.000061800434,0.000025222838,0.000013375918,0.000060438542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633026,0.0001669424,0.0028676088,0.00016387497,0.00030208554,0.00016920829],"domain_scores_gemma":[0.9939433,0.0015713888,0.0032061385,0.0002883158,0.0008197659,0.0001711231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013195096,0.000109813394,0.0010808985,0.000119625176,0.000027352678,6.9545797e-7,0.00014054103,0.00018776141,0.000021954891],"category_scores_gemma":[0.0006050185,0.00006807052,0.00042649833,0.00012427887,0.00043206778,0.000048383496,0.000015273095,0.0004902562,0.0000013116457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010274123,0.020016225,0.8490283,0.00020980371,0.00043366945,0.0000029205173,0.000090532776,0.0010225701,0.000022576725,0.00059676805,0.00032462436,0.1179779],"study_design_scores_gemma":[0.025263702,0.023232361,0.9459777,0.0003826559,0.00042850192,0.0000033449085,0.000012838824,0.00020593367,0.000016086417,0.00036472175,0.0040654605,0.000046724785],"about_ca_topic_score_codex":0.00009759091,"about_ca_topic_score_gemma":0.00040586124,"teacher_disagreement_score":0.11793118,"about_ca_system_score_codex":0.00048387036,"about_ca_system_score_gemma":0.0038947149,"threshold_uncertainty_score":0.6909057},"labels":[],"label_agreement":null},{"id":"W2600701166","doi":"10.1200/jco.2012.30.15_suppl.5587","title":"Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neurocognitive; Quality of life (healthcare); Head and neck cancer; Cancer; Cohort; Oncology; Cognition","score_opus":0.07310468548979104,"score_gpt":0.45012331212987683,"score_spread":0.3770186266400858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600701166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931494,0.0008712299,0.00017593232,0.002420583,0.001117185,0.0011066991,0.00002018316,0.000007748266,0.0011310542],"genre_scores_gemma":[0.9938689,0.0007070409,0.000225084,0.004442379,0.0005937454,0.00006207158,0.0000035862317,0.000018026954,0.00007918153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972796,0.0003417445,0.0013876775,0.00020371922,0.0003701334,0.0004171593],"domain_scores_gemma":[0.99641556,0.001246363,0.0009713223,0.00007712845,0.00069393014,0.00059569476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080986886,0.00018338153,0.001421772,0.00016065128,0.000044262622,0.0000062066874,0.000034274723,0.00017522811,0.000074863],"category_scores_gemma":[0.0014084949,0.00012266016,0.00011723683,0.00017509775,0.0001480027,0.00015873775,0.00003421096,0.00074025494,0.000011878545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026259374,0.0034618317,0.8688621,0.000014999194,0.000815171,0.000034638066,0.0003212351,0.00003004286,0.0000047754293,0.0000025198385,0.0017929215,0.09840037],"study_design_scores_gemma":[0.033600677,0.047499932,0.9024572,0.00028676944,0.001219411,0.000024293273,0.00023370607,0.000033171014,0.00001022192,0.000008043476,0.014524001,0.00010257383],"about_ca_topic_score_codex":0.00020296057,"about_ca_topic_score_gemma":0.0007438145,"teacher_disagreement_score":0.0982978,"about_ca_system_score_codex":0.0005751519,"about_ca_system_score_gemma":0.00048327513,"threshold_uncertainty_score":0.5001936},"labels":[],"label_agreement":null},{"id":"W2600702394","doi":"10.1200/jco.2012.30.15_suppl.8064","title":"MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Refractory (planetary science); Follicular lymphoma; Internal medicine; Lymphoma; Pharmacodynamics; Pharmacokinetics; Progressive disease; Proteasome inhibitor; Dosing; Gastroenterology; Chemotherapy; Multiple myeloma","score_opus":0.12521968750109824,"score_gpt":0.42252607432585504,"score_spread":0.2973063868247568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600702394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805826,0.00023388022,0.00012396676,0.00019493043,0.0006960305,0.00044968922,0.000055076158,0.00000538116,0.00018278904],"genre_scores_gemma":[0.99382937,0.0000326675,0.0029238358,0.00041566958,0.0023473066,0.000014354639,0.00039234414,0.000025164327,0.000019283341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963026,0.0010635629,0.0015783905,0.00035229741,0.0004158301,0.00028733994],"domain_scores_gemma":[0.9971992,0.00022519758,0.001406704,0.00047979617,0.00027333084,0.00041578064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034009472,0.00018425952,0.0005877036,0.00009441049,0.000059703358,0.000017344788,0.00045313945,0.00038502237,0.00005274463],"category_scores_gemma":[0.0019854938,0.00014288814,0.00008958203,0.00012137974,0.0001453037,0.00011625543,0.00020798328,0.00046617846,0.0000101052565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005823769,0.021128263,0.87838215,0.000008217065,0.00019661656,0.000026906388,0.00036655448,0.000016710284,0.0048602363,0.000011804871,0.00092994876,0.088248804],"study_design_scores_gemma":[0.034243144,0.029557282,0.8991338,0.000060391994,0.00012276965,0.00001627713,0.00031206143,0.00014012086,0.0015125768,0.00013378265,0.03447437,0.000293418],"about_ca_topic_score_codex":0.000041137588,"about_ca_topic_score_gemma":0.00012316779,"teacher_disagreement_score":0.087955385,"about_ca_system_score_codex":0.0000714054,"about_ca_system_score_gemma":0.0010250714,"threshold_uncertainty_score":0.58268094},"labels":[],"label_agreement":null},{"id":"W2600737274","doi":"10.1200/jco.2006.24.18_suppl.3544","title":"Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bevacizumab; Irinotecan; FOLFIRI; Regimen; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Chemotherapy regimen; Surgery; Cancer","score_opus":0.04532469909777934,"score_gpt":0.4051658561591145,"score_spread":0.3598411570613351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600737274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961891,0.0006968679,0.00002632029,0.002091321,0.00007693852,0.0007130172,0.000022558772,0.0000021827318,0.00018168951],"genre_scores_gemma":[0.99709123,0.0012075548,0.0014589975,0.00007702984,0.000071225724,0.00003334693,0.000010676667,0.000008845079,0.000041087616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985702,0.00006408271,0.000900278,0.00014339584,0.00019811619,0.00012392222],"domain_scores_gemma":[0.9973791,0.0014271797,0.00071290764,0.000042434578,0.0003449668,0.0000933876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029601346,0.00012741306,0.0010178537,0.0000905434,0.000046262066,0.000003297047,0.000024331606,0.00007160567,0.000015335972],"category_scores_gemma":[0.00023870719,0.00006852613,0.000069735026,0.000087575594,0.0002085609,0.000049859646,0.000017484319,0.00013200038,9.371781e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10891778,0.008145157,0.66649747,0.000057457695,0.0006508274,0.00008991037,0.00019101263,0.00008143373,0.000005601856,0.000117273776,0.000039884002,0.21520622],"study_design_scores_gemma":[0.06853632,0.12328182,0.8050626,0.0001346076,0.0005629902,0.000045220484,0.00003084302,0.000073203075,0.000026556067,0.0001171214,0.0020726027,0.000056108183],"about_ca_topic_score_codex":0.0004221569,"about_ca_topic_score_gemma":0.0057291808,"teacher_disagreement_score":0.21515012,"about_ca_system_score_codex":0.0002600108,"about_ca_system_score_gemma":0.0005426455,"threshold_uncertainty_score":0.31970173},"labels":[],"label_agreement":null},{"id":"W2600744694","doi":"10.1200/jco.2013.31.15_suppl.5515","title":"A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Asymptomatic; Progression-free survival; Hazard ratio; Nausea; Phases of clinical research; Oncology; Gastroenterology; Confidence interval; Clinical trial; Chemotherapy","score_opus":0.07820653171816491,"score_gpt":0.42061504543284634,"score_spread":0.3424085137146814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600744694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580336,0.00014760644,0.0000028697934,0.0006993435,0.00089186046,0.002157466,0.00006465704,0.0000061585492,0.00022666945],"genre_scores_gemma":[0.99779326,0.0004971005,0.0003633326,0.0009719859,0.00024086263,0.000013160479,0.00002626611,0.0000404401,0.000053612563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942078,0.00087216584,0.0035140826,0.00041551414,0.00063147163,0.00035897418],"domain_scores_gemma":[0.99292237,0.0010982403,0.0032996614,0.0003454791,0.0019563788,0.00037788766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011823908,0.00036702983,0.0021996724,0.00022861728,0.00013598171,0.00001964909,0.0004473043,0.00035819304,0.0002617775],"category_scores_gemma":[0.0014348695,0.00021484023,0.00016534408,0.00043350997,0.0003631214,0.00033254782,0.000285348,0.0015136247,0.0000038375224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12525013,0.07917733,0.697857,0.00007737179,0.0019410378,0.000069682515,0.005809066,0.000004252149,0.012144268,0.000020514766,0.0006290575,0.07702029],"study_design_scores_gemma":[0.12744726,0.129611,0.74085385,0.00032272315,0.00017238612,0.000007352563,0.0004859367,0.000045631263,0.0003816996,0.000012210469,0.00048607113,0.00017386842],"about_ca_topic_score_codex":0.0003484676,"about_ca_topic_score_gemma":0.00018483137,"teacher_disagreement_score":0.07684642,"about_ca_system_score_codex":0.00018959682,"about_ca_system_score_gemma":0.0012630969,"threshold_uncertainty_score":0.87609303},"labels":[],"label_agreement":null},{"id":"W2600790561","doi":"10.1200/jco.2013.31.15_suppl.6614","title":"International comparison on the factors influencing reimbursement of expensive cancer drugs.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Sunitinib; Erlotinib; Family medicine; Health care; Cancer; Internal medicine; Economic growth","score_opus":0.342264293485292,"score_gpt":0.4938104700091927,"score_spread":0.15154617652390068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600790561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354493,0.00026384857,0.000024130706,0.024174795,0.0023388676,0.0001028425,0.000018603998,0.0000018467209,0.037625745],"genre_scores_gemma":[0.99215,0.0008044741,0.00012366309,0.0062839566,0.0005235848,0.00000543231,6.330645e-7,0.000007822974,0.00010039532],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692917,0.00007094919,0.0026584638,0.00012711172,0.000058353828,0.0001559623],"domain_scores_gemma":[0.9947168,0.0016466246,0.0031866536,0.00013225847,0.00016914669,0.00014848492],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016104961,0.00009202024,0.00087084214,0.00011147529,0.000030611336,0.000020164507,0.00040320406,0.00013839715,0.002613118],"category_scores_gemma":[0.0012746938,0.000063998814,0.00032464552,0.0000532447,0.00013397208,0.0001373379,0.00006732163,0.00056407833,0.00013786244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000369256,0.0013796437,0.71314263,0.000014636675,0.0012860101,0.0000053812423,0.0024904883,0.00089674536,0.00009890627,0.14491852,0.08293805,0.052459724],"study_design_scores_gemma":[0.0018955666,0.0012488989,0.35719672,0.00003757609,0.000026728023,0.0000020178259,0.00095027656,0.0022815985,0.00044251277,0.020194182,0.615563,0.00016095278],"about_ca_topic_score_codex":0.00032869558,"about_ca_topic_score_gemma":0.000011603814,"teacher_disagreement_score":0.5326249,"about_ca_system_score_codex":0.00017840076,"about_ca_system_score_gemma":0.00014155671,"threshold_uncertainty_score":0.99829865},"labels":[],"label_agreement":null},{"id":"W2600794181","doi":"10.1200/jco.2017.35.4_suppl.394","title":"Outcomes of FOLFIRINOX (FFX) and gemcitabine+nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; Ontario Institute for Cancer Research; Hamilton Health Sciences; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Cancer registry; Pancreatic cancer; Population; Cancer; Internal medicine; Surgery; Oncology; Irinotecan","score_opus":0.15504928018812905,"score_gpt":0.5352517179870724,"score_spread":0.38020243779894336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600794181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990987,0.0005633313,0.000109224646,0.0046991096,0.00040743212,0.0007942348,0.000007639758,0.0000067251403,0.0024253204],"genre_scores_gemma":[0.9944851,0.00046816334,0.0036806047,0.0006461353,0.0002672278,0.00002753821,0.0000018743847,0.000023394896,0.00040000372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947559,0.0007485425,0.0031149231,0.00030732687,0.0006563332,0.0004169746],"domain_scores_gemma":[0.99032384,0.0054184487,0.0025874004,0.00047427713,0.0007574769,0.00043856163],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005330003,0.00021977232,0.003511292,0.00031222365,0.00013025524,0.000020364689,0.00038259447,0.00041811273,0.00019522296],"category_scores_gemma":[0.01985589,0.00015572023,0.00031139312,0.00012934768,0.0004245556,0.00022724328,0.0001363299,0.0010629338,0.0000039184592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007048429,0.0028497952,0.9596735,0.00011184892,0.0005763784,0.0008569371,0.00014270771,0.000048861577,0.00007374839,0.000083775114,0.00006405245,0.028469944],"study_design_scores_gemma":[0.027329441,0.013437256,0.9562631,0.0003311406,0.0006505408,0.000044579636,0.0003101026,0.00060147827,0.000008167388,0.0007209811,0.00018153088,0.00012164258],"about_ca_topic_score_codex":0.0017508686,"about_ca_topic_score_gemma":0.003065174,"teacher_disagreement_score":0.028348302,"about_ca_system_score_codex":0.0002529987,"about_ca_system_score_gemma":0.0033210958,"threshold_uncertainty_score":0.9884003},"labels":[],"label_agreement":null},{"id":"W2600797084","doi":"10.1200/jco.2013.31.15_suppl.2023","title":"Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Temozolomide; Oncology; Progression-free survival; Placebo; Radiation therapy; Gastroenterology; Overall survival; Chemotherapy; Pathology","score_opus":0.1157911030521943,"score_gpt":0.4956195926768929,"score_spread":0.37982848962469856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600797084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866723,0.0012226219,0.0001622636,0.008864379,0.0004115061,0.0025420054,0.00001299386,0.0000054267525,0.00010653865],"genre_scores_gemma":[0.9965408,0.00064689637,0.0012603044,0.0010124402,0.00030825794,0.00019090714,0.0000025481763,0.000019783256,0.000018090375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955323,0.0008332907,0.0026094683,0.00024044476,0.00052789453,0.00025662992],"domain_scores_gemma":[0.9894105,0.007889304,0.001488429,0.00030336503,0.00065634324,0.00025205943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00436837,0.00019270713,0.0018093621,0.00029261084,0.000073117706,0.0000236269,0.00019354334,0.00023877759,0.0001874906],"category_scores_gemma":[0.0028787628,0.00010975366,0.00036844308,0.0002583092,0.00020525916,0.00013073315,0.000029788029,0.0004035221,0.0000027637195],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051534314,0.04817591,0.1206326,0.00007059102,0.0032041816,0.00121334,0.0049867625,0.00010008213,0.0017952053,0.00010414151,0.040383875,0.727799],"study_design_scores_gemma":[0.34896076,0.15140402,0.47778377,0.00016138145,0.0015482461,0.00033589397,0.0048606386,0.0016842914,0.00024346697,0.00051890797,0.0123191355,0.00017948505],"about_ca_topic_score_codex":0.00011529853,"about_ca_topic_score_gemma":0.0004934186,"teacher_disagreement_score":0.7276195,"about_ca_system_score_codex":0.00025913946,"about_ca_system_score_gemma":0.0009332673,"threshold_uncertainty_score":0.44756246},"labels":[],"label_agreement":null},{"id":"W2600806432","doi":"10.1200/jco.2013.31.15_suppl.9523","title":"End-of-life care for Medicare beneficiaries with ovarian cancer: Evaluation of intensity and rate of hospitalizations.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Cancer; Ovarian cancer; Emergency medicine; Intensive care unit; End-of-life care; Emergency department; Population; Epidemiology; Internal medicine; Palliative care","score_opus":0.10822674111109093,"score_gpt":0.4603989014128475,"score_spread":0.3521721603017566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600806432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920376,0.0012542115,0.0005111712,0.004890457,0.00051121926,0.00044383787,0.00001667846,0.000002093309,0.0003327542],"genre_scores_gemma":[0.997515,0.0006788002,0.001154603,0.00036938934,0.00024234038,0.000019905798,0.000004813914,0.000007136831,0.000007976437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817264,0.00016229536,0.0012463294,0.00008932313,0.00025122045,0.0000781714],"domain_scores_gemma":[0.99230105,0.00070575275,0.0016005938,0.000102425576,0.0051533245,0.000136832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014236313,0.000066238914,0.0009733468,0.00007942744,0.00002894573,0.0000023711927,0.000054549473,0.00014834081,0.00017544767],"category_scores_gemma":[0.002690837,0.000043769927,0.00013793628,0.00010749293,0.00027798672,0.00008096006,0.000017989685,0.00019390957,1.7943138e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003755843,0.0006386787,0.79782903,0.00043264736,0.0010339253,0.0000038205694,0.0012784842,0.00048525952,0.0007213954,0.0013755538,0.0019019927,0.1905434],"study_design_scores_gemma":[0.010464158,0.012205171,0.9655014,0.0003893874,0.0022012105,0.000030652314,0.0022626712,0.0003783826,0.0011915539,0.00082800246,0.004479064,0.000068344765],"about_ca_topic_score_codex":0.0004557821,"about_ca_topic_score_gemma":0.0009223398,"teacher_disagreement_score":0.19047505,"about_ca_system_score_codex":0.00006578704,"about_ca_system_score_gemma":0.0032323005,"threshold_uncertainty_score":0.57339627},"labels":[],"label_agreement":null},{"id":"W2600840461","doi":"10.1200/jco.2015.33.15_suppl.e17708","title":"Implementation of lung cancer nurse coordinator significantly enhances patient care and delivery of appropriate chemotherapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Referral; Lung cancer; Internal medicine; Oncology; Cancer; Erlotinib; Radiation therapy; Triage; Family medicine; Emergency medicine; Epidermal growth factor receptor","score_opus":0.07644246636623764,"score_gpt":0.40323546146352185,"score_spread":0.3267929950972842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600840461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857361,0.010054601,0.00019903536,0.0004601023,0.0011898093,0.00014910736,0.00007522408,0.000001932834,0.0021340952],"genre_scores_gemma":[0.9945921,0.0038612061,0.0009667023,0.00028002533,0.00026267522,0.0000044503145,0.0000011216775,0.000011145956,0.00002059483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706954,0.000050170485,0.0025216872,0.00015612291,0.000053370146,0.00014911842],"domain_scores_gemma":[0.9946379,0.00020428542,0.0044743572,0.000102593294,0.00040694603,0.0001739129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012421294,0.000100397636,0.0011744979,0.0001182242,0.000016735457,0.0000072740863,0.00014329358,0.00017835309,0.00011872967],"category_scores_gemma":[0.000276958,0.00009329998,0.00019960884,0.00007400181,0.0001685737,0.00024092034,0.000023012713,0.00019965389,0.0000020791915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011397973,0.00028974074,0.5212249,0.00009119165,0.0003330478,0.000005552627,0.0038890287,0.00006232761,0.000089622336,0.0033338761,0.0022923949,0.4672485],"study_design_scores_gemma":[0.027662104,0.03540144,0.7552201,0.00028188503,0.00035443876,0.000022179544,0.020918448,0.00059229956,0.00917741,0.018637989,0.13087934,0.00085234584],"about_ca_topic_score_codex":0.000672267,"about_ca_topic_score_gemma":0.00016476102,"teacher_disagreement_score":0.46639615,"about_ca_system_score_codex":0.00016184899,"about_ca_system_score_gemma":0.0007367727,"threshold_uncertainty_score":0.38046628},"labels":[],"label_agreement":null},{"id":"W2600850467","doi":"10.1200/jco.2012.30.15_suppl.6049","title":"Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; University of Toronto; University Health Network; Ontario Clinical Oncology Group; Thunder Bay Regional Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Positron emission tomography; Prospective cohort study; Radiology; Breast cancer; Esophageal cancer; Lymphoma; PET-CT; Lung cancer; Cancer; Nuclear medicine; Internal medicine","score_opus":0.049648685293893165,"score_gpt":0.4591316398619256,"score_spread":0.40948295456803246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600850467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825048,0.0050605596,0.00077486545,0.006024401,0.003987257,0.001472198,0.0000057429693,0.00001285184,0.00015736012],"genre_scores_gemma":[0.9918733,0.0016982828,0.003687749,0.0008251253,0.0017473495,0.000107323474,0.0000022657625,0.000023436416,0.000035131612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963967,0.00050065166,0.002015546,0.00021679659,0.0005175048,0.00035280516],"domain_scores_gemma":[0.9918753,0.0048781065,0.0019362858,0.0002263022,0.0005962388,0.00048777426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005953923,0.00018085557,0.0014160647,0.00021424245,0.00009816845,0.000011083809,0.00027381655,0.00005985212,0.00006232327],"category_scores_gemma":[0.0042609563,0.00010093954,0.0009030078,0.00032263968,0.00026197082,0.00010865265,0.00007892921,0.0013317134,7.113903e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002241951,0.005824927,0.85654926,0.000049662925,0.0012984589,0.0000606763,0.00018738011,0.000012875998,0.000035118606,0.000013999353,0.005103647,0.12862203],"study_design_scores_gemma":[0.008133889,0.0075909123,0.9558063,0.000322453,0.0017698293,0.00016988027,0.00022934418,0.0016489547,0.00010692517,0.000036613674,0.024086643,0.000098224125],"about_ca_topic_score_codex":0.00010728963,"about_ca_topic_score_gemma":0.000016007172,"teacher_disagreement_score":0.1285238,"about_ca_system_score_codex":0.00012208837,"about_ca_system_score_gemma":0.0003584375,"threshold_uncertainty_score":0.5785706},"labels":[],"label_agreement":null},{"id":"W2600855551","doi":"10.1200/jco.2013.31.15_suppl.5002","title":"Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aflibercept; Medicine; Docetaxel; Placebo; Prednisone; Hazard ratio; Clinical endpoint; Internal medicine; Prostate cancer; Surgery; Bevacizumab; Randomized controlled trial; Urology; Oncology; Chemotherapy; Gastroenterology; Cancer; Confidence interval; Pathology","score_opus":0.24906357258083653,"score_gpt":0.5163570845611213,"score_spread":0.2672935119802847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600855551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766255,0.0019547867,0.00004451399,0.0037053353,0.00042989026,0.005730109,0.000029722345,0.000003384497,0.00043967756],"genre_scores_gemma":[0.9851715,0.006041196,0.0061916546,0.000033988075,0.00037357208,0.0006299614,0.0000123460895,0.00002162098,0.0015241362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966785,0.00034947827,0.002165738,0.00018735889,0.000387927,0.00023104316],"domain_scores_gemma":[0.99234253,0.004343002,0.0019754467,0.00014453549,0.00090669875,0.000287792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017682745,0.00017462861,0.0027098518,0.00013952528,0.00003538362,0.000011480335,0.00006716727,0.0001408387,0.00013833538],"category_scores_gemma":[0.00056256546,0.00008855307,0.0004470933,0.00010995585,0.0006197304,0.0001285,0.000013324561,0.0001633493,9.46765e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9593493,0.0029056766,0.00027820293,0.00013893459,0.0032725034,0.00004355678,0.000516099,0.000022994102,0.0004983057,0.000047162604,0.00021346097,0.03271382],"study_design_scores_gemma":[0.90529376,0.08834138,0.0005778053,0.00011466747,0.0026191634,0.000022499074,0.00029877163,0.000100637924,0.0012469736,0.00014274636,0.0011722865,0.00006931183],"about_ca_topic_score_codex":0.00027956505,"about_ca_topic_score_gemma":0.00016105616,"teacher_disagreement_score":0.085435696,"about_ca_system_score_codex":0.00016539027,"about_ca_system_score_gemma":0.0027067685,"threshold_uncertainty_score":0.4801691},"labels":[],"label_agreement":null},{"id":"W2600875206","doi":"10.1200/jco.2015.33.15_suppl.e22119","title":"The role of IL-17/IL-6 axis in the development of chronic lymphocytic leukemia.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Bone marrow; Peripheral blood mononuclear cell; Immunology; Cancer research; Leukemia; Interleukin; Interleukin 4; Tumor microenvironment; Cytokine; In vitro; Biology; Immune system","score_opus":0.13215124661092476,"score_gpt":0.45952233563395295,"score_spread":0.3273710890230282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600875206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838996,0.003467617,0.000048718448,0.0014987759,0.0005327677,0.00034792873,0.0000018536856,0.000004276882,0.010198465],"genre_scores_gemma":[0.996452,0.0007299785,0.001420319,0.00032956066,0.00071295036,0.000009245111,0.0000012449992,0.000016932972,0.00032780124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99321675,0.00088517816,0.003974612,0.00018240632,0.0012994397,0.00044162164],"domain_scores_gemma":[0.9894373,0.0070513524,0.0018608283,0.000497867,0.00081283913,0.00033985433],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01687237,0.00015625513,0.0013937707,0.00015307311,0.000049801154,0.000008452836,0.00081234414,0.00038143925,0.00004179079],"category_scores_gemma":[0.009270016,0.00007758023,0.0003764509,0.00037870265,0.0007486015,0.00007477342,0.00018941546,0.0010417794,0.00002519404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016259503,0.0022123693,0.007953576,0.0002757489,0.0012973811,0.0010571599,0.007322133,0.0014510506,0.0013603523,0.0012527251,0.019904906,0.9396531],"study_design_scores_gemma":[0.099989675,0.024661433,0.022185007,0.0006388597,0.0003977899,0.0022762727,0.007404493,0.01779047,0.0047578854,0.0037434075,0.81589365,0.00026103194],"about_ca_topic_score_codex":0.00020316026,"about_ca_topic_score_gemma":0.0005421854,"teacher_disagreement_score":0.9393921,"about_ca_system_score_codex":0.042340655,"about_ca_system_score_gemma":0.25217426,"threshold_uncertainty_score":0.9990753},"labels":[],"label_agreement":null},{"id":"W2600898566","doi":"10.1200/jco.2012.30.15_suppl.540","title":"BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Dysgeusia; Letrozole; Aromatase inhibitor; Anastrozole; Breast cancer; Oncology; Clinical endpoint; Adverse effect; Placebo; Population; Progression-free survival; Cancer; Clinical trial; Aromatase; Chemotherapy; Pathology","score_opus":0.05317573863883323,"score_gpt":0.4219023762950248,"score_spread":0.36872663765619157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600898566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857951,0.00073085225,0.000014662044,0.0074647614,0.0014816484,0.00055561773,0.000045497214,0.00001353189,0.0038983738],"genre_scores_gemma":[0.99348897,0.0014139091,0.0021780194,0.0011524683,0.0014018499,0.000027322505,0.00002156288,0.00004318661,0.00027274218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966047,0.00048186802,0.0014887273,0.0002746388,0.0005456157,0.0006044661],"domain_scores_gemma":[0.9955973,0.0012114368,0.0015263503,0.00018021831,0.00070226524,0.0007824283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009973901,0.00030897855,0.001809295,0.00018568448,0.00005352595,0.000007497821,0.00014964426,0.00036422675,0.00054319185],"category_scores_gemma":[0.00021788903,0.00019567748,0.00020417197,0.00038606903,0.00041752344,0.0003488736,0.000041731862,0.0012366165,0.000019415113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21664825,0.009610907,0.69661987,0.00002006757,0.0014023328,0.0005639978,0.00057414395,0.000008852405,0.00007952012,0.000016533568,0.0044226944,0.07003286],"study_design_scores_gemma":[0.07111125,0.04624558,0.87279993,0.000194265,0.00096143625,0.0002712057,0.00023586313,0.0000035235357,0.00007106534,0.0000075752846,0.007901989,0.0001963264],"about_ca_topic_score_codex":0.00033486672,"about_ca_topic_score_gemma":0.00075119094,"teacher_disagreement_score":0.17618008,"about_ca_system_score_codex":0.0008973637,"about_ca_system_score_gemma":0.0014753285,"threshold_uncertainty_score":0.7979496},"labels":[],"label_agreement":null},{"id":"W2600900713","doi":"10.1200/jco.2014.32.15_suppl.e17608","title":"Antiemetic recommendations for breast cancer patients receiving highly emetogenic chemotherapy: A systematic review incorporating network meta-analyses.","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Nausea; Vomiting; Chemotherapy-induced nausea and vomiting; Antiemetic; Regimen; Chemotherapy; Internal medicine; Breast cancer; Meta-analysis; Cyclophosphamide; Oncology; Anthracycline; Randomized controlled trial; Cancer","score_opus":0.4761298449697116,"score_gpt":0.5783689983849919,"score_spread":0.10223915341528028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600900713","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023359582,0.98562944,0.0008660236,0.007309303,0.0019152496,0.0040254905,0.000042419175,0.00001833501,0.00019140034],"genre_scores_gemma":[0.00004451543,0.9794156,0.0092722485,0.0076168044,0.0027202773,0.00036177435,0.000055763823,0.00009905059,0.00041397908],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.982652,0.0035729418,0.01226714,0.00047272473,0.0006080559,0.00042712237],"domain_scores_gemma":[0.96541995,0.008440414,0.023620347,0.0005976362,0.0015234916,0.0003981452],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.02051058,0.00057375745,0.02233457,0.00031130872,0.00011992889,0.000033950408,0.00053474214,0.00060366595,0.00025375446],"category_scores_gemma":[0.0103455745,0.00032805893,0.007887381,0.0006674808,0.000085043925,0.000100693665,0.00011361977,0.0013982865,0.00001916447],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067435976,0.0005155954,0.00004908846,0.47638178,0.03113989,0.000012000467,0.0000033178976,0.0000013369377,1.4963819e-8,0.000023937175,0.03745764,0.45434797],"study_design_scores_gemma":[0.0015203672,0.0014127815,0.00003233722,0.27341977,0.24426374,0.000090155816,0.0000026093098,0.000012594064,1.9884023e-8,0.00005598209,0.4789958,0.00019384558],"about_ca_topic_score_codex":0.0000075709645,"about_ca_topic_score_gemma":0.000011972323,"teacher_disagreement_score":0.45415413,"about_ca_system_score_codex":0.0004746592,"about_ca_system_score_gemma":0.001851004,"threshold_uncertainty_score":0.99991715},"labels":[],"label_agreement":null},{"id":"W2600905780","doi":"10.1200/jco.2014.32.15_suppl.e20651","title":"Outpatient massage impact on symptom distress in cancer patients and caregivers.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Massage; Physical therapy; Distress; Anxiety; Outpatient clinic; Cancer; Internal medicine; Psychiatry; Alternative medicine; Clinical psychology","score_opus":0.10542968275221894,"score_gpt":0.5059110923421045,"score_spread":0.4004814095898856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600905780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944427,0.00015368263,0.000012413565,0.002472254,0.0010124375,0.00012008314,0.000011519019,0.0000020026678,0.0017728921],"genre_scores_gemma":[0.99793804,0.00039618308,0.00004770114,0.00083180517,0.0007179921,0.000002064861,0.000003845049,0.000005374474,0.000056993456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982549,0.00025027175,0.0009675804,0.0001245802,0.00025562034,0.00014703858],"domain_scores_gemma":[0.997344,0.0015724484,0.0006441826,0.000067438144,0.00016947677,0.00020243348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008531048,0.00010478317,0.00091584097,0.000094148185,0.00002308762,0.0000023764705,0.000064810774,0.000039547944,0.000093438575],"category_scores_gemma":[0.0015275695,0.000060145743,0.00016200078,0.000051730654,0.0001392899,0.00003212786,0.00004970792,0.00052312925,0.0000015923225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001493063,0.000893628,0.8019709,0.000011851787,0.00013887377,0.000059933413,0.00025801285,0.000008680717,0.0000023979353,0.000020795898,0.0010205809,0.19412127],"study_design_scores_gemma":[0.01028765,0.033960115,0.93905514,0.00020762242,0.00011038762,0.000006208771,0.00021796889,0.000050789004,0.000007792919,0.000059289785,0.015986258,0.000050758288],"about_ca_topic_score_codex":0.00012572865,"about_ca_topic_score_gemma":0.00014266158,"teacher_disagreement_score":0.19407052,"about_ca_system_score_codex":0.00017162818,"about_ca_system_score_gemma":0.000111282934,"threshold_uncertainty_score":0.24526723},"labels":[],"label_agreement":null},{"id":"W2600914334","doi":"10.1200/jco.2012.30.15_suppl.9025","title":"Parenteral hydration (PH) in advanced cancer patients: A multi-center, double-blind, placebo-controlled randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Quality of life (healthcare); Delirium; Internal medicine; Cancer; Adverse effect; Intensive care medicine; Nursing","score_opus":0.34240063042961094,"score_gpt":0.572107895503877,"score_spread":0.22970726507426603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600914334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890585,0.002563715,0.00027723107,0.0013528258,0.00429762,0.001817039,0.000004406405,0.000006229358,0.0007750575],"genre_scores_gemma":[0.991077,0.0038939067,0.0023582163,0.0009204701,0.001436121,0.00012271694,0.00001234925,0.000015142555,0.00016404646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99394435,0.0011835614,0.004061104,0.00014758938,0.00036804032,0.0002953473],"domain_scores_gemma":[0.99146545,0.00427913,0.003182833,0.00012519775,0.00063487137,0.0003125478],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051199542,0.00017531867,0.0037591632,0.0002170357,0.00001828625,0.0000050459853,0.000119546065,0.00032285706,0.000101555575],"category_scores_gemma":[0.010340389,0.00011122717,0.00094128435,0.00012695968,0.00014461872,0.0002822363,0.000030312478,0.000695199,0.0000073513943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8594833,0.008576869,0.11936369,0.000022230779,0.0005204312,0.000014987175,0.0005966461,0.000018692954,0.000023567458,0.000015653584,0.00030832607,0.011055589],"study_design_scores_gemma":[0.9793006,0.0047240457,0.0040623923,0.00050303736,0.0005028201,0.000004166758,0.00013850055,0.00021314212,0.00006678032,0.000017780643,0.010375072,0.00009161644],"about_ca_topic_score_codex":0.000047745943,"about_ca_topic_score_gemma":0.00011160658,"teacher_disagreement_score":0.11981733,"about_ca_system_score_codex":0.00021542418,"about_ca_system_score_gemma":0.00055112876,"threshold_uncertainty_score":0.9979959},"labels":[],"label_agreement":null},{"id":"W2600917109","doi":"10.1200/jco.2014.32.15_suppl.9601","title":"Risk factors and prevalence of cognitive deficits in women with gynecologic malignancies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Montreal Cognitive Assessment; Cognition; Anxiety; Depression (economics); Physical therapy; Internal medicine; Psychiatry; Cognitive impairment","score_opus":0.055469951489311574,"score_gpt":0.39237018035501803,"score_spread":0.3369002288657065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600917109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694806,0.00042921246,0.000113615104,0.0005326744,0.0002334325,0.000267335,0.000009036373,0.000005044376,0.0014615933],"genre_scores_gemma":[0.9959281,0.0029944284,0.00027077584,0.00059905206,0.000122046855,0.000007486601,2.7633786e-7,0.0000094546,0.00006838227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973553,0.00052129594,0.0014340092,0.00018209955,0.0002587734,0.00024852532],"domain_scores_gemma":[0.98760563,0.009643396,0.0018870845,0.000072783645,0.0005848445,0.00020626953],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029155745,0.00014072309,0.0014191471,0.0001513285,0.000028277582,0.0000024587252,0.000069061214,0.0002312588,0.00008605527],"category_scores_gemma":[0.020235423,0.00008430745,0.000104211904,0.00016484573,0.00059733936,0.000076689146,0.00005404974,0.00080912036,0.000002379622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068340334,0.0008576575,0.9496693,0.000090108995,0.00033379433,0.000072977055,0.0006610137,0.0000067573546,0.000020611302,0.000010224269,0.00008089871,0.041362617],"study_design_scores_gemma":[0.009664681,0.044731613,0.9423927,0.00060158886,0.00048042994,0.00007904701,0.0012830824,0.000017674196,0.00006841576,0.00021486852,0.0003854284,0.000080444],"about_ca_topic_score_codex":0.000018903751,"about_ca_topic_score_gemma":0.000048750255,"teacher_disagreement_score":0.043873955,"about_ca_system_score_codex":0.00015737313,"about_ca_system_score_gemma":0.00051552773,"threshold_uncertainty_score":0.98801756},"labels":[],"label_agreement":null},{"id":"W2600932175","doi":"10.1200/jco.2013.31.15_suppl.e16088","title":"Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Université de Montréal; Université Laval; Sanofi (Canada); Sunnybrook Health Science Centre; University of Toronto; Moncton Hospital; London Health Sciences Centre; Grand River Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Quality of life (healthcare); Docetaxel; Internal medicine; Cancer; Oncology; Androgen deprivation therapy","score_opus":0.1631294014390921,"score_gpt":0.48985776265248515,"score_spread":0.32672836121339305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600932175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642605,0.000429264,0.000015675747,0.0017849456,0.00008009541,0.0007449292,0.00004489539,0.000003844637,0.00047030437],"genre_scores_gemma":[0.99692035,0.00041915436,0.001966715,0.0001376273,0.00007862402,0.000024630192,0.00001600613,0.000015870062,0.0004209996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996188,0.0005020536,0.0022304982,0.00016378265,0.0006914857,0.00022417233],"domain_scores_gemma":[0.9934755,0.00089020806,0.0026817848,0.00017855848,0.0024096046,0.0003643296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013904,0.00014208339,0.0015760491,0.00012261035,0.000026630378,0.000005912776,0.00009227456,0.00011605939,0.00022355778],"category_scores_gemma":[0.00093541417,0.000070396316,0.00017738524,0.00023342409,0.0004251829,0.00017217665,0.000017985718,0.00043729102,0.0000025641395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052382655,0.0030072883,0.92088443,0.00026781097,0.001479653,0.00007303367,0.00020908727,0.000029693572,0.0008275586,0.000020000147,0.0006612176,0.020157559],"study_design_scores_gemma":[0.02344149,0.030715086,0.9437336,0.00022348286,0.0004254262,0.0000062737004,0.00026954923,0.0000147408755,0.00062760635,0.000056010173,0.0004119586,0.00007481055],"about_ca_topic_score_codex":0.00095071236,"about_ca_topic_score_gemma":0.0004294284,"teacher_disagreement_score":0.028941166,"about_ca_system_score_codex":0.0001637739,"about_ca_system_score_gemma":0.0031841837,"threshold_uncertainty_score":0.5648605},"labels":[],"label_agreement":null},{"id":"W2600949427","doi":"10.1200/jco.2017.35.4_suppl.254","title":"A population-based analysis of urban-rural disparities in advanced pancreatic cancer (APC) management and outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Rurality; Gemcitabine; Pancreatic cancer; Internal medicine; FOLFIRINOX; Cancer; Residence; Rural area; Cancer registry; Population; Oncology; Demography; Environmental health; Colorectal cancer; Pathology","score_opus":0.0907414009825905,"score_gpt":0.4095549377271247,"score_spread":0.3188135367445342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600949427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134177,0.0018760453,0.00022391422,0.0022662426,0.0007314672,0.0001025568,0.000048194743,0.0000020407385,0.0034077591],"genre_scores_gemma":[0.9957409,0.00214502,0.001047266,0.0006166009,0.000101240454,0.0000075685307,0.0000021389535,0.000008722844,0.0003305796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969736,0.00003661138,0.0025850162,0.00016781504,0.000045297365,0.00019169695],"domain_scores_gemma":[0.99469775,0.0005123386,0.0043225777,0.00027974485,0.00006528955,0.00012230656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016939036,0.00011527376,0.0021849228,0.00041924763,0.000059084156,0.000032013606,0.0002874941,0.000173708,0.000111723624],"category_scores_gemma":[0.0012845396,0.00010664206,0.00042054357,0.00010457763,0.00015378033,0.00034550478,0.000052268675,0.00025595922,0.000002642791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000278389,0.00016197006,0.9665048,0.000023558921,0.00070643437,0.000010279146,0.000030306974,0.00097003835,1.5875925e-7,0.012191941,0.00009441485,0.01902771],"study_design_scores_gemma":[0.0027569255,0.00032197274,0.98686326,0.000043418273,0.00027143795,3.8468457e-7,0.000026012964,0.0014825558,6.227743e-7,0.005484543,0.0026388112,0.000110061505],"about_ca_topic_score_codex":0.0025876411,"about_ca_topic_score_gemma":0.0019800623,"teacher_disagreement_score":0.020358456,"about_ca_system_score_codex":0.00017481334,"about_ca_system_score_gemma":0.00010443472,"threshold_uncertainty_score":0.4348737},"labels":[],"label_agreement":null},{"id":"W2600960064","doi":"10.1200/jco.2012.30.15_suppl.6130","title":"Multidisciplinary assessment and reporting of fitness to drive in brain tumor patients: A gray matter.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Logistic regression; Family medicine; Demographics; Demography; Internal medicine","score_opus":0.3376425138435044,"score_gpt":0.6082955211792586,"score_spread":0.27065300733575415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600960064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384826,0.00019863076,0.0001926099,0.0030486637,0.00039081197,0.00015279245,0.0000018326102,0.0000017802686,0.0021646135],"genre_scores_gemma":[0.979471,0.000051049476,0.019404355,0.00075568253,0.00022941866,0.0000024639116,0.0000010695084,0.000010994253,0.00007393325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958354,0.00022101396,0.0034768155,0.000098078235,0.00020895728,0.00015973928],"domain_scores_gemma":[0.9933241,0.0016345223,0.0043931385,0.000100439785,0.000288692,0.0002591199],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035122535,0.00008213714,0.0013325299,0.00013629506,0.000009110111,0.000001196818,0.000058914684,0.000110234745,0.000064937965],"category_scores_gemma":[0.008908251,0.000056964862,0.00016066738,0.00010515769,0.00010875164,0.00007825073,0.00008136546,0.0003469859,0.0000030728938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004977938,0.0014180109,0.9880739,0.000074186915,0.000068842535,0.00012458934,0.0010195733,0.0000053985555,0.00031039136,0.000029968398,0.00070685765,0.007670531],"study_design_scores_gemma":[0.003765963,0.004105822,0.9870259,0.00094507466,0.000068784204,0.000043791704,0.00081702933,0.000008133426,0.00019278815,0.000091121554,0.0028847097,0.000050837833],"about_ca_topic_score_codex":0.000027816266,"about_ca_topic_score_gemma":0.00002160123,"teacher_disagreement_score":0.019211747,"about_ca_system_score_codex":0.000101296646,"about_ca_system_score_gemma":0.00037940277,"threshold_uncertainty_score":0.99944013},"labels":[],"label_agreement":null},{"id":"W2600971427","doi":"10.1200/jco.2013.31.15_suppl.8537","title":"Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Bendamustine; Tolerability; Internal medicine; Rituximab; Clinical endpoint; CHOP; Gastroenterology; Phases of clinical research; Lymphoma; Surgery; Adverse effect; Clinical trial","score_opus":0.03227101687520967,"score_gpt":0.3674593381366304,"score_spread":0.33518832126142073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600971427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078226,0.00084998325,0.0005911345,0.003891852,0.0006083836,0.0027554664,0.000317456,0.000024559771,0.00017890372],"genre_scores_gemma":[0.99188703,0.00031181393,0.0046802014,0.0020215544,0.00042027494,0.00022054277,0.00021108822,0.00007271377,0.00017476722],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940199,0.00045345284,0.003312618,0.00072161446,0.0008557048,0.0006366807],"domain_scores_gemma":[0.98755604,0.0064410456,0.0033254086,0.0006972568,0.0013582396,0.0006220373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009805489,0.00057835516,0.0038741957,0.00016708601,0.0002923171,0.00005055374,0.000493847,0.00037263936,0.00078163896],"category_scores_gemma":[0.0006228329,0.00028035472,0.00074823585,0.0003097232,0.0004309764,0.00023632101,0.00011038701,0.0004157884,0.000028875222],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15959519,0.117632195,0.17033046,0.00005528827,0.0055774483,0.0008890065,0.0009471691,0.000048098475,0.00001973604,0.0000028061252,0.029979223,0.51492333],"study_design_scores_gemma":[0.47300184,0.096699074,0.33632767,0.00019130869,0.005011405,0.00010417331,0.0006515549,0.0002291741,0.00019031961,0.0000220231,0.08720791,0.00036351837],"about_ca_topic_score_codex":0.0005602237,"about_ca_topic_score_gemma":0.00095868675,"teacher_disagreement_score":0.51455986,"about_ca_system_score_codex":0.0011355318,"about_ca_system_score_gemma":0.0023245993,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W2600973140","doi":"10.1200/jco.2014.32.15_suppl.e17661","title":"Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Manitoba","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Retrospective cohort study; Cohort; Stage (stratigraphy); Internal medicine; Hospital admission; Cancer; Emergency medicine","score_opus":0.06996706244504795,"score_gpt":0.43963645638551596,"score_spread":0.369669393940468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600973140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030405,0.0018590249,0.000044870263,0.005329341,0.0005158342,0.00044933424,0.000010993181,0.000014683914,0.0014718765],"genre_scores_gemma":[0.9890838,0.005817768,0.0009987628,0.001950258,0.0017166449,0.000015428139,0.000004528792,0.000046112014,0.00036669927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702156,0.0002710881,0.0013691266,0.00030952707,0.0006472086,0.00038146455],"domain_scores_gemma":[0.99560595,0.0011980216,0.0013726677,0.00025653144,0.0010049662,0.0005618552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010181236,0.00022488582,0.001487433,0.00011559361,0.000086081,0.000019838273,0.00023671839,0.0003101165,0.0003909393],"category_scores_gemma":[0.0010001872,0.00013251125,0.00030803448,0.00011685488,0.00015347789,0.0001172099,0.000077599936,0.0011801693,0.000004237974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012625159,0.0018437649,0.91449785,0.000049862312,0.00084312644,0.00010058467,0.00064075703,0.000012551489,0.00012689253,0.0000017062252,0.0021086792,0.06714908],"study_design_scores_gemma":[0.03454045,0.016043589,0.93165714,0.00058006187,0.0001898731,0.0000045121305,0.00008354461,0.000084588355,0.0006823244,0.00006386184,0.015910732,0.00015931639],"about_ca_topic_score_codex":0.00014323212,"about_ca_topic_score_gemma":0.00007550076,"teacher_disagreement_score":0.066989765,"about_ca_system_score_codex":0.00034487425,"about_ca_system_score_gemma":0.0009652275,"threshold_uncertainty_score":0.5403652},"labels":[],"label_agreement":null},{"id":"W2600997186","doi":"10.1200/jco.2017.35.6_suppl.26","title":"Genomic architecture of radioresistant prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Radioresistance; PTEN; Medicine; Prostate; Cancer; Radiation therapy; Genome instability; Copy-number variation; Cancer research; Oncology; Gene; Internal medicine; Biology; Genome; Genetics; DNA damage","score_opus":0.1472413046791093,"score_gpt":0.5243546875461824,"score_spread":0.3771133828670731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600997186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96831846,0.0038876373,0.000014338337,0.02108024,0.00088881596,0.00023404995,0.00001400593,0.000003238815,0.005559229],"genre_scores_gemma":[0.9868084,0.008328204,0.0014466237,0.00028719808,0.0010358229,0.000004223713,0.0000011601461,0.000013441229,0.002074889],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978274,0.00015513328,0.0013569471,0.0001302657,0.00031271856,0.0002175036],"domain_scores_gemma":[0.9963331,0.00047147583,0.0021280283,0.00031958925,0.00041784957,0.00032994893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018225736,0.00009668458,0.0012166,0.00008874542,0.00008625947,0.000011339557,0.00028705166,0.00019597713,0.00012606548],"category_scores_gemma":[0.0016004293,0.000056261997,0.00041983492,0.000034820514,0.00058987684,0.00005782479,0.00007422786,0.0007961039,0.000004669027],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020958442,0.0009080522,0.43799973,0.00012962657,0.0008771901,0.0014473507,0.00023282054,0.000014765342,0.0040209824,0.00007194809,0.0037374068,0.5296017],"study_design_scores_gemma":[0.01364469,0.010528677,0.84602565,0.0002468247,0.00036381398,0.00019344522,0.000052545456,0.000014895864,0.0013268495,0.0009079138,0.12662251,0.00007218717],"about_ca_topic_score_codex":0.000063039595,"about_ca_topic_score_gemma":0.000053893804,"teacher_disagreement_score":0.5295295,"about_ca_system_score_codex":0.00016000685,"about_ca_system_score_gemma":0.0031835486,"threshold_uncertainty_score":0.56474787},"labels":[],"label_agreement":null},{"id":"W2600997638","doi":"10.1200/jco.2013.31.15_suppl.8096","title":"Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for <i>ALK</i> gene rearrangements.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences North; University of British Columbia; Ottawa Hospital; University Health Network; McMaster University Medical Centre; Health Sciences Centre; University of Ottawa; McGill University; McGill University Health Centre; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Toronto; Dalhousie University; Jewish General Hospital","funders":"","keywords":"Immunohistochemistry; Fluorescence in situ hybridization; Medicine; Fish <Actinopterygii>; Context (archaeology); Crizotinib; Lung cancer; Pathology; Oncology; Internal medicine; Biology; Gene; Genetics; Fishery","score_opus":0.03625839351098122,"score_gpt":0.4253426449634531,"score_spread":0.3890842514524719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600997638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98296964,0.00033102054,0.00012016458,0.012947281,0.00037731155,0.0015596177,0.000052190306,0.000003988817,0.0016387693],"genre_scores_gemma":[0.986353,0.00029720296,0.009061569,0.0037012426,0.000212054,0.000062887,0.000016841415,0.000018374754,0.00027685487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980887,0.000102817576,0.001073792,0.00024600976,0.0001760465,0.00031261408],"domain_scores_gemma":[0.9977368,0.0003094768,0.00032867547,0.00015589622,0.00045526845,0.0010138722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009092591,0.00013982119,0.0007188304,0.00018405741,0.000088029075,0.000033943277,0.000090472575,0.0001381078,0.00006220706],"category_scores_gemma":[0.001046192,0.00011382766,0.00009273613,0.00010300107,0.000073678224,0.00013226316,0.000025910076,0.00029099023,0.0000034641798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047570285,0.0038446093,0.5832662,0.00014839803,0.0020348933,0.001436139,0.0048078545,0.000071472015,0.010503778,0.0000132697605,0.044420406,0.34469593],"study_design_scores_gemma":[0.038503405,0.010710405,0.8560151,0.00026702706,0.0012140296,0.00017421144,0.0026698215,0.00024501755,0.000379155,0.00006521892,0.08942218,0.00033444838],"about_ca_topic_score_codex":0.12983796,"about_ca_topic_score_gemma":0.30682585,"teacher_disagreement_score":0.34436148,"about_ca_system_score_codex":0.00096684054,"about_ca_system_score_gemma":0.0025389076,"threshold_uncertainty_score":0.87595654},"labels":[],"label_agreement":null},{"id":"W2601016168","doi":"10.1200/jco.2017.35.15_suppl.10037","title":"Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cancer; Radiation therapy; Proportional hazards model; Gastroenterology; Hazard ratio; Gastroesophageal Junction; Performance status; Chemotherapy; Surgery; Adenocarcinoma; Confidence interval","score_opus":0.092427492409345,"score_gpt":0.46241804466682823,"score_spread":0.36999055225748323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601016168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974789,0.00020774128,0.00022648096,0.021336678,0.0027095927,0.00047671548,0.000032157284,0.00000758836,0.00021399505],"genre_scores_gemma":[0.99019444,0.0007543264,0.0024840934,0.004442922,0.001326678,0.000031694202,0.0000040446234,0.00001871608,0.00074309815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978143,0.00010249563,0.0011140311,0.00021812283,0.00045619314,0.0002948825],"domain_scores_gemma":[0.99579674,0.0010730539,0.002163554,0.00037872995,0.00034934116,0.00023855455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006743472,0.00015306698,0.0011503067,0.000033576354,0.0001429235,0.000043694115,0.0005643205,0.0001285612,0.00028582083],"category_scores_gemma":[0.0013900908,0.000079753,0.00035717667,0.000041218012,0.0003492472,0.00016223536,0.000118372875,0.0004278363,0.0000026780258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035570762,0.00030457138,0.88456386,0.000010406123,0.0004072676,0.00008104015,0.00018560108,0.000008231178,4.6683115e-7,0.000017906532,0.008444157,0.10241942],"study_design_scores_gemma":[0.014231234,0.0017017442,0.86920357,0.00009656471,0.0004479592,0.0000021582346,0.00015444715,0.000031834734,0.0000044810936,0.00004534607,0.114015624,0.00006502399],"about_ca_topic_score_codex":0.0007210364,"about_ca_topic_score_gemma":0.0010598003,"teacher_disagreement_score":0.10557147,"about_ca_system_score_codex":0.00016599939,"about_ca_system_score_gemma":0.00060054497,"threshold_uncertainty_score":0.3252233},"labels":[],"label_agreement":null},{"id":"W2601024426","doi":"10.1200/jco.2013.31.15_suppl.7066","title":"Post hoc analysis of sustained efficacy/tolerability of ≥12 cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Imatinib; Post-hoc analysis; Clinical trial; Gastroenterology; Regimen; Myeloid leukemia; Oncology","score_opus":0.06646397282880954,"score_gpt":0.4469472522296863,"score_spread":0.38048327940087673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601024426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949219,0.001001485,0.000049548584,0.0022481482,0.00019673305,0.0005569802,0.000013123902,0.0000063286634,0.0010057223],"genre_scores_gemma":[0.99723214,0.0010326396,0.0010915884,0.00014304362,0.00027685208,0.000005639539,0.000008605821,0.000023160905,0.00018633505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99026453,0.0011591187,0.0066006994,0.00036466727,0.0010643497,0.00054662063],"domain_scores_gemma":[0.98424983,0.007888621,0.004077444,0.00074428803,0.0025508811,0.0004889105],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008187115,0.00024886156,0.004886488,0.0010987611,0.000020438783,0.0000053000012,0.00057367206,0.00068178785,0.0010547464],"category_scores_gemma":[0.013573695,0.00017997494,0.0015194062,0.0013030984,0.0010308754,0.00017279522,0.00021719723,0.0013108605,0.0000088092365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06928355,0.01740181,0.32783198,0.00420799,0.022634313,0.0018910178,0.002172772,0.015617765,0.1042863,0.0006888253,0.0024761087,0.43150756],"study_design_scores_gemma":[0.06335176,0.026167247,0.8774855,0.00033806945,0.0025725875,0.00011706564,0.00058584363,0.023501601,0.0048395447,0.00022778084,0.0006260267,0.00018695313],"about_ca_topic_score_codex":0.0022703845,"about_ca_topic_score_gemma":0.0011351586,"teacher_disagreement_score":0.54965353,"about_ca_system_score_codex":0.013074115,"about_ca_system_score_gemma":0.039646097,"threshold_uncertainty_score":0.99985844},"labels":[],"label_agreement":null},{"id":"W2601029316","doi":"10.1200/jco.2012.30.15_suppl.6605","title":"Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Gastroenterology; Rash; Nilotinib; Hypokalemia; Imatinib mesylate; Imatinib; Myeloid leukemia","score_opus":0.036510584720778234,"score_gpt":0.38490619678427845,"score_spread":0.3483956120635002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601029316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961378,0.00024988962,0.00006102209,0.0004927192,0.00089177204,0.0016855791,0.000013395984,0.000023158487,0.00044467257],"genre_scores_gemma":[0.9965053,0.00015484866,0.0022270558,0.0005019082,0.000316159,0.0000440527,0.000046580015,0.00006571553,0.00013834613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897723,0.0009509973,0.006257549,0.0006413564,0.0013598995,0.0010178563],"domain_scores_gemma":[0.9908964,0.0016979938,0.004721628,0.0008740443,0.00068793754,0.0011219853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004440096,0.0005876724,0.005125156,0.0010343853,0.00006985932,0.000005488553,0.0006177555,0.00077598705,0.0005311834],"category_scores_gemma":[0.002390188,0.0004098755,0.0010454362,0.0022231184,0.00022227893,0.0003625234,0.00026618008,0.0018606677,0.00020206264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059188833,0.017918162,0.95882326,0.000093508446,0.006971572,0.0003840254,0.001148267,0.0008973242,0.000079955425,0.000008344607,0.000342555,0.0074141333],"study_design_scores_gemma":[0.0538022,0.023539815,0.91335106,0.0003149036,0.0066980147,0.00010124707,0.00081140717,0.000473317,0.00012221359,0.000015209674,0.00043783954,0.00033277157],"about_ca_topic_score_codex":0.0001733441,"about_ca_topic_score_gemma":0.00043954208,"teacher_disagreement_score":0.047883313,"about_ca_system_score_codex":0.0052391533,"about_ca_system_score_gemma":0.00410832,"threshold_uncertainty_score":0.9998353},"labels":[],"label_agreement":null},{"id":"W2601038906","doi":"10.1200/jco.2017.35.5_suppl.144","title":"Utility of annual screening serum testosterone level in men on surveillance for clinical stage I testicular cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; St Joseph's Health Care; London Health Sciences Centre","funders":"","keywords":"Medicine; Testicular cancer; Testosterone (patch); Internal medicine; Orchiectomy; Stage (stratigraphy); Androgen deficiency; Androgen; Gynecology; Referral; Cancer; Endocrinology; Urology; Hormone","score_opus":0.41201245429134736,"score_gpt":0.572596110733235,"score_spread":0.16058365644188766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601038906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992952,0.0008253582,0.0003673655,0.0038776076,0.0006696802,0.00044738225,0.00033540247,0.0000059562462,0.0005192739],"genre_scores_gemma":[0.9925878,0.0004201531,0.0057049748,0.0004440067,0.000592332,0.0000068207046,0.000004576726,0.000017788021,0.00022156078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960847,0.00038664468,0.0026255164,0.00028392352,0.00034578002,0.00027343017],"domain_scores_gemma":[0.9906904,0.0043942244,0.0033849883,0.00048486516,0.0006175961,0.00042789747],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042247963,0.00016358413,0.0018982365,0.00006930151,0.0000719609,0.000009586194,0.00027703602,0.0003337618,0.00005450502],"category_scores_gemma":[0.024933562,0.000116815136,0.0006189899,0.000046526926,0.00035776926,0.000107534834,0.00008777692,0.0006289861,0.0000023003422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055897217,0.0028448731,0.7983468,0.000060501465,0.00033536792,0.00044307092,0.000013281189,0.000015079267,0.0000059000276,0.00001500564,0.00075637695,0.191574],"study_design_scores_gemma":[0.019279845,0.012788416,0.96212095,0.0003338768,0.00029703276,0.000028229091,0.000059016358,0.000699514,0.000019441657,0.00007727115,0.0042082584,0.000088172936],"about_ca_topic_score_codex":0.00015265612,"about_ca_topic_score_gemma":0.000330825,"teacher_disagreement_score":0.19148584,"about_ca_system_score_codex":0.000055935867,"about_ca_system_score_gemma":0.0014862176,"threshold_uncertainty_score":0.9832798},"labels":[],"label_agreement":null},{"id":"W2601060691","doi":"10.1200/jco.2012.30.15_suppl.e19514","title":"Health resource utilization and patient burden associated with SREs in a randomized controlled trial setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Zoledronic acid; Randomized controlled trial; Pathologic fracture; Internal medicine; Bone pain; Randomization; Incidence (geometry); Surgery; Spinal cord compression; Spinal cord","score_opus":0.09880931897850836,"score_gpt":0.4571322135486881,"score_spread":0.35832289457017974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601060691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666502,0.0018635546,0.00015385807,0.026019378,0.00042053557,0.0027711508,0.0000012666193,0.0000083608975,0.0021117202],"genre_scores_gemma":[0.9930985,0.00030652437,0.0011953501,0.004824682,0.00039066674,0.000029332497,0.0000049785313,0.000011992136,0.00013798728],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99157494,0.004252715,0.0033200087,0.000114091454,0.00048976747,0.00024845137],"domain_scores_gemma":[0.9861241,0.00895095,0.004153578,0.00010583466,0.00019804233,0.0004674863],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02111781,0.00011712411,0.0039192266,0.0001913393,0.000026045565,0.000007967705,0.000050506333,0.00013305053,0.00005630853],"category_scores_gemma":[0.04442408,0.00006722561,0.00035131696,0.00011666121,0.00015592607,0.00008443033,0.000029151895,0.00046768488,0.0000011953684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92901295,0.002198445,0.0061292495,0.00002339941,0.0006730622,0.00005692797,0.000529333,0.000008100403,2.711495e-7,0.00008222751,0.0025539745,0.05873203],"study_design_scores_gemma":[0.95541894,0.009107365,0.026154108,0.0002227783,0.0008796553,0.00001626153,0.00048921246,0.00055173493,2.3355435e-7,0.000081169135,0.007021916,0.00005659924],"about_ca_topic_score_codex":0.000016437336,"about_ca_topic_score_gemma":0.00001528632,"teacher_disagreement_score":0.05867543,"about_ca_system_score_codex":0.00010853235,"about_ca_system_score_gemma":0.0007907609,"threshold_uncertainty_score":0.96362513},"labels":[],"label_agreement":null},{"id":"W2601066100","doi":"10.1200/jco.2007.25.18_suppl.5138","title":"Determining issues of importance for patients with prostate cancer: Results of a web-based study in 2,128 patients with prostate cancer for the development of a quality of life (QL) instrument, the prostate cancer symptom scale (PCSS)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Disease; Quality of life (healthcare); Psychosocial; Cancer; Prostate; Gynecology; Oncology; Internal medicine; Nursing","score_opus":0.07740741043868354,"score_gpt":0.4456945527313827,"score_spread":0.36828714229269915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601066100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931824,0.00054806954,0.0000381724,0.0010805281,0.00047388932,0.004171198,0.00048355022,0.000003846282,0.00001831136],"genre_scores_gemma":[0.99765366,0.00025763919,0.001160612,0.00031682514,0.00010431423,0.0004216326,0.00001353425,0.000034482753,0.000037294976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929535,0.00031172176,0.0050449246,0.00033813392,0.00094057753,0.0004111579],"domain_scores_gemma":[0.98659235,0.0023990225,0.0076589137,0.00034016816,0.0028230734,0.0001864615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006033635,0.00026707983,0.0020161124,0.0001511198,0.00006977288,0.0000056922604,0.00030698447,0.0001513778,0.000008307166],"category_scores_gemma":[0.0011173959,0.0001359248,0.00023835238,0.00041024058,0.00042048196,0.000109493965,0.000058713355,0.0004362677,3.2186268e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12872578,0.002717512,0.80228406,0.00056283205,0.0005663589,0.000001919882,0.009294752,0.00013128023,0.00003126213,0.0000013810401,0.00004522387,0.05563762],"study_design_scores_gemma":[0.049523514,0.018397754,0.924345,0.0013090011,0.00040084092,2.7800073e-7,0.0039899973,0.000040717347,0.0008655154,0.000012255426,0.0009657939,0.00014932285],"about_ca_topic_score_codex":0.0017868011,"about_ca_topic_score_gemma":0.11590213,"teacher_disagreement_score":0.12206094,"about_ca_system_score_codex":0.00033169708,"about_ca_system_score_gemma":0.006329805,"threshold_uncertainty_score":0.9993034},"labels":[],"label_agreement":null},{"id":"W2601073632","doi":"10.1200/jco.2013.31.15_suppl.e19120","title":"Radiotherapy for intubated patients with malignant airway obstruction: Futile, or facilitating extubation?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Tracheal and airway disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Radiation therapy; Intubation; Clinical endpoint; Proportional hazards model; Logistic regression; Retrospective cohort study; Airway; Population; Surgery; Airway obstruction; Anesthesia; Internal medicine; Randomized controlled trial","score_opus":0.07011199732136303,"score_gpt":0.40961896866630526,"score_spread":0.33950697134494223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601073632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865726,0.0001259952,0.0032569242,0.008181358,0.00079828006,0.0006440273,0.0000068675317,0.000015894388,0.00039803772],"genre_scores_gemma":[0.9551153,0.00016068004,0.04110713,0.0017322365,0.0008049678,0.000030902764,0.000012813866,0.000023517116,0.0010124113],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975492,0.00014046887,0.0016698906,0.00016221036,0.00026448263,0.00021378593],"domain_scores_gemma":[0.9959003,0.0016092304,0.0011090658,0.000112968795,0.0009892433,0.00027923682],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072004646,0.00012809329,0.00090239255,0.00008310634,0.000060632505,0.000011211437,0.00009234501,0.00023485946,0.000936786],"category_scores_gemma":[0.0017104733,0.000068319554,0.0002483029,0.00013322216,0.00014773356,0.00019629656,0.000008781418,0.00043202264,0.000013009735],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008135735,0.0014295013,0.08835191,0.000060038994,0.00033683798,0.0000128144275,0.00022439867,0.00004527588,0.000051623723,0.000049497598,0.0055405786,0.8957618],"study_design_scores_gemma":[0.034939133,0.08480235,0.80070955,0.00018214693,0.00026016476,0.000112954614,0.0011151326,0.00087268726,0.00004882137,0.0006234454,0.07612293,0.00021070955],"about_ca_topic_score_codex":0.000014525226,"about_ca_topic_score_gemma":0.0000146554485,"teacher_disagreement_score":0.8955511,"about_ca_system_score_codex":0.00008687538,"about_ca_system_score_gemma":0.0006379389,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W2601086841","doi":"10.1200/jco.2014.32.15_suppl.8051","title":"A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; ERBB3; Progression-free survival; Log-rank test; Epidermal growth factor receptor; Cancer; Chemotherapy; Survival analysis","score_opus":0.12330918582681002,"score_gpt":0.5359127661219609,"score_spread":0.4126035802951509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601086841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993249,0.0000884234,0.00018228362,0.002495848,0.00079858245,0.0013952535,0.0000017479549,0.000006255347,0.0017826095],"genre_scores_gemma":[0.9965062,0.00014724075,0.002083422,0.0004024903,0.0007446156,0.000016846443,0.000021221816,0.000026796079,0.00005115907],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904707,0.0033346314,0.004587224,0.0002705072,0.00095992343,0.00037701547],"domain_scores_gemma":[0.9893995,0.0061338083,0.0027784281,0.00021516153,0.0011562011,0.00031690672],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022346865,0.0001813362,0.0031738013,0.0005266825,0.0000321895,0.000010321739,0.0002553663,0.0004081517,0.00013690302],"category_scores_gemma":[0.025910469,0.000126434,0.00039063577,0.0004765582,0.00047219647,0.0001346731,0.00005980082,0.0018044249,0.0000047962108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8792655,0.012059442,0.07852249,0.00007236067,0.00017202321,0.00016781228,0.00024180797,0.000027403483,0.0006009666,0.0002084728,0.0004575294,0.0282042],"study_design_scores_gemma":[0.90055954,0.064692065,0.029244497,0.00044737442,0.00014899585,0.000019308623,0.000061251645,0.00072713784,0.00008492719,0.0004675935,0.0034368967,0.00011041354],"about_ca_topic_score_codex":0.00014186942,"about_ca_topic_score_gemma":0.00012460233,"teacher_disagreement_score":0.052632622,"about_ca_system_score_codex":0.00028246792,"about_ca_system_score_gemma":0.0020166845,"threshold_uncertainty_score":0.9822947},"labels":[],"label_agreement":null},{"id":"W2601121006","doi":"10.1200/jco.2012.30.15_suppl.5110","title":"Validation of the predictive value of modeled HCG residual production “P” in low-risk gestational trophoblastic neoplasia (GTN) patients treated in GOG-174 phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Urology; Oncology; Gynecology; Nuclear medicine; Clinical trial","score_opus":0.05487770617768181,"score_gpt":0.4075386201721801,"score_spread":0.3526609139944983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601121006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996821,0.00006979518,0.0001017124,0.00045798914,0.001405308,0.0008567524,0.00004779599,0.0000036921874,0.0002359701],"genre_scores_gemma":[0.99844205,0.00010932982,0.00068137055,0.000040678176,0.00061649975,0.000022018816,0.000019344474,0.000014355343,0.00005436111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99431914,0.0012340333,0.0032557177,0.00018793774,0.0007795923,0.00022358049],"domain_scores_gemma":[0.9926511,0.0027028942,0.0032259508,0.00015872036,0.0010943678,0.00016698868],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023744816,0.00015766628,0.0011973447,0.00032338785,0.000036778663,0.000002618766,0.00011394201,0.00020334763,0.000031908534],"category_scores_gemma":[0.022032926,0.00010549235,0.00026883214,0.00048724757,0.00031125548,0.00020967396,0.00004247138,0.0006314037,0.000001928825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35610244,0.027157491,0.58580697,0.00012349169,0.0005710235,0.000021148675,0.0012421155,0.024893172,0.00035334317,0.00013411358,0.00064257433,0.002952153],"study_design_scores_gemma":[0.11561587,0.0110493135,0.86938477,0.00031790655,0.00064097374,0.000010726002,0.00025380185,0.0014610294,0.00062303926,0.00055122015,0.000021381373,0.00006997218],"about_ca_topic_score_codex":0.000053737847,"about_ca_topic_score_gemma":0.000019002246,"teacher_disagreement_score":0.28357783,"about_ca_system_score_codex":0.00027774728,"about_ca_system_score_gemma":0.0012186741,"threshold_uncertainty_score":0.9862049},"labels":[],"label_agreement":null},{"id":"W2601129256","doi":"10.1200/jco.2013.31.15_suppl.e16070","title":"How does stereotactic body radiotherapy compare to standard external beam radiotherapy or low-dose rate brachytherapy for low-risk prostate cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; External beam radiotherapy; Radiation therapy; Androgen deprivation therapy; Prospective cohort study; Hazard ratio; Univariate analysis; Cancer; Cohort; Prostate; Proportional hazards model; Urology; Oncology; Internal medicine; Multivariate analysis; Confidence interval","score_opus":0.07351191141618489,"score_gpt":0.4719658824772869,"score_spread":0.398453971061102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601129256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473222,0.005407109,0.0021831484,0.03957038,0.0022731968,0.0030809513,0.00011161779,0.000029668232,0.00002171357],"genre_scores_gemma":[0.88069,0.07384248,0.017152576,0.00959479,0.006951525,0.00053176295,0.000013538601,0.00017837199,0.01104496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951252,0.0007060641,0.0022321744,0.0004861111,0.0006644144,0.0007860341],"domain_scores_gemma":[0.9918804,0.0031005794,0.002027994,0.0004015001,0.0014349237,0.001154609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003071806,0.00040044705,0.0025974421,0.00027543856,0.00016682489,0.00017556886,0.000382968,0.0003108731,0.00082393014],"category_scores_gemma":[0.0012082371,0.00020520871,0.0007531585,0.00026744473,0.00032550286,0.00045304795,0.00003428101,0.0011945292,0.000008946895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20606516,0.0027847693,0.20277412,0.00032559436,0.0035799858,0.00084173697,0.0010748332,0.000084083156,0.016691267,0.000011267399,0.020933148,0.544834],"study_design_scores_gemma":[0.14565416,0.12973888,0.29652715,0.0015543965,0.0007680758,0.00048570093,0.0007128388,0.0014471592,0.010045034,0.00074829854,0.4114534,0.00086492614],"about_ca_topic_score_codex":0.000113223025,"about_ca_topic_score_gemma":0.00010867433,"teacher_disagreement_score":0.5439691,"about_ca_system_score_codex":0.00096867373,"about_ca_system_score_gemma":0.0033861964,"threshold_uncertainty_score":0.90214574},"labels":[],"label_agreement":null},{"id":"W2601129696","doi":"10.1200/jco.2015.33.15_suppl.10557","title":"Postoperative morbidity and mortality in a large series of primary retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the Transatlantic RPS Working Group.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Surgery; Ileus; Adverse effect; Complication; Incidence (geometry); Mortality rate; Radiation therapy; Internal medicine","score_opus":0.17053436020079074,"score_gpt":0.4177053380676426,"score_spread":0.24717097786685185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601129696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926857,0.0019302651,0.0000034495029,0.0044454737,0.00028933323,0.0004849622,0.000019225428,0.000005486054,0.00013615392],"genre_scores_gemma":[0.99769586,0.00063999806,0.00028446014,0.001039064,0.00029698355,0.000009683944,0.000012402224,0.000012296602,0.000009266766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614006,0.0013459019,0.0017232222,0.00022596837,0.00036067114,0.00020418137],"domain_scores_gemma":[0.99724036,0.0014517087,0.00069326087,0.00021950224,0.00015357812,0.00024155737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025335022,0.00016660083,0.0015537448,0.000057666293,0.00004341933,0.000010185048,0.00012717309,0.00018322626,0.000025743198],"category_scores_gemma":[0.0005870296,0.00009043058,0.000245133,0.000117124924,0.00022498793,0.000112909474,0.0000888098,0.0005780829,0.0000013878896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006578238,0.010123535,0.971258,0.000007968868,0.0007059011,0.002747389,0.0018624463,7.303483e-7,0.00013072076,0.0000048768275,0.00028117647,0.0062990477],"study_design_scores_gemma":[0.016998678,0.010479323,0.96886814,0.00017194575,0.00063597097,0.00022409984,0.0016157941,0.000021339858,0.000060977607,0.000034211065,0.000817617,0.00007191344],"about_ca_topic_score_codex":0.0011312808,"about_ca_topic_score_gemma":0.0047274227,"teacher_disagreement_score":0.010420442,"about_ca_system_score_codex":0.00027942448,"about_ca_system_score_gemma":0.0003178263,"threshold_uncertainty_score":0.3687652},"labels":[],"label_agreement":null},{"id":"W2601149910","doi":"10.1200/jco.2012.30.15_suppl.10010","title":"Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Adverse effect; Oncology; Population; Tolerability; Randomized controlled trial; Surgery; Confidence interval; Pathology","score_opus":0.08738783735493295,"score_gpt":0.46178673278012616,"score_spread":0.3743988954251932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601149910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864024,0.0013911494,0.0000855614,0.001750531,0.0065750405,0.0031818312,0.000025537478,0.000029215757,0.0005587448],"genre_scores_gemma":[0.98812777,0.0015476474,0.0028514795,0.0024321713,0.0046408046,0.000052392585,0.000032105567,0.000083157094,0.00023245702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9874821,0.0014329893,0.0079901535,0.00061305024,0.0015015618,0.0009802006],"domain_scores_gemma":[0.98650813,0.0065439604,0.004706587,0.0005966384,0.0006424023,0.001002272],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018738478,0.00051475666,0.00550553,0.00022801354,0.000121059544,0.000039038783,0.00047379194,0.0007993631,0.00017437598],"category_scores_gemma":[0.0138302175,0.0003612493,0.0033583785,0.00020961925,0.00019147217,0.00047393667,0.00010402811,0.0022171042,0.000015704169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61921895,0.009802876,0.16210869,0.0000060598272,0.0010549915,0.00039811895,0.00019583013,0.000008823467,0.0002212173,0.000008984449,0.00014770952,0.20682777],"study_design_scores_gemma":[0.7002611,0.05068521,0.245967,0.0003303547,0.00041223344,0.000028011318,0.000057440073,0.00016685121,0.00006859816,0.00019027383,0.0015629975,0.0002698801],"about_ca_topic_score_codex":0.00004897917,"about_ca_topic_score_gemma":0.00006917967,"teacher_disagreement_score":0.2065579,"about_ca_system_score_codex":0.0004562255,"about_ca_system_score_gemma":0.0015161666,"threshold_uncertainty_score":0.99988395},"labels":[],"label_agreement":null},{"id":"W2601151252","doi":"10.1200/jco.2012.30.15_suppl.tps5114","title":"ACRIN 6695 perfusion CT as prognostic imaging biomarker in ovarian cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Carboplatin; Response Evaluation Criteria in Solid Tumors; Ovarian cancer; Perfusion; Perfusion scanning; Chemotherapy; Oncology; Internal medicine; Radiology; Cancer; Phases of clinical research; Cisplatin","score_opus":0.16070802913942267,"score_gpt":0.5268508414949037,"score_spread":0.366142812355481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601151252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.912224,0.0034260014,0.00004900218,0.07269088,0.0043296954,0.00028889626,0.0000019232991,0.000010085445,0.0069795423],"genre_scores_gemma":[0.98565453,0.004184098,0.002061591,0.005691428,0.0021876083,0.000019039773,0.0000011565987,0.000026396443,0.00017412947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99620384,0.00052944006,0.002188648,0.00018956498,0.00042144064,0.000467094],"domain_scores_gemma":[0.99456483,0.0031412093,0.0011985367,0.00020524202,0.00026985924,0.00062033674],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053621833,0.00015520271,0.0012226367,0.00022959255,0.000032703767,0.000008682146,0.00018709792,0.00018181835,0.0015977819],"category_scores_gemma":[0.0048917555,0.000115280505,0.00035259736,0.00027167893,0.0001719656,0.00023565437,0.00009300166,0.0011880295,0.00007382631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001036141,0.0013225093,0.7469291,0.00002757248,0.000069200396,0.00082338176,0.0001049209,0.0000029889277,0.00040170047,0.00003173245,0.018826894,0.23042387],"study_design_scores_gemma":[0.005195957,0.001193588,0.79374504,0.00039762518,0.00026725768,0.001128392,0.00011014451,0.00012260275,0.00012163098,0.00011140912,0.1975089,0.00009744832],"about_ca_topic_score_codex":0.00033533762,"about_ca_topic_score_gemma":0.00013781832,"teacher_disagreement_score":0.23032643,"about_ca_system_score_codex":0.00050321396,"about_ca_system_score_gemma":0.0018558333,"threshold_uncertainty_score":0.9993149},"labels":[],"label_agreement":null},{"id":"W2601160995","doi":"10.1200/jco.2004.22.14_suppl.8525","title":"Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prednisone; Dexamethasone; Incidence (geometry); Internal medicine; Gastroenterology; Corticosteroid","score_opus":0.08692777188741585,"score_gpt":0.45612747869914366,"score_spread":0.3691997068117278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601160995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945491,0.00012755855,0.000054759174,0.0004043976,0.00031698696,0.004283408,0.000014145227,0.000011870491,0.00023779273],"genre_scores_gemma":[0.99763274,0.00038868978,0.0011978059,0.00021858611,0.00031259705,0.00017070897,0.0000062697745,0.000046336034,0.000026242125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550617,0.00059939455,0.0022069677,0.00039185208,0.0008497578,0.00044583197],"domain_scores_gemma":[0.9942886,0.0027699233,0.0016363354,0.0003846004,0.00046169362,0.0004588252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021019923,0.00034048356,0.0030013104,0.00039490807,0.00002822124,0.000009594423,0.00031612895,0.00063707115,0.000031142976],"category_scores_gemma":[0.002651877,0.00021119064,0.00024725316,0.00055895076,0.0009437279,0.00019650368,0.00011321654,0.0010998297,0.000004748734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2948563,0.0038108185,0.6054457,0.00041313053,0.008564814,0.0021067816,0.00066480064,0.0020055848,0.009034661,0.00016612299,0.00027839816,0.072652906],"study_design_scores_gemma":[0.17564829,0.10971413,0.70430166,0.0014816602,0.0018692035,0.0006701054,0.000034201585,0.00023340748,0.00545936,0.000045928744,0.00031961154,0.00022246939],"about_ca_topic_score_codex":0.001026096,"about_ca_topic_score_gemma":0.00044948512,"teacher_disagreement_score":0.11920802,"about_ca_system_score_codex":0.00221083,"about_ca_system_score_gemma":0.008477485,"threshold_uncertainty_score":0.9971435},"labels":[],"label_agreement":null},{"id":"W2601183302","doi":"10.1200/jco.2013.31.15_suppl.1102","title":"Study to explore the willingness of patients (pts) to undergo biopsy at the time of breast cancer (BC) recurrence.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Breast cancer; Biopsy; Internal medicine; Oncology; Family medicine; Surgery","score_opus":0.16521568473407583,"score_gpt":0.47547446204973554,"score_spread":0.3102587773156597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601183302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89351434,0.00005526136,0.000047096826,0.10473459,0.0009677273,0.0005100321,0.0000060499283,0.0000017767503,0.00016312244],"genre_scores_gemma":[0.99670833,0.00009981994,0.00015644479,0.0022582875,0.000504984,0.00000991076,0.0000012776214,0.000008557714,0.00025238848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99692357,0.00042370992,0.001731949,0.00013217021,0.00064092956,0.00014769191],"domain_scores_gemma":[0.99542224,0.0016190432,0.0011990267,0.00023053517,0.0012404018,0.00028875066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027828421,0.00009282242,0.00078984303,0.000058563524,0.00005057703,0.0000047140284,0.00026428563,0.00021322233,0.00055504806],"category_scores_gemma":[0.0011625623,0.00003855342,0.00021249126,0.00027951883,0.00056757283,0.000041224434,0.00014288838,0.000581888,0.000036128702],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047238637,0.008913834,0.4263917,0.0000705749,0.00075907435,0.000020817455,0.0068966453,0.000121863915,0.00048483963,0.00010813597,0.031253405,0.52025527],"study_design_scores_gemma":[0.0022681362,0.0075527034,0.9827755,0.00017104077,0.00018686095,0.000020310355,0.0010348929,0.000049401533,0.000026767086,0.0004128063,0.0054528927,0.000048653103],"about_ca_topic_score_codex":0.00020704081,"about_ca_topic_score_gemma":0.0001051755,"teacher_disagreement_score":0.55638385,"about_ca_system_score_codex":0.00009125619,"about_ca_system_score_gemma":0.0006189734,"threshold_uncertainty_score":0.6077387},"labels":[],"label_agreement":null},{"id":"W2601214088","doi":"10.1200/jco.2012.30.15_suppl.7590","title":"Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; non-small cell lung cancer (NSCLC); Clinical endpoint; Gastroenterology; Lung cancer; Population; Paclitaxel; Performance status; Cancer; Surgery; Chemotherapy; Oncology; Randomized controlled trial; Cisplatin","score_opus":0.04936182536150489,"score_gpt":0.43175248352997503,"score_spread":0.3823906581684701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601214088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025846,0.0017183134,0.000030658863,0.004071122,0.0008527808,0.0007899956,0.0000034873988,0.000006412135,0.0022687865],"genre_scores_gemma":[0.9938082,0.002744321,0.00095167826,0.0015687986,0.0004904044,0.000057794106,0.000008542783,0.000029961697,0.00034027552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973809,0.00027066676,0.0014286198,0.00020948166,0.00030346375,0.000406845],"domain_scores_gemma":[0.9968634,0.0010667697,0.0012562679,0.00013244085,0.00035897843,0.0003221196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010835773,0.00021941354,0.0012427833,0.00023076235,0.00003031876,0.0000051300985,0.00011663414,0.00030872182,0.00019136102],"category_scores_gemma":[0.00014786208,0.00014117894,0.0001389361,0.00028994342,0.00010577801,0.00021182606,0.000019313822,0.0010123644,0.0000050882118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02144616,0.010446432,0.87859935,0.00004291625,0.00018518305,0.00018398777,0.0008332558,0.00014412159,0.00009340791,0.000006269678,0.00045754248,0.087561354],"study_design_scores_gemma":[0.08793366,0.0736034,0.8296123,0.00029783286,0.00024753544,0.000035887268,0.00013311893,0.00011824516,0.000250145,0.000026267084,0.00758304,0.00015854875],"about_ca_topic_score_codex":0.00039416863,"about_ca_topic_score_gemma":0.0023508423,"teacher_disagreement_score":0.087402806,"about_ca_system_score_codex":0.0005591546,"about_ca_system_score_gemma":0.0013520615,"threshold_uncertainty_score":0.575711},"labels":[],"label_agreement":null},{"id":"W2601243611","doi":"10.1200/jco.2017.35.5_suppl.179","title":"Awareness among patients with cancer of the harms of continued smoking.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Survivorship curve; Smoking cessation; Logistic regression; Internal medicine; Cancer survivorship; Radiation therapy; Head and neck cancer; Pathology","score_opus":0.11237551080340627,"score_gpt":0.4602248704921552,"score_spread":0.34784935968874897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601243611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417925,0.000109720124,0.0000138642545,0.0016333401,0.0016503346,0.00015159087,0.000013565129,0.000001238618,0.0022470793],"genre_scores_gemma":[0.99838066,0.00016677302,0.0001691792,0.00072726805,0.0003235157,0.0000016981277,8.4055597e-7,0.000008994342,0.00022107341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789625,0.00014205357,0.0014023817,0.00009979321,0.00033898067,0.00012052463],"domain_scores_gemma":[0.9937009,0.00051247573,0.004549606,0.00035441865,0.0007519173,0.00013068628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010452489,0.000082689156,0.0011820998,0.00003596476,0.000060090657,0.0000043687046,0.00035122837,0.0001829395,0.00021319173],"category_scores_gemma":[0.0017335762,0.00004144201,0.00032555923,0.000034456658,0.0007028328,0.00011895899,0.00006721097,0.00054940506,2.527948e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031763823,0.00041097813,0.9423321,0.000041481537,0.00035924843,0.00001734673,0.00007950136,0.000012948997,0.000055121076,0.000005833008,0.0012965627,0.05221248],"study_design_scores_gemma":[0.01176279,0.0027946979,0.97203964,0.00028296758,0.0003487972,0.0000049142805,0.000029952656,0.000026415104,0.0005559576,0.000017383458,0.01209251,0.0000439804],"about_ca_topic_score_codex":0.0002940424,"about_ca_topic_score_gemma":0.00025897508,"teacher_disagreement_score":0.0521685,"about_ca_system_score_codex":0.00006916509,"about_ca_system_score_gemma":0.0019953032,"threshold_uncertainty_score":0.35395822},"labels":[],"label_agreement":null},{"id":"W2601246524","doi":"10.1200/jco.2017.35.6_suppl.56","title":"Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Toxicity; Prostate; Radiation therapy; Genitourinary system; Urology; Prospective cohort study; Cancer; Oncology; Internal medicine","score_opus":0.11265090351686542,"score_gpt":0.4970598012119385,"score_spread":0.3844088976950731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601246524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746958,0.0009461177,0.00008323978,0.02120914,0.0024114288,0.0005455596,0.00006081043,0.000008162636,0.000039714552],"genre_scores_gemma":[0.9548608,0.037429556,0.004986644,0.0018805383,0.00059556065,0.00001623993,0.0000043444225,0.000019792686,0.00020651745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963281,0.00022677815,0.0027704726,0.00025547578,0.00021183446,0.00020731743],"domain_scores_gemma":[0.9897086,0.0032602462,0.0053397925,0.00031778237,0.001032305,0.0003412466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033868086,0.00016568425,0.0024171725,0.00007075171,0.00012983754,0.000016931444,0.00014910252,0.00037090987,0.00003679121],"category_scores_gemma":[0.007084488,0.00010627964,0.0005808844,0.000035715508,0.000504124,0.00018623963,0.000049504008,0.00068973383,8.6065387e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077250428,0.0013024685,0.70446587,0.000025847316,0.0018260663,0.000077856814,0.000030907293,0.000011119868,0.000098613324,0.000018597255,0.00093646627,0.28348115],"study_design_scores_gemma":[0.022080904,0.01615718,0.9453277,0.0001369344,0.00087811943,0.000036440208,0.000014503985,0.00021354217,0.00050021807,0.0009331483,0.013631192,0.00009008762],"about_ca_topic_score_codex":0.000309874,"about_ca_topic_score_gemma":0.000105317435,"teacher_disagreement_score":0.28339106,"about_ca_system_score_codex":0.00015572087,"about_ca_system_score_gemma":0.0008607469,"threshold_uncertainty_score":0.8481305},"labels":[],"label_agreement":null},{"id":"W2601254283","doi":"10.1200/jco.2017.35.6_suppl.372","title":"Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Stage (stratigraphy); Chemotherapy; Perioperative; Internal medicine; Cancer; Urology; Population; Oncology; Multivariate analysis; Performance status; Nomogram; Surgery","score_opus":0.16018380278427885,"score_gpt":0.4829737571777138,"score_spread":0.32278995439343494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601254283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857793,0.0004894402,0.00012679817,0.011515188,0.0005654058,0.00049041276,0.00011383954,0.0000042650395,0.00091535714],"genre_scores_gemma":[0.9957342,0.0008336137,0.00107414,0.0013705704,0.00060299045,0.000046799774,0.000007427872,0.000020005791,0.0003102484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968224,0.0003206088,0.0015660471,0.00025921265,0.0008496584,0.00018203232],"domain_scores_gemma":[0.99407166,0.0012924337,0.002989746,0.00035269675,0.0011032626,0.0001901995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012334245,0.0001771467,0.0016398317,0.00015369375,0.00014833626,0.000014764533,0.00035070785,0.00021904807,0.0005904595],"category_scores_gemma":[0.0032010162,0.0000883885,0.0006822352,0.000317474,0.0006468703,0.00018658908,0.0000500739,0.0005247885,8.5769136e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008983522,0.0024100665,0.93357235,0.0000876181,0.020282336,0.00012960738,0.0008056989,0.00013496626,0.0056553697,0.00004997084,0.0009571627,0.02693133],"study_design_scores_gemma":[0.012396212,0.0030732716,0.9706005,0.00044595794,0.008490562,0.000028366154,0.00020978379,0.0003399604,0.0014035637,0.000011838428,0.002900048,0.00009994684],"about_ca_topic_score_codex":0.00050904026,"about_ca_topic_score_gemma":0.0025611073,"teacher_disagreement_score":0.037028138,"about_ca_system_score_codex":0.00027433006,"about_ca_system_score_gemma":0.0069602323,"threshold_uncertainty_score":0.9986694},"labels":[],"label_agreement":null},{"id":"W2601261053","doi":"10.1200/jco.2009.27.15_suppl.e11586","title":"External quality assurance of breast cancer pathologic reporting in Kenya","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; Toronto East General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Triple-negative breast cancer; Hormone receptor; Internal medicine; Cancer; Disease; Oncology; Gynecology; Family medicine","score_opus":0.38926823854249537,"score_gpt":0.5901174576442462,"score_spread":0.2008492191017508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601261053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866454,0.0011344537,0.0002621672,0.0086706765,0.0005566729,0.00007766549,0.0000030460121,0.0000048719003,0.002645051],"genre_scores_gemma":[0.9895713,0.00069403707,0.0054100365,0.0034346175,0.00083687925,8.530267e-7,2.405187e-7,0.000004018398,0.00004801756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925143,0.0004005324,0.00622176,0.00016997819,0.00046559476,0.00022781543],"domain_scores_gemma":[0.98937255,0.00081222923,0.008846095,0.00016461973,0.00059862895,0.0002058852],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01124068,0.00009985953,0.0017225515,0.000084928455,0.000016321204,0.0000038879216,0.0001587793,0.00028502752,0.00010547577],"category_scores_gemma":[0.0109674595,0.00007023065,0.00044871122,0.00018803799,0.00012213112,0.00013189271,0.000022594477,0.0009808132,0.0000016790091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026425354,0.00042432063,0.7788934,0.000017608794,0.000024756935,0.0025258102,0.000046880974,0.00007721294,0.0020793378,0.0000558863,0.0003558888,0.21285634],"study_design_scores_gemma":[0.002800246,0.0032418324,0.98902357,0.0005684397,0.000065519336,0.0023593777,0.00010171757,0.000026873213,0.00010162596,0.00094361964,0.00070331484,0.00006387041],"about_ca_topic_score_codex":0.00018980553,"about_ca_topic_score_gemma":0.00013894982,"teacher_disagreement_score":0.21279247,"about_ca_system_score_codex":0.00016473152,"about_ca_system_score_gemma":0.0014641308,"threshold_uncertainty_score":0.99736357},"labels":[],"label_agreement":null},{"id":"W2601261230","doi":"10.1200/jco.2013.31.15_suppl.5059","title":"Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Abiraterone acetate; Taxane; Docetaxel; Discontinuation; Adverse effect; Surgery; Cancer; Breast cancer; Androgen deprivation therapy","score_opus":0.10032107909518902,"score_gpt":0.49462519427479584,"score_spread":0.39430411517960684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601261230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787182,0.000068522815,0.000020310023,0.003113519,0.00009896443,0.017751362,0.0000591833,0.0000049400724,0.00016495217],"genre_scores_gemma":[0.992913,0.00003276063,0.0027210198,0.00021902159,0.000068806134,0.0039225095,0.0000073438446,0.000021386475,0.00009411733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952927,0.00047600688,0.0029519887,0.00026473895,0.00066293275,0.00035161633],"domain_scores_gemma":[0.99495184,0.0002619474,0.0028999718,0.00021645919,0.0014049102,0.00026484524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014063022,0.00021549432,0.0014531567,0.00013447947,0.000023326491,0.00003096321,0.00021059568,0.00013909161,0.00013115494],"category_scores_gemma":[0.00034523587,0.00012401832,0.00019967127,0.00036791136,0.0005024813,0.00036571053,0.00004860002,0.00050607114,0.0000019998063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24605872,0.0046187793,0.6285204,0.00051746867,0.00052776816,0.00025549365,0.00032083373,0.00007735044,0.0005272478,0.0000010961961,0.00017270244,0.1184021],"study_design_scores_gemma":[0.06881376,0.028519308,0.8984422,0.0014382175,0.00015342928,0.000008803946,0.00006004271,0.00009950494,0.0017495906,0.000036572546,0.00056954747,0.00010900173],"about_ca_topic_score_codex":0.00053557724,"about_ca_topic_score_gemma":0.0005194461,"teacher_disagreement_score":0.26992178,"about_ca_system_score_codex":0.00045363567,"about_ca_system_score_gemma":0.0030920883,"threshold_uncertainty_score":0.5485232},"labels":[],"label_agreement":null},{"id":"W2601277980","doi":"10.1200/jco.2013.31.15_suppl.11109","title":"Plasma osteopontin and the prognosis of pleural mesothelioma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Osteopontin; Internal medicine; Univariate analysis; Stage (stratigraphy); Gastroenterology; Proportional hazards model; Multivariate analysis; Population; Oncology; Pathology; Biology","score_opus":0.06382892372864055,"score_gpt":0.40832841553504373,"score_spread":0.34449949180640316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601277980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828455,0.00035648735,0.0000029262383,0.014417418,0.00018893431,0.00017305603,0.0000021049732,0.0000019475362,0.0020116281],"genre_scores_gemma":[0.9971109,0.00027288267,0.0009837941,0.0010701033,0.0002537714,0.000004787927,8.0663057e-7,0.000004781745,0.00029818527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984234,0.00018860644,0.0010341905,0.000063612584,0.0002107799,0.00007940757],"domain_scores_gemma":[0.9972567,0.0017111278,0.00072011375,0.00006409899,0.000090525245,0.00015746664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086954643,0.000057308385,0.0006068947,0.000034326124,0.000019195872,0.0000036898655,0.000068733425,0.00009202916,0.00031842178],"category_scores_gemma":[0.0012491356,0.000027171027,0.00024078581,0.00004008015,0.00051395607,0.000066335946,0.000037895596,0.00022336886,0.000021568725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006151984,0.001050788,0.897018,0.00003233587,0.00028570255,0.000034651122,0.00007280438,0.000004082614,0.00023321071,0.00037298593,0.0060381573,0.088705264],"study_design_scores_gemma":[0.0078595225,0.0033077884,0.9813614,0.000036747188,0.00027541415,0.00016190726,0.000120098324,0.00016576952,0.00009529522,0.00073674985,0.0058501726,0.000029144747],"about_ca_topic_score_codex":0.000022760478,"about_ca_topic_score_gemma":0.0000033963418,"teacher_disagreement_score":0.08867612,"about_ca_system_score_codex":0.00001543278,"about_ca_system_score_gemma":0.00013721597,"threshold_uncertainty_score":0.3486495},"labels":[],"label_agreement":null},{"id":"W2601293727","doi":"10.1200/jco.2017.35.4_suppl.588","title":"Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Oncology; Proportional hazards model; Internal medicine; Interquartile range; Bioinformatics; Biology","score_opus":0.3304909138278286,"score_gpt":0.589450765190123,"score_spread":0.2589598513622944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601293727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770715,0.0002248658,0.000023768014,0.013312115,0.0029195542,0.00029888336,0.0000073465076,0.000008525358,0.006133435],"genre_scores_gemma":[0.994415,0.00024591803,0.0008842087,0.0014795474,0.0017760171,0.0000072207154,0.0000013190147,0.00002211423,0.0011686472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950644,0.0007958134,0.0029596558,0.00031534344,0.00051817385,0.00034663524],"domain_scores_gemma":[0.99233115,0.0015775586,0.0040793144,0.00053878,0.0007437097,0.0007294892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004710204,0.0002248379,0.0033063267,0.00021097677,0.00014159792,0.000016247164,0.0006261799,0.00057645875,0.00062901597],"category_scores_gemma":[0.004724689,0.00014878447,0.0007194691,0.00009225132,0.0006886346,0.00022057249,0.00017642941,0.001350313,0.000015215332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049058604,0.004328302,0.8279587,0.00002867356,0.0007480657,0.0018195227,0.0003221253,0.000006206485,0.0014035687,0.000085753934,0.0020913081,0.15630192],"study_design_scores_gemma":[0.010220327,0.04549853,0.8993101,0.000048940525,0.0010897288,0.00018637672,0.0010307847,0.00005809022,0.000203585,0.00026216294,0.041959666,0.00013169656],"about_ca_topic_score_codex":0.0010152301,"about_ca_topic_score_gemma":0.0066420557,"teacher_disagreement_score":0.15617022,"about_ca_system_score_codex":0.00032026842,"about_ca_system_score_gemma":0.0031670632,"threshold_uncertainty_score":0.68872833},"labels":[],"label_agreement":null},{"id":"W2601300370","doi":"10.1200/jco.2017.35.6_suppl.271","title":"De novo metastatic prostate cancer: Patterns of PSA testing prediagnosis and disease characteristics.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Internal medicine; Prostate; Disease; Lower urinary tract symptoms; Metastasis; Prostate-specific antigen; Gynecology; Oncology","score_opus":0.18249097998541328,"score_gpt":0.496065846154031,"score_spread":0.31357486616861774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601300370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844456,0.0008074421,0.000018773928,0.013833024,0.00050334877,0.00019778374,0.00008787143,0.000003076875,0.00010308027],"genre_scores_gemma":[0.98997074,0.0068532885,0.0015390702,0.00093171065,0.00061517686,0.000024091136,0.0000017189943,0.000011836656,0.000052387677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811405,0.00010437082,0.0012878728,0.00013751717,0.0001885476,0.00016766417],"domain_scores_gemma":[0.9945646,0.0018227923,0.0024388772,0.00021076303,0.00034956177,0.0006134],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010295166,0.000102613245,0.0010913482,0.000047524114,0.00006323411,0.000021835305,0.00010560438,0.00006589025,0.00006133147],"category_scores_gemma":[0.009745467,0.00007121955,0.00020187096,0.000020899413,0.00016714628,0.00008794101,0.00006150783,0.00029787113,9.290682e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093367894,0.0011075499,0.752058,0.00013280474,0.00031509507,0.0010276971,0.00005670241,0.0000016258491,0.000020170548,0.000012595486,0.0002687051,0.24406537],"study_design_scores_gemma":[0.005429774,0.00427086,0.9839646,0.0006951252,0.0016042812,0.000120012584,0.000021958007,0.00007213321,0.000051114377,0.00016405746,0.0035499728,0.000056077144],"about_ca_topic_score_codex":0.00021186522,"about_ca_topic_score_gemma":0.00006645401,"teacher_disagreement_score":0.2440093,"about_ca_system_score_codex":0.00010918823,"about_ca_system_score_gemma":0.0016721524,"threshold_uncertainty_score":0.9985959},"labels":[],"label_agreement":null},{"id":"W2601316275","doi":"10.1200/jco.2013.31.15_suppl.3030","title":"Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Immunovaccine (Canada); University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; ELISPOT; Immunogenicity; Immune system; Cyclophosphamide; Ovarian cancer; Adverse effect; Internal medicine; Cohort; Cancer; Survivin; Immunology; Oncology; Chemotherapy; Gastroenterology; CD8","score_opus":0.04492855343445169,"score_gpt":0.41623267750299436,"score_spread":0.3713041240685427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601316275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473083,0.0020267682,0.000003777937,0.0006444983,0.0015856607,0.0007182128,0.000034300567,0.0000026370215,0.00025333493],"genre_scores_gemma":[0.99883103,0.00077568635,0.00002164717,0.00017183898,0.00002928912,0.00001910064,0.0000036682832,0.000013547887,0.00013419596],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98875064,0.006433567,0.0042249365,0.00018237266,0.00013320336,0.00027528836],"domain_scores_gemma":[0.98311305,0.011716028,0.004188291,0.00040171662,0.0005526951,0.000028190167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008811966,0.00020837357,0.0020846562,0.00018566613,0.000046656856,0.0000030261363,0.0006247091,0.00047149873,0.00046701301],"category_scores_gemma":[0.007311825,0.000116645984,0.00055981864,0.00026704857,0.0006206614,0.00011137306,0.0000998645,0.0010766025,0.000015767631],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3146329,0.029387344,0.15606223,0.00006047962,0.003855295,0.000021872016,0.0020188685,0.000037685724,0.19510749,0.000083124025,0.0022744897,0.29645824],"study_design_scores_gemma":[0.076151714,0.1323546,0.63836807,0.0002467112,0.00026706522,0.00001146394,0.00039571844,0.0000029499197,0.14678684,0.00007467427,0.005184349,0.00015586175],"about_ca_topic_score_codex":0.0022981907,"about_ca_topic_score_gemma":0.00008567854,"teacher_disagreement_score":0.48230585,"about_ca_system_score_codex":0.000070998074,"about_ca_system_score_gemma":0.00053028954,"threshold_uncertainty_score":0.8753466},"labels":[],"label_agreement":null},{"id":"W2601319269","doi":"10.1200/jco.2014.32.15_suppl.e21013","title":"Urinary metabolite profiling by nuclear magnetic resonance spectroscopy to distinguish control patients from Wilms tumor (WT) and WT tumor by stage.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Urine; Urinary system; Creatinine; Medicine; Metabolite; Histology; Urology; Internal medicine; Pathology; Gastroenterology","score_opus":0.01013029491191453,"score_gpt":0.3180938064320753,"score_spread":0.30796351152016077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601319269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991471,0.0059404117,0.00015337885,0.0006300814,0.0008005718,0.00018166592,0.00011977326,0.000005329872,0.0006978188],"genre_scores_gemma":[0.98959154,0.0009437595,0.002873445,0.0051862877,0.0010051609,0.000004757678,0.000023380882,0.000031151274,0.0003405038],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974861,0.00042301658,0.0012039524,0.00036238387,0.00021988059,0.00030467237],"domain_scores_gemma":[0.99808276,0.00023999692,0.0008737001,0.00018702971,0.00020582211,0.00041068316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087912945,0.00018696165,0.00080004253,0.000029086543,0.00006743597,0.000023044722,0.00026878217,0.00023391227,0.000028257533],"category_scores_gemma":[0.0017047013,0.00014048044,0.00019915572,0.000057494675,0.00019106382,0.000008679407,0.000095519674,0.00054011197,0.000007865095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018318752,0.0027789283,0.21643318,0.000065278575,0.0005945854,0.00023598588,0.000093986055,0.00005600732,0.5469433,0.00008216355,0.09254965,0.12184814],"study_design_scores_gemma":[0.008403879,0.021795826,0.04809188,0.000065460496,0.000185075,0.000036243517,0.000041341336,0.00015821448,0.011446097,0.00012800247,0.9093455,0.00030248653],"about_ca_topic_score_codex":0.000027507273,"about_ca_topic_score_gemma":0.0000028250543,"teacher_disagreement_score":0.8167958,"about_ca_system_score_codex":0.000029289205,"about_ca_system_score_gemma":0.00015834182,"threshold_uncertainty_score":0.5728626},"labels":[],"label_agreement":null},{"id":"W2601321703","doi":"10.1200/jco.2012.30.15_suppl.8049","title":"Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Follicular lymphoma; Chemotherapy; Internal medicine; Rituximab; Lymphoma; Fludarabine; Chemotherapy regimen; Oncology; Population; Surgery; Cancer; Gastroenterology; Cyclophosphamide","score_opus":0.05261087983352297,"score_gpt":0.39704901860647834,"score_spread":0.34443813877295537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601321703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972098,0.00086117163,0.000018985013,0.0010977212,0.00024767872,0.0004041057,0.000008632368,0.0000018099911,0.00015008243],"genre_scores_gemma":[0.9981643,0.00015842755,0.0005595459,0.0008968273,0.00019077268,0.00000973194,0.000009809138,0.000006556118,0.0000040189984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692476,0.0005142807,0.0020261332,0.000067061155,0.0003515241,0.00011625203],"domain_scores_gemma":[0.99682975,0.0016090161,0.0011650184,0.00015013566,0.00016802632,0.000078040066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023465022,0.00006251446,0.0009757032,0.000035006917,0.000019772135,0.00000865155,0.0001041811,0.00015806963,0.00011140274],"category_scores_gemma":[0.00043664358,0.000050809038,0.00037737485,0.00012667057,0.000042590687,0.00009653032,0.000005156319,0.00016468049,0.0000010388565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063251675,0.014758996,0.8504757,0.000010239259,0.00028248623,0.000048404694,0.00062430307,0.000005809138,0.00002310068,0.0000043292334,0.0001643641,0.13296974],"study_design_scores_gemma":[0.021973979,0.0057147746,0.97000664,0.00011558982,0.00038109138,0.00003769809,0.00054920657,0.000026320848,0.000053107047,0.00007381543,0.0010294701,0.00003827901],"about_ca_topic_score_codex":0.013789469,"about_ca_topic_score_gemma":0.0047431337,"teacher_disagreement_score":0.13293146,"about_ca_system_score_codex":0.00013721586,"about_ca_system_score_gemma":0.00043783864,"threshold_uncertainty_score":0.99277776},"labels":[],"label_agreement":null},{"id":"W2601358810","doi":"10.1200/jco.2017.35.6_suppl.260","title":"Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Androgen deprivation therapy; Prostate-specific antigen; Cancer; Urology","score_opus":0.17486007631299028,"score_gpt":0.5277195521479847,"score_spread":0.35285947583499444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601358810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96394163,0.0044571934,0.000009716266,0.023383206,0.00065554405,0.00035177378,0.000012504223,0.000004796429,0.007183661],"genre_scores_gemma":[0.9838715,0.008870132,0.001724201,0.00051153783,0.0005294187,0.000013418177,0.0000012817114,0.000016308752,0.004462161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971754,0.0003054871,0.0015276965,0.00020745535,0.0004331088,0.00035086303],"domain_scores_gemma":[0.9961608,0.00081884075,0.0017582703,0.00030112083,0.0005782982,0.0003826885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027939624,0.00013783126,0.001466186,0.000135801,0.000107845495,0.00003458709,0.00023586515,0.00016072256,0.00003907249],"category_scores_gemma":[0.0028760391,0.00008881189,0.00032569558,0.00008545838,0.00051154016,0.00025930122,0.00007110509,0.0011101741,0.000021044136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08749303,0.004106796,0.60616744,0.00018998075,0.0023338362,0.033299904,0.0019512401,0.000011220994,0.0014971142,0.0005362232,0.013218293,0.24919493],"study_design_scores_gemma":[0.018029168,0.005652495,0.95295393,0.0002587019,0.00026383772,0.000068121546,0.0001256656,0.000016921258,0.00025430074,0.0011817623,0.021100208,0.00009487675],"about_ca_topic_score_codex":0.0002010862,"about_ca_topic_score_gemma":0.00060424895,"teacher_disagreement_score":0.34678653,"about_ca_system_score_codex":0.00029652665,"about_ca_system_score_gemma":0.0025072698,"threshold_uncertainty_score":0.4823216},"labels":[],"label_agreement":null},{"id":"W2601367588","doi":"10.1200/jco.2012.30.15_suppl.9535","title":"Relationship of fusion protein status and outcome for children with intermediate-risk rhabdomyosarcoma: A Children's Oncology Group report.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Fusion gene; Rhabdomyosarcoma; Oncology; Cog; Internal medicine; Fluorescence in situ hybridization; Histology; Vincristine; Cyclophosphamide; Pathology; Chemotherapy; Gene; Sarcoma; Biology; Chromosome; Genetics","score_opus":0.08706878875872624,"score_gpt":0.4344399684153078,"score_spread":0.34737117965658154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601367588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944098,0.0014453644,0.0002501792,0.002251117,0.00034271707,0.0011344277,0.000018217977,0.000009671058,0.00013852867],"genre_scores_gemma":[0.9799201,0.0002864905,0.018534454,0.0003107021,0.00081626506,0.000047655187,0.000028297192,0.000025156498,0.00003088112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99589294,0.00047795975,0.0027399717,0.00021913413,0.00030107456,0.00036893162],"domain_scores_gemma":[0.9914616,0.003544799,0.0038672644,0.0002487489,0.0003095007,0.0005681194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038380316,0.00019000191,0.0017203401,0.00018597495,0.00006675792,0.0000052794567,0.00008923052,0.00042842023,0.00002814837],"category_scores_gemma":[0.006473961,0.000115047864,0.00040798762,0.000114271206,0.0003257483,0.00015042975,0.00006760788,0.00082516467,0.0000025584231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003605923,0.0050427364,0.9140711,0.000021719452,0.00059826375,0.00013373267,0.0001113459,6.102506e-7,0.000013212925,0.00025332853,0.0002833808,0.07586464],"study_design_scores_gemma":[0.016182467,0.024741277,0.9519377,0.000087921006,0.0013846038,0.0025872672,0.000067668996,0.0000030076,0.00004057743,0.0002825245,0.0025833596,0.00010164371],"about_ca_topic_score_codex":0.00006821167,"about_ca_topic_score_gemma":0.00006170972,"teacher_disagreement_score":0.075763,"about_ca_system_score_codex":0.00017651262,"about_ca_system_score_gemma":0.0005966102,"threshold_uncertainty_score":0.7750403},"labels":[],"label_agreement":null},{"id":"W2601373484","doi":"10.1200/jco.2013.31.15_suppl.e20560","title":"Association between musculoskeletal symptoms and serum vitamin D levels in women receiving aromatase inhibitor treatment.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Internal medicine; Vitamin D and neurology; Breast cancer; Joint pain; Osteoarthritis; Population; Physical therapy; Menopause; Aromatase inhibitor; Gynecology; Cancer; Aromatase; Pathology","score_opus":0.07256974778495039,"score_gpt":0.4440189025653819,"score_spread":0.3714491547804315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601373484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98552364,0.00020441817,0.0000041241215,0.013223588,0.0003191836,0.00032135626,0.0000131428405,0.000008479691,0.00038205337],"genre_scores_gemma":[0.99611306,0.0007997441,0.0005421509,0.00029305005,0.00134126,0.000023204531,0.0000021064513,0.0000144720125,0.00087094516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646527,0.00069655693,0.0017715589,0.00019674437,0.0004310695,0.00043877526],"domain_scores_gemma":[0.99287057,0.0051745544,0.0010505886,0.00012937278,0.0003083972,0.00046649916],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043230704,0.00015113976,0.0015245029,0.00022178251,0.000048156246,0.000018975594,0.00008910747,0.00039648992,0.00015410208],"category_scores_gemma":[0.011351105,0.00010147682,0.00021476971,0.00016678404,0.00014487458,0.00025770086,0.000094758,0.00081425434,0.000041173796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009542062,0.0005592356,0.724331,0.000033035023,0.00065750314,0.00013912967,0.00030279232,3.5483095e-7,0.00023062027,0.0000010932121,0.0023231765,0.27132663],"study_design_scores_gemma":[0.008646037,0.012807493,0.97225523,0.00015299108,0.00016553249,0.000034769837,0.0004685498,0.000013604606,0.00004810894,0.00017396631,0.0051504574,0.00008327301],"about_ca_topic_score_codex":0.000040250743,"about_ca_topic_score_gemma":0.000035763303,"teacher_disagreement_score":0.27124336,"about_ca_system_score_codex":0.0013693054,"about_ca_system_score_gemma":0.0005544923,"threshold_uncertainty_score":0.99697673},"labels":[],"label_agreement":null},{"id":"W2601373489","doi":"10.1200/jco.2012.30.15_suppl.7607","title":"Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Lung cancer; Quality of life (healthcare); Hazard ratio; Oncology; Proportional hazards model; Randomized controlled trial; Statistical significance; Cancer; Confidence interval","score_opus":0.24414952474483395,"score_gpt":0.5801434326413669,"score_spread":0.33599390789653294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601373489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838372,0.0045319283,0.000024283909,0.009456731,0.0014603299,0.00028608012,0.00005438045,0.0000040659347,0.00034500938],"genre_scores_gemma":[0.99553275,0.0025690317,0.00033659648,0.0009248187,0.00050241844,0.00001268417,0.000009178286,0.0000090990825,0.00010341164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944243,0.00081233465,0.004039749,0.00012144478,0.00036871186,0.00023346132],"domain_scores_gemma":[0.99319255,0.0018174035,0.0039770473,0.000178183,0.00040256573,0.00043223344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005340792,0.00010375094,0.002609941,0.00035119188,0.000018019775,0.0000013503992,0.000092898656,0.00024927914,0.0004135861],"category_scores_gemma":[0.0026152672,0.00005631198,0.0006052858,0.0006329196,0.00014595762,0.00012422842,0.000027127751,0.00044857472,5.5960066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016247517,0.0021663425,0.97593063,0.00018702255,0.0051323557,0.000009521777,0.0014012167,0.000055303055,0.0000115097555,0.00009325282,0.00020119615,0.013186905],"study_design_scores_gemma":[0.0058932826,0.0016470706,0.9876966,0.00021938894,0.0030352317,0.0000023648022,0.00021390639,0.00024131635,0.000006234309,0.000029275841,0.00096714083,0.00004819676],"about_ca_topic_score_codex":0.0066431086,"about_ca_topic_score_gemma":0.0035685203,"teacher_disagreement_score":0.013138708,"about_ca_system_score_codex":0.00031935802,"about_ca_system_score_gemma":0.0020518121,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W2601377141","doi":"10.1200/jco.2017.35.6_suppl.51","title":"Predicting disease progression in men with localized high risk prostate cancer undergoing radical prostatectomy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Nomogram; Medicine; Prostate cancer; Prostatectomy; Biochemical recurrence; Cohort; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Urology","score_opus":0.07481029464369106,"score_gpt":0.4920252350439141,"score_spread":0.41721494040022306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601377141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823882,0.0015475657,0.000032364307,0.0135478545,0.0003839681,0.0009324279,0.000012988071,0.000016463011,0.0011381432],"genre_scores_gemma":[0.98702145,0.00936936,0.002020828,0.00016865133,0.0007568129,0.00006024498,0.0000049452296,0.00003113334,0.0005665502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963063,0.00052119594,0.0016841778,0.0003185093,0.0007061089,0.00046373176],"domain_scores_gemma":[0.99463916,0.0012086487,0.002573015,0.00034620697,0.00037779316,0.00085518544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034274906,0.00018984206,0.0012476542,0.00014666254,0.00024332979,0.00005315152,0.00025760126,0.00023457935,0.00006548186],"category_scores_gemma":[0.0058410177,0.00010339706,0.00021379425,0.00010540647,0.000759272,0.00029450163,0.00012311069,0.0016118995,0.0000042680836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051922344,0.0011472565,0.8120274,0.0001196,0.00031412582,0.004181818,0.00011576288,0.000049038797,0.000016186641,0.000017967413,0.00033522845,0.12975326],"study_design_scores_gemma":[0.05360378,0.011443579,0.923681,0.0021930824,0.00048670554,0.0000805063,0.000124445,0.0011593025,0.00014172241,0.00076520507,0.0061823046,0.00013832009],"about_ca_topic_score_codex":0.00026456828,"about_ca_topic_score_gemma":0.0002943262,"teacher_disagreement_score":0.12961493,"about_ca_system_score_codex":0.00043318784,"about_ca_system_score_gemma":0.0062900945,"threshold_uncertainty_score":0.99934334},"labels":[],"label_agreement":null},{"id":"W2601381407","doi":"10.1200/jco.2013.31.15_suppl.tps2621","title":"A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Medicine; Polo-like kinase; Pharmacodynamics; PLK1; Pharmacokinetics; Cohort; Biopsy; Kinase; Pharmacology; Oncology; Internal medicine; Cell cycle; Cancer research; Cancer; Biology","score_opus":0.052749399392609475,"score_gpt":0.42989608457362444,"score_spread":0.37714668518101496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601381407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670744,0.0007483351,0.000506782,0.000038871178,0.0002531525,0.0017065638,0.000031818323,0.0000016445651,0.00000539443],"genre_scores_gemma":[0.9981971,0.00058605196,0.0009560692,0.00006735399,0.000071183116,0.00006533698,0.0000401337,0.000015966498,8.5126135e-7],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966693,0.0005210777,0.002054347,0.00022365089,0.0003835175,0.00014812486],"domain_scores_gemma":[0.9935111,0.0012953915,0.0030008059,0.00020497783,0.001902368,0.000085392516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016630968,0.00014743657,0.0009345274,0.00014451944,0.000018194989,0.0000032064258,0.00013660736,0.00017398833,0.000007342353],"category_scores_gemma":[0.0026587255,0.00011703576,0.00017934943,0.00016591631,0.00013878202,0.000026646381,0.00004818007,0.00015048613,1.3721277e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012002065,0.01204216,0.16066372,0.00021598191,0.00038640446,0.0000030378694,0.00018849935,0.0031651328,0.7224082,0.0000028418035,0.000033516342,0.08888843],"study_design_scores_gemma":[0.04063005,0.064304255,0.8086843,0.0007422533,0.0006754348,0.0000027630808,0.00017408821,0.0033782048,0.081097,0.00012473449,0.000015812268,0.00017112675],"about_ca_topic_score_codex":0.000064589556,"about_ca_topic_score_gemma":0.000091224996,"teacher_disagreement_score":0.64802057,"about_ca_system_score_codex":0.00007084574,"about_ca_system_score_gemma":0.0007375857,"threshold_uncertainty_score":0.47725797},"labels":[],"label_agreement":null},{"id":"W2601381879","doi":"10.1200/jco.2012.30.15_suppl.e14592","title":"Outcome of adjuvant therapy for biliary tract cancers.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biliary tract cancer; Internal medicine; Gallbladder; Gallbladder cancer; Radiation therapy; Gastroenterology; Cohort; Biliary tract; Adjuvant therapy; Klatskin tumor; Pathological; Bile duct; Surgery; Chemotherapy; Gemcitabine; Resection","score_opus":0.2961967864420045,"score_gpt":0.5264369301673725,"score_spread":0.230240143725368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601381879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97549,0.0127605125,0.00008766572,0.006546886,0.0028406335,0.00024481062,0.0000071230875,0.0000047759727,0.0020176067],"genre_scores_gemma":[0.9892338,0.0022583562,0.0023496074,0.002997913,0.0029586444,0.000006312337,8.678461e-7,0.000012938234,0.0001815782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745226,0.000108431595,0.0019080476,0.00009020404,0.00021380768,0.0002272334],"domain_scores_gemma":[0.996184,0.0018577324,0.001208513,0.00013702126,0.00035689617,0.00025587462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025716855,0.00010196172,0.0015645345,0.00007511337,0.000022552067,0.0000014692453,0.00010175556,0.00020139485,0.00008203148],"category_scores_gemma":[0.001513177,0.00006234074,0.0008005812,0.00006849727,0.00015357585,0.000092572925,0.000019177123,0.00043977093,0.000002750458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003269293,0.0011030902,0.844626,0.000038393515,0.00040812194,0.000023028095,0.0002629228,7.8514995e-7,0.00019288702,0.000037992286,0.010145654,0.1398918],"study_design_scores_gemma":[0.007260864,0.008575806,0.81776935,0.000031435957,0.00027883236,0.00011968825,0.00018548642,0.0000039136385,0.0001998917,0.000065612134,0.16545546,0.000053653544],"about_ca_topic_score_codex":0.000030880983,"about_ca_topic_score_gemma":0.000015077618,"teacher_disagreement_score":0.15530981,"about_ca_system_score_codex":0.00012441844,"about_ca_system_score_gemma":0.0007608495,"threshold_uncertainty_score":0.25421816},"labels":[],"label_agreement":null},{"id":"W2601389673","doi":"10.1200/jco.2017.35.6_suppl.120","title":"Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Prostate; Prospective cohort study; Toxicity; Nuclear medicine; Urology; Magnetic resonance imaging; Radiation therapy; Radiology; Cancer; Surgery; Internal medicine","score_opus":0.07189167551767468,"score_gpt":0.4642525220943132,"score_spread":0.39236084657663856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601389673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933366,0.00042855946,0.00010375453,0.0033954775,0.0006198625,0.0019314346,0.000103659084,0.0000051350976,0.00007547567],"genre_scores_gemma":[0.9929416,0.0049179047,0.001176569,0.0002278008,0.0004501566,0.00019957198,0.00000358505,0.000021538212,0.00006125202],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99717546,0.00018778026,0.0019037134,0.0002757469,0.00021355085,0.00024374973],"domain_scores_gemma":[0.9944428,0.0010149437,0.0034497948,0.00023274432,0.0005828944,0.0002767762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017125836,0.00019236571,0.0018298279,0.000111578905,0.000099111014,0.000022315631,0.00014372324,0.00024849793,0.000015353367],"category_scores_gemma":[0.002014904,0.00011457737,0.00027256238,0.00006995529,0.0005315792,0.000172951,0.00004184826,0.0006640637,2.5667356e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43655455,0.00904978,0.28388023,0.00004835447,0.0007825021,0.00022277668,0.0007432163,0.000002749958,0.00013321407,0.000013885112,0.00018989206,0.26837882],"study_design_scores_gemma":[0.3377263,0.20224114,0.45535988,0.00069862994,0.00042874506,0.000024925503,0.00011398849,0.000120220946,0.0016624315,0.00024746836,0.0012782954,0.000098012875],"about_ca_topic_score_codex":0.00030383113,"about_ca_topic_score_gemma":0.0013196104,"teacher_disagreement_score":0.2682808,"about_ca_system_score_codex":0.0003198233,"about_ca_system_score_gemma":0.0019276477,"threshold_uncertainty_score":0.46723297},"labels":[],"label_agreement":null},{"id":"W2601419225","doi":"10.1200/jco.2017.35.4_suppl.585","title":"Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Fish oil; Internal medicine; Gastroenterology; Cancer; Colorectal cancer; Confidence interval; Fish <Actinopterygii>; Biology","score_opus":0.05395039343760499,"score_gpt":0.3878577149390574,"score_spread":0.3339073215014524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601419225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96710837,0.01761172,0.00003597612,0.007995792,0.006717291,0.000192574,0.00016053198,0.0000023168004,0.00017545448],"genre_scores_gemma":[0.8609856,0.12799264,0.0004605303,0.002160828,0.008142519,0.000067383866,0.0000058392225,0.000020303025,0.00016435413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977887,0.00030079889,0.0009984111,0.00041454734,0.00019214574,0.00030534613],"domain_scores_gemma":[0.99756515,0.0002733168,0.0008988227,0.0004907622,0.00017267783,0.0005992502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014464953,0.00020995105,0.00090467685,0.00004810568,0.00009844651,0.00006421532,0.00040901703,0.00042533307,0.000027942397],"category_scores_gemma":[0.005168681,0.00017703201,0.000161819,0.000029856823,0.0006468648,0.00003702476,0.0005004567,0.0005303395,3.8019493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037833096,0.00027011416,0.87940365,0.000054786018,0.00011282958,0.000035268164,0.00004897572,0.0000017851844,0.0002693705,0.00004754701,0.026360465,0.08961191],"study_design_scores_gemma":[0.00546981,0.000984061,0.746761,0.00009377849,0.000098681696,0.000021650556,0.000014950279,0.000010712173,0.000068483474,0.00068691006,0.24562052,0.00016941149],"about_ca_topic_score_codex":0.00018827149,"about_ca_topic_score_gemma":0.009550765,"teacher_disagreement_score":0.21926005,"about_ca_system_score_codex":0.000036137142,"about_ca_system_score_gemma":0.00060342887,"threshold_uncertainty_score":0.72191554},"labels":[],"label_agreement":null},{"id":"W2601475143","doi":"10.1200/jco.2004.22.90140.4257","title":"Stimulation of natural killer (NK) cell and macrophage infiltration in pancreatic cancer with virulizin (V), an immunotherapeutic agent","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Infiltration (HVAC); Natural killer cell; Cancer research; Medicine; Pancreatic cancer; Cell; Pathology; Biology; Cytotoxic T cell; In vitro; Cancer; Internal medicine","score_opus":0.04566316185272936,"score_gpt":0.3817187661244594,"score_spread":0.33605560427173004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601475143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923012,0.0035449823,0.00027940652,0.00031630902,0.0031394523,0.00013048353,5.0970357e-7,0.000004867469,0.00028275332],"genre_scores_gemma":[0.99718493,0.0013484019,0.00034170802,0.0004946559,0.000067941364,0.0000031182951,0.000007703304,0.000009488831,0.0005420311],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99794763,0.0004592873,0.0012795937,0.00012685155,0.000052387975,0.000134242],"domain_scores_gemma":[0.9981634,0.00037047346,0.001149454,0.00009861576,0.00019036706,0.000027701506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008210838,0.00010899491,0.00060778466,0.0001402008,0.000037397465,0.000006182248,0.00008163381,0.00029090725,0.00032076158],"category_scores_gemma":[0.00012790751,0.00007679535,0.00009472143,0.00009526086,0.00016644398,0.00026470382,0.000012948722,0.0007050141,0.000012916725],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015509266,0.0023222454,0.045392837,0.000050757128,0.00041041806,0.00003740982,0.0013333184,0.0037385111,0.8730993,0.00014688735,0.00023037118,0.057728622],"study_design_scores_gemma":[0.031709224,0.022508033,0.81785846,0.0003198897,0.0003907408,0.00037665814,0.0010236407,0.00022388532,0.09910144,0.00027584634,0.025898121,0.00031404267],"about_ca_topic_score_codex":0.00023008793,"about_ca_topic_score_gemma":0.00020983901,"teacher_disagreement_score":0.7739979,"about_ca_system_score_codex":0.0001218376,"about_ca_system_score_gemma":0.000356716,"threshold_uncertainty_score":0.35121146},"labels":[],"label_agreement":null},{"id":"W2601511071","doi":"10.1200/jco.2013.31.15_suppl.550","title":"Post-surgical highly sensitive C-reactive protein (hsCRP) and prognosis in early stage in breast cancer (BC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Statistics Canada; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Body mass index; Gastroenterology; Proportional hazards model; Cancer; Stage (stratigraphy); Cohort; C-reactive protein; Oncology; Inflammation","score_opus":0.02470393259801971,"score_gpt":0.3638963565623769,"score_spread":0.33919242396435717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601511071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114025,0.00055457465,0.0000073335723,0.005625993,0.001686884,0.00039037154,0.000032545493,0.0000022886632,0.0005597543],"genre_scores_gemma":[0.9917228,0.0008899517,0.00045632548,0.00061010604,0.0058020446,0.000047182355,0.0000031067775,0.00001627407,0.00045221284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997539,0.00047718454,0.0012417804,0.00029483615,0.00015567194,0.0002915359],"domain_scores_gemma":[0.9983347,0.00017846882,0.0007232029,0.00010845515,0.000408692,0.00024649603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012164308,0.00015815259,0.00084074185,0.00010601733,0.00001926348,0.00001738434,0.00012911734,0.00049181364,0.000035655365],"category_scores_gemma":[0.00039982283,0.00012553959,0.00019093974,0.000098589946,0.000234845,0.00002742161,0.00009062539,0.0006803689,0.0000057252664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01164694,0.0031509195,0.68835807,0.0000629027,0.00050446566,0.00017348804,0.0007171703,0.000034556186,0.13656892,0.00045611704,0.004914122,0.15341234],"study_design_scores_gemma":[0.005426943,0.0025489996,0.8891423,0.00006942962,0.000030411891,0.00017975908,0.0002378586,0.000015636226,0.0020172438,0.000095789466,0.10005357,0.00018206667],"about_ca_topic_score_codex":0.0030922014,"about_ca_topic_score_gemma":0.0014944411,"teacher_disagreement_score":0.20078424,"about_ca_system_score_codex":0.000062111234,"about_ca_system_score_gemma":0.00075929303,"threshold_uncertainty_score":0.5119356},"labels":[],"label_agreement":null},{"id":"W2601517348","doi":"10.1200/jco.2012.30.15_suppl.4047","title":"Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Everolimus; Mucositis; Bevacizumab; Interim analysis; Sunitinib; Clinical endpoint; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Leukopenia; Progression-free survival; Adverse effect; Progressive disease; Rash; Surgery; Chemotherapy; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.11898701990433587,"score_gpt":0.49997134525514947,"score_spread":0.3809843253508136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601517348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995588,0.00041294433,0.000007087178,0.0023284676,0.0005712865,0.000679679,0.000025080608,0.0000067825267,0.00038068576],"genre_scores_gemma":[0.9973462,0.0005459293,0.00096911186,0.00029404424,0.00068363,0.0000072849994,0.000006411204,0.000021055692,0.00012632103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99221,0.0012455664,0.005093082,0.0002816542,0.00062814844,0.0005415669],"domain_scores_gemma":[0.98980826,0.0056086252,0.0031936122,0.00038019428,0.00034427753,0.0006650019],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025416599,0.00022447699,0.0034110125,0.00081905606,0.000024665655,0.000005077726,0.0002611503,0.00003214824,0.000051843],"category_scores_gemma":[0.02361773,0.00015961757,0.0006550627,0.00055795955,0.0004475194,0.00022166957,0.00021333521,0.0011739384,0.0000022177467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89174753,0.029397972,0.048824143,0.00016250082,0.0012168067,0.007591667,0.00013814543,0.00002093199,0.0026167156,0.000014146048,0.00059018726,0.017679272],"study_design_scores_gemma":[0.60289884,0.23140466,0.1435864,0.00029050178,0.0024688414,0.0027693573,0.00023590108,0.00053155806,0.0028580327,0.000028976105,0.01275238,0.00017457968],"about_ca_topic_score_codex":0.000055078228,"about_ca_topic_score_gemma":0.00006193461,"teacher_disagreement_score":0.2888487,"about_ca_system_score_codex":0.00007422032,"about_ca_system_score_gemma":0.00040360383,"threshold_uncertainty_score":0.98460674},"labels":[],"label_agreement":null},{"id":"W2601526318","doi":"10.1200/jco.2006.24.18_suppl.10082","title":"Competing risk events determining probability of cause-specific failure in nasopharyngeal carcinoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cumulative incidence; Nasopharyngeal carcinoma; Incidence (geometry); Survival analysis; Cohort; Distant metastasis; Internal medicine; Statistics; Oncology; Metastasis; Cancer; Radiation therapy","score_opus":0.08881425952069948,"score_gpt":0.4466953554891056,"score_spread":0.3578810959684061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601526318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644506,0.00038489964,0.0000645803,0.0010914879,0.00045984992,0.00021608088,0.000006584587,0.000004426224,0.0013270297],"genre_scores_gemma":[0.9893814,0.00008095129,0.009806794,0.000092383125,0.00058351795,0.0000036247982,0.0000038630155,0.00001014303,0.00003735504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968091,0.00036997822,0.002253934,0.00015604784,0.00023731614,0.00017360186],"domain_scores_gemma":[0.99652535,0.0011857252,0.0017280406,0.00014415577,0.0002861978,0.0001305333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001779284,0.00010098662,0.0010517357,0.00011165329,0.000030540697,0.000002774066,0.000090350564,0.00019309939,0.000052352654],"category_scores_gemma":[0.0005977281,0.00007319716,0.000298834,0.00013486385,0.00011230302,0.000077898774,0.000028397715,0.00062433485,0.0000030797682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000710153,0.0014487054,0.9709967,0.000031136584,0.00011076888,0.0003838068,0.00018427087,0.00008779656,0.00008886636,0.00005447803,0.00026522073,0.02563811],"study_design_scores_gemma":[0.008513627,0.003500104,0.97976804,0.00012007892,0.00031472923,0.00015464025,0.00017996528,0.00005134318,0.000058373058,0.0006659694,0.006619712,0.000053403666],"about_ca_topic_score_codex":0.00010162608,"about_ca_topic_score_gemma":0.00035882942,"teacher_disagreement_score":0.025584705,"about_ca_system_score_codex":0.00026794747,"about_ca_system_score_gemma":0.000993095,"threshold_uncertainty_score":0.29848936},"labels":[],"label_agreement":null},{"id":"W2601555696","doi":"10.1200/jco.2013.31.15_suppl.8535","title":"A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Ottawa Hospital; Jewish General Hospital; Pyrogenesis (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacodynamics; Internal medicine; Pharmacokinetics; Diffuse large B-cell lymphoma; Gastroenterology; Lymphoma; Follicular lymphoma; Phases of clinical research; Chemotherapy","score_opus":0.030448706834186188,"score_gpt":0.37551820467313407,"score_spread":0.34506949783894786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601555696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821705,0.0004228627,0.000038127157,0.00008051106,0.00023285796,0.00077704736,0.000015369666,0.000004347247,0.00021183374],"genre_scores_gemma":[0.99852985,0.0000712246,0.0007065348,0.00017258905,0.00024420975,0.000016478683,0.000021446496,0.000044595552,0.00019309549],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99555445,0.0010773074,0.001848343,0.00049737445,0.0005384259,0.00048408582],"domain_scores_gemma":[0.9967002,0.00019664991,0.001309277,0.00037791894,0.000892638,0.00052326603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015844629,0.00028272424,0.0011198445,0.00021988955,0.000092881295,0.000017501072,0.00030209188,0.0004442797,0.000023027758],"category_scores_gemma":[0.0007338938,0.00022339108,0.00019350632,0.00022782668,0.0002665405,0.0000416858,0.0002557115,0.0006190278,0.0000059571244],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019787932,0.6442869,0.1262776,0.00010578005,0.00043047025,0.00044240424,0.0024288464,0.000038684608,0.17947055,0.0000022600357,0.0086650215,0.018063603],"study_design_scores_gemma":[0.29393202,0.49070874,0.062091976,0.00007718115,0.00028932845,0.000045692494,0.0018817675,0.0001446558,0.13885164,0.00002326283,0.01123583,0.0007178993],"about_ca_topic_score_codex":0.00018986507,"about_ca_topic_score_gemma":0.00069900625,"teacher_disagreement_score":0.2741441,"about_ca_system_score_codex":0.0002088378,"about_ca_system_score_gemma":0.0008185043,"threshold_uncertainty_score":0.9109624},"labels":[],"label_agreement":null},{"id":"W2601560840","doi":"10.1200/jco.2015.33.15_suppl.e16095","title":"Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Prostate cancer; Prednisone; Randomized controlled trial; Placebo; Oncology; Prostate-specific antigen; Enzalutamide; Clinical trial; Cancer; Surgery; Pathology","score_opus":0.501077019749078,"score_gpt":0.5555932498792532,"score_spread":0.05451623013017515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601560840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991885,0.0031039587,0.0000026986634,0.004231124,0.000107177366,0.00029064898,0.00006750768,0.0000012055608,0.00031070053],"genre_scores_gemma":[0.99838626,0.00044874547,0.00028296487,0.00014804723,0.00002986488,0.00000937641,0.000002265232,0.00000697607,0.0006854929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968089,0.0005775216,0.00180732,0.0001258341,0.0005186294,0.00016178637],"domain_scores_gemma":[0.99631244,0.0013487285,0.0014635101,0.00018098776,0.0004901553,0.00020417977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002609129,0.00012181429,0.002473181,0.00026761598,0.000015960713,0.0000067483384,0.00010370495,0.000081976126,0.0000948396],"category_scores_gemma":[0.0012466145,0.0000519361,0.0012415702,0.00037236194,0.00030717047,0.00006945995,0.00003665049,0.00032269864,3.251479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020554505,0.006013616,0.70349723,0.000105744766,0.24955764,0.00032582428,0.0032352859,0.0054228664,0.0033631257,0.00006373522,0.0010411852,0.0068192547],"study_design_scores_gemma":[0.008687437,0.017105523,0.8983104,0.000041998457,0.07316467,0.000013142078,0.00085053616,0.00018620242,0.0011035001,0.00032049406,0.00014887369,0.000067207904],"about_ca_topic_score_codex":0.0006654446,"about_ca_topic_score_gemma":0.00084467046,"teacher_disagreement_score":0.19481319,"about_ca_system_score_codex":0.00027957515,"about_ca_system_score_gemma":0.0021005243,"threshold_uncertainty_score":0.372624},"labels":[],"label_agreement":null},{"id":"W2601571564","doi":"10.1200/jco.2013.31.15_suppl.tps656","title":"OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter tests.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Concordance; Breast cancer; Randomized controlled trial; Oncology; Population; Test (biology); Personalized medicine; Internal medicine; Cancer; Gynecology; Bioinformatics","score_opus":0.09235203774182987,"score_gpt":0.43452217432035484,"score_spread":0.34217013657852496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601571564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962668,0.0016291541,0.00037277892,0.00071157585,0.00066226395,0.00017440061,0.00004450423,0.0000014729462,0.0001370833],"genre_scores_gemma":[0.9741341,0.0032542408,0.02076086,0.00042258448,0.0012423187,0.000010648484,0.0000037757623,0.000020642678,0.0001508281],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99807936,0.00013519256,0.0012422604,0.00019326771,0.00013750099,0.00021240763],"domain_scores_gemma":[0.9975219,0.00036850988,0.0011579955,0.0001826407,0.0005381703,0.00023080608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035029353,0.00014864402,0.0007906026,0.000045913082,0.0000268133,0.000014640065,0.0001726225,0.00032840125,0.00016632624],"category_scores_gemma":[0.00037143377,0.00011091533,0.0004887462,0.000047578298,0.00023858086,0.000009197056,0.00005638881,0.00015030148,0.000005068394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009897473,0.006688298,0.3082226,0.000045995075,0.0027117385,0.00012352409,0.00039209548,0.011584496,0.24215657,0.00006009665,0.00796998,0.41014716],"study_design_scores_gemma":[0.030317247,0.06497573,0.7602689,0.00014691142,0.001350475,0.0009230248,0.0002701116,0.005862393,0.018466247,0.00016234216,0.116423555,0.00083303876],"about_ca_topic_score_codex":0.00057638966,"about_ca_topic_score_gemma":0.000037721864,"teacher_disagreement_score":0.45204633,"about_ca_system_score_codex":0.000093060364,"about_ca_system_score_gemma":0.00095965713,"threshold_uncertainty_score":0.4522996},"labels":[],"label_agreement":null},{"id":"W2601596974","doi":"10.1200/jco.2013.31.15_suppl.6585","title":"Identification of knowledge translation opportunities in the treatment of locally advanced breast cancer: Results of a national survey of physicians.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Knowledge translation; Psychological intervention; Family medicine; Clinical Practice; Medical physics; Cancer; Internal medicine; Nursing; Knowledge management","score_opus":0.36150451644383275,"score_gpt":0.5286172422382871,"score_spread":0.16711272579445435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601596974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929516,0.0012434028,0.000027296403,0.0040596947,0.00034585854,0.00037328672,0.0001753082,0.0000011161832,0.0008224581],"genre_scores_gemma":[0.9943025,0.005212111,0.00010558074,0.00008665375,0.00015187371,0.000016226437,0.00002500008,0.000005291363,0.000094760755],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99621195,0.0006412196,0.002697855,0.000092467715,0.00027117424,0.000085309475],"domain_scores_gemma":[0.9921154,0.003178925,0.0028925147,0.00009964094,0.0016727949,0.000040722884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020389548,0.00008524259,0.0010206973,0.00015059767,0.000008898328,9.878213e-7,0.00010508784,0.00012951432,0.000055091532],"category_scores_gemma":[0.00028346866,0.000054632845,0.00024655685,0.00020260773,0.0002838359,0.00009113114,0.0000044667217,0.00013571081,6.3087737e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01946627,0.017634863,0.06783246,0.0001419799,0.00075995893,0.000008790684,0.0033427018,0.0002846502,0.012273585,0.000098064935,0.0015275585,0.8766291],"study_design_scores_gemma":[0.015290839,0.01070384,0.9685389,0.00013383059,0.00028124935,0.000015186413,0.00034104675,0.00026827975,0.0029360012,0.00018212582,0.0012691269,0.00003962351],"about_ca_topic_score_codex":0.0006503604,"about_ca_topic_score_gemma":0.0014231106,"teacher_disagreement_score":0.9007064,"about_ca_system_score_codex":0.00012455278,"about_ca_system_score_gemma":0.0015693133,"threshold_uncertainty_score":0.27838945},"labels":[],"label_agreement":null},{"id":"W2601615263","doi":"10.1200/jco.2017.35.6_suppl.3","title":"Luminal and basal subtyping of prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Subtyping; Prostate; Oncology; Internal medicine; Tissue microarray; Basal (medicine); Androgen deprivation therapy; Cancer; Pathology","score_opus":0.21853675441988313,"score_gpt":0.5598049055431439,"score_spread":0.34126815112326075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601615263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773539,0.0020614043,0.0000036336662,0.017245,0.00077645085,0.00012551916,0.000004658712,0.0000017730719,0.0024276657],"genre_scores_gemma":[0.9890437,0.008129193,0.0006094061,0.00025821666,0.0009466372,0.0000023390364,6.099509e-7,0.00000737006,0.0010024912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984418,0.00010231901,0.0009628368,0.00010289493,0.0002277626,0.00016239664],"domain_scores_gemma":[0.99731976,0.0004547354,0.001394419,0.00015927784,0.00040606724,0.0002657191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001890591,0.000067979316,0.0008587048,0.00006005382,0.000079837875,0.000011044903,0.0001259126,0.00014928491,0.000060553877],"category_scores_gemma":[0.0017953747,0.00004221088,0.00017095883,0.000024688357,0.0005884449,0.00011342529,0.00007113998,0.00052490365,0.0000016399487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008097766,0.00042085952,0.7674583,0.000090711146,0.00030290385,0.0006031751,0.00012103565,5.5577357e-7,0.0005685692,0.000034704808,0.002197883,0.2201035],"study_design_scores_gemma":[0.0101875495,0.00896168,0.95853436,0.00027824118,0.00023278026,0.0001281757,0.000098030716,0.000037466052,0.0012657508,0.00043143696,0.019796433,0.000048116537],"about_ca_topic_score_codex":0.00008350935,"about_ca_topic_score_gemma":0.000043963253,"teacher_disagreement_score":0.22005539,"about_ca_system_score_codex":0.00006325167,"about_ca_system_score_gemma":0.001703687,"threshold_uncertainty_score":0.30222675},"labels":[],"label_agreement":null},{"id":"W2601626987","doi":"10.1200/jco.2012.30.15_suppl.5025","title":"Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Bevacizumab; Temsirolimus; Internal medicine; Regimen; Endometrial cancer; Oncology; Progression-free survival; Interim analysis; Surgery; Clinical trial; Cancer; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.28994901023392644,"score_gpt":0.566544020402582,"score_spread":0.27659501016865556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601626987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894222,0.003011551,0.00009380566,0.0010239768,0.0048548738,0.0006612402,0.00007649321,0.0000030185702,0.0008528634],"genre_scores_gemma":[0.98881483,0.0021162024,0.0018473641,0.00020962978,0.0069240103,0.000020481433,0.0000037275554,0.000010904778,0.000052864638],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960464,0.00027719367,0.002886191,0.00013338446,0.00040036495,0.0002564443],"domain_scores_gemma":[0.9902322,0.0059439065,0.0026973847,0.00012716754,0.0005396895,0.00045964768],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033904864,0.00013273269,0.0022412897,0.0002535207,0.000034395074,0.0000020394448,0.0001175092,0.00032645825,0.0001456233],"category_scores_gemma":[0.014202494,0.000088667366,0.0006277246,0.0003063808,0.00027013375,0.00012403858,0.00005709151,0.00041885037,5.6072247e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44058195,0.012082182,0.0025679474,0.000081640595,0.00054415915,0.000011578623,0.00008932616,3.3587992e-7,0.00029652737,0.000136089,0.00037784196,0.5432304],"study_design_scores_gemma":[0.68840426,0.26561448,0.003906253,0.00013936448,0.0016336407,0.000072248804,0.000050346516,0.000009656223,0.002325739,0.0004208917,0.037331615,0.00009150697],"about_ca_topic_score_codex":0.000045060446,"about_ca_topic_score_gemma":0.0000065942822,"teacher_disagreement_score":0.5431389,"about_ca_system_score_codex":0.000094336116,"about_ca_system_score_gemma":0.001130873,"threshold_uncertainty_score":0.9941013},"labels":[],"label_agreement":null},{"id":"W2601657417","doi":"10.1200/jco.2007.25.18_suppl.13016","title":"Effect of ketoconazole administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib in patients with advanced solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Bortezomib; Pharmacology; Ketoconazole; Adverse effect; Multiple myeloma; Pharmacodynamics; In vivo; CYP3A4; Internal medicine; Urology; Gastroenterology","score_opus":0.04048130438078471,"score_gpt":0.4824133161229638,"score_spread":0.44193201174217905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601657417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981302,0.00004725993,0.000029690958,0.0004463639,0.000114454946,0.0006267613,0.0000074912655,0.0000016217756,0.00059616426],"genre_scores_gemma":[0.9992107,0.00014587342,0.00036370885,0.00016885756,0.00008178241,0.0000037583338,0.0000044983917,0.000009329909,0.000011464393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751824,0.00033824754,0.0014384284,0.00010703933,0.00041568896,0.00018237084],"domain_scores_gemma":[0.9944669,0.003740449,0.001183054,0.00010197614,0.00029255945,0.00021506837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030756122,0.000109347115,0.0008895169,0.00012149088,0.000015675136,0.000001959118,0.000085859756,0.000099213496,0.000021969421],"category_scores_gemma":[0.0015636447,0.000056408488,0.000117841555,0.00012020045,0.00022018954,0.000047758404,0.000021178752,0.0005613433,7.2479014e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091784135,0.0026606447,0.67944354,0.000084386396,0.00028096233,0.00031023182,0.000033559496,0.00004153863,0.0008308536,0.000019605632,0.000035040484,0.22447549],"study_design_scores_gemma":[0.0355924,0.07870747,0.8673818,0.00017557984,0.00018288684,0.000029760102,0.000022588225,0.0004458654,0.017210845,0.000013366274,0.000191441,0.000045997363],"about_ca_topic_score_codex":0.000003644028,"about_ca_topic_score_gemma":0.000013803921,"teacher_disagreement_score":0.22442949,"about_ca_system_score_codex":0.00006604278,"about_ca_system_score_gemma":0.00038493882,"threshold_uncertainty_score":0.24387884},"labels":[],"label_agreement":null},{"id":"W2601662693","doi":"10.1200/jco.2017.35.4_suppl.758","title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Calgary; Baker Hughes (Canada); Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Hazard ratio; Neoadjuvant therapy; Proportional hazards model; Oncology; Stage (stratigraphy); Radiation therapy; Gastroenterology; Cancer; Confidence interval; Breast cancer","score_opus":0.019527155072391666,"score_gpt":0.3497224533861764,"score_spread":0.33019529831378475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601662693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541026,0.00028842667,0.000027132695,0.0019904024,0.00025789856,0.0015470057,0.000015866724,0.0000146224165,0.00044839765],"genre_scores_gemma":[0.99470514,0.0003925922,0.0032108421,0.0012925192,0.00022905327,0.000086171356,0.000005057226,0.000039928324,0.000038694845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971601,0.00022422802,0.0013298729,0.00045381242,0.00047485493,0.00035712664],"domain_scores_gemma":[0.99590796,0.00062418944,0.0015196784,0.00030300303,0.0007382539,0.0009068888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009132559,0.00028209668,0.0013042766,0.00023804403,0.00014181618,0.000047594072,0.00019035739,0.00028244132,0.000021584452],"category_scores_gemma":[0.002985705,0.00019147337,0.00008860041,0.00015870115,0.00044023688,0.00032569666,0.000100058554,0.00044276888,0.0000041367784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12690586,0.00045724338,0.6916904,0.000041552586,0.00042101406,0.00088503154,0.00009618802,0.00013007676,0.000032476884,0.0000025323345,0.00007510979,0.1792625],"study_design_scores_gemma":[0.04063768,0.028106442,0.9281308,0.00085612515,0.00042875335,0.00013987508,0.00006472169,0.00039119,0.00016333323,0.00001230783,0.00086215226,0.00020661986],"about_ca_topic_score_codex":0.00006872831,"about_ca_topic_score_gemma":0.00013127543,"teacher_disagreement_score":0.23644039,"about_ca_system_score_codex":0.0005617277,"about_ca_system_score_gemma":0.002518369,"threshold_uncertainty_score":0.78080577},"labels":[],"label_agreement":null},{"id":"W2601668897","doi":"10.1200/jco.2013.31.15_suppl.10032","title":"Estimated long-term outcomes in children newly diagnosed with standard risk acute lymphoblastic leukemia (ALL) based on similarly treated members of the childhood cancer survivor study (CCSS) cohort.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"","keywords":"Medicine; Cohort; Pediatrics; Population; Cancer; Sibling; Cohort study; Internal medicine","score_opus":0.0387951322370098,"score_gpt":0.4002198921035705,"score_spread":0.3614247598665607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601668897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950447,0.000052840544,0.0000910213,0.0013924435,0.00036920045,0.002748173,0.00008700738,0.000026181315,0.00018842342],"genre_scores_gemma":[0.99745625,0.0002947022,0.0005290544,0.001246979,0.00019724383,0.00009030458,0.000010278407,0.00007697692,0.00009818187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920527,0.0016766657,0.0032693497,0.0005288132,0.0017991381,0.00067335623],"domain_scores_gemma":[0.98786944,0.0067291306,0.002923251,0.00075122557,0.0010604366,0.00066649955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031558026,0.00047857026,0.0032521659,0.00041432527,0.00008734347,0.00003661609,0.00074155006,0.00055261253,0.00045795916],"category_scores_gemma":[0.006621533,0.00024699466,0.00058159453,0.0007060783,0.0006076973,0.00020191645,0.00014291196,0.0021045525,0.000014536975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009537096,0.0047341366,0.966493,0.000019384624,0.00345619,0.0008301578,0.00021920075,0.0039275386,0.000025234103,7.3764096e-7,0.0006502702,0.010107022],"study_design_scores_gemma":[0.06603862,0.024228936,0.90310305,0.0003961229,0.0026811988,0.00013737348,0.000084772386,0.0030341733,0.00006425655,0.0000071541517,0.0000127388885,0.00021158217],"about_ca_topic_score_codex":0.005986515,"about_ca_topic_score_gemma":0.0030469988,"teacher_disagreement_score":0.063389964,"about_ca_system_score_codex":0.0036833421,"about_ca_system_score_gemma":0.0116906185,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W2601678539","doi":"10.1200/jco.2017.35.6_suppl.417","title":"Molecular dissection of primary mediastinal germ cell tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Seminoma; KRAS; PTEN; Medicine; Cancer research; Germ cell tumors; Primary tumor; Cancer; Pathology; Internal medicine; Biology; Genetics; Metastasis; Chemotherapy; Colorectal cancer","score_opus":0.09463639195453762,"score_gpt":0.4669447576579466,"score_spread":0.37230836570340897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601678539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900105,0.0008588773,0.00016082395,0.001249683,0.0006971151,0.00009655648,0.0000024250176,0.0000039102542,0.0069201384],"genre_scores_gemma":[0.9967591,0.00015457963,0.002169838,0.00030211528,0.00051273894,0.0000011354692,0.0000022722422,0.000010284609,0.00008791563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980294,0.00012706702,0.0012989505,0.000111672205,0.00030964348,0.00012327392],"domain_scores_gemma":[0.9955135,0.00048871874,0.0030652701,0.00026832888,0.0003126145,0.0003515878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008749874,0.00008886943,0.0010127184,0.00005176809,0.00004633691,0.000007072633,0.00014748769,0.00015424528,0.000057209618],"category_scores_gemma":[0.0042486065,0.000060135335,0.0005387456,0.000023575782,0.00020687912,0.00007494765,0.000050442955,0.00036942193,0.000008469928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032954959,0.005368252,0.8123032,0.00014734764,0.00040161356,0.0078951465,0.000023561985,0.000009056213,0.0028521933,0.00007198455,0.00049249805,0.16713966],"study_design_scores_gemma":[0.0061520752,0.0077632437,0.98206985,0.00013365725,0.00079272233,0.0005770999,0.000014041066,0.000025696474,0.00091767736,0.00028610192,0.0012206859,0.000047143367],"about_ca_topic_score_codex":0.000015480222,"about_ca_topic_score_gemma":0.0000027860935,"teacher_disagreement_score":0.16976666,"about_ca_system_score_codex":0.000068005895,"about_ca_system_score_gemma":0.001245771,"threshold_uncertainty_score":0.5086286},"labels":[],"label_agreement":null},{"id":"W2601689261","doi":"10.1200/jco.2017.35.6_suppl.282","title":"Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Discontinuation; Docetaxel; Quality of life (healthcare); Internal medicine; Urothelial cancer; Cancer; Proportional hazards model; Oncology; Bladder cancer","score_opus":0.28357311814599295,"score_gpt":0.5467906929124001,"score_spread":0.26321757476640717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601689261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807789,0.0011379969,0.000006959859,0.014863991,0.001018379,0.0017522731,0.000027220152,0.000006411745,0.00040791513],"genre_scores_gemma":[0.9960091,0.001082962,0.0002740695,0.001979507,0.000500033,0.000056851615,0.0000023175733,0.00002707247,0.000068068985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99369574,0.0011644599,0.004065979,0.000266414,0.0005010239,0.00030641523],"domain_scores_gemma":[0.98869616,0.00351776,0.00624811,0.00060224603,0.00052449084,0.00041121722],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004210567,0.00021560607,0.00286433,0.000098963734,0.00011213825,0.0000092638875,0.0005288762,0.0003098649,0.000042392458],"category_scores_gemma":[0.011591578,0.0001346069,0.0005168578,0.00012790484,0.00038566889,0.00012386795,0.00003510378,0.0007070071,8.338801e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19274676,0.01268055,0.6426723,0.00030090794,0.002275569,0.000045258173,0.0033156625,0.00006315752,0.00030876248,0.00006891714,0.001658196,0.14386395],"study_design_scores_gemma":[0.1477187,0.057657436,0.790385,0.00019450237,0.00042471781,0.000009353283,0.0005357812,0.000023453616,0.00011930358,0.00017084813,0.0026590703,0.00010183694],"about_ca_topic_score_codex":0.0047383774,"about_ca_topic_score_gemma":0.0033990273,"teacher_disagreement_score":0.1477127,"about_ca_system_score_codex":0.00024345201,"about_ca_system_score_gemma":0.004962404,"threshold_uncertainty_score":0.9967342},"labels":[],"label_agreement":null},{"id":"W2601691317","doi":"10.1200/jco.2014.32.15_suppl.7086","title":"Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children’s Oncology Group.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Protocol (science); Cog; Randomized controlled trial; Clinical trial; Population; Internal medicine; Pediatrics; Alternative medicine","score_opus":0.16067143724366081,"score_gpt":0.5072604350043507,"score_spread":0.34658899776068985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601691317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9240224,0.00047921223,0.00003290887,0.07013657,0.00034995243,0.0007790297,0.000008652269,0.000009738517,0.004181579],"genre_scores_gemma":[0.9821602,0.0013848979,0.00034437218,0.014468451,0.0015597594,0.000014565278,0.000005599459,0.000017699707,0.00004445269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943099,0.002356413,0.002300044,0.00028452728,0.00046484184,0.00028428927],"domain_scores_gemma":[0.9751449,0.021959426,0.0021368633,0.00030579508,0.00017738619,0.00027561837],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011056877,0.00020107938,0.0018601257,0.000048668888,0.00012814881,0.00002329361,0.00023045279,0.00032124476,0.000117650925],"category_scores_gemma":[0.015326881,0.000079430094,0.00028206673,0.00014570952,0.0005006572,0.00007789703,0.00009508105,0.0021695455,0.0000072187004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13194384,0.0012208946,0.751652,0.000001664752,0.0011297328,0.00042591747,0.00004839091,0.0000014879138,0.0000050857366,0.00016222023,0.003237494,0.110171296],"study_design_scores_gemma":[0.08023679,0.020584563,0.77193004,0.000049376085,0.00086292054,0.0012407636,0.000065528184,0.000020095333,0.0000051932325,0.00020292,0.12471615,0.00008565907],"about_ca_topic_score_codex":0.0004182246,"about_ca_topic_score_gemma":0.0002757338,"teacher_disagreement_score":0.121478654,"about_ca_system_score_codex":0.0002619222,"about_ca_system_score_gemma":0.00041506326,"threshold_uncertainty_score":0.9929674},"labels":[],"label_agreement":null},{"id":"W2601703087","doi":"10.1200/jco.2012.30.15_suppl.6083","title":"Chemotherapy in the oldest old: The feasibility of cytotoxic therapy in the 80+ population.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Discontinuation; Cancer; Lung cancer; Population; Internal medicine; Performance status; Chemotherapy; Surgery; Retrospective cohort study","score_opus":0.293374716593269,"score_gpt":0.5595872208055418,"score_spread":0.26621250421227277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601703087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539471,0.0014085642,0.0000026029209,0.042539936,0.00060717145,0.00055261306,0.0000012575797,0.0000018005761,0.0009389128],"genre_scores_gemma":[0.9810197,0.0018631951,0.00009010296,0.015647085,0.0013082155,0.000013349659,0.0000014936546,0.0000071134996,0.000049767754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958258,0.0020921614,0.0014824942,0.000093140996,0.0002921958,0.00021415803],"domain_scores_gemma":[0.99306446,0.005609063,0.0009071731,0.0002637271,0.00008684074,0.00006875848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0115090795,0.00010601125,0.0007615784,0.00006882505,0.000038652866,0.000004508172,0.00032262123,0.00020467602,0.00024099575],"category_scores_gemma":[0.0006766343,0.00004037219,0.0003383857,0.00028431285,0.00022297504,0.00008021264,0.000013116741,0.001087674,0.0000036080874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036380275,0.005604082,0.9519782,0.0000065414615,0.00009830799,0.000027759255,0.0027648131,0.0000044689077,0.00021945534,0.00022253157,0.0022690017,0.033166777],"study_design_scores_gemma":[0.009430514,0.0058167176,0.9659628,0.000016500766,0.000083095525,0.00015634307,0.0005280987,0.000008176461,0.00004319042,0.00067870115,0.017239362,0.00003645838],"about_ca_topic_score_codex":0.00015227759,"about_ca_topic_score_gemma":0.00024777537,"teacher_disagreement_score":0.03313032,"about_ca_system_score_codex":0.00012569873,"about_ca_system_score_gemma":0.00030960707,"threshold_uncertainty_score":0.47254628},"labels":[],"label_agreement":null},{"id":"W2601705175","doi":"10.1200/jco.2015.33.15_suppl.4021","title":"Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Medicine; Stroma; Primary tumor; Adenocarcinoma; Pancreatic cancer; Oncology; Metastasis; Proportional hazards model; Internal medicine; Biomarker; Pathology; Cancer; Stage (stratigraphy); Lymph node; Gastroenterology; Urology; Immunohistochemistry","score_opus":0.342449486607945,"score_gpt":0.5377998299905261,"score_spread":0.19535034338258112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601705175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826063,0.0010484988,0.00017148616,0.0041882973,0.00038513067,0.00025460744,0.0000015420807,0.0000043594223,0.011339778],"genre_scores_gemma":[0.9936966,0.00022947413,0.0049088146,0.00046433933,0.00023160555,0.000005724779,0.0000023167981,0.00001156767,0.00044956114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952285,0.00093332597,0.0028982433,0.00016825175,0.00052648113,0.00024518167],"domain_scores_gemma":[0.99394304,0.0028268506,0.0016269749,0.0002564744,0.0008179878,0.00052869885],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008562134,0.00010761334,0.0020394095,0.0003168205,0.000012980176,0.0000035735936,0.00019254132,0.0003156953,0.00019775811],"category_scores_gemma":[0.017478395,0.000075925935,0.00027425252,0.0002898939,0.00040016047,0.000087096276,0.00004634517,0.00074686704,0.00006335934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007975663,0.0019812174,0.97609323,0.00004943896,0.0002719188,0.0011759369,0.00016842707,0.0000018579243,0.000845125,0.00031979682,0.0036505796,0.007466825],"study_design_scores_gemma":[0.010299623,0.014781682,0.96709746,0.00015339658,0.00040650673,0.0010476151,0.00064554723,0.00078685035,0.00006735179,0.001250625,0.0034036897,0.000059638835],"about_ca_topic_score_codex":0.00015030036,"about_ca_topic_score_gemma":0.000040020073,"teacher_disagreement_score":0.012800464,"about_ca_system_score_codex":0.00021212813,"about_ca_system_score_gemma":0.005624975,"threshold_uncertainty_score":0.9978464},"labels":[],"label_agreement":null},{"id":"W2601720937","doi":"10.1200/jco.2012.30.15_suppl.4118","title":"Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Sunitinib; Internal medicine; Placebo; Neuroendocrine tumors; Progression-free survival; Randomized controlled trial; Dosing; Gastroenterology; Overall survival; Urology; Oncology; Surgery; Cancer; Pathology","score_opus":0.0853334689336662,"score_gpt":0.44978975878626387,"score_spread":0.3644562898525977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601720937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479306,0.00012194876,0.0000024619605,0.00070601294,0.0012841623,0.0015964536,0.00007989746,0.000018863875,0.0013971402],"genre_scores_gemma":[0.9978515,0.00009605555,0.0007083839,0.00017163427,0.0008103765,0.000021242136,0.00014676237,0.00004374082,0.00015032748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99207383,0.0016713213,0.004016159,0.0003428523,0.0010953818,0.00080045196],"domain_scores_gemma":[0.98819166,0.0060641854,0.003602911,0.00042413597,0.0008404276,0.0008766526],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012680761,0.00030391332,0.0025415053,0.00041447728,0.00003622003,0.00001258486,0.0003424828,0.000040353574,0.00037114622],"category_scores_gemma":[0.013902124,0.00020151756,0.00028619537,0.0005423399,0.0004172965,0.00037496883,0.0001373375,0.0018000839,0.000012267342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9157684,0.018152574,0.053998485,0.000031172585,0.0004612684,0.0059152036,0.000029527695,0.000009043341,0.00010223784,0.0000050295607,0.0023150672,0.0032119786],"study_design_scores_gemma":[0.79984176,0.109526254,0.08231257,0.0002467449,0.00053966086,0.00025115378,0.00009827015,0.000059109418,0.0007978932,0.000019115745,0.006147533,0.00015995672],"about_ca_topic_score_codex":0.00013768864,"about_ca_topic_score_gemma":0.00007266398,"teacher_disagreement_score":0.11592667,"about_ca_system_score_codex":0.0001295203,"about_ca_system_score_gemma":0.0010924934,"threshold_uncertainty_score":0.9944042},"labels":[],"label_agreement":null},{"id":"W2601732916","doi":"10.1200/jco.2012.30.15_suppl.6071","title":"Burnout prevalence in medical and radiation oncologists at British Columbia Cancer Agency (BCCA).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Burnout; Medicine; Depersonalization; Emotional exhaustion; Workload; Distress; Family medicine; Clinical psychology","score_opus":0.06458404926302362,"score_gpt":0.5169545012253655,"score_spread":0.4523704519623418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601732916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533301,0.035155088,0.000091353206,0.0049922066,0.004122179,0.00022154435,0.000003992531,0.000009062008,0.0020744891],"genre_scores_gemma":[0.85305125,0.13143343,0.002354571,0.0063610966,0.004433665,0.000012881526,0.0000014556235,0.000014934309,0.0023367004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964705,0.0006463262,0.0019287682,0.00018920114,0.0004086477,0.00035652978],"domain_scores_gemma":[0.9948361,0.0030150656,0.0012224087,0.0001187968,0.00015429199,0.00065337366],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005310101,0.00009754236,0.0012467459,0.000057261255,0.00006910865,0.000008672195,0.0001570403,0.0009081153,0.0029629678],"category_scores_gemma":[0.0069155386,0.000099173456,0.00018693956,0.00012821218,0.0006812853,0.00022673968,0.00006155756,0.001256064,0.000007716044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055838696,0.00084468373,0.5899313,0.000041034837,0.00006707796,0.00075362716,0.0000979371,0.00000182623,0.000014846509,0.000006679754,0.0076429914,0.4000396],"study_design_scores_gemma":[0.0059558474,0.003310488,0.78124154,0.00020397277,0.00010834474,0.0035615263,0.000019560473,0.000043129927,0.0000025322431,0.00016330059,0.20531018,0.00007957947],"about_ca_topic_score_codex":0.0003718897,"about_ca_topic_score_gemma":0.0068074586,"teacher_disagreement_score":0.39996004,"about_ca_system_score_codex":0.0006344468,"about_ca_system_score_gemma":0.0016684198,"threshold_uncertainty_score":0.99794847},"labels":[],"label_agreement":null},{"id":"W2601739687","doi":"10.1200/jco.2017.35.6_suppl.342","title":"Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diagnosis and treatment of tuberculosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Campbell Scientific (Canada)","funders":"","keywords":"Medicine; Cystoscopy; Biopsy; Urology; Internal medicine; Mycobacterium phlei; Cytology; Surgery; Urinary system; Tuberculosis; Pathology; Mycobacterium","score_opus":0.13779276298026502,"score_gpt":0.45848556087089587,"score_spread":0.3206927978906309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601739687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804274,0.0001225546,0.0000016691575,0.010848601,0.00097529846,0.0002611562,0.0000091762795,0.000004452742,0.0073497095],"genre_scores_gemma":[0.9959756,0.00054363394,0.0013210739,0.0016035575,0.00038048488,0.0000034019092,0.000007729962,0.000020433652,0.00014406657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636567,0.0003719739,0.0023550566,0.00022231633,0.00041568076,0.00026933075],"domain_scores_gemma":[0.99296534,0.0023431007,0.0032765013,0.00047721688,0.0005842011,0.00035363206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016402432,0.0001821146,0.0019483416,0.00018117679,0.00006334456,0.000019075158,0.0003683425,0.0003517037,0.0003491316],"category_scores_gemma":[0.006294357,0.0001301829,0.0007290903,0.00006256863,0.00031608585,0.00017479912,0.00013103716,0.0006612318,0.000050313065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007780283,0.015097332,0.9021986,0.000048457157,0.00037122596,0.00057666306,0.00009942384,0.0000023205473,0.0008268431,0.000036544,0.0062778536,0.06668446],"study_design_scores_gemma":[0.024626272,0.013769021,0.93486285,0.0001897181,0.0004878417,0.000030842413,0.000027177897,0.000014487914,0.00084189436,0.00005928576,0.024994196,0.00009639394],"about_ca_topic_score_codex":0.000044512748,"about_ca_topic_score_gemma":0.000037274698,"teacher_disagreement_score":0.06658807,"about_ca_system_score_codex":0.00015086945,"about_ca_system_score_gemma":0.00053374795,"threshold_uncertainty_score":0.7535388},"labels":[],"label_agreement":null},{"id":"W2601750054","doi":"10.1200/jco.2014.32.15_suppl.e20673","title":"Early intervention of skin toxicities by panitumumab and clinical outcomes in the clinical setting.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Rash; Panitumumab; Common Terminology Criteria for Adverse Events; Dermatology; Cohort; Internal medicine; Clinical trial; Adverse effect; Surgery; Cetuximab; Cancer; Colorectal cancer","score_opus":0.09503591544547396,"score_gpt":0.49815566817386836,"score_spread":0.4031197527283944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601750054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988398,0.0006213665,0.000049810216,0.007900874,0.0010052384,0.00019154865,0.0000046779537,0.000003949858,0.0018245282],"genre_scores_gemma":[0.9951945,0.0014325697,0.0005559393,0.001990996,0.00060862605,0.0000038722806,0.0000012824142,0.00000872137,0.00020349618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933666,0.0017361204,0.0042177355,0.00018961719,0.00031437128,0.0001755304],"domain_scores_gemma":[0.9866077,0.010947275,0.0019018732,0.00017049567,0.0002278183,0.00014485896],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011468873,0.00013565278,0.0020197753,0.0000714088,0.00003514736,0.0000098900655,0.00016303874,0.00032081327,0.000030309222],"category_scores_gemma":[0.009100934,0.00007161991,0.0009168161,0.000076327844,0.00058727333,0.000070974624,0.00008149229,0.0010331747,0.0000029567918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018739289,0.0023454723,0.70865965,0.000016086957,0.00041923887,0.000035167235,0.00018039506,8.601704e-8,9.9341e-7,0.00006536517,0.0027358676,0.28366777],"study_design_scores_gemma":[0.010353682,0.033924643,0.93551415,0.00010112285,0.00041904073,0.00005059907,0.0006123754,0.000017798335,0.0000030848953,0.00052479486,0.01841991,0.000058780046],"about_ca_topic_score_codex":0.00010171255,"about_ca_topic_score_gemma":0.0003504179,"teacher_disagreement_score":0.283609,"about_ca_system_score_codex":0.00004903431,"about_ca_system_score_gemma":0.00018404015,"threshold_uncertainty_score":0.9992458},"labels":[],"label_agreement":null},{"id":"W2601754066","doi":"10.1200/jco.2017.35.6_suppl.465","title":"Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Surrogate endpoint; Renal cell carcinoma; Intensive care medicine; Internal medicine; Oncology","score_opus":0.33273249674227,"score_gpt":0.5536609135203823,"score_spread":0.22092841677811226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601754066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871573,0.0010056364,0.000024162846,0.004408589,0.00086289085,0.00030368255,0.0000043980995,0.0000029443029,0.006230435],"genre_scores_gemma":[0.9923629,0.00037278188,0.005928552,0.0004682765,0.0006439843,0.000003848032,0.000001299892,0.000013008276,0.00020534823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99391043,0.0015867134,0.0036475013,0.00027469298,0.00033271973,0.0002479395],"domain_scores_gemma":[0.99181736,0.0036265189,0.0032699977,0.00050099945,0.00026459896,0.0005205124],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015611756,0.00017255411,0.0029879222,0.00014518476,0.00006487451,0.000033275093,0.00021425608,0.0002444713,0.00018697334],"category_scores_gemma":[0.018199326,0.00011081149,0.00057712966,0.000036669888,0.00034701757,0.00016287077,0.000110739325,0.00087331823,0.000012881121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017101688,0.0036047597,0.8366215,0.00016851437,0.00031521672,0.012289517,0.00024015285,0.0000012875909,0.005423322,0.000043104545,0.003097154,0.12109375],"study_design_scores_gemma":[0.017834915,0.010817447,0.96199006,0.000069714864,0.00067086954,0.0007252826,0.000057871777,0.00004491009,0.0028214003,0.0011605327,0.003720643,0.00008636604],"about_ca_topic_score_codex":0.00009810869,"about_ca_topic_score_gemma":0.00007996899,"teacher_disagreement_score":0.12536852,"about_ca_system_score_codex":0.00018566343,"about_ca_system_score_gemma":0.0011922427,"threshold_uncertainty_score":0.9900708},"labels":[],"label_agreement":null},{"id":"W2601767411","doi":"10.1200/jco.2013.31.15_suppl.8542","title":"Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Gastroenterology; Regimen; Internal medicine; Dexamethasone; Adverse effect; Cohort; Toxicity","score_opus":0.10781353209332806,"score_gpt":0.45022822690405334,"score_spread":0.3424146948107253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601767411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915513,0.00094572705,0.00002298498,0.0036888623,0.0006746336,0.0021272667,0.000054100918,0.00003196563,0.00090320845],"genre_scores_gemma":[0.9945594,0.0013041133,0.0013292271,0.00039217758,0.0006305554,0.000046264486,0.00006687275,0.00006952023,0.0016018418],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9886232,0.0020258543,0.00630186,0.00081173686,0.0012834482,0.0009538966],"domain_scores_gemma":[0.98722214,0.005906448,0.0034234012,0.00082261907,0.0012088168,0.0014165795],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0057749446,0.0005567247,0.0039065867,0.00075001526,0.00032647964,0.000026367723,0.0005336621,0.00087466644,0.0006015848],"category_scores_gemma":[0.01402659,0.00040449377,0.00056086545,0.00055062654,0.0006584647,0.0004644708,0.00064395164,0.0027890052,0.000046370245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20400079,0.09993516,0.21254465,0.0001557246,0.0035332819,0.008147084,0.0038531846,0.000041416697,0.0071549197,0.0000107063515,0.0041161776,0.4565069],"study_design_scores_gemma":[0.27329335,0.12709135,0.591578,0.00038486088,0.0005162389,0.00043402993,0.00070369715,0.000750922,0.0005117124,0.00004650809,0.0043919263,0.00029738],"about_ca_topic_score_codex":0.00093020656,"about_ca_topic_score_gemma":0.0011632032,"teacher_disagreement_score":0.45620954,"about_ca_system_score_codex":0.0009515789,"about_ca_system_score_gemma":0.0026931383,"threshold_uncertainty_score":0.9998407},"labels":[],"label_agreement":null},{"id":"W2601772729","doi":"10.1200/jco.2009.27.15_suppl.7581","title":"Mesothelin as a marker of response in malignant pleural mesothelioma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Debulking; Malignancy; Mesothelioma; Radiological weapon; Radiology; Internal medicine; Surgery; Cancer; Pathology; Ovarian cancer","score_opus":0.07327661393572421,"score_gpt":0.459577317209495,"score_spread":0.3863007032737708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601772729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855107,0.00046141876,0.0000072098364,0.01160507,0.00018386434,0.00009583176,0.0000042410325,0.0000029302762,0.002128724],"genre_scores_gemma":[0.9935904,0.00025519435,0.0012800394,0.004118006,0.00018918522,7.5797743e-7,0.0000013275746,0.0000066395737,0.00055843877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971195,0.00049610436,0.0017909587,0.000111232,0.00034181232,0.00014042943],"domain_scores_gemma":[0.9973294,0.0014285666,0.00080498855,0.000119375545,0.00007444584,0.00024318104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002745812,0.00008959281,0.0008548289,0.0001615651,0.000010053099,0.0000018471544,0.00010262998,0.00017836888,0.00053600775],"category_scores_gemma":[0.0030417396,0.000059837534,0.00037631558,0.0001098026,0.0001370774,0.000064603926,0.000019681276,0.00032896377,0.000037257418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22626935,0.006336404,0.6825439,0.000020726282,0.0001719512,0.0028081457,0.00010083914,0.000053061645,0.009373724,0.0003064143,0.0024790268,0.069536485],"study_design_scores_gemma":[0.0054043564,0.017625667,0.96580315,0.00012441637,0.00011042245,0.0003766414,0.00006882542,0.000045861347,0.00031221818,0.0015653562,0.008508684,0.000054375767],"about_ca_topic_score_codex":0.000008220021,"about_ca_topic_score_gemma":0.0000032822118,"teacher_disagreement_score":0.2832593,"about_ca_system_score_codex":0.00009391877,"about_ca_system_score_gemma":0.0006626843,"threshold_uncertainty_score":0.5868909},"labels":[],"label_agreement":null},{"id":"W2601796919","doi":"10.1200/jco.2015.33.15_suppl.e14635","title":"Trends in lymph node (LN) harvest for colon cancer in routine clinical practice: Does node count matter in the real world?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Poisson regression; Colorectal cancer; Lymph node; Cancer registry; Cancer; Proportional hazards model; Population; Internal medicine; Surgery","score_opus":0.19225525747251887,"score_gpt":0.5500710513970979,"score_spread":0.357815793924579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601796919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8843779,0.00033084935,0.000007774122,0.09792297,0.0024300972,0.000439321,0.000018771218,0.0000063525913,0.014465959],"genre_scores_gemma":[0.9777275,0.00090916455,0.002064345,0.016072722,0.0018756108,0.00010769367,0.000008271659,0.000029756493,0.0012049676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923102,0.0018408747,0.004329468,0.00039610977,0.00063421676,0.0004891164],"domain_scores_gemma":[0.98522115,0.011755291,0.0018709089,0.0003014478,0.00044637936,0.00040484458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014967822,0.00023804844,0.0022014165,0.00041368548,0.00002230476,0.000023271543,0.00033038325,0.0005277827,0.00027062948],"category_scores_gemma":[0.0074294833,0.00013015336,0.00050707447,0.0006993396,0.0002786897,0.000272678,0.00008072056,0.0016221391,0.000021855474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032603774,0.00500666,0.9041087,0.00001764512,0.00014442293,0.0019311525,0.00027478582,0.000075505755,0.000002050454,0.000048273323,0.0067081675,0.04907884],"study_design_scores_gemma":[0.030798348,0.0041475976,0.83635324,0.00018763197,0.0002510529,0.00012379505,0.00027016472,0.0002472387,0.0000021870524,0.0002127931,0.1272878,0.00011812498],"about_ca_topic_score_codex":0.0017435941,"about_ca_topic_score_gemma":0.021768294,"teacher_disagreement_score":0.12057964,"about_ca_system_score_codex":0.001611685,"about_ca_system_score_gemma":0.0024370293,"threshold_uncertainty_score":0.9960819},"labels":[],"label_agreement":null},{"id":"W2601804042","doi":"10.1200/jco.2013.31.15_suppl.9502","title":"A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Queen's University; Baker Hughes (Canada); Health Sciences Centre","funders":"","keywords":"Medicine; Adverse effect; Clinical endpoint; Randomized controlled trial; Surgery; Anesthesia; Internal medicine; Urology","score_opus":0.21979699923443144,"score_gpt":0.47673673023122615,"score_spread":0.2569397309967947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601804042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96547604,0.00062468584,0.008089747,0.01472455,0.0040848777,0.0045588096,0.00006153764,0.000020123296,0.002359656],"genre_scores_gemma":[0.9680612,0.00019132637,0.029515766,0.0008176682,0.0009211824,0.0001040766,0.000034825098,0.000025991509,0.0003279809],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99230385,0.0016276188,0.0049391026,0.00021510944,0.0006594328,0.00025491358],"domain_scores_gemma":[0.9611562,0.030327946,0.0064334446,0.00037802264,0.001281164,0.00042322092],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011047556,0.00018740028,0.0034622082,0.0003344959,0.000040906813,0.000010378879,0.00016693407,0.00024331988,0.00086611864],"category_scores_gemma":[0.09470976,0.00013863348,0.0016966144,0.000198687,0.00035049432,0.00024230906,0.000045517038,0.00042623948,0.000014251546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9365042,0.007383427,0.00021259674,0.00017187333,0.0021157034,0.000032924152,0.000086569344,0.00008319263,0.0005549896,0.00016151874,0.0224749,0.030218134],"study_design_scores_gemma":[0.9468602,0.019968344,0.0016456904,0.0001055,0.0053304415,0.0000072583243,0.00051040825,0.0023288263,0.00014437444,0.0010315853,0.021953523,0.00011387331],"about_ca_topic_score_codex":0.000069281734,"about_ca_topic_score_gemma":0.00004731451,"teacher_disagreement_score":0.083662204,"about_ca_system_score_codex":0.00011370514,"about_ca_system_score_gemma":0.0009359078,"threshold_uncertainty_score":0.94833916},"labels":[],"label_agreement":null},{"id":"W2601829962","doi":"10.1200/jco.2012.30.15_suppl.e15177","title":"Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Princess Margaret Cancer Centre; Queen's University; London Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Docetaxel; Temsirolimus; Prostate cancer; Internal medicine; Oncology; Surrogate endpoint; Cancer; Urology; Clinical trial; Surgery; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.15714857045649616,"score_gpt":0.5088583835759543,"score_spread":0.3517098131194581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601829962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97488034,0.0058191256,0.00001259852,0.017353006,0.0009226749,0.0005164522,0.00003285922,0.0000056789654,0.00045726617],"genre_scores_gemma":[0.9874875,0.005016805,0.0012148606,0.0019128136,0.001023906,0.000050623486,0.0000012430572,0.00002220422,0.0032700447],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9963987,0.0006011454,0.0018407411,0.00016905954,0.0005177013,0.00047267645],"domain_scores_gemma":[0.9959856,0.0012495246,0.0009878497,0.00023248064,0.0008435999,0.00070089434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047439113,0.00015980113,0.0011523009,0.00017909368,0.000035161993,0.000008428074,0.00014235386,0.00022861167,0.00027609064],"category_scores_gemma":[0.0012740993,0.00009394299,0.00037134852,0.00022664959,0.00024774755,0.00016475837,0.00003142201,0.00063084654,0.000022889197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4975046,0.004104781,0.36072746,0.000095568284,0.0009569519,0.0010867934,0.0018862388,0.000015027429,0.032651957,0.00006395667,0.01214663,0.088760056],"study_design_scores_gemma":[0.0120400395,0.015516957,0.7980443,0.00023877747,0.00013148756,0.0001303979,0.00021159244,0.000005011078,0.0038327805,0.000059012855,0.16968198,0.00010761562],"about_ca_topic_score_codex":0.00007421593,"about_ca_topic_score_gemma":0.00005580829,"teacher_disagreement_score":0.48546454,"about_ca_system_score_codex":0.0003063787,"about_ca_system_score_gemma":0.0027743839,"threshold_uncertainty_score":0.49216378},"labels":[],"label_agreement":null},{"id":"W2601873859","doi":"10.1200/jco.2013.31.15_suppl.e18503","title":"En bloc resection of pulmonary sulcus non-small cell lung cancer invading the spine: A systematic review and pooled analysis.","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Sulcus; Lung cancer; Radiation therapy; Surgery; Chemotherapy; Chemoradiotherapy; Cancer; Radiology; Internal medicine","score_opus":0.09089678263406761,"score_gpt":0.48154301500985564,"score_spread":0.390646232375788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601873859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003734928,0.9938327,0.000012330343,0.0019432153,0.0005161039,0.0029183647,0.0000070621513,0.0000033967758,0.00039332954],"genre_scores_gemma":[0.0010450128,0.996501,0.00018103779,0.0007311618,0.00076624367,0.00031190316,0.0000070043943,0.000029729712,0.0004269077],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99169433,0.001826552,0.0055783186,0.0003102342,0.0003682495,0.00022233393],"domain_scores_gemma":[0.9870317,0.0034328615,0.008232746,0.00046629785,0.0005476328,0.00028878773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00594993,0.00034316367,0.012083437,0.00029755407,0.00004286626,0.0000135794435,0.00029011,0.0005821393,0.00011489135],"category_scores_gemma":[0.0017814407,0.00015699214,0.0025164343,0.00060387066,0.00010912127,0.000054328157,0.000100944744,0.0013268341,0.0000054137276],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042622112,0.00078763167,0.0014075841,0.88045007,0.02018183,0.000243618,0.000033249977,0.0000023255452,3.676802e-7,0.0000033812155,0.0022561196,0.094591215],"study_design_scores_gemma":[0.0013174259,0.002574707,0.0013222496,0.5012293,0.45152575,0.0004971267,0.000023052091,0.00006036519,7.352923e-7,0.0000049668915,0.04128351,0.00016080584],"about_ca_topic_score_codex":0.00012529931,"about_ca_topic_score_gemma":0.00007894759,"teacher_disagreement_score":0.4313439,"about_ca_system_score_codex":0.0007072678,"about_ca_system_score_gemma":0.0021838737,"threshold_uncertainty_score":0.8259996},"labels":[],"label_agreement":null},{"id":"W2601878594","doi":"10.1200/jco.2012.30.15_suppl.5105","title":"Prognostic significance of high-risk human papilloma virus (HPV), p16, and p53 status in women with vulvar squamous cell carcinoma (VSCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Immunohistochemistry; Tissue microarray; HPV infection; Incidence (geometry); Cancer; Carcinoma; Clinical significance; Cervical cancer; Cancer research","score_opus":0.07013682241519635,"score_gpt":0.4172816915391889,"score_spread":0.34714486912399256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601878594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940228,0.0020888275,0.000024843062,0.00038682687,0.00021934607,0.00039092716,0.000012468387,0.00000559196,0.0028483777],"genre_scores_gemma":[0.99733675,0.0006492067,0.00068624655,0.00041668158,0.0007826096,0.000018276514,0.0000015894626,0.000025904863,0.00008276329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959527,0.00064620347,0.0018656347,0.000225901,0.00059213385,0.0007173876],"domain_scores_gemma":[0.99417484,0.0029214998,0.0011603055,0.00022569948,0.00045836729,0.0010592936],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036560255,0.0001748256,0.0016091614,0.00020080028,0.0000467118,0.000008181268,0.00016034972,0.00031586553,0.00092840375],"category_scores_gemma":[0.0020173031,0.00011688184,0.000121872494,0.0002582091,0.0005075406,0.00013420913,0.00008305411,0.0015786537,0.00000761364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012186192,0.0027470752,0.8722305,0.00021396797,0.00006789071,0.0003428913,0.00061080593,0.000006479571,0.0007369666,0.000044485736,0.00025099394,0.1105617],"study_design_scores_gemma":[0.013549864,0.03463896,0.9458718,0.000022209522,0.00018682914,0.00007512787,0.0003878944,0.000008513031,0.0006695435,0.00022503363,0.0042470023,0.00011727366],"about_ca_topic_score_codex":0.00087466545,"about_ca_topic_score_gemma":0.00040361984,"teacher_disagreement_score":0.11044443,"about_ca_system_score_codex":0.00031770836,"about_ca_system_score_gemma":0.0013144459,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W2601892586","doi":"10.1200/jco.2013.31.15_suppl.2505","title":"First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Nausea; Neutropenia; Medicine; Pharmacodynamics; Pharmacokinetics; Vomiting; Tolerability; Adverse effect; Gastroenterology; Toxicity; Internal medicine; Pharmacology","score_opus":0.01891022661244057,"score_gpt":0.34881410576976846,"score_spread":0.3299038791573279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601892586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982981,0.000030503126,0.000008156707,0.00023781616,0.00044334054,0.00038988932,0.0000033261995,0.0000015765885,0.0005872564],"genre_scores_gemma":[0.998726,0.00008188899,0.00059577427,0.00015723474,0.00038619695,0.0000060174975,0.0000063658576,0.000021039106,0.000019466877],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970649,0.00018442913,0.0020826994,0.00023821346,0.00021093152,0.00021883646],"domain_scores_gemma":[0.99754095,0.00013089724,0.001687454,0.0001759339,0.00035563562,0.00010910014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006927275,0.0001507382,0.001031828,0.00015353708,0.000020892865,0.000004252915,0.00017218197,0.0003798455,0.000057730915],"category_scores_gemma":[0.00079019193,0.00011690392,0.00019853517,0.00016450648,0.00016562233,0.000024971332,0.000055648794,0.00049595296,0.0000018479243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47295815,0.03030536,0.34437552,0.00021998567,0.000624468,0.00022457754,0.0009239869,0.0011983865,0.06748219,0.00012934988,0.008914461,0.07264357],"study_design_scores_gemma":[0.26984203,0.17266783,0.52962625,0.00030240955,0.00009201033,0.000028906827,0.00029768114,0.0001480742,0.006503155,0.00038111175,0.019735117,0.0003754408],"about_ca_topic_score_codex":0.000052746924,"about_ca_topic_score_gemma":0.0004719227,"teacher_disagreement_score":0.20311609,"about_ca_system_score_codex":0.00007409344,"about_ca_system_score_gemma":0.00029446816,"threshold_uncertainty_score":0.47672033},"labels":[],"label_agreement":null},{"id":"W2601910404","doi":"10.1200/jco.2013.31.15_suppl.6622","title":"Concordance between abstracts, virtual meeting (VM) presentations, and final publication of phase III clinical trials presented at the Annual Meeting of the American Society of Clinical Oncology.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Concordance; Clinical trial; Presentation (obstetrics); Clinical Oncology; Clinical endpoint; MEDLINE; Family medicine; Inclusion (mineral); Medical physics; Internal medicine; Surgery; Psychology; Cancer","score_opus":0.8549346812967721,"score_gpt":0.6893358096662742,"score_spread":0.1655988716304979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601910404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746126,0.0005452373,0.000869783,0.020187352,0.00091126614,0.0011525524,0.00006610426,0.0000021906494,0.0016529333],"genre_scores_gemma":[0.9891915,0.00088525226,0.006248585,0.0010533837,0.0013280049,0.000018029827,0.000004948608,0.000013331457,0.0012569634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.78196996,0.11356176,0.09807599,0.00095899845,0.005000284,0.0004330198],"domain_scores_gemma":[0.21555033,0.5140721,0.25331798,0.0029045306,0.013382646,0.0007723876],"candidate_categories":["metaresearch","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5353562,0.00029580697,0.014181474,0.00015501698,0.0001866939,0.00009460685,0.0025393495,0.0005337223,0.0006500564],"category_scores_gemma":[0.5600438,0.00012067198,0.007274866,0.001022446,0.0033305152,0.00046720653,0.0006554198,0.0015697393,0.000029426441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070759346,0.0012093976,0.46270597,0.000025914089,0.0015839024,0.000001367458,0.00032480384,0.00006437394,0.00012676766,0.000081442384,0.17535305,0.3578154],"study_design_scores_gemma":[0.0077080783,0.0052642575,0.84600306,0.00011412124,0.0019216066,0.000021561647,0.0056017158,0.0022525808,0.00008184105,0.0007298641,0.13016081,0.00014054117],"about_ca_topic_score_codex":0.00021485922,"about_ca_topic_score_gemma":0.00009861265,"teacher_disagreement_score":0.5664196,"about_ca_system_score_codex":0.000048159833,"about_ca_system_score_gemma":0.0019792847,"threshold_uncertainty_score":0.99938184},"labels":[],"label_agreement":null},{"id":"W2601919113","doi":"10.1200/jco.2013.31.15_suppl.e14615","title":"Metformin and biomarkers relevant to neoplasia in nondiabetic patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Metformin; Medicine; Postprandial; Internal medicine; Endocrinology; Insulin; Diabetes mellitus; Type 2 diabetes; Insulin resistance; Population","score_opus":0.028752468338447128,"score_gpt":0.3704145162906953,"score_spread":0.34166204795224814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601919113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98041105,0.017498156,0.000032033113,0.00044055603,0.0008507236,0.00017111434,0.0000026512528,0.0000012384301,0.0005924499],"genre_scores_gemma":[0.9706985,0.021283748,0.0033213715,0.0040323264,0.00054248824,0.000013543609,0.000004254217,0.0000159608,0.00008782009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979582,0.000241175,0.0012292409,0.00019182438,0.00014165895,0.0002379371],"domain_scores_gemma":[0.9985884,0.00020574314,0.0005161591,0.00014425906,0.00022609507,0.0003193801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013895661,0.00011085379,0.0006143718,0.00009544652,0.000016777385,0.00001168486,0.00017111721,0.0002984505,0.00007766765],"category_scores_gemma":[0.0020340113,0.00008327449,0.00015024611,0.00009270221,0.000097893,0.000010811994,0.00008486938,0.00024653884,0.00002275263],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031957,0.00031807818,0.074230984,0.000009649463,0.000101293175,0.0000088633,0.00003348284,0.000004710694,0.0015648708,0.00001412784,0.014291459,0.9091029],"study_design_scores_gemma":[0.0035569626,0.0049051032,0.315863,0.000024048062,0.00004876994,0.000012569598,0.00006436733,0.000014621782,0.001493817,0.0003839149,0.67348874,0.00014410933],"about_ca_topic_score_codex":0.000019906762,"about_ca_topic_score_gemma":0.000059115988,"teacher_disagreement_score":0.9089588,"about_ca_system_score_codex":0.000023837805,"about_ca_system_score_gemma":0.00030639395,"threshold_uncertainty_score":0.33958352},"labels":[],"label_agreement":null},{"id":"W2601920003","doi":"10.1200/jco.2017.35.6_suppl.173","title":"Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Taxane; Enzalutamide; Prednisone; Adverse effect; Cancer; Gastroenterology; Urology; Androgen receptor; Oncology; Androgen deprivation therapy; Breast cancer","score_opus":0.10375789579384996,"score_gpt":0.47915824735057805,"score_spread":0.3754003515567281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601920003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613357,0.00026615022,0.000004414687,0.0021539968,0.0000976681,0.0011866101,0.000035027373,0.000003232981,0.00011930676],"genre_scores_gemma":[0.997679,0.0014138038,0.00054684264,0.00010091189,0.00005914937,0.00001778655,0.000005737877,0.000020399215,0.00015638952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972048,0.00034311195,0.0013801374,0.0002901671,0.0005166396,0.00026519314],"domain_scores_gemma":[0.99681526,0.0004539252,0.0017221201,0.00027226246,0.0004221522,0.00031425265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014937241,0.00019520959,0.0014053454,0.00014544456,0.00012009586,0.000031828287,0.000120896395,0.00008444039,0.000017196868],"category_scores_gemma":[0.00037816452,0.00010571306,0.000051774514,0.000084686406,0.00053997355,0.00020702965,0.000052861957,0.0005830906,7.743753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28564534,0.019833846,0.53483146,0.00014603997,0.0013950912,0.0014247949,0.001319818,0.00009856799,0.00024559686,0.0000099550325,0.000047628942,0.15500188],"study_design_scores_gemma":[0.14349161,0.11690377,0.73778373,0.00035819743,0.0005323503,0.000026168576,0.00030394277,0.000056068227,0.00013851997,0.000014572193,0.00030195343,0.000089112604],"about_ca_topic_score_codex":0.00017338719,"about_ca_topic_score_gemma":0.0015236794,"teacher_disagreement_score":0.20295228,"about_ca_system_score_codex":0.00013804997,"about_ca_system_score_gemma":0.00083484355,"threshold_uncertainty_score":0.43108532},"labels":[],"label_agreement":null},{"id":"W2601930516","doi":"10.1200/jco.2017.35.4_suppl.422","title":"Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Lanreotide; Medicine; Octreotide; Internal medicine; Somatostatin; Neuroendocrine tumors; Clinical endpoint; Dosing; Gastroenterology; Surgery; Randomized controlled trial; Hormone; Acromegaly","score_opus":0.11335553313207855,"score_gpt":0.508597574315542,"score_spread":0.3952420411834634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601930516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689209,0.005223573,0.0000102439535,0.019963482,0.00056494423,0.0017859354,0.000005393534,0.000015399351,0.0035101708],"genre_scores_gemma":[0.97188,0.02439649,0.0017238399,0.0012517907,0.00010892574,0.000021725935,0.0000022106406,0.00002723883,0.0005877571],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9924973,0.0010336955,0.0050060665,0.0002662907,0.0007823287,0.00041429285],"domain_scores_gemma":[0.9917519,0.0015285073,0.005075264,0.000784205,0.00043243123,0.0004276939],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029857443,0.00020113654,0.0036461682,0.00027239125,0.00004967845,0.000015655258,0.0007046281,0.000022467144,0.000071920345],"category_scores_gemma":[0.013003012,0.00013694416,0.0005389941,0.00018906257,0.00037723966,0.00022987413,0.0002640472,0.0011099008,0.00002717693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007759796,0.006924865,0.14888223,0.37644008,0.0015430852,0.43442002,0.000045287623,0.000029712832,0.00034613637,0.0007034106,0.008746203,0.01415918],"study_design_scores_gemma":[0.027958952,0.024379741,0.66577554,0.25133333,0.0023060571,0.021907158,0.00038606848,0.00031596827,0.0004830133,0.0012522911,0.0035236932,0.00037821147],"about_ca_topic_score_codex":0.00002733812,"about_ca_topic_score_gemma":0.000031199652,"teacher_disagreement_score":0.51689327,"about_ca_system_score_codex":0.000086837004,"about_ca_system_score_gemma":0.00043866792,"threshold_uncertainty_score":0.9953109},"labels":[],"label_agreement":null},{"id":"W2601931878","doi":"10.1200/jco.2015.33.15_suppl.6596","title":"Cancer mortality and published research output: Is there any relationship?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Clinical trial; Colorectal cancer; Prostate cancer; Breast cancer; Lung cancer; Disease; Oncology; Internal medicine; Demography; Gerontology","score_opus":0.5753949144085498,"score_gpt":0.6682941705060298,"score_spread":0.09289925609747995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601931878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9034681,0.008644309,0.00023877069,0.06910607,0.0026031486,0.00016948555,0.000003447761,0.000009050237,0.015757626],"genre_scores_gemma":[0.9785106,0.004304838,0.0047026626,0.0053253286,0.003827916,0.000005213685,8.380234e-7,0.000013897914,0.0033087041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965937,0.001032074,0.0014403438,0.00019407355,0.0004973752,0.00024243478],"domain_scores_gemma":[0.99223197,0.00484664,0.00082475727,0.00023257703,0.0012466909,0.00061738613],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013641961,0.00009039247,0.0009799917,0.00013656885,0.00007898657,0.00001215427,0.00016416355,0.0006257495,0.00028668318],"category_scores_gemma":[0.015232743,0.00005782683,0.00016875341,0.00021628903,0.0008713788,0.0002591517,0.00004981557,0.0022810122,0.000011807312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016697025,0.00056711433,0.8755405,0.00001295474,0.00024357474,0.00027490163,0.00033908515,0.0000049675846,0.0000040868235,0.0005843179,0.087302476,0.033456333],"study_design_scores_gemma":[0.004058091,0.0043873913,0.61461914,0.00003630264,0.000085520245,0.00019938461,0.00022336828,0.000041043895,0.0000040161767,0.009190727,0.3671137,0.000041294414],"about_ca_topic_score_codex":0.000042142732,"about_ca_topic_score_gemma":0.0000829778,"teacher_disagreement_score":0.2798112,"about_ca_system_score_codex":0.0002931539,"about_ca_system_score_gemma":0.0036376498,"threshold_uncertainty_score":0.9930624},"labels":[],"label_agreement":null},{"id":"W2601939566","doi":"10.1200/jco.2014.32.15_suppl.6514","title":"Does routine symptom screening with the Edmonton Symptom Assessment System (ESAS) decrease emergency department visits in breast cancer patients undergoing adjuvant chemotherapy?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Emergency department; Breast cancer; Cancer; Cohort; Population; Retrospective cohort study; Emergency medicine; Stage (stratigraphy); Internal medicine","score_opus":0.015152522352645307,"score_gpt":0.35719966784673807,"score_spread":0.34204714549409276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601939566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98953336,0.00053365604,0.0012586841,0.007183626,0.00084451167,0.0002887957,0.000025449974,0.000008074325,0.000323843],"genre_scores_gemma":[0.99530363,0.0014604884,0.0010661912,0.00090020645,0.0011404434,0.000043136904,0.000015162208,0.00003192724,0.00003878644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968362,0.0006465907,0.0013986158,0.00036912155,0.0003878169,0.00036168474],"domain_scores_gemma":[0.99712634,0.0003744394,0.0015591914,0.00027585344,0.00040868032,0.0002554701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015034593,0.0002780413,0.00089304574,0.0000557262,0.00012218271,0.000015435066,0.00030617038,0.00022210169,0.000031360094],"category_scores_gemma":[0.00018316621,0.00013184754,0.00027008718,0.0001145509,0.000098237324,0.000017021652,0.00012460245,0.00034843443,0.0000012917519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022271436,0.00095825066,0.94869214,0.000031711883,0.00084716326,0.000017827955,0.0000589935,0.00028616688,0.00006965187,0.000037134232,0.00079855806,0.04597528],"study_design_scores_gemma":[0.009225677,0.002536419,0.98158944,0.00023331674,0.00026068476,0.00004006868,0.00024491287,0.00012019671,0.00010798893,0.000010478188,0.0054409145,0.00018993337],"about_ca_topic_score_codex":0.00014340025,"about_ca_topic_score_gemma":0.0017460876,"teacher_disagreement_score":0.045785345,"about_ca_system_score_codex":0.00027383253,"about_ca_system_score_gemma":0.0006791877,"threshold_uncertainty_score":0.53765863},"labels":[],"label_agreement":null},{"id":"W2601946099","doi":"10.1200/jco.2014.32.15_suppl.tps5629","title":"Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Juravinski Cancer Centre; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cabozantinib; Oncology; Internal medicine; Clinical endpoint; Endometrial cancer; Progression-free survival; Cancer; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.2113546195443331,"score_gpt":0.511895850200911,"score_spread":0.3005412306565779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601946099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414915,0.000624668,0.000013329101,0.0016058736,0.0017569202,0.0016274707,0.000040687304,0.0000031665902,0.00017875417],"genre_scores_gemma":[0.99795806,0.0005898128,0.0003828037,0.00019087293,0.00077240256,0.000027465596,0.0000018003557,0.000016591048,0.000060203532],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99190444,0.0020427767,0.0048182043,0.00027338185,0.000701482,0.00025969523],"domain_scores_gemma":[0.9894746,0.00530833,0.0041488144,0.00034513857,0.00038538274,0.0003377624],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006396315,0.00022144734,0.0031870632,0.0003214852,0.000065588814,0.0000042547526,0.00023225028,0.00018690094,0.00019099482],"category_scores_gemma":[0.015403739,0.00011311355,0.0005305377,0.0004536645,0.00039895638,0.000050362138,0.00016831141,0.0009449039,9.5270883e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56635445,0.116809465,0.0104525,0.00008994692,0.0012868098,0.00034787334,0.0007386809,0.0000096294925,0.0009685119,0.00002157095,0.00054745574,0.30237308],"study_design_scores_gemma":[0.5682879,0.41388458,0.004729067,0.00017221906,0.0022236565,0.00014107501,0.00027468035,0.00014012695,0.0006639686,0.000052218806,0.009346595,0.00008388127],"about_ca_topic_score_codex":0.0001394787,"about_ca_topic_score_gemma":0.00040394097,"teacher_disagreement_score":0.3022892,"about_ca_system_score_codex":0.00011130865,"about_ca_system_score_gemma":0.001806385,"threshold_uncertainty_score":0.99288994},"labels":[],"label_agreement":null},{"id":"W2601947714","doi":"10.1200/jco.2017.35.6_suppl.e587","title":"Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; SABR volatility model; Prostate cancer; Abiraterone acetate; Oncology; Chemotherapy; Internal medicine; Lymph; Radiation therapy; Metastasis; Bone metastasis; Androgen deprivation therapy; Cancer; Radiology; Pathology","score_opus":0.17010034977483687,"score_gpt":0.512485317785779,"score_spread":0.3423849680109421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601947714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837153,0.005206889,0.000024283609,0.008833063,0.00033825685,0.0010134651,0.00001776216,0.00000506878,0.00084592646],"genre_scores_gemma":[0.96836907,0.025377419,0.0031418616,0.00032047392,0.00019142588,0.0000537352,0.0000011253792,0.000027019169,0.002517857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963541,0.0005265652,0.0018833699,0.0002891959,0.0005351777,0.0004115823],"domain_scores_gemma":[0.9950567,0.0010669433,0.0025311166,0.00037013425,0.0006168095,0.00035830145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025751404,0.0002046325,0.0014325824,0.00021046064,0.00011441919,0.000048296097,0.0003268847,0.00013040351,0.00019509418],"category_scores_gemma":[0.0009807771,0.00013200447,0.00022577659,0.00014137903,0.00036015635,0.00040444933,0.000056220215,0.0006342157,0.000004130819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07863292,0.004278404,0.6735271,0.00094967696,0.0048225606,0.003176845,0.00511274,0.00048911606,0.033511538,0.00007062557,0.0011214708,0.19430697],"study_design_scores_gemma":[0.032895714,0.025384635,0.92865574,0.0013910118,0.00034998526,0.0000815479,0.0005446941,0.00022916385,0.007747044,0.00044486922,0.0020677452,0.0002078498],"about_ca_topic_score_codex":0.00023565933,"about_ca_topic_score_gemma":0.00029744674,"teacher_disagreement_score":0.2551286,"about_ca_system_score_codex":0.0004695991,"about_ca_system_score_gemma":0.0031801306,"threshold_uncertainty_score":0.5641415},"labels":[],"label_agreement":null},{"id":"W2601953228","doi":"10.1200/jco.2007.25.18_suppl.6532","title":"The quality of phase I trial (P1T) abstracts submitted to ASCO meetings","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Limiting; Quality (philosophy); Quality Score; Rating scale; Medical physics; Statistics","score_opus":0.8494559102098228,"score_gpt":0.7573544482863453,"score_spread":0.09210146192347746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601953228","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389261,0.000047078476,0.041278873,0.0055674566,0.007357613,0.00073981745,0.000015553078,0.000017983062,0.006049543],"genre_scores_gemma":[0.4789698,0.000073959156,0.5155545,0.001256007,0.003960026,0.0000042630127,1.7887041e-7,0.000028433276,0.0001528505],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96981573,0.0070642424,0.020646485,0.0003531335,0.0014803752,0.0006400042],"domain_scores_gemma":[0.2979868,0.6858439,0.012973794,0.0006421262,0.0016306915,0.00092269614],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2126922,0.00020723286,0.003214487,0.00010279122,0.00009404952,0.000022513754,0.0008661805,0.0007372049,0.00016038533],"category_scores_gemma":[0.8068952,0.00012326565,0.0011300188,0.00028339704,0.00063725683,0.000069803835,0.00015277904,0.0017136765,0.000027407803],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3237376,0.008611908,0.0005601896,0.00006407338,0.0006864507,0.000185305,0.00016330645,0.000003009937,0.0007206357,0.045591496,0.014402212,0.60527384],"study_design_scores_gemma":[0.13828436,0.03076473,0.01971559,0.00012394733,0.00049895927,0.000029265222,0.0002737435,0.000008476724,0.0012154569,0.75337046,0.05544374,0.000271265],"about_ca_topic_score_codex":0.000017294407,"about_ca_topic_score_gemma":0.000058055368,"teacher_disagreement_score":0.707779,"about_ca_system_score_codex":0.00010863234,"about_ca_system_score_gemma":0.000929659,"threshold_uncertainty_score":0.81069905},"labels":[],"label_agreement":null},{"id":"W2601978884","doi":"10.1200/jco.2013.31.15_suppl.e19509","title":"Prolonged therapy with single-agent bortezomib (btz) in four patients (pts) with relapsed primary systemic AL amyloidosis treated in the CAN2007 phase II study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Cumulative dose; AL amyloidosis; Maintenance therapy; Bortezomib; Phases of clinical research; Surgery; Clinical trial; Multiple myeloma; Chemotherapy; Antibody; Immunology","score_opus":0.056515353272962116,"score_gpt":0.3699479900942198,"score_spread":0.31343263682125766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601978884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950066,0.0004828089,0.000012967647,0.0021543943,0.00019557023,0.0019004316,0.000006973251,0.0000070057017,0.00023321177],"genre_scores_gemma":[0.9950963,0.00059159345,0.00037596823,0.0033692205,0.0001670159,0.00026316155,0.000020993963,0.000042020583,0.00007368202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949822,0.0015863408,0.0020361068,0.00046616863,0.00048137337,0.00044780347],"domain_scores_gemma":[0.99660283,0.00058347936,0.0017631465,0.00045827773,0.00039028272,0.00020198374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019291517,0.00035889164,0.001286485,0.00017107086,0.000081018385,0.000029813622,0.00050020026,0.00038714788,0.000028963694],"category_scores_gemma":[0.00047431162,0.00018867073,0.00024152616,0.00029125033,0.00019680246,0.000030461293,0.00008044268,0.00068246963,0.000005638563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008682028,0.02294853,0.9291481,0.0000086137425,0.0006645452,0.00031950456,0.00037032168,0.00004604349,0.0018350328,6.6558135e-7,0.0017744192,0.03420222],"study_design_scores_gemma":[0.05441871,0.12721916,0.81291205,0.00009193833,0.00019445701,0.00013576343,0.0005941151,0.000007967176,0.00043461358,0.000004127055,0.003733775,0.00025333898],"about_ca_topic_score_codex":0.00027853434,"about_ca_topic_score_gemma":0.0013342211,"teacher_disagreement_score":0.11623604,"about_ca_system_score_codex":0.00028809253,"about_ca_system_score_gemma":0.00063031464,"threshold_uncertainty_score":0.7693769},"labels":[],"label_agreement":null},{"id":"W2601984683","doi":"10.1200/jco.2017.35.4_suppl.246","title":"A population-based study of biliary tract cancers (BTCs) in Alberta, Canada: How do our patients fare?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Stage (stratigraphy); Gallbladder; Ampulla of Vater; Oncology; Population; Gastroenterology; Demographics; Intrahepatic Cholangiocarcinoma; Biopsy; Chemotherapy; Carcinoma; Demography","score_opus":0.09268504950947146,"score_gpt":0.42510267890106684,"score_spread":0.33241762939159536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601984683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856768,0.00013393702,7.104498e-7,0.011831834,0.0015735774,0.0002859248,0.00000573366,0.0000013371373,0.0004901341],"genre_scores_gemma":[0.9986807,0.00003120446,0.000054633972,0.00069849164,0.00042461313,0.0000053985377,0.0000021439996,0.0000114726345,0.000091319984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744934,0.00021849755,0.0014861291,0.00018339764,0.00046804958,0.00019460023],"domain_scores_gemma":[0.99591833,0.0008580371,0.0022638016,0.00032610894,0.0004253452,0.00020836096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090186053,0.00013264256,0.0014934829,0.00011209147,0.00007487854,0.000010392169,0.00023694559,0.00015687059,0.000013308903],"category_scores_gemma":[0.0040181903,0.0000960314,0.00023940153,0.000060145776,0.000036295936,0.00009936793,0.00004348634,0.0006103334,4.0471275e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014579616,0.002023421,0.98058224,0.000024993615,0.0002170858,0.00027534738,0.00017975425,0.00004523942,0.0000011475648,0.0000016600256,0.0022689332,0.012922197],"study_design_scores_gemma":[0.013636883,0.0067713447,0.9765588,0.000100265854,0.00025659415,0.0000068739237,0.0008973515,0.000030615683,0.0000021499588,0.000011208515,0.0016470477,0.00008083621],"about_ca_topic_score_codex":0.59527576,"about_ca_topic_score_gemma":0.91172755,"teacher_disagreement_score":0.31645176,"about_ca_system_score_codex":0.0006864971,"about_ca_system_score_gemma":0.004433326,"threshold_uncertainty_score":0.786453},"labels":[],"label_agreement":null},{"id":"W2602028364","doi":"10.1200/jco.2017.35.6_suppl.63","title":"Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Adiponectin; Internal medicine; Prostatectomy; Cancer; Adipose tissue; Urology; Body mass index; Overweight; Prostate; Oncology; Obesity; Gastroenterology; Insulin resistance","score_opus":0.03248366535588817,"score_gpt":0.4093768544567076,"score_spread":0.3768931891008194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602028364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290085,0.0012207415,0.00009412655,0.0017900945,0.0023034888,0.00018572432,0.000007142825,0.0000011476818,0.0014966811],"genre_scores_gemma":[0.9879063,0.0042295456,0.0014715837,0.00015271391,0.0055174436,0.000011270944,0.000002927012,0.000011926399,0.0006963337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981357,0.00017797622,0.001190458,0.00015874601,0.0001769467,0.00016021157],"domain_scores_gemma":[0.99686354,0.00007279764,0.002284361,0.00027679157,0.00037953854,0.00012297623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015711475,0.00010064519,0.00064807374,0.00004958744,0.000045045887,0.000015072475,0.0003028765,0.00020558582,0.000021498136],"category_scores_gemma":[0.0013790672,0.00007416291,0.00009588587,0.00003625328,0.00028995698,0.000025351339,0.00007573585,0.00027641555,0.0000011833262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011301822,0.00042012852,0.44058904,0.00012050438,0.0002752996,0.000019390513,0.00091752014,0.0007361493,0.14055489,0.000073098076,0.009874878,0.39511728],"study_design_scores_gemma":[0.005707675,0.0055364007,0.6617651,0.00015612281,0.000110883404,0.000056681067,0.00015922029,0.00006280912,0.011404011,0.00014267965,0.31474704,0.0001514079],"about_ca_topic_score_codex":0.00014615654,"about_ca_topic_score_gemma":0.0019511112,"teacher_disagreement_score":0.39496586,"about_ca_system_score_codex":0.00003064411,"about_ca_system_score_gemma":0.0013521692,"threshold_uncertainty_score":0.30242756},"labels":[],"label_agreement":null},{"id":"W2602035838","doi":"10.1200/jco.2017.35.6_suppl.134","title":"AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Université de Montréal; Sanofi (Canada)","funders":"","keywords":"Taxane; Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Circulating tumor cell; Biomarker; Oncology; Internal medicine; Cancer; Breast cancer; Metastasis; Androgen deprivation therapy; Biology","score_opus":0.08197289625430612,"score_gpt":0.454776220245076,"score_spread":0.3728033239907699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602035838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950635,0.0015020858,0.00007180566,0.0025043094,0.00012546006,0.00035627812,0.000053467735,0.000002939926,0.0003201811],"genre_scores_gemma":[0.99445003,0.0037067996,0.0014745516,0.000121498415,0.000079968646,0.000005968744,0.000008074708,0.000013567784,0.00013953891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763453,0.000365295,0.0012248348,0.00027287955,0.00030217823,0.00020027172],"domain_scores_gemma":[0.9967477,0.00074765435,0.001576563,0.00019313776,0.00049259485,0.00024237942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022412615,0.00014327874,0.0012894935,0.00025298318,0.00012445863,0.000042696272,0.00006727647,0.00015524779,0.000057092362],"category_scores_gemma":[0.0016100121,0.00010209866,0.00019952744,0.00018589466,0.00061163795,0.00022611236,0.00006759889,0.0004004259,8.2328694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020914542,0.0009530768,0.9348612,0.000110061286,0.00435357,0.0013962194,0.000611534,0.00010416453,0.009325177,0.000045974368,0.000116245836,0.027208261],"study_design_scores_gemma":[0.00937405,0.0025058435,0.9802063,0.00022821047,0.0018824838,0.000046305264,0.0005636863,0.003623576,0.0006177126,0.00045093178,0.00039996958,0.00010092013],"about_ca_topic_score_codex":0.00467716,"about_ca_topic_score_gemma":0.0054588593,"teacher_disagreement_score":0.045345135,"about_ca_system_score_codex":0.00018894109,"about_ca_system_score_gemma":0.0008921845,"threshold_uncertainty_score":0.70704985},"labels":[],"label_agreement":null},{"id":"W2602042969","doi":"10.1200/jco.2013.31.15_suppl.1044","title":"Use of adjuvant chemotherapy and outcomes in women age 70 and older with HER2-positive (HER2+) or triple-negative (TN) breast cancer (BC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Chemotherapy; Trastuzumab; Oncology; Mastectomy; Stage (stratigraphy); Cancer; Gynecology","score_opus":0.03782367702563884,"score_gpt":0.38413484801079356,"score_spread":0.34631117098515474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602042969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923678,0.00044321927,0.000013790424,0.0067277723,0.000114954855,0.00024416414,0.00003596559,0.0000015841335,0.000050726598],"genre_scores_gemma":[0.9911349,0.005175378,0.0013306995,0.001816686,0.00016221021,0.000035499317,0.0000015226839,0.000017372995,0.0003257589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983757,0.0002260115,0.0008262807,0.00023081008,0.00012625047,0.00021494771],"domain_scores_gemma":[0.9981645,0.0005447491,0.00076608395,0.00011293968,0.000258753,0.00015297184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036279394,0.00018016763,0.0010684984,0.00005144897,0.000025675534,0.000012029751,0.000084358384,0.00022232045,0.00007170831],"category_scores_gemma":[0.0002487895,0.00010353979,0.00008916735,0.00006666939,0.0004638365,0.000023590497,0.000066685905,0.00023489507,5.465411e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010368246,0.0013352899,0.8396039,0.000025545809,0.0016512701,0.00011773011,0.0010641942,0.000007876509,0.00082564366,0.0000064982246,0.0012643938,0.14372943],"study_design_scores_gemma":[0.00879933,0.0042961766,0.98415923,0.00008348525,0.00006978072,0.00012258378,0.0004887405,0.000004109516,0.0005649012,0.00006217181,0.0012268621,0.0001226175],"about_ca_topic_score_codex":0.0010611473,"about_ca_topic_score_gemma":0.0012822143,"teacher_disagreement_score":0.14455536,"about_ca_system_score_codex":0.00007116566,"about_ca_system_score_gemma":0.00033396427,"threshold_uncertainty_score":0.422223},"labels":[],"label_agreement":null},{"id":"W2602047891","doi":"10.1200/jco.2017.35.15_suppl.4514","title":"Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; McMaster University; London Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Regional Municipality of Durham; CancerCare Manitoba; University Health Network; Ottawa Regional Cancer Foundation; Sunnybrook Hospital","funders":"","keywords":"Medicine; Toxicity; Clinical endpoint; Dosing; Internal medicine; Sunitinib; Phases of clinical research; Urology; Gastroenterology; Cancer; Surgery; Clinical trial; Oncology","score_opus":0.3432465780227212,"score_gpt":0.5581823151220743,"score_spread":0.2149357370993531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602047891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029624,0.0009643786,0.000057940826,0.004863141,0.000882628,0.0012588568,0.000029586206,0.000005840336,0.0016413686],"genre_scores_gemma":[0.99277186,0.0017145146,0.0029679642,0.00068644236,0.0009809901,0.000054569213,0.0000072227585,0.000031700187,0.00078473735],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99533933,0.00047701862,0.0030687887,0.00025785863,0.0005668878,0.00029008908],"domain_scores_gemma":[0.9896321,0.0029365604,0.0055485116,0.0005472865,0.000896271,0.00043926397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038017556,0.00023150745,0.0026049337,0.00015966225,0.00024218966,0.000016305883,0.0004382442,0.00020734062,0.00036858555],"category_scores_gemma":[0.0031226382,0.00014921036,0.0007649578,0.00006511908,0.0002619792,0.0001218603,0.000100234545,0.00064035767,0.000004210951],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121316165,0.16013046,0.03445559,0.00020590292,0.006375534,0.0033018528,0.0026036496,0.000057853387,0.0028858387,0.000054675907,0.0059177256,0.66269475],"study_design_scores_gemma":[0.2588041,0.609192,0.05217171,0.00016570235,0.003328853,0.000233869,0.0006166776,0.00006192561,0.0076721287,0.0005757658,0.06698743,0.00018979482],"about_ca_topic_score_codex":0.00021363102,"about_ca_topic_score_gemma":0.00021803188,"teacher_disagreement_score":0.662505,"about_ca_system_score_codex":0.00012368588,"about_ca_system_score_gemma":0.0018192002,"threshold_uncertainty_score":0.6084622},"labels":[],"label_agreement":null},{"id":"W2602048901","doi":"10.1200/jco.2015.33.15_suppl.5553","title":"Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Trabectedin; Medicine; Tolerability; Internal medicine; Context (archaeology); Progression-free survival; Oncology; Surgery; Chemotherapy; Gastroenterology; Adverse effect; Soft tissue sarcoma","score_opus":0.1860550349905799,"score_gpt":0.45382723773127653,"score_spread":0.26777220274069663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602048901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98529506,0.0009675288,0.00001558485,0.0097543895,0.0017141158,0.00036259167,0.000009570037,0.000008943782,0.0018722333],"genre_scores_gemma":[0.99620384,0.00043970149,0.0014484407,0.0011179377,0.0006440031,0.000018599892,0.0000075608737,0.000019759003,0.00010017205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971426,0.00028695332,0.0016325511,0.00022370917,0.00046059207,0.00025357548],"domain_scores_gemma":[0.99708664,0.0004040024,0.0010544833,0.00015911178,0.00066172844,0.0006340528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010722288,0.00015992102,0.0012356496,0.00014026304,0.000015619791,0.000009270708,0.00009341013,0.00024422686,0.00014829531],"category_scores_gemma":[0.0008582019,0.00009777548,0.00019339721,0.00024568228,0.00009005941,0.00009090885,0.00002229673,0.00061998423,0.000009881203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007711973,0.010011001,0.771706,0.000012681471,0.00035483137,0.00054693327,0.00018565821,0.000025274065,0.0000032410724,0.000014463723,0.007053321,0.20237464],"study_design_scores_gemma":[0.032719962,0.03728638,0.8729027,0.0003969712,0.00042261963,0.000039002083,0.000048931728,0.000019425235,0.00003244235,0.0000547222,0.05598091,0.00009593037],"about_ca_topic_score_codex":0.00015164493,"about_ca_topic_score_gemma":0.0006521695,"teacher_disagreement_score":0.2022787,"about_ca_system_score_codex":0.0010912528,"about_ca_system_score_gemma":0.0023024708,"threshold_uncertainty_score":0.40844846},"labels":[],"label_agreement":null},{"id":"W2602082246","doi":"10.1200/jco.2013.31.15_suppl.10014","title":"Prognostic implications of gain of 1q in favorable histology Wilms tumor: A report from the Children’s Oncology Group.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Wilms' tumor; Medicine; Multiplex ligation-dependent probe amplification; Stage (stratigraphy); Internal medicine; Oncology; Histology; Weight gain; Cohort; Body weight; Biology","score_opus":0.03417241470828731,"score_gpt":0.37435246717283616,"score_spread":0.34018005246454885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602082246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945963,0.002535928,0.00024490835,0.005240205,0.0005595164,0.0002877226,0.000010819475,0.0000020060509,0.0016592322],"genre_scores_gemma":[0.9960607,0.0009960308,0.0013072579,0.0011017865,0.0004020877,0.00002186627,0.000025005469,0.000012235643,0.000073015006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615127,0.00061794044,0.0026257755,0.00024212859,0.00013962925,0.00022323706],"domain_scores_gemma":[0.9951108,0.0010186706,0.0030248559,0.000343246,0.00037013876,0.00013226678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016408755,0.00012856467,0.0009686964,0.00006263033,0.00002864938,0.0000030860324,0.00045419307,0.0005517173,0.00007811832],"category_scores_gemma":[0.0026733854,0.000080244405,0.000374772,0.00013559285,0.0005856712,0.00000895393,0.00010627036,0.00067404617,0.000004834809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010311874,0.0020950742,0.855446,0.0000165345,0.0007955542,0.00017236522,0.00011500318,0.00031544192,0.061377183,0.0002083671,0.026777286,0.051650017],"study_design_scores_gemma":[0.002788159,0.006942178,0.9500511,0.00006041833,0.00019761758,0.0013118035,0.000112329224,0.000027778213,0.0019649223,0.0026352217,0.033774838,0.00013363198],"about_ca_topic_score_codex":0.0009069839,"about_ca_topic_score_gemma":0.0004118155,"teacher_disagreement_score":0.09460511,"about_ca_system_score_codex":0.00007125673,"about_ca_system_score_gemma":0.0013531205,"threshold_uncertainty_score":0.4255349},"labels":[],"label_agreement":null},{"id":"W2602090891","doi":"10.1200/jco.2009.27.15_suppl.4016","title":"High epiregulin (<i>EREG</i>) gene expression plus <i>K-ras</i> wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17—A phase III trial of cetuximab versus best supportive care (BSC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Epiregulin; Cetuximab; Medicine; Internal medicine; Oncology; Colorectal cancer; Hazard ratio; Epidermal growth factor receptor; Cancer; Amphiregulin; Confidence interval","score_opus":0.06714499457657482,"score_gpt":0.4433322052200702,"score_spread":0.3761872106434954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602090891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723036,0.005987802,0.0000020477103,0.0010366864,0.0024222115,0.001389906,0.0008895245,0.000008565325,0.0010328831],"genre_scores_gemma":[0.9821478,0.015665548,0.0006798824,0.00015643146,0.0010594057,0.00004119468,0.00015050553,0.000022792965,0.000076412674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934798,0.00046269965,0.004216797,0.00047656096,0.0008926445,0.00047153293],"domain_scores_gemma":[0.99056923,0.0033701463,0.004374576,0.00039730855,0.00097636663,0.0003123933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078207825,0.00041520465,0.0037543618,0.00019059089,0.00007384167,0.0000058140163,0.00028104696,0.00045160283,0.00008722995],"category_scores_gemma":[0.0013105136,0.00025167153,0.00079338485,0.00036154757,0.00047737433,0.000130687,0.000044819506,0.000549163,0.0000012188048],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85798913,0.017024726,0.0034552878,0.000025354633,0.0013006188,0.00047201238,0.0075000892,0.00027705455,0.0033878244,0.0000058543656,0.00085165835,0.107710406],"study_design_scores_gemma":[0.57178575,0.34799564,0.03788542,0.000404189,0.0022531822,0.00001805084,0.004769082,0.000012963862,0.02790132,0.000077972334,0.0066908505,0.00020557959],"about_ca_topic_score_codex":0.0017155282,"about_ca_topic_score_gemma":0.001691118,"teacher_disagreement_score":0.3309709,"about_ca_system_score_codex":0.0011883829,"about_ca_system_score_gemma":0.0029323166,"threshold_uncertainty_score":0.99999356},"labels":[],"label_agreement":null},{"id":"W2602102785","doi":"10.1200/jco.2013.31.15_suppl.1551","title":"Risk of hospital-related morbidity among survivors of breast cancer in British Columbia, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Poisson regression; Cohort; Survivorship curve; Relative risk; Cancer registry; Population; Cancer; Cohort study; Internal medicine; Pediatrics; Confidence interval; Environmental health","score_opus":0.021144368120279124,"score_gpt":0.3379734474628989,"score_spread":0.3168290793426198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602102785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935557,0.00056388683,0.0000025350025,0.0015793444,0.0032319482,0.00022509172,0.0001119474,0.00000319459,0.00072630343],"genre_scores_gemma":[0.99728334,0.0017614356,0.000037664624,0.00021514023,0.00030903026,0.0000058799337,0.0000019280733,0.000015402054,0.00037017398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995908,0.00047376094,0.0027563781,0.00016419204,0.0004641871,0.00023344261],"domain_scores_gemma":[0.994595,0.0010578207,0.002652984,0.00018376105,0.0011655259,0.00034493624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019061563,0.00008992242,0.001695417,0.00005832761,0.00001801519,0.000008528338,0.00018751042,0.00039146197,0.001719533],"category_scores_gemma":[0.0015186026,0.00010393354,0.00036480385,0.00028803558,0.00033999723,0.00011103126,0.00004548179,0.0010906169,0.0000011037845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013921829,0.0006603647,0.93796414,0.00005044192,0.00028174152,0.00019472596,0.00010683742,0.000023852126,0.000011676333,7.8657786e-7,0.007834972,0.05273126],"study_design_scores_gemma":[0.0032534492,0.0018208403,0.9924177,0.0003239901,0.00023815598,0.0000700666,0.00054715504,0.000052520092,0.000008634636,0.00010433681,0.0010715153,0.00009162969],"about_ca_topic_score_codex":0.99594736,"about_ca_topic_score_gemma":0.99940425,"teacher_disagreement_score":0.054453585,"about_ca_system_score_codex":0.00030928385,"about_ca_system_score_gemma":0.0045780214,"threshold_uncertainty_score":0.999193},"labels":[],"label_agreement":null},{"id":"W2602103946","doi":"10.1200/jco.2013.31.15_suppl.8048","title":"Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Queen's University; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology; Randomized controlled trial; Proportional hazards model; Confounding; Biomarker; Lung cancer; Gastroenterology","score_opus":0.06977165629076539,"score_gpt":0.3714392168695056,"score_spread":0.3016675605787402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602103946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908189,0.002378137,0.000120241675,0.0036869198,0.0024990134,0.0003508886,0.000023480572,0.00000237945,0.000120028904],"genre_scores_gemma":[0.99348587,0.0013332794,0.00023565795,0.0018273757,0.0030096474,0.000009560719,0.0000035377932,0.000012980287,0.00008210752],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99730396,0.0007130051,0.0013223247,0.0002589007,0.00019984313,0.00020195302],"domain_scores_gemma":[0.99675,0.0011319595,0.0013037293,0.00021301759,0.00038806503,0.00021322169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024296863,0.00015399592,0.0009653915,0.00012906552,0.00005221785,0.000016629647,0.00015287315,0.0003466212,0.000056576635],"category_scores_gemma":[0.0037050967,0.00009972453,0.00034534629,0.0001683387,0.0004457377,0.000016516331,0.00010506783,0.00030879973,0.0000021157605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10600562,0.0034834424,0.092920646,0.0001248477,0.037039567,0.000024184017,0.002681264,0.00022191835,0.28244716,0.00030255335,0.1420487,0.3327001],"study_design_scores_gemma":[0.044492636,0.034277093,0.75851506,0.00015707678,0.00651125,0.000106990265,0.0026940934,0.0009929265,0.010630136,0.00042076487,0.14067855,0.000523436],"about_ca_topic_score_codex":0.000023264214,"about_ca_topic_score_gemma":0.00004047317,"teacher_disagreement_score":0.6655944,"about_ca_system_score_codex":0.00001657032,"about_ca_system_score_gemma":0.0004237959,"threshold_uncertainty_score":0.44356143},"labels":[],"label_agreement":null},{"id":"W2602124370","doi":"10.1200/jco.2017.35.4_suppl.526","title":"Cost-effectiveness of surveillance after curative resection (CR) of metastatic colorectal cancer (CRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Asymptomatic; Colorectal cancer; Population; Cancer; Internal medicine; Surgery; Oncology","score_opus":0.23426271718291955,"score_gpt":0.5486705325880944,"score_spread":0.3144078154051748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602124370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930905,0.0015670293,0.000057074816,0.0009714177,0.001519305,0.00046535346,0.00003437831,0.0000025894285,0.0022923169],"genre_scores_gemma":[0.9973437,0.0018713026,0.00032972352,0.000060640137,0.00026800888,0.000050366783,0.0000010433608,0.000010424692,0.00006477662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972414,0.0006713638,0.0014490393,0.00016349943,0.0003150551,0.00015967099],"domain_scores_gemma":[0.9927891,0.002826778,0.0028608162,0.0001821716,0.0012070248,0.00013412953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026234486,0.00013348096,0.0020016392,0.0000813142,0.00007008713,0.000005742281,0.00013482559,0.00014118174,0.00010710747],"category_scores_gemma":[0.004389997,0.00008570683,0.0004660813,0.000073792195,0.00060364464,0.00013001637,0.00007264954,0.00041621772,0.0000014191127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06691834,0.001607186,0.85937047,0.00021397592,0.002311475,0.00027402234,0.00027095203,0.000017838236,0.0011621749,0.000037111888,0.00029810242,0.067518346],"study_design_scores_gemma":[0.008026,0.02008068,0.9651352,0.00031977711,0.00043475025,0.000061438135,0.00011987515,0.000022182334,0.0033486087,0.00021105274,0.0021741453,0.00006625003],"about_ca_topic_score_codex":0.00030547587,"about_ca_topic_score_gemma":0.0015851776,"teacher_disagreement_score":0.10576477,"about_ca_system_score_codex":0.00023466183,"about_ca_system_score_gemma":0.0010391176,"threshold_uncertainty_score":0.5255554},"labels":[],"label_agreement":null},{"id":"W2602145672","doi":"10.1200/jco.2017.35.4_suppl.297","title":"Multivariate assessment of SPARC expression in resected pancreatic ductal adenocarcinoma to identify subgroups that are sensitive to adjuvant gemcitabine.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia; Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Cohort; Internal medicine; Biomarker; Stromal cell; Tissue microarray; Lymphovascular invasion; Multivariate analysis; Immunohistochemistry; Pancreatic ductal adenocarcinoma; Pathology; Pancreatic cancer; Cancer; Metastasis; Biology","score_opus":0.24040376370221864,"score_gpt":0.5550386677741024,"score_spread":0.31463490407188377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602145672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846654,0.00009398541,0.0010586923,0.009939934,0.00077873946,0.00081287115,0.00001244019,0.000006880889,0.0026310608],"genre_scores_gemma":[0.9774465,0.00019851244,0.020677127,0.0006284744,0.00060207,0.00001951032,0.0000031244317,0.000024597415,0.00040009516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942139,0.0013229416,0.0026333975,0.00040852712,0.0009003149,0.00052091473],"domain_scores_gemma":[0.9908282,0.003828626,0.0026261457,0.0007027516,0.001081775,0.00093246624],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0072150226,0.0002292574,0.0033695328,0.00047673742,0.00012544688,0.000024510075,0.0004997841,0.0005242116,0.00016710287],"category_scores_gemma":[0.020972738,0.00016321162,0.00038781032,0.00017520948,0.00034882638,0.0001986417,0.00044253588,0.0015021084,0.000024817911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008049464,0.0015395943,0.95536596,0.00007083419,0.0003233885,0.0049720486,0.00043606965,0.000012740971,0.02538884,0.000031889256,0.0014462846,0.0023628923],"study_design_scores_gemma":[0.010210804,0.010025348,0.9748758,0.0012076499,0.00038051506,0.00036021895,0.0008391794,0.000480903,0.0010322056,0.00013023164,0.00031819593,0.00013891961],"about_ca_topic_score_codex":0.00026887556,"about_ca_topic_score_gemma":0.00034902166,"teacher_disagreement_score":0.024356635,"about_ca_system_score_codex":0.00042226235,"about_ca_system_score_gemma":0.0019155486,"threshold_uncertainty_score":0.98727405},"labels":[],"label_agreement":null},{"id":"W2602147626","doi":"10.1200/jco.2012.30.15_suppl.e14001","title":"Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Chemotherapy; Odds ratio; Cancer; Stage (stratigraphy); Population; Oncology","score_opus":0.11642052621228163,"score_gpt":0.4525099245178988,"score_spread":0.3360893983056171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602147626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407,0.0010062887,0.000005336244,0.001323563,0.0022878507,0.000372626,0.000013540523,0.0000041796125,0.00091660226],"genre_scores_gemma":[0.99798477,0.00056603615,0.0005861672,0.000105862855,0.0005327026,0.000007644231,0.0000011984201,0.000015689075,0.0001999136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561226,0.00048683275,0.0028432747,0.00016558147,0.0005483677,0.00034367017],"domain_scores_gemma":[0.9956471,0.001079653,0.002281474,0.00025619764,0.00045983374,0.00027576208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013264278,0.0001642233,0.0015544903,0.00011571146,0.000035267913,0.000002939457,0.00021693329,0.00039343236,0.00026148808],"category_scores_gemma":[0.0019689065,0.000102063554,0.0006053914,0.00020782364,0.00033690882,0.00018014843,0.00007620345,0.00062339427,0.000003733774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023988532,0.005233552,0.91299146,0.00008242348,0.00020254265,0.000014556844,0.0012296031,0.0000057416178,0.0014093112,0.0000017898244,0.00026921893,0.07616097],"study_design_scores_gemma":[0.011684861,0.0054005017,0.9722528,0.00033162173,0.00027259748,0.000028587448,0.00018942746,0.000025263444,0.0071108164,0.000033540633,0.0025975218,0.000072497445],"about_ca_topic_score_codex":0.0004902763,"about_ca_topic_score_gemma":0.0018029569,"teacher_disagreement_score":0.076088466,"about_ca_system_score_codex":0.0003533051,"about_ca_system_score_gemma":0.00077678997,"threshold_uncertainty_score":0.41620308},"labels":[],"label_agreement":null},{"id":"W2602167998","doi":"10.1200/jco.2013.31.15_suppl.9595","title":"Perceptions of benefits and harms of alcohol consumption as predictors of alcohol cessation in adult cancer survivors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre; Public Health Ontario; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Abstinence; Logistic regression; Smoking cessation; Cancer; Cancer survivorship; Survivorship curve; Odds ratio; Demography; Environmental health; Psychiatry; Internal medicine","score_opus":0.2081236619295979,"score_gpt":0.5042760619046054,"score_spread":0.29615239997500753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602167998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503994,0.0006017363,0.000025047364,0.002823039,0.000650137,0.0004892951,0.00001277416,0.00000461126,0.00035344413],"genre_scores_gemma":[0.9867697,0.011823732,0.00044726397,0.00066304044,0.00021550654,0.000015262165,0.0000045751412,0.000011061866,0.00004989382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605465,0.0004387759,0.0028120312,0.00015377546,0.0003710295,0.00016972756],"domain_scores_gemma":[0.9941709,0.0016461662,0.0025098498,0.00014261468,0.0012369008,0.00029354834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020473835,0.00011685108,0.0013624274,0.0003101263,0.000020986095,0.0000025683462,0.00008977833,0.00042630386,0.0007573062],"category_scores_gemma":[0.0024616963,0.00009057469,0.00020757248,0.0001489536,0.0004065687,0.00017319596,0.000032155738,0.00060283433,0.000010802323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092738285,0.00079051056,0.9596212,0.00037605595,0.00013213282,0.0000053170234,0.00040886475,0.000042011103,0.0028292872,0.0001957921,0.0004040796,0.034267362],"study_design_scores_gemma":[0.007289999,0.00359475,0.9870442,0.0005993666,0.0002425005,0.00005621615,0.00023721856,0.0002851324,0.00031113616,0.00008337926,0.00019495505,0.000061124745],"about_ca_topic_score_codex":0.0013724349,"about_ca_topic_score_gemma":0.0010363223,"teacher_disagreement_score":0.034206238,"about_ca_system_score_codex":0.000087989516,"about_ca_system_score_gemma":0.0008103215,"threshold_uncertainty_score":0.82919717},"labels":[],"label_agreement":null},{"id":"W2602197113","doi":"10.1200/jco.2017.35.4_suppl.479","title":"Sorafenib treatment in recurrent hepatocellular carcinoma post liver transplantation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Internal medicine; Gastroenterology; Liver transplantation; Hepatitis C; Liver disease; Population; Adverse effect; Transplantation; Surgery","score_opus":0.2539189499979211,"score_gpt":0.4235836214371172,"score_spread":0.1696646714391961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602197113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866445,0.0017861322,0.00002344214,0.005313629,0.00090312544,0.00041091448,0.000009482906,0.0000065844833,0.0028822303],"genre_scores_gemma":[0.99236643,0.0049966513,0.00122913,0.00031749942,0.000751598,0.000012442744,0.00001299574,0.000018265118,0.00029498385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970425,0.0003644289,0.0018019368,0.00023240491,0.0002907078,0.000268029],"domain_scores_gemma":[0.9968944,0.00061997934,0.0013986147,0.00036148107,0.00031466284,0.00041083543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014501933,0.00019810066,0.0014033578,0.00017149048,0.00010709345,0.000025859996,0.0002133625,0.00037169812,0.00019977709],"category_scores_gemma":[0.0006723167,0.00013576429,0.0007774367,0.00004984983,0.00018346493,0.00018053107,0.000023757091,0.0005260087,0.000059164846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003878526,0.0021162753,0.8288852,0.00004426963,0.00018478038,0.034873117,0.00028916603,2.098909e-7,0.000095244985,0.00004432881,0.00012312223,0.12946574],"study_design_scores_gemma":[0.015173371,0.019889187,0.9430871,0.00011473763,0.00087864854,0.0010411128,0.000050781196,0.00068903697,0.00080539426,0.000069458205,0.018074892,0.00012627454],"about_ca_topic_score_codex":0.00031970284,"about_ca_topic_score_gemma":0.0002619293,"teacher_disagreement_score":0.12933947,"about_ca_system_score_codex":0.00028800784,"about_ca_system_score_gemma":0.0014128571,"threshold_uncertainty_score":0.5536307},"labels":[],"label_agreement":null},{"id":"W2602244356","doi":"10.1200/jco.2009.27.15_suppl.e17559","title":"Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; McMaster University; BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Institutional review board; Statistical significance; Internal medicine; Cancer registry; Odds ratio; Oncology; Surgery","score_opus":0.0625923300848927,"score_gpt":0.45909779775988274,"score_spread":0.39650546767499006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602244356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883148,0.008479659,0.00000849504,0.0016365937,0.0008452714,0.00039018277,0.000046621586,0.0000037131942,0.00027466594],"genre_scores_gemma":[0.98685783,0.011282272,0.00011043228,0.0013247688,0.0003775821,0.000007100732,0.0000034561451,0.0000109750445,0.000025604719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961404,0.000859446,0.0022225354,0.00019804938,0.00036875674,0.0002108044],"domain_scores_gemma":[0.9930759,0.0042416407,0.002106814,0.0001555112,0.00023357393,0.00018655328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017153812,0.00016811377,0.0024248585,0.00017730422,0.000012582497,0.000002265985,0.00017776218,0.0002057185,0.0003008484],"category_scores_gemma":[0.0009686396,0.00010948241,0.0005387304,0.00021625134,0.00016696607,0.00007209905,0.000009575041,0.0007915998,8.853428e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028378785,0.0008251239,0.6446405,0.00011610113,0.0005585758,0.00012921229,0.0002028238,0.00019324421,0.0068252436,0.000008581894,0.00028498055,0.31783682],"study_design_scores_gemma":[0.026008312,0.03356405,0.93071556,0.0015176928,0.0004493955,0.000020486334,0.00006276333,0.00024519852,0.0042720456,0.000047520898,0.0029807608,0.00011619111],"about_ca_topic_score_codex":0.000952212,"about_ca_topic_score_gemma":0.00088055537,"teacher_disagreement_score":0.31772065,"about_ca_system_score_codex":0.00025156682,"about_ca_system_score_gemma":0.001318339,"threshold_uncertainty_score":0.4464563},"labels":[],"label_agreement":null},{"id":"W2602250429","doi":"10.1200/jco.2017.35.6_suppl.186","title":"Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Loss of heterozygosity; Internal medicine; Metastasis; Oncology; PTEN; Germline; Somatic cell; Cancer; Cancer research; Allele; Gene; Biology; Genetics","score_opus":0.0654151293554788,"score_gpt":0.40480526206015327,"score_spread":0.33939013270467444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602250429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984068,0.00015828699,0.00008548392,0.00043508914,0.00042030003,0.00031557571,0.00003746176,0.0000015835348,0.0001394195],"genre_scores_gemma":[0.99746007,0.00020301422,0.00180698,0.00019824543,0.00026131465,0.000009480035,0.000016077543,0.000019448904,0.000025355599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778694,0.00018261932,0.0013622027,0.0002672253,0.00019191418,0.00020910401],"domain_scores_gemma":[0.99623346,0.00069573114,0.0021979958,0.0002433567,0.00040279675,0.00022668377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010269169,0.0001545119,0.0006638235,0.000046133126,0.00013713427,0.000057559067,0.00017692799,0.00013546912,0.0000075170583],"category_scores_gemma":[0.003681142,0.000104409686,0.00010782301,0.000039319908,0.00036651338,0.00002283496,0.00006943796,0.00041501757,4.9757875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017772372,0.0004976981,0.99057657,0.0000134407,0.00018444164,0.00009522785,0.000043234133,0.00033939703,0.00012806978,0.000027350334,0.00008854403,0.00622878],"study_design_scores_gemma":[0.0062325764,0.007495165,0.9839964,0.00009015658,0.00020314427,0.000019281913,0.0000769609,0.00007583782,0.000044320648,0.000056967936,0.0015642027,0.00014498856],"about_ca_topic_score_codex":0.00008718977,"about_ca_topic_score_gemma":0.0022863648,"teacher_disagreement_score":0.0069974666,"about_ca_system_score_codex":0.000040906485,"about_ca_system_score_gemma":0.001537965,"threshold_uncertainty_score":0.44069368},"labels":[],"label_agreement":null},{"id":"W2602279085","doi":"10.1200/jco.2017.35.4_suppl.705","title":"Oncopre: A new chemotherapy benefit prediction algorithm to assist treatment decision making.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Microsatellite instability; Medicine; Colorectal cancer; Oncology; Internal medicine; Numeracy; Epidemiology; Cancer; Adjuvant therapy; Pathological; Clinical trial; Intensive care medicine","score_opus":0.14011962282085483,"score_gpt":0.5145472557540577,"score_spread":0.37442763293320286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602279085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341601,0.0013409657,0.00450282,0.039477684,0.0055346396,0.0006395122,0.000020601132,0.000024825531,0.01429883],"genre_scores_gemma":[0.9184863,0.0031201309,0.066155314,0.0031425187,0.0055254684,0.000013321961,0.0000015900739,0.000027206852,0.0035281668],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99783915,0.000043949472,0.0013408659,0.00022708693,0.0003469372,0.00020201126],"domain_scores_gemma":[0.9969888,0.00067514204,0.0012563018,0.00034327884,0.0002918149,0.00044470365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007335302,0.00016752529,0.0013633199,0.00008677944,0.000196866,0.000034555684,0.00017104857,0.00024364376,0.00019246175],"category_scores_gemma":[0.001283993,0.00010240695,0.0005484977,0.00004995622,0.0000910416,0.00010159382,0.000061024308,0.00028461817,0.000025194491],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071399887,0.0012721336,0.069077946,0.0000023637378,0.0006699312,0.00031658562,0.0001355394,0.0000042726197,0.000007832134,0.000010775748,0.010003925,0.9113587],"study_design_scores_gemma":[0.010572622,0.037530642,0.68073237,0.00014922976,0.00036287872,0.00018461651,0.000031661755,0.000067436966,0.00002585496,0.0006160557,0.26966703,0.000059589576],"about_ca_topic_score_codex":0.00009953959,"about_ca_topic_score_gemma":0.0003091582,"teacher_disagreement_score":0.9112991,"about_ca_system_score_codex":0.000745978,"about_ca_system_score_gemma":0.0010704616,"threshold_uncertainty_score":0.4176034},"labels":[],"label_agreement":null},{"id":"W2602280431","doi":"10.1200/jco.2014.32.15_suppl.e20681","title":"Retrospective analysis of outpatient acupuncture treatments at MD Anderson Cancer Center.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acupuncture Treatment Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acupuncture; Nausea; Physical therapy; Depression (economics); Anxiety; Distress; Cancer; Internal medicine; Psychiatry; Alternative medicine","score_opus":0.12778441112069683,"score_gpt":0.5232714529498497,"score_spread":0.39548704182915284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602280431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895872,0.0008575252,0.000103145685,0.0048157764,0.00060604175,0.00031261312,0.000028637654,0.000007614549,0.0036814718],"genre_scores_gemma":[0.9935845,0.0033408746,0.0007129789,0.0008269626,0.0004907382,0.000008823076,0.000014851896,0.000013055241,0.0010071946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653393,0.0004914381,0.001664971,0.00026298987,0.000759487,0.00028718854],"domain_scores_gemma":[0.99502933,0.0014976052,0.0019720402,0.00026442215,0.00086918625,0.00036743877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014039379,0.00027732574,0.003686337,0.00033246848,0.000058819973,0.0000037532566,0.00013462288,0.00033306927,0.00044353085],"category_scores_gemma":[0.0034558584,0.00011276871,0.0016334854,0.00041906268,0.00030796096,0.000061000694,0.00010355247,0.0006078435,0.0000064245883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004059073,0.002595914,0.9452576,0.000024196645,0.019890472,0.00012820507,0.0003331771,0.000024917239,0.00010897408,0.000018166087,0.011255797,0.01630349],"study_design_scores_gemma":[0.008179206,0.019410169,0.9407234,0.00006476106,0.012432834,0.000027859634,0.00008998593,0.00009954997,0.00017689253,0.000053982036,0.018666202,0.00007514448],"about_ca_topic_score_codex":0.00005513118,"about_ca_topic_score_gemma":0.0004408824,"teacher_disagreement_score":0.016814254,"about_ca_system_score_codex":0.0012618497,"about_ca_system_score_gemma":0.00037191965,"threshold_uncertainty_score":0.4856352},"labels":[],"label_agreement":null},{"id":"W2602281547","doi":"10.1200/jco.2017.35.4_suppl.660","title":"Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Irinotecan; Gastroenterology; Colorectal cancer; Clinical endpoint; Regorafenib; Refractory (planetary science); Oxaliplatin; Progression-free survival; Placebo; Clinical trial; Cancer; Chemotherapy","score_opus":0.09893982140482208,"score_gpt":0.4757736319774503,"score_spread":0.3768338105726282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602281547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909058,0.0019385245,0.000008262218,0.0015564366,0.0009888873,0.0039566457,0.00038286,0.0000041759504,0.00025837673],"genre_scores_gemma":[0.9963107,0.0024636595,0.00009337547,0.000053979726,0.00021465289,0.00044654336,0.000010173768,0.000030248308,0.00037666294],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99640864,0.00035421457,0.0018964282,0.00038549208,0.0006104484,0.00034475877],"domain_scores_gemma":[0.9922448,0.0025023746,0.0033044578,0.0005084744,0.0012278465,0.00021204537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006519408,0.00036353903,0.0027581777,0.00011985413,0.00031403606,0.000017800243,0.00035945865,0.00020242359,0.00006870683],"category_scores_gemma":[0.0009176629,0.00016391439,0.00074434147,0.00017236215,0.0005300962,0.0000989589,0.00006888895,0.0002895039,5.853573e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49301487,0.015873514,0.26975212,0.00002986176,0.009946393,0.00010811288,0.02431333,0.00009135958,0.000047520123,0.0000013062406,0.0006452143,0.18617639],"study_design_scores_gemma":[0.26334858,0.4682856,0.2158637,0.0001793988,0.007959311,0.0000045456713,0.022388643,0.00003980178,0.0008799568,0.0000030345761,0.020848632,0.00019880365],"about_ca_topic_score_codex":0.0026050035,"about_ca_topic_score_gemma":0.040401507,"teacher_disagreement_score":0.45241207,"about_ca_system_score_codex":0.004011661,"about_ca_system_score_gemma":0.0028922774,"threshold_uncertainty_score":0.99981177},"labels":[],"label_agreement":null},{"id":"W2602299717","doi":"10.1200/jco.2013.31.15_suppl.e17531","title":"Cancer Care Ontario’s lung disease pathway initiative: Building resources for lung cancer quality care.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Agency (philosophy); Quality management; Quality of life (healthcare); Cancer; Health care; Care pathway; Nursing; Family medicine; Oncology; Operations management; Management system; Internal medicine; Political science","score_opus":0.38690790573479,"score_gpt":0.6303319009191108,"score_spread":0.24342399518432084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602299717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631107,0.0052579246,0.0014484617,0.025134325,0.0030849003,0.0012602434,0.00008811898,0.000019546305,0.0005957792],"genre_scores_gemma":[0.9730574,0.000635395,0.00875857,0.01258008,0.0044357437,0.00019355916,0.000023201652,0.000041245617,0.0002748186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923831,0.0008613786,0.0053490824,0.00038051847,0.00062264374,0.00040326946],"domain_scores_gemma":[0.97947866,0.011311708,0.004449917,0.00029270447,0.0035670071,0.0008999988],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036566253,0.00023467583,0.0016411092,0.00012330378,0.00013342757,0.00003628844,0.00024402195,0.0003636678,0.00159001],"category_scores_gemma":[0.022864595,0.00017856275,0.00084158,0.00013150314,0.0001818695,0.00049133564,0.0001054,0.001391615,0.0000047452672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005502862,0.0004848406,0.76643664,0.00041485872,0.00065235345,0.00007774986,0.0030745396,0.00016650357,0.00014127317,0.00004310231,0.024811663,0.1981936],"study_design_scores_gemma":[0.011512933,0.0021486643,0.77380675,0.00041844504,0.001765856,0.000011466228,0.005137258,0.0006142819,0.00003783842,0.00018640546,0.20413049,0.00022958513],"about_ca_topic_score_codex":0.015793515,"about_ca_topic_score_gemma":0.034429695,"teacher_disagreement_score":0.19796401,"about_ca_system_score_codex":0.001883295,"about_ca_system_score_gemma":0.009499252,"threshold_uncertainty_score":0.99932265},"labels":[],"label_agreement":null},{"id":"W2602302584","doi":"10.1200/jco.2012.30.15_suppl.4514","title":"A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; Juravinski Cancer Centre; Interior Health; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Chills; Clinical endpoint; Urology; Gastroenterology; Oncology; Cancer; Endocrinology; Randomized controlled trial","score_opus":0.11296192652770543,"score_gpt":0.4852489597762404,"score_spread":0.37228703324853496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602302584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972083,0.0005376613,0.000073955656,0.00024776888,0.00033397376,0.001445514,0.000015204669,0.000001681862,0.00013595141],"genre_scores_gemma":[0.9981671,0.0002793087,0.0010671286,0.000042471536,0.00023633025,0.00008377899,0.000011290757,0.000019454867,0.000093157745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945871,0.0020630609,0.002238574,0.00021704638,0.00053260446,0.00036161946],"domain_scores_gemma":[0.9969341,0.0005372152,0.0013886091,0.00023523533,0.0006282354,0.0002765625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057882695,0.00016243974,0.0014540125,0.00012896593,0.000048409303,0.000007214823,0.00020375533,0.00018983682,0.00003387348],"category_scores_gemma":[0.003511254,0.00010954616,0.00018635596,0.00017150166,0.0002276871,0.000025684098,0.00011244539,0.0004988703,0.0000011864004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9448255,0.016709201,0.007674068,0.00003980162,0.000998991,0.00005421128,0.0009296011,0.00024260911,0.008180014,0.0000051577,0.00016808703,0.020172782],"study_design_scores_gemma":[0.8648819,0.12051507,0.00743788,0.000058841943,0.00037286093,0.000009161388,0.00056114787,0.00008503935,0.0041857786,0.000009512607,0.0017186892,0.00016411333],"about_ca_topic_score_codex":0.00023634794,"about_ca_topic_score_gemma":0.0009426652,"teacher_disagreement_score":0.10380587,"about_ca_system_score_codex":0.00013901114,"about_ca_system_score_gemma":0.0015486313,"threshold_uncertainty_score":0.44671628},"labels":[],"label_agreement":null},{"id":"W2602325446","doi":"10.1200/jco.2012.30.15_suppl.2001","title":"A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Temozolomide; Medicine; Oncology; Recursive partitioning; Internal medicine; Radiation therapy; Multivariate analysis; Biomarker; Glioma; Clinical trial; Computational biology; Cancer research; Biology; Genetics","score_opus":0.09446313247374671,"score_gpt":0.4127070202063124,"score_spread":0.3182438877325657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602325446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58293015,0.00089049374,0.4128904,0.0010053457,0.0010083212,0.000443793,0.00004733933,0.000006588798,0.00077755906],"genre_scores_gemma":[0.9529666,0.0001371204,0.044346873,0.0013203208,0.0010290454,0.00001775557,0.000053094598,0.000016613232,0.00011258281],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973706,0.0001270451,0.0018027149,0.00016063963,0.00016024904,0.000378736],"domain_scores_gemma":[0.99680704,0.00037607917,0.0018096663,0.00023286635,0.00042909372,0.00034527012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003681086,0.00015942175,0.0008098532,0.00012733361,0.00007923807,0.000016165584,0.00021480532,0.0005659855,0.000028319573],"category_scores_gemma":[0.0011737852,0.00012586497,0.0009899766,0.00016845856,0.00010175392,0.000021497679,0.000057844492,0.00030186045,0.0000044867957],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054332234,0.007759294,0.074262254,0.00043955713,0.019155813,0.000043190656,0.00089581223,0.16160566,0.02018246,0.002597743,0.15012845,0.50859755],"study_design_scores_gemma":[0.008331512,0.005763102,0.0068320376,0.00006433616,0.002112976,0.00003819014,0.00011845341,0.8899461,0.0023417624,0.0007323332,0.08327909,0.0004401064],"about_ca_topic_score_codex":0.0000013021884,"about_ca_topic_score_gemma":0.00002920771,"teacher_disagreement_score":0.72834045,"about_ca_system_score_codex":0.000047018177,"about_ca_system_score_gemma":0.00050697505,"threshold_uncertainty_score":0.51326245},"labels":[],"label_agreement":null},{"id":"W2602342955","doi":"10.1200/jco.2017.35.4_suppl.545","title":"Topographical incidence and survival analysis of gastrointestinal tract cancer in adolescent and young adults compared with older adults in the United States.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Young adult; Epidemiology; Colorectal cancer; Cancer; Internal medicine; Disease; Oncology","score_opus":0.07477609506736685,"score_gpt":0.42776841362506407,"score_spread":0.3529923185576972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602342955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594915,0.00026968715,0.000037802736,0.003376605,0.000104863226,0.0001756977,0.000012543865,0.0000013721574,0.00007225679],"genre_scores_gemma":[0.9969012,0.00183879,0.0003921665,0.00076166796,0.00008882045,0.0000027536375,0.000006200668,0.0000052952437,0.0000031037416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758136,0.00038235713,0.0013511892,0.00019033044,0.0003110435,0.00018370275],"domain_scores_gemma":[0.9968596,0.0011590496,0.0013018318,0.00020582524,0.00028689578,0.00018677027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023014287,0.00011825276,0.0012900105,0.00035917724,0.000040509774,0.000014736663,0.00019255865,0.000103651044,0.000035733956],"category_scores_gemma":[0.0009330815,0.000068737616,0.00014491884,0.00029163103,0.00057249534,0.000115078896,0.000039061393,0.0009952893,5.566944e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013477251,0.00078187184,0.96754366,0.000058880687,0.00016791624,0.000718485,0.0008124704,0.000110915644,0.0000064328797,0.0000044774924,0.000037637452,0.016280014],"study_design_scores_gemma":[0.012489672,0.0030621614,0.9743356,0.0008993399,0.00051404955,0.00028430007,0.0014186234,0.0068024495,0.000001296336,0.0000051463726,0.00012249289,0.00006487261],"about_ca_topic_score_codex":0.0035211504,"about_ca_topic_score_gemma":0.025358044,"teacher_disagreement_score":0.021836892,"about_ca_system_score_codex":0.00006565064,"about_ca_system_score_gemma":0.00055705395,"threshold_uncertainty_score":0.99242663},"labels":[],"label_agreement":null},{"id":"W2602358743","doi":"10.1200/jco.2017.35.6_suppl.468","title":"Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Ottawa Hospital; University Health Network; CancerCare Manitoba; McMaster University; Sunnybrook Health Science Centre; Montreal General Hospital; Juravinski Cancer Centre; University of Calgary; Princess Margaret Cancer Centre; Hôtel-Dieu de Québec; BC Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Renal cell carcinoma; Internal medicine; Dosing; Urology; Proportional hazards model; Oncology; Toxicity; Kidney cancer; Gastroenterology","score_opus":0.13482162064300587,"score_gpt":0.39222614925670485,"score_spread":0.257404528613699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602358743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917377,0.000055772296,0.000010499621,0.003318341,0.00047893677,0.0011475171,0.0008226143,0.000009875316,0.004982645],"genre_scores_gemma":[0.9954277,0.000046408804,0.0032585817,0.0005926777,0.0003152623,0.000039474304,0.0002059325,0.000035624995,0.00007833218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517876,0.0007256301,0.002247302,0.0002963263,0.0010297261,0.0005222425],"domain_scores_gemma":[0.99118346,0.0019957742,0.0040000575,0.000687201,0.0010385108,0.0010949945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018460376,0.00039115432,0.0017875952,0.00024821234,0.00039946058,0.00015715942,0.00036622753,0.00023650755,0.00006602369],"category_scores_gemma":[0.0011586382,0.00017157698,0.00018119106,0.00017859077,0.00039815556,0.000490081,0.000041981693,0.0008454407,0.0000071176837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37671155,0.0006885816,0.5903329,0.00006644204,0.0014223827,0.0035297468,0.0021686747,0.00008320955,0.0000016907096,0.0000134701495,0.0007078579,0.024273472],"study_design_scores_gemma":[0.16854893,0.07688274,0.73491323,0.000941234,0.0025296495,0.00011695984,0.0013517397,0.00003270366,0.0001914213,0.000002588156,0.014257013,0.0002317903],"about_ca_topic_score_codex":0.09782696,"about_ca_topic_score_gemma":0.3644581,"teacher_disagreement_score":0.26663116,"about_ca_system_score_codex":0.0029866411,"about_ca_system_score_gemma":0.015487612,"threshold_uncertainty_score":0.99009365},"labels":[],"label_agreement":null},{"id":"W2602364135","doi":"10.1200/jco.2013.31.15_suppl.e14595","title":"Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil based regimens in the treatment of metastatic colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oxaliplatin; Capecitabine; Internal medicine; Colorectal cancer; Oncology; Retrospective cohort study; Fluorouracil; Toxicity; Progression-free survival; Chemotherapy; Cancer","score_opus":0.1454874759263934,"score_gpt":0.5129613173902648,"score_spread":0.3674738414638714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602364135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894823,0.00038397178,0.0000049922173,0.00901392,0.00036183855,0.00051398366,0.000015398356,0.0000020450314,0.00022154237],"genre_scores_gemma":[0.99558514,0.0025738725,0.00059873017,0.0010524571,0.000112477916,0.000022191638,0.0000033171286,0.000006918299,0.000044907803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954116,0.0010202567,0.0028742682,0.000210008,0.00028877074,0.0001951203],"domain_scores_gemma":[0.9916473,0.005716798,0.0018730676,0.00016028562,0.00044183488,0.00016073068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002624148,0.00016258485,0.0035077587,0.0004203821,0.000014473133,0.000004136254,0.00012786516,0.00021336207,0.00024941127],"category_scores_gemma":[0.0011793773,0.00008919736,0.00090666395,0.00057410385,0.0004690262,0.0000666645,0.000027532502,0.0005127351,0.0000011370781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004209029,0.014471668,0.9601664,0.000011976031,0.004602947,0.00025982774,0.00051739503,0.00003233541,0.00012791457,0.000015625978,0.00025147822,0.015333427],"study_design_scores_gemma":[0.01743137,0.038240246,0.9367834,0.00002930022,0.005991541,0.000024402627,0.00030938396,0.00071129366,0.000119137985,0.00013973427,0.0001603977,0.00005982749],"about_ca_topic_score_codex":0.0016990528,"about_ca_topic_score_gemma":0.0074181813,"teacher_disagreement_score":0.023768578,"about_ca_system_score_codex":0.0003993211,"about_ca_system_score_gemma":0.00082429725,"threshold_uncertainty_score":0.41395193},"labels":[],"label_agreement":null},{"id":"W2602369513","doi":"10.1200/jco.2016.71.3024","title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Fludarabine; Lymphoma; Chemotherapy; Chimeric antigen receptor; Follicular lymphoma; Cyclophosphamide; Mantle cell lymphoma; Gastroenterology; Internal medicine; Immunology; T cell; Immune system","score_opus":0.1467258729733652,"score_gpt":0.46062969264205533,"score_spread":0.31390381966869013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602369513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774203,0.00015849365,0.000028003853,0.017568449,0.0018994715,0.00030768165,0.000046535482,0.000023835739,0.0025472497],"genre_scores_gemma":[0.98000216,0.0010181416,0.00047060326,0.00150767,0.0013525342,0.0000029843345,0.000008816227,0.000064962805,0.015572144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503607,0.00092954485,0.0021948968,0.00038985262,0.0008748884,0.0005747576],"domain_scores_gemma":[0.9903299,0.0024218706,0.0044634994,0.000758375,0.0010991453,0.00092716765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004436018,0.00028341232,0.0025276183,0.0001782927,0.00029034493,0.00005981677,0.00077739835,0.0007566557,0.0047093015],"category_scores_gemma":[0.0077354005,0.00018460705,0.000488243,0.00018273068,0.0008413096,0.00021951002,0.00017360112,0.0014863805,0.000075017546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061185085,0.004685826,0.3497611,0.000042307154,0.0028795947,0.0021330852,0.000313883,0.0000048596694,0.32234818,0.000007738519,0.19964679,0.11205815],"study_design_scores_gemma":[0.017621929,0.012086934,0.7664518,0.00063462113,0.0002656098,0.00015108121,0.00018070824,0.000025720736,0.0108589865,0.000043328433,0.1914572,0.00022210227],"about_ca_topic_score_codex":0.00009041276,"about_ca_topic_score_gemma":0.00007514347,"teacher_disagreement_score":0.41669068,"about_ca_system_score_codex":0.00047230112,"about_ca_system_score_gemma":0.002154152,"threshold_uncertainty_score":0.9962005},"labels":[],"label_agreement":null},{"id":"W2602370955","doi":"10.1200/jco.2017.35.6_suppl.149","title":"Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Indel; Gene; Cancer; Genotype; Genetics; Single-nucleotide polymorphism; Biology","score_opus":0.05446264490831547,"score_gpt":0.40597651709490956,"score_spread":0.3515138721865941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602370955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964725,0.00042739048,0.00015060914,0.0023722176,0.00020783306,0.00016825064,0.000017081851,0.0000011315805,0.00018299386],"genre_scores_gemma":[0.99711573,0.000587692,0.0016153775,0.00036130002,0.00022104933,0.000013705417,0.000004767937,0.000010622004,0.000069759684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998693,0.00012606716,0.0007301911,0.00015665608,0.0001513306,0.00014277599],"domain_scores_gemma":[0.9974534,0.00028109716,0.0017487722,0.0001488537,0.00028071593,0.000087198816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010523789,0.00009890506,0.0004180129,0.000037293983,0.00012358416,0.000062804786,0.000098371784,0.000056868594,0.00000438353],"category_scores_gemma":[0.0012507623,0.0000671715,0.00006619357,0.000027866321,0.00007884908,0.000021724076,0.000025147745,0.00020656908,2.6836187e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013418677,0.00024636238,0.9812142,0.000008881691,0.00028144094,0.0001407084,0.00007225397,0.0009970219,0.0076956684,0.00011510988,0.00012258391,0.0077638803],"study_design_scores_gemma":[0.005085206,0.0032837573,0.9879471,0.000044645127,0.00009068667,0.00007299804,0.00010693279,0.0001443419,0.00067168847,0.00020302474,0.002234926,0.000114710805],"about_ca_topic_score_codex":0.0003017199,"about_ca_topic_score_gemma":0.0070072343,"teacher_disagreement_score":0.0076491693,"about_ca_system_score_codex":0.00011800721,"about_ca_system_score_gemma":0.0011756974,"threshold_uncertainty_score":0.39102012},"labels":[],"label_agreement":null},{"id":"W2602376823","doi":"10.1200/jco.2017.35.4_suppl.745","title":"Phase I/II trial of dose reduced capecitabine in elderly or frail patients with untreated advanced colorectal cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Burnaby Hospital; Ottawa Hospital; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Population; Gastroenterology; Colorectal cancer; Surgery; Toxicity; Chemotherapy; Diarrhea; Cancer","score_opus":0.09280002791905397,"score_gpt":0.48043487381257644,"score_spread":0.3876348458935225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602376823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927048,0.00022714767,0.0000010408907,0.0029515259,0.0013876581,0.00072924857,0.000024911984,0.0000054134875,0.0019682483],"genre_scores_gemma":[0.9975903,0.00077485014,0.0005883385,0.00012600089,0.0005199991,0.00003313452,0.00000447924,0.000016905418,0.0003460046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969604,0.0001559306,0.0019973076,0.00023269138,0.00039216218,0.0002614995],"domain_scores_gemma":[0.9951313,0.0007075867,0.0029319478,0.00023411725,0.0007485929,0.00024645304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007049919,0.00019897665,0.002226264,0.00011878999,0.00013652242,0.000008186666,0.00019820353,0.00024415366,0.00016608415],"category_scores_gemma":[0.0033967153,0.00010915776,0.0002805952,0.00012189171,0.0003981041,0.00016240806,0.00007300299,0.0005635397,0.0000010542313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5624567,0.0147973895,0.057950314,0.000015635185,0.0005931067,0.0003872945,0.00018731723,0.000003137194,0.00015850576,0.0000038953394,0.00030122636,0.3631454],"study_design_scores_gemma":[0.38154492,0.26746073,0.34703636,0.00018007524,0.0003780538,0.000013193025,0.000066972934,0.0000069975436,0.0001796013,0.000015220271,0.00303919,0.000078677454],"about_ca_topic_score_codex":0.00023053413,"about_ca_topic_score_gemma":0.0024476678,"teacher_disagreement_score":0.36306676,"about_ca_system_score_codex":0.00030727795,"about_ca_system_score_gemma":0.0021441302,"threshold_uncertainty_score":0.44513243},"labels":[],"label_agreement":null},{"id":"W2602398819","doi":"10.1200/jco.2007.25.18_suppl.5547","title":"Cervix cancer regression measured using weekly MR imaging during fractionated radiotherapy: Radiobiologic modeling and correlation with tumor hypoxia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nuclear medicine; Magnetic resonance imaging; Radiation therapy; Tumor hypoxia; Cervix; Linear regression; Cancer; Hypoxia (environmental); Radiology; Internal medicine","score_opus":0.12888133516933256,"score_gpt":0.46195185517575904,"score_spread":0.33307052000642645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602398819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710214,0.0053687757,0.015662124,0.0063243653,0.0012551591,0.00021276863,0.0000013467114,0.000022107208,0.00013193628],"genre_scores_gemma":[0.9733516,0.0038660613,0.019917617,0.0012201031,0.0015804075,0.0000027365859,0.0000011395068,0.000031614105,0.00002873443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970789,0.00026617278,0.0017074785,0.00026764703,0.00039290413,0.0002869264],"domain_scores_gemma":[0.99591035,0.001176199,0.0018263918,0.00014426859,0.00062153133,0.00032128656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035090488,0.00018025254,0.0010982612,0.00023165107,0.00011693967,0.00001295533,0.00008971775,0.0002588844,0.0001078111],"category_scores_gemma":[0.00069441006,0.00011911703,0.00017508767,0.00021137898,0.00015653574,0.0002437005,0.000023311377,0.0011379913,7.496085e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013457117,0.00047041688,0.8953369,0.00006704492,0.00043641136,0.0009976648,0.00016481956,0.019490566,0.020184683,0.0000054062225,0.0004424559,0.048946496],"study_design_scores_gemma":[0.02364755,0.00414726,0.7054283,0.0022131712,0.0011456907,0.0068067648,0.0005404515,0.24861759,0.0012369537,0.00015058159,0.005654149,0.00041153285],"about_ca_topic_score_codex":0.00013197525,"about_ca_topic_score_gemma":0.00006711347,"teacher_disagreement_score":0.22912702,"about_ca_system_score_codex":0.0007926979,"about_ca_system_score_gemma":0.00093638786,"threshold_uncertainty_score":0.49440694},"labels":[],"label_agreement":null},{"id":"W2602417323","doi":"10.1200/jco.2012.30.15_suppl.e17532","title":"Stage III NSCLC: How many patients are really suitable for radical treatment approaches?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Surgery; Retrospective cohort study; Cancer; Radical surgery; Population; Cohort; Internal medicine","score_opus":0.25981133431041764,"score_gpt":0.45330766061470373,"score_spread":0.1934963263042861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602417323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778278,0.0018440601,0.00024999626,0.0093484465,0.0018532878,0.00080631656,0.000031934054,0.000012838949,0.008025337],"genre_scores_gemma":[0.98796475,0.0007731059,0.003327267,0.0007453732,0.002076127,0.00005198931,0.000011147533,0.000021930684,0.0050282804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976436,0.00018462473,0.0012166214,0.00018658604,0.0003201137,0.00044847914],"domain_scores_gemma":[0.99623114,0.0013588492,0.0013665095,0.00016492339,0.00031027244,0.0005683287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014219222,0.00019865064,0.001753408,0.00006084954,0.00009376042,0.000010687666,0.00009470754,0.00032591328,0.00007562133],"category_scores_gemma":[0.0014290747,0.00011744202,0.0007138669,0.00007256459,0.00016437746,0.00014691302,0.00004514216,0.00036815082,0.0000056162985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013952533,0.01193419,0.700641,0.0000474196,0.0018092423,0.00010118757,0.0004141809,0.0000013394122,0.00000530861,0.0003005341,0.014691915,0.2561012],"study_design_scores_gemma":[0.022731286,0.030079912,0.55220735,0.00004172052,0.00081804494,0.000037634698,0.0004544753,0.00001882671,0.000025511255,0.000030387451,0.3934588,0.00009602161],"about_ca_topic_score_codex":0.000017014278,"about_ca_topic_score_gemma":0.00004875796,"teacher_disagreement_score":0.3787669,"about_ca_system_score_codex":0.0006490536,"about_ca_system_score_gemma":0.0005808182,"threshold_uncertainty_score":0.47891465},"labels":[],"label_agreement":null},{"id":"W2602425744","doi":"10.1200/jco.2007.25.18_suppl.6559","title":"Willingness to pay for new hormone-refractory prostate cancer (HRPC) therapies: Experience from Ontario hospitals","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Formulary; Medicine; Family medicine; Docetaxel; Willingness to pay; Government (linguistics); Payment; Prostate cancer; Reimbursement; Finance; Cancer; Health care; Business; Internal medicine; Political science","score_opus":0.5073054240140136,"score_gpt":0.5654540665619022,"score_spread":0.05814864254788865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602425744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.923768,0.004644424,0.017179307,0.04764189,0.0054829894,0.00072659925,0.00008570497,0.000012632076,0.0004584801],"genre_scores_gemma":[0.91451013,0.0017445956,0.032137893,0.042171355,0.006243069,0.00006987735,0.000007227587,0.00005381536,0.0030620578],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98711157,0.00024734822,0.01151838,0.00046200794,0.00015552774,0.00050517777],"domain_scores_gemma":[0.98108494,0.008255168,0.009197853,0.00033803718,0.0003173769,0.00080664566],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032664254,0.00020579387,0.0025132536,0.0001830409,0.00011043322,0.000048079157,0.00050844066,0.00043308438,0.0005202116],"category_scores_gemma":[0.011173445,0.00018284208,0.00045386865,0.00012553898,0.000094823554,0.00054532394,0.000048252856,0.00064030895,0.0001751835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023274648,0.00074813643,0.786533,0.000040148057,0.00055389176,0.00001988594,0.040331643,0.00019988995,0.00002737365,0.0024124319,0.09534611,0.07146003],"study_design_scores_gemma":[0.002181366,0.0018897097,0.41524854,0.00004388209,0.000014113684,0.0000020980845,0.0011075306,0.000026956373,0.000004221329,0.0074406397,0.57186556,0.00017538275],"about_ca_topic_score_codex":0.022178655,"about_ca_topic_score_gemma":0.029044079,"teacher_disagreement_score":0.47651944,"about_ca_system_score_codex":0.0014269524,"about_ca_system_score_gemma":0.0028777584,"threshold_uncertainty_score":0.99715585},"labels":[],"label_agreement":null},{"id":"W2602463386","doi":"10.1200/jco.2014.32.15_suppl.4024","title":"Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Multivariate analysis; Univariate analysis; Oncology; Prognostic model; Cancer; Clinical trial; Overall survival","score_opus":0.23630391057160902,"score_gpt":0.5292224860337237,"score_spread":0.29291857546211464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602463386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924087,0.0001778223,0.0008234248,0.0028813498,0.00076593045,0.0021071667,0.0000045614215,0.0000054057437,0.0008256558],"genre_scores_gemma":[0.9938961,0.00043175087,0.0034246258,0.0009207047,0.0007525674,0.00013400162,0.0000010056785,0.000022097018,0.00041713566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99419075,0.0016358289,0.0029259506,0.00026043295,0.000625275,0.00036173486],"domain_scores_gemma":[0.9915047,0.0053304,0.0016577494,0.0003594941,0.0008317002,0.0003159446],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009912076,0.00016392564,0.002750885,0.00011793213,0.00005367831,0.0000050676026,0.00037206124,0.00039676676,0.000043984186],"category_scores_gemma":[0.009873097,0.00009525171,0.0004031157,0.0001636205,0.00025980832,0.000107732805,0.00008119654,0.0009378733,0.0000013834641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13414022,0.013256686,0.8060987,0.00010448389,0.000534731,0.00003600825,0.0005647255,0.0013260287,0.0001351674,0.00016568028,0.00050955446,0.043128025],"study_design_scores_gemma":[0.22224168,0.088309355,0.60436267,0.00027474127,0.0012389,0.000022105121,0.0005671418,0.079693176,0.000017154733,0.0014621969,0.0016669362,0.00014396122],"about_ca_topic_score_codex":0.000119057266,"about_ca_topic_score_gemma":0.001513442,"teacher_disagreement_score":0.20173605,"about_ca_system_score_codex":0.0002092865,"about_ca_system_score_gemma":0.0037925683,"threshold_uncertainty_score":0.99846715},"labels":[],"label_agreement":null},{"id":"W2602475246","doi":"10.1200/jco.2012.30.15_suppl.9027","title":"Curcumin for radiation dermatitis: A randomized, double-blind, placebo-controlled clinical trial of 30 breast cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Placebo; Erythema; Radiation therapy; Internal medicine; Randomized controlled trial; Cancer; Surgery; Pathology","score_opus":0.11223237648389699,"score_gpt":0.48202641869464896,"score_spread":0.36979404221075196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602475246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97776806,0.0009956972,0.0013859677,0.007399557,0.0067575295,0.004806937,0.00002714229,0.000013762819,0.0008453359],"genre_scores_gemma":[0.98643625,0.0017043281,0.0018131918,0.0024129448,0.007300185,0.00015470682,0.000010684624,0.00003801851,0.00012967756],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98887223,0.001756997,0.0081785275,0.00021401684,0.0005807009,0.00039750073],"domain_scores_gemma":[0.97353804,0.016733823,0.007762293,0.00023837945,0.0011131498,0.0006143322],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016960038,0.00023703213,0.005542993,0.00019423926,0.00004391638,0.000008608317,0.00020719656,0.0011013348,0.0005623797],"category_scores_gemma":[0.013631073,0.00015819738,0.002713618,0.00014252146,0.00041608885,0.00024332487,0.00003228165,0.0012554862,0.000013520374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8905279,0.008340399,0.017313108,0.00004254773,0.0023691398,0.0000058408255,0.00013913984,0.000008625139,0.0000123861455,0.00007098614,0.00708089,0.07408906],"study_design_scores_gemma":[0.9663735,0.0074387165,0.011215532,0.00013888854,0.0028350002,0.00006725459,0.000022340888,0.00029325942,0.00008966753,0.00013240239,0.011258266,0.00013516482],"about_ca_topic_score_codex":0.000026030088,"about_ca_topic_score_gemma":0.00000819438,"teacher_disagreement_score":0.07584563,"about_ca_system_score_codex":0.00023439272,"about_ca_system_score_gemma":0.001784293,"threshold_uncertainty_score":0.99467754},"labels":[],"label_agreement":null},{"id":"W2602479208","doi":"10.1200/jco.2013.31.15_suppl.e20507","title":"Effective routine electronic symptom screening and use of evidence to improve cancer symptom management in Ontario, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Health and Risk Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Anxiety; Cancer; Feeling; MEDLINE; Family medicine; Psychiatry; Internal medicine","score_opus":0.09661422756090404,"score_gpt":0.42839302416389724,"score_spread":0.3317787966029932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602479208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281627,0.0011891957,0.00020039747,0.004303195,0.0005688183,0.0008546352,0.0000012140761,0.0000024238977,0.00006383821],"genre_scores_gemma":[0.9940579,0.0019678,0.0012542559,0.0022138918,0.00022849934,0.00002550874,4.6406882e-7,0.000010718833,0.00024097085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719185,0.0003212634,0.0015128856,0.00020779592,0.0003954916,0.00037068772],"domain_scores_gemma":[0.99624544,0.0020454538,0.00067614,0.0001767898,0.00033956143,0.0005165843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002224789,0.00012594921,0.0013393768,0.00014579992,0.000021801707,0.0000067690503,0.000089198125,0.00017482832,0.00007583755],"category_scores_gemma":[0.0015855717,0.00008141458,0.0002481758,0.00014732774,0.00005949446,0.00013872769,0.00007229075,0.001016586,0.0000011682282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016804122,0.00013335704,0.6995668,0.00007401237,0.00068840757,0.00015205044,0.00011011558,0.00012450175,0.00005187059,0.00001411681,0.0012371546,0.29616722],"study_design_scores_gemma":[0.003788658,0.0036400054,0.96835345,0.0005135565,0.00037394257,0.00006336152,0.000067099514,0.0000805028,0.000041156076,0.000016404272,0.022984859,0.000076976314],"about_ca_topic_score_codex":0.897566,"about_ca_topic_score_gemma":0.93529564,"teacher_disagreement_score":0.29609025,"about_ca_system_score_codex":0.0012994801,"about_ca_system_score_gemma":0.0046193902,"threshold_uncertainty_score":0.81946},"labels":[],"label_agreement":null},{"id":"W2602480215","doi":"10.1200/jco.2017.35.4_suppl.155","title":"Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Dysphagia Assessment and Management","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Dysphagia; Odynophagia; Swallowing; Family medicine; Physical therapy; Generalizability theory; Surgery","score_opus":0.35276706873523145,"score_gpt":0.607969602355176,"score_spread":0.2552025336199446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602480215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99109846,0.00014479714,0.0028294264,0.0016333745,0.0011879684,0.0017294013,0.000014366419,0.000015199736,0.0013470012],"genre_scores_gemma":[0.97891206,0.000070190625,0.020225504,0.00021151577,0.00040261442,0.000041642317,0.0000098569235,0.000019876321,0.00010675878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915422,0.0011946424,0.0058228998,0.00040392036,0.00036202426,0.0006743024],"domain_scores_gemma":[0.98546994,0.0024064723,0.010064496,0.0007545881,0.0010466333,0.00025786198],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018123714,0.00019206987,0.0015306087,0.00009936114,0.00093510456,0.000019832916,0.00045557442,0.00034618244,0.00021696869],"category_scores_gemma":[0.0086278645,0.00014663831,0.00040075765,0.000054843324,0.00022537261,0.00052564486,0.0007500674,0.0011945402,8.462007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018096408,0.00058943155,0.856932,0.00019852837,0.0002590569,0.000013962986,0.0006459034,0.0000035373696,0.000022909044,0.00037385445,0.0001422151,0.13900897],"study_design_scores_gemma":[0.008738283,0.005702348,0.97050357,0.00003821732,0.00041509673,0.0000036844865,0.0041640545,0.00036378353,0.000014534252,0.0009077026,0.009015137,0.0001335794],"about_ca_topic_score_codex":0.00009234172,"about_ca_topic_score_gemma":0.0005304373,"teacher_disagreement_score":0.1388754,"about_ca_system_score_codex":0.0003223431,"about_ca_system_score_gemma":0.0012510729,"threshold_uncertainty_score":0.9997229},"labels":[],"label_agreement":null},{"id":"W2602485186","doi":"10.1200/jco.2006.24.18_suppl.6014","title":"Understanding and preferences for receiving prognostic information: A comparison of the views of Australian and Canadian patients with metastatic cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cancer; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Lung cancer; Colorectal cancer; Family medicine","score_opus":0.6136343675185694,"score_gpt":0.5540163083494851,"score_spread":0.05961805916908425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602485186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972902,0.00038530806,0.00017155624,0.0014000604,0.0001226767,0.0002451825,0.000018375664,5.172772e-7,0.0003661111],"genre_scores_gemma":[0.99693894,0.0001562914,0.0027621519,0.000084123676,0.000038389946,0.0000022571533,0.0000020273267,0.0000020883974,0.000013706895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986115,0.00008589181,0.0010454273,0.000038708768,0.00013826218,0.00008017112],"domain_scores_gemma":[0.9969655,0.00120086,0.0013768072,0.000039275692,0.00033003237,0.000087505556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000568041,0.00005134149,0.00065973663,0.00006476977,0.000021639282,0.0000029334371,0.00004308714,0.000058807596,0.000007740394],"category_scores_gemma":[0.0011735007,0.000027202314,0.000057365974,0.00007230975,0.00019057615,0.00008747151,0.000007757545,0.00014352055,2.8210028e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034610037,0.00008455767,0.9907057,0.000177029,0.00011558852,4.871867e-7,0.0006068806,0.00002050672,0.000002375926,0.000090526766,0.0007373247,0.00711289],"study_design_scores_gemma":[0.003010898,0.0039032754,0.9785864,0.0011236282,0.00043630606,0.000002832535,0.0014351102,0.000060591825,0.0000547026,0.0003798713,0.010972626,0.000033776807],"about_ca_topic_score_codex":0.0024025114,"about_ca_topic_score_gemma":0.03174399,"teacher_disagreement_score":0.029341476,"about_ca_system_score_codex":0.00006234508,"about_ca_system_score_gemma":0.00067257974,"threshold_uncertainty_score":0.9859242},"labels":[],"label_agreement":null},{"id":"W2602498213","doi":"10.1200/jco.2013.31.15_suppl.e14664","title":"Outcomes of oxaliplatin-based adjuvant chemotherapy in pathologically lymph node positive (ypN+) rectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oxaliplatin; FOLFOX; Colorectal cancer; Internal medicine; Bevacizumab; Capecitabine; Adjuvant; Oncology; Lymph node; Chemotherapy; Surgery; Cancer","score_opus":0.09106590337921527,"score_gpt":0.4630214747504055,"score_spread":0.37195557137119023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602498213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98005235,0.00037144005,0.000027418175,0.015123367,0.00068386225,0.00040879785,0.000011845144,0.000010845435,0.0033100422],"genre_scores_gemma":[0.98908263,0.00038994596,0.0046584583,0.005459302,0.00021945228,0.000029218118,0.000002883211,0.000020492385,0.00013762234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569654,0.00052923546,0.0027311184,0.000260411,0.0004670207,0.0003156944],"domain_scores_gemma":[0.9939168,0.0030714714,0.0018543073,0.00019285541,0.0006026437,0.00036189985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014619941,0.00021834458,0.0026073882,0.00015960129,0.00001930832,0.0000056087597,0.00019091598,0.00048619768,0.0010924065],"category_scores_gemma":[0.0020547286,0.00013578536,0.0007277737,0.00024439878,0.00030395642,0.000090202375,0.000041293428,0.00071791455,0.00001871104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005691046,0.0028699152,0.84141624,0.000016154145,0.00022703019,0.000754669,0.00006483204,0.000043609707,0.0006943705,0.000011438355,0.00021715277,0.14799355],"study_design_scores_gemma":[0.01893684,0.009008442,0.9700931,0.000183975,0.00014322341,0.00012495762,0.000044478857,0.0002063897,0.00039973523,0.00022517808,0.0005181022,0.00011562596],"about_ca_topic_score_codex":0.0003306936,"about_ca_topic_score_gemma":0.0000616542,"teacher_disagreement_score":0.14787793,"about_ca_system_score_codex":0.0004915836,"about_ca_system_score_gemma":0.0015368863,"threshold_uncertainty_score":0.9998207},"labels":[],"label_agreement":null},{"id":"W2602505397","doi":"10.1200/jco.2009.27.15_suppl.6068","title":"Neurocognitive outcomes of head and neck chemoradiotherapy: A pilot study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Neurocognitive; Head and neck cancer; Quality of life (healthcare); Univariate analysis; Internal medicine; Cognition; Radiation therapy; Affect (linguistics); Pediatrics; Multivariate analysis; Psychiatry","score_opus":0.16136221402929787,"score_gpt":0.5032942768107777,"score_spread":0.3419320627814798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602505397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825853,0.00049241073,0.000026361215,0.013396281,0.00047383909,0.0005108181,0.0000023143336,0.000009289185,0.0025033564],"genre_scores_gemma":[0.99087447,0.00082503684,0.0005578784,0.0070860116,0.00046540535,0.0000027126061,2.5468842e-7,0.000011348774,0.00017690076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997134,0.00029403582,0.0018845428,0.0001775959,0.00032804994,0.00018182781],"domain_scores_gemma":[0.99583983,0.0018032785,0.0013826401,0.00010853246,0.0006357705,0.00022992045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014184223,0.00015445787,0.0021969727,0.00014384554,0.0000337142,0.000004121364,0.00007819465,0.00010104508,0.000050319184],"category_scores_gemma":[0.0035511309,0.00010541238,0.00023979202,0.00014697152,0.0002438306,0.000078894634,0.000030064828,0.00075928454,0.0000030232761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015254647,0.014189096,0.80477875,0.000014295149,0.0013065239,0.00051060435,0.00041223908,7.568352e-7,0.00022164125,0.000011611902,0.001121785,0.16217802],"study_design_scores_gemma":[0.02154416,0.20369098,0.77191657,0.00007666322,0.00058564445,0.0001895183,0.00037678625,0.0000045455186,0.000031548,0.00017272746,0.0013473011,0.00006357071],"about_ca_topic_score_codex":0.000013233468,"about_ca_topic_score_gemma":0.00002210544,"teacher_disagreement_score":0.18950188,"about_ca_system_score_codex":0.00006900124,"about_ca_system_score_gemma":0.00044703193,"threshold_uncertainty_score":0.42985922},"labels":[],"label_agreement":null},{"id":"W2602545390","doi":"10.1200/jco.2004.22.90140.4575","title":"Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Placebo; Zoledronic acid; Prostate cancer; Clinical endpoint; Internal medicine; Urology; Exploratory analysis; Confidence interval; Surgery; Cancer; Randomized controlled trial; Pathology","score_opus":0.07053870449685215,"score_gpt":0.4847885505464505,"score_spread":0.41424984604959836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602545390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940396,0.0014257176,0.00039062745,0.0077001583,0.00009517107,0.0007228615,0.000007414948,0.0000017391609,0.00025236473],"genre_scores_gemma":[0.9940034,0.0010744253,0.0045652892,0.00016388188,0.000045875273,0.000044061882,0.0000022496204,0.0000066991092,0.00009410681],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982981,0.0000448434,0.0013279472,0.00007656746,0.00012656313,0.00012595042],"domain_scores_gemma":[0.99738616,0.0005444537,0.0015574193,0.00009830525,0.00032571497,0.000087956636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080047635,0.00005757638,0.0006730993,0.000046387722,0.000017293969,8.160933e-7,0.00005956805,0.000083185485,0.0000071735267],"category_scores_gemma":[0.0002658969,0.00003192812,0.00015530412,0.00008663056,0.000111038746,0.000050783823,0.0000090888725,0.0002509094,3.717021e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014000776,0.0040133125,0.19402783,0.00021644872,0.00060648477,0.000021851021,0.0005209511,0.0014776787,0.0009060786,0.0009330417,0.000054351924,0.7832212],"study_design_scores_gemma":[0.035241228,0.019306952,0.9386352,0.00072968466,0.0004496193,0.000059410177,0.00016316955,0.00008861262,0.0007144896,0.0016411575,0.0029280842,0.00004239131],"about_ca_topic_score_codex":0.00007137784,"about_ca_topic_score_gemma":0.00075731013,"teacher_disagreement_score":0.7831788,"about_ca_system_score_codex":0.00010976597,"about_ca_system_score_gemma":0.0010102477,"threshold_uncertainty_score":0.17921361},"labels":[],"label_agreement":null},{"id":"W2602547068","doi":"10.1200/jco.2017.35.6_suppl.24","title":"Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Medicine; Prostatectomy; Anxiety; Prospective cohort study; Internal medicine; Oncology; Prostate cancer; Cancer; Bioinformatics; Psychiatry","score_opus":0.1563291468053269,"score_gpt":0.5464317188724948,"score_spread":0.39010257206716786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602547068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99155426,0.0001750207,0.000021264546,0.0009456741,0.0010713544,0.0050504496,0.00023878909,0.000025524358,0.00091765367],"genre_scores_gemma":[0.99539423,0.00020193869,0.0032909927,0.00013855349,0.00053043384,0.00029645304,0.000011169252,0.00005642078,0.00007980282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9825734,0.01030302,0.0051100254,0.0006430351,0.0007498673,0.0006206375],"domain_scores_gemma":[0.9044441,0.07885671,0.013334038,0.0018029301,0.0010419983,0.00052025146],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0061754505,0.0004193048,0.0029340116,0.00018690986,0.0010970059,0.000017893652,0.0009955438,0.0007594043,0.00009487883],"category_scores_gemma":[0.06680976,0.00022480154,0.00043716095,0.00010986713,0.0007693831,0.00025850537,0.00054603716,0.002725499,0.00006122875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09348061,0.003657043,0.83711004,0.000026519276,0.0004998285,0.00048249008,0.0054102144,0.000055678254,0.000007854135,0.0000031043987,0.00032672723,0.058939908],"study_design_scores_gemma":[0.048565455,0.11876664,0.8289841,0.0012754684,0.00043801405,0.00001103125,0.0010098482,0.00025631912,0.000036908124,0.00021619612,0.00028182482,0.00015821194],"about_ca_topic_score_codex":0.001692764,"about_ca_topic_score_gemma":0.0039490806,"teacher_disagreement_score":0.1151096,"about_ca_system_score_codex":0.0021622009,"about_ca_system_score_gemma":0.0021403262,"threshold_uncertainty_score":0.99957526},"labels":[],"label_agreement":null},{"id":"W2602579884","doi":"10.1200/jco.2013.31.15_suppl.tps4590","title":"ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Chromophobe cell; Clinical endpoint; Internal medicine; Oncology; Renal cell carcinoma; Clear cell renal cell carcinoma; Clinical trial; Randomized controlled trial; Pathology; Clear cell","score_opus":0.08744602347207388,"score_gpt":0.3995117048112673,"score_spread":0.31206568133919343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602579884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895521,0.00013764662,0.000028999611,0.0005455254,0.0008742921,0.0021949012,0.0000056066,0.000004401433,0.006656549],"genre_scores_gemma":[0.9950519,0.00006428062,0.0039284476,0.00024500367,0.0003667096,0.000033444092,0.000012920219,0.000034799166,0.000262486],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99290305,0.0014731152,0.0041429847,0.00028403933,0.0008079864,0.00038882022],"domain_scores_gemma":[0.9892212,0.0053639896,0.0036156697,0.00034973692,0.00087951275,0.00056986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034765578,0.0002943197,0.004095801,0.00034111438,0.00003645084,0.000009074457,0.00022647735,0.00027538126,0.0005796508],"category_scores_gemma":[0.001954313,0.00017906811,0.00093116146,0.00023601753,0.00037740238,0.00017348675,0.000078962694,0.0010661626,0.000038637274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96542144,0.022132633,0.0038169404,0.000060652197,0.00046182534,0.00064039073,0.00019624076,0.000017826469,0.00019393618,0.0000028177183,0.00073665055,0.006318628],"study_design_scores_gemma":[0.7747268,0.20248024,0.019570628,0.00006047329,0.0016902424,0.000016812104,0.000104080864,0.000097777636,0.0008231975,0.000033648914,0.00027689524,0.0001191705],"about_ca_topic_score_codex":0.00015333499,"about_ca_topic_score_gemma":0.000018174378,"teacher_disagreement_score":0.19069463,"about_ca_system_score_codex":0.00023732749,"about_ca_system_score_gemma":0.0016833103,"threshold_uncertainty_score":0.7302186},"labels":[],"label_agreement":null},{"id":"W2602581787","doi":"10.1200/jco.2013.31.15_suppl.10554","title":"Patterns of toxicities and outcome in children versus adolescents/young adults (AYA) with metastatic rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG) Soft Tissue Sarcoma Committee.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cog; Rhabdomyosarcoma; Incidence (geometry); Young adult; Internal medicine; Nausea; Exact test; Vomiting; Soft tissue sarcoma; Pediatrics; Sarcoma; Surgery; Soft tissue; Pathology","score_opus":0.05888340323673278,"score_gpt":0.38980454328420405,"score_spread":0.33092114004747125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602581787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894392,0.0018312875,0.00006660739,0.006841203,0.0005119744,0.0011669219,0.00003511035,0.000011242384,0.00009648487],"genre_scores_gemma":[0.9945479,0.0005926113,0.0027196296,0.0015175294,0.0004850992,0.00005378222,0.000032556964,0.00003538741,0.000015479058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994393,0.00085699593,0.003398141,0.00038945448,0.0005598636,0.0004025267],"domain_scores_gemma":[0.99176776,0.0043949718,0.0026825215,0.00048329256,0.00030033212,0.00037114436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016425604,0.0003334002,0.002550761,0.00016140839,0.000061912186,0.00002167354,0.00032352976,0.00031925825,0.00015447589],"category_scores_gemma":[0.0015008717,0.00018724136,0.00036809657,0.00013614449,0.00040520763,0.00017346442,0.00015711316,0.0011949551,0.000011069703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004479224,0.004482166,0.8920242,0.000023796378,0.0013684197,0.0016737907,0.00024469345,0.0000017429577,0.000010158051,0.0000195594,0.00045345488,0.09521877],"study_design_scores_gemma":[0.032360047,0.0151370345,0.9454923,0.00047684636,0.0012803499,0.0039382908,0.0005756667,0.00001572245,0.0000309369,0.00011071492,0.000418974,0.0001630731],"about_ca_topic_score_codex":0.0046031657,"about_ca_topic_score_gemma":0.0030569567,"teacher_disagreement_score":0.09505569,"about_ca_system_score_codex":0.00020421912,"about_ca_system_score_gemma":0.0004290945,"threshold_uncertainty_score":0.7635481},"labels":[],"label_agreement":null},{"id":"W2602599927","doi":"10.1200/jco.2013.31.15_suppl.e20045","title":"Outcome and prognostic factors in BRAF mutation positive metastatic melanoma treated with a BRAF inhibitor: A population-based study in British Columbia.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Vemurafenib; Medicine; Internal medicine; Melanoma; Oncology; Metastatic melanoma; Asymptomatic; Population; V600E; Clinical trial; Mutation; Gastroenterology; Cancer; Cancer research","score_opus":0.04258170396466641,"score_gpt":0.35631837989130954,"score_spread":0.3137366759266431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602599927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989522,0.00006279376,0.000040114894,0.000103216684,0.00010574021,0.00068591814,0.000008849307,0.0000031529282,0.00003801839],"genre_scores_gemma":[0.9990265,0.000006001453,0.0005808455,0.00018947992,0.00008002373,0.000025236672,0.000035716803,0.000015032032,0.000041162126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997287,0.0006708163,0.0014447568,0.0002464047,0.00016458688,0.00018646542],"domain_scores_gemma":[0.99825555,0.0005953613,0.00070898276,0.00009622574,0.00019023207,0.00015364689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008688092,0.00011321587,0.0007304592,0.000088916015,0.000029463848,0.000056371246,0.00009116936,0.0001970764,0.000024266132],"category_scores_gemma":[0.0014343379,0.00011296226,0.00009253554,0.00012960583,0.000059692535,0.000020929827,0.000027910848,0.00031033187,0.0000012683915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021979207,0.0014101936,0.9920686,0.000011128343,0.0000794371,0.0005213223,0.00005148997,0.000039884988,0.00038750266,5.819799e-7,0.000036302434,0.0051737837],"study_design_scores_gemma":[0.00647915,0.016106887,0.976417,0.00004824185,0.00007820079,0.000120346725,0.0004169938,0.0000874418,0.00006347957,0.000034973265,0.000022722192,0.00012457278],"about_ca_topic_score_codex":0.007867989,"about_ca_topic_score_gemma":0.13363339,"teacher_disagreement_score":0.1257654,"about_ca_system_score_codex":0.000049149523,"about_ca_system_score_gemma":0.0003418556,"threshold_uncertainty_score":0.9987387},"labels":[],"label_agreement":null},{"id":"W2602619722","doi":"10.1200/jco.2013.31.15_suppl.6625","title":"Impact of center case volume on cardiotoxicity during adjuvant trastuzumab in breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto; University Health Network; St. Michael's Hospital","funders":"","keywords":"Medicine; Cardiotoxicity; Trastuzumab; Internal medicine; Breast cancer; Heart failure; Cohort; Discontinuation; Cancer; Oncology; Cardiology; Chemotherapy","score_opus":0.061540059034962166,"score_gpt":0.445213537117807,"score_spread":0.3836734780828448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602619722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961403,0.000078457575,0.000012900418,0.0023363463,0.00043325953,0.00029185967,0.000024106968,0.0000054975194,0.0006772572],"genre_scores_gemma":[0.99800944,0.0003729719,0.00010242135,0.00044020583,0.0009932822,0.000005918739,0.000001224839,0.000016643147,0.000057888836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997165,0.00032199977,0.0017994047,0.00016850789,0.00029768722,0.00024736943],"domain_scores_gemma":[0.99768436,0.00036895415,0.0010497834,0.0001808424,0.0003811954,0.00033489478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011311488,0.00014757173,0.0016317747,0.00017417964,0.00002319653,0.000005781949,0.000089008,0.0003765799,0.0004020839],"category_scores_gemma":[0.00040793684,0.000104358405,0.0010080235,0.00014821082,0.0001312516,0.0001458422,0.00002037971,0.0010449273,0.000009740668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054577393,0.00307723,0.7952425,0.0000775666,0.0009396959,0.004036579,0.00031961847,0.00034797954,0.054902237,0.0000030236456,0.0014966929,0.13409914],"study_design_scores_gemma":[0.0108341845,0.0049569733,0.9651255,0.0002614306,0.00010699135,0.01504807,0.000108491135,0.00012171108,0.0032047187,0.000024590798,0.00011838985,0.00008896279],"about_ca_topic_score_codex":0.0007634509,"about_ca_topic_score_gemma":0.00008078919,"teacher_disagreement_score":0.16988298,"about_ca_system_score_codex":0.000769375,"about_ca_system_score_gemma":0.0009997904,"threshold_uncertainty_score":0.45397472},"labels":[],"label_agreement":null},{"id":"W2602628627","doi":"10.1200/jco.2014.32.15_suppl.e22078","title":"Whole-genome DNA and RNA sequencing in patients with metastatic colorectal cancer (mCRC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; Bevacizumab; Cancer research; Wnt signaling pathway; Cancer; Internal medicine; Gene; Biology; Genetics; Chemotherapy","score_opus":0.033279969763729086,"score_gpt":0.3562276916923835,"score_spread":0.3229477219286544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602628627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812526,0.00039335186,0.00018107585,0.00040103556,0.00041318164,0.00009681091,0.00001834423,0.0000010090962,0.00036991964],"genre_scores_gemma":[0.9967491,0.00048562133,0.0011965284,0.0010239687,0.00049385405,0.000003845845,0.00001041006,0.00001387378,0.00002282124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847895,0.00018268262,0.00085603155,0.00017814584,0.00012563892,0.00017856206],"domain_scores_gemma":[0.9985006,0.0003318034,0.0006934769,0.00009576985,0.00020427229,0.00017407331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011058397,0.00010791838,0.0005547183,0.000052182553,0.000024200814,0.000011692341,0.00012534551,0.00015013787,0.0000107178075],"category_scores_gemma":[0.0010904993,0.000080723104,0.00008825243,0.000054984357,0.00013808893,0.0000063657753,0.00006509881,0.00027086228,0.0000013512699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007873982,0.0010966584,0.7570001,0.00006082398,0.0007197164,0.00010045722,0.00023755549,0.002766033,0.08374662,0.0001703652,0.0013512796,0.14487639],"study_design_scores_gemma":[0.012330238,0.019280367,0.85932446,0.000053549855,0.00018764174,0.000030210684,0.000064921805,0.00015099312,0.0016803567,0.00032645056,0.106290035,0.00028078086],"about_ca_topic_score_codex":0.000037199414,"about_ca_topic_score_gemma":0.0005520074,"teacher_disagreement_score":0.14459561,"about_ca_system_score_codex":0.000097170356,"about_ca_system_score_gemma":0.00087758165,"threshold_uncertainty_score":0.32917926},"labels":[],"label_agreement":null},{"id":"W2602637482","doi":"10.1200/jco.2017.35.5_suppl.194","title":"Evaluating an educational intervention to alleviate distress among men with newly-diagnosed prostate cancer and their partners.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Distress; Anxiety; Affect (linguistics); Prostate cancer; Session (web analytics); Attendance; Clinical psychology; Cancer; Internal medicine; Physical therapy; Psychiatry; Psychology","score_opus":0.18019985122420265,"score_gpt":0.553237371492995,"score_spread":0.37303752026879233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602637482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806532,0.0003121276,0.000049002618,0.016789733,0.00070845673,0.00022967678,0.000008909656,0.0000038957946,0.0012449598],"genre_scores_gemma":[0.99636996,0.0002969558,0.00048233586,0.0006674249,0.0012853916,0.000028918404,0.000007154182,0.00001280168,0.00084904104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831516,0.0002439356,0.00087569293,0.0001846378,0.00022774111,0.00015283741],"domain_scores_gemma":[0.99693906,0.0005391731,0.001371557,0.00022313745,0.00049855054,0.00042851927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002352876,0.00010631231,0.0006533431,0.000047184232,0.00011045567,0.000047879414,0.00015442763,0.00011492259,0.000104849845],"category_scores_gemma":[0.0015616028,0.00006520708,0.000147907,0.00003155268,0.00019583806,0.00022839285,0.000055785287,0.0004092797,0.0000013241226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003188188,0.00044066293,0.5135839,0.000035388533,0.00017939316,0.000043749205,0.0012587718,0.000033929668,0.00003610087,0.000024352452,0.0008964498,0.48027912],"study_design_scores_gemma":[0.0065551987,0.008670001,0.97530645,0.0005000823,0.00019149604,0.00004140295,0.0012831471,0.00030144412,0.00003324293,0.00019531838,0.0068349107,0.0000873072],"about_ca_topic_score_codex":0.0010205391,"about_ca_topic_score_gemma":0.011803165,"teacher_disagreement_score":0.4801918,"about_ca_system_score_codex":0.000098308585,"about_ca_system_score_gemma":0.0007694164,"threshold_uncertainty_score":0.6586443},"labels":[],"label_agreement":null},{"id":"W2602648804","doi":"10.1200/jco.2017.35.4_suppl.421","title":"Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Cancer; Pancreatic cancer; Cohort; Oncology; Chemotherapy; Stage (stratigraphy); Surgical oncology","score_opus":0.14685507219764926,"score_gpt":0.5291919823552195,"score_spread":0.3823369101575702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602648804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95163316,0.0027922539,0.00003316606,0.018927945,0.0017523487,0.00045567748,0.000008026929,0.000014279307,0.024383126],"genre_scores_gemma":[0.9798835,0.010100547,0.004756727,0.0027797632,0.001785743,0.000023098217,0.000008463972,0.000034110733,0.00062807783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99463725,0.0011152896,0.0026492374,0.00036814171,0.0006390784,0.00059098785],"domain_scores_gemma":[0.9919523,0.0033823263,0.0026351393,0.000644157,0.0007847879,0.00060131366],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060471175,0.00022818071,0.0040702457,0.0002165661,0.00020129053,0.000023662782,0.0006914362,0.0010005311,0.00019151813],"category_scores_gemma":[0.008733177,0.00016900855,0.0007206154,0.00013539728,0.0006408965,0.00018350898,0.00016998593,0.0023690904,0.000019549072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009500128,0.0008303229,0.7527274,0.0000776454,0.0005022264,0.0031882462,0.00030073483,0.0000038696785,0.00029186395,0.000011806107,0.0023003994,0.2302654],"study_design_scores_gemma":[0.023386288,0.010663645,0.8992919,0.00041716624,0.00023440458,0.0002039958,0.00021968079,0.00010725071,0.000025139883,0.00010045009,0.065205574,0.0001445523],"about_ca_topic_score_codex":0.0005594145,"about_ca_topic_score_gemma":0.0021731087,"teacher_disagreement_score":0.23012084,"about_ca_system_score_codex":0.001429678,"about_ca_system_score_gemma":0.01064855,"threshold_uncertainty_score":0.99993247},"labels":[],"label_agreement":null},{"id":"W2602655477","doi":"10.1200/jco.2017.35.5_suppl.160","title":"Prevalence of sarcopenia and predictors of body composition among women with early-stage breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sarcopenia; Medicine; Breast cancer; Odds ratio; Internal medicine; Body mass index; Confidence interval; Cancer; Bioelectrical impedance analysis; Stage (stratigraphy)","score_opus":0.08294669161451843,"score_gpt":0.47133562719368804,"score_spread":0.38838893557916965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602655477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951809,0.00014867252,0.000022830583,0.003538191,0.0003128592,0.00015774641,0.00002539673,0.0000028648271,0.00061054755],"genre_scores_gemma":[0.9966085,0.0017180495,0.0008302898,0.00027357932,0.0003985548,0.0000029596417,2.9228238e-7,0.000007207764,0.00016055662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980653,0.00015087322,0.0012856487,0.000101721154,0.00025465927,0.00014179802],"domain_scores_gemma":[0.9959285,0.00036172164,0.0027901237,0.00016886443,0.00042533546,0.00032545745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017354109,0.00006934478,0.0008922538,0.00006780906,0.00006269865,0.000006052436,0.00013031585,0.00014667571,0.00014356033],"category_scores_gemma":[0.00024623057,0.00004776091,0.00006866866,0.000028278178,0.0006456808,0.00015927412,0.000038944007,0.0004827613,4.41697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006716126,0.00051003037,0.98586583,0.0006657692,0.000117166535,0.00006981009,0.00017761726,0.0000014070641,0.0006423515,0.0000263056,0.0001902531,0.0050173607],"study_design_scores_gemma":[0.006502553,0.008109799,0.9830609,0.0011294241,0.00014892011,0.0001461094,0.000059814745,0.000029874158,0.00018205261,0.00003360699,0.00055818853,0.00003876737],"about_ca_topic_score_codex":0.00009166532,"about_ca_topic_score_gemma":0.000017241107,"teacher_disagreement_score":0.0075997687,"about_ca_system_score_codex":0.000074084004,"about_ca_system_score_gemma":0.00059711887,"threshold_uncertainty_score":0.23790377},"labels":[],"label_agreement":null},{"id":"W2602658251","doi":"10.1200/jco.2015.33.15_suppl.581","title":"Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively-designed Ontario population-based validation study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Mount Sinai Hospital; Kingston General Hospital; Juravinski Hospital; Queen's University; London Health Sciences Centre; Health Sciences North; University of Toronto; Ottawa Hospital; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Comedo; Internal medicine; Population; Ductal carcinoma; Breast cancer; Correlation; Oncology; Cancer","score_opus":0.1782403021238841,"score_gpt":0.41820763417986745,"score_spread":0.23996733205598336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602658251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543333,0.0001925006,0.00024790413,0.0032305233,0.00035904683,0.0003419685,0.000005502421,0.000002035699,0.0001872067],"genre_scores_gemma":[0.9982814,0.000015561653,0.00039306702,0.00051877165,0.0007145047,0.000018937273,0.00003242165,0.00000571115,0.000019629822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975601,0.0010344947,0.00086756016,0.00017765933,0.0002575476,0.000102624916],"domain_scores_gemma":[0.99761647,0.0011566683,0.0008337948,0.00013110992,0.00020406427,0.000057901554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039140517,0.00010736825,0.00039718117,0.00003929153,0.00008438246,0.000017170594,0.00014192307,0.00019830865,0.0000043471305],"category_scores_gemma":[0.0016645213,0.000056540328,0.00012004791,0.00007910743,0.00013013228,0.000011442825,0.000028641272,0.00041803828,9.108388e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009416407,0.00060940057,0.99283594,0.0000010678575,0.000075558084,0.000018314884,0.00043219028,0.00026643762,0.0000051302063,0.0000323104,0.0006019228,0.0041800947],"study_design_scores_gemma":[0.0037320245,0.0053502917,0.98841,0.000008419153,0.00014829253,0.00004876116,0.00036998265,0.000005724275,0.000011887359,0.0014926464,0.00036222005,0.000059743485],"about_ca_topic_score_codex":0.00054389046,"about_ca_topic_score_gemma":0.0055561597,"teacher_disagreement_score":0.005012269,"about_ca_system_score_codex":0.00012512624,"about_ca_system_score_gemma":0.000699398,"threshold_uncertainty_score":0.31004673},"labels":[],"label_agreement":null},{"id":"W2602664464","doi":"10.1200/jco.2017.35.4_suppl.132","title":"Quality of life (QOL) in esophageal cancer patients treated with tri-modality therapy: Is the CROSS protocol better?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nausea; Internal medicine; Esophageal cancer; Quality of life (healthcare); Esophagectomy; Carboplatin; Regimen; Vomiting; Cancer; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.23771428234472636,"score_gpt":0.579544302588893,"score_spread":0.34183002024416664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602664464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765978,0.00020441513,0.0000023102457,0.011151815,0.00011268606,0.011309404,0.000025281106,0.0000034587174,0.0005928574],"genre_scores_gemma":[0.99474597,0.00013741036,0.000114026625,0.0019636883,0.00044377,0.0024404374,0.0000013750888,0.000014123775,0.0001391757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99558944,0.0008833634,0.0022553015,0.0002238892,0.00074951694,0.00029846616],"domain_scores_gemma":[0.99396765,0.0011410508,0.003162204,0.00051153224,0.0008258964,0.00039165074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040767784,0.00016413315,0.00155151,0.00006183988,0.00012433021,0.000027953904,0.00041394052,0.00024260364,0.00022574696],"category_scores_gemma":[0.0023494593,0.00007611441,0.00039094948,0.00008968398,0.00074478664,0.0001609379,0.00006910459,0.00096769625,0.0000032319383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04097556,0.0035765069,0.8788259,0.000056320547,0.00046560896,0.0001822268,0.000100638994,0.0000017450047,0.000004880812,0.000009793741,0.00035335327,0.07544748],"study_design_scores_gemma":[0.044305176,0.017282823,0.9363783,0.00008544353,0.00004592978,0.000005397588,0.0000111487325,0.000007386405,0.00032646666,0.00018182346,0.0013126957,0.000057423942],"about_ca_topic_score_codex":0.0017547627,"about_ca_topic_score_gemma":0.00060046604,"teacher_disagreement_score":0.075390056,"about_ca_system_score_codex":0.00025290847,"about_ca_system_score_gemma":0.0026640466,"threshold_uncertainty_score":0.47259045},"labels":[],"label_agreement":null},{"id":"W2602667334","doi":"10.1200/jco.2017.35.6_suppl.334","title":"Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Internal medicine; Oncology; Gene; ARID1A; Cancer; Exon; Indel; Mutation; Genetics; Single-nucleotide polymorphism; Genotype; Biology","score_opus":0.03770373063919583,"score_gpt":0.3783289969253633,"score_spread":0.34062526628616746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602667334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721324,0.00021028634,0.0002978385,0.0014280044,0.00027242838,0.00011143646,0.000005485261,0.0000010292091,0.00046026226],"genre_scores_gemma":[0.9974068,0.00020244259,0.0015081755,0.00041352975,0.00040583612,0.000004658123,0.0000024073117,0.0000096834065,0.000046496127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989488,0.00009461888,0.0005733325,0.00014199878,0.000114906725,0.00012633143],"domain_scores_gemma":[0.99798465,0.00026048723,0.0013233633,0.00015863469,0.00019463667,0.00007824767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008082187,0.00008378346,0.00037880652,0.000030878175,0.000098623445,0.000032888704,0.000111696456,0.0000852739,0.0000023250818],"category_scores_gemma":[0.0017233745,0.00005825332,0.000069883776,0.000018242787,0.000067572204,0.000014821349,0.000033842534,0.00021333084,3.5927744e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000927344,0.00015802155,0.9877166,0.000002475736,0.000069146794,0.00007240203,0.000022920289,0.00023440359,0.0035849833,0.00007116058,0.00005219013,0.0070883213],"study_design_scores_gemma":[0.006354584,0.003822527,0.98592836,0.000016710654,0.00003242598,0.00009067261,0.00004612142,0.00007445722,0.00067301124,0.00013723898,0.0027363498,0.000087573135],"about_ca_topic_score_codex":0.000073631156,"about_ca_topic_score_gemma":0.0010086134,"teacher_disagreement_score":0.0070007485,"about_ca_system_score_codex":0.00008408965,"about_ca_system_score_gemma":0.0006750028,"threshold_uncertainty_score":0.23755014},"labels":[],"label_agreement":null},{"id":"W2602672885","doi":"10.1200/jco.2013.31.15_suppl.564","title":"Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Hamilton Health Sciences; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; Queen's University","funders":"","keywords":"Medicine; Exemestane; Anastrozole; Internal medicine; Letrozole; Breast cancer; Oncology; Cancer; Adjuvant therapy; Tamoxifen","score_opus":0.25716147792904726,"score_gpt":0.5203012545906464,"score_spread":0.2631397766615991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602672885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969084,0.0011071577,0.00043239314,0.003941975,0.0015343662,0.00021342379,0.0000020823006,0.000008552268,0.003069233],"genre_scores_gemma":[0.9765553,0.00041354453,0.021430928,0.000715353,0.00078366353,0.0000035842686,0.0000013152659,0.0000206416,0.00007569822],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99610555,0.00035545934,0.0026791687,0.00017218191,0.00037094447,0.0003167015],"domain_scores_gemma":[0.9942792,0.0024930837,0.0021499894,0.00021674509,0.00053980947,0.00032118935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019805073,0.00015222529,0.001771822,0.00017394953,0.000017104201,0.0000039918364,0.0002013112,0.00026548476,0.00044177772],"category_scores_gemma":[0.0024850639,0.00011322775,0.00033698796,0.00016862317,0.00025304413,0.00016315034,0.00006014425,0.0011829047,0.000027771532],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019438995,0.0015960679,0.4189761,0.00007111562,0.00042825632,0.0007554542,0.0002639489,0.0002601045,0.0017662289,0.00022669314,0.00033963297,0.5558774],"study_design_scores_gemma":[0.025568042,0.013005771,0.9352214,0.00038083762,0.00020549029,0.0003802774,0.0009919779,0.00025326366,0.00023688635,0.0006796974,0.022948423,0.00012795052],"about_ca_topic_score_codex":0.00013439133,"about_ca_topic_score_gemma":0.00006331283,"teacher_disagreement_score":0.5557495,"about_ca_system_score_codex":0.0002587363,"about_ca_system_score_gemma":0.0009283238,"threshold_uncertainty_score":0.51391983},"labels":[],"label_agreement":null},{"id":"W2602683295","doi":"10.1200/jco.2013.31.15_suppl.6628","title":"The use of routine surveillance imaging scans in women with early breast cancer (EBC) treated in Ontario, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Cancer registry; Breast cancer; Cancer; Medical imaging; Stage (stratigraphy); Radiology; Population; Logistic regression; Medical record; Internal medicine","score_opus":0.0341312886401664,"score_gpt":0.32375837979808464,"score_spread":0.28962709115791824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602683295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942681,0.00031381528,0.0000036921138,0.005015137,0.00018559651,0.00011102121,0.000015532512,8.484124e-7,0.00008626148],"genre_scores_gemma":[0.99872667,0.00038532232,0.00009934975,0.00052096846,0.0001110596,0.000022770158,0.0000015603018,0.000010479683,0.0001218491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981106,0.00025729262,0.0010236045,0.0001618357,0.00015679374,0.00028986216],"domain_scores_gemma":[0.99822617,0.00040689443,0.0007683273,0.0001581036,0.00033231906,0.00010818932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058912334,0.00012668582,0.00061966496,0.00003507807,0.000028719303,0.000010297475,0.00016923185,0.00009411993,0.00003637312],"category_scores_gemma":[0.000207989,0.000074336334,0.000059470127,0.00010654291,0.00019589765,0.000013132055,0.00005442967,0.0003227265,3.042219e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026373994,0.00018443503,0.9709589,0.0000021683802,0.00018482844,0.000043798234,0.00008360996,0.00020750402,0.00014047195,0.0000011176523,0.001413552,0.024142217],"study_design_scores_gemma":[0.0033084957,0.00060111866,0.9886932,0.000037586175,0.000014786526,0.000051701947,0.0001065759,0.000012138686,0.00004429228,0.0000072914613,0.007044049,0.00007880957],"about_ca_topic_score_codex":0.9448662,"about_ca_topic_score_gemma":0.99644893,"teacher_disagreement_score":0.051582776,"about_ca_system_score_codex":0.0005760011,"about_ca_system_score_gemma":0.0029032629,"threshold_uncertainty_score":0.5150264},"labels":[],"label_agreement":null},{"id":"W2602692503","doi":"10.1200/jco.2017.35.4_suppl.498","title":"Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Tolerability; Capecitabine; FOLFIRINOX; Pancreatic cancer; Gastroenterology; Progressive disease; Neutropenia; Surgery; Oncology; Cancer; Chemotherapy; Adverse effect; Oxaliplatin","score_opus":0.31258667225546877,"score_gpt":0.5547722455396463,"score_spread":0.24218557328417756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602692503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489135,0.00031475312,0.0000219443,0.0018217074,0.00065360713,0.0008644364,0.000009264102,0.000004063232,0.0014189035],"genre_scores_gemma":[0.99529123,0.0010685666,0.002182534,0.0003674132,0.00031283268,0.00002942297,0.0000017342755,0.00002034541,0.0007258939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99373114,0.0011225077,0.003745127,0.00026306688,0.0007414877,0.00039669714],"domain_scores_gemma":[0.98913324,0.0049543777,0.0037256184,0.00063908094,0.0010878188,0.00045983787],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005758476,0.00019059729,0.0039079115,0.00030522482,0.00009859225,0.000018985937,0.0004675079,0.0002764872,0.00022041732],"category_scores_gemma":[0.029618412,0.00012979165,0.00036678897,0.00013807953,0.00056252157,0.00029046496,0.00017764694,0.0012945525,0.000011079368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010255544,0.009794296,0.9582751,0.0000871737,0.0010333651,0.0009995068,0.000553721,0.000010309868,0.000016664195,0.000030799638,0.0008977436,0.018045798],"study_design_scores_gemma":[0.038360655,0.032411184,0.9246611,0.0002508714,0.0014416161,0.000048503076,0.00072008336,0.00032782252,0.0000039064735,0.00018854698,0.0014933007,0.00009239161],"about_ca_topic_score_codex":0.002215412,"about_ca_topic_score_gemma":0.0024155776,"teacher_disagreement_score":0.033613957,"about_ca_system_score_codex":0.00038075753,"about_ca_system_score_gemma":0.00341388,"threshold_uncertainty_score":0.9785555},"labels":[],"label_agreement":null},{"id":"W2602724080","doi":"10.1200/jco.2012.30.15_suppl.3527","title":"Adjuvant chemotherapy (AC) use and outcomes in stage II colon cancer (CC) with and without poor prognostic features.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Perineural invasion; Stage (stratigraphy); Lymphovascular invasion; Proportional hazards model; Oncology; Adjuvant; Cancer; Gastroenterology; Metastasis","score_opus":0.10143552834737052,"score_gpt":0.46410109742116495,"score_spread":0.36266556907379444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602724080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841753,0.0055692326,0.0000021395208,0.009374449,0.0003143048,0.00033283848,0.000005867551,0.0000050053727,0.00022081088],"genre_scores_gemma":[0.9901231,0.005037009,0.0009834428,0.0025886237,0.0002681991,0.000016075499,5.024173e-7,0.00001381965,0.00096924056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864507,0.00010523186,0.0006949909,0.00013636265,0.00018382992,0.0002344895],"domain_scores_gemma":[0.99820054,0.0007893579,0.0005296981,0.000067963185,0.00014280519,0.00026961052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070785003,0.00014610609,0.0013251032,0.00007169587,0.00004921691,0.000009052752,0.000035483605,0.00016090668,0.000024874265],"category_scores_gemma":[0.0007469964,0.00007677276,0.00008359368,0.00006749349,0.00023265544,0.00015229089,0.000042409898,0.0004867732,2.9395443e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066922824,0.0022845573,0.948649,0.000023565208,0.0005065425,0.0001247165,0.0005901245,3.5792644e-7,0.000018390787,0.00001444099,0.0004330857,0.04066294],"study_design_scores_gemma":[0.021718537,0.013071839,0.9453893,0.00011722604,0.0003392881,0.00020389039,0.00018387607,0.0000049837136,0.000017251183,0.000008892813,0.018865312,0.000079618345],"about_ca_topic_score_codex":0.00018667248,"about_ca_topic_score_gemma":0.0017044179,"teacher_disagreement_score":0.040583324,"about_ca_system_score_codex":0.00012834935,"about_ca_system_score_gemma":0.0003602098,"threshold_uncertainty_score":0.31307024},"labels":[],"label_agreement":null},{"id":"W2602728909","doi":"10.1200/jco.2013.31.15_suppl.7116","title":"A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Medicine; Azacitidine; Decitabine; Myelodysplastic syndromes; Lenalidomide; Internal medicine; Pharmacodynamics; Cytarabine; Gastroenterology; Phases of clinical research; Oncology; Bone marrow; Pharmacokinetics; Leukemia; Multiple myeloma; Clinical trial","score_opus":0.029897635690092076,"score_gpt":0.39435186092958446,"score_spread":0.3644542252394924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602728909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986582,0.000050934894,0.000043977656,0.00014764242,0.00016021011,0.0008387966,0.0000068715453,0.000003449321,0.00008995159],"genre_scores_gemma":[0.9990843,0.00001572059,0.00058686646,0.000072310555,0.000080424354,0.000031270803,0.000028958453,0.000033403543,0.00006676547],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99581873,0.0009975298,0.0018596573,0.0003938205,0.00056471664,0.00036556367],"domain_scores_gemma":[0.9968345,0.00028049244,0.0011975834,0.0002693172,0.001128373,0.0002897394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016423286,0.00022847703,0.0010889781,0.00038832892,0.000052014893,0.000009799134,0.0002739983,0.00033912412,0.000030008023],"category_scores_gemma":[0.0013062853,0.00017300886,0.00008950972,0.00042679126,0.00031391793,0.000055802266,0.00010565383,0.0008834707,0.0000045362144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086814135,0.31059024,0.51412445,0.0001399318,0.0008778386,0.001547893,0.0023914417,0.0010852836,0.0329176,0.000018924246,0.0029880605,0.04650419],"study_design_scores_gemma":[0.08338,0.49368522,0.41640165,0.00012562877,0.00008090369,0.0000990227,0.00057786366,0.0001628945,0.0048494893,0.000024084395,0.0003104474,0.00030281013],"about_ca_topic_score_codex":0.00027977448,"about_ca_topic_score_gemma":0.0019479077,"teacher_disagreement_score":0.18309498,"about_ca_system_score_codex":0.00023798885,"about_ca_system_score_gemma":0.0011474219,"threshold_uncertainty_score":0.7055096},"labels":[],"label_agreement":null},{"id":"W2602730024","doi":"10.1200/jco.2017.35.6_suppl.288","title":"Long-term incidence of venous thromboembolic events following cystectomy: A population-based analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cystectomy; Pulmonary embolism; Cumulative incidence; Interquartile range; Bladder cancer; Deep vein; Incidence (geometry); Population; Surgery; Thrombosis; Internal medicine; Cohort; Cancer","score_opus":0.10413616232066382,"score_gpt":0.490483556115177,"score_spread":0.3863473937945132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602730024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658585,0.00031306408,0.00033553547,0.0008996844,0.0010086205,0.00016964806,0.000004100026,0.00000565045,0.0006778778],"genre_scores_gemma":[0.99787974,0.000067207286,0.00095826684,0.0005255714,0.00048951927,0.0000027459696,0.0000047581575,0.000012838373,0.00005934763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971156,0.00023080115,0.0018342546,0.00017340592,0.00046200212,0.00018391824],"domain_scores_gemma":[0.9954863,0.00053777144,0.0029658508,0.00046754067,0.00028223277,0.0002602833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015843713,0.00012835125,0.0022154609,0.00019506144,0.00010589654,0.000010188834,0.00030457453,0.00025973527,0.00009805068],"category_scores_gemma":[0.002342747,0.00009284223,0.0013467763,0.00013426552,0.00008850978,0.00014023065,0.0000430532,0.00042175542,0.0000070283763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009458642,0.0015554446,0.9740561,0.00002956151,0.0023798223,0.000545287,0.000038877428,0.00004099398,0.00006232621,0.0000058822843,0.000019568195,0.020320266],"study_design_scores_gemma":[0.00745832,0.0057541938,0.98070294,0.000186023,0.005414752,0.000041581017,0.000006289339,0.00006765761,0.00007194398,0.00015208035,0.00007635275,0.00006789178],"about_ca_topic_score_codex":0.0003742767,"about_ca_topic_score_gemma":0.00032828038,"teacher_disagreement_score":0.020252375,"about_ca_system_score_codex":0.00016382831,"about_ca_system_score_gemma":0.0015313092,"threshold_uncertainty_score":0.3785996},"labels":[],"label_agreement":null},{"id":"W2602732924","doi":"10.1200/jco.2007.25.18_suppl.6598","title":"Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer (MBC) with doxorubicin or pegylated liposomal doxorubicin: Development of a prediction model","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada); Regional Municipality of Durham; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Neutropenia; Febrile neutropenia; Chemotherapy; Anthracycline; Doxorubicin; Internal medicine; Oncology; Absolute neutrophil count; Surgery; Cancer; Breast cancer","score_opus":0.10344833143696708,"score_gpt":0.44303761872125735,"score_spread":0.3395892872842903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602732924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544649,0.000048937298,0.04255507,0.0010077367,0.0004811864,0.001235099,0.00014057923,0.000016632552,0.00004983485],"genre_scores_gemma":[0.9590076,0.00023942505,0.039595105,0.0003912899,0.00035373212,0.0001097623,0.000023443974,0.000042051124,0.00023757784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996424,0.00008229328,0.0025633997,0.00027005476,0.0003306804,0.00032955752],"domain_scores_gemma":[0.9947301,0.0008561148,0.0025865915,0.00018814225,0.0013497694,0.00028929638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013557831,0.00019140982,0.0011736021,0.00020462813,0.0002514282,0.000009116031,0.00014333885,0.00016735146,0.00006517797],"category_scores_gemma":[0.00018203499,0.00012618212,0.00033274846,0.00023314524,0.0001100435,0.00016310423,0.00003405865,0.00042265028,0.0000012625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18174952,0.010487446,0.61734134,0.0009112306,0.006061943,0.000035826673,0.0014691334,0.0048576905,0.042498693,0.00017546519,0.0016736028,0.13273813],"study_design_scores_gemma":[0.03478421,0.0070343018,0.9439082,0.00032797465,0.0015924625,0.0002450154,0.00009998525,0.0009968622,0.00887839,0.000083514504,0.0018952943,0.00015376644],"about_ca_topic_score_codex":0.000050118644,"about_ca_topic_score_gemma":0.0008200815,"teacher_disagreement_score":0.3265669,"about_ca_system_score_codex":0.00067832373,"about_ca_system_score_gemma":0.0016242877,"threshold_uncertainty_score":0.5145557},"labels":[],"label_agreement":null},{"id":"W2602742435","doi":"10.1200/jco.2015.33.15_suppl.e15541","title":"Is there a gender effect in bladder cancer?: A population-based study of practice and outcomes.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Cancer registry; Population; Cancer; Cohort; Proportional hazards model; Internal medicine; Gynecology; Surgery; Oncology; Environmental health","score_opus":0.18315755291984348,"score_gpt":0.5335265469531486,"score_spread":0.3503689940333051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602742435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921624,0.00089460384,0.000009073896,0.0050538955,0.00044198486,0.00039600872,0.0000027142553,0.0000029679811,0.0010363203],"genre_scores_gemma":[0.9956317,0.00007293248,0.00043294532,0.0035921661,0.00019698343,0.000009981324,4.6757378e-7,0.000011566008,0.00005123443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974116,0.00067531446,0.001290423,0.00013718761,0.0003683573,0.0001170803],"domain_scores_gemma":[0.99606615,0.002245814,0.0009924244,0.00013278113,0.00032513397,0.00023768227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023305914,0.00010811469,0.0012154757,0.00010197627,0.0000111629015,0.0000037306406,0.000062172716,0.00017747072,0.00007081619],"category_scores_gemma":[0.002951113,0.0000658725,0.0001484905,0.00011274695,0.000036260622,0.00008556319,0.000018857325,0.0004564883,0.0000018796999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053927647,0.0035686449,0.9702358,0.000019833791,0.00065515103,0.00028400696,0.000726158,0.000030732368,0.0000021694648,0.0000022972051,0.00048954645,0.01859287],"study_design_scores_gemma":[0.031199858,0.022950029,0.942743,0.000040201307,0.0009322146,0.000028967002,0.000586956,0.000042969576,0.000007887791,0.00008186021,0.0013364776,0.000049583385],"about_ca_topic_score_codex":0.0013920078,"about_ca_topic_score_gemma":0.00043155247,"teacher_disagreement_score":0.02749283,"about_ca_system_score_codex":0.00015544117,"about_ca_system_score_gemma":0.0013435468,"threshold_uncertainty_score":0.3532971},"labels":[],"label_agreement":null},{"id":"W2602744397","doi":"10.1200/jco.2017.35.4_suppl.687","title":"Application of the ASCO framework for assessing value in metastatic colorectal cancer clinical trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Alberta Children's Hospital; Foothills Medical Centre; BC Cancer Agency; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Clinical trial; Internal medicine; Oncology; Statistical significance; Quality of life (healthcare); Randomized controlled trial; Cancer; Citation; Library science","score_opus":0.4032752108834922,"score_gpt":0.5565721699143205,"score_spread":0.15329695903082824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602744397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9223079,0.0018292938,0.053998116,0.010200519,0.008058105,0.0006024995,0.00007797993,0.0000029222492,0.002922637],"genre_scores_gemma":[0.9838894,0.0012980973,0.012268601,0.00078507105,0.0016747976,0.00002665617,4.9390246e-7,0.000016903961,0.000040003473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921722,0.00042785273,0.006865846,0.0002490372,0.000055429773,0.00022962464],"domain_scores_gemma":[0.97377944,0.008223063,0.0172917,0.000379061,0.0001850522,0.00014170431],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0323125,0.00012295615,0.0028267489,0.00009542739,0.000118991695,0.000059440863,0.0007917999,0.00048424327,0.000045766825],"category_scores_gemma":[0.07286411,0.00009301853,0.0011317809,0.00006856287,0.0004254007,0.00042245485,0.00009026145,0.00093911187,0.0000075399844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007483293,0.0005029345,0.6630369,0.00002334759,0.00022782512,0.0000021944682,0.000058361977,0.00027310115,0.0000052197397,0.12728,0.0005996612,0.20724216],"study_design_scores_gemma":[0.0031101413,0.00063599495,0.7455284,0.00007309924,0.000077175995,0.0000028322363,0.000028113755,0.0023846885,0.000022389884,0.21346842,0.03457169,0.00009703744],"about_ca_topic_score_codex":0.00030826975,"about_ca_topic_score_gemma":0.00019834773,"teacher_disagreement_score":0.20714512,"about_ca_system_score_codex":0.00018208387,"about_ca_system_score_gemma":0.001013973,"threshold_uncertainty_score":0.9964379},"labels":[],"label_agreement":null},{"id":"W2602770803","doi":"10.1200/jco.2012.30.15_suppl.e15202","title":"NF-κB p65 as a prognostic tool in prostate cancer: An immunohistochemical study from biopsy samples.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Prostatectomy; Prostate cancer; Medicine; Immunohistochemistry; Tissue microarray; Biopsy; Pathology; Biochemical recurrence; Cancer; Oncology; Prostate; PCA3; Internal medicine","score_opus":0.08073663773599861,"score_gpt":0.47472602900622296,"score_spread":0.39398939127022437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602770803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427253,0.003051247,0.00029192845,0.00043951604,0.0011501859,0.00061578385,0.000022664179,0.000006250042,0.00014992067],"genre_scores_gemma":[0.99520034,0.0007694492,0.0017929764,0.00047022762,0.0015294577,0.00006651336,0.00002695288,0.00004182157,0.00010228037],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99566364,0.0009813667,0.0019023034,0.00040297952,0.00047291085,0.00057677546],"domain_scores_gemma":[0.99756056,0.00034813015,0.00088923716,0.0004371591,0.00037238415,0.000392542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033246966,0.00022492686,0.0009021902,0.0001258082,0.000046926787,0.000022497965,0.0005225801,0.0005612802,0.00016375828],"category_scores_gemma":[0.0038152877,0.00019274933,0.00029842384,0.00019579007,0.00019078229,0.00002548442,0.00025027242,0.0012149105,0.000019908222],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010428583,0.010544709,0.21485816,0.000019461095,0.00092204503,0.000604946,0.00066850975,0.00012398862,0.6651902,0.00004875855,0.0013532138,0.09523738],"study_design_scores_gemma":[0.04600253,0.07594822,0.5527934,0.00033724998,0.0010972958,0.001332302,0.003017082,0.00025561324,0.15311535,0.0017264839,0.16239706,0.0019774535],"about_ca_topic_score_codex":0.00058973185,"about_ca_topic_score_gemma":0.00024408255,"teacher_disagreement_score":0.5120749,"about_ca_system_score_codex":0.00018475468,"about_ca_system_score_gemma":0.0020829772,"threshold_uncertainty_score":0.78600895},"labels":[],"label_agreement":null},{"id":"W2602774809","doi":"10.1200/jco.2017.35.4_suppl.426","title":"Sequential treatment in patients with metastatic pancreatic neuroendocrine tumors after progression on first-line therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neuroendocrine tumors; Internal medicine; Radiation therapy; Radionuclide therapy; Chemotherapy; Gastroenterology; Oncology; Surgery","score_opus":0.11966583324612745,"score_gpt":0.4917199343949189,"score_spread":0.37205410114879145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602774809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903158,0.00013897363,0.0000034639368,0.0077921203,0.00037262932,0.0008451118,0.0000048160637,0.00000841628,0.00051866897],"genre_scores_gemma":[0.9968551,0.00081167574,0.001024085,0.0006550321,0.000361702,0.000046297264,0.0000031623335,0.000033884247,0.00020910545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964632,0.0004898207,0.0015989247,0.00030067065,0.00072111335,0.0004263041],"domain_scores_gemma":[0.99602675,0.0010305408,0.0016947456,0.00050905976,0.00028996076,0.0004489573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005265114,0.00024214915,0.0015462424,0.00021166443,0.00010060448,0.000030507013,0.00026106508,0.000017452807,0.00011568832],"category_scores_gemma":[0.0029819764,0.00012698356,0.00029413134,0.00007400266,0.00029741524,0.00023612836,0.00006832319,0.00081644906,0.0000177136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05722671,0.007978076,0.76420647,0.000030548446,0.00020470594,0.04547891,0.000014975946,0.000022885364,0.00000690208,0.0000048784423,0.00007552568,0.12474941],"study_design_scores_gemma":[0.034244724,0.12624499,0.8252538,0.00032081167,0.00012973277,0.0006237044,0.0000074785335,0.000025389325,0.00023569512,0.000072278766,0.012749494,0.00009191021],"about_ca_topic_score_codex":0.000026761392,"about_ca_topic_score_gemma":0.00014407314,"teacher_disagreement_score":0.1246575,"about_ca_system_score_codex":0.00019627593,"about_ca_system_score_gemma":0.0006013193,"threshold_uncertainty_score":0.51782393},"labels":[],"label_agreement":null},{"id":"W2602775013","doi":"10.1200/jco.2016.72.0466","title":"Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Cancer Care Ontario; American Society of Clinical Oncology; National Comprehensive Cancer Network; American Society for Radiation Oncology","keywords":"Brachytherapy; Medicine; Prostate cancer; Androgen deprivation therapy; Guideline; Randomized controlled trial; Cancer; Prostatectomy; Clinical trial; Oncology; Radiation therapy; External beam radiotherapy; Urology; Internal medicine; Pathology","score_opus":0.14532136290473507,"score_gpt":0.5150786199656193,"score_spread":0.36975725706088425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602775013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590331,0.001367092,0.000066438384,0.03569673,0.0021589298,0.0011949008,0.00017580541,0.000009138417,0.00029787407],"genre_scores_gemma":[0.91952074,0.028541071,0.037051573,0.011861967,0.0023911255,0.00018027368,0.000053246866,0.000061236344,0.000338788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99344134,0.00023420795,0.0049306797,0.00045843385,0.00050489686,0.0004304125],"domain_scores_gemma":[0.9836822,0.00093103456,0.011080778,0.0005546449,0.0031634683,0.0005878415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002701336,0.00029926072,0.0038776544,0.00004510576,0.00017306591,0.00002025641,0.0003242309,0.00038953347,0.00015756048],"category_scores_gemma":[0.000853433,0.00018363162,0.0014444903,0.0000655134,0.0010831534,0.00019144513,0.00009777458,0.0011123898,0.0000022733825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013573654,0.002587838,0.5274391,0.000047145502,0.0014387142,0.00003689085,0.00031847955,0.000017423934,0.0000034921325,0.000004645023,0.019810533,0.43472207],"study_design_scores_gemma":[0.02556778,0.042809665,0.54469657,0.00024120056,0.00085948734,0.0000063339453,0.00014360418,0.00002353917,0.000049571656,0.000040910392,0.3854457,0.00011562946],"about_ca_topic_score_codex":0.004982689,"about_ca_topic_score_gemma":0.017594226,"teacher_disagreement_score":0.43460643,"about_ca_system_score_codex":0.0011828764,"about_ca_system_score_gemma":0.011595124,"threshold_uncertainty_score":0.99400824},"labels":[],"label_agreement":null},{"id":"W2602842511","doi":"10.1200/jco.2017.35.6_suppl.482","title":"Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Chromophobe cell; Oncology; Clear cell; Cohort; Clinical trial; Cabozantinib; Blockade; Clear cell renal cell carcinoma; Urology; Receptor","score_opus":0.15790196786822377,"score_gpt":0.4646922793092297,"score_spread":0.3067903114410059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602842511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780465,0.00035724122,0.000053424228,0.002091426,0.0018760513,0.00043260158,0.000006060466,0.00000528682,0.017131414],"genre_scores_gemma":[0.99185556,0.0004028603,0.005157986,0.00033463116,0.0012745913,0.0000046562895,0.0000017399565,0.000041507334,0.00092648616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919175,0.0012752209,0.005088187,0.000468456,0.00076421,0.00048642443],"domain_scores_gemma":[0.9869881,0.0037955192,0.0069009517,0.00094329345,0.00053340656,0.00083867833],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008072344,0.00032823632,0.0037445102,0.00027855122,0.000090801484,0.000021383841,0.00058364804,0.00064108364,0.00015472477],"category_scores_gemma":[0.004017571,0.00023773534,0.0016410612,0.00012214266,0.0007909332,0.00026089622,0.00025627355,0.0025152455,0.000059573562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01362176,0.010929278,0.8878405,0.00022422896,0.00029986494,0.006989076,0.00013227227,0.000018039578,0.0077355127,0.0000061018136,0.003784795,0.06841859],"study_design_scores_gemma":[0.020340882,0.03281892,0.9230026,0.00016396967,0.0009277332,0.00020208374,0.000087489316,0.00018018954,0.017603135,0.000093788214,0.0043964144,0.0001827816],"about_ca_topic_score_codex":0.00023249861,"about_ca_topic_score_gemma":0.00010858257,"teacher_disagreement_score":0.06823581,"about_ca_system_score_codex":0.00030703546,"about_ca_system_score_gemma":0.0029494881,"threshold_uncertainty_score":0.999786},"labels":[],"label_agreement":null},{"id":"W2602918057","doi":"10.1200/jco.2013.31.15_suppl.9029","title":"Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in <i>BRAF</i> V600-dependent advanced solid tumors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; MEK inhibitor; Internal medicine; Nausea; Adverse effect; Melanoma; Oncology; Cancer; Gastroenterology; Colorectal cancer; Pharmacology; Cancer research; MAPK/ERK pathway; Kinase","score_opus":0.06499674081682533,"score_gpt":0.39974818246612964,"score_spread":0.3347514416493043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602918057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479073,0.0001108936,0.00003727478,0.0026770309,0.0007273452,0.0013396593,0.00002546452,0.0000033793483,0.0002882372],"genre_scores_gemma":[0.9982183,0.000044683315,0.000546595,0.0005821531,0.00036501364,0.000052308907,0.00002945968,0.00002258144,0.0001388996],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99490947,0.0014363647,0.0025314612,0.00040783774,0.00043618534,0.00027871496],"domain_scores_gemma":[0.9961171,0.0005471774,0.0023359358,0.00046031206,0.00039798857,0.00014145041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029694855,0.00022833103,0.000979416,0.000084254796,0.00009491513,0.000033473712,0.00076765823,0.0003774472,0.00001734058],"category_scores_gemma":[0.0014704579,0.00012963997,0.00011592057,0.00022700733,0.00019896269,0.00006721203,0.00054159935,0.00080803887,0.0000029815396],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12911075,0.10262068,0.056710735,0.00004735726,0.0007520793,0.0005155971,0.004339742,0.00159691,0.46740773,0.000094100775,0.015271024,0.22153327],"study_design_scores_gemma":[0.2772828,0.29427427,0.34751052,0.0004931377,0.00036068208,0.00017273873,0.004520745,0.0013152399,0.062757865,0.00095945573,0.009577157,0.00077536487],"about_ca_topic_score_codex":0.00031058388,"about_ca_topic_score_gemma":0.0023126039,"teacher_disagreement_score":0.40464988,"about_ca_system_score_codex":0.00007156323,"about_ca_system_score_gemma":0.0006965295,"threshold_uncertainty_score":0.5286564},"labels":[],"label_agreement":null},{"id":"W2602939951","doi":"10.1200/jco.2017.35.4_suppl.680","title":"Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Capecitabine; Medicine; Anal cancer; Internal medicine; Adverse effect; Chemoradiotherapy; Fluorouracil; Cancer; Radiation therapy; Surgery; Oncology; Colorectal cancer","score_opus":0.2865312685354337,"score_gpt":0.5472855986383289,"score_spread":0.2607543301028952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602939951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932341,0.00039296472,0.0000039998818,0.004492757,0.00031656923,0.00016693497,0.0000022511106,6.9046297e-7,0.0013897636],"genre_scores_gemma":[0.99889976,0.00046542563,0.0002904549,0.0000518229,0.00022890868,0.000004027141,0.0000011395454,0.0000039405163,0.000054518918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796474,0.00020701117,0.0013758517,0.00008700809,0.0002585595,0.00010683048],"domain_scores_gemma":[0.99617666,0.0016453621,0.0017581796,0.00015245982,0.00019861749,0.00006871165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096847117,0.00008073871,0.001206521,0.00010425274,0.000024090501,0.000003507109,0.00015176453,0.00012353681,0.000055405635],"category_scores_gemma":[0.00084831583,0.000038258404,0.00016305028,0.00010350171,0.00021865556,0.00005214628,0.000012916997,0.00031768758,4.5250698e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039795496,0.005125509,0.85033023,0.000026729618,0.00009964022,0.0005456688,0.00059074967,0.00002811221,0.00012168149,0.00007250349,0.00012247727,0.103141226],"study_design_scores_gemma":[0.025419824,0.073262714,0.89801866,0.00013022302,0.000190621,0.000043743246,0.0005336686,0.0006739889,0.00026466866,0.000029639556,0.0013972535,0.000035026595],"about_ca_topic_score_codex":0.0008758151,"about_ca_topic_score_gemma":0.022570634,"teacher_disagreement_score":0.1031062,"about_ca_system_score_codex":0.00015185462,"about_ca_system_score_gemma":0.00071276125,"threshold_uncertainty_score":0.9952649},"labels":[],"label_agreement":null},{"id":"W2602979286","doi":"10.1200/jco.2014.32.15_suppl.1031","title":"Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Cyclophosphamide; Randomized controlled trial; Chemotherapy; Mastectomy; Adjuvant; Radiation therapy; Cancer","score_opus":0.14146889658274037,"score_gpt":0.47284101024574293,"score_spread":0.33137211366300257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602979286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951722,0.0026266081,0.00067205325,0.00049503683,0.00066560484,0.00034081668,0.000011977007,8.8281683e-7,0.000014800853],"genre_scores_gemma":[0.99848354,0.00025190043,0.0003534472,0.00017197862,0.00070018345,0.000011672219,0.000009190884,0.0000094367715,0.00000863276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979968,0.00078939035,0.00075324206,0.00016121888,0.000195697,0.00010366568],"domain_scores_gemma":[0.9977904,0.00049460476,0.0011683123,0.00014819959,0.00033886594,0.000059622864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027827937,0.00011724852,0.0005447343,0.00002523623,0.000058071288,0.0000037929394,0.0000898669,0.00024380596,0.000003013791],"category_scores_gemma":[0.001332468,0.0000660571,0.00037049776,0.000026350363,0.00015068449,0.000005292039,0.000044727796,0.00010529935,1.7888698e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011441549,0.0002472682,0.67203367,0.000012734565,0.0006027661,7.219637e-7,0.000017310222,0.00046829836,0.010147169,0.0000044830667,0.000075920325,0.3152455],"study_design_scores_gemma":[0.009122811,0.0049890825,0.9759522,0.000018842704,0.0014596373,0.000060900675,0.00000529669,0.00043096818,0.0066455016,0.00008033341,0.0011646966,0.00006969186],"about_ca_topic_score_codex":0.000006430095,"about_ca_topic_score_gemma":0.00010788282,"teacher_disagreement_score":0.31517583,"about_ca_system_score_codex":0.0001420967,"about_ca_system_score_gemma":0.000392955,"threshold_uncertainty_score":0.26937306},"labels":[],"label_agreement":null},{"id":"W2602982162","doi":"10.1200/jco.2012.30.15_suppl.516","title":"Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Exemestane; Cohort; Chemotherapy; Breast cancer; Tamoxifen; Multivariate analysis; Cancer","score_opus":0.09514570156451081,"score_gpt":0.47282625460287575,"score_spread":0.37768055303836495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602982162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555516,0.0007961195,0.00087314594,0.00067520817,0.0011640849,0.0006575885,0.000017178647,0.000007217502,0.00025429743],"genre_scores_gemma":[0.99089473,0.00013818343,0.0069119744,0.00046131184,0.0014961063,0.00003173901,0.0000041285193,0.000019252037,0.00004255804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560815,0.0013830825,0.0022366743,0.00016462263,0.00032274605,0.0002847011],"domain_scores_gemma":[0.9940532,0.0031826792,0.0018771371,0.00031785504,0.0003681716,0.00020099299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010375561,0.00013512453,0.0011335247,0.000105853185,0.0000401237,0.0000028608915,0.00023874221,0.00041000382,0.000029234598],"category_scores_gemma":[0.0054330877,0.000083979205,0.00032214227,0.00012132557,0.0003058129,0.00021398632,0.00002797763,0.0012995248,0.0000035709047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024966888,0.011501771,0.78777814,0.000018990879,0.0003320925,0.00010129165,0.0045314305,0.000012959678,0.00991817,0.00007476951,0.00022449567,0.16053899],"study_design_scores_gemma":[0.014326379,0.040403742,0.9325377,0.000036191264,0.0004363628,0.000893076,0.0025468285,0.000022906912,0.0003109269,0.0007567204,0.007660228,0.0000689665],"about_ca_topic_score_codex":0.000038558315,"about_ca_topic_score_gemma":0.000021565198,"teacher_disagreement_score":0.16047002,"about_ca_system_score_codex":0.00016105949,"about_ca_system_score_gemma":0.0005223439,"threshold_uncertainty_score":0.6504306},"labels":[],"label_agreement":null},{"id":"W2602985853","doi":"10.1200/jco.2012.30.15_suppl.6039","title":"Do patient-reported symptoms predict for emergency department visits? A population-based analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Queen's University; McMaster University; Institute for Clinical Evaluative Sciences; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Emergency department; Cohort; Depression (economics); Nausea; Ambulatory; Logistic regression; Anxiety; Population; Emergency medicine; Pediatrics; Internal medicine; Psychiatry","score_opus":0.08424802816907821,"score_gpt":0.4574714629781462,"score_spread":0.373223434809068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602985853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991567,0.00097493886,0.0026082743,0.0013018859,0.0043271407,0.00033017655,0.000016122085,0.000013277702,0.0005125082],"genre_scores_gemma":[0.9959001,0.00007262966,0.00094011193,0.0011016936,0.0018208128,0.000020987061,0.000052356118,0.000014886195,0.00007645155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960035,0.00025390653,0.0028354821,0.00016347003,0.0004545143,0.00028909434],"domain_scores_gemma":[0.995423,0.000896783,0.0022340321,0.00024128758,0.0006271862,0.0005776756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002485569,0.00013153914,0.001349696,0.00022285657,0.000043479788,0.0000048766806,0.00008732475,0.00029380247,0.0005252777],"category_scores_gemma":[0.0021111732,0.00009453142,0.0013855047,0.00035614887,0.000026002706,0.00009915931,0.000017770903,0.00035565326,0.0000041242347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021746783,0.0013164929,0.93657035,0.000023693055,0.002168261,0.000027606908,0.00008768527,0.00008564748,0.0000071155173,0.00003944289,0.0024703294,0.05502873],"study_design_scores_gemma":[0.0033523524,0.006298991,0.92177737,0.000025255353,0.0053746966,0.000031009295,0.00006920256,0.00028853395,0.000017621573,0.00007588711,0.06259652,0.0000925369],"about_ca_topic_score_codex":0.000056345416,"about_ca_topic_score_gemma":0.00022995123,"teacher_disagreement_score":0.060126193,"about_ca_system_score_codex":0.00019136343,"about_ca_system_score_gemma":0.0005961461,"threshold_uncertainty_score":0.57514226},"labels":[],"label_agreement":null},{"id":"W2602996125","doi":"10.1200/jco.2012.30.15_suppl.e19570","title":"Pain severity and impairment of activity between pegfilgrastim (P) and fixed-dose filgrastim (F) in women with early-stage breast cancer receiving chemotherapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Chemotherapy; Febrile neutropenia; Pegfilgrastim; Chemotherapy regimen; Regimen; Docetaxel; Oncology; Neutropenia; Cancer","score_opus":0.05266422955596968,"score_gpt":0.41324417842477457,"score_spread":0.3605799488688049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602996125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958767,0.00014987944,0.00010502766,0.0033643723,0.00015960715,0.000190093,0.000017722474,0.000005004589,0.00013157562],"genre_scores_gemma":[0.99755645,0.0007872629,0.0005045533,0.0005194132,0.00055206555,0.0000110614565,2.8200418e-7,0.000014078397,0.000054836015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981057,0.0004341024,0.00082572614,0.00014455512,0.00019977432,0.00029010858],"domain_scores_gemma":[0.9973189,0.0011843735,0.0008176892,0.0001064271,0.00012993721,0.00044262674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003658178,0.00013202833,0.0011142901,0.00010342078,0.000034713146,0.000006435916,0.000054545468,0.00019574385,0.0001775611],"category_scores_gemma":[0.00023506359,0.00009160597,0.00008050318,0.0001498427,0.00024340786,0.00019297452,0.000038766477,0.0007776652,4.2144887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004701895,0.0006999702,0.80172646,0.000060424514,0.00018769079,0.000019780828,0.0004112274,0.0000027794206,0.00026733073,0.00000123812,0.00012128473,0.19179991],"study_design_scores_gemma":[0.005867826,0.006132256,0.9851748,0.00019325387,0.000120448996,0.00017449544,0.00015674997,0.000014098621,0.000071194416,0.000018900657,0.0019881,0.00008790279],"about_ca_topic_score_codex":0.00033619875,"about_ca_topic_score_gemma":0.0001707358,"teacher_disagreement_score":0.191712,"about_ca_system_score_codex":0.0002254396,"about_ca_system_score_gemma":0.00054355816,"threshold_uncertainty_score":0.3735583},"labels":[],"label_agreement":null},{"id":"W2602997871","doi":"10.1200/jco.2017.35.4_suppl.468","title":"Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Oncology; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Cancer registry; Cancer; Irinotecan","score_opus":0.18525829124870785,"score_gpt":0.5277965098304092,"score_spread":0.3425382185817013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602997871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444103,0.00054756727,0.000035392633,0.001954316,0.0004196346,0.0003359062,0.000002369246,0.0000038850544,0.002259917],"genre_scores_gemma":[0.9913887,0.0030211285,0.00408744,0.00008702877,0.0006328283,0.000011363374,8.482977e-7,0.00001383527,0.00075687823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639344,0.00032740255,0.002451557,0.0002043826,0.00031668367,0.00030651165],"domain_scores_gemma":[0.9946172,0.0019112658,0.0024511772,0.00029225816,0.0004144104,0.00031367128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024125825,0.00015225168,0.0025905466,0.00019626756,0.000100127945,0.000006716233,0.00023579251,0.00041393237,0.00015960688],"category_scores_gemma":[0.007920638,0.000103322665,0.00038536626,0.000080729,0.0004252306,0.00014929418,0.000057212546,0.0006087274,0.000012987205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007029175,0.0023018012,0.93043995,0.000052787516,0.00022793947,0.0013335228,0.00009895547,0.0000055526266,0.00019275633,0.000011957079,0.000078312034,0.05822727],"study_design_scores_gemma":[0.016072288,0.03762949,0.9415665,0.0002302144,0.0005510511,0.0009825461,0.000076422395,0.0010221222,0.000249442,0.0002662918,0.0012820803,0.00007153813],"about_ca_topic_score_codex":0.00022066038,"about_ca_topic_score_gemma":0.0013128518,"teacher_disagreement_score":0.05815573,"about_ca_system_score_codex":0.0003637081,"about_ca_system_score_gemma":0.0018721467,"threshold_uncertainty_score":0.9482316},"labels":[],"label_agreement":null},{"id":"W2603035054","doi":"10.1200/jco.2017.35.4_suppl.710","title":"Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"FOLFOX; Medicine; Colorectal cancer; Internal medicine; Stage (stratigraphy); Proportional hazards model; Gastroenterology; Adjuvant; Log-rank test; Oncology; Oxaliplatin; Adjuvant therapy; Cancer; Surgery","score_opus":0.33497542999812235,"score_gpt":0.5879059547650127,"score_spread":0.2529305247668904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603035054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643124,0.0023028846,9.369816e-7,0.0035703797,0.0013488188,0.0002560774,0.000029390298,0.000001225994,0.0060590594],"genre_scores_gemma":[0.9915113,0.0076705725,0.000055430075,0.00004171473,0.0005226291,0.000009264101,9.524497e-7,0.0000065605823,0.00018157842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775034,0.00023790589,0.0014234975,0.000116872776,0.00029233508,0.00017903402],"domain_scores_gemma":[0.995203,0.0018265255,0.0023009023,0.0002847868,0.0002748711,0.00010989784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012375063,0.00013165465,0.0019277651,0.000059832604,0.00006326331,0.0000047989565,0.00019932487,0.00015053911,0.000107686865],"category_scores_gemma":[0.0010890102,0.0000624293,0.00072384183,0.00005236624,0.00035011058,0.000053310887,0.000037796966,0.00024999195,7.0430383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06364481,0.005358395,0.72835106,0.00002685512,0.0026115146,0.0008068806,0.0014904382,0.000037506066,0.00014839547,0.000069737216,0.0008627831,0.19659163],"study_design_scores_gemma":[0.028078867,0.08479555,0.88049376,0.00006087864,0.00059671915,0.000015706502,0.00052483816,0.000015577509,0.00007646882,0.000030829768,0.005266272,0.000044529548],"about_ca_topic_score_codex":0.005181595,"about_ca_topic_score_gemma":0.0073230974,"teacher_disagreement_score":0.19654709,"about_ca_system_score_codex":0.00051932724,"about_ca_system_score_gemma":0.0017058755,"threshold_uncertainty_score":0.78330564},"labels":[],"label_agreement":null},{"id":"W2603037406","doi":"10.1200/jco.2009.27.15_suppl.9555","title":"Childhood, adolescent, and young adult cancer survivors (CAYACS) research program of British Columbia: Data linkage: Results to date","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Interior Health","funders":"","keywords":"Medicine; Population; Pediatrics; Cohort; Retrospective cohort study; Record linkage; Cohort study; Cancer; Demography; Odds ratio; Gerontology; Surgery; Internal medicine; Environmental health","score_opus":0.23085049764369395,"score_gpt":0.5394144573209293,"score_spread":0.3085639596772354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603037406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95464724,0.0017414481,0.000019828743,0.038916804,0.0015997479,0.0010666338,0.000353908,0.000032904416,0.0016214935],"genre_scores_gemma":[0.9704665,0.00937113,0.00780136,0.007581472,0.0038784838,0.000009242784,0.000052018077,0.000040785722,0.00079901755],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9905263,0.0017561455,0.0047833165,0.0007490063,0.0015324651,0.0006527197],"domain_scores_gemma":[0.99113333,0.0021036146,0.0020527248,0.0010634001,0.0024477337,0.0011992153],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019474197,0.00018416737,0.0023494912,0.00018817927,0.000105511324,0.000091367525,0.0009632654,0.00059992535,0.000051992316],"category_scores_gemma":[0.024602156,0.00021679045,0.00028559254,0.00066121155,0.00055800634,0.00028799975,0.00047046022,0.0029773342,0.000007770486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035293084,0.0065083727,0.19124767,0.00016592968,0.00034369525,0.0005530454,0.0005531281,0.0000025815075,0.000029708623,0.0000068547683,0.2010306,0.5960291],"study_design_scores_gemma":[0.010013653,0.016997585,0.8928436,0.0018543522,0.0002507045,0.0006185664,0.00054016715,0.000036105648,0.000008870167,0.00012402252,0.076525815,0.00018654726],"about_ca_topic_score_codex":0.046198733,"about_ca_topic_score_gemma":0.31051707,"teacher_disagreement_score":0.70159596,"about_ca_system_score_codex":0.0001223091,"about_ca_system_score_gemma":0.0028969317,"threshold_uncertainty_score":0.99932283},"labels":[],"label_agreement":null},{"id":"W2603040888","doi":"10.1200/jco.2013.31.15_suppl.9625","title":"Population-based patterns of granulocyte colony stimulating factor (GCSF) use in breast cancer (BrCa) patients receiving myelosuppressive chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Cohort; Population; Febrile neutropenia; Chemotherapy; Granulocyte colony-stimulating factor; Breast cancer; Cancer; Surgery","score_opus":0.07686670506647694,"score_gpt":0.42493043319335544,"score_spread":0.34806372812687847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603040888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957385,0.000020507336,0.00010686193,0.002791353,0.0008533604,0.0003821236,0.000027540445,0.000007288662,0.00007243209],"genre_scores_gemma":[0.99718416,0.00010772562,0.0004732355,0.0017077717,0.00041227048,0.000016996477,0.0000061740975,0.00002267742,0.000068987836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969783,0.00029883182,0.0020176796,0.00017206285,0.00032216427,0.000210981],"domain_scores_gemma":[0.9951887,0.0017252301,0.0019079036,0.0001552561,0.000804462,0.00021844843],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041004963,0.0001374828,0.0011633051,0.00016928586,0.000034717745,0.0000129406335,0.000106765365,0.00025854958,0.0011077798],"category_scores_gemma":[0.0008516176,0.00010415101,0.00031012026,0.00015363967,0.0000565013,0.00026691987,0.000022117334,0.00069466897,0.0000039562387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010274426,0.0009033759,0.92808586,0.000037936832,0.000103557286,0.000012148192,0.000056739613,0.0007030896,0.00039098374,0.0000015677278,0.00027474973,0.068402536],"study_design_scores_gemma":[0.009533133,0.0017891639,0.98688763,0.00040273796,0.000096532705,0.000014857554,0.000019544126,0.00046161033,0.00012247336,0.000017199472,0.00056435645,0.000090765105],"about_ca_topic_score_codex":0.0028975243,"about_ca_topic_score_gemma":0.00085773785,"teacher_disagreement_score":0.06831177,"about_ca_system_score_codex":0.00030649084,"about_ca_system_score_gemma":0.0007546668,"threshold_uncertainty_score":0.99980533},"labels":[],"label_agreement":null},{"id":"W2603044866","doi":"10.1200/jco.2017.35.4_suppl.tps213","title":"Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Nivolumab; Oxaliplatin; Internal medicine; Ipilimumab; Cancer; Oncology; Phases of clinical research; Chemotherapy; Gastroenterology; Immunotherapy; Colorectal cancer","score_opus":0.17996224090925803,"score_gpt":0.49461280046324624,"score_spread":0.31465055955398824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603044866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224037,0.00017339225,0.00018848323,0.0005010947,0.0020277435,0.0045905793,0.000013371936,0.00001733931,0.0002476202],"genre_scores_gemma":[0.99229056,0.0008945106,0.005064551,0.00018003074,0.00028745495,0.0001313664,0.000015258396,0.00005094325,0.0010853579],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99274087,0.0010082163,0.0042559295,0.0005278055,0.00088082463,0.00058632705],"domain_scores_gemma":[0.9892353,0.0018747525,0.00697,0.000648408,0.0008365432,0.00043502648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035264422,0.0004522796,0.0050412463,0.00041499845,0.0001677329,0.00007304978,0.00077103375,0.00016991183,0.00037363527],"category_scores_gemma":[0.006353653,0.00026497224,0.00029392983,0.0003996088,0.00035983374,0.00065787183,0.00034153543,0.0009212469,0.000005905172],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8603674,0.015040012,0.031837065,0.00017060777,0.002143394,0.0013328667,0.00045374376,0.00041433473,0.0000081743965,0.0000022146019,0.00042148362,0.08780867],"study_design_scores_gemma":[0.82902145,0.11596982,0.046100844,0.0004915505,0.004177151,0.00003727033,0.00086497026,0.0029258968,0.000012363765,0.000002936682,0.0002209442,0.00017476917],"about_ca_topic_score_codex":0.001113115,"about_ca_topic_score_gemma":0.0035971794,"teacher_disagreement_score":0.10092981,"about_ca_system_score_codex":0.0012118502,"about_ca_system_score_gemma":0.0024247256,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W2603056587","doi":"10.1200/jco.2014.32.15_suppl.1058","title":"Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Eribulin; Taxane; Febrile neutropenia; Mucositis; Neutropenia; Anthracycline; Clinical endpoint; Cyclophosphamide; Gastroenterology; Chemotherapy; Surgery; Oncology; Cancer; Metastatic breast cancer; Clinical trial","score_opus":0.05818724985628228,"score_gpt":0.4897362801187247,"score_spread":0.43154903026244246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603056587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96716404,0.0006737357,0.00034352895,0.027929815,0.0010875922,0.0024433404,0.000027810553,0.000024596138,0.00030552718],"genre_scores_gemma":[0.9761245,0.005067744,0.006619383,0.0088858465,0.0017537987,0.0002957639,0.0000066893463,0.00007715244,0.0011690833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898903,0.0033364724,0.004684215,0.0006995883,0.00066502084,0.000724424],"domain_scores_gemma":[0.9810283,0.013017861,0.004066813,0.0003030764,0.00066342537,0.00092048646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.014799401,0.0005224044,0.006007043,0.00016577441,0.000120361845,0.000020513897,0.00022876341,0.0005959865,0.000600713],"category_scores_gemma":[0.0037768576,0.00028957915,0.00045637912,0.00036773933,0.0012022821,0.00021014182,0.00006507953,0.0018172974,0.0000032044875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70386887,0.00885731,0.0028033264,0.000026961605,0.0015235223,0.00036447507,0.0005708588,0.000027121265,0.00034402215,0.000004735477,0.001958588,0.2796502],"study_design_scores_gemma":[0.75207436,0.22951601,0.0061284103,0.00047864774,0.0011016557,0.0003010801,0.0003391967,0.00050291535,0.00010931233,0.00010205337,0.0090687,0.00027766553],"about_ca_topic_score_codex":0.00024135537,"about_ca_topic_score_gemma":0.0006381234,"teacher_disagreement_score":0.27937254,"about_ca_system_score_codex":0.00059516926,"about_ca_system_score_gemma":0.0038702236,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W2603065283","doi":"10.1200/jco.2012.30.15_suppl.538","title":"Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Sunnybrook Health Science Centre; University of Toronto; Jewish General Hospital; McGill University; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Tamoxifen; Oncology; Cancer; Lymph node; Gynecology; Gastroenterology","score_opus":0.21124170815959886,"score_gpt":0.5099281700844166,"score_spread":0.29868646192481774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603065283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761761,0.014124211,0.00000897611,0.0068385503,0.001544242,0.00062293495,0.0000548712,0.0000048184875,0.00062531384],"genre_scores_gemma":[0.9700728,0.027550027,0.0005776978,0.00051742117,0.0011225578,0.000030810224,0.0000020313985,0.000018770968,0.0001078712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993773,0.0015727142,0.0037520037,0.00020897506,0.00035360572,0.0003397065],"domain_scores_gemma":[0.98435956,0.011892402,0.002768642,0.00017624891,0.00022609912,0.0005770231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013640074,0.0002094823,0.0051938468,0.0001849893,0.000025393916,0.000009515309,0.00008800452,0.00031500918,0.00028454795],"category_scores_gemma":[0.0061161737,0.00013266498,0.00068832806,0.00012184788,0.00040056286,0.00016479344,0.00006753568,0.00062641304,0.0000032298055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3402765,0.0021906178,0.57219994,0.000087854474,0.0015050235,0.0002699799,0.00041796657,0.0000062780437,0.000068593195,0.00013210902,0.0013826169,0.081462495],"study_design_scores_gemma":[0.40129948,0.0032228527,0.58491045,0.00028685233,0.0017698738,0.00013996288,0.00007023548,0.00001796675,0.0001473678,0.00008880124,0.007943345,0.00010282795],"about_ca_topic_score_codex":0.00087206543,"about_ca_topic_score_gemma":0.0003622963,"teacher_disagreement_score":0.08135967,"about_ca_system_score_codex":0.0002109379,"about_ca_system_score_gemma":0.0007451457,"threshold_uncertainty_score":0.7322073},"labels":[],"label_agreement":null},{"id":"W2603065939","doi":"10.1200/jco.2017.35.6_suppl.42","title":"Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Radiation therapy; Brachytherapy; Cancer; Prostate; Internal medicine; Stage (stratigraphy); Oncology; Urology; Surgery","score_opus":0.12701812990568495,"score_gpt":0.5263233611163263,"score_spread":0.3993052312106413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603065939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893374,0.002325428,0.000040530962,0.0060687517,0.0013639145,0.00065492984,0.000032472508,0.000004639131,0.00017196678],"genre_scores_gemma":[0.9684235,0.03027187,0.00037948266,0.00026978835,0.00037537783,0.00003091769,0.0000040192326,0.000012715021,0.00023234519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978787,0.0002879817,0.0012040085,0.00017114516,0.00024060086,0.00021761481],"domain_scores_gemma":[0.99382216,0.0027213532,0.0026835108,0.00018706138,0.00037710596,0.0002088286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029052452,0.00012282135,0.0015467231,0.00007976966,0.00012958319,0.00001586789,0.00016734548,0.00023773756,0.000017934899],"category_scores_gemma":[0.0055565853,0.00007097557,0.00047263099,0.000036288322,0.00036876104,0.00015475965,0.00004634927,0.0004602486,6.537226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011872371,0.00034679516,0.5522653,0.000027168955,0.0006832662,0.000049282004,0.00015563301,0.0000017039712,0.00008065373,0.0000035432508,0.0001508397,0.43436342],"study_design_scores_gemma":[0.033089172,0.013376503,0.9458129,0.00009599872,0.00016364614,0.0000068443032,0.00011315408,0.000091661714,0.0008592741,0.0004389127,0.0058850423,0.00006692607],"about_ca_topic_score_codex":0.00009120387,"about_ca_topic_score_gemma":0.00008975711,"teacher_disagreement_score":0.43429652,"about_ca_system_score_codex":0.00017476604,"about_ca_system_score_gemma":0.0014709801,"threshold_uncertainty_score":0.6652153},"labels":[],"label_agreement":null},{"id":"W2603066322","doi":"10.1200/jco.2013.31.15_suppl.3511","title":"Analysis of <i>KRAS/NRAS</i> and <i>BRAF</i> mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; FOLFOX; Medicine; Colorectal cancer; Internal medicine; Oncology; Panitumumab; Exon; Cancer; Oxaliplatin; Biology; Genetics","score_opus":0.16159965448711822,"score_gpt":0.5046622561647532,"score_spread":0.343062601677635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603066322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931172,0.0015915048,0.000040246076,0.002615286,0.0003664226,0.0018692171,0.000058655176,0.000004077082,0.0003373484],"genre_scores_gemma":[0.9973404,0.001512184,0.00032131412,0.00024023664,0.0001456943,0.00034579932,0.000012824057,0.000013466954,0.000068097834],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9963959,0.00034234053,0.0023849853,0.00025507182,0.00038119146,0.00024053834],"domain_scores_gemma":[0.99105024,0.006209343,0.0017930444,0.00018459829,0.000603983,0.00015880496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010967712,0.0002282447,0.0026850705,0.0002895716,0.00009159861,0.000010261901,0.0001418218,0.000115054245,0.00011208761],"category_scores_gemma":[0.001083345,0.00012749169,0.00064154563,0.0005502047,0.0002606438,0.00010062972,0.000043475276,0.0002620873,9.2589977e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.142695,0.102337874,0.17553224,0.00017445497,0.08573117,0.00070791837,0.02995882,0.0017733693,0.00047467428,0.00010889524,0.0012908643,0.45921472],"study_design_scores_gemma":[0.25696352,0.36494467,0.2974908,0.00009896524,0.056394305,0.00006530663,0.016680347,0.0023748036,0.00029671137,0.0002551239,0.004169989,0.00026545618],"about_ca_topic_score_codex":0.0028320039,"about_ca_topic_score_gemma":0.018341824,"teacher_disagreement_score":0.45894927,"about_ca_system_score_codex":0.00036557182,"about_ca_system_score_gemma":0.0009799857,"threshold_uncertainty_score":0.9995709},"labels":[],"label_agreement":null},{"id":"W2603068525","doi":"10.1200/jco.2012.30.15_suppl.e19527","title":"Palliative inpatient chemotherapy: Clinical benefit or harm?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Palliative care; Lung cancer; Performance status; Cancer; Regimen; Chemotherapy; Internal medicine","score_opus":0.35669271422426807,"score_gpt":0.5980000917517748,"score_spread":0.24130737752750675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603068525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696599,0.0011911392,0.000063537904,0.015852572,0.0066799503,0.00029353026,0.000005708136,0.000014132248,0.006239516],"genre_scores_gemma":[0.95673794,0.0055097262,0.0042938194,0.021273749,0.009401963,0.000008059881,0.000004674464,0.000026516167,0.0027435436],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956671,0.00042434386,0.0030428874,0.00017313332,0.00031468083,0.00037788207],"domain_scores_gemma":[0.9926888,0.003776295,0.00207791,0.0001679057,0.00041524513,0.00087389234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037544298,0.00017570655,0.0018856607,0.000093588525,0.000038294587,0.0000045729485,0.00014999461,0.00053415424,0.003027788],"category_scores_gemma":[0.0014825406,0.00010438917,0.00081981794,0.00014288278,0.00026011543,0.00013730788,0.000048271893,0.0012399759,0.00011341645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020852873,0.011119608,0.6108832,0.000016955779,0.0012652108,0.00022059944,0.00033458683,0.0000010488469,0.000032952656,0.00010291168,0.050889555,0.30428055],"study_design_scores_gemma":[0.014556244,0.024751494,0.4693545,0.000033782122,0.0005978698,0.0001329736,0.000060463346,0.0000107566275,0.00007880856,0.00008568947,0.49026188,0.0000755507],"about_ca_topic_score_codex":0.000008344807,"about_ca_topic_score_gemma":0.000016088194,"teacher_disagreement_score":0.4393723,"about_ca_system_score_codex":0.00023572108,"about_ca_system_score_gemma":0.0013249628,"threshold_uncertainty_score":0.99788356},"labels":[],"label_agreement":null},{"id":"W2603081877","doi":"10.1200/jco.2014.32.15_suppl.6516","title":"Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Ottawa Hospital; BC Cancer Agency; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Oxaliplatin; Internal medicine; Stage (stratigraphy); Radiation therapy; Chemotherapy; Breast cancer; Anemia; Cancer registry; Surgery; Oncology","score_opus":0.08939989647489553,"score_gpt":0.48636731211729756,"score_spread":0.396967415642402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603081877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898172,0.000190309,0.000701171,0.002779216,0.004006595,0.00057391217,0.000009038442,0.00001398193,0.0019085904],"genre_scores_gemma":[0.9860557,0.0006359912,0.010834343,0.0012148503,0.0010146751,0.000025011575,0.0000075415055,0.000028835098,0.00018306577],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941697,0.00049513415,0.004232964,0.00030756515,0.0004939903,0.00030061603],"domain_scores_gemma":[0.9860556,0.008230211,0.0037057262,0.00023356536,0.0012964312,0.0004784375],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003812714,0.00020249859,0.0028337676,0.00010709057,0.000038162507,0.000005571862,0.00019930759,0.0005014249,0.00007145362],"category_scores_gemma":[0.020715231,0.00014201505,0.0012412601,0.00015952134,0.00020742614,0.0001414792,0.00005030616,0.0007151118,0.000005409669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066654976,0.0013534938,0.4738147,0.000026088639,0.000320716,0.000009890199,0.000017915832,0.000020945956,0.000011386125,0.000022330672,0.00030706025,0.51742995],"study_design_scores_gemma":[0.027542131,0.048685778,0.8945712,0.00019472891,0.0005008248,0.0000132188725,0.000015830692,0.00026705206,0.000078866535,0.00042510955,0.027587522,0.00011774791],"about_ca_topic_score_codex":0.000027795928,"about_ca_topic_score_gemma":0.000100337995,"teacher_disagreement_score":0.5173122,"about_ca_system_score_codex":0.00029603567,"about_ca_system_score_gemma":0.0012543882,"threshold_uncertainty_score":0.9875337},"labels":[],"label_agreement":null},{"id":"W2603119564","doi":"10.1200/jco.2017.35.6_suppl.e577","title":"A probabilistic threshold analysis of metformin (Met) with enzalutamide (Enza) to determine the cost and added efficacy needed to make such a combination theray cost-effective (CE).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Actuarial science; Willingness to pay; Economics; Microeconomics","score_opus":0.5079145955296129,"score_gpt":0.5486966992521218,"score_spread":0.0407821037225089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603119564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666204,0.00017513636,0.0024318786,0.0264894,0.0004301351,0.0027738034,0.00006871397,0.000005812936,0.0010047207],"genre_scores_gemma":[0.988961,0.000059292604,0.002462149,0.007973737,0.00026581358,0.00016780975,0.0000037095197,0.000020089386,0.000086439286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99184906,0.0008376578,0.006413523,0.0003979226,0.00018710925,0.00031474387],"domain_scores_gemma":[0.97565126,0.013139482,0.009624087,0.0006934098,0.0004646078,0.00042713137],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.042262096,0.0001978803,0.0031413436,0.0005837272,0.00023568986,0.0000976777,0.00062555977,0.00025229566,0.000078924604],"category_scores_gemma":[0.03735772,0.0001484252,0.00037524753,0.00034706228,0.0002831975,0.00027166153,0.00012116075,0.00047766592,0.000033880846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010764804,0.0048680534,0.6335009,0.00034845166,0.010992492,0.00006726683,0.011009757,0.011521305,0.0000677418,0.052561015,0.0057243975,0.25857383],"study_design_scores_gemma":[0.0068639186,0.0068533774,0.9536728,0.00012784128,0.00071043917,0.000027729468,0.0010087376,0.007941155,0.000022616081,0.0030902205,0.019407261,0.00027385974],"about_ca_topic_score_codex":0.0004466993,"about_ca_topic_score_gemma":0.0023520875,"teacher_disagreement_score":0.32017195,"about_ca_system_score_codex":0.00042733896,"about_ca_system_score_gemma":0.00046755018,"threshold_uncertainty_score":0.9861927},"labels":[],"label_agreement":null},{"id":"W2603127297","doi":"10.1200/jco.2017.35.4_suppl.195","title":"Recurrence patterns in esophageal cancer patients undergoing curative trimodality therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Carboplatin; Esophagus; Adenocarcinoma; Esophageal cancer; Cancer; Surgery; Median follow-up; Chemotherapy; Internal medicine; Cisplatin","score_opus":0.22973265901647094,"score_gpt":0.5525545086871854,"score_spread":0.3228218496707144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603127297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892736,0.0018536288,0.00002548313,0.006420377,0.0009853159,0.00030097092,0.000013279624,0.0000030198323,0.0011243445],"genre_scores_gemma":[0.99136585,0.006981361,0.0001475447,0.000779828,0.0005843353,0.000013005147,0.0000021955211,0.000009467989,0.000116431715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723864,0.0004627303,0.0013719576,0.00020154868,0.0004484943,0.00027664492],"domain_scores_gemma":[0.9959474,0.0012518528,0.0017129433,0.00026143598,0.00044148974,0.00038484466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019113724,0.00012507488,0.001035359,0.0000826447,0.00009863111,0.000023868439,0.00027443055,0.00019424796,0.00018967362],"category_scores_gemma":[0.0040019793,0.00008138719,0.00029834607,0.00004869988,0.00016763697,0.00024987265,0.00007040559,0.0010390924,0.000008350654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035357955,0.0019095786,0.7785595,0.000014232592,0.00015390091,0.00076576276,0.00009159899,0.0000012829738,0.0000010858957,0.000040647243,0.00028024582,0.21464635],"study_design_scores_gemma":[0.018694814,0.013745211,0.9657824,0.00022206795,0.000038800565,0.000013212784,0.000027461021,0.000015076436,0.000105880594,0.00050987845,0.0007889787,0.00005622593],"about_ca_topic_score_codex":0.0003372502,"about_ca_topic_score_gemma":0.001019191,"teacher_disagreement_score":0.21459013,"about_ca_system_score_codex":0.00042810902,"about_ca_system_score_gemma":0.0030624033,"threshold_uncertainty_score":0.54325724},"labels":[],"label_agreement":null},{"id":"W2603133327","doi":"10.1200/jco.2017.35.4_suppl.719","title":"Impact of time to surgery in locally advanced rectal cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Hazard ratio; Colorectal cancer; Surgery; Proportional hazards model; Incidence (geometry); Cancer; Neoadjuvant therapy; Retrospective cohort study; Internal medicine; Confidence interval; Breast cancer","score_opus":0.11648017226888761,"score_gpt":0.5223361717053068,"score_spread":0.40585599943641915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603133327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923171,0.00013233462,0.000002712827,0.0017030289,0.00084962434,0.00024772118,0.000010915668,0.0000036719548,0.004732892],"genre_scores_gemma":[0.99831474,0.00032874948,0.00034736918,0.0003175723,0.00033819847,0.00000782673,0.0000015027764,0.000015479178,0.00032854528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968462,0.0002133147,0.002131715,0.00018569587,0.00036443205,0.00025862743],"domain_scores_gemma":[0.9942614,0.00215496,0.002204617,0.00027032068,0.00061659963,0.0004921357],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015997192,0.0001405833,0.0020950816,0.00017055387,0.000028590957,0.0000065585646,0.00020756123,0.00025686447,0.00089876226],"category_scores_gemma":[0.010903309,0.000093778326,0.0008739359,0.00011718896,0.0001625145,0.00015095223,0.00009197774,0.0005339448,0.000047214486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015124121,0.0017878069,0.674984,0.000008313748,0.00021916493,0.00031117472,0.00001835835,0.00003497118,0.000071687515,3.837129e-7,0.0015366984,0.30590332],"study_design_scores_gemma":[0.007601277,0.01843897,0.969339,0.0002976165,0.000097364486,0.000026374031,0.0000024090268,0.000019085455,0.00006335089,0.00002957934,0.004007275,0.00007766591],"about_ca_topic_score_codex":0.00023480276,"about_ca_topic_score_gemma":0.00015624822,"teacher_disagreement_score":0.30582565,"about_ca_system_score_codex":0.0006559937,"about_ca_system_score_gemma":0.0026083423,"threshold_uncertainty_score":0.9974283},"labels":[],"label_agreement":null},{"id":"W2603154585","doi":"10.1200/jco.2006.24.18_suppl.17035","title":"Prognostic value of baseline inflammatory markers in inoperable non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Univariate analysis; Lung cancer; Cohort; White blood cell; Multivariate analysis; C-reactive protein; Survival analysis; Stage (stratigraphy); Log-rank test; Oncology; Inflammation","score_opus":0.01766781058340602,"score_gpt":0.3431681046142711,"score_spread":0.3255002940308651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603154585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840234,0.0058414433,0.00048299847,0.00034177845,0.0066113346,0.00021386435,0.000009449065,0.0000020457558,0.002473685],"genre_scores_gemma":[0.97503763,0.004383349,0.0022301269,0.0007224538,0.016772965,0.0000152456905,0.000008766605,0.0000260367,0.00080343965],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968914,0.00042712723,0.0020191963,0.00022002097,0.00017174052,0.00027055392],"domain_scores_gemma":[0.99778897,0.00034451118,0.001195014,0.00019040307,0.0003341405,0.00014694252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029222823,0.00015023685,0.0008333676,0.00010115734,0.000020413072,0.0000056340987,0.00025497915,0.00044342145,0.000048232618],"category_scores_gemma":[0.0008406171,0.00012606317,0.00033630474,0.00010540105,0.00014385172,0.000008429177,0.00007442626,0.00047729493,0.0000015188491],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003307979,0.0017070154,0.7630183,0.00021317413,0.00020790356,0.000017166562,0.000056436922,0.005621261,0.10805623,0.00006245081,0.0924273,0.025304746],"study_design_scores_gemma":[0.008240942,0.0021105367,0.43392107,0.0001672358,0.00025341392,0.000029279436,0.00006986219,0.0007387545,0.007172404,0.000057980134,0.5469837,0.00025482653],"about_ca_topic_score_codex":0.00031406787,"about_ca_topic_score_gemma":0.00081555184,"teacher_disagreement_score":0.4545564,"about_ca_system_score_codex":0.00004984507,"about_ca_system_score_gemma":0.0024237393,"threshold_uncertainty_score":0.51407063},"labels":[],"label_agreement":null},{"id":"W2603167024","doi":"10.1200/jco.2014.32.15_suppl.617","title":"Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Taxane; Metastatic breast cancer; Oncology; Breast cancer; Multivariate analysis; Univariate analysis; Cancer","score_opus":0.08082417327815228,"score_gpt":0.4823661614697947,"score_spread":0.40154198819164244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603167024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434733,0.000054772485,0.000005592729,0.004180886,0.0001732234,0.0008936268,0.00004442605,0.000007460117,0.00029269813],"genre_scores_gemma":[0.99847454,0.00018535192,0.00025125465,0.0006463015,0.00014415856,0.000041641302,0.0000054117054,0.000044724795,0.00020661396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946054,0.0014183752,0.0024232175,0.0003376437,0.000762725,0.00045259873],"domain_scores_gemma":[0.9924605,0.0049807327,0.0014321902,0.00025711616,0.00042295078,0.00044653733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004623549,0.00029738536,0.0028450687,0.00035763532,0.000028876235,0.000009938832,0.00020053252,0.00027190967,0.00026412794],"category_scores_gemma":[0.002699914,0.00015476877,0.0001407579,0.0005310948,0.00035774524,0.000091810994,0.00004570959,0.0015170042,0.00000528807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07537517,0.0027776046,0.8299889,0.00044984516,0.00025353298,0.00064746145,0.000109759625,0.00013984917,0.0000050298117,0.000001982457,0.00018862021,0.09006227],"study_design_scores_gemma":[0.048516415,0.165604,0.7828324,0.0011921091,0.00030776975,0.00019413703,0.00003084239,0.00045949843,0.00007333382,0.000005017684,0.00065549737,0.00012897656],"about_ca_topic_score_codex":0.0009862763,"about_ca_topic_score_gemma":0.012457258,"teacher_disagreement_score":0.16282639,"about_ca_system_score_codex":0.00052428315,"about_ca_system_score_gemma":0.0011577958,"threshold_uncertainty_score":0.69514424},"labels":[],"label_agreement":null},{"id":"W2603191492","doi":"10.1200/jco.2012.30.15_suppl.1025","title":"NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Montreal General Hospital; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pazopanib; Medicine; Internal medicine; Breast cancer; Clinical endpoint; Regimen; Oncology; Phases of clinical research; Chemotherapy; Tyrosine-kinase inhibitor; Cancer; Urology; Gastroenterology; Clinical trial","score_opus":0.08320078400952502,"score_gpt":0.5089545598580594,"score_spread":0.42575377584853435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603191492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745939,0.008811336,0.00007096719,0.011783439,0.0031600546,0.0011852327,0.000049713282,0.000009813937,0.0003355595],"genre_scores_gemma":[0.9801178,0.012405531,0.0018678408,0.0027439615,0.0024029615,0.00006308753,0.0000037724515,0.000033121854,0.0003619467],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964991,0.0003521979,0.0021371746,0.00027335776,0.00029056385,0.000447564],"domain_scores_gemma":[0.993584,0.0035150014,0.0017542572,0.00014231242,0.0003661791,0.0006382557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002521484,0.00027472092,0.00227836,0.00011531286,0.00010439145,0.000006902625,0.00010947378,0.00038372356,0.0001853779],"category_scores_gemma":[0.00093259383,0.00019004742,0.00059437944,0.0001289382,0.00035693476,0.00025571787,0.000057084926,0.00062341645,0.0000012595356],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3739698,0.0089566205,0.01839556,0.000045515484,0.0016269037,0.000117114796,0.000777007,0.0000029308524,0.0050234674,0.000064431304,0.0016992483,0.5893214],"study_design_scores_gemma":[0.64721805,0.18179138,0.08786863,0.0003613405,0.0022514635,0.0005147575,0.0007275088,0.00004134967,0.0035913538,0.0008509126,0.07446071,0.00032257714],"about_ca_topic_score_codex":0.00017179383,"about_ca_topic_score_gemma":0.00007000372,"teacher_disagreement_score":0.5889988,"about_ca_system_score_codex":0.00016783712,"about_ca_system_score_gemma":0.0012498224,"threshold_uncertainty_score":0.77499086},"labels":[],"label_agreement":null},{"id":"W2603213530","doi":"10.1200/jco.2009.27.15_suppl.e19560","title":"Regression of follicular lymphoma with alternative therapy using Devil's Claw (DC); Coincidence or causation?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Follicular lymphoma; Cancer; Lymphoma; Internal medicine; Proportional hazards model; Oncology; Gastroenterology; Surgery","score_opus":0.1153053701315951,"score_gpt":0.4447166169517118,"score_spread":0.3294112468201167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603213530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957755,0.001448074,0.0007554411,0.0014115995,0.00030066262,0.000104039435,0.0000024213186,0.0000017757835,0.00020047887],"genre_scores_gemma":[0.98894376,0.002280477,0.006933834,0.0009059453,0.00080925704,5.183958e-7,0.0000015387203,0.0000090365065,0.00011564812],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800116,0.00038124504,0.0010025974,0.0002014098,0.0002606523,0.00015290861],"domain_scores_gemma":[0.9972079,0.0003005712,0.0017158214,0.00020200775,0.00046291118,0.00011080722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012440667,0.00013890801,0.0006956617,0.000048575028,0.0000483594,0.000007938255,0.00022479228,0.00029053024,0.000021141741],"category_scores_gemma":[0.001030323,0.00007233442,0.00024418448,0.00009187248,0.00019027111,0.00001814517,0.000029075743,0.00018923233,4.3968197e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023452733,0.0015602496,0.007464565,0.000014961613,0.0007320985,0.0005755049,0.00010876883,0.0003101613,0.29614064,0.00015934114,0.0011073465,0.66837364],"study_design_scores_gemma":[0.010024456,0.05041081,0.062801264,0.00034392666,0.0002507401,0.0022637574,0.00037038393,0.00026057375,0.80582535,0.0010018948,0.06596556,0.00048130125],"about_ca_topic_score_codex":0.000021972293,"about_ca_topic_score_gemma":0.000020336138,"teacher_disagreement_score":0.66789234,"about_ca_system_score_codex":0.00003976922,"about_ca_system_score_gemma":0.0007905628,"threshold_uncertainty_score":0.2949712},"labels":[],"label_agreement":null},{"id":"W2603232398","doi":"10.1200/jco.2012.30.15_suppl.tps1139","title":"Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Hôtel-Dieu de Montréal; Hôpital du Saint-Sacrement; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Chemotherapy; Oncology; Internal medicine; Triple-negative breast cancer; Metastatic breast cancer; Clinical trial; Biopsy; Cancer; Targeted therapy; Drug resistance","score_opus":0.0562463011033803,"score_gpt":0.4386035183536843,"score_spread":0.38235721725030397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603232398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313664,0.00011236004,0.0003672683,0.002521927,0.00230729,0.0013216808,0.000058813574,0.0000014532421,0.00017254258],"genre_scores_gemma":[0.9933283,0.00027868053,0.0020783278,0.0022349798,0.0019255824,0.00006339771,0.0000014633873,0.000020981752,0.00006832762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621856,0.00063496205,0.002297933,0.0002861263,0.0002648266,0.00029756487],"domain_scores_gemma":[0.9964892,0.0009079846,0.001400882,0.00028145692,0.0005931259,0.00032732275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037061002,0.00016687262,0.0009806778,0.000071954586,0.000040807783,0.000009445054,0.00042606343,0.0002926116,0.000031597057],"category_scores_gemma":[0.003912051,0.0001136593,0.00035857674,0.00022622189,0.0001264072,0.000008823375,0.00016221586,0.00044524125,0.00000425416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2967019,0.020858072,0.6282952,0.0000090948015,0.0011307906,0.00001817869,0.001794818,0.00007541718,0.0023693924,0.00029796595,0.007095754,0.041353416],"study_design_scores_gemma":[0.06199235,0.023543216,0.9051182,0.000028191247,0.000122104,0.0000060005123,0.0005208242,0.0000020223565,0.0017855897,0.0004287955,0.006271915,0.00018077216],"about_ca_topic_score_codex":0.000059632275,"about_ca_topic_score_gemma":0.00084162166,"teacher_disagreement_score":0.27682304,"about_ca_system_score_codex":0.000116514486,"about_ca_system_score_gemma":0.00077668065,"threshold_uncertainty_score":0.46833736},"labels":[],"label_agreement":null},{"id":"W2603251482","doi":"10.1200/jco.2014.32.15_suppl.5021","title":"Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Abiraterone; Comparative genomic hybridization; Cancer research; Cancer; Genetics; Chromosome; Biology; Gene","score_opus":0.08041507329046181,"score_gpt":0.4194641877961967,"score_spread":0.3390491145057349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603251482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986638,0.00029604786,0.000010766597,0.00039431063,0.00006370186,0.0003955934,0.000040420804,0.0000032740063,0.00013209604],"genre_scores_gemma":[0.9981102,0.0003706762,0.001274118,0.00008264783,0.00004633195,0.000012859842,0.000017377877,0.000018418523,0.00006742179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613494,0.0005395259,0.0023631693,0.00024604946,0.00043654675,0.00027977332],"domain_scores_gemma":[0.99557483,0.0010804266,0.0022878447,0.00016546318,0.0006415998,0.0002498141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017833398,0.0001780864,0.0020977317,0.0005093827,0.000030973955,0.000008782472,0.00009617922,0.00009770019,0.0000476934],"category_scores_gemma":[0.0006755056,0.00011138028,0.00023362429,0.0005603709,0.0003499153,0.00011437179,0.000032480675,0.00041243774,6.400224e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013795061,0.0012252213,0.94095033,0.00019401379,0.0033236255,0.00023983969,0.00049485796,0.0014524903,0.01325029,0.000011033143,0.000013672609,0.025049545],"study_design_scores_gemma":[0.020290805,0.011052211,0.9588409,0.00025998094,0.0032591424,0.000022614871,0.0001949795,0.0032641252,0.0025837005,0.00003367766,0.00009583522,0.00010203188],"about_ca_topic_score_codex":0.00039365154,"about_ca_topic_score_gemma":0.0011209389,"teacher_disagreement_score":0.024947513,"about_ca_system_score_codex":0.00024353681,"about_ca_system_score_gemma":0.0010246634,"threshold_uncertainty_score":0.4541956},"labels":[],"label_agreement":null},{"id":"W2603273957","doi":"10.1200/jco.2017.35.5_suppl.146","title":"Immediate-term chemotherapy-related cognitive impairment (CRCI) following administration of intravenous (IV) chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Alberta Health Services; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Chemotherapy; Chemotherapy regimen; Chemotherapy-induced peripheral neuropathy; Internal medicine; Anesthesia; Surgery; Peripheral neuropathy","score_opus":0.07089204889339613,"score_gpt":0.45458445505264766,"score_spread":0.38369240615925154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603273957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798625,0.00045407194,0.00012156895,0.011643832,0.0025777805,0.00074451475,0.000010081421,0.000017672442,0.0045679556],"genre_scores_gemma":[0.99420744,0.002237965,0.0003821366,0.0016166382,0.0011275107,0.0000111716145,0.000006850037,0.000040643314,0.0003696614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99534816,0.00025859463,0.0031263821,0.00029858947,0.0005953453,0.00037295363],"domain_scores_gemma":[0.9918747,0.0013970875,0.0052071004,0.00031028394,0.00084416865,0.00036667945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029040747,0.00027986322,0.0022217054,0.00016358696,0.00018623368,0.000023997287,0.00027887776,0.00057312526,0.0003045435],"category_scores_gemma":[0.00347684,0.00021977801,0.0011245972,0.000098327764,0.00064861093,0.00023585657,0.00007277919,0.0011514993,0.000019399897],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051507052,0.011553981,0.27432376,0.00017629111,0.010868496,0.002672232,0.0027631966,0.0000023312732,0.0024563298,0.00003738624,0.0026263774,0.64101255],"study_design_scores_gemma":[0.041102998,0.038608428,0.9119027,0.0009287233,0.0015302,0.00046828177,0.00067593827,0.000038483613,0.0026534717,0.00034608768,0.0015255893,0.0002190463],"about_ca_topic_score_codex":0.000019399573,"about_ca_topic_score_gemma":0.000020651181,"teacher_disagreement_score":0.6407935,"about_ca_system_score_codex":0.00026325948,"about_ca_system_score_gemma":0.0018672383,"threshold_uncertainty_score":0.89622873},"labels":[],"label_agreement":null},{"id":"W2603302103","doi":"10.1200/jco.2012.30.15_suppl.6035","title":"Results of a cluster randomized trial to evaluate a nursing lead supportive care intervention in newly diagnosed breast and colorectal cancer patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Intervention (counseling); Colorectal cancer; Breast cancer; Quality of life (healthcare); Cluster randomised controlled trial; Nursing; Distress; Family medicine; Cancer; Internal medicine","score_opus":0.06739205736300755,"score_gpt":0.47262782584641805,"score_spread":0.4052357684834105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603302103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914004,0.0008318987,0.000041659707,0.0023697491,0.0036947269,0.0010387391,0.000029927121,0.000002847021,0.00059000426],"genre_scores_gemma":[0.9981322,0.00016708879,0.00013561046,0.00042282257,0.0010559044,0.000035251178,0.000008739106,0.000011329299,0.000031018255],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950485,0.0014822887,0.002741705,0.00014928129,0.0003500805,0.00022814023],"domain_scores_gemma":[0.99454683,0.002639726,0.0016790215,0.000077049015,0.0007437535,0.00031361147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005698486,0.0001194348,0.0018818281,0.0001849133,0.000013791583,0.0000048140355,0.00006665466,0.00025669855,0.00004766822],"category_scores_gemma":[0.006479592,0.00008419917,0.00055523776,0.0001426172,0.00019655052,0.00012313247,0.000034549386,0.000506577,0.0000014486334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73006403,0.001569428,0.03307307,0.000034707304,0.00012796695,0.000016918779,0.0058113285,0.0000031660124,0.000012253854,0.0000027772212,0.00055675633,0.22872756],"study_design_scores_gemma":[0.7797219,0.011976627,0.20455019,0.0007522135,0.0005627574,0.000028785467,0.0017959414,0.000029877869,0.000051277828,0.00001826374,0.00044085903,0.00007130814],"about_ca_topic_score_codex":0.0006801039,"about_ca_topic_score_gemma":0.0024380602,"teacher_disagreement_score":0.22865626,"about_ca_system_score_codex":0.00035656715,"about_ca_system_score_gemma":0.00062071346,"threshold_uncertainty_score":0.7757145},"labels":[],"label_agreement":null},{"id":"W2603321949","doi":"10.1200/jco.2013.31.15_suppl.1578","title":"Individual insulin use and the risk of breast cancer: An international clinical epidemiology study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Insulin glargine; Internal medicine; Odds ratio; Type 2 diabetes; Diabetes mellitus; Relative risk; Cancer; Epidemiology; Insulin; Confidence interval; Oncology; Endocrinology","score_opus":0.30378271695795567,"score_gpt":0.5523325562063671,"score_spread":0.24854983924841145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603321949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98244655,0.00037035535,0.000038778453,0.014344356,0.0022865469,0.00037298986,0.00004577609,0.0000046080218,0.000090012414],"genre_scores_gemma":[0.9819553,0.011400351,0.00093705906,0.0032100938,0.002440709,0.000008831855,0.0000022137667,0.000011409916,0.00003406117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912559,0.003555874,0.004463701,0.0002280347,0.00030837746,0.00018813947],"domain_scores_gemma":[0.9771661,0.017148077,0.00420291,0.00026350183,0.0007887388,0.0004306778],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01682864,0.00013282111,0.0023275537,0.00009927167,0.000040308263,0.000013112812,0.0003196509,0.00038041107,0.00040978144],"category_scores_gemma":[0.019393394,0.00006735198,0.0005350153,0.00008318715,0.0011049528,0.00028752515,0.00013659339,0.0017393873,0.0000054096618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005032697,0.0016141925,0.7509191,0.0000030241451,0.0010425863,0.000019192157,0.00018840573,0.000009188811,9.121806e-7,0.000092524715,0.0016306507,0.2394475],"study_design_scores_gemma":[0.017830325,0.007814377,0.9647177,0.00003005737,0.00082354015,0.00022383861,0.00039822466,0.00027774394,3.2989e-7,0.00062236603,0.0072014434,0.00006007286],"about_ca_topic_score_codex":0.0032093048,"about_ca_topic_score_gemma":0.00050076697,"teacher_disagreement_score":0.23938744,"about_ca_system_score_codex":0.00005152284,"about_ca_system_score_gemma":0.00083165447,"threshold_uncertainty_score":0.9888667},"labels":[],"label_agreement":null},{"id":"W2603325266","doi":"10.1200/jco.2014.32.15_suppl.11127","title":"Essential experimental steps and estimates of renal carcinoma initiating cells.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Clonogenic assay; Clear cell renal cell carcinoma; Stromal cell; Anoikis; Flow cytometry; Cancer research; Ex vivo; Viability assay; Medicine; Cell culture; Pathology; Cancer cell; Biology; Cancer; Renal cell carcinoma; In vitro; Immunology; Internal medicine","score_opus":0.0975193798602219,"score_gpt":0.4595916461334966,"score_spread":0.3620722662732747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603325266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941089,0.0008928758,0.0006479718,0.0005281004,0.000853855,0.00006583596,0.0000018493718,0.000003038279,0.0028975802],"genre_scores_gemma":[0.9856838,0.00015128401,0.012551424,0.0004895081,0.0010834024,7.7103067e-7,7.8766976e-7,0.000009957716,0.000029072778],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978878,0.00014300171,0.0014979726,0.000117143325,0.00021817505,0.00013594668],"domain_scores_gemma":[0.99729866,0.0010380257,0.0011315837,0.00009681332,0.00018233417,0.00025258842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016636928,0.000088687666,0.0010730734,0.000071166476,0.000023490693,0.0000050487834,0.00006553702,0.00014919268,0.00014755796],"category_scores_gemma":[0.0007662535,0.00006454203,0.00025700856,0.000049519207,0.00022234695,0.000057006444,0.000052301617,0.00038652655,0.0000019912127],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009894149,0.0043399087,0.17454204,0.00035514662,0.00089567836,0.0007208155,0.0009886316,0.000044519726,0.35067692,0.0006148,0.0065899757,0.4503374],"study_design_scores_gemma":[0.0384668,0.05726809,0.17161465,0.00050112203,0.0021473926,0.001854298,0.0012990076,0.002169071,0.657983,0.00046200756,0.06586315,0.00037140667],"about_ca_topic_score_codex":0.000028205432,"about_ca_topic_score_gemma":0.0000061938244,"teacher_disagreement_score":0.449966,"about_ca_system_score_codex":0.00003264186,"about_ca_system_score_gemma":0.00041086727,"threshold_uncertainty_score":0.26319477},"labels":[],"label_agreement":null},{"id":"W2603328336","doi":"10.1200/jco.2007.25.18_suppl.16033","title":"Use of systemic therapy in women with recurrent ovarian cancer—Development of a national clinical practice guideline","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Guideline; Medicine; Context (archaeology); Family medicine; Psychosocial; Gynecology; Pathology","score_opus":0.5301416376128623,"score_gpt":0.6383174734253626,"score_spread":0.10817583581250034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603328336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98068464,0.0003966029,0.0051168627,0.011638211,0.0013070976,0.0005498617,0.0000070229057,0.000005998359,0.00029370157],"genre_scores_gemma":[0.8077096,0.002514807,0.18181257,0.006838168,0.0010694033,0.00000883235,0.000005815488,0.00002172148,0.000019132629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9789431,0.0012065613,0.017861538,0.00029008853,0.0013748795,0.00032380974],"domain_scores_gemma":[0.95020145,0.029382946,0.013441514,0.00025037816,0.0062853773,0.0004383357],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05896645,0.00018185061,0.002112181,0.00032827596,0.000022792006,0.000006255705,0.00020402705,0.00042288567,0.00015248242],"category_scores_gemma":[0.08195509,0.00012688298,0.00026420483,0.0004466975,0.00020258878,0.0004188668,0.00006312902,0.0014039695,0.0000030225099],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08822841,0.0065126605,0.09737831,0.000061497274,0.0010083831,0.00022110072,0.0007191354,0.000113063885,0.0005286677,0.00007157737,0.003884461,0.80127275],"study_design_scores_gemma":[0.03183821,0.02919988,0.60342604,0.0010149392,0.0003077192,0.0006998423,0.0027671757,0.00018464519,0.00014548677,0.000117915835,0.33009112,0.00020703945],"about_ca_topic_score_codex":0.00012833918,"about_ca_topic_score_gemma":0.00030480177,"teacher_disagreement_score":0.8010657,"about_ca_system_score_codex":0.00068522285,"about_ca_system_score_gemma":0.012533467,"threshold_uncertainty_score":0.9930645},"labels":[],"label_agreement":null},{"id":"W2603335608","doi":"10.1200/jco.2013.31.15_suppl.11002","title":"Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Amplicon; Oncology; Internal medicine; Ovarian cancer; non-small cell lung cancer (NSCLC); Breast cancer; Cancer; Lung cancer; Colorectal cancer; Gene; Polymerase chain reaction; Genetics; Biology","score_opus":0.10832600137558142,"score_gpt":0.41071751934345635,"score_spread":0.30239151796787495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603335608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938062,0.0029067143,0.0012529307,0.00034743504,0.0011707728,0.00045236724,0.000010498817,0.000002939338,0.00005017987],"genre_scores_gemma":[0.9861953,0.0024631443,0.009581475,0.00066386734,0.0010247972,0.00001291262,0.000022577464,0.000024985682,0.00001092862],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975304,0.00029083213,0.0014218858,0.00029900097,0.00014852811,0.00030936697],"domain_scores_gemma":[0.99791694,0.00015528857,0.0010945424,0.00014307903,0.00045953368,0.00023064805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009570478,0.00018561393,0.0006751379,0.00009345528,0.00004822166,0.000037894093,0.0001620873,0.00038616202,0.000040397153],"category_scores_gemma":[0.0016157392,0.00015580525,0.00018613474,0.00013222457,0.00009891487,0.00003288145,0.00008121689,0.00046341686,6.184711e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006378499,0.00012655674,0.021571854,0.000021138845,0.00021236575,0.00005457852,0.000090469184,0.040203094,0.8776844,0.000024044719,0.00021313559,0.053419836],"study_design_scores_gemma":[0.20907027,0.026320523,0.043519445,0.0010270394,0.0009624081,0.00032283584,0.0033331944,0.2357393,0.45243245,0.0012120334,0.023133181,0.0029272942],"about_ca_topic_score_codex":0.0013849186,"about_ca_topic_score_gemma":0.0013475384,"teacher_disagreement_score":0.42525196,"about_ca_system_score_codex":0.00060424936,"about_ca_system_score_gemma":0.0038567951,"threshold_uncertainty_score":0.6841789},"labels":[],"label_agreement":null},{"id":"W2603366817","doi":"10.1200/jco.2007.25.18_suppl.18511","title":"Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): Final results of a phase II trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vorinostat; Gastroenterology; Internal medicine; Diffuse large B-cell lymphoma; Clinical endpoint; Phases of clinical research; Refractory (planetary science); Progressive disease; Nausea; Surgery; Toxicity; Lymphoma; Clinical trial; Chemotherapy; Histone deacetylase","score_opus":0.07936872297622341,"score_gpt":0.4543974365386984,"score_spread":0.375028713562475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603366817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576426,0.000479507,0.00018772234,0.00040974046,0.0013456816,0.0003314945,0.000048951293,0.000004609035,0.0014280622],"genre_scores_gemma":[0.9957679,0.0002812181,0.0013578399,0.00027039275,0.0013727484,0.000003814777,0.000034097713,0.000032037573,0.0008799839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930103,0.0010164793,0.004250349,0.00044354607,0.00060998154,0.000669365],"domain_scores_gemma":[0.99562055,0.000950695,0.0020693399,0.00046535677,0.00043576144,0.00045829054],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011607033,0.00024516802,0.0013323177,0.00030333345,0.000071658484,0.0000080333775,0.0005508555,0.0009803427,0.000019327508],"category_scores_gemma":[0.00841823,0.00021195578,0.0006715904,0.00027866912,0.00034300704,0.000013100116,0.00027029405,0.0009371916,0.000012636591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5385522,0.086954154,0.001027608,0.000037472688,0.00019958228,0.0020102672,0.00023862979,0.000013257773,0.28474653,0.000019838286,0.013810665,0.07238978],"study_design_scores_gemma":[0.6463483,0.07175224,0.0013405057,0.000049052018,0.00007059759,0.0001599726,0.00009642719,0.000097843236,0.15358862,0.000042250056,0.12620679,0.00024740762],"about_ca_topic_score_codex":0.000046142086,"about_ca_topic_score_gemma":0.0007198127,"teacher_disagreement_score":0.1311579,"about_ca_system_score_codex":0.00016186593,"about_ca_system_score_gemma":0.0019756237,"threshold_uncertainty_score":0.99993426},"labels":[],"label_agreement":null},{"id":"W2603380120","doi":"10.1200/jco.2013.31.15_suppl.e19024","title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Incidence (geometry); Oncology; Population; Gastroenterology; Surgery","score_opus":0.0839091978141601,"score_gpt":0.5020959992532966,"score_spread":0.4181868014391365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603380120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98448867,0.008935157,0.000009149663,0.0054235174,0.0004939828,0.00033061975,0.00000455035,0.0000015457277,0.00031280686],"genre_scores_gemma":[0.9642084,0.03398548,0.00074032176,0.0005201197,0.00045898935,0.000015657917,4.3140852e-7,0.0000085523125,0.0000620043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963153,0.00037068152,0.0027547032,0.00015182603,0.00020159216,0.00020587583],"domain_scores_gemma":[0.98999953,0.007302466,0.0018214469,0.00018205297,0.00034955665,0.0003449507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035226396,0.00011659823,0.0015432402,0.00006850676,0.000027255724,0.000010565955,0.000105992614,0.00019594005,0.0001424608],"category_scores_gemma":[0.001992636,0.000058290378,0.0006424636,0.00010855097,0.00029366658,0.00007782644,0.000065912755,0.0007068598,0.0000037285092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009115858,0.0015388016,0.8667978,0.000023050226,0.00038013776,0.00018480918,0.00003802891,0.000014763038,0.000034418477,0.000005595338,0.0066040326,0.123466946],"study_design_scores_gemma":[0.0070549515,0.011476871,0.9786517,0.00019475514,0.00056773244,0.000087693494,0.00006707515,0.00024689696,0.00004823497,0.00008019152,0.0014732358,0.000050664807],"about_ca_topic_score_codex":0.0023409436,"about_ca_topic_score_gemma":0.0014553727,"teacher_disagreement_score":0.12341628,"about_ca_system_score_codex":0.00020479033,"about_ca_system_score_gemma":0.0018034003,"threshold_uncertainty_score":0.3538822},"labels":[],"label_agreement":null},{"id":"W2603384438","doi":"10.1200/jco.2016.71.7397","title":"Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":715,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Urology; Prostate; Regimen; Radiation therapy; Randomized controlled trial; Prostate-specific antigen; Hormonal therapy; Cancer; Internal medicine; Dose fractionation; Oncology; Surgery; Confidence interval","score_opus":0.14735430406257796,"score_gpt":0.509762074297179,"score_spread":0.362407770234601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603384438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9405148,0.0065811463,0.0001642321,0.04471761,0.0032997269,0.004279147,0.000042265114,0.0000038507264,0.00039722],"genre_scores_gemma":[0.9190593,0.07807695,0.0007223732,0.00027692816,0.0010708008,0.000360862,0.0000049699106,0.0000119811975,0.0004158702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971584,0.0002918099,0.0020935556,0.00011473718,0.00022401524,0.00011750135],"domain_scores_gemma":[0.98695695,0.0063605774,0.0056748837,0.00026646984,0.0006291317,0.00011201089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025971683,0.00010529095,0.0021542064,0.000051146988,0.00007378024,0.000007103489,0.000106359264,0.0001561177,0.00004670777],"category_scores_gemma":[0.0037743722,0.000049930764,0.0009921263,0.00003087278,0.0003776216,0.000090238296,0.000009502376,0.00012906347,5.599436e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6789923,0.0028087515,0.002059961,0.000017743963,0.0019874526,0.000012325604,0.00010866793,0.00003248763,0.000019540927,0.0000697115,0.00078099355,0.31311008],"study_design_scores_gemma":[0.8573287,0.031476814,0.008057185,0.000084201165,0.0025977425,0.000008759147,0.000031967204,0.00035371046,0.0012178621,0.00044563177,0.09836037,0.00003703278],"about_ca_topic_score_codex":0.0002979525,"about_ca_topic_score_gemma":0.000027944378,"teacher_disagreement_score":0.31307304,"about_ca_system_score_codex":0.00024288638,"about_ca_system_score_gemma":0.0015400292,"threshold_uncertainty_score":0.45185485},"labels":[],"label_agreement":null},{"id":"W2603415112","doi":"10.1200/jco.2012.30.15_suppl.7606","title":"Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Chemotherapy; Oncology; Cancer; Systemic therapy; Performance status; Cisplatin; Breast cancer","score_opus":0.22242848051654968,"score_gpt":0.4330023733228404,"score_spread":0.21057389280629074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603415112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820948,0.0038325726,0.0008241754,0.0016437258,0.00226225,0.00011338443,0.00006251246,0.0000027501017,0.009163779],"genre_scores_gemma":[0.992848,0.003808224,0.001286659,0.0012489721,0.0004549547,0.0000023862658,0.0000013123417,0.000013552314,0.0003359555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996802,0.00007017222,0.0027041778,0.00012881124,0.000036476056,0.0002583922],"domain_scores_gemma":[0.9956359,0.00077063567,0.003043126,0.0001551547,0.0000682028,0.0003269343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024481982,0.00013135474,0.0017239223,0.00013027426,0.000022689535,0.000009968108,0.00013889036,0.00016375602,0.00036336356],"category_scores_gemma":[0.0011571363,0.00010580654,0.00038094757,0.000044641205,0.000108248554,0.00035390945,0.00003700936,0.000221786,0.000054333894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015441014,0.0007392811,0.8636742,0.0000071884942,0.00034349435,0.000009352492,0.00014383654,0.0000038761755,5.7258444e-7,0.013855049,0.0011450199,0.11992368],"study_design_scores_gemma":[0.003383832,0.002123281,0.8452161,0.000017264218,0.000070718634,0.000022062373,0.000054825257,0.000022361733,0.000006609423,0.0017718275,0.14720605,0.00010509096],"about_ca_topic_score_codex":0.00025251033,"about_ca_topic_score_gemma":0.00004596689,"teacher_disagreement_score":0.14606103,"about_ca_system_score_codex":0.00022542826,"about_ca_system_score_gemma":0.00016091281,"threshold_uncertainty_score":0.43146655},"labels":[],"label_agreement":null},{"id":"W2603416025","doi":"10.1200/jco.2014.32.15_suppl.9584","title":"Patients’ expectations of oncologists and primary care providers (PCPs) in addressing reproductive and sexual health.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Health and Technologies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Reproductive health; Logistic regression; Family medicine; Infertility; Oncofertility; Cancer; Distress; Primary care; Sexual function; Gynecology; Reproductive medicine; Fertility; Fertility preservation; Pregnancy; Internal medicine; Population; Clinical psychology","score_opus":0.1751730365941926,"score_gpt":0.49109671083369927,"score_spread":0.3159236742395067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603416025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98091674,0.0037944752,0.00003195993,0.013728634,0.00033740303,0.00039868514,0.0000018147559,0.000010855615,0.00077945227],"genre_scores_gemma":[0.9899028,0.0006124887,0.008400799,0.0007534505,0.00030004475,0.0000061360993,0.0000030723343,0.000008244139,0.000012942766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99698746,0.00050417235,0.00179929,0.0003210736,0.00019753365,0.0001904702],"domain_scores_gemma":[0.99585515,0.0013600307,0.0018204196,0.0002125814,0.00056485017,0.0001869552],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024681343,0.00009769977,0.0012479889,0.00021270018,0.000045374763,0.000003852629,0.00006407147,0.00025052816,0.0000015935932],"category_scores_gemma":[0.016069101,0.0000716918,0.00005977315,0.00013775523,0.00061358203,0.00012346638,0.000065138054,0.00076773204,3.1800283e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011951608,0.0005113612,0.4765103,0.00037850242,0.000029043696,0.000013570558,0.0012791818,0.0000015417623,0.000039282022,0.00006135899,0.0003216663,0.51965904],"study_design_scores_gemma":[0.004917056,0.022477372,0.96169406,0.00019818242,0.000042831038,0.00007830015,0.005949353,0.00000634754,0.00005889336,0.000557122,0.0039615124,0.000058981663],"about_ca_topic_score_codex":0.000047173773,"about_ca_topic_score_gemma":0.00005893029,"teacher_disagreement_score":0.51960003,"about_ca_system_score_codex":0.000203162,"about_ca_system_score_gemma":0.0014438776,"threshold_uncertainty_score":0.992219},"labels":[],"label_agreement":null},{"id":"W2603419515","doi":"10.1200/jco.2017.35.5_suppl.211","title":"A feasibility study of a new smartphone application for patients with cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social and Behavioral Studies","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Smartphone app; Clinical endpoint; Cancer; Internal medicine; World Wide Web; Clinical trial; Computer science","score_opus":0.4302852003436249,"score_gpt":0.6117856354354848,"score_spread":0.18150043509185992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603419515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951965,0.000033391574,0.000043637483,0.0029180218,0.0007431867,0.00062111387,0.0000037341254,0.000002915335,0.00043750685],"genre_scores_gemma":[0.9984339,0.000069744914,0.00036842035,0.00005889047,0.00089500763,0.000016001242,1.8724428e-7,0.0000033211738,0.00015451197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998437,0.00018931768,0.0008313371,0.00010893597,0.0003106373,0.00012276831],"domain_scores_gemma":[0.99581885,0.0005822063,0.0025325662,0.00012639519,0.00079691934,0.00014305896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020552725,0.000054241274,0.00065033627,0.000015062855,0.00042493767,0.000012709611,0.00031700934,0.00012403184,0.000016527383],"category_scores_gemma":[0.002811934,0.000035268837,0.00014392905,0.00004663256,0.00036550133,0.00012708361,0.00004090366,0.00016481582,6.8474014e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011109939,0.0029116282,0.78198195,0.0000019806164,0.000051269006,6.4936484e-7,0.001969551,3.0842193e-7,9.455223e-7,0.000035259327,0.0007006157,0.21123485],"study_design_scores_gemma":[0.005333687,0.007385306,0.96960676,0.000008970977,0.0001569151,4.532995e-8,0.0022542854,2.9405513e-7,0.0000010733651,0.00086638855,0.014344602,0.00004169986],"about_ca_topic_score_codex":0.008468631,"about_ca_topic_score_gemma":0.04456371,"teacher_disagreement_score":0.21119314,"about_ca_system_score_codex":0.00010662327,"about_ca_system_score_gemma":0.001108673,"threshold_uncertainty_score":0.9981341},"labels":[],"label_agreement":null},{"id":"W2603425088","doi":"10.1200/jco.2013.31.15_suppl.5037","title":"Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Denosumab; Internal medicine; Interim analysis; Zoledronic acid; Prednisone; Cancer; Post-hoc analysis; Oncology; Performance status; Placebo; Abiraterone acetate; Surgery; Androgen deprivation therapy; Urology; Randomized controlled trial; Osteoporosis; Pathology","score_opus":0.09356829627849418,"score_gpt":0.4638602741999951,"score_spread":0.3702919779215009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603425088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476624,0.000528266,0.0000030937856,0.0025416499,0.00013123728,0.0018454463,0.00007305534,0.000012706987,0.00009833699],"genre_scores_gemma":[0.99604625,0.0014735918,0.0011029906,0.00038797417,0.000070624425,0.000099241064,0.000014228477,0.00005007517,0.00075502944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552834,0.0005380255,0.0024678342,0.00031150517,0.00066928926,0.00048502322],"domain_scores_gemma":[0.9952662,0.00096220674,0.0020679922,0.00026400297,0.0010498877,0.00038973067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010216666,0.00035571805,0.0025527831,0.00029682668,0.000049086997,0.000027450691,0.00015929756,0.00019801366,0.00061658846],"category_scores_gemma":[0.00046322754,0.00016308945,0.0003833056,0.0003164864,0.0004089077,0.00026796007,0.000020970208,0.0007062795,0.000008668121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078161255,0.0052085146,0.8665868,0.00008005114,0.0030820426,0.0002513639,0.0008541391,0.00005960485,0.003347973,0.000002254635,0.00028623725,0.04207975],"study_design_scores_gemma":[0.05558719,0.07582539,0.86600363,0.00028351886,0.00028750673,0.000023741835,0.00021839645,0.00007706009,0.0013363429,0.000039127273,0.00016307327,0.0001550013],"about_ca_topic_score_codex":0.0006479757,"about_ca_topic_score_gemma":0.00066438265,"teacher_disagreement_score":0.07061688,"about_ca_system_score_codex":0.000667386,"about_ca_system_score_gemma":0.0029201123,"threshold_uncertainty_score":0.6751211},"labels":[],"label_agreement":null},{"id":"W2603427546","doi":"10.1200/jco.2017.35.5_suppl.11","title":"Total and cancer-attributable phase-based costs for childhood cancer care: A population-based study in British Columbia, Canada.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Institute for Clinical Evaluative Sciences; Centre for Addiction and Mental Health; University of Toronto; BC Children's Hospital; Toronto General Hospital; University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Cancer registry; Cohort; Population; Total cost; Cohort study; Relative survival; Health care; Demography; Pediatrics; Gerontology; Internal medicine; Environmental health","score_opus":0.08557913776982001,"score_gpt":0.4720509125931748,"score_spread":0.38647177482335476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603427546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98056024,0.0016709884,0.000028048102,0.013901213,0.0021817407,0.0012761679,0.0003349776,0.000008522865,0.000038079943],"genre_scores_gemma":[0.9933257,0.000091611764,0.0005032733,0.004349528,0.0015046366,0.0000893416,0.000019211515,0.00003244497,0.00008425278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575853,0.00041001552,0.0024288637,0.00038327265,0.00062038447,0.00039890895],"domain_scores_gemma":[0.9937753,0.0020748293,0.0024951631,0.00036448758,0.000737738,0.0005524828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027716039,0.00016095133,0.0021453858,0.00006696036,0.0002873852,0.00012766205,0.00027193458,0.00028500968,0.00011236258],"category_scores_gemma":[0.0063509233,0.0002057872,0.00026453598,0.000091739945,0.00011859533,0.00015620282,0.00004666066,0.0008241346,1.9787737e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011705104,0.0027990462,0.89990234,0.00009460181,0.00021367209,0.00027051868,0.00013632033,0.000092791364,0.0000031915692,3.678619e-7,0.0034394357,0.091877185],"study_design_scores_gemma":[0.050701786,0.0073651597,0.9351594,0.0005757422,0.0004158768,0.00003329221,0.00044921844,0.0001716682,0.0000051376423,0.000013924984,0.004919504,0.00018933533],"about_ca_topic_score_codex":0.96517795,"about_ca_topic_score_gemma":0.99847966,"teacher_disagreement_score":0.09168784,"about_ca_system_score_codex":0.001505587,"about_ca_system_score_gemma":0.019857936,"threshold_uncertainty_score":0.9856986},"labels":[],"label_agreement":null},{"id":"W2603467063","doi":"10.1200/jco.2013.31.15_suppl.8588","title":"Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Vancouver General Hospital; Royal Victoria Regional Health Centre; University of Alberta; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Population; Adverse effect; Surgery; Internal medicine; Multiple myeloma","score_opus":0.09232298271356609,"score_gpt":0.4453981457106731,"score_spread":0.353075162997107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603467063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581,0.00032882104,0.000015862139,0.0012215438,0.00015060512,0.002332414,0.0000071495274,0.0000048279453,0.00012882505],"genre_scores_gemma":[0.9967476,0.0008070127,0.0016601951,0.0003625493,0.00018648525,0.000035669887,0.000009115709,0.000024850637,0.00016652852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942517,0.0016359285,0.0027571418,0.00033024146,0.0006193589,0.00040560658],"domain_scores_gemma":[0.9870774,0.010112074,0.0015954629,0.0003352626,0.00037484712,0.0005049098],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003769213,0.0002544019,0.0022256926,0.0003181075,0.00006732301,0.000015538462,0.00020692934,0.00037023402,0.00010760414],"category_scores_gemma":[0.0127201425,0.00012617272,0.00019237693,0.00027286293,0.0004992039,0.00018211339,0.000103748454,0.0012402325,0.000003939174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36399135,0.0138825625,0.4675708,0.00004083932,0.00024189804,0.000721135,0.0003124736,0.0000014654356,0.00016800953,9.649287e-7,0.00003459479,0.15303388],"study_design_scores_gemma":[0.3811002,0.052488178,0.5654769,0.00022041335,0.000120064105,0.00010047766,0.000080832186,0.00014710544,0.00003765443,0.0000066125544,0.00014746739,0.000074114134],"about_ca_topic_score_codex":0.00015112442,"about_ca_topic_score_gemma":0.0005519662,"teacher_disagreement_score":0.15295976,"about_ca_system_score_codex":0.00015796367,"about_ca_system_score_gemma":0.0008525766,"threshold_uncertainty_score":0.9955961},"labels":[],"label_agreement":null},{"id":"W2603478463","doi":"10.1200/jco.2017.35.6_suppl.78","title":"Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Urology; Goserelin; Antiandrogen; Bicalutamide; Androgen; Proportional hazards model; Analysis of variance; Cancer; Prostate; Internal medicine; Gynecology; Hormone; Androgen receptor","score_opus":0.4389825818582998,"score_gpt":0.5582691456226296,"score_spread":0.11928656376432983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603478463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824376,0.0022724015,0.000008144897,0.0074377144,0.0002411513,0.0011499933,0.0005592481,0.0000028579889,0.00008475456],"genre_scores_gemma":[0.992997,0.0061137807,0.00011330707,0.0000939556,0.00040616063,0.00002811607,0.000033479668,0.000013259169,0.0002009623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722624,0.0004353845,0.0015817741,0.0002618872,0.0003208636,0.0001738433],"domain_scores_gemma":[0.9925256,0.004519241,0.002020408,0.0005927537,0.00019561147,0.00014643233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032251624,0.00013278866,0.0011483264,0.00007996259,0.00014466612,0.00002524084,0.00038104516,0.00020590844,0.00008110026],"category_scores_gemma":[0.0038320606,0.000068151865,0.0001339445,0.000055352448,0.00064884755,0.00026107774,0.00025742155,0.0007824831,0.0000014982071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045943595,0.00063645473,0.7972719,0.000007958227,0.0005811986,0.000055542216,0.0007364505,1.2054306e-7,0.000052350715,0.0000014751412,0.000086591834,0.15462634],"study_design_scores_gemma":[0.12248574,0.0058844206,0.8694899,0.00011956963,0.00028626583,0.0000052660193,0.00007809554,0.000020775564,0.00030802208,0.00081755803,0.00044954297,0.000054855773],"about_ca_topic_score_codex":0.00029971387,"about_ca_topic_score_gemma":0.00084162806,"teacher_disagreement_score":0.15457149,"about_ca_system_score_codex":0.00017786592,"about_ca_system_score_gemma":0.00090663304,"threshold_uncertainty_score":0.45876113},"labels":[],"label_agreement":null},{"id":"W2603488760","doi":"10.1200/jco.2013.31.15_suppl.4053","title":"Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Queen's University; Ottawa Hospital; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Quality of life (healthcare); Placebo; Pancreatic cancer; Proportional hazards model; Adverse effect; Performance status; Erlotinib; Cancer; Statistical significance; Gastroenterology; Pathology","score_opus":0.27265648516569996,"score_gpt":0.5949909621317818,"score_spread":0.32233447696608186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603488760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949313,0.00022852022,0.0001266409,0.0022680585,0.0010304503,0.0010298206,0.000023931489,0.0000045570373,0.00035672286],"genre_scores_gemma":[0.9924322,0.0021632405,0.0041482775,0.0003818477,0.00073167356,0.00004859037,0.0000065421,0.000014479761,0.00007317284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98481315,0.0030252775,0.010700992,0.000304814,0.00083695544,0.00031883424],"domain_scores_gemma":[0.970864,0.02062786,0.006222028,0.000376033,0.0014284693,0.0004815864],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019360604,0.0001809587,0.005159551,0.00037621937,0.00001471186,0.0000033461677,0.00044970465,0.0005242228,0.0004694946],"category_scores_gemma":[0.06217874,0.00013056636,0.0005845757,0.00028350006,0.00082731404,0.0002685602,0.0000886394,0.0013729535,0.0000018682438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13249502,0.010879846,0.8136691,0.00011731329,0.0004405854,0.00004119618,0.00016116115,0.00006191369,0.00058272993,0.000043503802,0.00006617181,0.04144149],"study_design_scores_gemma":[0.17327692,0.020800548,0.8022854,0.00034018207,0.00020341632,0.000005229402,0.00042832413,0.0022400892,0.000045989196,0.00023194218,0.0000651865,0.00007681005],"about_ca_topic_score_codex":0.0016248119,"about_ca_topic_score_gemma":0.0010223897,"teacher_disagreement_score":0.042818137,"about_ca_system_score_codex":0.00018036463,"about_ca_system_score_gemma":0.00499323,"threshold_uncertainty_score":0.9457209},"labels":[],"label_agreement":null},{"id":"W2603493185","doi":"10.1200/jco.2012.30.15_suppl.e13603","title":"MLN9708, an investigational proteasome inhibitor, in patients (pts) with solid tumors: Updated phase I results.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Internal medicine; Nausea; Adverse effect; Cancer; Lung cancer; Gastroenterology; Surgery","score_opus":0.07404373140794203,"score_gpt":0.4107658553401082,"score_spread":0.33672212393216616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603493185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749154,0.00008989962,0.000062489926,0.0005410846,0.00043650184,0.0002948381,0.000033043427,0.000005059112,0.0010455609],"genre_scores_gemma":[0.9925975,0.000022682283,0.0039155143,0.0011577288,0.0020322392,0.000012058418,0.00016778335,0.000021272206,0.00007318481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964879,0.00071890536,0.0018823968,0.00023678025,0.00031748074,0.0003564968],"domain_scores_gemma":[0.99719715,0.00010971256,0.0014821015,0.00022538984,0.00043307626,0.0005525692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003475943,0.00017215857,0.00063464826,0.00009693476,0.000042374617,0.000013107406,0.00025506585,0.00042166366,0.00003263897],"category_scores_gemma":[0.0022010899,0.00012682469,0.00013895285,0.00012940368,0.00024272999,0.000046738085,0.00007441484,0.00064227096,0.000012679972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054707225,0.033964343,0.7297702,0.000057484383,0.00052783114,0.00017300504,0.00072665745,0.00017950099,0.059086964,0.0005125754,0.017711088,0.10258315],"study_design_scores_gemma":[0.08606482,0.12768175,0.40891245,0.00025752521,0.000150679,0.00026225473,0.00023334684,0.00011612918,0.1108907,0.00075861416,0.26372546,0.00094625505],"about_ca_topic_score_codex":0.000007782216,"about_ca_topic_score_gemma":0.000023422655,"teacher_disagreement_score":0.3208577,"about_ca_system_score_codex":0.000049624676,"about_ca_system_score_gemma":0.0011637615,"threshold_uncertainty_score":0.51717603},"labels":[],"label_agreement":null},{"id":"W2603507032","doi":"10.1200/jco.2017.35.4_suppl.325","title":"Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Chemotherapy; Gastroenterology; Pancreatic cancer; Population; Regimen; Irinotecan; Bilirubin; Cancer; Surgery; Colorectal cancer","score_opus":0.08190994850301353,"score_gpt":0.49741703458097053,"score_spread":0.415507086077957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603507032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585253,0.00017755527,0.000014400977,0.002403377,0.0003331392,0.0010427042,0.000010388634,0.000005387224,0.00016053062],"genre_scores_gemma":[0.9983912,0.0005254345,0.00036871177,0.00031058575,0.00012979911,0.0000313936,0.0000047291705,0.000021318436,0.00021679484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601907,0.0008142385,0.0020628192,0.00024784904,0.0006005018,0.0002555216],"domain_scores_gemma":[0.9876974,0.007905454,0.0028147819,0.0004910916,0.00059975695,0.0004915152],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038393303,0.00019626597,0.0028689757,0.0001833026,0.00012392091,0.000008510449,0.00023524495,0.00020133206,0.00013378689],"category_scores_gemma":[0.033292938,0.00012069838,0.00032740785,0.00009359169,0.00026708056,0.00008876817,0.000060342583,0.0005384642,0.0000011475029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027528623,0.0042235996,0.9194045,0.00027540687,0.0006844513,0.000116167335,0.000055887594,0.000084810505,0.000057586003,0.0000032325677,0.00006610494,0.047499653],"study_design_scores_gemma":[0.030698335,0.041645937,0.9251955,0.00057891954,0.0010311006,0.0000014846562,0.000018004437,0.0005147983,0.000076502714,0.00007512722,0.00008252235,0.000081753606],"about_ca_topic_score_codex":0.00035723345,"about_ca_topic_score_gemma":0.00026065073,"teacher_disagreement_score":0.047417898,"about_ca_system_score_codex":0.00017378277,"about_ca_system_score_gemma":0.0009740741,"threshold_uncertainty_score":0.97485006},"labels":[],"label_agreement":null},{"id":"W2603522666","doi":"10.1200/jco.2013.31.15_suppl.tps3647","title":"A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; McGill University; Jewish General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University of Alberta; Alberta Health Services; Queen's University","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Hazard ratio; Internal medicine; Observational study; Physical therapy; Colorectal cancer; Body mass index; Clinical trial; Cancer; Confidence interval","score_opus":0.05095930649844339,"score_gpt":0.4577214403157089,"score_spread":0.4067621338172655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603522666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849084,0.000029253724,0.000004212805,0.00044407233,0.0011018328,0.013292413,0.00013170345,0.000010456501,0.00007766176],"genre_scores_gemma":[0.9984304,0.000055386176,0.000009756681,0.00006140131,0.00057759456,0.00061559037,0.000003161378,0.00002764906,0.00021910398],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908564,0.004472314,0.002752211,0.00031657552,0.001245484,0.00035700592],"domain_scores_gemma":[0.9852214,0.00703772,0.0058150506,0.0005776148,0.0008773642,0.00047086753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045794123,0.0003336917,0.0072804675,0.00017368786,0.00006858085,0.000012166145,0.00039162565,0.00023162806,0.00020814656],"category_scores_gemma":[0.006708969,0.0001433094,0.0017499177,0.00035467694,0.00045298843,0.00013318604,0.00011465976,0.0014087134,5.2566065e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8075621,0.119013034,0.054030217,0.00003519702,0.0022870786,0.000055037297,0.0008436287,0.00011884581,0.0000111446125,0.0000043316645,0.00017410138,0.015865255],"study_design_scores_gemma":[0.63985944,0.1702385,0.18764047,0.0001169157,0.001364416,4.3892268e-7,0.00030832025,0.00032978767,0.000008547423,0.0000119518945,0.00002897423,0.000092223476],"about_ca_topic_score_codex":0.00925254,"about_ca_topic_score_gemma":0.005048147,"teacher_disagreement_score":0.16770267,"about_ca_system_score_codex":0.00040325144,"about_ca_system_score_gemma":0.0040335543,"threshold_uncertainty_score":0.9973449},"labels":[],"label_agreement":null},{"id":"W2603534747","doi":"10.1200/jco.2007.25.18_suppl.3572","title":"Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Viral shedding; Oncolytic virus; Chills; Gastroenterology; Internal medicine; Virology; Cancer; Virus","score_opus":0.1095485912658469,"score_gpt":0.499715115113097,"score_spread":0.39016652384725015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603534747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984502,0.00016874947,0.000069823654,0.00020724392,0.00035965655,0.00050992676,0.000026733751,0.0000017309217,0.00020590586],"genre_scores_gemma":[0.998018,0.0001570643,0.0010218797,0.00035541476,0.0003288643,0.0000043086357,0.000006803724,0.00002228766,0.00008536602],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9960537,0.0004193089,0.0024041773,0.00028776113,0.00052625255,0.0003087835],"domain_scores_gemma":[0.9954807,0.00042824945,0.0019344985,0.00038140579,0.0014285526,0.0003465855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033344687,0.00016019942,0.0009821706,0.00014991427,0.00003026631,0.0000037490745,0.00041780347,0.00024670127,0.000022690196],"category_scores_gemma":[0.002093572,0.00011929428,0.00016401522,0.00027773585,0.0001751685,0.000007731969,0.0000937566,0.00042071682,0.0000017200881],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57381743,0.017201385,0.026929354,0.000021705344,0.00068223866,0.00012429409,0.00038713007,0.00033171632,0.059445556,8.2438913e-7,0.00054137124,0.320517],"study_design_scores_gemma":[0.060694873,0.80063635,0.072410345,0.00008871225,0.00017652816,0.000014480029,0.00034923322,0.0000057433153,0.05474256,0.000008910891,0.010670499,0.00020176404],"about_ca_topic_score_codex":0.0000542688,"about_ca_topic_score_gemma":0.0021770806,"teacher_disagreement_score":0.783435,"about_ca_system_score_codex":0.000072497125,"about_ca_system_score_gemma":0.0018952572,"threshold_uncertainty_score":0.48646796},"labels":[],"label_agreement":null},{"id":"W2603540638","doi":"10.1200/jco.2013.31.15_suppl.10537","title":"Does a diagnosis of GIST predict a second primary cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Pediatric Oncology Group","funders":"","keywords":"GiST; Medicine; Incidence (geometry); Malignancy; Population; Confidence interval; Relative risk; Internal medicine; Cancer; Cohort; Retrospective cohort study; Stage (stratigraphy); Gastroenterology; Oncology","score_opus":0.07992411018448055,"score_gpt":0.432830839727377,"score_spread":0.3529067295428965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603540638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682724,0.0011904353,0.000020524622,0.012303249,0.00235795,0.00031916107,0.000026413798,0.000008229591,0.015501643],"genre_scores_gemma":[0.975826,0.005153961,0.002878947,0.011667748,0.0022247809,0.00004285686,0.000004608659,0.000021614027,0.0021794308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963167,0.00024750456,0.0026793114,0.00017854384,0.00035153708,0.00022640337],"domain_scores_gemma":[0.9942946,0.0024184028,0.0020384581,0.00022327823,0.0005735456,0.00045173516],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014668818,0.0001359656,0.001905132,0.00012160489,0.00002467897,0.000006663416,0.00020691703,0.00034432267,0.009617566],"category_scores_gemma":[0.0014932075,0.00007248386,0.0006415056,0.00010826984,0.00035647588,0.00022192416,0.000057922014,0.0009024388,0.000017140668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018677858,0.001020411,0.5245886,0.00023860931,0.00067963067,0.00015945647,0.000122368,0.000004566705,0.0006660233,0.000014502542,0.08406352,0.3865745],"study_design_scores_gemma":[0.0062881648,0.006383102,0.66037804,0.0001568785,0.00028944752,0.00007319698,0.00008396745,0.000037449954,0.00044463022,0.00014485113,0.32564142,0.00007886839],"about_ca_topic_score_codex":0.00016841764,"about_ca_topic_score_gemma":0.0001451757,"teacher_disagreement_score":0.38649565,"about_ca_system_score_codex":0.00024238128,"about_ca_system_score_gemma":0.0033674352,"threshold_uncertainty_score":0.99128777},"labels":[],"label_agreement":null},{"id":"W2603540908","doi":"10.1200/jco.2013.31.15_suppl.2595","title":"Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Dosing; Pharmacokinetics; Fluorouracil; Body surface area; Area under the curve; Internal medicine; Urology; Gastroenterology; Toxicity; Colorectal cancer; Nomogram; Clinical trial; Pharmacology; Oncology; Cancer; Chemotherapy","score_opus":0.15848521149857622,"score_gpt":0.5496761838370954,"score_spread":0.3911909723385192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603540908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9446194,0.0024573123,0.0002739706,0.02231282,0.001079316,0.00067912624,0.0000017026654,0.000008515609,0.028567802],"genre_scores_gemma":[0.98438585,0.0048648077,0.006888917,0.0026874307,0.00095876865,0.00002664698,0.0000013047173,0.000011434349,0.00017485103],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946172,0.0005200682,0.004123384,0.00019211306,0.00035832357,0.00018891091],"domain_scores_gemma":[0.9914173,0.004403617,0.0026723996,0.0001789535,0.0010710636,0.00025668374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037890475,0.00012658606,0.001638117,0.00010807577,0.000019221125,0.000004559382,0.00013291693,0.00027013084,0.00022750595],"category_scores_gemma":[0.00817069,0.00008486501,0.00046465787,0.00018750259,0.00022572014,0.00017016433,0.000060832517,0.0008513503,0.000050046227],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002984852,0.004024951,0.1676235,0.000031979598,0.0004620789,0.00022361886,0.00008488792,0.000007854565,0.00015493057,0.00006906561,0.010736486,0.8135958],"study_design_scores_gemma":[0.010763015,0.012115261,0.84270805,0.00005540363,0.0005812061,0.0003377869,0.00017830943,0.00047951483,0.00006274491,0.00029849826,0.13234396,0.00007625168],"about_ca_topic_score_codex":0.00020493654,"about_ca_topic_score_gemma":0.00004521222,"teacher_disagreement_score":0.81351954,"about_ca_system_score_codex":0.0001549373,"about_ca_system_score_gemma":0.00080502895,"threshold_uncertainty_score":0.978167},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2603575264","doi":"10.1200/jco.2012.30.15_suppl.3047","title":"Clinical and correlative science results in a phase II study of UCN-01in combination with irinotecan in recurrent triple-negative breast cancer (TNBC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Triple-negative breast cancer; Irinotecan; Taxane; Neutropenia; Internal medicine; Oncology; Phases of clinical research; Cancer; Vomiting; Peripheral blood mononuclear cell; Breast cancer; Gastroenterology; Chemotherapy","score_opus":0.1677929814383985,"score_gpt":0.5610055274139666,"score_spread":0.3932125459755681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603575264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939078,0.0002818778,0.000004049442,0.0031801024,0.0013518662,0.0007311935,0.00001589404,0.0000028485522,0.0005243492],"genre_scores_gemma":[0.99849826,0.0005950475,0.00021913933,0.00023649416,0.00036403266,0.000016353712,0.000001276908,0.000007748375,0.00006167044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953708,0.00091041595,0.0027821572,0.0002602118,0.0003877057,0.00028873162],"domain_scores_gemma":[0.9943662,0.0025550292,0.0020682602,0.00011756256,0.00051487534,0.0003780324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007428942,0.00014455267,0.0015267789,0.00039498816,0.000046844336,0.0000033204772,0.00012161929,0.00019144238,0.00004416487],"category_scores_gemma":[0.0017851031,0.00009687087,0.00010221697,0.0006273568,0.0009762917,0.00027113824,0.00007854782,0.0012235002,7.7222427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066388585,0.059863545,0.6962265,0.000010792336,0.00017223481,0.00017276363,0.004118524,0.000007688118,0.000031050968,0.000028362461,0.00022553132,0.17275447],"study_design_scores_gemma":[0.11115437,0.11680587,0.7698147,0.00016864773,0.0002869925,0.00011057338,0.0010414136,0.00016884285,0.000024068868,0.000042770745,0.00031108814,0.000070622635],"about_ca_topic_score_codex":0.00037206316,"about_ca_topic_score_gemma":0.0018874727,"teacher_disagreement_score":0.17268384,"about_ca_system_score_codex":0.00036817102,"about_ca_system_score_gemma":0.002049512,"threshold_uncertainty_score":0.5315568},"labels":[],"label_agreement":null},{"id":"W2603579700","doi":"10.1200/jco.2009.27.15_suppl.8045","title":"Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): Subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Internal medicine; Pemetrexed; Oncology; Hazard ratio; Gemcitabine; Population; Subgroup analysis; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.07379111199909638,"score_gpt":0.47491572716304753,"score_spread":0.40112461516395115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603579700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965036,0.0005058372,0.00009330613,0.00040119328,0.00037964145,0.0011706052,0.000034524182,0.000003929968,0.0009073957],"genre_scores_gemma":[0.9981898,0.0003262287,0.0012176397,0.000041398347,0.000108662665,0.000022804696,0.000036769874,0.000016922699,0.00003977605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434525,0.00025460773,0.0042962735,0.00033349276,0.00046311622,0.00030724652],"domain_scores_gemma":[0.9942784,0.0012415727,0.0034040804,0.000319221,0.0005027981,0.0002539534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008209526,0.00027791128,0.0034515443,0.0009515437,0.000030215266,0.000003945485,0.0001766242,0.00020226231,0.00008007406],"category_scores_gemma":[0.00052735227,0.0002107825,0.00069284503,0.001256452,0.00008952643,0.00011067063,0.00003143003,0.000386363,5.206866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035001744,0.060371947,0.7784003,0.00005510558,0.0027230685,0.00015854074,0.0041951123,0.010153219,0.00013217394,0.0000035000785,0.00001640477,0.10878888],"study_design_scores_gemma":[0.19172376,0.04567747,0.74964905,0.00027497404,0.007093459,0.0000013122456,0.000996068,0.0043100016,0.000105502266,0.0000030365268,0.000053846034,0.0001115077],"about_ca_topic_score_codex":0.0008867978,"about_ca_topic_score_gemma":0.007848891,"teacher_disagreement_score":0.15672202,"about_ca_system_score_codex":0.0008175915,"about_ca_system_score_gemma":0.0008949195,"threshold_uncertainty_score":0.85954607},"labels":[],"label_agreement":null},{"id":"W2603586386","doi":"10.1200/jco.2012.30.15_suppl.3628","title":"Use of gene set analysis (GSA) for molecular classification of responders and nonresponders to FOLFOX therapy in colorectal cancer (CRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"FOLFOX; Oxaliplatin; Colorectal cancer; Gene; Medicine; Significance analysis of microarrays; Microarray; Gene expression; Gene expression profiling; Microarray analysis techniques; Oncology; Cancer; Cancer research; Genetics; Biology; Internal medicine","score_opus":0.30781773644237936,"score_gpt":0.5230876756742631,"score_spread":0.2152699392318837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603586386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940853,0.0017204846,0.00034879264,0.0031691706,0.00021906935,0.00037443862,0.000024032479,0.0000016181473,0.000057107485],"genre_scores_gemma":[0.99404246,0.0018429917,0.0034169229,0.000527159,0.00010593873,0.000024479958,0.000003020977,0.000009057074,0.00002798619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978751,0.0002713299,0.0013249823,0.00013299912,0.00021765224,0.0001779205],"domain_scores_gemma":[0.9964101,0.001937778,0.0009526945,0.00009497433,0.00041344226,0.0001910101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017451944,0.00010364365,0.0013280207,0.00036986504,0.000016735576,0.0000026839555,0.000058164704,0.00017610255,0.000023260882],"category_scores_gemma":[0.0015841243,0.00007310101,0.00039288984,0.00041357081,0.00014272654,0.00008289673,0.000019250641,0.00017221774,1.5930631e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051547665,0.001314977,0.83795005,0.00002297359,0.0036796774,0.00002062886,0.0011212,0.00011407973,0.03934323,0.000052045576,0.0004893855,0.0643441],"study_design_scores_gemma":[0.004856435,0.011995259,0.9727879,0.000025819736,0.0011265409,0.000008659,0.00042636483,0.00012109661,0.005000208,0.00002359796,0.0035662518,0.00006186728],"about_ca_topic_score_codex":0.00012332444,"about_ca_topic_score_gemma":0.0004134216,"teacher_disagreement_score":0.13483787,"about_ca_system_score_codex":0.00016303669,"about_ca_system_score_gemma":0.0004785351,"threshold_uncertainty_score":0.29809725},"labels":[],"label_agreement":null},{"id":"W2603609760","doi":"10.1200/jco.2017.35.4_suppl.699","title":"Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Queen's University; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cetuximab; Quartile; Internal medicine; Colorectal cancer; KRAS; Population; Progression-free survival; Pharmacokinetics; Gastroenterology; Oncology; Confidence interval; Cancer; Overall survival","score_opus":0.10138674971268885,"score_gpt":0.4622945622062024,"score_spread":0.36090781249351356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603609760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076676,0.00071851065,0.0000031193015,0.0034962513,0.0007872576,0.0002174916,0.0000064094106,0.0000033471329,0.004000848],"genre_scores_gemma":[0.9971121,0.001537752,0.0005623702,0.00036001176,0.00027198283,0.0000094942625,5.931193e-7,0.0000126344285,0.00013305461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815905,0.00015539778,0.0009840702,0.00018809795,0.0003002265,0.00021315124],"domain_scores_gemma":[0.9975492,0.00053999503,0.0012423877,0.00013758377,0.00032961936,0.00020121252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009544907,0.00013863617,0.001495375,0.00006274419,0.00011139492,0.000019096731,0.000120976896,0.00010503243,0.000048889717],"category_scores_gemma":[0.0012881497,0.000082557824,0.00014073498,0.00004731983,0.0004058099,0.00014556883,0.00007137882,0.0005318279,0.0000026107994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016144287,0.001327095,0.8131758,0.000020962936,0.0004487388,0.0003555202,0.0001154808,0.0000023406858,0.0000037196596,0.000018018605,0.0002352293,0.16815282],"study_design_scores_gemma":[0.025433157,0.021297641,0.9463665,0.0001328703,0.00034972292,0.000038242415,0.000088127985,0.000022219396,0.00001123258,0.00006304018,0.0061168117,0.00008043982],"about_ca_topic_score_codex":0.00023263144,"about_ca_topic_score_gemma":0.0027849916,"teacher_disagreement_score":0.16807239,"about_ca_system_score_codex":0.00019191211,"about_ca_system_score_gemma":0.0006531392,"threshold_uncertainty_score":0.336661},"labels":[],"label_agreement":null},{"id":"W2603616054","doi":"10.1200/jco.2012.30.15_suppl.tps7618","title":"Weekly <i>nab</i>-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of patient-reported neuropathy and taxane-associated symptoms.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Taxane; Internal medicine; Tolerability; Carboplatin; Common Terminology Criteria for Adverse Events; Clinical endpoint; Paclitaxel; Oncology; Lung cancer; Adverse effect; Peripheral neuropathy; Gastroenterology; Cancer; Chemotherapy; Clinical trial; Breast cancer; Diabetes mellitus","score_opus":0.027568258179016925,"score_gpt":0.38018836991791655,"score_spread":0.3526201117388996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603616054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969809,0.0009773584,0.000007366591,0.00069266604,0.0003376538,0.0006660537,0.000009959455,0.000005409426,0.00032260647],"genre_scores_gemma":[0.99717516,0.0017134888,0.0001629366,0.0007526144,0.00006871425,0.000029169552,0.000024528737,0.00002393109,0.000049445684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669415,0.0004049139,0.0019763347,0.00023929421,0.00035602137,0.00032928688],"domain_scores_gemma":[0.9949512,0.0010166175,0.0030766225,0.00014343894,0.000541381,0.0002707581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009967433,0.000221965,0.0018017141,0.00049960735,0.000026176187,0.0000040605673,0.0000786976,0.0002582475,0.00005971411],"category_scores_gemma":[0.00030151152,0.00015068844,0.00018937112,0.00087753485,0.00012650916,0.0001538863,0.000025725383,0.00065647636,3.0425872e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015970733,0.011107185,0.9420346,0.000028086513,0.0015654,0.0001659476,0.0009136789,0.0004672928,0.00015910766,0.0000012947697,0.000048291957,0.027538406],"study_design_scores_gemma":[0.050621215,0.04322054,0.9024109,0.0001592256,0.002397205,0.000011257496,0.000095048155,0.00047590886,0.000207899,0.0000033902234,0.00026739232,0.00013002164],"about_ca_topic_score_codex":0.0005552099,"about_ca_topic_score_gemma":0.0017368679,"teacher_disagreement_score":0.039623678,"about_ca_system_score_codex":0.00034924728,"about_ca_system_score_gemma":0.0007092299,"threshold_uncertainty_score":0.6144896},"labels":[],"label_agreement":null},{"id":"W2603622689","doi":"10.1200/jco.2017.35.6_suppl.22","title":"The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; 5 Alpha-Reductase Inhibitor; Internal medicine; Biopsy; Prostate; Cancer; Prostate biopsy; Gynecology; Finasteride","score_opus":0.20376476232072682,"score_gpt":0.47424759404870237,"score_spread":0.27048283172797555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603622689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677794,0.00022080664,5.7784456e-7,0.031232873,0.00014785396,0.0005473888,0.000011150138,0.0000013680618,0.00005856816],"genre_scores_gemma":[0.99719137,0.00230293,0.000057140755,0.00012301,0.000087356784,0.000013137292,0.0000015478348,0.000004558539,0.00021893343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978223,0.0009809538,0.0007032793,0.00012414489,0.0002362811,0.0001330551],"domain_scores_gemma":[0.9931491,0.004542935,0.0016919276,0.00020477588,0.00034119913,0.000070064154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004877912,0.000080944235,0.0005790908,0.000043806198,0.00017320896,0.000034749497,0.00011168395,0.00010745384,8.166146e-7],"category_scores_gemma":[0.005909466,0.000029595252,0.000055669014,0.000051766747,0.00036849175,0.0001485348,0.000041560143,0.0005610656,1.3164305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00426045,0.0007163663,0.9478764,0.0000061296637,0.00019754219,0.00017117093,0.0013181518,8.8099705e-7,0.000073376556,0.000004119026,0.00036537313,0.04501007],"study_design_scores_gemma":[0.0049996194,0.0077914395,0.98253846,0.000029201827,0.00005767373,0.0000435949,0.00310829,0.000020531254,0.000044757206,0.0000905195,0.0012440849,0.00003180904],"about_ca_topic_score_codex":0.00020805393,"about_ca_topic_score_gemma":0.001190819,"teacher_disagreement_score":0.044978265,"about_ca_system_score_codex":0.00013328662,"about_ca_system_score_gemma":0.00050039205,"threshold_uncertainty_score":0.707461},"labels":[],"label_agreement":null},{"id":"W2603632799","doi":"10.1200/jco.2012.30.15_suppl.8018","title":"Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Clinical endpoint; Multiple myeloma; Refractory (planetary science); Gastroenterology; Dexamethasone; Placebo; Randomized controlled trial; Urology; Surgery","score_opus":0.1848560529788988,"score_gpt":0.4819584062365803,"score_spread":0.29710235325768153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603632799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876737,0.0013336708,0.000091932154,0.0007363675,0.0017076067,0.004692522,0.000003976449,0.000030943993,0.0037293101],"genre_scores_gemma":[0.99564075,0.0003206499,0.0016946198,0.0001861266,0.0014206897,0.00022923149,0.000017834915,0.000058685437,0.00043141036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99060035,0.002017791,0.00460727,0.00046071492,0.0012493434,0.0010645451],"domain_scores_gemma":[0.9818522,0.0126044145,0.0027852762,0.0005479704,0.00063212233,0.0015780481],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012761456,0.00048808687,0.0071750665,0.0006000145,0.00017759686,0.00003067888,0.0003606383,0.000523541,0.00017450518],"category_scores_gemma":[0.009672919,0.0003011449,0.0009963296,0.0003660672,0.00046362987,0.0005345959,0.00018330789,0.0026158935,0.000053368036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8181522,0.056102198,0.10456665,0.000021517437,0.0043310635,0.0026224027,0.0006708241,0.000059287006,0.00004317921,0.00001014187,0.00035715458,0.013063419],"study_design_scores_gemma":[0.9151055,0.05787027,0.01951629,0.0001338533,0.0020518554,0.00024212539,0.00086180156,0.0020950735,0.00004193436,0.0000064961296,0.0018271105,0.0002476702],"about_ca_topic_score_codex":0.0002849975,"about_ca_topic_score_gemma":0.0010167619,"teacher_disagreement_score":0.096953355,"about_ca_system_score_codex":0.0008510621,"about_ca_system_score_gemma":0.0023888443,"threshold_uncertainty_score":0.9999441},"labels":[],"label_agreement":null},{"id":"W2603670806","doi":"10.1200/jco.2014.32.15_suppl.8518","title":"A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Nausea; Vomiting; Gastroenterology; Pharmacodynamics; Internal medicine; Lymphoma; Dosing; Pharmacokinetics; Chemotherapy","score_opus":0.021563124809401178,"score_gpt":0.350336173064348,"score_spread":0.3287730482549468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603670806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988238,0.000009014726,0.000056221288,0.00008883295,0.0004433083,0.00029290505,0.0000031321354,0.0000020019218,0.00028076224],"genre_scores_gemma":[0.99902815,0.000010183709,0.00040983543,0.00018790492,0.0003209912,0.0000016230285,0.0000054601906,0.000019375937,0.000016490058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974766,0.00052022655,0.0013994308,0.00020416218,0.000261871,0.00013775409],"domain_scores_gemma":[0.997388,0.00010082539,0.0016448869,0.00022008688,0.0005656376,0.00008058772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009817702,0.00013471718,0.0006674103,0.00007274146,0.000031726682,0.0000044844787,0.00017604177,0.00031589105,0.000009946813],"category_scores_gemma":[0.0007026724,0.000082464474,0.00016973577,0.00019898407,0.00012864651,0.00001360169,0.00006236836,0.000263599,7.610398e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03638938,0.019402344,0.7785113,0.000025307356,0.00052168895,0.000010340993,0.00056895206,0.00020367691,0.02771968,0.000009654322,0.0024334,0.13420428],"study_design_scores_gemma":[0.027353244,0.087415814,0.87885326,0.000038723974,0.00014840302,0.000013129021,0.00018852537,0.00020798921,0.002768394,0.000023210672,0.0028879968,0.00010129982],"about_ca_topic_score_codex":0.000036642,"about_ca_topic_score_gemma":0.00013128975,"teacher_disagreement_score":0.13410299,"about_ca_system_score_codex":0.000043728964,"about_ca_system_score_gemma":0.00027694728,"threshold_uncertainty_score":0.33628038},"labels":[],"label_agreement":null},{"id":"W2603681974","doi":"10.1200/jco.2012.30.15_suppl.10620","title":"Serum activinA and TGF-β as biomarkers of breast cancer bone metastasis behavior.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Bone metastasis; Oncology; Biomarker; Breast cancer; N-terminal telopeptide; Bone resorption; Cancer; Metastasis; Alkaline phosphatase; Osteocalcin","score_opus":0.14969147871445082,"score_gpt":0.5288066990752556,"score_spread":0.37911522036080475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603681974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847345,0.0026670469,0.0000030823337,0.01053424,0.0009612161,0.00016857332,0.000026580241,0.0000038117998,0.00090095145],"genre_scores_gemma":[0.9948384,0.0022040543,0.0012581024,0.0011654093,0.00034849535,0.0000057773004,9.2090545e-7,0.0000123164555,0.00016651284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767125,0.00025530581,0.001435728,0.000104335515,0.00025110488,0.00028229065],"domain_scores_gemma":[0.9967464,0.0006943761,0.0013754747,0.00012266207,0.00022655085,0.0008344978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019000634,0.000111083114,0.0012663131,0.00010920341,0.00002964781,0.0000020371338,0.000046180365,0.00027222015,0.00037139244],"category_scores_gemma":[0.0005028751,0.000073931464,0.00027478143,0.000103608574,0.00019292865,0.00014586316,0.000032943764,0.0004620811,0.000009146868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028651843,0.002228465,0.64828295,0.000033129374,0.00050627824,0.00013372484,0.000036487232,3.376023e-8,0.00011756497,0.00001548833,0.00092346256,0.34485722],"study_design_scores_gemma":[0.0066661346,0.004152128,0.9709165,0.00006989586,0.001651753,0.0022605082,0.00007431035,0.0000012543735,0.00015508677,0.000026572874,0.013973936,0.00005190131],"about_ca_topic_score_codex":0.00030725353,"about_ca_topic_score_gemma":0.000057254576,"teacher_disagreement_score":0.34480533,"about_ca_system_score_codex":0.00010968556,"about_ca_system_score_gemma":0.0010823298,"threshold_uncertainty_score":0.40664867},"labels":[],"label_agreement":null},{"id":"W2603682673","doi":"10.1200/jco.2017.35.6_suppl.e590","title":"Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Metastasis; Oncology; Systemic therapy; Tumour heterogeneity; Cancer; Univariate analysis; Internal medicine; Pathology; Multivariate analysis; Breast cancer","score_opus":0.09134491045388134,"score_gpt":0.4719387357795939,"score_spread":0.38059382532571256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603682673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98544437,0.00094338774,0.00045689978,0.009832664,0.002620181,0.00051811605,0.000041128704,0.0000104089695,0.00013284627],"genre_scores_gemma":[0.9814563,0.00081727793,0.011996731,0.00504577,0.0005891523,0.000010909834,0.0000045014594,0.000030421657,0.000048970636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99406296,0.0012857204,0.003367582,0.00030580058,0.00061146886,0.00036643932],"domain_scores_gemma":[0.99201757,0.0016899379,0.004523652,0.00053544616,0.0007380759,0.00049529935],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0046910364,0.00023002991,0.0021192136,0.00014131989,0.00013770904,0.000045297293,0.0004312577,0.0000754208,0.00006977666],"category_scores_gemma":[0.017872544,0.00015764037,0.00053075684,0.00008754663,0.0005117989,0.0001882733,0.00015909599,0.0009253172,0.0000040006476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05102685,0.002185974,0.2052504,0.000387463,0.0020399631,0.005356692,0.0031465997,0.0013041251,0.011779814,0.00008244095,0.0066899983,0.7107497],"study_design_scores_gemma":[0.079502285,0.15014033,0.54457045,0.010766901,0.004523827,0.024758069,0.004229022,0.006791831,0.009712274,0.004734413,0.15821129,0.002059342],"about_ca_topic_score_codex":0.00044799357,"about_ca_topic_score_gemma":0.00001835853,"teacher_disagreement_score":0.70869035,"about_ca_system_score_codex":0.0002806056,"about_ca_system_score_gemma":0.0016868606,"threshold_uncertainty_score":0.9904003},"labels":[],"label_agreement":null},{"id":"W2603697950","doi":"10.1200/jco.2017.35.6_suppl.245","title":"Eligibility criteria requirements and adherence in advanced prostate cancer trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Generalizability theory; Clinical trial; Population; Internal medicine; Cancer; Oncology; Intensive care medicine","score_opus":0.4552741150111095,"score_gpt":0.6662526710499402,"score_spread":0.21097855603883076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603697950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982934,0.0026225424,0.0000025504787,0.011325428,0.0011755531,0.0004346236,0.0000074501227,0.0000029946436,0.0014948341],"genre_scores_gemma":[0.9816488,0.015872821,0.00091264304,0.00036450976,0.00048966694,0.000018010687,9.91315e-7,0.0000076279844,0.00068490405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671435,0.0005318295,0.002037044,0.0002100324,0.0002738757,0.00023284553],"domain_scores_gemma":[0.9962509,0.0009637706,0.0018319149,0.0002659702,0.0003697394,0.0003176693],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009212248,0.00010196203,0.0016073685,0.000073635725,0.00007417169,0.000028383414,0.00016642692,0.00019343487,0.00015483932],"category_scores_gemma":[0.013088963,0.00006184119,0.00019338603,0.00003929594,0.00038360542,0.00025831274,0.00009359756,0.0006479731,0.0000033318975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015935477,0.0005407305,0.57065374,0.000050633673,0.00011893797,0.00044309153,0.000096039366,3.737176e-7,0.0010387911,0.000008114521,0.0008573654,0.41025668],"study_design_scores_gemma":[0.025775557,0.008246573,0.94926715,0.00038343132,0.00012490088,0.000032010772,0.000063069594,0.000027623395,0.0005614111,0.0014017267,0.014049889,0.000066631655],"about_ca_topic_score_codex":0.000100956924,"about_ca_topic_score_gemma":0.00018922487,"teacher_disagreement_score":0.41019005,"about_ca_system_score_codex":0.0001878055,"about_ca_system_score_gemma":0.0016965701,"threshold_uncertainty_score":0.9952242},"labels":[],"label_agreement":null},{"id":"W2603747793","doi":"10.1200/jco.2013.31.15_suppl.tps4593","title":"A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University of Alberta; University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Pazopanib; Ipilimumab; Sunitinib; Renal cell carcinoma; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Pharmacology; Cancer; Immunotherapy","score_opus":0.07959710117448439,"score_gpt":0.4098850430227954,"score_spread":0.330287941848311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603747793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746066,0.000086773616,0.000023060917,0.0005755598,0.0002279503,0.0012921084,0.0000050445633,0.0000052675337,0.00032355328],"genre_scores_gemma":[0.9985068,0.00006471612,0.0007718206,0.00041832673,0.0000781561,0.000027050028,0.000008219332,0.000028741424,0.0000961913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948338,0.00089727825,0.0030492852,0.00027528108,0.00062341767,0.0003209152],"domain_scores_gemma":[0.9952675,0.001210126,0.0023379496,0.00026839573,0.00070265646,0.00021337901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022297278,0.00023447389,0.0018742549,0.00046847484,0.000031655763,0.000013250779,0.0002146363,0.00018109345,0.00026599516],"category_scores_gemma":[0.00043493867,0.00013969878,0.00017476421,0.000567014,0.00024815067,0.00026086625,0.0000347565,0.0009191641,0.0000046551904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14820136,0.09100024,0.66323316,0.00012463493,0.00050322706,0.00097019476,0.0015798502,0.000020094634,0.0004191321,0.0000034098362,0.0005535079,0.093391165],"study_design_scores_gemma":[0.20639732,0.19793648,0.59211236,0.00023308885,0.00029568496,0.00007511667,0.002232323,0.000102137965,0.00019752767,0.000011729327,0.00027954238,0.00012669517],"about_ca_topic_score_codex":0.000921204,"about_ca_topic_score_gemma":0.001970754,"teacher_disagreement_score":0.10693624,"about_ca_system_score_codex":0.00031925688,"about_ca_system_score_gemma":0.0017485461,"threshold_uncertainty_score":0.5696751},"labels":[],"label_agreement":null},{"id":"W2603765210","doi":"10.1200/jco.2014.32.15_suppl.521","title":"Comparison of breast cancer recurrence and outcome patterns between patients treated in 1986-1992 and 2004-2008.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Hazard ratio; Breast cancer; Cohort; Internal medicine; Confidence interval; Estrogen receptor; Oncology; Cancer; Proportional hazards model; Demography","score_opus":0.0908489920310265,"score_gpt":0.46821655808514356,"score_spread":0.37736756605411703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603765210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775594,0.0008514434,0.000037040085,0.0009512146,0.00020268238,0.00007104407,0.00007068894,0.0000011160431,0.000058837304],"genre_scores_gemma":[0.9986388,0.0007510961,0.00013771368,0.00016159656,0.0002837573,0.0000030383762,0.0000091535385,0.000007605426,0.000007239459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980086,0.0002613592,0.0012775807,0.00018648301,0.00011627548,0.00014971639],"domain_scores_gemma":[0.99830866,0.00032416362,0.0009880062,0.0001008828,0.00015419319,0.0001240699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058351026,0.00012340338,0.00095242006,0.000051520474,0.000021653876,0.0000036499664,0.00009995574,0.00022472153,0.000006727875],"category_scores_gemma":[0.00037664088,0.0000921405,0.00009248963,0.0000482819,0.00018398112,0.0000065991153,0.000086474814,0.00023082754,3.2565902e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043454833,0.00036662194,0.8826144,0.000016652508,0.00012015766,0.0000015451235,0.00003772088,0.0000034852403,0.000042125725,0.000001853074,0.00026057617,0.11610036],"study_design_scores_gemma":[0.004046652,0.0020738663,0.99178535,0.000057676098,0.000109437926,0.0000086167065,0.000023975115,0.0000086412665,0.0001607262,0.000021016416,0.0016217721,0.00008225604],"about_ca_topic_score_codex":0.0003392985,"about_ca_topic_score_gemma":0.000814883,"teacher_disagreement_score":0.1160181,"about_ca_system_score_codex":0.000031122472,"about_ca_system_score_gemma":0.00008533921,"threshold_uncertainty_score":0.37573805},"labels":[],"label_agreement":null},{"id":"W2603814150","doi":"10.1200/jco.2012.30.15_suppl.9586","title":"A national survey of general internists' preferences and knowledge gaps regarding the care of childhood cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Specialty; Family medicine; Concordance; Logistic regression; Vignette; Demography; Pediatrics; Internal medicine","score_opus":0.20468520050806627,"score_gpt":0.5013159589339163,"score_spread":0.29663075842585007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603814150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766134,0.015483053,0.000024316316,0.0017528808,0.002002425,0.00016244204,0.000046933434,0.000004150073,0.0039104032],"genre_scores_gemma":[0.99498844,0.001848367,0.0005272693,0.0005400525,0.0019932217,0.0000035680243,0.0000060141283,0.000014389458,0.00007866977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99472713,0.0017671911,0.0025255452,0.00015415868,0.00060381676,0.00022213861],"domain_scores_gemma":[0.9902868,0.0049792263,0.0024827032,0.00017538358,0.0017994419,0.00027643307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010749053,0.00014653703,0.0015723765,0.00011785218,0.000041892497,0.000005849127,0.0002568883,0.00026595787,0.00008629269],"category_scores_gemma":[0.008342024,0.00009032482,0.00033450266,0.00017788362,0.0004619407,0.00013218896,0.00013214893,0.00078908843,0.0000016388844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001060666,0.0010387725,0.9570332,0.00015449313,0.0006128457,0.0000020797906,0.005876154,0.000005278295,0.00003766256,0.00021610854,0.0022672615,0.031695433],"study_design_scores_gemma":[0.002883993,0.0020419362,0.9841956,0.0003303161,0.00022624427,0.00007207024,0.00088547246,0.000011985764,0.00019690389,0.000107587904,0.008963034,0.000084894265],"about_ca_topic_score_codex":0.0026670634,"about_ca_topic_score_gemma":0.011767988,"teacher_disagreement_score":0.031610537,"about_ca_system_score_codex":0.00010992896,"about_ca_system_score_gemma":0.0028448487,"threshold_uncertainty_score":0.99867845},"labels":[],"label_agreement":null},{"id":"W2603814443","doi":"10.1200/jco.2013.31.15_suppl.7602","title":"Thymic carcinoma: A cohort study of prognostic factors after surgical resection from the European Society of Thoracic Surgeons database.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Cumulative incidence; Multivariate analysis; Incidence (geometry); Thymic carcinoma; Radiation therapy; Univariate analysis; Stage (stratigraphy); T-stage; Proportional hazards model; Internal medicine; Cohort; Surgery; Chemotherapy; Oncology; Database; Cancer","score_opus":0.10419871041510034,"score_gpt":0.42874864272151275,"score_spread":0.3245499323064124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603814443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681324,0.00024071452,0.000020995749,0.0010490891,0.00053312705,0.0006669102,0.000020123352,0.0000054921757,0.0006503383],"genre_scores_gemma":[0.9987577,0.00014397434,0.00021167901,0.00012969968,0.0006387229,0.000007709123,0.000010822915,0.000020790849,0.00007885823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943339,0.0021774757,0.0025064358,0.00022052688,0.0005583164,0.00020330498],"domain_scores_gemma":[0.9919077,0.00509881,0.0017216966,0.00040370107,0.0006268818,0.00024118675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005544981,0.00015313229,0.001421975,0.000054640408,0.000043078806,0.000008177462,0.00023360035,0.00017392616,0.00041806008],"category_scores_gemma":[0.0016666966,0.00007901297,0.0006805302,0.00017585704,0.00028586798,0.00010078856,0.00013114129,0.0010544698,0.000012739214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016114715,0.003208162,0.98690766,0.000026415863,0.0005586107,0.00021855478,0.0005069116,9.372525e-7,0.00012248463,0.0000032702806,0.0025928707,0.0042426274],"study_design_scores_gemma":[0.0028467043,0.008129123,0.9846726,0.00011429298,0.0007673981,0.00010423221,0.0012868436,0.000041541065,0.00003833941,0.00004298125,0.0018896437,0.0000662759],"about_ca_topic_score_codex":0.00096447545,"about_ca_topic_score_gemma":0.00016583734,"teacher_disagreement_score":0.0049209604,"about_ca_system_score_codex":0.0000414093,"about_ca_system_score_gemma":0.00040028142,"threshold_uncertainty_score":0.45812052},"labels":[],"label_agreement":null},{"id":"W2603826687","doi":"10.1200/jco.2018.36.6_suppl.74","title":"The diverse genomic landscape of low−risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Oncology; Prostate biopsy; Quartile; Internal medicine; PTEN; Cancer; Population; Pathology; Confidence interval; Biology; Genetics","score_opus":0.11088025227615413,"score_gpt":0.5013645893553553,"score_spread":0.3904843370792012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603826687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98701996,0.0029477642,0.0000055886294,0.005948609,0.0013162068,0.00019398876,0.000011580258,0.0000034708094,0.0025528339],"genre_scores_gemma":[0.96870065,0.026868833,0.00024881013,0.00030704337,0.0018860268,0.0000037069046,9.155831e-7,0.0000096040885,0.0019744402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997831,0.0002778858,0.0012798017,0.00010545175,0.00028379165,0.00022206294],"domain_scores_gemma":[0.995976,0.0015569419,0.0013500296,0.00016323088,0.0007190561,0.00023475559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028808746,0.000077299745,0.000685071,0.00005624733,0.000100794095,0.000006280514,0.0001729622,0.00014607262,0.00021435917],"category_scores_gemma":[0.0016692126,0.00003661798,0.00028805094,0.00010977287,0.0006985909,0.000044807126,0.00006991973,0.00062067277,0.000028844232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018306993,0.0006401082,0.61047953,0.000031484753,0.00078536576,0.00022150394,0.0003579202,0.0000044720027,0.00045876874,0.000033300326,0.021961488,0.34671906],"study_design_scores_gemma":[0.015980402,0.026682634,0.6927366,0.0001519864,0.0005133426,0.00009189979,0.0005917219,0.00014542497,0.0010477912,0.0005516934,0.26142633,0.000080114005],"about_ca_topic_score_codex":0.00004700707,"about_ca_topic_score_gemma":0.000107045664,"teacher_disagreement_score":0.34663895,"about_ca_system_score_codex":0.00010511174,"about_ca_system_score_gemma":0.002183797,"threshold_uncertainty_score":0.38739622},"labels":[],"label_agreement":null},{"id":"W2603830880","doi":"10.1200/jco.2009.27.15_suppl.9565","title":"Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Thrombosis; Pulmonary embolism; Internal medicine; Surgery; Cancer; Hazard ratio; Deep vein; Low molecular weight heparin; Vitamin K antagonist; Body mass index; Anticoagulant; Proportional hazards model; Warfarin; Confidence interval; Atrial fibrillation","score_opus":0.07319900428181632,"score_gpt":0.4255467211793356,"score_spread":0.3523477168975193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603830880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942094,0.00033064466,0.000004728865,0.003740949,0.00065621146,0.0002204207,0.0000016463968,0.0000036657202,0.00083231693],"genre_scores_gemma":[0.9949349,0.0039438917,0.000366568,0.00058611395,0.00015130974,0.0000011275935,0.00000113134,0.0000065698227,0.00000838181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780726,0.00010104604,0.0015180785,0.00012803359,0.00028697858,0.00015857547],"domain_scores_gemma":[0.9981269,0.00027016993,0.0011216014,0.000084291394,0.00022946451,0.00016755908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010761484,0.00009531241,0.0014111493,0.00015312519,0.000014430042,0.0000033222454,0.00006899896,0.00016229476,0.000052923053],"category_scores_gemma":[0.00035712993,0.000060532882,0.0001145161,0.00014454909,0.00010548017,0.0000789815,0.000023670153,0.00042369714,5.559223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007610197,0.003735263,0.93910253,0.000031950018,0.00038917342,0.000020704794,0.0001787849,0.000019171002,0.000018548797,0.000097089105,0.0015356931,0.05411008],"study_design_scores_gemma":[0.00802269,0.020702723,0.9686884,0.00056094216,0.00058027805,0.0000036284102,0.000053076405,0.000029395249,0.000014041151,0.00008056468,0.0012082556,0.000055957567],"about_ca_topic_score_codex":0.000025544065,"about_ca_topic_score_gemma":0.000021933587,"teacher_disagreement_score":0.054054122,"about_ca_system_score_codex":0.00007262747,"about_ca_system_score_gemma":0.0002474391,"threshold_uncertainty_score":0.24684593},"labels":[],"label_agreement":null},{"id":"W2603845531","doi":"10.1200/jco.2014.32.15_suppl.e17630","title":"A retrospective analysis of integrative medicine consultations at a major cancer center: Reasons for consultation, symptom burden, quality of life, and satisfaction.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Family medicine; Integrative medicine; Pain medicine; Patient satisfaction; Distress; Scale (ratio); Alternative medicine; Rating scale; Physical therapy; Psychiatry; Nursing; Clinical psychology","score_opus":0.1309868688135317,"score_gpt":0.5202728871360197,"score_spread":0.389286018322488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603845531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834056,0.0005427433,0.0037532952,0.01076143,0.00044419614,0.00033214584,0.00020963134,0.0000036525485,0.000547305],"genre_scores_gemma":[0.9956381,0.0012277205,0.0019183008,0.00048528946,0.00054500217,0.000015204209,0.000020416765,0.0000059937774,0.00014401124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614716,0.0005197979,0.0026954273,0.0001881969,0.00033040458,0.00011902739],"domain_scores_gemma":[0.9826175,0.01056552,0.0035167348,0.000116797615,0.0029727048,0.0002107494],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027331419,0.00013850149,0.0026757068,0.00030406573,0.00007026468,0.0000012903959,0.00006488364,0.000055857265,0.0002496807],"category_scores_gemma":[0.041906286,0.00008282119,0.0003658253,0.0003976534,0.0009846555,0.000053928732,0.000038943923,0.00028714692,2.110301e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034552459,0.00026342864,0.9650566,0.00007473696,0.008353784,0.0000019870452,0.002298568,0.000010311199,0.00044230113,0.0019324727,0.0015370311,0.01657353],"study_design_scores_gemma":[0.015665637,0.007842461,0.9644893,0.00021462241,0.00388611,0.000008598963,0.0039284267,0.00026754773,0.00003179734,0.00051987334,0.003084973,0.00006066919],"about_ca_topic_score_codex":0.00096040673,"about_ca_topic_score_gemma":0.0039097564,"teacher_disagreement_score":0.039173145,"about_ca_system_score_codex":0.00014195812,"about_ca_system_score_gemma":0.00037745386,"threshold_uncertainty_score":0.9661642},"labels":[],"label_agreement":null},{"id":"W2603848217","doi":"10.1200/jco.2013.31.15_suppl.e17564","title":"Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Adjuvant; Endocrine system; Oncology; Gynecology; Adverse effect; Internal medicine; Cancer; Hormone","score_opus":0.14093288341092883,"score_gpt":0.47818790494957014,"score_spread":0.3372550215386413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603848217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953071,0.00080858974,0.00016782692,0.0433247,0.0012085111,0.00038607512,0.000021542499,0.000021232143,0.0009905443],"genre_scores_gemma":[0.9881583,0.00066270854,0.0018880657,0.006787262,0.0019265314,0.000023702536,0.000001759762,0.000041685154,0.0005099854],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958825,0.00040402552,0.00238303,0.0002898957,0.00051464577,0.00052589545],"domain_scores_gemma":[0.99574804,0.0011961135,0.0015365817,0.00027082537,0.00070749363,0.0005409157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012089644,0.00024385551,0.0020568757,0.00022083257,0.00003180542,0.00001213386,0.00021907307,0.00033715027,0.0008356886],"category_scores_gemma":[0.0007643535,0.00017805747,0.00047046362,0.00024109035,0.00036695975,0.0003704357,0.000080033555,0.0019870123,0.000053321746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008461749,0.0017282484,0.41486794,0.000054224318,0.00072250556,0.0029676564,0.0006090846,0.00015371245,0.005064284,0.00014871823,0.0011066572,0.5641152],"study_design_scores_gemma":[0.015455263,0.004095067,0.94132304,0.00025120866,0.00017795412,0.001693897,0.00054809696,0.00013943342,0.001004503,0.00035954962,0.03475767,0.00019429205],"about_ca_topic_score_codex":0.0005007094,"about_ca_topic_score_gemma":0.0004705344,"teacher_disagreement_score":0.5639209,"about_ca_system_score_codex":0.00062218413,"about_ca_system_score_gemma":0.001948934,"threshold_uncertainty_score":0.9150204},"labels":[],"label_agreement":null},{"id":"W2603868241","doi":"10.1200/jco.2012.30.15_suppl.e14706","title":"Multistage phase II design for mixed tumor response and time-to-event endpoints: An application for screening new drugs in hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Surrogate endpoint; Oncology; Internal medicine; Early stopping; Progression-free survival; Hepatocellular carcinoma; Hazard ratio; Phases of clinical research; Randomized controlled trial; Clinical trial; Overall survival; Confidence interval; Machine learning","score_opus":0.590656214930436,"score_gpt":0.6152416354378769,"score_spread":0.024585420507440947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603868241","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4068635,0.000049616792,0.5898266,0.0013303872,0.0003618071,0.0015128282,0.000036264002,0.000010674677,0.000008363799],"genre_scores_gemma":[0.2696607,0.000005334221,0.72824764,0.00054230733,0.0012361435,0.00010357242,0.000001613851,0.000042793767,0.00015987548],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9892331,0.0047526187,0.004757484,0.00038637672,0.00033295323,0.000537471],"domain_scores_gemma":[0.8088386,0.18718459,0.0023065917,0.00031908645,0.0003222342,0.0010289213],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06279633,0.0002429228,0.002210897,0.00019506825,0.00009872671,0.000017921227,0.0003634542,0.0004367276,0.000076211836],"category_scores_gemma":[0.28617993,0.00020354119,0.00040905623,0.00015196466,0.00015154333,0.00019454374,0.00011828111,0.0006030297,0.00000894493],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15643838,0.011018379,0.0033348864,0.00017981212,0.00027612908,0.00006269009,0.0013172865,0.000036812875,0.008010218,0.005982799,0.012199943,0.80114263],"study_design_scores_gemma":[0.112544745,0.1156442,0.016116677,0.00044344825,0.0016021193,0.000177209,0.0008020112,0.083922006,0.008252286,0.5724588,0.08681631,0.0012201727],"about_ca_topic_score_codex":0.0000073839806,"about_ca_topic_score_gemma":0.0000023873336,"teacher_disagreement_score":0.79992247,"about_ca_system_score_codex":0.00014648703,"about_ca_system_score_gemma":0.0006561793,"threshold_uncertainty_score":0.96504843},"labels":[],"label_agreement":null},{"id":"W2603871637","doi":"10.1200/jco.2012.30.15_suppl.e11005","title":"Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Anastrozole; Exemestane; Internal medicine; Clinical trial; Endocrine system; Hormonal therapy; Randomized controlled trial; Placebo; Adjuvant therapy; Cancer; Oncology; Breast cancer; Aromatase; Hormone; Alternative medicine; Pathology","score_opus":0.021401583542942696,"score_gpt":0.34319306935953053,"score_spread":0.32179148581658784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603871637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973859,0.0010934123,0.000015695958,0.00012544646,0.0011331558,0.00014468758,0.000024987356,0.0000016146247,0.000075053875],"genre_scores_gemma":[0.99627244,0.0025294553,0.0002102214,0.00020639836,0.0006515989,0.0000026786313,0.00005086617,0.000018040388,0.000058319583],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977944,0.000405199,0.0013085289,0.00011815538,0.00018224707,0.00019146672],"domain_scores_gemma":[0.9978025,0.00011881074,0.0015065938,0.00017183243,0.00023072319,0.00016953252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008344968,0.0001150336,0.00062500604,0.000063732215,0.000009416367,0.0000023228038,0.00013453653,0.00037142215,0.000050054496],"category_scores_gemma":[0.00040156062,0.00008676776,0.00032408783,0.000068079135,0.0001384644,0.000016113427,0.000052727493,0.0002837669,0.000006288216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007547505,0.0023316876,0.40556163,0.000022002649,0.00041481166,0.000023608709,0.00016215399,0.000003975932,0.49471372,0.0000028591328,0.0006607941,0.08855526],"study_design_scores_gemma":[0.003798957,0.0069698314,0.80833936,0.000046126617,0.000075143114,0.00001682821,0.000013430388,0.0000030261353,0.15316981,0.000008775936,0.027454881,0.0001038023],"about_ca_topic_score_codex":0.0000034316004,"about_ca_topic_score_gemma":8.360115e-7,"teacher_disagreement_score":0.40277776,"about_ca_system_score_codex":0.000013950275,"about_ca_system_score_gemma":0.00015489881,"threshold_uncertainty_score":0.35382864},"labels":[],"label_agreement":null},{"id":"W2603873395","doi":"10.1200/jco.2013.31.15_suppl.e22042","title":"ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Immunohistochemistry; Internal medicine; Fish <Actinopterygii>; Lung cancer; Oncology; Pathology; Biology","score_opus":0.03635374449625242,"score_gpt":0.4636437514692342,"score_spread":0.4272900069729818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603873395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842316,0.00014032074,0.00048767112,0.0015681628,0.0006359199,0.0005540502,0.0000061660135,0.0000068810705,0.012369248],"genre_scores_gemma":[0.99458325,0.00005627386,0.0040509393,0.00037384624,0.0004352997,0.000014733468,0.000023433882,0.000017554605,0.00044464413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778825,0.00015388476,0.0013793366,0.00020058519,0.0003114735,0.00016647782],"domain_scores_gemma":[0.9974476,0.00034835673,0.0009529644,0.00019700381,0.00082046335,0.00023361944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079519727,0.0001331072,0.00074056187,0.00012321863,0.00003833377,0.000020544121,0.00014424215,0.00017460075,0.00018645194],"category_scores_gemma":[0.0002960043,0.00009237916,0.00012976867,0.00011190455,0.00010465541,0.00012945865,0.000026944757,0.00053312426,0.000007161334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018798969,0.004648842,0.9776565,0.000025646219,0.00041888174,0.0009505773,0.0007728331,0.000119996104,0.0023816393,0.000006400053,0.00093433814,0.010204453],"study_design_scores_gemma":[0.020761725,0.010315723,0.963507,0.00010017748,0.0005378441,0.00025674084,0.0018142681,0.00044801628,0.00014479522,0.000021009819,0.0019832072,0.00010947222],"about_ca_topic_score_codex":0.00023482715,"about_ca_topic_score_gemma":0.000050484035,"teacher_disagreement_score":0.018881828,"about_ca_system_score_codex":0.00044748522,"about_ca_system_score_gemma":0.0020478505,"threshold_uncertainty_score":0.37671128},"labels":[],"label_agreement":null},{"id":"W2603885478","doi":"10.1200/jco.2013.31.15_suppl.7526","title":"Accelerated hypofractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): Results of a phase I/II study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Radiation therapy; Extrapleural Pneumonectomy; Mesothelioma; Stage (stratigraphy); Surgery; Nuclear medicine; Radiology; Pneumonectomy; Lung cancer; Internal medicine; Randomized controlled trial; Pathology","score_opus":0.13118537207704445,"score_gpt":0.46002681447072863,"score_spread":0.3288414423936842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603885478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943057,0.00034703186,0.000044762302,0.003256094,0.00063107884,0.0012159297,0.00011067816,0.000021829797,0.000066940935],"genre_scores_gemma":[0.9974661,0.0002526798,0.0004185239,0.000979921,0.00027679218,0.000036016754,0.00017430384,0.000026946627,0.00036872618],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9957649,0.00041801858,0.00276721,0.00029791368,0.000499555,0.00025240428],"domain_scores_gemma":[0.99514335,0.0013023884,0.0022187238,0.0002020186,0.0007559048,0.0003776332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014853652,0.00022659925,0.0013849998,0.00017380358,0.000109132474,0.000012634768,0.00016007017,0.00028545564,0.00019025443],"category_scores_gemma":[0.0019299652,0.0001569995,0.0005721279,0.00024161008,0.00016051107,0.0003824296,0.00003900151,0.0004883796,0.000013396553],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18481633,0.050881624,0.1485555,0.000046824152,0.0027426856,0.0002463001,0.0002848851,0.00011585128,0.32944748,0.0000041604726,0.053577643,0.22928073],"study_design_scores_gemma":[0.06305047,0.06224015,0.8552598,0.000053040992,0.0005193996,0.00015545692,0.00023451589,0.003286032,0.008790902,0.00014480634,0.006060763,0.00020470413],"about_ca_topic_score_codex":0.000097027965,"about_ca_topic_score_gemma":0.000004345108,"teacher_disagreement_score":0.70670426,"about_ca_system_score_codex":0.00016411286,"about_ca_system_score_gemma":0.0003572497,"threshold_uncertainty_score":0.64022535},"labels":[],"label_agreement":null},{"id":"W2603892395","doi":"10.1200/jco.2013.31.15_suppl.1521","title":"The relationship between serum vitamin D levels and breast cancer prognosis: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; McGill University","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Meta-analysis; Internal medicine; Oncology; Vitamin D and neurology; Proportional hazards model; Cancer; Confidence interval","score_opus":0.480817214624298,"score_gpt":0.5511869942984399,"score_spread":0.07036977967414187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603892395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7608813,0.003839724,0.000045379344,0.2343402,0.00014544038,0.00036116314,0.000021821015,0.000006756303,0.0003582059],"genre_scores_gemma":[0.995522,0.00047777742,0.0007640933,0.0009041985,0.0007535216,0.000055473945,4.9853384e-7,0.000010333828,0.0015121067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959405,0.0010282601,0.0019977416,0.00018385008,0.0005511809,0.00029845943],"domain_scores_gemma":[0.9789676,0.018108658,0.0012521334,0.00021157683,0.0010282531,0.00043177613],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068499697,0.00013430724,0.0023837376,0.00016558499,0.00018506414,0.000034452565,0.00019349807,0.00024691276,0.00029004295],"category_scores_gemma":[0.010503435,0.000060818853,0.0012628854,0.0004006416,0.0005796374,0.00015860608,0.00012737616,0.001277037,0.000022238413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006396724,0.00016348476,0.9012743,0.000015303203,0.073650256,0.000030155597,0.000055479086,0.0000016943661,0.0000033847948,0.000052225983,0.005966907,0.018722845],"study_design_scores_gemma":[0.0012625527,0.0011675971,0.9090562,0.000011027537,0.0846434,0.000068476176,0.00017391823,0.000017958824,0.0000026590658,0.0006363324,0.0029060612,0.000053832417],"about_ca_topic_score_codex":0.00006006017,"about_ca_topic_score_gemma":0.00014770268,"teacher_disagreement_score":0.23464069,"about_ca_system_score_codex":0.000083351166,"about_ca_system_score_gemma":0.0006998659,"threshold_uncertainty_score":0.9978315},"labels":[],"label_agreement":null},{"id":"W2603919711","doi":"10.1200/jco.2017.35.5_suppl.54","title":"Identifying critical data elements for a provincial transition plan from a primary care perspective.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Thematic analysis; Government (linguistics); Health care; Survivorship curve; Focus group; Delphi method; Family medicine; Nursing; Cancer; Qualitative research; Political science; Business; Computer science","score_opus":0.7010127970578537,"score_gpt":0.6744375886231636,"score_spread":0.02657520843469008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603919711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80890787,0.00069531833,0.057987195,0.11874509,0.007998597,0.0017120598,0.0011096615,0.000032073505,0.0028121616],"genre_scores_gemma":[0.8941739,0.0001576622,0.09182887,0.005316639,0.008132486,0.000008278999,0.00033728027,0.000026579522,0.00001829186],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99450964,0.0004050694,0.0038976956,0.00039740233,0.00054573687,0.0002444849],"domain_scores_gemma":[0.9850647,0.008960665,0.0031250431,0.00076244806,0.0017257436,0.00036142938],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0064124567,0.00013874771,0.0012085525,0.00007460715,0.00024092157,0.0000748422,0.00060520624,0.0003792786,0.000121448014],"category_scores_gemma":[0.09717778,0.00011513659,0.00041087854,0.000026713868,0.00027188548,0.00095849996,0.00020971791,0.0010670783,0.000011410994],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050364085,0.0050596367,0.06240968,0.00047473,0.0016512688,0.001376853,0.0022285692,0.0000019601498,0.0017134398,0.00084167585,0.027063562,0.8468145],"study_design_scores_gemma":[0.06703288,0.027055474,0.74335337,0.0008389892,0.007930378,0.00043686223,0.018153096,0.0015653505,0.00011375322,0.01440196,0.11864099,0.00047688745],"about_ca_topic_score_codex":0.00032829112,"about_ca_topic_score_gemma":0.00072817213,"teacher_disagreement_score":0.8463377,"about_ca_system_score_codex":0.00039150257,"about_ca_system_score_gemma":0.0033406548,"threshold_uncertainty_score":0.9104271},"labels":[],"label_agreement":null},{"id":"W2603947135","doi":"10.1200/jco.2014.32.15_suppl.4576","title":"The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Underweight; Overweight; Renal cell carcinoma; Internal medicine; Body mass index; Obesity; Cancer; Gastroenterology","score_opus":0.15217479311176552,"score_gpt":0.4540940458671373,"score_spread":0.3019192527553718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603947135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287945,0.0010588462,0.00008787436,0.0032079164,0.0006630459,0.000612896,0.00041380696,0.00000411726,0.001072051],"genre_scores_gemma":[0.996141,0.0013463602,0.001298867,0.00038883003,0.00042511022,0.000023056458,0.00007161412,0.000031147854,0.0002739954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918057,0.0019299258,0.004585977,0.0003758715,0.00092785456,0.00037470637],"domain_scores_gemma":[0.97931665,0.01449605,0.0046204044,0.00070298027,0.00053869816,0.00032522343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00479433,0.00037944157,0.002189866,0.00020950957,0.000055636276,0.000016508151,0.0005692543,0.00015775718,0.00021730183],"category_scores_gemma":[0.0023457818,0.00016405286,0.0011484339,0.00021340996,0.00041485674,0.00009298095,0.0000668378,0.00094870804,0.0000075248513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07706127,0.008458189,0.8489589,0.00003136992,0.0037772115,0.0011429113,0.00046422434,0.003059312,0.028831491,0.000037478316,0.003913368,0.02426426],"study_design_scores_gemma":[0.040752213,0.03395914,0.89471114,0.00011738409,0.001022082,0.000049408398,0.00023479476,0.0021474508,0.024134824,0.00024438323,0.0024647545,0.00016242023],"about_ca_topic_score_codex":0.0040712105,"about_ca_topic_score_gemma":0.0005717665,"teacher_disagreement_score":0.04575223,"about_ca_system_score_codex":0.00080952985,"about_ca_system_score_gemma":0.0020752538,"threshold_uncertainty_score":0.66898817},"labels":[],"label_agreement":null},{"id":"W2603971309","doi":"10.1200/jco.2017.35.6_suppl.493","title":"Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Sorafenib; Axitinib; Hazard ratio; Proportional hazards model; Oncology; Confidence interval; Renal cell carcinoma; Cohort; Adverse effect; Cancer; Hepatocellular carcinoma","score_opus":0.09226972924427522,"score_gpt":0.4067554915371706,"score_spread":0.3144857622928954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603971309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994206,0.000085312975,0.000005659942,0.0020329177,0.00056998484,0.000765321,0.0000038522126,0.000003868112,0.0023270862],"genre_scores_gemma":[0.9977148,0.00003636079,0.0015075165,0.00021776838,0.00024551328,0.000012876054,0.000002988743,0.00002319322,0.00023893932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653196,0.00041891568,0.0019069737,0.0002637678,0.00058812223,0.0002902655],"domain_scores_gemma":[0.9955315,0.00093106256,0.0023557327,0.0003891335,0.00033132182,0.00046122578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021680195,0.00022217615,0.0019735924,0.00016665032,0.000080234444,0.00002871738,0.00019515953,0.00019925102,0.00003682635],"category_scores_gemma":[0.0015075417,0.00012740589,0.00025459248,0.00004720688,0.00033521655,0.00021069228,0.000102688646,0.0008707477,0.000008161955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051894737,0.0025298554,0.9809965,0.00006814853,0.00017845306,0.0015284714,0.000066136075,0.0000019327165,0.000033233315,0.0000064910796,0.00008260567,0.009318705],"study_design_scores_gemma":[0.027001021,0.025054606,0.94539255,0.00007634474,0.00044209944,0.000061030005,0.000048144724,0.000008026968,0.00054884376,0.000055384444,0.0011980928,0.000113829476],"about_ca_topic_score_codex":0.00010170788,"about_ca_topic_score_gemma":0.000096047115,"teacher_disagreement_score":0.035603918,"about_ca_system_score_codex":0.00019198832,"about_ca_system_score_gemma":0.0008255568,"threshold_uncertainty_score":0.5195461},"labels":[],"label_agreement":null},{"id":"W2603975029","doi":"10.1200/jco.2013.31.15_suppl.4006","title":"HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Folinic acid; Pancreatic cancer; Hazard ratio; Oncology; Randomized controlled trial; Cancer; Gastroenterology; Fluorouracil; Confidence interval","score_opus":0.2214233680647455,"score_gpt":0.46336126409136835,"score_spread":0.24193789602662286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603975029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763254,0.00055876473,0.000047735375,0.018313251,0.00095983763,0.0015306817,0.000027406793,0.000008066111,0.0022288708],"genre_scores_gemma":[0.9940789,0.0005882724,0.0012227901,0.0021958589,0.0010684025,0.000040276507,0.0000041466733,0.00002930804,0.0007720976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99066365,0.0032528366,0.0042482666,0.00034579358,0.000987863,0.00050162105],"domain_scores_gemma":[0.97711366,0.017672345,0.0024500238,0.00044141998,0.0013744356,0.0009481219],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012233063,0.00027797482,0.004732301,0.00025085223,0.000089839996,0.000016805303,0.00035645484,0.00037448568,0.0010066209],"category_scores_gemma":[0.051569805,0.00014624688,0.00054769893,0.00023495682,0.000632286,0.00011976968,0.00017091018,0.0013545766,0.00006996581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007968417,0.0018063895,0.95964664,0.000058425125,0.00099837,0.00019872657,0.00032581313,0.0000019674144,0.00034302994,0.00013898427,0.012251743,0.016261483],"study_design_scores_gemma":[0.013074001,0.03568398,0.946438,0.00037400244,0.0010140529,0.0001420678,0.00042068656,0.00021074255,0.00005946334,0.00045645234,0.002004773,0.000121790465],"about_ca_topic_score_codex":0.000091817674,"about_ca_topic_score_gemma":0.000025041023,"teacher_disagreement_score":0.03933674,"about_ca_system_score_codex":0.00017324468,"about_ca_system_score_gemma":0.0015582079,"threshold_uncertainty_score":0.9999066},"labels":[],"label_agreement":null},{"id":"W2603977557","doi":"10.1200/jco.2017.35.4_suppl.593","title":"Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Irinotecan; Colorectal cancer; Bevacizumab; Internal medicine; Cancer; FOLFIRI; Tolerability; Oncology; Phases of clinical research; Combination therapy; Pharmacology; Gastroenterology; Adverse effect; Chemotherapy","score_opus":0.28323780627631084,"score_gpt":0.5737039434525277,"score_spread":0.2904661371762169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603977557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949516,0.0003739648,0.000017438659,0.0032996822,0.0052936054,0.0010410371,0.00021527255,0.0000131002525,0.00025072164],"genre_scores_gemma":[0.99597234,0.0005902058,0.00007821853,0.0014866064,0.0015483467,0.000095880925,0.0000079301035,0.000040895833,0.0001795559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954709,0.000937899,0.00214366,0.0005090934,0.00049956253,0.0004388984],"domain_scores_gemma":[0.9927837,0.0006962186,0.0039933496,0.00026061857,0.0017083824,0.0005577276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016698425,0.00037690465,0.0017281236,0.00017609111,0.00078830094,0.00005970369,0.00040340557,0.0005807364,0.0003465163],"category_scores_gemma":[0.0005251337,0.0002919934,0.00020327278,0.00019005836,0.0006352836,0.0004365528,0.00032271934,0.0012743531,0.0000030965102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037695114,0.026211645,0.75064313,0.00017374511,0.001799253,0.00046668146,0.0023405137,0.00010758369,0.004837951,0.000021941323,0.0042057484,0.17149669],"study_design_scores_gemma":[0.1177379,0.050770495,0.7634136,0.0006769111,0.0023640606,0.000092999835,0.0017607382,0.0003318222,0.02056927,0.000041552285,0.04139785,0.0008428144],"about_ca_topic_score_codex":0.00035445133,"about_ca_topic_score_gemma":0.00480737,"teacher_disagreement_score":0.17065388,"about_ca_system_score_codex":0.00031056404,"about_ca_system_score_gemma":0.0012236205,"threshold_uncertainty_score":0.9999532},"labels":[],"label_agreement":null},{"id":"W2604002706","doi":"10.1200/jco.2004.22.90140.3147","title":"Gene expression changes during acquired resistance to tamoxifen; a preclinical model of post-menopausal breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aromatase; Breast cancer; Tamoxifen; Cancer research; Medicine; Estrogen; Cancer; Internal medicine; Aromatase inhibitor; Exemestane","score_opus":0.04255501184733491,"score_gpt":0.3947881427643051,"score_spread":0.3522331309169702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604002706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218285,0.001654023,0.00031517452,0.004970961,0.0005408453,0.00016546102,0.000038066093,0.0000050117246,0.0001276256],"genre_scores_gemma":[0.9874234,0.00175899,0.008650885,0.0008038885,0.0010729743,0.0000092624705,0.0000043917667,0.000024953084,0.00025123544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975134,0.00024509846,0.0014055341,0.0002946731,0.00026047922,0.00028079716],"domain_scores_gemma":[0.99760896,0.00013110676,0.0011494266,0.00025694535,0.00046343642,0.00039014933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011639578,0.0001680371,0.00080334523,0.00007011874,0.00005031432,0.000005842284,0.00033182712,0.0006850989,0.00001260709],"category_scores_gemma":[0.00077855034,0.00012558256,0.00025695443,0.00009011999,0.00016332342,0.000009736507,0.00016945494,0.00036942802,0.0000034355708],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009871234,0.0006766932,0.001013418,0.000028460841,0.0001952237,0.000059462192,0.000069372145,0.0035009414,0.9810657,0.000010215801,0.00042118013,0.0030880866],"study_design_scores_gemma":[0.007881505,0.010689896,0.023531277,0.00032296535,0.00020045844,0.00022173046,0.000034800858,0.000032228785,0.9554342,0.00020809144,0.0011678436,0.00027502642],"about_ca_topic_score_codex":0.0000062264467,"about_ca_topic_score_gemma":0.00005110324,"teacher_disagreement_score":0.025631534,"about_ca_system_score_codex":0.000060620867,"about_ca_system_score_gemma":0.0010095958,"threshold_uncertainty_score":0.528411},"labels":[],"label_agreement":null},{"id":"W2604003845","doi":"10.1200/jco.2017.35.4_suppl.tps212","title":"CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Cancer; Esophageal cancer; Gastroesophageal Junction; Oncology; Chemoradiotherapy; Placebo; Gastroenterology; Surgery; Adenocarcinoma; Immunotherapy; Pathology","score_opus":0.15638881062353543,"score_gpt":0.5103783892273519,"score_spread":0.35398957860381647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604003845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396926,0.00034243558,0.000027619211,0.000822038,0.0010613181,0.0032893666,0.000013248328,0.000012663592,0.00046205398],"genre_scores_gemma":[0.9965411,0.00042221908,0.00044240424,0.00013778167,0.00082923827,0.00017248343,0.000007654709,0.00004372253,0.0014033864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99308085,0.0011402413,0.0033961665,0.00047097012,0.0013146645,0.0005971049],"domain_scores_gemma":[0.99166924,0.0015322055,0.0040738224,0.000653914,0.0013314872,0.0007393474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050503663,0.00035383864,0.003755509,0.00039548363,0.00018094169,0.00004580729,0.00048023398,0.0003563162,0.00070394605],"category_scores_gemma":[0.0038711668,0.00018762832,0.00047116823,0.00026875015,0.0006315121,0.00039262135,0.00014690902,0.0016141067,0.000012068554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7594422,0.024610015,0.1864237,0.000074343,0.0014514822,0.007845189,0.00026063598,0.000028047909,0.000003114896,0.000002789741,0.0004311905,0.019427279],"study_design_scores_gemma":[0.7027706,0.1400923,0.1554663,0.00025363095,0.0008198626,0.00010175112,0.00015205893,0.000085520835,0.000066025794,0.000009008681,0.00008636381,0.000096595846],"about_ca_topic_score_codex":0.0013513991,"about_ca_topic_score_gemma":0.0052007763,"teacher_disagreement_score":0.11548228,"about_ca_system_score_codex":0.00075194665,"about_ca_system_score_gemma":0.0045330427,"threshold_uncertainty_score":0.8041423},"labels":[],"label_agreement":null},{"id":"W2604005355","doi":"10.1200/jco.2017.35.4_suppl.609","title":"A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Selumetinib; Medicine; KRAS; Colorectal cancer; Internal medicine; Oncology; Rash; Wnt signaling pathway; MEK inhibitor; Cancer; Oxaliplatin; Regorafenib; Pharmacology; MAPK/ERK pathway; Kinase","score_opus":0.05581443802025618,"score_gpt":0.4594876846142211,"score_spread":0.403673246593965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604005355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981503,0.00011175638,0.0000013456938,0.00032952896,0.00018324085,0.0011165779,0.000008396697,0.0000017944958,0.000097070864],"genre_scores_gemma":[0.9994182,0.00019015647,0.00025499924,0.000046470755,0.000029587025,0.00003936922,0.0000015796866,0.000011726271,0.000007897775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744517,0.00031621256,0.0014396076,0.00020220017,0.00043998696,0.00015685121],"domain_scores_gemma":[0.99634254,0.00037535705,0.002493203,0.0001923119,0.00048300656,0.000113567396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011472339,0.00015052501,0.0016269227,0.000111646536,0.00006572381,0.0000055057844,0.00013964594,0.000068404355,0.000008618307],"category_scores_gemma":[0.00075538224,0.00007771012,0.00007661435,0.00013606786,0.0003392092,0.00017409639,0.00006133899,0.00040652952,5.1495615e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037913404,0.019174993,0.9024866,0.00002892335,0.00039154352,0.00011439043,0.0013853728,0.000038361533,0.000053606153,0.000002685585,0.000004556076,0.038405564],"study_design_scores_gemma":[0.062147126,0.11469667,0.82066226,0.00027257737,0.00043511973,0.000009878056,0.0015092575,0.00006212714,0.00010583896,0.000023038148,0.000012702742,0.00006341033],"about_ca_topic_score_codex":0.00047805742,"about_ca_topic_score_gemma":0.0069445358,"teacher_disagreement_score":0.09552167,"about_ca_system_score_codex":0.00015464351,"about_ca_system_score_gemma":0.0006505787,"threshold_uncertainty_score":0.3875214},"labels":[],"label_agreement":null},{"id":"W2604034011","doi":"10.1200/jco.2009.27.15_suppl.2036","title":"A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with glioblastoma multiforme (GBM)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Neutropenia; Temozolomide; Pharmacokinetics; Pharmacology; Febrile neutropenia; Internal medicine; Radiation therapy; Gastroenterology; Oncology; Toxicity","score_opus":0.06061430077735799,"score_gpt":0.44854282990932715,"score_spread":0.3879285291319692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604034011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977832,0.00010164827,0.0000021150888,0.0013420886,0.00012171939,0.00044734532,0.0000016687002,0.0000032120702,0.00019703145],"genre_scores_gemma":[0.9987739,0.00007878533,0.0005471413,0.00047881418,0.000102868,0.0000032466269,7.167151e-7,0.000007419102,0.000007162635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973635,0.00020042981,0.001795725,0.00015982188,0.00031005492,0.00017043373],"domain_scores_gemma":[0.9973737,0.00075494405,0.0011909136,0.00014093771,0.00026862245,0.0002708802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795979,0.00012733962,0.0013962872,0.00020855095,0.00001751095,0.000003990941,0.00006982803,0.0001547177,0.000020617772],"category_scores_gemma":[0.0009076808,0.00007485611,0.00013142732,0.00016247245,0.00008530322,0.000080705584,0.000019664574,0.00040194954,0.0000020032605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016406836,0.08724407,0.67214245,0.0000075415473,0.00022434565,0.001004841,0.00025243429,0.000005421706,0.000044077722,0.0000051288675,0.00022223701,0.2224406],"study_design_scores_gemma":[0.11051993,0.2403574,0.64772546,0.00008672486,0.00026094032,0.0000698437,0.00024744324,0.000031177857,0.000086078304,0.000021807911,0.0005475836,0.000045592253],"about_ca_topic_score_codex":0.00001716918,"about_ca_topic_score_gemma":0.00011264701,"teacher_disagreement_score":0.22239502,"about_ca_system_score_codex":0.000089362526,"about_ca_system_score_gemma":0.00023834032,"threshold_uncertainty_score":0.30525434},"labels":[],"label_agreement":null},{"id":"W2604044102","doi":"10.1200/jco.2007.25.18_suppl.3567","title":"An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Metastasis; Metastatic breast cancer; Oncology; Cancer; Cancer research","score_opus":0.07505652167685024,"score_gpt":0.46856711596196593,"score_spread":0.3935105942851157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604044102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998155,0.00022761356,0.00026074197,0.00021817087,0.0003175108,0.00047442556,0.00000379748,0.0000021880303,0.00034053274],"genre_scores_gemma":[0.998557,0.00012997197,0.00069980236,0.00014317197,0.0003810845,0.0000021732271,0.0000033161778,0.000022790748,0.000060731047],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99675274,0.0006051119,0.0018756615,0.00029887125,0.0002263308,0.0002412567],"domain_scores_gemma":[0.9973052,0.0002589553,0.0017088619,0.00034742296,0.00019478097,0.00018479192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003678227,0.00016126297,0.00082153414,0.00006472705,0.000078582045,0.000024908908,0.00050271786,0.0003237052,0.000008550432],"category_scores_gemma":[0.00046473087,0.000109405715,0.00007250867,0.00018856148,0.00027253054,0.000025039013,0.00021748859,0.00054001535,3.363838e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042030253,0.016862083,0.10500592,0.000028602375,0.00046213754,0.00023412648,0.00091924047,0.002385987,0.59173226,0.000022467351,0.00016250547,0.24015442],"study_design_scores_gemma":[0.07127683,0.07545382,0.7809966,0.00022673048,0.00022604337,0.00039513066,0.0016963081,0.00033352303,0.059962593,0.000033227872,0.009020388,0.00037877294],"about_ca_topic_score_codex":0.00009634923,"about_ca_topic_score_gemma":0.0019792703,"teacher_disagreement_score":0.6759907,"about_ca_system_score_codex":0.00006391087,"about_ca_system_score_gemma":0.0007527238,"threshold_uncertainty_score":0.44614354},"labels":[],"label_agreement":null},{"id":"W2604078270","doi":"10.1200/jco.2006.24.18_suppl.5017","title":"Angiogenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Internal medicine; Ovarian cancer; Angiogenesis; Oncology; Vascular endothelial growth factor; Chemotherapy; Lung cancer; Gastroenterology; Cancer; VEGF receptors","score_opus":0.042958705309872496,"score_gpt":0.3660125625494076,"score_spread":0.3230538572395351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604078270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920932,0.0046982034,0.00008004597,0.00067551335,0.001788933,0.00041437152,0.00012192253,0.000008112753,0.00011968574],"genre_scores_gemma":[0.9911846,0.0030924361,0.00072591635,0.00074462325,0.0038868354,0.000031915566,0.000050566356,0.000042126936,0.00024101448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99492496,0.0008345276,0.0029743155,0.0004983755,0.0003207176,0.00044709555],"domain_scores_gemma":[0.9963071,0.00045910678,0.002216786,0.00026566756,0.00037480655,0.00037654943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027686278,0.00031102877,0.0017498384,0.000116509524,0.00005998591,0.000021780994,0.00021946344,0.00078237907,0.000029180723],"category_scores_gemma":[0.0011183278,0.00021105033,0.00044145357,0.00022964014,0.0004399472,0.000012855223,0.0000672782,0.000609234,0.000001726187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14756562,0.0035130142,0.7822875,0.000011162864,0.00088138017,0.00036874835,0.000017137503,0.00013367526,0.0035591233,0.000015861488,0.0015601866,0.060086634],"study_design_scores_gemma":[0.11827866,0.012922005,0.81490386,0.00008492613,0.0005593293,0.00014939961,0.00001814669,0.000026159983,0.0013554272,0.000032128508,0.05126831,0.00040163222],"about_ca_topic_score_codex":0.000501715,"about_ca_topic_score_gemma":0.004270325,"teacher_disagreement_score":0.059685003,"about_ca_system_score_codex":0.00010252423,"about_ca_system_score_gemma":0.0019974331,"threshold_uncertainty_score":0.86063826},"labels":[],"label_agreement":null},{"id":"W2604096873","doi":"10.1200/jco.2013.31.15_suppl.6592","title":"Hepatitis B reactivation in HBsAg-/cAb+ patients receiving rituximab: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; HBsAg; Rituximab; Hepatitis B virus; Internal medicine; Hepatitis B; Meta-analysis; Relative risk; Immunology; Gastroenterology; Virology; Lymphoma; Virus; Confidence interval","score_opus":0.24784476749573867,"score_gpt":0.47745540706674405,"score_spread":0.2296106395710054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604096873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822527,0.00040404298,0.00017306859,0.010919808,0.00048882246,0.00034726106,0.0000030887509,0.000010289726,0.005400905],"genre_scores_gemma":[0.9886063,0.001183528,0.005931976,0.0035769101,0.00034198686,0.0000242274,0.000004895616,0.000016002135,0.00031418639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943667,0.00086376467,0.0036789747,0.00023960792,0.00056792935,0.00028303888],"domain_scores_gemma":[0.9925024,0.0032479526,0.0024307072,0.00025021107,0.0012780637,0.00029066866],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036279254,0.00017148028,0.004159367,0.0004934574,0.000039441915,0.000014392806,0.00014544268,0.00034298445,0.0010859877],"category_scores_gemma":[0.016238948,0.00011708238,0.0017214799,0.00060320523,0.00013183095,0.00036240727,0.00007164926,0.00105729,0.00013088658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020209995,0.0021289648,0.93069637,0.000010836184,0.029276315,0.000093538896,0.00013506,0.000008251113,0.000018859615,0.00002117222,0.005248323,0.03216023],"study_design_scores_gemma":[0.003911111,0.002824139,0.9484083,0.000016183736,0.035665482,0.000011942442,0.000019914192,0.00012269124,0.00001351791,0.00040166575,0.008510908,0.00009412098],"about_ca_topic_score_codex":0.00337808,"about_ca_topic_score_gemma":0.006866416,"teacher_disagreement_score":0.03206611,"about_ca_system_score_codex":0.0002833675,"about_ca_system_score_gemma":0.00045809522,"threshold_uncertainty_score":0.99982715},"labels":[],"label_agreement":null},{"id":"W2604105114","doi":"10.1200/jco.2012.30.15_suppl.tps8114","title":"A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Dexamethasone; Bortezomib; Antibody-dependent cell-mediated cytotoxicity; Internal medicine; Refractory (planetary science); Phases of clinical research; Progression-free survival; Oncology; Gastroenterology; Urology; Multiple myeloma; Chemotherapy; Antibody; Monoclonal antibody; Immunology","score_opus":0.10603643779784919,"score_gpt":0.4578265074100374,"score_spread":0.35179006961218817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604105114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951695,0.00029196223,0.000078683755,0.00029346105,0.0003710044,0.0031132037,0.000014390436,0.000019989167,0.000647808],"genre_scores_gemma":[0.99282664,0.00024091311,0.0057192883,0.00023475032,0.0004168721,0.000098785546,0.00001708412,0.000075432086,0.00037021146],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903762,0.002473901,0.004233404,0.00046194743,0.0015888978,0.0008656647],"domain_scores_gemma":[0.9863663,0.00684334,0.0037256605,0.0006129936,0.0011594016,0.0012923505],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006965532,0.00048093573,0.005538216,0.00058380095,0.00010899416,0.000012064841,0.0003311546,0.00047624143,0.000272711],"category_scores_gemma":[0.011070641,0.00024758186,0.00047923625,0.0005393348,0.0006552646,0.0004689468,0.00014214126,0.0019184536,0.000014799846],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4279548,0.07153731,0.44940752,0.00003397573,0.001645702,0.00064168323,0.000729658,0.0000039556767,0.000022605487,0.0000019035625,0.00009868807,0.04792221],"study_design_scores_gemma":[0.51565814,0.15183412,0.32928428,0.00022869119,0.00088465185,0.00012628804,0.00055772736,0.00013251844,0.00004548153,0.0000034454542,0.0010864248,0.00015824397],"about_ca_topic_score_codex":0.00033123704,"about_ca_topic_score_gemma":0.0009091881,"teacher_disagreement_score":0.12012325,"about_ca_system_score_codex":0.00048352417,"about_ca_system_score_gemma":0.0024422419,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2604105292","doi":"10.1200/jco.2013.31.15_suppl.9642","title":"High-dose Asian ginseng (Panax ginseng) for cancer-related fatigue (CRF): A preliminary report.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ginseng Biological Effects and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer-related fatigue; Adverse effect; Ginseng; Internal medicine; Anxiety; Cancer; Depression (economics); Quality of life (healthcare); Physical therapy; Psychiatry; Alternative medicine","score_opus":0.08190239887632156,"score_gpt":0.43567294737282114,"score_spread":0.3537705484964996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604105292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761524,0.0006944013,0.0023376273,0.017718539,0.0013786666,0.0008015953,0.000021377931,0.00002075978,0.00087463914],"genre_scores_gemma":[0.98339957,0.000801727,0.012075901,0.0012867865,0.0014704142,0.0001436305,0.00005239536,0.000026478807,0.00074308447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671745,0.0003461908,0.002056841,0.0003852707,0.0001547789,0.00033944877],"domain_scores_gemma":[0.99609864,0.00075323455,0.0018483157,0.000357506,0.0005737947,0.00036849637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012507727,0.00020897899,0.0008747972,0.000055325047,0.00010396525,0.000021456832,0.00035417112,0.0008131826,0.0001084546],"category_scores_gemma":[0.0030345998,0.00014676238,0.00056736363,0.00010811954,0.00021652383,0.000011923839,0.000095362506,0.0005541073,0.00001470928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031155858,0.0052700005,0.010193839,0.0001253002,0.0020795432,0.0004588172,0.00012143241,0.0007935449,0.17431313,0.0020868515,0.15564725,0.6457947],"study_design_scores_gemma":[0.008210899,0.02735584,0.20886342,0.000083621315,0.0004369444,0.00086551975,0.00013457864,0.0006766896,0.00610003,0.003922835,0.7427645,0.0005851572],"about_ca_topic_score_codex":0.00010762745,"about_ca_topic_score_gemma":0.000044477263,"teacher_disagreement_score":0.64520955,"about_ca_system_score_codex":0.000046791563,"about_ca_system_score_gemma":0.0007168887,"threshold_uncertainty_score":0.6272009},"labels":[],"label_agreement":null},{"id":"W2604115813","doi":"10.1200/jco.2017.35.8_suppl.189","title":"A priority educational program at Princess Margaret Cancer Centre.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Documentation; Medical education; Medicine; Session (web analytics); Quality assurance; Class (philosophy); Task (project management); Computer science","score_opus":0.685770732502196,"score_gpt":0.739736283331932,"score_spread":0.053965550829735975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604115813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69689435,0.00035126935,0.0000076029305,0.27705386,0.0034830095,0.00038169647,0.000005050061,0.000009905784,0.021813242],"genre_scores_gemma":[0.9553093,0.005632199,0.012698155,0.0032173987,0.006820781,0.000017876377,0.0000027434633,0.000025629513,0.016275974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949493,0.00045894345,0.002590773,0.0003096547,0.0013069294,0.0003844135],"domain_scores_gemma":[0.9726752,0.01983567,0.003263773,0.00070794666,0.0025350356,0.0009823659],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014791413,0.000130836,0.0013052863,0.000068313966,0.0002575744,0.000046987316,0.000835078,0.0010062151,0.0017199884],"category_scores_gemma":[0.14763609,0.000091050286,0.0005986481,0.000057663132,0.0013112532,0.00015380044,0.00048281671,0.004673308,0.000085766565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024730335,0.0031681617,0.76605445,0.00009775931,0.0002667494,0.00024955842,0.000045565073,6.3298864e-7,0.000020201309,0.0025671578,0.010055534,0.21500117],"study_design_scores_gemma":[0.003671355,0.003199943,0.7431119,0.00025392562,0.00013838946,0.00009025128,0.00001746511,0.000027139611,0.000030409145,0.010042103,0.23934712,0.00007001735],"about_ca_topic_score_codex":0.00009916529,"about_ca_topic_score_gemma":0.0018578996,"teacher_disagreement_score":0.27383646,"about_ca_system_score_codex":0.00052071054,"about_ca_system_score_gemma":0.01249608,"threshold_uncertainty_score":0.9991926},"labels":[],"label_agreement":null},{"id":"W2604117078","doi":"10.1200/jco.2004.22.14_suppl.611","title":"The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Breast cancer; Oncology; Value (mathematics); Cancer; Internal medicine; Statistics","score_opus":0.0519062164857443,"score_gpt":0.42219272848660727,"score_spread":0.370286512000863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604117078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868176,0.0006372517,0.00002565534,0.011685091,0.00043280306,0.00018263528,0.000032003376,8.3355127e-7,0.00018614312],"genre_scores_gemma":[0.99731994,0.0015719457,0.00026266064,0.00050996017,0.00025713578,0.000011771684,7.3944193e-7,0.000010537658,0.000055309643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976014,0.00043466123,0.001427817,0.00013455673,0.0002377284,0.00016385347],"domain_scores_gemma":[0.99638593,0.0010685064,0.0017894674,0.00027455576,0.0004337971,0.00004774866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092743407,0.00012582807,0.0006374349,0.000016207601,0.000053948148,0.000003831453,0.00042634775,0.00020691859,0.000020342892],"category_scores_gemma":[0.0019004327,0.000047859234,0.000356335,0.00012921213,0.0006949651,0.000006048249,0.00014473424,0.00030017272,7.368191e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004379169,0.0010021422,0.9736101,0.000030082547,0.00079548213,0.000008804352,0.0002732517,0.000339216,0.008960714,0.00034350957,0.00015620979,0.010101337],"study_design_scores_gemma":[0.003784719,0.0005561622,0.98400897,0.000134222,0.00016852176,0.00007657664,0.00033337137,0.000008431308,0.009248328,0.00069458,0.0009251538,0.00006098914],"about_ca_topic_score_codex":0.0004483767,"about_ca_topic_score_gemma":0.0010055876,"teacher_disagreement_score":0.011175131,"about_ca_system_score_codex":0.00006626695,"about_ca_system_score_gemma":0.0018695153,"threshold_uncertainty_score":0.331644},"labels":[],"label_agreement":null},{"id":"W2604121015","doi":"10.1200/jco.2013.31.15_suppl.627","title":"Prognostic and predictive value of a low estrogen receptor expression in breast cancer: A retrospective study from a reference center.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Tamoxifen; Estrogen; Hormonal therapy; Internal medicine; Oncology; Gynecology; Progesterone receptor; Cancer","score_opus":0.020006251961804604,"score_gpt":0.35880684262118273,"score_spread":0.3388005906593781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604121015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979159,0.00095425855,0.000022659278,0.00028764148,0.00026548945,0.0004164527,0.00005001924,0.000001949029,0.00008561753],"genre_scores_gemma":[0.9975777,0.001394524,0.0006181176,0.000064463784,0.0002912086,0.000024219578,0.000008005282,0.000011128658,0.000010616961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774283,0.00062692515,0.0010431509,0.0002535119,0.00017026199,0.0001633407],"domain_scores_gemma":[0.9982014,0.00021771285,0.0009664109,0.0001377863,0.00029776923,0.00017893678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006608631,0.00012815058,0.00067971105,0.0000504739,0.000020420024,0.0000069593075,0.00016916664,0.0004090345,0.00003003218],"category_scores_gemma":[0.0006608081,0.000089851594,0.00012392546,0.00007370676,0.0001540546,0.000013857791,0.00012088027,0.0005756782,0.0000022326124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002508211,0.0021262055,0.91154206,0.000008579094,0.00027646226,0.0000260118,0.00015462462,0.000020436657,0.07675221,0.000002945663,0.0004383782,0.006143894],"study_design_scores_gemma":[0.0048188088,0.011578043,0.97861236,0.00020543682,0.00008495881,0.00004034631,0.000312034,0.00009906474,0.0039332914,0.0001051607,0.00011704149,0.000093466246],"about_ca_topic_score_codex":0.00012788402,"about_ca_topic_score_gemma":0.000014265738,"teacher_disagreement_score":0.07281891,"about_ca_system_score_codex":0.000045745775,"about_ca_system_score_gemma":0.00038009524,"threshold_uncertainty_score":0.36640418},"labels":[],"label_agreement":null},{"id":"W2604128982","doi":"10.1200/jco.2012.30.15_suppl.6006","title":"A comparison of primary care providers’ and oncologists’ preferences for different models of cancer survivorship care.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; BC Cancer Agency","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Psychosocial; Cancer; Breast cancer; Cancer survivorship; Multivariate analysis; Primary care; Colorectal cancer; Internal medicine","score_opus":0.640184142364773,"score_gpt":0.6035303050843581,"score_spread":0.036653837280414825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604128982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95464236,0.04202405,0.0003512483,0.00038949313,0.0007325477,0.00034011906,0.00003069003,0.0000031870363,0.0014863046],"genre_scores_gemma":[0.990812,0.0040218867,0.004480769,0.00014788102,0.0004832999,0.000012339264,0.000008027136,0.000009934114,0.000023838325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969344,0.0003254491,0.002097523,0.00012474263,0.00031017401,0.000207699],"domain_scores_gemma":[0.9919245,0.0041593304,0.0024582616,0.00012322814,0.0010982733,0.00023636625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097114156,0.00013629325,0.0024653182,0.00009179457,0.000017137138,0.0000018678724,0.00013525678,0.0003532422,0.000013513633],"category_scores_gemma":[0.001498519,0.00008672875,0.00036367602,0.000059658436,0.00038002606,0.0001062908,0.000053447162,0.0004017769,1.10349504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003545624,0.0009628885,0.91413796,0.0014855016,0.0003484465,0.0000022612494,0.008931077,0.00002668317,0.00026184946,0.00009281997,0.00032639684,0.06987849],"study_design_scores_gemma":[0.008120348,0.022984216,0.93452024,0.001820761,0.0014216951,0.000006549422,0.017528052,0.000101175145,0.0045296573,0.000486782,0.00832954,0.00015098017],"about_ca_topic_score_codex":0.00031927516,"about_ca_topic_score_gemma":0.00079853786,"teacher_disagreement_score":0.06972751,"about_ca_system_score_codex":0.00017036076,"about_ca_system_score_gemma":0.0010631835,"threshold_uncertainty_score":0.35366958},"labels":[],"label_agreement":null},{"id":"W2604132510","doi":"10.1200/jco.2017.35.8_suppl.97","title":"Interventions to improve oral chemotherapy safety and quality: A systematic and grey literature review.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CINAHL; Psychological intervention; Intensive care medicine; Systematic review; MEDLINE; Population; Family medicine; Nursing; Environmental health","score_opus":0.1996452609963377,"score_gpt":0.5687444447741375,"score_spread":0.3690991837777998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604132510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50732756,0.2149247,0.00028572217,0.26879224,0.00267799,0.0016851741,0.000018513107,0.000014318474,0.0042738095],"genre_scores_gemma":[0.56502706,0.39190012,0.0045307465,0.03429554,0.0014522204,0.000017472421,0.0000010940021,0.000023101995,0.0027526661],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99728537,0.00032720735,0.0019868668,0.00013626681,0.00014846971,0.00011580408],"domain_scores_gemma":[0.99683565,0.0007052195,0.0015007628,0.00024145184,0.00041440313,0.00030249546],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054994524,0.00009559264,0.0022891227,0.000043679684,0.00010061538,0.00003111767,0.00010080026,0.00014938442,0.000015055319],"category_scores_gemma":[0.012436592,0.00005664969,0.0003356862,0.000034945435,0.00013779917,0.00010968376,0.000076149525,0.00048725872,0.000002621789],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010514382,0.0018307179,0.0857128,0.27431113,0.001986845,0.0008347545,0.0016620816,5.0776396e-8,0.00027995626,0.0011785603,0.023509052,0.5981797],"study_design_scores_gemma":[0.015354013,0.020982286,0.70500976,0.20545036,0.001274061,0.0008418092,0.00017133157,0.0000053074914,0.00001140391,0.00027846155,0.050441734,0.00017949972],"about_ca_topic_score_codex":0.00000654818,"about_ca_topic_score_gemma":0.000058259426,"teacher_disagreement_score":0.6192969,"about_ca_system_score_codex":0.000040074334,"about_ca_system_score_gemma":0.00017619273,"threshold_uncertainty_score":0.9958821},"labels":[],"label_agreement":null},{"id":"W2604138607","doi":"10.1200/jco.2017.35.8_suppl.22","title":"Funding model for stem cell transplant.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Cancer Care Ontario","funders":"","keywords":"Activity-based costing; Medicine; Procurement; Health care; Tariff; Ambulatory care; Revenue; Operations management; Medical emergency; Business; Finance; Accounting; Marketing","score_opus":0.7353757196768027,"score_gpt":0.6512257321215816,"score_spread":0.08414998755522107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604138607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8178259,0.0001128428,0.12287837,0.050252147,0.003322194,0.00051100226,0.000021322068,0.000012554368,0.005063669],"genre_scores_gemma":[0.96286273,0.00041372844,0.029760724,0.003775365,0.0020140242,0.000003814842,0.0000033478623,0.000019257524,0.0011470005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99510735,0.0001614906,0.0040338617,0.00017003491,0.00030065366,0.00022660977],"domain_scores_gemma":[0.98627144,0.007465362,0.004926745,0.00033182712,0.00061430084,0.00039035114],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009767985,0.00010619234,0.0011671891,0.00006374137,0.000148852,0.000026384627,0.00028827033,0.00033472176,0.00005316023],"category_scores_gemma":[0.008659534,0.0000792443,0.0006812408,0.000019539835,0.00013246677,0.00033640183,0.000037941558,0.00080859155,0.0000140061165],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022030631,0.0029304374,0.08289428,0.00019883265,0.0005293975,0.0004305778,0.0003569683,0.00044182118,0.0014753973,0.0006115793,0.03586822,0.85223186],"study_design_scores_gemma":[0.111338235,0.047951005,0.15532018,0.00052062335,0.0070906063,0.0012489506,0.0011521732,0.2864205,0.0008915065,0.008155816,0.37926948,0.00064090145],"about_ca_topic_score_codex":0.00000945345,"about_ca_topic_score_gemma":0.00004125567,"teacher_disagreement_score":0.85159093,"about_ca_system_score_codex":0.00008655956,"about_ca_system_score_gemma":0.0017357478,"threshold_uncertainty_score":0.99969095},"labels":[],"label_agreement":null},{"id":"W2604181987","doi":"10.1200/jco.2017.35.8_suppl.136","title":"Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs. the 32-combined item HAQ-DI + WHODAS (HW) survey: A quality improvement controlled trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Physical therapy; Quality of life (healthcare); Surgery","score_opus":0.16874329380482705,"score_gpt":0.5136876867493378,"score_spread":0.3449443929445108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604181987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97518766,0.00031470487,0.0031448365,0.011531651,0.0065168045,0.0016477357,0.00001753803,0.000025649279,0.0016134168],"genre_scores_gemma":[0.9915174,0.00052323745,0.00004923414,0.003897962,0.0034236396,0.00007246578,0.000029447216,0.000036498186,0.0004501122],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9867391,0.0070188176,0.0039198897,0.0005199573,0.0011045345,0.00069770217],"domain_scores_gemma":[0.9757007,0.015424627,0.006278531,0.0010017725,0.00126024,0.00033413482],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.039197348,0.00038532665,0.004176272,0.00006640921,0.00045834426,0.00014696766,0.0006975162,0.00050885364,0.00010171667],"category_scores_gemma":[0.016905185,0.00022244762,0.0015576096,0.00016032171,0.00037985004,0.00030643996,0.00019677992,0.00278531,0.0000097219645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7074135,0.006580075,0.23655856,0.00006483577,0.0027658746,0.000059471367,0.00028680218,0.00002125079,0.0002562655,0.0017690666,0.0015653422,0.042658936],"study_design_scores_gemma":[0.23032849,0.03425326,0.72914577,0.00007419111,0.0007561999,0.000015843563,0.00011628112,0.0002979973,0.000019641158,0.001430797,0.0033738697,0.00018766342],"about_ca_topic_score_codex":0.0036289464,"about_ca_topic_score_gemma":0.014236987,"teacher_disagreement_score":0.4925872,"about_ca_system_score_codex":0.0007109444,"about_ca_system_score_gemma":0.0039551305,"threshold_uncertainty_score":0.9995153},"labels":[],"label_agreement":null},{"id":"W2604206125","doi":"10.1200/jco.2017.35.8_suppl.186","title":"Clinical trials in Ontario’s quality-based funding model.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Reimbursement; Medicine; Clinical trial; Randomized controlled trial; Payment; Health care; Family medicine; Business; Surgery; Finance; Internal medicine; Economic growth","score_opus":0.9577982797364073,"score_gpt":0.7267258090049233,"score_spread":0.23107247073148396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604206125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8566127,0.00038371145,0.012793807,0.1052339,0.008222631,0.00051930937,0.00003835778,0.0000114772465,0.01618411],"genre_scores_gemma":[0.9472873,0.0001988548,0.02514193,0.02403197,0.002338837,0.00001418236,0.0000034562488,0.000028004963,0.0009554564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.929316,0.010495736,0.05877462,0.00061364885,0.00023836808,0.0005616369],"domain_scores_gemma":[0.8529438,0.06632818,0.07833053,0.0012108822,0.0003260744,0.0008605596],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5930497,0.00020966826,0.008844881,0.00040882907,0.00022024242,0.00012379706,0.0010706193,0.0009800047,0.0006245524],"category_scores_gemma":[0.40806884,0.00021292955,0.0017038643,0.00005344174,0.0003369149,0.00073931745,0.00011247342,0.0021318174,0.00034366045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007031778,0.00096873945,0.9484677,0.00004987889,0.00017666188,0.000025149155,0.00021827446,0.0014078523,4.181633e-7,0.030479835,0.0121683385,0.005333993],"study_design_scores_gemma":[0.009757679,0.0013425368,0.7977093,0.00014160667,0.000035399487,0.0000063739103,0.00013363922,0.012992569,3.7730317e-7,0.052158874,0.12545747,0.00026416947],"about_ca_topic_score_codex":0.010538208,"about_ca_topic_score_gemma":0.06492486,"teacher_disagreement_score":0.18498085,"about_ca_system_score_codex":0.0013332298,"about_ca_system_score_gemma":0.006002278,"threshold_uncertainty_score":0.9996328},"labels":[],"label_agreement":null},{"id":"W2604210007","doi":"10.1200/jco.2017.35.8_suppl.234","title":"Sensitivity and specificity of self-reported cancer history compared to cancer registry.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer registry; Concordance; Cancer; Cohort; Medical record; Family medicine; Cohort study; Medical history; Internal medicine","score_opus":0.43179327113296834,"score_gpt":0.5383082335200834,"score_spread":0.10651496238711505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604210007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829392,0.0012804073,0.00006168109,0.009200443,0.0018602334,0.00012571014,0.000009007054,0.000006942612,0.004516402],"genre_scores_gemma":[0.992126,0.0013585915,0.002839007,0.0019516,0.0013791281,0.0000020599985,4.9033287e-7,0.000008052697,0.00033510212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974999,0.00017397747,0.0015562614,0.0001956666,0.00039074148,0.00018347274],"domain_scores_gemma":[0.9942601,0.00045362013,0.0035667738,0.00035809513,0.0008970336,0.00046437857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029290395,0.00011029527,0.0014514674,0.000055834313,0.00006435993,0.000007569481,0.00015032367,0.0002295952,0.00015224703],"category_scores_gemma":[0.003692261,0.000086323016,0.00023804653,0.000034589822,0.00032277868,0.000119050455,0.00008817502,0.0006252245,0.0000018196182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039325827,0.00035231782,0.8950512,0.00004535394,0.0005390991,0.0015133002,0.00017991826,0.000031597312,0.0014454613,0.000033135806,0.044464663,0.052411363],"study_design_scores_gemma":[0.0021987397,0.001256024,0.79159224,0.00025043054,0.00042683797,0.00029931936,0.00006427655,0.00008966364,0.00016995837,0.000020750684,0.2035618,0.0000699712],"about_ca_topic_score_codex":0.0040118876,"about_ca_topic_score_gemma":0.0038621307,"teacher_disagreement_score":0.15909714,"about_ca_system_score_codex":0.00059231377,"about_ca_system_score_gemma":0.0029229952,"threshold_uncertainty_score":0.6064801},"labels":[],"label_agreement":null},{"id":"W2604234246","doi":"10.1200/jco.2012.30.15_suppl.9503","title":"The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Dexrazoxane; Cardiotoxicity; Doxorubicin; Trastuzumab; Troponin complex; Etoposide; Internal medicine; Ifosfamide; Chemotherapy; Troponin I; Cardiology; Urology; Oncology; Anthracycline; Breast cancer; Cancer; Myocardial infarction","score_opus":0.02072057181739062,"score_gpt":0.34668280493075604,"score_spread":0.3259622331133654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604234246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709964,0.00066108315,0.0000028847621,0.00040867968,0.0006816261,0.00040634035,0.000003591867,0.0000034730617,0.00073268666],"genre_scores_gemma":[0.998224,0.0006740733,0.0001544303,0.0005540787,0.00030022787,0.0000035529956,0.0000031809295,0.000014638896,0.00007180735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770784,0.00048147383,0.0010819292,0.000116595016,0.0003130526,0.0002991125],"domain_scores_gemma":[0.9943245,0.004106515,0.0008868635,0.00016238373,0.00021251007,0.00030721707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017041351,0.00013064824,0.0010752362,0.00009318033,0.000035445482,0.000005461631,0.00006050987,0.00026636958,0.0000111755735],"category_scores_gemma":[0.0012453062,0.000070424336,0.00019998706,0.00012467154,0.00019754334,0.0000960366,0.000020082656,0.00064109464,0.000002054693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061251936,0.0011071335,0.87742084,0.00007662695,0.00039661606,0.000049848226,0.00031002756,0.000001190429,0.009489081,0.000065954286,0.0002246105,0.10473289],"study_design_scores_gemma":[0.011682152,0.015378609,0.91372746,0.00025194496,0.0002146031,0.000036708007,0.000104428706,0.0000016605546,0.05149178,0.000038234484,0.006999812,0.00007258226],"about_ca_topic_score_codex":0.000017833037,"about_ca_topic_score_gemma":0.000044875927,"teacher_disagreement_score":0.10466031,"about_ca_system_score_codex":0.00011687846,"about_ca_system_score_gemma":0.00029632638,"threshold_uncertainty_score":0.2871821},"labels":[],"label_agreement":null},{"id":"W2604245147","doi":"10.1200/jco.2012.30.15_suppl.e13602","title":"MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Erlotinib; Medicine; Rash; Adverse effect; Internal medicine; Pharmacodynamics; Pharmacology; Pharmacokinetics; Tyrosine-kinase inhibitor; Gastroenterology; Oncology; Epidermal growth factor receptor; Cancer","score_opus":0.022808141106889994,"score_gpt":0.3525868577803213,"score_spread":0.3297787166734313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604245147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758446,0.0012222986,0.000036174257,0.00014646332,0.00075102405,0.0002166163,0.000009179571,0.0000014095684,0.00003238501],"genre_scores_gemma":[0.9928129,0.00041057373,0.0060961805,0.00017102809,0.0004524158,0.0000060325406,0.000019535384,0.000015085657,0.000016256932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808663,0.00026402954,0.0010967834,0.00015660247,0.00017400386,0.00022197598],"domain_scores_gemma":[0.99831367,0.000108718596,0.0009893894,0.00011112644,0.0003078868,0.00016921076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011727932,0.00012643475,0.00079260574,0.00008440665,0.000013236313,0.0000033466536,0.00008943869,0.00021765417,0.00000846085],"category_scores_gemma":[0.0008358613,0.00008962432,0.00007109762,0.00013085343,0.00016306282,0.00002810493,0.000042375006,0.00033678694,4.848538e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01798104,0.004687838,0.8699541,0.00003914591,0.00010519119,0.0000056322674,0.00019144885,0.00006187,0.02912052,0.0000328571,0.00039293687,0.07742739],"study_design_scores_gemma":[0.02765218,0.01702991,0.9283222,0.00012863199,0.000056896963,0.000010043064,0.00010275818,0.000010096236,0.009618853,0.000015614183,0.016889999,0.0001627991],"about_ca_topic_score_codex":0.000017867791,"about_ca_topic_score_gemma":0.00018215679,"teacher_disagreement_score":0.077264585,"about_ca_system_score_codex":0.000030467132,"about_ca_system_score_gemma":0.0002923506,"threshold_uncertainty_score":0.36547738},"labels":[],"label_agreement":null},{"id":"W2604262640","doi":"10.1200/jco.2017.35.8_suppl.86","title":"Stakeholder perspectives on the use of telehealth to improve ambulatory care for chemotherapy patients in a large urban cancer centre.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Telehealth; Medicine; Ambulatory; Nursing; Stakeholder; Pharmacist; Family medicine; Ambulatory care; Health care; Medical emergency; Telemedicine; Public relations; Surgery; Pharmacy","score_opus":0.4969558665421689,"score_gpt":0.5864625545324643,"score_spread":0.08950668799029543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604262640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455899,0.000083308696,0.00008975156,0.052083645,0.0009782449,0.0010535235,0.000057083285,0.000002392558,0.00006214297],"genre_scores_gemma":[0.9832655,0.0004420023,0.0021972212,0.013026334,0.00097567565,0.000012398571,0.0000028784762,0.000017793325,0.000060186354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962375,0.0003317908,0.0026302135,0.00021415133,0.00034526997,0.0002410325],"domain_scores_gemma":[0.98791856,0.0064383885,0.0035550063,0.00039480976,0.001466733,0.00022652974],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032973324,0.00011548898,0.0009671975,0.00008552022,0.000084656385,0.000015235321,0.00021190687,0.00019771898,0.000083381055],"category_scores_gemma":[0.044628546,0.00007145736,0.00031303268,0.000050184357,0.000116182884,0.00017832623,0.000046433564,0.0007003548,0.0000020213988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012508812,0.0027942357,0.73563987,0.000048793692,0.00019283831,0.0000114982895,0.0030986452,0.000013495431,0.000051142335,0.0001593055,0.019110981,0.22637036],"study_design_scores_gemma":[0.015658703,0.009358048,0.80245507,0.00013520001,0.00012632017,0.0000010859327,0.0039424463,0.00006161308,0.000054126704,0.00003526301,0.16810772,0.00006438649],"about_ca_topic_score_codex":0.00031277692,"about_ca_topic_score_gemma":0.0019781808,"teacher_disagreement_score":0.22630598,"about_ca_system_score_codex":0.0003735492,"about_ca_system_score_gemma":0.0014667703,"threshold_uncertainty_score":0.96341896},"labels":[],"label_agreement":null},{"id":"W2604275661","doi":"10.1200/jco.2013.31.15_suppl.7520","title":"Blinded assessment of radiological changes after stereotactic ablative radiotherapy (SABR) for early-stage lung cancer: Local recurrences versus fibrosis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; SABR volatility model; Stage (stratigraphy); Radiation therapy; Lung cancer; Radiology; Ablative case; Nuclear medicine; Surgery; Internal medicine","score_opus":0.1442026329271306,"score_gpt":0.5203638961639474,"score_spread":0.3761612632368168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604275661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787361,0.0042571463,0.0009876556,0.012273569,0.0023872927,0.0010161179,0.000029207322,0.000008260992,0.00030467517],"genre_scores_gemma":[0.98149663,0.008137907,0.007956878,0.0009164147,0.0010919125,0.00026469375,0.000002896622,0.000016861783,0.00011582019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971176,0.00037895358,0.0015753434,0.00027179165,0.00035315307,0.0003031694],"domain_scores_gemma":[0.9926907,0.004448307,0.0017539703,0.000184434,0.0005833717,0.00033921454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012359604,0.00020204438,0.0018194504,0.00010603445,0.00003513048,0.000014731269,0.00015282832,0.00037251943,0.00093683455],"category_scores_gemma":[0.00043768797,0.00012230288,0.0005672533,0.000111891735,0.00034907894,0.00013679158,0.000029478915,0.00055518764,0.0000017249172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024061484,0.0033117442,0.72182107,0.00022217009,0.0048386124,0.00013060188,0.00040145282,0.000059252212,0.00005346091,0.00013193852,0.00651247,0.23845573],"study_design_scores_gemma":[0.026011191,0.057685692,0.894047,0.0003610624,0.0011033802,0.000021499673,0.00017778251,0.0011552043,0.00011510276,0.0000672957,0.019101074,0.00015369951],"about_ca_topic_score_codex":0.00015477774,"about_ca_topic_score_gemma":0.00013191528,"teacher_disagreement_score":0.23830202,"about_ca_system_score_codex":0.0007698595,"about_ca_system_score_gemma":0.001231601,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W2604289439","doi":"10.1200/jco.2014.32.15_suppl.e17700","title":"Population-based analysis of time to palliative chemotherapy (TPC) and survival in advanced non-small cell lung cancer (NSCLC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Proportional hazards model; Chemotherapy; Population; Cancer; Cancer registry; Stage (stratigraphy)","score_opus":0.034304220876474854,"score_gpt":0.4681306263126796,"score_spread":0.43382640543620477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604289439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933979,0.00017325662,0.001314252,0.0034572852,0.0001729739,0.00021763465,0.000009710312,0.0000025633592,0.0012544484],"genre_scores_gemma":[0.9925012,0.00016945458,0.0051803226,0.0016857524,0.00015354408,0.000007836346,0.000008257972,0.00001015065,0.00028347556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982457,0.00016134963,0.0011549059,0.00014797706,0.00016694442,0.00012308269],"domain_scores_gemma":[0.9971967,0.0013436778,0.0008809885,0.000109078755,0.00027568525,0.000193894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091575587,0.00009427746,0.0012795393,0.00026506302,0.000016198117,0.0000031286343,0.000059539238,0.00013277703,0.00021468184],"category_scores_gemma":[0.00042500484,0.00006841695,0.00024810724,0.00036231338,0.00003190618,0.00003478776,0.0000093485105,0.00020950704,0.000001923155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013775874,0.0006743811,0.95089823,0.000026442689,0.0009357547,0.000010195165,0.00030646683,0.0048814546,0.00022950256,0.0000051772427,0.00009116587,0.040563647],"study_design_scores_gemma":[0.008821495,0.0024407385,0.97710204,0.000096608404,0.0019323551,4.360667e-7,0.000044791133,0.0080223335,0.000086313536,0.000018241257,0.0013732004,0.00006142403],"about_ca_topic_score_codex":0.00031471136,"about_ca_topic_score_gemma":0.00058091653,"teacher_disagreement_score":0.04050222,"about_ca_system_score_codex":0.00018930636,"about_ca_system_score_gemma":0.00071211916,"threshold_uncertainty_score":0.2789962},"labels":[],"label_agreement":null},{"id":"W2604327288","doi":"10.1200/jco.2017.35.8_suppl.122","title":"Quality of care improvements resulting from a model of care that incorporates the primary clerk into the care team.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor","funders":"","keywords":"Medicine; Workload; Outpatient clinic; Primary care; Ambulatory care; Quality (philosophy); Quality management; Medical emergency; Family medicine; Nursing; Health care; Service (business); Internal medicine","score_opus":0.21692569442098114,"score_gpt":0.4250152746950556,"score_spread":0.20808958027407448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604327288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96560806,0.009091582,0.00019766776,0.0017954044,0.0013167664,0.00021615531,0.00024982681,0.0000028512834,0.021521697],"genre_scores_gemma":[0.99536544,0.0014955578,0.0016743976,0.00077049714,0.0006115042,0.0000047444614,0.000007089902,0.000017555241,0.000053222786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580425,0.00013200557,0.0034960127,0.0002530333,0.00010019026,0.00021452372],"domain_scores_gemma":[0.9851486,0.0011605481,0.01234533,0.00068638753,0.0005473968,0.00011173206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031135997,0.00016125699,0.0017649723,0.00006351562,0.00025818052,0.000046070334,0.001162246,0.0003585341,0.000018216808],"category_scores_gemma":[0.0035508699,0.00010706472,0.00064772676,0.000038474926,0.00058347627,0.00037614582,0.0003190894,0.0007173419,0.0000061760456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017888116,0.00018398801,0.78922236,0.00015291868,0.0003467044,0.0000031981947,0.014433821,0.0006106707,0.00007056955,0.004064923,0.0005932007,0.18852887],"study_design_scores_gemma":[0.0043856143,0.0021604658,0.93877363,0.00012079534,0.00008242869,7.9482464e-7,0.011463613,0.0005182841,0.00028504257,0.031446762,0.010531483,0.00023111347],"about_ca_topic_score_codex":0.002887411,"about_ca_topic_score_gemma":0.0018141771,"teacher_disagreement_score":0.18829775,"about_ca_system_score_codex":0.0003088744,"about_ca_system_score_gemma":0.00083934533,"threshold_uncertainty_score":0.43659726},"labels":[],"label_agreement":null},{"id":"W2604352850","doi":"10.1200/jco.2013.31.15_suppl.4077","title":"Promoter polymorphisms of the SWI/SNF chromatin remodeling complex molecule, BRM, and esophageal adenocarcinoma outcome.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Proportional hazards model; Carcinogenesis; Chromatin remodeling; Adenocarcinoma; Esophageal cancer; Cancer; SMARCA4; Lung cancer; SWI/SNF; Cancer research; Confidence interval; Chromatin; Gene; Biology; Genetics","score_opus":0.09010170801679943,"score_gpt":0.39566662570078226,"score_spread":0.30556491768398286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604352850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941108,0.0013626968,0.00088921783,0.00232473,0.00042121622,0.000178712,0.000004027011,0.0000033125277,0.0007052563],"genre_scores_gemma":[0.99106616,0.00014871574,0.0063306475,0.0015690468,0.0006217013,0.0000030616866,0.0000024964763,0.000017288907,0.00024089373],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99702895,0.00034054284,0.001931667,0.00021840776,0.00026793935,0.00021248778],"domain_scores_gemma":[0.9975683,0.00014778935,0.0014322704,0.00031475202,0.0003672838,0.0001696035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012384297,0.0001552519,0.0007255782,0.00003663738,0.00005729746,0.00001442473,0.00036840822,0.0003921525,0.00007501814],"category_scores_gemma":[0.0008141085,0.00009876302,0.00039715253,0.000064731474,0.00028009524,0.000009855201,0.00019817894,0.0004588631,0.0000044532367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007140362,0.00094299414,0.17601006,0.0001324806,0.00055222365,0.000037987982,0.00023710894,0.00074473675,0.67901826,0.00012602347,0.010876193,0.13060792],"study_design_scores_gemma":[0.0077366447,0.0070325066,0.9280526,0.00016327656,0.00032829406,0.00097126624,0.00018209807,0.012844026,0.034755856,0.0013971031,0.006071998,0.0004643394],"about_ca_topic_score_codex":0.000053721153,"about_ca_topic_score_gemma":0.000013623027,"teacher_disagreement_score":0.75204253,"about_ca_system_score_codex":0.000024598936,"about_ca_system_score_gemma":0.00041815185,"threshold_uncertainty_score":0.4027439},"labels":[],"label_agreement":null},{"id":"W2604367174","doi":"10.1200/jco.2017.35.8_suppl.217","title":"Improving consistency of high quality diagnosis, staging, and treatment using measurement.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Medical physics; Lymph node; Pathology","score_opus":0.7622215941995647,"score_gpt":0.6510135928263063,"score_spread":0.11120800137325837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604367174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622936,0.0003451644,0.0007425593,0.011052113,0.001103772,0.00024281601,0.000007929742,0.0000039996544,0.0002722696],"genre_scores_gemma":[0.97826266,0.0011124995,0.01901205,0.0007874209,0.0007944846,0.0000023220175,0.0000010434939,0.000011402023,0.000016089394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99352974,0.0006406434,0.0049247243,0.0001956352,0.00054219284,0.00016709507],"domain_scores_gemma":[0.9831988,0.0051809414,0.0094784405,0.00040783317,0.0014228463,0.0003111034],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013296712,0.00012556056,0.0015955023,0.000070363676,0.00012377446,0.000021586371,0.0001320911,0.0002106673,0.00007885701],"category_scores_gemma":[0.08652752,0.00009015576,0.00034906168,0.000027511429,0.00039481156,0.0002811096,0.00008944185,0.00043492098,0.0000013183792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015409706,0.0012498959,0.55677885,0.000040733372,0.00037817037,0.00008337716,0.000038098726,0.0000021399346,0.0011860067,0.000116543204,0.00017594775,0.43840924],"study_design_scores_gemma":[0.015809316,0.01088958,0.96277905,0.00015741606,0.0016249436,0.00011290472,0.00031882426,0.00013669087,0.00049952685,0.0005463544,0.0070279418,0.000097442025],"about_ca_topic_score_codex":0.0028270925,"about_ca_topic_score_gemma":0.0005397888,"teacher_disagreement_score":0.43831182,"about_ca_system_score_codex":0.0002905544,"about_ca_system_score_gemma":0.0024576103,"threshold_uncertainty_score":0.9211671},"labels":[],"label_agreement":null},{"id":"W2604374439","doi":"10.1200/jco.2017.35.8_suppl.152","title":"The role of annual personal health visits (APHV) on patients' with cancer knowledge and perceptions of the harms of continued smoking.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Health and Risk Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Smoking cessation; Survivorship curve; Logistic regression; Quality of life (healthcare); Odds ratio; Odds; Family medicine; Cancer survivorship; Demography; Gerontology; Internal medicine; Pathology; Nursing","score_opus":0.035108721196993285,"score_gpt":0.442211487338651,"score_spread":0.40710276614165775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604374439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247974,0.002730753,0.000003847375,0.0034712125,0.0006556621,0.00022467306,0.00004491047,0.0000010055995,0.00038822295],"genre_scores_gemma":[0.99641126,0.002865085,0.000043876986,0.00025953865,0.00035382103,0.0000015177418,6.300544e-7,0.000007547281,0.00005671948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978416,0.00037393585,0.0011680581,0.000098163575,0.00036159292,0.00015664857],"domain_scores_gemma":[0.9953074,0.0008937913,0.0025309068,0.00025648807,0.00079159625,0.00021980234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022798292,0.00008210449,0.0010618531,0.00004181404,0.00018441147,0.0000032159612,0.00016961542,0.00014864592,0.000018401517],"category_scores_gemma":[0.0014502835,0.000035364443,0.00045233764,0.000043590135,0.00060717814,0.00004066401,0.000048456604,0.00063113804,2.7487368e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022265916,0.00052504794,0.77308077,0.000045179855,0.00032001498,0.0000012905231,0.0011483682,0.000001374134,0.000008805869,0.000028819311,0.00058757095,0.2220262],"study_design_scores_gemma":[0.0054887505,0.005869964,0.9594366,0.00029207836,0.00023605823,0.000014215889,0.0008234613,0.000011585924,0.000025819825,0.000018945739,0.027751788,0.000030739036],"about_ca_topic_score_codex":0.00026734534,"about_ca_topic_score_gemma":0.00044373833,"teacher_disagreement_score":0.22199546,"about_ca_system_score_codex":0.00006163032,"about_ca_system_score_gemma":0.0018925316,"threshold_uncertainty_score":0.335727},"labels":[],"label_agreement":null},{"id":"W2604376325","doi":"10.1200/jco.2017.35.8_suppl.53","title":"Developing and evaluating new models of care in hematology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Survivorship curve; Specialty; Health care; Family medicine; Cancer survivorship; Cohort; Cancer; Internal medicine","score_opus":0.39848522917504603,"score_gpt":0.5706012786670833,"score_spread":0.1721160494920373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604376325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857715,0.0024793502,0.00032796327,0.0059823277,0.0004924964,0.00009717773,5.864844e-7,0.0000014953922,0.0048471224],"genre_scores_gemma":[0.9653475,0.0009777125,0.032253962,0.0010887639,0.0002756358,4.9296955e-7,4.6820332e-7,0.000005841487,0.00004959673],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979184,0.00014064329,0.0015558826,0.00010766051,0.00015821027,0.00011916898],"domain_scores_gemma":[0.9969187,0.0008458767,0.0016560081,0.00016502914,0.0002510645,0.00016332245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019233874,0.00006665254,0.0012177959,0.000078702855,0.000037363756,0.000004921799,0.00013915772,0.00023017773,0.000034923683],"category_scores_gemma":[0.0038260794,0.000050473867,0.00014164082,0.000021945023,0.00015935641,0.00015655391,0.00006950174,0.00052594056,6.532437e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003266985,0.00008398849,0.19727343,0.0001493681,0.00011901338,0.00029168013,0.00079808506,0.00006934578,0.00010863152,0.00088108855,0.00039113293,0.79656726],"study_design_scores_gemma":[0.035508208,0.01630582,0.9190749,0.0011903719,0.0003413641,0.0009976319,0.0018226247,0.0037802402,0.00046615698,0.0090245,0.011291576,0.00019658884],"about_ca_topic_score_codex":0.00006737777,"about_ca_topic_score_gemma":0.00025139624,"teacher_disagreement_score":0.7963707,"about_ca_system_score_codex":0.000108095825,"about_ca_system_score_gemma":0.004556825,"threshold_uncertainty_score":0.8083612},"labels":[],"label_agreement":null},{"id":"W2604385294","doi":"10.1200/jco.2017.35.8_suppl.14","title":"Optimizing formulary decisions.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Formulary; Medicine; Health care; Actuarial science; Family medicine; Pediatrics; Emergency medicine","score_opus":0.8176169732620548,"score_gpt":0.6367522146851258,"score_spread":0.18086475857692907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604385294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6287573,0.004497974,0.025876068,0.25290707,0.013529439,0.00044092792,0.000043830074,0.000021695583,0.07392571],"genre_scores_gemma":[0.8945276,0.0016225331,0.075232685,0.02411301,0.0037063158,0.000006105699,0.0000016377957,0.000028290835,0.00076181843],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98526055,0.0005168736,0.0135288695,0.0002685764,0.00012617838,0.00029896977],"domain_scores_gemma":[0.96599483,0.009414636,0.023193184,0.0007127573,0.00023547963,0.00044907982],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08039479,0.000123668,0.0026276454,0.00021170435,0.00035365293,0.00009825683,0.0009223131,0.00043192884,0.0004024808],"category_scores_gemma":[0.13680121,0.00012390486,0.0006030601,0.000035915262,0.00019428552,0.0009623858,0.00014707612,0.0007303441,0.0010167559],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085408695,0.0018588966,0.37189952,0.00010411185,0.0009347532,0.00023501697,0.001334925,0.0005596728,0.0000041660405,0.18740746,0.30871883,0.12608854],"study_design_scores_gemma":[0.0038716774,0.0014406543,0.23514225,0.000113905844,0.000024890967,0.00007335427,0.000256428,0.0018340161,0.0000018508979,0.06899796,0.6880365,0.00020653376],"about_ca_topic_score_codex":0.00008525973,"about_ca_topic_score_gemma":0.00006436505,"teacher_disagreement_score":0.37931764,"about_ca_system_score_codex":0.0003026805,"about_ca_system_score_gemma":0.00089044456,"threshold_uncertainty_score":0.99976104},"labels":[],"label_agreement":null},{"id":"W2604392817","doi":"10.1200/jco.2017.35.8_suppl.1","title":"An evaluation of the breast cancer Well Follow-up Care Initiative using administrative databases: A new model of analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Radiation oncologist; Comorbidity; Cancer; Residence; Health care; Generalized estimating equation; Emergency medicine; Family medicine; Database; Internal medicine; Demography; Radiation therapy","score_opus":0.7272760352102275,"score_gpt":0.635350115620049,"score_spread":0.0919259195901786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604392817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401915,0.00037122163,0.0016198364,0.0014665042,0.0004599009,0.0001905404,0.00010181214,0.0000012719714,0.0017697474],"genre_scores_gemma":[0.99546176,0.00010681207,0.003411289,0.0005188698,0.00047085687,0.000001332964,0.000003932084,0.000006001352,0.000019121464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668807,0.0005504365,0.0015997463,0.00016452813,0.0008643729,0.0001328571],"domain_scores_gemma":[0.9914576,0.00034229556,0.004703002,0.00047645235,0.0027918087,0.00022887962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003358706,0.0001058973,0.0012685689,0.00008787311,0.00009422807,0.000008693215,0.00037393553,0.00015724424,0.0001466778],"category_scores_gemma":[0.0027198477,0.000065840446,0.0006165452,0.00015836311,0.0003166753,0.00036801846,0.00006997041,0.00047254196,3.3613733e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073921285,0.00048415796,0.9085427,0.00004154604,0.0026873515,0.000031366802,0.0020655852,0.027433025,0.00097245484,0.0001246061,0.0006299472,0.049595136],"study_design_scores_gemma":[0.008791147,0.0031526077,0.86548257,0.00053640746,0.015913442,0.00006738133,0.0043197167,0.100298636,0.0008228905,0.00036921876,0.00013669381,0.00010930512],"about_ca_topic_score_codex":0.0013025083,"about_ca_topic_score_gemma":0.0039693913,"teacher_disagreement_score":0.072865605,"about_ca_system_score_codex":0.0002477665,"about_ca_system_score_gemma":0.011898147,"threshold_uncertainty_score":0.9937035},"labels":[],"label_agreement":null},{"id":"W2604430918","doi":"10.1200/jco.2017.35.8_suppl.180","title":"Evidence-based guidance for peer review “best practices” in radiation oncology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; Regional Municipality of Durham; Queen's University","funders":"","keywords":"Medicine; Best practice; Radiation oncology; Medical physics; Quality assurance; Radiation oncologist; Radiation therapy; Medical education; Surgery; Pathology","score_opus":0.5152404597335666,"score_gpt":0.675368282241871,"score_spread":0.16012782250830437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604430918","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023025388,0.12085463,0.0048029264,0.82746786,0.009431415,0.0015068504,0.0000057486627,0.000012771247,0.012892382],"genre_scores_gemma":[0.12794645,0.532711,0.18800455,0.1279492,0.014813065,0.00012970851,0.000009239037,0.00006336339,0.00837341],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954399,0.0008432517,0.002759869,0.0002563222,0.00043859685,0.00026204795],"domain_scores_gemma":[0.96822256,0.016712517,0.012522708,0.00054020726,0.0017214837,0.00028053997],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022858288,0.00014646749,0.0020054826,0.00010434939,0.00014164935,0.0000122360525,0.00048854784,0.00070683606,0.00016302621],"category_scores_gemma":[0.23607707,0.000103962455,0.00051271793,0.000074700205,0.0005096174,0.00061504793,0.000028980343,0.0013772101,0.000020336223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009013843,0.002021861,0.083180636,0.00037829403,0.0001512668,0.0006244049,0.000027779937,0.00002620516,0.00007381875,0.00013571435,0.07731183,0.8270543],"study_design_scores_gemma":[0.010683888,0.018857772,0.072273366,0.0034403126,0.00040782272,0.0003124811,0.000018083276,0.00023756947,0.000027432567,0.0003579803,0.8932862,0.00009706423],"about_ca_topic_score_codex":0.000013427858,"about_ca_topic_score_gemma":0.00007995925,"teacher_disagreement_score":0.8269573,"about_ca_system_score_codex":0.0005842341,"about_ca_system_score_gemma":0.0056831753,"threshold_uncertainty_score":0.9999537},"labels":[],"label_agreement":null},{"id":"W2604441806","doi":"10.1200/jco.2012.30.15_suppl.7541","title":"A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Phases of clinical research; Nausea; Adverse effect; Chemotherapy; Pemetrexed; Gastroenterology; Aflibercept; Oncology; Chemotherapy regimen; Surgery; Cisplatin; Bevacizumab","score_opus":0.03250744216774533,"score_gpt":0.43348421097930134,"score_spread":0.40097676881155603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604441806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725485,0.00046435444,0.000065075685,0.00018328564,0.00014886215,0.0016933379,0.0000074587665,0.000003334727,0.00017943453],"genre_scores_gemma":[0.99641085,0.00011553618,0.0031415317,0.00013515817,0.00003628339,0.000048576127,0.000008811679,0.000020701744,0.00008252941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764085,0.0002545938,0.0014120928,0.00017472911,0.00026887673,0.00024886432],"domain_scores_gemma":[0.9974845,0.00049848674,0.0012950004,0.00012522425,0.00036915948,0.0002276487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006705423,0.0001666484,0.0010867565,0.00026651687,0.000029762228,0.0000036769325,0.000059183923,0.00008808911,0.000036862],"category_scores_gemma":[0.00017723338,0.00010274505,0.00005958456,0.00028806378,0.00007590018,0.00020847001,0.000026503123,0.00040692015,4.551382e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012173499,0.057780456,0.8700212,0.00008267132,0.0003030233,0.00008058462,0.005585327,0.0001013772,0.000014240614,7.821455e-7,0.000024703893,0.053832084],"study_design_scores_gemma":[0.1689622,0.06683154,0.76111984,0.00037129322,0.0012219988,0.0000062061085,0.0010719361,0.0002674474,0.000015088895,0.0000014447915,0.000048414167,0.000082588274],"about_ca_topic_score_codex":0.00023188714,"about_ca_topic_score_gemma":0.0012060676,"teacher_disagreement_score":0.15678869,"about_ca_system_score_codex":0.0002816106,"about_ca_system_score_gemma":0.0005394351,"threshold_uncertainty_score":0.41898215},"labels":[],"label_agreement":null},{"id":"W2604445332","doi":"10.1200/jco.2013.31.15_suppl.tps4157","title":"INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital","funders":"","keywords":"Medicine; Regorafenib; Clinical endpoint; Internal medicine; Bevacizumab; Placebo; Oncology; Phases of clinical research; Surrogate endpoint; Adverse effect; Ramucirumab; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Colorectal cancer; Pathology","score_opus":0.14614167506953116,"score_gpt":0.4933522990577978,"score_spread":0.34721062398826663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604445332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818575,0.0006480466,0.00013716065,0.0050369846,0.0011805465,0.010672591,0.0000035393257,0.000014919259,0.00044871928],"genre_scores_gemma":[0.9959981,0.00029446871,0.0005511069,0.00034809005,0.0007805981,0.00050163124,0.000003439041,0.000030999727,0.001491557],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9846448,0.0046794214,0.008805807,0.0004372641,0.0009304704,0.0005022932],"domain_scores_gemma":[0.97861356,0.01193162,0.0078937905,0.00045327624,0.0007122574,0.00039552414],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02407323,0.0004246754,0.008230535,0.0005973965,0.00008885116,0.000035363173,0.0005542504,0.00020212153,0.0008137159],"category_scores_gemma":[0.0135970535,0.00022074564,0.0012996264,0.0006548827,0.00033806323,0.0003040433,0.00014544734,0.0020543775,0.00000584704],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8691029,0.028728243,0.029707003,0.000021477035,0.0018423764,0.000340659,0.00072206307,0.00006477616,0.0001324883,0.000007075081,0.0049362727,0.06439465],"study_design_scores_gemma":[0.90221804,0.07140397,0.012990318,0.00015985433,0.003137908,0.00008284473,0.008911525,0.00014991817,0.00000717483,0.000041659467,0.00076606893,0.00013072538],"about_ca_topic_score_codex":0.0010463875,"about_ca_topic_score_gemma":0.0008851605,"teacher_disagreement_score":0.06426393,"about_ca_system_score_codex":0.0003387575,"about_ca_system_score_gemma":0.0009783228,"threshold_uncertainty_score":0.9947118},"labels":[],"label_agreement":null},{"id":"W2604489617","doi":"10.1200/jco.2004.22.14_suppl.624","title":"Risk of radiation pneumonitis in breast cancer patients treated with adjuvant taxanes and radiation","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Pneumonitis; Paclitaxel; Internal medicine; Adjuvant; Cancer; Oncology; Retrospective cohort study; Concomitant; Chemotherapy; Radiation Pneumonitis; Surgery; Lung","score_opus":0.03415493484110391,"score_gpt":0.41780437077431004,"score_spread":0.3836494359332061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604489617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523294,0.0008737737,0.000003994965,0.003257917,0.0002788068,0.0001863353,0.000028532822,0.0000028546312,0.00013486974],"genre_scores_gemma":[0.9873353,0.011884627,0.0001069124,0.0003197114,0.00031335338,0.000005728511,0.0000075033445,0.000007793403,0.000019025962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844134,0.00019005277,0.00100281,0.000106088686,0.00014826357,0.00011146089],"domain_scores_gemma":[0.9977469,0.0004086467,0.0014459108,0.00004695384,0.00020821978,0.00014336282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045050884,0.00008674656,0.00079832674,0.00013933059,0.000015967038,0.0000020162895,0.000032291704,0.00016345414,0.00005980201],"category_scores_gemma":[0.0001664133,0.000057155725,0.0000925219,0.0001333077,0.00011130858,0.00009143527,0.000007357974,0.00032640382,9.312397e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047318614,0.0015671535,0.7407843,0.000011811695,0.00020532185,0.000083603234,0.000109498724,0.00009442799,0.000071279974,0.000003327534,0.00010558188,0.2522318],"study_design_scores_gemma":[0.029471703,0.01224206,0.95596373,0.000086108834,0.00064171193,0.00012949109,0.00002340558,0.000020943196,0.00026184414,0.000044985405,0.0010660643,0.000047931324],"about_ca_topic_score_codex":0.0007959357,"about_ca_topic_score_gemma":0.00037783317,"teacher_disagreement_score":0.25218388,"about_ca_system_score_codex":0.00025220294,"about_ca_system_score_gemma":0.000680392,"threshold_uncertainty_score":0.23307428},"labels":[],"label_agreement":null},{"id":"W2604491664","doi":"10.1200/jco.2017.35.8_suppl.24","title":"Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Quality of life (healthcare); Internal medicine; Stage (stratigraphy); Disease; Cancer; Performance status; Oncology; Gastroenterology","score_opus":0.24733708369365656,"score_gpt":0.4770882249827215,"score_spread":0.22975114128906496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604491664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669308,0.009496208,0.00014643879,0.020781271,0.00084678945,0.00028295387,0.00036652706,0.0000035178025,0.0011454931],"genre_scores_gemma":[0.9930045,0.003368371,0.00043347495,0.0029208022,0.00014708647,0.0000037707941,0.0000036196864,0.000015887463,0.000102488055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99324894,0.00031121832,0.00562235,0.00032873955,0.00008299755,0.00040577873],"domain_scores_gemma":[0.98432845,0.00085956044,0.013794698,0.00037304737,0.00017128346,0.0004729403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013803158,0.00017182918,0.0031808345,0.00017889212,0.00014724828,0.000037404236,0.00036767652,0.00024037424,0.00022553599],"category_scores_gemma":[0.005871341,0.00015059658,0.00023186357,0.00007381915,0.0004828326,0.0005767026,0.000108693064,0.0006925102,0.0000036632591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012298244,0.0005723659,0.9519012,0.000106373394,0.00017618501,0.0000034597902,0.00017296654,0.000038544855,7.1594705e-8,0.0051129116,0.0027078365,0.037978254],"study_design_scores_gemma":[0.007027124,0.0022325688,0.97894156,0.00010175638,0.0000088749175,8.892992e-7,0.00003290189,0.00011334511,4.95882e-7,0.0023140155,0.009089137,0.00013733718],"about_ca_topic_score_codex":0.015553722,"about_ca_topic_score_gemma":0.012285919,"teacher_disagreement_score":0.037840918,"about_ca_system_score_codex":0.00031348877,"about_ca_system_score_gemma":0.0020127005,"threshold_uncertainty_score":0.9910018},"labels":[],"label_agreement":null},{"id":"W2604493396","doi":"10.1200/jco.2017.35.8_suppl.111","title":"Systematically implementing an electronic platform to improve patient experience measurement in Ontario, Canada.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Software deployment; Medicine; Stakeholder; Stakeholder engagement; Patient experience; Quality (philosophy); Quality management; Process management; Operations management; Nursing; Health care; Public relations; Business; Computer science; Management system; Political science","score_opus":0.40366448912534103,"score_gpt":0.5545722452378647,"score_spread":0.15090775611252372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604493396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838734,0.000019674859,0.0004550845,0.012144204,0.001551485,0.0006935206,0.000001673952,0.0000042578226,0.0012566829],"genre_scores_gemma":[0.9894361,0.0000116792735,0.0044242707,0.005600913,0.0004533159,0.000020316305,0.0000018898669,0.000015727597,0.0000357741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905957,0.00030434597,0.0069087306,0.00030791495,0.0012903768,0.0005929091],"domain_scores_gemma":[0.99117464,0.0014544623,0.0047865342,0.00059575716,0.0012748658,0.00071372517],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014883968,0.00016895821,0.0014086235,0.00009406281,0.00014078405,0.000048015132,0.00041894338,0.00018061177,0.00027421868],"category_scores_gemma":[0.04535413,0.00013014562,0.00020994536,0.00005406141,0.000063142244,0.0004883843,0.00017930042,0.0013599277,0.000005704737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077431495,0.0029577394,0.49764973,0.00011190525,0.00047095574,0.0011408004,0.0017185009,0.000040312458,0.0018067664,0.00043866033,0.0050963024,0.4808252],"study_design_scores_gemma":[0.010980597,0.02772293,0.82742983,0.00039416895,0.0003474225,0.0002664987,0.0031990127,0.00032142233,0.00026320273,0.0003746814,0.12844133,0.0002588863],"about_ca_topic_score_codex":0.68190676,"about_ca_topic_score_gemma":0.99418706,"teacher_disagreement_score":0.4805663,"about_ca_system_score_codex":0.003656693,"about_ca_system_score_gemma":0.022315456,"threshold_uncertainty_score":0.98322713},"labels":[],"label_agreement":null},{"id":"W2604499605","doi":"10.1200/jco.2004.22.90140.5043","title":"Is neoadjuvant chemotherapy a realistic alternative to primary surgery for women with advanced ovarian cancer?","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Ovarian cancer; Stage (stratigraphy); Oncology; Internal medicine; Paclitaxel; Cancer; Surgery; Cisplatin","score_opus":0.10342443646081402,"score_gpt":0.46166550706924525,"score_spread":0.35824107060843124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604499605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8055684,0.00051267206,0.0030238098,0.1873137,0.0014412729,0.0008965619,0.000051404146,0.000013893157,0.0011783033],"genre_scores_gemma":[0.93329954,0.0028409977,0.021743754,0.039677773,0.0019495933,0.00019603547,0.0000037513364,0.00004141246,0.00024711533],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976055,0.00007245163,0.0014120921,0.00027092657,0.0003077225,0.0003313284],"domain_scores_gemma":[0.9959622,0.0015645371,0.0011813863,0.00019807299,0.000500516,0.0005932728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013005651,0.00017293134,0.0017667343,0.00012151332,0.000037620706,0.000009550434,0.00010677884,0.00015940511,0.00012558317],"category_scores_gemma":[0.00057010335,0.00011028655,0.00032044345,0.00015717495,0.0000870257,0.0000784745,0.000016285583,0.00032493024,0.000004841091],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041704047,0.003334652,0.022122668,0.00009020779,0.0019728139,0.0010116189,0.0009978879,0.00046351142,0.000063558335,0.00022209357,0.006963057,0.9210539],"study_design_scores_gemma":[0.04929297,0.053313326,0.66582596,0.00096190505,0.000528234,0.00034051406,0.00018921492,0.000012396613,0.0004848657,0.0029996224,0.22579582,0.0002551545],"about_ca_topic_score_codex":0.00010868209,"about_ca_topic_score_gemma":0.000069186564,"teacher_disagreement_score":0.9207987,"about_ca_system_score_codex":0.0014471109,"about_ca_system_score_gemma":0.0042901537,"threshold_uncertainty_score":0.7610549},"labels":[],"label_agreement":null},{"id":"W2604502265","doi":"10.1200/jco.2004.22.90140.7038","title":"Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Clinical endpoint; Carboplatin; Interim analysis; Febrile neutropenia; Lung cancer; Toxicity; Placebo; Gastroenterology; Phases of clinical research; Surgery; Chemotherapy; Oncology; Randomized controlled trial; Cisplatin; Pathology","score_opus":0.04040965542454393,"score_gpt":0.429095674913167,"score_spread":0.3886860194886231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604502265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953039,0.0005601522,0.00033324325,0.0018259445,0.00011418408,0.0014849752,0.000005287698,0.0000070612955,0.00036522988],"genre_scores_gemma":[0.9966743,0.00030652102,0.0022450595,0.00035214753,0.00017019453,0.000063835825,0.000004696152,0.000021026744,0.00016222624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99459857,0.00074228225,0.0035971033,0.00031816927,0.00047846895,0.0002653826],"domain_scores_gemma":[0.9953607,0.0011275706,0.0025188064,0.00019099494,0.00048855937,0.000313406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048028803,0.00024366895,0.0032185214,0.000591563,0.00004308487,0.000009036598,0.000105856285,0.00029315104,0.0000966718],"category_scores_gemma":[0.0014086482,0.00017120579,0.00038569735,0.000531242,0.00022474445,0.00018381786,0.000055914483,0.0010569054,6.38914e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79740465,0.08724327,0.04764573,0.00051138666,0.0016885464,0.0045414744,0.006538179,0.0032028893,0.030015456,0.00007784983,0.00015790555,0.020972678],"study_design_scores_gemma":[0.95544606,0.026338318,0.0086948015,0.0015660672,0.0011915795,0.0000615979,0.0023232333,0.0013463184,0.0026092427,0.00015675164,0.000052781423,0.00021325624],"about_ca_topic_score_codex":0.0007196205,"about_ca_topic_score_gemma":0.0025922589,"teacher_disagreement_score":0.15804142,"about_ca_system_score_codex":0.00029312822,"about_ca_system_score_gemma":0.0013008448,"threshold_uncertainty_score":0.69815695},"labels":[],"label_agreement":null},{"id":"W2604513601","doi":"10.1200/jco.2017.35.8_suppl.40","title":"Establishing best practice recommendations for systemic treatment regimen development and maintenance.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Regimen; Best practice; Multidisciplinary approach; Intensive care medicine; Systemic therapy; Oncology; Medical physics; Internal medicine; Cancer","score_opus":0.2717434464521167,"score_gpt":0.45334074646406125,"score_spread":0.18159730001194457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604513601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61295235,0.009842178,0.021517018,0.21569286,0.011834109,0.001190876,0.00011221598,0.000020968833,0.12683739],"genre_scores_gemma":[0.89927924,0.012578893,0.078529835,0.0024399776,0.0023110907,0.00004160996,0.0000043183704,0.00003503821,0.0047800215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711865,0.000038067206,0.0023692052,0.0002202269,0.000025240637,0.00022862303],"domain_scores_gemma":[0.9915691,0.0015192411,0.006216831,0.00025360586,0.0002333219,0.00020792625],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042532855,0.00011848963,0.0010939848,0.0000911376,0.00029501982,0.00015563148,0.00029426854,0.0002276242,0.000027461896],"category_scores_gemma":[0.009977264,0.00010623032,0.00019504142,0.000018608505,0.00011846711,0.0011003974,0.00004893527,0.0002428483,0.000035859295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012932863,0.0012222453,0.026958864,0.00003915232,0.0008539212,0.000071767034,0.0011492459,0.000016864691,0.0000021960122,0.10309976,0.031967953,0.83332473],"study_design_scores_gemma":[0.0035496424,0.0023434663,0.00733157,0.00007962957,0.000056117588,0.00014648937,0.00035868402,0.00006156742,0.000006496906,0.00598599,0.97995365,0.0001267137],"about_ca_topic_score_codex":0.00013163553,"about_ca_topic_score_gemma":0.000076353244,"teacher_disagreement_score":0.94798565,"about_ca_system_score_codex":0.00045153894,"about_ca_system_score_gemma":0.00063722586,"threshold_uncertainty_score":0.9983621},"labels":[],"label_agreement":null},{"id":"W2604516494","doi":"10.1200/jco.2015.33.15_suppl.e12519","title":"Prevalence of <i>PALB2</i> mutations in the Creighton University breast cancer family registry.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"PALB2; Breast cancer; Medicine; Germline mutation; Cancer; Oncology; Genetics; Family history; Internal medicine; Mutation; Cancer research; Gene; Biology","score_opus":0.09399823903473024,"score_gpt":0.4155136011328639,"score_spread":0.32151536209813364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604516494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880947,0.00096205,0.00034024747,0.004852046,0.00061634777,0.00008769112,0.000061775,0.000001161783,0.004269213],"genre_scores_gemma":[0.9959414,0.0011466339,0.0013819851,0.00074002525,0.00044190825,0.0000013155341,0.0000038510752,0.000005359611,0.00033749925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983344,0.00048565856,0.0007418138,0.0001306689,0.00019995021,0.00010749735],"domain_scores_gemma":[0.9979782,0.00023436082,0.00095488725,0.00021267515,0.00052941055,0.00009046842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001902811,0.00006810646,0.00028284366,0.000044662673,0.000021547214,0.000003603125,0.00044132464,0.00021859539,0.000014137326],"category_scores_gemma":[0.00070275174,0.00004985114,0.00015400822,0.00014582598,0.00028851672,0.000009146016,0.000054322813,0.0003014159,0.000001502258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006928682,0.003017301,0.64850765,0.00014436775,0.00065196364,0.00034337598,0.0015967159,0.008973138,0.013175968,0.00092920737,0.22334431,0.0923873],"study_design_scores_gemma":[0.004961141,0.002821428,0.72381204,0.000066814915,0.00023468157,0.0003147503,0.002280454,0.00006684611,0.0007841138,0.00069089676,0.26380682,0.00015998897],"about_ca_topic_score_codex":0.00007985196,"about_ca_topic_score_gemma":0.00016256933,"teacher_disagreement_score":0.09222731,"about_ca_system_score_codex":0.000101937374,"about_ca_system_score_gemma":0.0030849914,"threshold_uncertainty_score":0.5472642},"labels":[],"label_agreement":null},{"id":"W2604532080","doi":"10.1200/jco.2017.35.8_suppl.245","title":"Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Queen's University","funders":"","keywords":"FOLFIRINOX; Gemcitabine; Medicine; Pancreatic cancer; Population; Internal medicine; Cancer registry; Cancer; Chemotherapy; Oncology; Surgery; Irinotecan; Colorectal cancer","score_opus":0.1786638204374846,"score_gpt":0.5651582495158985,"score_spread":0.3864944290784139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604532080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996014,0.0003951844,0.0003359072,0.0014289696,0.00049300306,0.0009012475,0.000007260378,0.0000034494233,0.0004209607],"genre_scores_gemma":[0.9949129,0.00022358366,0.0042271838,0.0001331071,0.00037016737,0.000046411056,0.0000015467448,0.000011958129,0.00007312125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973602,0.00052548875,0.0014782918,0.00017519064,0.00027082782,0.00018997017],"domain_scores_gemma":[0.98874927,0.008023505,0.0019289601,0.000290738,0.00073535123,0.00027219395],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066839005,0.00010508234,0.0021664884,0.00009198107,0.00012637644,0.000007662998,0.00018285743,0.000248291,0.00003117815],"category_scores_gemma":[0.0146717075,0.00007286761,0.00028189746,0.000035589994,0.0002263812,0.00008298893,0.00004421559,0.00040914878,6.572071e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018529668,0.0015432116,0.89734757,0.00018597735,0.00048177395,0.000073541756,0.000024033789,0.000008743647,0.00017544869,0.000078428006,0.000044373344,0.08150721],"study_design_scores_gemma":[0.025433272,0.022296743,0.9490209,0.00027891877,0.0008607429,0.000024323084,0.00006143897,0.00027353226,0.00004809086,0.000527521,0.0011182881,0.000056221917],"about_ca_topic_score_codex":0.0002221956,"about_ca_topic_score_gemma":0.00019026428,"teacher_disagreement_score":0.08145099,"about_ca_system_score_codex":0.000107755244,"about_ca_system_score_gemma":0.0019257086,"threshold_uncertainty_score":0.99362814},"labels":[],"label_agreement":null},{"id":"W2604552037","doi":"10.1200/jco.2017.35.8_suppl.188","title":"Driving quality improvements of radiation treatment services through a centralized performance management approach.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Quality management; Medicine; Lagging; Quality (philosophy); Operations management; Patient safety; Health care; Nursing; Process management; Business; Management system","score_opus":0.13448314257073327,"score_gpt":0.5526396430670473,"score_spread":0.41815650049631403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604552037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97934747,0.0005537648,0.002125267,0.0016210616,0.0019005815,0.00036710067,0.0000020291407,0.0000070043875,0.014075706],"genre_scores_gemma":[0.9428292,0.017077528,0.03767028,0.00090292597,0.0009604706,0.0000070756823,0.0000034356187,0.00001067408,0.00053840625],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972035,0.00025452266,0.0019095965,0.00017322459,0.00026136462,0.00019779046],"domain_scores_gemma":[0.9947248,0.00044098892,0.0041707684,0.00038906216,0.00014025049,0.0001341461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019986953,0.00013019022,0.0013328785,0.000046248726,0.00014035641,0.000007555587,0.00027814097,0.00026608174,0.000047058693],"category_scores_gemma":[0.00023720322,0.00008443557,0.00036825516,0.000033166925,0.00029943854,0.00030952424,0.000044889937,0.00031259604,0.0000025951097],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033348247,0.0025004442,0.3436735,0.00016436553,0.0009552507,0.000048738908,0.0003055633,0.000030527197,0.0001244098,0.00033093072,0.00008306403,0.64844835],"study_design_scores_gemma":[0.020885259,0.011077737,0.87717986,0.00012640476,0.00044901052,0.00005910848,0.0002383562,0.00030659325,0.0005149102,0.00037431557,0.088698015,0.00009043394],"about_ca_topic_score_codex":0.000022870794,"about_ca_topic_score_gemma":0.000008822708,"teacher_disagreement_score":0.6483579,"about_ca_system_score_codex":0.0002699488,"about_ca_system_score_gemma":0.00029001132,"threshold_uncertainty_score":0.34431824},"labels":[],"label_agreement":null},{"id":"W2604552051","doi":"10.1200/jco.2014.32.15_suppl.6041","title":"Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Placebo; Head and neck squamous-cell carcinoma; PTEN; Cancer; Gene signature; Progression-free survival; Gene expression; Head and neck cancer; Gene; Overall survival; Pathology; PI3K/AKT/mTOR pathway; Biology","score_opus":0.05184242678341498,"score_gpt":0.3564143244076636,"score_spread":0.3045718976242486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604552051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998618,0.000118571144,0.0002066134,0.00004466772,0.00025641875,0.00045049793,0.0000729092,8.0817483e-7,0.00023152365],"genre_scores_gemma":[0.99867284,0.000054374093,0.0008663935,0.00008077899,0.00024964238,0.000006821069,0.00002848441,0.000016200218,0.000024449195],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996647,0.00094322074,0.0016297046,0.00026820926,0.00033652765,0.00017536433],"domain_scores_gemma":[0.99527276,0.00058023416,0.0026916268,0.0003327513,0.0009456601,0.00017697859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015943771,0.00016893964,0.0011037766,0.000097904645,0.00002736049,0.000003961662,0.00025858672,0.0004334152,0.000017125762],"category_scores_gemma":[0.002441838,0.00013022478,0.00017052382,0.000111603935,0.00017148533,0.000017888562,0.00013723559,0.0004586999,1.0703729e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011970179,0.010942949,0.6510503,0.00007555304,0.000097973156,0.000013164365,0.00048338732,0.0021372566,0.32093695,0.0000044918525,0.00058507686,0.0017027005],"study_design_scores_gemma":[0.014865204,0.071030065,0.41283572,0.000041060383,0.00016284983,0.000004432969,0.0002257761,0.00022549965,0.50017786,0.000017906515,0.00027750444,0.00013613045],"about_ca_topic_score_codex":0.00034762893,"about_ca_topic_score_gemma":0.0008958879,"teacher_disagreement_score":0.23821461,"about_ca_system_score_codex":0.000047584075,"about_ca_system_score_gemma":0.0013275964,"threshold_uncertainty_score":0.53104126},"labels":[],"label_agreement":null},{"id":"W2604565681","doi":"10.1200/jco.2004.22.90140.4716","title":"Preliminary results of phase II trial of concomitant administration of intra-vesical reduced dose Bacillus Calmette- Guerin (BCG) and interferon a 2B (IFN) in the prevention of recurrence of superficial bladder cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concomitant; Cystoscopy; Urology; Surgery; Bladder cancer; Urinary system; Cancer; Internal medicine; Gastroenterology","score_opus":0.13201078615437872,"score_gpt":0.4775697687222078,"score_spread":0.3455589825678291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604565681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957279,0.0004161314,0.000048820046,0.0022257415,0.00058423646,0.00067279505,0.0000872503,0.0000012561782,0.00023584306],"genre_scores_gemma":[0.99820536,0.000753279,0.00061414856,0.000054216576,0.00033473503,0.000010527068,0.000006553425,0.000007849297,0.000013341725],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947046,0.0006255214,0.0039237947,0.00018294298,0.00042511884,0.00013800163],"domain_scores_gemma":[0.99538505,0.0010765156,0.0027933232,0.0002030925,0.0004377212,0.00010428198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025414014,0.00014075106,0.0015827076,0.00013711936,0.000014558041,0.0000014471791,0.00016439697,0.00030251875,0.000030511754],"category_scores_gemma":[0.0022751652,0.000092429735,0.00033119402,0.0001955338,0.0005570353,0.00009071559,0.000040798448,0.0004980253,9.329728e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8040256,0.020027138,0.000488128,0.0002064806,0.0004918522,0.000082376464,0.0025947539,0.000023529139,0.03058319,0.00009395276,0.00016260282,0.1412204],"study_design_scores_gemma":[0.2923984,0.59282136,0.030508976,0.0014720884,0.0014267772,0.00013533374,0.00086878834,0.00004999512,0.07925222,0.00074197777,0.00020595256,0.00011817253],"about_ca_topic_score_codex":0.00023583855,"about_ca_topic_score_gemma":0.00025359762,"teacher_disagreement_score":0.5727942,"about_ca_system_score_codex":0.00008990432,"about_ca_system_score_gemma":0.002688712,"threshold_uncertainty_score":0.47696593},"labels":[],"label_agreement":null},{"id":"W2604567283","doi":"10.1200/jco.2017.35.8_suppl.58","title":"Measuring palliative and end-of-life care for cancer patients who die in hospital in Canada.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; St. Michael's Hospital; Queen's University; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Palliative care; Emergency medicine; Emergency department; Cancer; Place of death; Acute care; Ambulatory care; End-of-life care; Ambulatory; Health care; Internal medicine; Nursing","score_opus":0.31858007782387476,"score_gpt":0.5240737024911324,"score_spread":0.20549362466725762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604567283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220526,0.0040498143,0.0000072960115,0.0021542988,0.0008292152,0.00021212261,0.000032521166,5.7631394e-7,0.0005089141],"genre_scores_gemma":[0.99399227,0.0047520357,0.00070091337,0.00025140072,0.00027449074,0.000006481006,0.0000016873685,0.000008446839,0.000012257617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978162,0.00010511041,0.0015138153,0.0001293926,0.00025948777,0.00017600335],"domain_scores_gemma":[0.99552155,0.001588481,0.0018721761,0.00011725453,0.00070244033,0.00019807307],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00067971466,0.00009869122,0.0014398795,0.000078827004,0.000026861704,0.000003088223,0.0001502056,0.00015606383,0.0000091299535],"category_scores_gemma":[0.011600741,0.00007543352,0.0001377236,0.000031505315,0.00015828433,0.00008735839,0.000050784438,0.0004011076,9.419908e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011892631,0.00024998008,0.9394559,0.00013604751,0.00011090822,0.000059494327,0.001475665,0.000008391163,0.0000046779564,0.000009619119,0.00023496593,0.05706506],"study_design_scores_gemma":[0.009003141,0.0031281416,0.9695935,0.0013230586,0.00007414233,3.5021702e-7,0.0013535318,0.000030018196,0.00014880151,0.000056332414,0.01522006,0.00006887491],"about_ca_topic_score_codex":0.15504718,"about_ca_topic_score_gemma":0.77903897,"teacher_disagreement_score":0.6239918,"about_ca_system_score_codex":0.00045696695,"about_ca_system_score_gemma":0.0051021413,"threshold_uncertainty_score":0.99672496},"labels":[],"label_agreement":null},{"id":"W2604592056","doi":"10.1200/jco.2017.35.8_suppl.193","title":"Driving quality improvement with public reporting: Use of imaging tests outside guidelines for early-stage breast cancer in Ontario.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; Ottawa Hospital; University of Ottawa; Institute for Clinical Evaluative Sciences; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Cancer; Cancer registry; Breast imaging; Medical physics; Asymptomatic; Mammography; Surgery; Internal medicine","score_opus":0.7549864279725109,"score_gpt":0.6650535894129884,"score_spread":0.0899328385595225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604592056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90959805,0.00001817446,0.0016319756,0.08713493,0.00095252245,0.0005293967,0.000015592683,0.0000068340373,0.00011251943],"genre_scores_gemma":[0.9608825,0.00007344394,0.03442213,0.003369726,0.00085167185,0.000016487176,0.0000040299733,0.000026404998,0.0003536476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9840416,0.0002747662,0.014376889,0.00033908218,0.0006120692,0.00035559497],"domain_scores_gemma":[0.9521556,0.0069466857,0.034374602,0.0006340811,0.0055083097,0.0003807373],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022995748,0.00018620826,0.0019609865,0.00015445454,0.000095054595,0.00007194936,0.00027796137,0.00020016877,0.00014130143],"category_scores_gemma":[0.23017101,0.00013087256,0.00047651955,0.000066697845,0.00026232094,0.0010457813,0.00015684214,0.0010801407,6.9086514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028504743,0.0007432185,0.8179711,0.00003929627,0.00020489753,0.00017248151,0.000057314875,0.00003452701,0.0005405538,0.000020888865,0.00095689035,0.17640834],"study_design_scores_gemma":[0.009909959,0.0028193293,0.96804434,0.0003364494,0.00033665766,0.00016264291,0.00025807333,0.00034249044,0.00005661226,0.0001240458,0.017481504,0.00012789095],"about_ca_topic_score_codex":0.07394886,"about_ca_topic_score_gemma":0.38459098,"teacher_disagreement_score":0.31064212,"about_ca_system_score_codex":0.0005343546,"about_ca_system_score_gemma":0.0069865324,"threshold_uncertainty_score":0.9986429},"labels":[],"label_agreement":null},{"id":"W2604598681","doi":"10.1200/jco.2013.31.15_suppl.9500","title":"Magnetic resonance guided focused ultrasound surgery for palliation of painful bone metastasis: Results of a multicenter phase III trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Adverse effect; Bone metastasis; Brief Pain Inventory; Randomized controlled trial; Visual analogue scale; Blinding; Surgery; Magnetic resonance imaging; Metastasis; Cancer; Radiology; Chronic pain; Physical therapy; Internal medicine","score_opus":0.17807565761969518,"score_gpt":0.46295192217316783,"score_spread":0.28487626455347265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604598681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984002,0.0016189107,0.0023405866,0.007903996,0.0011023302,0.0024742053,0.000071824914,0.000009726215,0.00047642516],"genre_scores_gemma":[0.9626554,0.0008330246,0.033834264,0.0014726694,0.0004815175,0.00006161992,0.000026716923,0.000026395212,0.0006083457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990543,0.00092812255,0.0073282626,0.00025004445,0.00067174196,0.00027882715],"domain_scores_gemma":[0.97556853,0.015651282,0.006379178,0.00042368847,0.0016040112,0.00037330974],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012679397,0.00018317264,0.0026807261,0.00029006088,0.000021380129,0.000008903399,0.00017561697,0.00020527317,0.0003509808],"category_scores_gemma":[0.05992984,0.00013612462,0.0011413818,0.0002073716,0.0002267987,0.0001711174,0.00003440089,0.00031946882,0.0000057507714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44931978,0.013783781,0.0023580964,0.00044963864,0.0008028058,0.00011503023,0.00013054097,0.000005247898,0.00087965425,0.00006642676,0.1301194,0.40196958],"study_design_scores_gemma":[0.7665932,0.051489424,0.059573658,0.00066966965,0.0047577918,0.000029759089,0.00040829892,0.0012218066,0.00064077263,0.001004998,0.11335576,0.00025484132],"about_ca_topic_score_codex":0.000039263105,"about_ca_topic_score_gemma":0.000009369016,"teacher_disagreement_score":0.40171474,"about_ca_system_score_codex":0.000060055227,"about_ca_system_score_gemma":0.00083910476,"threshold_uncertainty_score":0.94798875},"labels":[],"label_agreement":null},{"id":"W2604622724","doi":"10.1200/jco.2017.35.8_suppl.196","title":"Multidisciplinary cancer conferences as a forum for early identification of patients who can benefit from a palliative approach to care: INTEGRATE quality improvement project.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Multidisciplinary approach; Advance care planning; Surprise; Quality of life (healthcare); Family medicine; Cancer; Nursing; Internal medicine; Psychology","score_opus":0.4234266770001677,"score_gpt":0.598453464141718,"score_spread":0.1750267871415503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604622724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938774,0.00026131052,0.00081087626,0.001643978,0.0006523273,0.00091127463,0.00030081332,0.0000032292005,0.0015387823],"genre_scores_gemma":[0.99326783,0.00043859996,0.0053966823,0.00018205006,0.00025161356,0.00007367055,0.000025264686,0.000014678188,0.00034959163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696857,0.00013325439,0.0021394119,0.00024428,0.00033991478,0.0001745958],"domain_scores_gemma":[0.9922633,0.00084922684,0.0044562262,0.00028115942,0.0019687219,0.00018135016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010019678,0.00013880512,0.0013635299,0.00009171708,0.000072014176,0.000013806922,0.00030930122,0.00022608065,0.000012354408],"category_scores_gemma":[0.0045508784,0.000095082665,0.00035126417,0.000050345185,0.00021182666,0.00009184812,0.00009722891,0.00028353464,0.0000011287144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004965848,0.0010530979,0.87203014,0.00011798632,0.0005151253,0.0000022895751,0.0065923696,0.0000032562834,0.00042086202,0.00036961172,0.00035039228,0.11357905],"study_design_scores_gemma":[0.00643576,0.010283972,0.9661699,0.00056626747,0.00031420856,1.53011e-7,0.0076933303,0.00006750296,0.0033733891,0.0010946553,0.0038960108,0.00010487633],"about_ca_topic_score_codex":0.006025417,"about_ca_topic_score_gemma":0.0024145867,"teacher_disagreement_score":0.113474175,"about_ca_system_score_codex":0.00016348361,"about_ca_system_score_gemma":0.0013068019,"threshold_uncertainty_score":0.91086674},"labels":[],"label_agreement":null},{"id":"W2604633132","doi":"10.1200/jco.2007.25.18_suppl.17018","title":"Preferences for breast cancer prevention among BRCA mutation carriers","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; BRCA mutation; Breast cancer; Logistic regression; Cancer; Gynecology; Oncology; Obstetrics; Demography; Prophylactic Mastectomy; Ovarian cancer; Mammography; Genetic testing; Internal medicine; Mastectomy","score_opus":0.07280678561160643,"score_gpt":0.4672708919072514,"score_spread":0.394464106295645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604633132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764889,0.00047452503,0.019111814,0.0010243373,0.0020768633,0.00019936389,0.000024973706,0.0000030510175,0.00059617433],"genre_scores_gemma":[0.9906713,0.0003108142,0.005978926,0.000426077,0.0022705467,0.00001468723,0.000011647945,0.000012945772,0.00030307772],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981346,0.00015203394,0.0012092334,0.00017455738,0.00015333385,0.00017623305],"domain_scores_gemma":[0.997518,0.00030407473,0.0012779481,0.00011028858,0.0006452746,0.0001443816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030918787,0.000088549954,0.00034460757,0.000059063143,0.000048480582,0.000009190296,0.00017260882,0.00037865434,0.000048030295],"category_scores_gemma":[0.0009786593,0.0000739435,0.00029336673,0.00007254884,0.0001687805,0.000012505256,0.0000262735,0.00021456335,0.0000010020142],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003330318,0.00036944274,0.0939915,0.000026364949,0.00057130115,0.000011121389,0.00012262682,0.00095275836,0.005726515,0.00005527497,0.013030657,0.8818121],"study_design_scores_gemma":[0.0055334214,0.0061199903,0.88100344,0.000054159817,0.00030256738,0.00016436233,0.0005140994,0.0001000524,0.010799851,0.002112704,0.09307414,0.00022122762],"about_ca_topic_score_codex":0.000016951082,"about_ca_topic_score_gemma":0.00071237434,"teacher_disagreement_score":0.8815909,"about_ca_system_score_codex":0.00011463349,"about_ca_system_score_gemma":0.0016037629,"threshold_uncertainty_score":0.30153283},"labels":[],"label_agreement":null},{"id":"W2604651900","doi":"10.1200/jco.2017.35.8_suppl.104","title":"Survey of community pharmacists regarding their role and desire for managing chemotherapy related toxicities in cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario","funders":"","keywords":"Medicine; Pharmacy; Family medicine; Pharmacist; Demographics; Medication therapy management; Community practice","score_opus":0.528794654363687,"score_gpt":0.5904438490067118,"score_spread":0.06164919464302476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604651900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945061,0.0005575124,0.000013796705,0.0025482455,0.0005555171,0.00022350723,0.000012093097,0.0000024753983,0.0015807055],"genre_scores_gemma":[0.9957791,0.0025373464,0.00015248329,0.0013801565,0.000078167875,0.0000024044487,0.0000028882812,0.0000107195965,0.000056713176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975571,0.0007656432,0.0013288708,0.000070724964,0.00013229126,0.00014534043],"domain_scores_gemma":[0.9915092,0.005679903,0.0020873917,0.0001571905,0.00042144224,0.0001448934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006143593,0.000090777874,0.0009950553,0.0000672657,0.00011335938,0.000011115496,0.00018486999,0.00015881177,0.000025488896],"category_scores_gemma":[0.007081418,0.00006254737,0.00014729513,0.00004230571,0.00023404814,0.00021458915,0.00006344757,0.00095590804,2.1270935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046144444,0.0007483399,0.76485074,0.000066599045,0.00019944122,0.0000050313733,0.00032996724,0.000002950116,0.000059297607,0.000016560214,0.000116142684,0.22899048],"study_design_scores_gemma":[0.014709898,0.0027813918,0.9774446,0.00013722749,0.000119212586,0.0000101004625,0.00013011025,0.00077271275,0.0003182791,0.0011263466,0.0023895716,0.000060550476],"about_ca_topic_score_codex":0.00016434546,"about_ca_topic_score_gemma":0.000088922185,"teacher_disagreement_score":0.22892994,"about_ca_system_score_codex":0.00006117762,"about_ca_system_score_gemma":0.00022627495,"threshold_uncertainty_score":0.847763},"labels":[],"label_agreement":null},{"id":"W2604674382","doi":"10.1200/jco.2017.35.8_suppl.221","title":"Are we choosing wisely? Operationalizing Choosing Wisely in the Ontario cancer system.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Ontario Institute for Cancer Research; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cohort; Population; Diffuse large B-cell lymphoma; Cancer; Cumulative incidence; Incidence (geometry); Internal medicine; Lymphoma; Oncology; Surgery","score_opus":0.34934452031620683,"score_gpt":0.44718192577533317,"score_spread":0.09783740545912634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604674382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90905875,0.0053360923,0.00038733144,0.034113478,0.0058193263,0.00021991214,0.000024017885,0.000006565214,0.04503453],"genre_scores_gemma":[0.9920214,0.0015268004,0.0006157994,0.0029110082,0.0024207027,0.00000980781,5.5810915e-7,0.000018552973,0.00047536351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961243,0.00010909259,0.0030806053,0.00027502782,0.00008033677,0.00033061017],"domain_scores_gemma":[0.991187,0.0005175169,0.007560078,0.00039318093,0.0001814697,0.0001607752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005929064,0.00016787054,0.0014929357,0.00014814157,0.00034545528,0.00025816954,0.000876466,0.00034661693,0.00018198513],"category_scores_gemma":[0.0023539504,0.0001361957,0.00039384552,0.00005671586,0.00020378301,0.0009351558,0.000076400764,0.0011005442,0.000055084747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028177607,0.00026123735,0.9484163,0.00003178024,0.0001366746,0.00013333581,0.0010913167,0.0005635923,0.0000020971293,0.025555465,0.0054715257,0.018054929],"study_design_scores_gemma":[0.0018663283,0.00023881503,0.70459354,0.00023147686,0.00002348225,0.000037576126,0.00025234921,0.00021851753,0.0000020001755,0.004211122,0.28818277,0.00014205168],"about_ca_topic_score_codex":0.008502361,"about_ca_topic_score_gemma":0.039917286,"teacher_disagreement_score":0.28271124,"about_ca_system_score_codex":0.001064405,"about_ca_system_score_gemma":0.0009231411,"threshold_uncertainty_score":0.9981001},"labels":[],"label_agreement":null},{"id":"W2604691720","doi":"10.1200/jco.2012.30.15_suppl.517","title":"Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Immunohistochemistry; Oncology; Breast cancer; Internal medicine; Hazard ratio; Proportional hazards model; Univariate; Algorithm; Univariate analysis; Cancer; Gynecology; Multivariate analysis; Multivariate statistics; Confidence interval; Machine learning; Computer science","score_opus":0.5361192643362197,"score_gpt":0.5720454570989529,"score_spread":0.03592619276273323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604691720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925702,0.00088338234,0.005035859,0.00035792132,0.00054499926,0.0002897721,0.00025796986,0.0000010516917,0.000058852012],"genre_scores_gemma":[0.9777522,0.00084879226,0.020963503,0.000013031691,0.00039687642,0.0000066340335,0.000004414591,0.0000081405105,0.000006371619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970106,0.00050924544,0.0018233863,0.000107736116,0.00039293847,0.00015611366],"domain_scores_gemma":[0.9946287,0.0022717994,0.0021509344,0.00007902881,0.0007245534,0.0001449736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068754284,0.00006890268,0.0008603301,0.00018259177,0.000013783204,0.0000016531519,0.00007147996,0.00021183261,0.000040194842],"category_scores_gemma":[0.0027974956,0.000054815086,0.00017804992,0.00017131898,0.00038156752,0.00017478145,0.000026822536,0.00048822924,1.5442882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037360778,0.0011805975,0.94651943,0.00023988911,0.00022326446,0.000001640776,0.0005663956,0.00009491966,0.000704005,0.00024173404,0.00009176293,0.046400305],"study_design_scores_gemma":[0.0052229855,0.0041648266,0.98368233,0.00049688324,0.0002706003,0.000051339703,0.00030043197,0.00415422,0.0010722508,0.00036146413,0.00018423285,0.00003842949],"about_ca_topic_score_codex":0.0002327895,"about_ca_topic_score_gemma":0.00001846171,"teacher_disagreement_score":0.046361875,"about_ca_system_score_codex":0.00014537224,"about_ca_system_score_gemma":0.0012311905,"threshold_uncertainty_score":0.33490658},"labels":[],"label_agreement":null},{"id":"W2604709294","doi":"10.1200/jco.2004.22.90140.3772","title":"Linear regression is a reproducible model of tumor response to pre-operative endorectal brachytherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Brachytherapy; Linear regression; Oncology; Radiology; Internal medicine; Radiation therapy; Statistics","score_opus":0.08667919022008272,"score_gpt":0.5030077746902517,"score_spread":0.41632858447016896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604709294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93280435,0.00022144719,0.007442445,0.058323264,0.0005457396,0.00021732542,0.0000026452674,0.000010165716,0.0004326205],"genre_scores_gemma":[0.88912475,0.0002224039,0.0977383,0.01134518,0.00092319585,0.0000029503417,6.836721e-7,0.000024229275,0.00061829423],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99636,0.0005066622,0.0021234113,0.0003111027,0.00047546646,0.00022335688],"domain_scores_gemma":[0.99607056,0.0012395193,0.001284278,0.0003413192,0.00054585555,0.0005184849],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007975504,0.0001440041,0.0014193717,0.00019685629,0.000045315777,0.000005822326,0.00019494745,0.00019613732,0.00006972297],"category_scores_gemma":[0.02169492,0.00009184433,0.0004314843,0.00019444386,0.00021737517,0.000094907264,0.000061625884,0.0015048698,0.000009203383],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24583137,0.008866279,0.0299094,0.00015006939,0.0011147048,0.003372355,0.013456384,0.04915484,0.31443942,0.00037304996,0.017160738,0.3161714],"study_design_scores_gemma":[0.123592764,0.2348833,0.17277204,0.0058490834,0.0015133313,0.01010036,0.0011127143,0.17077227,0.11211651,0.012835747,0.15318441,0.0012674899],"about_ca_topic_score_codex":0.000022408962,"about_ca_topic_score_gemma":0.0000020314142,"teacher_disagreement_score":0.31490391,"about_ca_system_score_codex":0.00013549668,"about_ca_system_score_gemma":0.0026355141,"threshold_uncertainty_score":0.98654574},"labels":[],"label_agreement":null},{"id":"W2604716799","doi":"10.1200/jco.2013.31.15_suppl.555","title":"A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Metastatic breast cancer; Population; Breast cancer; Taxane; Progression-free survival; Clinical endpoint; Anthracycline; Cancer; Chemotherapy; Clinical trial","score_opus":0.16179686464203244,"score_gpt":0.4976812030909953,"score_spread":0.3358843384489628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604716799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97438,0.0003394961,0.0001429104,0.022122132,0.0012118847,0.0015494822,0.00016379068,0.000006746284,0.00008353512],"genre_scores_gemma":[0.9950598,0.00029971375,0.00078604004,0.0016866851,0.001688785,0.00021690788,0.000020544228,0.000017259705,0.0002242658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960032,0.00090875325,0.0021985488,0.00025218527,0.0003403815,0.00029689295],"domain_scores_gemma":[0.9870951,0.010372573,0.0016437572,0.00016679356,0.00046891562,0.00025285565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001075463,0.00019812713,0.0020216648,0.00017413212,0.000048450245,0.000020778847,0.0001784787,0.00015121784,0.0020402428],"category_scores_gemma":[0.0018928426,0.00011034224,0.00092133175,0.0003587627,0.00012311112,0.00013258972,0.000035404715,0.00064054114,0.0000064400424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09358069,0.003895354,0.8657594,0.000021158428,0.008047637,0.00016040713,0.00035086164,0.000114048096,0.000058641326,0.00004296003,0.002096719,0.025872126],"study_design_scores_gemma":[0.07601727,0.006106851,0.9079735,0.00004795566,0.0049414653,0.00001783078,0.00012148021,0.00068031496,0.0000049382115,0.0013869777,0.0026029872,0.00009842646],"about_ca_topic_score_codex":0.0111132,"about_ca_topic_score_gemma":0.011630175,"teacher_disagreement_score":0.04221411,"about_ca_system_score_codex":0.000408261,"about_ca_system_score_gemma":0.0010583128,"threshold_uncertainty_score":0.99887204},"labels":[],"label_agreement":null},{"id":"W2604717878","doi":"10.1200/jco.2017.35.8_suppl.201","title":"The impact of interruptions on physician workflow, productivity, and delivery of care.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electronic Health Records Systems","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Percentile; Family medicine; Medical record; Patient satisfaction; Emergency medicine; Medical emergency; Nursing; Internal medicine","score_opus":0.2819803902388351,"score_gpt":0.6250146908385019,"score_spread":0.34303430059966683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604717878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276514,0.0006063033,0.000015418203,0.0046822457,0.0026736916,0.00039930284,0.0000065373356,0.00000318028,0.008848194],"genre_scores_gemma":[0.9966686,0.0009672908,0.000112174144,0.00015259173,0.0018945656,0.0000070438527,2.690896e-7,0.000012343083,0.00018516417],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941888,0.0023500242,0.002731747,0.00013999213,0.00023604851,0.00035342234],"domain_scores_gemma":[0.9830487,0.0083226375,0.0070157177,0.0005177159,0.0008872601,0.00020800995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076641697,0.00010658414,0.0012562345,0.00007115725,0.00056137907,0.0000055997875,0.00044982333,0.00033454705,0.000012948635],"category_scores_gemma":[0.007394582,0.0000583703,0.00039070327,0.00005089213,0.00046333022,0.00012946237,0.00014067237,0.0019211856,0.000008239703],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035725625,0.000865176,0.3197676,0.00026434695,0.00045128787,0.000012226579,0.0019082997,0.000018734783,0.00023478315,0.00097384903,0.0077955322,0.66413563],"study_design_scores_gemma":[0.0024482398,0.017479021,0.9616182,0.0008440937,0.00007341334,0.000010221633,0.0010628621,0.00004229245,0.000021460512,0.0013962451,0.014935521,0.000068431735],"about_ca_topic_score_codex":0.0005850188,"about_ca_topic_score_gemma":0.0014195474,"teacher_disagreement_score":0.6640672,"about_ca_system_score_codex":0.00033666962,"about_ca_system_score_gemma":0.0051208334,"threshold_uncertainty_score":0.9084139},"labels":[],"label_agreement":null},{"id":"W2604726216","doi":"10.1200/jco.2017.35.8_suppl.115","title":"Faster and better: Improving the diagnostic phase of lung cancer at a system level.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Referral; Lung cancer; Patient experience; Cancer; Medical diagnosis; Diagnostic test; Multidisciplinary approach; Health care; Medical emergency; Family medicine; Emergency medicine; Radiology; Oncology; Internal medicine","score_opus":0.3270860245492868,"score_gpt":0.5457009950700271,"score_spread":0.2186149705207403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604726216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730457,0.0021479984,0.00020192786,0.00824728,0.001070918,0.00015412102,0.000008304098,0.0000026847765,0.0008622091],"genre_scores_gemma":[0.99594337,0.00040893644,0.00046878576,0.0016769253,0.0013683793,0.0000041481762,2.1792208e-7,0.0000072638604,0.000121964666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794173,0.00015147074,0.0013262288,0.00012208114,0.0002908304,0.00016765046],"domain_scores_gemma":[0.994553,0.002262652,0.0023991712,0.00026309086,0.00031800757,0.00020403352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025238516,0.000088597066,0.000922339,0.000031976913,0.00014462823,0.000017681316,0.0002366236,0.0001708169,0.000041786716],"category_scores_gemma":[0.005956561,0.00004865327,0.0002300023,0.000022868167,0.0003203858,0.00013160282,0.00014926287,0.0005072343,0.0000016642407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00222883,0.00014921399,0.673104,0.0001672213,0.0002782222,0.000680974,0.00015255295,0.0000033880635,0.0006171693,0.000041863117,0.004076768,0.31849977],"study_design_scores_gemma":[0.013005885,0.0064931493,0.9597912,0.0013792841,0.0013684724,0.0012123573,0.00033563847,0.0011617381,0.00034169608,0.000024561503,0.014782014,0.00010399133],"about_ca_topic_score_codex":0.0002590793,"about_ca_topic_score_gemma":0.00020670335,"teacher_disagreement_score":0.3183958,"about_ca_system_score_codex":0.00016052891,"about_ca_system_score_gemma":0.0005906677,"threshold_uncertainty_score":0.71309894},"labels":[],"label_agreement":null},{"id":"W2604736864","doi":"10.1200/jco.2017.35.8_suppl.118","title":"Creating an educational quality improvement program for radiation oncology residents in McGill University.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Radiation oncology; Curriculum; Medical education; Seniority; Quality (philosophy); Internal medicine; Pedagogy; Radiation therapy; Psychology","score_opus":0.15012736603400909,"score_gpt":0.6112870676290396,"score_spread":0.4611597015950305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604736864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577611,0.00013135979,0.00038529467,0.031960595,0.003116621,0.0007612375,0.000017891864,0.000009885582,0.005856029],"genre_scores_gemma":[0.87807184,0.0016125313,0.11035959,0.0032425425,0.004392999,0.000016155895,0.000016730652,0.000019950281,0.0022676727],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99742746,0.00048006343,0.0015048995,0.00020896945,0.00017258716,0.00020601322],"domain_scores_gemma":[0.99276096,0.0032991811,0.0030558982,0.00025171757,0.0003888252,0.00024343086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049240175,0.000095961834,0.0009809851,0.00012040585,0.0002559024,0.0000055961755,0.00029114916,0.00049044157,0.00006456596],"category_scores_gemma":[0.0076766065,0.00007995193,0.0002471663,0.000042418604,0.0002912308,0.00033927924,0.000035095036,0.00064679433,0.0000020696932],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006769874,0.0041168015,0.14769597,0.000022911214,0.00014840117,0.000093328315,0.00010861757,0.00001691418,0.00016790151,0.0014549347,0.00089893636,0.8385054],"study_design_scores_gemma":[0.012587559,0.02386471,0.6728269,0.000037955386,0.00009194319,0.00006184646,0.00019571446,0.000121492194,0.000025927971,0.0023936878,0.2877231,0.0000691761],"about_ca_topic_score_codex":0.00009638461,"about_ca_topic_score_gemma":0.00048626872,"teacher_disagreement_score":0.83843625,"about_ca_system_score_codex":0.0011046558,"about_ca_system_score_gemma":0.0023277646,"threshold_uncertainty_score":0.91901696},"labels":[],"label_agreement":null},{"id":"W2604750780","doi":"10.1200/jco.2012.30.15_suppl.10609","title":"The lipid metabolome of clear cell renal cell carcinoma (CCRCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Clear cell renal cell carcinoma; Lipidomics; Kidney cancer; Metabolomics; Renal cell carcinoma; Medicine; Liquid chromatography–mass spectrometry; Metabolome; False discovery rate; Mass spectrometry; Clear cell; Cancer research; Chromatography; Internal medicine; Chemistry; Biochemistry","score_opus":0.047018981083890875,"score_gpt":0.37260507622750394,"score_spread":0.3255860951436131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604750780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493854,0.017093012,0.00017404725,0.0006570552,0.023979487,0.0001052751,0.000009086521,0.0000023164134,0.008594315],"genre_scores_gemma":[0.94389,0.006036896,0.0011301188,0.0006779554,0.046647187,0.0000025420184,0.0000028336824,0.000021174785,0.0015912972],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.996832,0.00060465623,0.0017579682,0.00016341856,0.00025446425,0.00038749093],"domain_scores_gemma":[0.996713,0.00048223854,0.0017626924,0.00034607027,0.00034274138,0.00035325566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039491314,0.0001520562,0.0008268246,0.000044657187,0.00007236735,0.000008117168,0.00044830094,0.0004426356,0.00004928221],"category_scores_gemma":[0.00087563915,0.00009670161,0.00070177997,0.000076834,0.0003241001,0.000011681805,0.00014449129,0.000564422,0.000014000408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071002375,0.0026748239,0.035860512,0.000058482638,0.00038804923,0.0000024572669,0.0002655166,0.00003659512,0.48851022,0.00039908005,0.38154757,0.08315648],"study_design_scores_gemma":[0.0022453538,0.0029688778,0.0354798,0.000003633519,0.00018332589,0.00003904317,0.00011618177,0.0000028407565,0.03141932,0.000033295695,0.92740405,0.000104266175],"about_ca_topic_score_codex":0.0000149553725,"about_ca_topic_score_gemma":0.000020707717,"teacher_disagreement_score":0.54585654,"about_ca_system_score_codex":0.000017928824,"about_ca_system_score_gemma":0.00079032424,"threshold_uncertainty_score":0.3943377},"labels":[],"label_agreement":null},{"id":"W2604788765","doi":"10.1200/jco.2009.27.15_suppl.6026","title":"A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Clinical endpoint; Dosing; Phases of clinical research; Nasopharyngeal carcinoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Oncology; Randomized controlled trial; Surgery; Adverse effect; Clinical trial; Radiation therapy","score_opus":0.05884612129321212,"score_gpt":0.44401686566541854,"score_spread":0.38517074437220644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604788765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721706,0.0002863245,0.00002752,0.0008777463,0.00016624921,0.0012154507,0.0000018082757,0.000008948355,0.00019890105],"genre_scores_gemma":[0.99751073,0.000032299948,0.0014023492,0.0007969475,0.0001841561,0.000007841068,0.0000026527916,0.000015964137,0.000047048972],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952675,0.00088271743,0.0029579306,0.00019998488,0.00044444352,0.00024741574],"domain_scores_gemma":[0.995718,0.0009343779,0.0022495196,0.00020839598,0.00062661944,0.00026309968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024554895,0.0001864549,0.0035926397,0.00021504718,0.000025235915,0.000002514292,0.00015010206,0.00018089116,0.00005025004],"category_scores_gemma":[0.0012270692,0.000110799905,0.00032241544,0.00026911494,0.0002023921,0.00014364965,0.000023713263,0.0007234352,9.351101e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55094737,0.03631116,0.26274395,0.000007969608,0.00036657977,0.0003193495,0.0007175529,0.000016388307,0.000022519316,0.000004067366,0.000030580235,0.14851253],"study_design_scores_gemma":[0.5135035,0.15111138,0.33434814,0.00006838202,0.00045775576,0.00003673942,0.000104245664,0.000023943954,0.000020214391,0.000055098335,0.00021287563,0.000057696554],"about_ca_topic_score_codex":0.000042031235,"about_ca_topic_score_gemma":0.000041997635,"teacher_disagreement_score":0.14845483,"about_ca_system_score_codex":0.00015578468,"about_ca_system_score_gemma":0.00065655704,"threshold_uncertainty_score":0.4518289},"labels":[],"label_agreement":null},{"id":"W2604794283","doi":"10.1200/jco.2014.32.15_suppl.e20638","title":"Validation of the numerical rating scale versions of the Edmonton Symptom Assessment Aystem (ESAS) and ESAS-r among outpatients with advanced cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rating scale; Distress; Test (biology); Physical therapy; Ambulatory; Cancer; Palliative care; Family medicine; Internal medicine; Clinical psychology; Nursing","score_opus":0.03495876020340564,"score_gpt":0.41186879888907724,"score_spread":0.3769100386856716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604794283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944502,0.000084965446,0.0003763008,0.0024302162,0.0012974495,0.00021398185,0.0000037119087,0.0000025278887,0.0011406092],"genre_scores_gemma":[0.9988448,0.00007946879,0.00045382747,0.00031091145,0.00023757412,0.000004816551,5.908781e-7,0.000008636557,0.00005938696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975667,0.00057333027,0.0011452617,0.00012151237,0.00047684982,0.00011633914],"domain_scores_gemma":[0.996168,0.0009744861,0.002070147,0.00021403657,0.00044647593,0.00012684427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013070817,0.0000895971,0.0007685332,0.000029110073,0.00006217796,0.0000039490415,0.0001586689,0.00013986163,0.000018979761],"category_scores_gemma":[0.0006778072,0.00004305845,0.0002336823,0.00015294817,0.0002897522,0.000075371674,0.00007515317,0.0005147256,1.4023924e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080140214,0.0002711243,0.9681439,0.00006486503,0.00010163893,0.0000014446297,0.0004200137,0.00027366896,0.0003945702,0.000038194146,0.000115770636,0.029373404],"study_design_scores_gemma":[0.004142804,0.0045573344,0.98582655,0.0006780689,0.00041305018,0.000016019942,0.00088276423,0.0005311001,0.0012335028,0.000033429948,0.0016306367,0.000054714994],"about_ca_topic_score_codex":0.00022226087,"about_ca_topic_score_gemma":0.0005474025,"teacher_disagreement_score":0.029318688,"about_ca_system_score_codex":0.00012585083,"about_ca_system_score_gemma":0.0006815513,"threshold_uncertainty_score":0.22362551},"labels":[],"label_agreement":null},{"id":"W2604879053","doi":"10.1200/jco.2017.35.8_suppl.218","title":"Improving the measurement of clinician response to symptom screening: Auditing the symptom management of cancer patients in Ontario.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Concordance; Psychological intervention; Chart; Family medicine; Quality management; Nursing; Operations management; Internal medicine","score_opus":0.41449888248726446,"score_gpt":0.5648648710503349,"score_spread":0.15036598856307043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604879053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667497,0.000051646603,0.00027230187,0.030162692,0.0014721671,0.0007495106,0.0000040530504,0.0000026499172,0.00053525704],"genre_scores_gemma":[0.9924164,0.00012547632,0.00407492,0.0028620039,0.00040898455,0.000013855139,8.601816e-7,0.000016937724,0.00008056775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904932,0.0010836511,0.0066892537,0.00024340776,0.001210783,0.00027972754],"domain_scores_gemma":[0.97848845,0.00845957,0.010428069,0.00070291816,0.0017130639,0.00020792196],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03822188,0.00015310719,0.0012027537,0.000120333774,0.00014192778,0.000019861487,0.00070433517,0.00018875567,0.000078655416],"category_scores_gemma":[0.045250874,0.00008702698,0.00046604034,0.00011273783,0.0002779618,0.00018033196,0.00036964667,0.0012496113,0.0000032039447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01794479,0.0009766422,0.68381983,0.00003627328,0.0005191949,0.000042454805,0.00036265762,0.00008866281,0.00016925225,0.000024066601,0.00076344813,0.2952527],"study_design_scores_gemma":[0.009153134,0.00565411,0.96802515,0.0007032784,0.00078344776,0.0000051283873,0.000984548,0.00014091856,0.00007887135,0.00006845215,0.014327215,0.000075765354],"about_ca_topic_score_codex":0.01642292,"about_ca_topic_score_gemma":0.06386204,"teacher_disagreement_score":0.29517695,"about_ca_system_score_codex":0.00051782886,"about_ca_system_score_gemma":0.0022563275,"threshold_uncertainty_score":0.990353},"labels":[],"label_agreement":null},{"id":"W2604888638","doi":"10.1200/jco.2004.22.90140.706","title":"Trastuzumab (T) and docetaxel (D) for the treatment of HER2 metastatic breast cancer (MBC): A literature based (LB) and individual patient data (IPD) meta-analysis (MA) of phase II trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Metastatic breast cancer; Oncology; Trastuzumab; Breast cancer; Meta-analysis; Clinical trial; Cochrane Library; MEDLINE; CINAHL; Cancer","score_opus":0.41150323797398336,"score_gpt":0.5572722318948445,"score_spread":0.14576899392086118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604888638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581158,0.024078824,0.00027585283,0.013385493,0.00043279852,0.0012051096,0.0024873638,0.0000029009122,0.000015832156],"genre_scores_gemma":[0.9913009,0.0037066392,0.0034641966,0.0008969053,0.0004296215,0.0000672515,0.00008257901,0.000012557541,0.000039386607],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967717,0.0003809847,0.0020522259,0.00028299194,0.00032801184,0.00018409333],"domain_scores_gemma":[0.9938357,0.0031367894,0.0021201172,0.00031802637,0.00035271712,0.00023665019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015583694,0.00021649135,0.003256429,0.00020347194,0.00006672379,0.000010479887,0.00016916127,0.00016878241,0.00026895225],"category_scores_gemma":[0.00025963737,0.00010646851,0.0012888903,0.00029226491,0.00033485188,0.00010065134,0.000046981993,0.00026998232,8.526083e-8],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25485927,0.063628174,0.0013024547,0.0001389265,0.41486838,0.00025486213,0.002326732,0.00028635628,0.00018877423,0.000044957196,0.0013564407,0.26074466],"study_design_scores_gemma":[0.27333868,0.1566664,0.0042770873,0.000025295016,0.55224633,0.00016040477,0.00016514743,0.0003785396,0.00020643424,0.00011413496,0.01231699,0.000104557905],"about_ca_topic_score_codex":0.00014532222,"about_ca_topic_score_gemma":0.00032527448,"teacher_disagreement_score":0.26064008,"about_ca_system_score_codex":0.0001151769,"about_ca_system_score_gemma":0.0014067305,"threshold_uncertainty_score":0.43416598},"labels":[],"label_agreement":null},{"id":"W2604893790","doi":"10.1200/jco.2017.35.8_suppl.13","title":"Understanding the financial impact of beyond use date in a publicly funded cancer system.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Vial; Medicine; Pharmacy; Database; Computer science; Family medicine; Chromatography","score_opus":0.6625530062787293,"score_gpt":0.6312455907732453,"score_spread":0.03130741550548399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604893790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804004,0.00007574479,0.0010098636,0.0061280564,0.0063959197,0.00028588984,0.000018959905,0.000006880989,0.005678297],"genre_scores_gemma":[0.9972917,0.00019151434,0.00032407886,0.000481319,0.0015160764,0.000005603919,5.8640404e-7,0.000015189912,0.00017397507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99441296,0.0014123719,0.003233881,0.00016324768,0.00034373347,0.00043380505],"domain_scores_gemma":[0.97832334,0.013613604,0.006900481,0.00044487813,0.0004997205,0.00021799841],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010920533,0.00013440302,0.001377524,0.00015617123,0.0004861581,0.000027910499,0.00072579144,0.00051774795,0.00013114033],"category_scores_gemma":[0.03067659,0.000075156255,0.00042878924,0.00010952284,0.0003702222,0.00041293172,0.00021681962,0.0020759208,0.000013593438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021514762,0.00021368235,0.9825386,0.00006800765,0.00015382377,0.00011256534,0.00056984095,0.00013818975,0.00001242918,0.0045867055,0.00674241,0.002712281],"study_design_scores_gemma":[0.0057593193,0.0012265404,0.98595244,0.0007095902,0.00011124236,0.000020222638,0.0012035245,0.0007031011,0.000001267222,0.0011201792,0.0031106325,0.00008192026],"about_ca_topic_score_codex":0.0035855398,"about_ca_topic_score_gemma":0.013794427,"teacher_disagreement_score":0.019756056,"about_ca_system_score_codex":0.0005998855,"about_ca_system_score_gemma":0.008098348,"threshold_uncertainty_score":0.9975248},"labels":[],"label_agreement":null},{"id":"W2604916132","doi":"10.1200/jco.2013.31.15_suppl.6092","title":"Sequential TKI treatments for iodine-refractory differentiated thyroid carcinomas.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Sorafenib; Sunitinib; Internal medicine; Refractory (planetary science); Clinical endpoint; Oncology; Vandetanib; Progression-free survival; Tyrosine-kinase inhibitor; Gastroenterology; Clinical trial; Cancer; Overall survival; Hepatocellular carcinoma","score_opus":0.15076202784747986,"score_gpt":0.4563411557806761,"score_spread":0.3055791279331962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604916132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872417,0.001819493,0.000100236146,0.006468502,0.0020632732,0.0007275594,0.000016451451,0.000016315493,0.0015465026],"genre_scores_gemma":[0.99256444,0.0013365912,0.001754264,0.001460085,0.001783719,0.00008401848,0.000021126143,0.000028889106,0.0009668587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690473,0.00019235906,0.0020287936,0.00024394323,0.00030236252,0.00032782694],"domain_scores_gemma":[0.9959303,0.0012403134,0.0014560289,0.00023282436,0.0005806468,0.0005598668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057319814,0.00021292975,0.0015977793,0.00011819769,0.0000561625,0.000017797593,0.00014055501,0.0003666059,0.000676579],"category_scores_gemma":[0.00064845936,0.00013400707,0.0009966182,0.00007481146,0.00014333242,0.00014283991,0.00003611487,0.00045727802,0.000079162695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008457533,0.020864476,0.4630553,0.00008454062,0.007503878,0.00075456785,0.00019362896,0.0000082612805,0.0053357054,0.0003133434,0.15551552,0.33791324],"study_design_scores_gemma":[0.0384659,0.042116374,0.85285413,0.000086718384,0.0027975936,0.0002043338,0.00007026884,0.00006608403,0.0010997712,0.00078423356,0.061287627,0.00016698167],"about_ca_topic_score_codex":0.00009978073,"about_ca_topic_score_gemma":0.000023365008,"teacher_disagreement_score":0.3897988,"about_ca_system_score_codex":0.00040721052,"about_ca_system_score_gemma":0.0009854872,"threshold_uncertainty_score":0.7408066},"labels":[],"label_agreement":null},{"id":"W2604924954","doi":"10.1200/jco.2017.35.8_suppl.51","title":"Reviewing systemic treatment regimens to reduce unintentional errors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Regimen; Multidisciplinary approach; Quality (philosophy); Harm; Medical emergency; Intensive care medicine; Internal medicine; Psychology","score_opus":0.8289441698938937,"score_gpt":0.6382611275518195,"score_spread":0.19068304234207423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604924954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6703724,0.005268013,0.0020980195,0.29049587,0.010082731,0.0008103002,0.000061309016,0.000017441767,0.020793898],"genre_scores_gemma":[0.96401566,0.0022318382,0.011135041,0.013847427,0.004117285,0.000030065261,0.0000034166221,0.000031231077,0.004588007],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856609,0.0009073055,0.012601977,0.00037499404,0.00013140052,0.00032343625],"domain_scores_gemma":[0.9770061,0.0028043976,0.018570125,0.00073424965,0.00032106694,0.0005641003],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.052468475,0.00016856349,0.0031635785,0.00022835046,0.00028989717,0.00007362359,0.0006704087,0.0003096311,0.00028253498],"category_scores_gemma":[0.04769242,0.00016074379,0.0006825859,0.000054349937,0.00013995233,0.0004520392,0.000086942004,0.0004026516,0.0016729449],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012754741,0.0030695114,0.37410474,0.0006467012,0.002327815,0.00025682972,0.0025076729,0.0005780525,0.000041074058,0.20363447,0.34107047,0.070487194],"study_design_scores_gemma":[0.0035448694,0.003360584,0.14140067,0.0006032876,0.00006384712,0.00024758957,0.0004315141,0.00023063908,0.0000030841402,0.0068572075,0.8430115,0.00024522256],"about_ca_topic_score_codex":0.00021338297,"about_ca_topic_score_gemma":0.00007509462,"teacher_disagreement_score":0.501941,"about_ca_system_score_codex":0.0012583131,"about_ca_system_score_gemma":0.0011745975,"threshold_uncertainty_score":0.9991044},"labels":[],"label_agreement":null},{"id":"W2604984698","doi":"10.1200/jco.2017.35.8_suppl.50","title":"Effect of the establishment of a hematological multidisciplinary oral chemotherapy clinic at a community hospital on the number of emergency department visits.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto East General Hospital","funders":"","keywords":"Medicine; Emergency department; Adverse effect; Pharmacist; Emergency medicine; Medical record; Internal medicine; Pharmacy; Family medicine","score_opus":0.12107626743658084,"score_gpt":0.5189730152565961,"score_spread":0.3978967478200153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604984698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892117,0.000108315115,0.000003775439,0.006518454,0.0010183343,0.0007283513,0.000008552232,0.0000030758486,0.0023994525],"genre_scores_gemma":[0.99859214,0.00057596876,0.0002165896,0.00015391587,0.00018776287,0.000011259013,0.0000012021652,0.000016656059,0.00024450064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925709,0.0030613274,0.00298105,0.00017231354,0.00092136033,0.0002930718],"domain_scores_gemma":[0.9830893,0.010260641,0.004620671,0.0013246477,0.00048802866,0.00021666016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013553533,0.00019677391,0.0021281536,0.000039981005,0.00022522356,0.0000048659163,0.0012023253,0.0004129778,0.0007547941],"category_scores_gemma":[0.014335513,0.00008500092,0.0013020341,0.00010297788,0.0011367509,0.000062809115,0.00082371524,0.0015897248,0.00001660163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035885,0.013194218,0.91507894,0.0005290042,0.0016334433,0.000240089,0.00075605273,0.0000088518145,0.00058712566,0.00019635497,0.010541685,0.021349223],"study_design_scores_gemma":[0.05259626,0.07137846,0.85802907,0.00066098623,0.00063651585,0.0004008561,0.00025203725,0.00036700992,0.013289861,0.0006946272,0.0015450624,0.00014922356],"about_ca_topic_score_codex":0.00011886483,"about_ca_topic_score_gemma":0.000046242225,"teacher_disagreement_score":0.058184247,"about_ca_system_score_codex":0.0013752688,"about_ca_system_score_gemma":0.0031268352,"threshold_uncertainty_score":0.9939672},"labels":[],"label_agreement":null},{"id":"W2604988164","doi":"10.1200/jco.2017.35.8_suppl.31","title":"Toxicity of high-dose interferon for high-risk melanoma in Ontario: A population-based study of health services use.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Discontinuation; Population; Mental health; Propensity score matching; Cancer registry; Toxicity; Internal medicine; Psychiatry; Environmental health","score_opus":0.5582585478599233,"score_gpt":0.5501806954791073,"score_spread":0.008077852380816042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604988164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891126,0.00009986508,0.0006034643,0.0075192917,0.0017217003,0.0008078982,0.00009939944,0.0000030220185,0.000032770065],"genre_scores_gemma":[0.9930365,0.0000290536,0.004945881,0.0016897816,0.00022049653,0.000015986432,0.000008202739,0.000015656236,0.000038460785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98238623,0.0013520558,0.015573725,0.00031206838,0.00012660032,0.00024929264],"domain_scores_gemma":[0.95586765,0.0068154465,0.036350984,0.0005466293,0.00024874497,0.00017055497],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.048704177,0.00014455788,0.0038054604,0.00034787372,0.0001303065,0.000029762024,0.00057164667,0.00029299536,0.00008636207],"category_scores_gemma":[0.010134196,0.00015004801,0.0002871883,0.000051510215,0.00006613398,0.0004914872,0.000067133216,0.00050909934,0.000008340826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000934984,0.0022243166,0.9911237,0.00018858946,0.00014892487,0.0000014606082,0.0009610949,0.0007524894,2.4248766e-7,0.0017873623,0.00017750254,0.0016993502],"study_design_scores_gemma":[0.008677369,0.011397567,0.9704592,0.00017002191,0.000025991822,9.36456e-7,0.0005485222,0.0007410507,0.0000013701391,0.0072699725,0.0006048777,0.00010307896],"about_ca_topic_score_codex":0.40037188,"about_ca_topic_score_gemma":0.6700988,"teacher_disagreement_score":0.26972693,"about_ca_system_score_codex":0.000888233,"about_ca_system_score_gemma":0.0014102925,"threshold_uncertainty_score":0.9982039},"labels":[],"label_agreement":null},{"id":"W2605079961","doi":"10.1200/jco.2012.30.15_suppl.e15118","title":"A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Systems, Applications & Products in Data Processing (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metformin; Prostate cancer; Tolerability; Prostatectomy; Internal medicine; Adverse effect; Urology; Diabetes mellitus; Cancer; Prostate; Oncology; Insulin; Endocrinology","score_opus":0.11948475732227351,"score_gpt":0.4796738490664636,"score_spread":0.3601890917441901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605079961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9205738,0.07810549,0.000057816844,0.00013772206,0.00060550915,0.00033031427,0.0000069840785,7.10031e-7,0.00018169351],"genre_scores_gemma":[0.9901866,0.0071563586,0.00153568,0.000269231,0.0007763506,0.00001569631,0.0000049563273,0.000010738539,0.00004439083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975425,0.00052415585,0.0013197724,0.00013922513,0.0002568712,0.00021744691],"domain_scores_gemma":[0.99813616,0.00018055055,0.0010757793,0.00014696045,0.00026724246,0.00019328688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054455404,0.00010949848,0.00073924963,0.00007714692,0.00002184565,0.0000038676117,0.00011073899,0.00024602248,0.00006818855],"category_scores_gemma":[0.0013358666,0.00007369114,0.000106517095,0.00008783107,0.00016789466,0.000017628334,0.00005415964,0.00020656089,7.7125617e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029005283,0.0029097092,0.008303581,0.000018167935,0.00017916542,0.000009797118,0.00014490621,0.0000033653394,0.0033600335,0.00001948914,0.00072897656,0.9553175],"study_design_scores_gemma":[0.3705086,0.11825225,0.06999823,0.00010080016,0.00096106663,0.00020582328,0.0003872334,0.00017880125,0.020279454,0.0003203285,0.41844377,0.00036362832],"about_ca_topic_score_codex":0.0000062788235,"about_ca_topic_score_gemma":0.000036988717,"teacher_disagreement_score":0.9549539,"about_ca_system_score_codex":0.000020829013,"about_ca_system_score_gemma":0.00084727217,"threshold_uncertainty_score":0.30050376},"labels":[],"label_agreement":null},{"id":"W2605100271","doi":"10.1200/jco.2017.35.8_suppl.208","title":"Reliability of administrative data for evaluating the quality of systemic treatment for cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Institute for Clinical Evaluative Sciences; Trillium Health Centre; University of Toronto; Health Sciences Centre; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Cancer registry; Documentation; Medical record; Breast cancer; Cancer; Reliability (semiconductor); Chart; Retrospective cohort study; Gold standard (test); Quality (philosophy); Internal medicine; Statistics; Computer science","score_opus":0.9500836801451111,"score_gpt":0.7439243315741372,"score_spread":0.20615934857097395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605100271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404184,0.0018347478,0.005376339,0.04479015,0.0026041712,0.0017998707,0.002706758,0.000002865615,0.0004667049],"genre_scores_gemma":[0.98487854,0.00055267144,0.012592055,0.00070800335,0.0009976082,0.000098154276,0.000012110436,0.000012525931,0.0001483018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9818679,0.0014463896,0.015969561,0.00036901358,0.00013151852,0.0002156285],"domain_scores_gemma":[0.9086727,0.04054687,0.048102394,0.0015903888,0.00093382294,0.00015385025],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15295118,0.0001273689,0.0033156264,0.0000571535,0.0002176192,0.00002101651,0.001164175,0.00026192053,0.000039379116],"category_scores_gemma":[0.1839871,0.000095792166,0.0005659538,0.000029287288,0.00038295766,0.00035340167,0.00009776349,0.00020311616,0.000004121296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013774337,0.0055885934,0.73181856,0.0051811705,0.0039104098,0.0000018430129,0.005468341,0.0014292062,0.00014858534,0.11599241,0.026883109,0.08980344],"study_design_scores_gemma":[0.025038539,0.04012829,0.7422509,0.00085316325,0.0005558379,0.000019055864,0.005301503,0.028128147,0.00006744822,0.07874048,0.078416415,0.00050022575],"about_ca_topic_score_codex":0.0010360917,"about_ca_topic_score_gemma":0.0007513529,"teacher_disagreement_score":0.08930322,"about_ca_system_score_codex":0.0004895011,"about_ca_system_score_gemma":0.0034120507,"threshold_uncertainty_score":0.87221503},"labels":[],"label_agreement":null},{"id":"W2605108538","doi":"10.1200/jco.2004.22.90140.4655","title":"Change in bone alkaline phosphatase as an outcome predictor in men with hormone-refractory prostate cancer metastasized to bone","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Hazard ratio; Urology; Alkaline phosphatase; Proportional hazards model; Placebo; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.1267942869181265,"score_gpt":0.4918057462744774,"score_spread":0.3650114593563509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605108538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684725,0.0052175997,0.000004964191,0.024553737,0.0003422217,0.0011690486,0.00005104794,0.000012765811,0.00017613536],"genre_scores_gemma":[0.9812562,0.0037463687,0.0034213597,0.010821746,0.00040465017,0.00011675955,0.000022116497,0.00003367348,0.00017716706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545807,0.00031503921,0.0029199992,0.0003153663,0.000484301,0.00050720363],"domain_scores_gemma":[0.9966231,0.00035797214,0.0012497992,0.00025317227,0.00023394586,0.0012820307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029431868,0.00023116065,0.0021954328,0.000340297,0.000026266862,0.0000067432,0.00011019264,0.00030814332,0.00010493797],"category_scores_gemma":[0.001075252,0.00015017792,0.00016390155,0.0003661054,0.00010586853,0.0003048715,0.0000394517,0.0011471906,0.000031866366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11444023,0.01631068,0.65837586,0.0000964764,0.0004141675,0.025902467,0.0016402253,0.000058118512,0.00013081574,0.00007796929,0.0007832479,0.18176971],"study_design_scores_gemma":[0.077561,0.043735113,0.842194,0.00025846672,0.00033825717,0.00044368548,0.00012631489,0.000016702004,0.000037188238,0.00017777931,0.034955367,0.00015610478],"about_ca_topic_score_codex":0.0048811412,"about_ca_topic_score_gemma":0.008491157,"teacher_disagreement_score":0.18381813,"about_ca_system_score_codex":0.00071943976,"about_ca_system_score_gemma":0.0025538371,"threshold_uncertainty_score":0.73788583},"labels":[],"label_agreement":null},{"id":"W2605117686","doi":"10.1200/jco.2017.35.8_suppl.190","title":"Utilizing patient reported outcomes for patients recieving oral chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Capecitabine; Chemotherapy; Quality of life (healthcare); Intensive care medicine; Physical therapy; Internal medicine; Cancer; Nursing; Colorectal cancer","score_opus":0.30154577000438787,"score_gpt":0.5701173914839619,"score_spread":0.26857162147957403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605117686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97968066,0.0000906671,0.000029655163,0.011369975,0.0043038246,0.0003949314,0.0000029717519,0.000008004215,0.0041193],"genre_scores_gemma":[0.98929876,0.00032358375,0.0047379294,0.0042547267,0.0007396414,0.0000089588475,0.0000033951912,0.000018031556,0.0006149699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729556,0.000111132096,0.0019897667,0.00016898426,0.00021765711,0.00021687573],"domain_scores_gemma":[0.99385977,0.0012409048,0.0037790886,0.00027020762,0.00058856426,0.00026144992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014939532,0.00012571765,0.0013734251,0.000064392785,0.00014209026,0.000015441821,0.00015992412,0.0002578701,0.00014671376],"category_scores_gemma":[0.0058170073,0.00008354499,0.0006849974,0.000023861967,0.00014816415,0.00012309002,0.00004484585,0.00041404794,0.000003569305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004241265,0.002360392,0.6356716,0.000011593835,0.0005987754,0.00011989019,0.000060215432,2.8728664e-7,0.00004298429,0.000011387651,0.009929104,0.34695247],"study_design_scores_gemma":[0.019091971,0.01729458,0.71136326,0.00004101917,0.0004993448,0.00004929821,0.000025015988,0.000017471903,0.00008181387,0.00016860144,0.25130367,0.000063956795],"about_ca_topic_score_codex":0.000017502245,"about_ca_topic_score_gemma":0.00001696122,"teacher_disagreement_score":0.3468885,"about_ca_system_score_codex":0.00015768023,"about_ca_system_score_gemma":0.0006736752,"threshold_uncertainty_score":0.6963921},"labels":[],"label_agreement":null},{"id":"W2605126653","doi":"10.1200/jco.2004.22.90140.8537","title":"Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"CD117; Medicine; GiST; Population; Stromal tumor; Imatinib mesylate; Internal medicine; Gastroenterology; CD34; Pathology; Imatinib; Stromal cell","score_opus":0.09480847425614362,"score_gpt":0.45963531132341,"score_spread":0.3648268370672664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605126653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995382,0.00017666267,0.0009703909,0.002619868,0.00020856009,0.00017930036,0.000007530143,0.000007795529,0.00044785376],"genre_scores_gemma":[0.93878734,0.00025300513,0.059568208,0.0002860135,0.0010587189,0.000001436236,0.0000028203797,0.000017329805,0.000025126426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511045,0.0003528127,0.0034117023,0.00023504894,0.0005388889,0.00035110637],"domain_scores_gemma":[0.99463737,0.001387335,0.0020088663,0.00020200144,0.00074466015,0.001019748],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032227607,0.00017676518,0.0017841395,0.00016820966,0.000027023245,0.000008421723,0.00015965868,0.00012110241,0.000044845303],"category_scores_gemma":[0.012662623,0.0001271561,0.00059306726,0.00014291164,0.00062447635,0.00006455304,0.00009578128,0.0013689046,0.0000131451025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040374314,0.003416693,0.9610357,0.00007297001,0.00014159513,0.01606211,0.000008123115,0.0000029554412,0.00028660643,0.00038807385,0.000117802905,0.01442991],"study_design_scores_gemma":[0.0103408545,0.05948266,0.91387016,0.00022852447,0.00044712878,0.0146239195,0.000036943115,0.000013237917,0.00005985875,0.0006298761,0.00019619607,0.00007066134],"about_ca_topic_score_codex":0.000014816061,"about_ca_topic_score_gemma":0.0000027010824,"teacher_disagreement_score":0.058597818,"about_ca_system_score_codex":0.000081332255,"about_ca_system_score_gemma":0.002609592,"threshold_uncertainty_score":0.99565417},"labels":[],"label_agreement":null},{"id":"W2605131338","doi":"10.1200/jco.2017.35.8_suppl.167","title":"Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Family medicine; Demographics; Medical record; Questionnaire; Surgery","score_opus":0.5388286004349858,"score_gpt":0.7055443473136181,"score_spread":0.16671574687863233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605131338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481944,0.00094576384,0.010595545,0.027716324,0.0030903686,0.005769285,0.000022732616,0.00002219475,0.0036434147],"genre_scores_gemma":[0.9870068,0.006661137,0.0030988446,0.0013296816,0.0013914224,0.0003915119,0.000004076371,0.000010470362,0.000106074796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892208,0.0026818377,0.006832309,0.00018536426,0.00037696067,0.00070271187],"domain_scores_gemma":[0.9731668,0.014594055,0.0076780254,0.0005142948,0.0033817359,0.0006650578],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06472011,0.00010864395,0.0012711952,0.00017496859,0.0018085069,0.00001520441,0.0004417289,0.0007831213,0.000029274923],"category_scores_gemma":[0.07206163,0.00008421658,0.00025658816,0.00012076118,0.00064064754,0.0005920516,0.00018318418,0.0029580765,0.000016033044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00360623,0.00044539012,0.6683759,0.0005459851,0.000039245097,6.871884e-7,0.00022224801,9.4390697e-7,0.0000027176159,0.0071266787,0.014450625,0.30518332],"study_design_scores_gemma":[0.007858086,0.006115278,0.6472693,0.00021848189,0.00005430217,0.000014828288,0.0003319995,0.0005636284,0.0000029599755,0.017689593,0.31981236,0.00006916793],"about_ca_topic_score_codex":0.00017382551,"about_ca_topic_score_gemma":0.0005859713,"teacher_disagreement_score":0.30536175,"about_ca_system_score_codex":0.00029971116,"about_ca_system_score_gemma":0.009464038,"threshold_uncertainty_score":0.999491},"labels":[],"label_agreement":null},{"id":"W2605159918","doi":"10.1200/jco.2017.35.8_suppl.223","title":"Measurement of person-centered care delivery of adult oncology in Ontario, Canada.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Delphi method; Accreditation; Guideline; Likert scale; Delphi; Psychological intervention; Deliverable; Health care; Scale (ratio); Best practice; Family medicine; Nursing; Medical education; Psychology","score_opus":0.5315675688304495,"score_gpt":0.5454514854296352,"score_spread":0.013883916599185642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605159918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788173,0.00018385204,0.000027646303,0.01366967,0.002484771,0.00027581272,0.000007943407,0.0000015571129,0.0045314864],"genre_scores_gemma":[0.9951181,0.00021758334,0.0027195862,0.0014758108,0.00039415082,0.000002093683,0.000003759682,0.000011990716,0.000056943267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921184,0.0005905896,0.005945803,0.00019879449,0.00091380626,0.00023258214],"domain_scores_gemma":[0.98349845,0.0024000392,0.009057632,0.00042449488,0.004312347,0.00030703555],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005672669,0.00013786156,0.0020213488,0.00012014678,0.000042785145,0.0000037805764,0.0003639195,0.00035893405,0.00032045692],"category_scores_gemma":[0.040874504,0.0001120341,0.0004302491,0.00004777381,0.0002533359,0.00017070673,0.000092964074,0.0013112215,0.0000015618814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010329147,0.0018791998,0.8637414,0.00011132869,0.00045330203,0.00047940385,0.0005589164,0.000014982708,0.00068609556,0.000021950927,0.009965489,0.111758806],"study_design_scores_gemma":[0.017915126,0.011319283,0.92191267,0.0003772579,0.00057613984,0.00008922595,0.00368095,0.000033657863,0.00027795002,0.000023351091,0.043707453,0.00008696612],"about_ca_topic_score_codex":0.8537252,"about_ca_topic_score_gemma":0.9950215,"teacher_disagreement_score":0.14129631,"about_ca_system_score_codex":0.0022815405,"about_ca_system_score_gemma":0.03368356,"threshold_uncertainty_score":0.97179455},"labels":[],"label_agreement":null},{"id":"W2605189400","doi":"10.1200/jco.2012.30.15_suppl.tps2614","title":"A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Temsirolimus; Renal cell carcinoma; Tolerability; Internal medicine; Oncology; Everolimus; Bevacizumab; Pharmacology; Urology; Adverse effect; Chemotherapy; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Apoptosis","score_opus":0.1887988785238983,"score_gpt":0.45908818947588187,"score_spread":0.2702893109519836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605189400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724203,0.00023116307,0.00002032697,0.00016018968,0.00038903445,0.0009027669,0.0000068017966,0.000004465139,0.0010432113],"genre_scores_gemma":[0.99700546,0.000018138015,0.0021653764,0.00024882975,0.00034462212,0.000011977932,0.0000068704153,0.000031171727,0.00016753073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942855,0.0010744559,0.0032212345,0.0002122485,0.00077797176,0.00042854578],"domain_scores_gemma":[0.99386615,0.0020866417,0.0024787046,0.00032539677,0.00058771536,0.00065537007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029584814,0.00024693515,0.0024193735,0.00031915706,0.000025744004,0.0000047863973,0.00018447025,0.00016761081,0.00022251144],"category_scores_gemma":[0.0011280273,0.00013746426,0.00029151063,0.0003164431,0.00015875197,0.00017940522,0.00006401625,0.0009386273,0.000011219572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0589195,0.081382245,0.843451,0.000079826445,0.0004419048,0.0021080791,0.001368898,0.000016809,0.000057890582,0.000004074724,0.0002936941,0.011876053],"study_design_scores_gemma":[0.114052646,0.17996186,0.7020476,0.00006846504,0.0014048243,0.00015403556,0.0013485161,0.000013140248,0.00025586158,0.0000050133353,0.00058037776,0.00010768781],"about_ca_topic_score_codex":0.000077831326,"about_ca_topic_score_gemma":0.00009813234,"teacher_disagreement_score":0.14140345,"about_ca_system_score_codex":0.00035868186,"about_ca_system_score_gemma":0.0016935186,"threshold_uncertainty_score":0.56056297},"labels":[],"label_agreement":null},{"id":"W2605217617","doi":"10.1200/jco.2017.35.8_suppl.153","title":"Trends in the content and format of main and optional consent forms in oncology clinical trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Readability; Medicine; Clinical trial; Medical physics; Family medicine; Internal medicine","score_opus":0.9394631780072716,"score_gpt":0.7719339495133768,"score_spread":0.16752922849389484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605217617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8791914,0.0004905155,0.00003381017,0.112120494,0.00076039333,0.00029401618,0.000007481404,0.0000014944407,0.007100413],"genre_scores_gemma":[0.9786497,0.014381297,0.0021272525,0.003876266,0.0006923893,0.000007120166,0.0000016601433,0.000009145968,0.00025520855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98241895,0.005810554,0.010092806,0.00032322266,0.00096197095,0.00039250805],"domain_scores_gemma":[0.7001584,0.29048187,0.0071424753,0.0006927508,0.00080490333,0.0007195677],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.20682287,0.00014171629,0.0033111705,0.00030223708,0.00007525228,0.000025941006,0.0005089736,0.0015245192,0.00008287786],"category_scores_gemma":[0.3455288,0.00007564749,0.0006256587,0.000089750974,0.0029576293,0.00015567227,0.0003071443,0.0062742876,0.0000023410685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014715527,0.0028971643,0.6026034,0.000073844574,0.00020595775,0.0010295202,0.0002491749,0.0000010120518,0.000036839367,0.013381644,0.001673913,0.36313203],"study_design_scores_gemma":[0.025957087,0.01919164,0.91651976,0.00030014364,0.00014489786,0.00070289994,0.0007308554,0.00015627201,0.000004522402,0.022768417,0.013453338,0.00007016139],"about_ca_topic_score_codex":0.00009197409,"about_ca_topic_score_gemma":0.003281705,"teacher_disagreement_score":0.36306188,"about_ca_system_score_codex":0.00013312114,"about_ca_system_score_gemma":0.0031303463,"threshold_uncertainty_score":0.9997717},"labels":[],"label_agreement":null},{"id":"W2605243727","doi":"10.1200/jco.2006.24.18_suppl.4080","title":"SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Toxicity; Chemotherapy; Internal medicine; Phases of clinical research; Surgery; Radiation therapy; Gastroenterology; Urology","score_opus":0.1958511671009453,"score_gpt":0.52948964962486,"score_spread":0.3336384825239147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605243727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875061,0.001303737,0.000028321414,0.009223854,0.00019381769,0.0006790667,0.0000050950516,0.0000055678256,0.0010544743],"genre_scores_gemma":[0.9958919,0.00036604624,0.00091950566,0.0013174051,0.00052241277,0.000022877512,0.0000013332935,0.000013730411,0.00094478216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964722,0.00028802312,0.002449431,0.00019740398,0.00037939937,0.00021354768],"domain_scores_gemma":[0.99648225,0.0016476181,0.0010922158,0.00030877072,0.0002725181,0.00019662228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019393977,0.00014914667,0.0012595911,0.000056460165,0.00007731896,0.000004853984,0.00032185242,0.00014424574,0.0003919613],"category_scores_gemma":[0.0016232298,0.000078981306,0.00034916008,0.00036334124,0.00023630375,0.00007822152,0.000055139863,0.00097557314,0.0000048811617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08749277,0.19537829,0.48811182,0.00018628124,0.0014937648,0.003481539,0.0009041365,0.0017307113,0.033737417,0.00043481193,0.003431058,0.1836174],"study_design_scores_gemma":[0.1767356,0.12532537,0.5724892,0.00025931344,0.0012908165,0.0014495786,0.000984805,0.0005995341,0.041862376,0.0021813198,0.076490924,0.00033119216],"about_ca_topic_score_codex":0.00002905636,"about_ca_topic_score_gemma":0.000037754016,"teacher_disagreement_score":0.1832862,"about_ca_system_score_codex":0.00008205932,"about_ca_system_score_gemma":0.0009313769,"threshold_uncertainty_score":0.42917016},"labels":[],"label_agreement":null},{"id":"W2605255821","doi":"10.1200/jco.2004.22.90140.6153","title":"Development of a QOL module for head and neck cancer patients with enteral feeding tubes","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck cancer; Quality of life (healthcare); Feeding tube; Larynx; Enteral administration; Cancer; Radiation therapy; Internal medicine; Physical therapy; Surgery; Parenteral nutrition; Nursing","score_opus":0.11957226754150134,"score_gpt":0.4674364906544131,"score_spread":0.34786422311291176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605255821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603105,0.00036914446,0.00013787858,0.0026473587,0.0004335678,0.00018124298,0.0000024934554,0.0000024296867,0.00019484089],"genre_scores_gemma":[0.97001785,0.00023958216,0.028607717,0.0007551008,0.00033601953,0.000008950127,5.775037e-7,0.00000787622,0.000026353202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984459,0.000019827397,0.0011079011,0.00010023119,0.000181479,0.00014465637],"domain_scores_gemma":[0.9987426,0.00024145536,0.0004126998,0.00003995669,0.00040298342,0.00016032906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000505983,0.00007976082,0.0009923192,0.00005057062,0.00003949082,0.0000021943893,0.000041705778,0.00009257305,0.0000083686045],"category_scores_gemma":[0.00040348084,0.000048196303,0.000102425154,0.000044526627,0.0000952359,0.00005412266,0.000025178777,0.00021345771,2.7211743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075358343,0.001663197,0.856267,0.00013514845,0.0005488373,0.000018504572,0.0010950789,0.000009822973,0.00018365432,0.00003612162,0.00046711866,0.1320397],"study_design_scores_gemma":[0.022915686,0.016303489,0.93994665,0.0006841692,0.00014680414,0.000015695208,0.000093384995,0.000005704801,0.00041599388,0.000055955683,0.019356204,0.000060261384],"about_ca_topic_score_codex":0.000014023268,"about_ca_topic_score_gemma":0.00014036393,"teacher_disagreement_score":0.13197944,"about_ca_system_score_codex":0.00013065616,"about_ca_system_score_gemma":0.0011538024,"threshold_uncertainty_score":0.2046796},"labels":[],"label_agreement":null},{"id":"W2605279043","doi":"10.1200/jco.2017.35.8_suppl.182","title":"A person-centered e-proms multi-faceted intervention to improve patient experience and health outcomes: A multi-site implementation study in diverse ambulatory oncology practices.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; St Mary's Hospital Centre; Health Sciences North; Cancer Care Ontario; Jewish General Hospital; McGill University Health Centre; Juravinski Cancer Centre; Northeast Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Patient-reported outcome; Prom; Patient satisfaction; Focus group; Coaching; Anxiety; Intervention (counseling); Family medicine; Health coaching; Patient experience; Debriefing; Physical therapy; Hospital Anxiety and Depression Scale; Health care; Quality of life (healthcare); Nursing; Psychiatry; Psychology","score_opus":0.7335172897206141,"score_gpt":0.6916565757259047,"score_spread":0.041860713994709475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605279043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705595,0.00005620274,0.00086326693,0.024074629,0.0021080144,0.002298225,0.000014171772,0.00001143076,0.000014596502],"genre_scores_gemma":[0.97507304,0.00012402577,0.018943937,0.0055149957,0.00022363194,0.000055931563,0.000008476201,0.00002202125,0.000033964225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912402,0.0016824636,0.0056206756,0.0005381421,0.00052923744,0.0003892783],"domain_scores_gemma":[0.9824445,0.0017962346,0.013949259,0.00048522148,0.00065757224,0.0006671583],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012173602,0.00023638694,0.0017632522,0.0002832665,0.00019366147,0.000062305284,0.0002689361,0.00025297765,0.0001062583],"category_scores_gemma":[0.033518728,0.00019096288,0.00034025428,0.000099337434,0.00017619687,0.00088295457,0.00033368898,0.001194197,0.000017913979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026956294,0.0069189486,0.62770593,0.000024276165,0.00018277664,0.00027213703,0.006600002,0.0000017258074,0.0001679492,9.52203e-7,0.00027130157,0.3551584],"study_design_scores_gemma":[0.044995077,0.038414486,0.85582644,0.000092222275,0.00024081953,0.000077557204,0.056633066,0.0005886769,0.000010320844,0.0000024535836,0.0029898745,0.00012899979],"about_ca_topic_score_codex":0.0058163144,"about_ca_topic_score_gemma":0.0196382,"teacher_disagreement_score":0.3550294,"about_ca_system_score_codex":0.00093368866,"about_ca_system_score_gemma":0.0013780184,"threshold_uncertainty_score":0.99825084},"labels":[],"label_agreement":null},{"id":"W2605288103","doi":"10.1200/jco.2017.35.8_suppl.100","title":"Standardized symptom screening: Cancer Care Ontario's expanded prostate cancer index composite for clinical practice (EPIC-CP) provincial implementation approach.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"EPIC; Medicine; Stakeholder; Stakeholder engagement; Family medicine; Working group; Medical education; Nursing; Public relations; Political science","score_opus":0.4145989731325296,"score_gpt":0.6500186035953925,"score_spread":0.23541963046286296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605288103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9301887,0.00087317015,0.01374319,0.04258828,0.006791076,0.0040327273,0.00026800742,0.00004102967,0.0014738112],"genre_scores_gemma":[0.86148983,0.002602928,0.11694895,0.0092615895,0.008826388,0.00026063895,0.00014247924,0.00009111801,0.00037610115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9875279,0.0012206791,0.008802853,0.0006664078,0.0012051266,0.00057699817],"domain_scores_gemma":[0.96993655,0.008693333,0.014760133,0.00063693535,0.00521347,0.0007595879],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015134657,0.0003645715,0.0027186926,0.00014621242,0.00051013427,0.00016292612,0.00053450983,0.0007117835,0.00032200164],"category_scores_gemma":[0.033825364,0.00029081796,0.001209038,0.00008957415,0.00046762943,0.0013257033,0.00024486144,0.0023416246,0.0000032177077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042341657,0.001081629,0.5005388,0.00008459685,0.0012264994,0.00009382563,0.0007471905,0.000038629092,0.000034958815,0.000032414588,0.00973339,0.44404635],"study_design_scores_gemma":[0.049675226,0.00909738,0.5387331,0.00015529717,0.0028066575,0.0001244406,0.0030191462,0.00021328838,0.000051691233,0.00012455918,0.3957405,0.00025869554],"about_ca_topic_score_codex":0.020160725,"about_ca_topic_score_gemma":0.054918095,"teacher_disagreement_score":0.44378766,"about_ca_system_score_codex":0.0011801666,"about_ca_system_score_gemma":0.015316579,"threshold_uncertainty_score":0.99996},"labels":[],"label_agreement":null},{"id":"W2605305617","doi":"10.1200/jco.2012.30.15_suppl.6619","title":"Initial characterization of the toxicity and efficacy of elacytarabine (CP-4055), a novel antileukemic agent, using a multidimensional exposure-response relationship model.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacokinetics; Medicine; Toxicity; Dosing; Pharmacology; Population; Pharmacodynamics; Oncology; Internal medicine","score_opus":0.265419063122809,"score_gpt":0.5002150856960331,"score_spread":0.23479602257322413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605305617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968304,0.0001796278,0.0008036034,0.0010429843,0.000845784,0.0002419358,0.000018930152,0.0000028731588,0.000033838536],"genre_scores_gemma":[0.99617916,0.00006844864,0.002634281,0.00052045553,0.0005266845,0.0000014036683,0.0000039463675,0.000010576339,0.000055045828],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973642,0.00054922263,0.0015983463,0.00009955997,0.00023490813,0.00015372805],"domain_scores_gemma":[0.9949605,0.0026542807,0.0018048934,0.00011799707,0.00028207188,0.00018029466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002370769,0.000107339336,0.00082786335,0.000110755296,0.000043965265,0.0000013518377,0.000067935434,0.00026018897,0.000042619886],"category_scores_gemma":[0.002306301,0.000070107206,0.00028635593,0.00013393503,0.00027245312,0.0001332849,0.000055603297,0.00048219954,5.433653e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029518519,0.0053046304,0.30450726,0.000030303398,0.00027766608,0.000010803438,0.00046606892,0.00027051102,0.6574069,0.00007908444,0.000055986373,0.002072241],"study_design_scores_gemma":[0.018550007,0.0037101742,0.9609979,0.000106070016,0.0008127487,0.00030202346,0.000016739255,0.005206479,0.009816191,0.000020255751,0.00040034193,0.0000610973],"about_ca_topic_score_codex":0.000009729388,"about_ca_topic_score_gemma":0.0000027837636,"teacher_disagreement_score":0.6564906,"about_ca_system_score_codex":0.0001294174,"about_ca_system_score_gemma":0.0012192919,"threshold_uncertainty_score":0.28588888},"labels":[],"label_agreement":null},{"id":"W2605311401","doi":"10.1200/jco.2017.35.8_suppl.236","title":"Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Chemotherapy; Poisson regression; Internal medicine; Cancer; Cancer registry; Proportional hazards model; Lung cancer; Population; Oncology; Perioperative; Surgery","score_opus":0.26235875388508795,"score_gpt":0.5896026815244145,"score_spread":0.3272439276393266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605311401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9334537,0.0019400998,0.000046344176,0.0619555,0.0013108251,0.0005540334,0.00001918941,0.000004898665,0.0007154385],"genre_scores_gemma":[0.9696716,0.02133526,0.0046487707,0.0031590492,0.0010121814,0.000041238458,0.000005340642,0.000017366228,0.00010920262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968786,0.00033548466,0.0021515389,0.00022893529,0.00022307958,0.00018236626],"domain_scores_gemma":[0.99064744,0.005838379,0.002551159,0.00020126275,0.00050994114,0.00025181726],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004686048,0.00012716165,0.0016259352,0.00007861507,0.00007870711,0.000024231509,0.000121332414,0.00030186825,0.00006836093],"category_scores_gemma":[0.018111354,0.000084088526,0.00039712017,0.000044202465,0.00023983586,0.00021474897,0.00004438812,0.0005109174,0.0000011142349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010634331,0.0033896999,0.65022415,0.000016858063,0.0005588282,0.00029073193,0.000027437807,9.777244e-7,0.00001223366,0.00005579037,0.0015139343,0.333275],"study_design_scores_gemma":[0.01941944,0.009310904,0.8757155,0.00010646749,0.00060091645,0.00012977154,0.000066051114,0.00018541857,0.000064355394,0.00016243142,0.094172634,0.00006608842],"about_ca_topic_score_codex":0.00019734136,"about_ca_topic_score_gemma":0.00064683607,"teacher_disagreement_score":0.33320892,"about_ca_system_score_codex":0.00016424472,"about_ca_system_score_gemma":0.0011243088,"threshold_uncertainty_score":0.9901595},"labels":[],"label_agreement":null},{"id":"W2605325696","doi":"10.1200/jco.2017.35.8_suppl.179","title":"The implementation of a streamlined process for biomarker testing in medical oncology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Biomarker; Upload; Documentation; Test (biology); Receipt; Requisition; Medical physics; Computer science; World Wide Web","score_opus":0.3004263129697443,"score_gpt":0.530430524539249,"score_spread":0.23000421156950468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605325696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598848,0.0006346246,0.0006092796,0.026312802,0.001989446,0.00024711937,0.000031019525,0.0000023486484,0.0102885505],"genre_scores_gemma":[0.9970862,0.0006168003,0.00089298823,0.0008738752,0.0004616893,0.000012096895,7.4360963e-7,0.000009640804,0.000045940113],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959959,0.00005123275,0.0035167085,0.000151538,0.000055470417,0.00022914301],"domain_scores_gemma":[0.989244,0.0029631145,0.00718717,0.00019799982,0.0002628083,0.00014490848],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010589453,0.00008290037,0.0010472883,0.000090608046,0.00013424063,0.00002593749,0.00059065357,0.0002872344,0.00007553689],"category_scores_gemma":[0.023434125,0.000063448606,0.0002380381,0.00004958793,0.00032204474,0.00027690138,0.00005563933,0.0003658752,0.0000051655975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005961646,0.00023925607,0.41743872,0.000012869477,0.0000846332,0.000013235322,0.0000892222,0.000006722909,0.0000022364834,0.0063695046,0.001530201,0.5736172],"study_design_scores_gemma":[0.0069261803,0.0031745564,0.7871328,0.00004129007,0.000017635313,0.000017061222,0.00028572977,0.0010460209,0.000019429272,0.039813098,0.1614291,0.000097083815],"about_ca_topic_score_codex":0.00022569828,"about_ca_topic_score_gemma":0.0012912768,"teacher_disagreement_score":0.5735201,"about_ca_system_score_codex":0.00014581239,"about_ca_system_score_gemma":0.0015780012,"threshold_uncertainty_score":0.9847919},"labels":[],"label_agreement":null},{"id":"W2605337228","doi":"10.1200/jco.2014.32.15_suppl.5519","title":"A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Paclitaxel; Medicine; Hazard ratio; Internal medicine; Ovarian cancer; Progression-free survival; Monoclonal antibody; Oncology; Refractory (planetary science); Chemotherapy; Gastroenterology; Cancer; Urology; Confidence interval; Antibody; Immunology","score_opus":0.07753090838274025,"score_gpt":0.4464672778584613,"score_spread":0.36893636947572106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605337228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939503,0.00012890887,0.00005682262,0.0020400262,0.0004934827,0.0023179948,0.000017886105,0.0000078619605,0.0009867186],"genre_scores_gemma":[0.9958828,0.000060034694,0.003346137,0.0002627441,0.00023319948,0.00008618642,0.000040646195,0.00004251675,0.00004575297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924562,0.0018392473,0.003917052,0.0005081942,0.00085125485,0.0004280305],"domain_scores_gemma":[0.9906052,0.003737434,0.004144413,0.0003524981,0.000802408,0.0003580432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067200395,0.00036559152,0.0038789099,0.0004060559,0.00012028623,0.000030306956,0.00033453963,0.00031342654,0.00007380708],"category_scores_gemma":[0.0023923086,0.00024110707,0.0001807929,0.0004281267,0.0003110881,0.000351472,0.00012275681,0.0011351338,0.0000014232787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6106844,0.12155531,0.25212166,0.000054368753,0.0015267576,0.0003865306,0.0010717881,0.000038578706,0.00009263913,0.00028684162,0.00026997505,0.0119111445],"study_design_scores_gemma":[0.5385044,0.18878654,0.2704478,0.0004036166,0.00060614845,0.0000035059618,0.00054246094,0.00010172628,0.0000053347394,0.0000863079,0.000366887,0.00014525445],"about_ca_topic_score_codex":0.0014725206,"about_ca_topic_score_gemma":0.0025626216,"teacher_disagreement_score":0.072179966,"about_ca_system_score_codex":0.0008746399,"about_ca_system_score_gemma":0.0018579067,"threshold_uncertainty_score":0.9832061},"labels":[],"label_agreement":null},{"id":"W2605339784","doi":"10.1200/jco.2017.35.8_suppl.225","title":"Understanding the patient experience of cancer treatment in Ontario, Canada: A qualitative study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Patient experience; Family medicine; Qualitative research; Cancer; Anxiety; Dignity; Patient satisfaction; Nursing; Empathy; Patient education; Health care; Psychiatry; Internal medicine","score_opus":0.7285551526624957,"score_gpt":0.6716583262386957,"score_spread":0.05689682642380001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605339784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877154,0.00006431596,0.000021558464,0.005566288,0.004616004,0.0006644159,0.000008268705,0.000001365129,0.0013423712],"genre_scores_gemma":[0.9988925,0.00007383106,0.00006737958,0.00058206456,0.00012951798,0.000082063285,2.1495416e-7,0.0000060518782,0.00016640041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99273854,0.0034075712,0.0030545844,0.00013680727,0.0004092748,0.00025322995],"domain_scores_gemma":[0.9856086,0.007717209,0.005857799,0.0003025092,0.00034541654,0.00016849418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028589775,0.0000981979,0.00091755023,0.000053740303,0.00053365465,0.0000028585312,0.00027279335,0.00016760886,0.00034822212],"category_scores_gemma":[0.003204948,0.000056069555,0.000107013475,0.000044827324,0.00020104335,0.00011107775,0.00007611281,0.0011833574,0.0000011948058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005841809,0.00022043083,0.80148757,0.00000715107,0.000073067815,0.000039895494,0.19421427,0.000024901998,5.2292876e-7,0.00012905276,0.00050216663,0.0027168237],"study_design_scores_gemma":[0.0021119819,0.0032405448,0.7246288,0.000107962034,0.000024460685,8.102875e-7,0.26653883,0.0000064718156,9.138966e-7,0.00029619737,0.0030062643,0.000036749807],"about_ca_topic_score_codex":0.9887604,"about_ca_topic_score_gemma":0.999646,"teacher_disagreement_score":0.07685874,"about_ca_system_score_codex":0.0075916685,"about_ca_system_score_gemma":0.020882526,"threshold_uncertainty_score":0.996218},"labels":[],"label_agreement":null},{"id":"W2605345821","doi":"10.1200/jco.2004.22.90140.4","title":"A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC)","year":2004,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Mitoxantrone; Docetaxel; Neutropenia; Clinical endpoint; Internal medicine; Prednisone; Phases of clinical research; Gastroenterology; Toxicity; Prostate cancer; Bone pain; Estramustine; Refractory (planetary science); Urology; Surgery; Chemotherapy; Oncology; Cancer; Randomized controlled trial","score_opus":0.08013408898120648,"score_gpt":0.4882761833763798,"score_spread":0.4081420943951733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605345821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90148836,0.0892721,0.000030421957,0.006556692,0.0014716949,0.0009690404,0.00007144163,0.000003801899,0.00013644526],"genre_scores_gemma":[0.96352553,0.033652052,0.001138524,0.00023903455,0.000764766,0.000017341177,0.000012056962,0.000032424105,0.00061825855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994374,0.00049183005,0.0033954293,0.00034025527,0.00073624525,0.00066226016],"domain_scores_gemma":[0.9946048,0.0009507442,0.0026767221,0.00020983879,0.00084831624,0.00070956635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017488135,0.00029960694,0.0026858146,0.00026276687,0.00005087125,0.000014227125,0.00017703827,0.0005038201,0.00010733673],"category_scores_gemma":[0.00068345724,0.00019752872,0.0002465544,0.00025948798,0.0011636703,0.00033739864,0.00009089465,0.0018376245,0.0000060680673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14753172,0.036434162,0.51222956,0.00025989942,0.001188825,0.0005454897,0.001784421,0.000124184,0.00024891406,0.000015183335,0.000773131,0.2988645],"study_design_scores_gemma":[0.29162377,0.09619749,0.5905227,0.0018655225,0.000993728,0.00001856546,0.00063521945,0.00015579796,0.00022508147,0.000052021103,0.0175238,0.00018629423],"about_ca_topic_score_codex":0.00046468645,"about_ca_topic_score_gemma":0.00040815512,"teacher_disagreement_score":0.29867822,"about_ca_system_score_codex":0.0008785998,"about_ca_system_score_gemma":0.0034257965,"threshold_uncertainty_score":0.8054987},"labels":[],"label_agreement":null},{"id":"W2605366013","doi":"10.1200/jco.2006.24.18_suppl.6104","title":"Use of placebo in cancer medicine: The experience of a National Clinical Trials organization","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Placebo; Clinical trial; Blinding; Randomization; Cancer; Internal medicine; Physical therapy; Alternative medicine; Pathology","score_opus":0.8818372978404546,"score_gpt":0.7605807381332862,"score_spread":0.12125655970716842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605366013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95088047,0.00035490864,0.00033973673,0.04524807,0.0014599732,0.00039289662,0.000005359281,0.000003584134,0.0013149775],"genre_scores_gemma":[0.9890883,0.0040215706,0.0017817552,0.0022739049,0.0024200755,0.0000042165875,0.0000019577371,0.000015020463,0.0003931934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9803534,0.004902733,0.012251198,0.00024252293,0.0020384016,0.00021174828],"domain_scores_gemma":[0.58149695,0.400035,0.009386043,0.00042388457,0.008334729,0.00032338875],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.10647197,0.000112038215,0.002647732,0.00020780333,0.000027046402,0.0000049136233,0.00040838725,0.0009769973,0.00059624785],"category_scores_gemma":[0.6666641,0.000060669114,0.00046528212,0.0006607384,0.0017292778,0.00012165448,0.000110174435,0.0032985692,0.0000031325874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008110637,0.0031286937,0.9489895,0.0000883207,0.00024140412,0.00008378032,0.00040859976,0.00024018441,0.0012925359,0.009019627,0.012030094,0.016366642],"study_design_scores_gemma":[0.015637545,0.007975248,0.9445928,0.0008664521,0.00024058575,0.000064534,0.00046720382,0.00033698455,0.000672967,0.013707897,0.015345637,0.00009216487],"about_ca_topic_score_codex":0.000461179,"about_ca_topic_score_gemma":0.000774612,"teacher_disagreement_score":0.56019217,"about_ca_system_score_codex":0.00015601507,"about_ca_system_score_gemma":0.007275849,"threshold_uncertainty_score":0.99900085},"labels":[],"label_agreement":null},{"id":"W2605601673","doi":"10.1200/jco.2016.70.3439","title":"Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Through Family-Based Outreach","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Medicine; Genetic testing; Population; Genetic counseling; Outreach; Ovarian cancer; Family medicine; Cancer; Oncology; Gynecology; Internal medicine; Genetics; Environmental health","score_opus":0.052958005387987096,"score_gpt":0.42025791910501625,"score_spread":0.36729991371702914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605601673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629783,0.0013688917,0.032344688,0.0022540123,0.0006337024,0.00024681722,0.00001748951,0.0000027588642,0.00015336029],"genre_scores_gemma":[0.94901645,0.0007752033,0.04835917,0.0013258354,0.00045601669,0.0000078931325,0.000006542398,0.000018563993,0.000034327957],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976653,0.00028521492,0.0013644175,0.00030408832,0.00022513748,0.00015584055],"domain_scores_gemma":[0.9966011,0.00034052393,0.0018787025,0.000409501,0.0005731292,0.00019701383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016235807,0.00013620435,0.0005387777,0.00005347638,0.00014582362,0.00005976735,0.00028394416,0.0004230959,0.0000032546202],"category_scores_gemma":[0.004300489,0.0001227285,0.00013754731,0.000053046,0.00044375221,0.000027248008,0.00006516889,0.00030893565,9.846445e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007888231,0.001400047,0.07222431,0.0002908279,0.001151571,0.00020331485,0.0026048895,0.0034301977,0.509537,0.00039057352,0.0055291825,0.39534986],"study_design_scores_gemma":[0.018862506,0.017865576,0.71204644,0.00051451963,0.0015280531,0.0005328931,0.0024254706,0.0017691085,0.13078336,0.007846434,0.10473834,0.0010873218],"about_ca_topic_score_codex":0.000045730158,"about_ca_topic_score_gemma":0.000057114557,"teacher_disagreement_score":0.6398221,"about_ca_system_score_codex":0.0000511493,"about_ca_system_score_gemma":0.001181086,"threshold_uncertainty_score":0.51483977},"labels":[],"label_agreement":null},{"id":"W2605606572","doi":"10.1200/jco.2014.32.15_suppl.e19542","title":"Safety and use of bendamustine from the Bendamustine Expanded Access Trial in Canada (Bend-ACT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; CancerCare Manitoba; University of Calgary; Hôpital de l'Enfant-Jésus; Dalhousie University; BC Cancer Agency; University of Manitoba; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bendamustine; Rituximab; Internal medicine; Regimen; Adverse effect; Chronic lymphocytic leukemia; Refractory (planetary science); Surgery; Leukemia; Lymphoma","score_opus":0.21031669238799813,"score_gpt":0.48222720906942623,"score_spread":0.27191051668142807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605606572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891765,0.00019154394,0.00009037812,0.00857325,0.0011284889,0.00034286865,0.000017497317,0.000002775636,0.00047670372],"genre_scores_gemma":[0.99487275,0.00079121446,0.0006205284,0.0018570737,0.0017451291,0.0000022241131,0.000006919325,0.000016413573,0.000087766784],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99460745,0.0009553262,0.0031652634,0.0002277944,0.0007196654,0.00032447773],"domain_scores_gemma":[0.97440904,0.022783717,0.0016221587,0.0003635939,0.00039392695,0.00042756842],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045247246,0.00015224768,0.0018217576,0.000087929984,0.00003561409,0.000016011836,0.00038623268,0.00027121912,0.00031433275],"category_scores_gemma":[0.026304906,0.00008909979,0.00020199534,0.00020164122,0.00031650052,0.00015608595,0.00023831638,0.0012702566,0.0000011604014],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.42099145,0.0014746628,0.18348856,0.00010222594,0.0007624646,0.0013886179,0.00022990597,0.00035744812,0.00020800145,0.00018688697,0.017914351,0.37289542],"study_design_scores_gemma":[0.42076197,0.008572289,0.45784116,0.00025438663,0.00037299294,0.00036062024,0.00016426278,0.006092242,0.0001453478,0.00023341893,0.105048545,0.00015275864],"about_ca_topic_score_codex":0.52839607,"about_ca_topic_score_gemma":0.65718496,"teacher_disagreement_score":0.37274268,"about_ca_system_score_codex":0.003844973,"about_ca_system_score_gemma":0.049244292,"threshold_uncertainty_score":0.9999791},"labels":[],"label_agreement":null},{"id":"W2605731415","doi":"10.1200/jco.2012.30.15_suppl.10088","title":"Diagnosis and initial evaluation of patients with gastrointestinal stromal tumor (GIST): An observational study of 1,226 patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; GiST; Radiology; Endoscopic ultrasound; Biopsy; Endoscopy; Stromal tumor; Internal medicine; Stromal cell","score_opus":0.43707081248989677,"score_gpt":0.5350366809297284,"score_spread":0.09796586843983168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605731415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891335,0.000030257748,0.000014145327,0.0001393981,0.00010988511,0.0006714432,0.000020139605,0.0000025718714,0.00009878236],"genre_scores_gemma":[0.99293864,0.0000031376749,0.0066913804,0.00005410853,0.00025596918,0.000017661152,0.000025102923,0.000011851452,0.0000021476492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956152,0.0008084458,0.0017535009,0.00014653668,0.0014276827,0.00024867605],"domain_scores_gemma":[0.9928542,0.0013004426,0.0018841176,0.00014640352,0.0032770003,0.000537885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003383068,0.00013662537,0.0009314532,0.0001364653,0.00003171811,0.00000431606,0.00009304923,0.000039767227,0.00011291098],"category_scores_gemma":[0.0072893244,0.00008911251,0.000118261334,0.00011647602,0.0002324279,0.00026346737,0.000050409766,0.00042504555,0.000001049713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008018304,0.035872474,0.9387563,0.000026586065,0.00016655012,0.00004701264,0.0000868977,0.00001117907,0.000007922702,0.000012015459,0.000057054825,0.016937729],"study_design_scores_gemma":[0.020895697,0.16098104,0.81679934,0.0001362693,0.00063165167,0.00012486533,0.00026327514,0.00005690597,0.00001966242,0.000026690197,0.000020472597,0.00004412806],"about_ca_topic_score_codex":0.000039741164,"about_ca_topic_score_gemma":0.000035304605,"teacher_disagreement_score":0.12510857,"about_ca_system_score_codex":0.00012452524,"about_ca_system_score_gemma":0.00097003614,"threshold_uncertainty_score":0.8726528},"labels":[],"label_agreement":null},{"id":"W2605822943","doi":"10.1200/jco.2012.30.15_suppl.tps8604","title":"OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncolytic virus; Clinical endpoint; Internal medicine; Melanoma; Stage (stratigraphy); Randomized controlled trial; Clinical trial; Phases of clinical research; Oncology; Immune system; Gastroenterology; Urology; Surgery; Immunology; Cancer; Cancer research","score_opus":0.1822183919849854,"score_gpt":0.5002039924997621,"score_spread":0.3179856005147767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605822943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863306,0.002362588,0.00041446707,0.004296118,0.00041688915,0.0054202927,0.000042722808,0.0000053347276,0.0007109621],"genre_scores_gemma":[0.99366736,0.002087719,0.001407969,0.000303709,0.00080449175,0.00010026992,0.0000062217446,0.00003367814,0.0015885741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99395764,0.0017996888,0.0028867538,0.000251586,0.0006586848,0.0004456454],"domain_scores_gemma":[0.96966183,0.027041439,0.0015970459,0.00046697535,0.0006754185,0.00055730063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013536276,0.0002615068,0.003459422,0.00012822158,0.00011817126,0.000018148494,0.00025798078,0.00022592758,0.00055606867],"category_scores_gemma":[0.003649509,0.00011436174,0.0005907044,0.00018188353,0.00090842304,0.000069993774,0.00008189336,0.00046111495,0.0000010839221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.942212,0.0047200182,0.00047591073,0.000038943384,0.0032672011,0.000068801506,0.0014608192,0.000044645647,0.003020132,0.00004795876,0.0002546085,0.044389002],"study_design_scores_gemma":[0.86327136,0.097803354,0.000862246,0.00009125245,0.0026139037,0.00040275647,0.000545073,0.00069133664,0.0013356094,0.000018929124,0.03224922,0.00011498928],"about_ca_topic_score_codex":0.00009601117,"about_ca_topic_score_gemma":0.00012999165,"teacher_disagreement_score":0.09308334,"about_ca_system_score_codex":0.00014590754,"about_ca_system_score_gemma":0.0012585219,"threshold_uncertainty_score":0.6088562},"labels":[],"label_agreement":null},{"id":"W2605848529","doi":"10.1200/jco.2015.33.15_suppl.580","title":"Impact on relapse free survival (RFS) of time to hormone therapy (HTx) after diagnosis (Dx) of low risk hormone receptor positive (HR+) early breast cancer (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Internal medicine; Confidence interval; Proportional hazards model; Univariate analysis; Stage (stratigraphy); Oncology; Hormone receptor; Cancer; Gastroenterology; Multivariate analysis","score_opus":0.03280804507344525,"score_gpt":0.3809859552519708,"score_spread":0.34817791017852556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605848529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911156,0.00357683,0.000021708947,0.0032968519,0.00050967134,0.00023166735,0.00093122566,0.0000037634074,0.0003126509],"genre_scores_gemma":[0.9880417,0.009610288,0.0005353714,0.00041459495,0.0012074743,0.000036094454,0.000010671526,0.00003666227,0.000107128195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670184,0.0006920089,0.0015156195,0.00033203166,0.00044288512,0.00031560706],"domain_scores_gemma":[0.99555,0.00070655247,0.0017681419,0.00042200927,0.0011106046,0.00044269094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015065284,0.00029580947,0.0014446733,0.00010236522,0.00003059415,0.0000069457956,0.00038696534,0.0004624397,0.00013465338],"category_scores_gemma":[0.0011131814,0.00020157566,0.00069924886,0.00016358742,0.00030545137,0.00001676533,0.00017786984,0.0004326816,0.000033932378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15285954,0.007143201,0.62797815,0.00001081389,0.0060101133,0.00008540381,0.00057345437,0.0002592861,0.013798034,0.0000042963147,0.0918518,0.09942589],"study_design_scores_gemma":[0.008992058,0.032288257,0.9518557,0.0000688867,0.00023250756,0.00002317987,0.000045097462,0.0000017418799,0.0041736565,0.000053690124,0.002067728,0.00019746764],"about_ca_topic_score_codex":0.0010196841,"about_ca_topic_score_gemma":0.000118186996,"teacher_disagreement_score":0.32387754,"about_ca_system_score_codex":0.00018497114,"about_ca_system_score_gemma":0.00084727857,"threshold_uncertainty_score":0.8220017},"labels":[],"label_agreement":null},{"id":"W2606176026","doi":"10.1200/jco.2012.30.15_suppl.7029","title":"Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Cisplatin; Mesothelioma; Internal medicine; Clinical endpoint; Carboplatin; Progression-free survival; Chemotherapy; Phases of clinical research; Oncology; Randomized controlled trial; Surgery; Pathology","score_opus":0.07018429908058689,"score_gpt":0.44542875728775067,"score_spread":0.3752444582071638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606176026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780625,0.00013206532,0.000040124323,0.00040113844,0.0003944921,0.00083731656,0.000014029099,0.000004303805,0.00037029624],"genre_scores_gemma":[0.99451905,0.00006705109,0.0043860157,0.00044636344,0.0003422871,0.000014999786,0.000014009709,0.000019150599,0.00019104837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99639094,0.0004668738,0.0021224215,0.00014468595,0.0006279476,0.00024710275],"domain_scores_gemma":[0.9957376,0.0016222715,0.0019634338,0.00014257804,0.00014649889,0.00038758793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001959585,0.00017339452,0.0022316384,0.00016253302,0.000029261137,0.0000024120407,0.000097096316,0.00014589012,0.00032253235],"category_scores_gemma":[0.0017035606,0.00008191394,0.00031052943,0.00016307633,0.00036123814,0.00021569723,0.000037363978,0.00035615347,0.000004818682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64885837,0.01261561,0.32365105,0.000018596147,0.00024334142,0.00004694685,0.00005165365,0.000012489312,0.000018794532,0.000010364323,0.00007157964,0.01440123],"study_design_scores_gemma":[0.6845049,0.06905076,0.24476929,0.0001635548,0.0006165094,0.000035203444,0.000048493584,0.00003126791,0.000047458976,0.000016889815,0.00063229154,0.00008331965],"about_ca_topic_score_codex":0.000011234076,"about_ca_topic_score_gemma":0.000017166141,"teacher_disagreement_score":0.07888174,"about_ca_system_score_codex":0.00009027032,"about_ca_system_score_gemma":0.00046305437,"threshold_uncertainty_score":0.35315028},"labels":[],"label_agreement":null},{"id":"W2606264658","doi":"10.1200/jco.2013.31.15_suppl.4565","title":"Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Histology; Internal medicine; Renal cell carcinoma; Gastroenterology; Oncology","score_opus":0.18879463578957192,"score_gpt":0.45950825965868075,"score_spread":0.2707136238691088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606264658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629239,0.0007550502,0.00004311895,0.03188326,0.0013361424,0.00025045252,0.00017865065,0.0000036131837,0.002625806],"genre_scores_gemma":[0.98978585,0.0005132505,0.004937555,0.0037201568,0.0007693978,0.000007478672,0.00003663643,0.000010942802,0.0002187385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956873,0.00029727674,0.0031895621,0.00018547903,0.00048429685,0.00015608902],"domain_scores_gemma":[0.9892129,0.007387167,0.0022921558,0.00034878938,0.0004972282,0.00026178142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019028606,0.0001275157,0.0011464842,0.000064236236,0.000026310889,0.000012494351,0.0002979462,0.000102154656,0.0009031438],"category_scores_gemma":[0.00324141,0.00006840272,0.00051074266,0.00006888384,0.00021820102,0.000109378256,0.00010256252,0.00058867683,0.00006338846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038007377,0.0041553667,0.84414876,0.000019130737,0.0009937022,0.00079434423,0.00019144344,0.00001279878,0.0008280336,0.00010293217,0.11385466,0.031098105],"study_design_scores_gemma":[0.019384844,0.0040441,0.91226065,0.00009333262,0.0008495935,0.00016223565,0.00026690142,0.00012544544,0.001588221,0.0002539418,0.06089172,0.0000790246],"about_ca_topic_score_codex":0.0012707799,"about_ca_topic_score_gemma":0.00019627834,"teacher_disagreement_score":0.0681119,"about_ca_system_score_codex":0.00012806438,"about_ca_system_score_gemma":0.00077413034,"threshold_uncertainty_score":0.98887914},"labels":[],"label_agreement":null},{"id":"W2606272469","doi":"10.1200/jco.2014.32.15_suppl.6024","title":"Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Internal medicine; Regimen; Oncology; Chemoradiotherapy; Hazard ratio; Meta-analysis; Randomized controlled trial; Radiation therapy; Confidence interval","score_opus":0.20475025014127393,"score_gpt":0.4751813931519466,"score_spread":0.2704311430106726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606272469","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3782974,0.068522416,0.116351955,0.3935431,0.007953313,0.003323133,0.0000493381,0.0001239471,0.03183542],"genre_scores_gemma":[0.9149066,0.00071994343,0.056482747,0.02156711,0.0049932697,0.000037213722,0.000006159456,0.000032835866,0.0012540837],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625385,0.00039558465,0.002321416,0.00029442785,0.00036158643,0.0003731326],"domain_scores_gemma":[0.9929731,0.0037912899,0.0017976057,0.00029452634,0.0006826721,0.00046081346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047068326,0.00020921722,0.006442662,0.00013046798,0.0000831439,0.0000066268904,0.00019101276,0.0002963269,0.00017244145],"category_scores_gemma":[0.0015262597,0.00013291351,0.004118832,0.00032017258,0.00020416122,0.00007046081,0.000026014703,0.00060468476,0.000003371414],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036508217,0.003647632,0.06460342,0.00019289933,0.47722256,0.0006103118,0.00039692363,0.0016210485,0.0002083088,0.0037381875,0.25371286,0.15753761],"study_design_scores_gemma":[0.018923553,0.029720902,0.07578135,0.000018396597,0.19025329,0.0001975751,0.000040140843,0.0016792394,0.000030701824,0.0018958309,0.6812106,0.00024845003],"about_ca_topic_score_codex":0.0000068020754,"about_ca_topic_score_gemma":0.00007828541,"teacher_disagreement_score":0.5366093,"about_ca_system_score_codex":0.00010857292,"about_ca_system_score_gemma":0.000900236,"threshold_uncertainty_score":0.5420056},"labels":[],"label_agreement":null},{"id":"W2607240957","doi":"10.1200/jco.2007.25.18_suppl.6509","title":"When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Colorectal cancer; Quality of life (healthcare); Decision aids; Anxiety; Cancer; Patient satisfaction; Internal medicine; Oncology; Family medicine; Physical therapy; Surgery; Alternative medicine; Nursing; Psychiatry","score_opus":0.28450023053079854,"score_gpt":0.582069307091191,"score_spread":0.29756907656039244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607240957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96029145,0.0016836316,0.00018361144,0.026912604,0.0072491514,0.002752516,0.000012619281,0.000007948636,0.0009064713],"genre_scores_gemma":[0.9813332,0.0019981845,0.007970552,0.0077198837,0.0007402791,0.00017479148,0.000001379668,0.000019430985,0.000042312193],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9809189,0.008034417,0.009564575,0.00022390492,0.000777133,0.0004810643],"domain_scores_gemma":[0.91822326,0.071630605,0.008174006,0.00045725418,0.0012266046,0.00028829146],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016310444,0.00016689357,0.0023986686,0.00021503039,0.0002013072,0.0000029323141,0.0007123139,0.0007243089,0.0003087941],"category_scores_gemma":[0.03343469,0.00009838373,0.0006498929,0.00028415205,0.00041135002,0.00014737132,0.00027616546,0.0032023157,0.000015449301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8432238,0.00075085287,0.01617031,0.00002929098,0.00008058042,0.000013066458,0.008855694,0.000026004218,0.00001631281,0.00020318042,0.0027751036,0.12785581],"study_design_scores_gemma":[0.8877198,0.007142499,0.011072435,0.0005811693,0.00010174311,0.000005735704,0.0042066206,0.00019159603,0.000048219317,0.0041556354,0.08465648,0.000118082244],"about_ca_topic_score_codex":0.00052202,"about_ca_topic_score_gemma":0.0024716153,"teacher_disagreement_score":0.12773773,"about_ca_system_score_codex":0.0005624556,"about_ca_system_score_gemma":0.0043286197,"threshold_uncertainty_score":0.99909735},"labels":[],"label_agreement":null},{"id":"W2607303732","doi":"10.1200/jco.2012.30.15_suppl.8003","title":"Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Epstein–Barr virus; Lymphoma; Virus; Medicine; Viral load; In situ hybridization; Virology; Pathology; Biology; Gene; Messenger RNA","score_opus":0.06689336974357489,"score_gpt":0.4617715261991763,"score_spread":0.39487815645560137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607303732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355894,0.00042273922,0.0000028466047,0.0021771197,0.0008538362,0.0004173398,0.0000033612953,0.0000055585797,0.0025582567],"genre_scores_gemma":[0.99730074,0.00011664475,0.00019995663,0.0017415861,0.00035256107,0.000011245648,8.6921506e-7,0.00002101153,0.00025536606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935791,0.0019041894,0.0033892277,0.00018732749,0.00048196904,0.0004581856],"domain_scores_gemma":[0.9947073,0.0025527584,0.0019509874,0.00020225371,0.00017824405,0.0004084851],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012274282,0.0001777746,0.002101267,0.0004301534,0.000020099953,0.0000047679646,0.0001857645,0.0003596713,0.0002650032],"category_scores_gemma":[0.009628945,0.00013807797,0.00041229287,0.00037247065,0.00017453771,0.00018400626,0.000064406835,0.000819676,0.0000172339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32854486,0.0332642,0.56991607,0.000019076511,0.0003291143,0.0025915322,0.0017798395,0.000008962655,0.00078965514,0.00002594901,0.0024539586,0.060276806],"study_design_scores_gemma":[0.16091685,0.050107762,0.77400386,0.00014081124,0.00025183975,0.0002491692,0.0037943844,0.000094366536,0.00008626582,0.00013415552,0.010082194,0.000138357],"about_ca_topic_score_codex":0.00019470553,"about_ca_topic_score_gemma":0.00025356712,"teacher_disagreement_score":0.20408781,"about_ca_system_score_codex":0.00053100236,"about_ca_system_score_gemma":0.0026193294,"threshold_uncertainty_score":0.9987134},"labels":[],"label_agreement":null},{"id":"W2607480359","doi":"10.1200/jco.2012.30.15_suppl.4565","title":"Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Concordance; Prostate cancer; Cohort; Oncology; Internal medicine; Proportional hazards model; Cancer","score_opus":0.24328308978344182,"score_gpt":0.5724689664462035,"score_spread":0.32918587666276167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607480359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892419,0.002112123,0.000103160106,0.00377904,0.0033695854,0.0010870635,0.000028709303,0.000009439441,0.00026898718],"genre_scores_gemma":[0.9759383,0.010744956,0.008156071,0.00025376768,0.0044846763,0.000054297634,0.000014873411,0.0000300663,0.00032296567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911531,0.0014743112,0.0061268928,0.00027839572,0.00046455176,0.0005027365],"domain_scores_gemma":[0.98645544,0.007495072,0.0044225035,0.00022414314,0.00076446595,0.0006383832],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022544928,0.00016808334,0.002078495,0.00018030893,0.000052328574,0.000007788157,0.00018053308,0.00073036016,0.000074689386],"category_scores_gemma":[0.012210888,0.000107100146,0.0007779813,0.00017275095,0.00045557314,0.00022456769,0.000092736314,0.0017917798,0.000007022517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01564732,0.0031531593,0.69581014,0.00007469941,0.00035578833,0.000030788193,0.00012654816,0.000007539382,0.00010011019,0.000020124182,0.0013773688,0.28329644],"study_design_scores_gemma":[0.02714992,0.020235972,0.92825294,0.00040367688,0.0006381713,0.000030969906,0.00014653185,0.00026754092,0.00046314226,0.00029445448,0.022014838,0.00010183325],"about_ca_topic_score_codex":0.000041979696,"about_ca_topic_score_gemma":0.000022738303,"teacher_disagreement_score":0.2831946,"about_ca_system_score_codex":0.00026357133,"about_ca_system_score_gemma":0.0029097057,"threshold_uncertainty_score":0.99610966},"labels":[],"label_agreement":null},{"id":"W2607754295","doi":"10.1200/jco.2016.70.5319","title":"Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Guideline; Cancer; Immunohistochemistry; Metastatic breast cancer; Biomarker; Gynecology; Pathology","score_opus":0.47689772601224484,"score_gpt":0.6404764171538218,"score_spread":0.16357869114157692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607754295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513592,0.000081036145,0.00015096285,0.04658877,0.00042086496,0.00035428238,0.00048000773,0.0000051357324,0.0005597288],"genre_scores_gemma":[0.94478035,0.0016446625,0.051383104,0.0013984627,0.00071557314,0.00001240327,0.00000829281,0.000016859298,0.000040318315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98946,0.001758276,0.0073647466,0.00043545084,0.00055763166,0.00042391926],"domain_scores_gemma":[0.97532254,0.009498002,0.011222186,0.00047581474,0.0028609252,0.0006205178],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.012250638,0.00022560963,0.006027276,0.0004982785,0.00011428382,0.0000074740797,0.00057213736,0.00033021948,0.0003372873],"category_scores_gemma":[0.01396277,0.00017770169,0.0008989936,0.0009858003,0.003056703,0.00015923494,0.00036382672,0.0017195508,0.0000016318785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016350676,0.0014824289,0.81612533,0.000041393683,0.0013869506,0.000033432476,0.0002603401,0.00004596174,0.0013918161,0.000009273993,0.021691931,0.15589608],"study_design_scores_gemma":[0.0035610392,0.011241202,0.9749068,0.00023219858,0.0008032638,0.000029993258,0.0025745865,0.0010277613,0.00011541466,0.000020673298,0.005349479,0.00013757759],"about_ca_topic_score_codex":0.006857608,"about_ca_topic_score_gemma":0.0025280968,"teacher_disagreement_score":0.1587815,"about_ca_system_score_codex":0.00041251985,"about_ca_system_score_gemma":0.0031125161,"threshold_uncertainty_score":0.9997558},"labels":[],"label_agreement":null},{"id":"W2607970143","doi":"10.1200/jco.2017.72.4401","title":"Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Cancer Care Ontario; American Society of Clinical Oncology; American Society for Radiation Oncology","keywords":"Medicine; Guideline; Adjuvant therapy; Oncology; Radiation therapy; Internal medicine; Lung cancer; Adjuvant; Stage (stratigraphy); Clinical trial; Disease; Cancer; Pathology","score_opus":0.36356601136335404,"score_gpt":0.595801897913887,"score_spread":0.232235886550533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607970143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020053832,0.96117985,0.00019854365,0.0064002727,0.0053212172,0.0061391583,0.00035483105,0.00002149626,0.00033079114],"genre_scores_gemma":[0.0021130943,0.9590855,0.023359181,0.008870061,0.0055526784,0.00043288583,0.00017813349,0.00013916938,0.00026926686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9784754,0.0030862412,0.0155603625,0.0012864002,0.000861421,0.00073016534],"domain_scores_gemma":[0.9494379,0.015886327,0.02838851,0.0011649906,0.0038566163,0.0012656488],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.016204951,0.0008996542,0.017535625,0.00019412673,0.000209781,0.000053410196,0.00086451176,0.0020062702,0.000107477266],"category_scores_gemma":[0.004604024,0.00058630167,0.0052156216,0.00025390906,0.0008044411,0.00020594274,0.00022443256,0.0037388946,0.000007048035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012288589,0.0030825026,0.022822484,0.0026275339,0.007844549,0.00022439595,0.0004966875,0.00000924868,7.97684e-7,0.0000036852807,0.05152917,0.8990704],"study_design_scores_gemma":[0.029195154,0.05271514,0.017278,0.0074974406,0.008453261,0.00015765196,0.0003978459,0.000066000495,0.0000013244996,0.0000027351252,0.8837882,0.00044720536],"about_ca_topic_score_codex":0.008198379,"about_ca_topic_score_gemma":0.010416627,"teacher_disagreement_score":0.89862317,"about_ca_system_score_codex":0.004741253,"about_ca_system_score_gemma":0.045887765,"threshold_uncertainty_score":0.9996588},"labels":[],"label_agreement":null},{"id":"W2608082715","doi":"10.1200/jco.2012.30.15_suppl.6002","title":"An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Cancer; Lung cancer; Oncology; Hazard ratio; Colorectal cancer; Proportional hazards model; Quality of life (healthcare); Nausea; Breast cancer; Confidence interval","score_opus":0.5061346646789477,"score_gpt":0.5786047145399951,"score_spread":0.07247004986104733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608082715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973627,0.0001575329,0.000023706429,0.00034942818,0.0015661126,0.0004341965,0.00006236043,0.000002135602,0.000041824864],"genre_scores_gemma":[0.99789697,0.00008277174,0.0004973526,0.00023717078,0.0012376176,0.0000047131107,0.000030041265,0.00000864901,0.000004713906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962805,0.0005720629,0.0025016984,0.00016121713,0.0003365539,0.0001479759],"domain_scores_gemma":[0.9914323,0.0057795662,0.001964262,0.00020606954,0.0002655782,0.00035219605],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039217486,0.00010383803,0.0013945653,0.00010117887,0.000014471821,0.0000037860552,0.00024471953,0.00015624896,0.00007032811],"category_scores_gemma":[0.019136354,0.00006977314,0.000112149406,0.00005188997,0.00015238141,0.00028361232,0.00009979453,0.0004199586,8.716011e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003995674,0.0034323826,0.974204,0.00007047554,0.00040289946,0.0000021994686,0.0010309707,0.000013158659,0.0007516498,0.000017684542,0.000035220226,0.016043669],"study_design_scores_gemma":[0.016947247,0.008337182,0.97216094,0.0000512698,0.00017282083,0.0000023015534,0.0013168629,0.00062930444,0.00003814196,0.000017085014,0.00026714618,0.000059711154],"about_ca_topic_score_codex":0.00045863038,"about_ca_topic_score_gemma":0.0007777952,"teacher_disagreement_score":0.015983956,"about_ca_system_score_codex":0.000086659486,"about_ca_system_score_gemma":0.0010166584,"threshold_uncertainty_score":0.98912585},"labels":[],"label_agreement":null},{"id":"W2608082925","doi":"10.1200/jco.2016.69.4935","title":"Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIH Office of the Director; Instituto de Salud Carlos III; European Social Fund; Medical Research Council; QIMR Berghofer Medical Research Institute; School of Medicine; National Institutes of Health; Universitätsklinikum Köln; KWF Kankerbestrijding; Fox Chase Cancer Center; Ministero dello Sviluppo Economico; Università degli Studi di Udine; Royal Marsden NHS Foundation Trust; Fondazione Italiana per la Ricerca sul Cancro; Hospices Civils de Lyon; National Health and Medical Research Council; Deutsche Krebshilfe; Medizinische Universität Wien; Medizinischen Hochschule Hannover; Universitair Medisch Centrum Groningen; Cancer Council Queensland; Leids Universitair Medisch Centrum; Centre Hospitalier Universitaire de Québec; Medical Center, University of Pittsburgh; Westfälische Wilhelms-Universität Münster; Centre National de la Recherche Scientifique; European Commission; Canadian Institutes of Health Research; Lietuvos Mokslo Taryba; Peter MacCallum Cancer Centre; Odense Universitetshospital; Universitair Ziekenhuis Gent; Aalborg Universitetshospital; Gentofte Hospital; Fondation ARC pour la Recherche sur le Cancer; Istituto Toscano Tumori; Harvard T.H. Chan School of Public Health; Hungarian Scientific Research Fund; Unicancer; General Secretariat for Research and Technology; Háskóli Íslands; Landspítali Háskólasjúkrahús; Erasmus Medisch Centrum; Ministerio de Economía y Competitividad; Ministero della Salute; University of Toronto; McGill University; Generalitat de Catalunya; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Soonchunhyang University; Universiteit Gent; Sapienza Università di Roma; National Breast Cancer Foundation; National Cancer Institute; Seoul National University; Institut Claudius Regaud; Ministério da Ciência, Tecnologia e Inovação; Ohio State University; Universiteit Leiden; Centre Léon Bérard; Government of Canada; Memorial Sloan-Kettering Cancer Center; Istituto Oncologico Veneto; Helsingin Yliopisto; Université Laval; Radboud Universitair Medisch Centrum; Universität Wien; Radboud Universiteit; Cancer Australia; Université de Lyon; Fonds Wetenschappelijk Onderzoek; Huntsman Cancer Institute; Cancer Research UK; Associazione Italiana per la Ricerca sul Cancro; Beckman Research Institute, City of Hope; Fondation du cancer du sein du Québec; Wellcome Trust; Deutsches Krebsforschungszentrum; Cancer Research Institute; Kansas Bioscience Authority; Dr. Ralph and Marian Falk Medical Research Trust; Institut Bergonié; Cancer Center, University of Kansas; Cancerfonden; Rigshospitalet; Ministère du Développement Économique, de l’Innovation et de l’Exportation; Fundación Mutua Madrileña; David F. and Margaret T. Grohne Family Foundation; Breast Cancer Research Foundation; University of Pittsburgh; Jewish General Hospital; National Institute for Health and Care Research; Aarhus Universitetshospital; Aalborg Universitet; Genome Canada; Creighton University; Institut Català de la Salut; Institut Gustave-Roussy; University of Pennsylvania; Fundación Cellex; Aarhus Universitet; College of Medicine, Seoul National University; Susan G. Komen for the Cure","keywords":"Medicine; Breast cancer; Prostate cancer; Polygenic risk score; Oncology; Lifetime risk; Mutation; Internal medicine; Prostate; Cancer; Genetics; Gene; Single-nucleotide polymorphism; Genotype; Biology","score_opus":0.08794779622729612,"score_gpt":0.4295472766840866,"score_spread":0.34159948045679045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608082925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955525,0.0028080402,0.0001279689,0.00047977947,0.00070007093,0.00012995402,0.00010810202,0.0000011257293,0.000092474955],"genre_scores_gemma":[0.99152476,0.006276596,0.0015895482,0.00010918601,0.00045744042,0.000004737672,0.0000034277582,0.000012386438,0.0000219374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982714,0.00023983253,0.0010087059,0.00021061642,0.0001293069,0.00014015123],"domain_scores_gemma":[0.9973265,0.00010878857,0.0019999293,0.00019519616,0.00025254203,0.00011703295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014944499,0.000097562785,0.00043142104,0.00006704116,0.00010236106,0.000019946856,0.00013957889,0.00028771098,0.0000071619565],"category_scores_gemma":[0.00091998593,0.00008845864,0.000096038806,0.000038578524,0.0004982357,0.000026748285,0.00009317787,0.00032016588,1.3336663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010483376,0.00008940285,0.87367225,0.000021837346,0.0001792448,0.000018170249,0.00015132953,0.0007948157,0.018026488,0.000003825279,0.00017817531,0.10581614],"study_design_scores_gemma":[0.003761914,0.0013057762,0.98876935,0.00006598021,0.0001779487,0.00041729942,0.00016515155,0.0006395679,0.00327444,0.00019391745,0.0011422987,0.00008638314],"about_ca_topic_score_codex":0.0005988888,"about_ca_topic_score_gemma":0.0007269382,"teacher_disagreement_score":0.11509709,"about_ca_system_score_codex":0.00007150966,"about_ca_system_score_gemma":0.0009709121,"threshold_uncertainty_score":0.36072388},"labels":[],"label_agreement":null},{"id":"W2608461130","doi":"10.1200/jco.2017.72.8030","title":"Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Hormonal therapy; Abiraterone acetate; Oncology; Internal medicine; Clinical trial; Chemotherapy; Context (archaeology); Docetaxel; Population; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.45946857788749174,"score_gpt":0.6328043055020732,"score_spread":0.1733357276145815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608461130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004072526,0.97306424,0.00006134689,0.013021334,0.0024462221,0.0054391306,0.0005921913,0.000023386694,0.0012796285],"genre_scores_gemma":[0.0003939523,0.9776823,0.00957157,0.001135982,0.0081271995,0.00027009743,0.00022130141,0.00013040117,0.0024671797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9832139,0.0020196221,0.011815195,0.0010059301,0.0011694971,0.0007758297],"domain_scores_gemma":[0.9644981,0.010840156,0.020250227,0.0007698747,0.0025323853,0.0011092348],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.015786326,0.0007588227,0.014473421,0.00021975479,0.00020776853,0.00004030547,0.000874815,0.0019765904,0.00022669566],"category_scores_gemma":[0.0019466011,0.00041817306,0.0059507326,0.00027474636,0.0032679993,0.0002034491,0.00013618455,0.00437495,0.000006071479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049193628,0.0056389202,0.0028783532,0.002444996,0.007688219,0.00015657212,0.000054671214,8.54492e-7,0.0000035870648,0.000018416682,0.036703113,0.8952187],"study_design_scores_gemma":[0.030178249,0.10983291,0.009860979,0.0037480479,0.0016372134,0.00020315964,0.000070518945,0.000044583794,0.0000038024775,0.000060604565,0.84402853,0.00033139522],"about_ca_topic_score_codex":0.00006501298,"about_ca_topic_score_gemma":0.00010016501,"teacher_disagreement_score":0.89488727,"about_ca_system_score_codex":0.000655837,"about_ca_system_score_gemma":0.049417615,"threshold_uncertainty_score":0.999827},"labels":[],"label_agreement":null},{"id":"W2609015711","doi":"10.1200/jco.2016.71.2893","title":"Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; World Health Organization","keywords":"KRAS; Medicine; Hazard ratio; Internal medicine; Oncology; Adenocarcinoma; Proportional hazards model; Lung cancer; Stage (stratigraphy); Chemotherapy; Cancer; Colorectal cancer; Confidence interval; Biology","score_opus":0.045219409724995316,"score_gpt":0.44734358681033815,"score_spread":0.4021241770853428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609015711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657893,0.00042303817,0.00024580926,0.0008498027,0.00020878502,0.0014851878,0.00007020258,0.0000019162962,0.00013631175],"genre_scores_gemma":[0.9980853,0.00096439617,0.00061128807,0.00016292316,0.000047256402,0.000040329764,0.000007939821,0.000013672771,0.00006689905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961943,0.00076030404,0.002365938,0.0001750389,0.00033725626,0.0001671661],"domain_scores_gemma":[0.9888952,0.0045351437,0.0055813813,0.0002376936,0.0006355104,0.000115079565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021655618,0.0001433542,0.0023452502,0.0002875323,0.000037651178,0.00000801659,0.00013644162,0.00018952331,0.000013090834],"category_scores_gemma":[0.004192783,0.00007500886,0.00028734142,0.00044564728,0.0002646049,0.00011966261,0.000027676686,0.0003710145,3.645558e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023206806,0.0017278378,0.9559821,0.00035142706,0.0037770316,0.00013887172,0.0020047089,0.0013374006,0.002384371,0.00000427292,0.000026703909,0.00905851],"study_design_scores_gemma":[0.039905287,0.01202793,0.9300635,0.0008342614,0.010647284,0.000005020785,0.00019113942,0.002771686,0.0034516721,0.000024696596,0.000017589819,0.000059927348],"about_ca_topic_score_codex":0.0009718792,"about_ca_topic_score_gemma":0.003385086,"teacher_disagreement_score":0.025918555,"about_ca_system_score_codex":0.000176745,"about_ca_system_score_gemma":0.0019676567,"threshold_uncertainty_score":0.50194556},"labels":[],"label_agreement":null},{"id":"W2609600658","doi":"10.1200/jco.2009.27.15_suppl.1067","title":"A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Rash; Taxane; Gastroenterology; Mucositis; Metastatic breast cancer; Cancer; Chemotherapy; Oncology; Surgery","score_opus":0.14103104228452873,"score_gpt":0.5760817173539257,"score_spread":0.43505067506939693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609600658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464554,0.0001228724,0.000042321135,0.0033454802,0.00036516946,0.0011467139,0.000026197898,0.000009354568,0.0002963479],"genre_scores_gemma":[0.9958004,0.00032453114,0.0017769135,0.0015933933,0.0002964937,0.00001468167,0.000004848165,0.000030579013,0.00015819498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99354464,0.0010886869,0.0033632754,0.00037472355,0.0011469655,0.00048168993],"domain_scores_gemma":[0.99441075,0.0010243481,0.0018807547,0.00040061414,0.0015700886,0.00071341393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003687989,0.0002464678,0.0025237575,0.00034439447,0.00005081883,0.000010042726,0.00038835863,0.00016957364,0.00041265716],"category_scores_gemma":[0.0015897162,0.0001495454,0.00018673122,0.00059092895,0.00029469756,0.0003064255,0.00006393597,0.0016053072,0.000004051486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1224123,0.12093161,0.24797924,0.00009584285,0.00051712483,0.0026490134,0.0009200488,0.00023583634,0.0003789263,0.0000076204005,0.00086684263,0.5030056],"study_design_scores_gemma":[0.119729675,0.39353508,0.48226947,0.0006219501,0.00039887457,0.00020024288,0.0009225625,0.00018586213,0.000065517714,0.000046879584,0.0018540759,0.00016981806],"about_ca_topic_score_codex":0.00029721693,"about_ca_topic_score_gemma":0.0021967567,"teacher_disagreement_score":0.5028358,"about_ca_system_score_codex":0.00039869462,"about_ca_system_score_gemma":0.004827454,"threshold_uncertainty_score":0.8563696},"labels":[],"label_agreement":null},{"id":"W2609778940","doi":"10.1200/jco.2012.30.15_suppl.7586","title":"Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Single-nucleotide polymorphism; Medicine; Oncology; Internal medicine; Lung cancer; Hazard ratio; Genotype; Biology; Genetics; Gene; Confidence interval","score_opus":0.05036446819673839,"score_gpt":0.38306842211244996,"score_spread":0.33270395391571156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609778940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952135,0.0007299173,0.000023817915,0.00041080246,0.00095491164,0.00037044488,0.00006553452,0.0000039587585,0.002227077],"genre_scores_gemma":[0.9980378,0.00022823551,0.00064261485,0.00027871903,0.00038442525,0.00000566741,0.0000057816997,0.00002160752,0.00039514125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771315,0.00025096475,0.0013002119,0.000121115976,0.00038429158,0.00023026754],"domain_scores_gemma":[0.99533975,0.0009103911,0.0029013203,0.00012646736,0.0005083072,0.00021376275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079981674,0.00014085189,0.0008616423,0.00006421063,0.000046096193,0.000004358184,0.00009057942,0.00018679565,0.00008638451],"category_scores_gemma":[0.00027823236,0.00008215225,0.00019613365,0.00014444834,0.00010880498,0.00009487116,0.000037629554,0.00035896944,7.8899967e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010545846,0.0021650696,0.9800563,0.000062555475,0.0007155539,0.000008807176,0.00086173025,0.000031831707,0.0063342866,0.0000041833528,0.000344727,0.008360395],"study_design_scores_gemma":[0.013896872,0.0040426203,0.9692092,0.00021628951,0.0021916565,0.000006186398,0.0001952708,0.000080690086,0.008329429,0.000004395606,0.0017385798,0.00008879592],"about_ca_topic_score_codex":0.00015932893,"about_ca_topic_score_gemma":0.000080112724,"teacher_disagreement_score":0.012842287,"about_ca_system_score_codex":0.00032124444,"about_ca_system_score_gemma":0.0008995818,"threshold_uncertainty_score":0.33500713},"labels":[],"label_agreement":null},{"id":"W2610814060","doi":"10.1200/jco.2009.27.15_suppl.3584","title":"A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Toxicity; Internal medicine; Clinical endpoint; Pharmacokinetics; Cancer; Pharmacology; Oncology; Gastroenterology; Clinical trial","score_opus":0.041163394889915404,"score_gpt":0.44637089097630206,"score_spread":0.4052074960863867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610814060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871004,0.00031235442,0.000009888119,0.0005366309,0.00009088008,0.0002878411,0.000003083199,4.9359045e-7,0.00004879611],"genre_scores_gemma":[0.99925727,0.0003799,0.0000871405,0.00019194323,0.000057538567,0.0000028571378,0.0000013065044,0.000006006344,0.000016053607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980749,0.0004697594,0.000963852,0.00013078628,0.00024326253,0.000117442774],"domain_scores_gemma":[0.99829125,0.00010465311,0.000956406,0.00017314221,0.0004111784,0.00006336211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011869584,0.00007783864,0.00050184655,0.00006119573,0.00001741935,0.0000019993531,0.00019257823,0.00012263052,0.0000066075063],"category_scores_gemma":[0.00045959823,0.000048078095,0.000071413844,0.00013826852,0.0001363597,0.0000060227644,0.000038708815,0.000281823,7.1884514e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06533174,0.029612467,0.1569086,0.00001538972,0.00025616074,0.000015010602,0.00037166482,0.00038079722,0.064607866,0.000007841244,0.00008137965,0.6824111],"study_design_scores_gemma":[0.048016295,0.3818545,0.550033,0.000047005764,0.00006615605,0.000005124839,0.00017825972,0.000033960212,0.019313624,0.000100095334,0.00027179127,0.00008022764],"about_ca_topic_score_codex":0.000015124538,"about_ca_topic_score_gemma":0.00036364575,"teacher_disagreement_score":0.68233085,"about_ca_system_score_codex":0.000029367837,"about_ca_system_score_gemma":0.0003843858,"threshold_uncertainty_score":0.19605678},"labels":[],"label_agreement":null},{"id":"W2610847041","doi":"10.1200/jco.2013.31.15_suppl.9588","title":"Discussions regarding reproductive and sexual health among young adult survivors of cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Infertility; Reproductive health; Cancer; Distress; Radiation therapy; Population; Testicular cancer; Cohort; Sexual dysfunction; Young adult; Breast cancer; Gynecology; Internal medicine; Pregnancy; Clinical psychology","score_opus":0.10600197054507021,"score_gpt":0.47583399964817397,"score_spread":0.36983202910310375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610847041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95579,0.00032533926,0.000039214556,0.035545774,0.0034248445,0.00022580831,0.0000045360093,0.000008640553,0.0046358686],"genre_scores_gemma":[0.9946882,0.0014153603,0.00091156975,0.00067241973,0.0013913047,0.0000069661405,3.9862582e-7,0.00000966976,0.0009040886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99528897,0.0016854922,0.0020113804,0.00024186,0.00046461003,0.00030768514],"domain_scores_gemma":[0.993206,0.0023484852,0.0028838464,0.00017627804,0.0008294288,0.0005559173],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008708198,0.00009403464,0.0010326919,0.000088316076,0.00024964864,0.000018752198,0.0002754721,0.000267985,0.0001466678],"category_scores_gemma":[0.016054735,0.00006387657,0.00015412978,0.00022294233,0.0012637047,0.00043780162,0.00008656904,0.00069365307,0.00000285252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009180111,0.00020716093,0.88257486,0.000015662694,0.000088889145,0.000012363069,0.0073949588,0.000011081576,0.000011365356,0.0011682828,0.011228446,0.09719514],"study_design_scores_gemma":[0.0008646521,0.00136493,0.9367518,0.000079660276,0.000046626923,0.000009852793,0.04875757,0.000017358501,0.0000057596135,0.0021031667,0.009892843,0.000105792016],"about_ca_topic_score_codex":0.08625223,"about_ca_topic_score_gemma":0.06860613,"teacher_disagreement_score":0.09708935,"about_ca_system_score_codex":0.00020113759,"about_ca_system_score_gemma":0.0023166656,"threshold_uncertainty_score":0.99223346},"labels":[],"label_agreement":null},{"id":"W2610889635","doi":"10.1200/jco.2016.71.7017","title":"Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":454,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute for Health and Care Research; Gilead Sciences; Pfizer","keywords":"Medicine; Guideline; Transplantation; Intensive care medicine; Febrile neutropenia; Hematopoietic stem cell transplantation; Neutropenia; Cancer; Internal medicine; Oncology; Pathology; Chemotherapy","score_opus":0.18402272703742475,"score_gpt":0.5107447241855317,"score_spread":0.326721997148107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610889635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004959254,0.9907577,0.00014649406,0.0017050763,0.0005539325,0.0014884339,0.000042015752,0.000002028226,0.00034504363],"genre_scores_gemma":[0.0009203438,0.99722594,0.0007940958,0.00032650298,0.00030587945,0.00006307662,0.000008572401,0.000020667918,0.00033493247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971869,0.00014209296,0.0021654803,0.00020386574,0.00016399208,0.00013769248],"domain_scores_gemma":[0.99613744,0.00042696876,0.002898926,0.00023479002,0.00018542956,0.00011642048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017039328,0.00017940314,0.002342134,0.00008160099,0.00006245461,0.000013991777,0.00018312833,0.00023157167,0.000020334981],"category_scores_gemma":[0.0000174434,0.000090624184,0.0002890907,0.00005874716,0.00019486425,0.000078726036,0.00003650479,0.0005877505,8.8355335e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008268509,0.00025379704,0.0038233735,0.003433835,0.0012233783,0.00006916132,0.000021022763,0.0000035171886,1.3915252e-7,0.000042561824,0.002218875,0.9880835],"study_design_scores_gemma":[0.007430089,0.0018607897,0.021141747,0.0074830223,0.010575919,0.0011262132,0.000016360573,0.000001930471,6.3872267e-7,0.000018073988,0.95024174,0.00010348312],"about_ca_topic_score_codex":0.000033978475,"about_ca_topic_score_gemma":0.00008288964,"teacher_disagreement_score":0.98798,"about_ca_system_score_codex":0.00006589644,"about_ca_system_score_gemma":0.0006453734,"threshold_uncertainty_score":0.3695547},"labels":[],"label_agreement":null},{"id":"W2611233189","doi":"10.1200/jco.2012.30.15_suppl.2102","title":"Correlation between CD4 lymphocytes count and the opportunistic infections in treated glioblastoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Lymphocytopenia; Cohort; Internal medicine; Temozolomide; Immunosuppression; Pneumonia; Glioblastoma; Bacteremia; Opportunistic infection; Immunology; Gastroenterology; Lymphocyte; Antibiotics; Chemotherapy; Viral disease; Human immunodeficiency virus (HIV)","score_opus":0.1258092605359505,"score_gpt":0.46141468420080056,"score_spread":0.33560542366485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611233189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212813,0.000428005,0.00010245996,0.004647182,0.0003763268,0.00017156995,0.000003848812,0.000004982151,0.0021374803],"genre_scores_gemma":[0.9964963,0.0016450888,0.00009544303,0.00059172424,0.0010748726,0.000005996164,0.0000034519826,0.000006391426,0.00008070545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777186,0.0005582392,0.0011781108,0.00006925963,0.00021627429,0.0002062342],"domain_scores_gemma":[0.9897744,0.0088802725,0.00058868254,0.000096122,0.00020788585,0.00045262525],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004707324,0.00007255281,0.0007728247,0.0001379559,0.00004118736,0.0000091846405,0.000045209275,0.00021663641,0.00013158093],"category_scores_gemma":[0.010979491,0.00004007534,0.0001504658,0.00015391297,0.00029422028,0.00013104794,0.000031838754,0.0005834816,0.000019865025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026333889,0.00056906726,0.9696857,0.000010256393,0.000103897626,0.00007361712,0.00006610572,0.0000015161095,0.000009375048,0.0002775713,0.0015415954,0.025027933],"study_design_scores_gemma":[0.01121908,0.00441952,0.9577203,0.00005780417,0.0002710356,0.00042769994,0.000053492648,0.0001945545,0.000008326448,0.00017479455,0.025414858,0.00003856401],"about_ca_topic_score_codex":0.00008752954,"about_ca_topic_score_gemma":0.000050095874,"teacher_disagreement_score":0.024989368,"about_ca_system_score_codex":0.00016048277,"about_ca_system_score_gemma":0.00075375644,"threshold_uncertainty_score":0.99735147},"labels":[],"label_agreement":null},{"id":"W2611252707","doi":"10.1200/jco.2007.25.18_suppl.7571","title":"Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (<i>EGFR</i>) gene and codons 12 and 13 of the <i>KRAS</i> gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Exon; Gefitinib; Epidermal growth factor receptor; Erlotinib; Polysomy; Molecular biology; Medicine; Copy-number variation; Gene; EGFR inhibitors; Point mutation; Cancer research; Cancer; Biology; Mutation; Internal medicine; Genetics; Fluorescence in situ hybridization; Genome","score_opus":0.05193385057218633,"score_gpt":0.43144863797094735,"score_spread":0.379514787398761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611252707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559885,0.0023469091,0.000026199568,0.0009212412,0.00021744345,0.0004904665,0.00024287657,0.0000010968148,0.00015489952],"genre_scores_gemma":[0.99626637,0.002526478,0.00065317634,0.00043080054,0.000055921893,0.000012603431,0.000007309386,0.00001197839,0.000035359306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976464,0.00017509915,0.0015225153,0.00017552148,0.00031777425,0.00016272094],"domain_scores_gemma":[0.9969124,0.0004185949,0.0017498448,0.0001091797,0.0006740232,0.00013592542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051867595,0.00014694186,0.0009619083,0.00016096196,0.00002920896,0.000002265168,0.00010416268,0.00016534446,0.000024566094],"category_scores_gemma":[0.00027615545,0.000079635865,0.0001241169,0.0003463612,0.00048244387,0.00007762388,0.00005284905,0.00031152027,1.595561e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014797306,0.0007298666,0.9736865,0.00010823337,0.0006176366,0.000010922723,0.00045017948,0.0003591375,0.020769872,0.000007214434,0.000104103885,0.0016766042],"study_design_scores_gemma":[0.011217111,0.0009352697,0.9506713,0.00035528492,0.00078366796,0.000007686395,0.000066045075,0.00006228767,0.035654284,0.000008528001,0.00017051623,0.000068014066],"about_ca_topic_score_codex":0.0062759095,"about_ca_topic_score_gemma":0.010927005,"teacher_disagreement_score":0.023015194,"about_ca_system_score_codex":0.00020018022,"about_ca_system_score_gemma":0.0019681023,"threshold_uncertainty_score":0.948734},"labels":[],"label_agreement":null},{"id":"W2611735771","doi":"10.1200/jco.2014.32.15_suppl.6560","title":"Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Baker Hughes (Canada); Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Regimen; Oncology","score_opus":0.1965401599889811,"score_gpt":0.5360588682049996,"score_spread":0.3395187082160185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611735771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98121476,0.0014817027,0.011358289,0.0019893108,0.0029757977,0.00077674974,0.000059650167,0.0000025537129,0.00014117903],"genre_scores_gemma":[0.9835438,0.009247452,0.0028469851,0.002516474,0.001720863,0.00003976558,0.000043926982,0.000024515237,0.000016187829],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9678319,0.01602464,0.014669544,0.00064193265,0.00035167628,0.00048030532],"domain_scores_gemma":[0.95968556,0.030866046,0.0082743075,0.00042693672,0.000352295,0.00039487792],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08920736,0.0002727293,0.004407167,0.0000995993,0.00004573747,0.000018537541,0.0003611819,0.0008223275,0.00002082289],"category_scores_gemma":[0.16955535,0.00023426554,0.0006299901,0.00016775615,0.00047848365,0.000029604158,0.00014699301,0.0011790193,0.0000020124073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019155592,0.0037855026,0.17644964,0.000067425346,0.0002619988,0.00016031727,0.00013392823,0.003226912,0.0021021923,0.0005447233,0.0091146715,0.7849971],"study_design_scores_gemma":[0.13884957,0.023823265,0.64925337,0.0005333814,0.0010651018,0.00015482148,0.00044512935,0.026679771,0.00361982,0.004759246,0.14971602,0.0011004878],"about_ca_topic_score_codex":0.0077840965,"about_ca_topic_score_gemma":0.27253,"teacher_disagreement_score":0.7838966,"about_ca_system_score_codex":0.00019946307,"about_ca_system_score_gemma":0.004189869,"threshold_uncertainty_score":0.99882317},"labels":[],"label_agreement":null},{"id":"W2611949374","doi":"10.1200/jco.2006.05.8834","title":"In Reply","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"Medicine","score_opus":0.03059073391799313,"score_gpt":0.4134333947945955,"score_spread":0.3828426608766024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611949374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98630756,0.001358011,0.00006112427,0.0021640859,0.00083814864,0.000041302636,3.7420375e-7,0.0000013057415,0.009228093],"genre_scores_gemma":[0.9939473,0.0004168106,0.0013282332,0.0017864933,0.0016849265,7.6063844e-7,0.0000020451614,0.000007965701,0.0008254237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829525,0.00025955748,0.0011148154,0.000109394234,0.000089971945,0.000131019],"domain_scores_gemma":[0.99898314,0.00015509079,0.0005881325,0.00010790475,0.000087693355,0.00007800908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017073776,0.00006372732,0.0003821218,0.000044996657,0.0000113961405,0.0000032846474,0.0001283433,0.00036155124,0.000014827516],"category_scores_gemma":[0.00074410124,0.000046767294,0.00023892317,0.000058215956,0.00008011219,0.0000036518502,0.0000330494,0.00041660285,0.00001228709],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074015222,0.005068494,0.20936656,0.000023874298,0.0004282761,0.0033334505,0.000031566724,0.0008799212,0.24044769,0.0016128297,0.4262018,0.10520402],"study_design_scores_gemma":[0.0046944814,0.008211484,0.07126854,0.000016949998,0.000041426167,0.0004650332,0.00001481427,0.000023406617,0.014069899,0.0012864514,0.89978355,0.00012398105],"about_ca_topic_score_codex":0.000019728446,"about_ca_topic_score_gemma":0.00001718654,"teacher_disagreement_score":0.47358176,"about_ca_system_score_codex":0.00001515617,"about_ca_system_score_gemma":0.00035673124,"threshold_uncertainty_score":0.27886143},"labels":[],"label_agreement":null},{"id":"W2612044866","doi":"10.1200/jco.2015.33.15_suppl.e11543","title":"Evaluating usefulness of ING1 expression in stroma as a prognostic biomarker in breast cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Breast cancer; Stromal cell; Cancer research; Medicine; Immunohistochemistry; Cancer; Tamoxifen; Tissue inhibitor of metalloproteinase; Estrogen receptor; Metastasis; PTEN; Pathology; Internal medicine; Matrix metalloproteinase; Biology; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.20999827063258303,"score_gpt":0.5046915818406752,"score_spread":0.29469331120809217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612044866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972021,0.0012686573,0.000047201767,0.00064786966,0.00049995846,0.00013335246,0.000011444754,0.0000012032107,0.0001882056],"genre_scores_gemma":[0.99769706,0.00034324604,0.0013051282,0.00023495291,0.00037556645,0.000010869611,0.000005685481,0.000010625167,0.000016875061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972098,0.00067477714,0.0015029918,0.00018760285,0.00024703238,0.00017782972],"domain_scores_gemma":[0.9979693,0.00022933315,0.00093010504,0.00014377278,0.0004740188,0.0002534614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026783824,0.00010027701,0.0005432102,0.000106040505,0.000011238313,0.000005387075,0.000191629,0.00030481338,0.000025036245],"category_scores_gemma":[0.0037128308,0.00008383085,0.00015218789,0.000114658826,0.00013126321,0.000008913686,0.000086513086,0.00022958165,0.0000011635879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061074193,0.0019301828,0.8933827,0.00004302501,0.000043467626,0.00009313615,0.000081286606,0.00031287535,0.06883608,0.0000048021134,0.0011748765,0.02799011],"study_design_scores_gemma":[0.011026991,0.0048906486,0.97528267,0.00030168603,0.000059585196,0.00010375283,0.00036117292,0.00025474117,0.0055342335,0.0007883647,0.0012566056,0.00013954687],"about_ca_topic_score_codex":0.000048862934,"about_ca_topic_score_gemma":0.00012184091,"teacher_disagreement_score":0.081899926,"about_ca_system_score_codex":0.000049520328,"about_ca_system_score_gemma":0.0020437415,"threshold_uncertainty_score":0.44448736},"labels":[],"label_agreement":null},{"id":"W2612138077","doi":"10.1200/jco.2014.32.15_suppl.tps9121","title":"MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Vismodegib; Medicine; Regimen; Basal cell carcinoma; Internal medicine; Oncology; Placebo; Urology; Surgery; Pathology; Basal cell","score_opus":0.06129955787227237,"score_gpt":0.39359794355476546,"score_spread":0.3322983856824931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612138077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951941,0.00016326585,0.0012842215,0.0006124088,0.00038274235,0.0022317355,0.0000054917123,0.0000024168635,0.00012365197],"genre_scores_gemma":[0.99833566,0.000050416864,0.0007000552,0.00045304833,0.00032785066,0.000044741984,0.000005247465,0.00002421782,0.0000587507],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99454665,0.0020713108,0.0023464393,0.00037953982,0.0003554699,0.00030057455],"domain_scores_gemma":[0.9940748,0.0031336555,0.0016772667,0.00037671553,0.0005070687,0.00023047367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055076024,0.0002761184,0.0023116092,0.000109631925,0.000094370174,0.000013291509,0.00034026103,0.00017504401,0.0000036762024],"category_scores_gemma":[0.0027341575,0.00014580209,0.00033604013,0.00008774141,0.0003114715,0.000008669022,0.00029019357,0.00050307345,7.619124e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80809915,0.011855627,0.17598903,0.000011958831,0.00068095315,0.000012175863,0.00064116163,0.00036697809,0.0010009764,0.0000060254065,0.00014463473,0.0011913003],"study_design_scores_gemma":[0.9091337,0.028281592,0.05970866,0.000047149537,0.0004607628,0.0000018715688,0.00024337927,0.0002700355,0.0009939104,0.0000064241863,0.0006817828,0.00017075671],"about_ca_topic_score_codex":0.000025155367,"about_ca_topic_score_gemma":0.00019614353,"teacher_disagreement_score":0.11628038,"about_ca_system_score_codex":0.000035776484,"about_ca_system_score_gemma":0.00019775296,"threshold_uncertainty_score":0.59456366},"labels":[],"label_agreement":null},{"id":"W2612460126","doi":"10.1200/jco.2016.34.18_suppl.lba5503","title":"OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal; McGill University; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Debulking; Clinical endpoint; Ovarian cancer; Randomized controlled trial; Gynecologic oncology; Chemotherapy; Surgery; Cisplatin; Internal medicine; Oncology; Urology; Cancer","score_opus":0.07684005521383697,"score_gpt":0.44211323446607603,"score_spread":0.36527317925223907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612460126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802769,0.002104575,0.0001293854,0.012624377,0.003738098,0.0010356678,0.000011960602,0.000014740641,0.00006433615],"genre_scores_gemma":[0.98141277,0.014577017,0.0012090196,0.0011456495,0.0014197581,0.00015454483,0.0000011844243,0.000048301197,0.000031758504],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939735,0.000878495,0.003661109,0.00049627735,0.00047684574,0.0005137827],"domain_scores_gemma":[0.9887296,0.008067486,0.0023003304,0.00026262025,0.00025381098,0.0003861834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004839964,0.0003840041,0.004811422,0.00034846345,0.00008271842,0.00001690185,0.00020190007,0.00044796133,0.0005880329],"category_scores_gemma":[0.0018280635,0.00022750467,0.0009843053,0.0002484213,0.00034610156,0.00017935804,0.00007470858,0.00070478796,9.959517e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28626418,0.012928543,0.045443878,0.000025013458,0.003481246,0.0010826989,0.0014670717,0.000013091434,0.00096055696,0.000013392808,0.000132768,0.6481876],"study_design_scores_gemma":[0.8427707,0.051653627,0.09835342,0.0008989779,0.0016344615,0.00010023878,0.00059789506,0.00015924062,0.0008415475,0.0000778894,0.0025859524,0.00032608403],"about_ca_topic_score_codex":0.0007755677,"about_ca_topic_score_gemma":0.00085931324,"teacher_disagreement_score":0.6478615,"about_ca_system_score_codex":0.00077114947,"about_ca_system_score_gemma":0.0018969883,"threshold_uncertainty_score":0.9277371},"labels":[],"label_agreement":null},{"id":"W2612597991","doi":"10.1200/jco.2015.33.15_suppl.tps9636","title":"Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Ontario Clinical Oncology Group; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Psychosocial; Neurocognitive; Cancer; Prospective cohort study; Breast cancer; Geriatric oncology; Cohort; Internal medicine; Oncology; Cognition; Psychiatry","score_opus":0.11344521242043507,"score_gpt":0.46870068129006287,"score_spread":0.3552554688696278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612597991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97828406,0.0019731412,0.000045650744,0.009155692,0.00538993,0.00041077554,0.000006055967,0.000019959241,0.004714708],"genre_scores_gemma":[0.9906953,0.0058148424,0.00031862987,0.0014794626,0.0011770721,0.000044666474,0.000003123147,0.000022424265,0.00044451095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963395,0.00039821252,0.0022011863,0.00026896555,0.00048166988,0.00031049442],"domain_scores_gemma":[0.99529517,0.0008819116,0.0014181602,0.000057746565,0.0019145453,0.00043248764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023755475,0.0001975106,0.0013857958,0.00022029501,0.00005975024,0.000008434533,0.0000665725,0.0004636679,0.00010519415],"category_scores_gemma":[0.003652676,0.00015733273,0.00016493611,0.00031525092,0.00026205907,0.00015166504,0.000056939312,0.0012761622,0.000014367446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074639865,0.0011592808,0.8280728,0.00003062701,0.0011264752,0.0001731145,0.0027276278,0.00000613643,0.000011640166,0.000014401004,0.0038458414,0.15536807],"study_design_scores_gemma":[0.02750015,0.004992381,0.9537437,0.00077207916,0.0006966895,0.00020291237,0.0021881575,0.00006265143,0.00004379551,0.00018542999,0.009423714,0.00018831863],"about_ca_topic_score_codex":0.0017664712,"about_ca_topic_score_gemma":0.023701936,"teacher_disagreement_score":0.15517975,"about_ca_system_score_codex":0.00096717395,"about_ca_system_score_gemma":0.0036046219,"threshold_uncertainty_score":0.99411297},"labels":[],"label_agreement":null},{"id":"W2612933814","doi":"10.1200/jco.2012.30.15_suppl.e13107","title":"Designing a web application for personalized medicine trials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Scientific Computing and Data Management","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Genomics; Personalized medicine; Precision medicine; Clinical trial; Biorepository; Informatics; Health informatics; Biobank; Medical physics; Bioinformatics; Pathology; Genome","score_opus":0.7644491836734301,"score_gpt":0.6585143255559709,"score_spread":0.10593485811745917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612933814","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040745795,0.00091500947,0.91730785,0.022914713,0.012060287,0.00045333558,0.000005987266,0.000015104464,0.005581889],"genre_scores_gemma":[0.9275523,0.00005257308,0.06100236,0.0023458735,0.007025387,0.000010385922,0.000002867578,0.000008037098,0.0020002043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910616,0.0021878744,0.005118986,0.00026576244,0.0011259709,0.00023977748],"domain_scores_gemma":[0.917283,0.0737598,0.006824526,0.0005251944,0.00111103,0.00049645215],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.25376394,0.00008441383,0.0014904704,0.00026965304,0.000099059216,0.00003987785,0.0008047244,0.00014662718,0.0002608394],"category_scores_gemma":[0.2219799,0.000045768797,0.00052344694,0.00038319043,0.00024242833,0.0002698476,0.000111433714,0.000275359,0.00007555972],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070986745,0.00029951136,0.0048895697,0.0000026173516,0.00006594891,0.0000021534302,0.0001910012,0.000019904459,0.00026667802,0.0051879613,0.28877535,0.69958943],"study_design_scores_gemma":[0.003911534,0.0012161218,0.0052930927,0.000015423839,0.00013856664,0.000019307476,0.00073452375,0.002174694,0.000013585361,0.010713706,0.9757135,0.000055948152],"about_ca_topic_score_codex":0.0000034471277,"about_ca_topic_score_gemma":0.0000034599602,"teacher_disagreement_score":0.8868065,"about_ca_system_score_codex":0.000049480437,"about_ca_system_score_gemma":0.00042678413,"threshold_uncertainty_score":0.7845737},"labels":[],"label_agreement":null},{"id":"W2613100125","doi":"10.1200/jco.2013.31.15_suppl.3639","title":"Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"DiagnoCure (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Lymphovascular invasion; Internal medicine; Stage (stratigraphy); T-stage; Clinical endpoint; Oncology; Proportional hazards model; Cancer; Lymph node; Colorectal cancer; Gastroenterology; Metastasis; Clinical trial","score_opus":0.0865381617090503,"score_gpt":0.4671039422869971,"score_spread":0.38056578057794677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613100125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995072,0.0011377351,0.0000017873173,0.0012487523,0.0008145169,0.0003777709,0.000009147435,0.0000029659686,0.0013353254],"genre_scores_gemma":[0.99514556,0.0033903872,0.0004560406,0.0004872135,0.0001482048,0.000051302537,0.0000014406163,0.000010588031,0.00030924683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672174,0.00027623688,0.0021733495,0.00021779585,0.00034237432,0.00026847306],"domain_scores_gemma":[0.9967996,0.00096980494,0.0014658112,0.00014453208,0.0004185332,0.00020174621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084281893,0.00016161441,0.0015015618,0.00018401645,0.00003706873,0.000004298578,0.00013983784,0.0002605869,0.0002488922],"category_scores_gemma":[0.002290527,0.000104185754,0.0002292923,0.00018089892,0.00019043531,0.00015023591,0.00013705716,0.0004954221,0.0000070997517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004285584,0.007273956,0.7571494,0.000052781717,0.000065356995,0.0002846359,0.00055901974,0.000006723722,0.0003942072,0.0000037489835,0.00062922545,0.22929536],"study_design_scores_gemma":[0.022818787,0.011778434,0.9584456,0.00087263086,0.000081492806,0.000015387413,0.0002634879,0.00007530514,0.00052335224,0.00011353959,0.004913948,0.00009804152],"about_ca_topic_score_codex":0.0011585434,"about_ca_topic_score_gemma":0.0011652359,"teacher_disagreement_score":0.22919732,"about_ca_system_score_codex":0.0004944026,"about_ca_system_score_gemma":0.0010477747,"threshold_uncertainty_score":0.42485717},"labels":[],"label_agreement":null},{"id":"W2613276365","doi":"10.1200/jco.2017.35.15_suppl.6078","title":"Phase II study: Induction chemotherapy &amp; transoral surgery as definitive tx for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—A novel approach.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Neck dissection; Induction chemotherapy; Surgery; Stage (stratigraphy); Regimen; Head and neck squamous-cell carcinoma; Internal medicine; Radiation therapy; Cancer; Head and neck cancer; Oncology","score_opus":0.24760229920842305,"score_gpt":0.48637098531434647,"score_spread":0.23876868610592342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613276365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850527,0.00047268625,0.0015962622,0.006570925,0.0021808278,0.00086152507,0.000018618879,0.000015252887,0.0032312155],"genre_scores_gemma":[0.9891653,0.00032405238,0.0055885185,0.0020512193,0.0022420024,0.000045913173,0.0000073575998,0.000042773903,0.00053283374],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99636525,0.00020640381,0.002221227,0.00038614712,0.00040789356,0.0004130886],"domain_scores_gemma":[0.9945085,0.0017180517,0.0021720973,0.0003702084,0.0007908977,0.0004402627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031575284,0.00026815405,0.0029464199,0.00013618731,0.00043264657,0.000019279692,0.00025087025,0.00040397226,0.00004607794],"category_scores_gemma":[0.003321855,0.00020077944,0.0008568804,0.00007472973,0.00037998884,0.00024788114,0.000048963575,0.0010257511,0.0000059818535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09613953,0.06874218,0.021666925,0.00021285118,0.0006664063,0.00042720803,0.0027324923,0.000011107061,0.0031307116,0.000041130417,0.009248713,0.79698074],"study_design_scores_gemma":[0.26051116,0.378623,0.2033788,0.00016107595,0.0018187342,0.0006958177,0.0026609632,0.000118182645,0.0014211921,0.00025618088,0.14968456,0.00067033566],"about_ca_topic_score_codex":0.000056405297,"about_ca_topic_score_gemma":0.000084891246,"teacher_disagreement_score":0.7963104,"about_ca_system_score_codex":0.00017765482,"about_ca_system_score_gemma":0.0023632138,"threshold_uncertainty_score":0.8187548},"labels":[],"label_agreement":null},{"id":"W2613615379","doi":"10.1200/jco.2016.34.18_suppl.lba506","title":"Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Sunnybrook Health Science Centre; The Quebec Population Health Research Network","funders":"","keywords":"Letrozole; Medicine; Quality of life (healthcare); Aromatase inhibitor; Clinical endpoint; Placebo; Internal medicine; Randomized controlled trial; Tamoxifen; Breast cancer; Population; Oncology; Gynecology; Cancer","score_opus":0.03197038114061333,"score_gpt":0.3784559607070892,"score_spread":0.34648557956647585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613615379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979162,0.00029776833,0.00005381971,0.00016712064,0.0003918844,0.000768204,0.00039607903,0.000003213191,0.0000057075163],"genre_scores_gemma":[0.9980181,0.00042090306,0.000951425,0.00014640453,0.0003135445,0.000075808166,0.00002853881,0.000028028551,0.000017237622],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963034,0.00083162123,0.0021077776,0.00024917754,0.00024091713,0.00026711044],"domain_scores_gemma":[0.9958462,0.0012476508,0.0023675878,0.00018760897,0.00016382808,0.00018711104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018753018,0.00016947638,0.0016274694,0.000081453436,0.000014704806,0.000006868251,0.00015449185,0.00037010864,0.000049711143],"category_scores_gemma":[0.00090407406,0.000096876545,0.00024668852,0.00006458959,0.00027725467,0.000021545286,0.000051133393,0.00023449135,3.4847653e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83182025,0.0012668492,0.008331201,0.0000070918422,0.0008250358,0.00013113735,0.00016147598,0.0000042827173,0.119510256,6.0984394e-7,0.00007811447,0.0378637],"study_design_scores_gemma":[0.8658471,0.044984184,0.07024574,0.00019342918,0.00019050462,0.000046862897,0.00012421017,0.000009440684,0.017490076,0.000029028095,0.0006104527,0.00022896368],"about_ca_topic_score_codex":0.00014495154,"about_ca_topic_score_gemma":0.000031448624,"teacher_disagreement_score":0.10202018,"about_ca_system_score_codex":0.000050025923,"about_ca_system_score_gemma":0.00047893266,"threshold_uncertainty_score":0.39505106},"labels":[],"label_agreement":null},{"id":"W2613742728","doi":"10.1200/jco.2013.31.15_suppl.1033","title":"Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; University Health Network; Health Sciences Centre; Hôpital du Saint-Sacrement; University of British Columbia; Queen's University; Princess Margaret Cancer Centre; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; BC Cancer Agency; Hamilton Health Sciences; University of Toronto","funders":"","keywords":"Medicine; Metformin; Placebo; Body mass index; Internal medicine; Breast cancer; Leptin; Insulin; Cancer; Obesity","score_opus":0.03839038761044171,"score_gpt":0.4277222973384736,"score_spread":0.3893319097280319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613742728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904209,0.0003853696,0.0000023246025,0.0003519318,0.0033820965,0.0050837374,0.000021234073,0.000004628726,0.00034780064],"genre_scores_gemma":[0.9975877,0.0012977854,0.00003876616,0.00017578731,0.0005839822,0.00021249734,0.0000033512076,0.000024366456,0.000075762226],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99189246,0.002677889,0.004223379,0.00027335066,0.0005623891,0.00037054537],"domain_scores_gemma":[0.9808118,0.015710855,0.0026370846,0.0001652709,0.00028387323,0.00039113124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005768916,0.0003288708,0.007720627,0.0004912318,0.000021301292,0.000013234715,0.00014344584,0.00048611578,0.0005690812],"category_scores_gemma":[0.00721638,0.00017793344,0.0011907112,0.00015479531,0.00026062434,0.00020024544,0.000050254443,0.0011926693,0.0000052061305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80220497,0.0015776613,0.1773578,0.000029784867,0.0007988615,0.000056692177,0.00029231486,0.000008013641,0.000015605814,0.000005124353,0.000049645034,0.017603561],"study_design_scores_gemma":[0.7360573,0.015476206,0.24669242,0.00015498474,0.00084901805,0.0000032943253,0.000042997093,0.00020975452,0.00009499098,0.0000050925855,0.0003065876,0.000107372034],"about_ca_topic_score_codex":0.004737069,"about_ca_topic_score_gemma":0.0015403462,"teacher_disagreement_score":0.06933464,"about_ca_system_score_codex":0.0002725218,"about_ca_system_score_gemma":0.0006851021,"threshold_uncertainty_score":0.8639202},"labels":[],"label_agreement":null},{"id":"W2613801984","doi":"10.1200/jco.2013.31.15_suppl.7071","title":"Quality of life (QOL) and physical function in one-year adult and elderly survivors of acute myeloid leukemia (AML).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Grip strength; Prospective cohort study; Internal medicine; Myeloid leukemia; Longitudinal study; Physical therapy; Pathology","score_opus":0.10019789548511553,"score_gpt":0.4559775932760604,"score_spread":0.35577969779094487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613801984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953991,0.0002348279,0.000018241326,0.0029954386,0.00041924103,0.00018651728,0.000004652634,0.0000029124335,0.00073903624],"genre_scores_gemma":[0.9966933,0.0015687756,0.00042892745,0.00067038066,0.00052911794,0.0000038764806,0.0000018714136,0.0000076869155,0.00009603153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997435,0.0004325812,0.0016477304,0.00014386566,0.00020223753,0.00013861984],"domain_scores_gemma":[0.9961619,0.0018667219,0.0012398908,0.000092539354,0.00038125084,0.0002577065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012089615,0.00010186395,0.0015371686,0.000100858364,0.000011980707,0.000002598329,0.000054382323,0.00025997663,0.00012213257],"category_scores_gemma":[0.0007396223,0.000075250755,0.00019646139,0.00010048011,0.00031237132,0.00011074351,0.000035495486,0.00056288147,0.0000033443755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016425896,0.0030530563,0.8611384,0.00015692407,0.001282404,0.000024113753,0.00046532243,0.0000032078713,0.012062103,0.00030432612,0.0017034939,0.10338073],"study_design_scores_gemma":[0.014414818,0.020860344,0.9619084,0.00004805862,0.0005257184,0.000018304558,0.00019413584,0.000054822183,0.00027004085,0.0009411416,0.00070257444,0.00006164147],"about_ca_topic_score_codex":0.0008910211,"about_ca_topic_score_gemma":0.00035608932,"teacher_disagreement_score":0.10331909,"about_ca_system_score_codex":0.00008099429,"about_ca_system_score_gemma":0.0007420536,"threshold_uncertainty_score":0.3068637},"labels":[],"label_agreement":null},{"id":"W2613862004","doi":"10.1200/jco.2013.31.15_suppl.e20522","title":"Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Odds ratio; Stage (stratigraphy); Colorectal cancer; Multivariate analysis; Chemotherapy; Cancer; Population; Oncology","score_opus":0.11389525671766677,"score_gpt":0.4821860505146417,"score_spread":0.36829079379697494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613862004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871836,0.00021892104,0.00004730128,0.008006815,0.001418475,0.0007424574,0.000016583837,0.0000052033784,0.0023606746],"genre_scores_gemma":[0.98767185,0.0006776986,0.0100786565,0.0006660456,0.0005101729,0.000029875038,0.0000032399782,0.000017024393,0.0003454494],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99578464,0.000282644,0.0029920007,0.0001825563,0.00052226696,0.0002359119],"domain_scores_gemma":[0.9939237,0.0017483045,0.002208409,0.00019943202,0.0014356744,0.0004844817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007337621,0.00016133359,0.0019753221,0.00014741029,0.000017884808,0.000003670802,0.00016894483,0.00031838156,0.0013062628],"category_scores_gemma":[0.0017063447,0.00010610748,0.0005471413,0.00015015011,0.00019056676,0.00009314276,0.000041200867,0.00037416638,0.000016232965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012204949,0.0067706793,0.3130293,0.000038697537,0.00057891384,0.0000274748,0.00026351985,0.000012979885,0.0013662053,0.000012439713,0.0061629633,0.6705163],"study_design_scores_gemma":[0.011536529,0.11340736,0.83509415,0.00014192495,0.00033043764,0.000019766941,0.000077921424,0.000051787967,0.0016712245,0.00003998302,0.03755341,0.000075505784],"about_ca_topic_score_codex":0.00028689584,"about_ca_topic_score_gemma":0.00011851239,"teacher_disagreement_score":0.67044085,"about_ca_system_score_codex":0.00042538135,"about_ca_system_score_gemma":0.0020625032,"threshold_uncertainty_score":0.99960667},"labels":[],"label_agreement":null},{"id":"W2614122799","doi":"10.1200/jco.2002.08.025","title":"Attitudes of Terminally Ill Cancer Patients About Euthanasia and Assisted Suicide: Predominance of Psychosocial Determinants and Beliefs Over Symptom Distress and Subsequent Survival","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital","funders":"","keywords":"Medicine; Nausea; Distress; Psychosocial; Anxiety; Cancer; Palliative care; Psychiatry; Depression (economics); Clinical psychology; Univariate analysis; Somatization; Multivariate analysis; Suicidal ideation; Internal medicine; Poison control; Suicide prevention; Medical emergency","score_opus":0.31388307729026865,"score_gpt":0.5465580295610443,"score_spread":0.23267495227077561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614122799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175173,0.006970168,0.0000041618355,0.00034718527,0.00045464427,0.00014155607,0.000066656394,0.0000018352106,0.00026203555],"genre_scores_gemma":[0.981419,0.017618809,0.000503099,0.00012842176,0.00024755535,0.0000023083094,0.0000016603374,0.0000110613255,0.00006804044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973035,0.00022299944,0.0017762891,0.00019095001,0.00033413645,0.0001721169],"domain_scores_gemma":[0.99570024,0.0012444363,0.0020954127,0.000109930785,0.0006385362,0.00021146901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006750969,0.00015021062,0.0016225347,0.00007847317,0.000025339581,0.000004266571,0.00009511166,0.00027213147,0.00004520647],"category_scores_gemma":[0.0016405185,0.00011169582,0.0001673304,0.00007839616,0.0007036722,0.00009574285,0.000055798755,0.00030060383,1.6053919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012534073,0.0010179194,0.8903659,0.00028426692,0.00023251504,0.00006179215,0.0004876685,2.105805e-7,0.00025558035,0.000011125428,0.0001828715,0.10584676],"study_design_scores_gemma":[0.0071309563,0.004603651,0.9842938,0.0018052685,0.0003392649,0.000024859526,0.00005872162,0.000024393075,0.0003390899,0.000024037521,0.0012658561,0.00009009845],"about_ca_topic_score_codex":0.0001363329,"about_ca_topic_score_gemma":0.0003950312,"teacher_disagreement_score":0.10575666,"about_ca_system_score_codex":0.00004647683,"about_ca_system_score_gemma":0.00014557458,"threshold_uncertainty_score":0.45548236},"labels":[],"label_agreement":null},{"id":"W2614673696","doi":"10.1200/jco.2013.31.15_suppl.e14630","title":"Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Waterloo; Juravinski Cancer Centre","funders":"","keywords":"FOLFIRI; Medicine; Bevacizumab; Colorectal cancer; Internal medicine; Body mass index; Incidence (geometry); Risk factor; Surgery; Oncology; Fluorouracil; Gastroenterology; Cancer; Irinotecan; Chemotherapy","score_opus":0.040907777133051486,"score_gpt":0.38489390125262396,"score_spread":0.34398612411957247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614673696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384475,0.0006931312,0.00004789229,0.00037119706,0.004357886,0.00032138076,0.000008213724,0.000002805524,0.00035273383],"genre_scores_gemma":[0.9939237,0.0011600279,0.0005607159,0.0006197497,0.0034438372,0.000034317403,0.000013131829,0.00002266569,0.00022185527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742174,0.00039651708,0.0013841112,0.00024648834,0.00024820887,0.0003029305],"domain_scores_gemma":[0.99794036,0.00018660621,0.0010319006,0.0001397259,0.0004514497,0.00024992868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069031864,0.00017796452,0.0010116252,0.00008211524,0.000029033432,0.0000074582326,0.00023739017,0.00025737603,0.00013402855],"category_scores_gemma":[0.000664025,0.0001215966,0.00025343618,0.00012776862,0.00014546548,0.00001897078,0.000059157002,0.00039151122,0.000013595428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006220439,0.0029363541,0.89240867,0.000036489073,0.0011001712,0.000007466871,0.00016066905,0.00052854477,0.006547179,0.000017702992,0.030049298,0.05998699],"study_design_scores_gemma":[0.0143981995,0.009173569,0.9182192,0.000051288633,0.00023988116,0.00003578128,0.000071934584,0.00006418716,0.00057975197,0.000092039205,0.056866,0.00020815698],"about_ca_topic_score_codex":0.00034990706,"about_ca_topic_score_gemma":0.0012310812,"teacher_disagreement_score":0.059778832,"about_ca_system_score_codex":0.00011274904,"about_ca_system_score_gemma":0.0012855846,"threshold_uncertainty_score":0.49585652},"labels":[],"label_agreement":null},{"id":"W2614821999","doi":"10.1200/jco.2013.31.15_suppl.5039","title":"A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Dasatinib; Docetaxel; Oncology; Androgen deprivation therapy; N-terminal telopeptide; Urology; Gastroenterology; Cancer; Randomized controlled trial; Surgery; Alkaline phosphatase; Receptor; Osteocalcin; Tyrosine kinase","score_opus":0.13470984353906953,"score_gpt":0.5026620645599288,"score_spread":0.3679522210208592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614821999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354464,0.00030417801,0.0000012004293,0.0018085436,0.0004155029,0.0029760918,0.000016384629,0.0000065003533,0.0009269715],"genre_scores_gemma":[0.99786973,0.0008522354,0.0002511468,0.00015292049,0.00023532193,0.00014702359,0.000014626947,0.000023141321,0.00045382636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949634,0.00085472234,0.0028166194,0.00026523578,0.0007553277,0.0003446622],"domain_scores_gemma":[0.9950299,0.0020629475,0.0014963853,0.00021839648,0.0008164138,0.00037594486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018764988,0.00020982175,0.0025648568,0.00022847315,0.00006260103,0.000012726215,0.0001576251,0.0001977546,0.0008303564],"category_scores_gemma":[0.0011445832,0.00011899485,0.0002642444,0.00028038953,0.0003449675,0.00019779472,0.000037887366,0.00080867414,0.000008597068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9078948,0.016649563,0.018141808,0.000043793418,0.001253744,0.00032907302,0.0019046664,0.0000747617,0.00012738799,0.0000026471143,0.0007083171,0.05286947],"study_design_scores_gemma":[0.83140105,0.11548852,0.050601672,0.00019202361,0.0006240462,0.000006351059,0.00076858996,0.00014302378,0.00006550047,0.000026138829,0.0005762847,0.0001068213],"about_ca_topic_score_codex":0.00089385064,"about_ca_topic_score_gemma":0.00082648144,"teacher_disagreement_score":0.098838955,"about_ca_system_score_codex":0.00030456515,"about_ca_system_score_gemma":0.002322251,"threshold_uncertainty_score":0.909182},"labels":[],"label_agreement":null},{"id":"W2615544166","doi":"10.1200/jco.2013.31.15_suppl.e17007","title":"Designing a survivorship program for head and neck cancer patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Survivorship curve; Medicine; Psychosocial; Cancer survivorship; Scope (computer science); Scope of practice; Family medicine; Gerontology; Nursing; Cancer; Health care; Psychiatry","score_opus":0.190831671039531,"score_gpt":0.5050536339722244,"score_spread":0.31422196293269333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615544166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867239,0.00015984074,0.00012473509,0.0060327263,0.0027425461,0.0006494026,0.0000020609955,0.00001502843,0.003549761],"genre_scores_gemma":[0.98013306,0.00027424094,0.016398339,0.0015132799,0.001262065,0.00008325393,7.004978e-7,0.000012124528,0.00032296477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731636,0.0006602013,0.0012688572,0.00013843853,0.00029397267,0.0003221687],"domain_scores_gemma":[0.9931132,0.004492399,0.0011297258,0.00006315831,0.0008291509,0.0003723411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004697135,0.00008204923,0.0006431756,0.000051002073,0.00016877755,0.000047696365,0.00023072412,0.00033839906,0.00015298201],"category_scores_gemma":[0.007481669,0.000062628955,0.00019255326,0.0001121284,0.00042290197,0.00031354412,0.000033616492,0.00038702248,0.000007638973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014009992,0.00057360064,0.53497535,0.000009361312,0.000043935655,0.0000036434274,0.0008875797,0.0000013884603,0.0000025713193,0.00035879284,0.008256795,0.45474687],"study_design_scores_gemma":[0.002776682,0.0055088764,0.60660243,0.00005397315,0.00006400274,0.0000016347317,0.0012451541,0.000031091007,0.0000056733443,0.004571951,0.37900752,0.00013099126],"about_ca_topic_score_codex":0.0025830474,"about_ca_topic_score_gemma":0.004089098,"teacher_disagreement_score":0.45461586,"about_ca_system_score_codex":0.00010150037,"about_ca_system_score_gemma":0.0012457649,"threshold_uncertainty_score":0.8956797},"labels":[],"label_agreement":null},{"id":"W2615663954","doi":"10.1200/jco.2014.32.15_suppl.3057","title":"A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Adverse effect; Consolidated Standards of Reporting Trials; Internal medicine; MEDLINE; Confidence interval; Systematic review","score_opus":0.27038554086918604,"score_gpt":0.5699617890490783,"score_spread":0.2995762481798923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615663954","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085519656,0.98913306,0.0000140176935,0.00056868524,0.0043328516,0.0046979194,0.000008609142,0.000009080664,0.00038056207],"genre_scores_gemma":[0.0007354099,0.9974202,0.0003118961,0.00036701054,0.00083261664,0.000073042014,0.000020566707,0.000069680915,0.00016958374],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.77526426,0.018611109,0.20414259,0.0005076776,0.0010610136,0.00041335367],"domain_scores_gemma":[0.6956469,0.024147645,0.27760315,0.0011262953,0.001124892,0.00035110864],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.37718326,0.0006253833,0.05124045,0.00063899276,0.000024118515,0.000004483997,0.00064081035,0.0023188028,0.00028578276],"category_scores_gemma":[0.35988414,0.00037159488,0.034231503,0.0008217558,0.00057903246,0.000083882056,0.00017064334,0.0038851008,0.000012402822],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027394847,0.0015421677,0.00007558413,0.6352636,0.0053757876,0.00037565795,0.00002433911,3.1621994e-7,0.000007767261,0.000005912426,0.0003113608,0.354278],"study_design_scores_gemma":[0.0115460465,0.0069270693,0.00049255055,0.8416497,0.019058999,0.0014823354,0.000050554085,0.0000036783388,0.0000063759308,0.00001833645,0.1185092,0.00025513384],"about_ca_topic_score_codex":0.000054498014,"about_ca_topic_score_gemma":0.000006873134,"teacher_disagreement_score":0.35402286,"about_ca_system_score_codex":0.00055535516,"about_ca_system_score_gemma":0.0071431603,"threshold_uncertainty_score":0.9998736},"labels":[{"model":"gemma","categories":["metaresearch","metaepi_broad"],"domain":"reporting","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"reporting","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2615856394","doi":"10.1200/jco.2012.30.15_suppl.4500","title":"Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ejection fraction; Sunitinib; Heart failure; Clinical endpoint; Internal medicine; Cardiology; Renal cell carcinoma; Placebo; Myocardial infarction; Population; Sorafenib; Clinical trial; Pathology","score_opus":0.1357241711022873,"score_gpt":0.4367950224942761,"score_spread":0.3010708513919888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615856394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948887,0.00020970331,0.00019977894,0.00039187577,0.0008178876,0.0023147848,0.00009166683,0.000008329033,0.0010772442],"genre_scores_gemma":[0.99345326,0.00012165262,0.0039011214,0.00020054332,0.001422213,0.000072737465,0.00009481199,0.000043867673,0.00068976096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919096,0.0014872616,0.0047122566,0.00035784562,0.0008732516,0.00065974134],"domain_scores_gemma":[0.98708296,0.0067301583,0.0036383017,0.00047907126,0.0012122125,0.000857291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005827327,0.00035554788,0.0043797097,0.00073609996,0.000069863454,0.0000118778935,0.00025303246,0.00058906834,0.00038958635],"category_scores_gemma":[0.0038146572,0.00019940222,0.0014318696,0.0009849755,0.00031462678,0.00018856545,0.000071708586,0.0010098165,0.0000046036507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77984154,0.014591841,0.18734902,0.00007655052,0.002185944,0.00034645468,0.00032161965,0.000026995758,0.00015094731,0.0000059383165,0.00095505785,0.014148092],"study_design_scores_gemma":[0.56894183,0.17018805,0.2324321,0.00009305702,0.008535662,0.000046127163,0.00031760044,0.000062302664,0.0014263703,0.000005146806,0.01771949,0.000232265],"about_ca_topic_score_codex":0.000124373,"about_ca_topic_score_gemma":0.00025503206,"teacher_disagreement_score":0.21089971,"about_ca_system_score_codex":0.00059103424,"about_ca_system_score_gemma":0.0035226995,"threshold_uncertainty_score":0.8131386},"labels":[],"label_agreement":null},{"id":"W2616165377","doi":"10.1200/jco.2013.31.15_suppl.4049","title":"Clinical characterization of hypoxia in pancreatic ductal adenocarcinoma (PDAC) by <sup>18</sup>F-FAZA PET and pimonidazole.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Hypoxia (environmental); Medicine; Tumor hypoxia; Pancreatic ductal adenocarcinoma; Immunohistochemistry; Positron emission tomography; Nuclear medicine; Pancreatic cancer; Adenocarcinoma; Pathology; Cancer; Internal medicine; Radiation therapy; Chemistry; Oxygen","score_opus":0.03831307128772141,"score_gpt":0.35847876136831164,"score_spread":0.3201656900805902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616165377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945137,0.0027058383,0.00012637975,0.0008909073,0.0011922226,0.00024108334,0.000019288831,0.0000029887162,0.00030760615],"genre_scores_gemma":[0.98289526,0.0117182555,0.0010201741,0.00091834506,0.0030732397,0.000010326449,0.000036244957,0.00002397968,0.00030415846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563736,0.00068650517,0.0028294227,0.00033600317,0.00021704078,0.00029369316],"domain_scores_gemma":[0.99709475,0.0003761914,0.0016134065,0.0002583771,0.00032643485,0.00033083794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021236772,0.00019575006,0.0013285715,0.00009221799,0.000028465482,0.000016043561,0.0002703694,0.0005214107,0.00013389144],"category_scores_gemma":[0.0016946794,0.00016333828,0.00036559423,0.000104457526,0.00037942576,0.00003057319,0.00012764672,0.00061199296,0.000008903915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018363987,0.001658526,0.6515172,0.00006028225,0.00040559552,0.00004658467,0.00010281509,0.000013327491,0.25074446,0.000034953628,0.016308442,0.07727142],"study_design_scores_gemma":[0.004991557,0.0038699696,0.9093431,0.000040819214,0.00016831812,0.000280602,0.00012051015,0.00018542194,0.0011015014,0.00011831832,0.07958378,0.00019605483],"about_ca_topic_score_codex":0.000047198024,"about_ca_topic_score_gemma":0.000017700751,"teacher_disagreement_score":0.25782594,"about_ca_system_score_codex":0.000021680215,"about_ca_system_score_gemma":0.00060169667,"threshold_uncertainty_score":0.66607416},"labels":[],"label_agreement":null},{"id":"W2616373451","doi":"10.1200/jco.2014.32.15_suppl.e19056","title":"Referral to a cancer center (CC), medical oncologist (MO), and use of systemic treatment (ST) in stage IV non-small cell lung cancer (NSCLC) patients: Comparison of years 2003-2006 and 2010 cohorts in a single Canadian institution.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Referral; Internal medicine; Cohort; Stage (stratigraphy); Lung cancer; Cancer registry; Cancer; Surgery; Family medicine","score_opus":0.08267592595053168,"score_gpt":0.4478556017995932,"score_spread":0.3651796758490615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616373451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620545,0.000926095,0.000026045536,0.00100552,0.0008623329,0.00059531565,0.00011423093,0.0000018471617,0.00026314973],"genre_scores_gemma":[0.9972372,0.0011571319,0.0005408277,0.0007040246,0.00011493608,0.000030723444,0.000010024732,0.000010592661,0.00019453155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746364,0.00021767573,0.0016470405,0.00020235592,0.00023371844,0.00023555387],"domain_scores_gemma":[0.9978826,0.00035040718,0.00079958135,0.00010766538,0.0003155442,0.0005441795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059807586,0.00013543047,0.001296644,0.00027764318,0.00002091474,0.0000064574515,0.0000668532,0.00030404332,0.00003435716],"category_scores_gemma":[0.00057842967,0.0000997929,0.00007519826,0.00018434576,0.00018600545,0.00007831886,0.000028508934,0.00034127498,4.1422192e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082571537,0.003766519,0.9669267,0.000089205736,0.00014728625,0.000099717654,0.00089466537,0.00016107655,0.000020633835,0.000007797699,0.0021859715,0.02487471],"study_design_scores_gemma":[0.022048889,0.0065144086,0.9484571,0.0010936763,0.00033436585,0.000017747123,0.00020602546,0.0005700287,0.000014176977,0.000001478634,0.020652736,0.000089319314],"about_ca_topic_score_codex":0.14061476,"about_ca_topic_score_gemma":0.5291575,"teacher_disagreement_score":0.38854274,"about_ca_system_score_codex":0.0016266908,"about_ca_system_score_gemma":0.00432122,"threshold_uncertainty_score":0.86510795},"labels":[],"label_agreement":null},{"id":"W2616703178","doi":"10.1200/jco.2012.30.15_suppl.6011","title":"Insurance status and cancer disparities in adolescents and young adults age 15 to 39: National Cancer Data Base, 1998-2003.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Hazard ratio; Cancer; Cancer registry; Stage (stratigraphy); Confidence interval; Thyroid cancer; Young adult; Internal medicine; Oncology","score_opus":0.15724447206011333,"score_gpt":0.4848357347312848,"score_spread":0.32759126267117145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616703178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97397685,0.013543157,0.000017182212,0.008607525,0.0031790517,0.00026729412,0.00021775621,0.0000066728776,0.00018450411],"genre_scores_gemma":[0.97402525,0.009823719,0.0011104601,0.012172266,0.0027283893,0.000011213897,0.000011981143,0.000019007935,0.00009772368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643546,0.00041109684,0.001786187,0.00029133554,0.00065081794,0.00042508825],"domain_scores_gemma":[0.9971827,0.00054344017,0.0008175413,0.0002246689,0.00039042556,0.0008412126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037622268,0.0001673229,0.0011766666,0.00015077926,0.000040956336,0.000016410495,0.00019814505,0.00024110284,0.000036169855],"category_scores_gemma":[0.0059811817,0.00013867168,0.000060681505,0.00024308683,0.00023499137,0.0004335976,0.00022116568,0.00092786364,0.0000036160218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028586462,0.0007752843,0.9479364,0.00018974677,0.00010900619,0.000052021238,0.0007797739,0.0000033931908,0.000009766499,0.000029215276,0.009198198,0.038058512],"study_design_scores_gemma":[0.0066737733,0.00077059586,0.9383824,0.0012979216,0.00007852716,0.00006513415,0.00020341238,0.000049478454,0.000003927022,0.0000397957,0.052300733,0.00013433125],"about_ca_topic_score_codex":0.004588462,"about_ca_topic_score_gemma":0.020031389,"teacher_disagreement_score":0.043102536,"about_ca_system_score_codex":0.00026892903,"about_ca_system_score_gemma":0.001869777,"threshold_uncertainty_score":0.9978505},"labels":[],"label_agreement":null},{"id":"W2618217372","doi":"10.1200/jco.2013.31.15_suppl.1592","title":"A survey of clinical prediction tools in colorectal and lung cancers and melanoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Lung cancer; Oncology; Population; Disease; Internal medicine; Stage (stratigraphy); Cancer; Medical physics","score_opus":0.10146154072787807,"score_gpt":0.4793669966953422,"score_spread":0.37790545596746417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618217372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377024,0.0007389815,0.00009543613,0.0033230658,0.0009265669,0.00018861966,0.000004668279,0.0000038075345,0.0009485934],"genre_scores_gemma":[0.9948002,0.0020040898,0.0018738688,0.0007991724,0.00047164655,0.0000025722322,0.000003347118,0.000009498316,0.000035610625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577665,0.00089905405,0.0027692937,0.0001700675,0.00022286442,0.00016208988],"domain_scores_gemma":[0.99163395,0.006306918,0.0012740851,0.000077536926,0.0003038169,0.00040367525],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010286231,0.00008986258,0.0014861427,0.00011085945,0.00001769727,0.0000105274885,0.0000756191,0.00033710914,0.000054102595],"category_scores_gemma":[0.02595665,0.00006376359,0.00013490806,0.000109326924,0.00046624136,0.00013484988,0.000050834722,0.0014621407,0.0000010817917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085879856,0.00019933908,0.77404004,0.000025312904,0.000114736315,0.00006181407,0.0000506928,0.0000087878025,0.00007705143,0.000012373293,0.001787085,0.22276394],"study_design_scores_gemma":[0.006508421,0.0050906283,0.9733465,0.00013291374,0.000112359216,0.00021500875,0.000049876104,0.013271709,0.0000050017493,0.00008162486,0.0011384219,0.000047582256],"about_ca_topic_score_codex":0.00077233784,"about_ca_topic_score_gemma":0.00016664572,"teacher_disagreement_score":0.22271636,"about_ca_system_score_codex":0.000066080866,"about_ca_system_score_gemma":0.0010703979,"threshold_uncertainty_score":0.9822481},"labels":[],"label_agreement":null},{"id":"W2618647272","doi":"10.1200/jco.2016.71.6902","title":"Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Universitair Medisch Centrum Groningen; Leids Universitair Medisch Centrum; Radboud Universitair Medisch Centrum; Santen; Radboud Universiteit; Rijksuniversiteit Groningen; Erasmus Medisch Centrum; Vrije Universiteit Amsterdam; Universiteit Leiden","keywords":"Medicine; Cohort; Cumulative incidence; Cancer; Breast cancer; Hazard ratio; Internal medicine; Oncology; Incidence (geometry); Sarcoma; Proportional hazards model; Absolute risk reduction; Cancer registry; Cohort study; Confidence interval; Pathology","score_opus":0.06517053076350447,"score_gpt":0.4504920616274109,"score_spread":0.3853215308639064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618647272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245405,0.0016383859,0.000003558454,0.0041216123,0.00061480433,0.0008996907,0.00003622901,0.0000024745234,0.00022917405],"genre_scores_gemma":[0.99360895,0.0049901414,0.00014600862,0.0005025636,0.00066350336,0.000026396285,0.0000010828785,0.00002233954,0.000039017606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941164,0.0010528334,0.0036241806,0.00025227637,0.00070677313,0.000247508],"domain_scores_gemma":[0.991605,0.0013233507,0.0057213227,0.0008254861,0.0003505441,0.00017432448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049615894,0.00022210437,0.0026664413,0.00012393913,0.00003967025,0.000008660348,0.0004435717,0.00027443416,0.00023341301],"category_scores_gemma":[0.0007664775,0.0001244983,0.00077268935,0.000075839875,0.00043246368,0.00009199251,0.00005522924,0.0005347939,0.0000019310291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060748057,0.014101379,0.9283323,0.000042868356,0.001804532,0.00019995842,0.0070139146,0.000009800424,0.00010347715,0.0000036874287,0.000033434622,0.042279806],"study_design_scores_gemma":[0.016822735,0.02328374,0.95592874,0.00031998137,0.00111335,0.000065488246,0.00071423606,0.000005053089,0.0011956992,0.00011034338,0.0003446591,0.000095999356],"about_ca_topic_score_codex":0.001566453,"about_ca_topic_score_gemma":0.005630472,"teacher_disagreement_score":0.04218381,"about_ca_system_score_codex":0.00015830496,"about_ca_system_score_gemma":0.0011470385,"threshold_uncertainty_score":0.50768936},"labels":[],"label_agreement":null},{"id":"W2619344661","doi":"10.1200/jco.2015.33.15_suppl.10074","title":"Temporal changes in treatment exposures in the Childhood Cancer Survivor Study (CCSS).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cohort; Soft tissue sarcoma; Cancer; Psychosocial; Sarcoma; Logistic regression; Internal medicine; Cohort study; Medical record; Pathology","score_opus":0.32570077588483903,"score_gpt":0.5369072765983807,"score_spread":0.21120650071354163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619344661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9292942,0.0033918908,0.000001926988,0.06410834,0.0016357745,0.00075406075,0.000004703446,0.00000840677,0.00080066884],"genre_scores_gemma":[0.98593134,0.0011517075,0.00017827905,0.009673517,0.0028754752,0.000044878394,0.000002282944,0.000020123136,0.00012239073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297184,0.0028836601,0.002731588,0.00027417621,0.0008058717,0.00033285323],"domain_scores_gemma":[0.995112,0.0025341145,0.0013807754,0.0003547817,0.00024544128,0.0003728755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01296304,0.00021783475,0.0020423904,0.00024722735,0.00002502496,0.000014422179,0.0003390792,0.00029113737,0.0000700079],"category_scores_gemma":[0.002849091,0.000124129,0.00029505073,0.0003429238,0.00013914265,0.00011239654,0.000052921223,0.0011094115,0.000009760927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024328893,0.013870978,0.9314014,0.0000116394895,0.00024991564,0.0010242892,0.015675655,0.000020940766,0.000001728193,0.000008029784,0.003951189,0.03135135],"study_design_scores_gemma":[0.021310475,0.037487224,0.8695154,0.00012802884,0.00018571637,0.00013677303,0.012737389,0.000005973892,0.000007980511,0.0001034589,0.05827074,0.00011083312],"about_ca_topic_score_codex":0.006069927,"about_ca_topic_score_gemma":0.16478129,"teacher_disagreement_score":0.15871136,"about_ca_system_score_codex":0.000479196,"about_ca_system_score_gemma":0.0030707058,"threshold_uncertainty_score":0.9175954},"labels":[],"label_agreement":null},{"id":"W2620601800","doi":"10.1200/jco.2012.30.15_suppl.e19522","title":"An innovative approach to post-treatment cancer care: The After Cancer Treatment Transition Clinic (ACTT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Cancer; Colorectal cancer; Breast cancer; Population; Health care; Family medicine; Oncology nursing; Quality of life (healthcare); Ambulatory care; Cancer survivor; Nursing; Internal medicine","score_opus":0.12705212103963726,"score_gpt":0.49262799527021683,"score_spread":0.3655758742305796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620601800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728379,0.00559275,0.0001343392,0.01485805,0.00349459,0.0005926508,0.00007046523,0.000011814178,0.0024073992],"genre_scores_gemma":[0.97906244,0.0021851712,0.00044298006,0.012076273,0.0054993993,0.00035254686,0.000014313459,0.00002736844,0.00033953498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99703836,0.00057559344,0.0014546999,0.00023079301,0.0003298049,0.00037076755],"domain_scores_gemma":[0.9968766,0.0005424617,0.00067892874,0.00029845102,0.0010114969,0.0005920807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011682481,0.00023132892,0.001217517,0.00010557696,0.000062198706,0.000012020275,0.0001311136,0.00032917177,0.0005368186],"category_scores_gemma":[0.0001293056,0.00011906489,0.0005105619,0.0002983241,0.00014127797,0.00017499662,0.000014433194,0.00051209127,0.00002134749],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017063884,0.0062804245,0.16727716,0.000038516537,0.0013611147,0.00007585373,0.045571208,0.000045901077,0.00013805598,0.000025997546,0.00097611855,0.7611458],"study_design_scores_gemma":[0.006945644,0.035442125,0.49926066,0.00009119993,0.0015161703,0.0001110388,0.010006165,0.00001141279,0.00031526142,0.0000083058885,0.4460877,0.00020432669],"about_ca_topic_score_codex":0.0021701509,"about_ca_topic_score_gemma":0.004369989,"teacher_disagreement_score":0.76094145,"about_ca_system_score_codex":0.0014572912,"about_ca_system_score_gemma":0.0023610254,"threshold_uncertainty_score":0.5877787},"labels":[],"label_agreement":null},{"id":"W2620775100","doi":"10.1200/jco.2012.30.15_suppl.9563","title":"Preclinical study of a Bcl-2 inhibitor in neuroblastoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Autophagy; Neuroblastoma; Chemotherapy; Apoptosis; Cancer research; Programmed cell death; Oncology; Internal medicine; Pharmacology; Cell culture; Biology","score_opus":0.24944647053067864,"score_gpt":0.5534806558741816,"score_spread":0.30403418534350296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620775100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601895,0.0001831091,0.0000033094389,0.0011659786,0.0009835308,0.00040667097,0.0000010335228,0.000005375705,0.0012320495],"genre_scores_gemma":[0.99787134,0.00011660422,0.000474122,0.0003684895,0.0009978096,0.000005395749,3.0939046e-7,0.000016644999,0.00014930723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454385,0.0011675088,0.0031637996,0.00016252145,0.0005937506,0.00036855458],"domain_scores_gemma":[0.9938695,0.003593804,0.0012868362,0.00023403097,0.0002842714,0.0007315866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003956331,0.0001277877,0.0016039272,0.00026498534,0.000015285552,0.0000031179775,0.00015840138,0.00024059793,0.00007905058],"category_scores_gemma":[0.007921568,0.000085313484,0.0003816567,0.00024470338,0.00016078452,0.00016380366,0.00010013941,0.00136737,0.0000352532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011935205,0.05260507,0.88186616,0.000029083163,0.00030289774,0.0015625141,0.00023610561,0.0000031550471,0.00044542213,0.000011074666,0.0015811162,0.049422175],"study_design_scores_gemma":[0.021495128,0.079556964,0.8932513,0.00007955705,0.00017517636,0.00039124556,0.0002118694,0.000011531988,0.00021014862,0.000027668404,0.0045379335,0.000051496925],"about_ca_topic_score_codex":0.000017850416,"about_ca_topic_score_gemma":0.00006199919,"teacher_disagreement_score":0.04937068,"about_ca_system_score_codex":0.000079525526,"about_ca_system_score_gemma":0.0009659253,"threshold_uncertainty_score":0.9483429},"labels":[],"label_agreement":null},{"id":"W2620809624","doi":"10.1200/jco.2013.31.15_suppl.e22041","title":"Sensitive detection of tumor nucleic acids in plasma by mutation-enriched next generation sequencing.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nucleic acid; Concordance; DNA sequencing; Computational biology; DNA profiling; Locked nucleic acid; Mutation rate; COLD-PCR; Biology; Mutation; DNA; Genetics; Gene; Point mutation; Oligonucleotide","score_opus":0.059748287678664275,"score_gpt":0.35242723537239734,"score_spread":0.29267894769373304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620809624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965406,0.00019842558,0.001946996,0.00035075113,0.0006331096,0.00011235836,0.0000052082437,0.0000011530279,0.00021136826],"genre_scores_gemma":[0.9958592,0.0004180257,0.0022732364,0.00072571076,0.000669804,0.000004166032,0.000011803786,0.000010268479,0.000027803615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998254,0.00019857373,0.001181032,0.00014030073,0.000104991486,0.000121094],"domain_scores_gemma":[0.99808496,0.00030699823,0.0009942958,0.00009777882,0.000416221,0.00009975857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079276337,0.000083719584,0.00040476045,0.000058244008,0.000019115316,0.000011216932,0.00008578211,0.00024388265,0.000014617002],"category_scores_gemma":[0.0020180056,0.00007552888,0.00014700824,0.00007160567,0.000086569045,0.000013242391,0.000031746396,0.00024144902,0.00000642461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002493071,0.00016901329,0.0020128265,0.0000046736495,0.000053214295,0.000021703994,0.0000496089,0.00054495595,0.96232986,0.000011060165,0.0015357665,0.03301801],"study_design_scores_gemma":[0.0073523237,0.014206298,0.05385268,0.000028597247,0.00012408032,0.00034078112,0.0008087033,0.015106335,0.89345175,0.00046965174,0.0139296455,0.00032913202],"about_ca_topic_score_codex":0.00012284519,"about_ca_topic_score_gemma":0.00030912503,"teacher_disagreement_score":0.068878084,"about_ca_system_score_codex":0.00009234151,"about_ca_system_score_gemma":0.0005949113,"threshold_uncertainty_score":0.30799782},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2620900699","doi":"10.1200/jco.2013.31.15_suppl.e14607","title":"Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Raltitrexed; Medicine; Cardiotoxicity; Internal medicine; Colorectal cancer; Myocardial infarction; Angina; Population; Oxaliplatin; Cancer; Cardiology; Chemotherapy; Oncology; Surgery","score_opus":0.05836635085718867,"score_gpt":0.41457441583334886,"score_spread":0.3562080649761602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620900699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392885,0.001653311,7.816901e-7,0.0016612874,0.00045327764,0.00072203035,0.00001971304,0.0000021812239,0.0015585778],"genre_scores_gemma":[0.99620366,0.0029958826,0.00031991035,0.00018751621,0.00014868451,0.000060352377,0.0000020246162,0.000009147792,0.00007284536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974524,0.00032329842,0.0014821495,0.00013016006,0.000430205,0.00018179142],"domain_scores_gemma":[0.9963943,0.0015591762,0.0011979607,0.00013620741,0.00060839386,0.000103956256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005627824,0.00015849553,0.0022678252,0.000083854415,0.000024457548,0.000003266605,0.000103915176,0.00014288776,0.000080147554],"category_scores_gemma":[0.00035064502,0.00006855357,0.000563882,0.00015214345,0.00024594794,0.000067705776,0.000017483626,0.00022698926,0.0000019615998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030125796,0.0042063985,0.9057899,0.000016946178,0.0016492899,0.000042440406,0.0008218334,0.000007958926,0.000026338917,0.0000062493104,0.00045066865,0.083969414],"study_design_scores_gemma":[0.009762218,0.038802747,0.94727737,0.000046139885,0.00071468967,0.000006221137,0.0003508749,0.0000049244727,0.00017913147,0.000016565193,0.0027821092,0.00005698653],"about_ca_topic_score_codex":0.0010242672,"about_ca_topic_score_gemma":0.0006125617,"teacher_disagreement_score":0.083912425,"about_ca_system_score_codex":0.00030038747,"about_ca_system_score_gemma":0.00063451467,"threshold_uncertainty_score":0.27955335},"labels":[],"label_agreement":null},{"id":"W2621024184","doi":"10.1200/jco.2016.71.6894","title":"Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"European Society for Medical Oncology; American Society of Clinical Oncology","keywords":"Medicine; Nice; Intraclass correlation; Clinical Oncology; Clinical trial; Internal medicine; Family medicine; Oncology; Cancer","score_opus":0.19578834237065734,"score_gpt":0.4621627813691317,"score_spread":0.26637443899847435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621024184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9124239,0.0033636114,0.0008513185,0.06183278,0.0055353013,0.0005429852,0.00017871619,0.000008274525,0.015263114],"genre_scores_gemma":[0.9206328,0.05466577,0.011070632,0.008523935,0.0049510337,0.0000068384975,0.0000019654922,0.000055653472,0.000091363945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97109234,0.00356078,0.023102125,0.0009008987,0.00060683297,0.00073699886],"domain_scores_gemma":[0.9080893,0.043677717,0.04453873,0.0017447503,0.0012192157,0.0007302768],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.120862074,0.000459355,0.010118234,0.00008418172,0.0003522957,0.00005065903,0.0037829739,0.0022900745,0.00024047529],"category_scores_gemma":[0.048716795,0.00027428713,0.005840691,0.00022938225,0.025499145,0.0002842189,0.0012476769,0.006112032,0.00001739702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039327587,0.0017586208,0.49453956,0.000055062388,0.001909275,0.0000115786315,0.0005519655,0.000035987876,0.0000011670734,0.03704081,0.00694747,0.45321575],"study_design_scores_gemma":[0.013394482,0.008635664,0.82073253,0.00020393434,0.0005277033,0.00007584128,0.0010267278,0.0008627424,0.00000454753,0.03801197,0.116256505,0.00026736176],"about_ca_topic_score_codex":0.00079247006,"about_ca_topic_score_gemma":0.00039152754,"teacher_disagreement_score":0.4529484,"about_ca_system_score_codex":0.00011838606,"about_ca_system_score_gemma":0.003675453,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W2621569204","doi":"10.1200/jco.2017.35.15_suppl.1039","title":"Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Internal medicine; Hazard ratio; Letrozole; Breast cancer; Population; Progression-free survival; Oncology; Metastatic breast cancer; Adverse effect; Cancer; Estrogen receptor; Gynecology; Tamoxifen; Confidence interval; Overall survival","score_opus":0.05956333864583405,"score_gpt":0.44140055268790485,"score_spread":0.38183721404207077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621569204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975585,0.0019699142,0.00007804808,0.019317193,0.0014688353,0.0009643887,0.00028932485,0.00003114521,0.0002961705],"genre_scores_gemma":[0.98540217,0.007611708,0.0024310912,0.0024080535,0.0018557056,0.000050439878,0.000018047085,0.0000953416,0.0001274463],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99362797,0.0007300078,0.0033259091,0.0007355045,0.0007006247,0.0008799851],"domain_scores_gemma":[0.9898938,0.0029345814,0.0046233833,0.00058999506,0.0011074132,0.000850827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001659558,0.00059113133,0.0029126022,0.00015110783,0.000589102,0.00006197654,0.000567164,0.00069492176,0.0008185481],"category_scores_gemma":[0.0029539112,0.00045034292,0.0005912484,0.00017982532,0.0014644656,0.00081266824,0.00024938962,0.0022429316,0.000027517064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058486402,0.0025291655,0.23522209,0.000048947626,0.0011042081,0.00033419905,0.0027554664,0.000064958236,0.002778734,0.00011327433,0.00016009006,0.6964025],"study_design_scores_gemma":[0.04743824,0.014801263,0.91213685,0.00069343916,0.00012018461,0.0003865578,0.0006213062,0.00001492297,0.0034379933,0.0005544699,0.01931052,0.0004842658],"about_ca_topic_score_codex":0.0007026301,"about_ca_topic_score_gemma":0.00074299384,"teacher_disagreement_score":0.6959182,"about_ca_system_score_codex":0.0010108674,"about_ca_system_score_gemma":0.0009978823,"threshold_uncertainty_score":0.99979484},"labels":[],"label_agreement":null},{"id":"W2621632868","doi":"10.1200/jco.2017.35.15_suppl.1073","title":"NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Clinical endpoint; Breast cancer; Cancer; Internal medicine; Oncology; Progression-free survival; Clinical trial; Chemotherapy","score_opus":0.8008834520995359,"score_gpt":0.6377232922376447,"score_spread":0.16316015986189125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621632868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8626569,0.002031714,0.0016077572,0.1223628,0.008622679,0.0012927572,0.00035446868,0.000016290685,0.0010546279],"genre_scores_gemma":[0.9747185,0.004047308,0.006313215,0.009529626,0.005042829,0.000105655694,0.000004977229,0.000053411364,0.000184462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97202104,0.0030159305,0.023482945,0.0007245093,0.00020953726,0.00054603536],"domain_scores_gemma":[0.94556004,0.01932251,0.03370288,0.0006529411,0.0002391508,0.00052246806],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23042296,0.00029332202,0.0062905266,0.00031397134,0.00027703942,0.00015900464,0.0006464685,0.00036268076,0.00017087712],"category_scores_gemma":[0.059984505,0.00027833506,0.00081115315,0.000076955424,0.0002724421,0.0005636658,0.00012533698,0.0012734453,0.000026602054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002090637,0.001058217,0.8239306,0.00019610199,0.00082249136,0.00018219755,0.0002543944,0.00017479705,0.0000016163118,0.0051728697,0.006420165,0.15969586],"study_design_scores_gemma":[0.01001275,0.001027605,0.93167233,0.00069032435,0.00014553205,0.00038583155,0.00024617123,0.002042001,6.3947454e-7,0.012139128,0.041299306,0.00033837382],"about_ca_topic_score_codex":0.0011579721,"about_ca_topic_score_gemma":0.0020704742,"teacher_disagreement_score":0.17043845,"about_ca_system_score_codex":0.0007797135,"about_ca_system_score_gemma":0.0011304233,"threshold_uncertainty_score":0.99996686},"labels":[],"label_agreement":null},{"id":"W2621691171","doi":"10.1200/jco.2017.35.15_suppl.e12049","title":"Impact of Oncotype-DX testing on choice of chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Waterloo","funders":"","keywords":"Medicine; Anthracycline; Chemotherapy; Internal medicine; Oncology; Regimen; Cohort; Breast cancer; Chemotherapy regimen; Stage (stratigraphy); Cancer; Gynecology","score_opus":0.2913653842463091,"score_gpt":0.4824224996297513,"score_spread":0.19105711538344222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621691171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9158038,0.00038614956,0.00010282209,0.000939343,0.001169078,0.00006746886,0.000029492016,0.000002367468,0.081499495],"genre_scores_gemma":[0.9963819,0.0005070685,0.0014857717,0.00034073688,0.001051981,6.0242496e-7,2.6840144e-7,0.000017293545,0.00021440582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963968,0.000035991496,0.0031404293,0.00016935101,0.000048096288,0.0002093508],"domain_scores_gemma":[0.9863611,0.001562755,0.0112116495,0.00041997587,0.00026914058,0.00017536654],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029816316,0.00012756333,0.0018934278,0.00014540846,0.00005910941,0.000018290615,0.0006050188,0.00032966974,0.00022331809],"category_scores_gemma":[0.015005733,0.000110160094,0.00073557114,0.000053691492,0.0003060994,0.00030750848,0.000051372448,0.0005165016,0.000038556016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006945424,0.0006560882,0.86009604,0.000013880882,0.0002688345,0.000007888778,0.000041466723,0.00012402037,0.000041372237,0.0041588335,0.0017834977,0.13211353],"study_design_scores_gemma":[0.0030043845,0.00809191,0.9608096,0.00005202816,0.00001543807,0.000006497601,0.0000047326475,0.00012553549,0.000044906228,0.008738274,0.019004755,0.00010194656],"about_ca_topic_score_codex":0.00054419803,"about_ca_topic_score_gemma":0.000045645145,"teacher_disagreement_score":0.13201159,"about_ca_system_score_codex":0.00016042328,"about_ca_system_score_gemma":0.00053431076,"threshold_uncertainty_score":0.9932913},"labels":[],"label_agreement":null},{"id":"W2621772424","doi":"10.1200/jco.2017.35.15_suppl.tps1114","title":"A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Fulvestrant; Medicine; Bromodomain; Tolerability; Estrogen receptor; Pharmacodynamics; Breast cancer; Pharmacology; Metastatic breast cancer; Estrogen; Oncology; BRD4; Cancer; Pharmacokinetics; Internal medicine; Cancer research; Adverse effect; Histone; Biology","score_opus":0.05238871350406102,"score_gpt":0.44234377517269047,"score_spread":0.3899550616686295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621772424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944319,0.0000625273,0.00013789511,0.004636816,0.00019684338,0.0004946136,0.000009294611,0.0000012528124,0.000028859726],"genre_scores_gemma":[0.9982479,0.0010241525,0.00029566858,0.0002466382,0.00015817993,0.000006180054,0.000002204374,0.0000092036535,0.000009843121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978808,0.0005834382,0.0010022561,0.00022628279,0.00018123104,0.00012598996],"domain_scores_gemma":[0.9980302,0.00018608071,0.0012306946,0.00017683262,0.00020635854,0.0001698631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027807723,0.00012144434,0.0005148594,0.000070907896,0.00008646615,0.000017428722,0.00017437199,0.00013361088,0.0000025208049],"category_scores_gemma":[0.0005144271,0.00007487054,0.00004793687,0.00007293274,0.00040299,0.000034594996,0.00012229935,0.0004620665,6.851263e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028792126,0.008857207,0.61176497,0.000021829128,0.00016462928,0.000058417834,0.00027034574,0.00016450568,0.03500495,0.000013068622,0.000058428224,0.31482953],"study_design_scores_gemma":[0.02940256,0.028450048,0.93610847,0.00009667085,0.00009930199,0.00004979688,0.00012273292,0.0013871416,0.003913281,0.000029416053,0.00022975811,0.00011080581],"about_ca_topic_score_codex":0.00015666048,"about_ca_topic_score_gemma":0.0022066592,"teacher_disagreement_score":0.3243435,"about_ca_system_score_codex":0.00002757516,"about_ca_system_score_gemma":0.00051942066,"threshold_uncertainty_score":0.30531323},"labels":[],"label_agreement":null},{"id":"W2621928438","doi":"10.1200/jco.2017.35.15_suppl.e12048","title":"Association of fatigue and insomnia with inflammatory cytokine and hematopoetic stem cell levels in breast cancer patients undergoing adjuvant radiation therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Gastroenterology; Oncology; Anxiety; Cancer; Psychiatry","score_opus":0.06378666533362046,"score_gpt":0.388157637150548,"score_spread":0.32437097181692753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621928438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588937,0.0008048729,0.000008652763,0.0025916311,0.00036357838,0.00013657649,0.000010294724,0.0000018576841,0.00019317203],"genre_scores_gemma":[0.99519837,0.0042391843,0.00003424817,0.00026928735,0.00019444728,0.00000255347,7.270736e-7,0.000009044662,0.00005215135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841887,0.00018034533,0.0009321861,0.00010763217,0.00025337623,0.0001075727],"domain_scores_gemma":[0.9964163,0.00066679716,0.0023733026,0.0001030737,0.00032035925,0.00012020858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011951032,0.00008354088,0.00073371944,0.000076382516,0.00003854721,0.000011993889,0.00006122945,0.00020102542,0.000013945717],"category_scores_gemma":[0.00021212891,0.000058503032,0.00006085325,0.000035167224,0.000074047304,0.00016140427,0.000024809315,0.0003511885,1.8215866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012131451,0.00024016773,0.9003984,0.00008321782,0.000083858286,0.000019333233,0.00049343833,0.00000387735,0.000077050536,0.000006730032,0.00006497128,0.09731586],"study_design_scores_gemma":[0.012642929,0.0022569152,0.9833767,0.0003103698,0.0000946197,0.000018517412,0.0001647623,0.000026392076,0.0001529774,0.000034068675,0.0008641905,0.000057595615],"about_ca_topic_score_codex":0.00010834478,"about_ca_topic_score_gemma":0.0018653384,"teacher_disagreement_score":0.09725827,"about_ca_system_score_codex":0.00018563804,"about_ca_system_score_gemma":0.00068464613,"threshold_uncertainty_score":0.23856844},"labels":[],"label_agreement":null},{"id":"W2621961553","doi":"10.1200/jco.2017.35.15_suppl.549","title":"Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Number needed to harm; Internal medicine; Discontinuation; Adverse effect; Tolerability; Odds ratio; Hazard ratio; Oncology; Aromatase inhibitor; Adjuvant therapy; Placebo; Cancer; Surgery; Number needed to treat; Relative risk; Confidence interval; Aromatase; Pathology","score_opus":0.1314075737076167,"score_gpt":0.4839891607222014,"score_spread":0.3525815870145847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621961553","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018026857,0.9964231,8.82484e-7,0.0001856463,0.00019855688,0.0011438838,0.00021796189,0.0000012662689,0.000026007861],"genre_scores_gemma":[0.0021901277,0.9970669,0.000053195192,0.00037604678,0.00013588129,0.000057971727,0.000056111243,0.000024719398,0.000039048282],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99163,0.002598221,0.004915822,0.00036873246,0.00027035223,0.00021686986],"domain_scores_gemma":[0.9887994,0.0004630664,0.009600065,0.0005345957,0.00036935543,0.0002335414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043017296,0.00040052438,0.014371984,0.0001974304,0.000032147214,0.000011750466,0.0004887374,0.0010460645,0.000027527925],"category_scores_gemma":[0.0014665594,0.00021290111,0.0036169786,0.00017432889,0.00021479004,0.000010755081,0.0001401222,0.0008613724,0.0000015799272],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070179655,0.0048682257,0.00021180556,0.31972307,0.49852777,0.0002982039,0.000018070567,0.0000021664193,0.000027560724,0.000008338731,0.0016025617,0.17401046],"study_design_scores_gemma":[0.0020842215,0.00886613,0.00033969496,0.022665985,0.927263,0.00032717997,0.0000041767316,7.1166227e-7,0.000014523911,0.000011431012,0.03800431,0.0004186408],"about_ca_topic_score_codex":0.000016192986,"about_ca_topic_score_gemma":0.0000200341,"teacher_disagreement_score":0.42873526,"about_ca_system_score_codex":0.000047560618,"about_ca_system_score_gemma":0.001036227,"threshold_uncertainty_score":0.9824401},"labels":[],"label_agreement":null},{"id":"W2622028593","doi":"10.1200/jco.2017.35.15_suppl.581","title":"Comparing outcomes of neoadjuvant endocrine therapy versus chemotherapy in ER-positive breast cancer: Results from a prospective institutional database.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Neoadjuvant therapy; Stage (stratigraphy); Internal medicine; Oncology; Chemotherapy; Population; Cancer; Prospective cohort study; Gynecology","score_opus":0.11272115007320714,"score_gpt":0.45354844488516166,"score_spread":0.3408272948119545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622028593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070424,0.0008316836,0.000040196526,0.005564467,0.0011898425,0.00015077497,0.0005115364,0.0000020688867,0.0010052195],"genre_scores_gemma":[0.99336565,0.0045675808,0.00090154883,0.0002676117,0.0008252752,0.0000095377945,0.00003492916,0.000010414366,0.000017450237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796194,0.00014676999,0.0012190482,0.00028414035,0.00020288392,0.00018520922],"domain_scores_gemma":[0.99692786,0.00044487193,0.0018624979,0.00033982686,0.0003300906,0.00009486167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000590834,0.0001692125,0.0010340407,0.000045824385,0.00009736778,0.0000111303325,0.0003765675,0.00014681963,0.000014762057],"category_scores_gemma":[0.0008149508,0.000123336,0.00026344717,0.000032639335,0.00048764885,0.000023564755,0.00015602128,0.0003248639,0.0000010854479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051693365,0.0013592142,0.889055,0.0000025587783,0.001570875,0.00008961885,0.00011588799,0.00006218577,0.0017728215,0.00007964958,0.00027551607,0.053923305],"study_design_scores_gemma":[0.04057674,0.0015396089,0.95195264,0.000069477064,0.00006203235,0.00002645441,0.000058520814,0.000013515163,0.0035728766,0.000090425274,0.0019309152,0.00010680164],"about_ca_topic_score_codex":0.0018407508,"about_ca_topic_score_gemma":0.0023466025,"teacher_disagreement_score":0.06289763,"about_ca_system_score_codex":0.00013259122,"about_ca_system_score_gemma":0.0007946209,"threshold_uncertainty_score":0.5029496},"labels":[],"label_agreement":null},{"id":"W2622134420","doi":"10.1200/jco.2017.35.15_suppl.e12104","title":"Postmastectomy radiation in women with node positive breast cancer in the Ontario population.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Population; Radiation therapy; Cancer; Cancer registry; Comorbidity; Randomized controlled trial; Logistic regression; Internal medicine; Environmental health","score_opus":0.03183717703252302,"score_gpt":0.39561680856294323,"score_spread":0.3637796315304202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622134420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889587,0.00017578083,0.0000073189267,0.009902736,0.00024614937,0.000096677024,0.000011899176,5.8281444e-7,0.00060014374],"genre_scores_gemma":[0.9979721,0.00022225756,0.00014483967,0.0011410575,0.0004623802,0.000016095659,0.0000029115292,0.0000062850013,0.000032109583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987655,0.00021412071,0.0005894822,0.00013832204,0.00013110646,0.00016145379],"domain_scores_gemma":[0.9986166,0.00013430437,0.0008991596,0.00018441585,0.000113885006,0.000051687628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093667203,0.000091539434,0.00039849017,0.000038235747,0.00006998473,0.000016901933,0.00023782405,0.00015217184,0.00002134252],"category_scores_gemma":[0.0001980607,0.000053883345,0.00006688782,0.00003199225,0.000099054116,0.000015638203,0.000045259367,0.00031739796,8.7605235e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004406776,0.0003211979,0.92922515,0.0000016671222,0.00013316849,0.00006456038,0.0005512669,0.00012311779,0.000041947875,0.0000073107904,0.00010600301,0.06501781],"study_design_scores_gemma":[0.0045286943,0.0011966159,0.9916899,0.00003358751,0.000031464588,0.00011828099,0.00016346073,0.0000024720964,0.000017827131,0.00006603188,0.0020888196,0.000062811814],"about_ca_topic_score_codex":0.010219036,"about_ca_topic_score_gemma":0.12737255,"teacher_disagreement_score":0.11715351,"about_ca_system_score_codex":0.0003188709,"about_ca_system_score_gemma":0.0005994899,"threshold_uncertainty_score":0.996372},"labels":[],"label_agreement":null},{"id":"W2622248187","doi":"10.1200/jco.2017.35.15_suppl.tps1115","title":"A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Discontinuation; Palbociclib; Internal medicine; Chemotherapy; Breast cancer; Oncology; Clinical endpoint; Cancer; Clinical trial; Surgery","score_opus":0.1789631524317453,"score_gpt":0.5420921992405614,"score_spread":0.3631290468088161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622248187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975956,0.00022580707,0.00002374366,0.0037769303,0.0003194882,0.005478611,0.00011588323,0.000010656211,0.0002893243],"genre_scores_gemma":[0.98970985,0.00061611726,0.0083808,0.0002698046,0.00030233042,0.00046443677,0.0000149769085,0.00006232053,0.00017938056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99309415,0.0022916887,0.0028062572,0.00057571335,0.0006315728,0.00060063094],"domain_scores_gemma":[0.98908645,0.005084348,0.004249875,0.00048036544,0.00068818935,0.00041077676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029919734,0.000512642,0.004192127,0.00029079188,0.00015143135,0.000068620684,0.00036661455,0.00010785065,0.00021574553],"category_scores_gemma":[0.0012342698,0.00031491325,0.0002751718,0.00023891414,0.00043700598,0.0004339969,0.000069493646,0.00065225613,0.000003238316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58747965,0.029979058,0.057930365,0.000008066002,0.0021817426,0.0005177359,0.00094714825,0.00029617615,0.000025320413,0.0000022657446,0.0000055234673,0.32062694],"study_design_scores_gemma":[0.66347474,0.081225835,0.25109953,0.00031147877,0.0010980295,0.000011526497,0.00083000166,0.0016721202,0.000028137638,0.000020563828,0.00004041747,0.00018765098],"about_ca_topic_score_codex":0.00498223,"about_ca_topic_score_gemma":0.012631654,"teacher_disagreement_score":0.32043928,"about_ca_system_score_codex":0.0037807499,"about_ca_system_score_gemma":0.0037569476,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2622249265","doi":"10.1200/jco.2017.35.15_suppl.1038","title":"Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Letrozole; Clinical endpoint; Progression-free survival; Internal medicine; Interim analysis; Breast cancer; Cancer; Oncology; Gynecology; Surgery; Clinical trial; Chemotherapy; Tamoxifen","score_opus":0.07992102643971791,"score_gpt":0.4703164477870385,"score_spread":0.39039542134732064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622249265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654848,0.0008416828,0.0001728349,0.028787129,0.0019617043,0.0007914337,0.0011013139,0.000017787617,0.0008413428],"genre_scores_gemma":[0.9865843,0.0034454342,0.0054706833,0.0008140694,0.003242832,0.00003138653,0.000059255042,0.000055538938,0.00029648468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930441,0.0006318178,0.004568368,0.000548163,0.0007155026,0.0004920851],"domain_scores_gemma":[0.9864713,0.0030485897,0.007893722,0.00071155454,0.0013465636,0.0005282951],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002551384,0.00038526495,0.003284866,0.0002118796,0.0001467044,0.00001939773,0.000609776,0.00063874014,0.00037118458],"category_scores_gemma":[0.006399938,0.00030385534,0.0006853683,0.00022419696,0.0010469052,0.0005913508,0.00015769481,0.0018905372,0.000013550317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7065898,0.006002137,0.0050517037,0.000013265318,0.0010312635,0.0004636919,0.00049174216,0.00018997036,0.001957858,0.000012193107,0.001078551,0.27711782],"study_design_scores_gemma":[0.6779444,0.03216398,0.25216252,0.0009988614,0.000585327,0.00013054842,0.00045106793,0.00033290006,0.0023384078,0.0011849663,0.0313055,0.00040153743],"about_ca_topic_score_codex":0.0016827115,"about_ca_topic_score_gemma":0.001843817,"teacher_disagreement_score":0.2767163,"about_ca_system_score_codex":0.00065910927,"about_ca_system_score_gemma":0.0016657922,"threshold_uncertainty_score":0.99994135},"labels":[],"label_agreement":null},{"id":"W2622352423","doi":"10.1200/jco.2017.35.15_suppl.1050","title":"Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Palbociclib; Population; Breast cancer; Fulvestrant; Gastroenterology; Cancer; Gynecology; Estrogen receptor; Metastatic breast cancer; Confidence interval","score_opus":0.04091000471739364,"score_gpt":0.3839514400226887,"score_spread":0.3430414353052951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622352423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907335,0.0010063841,0.000029906101,0.005935906,0.00071668247,0.00084334286,0.00051413226,0.000019899242,0.00020021558],"genre_scores_gemma":[0.9931638,0.0016986049,0.0033430818,0.00041821512,0.0011036148,0.0001062499,0.0000123454065,0.00007678651,0.000077298086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99356717,0.000570712,0.00362777,0.000635653,0.0007825023,0.00081618415],"domain_scores_gemma":[0.9909303,0.0017732969,0.005184137,0.0005609247,0.0008932919,0.00065804593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013039184,0.00050458737,0.003541534,0.00030000327,0.00013515244,0.000023404757,0.00064490194,0.00045726413,0.000398425],"category_scores_gemma":[0.0015330993,0.00036910162,0.0003305221,0.00023593109,0.0012360672,0.0007161253,0.00013037673,0.002055459,0.0000035350693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21746027,0.0026830395,0.60317296,0.00011985093,0.001750405,0.0011953664,0.004154432,0.00014639793,0.033793923,0.00005999125,0.000074227755,0.13538916],"study_design_scores_gemma":[0.04004905,0.012701365,0.9410118,0.0011983812,0.00014887165,0.000095840565,0.0009954724,0.000012066741,0.0022694566,0.0005563383,0.00063116127,0.00033022277],"about_ca_topic_score_codex":0.001733663,"about_ca_topic_score_gemma":0.0032223521,"teacher_disagreement_score":0.33783883,"about_ca_system_score_codex":0.0016868764,"about_ca_system_score_gemma":0.001967957,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W2622613223","doi":"10.1200/jco.2017.35.15_suppl.1088","title":"Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Nausea; Cohort; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy","score_opus":0.2259555002164314,"score_gpt":0.540515536048429,"score_spread":0.31456003583199754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622613223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161966,0.0014788347,0.00026759075,0.011317902,0.0018185249,0.0020430458,0.0012177699,0.000007792348,0.00022891197],"genre_scores_gemma":[0.9899946,0.005273102,0.0010265209,0.0018019965,0.0014804024,0.000056799512,0.0000629019,0.000038668124,0.00026503394],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9950902,0.0005503491,0.0030117892,0.0004824385,0.0005662506,0.00029901013],"domain_scores_gemma":[0.98752964,0.0048135347,0.0052733924,0.0011075387,0.00097255845,0.00030332353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035880064,0.00028749442,0.002589001,0.00012622408,0.00023093312,0.000029946936,0.00096616347,0.00027263086,0.0005703062],"category_scores_gemma":[0.0031476668,0.00019584064,0.0006051205,0.00009323787,0.00058050227,0.0003841242,0.00017499039,0.0007595991,0.0000037524055],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6385007,0.027344776,0.02399877,0.000039976796,0.010672562,0.00048017473,0.0008399884,0.0000067163155,0.00037825122,0.000002724268,0.00840528,0.2893301],"study_design_scores_gemma":[0.2063365,0.14308019,0.63719803,0.00034976564,0.0031990074,0.0002838441,0.0010617432,0.00060552155,0.0004801135,0.0002683467,0.00692447,0.00021247147],"about_ca_topic_score_codex":0.0030565583,"about_ca_topic_score_gemma":0.0007726608,"teacher_disagreement_score":0.61319923,"about_ca_system_score_codex":0.00020283986,"about_ca_system_score_gemma":0.0023214214,"threshold_uncertainty_score":0.7986149},"labels":[],"label_agreement":null},{"id":"W2622706150","doi":"10.1200/jco.2017.35.15_suppl.1084","title":"A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Paclitaxel; Internal medicine; Taxane; Cancer; Oncology; Adverse effect; Pharmacology","score_opus":0.438716383470474,"score_gpt":0.6221150318501938,"score_spread":0.1833986483797198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622706150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940593,0.00030439923,0.000011306797,0.0029639911,0.0010736763,0.00047465603,0.00004806815,0.0000055866603,0.0010590025],"genre_scores_gemma":[0.9981146,0.0006585956,0.0001974991,0.00045349938,0.00033821698,0.000015451806,0.0000010678267,0.000017784458,0.00020329283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509746,0.0018426041,0.002199017,0.00025572078,0.00025453608,0.0003506847],"domain_scores_gemma":[0.99350524,0.0013529515,0.0040253913,0.00028810583,0.00047086895,0.00035744318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040950566,0.00021790335,0.0017510743,0.00015777834,0.00017021305,0.000021071017,0.000629122,0.00026494585,0.00041646496],"category_scores_gemma":[0.0006579674,0.00014582241,0.00025350324,0.00012680756,0.00061581907,0.00025347783,0.00009581191,0.001487455,0.0000053898866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020002818,0.045623682,0.782047,0.000044238448,0.0016219259,0.0024735094,0.0006264312,0.000043926768,0.00059451465,0.000035128687,0.0012575787,0.14562926],"study_design_scores_gemma":[0.07847775,0.047599908,0.8590037,0.00015437164,0.0015032479,0.0004780463,0.0012906382,0.00033066957,0.00025571822,0.00011706066,0.010544313,0.00024453874],"about_ca_topic_score_codex":0.00034884308,"about_ca_topic_score_gemma":0.0012215886,"teacher_disagreement_score":0.14538471,"about_ca_system_score_codex":0.00011646403,"about_ca_system_score_gemma":0.0008677982,"threshold_uncertainty_score":0.64623344},"labels":[],"label_agreement":null},{"id":"W2623152276","doi":"10.1200/jco.2017.35.15_suppl.1020","title":"Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Letrozole; Medicine; Internal medicine; Hazard ratio; Quality of life (healthcare); Placebo; Oncology; Breast cancer; Nausea; Context (archaeology); Cancer; Confidence interval; Tamoxifen","score_opus":0.07319948994419362,"score_gpt":0.4246753327745315,"score_spread":0.3514758428303379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623152276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799111,0.0009767376,0.000067488,0.014968965,0.00032198065,0.0007429061,0.0025420904,0.000030998857,0.0004377206],"genre_scores_gemma":[0.99094146,0.0009964688,0.0061630984,0.0008256714,0.0006697022,0.000031147698,0.000071077906,0.000089029534,0.00021234335],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99001694,0.0015944621,0.00590371,0.00069197326,0.0010652386,0.0007276897],"domain_scores_gemma":[0.97404915,0.0034750127,0.017769698,0.00075086526,0.0028271629,0.0011281266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00262479,0.0005645419,0.0053396914,0.00020267873,0.0002763853,0.000017569222,0.0005911092,0.0005763082,0.00044088348],"category_scores_gemma":[0.00337562,0.00038073552,0.00033953876,0.00028087752,0.0022116594,0.00068032026,0.00011997331,0.0018325315,0.0000064942537],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6339304,0.0053367033,0.19128886,0.00017297007,0.008813576,0.00019482602,0.0039874404,0.00010539132,0.033546325,0.00009808981,0.00061732956,0.12190811],"study_design_scores_gemma":[0.053013287,0.042129997,0.89933,0.0008409229,0.00025956507,0.00009156877,0.00095197296,0.000004873394,0.0024099834,0.0002045105,0.0004131346,0.00035015048],"about_ca_topic_score_codex":0.0059921923,"about_ca_topic_score_gemma":0.0007014086,"teacher_disagreement_score":0.7080412,"about_ca_system_score_codex":0.0011653554,"about_ca_system_score_gemma":0.0035928579,"threshold_uncertainty_score":0.99986446},"labels":[],"label_agreement":null},{"id":"W2623163584","doi":"10.1200/jco.2017.35.15_suppl.6552","title":"Temporal trends in the intensity and duration of oncologic care among colorectal cancer (CRC) patients (pts).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Referral; Cancer; Internal medicine; Colorectal cancer; Radiation therapy; Family medicine","score_opus":0.13864485858905326,"score_gpt":0.4066088335132628,"score_spread":0.26796397492420954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623163584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843169,0.0006323833,0.00001115725,0.002075002,0.0015434416,0.00009415486,0.000034613407,0.0000014418641,0.011290918],"genre_scores_gemma":[0.998184,0.0007795501,0.0001350137,0.0004311896,0.00040803343,0.0000041007715,0.0000025000754,0.0000064639094,0.00004911256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973913,0.00007139532,0.0021602055,0.00016816119,0.000044804863,0.00016417155],"domain_scores_gemma":[0.9940681,0.00028914484,0.0051682964,0.00017372944,0.00021296855,0.00008775916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002265698,0.00010185266,0.0011402222,0.00014430688,0.00009952837,0.000036386507,0.00037875574,0.0003084338,0.00006892388],"category_scores_gemma":[0.0021677436,0.00007655996,0.00022346462,0.000053376392,0.00043381497,0.0004351251,0.00007308399,0.00050660124,0.0000035155585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004585164,0.00021683576,0.92401296,0.0000064991636,0.000035562694,0.000010892935,0.00057730294,0.000007937771,6.4787434e-7,0.0009180696,0.00090491073,0.072849855],"study_design_scores_gemma":[0.0025461803,0.0025323208,0.981438,0.000019058833,0.000018320936,0.0000033985907,0.00021222436,0.000067858586,0.0000055561754,0.0021307669,0.010943324,0.00008300652],"about_ca_topic_score_codex":0.0012769465,"about_ca_topic_score_gemma":0.004320039,"teacher_disagreement_score":0.07276685,"about_ca_system_score_codex":0.00019052652,"about_ca_system_score_gemma":0.00017674296,"threshold_uncertainty_score":0.31220245},"labels":[],"label_agreement":null},{"id":"W2623294256","doi":"10.1200/jco.2015.33.15_suppl.10023","title":"Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Children’s Oncology Group AREN0532.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Nephrectomy; Internal medicine; Wilms' tumor; Hazard ratio; Loss of heterozygosity; Stage (stratigraphy); Oncology; Histology; Gastroenterology; Pathology; Surgery; Kidney; Allele; Confidence interval","score_opus":0.06357484552107187,"score_gpt":0.40989064431895367,"score_spread":0.34631579879788177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623294256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98817074,0.0023356413,0.000604273,0.00055736717,0.007576566,0.00037414604,0.00006136688,0.00001074856,0.0003091586],"genre_scores_gemma":[0.9852416,0.0025302859,0.006845421,0.0009613637,0.004217984,0.0000125894985,0.00008062234,0.000031858464,0.000078296245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927117,0.0012193314,0.0047551333,0.0006144224,0.0003065814,0.00039280654],"domain_scores_gemma":[0.9918213,0.0020098863,0.0045656427,0.00036691668,0.00049945974,0.0007367755],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0072640195,0.00029683087,0.0022123046,0.000088426714,0.000064600776,0.000011754594,0.00042526823,0.001622505,0.000007827461],"category_scores_gemma":[0.019395275,0.00020024611,0.0014691848,0.00010451231,0.0006631932,0.000020598714,0.00022430265,0.0013524694,0.0000025816266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061407904,0.0012766401,0.9529058,0.000009414174,0.0017316319,0.0004512937,0.000037535698,0.000036258654,0.000446067,0.000008016187,0.010414783,0.026541805],"study_design_scores_gemma":[0.022115985,0.05251394,0.647858,0.00012634369,0.0012319634,0.0009048145,0.00020457218,0.000051631625,0.0002917737,0.0007443381,0.27348092,0.0004756745],"about_ca_topic_score_codex":0.00007787923,"about_ca_topic_score_gemma":0.00007155899,"teacher_disagreement_score":0.30504772,"about_ca_system_score_codex":0.00009412564,"about_ca_system_score_gemma":0.0020625717,"threshold_uncertainty_score":0.9996736},"labels":[],"label_agreement":null},{"id":"W2623601143","doi":"10.1200/jco.2017.35.15_suppl.e12127","title":"Neutropenic complications with neo/adjuvant adriamycin and cyclophosphamide in early stage breast cancer patients: A prospective study at the McGill University health center.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Breast cancer; Febrile neutropenia; Cyclophosphamide; Internal medicine; Prospective cohort study; Regimen; Incidence (geometry); Neutropenia; Proportional hazards model; Single Center; Surgery; Cancer; Gastroenterology; Confidence interval; Chemotherapy","score_opus":0.06273654715712572,"score_gpt":0.42405146941229205,"score_spread":0.3613149222551663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623601143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97005403,0.00006266352,0.0000035247933,0.027858747,0.00030939345,0.00083441637,0.0001956466,0.0000048326983,0.0006767396],"genre_scores_gemma":[0.9971102,0.0008109648,0.000033744414,0.0012389204,0.00011782285,0.000007929394,0.0000010482291,0.000010766387,0.00066862354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982808,0.0003356544,0.0007661132,0.00022607214,0.00019892372,0.00019241145],"domain_scores_gemma":[0.9971814,0.0002847106,0.0015717424,0.00031477684,0.0003838957,0.00026345067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007899168,0.0001114371,0.00079424866,0.0000573308,0.0004799676,0.000010341735,0.00020717595,0.00006942597,0.00003978981],"category_scores_gemma":[0.00011660212,0.00006584567,0.00010598974,0.00009020156,0.0002883832,0.00018272585,0.0001483708,0.00072949793,0.0000037723764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004644479,0.0026954606,0.9838642,0.00000720643,0.00018498502,0.00010568408,0.0002113225,0.000010515817,0.0000033423958,0.00005387389,0.0007768345,0.0074421335],"study_design_scores_gemma":[0.015407577,0.009517539,0.94676834,0.00008856885,0.0001376643,0.00011451094,0.00031549236,0.0000026596522,0.0000014701419,0.000010566643,0.02757544,0.000060161463],"about_ca_topic_score_codex":0.003695306,"about_ca_topic_score_gemma":0.02919458,"teacher_disagreement_score":0.037095815,"about_ca_system_score_codex":0.0008807383,"about_ca_system_score_gemma":0.0008295784,"threshold_uncertainty_score":0.9885201},"labels":[],"label_agreement":null},{"id":"W2624006583","doi":"10.1200/jco.2017.35.15_suppl.528","title":"Refined estimates of local recurrence risks and the impact of the DCIS score adjusting for clinico-pathological features: Meta-analysis of E5194 and Ontario DCIS cohort studies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cohort; Hazard ratio; Proportional hazards model; Internal medicine; Oncology; Pathological; Breast cancer; Nuclear medicine; Cancer; Confidence interval","score_opus":0.41465569646669137,"score_gpt":0.5459455964163333,"score_spread":0.13128989994964196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624006583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865693,0.011226554,0.00022019613,0.0013775387,0.0001988581,0.00025305757,0.00006854771,8.330434e-7,0.000085128726],"genre_scores_gemma":[0.99486315,0.0030789345,0.0018016623,0.000104973755,0.0000996812,0.00001414428,0.0000031286495,0.000006594554,0.000027724955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971852,0.00042013917,0.0017616432,0.00027336724,0.00019307615,0.00016658391],"domain_scores_gemma":[0.9905572,0.0035389245,0.0045673745,0.0004835468,0.0007768513,0.00007611359],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.0043904684,0.00019395072,0.0029944368,0.00004433812,0.0001635301,0.000008666776,0.00041966917,0.00029843108,0.000007666474],"category_scores_gemma":[0.010978309,0.000081700906,0.0020626911,0.0000698643,0.0028777202,0.000009028429,0.00040045998,0.0003613296,3.3407883e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061375336,0.00040615685,0.8512763,0.00003501381,0.12371966,0.000006608736,0.0002917653,0.00018972266,0.00014461139,0.000044192115,0.0006362014,0.017112272],"study_design_scores_gemma":[0.0033476478,0.0030629693,0.9158321,0.00002489581,0.076395,0.000036452566,0.00020164817,0.000045003846,0.00041120953,0.00048236555,0.00008771065,0.000072996256],"about_ca_topic_score_codex":0.0014653794,"about_ca_topic_score_gemma":0.0059509794,"teacher_disagreement_score":0.06455584,"about_ca_system_score_codex":0.000041411688,"about_ca_system_score_gemma":0.00047611978,"threshold_uncertainty_score":0.99983585},"labels":[],"label_agreement":null},{"id":"W2624122418","doi":"10.1200/jco.2017.35.15_suppl.547","title":"Adjustments in relative dose intensity (RDI) for FECD chemotherapy in breast cancer: A population analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Docetaxel; Breast cancer; Taxane; Internal medicine; Chemotherapy; Oncology; Population; Cancer","score_opus":0.07798959976275067,"score_gpt":0.47828811401468907,"score_spread":0.4002985142519384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624122418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99021393,0.00035799653,0.00011883249,0.008493177,0.0004819936,0.00016669033,0.000025353203,0.0000012114375,0.0001408148],"genre_scores_gemma":[0.9964158,0.0014026347,0.0008478357,0.0007602642,0.00049408205,0.000017886976,0.0000130166345,0.000009150291,0.000039334096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983229,0.00014572345,0.0010227009,0.00022853354,0.000103764934,0.00017635724],"domain_scores_gemma":[0.9977455,0.00015905184,0.0015371726,0.00022671849,0.0002527792,0.000078739744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011456838,0.00012159028,0.0009799915,0.00011014475,0.00006252814,0.000009350921,0.00020623895,0.0002900394,0.0000105883],"category_scores_gemma":[0.0006673414,0.00009590588,0.00040824106,0.00007711557,0.00011777018,0.000018884051,0.00007089845,0.00024146019,5.9072335e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058668484,0.00058133784,0.9413013,0.000004274702,0.0011428371,0.000019054383,0.00005125129,0.000106165775,0.00010988589,0.000017294557,0.0003207132,0.050479066],"study_design_scores_gemma":[0.008267428,0.0007380743,0.98882586,0.000028156046,0.0003057312,0.000014071585,0.000036745565,0.00008434165,0.000058379257,0.0003925537,0.0011633867,0.00008529311],"about_ca_topic_score_codex":0.00077155087,"about_ca_topic_score_gemma":0.005025404,"teacher_disagreement_score":0.05039377,"about_ca_system_score_codex":0.00018878677,"about_ca_system_score_gemma":0.00025260783,"threshold_uncertainty_score":0.39109284},"labels":[],"label_agreement":null},{"id":"W2624305751","doi":"10.1200/jco.2017.35.15_suppl.1089","title":"Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Internal medicine; Breast cancer; Prostate cancer; Oncology; Subgroup analysis; Triple-negative breast cancer; Phases of clinical research; Cancer; Androgen receptor; Gastroenterology; Clinical trial; Confidence interval","score_opus":0.06474043651843095,"score_gpt":0.44481990587863457,"score_spread":0.38007946936020365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624305751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959319,0.00045066056,0.0000023970763,0.00090941595,0.00019668486,0.0013880947,0.0010900412,0.0000049286646,0.000025861045],"genre_scores_gemma":[0.9962891,0.002947591,0.00010622636,0.00007561616,0.00038436364,0.00006780669,0.00005920242,0.00003383297,0.000036265163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493784,0.0011531642,0.0021965338,0.00049220695,0.000826896,0.0003933875],"domain_scores_gemma":[0.992242,0.0022561015,0.0031797253,0.00042898286,0.0014809477,0.0004122482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013426007,0.00034021444,0.0030506493,0.000529274,0.00008145874,0.000023008008,0.00034109235,0.0002863929,0.0002037076],"category_scores_gemma":[0.0006601495,0.00019815199,0.00029335613,0.0005505732,0.00048267673,0.0003946884,0.000065254964,0.0008411166,5.334242e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15380219,0.025784632,0.7673277,0.000018751367,0.0045349877,0.00052659976,0.0014466767,0.00008008267,0.00016383933,4.321811e-7,0.000020375084,0.046293695],"study_design_scores_gemma":[0.12646376,0.041022565,0.8288234,0.0005875027,0.00156845,0.000009678304,0.00067704445,0.00008586339,0.0005769755,0.000008477327,0.0000122101565,0.00016410835],"about_ca_topic_score_codex":0.032365788,"about_ca_topic_score_gemma":0.042572394,"teacher_disagreement_score":0.061495643,"about_ca_system_score_codex":0.00060978,"about_ca_system_score_gemma":0.0021594814,"threshold_uncertainty_score":0.97489816},"labels":[],"label_agreement":null},{"id":"W2624337602","doi":"10.1200/jco.2017.35.15_suppl.1035","title":"Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Lapatinib; Trastuzumab; Internal medicine; Adverse effect; Breast cancer; Oncology; Cancer; Neutropenia; Gastroenterology; Chemotherapy","score_opus":0.14198405875232165,"score_gpt":0.5204173110677532,"score_spread":0.37843325231543157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624337602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219036,0.00021027606,0.000036963826,0.003288636,0.00051043724,0.00023027149,0.000010539022,0.0000035097642,0.0035189993],"genre_scores_gemma":[0.9959464,0.000593592,0.002217898,0.0002394937,0.00064215594,0.0000017931293,0.000012234348,0.000016645845,0.00032980237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965353,0.0003204217,0.0019316407,0.00021476235,0.0006927949,0.0003051006],"domain_scores_gemma":[0.9955285,0.0007206528,0.0023539204,0.0003106115,0.0007358705,0.00035041958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019261977,0.0001529497,0.0013887408,0.00019510386,0.00010516416,0.000021359698,0.00030311412,0.000286158,0.000202714],"category_scores_gemma":[0.0018582435,0.0000977743,0.00028445464,0.0001130328,0.0005941407,0.00022703136,0.00008899424,0.0010485747,0.000008241981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02875017,0.005328865,0.8000711,0.00008323154,0.0002051693,0.00051510625,0.00013123496,0.000017056487,0.001960772,0.000026719967,0.00092027284,0.16199028],"study_design_scores_gemma":[0.026719565,0.022036687,0.9315552,0.0005361419,0.000087864944,0.000041742023,0.000048089427,0.00032191546,0.0005145909,0.00007303979,0.017963516,0.00010162425],"about_ca_topic_score_codex":0.00041836037,"about_ca_topic_score_gemma":0.00019245635,"teacher_disagreement_score":0.16188867,"about_ca_system_score_codex":0.00016992324,"about_ca_system_score_gemma":0.0013892788,"threshold_uncertainty_score":0.45555934},"labels":[],"label_agreement":null},{"id":"W2624341173","doi":"10.1200/jco.2017.35.15_suppl.104","title":"Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Pharmacology; Pharmacodynamics; Immunogenicity; Adverse effect; Internal medicine; Pharmacokinetics; Cancer; Immunotherapy; Immunology; Immune system","score_opus":0.06905777210190539,"score_gpt":0.4292556546783504,"score_spread":0.360197882576445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624341173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997256,0.00016206803,0.00000544677,0.0011554412,0.00029924538,0.0010040592,0.000011446309,0.000004711883,0.00010157877],"genre_scores_gemma":[0.9988712,0.00029358946,0.0006130541,0.00009054941,0.000043280743,0.000011740557,0.0000049510104,0.00002302152,0.000048614926],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9953138,0.0003752114,0.0033468888,0.00030478273,0.0004245784,0.00023469594],"domain_scores_gemma":[0.9928683,0.0007900408,0.0053335708,0.0004082192,0.00044194513,0.00015791002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019529732,0.00020190139,0.0021055085,0.0002679459,0.000053021817,0.000012184526,0.00021891775,0.00022271965,0.000017192651],"category_scores_gemma":[0.0016104365,0.00014024241,0.00013901989,0.00021502675,0.0003684896,0.00024145664,0.000056771518,0.00073609356,4.8165674e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5970217,0.023475563,0.18389767,0.00011187069,0.0006899263,0.0010089221,0.0020343878,0.0000271196,0.09190329,0.0000011346043,0.000041674557,0.09978672],"study_design_scores_gemma":[0.15637198,0.17062908,0.66327405,0.0007510462,0.00016703618,0.00017644945,0.00066784746,0.00014156723,0.007644003,0.00000909186,0.00005281535,0.000115038216],"about_ca_topic_score_codex":0.00043778378,"about_ca_topic_score_gemma":0.00082232076,"teacher_disagreement_score":0.47937638,"about_ca_system_score_codex":0.00019840762,"about_ca_system_score_gemma":0.0012188286,"threshold_uncertainty_score":0.57189196},"labels":[],"label_agreement":null},{"id":"W2624483458","doi":"10.1200/jco.2017.35.15_suppl.1008","title":"Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Tolerability; Adverse effect; Immunotherapy","score_opus":0.15072636432771547,"score_gpt":0.524890833082499,"score_spread":0.3741644687547835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624483458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143237,0.0007748693,0.0001909932,0.0037140641,0.0012259654,0.0022381179,0.00008635658,0.000010711759,0.00032656273],"genre_scores_gemma":[0.9938853,0.0026752613,0.00091824756,0.0008914674,0.0007789584,0.00009624725,0.0000038220182,0.000041671687,0.0007090392],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994874,0.0005717153,0.0034182176,0.00032723963,0.00046603143,0.00034279624],"domain_scores_gemma":[0.9903578,0.0018129839,0.0058671758,0.0005686745,0.0010733051,0.0003200373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003913015,0.0002755679,0.0029463253,0.00017745986,0.00017489847,0.000027005688,0.0004510808,0.00026329566,0.0003295922],"category_scores_gemma":[0.0017908085,0.00018481532,0.0010049652,0.00011973776,0.00047187658,0.0002175461,0.000035274825,0.00060125394,0.0000017891579],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40419716,0.023738638,0.105576575,0.00010839883,0.0099450005,0.00026427882,0.00084783474,0.000007882505,0.0014732608,0.000007371563,0.0046078917,0.44922572],"study_design_scores_gemma":[0.3244186,0.10567674,0.5544802,0.00030249104,0.003775705,0.00041695283,0.0005950746,0.0002613241,0.000735929,0.00013288794,0.008963955,0.00024011977],"about_ca_topic_score_codex":0.0009008944,"about_ca_topic_score_gemma":0.0004719401,"teacher_disagreement_score":0.44898558,"about_ca_system_score_codex":0.00029679367,"about_ca_system_score_gemma":0.0020970118,"threshold_uncertainty_score":0.753655},"labels":[],"label_agreement":null},{"id":"W2624627283","doi":"10.1200/jco.2017.35.15_suppl.524","title":"Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Oncology; Breast cancer; PTEN; Copy-number variation; Copy number analysis; Hazard ratio; Internal medicine; Context (archaeology); Targeted therapy; CDKN2A; Cancer; GNAS complex locus; Bioinformatics; Gene; PI3K/AKT/mTOR pathway; Biology; Genetics; Confidence interval; Genome","score_opus":0.08682287815780797,"score_gpt":0.4572334076116148,"score_spread":0.3704105294538068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624627283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930215,0.0005134147,0.0019302315,0.0032753004,0.0005563815,0.0004895632,0.00015087702,0.000004834271,0.000057910995],"genre_scores_gemma":[0.993189,0.00093955477,0.00402403,0.0008585615,0.0008646777,0.00005613166,0.000020730873,0.000024592911,0.000022761385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811405,0.00012599587,0.0010410489,0.00032910664,0.00011870392,0.00027112165],"domain_scores_gemma":[0.99710196,0.0003774268,0.0011196238,0.0002871025,0.0007967726,0.0003170953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006566426,0.00016708978,0.00059361616,0.00006216263,0.00029099899,0.000107679836,0.0002723423,0.00016320164,0.000011526612],"category_scores_gemma":[0.0025310272,0.00013596623,0.0002257316,0.000078490135,0.00013167193,0.000017700113,0.000111398826,0.00017078443,0.0000014281945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030823466,0.0002680553,0.6453805,0.00001420414,0.00058346684,0.000013025598,0.00016624451,0.00014572492,0.30520496,0.000057086992,0.0055079856,0.03957638],"study_design_scores_gemma":[0.0016392744,0.0057967557,0.961051,0.000030566036,0.00011446535,0.00006460882,0.000076914526,0.000014231156,0.007559604,0.00028724733,0.02318475,0.00018062381],"about_ca_topic_score_codex":0.00039406403,"about_ca_topic_score_gemma":0.0013647586,"teacher_disagreement_score":0.31567043,"about_ca_system_score_codex":0.00013582742,"about_ca_system_score_gemma":0.000784214,"threshold_uncertainty_score":0.55445415},"labels":[],"label_agreement":null},{"id":"W2624770203","doi":"10.1200/jco.2014.32.15_suppl.tps5620","title":"Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Cancer Care Ontario; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Phases of clinical research; Ovarian carcinoma; Oncology; Internal medicine; Ovarian cancer; Phase (matter); Clinical trial; Cancer","score_opus":0.09546610559454094,"score_gpt":0.44151368234750143,"score_spread":0.3460475767529605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624770203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324566,0.000017236865,0.000019179353,0.003057126,0.001181545,0.0015599304,0.000024422234,0.000003679662,0.0008911928],"genre_scores_gemma":[0.99791545,0.000010321857,0.00073829235,0.0007515469,0.00043721346,0.000021547932,0.0000027510748,0.000021731303,0.00010116588],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99527943,0.00079459196,0.0027582836,0.00028104943,0.00064910983,0.00023754478],"domain_scores_gemma":[0.994561,0.0008698581,0.0029877264,0.00049768004,0.00064801506,0.0004356978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019615155,0.00020195027,0.0020010888,0.00010945182,0.00009034299,0.0000055310647,0.00029782703,0.00020376545,0.00015212291],"category_scores_gemma":[0.0011447512,0.00010985811,0.00039302188,0.00020497577,0.00019911541,0.00005939957,0.00017163022,0.000514763,0.0000018077552],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39657784,0.25429124,0.28775188,0.000048231916,0.00075116934,0.00014144905,0.0010877904,0.000006703418,0.000026838694,0.00005101416,0.0013825428,0.057883326],"study_design_scores_gemma":[0.37927854,0.4387956,0.16771854,0.000064257845,0.0010875963,0.000009919549,0.00013721146,0.000007278726,0.00019798841,0.000010602834,0.012623595,0.00006884251],"about_ca_topic_score_codex":0.00008284627,"about_ca_topic_score_gemma":0.00012620927,"teacher_disagreement_score":0.18450437,"about_ca_system_score_codex":0.00011743095,"about_ca_system_score_gemma":0.0013491738,"threshold_uncertainty_score":0.44798836},"labels":[],"label_agreement":null},{"id":"W2624841205","doi":"10.1200/jco.2016.71.7454","title":"Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Clinical endpoint; Lung cancer; Phases of clinical research; Internal medicine; Adverse effect; Chemotherapy; Randomized controlled trial; Gastroenterology; Surgery; Cisplatin","score_opus":0.13933934224863498,"score_gpt":0.5256645909311786,"score_spread":0.3863252486825436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624841205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911659,0.0019653381,0.000104421415,0.0028226143,0.00030805316,0.0027233243,0.000009181391,0.000011310954,0.0008898659],"genre_scores_gemma":[0.991867,0.003938229,0.0020980875,0.0004960791,0.00033215428,0.00009785191,8.104454e-7,0.00003117225,0.001138599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99494976,0.001300462,0.0023981691,0.00038115782,0.0005566059,0.00041383103],"domain_scores_gemma":[0.9908943,0.0044461796,0.0028652125,0.00040375764,0.0008969125,0.0004936039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052198907,0.00028580343,0.004246681,0.00020618935,0.00024031251,0.00004000775,0.00028646793,0.00020803757,0.00006339632],"category_scores_gemma":[0.008165558,0.00015461593,0.0002269233,0.0001012823,0.0008001339,0.00016623891,0.00034853283,0.0013747785,0.0000010107999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5527285,0.0031097303,0.42521936,0.000104578954,0.0015878149,0.0061460864,0.0020598548,0.000016183372,0.0001364851,0.000002689722,0.00017585569,0.008712919],"study_design_scores_gemma":[0.83721054,0.018620118,0.13084218,0.00093106664,0.0020838701,0.0001224087,0.0029805775,0.006606842,0.00010640171,0.000008171192,0.00030088308,0.00018695994],"about_ca_topic_score_codex":0.0040670307,"about_ca_topic_score_gemma":0.016358599,"teacher_disagreement_score":0.29437718,"about_ca_system_score_codex":0.00031071837,"about_ca_system_score_gemma":0.002172532,"threshold_uncertainty_score":0.9775526},"labels":[],"label_agreement":null},{"id":"W2624981566","doi":"10.1200/jco.2014.32.15_suppl.5090","title":"Distinguishing aggressive versus nonaggressive prostate cancer using a novel prognostic proteomics biopsy test, ProMark.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; Impact; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Proteomics; Biopsy; Internal medicine","score_opus":0.07461875576495768,"score_gpt":0.42259600712601125,"score_spread":0.34797725136105356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624981566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685932,0.00239213,0.002714047,0.00078768854,0.024242384,0.0005543731,0.00004703079,0.000009607261,0.0006595434],"genre_scores_gemma":[0.8740596,0.0017866498,0.05251639,0.0008004745,0.0703616,0.000065111046,0.000019177942,0.00008634638,0.000304606],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.996982,0.00028250227,0.0016283562,0.00039296487,0.00029462087,0.00041956024],"domain_scores_gemma":[0.9933862,0.0008360322,0.0042835884,0.00025846553,0.0008919551,0.00034375594],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001952207,0.00024825503,0.00096497184,0.000073622425,0.00011163375,0.000038709073,0.00037543112,0.00047590144,0.000014194891],"category_scores_gemma":[0.028584223,0.0001956798,0.00039650252,0.00012812344,0.00033456145,0.00001801284,0.00018176394,0.0006795946,0.0000020571897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020403922,0.00457,0.22544318,0.00031187324,0.0018911229,0.000055828357,0.0006327731,0.0023061703,0.4743418,0.00023060126,0.016638182,0.2531745],"study_design_scores_gemma":[0.029242648,0.016921002,0.06721848,0.0010576586,0.0012042241,0.0010186945,0.00023686056,0.0025693965,0.0050202203,0.00032154575,0.87415975,0.0010295374],"about_ca_topic_score_codex":0.000051619772,"about_ca_topic_score_gemma":0.000083643,"teacher_disagreement_score":0.85752153,"about_ca_system_score_codex":0.00008344739,"about_ca_system_score_gemma":0.0022226733,"threshold_uncertainty_score":0.9795984},"labels":[],"label_agreement":null},{"id":"W2625416898","doi":"10.1200/jco.2017.35.15_suppl.7500","title":"First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Rituximab; Vincristine; Prednisone; Internal medicine; CHOP; Hazard ratio; Gastroenterology; Cyclophosphamide; Mantle cell lymphoma; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval","score_opus":0.14402185482939456,"score_gpt":0.45239754558155587,"score_spread":0.3083756907521613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625416898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919843,0.00006972593,0.0000014140444,0.004868964,0.0011348135,0.0007772539,0.00004247992,0.0000034189115,0.0011175943],"genre_scores_gemma":[0.99660486,0.0005838075,0.00049101963,0.00020691154,0.00042299932,0.000011336531,0.00000251121,0.00001722858,0.0016593258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996206,0.0002701838,0.0024920227,0.00023510879,0.00058731413,0.00020937229],"domain_scores_gemma":[0.9918908,0.002112063,0.0042411974,0.00078706926,0.0007124506,0.00025643894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009466729,0.00020615985,0.0019546954,0.00006805595,0.00013174645,0.000010843708,0.00032348323,0.00022426437,0.00011667244],"category_scores_gemma":[0.0040363506,0.0000757883,0.0005540244,0.000085824664,0.00033945954,0.00008966866,0.00009027717,0.00020909694,0.000007072967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07462805,0.030290931,0.83861005,0.000020745125,0.0016431676,0.00043609666,0.0003281704,0.0000048309766,0.0000017512455,0.000009513298,0.0018292379,0.05219744],"study_design_scores_gemma":[0.11212054,0.10373659,0.7595628,0.00022890473,0.0013721676,0.000042062606,0.0000825431,0.000004224993,0.00013786441,0.000018919813,0.022631286,0.00006211052],"about_ca_topic_score_codex":0.00029721693,"about_ca_topic_score_gemma":0.002274654,"teacher_disagreement_score":0.079047285,"about_ca_system_score_codex":0.0002605373,"about_ca_system_score_gemma":0.0014522492,"threshold_uncertainty_score":0.48321804},"labels":[],"label_agreement":null},{"id":"W2625444591","doi":"10.1200/jco.2013.31.15_suppl.11085","title":"The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Guideline; Medicine; Lung cancer; Family medicine; Test (biology); Oncology; Internal medicine; Pathology","score_opus":0.06652384845840413,"score_gpt":0.49076404251944145,"score_spread":0.4242401940610373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625444591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561719,0.0045601795,0.004883235,0.030378588,0.0017143342,0.0019933395,0.000022490958,0.00000683048,0.00026912798],"genre_scores_gemma":[0.9816418,0.0004661581,0.014284569,0.0021455032,0.0010632736,0.00014715099,0.0000068109644,0.000018459377,0.00022622151],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819416,0.00006614039,0.0013520264,0.000098414464,0.00014659243,0.00014266017],"domain_scores_gemma":[0.99364376,0.0031478398,0.0011640402,0.000080273945,0.0018562501,0.00010783747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010341957,0.00008095768,0.00043053477,0.000031438783,0.0001308321,0.000011239251,0.00006170933,0.00010815247,0.000013255661],"category_scores_gemma":[0.0048630587,0.00003858023,0.00017770525,0.00008622797,0.000107955806,0.000060270624,0.000017954118,0.0001870424,2.8288525e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016267297,0.0012267192,0.18741605,0.00010511328,0.0013633844,0.0000029945345,0.00017748038,0.0002247496,0.0027785134,0.00014012892,0.1377155,0.6672226],"study_design_scores_gemma":[0.03520299,0.02313309,0.28597835,0.00043144016,0.0057632914,0.00007015857,0.00025589505,0.015848612,0.0021806578,0.0013108125,0.62960297,0.00022170835],"about_ca_topic_score_codex":0.0002210064,"about_ca_topic_score_gemma":0.00009599143,"teacher_disagreement_score":0.66700095,"about_ca_system_score_codex":0.0001226462,"about_ca_system_score_gemma":0.00071655243,"threshold_uncertainty_score":0.58218867},"labels":[],"label_agreement":null},{"id":"W2625534434","doi":"10.1200/jco.2017.35.18_suppl.lba10500","title":"Temporal trends in chronic disease among survivors of childhood cancer diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Cumulative incidence; Hazard ratio; Cancer; Incidence (geometry); Proportional hazards model; Cohort; Pediatrics; Confidence interval; Internal medicine","score_opus":0.1379309319350012,"score_gpt":0.5133653628192814,"score_spread":0.3754344308842802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625534434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963716,0.008586305,0.000014065287,0.021937076,0.0041968673,0.0010586475,0.00024610144,0.000026647464,0.00021831035],"genre_scores_gemma":[0.989055,0.0025054717,0.00008093432,0.0018391041,0.0061414554,0.000109459674,0.000023618975,0.00008902494,0.00015595065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9880264,0.0016513264,0.0068802475,0.00090293767,0.0017014673,0.0008376388],"domain_scores_gemma":[0.9811494,0.0046726284,0.010293433,0.002124747,0.00068612496,0.0010737175],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011892701,0.0005714788,0.0042376295,0.00021894295,0.00036590168,0.00008583955,0.0017121987,0.0006228217,0.00062737917],"category_scores_gemma":[0.0119520705,0.0003858982,0.0014765454,0.00042423673,0.0013396959,0.0005764775,0.0005235712,0.0029427123,0.000005187746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025544937,0.007342953,0.9210984,0.00003906123,0.0016553038,0.0028075017,0.004148636,0.00009419455,0.000004343723,0.000003462615,0.0025379963,0.057713635],"study_design_scores_gemma":[0.020520724,0.0039709336,0.9659077,0.0010249601,0.0010856749,0.000048184473,0.001465529,0.00004379406,0.000012293851,0.00015513568,0.0054003135,0.00036474486],"about_ca_topic_score_codex":0.1267133,"about_ca_topic_score_gemma":0.6478223,"teacher_disagreement_score":0.52110904,"about_ca_system_score_codex":0.00075869757,"about_ca_system_score_gemma":0.007947769,"threshold_uncertainty_score":0.9998593},"labels":[],"label_agreement":null},{"id":"W2625620449","doi":"10.1200/jco.2017.35.15_suppl.4114","title":"Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (R0) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Adjuvant; Chemotherapy; Subgroup analysis; Oncology; Odds ratio; Adjuvant therapy; Pancreatic cancer; Resection margin; Gastroenterology; Surgery; Cancer; Resection","score_opus":0.3929422356648704,"score_gpt":0.5573090613199801,"score_spread":0.16436682565510974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625620449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041009327,0.9904107,0.000012122755,0.0016616075,0.000058022182,0.0034185697,0.000017428154,0.000004238051,0.00031639042],"genre_scores_gemma":[0.0026385635,0.9944223,0.00097282894,0.0009748824,0.00011547387,0.0001382612,0.0000090272115,0.000038259157,0.0006903848],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9893199,0.003463514,0.005651532,0.00056730426,0.00062607875,0.00037166485],"domain_scores_gemma":[0.98480105,0.0065230355,0.0069360016,0.00060290546,0.0005674308,0.0005695989],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010630217,0.0005279184,0.032639794,0.00065114675,0.00009494599,0.00003566098,0.00026138,0.0008415478,0.00013030709],"category_scores_gemma":[0.009333438,0.00026539684,0.0015577506,0.000345583,0.0007111406,0.00014732593,0.00012635975,0.00213559,0.0000046546543],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017262204,0.0010975301,0.23642544,0.5166264,0.20861183,0.0008126543,0.000114379945,4.3718963e-8,7.7634255e-9,0.000015740987,0.00019337982,0.034376327],"study_design_scores_gemma":[0.006662113,0.011978747,0.11386316,0.02858108,0.8322612,0.00092033995,0.000032347114,0.000011882714,8.208799e-9,0.00003612154,0.0054089664,0.00024404163],"about_ca_topic_score_codex":0.00006609889,"about_ca_topic_score_gemma":0.00012704777,"teacher_disagreement_score":0.62364936,"about_ca_system_score_codex":0.00026929443,"about_ca_system_score_gemma":0.0013782883,"threshold_uncertainty_score":0.9999798},"labels":[],"label_agreement":null},{"id":"W2625696367","doi":"10.1200/jco.2017.35.15_suppl.522","title":"Multi-institutional comparison of breast cancer risk stratification by 70-gene signature and 21-gene assay.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Risk stratification; Internal medicine; Breast cancer; Gene; Oncology; Gastroenterology; Cancer; Genetics; Biology","score_opus":0.07142758529915959,"score_gpt":0.4483907524435584,"score_spread":0.3769631671443988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625696367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875382,0.00601262,0.001384628,0.0035426652,0.0008610639,0.00010379933,0.0004096001,0.0000022134568,0.00014521711],"genre_scores_gemma":[0.9911191,0.0041716616,0.0037670215,0.00012679795,0.00072154065,0.000005534053,0.000029236347,0.000008319319,0.000050796392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826777,0.00021108396,0.0009950163,0.00021966426,0.00017333344,0.0001331126],"domain_scores_gemma":[0.99651337,0.00016528237,0.0025149833,0.00023986447,0.00043380956,0.00013270228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090069504,0.00014038019,0.00069343817,0.00002340076,0.00019750131,0.000014471727,0.00024589017,0.0003868577,0.00001489853],"category_scores_gemma":[0.00082316,0.0001013721,0.00019009055,0.000019831556,0.0005491297,0.000014029478,0.0000924907,0.00035555044,8.8599415e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018435813,0.0016685581,0.7099489,0.00001559887,0.0010925306,0.00001049681,0.00005172337,0.00012193909,0.16482675,0.000024211926,0.007092345,0.113303386],"study_design_scores_gemma":[0.004027429,0.0009270444,0.95512015,0.000024261219,0.00028337626,0.00006593353,0.000042626656,0.000092533424,0.03198825,0.000043708817,0.0072706086,0.0001140631],"about_ca_topic_score_codex":0.00013513696,"about_ca_topic_score_gemma":0.0003112878,"teacher_disagreement_score":0.2451713,"about_ca_system_score_codex":0.000043230553,"about_ca_system_score_gemma":0.0005640286,"threshold_uncertainty_score":0.41338342},"labels":[],"label_agreement":null},{"id":"W2625905438","doi":"10.1200/jco.2017.35.15_suppl.e12000","title":"Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Internal medicine; Hazard ratio; Oncology; Stage (stratigraphy); Cancer; Proportional hazards model; Cumulative incidence; Incidence (geometry); Cancer registry; Gynecology; Cohort; Univariate analysis; Tamoxifen; Multivariate analysis; Confidence interval","score_opus":0.0678346777309012,"score_gpt":0.39631754172018857,"score_spread":0.3284828639892874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625905438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553615,0.00032839182,0.000021728467,0.0029778925,0.00053651835,0.00007663948,0.00015067602,0.0000014293469,0.00037058184],"genre_scores_gemma":[0.9971607,0.0009651141,0.0007424701,0.00036562132,0.00059696514,0.000011766607,0.000001980848,0.000015011579,0.00014038669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982751,0.00014071817,0.0009665742,0.00020755322,0.0001500252,0.00026005023],"domain_scores_gemma":[0.99720585,0.000198514,0.0018438864,0.00036317986,0.00023283913,0.00015572518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007263854,0.00015002441,0.0010145176,0.00003985982,0.000052257852,0.000011115904,0.0004160449,0.00025886454,0.00009862457],"category_scores_gemma":[0.00029408198,0.00009874413,0.00016397731,0.000016925875,0.00034221096,0.000012115494,0.00016189791,0.00028336636,0.0000043603577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039247912,0.000527359,0.95660883,0.000005494756,0.0008339523,0.00008989728,0.00008003791,0.000013847281,0.00038611388,0.000005838125,0.0001900957,0.037333768],"study_design_scores_gemma":[0.0054822387,0.0017263362,0.986079,0.00003160078,0.00008597869,0.000017257707,0.00020003236,6.174537e-7,0.00032857855,0.000055459594,0.0058916803,0.00010126151],"about_ca_topic_score_codex":0.0038383468,"about_ca_topic_score_gemma":0.015130159,"teacher_disagreement_score":0.037232503,"about_ca_system_score_codex":0.00013070773,"about_ca_system_score_gemma":0.0006054301,"threshold_uncertainty_score":0.8442984},"labels":[],"label_agreement":null},{"id":"W2625982844","doi":"10.1200/jco.2017.77.1097","title":"Managing Cancer and Living Meaningfully (CALM): A Randomized Controlled Trial of a Psychological Intervention for Patients With Advanced Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Randomized controlled trial; Cancer; Distress; Depression (economics); Population; Randomization; Clinical endpoint; Quality of life (healthcare); Intention-to-treat analysis; Adverse effect; Physical therapy; Internal medicine; Clinical psychology","score_opus":0.061751667542509325,"score_gpt":0.48073977973105886,"score_spread":0.41898811218854953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625982844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896285,0.0008193625,0.0017038658,0.002076587,0.0032323424,0.0019531723,0.0000044616395,0.0000063797593,0.0005753448],"genre_scores_gemma":[0.9952482,0.0011103502,0.0012031178,0.00069245085,0.0013942169,0.00019995034,8.0785014e-7,0.000014239968,0.0001366497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965205,0.00053393835,0.0022785456,0.00019746022,0.00029295543,0.00017659055],"domain_scores_gemma":[0.9917309,0.0040753954,0.0027234529,0.00010416533,0.0011907187,0.00017533921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044631166,0.00013288077,0.0031866862,0.00010553722,0.00003456753,0.0000071727322,0.00008804213,0.00020677963,0.00014048506],"category_scores_gemma":[0.0055892915,0.00007377183,0.00082982663,0.00008713241,0.0003882894,0.00008111087,0.000029199262,0.00035820727,2.482401e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8106127,0.0011910502,0.008540121,0.000051672454,0.00066986284,0.00000538687,0.00021046052,0.0000018813715,0.000008487199,0.000031837924,0.00015073732,0.17852582],"study_design_scores_gemma":[0.9388665,0.045278393,0.011345187,0.00090469874,0.0014178107,0.00000779108,0.00012508349,0.00017042582,0.000005681556,0.0002651978,0.0015341558,0.00007908975],"about_ca_topic_score_codex":0.00007253363,"about_ca_topic_score_gemma":0.0005729851,"teacher_disagreement_score":0.17844673,"about_ca_system_score_codex":0.000079967,"about_ca_system_score_gemma":0.00027536706,"threshold_uncertainty_score":0.66913074},"labels":[],"label_agreement":null},{"id":"W2625985775","doi":"10.1200/jco.2015.33.15_suppl.e20528","title":"Does frailty affect response to chemotherapy in older men with metastatic castration-resistant prostate cancer?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Grip strength; Quality of life (healthcare); Docetaxel; Performance status; Internal medicine; Cancer; Physical therapy; Gerontology; Oncology","score_opus":0.12051923648466692,"score_gpt":0.4816054161730945,"score_spread":0.3610861796884276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625985775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9069824,0.00012534723,0.000084636595,0.09102472,0.0004832853,0.0006804293,0.000008368136,0.000010585069,0.00060021935],"genre_scores_gemma":[0.9822196,0.00010939518,0.010686317,0.0041704895,0.00043010726,0.00002994191,0.0000012766163,0.000029728953,0.0023231616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99610263,0.00095991715,0.0018066443,0.00024188602,0.00058823114,0.00030067313],"domain_scores_gemma":[0.9950487,0.0023871346,0.00096586806,0.0002415181,0.00063784455,0.00071892526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062202234,0.00017967871,0.0013923127,0.00020712943,0.000019408302,0.00001543406,0.00016326236,0.00016649319,0.00011109616],"category_scores_gemma":[0.005221228,0.000089878915,0.00015890539,0.0003026145,0.00015659504,0.00014517976,0.000024211107,0.00078855397,0.000014237581],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49881577,0.0047890567,0.24374169,0.00016267636,0.0013231098,0.0089068115,0.008240604,0.00086937845,0.008317195,0.000027474545,0.053840213,0.17096601],"study_design_scores_gemma":[0.041466832,0.039667003,0.86037165,0.00058639934,0.00025483037,0.00033559176,0.001150432,0.00011186971,0.0009007482,0.00020719274,0.054750808,0.00019665612],"about_ca_topic_score_codex":0.00018367442,"about_ca_topic_score_gemma":0.0017512419,"teacher_disagreement_score":0.61662996,"about_ca_system_score_codex":0.0004722311,"about_ca_system_score_gemma":0.004562994,"threshold_uncertainty_score":0.8094555},"labels":[],"label_agreement":null},{"id":"W2626064256","doi":"10.1200/jco.2017.35.15_suppl.1067","title":"Treat ER<sup>+</sup>ight: Canadian prospective observational study in post-menopausal HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer women—First interim analysis (IA).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Hôpital du Sacré-Cœur de Montréal; Université Laval; Grand River Hospital; BC Cancer Agency; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Interim analysis; Adverse effect; Interim; Observational study; Oncology; Internal medicine; Breast cancer; Dosing; Clinical trial; Cancer; Gynecology","score_opus":0.046826447404191854,"score_gpt":0.409534119681415,"score_spread":0.36270767227722317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626064256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992521,0.000678258,0.000020109941,0.0042632115,0.0003688028,0.000833148,0.00018675344,0.000010462092,0.0011182656],"genre_scores_gemma":[0.99541277,0.0007468576,0.0003530968,0.0009892134,0.0014095427,0.00015214084,0.00007744427,0.00006577468,0.0007931847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941064,0.0009109007,0.0025116492,0.0009218822,0.0005405477,0.0010085792],"domain_scores_gemma":[0.9947692,0.00043910122,0.0018015233,0.0008539572,0.0009989141,0.0011373146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026610126,0.00057619304,0.0020789464,0.00048517835,0.00047907454,0.00012199107,0.0011458669,0.0011714331,0.00035606863],"category_scores_gemma":[0.0016857411,0.00046444853,0.0006885874,0.00042095274,0.0005092765,0.00010234645,0.00030670696,0.0016707247,0.000029918181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009361154,0.004214338,0.909186,0.00003777416,0.007905422,0.0015529502,0.0023062618,0.043481063,0.0017926863,0.0000429332,0.001232749,0.018886657],"study_design_scores_gemma":[0.013947687,0.023109486,0.93919706,0.0001244705,0.0018035687,0.00038840534,0.0030428912,0.004373601,0.00033947997,0.00012786886,0.012659355,0.000886145],"about_ca_topic_score_codex":0.008562919,"about_ca_topic_score_gemma":0.033832427,"teacher_disagreement_score":0.039107464,"about_ca_system_score_codex":0.0010892339,"about_ca_system_score_gemma":0.0037663276,"threshold_uncertainty_score":0.9997807},"labels":[],"label_agreement":null},{"id":"W2626200828","doi":"10.1200/jco.2017.35.18_suppl.lba3","title":"LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Androgen deprivation therapy; Internal medicine; Interim analysis; Docetaxel; Prednisone; Randomization; Oncology; Hypokalemia; Randomized controlled trial; Adverse effect; Progression-free survival; Cancer; Urology; Chemotherapy","score_opus":0.18564204016041563,"score_gpt":0.5032530866104884,"score_spread":0.31761104645007276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626200828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877079,0.0017134049,0.00023630643,0.004029013,0.0004732638,0.0056981123,0.000030521194,0.000009102936,0.00010235186],"genre_scores_gemma":[0.93872774,0.05743632,0.0023207564,0.00012254257,0.00044667377,0.00042525836,0.000018144856,0.000032627548,0.0004699157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99441975,0.0011709878,0.0030117251,0.00032642542,0.0006817096,0.0003894151],"domain_scores_gemma":[0.99016863,0.0030100173,0.005355313,0.0004155848,0.00069330115,0.00035716745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069685816,0.00027746643,0.0037769505,0.00026141768,0.00013083128,0.000048009766,0.00032406524,0.00025500794,0.00007934757],"category_scores_gemma":[0.0019289178,0.00014233633,0.00039436077,0.00018594555,0.00080258976,0.00038258522,0.00006554482,0.0009757531,0.0000023257617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89850956,0.0041672494,0.0046669506,0.000040817788,0.0028756578,0.0013306105,0.0009708041,0.00024577434,0.00018419985,0.000007790103,0.00018645341,0.08681415],"study_design_scores_gemma":[0.94306713,0.04901784,0.0039648144,0.00023526144,0.0011555462,0.000042985586,0.00012037675,0.0004260209,0.0010137436,0.00017694893,0.0006378891,0.00014143022],"about_ca_topic_score_codex":0.0013675047,"about_ca_topic_score_gemma":0.00083964074,"teacher_disagreement_score":0.086672716,"about_ca_system_score_codex":0.00031263675,"about_ca_system_score_gemma":0.005584161,"threshold_uncertainty_score":0.9906061},"labels":[],"label_agreement":null},{"id":"W2626313564","doi":"10.1200/jco.2013.31.15_suppl.10048","title":"Targeting apoptosis and autophagy by a novel bcl-2 inhibitor, GX15-070, in neuroblastoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Computer Research Institute of Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Apoptosis; Annexin; Programmed cell death; Autophagy; Cancer research; In vivo; Neuroblastoma; Medicine; Viability assay; Cisplatin; Caspase 3; Annexin A5; Cell culture; MTT assay; Biology; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.06657121509587773,"score_gpt":0.4261290595063224,"score_spread":0.3595578444104447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626313564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901438,0.00032147847,0.000046863406,0.007889326,0.00045975097,0.0002973473,0.0000028641707,0.000010791133,0.0008278209],"genre_scores_gemma":[0.99420583,0.0006389158,0.0023777445,0.0019162181,0.00044432428,0.0000104718265,0.0000017076205,0.000022669297,0.00038210492],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968124,0.00032011338,0.0018314589,0.00024955146,0.00039392896,0.00039256294],"domain_scores_gemma":[0.9963659,0.0017943379,0.0007440448,0.00013026205,0.0002684842,0.0006969712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001263128,0.00016016999,0.0011300842,0.0002030811,0.000037019334,0.000021827671,0.00012066059,0.0002728967,0.00015285908],"category_scores_gemma":[0.0038920871,0.000113017406,0.00020766548,0.00018378555,0.0002054275,0.00022526631,0.000102654514,0.0012360074,0.000059830585],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007419234,0.019044638,0.12587276,0.00019467618,0.0008465408,0.0026622682,0.00023582792,0.000019699934,0.40172338,0.000077845965,0.14233112,0.299572],"study_design_scores_gemma":[0.0771917,0.08111968,0.7342302,0.0005785913,0.00038149874,0.0024090568,0.00030542703,0.0020236603,0.016201926,0.0005555985,0.084483445,0.00051917497],"about_ca_topic_score_codex":0.00006190974,"about_ca_topic_score_gemma":0.0000070248807,"teacher_disagreement_score":0.6083575,"about_ca_system_score_codex":0.00009867905,"about_ca_system_score_gemma":0.00056184985,"threshold_uncertainty_score":0.53699064},"labels":[],"label_agreement":null},{"id":"W2626410750","doi":"10.1200/jco.2017.35.15_suppl.tps9106","title":"METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Clinical endpoint; Neurocognitive; Internal medicine; Lung cancer; Oncology; Population; Clinical trial; Radiation therapy","score_opus":0.2105185691402989,"score_gpt":0.5282297054838134,"score_spread":0.31771113634351456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626410750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878515,0.00031869378,0.00015563409,0.010220974,0.000561699,0.0004688262,0.000033775897,0.0000037809232,0.00038514176],"genre_scores_gemma":[0.994239,0.00007589858,0.0042209877,0.00065330777,0.0006969498,0.000022490869,0.000004823839,0.000014529558,0.00007201322],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972855,0.00029933572,0.0017612105,0.00018565038,0.0003047245,0.00016360014],"domain_scores_gemma":[0.9884985,0.007381772,0.0029533068,0.00042487629,0.00045141552,0.00029012945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002510996,0.00013661705,0.002079013,0.00008481374,0.00007893022,0.000016397222,0.0001908088,0.00018265906,0.0003005177],"category_scores_gemma":[0.0075641703,0.00007876769,0.00052232575,0.00003932575,0.00016199275,0.000107592525,0.00003814997,0.00030037534,0.000003769024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037825823,0.072705306,0.39772847,0.00003493539,0.009016741,0.00468795,0.00029497582,0.0000058565406,0.0003618608,0.00007150355,0.058619812,0.41864678],"study_design_scores_gemma":[0.20836332,0.21505322,0.4728611,0.0003757923,0.008865995,0.00032111778,0.0012563138,0.000066982946,0.0016951107,0.00041712928,0.090499066,0.0002248405],"about_ca_topic_score_codex":0.00010792338,"about_ca_topic_score_gemma":0.00013229763,"teacher_disagreement_score":0.41842192,"about_ca_system_score_codex":0.000036417587,"about_ca_system_score_gemma":0.0006388279,"threshold_uncertainty_score":0.9055565},"labels":[],"label_agreement":null},{"id":"W2626656823","doi":"10.1200/jco.2014.32.15_suppl.tps11136","title":"A prospective study to compare qPCR to IHC and FISH for the detection of anaplastic lymphoma kinase (ALK) fusions in FFPE specimens from NSCLC patients (<i>PCRTALK</i>).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Foundation; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Medicine; Lung cancer; Oncology; ALK inhibitor; Internal medicine; Ceritinib; Cancer; ROS1; Alectinib; Clinical trial; Pathology; Adenocarcinoma","score_opus":0.04696207987794973,"score_gpt":0.4361324568823926,"score_spread":0.3891703770044429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626656823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947712,0.00004059182,0.0008364258,0.001946894,0.0007083456,0.0013251164,0.000037461592,0.0000034523653,0.0003305036],"genre_scores_gemma":[0.9977842,0.000014251585,0.0007802296,0.00097326277,0.00035571223,0.000043838932,0.0000025954475,0.000010161532,0.000035768626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998275,0.00016458085,0.0010505458,0.0001779497,0.00019808013,0.0001338776],"domain_scores_gemma":[0.9958907,0.002831482,0.0004905687,0.00013995732,0.00041036517,0.00023697046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062884414,0.00009967119,0.0007474354,0.000115816074,0.000064135005,0.0000071074837,0.00007929198,0.00005545873,0.000017229682],"category_scores_gemma":[0.0027807045,0.00006081572,0.00012564135,0.00016678555,0.000054054144,0.000043748856,0.000045979035,0.00016019848,0.0000025416157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008567039,0.006408554,0.8198121,0.000010326954,0.0004966924,0.000025465526,0.0024707809,0.00006986472,0.00014014401,0.000020871345,0.00057725335,0.16140088],"study_design_scores_gemma":[0.016611423,0.029611152,0.94586736,0.00008257361,0.0006400879,0.000005593319,0.0012019948,0.000120321696,0.000041067975,0.00013672582,0.0056284657,0.000053254178],"about_ca_topic_score_codex":0.00027557934,"about_ca_topic_score_gemma":0.008284317,"teacher_disagreement_score":0.16134763,"about_ca_system_score_codex":0.0002133532,"about_ca_system_score_gemma":0.0002795494,"threshold_uncertainty_score":0.46228433},"labels":[],"label_agreement":null},{"id":"W2626751126","doi":"10.1200/jco.2017.72.3569","title":"Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Aspirin; Colorectal cancer; Internal medicine; KRAS; Hazard ratio; Microsatellite instability; Proportional hazards model; Population; Cancer; Oncology; Confidence interval; Allele","score_opus":0.04100215818052255,"score_gpt":0.37376226113635647,"score_spread":0.3327601029558339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626751126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998535,0.000030452871,0.0000053118097,0.00026030967,0.0006478809,0.0002948766,0.000004141273,0.0000024858869,0.00021954463],"genre_scores_gemma":[0.99915504,0.000026601721,0.00037060012,0.00017126501,0.0002334349,0.0000031315728,3.2707595e-7,0.000015183871,0.00002440841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816895,0.00026268495,0.0010182416,0.00014594769,0.0002461481,0.00015805167],"domain_scores_gemma":[0.9970577,0.00093384745,0.001416513,0.00011810241,0.00019287251,0.00028097778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024028332,0.00011091711,0.00089899177,0.00012814229,0.0000506352,0.000014681633,0.00007289802,0.00015462202,0.000018974853],"category_scores_gemma":[0.0018672126,0.0000773814,0.00006872633,0.000033321,0.00032304105,0.00023623688,0.000054950047,0.00047579827,7.378509e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005194762,0.0001595851,0.9852173,0.000055055276,0.00008687616,0.00018705615,0.00021398529,0.000012626952,0.00016442104,0.00000464989,0.000080311496,0.008623411],"study_design_scores_gemma":[0.0077672955,0.002400293,0.98838943,0.0004815241,0.00010653738,0.000016560924,0.000044865345,0.00015285962,0.00009667014,0.0000035231833,0.00046117292,0.00007924064],"about_ca_topic_score_codex":0.00013659992,"about_ca_topic_score_gemma":0.0009397407,"teacher_disagreement_score":0.00854417,"about_ca_system_score_codex":0.00005411177,"about_ca_system_score_gemma":0.00034932257,"threshold_uncertainty_score":0.3155522},"labels":[],"label_agreement":null},{"id":"W2626989451","doi":"10.1200/jco.2017.35.18_suppl.lba10012","title":"Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Sex hormone-binding globulin; Internal medicine; Genotyping; Adverse effect; Population; Hazard ratio; Gynecology; Endocrinology; Hormone; Genotype; Confidence interval; Genetics; Biology","score_opus":0.10347763390650425,"score_gpt":0.48962041007728035,"score_spread":0.3861427761707761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626989451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914024,0.00010028573,0.000031579817,0.0074276826,0.00031728303,0.00067557994,0.000016637474,0.0000052320115,0.00002332384],"genre_scores_gemma":[0.9944586,0.000028281138,0.0024121013,0.0028959278,0.000116234645,0.000024701067,0.0000018161162,0.000020172323,0.000042166594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970845,0.00034913313,0.0017615539,0.00021504085,0.00035530707,0.00023446536],"domain_scores_gemma":[0.9948705,0.001391386,0.0025248812,0.00041279805,0.000247324,0.00055313617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085408206,0.00016109289,0.0015258329,0.0001605154,0.000059899754,0.0000066600132,0.0001719619,0.000069229136,0.0000442038],"category_scores_gemma":[0.0049190586,0.00011129396,0.00033130604,0.00011638417,0.0001596559,0.00006924861,0.00003779488,0.00042302546,0.000006058443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035502065,0.0089802295,0.94509953,0.000026206242,0.00034235333,0.00064029987,0.0002629348,0.0002257087,3.495097e-7,6.7124205e-7,0.000027275555,0.04084426],"study_design_scores_gemma":[0.017353741,0.010842783,0.9706614,0.00013241336,0.000326183,0.0000050652857,0.0001487419,0.00013954156,4.6910185e-7,0.000005685223,0.00030167733,0.00008227537],"about_ca_topic_score_codex":0.0042705066,"about_ca_topic_score_gemma":0.03824661,"teacher_disagreement_score":0.040761985,"about_ca_system_score_codex":0.00023376907,"about_ca_system_score_gemma":0.0012632783,"threshold_uncertainty_score":0.9793029},"labels":[],"label_agreement":null},{"id":"W2627042863","doi":"10.1200/jco.2016.34.15_suppl.e18200","title":"Will academic and community physicians engage and share knowledge in an online physician social network? Lessons from the Radiation Oncology Community","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radiation oncology; Medicine; Medical education; Quarter (Canadian coin); Family medicine; Internal medicine; Radiation therapy","score_opus":0.5344782807099057,"score_gpt":0.6039480889203614,"score_spread":0.06946980821045579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2627042863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91013134,0.0006297847,0.000013500256,0.0856354,0.0028178797,0.00032354513,0.000034392964,0.000012045903,0.00040209095],"genre_scores_gemma":[0.98112583,0.0031094395,0.00018682572,0.0037969926,0.0117329545,0.000019926645,0.000010483442,0.0000128111,0.000004754161],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.96236414,0.035624675,0.0013161043,0.00012565473,0.00021629686,0.0003531377],"domain_scores_gemma":[0.91667575,0.081077814,0.0016118671,0.00015961325,0.00023533773,0.00023960735],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.017039282,0.0001226364,0.00086964574,0.00005145871,0.0016887449,0.00001893604,0.0005878965,0.0007996878,0.000015676611],"category_scores_gemma":[0.017953344,0.00008540138,0.00010343926,0.00025720347,0.001484424,0.0006128836,0.00013488781,0.005446529,0.0000021018095],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017477943,0.0011441836,0.09663055,0.000004799364,0.000026993606,0.0000016354143,0.08740401,6.858973e-7,0.000043884545,0.00077442185,0.0009594231,0.8128346],"study_design_scores_gemma":[0.0017154837,0.0013329069,0.86418563,0.00010078536,0.00006108024,8.917256e-7,0.04360799,0.000012481509,0.0000013122717,0.011685035,0.07720391,0.000092477225],"about_ca_topic_score_codex":0.00433575,"about_ca_topic_score_gemma":0.088968724,"teacher_disagreement_score":0.8127422,"about_ca_system_score_codex":0.0004807982,"about_ca_system_score_gemma":0.0020619917,"threshold_uncertainty_score":0.9996109},"labels":[],"label_agreement":null},{"id":"W2630601502","doi":"10.1200/jco.2017.35.15_suppl.e12030","title":"Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Internal medicine; Oncology; Breast cancer; Clinical trial; Discontinuation; Cancer; Disease; Metastatic breast cancer; Chemotherapy","score_opus":0.057735540386877116,"score_gpt":0.46763188812585477,"score_spread":0.40989634773897765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2630601502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918546,0.00033502557,7.186326e-7,0.005809155,0.00092286064,0.00032731143,0.00014670259,0.0000032141552,0.00060039107],"genre_scores_gemma":[0.9973953,0.00085327873,0.00003957256,0.0008953354,0.00045419156,0.000009190746,0.00000722135,0.000016229258,0.0003296831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976371,0.00033880412,0.001260777,0.00019256574,0.00030117863,0.00026955258],"domain_scores_gemma":[0.99589425,0.0006037674,0.0024542138,0.00016116996,0.00063122925,0.0002553955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007186647,0.00016308374,0.0016426183,0.00008273123,0.000074551404,0.000005777799,0.00016604846,0.00029500373,0.0004766163],"category_scores_gemma":[0.00028491288,0.00010670832,0.0003258347,0.00006591154,0.00035840654,0.00012147633,0.00006348413,0.00059610483,0.0000021280093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017711373,0.004728883,0.9492362,0.000021008205,0.0015648573,0.00025251,0.00018217476,0.000018443243,0.00012913313,9.661808e-7,0.0025790203,0.023575442],"study_design_scores_gemma":[0.026165439,0.0056825615,0.9653618,0.00035661462,0.0008907818,0.00002390757,0.00002118976,0.000015533058,0.00047443275,0.000007809234,0.00090685143,0.00009310452],"about_ca_topic_score_codex":0.0018198554,"about_ca_topic_score_gemma":0.0063250223,"teacher_disagreement_score":0.023482338,"about_ca_system_score_codex":0.0009858256,"about_ca_system_score_gemma":0.0014864479,"threshold_uncertainty_score":0.52186143},"labels":[],"label_agreement":null},{"id":"W2640351411","doi":"10.1200/jco.2017.35.15_suppl.2534","title":"Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Clinical trial; Progressive disease; Lung cancer; Cancer; Oncology; Target lesion; Internal medicine; Placebo; Clinical endpoint; Lesion; Chemotherapy; Radiology; Phases of clinical research; Pathology","score_opus":0.5320876877449999,"score_gpt":0.5820127522052523,"score_spread":0.049925064460252355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2640351411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956562,0.0002450984,0.00021695212,0.0009986387,0.0011486153,0.00084906124,0.00078583177,0.0000031313657,0.00009648871],"genre_scores_gemma":[0.99015313,0.002178961,0.0064641796,0.00036043726,0.0005548975,0.00002469329,0.0001747467,0.000018061146,0.00007086302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905296,0.001773768,0.006557789,0.00036738216,0.0005443227,0.00022712848],"domain_scores_gemma":[0.9732302,0.009856538,0.015355673,0.000455533,0.0007790031,0.00032306922],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013765403,0.00020262116,0.0041865627,0.00040553854,0.00008134504,0.00001588963,0.00026739525,0.0004011452,0.00010485577],"category_scores_gemma":[0.01679241,0.00013706293,0.0010020657,0.0002547781,0.0006348662,0.00018264937,0.00011866302,0.0005104772,2.2605936e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14855893,0.005701217,0.65810543,0.00010170845,0.022655673,0.00010778953,0.0004338306,0.00006737642,0.0015915892,0.000008168281,0.0059344675,0.1567338],"study_design_scores_gemma":[0.05759104,0.030291488,0.8595366,0.00057342905,0.03437845,0.000017570643,0.00011274724,0.00044092123,0.0017892732,0.00002527613,0.015093775,0.00014942947],"about_ca_topic_score_codex":0.0003965393,"about_ca_topic_score_gemma":0.0005134796,"teacher_disagreement_score":0.20143114,"about_ca_system_score_codex":0.00011101862,"about_ca_system_score_gemma":0.0008930636,"threshold_uncertainty_score":0.9914896},"labels":[],"label_agreement":null},{"id":"W2642497087","doi":"10.1200/jco.2013.31.15_suppl.1597","title":"Androgen deprivation therapy and survival in patients with lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Lung cancer; Androgen deprivation therapy; Internal medicine; Cancer; Oncology; Cancer registry; Proportional hazards model; Population; Finasteride; Hazard ratio; Epidemiology; Prostate cancer; Gynecology; Prostate; Confidence interval","score_opus":0.07602882824092337,"score_gpt":0.41845361118827545,"score_spread":0.34242478294735207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2642497087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952852,0.0005621363,0.000017986538,0.0027959668,0.0003480843,0.00023475003,0.0000010199087,0.0000023245823,0.00075250084],"genre_scores_gemma":[0.99479485,0.001568877,0.0007983699,0.0025190834,0.00026654487,0.0000047296317,0.0000021716012,0.000007593534,0.000037757218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862874,0.00013678595,0.0008448528,0.000098971606,0.00017782276,0.00011284707],"domain_scores_gemma":[0.9985573,0.00043139627,0.0005294327,0.0000713524,0.0002496096,0.00016089957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068945845,0.00006786371,0.00064224645,0.000065333945,0.000014206778,0.0000054462566,0.00004992343,0.00013678378,0.00032579107],"category_scores_gemma":[0.0002442522,0.000041551826,0.00006392018,0.000066743414,0.000076174576,0.00016271608,0.000012431406,0.0004025057,0.0000012939797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021790983,0.00023819777,0.74316776,0.0000073151896,0.000091134076,0.000012735242,0.000044887816,0.000004509729,0.000013691728,0.0000046796913,0.00054232485,0.25369367],"study_design_scores_gemma":[0.016360987,0.004467194,0.97232145,0.000036877038,0.00003417678,0.0000073423266,0.000023581175,0.00013159572,0.000011177971,0.00002719437,0.006532373,0.00004606959],"about_ca_topic_score_codex":0.00010351196,"about_ca_topic_score_gemma":0.00007609182,"teacher_disagreement_score":0.2536476,"about_ca_system_score_codex":0.000105003375,"about_ca_system_score_gemma":0.0007277568,"threshold_uncertainty_score":0.35671836},"labels":[],"label_agreement":null},{"id":"W2643935873","doi":"10.1200/jco.2017.35.15_suppl.2502","title":"Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Ceritinib; Anaplastic lymphoma kinase; Maculopapular rash; Gastroenterology; Rash; Nivolumab; Lung cancer; Oncology; Cancer; Immunotherapy","score_opus":0.027392140811896774,"score_gpt":0.42423401251126663,"score_spread":0.39684187169936985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2643935873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845832,0.00038325146,0.00012685337,0.0016700039,0.0012630705,0.0005416496,0.000032557964,0.0000065241434,0.011392881],"genre_scores_gemma":[0.99513674,0.00038490744,0.0023531686,0.0009006749,0.0005011751,0.000026534832,0.000010138979,0.000031169588,0.00065551297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758416,0.00012702684,0.001343153,0.00028903954,0.0003142934,0.0003423368],"domain_scores_gemma":[0.9959953,0.0005736854,0.002041089,0.00031407052,0.0006609173,0.0004149605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042160612,0.00020907471,0.0012694455,0.00013369933,0.00015701297,0.000027415814,0.0002334592,0.00025642494,0.00007750528],"category_scores_gemma":[0.0006551793,0.00014702795,0.0002469898,0.00008203192,0.00021401144,0.00025310935,0.000061013292,0.0004844449,0.00000825675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01899625,0.004496125,0.7297627,0.00009121026,0.0006210558,0.0021852572,0.00056888023,0.00020795682,0.000031059335,0.000017241184,0.0009156813,0.2421066],"study_design_scores_gemma":[0.07440897,0.017161733,0.903014,0.0007851394,0.0009682703,0.000044605207,0.00018897891,0.0002669863,0.00007316298,0.000015990656,0.0029158387,0.00015633737],"about_ca_topic_score_codex":0.00037825885,"about_ca_topic_score_gemma":0.001041614,"teacher_disagreement_score":0.24195026,"about_ca_system_score_codex":0.0011161634,"about_ca_system_score_gemma":0.004505341,"threshold_uncertainty_score":0.79922813},"labels":[],"label_agreement":null},{"id":"W2645449880","doi":"10.1200/jco.2017.35.15_suppl.2515","title":"Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; GiST; Internal medicine; Pharmacokinetics; Gastroenterology; Adverse effect; Stromal tumor; Pharmacology; Oncology; Stromal cell","score_opus":0.1028304573164567,"score_gpt":0.4837185445224928,"score_spread":0.3808880872060361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2645449880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983905,0.000035582936,0.00001406212,0.00059365697,0.00008371004,0.00060677796,0.000012549007,0.0000044608273,0.00025869018],"genre_scores_gemma":[0.9959536,0.000010467355,0.0035578094,0.00010738844,0.00030708627,0.000008746187,0.0000010363881,0.000022633954,0.000031218355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967231,0.00033328644,0.0017416647,0.00029268744,0.0005374498,0.00037181037],"domain_scores_gemma":[0.9959196,0.0007405662,0.001994381,0.00025425988,0.00045799502,0.0006332297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001236113,0.00021943613,0.0015451894,0.000177218,0.000077381046,0.00002819158,0.00019076554,0.00004312873,0.00003972209],"category_scores_gemma":[0.002878075,0.0001419792,0.00011653317,0.000057665624,0.0006212109,0.00013278947,0.00015316054,0.00088533625,0.0000023261541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02361343,0.017958552,0.939298,0.000050191,0.00019841712,0.006370694,0.00011715948,0.000002354585,0.00035818203,0.000004324298,0.00009862867,0.011930102],"study_design_scores_gemma":[0.06834904,0.19353242,0.73410195,0.00053635944,0.0002684743,0.0024971138,0.0003294704,0.00013138469,0.00008330871,0.000015086864,0.00008146689,0.00007390855],"about_ca_topic_score_codex":0.00013863345,"about_ca_topic_score_gemma":0.0001418537,"teacher_disagreement_score":0.205196,"about_ca_system_score_codex":0.000088913555,"about_ca_system_score_gemma":0.0006429869,"threshold_uncertainty_score":0.57897437},"labels":[],"label_agreement":null},{"id":"W2648056393","doi":"10.1200/jco.2013.31.15_suppl.e15153","title":"Experience with perioperative chemotherapy (ECC or ECF) for gastroesophageal cancer in British Columbia: A multicenter experience.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Perioperative; Surgery; Chemotherapy; Esophageal cancer; Cancer; Cohort; Internal medicine","score_opus":0.07141751020716762,"score_gpt":0.4456009974040795,"score_spread":0.37418348719691186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2648056393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940195,0.00015224087,0.00029681626,0.0037077097,0.0006727813,0.000886244,0.0000034299915,0.000007781496,0.0002534776],"genre_scores_gemma":[0.981497,0.0006412369,0.007387637,0.0060850475,0.000783371,0.00025422554,8.3829565e-7,0.000019928693,0.003330732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975884,0.00009284825,0.0014548093,0.00024728978,0.00027750796,0.00033912717],"domain_scores_gemma":[0.99794585,0.0005135758,0.0007177058,0.00012823021,0.00042656282,0.00026809465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005295813,0.00011700971,0.0011756513,0.000058113892,0.000049828494,0.00008173715,0.00017800738,0.00014989328,0.0036743395],"category_scores_gemma":[0.000640681,0.00009827201,0.00022391081,0.00016330212,0.00028836913,0.00029449703,0.00003235434,0.00044284321,0.0000035311903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026921304,0.0007353224,0.8686377,0.000025642723,0.00013400184,0.00045607184,0.0017285355,0.000009079595,0.000036481946,9.424012e-7,0.0053390483,0.12020509],"study_design_scores_gemma":[0.022268845,0.009490691,0.9417665,0.00018544562,0.00007172051,0.00016186887,0.005369262,0.00027982864,0.000018686982,0.000005673128,0.020283265,0.00009819587],"about_ca_topic_score_codex":0.0026022864,"about_ca_topic_score_gemma":0.02648942,"teacher_disagreement_score":0.12010689,"about_ca_system_score_codex":0.00020771247,"about_ca_system_score_gemma":0.00077907194,"threshold_uncertainty_score":0.99723643},"labels":[],"label_agreement":null},{"id":"W2651525809","doi":"10.1200/jco.2017.72.7511","title":"Response Assessment in Neuro-Oncology Clinical Trials","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Western University","funders":"National Cancer Institute; U.S. Food and Drug Administration","keywords":"Medicine; Clinical trial; Oncology; Internal medicine; Brain tumor; Drug development; Clinical Oncology; Medical physics; Cancer; Pathology; Drug; Pharmacology","score_opus":0.7407465676954813,"score_gpt":0.7153127173227363,"score_spread":0.025433850372745037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2651525809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001592541,0.9691104,0.00000888441,0.014873103,0.010110709,0.0017414256,0.000022554683,0.000011695784,0.0025286472],"genre_scores_gemma":[0.0004289474,0.99079573,0.00203669,0.002019871,0.004418325,0.00007965453,0.000012130527,0.00007153256,0.00013713207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.91922635,0.05278198,0.025818123,0.0007818224,0.00078636105,0.0006053416],"domain_scores_gemma":[0.79037565,0.17497961,0.031266566,0.0012576217,0.0006438176,0.0014767089],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.16841158,0.00061648374,0.03087292,0.00082251773,0.00007499231,0.000041668092,0.0008028505,0.0040799016,0.00029873117],"category_scores_gemma":[0.22430612,0.0003629454,0.009073605,0.00020978217,0.0005547882,0.000111804,0.0002737064,0.00763878,0.00011956151],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006444491,0.010089772,0.00459952,0.0005807834,0.0021852066,0.025257435,0.0000075716985,2.9074798e-7,4.1079886e-7,0.000051809522,0.015749117,0.9350336],"study_design_scores_gemma":[0.01963475,0.033798203,0.021869829,0.006350739,0.008916266,0.0021848292,0.000013047965,0.0000035455569,1.1174301e-7,0.00008088004,0.90692896,0.00021885072],"about_ca_topic_score_codex":0.000009646818,"about_ca_topic_score_gemma":0.000036087647,"teacher_disagreement_score":0.93481475,"about_ca_system_score_codex":0.0011852385,"about_ca_system_score_gemma":0.03189562,"threshold_uncertainty_score":0.9998823},"labels":[],"label_agreement":null},{"id":"W2654215783","doi":"10.1200/jco.2016.34.15_suppl.1532","title":"Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Germline; MUTYH; Medicine; CDKN2A; CHEK2; PALB2; Genetic testing; Cancer; Germline mutation; BAP1; Li–Fraumeni syndrome; Lynch syndrome; PTEN; Colorectal cancer; MLH1; Genetics; Oncology; Internal medicine; Gene; DNA mismatch repair; Biology; Mutation","score_opus":0.04783166040565423,"score_gpt":0.42724660074494614,"score_spread":0.3794149403392919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2654215783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966695,0.00043955402,0.00040683575,0.00064677664,0.0013520713,0.00039354863,0.000031139036,0.000002904454,0.000057702237],"genre_scores_gemma":[0.99341613,0.001391685,0.0036207815,0.0005950443,0.0007857275,0.000057145127,0.000009806205,0.000021171725,0.000102495294],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99772,0.000084991734,0.0016016166,0.00022071533,0.00011846805,0.0002541798],"domain_scores_gemma":[0.9979326,0.000534314,0.00095906045,0.00013280337,0.0002902592,0.00015097366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011034848,0.00012124774,0.0005743724,0.000072890565,0.000028404871,0.000011926415,0.00023170654,0.00026490507,0.000018381028],"category_scores_gemma":[0.0030831837,0.00008623597,0.0003035349,0.00005218978,0.00009854328,0.000011646709,0.00009445655,0.00015932022,0.0000028669303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029587597,0.0012336216,0.23543243,0.000046897938,0.00020850028,0.00003346672,0.00007569823,0.0001318456,0.26110134,0.00004818857,0.0025901333,0.4961391],"study_design_scores_gemma":[0.051754694,0.034000125,0.69306946,0.00052868074,0.00033157846,0.000071761635,0.00019445781,0.00021694315,0.04879383,0.0024992584,0.16771236,0.0008268742],"about_ca_topic_score_codex":0.000018915482,"about_ca_topic_score_gemma":0.0005258216,"teacher_disagreement_score":0.49531224,"about_ca_system_score_codex":0.00027786844,"about_ca_system_score_gemma":0.0011735046,"threshold_uncertainty_score":0.36910814},"labels":[],"label_agreement":null},{"id":"W2654683002","doi":"10.1200/jco.2016.34.15_suppl.e20510","title":"Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Erlotinib; Gastroenterology; Population; Lung cancer; Clinical trial; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.17038854741746326,"score_gpt":0.5311208798933007,"score_spread":0.36073233247583747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2654683002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98453456,0.001096457,0.00006726407,0.003886398,0.001002534,0.008412193,0.00017259187,0.0000014346866,0.00082656386],"genre_scores_gemma":[0.99805844,0.00019658309,0.0007233213,0.000071896124,0.00031553302,0.0003682344,0.000004218675,0.000014927184,0.00024686463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99445575,0.0014651116,0.003121031,0.00017908288,0.00060302985,0.00017596234],"domain_scores_gemma":[0.97789544,0.015954204,0.004561943,0.0004240276,0.0010916017,0.00007277306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007971409,0.00017805764,0.0019218598,0.00007404013,0.000047013542,0.000004249784,0.00037347866,0.00017384464,0.00011425414],"category_scores_gemma":[0.0071854936,0.000064276595,0.0006135087,0.00016634117,0.00041524752,0.000093046656,0.000036336853,0.0001950369,2.8160855e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89650047,0.01847649,0.0024719446,0.00012360205,0.0009974127,0.000008875096,0.0011106528,0.00008308278,0.003412651,0.000059817972,0.00041080534,0.07634417],"study_design_scores_gemma":[0.9153643,0.06293303,0.0050073634,0.00012845403,0.006550462,0.000011928127,0.0004213022,0.0009531076,0.007824227,0.00016875195,0.00057786424,0.000059192702],"about_ca_topic_score_codex":0.00005666981,"about_ca_topic_score_gemma":0.00014556188,"teacher_disagreement_score":0.076284975,"about_ca_system_score_codex":0.0003143561,"about_ca_system_score_gemma":0.0042943307,"threshold_uncertainty_score":0.8602226},"labels":[],"label_agreement":null},{"id":"W2654698479","doi":"10.1200/jco.2016.34.15_suppl.e12024","title":"Utilization of the 21-gene assay for breast cancer treatment decision-making in Alberta.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Logistic regression; Cancer; Lymph node; Oncology; Gynecology","score_opus":0.0634211393408942,"score_gpt":0.4394451935015541,"score_spread":0.37602405416065987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2654698479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98843646,0.0005768301,0.005140908,0.0041382485,0.0013056807,0.0001603626,0.00007723113,3.955667e-7,0.00016390569],"genre_scores_gemma":[0.9943864,0.0033143929,0.001091777,0.00042791816,0.00066632236,0.0000074685745,8.859541e-7,0.000008811036,0.00009602387],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99864906,0.00010726088,0.00093172194,0.00012037496,0.0000798271,0.00011175544],"domain_scores_gemma":[0.99678695,0.001947589,0.0008300481,0.00014993179,0.00023116883,0.000054309425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007792487,0.00007195361,0.00036807611,0.00002740342,0.00001798276,0.0000028389265,0.0001604305,0.00020204642,0.000024060517],"category_scores_gemma":[0.0027681983,0.00003625036,0.00027709466,0.000045897563,0.00007607941,0.0000030357605,0.000048020916,0.000054730022,4.4571593e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020455695,0.00044522097,0.0895037,0.000003862822,0.00010944654,0.000002681572,0.000019138699,0.00024791475,0.012187311,0.000112555426,0.0013747503,0.89394784],"study_design_scores_gemma":[0.013617235,0.0074645756,0.64698625,0.0003741769,0.00025883803,0.00011334411,0.000038587175,0.00018088607,0.03893648,0.003720073,0.28806952,0.00024003924],"about_ca_topic_score_codex":0.00005359082,"about_ca_topic_score_gemma":0.0026251092,"teacher_disagreement_score":0.8937078,"about_ca_system_score_codex":0.00009810059,"about_ca_system_score_gemma":0.0009963671,"threshold_uncertainty_score":0.33139917},"labels":[],"label_agreement":null},{"id":"W2658615277","doi":"10.1200/jco.2013.31.15_suppl.5508","title":"Screening for Lynch syndrome in unselected women with endometrial cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lynch syndrome; Medicine; MSH6; Endometrial cancer; MLH1; Germline mutation; Prospective cohort study; Family history; Internal medicine; Population; Cancer; Gynecology; Oncology; Cohort; Gastroenterology; Mutation; Colorectal cancer; Genetics; DNA mismatch repair; Biology","score_opus":0.13281795392258497,"score_gpt":0.45934925843189567,"score_spread":0.32653130450931067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2658615277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354553,0.00029760494,0.00063277915,0.0032871754,0.0011558741,0.0007050162,0.000003107642,0.000008331976,0.00036458767],"genre_scores_gemma":[0.98041,0.00014170639,0.017038846,0.0011569171,0.0008877619,0.00012400885,0.0000012559296,0.00002449805,0.00021501712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99698526,0.00021734653,0.0018326998,0.00019656683,0.00036003473,0.00040811618],"domain_scores_gemma":[0.9937834,0.0039333655,0.0011272137,0.00013027008,0.00061780424,0.00040792878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022042298,0.00013816365,0.0015697995,0.00029328594,0.000022896866,0.000010287322,0.00017040482,0.0003514921,0.00078241795],"category_scores_gemma":[0.00522762,0.00009172725,0.00018146835,0.00046084545,0.00015285333,0.000089733825,0.000025984784,0.0008849191,0.0000058619394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049258176,0.0015428207,0.38695526,0.00010175928,0.0011363749,0.0006088632,0.00030980274,0.0002987806,0.0017483952,0.000018509822,0.0069747684,0.5510465],"study_design_scores_gemma":[0.034123857,0.07517603,0.86874235,0.00020965343,0.00017817836,0.0008475905,0.00016910877,0.00026048938,0.00021885731,0.0003362492,0.019577937,0.00015969359],"about_ca_topic_score_codex":0.000103253624,"about_ca_topic_score_gemma":0.00013094403,"teacher_disagreement_score":0.5508868,"about_ca_system_score_codex":0.00047394144,"about_ca_system_score_gemma":0.0022623404,"threshold_uncertainty_score":0.8566928},"labels":[],"label_agreement":null},{"id":"W2659827805","doi":"10.1200/jco.2017.35.15_suppl.e12538","title":"Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Exemestane; Everolimus; Internal medicine; Metastatic breast cancer; Breast cancer; Cohort; Oncology; Adverse effect; Population; Cancer; Progression-free survival; Toxicity; Letrozole; Aromatase inhibitor; Chemotherapy; Aromatase","score_opus":0.08937730650384973,"score_gpt":0.5096555776797362,"score_spread":0.4202782711758865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2659827805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979849,0.00050329586,0.0009626646,0.015858797,0.0008610622,0.00039366807,0.000027523272,0.000012082007,0.0015319097],"genre_scores_gemma":[0.97744113,0.0013451233,0.017778793,0.0013175589,0.0013461501,0.000034636738,8.9659494e-7,0.000027652946,0.00070804614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980661,0.00007521534,0.0010551758,0.0002563092,0.0002587778,0.000288378],"domain_scores_gemma":[0.9953505,0.0009842234,0.002213257,0.0003059529,0.0007381422,0.00040792036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007214122,0.00016880568,0.0012972628,0.000069800306,0.00017996828,0.000019746361,0.00022055903,0.00014439937,0.000045985627],"category_scores_gemma":[0.0005955244,0.00011156541,0.00017590744,0.000051145435,0.0008338769,0.00039098877,0.00005378771,0.0005223156,7.6451573e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062055815,0.00042183057,0.15472671,0.000038306902,0.00037636491,0.00046236007,0.0004726999,0.000017358838,0.0010132034,0.00023938356,0.00010998778,0.78006595],"study_design_scores_gemma":[0.019206231,0.009166507,0.9497355,0.00047778,0.00029281015,0.0015271504,0.00032563848,0.000042021074,0.00032996095,0.0005552138,0.01818363,0.0001575318],"about_ca_topic_score_codex":0.00007693442,"about_ca_topic_score_gemma":0.00041369098,"teacher_disagreement_score":0.79500884,"about_ca_system_score_codex":0.00020620019,"about_ca_system_score_gemma":0.001083088,"threshold_uncertainty_score":0.45495054},"labels":[],"label_agreement":null},{"id":"W2663821008","doi":"10.1200/jco.2017.35.15_suppl.2562","title":"Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of <sup>177</sup>Lu DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prospective cohort study; Internal medicine; Oncology; Biomarker; Nuclear medicine; Urology","score_opus":0.12194362726192376,"score_gpt":0.4982053091989315,"score_spread":0.37626168193700776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2663821008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905955,0.00032263165,0.000003006561,0.0060180114,0.00014345458,0.0017226685,0.00013706813,0.00000411945,0.0010535191],"genre_scores_gemma":[0.99644446,0.0019228131,0.0005796679,0.00008695248,0.00027335755,0.000088636654,0.000008052703,0.00003355244,0.0005625196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950594,0.0006923695,0.0025472967,0.00043888926,0.0007630959,0.0004989689],"domain_scores_gemma":[0.99465793,0.0011611697,0.0028042844,0.00043123026,0.00055237877,0.000392983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003611652,0.00030516263,0.002605238,0.00038199514,0.00007527873,0.000030341163,0.00028930523,0.00011703592,0.00007773341],"category_scores_gemma":[0.0015456578,0.00018836102,0.00027053247,0.0001859352,0.00062829896,0.00024491872,0.000090671594,0.0014106069,0.0000013096113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5782507,0.008417604,0.37108845,0.0005057979,0.0012808933,0.01679315,0.0015972155,0.000090887355,0.0005546989,0.000106878964,0.00039621344,0.020917522],"study_design_scores_gemma":[0.527439,0.13056874,0.32929435,0.0027844568,0.000962662,0.0006695487,0.0034327824,0.00045936505,0.0021335464,0.00065625797,0.0012758382,0.00032346445],"about_ca_topic_score_codex":0.0008210778,"about_ca_topic_score_gemma":0.0034982716,"teacher_disagreement_score":0.122151144,"about_ca_system_score_codex":0.00040071635,"about_ca_system_score_gemma":0.0031543202,"threshold_uncertainty_score":0.7681139},"labels":[],"label_agreement":null},{"id":"W2665750361","doi":"10.1200/jco.2016.34.15_suppl.e12079","title":"Outcomes of chemotherapy/trastuzumab treated locally advanced HER2+ breast cancer in British Columbia between 2005 and 2010.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Cohort; Chemotherapy; Oncology; Cancer; Stage (stratigraphy); Gynecology","score_opus":0.024109134984418246,"score_gpt":0.3726809687984157,"score_spread":0.3485718338139975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2665750361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338174,0.0011361071,0.00006130948,0.004813901,0.00027103612,0.00011628869,0.00014874096,0.0000028473073,0.00006801443],"genre_scores_gemma":[0.9905732,0.0076687434,0.00046828043,0.0003480842,0.0003596832,0.000008105039,0.0000023130633,0.000018691973,0.0005528879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978939,0.00017652263,0.00129853,0.00024261173,0.0001445956,0.00024381837],"domain_scores_gemma":[0.9981713,0.00036017812,0.0009303383,0.00013915113,0.00024289908,0.0001560903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006124569,0.0001232697,0.00111553,0.000031654356,0.00002526432,0.000009026768,0.00015919161,0.0003191011,0.000117513446],"category_scores_gemma":[0.0002774231,0.000107684,0.00021135675,0.00005827042,0.00035466152,0.000012738186,0.00006547198,0.00016849102,9.408608e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047130103,0.0002972228,0.66529375,0.0000050801564,0.0004107937,0.000020253672,0.0000074321574,0.0000014364726,0.00092266646,2.9278726e-7,0.0013264568,0.33124328],"study_design_scores_gemma":[0.010681979,0.0014826758,0.9821291,0.000116704316,0.00009792273,0.000091882364,0.000032636104,3.5093487e-7,0.00027194025,0.00006293638,0.0049163834,0.0001154893],"about_ca_topic_score_codex":0.0025197724,"about_ca_topic_score_gemma":0.051667348,"teacher_disagreement_score":0.3311278,"about_ca_system_score_codex":0.00009376938,"about_ca_system_score_gemma":0.00048913836,"threshold_uncertainty_score":0.96563727},"labels":[],"label_agreement":null},{"id":"W2666786416","doi":"10.1200/jco.2017.35.15_suppl.1548","title":"Use of a marketing plan for recruitment to a lung cancer screening study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ontario Clinical Oncology Group; Memorial University of Newfoundland; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; BC Cancer Agency; Brock University; University of Calgary; Princess Margaret Cancer Centre; Toronto Metropolitan University; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lung cancer; Newsprint; Lung cancer screening; Family medicine; Psychological intervention; Surgery; Internal medicine; Nursing","score_opus":0.8420284548449493,"score_gpt":0.6988236664625629,"score_spread":0.14320478838238637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2666786416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545102,0.00010183434,0.00020406314,0.031350356,0.011292036,0.002229071,0.0000040843815,0.000004019426,0.00030432618],"genre_scores_gemma":[0.97170126,0.00034653084,0.020625023,0.0007262165,0.0061183316,0.00038199467,1.9153755e-7,0.000010515546,0.00008994698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574524,0.0018683947,0.0016154377,0.00013012458,0.00038910817,0.0002516877],"domain_scores_gemma":[0.9604301,0.034935337,0.0033953735,0.00015801803,0.00071404246,0.00036712526],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025617704,0.0000611737,0.0007066742,0.00007404522,0.00047581055,0.000040255025,0.000406553,0.00020196813,0.000049447437],"category_scores_gemma":[0.2149255,0.000053131924,0.00018226328,0.00006692247,0.00017940096,0.0002201215,0.000055235843,0.00032753742,6.4348603e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014634342,0.00036002163,0.56127477,0.000012921535,0.0000768038,0.000004190431,0.008002907,0.000007938631,0.0000028421716,0.000051709943,0.0028886306,0.42585385],"study_design_scores_gemma":[0.00096120173,0.0016604769,0.75980836,0.0001298542,0.00009778802,4.1934598e-7,0.003774635,0.00002888559,0.0000018574474,0.00004358796,0.2334447,0.000048245325],"about_ca_topic_score_codex":0.0043664575,"about_ca_topic_score_gemma":0.0090837125,"teacher_disagreement_score":0.4258056,"about_ca_system_score_codex":0.00028239985,"about_ca_system_score_gemma":0.0029082354,"threshold_uncertainty_score":0.8878636},"labels":[],"label_agreement":null},{"id":"W2667222187","doi":"10.1200/jco.2017.35.15_suppl.1527","title":"PALB2 mutations in high-risk women with breast or ovarian cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"PALB2; Breast cancer; Medicine; Ovarian cancer; Genetic testing; Penetrance; Oncology; Cancer; BRCA mutation; Genetic counseling; Family history; Internal medicine; Gynecology; Mutation; Germline mutation; Genetics; Gene; Biology; Phenotype","score_opus":0.053364360729387404,"score_gpt":0.4323545870834417,"score_spread":0.3789902263540543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2667222187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926052,0.00011158399,0.0004377969,0.004999773,0.0009684435,0.00009499867,0.000037115173,0.0000019727922,0.00074312213],"genre_scores_gemma":[0.9918377,0.0008210052,0.005001088,0.00052078586,0.001370985,0.000026151733,0.000003469796,0.000016956214,0.00040188592],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99816096,0.00025851344,0.0009949855,0.00020797104,0.00015363334,0.0002239087],"domain_scores_gemma":[0.9970173,0.00021407411,0.0018818374,0.00037485122,0.00033196458,0.00017996394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016051767,0.00010934397,0.0005209432,0.00005754018,0.00012997723,0.000030096126,0.00044074154,0.00030952867,0.0001553786],"category_scores_gemma":[0.0016924002,0.0000738185,0.000089657966,0.000058740825,0.00033577965,0.000015245722,0.00008393599,0.0004771775,0.000004773756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009838209,0.0007886351,0.48234433,0.000013231317,0.0006969347,0.0003106195,0.0002677663,0.0019002807,0.0011357013,0.00007893736,0.003671449,0.4989539],"study_design_scores_gemma":[0.006529335,0.004959976,0.94515884,0.000032101685,0.000082975705,0.0002616442,0.00022534971,0.000029352306,0.0002877374,0.0004822736,0.041814566,0.00013586476],"about_ca_topic_score_codex":0.0002604156,"about_ca_topic_score_gemma":0.004321046,"teacher_disagreement_score":0.49881804,"about_ca_system_score_codex":0.00018879493,"about_ca_system_score_gemma":0.0035589265,"threshold_uncertainty_score":0.6313383},"labels":[],"label_agreement":null},{"id":"W2667350721","doi":"10.1200/jco.2017.35.15_suppl.e12573","title":"Feasibility and preliminary results of A Lifestyle Intervention via Email (ALIVE) in minority breast cancer survivors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Ethnic group; Psychological intervention; Randomized controlled trial; Cancer; Gerontology; African american; Intervention (counseling); Physical activity; Survivorship curve; Ethnically diverse; Descriptive statistics; Physical therapy; Demography; Internal medicine; Population; Psychiatry","score_opus":0.21608910224812275,"score_gpt":0.5891488429291531,"score_spread":0.3730597406810304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2667350721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97852993,0.0007603709,0.00008258146,0.015843453,0.0017547297,0.0010995382,0.00009362852,0.0000058118812,0.0018299839],"genre_scores_gemma":[0.99364704,0.0038610345,0.000547137,0.00066876895,0.00085438276,0.00015993153,0.0000031204195,0.000008049041,0.00025054475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99193376,0.0023101803,0.0049196477,0.00026296696,0.00021563246,0.00035783602],"domain_scores_gemma":[0.98693043,0.004077527,0.007233085,0.0004902889,0.0007194198,0.00054924353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015449016,0.000113826805,0.0012237689,0.0001046954,0.00033547546,0.0000039568426,0.00034123863,0.0005980463,0.0001036671],"category_scores_gemma":[0.0067364164,0.00009052064,0.00020118062,0.000071031085,0.00033427833,0.00020597254,0.00018864732,0.0016557459,0.000008567179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008799728,0.0012161395,0.82367295,0.00048374565,0.000018940027,0.00001177186,0.00019996738,0.0000012271394,0.0000043551254,0.0001405558,0.0022506071,0.16320002],"study_design_scores_gemma":[0.00821761,0.0022291818,0.96989065,0.0004111507,0.000049428614,0.000020353586,0.0001831266,0.000113753325,0.0000010530383,0.001029928,0.017794471,0.000059303933],"about_ca_topic_score_codex":0.017637832,"about_ca_topic_score_gemma":0.051144164,"teacher_disagreement_score":0.16314071,"about_ca_system_score_codex":0.00024750063,"about_ca_system_score_gemma":0.0022516744,"threshold_uncertainty_score":0.9889038},"labels":[],"label_agreement":null},{"id":"W2675199969","doi":"10.1200/jco.2017.35.15_suppl.2029","title":"Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Neurocognitive; Sensorineural hearing loss; Hearing loss; Prospective cohort study; Cohort; Pediatrics; Audiology; Surgery; Internal medicine; Cognition; Psychiatry","score_opus":0.12215381249386094,"score_gpt":0.4546360222019222,"score_spread":0.33248220970806125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2675199969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904432,0.000119895274,0.000002365519,0.008519579,0.0002139542,0.00032448795,0.000009949814,0.000003106454,0.0003634607],"genre_scores_gemma":[0.99826235,0.0001286302,0.00044514245,0.00061503117,0.00044372675,0.000013228452,0.0000018200193,0.000017042052,0.00007305764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973053,0.0001969731,0.0017543482,0.0002149148,0.00028424864,0.0002442704],"domain_scores_gemma":[0.99676955,0.0007824072,0.0016856722,0.00026912845,0.00021589539,0.00027737653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065669167,0.00018192841,0.0017269714,0.00014010759,0.000040925763,0.000013170896,0.00010397111,0.00014577313,0.000048520473],"category_scores_gemma":[0.00092174544,0.00010330952,0.0004405861,0.000044890196,0.00027081333,0.00009944039,0.00004611277,0.0003402947,0.000006773359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004090928,0.004411227,0.95795184,0.000008925665,0.0004907768,0.008271771,0.000054348235,0.000007893053,0.000065748376,0.000017546778,0.000025079255,0.024603922],"study_design_scores_gemma":[0.020126726,0.022159945,0.95404154,0.00016115367,0.00037720258,0.0022123083,0.00002521729,0.000012156014,0.00048464356,0.00002984948,0.0002870755,0.000082207844],"about_ca_topic_score_codex":0.00010297014,"about_ca_topic_score_gemma":0.000107812106,"teacher_disagreement_score":0.024521714,"about_ca_system_score_codex":0.00012823506,"about_ca_system_score_gemma":0.0003996195,"threshold_uncertainty_score":0.421284},"labels":[],"label_agreement":null},{"id":"W2681416368","doi":"10.1200/jco.2016.34.15_suppl.1576","title":"Breast cancer mortality and mammography screening in Europe, the United States of America, Canada, and Australia.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mammography; Demography; Breast cancer screening; Breast cancer; Mortality rate; Mammography screening; Cancer; Surgery; Internal medicine","score_opus":0.2554172894005172,"score_gpt":0.48989451690736835,"score_spread":0.23447722750685113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2681416368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858157,0.00036579205,0.00007216227,0.013453426,0.00013363651,0.000061278064,0.000029502158,0.0000013176913,0.000067190216],"genre_scores_gemma":[0.99389327,0.0029412115,0.00038539487,0.0025539699,0.00017408853,9.164525e-7,7.348109e-7,0.0000046105943,0.000045782075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981024,0.0002639714,0.001093366,0.000109697154,0.00026711603,0.00016343548],"domain_scores_gemma":[0.99728787,0.0011282944,0.00081912486,0.00009566273,0.00045070003,0.00021832515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014182543,0.000079708385,0.0006600488,0.00008166919,0.000020754556,0.000003772374,0.000092283844,0.000079215395,0.000048059672],"category_scores_gemma":[0.000701088,0.000038532322,0.00006306635,0.00034986448,0.00044702645,0.00006815424,0.00004069341,0.00037037948,1.254033e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010027268,0.00004362612,0.93005955,0.000010221877,0.00012995455,0.00019333973,0.00002783088,0.000018426334,0.000039386636,0.000014642108,0.0027178389,0.06574243],"study_design_scores_gemma":[0.0019294112,0.0008841002,0.978293,0.00024875006,0.00013501877,0.00027891048,0.00019799967,0.000036405007,0.000011220684,0.00003883347,0.017901134,0.00004523409],"about_ca_topic_score_codex":0.5266623,"about_ca_topic_score_gemma":0.3337262,"teacher_disagreement_score":0.19293608,"about_ca_system_score_codex":0.000038389466,"about_ca_system_score_gemma":0.0008625003,"threshold_uncertainty_score":0.6784316},"labels":[],"label_agreement":null},{"id":"W2684146816","doi":"10.1200/jco.2017.35.15_suppl.2037","title":"Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Isocitrate dehydrogenase; Glioma; Medicine; IDH1; Gastroenterology; Internal medicine; Pathology; Molecular biology; Cancer research; Biology; Mutant; Genetics; Biochemistry; Gene","score_opus":0.26941546001791855,"score_gpt":0.5439356971028371,"score_spread":0.2745202370849185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2684146816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310464,0.0014585174,0.0000032511439,0.0035618772,0.00092455244,0.00023483344,0.0000141838955,0.0000041302706,0.0006939989],"genre_scores_gemma":[0.99838316,0.00050301204,0.0007615279,0.00011575005,0.00018679329,0.0000020790899,0.0000026506918,0.000017347924,0.000027674612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616426,0.0003097442,0.002709333,0.00021958035,0.00033073145,0.00026635718],"domain_scores_gemma":[0.9938348,0.0014087918,0.0035916914,0.00035890465,0.00045561042,0.00035021227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018100957,0.00019111247,0.002429823,0.00020809572,0.000061046056,0.000012879457,0.00023278322,0.00042090082,0.000109617875],"category_scores_gemma":[0.0026055793,0.00014261501,0.00028336977,0.00014756211,0.00047783015,0.00014489179,0.000094003284,0.0005808693,0.000009905869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009599118,0.0064202975,0.9117464,0.0001198129,0.0013605761,0.0026879595,0.000410526,0.00016829486,0.01770878,0.00009250665,0.001052202,0.048633534],"study_design_scores_gemma":[0.037185658,0.025971204,0.8677686,0.00034073702,0.00097175664,0.00015896393,0.00019208675,0.00064184994,0.062426716,0.00026013795,0.003925226,0.00015706742],"about_ca_topic_score_codex":0.000117703385,"about_ca_topic_score_gemma":0.0003062241,"teacher_disagreement_score":0.048476465,"about_ca_system_score_codex":0.00010168029,"about_ca_system_score_gemma":0.000756795,"threshold_uncertainty_score":0.5815671},"labels":[],"label_agreement":null},{"id":"W2684706175","doi":"10.1200/jco.2016.34.15_suppl.e21625","title":"The impact of a simplified documentation method for the Edmonton Classification System for Cancer Pain (ECS-CP) on clinician utilization.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Documentation; Intervention (counseling); Cancer; Palliative care; Physical therapy; Internal medicine; Nursing","score_opus":0.28499134453999214,"score_gpt":0.5814757068284829,"score_spread":0.2964843622884908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2684706175","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09846147,0.0009868284,0.80259275,0.0885527,0.0035589805,0.0042131445,0.00004498972,0.000029246672,0.0015598865],"genre_scores_gemma":[0.9905202,0.0017483206,0.0040047965,0.0011486015,0.0017935865,0.00012634476,0.000003861526,0.000020018531,0.0006342815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963565,0.0009994135,0.002067152,0.00014887446,0.00024133667,0.00018673313],"domain_scores_gemma":[0.95830256,0.037880443,0.0027688255,0.0002450371,0.00069708197,0.000106047366],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01912713,0.00010919723,0.0007043831,0.00007393373,0.00012057278,0.0000140996135,0.00021759684,0.00019883433,0.000018045494],"category_scores_gemma":[0.012318021,0.000041699557,0.0007309644,0.00010601995,0.00010835221,0.00007801206,0.000014895581,0.0001863008,0.0000017927937],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013370049,0.00041017827,0.024361355,0.00008477873,0.0009429191,0.0000014845458,0.000091088565,0.0001044334,0.0009913231,0.004853956,0.02925432,0.9255341],"study_design_scores_gemma":[0.01732166,0.021684857,0.6903776,0.000523879,0.0014101311,0.0000030882973,0.0016183306,0.027894,0.00038397376,0.0028933336,0.23575293,0.00013623679],"about_ca_topic_score_codex":0.000029465355,"about_ca_topic_score_gemma":0.00005958252,"teacher_disagreement_score":0.9253979,"about_ca_system_score_codex":0.00031206335,"about_ca_system_score_gemma":0.00069660903,"threshold_uncertainty_score":0.99600166},"labels":[],"label_agreement":null},{"id":"W2690802826","doi":"10.1200/jco.2017.35.15_suppl.2004","title":"Vemurafenib in patients with <i>BRAF</i><sup>V600</sup> mutant glioma: A cohort of the histology-independent VE-basket study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Vemurafenib; Anaplastic astrocytoma; Internal medicine; Oncology; Glioma; Pilocytic astrocytoma; Pleomorphic xanthoastrocytoma; Ganglioglioma; Cohort; Astrocytoma; Gastroenterology; Cancer research; Cancer; Metastatic melanoma; Epilepsy","score_opus":0.04972984391204795,"score_gpt":0.3890667716708932,"score_spread":0.3393369277588453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2690802826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929728,0.00009725334,0.0000011822108,0.0044536046,0.0007799494,0.00093206693,0.000006808308,0.000004247632,0.0007520694],"genre_scores_gemma":[0.9990641,0.0000327499,0.00014493134,0.0004670546,0.00022215629,0.00001921102,0.0000014327095,0.000020332023,0.000028073673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593025,0.0005313467,0.0021586206,0.00029483932,0.0007833245,0.00030161734],"domain_scores_gemma":[0.9940624,0.000953172,0.0033573431,0.00079382444,0.0005547031,0.00027852005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024138514,0.0002170306,0.0020110726,0.00016711888,0.00012315663,0.000014558304,0.0005355839,0.00032499337,0.0000631684],"category_scores_gemma":[0.0023201858,0.000111956164,0.0004088103,0.00012230419,0.0004710009,0.000092319744,0.00017715445,0.0009320651,0.000007116746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004560507,0.01868484,0.9607056,0.000012993265,0.00087289035,0.00204667,0.00023101312,0.000029168752,0.000032687392,0.000020820538,0.00043975675,0.012363092],"study_design_scores_gemma":[0.03914158,0.022284329,0.9343501,0.00015550999,0.00095516955,0.00016944607,0.0001438431,0.00001557536,0.00012272182,0.000036700218,0.002531575,0.00009347447],"about_ca_topic_score_codex":0.00010869736,"about_ca_topic_score_gemma":0.00047682933,"teacher_disagreement_score":0.034581073,"about_ca_system_score_codex":0.00030941793,"about_ca_system_score_gemma":0.001011671,"threshold_uncertainty_score":0.45654398},"labels":[],"label_agreement":null},{"id":"W2692549261","doi":"10.1200/jco.2017.35.15_suppl.e12534","title":"Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Pfizer (Canada); Hôpital du Saint-Sacrement; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Hazard ratio; Gastroenterology; Palbociclib; Expanded access; Surgery; Toxicity; Cancer; Breast cancer; Metastatic breast cancer; Confidence interval","score_opus":0.055903277375688704,"score_gpt":0.42061661476255563,"score_spread":0.36471333738686695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2692549261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983355,0.00023782003,0.00005651813,0.0115152635,0.00041380932,0.0029721141,0.0012012294,0.000013572363,0.00023470633],"genre_scores_gemma":[0.993662,0.0010507506,0.0039383355,0.0005504325,0.00038863363,0.00017998142,0.00007097888,0.00007660135,0.000082290724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948726,0.0005195153,0.0027129934,0.0005150607,0.00069534354,0.00068446307],"domain_scores_gemma":[0.9887412,0.0013311072,0.006197451,0.0005650316,0.0026259518,0.0005392358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011551903,0.00046606222,0.0024020127,0.00021677109,0.0003488529,0.00003516428,0.0008168508,0.00031102594,0.000059279275],"category_scores_gemma":[0.0016831309,0.0002652096,0.0002935981,0.00027111277,0.0012969268,0.0006382944,0.00012183455,0.0011329949,5.001379e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32540855,0.0036509035,0.39576048,0.00013713702,0.0020640218,0.000062547755,0.0017512365,0.0003146796,0.001374321,0.000073253505,0.00011883488,0.26928404],"study_design_scores_gemma":[0.09225549,0.030544806,0.8690707,0.0008060008,0.00019247175,0.000051900544,0.0002067385,0.000034036842,0.004260378,0.00017431536,0.0020981273,0.00030503864],"about_ca_topic_score_codex":0.03258354,"about_ca_topic_score_gemma":0.28960943,"teacher_disagreement_score":0.4733102,"about_ca_system_score_codex":0.001237645,"about_ca_system_score_gemma":0.0046484126,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W2694108262","doi":"10.1200/jco.2017.73.9516","title":"Insights From Molecular Profiling of Adult Glioma","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Profiling (computer programming); Medicine; Brain tumor; Glioma; Computational biology; Biomarker; Biomarker discovery; Gene expression profiling; Brain cancer; Bioinformatics; Pathology; Cancer; Biology; Internal medicine; Cancer research; Gene; Proteomics; Computer science; Genetics; Gene expression","score_opus":0.2562676456462747,"score_gpt":0.5373570908165608,"score_spread":0.2810894451702861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2694108262","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020501276,0.9753504,0.0000082658435,0.0003714559,0.0016752542,0.0004827173,0.000017298886,0.000004816459,0.0015885502],"genre_scores_gemma":[0.0059190653,0.989394,0.0030154374,0.00017068515,0.0014078183,0.000014482379,0.000025821577,0.00004009477,0.000012565806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932894,0.00061989506,0.005121426,0.0002962913,0.0004898494,0.00018309848],"domain_scores_gemma":[0.9851861,0.0028182769,0.010068375,0.0006156395,0.0008724336,0.00043919383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067653833,0.00032887564,0.009012985,0.0002973564,0.000034684734,0.000011751816,0.0004125082,0.0012682001,0.000045714758],"category_scores_gemma":[0.0067845816,0.0001898744,0.0032989304,0.000106730215,0.00022388087,0.000059630423,0.00010562256,0.0013183559,0.000034140354],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024541956,0.00263784,0.00030791305,0.0016828749,0.0035603896,0.010557749,0.000008745393,2.3728401e-7,0.00002030626,0.00038909106,0.00034992993,0.9802395],"study_design_scores_gemma":[0.006079696,0.0072360225,0.0005534887,0.020398695,0.013110007,0.00053836545,0.000010332605,0.0000024488584,0.00020548012,0.000631356,0.9510558,0.00017827643],"about_ca_topic_score_codex":0.000027624486,"about_ca_topic_score_gemma":0.000007885171,"teacher_disagreement_score":0.98006123,"about_ca_system_score_codex":0.00015309517,"about_ca_system_score_gemma":0.00334107,"threshold_uncertainty_score":0.9781521},"labels":[],"label_agreement":null},{"id":"W2694871785","doi":"10.1200/jco.2017.35.15_suppl.5032","title":"Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Enzalutamide; Pharmacokinetics; Prostate cancer; Adverse effect; Internal medicine; Abiraterone acetate; Gastroenterology; Nausea; Pharmacology; Dosing; Androgen receptor; Oncology; Urology; Cancer; Androgen deprivation therapy","score_opus":0.10930470014158167,"score_gpt":0.4681243312694845,"score_spread":0.3588196311279028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2694871785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127126,0.0019569427,0.000012239898,0.005483786,0.00014853623,0.00092645665,0.00005766321,0.000004732601,0.00013836878],"genre_scores_gemma":[0.9883584,0.0030351598,0.007928361,0.00012849497,0.00025746253,0.000036506295,0.000005726335,0.000026929822,0.00022298945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965679,0.00034185703,0.0019243781,0.00033131137,0.0004597002,0.000374827],"domain_scores_gemma":[0.9967076,0.0006780393,0.0015748403,0.00023262018,0.00039952976,0.00040737868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002508903,0.00023934552,0.001518256,0.00015586324,0.000109200075,0.00006481869,0.0001535818,0.00015937147,0.000064428306],"category_scores_gemma":[0.0004719026,0.0001379373,0.00011811453,0.00009857066,0.0010653883,0.00027876705,0.00013054862,0.0006835879,7.0509844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21117848,0.0038115236,0.56973225,0.0008538744,0.0011406507,0.0045141946,0.0027065424,0.00002098249,0.021042123,0.0000081635135,0.00016894561,0.18482225],"study_design_scores_gemma":[0.07352491,0.022947883,0.889125,0.0022447773,0.00097178103,0.0009954484,0.0006150615,0.00024961692,0.0049107177,0.00013813199,0.003973946,0.00030272896],"about_ca_topic_score_codex":0.00011473858,"about_ca_topic_score_gemma":0.0005020464,"teacher_disagreement_score":0.31939274,"about_ca_system_score_codex":0.00021098171,"about_ca_system_score_gemma":0.0018753627,"threshold_uncertainty_score":0.56249195},"labels":[],"label_agreement":null},{"id":"W2695844310","doi":"10.1200/jco.2016.34.15_suppl.6019","title":"Clinical relevance of lymph node ratio in resected oral cavity squamous cell carcinoma in patients with N2 disease.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Perineural invasion; Lymphovascular invasion; Lymph node; Neck dissection; Lymph; Chemotherapy; Radiation therapy; Internal medicine; Retrospective cohort study; Metastasis; Gastroenterology; Cancer; Oncology; Urology; Pathology","score_opus":0.06649666512279503,"score_gpt":0.4182310413551535,"score_spread":0.3517343762323585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2695844310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485695,0.00030963865,0.000018222496,0.003762659,0.0005131175,0.00029127672,0.000017726861,0.0000032466598,0.00022716788],"genre_scores_gemma":[0.9980681,0.00037232292,0.0005805044,0.00060826726,0.0002733188,0.000008870093,0.000003232668,0.00001583595,0.00006957407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954442,0.0006862151,0.002930679,0.00027063108,0.00041826558,0.0002500018],"domain_scores_gemma":[0.99295044,0.004285546,0.0015807669,0.00028873648,0.00046437612,0.00043015066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018551912,0.00014462713,0.0016090344,0.00013975285,0.000012443181,0.0000026793289,0.00013202714,0.00025585075,0.00007280316],"category_scores_gemma":[0.004430356,0.00007864299,0.00031531247,0.00018661066,0.00026796426,0.00010151483,0.000045676396,0.00047748355,0.0000065561526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02335591,0.010368234,0.92207295,0.000034073913,0.000041332114,0.00067798264,0.000021515933,0.0000149546495,0.0000081474345,0.000010047315,0.00062519143,0.04276966],"study_design_scores_gemma":[0.051279105,0.012372929,0.93438864,0.0002586502,0.00018869067,0.0000055550317,0.000009359181,0.000020200156,0.00004023608,0.00005890143,0.0012966509,0.00008105994],"about_ca_topic_score_codex":0.00017586698,"about_ca_topic_score_gemma":0.00071099226,"teacher_disagreement_score":0.0426886,"about_ca_system_score_codex":0.00046958317,"about_ca_system_score_gemma":0.0021877436,"threshold_uncertainty_score":0.530387},"labels":[],"label_agreement":null},{"id":"W2701283879","doi":"10.1200/jco.2017.72.7842","title":"Medulloblastoma: From Myth to Molecular","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Medicine; Oncology; Radiation therapy; Vismodegib; Internal medicine; Chemotherapy; Sonic hedgehog; Pathology","score_opus":0.35223438976537286,"score_gpt":0.5887818308532463,"score_spread":0.23654744108787346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2701283879","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007538781,0.9882307,0.000019793626,0.004974003,0.002770447,0.0005160302,0.000025494488,0.0000074049153,0.0027022287],"genre_scores_gemma":[0.00020626206,0.9917152,0.002998742,0.0022734867,0.0026020575,0.000022302085,0.000014749223,0.0000492288,0.00011797105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99434555,0.0005697008,0.0039643142,0.00035120384,0.00049218774,0.00027705022],"domain_scores_gemma":[0.9900321,0.0028162133,0.005023055,0.0006941296,0.0003713553,0.0010631988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019229493,0.00035784513,0.009099469,0.00025727702,0.000043818334,0.000024520501,0.00048719268,0.0011351733,0.00021916261],"category_scores_gemma":[0.00714516,0.00021190791,0.003376646,0.00009161037,0.000117406365,0.00004352311,0.00015347128,0.0014507998,0.0004039219],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018123184,0.001735642,0.000103840066,0.0003843155,0.0025438862,0.0113192145,0.000007048636,2.0863314e-7,5.1699215e-7,0.00002997779,0.01955687,0.96413726],"study_design_scores_gemma":[0.0031966919,0.007473354,0.0005836235,0.009438323,0.009112474,0.00062452955,0.0000040514014,3.0914356e-7,0.0000021603312,0.000094005474,0.969319,0.00015150446],"about_ca_topic_score_codex":0.000021008536,"about_ca_topic_score_gemma":0.000013071737,"teacher_disagreement_score":0.96398574,"about_ca_system_score_codex":0.0002982617,"about_ca_system_score_gemma":0.003691544,"threshold_uncertainty_score":0.87554955},"labels":[],"label_agreement":null},{"id":"W2702220459","doi":"10.1200/jco.2016.34.15_suppl.1014","title":"Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Epirubicin; Fluorouracil; Hazard ratio; Breast cancer; Neoadjuvant therapy; Oncology; Bevacizumab; Gastroenterology; Chemotherapy; Cancer; Confidence interval","score_opus":0.049282086248313914,"score_gpt":0.40586575050859663,"score_spread":0.3565836642602827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2702220459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438598,0.0009372283,0.000077058336,0.051479395,0.00096200383,0.0019396696,0.00063281495,0.000011751514,0.00010027412],"genre_scores_gemma":[0.98703474,0.0028372526,0.00061366893,0.0034017256,0.0016747062,0.00043241555,0.000005190741,0.000048989907,0.0039513027],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972147,0.0003114041,0.0012579104,0.00040197626,0.00031631446,0.0004977021],"domain_scores_gemma":[0.99117905,0.0062527293,0.0010352455,0.00025579726,0.00034072177,0.0009364357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017317319,0.0002738177,0.001627282,0.00006742817,0.000120621546,0.000020217616,0.0002106485,0.00022489313,0.0001884738],"category_scores_gemma":[0.0010806749,0.00014084563,0.00029281856,0.00008720881,0.00032884526,0.00014296258,0.00008635518,0.00030198874,0.0000030242606],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73186225,0.0012475979,0.037422016,0.000055820798,0.0018275543,0.00016175836,0.00060373324,0.0000024969218,0.0014179122,0.000038045724,0.08588771,0.13947311],"study_design_scores_gemma":[0.36748862,0.053922944,0.3973469,0.00021973194,0.0018911442,0.00017160102,0.00018944404,0.000017810322,0.00018032182,0.0010589482,0.17718881,0.00032372],"about_ca_topic_score_codex":0.00014185869,"about_ca_topic_score_gemma":0.00057649746,"teacher_disagreement_score":0.36437362,"about_ca_system_score_codex":0.0005748393,"about_ca_system_score_gemma":0.0011092894,"threshold_uncertainty_score":0.5743518},"labels":[],"label_agreement":null},{"id":"W2702886506","doi":"10.1200/jco.2016.34.15_suppl.507","title":"PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Letrozole; Clinical endpoint; Internal medicine; Hazard ratio; Breast cancer; Cancer; Progression-free survival; Adverse effect; Oncology; Gynecology; Randomized controlled trial; Metastatic breast cancer; Confidence interval; Tamoxifen; Overall survival","score_opus":0.042529828937183864,"score_gpt":0.4039353674576152,"score_spread":0.36140553852043134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2702886506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768896,0.00045862864,0.0006532563,0.009098107,0.00039943805,0.0008593499,0.0003846194,0.000028078506,0.00042956098],"genre_scores_gemma":[0.98785156,0.0004029858,0.008559393,0.0015151217,0.0013207215,0.00007192846,0.000019634785,0.00007880771,0.00017983715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937519,0.0005156895,0.0034467625,0.0005861861,0.0009906038,0.00070886494],"domain_scores_gemma":[0.9911332,0.0024188978,0.004347284,0.00056135963,0.0008681803,0.0006710397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017106001,0.00044950237,0.0037825154,0.0002602124,0.00005036652,0.000009453734,0.00035852558,0.00032970143,0.00022596327],"category_scores_gemma":[0.00034227464,0.0002303586,0.00016499464,0.00044716243,0.001026989,0.00046769623,0.00006609793,0.0010794522,0.0000041183766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76490504,0.005309836,0.0108516775,0.000028242934,0.0011628541,0.0011225679,0.000470172,0.00010573128,0.008204206,0.0000059740437,0.00010390133,0.20772977],"study_design_scores_gemma":[0.7184447,0.09296251,0.17567958,0.0015429009,0.0004322712,0.0007056424,0.00062257366,0.000009048992,0.00055673515,0.000094314106,0.008605695,0.00034402026],"about_ca_topic_score_codex":0.00031072673,"about_ca_topic_score_gemma":0.00087480474,"teacher_disagreement_score":0.20738575,"about_ca_system_score_codex":0.0010525141,"about_ca_system_score_gemma":0.003917209,"threshold_uncertainty_score":0.93937504},"labels":[],"label_agreement":null},{"id":"W2703678370","doi":"10.1200/jco.2016.34.15_suppl.101","title":"A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Agonist; Internal medicine; Antibody; Pharmacokinetics; Immunotherapy; Adverse effect; Oncology; Pharmacology; Cancer; Pembrolizumab; Immunology; Receptor","score_opus":0.03716742583024048,"score_gpt":0.4133332806145038,"score_spread":0.37616585478426334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2703678370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344474,0.0001358582,0.000009453974,0.0051978603,0.00043647754,0.0006417074,0.0000030143124,0.000002376679,0.00012848653],"genre_scores_gemma":[0.9989686,0.00015496994,0.00006216265,0.00053814985,0.00019940725,0.0000067598476,3.4086062e-7,0.000009605805,0.000059986756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99710524,0.0005270455,0.0017598292,0.00013214754,0.0003388421,0.00013688934],"domain_scores_gemma":[0.9966643,0.0011105209,0.0016878636,0.00020324028,0.0002504793,0.00008360052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019118694,0.00010644328,0.00092012325,0.000060916827,0.000046946127,0.000005309542,0.00013008126,0.0001130527,0.00002293173],"category_scores_gemma":[0.0009994562,0.000037304122,0.00017566244,0.0001495814,0.000548906,0.00009548642,0.000043049542,0.00036541084,6.1133835e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29776326,0.0097450735,0.23979612,0.000013652715,0.0003192,0.000034826757,0.00064530247,0.000002909897,0.00059571146,0.000012499785,0.00016010094,0.45091134],"study_design_scores_gemma":[0.19159855,0.03551963,0.7704545,0.00024964075,0.00014625346,0.000024696517,0.00025794018,0.000010619963,0.00012195256,0.00005519261,0.0015115683,0.000049412545],"about_ca_topic_score_codex":0.000032854987,"about_ca_topic_score_gemma":0.00015583729,"teacher_disagreement_score":0.5306584,"about_ca_system_score_codex":0.00011510781,"about_ca_system_score_gemma":0.00049248483,"threshold_uncertainty_score":0.2022467},"labels":[],"label_agreement":null},{"id":"W2707069039","doi":"10.1200/jco.2017.35.15_suppl.2539","title":"FDA analysis of patient enrollment by region in clinical trials for approved oncological indications.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Latin Americans; Internal medicine; Clinical Oncology; Family medicine; Cancer; Demography","score_opus":0.8797479166165305,"score_gpt":0.6769772683289579,"score_spread":0.20277064828757263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2707069039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8876243,0.001065663,0.010293219,0.094879955,0.0029101223,0.001288082,0.00018101708,0.0000061340916,0.0017514618],"genre_scores_gemma":[0.9829186,0.0011057055,0.007092815,0.007876079,0.0007854504,0.000072510724,0.00001890344,0.000014295206,0.00011561005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95763016,0.004761891,0.0366389,0.00048500582,0.00017093985,0.00031307954],"domain_scores_gemma":[0.8860732,0.04349567,0.06885845,0.00078063965,0.00037319429,0.00041887615],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.22049761,0.00016511239,0.0076099625,0.0006061644,0.00013663346,0.0000406361,0.0007590133,0.00085473113,0.00012321476],"category_scores_gemma":[0.2906401,0.00015146002,0.001936416,0.00018553236,0.00036799203,0.00031385198,0.00009779029,0.00069917995,0.000028503933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018519247,0.0049383175,0.83737403,0.00007521438,0.0028396721,0.0000092909895,0.00043948673,0.0002245737,0.0000018050827,0.018301906,0.08195352,0.051990293],"study_design_scores_gemma":[0.010057314,0.0070979963,0.6975981,0.000062695384,0.00055191835,0.0000044267667,0.0004861292,0.0044462685,0.0000029341581,0.016476154,0.26297298,0.00024308085],"about_ca_topic_score_codex":0.00017881281,"about_ca_topic_score_gemma":0.00024779138,"teacher_disagreement_score":0.18101947,"about_ca_system_score_codex":0.00051732565,"about_ca_system_score_gemma":0.0010673519,"threshold_uncertainty_score":0.8026618},"labels":[],"label_agreement":null},{"id":"W2709260524","doi":"10.1200/jco.2016.34.15_suppl.tps626","title":"Tamoxifen versus aromatase inhibitors for the adjuvant treatment of breast cancer in older women: A feasibility study to examine differences in cognitive outcomes.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Anastrozole; Tamoxifen; Letrozole; Breast cancer; Oncology; Adverse effect; Cognition; Internal medicine; Exemestane; Aromatase; Aromatase inhibitor; Gynecology; Cancer; Gerontology; Psychiatry","score_opus":0.20537903141823072,"score_gpt":0.50633184310579,"score_spread":0.30095281168755933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2709260524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98199856,0.00030996956,0.0000208116,0.013803127,0.0012187673,0.002409288,0.00020616961,0.00000410581,0.000029168408],"genre_scores_gemma":[0.9983882,0.00048550064,0.000021484557,0.00036087746,0.0003279732,0.00029962318,6.891924e-7,0.000012213424,0.000103467035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964027,0.00043356285,0.002197128,0.00029159512,0.00034091508,0.00033413694],"domain_scores_gemma":[0.98581314,0.012281432,0.001031387,0.00016212082,0.00047551884,0.00023641868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00224003,0.00021051803,0.0020865158,0.00020790327,0.000029762026,0.0000032833864,0.00011589334,0.00012796713,0.00015215813],"category_scores_gemma":[0.00479072,0.00009274818,0.00029632525,0.00024154093,0.00030163783,0.00007237393,0.000065409586,0.0002589859,0.0000023305408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03568411,0.01333841,0.7977375,0.0000121767835,0.00090941606,0.0001053816,0.0021869026,0.0000012103669,0.000024956582,5.4854576e-7,0.00014115724,0.14985824],"study_design_scores_gemma":[0.071993575,0.050780434,0.8694878,0.0003699523,0.00044120016,0.000011062901,0.006678905,0.000003483809,0.00002949651,0.000024108389,0.00009235869,0.000087585395],"about_ca_topic_score_codex":0.00024027843,"about_ca_topic_score_gemma":0.003477096,"teacher_disagreement_score":0.14977066,"about_ca_system_score_codex":0.0013840178,"about_ca_system_score_gemma":0.000892067,"threshold_uncertainty_score":0.5735286},"labels":[],"label_agreement":null},{"id":"W2710457918","doi":"10.1200/jco.2016.34.15_suppl.1070","title":"Analysis of BRCA1-related functional associations in sporadic triple negative breast cancer: A network-based approach.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Transcriptome; Medicine; Computational biology; Cancer research; Bioinformatics; Cancer; Gene; Biology; Genetics; Gene expression; Internal medicine","score_opus":0.04159433938355653,"score_gpt":0.35129169084833745,"score_spread":0.30969735146478095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2710457918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671911,0.0007080164,0.024524897,0.0037927907,0.001342836,0.00022246699,0.00021636029,0.0000041277026,0.0019973945],"genre_scores_gemma":[0.99702334,0.0003902771,0.0013659726,0.00051856274,0.0005130863,0.0000040842847,0.000034966764,0.000007714473,0.00014198259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971751,0.00029939527,0.0020091878,0.00014642999,0.00016958082,0.00020032504],"domain_scores_gemma":[0.99654377,0.0004866965,0.002359518,0.00014653828,0.0003333984,0.00013009387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002595399,0.00010527173,0.0008972902,0.00015329724,0.000028247521,0.0000042170464,0.00017338421,0.00047694767,0.00010504355],"category_scores_gemma":[0.00044692107,0.00006996875,0.0006001105,0.00045394944,0.00016896903,0.0000085915135,0.00003785313,0.00029435774,0.0000012522265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003580856,0.0017040846,0.72632885,0.000012365497,0.0072963717,0.000012331316,0.00007242638,0.10683592,0.00087430025,0.0005523065,0.012469285,0.1402609],"study_design_scores_gemma":[0.007401385,0.0012097871,0.9731032,0.000035133886,0.0009578752,0.0000137279785,0.000036074136,0.012341096,0.00004257299,0.00061647553,0.004088216,0.00015440781],"about_ca_topic_score_codex":0.000036949597,"about_ca_topic_score_gemma":0.00028925977,"teacher_disagreement_score":0.24677439,"about_ca_system_score_codex":0.00009042099,"about_ca_system_score_gemma":0.00112825,"threshold_uncertainty_score":0.3678657},"labels":[],"label_agreement":null},{"id":"W2716435817","doi":"10.1200/jco.2017.35.15_suppl.tps2082","title":"Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Delmar (Canada)","funders":"","keywords":"Temozolomide; Medicine; Bevacizumab; Lomustine; Oncology; Internal medicine; Phases of clinical research; Glioma; Dacarbazine; Regimen; Clinical trial; Cancer; Chemotherapy; Cancer research; Cyclophosphamide; Vincristine","score_opus":0.20683267702563027,"score_gpt":0.5357028246284492,"score_spread":0.32887014760281896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2716435817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243075,0.00015481845,0.000006043151,0.004774594,0.001041492,0.00036125426,0.000009679202,0.0000031127258,0.0012182677],"genre_scores_gemma":[0.99706835,0.00024788076,0.0015334354,0.0004250392,0.00066816836,0.000004176081,0.0000017106624,0.000015851867,0.00003536831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914784,0.0011039968,0.0064299935,0.00022798468,0.0005302672,0.00022938263],"domain_scores_gemma":[0.98324466,0.00622983,0.008858493,0.0005266483,0.0006987116,0.00044165982],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016110191,0.00016273445,0.0040424415,0.00015793493,0.000046682922,0.000013382139,0.00027773198,0.00044712634,0.00012854587],"category_scores_gemma":[0.035162114,0.00009018636,0.0010001905,0.0000695923,0.0004210995,0.000113092035,0.00007856283,0.0007593786,0.000010542241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024744933,0.010655495,0.8549649,0.000021150136,0.0006652057,0.000564904,0.000017115899,0.0000016977425,0.000024625137,0.00004575724,0.0018088736,0.10648531],"study_design_scores_gemma":[0.05292498,0.0382642,0.8981721,0.0003621286,0.00073545345,0.000014529748,0.000018560795,0.0000066468715,0.00018834561,0.00013038893,0.009109782,0.00007291472],"about_ca_topic_score_codex":0.00002288873,"about_ca_topic_score_gemma":0.00010093062,"teacher_disagreement_score":0.10641239,"about_ca_system_score_codex":0.00010480352,"about_ca_system_score_gemma":0.0010964164,"threshold_uncertainty_score":0.9729651},"labels":[],"label_agreement":null},{"id":"W2719427713","doi":"10.1200/jco.2016.34.15_suppl.505","title":"Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Endocrine system; Gynecology; Cancer; Hormone","score_opus":0.029081499678590195,"score_gpt":0.37506000762556946,"score_spread":0.34597850794697926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2719427713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977536,0.00068152725,0.000009719951,0.0010667111,0.00027551598,0.000085927975,0.000047554582,0.0000019799022,0.000077421806],"genre_scores_gemma":[0.99113065,0.008276121,0.00016967772,0.000113843904,0.00022923163,0.000009014408,0.0000011803178,0.00001393349,0.000056318535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982035,0.00021820594,0.0009894421,0.00018517418,0.00018792455,0.00021574114],"domain_scores_gemma":[0.9982327,0.0001941819,0.0010442307,0.00016133618,0.0002639567,0.00010358371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005858018,0.00011901512,0.00069464295,0.00007224456,0.000008203031,0.0000016492445,0.00019706934,0.0001379116,0.0000396543],"category_scores_gemma":[0.0002076762,0.00007382872,0.00011352406,0.00010537152,0.00030738997,0.00001058977,0.00006865126,0.00017974671,7.4633436e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011655708,0.0009417916,0.8660117,0.000015596706,0.00085255445,0.00007689196,0.0002234347,0.000029716197,0.020066526,0.0000075893217,0.00021452211,0.099904016],"study_design_scores_gemma":[0.008032587,0.003440044,0.98190707,0.00014631462,0.000032177657,0.00010351922,0.00006927477,2.4161233e-7,0.0033035711,0.000019079533,0.0028651145,0.000081033206],"about_ca_topic_score_codex":0.00009407648,"about_ca_topic_score_gemma":0.0003121415,"teacher_disagreement_score":0.11589538,"about_ca_system_score_codex":0.000095348914,"about_ca_system_score_gemma":0.0009767013,"threshold_uncertainty_score":0.3010648},"labels":[],"label_agreement":null},{"id":"W2722759707","doi":"10.1200/jco.2017.35.15_suppl.e13525","title":"BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Tolerability; Internal medicine; Temozolomide; Oncology; Cancer; Bevacizumab; Pharmacology; Gastroenterology; Adverse effect; Chemotherapy","score_opus":0.29302632920703436,"score_gpt":0.5846921575951359,"score_spread":0.29166582838810157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2722759707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924723,0.000047461293,0.00009382258,0.0021599857,0.003353493,0.0013842266,0.000048077658,0.000010069513,0.00043058474],"genre_scores_gemma":[0.99746174,0.00016285162,0.0007912014,0.0008815081,0.000528501,0.000034448538,0.000007707102,0.000032521115,0.000099553756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99328494,0.0017849198,0.0035623824,0.0004658249,0.00044385748,0.0004580784],"domain_scores_gemma":[0.98764426,0.0029899552,0.006340353,0.00039611466,0.0021809342,0.0004483856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055323816,0.00032541153,0.0020466303,0.00022531104,0.000403241,0.000028507882,0.0008071174,0.0006578359,0.0000845498],"category_scores_gemma":[0.0037909083,0.00020670066,0.00035086134,0.00015490506,0.00089361996,0.00036264115,0.00019098257,0.0020674712,0.0000047868352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09277454,0.07311734,0.66163576,0.000043447013,0.0008819151,0.00020930915,0.00033260538,0.00001531069,0.000029359491,0.00011301449,0.0031171408,0.16773026],"study_design_scores_gemma":[0.14742905,0.21757665,0.60151,0.00016126371,0.00073421036,0.000032275228,0.00045619803,0.0005341942,0.00013160169,0.00018839852,0.030946488,0.00029968657],"about_ca_topic_score_codex":0.000023035069,"about_ca_topic_score_gemma":0.0008910468,"teacher_disagreement_score":0.16743056,"about_ca_system_score_codex":0.00013243842,"about_ca_system_score_gemma":0.0008173445,"threshold_uncertainty_score":0.8982249},"labels":[],"label_agreement":null},{"id":"W2724509358","doi":"10.1200/jco.2016.34.15_suppl.513","title":"Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Taxane; Pertuzumab; Oncology; Metastatic breast cancer; Trastuzumab; Breast cancer; Cancer","score_opus":0.11911141006963032,"score_gpt":0.4730821111620033,"score_spread":0.353970701092373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724509358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389863,0.00012256672,0.00011545535,0.004433707,0.00013679557,0.0011170774,0.00012243839,0.000004045337,0.000049294187],"genre_scores_gemma":[0.9974776,0.000122191,0.0020081715,0.00025936533,0.000052657626,0.000024578852,0.000009651399,0.000026537546,0.00001928386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99343264,0.0015191581,0.0036038407,0.00034034532,0.00079278304,0.0003112304],"domain_scores_gemma":[0.9919727,0.0035874473,0.0032212823,0.0002907968,0.00065489096,0.00027287164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004999945,0.00025498806,0.0024871388,0.00048512028,0.000023272309,0.000004744322,0.00017116392,0.00011390502,0.000049912058],"category_scores_gemma":[0.0020249663,0.00012804974,0.00021851924,0.0005386432,0.00023361795,0.00018567796,0.00005158294,0.0005133802,0.0000010179958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11811762,0.18227725,0.37474218,0.00010866083,0.0023841108,0.0019641467,0.0013052701,0.00015633572,0.00018399676,0.00003728785,0.00026173063,0.31846142],"study_design_scores_gemma":[0.32501614,0.10780898,0.56335926,0.0012237584,0.0011628332,0.00013110506,0.00065144285,0.00004173319,0.00010739623,0.00004205857,0.00033024114,0.0001250564],"about_ca_topic_score_codex":0.0013512848,"about_ca_topic_score_gemma":0.0067390436,"teacher_disagreement_score":0.31833637,"about_ca_system_score_codex":0.00041108514,"about_ca_system_score_gemma":0.0012161061,"threshold_uncertainty_score":0.5221717},"labels":[],"label_agreement":null},{"id":"W2724641768","doi":"10.1200/jco.2017.35.15_suppl.tps2086","title":"Cognitive support program for patients with brain metastases.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Psychological intervention; Cognition; Intervention (counseling); Cognitive training; Executive functions; Clinical psychology; Psychiatry; Nursing","score_opus":0.12873180389646635,"score_gpt":0.5258570993925618,"score_spread":0.39712529549609543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724641768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660323,0.0000713804,0.0004745916,0.0215341,0.0016584028,0.0021304104,0.00007920019,0.000021308902,0.007998252],"genre_scores_gemma":[0.9897298,0.000087565924,0.0046811122,0.0036887815,0.0010618865,0.00006032266,0.000019475108,0.000024747835,0.0006462779],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99759465,0.000150151,0.0013996208,0.00019941106,0.00037277088,0.00028336578],"domain_scores_gemma":[0.9912576,0.0030676934,0.002922523,0.00017111177,0.0022482767,0.00033278842],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002257189,0.0001543792,0.0014179152,0.00008298839,0.00017902485,0.000021372385,0.00014749574,0.00020260578,0.00012125529],"category_scores_gemma":[0.020971544,0.00009662496,0.00046321278,0.000041347103,0.00065443356,0.00018657673,0.0000681059,0.0006455733,0.000013607068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020375948,0.005273267,0.37179384,0.00003583542,0.0020623244,0.00021914077,0.000050126542,1.5796292e-7,0.0000011271653,0.000017316554,0.028218534,0.57195234],"study_design_scores_gemma":[0.03768811,0.10468217,0.7112066,0.00020319204,0.0017433122,0.00006655415,0.000105838975,0.0000047195354,0.000016494512,0.00010225757,0.14408243,0.000098284865],"about_ca_topic_score_codex":0.0000051522957,"about_ca_topic_score_gemma":0.000029790808,"teacher_disagreement_score":0.57185405,"about_ca_system_score_codex":0.00010140915,"about_ca_system_score_gemma":0.0013063174,"threshold_uncertainty_score":0.98727524},"labels":[],"label_agreement":null},{"id":"W2725020420","doi":"10.1200/jco.2017.35.15_suppl.2570","title":"A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Adverse effect; Nausea; Toxicity; Pharmacology; Internal medicine","score_opus":0.030190739414458462,"score_gpt":0.4015944852564905,"score_spread":0.37140374584203206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725020420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988797,0.00011608585,0.000013592746,0.00033920034,0.00009371043,0.00054042303,0.00000464888,9.2738446e-7,0.000011741082],"genre_scores_gemma":[0.9995837,0.000100370984,0.00011201618,0.000083266874,0.00007675864,0.000018417317,0.0000019985248,0.000015143044,0.000008335785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979322,0.00033337428,0.001088475,0.0002530314,0.00022305726,0.00016986934],"domain_scores_gemma":[0.9974494,0.00017989453,0.0017845214,0.0002001359,0.00031060338,0.00007545898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011545614,0.00015645214,0.00076646486,0.00010530762,0.000059714894,0.000014168163,0.0001768354,0.00017624603,0.000001972109],"category_scores_gemma":[0.00040800797,0.00009421278,0.00003921753,0.00007775366,0.00036226303,0.000030654024,0.00007328682,0.00037852355,5.952417e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06469717,0.01014065,0.8889599,0.0000328325,0.00022093793,0.00007865964,0.0016439164,0.0004843452,0.027372126,0.0000029064438,0.00005815891,0.006308417],"study_design_scores_gemma":[0.06387229,0.11179068,0.8109917,0.00017707662,0.000049337268,0.00001207061,0.00058178196,0.000026952923,0.012256364,0.000029886904,0.000077221826,0.00013463186],"about_ca_topic_score_codex":0.00010037995,"about_ca_topic_score_gemma":0.0034682634,"teacher_disagreement_score":0.10165003,"about_ca_system_score_codex":0.000068433525,"about_ca_system_score_gemma":0.0003467596,"threshold_uncertainty_score":0.38418856},"labels":[],"label_agreement":null},{"id":"W2725418929","doi":"10.1200/jco.2017.35.15_suppl.6574","title":"Association between progression-free survival and health-related quality of life in oncology: A systematic review and regression analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University; Impact","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Meta-analysis; Clinical trial; MEDLINE; Randomized controlled trial; Oncology; Progression-free survival; Overall survival","score_opus":0.4791762024296307,"score_gpt":0.5551634425279253,"score_spread":0.07598724009829455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725418929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037592888,0.9919906,0.000014638692,0.0045101373,0.0006608818,0.0009222514,0.00013759633,0.0000036085708,0.0013843239],"genre_scores_gemma":[0.00108324,0.9978818,0.00024661914,0.0002965086,0.00025501265,0.000019354748,0.000012749955,0.000021176797,0.00018347925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9799799,0.001801203,0.017352888,0.00042658238,0.00012507704,0.00031435338],"domain_scores_gemma":[0.92863005,0.005248131,0.06496388,0.0005560282,0.00020494175,0.0003969508],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.057807256,0.00031429957,0.027333036,0.0005862177,0.000071953174,0.000030779953,0.0006307569,0.0015036133,0.00003430093],"category_scores_gemma":[0.049075373,0.00023784464,0.0014070346,0.00030344605,0.0001937812,0.00026407358,0.00022672444,0.001555149,0.0000081442395],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008401745,0.00046964074,0.18346906,0.38135156,0.008440872,0.00001757561,0.00007853034,3.8466413e-7,1.0803983e-9,0.0021239433,0.0021046754,0.42185974],"study_design_scores_gemma":[0.005518426,0.0035623552,0.22601335,0.25245872,0.0139879035,0.000020802543,0.00003132892,0.000009364935,3.9954453e-9,0.0070850155,0.4906137,0.0006990433],"about_ca_topic_score_codex":0.00030551382,"about_ca_topic_score_gemma":0.00042430175,"teacher_disagreement_score":0.48850903,"about_ca_system_score_codex":0.00089666055,"about_ca_system_score_gemma":0.002032961,"threshold_uncertainty_score":0.99979264},"labels":[],"label_agreement":null},{"id":"W2725442277","doi":"10.1200/jco.2014.32.15_suppl.547","title":"Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Breast cancer; Androgen receptor; Estrogen receptor; Progesterone receptor; Internal medicine; Cancer; Oncology; Lymph node; Gynecology; Pathology; Prostate cancer","score_opus":0.040874422296685184,"score_gpt":0.3788406444531534,"score_spread":0.3379662221564682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725442277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858448,0.00192458,0.000047726156,0.011295453,0.00059826224,0.00010449341,0.000033898832,0.000002116646,0.0001486826],"genre_scores_gemma":[0.9910102,0.0060579297,0.00034235526,0.0005406351,0.0019506096,0.000013745538,0.0000062240756,0.00000972154,0.000068618225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770266,0.0007502782,0.0009580794,0.00020892196,0.00018864204,0.0001914262],"domain_scores_gemma":[0.9973649,0.0008791546,0.0012310825,0.00014085144,0.00026733676,0.00011671969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026920172,0.00012244197,0.00067020685,0.000030526007,0.000062645246,0.000011949267,0.0001941988,0.00032226194,0.000013579794],"category_scores_gemma":[0.0017164397,0.00007530723,0.00016124028,0.00007052266,0.00020677301,0.000010301802,0.00011556562,0.00036379314,0.0000026710916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014262582,0.000109669956,0.9447516,0.0000047658436,0.00026257284,0.000001836685,0.00008283859,0.000004354152,0.0006550174,0.000008520721,0.0038279733,0.048864566],"study_design_scores_gemma":[0.0063959514,0.00077393075,0.9689757,0.000065126835,0.00014282281,0.000019783449,0.000026303327,0.000002854642,0.0015533158,0.00023622955,0.021715427,0.000092528],"about_ca_topic_score_codex":0.00010006725,"about_ca_topic_score_gemma":0.00013439503,"teacher_disagreement_score":0.048772037,"about_ca_system_score_codex":0.000087970584,"about_ca_system_score_gemma":0.00027757854,"threshold_uncertainty_score":0.30709398},"labels":[],"label_agreement":null},{"id":"W2725557045","doi":"10.1200/jco.2017.73.8567","title":"Reply to T.J. Powles et al","year":2017,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.15364047627747526,"score_gpt":0.5749700092059125,"score_spread":0.4213295329284372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725557045","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043442575,0.003353121,0.0002044923,0.9106248,0.029826561,0.0003956613,0.0000561304,0.000008163717,0.051186826],"genre_scores_gemma":[0.003984579,0.0031698777,0.0072266096,0.92034686,0.026207766,0.000011764538,0.00003065252,0.0000594581,0.03896242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931129,0.0010151858,0.0041546226,0.000454255,0.00069080305,0.0005722109],"domain_scores_gemma":[0.9867835,0.0049698763,0.0054466305,0.00073898537,0.0010970468,0.0009639647],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005058819,0.00037381062,0.003431501,0.00024200437,0.00015093312,0.00005705991,0.00060365244,0.0012410256,0.0011391612],"category_scores_gemma":[0.013257519,0.00026242618,0.0014647227,0.000076528784,0.0004395784,0.00019844284,0.00014715362,0.0048731286,0.00085336086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010503961,0.0011281479,0.0064826263,0.000050712373,0.0023944315,0.014067183,0.00022640082,0.0000105342315,0.000007069754,0.00014296612,0.81297666,0.16146286],"study_design_scores_gemma":[0.006988491,0.020414516,0.048415884,0.0012082238,0.0032151144,0.0016873297,0.00006444956,0.000004807638,0.0000037775558,0.00031805548,0.91747445,0.00020489868],"about_ca_topic_score_codex":0.00023677095,"about_ca_topic_score_gemma":0.000058294947,"teacher_disagreement_score":0.16125795,"about_ca_system_score_codex":0.00084094517,"about_ca_system_score_gemma":0.011034919,"threshold_uncertainty_score":0.9999828},"labels":[],"label_agreement":null},{"id":"W2726186366","doi":"10.1200/jco.2017.35.15_suppl.5002","title":"A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Clinical endpoint; Prednisone; Oncology; Urology; Gastroenterology; Cancer; Randomized controlled trial; Androgen receptor","score_opus":0.1569140365483028,"score_gpt":0.5432351185979689,"score_spread":0.3863210820496661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726186366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350506,0.00039941867,0.000047661943,0.0014964532,0.00058233144,0.0036750727,0.00013186342,0.0000062071626,0.00015591264],"genre_scores_gemma":[0.9956723,0.00056674023,0.0015466829,0.00014883211,0.00033659837,0.00025387466,0.000014483516,0.00003317662,0.0014273151],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99507076,0.0005375486,0.0029287066,0.00031979388,0.000765377,0.0003778057],"domain_scores_gemma":[0.9911505,0.0017374048,0.004320451,0.0004153465,0.0019859273,0.00039039453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004193506,0.00024562384,0.0029780508,0.00013570508,0.0003188285,0.000057110134,0.0002796992,0.0001557341,0.00012976635],"category_scores_gemma":[0.003638265,0.00013534282,0.00045187928,0.000073221454,0.0008284356,0.0003440004,0.00008748449,0.00052837125,0.0000013416075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8699802,0.02337867,0.07808064,0.00015238475,0.0031931808,0.00028483872,0.001081665,0.000031412692,0.00039840268,0.000015139012,0.000577787,0.02282563],"study_design_scores_gemma":[0.7731149,0.12837249,0.09345243,0.00020770816,0.001979051,0.0000131869665,0.0002041957,0.0001412811,0.00043905532,0.00012451826,0.0018289436,0.00012224894],"about_ca_topic_score_codex":0.00031109081,"about_ca_topic_score_gemma":0.00052140665,"teacher_disagreement_score":0.10499382,"about_ca_system_score_codex":0.00023169827,"about_ca_system_score_gemma":0.0024131949,"threshold_uncertainty_score":0.551912},"labels":[],"label_agreement":null},{"id":"W2727112076","doi":"10.1200/jco.2017.35.15_suppl.e21060","title":"Non-classical BRAF melanoma: A retrospective review of disease characteristics and prognostic implications.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; V600E; Melanoma; Retrospective cohort study; Internal medicine; Oncology; Cohort; Cancer; Disease; Mutation; Vemurafenib; Cancer research; Metastatic melanoma; Gene; Genetics; Biology","score_opus":0.14645723722527285,"score_gpt":0.4762306594476197,"score_spread":0.32977342222234685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727112076","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005741425,0.9963941,0.00006176167,0.0005537165,0.00075650495,0.00058928295,0.00014780858,0.0000020214507,0.0009206661],"genre_scores_gemma":[0.0013660627,0.9957562,0.00035531516,0.0002967907,0.0018459877,0.000031550506,0.00010514131,0.000031662763,0.00021127702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954617,0.0004866084,0.003252178,0.000389906,0.0001987819,0.00021082004],"domain_scores_gemma":[0.9906515,0.00048982084,0.007113685,0.00065044867,0.0006032386,0.00049131346],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023077712,0.0003029666,0.004257192,0.00007050137,0.000059677233,0.000014564027,0.0005690072,0.0007569549,0.000017977627],"category_scores_gemma":[0.011848491,0.00021188267,0.0012418098,0.00005516187,0.00041158986,0.000007255808,0.00026336763,0.0007946471,0.000007125048],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015676937,0.0005307595,0.0033437526,0.02130088,0.0005033155,0.000102146914,0.0000020969017,2.9373552e-9,0.000008687998,0.00013265689,0.0074817785,0.96643716],"study_design_scores_gemma":[0.00058099104,0.0037882242,0.02679977,0.019243866,0.002239633,0.0002555138,6.7973326e-7,3.787091e-7,0.0000010538515,0.00008073831,0.94681776,0.00019136627],"about_ca_topic_score_codex":8.410105e-7,"about_ca_topic_score_gemma":0.0000018852584,"teacher_disagreement_score":0.9662458,"about_ca_system_score_codex":0.000041779414,"about_ca_system_score_gemma":0.0036440492,"threshold_uncertainty_score":0.9964751},"labels":[],"label_agreement":null},{"id":"W2727257455","doi":"10.1200/jco.2017.35.15_suppl.10563","title":"Infection related late mortality in survivors of childhood cancer with asplenia or radiation-induced hyposplenism: A report from the Childhood Cancer Survivor Study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Abdominal Trauma and Injuries","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Splenectomy; Radiation therapy; Asplenia; Cumulative incidence; Relative risk; Incidence (geometry); Sepsis; Surgery; Confidence interval; Pediatrics; Internal medicine; Spleen; Transplantation","score_opus":0.1288682227377861,"score_gpt":0.4828281607178734,"score_spread":0.3539599379800873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727257455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912503,0.00026766877,0.000004336015,0.0051605324,0.001935137,0.00067588675,0.00002098728,0.000010207714,0.00067499356],"genre_scores_gemma":[0.99697286,0.0014333852,0.00010215637,0.0003097004,0.0009775987,0.000027211981,0.0000044394997,0.000026491176,0.00014615551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99492246,0.0007591744,0.0031868692,0.0003162853,0.00056944456,0.00024575062],"domain_scores_gemma":[0.99117124,0.0017091612,0.0057457155,0.0006316402,0.00053251616,0.00020973307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047041415,0.00022077221,0.0019267928,0.0000946086,0.00017491983,0.000023861408,0.00029996512,0.00040257085,0.00025383523],"category_scores_gemma":[0.0056792307,0.00011602365,0.00033457763,0.00018885419,0.00032145044,0.00029860897,0.000068827525,0.0014992966,0.0000025337217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040668533,0.0029529743,0.95281,0.000010944356,0.0015467723,0.0007768463,0.0015433312,0.000033515546,0.000045696284,0.0000055058026,0.00014349834,0.036064062],"study_design_scores_gemma":[0.010416959,0.007749005,0.97855055,0.0002810137,0.0012202903,0.0001666254,0.0002945734,0.000022031754,0.00012997512,0.00015213527,0.00088455924,0.00013228292],"about_ca_topic_score_codex":0.043822777,"about_ca_topic_score_gemma":0.11385949,"teacher_disagreement_score":0.07003672,"about_ca_system_score_codex":0.00015515575,"about_ca_system_score_gemma":0.0033906482,"threshold_uncertainty_score":0.9625445},"labels":[],"label_agreement":null},{"id":"W2727639205","doi":"10.1200/jco.2016.34.15_suppl.e13067","title":"Relationship between physical activity and cardiovascular disease risk factors in cancer survivors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Wellbeing Research","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; National Health and Nutrition Examination Survey; Blood pressure; Internal medicine; Risk factor; Population; Cancer; Logistic regression; Environmental health","score_opus":0.39265510851839214,"score_gpt":0.6131200545853529,"score_spread":0.22046494606696077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727639205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908512,0.000295157,0.0002111981,0.007380755,0.00070976577,0.0002571836,0.000031691583,0.000006994149,0.00025603123],"genre_scores_gemma":[0.99649686,0.0012327341,0.000032334494,0.000103730665,0.0019353172,0.000011869889,3.9544378e-7,0.0000130393855,0.0001737295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906302,0.0070175603,0.0012487372,0.00022034819,0.0004332941,0.0004498421],"domain_scores_gemma":[0.95272815,0.04501914,0.00081690634,0.0002243991,0.00021519272,0.0009961932],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012154736,0.00010466317,0.0011976762,0.00013270532,0.00020993709,0.0000026872187,0.00015521176,0.00038821675,0.00005571193],"category_scores_gemma":[0.031901646,0.000057712397,0.00036573954,0.00015492024,0.0002036798,0.00017648828,0.000089957575,0.0025001937,0.000028632576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004720724,0.00019767041,0.89100444,0.000049733047,0.00008147052,0.000026226395,0.00018539555,0.00000610176,0.0000013119829,0.000047478225,0.0002825041,0.10764558],"study_design_scores_gemma":[0.0024127096,0.00049688225,0.9768302,0.000121947814,0.000113126436,2.753684e-7,0.00006377458,0.000018664985,0.0000013021889,0.001750855,0.018124457,0.00006582836],"about_ca_topic_score_codex":0.0034586934,"about_ca_topic_score_gemma":0.0008513616,"teacher_disagreement_score":0.10757975,"about_ca_system_score_codex":0.0002511944,"about_ca_system_score_gemma":0.0035553763,"threshold_uncertainty_score":0.9998011},"labels":[],"label_agreement":null},{"id":"W2728580199","doi":"10.1200/jco.2013.31.15_suppl.3593","title":"Natural history and outcomes of synchronous and metachronous colorectal cancers (CRC): A population-based analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Rectum; Proportional hazards model; Oncology; Natural history; Cancer; Population; Chemotherapy; Gastroenterology","score_opus":0.04481300208295771,"score_gpt":0.3899589335891298,"score_spread":0.3451459315061721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728580199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301964,0.0039856243,0.000050605293,0.0015976483,0.0007147561,0.00018359954,0.0000033538618,0.000005177276,0.00043958097],"genre_scores_gemma":[0.99377745,0.00029605036,0.0031795977,0.0024514846,0.0001634042,0.000003821657,0.000008233468,0.000008832254,0.00011112195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764645,0.00021477751,0.0015900884,0.00017046512,0.00022369045,0.00015450045],"domain_scores_gemma":[0.99625325,0.0016835342,0.001377712,0.000118815224,0.00027976642,0.00028694133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008785031,0.00012743003,0.001994103,0.00025297358,0.000024471085,0.0000043584764,0.00007399856,0.00020402278,0.00047904882],"category_scores_gemma":[0.0009709962,0.00008920218,0.00044959705,0.00010521142,0.00029122614,0.00013750102,0.000022174698,0.00052635267,0.0000010138515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010267925,0.0001993208,0.937835,0.000047410882,0.0023630902,0.000048559545,0.00010204438,0.00011823524,0.00021522514,0.000012864784,0.0010836851,0.056947783],"study_design_scores_gemma":[0.004777276,0.003275448,0.9823062,0.0000140840575,0.0019645768,0.000044173914,0.00005708782,0.003830323,0.000012122559,0.000019363664,0.0036175826,0.000081806764],"about_ca_topic_score_codex":0.0014251934,"about_ca_topic_score_gemma":0.00060719455,"teacher_disagreement_score":0.056865975,"about_ca_system_score_codex":0.00078624353,"about_ca_system_score_gemma":0.0022944696,"threshold_uncertainty_score":0.52452487},"labels":[],"label_agreement":null},{"id":"W2728890777","doi":"10.1200/jco.2017.35.15_suppl.1029","title":"Burden of out-of-pocket spending among high-deductible health plan members with metastatic breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Deductible; Residence; Demography; Breast cancer; Health care; Socioeconomic status; Gerontology; Cancer; Environmental health; Internal medicine; Actuarial science; Population","score_opus":0.20045628053030534,"score_gpt":0.4317389225813,"score_spread":0.23128264205099464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728890777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812824,0.0011164646,0.0003332504,0.0062813493,0.0034971244,0.00015596129,0.00022318083,0.0000036061097,0.007106652],"genre_scores_gemma":[0.99375165,0.0020097194,0.0027101836,0.00021829683,0.0010070511,0.0000024127405,0.0000014021678,0.000023187042,0.000276117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585456,0.00007054301,0.003430288,0.00024098344,0.00007790411,0.00032570033],"domain_scores_gemma":[0.9849438,0.0004277166,0.013768286,0.0003827807,0.00016013009,0.00031730553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00381073,0.00016298577,0.0026209399,0.00019580474,0.0001125701,0.00003222836,0.00060741906,0.00017353111,0.00061703887],"category_scores_gemma":[0.0007654292,0.00014056118,0.00033746654,0.000056704677,0.0005715284,0.0006194163,0.00007433547,0.0005360213,0.000013440384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024389026,0.0007180737,0.8636642,0.00019674713,0.0014960323,0.00006826827,0.0010579348,0.0014585897,0.000006294908,0.024285885,0.0053885216,0.099220514],"study_design_scores_gemma":[0.006195095,0.004797055,0.960628,0.0003077699,0.000120154706,0.00009191703,0.00040746023,0.00020189842,0.000042771288,0.010001035,0.016921517,0.0002853323],"about_ca_topic_score_codex":0.007067057,"about_ca_topic_score_gemma":0.0014796485,"teacher_disagreement_score":0.09893519,"about_ca_system_score_codex":0.00023852644,"about_ca_system_score_gemma":0.00096754916,"threshold_uncertainty_score":0.999545},"labels":[],"label_agreement":null},{"id":"W2728955009","doi":"10.1200/jco.2017.35.15_suppl.505","title":"Targeted sequencing in a phase III trial of luminal breast cancer: Identification of novel targets.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Context (archaeology); Oncology; Cancer; Internal medicine; Exemestane; Bioinformatics; Tamoxifen; Biology","score_opus":0.08615688850888431,"score_gpt":0.4543350189177182,"score_spread":0.3681781304088339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728955009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995738,0.00043059138,0.0009002775,0.0006671163,0.001859662,0.00014673437,0.0000973389,5.353933e-7,0.00015972911],"genre_scores_gemma":[0.9959551,0.0017641376,0.0007039351,0.00009545309,0.0014304081,0.000004403727,0.000007816227,0.00000875525,0.000030005705],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997144,0.00008891139,0.002319464,0.00015888772,0.00015196035,0.00013682236],"domain_scores_gemma":[0.99451494,0.00018011408,0.0044417884,0.0002977425,0.000461019,0.0001043682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022916307,0.00008897279,0.0007659333,0.00006554229,0.000036006848,0.000009149092,0.0003723805,0.00028454428,0.000014404707],"category_scores_gemma":[0.0027546466,0.000079668076,0.00028882304,0.0000361751,0.000260386,0.000010568316,0.00009097813,0.00024317621,2.6790488e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09527703,0.0032641515,0.008736949,0.0000436557,0.00031179414,0.00003773453,0.00010017941,0.0008339295,0.82705855,0.0001238004,0.001285102,0.062927134],"study_design_scores_gemma":[0.5574754,0.028440308,0.1504884,0.000273049,0.0006370811,0.00021571411,0.0003818395,0.0025771202,0.2348059,0.0005345899,0.023613365,0.0005572342],"about_ca_topic_score_codex":0.00033804314,"about_ca_topic_score_gemma":0.00037769484,"teacher_disagreement_score":0.5922527,"about_ca_system_score_codex":0.00008397912,"about_ca_system_score_gemma":0.0023401761,"threshold_uncertainty_score":0.41513717},"labels":[],"label_agreement":null},{"id":"W2728990440","doi":"10.1200/jco.2017.35.15_suppl.2063","title":"Heterogeneous spectrum of childhood and adult SHH medulloblastoma: Clinical, radiogenomic features, patterns of failure and survival.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Medulloblastoma; Sonic hedgehog; Cohort; Internal medicine; Gastroenterology; Oncology; Pathology; Biology; Gene","score_opus":0.046916782453318255,"score_gpt":0.4021199849185419,"score_spread":0.35520320246522363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728990440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869955,0.0016669558,0.0000060399957,0.010161117,0.00074355997,0.0002173156,0.000028443956,0.0000034615266,0.00017759623],"genre_scores_gemma":[0.9909733,0.0070433985,0.0008078106,0.00036586873,0.0007693743,0.0000018097198,0.0000024481342,0.00001956312,0.000016453909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963616,0.0003353797,0.0025264223,0.00026992837,0.0002903538,0.00021632802],"domain_scores_gemma":[0.9935377,0.001615949,0.003640624,0.00045233444,0.0002802044,0.0004731939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018694907,0.0001904332,0.002416003,0.00010843324,0.00007166435,0.00001609344,0.00022901114,0.00045898271,0.00004501151],"category_scores_gemma":[0.0028616872,0.00012876623,0.0006052923,0.000027492848,0.00050182675,0.00007079733,0.00014210732,0.0006401817,0.0000014908723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012720539,0.0032833267,0.94835335,0.000064305816,0.001418276,0.00089447654,0.00006183082,0.0000017496998,0.00017165432,0.00011416837,0.00081344834,0.043551333],"study_design_scores_gemma":[0.015183252,0.014363062,0.9639644,0.00021712977,0.00092710525,0.001350371,0.00006827772,0.000006501748,0.0009177304,0.00021180561,0.0026971695,0.000093173396],"about_ca_topic_score_codex":0.000080985716,"about_ca_topic_score_gemma":0.0005126104,"teacher_disagreement_score":0.04345816,"about_ca_system_score_codex":0.000034018532,"about_ca_system_score_gemma":0.00039099983,"threshold_uncertainty_score":0.5250935},"labels":[],"label_agreement":null},{"id":"W2730272516","doi":"10.1200/jco.2016.34.15_suppl.10015","title":"Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Plant Molecular Biology Research","field":"Agricultural and Biological Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Genome-wide association study; Single-nucleotide polymorphism; Minor allele frequency; Hearing loss; Wolfram syndrome; Medicine; 1000 Genomes Project; Genetics; SNP; Genetic association; Expression quantitative trait loci; Oncology; Genotype; Diabetes mellitus; Biology; Endocrinology; Audiology; Gene","score_opus":0.0816660284993141,"score_gpt":0.3869147397535783,"score_spread":0.3052487112542642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730272516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201685,0.00008726681,0.00000426716,0.0070028277,0.00037644265,0.000406272,0.0000321936,0.0000073900405,0.00006647205],"genre_scores_gemma":[0.99915516,0.0001525905,0.00007788911,0.0003404732,0.00009441666,0.0000117039,0.0000049827595,0.000002654945,0.00016013494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934145,0.002623351,0.002565844,0.0003358082,0.0005447443,0.0005157111],"domain_scores_gemma":[0.9872383,0.010396757,0.0016250925,0.000077132456,0.00040833844,0.0002544045],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01249642,0.00016146785,0.0013453672,0.0001186986,0.00004220558,0.000010817928,0.00048939476,0.0006742021,0.00013457044],"category_scores_gemma":[0.02237813,0.00006448586,0.00022241406,0.0007898425,0.00007844499,0.000096793185,0.00018374686,0.0008692889,0.00001841034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037611803,0.0014402736,0.9626613,0.0000022544953,0.0001817906,0.0018371221,0.00006303447,0.00011785051,0.028423948,0.0000022030101,0.000044865938,0.0048492346],"study_design_scores_gemma":[0.0019666194,0.005287574,0.99180603,0.00010740998,0.0000378724,0.00004755991,0.00004840979,0.000014230381,0.00006556904,0.00017037842,0.00031575677,0.00013261312],"about_ca_topic_score_codex":0.0013505897,"about_ca_topic_score_gemma":0.014970516,"teacher_disagreement_score":0.029144702,"about_ca_system_score_codex":0.0006297311,"about_ca_system_score_gemma":0.0002873836,"threshold_uncertainty_score":0.9858568},"labels":[],"label_agreement":null},{"id":"W2730312532","doi":"10.1200/jco.2016.69.8076","title":"Regionalization and Outcomes of Lung Cancer Surgery in Ontario, Canada","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Odds ratio; Lung cancer; Odds; Lung cancer surgery; Incentive; Interrupted Time Series Analysis; Cancer; Health care; Surgery; Demography; Emergency medicine; Internal medicine; Logistic regression","score_opus":0.21686511226317878,"score_gpt":0.5302308142677649,"score_spread":0.3133657020045861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730312532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98176086,0.0003222696,0.000013034888,0.014780953,0.00056368473,0.00008546069,0.0000010300564,5.7032076e-7,0.002472111],"genre_scores_gemma":[0.9963292,0.0010956682,0.0003432086,0.00084236753,0.00014408813,0.0000022052393,7.0404485e-7,0.0000041490243,0.001238435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979737,0.00017414796,0.0013693109,0.0000832229,0.0002695731,0.00013004344],"domain_scores_gemma":[0.9947543,0.0031366656,0.0014730705,0.00014784181,0.00030471158,0.00018341599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026931185,0.00005755192,0.0015295699,0.0000788531,0.000038842376,0.0000032776804,0.00009538187,0.00018611902,0.00022332968],"category_scores_gemma":[0.0071727172,0.000039226266,0.00011535845,0.000023890205,0.00024181147,0.00006514773,0.000038859467,0.0005098379,1.6060228e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080322137,0.00020271176,0.98175853,0.000028377995,0.00021558868,0.0003890135,0.000047589103,0.0000012087067,0.000003557185,0.000063408814,0.009577484,0.0069093215],"study_design_scores_gemma":[0.0024997613,0.0003805617,0.9877103,0.00012898556,0.0001708285,0.00006447694,0.000021949183,0.000091265516,0.000002490815,0.00012311124,0.008774819,0.00003144011],"about_ca_topic_score_codex":0.8438027,"about_ca_topic_score_gemma":0.98352087,"teacher_disagreement_score":0.1397182,"about_ca_system_score_codex":0.00038744797,"about_ca_system_score_gemma":0.018584691,"threshold_uncertainty_score":0.986979},"labels":[],"label_agreement":null},{"id":"W2731312174","doi":"10.1200/jco.2017.35.15_suppl.106","title":"A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Adverse effect; Oncology; Nausea; Cancer; Gastroenterology; Clinical trial","score_opus":0.12336007878596328,"score_gpt":0.5077908715803896,"score_spread":0.3844307927944263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731312174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973703,0.000095647454,0.00007043638,0.00039758036,0.00054684957,0.00060547347,0.0001413373,0.000004788931,0.0007675646],"genre_scores_gemma":[0.9986103,0.00010464477,0.000620153,0.00025413267,0.0002189918,0.000012485865,0.000016335971,0.000022793181,0.0001401637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954354,0.00038476137,0.0029031206,0.00025903218,0.0007761819,0.00024148043],"domain_scores_gemma":[0.9917222,0.0005015449,0.005682399,0.0005886201,0.0011603255,0.0003448891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013547532,0.00021993817,0.0032361771,0.00034013906,0.00008576811,0.000011784154,0.00037696995,0.00015389457,0.0006025491],"category_scores_gemma":[0.0010884611,0.00013643599,0.00064661005,0.0002908696,0.00033484813,0.000167369,0.00006546847,0.0005254618,0.0000024695184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035552632,0.039295033,0.8316533,0.000038175753,0.022161948,0.00030725624,0.00057860935,0.00006756819,0.000046593,0.000008499205,0.00032634573,0.06996407],"study_design_scores_gemma":[0.09006781,0.08913716,0.79178673,0.000076577104,0.02680816,0.000008344239,0.0003190761,0.0001259525,0.00015256208,0.000021774335,0.0013839637,0.00011190318],"about_ca_topic_score_codex":0.00090738264,"about_ca_topic_score_gemma":0.00085419335,"teacher_disagreement_score":0.069852166,"about_ca_system_score_codex":0.00012774074,"about_ca_system_score_gemma":0.0021516713,"threshold_uncertainty_score":0.65974903},"labels":[],"label_agreement":null},{"id":"W2732225635","doi":"10.1200/jco.2016.72.0946","title":"Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Medical Research Council; Canadian Cancer Society Research Institute; National Institutes of Health; Ipsen; National Health and Medical Research Council; Cancer Research UK; National Institute for Health and Care Research; NRG Oncology; American College of Radiology Imaging Network; AstraZeneca; National Cancer Research Institute; Les Laboratories Pierre Fabre; NIHR Cambridge Biomedical Research Centre; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Oncosuisse; Pfizer; Cancer Research Institute","keywords":"Exemestane; Medicine; Tamoxifen; Breast cancer; Internal medicine; Oncology; Gynecology; Cancer","score_opus":0.14395007342083438,"score_gpt":0.4836322434678865,"score_spread":0.33968217004705215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732225635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700654,0.0015533275,0.0000014929308,0.0006726733,0.00038748016,0.00027233193,0.000012380408,8.03362e-7,0.00009299515],"genre_scores_gemma":[0.99111307,0.008180359,0.000025070593,0.00013328939,0.0004775735,0.000016384309,0.0000016940241,0.000006087268,0.000046482743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973962,0.0010088069,0.0011418946,0.0001637713,0.00016257713,0.00012676152],"domain_scores_gemma":[0.99742794,0.0006892805,0.0015034345,0.00018838196,0.000072877796,0.0001181011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040211864,0.000105587096,0.00082375,0.000034167,0.00004186149,0.000025069163,0.00027203793,0.00017442793,0.000015936086],"category_scores_gemma":[0.001192351,0.000056448676,0.00016751092,0.000018044891,0.00026149073,0.0000124750895,0.00007880235,0.00024959643,2.835064e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006786761,0.0020831763,0.819925,0.0000029535868,0.00081707415,0.000045014716,0.0004189519,0.000002837838,0.0060909805,0.000009794715,0.000075015836,0.16374245],"study_design_scores_gemma":[0.013088562,0.009125187,0.97574514,0.000013539605,0.000049766848,0.000033599896,0.00039552877,0.0000048999655,0.00010963821,0.000019125813,0.0013555001,0.000059496695],"about_ca_topic_score_codex":0.0003895202,"about_ca_topic_score_gemma":0.00025576982,"teacher_disagreement_score":0.16368297,"about_ca_system_score_codex":0.000024369396,"about_ca_system_score_gemma":0.00023357023,"threshold_uncertainty_score":0.23019102},"labels":[],"label_agreement":null},{"id":"W2734451381","doi":"10.1200/jco.2017.35.15_suppl.4507","title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Pazopanib; Clinical endpoint; Placebo; Renal cell carcinoma; Tolerability; Internal medicine; Discontinuation; Nephrectomy; Adverse effect; Surgery; Intention-to-treat analysis; Phases of clinical research; Urology; Gastroenterology; Randomized controlled trial; Clinical trial; Kidney; Pathology; Sunitinib","score_opus":0.06148641616435672,"score_gpt":0.3987801206706259,"score_spread":0.33729370450626917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734451381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922969,0.00027321032,0.00009588504,0.00057938235,0.0014213297,0.0028414698,0.0000070855026,0.0000057928987,0.0024789413],"genre_scores_gemma":[0.99580973,0.00008357841,0.0031060786,0.00014188945,0.00060858275,0.000085205014,0.0000064890937,0.00003440259,0.00012406326],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934991,0.0010800544,0.0038379899,0.0003646324,0.0008184214,0.00039977714],"domain_scores_gemma":[0.9900231,0.0029281687,0.00518576,0.0006478507,0.0007067788,0.0005083486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004125246,0.00032940213,0.0043801456,0.0002287326,0.00005995601,0.000016195816,0.0003477819,0.00042883412,0.00014119862],"category_scores_gemma":[0.0040666074,0.00019938484,0.0009458847,0.00008585068,0.0006227121,0.00020998275,0.00010412607,0.0012046506,0.000008278472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93085295,0.0070696264,0.018483302,0.00004313459,0.00040209154,0.0019240546,0.00009134192,0.000016982625,0.000072902,0.0000030809135,0.000072801384,0.040967707],"study_design_scores_gemma":[0.8121994,0.09222889,0.09265528,0.00018858476,0.0010682298,0.000024125522,0.000028504175,0.000043660977,0.0007363804,0.000022380324,0.0006549578,0.00014960003],"about_ca_topic_score_codex":0.00006738594,"about_ca_topic_score_gemma":0.000086617,"teacher_disagreement_score":0.118653566,"about_ca_system_score_codex":0.00031725437,"about_ca_system_score_gemma":0.0019988602,"threshold_uncertainty_score":0.8130678},"labels":[],"label_agreement":null},{"id":"W2734560446","doi":"10.1200/jco.2013.31.15_suppl.e12031","title":"Quality of life (QoL) and symptoms evaluation in metastatic breast cancer (MBC) patients (pts) treated with eribulin: Preliminary results of a prospective observational study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Eribulin; Tolerability; Internal medicine; Taxane; Metastatic breast cancer; Capecitabine; Anthracycline; Neutropenia; Breast cancer; Adverse effect; Surgery; Gastroenterology; Chemotherapy; Cancer","score_opus":0.2666592212623247,"score_gpt":0.5288009329294016,"score_spread":0.26214171166707684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734560446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597996,0.00022050075,0.0000026854555,0.00199131,0.0001495897,0.001436645,0.000053623407,0.0000024352487,0.00016327301],"genre_scores_gemma":[0.99901414,0.00010032725,0.00037003093,0.00023914022,0.00012464297,0.00008537045,0.000016308333,0.000008519826,0.00004154349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956146,0.0009844945,0.002559523,0.00019605739,0.00051705487,0.00012828046],"domain_scores_gemma":[0.99316084,0.0019313573,0.0026122518,0.00010638439,0.0020156885,0.00017348585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002734213,0.00012685741,0.0014268359,0.00012616826,0.00001591091,0.0000025638342,0.000064893495,0.000116291,0.00019230919],"category_scores_gemma":[0.0015330865,0.00008097601,0.000113769485,0.00022240196,0.00020518914,0.00015235889,0.000027979995,0.00033057242,8.469441e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061170947,0.012786715,0.89465225,0.000049587736,0.0010462821,0.000012339693,0.00051913573,0.0000811925,0.00006348963,0.0000049659307,0.00031977153,0.02929333],"study_design_scores_gemma":[0.056374826,0.05926524,0.88264215,0.00009577848,0.0008920826,0.000013976579,0.00023839473,0.00029270985,0.00001978954,0.00008430119,0.000023256815,0.000057471618],"about_ca_topic_score_codex":0.0012343691,"about_ca_topic_score_gemma":0.0005312717,"teacher_disagreement_score":0.046478525,"about_ca_system_score_codex":0.00027260763,"about_ca_system_score_gemma":0.0018658042,"threshold_uncertainty_score":0.33098564},"labels":[],"label_agreement":null},{"id":"W2734681090","doi":"10.1200/jco.2016.34.15_suppl.4543","title":"Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemotherapy-induced peripheral neuropathy; Peripheral neuropathy; Internal medicine; Genome-wide association study; Imputation (statistics); Single-nucleotide polymorphism; Cumulative dose; Oncology; Sensory neuropathy; Cancer; Cisplatin; Chemotherapy; Genotype; Gene; Genetics; Endocrinology; Diabetes mellitus","score_opus":0.1284873427186085,"score_gpt":0.47914271761906174,"score_spread":0.35065537490045323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734681090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910848,0.00020686534,0.0000097679485,0.006164819,0.0017162268,0.00032153894,0.0000033239269,0.000005277694,0.00048739376],"genre_scores_gemma":[0.99700415,0.0005489505,0.0000807935,0.0010298456,0.00089198194,0.000011271826,5.513343e-7,0.000015225316,0.000417239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631935,0.0008630341,0.0020670977,0.00017793881,0.0003459204,0.00022666938],"domain_scores_gemma":[0.99239224,0.00480921,0.0020211055,0.00012215742,0.0004585133,0.00019675419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024640136,0.0001267848,0.0014366786,0.0001404654,0.000018782921,0.00000267524,0.000115416384,0.00025092825,0.00045469575],"category_scores_gemma":[0.0045466665,0.00007731221,0.00025070168,0.00018123872,0.000046740148,0.00008302677,0.00003643573,0.0005225291,0.00000622872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031036707,0.0058113686,0.9654568,0.000010593202,0.0003862002,0.00061998895,0.00032113306,0.000017526616,0.0060945894,0.0000015468584,0.00027925934,0.017897334],"study_design_scores_gemma":[0.019870803,0.026221685,0.9477249,0.000046986293,0.00051409553,0.000018769915,0.000100642974,0.000011795596,0.00011788409,0.000029863684,0.005273379,0.00006922763],"about_ca_topic_score_codex":0.0004074998,"about_ca_topic_score_gemma":0.0024401296,"teacher_disagreement_score":0.020410316,"about_ca_system_score_codex":0.0006879734,"about_ca_system_score_gemma":0.0010630045,"threshold_uncertainty_score":0.5443113},"labels":[],"label_agreement":null},{"id":"W2734805236","doi":"10.1200/jco.2017.35.15_suppl.8506","title":"Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Gastroenterology; Progression-free survival; Clinical endpoint; Pemetrexed; Confidence interval; Placebo; Urology; Randomized controlled trial; Cisplatin; Chemotherapy; Pathology","score_opus":0.07346927153434472,"score_gpt":0.4038931658029776,"score_spread":0.3304238942686329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734805236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930029,0.00010766832,0.0000056941026,0.003499303,0.0009540956,0.00065289857,0.00021955505,0.000007944248,0.001549936],"genre_scores_gemma":[0.99733067,0.00013345473,0.00055877236,0.00077022414,0.000668224,0.000008303787,0.000058838985,0.000035612866,0.00043590897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994495,0.000711548,0.002779921,0.00044758854,0.0012179653,0.00034799124],"domain_scores_gemma":[0.99165666,0.0033152872,0.0036415104,0.00071611133,0.00029642263,0.00037401216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024217977,0.00032367453,0.0017685951,0.000122018566,0.00015422593,0.000037073045,0.000675675,0.00034541418,0.00027353232],"category_scores_gemma":[0.004443056,0.00018050885,0.00041906172,0.00010837699,0.00042225275,0.0002610584,0.00025727288,0.0011504854,0.000029311233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10864764,0.00796317,0.8698566,0.000020283225,0.00057191047,0.00061301095,0.0005142141,0.000065563814,0.00005903643,0.000014927322,0.003961012,0.0077126576],"study_design_scores_gemma":[0.046573117,0.020221474,0.928719,0.00030593554,0.0005833212,0.000040458264,0.00079488405,0.00014977985,0.000040265324,0.00013844046,0.0022537163,0.0001795941],"about_ca_topic_score_codex":0.00079894584,"about_ca_topic_score_gemma":0.0014091159,"teacher_disagreement_score":0.06207452,"about_ca_system_score_codex":0.00023184378,"about_ca_system_score_gemma":0.0004534497,"threshold_uncertainty_score":0.7360937},"labels":[],"label_agreement":null},{"id":"W2734872002","doi":"10.1200/jco.2017.35.15_suppl.tps3101","title":"A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; Tolerability; CD47; Immune checkpoint; Blockade; Immune system; Cancer research; Immunology; Internal medicine; Receptor; Adverse effect","score_opus":0.08247291652155142,"score_gpt":0.41280039837092064,"score_spread":0.3303274818493692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734872002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528635,0.0010055077,0.00007422197,0.00066856045,0.00232256,0.00040480844,0.000008571921,0.000009833439,0.00021960585],"genre_scores_gemma":[0.99783117,0.000579615,0.0009552684,0.000055885295,0.00040963126,0.000009917782,0.000014776703,0.000026066658,0.00011767385],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99468035,0.0006491287,0.0038270452,0.00032405503,0.00013572804,0.00038367658],"domain_scores_gemma":[0.9914117,0.0015602121,0.0062121577,0.00035601365,0.0003643038,0.00009563872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045897183,0.00025898588,0.0020706232,0.00023987907,0.00022163871,0.000045759647,0.00039318128,0.00070774497,0.000100455865],"category_scores_gemma":[0.006411554,0.00017509301,0.00031268568,0.00012520958,0.0006833434,0.00064534246,0.00015067728,0.0013231373,0.0000038732255],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23288798,0.006188991,0.0034382038,0.000055850138,0.00034219268,0.000212793,0.00040993956,0.000018498273,0.7077476,0.000029300614,0.00015512975,0.048513547],"study_design_scores_gemma":[0.4850526,0.11833646,0.26599678,0.0014999001,0.00061523274,0.0021427923,0.0009884764,0.000448744,0.11894454,0.0001687178,0.00506484,0.0007409098],"about_ca_topic_score_codex":0.00012509315,"about_ca_topic_score_gemma":0.00011736979,"teacher_disagreement_score":0.58880305,"about_ca_system_score_codex":0.00014886154,"about_ca_system_score_gemma":0.0012968652,"threshold_uncertainty_score":0.7675692},"labels":[],"label_agreement":null},{"id":"W2734875224","doi":"10.1200/jco.2017.35.15_suppl.5008","title":"Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Randomized controlled trial; Hazard ratio; Quality of life (healthcare); Confidence interval; Radiation therapy; Internal medicine; Proportional hazards model; Urology; Surgery; Oncology; Cancer","score_opus":0.18353912180918638,"score_gpt":0.5299372098789196,"score_spread":0.34639808806973316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734875224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911975,0.0009914942,0.000029813815,0.00571995,0.000515406,0.0012521053,0.000025694198,0.0000019354952,0.00026609274],"genre_scores_gemma":[0.9565144,0.04224098,0.0005155351,0.000050147482,0.00042051147,0.000029561059,0.000009615447,0.0000069113507,0.00021233433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947988,0.00085175666,0.0037112362,0.00013685391,0.00035970545,0.0001416897],"domain_scores_gemma":[0.9895235,0.0023578594,0.0070666415,0.00023381723,0.0007001564,0.00011804484],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0103763435,0.000092197035,0.0021260218,0.00016014607,0.000049344217,0.000007710145,0.00015008647,0.00021130354,0.000030445952],"category_scores_gemma":[0.013158084,0.00005419815,0.00041489207,0.000078103585,0.00041034012,0.00014378964,0.000026068128,0.00049251947,5.396251e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.771724,0.0021501256,0.01669228,0.000016229455,0.00045416324,0.00007846312,0.00022767212,0.000009479498,0.00038313709,0.00001555544,0.00023799026,0.20801093],"study_design_scores_gemma":[0.9406395,0.0203395,0.031778567,0.00017317437,0.0002705492,0.000008837008,0.000028474045,0.00018537237,0.004507465,0.0008365708,0.0011892549,0.00004275527],"about_ca_topic_score_codex":0.0007558424,"about_ca_topic_score_gemma":0.00012037977,"teacher_disagreement_score":0.20796816,"about_ca_system_score_codex":0.00010200581,"about_ca_system_score_gemma":0.0022358112,"threshold_uncertainty_score":0.9951545},"labels":[],"label_agreement":null},{"id":"W2735008482","doi":"10.1200/jco.2013.31.15_suppl.1579","title":"The impact of body mass index on survival in stage 3 and 4 lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Underweight; Body mass index; Internal medicine; Overweight; Lung cancer; Stage (stratigraphy); Obesity paradox; Hazard ratio; Cancer; Proportional hazards model; Comorbidity; Gastroenterology; Oncology; Confidence interval","score_opus":0.0938281191878941,"score_gpt":0.5300742077406231,"score_spread":0.43624608855272895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735008482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938412,0.0005917781,0.000011634907,0.0032684421,0.0006765598,0.00015309667,0.0000042314655,0.0000014162393,0.0014516606],"genre_scores_gemma":[0.99583066,0.0032310544,0.000025971452,0.00019881137,0.00046577232,0.0000025133409,2.04831e-7,0.000007341737,0.00023765501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810445,0.00020806694,0.0012369067,0.00008374361,0.0002048969,0.00016194153],"domain_scores_gemma":[0.99645656,0.0021165768,0.0009313787,0.00011182521,0.00017574154,0.0002078999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017629558,0.00007922346,0.00085921655,0.00006645928,0.000019098856,0.0000071852355,0.000088636334,0.00018424493,0.00024490184],"category_scores_gemma":[0.0010711439,0.000038736787,0.00025076364,0.00007866951,0.00017063468,0.0000559961,0.000021181524,0.0008164245,0.0000013309373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022499308,0.00024482043,0.94590783,0.000010571011,0.0001912207,0.000043659795,0.00003788702,0.00006422217,0.00020548457,0.000033802087,0.0024105082,0.04860009],"study_design_scores_gemma":[0.0040798103,0.0063863643,0.98511004,0.000063879284,0.00004583501,0.000010169844,0.00010733375,0.00081284554,0.000015098287,0.00012156356,0.003209935,0.000037137757],"about_ca_topic_score_codex":0.0028636125,"about_ca_topic_score_gemma":0.00046148722,"teacher_disagreement_score":0.04856295,"about_ca_system_score_codex":0.00019712702,"about_ca_system_score_gemma":0.0010940016,"threshold_uncertainty_score":0.43289444},"labels":[],"label_agreement":null},{"id":"W2735026933","doi":"10.1200/jco.2017.35.15_suppl.5575","title":"Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Proportional hazards model; Carboplatin; Ovarian cancer; Logistic regression; Cancer; Surgery; Oncology; Cisplatin","score_opus":0.05070146682993377,"score_gpt":0.394004814131398,"score_spread":0.3433033473014642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735026933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935631,0.00017304745,0.000024229774,0.0043952083,0.00072173413,0.0009329332,0.000024686433,0.0000029917646,0.00016205144],"genre_scores_gemma":[0.9976911,0.0010559614,0.0003440376,0.0002497727,0.000573618,0.000011844011,0.0000016849264,0.00002667526,0.000045289464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968737,0.00023461525,0.0018113945,0.0002889077,0.0005692928,0.00022209734],"domain_scores_gemma":[0.995509,0.00076288346,0.0023881483,0.00037595702,0.000783881,0.00018012867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017461837,0.0002237495,0.001806607,0.000104162806,0.0000903051,0.00002124151,0.00020967769,0.00021858008,0.00002528447],"category_scores_gemma":[0.00036503226,0.00012798248,0.00022951493,0.00006770171,0.00034415812,0.00012183123,0.000063709536,0.0005600679,1.5940475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00914675,0.0037151743,0.8267477,0.000022847576,0.0017827121,0.0000500364,0.0014448123,0.000016143771,0.000009976686,0.00001176352,0.0000325271,0.15701951],"study_design_scores_gemma":[0.02463591,0.020326626,0.9528825,0.00061416376,0.0006299901,0.000006818748,0.00030139377,0.000045872486,0.000090084286,0.000017360058,0.00034652828,0.00010273885],"about_ca_topic_score_codex":0.00047868822,"about_ca_topic_score_gemma":0.0014814566,"teacher_disagreement_score":0.15691677,"about_ca_system_score_codex":0.00015632126,"about_ca_system_score_gemma":0.000748852,"threshold_uncertainty_score":0.5218974},"labels":[],"label_agreement":null},{"id":"W2735060120","doi":"10.1200/jco.2017.35.15_suppl.5502","title":"Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Endometrial cancer; Carboplatin; Radiation therapy; Internal medicine; Randomized controlled trial; Chemotherapy; Stage (stratigraphy); Survival analysis; Surgery; Gastroenterology; Urology; Cancer; Cisplatin","score_opus":0.12051250793628143,"score_gpt":0.45332855671237127,"score_spread":0.33281604877608983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735060120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490846,0.00057805394,0.000036567697,0.008076718,0.004695085,0.0011603327,0.000085233325,0.000002561906,0.0004569883],"genre_scores_gemma":[0.9818341,0.014030237,0.00075594767,0.00023313734,0.002910638,0.00005074176,0.0000040644595,0.000012459344,0.00016868026],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965756,0.00034802794,0.0021743313,0.00018172956,0.0005592708,0.00016103005],"domain_scores_gemma":[0.9853969,0.007168819,0.006461318,0.0002641383,0.0005480613,0.00016076532],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005410392,0.00014003464,0.002333156,0.00013205581,0.00007356706,0.000012204422,0.00030688717,0.00021750883,0.00007416603],"category_scores_gemma":[0.01574399,0.00006856453,0.0005141864,0.00010545925,0.0004761556,0.00009350127,0.00003568242,0.0003630281,1.8354778e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6940115,0.0008894241,0.0032445749,0.00000822772,0.001953881,0.000006201005,0.000072537405,0.000004120327,0.000074392934,0.000022246499,0.00020707404,0.29950583],"study_design_scores_gemma":[0.8696217,0.041722044,0.07928724,0.000056005374,0.00054935593,0.000008691891,0.000028114171,0.000020457055,0.0010236076,0.00046591143,0.007160037,0.000056840512],"about_ca_topic_score_codex":0.00037589425,"about_ca_topic_score_gemma":0.0000712091,"teacher_disagreement_score":0.299449,"about_ca_system_score_codex":0.00017723713,"about_ca_system_score_gemma":0.0011687683,"threshold_uncertainty_score":0.9925468},"labels":[],"label_agreement":null},{"id":"W2735381707","doi":"10.1200/jco.2007.25.18_suppl.5111","title":"Cost effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bayer (Canada); Women's College Hospital; University Health Network","funders":"","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Internal medicine; Incremental cost-effectiveness ratio; Oncology; Cost effectiveness; Hepatocellular carcinoma; Cost-effectiveness analysis","score_opus":0.10373986699389474,"score_gpt":0.4384161166538799,"score_spread":0.33467624965998516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735381707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917463,0.0010086948,0.00001644446,0.00013476059,0.001145463,0.00049707614,0.000008381612,0.0000014106683,0.005441467],"genre_scores_gemma":[0.9989659,0.00007398643,0.00065217,0.00008132202,0.00017500637,0.0000055190253,0.000009173802,0.000017490947,0.000019413465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955943,0.00065306405,0.0026512877,0.00023753193,0.00047516814,0.0003886462],"domain_scores_gemma":[0.991464,0.0059698545,0.0014289429,0.0001990252,0.0005355097,0.0004026191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031260878,0.00018379327,0.0018536784,0.00025525736,0.000012586592,0.0000015553046,0.00015378297,0.0002679601,0.00003748784],"category_scores_gemma":[0.0013669232,0.00014484389,0.00029866846,0.00028413758,0.00012626292,0.000068748384,0.000045341818,0.0010473969,0.0000029169203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07224116,0.0013532961,0.8511261,0.00020185915,0.00008183867,0.016865117,0.00024210293,0.0003975499,0.001377184,0.0000062255144,0.000041990716,0.056065608],"study_design_scores_gemma":[0.03525311,0.022657821,0.91635364,0.00023376977,0.00018144639,0.00011612635,0.0022390452,0.000008346111,0.02205834,0.000010935784,0.00078423374,0.00010317031],"about_ca_topic_score_codex":0.11552531,"about_ca_topic_score_gemma":0.6955101,"teacher_disagreement_score":0.5799848,"about_ca_system_score_codex":0.003983379,"about_ca_system_score_gemma":0.011646122,"threshold_uncertainty_score":0.99984014},"labels":[],"label_agreement":null},{"id":"W2735428460","doi":"10.1200/jco.2016.34.15_suppl.521","title":"Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University; Queen's University","funders":"","keywords":"Medicine; Anastrozole; Exemestane; Breast cancer; Oncology; Stage (stratigraphy); Internal medicine; Cancer; Aromatase; Aromatase inhibitor; Gynecology","score_opus":0.05272458359911692,"score_gpt":0.3851508227285753,"score_spread":0.3324262391294584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735428460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954038,0.00039850615,0.0000038505787,0.0032323939,0.00027503082,0.00040540157,0.00019876492,0.0000016629878,0.00008056883],"genre_scores_gemma":[0.9932358,0.0051120264,0.000105856045,0.0007882848,0.00028974947,0.000040533378,0.0000047639714,0.000022813714,0.00040015185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958547,0.0013921038,0.0017657923,0.0002671112,0.00025476472,0.00046553192],"domain_scores_gemma":[0.9960614,0.0016417131,0.001497417,0.0002279,0.00023141266,0.0003401948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031993203,0.00022800824,0.0014192975,0.00017913948,0.00003727118,0.000013308847,0.00039803007,0.00057954853,0.00018313529],"category_scores_gemma":[0.0021323177,0.00009333306,0.00021555653,0.00024597402,0.0003358238,0.000022440172,0.00004624457,0.0005073414,0.0000020255666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029248577,0.0006851172,0.92398137,0.00003230589,0.001192753,0.0031321214,0.00035328802,0.000079334925,0.02452935,0.000020985783,0.00075240975,0.01599237],"study_design_scores_gemma":[0.017483488,0.016105067,0.95526904,0.00033108235,0.00021202293,0.00032236302,0.0006446753,0.0000018218193,0.0052016145,0.000025757781,0.0041285614,0.00027453311],"about_ca_topic_score_codex":0.025293348,"about_ca_topic_score_gemma":0.52595824,"teacher_disagreement_score":0.5006649,"about_ca_system_score_codex":0.00033071343,"about_ca_system_score_gemma":0.0066645015,"threshold_uncertainty_score":0.9989668},"labels":[],"label_agreement":null},{"id":"W2735633287","doi":"10.1200/jco.2017.35.15_suppl.3517","title":"Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuts composition and effects","field":"Nursing","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Glycemic load; Type 2 diabetes; Cancer; Prospective cohort study; Colorectal cancer; Surgery; Glycemic index; Diabetes mellitus; Glycemic; Confidence interval; Insulin; Endocrinology","score_opus":0.14131194729936958,"score_gpt":0.4841160872620551,"score_spread":0.3428041399626855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735633287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983331,0.00018848071,0.000010952486,0.007416505,0.007966299,0.00015893044,0.000049345213,0.0000067435544,0.00087174604],"genre_scores_gemma":[0.99693406,0.00072623126,0.00034432893,0.0010969223,0.00077667634,0.000002483813,0.0000071016498,0.00001024259,0.00010198442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704283,0.0007037845,0.0016017981,0.0002131961,0.0002371189,0.00020125155],"domain_scores_gemma":[0.9944141,0.0026161142,0.0023351738,0.0002034832,0.00020868648,0.00022247371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021318807,0.000114815215,0.0008751939,0.000051439358,0.00013582797,0.00005103126,0.00022878114,0.00034181992,0.00007014719],"category_scores_gemma":[0.0030067146,0.00009507756,0.0001234497,0.000024735824,0.0002650068,0.0002784575,0.000065195454,0.0007958523,0.000014890773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03301191,0.0014381305,0.83251864,0.00003153677,0.00007414175,0.00021344062,0.00034084567,0.000034757664,0.0005918807,0.000043728367,0.006478134,0.12522286],"study_design_scores_gemma":[0.025850505,0.0029707318,0.9463983,0.00022702082,0.00005787777,0.0000026803705,0.000025281379,0.0002546502,0.00014969854,0.00022366617,0.023731697,0.0001078705],"about_ca_topic_score_codex":0.00079038116,"about_ca_topic_score_gemma":0.0022826844,"teacher_disagreement_score":0.12511499,"about_ca_system_score_codex":0.00018758903,"about_ca_system_score_gemma":0.0001455619,"threshold_uncertainty_score":0.38771504},"labels":[],"label_agreement":null},{"id":"W2736373206","doi":"10.1200/jco.2017.35.15_suppl.10525","title":"Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1<sup>+</sup> advanced, relapsed, or refractory solid tumor or lymphoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Refractory (planetary science); Internal medicine; Metastatic melanoma; Lymphoma; Phases of clinical research; Oncology; Melanoma; Cancer; Progressive disease; Disease; Surgery; Nuclear medicine; Clinical trial; Immunotherapy; Cancer research","score_opus":0.0674205008324529,"score_gpt":0.4443536176567062,"score_spread":0.37693311682425334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736373206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618644,0.00042826182,0.000013632243,0.00051168416,0.0010726167,0.0012050765,0.000020783269,0.000017347267,0.00054415787],"genre_scores_gemma":[0.9933852,0.0022205177,0.0016082235,0.00095129537,0.000841227,0.000038644343,0.000004804032,0.00007128929,0.00087880867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925813,0.0006834722,0.0046380255,0.0005708377,0.000933793,0.00059259334],"domain_scores_gemma":[0.98855084,0.002521172,0.0066215605,0.0009575421,0.0008422226,0.00050664844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024543738,0.000449251,0.0031766153,0.00045243555,0.00018194974,0.000027447788,0.0007708463,0.00045236354,0.00040478862],"category_scores_gemma":[0.0074631427,0.00024760835,0.0004792089,0.00038866384,0.0004306846,0.0005620115,0.00014822223,0.0010984986,0.000010251989],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59310395,0.03116002,0.07115124,0.00012778657,0.00049153465,0.003778843,0.0007059772,0.000041123145,0.000066183784,5.5577755e-7,0.000619747,0.29875305],"study_design_scores_gemma":[0.37374055,0.301103,0.30345818,0.00045894022,0.0008103082,0.00057914905,0.002536375,0.000113691916,0.000061869345,0.0000074024065,0.016788619,0.0003418972],"about_ca_topic_score_codex":0.00009094502,"about_ca_topic_score_gemma":0.0010529609,"teacher_disagreement_score":0.29841113,"about_ca_system_score_codex":0.0006264551,"about_ca_system_score_gemma":0.0054343063,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2736524699","doi":"10.1200/jco.2016.34.15_suppl.2566","title":"Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Mucositis; Docetaxel; Internal medicine; Lung cancer; Oncology; Cancer; Nausea; Neutropenia; Rash; Adverse effect; Cisplatin; Chemotherapy; Pharmacology","score_opus":0.07143554523852524,"score_gpt":0.49383403129225345,"score_spread":0.4223984860537282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736524699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913106,0.00010261194,0.000030193558,0.007025578,0.00040160265,0.00043213094,0.0000053767235,0.0000026648552,0.0006892691],"genre_scores_gemma":[0.9988686,0.00008246173,0.00029682383,0.00034872163,0.00021387596,0.0000064822557,5.794979e-7,0.000008615618,0.00017387094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791425,0.00028920305,0.0012974663,0.00012470492,0.00026677156,0.00010760996],"domain_scores_gemma":[0.9969793,0.0012628076,0.0011753498,0.00014978866,0.0003057366,0.00012700666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010669307,0.00008773125,0.00073835993,0.00008878773,0.000032100736,0.0000044008357,0.00007928821,0.00011163992,0.00003434773],"category_scores_gemma":[0.0011557358,0.000036544483,0.00008959222,0.00012700909,0.00016369375,0.00011785466,0.000031576987,0.00029258276,0.0000011600279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006760967,0.026242265,0.7600851,0.000028726396,0.0006078184,0.00025934007,0.0010826341,0.0000025850502,0.0005133286,0.00022594817,0.0014427861,0.20274848],"study_design_scores_gemma":[0.15192395,0.07669035,0.76106554,0.00043047438,0.0010198769,0.0002350728,0.0011496607,0.000021057127,0.00030266575,0.00028937648,0.006788153,0.000083796374],"about_ca_topic_score_codex":0.000023780274,"about_ca_topic_score_gemma":0.0001302077,"teacher_disagreement_score":0.20266467,"about_ca_system_score_codex":0.00010156378,"about_ca_system_score_gemma":0.0007219111,"threshold_uncertainty_score":0.14902408},"labels":[],"label_agreement":null},{"id":"W2736721690","doi":"10.1200/jco.2012.30.15_suppl.e14568","title":"The impact of HER2 positivity on survival in metastatic gastric and GEJ cancer in the province of British Columbia: An updated analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cancer; Adenocarcinoma; Oncology; Gastroenterology; Immunohistochemistry","score_opus":0.07213981281943703,"score_gpt":0.4612783686129653,"score_spread":0.38913855579352824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736721690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780184,0.00043546566,0.00001872396,0.001048582,0.00016257093,0.00021430866,0.00001436792,0.0000010727002,0.0003030514],"genre_scores_gemma":[0.9988228,0.0006385176,0.00009586791,0.000208409,0.00013344952,0.0000023638827,0.000002030099,0.0000046413907,0.000091920876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700403,0.0010329143,0.0013568279,0.000094385025,0.000300923,0.00021092517],"domain_scores_gemma":[0.9965223,0.0019048504,0.0011830766,0.00014674492,0.00012896322,0.000114062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069447206,0.00006725203,0.0011811338,0.00012751934,0.000018584487,0.000013659739,0.00015224003,0.00007244591,0.00006009987],"category_scores_gemma":[0.0007040192,0.00004502808,0.0003099607,0.0005986082,0.00018561757,0.00011656883,0.000032229793,0.000520899,1.777942e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091370416,0.0013116815,0.9429805,0.000011087425,0.00071182125,0.00011513709,0.000049267386,0.0001166387,0.000007184186,0.000007143713,0.0012542725,0.052521538],"study_design_scores_gemma":[0.0031889086,0.0043898756,0.9906772,0.000030167017,0.00092503254,0.000040254083,0.00024847183,0.00017922277,7.020094e-7,0.00004071061,0.0002457796,0.000033717588],"about_ca_topic_score_codex":0.017226983,"about_ca_topic_score_gemma":0.13522542,"teacher_disagreement_score":0.117998436,"about_ca_system_score_codex":0.00012443909,"about_ca_system_score_gemma":0.0005251869,"threshold_uncertainty_score":0.98931736},"labels":[],"label_agreement":null},{"id":"W2737219695","doi":"10.1200/jco.2018.36.6_suppl.tps527","title":"S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"","keywords":"Medicine; Atezolizumab; Cystectomy; Bladder cancer; Clinical endpoint; Oncology; Internal medicine; Population; Immunotherapy; Cancer; Urology; Pembrolizumab; Randomized controlled trial","score_opus":0.16962735630686301,"score_gpt":0.5273361999820035,"score_spread":0.35770884367514055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737219695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851631,0.00044180936,0.000020036357,0.005283109,0.0028371355,0.0005062326,0.000021966844,0.0000055793316,0.0057210526],"genre_scores_gemma":[0.99142575,0.0013112781,0.00061611395,0.0022813075,0.0037312906,0.000015281372,0.000001966407,0.000021461816,0.00059552403],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958972,0.00051711407,0.0026466774,0.00023017345,0.00041613344,0.00029272097],"domain_scores_gemma":[0.9951009,0.0016715734,0.0017916342,0.00023878152,0.00084251777,0.0003545759],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017504309,0.00017414139,0.0018633406,0.0002244057,0.000048369257,0.000003825311,0.00019365668,0.00041651307,0.0011155374],"category_scores_gemma":[0.0041513927,0.00012454332,0.00051680254,0.0002561559,0.0005010116,0.00011770437,0.00007583227,0.00071939256,0.000023160057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6690548,0.01669833,0.0072346064,0.000034496672,0.0012739754,0.0012693808,0.0012357523,0.000003975959,0.0019474939,0.00005791261,0.011163196,0.29002607],"study_design_scores_gemma":[0.5624724,0.3354745,0.039028622,0.00034481625,0.0010563812,0.00023225129,0.00035813998,0.000023641673,0.005209382,0.0006715587,0.05494496,0.0001833612],"about_ca_topic_score_codex":0.0002525229,"about_ca_topic_score_gemma":0.0006804272,"teacher_disagreement_score":0.31877616,"about_ca_system_score_codex":0.00026311912,"about_ca_system_score_gemma":0.0063260337,"threshold_uncertainty_score":0.9997976},"labels":[],"label_agreement":null},{"id":"W2737220576","doi":"10.1200/jco.2013.31.15_suppl.574","title":"Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre; McMaster University; Grand River Hospital; Ottawa Hospital; BC Cancer Agency; Health Sciences Centre; Ontario Clinical Oncology Group; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; N-terminal telopeptide; Placebo; Bone remodeling; Gastroenterology; Vandetanib; Fulvestrant; Breast cancer; Oncology; Urology; Endocrinology; Cancer; Estrogen receptor; Pathology; Receptor; Osteocalcin","score_opus":0.042590186934656354,"score_gpt":0.416951622254952,"score_spread":0.37436143532029564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737220576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820804,0.0013833382,0.00028737227,0.004015795,0.0008220334,0.011172659,0.00006939799,0.000019662535,0.00014932778],"genre_scores_gemma":[0.9916905,0.00096770335,0.0038850787,0.00059545913,0.0009629298,0.0011400959,0.000005617282,0.00007840818,0.00067417],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877896,0.0028981774,0.0069085388,0.000547124,0.0010746586,0.0007819037],"domain_scores_gemma":[0.9842143,0.0070188334,0.0062697083,0.00040751387,0.0013016114,0.00078801706],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0086894985,0.00059381797,0.010887748,0.00048233572,0.00009050779,0.000020153899,0.00028455962,0.00034453813,0.0012399572],"category_scores_gemma":[0.002449098,0.000329905,0.0006248206,0.00048015043,0.00095970003,0.00047751344,0.00009111355,0.001588056,0.000008502156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8904309,0.025639623,0.00011986358,0.000044899476,0.00577399,0.0016416765,0.0023377086,0.00006775845,0.00274305,0.000007950653,0.00013329157,0.07105928],"study_design_scores_gemma":[0.8276131,0.16180006,0.0022730085,0.00032798454,0.0025972733,0.001969507,0.0026245362,0.00016106258,0.00004382086,0.00012404777,0.00018029936,0.00028531512],"about_ca_topic_score_codex":0.00036117225,"about_ca_topic_score_gemma":0.0002809496,"teacher_disagreement_score":0.13616043,"about_ca_system_score_codex":0.001057411,"about_ca_system_score_gemma":0.0068222987,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W2737231281","doi":"10.1200/jco.2016.34.15_suppl.5006","title":"Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cabazitaxel; Docetaxel; Medicine; Regimen; Clinical endpoint; Prostate cancer; Internal medicine; Mitoxantrone; Urology; Chemotherapy; Surgery; Cancer; Randomized controlled trial; Androgen deprivation therapy","score_opus":0.11248796443945806,"score_gpt":0.4847442914826962,"score_spread":0.37225632704323813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737231281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883244,0.0006660611,0.000055613604,0.008441307,0.0003527811,0.0018233485,0.000053752778,0.000009572401,0.000273159],"genre_scores_gemma":[0.9969047,0.0009163905,0.00056754955,0.000496363,0.00026269798,0.00008564137,0.000005371426,0.000035842626,0.0007254909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956421,0.00039117815,0.002249356,0.0003683248,0.00086059765,0.00048840203],"domain_scores_gemma":[0.99570817,0.001056922,0.0014953272,0.0002638875,0.0009807895,0.0004949026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021334235,0.0002682098,0.0017465927,0.00026442646,0.00006998819,0.000019382975,0.00019242411,0.00014258946,0.00039270445],"category_scores_gemma":[0.00058159645,0.0001282172,0.0002473234,0.00033577485,0.0003437096,0.00027519692,0.000038416303,0.00069943856,0.000009966015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14180592,0.024567297,0.66763335,0.000053333788,0.002009321,0.0024935938,0.001060032,0.000006675574,0.00024705165,0.000018107032,0.00091721787,0.15918812],"study_design_scores_gemma":[0.24873963,0.089620814,0.6549187,0.00047035396,0.0007562405,0.000035889698,0.0006906543,0.000022619919,0.00012241237,0.0002767792,0.004134398,0.00021151888],"about_ca_topic_score_codex":0.00030717623,"about_ca_topic_score_gemma":0.0032636174,"teacher_disagreement_score":0.1589766,"about_ca_system_score_codex":0.0007595682,"about_ca_system_score_gemma":0.0035478456,"threshold_uncertainty_score":0.6293726},"labels":[],"label_agreement":null},{"id":"W2737281927","doi":"10.1200/jco.2016.34.15_suppl.5540","title":"Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cutoff; Internal medicine; Oncology; Loss of heterozygosity; Gastroenterology; Allele; Gene; Genetics","score_opus":0.14710673438001953,"score_gpt":0.44752144419607326,"score_spread":0.3004147098160537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737281927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996547,0.00005052784,0.00014672597,0.0016001221,0.0004914984,0.0010309654,0.000049635357,0.0000025882002,0.00008095929],"genre_scores_gemma":[0.9981735,0.00007645235,0.0011877888,0.00021167276,0.00025229822,0.000031276482,0.0000033543065,0.000018921937,0.00004478718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944207,0.00053796184,0.0040841214,0.00025927584,0.00045212897,0.0002457813],"domain_scores_gemma":[0.9941122,0.0013415344,0.0034713126,0.00034779267,0.0005499351,0.00017725663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025177677,0.00016800857,0.0020588622,0.00028656874,0.0000189983,0.0000014999932,0.00022034578,0.00023887768,0.00011339785],"category_scores_gemma":[0.00067621464,0.00010710949,0.00023924132,0.00017359747,0.00028853217,0.00008348837,0.00006431241,0.00040264628,4.7622433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10172181,0.050001472,0.82330763,0.00009808668,0.0004808378,0.000101814825,0.00093082216,0.000029456149,0.003358431,0.00013218955,0.00086077116,0.018976657],"study_design_scores_gemma":[0.1602084,0.13941607,0.6943634,0.0003681489,0.00019463757,0.000013715459,0.0001289168,0.000006695393,0.0022483359,0.00030834702,0.002648611,0.00009470822],"about_ca_topic_score_codex":0.0001373412,"about_ca_topic_score_gemma":0.00036748365,"teacher_disagreement_score":0.12894425,"about_ca_system_score_codex":0.00034230135,"about_ca_system_score_gemma":0.0008728692,"threshold_uncertainty_score":0.43677983},"labels":[],"label_agreement":null},{"id":"W2737686344","doi":"10.1200/jco.2017.35.15_suppl.7535","title":"Copanlisib in patients with relapsed or refractory follicular lymphoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Gastroenterology; Follicular lymphoma; Phases of clinical research; Bendamustine; Lymphoma; Surgery; Chemotherapy; Rituximab","score_opus":0.09130624193372662,"score_gpt":0.44105235070447285,"score_spread":0.34974610877074624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737686344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215746,0.00014487721,0.0000029496641,0.0031637684,0.0007643044,0.00021647732,0.0000022134182,0.0000043390396,0.0035436356],"genre_scores_gemma":[0.99607503,0.00035720607,0.0015321504,0.0013290094,0.00039053435,0.000005052489,0.0000026895855,0.0000148220115,0.00029352732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975098,0.00018489429,0.0015201434,0.00017985448,0.00039909413,0.00020624309],"domain_scores_gemma":[0.99572885,0.0009699925,0.002181145,0.00043277693,0.00034955755,0.00033769687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012657109,0.00013478685,0.001362342,0.00008994024,0.00007331814,0.000018711258,0.0002068862,0.00031425172,0.00010339843],"category_scores_gemma":[0.0039385683,0.00006909466,0.00027967108,0.000045563498,0.0001898966,0.00018125983,0.000051355426,0.00029327665,0.000027264088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014134996,0.007744124,0.8102971,0.00000880656,0.00028536833,0.0030235886,0.00002502498,9.089521e-7,0.0000010436735,0.000025446454,0.002170155,0.16228347],"study_design_scores_gemma":[0.06169529,0.026954353,0.8476752,0.00019713154,0.00028354727,0.000078604375,0.00001758031,0.000004114062,0.000013727173,0.000033211916,0.0629783,0.00006893662],"about_ca_topic_score_codex":0.000050514234,"about_ca_topic_score_gemma":0.00010480493,"teacher_disagreement_score":0.16221452,"about_ca_system_score_codex":0.00037861458,"about_ca_system_score_gemma":0.0018061033,"threshold_uncertainty_score":0.47151184},"labels":[],"label_agreement":null},{"id":"W2737709286","doi":"10.1200/jco.2013.31.15_suppl.e11522","title":"Adherence to adjuvant hormone therapy (AHT) in early breast cancer (BC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Relative risk; Randomized controlled trial; Cancer; Hormonal therapy; Publication bias; Odds ratio; Confidence interval","score_opus":0.07373976840698179,"score_gpt":0.4395000274531261,"score_spread":0.3657602590461443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737709286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901427,0.0017418807,0.00017806992,0.006151162,0.0009567539,0.00020401692,0.000008728252,0.0000024578305,0.0006142105],"genre_scores_gemma":[0.98936146,0.0033584565,0.0023279076,0.0032855854,0.0012770654,0.000042446143,0.0000015108503,0.000017157428,0.00032838396],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978117,0.0002472292,0.0012954416,0.00022743284,0.00018032624,0.00023789576],"domain_scores_gemma":[0.99827564,0.00015160529,0.0006352729,0.000216446,0.0004829331,0.0002381152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010196844,0.00012292349,0.00054746715,0.00007599248,0.000021884625,0.000015523303,0.00035809792,0.00033930907,0.00025557252],"category_scores_gemma":[0.00039567298,0.00009476286,0.00019848654,0.0001431801,0.00011410608,0.000013031301,0.00007827616,0.00041811302,0.00006324233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018539542,0.00068478327,0.11816635,0.0000037731315,0.00020229179,0.00003726318,0.00018077853,0.00038981828,0.054006994,0.000016478029,0.054344878,0.77011263],"study_design_scores_gemma":[0.0031674667,0.007153621,0.920417,0.000021900565,0.000015127208,0.00006576453,0.00007137105,0.000019767764,0.0019688911,0.00023555438,0.06671611,0.0001474346],"about_ca_topic_score_codex":0.0005495292,"about_ca_topic_score_gemma":0.0004166537,"teacher_disagreement_score":0.8022506,"about_ca_system_score_codex":0.00011568814,"about_ca_system_score_gemma":0.0014264213,"threshold_uncertainty_score":0.38643172},"labels":[],"label_agreement":null},{"id":"W2737947225","doi":"10.1200/jco.2014.32.15_suppl.e17529","title":"Pattern of use of PET/CT scanning in gastrointestinal cancers in one cancer center in Saudi Arabia.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; PET-CT; Pancreatic cancer; Radiology; Stage (stratigraphy); Esophageal cancer; Computed tomography; Nuclear medicine; Internal medicine","score_opus":0.09889790492067362,"score_gpt":0.4472949069536079,"score_spread":0.3483970020329343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737947225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282587,0.00008267386,0.0005617023,0.005815117,0.00032797796,0.000091561764,0.0000015980075,0.0000017671437,0.00029173944],"genre_scores_gemma":[0.99205506,0.0002761178,0.005757204,0.0015772892,0.00028968565,0.0000019661097,9.674757e-7,0.000013469767,0.000028224837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961549,0.00050940795,0.002605956,0.00015908641,0.00030619514,0.00026446857],"domain_scores_gemma":[0.99600023,0.0019642378,0.0015556032,0.00012228209,0.00016255169,0.0001951185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040377364,0.00010640625,0.0015167791,0.0003364992,0.0000060828606,0.000003158646,0.00014350997,0.00003780791,0.00007627907],"category_scores_gemma":[0.007915137,0.00008645893,0.0001897434,0.00019504083,0.00024708192,0.00008305023,0.00004551597,0.0017613261,6.4446147e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087841664,0.00070550136,0.9139364,0.00008867957,0.000029157816,0.00093613256,0.000075350574,0.0027019244,0.00035251878,0.000006584824,0.00023944164,0.080049895],"study_design_scores_gemma":[0.008801081,0.0024847407,0.9655093,0.0040376806,0.000039382565,0.0007531192,0.00006135481,0.016479658,0.00002468618,0.000046707013,0.001698199,0.00006408841],"about_ca_topic_score_codex":0.003754016,"about_ca_topic_score_gemma":0.0024085222,"teacher_disagreement_score":0.079985805,"about_ca_system_score_codex":0.00031096666,"about_ca_system_score_gemma":0.00095606345,"threshold_uncertainty_score":0.94757307},"labels":[],"label_agreement":null},{"id":"W2738261498","doi":"10.1200/jco.2017.35.15_suppl.1544","title":"Does the extent of therapy differ between breast cancers detected by screening mammogram and non-screening methods?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Mammography; Radiation therapy; Psychosocial; Cancer; Stage (stratigraphy); Mastectomy; Oncology; Internal medicine; Gynecology; Obstetrics","score_opus":0.23468448446733492,"score_gpt":0.5361286901701464,"score_spread":0.3014442057028115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738261498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96723974,0.0012282815,0.01938204,0.010850894,0.0005936833,0.00026159213,0.000017081928,0.000007953706,0.0004187612],"genre_scores_gemma":[0.9613017,0.0016975002,0.03475346,0.00091154757,0.001211458,0.00000413308,0.0000014231802,0.000017858336,0.00010093376],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99670047,0.00044705445,0.0018240069,0.00023343618,0.00047743076,0.00031763333],"domain_scores_gemma":[0.9931887,0.002452875,0.0030568673,0.0004282305,0.00048614672,0.00038718758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049893265,0.0001871855,0.0015616394,0.00006701386,0.00025383857,0.000043793985,0.000498041,0.00033422696,0.00004554914],"category_scores_gemma":[0.0018971753,0.00008541895,0.00047167833,0.00007536064,0.0007382811,0.0001994371,0.00014339482,0.0011490886,4.6274894e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001889912,0.000048472033,0.4156644,0.000008294884,0.00040701617,0.00004059205,0.000060244525,0.0000033435506,0.00097174663,0.000003295459,0.00039875117,0.58050394],"study_design_scores_gemma":[0.0051902416,0.0041055433,0.97240114,0.0003056624,0.0004039865,0.00020449991,0.00037939992,0.00018654007,0.0011528382,0.00016510213,0.015393587,0.00011147718],"about_ca_topic_score_codex":0.00078986335,"about_ca_topic_score_gemma":0.000102804486,"teacher_disagreement_score":0.5803924,"about_ca_system_score_codex":0.00006903091,"about_ca_system_score_gemma":0.00039262246,"threshold_uncertainty_score":0.49922824},"labels":[],"label_agreement":null},{"id":"W2738407951","doi":"10.1200/jco.2017.35.15_suppl.9518","title":"A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with <i>BRAF V600</i>-mutant solid tumors and melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MEK inhibitor; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Melanoma; Palbociclib; Clinical endpoint; Pharmacokinetics; Pharmacology; Cancer; Phases of clinical research; Kinase; Cancer research; MAPK/ERK pathway; Clinical trial","score_opus":0.1003029350503233,"score_gpt":0.4806479685953801,"score_spread":0.38034503354505683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738407951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550736,0.00022937171,0.00008583411,0.002328311,0.00033450243,0.001393553,0.000005874338,0.000015770107,0.000099423574],"genre_scores_gemma":[0.99632955,0.00013117638,0.0025886146,0.00046262113,0.00037058504,0.000031780248,0.0000055195273,0.00004436374,0.00003580387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563324,0.00069021684,0.0021249864,0.000443356,0.00077772106,0.00033048645],"domain_scores_gemma":[0.99376434,0.001001414,0.0037825028,0.0003453311,0.0007577923,0.00034860233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004094806,0.00030352146,0.0017969575,0.00022829039,0.00029757188,0.000056867902,0.00019105013,0.00019902554,0.000021123426],"category_scores_gemma":[0.0019484033,0.00019532963,0.000106306536,0.00016575873,0.00050097704,0.00064402935,0.00009245918,0.00095414405,9.2822637e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05393999,0.012202702,0.5625945,0.000021687889,0.00033956356,0.00023400996,0.0015401201,0.000010835224,0.00054465624,0.00001209576,0.000010995851,0.36854887],"study_design_scores_gemma":[0.16744934,0.17692932,0.65281045,0.0003325726,0.00023899808,0.00023354377,0.00068785046,0.00036414032,0.00020739375,0.0002470575,0.00031481875,0.0001844955],"about_ca_topic_score_codex":0.000050540566,"about_ca_topic_score_gemma":0.00019856327,"teacher_disagreement_score":0.36836436,"about_ca_system_score_codex":0.00019270221,"about_ca_system_score_gemma":0.0009849626,"threshold_uncertainty_score":0.79653114},"labels":[],"label_agreement":null},{"id":"W2738422874","doi":"10.1200/jco.2012.30.15_suppl.3003","title":"A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nausea; Internal medicine; Adverse effect; Mucositis; Rash; Tolerability; Gastroenterology; Discontinuation; Vomiting; Stomatitis; Pharmacology; Toxicity","score_opus":0.08132306757161836,"score_gpt":0.453343260162962,"score_spread":0.37202019259134367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738422874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568295,0.000104491584,0.000006611608,0.00161735,0.00051654136,0.0019416567,0.0000042796823,0.000004960986,0.000121169374],"genre_scores_gemma":[0.9990581,0.000029741374,0.00030729326,0.00031609501,0.0001572843,0.000060239887,0.0000049703895,0.0000198,0.00004642245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627554,0.0008727506,0.0017627021,0.0002100559,0.00056775624,0.00031117516],"domain_scores_gemma":[0.9964254,0.000703328,0.0017827214,0.00019363569,0.0007597999,0.00013514672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016542155,0.00021183328,0.0014061071,0.00012688067,0.00008548944,0.000015101717,0.00022160965,0.00013090744,0.000013570412],"category_scores_gemma":[0.0010381602,0.00009624589,0.0000722085,0.00067284907,0.00022213324,0.0003706232,0.0001493995,0.000809966,0.0000010891829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046741102,0.07871646,0.8136507,0.000016671764,0.0003339811,0.00004501598,0.002085812,0.000014916527,0.00013186727,0.0000053964145,0.00023629493,0.058021765],"study_design_scores_gemma":[0.14341411,0.091687046,0.76235086,0.00021412424,0.00030857,0.000012762319,0.0013859507,0.00007628269,0.00013679739,0.0000051968123,0.0003202328,0.00008808293],"about_ca_topic_score_codex":0.000120188735,"about_ca_topic_score_gemma":0.0035179101,"teacher_disagreement_score":0.096673004,"about_ca_system_score_codex":0.00044024838,"about_ca_system_score_gemma":0.00057214225,"threshold_uncertainty_score":0.39247933},"labels":[],"label_agreement":null},{"id":"W2738553575","doi":"10.1200/jco.2017.35.15_suppl.e13078","title":"Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Immunohistochemistry; Breast cancer; Trastuzumab; Internal medicine; Oncology; Cancer; Retrospective cohort study; Gynecology","score_opus":0.5335075287104397,"score_gpt":0.6202554639857291,"score_spread":0.08674793527528935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738553575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97161067,0.00045278302,0.00013473339,0.024361715,0.00053686695,0.00013407815,0.00008849976,0.000002790052,0.0026778816],"genre_scores_gemma":[0.99531066,0.00021696094,0.0013298335,0.00018394514,0.0011484503,0.0000041958165,0.0000016592583,0.000014693806,0.0017896225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974808,0.00020763297,0.0014573737,0.00016601352,0.0004944365,0.00019371032],"domain_scores_gemma":[0.9948571,0.0022899355,0.0014238545,0.00037230656,0.0005489794,0.00050782313],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037065514,0.00009470915,0.0010432939,0.000055580447,0.000105218234,0.00001313886,0.0003258553,0.00036207313,0.00017184137],"category_scores_gemma":[0.008551613,0.00007134363,0.00016981192,0.0000461015,0.00038237966,0.000089556306,0.00015578183,0.0010753624,0.0000052184887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015546497,0.00020897517,0.90324754,0.000069480186,0.0000683878,0.0000355122,0.000051925334,5.8734565e-7,0.009987629,0.00000822687,0.02265691,0.06211017],"study_design_scores_gemma":[0.0031227686,0.0015249909,0.9726839,0.00033037097,0.00009445591,0.00006595924,0.00003970391,0.0000018280616,0.0018268554,0.00010648623,0.020139575,0.00006312506],"about_ca_topic_score_codex":0.00029618526,"about_ca_topic_score_gemma":0.000018352377,"teacher_disagreement_score":0.069436334,"about_ca_system_score_codex":0.00019611552,"about_ca_system_score_gemma":0.0015953915,"threshold_uncertainty_score":0.9997998},"labels":[],"label_agreement":null},{"id":"W2738957157","doi":"10.1200/jco.2015.33.15_suppl.e17663","title":"Does a personalized multifaceted care plan (PMCP) improve quality of care?","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Guelph; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Intervention (counseling); Randomized controlled trial; Cancer; Focus group; Internal medicine; Physical therapy; Family medicine; Oncology; Nursing","score_opus":0.2293978261265122,"score_gpt":0.4420828396677563,"score_spread":0.2126850135412441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738957157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651542,0.0063804607,0.0009132495,0.0013939246,0.005807364,0.00018971223,0.0002665392,0.0000093350245,0.019885272],"genre_scores_gemma":[0.9942974,0.0005655621,0.0030014946,0.0006708993,0.0009675011,0.0000032017754,0.0000042898214,0.000018793902,0.00047084983],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.995013,0.0001495181,0.004221665,0.00026154346,0.00008254242,0.0002717102],"domain_scores_gemma":[0.99231595,0.0007297323,0.0056091137,0.00025672323,0.00066743064,0.00042104235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003706973,0.00016224985,0.002403452,0.00014658847,0.00003202803,0.000017740269,0.00038557663,0.00049317285,0.00019338843],"category_scores_gemma":[0.005286641,0.00011844281,0.0007065945,0.0000853891,0.00030890672,0.00028265678,0.000054564258,0.0006041802,0.00006124386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011712003,0.0012929302,0.6705357,0.00033998903,0.0009933141,0.00007600816,0.02135122,0.00021062695,0.00007083693,0.028940516,0.004328565,0.26014832],"study_design_scores_gemma":[0.024947952,0.010587374,0.24068007,0.00007667823,0.0001004937,0.000013770787,0.01446016,0.00015958233,0.00021635846,0.015528254,0.6926318,0.0005975245],"about_ca_topic_score_codex":0.00047423344,"about_ca_topic_score_gemma":0.00025963612,"teacher_disagreement_score":0.68830323,"about_ca_system_score_codex":0.00039355308,"about_ca_system_score_gemma":0.0010680831,"threshold_uncertainty_score":0.63289845},"labels":[],"label_agreement":null},{"id":"W2739116172","doi":"10.1200/jco.2017.35.15_suppl.9506","title":"COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600–mutant (mut) melanoma brain metastases (MBM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Cohort; Internal medicine; Asymptomatic; Metastatic melanoma; Melanoma; Oncology; Phases of clinical research; Regimen; Gastroenterology; Clinical trial; Cancer; Vemurafenib; Cancer research","score_opus":0.07614107715406832,"score_gpt":0.43872515072238355,"score_spread":0.36258407356831523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739116172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579287,0.000027370756,0.000010592116,0.0021290055,0.000085305815,0.00021045931,0.00004571824,0.0000071929258,0.0016914966],"genre_scores_gemma":[0.9992829,0.000033080283,0.00024386025,0.00015961452,0.00011831663,0.000015009521,0.000014841556,0.000016968215,0.0001153995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965942,0.00021924038,0.0022928999,0.00030189016,0.0003820641,0.00020970816],"domain_scores_gemma":[0.9928092,0.002247354,0.003862346,0.0005141463,0.0003260472,0.00024093219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001978687,0.00019615951,0.0013263598,0.000063078696,0.0002009715,0.000026601972,0.00052729296,0.000269211,0.00012247106],"category_scores_gemma":[0.003258632,0.000152522,0.00016442302,0.00008546558,0.00039911387,0.00021494036,0.00016833677,0.0008107487,0.0000011100979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011902849,0.18391168,0.5762992,0.0001949034,0.001032992,0.0003646431,0.001444888,0.000020148791,0.012954848,0.00038560678,0.0015088209,0.2099794],"study_design_scores_gemma":[0.3860334,0.11119288,0.3920422,0.0006439841,0.0017473808,0.00028929109,0.0040977756,0.00031344636,0.053273413,0.002858136,0.046412203,0.0010959166],"about_ca_topic_score_codex":0.00004593419,"about_ca_topic_score_gemma":0.00013556945,"teacher_disagreement_score":0.37413052,"about_ca_system_score_codex":0.000059575406,"about_ca_system_score_gemma":0.00030334503,"threshold_uncertainty_score":0.62196666},"labels":[],"label_agreement":null},{"id":"W2739368227","doi":"10.1200/jco.2017.35.15_suppl.2073","title":"Neurocognitive function testing and health related quality of life in stage IV lung cancer patients with and without brain metastases.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Neurocognitive; Lung cancer; Internal medicine; Quality of life (healthcare); Stage (stratigraphy); Oncology; Cancer; Gastroenterology; Cognition","score_opus":0.3114774786996251,"score_gpt":0.5797852137703787,"score_spread":0.2683077350707536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739368227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875245,0.0010772136,0.000018350998,0.010546596,0.00015776661,0.00038119446,0.00001527384,0.000002940442,0.00027614651],"genre_scores_gemma":[0.99755156,0.00054161175,0.00052354217,0.001209245,0.00010516879,0.0000050394874,8.5585026e-7,0.000009297235,0.000053674485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969671,0.0007066583,0.0016266434,0.00017414377,0.0003438155,0.00018168408],"domain_scores_gemma":[0.99305105,0.0025782865,0.0032367017,0.00012018302,0.0007055797,0.0003082152],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00628349,0.00009324335,0.001408227,0.00009148589,0.00009465016,0.000009412223,0.000060869355,0.000090896276,0.000011105925],"category_scores_gemma":[0.03133062,0.00005968053,0.000052286003,0.000072280665,0.00047454785,0.00016517281,0.00009280552,0.00080577,1.0824584e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006650407,0.0003904117,0.95831484,0.00021729522,0.00036740748,0.00002236379,0.00013937383,0.00000304364,0.000010793742,0.000008723331,0.00027044,0.033604912],"study_design_scores_gemma":[0.017265208,0.010845168,0.9708858,0.00041876134,0.00012583149,0.0000064620963,0.000108084474,0.000084776235,0.000001544248,0.00003983652,0.00017061426,0.000047929818],"about_ca_topic_score_codex":0.0017628933,"about_ca_topic_score_gemma":0.0015604472,"teacher_disagreement_score":0.033556983,"about_ca_system_score_codex":0.00012642278,"about_ca_system_score_gemma":0.0017464968,"threshold_uncertainty_score":0.9768289},"labels":[],"label_agreement":null},{"id":"W2739400913","doi":"10.1200/jco.2016.34.15_suppl.tps11072","title":"The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Phases of clinical research; Oncology; Gastroenterology; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.08717057022810526,"score_gpt":0.4517596671861356,"score_spread":0.3645890969580303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739400913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002886,0.00091459963,0.000015513408,0.0016564765,0.0011478483,0.006164969,0.000008904785,0.0000127771955,0.000050074206],"genre_scores_gemma":[0.99784815,0.00088619266,0.0005857373,0.000101835256,0.00020335622,0.00028361057,0.0000053008725,0.000045663353,0.000040126997],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99083894,0.002180236,0.0049323365,0.0005079826,0.0009668108,0.00057369913],"domain_scores_gemma":[0.9794496,0.015500971,0.002964198,0.0005906224,0.0010830876,0.00041147752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048605227,0.00041151675,0.0035433657,0.0004250277,0.00007708502,0.000017976272,0.00043691538,0.00025091125,0.00004034817],"category_scores_gemma":[0.0050395047,0.00018642504,0.0004375542,0.00051852997,0.00029523592,0.00024162461,0.00014943168,0.0009082678,0.0000066634666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49180874,0.0775765,0.3654951,0.000010180381,0.00096609344,0.00039594033,0.00025532854,0.000024606712,0.000010636368,0.0000029728214,0.000028145894,0.063425735],"study_design_scores_gemma":[0.69806814,0.06307747,0.23586741,0.00031801895,0.00087286206,0.000010529688,0.0012033511,0.00007770734,0.000048528564,0.0000097551365,0.00030797234,0.00013824296],"about_ca_topic_score_codex":0.0001408724,"about_ca_topic_score_gemma":0.004500964,"teacher_disagreement_score":0.2062594,"about_ca_system_score_codex":0.00037147067,"about_ca_system_score_gemma":0.000811468,"threshold_uncertainty_score":0.7602192},"labels":[],"label_agreement":null},{"id":"W2741030312","doi":"10.1200/jco.2012.30.15_suppl.4613","title":"Xp11.2 translocations in adult renal cell carcinomas with clear cell and papillary features.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; London Health Sciences Centre; University of Toronto; St. Michael's Hospital; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"TFE3; Chromophobe cell; Clear cell; Pathology; Medicine; Renal cell carcinoma; Immunohistochemistry; Clear cell renal cell carcinoma; Tissue microarray; Chromosomal translocation; Papillary renal cell carcinomas; Histology; Psammoma body; Stage (stratigraphy); Biology; Gene","score_opus":0.06206653491599756,"score_gpt":0.37321706619228284,"score_spread":0.3111505312762853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741030312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760577,0.0043543624,0.000032633307,0.0041188737,0.00027172215,0.00023813854,0.0000020223413,0.0000065131517,0.014918003],"genre_scores_gemma":[0.99076015,0.0013188678,0.00547098,0.0011333429,0.00077826163,0.000004483417,0.0000032584362,0.000024482444,0.00050617463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738485,0.00037349766,0.0013736321,0.00018117938,0.0003435606,0.00034327575],"domain_scores_gemma":[0.9971695,0.0009509324,0.0007229018,0.0002012732,0.00027896254,0.00067642005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001412646,0.0001765801,0.0010877457,0.00016600238,0.00004094789,0.000006781078,0.00009501882,0.0003648586,0.00005494446],"category_scores_gemma":[0.00024359323,0.00011171978,0.00023547122,0.00015763385,0.00019369657,0.00013635111,0.00002307696,0.0011885079,0.000014244821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010770397,0.005680447,0.9463139,0.00017229134,0.00022258484,0.0023512358,0.0013214186,0.0000336784,0.0021624162,0.00010041856,0.0040956484,0.026775565],"study_design_scores_gemma":[0.011723024,0.015956737,0.9533065,0.000094513314,0.0005854763,0.0015807821,0.00040365913,0.000013613947,0.0025698855,0.000022076552,0.01361286,0.00013090493],"about_ca_topic_score_codex":0.000054563603,"about_ca_topic_score_gemma":0.00010803927,"teacher_disagreement_score":0.02664466,"about_ca_system_score_codex":0.00016606673,"about_ca_system_score_gemma":0.00072036654,"threshold_uncertainty_score":0.51635414},"labels":[],"label_agreement":null},{"id":"W2741035828","doi":"10.1200/jco.2012.30.15_suppl.tps8116","title":"Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Tolerability; Multiple myeloma; Apoptosis; In vivo; Pharmacology; Internal medicine; Cancer research; Adverse effect; Biology","score_opus":0.08459361967065941,"score_gpt":0.4395891438832487,"score_spread":0.3549955242125893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741035828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977864,0.00015281068,0.00018744527,0.00044812946,0.00021924438,0.0011025117,0.000044697037,0.000001733584,0.000057049063],"genre_scores_gemma":[0.99804443,0.0001005433,0.0012138141,0.00034962178,0.00017422508,0.000020453212,0.000033089957,0.000013368046,0.00005047646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967294,0.0008578902,0.0017296489,0.00023867466,0.00023132675,0.00021308202],"domain_scores_gemma":[0.9974125,0.0006961759,0.0009820045,0.00035832505,0.0003089057,0.0002420672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003624175,0.00014901493,0.0007288238,0.00004528688,0.0000995453,0.000010121019,0.0003471822,0.00018856172,0.000012062256],"category_scores_gemma":[0.0034010354,0.00008569111,0.00005088109,0.00014428962,0.00015299888,0.000029591307,0.0003250767,0.00034064596,0.0000010041828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059898186,0.0633118,0.5318727,0.000011944639,0.00017514294,0.000002486089,0.00081021,0.000012522379,0.026207987,0.0000055668256,0.0006032236,0.31708822],"study_design_scores_gemma":[0.042400368,0.05244109,0.8808584,0.000017675984,0.00011082526,0.000004664117,0.00020095932,0.00005430115,0.0007857573,0.0000065852796,0.022996226,0.00012315347],"about_ca_topic_score_codex":0.0000335391,"about_ca_topic_score_gemma":0.00025651677,"teacher_disagreement_score":0.3489857,"about_ca_system_score_codex":0.00003255516,"about_ca_system_score_gemma":0.00035152532,"threshold_uncertainty_score":0.40716028},"labels":[],"label_agreement":null},{"id":"W2741776602","doi":"10.1200/jco.2017.35.15_suppl.e18162","title":"Genome-wide association study (GWAS) of chemotherapy-induced Raynaud's phenomenon (RP) to reveal shared pathways with cardiovascular disease (CVD).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Genome-wide association study; Medicine; SNP; Internal medicine; Oncology; Single-nucleotide polymorphism; Genotyping; Genetic association; Genotype; Genetics; Biology; Gene","score_opus":0.12037032013299,"score_gpt":0.4169826920248757,"score_spread":0.2966123718918857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741776602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876128,0.00050195423,0.00003121902,0.009569015,0.0005004824,0.0008705688,0.000015027055,0.000006853677,0.00089211075],"genre_scores_gemma":[0.99637634,0.00048661153,0.0005366389,0.0012304656,0.0011668319,0.00003343675,0.000003515306,0.000028133081,0.00013802278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667895,0.00031445228,0.0016022933,0.00030128664,0.0008492852,0.00025372478],"domain_scores_gemma":[0.99443054,0.0009395804,0.0025270346,0.0007637325,0.0006965025,0.00064262096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036037397,0.0001840097,0.0021259098,0.000097574004,0.000104610765,0.00002745633,0.00026598648,0.00017773556,0.00008731537],"category_scores_gemma":[0.0034831527,0.00012523736,0.0008701236,0.00007332224,0.00004963581,0.00011997515,0.00006781516,0.00044370312,0.0000124234075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068682674,0.006509275,0.92900085,0.00003106446,0.006447906,0.00087913394,0.00043973693,0.000060931445,0.00011101334,0.000002947177,0.0007955733,0.04885329],"study_design_scores_gemma":[0.019187944,0.021366341,0.94475824,0.00012043119,0.0024069333,0.000008031998,0.00015844627,0.000002853159,0.0000604073,0.000040420164,0.011778861,0.00011107937],"about_ca_topic_score_codex":0.00011007504,"about_ca_topic_score_gemma":0.00007383808,"teacher_disagreement_score":0.048742212,"about_ca_system_score_codex":0.00078453205,"about_ca_system_score_gemma":0.0013332495,"threshold_uncertainty_score":0.51070315},"labels":[],"label_agreement":null},{"id":"W2742168597","doi":"10.1200/jco.2012.30.15_suppl.e21090","title":"Association of core needle biopsies with increase in metastatic dissemination of breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Metastasis; Breast cancer; Pathology; Cancer; Metastatic breast cancer; Cancer cell; Biopsy; Internal medicine","score_opus":0.05864333662103883,"score_gpt":0.47282870968877416,"score_spread":0.41418537306773534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742168597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982701,0.00072498375,0.000022326705,0.0005264904,0.0001054518,0.00006938247,0.00004735175,4.1017924e-7,0.00023351384],"genre_scores_gemma":[0.9983392,0.00093715015,0.0003937775,0.00004002353,0.00016641762,0.000004152072,0.000009084007,0.00000505965,0.000105167834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871814,0.00018318782,0.00070711493,0.000060721377,0.00019487034,0.00013594591],"domain_scores_gemma":[0.99797696,0.0003289734,0.0011890265,0.00006957418,0.00032335223,0.00011210568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014047041,0.0000564726,0.00041710318,0.00006209763,0.00000810528,0.0000016108285,0.00007709017,0.000104625506,0.000033228098],"category_scores_gemma":[0.0011656692,0.00003882383,0.000105021354,0.0000986632,0.00007474205,0.000011914061,0.000025537372,0.00013590918,4.1930514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029808271,0.0013221933,0.95856565,0.000027241322,0.00041736994,0.00000699004,0.000059170223,0.000020529636,0.014596794,0.000011946754,0.0011185019,0.02087278],"study_design_scores_gemma":[0.0028493828,0.0036865203,0.9824491,0.00008583158,0.00015624326,0.000043588527,0.00016855517,0.000012500534,0.008849177,0.000029437702,0.0016170478,0.000052575775],"about_ca_topic_score_codex":0.0003172336,"about_ca_topic_score_gemma":0.00073252706,"teacher_disagreement_score":0.023883484,"about_ca_system_score_codex":0.000081669816,"about_ca_system_score_gemma":0.0004956422,"threshold_uncertainty_score":0.15831898},"labels":[],"label_agreement":null},{"id":"W2742417192","doi":"10.1200/jco.2016.72.0748","title":"Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Cancer Institute","keywords":"Medicine; Nomogram; Oncology; Internal medicine; Proportional hazards model; Concordance; Chemoradiotherapy; Progression-free survival; Cohort; Radiation therapy; Cancer; Overall survival","score_opus":0.09283745636963515,"score_gpt":0.45385791022286787,"score_spread":0.3610204538532327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742417192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978832,0.00027689867,0.0000069295825,0.0009299515,0.00026778554,0.00015731598,0.000004588366,8.1775147e-7,0.00047253087],"genre_scores_gemma":[0.99661106,0.00054345524,0.0026694709,0.00005048711,0.0001050616,0.0000034167751,7.7204004e-7,0.00000448397,0.000011773835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985367,0.00007524123,0.00093462894,0.00009524785,0.00026955022,0.000088599976],"domain_scores_gemma":[0.99776345,0.00029626035,0.001369201,0.000101648395,0.00036275707,0.000106682404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009877954,0.00006646022,0.00098448,0.000045226127,0.00003370441,0.0000027998753,0.00007181857,0.00010161644,0.0000064101214],"category_scores_gemma":[0.000991322,0.00003955263,0.00003682209,0.000021169755,0.00027615277,0.00008942452,0.00008513269,0.0002291039,4.140225e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006153176,0.00063677627,0.85469437,0.00006158638,0.0001573106,0.000015725296,0.00035302684,6.1770874e-7,0.00001615415,0.0000072713415,0.000060508097,0.13784347],"study_design_scores_gemma":[0.013439193,0.010455681,0.9744614,0.0005272974,0.000092933056,0.000002860198,0.00005675988,0.000006707359,0.00023626519,0.00003186715,0.00065336307,0.000035671226],"about_ca_topic_score_codex":0.00004053262,"about_ca_topic_score_gemma":0.00015626567,"teacher_disagreement_score":0.1378078,"about_ca_system_score_codex":0.000046551144,"about_ca_system_score_gemma":0.00065223593,"threshold_uncertainty_score":0.16129093},"labels":[],"label_agreement":null},{"id":"W2743569343","doi":"10.1200/jco.2014.32.15_suppl.2540","title":"Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Hepatocellular carcinoma; Adverse effect; Vomiting; Internal medicine; Sorafenib; Gastroenterology; Angiopoietin receptor; Oncology; Angiogenesis","score_opus":0.052897575251787975,"score_gpt":0.4142752304600787,"score_spread":0.36137765520829074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743569343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751806,0.00089618796,0.00011124285,0.00026801112,0.00030588254,0.00032768032,0.000044753786,0.0000037204584,0.0005244729],"genre_scores_gemma":[0.99779695,0.00022209092,0.00033596877,0.00020697534,0.0012586964,0.000008965748,0.00006699329,0.000029670662,0.00007367991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956197,0.000736083,0.0024880324,0.000540332,0.00030798433,0.0003078527],"domain_scores_gemma":[0.99654126,0.00047416007,0.001910644,0.00037962646,0.00044272002,0.00025157636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026417652,0.00025936356,0.0013998592,0.00012240498,0.00011102327,0.000014109564,0.00036593762,0.0005234639,0.000033634995],"category_scores_gemma":[0.0008630054,0.00021851063,0.00042219626,0.00011062447,0.00026543761,0.000013013489,0.00017280385,0.00044672677,0.0000014733628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00558206,0.00687968,0.9126145,0.00001801291,0.0006842244,0.00015984218,0.00041412597,0.000053889482,0.066178404,0.000036773108,0.0030024615,0.004376026],"study_design_scores_gemma":[0.0424286,0.06019589,0.8680171,0.000077706594,0.0005219207,0.000066043445,0.0005086671,0.0004751702,0.009561276,0.00035116682,0.017367413,0.00042905335],"about_ca_topic_score_codex":0.0008668903,"about_ca_topic_score_gemma":0.00096079096,"teacher_disagreement_score":0.056617126,"about_ca_system_score_codex":0.000052630574,"about_ca_system_score_gemma":0.00031425888,"threshold_uncertainty_score":0.8910605},"labels":[],"label_agreement":null},{"id":"W2744113360","doi":"10.1200/jco.2009.27.15_suppl.10524","title":"A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Chills; Sarcoma; Internal medicine; Chemotherapy; Synovial sarcoma; Gastroenterology; Surgery; Oncology; Pathology","score_opus":0.05988426736140363,"score_gpt":0.4507042876195266,"score_spread":0.39082002025812296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744113360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613774,0.0018884008,0.000040072602,0.0012196151,0.000060927287,0.00062517595,0.0000062066283,6.486738e-7,0.000021229542],"genre_scores_gemma":[0.99840635,0.0006670612,0.00026620226,0.00050412863,0.00011694331,0.000005398414,0.0000035780486,0.000008183755,0.000022170083],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972847,0.00093264587,0.00112029,0.00016826311,0.00031500516,0.00017907369],"domain_scores_gemma":[0.9982896,0.0003511216,0.00067934603,0.00030662768,0.00027193496,0.000101365375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019040712,0.00012333204,0.0007223498,0.00008111849,0.00004834409,0.0000053790936,0.00024656384,0.00008725051,0.000008479083],"category_scores_gemma":[0.00034363347,0.000059946586,0.00009187161,0.00019036507,0.00013332645,0.0000049042133,0.000033807795,0.00021146488,4.3858643e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08561404,0.06695477,0.013655631,0.000012706624,0.00087043375,0.00018709883,0.003952903,0.0002614089,0.015727669,0.0000037522984,0.0005286453,0.81223094],"study_design_scores_gemma":[0.022405228,0.92113245,0.042192418,0.000015375419,0.00028804727,0.000030030844,0.00061276235,0.000026827589,0.003968906,0.000045358014,0.009186653,0.00009597162],"about_ca_topic_score_codex":0.000028184262,"about_ca_topic_score_gemma":0.0004999965,"teacher_disagreement_score":0.85417765,"about_ca_system_score_codex":0.000028521139,"about_ca_system_score_gemma":0.0003523152,"threshold_uncertainty_score":0.24445508},"labels":[],"label_agreement":null},{"id":"W2745149700","doi":"10.1200/jco.2013.31.15_suppl.5502","title":"Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University; Hôpital Notre-Dame; Vancouver Coastal Health; Baker Hughes (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Topotecan; Carboplatin; Internal medicine; Regimen; Hazard ratio; Clinical endpoint; Paclitaxel; Chemotherapy; Progression-free survival; Adverse effect; Cisplatin; Oncology; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.12307816601852095,"score_gpt":0.47724778680149776,"score_spread":0.3541696207829768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745149700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195236,0.0006084224,0.000059685597,0.002470046,0.0007133657,0.004033646,0.0000723536,0.0000040935975,0.00008604825],"genre_scores_gemma":[0.99622434,0.0014403665,0.0015122337,0.00012029917,0.00043367824,0.0002017669,0.000004632592,0.000026874024,0.00003582997],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936082,0.000605987,0.004639118,0.00040982637,0.00045574643,0.0002811518],"domain_scores_gemma":[0.9894395,0.0053788815,0.0039320486,0.00030084426,0.0006713115,0.0002774087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035105068,0.00028481317,0.004190777,0.00025853142,0.000043730517,0.000008113754,0.00013561062,0.00027470742,0.00008272315],"category_scores_gemma":[0.0023126896,0.00020416315,0.000387761,0.00020370459,0.0003244177,0.00011862522,0.00005934656,0.0004985729,1.7094224e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81493086,0.029430272,0.020874651,0.00014421875,0.003039101,0.00014714098,0.0043112272,0.00017207018,0.0007384068,0.000020931275,0.000110537105,0.12608057],"study_design_scores_gemma":[0.84240645,0.0944778,0.05769719,0.00030157168,0.0018688106,0.000023019466,0.0016184418,0.0006401119,0.00043009213,0.00015417063,0.00024142719,0.0001409327],"about_ca_topic_score_codex":0.0030225785,"about_ca_topic_score_gemma":0.0038466905,"teacher_disagreement_score":0.12593964,"about_ca_system_score_codex":0.0001608523,"about_ca_system_score_gemma":0.00084081304,"threshold_uncertainty_score":0.8325532},"labels":[],"label_agreement":null},{"id":"W2745601792","doi":"10.1200/jco.2017.35.15_suppl.9011","title":"KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.06695172355110598,"score_gpt":0.42704922656710764,"score_spread":0.36009750301600163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745601792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992025,0.00007722511,0.00011028556,0.0023963046,0.00075839745,0.00043341165,0.000014228878,0.00000955292,0.0041755517],"genre_scores_gemma":[0.9946301,0.00026343967,0.0028448084,0.0008255159,0.0006546277,0.000007345692,0.000011233553,0.000030372206,0.00073254574],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979012,0.00011070217,0.0011666254,0.00020104641,0.0003589513,0.0002614516],"domain_scores_gemma":[0.99558264,0.0007489133,0.0022524726,0.0003602596,0.00080105115,0.00025468162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010245511,0.00016706772,0.0012413833,0.00006298373,0.00013516059,0.000024275405,0.00023660641,0.00025804545,0.00010583064],"category_scores_gemma":[0.0010394666,0.0000928287,0.0003319519,0.000036877656,0.0003460992,0.00019561652,0.000023049493,0.0004596899,0.0000038779785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42547795,0.0028137465,0.3969409,0.000029214245,0.0010413326,0.00012676087,0.000025344107,0.0000038198123,0.000081330516,0.000034041717,0.0019445478,0.17148103],"study_design_scores_gemma":[0.1126812,0.059316956,0.75007075,0.00016918489,0.0003408525,0.000042583226,0.000020691585,0.000009032765,0.00003789448,0.00003335083,0.07715861,0.00011887288],"about_ca_topic_score_codex":0.000039189403,"about_ca_topic_score_gemma":0.000074886135,"teacher_disagreement_score":0.3531299,"about_ca_system_score_codex":0.00013515682,"about_ca_system_score_gemma":0.00088812655,"threshold_uncertainty_score":0.37854445},"labels":[],"label_agreement":null},{"id":"W2745636200","doi":"10.1200/jco.2017.35.15_suppl.10523","title":"Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Adverse effect; Quality of life (healthcare); Internal medicine; Interim analysis; Transplantation; Clinical trial; Refractory (planetary science); Surgery; Oncology","score_opus":0.07681099857292675,"score_gpt":0.42978525930950356,"score_spread":0.3529742607365768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745636200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952247,0.00023705223,0.000016828388,0.00039387855,0.0011741482,0.00040347417,0.0000044589437,0.0000070870265,0.002538386],"genre_scores_gemma":[0.99650466,0.001659281,0.0006134919,0.00041234875,0.0004261357,0.0000050296444,0.000004464328,0.000036756952,0.00033780828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933963,0.0007310451,0.0039720275,0.0003636485,0.0011186632,0.00041831104],"domain_scores_gemma":[0.98949003,0.0025825873,0.0056087077,0.0006068923,0.0010150505,0.00069674244],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004003853,0.000234543,0.0021943767,0.00029460818,0.00008489673,0.000024781222,0.00031505007,0.0005546341,0.00009645911],"category_scores_gemma":[0.014028044,0.00016834341,0.0004957563,0.00014882398,0.00027751992,0.00028861884,0.0001724296,0.001502996,0.0000052181254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017062513,0.002510357,0.954718,0.000110416826,0.00058890897,0.0009357615,0.00028842603,0.000004609555,0.00076691824,0.0000046200985,0.00036480962,0.022644663],"study_design_scores_gemma":[0.045507364,0.017863583,0.934828,0.0001247743,0.0006505891,0.000069606336,0.00012312767,0.000055754193,0.000064182386,0.000041640506,0.0005123139,0.00015908279],"about_ca_topic_score_codex":0.0004169099,"about_ca_topic_score_gemma":0.00027950027,"teacher_disagreement_score":0.028444849,"about_ca_system_score_codex":0.000545733,"about_ca_system_score_gemma":0.0038825697,"threshold_uncertainty_score":0.99427724},"labels":[],"label_agreement":null},{"id":"W2745671375","doi":"10.1200/jco.2017.35.15_suppl.3063","title":"Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAF<sup>V600</sup>-mutant metastatic melanoma (mel): Updated safety and clinical activity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Vemurafenib; Maculopapular rash; Rash; Nausea; Internal medicine; Melanoma; Atezolizumab; CD8; Adverse effect; Oncology; Gastroenterology; Metastatic melanoma; Pharmacology; Nivolumab; Cancer; Cancer research; Immune system; Immunotherapy; Immunology","score_opus":0.08158401592202198,"score_gpt":0.42470405659330257,"score_spread":0.3431200406712806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745671375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198484,0.0003596644,0.0002518784,0.0022778446,0.001128272,0.000277074,0.00003550624,0.000006815277,0.0036780715],"genre_scores_gemma":[0.9935062,0.0024918471,0.0017126936,0.0007027674,0.0011606839,0.000003689039,0.000020430554,0.000035738016,0.00036594528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99387693,0.0015816728,0.0031620744,0.00057845877,0.00030760828,0.0004932649],"domain_scores_gemma":[0.9942828,0.0009931212,0.0030951572,0.00077874743,0.0002836918,0.00056651497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006670812,0.00031950188,0.0019778097,0.00011531809,0.00019082587,0.00006350892,0.0008040081,0.0008466874,0.00008756107],"category_scores_gemma":[0.006217684,0.00025378566,0.0006180151,0.00006851315,0.00071805733,0.00004190162,0.00046690705,0.0012444983,0.000024300458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032446824,0.00524861,0.26319042,0.000073708776,0.0022668152,0.0039842315,0.00017623896,0.00009223404,0.022316048,0.00061512686,0.004862514,0.6647272],"study_design_scores_gemma":[0.024582727,0.020362083,0.56355625,0.00009318643,0.00048397723,0.0012209053,0.00013194302,0.0007728189,0.0038528547,0.00043485183,0.3839253,0.0005831188],"about_ca_topic_score_codex":0.000058573667,"about_ca_topic_score_gemma":0.00029284816,"teacher_disagreement_score":0.6641441,"about_ca_system_score_codex":0.000051761763,"about_ca_system_score_gemma":0.001282478,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W2746091303","doi":"10.1200/jco.2017.73.0226","title":"Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Cabozantinib; Lenvatinib; Pazopanib; Sorafenib; Internal medicine; Response Evaluation Criteria in Solid Tumors; Medullary thyroid cancer; Oncology; Thyroid cancer; Sunitinib; Refractory (planetary science); Tyrosine-kinase inhibitor; Adverse effect; Population; Axitinib; Cancer; Clinical trial; Phases of clinical research; Hepatocellular carcinoma","score_opus":0.07839486005662127,"score_gpt":0.4642816191764927,"score_spread":0.3858867591198714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746091303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838909,0.0008549328,0.00003152212,0.007458684,0.005485571,0.0014917628,0.00029259897,0.000011579073,0.00048247335],"genre_scores_gemma":[0.9895232,0.005117395,0.0010266782,0.0009940715,0.0029212022,0.00010553799,0.000104779225,0.000042024054,0.00016512888],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99536735,0.00029626835,0.0029544453,0.00042023417,0.0006122402,0.00034946736],"domain_scores_gemma":[0.9897362,0.0016846488,0.0063625323,0.00048718994,0.0013154174,0.0004140169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013923143,0.00030998813,0.0020859865,0.00017452006,0.00019426121,0.000028381353,0.00044207004,0.00046191027,0.00011489931],"category_scores_gemma":[0.0029393842,0.00019281873,0.0007204661,0.000055921926,0.00042633625,0.00025728077,0.00012262168,0.00071679434,0.000002832845],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6829194,0.059010204,0.035974458,0.000019372403,0.0017654005,0.00019131426,0.00017742997,0.0000011830276,0.0013585223,0.00003340879,0.0058051255,0.21274419],"study_design_scores_gemma":[0.49935123,0.25263336,0.14436515,0.00021761135,0.0005713728,0.000009947908,0.00003167822,0.000014637625,0.0009414165,0.000034267017,0.10169715,0.00013218357],"about_ca_topic_score_codex":0.0001998655,"about_ca_topic_score_gemma":0.00023718175,"teacher_disagreement_score":0.21261202,"about_ca_system_score_codex":0.00038294765,"about_ca_system_score_gemma":0.0014288615,"threshold_uncertainty_score":0.78629196},"labels":[],"label_agreement":null},{"id":"W2746282229","doi":"10.1200/jco.2017.35.15_suppl.e20503","title":"Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Adverse effect; Crizotinib; Refractory (planetary science); Nausea; Lung cancer; Ceritinib; Vomiting; Phases of clinical research; Surgery; Randomized controlled trial; Clinical trial","score_opus":0.07764790315109184,"score_gpt":0.5180193048804581,"score_spread":0.4403714017293663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746282229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705661,0.0024288758,0.00016931779,0.007305462,0.0049095764,0.0014731088,0.00006031184,0.00001149241,0.0130757885],"genre_scores_gemma":[0.9875019,0.0026371353,0.002986763,0.002029046,0.0035192056,0.0000946972,0.00002731786,0.000038574086,0.0011653149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948175,0.0006321423,0.0034507895,0.00036192354,0.0003704342,0.000367216],"domain_scores_gemma":[0.99002653,0.004055348,0.004473773,0.00047917644,0.00042318855,0.00054198736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030878666,0.00027180332,0.0033209075,0.00015598017,0.0001505656,0.00005549134,0.00037810643,0.00048038812,0.0008225396],"category_scores_gemma":[0.004812016,0.00018427825,0.0010350638,0.00006494342,0.00040916284,0.00026598445,0.00007956238,0.00126783,0.000023243465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8610249,0.011794686,0.024827622,0.00005636996,0.0023452798,0.001712531,0.00088905665,0.000014183948,0.00048726838,0.000028100754,0.009548207,0.087271765],"study_design_scores_gemma":[0.94398475,0.0064875493,0.020303199,0.0004218809,0.0032899552,0.000024651967,0.0001357332,0.00046694418,0.00021858238,0.00025285973,0.024228793,0.00018513155],"about_ca_topic_score_codex":0.0018125053,"about_ca_topic_score_gemma":0.0006336769,"teacher_disagreement_score":0.08708663,"about_ca_system_score_codex":0.0003160879,"about_ca_system_score_gemma":0.0047546895,"threshold_uncertainty_score":0.9006232},"labels":[],"label_agreement":null},{"id":"W2746522528","doi":"10.1200/jco.2016.34.15_suppl.1043","title":"Breast cancer histology and non-sentinel lymph node involvement following a positive sentinel lymph node biopsy: A multi-institutional cohort study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Sentinel lymph node; Breast cancer; Axillary Lymph Node Dissection; Lymphovascular invasion; Sentinel node; Biopsy; Context (archaeology); Univariate analysis; Lymph node; Axilla; Histology; Radiology; Cancer; Pathology; Metastasis; Internal medicine; Multivariate analysis","score_opus":0.03871188174529023,"score_gpt":0.37836641088115874,"score_spread":0.3396545291358685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746522528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899131,0.0009029514,0.0012451613,0.0059262323,0.001499914,0.00021696853,0.00006463213,0.000007642236,0.00022338597],"genre_scores_gemma":[0.9949565,0.00093179627,0.0011578473,0.0015598495,0.0011254202,0.000056788744,0.000010503607,0.000026390544,0.0001748999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682254,0.00035232946,0.0015315211,0.00056904455,0.00031740483,0.00040716078],"domain_scores_gemma":[0.9975081,0.00032195676,0.0011586038,0.0002537032,0.00047464744,0.00028298853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012501534,0.000331682,0.0012486689,0.000103580875,0.00017598543,0.000013265419,0.00024802212,0.00036752745,0.000026378564],"category_scores_gemma":[0.00038761256,0.00020967443,0.00051788165,0.000091438225,0.0005065174,0.000021702695,0.00032454042,0.00019016382,0.000008328788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016371286,0.0023373591,0.9773945,0.000010568664,0.0028761688,0.00038045083,0.00005250004,0.00000804449,0.00651781,0.000010448637,0.0002890391,0.0084859505],"study_design_scores_gemma":[0.017492931,0.00020838047,0.9796656,0.00010772922,0.0007176446,0.00075454265,0.00011613861,0.000022379434,0.00014765467,0.000014784332,0.0005163139,0.0002359295],"about_ca_topic_score_codex":0.000283704,"about_ca_topic_score_gemma":0.000054146592,"teacher_disagreement_score":0.015855802,"about_ca_system_score_codex":0.00036772116,"about_ca_system_score_gemma":0.0013102884,"threshold_uncertainty_score":0.8550275},"labels":[],"label_agreement":null},{"id":"W2746534274","doi":"10.1200/jco.2017.35.15_suppl.tps2607","title":"A phase I study of SRA737 (formerly known as CCT245737) administered orally in patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine; Cisplatin; Chemotherapy; Pharmacology","score_opus":0.05965606195111009,"score_gpt":0.47137523080101434,"score_spread":0.4117191688499042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746534274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765056,0.00020749745,0.000014322751,0.00032247923,0.00073859806,0.00028289197,0.00002125348,8.5346886e-7,0.00076155446],"genre_scores_gemma":[0.9982878,0.00047189387,0.0004917947,0.00030500817,0.00034441377,0.00000891059,0.000005287567,0.000015992235,0.00006887818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978192,0.000117054784,0.0014422896,0.00022231162,0.00020432928,0.00019482059],"domain_scores_gemma":[0.9961046,0.00016216032,0.0026183499,0.00041444862,0.0005102984,0.0001901233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007144336,0.00013818932,0.000829623,0.000053969292,0.000056853085,0.000017760725,0.0004667956,0.00021293118,0.000020807343],"category_scores_gemma":[0.0019427505,0.00010441495,0.00015133512,0.00003700137,0.00016956149,0.000014043998,0.00013223113,0.00029991832,0.0000014199294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029401822,0.018615846,0.5128669,0.000017599168,0.00039328873,0.000118031814,0.00018605063,0.00013779366,0.0011679495,0.000016126745,0.0005346667,0.4365439],"study_design_scores_gemma":[0.07318615,0.33853817,0.55787474,0.00008357272,0.00018207077,0.000009811442,0.0003016389,0.000012235568,0.0008407797,0.00007413804,0.028668292,0.00022839704],"about_ca_topic_score_codex":0.00013575316,"about_ca_topic_score_gemma":0.0017772145,"teacher_disagreement_score":0.4363155,"about_ca_system_score_codex":0.000044004737,"about_ca_system_score_gemma":0.0014804766,"threshold_uncertainty_score":0.4257918},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2747077830","doi":"10.1200/jco.2012.30.15_suppl.10081","title":"EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Randomization; Osteosarcoma; Etoposide; Randomized controlled trial; Surgery; Internal medicine; Chemotherapy; Neoadjuvant therapy; Cancer; Pathology; Breast cancer","score_opus":0.21458961798682524,"score_gpt":0.4727163301160005,"score_spread":0.25812671212917526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747077830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959904,0.00059438974,0.0000020372609,0.0015669862,0.0007463467,0.0009119118,0.000030225525,0.000006629824,0.00015107381],"genre_scores_gemma":[0.9967819,0.0009140661,0.0009375355,0.0003408028,0.0009218052,0.000035732435,0.000017694596,0.000023574841,0.000026875143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969438,0.000406554,0.0017767445,0.00018563603,0.00039992316,0.0002873858],"domain_scores_gemma":[0.99599636,0.001253727,0.0016837292,0.00022838126,0.00030639526,0.00053139596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072489376,0.00022347705,0.0018320915,0.00011727687,0.000041241256,0.0000074733525,0.00007668125,0.00019372665,0.00006375153],"category_scores_gemma":[0.00038796227,0.00012615754,0.000241929,0.00008585587,0.0002147613,0.00011435104,0.000037209524,0.00026969748,0.0000055440582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003109797,0.041133728,0.77003884,0.0000118577245,0.0009792644,0.0004101963,0.0005346419,8.214529e-8,0.0000052041974,0.00001649398,0.00012162972,0.18363824],"study_design_scores_gemma":[0.026117181,0.08035168,0.8812129,0.000071533956,0.0016202738,0.00017755711,0.00037739764,0.0000010776201,0.00012345257,0.00001066433,0.009846074,0.00009021834],"about_ca_topic_score_codex":0.00007916496,"about_ca_topic_score_gemma":0.000027132182,"teacher_disagreement_score":0.18354803,"about_ca_system_score_codex":0.00020176767,"about_ca_system_score_gemma":0.00026272534,"threshold_uncertainty_score":0.51445556},"labels":[],"label_agreement":null},{"id":"W2747211312","doi":"10.1200/jco.2017.35.15_suppl.tps7068","title":"A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Internal medicine; Surgery; Gastroenterology; Clinical trial; Adverse effect","score_opus":0.17253060229991982,"score_gpt":0.5040483404656478,"score_spread":0.33151773816572805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747211312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891655,0.00007495065,0.00013163916,0.004367063,0.00073148997,0.0051609976,0.00016242315,0.000007335687,0.00019861499],"genre_scores_gemma":[0.99193805,0.0018451979,0.0035021133,0.0012994111,0.0007535608,0.000288784,0.000088679815,0.00005291664,0.0002312879],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934296,0.0007388559,0.0040822146,0.00050958025,0.0007325228,0.0005072048],"domain_scores_gemma":[0.9873529,0.0033659898,0.004718155,0.00073324115,0.0034970627,0.00033267116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025150066,0.00040169875,0.0032173283,0.00039847972,0.00027149354,0.000060320086,0.001015561,0.00043036893,0.000069250906],"category_scores_gemma":[0.006351569,0.00025054574,0.0003797777,0.00028638678,0.0006182955,0.0005552488,0.00023231648,0.0008699797,0.0000017960003],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3630945,0.17273119,0.012722055,0.00015585359,0.004768846,0.0044774064,0.0190646,0.000026335272,0.010751668,0.000021047023,0.004772307,0.40741417],"study_design_scores_gemma":[0.5306304,0.39984137,0.045622405,0.0005169547,0.0012537587,0.00037168158,0.010747021,0.00084827683,0.0070720892,0.0000651884,0.0027609048,0.00026994405],"about_ca_topic_score_codex":0.0009701101,"about_ca_topic_score_gemma":0.0005555043,"teacher_disagreement_score":0.40714425,"about_ca_system_score_codex":0.0012968008,"about_ca_system_score_gemma":0.002768332,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W2747247135","doi":"10.1200/jco.2014.32.15_suppl.e15264","title":"Comparative eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent FOLFIRINOX (FIO) versus nab-paclitaxel plus gemcitabine (NG).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Performance status; Regimen; Univariate analysis; Bilirubin; Surgery; Cancer; Oncology; Irinotecan; Multivariate analysis","score_opus":0.34026335108288286,"score_gpt":0.5456973341506709,"score_spread":0.20543398306778804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747247135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412925,0.00072737463,0.007245936,0.0028501183,0.001167735,0.0014632503,0.00004713846,0.000012230836,0.002356954],"genre_scores_gemma":[0.98337,0.000478832,0.014629535,0.00053799385,0.0006368431,0.00006037786,0.00003045061,0.0000275641,0.0002283762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921051,0.0013330496,0.0046515623,0.0004544742,0.0008622883,0.0005934733],"domain_scores_gemma":[0.9649956,0.026563024,0.003693075,0.0005337363,0.0034097529,0.00080481777],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0070455284,0.00034726007,0.005469034,0.000262783,0.000107507025,0.000009331112,0.00040790965,0.00042086915,0.00015519116],"category_scores_gemma":[0.03194268,0.00024125986,0.0010387931,0.00027583438,0.0009748728,0.00014218714,0.00015097231,0.0011510914,0.000029069795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09368972,0.009126389,0.86684954,0.00078206765,0.0051154667,0.000070197675,0.0014268365,0.00008617237,0.00004309246,0.0011453802,0.007150568,0.014514573],"study_design_scores_gemma":[0.069365375,0.10713582,0.80280846,0.00033548393,0.003181421,0.000028974653,0.0006758198,0.0062485537,0.0000998991,0.0034266026,0.0064669033,0.00022670289],"about_ca_topic_score_codex":0.000066044864,"about_ca_topic_score_gemma":0.00018743053,"teacher_disagreement_score":0.09800943,"about_ca_system_score_codex":0.0006563224,"about_ca_system_score_gemma":0.002372598,"threshold_uncertainty_score":0.98382914},"labels":[],"label_agreement":null},{"id":"W2747599761","doi":"10.1200/jco.2007.25.18_suppl.6569","title":"A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Context (archaeology); Clinical trial; Cytotoxic T cell; Oncology; Internal medicine; Surrogate endpoint; Biology","score_opus":0.5079036047924194,"score_gpt":0.5775378653698081,"score_spread":0.06963426057738875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747599761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003956125,0.9864127,0.0005359642,0.000081347105,0.0058028474,0.002210294,0.00060349016,0.0000025281875,0.00039471773],"genre_scores_gemma":[0.0007464499,0.9877984,0.0042407345,0.00047141282,0.0062415604,0.000033619253,0.00031928366,0.000071084076,0.00007745383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9797032,0.0031442582,0.015618002,0.00055262836,0.000568717,0.00041322663],"domain_scores_gemma":[0.953548,0.014366705,0.029882478,0.00074725534,0.0009880905,0.00046744823],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033217452,0.0005673333,0.011256081,0.00020134206,0.000045780063,0.000012965573,0.0007911046,0.0018362823,0.000097131255],"category_scores_gemma":[0.060176082,0.00044615223,0.003648818,0.0001689497,0.0003219679,0.000010830506,0.00026492472,0.0012439372,0.0000065592913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06775872,0.0032710228,0.000001045237,0.0070506735,0.0027948904,0.00013626395,0.000012970679,0.0000030546285,0.0009952454,0.0000025462748,0.028600411,0.8893732],"study_design_scores_gemma":[0.059485223,0.05274435,0.0000045219335,0.026053557,0.004627965,0.000037287882,0.0000076506985,0.000003998507,0.00029981942,0.000019568846,0.85636294,0.00035311806],"about_ca_topic_score_codex":0.000020688227,"about_ca_topic_score_gemma":0.000007206644,"teacher_disagreement_score":0.88902,"about_ca_system_score_codex":0.0001955871,"about_ca_system_score_gemma":0.018574348,"threshold_uncertainty_score":0.999799},"labels":[],"label_agreement":null},{"id":"W2748477083","doi":"10.1200/jco.2014.32.15_suppl.8099","title":"Lung cancer in never-smokers from the Princess Margaret Cancer Centre.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Internal medicine; Malignancy; Stage (stratigraphy); KRAS; Adenocarcinoma; Oncology; Epidemiology; Gastroenterology; Colorectal cancer","score_opus":0.06464135926973903,"score_gpt":0.4752126365681126,"score_spread":0.41057127729837356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748477083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83687824,0.0042221774,0.000025127609,0.15422903,0.0030064548,0.0002311272,0.000014068427,0.000005570676,0.001388181],"genre_scores_gemma":[0.9734965,0.009507314,0.00028963023,0.013714323,0.0027674555,0.00001832016,0.0000019632014,0.000015234043,0.00018927388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997436,0.0004303306,0.0013702502,0.00019847392,0.00032555033,0.00023941066],"domain_scores_gemma":[0.9954456,0.0029161214,0.0009852091,0.000207789,0.00019502993,0.0002502306],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015058948,0.00012916396,0.0010580994,0.00003900964,0.000031605374,0.0000098114915,0.00020149138,0.0002308871,0.00095063733],"category_scores_gemma":[0.0008401493,0.00006836809,0.0003150857,0.00011312252,0.00012364409,0.00009083216,0.000048505528,0.000765423,0.0000065598488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093085156,0.00060175214,0.8464053,0.000014118482,0.00046078357,0.000117275194,0.00013306597,0.00009824364,0.0000035708536,0.000090898764,0.028259838,0.122884244],"study_design_scores_gemma":[0.0066429228,0.0007517661,0.7710309,0.00038965605,0.00050590606,0.000007140689,0.000054725788,0.00029211893,0.000028393639,0.00014062035,0.22009662,0.000059224913],"about_ca_topic_score_codex":0.0029261697,"about_ca_topic_score_gemma":0.0077955094,"teacher_disagreement_score":0.19183679,"about_ca_system_score_codex":0.00079488615,"about_ca_system_score_gemma":0.0014842422,"threshold_uncertainty_score":0.9999626},"labels":[],"label_agreement":null},{"id":"W2748693890","doi":"10.1200/jco.2012.30.15_suppl.3007","title":"First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Crizotinib; Oncology; Gastroenterology; Lung cancer","score_opus":0.08638177473718214,"score_gpt":0.544109239422946,"score_spread":0.45772746468576386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748693890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393,0.00027263185,0.0000034879354,0.0025069553,0.0011261259,0.00039963677,0.0000015161484,0.0000021147744,0.0017575563],"genre_scores_gemma":[0.99839985,0.000043640757,0.00021101217,0.0004935699,0.00068869063,0.000010113074,5.23463e-7,0.000008814242,0.0001437999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732655,0.00023192119,0.0019381634,0.00009057033,0.0002266495,0.00018611918],"domain_scores_gemma":[0.99784935,0.0005805384,0.0011110675,0.00016392197,0.00012973786,0.00016540212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013688946,0.000084281404,0.0009668085,0.00010452494,0.000030161378,0.000001814872,0.00010751315,0.00010874391,0.000060736944],"category_scores_gemma":[0.0010148751,0.000047707174,0.00019155946,0.00016545005,0.0000825,0.00011143708,0.00003753756,0.0005473569,0.0000023936727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018790605,0.03888129,0.9282836,0.000025208996,0.00023252086,0.00024774863,0.0027551258,0.000118445896,0.0002713152,0.00006016468,0.0008342485,0.026411291],"study_design_scores_gemma":[0.043365195,0.019195192,0.92057544,0.00017500589,0.00033048034,0.000067221285,0.0015917211,0.000013662635,0.00015141949,0.00010894174,0.014370189,0.000055533004],"about_ca_topic_score_codex":0.000052431453,"about_ca_topic_score_gemma":0.0004305721,"teacher_disagreement_score":0.041486133,"about_ca_system_score_codex":0.00023129156,"about_ca_system_score_gemma":0.00054869126,"threshold_uncertainty_score":0.23780239},"labels":[],"label_agreement":null},{"id":"W2748791006","doi":"10.1200/jco.2012.30.15_suppl.1557","title":"A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Clinical trial; Physical therapy; Adverse effect; Chemotherapy-induced peripheral neuropathy; Peripheral neuropathy; Patient-reported outcome; Psychological intervention; Randomized controlled trial; Quality of life (healthcare); Internal medicine","score_opus":0.26279268825581004,"score_gpt":0.5315475255132972,"score_spread":0.26875483725748717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748791006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096745,0.0032161784,0.000033903027,0.0030697954,0.0011128741,0.00017835117,0.000005309012,0.0000037508419,0.0014123601],"genre_scores_gemma":[0.9977664,0.00026674985,0.00025054868,0.00087823544,0.0007971932,0.0000013413066,0.0000016177028,0.00000908148,0.000028832303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657583,0.0011580153,0.0016777784,0.000089241854,0.00031890222,0.00018024688],"domain_scores_gemma":[0.9948858,0.0028214932,0.0015825209,0.00012875478,0.0003544036,0.00022705365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032528501,0.000114874965,0.0017225108,0.000057408262,0.00004049408,0.00000330747,0.000114426904,0.00020919494,0.00019042661],"category_scores_gemma":[0.0015651895,0.00006621933,0.00036584635,0.0000847706,0.0005451681,0.000087656284,0.000057272588,0.00055995287,8.728469e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035761155,0.006177614,0.8558465,0.00006883637,0.0004839458,0.00003244623,0.0014723989,0.0000054263683,0.02758299,0.00005252591,0.009913365,0.0626028],"study_design_scores_gemma":[0.037864458,0.036123898,0.82975465,0.00013043523,0.0024962858,0.0004473617,0.00070992386,0.0003872067,0.010378338,0.00015906488,0.08141416,0.00013420964],"about_ca_topic_score_codex":0.000038001544,"about_ca_topic_score_gemma":0.00004053002,"teacher_disagreement_score":0.07150079,"about_ca_system_score_codex":0.00007757605,"about_ca_system_score_gemma":0.000261237,"threshold_uncertainty_score":0.27003458},"labels":[],"label_agreement":null},{"id":"W2748908606","doi":"10.1200/jco.2015.33.15_suppl.tps5072","title":"A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Tolerability; Oncology; Internal medicine; Clinical endpoint; Androgen receptor; Abiraterone; Phases of clinical research; Abiraterone acetate; Pharmacokinetics; Pharmacology; Adverse effect; Cancer; Androgen deprivation therapy; Clinical trial","score_opus":0.21696765625155973,"score_gpt":0.5335928390271395,"score_spread":0.31662518277557977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748908606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964986,0.0003698052,0.00003993751,0.001015378,0.00006165065,0.0018848546,0.00004017252,0.0000024994383,0.00008712071],"genre_scores_gemma":[0.99421155,0.00023824595,0.005190601,0.000045560984,0.00007306467,0.00006873963,0.0000022901916,0.000019594407,0.00015032801],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966258,0.0005257579,0.0016522208,0.00028185855,0.00064424647,0.0002701075],"domain_scores_gemma":[0.9966881,0.0004672352,0.0016328145,0.00017806236,0.000645405,0.0003883388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031616578,0.0001994065,0.0017200715,0.00018699042,0.000032088286,0.000018806126,0.00013392667,0.00009558655,0.000016371761],"category_scores_gemma":[0.0002810222,0.00009743416,0.000042948697,0.00029528307,0.0004560758,0.00034222272,0.00009707954,0.0005614307,2.4221032e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7612881,0.05752606,0.118173525,0.00033955034,0.00089031603,0.009384415,0.003120443,0.000017234217,0.009879628,0.000004350133,0.000050735292,0.03932562],"study_design_scores_gemma":[0.40689364,0.37725314,0.20263356,0.0024139339,0.0009936563,0.0008657052,0.00407276,0.00020413636,0.004047284,0.000038842576,0.0003558151,0.00022753883],"about_ca_topic_score_codex":0.00036888546,"about_ca_topic_score_gemma":0.0031911565,"teacher_disagreement_score":0.3543945,"about_ca_system_score_codex":0.00026666714,"about_ca_system_score_gemma":0.005435852,"threshold_uncertainty_score":0.96429676},"labels":[],"label_agreement":null},{"id":"W2749878693","doi":"10.1200/jco.2017.35.15_suppl.4003","title":"KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Cohort; Internal medicine; Cancer; Discontinuation; Oncology; Gastroenterology; Surgery; Adverse effect; Immunotherapy","score_opus":0.045032076992573555,"score_gpt":0.4131629942430535,"score_spread":0.36813091725047997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749878693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571323,0.0004026953,0.000045472985,0.0017662634,0.0003200421,0.0006398159,0.0000032310186,0.0000054815678,0.0011037512],"genre_scores_gemma":[0.9935871,0.004498838,0.0010246232,0.00039546826,0.00018819439,0.0000059621116,0.0000023118685,0.000017721863,0.00027979378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973387,0.00014357902,0.0017175636,0.00021441143,0.00034204376,0.0002436668],"domain_scores_gemma":[0.9959389,0.00055676233,0.0026444711,0.00032279998,0.0003158689,0.00022118243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010452243,0.00016465654,0.0017166031,0.00017505139,0.000054345397,0.000011044776,0.00022016373,0.00017224415,0.00006805953],"category_scores_gemma":[0.001027624,0.000108005166,0.00017643993,0.00011712082,0.00024952897,0.00016048146,0.000055180608,0.00050502125,8.3828263e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042030424,0.00070473977,0.70985,0.00003103889,0.0003115234,0.0000552034,0.000029570023,0.00003321464,0.0000047292083,0.000005918477,0.00019564395,0.24674802],"study_design_scores_gemma":[0.0794871,0.013616828,0.90167487,0.00025094106,0.00041453226,0.0000123480295,0.0000123753225,0.00002415367,0.0000071758404,0.00001251303,0.0044073244,0.000079852274],"about_ca_topic_score_codex":0.00012411752,"about_ca_topic_score_gemma":0.00014372673,"teacher_disagreement_score":0.24666816,"about_ca_system_score_codex":0.00018760806,"about_ca_system_score_gemma":0.0005273567,"threshold_uncertainty_score":0.44043228},"labels":[],"label_agreement":null},{"id":"W2749990448","doi":"10.1200/jco.2004.22.14_suppl.6087","title":"Severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer: A cost of illness analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Diarrhea; Chemotherapy; Colorectal cancer; Anemia; Internal medicine; Retrospective cohort study; Cancer; Cohort; Neutropenia; Surgery","score_opus":0.045769477663907564,"score_gpt":0.4206567120051923,"score_spread":0.37488723434128474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749990448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637324,0.000041767627,0.000060324273,0.0021601804,0.00042930376,0.00027043495,0.0000068814675,0.0000041214093,0.0006537555],"genre_scores_gemma":[0.9982707,0.00024307186,0.00026289606,0.00094353507,0.00023810279,0.000011676653,0.0000024492974,0.000012213731,0.000015381862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978366,0.00014222118,0.0014074404,0.0001452085,0.0002998875,0.00016863983],"domain_scores_gemma":[0.9975964,0.0003298752,0.0012292225,0.000117551,0.00051511533,0.00021187078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069621316,0.00010888984,0.0015399252,0.00026031942,0.000024442186,0.0000033833937,0.00010304972,0.00023610158,0.00017956183],"category_scores_gemma":[0.000258427,0.000072497736,0.00036507673,0.0007823828,0.00013263684,0.000086109234,0.000014831422,0.0006983031,0.0000017060443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009225476,0.0024630597,0.9454793,0.000011824668,0.0012830438,0.00005723654,0.000187342,0.0007027852,0.00012889548,0.00002031724,0.000061774765,0.04037896],"study_design_scores_gemma":[0.024299892,0.010492711,0.9618816,0.000087616856,0.000961894,0.00002600013,0.00006100263,0.0000048703146,0.0006922046,0.00004347024,0.0013611432,0.00008763183],"about_ca_topic_score_codex":0.00034117806,"about_ca_topic_score_gemma":0.0019025254,"teacher_disagreement_score":0.04029133,"about_ca_system_score_codex":0.00037312787,"about_ca_system_score_gemma":0.0020449387,"threshold_uncertainty_score":0.36276335},"labels":[],"label_agreement":null},{"id":"W2750960034","doi":"10.1200/jco.2016.34.15_suppl.e18175","title":"Oncology education for internal medicine residents: The value of participating in a medical oncology rotation.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Sunnybrook Health Science Centre; Health Sciences Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Cancer; Family medicine; Internal medicine","score_opus":0.12538494046400847,"score_gpt":0.605988243818695,"score_spread":0.4806033033546865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750960034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59492743,0.0026800714,0.026502628,0.35403866,0.010668617,0.00091568194,0.000003981011,0.000012598973,0.010250308],"genre_scores_gemma":[0.94394326,0.0051565752,0.02123311,0.021132385,0.0076468885,0.00017011058,0.0000021391895,0.000029688455,0.0006858435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992906,0.0017042153,0.00433955,0.00023422064,0.00049809826,0.00031794063],"domain_scores_gemma":[0.9625173,0.03223647,0.0037774115,0.0002458267,0.00086034345,0.00036265203],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013547388,0.00015408818,0.001953767,0.0002382811,0.00005345106,0.0000014674541,0.0004257341,0.00085994136,0.0007060794],"category_scores_gemma":[0.05142691,0.000071974755,0.00034112285,0.00019918631,0.0015456984,0.00013529157,0.000054354354,0.0010548376,0.000005455694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010494688,0.0028324,0.082255304,0.00004249012,0.00031659933,0.00019161678,0.00077080296,0.000013116479,0.00045503577,0.0051983963,0.015995067,0.8814345],"study_design_scores_gemma":[0.037358526,0.069228604,0.26040927,0.0016683921,0.00053998025,0.0023772668,0.0016127462,0.0004142743,0.00020016608,0.024916498,0.60111463,0.00015963281],"about_ca_topic_score_codex":0.000060002232,"about_ca_topic_score_gemma":0.00026260462,"teacher_disagreement_score":0.8812749,"about_ca_system_score_codex":0.0007761277,"about_ca_system_score_gemma":0.009812062,"threshold_uncertainty_score":0.9958014},"labels":[],"label_agreement":null},{"id":"W2751303857","doi":"10.1200/jco.2014.32.15_suppl.9530","title":"Efficacy of a video-based psychological intervention for cancer-related insomnia: Results of a randomized controlled trial.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Insomnia; Randomized controlled trial; Sleep onset; Sleep onset latency; Medicine; Cognitive behavioral therapy for insomnia; Actigraphy; Physical therapy; Cognitive behavioral therapy; Psychiatry; Internal medicine","score_opus":0.12419132006844404,"score_gpt":0.5173857450953473,"score_spread":0.39319442502690327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751303857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718607,0.00021154754,0.0020841847,0.008474529,0.0073685367,0.0035460573,0.0000108169115,0.000019324645,0.006424288],"genre_scores_gemma":[0.99589527,0.00021454619,0.0024139893,0.000375118,0.0007865083,0.00010903104,0.0000021091082,0.000010405369,0.00019305029],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.981244,0.008887081,0.00877882,0.00023041193,0.0005987766,0.00026087358],"domain_scores_gemma":[0.922492,0.06444983,0.011371606,0.00019234247,0.0012801645,0.00021401608],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.066472255,0.00014229704,0.005519472,0.00019884312,0.00007142501,0.000009798596,0.0005155227,0.00079314515,0.0001232987],"category_scores_gemma":[0.18594263,0.000092202725,0.0034344401,0.0002466505,0.0011134553,0.000097356555,0.00002699372,0.00056862796,0.000001971562],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.957364,0.0050515956,0.00014501199,0.000019018387,0.00058803876,0.000004529875,0.00045189407,0.00009305288,0.000020375486,0.0020611656,0.0016864879,0.03251481],"study_design_scores_gemma":[0.9644805,0.010920299,0.0010967462,0.00016278333,0.00081444794,0.000001119864,0.00014330872,0.0004937855,0.000020996546,0.0037377886,0.018038714,0.0000894898],"about_ca_topic_score_codex":0.00025721444,"about_ca_topic_score_gemma":0.00026770198,"teacher_disagreement_score":0.11947038,"about_ca_system_score_codex":0.000106962536,"about_ca_system_score_gemma":0.0011868028,"threshold_uncertainty_score":0.96126324},"labels":[],"label_agreement":null},{"id":"W2751740210","doi":"10.1200/jco.2017.73.7817","title":"Changes in Insurance Coverage and Stage at Diagnosis Among Nonelderly Patients With Cancer After the Affordable Care Act","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology; American Cancer Society","keywords":"Medicine; Medicaid; Health insurance; Cancer; Demographics; Patient Protection and Affordable Care Act; Stage (stratigraphy); Internal medicine; Demography; Cancer stage; Quarter (Canadian coin); Colorectal cancer; Health care","score_opus":0.06342111456393454,"score_gpt":0.3486570528237167,"score_spread":0.2852359382597821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751740210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889992,0.0029190353,0.000008400772,0.0024036937,0.0009863034,0.00018614944,0.00016406208,0.0000018316922,0.0043313126],"genre_scores_gemma":[0.98936987,0.008740713,0.000054211792,0.0010313288,0.0003517065,0.00003775327,9.003794e-7,0.000016189626,0.00039733443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835163,0.000039170354,0.001089227,0.00021674913,0.000047206795,0.00025603359],"domain_scores_gemma":[0.9961127,0.00040913414,0.0029430047,0.0002823127,0.00011041062,0.00014245066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010098757,0.00013471114,0.000976962,0.00007588269,0.00015536688,0.00007549188,0.0003343945,0.00022326851,0.00023776435],"category_scores_gemma":[0.0007638191,0.00009416605,0.00011916178,0.000034287823,0.00034021918,0.0005500703,0.00011042235,0.00046355944,0.000010181814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009849815,0.00011899537,0.95672566,0.000016687929,0.000057355883,0.000026524769,0.00036852455,0.00003857848,4.4109793e-8,0.00012418044,0.00027118114,0.0412673],"study_design_scores_gemma":[0.003249037,0.0012913897,0.91685313,0.000060583367,0.000011914988,0.0000011462297,0.00003707964,0.0000085002275,0.0000027074643,0.00032993403,0.078031935,0.00012262934],"about_ca_topic_score_codex":0.0010018379,"about_ca_topic_score_gemma":0.028886588,"teacher_disagreement_score":0.077760756,"about_ca_system_score_codex":0.00025363092,"about_ca_system_score_gemma":0.00015698004,"threshold_uncertainty_score":0.9888337},"labels":[],"label_agreement":null},{"id":"W2752563952","doi":"10.1200/jco.2017.73.3246","title":"First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Cancer Institute; Pfizer; Eli Lilly and Company","keywords":"Medicine; Tamoxifen; Fulvestrant; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Pharmacokinetics; Cancer; Gastroenterology; Pharmacology; Urology","score_opus":0.12391452297016595,"score_gpt":0.5287560360576353,"score_spread":0.4048415130874694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752563952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912048,0.00040411254,8.5530144e-7,0.006487004,0.00077399105,0.00059233187,0.000017097427,0.000002685589,0.0005171065],"genre_scores_gemma":[0.9979376,0.0004363625,0.000074426294,0.00067168626,0.0005241108,0.000057407422,3.9962035e-7,0.000017294387,0.00028070412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663377,0.0005671503,0.0019126202,0.00020825179,0.00035338505,0.0003247973],"domain_scores_gemma":[0.99563426,0.0008344847,0.0026506332,0.00041098197,0.00022673143,0.00024289242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018238653,0.00017753577,0.0019464318,0.00017342965,0.000086085216,0.000009693656,0.00042168234,0.00008946577,0.00039671917],"category_scores_gemma":[0.00041409035,0.00009568027,0.00020262106,0.00012842125,0.0003380509,0.0001767795,0.00010115462,0.0009858004,0.0000013525911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029371668,0.0367603,0.8799882,0.00006266203,0.0017120289,0.0024062213,0.0020835195,0.000086122745,0.0006206665,0.000017039863,0.00045333995,0.046438247],"study_design_scores_gemma":[0.07653665,0.021724219,0.8918645,0.0001118974,0.0009300001,0.0002408926,0.00046444923,0.00001587887,0.00006835238,0.0001147179,0.007846452,0.000082003404],"about_ca_topic_score_codex":0.0011707708,"about_ca_topic_score_gemma":0.0040149107,"teacher_disagreement_score":0.047164984,"about_ca_system_score_codex":0.00038274706,"about_ca_system_score_gemma":0.0012336522,"threshold_uncertainty_score":0.43437967},"labels":[],"label_agreement":null},{"id":"W2752873349","doi":"10.1200/jco.2013.31.15_suppl.5518","title":"Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Carboplatin; Febrile neutropenia; Tolerability; Oncology; Adverse effect; Cancer; Phases of clinical research; Taxane; Gastroenterology; Chemotherapy; Cisplatin; Breast cancer","score_opus":0.02880463901628139,"score_gpt":0.3556495586213135,"score_spread":0.3268449196050321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752873349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945753,0.00032792028,0.0001777721,0.0020227756,0.0014193256,0.00064977625,0.00021762276,0.000006578515,0.0006029091],"genre_scores_gemma":[0.9954031,0.00023083635,0.0018175085,0.00087610265,0.0014616958,0.00004418288,0.000020435487,0.000057819718,0.000088308945],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9944061,0.0008315549,0.0029383472,0.0005785273,0.00067129947,0.0005741923],"domain_scores_gemma":[0.9934143,0.0006046371,0.0039094756,0.00046858654,0.0012860021,0.0003170244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020882746,0.00038652882,0.0013764607,0.00010376756,0.00010215443,0.000027789876,0.00050067634,0.000657174,0.000069901405],"category_scores_gemma":[0.00190827,0.00023617657,0.0002795112,0.00032322865,0.00052827713,0.000036725913,0.00017947338,0.0012297931,0.000002272953],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09234611,0.0061906176,0.29522592,0.00021641886,0.0032529847,0.0006020334,0.0022352836,0.01713593,0.47267428,0.00007427458,0.0112681305,0.09877802],"study_design_scores_gemma":[0.23217708,0.076551065,0.36485344,0.0037984776,0.0014033903,0.0002899182,0.0019662175,0.0041848226,0.26289454,0.00023744769,0.04905444,0.0025891587],"about_ca_topic_score_codex":0.001951318,"about_ca_topic_score_gemma":0.0018998872,"teacher_disagreement_score":0.20977972,"about_ca_system_score_codex":0.000410215,"about_ca_system_score_gemma":0.0036821768,"threshold_uncertainty_score":0.9631001},"labels":[],"label_agreement":null},{"id":"W2752996975","doi":"10.1200/jco.2016.34.15_suppl.5019","title":"Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Enzalutamide; Prostate; Cancer; Pathology; Oncology; Internal medicine; Androgen receptor","score_opus":0.08894000060709614,"score_gpt":0.43266410679572326,"score_spread":0.34372410618862714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752996975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960627,0.003737592,0.000015334695,0.030792022,0.0016450661,0.0015308843,0.0015896035,0.000019007262,0.00004348653],"genre_scores_gemma":[0.82876885,0.16650929,0.00024824546,0.0011717555,0.0013927473,0.00012145521,0.00005285246,0.000063897816,0.0016709259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99248976,0.0012360504,0.004236971,0.00075295963,0.000573127,0.0007111312],"domain_scores_gemma":[0.9907777,0.0038710625,0.003209843,0.0004148204,0.0009113701,0.00081522827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028264693,0.00043970448,0.0023665777,0.00015800456,0.00013041195,0.000046131663,0.0003317006,0.00022340535,0.00009986519],"category_scores_gemma":[0.0017703816,0.00022055673,0.00037721006,0.0002310923,0.0018189446,0.00027394164,0.0003378194,0.0013988016,0.000007228051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048300404,0.0009621624,0.6865506,0.00016423063,0.0009245449,0.0005866343,0.00081368315,0.0000046744876,0.015308518,0.000005594524,0.0016550288,0.2447239],"study_design_scores_gemma":[0.035150487,0.007712622,0.92267156,0.0010559481,0.0011983835,0.0001204026,0.00020523474,0.00010602084,0.0018820219,0.0001727751,0.029461533,0.00026301667],"about_ca_topic_score_codex":0.0007118394,"about_ca_topic_score_gemma":0.0013583553,"teacher_disagreement_score":0.2444609,"about_ca_system_score_codex":0.00026023263,"about_ca_system_score_gemma":0.003521118,"threshold_uncertainty_score":0.8994042},"labels":[],"label_agreement":null},{"id":"W2753107847","doi":"10.1200/jco.2006.24.18_suppl.16034","title":"Quality indicators for end-of-life breast cancer care: Is there agreement between stakeholder groups?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; York University; University of Toronto; Dalhousie University","funders":"","keywords":"Focus group; Medicine; Delphi method; Thematic analysis; Stakeholder; Nursing; Multidisciplinary approach; Health care; Audit; Delphi; Breast cancer; Family medicine; Qualitative research; Cancer","score_opus":0.497513193603575,"score_gpt":0.6120904369722768,"score_spread":0.11457724336870184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753107847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9459703,0.0007866534,0.00077960774,0.039052837,0.0008834433,0.0005498422,0.00020552981,0.000016489701,0.011755294],"genre_scores_gemma":[0.99386173,0.0004492419,0.0018897933,0.00059251214,0.0029251562,0.000020709616,0.0000022384104,0.000013455197,0.00024515577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396074,0.0014612885,0.0027664914,0.00021109756,0.0011790049,0.00042140202],"domain_scores_gemma":[0.9902125,0.0055769156,0.0027048073,0.00019397815,0.000942893,0.00036890717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014223215,0.00011700873,0.0011032916,0.00017420495,0.00015934084,0.000022710889,0.00075975084,0.00056903594,0.0008292526],"category_scores_gemma":[0.0023961805,0.0000915227,0.00052101247,0.0003239948,0.00095621054,0.00015292014,0.00008765837,0.0007532917,0.0000050907806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034632377,0.00042285552,0.7076703,0.00003718826,0.00015638271,0.000009261577,0.000907681,0.000002821974,0.000010080235,0.0031363752,0.028454382,0.25884637],"study_design_scores_gemma":[0.0015559839,0.0008740663,0.6849824,0.000035352565,0.00006334633,0.0000010305138,0.0023403885,6.7669947e-7,0.000054233424,0.0046993895,0.30528763,0.000105454936],"about_ca_topic_score_codex":0.00537245,"about_ca_topic_score_gemma":0.0045524137,"teacher_disagreement_score":0.27683327,"about_ca_system_score_codex":0.0004660864,"about_ca_system_score_gemma":0.005278895,"threshold_uncertainty_score":0.93645334},"labels":[],"label_agreement":null},{"id":"W2753687864","doi":"10.1200/jco.2017.35.15_suppl.e14587","title":"Effect of high-dose corticosteroids on CD4+ or CD8+ lymphocyte proliferation or IL-2 production after stimulation with pembrolizumab.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pembrolizumab; Peripheral blood mononuclear cell; Prednisone; CD8; Immune system; Lymphocyte; Melanoma; Internal medicine; Stimulation; Immunology; IL-2 receptor; Pharmacology; Immunotherapy; Endocrinology; T cell; Cancer research; In vitro; Biology","score_opus":0.07150106635071538,"score_gpt":0.44700487998762045,"score_spread":0.3755038136369051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753687864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426776,0.000065306645,0.000067860594,0.0030500263,0.0017423409,0.00061611144,0.000002717501,0.000008041116,0.00017982538],"genre_scores_gemma":[0.996471,0.0003384194,0.00050080963,0.0005251341,0.0014413665,0.000016952852,0.0000029153173,0.000019306226,0.0006841044],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99720395,0.00042890612,0.001585632,0.00020685414,0.00041786954,0.00015681669],"domain_scores_gemma":[0.99558467,0.00082748465,0.0026349647,0.0003854263,0.00043005956,0.00013738783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025014945,0.00015734007,0.0011088073,0.000112945665,0.00008572045,0.000022561897,0.00012362361,0.00027811065,0.0001489504],"category_scores_gemma":[0.0034328052,0.00007683764,0.00023188804,0.00006965185,0.00028473904,0.00024425233,0.000020407488,0.00037604113,0.0000059249123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6229589,0.0006811021,0.036685176,0.00010454579,0.00033157456,0.00024138577,0.000053910877,0.000043546715,0.0016589713,0.0000025460718,0.00029178604,0.33694658],"study_design_scores_gemma":[0.048374142,0.1776132,0.75702846,0.0006289827,0.0006948291,0.0008535718,0.000010648772,0.00017536897,0.010541927,0.000016830378,0.003947035,0.000114984236],"about_ca_topic_score_codex":0.000024200972,"about_ca_topic_score_gemma":0.000111309426,"teacher_disagreement_score":0.7203433,"about_ca_system_score_codex":0.0002647535,"about_ca_system_score_gemma":0.0013643308,"threshold_uncertainty_score":0.41096365},"labels":[],"label_agreement":null},{"id":"W2753951056","doi":"10.1200/jco.2017.73.2800","title":"Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":231,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Thomas Hospital","funders":"National Cancer Institute","keywords":"Medicine; Anxiety; Hospital Anxiety and Depression Scale; Mood; Quality of life (healthcare); Depression (economics); Palliative care; Randomized controlled trial; Internal medicine; Transplantation; Psychiatry","score_opus":0.20597354818581898,"score_gpt":0.5402878491252668,"score_spread":0.33431430093944786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753951056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314845,0.0014158369,0.00006602099,0.0005248018,0.001689368,0.0011096674,0.00018123607,0.000005972765,0.0018586507],"genre_scores_gemma":[0.9928879,0.0059991837,0.00028456145,0.000082150706,0.0006484082,0.000026604615,0.000011420323,0.000018567498,0.000041214724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.987769,0.0037423212,0.0070852092,0.00038653807,0.0007352553,0.00028165823],"domain_scores_gemma":[0.9711091,0.020571532,0.0068640294,0.00055890763,0.00053138204,0.00036504483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008186276,0.00030819778,0.0065397876,0.00013211755,0.000050989103,0.000006628083,0.0004384514,0.0007855923,0.000029580948],"category_scores_gemma":[0.006812963,0.00017760048,0.0027727254,0.00005938949,0.0011569798,0.00006666559,0.000039355455,0.00126916,0.0000031999657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92877364,0.0036100266,0.048556205,0.0007823358,0.0007824584,0.000932822,0.0032434573,0.000009184636,0.000079841375,0.000009764377,0.000049633247,0.013170629],"study_design_scores_gemma":[0.83993345,0.0842959,0.061246127,0.0050017624,0.0024056283,0.000020758192,0.00025568603,0.000019615123,0.006336572,0.000026643998,0.0002903733,0.000167481],"about_ca_topic_score_codex":0.00002285106,"about_ca_topic_score_gemma":0.000019979,"teacher_disagreement_score":0.08884019,"about_ca_system_score_codex":0.000060066344,"about_ca_system_score_gemma":0.0002191174,"threshold_uncertainty_score":0.81562454},"labels":[],"label_agreement":null},{"id":"W2754251024","doi":"10.1200/jco.2017.35.15_suppl.tps4149","title":"The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1<sup>st</sup> line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Baker Hughes (Canada); University of Ottawa; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network; McGill University","funders":"","keywords":"Medicine; Gemcitabine; Durvalumab; Tremelimumab; Internal medicine; Oncology; Paclitaxel; Immunogenicity; Cancer; Immunotherapy; Antigen; Immunology; Nivolumab; Ipilimumab","score_opus":0.1627107659367999,"score_gpt":0.5054009264514338,"score_spread":0.34269016051463386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754251024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716817,0.009383626,0.000027012109,0.013420117,0.00048853294,0.0043643196,0.000017032915,0.000013770259,0.00060388574],"genre_scores_gemma":[0.97800934,0.01832347,0.0012475847,0.00046126006,0.0008900778,0.00017046578,0.000005484626,0.000056866218,0.0008354503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9853376,0.0055469377,0.006456333,0.0006642704,0.0011847636,0.00081009034],"domain_scores_gemma":[0.9700507,0.022273386,0.004657277,0.0011089393,0.001062873,0.0008468164],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.027502062,0.0005436481,0.008082886,0.00046078768,0.00064768305,0.00008765146,0.0007174534,0.0005371428,0.00017058817],"category_scores_gemma":[0.056168985,0.00031112178,0.0007816962,0.00024921895,0.0029677202,0.000352576,0.00037889756,0.0021115309,0.000006279113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.835474,0.016156709,0.10812779,0.00010776913,0.0040152115,0.0020036194,0.0026756101,0.0000028386519,0.000059387465,0.00023455065,0.000560847,0.030581659],"study_design_scores_gemma":[0.711495,0.15363947,0.122251004,0.00019035918,0.002780163,0.0009007535,0.0030561897,0.0021883287,0.0000049364317,0.0024701497,0.00080948754,0.00021417181],"about_ca_topic_score_codex":0.00058843975,"about_ca_topic_score_gemma":0.0002854947,"teacher_disagreement_score":0.13748276,"about_ca_system_score_codex":0.00017207908,"about_ca_system_score_gemma":0.0025078026,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W2754266983","doi":"10.1200/jco.2017.35.15_suppl.e20669","title":"Survival impact of aggressive treatment on patients with oligometastatic non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Single Center; Oncology; Cancer; Performance status; Lung; Gastroenterology","score_opus":0.07681843139598216,"score_gpt":0.4787242167352677,"score_spread":0.40190578533928556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754266983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389976,0.00040394088,0.000009716597,0.0010617767,0.000939586,0.00044134565,0.00004035207,0.000002453464,0.0032010516],"genre_scores_gemma":[0.9964207,0.0021438277,0.00055670104,0.0001694781,0.0004947408,0.000018644221,0.000004153129,0.000022113667,0.00016968472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977656,0.00015698739,0.0012601402,0.00020718899,0.0003665455,0.00024351125],"domain_scores_gemma":[0.99113,0.0011283727,0.006345531,0.00041235826,0.0005785596,0.00040519444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051916874,0.00021515675,0.001825436,0.000095016214,0.00007280375,0.000013625585,0.00017755682,0.00016126776,0.00012689228],"category_scores_gemma":[0.0005984985,0.00010629115,0.00071105565,0.000041935433,0.00017084034,0.00007301709,0.000030910644,0.00032756332,0.0000057690627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073735896,0.008143555,0.9226326,0.000052002822,0.0025226993,0.0005318936,0.00012379691,0.00009273878,0.0000051470092,0.0000037323211,0.0009338608,0.057584412],"study_design_scores_gemma":[0.030761855,0.070226036,0.89557433,0.0007117776,0.001992857,0.00001083251,0.00001766269,0.000029038083,0.00022492571,0.000009479075,0.0003556001,0.000085576765],"about_ca_topic_score_codex":0.00054980745,"about_ca_topic_score_gemma":0.00023594766,"teacher_disagreement_score":0.06208248,"about_ca_system_score_codex":0.0010495447,"about_ca_system_score_gemma":0.0027557793,"threshold_uncertainty_score":0.4888634},"labels":[],"label_agreement":null},{"id":"W2754941761","doi":"10.1200/jco.2012.30.15_suppl.4522","title":"Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Chemotherapy; Gemcitabine; Oncology; Proportional hazards model; Paclitaxel; Carboplatin; Performance status; Gastroenterology; Urology; Cisplatin","score_opus":0.08035251361175413,"score_gpt":0.4181253611300205,"score_spread":0.3377728475182664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754941761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047714,0.0043238453,0.00002593494,0.0014111309,0.0015986549,0.00079082325,0.000024835968,0.000021397022,0.0013262449],"genre_scores_gemma":[0.9906937,0.0009490065,0.0012831211,0.0029763784,0.0031667699,0.000022660257,0.0000056473546,0.000056249828,0.0008464927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960009,0.00053715735,0.0022665607,0.00027333846,0.0004023779,0.00051965826],"domain_scores_gemma":[0.99557185,0.0020392598,0.001330154,0.00027062415,0.00024264996,0.0005454768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00146143,0.00027680115,0.0019196266,0.00015519514,0.00004020105,0.000010907721,0.00021253404,0.00049241376,0.0025351306],"category_scores_gemma":[0.001452922,0.00019230467,0.0004845722,0.00016129049,0.00010306961,0.00024120833,0.00003350273,0.0010151697,0.00016940503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012523146,0.0031333768,0.71840745,0.000040930765,0.0005357266,0.00031953544,0.0012187427,0.0000024610733,0.009038298,0.0000032664645,0.00026065807,0.2545164],"study_design_scores_gemma":[0.033837173,0.014970764,0.93077666,0.00045248918,0.00021033477,0.00063079136,0.00016134977,0.00003203141,0.0018706532,0.00010320764,0.016737457,0.00021709087],"about_ca_topic_score_codex":0.000071116905,"about_ca_topic_score_gemma":0.0000274857,"teacher_disagreement_score":0.25429928,"about_ca_system_score_codex":0.0003597464,"about_ca_system_score_gemma":0.0018216254,"threshold_uncertainty_score":0.99837667},"labels":[],"label_agreement":null},{"id":"W2755019703","doi":"10.1200/jco.2017.72.7925","title":"Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Autologous stem-cell transplantation; Internal medicine; Cohort; Gene expression profiling; Lymphoma; Prognostic model; Transplantation; Pathology; Overall survival; Gene expression; Gene; Biology","score_opus":0.10670400338220576,"score_gpt":0.43843369842636326,"score_spread":0.3317296950441575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755019703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685145,0.000093565824,0.00023429714,0.027145524,0.000894207,0.00044065848,0.000016172746,0.000011283185,0.002649817],"genre_scores_gemma":[0.9933284,0.00036816558,0.0029723102,0.0026136152,0.0002761508,0.000023779832,0.0000035613687,0.00001694914,0.00039706062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676913,0.00025877295,0.002007878,0.0002558755,0.00041106268,0.00029730424],"domain_scores_gemma":[0.9956819,0.0019437355,0.0012513334,0.00032910716,0.0002767038,0.00051724067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014929493,0.00018540365,0.0016732207,0.00015880317,0.00007735679,0.000028254999,0.00027890687,0.00043189706,0.000016731796],"category_scores_gemma":[0.0016179313,0.00012065283,0.00048101117,0.000044090873,0.00014527039,0.00015064434,0.000047851314,0.00033046756,0.00004145419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037718846,0.0061437585,0.76935613,0.00003629193,0.00017606567,0.0039910492,0.00015535514,0.00013605802,0.000052254592,0.00011018995,0.0006226037,0.21544835],"study_design_scores_gemma":[0.019488791,0.013236725,0.9634268,0.00014763029,0.00059438194,0.00029376964,0.00004793005,0.0012800123,0.00009570097,0.00019021459,0.0010932897,0.00010472319],"about_ca_topic_score_codex":0.000033642347,"about_ca_topic_score_gemma":0.00015466388,"teacher_disagreement_score":0.21534362,"about_ca_system_score_codex":0.00029803527,"about_ca_system_score_gemma":0.0017396645,"threshold_uncertainty_score":0.49200797},"labels":[],"label_agreement":null},{"id":"W2755320026","doi":"10.1200/jco.2018.36.4_suppl.tps192","title":"CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Cancer; Oncology; Chemotherapy; Phases of clinical research; Gastroenterology; Immunotherapy","score_opus":0.09015254805863154,"score_gpt":0.4607542864208127,"score_spread":0.37060173836218113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755320026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925492,0.00015690034,0.00022878822,0.0006166605,0.0020342008,0.0041739144,0.000008191828,0.00002334066,0.00020883695],"genre_scores_gemma":[0.99360967,0.0010214477,0.0028679604,0.0006364223,0.0006605951,0.000087961744,0.000012620861,0.00005781361,0.0010454846],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932617,0.00081573403,0.0039624823,0.00054224435,0.0008067965,0.0006110208],"domain_scores_gemma":[0.9925965,0.0013124706,0.004166745,0.00044553762,0.0010752286,0.000403498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027352045,0.00044008228,0.0043239873,0.00045486062,0.00008913928,0.000031196,0.0005236871,0.0002448238,0.0008269441],"category_scores_gemma":[0.0016428631,0.00026275383,0.00027051254,0.00089531014,0.00041677328,0.00044539786,0.00017370307,0.0008094824,0.0000075246844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8061541,0.023421831,0.059368253,0.00006504279,0.0017656366,0.0003495615,0.00052012136,0.000029113915,0.000014147416,8.636e-7,0.0011173718,0.10719397],"study_design_scores_gemma":[0.79351485,0.15003373,0.05228849,0.0003414648,0.0017866014,0.000022370334,0.00057874725,0.00038587116,0.000026184327,0.000002327185,0.0008536803,0.00016569649],"about_ca_topic_score_codex":0.00067295623,"about_ca_topic_score_gemma":0.0043454645,"teacher_disagreement_score":0.12661189,"about_ca_system_score_codex":0.0007479733,"about_ca_system_score_gemma":0.001467047,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W2755364308","doi":"10.1200/jco.2017.35.15_suppl.e15723","title":"Efficacy and tolerability of second-line <i>nab</i>-paclitaxel and gemcitabine (NG) after failing first-line FOLFIRINOX in patients (pts) with advanced pancreatic cancer (APC): A single-institution experience.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Irinotecan; Oxaliplatin; Tolerability; Neutropenia; Internal medicine; Regimen; Oncology; Capecitabine; Pancreatic cancer; Progression-free survival; Performance status; Chemotherapy; Chemotherapy regimen; Surgery; Cancer; Adverse effect; Colorectal cancer","score_opus":0.09823706368127269,"score_gpt":0.4553555421327203,"score_spread":0.3571184784514476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755364308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539346,0.001032302,0.000107677304,0.002070849,0.0002651568,0.0006214431,0.000010250201,0.0000050971794,0.00049379095],"genre_scores_gemma":[0.99459285,0.00147707,0.0032292574,0.0003013318,0.00025603783,0.00003544871,0.0000020689922,0.000014399863,0.00009153144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642044,0.00025791445,0.0022159647,0.00035823774,0.00039927996,0.00034813336],"domain_scores_gemma":[0.99507946,0.0017502134,0.0017172275,0.00040231712,0.000630551,0.000420236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020953824,0.0002117497,0.002322036,0.00014539121,0.0001217596,0.000018372331,0.0001766878,0.0003502786,0.00013626496],"category_scores_gemma":[0.0066149146,0.00014208682,0.00012818733,0.000094060044,0.001411332,0.00034506104,0.00013661962,0.000809433,0.0000010149769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02480167,0.002479382,0.9053546,0.00020621606,0.00017411102,0.00016702086,0.0005018048,0.000015208392,0.00014723523,0.00001045047,0.000012859602,0.066129416],"study_design_scores_gemma":[0.030414887,0.022844357,0.94371986,0.0008116459,0.0003415102,0.000063527936,0.00012896668,0.0002575745,0.00008936902,0.00010843298,0.0010938484,0.00012602749],"about_ca_topic_score_codex":0.00012919714,"about_ca_topic_score_gemma":0.0013216381,"teacher_disagreement_score":0.06600339,"about_ca_system_score_codex":0.00021652685,"about_ca_system_score_gemma":0.000875075,"threshold_uncertainty_score":0.7919149},"labels":[],"label_agreement":null},{"id":"W2755539625","doi":"10.1200/jco.2015.33.15_suppl.6504","title":"Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Cetuximab; Bevacizumab; Irinotecan; Oncology; Colorectal cancer; Oxaliplatin; Internal medicine; Chemotherapy; KRAS; Pemetrexed; Cancer; Cisplatin","score_opus":0.24061730863509928,"score_gpt":0.4509329912060501,"score_spread":0.21031568257095085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755539625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98470086,0.0014061927,0.0071102222,0.001977346,0.0011155827,0.00041137257,0.0005649376,0.000004684743,0.0027088022],"genre_scores_gemma":[0.99096906,0.0012418462,0.006216519,0.0007509816,0.00040427357,0.00002590271,0.0000053078534,0.00003480627,0.00035130657],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99547213,0.0000659143,0.0038202503,0.0002809898,0.0000648597,0.0002958448],"domain_scores_gemma":[0.99100894,0.0013073343,0.0067668124,0.00022083882,0.000390919,0.00030518518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035729993,0.00019471315,0.0035921657,0.00044756345,0.00002435415,0.000013556716,0.00038352207,0.00025522523,0.0006257461],"category_scores_gemma":[0.0011629814,0.00015113514,0.0007957612,0.00027703858,0.00034128872,0.00028647046,0.00002952274,0.00029001007,0.000011665429],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06792783,0.004094763,0.6383185,0.00020257382,0.030670729,0.000050003284,0.0023250985,0.03574662,0.000034695142,0.024493659,0.0153795425,0.180756],"study_design_scores_gemma":[0.06691904,0.04635998,0.41016096,0.00013709346,0.0049519716,0.000050971652,0.00089980685,0.027531857,0.0008170376,0.015502491,0.42549527,0.0011735025],"about_ca_topic_score_codex":0.00069342635,"about_ca_topic_score_gemma":0.0018960342,"teacher_disagreement_score":0.41011575,"about_ca_system_score_codex":0.00050333067,"about_ca_system_score_gemma":0.0021473318,"threshold_uncertainty_score":0.6851481},"labels":[],"label_agreement":null},{"id":"W2755683584","doi":"10.1200/jco.2013.31.15_suppl.6536","title":"Cancer care coordination systematic review and meta-analysis: Twenty-two years of empirical studies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Meta-analysis; Randomized controlled trial; Systematic review; Multidisciplinary approach; Survivorship curve; MEDLINE; Family medicine; Coding (social sciences); Cancer; Nursing; Pathology","score_opus":0.5047616334466244,"score_gpt":0.6090309753248273,"score_spread":0.10426934187820291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755683584","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20319599,0.7677619,0.000079245365,0.0273719,0.00027630918,0.0009284284,0.000005203766,0.0000058234164,0.00037522204],"genre_scores_gemma":[0.97062033,0.018162405,0.000992202,0.009856775,0.00014115396,0.0000338071,9.023866e-7,0.0000058953638,0.0001865086],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960757,0.0005675848,0.002667838,0.00013910745,0.0004270444,0.00012276012],"domain_scores_gemma":[0.99419063,0.0012454925,0.0023914701,0.00017163897,0.0018012392,0.00019952114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029226944,0.00009866035,0.0053404737,0.00010934608,0.000017117774,0.0000051080497,0.000113399416,0.00012256745,0.00025111035],"category_scores_gemma":[0.0049097342,0.000058822057,0.0012575747,0.00031669097,0.00013756315,0.00011175072,0.00004528582,0.00038345173,0.0000060823295],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005532328,0.0007529274,0.11937869,0.10542428,0.7016553,0.00047066488,0.0018829455,0.00016372984,0.000023097942,0.000090770605,0.05832064,0.01128368],"study_design_scores_gemma":[0.0016704736,0.0026605418,0.03471165,0.0026096872,0.9554576,0.0001002111,0.0016506499,0.000042651936,0.000004226861,0.00009486429,0.00090701866,0.00009036829],"about_ca_topic_score_codex":0.00011532054,"about_ca_topic_score_gemma":0.00008692237,"teacher_disagreement_score":0.76742435,"about_ca_system_score_codex":0.00012881232,"about_ca_system_score_gemma":0.00042394575,"threshold_uncertainty_score":0.58777654},"labels":[],"label_agreement":null},{"id":"W2755843609","doi":"10.1200/jco.2017.35.15_suppl.9071","title":"Afatinib in patients with metastatic <i>HER2</i>-mutant lung cancers: An international multicenter study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Lung cancer; Clinical endpoint; T790M; Trastuzumab; KRAS; Exon; Point mutation; Cancer; Epidermal growth factor receptor; Gefitinib; Mutant; Clinical trial; Breast cancer; Biology; Genetics","score_opus":0.08792403434115671,"score_gpt":0.5279885917996495,"score_spread":0.4400645574584928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755843609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944618,0.000022088561,0.000041404062,0.001685924,0.0013523333,0.00045578773,0.000009380108,0.0000034984869,0.0019678178],"genre_scores_gemma":[0.9960438,0.00004041428,0.002753102,0.00067839166,0.00036102193,0.000010877866,0.0000065878653,0.000013040534,0.000092776194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791485,0.00017147981,0.0012145956,0.00017049142,0.00038033194,0.00014826616],"domain_scores_gemma":[0.9971518,0.00025851652,0.0015992388,0.0002698672,0.00049274374,0.00022786003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009117737,0.000107809305,0.00075067853,0.0000942425,0.00006681223,0.000031769483,0.00023520294,0.00006650766,0.00013518613],"category_scores_gemma":[0.0010110908,0.000064819935,0.00011866211,0.000034483888,0.00010778944,0.00043219284,0.00003818462,0.00041828142,0.000003902756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004576693,0.006734605,0.9532032,0.000006900903,0.00096272014,0.00050859054,0.00063376484,0.0000304016,0.0000016373649,0.000007886992,0.00011024254,0.033223342],"study_design_scores_gemma":[0.036644217,0.013085609,0.9456977,0.00010350109,0.00072515564,0.000010767664,0.00048174418,0.00020574903,0.0000025669303,0.000014350063,0.0029668906,0.00006170399],"about_ca_topic_score_codex":0.00024514282,"about_ca_topic_score_gemma":0.000883612,"teacher_disagreement_score":0.03316164,"about_ca_system_score_codex":0.00043923926,"about_ca_system_score_gemma":0.0011921834,"threshold_uncertainty_score":0.26432803},"labels":[],"label_agreement":null},{"id":"W2756225528","doi":"10.1200/jco.2013.31.15_suppl.e19518","title":"Lack of effect of bendamustine on Fridericia corrected QT interval (QTcF) in a phase III study of bendamustine-rituximab in advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Bendamustine; Medicine; QT interval; Rituximab; Internal medicine; Mantle cell lymphoma; Cardiology; Lymphoma","score_opus":0.06540326270168666,"score_gpt":0.4896914087772768,"score_spread":0.4242881460755901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756225528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637115,0.00016437208,0.000022792094,0.00034454936,0.0009071386,0.0014642242,0.000020016345,0.0000068943364,0.00069886027],"genre_scores_gemma":[0.9985186,0.00013064005,0.0007211786,0.00023724604,0.00013908325,0.000051927833,0.000009904663,0.000031736196,0.00015970296],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939089,0.00062589865,0.00433906,0.00031761467,0.00048613062,0.0003224042],"domain_scores_gemma":[0.9926959,0.0029384252,0.0032630225,0.00031975145,0.00056472165,0.00021815771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014725727,0.0002939088,0.003351497,0.0005347177,0.000020795804,0.000004369912,0.00024183946,0.00029507012,0.0002501294],"category_scores_gemma":[0.001852098,0.00019297216,0.0003852079,0.00051479856,0.00017229236,0.00013317441,0.00009253913,0.00042800623,0.000008036899],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09741665,0.14840542,0.11005087,0.0005844257,0.0010476124,0.0018940095,0.0041274657,0.00039955036,0.0032481954,0.0000044369353,0.0009807298,0.63184065],"study_design_scores_gemma":[0.3983972,0.19156814,0.39657694,0.0013972013,0.0011482406,0.00016871023,0.0030442937,0.0011011974,0.0058860844,0.000017657676,0.0004922743,0.00020205011],"about_ca_topic_score_codex":0.0010186688,"about_ca_topic_score_gemma":0.0007580087,"teacher_disagreement_score":0.6316386,"about_ca_system_score_codex":0.00045619567,"about_ca_system_score_gemma":0.0013829118,"threshold_uncertainty_score":0.7869176},"labels":[],"label_agreement":null},{"id":"W2756719694","doi":"10.1200/jco.2017.35.15_suppl.tps7577","title":"CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Nivolumab; CD30; Mycosis fungoides; Anaplastic large-cell lymphoma; Lymphoma; Internal medicine; Oncology; Cancer research; Immunotherapy; Cancer","score_opus":0.06945349368179177,"score_gpt":0.45274504277057276,"score_spread":0.383291549088781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756719694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968484,0.00015222677,0.000017234837,0.00085149053,0.00056738267,0.00093851535,0.000008341272,0.000005283786,0.00061113003],"genre_scores_gemma":[0.9981466,0.00014788196,0.0011191722,0.00023600397,0.00026207278,0.000008652213,0.0000034095415,0.000026916343,0.000049319326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562097,0.00046438837,0.0025894132,0.0003679296,0.00064158184,0.00031573235],"domain_scores_gemma":[0.9942246,0.0012191246,0.0030213376,0.0005620857,0.00048452913,0.00048833265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030927819,0.0002506687,0.0023135846,0.0001985678,0.00012867732,0.00003248472,0.00026566742,0.00020617976,0.00003342108],"category_scores_gemma":[0.003013058,0.00016375692,0.00024507125,0.0000880728,0.00025273708,0.00021036691,0.00018313057,0.00043303,0.000007544632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05297907,0.0398376,0.6820093,0.00002815054,0.0004983909,0.00064958696,0.0008115475,0.000023344042,0.000027195434,0.0000018057284,0.00015986859,0.22297418],"study_design_scores_gemma":[0.21287651,0.05381633,0.7308399,0.000487849,0.00061142375,0.000029898718,0.00015318878,0.00009925822,0.000055573622,0.000006279444,0.000914079,0.000109715795],"about_ca_topic_score_codex":0.00013961364,"about_ca_topic_score_gemma":0.00008297473,"teacher_disagreement_score":0.22286446,"about_ca_system_score_codex":0.00058294326,"about_ca_system_score_gemma":0.0015556297,"threshold_uncertainty_score":0.66778135},"labels":[],"label_agreement":null},{"id":"W2756901142","doi":"10.1200/jco.2017.35.15_suppl.10005","title":"Effect of inpatient palliative care during hematopoietic stem cell transplantation (HCT) hospitalization on psychological distress at six months post-HCT.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Hospital Anxiety and Depression Scale; Anxiety; Mood; Transplantation; Depression (economics); Quality of life (healthcare); Intervention (counseling); Distress; Randomized controlled trial; Internal medicine; Physical therapy; Psychiatry; Clinical psychology; Nursing","score_opus":0.0447899747421999,"score_gpt":0.43350262143111606,"score_spread":0.38871264668891614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756901142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948817,0.00032451135,0.000041573498,0.0006512422,0.0016935691,0.00034437902,0.000033636916,0.000007570417,0.0020218284],"genre_scores_gemma":[0.9987057,0.00064344535,0.000025518539,0.00016641115,0.00033564403,0.0000083798,0.00002041965,0.000015398382,0.0000790705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972627,0.00050550676,0.0013846579,0.00023004203,0.0004445169,0.00017257285],"domain_scores_gemma":[0.995713,0.0010884076,0.002214063,0.00030991592,0.00044886995,0.00022574655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077048043,0.00016582318,0.0011343879,0.00006763146,0.00011178361,0.000011407075,0.00020557285,0.00038178414,0.00005002813],"category_scores_gemma":[0.00043630903,0.00011101624,0.00049877143,0.0000437587,0.00018281383,0.00008148161,0.00003593967,0.00051344594,0.0000072259363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049721166,0.0018341974,0.8473584,0.0020022357,0.00023643083,0.0012433872,0.0076113506,0.000119406395,0.0012359101,0.000045945708,0.00015808493,0.088433474],"study_design_scores_gemma":[0.010055995,0.048138004,0.9287945,0.00060331984,0.00048900326,0.00004750041,0.00063216593,0.000011717907,0.010887109,0.000010737315,0.00020965695,0.000120311415],"about_ca_topic_score_codex":0.00003696152,"about_ca_topic_score_gemma":0.00022894124,"teacher_disagreement_score":0.08831316,"about_ca_system_score_codex":0.00023868596,"about_ca_system_score_gemma":0.000094625626,"threshold_uncertainty_score":0.45271108},"labels":[],"label_agreement":null},{"id":"W2756988206","doi":"10.1200/jco.2012.30.15_suppl.1123","title":"Long-term rates of breast cancer in a population of women with ductal carcinoma in situ treated by breast-conserving surgery.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Queen's University; London Health Sciences Centre; Women's College Hospital; University Health Network; University of Toronto; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast-conserving surgery; Radiation therapy; Breast cancer; Mastectomy; Ductal carcinoma; Cohort; Population; Oncology; Cancer; Internal medicine; Surgery; Gynecology","score_opus":0.03760878838217629,"score_gpt":0.37884060485575993,"score_spread":0.34123181647358364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756988206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768907,0.0013936423,0.0000020876632,0.00058191194,0.0001704724,0.000084589024,0.000043095504,0.0000010633391,0.000034044],"genre_scores_gemma":[0.9991929,0.00041705655,0.000037112786,0.00006937851,0.00023785088,0.0000105891995,0.000014134158,0.000013266938,0.000007715373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778754,0.000314722,0.00131111,0.0001486122,0.00013517441,0.00030285682],"domain_scores_gemma":[0.9979614,0.00031154655,0.0012747413,0.000120907396,0.00019868871,0.00013271836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001089953,0.00014094001,0.001012984,0.00011079023,0.000012045608,0.0000021161397,0.000102729435,0.00022006326,0.000029010609],"category_scores_gemma":[0.0001593935,0.00010380644,0.00013099509,0.00015704063,0.00014628257,0.000019929732,0.000050615672,0.00017901741,2.4736798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057597044,0.0011289102,0.973565,0.000034065954,0.0002556879,0.000029553727,0.0001378746,0.00001124409,0.008278011,0.000001041761,0.00007605062,0.010722872],"study_design_scores_gemma":[0.003042016,0.0007405723,0.9932086,0.000102377155,0.00006557111,0.0003399569,0.00008296708,0.0000014421395,0.0023036848,0.0000041550093,0.000015627533,0.000093032824],"about_ca_topic_score_codex":0.0011646829,"about_ca_topic_score_gemma":0.0023106842,"teacher_disagreement_score":0.019643614,"about_ca_system_score_codex":0.00020595458,"about_ca_system_score_gemma":0.00041738088,"threshold_uncertainty_score":0.42331037},"labels":[],"label_agreement":null},{"id":"W2756994529","doi":"10.1200/jco.2017.35.15_suppl.11506","title":"Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Medicine; Osimertinib; Lung cancer; Cancer research; Tumor progression; Oncology; Internal medicine; Tolerability; Cancer; Gefitinib; Epidermal growth factor receptor; Erlotinib; Adverse effect","score_opus":0.061520828854786255,"score_gpt":0.46344675650710715,"score_spread":0.4019259276523209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756994529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322104,0.0016088877,0.00013106051,0.0016572463,0.0014082064,0.00085239054,0.000018404364,0.000007102796,0.0010956583],"genre_scores_gemma":[0.98508275,0.000367465,0.012967965,0.00035369763,0.0010481073,0.000055272165,0.000008196798,0.000028935454,0.000087594766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969507,0.0001973134,0.0019436954,0.00031224752,0.00031536657,0.00028068622],"domain_scores_gemma":[0.99574524,0.00050778023,0.0027216736,0.0002982269,0.0005004775,0.00022661228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001288839,0.00019669073,0.0012553076,0.00017652544,0.00019186674,0.000023625564,0.0001863199,0.0002074426,0.000014238378],"category_scores_gemma":[0.0017171539,0.00013831283,0.00038619596,0.000103156955,0.00011212899,0.00016580496,0.00005387668,0.0006558738,0.0000015255335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0108116185,0.0037309793,0.60532624,0.00022880135,0.0006147261,0.0014261461,0.0010348345,0.0005181803,0.33754298,0.00009355369,0.0005172084,0.03815476],"study_design_scores_gemma":[0.043264553,0.020704955,0.75263095,0.0033517554,0.0019108662,0.000054608474,0.00055937335,0.0015649803,0.17302813,0.00018273138,0.0023675465,0.0003795651],"about_ca_topic_score_codex":0.00012977034,"about_ca_topic_score_gemma":0.00045988106,"teacher_disagreement_score":0.16451484,"about_ca_system_score_codex":0.00075780536,"about_ca_system_score_gemma":0.0037186844,"threshold_uncertainty_score":0.6596787},"labels":[],"label_agreement":null},{"id":"W2757276454","doi":"10.1200/jco.2017.35.15_suppl.e16500","title":"Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castration-resistant prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Zoledronic acid; Denosumab; Concomitant; Internal medicine; Enzalutamide; Docetaxel; Androgen deprivation therapy; Urology; Oncology; Bone metastasis; Cabozantinib; Cancer; Osteoporosis; Androgen receptor","score_opus":0.4590000686600946,"score_gpt":0.6220015272154118,"score_spread":0.16300145855531722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757276454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819566,0.002724683,0.00001417611,0.0074613704,0.00021061374,0.0012332452,0.00008320996,0.0000012347525,0.00007580041],"genre_scores_gemma":[0.9960157,0.0020379713,0.0014497286,0.0001728943,0.0001906939,0.000049740993,0.000008052653,0.000012113319,0.00006306771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967924,0.00048045072,0.0018466124,0.0001328524,0.0005022428,0.0002454437],"domain_scores_gemma":[0.9936026,0.0022074336,0.002942887,0.0003154341,0.0008255087,0.00010615218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007768594,0.00012483573,0.0010763783,0.000067513254,0.000132165,0.000018507393,0.00031005184,0.000099554796,0.000054454915],"category_scores_gemma":[0.0036208672,0.00005147796,0.00056709885,0.0001081151,0.00037001778,0.00011119167,0.000027482038,0.0005951179,2.6010468e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13580751,0.01084888,0.39431846,0.00029622778,0.0063264575,0.00037051534,0.0059691262,0.0017857472,0.10620936,0.00007833956,0.0029670482,0.3350223],"study_design_scores_gemma":[0.033912547,0.034764834,0.9240667,0.00022452229,0.00036869422,0.000049310715,0.00044905045,0.0031412204,0.002236019,0.0004410792,0.0002768499,0.00006912273],"about_ca_topic_score_codex":0.00056369696,"about_ca_topic_score_gemma":0.00016415582,"teacher_disagreement_score":0.52974826,"about_ca_system_score_codex":0.00014268447,"about_ca_system_score_gemma":0.0038835127,"threshold_uncertainty_score":0.6889185},"labels":[],"label_agreement":null},{"id":"W2757427979","doi":"10.1200/jco.2017.35.15_suppl.9504","title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Discontinuation; Medicine; Pembrolizumab; Population; Ipilimumab; Internal medicine; Family medicine; Cancer; Immunotherapy","score_opus":0.12402998275954939,"score_gpt":0.4848306160490523,"score_spread":0.3608006332895029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757427979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449474,0.00016862413,0.000007690314,0.0025431288,0.00066014106,0.0012293897,0.000011057356,0.000006242665,0.00087900145],"genre_scores_gemma":[0.9981817,0.0002678587,0.00009145384,0.0010397831,0.0001924892,0.000026476799,0.0000073314195,0.000023050481,0.00016984095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567443,0.0007871787,0.0023474344,0.0003093457,0.0005225948,0.00035904415],"domain_scores_gemma":[0.99509317,0.0014114561,0.0024070444,0.00067336904,0.0002471977,0.00016777987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018430148,0.00028690908,0.0021454683,0.00020515693,0.0001394492,0.000039760835,0.00054488593,0.00023881756,0.00008606073],"category_scores_gemma":[0.0007461807,0.00014663361,0.00043900148,0.0001262687,0.00037018288,0.00023369901,0.00005250654,0.0007968454,0.0000059418117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10298025,0.017503705,0.704962,0.000009398764,0.0006040829,0.0011441465,0.00081510504,0.0000021140847,0.000014409248,0.0000017695792,0.000060570776,0.17190245],"study_design_scores_gemma":[0.20845623,0.08026011,0.7094069,0.00011956239,0.0002736875,0.00006575194,0.00045991363,0.000012614781,0.000005310213,0.000009991198,0.000818171,0.00011173121],"about_ca_topic_score_codex":0.0002291124,"about_ca_topic_score_gemma":0.0021187812,"teacher_disagreement_score":0.17179072,"about_ca_system_score_codex":0.00052643515,"about_ca_system_score_gemma":0.00077600044,"threshold_uncertainty_score":0.5979545},"labels":[],"label_agreement":null},{"id":"W2757829418","doi":"10.1200/jco.2009.27.15_suppl.557","title":"Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Anastrozole; Breast cancer; Tamoxifen; Cost effectiveness; Gynecology; Goserelin; Internal medicine; Randomized controlled trial; Quality-adjusted life year; Oncology; Cancer","score_opus":0.10414754638523868,"score_gpt":0.49166512905062587,"score_spread":0.38751758266538716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757829418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872015,0.0016976709,0.000008414926,0.008575525,0.000458683,0.00068431615,0.000048681137,0.000006002079,0.0013191954],"genre_scores_gemma":[0.99520975,0.0019151383,0.00013325553,0.0020495162,0.00056863786,0.00004839536,0.0000033246802,0.000017476485,0.00005448693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726975,0.0007521312,0.0010450226,0.0002494791,0.0002555098,0.00042812934],"domain_scores_gemma":[0.9970815,0.00092611293,0.0007689154,0.00014431658,0.0005223654,0.00055679574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00132018,0.00019839477,0.0016746831,0.00024935644,0.000024590667,0.000006207995,0.00016032186,0.00020345172,0.0006049038],"category_scores_gemma":[0.00012870452,0.00013651494,0.0001388861,0.00024067552,0.00018346791,0.00013478473,0.000013660061,0.00096621667,0.000003330068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2709337,0.0081098005,0.5631207,0.0000346329,0.003762292,0.005023785,0.0058572623,0.0002692936,0.011887003,0.00030340248,0.00051683147,0.13018125],"study_design_scores_gemma":[0.039517432,0.03932878,0.9167021,0.00018095692,0.00023817945,0.00030127924,0.0003532306,0.000012233498,0.00054688106,0.0005312077,0.0021721849,0.00011552108],"about_ca_topic_score_codex":0.07535961,"about_ca_topic_score_gemma":0.0936233,"teacher_disagreement_score":0.35358137,"about_ca_system_score_codex":0.0037327765,"about_ca_system_score_gemma":0.009876975,"threshold_uncertainty_score":0.9957361},"labels":[],"label_agreement":null},{"id":"W2757886480","doi":"10.1200/jco.2013.31.15_suppl.e11574","title":"Breast cancer biomarker discordance between primary and sites of metastasis: A systematic review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Biomarker; Breast cancer; Oncology; Cancer; Internal medicine; Metastasis; Primary tumor; Brain metastasis; Lymph node; Lung cancer; Disease","score_opus":0.1098867776772774,"score_gpt":0.4728457450860793,"score_spread":0.3629589674088019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757886480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7824226,0.18564305,0.0006302619,0.02885798,0.0004527456,0.0015112688,0.00005470485,0.000014869104,0.00041251906],"genre_scores_gemma":[0.9646113,0.023890086,0.0062925816,0.004374223,0.0005973767,0.000050328374,0.0000026221394,0.00002505389,0.00015644768],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957035,0.00048299722,0.0030697153,0.00016651115,0.0003879019,0.00018933872],"domain_scores_gemma":[0.99359477,0.0018052896,0.003309895,0.00024181862,0.0007495715,0.00029866895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024395941,0.00015999384,0.0035007652,0.00009096864,0.00001949837,0.0000051320067,0.0001598321,0.00014853026,0.0001856456],"category_scores_gemma":[0.0011760846,0.000094596595,0.0003899286,0.00016828194,0.00035037688,0.00025034434,0.000060569,0.00049128453,0.0000075559838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002509795,0.0012840912,0.32168767,0.21162856,0.0064664544,0.00016212121,0.0001440926,0.0000012894427,0.0039007168,0.00007341352,0.0033073262,0.44883448],"study_design_scores_gemma":[0.004496435,0.0020567249,0.9231367,0.06209475,0.00454832,0.0018427502,0.000108910615,0.000008683342,0.00007206689,0.00040809903,0.0010728536,0.00015372215],"about_ca_topic_score_codex":0.000030883246,"about_ca_topic_score_gemma":0.000005823226,"teacher_disagreement_score":0.601449,"about_ca_system_score_codex":0.00011351896,"about_ca_system_score_gemma":0.0006498823,"threshold_uncertainty_score":0.38575372},"labels":[],"label_agreement":null},{"id":"W2757903624","doi":"10.1200/jco.2017.73.4491","title":"Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"American Society of Clinical Oncology","keywords":"Medicine; Breast cancer; Insulin glargine; Hazard ratio; Internal medicine; Type 2 diabetes; Insulin; Population; Cohort; Diabetes mellitus; Cancer; Proportional hazards model; Incidence (geometry); Cumulative incidence; Endocrinology; Confidence interval","score_opus":0.06653773560415881,"score_gpt":0.40823137083141375,"score_spread":0.34169363522725493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757903624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802501,0.019018931,0.000013276019,0.00015853619,0.0004494241,0.000061019473,0.000008693688,9.65065e-7,0.00003901435],"genre_scores_gemma":[0.94403166,0.054568347,0.00022264269,0.00056812464,0.0005691043,0.0000037880104,0.0000011080606,0.000011581458,0.000023668945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832976,0.00019073747,0.00089816307,0.00019702053,0.00014275656,0.00024153799],"domain_scores_gemma":[0.9973128,0.00019918202,0.0016906721,0.00026175045,0.0003535144,0.00018210252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001326369,0.00011770696,0.0007559892,0.000051482617,0.000046349604,0.000027489516,0.0002724226,0.0002666566,0.000041385567],"category_scores_gemma":[0.0013480801,0.000085533466,0.00007315408,0.00004872106,0.00036867562,0.000035680398,0.00012636885,0.00034667042,5.289729e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011777093,0.00012214354,0.62994874,0.000021007276,0.00011017132,0.000029164328,0.000029909337,0.000014780538,0.0013609044,0.0000010704925,0.000057852732,0.36712655],"study_design_scores_gemma":[0.0020099808,0.0019883937,0.9902211,0.00012835348,0.000052854513,0.000023883153,0.000020075779,0.000009278137,0.0012829676,0.000019074085,0.0041389265,0.00010511229],"about_ca_topic_score_codex":0.000054613603,"about_ca_topic_score_gemma":0.0006683415,"teacher_disagreement_score":0.36702147,"about_ca_system_score_codex":0.000033749187,"about_ca_system_score_gemma":0.0007053645,"threshold_uncertainty_score":0.34879532},"labels":[],"label_agreement":null},{"id":"W2758550989","doi":"10.1200/jco.2017.35.15_suppl.8028","title":"Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Clinical endpoint; Discontinuation; Multiple myeloma; Dexamethasone; Gastroenterology; Oncology; Randomized controlled trial","score_opus":0.2201404032116821,"score_gpt":0.5047877075079944,"score_spread":0.2846473042963123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758550989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928982,0.00048787054,0.000048177593,0.0014254958,0.0014849963,0.0010634906,0.000019860285,0.000015212412,0.0025566488],"genre_scores_gemma":[0.9938047,0.0007304028,0.0030352375,0.0002110744,0.0007802265,0.000029028775,0.000005864611,0.000053107473,0.0013503663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99243647,0.0014224765,0.003755022,0.00050737493,0.0011894963,0.00068918767],"domain_scores_gemma":[0.988933,0.004501127,0.0037499468,0.0010838073,0.00076903345,0.0009630754],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006981675,0.0003481062,0.003244776,0.00046632864,0.00016156779,0.0000358597,0.0007536091,0.00061446364,0.00040920055],"category_scores_gemma":[0.028418195,0.00025958565,0.00094620156,0.00016590982,0.00054013124,0.0002759494,0.00027337688,0.0021102426,0.000077369456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14746244,0.03159454,0.41277134,0.00010572022,0.0022764564,0.018496878,0.0006624419,0.0000051931193,0.0009999304,0.000044037228,0.0019187578,0.38366225],"study_design_scores_gemma":[0.2536529,0.055499814,0.68141526,0.0002806526,0.0004814602,0.00027868757,0.0007520407,0.0003381272,0.0003258484,0.0001311786,0.006650845,0.00019315872],"about_ca_topic_score_codex":0.0006143568,"about_ca_topic_score_gemma":0.0012130496,"teacher_disagreement_score":0.38346907,"about_ca_system_score_codex":0.00061970373,"about_ca_system_score_gemma":0.0033868935,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W2758553293","doi":"10.1200/jco.2017.35.15_suppl.tps2619","title":"Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Internal medicine; Discontinuation; Oncology; Immune checkpoint; Cancer; Colorectal cancer; Adverse effect; Cancer research; Pharmacokinetics; Immunotherapy","score_opus":0.05245963507880342,"score_gpt":0.4571021757064691,"score_spread":0.4046425406276657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758553293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987216,0.000060939492,0.000025334335,0.00011366095,0.0006481528,0.00020082899,0.000012046827,8.7289476e-7,0.00021656736],"genre_scores_gemma":[0.9984568,0.00010191811,0.00074439816,0.00020062242,0.00045643636,0.0000030162205,0.000007894826,0.000014914302,0.000014035443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783844,0.00016904008,0.0014203911,0.00021025141,0.0001868217,0.00017505343],"domain_scores_gemma":[0.9967436,0.000114624774,0.0021162056,0.0004218037,0.000413552,0.00019017857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010553371,0.00012054991,0.0008272536,0.000052021835,0.00005344042,0.00001580205,0.00039452466,0.00019023383,0.000008025146],"category_scores_gemma":[0.0017735473,0.0000924825,0.00011703629,0.0000286801,0.00017018418,0.000016793645,0.00013609478,0.0003139975,7.128356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01646277,0.030486977,0.7808308,0.000009639567,0.00018934939,0.00013704342,0.00013223775,0.00033363161,0.0023824458,0.000012902343,0.00050432223,0.16851789],"study_design_scores_gemma":[0.053379424,0.18562189,0.75211054,0.0000376421,0.0000891229,0.000007796875,0.0002316256,0.00002652243,0.0018670141,0.000074245625,0.00637508,0.00017910171],"about_ca_topic_score_codex":0.00004243764,"about_ca_topic_score_gemma":0.00077348755,"teacher_disagreement_score":0.16833879,"about_ca_system_score_codex":0.000030172065,"about_ca_system_score_gemma":0.0007141937,"threshold_uncertainty_score":0.37713268},"labels":[],"label_agreement":null},{"id":"W2758972505","doi":"10.1200/jco.2017.35.15_suppl.e13114","title":"Prognostic implication of GATA3 gene mutation on survival in invasive ductal carcinoma of the breast.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; GATA3; Breast cancer; Estrogen receptor; Oncology; Internal medicine; Ductal carcinoma; Carcinoma; Cancer; Male breast cancer; Pathology; Gene; Biology; Transcription factor; Genetics","score_opus":0.13515953814762774,"score_gpt":0.4667171003675455,"score_spread":0.3315575622199177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758972505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890293,0.0001042468,0.000003143268,0.009451279,0.00060084637,0.0002501154,0.000010827277,7.104974e-7,0.00054955087],"genre_scores_gemma":[0.9991362,0.00020653525,0.00015722096,0.00013054616,0.00034380096,0.00000639191,0.0000021610429,0.0000056745953,0.000011455191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817675,0.00017961423,0.0012188039,0.000102006234,0.00023736295,0.0000854661],"domain_scores_gemma":[0.99534935,0.0014994225,0.002451486,0.00027763608,0.00034215202,0.000079971105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010119831,0.00006595094,0.00070183555,0.00005454975,0.000027931575,0.000003367854,0.0001536201,0.00012435726,0.000018908155],"category_scores_gemma":[0.0033058717,0.000038783663,0.00026082864,0.000045109206,0.00019040816,0.000051913335,0.00003946129,0.00026862975,0.0000016388609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012879785,0.0017891813,0.9649752,0.000025428748,0.000107632855,0.00012400933,0.000072378345,0.000012437367,0.0005995695,0.00015414074,0.00009945199,0.030752601],"study_design_scores_gemma":[0.0050971173,0.0054571186,0.98478246,0.00017456288,0.00022886173,0.00034734933,0.000045018714,0.000011280001,0.0034647288,0.00029411327,0.000069857866,0.000027541122],"about_ca_topic_score_codex":0.00024310844,"about_ca_topic_score_gemma":0.00041829576,"teacher_disagreement_score":0.03072506,"about_ca_system_score_codex":0.00012561135,"about_ca_system_score_gemma":0.0010915078,"threshold_uncertainty_score":0.3957676},"labels":[],"label_agreement":null},{"id":"W2759185183","doi":"10.1200/jco.2013.31.15_suppl.e19147","title":"Phase I/II trial of combination nab-paclitaxel and pemetrexed in advanced solid tumor patients (pts) with emphasis on non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Neutropenia; Internal medicine; Oncology; Lung cancer; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Toxicity; Progressive disease; Clinical endpoint; Chemotherapy; Gastroenterology; Surgery; Clinical trial; Cisplatin","score_opus":0.03792672054753038,"score_gpt":0.4652624784664411,"score_spread":0.4273357579189107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759185183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520624,0.00023376042,0.000039721614,0.0016432443,0.0006266931,0.0010743798,0.00001059612,0.000003401536,0.001161937],"genre_scores_gemma":[0.99716294,0.00035811632,0.0014493337,0.0006211411,0.00017002462,0.000057938472,0.000006953153,0.00001563864,0.00015789144],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977835,0.00012789025,0.0014620487,0.00017846521,0.0002727976,0.00017529],"domain_scores_gemma":[0.9969727,0.0005748232,0.0015140823,0.00011917107,0.0005935338,0.00022573395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050596765,0.00013671324,0.0010347392,0.00019542094,0.00003758987,0.000005453663,0.00006892824,0.00013235258,0.00007317],"category_scores_gemma":[0.0005635746,0.0000888782,0.00014957257,0.00015462427,0.000099156714,0.00014555853,0.000021829293,0.00037131624,0.0000017487064],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14141214,0.08460484,0.17414019,0.00022143923,0.0008684133,0.00017924931,0.0015005438,0.00011666675,0.00058365957,0.000043083026,0.0012280607,0.5951017],"study_design_scores_gemma":[0.5898577,0.17372735,0.23322518,0.0005253804,0.0007797294,0.000009527041,0.00024184931,0.00019289817,0.00045998368,0.00009584661,0.0007710559,0.00011352848],"about_ca_topic_score_codex":0.00017199,"about_ca_topic_score_gemma":0.00009063615,"teacher_disagreement_score":0.59498817,"about_ca_system_score_codex":0.0003433108,"about_ca_system_score_gemma":0.0014306876,"threshold_uncertainty_score":0.36243477},"labels":[],"label_agreement":null},{"id":"W2759538879","doi":"10.1200/jco.2012.30.15_suppl.e18567","title":"Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; Arginine deiminase; CpG site; DNA methylation; Arginine; Argininosuccinate lyase; Medicine; Epigenetics; Multiple myeloma; Argininosuccinate synthase; Cancer research; Molecular biology; Oncology; Gene; Internal medicine; Biology; Genetics; Gene expression; Citrulline; Amino acid","score_opus":0.09565323574862189,"score_gpt":0.4378951256903318,"score_spread":0.3422418899417099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759538879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407107,0.001100184,0.00047130298,0.0029245133,0.00052698015,0.00017806489,0.000005307778,0.0000013047691,0.00072126003],"genre_scores_gemma":[0.99652153,0.00026598058,0.0013350077,0.0007702488,0.00096287526,0.000012442675,0.000005050041,0.0000103533,0.00011652216],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823284,0.00041213396,0.00077422743,0.00012049548,0.00017387621,0.0002864479],"domain_scores_gemma":[0.9986678,0.00040176994,0.00036731255,0.00017798561,0.00012026773,0.00026489035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019895069,0.00008887417,0.00033998236,0.000066292974,0.00003522164,0.0000065291943,0.00020216199,0.00017382175,0.00003884222],"category_scores_gemma":[0.0030696208,0.0000547825,0.00016279046,0.000115215116,0.00008641411,0.000007901718,0.00008414625,0.00029323055,0.000023955752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050812485,0.003507843,0.45534974,0.000012343902,0.0003574552,0.000111052635,0.00026302162,0.0002586942,0.096706554,0.00008796591,0.0041710865,0.434093],"study_design_scores_gemma":[0.0030578915,0.0056191683,0.43977454,0.000018804834,0.000016589242,0.00008828181,0.000103318496,0.000020292406,0.055699393,0.00015074445,0.49534377,0.000107191205],"about_ca_topic_score_codex":0.0000416978,"about_ca_topic_score_gemma":0.00023307216,"teacher_disagreement_score":0.4911727,"about_ca_system_score_codex":0.000067030785,"about_ca_system_score_gemma":0.000450183,"threshold_uncertainty_score":0.36748445},"labels":[],"label_agreement":null},{"id":"W2759568715","doi":"10.1200/jco.2017.35.15_suppl.e13113","title":"Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia; University of British Columbia; BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Germline; Genetic counseling; Context (archaeology); Cancer; Penetrance; Genetic testing; Li–Fraumeni syndrome; Oncology; Internal medicine; Germline mutation; Bioinformatics; Genetics; Mutation; Gene; Biology; Phenotype","score_opus":0.0683395937149716,"score_gpt":0.4428616389684622,"score_spread":0.3745220452534906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759568715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992499,0.001050353,0.00014263332,0.0022302244,0.0007330976,0.00015695713,0.000031217154,7.6698086e-7,0.0031557858],"genre_scores_gemma":[0.99335146,0.003073465,0.00223929,0.00058945554,0.00057913095,0.0000034655895,0.0000062075233,0.00001241862,0.00014510375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736345,0.00018826802,0.0018961744,0.00017754747,0.00015863484,0.00021592833],"domain_scores_gemma":[0.9960367,0.00039287066,0.0027174407,0.00048093288,0.0002713629,0.000100684825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037959805,0.00012186611,0.00085673446,0.000040352243,0.00006795025,0.000010116728,0.0007279575,0.00026204347,0.000016366881],"category_scores_gemma":[0.0010405591,0.00008664408,0.00034091377,0.000042273336,0.0004797654,0.000009827615,0.0003363511,0.00042079575,0.0000018020388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012929492,0.005510213,0.3763813,0.00055277575,0.003772522,0.0032205363,0.0013334344,0.006408451,0.36819246,0.00283215,0.010949903,0.20791677],"study_design_scores_gemma":[0.010754944,0.012039211,0.72181743,0.00021578927,0.00045280668,0.00025040994,0.0011469875,0.0001392595,0.010584011,0.0011177756,0.24117944,0.00030194136],"about_ca_topic_score_codex":0.000049067923,"about_ca_topic_score_gemma":0.00017551769,"teacher_disagreement_score":0.35760844,"about_ca_system_score_codex":0.000113351474,"about_ca_system_score_gemma":0.0013254569,"threshold_uncertainty_score":0.3533243},"labels":[],"label_agreement":null},{"id":"W2759808499","doi":"10.1200/jco.2017.35.15_suppl.9036","title":"ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; T790M; Internal medicine; Discontinuation; Lung cancer; Oncology; Interstitial lung disease; Interim analysis; Chemotherapy; Cancer; Surgery; Gastroenterology; Clinical trial; Lung; Erlotinib; Adenocarcinoma; Epidermal growth factor receptor; ROS1","score_opus":0.06083654637233833,"score_gpt":0.4858123714878276,"score_spread":0.42497582511548926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759808499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886728,0.00011568,0.000010405689,0.00092437,0.00047331006,0.000958344,0.000017723129,0.0000030837202,0.008824291],"genre_scores_gemma":[0.99771047,0.00029519785,0.0006916875,0.00017138029,0.00031989152,0.000039301318,0.0000043018404,0.000019175774,0.0007485977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747276,0.00019054777,0.001591902,0.00022749009,0.00029270662,0.00022459032],"domain_scores_gemma":[0.99578595,0.000486071,0.0026461463,0.00030938882,0.00050879177,0.00026366772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049379683,0.00017801824,0.0013904341,0.00016969105,0.00008400484,0.000012346788,0.00016562393,0.00013338515,0.00004870727],"category_scores_gemma":[0.00016794704,0.00010692335,0.00021723552,0.00009611209,0.00011505098,0.00011315063,0.000040395837,0.00040208924,0.0000022626623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071287546,0.021952305,0.92005605,0.00001768468,0.0012327683,0.00039402873,0.0015577468,0.000039635106,0.0000061980036,0.000002093596,0.00025034903,0.047362365],"study_design_scores_gemma":[0.05881358,0.053207017,0.884386,0.0003217332,0.0021709763,0.0000047366098,0.0004899306,0.00002773446,0.00007531951,0.000004030933,0.00041933378,0.00007963102],"about_ca_topic_score_codex":0.0037367104,"about_ca_topic_score_gemma":0.007455198,"teacher_disagreement_score":0.051684827,"about_ca_system_score_codex":0.0007459045,"about_ca_system_score_gemma":0.0023008278,"threshold_uncertainty_score":0.5648813},"labels":[],"label_agreement":null},{"id":"W2760735711","doi":"10.1200/jco.2017.35.15_suppl.4501","title":"Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Paclitaxel; Pembrolizumab; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Phases of clinical research; Cancer; Chemotherapy; Clinical trial; Confidence interval","score_opus":0.34443439443311963,"score_gpt":0.5819199167132969,"score_spread":0.23748552228017727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760735711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900367,0.0006884651,0.000034732675,0.0020936318,0.003833294,0.0009914548,0.0002893133,0.000009736587,0.002022634],"genre_scores_gemma":[0.9951516,0.0017318112,0.0010921404,0.00035872284,0.0011551557,0.000046898018,0.000019676861,0.000039721723,0.0004042761],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993623,0.0009178586,0.003668051,0.0005738486,0.0007636878,0.00045352633],"domain_scores_gemma":[0.99108875,0.002301209,0.004446156,0.0009561379,0.0006396196,0.0005681464],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002185091,0.0003788852,0.004318529,0.0003714057,0.00015637602,0.00005651677,0.0011182277,0.0004216602,0.00093431515],"category_scores_gemma":[0.004596986,0.0002611266,0.00049629336,0.0003959486,0.00029465696,0.0004571893,0.00032071862,0.0011978539,0.000009798926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6177699,0.047947653,0.15654655,0.000032225133,0.009929856,0.0018632612,0.00057771866,0.000059151458,0.00025551554,0.00001059269,0.00070989836,0.16429766],"study_design_scores_gemma":[0.52299225,0.14040512,0.31785125,0.0002506245,0.009088262,0.000017425547,0.0011084987,0.00025592576,0.00014046786,0.00008814413,0.007485949,0.00031608262],"about_ca_topic_score_codex":0.004901,"about_ca_topic_score_gemma":0.021465605,"teacher_disagreement_score":0.16398157,"about_ca_system_score_codex":0.0003732676,"about_ca_system_score_gemma":0.002896602,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W2760908566","doi":"10.1200/jco.2016.34.15_suppl.tps10587","title":"A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; SMARCB1; Synovial sarcoma; EZH2; Cancer research; SMARCA4; Epithelioid sarcoma; Internal medicine; Sarcoma; Chromatin remodeling; Oncology; Pathology; Chromatin; Biology","score_opus":0.06141633266939515,"score_gpt":0.4145799057125616,"score_spread":0.3531635730431664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760908566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835575,0.00012474142,0.000066382134,0.00042629786,0.0005925408,0.00027962594,0.000008019858,0.000002598189,0.00014404919],"genre_scores_gemma":[0.99758154,0.00036606376,0.00041980177,0.00023949203,0.001097201,0.0000074721524,5.2139995e-7,0.000019575074,0.00026831927],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9965601,0.0008495768,0.0017965345,0.00025483136,0.00032750174,0.0002114861],"domain_scores_gemma":[0.99614567,0.0011474654,0.0019334394,0.0002889025,0.0003482775,0.00013622364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017973428,0.00016063293,0.0007941894,0.000087312714,0.00003594175,0.000004909908,0.00033617628,0.00027717277,0.00003277092],"category_scores_gemma":[0.005478039,0.00006550257,0.00019088558,0.00023917045,0.00020393443,0.000011723212,0.00011081722,0.00046702684,0.0000013795755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27812126,0.057632625,0.287343,0.00018694214,0.0012527794,0.0017022424,0.0025246271,0.0002485467,0.073101275,0.000010795141,0.010654388,0.28722152],"study_design_scores_gemma":[0.23814851,0.575235,0.13795741,0.00078559504,0.00093679846,0.00056793407,0.0043254783,0.000085509666,0.026061406,0.00022422557,0.014761191,0.0009109542],"about_ca_topic_score_codex":0.000025850359,"about_ca_topic_score_gemma":0.0009034127,"teacher_disagreement_score":0.5176024,"about_ca_system_score_codex":0.00007638501,"about_ca_system_score_gemma":0.0028581584,"threshold_uncertainty_score":0.655812},"labels":[],"label_agreement":null},{"id":"W2760922042","doi":"10.1200/jco.2016.70.4767","title":"Prevalence and Predictors of Sperm Banking in Adolescents Newly Diagnosed With Cancer: Examination of Adolescent, Parent, and Provider Factors Influencing Fertility Preservation Outcomes","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute","keywords":"Medicine; Logistic regression; Fertility; Odds ratio; Observational study; Fertility preservation; Sperm bank; Demography; Gynecology; Population; Internal medicine","score_opus":0.1267298093695275,"score_gpt":0.43028059130529694,"score_spread":0.30355078193576945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760922042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820143,0.00071607984,0.000018894394,0.00036758592,0.0002697881,0.000385896,0.0000046324176,0.000002598841,0.000033081185],"genre_scores_gemma":[0.99895597,0.0007843105,0.00010403012,0.00005140114,0.000085442494,0.0000030768347,6.545275e-7,0.000005283614,0.0000098428945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758464,0.00039584388,0.001422722,0.00024724993,0.00022251613,0.00012705065],"domain_scores_gemma":[0.9962373,0.00047488426,0.002449899,0.0002689029,0.00045591153,0.000113117974],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025144543,0.00011594856,0.00097634067,0.000081700164,0.000044064316,0.000004351877,0.00013233535,0.00023665409,0.000005974292],"category_scores_gemma":[0.008850652,0.0000730663,0.000079187426,0.000041965628,0.0006348994,0.00037524034,0.00007457378,0.00047717273,3.138498e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056695635,0.0007365897,0.97278875,0.00065545563,0.00009565791,0.000011040567,0.0005696596,0.0000034993811,0.00032968633,0.0000014439241,0.0000031645516,0.01913548],"study_design_scores_gemma":[0.004516288,0.0022974596,0.9910958,0.0012479377,0.0001791689,0.0000050196363,0.00013535893,0.000031424683,0.00037948834,0.00004233385,0.000015588346,0.00005415727],"about_ca_topic_score_codex":0.00022778487,"about_ca_topic_score_gemma":0.00027859205,"teacher_disagreement_score":0.019081322,"about_ca_system_score_codex":0.00007703385,"about_ca_system_score_gemma":0.00039808222,"threshold_uncertainty_score":0.99949825},"labels":[],"label_agreement":null},{"id":"W2761077531","doi":"10.1200/jco.2017.35.15_suppl.e18339","title":"Cost effectiveness of treating endemic Burkitt lymphoma in Uganda.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cost effectiveness; Gross domestic product; Per capita; Economic evaluation; Cohort; Health care; Environmental health; Population; Internal medicine; Economic growth","score_opus":0.18464470412989129,"score_gpt":0.512403221797509,"score_spread":0.32775851766761765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761077531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990744,0.00040157765,0.000013771903,0.0010352521,0.0007128469,0.00022731116,0.0000025348154,0.0000028763393,0.0068598464],"genre_scores_gemma":[0.99798197,0.00074343773,0.0006519753,0.00017200767,0.00039234722,0.000008376859,0.000001160617,0.000009816218,0.000038930888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723125,0.00047967528,0.0017255606,0.00014984241,0.00023439131,0.00017927116],"domain_scores_gemma":[0.9920744,0.0049059587,0.0022658084,0.00029152713,0.00024733212,0.00021501094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041265297,0.000115663686,0.001737167,0.00010410059,0.0000514119,0.00000899309,0.00018567343,0.0003058349,0.000032431137],"category_scores_gemma":[0.00703274,0.00007621583,0.00043659026,0.000045416302,0.00018775766,0.00010349493,0.000059016784,0.00023972755,0.000007938358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032139812,0.0025762266,0.70808566,0.000044069417,0.00022035146,0.001119449,0.00004138474,0.0000037070706,0.00020985267,0.0001084674,0.000090009235,0.28428683],"study_design_scores_gemma":[0.030743048,0.0067021493,0.95534825,0.00064874685,0.0002794358,0.0003739705,0.000048772614,0.000030002644,0.001907897,0.00024514305,0.0036167912,0.00005579589],"about_ca_topic_score_codex":0.0001600202,"about_ca_topic_score_gemma":0.000054080032,"teacher_disagreement_score":0.28423104,"about_ca_system_score_codex":0.00037369214,"about_ca_system_score_gemma":0.0013146779,"threshold_uncertainty_score":0.84193546},"labels":[],"label_agreement":null},{"id":"W2761165227","doi":"10.1200/jco.2015.33.15_suppl.10572","title":"Local control following resection of primary retroperitoneal sarcoma with and without preoperative radiotherapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Sarcoma; Surgery; Biopsy; Cohort; External beam radiotherapy; Clinical endpoint; Radiology; Brachytherapy; Internal medicine; Randomized controlled trial; Pathology","score_opus":0.0908725354570402,"score_gpt":0.4253720199723277,"score_spread":0.3344994845152875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761165227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792154,0.005546161,0.0014615919,0.003205273,0.00045760314,0.0002561329,0.0000012438087,0.0000048968836,0.0011455476],"genre_scores_gemma":[0.99065953,0.0004909864,0.007322876,0.001037168,0.00040676846,0.000005115162,9.052689e-7,0.000014162113,0.00006250773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778235,0.0004554235,0.0011287808,0.00014225772,0.00035839557,0.00013279304],"domain_scores_gemma":[0.9978168,0.00060406444,0.00073379616,0.00011762571,0.00038934156,0.00033837705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019158748,0.00011209035,0.0014839143,0.00007599569,0.000023862647,0.0000046705363,0.000052798638,0.00019156482,0.000010280017],"category_scores_gemma":[0.0006163074,0.00006289453,0.00022249996,0.00007714779,0.0002632019,0.000106878775,0.000014025276,0.00043998772,7.83458e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022489643,0.001889094,0.9116362,0.000015753083,0.0012664961,0.00059118343,0.00021466737,0.000016780448,0.00019311333,0.000021942473,0.0009677859,0.060697377],"study_design_scores_gemma":[0.05332244,0.090320155,0.84498775,0.00023337481,0.0009107154,0.0015485678,0.0003764263,0.00029284772,0.00029455026,0.00004418055,0.007579111,0.000089910995],"about_ca_topic_score_codex":0.00004046182,"about_ca_topic_score_gemma":0.000036071728,"teacher_disagreement_score":0.08843106,"about_ca_system_score_codex":0.00023853387,"about_ca_system_score_gemma":0.0011871553,"threshold_uncertainty_score":0.25647643},"labels":[],"label_agreement":null},{"id":"W2761245920","doi":"10.1200/jco.2014.32.15_suppl.3028","title":"Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Bendamustine; Medicine; Tolerability; Internal medicine; Neutropenia; Rituximab; Adverse effect; Nausea; Chronic lymphocytic leukemia; Population; Gastroenterology; Surgery; Leukemia; Toxicity; Lymphoma","score_opus":0.21176519100844415,"score_gpt":0.5352959847158193,"score_spread":0.32353079370737514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761245920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955591,0.0003513217,0.000015473728,0.0018587107,0.00044028176,0.00075915037,0.0000045482857,0.0000064782757,0.0010049375],"genre_scores_gemma":[0.99517405,0.00084156776,0.0028875777,0.0003022264,0.00057364604,0.000009539043,0.0000034979073,0.000030759544,0.00017714463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949642,0.0008122648,0.0027053116,0.00041196684,0.0007336603,0.00037259865],"domain_scores_gemma":[0.9885049,0.008188866,0.0016359228,0.00037661943,0.00063077774,0.0006629451],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006543904,0.00022310913,0.0024257703,0.00027739565,0.000046907604,0.000015569241,0.0003435143,0.00038930678,0.00010965079],"category_scores_gemma":[0.016353276,0.0001362896,0.00005843156,0.00031463004,0.0005935621,0.00021343521,0.00033617398,0.0015575422,0.000002886024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5754999,0.07684459,0.008200884,0.00045732857,0.0007931767,0.005469083,0.0015027527,0.000007964728,0.00013550474,0.000054018623,0.0023051484,0.32872963],"study_design_scores_gemma":[0.7012341,0.2769666,0.009463022,0.0006020041,0.00043709207,0.0008616591,0.0013503084,0.0033749407,0.000017972847,0.000022183314,0.005538575,0.00013155978],"about_ca_topic_score_codex":0.000391348,"about_ca_topic_score_gemma":0.0018977972,"teacher_disagreement_score":0.32859808,"about_ca_system_score_codex":0.0011925462,"about_ca_system_score_gemma":0.00857303,"threshold_uncertainty_score":0.9970474},"labels":[],"label_agreement":null},{"id":"W2761396813","doi":"10.1200/jco.2017.35.15_suppl.tps4136","title":"Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Placebo; Ramucirumab; Hazard ratio; Bevacizumab; Population; Oncology; Adverse effect; Refractory (planetary science); Surrogate endpoint; Phases of clinical research; Cancer; Clinical trial; Chemotherapy; Colorectal cancer; Confidence interval; Pathology","score_opus":0.18917005781295534,"score_gpt":0.5260266435446584,"score_spread":0.3368565857317031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761396813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885266,0.00007268163,0.00009826932,0.0038796829,0.0020773788,0.0048100865,0.000011842099,0.000013062665,0.0005104411],"genre_scores_gemma":[0.99611944,0.00012379242,0.0005774882,0.00021464743,0.0013450321,0.000130951,0.000007921425,0.0000335375,0.0014471635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98977643,0.0022262824,0.0061757406,0.00046223198,0.0009464836,0.00041279924],"domain_scores_gemma":[0.98546195,0.0031669321,0.009536291,0.0007022051,0.0007487774,0.00038386195],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018715203,0.00037782206,0.0047874977,0.0003647641,0.00020431455,0.00008230128,0.0011608348,0.00016858846,0.0006387728],"category_scores_gemma":[0.01298615,0.00021819817,0.00076275435,0.00017306453,0.00030980917,0.0005475771,0.00021605953,0.0017809789,0.0000021195558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73878366,0.021684607,0.2113493,0.00001141228,0.0015510006,0.00077542185,0.00066432613,0.000044730863,0.00054246053,0.000007137181,0.00077205116,0.023813918],"study_design_scores_gemma":[0.8145141,0.054452766,0.12218234,0.00012379841,0.0016441661,0.000077988225,0.005589887,0.00012792196,0.000022957725,0.000012153293,0.0011298489,0.00012206267],"about_ca_topic_score_codex":0.0004317224,"about_ca_topic_score_gemma":0.0018064504,"teacher_disagreement_score":0.089166954,"about_ca_system_score_codex":0.00035279905,"about_ca_system_score_gemma":0.001029875,"threshold_uncertainty_score":0.9953279},"labels":[],"label_agreement":null},{"id":"W2761608404","doi":"10.1200/jco.2017.35.15_suppl.e15653","title":"Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of British Columbia; University of Calgary; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Akaike information criterion; Internal medicine; Liver cancer; Stage (stratigraphy); Oncology; Survival analysis; Cancer; Log-rank test; Statistics","score_opus":0.32001360327380074,"score_gpt":0.42168987468182556,"score_spread":0.10167627140802482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761608404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361223,0.00021668887,0.00014160779,0.0038813613,0.00023197684,0.0012933736,0.00034751082,0.000004232786,0.00027101682],"genre_scores_gemma":[0.99645245,0.00003499666,0.00268971,0.00023759308,0.00022196663,0.000026954642,0.00024040142,0.000028643059,0.00006725632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964913,0.00036134952,0.00213496,0.000304389,0.00033682442,0.00037118062],"domain_scores_gemma":[0.9942992,0.001548337,0.0023797557,0.0005953504,0.0006748341,0.00050256506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016252932,0.00022195654,0.0017983319,0.00016451217,0.0001431648,0.00002391441,0.00040339757,0.00033285483,0.000012127041],"category_scores_gemma":[0.0021241421,0.00012727185,0.0003800752,0.00007661173,0.0002839408,0.00018456942,0.000054814107,0.0006366766,0.0000039392476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0108098425,0.0039990274,0.9780244,0.000026257761,0.00035869898,0.00044210255,0.00031906745,0.000006174684,0.000011927268,0.0000070510937,0.001003873,0.0049915705],"study_design_scores_gemma":[0.048339516,0.010080285,0.9020495,0.00026703518,0.00083535624,0.000009734066,0.000097219985,0.03495278,0.00021653247,0.000019453144,0.0030048918,0.00012774137],"about_ca_topic_score_codex":0.018454364,"about_ca_topic_score_gemma":0.04065084,"teacher_disagreement_score":0.07597495,"about_ca_system_score_codex":0.00019012051,"about_ca_system_score_gemma":0.0015377298,"threshold_uncertainty_score":0.9880818},"labels":[],"label_agreement":null},{"id":"W2761728807","doi":"10.1200/jco.2017.35.15_suppl.4580","title":"Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Ottawa Regional Cancer Foundation; University of Alberta; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Internal medicine; Oncology; Population; Proportional hazards model; Surgery; Confidence interval","score_opus":0.15717320344868443,"score_gpt":0.40647978945797664,"score_spread":0.2493065860092922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761728807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335236,0.00059857604,0.00006818765,0.007553615,0.002774075,0.0007177814,0.00026267543,0.000010477761,0.004662237],"genre_scores_gemma":[0.99039924,0.0001611837,0.0062583,0.001095884,0.0014903005,0.00001949529,0.00020440914,0.000055822515,0.00031537967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98971194,0.0013419533,0.0060364576,0.0007611785,0.0015042461,0.00064422656],"domain_scores_gemma":[0.9840881,0.005912736,0.0071142092,0.0012469534,0.0008962648,0.00074170466],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0070326994,0.00051341025,0.0022818043,0.0003304356,0.00028303737,0.0001260603,0.00128055,0.0002872281,0.00016856968],"category_scores_gemma":[0.009403917,0.00033150963,0.0009954809,0.00015973375,0.00061124674,0.0005538113,0.0006563215,0.0023368606,0.000059033082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02445187,0.008568041,0.90307003,0.00010887867,0.00086444017,0.013776033,0.0015026672,0.000071419745,0.007965217,0.000026439848,0.018775947,0.020819023],"study_design_scores_gemma":[0.04813228,0.011729271,0.91069055,0.00030128265,0.0016657732,0.0002241559,0.00064437685,0.00037847002,0.017101415,0.0002680736,0.008499221,0.00036515974],"about_ca_topic_score_codex":0.0020799004,"about_ca_topic_score_gemma":0.0009577315,"teacher_disagreement_score":0.023680411,"about_ca_system_score_codex":0.0008563897,"about_ca_system_score_gemma":0.0023392464,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W2761911056","doi":"10.1200/jco.2017.35.15_suppl.e15753","title":"A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Chills; Pembrolizumab; Internal medicine; Gastroenterology; Chemotherapy; Oncology; Cancer; Immunotherapy","score_opus":0.05148698062257427,"score_gpt":0.40939242927656233,"score_spread":0.35790544865398805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761911056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990771,0.0001228019,0.0000034391921,0.00036486867,0.000039341965,0.0003074816,0.0000023755144,2.285517e-7,0.00008239725],"genre_scores_gemma":[0.99964887,0.0001129425,0.00014432686,0.00003863262,0.000017926768,0.0000056017607,0.0000012870198,0.0000068228383,0.000023609038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853337,0.00034886718,0.00066477724,0.00012803271,0.00022136031,0.00010361343],"domain_scores_gemma":[0.9981857,0.00010175179,0.0012102703,0.0002531423,0.00019241664,0.000056753768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007568642,0.000074884156,0.0005155587,0.00005274666,0.000026819318,0.0000057821776,0.00020394116,0.000072606636,0.0000024006836],"category_scores_gemma":[0.00042862352,0.000040885578,0.00005692478,0.000049037415,0.00021743527,0.000010242695,0.00005713516,0.00020653034,7.9611624e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014130456,0.004091862,0.97278327,0.00001202202,0.00023650983,0.000032623506,0.00013008657,0.0000069229354,0.00011368317,0.000005403939,0.00002577943,0.0084313955],"study_design_scores_gemma":[0.043566715,0.03558455,0.9199521,0.000050865096,0.00005740353,0.00001115959,0.00013462055,0.000005332903,0.00046413916,0.000060450853,0.00007577126,0.000036897596],"about_ca_topic_score_codex":0.00036739866,"about_ca_topic_score_gemma":0.0033049984,"teacher_disagreement_score":0.05283116,"about_ca_system_score_codex":0.000031724394,"about_ca_system_score_gemma":0.00039974976,"threshold_uncertainty_score":0.18442668},"labels":[],"label_agreement":null},{"id":"W2762226752","doi":"10.1200/jco.2017.75.4648","title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"American Society of Clinical Oncology; Gilead Sciences; Bayer","keywords":"Medicine; Internal medicine; Adverse effect; Lymphoma; Phases of clinical research; Gastroenterology; Refractory (planetary science); Oncology; Phosphatidylinositol; Progression-free survival; Chemotherapy; Kinase","score_opus":0.11078530689965123,"score_gpt":0.4613984961863448,"score_spread":0.3506131892866936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762226752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428595,0.000992309,0.0000062299086,0.009746841,0.0014287408,0.0002660134,0.000008248604,0.000007884953,0.0032577957],"genre_scores_gemma":[0.99291766,0.0024033806,0.00083150883,0.0026790805,0.00073279446,0.000012587136,0.000006811006,0.000017276234,0.0003989016],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964038,0.0002993048,0.0023831658,0.00024015045,0.00041316226,0.00026039055],"domain_scores_gemma":[0.9944965,0.0014865104,0.0028877386,0.00041437583,0.0002724634,0.0004424114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019888943,0.00017708939,0.0014870008,0.00011279213,0.00010754097,0.000026611177,0.00017058098,0.00043104327,0.00017019863],"category_scores_gemma":[0.005177686,0.000112860245,0.0004029841,0.000058202808,0.00023431802,0.00019606616,0.00007511123,0.00045191217,0.00004614803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013761155,0.015215326,0.42282882,0.000033289456,0.0002575862,0.010739889,0.00011470327,0.000001429023,0.00026691888,0.00008778157,0.037494916,0.4991982],"study_design_scores_gemma":[0.048632376,0.016110433,0.81341475,0.000451272,0.00025829877,0.00042175324,0.00007447537,0.000023139968,0.0025359849,0.00007898467,0.11788367,0.00011484246],"about_ca_topic_score_codex":0.00013981768,"about_ca_topic_score_gemma":0.00012509037,"teacher_disagreement_score":0.49908334,"about_ca_system_score_codex":0.0006648129,"about_ca_system_score_gemma":0.0019475375,"threshold_uncertainty_score":0.61985475},"labels":[],"label_agreement":null},{"id":"W2762521795","doi":"10.1200/jco.2017.35.15_suppl.5507","title":"Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Placebo; Olaparib; Quality of life (healthcare); Ovarian cancer; Oncology; Adverse effect; Chemotherapy; Clinical endpoint; Cancer; Clinical trial; Confidence interval","score_opus":0.06214157983906568,"score_gpt":0.41788212337797864,"score_spread":0.35574054353891293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762521795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420846,0.00016756658,0.00040151292,0.0035576483,0.0005563012,0.00095972646,0.00006135089,0.000006031287,0.00008138523],"genre_scores_gemma":[0.99529445,0.000111081776,0.0030565918,0.0012947115,0.00009402381,0.000023028062,0.000040031737,0.000041621905,0.00004445986],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995063,0.00076835847,0.0029138257,0.000468169,0.0004032346,0.00038340146],"domain_scores_gemma":[0.99156773,0.0004219378,0.0065452643,0.00046765406,0.0007098136,0.00028760036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018695259,0.00030935078,0.0021642037,0.0000894888,0.00016553079,0.000027988204,0.0002907988,0.0003857152,0.000012150587],"category_scores_gemma":[0.0011708285,0.00020733304,0.00020796759,0.000109203924,0.0005509807,0.000038754926,0.000076967626,0.0006368465,2.8010732e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54440075,0.0032848776,0.42763883,0.000034766337,0.0025440324,0.00006813957,0.00087000965,0.0005822632,0.00044329787,0.000007619948,0.0005250207,0.019600375],"study_design_scores_gemma":[0.47403327,0.023549443,0.5003126,0.00027293124,0.00014171093,0.000017913253,0.00036148774,0.000119084354,0.00045401967,0.000018448582,0.00041037687,0.00030866437],"about_ca_topic_score_codex":0.00052685064,"about_ca_topic_score_gemma":0.0025200222,"teacher_disagreement_score":0.07267382,"about_ca_system_score_codex":0.00021935765,"about_ca_system_score_gemma":0.0026748455,"threshold_uncertainty_score":0.8454796},"labels":[],"label_agreement":null},{"id":"W2762638624","doi":"10.1200/jco.2017.35.15_suppl.9500","title":"A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Discontinuation; Adverse effect; Melanoma; Adjuvant; Toxicity; Neutropenia; Oncology; Phases of clinical research; Clinical endpoint; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy; Cancer research","score_opus":0.0839105979199141,"score_gpt":0.43963433228209137,"score_spread":0.35572373436217725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762638624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622446,0.00016325316,0.000102968756,0.0012810525,0.00078742485,0.00087885006,0.00016096568,0.0000138437135,0.00038716893],"genre_scores_gemma":[0.9974208,0.00056246977,0.0005381448,0.00002830816,0.0007137315,0.0000615287,0.000020857537,0.000034014796,0.0006201534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99369884,0.0005258242,0.004602571,0.00046929976,0.00038726657,0.0003162003],"domain_scores_gemma":[0.97342044,0.016233206,0.0082488125,0.0012193843,0.0006058024,0.0002723834],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034660255,0.00033461422,0.0032204993,0.000062770516,0.00030897482,0.000030250241,0.0013803509,0.000553307,0.0004658235],"category_scores_gemma":[0.01913024,0.00020543685,0.0008633528,0.00009228323,0.0010923091,0.00014898206,0.00060142454,0.0012365981,0.0000016582206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9166134,0.014115215,0.00033305062,0.00011302839,0.0016888448,0.000032554704,0.00063646864,0.000014427968,0.0084323315,0.000037122794,0.000815009,0.057168562],"study_design_scores_gemma":[0.93167335,0.031962864,0.0074724513,0.00035304332,0.002948213,0.000050681163,0.0011361089,0.00047463205,0.020519665,0.0003687773,0.002762373,0.00027784103],"about_ca_topic_score_codex":0.0001808424,"about_ca_topic_score_gemma":0.00022516548,"teacher_disagreement_score":0.056890722,"about_ca_system_score_codex":0.00013403154,"about_ca_system_score_gemma":0.0005773973,"threshold_uncertainty_score":0.98913205},"labels":[],"label_agreement":null},{"id":"W2762653748","doi":"10.1200/jco.2017.35.15_suppl.9074","title":"Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i><sup>V600</sup> mutation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Vemurafenib; Internal medicine; Oncology; Cohort; Clinical endpoint; Rash; Lung cancer; Adverse effect; Expanded access; Progression-free survival; non-small cell lung cancer (NSCLC); Nausea; Cancer; Clinical trial; Metastatic melanoma; Overall survival","score_opus":0.029809604321270836,"score_gpt":0.3542964915474961,"score_spread":0.32448688722622526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762653748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571085,0.00018888393,0.00021075548,0.00027927972,0.0003035207,0.00025762746,0.000010577369,0.0000017124629,0.0030367994],"genre_scores_gemma":[0.9968931,0.00019220212,0.0018242038,0.0003171192,0.0005357334,0.0000083631385,0.000010763764,0.00002323162,0.0001952979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978385,0.00018462642,0.0012217975,0.00026817742,0.00023136342,0.00025554156],"domain_scores_gemma":[0.9965046,0.00020945043,0.002222386,0.00040137552,0.00045525868,0.00020694801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082739897,0.0001776008,0.0007948073,0.00006489409,0.0000699447,0.000016818054,0.00047455574,0.00036352346,0.000021700658],"category_scores_gemma":[0.00047582228,0.00011980253,0.00019095758,0.000048078917,0.00023969717,0.00001645052,0.00009712587,0.00044337654,0.0000023904586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009581666,0.0024570753,0.9542441,0.00007146942,0.0003099805,0.00022636214,0.0002581198,0.0014699867,0.002577239,0.000012783085,0.0012782816,0.027512984],"study_design_scores_gemma":[0.03228326,0.019909447,0.92710197,0.00021527546,0.00023957703,0.00003723959,0.00007390939,0.00014414042,0.008163633,0.000011810849,0.011554855,0.00026490298],"about_ca_topic_score_codex":0.00006925771,"about_ca_topic_score_gemma":0.00022300587,"teacher_disagreement_score":0.02724808,"about_ca_system_score_codex":0.000035767705,"about_ca_system_score_gemma":0.0012917443,"threshold_uncertainty_score":0.48854053},"labels":[],"label_agreement":null},{"id":"W2763012859","doi":"10.1200/jco.2017.35.15_suppl.9093","title":"Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Nivolumab; Oncology; Rash; Adverse effect; Diarrhea; Cohort; Ipilimumab; Gastroenterology; Clinical trial; Immunotherapy; Cancer","score_opus":0.17941705955805842,"score_gpt":0.4993057137901145,"score_spread":0.3198886542320561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763012859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974512,0.002670497,0.0002073292,0.018617362,0.0024793874,0.0006238091,0.000033791766,0.000014919664,0.00084094517],"genre_scores_gemma":[0.9825799,0.009307582,0.002161885,0.0019814149,0.0013785971,0.00002619305,0.000012570956,0.000034510904,0.0025173393],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969707,0.000104611114,0.0020285612,0.0003168345,0.0002601404,0.00031916858],"domain_scores_gemma":[0.9943565,0.0020302364,0.002461538,0.0005138065,0.00026825472,0.0003696437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011247005,0.00026226896,0.00208224,0.000078693185,0.00024148921,0.00004260862,0.00027962052,0.00043242075,0.00029684012],"category_scores_gemma":[0.0020731941,0.0001711647,0.0008972788,0.000027476277,0.0003982162,0.00021893115,0.000067141016,0.00039422122,0.000012975243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089788914,0.0015004581,0.13956328,0.000047719033,0.002141368,0.0005027054,0.000169425,0.0000031694487,0.0005780221,0.000012045222,0.00044825955,0.76524466],"study_design_scores_gemma":[0.115234084,0.032538515,0.7862044,0.00031534274,0.0010886414,0.00024581543,0.000060752747,0.00008147019,0.00045857657,0.0003476758,0.06321537,0.00020935954],"about_ca_topic_score_codex":0.00017591058,"about_ca_topic_score_gemma":0.00079940323,"teacher_disagreement_score":0.7650353,"about_ca_system_score_codex":0.00044617927,"about_ca_system_score_gemma":0.0010851414,"threshold_uncertainty_score":0.69798946},"labels":[],"label_agreement":null},{"id":"W2763073378","doi":"10.1200/jco.2017.35.15_suppl.tps5091","title":"PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; PARP inhibitor; Prostate cancer; Internal medicine; Oncology; Cancer; Cancer research; Poly ADP ribose polymerase; Polymerase; Gene; Androgen receptor; Genetics; Biology","score_opus":0.1398554968757785,"score_gpt":0.5108660853555113,"score_spread":0.3710105884797328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763073378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223346,0.00020317803,0.000090718524,0.0036223163,0.0010506025,0.0025923934,0.000008300717,0.000011649477,0.00018735931],"genre_scores_gemma":[0.9930293,0.00026080437,0.0054835305,0.00052181026,0.00031970127,0.00022375278,0.000010323594,0.000018188259,0.00013257847],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483216,0.0011609923,0.0030146253,0.0002634071,0.0005186772,0.00021012365],"domain_scores_gemma":[0.9919728,0.0015819808,0.0050299456,0.00024660715,0.0009793901,0.00018927148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008765894,0.00016860593,0.0019787184,0.00016039769,0.00017522747,0.000051481653,0.00010125878,0.00016520951,0.000059516155],"category_scores_gemma":[0.006981861,0.0001133268,0.00025368328,0.0000740782,0.0004459368,0.00037121627,0.000022356091,0.0006268911,9.459628e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93224436,0.0024438202,0.005261798,0.00003800698,0.00054177287,0.00016036264,0.0005036528,0.0000143138095,0.00013455389,0.00003833453,0.00017094385,0.05844811],"study_design_scores_gemma":[0.92994857,0.038308296,0.028550997,0.00030925492,0.00069160183,0.000058468322,0.00005836229,0.00092549477,0.000033655328,0.0007542301,0.00024335452,0.000117728516],"about_ca_topic_score_codex":0.00013490235,"about_ca_topic_score_gemma":0.0003714495,"teacher_disagreement_score":0.05833038,"about_ca_system_score_codex":0.0003414594,"about_ca_system_score_gemma":0.0025121728,"threshold_uncertainty_score":0.8358444},"labels":[],"label_agreement":null},{"id":"W2763263669","doi":"10.1200/jco.2012.30.15_suppl.tps4683","title":"Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Renal cell carcinoma; Discontinuation; Vascular endothelial growth factor; Temsirolimus; Internal medicine; Oncology; Progressive disease; Tyrosine-kinase inhibitor; Platelet-derived growth factor receptor; PI3K/AKT/mTOR pathway; Cancer research; Clinical trial; Cancer; Hepatocellular carcinoma; Chemotherapy; Growth factor; Discovery and development of mTOR inhibitors; Receptor; Signal transduction; VEGF receptors","score_opus":0.06125033449545109,"score_gpt":0.3716325511553506,"score_spread":0.3103822166598995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763263669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964755,0.0016702696,0.000016448275,0.00025012708,0.0006830007,0.00075198896,0.000021457088,0.000003310197,0.0001278823],"genre_scores_gemma":[0.995264,0.000058323327,0.0039736917,0.00008202669,0.00055088085,0.000012217972,0.000011811897,0.000029654735,0.000017408342],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99514323,0.0006911883,0.0029477365,0.00022169929,0.00062430394,0.00037181514],"domain_scores_gemma":[0.99459237,0.0015328549,0.0027144372,0.00026123258,0.00045216212,0.00044692244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019733373,0.0002625006,0.0025068047,0.0003135147,0.000017611894,0.00000443979,0.00011703,0.00028134152,0.00011974996],"category_scores_gemma":[0.0005151888,0.00016602108,0.00058474875,0.00022431512,0.0003308807,0.00018701317,0.00005213542,0.00059021846,0.0000022663346],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55457914,0.01860287,0.41700056,0.00011924006,0.0010090645,0.00033247063,0.0005992915,0.000001473657,0.0017741615,0.000011304953,0.00018461698,0.0057857865],"study_design_scores_gemma":[0.49699923,0.08994025,0.40559044,0.00009248669,0.0016696987,0.00003496673,0.00021997101,0.0000036786944,0.004801959,0.000016892092,0.00049498345,0.00013543914],"about_ca_topic_score_codex":0.000024916266,"about_ca_topic_score_gemma":0.000021389076,"teacher_disagreement_score":0.07133738,"about_ca_system_score_codex":0.00014763125,"about_ca_system_score_gemma":0.00078590855,"threshold_uncertainty_score":0.67701435},"labels":[],"label_agreement":null},{"id":"W2763669093","doi":"10.1200/jco.2017.35.15_suppl.5560","title":"The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Regimen; Oncology; Randomization; Placebo; Ovarian cancer; Population; Cohort; Progression-free survival; Chemotherapy regimen; Surgery; Cancer; Randomized controlled trial; Pathology","score_opus":0.15170531100399004,"score_gpt":0.5279345403881305,"score_spread":0.37622922938414044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763669093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824248,0.00012282268,0.0001079464,0.007828264,0.004056696,0.00060014287,0.00005365957,0.000008563819,0.0047971075],"genre_scores_gemma":[0.99440986,0.0004371733,0.0009618311,0.00065214775,0.0032803465,0.000017099745,0.0000052393375,0.0000322383,0.00020409015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945216,0.00057628856,0.0033393996,0.00025680749,0.0009503918,0.00035551027],"domain_scores_gemma":[0.9880885,0.0023128325,0.0071143843,0.00066836266,0.0014555568,0.00036036954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003983619,0.00021707239,0.0017576107,0.000073370116,0.00034222688,0.000046133282,0.0005741087,0.0004270621,0.00082476105],"category_scores_gemma":[0.003417567,0.00012242295,0.0004142447,0.00012082606,0.0010289847,0.00023630154,0.000083755316,0.001263599,0.000007752754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7771234,0.0049655885,0.15128459,0.00002703518,0.001245786,0.00022591182,0.00021772766,0.0000027626404,0.00036559405,0.0004534505,0.00686359,0.057224605],"study_design_scores_gemma":[0.55657053,0.035019584,0.25086007,0.0003829785,0.0007503233,0.000051983003,0.00008536517,0.00002295195,0.0007774565,0.0007800202,0.15446612,0.00023266331],"about_ca_topic_score_codex":0.0002032839,"about_ca_topic_score_gemma":0.0007999888,"teacher_disagreement_score":0.22055286,"about_ca_system_score_codex":0.0002500004,"about_ca_system_score_gemma":0.0033783284,"threshold_uncertainty_score":0.90305555},"labels":[],"label_agreement":null},{"id":"W2763906206","doi":"10.1200/jco.2014.32.15_suppl.e16106","title":"Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Incidence (geometry); Cancer; Metastasis; Bone pain; Bone metastasis; Internal medicine","score_opus":0.26775158238252716,"score_gpt":0.5688397907845494,"score_spread":0.3010882084020222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763906206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400413,0.0006910075,0.000052916635,0.0036394391,0.00039344432,0.00057209056,0.000040334387,0.0000037724565,0.00060285046],"genre_scores_gemma":[0.99534625,0.0012523021,0.0024781493,0.0002586972,0.00026418697,0.000064258755,0.000006285753,0.000013984411,0.00031587912],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963139,0.0011035994,0.0018974026,0.00013030635,0.0002619692,0.0002927923],"domain_scores_gemma":[0.99454015,0.0034402485,0.0011357617,0.00019185948,0.00043129802,0.00026068892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003928165,0.00013475007,0.001365581,0.00013978823,0.00006200351,0.000006541798,0.00014212378,0.00012356773,0.000047938513],"category_scores_gemma":[0.0019377079,0.000083138526,0.0003121536,0.00014172743,0.0003722494,0.00008273265,0.000030890285,0.0006137195,0.0000010806906],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108963735,0.015051725,0.13170822,0.00066591403,0.0014989978,0.0010116717,0.011628677,0.00014564607,0.006802862,0.00018744831,0.0010488328,0.7212863],"study_design_scores_gemma":[0.18439308,0.24479908,0.45048568,0.0017706623,0.0016880325,0.00036295573,0.008850306,0.0016789837,0.026516361,0.003541284,0.07542633,0.00048723933],"about_ca_topic_score_codex":0.0005190699,"about_ca_topic_score_gemma":0.00082825817,"teacher_disagreement_score":0.720799,"about_ca_system_score_codex":0.00038219258,"about_ca_system_score_gemma":0.0022614903,"threshold_uncertainty_score":0.4011787},"labels":[],"label_agreement":null},{"id":"W2763930264","doi":"10.1200/jco.2017.35.15_suppl.tps4131","title":"CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Cancer; Nivolumab; Placebo; Gastroesophageal Junction; Oncology; Adjuvant; Randomization; Chemotherapy; Esophageal cancer; Gastroenterology; Surgery; Clinical trial; Adenocarcinoma; Immunotherapy; Pathology","score_opus":0.21583951908380988,"score_gpt":0.538471722240513,"score_spread":0.3226322031567031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763930264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923481,0.0011474937,0.000054004224,0.0016986438,0.0008971942,0.0032349038,0.000012359425,0.000015986763,0.00059132965],"genre_scores_gemma":[0.9946582,0.0011263465,0.0007217879,0.00014105499,0.0011248133,0.00022277242,0.0000052773294,0.000045395253,0.001954371],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99257845,0.0013501296,0.0036730133,0.0004982202,0.0012530447,0.00064714835],"domain_scores_gemma":[0.9908513,0.0022703626,0.0042928103,0.00069507095,0.0010622655,0.0008281864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069493554,0.0003733126,0.0044995886,0.0004423898,0.00019550663,0.000048505695,0.0005235745,0.0003722242,0.0007139832],"category_scores_gemma":[0.0044407556,0.0001956003,0.00050811784,0.0002940147,0.0007412529,0.0003785193,0.00015174325,0.001845006,0.00001042407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86600536,0.0153971845,0.06201162,0.00011605242,0.0018071751,0.02427102,0.00045917134,0.000051360388,0.00001875741,0.000006681907,0.00048148766,0.029374158],"study_design_scores_gemma":[0.80452657,0.11705309,0.07501925,0.00041505814,0.0011596555,0.0006594297,0.00044120464,0.00023995603,0.00022800059,0.000019366036,0.00011996856,0.00011843082],"about_ca_topic_score_codex":0.0022624154,"about_ca_topic_score_gemma":0.0118642645,"teacher_disagreement_score":0.10165591,"about_ca_system_score_codex":0.000721477,"about_ca_system_score_gemma":0.0067082355,"threshold_uncertainty_score":0.9989228},"labels":[],"label_agreement":null},{"id":"W2763936022","doi":"10.1200/jco.2017.35.15_suppl.5522","title":"Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Baker Hughes (Canada); University of Toronto; University Health Network","funders":"","keywords":"Medicine; PTEN; Internal medicine; Nausea; Gastroenterology; Cancer; Progression-free survival; Phases of clinical research; ARID1A; Oncology; Chemotherapy; Surgery; Mutation; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.16176038930110476,"score_gpt":0.5318248873649225,"score_spread":0.37006449806381775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763936022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986177,0.00033602325,0.0000061154515,0.009631885,0.0019042095,0.0012085848,0.0000178754,0.0000026677162,0.000715608],"genre_scores_gemma":[0.9971412,0.0011313751,0.0003945649,0.00065020745,0.00056145847,0.000023856914,6.6317193e-7,0.000019260318,0.00007745825],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99393433,0.0010118854,0.0039724354,0.0003400865,0.0004944603,0.0002468068],"domain_scores_gemma":[0.9929519,0.0010044797,0.004666039,0.0006726994,0.00036297823,0.00034187018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004864467,0.00020043709,0.002539257,0.000097493896,0.00014014581,0.000012172729,0.0004276846,0.00039299435,0.00015193335],"category_scores_gemma":[0.0027388243,0.00012269431,0.00057772634,0.00009826564,0.00076663896,0.000101982405,0.00033602273,0.00105468,6.02649e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21961515,0.19819574,0.4000697,0.00006634926,0.0015304238,0.0014414546,0.00067018025,0.000008836396,0.00018723254,0.00015775472,0.0010511536,0.17700602],"study_design_scores_gemma":[0.56471306,0.21616836,0.20494474,0.00021886302,0.0016078367,0.000032094722,0.00022715634,0.00005116506,0.00041773554,0.00012998702,0.011380025,0.00010897505],"about_ca_topic_score_codex":0.00044981673,"about_ca_topic_score_gemma":0.0005058796,"teacher_disagreement_score":0.3450979,"about_ca_system_score_codex":0.000090445355,"about_ca_system_score_gemma":0.0021169123,"threshold_uncertainty_score":0.5003329},"labels":[],"label_agreement":null},{"id":"W2763963750","doi":"10.1200/jco.2017.35.15_suppl.tps4596","title":"A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Perioperative; Stage (stratigraphy); Internal medicine; Kidney cancer; Clinical trial; Adjuvant; Surgery; Oncology; Immunotherapy; Cancer; Kidney","score_opus":0.10104672841586478,"score_gpt":0.41046365010632746,"score_spread":0.3094169216904627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763963750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944025,0.00009382284,0.00020801868,0.000554024,0.00044889504,0.0020827116,0.0000010361481,0.000008700375,0.0022002854],"genre_scores_gemma":[0.9950972,0.00002951572,0.003870259,0.0003123776,0.00033734945,0.000036123467,0.00000779612,0.00003181866,0.00027753835],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99407613,0.0012717436,0.0032290192,0.00038506172,0.0006957302,0.00034229495],"domain_scores_gemma":[0.9930648,0.001695321,0.0035744263,0.0004995186,0.00078601204,0.00037987955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039322926,0.00030811428,0.0040687947,0.00019308187,0.00020945181,0.00007060626,0.00029391234,0.0002484157,0.0000774765],"category_scores_gemma":[0.002295528,0.00019219039,0.00050464773,0.00010595159,0.00038903777,0.00037583295,0.00011228456,0.0011081953,0.000009883264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36781868,0.010365101,0.61773413,0.000019551957,0.0003255905,0.00076278445,0.00060189806,0.00003990892,0.00003000662,0.0000069014272,0.00005078463,0.0022446492],"study_design_scores_gemma":[0.49092647,0.030357815,0.47669828,0.000106718195,0.0006321622,0.000021127797,0.00018949441,0.0006289029,0.00007811136,0.000008854898,0.00024640214,0.00010564918],"about_ca_topic_score_codex":0.00034112105,"about_ca_topic_score_gemma":0.0006383496,"teacher_disagreement_score":0.14103585,"about_ca_system_score_codex":0.000613723,"about_ca_system_score_gemma":0.0017214214,"threshold_uncertainty_score":0.7837297},"labels":[],"label_agreement":null},{"id":"W2764006529","doi":"10.1200/jco.2017.35.15_suppl.9013","title":"A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dosing; Medicine; Pembrolizumab; Lung cancer; Population; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.08819770977649027,"score_gpt":0.45779028894337037,"score_spread":0.3695925791668801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764006529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916941,0.0023010513,0.00011732926,0.0028669292,0.0011657648,0.000217914,0.00002681852,0.0000024113817,0.0016077135],"genre_scores_gemma":[0.99420685,0.0040011327,0.0008578814,0.00037874252,0.00041321313,0.000003457059,0.000004351513,0.000016095859,0.000118303054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962404,0.00022789832,0.0028179162,0.00023457666,0.0002248888,0.00025434734],"domain_scores_gemma":[0.9920294,0.001923898,0.0051597054,0.00031576105,0.00039888214,0.0001723032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002424061,0.00017755535,0.0025859824,0.00043468404,0.00008306572,0.00001524991,0.0003290731,0.00034932917,0.000312896],"category_scores_gemma":[0.0007906117,0.00014465266,0.0013757445,0.00022289484,0.00045818283,0.00013882075,0.00006560336,0.0006218281,6.0754724e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39147574,0.003055315,0.4831864,0.00035436367,0.015055837,0.00043235577,0.0020302336,0.00093501894,0.019936081,0.000013852607,0.0005096838,0.08301514],"study_design_scores_gemma":[0.081572734,0.007842435,0.8900156,0.00075356936,0.0072305403,0.000027989356,0.00027941263,0.0070217717,0.0036577098,0.00000952729,0.0014044163,0.0001843142],"about_ca_topic_score_codex":0.0014975544,"about_ca_topic_score_gemma":0.0019790288,"teacher_disagreement_score":0.40682918,"about_ca_system_score_codex":0.0005281781,"about_ca_system_score_gemma":0.001677102,"threshold_uncertainty_score":0.5898764},"labels":[],"label_agreement":null},{"id":"W2764059143","doi":"10.1200/jco.2017.35.15_suppl.6584","title":"CEASE: A novel patient directed electronic smoking cessation platform for cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Smoking cessation; Referral; Cancer; Ambulatory; Family medicine; Emergency medicine; Internal medicine","score_opus":0.24965299248839481,"score_gpt":0.5096405083532479,"score_spread":0.25998751586485314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764059143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237806,0.00038519505,0.00046948888,0.0033242262,0.001697753,0.00028028764,0.000012903393,0.000010907722,0.0014411607],"genre_scores_gemma":[0.9952408,0.00034040402,0.0013059506,0.001886902,0.0011396251,0.000014590402,0.0000062754857,0.000012695252,0.00005275996],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99758554,0.000037094596,0.0014896593,0.00016336073,0.00040694655,0.0003173745],"domain_scores_gemma":[0.9948522,0.00057481823,0.0030372688,0.00019698199,0.0010950303,0.00024372456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014627826,0.00011121562,0.0008490287,0.0000638354,0.00018121641,0.000025493235,0.00021028412,0.00027485067,0.000061323306],"category_scores_gemma":[0.0063764234,0.000081318045,0.00038256,0.000044538287,0.000100965066,0.00029833772,0.000046723027,0.00063445634,0.0000013232503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006172681,0.0009450373,0.34935006,0.00002938362,0.00038885736,0.000029795643,0.00010562369,0.000038867063,0.00010528036,0.0002993801,0.0045855083,0.6379495],"study_design_scores_gemma":[0.013181992,0.015405057,0.6961794,0.00029348762,0.0005287897,0.00004068917,0.000066290675,0.0006966554,0.00021530999,0.00057335064,0.27269128,0.00012773024],"about_ca_topic_score_codex":0.00015590255,"about_ca_topic_score_gemma":0.00031251038,"teacher_disagreement_score":0.6378218,"about_ca_system_score_codex":0.000490316,"about_ca_system_score_gemma":0.0018630985,"threshold_uncertainty_score":0.7633635},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2764070276","doi":"10.1200/jco.2017.35.15_suppl.e20502","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Internal medicine; Brain metastasis; Nausea; Lung cancer; Refractory (planetary science); ALK inhibitor; Adverse effect; Vomiting; Gastroenterology; Oncology; Surgery; Cancer; Metastasis","score_opus":0.06366795087877529,"score_gpt":0.4881444277727967,"score_spread":0.4244764768940214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764070276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857901,0.0007303498,0.000039893705,0.007379037,0.00079344236,0.0017611608,0.000026725822,0.000003080152,0.0034762453],"genre_scores_gemma":[0.9951673,0.0006161098,0.00079774775,0.0025343013,0.00055320445,0.00008329823,0.000010887286,0.000019353622,0.00021780531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99614614,0.0010124135,0.001987817,0.0002483732,0.00034349549,0.0002617476],"domain_scores_gemma":[0.99217165,0.0045323865,0.0025029602,0.00030722324,0.00025182546,0.00023394408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00447913,0.00019897436,0.0019726541,0.00013669905,0.00011273041,0.000044514265,0.00024057367,0.00019399436,0.000076545235],"category_scores_gemma":[0.003984575,0.00010228398,0.000313487,0.00007650611,0.0003980376,0.0002072433,0.000043537326,0.00086716417,0.0000015097636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77355087,0.014227316,0.12566595,0.00007358951,0.0010106595,0.0007875059,0.0015991611,0.000012368341,0.000021138138,0.00003075133,0.0036235882,0.07939711],"study_design_scores_gemma":[0.867694,0.01377625,0.10965161,0.00028706793,0.0015792997,0.000023749833,0.00021655452,0.0000911355,0.000014552187,0.000044304303,0.0065123853,0.00010907719],"about_ca_topic_score_codex":0.0006078143,"about_ca_topic_score_gemma":0.0009504657,"teacher_disagreement_score":0.09414315,"about_ca_system_score_codex":0.00014850027,"about_ca_system_score_gemma":0.0020175027,"threshold_uncertainty_score":0.47701964},"labels":[],"label_agreement":null},{"id":"W2765291642","doi":"10.1200/jco.2013.31.15_suppl.e13502","title":"Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Nausea; Gastroenterology; Dysgeusia; Chemotherapy; Surgery; Adverse effect","score_opus":0.07804680590373032,"score_gpt":0.4016781343289256,"score_spread":0.32363132842519526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765291642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593294,0.00020136223,0.00002021206,0.0013438354,0.0004153054,0.0018781781,0.000071380746,0.00000982822,0.0001269774],"genre_scores_gemma":[0.9964225,0.00024278066,0.0027532922,0.00022105536,0.00023219871,0.000029224935,0.000026955777,0.00004369606,0.000028259006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902902,0.0014125466,0.006079997,0.00045908376,0.0013469276,0.0004112357],"domain_scores_gemma":[0.9853635,0.003327434,0.0070163757,0.00039120467,0.0035182168,0.00038325688],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004539975,0.00039673774,0.0028780212,0.00046109167,0.00006858953,0.000013802789,0.00027335738,0.00038939383,0.000041451043],"category_scores_gemma":[0.010110643,0.00023306785,0.0002631787,0.000711054,0.0007071055,0.0004940059,0.00012550787,0.0015280022,0.000004027263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16292809,0.048575196,0.6195202,0.0003798336,0.0011049215,0.000070794435,0.0090793725,0.000023549024,0.012534067,0.000033291337,0.0010568064,0.14469391],"study_design_scores_gemma":[0.09518869,0.2555613,0.64324677,0.0007199435,0.00029730928,0.000023665652,0.00295763,0.00013635436,0.0015301718,0.000052780557,0.00008715057,0.00019825822],"about_ca_topic_score_codex":0.00018686675,"about_ca_topic_score_gemma":0.0000378897,"teacher_disagreement_score":0.2069861,"about_ca_system_score_codex":0.00016481611,"about_ca_system_score_gemma":0.0016853841,"threshold_uncertainty_score":0.9982276},"labels":[],"label_agreement":null},{"id":"W2765663344","doi":"10.1200/jco.2017.74.7451","title":"MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Proportional hazards model; Oncology; microRNA; Hazard ratio; Internal medicine; Myeloid leukemia; Gene; Confidence interval; Genetics; Biology","score_opus":0.049694568541407934,"score_gpt":0.39813441255922033,"score_spread":0.3484398440178124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765663344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439746,0.00048458588,0.0021056915,0.0016093324,0.0007931695,0.00011904227,0.000018097222,0.0000033196955,0.00046931327],"genre_scores_gemma":[0.992541,0.0007149256,0.004890016,0.0003524162,0.0013446017,0.000004567044,0.000015536314,0.000022321803,0.00011461242],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99722654,0.0003432733,0.0016147739,0.0002873531,0.00026567493,0.0002624032],"domain_scores_gemma":[0.9958305,0.00023692337,0.0027347247,0.00069399393,0.00023129235,0.00027257687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023313987,0.00016729906,0.00067319465,0.00011276172,0.00010071155,0.000029692681,0.0011262267,0.00065265194,0.000019094548],"category_scores_gemma":[0.0040346533,0.0001391948,0.00042978278,0.000043768403,0.00019413479,0.000018963541,0.00031484087,0.0005274924,0.000006721493],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005914772,0.0016099303,0.4153695,0.00006408468,0.00030356523,0.000346451,0.000034726414,0.012621904,0.52850044,0.00004120482,0.022797685,0.012395699],"study_design_scores_gemma":[0.016920308,0.0028018449,0.9012996,0.00008066608,0.00039636972,0.00004893677,0.000019373228,0.0055669127,0.06259655,0.002026116,0.007744176,0.00049917976],"about_ca_topic_score_codex":0.000006838743,"about_ca_topic_score_gemma":0.000070430775,"teacher_disagreement_score":0.48593006,"about_ca_system_score_codex":0.000105218,"about_ca_system_score_gemma":0.0029167098,"threshold_uncertainty_score":0.5676199},"labels":[],"label_agreement":null},{"id":"W2765774285","doi":"10.1200/jco.2017.75.4614","title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Denosumab; Breast cancer; Guideline; Dosing; Cancer; Clinical trial; Zoledronic acid; Oncology; Bone pain; Referral; Internal medicine; Surgery; Osteoporosis; Pathology","score_opus":0.27735346720949405,"score_gpt":0.5816377808322682,"score_spread":0.3042843136227742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765774285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98343825,0.0010627493,0.000015065977,0.013212448,0.0012583674,0.00039805958,0.00007920599,0.000006082423,0.00052974245],"genre_scores_gemma":[0.9694784,0.00487884,0.02064465,0.004150034,0.00069854973,0.000016167682,0.0000135293685,0.000029942355,0.000089846646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903193,0.0007968823,0.007460676,0.00038949278,0.0005594106,0.0004742376],"domain_scores_gemma":[0.98514515,0.0009203028,0.011262612,0.00059246825,0.0011921773,0.000887282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053596413,0.00025470115,0.0047786897,0.000106506675,0.0001031229,0.000008162285,0.00038922357,0.0004705239,0.00024487806],"category_scores_gemma":[0.0011940937,0.00018723492,0.0011638843,0.00012107162,0.0008664159,0.00023848111,0.00013719036,0.0017602253,0.0000040129153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056893886,0.0027884268,0.5597826,0.000063350155,0.0006248121,0.000134003,0.0004191411,0.000023314125,0.000024232731,0.0000040154764,0.0014735308,0.42897314],"study_design_scores_gemma":[0.023947861,0.011222237,0.91074395,0.00030227262,0.0011732959,0.00010162671,0.00068962615,0.00037745867,0.000022654996,0.00010201343,0.05119403,0.00012295246],"about_ca_topic_score_codex":0.07720282,"about_ca_topic_score_gemma":0.16088402,"teacher_disagreement_score":0.4288502,"about_ca_system_score_codex":0.00091854157,"about_ca_system_score_gemma":0.0139147155,"threshold_uncertainty_score":0.9916755},"labels":[],"label_agreement":null},{"id":"W2766122987","doi":"10.1200/jco.2017.35.15_suppl.e16528","title":"Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Abiraterone acetate; Prednisone; Internal medicine; Prostate cancer; Placebo; Post-hoc analysis; Proportional hazards model; Randomization; Logistic regression; Prostate-specific antigen; Oncology; Univariate analysis; Randomized controlled trial; Multivariate analysis; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.19509677854061214,"score_gpt":0.46550736720885977,"score_spread":0.27041058866824763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766122987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931405,0.0007443386,0.0000685645,0.002080093,0.0005277879,0.0022145081,0.0003245923,0.000023329967,0.000876276],"genre_scores_gemma":[0.9879339,0.0066383327,0.001452455,0.000071578055,0.00048155055,0.000047555775,0.00027385107,0.000070684764,0.0030301108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931018,0.0009587718,0.0031327885,0.00076869904,0.0012757783,0.0007622031],"domain_scores_gemma":[0.9911824,0.001821546,0.0038929998,0.0013267449,0.0011503461,0.0006259599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00468638,0.00048330377,0.0046189344,0.00058818015,0.00020370513,0.00010932702,0.0009248957,0.0005602038,0.00026885123],"category_scores_gemma":[0.001165248,0.00026357322,0.00040318465,0.0006002956,0.0012422685,0.0006956014,0.00025587133,0.0013973629,0.0000075145836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8908747,0.0024874257,0.08430596,0.00009214574,0.008862063,0.004321906,0.0010562954,0.0005960818,0.00044002925,0.000009924296,0.0008054149,0.00614806],"study_design_scores_gemma":[0.4705895,0.11064946,0.40412965,0.00047952108,0.0050283885,0.00016842123,0.0008978014,0.0038386192,0.00018587727,0.000014555294,0.0036256784,0.0003925565],"about_ca_topic_score_codex":0.0006710778,"about_ca_topic_score_gemma":0.0030592568,"teacher_disagreement_score":0.42028522,"about_ca_system_score_codex":0.00070636795,"about_ca_system_score_gemma":0.0065777563,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W2766257935","doi":"10.1200/jco.2017.35.15_suppl.11583","title":"Role of ERBB signaling in RET-rearranged lung cancer and contribution of EGFR amplification to cabozantinib resistance.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cabozantinib; Cancer research; Vandetanib; Erlotinib; Crizotinib; Medicine; Afatinib; Gefitinib; Lung cancer; EGFR inhibitors; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Tyrosine kinase; Internal medicine; Receptor","score_opus":0.06657449776878374,"score_gpt":0.5173603709212642,"score_spread":0.4507858731524804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766257935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910904,0.0018884292,0.000107855005,0.006991197,0.00025385624,0.00024831717,0.000013186021,0.0000016132573,0.0013865039],"genre_scores_gemma":[0.9972958,0.0006996024,0.0014852618,0.000161881,0.00021914062,0.00000512184,0.0000025003915,0.0000055937417,0.0001251095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828136,0.000092992195,0.0012545732,0.00010579883,0.00016367805,0.000101612575],"domain_scores_gemma":[0.99689186,0.00045186363,0.0017912111,0.00015854977,0.00057934254,0.00012719717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013747575,0.000059956856,0.00077629875,0.000085879015,0.000044195862,0.0000054787993,0.00007984292,0.00014492714,0.0000235983],"category_scores_gemma":[0.0024671764,0.00004533088,0.0001064467,0.000055816123,0.00011509278,0.000084825966,0.000017707733,0.00021794025,3.534914e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006786053,0.0008832036,0.87356895,0.00009765817,0.0004912422,0.000041556257,0.0009582078,0.00004256172,0.04850583,0.0011607213,0.00069156295,0.06677246],"study_design_scores_gemma":[0.007747395,0.001295534,0.97628236,0.0005560084,0.00048966333,0.000008273032,0.00020934631,0.000047466383,0.0031698423,0.00038727073,0.009760802,0.000046056764],"about_ca_topic_score_codex":0.00022723386,"about_ca_topic_score_gemma":0.00067712006,"teacher_disagreement_score":0.1027134,"about_ca_system_score_codex":0.00012214041,"about_ca_system_score_gemma":0.0007656292,"threshold_uncertainty_score":0.29536188},"labels":[],"label_agreement":null},{"id":"W2766357896","doi":"10.1200/jco.2013.31.15_suppl.2031","title":"Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Topotecan; Radiation therapy; Population; Oncology; Surgery; Nuclear medicine; Chemotherapy","score_opus":0.10582875094452406,"score_gpt":0.4700950265066752,"score_spread":0.36426627556215113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766357896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937615,0.00014971213,0.00063166296,0.0026922964,0.0000827516,0.0025355415,0.000044569384,0.0000066684897,0.00009532504],"genre_scores_gemma":[0.98502314,0.00006307471,0.011735461,0.0025023131,0.00012247403,0.00011457383,0.000060498653,0.00004400631,0.00033446122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490786,0.0012961169,0.0022140513,0.00049674534,0.00068498484,0.00040023404],"domain_scores_gemma":[0.9942583,0.0011535366,0.0027805858,0.00047035588,0.00080321747,0.0005340394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033281383,0.00036595663,0.0031882569,0.0005231239,0.00007063026,0.00005133465,0.000381088,0.0001831969,0.0004106721],"category_scores_gemma":[0.00023446979,0.000185917,0.00017318291,0.00115615,0.00021024015,0.00046607835,0.000058976846,0.000726048,0.0000017505354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08301415,0.055987466,0.65415835,0.00003130459,0.007906308,0.0006132696,0.0010273231,0.00062409963,0.00006503694,0.0000024471535,0.0010405723,0.19552967],"study_design_scores_gemma":[0.24878253,0.24021284,0.499355,0.00014662564,0.0059945085,0.00003027968,0.0010056414,0.002953845,0.000059442966,0.0000037585319,0.0012085509,0.0002469967],"about_ca_topic_score_codex":0.0028843847,"about_ca_topic_score_gemma":0.009938489,"teacher_disagreement_score":0.19528267,"about_ca_system_score_codex":0.00031096302,"about_ca_system_score_gemma":0.002782808,"threshold_uncertainty_score":0.75814754},"labels":[],"label_agreement":null},{"id":"W2766489122","doi":"10.1200/jco.2017.73.8195","title":"International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Peripheral T-cell lymphoma; Internal medicine; Lymphoma; Population; Cohort; Refractory (planetary science); Clinical endpoint; Progression-free survival; Young adult; Overall survival; Surgery; Clinical trial; T cell; Immunology","score_opus":0.10389749999057629,"score_gpt":0.4602181108227659,"score_spread":0.35632061083218963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766489122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96456546,0.0003491092,0.000015541582,0.00946474,0.0036885475,0.00016332597,0.000013091885,0.0000027732096,0.02173741],"genre_scores_gemma":[0.99431497,0.0023786186,0.0019551397,0.0002105016,0.00062242517,0.000005919493,0.000004175545,0.000012490514,0.0004957527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996757,0.00030630297,0.0019348455,0.00021704704,0.00058169384,0.00020315728],"domain_scores_gemma":[0.9958636,0.0010365781,0.0020810368,0.0004193789,0.000300886,0.00029849293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026691542,0.00015534354,0.0013872769,0.000094405914,0.00006199955,0.000022154376,0.00038312384,0.00025812158,0.00017633397],"category_scores_gemma":[0.0015670168,0.000111088164,0.0004035361,0.000027781407,0.00027346413,0.00013903658,0.0003154277,0.00024846866,0.0000024767849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019357139,0.0056026326,0.9400962,0.00002209868,0.00035143716,0.0012961933,0.000052201693,0.000010328979,0.00019763803,0.0003391326,0.0007063883,0.04939003],"study_design_scores_gemma":[0.036460225,0.004445852,0.93941617,0.00009241614,0.00018026265,0.00015676442,0.00008598015,0.0002839977,0.00015261215,0.00018527368,0.018457817,0.000082659004],"about_ca_topic_score_codex":0.00024364032,"about_ca_topic_score_gemma":0.00071260304,"teacher_disagreement_score":0.04930737,"about_ca_system_score_codex":0.00078514346,"about_ca_system_score_gemma":0.0011898543,"threshold_uncertainty_score":0.45300436},"labels":[],"label_agreement":null},{"id":"W2766663577","doi":"10.1200/jco.2017.35.15_suppl.5036","title":"Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Montreal Cognitive Assessment; Medicine; Enzalutamide; Quality of life (healthcare); Internal medicine; Prostate cancer; Depression (economics); Randomized controlled trial; Oncology; Physical therapy; Cognitive impairment; Cancer; Disease; Androgen receptor","score_opus":0.1813795727884055,"score_gpt":0.539802924045878,"score_spread":0.35842335125747254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766663577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927209,0.0011946231,0.000756004,0.0008515289,0.0005912663,0.003658822,0.00013637119,0.000004277769,0.000086213884],"genre_scores_gemma":[0.99746525,0.0012584036,0.00071559014,0.0001400166,0.00013150353,0.0002103469,0.0000046855453,0.000021118913,0.000053110052],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916425,0.0018129405,0.0053508556,0.00033317885,0.0005923663,0.0002681814],"domain_scores_gemma":[0.9814106,0.0059106247,0.010253237,0.00022529007,0.001969835,0.0002303699],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010349573,0.00025387897,0.005399097,0.00023096375,0.00012672153,0.000009439867,0.00012780284,0.00017453321,0.00002926027],"category_scores_gemma":[0.015700234,0.00017637869,0.00045357514,0.00010504563,0.0008805573,0.00022265274,0.00014819758,0.0006169124,1.020769e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8556832,0.01393093,0.09692441,0.00077896647,0.0055647762,0.000054049433,0.0017661388,0.00012835771,0.00528754,0.000010510387,0.00005027249,0.019820847],"study_design_scores_gemma":[0.47737363,0.048235293,0.4653033,0.00094218086,0.003981266,0.0000060409943,0.0029123449,0.00050314516,0.00048252204,0.00015386933,0.000009041938,0.00009733887],"about_ca_topic_score_codex":0.0007531446,"about_ca_topic_score_gemma":0.0013647065,"teacher_disagreement_score":0.37830955,"about_ca_system_score_codex":0.00018408701,"about_ca_system_score_gemma":0.0021406813,"threshold_uncertainty_score":0.99259096},"labels":[],"label_agreement":null},{"id":"W2767038813","doi":"10.1200/jco.2013.31.15_suppl.6557","title":"NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; The Quebec Population Health Research Network","funders":"","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Body mass index; Breast cancer; Demography; Logistic regression; Aromatase inhibitor; Ethnic group; Gynecology; Cancer; Aromatase","score_opus":0.04039265677982978,"score_gpt":0.40274872695327674,"score_spread":0.36235607017344695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767038813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924226,0.004600794,0.00007954915,0.0013389338,0.0010687173,0.00038344794,0.00006160117,0.000004013247,0.000040370443],"genre_scores_gemma":[0.99508506,0.002230316,0.00028474146,0.00031899154,0.0019038826,0.00004157111,0.000007125561,0.000015238449,0.0001130498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967475,0.0008503184,0.0016754249,0.00024676233,0.00018924935,0.0002907678],"domain_scores_gemma":[0.99560416,0.0005908156,0.0027848377,0.0002395819,0.00044826677,0.0003323443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035147613,0.00016624227,0.0008151037,0.00004278393,0.000104595725,0.000016298332,0.00022289068,0.00062138896,0.000047907783],"category_scores_gemma":[0.0018992183,0.000105394094,0.00035444158,0.00008335337,0.0005517895,0.00002311758,0.000097773,0.0006910806,0.0000019854162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014650965,0.0023781306,0.33619756,0.00039931372,0.0035075245,0.000020811363,0.0008165129,0.00018014286,0.159215,0.00013733414,0.019657763,0.46283895],"study_design_scores_gemma":[0.0061607184,0.005405984,0.9779569,0.00007110964,0.00032768538,0.00012365582,0.00048258068,0.000120668316,0.0034961088,0.00044319243,0.0051288055,0.00028258096],"about_ca_topic_score_codex":0.00022785884,"about_ca_topic_score_gemma":0.000053517564,"teacher_disagreement_score":0.64175934,"about_ca_system_score_codex":0.00005583661,"about_ca_system_score_gemma":0.0006308633,"threshold_uncertainty_score":0.47927207},"labels":[],"label_agreement":null},{"id":"W2767125962","doi":"10.1200/jco.2017.35.15_suppl.e16529","title":"Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory post-hoc analysis of COU-AA-302 trial data.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Post-hoc analysis; Placebo; Internal medicine; Oncology; Abiraterone acetate; Proportional hazards model; Clinical trial; Brief Pain Inventory; Prostate-specific antigen; Urology; Cancer; Androgen deprivation therapy; Physical therapy; Pathology","score_opus":0.32248500850765155,"score_gpt":0.5471662874615635,"score_spread":0.22468127895391193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767125962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963832,0.00015397964,0.0000038310623,0.00087700697,0.0006291048,0.0012449019,0.0006508189,0.000006502514,0.000050652154],"genre_scores_gemma":[0.9967688,0.0015984082,0.0006957643,0.00011325359,0.00021864672,0.00003903822,0.0001928456,0.00002938059,0.00034387948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99141425,0.0014395667,0.0053220685,0.00047672723,0.0009727907,0.00037461697],"domain_scores_gemma":[0.9882974,0.0023037235,0.0062221303,0.0009795815,0.0016451105,0.00055206986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064367503,0.00027933464,0.0042372546,0.00048512337,0.000082972954,0.000028855871,0.00061959046,0.00028340452,0.0001551006],"category_scores_gemma":[0.004740591,0.00014812546,0.0004899304,0.0003554631,0.0009500804,0.000671853,0.00013989335,0.0008418664,0.0000015915622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39708528,0.0049184724,0.5813835,0.00005538517,0.006624758,0.0004718006,0.0002673026,0.000043714317,0.00005202479,0.0000011368395,0.00010664721,0.008989947],"study_design_scores_gemma":[0.17202282,0.06977093,0.75095266,0.00015976197,0.005954804,0.0000037484995,0.00038558946,0.00030471085,0.00006618843,0.0000047670096,0.0002561984,0.000117824646],"about_ca_topic_score_codex":0.00049312774,"about_ca_topic_score_gemma":0.009222796,"teacher_disagreement_score":0.22506247,"about_ca_system_score_codex":0.0001822363,"about_ca_system_score_gemma":0.005733924,"threshold_uncertainty_score":0.99990267},"labels":[],"label_agreement":null},{"id":"W2767187621","doi":"10.1200/jco.2017.74.0340","title":"Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Depression (economics); Constipation; Anxiety; Odds ratio; Distress; Cancer; Logistic regression; Quality of life (healthcare); Internal medicine; Confidence interval; Population; Physical therapy; Psychiatry","score_opus":0.1436272450519175,"score_gpt":0.5395825510761154,"score_spread":0.39595530602419793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767187621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964221,0.00088657596,0.00001427592,0.0008325663,0.0004942874,0.00012276716,0.000043967815,0.0000011135105,0.0011823572],"genre_scores_gemma":[0.9970512,0.00095776154,0.0017354294,0.00008091728,0.0001504774,0.0000014588659,0.0000035870332,0.0000065753006,0.000012609706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982311,0.00008170707,0.0012646591,0.00007870182,0.00024909698,0.00009470081],"domain_scores_gemma":[0.99647385,0.0003884231,0.0018888534,0.00015668262,0.0009817856,0.0001104106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003368112,0.00006982182,0.0011217782,0.00007553733,0.000015310174,8.830888e-7,0.00012764538,0.00015555984,0.0000288745],"category_scores_gemma":[0.0015677109,0.000046244073,0.000213226,0.000044349385,0.00031631035,0.00009853136,0.000014974498,0.00032401204,2.1827e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060116216,0.00078173314,0.9664963,0.00008500886,0.0002002685,0.00003052166,0.0012287621,0.000028338556,0.000044737433,0.0000115322155,0.00007179668,0.025009416],"study_design_scores_gemma":[0.010344099,0.024236087,0.9602278,0.0012829232,0.00023660592,0.0000014643521,0.0005746894,0.0000022735976,0.00039260538,0.000015001613,0.002647818,0.00003866492],"about_ca_topic_score_codex":0.000049274924,"about_ca_topic_score_gemma":0.0002355703,"teacher_disagreement_score":0.02497075,"about_ca_system_score_codex":0.00005814581,"about_ca_system_score_gemma":0.0007422737,"threshold_uncertainty_score":0.18857785},"labels":[],"label_agreement":null},{"id":"W2767298955","doi":"10.1200/jco.2016.34.15_suppl.10511","title":"Combined clinical and genetic risk prediction of central nervous system subsequent neoplasms (CNS SNs) in childhood cancer survivors (CCS): A report from the COG ALTE03N1 study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Nomogram; Cog; Receiver operating characteristic; Oncology; Cancer; Internal medicine; Genotyping; Single-nucleotide polymorphism; Area under the curve; Clinical endpoint; Genotype; Genetics; Gene; Clinical trial; Biology","score_opus":0.06366304032156847,"score_gpt":0.39347284462499243,"score_spread":0.329809804303424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767298955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911555,0.0010161003,0.000026349026,0.0041977223,0.0026573425,0.0008138759,0.000073113355,0.000010642929,0.000049371407],"genre_scores_gemma":[0.99527436,0.0032607617,0.00018908024,0.00017999695,0.0010359347,0.00002725739,0.000003021956,0.000019751536,0.000009850752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923437,0.0016772066,0.0048330505,0.00035984602,0.00049190584,0.0002942492],"domain_scores_gemma":[0.9899264,0.005596768,0.0033419912,0.00038754978,0.00031968852,0.00042762718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038417152,0.00019618713,0.001930652,0.000085725245,0.00004875564,0.000008808466,0.0001655839,0.00035209247,0.000041790263],"category_scores_gemma":[0.0031947931,0.000094358154,0.0004693624,0.00014129232,0.00032124616,0.00005832172,0.000076469296,0.00068694685,0.0000026517132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021267445,0.00654985,0.937551,0.000011136673,0.0013013969,0.003191317,0.00020533524,0.000026069454,0.000032899,0.000007869303,0.00056555413,0.048430834],"study_design_scores_gemma":[0.023413086,0.012415899,0.9601142,0.00042729962,0.0018151778,0.0004889514,0.00041179545,0.000080953454,0.000033040644,0.000056439665,0.0006702216,0.00007297833],"about_ca_topic_score_codex":0.0027628068,"about_ca_topic_score_gemma":0.005047093,"teacher_disagreement_score":0.048357856,"about_ca_system_score_codex":0.00020145938,"about_ca_system_score_gemma":0.0010912574,"threshold_uncertainty_score":0.4176556},"labels":[],"label_agreement":null},{"id":"W2767552555","doi":"10.1200/jco.2014.32.15_suppl.567","title":"Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Progesterone receptor; Estrogen receptor; Internal medicine; Breast cancer; Oncology; Proportional hazards model; Cancer; Survival analysis; Estrogen","score_opus":0.030758493639350435,"score_gpt":0.39563303830546254,"score_spread":0.3648745446661121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767552555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430406,0.00087520597,0.00007196235,0.0025976778,0.0014727081,0.00025636822,0.00005997541,0.000004674429,0.00035734172],"genre_scores_gemma":[0.9865012,0.005182598,0.005510446,0.0009378208,0.0016454102,0.000009394828,0.000015621641,0.000030939078,0.00016658078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995339,0.0014971747,0.0022855608,0.0003619164,0.00023639602,0.0002800016],"domain_scores_gemma":[0.9941273,0.0020786251,0.0024988903,0.00022972033,0.0006246123,0.000440886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030236812,0.00023932138,0.001520287,0.00006167479,0.00005403472,0.000010344145,0.00029170388,0.0009601641,0.000038006892],"category_scores_gemma":[0.0040942053,0.0001688564,0.0006108062,0.000086760396,0.00075127016,0.000016948596,0.00017254136,0.00085639773,0.000009786911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059128003,0.0015972872,0.7941074,0.00004144965,0.0027442768,0.000023966923,0.00010580478,0.000015136846,0.027371325,0.00016113966,0.00689748,0.16102196],"study_design_scores_gemma":[0.015860032,0.047066312,0.86977834,0.00033252375,0.00093590457,0.0004050046,0.00026157693,0.0000306543,0.03973843,0.00030900427,0.024675917,0.0006062984],"about_ca_topic_score_codex":0.000027436154,"about_ca_topic_score_gemma":0.000020020185,"teacher_disagreement_score":0.16041566,"about_ca_system_score_codex":0.000034788,"about_ca_system_score_gemma":0.00092976575,"threshold_uncertainty_score":0.7405665},"labels":[],"label_agreement":null},{"id":"W2767597781","doi":"10.1200/jco.2017.35.15_suppl.10006","title":"American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Colorectal cancer; Internal medicine; Cancer; Confidence interval; Surgery","score_opus":0.2564106006009677,"score_gpt":0.5503343975302395,"score_spread":0.2939237969292718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767597781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84243476,0.0049646404,0.000008581745,0.1513899,0.00075169036,0.00030540815,0.00009910952,0.0000068466534,0.000039065537],"genre_scores_gemma":[0.8391025,0.15187474,0.0016740938,0.004668073,0.0024741855,0.00014681948,0.0000014304269,0.000016091719,0.00004204814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764794,0.00030050706,0.0010257128,0.000363372,0.00034110827,0.00032137142],"domain_scores_gemma":[0.9958282,0.0012499584,0.0013436261,0.0003359003,0.00042056566,0.0008217654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014698076,0.00019607913,0.0014517651,0.00005468037,0.00015986583,0.00004421344,0.00019739202,0.00020661963,0.000037922076],"category_scores_gemma":[0.0043822057,0.00015759924,0.00020782687,0.00006593762,0.0009289371,0.00029790454,0.00021697622,0.0010297096,4.985045e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032608123,0.0012351391,0.7927145,0.00032380715,0.000080620426,0.0001527727,0.000116882744,4.9233404e-7,0.000034363842,0.000029760105,0.025637979,0.17641291],"study_design_scores_gemma":[0.012465544,0.0014205006,0.94665456,0.0011887886,0.00023589467,0.000022323196,0.00007399023,0.00046544537,0.00001358243,0.0019164142,0.035387613,0.000155366],"about_ca_topic_score_codex":0.00084398675,"about_ca_topic_score_gemma":0.0017826625,"teacher_disagreement_score":0.17625755,"about_ca_system_score_codex":0.00021228222,"about_ca_system_score_gemma":0.0008602236,"threshold_uncertainty_score":0.64267105},"labels":[],"label_agreement":null},{"id":"W2768342326","doi":"10.1200/jco.2017.35.31_suppl.237","title":"Health-related quality of life in patients with advanced colorectal cancer treated with dose reduced capecitabine.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; University of Ottawa; Ottawa Hospital; London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Capecitabine; Medicine; Quality of life (healthcare); Internal medicine; Colorectal cancer; Cancer; Chemotherapy; Oncology; Nursing","score_opus":0.10321545054379942,"score_gpt":0.46749159806626717,"score_spread":0.36427614752246773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768342326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084044,0.0007283456,7.320424e-7,0.0059351064,0.0003537947,0.00049309706,0.000015555981,0.0000060978896,0.0016268536],"genre_scores_gemma":[0.9984251,0.00059495925,0.0004530089,0.00028724913,0.00011100874,0.000016506538,0.0000041481894,0.000016715392,0.00009127911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962002,0.00031514998,0.0025822197,0.00022989746,0.0004073819,0.0002651403],"domain_scores_gemma":[0.99318826,0.0005872439,0.0048737135,0.000233709,0.00076701783,0.00035007257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012009469,0.00018528051,0.002855958,0.00009707764,0.00010233842,0.000006335549,0.00014962691,0.00019060138,0.000053324657],"category_scores_gemma":[0.0020549512,0.000102566104,0.00020328551,0.00012505591,0.00044450394,0.00013571944,0.0000422236,0.0005954329,9.4784934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08308733,0.0026664615,0.8383147,0.00003770461,0.00080778095,0.00007152036,0.00018224228,0.000017520526,0.000022496512,0.000010135389,0.00012836553,0.07465371],"study_design_scores_gemma":[0.046982206,0.044137836,0.9078988,0.00030412394,0.00016647959,0.000008972524,0.00009738597,0.0000050936324,0.000023727958,0.0000118097205,0.0002700565,0.000093517454],"about_ca_topic_score_codex":0.0018131508,"about_ca_topic_score_gemma":0.0053812684,"teacher_disagreement_score":0.07456019,"about_ca_system_score_codex":0.0004204637,"about_ca_system_score_gemma":0.002545943,"threshold_uncertainty_score":0.45163935},"labels":[],"label_agreement":null},{"id":"W2768372460","doi":"10.1200/jco.2017.35.31_suppl.106","title":"The expanding role of patients in integrated cancer network governance.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; École Nationale d'Administration Publique; Université de Sherbrooke","funders":"","keywords":"Operationalization; Corporate governance; Medicine; Focus group; Cancer; Politics; Nursing research; Public relations; Process management; Nursing; Business; Political science; Marketing","score_opus":0.30893807864122913,"score_gpt":0.6036304056556997,"score_spread":0.29469232701447057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768372460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820639,0.00042817247,0.000034669014,0.013455765,0.0025537966,0.00017557762,0.000004453604,0.0000018671378,0.0012817929],"genre_scores_gemma":[0.9920767,0.004397206,0.0011071436,0.0009846403,0.0013399258,0.000003175767,0.0000016558632,0.000009195491,0.000080385216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949968,0.0003695063,0.0039883745,0.000107936954,0.00034714775,0.00019023655],"domain_scores_gemma":[0.98449373,0.006937503,0.0074214246,0.00027081682,0.00074062136,0.00013589337],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0072896644,0.000079556485,0.00088293426,0.00002204501,0.00009811745,0.000015019731,0.0002983278,0.00019392061,0.00010169243],"category_scores_gemma":[0.06015706,0.000046100766,0.00025258027,0.00006663431,0.00022986314,0.00021116984,0.000092726,0.0009720366,0.0000035126734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003032908,0.00033059978,0.6209388,0.0000033470283,0.00007743968,0.00001483035,0.000021308637,0.000025961706,0.000014467565,0.000081983606,0.004193567,0.3712648],"study_design_scores_gemma":[0.0062869657,0.002296802,0.87207705,0.00014778537,0.00013325893,0.000005104537,0.00017016915,0.00022859153,0.000021651656,0.00090752606,0.11768773,0.00003736658],"about_ca_topic_score_codex":0.0006043441,"about_ca_topic_score_gemma":0.0025766867,"teacher_disagreement_score":0.3712274,"about_ca_system_score_codex":0.00017690059,"about_ca_system_score_gemma":0.0013389435,"threshold_uncertainty_score":0.9477596},"labels":[],"label_agreement":null},{"id":"W2768467887","doi":"10.1200/jco.2017.35.31_suppl.148","title":"Perceptions of palliative care: Cancer and non-cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Palliative care; Medicine; Qualitative research; Family medicine; Quality of life (healthcare); Cancer; End-of-life care; Disease; Medical diagnosis; Nursing; Internal medicine","score_opus":0.431355174250708,"score_gpt":0.6349135432278284,"score_spread":0.20355836897712043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768467887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821271,0.005140684,0.000077126024,0.0068328716,0.00092015835,0.00008891392,0.000020655838,0.0000015881268,0.0047909208],"genre_scores_gemma":[0.9507395,0.04461831,0.002847964,0.00046140837,0.0010607975,0.0000034439408,7.1018496e-7,0.000007226323,0.00026063516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833155,0.00007886032,0.0011649854,0.00010745641,0.0002025848,0.0001145934],"domain_scores_gemma":[0.9955969,0.0009401487,0.002175153,0.00017814124,0.00091489573,0.0001947874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059700257,0.00008511596,0.0012586763,0.000054569307,0.000056035256,0.000004071628,0.00015211788,0.0002269701,0.00016499561],"category_scores_gemma":[0.0027906524,0.0000588845,0.00028943722,0.000031764746,0.0005671881,0.00008010282,0.00005454009,0.00046624846,0.0000021240694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008289918,0.00020425512,0.88300097,0.00008692427,0.00032204934,0.00004081436,0.0015147892,0.000003899418,0.00059735664,0.000028408858,0.0017902004,0.11158132],"study_design_scores_gemma":[0.0041185096,0.0036634426,0.94573736,0.0008844508,0.00045431193,0.0000039684537,0.0014656018,0.000019725463,0.00046740557,0.00010278873,0.043029405,0.00005303075],"about_ca_topic_score_codex":0.00030788383,"about_ca_topic_score_gemma":0.00034261693,"teacher_disagreement_score":0.111528285,"about_ca_system_score_codex":0.00008428041,"about_ca_system_score_gemma":0.0010473485,"threshold_uncertainty_score":0.33408734},"labels":[],"label_agreement":null},{"id":"W2768546764","doi":"10.1200/jco.2017.35.31_suppl.113","title":"Preliminary results of a randomized controlled trial of early integration of specialist palliative care within a tertiary cancer center in the Czech Republic.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Anxiety; Cancer; Clinical trial; Randomized controlled trial; Depression (economics); Czech; Internal medicine; Family medicine; Nursing; Psychiatry","score_opus":0.2906008695724327,"score_gpt":0.5585930687464543,"score_spread":0.2679921991740216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768546764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876167,0.0010419938,0.000045162175,0.0045949626,0.0012348485,0.001482537,0.000036588815,0.0000013915972,0.0039457725],"genre_scores_gemma":[0.9957625,0.0020008897,0.0009805987,0.00021839794,0.00089890335,0.000030874817,0.0000054428606,0.0000075302496,0.00009481841],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9914293,0.0021170888,0.005646291,0.00014682296,0.0005383256,0.0001221174],"domain_scores_gemma":[0.9767794,0.009303101,0.011695356,0.0003482574,0.0017957861,0.00007811695],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00926134,0.0001353064,0.00450736,0.0001679879,0.000024217923,0.000006404876,0.00034891968,0.0003181546,0.000021107224],"category_scores_gemma":[0.058375407,0.00006829632,0.0011772092,0.00007923711,0.000724555,0.00012122199,0.00004752708,0.00065989705,2.0021412e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9523849,0.0013452824,0.027461704,0.00006995169,0.00078855077,0.00006746225,0.010962249,0.0000048515953,0.0001491514,0.00010344718,0.0005828848,0.0060795466],"study_design_scores_gemma":[0.88801867,0.016532527,0.08865067,0.002017209,0.0008655271,0.000004200203,0.002224552,0.00006231149,0.00074421597,0.00020015075,0.0006268855,0.00005306148],"about_ca_topic_score_codex":0.0007320755,"about_ca_topic_score_gemma":0.0005948305,"teacher_disagreement_score":0.06436624,"about_ca_system_score_codex":0.00007112973,"about_ca_system_score_gemma":0.0012855699,"threshold_uncertainty_score":0.9495563},"labels":[],"label_agreement":null},{"id":"W2768584651","doi":"10.1200/jco.2017.35.31_suppl.240","title":"Frequency of concomitant use of opioids and psychoactive medications among cancer patients referred to outpatient palliative care at a comprehensive cancer center.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concomitant; Palliative care; Cancer pain; Opioid; Cancer; Exact test; Anxiety; Internal medicine; Psychiatry; Nursing","score_opus":0.45427177068951397,"score_gpt":0.5869286314065144,"score_spread":0.13265686071700045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768584651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422204,0.0016947823,0.00002698986,0.0015511041,0.001368676,0.00038334352,0.0003363888,0.000002119657,0.0004145324],"genre_scores_gemma":[0.9890399,0.0076943524,0.0025390263,0.00044599225,0.00020230576,0.00001647303,0.000010591688,0.000012725776,0.00003865863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692714,0.00024667935,0.0020078819,0.00020835303,0.0004398961,0.00017005304],"domain_scores_gemma":[0.9895711,0.0018911924,0.004497157,0.00030058654,0.0033681968,0.00037175836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002676149,0.00015509543,0.0016782548,0.00011291607,0.00006377372,0.0000040488585,0.00020979419,0.00026633922,0.000054885935],"category_scores_gemma":[0.0044070887,0.00011230507,0.00027866935,0.00006742299,0.00072382216,0.00013869768,0.00012091227,0.00043402007,7.080596e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019419857,0.0007589701,0.9762769,0.00011554581,0.00089948124,0.000016226952,0.0059841056,0.000006738476,0.00034497216,0.00002184965,0.0013545557,0.012278707],"study_design_scores_gemma":[0.0069069117,0.0057563027,0.9745667,0.0020970611,0.00048692882,8.5338957e-7,0.0013054998,0.000012589561,0.0008305021,0.000029231149,0.007918834,0.0000885605],"about_ca_topic_score_codex":0.0015487408,"about_ca_topic_score_gemma":0.0019950846,"teacher_disagreement_score":0.012190146,"about_ca_system_score_codex":0.0003565266,"about_ca_system_score_gemma":0.0007377484,"threshold_uncertainty_score":0.52760154},"labels":[],"label_agreement":null},{"id":"W2768609007","doi":"10.1200/jco.2017.35.31_suppl.133","title":"Health-related quality of life of postmenopausal women with hormone receptor–positive, HER2- advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Letrozole; Medicine; Quality of life (healthcare); Internal medicine; Breast cancer; Hazard ratio; Placebo; Nausea; Oncology; Cancer; Confidence interval; Tamoxifen","score_opus":0.06706628399460873,"score_gpt":0.4317828630791085,"score_spread":0.3647165790844998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768609007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759236,0.0021900123,0.00006806372,0.019779606,0.00026357808,0.0004116295,0.00087234477,0.00001813838,0.0004730112],"genre_scores_gemma":[0.99076,0.0017101729,0.005889203,0.00088492193,0.00044133374,0.000014005914,0.000029491703,0.000053620202,0.00021724559],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927867,0.0007965266,0.004686381,0.00043753744,0.0008045066,0.0004883431],"domain_scores_gemma":[0.9811413,0.0018727923,0.013741243,0.000702935,0.0017161677,0.000825554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027403915,0.0003390468,0.004111041,0.00012558847,0.00012435696,0.000009668839,0.00042014185,0.00039295224,0.00015208012],"category_scores_gemma":[0.0016444918,0.0002191647,0.0002176315,0.00019874112,0.001335488,0.0003760559,0.00007552838,0.001211512,0.0000034776633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5991886,0.0034828086,0.15037982,0.00008720315,0.004215641,0.00018028666,0.00086373277,0.00022979677,0.01048308,0.000029221654,0.00035756576,0.2305022],"study_design_scores_gemma":[0.053269427,0.03631629,0.906439,0.000794077,0.00022605916,0.00015973106,0.00045561808,0.000009073591,0.00043262684,0.00008921632,0.0016065926,0.00020228559],"about_ca_topic_score_codex":0.00311747,"about_ca_topic_score_gemma":0.00051085884,"teacher_disagreement_score":0.75605917,"about_ca_system_score_codex":0.0006294455,"about_ca_system_score_gemma":0.003810543,"threshold_uncertainty_score":0.8937277},"labels":[],"label_agreement":null},{"id":"W2768623599","doi":"10.1200/jco.2017.35.31_suppl.67","title":"Integration of end-of-life care in clinical trials for advanced malignancies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Checklist; Palliative care; Cancer; Clinical trial; End-of-life care; Advance care planning; Internal medicine; Performance status; Oncology; Family medicine; Nursing","score_opus":0.6809176289185972,"score_gpt":0.6673889345821071,"score_spread":0.013528694336490066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768623599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878914,0.003538995,0.0012150053,0.0026101212,0.0024313843,0.00043540666,0.000031790198,0.0000026488408,0.001843291],"genre_scores_gemma":[0.96973723,0.005341253,0.023294823,0.00041952875,0.0011150701,0.000006010932,0.0000064111787,0.000011885016,0.00006777227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9907203,0.0009965812,0.0076326113,0.00017094816,0.00031188075,0.00016768697],"domain_scores_gemma":[0.97121793,0.016087057,0.010348422,0.00035445858,0.0017550364,0.00023711867],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015409879,0.00012780892,0.0041540777,0.00014408217,0.000025133357,0.0000036218935,0.0003066063,0.0005425433,0.00004577317],"category_scores_gemma":[0.21655256,0.00008667618,0.0013154016,0.000060319464,0.00053048925,0.00013590504,0.000050576084,0.00062071596,0.0000012381471],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023141077,0.001153772,0.33034444,0.00028147578,0.0003949044,0.00005099017,0.000720396,0.0000126222985,0.0029782841,0.0005769377,0.0015453794,0.6387997],"study_design_scores_gemma":[0.05768336,0.04591296,0.69345385,0.004718359,0.0010970264,0.000016490512,0.0042900164,0.00011865848,0.011611766,0.0016158009,0.17926797,0.00021376382],"about_ca_topic_score_codex":0.00003645284,"about_ca_topic_score_gemma":0.00022165377,"teacher_disagreement_score":0.6385859,"about_ca_system_score_codex":0.00007262157,"about_ca_system_score_gemma":0.0025680566,"threshold_uncertainty_score":0.79004675},"labels":[],"label_agreement":null},{"id":"W2768711338","doi":"10.1200/jco.2017.35.31_suppl.245","title":"Cannabis use in palliative care: The prevalence and clinical characteristics.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cannabis; Internal medicine; Palliative care; Medical cannabis; Psychiatry","score_opus":0.20037801512735687,"score_gpt":0.5321988482120822,"score_spread":0.3318208330847253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768711338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9217004,0.00056445884,0.0000052600462,0.075641535,0.001117753,0.00026338577,0.000009503424,0.0000024032963,0.00069531036],"genre_scores_gemma":[0.98513913,0.006713602,0.00018205312,0.0020339629,0.001531239,0.0000061291257,6.89297e-7,0.000012825573,0.004380364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962208,0.0006577922,0.0022101242,0.000232027,0.00040768072,0.0002715326],"domain_scores_gemma":[0.99544674,0.00084908365,0.0019154359,0.0004989074,0.0008385747,0.0004512822],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006015616,0.00011888351,0.0012089638,0.00006865342,0.00014444964,0.00007533545,0.00040695773,0.00037345424,0.00007338494],"category_scores_gemma":[0.032673515,0.00006677898,0.00037889974,0.00004849437,0.001234631,0.00017273311,0.00021327303,0.0020857495,0.000006445042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00182739,0.00041008124,0.8569336,0.00006920848,0.00008763566,0.00067239656,0.00016013459,9.172903e-8,0.0000057641937,0.00006347522,0.014524492,0.12524574],"study_design_scores_gemma":[0.003429139,0.0043861074,0.8010751,0.00011772994,0.00014256296,0.00006902147,0.000098108336,0.00002988937,0.0000033669196,0.000051154067,0.19054203,0.00005579447],"about_ca_topic_score_codex":0.00019826832,"about_ca_topic_score_gemma":0.0005919572,"teacher_disagreement_score":0.17601754,"about_ca_system_score_codex":0.00012659337,"about_ca_system_score_gemma":0.002193007,"threshold_uncertainty_score":0.9754747},"labels":[],"label_agreement":null},{"id":"W2768759003","doi":"10.1200/jco.2017.35.31_suppl.158","title":"Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intestinal and Peritoneal Adhesions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Gynecologic oncology; Ambulatory care; Nursing; Health care; Oncology","score_opus":0.14090982991499768,"score_gpt":0.4936917672381142,"score_spread":0.3527819373231165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768759003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795553,0.000054883312,0.00054240937,0.011685738,0.0017103881,0.00077172025,0.000007878409,0.00001970354,0.005651986],"genre_scores_gemma":[0.89975065,0.00037977684,0.09471709,0.0011477871,0.0013756591,0.0002080184,0.0000016103072,0.000016645685,0.0024027743],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796444,0.00004898097,0.0011927536,0.00021072464,0.00024847555,0.00033463785],"domain_scores_gemma":[0.99653393,0.00062108296,0.0016968615,0.00022755099,0.0005399649,0.00038063258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012520354,0.00013725366,0.0009702911,0.000049838418,0.00021707246,0.000021834292,0.00024021235,0.00022738757,0.00012732072],"category_scores_gemma":[0.0017078784,0.000077548655,0.00023740878,0.000037644488,0.00031536949,0.00011664846,0.000064478794,0.00055100315,0.000004870149],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01783327,0.002996116,0.022817185,0.00013065322,0.0004171402,0.00061380205,0.00004805014,0.000034937853,0.0006860486,0.0005027101,0.0008709495,0.9530491],"study_design_scores_gemma":[0.009694967,0.055986527,0.7260963,0.0002263647,0.0002895355,0.0007377385,0.0002301761,0.00014983823,0.00008065931,0.0006447192,0.20574863,0.00011457961],"about_ca_topic_score_codex":0.000012797793,"about_ca_topic_score_gemma":0.000045721717,"teacher_disagreement_score":0.95293456,"about_ca_system_score_codex":0.00022278672,"about_ca_system_score_gemma":0.0005170672,"threshold_uncertainty_score":0.31623423},"labels":[],"label_agreement":null},{"id":"W2768821712","doi":"10.1200/jco.2017.35.31_suppl.31","title":"Systematic review on shared decision making for patients with lung cancer: Effects on distress and health care utilization.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; CINAHL; Distress; Blinding; Randomized controlled trial; Health care; MEDLINE; Lung cancer; Systematic review; Quality of life (healthcare); Intensive care medicine; Family medicine; Psychological intervention; Psychiatry; Internal medicine; Clinical psychology; Nursing","score_opus":0.4083127134520907,"score_gpt":0.6297644001250763,"score_spread":0.2214516866729856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768821712","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27737856,0.48029435,0.0023816668,0.15161268,0.024387509,0.06059507,0.00088442554,0.00014350638,0.0023222202],"genre_scores_gemma":[0.9659551,0.014068387,0.0028689108,0.016120262,0.00038472653,0.0005198403,0.000025330848,0.000037064496,0.000020373152],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9930515,0.002460469,0.0034340462,0.00025911618,0.0004714263,0.00032338937],"domain_scores_gemma":[0.97137535,0.015831914,0.010009819,0.0008939783,0.0015677199,0.0003212079],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.002333122,0.00018121135,0.0019986522,0.00008811276,0.0013040642,0.00001886083,0.0006244336,0.00028524973,0.000016533426],"category_scores_gemma":[0.022936327,0.00011373734,0.00017134385,0.000058371254,0.000078823236,0.00017320507,0.00015434409,0.0010521829,0.000004033065],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033031527,0.0005391585,0.42606768,0.41737255,0.00023078136,0.000008732061,0.0020799474,0.000009377294,2.4871674e-8,0.00045510943,0.014759126,0.13517436],"study_design_scores_gemma":[0.007431249,0.009584745,0.38514575,0.59428936,0.00034431397,0.0000014714329,0.0004501761,0.00015407943,1.5598515e-7,0.00013558002,0.0023104611,0.00015262495],"about_ca_topic_score_codex":0.000034979388,"about_ca_topic_score_gemma":0.00029982597,"teacher_disagreement_score":0.6885765,"about_ca_system_score_codex":0.00077459746,"about_ca_system_score_gemma":0.001696287,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W2769029338","doi":"10.1200/jco.2017.35.31_suppl.251","title":"Biomarkers to evaluate distress in cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biopsychosocial model; Distress; Clinical psychology; Biomarker; Cancer; Anger; Population; Internal medicine; Anxiety; Oncology; Psychiatry","score_opus":0.13963359664303074,"score_gpt":0.5186643010705747,"score_spread":0.37903070442754394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769029338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97320724,0.0006302611,0.000004641407,0.021195922,0.0025111968,0.00020123846,0.000005737543,0.0000033174783,0.002240435],"genre_scores_gemma":[0.9938274,0.0018105273,0.0002451843,0.002096916,0.0014057284,0.000008717452,0.0000014246693,0.000015032252,0.000589045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972119,0.00033862446,0.00166981,0.00017210016,0.00035928338,0.0002483122],"domain_scores_gemma":[0.9964974,0.00081742724,0.0015508656,0.00034986198,0.00041200867,0.0003724323],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026039686,0.00011933476,0.0011941843,0.00014241062,0.00007093298,0.000020241747,0.00032681006,0.00023340537,0.00017848423],"category_scores_gemma":[0.008370996,0.000085169086,0.00037003667,0.000064383974,0.000248026,0.00012040733,0.00007147338,0.00054357544,0.00002168264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015601098,0.001167765,0.49198237,0.000020008843,0.00015861158,0.00028905194,0.00008662456,0.000007424744,0.000059836362,0.0000041003987,0.0123711005,0.47825202],"study_design_scores_gemma":[0.007909044,0.0051310537,0.77197534,0.00025085805,0.00013297514,0.000036047823,0.000040050014,0.00002469198,0.000047740465,0.000023507184,0.21435738,0.00007129968],"about_ca_topic_score_codex":0.00046310836,"about_ca_topic_score_gemma":0.000620654,"teacher_disagreement_score":0.4781807,"about_ca_system_score_codex":0.00026846243,"about_ca_system_score_gemma":0.0014190844,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2769065023","doi":"10.1200/jco.2013.31.15_suppl.e16025","title":"The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Quarter (Canadian coin); Cancer; Internal medicine","score_opus":0.10807726924368355,"score_gpt":0.4927880338695398,"score_spread":0.38471076462585624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769065023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90820664,0.008317431,0.0000042590373,0.07868533,0.0008652065,0.00057865225,0.00001586488,0.000004646855,0.0033219692],"genre_scores_gemma":[0.985791,0.011211445,0.0004590025,0.00018812851,0.0007577271,0.000028164968,0.0000017527684,0.000011866376,0.0015508652],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99740314,0.0003062125,0.001604197,0.00013023072,0.00033292023,0.00022332082],"domain_scores_gemma":[0.9954602,0.0019007782,0.0012220026,0.0001614548,0.00095412455,0.00030145288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001933529,0.000098208926,0.000875087,0.000070135306,0.000070921196,0.000015238865,0.00017366477,0.000099307195,0.0005048886],"category_scores_gemma":[0.0012548561,0.000048739363,0.00031428036,0.00007279471,0.0005333712,0.00010879896,0.000034020224,0.00057230465,0.000026460368],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025770355,0.0018452654,0.04719961,0.0003265872,0.009564557,0.00138867,0.0058782925,0.00041832682,0.0063919877,0.00465126,0.09436248,0.8022026],"study_design_scores_gemma":[0.06292736,0.07104011,0.44036856,0.0009740303,0.003554373,0.0008021151,0.05032577,0.0021119502,0.0031547993,0.022080634,0.34211084,0.00054944365],"about_ca_topic_score_codex":0.0013613974,"about_ca_topic_score_gemma":0.00028745923,"teacher_disagreement_score":0.80165315,"about_ca_system_score_codex":0.0006080089,"about_ca_system_score_gemma":0.0062503815,"threshold_uncertainty_score":0.9993833},"labels":[],"label_agreement":null},{"id":"W2769097388","doi":"10.1200/jco.2017.35.31_suppl.129","title":"Impact of palliative care (PC) consultation on quality of end-of-life (EOL) care in advanced cancer patients receiving care at a tertiary cancer center (TCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Palliative care; Cancer; Cancer registry; Quality of life (healthcare); Emergency department; Emergency medicine; Advance care planning; Medical record; Family medicine; Internal medicine; Nursing","score_opus":0.3064822259038969,"score_gpt":0.6097747862585198,"score_spread":0.3032925603546229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769097388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911441,0.005955684,0.0000041429275,0.0002883131,0.0008772202,0.00036241824,0.0004245525,0.0000027281378,0.00094080105],"genre_scores_gemma":[0.9929861,0.006075013,0.00044502402,0.00019198081,0.00022019613,0.00001146199,0.00003477111,0.000018746341,0.000016699989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952692,0.0005782374,0.0030948052,0.00024906878,0.00056277623,0.00024591628],"domain_scores_gemma":[0.9864858,0.0026051097,0.006819473,0.00032206255,0.0035275468,0.0002400576],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006254268,0.00021671134,0.0023270394,0.00016805096,0.000045589928,0.000002872357,0.0002655025,0.0003686212,0.00010030703],"category_scores_gemma":[0.0119310245,0.00015721015,0.0006819057,0.00009979776,0.00042440195,0.0001426622,0.00009475309,0.0006029913,7.757388e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011338658,0.00061516,0.897071,0.0006674054,0.00044678713,0.000016164337,0.01769896,0.00017614936,0.00048626366,0.0000030550023,0.000106792955,0.07137359],"study_design_scores_gemma":[0.017254164,0.007159408,0.96208346,0.0043189772,0.00019269875,3.53206e-7,0.005613578,0.0000072986722,0.0023774942,0.00000795858,0.000864571,0.00012005449],"about_ca_topic_score_codex":0.0028564683,"about_ca_topic_score_gemma":0.008914588,"teacher_disagreement_score":0.07125354,"about_ca_system_score_codex":0.0010655767,"about_ca_system_score_gemma":0.002413583,"threshold_uncertainty_score":0.9963919},"labels":[],"label_agreement":null},{"id":"W2769183355","doi":"10.1200/jco.2017.35.31_suppl.131","title":"The outcome of outpatient palliative care service at Yonsei Cancer Center, a tertiary cancer center in Korea.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Cancer; Nausea; Depression (economics); Outpatient clinic; Quality of life (healthcare); Constipation; Internal medicine; Lung cancer; Cancer pain; Distress; Anxiety; Physical therapy; Psychiatry; Nursing","score_opus":0.43869850761988954,"score_gpt":0.6047096673504976,"score_spread":0.16601115973060804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769183355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97330314,0.005299566,0.0000047054364,0.017324464,0.0022659309,0.00022341737,0.00007544881,0.0000025524505,0.0015007718],"genre_scores_gemma":[0.9815154,0.01397884,0.00027859627,0.0033220556,0.0005813155,0.000013899412,0.000004041363,0.000015503338,0.00029033775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644524,0.0003320307,0.0023844568,0.00017650172,0.00039463327,0.00026716825],"domain_scores_gemma":[0.9932918,0.0015722438,0.0034468933,0.00036741042,0.0011086527,0.00021299273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009822354,0.00016181567,0.0014549984,0.000071097245,0.000087140994,0.0000067928822,0.0004285589,0.00028461107,0.00007351274],"category_scores_gemma":[0.0025506793,0.000092410286,0.00045399863,0.00006158472,0.00032810422,0.00008738099,0.00020093127,0.00075758557,0.000004373707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003470107,0.00064949814,0.9645862,0.00014516222,0.00036448307,0.000118765376,0.0029861454,0.000010136492,0.000039401883,0.000008236361,0.0015348746,0.026087001],"study_design_scores_gemma":[0.0079034455,0.0016487604,0.8697778,0.0014815753,0.00019034947,0.000005577026,0.0011830764,0.000028738737,0.00028856398,0.000023217694,0.117391564,0.00007734357],"about_ca_topic_score_codex":0.0016634158,"about_ca_topic_score_gemma":0.017487938,"teacher_disagreement_score":0.11585669,"about_ca_system_score_codex":0.0004507332,"about_ca_system_score_gemma":0.0007730209,"threshold_uncertainty_score":0.9758679},"labels":[],"label_agreement":null},{"id":"W2769234704","doi":"10.1200/jco.2017.35.31_suppl.58","title":"Goals of care documentation in advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Referral; Palliative care; Documentation; Cancer; Guideline; Cohort; Retrospective cohort study; Advance care planning; Emergency medicine; Family medicine; Internal medicine; Nursing; Pathology","score_opus":0.14189237419110404,"score_gpt":0.4801129488918828,"score_spread":0.3382205747007787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769234704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9450395,0.0049220747,0.00010931804,0.0024381354,0.0026804302,0.00009448044,0.0000306846,0.0000015460089,0.04468384],"genre_scores_gemma":[0.99197084,0.0058669015,0.0010756097,0.00039356473,0.00046518844,0.0000036260356,6.13144e-7,0.000008921611,0.00021471767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968412,0.00003122431,0.0027862294,0.00014716938,0.000032285123,0.00016190126],"domain_scores_gemma":[0.9926132,0.0002635684,0.0066328477,0.00023249433,0.0001520029,0.00010588785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016970378,0.00008139736,0.0013322262,0.00012552923,0.000046100286,0.000022865937,0.00040157494,0.00022133268,0.00028316418],"category_scores_gemma":[0.0025536036,0.00008158079,0.00027693235,0.000034122822,0.00016009006,0.000686549,0.000048132075,0.0003405226,0.000023452254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006413977,0.00015245262,0.7660349,0.000026515705,0.000056907393,0.000016399828,0.0002987783,0.0002169974,0.000011675005,0.014997692,0.00055777846,0.21698847],"study_design_scores_gemma":[0.0038814228,0.0016424462,0.90857464,0.000063598774,0.00001162134,0.0000023087728,0.0001514578,0.000028573328,0.00007226258,0.015924074,0.06955279,0.00009482633],"about_ca_topic_score_codex":0.0004853305,"about_ca_topic_score_gemma":0.00078117265,"teacher_disagreement_score":0.21689366,"about_ca_system_score_codex":0.00022878048,"about_ca_system_score_gemma":0.0003905247,"threshold_uncertainty_score":0.3326768},"labels":[],"label_agreement":null},{"id":"W2769388341","doi":"10.1200/jco.2017.35.31_suppl.190","title":"Inclusion of spiritual pain in patient reported outcome assessments as part of an integrative medicine physician consultation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anxiety; Integrative medicine; Logistic regression; Depression (economics); Family medicine; Demographics; Distress; Alternative medicine; Psychiatry; Clinical psychology; Physical therapy; Internal medicine; Demography","score_opus":0.40825752666209003,"score_gpt":0.624680698937566,"score_spread":0.21642317227547592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769388341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907723,0.0002504524,0.00014876235,0.0033789624,0.0006478091,0.00018586361,0.0000051538,0.0000022052236,0.0046085017],"genre_scores_gemma":[0.99464375,0.00043965594,0.0031621524,0.0013768818,0.00031814913,0.0000018804166,0.000008514928,0.000007937618,0.000041064315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941597,0.0008028579,0.004207761,0.0001508821,0.0005532539,0.00012557377],"domain_scores_gemma":[0.98633814,0.003544111,0.008186241,0.00029775064,0.0014133194,0.00022046277],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055974373,0.00012991363,0.0021897927,0.00016099561,0.000045984754,0.0000018099653,0.00021232071,0.000239966,0.000052493222],"category_scores_gemma":[0.06364495,0.000080028476,0.00024012841,0.00009797067,0.0006727619,0.0001591737,0.00013616917,0.00058572675,6.917576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005921196,0.0035621002,0.6179714,0.000094079944,0.0005379685,0.00075592834,0.004329182,0.0000107693995,0.001849425,0.0002369534,0.0010151686,0.3637158],"study_design_scores_gemma":[0.02635725,0.11405519,0.7976603,0.005753359,0.00075395906,0.000046201963,0.013849804,0.00040123303,0.0036380906,0.003286583,0.034003448,0.0001945733],"about_ca_topic_score_codex":0.0003104366,"about_ca_topic_score_gemma":0.00015292417,"teacher_disagreement_score":0.36352122,"about_ca_system_score_codex":0.00008898185,"about_ca_system_score_gemma":0.0010783591,"threshold_uncertainty_score":0.94424236},"labels":[],"label_agreement":null},{"id":"W2769396756","doi":"10.1200/jco.2017.35.31_suppl.187","title":"Exploring the relationship of self-reported lack of appetite to patient characteristics and symptom burden.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Underweight; Appetite; Overweight; Body mass index; Anorexia; Palliative care; Internal medicine; Cancer; Weight loss; Outpatient clinic; Univariate analysis; Cachexia; Obesity; Physical therapy; Multivariate analysis","score_opus":0.5901428975989088,"score_gpt":0.5443888232280798,"score_spread":0.04575407437082901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769396756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972681,0.00005486885,0.000044246888,0.0253938,0.0008670556,0.00014506245,0.0000019422682,0.0000033402173,0.0008086776],"genre_scores_gemma":[0.99445224,0.00075615675,0.0031935733,0.00092124025,0.0006305823,0.0000024350256,5.2786226e-7,0.000006050812,0.00003718474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973789,0.0001568983,0.0020752628,0.00007616011,0.00021418632,0.00009858229],"domain_scores_gemma":[0.99421746,0.0019281771,0.002927711,0.00023605741,0.00046943055,0.00022115218],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002502993,0.00005485356,0.0007235553,0.00007525358,0.00008572034,0.000005912847,0.00009788107,0.000093923256,0.000015838092],"category_scores_gemma":[0.009184167,0.00003533358,0.000119500226,0.000039359795,0.00013869967,0.000071692106,0.00005391025,0.0005037183,0.0000026750506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010291329,0.0004459794,0.9445332,0.00019935546,0.00015569829,0.000086974906,0.00081115676,0.0000012113622,0.00017218868,0.0008140079,0.00047882466,0.051272262],"study_design_scores_gemma":[0.0017057298,0.0027208102,0.9640851,0.00057730137,0.00016050503,0.00012750251,0.00015448213,0.000028815086,0.00004811434,0.00022280973,0.030139226,0.000029630593],"about_ca_topic_score_codex":0.000009863409,"about_ca_topic_score_gemma":0.0000032439166,"teacher_disagreement_score":0.05124263,"about_ca_system_score_codex":0.000032962227,"about_ca_system_score_gemma":0.0003470287,"threshold_uncertainty_score":0.9991619},"labels":[],"label_agreement":null},{"id":"W2769508931","doi":"10.1200/jco.2017.35.31_suppl.13","title":"Code status communication training in Canadian postgraduate oncology programs: A needs assessment survey.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Cancer Care Ontario; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Curriculum; Oncology; Radiation oncology; Medical education; Inclusion (mineral); Internal medicine; Certification; Graduate medical education; Family medicine; Radiation therapy; Psychology; Accreditation","score_opus":0.2918630962709412,"score_gpt":0.6047032506901554,"score_spread":0.3128401544192142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769508931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9242753,0.0009758105,0.00022769345,0.043563206,0.0031410237,0.00051037106,0.000014918908,0.000012166816,0.027279513],"genre_scores_gemma":[0.96793354,0.0055180024,0.021905053,0.0036378286,0.00067755114,0.000011777107,0.000022791237,0.000023206583,0.00027025124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945609,0.0019694434,0.002383854,0.00018971338,0.00025029713,0.00064579234],"domain_scores_gemma":[0.9911569,0.0037814952,0.0029570027,0.000615755,0.00053610123,0.0009527709],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014374638,0.0001707701,0.0019091808,0.00035367158,0.00026789217,0.000025559646,0.0005988122,0.000816269,0.000080464095],"category_scores_gemma":[0.0075505837,0.00013318534,0.00027778934,0.000144065,0.0010460196,0.00024869127,0.00006380726,0.0024430836,0.0000067519677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013316756,0.000641534,0.5761045,0.000006566155,0.0001919517,0.0006661055,0.00092216465,0.000011182938,0.000009612453,0.00037932367,0.00051336683,0.419222],"study_design_scores_gemma":[0.0068839905,0.009394965,0.6177165,0.00008557392,0.00007474966,0.00041072365,0.0006909244,0.00019946427,0.0000011496843,0.0006566721,0.363797,0.00008830642],"about_ca_topic_score_codex":0.027661644,"about_ca_topic_score_gemma":0.5898472,"teacher_disagreement_score":0.5621856,"about_ca_system_score_codex":0.0018468809,"about_ca_system_score_gemma":0.022230854,"threshold_uncertainty_score":0.9998583},"labels":[],"label_agreement":null},{"id":"W2769528664","doi":"10.1200/jco.2017.35.31_suppl.64","title":"Disruption or innovation? A qualitative study on the use of electronic patient-physician communication in patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Interpersonal communication; Context (archaeology); Health care; Qualitative research; Nursing; Apprehension; Patient portal; Teamwork; Family medicine; Psychology; Social psychology","score_opus":0.6012500299030541,"score_gpt":0.6395559161615543,"score_spread":0.03830588625850018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769528664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98704696,0.000067525296,0.000015167715,0.010297771,0.00042693038,0.001893281,0.000018840696,0.0000062489567,0.00022726481],"genre_scores_gemma":[0.99678946,0.0001796991,0.00057488796,0.0021546236,0.000063057625,0.00017701562,0.000009354507,0.000019922132,0.000032001197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98620564,0.008957523,0.0038140176,0.00018209917,0.00052805484,0.0003126841],"domain_scores_gemma":[0.970054,0.013679688,0.012104277,0.0013231912,0.0027629286,0.00007596056],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030415696,0.00015575699,0.0009525008,0.00018296616,0.0007652629,0.0000114968425,0.0008802565,0.00022187165,0.000029965375],"category_scores_gemma":[0.011588345,0.00008520839,0.000086733475,0.00035519293,0.00032219358,0.0005863979,0.00018734377,0.0024381368,0.0000058493515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015803032,0.005150031,0.8398374,0.000043615146,0.0001772776,0.000002040908,0.073581316,0.00013831747,0.0000034129666,0.0041217003,0.000495931,0.060645938],"study_design_scores_gemma":[0.0071975538,0.02021839,0.90567195,0.00070247793,0.000050359497,1.3391505e-7,0.060006674,0.000054772274,0.0000024852393,0.00083713885,0.0051512606,0.00010681968],"about_ca_topic_score_codex":0.0005982311,"about_ca_topic_score_gemma":0.005215856,"teacher_disagreement_score":0.065834545,"about_ca_system_score_codex":0.00061283994,"about_ca_system_score_gemma":0.0030669505,"threshold_uncertainty_score":0.99986327},"labels":[],"label_agreement":null},{"id":"W2769593259","doi":"10.1200/jco.2017.35.31_suppl.199","title":"Palliative versus nonpalliative patients’ perceptions of the effect of alcohol consumption on clinical outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Centre for Addiction and Mental Health; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Cancer; Alcohol consumption; Breast cancer; Family medicine; Internal medicine; Alcohol; Nursing","score_opus":0.5058865391609768,"score_gpt":0.6307431093952721,"score_spread":0.1248565702342953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769593259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140686,0.00009815304,0.00003583048,0.0014367466,0.003320656,0.0003736185,0.000033464385,0.0000031918582,0.003291465],"genre_scores_gemma":[0.99646705,0.0018713099,0.0008226774,0.0003026978,0.0004123107,0.0000036698036,0.0000035132,0.00001299089,0.00010378923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944932,0.0012837657,0.003217904,0.00019866788,0.00062791625,0.00017853158],"domain_scores_gemma":[0.9735725,0.017228538,0.007328898,0.00055873534,0.0010921829,0.00021918098],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036814741,0.00018779688,0.002509271,0.00008826666,0.000084876665,0.00000427247,0.00045307758,0.00049379055,0.00012339259],"category_scores_gemma":[0.046732005,0.00010176175,0.001632077,0.00006083181,0.001374514,0.00009467317,0.00012429064,0.0011572891,0.000019601286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011929897,0.0012741238,0.96848524,0.00007508541,0.0011389375,0.000012484249,0.00026877425,0.0000063196057,0.000034737608,0.0000809352,0.0010111866,0.015682254],"study_design_scores_gemma":[0.024866445,0.03703121,0.93309116,0.0008347687,0.0009925509,9.856539e-7,0.00010833844,0.000014027042,0.00041552776,0.000053252625,0.0025182748,0.00007345915],"about_ca_topic_score_codex":0.000029560706,"about_ca_topic_score_gemma":0.0000407745,"teacher_disagreement_score":0.04305053,"about_ca_system_score_codex":0.00011923551,"about_ca_system_score_gemma":0.00047320826,"threshold_uncertainty_score":0.96129775},"labels":[],"label_agreement":null},{"id":"W2769625922","doi":"10.1200/jco.2017.35.31_suppl.51","title":"Assessing caregiver satisfaction with care on an acute palliative care unit.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Family medicine; Nursing; Unit (ring theory); Patient satisfaction; Residence; Psychology","score_opus":0.502628148384202,"score_gpt":0.6328072086944412,"score_spread":0.13017906031023918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769625922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98817813,0.00059262593,0.00016202878,0.0012074028,0.0009216763,0.000121798126,0.000009500978,0.000007959415,0.0087988805],"genre_scores_gemma":[0.9916989,0.0009980187,0.0056594294,0.00052559056,0.0010347399,0.0000015359797,0.000008543885,0.000018181914,0.000055053893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979091,0.00031669246,0.0009786022,0.00019467704,0.00042409098,0.00017679582],"domain_scores_gemma":[0.99416447,0.00093274255,0.0025251764,0.00036412725,0.0017090928,0.0003044001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053122407,0.00015679035,0.0012595884,0.0001013989,0.00015376847,0.000033444452,0.00019362276,0.00034338448,0.000034098037],"category_scores_gemma":[0.0016186936,0.00010079481,0.00027457438,0.000048581747,0.0003385707,0.00041368674,0.000034583172,0.0009261715,0.0000053396466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002418366,0.0001536782,0.8196955,0.000048332593,0.00048001585,0.00082299096,0.005376269,0.00001668153,0.00009073455,0.000055811815,0.00015797469,0.17068368],"study_design_scores_gemma":[0.0062865512,0.021100927,0.9308255,0.0011195822,0.00080317317,0.00003472483,0.023671811,0.00000872913,0.00048660696,0.00003799764,0.015513597,0.00011080399],"about_ca_topic_score_codex":0.00019499601,"about_ca_topic_score_gemma":0.0007480831,"teacher_disagreement_score":0.17057288,"about_ca_system_score_codex":0.00022435133,"about_ca_system_score_gemma":0.0013706199,"threshold_uncertainty_score":0.4110293},"labels":[],"label_agreement":null},{"id":"W2769886432","doi":"10.1200/jco.2017.35.31_suppl.174","title":"Optimizing dosing in navigation interventions across the cancer continuum: A planned secondary data analysis from the Patient Care Connect implementation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; CLARITY; Phone; Population; Repeated measures design; Quarter (Canadian coin); Cancer; Family medicine; Gerontology; Nursing; Environmental health; Statistics","score_opus":0.3894251434501564,"score_gpt":0.6049414153290976,"score_spread":0.21551627187894123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769886432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318803,0.0029974515,0.00042241265,0.011994676,0.0008131679,0.00019875249,0.00022124281,0.000002852235,0.00016144157],"genre_scores_gemma":[0.9957485,0.00029783777,0.0014037369,0.0018431018,0.0005971751,0.000006900322,0.00009193233,0.000005481823,0.00000533368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719393,0.0003981807,0.0017313301,0.00020630597,0.00028513247,0.000185139],"domain_scores_gemma":[0.9949346,0.0014383384,0.002546342,0.000634717,0.00035128742,0.00009469778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032826236,0.00008824476,0.0007322829,0.000035493635,0.0003412861,0.00009856581,0.0007091735,0.00011766426,0.000185938],"category_scores_gemma":[0.0015818047,0.000048247377,0.0004451378,0.00011921745,0.00019172908,0.0003397588,0.0003053467,0.00083328504,0.0000014669638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087822403,0.000065431785,0.6528476,0.000009510021,0.0010407646,0.00014088895,0.0036113146,0.00015733605,0.000015227466,0.0000057208035,0.0021406144,0.3390874],"study_design_scores_gemma":[0.003945789,0.0015238345,0.95012856,0.00046278263,0.0016447359,0.00002408298,0.033484947,0.00034640578,0.000042690288,0.000059077905,0.008272286,0.00006482042],"about_ca_topic_score_codex":0.00621819,"about_ca_topic_score_gemma":0.083086185,"teacher_disagreement_score":0.33902258,"about_ca_system_score_codex":0.00018190117,"about_ca_system_score_gemma":0.0007715504,"threshold_uncertainty_score":0.94000846},"labels":[],"label_agreement":null},{"id":"W2769895972","doi":"10.1200/jco.2017.74.0449","title":"Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children; Blood Cancer UK; CHILDREN with CANCER UK; Cancer Research UK; Jazz Pharmaceuticals","keywords":"Minimal residual disease; Medicine; Oncology; Hazard ratio; Internal medicine; Immunophenotyping; Cytogenetics; Acute lymphocytic leukemia; Fluorescence in situ hybridization; Population; Leukemia; Immunology; Confidence interval; Lymphoblastic Leukemia; Genetics; Chromosome; Biology; Gene; Flow cytometry","score_opus":0.0716205107658136,"score_gpt":0.43075535910889456,"score_spread":0.35913484834308096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769895972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902727,0.0005146712,0.00090902974,0.0049467823,0.0012959904,0.00033115546,0.000008029274,0.00001166187,0.0017099954],"genre_scores_gemma":[0.9899312,0.0030693472,0.0033875394,0.00031058383,0.0029017206,0.000009937715,0.000011263808,0.000029232404,0.00034912524],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99531806,0.00041736074,0.0027602813,0.00037212032,0.00074299076,0.00038918882],"domain_scores_gemma":[0.9929114,0.0023834242,0.0026369768,0.0006201896,0.0007260026,0.0007220033],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032633978,0.0002014469,0.0011423265,0.00038660096,0.00012366188,0.00008441301,0.00060400984,0.00044645602,0.000059016744],"category_scores_gemma":[0.012817138,0.00015456359,0.00035328337,0.00016167932,0.00041999586,0.00047699537,0.0001491639,0.0011111604,0.00008250266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11755557,0.0040185833,0.32938924,0.0004493733,0.00089122605,0.016993005,0.0009282694,0.00019728823,0.0066454904,0.0010920834,0.022837339,0.49900252],"study_design_scores_gemma":[0.0116037335,0.0048669865,0.9761269,0.00013614724,0.00050422,0.00024271436,0.00006459931,0.0042959633,0.00007743248,0.0007575913,0.0011817525,0.00014192334],"about_ca_topic_score_codex":0.000018195102,"about_ca_topic_score_gemma":0.000032189135,"teacher_disagreement_score":0.6467377,"about_ca_system_score_codex":0.0016515452,"about_ca_system_score_gemma":0.011145629,"threshold_uncertainty_score":0.9954983},"labels":[],"label_agreement":null},{"id":"W2769920812","doi":"10.1200/jco.2017.35.31_suppl.198","title":"Perceptions on the effect of physical activity on quality of life, overall survival, and fatigue in palliative cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Centre for Addiction and Mental Health; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Odds ratio; Survivorship curve; Confidence interval; Cross-sectional study; Cancer survivorship; Cancer; Physical therapy; Logistic regression; Internal medicine; Nursing","score_opus":0.23902219423485044,"score_gpt":0.5442012990429698,"score_spread":0.30517910480811933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769920812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932931,0.000022389504,0.000005744959,0.004125473,0.00060969556,0.0001907102,0.000021515687,0.0000011708669,0.0017301893],"genre_scores_gemma":[0.9991007,0.00023061295,0.0000042060774,0.00025949898,0.0003666261,0.0000057166744,5.546827e-7,0.0000061208966,0.000025961013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741906,0.0012241041,0.0007701083,0.000126005,0.00035596878,0.0001047535],"domain_scores_gemma":[0.98988813,0.0076886225,0.0018267744,0.00023952407,0.000227927,0.00012900917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024608334,0.000100763915,0.0013335509,0.000043305612,0.000045186367,0.0000044949165,0.00014160457,0.00016367038,0.000042786814],"category_scores_gemma":[0.007943366,0.0000543239,0.0003468081,0.000035382443,0.00036796863,0.000056569254,0.000045250148,0.0008111202,7.580846e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00998405,0.0015337843,0.95401263,0.00006752688,0.0001448103,0.0000035400128,0.00043378276,0.000011778363,0.00018985855,0.0002449398,0.00017159026,0.033201724],"study_design_scores_gemma":[0.005466833,0.017738188,0.97578907,0.00021258215,0.00008955242,1.6805035e-7,0.00008227311,0.00002896903,0.00025254115,0.00009024505,0.00020468238,0.00004489866],"about_ca_topic_score_codex":0.0013181309,"about_ca_topic_score_gemma":0.0025628796,"teacher_disagreement_score":0.033156823,"about_ca_system_score_codex":0.00009201165,"about_ca_system_score_gemma":0.00033162473,"threshold_uncertainty_score":0.9509525},"labels":[],"label_agreement":null},{"id":"W2769943794","doi":"10.1200/jco.2017.76.0645","title":"Reply to D.T.W. Jones et al","year":2017,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Humanities","score_opus":0.31410172871791164,"score_gpt":0.6230269659975991,"score_spread":0.30892523727968746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769943794","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013367714,0.000877831,0.000024198776,0.9707858,0.0055921385,0.00034565246,0.000012461072,0.0000127053145,0.021012438],"genre_scores_gemma":[0.00042175388,0.0028427055,0.0024249963,0.9556075,0.024020717,0.000010561294,0.0000062173717,0.000049803693,0.014615783],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941082,0.0008363473,0.0028564106,0.00039703783,0.0012935916,0.00050843356],"domain_scores_gemma":[0.9888683,0.005037038,0.0033275587,0.00080950797,0.0014276569,0.00052994175],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008088472,0.00026953197,0.0036742538,0.0002896489,0.00008669062,0.00003557649,0.00072417303,0.0010052469,0.00022436705],"category_scores_gemma":[0.04131779,0.00017493375,0.0011407564,0.00006909332,0.0004687654,0.00010631064,0.00037870256,0.009980374,0.00021212468],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019430659,0.00021837572,0.0027812668,0.000085247484,0.0011988238,0.023552623,0.000048136324,3.9712103e-7,0.000005783713,0.0000042964148,0.946318,0.023844017],"study_design_scores_gemma":[0.0034835362,0.015712913,0.017626079,0.0005700108,0.0004176051,0.0013263418,0.0000121270905,7.777892e-7,0.000004146448,0.00015934519,0.96054053,0.00014656373],"about_ca_topic_score_codex":0.000092261864,"about_ca_topic_score_gemma":0.000024650813,"teacher_disagreement_score":0.03322932,"about_ca_system_score_codex":0.00041262337,"about_ca_system_score_gemma":0.006194397,"threshold_uncertainty_score":0.99943954},"labels":[],"label_agreement":null},{"id":"W2769968157","doi":"10.1200/jco.2017.35.31_suppl.119","title":"Impact of pharmacy interventions on pain management in an oncology palliative medicine (PM) outpatient clinic.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical endpoint; Pharmacy; McNemar's test; Pharmacist; Regimen; Palliative care; Physical therapy; Psychological intervention; Quality of life (healthcare); Cancer pain; Internal medicine; Outpatient clinic; Performance status; Cancer; Clinical trial; Family medicine; Nursing","score_opus":0.48154132006747746,"score_gpt":0.6737666908397559,"score_spread":0.19222537077227847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769968157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678017,0.00035826347,0.000055095028,0.011958831,0.002380109,0.00059635146,0.000009760459,0.0000063639754,0.01683352],"genre_scores_gemma":[0.99341077,0.0021691278,0.00081690855,0.0017519337,0.001211815,0.00001892551,0.0000100419165,0.000017721046,0.0005927437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993805,0.0016707382,0.0036309205,0.00027318185,0.00032428544,0.00029590598],"domain_scores_gemma":[0.9910542,0.0028477055,0.0048138793,0.00039762497,0.00041655864,0.00047005466],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0080348225,0.0002129718,0.002261819,0.00037439202,0.00006895273,0.0000056629183,0.00040947617,0.00029367683,0.0020133317],"category_scores_gemma":[0.0026718567,0.00013865888,0.0011059928,0.00009474282,0.00057678536,0.00014627843,0.00010132926,0.0012329598,0.000022303027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023563549,0.018927593,0.5056474,0.00008071072,0.0015919895,0.0013872413,0.00040449033,0.000025285923,0.00004848475,0.00007751725,0.010952869,0.43729284],"study_design_scores_gemma":[0.03953963,0.19872682,0.736022,0.000454491,0.001058016,0.000026394222,0.00020142167,0.000151668,0.000012606199,0.00039991547,0.023315638,0.00009141554],"about_ca_topic_score_codex":0.00021240074,"about_ca_topic_score_gemma":0.00040851394,"teacher_disagreement_score":0.4372014,"about_ca_system_score_codex":0.000778975,"about_ca_system_score_gemma":0.0009442871,"threshold_uncertainty_score":0.998899},"labels":[],"label_agreement":null},{"id":"W2770030313","doi":"10.1200/jco.2017.35.31_suppl.98","title":"Nurses’ roles and responsibilities in the provision of early palliative care: A grounded theory study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palliative care; Grounded theory; Medicine; Nursing; Referral; Qualitative research; Family medicine","score_opus":0.3845659827669512,"score_gpt":0.6064325866725008,"score_spread":0.22186660390554958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770030313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925098,0.0022395502,0.000013662472,0.0018508919,0.00031392736,0.00031576413,0.0000028400286,0.0000016077125,0.0027519462],"genre_scores_gemma":[0.997874,0.0009466186,0.00059955596,0.00020371888,0.00025638976,0.0000032167516,3.0141106e-7,0.0000060152906,0.00011015665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653345,0.0014342546,0.001441291,0.00012875591,0.00034694286,0.0001152755],"domain_scores_gemma":[0.9894431,0.007779331,0.0018464891,0.00030681497,0.00054616045,0.00007805633],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005805656,0.000095279545,0.0011491476,0.00009526777,0.000052274198,0.000011042886,0.0002644144,0.00017738163,0.000008920865],"category_scores_gemma":[0.018444732,0.000050884883,0.00020505177,0.00004567248,0.00067939993,0.00011486595,0.0000634782,0.00058921543,6.7349384e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013455523,0.0011697258,0.87384945,0.00004923082,0.00019023514,0.00022162986,0.042283963,5.0773093e-7,0.00004798529,0.0010984137,0.00008899182,0.067544356],"study_design_scores_gemma":[0.005599286,0.022255572,0.90390396,0.00048171156,0.00020933288,0.000009058045,0.060686275,0.0000024941555,0.00006943323,0.0044074273,0.002332697,0.000042778745],"about_ca_topic_score_codex":0.00011175871,"about_ca_topic_score_gemma":0.00033485083,"teacher_disagreement_score":0.06750158,"about_ca_system_score_codex":0.000047106038,"about_ca_system_score_gemma":0.00065999234,"threshold_uncertainty_score":0.98982334},"labels":[],"label_agreement":null},{"id":"W2770051813","doi":"10.1200/jco.2017.35.31_suppl.96","title":"A grounded theory analysis of oncology nurses' perceptions of early palliative care in the context of ambulatory care.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nursing; Context (archaeology); Palliative care; Grounded theory; Ambulatory care; Safeguarding; Family medicine; Qualitative research; Health care","score_opus":0.31991146526037584,"score_gpt":0.5932461803210437,"score_spread":0.27333471506066787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770051813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810875,0.0024227002,0.00007952772,0.00080166856,0.0004779479,0.00020566181,0.00004287228,0.0000017175803,0.00785912],"genre_scores_gemma":[0.99670786,0.0018318787,0.0008124056,0.00036441203,0.00022309822,0.000003986493,0.000006638616,0.000009245928,0.000040502495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495685,0.0014657436,0.0027971426,0.00016616579,0.00043972267,0.00017434871],"domain_scores_gemma":[0.98569417,0.0066340584,0.00510583,0.0005028003,0.0019363988,0.00012675041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028557496,0.00014427895,0.0030045176,0.00038094504,0.000046946396,0.0000033483914,0.0005202136,0.00047253803,0.000107402295],"category_scores_gemma":[0.006813599,0.000091551614,0.0012487855,0.00024761193,0.0015152369,0.00009191004,0.0000635339,0.0008078565,0.0000015496042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050735287,0.0014445699,0.8695091,0.00011529408,0.002872394,0.00010118846,0.061635304,0.00001704214,0.0003500939,0.0015900865,0.00015306454,0.057138324],"study_design_scores_gemma":[0.0053415,0.013328955,0.86417896,0.0003826673,0.0036675248,0.0000044882963,0.10883552,0.000012313735,0.00015271622,0.00033740583,0.0036944894,0.000063457715],"about_ca_topic_score_codex":0.00050166674,"about_ca_topic_score_gemma":0.0021625008,"teacher_disagreement_score":0.057074867,"about_ca_system_score_codex":0.00020807213,"about_ca_system_score_gemma":0.001549011,"threshold_uncertainty_score":0.8157006},"labels":[],"label_agreement":null},{"id":"W2770089246","doi":"10.1200/jco.2017.35.31_suppl.46","title":"The PULSES project: Teaching the vital elements of code status discussions to oncology residents.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Ottawa Hospital; Pediatric Oncology Group; Cancer Care Ontario; McMaster University","funders":"","keywords":"Medicine; Radiation oncology; Randomization; Internal medicine; Randomized controlled trial; Medical physics; Oncology; Medical education; Radiation therapy","score_opus":0.14090959036623843,"score_gpt":0.6039841301371643,"score_spread":0.46307453977092594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770089246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7425357,0.0014946894,0.0013987974,0.20946535,0.011338098,0.0012424415,0.000028246923,0.000015282649,0.03248139],"genre_scores_gemma":[0.9678261,0.0050665047,0.014367951,0.005771496,0.00348482,0.00001945815,0.0000016149133,0.000027480477,0.0034345677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99520046,0.0012491373,0.002517393,0.00019652344,0.00042015783,0.00041634406],"domain_scores_gemma":[0.9868337,0.008101131,0.003781861,0.0006574797,0.00033121402,0.00029464602],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008518427,0.00014989953,0.001267927,0.00008001977,0.0009293308,0.000021425305,0.0008833233,0.00037571014,0.000049797272],"category_scores_gemma":[0.02645496,0.000060980372,0.00043301517,0.00005540995,0.0013309716,0.00016450572,0.00022829817,0.0020042611,0.000008470164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009620766,0.0019047754,0.16279821,0.000013831599,0.00080180384,0.00037553225,0.0009341723,0.000013650102,0.00055366533,0.001684328,0.04984957,0.7714497],"study_design_scores_gemma":[0.004288909,0.014213521,0.2529703,0.000086413136,0.00022241802,0.0002854393,0.0010241981,0.000016838272,0.00004530005,0.0012389616,0.72554237,0.00006533561],"about_ca_topic_score_codex":0.00005221662,"about_ca_topic_score_gemma":0.0004971073,"teacher_disagreement_score":0.77138436,"about_ca_system_score_codex":0.00028218483,"about_ca_system_score_gemma":0.0025813852,"threshold_uncertainty_score":0.9817456},"labels":[],"label_agreement":null},{"id":"W2770135123","doi":"10.1200/jco.2012.30.15_suppl.4033","title":"Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Liver transplantation; Internal medicine; Population; Observational study; Cohort; Transplantation; Environmental health","score_opus":0.25618604423914315,"score_gpt":0.3892848097175901,"score_spread":0.13309876547844696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770135123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430966,0.00016012907,0.00010807784,0.002799774,0.0010518491,0.0014468657,0.00005504641,0.000005594024,0.00006298757],"genre_scores_gemma":[0.9986445,0.00006400253,0.00016249978,0.00029237932,0.00073039654,0.000020583317,0.000037839232,0.0000140020975,0.000033806216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957987,0.000918882,0.0023194298,0.00016449226,0.00059656595,0.00020189631],"domain_scores_gemma":[0.99623924,0.00066448346,0.0021289685,0.00047110554,0.00033227017,0.00016391238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021981427,0.00016608958,0.0010897359,0.0000467477,0.00009917417,0.000008594858,0.0003221739,0.0001556548,0.00008302595],"category_scores_gemma":[0.00038699197,0.00009163947,0.0005060202,0.00025992905,0.00007806623,0.0001412937,0.000155088,0.000334149,0.000004300916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006441609,0.007884,0.9855878,0.000028263328,0.00091266254,0.0000683724,0.0007782581,9.823782e-7,0.00006427104,0.00004823565,0.00008493995,0.0038980758],"study_design_scores_gemma":[0.0046283463,0.004284334,0.9866841,0.000070331436,0.0023103575,0.000016509259,0.0005810299,0.00015800919,0.00003439666,0.000033144395,0.0011289053,0.0000705238],"about_ca_topic_score_codex":0.0006298497,"about_ca_topic_score_gemma":0.00024081924,"teacher_disagreement_score":0.004334815,"about_ca_system_score_codex":0.00015346354,"about_ca_system_score_gemma":0.00016404738,"threshold_uncertainty_score":0.37369493},"labels":[],"label_agreement":null},{"id":"W2770163744","doi":"10.1200/jco.2017.35.31_suppl.228","title":"Frequency and factors predicting the risk for aberrant opioid use in patients receiving outpatient palliative care at a comprehensive cancer center.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anxiety; Odds ratio; Palliative care; Multivariate analysis; Internal medicine; Cancer pain; Opioid; Cancer; Depression (economics); Distress; Physical therapy; Psychiatry; Nursing","score_opus":0.1651606116451845,"score_gpt":0.4496656648360107,"score_spread":0.2845050531908262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770163744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427444,0.0007720982,0.000012636128,0.00074838416,0.003415286,0.0005305377,0.00011963625,0.0000034221014,0.00012356312],"genre_scores_gemma":[0.99698526,0.001845048,0.00016397463,0.00048597265,0.0004536906,0.000015445743,0.0000075869166,0.000014847722,0.00002818529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977476,0.00030861163,0.0012516484,0.00020264756,0.0002644849,0.00022498236],"domain_scores_gemma":[0.9934955,0.0027322362,0.0024960027,0.0002347422,0.00083952706,0.00020196951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000618355,0.00014224701,0.00091852853,0.000049441252,0.00025003482,0.000026902253,0.00017573361,0.00023719706,0.000013475055],"category_scores_gemma":[0.0050727483,0.000082981416,0.00030338552,0.00002949061,0.00021528339,0.00014445206,0.000117558804,0.00082807435,3.4466467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017688207,0.00021928281,0.9620007,0.000059707338,0.00017283586,0.0000141254795,0.008215677,0.000006503996,0.0000039367,0.0000025136724,0.00020573928,0.027330123],"study_design_scores_gemma":[0.008040828,0.0042252513,0.97859603,0.0004211446,0.00023466337,0.0000020428554,0.0026251134,0.000049781014,0.000012522427,0.000037727103,0.005676428,0.00007844983],"about_ca_topic_score_codex":0.0023276873,"about_ca_topic_score_gemma":0.026356671,"teacher_disagreement_score":0.027251672,"about_ca_system_score_codex":0.00046129283,"about_ca_system_score_gemma":0.00039450315,"threshold_uncertainty_score":0.9914098},"labels":[],"label_agreement":null},{"id":"W2770420991","doi":"10.1200/jco.2017.35.31_suppl.128","title":"Palliative Care Early and Systematic (PaCES): A survey of colorectal cancer clinicians of barriers and facilitators to early palliative care integration.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palliative care; Nursing; Documentation; Family medicine; Colorectal cancer; Health care; Cancer; Internal medicine","score_opus":0.28936710987823616,"score_gpt":0.5533528634652827,"score_spread":0.2639857535870465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770420991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905677,0.007078728,0.00010792228,0.0004865344,0.0005766811,0.0005929882,0.0002963652,0.0000033991387,0.0002897212],"genre_scores_gemma":[0.99531615,0.0027214882,0.001668144,0.00012092353,0.000109353205,0.00001364148,0.0000039821375,0.000014958809,0.000031357253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546033,0.0009091835,0.002733858,0.00025278027,0.00044257176,0.00020130056],"domain_scores_gemma":[0.98652726,0.0051803687,0.0041480046,0.00024769106,0.003415012,0.00048164165],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022039132,0.000213407,0.003047681,0.00016690411,0.00007948404,0.000014228455,0.00024635033,0.00039724124,0.000016491],"category_scores_gemma":[0.03159915,0.00014898463,0.00032294297,0.00012874162,0.00081202725,0.00014217672,0.00009374705,0.0005851654,0.000001035998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031403864,0.00007938432,0.9547665,0.0021989238,0.00077552407,0.000034991357,0.03471666,0.0000045781117,0.00012738838,0.000032429154,0.00008860754,0.0040346035],"study_design_scores_gemma":[0.003672083,0.013527108,0.94517154,0.008220047,0.00060587545,0.0000018260531,0.027921725,0.000018066203,0.0005728071,0.000030061754,0.00014177152,0.00011707536],"about_ca_topic_score_codex":0.0033785172,"about_ca_topic_score_gemma":0.0065473393,"teacher_disagreement_score":0.029395236,"about_ca_system_score_codex":0.00015776775,"about_ca_system_score_gemma":0.0013673804,"threshold_uncertainty_score":0.9765581},"labels":[],"label_agreement":null},{"id":"W2770476674","doi":"10.1200/jco.2017.35.31_suppl.45","title":"Does prognostic uncertainty affect discussions of prognosis? Lessons from a survey of hematologic oncologists.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Affect (linguistics); Disease; Hematology; Family medicine; Oncology; Intensive care medicine","score_opus":0.2810114007651867,"score_gpt":0.46431436927837255,"score_spread":0.18330296851318584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770476674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834516,0.00088375394,0.00039157862,0.007007622,0.0029708561,0.00027131423,0.0004956824,0.000005856853,0.0045217066],"genre_scores_gemma":[0.99653023,0.0013863771,0.0014097912,0.00017366114,0.00035075637,0.000009286509,0.0000066790044,0.000016534666,0.000116700496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457407,0.00029187187,0.00441666,0.00033131812,0.00007498728,0.00031111302],"domain_scores_gemma":[0.98064595,0.004525901,0.013657069,0.00054146216,0.0003791757,0.00025046614],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0069683124,0.00019344979,0.0032435635,0.00014325985,0.00012284915,0.000033925025,0.0010099116,0.0005795291,0.0002269294],"category_scores_gemma":[0.03884126,0.00011687246,0.000689625,0.00008063571,0.0009880002,0.00035820948,0.00020646484,0.0006598162,0.000024600266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000709505,0.0012570749,0.9669599,0.000032007527,0.00030406864,0.000027092296,0.000081323495,0.00004083577,0.000008901417,0.008576522,0.0013253696,0.020677386],"study_design_scores_gemma":[0.0022180248,0.0027913235,0.9578663,0.00011795237,0.00006883369,0.000005077133,0.00004541316,0.00012123552,0.000052363976,0.03051868,0.0060372017,0.00015759865],"about_ca_topic_score_codex":0.0030261364,"about_ca_topic_score_gemma":0.0032932155,"teacher_disagreement_score":0.031872947,"about_ca_system_score_codex":0.0001325202,"about_ca_system_score_gemma":0.00077831745,"threshold_uncertainty_score":0.969255},"labels":[],"label_agreement":null},{"id":"W2770649609","doi":"10.1200/jco.2017.35.31_suppl.83","title":"Quality matters: Patterns of palliative interventions in metastatic colorectal cancer (mCRC) patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Psychological intervention; Referral; Palliative care; Quality of life (healthcare); Colorectal cancer; Radiation therapy; Chemotherapy; Cancer; End-of-life care; Disease; Internal medicine; Surgery; General surgery; Family medicine; Nursing","score_opus":0.5858100044279748,"score_gpt":0.6485019035728747,"score_spread":0.06269189914489992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770649609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333894,0.00044454527,0.0002322164,0.0042771264,0.0009254014,0.00016623647,0.0000638312,0.0000018836992,0.0005497872],"genre_scores_gemma":[0.99594647,0.0013168873,0.0018263654,0.00063333585,0.00018193788,0.0000063019615,0.0000049879413,0.000008733686,0.00007499118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580157,0.0005476462,0.0030468993,0.00013209126,0.0003160614,0.00015572106],"domain_scores_gemma":[0.9916422,0.002201347,0.0050420724,0.00019034617,0.0007678153,0.00015621383],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023116332,0.0001101398,0.0017939254,0.00012568133,0.000026510817,0.0000052487076,0.00024955798,0.00014721959,0.0002524091],"category_scores_gemma":[0.008514011,0.00007986553,0.0007509014,0.000050486342,0.0002815811,0.0001372033,0.00008140279,0.00055592594,0.0000035541823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017068539,0.0020559172,0.9601993,0.0002471245,0.0005508002,0.0000638756,0.0006868255,0.0000039841734,0.00006267238,0.00006165579,0.0005086903,0.033852294],"study_design_scores_gemma":[0.0076137953,0.0055262824,0.9793412,0.00210939,0.00029959294,0.0000018314773,0.00057782367,0.000010286781,0.00037088507,0.00026898496,0.0038145576,0.000065358734],"about_ca_topic_score_codex":0.00073998934,"about_ca_topic_score_gemma":0.0017863708,"teacher_disagreement_score":0.033786934,"about_ca_system_score_codex":0.00014238358,"about_ca_system_score_gemma":0.00051058637,"threshold_uncertainty_score":0.9998377},"labels":[],"label_agreement":null},{"id":"W2770915291","doi":"10.1200/jco.2017.35.31_suppl.124","title":"The influence of a cachexia clinic on palliative care integration in oncology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cachexia; Weight loss; Palliative care; Anorexia; Referral; Cancer; Outpatient clinic; Specialty; Internal medicine; Physical therapy; Obesity; Family medicine","score_opus":0.344118150303101,"score_gpt":0.619147334872171,"score_spread":0.27502918456907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770915291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516472,0.00031427314,0.000011407088,0.03827309,0.0009749798,0.00021424137,0.0000015663062,0.0000027829867,0.008560463],"genre_scores_gemma":[0.9915,0.0029254244,0.0012421905,0.0036693865,0.00052411336,0.000004754597,7.16146e-7,0.0000062122563,0.00012719542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964178,0.0005396455,0.002503946,0.000119146316,0.00025192555,0.0001675057],"domain_scores_gemma":[0.99032813,0.004740669,0.0036703371,0.00028216877,0.0007875314,0.00019114155],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004921437,0.0000826842,0.0010226786,0.000095841,0.00014110129,0.000009006853,0.00027203796,0.00037054272,0.000027543128],"category_scores_gemma":[0.017549045,0.000048167578,0.00024837148,0.000053885007,0.00045944392,0.00008130043,0.00004039327,0.0017068422,0.000017047538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01012335,0.0013854722,0.54827714,0.00008458615,0.00008375942,0.00033549822,0.0012555133,0.000019436404,0.00013885225,0.001018344,0.002209265,0.4350688],"study_design_scores_gemma":[0.0067214887,0.0128854625,0.93046796,0.00067284296,0.000056289573,0.000019920022,0.0010743517,0.000029179222,0.000062779756,0.0011241755,0.04684594,0.000039588398],"about_ca_topic_score_codex":0.000039130948,"about_ca_topic_score_gemma":0.00048936496,"teacher_disagreement_score":0.43502918,"about_ca_system_score_codex":0.00030296727,"about_ca_system_score_gemma":0.0019494176,"threshold_uncertainty_score":0.99072653},"labels":[],"label_agreement":null},{"id":"W2770986068","doi":"10.1200/jco.2017.35.31_suppl.35","title":"Anxiety in breast cancer patients treated with neoadjuvant therapy: Effects on surgical plan and role of supportive care.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wilfrid Laurier University; BC Cancer Agency; University of Waterloo","funders":"","keywords":"Medicine; Anxiety; Breast cancer; Psychosocial; Mastectomy; Cancer; Surgery; Internal medicine; Psychiatry","score_opus":0.18131796761902239,"score_gpt":0.517994376169647,"score_spread":0.33667640855062464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770986068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243486,0.0009582342,1.3873604e-7,0.0039971243,0.00050812174,0.00063718995,0.000050993713,0.0000055470464,0.0014078127],"genre_scores_gemma":[0.9960236,0.002910313,0.000093233626,0.0006453292,0.00024688948,0.000042116662,0.0000065436743,0.000017028911,0.00001494691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99465233,0.002435127,0.0020954679,0.00020648573,0.0003084333,0.00030217314],"domain_scores_gemma":[0.9896526,0.0042625186,0.004402546,0.0004701819,0.00090780226,0.00030439824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097482116,0.00014935379,0.0011990297,0.000104513965,0.00027418707,0.000004841939,0.00040259198,0.0004717321,0.000045516135],"category_scores_gemma":[0.00091571495,0.00009371825,0.00011474732,0.000060269496,0.00025828934,0.00014677957,0.00013024142,0.0016362416,0.0000033506178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007717249,0.00053754007,0.86295027,0.00007175263,0.000060225626,0.00003014685,0.0023829523,0.0000021289309,0.000005915822,0.000029108329,0.00014493683,0.1260678],"study_design_scores_gemma":[0.01384241,0.007122066,0.9711086,0.00076494855,0.000030492114,0.0000078939975,0.0014973914,0.000017456674,0.00002901172,0.00006267795,0.0054313624,0.000085700165],"about_ca_topic_score_codex":0.001368102,"about_ca_topic_score_gemma":0.0009790517,"teacher_disagreement_score":0.1259821,"about_ca_system_score_codex":0.00025367874,"about_ca_system_score_gemma":0.0015965847,"threshold_uncertainty_score":0.7108747},"labels":[],"label_agreement":null},{"id":"W2771121563","doi":"10.1200/jco.2015.33.15_suppl.e17681","title":"Palliative chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC): Investigating disparities between patients who are treated versus those who are not.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Palliative care; Performance status; Thrombocytosis; Anemia; Proportional hazards model; Chemotherapy; Multivariate analysis; Gastroenterology; Cancer; Exact test; Demographics","score_opus":0.1220872587877821,"score_gpt":0.46518319629160665,"score_spread":0.34309593750382456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771121563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98330253,0.0011246366,0.0011390491,0.011807498,0.0015127636,0.0005303183,0.000028471555,0.000018565626,0.00053615967],"genre_scores_gemma":[0.97785896,0.001615852,0.011007131,0.0059744576,0.0028482175,0.000032693588,0.000021251475,0.00007284043,0.0005685908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965771,0.00031685666,0.0019133999,0.00031289074,0.00045519034,0.00042455315],"domain_scores_gemma":[0.99115056,0.0034810505,0.0032428126,0.00018803743,0.0010183977,0.0009191366],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002044803,0.00026504227,0.002219206,0.0001123231,0.00009484863,0.000024389,0.00026057696,0.0002762554,0.00001685803],"category_scores_gemma":[0.00985408,0.00019697416,0.0004437272,0.00015012703,0.00028211967,0.00014192387,0.000058921305,0.0015739035,0.0000018241161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032923468,0.00043178114,0.9013681,0.00015738666,0.00038897558,0.00005489483,0.00041510482,0.00019289635,0.00002612142,0.0000069017347,0.01022571,0.083439775],"study_design_scores_gemma":[0.068105474,0.008217342,0.88628066,0.0031628269,0.00094575726,0.0000042294137,0.00062715274,0.008534445,0.00039447134,0.00015535082,0.023240136,0.00033215797],"about_ca_topic_score_codex":0.00009063855,"about_ca_topic_score_gemma":0.00003474515,"teacher_disagreement_score":0.08310761,"about_ca_system_score_codex":0.00039456514,"about_ca_system_score_gemma":0.001241443,"threshold_uncertainty_score":0.99848634},"labels":[],"label_agreement":null},{"id":"W2771820077","doi":"10.1200/jco.2017.35.15_suppl.e18080","title":"Delivering global cancer care: An international study of medical oncology workload.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"","keywords":"Medicine; Workload; Context (archaeology); Snowball sampling; Global health; Family medicine; Internal medicine; Nursing; Public health; Pathology","score_opus":0.16962389008157686,"score_gpt":0.6435051232653975,"score_spread":0.4738812331838207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771820077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685946,0.001426843,0.00040534965,0.010565764,0.011585035,0.0001996125,0.00000466837,0.000008402559,0.007209711],"genre_scores_gemma":[0.9793844,0.008086854,0.0044842046,0.0021168324,0.005863501,0.0000058749224,8.8087893e-7,0.00001183798,0.00004560268],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99602664,0.0004977499,0.002197516,0.0002425976,0.0008145229,0.00022099892],"domain_scores_gemma":[0.9941214,0.001030833,0.0031525095,0.00041491372,0.0007735939,0.0005067667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032433972,0.00014254848,0.0016843749,0.00007083099,0.00013339303,0.000009765074,0.0011044015,0.0008536786,0.0006636652],"category_scores_gemma":[0.0047542294,0.00010184534,0.00030892759,0.000051289295,0.0007835495,0.0002804485,0.00017769201,0.0013253079,0.000003821841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004555562,0.0036323196,0.46750087,0.00000818914,0.00061621965,0.0015746031,0.0004263059,0.00004166957,0.000008411863,0.00009801031,0.0002661773,0.52127165],"study_design_scores_gemma":[0.022019537,0.03920045,0.77742004,0.00016827219,0.00039163575,0.00091949914,0.0015172511,0.00017700913,0.000008914985,0.00019708778,0.15787137,0.000108929686],"about_ca_topic_score_codex":0.000275093,"about_ca_topic_score_gemma":0.0019922229,"teacher_disagreement_score":0.52116275,"about_ca_system_score_codex":0.0006610613,"about_ca_system_score_gemma":0.003848162,"threshold_uncertainty_score":0.72666687},"labels":[],"label_agreement":null},{"id":"W2772134916","doi":"10.1200/jco.2013.31.15_suppl.4582","title":"Overcoming sunitinib-induced resistance by dose escalation in renal cell carcinoma: Evidence in animal models and patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Internal medicine; Sorafenib; Oncology; Urology; Hepatocellular carcinoma","score_opus":0.17478842733452415,"score_gpt":0.4054529330704463,"score_spread":0.23066450573592212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772134916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448377,0.001115988,0.000015124226,0.002101205,0.00013924771,0.00039729688,0.0000012331793,0.0000033013118,0.0017428271],"genre_scores_gemma":[0.99737245,0.00026061398,0.0016628477,0.00041358641,0.0001480741,0.000009616801,0.0000026076832,0.000015006821,0.00011517202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629974,0.0005748093,0.0022259303,0.00025527427,0.00037384647,0.00027038506],"domain_scores_gemma":[0.9958618,0.0022552875,0.0010751778,0.00015965597,0.0003337699,0.0003143012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018692232,0.00015948853,0.00105913,0.00019901717,0.000022507606,0.000014004391,0.000106934196,0.00032974695,0.000038532933],"category_scores_gemma":[0.0014527108,0.00012364228,0.0001520433,0.00017234623,0.00009106797,0.0004904413,0.00005524616,0.0009391367,0.0000060331345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060037985,0.0022343136,0.96431243,0.00007647267,0.000025812571,0.0005605254,0.00033742044,0.000025586167,0.010374874,0.000028378097,0.0015009844,0.014519419],"study_design_scores_gemma":[0.010277558,0.0076586483,0.97922903,0.0002816655,0.000072897434,0.000029619961,0.00008465366,0.0007105377,0.0010074838,0.00036165505,0.00018226191,0.0001039605],"about_ca_topic_score_codex":0.00024336558,"about_ca_topic_score_gemma":0.00018099806,"teacher_disagreement_score":0.014916643,"about_ca_system_score_codex":0.0004316588,"about_ca_system_score_gemma":0.00053644186,"threshold_uncertainty_score":0.5041986},"labels":[],"label_agreement":null},{"id":"W2773362283","doi":"10.1200/jco.2014.32.15_suppl.e20675","title":"Meditation effects on physical, psychological, and symptom distress in an outpatient integrative medicine clinic.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meditation; Medicine; Anxiety; Distress; Outpatient clinic; Physical therapy; Nausea; Clinical psychology; Psychiatry; Internal medicine","score_opus":0.1764662415932627,"score_gpt":0.568991099326092,"score_spread":0.3925248577328293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773362283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640066,0.00010759537,0.00015778857,0.008582387,0.0017058103,0.00025588926,0.0000013317133,0.0000071158165,0.0027814014],"genre_scores_gemma":[0.9921393,0.0003617934,0.00037553912,0.0030729014,0.00397744,0.000007820351,0.00000981471,0.000008458901,0.00004692402],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963255,0.0011747547,0.0016532941,0.00027570408,0.00039348722,0.00017728962],"domain_scores_gemma":[0.987396,0.010763326,0.0010844233,0.00015260189,0.00028279424,0.00032083102],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027614569,0.00018784392,0.0017826228,0.0001577929,0.000041080577,0.0000035568653,0.00012669787,0.00007732271,0.000055447643],"category_scores_gemma":[0.010882104,0.00009528894,0.00015676513,0.00011870872,0.0005749302,0.00009119722,0.00004276141,0.0010882827,0.0000066247353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004375157,0.0046381857,0.23979753,0.000053785458,0.00018290833,0.00021862575,0.0022759698,0.0000018705523,0.00013406383,0.000583609,0.0024044935,0.7453338],"study_design_scores_gemma":[0.013494669,0.21623382,0.75741357,0.0008532311,0.00021585559,0.000029924957,0.0015384374,0.00019486071,0.000028122891,0.002650734,0.0072543593,0.00009243242],"about_ca_topic_score_codex":0.000010083524,"about_ca_topic_score_gemma":0.0000523427,"teacher_disagreement_score":0.74524134,"about_ca_system_score_codex":0.00006348407,"about_ca_system_score_gemma":0.000048793536,"threshold_uncertainty_score":0.99744964},"labels":[],"label_agreement":null},{"id":"W2774213581","doi":"10.1200/jco.2017.74.1173","title":"Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Medical School, University of Michigan; Feinberg School of Medicine; School of Medicine; University of California, San Francisco; Brown University; Tulane University; Astellas Pharma; Erasmus Medisch Centrum; University of Oxford; Harvard T.H. Chan School of Public Health; National Institute for Health and Care Research; Perelman School of Medicine, University of Pennsylvania; Vanderbilt University Medical Center; Cedars-Sinai Medical Center; Janssen Pharmaceuticals; Prostate Cancer Foundation; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; University of Washington; Vanderbilt University; University of Chicago; University of Texas MD Anderson Cancer Center; Pfizer; Northwestern University; Ohio State University; University of California, San Diego; Yale University; University of Toronto; Cleveland Clinic; University of Pennsylvania","keywords":"Genetic testing; Medicine; Genetic counseling; Prostate cancer; Consensus conference; Family medicine; Oncology; Cancer; Internal medicine; Genetics; Biology","score_opus":0.5101277397551851,"score_gpt":0.5943517696159184,"score_spread":0.0842240298607333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774213581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005723097,0.98690593,0.000002370181,0.0018748852,0.0012993076,0.0030216444,0.0007977961,0.000012989835,0.00036197036],"genre_scores_gemma":[0.0018638602,0.9913692,0.0027954543,0.00007207459,0.0019160194,0.00036704782,0.000028129967,0.00008628725,0.0015019522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924309,0.0007711556,0.005011014,0.00054047373,0.00057456084,0.0006718789],"domain_scores_gemma":[0.97850066,0.0037412113,0.013270283,0.00055577554,0.0032891124,0.0006429567],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033191056,0.0005211265,0.007309768,0.00030359442,0.00018276954,0.000038627968,0.00057211885,0.0010152232,0.000081414066],"category_scores_gemma":[0.00820917,0.00032607326,0.0014356471,0.00020741344,0.0010444071,0.00007254277,0.00015904855,0.0023996087,0.000006486339],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030829946,0.0005968796,0.016242785,0.0073993676,0.0023374858,0.00038716092,0.00013623404,0.000004390141,0.0000125624465,0.0000033768997,0.0026225739,0.9671742],"study_design_scores_gemma":[0.009009976,0.011167677,0.013285039,0.022898039,0.0068327473,0.00036892676,0.000046179957,0.00010204142,0.000005670907,0.00031585456,0.9356735,0.0002943857],"about_ca_topic_score_codex":0.00041928684,"about_ca_topic_score_gemma":0.00023831929,"teacher_disagreement_score":0.9668798,"about_ca_system_score_codex":0.0004792107,"about_ca_system_score_gemma":0.027291702,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W2774279352","doi":"10.1200/jco.2017.74.2577","title":"Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Population; Gene; Oncology; Genetics; Internal medicine; Environmental health; Biology","score_opus":0.14473287420469114,"score_gpt":0.4994094212382582,"score_spread":0.3546765470335671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774279352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98879325,0.00020832881,0.0030786798,0.006039604,0.0014505824,0.00032634576,0.000006804674,0.0000013678118,0.00009505533],"genre_scores_gemma":[0.99480003,0.00001332735,0.0028413418,0.0012970315,0.0010051355,0.0000049937325,0.00000179108,0.000011731436,0.000024597008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703217,0.0010280038,0.0014144521,0.00015076436,0.00023299623,0.00014161548],"domain_scores_gemma":[0.99560887,0.0005786951,0.0026594293,0.00063978904,0.0004035935,0.0001096276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00646373,0.000089516674,0.00052361615,0.000031504405,0.00026338606,0.000021558817,0.0006527291,0.00011926624,0.0000044725257],"category_scores_gemma":[0.0030129142,0.000049535007,0.00020930717,0.00004506783,0.00010569205,0.000004338524,0.00012430752,0.00024308993,0.000001000408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023899546,0.0016878251,0.83283645,0.00003530075,0.0007361472,0.000041069117,0.00029774688,0.012426288,0.008533472,0.0000681284,0.0031897754,0.13775782],"study_design_scores_gemma":[0.0049896454,0.0141820125,0.95893407,0.00012340305,0.0003002494,0.00013319356,0.0013742789,0.0022306335,0.004324741,0.00003199387,0.013167727,0.00020807501],"about_ca_topic_score_codex":0.00020452292,"about_ca_topic_score_gemma":0.00078375783,"teacher_disagreement_score":0.13754976,"about_ca_system_score_codex":0.00021650072,"about_ca_system_score_gemma":0.0017883326,"threshold_uncertainty_score":0.36069572},"labels":[],"label_agreement":null},{"id":"W2774364554","doi":"10.1200/jco.2017.75.8995","title":"Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":347,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Psychological intervention; Psychosocial; Family medicine; Cancer; Sexual dysfunction; Gynecology; Intensive care medicine; Nursing; Psychiatry; Internal medicine; Pathology","score_opus":0.27455485407799535,"score_gpt":0.5825765429295541,"score_spread":0.30802168885155873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774364554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9429388,0.001698348,0.0024208657,0.045912836,0.0044453833,0.00089234964,0.000088787725,0.000011816095,0.0015908293],"genre_scores_gemma":[0.94033176,0.004008553,0.044022966,0.007790449,0.0031667715,0.00006571453,0.000032264623,0.00004995675,0.00053157686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9844159,0.0013862691,0.012354175,0.00056743214,0.00086430425,0.00041191094],"domain_scores_gemma":[0.97362775,0.0037002503,0.015135462,0.0007399342,0.0060823546,0.0007142289],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01387605,0.0002908346,0.0045360685,0.00016221116,0.00008981627,0.000016066519,0.00065672514,0.0007452268,0.00030001623],"category_scores_gemma":[0.011150998,0.0002194944,0.0014732869,0.00030307163,0.0009868395,0.00029752895,0.00026512725,0.0027020501,0.00000255684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009661539,0.002791988,0.5868209,0.0002428174,0.0007081803,0.00007137072,0.0029594793,0.0012568149,0.000009273027,0.000009040858,0.01642154,0.37904707],"study_design_scores_gemma":[0.013608797,0.03801772,0.5533775,0.000993081,0.0016074011,0.000056305944,0.01326259,0.00027679745,0.0000071301674,0.000009685605,0.3785905,0.00019249693],"about_ca_topic_score_codex":0.31056008,"about_ca_topic_score_gemma":0.93019986,"teacher_disagreement_score":0.61963975,"about_ca_system_score_codex":0.0009341993,"about_ca_system_score_gemma":0.018661954,"threshold_uncertainty_score":0.99959874},"labels":[],"label_agreement":null},{"id":"W2774464689","doi":"10.1200/jco.2017.35.15_suppl.10515","title":"Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children’s Oncology Group report.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cytarabine; Etoposide; Mitoxantrone; Internal medicine; Chemotherapy; Oncology; Induction chemotherapy; Hazard ratio; Idarubicin; Leukemia; Surgery; Confidence interval","score_opus":0.05032753287687038,"score_gpt":0.42965592205768055,"score_spread":0.3793283891808102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774464689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865492,0.00007297279,0.000070510716,0.0080804145,0.0017240304,0.0007099746,0.000018189845,0.000016874958,0.002757833],"genre_scores_gemma":[0.9873472,0.0022194409,0.0064570094,0.0012829322,0.0020380286,0.000015527985,0.000020994983,0.00006664157,0.00055224856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939291,0.00078236824,0.0030316396,0.000550932,0.0009975977,0.0007084024],"domain_scores_gemma":[0.98743933,0.0030714762,0.0065947147,0.0010213624,0.0010900447,0.0007830534],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005798725,0.00034510923,0.0028504555,0.00031904262,0.00022154508,0.00004237412,0.0008545665,0.001162452,0.00015118194],"category_scores_gemma":[0.012479868,0.00023427652,0.0005787716,0.00015527259,0.0010727164,0.00038288368,0.0002292281,0.004533201,0.00003962327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06784217,0.002211749,0.7702408,0.000011985012,0.0018395184,0.01008869,0.00010842087,0.000013411451,0.000012124089,0.000013161325,0.006771304,0.14084668],"study_design_scores_gemma":[0.085116416,0.04305532,0.85757077,0.0001290907,0.00062160456,0.0013586261,0.000064993845,0.00007265256,0.000021786498,0.00007683237,0.011714015,0.00019788061],"about_ca_topic_score_codex":0.000398191,"about_ca_topic_score_gemma":0.00054358266,"teacher_disagreement_score":0.14064881,"about_ca_system_score_codex":0.0029201743,"about_ca_system_score_gemma":0.008549805,"threshold_uncertainty_score":0.9977634},"labels":[],"label_agreement":null},{"id":"W2775037883","doi":"10.1200/jco.2012.30.15_suppl.e13541","title":"Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab (BEV) or cediranib (CED).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lactate dehydrogenase; Internal medicine; Isozyme; Bevacizumab; Gastroenterology; Chemotherapy; Colorectal cancer; Cancer; Enzyme; Biochemistry; Chemistry","score_opus":0.03168039937560289,"score_gpt":0.3716134806597766,"score_spread":0.3399330812841737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775037883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975177,0.0012261844,0.000060051625,0.00013919394,0.00050174526,0.0003263828,0.000030000092,0.0000033736205,0.0001953481],"genre_scores_gemma":[0.9951761,0.0024728726,0.0011019936,0.0003735759,0.0006296816,0.000017859107,0.000020311049,0.000028433351,0.00017921558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797124,0.0001996791,0.0011401422,0.00020910516,0.00019699657,0.0002828329],"domain_scores_gemma":[0.998066,0.00014559264,0.0011831945,0.00012327597,0.00025395476,0.00022795412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547688,0.00018649014,0.00086498685,0.0000751474,0.000027864453,0.0000047214794,0.00011298925,0.00031371345,0.00006875235],"category_scores_gemma":[0.00026978774,0.000115979994,0.000117734126,0.00013144959,0.00018831063,0.000032360036,0.000023795023,0.00031804817,9.534457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051945467,0.0015469611,0.8400583,0.000030433985,0.00031065877,0.000010272172,0.00019812303,0.0002174053,0.012318946,0.0000050958106,0.00044970913,0.0929086],"study_design_scores_gemma":[0.04197263,0.021291537,0.85633284,0.000102428145,0.00031921835,0.00012881884,0.00013295515,0.00014119997,0.02212916,0.0000063420666,0.057066377,0.0003765013],"about_ca_topic_score_codex":0.00005871263,"about_ca_topic_score_gemma":0.0006100903,"teacher_disagreement_score":0.0925321,"about_ca_system_score_codex":0.000050763323,"about_ca_system_score_gemma":0.00048344166,"threshold_uncertainty_score":0.47295266},"labels":[],"label_agreement":null},{"id":"W2775092792","doi":"10.1200/jco.2017.76.1759","title":"Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Observational study; Cancer; Primary tumor; Bladder cancer; Oncology; Bladder tumor; Metastasis; Internal medicine","score_opus":0.3962684184728819,"score_gpt":0.48906602908257985,"score_spread":0.09279761060969793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775092792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819341,0.0013652438,0.00005251202,0.014742131,0.001097876,0.0003073967,0.00008310036,0.0000022290387,0.000415443],"genre_scores_gemma":[0.978571,0.0010379249,0.017837401,0.0013577145,0.0008581341,0.000008353358,0.000037260583,0.00001768423,0.00027451437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964921,0.00038603126,0.0020941198,0.0002587339,0.0005772353,0.00019180102],"domain_scores_gemma":[0.994575,0.001782095,0.0023320979,0.0009128554,0.00018441098,0.0002135441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014099354,0.00015518637,0.001580034,0.000062159306,0.000072832285,0.00001507819,0.00071988103,0.00013894791,0.00018883093],"category_scores_gemma":[0.0023268526,0.00008392572,0.00042696664,0.00005554733,0.0004456656,0.00017282802,0.00021333586,0.0004494391,0.0000045145275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036713749,0.004120348,0.851351,0.000023744406,0.0014445998,0.0024155572,0.00011138225,0.000020909185,0.0011369472,0.000031007374,0.0024741536,0.13319898],"study_design_scores_gemma":[0.010890273,0.004066034,0.96197873,0.0001251762,0.0013440314,0.00019961045,0.000023672257,0.00008447081,0.00031242313,0.00023850989,0.02067387,0.00006321003],"about_ca_topic_score_codex":0.00090280303,"about_ca_topic_score_gemma":0.0005754977,"teacher_disagreement_score":0.13313577,"about_ca_system_score_codex":0.00048733276,"about_ca_system_score_gemma":0.0037729396,"threshold_uncertainty_score":0.6693033},"labels":[],"label_agreement":null},{"id":"W2777157380","doi":"10.1200/jco.2017.35.15_suppl.11059","title":"Immunoprofiling in alveolar soft part sarcoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Alveolar soft part sarcoma; Sarcoma; CD8; Exome sequencing; Soft tissue sarcoma; Internal medicine; Gastroenterology; Pathology; Oncology; Immune system; Immunology; Mutation; Biology","score_opus":0.2062289885145137,"score_gpt":0.5101657554224591,"score_spread":0.3039367669079454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777157380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750412,0.0024427548,0.00001144888,0.01507232,0.001660678,0.00012980953,0.0000010131943,0.0000045820757,0.005636176],"genre_scores_gemma":[0.9930363,0.0016151534,0.0024941217,0.001535384,0.001140819,0.00000426188,9.899516e-7,0.000011842092,0.00016109053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972802,0.00019644071,0.0019108293,0.00014730153,0.0002472017,0.00021804022],"domain_scores_gemma":[0.9959635,0.0014615303,0.0017325239,0.00040127282,0.00019746716,0.0002436745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033251254,0.00010692901,0.0013044953,0.00008725159,0.000093881936,0.000019911071,0.00024204626,0.00028563093,0.0001580582],"category_scores_gemma":[0.0062259655,0.00007227292,0.00051134336,0.000031401963,0.00018134328,0.00013221064,0.00007803333,0.0008377155,0.000052100284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008457233,0.0023514556,0.73584604,0.000007172405,0.00018949246,0.0029725207,0.000024230843,0.0000014945545,0.000038524642,0.00009906449,0.0013265223,0.25629777],"study_design_scores_gemma":[0.009437691,0.0035523497,0.8743439,0.000178363,0.00019270669,0.0003765242,0.000050350944,0.000033040866,0.00013404449,0.0005173335,0.11112463,0.00005906819],"about_ca_topic_score_codex":0.000051324394,"about_ca_topic_score_gemma":0.000055764813,"teacher_disagreement_score":0.2562387,"about_ca_system_score_codex":0.000121578916,"about_ca_system_score_gemma":0.0007742795,"threshold_uncertainty_score":0.7453512},"labels":[],"label_agreement":null},{"id":"W2777184452","doi":"10.1200/jco.2014.32.15_suppl.e20667","title":"Assessment of a dyspnea clinic for patients with thoracic malignancies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Malignancy; Palliative care; Spirometry; Performance status; Quality of life (healthcare); Cancer; Physical therapy; Internal medicine; Asthma","score_opus":0.11607526700808632,"score_gpt":0.5213027307216007,"score_spread":0.40522746371351437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777184452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852619,0.00012476402,0.0021018889,0.0028109814,0.0010236712,0.0003207373,0.0000054822217,0.0000050898407,0.008345481],"genre_scores_gemma":[0.97450465,0.00021659359,0.022716608,0.0016650112,0.0006366417,0.000008091947,0.000001812374,0.000013395677,0.00023719067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970323,0.00022466297,0.0020725185,0.00014012674,0.00034121625,0.00018917289],"domain_scores_gemma":[0.9934151,0.0031752093,0.0019238441,0.00015908708,0.0011106683,0.0002160921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036898972,0.00010453183,0.0019193966,0.00007079635,0.000031794436,0.000002357937,0.000103951956,0.00019271628,0.00006145671],"category_scores_gemma":[0.0034019428,0.000060529477,0.00037227446,0.000086884866,0.00019840857,0.000051591025,0.000030064974,0.0004259502,0.0000030076742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004751815,0.0028182766,0.8144289,0.0001604935,0.00045783998,0.00001431802,0.000045417146,0.0000018743493,0.000027502254,0.00014942064,0.0053787474,0.17176536],"study_design_scores_gemma":[0.010018378,0.072722465,0.82534844,0.00025309817,0.0004250063,0.000011622689,0.00003872043,0.000052300693,0.000018895857,0.00015716857,0.09089225,0.00006163781],"about_ca_topic_score_codex":0.0000021627868,"about_ca_topic_score_gemma":0.000010891555,"teacher_disagreement_score":0.17170373,"about_ca_system_score_codex":0.00007318216,"about_ca_system_score_gemma":0.0012548575,"threshold_uncertainty_score":0.40726888},"labels":[],"label_agreement":null},{"id":"W2777288228","doi":"10.1200/jco.2013.31.15_suppl.2005","title":"Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temozolomide; Internal medicine; Bevacizumab; Clinical endpoint; Discontinuation; Quality of life (healthcare); Placebo; Progression-free survival; Toxicity; Oncology; Gastroenterology; Radiation therapy; Randomized controlled trial; Surgery; Chemotherapy; Pathology","score_opus":0.11436417716530123,"score_gpt":0.48442403120896715,"score_spread":0.3700598540436659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777288228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840195,0.0052303337,0.0000033897738,0.008885809,0.00030878955,0.0014989903,0.00000577697,0.0000067060478,0.00004068936],"genre_scores_gemma":[0.9964574,0.0021808115,0.00074149756,0.00043604866,0.00011569872,0.00004133056,0.0000014268219,0.000020806732,0.0000049610853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99106765,0.0018057317,0.0059027807,0.00033487895,0.00056464755,0.00032431347],"domain_scores_gemma":[0.9899965,0.00499522,0.0037003213,0.00036167825,0.00032579596,0.0006204928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068920804,0.00023930751,0.0037866586,0.00046432522,0.00003190521,0.00000953529,0.00018564309,0.00038030214,0.000100124045],"category_scores_gemma":[0.004465978,0.00016615786,0.00022574629,0.00038532203,0.0003111577,0.00014298227,0.00009947685,0.0007843936,8.5174725e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015135669,0.034303278,0.81601423,0.00010123625,0.0005540143,0.00056027394,0.0014303506,0.000010133429,0.00035312155,0.000028692086,0.0007629132,0.13074607],"study_design_scores_gemma":[0.17045483,0.05379821,0.77341837,0.00030959395,0.00009160563,0.000062797866,0.0013195655,0.00013671844,0.0000486746,0.00018041831,0.000082553765,0.00009666714],"about_ca_topic_score_codex":0.0025970938,"about_ca_topic_score_gemma":0.0043401285,"teacher_disagreement_score":0.15531917,"about_ca_system_score_codex":0.00019540843,"about_ca_system_score_gemma":0.0010039755,"threshold_uncertainty_score":0.6775721},"labels":[],"label_agreement":null},{"id":"W2777609976","doi":"10.1200/jco.2017.35.15_suppl.2574","title":"Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Nausea; Neutropenia; Vomiting; Pharmacokinetics; Tolerability; Adverse effect; Pharmacodynamics; Internal medicine; Oncology; Cancer; Pharmacology; Gastroenterology; Toxicity","score_opus":0.25449380799468213,"score_gpt":0.49530045135956,"score_spread":0.2408066433648779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777609976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887538,0.001226077,0.0007821066,0.0042956807,0.0013376566,0.00040683703,0.00025166295,0.0000045262123,0.0029416743],"genre_scores_gemma":[0.98668176,0.0006515586,0.010020095,0.00029873953,0.0009388032,0.0000058571213,0.0000016224102,0.0000261529,0.0013754041],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99511755,0.00020549081,0.003692717,0.00027228406,0.00041676508,0.0002951773],"domain_scores_gemma":[0.9898369,0.0006298314,0.00781777,0.0004491112,0.0008872633,0.00037913796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048001977,0.00017245763,0.0020360984,0.00009537659,0.00007003642,0.000010980749,0.00037141028,0.00032468364,0.000101977384],"category_scores_gemma":[0.0027030187,0.000129437,0.00061969325,0.00007719653,0.00040214142,0.00010161927,0.00011180817,0.0008449578,0.0000017799964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009383164,0.003818532,0.00024415125,0.00023530163,0.00048782324,0.00012773147,0.00017793344,0.00003245381,0.79382175,0.000019738256,0.007900828,0.1837506],"study_design_scores_gemma":[0.049443033,0.015564682,0.00097240997,0.0012253129,0.000851786,0.000057619534,0.00019143683,0.00015471558,0.83427024,0.000025797008,0.09705419,0.0001887995],"about_ca_topic_score_codex":0.00060352986,"about_ca_topic_score_gemma":0.000060184582,"teacher_disagreement_score":0.1835618,"about_ca_system_score_codex":0.00012560724,"about_ca_system_score_gemma":0.0022821012,"threshold_uncertainty_score":0.5278288},"labels":[],"label_agreement":null},{"id":"W2780073276","doi":"10.1200/jco.2017.35.15_suppl.e20504","title":"Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Adverse effect; Discontinuation; Oncology; Phases of clinical research; Gastroenterology; Cancer; Clinical trial; Pembrolizumab; Immunotherapy","score_opus":0.1417976650562891,"score_gpt":0.5247077997151413,"score_spread":0.38291013465885215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780073276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98803306,0.00023762022,0.00004880982,0.009013907,0.0013244019,0.00040398486,0.000061013416,0.000005209573,0.00087200885],"genre_scores_gemma":[0.9944749,0.00365675,0.0007564886,0.00036023077,0.0006157137,0.0000012647486,0.000006381207,0.000012955441,0.00011532954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9939132,0.0007632122,0.0044793203,0.00032129695,0.00032608083,0.0001969086],"domain_scores_gemma":[0.9898389,0.004022193,0.0049644485,0.0005865461,0.0003196097,0.000268293],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009321496,0.00015961449,0.0023311162,0.00009924185,0.00008536811,0.000011636813,0.00029127835,0.00044312488,0.00009137645],"category_scores_gemma":[0.01285681,0.00011460783,0.00047194684,0.00008369772,0.0005932051,0.00020259141,0.000115212715,0.0012027064,0.0000016911282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33940962,0.008840125,0.13488795,0.000006167685,0.00058408687,0.00043098346,0.00009904434,0.0000015917868,0.00024661288,7.304537e-7,0.00024134383,0.51525176],"study_design_scores_gemma":[0.16825096,0.034819443,0.77238524,0.00018399917,0.00030608932,0.000035455836,0.00011017384,0.0001966761,0.00008007603,0.000040438917,0.02350456,0.00008688194],"about_ca_topic_score_codex":0.000625107,"about_ca_topic_score_gemma":0.0025017383,"teacher_disagreement_score":0.6374973,"about_ca_system_score_codex":0.00011196107,"about_ca_system_score_gemma":0.00087965396,"threshold_uncertainty_score":0.9954583},"labels":[],"label_agreement":null},{"id":"W2780350829","doi":"10.1200/jco.2016.34.15_suppl.2578","title":"Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Pharmacokinetics; Internal medicine; Cancer; Melanoma; Gastroenterology; Refractory (planetary science); Cmax; Toxicity; Cohort; Oncology; Urology","score_opus":0.0724240469470236,"score_gpt":0.40042437631507255,"score_spread":0.32800032936804896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780350829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971658,0.00010113681,0.0004672271,0.000086011765,0.0015020022,0.0005848095,0.0000042606043,0.000004647063,0.00008409787],"genre_scores_gemma":[0.9988322,0.000091165086,0.00024067123,0.00013604853,0.0006018873,0.00002669964,0.0000056752197,0.000024776733,0.000040825038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964902,0.00081839587,0.0017665245,0.00035510125,0.0003353995,0.00023440392],"domain_scores_gemma":[0.99740297,0.00022746356,0.001572292,0.0002450492,0.00034502652,0.0002072054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001372113,0.00018924638,0.0007902072,0.000112739544,0.000038490303,0.000007027395,0.00021614766,0.00018620759,0.0000743284],"category_scores_gemma":[0.000495952,0.00011722032,0.00012351735,0.00016751059,0.00008425301,0.000022828171,0.000057551868,0.00026541934,0.0000014438128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011598952,0.045362037,0.56769115,0.000010822543,0.0002810044,0.00006511822,0.0002387033,0.00007347926,0.08126716,9.3000125e-7,0.00006254632,0.2933481],"study_design_scores_gemma":[0.09378475,0.33254248,0.5609606,0.00012825863,0.00045516485,0.000015503065,0.0010271989,0.000018571925,0.005229225,0.000018077735,0.005527946,0.00029221748],"about_ca_topic_score_codex":0.000026746713,"about_ca_topic_score_gemma":0.000876562,"teacher_disagreement_score":0.2930559,"about_ca_system_score_codex":0.000086354514,"about_ca_system_score_gemma":0.00025982558,"threshold_uncertainty_score":0.4780106},"labels":[],"label_agreement":null},{"id":"W2781821596","doi":"10.1200/jco.2017.75.8490","title":"Population-Based Genetic Testing for <i>BRCA1</i> and <i>BRCA2</i>","year":2018,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Genetic testing; Population; BRCA2 Protein; Genetics; Oncology; Mutation; Internal medicine; Germline mutation; Gene; Biology; Environmental health","score_opus":0.09614404271236082,"score_gpt":0.4247962205130077,"score_spread":0.32865217780064687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781821596","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21224906,0.007004166,0.017493164,0.7432104,0.016318975,0.0015588036,0.00027492156,0.000030313584,0.0018602007],"genre_scores_gemma":[0.03298504,0.0001982644,0.15218864,0.7562761,0.057393853,0.000045037097,0.00022145835,0.00012929628,0.00056230905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996367,0.0003914442,0.0022041916,0.00045770864,0.000262138,0.00031752672],"domain_scores_gemma":[0.9936029,0.002008307,0.002807313,0.0003597442,0.0010816328,0.00014013425],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018067635,0.00026622228,0.00107986,0.000106689135,0.00009033088,0.000029203871,0.000394383,0.0020554815,0.000020293593],"category_scores_gemma":[0.006427743,0.00023298337,0.0004623021,0.00008947883,0.00027875367,0.000004695888,0.00008278436,0.0011334056,0.0000037872812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029561884,0.00008169199,0.012314645,0.0000839915,0.00028467944,0.000054857515,0.0000052777273,0.00012707966,0.00040628063,0.000001000132,0.9507732,0.035571672],"study_design_scores_gemma":[0.002401306,0.0072061326,0.011259652,0.000066001194,0.00034074872,0.00016678721,0.000004238837,0.00016349928,0.00022648918,0.00045860646,0.9774454,0.000261121],"about_ca_topic_score_codex":0.000011868072,"about_ca_topic_score_gemma":0.000025786278,"teacher_disagreement_score":0.17926402,"about_ca_system_score_codex":0.00012141116,"about_ca_system_score_gemma":0.0030195746,"threshold_uncertainty_score":0.99924004},"labels":[],"label_agreement":null},{"id":"W2782600446","doi":"10.1200/jco.2017.76.6402","title":"Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"School of Medicine, Indiana University; University of Nebraska Medical Center; Massachusetts General Hospital","keywords":"Medicine; Zoledronic acid; Denosumab; Guideline; Multiple myeloma; Internal medicine; Osteonecrosis of the jaw; Randomized controlled trial; Adverse effect; Observational study; Intensive care medicine; Cochrane Library; Oncology; Surgery; Osteoporosis; Pathology; Bisphosphonate","score_opus":0.2812332512698629,"score_gpt":0.5934403427253425,"score_spread":0.3122070914554796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782600446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96808195,0.0006657287,0.00023641146,0.024665749,0.0023247942,0.0005163704,0.000015749605,0.0000145682825,0.0034786728],"genre_scores_gemma":[0.82598597,0.0047873887,0.14683183,0.020045547,0.0022239045,0.000005330341,0.000010890776,0.00003563732,0.000073498726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97696126,0.0031953782,0.01786506,0.0005474463,0.00079834246,0.0006325285],"domain_scores_gemma":[0.96315676,0.016097337,0.016284214,0.0005994527,0.0026036634,0.001258553],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.028804028,0.00029956197,0.0060557267,0.00016847071,0.00006558129,0.000004346769,0.00033495255,0.0012956172,0.00012649849],"category_scores_gemma":[0.04645149,0.00022678077,0.001905167,0.00048035372,0.0021824646,0.00023577247,0.00023064292,0.0029907383,0.00005682102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018673722,0.012288411,0.48001748,0.00004311889,0.00082270417,0.0003698757,0.00013092322,0.0000034793707,0.000050384428,0.000024418421,0.020204261,0.46737123],"study_design_scores_gemma":[0.02362344,0.035545506,0.5077864,0.00012509595,0.00069502153,0.00030592023,0.0005637738,0.0012798634,0.00003556204,0.00013751036,0.42978784,0.00011404943],"about_ca_topic_score_codex":0.0006335012,"about_ca_topic_score_gemma":0.0005056901,"teacher_disagreement_score":0.46725717,"about_ca_system_score_codex":0.00027007048,"about_ca_system_score_gemma":0.0070696,"threshold_uncertainty_score":0.9993094},"labels":[],"label_agreement":null},{"id":"W2782629081","doi":"10.1200/jco.2016.34.15_suppl.tps2604","title":"ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Trametinib; Oncology; Cancer; Melanoma; V600E; Gastroenterology; Cancer research; Mutation","score_opus":0.07249467770115313,"score_gpt":0.42168217148076775,"score_spread":0.3491874937796146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782629081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966292,0.00022242648,0.000052754553,0.0021651874,0.00016007916,0.0006875509,0.000021868713,8.513755e-7,0.00006011166],"genre_scores_gemma":[0.99725014,0.0012824141,0.00031295075,0.0010365028,0.00007278071,0.000009052717,0.0000037520485,0.000011867657,0.000020562584],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99820197,0.0003531529,0.0009713098,0.00021250808,0.00012772862,0.00013333847],"domain_scores_gemma":[0.99787843,0.00078235834,0.0007411404,0.0001640637,0.00026014794,0.00017383025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014393401,0.000113438495,0.0005250346,0.000048107842,0.000037017067,0.000016847333,0.00024436935,0.00012794795,0.0000046524747],"category_scores_gemma":[0.0016034659,0.000060319715,0.00003133421,0.00009797478,0.00021472879,0.000011177567,0.0001382319,0.00016481458,2.460797e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049256645,0.01231784,0.27747622,0.000010175616,0.00048262958,0.00003245323,0.0007050903,0.00007741771,0.006500102,0.00007830793,0.0011082618,0.6519548],"study_design_scores_gemma":[0.21350019,0.11728299,0.64964193,0.00011680434,0.00011557039,0.000016919132,0.00026370725,0.000025877931,0.001925383,0.00019236923,0.01669478,0.00022346574],"about_ca_topic_score_codex":0.00007437476,"about_ca_topic_score_gemma":0.00050484174,"teacher_disagreement_score":0.6517314,"about_ca_system_score_codex":0.00004613461,"about_ca_system_score_gemma":0.00067677087,"threshold_uncertainty_score":0.24597666},"labels":[],"label_agreement":null},{"id":"W2783614467","doi":"10.1200/jco.2017.35.15_suppl.4500","title":"Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer research; Biology; DNA methylation; APOBEC; Germline mutation; microRNA; Somatic cell; Gene; Mutation; CpG site; Medicine; Gene expression; Genetics","score_opus":0.10829738884019939,"score_gpt":0.4407294001944145,"score_spread":0.3324320113542151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783614467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958252,0.00020500539,0.0004464738,0.0020719145,0.00045369542,0.00013732805,0.000028144053,0.000002504178,0.0008297609],"genre_scores_gemma":[0.99705523,0.00083185657,0.0006627505,0.0010287347,0.0003210147,0.0000015643469,0.000009513732,0.000009514744,0.0000797904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818194,0.00016843784,0.0011651923,0.00014479388,0.0002280333,0.000111622954],"domain_scores_gemma":[0.99649453,0.0004176708,0.0020449422,0.00026937702,0.0005578447,0.00021565337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004255887,0.00010124473,0.0014633157,0.0001691497,0.00005561773,0.000011114006,0.00012626807,0.00020030396,0.00006878307],"category_scores_gemma":[0.0010286473,0.00007394173,0.0004940056,0.00007752717,0.00027679317,0.00009543396,0.000049764334,0.0002715565,0.0000017820572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030327644,0.0010003971,0.76073194,0.00006478695,0.006605381,0.0009633587,0.00027686547,0.0000064600003,0.05527423,0.00010474391,0.00004900262,0.17189008],"study_design_scores_gemma":[0.0053039417,0.004659183,0.97790724,0.000041542397,0.005197305,0.000048007256,0.000031261607,0.000069509464,0.0018026942,0.000051528197,0.004833442,0.000054366017],"about_ca_topic_score_codex":0.000052586114,"about_ca_topic_score_gemma":0.000015869527,"teacher_disagreement_score":0.21717529,"about_ca_system_score_codex":0.000038919425,"about_ca_system_score_gemma":0.0006914564,"threshold_uncertainty_score":0.30152562},"labels":[],"label_agreement":null},{"id":"W2783631626","doi":"10.1200/jco.2017.74.6941","title":"Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bayer (Canada); Sanofi (Canada)","funders":"","keywords":"Medicine; Context (archaeology); Soft tissue sarcoma; Soft tissue; Perioperative; Sarcoma; Classification scheme; Surgery; Nuclear medicine; Pathology","score_opus":0.15544210086165486,"score_gpt":0.5020980381128045,"score_spread":0.3466559372511496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783631626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709954,0.0023344816,0.023445688,0.0018013091,0.0009053443,0.00027672423,0.000014920995,0.00000248393,0.000223623],"genre_scores_gemma":[0.99724704,0.0007072056,0.0012482766,0.00009801845,0.00063769764,0.000019082438,0.000004229485,0.0000069958755,0.000031430885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967167,0.00071485806,0.0020023708,0.00014602744,0.0002996345,0.00012045782],"domain_scores_gemma":[0.9904427,0.0052369176,0.0028665937,0.00024617082,0.0011077464,0.000099879784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046979333,0.000083828134,0.0011521582,0.00020519094,0.000043066626,0.0000084091025,0.0001028663,0.00022389002,0.00005000034],"category_scores_gemma":[0.00265699,0.000046387115,0.0005316849,0.0003667652,0.00041016962,0.0000711475,0.000020210802,0.0002994439,0.000002598382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023158435,0.0015515499,0.6927403,0.000042285148,0.0020920518,0.000016347378,0.0000670816,0.00005498728,0.00008818832,0.000057769295,0.000936535,0.30003703],"study_design_scores_gemma":[0.002140433,0.0070382734,0.9654285,0.00016382089,0.0061306427,0.000035683915,0.00040110605,0.0067357467,0.00033887217,0.00007546214,0.011472145,0.00003935698],"about_ca_topic_score_codex":0.00008934138,"about_ca_topic_score_gemma":0.00013186196,"teacher_disagreement_score":0.29999766,"about_ca_system_score_codex":0.00012020986,"about_ca_system_score_gemma":0.00042456973,"threshold_uncertainty_score":0.3180857},"labels":[],"label_agreement":null},{"id":"W2784039033","doi":"10.1200/jco.2017.75.7500","title":"Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Letrozole; Medicine; Quality of life (healthcare); Placebo; Breast cancer; Internal medicine; Randomized controlled trial; Clinical trial; Aromatase inhibitor; Population; Cancer; Gynecology; Aromatase; Alternative medicine","score_opus":0.10857888486799892,"score_gpt":0.48333363640498517,"score_spread":0.37475475153698623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784039033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932056,0.0023105901,0.0001919176,0.0007472727,0.0024761995,0.00044681912,0.00005063636,0.0000016834389,0.00056926877],"genre_scores_gemma":[0.9929095,0.0012733755,0.0018377221,0.0006566133,0.0031921347,0.000009869002,0.00001009641,0.000015198156,0.00009549515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99226177,0.0033118366,0.0037204074,0.00021299548,0.0002521971,0.00024080384],"domain_scores_gemma":[0.99339235,0.0023044199,0.00312135,0.000229414,0.00037647923,0.00057597837],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014680521,0.00013616025,0.0028498548,0.00012427199,0.00002775729,0.000005710788,0.0002956014,0.0006726148,0.00022842371],"category_scores_gemma":[0.023924459,0.000098115306,0.0011034292,0.0001031058,0.00034627493,0.000005763937,0.00006591809,0.00035143626,0.000008530777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8669579,0.0004339763,0.00081784744,0.00000896605,0.0013829035,0.000018199422,0.000062764964,0.000013722795,0.07101041,0.000059261543,0.006036363,0.053197674],"study_design_scores_gemma":[0.8966616,0.019459026,0.007923751,0.00010040233,0.0006119459,0.000007430077,0.00007488623,0.0000270177,0.0127518345,0.00030895678,0.061832406,0.0002407889],"about_ca_topic_score_codex":0.009288701,"about_ca_topic_score_gemma":0.0072115026,"teacher_disagreement_score":0.058258574,"about_ca_system_score_codex":0.000050609284,"about_ca_system_score_gemma":0.0023333104,"threshold_uncertainty_score":0.99730855},"labels":[],"label_agreement":null},{"id":"W2784273036","doi":"10.1200/jco.2017.35.15_suppl.2576","title":"Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Pharmacokinetics; Adverse effect; Folate receptor; Pharmacology; Toxicity; Therapeutic index; Conjugate; Phases of clinical research; Drug; Internal medicine; Oncology; Cancer; Cancer cell","score_opus":0.190155839025728,"score_gpt":0.5179086091889112,"score_spread":0.32775277016318327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784273036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065036,0.00011300177,0.000009258512,0.0056029703,0.0011497049,0.00046593422,0.0000030539213,0.000004866341,0.0020008662],"genre_scores_gemma":[0.99742085,0.00019694804,0.00025406768,0.00035538775,0.00059780525,0.0000026458674,0.0000013563241,0.000015836136,0.0011551104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962193,0.0008095611,0.0020387834,0.00018027055,0.0005182643,0.00023385818],"domain_scores_gemma":[0.9948269,0.0009040118,0.0025720994,0.0006049161,0.000797504,0.0002945786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004753836,0.00012413418,0.0011306261,0.000095468175,0.0001747689,0.000022966713,0.0005396216,0.00025160416,0.00015495764],"category_scores_gemma":[0.0067825005,0.00007015845,0.0004581942,0.0000954037,0.00031431246,0.00013188213,0.00019075883,0.0012808584,0.00002506568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036784533,0.0646718,0.41964513,0.00011928316,0.002981627,0.0013534641,0.0020234343,0.000025268335,0.060351904,0.00008798124,0.017565921,0.39438966],"study_design_scores_gemma":[0.076957256,0.07639355,0.818361,0.0001931536,0.00082744594,0.00011175899,0.00062750536,0.0008326959,0.005994696,0.00025005775,0.019277755,0.00017312325],"about_ca_topic_score_codex":0.00010133878,"about_ca_topic_score_gemma":0.00014750444,"teacher_disagreement_score":0.39871588,"about_ca_system_score_codex":0.00007126694,"about_ca_system_score_gemma":0.00093717047,"threshold_uncertainty_score":0.8119776},"labels":[],"label_agreement":null},{"id":"W2784334312","doi":"10.1200/jco.2017.74.8244","title":"Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Psychosocial; Randomized controlled trial; Quality of life (healthcare); Intervention (counseling); Distress; Physical therapy; Clinical psychology; Psychiatry; Surgery; Nursing","score_opus":0.07394825971660586,"score_gpt":0.4780567858388581,"score_spread":0.40410852612225223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784334312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631627,0.0015430414,0.000108589265,0.0066890833,0.012912626,0.0012153559,0.000008826896,0.00000887939,0.014350862],"genre_scores_gemma":[0.98366547,0.0011688144,0.00059810065,0.0011924168,0.011806126,0.000099534416,6.689891e-7,0.000016674403,0.0014522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923277,0.0014697133,0.0052120797,0.00018894712,0.0005762191,0.00022537282],"domain_scores_gemma":[0.9870583,0.006876077,0.0038734472,0.00027142986,0.0016004168,0.00032037034],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015101836,0.00014754462,0.005739157,0.00015696605,0.00002302706,0.000007059237,0.00014884473,0.00037955487,0.0005076161],"category_scores_gemma":[0.024623355,0.00008798616,0.002078773,0.00013111321,0.0006216284,0.000084692714,0.000043512624,0.000773168,0.000009213538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9849604,0.0006928345,0.0005946333,0.000021858928,0.0010139478,0.00023310659,0.00032535847,2.7869737e-7,0.00023168871,0.00002187866,0.0048735803,0.0070304684],"study_design_scores_gemma":[0.9384002,0.012908762,0.0025658277,0.0002380777,0.0016995446,0.00003668727,0.00007880882,0.000029543135,0.00016814975,0.00011879336,0.043678418,0.00007718055],"about_ca_topic_score_codex":0.000294387,"about_ca_topic_score_gemma":0.0006142315,"teacher_disagreement_score":0.04656016,"about_ca_system_score_codex":0.00013798558,"about_ca_system_score_gemma":0.0021850606,"threshold_uncertainty_score":0.9835926},"labels":[],"label_agreement":null},{"id":"W2784379909","doi":"10.1200/jco.2017.76.4365","title":"What Is the “Home” in Home-Based Exercise? The Need to Define Independent Exercise for Survivors of Cancer","year":2018,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Physical therapy; Gerontology; Internal medicine","score_opus":0.08876188079846127,"score_gpt":0.4310832385239396,"score_spread":0.34232135772547834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784379909","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1200561,0.00803954,0.00006479555,0.8537549,0.016359178,0.0015087065,0.00007898632,0.0000072808966,0.0001305139],"genre_scores_gemma":[0.089712,0.014623155,0.00024384097,0.87773734,0.014931004,0.00028662026,0.00002979155,0.00012771176,0.0023085258],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935617,0.0006244551,0.00367125,0.0004370103,0.0011374434,0.0005681382],"domain_scores_gemma":[0.9881972,0.006206636,0.003007997,0.00080645614,0.0015027854,0.0002789099],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0065761306,0.00040796315,0.0035504946,0.00039775055,0.000068633104,0.000046618457,0.0010132022,0.0018482708,0.0005010756],"category_scores_gemma":[0.00093071564,0.0002122364,0.0016182169,0.0005047115,0.0005091156,0.00010966738,0.00014224721,0.0040014326,0.000014178374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012166708,0.00046564764,0.016579453,0.00045302403,0.0003907451,0.00028663853,0.0012569544,0.000022453065,0.0000058625806,0.0000033784147,0.86244917,0.10591996],"study_design_scores_gemma":[0.00715573,0.0057780733,0.023769125,0.0032020228,0.0017205124,0.000032333643,0.0012017845,0.000025646925,0.00010042261,0.00039402777,0.9563412,0.0002790932],"about_ca_topic_score_codex":0.0022883548,"about_ca_topic_score_gemma":0.015767667,"teacher_disagreement_score":0.105640866,"about_ca_system_score_codex":0.00040591133,"about_ca_system_score_gemma":0.0038693417,"threshold_uncertainty_score":0.9994475},"labels":[],"label_agreement":null},{"id":"W2784790049","doi":"10.1200/jco.2017.75.6312","title":"Predictors of Specialized Pediatric Palliative Care Involvement and Impact on Patterns of End-of-Life Care in Children With Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kimberly-Clark (Canada)","funders":"Canadian Institutes of Health Research; Institute for Clinical Evaluative Sciences; American Society of Clinical Oncology","keywords":"Medicine; Palliative care; Cancer; Emergency medicine; Population; Intensive care unit; Cohort; Retrospective cohort study; Odds; Odds ratio; End-of-life care; Cohort study; Intensive care; Cancer registry; Logistic regression; Intensive care medicine; Internal medicine; Nursing","score_opus":0.08975706420355735,"score_gpt":0.4663423822556916,"score_spread":0.37658531805213424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784790049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995929,0.0021090072,0.000010525865,0.00066020776,0.00055208727,0.00040903877,0.00015242727,0.000002992135,0.00017468918],"genre_scores_gemma":[0.9940074,0.0024553766,0.0002897855,0.0005375329,0.0026759428,0.000003403211,0.0000083239875,0.00001832261,0.000003890591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957266,0.00049961044,0.0026641318,0.00021490143,0.0006935741,0.00020122514],"domain_scores_gemma":[0.9940103,0.0011149239,0.0034098271,0.00021378601,0.0009179674,0.0003331814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012878797,0.00018583525,0.0021382582,0.00026786895,0.00001540895,0.0000021667358,0.000167599,0.0002609179,0.00017720438],"category_scores_gemma":[0.0012325424,0.000120990975,0.00032509136,0.00021286786,0.0003471542,0.000054857675,0.000058870486,0.00059988647,4.268591e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008651876,0.0007211399,0.9757112,0.00025331922,0.00075210613,0.00001041562,0.007917462,0.000018011708,0.000007899992,0.000008268023,0.00021252519,0.005735757],"study_design_scores_gemma":[0.014186522,0.038987666,0.94243634,0.00055150443,0.0005479915,0.000004536969,0.002742387,0.0000015896683,0.00021411067,0.000011132583,0.00022524026,0.00009100878],"about_ca_topic_score_codex":0.0021151719,"about_ca_topic_score_gemma":0.005655084,"teacher_disagreement_score":0.038266525,"about_ca_system_score_codex":0.00027618965,"about_ca_system_score_gemma":0.003818688,"threshold_uncertainty_score":0.6774189},"labels":[],"label_agreement":null},{"id":"W2784999170","doi":"10.1200/jco.2012.30.15_suppl.549","title":"A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Onco<i>type</i> DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Confidence interval; Tamoxifen; Oncology; Prospective cohort study; Stage (stratigraphy); Cancer; Chemotherapy; Estrogen receptor; Adjuvant chemotherapy; Gynecology; Disease; Informed consent; Alternative medicine; Pathology","score_opus":0.07874989122551011,"score_gpt":0.46074706219529826,"score_spread":0.38199717096978814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784999170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953934,0.0005891719,0.000004906696,0.0011681071,0.001696438,0.0006662293,0.00025944487,8.568711e-7,0.00022142247],"genre_scores_gemma":[0.9983769,0.00044514282,0.00013553658,0.0003845758,0.0006088484,0.000017241642,0.0000025102956,0.000015841639,0.000013415355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99413925,0.0025847913,0.002276017,0.00030983132,0.00029416382,0.00039595185],"domain_scores_gemma":[0.9958303,0.00068707153,0.0020895344,0.00039653623,0.00072456273,0.00027199797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005074062,0.0001948221,0.0008936814,0.000081030346,0.00004866143,0.0000039903184,0.0007299541,0.00061404944,0.000043980544],"category_scores_gemma":[0.00405574,0.000117773314,0.00048935314,0.0004881311,0.00061956065,0.000023894927,0.00022573576,0.0017255965,9.627072e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020718477,0.0014237822,0.9852193,0.0000045118563,0.0003351203,0.0000025517263,0.00075127516,0.00024074409,0.0030544447,0.0000033851932,0.00075959397,0.0061334325],"study_design_scores_gemma":[0.002994274,0.0021167824,0.9895183,0.00010597126,0.000090269954,0.000035164107,0.00053889607,0.000026868942,0.0042428183,0.000058580576,0.00016448808,0.00010762138],"about_ca_topic_score_codex":0.012198924,"about_ca_topic_score_gemma":0.0437919,"teacher_disagreement_score":0.031592976,"about_ca_system_score_codex":0.00090561266,"about_ca_system_score_gemma":0.008164939,"threshold_uncertainty_score":0.99745786},"labels":[],"label_agreement":null},{"id":"W2785714424","doi":"10.1200/jco.2013.31.15_suppl.8052","title":"Molecular marker assessments for epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) and histoscore (H-score) in the phase III SELECT trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Immunohistochemistry; Internal medicine; Oncology; Lung cancer; Population; Biomarker; Progression-free survival; Cetuximab; Phases of clinical research; Clinical trial; Gastroenterology; Cancer; Pathology; Chemotherapy; Colorectal cancer","score_opus":0.06635778604162187,"score_gpt":0.4973250380851857,"score_spread":0.4309672520435638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785714424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040854,0.0010889543,0.0007282101,0.0051525543,0.00056197855,0.0010839043,0.000016520351,0.0000047944527,0.00095454697],"genre_scores_gemma":[0.9934952,0.00034060862,0.0030965926,0.0020939147,0.0003521843,0.00014123727,0.00003442673,0.000017711434,0.00042812235],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975936,0.00029633116,0.0014673002,0.00019209566,0.0002449992,0.00020570529],"domain_scores_gemma":[0.9969012,0.0014472123,0.0010193805,0.00015121112,0.00028419506,0.00019680317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010224321,0.0001453658,0.00085418375,0.000053424774,0.0000591136,0.000016759663,0.00013776064,0.00026167062,0.00020640634],"category_scores_gemma":[0.0013443471,0.00008446272,0.00026924652,0.000071315124,0.00011245927,0.00013998109,0.000022405075,0.0005450006,0.0000022450818],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1115563,0.015979478,0.015320494,0.00020734762,0.0014897891,0.0003424178,0.0008161017,0.0000015384978,0.34366748,0.000058335892,0.31261817,0.19794254],"study_design_scores_gemma":[0.72751635,0.057492524,0.02860768,0.0005508683,0.0020150729,0.00042276387,0.000812699,0.00019713187,0.0137872705,0.0008727078,0.16721727,0.0005076855],"about_ca_topic_score_codex":0.000041144005,"about_ca_topic_score_gemma":8.7331546e-7,"teacher_disagreement_score":0.61596,"about_ca_system_score_codex":0.00028237837,"about_ca_system_score_gemma":0.0008532211,"threshold_uncertainty_score":0.344429},"labels":[],"label_agreement":null},{"id":"W2786168520","doi":"10.1200/jco.2014.32.15_suppl.tps7119","title":"An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Nivolumab; Nilotinib; Tolerability; Internal medicine; Oncology; Myeloid leukemia; Pharmacology; Imatinib; Immunotherapy; Cancer; Adverse effect","score_opus":0.10616471924736708,"score_gpt":0.4579118950979487,"score_spread":0.35174717585058163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786168520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995936,0.00007683047,0.00017863508,0.00017919326,0.00034155516,0.002725609,0.000014931162,0.000033654076,0.0005136185],"genre_scores_gemma":[0.99178725,0.00010301796,0.0066157617,0.0003040889,0.0006313263,0.000041071788,0.00036164408,0.00008258476,0.00007322347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99087733,0.0021291133,0.0044531375,0.0007824194,0.0011096917,0.000648322],"domain_scores_gemma":[0.9916781,0.0011208409,0.004270312,0.0008315155,0.001065878,0.0010333502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045578475,0.00050613814,0.0030819871,0.00041357518,0.00011293914,0.00005490449,0.0007777045,0.00063426996,0.000111520116],"category_scores_gemma":[0.0015135397,0.0003782126,0.00017523041,0.00058581174,0.00044508823,0.0008343483,0.00015517075,0.001388155,0.000013909299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015762549,0.06836507,0.819881,0.00011190401,0.00045120428,0.00025874024,0.00051782577,0.0003747086,0.0013741859,0.000028107865,0.00011872014,0.092755966],"study_design_scores_gemma":[0.22245762,0.2004978,0.56723434,0.00028022059,0.00076303544,0.00005510736,0.000111075475,0.007709216,0.00023757461,0.00004695096,0.0003594063,0.00024763128],"about_ca_topic_score_codex":0.0008814656,"about_ca_topic_score_gemma":0.0010785753,"teacher_disagreement_score":0.25264665,"about_ca_system_score_codex":0.0039729048,"about_ca_system_score_gemma":0.010695327,"threshold_uncertainty_score":0.99986696},"labels":[],"label_agreement":null},{"id":"W2786647130","doi":"10.1200/jco.2016.34.15_suppl.tps5090","title":"Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Hazard ratio; Clinical endpoint; Cancer; Clinical trial; Androgen receptor; Confidence interval","score_opus":0.2290558006825888,"score_gpt":0.5371807235506563,"score_spread":0.3081249228680675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786647130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653983,0.0019936028,0.00045172626,0.02573481,0.0012097626,0.0051041627,0.000050861032,0.0000053041126,0.000051463754],"genre_scores_gemma":[0.9705979,0.025358493,0.00073967286,0.0006124998,0.0018133465,0.00044358737,0.000008913386,0.000026523694,0.00039901427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99499506,0.0009018076,0.003078417,0.00022423679,0.00047837466,0.00032209323],"domain_scores_gemma":[0.98630756,0.0105258385,0.002137183,0.00023899211,0.0005783355,0.00021207513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009147246,0.00017190131,0.0018620229,0.00019266,0.000054905937,0.000009253758,0.00021950495,0.00019743206,0.00013395217],"category_scores_gemma":[0.0077503948,0.00007281961,0.00072358927,0.00021674126,0.00033232413,0.00013764681,0.000027950498,0.00042227286,0.0000017358738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69630414,0.0034273816,0.0012888848,0.000026352192,0.00061565917,0.000053536263,0.00014047665,0.0000068118093,0.000763583,0.000015695014,0.00072636147,0.2966311],"study_design_scores_gemma":[0.8962451,0.06222962,0.0007164611,0.00015589698,0.00039322238,0.000017107026,0.000042033673,0.00006962811,0.004106296,0.0013082626,0.034640666,0.00007566571],"about_ca_topic_score_codex":0.000037447153,"about_ca_topic_score_gemma":0.00008945126,"teacher_disagreement_score":0.29655543,"about_ca_system_score_codex":0.00023457043,"about_ca_system_score_gemma":0.002884775,"threshold_uncertainty_score":0.9278506},"labels":[],"label_agreement":null},{"id":"W2787816336","doi":"10.1200/jco.2017.35.15_suppl.tps5603","title":"ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic <i>BRCA1-</i> or <i>BRCA2-</i>mutated, relapsed, high-grade ovarian carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; PARP inhibitor; BRCA mutation; Oncology; Germline mutation; Chemotherapy; Olaparib; Ovarian cancer; Regimen; Cancer; Mutation; Poly ADP ribose polymerase; Biology; Genetics; Polymerase","score_opus":0.12385259067240226,"score_gpt":0.4860857614442218,"score_spread":0.3622331707718195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787816336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208345,0.000071679366,0.00013791402,0.020236207,0.0052769403,0.001917197,0.000017941169,0.000015934722,0.00024275355],"genre_scores_gemma":[0.98903364,0.00059295737,0.002573678,0.0049740025,0.0022183866,0.00006759487,0.000006331704,0.0000561922,0.00047722613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907161,0.0020450382,0.0055262907,0.00044440187,0.00090103515,0.00036710777],"domain_scores_gemma":[0.9875072,0.0034100316,0.0068542305,0.001149577,0.00068417395,0.00039473444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069766194,0.00035211956,0.0035390016,0.0002582212,0.00016339577,0.00006170303,0.0010986456,0.0004939686,0.00062558294],"category_scores_gemma":[0.0078820735,0.00018807975,0.00072686956,0.00018854838,0.00088788493,0.00050199474,0.00013583213,0.0016559412,0.0000071685818],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87773204,0.034654457,0.06812872,0.00006844614,0.0016153984,0.001399925,0.0025516376,0.000050839906,0.0019934045,0.00006152822,0.0017610082,0.0099825645],"study_design_scores_gemma":[0.8881212,0.018185005,0.08053874,0.00051150535,0.00073094654,0.00040914546,0.0007383004,0.0011541527,0.0021249,0.0004060703,0.0068369503,0.00024312004],"about_ca_topic_score_codex":0.00023609477,"about_ca_topic_score_gemma":0.0005071948,"teacher_disagreement_score":0.016950198,"about_ca_system_score_codex":0.00031781633,"about_ca_system_score_gemma":0.0019292528,"threshold_uncertainty_score":0.9436148},"labels":[],"label_agreement":null},{"id":"W2788268342","doi":"10.1200/jco.2017.75.2501","title":"Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Deductible; Hazard ratio; Stage (stratigraphy); Cancer; Internal medicine; Confidence interval","score_opus":0.10270344011454609,"score_gpt":0.385358687987523,"score_spread":0.2826552478729769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788268342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97744185,0.0055255173,0.00005852789,0.009286398,0.0036634055,0.00011703566,0.00021161561,0.0000055708883,0.003690088],"genre_scores_gemma":[0.971936,0.021008393,0.00074631226,0.0018346464,0.0039591873,0.0000502019,4.296608e-7,0.000017665414,0.00044716726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731433,0.000046046644,0.0020543418,0.00027331075,0.000037131656,0.00027481565],"domain_scores_gemma":[0.9971511,0.00031599152,0.0019057083,0.0001742532,0.00015927227,0.00029369252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011889423,0.00015968956,0.0013423413,0.00013198818,0.00005879536,0.00003141523,0.00015705306,0.00025961557,0.0014794191],"category_scores_gemma":[0.00024613456,0.0001350443,0.00026000832,0.00008808186,0.00034898962,0.0003663073,0.00004378235,0.00025250798,0.00013949686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009556253,0.00052828295,0.7403183,0.000004891922,0.00022004162,0.000024307084,0.00014231857,0.000004178672,8.4398687e-7,0.0028963955,0.0033791014,0.2515257],"study_design_scores_gemma":[0.002519033,0.003054646,0.7345267,0.000022875967,0.000025126392,0.000047849688,0.000014215033,0.000009733072,0.000019635168,0.0055012065,0.25413454,0.00012445814],"about_ca_topic_score_codex":0.00067265466,"about_ca_topic_score_gemma":0.00038728822,"teacher_disagreement_score":0.25140125,"about_ca_system_score_codex":0.0003553388,"about_ca_system_score_gemma":0.00032820393,"threshold_uncertainty_score":0.99943334},"labels":[],"label_agreement":null},{"id":"W2788302487","doi":"10.1200/jco.2013.31.15_suppl.3548","title":"Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Meta-analysis; Colorectal cancer; Oncology; Stage (stratigraphy); Adjuvant therapy; Cancer; Chemotherapy; Randomized controlled trial; Confidence interval; Surgery","score_opus":0.20115244898029525,"score_gpt":0.5077031386868485,"score_spread":0.3065506897065532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788302487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6484463,0.28426576,0.000099370445,0.06411407,0.00020740904,0.0024085538,0.00004976937,0.000006945618,0.00040183542],"genre_scores_gemma":[0.95124406,0.030025747,0.0009331394,0.014449948,0.00015902429,0.00010006054,0.0000033367605,0.000013949238,0.0030707682],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99638283,0.00027412715,0.0028088822,0.00014018743,0.0002578473,0.000136135],"domain_scores_gemma":[0.9939564,0.0020496447,0.0026793482,0.00016373648,0.00091254694,0.00023832428],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003136486,0.00012503135,0.007959591,0.00012394006,0.00002822723,0.0000036215952,0.000109925444,0.00015760523,0.0012533772],"category_scores_gemma":[0.0022700618,0.00006658694,0.002314278,0.0002439822,0.00012715154,0.000055192108,0.000028540633,0.00028270925,0.0000014306054],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003843683,0.0036930074,0.0055668554,0.27873668,0.6838506,0.00015344983,0.0003995343,0.000019695888,0.0017452404,0.00036970843,0.01620049,0.005421072],"study_design_scores_gemma":[0.0034252668,0.015205259,0.014701551,0.0015504238,0.96247536,0.00006285839,0.000081235026,0.0003433418,0.00008175255,0.000091225695,0.0018748074,0.00010692951],"about_ca_topic_score_codex":0.00006159802,"about_ca_topic_score_gemma":0.000085917425,"teacher_disagreement_score":0.30279773,"about_ca_system_score_codex":0.000046842033,"about_ca_system_score_gemma":0.00036262968,"threshold_uncertainty_score":0.9996596},"labels":[],"label_agreement":null},{"id":"W2788691011","doi":"10.1200/jco.2017.77.6211","title":"Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Febrile neutropenia; Intensive care medicine; Family medicine; Internal medicine; Neutropenia; Pathology","score_opus":0.1429613731944847,"score_gpt":0.5397809796135389,"score_spread":0.39681960641905417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788691011","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044840112,0.9328835,0.0010688918,0.008529624,0.004210375,0.006279329,0.0005179853,0.000038948863,0.0016312248],"genre_scores_gemma":[0.001937126,0.9603289,0.032785274,0.0035238727,0.0011891936,0.00006245694,0.00004431378,0.00006072985,0.00006812711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98140717,0.0022853438,0.014691968,0.000741603,0.00047104704,0.00040289716],"domain_scores_gemma":[0.9673889,0.009552386,0.020032333,0.0005104229,0.0019280384,0.0005878945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072473483,0.00049532583,0.011486211,0.00014856909,0.000052812666,0.0000074778586,0.00030237934,0.0011026995,0.000041056122],"category_scores_gemma":[0.0030108083,0.00035103018,0.0039315885,0.0005606439,0.0026998173,0.00015951974,0.0003503183,0.0018352761,0.0000020969078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060535455,0.0073870616,0.02551755,0.006351983,0.004780191,0.00007328164,0.000057340298,0.0000017268587,2.8418262e-7,0.000032941272,0.041959878,0.9077842],"study_design_scores_gemma":[0.015026691,0.043798868,0.015591107,0.0056489347,0.01203662,0.00024169162,0.00028376453,0.000050422575,4.1808548e-7,0.000034371165,0.9070461,0.00024100853],"about_ca_topic_score_codex":0.00016885447,"about_ca_topic_score_gemma":0.000041175575,"teacher_disagreement_score":0.9075432,"about_ca_system_score_codex":0.00025298304,"about_ca_system_score_gemma":0.0034847513,"threshold_uncertainty_score":0.99989414},"labels":[],"label_agreement":null},{"id":"W2789314039","doi":"10.1200/jco.2018.36.6_suppl.177","title":"Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict castrate resistant prostate cancer?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Prostatectomy; Urology; Logistic regression; Proportional hazards model; Internal medicine; Log-rank test; Metastasis; Oncology; Cancer; Gynecology","score_opus":0.17696429631986602,"score_gpt":0.4961325265548144,"score_spread":0.31916823023494834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789314039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9349647,0.0009055591,0.0000019775414,0.061939083,0.0010847095,0.00043620978,0.0000699724,0.000009054721,0.00058873696],"genre_scores_gemma":[0.99426717,0.0014071811,0.00043470334,0.002260529,0.0008501219,0.00005693963,0.0000060123907,0.000022067714,0.0006952753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959882,0.00043970323,0.002040152,0.00035171115,0.0006323123,0.000547915],"domain_scores_gemma":[0.9959072,0.0015682612,0.0006386171,0.00032563068,0.00068803196,0.0008722778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037313374,0.00019015299,0.001313345,0.0003414113,0.000035627596,0.000017617229,0.00022828348,0.00035042167,0.0003815284],"category_scores_gemma":[0.0047621727,0.00012669989,0.00032728203,0.0005183338,0.00057442643,0.00008505885,0.00012268491,0.0008798956,0.000017797323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12986186,0.0023376292,0.6606529,0.00015403678,0.0006281202,0.011026462,0.00092844013,5.335683e-7,0.008568733,0.000011441032,0.120409064,0.06542082],"study_design_scores_gemma":[0.012245882,0.018708182,0.89681995,0.001443389,0.00024805916,0.00031828013,0.00017871204,0.000035546,0.004780416,0.00056152244,0.064407155,0.00025288056],"about_ca_topic_score_codex":0.00042916485,"about_ca_topic_score_gemma":0.0017127714,"teacher_disagreement_score":0.23616712,"about_ca_system_score_codex":0.000531317,"about_ca_system_score_gemma":0.0065821237,"threshold_uncertainty_score":0.99904966},"labels":[],"label_agreement":null},{"id":"W2789365412","doi":"10.1200/jco.2018.36.6_suppl.31","title":"Cell surface GRP78 activation by anti-GRP78 autoantibodies in relation to prostate tumour growth via tissue factor activation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Autoantibody; DU145; Tissue factor; Medicine; Cancer research; Cell growth; Prostate cancer; Downregulation and upregulation; Cell; Immunology; Antibody; Endocrinology; Internal medicine; LNCaP; Cancer; Biology; Biochemistry","score_opus":0.028097001467375024,"score_gpt":0.38021707202312693,"score_spread":0.3521200705557519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789365412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914767,0.000088706176,0.004620973,0.0022268551,0.00046183504,0.00020830763,0.00001507628,0.000005480897,0.00089605106],"genre_scores_gemma":[0.99586624,0.0002456939,0.0021971434,0.0007184701,0.00057409034,0.0000027303183,0.000029232611,0.000018257479,0.00034815492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977435,0.0003116711,0.0012126185,0.00027575842,0.00022112946,0.00023531646],"domain_scores_gemma":[0.99787855,0.00024203403,0.0009854705,0.00013966409,0.00051135465,0.00024290477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006946541,0.00015662721,0.0004978343,0.000073757146,0.000057010617,0.000020793505,0.00018436216,0.0003373853,0.00003909826],"category_scores_gemma":[0.001893816,0.00012935174,0.00013272977,0.0001330349,0.000120020064,0.000035916964,0.000073269795,0.0003271626,0.000020741174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013708054,0.00073592254,0.076718956,0.000023997885,0.000050072187,0.000015812646,0.00012900204,0.00023007544,0.90125394,0.000020417025,0.015124274,0.004326704],"study_design_scores_gemma":[0.0033735284,0.0063284487,0.30870005,0.00006702837,0.00003695238,0.000013063982,0.00009966769,0.00017072995,0.6533623,0.00021322626,0.027371362,0.0002636453],"about_ca_topic_score_codex":0.00004903931,"about_ca_topic_score_gemma":0.000014437092,"teacher_disagreement_score":0.24789168,"about_ca_system_score_codex":0.000054997832,"about_ca_system_score_gemma":0.00039911986,"threshold_uncertainty_score":0.5274811},"labels":[],"label_agreement":null},{"id":"W2789446608","doi":"10.1200/jco.2018.36.6_suppl.125","title":"Validation of a genomic risk classifier to predict metastasis and prostate cancer-specific mortality in men with positive lymph nodes.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Oncology; Internal medicine; Nomogram; Metastasis; Adjuvant; Adjuvant therapy; Logistic regression; Cohort; Lymph node; Proportional hazards model; Cancer","score_opus":0.12874924338815455,"score_gpt":0.4716844526941577,"score_spread":0.3429352093060032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789446608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948286,0.0006900249,0.00007132374,0.0023483967,0.000141057,0.00044548835,0.00005439493,0.0000029490889,0.0014177676],"genre_scores_gemma":[0.99311596,0.0047177854,0.0014544082,0.00015588565,0.00036325364,0.00001455507,0.0000041447347,0.000011996956,0.00016201736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766606,0.0004111813,0.0011846973,0.00020660582,0.00032536915,0.0002060778],"domain_scores_gemma":[0.99757934,0.0005044277,0.0008761698,0.00013569808,0.00060868147,0.00029571156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026105412,0.00010800317,0.0009535667,0.00017571666,0.00003233674,0.000007828377,0.000079384896,0.00013651437,0.00007754621],"category_scores_gemma":[0.00029787028,0.00006486326,0.000104571714,0.00019411305,0.00042449572,0.00009653608,0.000046716792,0.0003714788,0.0000036649938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018073156,0.00062532385,0.912385,0.0000260654,0.0006899032,0.00016990516,0.0006463195,0.000015830305,0.0014017776,0.000011192961,0.0004894991,0.06546603],"study_design_scores_gemma":[0.010879662,0.010089136,0.97305834,0.00015426452,0.0004032485,0.000045856512,0.00024338737,0.00008569709,0.0033617504,0.00012475932,0.001492335,0.000061532046],"about_ca_topic_score_codex":0.00026861992,"about_ca_topic_score_gemma":0.000088004585,"teacher_disagreement_score":0.0654045,"about_ca_system_score_codex":0.0003506471,"about_ca_system_score_gemma":0.0014865526,"threshold_uncertainty_score":0.26450473},"labels":[],"label_agreement":null},{"id":"W2789521745","doi":"10.1200/jco.2018.36.6_suppl.161","title":"SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Abiraterone acetate; Clinical endpoint; Randomization; Metastasis; Oncology; Urology; Randomized controlled trial; Doubling time; Cancer; Placebo; Androgen deprivation therapy; Pathology; Cell","score_opus":0.20043449565867036,"score_gpt":0.526148373794619,"score_spread":0.32571387813594865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789521745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390286,0.00019774852,0.000011928625,0.00091274374,0.00080803887,0.0034130004,0.000013511941,0.0000052952078,0.00073485624],"genre_scores_gemma":[0.9981583,0.00032315592,0.0005184543,0.00010258632,0.00041386634,0.0001215565,0.0000087162625,0.000023975093,0.00032940166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943275,0.0010887187,0.0030476174,0.00028688574,0.00086346775,0.00038581644],"domain_scores_gemma":[0.99306625,0.0026755894,0.0022483529,0.000234346,0.0014236325,0.00035183932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046010297,0.0002190316,0.002539105,0.00031499294,0.000063898755,0.000011246558,0.0001604172,0.00017977088,0.00021334596],"category_scores_gemma":[0.0013877103,0.00012615079,0.0002497723,0.00038409219,0.00070029846,0.00016254814,0.00004419232,0.0008603242,0.000009108842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90423185,0.012190658,0.069582954,0.000059013222,0.0017154274,0.0004702148,0.0017931903,0.000030825446,0.00006609736,0.000008739568,0.00022114239,0.009629879],"study_design_scores_gemma":[0.8704489,0.101083934,0.02499707,0.00023325284,0.0011820786,0.000007763694,0.0011466774,0.00009250773,0.00014272967,0.000022550434,0.0005364104,0.0001061512],"about_ca_topic_score_codex":0.00041204868,"about_ca_topic_score_gemma":0.003601458,"teacher_disagreement_score":0.08889327,"about_ca_system_score_codex":0.00039008388,"about_ca_system_score_gemma":0.003117737,"threshold_uncertainty_score":0.5530731},"labels":[],"label_agreement":null},{"id":"W2789636480","doi":"10.1200/jco.2018.36.6_suppl.448","title":"Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Nomogram; Urology; Internal medicine; Perioperative; Proportional hazards model; Chemotherapy; Odds ratio; Oncology; Cumulative incidence; Surgery; Cancer; Cohort","score_opus":0.018127789149063416,"score_gpt":0.34901620782591125,"score_spread":0.3308884186768478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789636480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983023,0.00037962693,0.00013696826,0.0002648034,0.0001675762,0.00063556497,0.000052063693,0.000002746891,0.00005839461],"genre_scores_gemma":[0.9987148,0.00022810177,0.00056714594,0.00028147188,0.00016095549,0.000021885578,0.0000015925127,0.000016585262,0.0000074660293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977356,0.00034738594,0.0012376034,0.00022124563,0.0003095709,0.000148593],"domain_scores_gemma":[0.9979503,0.0004009454,0.0008336852,0.0001266285,0.00048674305,0.0002016992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005892751,0.0001503923,0.0010174233,0.00010551806,0.00002433724,0.000004222386,0.000049982293,0.00018924853,0.000100736484],"category_scores_gemma":[0.0002264078,0.00009100681,0.00010734894,0.00010390795,0.00086434174,0.00007999851,0.000024218822,0.0004286509,3.0720807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041107193,0.005145135,0.9151924,0.000031248466,0.00058629416,0.00004838594,0.0020191441,0.0000036512547,0.00005070912,7.111014e-7,0.000012159087,0.035802927],"study_design_scores_gemma":[0.052966233,0.054597747,0.8895352,0.00024715907,0.0006477541,0.0000056506965,0.0010797774,0.00019000686,0.0002511776,0.0000062739778,0.0004119548,0.000061075414],"about_ca_topic_score_codex":0.00031801494,"about_ca_topic_score_gemma":0.0009933704,"teacher_disagreement_score":0.049452614,"about_ca_system_score_codex":0.000110515895,"about_ca_system_score_gemma":0.0006766624,"threshold_uncertainty_score":0.371115},"labels":[],"label_agreement":null},{"id":"W2789685576","doi":"10.1200/jco.2018.36.6_suppl.82","title":"Perspectives of prostate cancer patients about active surveillance.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre; University of Manitoba; McGill University Health Centre; Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Distrust; Focus group; Viewpoints; Disease; Prostate cancer; Qualitative research; Family medicine; Cancer; Quality of life (healthcare); Nursing; Psychology; Pathology; Psychotherapist; Internal medicine","score_opus":0.33648538076986306,"score_gpt":0.5937365880255543,"score_spread":0.2572512072556912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789685576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97847927,0.0016142927,0.0000065489444,0.008531476,0.00450509,0.0005959467,0.00006201254,0.000012652663,0.006192712],"genre_scores_gemma":[0.9935271,0.0023514477,0.0011152353,0.0013326257,0.0014041921,0.00003413092,0.000003241438,0.000020185857,0.00021182075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911013,0.0040996,0.0038194347,0.00020040951,0.00041499428,0.00036420938],"domain_scores_gemma":[0.97904116,0.0065554525,0.007106346,0.0003967622,0.0065983175,0.00030198306],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021833482,0.00013153284,0.0012260338,0.0001367117,0.00026909233,0.0000020586915,0.0005111612,0.000464452,0.00068487675],"category_scores_gemma":[0.011785825,0.000098332086,0.0002476133,0.0002295486,0.0006551756,0.00019658895,0.00021181384,0.0017941768,0.000050711107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030253404,0.00080617657,0.9108628,0.00007356389,0.0001455465,0.0000019664012,0.023283184,0.0000012551474,0.000009713498,0.00023509284,0.00633717,0.05521817],"study_design_scores_gemma":[0.004400636,0.0060670325,0.91692346,0.0002693302,0.000031034735,8.3728304e-7,0.015421013,0.00002244604,0.000017686565,0.0006914982,0.056063436,0.00009161429],"about_ca_topic_score_codex":0.00036274822,"about_ca_topic_score_gemma":0.0008986607,"teacher_disagreement_score":0.05512656,"about_ca_system_score_codex":0.00050316245,"about_ca_system_score_gemma":0.0045934366,"threshold_uncertainty_score":0.99653834},"labels":[],"label_agreement":null},{"id":"W2789745920","doi":"10.1200/jco.2018.36.6_suppl.483","title":"Transcriptome-wide analysis of alternative splicing events in bladder cancer: Novel biomarkers discovery for early diagnosis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Alternative splicing; RNA splicing; Computational biology; Gene; Spliceosome; Biology; Bladder cancer; Transcriptome; Intron; Gene expression; Bioinformatics; Medicine; Messenger RNA; Cancer research; Cancer; Genetics; RNA","score_opus":0.12227715883377618,"score_gpt":0.4749567653030908,"score_spread":0.3526796064693146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789745920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991717,0.00037674053,0.0028457588,0.002996352,0.0012478294,0.00036414337,0.00007678608,0.0000030809654,0.0003723396],"genre_scores_gemma":[0.9951533,0.0009330681,0.0013682591,0.0015997645,0.00076487154,0.000036605397,0.0000038552926,0.000018206669,0.00012205402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969222,0.00015081481,0.0021090028,0.00023572368,0.00032838856,0.00025387167],"domain_scores_gemma":[0.995742,0.0020635796,0.001362493,0.00015918456,0.00046521233,0.00020751728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014742746,0.00015366825,0.0018720604,0.00049330544,0.000025682593,0.000004325294,0.0001728855,0.00022352827,0.00010355174],"category_scores_gemma":[0.0010878684,0.000110120665,0.000995764,0.00055165123,0.00022646626,0.0001963856,0.000020437099,0.000313875,0.0000012141345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008245189,0.0022828258,0.95749915,0.000021860918,0.011687471,0.000031123254,0.0004893038,0.00003362201,0.00065379555,0.000026824364,0.00041190637,0.018616939],"study_design_scores_gemma":[0.014746434,0.011045968,0.96261245,0.0001952635,0.0063900733,0.000006482063,0.00011508977,0.00017231666,0.0016170351,0.00017878233,0.0028239517,0.000096128184],"about_ca_topic_score_codex":0.0013504279,"about_ca_topic_score_gemma":0.0016737503,"teacher_disagreement_score":0.018520812,"about_ca_system_score_codex":0.00024920347,"about_ca_system_score_gemma":0.0009448321,"threshold_uncertainty_score":0.44905904},"labels":[],"label_agreement":null},{"id":"W2789775411","doi":"10.1200/jco.2018.36.4_suppl.180","title":"Enrollment of esophago-gastric cancer patients in a clinical fast-track program and it’s affect on time to treatment and quality of life.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Dysphagia; Cancer; Quality of life (healthcare); Esophageal cancer; Internal medicine; Clinical endpoint; Stage (stratigraphy); Surgery; Clinical trial","score_opus":0.1506346016803077,"score_gpt":0.5183382619403877,"score_spread":0.36770366026007995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789775411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391216,0.00017124129,0.000004959375,0.00415506,0.00041480863,0.0007003929,0.0000076328315,0.000003872667,0.00062986655],"genre_scores_gemma":[0.9954193,0.0009174074,0.001179403,0.0016422273,0.00051770546,0.0000127501835,0.000001333343,0.000008942695,0.00030090584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995877,0.00048262204,0.002912402,0.00022612284,0.00030799987,0.00019385021],"domain_scores_gemma":[0.9957633,0.0018045156,0.0016325623,0.0001484804,0.00027044115,0.00038067246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029791968,0.00014349159,0.0018909231,0.00020545845,0.000013572919,0.000004360856,0.0000857236,0.000188636,0.00012635924],"category_scores_gemma":[0.002458715,0.000094385025,0.00028504845,0.00019322366,0.0002696581,0.000042112744,0.00007056727,0.00028735903,0.000006563031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061937096,0.0037455186,0.6162126,0.00003754146,0.00023970686,0.000008888348,0.00008025177,0.0000015846981,0.000006853093,0.000004796592,0.0011672018,0.37230137],"study_design_scores_gemma":[0.015623257,0.09391533,0.8812029,0.0001259151,0.0002387428,0.0000023247953,0.00004029164,0.000022233522,0.000015500977,0.000010696816,0.008748478,0.000054344062],"about_ca_topic_score_codex":0.00012516996,"about_ca_topic_score_gemma":0.00024726082,"teacher_disagreement_score":0.372247,"about_ca_system_score_codex":0.00014076199,"about_ca_system_score_gemma":0.00046194348,"threshold_uncertainty_score":0.38489097},"labels":[],"label_agreement":null},{"id":"W2789800123","doi":"10.1200/jco.2018.36.6_suppl.412","title":"RNA-sequencing to identify three different molecular grades and immune checkpoint cascades with distinct clinical behaviour in NMIBC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Grading (engineering); Immune checkpoint; Bladder cancer; Oncology; Neuroblastoma RAS viral oncogene homolog; Cancer research; Internal medicine; Cancer; Biology; KRAS; Immunotherapy","score_opus":0.13006698591338242,"score_gpt":0.48517773374710854,"score_spread":0.3551107478337261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789800123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247265,0.0005625807,0.0006655636,0.004426712,0.00078245107,0.0003409076,0.0000034908444,0.000009930114,0.0007357436],"genre_scores_gemma":[0.99502856,0.00016301595,0.0026836582,0.0009861053,0.0010291914,0.00000919395,0.0000013058952,0.000028451544,0.00007049558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958285,0.0003626261,0.0027504775,0.0003349553,0.00040046126,0.00032298322],"domain_scores_gemma":[0.9971624,0.00071148574,0.00094354333,0.0002591466,0.00031630023,0.00060709484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023787154,0.00022307278,0.0017753969,0.00015335844,0.00004816841,0.000021115704,0.00017558825,0.0003470383,0.00007897054],"category_scores_gemma":[0.0015820477,0.00013572504,0.0003761535,0.00015110159,0.00048765473,0.000087752356,0.00010403297,0.0010649994,0.000012015657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00561671,0.0014288581,0.92900723,0.000024585881,0.00041538727,0.002700991,0.00019007425,8.8159175e-7,0.0022164814,0.000042446813,0.000113853144,0.05824247],"study_design_scores_gemma":[0.009731996,0.028809616,0.95638055,0.00034573136,0.00061553676,0.00074019027,0.00013496354,0.00001526481,0.0020449609,0.0006480486,0.000397506,0.00013563836],"about_ca_topic_score_codex":0.0002675358,"about_ca_topic_score_gemma":0.0011910876,"teacher_disagreement_score":0.058106832,"about_ca_system_score_codex":0.00023700597,"about_ca_system_score_gemma":0.0008771743,"threshold_uncertainty_score":0.5534706},"labels":[],"label_agreement":null},{"id":"W2789828472","doi":"10.1200/jco.2018.36.6_suppl.201","title":"Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naive prostate cancer: Results from LATITUDE.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Poisson regression; Abiraterone acetate; Radiation therapy; Prednisone; Internal medicine; Urology; Cancer; Population","score_opus":0.23642984274115264,"score_gpt":0.5089289953838686,"score_spread":0.27249915264271596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789828472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626286,0.00093667716,0.0003246062,0.010907766,0.00035163658,0.0007901081,0.00007009237,0.000009362782,0.0003468841],"genre_scores_gemma":[0.9904245,0.004197424,0.0034162935,0.00090423157,0.00067190983,0.000024966808,0.000075745054,0.000021395119,0.00026349633],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99518275,0.00069601566,0.0026727484,0.00030532142,0.0008584896,0.000284683],"domain_scores_gemma":[0.9958284,0.0012633548,0.0013705735,0.00022935761,0.00087431393,0.00043400732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033875725,0.00016403131,0.001216723,0.00023955984,0.00004607079,0.0000127020785,0.00019768819,0.0002645771,0.0002485475],"category_scores_gemma":[0.0032568304,0.00011159057,0.00015188428,0.00042501587,0.0003384532,0.00015749542,0.000057654102,0.0005557996,0.000011752119],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16464476,0.0034210775,0.13881657,0.00008717729,0.0018198086,0.0010414756,0.010224297,0.0005833071,0.0044456166,0.000062011146,0.006025945,0.66882795],"study_design_scores_gemma":[0.14735894,0.047052108,0.72547626,0.0016353241,0.00059100153,0.00012642023,0.0013146017,0.006604329,0.02388747,0.0013869388,0.044164084,0.0004025171],"about_ca_topic_score_codex":0.00046254348,"about_ca_topic_score_gemma":0.001260725,"teacher_disagreement_score":0.66842544,"about_ca_system_score_codex":0.00032769062,"about_ca_system_score_gemma":0.003607288,"threshold_uncertainty_score":0.6399174},"labels":[],"label_agreement":null},{"id":"W2789850132","doi":"10.1200/jco.2018.36.6_suppl.92","title":"Microrna-198: A novel tumor suppressor in prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"LNCaP; DU145; Cancer research; Gene knockdown; Prostate cancer; microRNA; Biology; Cell growth; Cancer; Gene silencing; Carcinogenesis; Tumor suppressor gene; Chromoplexy; Cell culture; PCA3; Gene; Genetics","score_opus":0.06898430656878461,"score_gpt":0.46188436591077503,"score_spread":0.3929000593419904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789850132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900572,0.001129125,0.0019472985,0.0033792728,0.0018711245,0.00028005632,0.000024381432,0.000003994589,0.001307564],"genre_scores_gemma":[0.99115497,0.0007308141,0.0031849574,0.0021365655,0.002215241,0.000016151023,0.0000046131345,0.00003324309,0.00052342477],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712825,0.00032456504,0.0015289988,0.00031817614,0.00028904082,0.0004109971],"domain_scores_gemma":[0.9977528,0.00014399251,0.00090999017,0.00026954664,0.00064633664,0.00027736838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022500015,0.00015023534,0.0006707673,0.00012915273,0.00003894338,0.000015692309,0.00044597618,0.00035968516,0.00012987458],"category_scores_gemma":[0.0022176388,0.00012670178,0.00030141612,0.00018236245,0.00034969937,0.000008328136,0.0002040681,0.00081592484,0.000017799277],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043789935,0.0007341532,0.0010492876,0.000015240127,0.00018735144,0.00023689309,0.000055486198,0.00007408026,0.9689756,0.00003890528,0.008075632,0.01617836],"study_design_scores_gemma":[0.0094896825,0.013809826,0.007281038,0.00010104301,0.00006287577,0.00045827933,0.00007889219,0.00017780265,0.44522086,0.00018409651,0.5228813,0.00025427443],"about_ca_topic_score_codex":0.0000804647,"about_ca_topic_score_gemma":0.0006505839,"teacher_disagreement_score":0.5237548,"about_ca_system_score_codex":0.000103845516,"about_ca_system_score_gemma":0.0020091815,"threshold_uncertainty_score":0.5166749},"labels":[],"label_agreement":null},{"id":"W2789877692","doi":"10.1200/jco.2018.36.6_suppl.225","title":"Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Docetaxel; Cabozantinib; Oncology; Internal medicine; Prostate cancer; Hazard ratio; Proportional hazards model; Enzalutamide; Cancer; Confidence interval; Androgen receptor","score_opus":0.3196519608841015,"score_gpt":0.6077363090943942,"score_spread":0.2880843482102927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789877692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099976,0.0013325223,0.0005859166,0.004235842,0.001280447,0.0010360336,0.00011918343,0.000008042976,0.0004022395],"genre_scores_gemma":[0.9924675,0.0007398809,0.004660249,0.00036817274,0.00080681243,0.0000465544,0.000037024816,0.000020208669,0.0008535442],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937087,0.000767468,0.004345875,0.00025314552,0.0005675719,0.0003572095],"domain_scores_gemma":[0.9899462,0.0045521115,0.0033280847,0.00022333457,0.0015426963,0.00040755808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011111678,0.00018207911,0.0039996025,0.00049511524,0.000093024566,0.000017728637,0.00016277232,0.00014729344,0.00031490394],"category_scores_gemma":[0.005293256,0.000111906316,0.0020044069,0.000751956,0.0003597403,0.00013972832,0.000029492321,0.0004259737,0.0000020900802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44295087,0.018470356,0.049717303,0.00043228013,0.1290286,0.0021050298,0.0023546624,0.00017973174,0.051094595,0.00094365695,0.011617144,0.29110578],"study_design_scores_gemma":[0.61198616,0.14753309,0.03899994,0.00069579965,0.119393855,0.00006377708,0.0012737827,0.0064856894,0.017983377,0.0018864837,0.053146522,0.0005515132],"about_ca_topic_score_codex":0.00017003343,"about_ca_topic_score_gemma":0.0004954592,"teacher_disagreement_score":0.29055426,"about_ca_system_score_codex":0.00015431666,"about_ca_system_score_gemma":0.003770661,"threshold_uncertainty_score":0.66889906},"labels":[],"label_agreement":null},{"id":"W2789908368","doi":"10.1200/jco.2018.36.4_suppl.25","title":"Association of liquid biopsy and gastric cancer patients' prognosis: Comprehensive synopsis and a meta-analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Liquid biopsy; Internal medicine; Hazard ratio; Meta-analysis; Circulating tumor cell; Cancer; Confidence interval; Oncology; Subgroup analysis; Biopsy; Gastroenterology; Metastasis","score_opus":0.07260381519047841,"score_gpt":0.4050377672815746,"score_spread":0.33243395209109616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789908368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944453,0.0035821754,0.00009933026,0.0014351727,0.00021917789,0.0000866666,0.000052353436,7.646907e-7,0.000079058285],"genre_scores_gemma":[0.99332845,0.0036730915,0.0015684726,0.0009546192,0.00039507882,0.0000053527297,0.00000523019,0.0000065776007,0.000063144056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833673,0.00019577183,0.0010382584,0.00016880172,0.00013963354,0.00012077277],"domain_scores_gemma":[0.996466,0.00046369573,0.0017766267,0.00009067396,0.0010734439,0.0001295764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007615213,0.00009383351,0.0010959876,0.000080343714,0.000027511061,0.0000084308585,0.0000855201,0.0002527974,0.00003261229],"category_scores_gemma":[0.0012996508,0.00007027635,0.0004627598,0.00013005229,0.00016421879,0.000004535614,0.00008708115,0.00013862496,4.1688494e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033636044,0.0016464851,0.785022,0.00004383442,0.1773983,0.0000114370605,0.00013585783,0.00005837598,0.009681158,0.000046005207,0.013097912,0.0094950395],"study_design_scores_gemma":[0.0048683835,0.034944486,0.62480444,0.0000073618653,0.23246968,0.000023903853,0.00009491955,0.00006775911,0.0055249287,0.00011159838,0.09678389,0.00029866182],"about_ca_topic_score_codex":0.00004015185,"about_ca_topic_score_gemma":0.00016278769,"teacher_disagreement_score":0.16021757,"about_ca_system_score_codex":0.000026301434,"about_ca_system_score_gemma":0.000251258,"threshold_uncertainty_score":0.28657866},"labels":[],"label_agreement":null},{"id":"W2789984763","doi":"10.1200/jco.2018.36.6_suppl.426","title":"Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Metastatic Urothelial Carcinoma; Cisplatin; Retrospective cohort study; Urothelial carcinoma; Oncology; Proportional hazards model; Chemotherapy; Nomogram; Internal medicine; Urology; Cancer; Bladder cancer","score_opus":0.09649097531424405,"score_gpt":0.5002311399256388,"score_spread":0.4037401646113948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789984763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598944,0.00012034203,0.0009145401,0.00090091635,0.0004747704,0.00037467896,0.0000797306,0.00000367732,0.001141897],"genre_scores_gemma":[0.9879254,0.00011904713,0.0104549555,0.00035283595,0.0010421169,0.00000482649,0.0000034496293,0.000025800646,0.00007155235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970158,0.0001034627,0.0022694226,0.00014448086,0.00027873288,0.00018810979],"domain_scores_gemma":[0.994578,0.0015412276,0.0024340127,0.00022365534,0.0010338579,0.00018924811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008702595,0.00015302325,0.0018227319,0.00008633759,0.000019425644,0.0000011444268,0.00014818733,0.0002773563,0.000528369],"category_scores_gemma":[0.0011196701,0.000100257435,0.001048187,0.00011422615,0.0004259207,0.000051851046,0.000013769865,0.0002331266,0.0000024551807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073477976,0.0048448467,0.81274825,0.00018005229,0.0012169926,0.00002190522,0.0002273481,0.00006399084,0.0071402094,0.000030817147,0.0011680797,0.09887954],"study_design_scores_gemma":[0.071825854,0.098915905,0.78479606,0.00028984214,0.0007718494,0.000076782846,0.00003844778,0.0002643317,0.038527876,0.0008252596,0.003538808,0.00012898524],"about_ca_topic_score_codex":0.00009595731,"about_ca_topic_score_gemma":0.00003493536,"teacher_disagreement_score":0.098750554,"about_ca_system_score_codex":0.00009830136,"about_ca_system_score_gemma":0.0021384356,"threshold_uncertainty_score":0.578527},"labels":[],"label_agreement":null},{"id":"W2790042221","doi":"10.1200/jco.2018.36.6_suppl.2","title":"Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; Medicine; Subclass; Cancer research; Cancer; Oncology; Androgen; Transcriptome; Internal medicine; Biomarker; Gene expression; Immunology; Biology; Hormone; Gene; Genetics; Antibody","score_opus":0.08516729541103782,"score_gpt":0.44306419021736576,"score_spread":0.3578968948063279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790042221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722236,0.0002605553,0.00004363139,0.0016255064,0.00035823122,0.0003787954,0.000048337562,0.0000023441141,0.000060217313],"genre_scores_gemma":[0.99405694,0.0054668454,0.00010249627,0.00007323814,0.00019581473,0.000009357711,0.000012750944,0.000008696751,0.000073854455],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979895,0.0003085816,0.0011926072,0.00015265067,0.00022236476,0.00013429433],"domain_scores_gemma":[0.99769104,0.0002158851,0.0013461593,0.00010016051,0.00051891676,0.00012781608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013483262,0.00008303293,0.0008854448,0.00014649688,0.000017815495,0.0000033119484,0.00006509657,0.000184869,0.00002655883],"category_scores_gemma":[0.00020960397,0.00006110462,0.0001365324,0.00016344064,0.00042386472,0.00018571176,0.000019064715,0.00031523916,9.224106e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020156408,0.0011893868,0.23282719,0.00018788356,0.00021069868,0.000013897932,0.00041365562,3.1161093e-7,0.5825733,0.0000017889987,0.000025995494,0.16239952],"study_design_scores_gemma":[0.005129641,0.0040766587,0.7046322,0.00015012687,0.00008103108,0.00001221217,0.000023471366,0.00004207312,0.28529054,0.000021795811,0.00050455844,0.00003565341],"about_ca_topic_score_codex":0.00003519213,"about_ca_topic_score_gemma":0.000060466213,"teacher_disagreement_score":0.47180507,"about_ca_system_score_codex":0.00022908473,"about_ca_system_score_gemma":0.0014124697,"threshold_uncertainty_score":0.25056607},"labels":[],"label_agreement":null},{"id":"W2790064496","doi":"10.1200/jco.2018.36.6_suppl.68","title":"A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Internal medicine; Hazard ratio; Oncology; Radiation therapy; Cohort; Prospective cohort study; Prostate; Clinical endpoint; Cancer; Androgen deprivation therapy; Prostatectomy; Hormonal therapy; Clinical trial; Confidence interval","score_opus":0.04751857577989758,"score_gpt":0.42676588052566283,"score_spread":0.37924730474576523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790064496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940707,0.0013053196,0.000066165616,0.0026700802,0.00037091228,0.0012372715,0.00007529401,0.000007860774,0.00019637524],"genre_scores_gemma":[0.9932136,0.0036971457,0.0013597541,0.0005472128,0.0009109683,0.00016599867,0.000008363673,0.000025047833,0.000071885166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684346,0.0003986287,0.0017244782,0.0003078515,0.00039505732,0.0003305444],"domain_scores_gemma":[0.996739,0.00065221224,0.0011900357,0.0001751341,0.00086631015,0.00037733273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021112268,0.00018186617,0.0012335416,0.0003189079,0.000026429485,0.000008466906,0.00013618158,0.00037232172,0.000084104315],"category_scores_gemma":[0.001513521,0.00011757011,0.00027990964,0.0003411415,0.00067052344,0.000080016296,0.00004396057,0.00097642874,0.000013077385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07341798,0.0011262437,0.8909602,0.000017149623,0.00053243607,0.00016935695,0.0006707132,0.0000029283897,0.00447315,0.000001974314,0.0009929924,0.027634876],"study_design_scores_gemma":[0.019982098,0.029384265,0.943523,0.0002075715,0.00020069402,0.000024248746,0.00010406177,0.00013334406,0.004281899,0.00013712187,0.0019179012,0.00010381091],"about_ca_topic_score_codex":0.00008525944,"about_ca_topic_score_gemma":0.000107482505,"teacher_disagreement_score":0.05343588,"about_ca_system_score_codex":0.0006203636,"about_ca_system_score_gemma":0.0031918555,"threshold_uncertainty_score":0.5662215},"labels":[],"label_agreement":null},{"id":"W2790074491","doi":"10.1200/jco.2018.36.6_suppl.354","title":"Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Western University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Androgen deprivation therapy; Internal medicine; Hazard ratio; Subgroup analysis; Meta-analysis; Castration; Oncology; Toxicity; Cancer; Confidence interval","score_opus":0.11342769064778459,"score_gpt":0.4681460112735128,"score_spread":0.3547183206257282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790074491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923798,0.00035013066,0.00008422669,0.0051120147,0.0000927948,0.00037545327,0.000037805454,0.000003202373,0.0015645787],"genre_scores_gemma":[0.99482477,0.0011750344,0.0025954002,0.000126098,0.0001927232,0.00001002726,0.000007974546,0.00001006884,0.001057914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970876,0.00048903114,0.0015367882,0.0002126299,0.00045137093,0.00022258639],"domain_scores_gemma":[0.9965003,0.000957324,0.001145869,0.00016842893,0.0010106675,0.0002173733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023366406,0.00013235254,0.0015883038,0.0003700167,0.000038082362,0.000012807933,0.00008134443,0.000113357026,0.00007683327],"category_scores_gemma":[0.0008173055,0.00007516501,0.00013619359,0.0007227819,0.00053533353,0.00015977242,0.000028007116,0.0003803352,6.9321186e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3412297,0.005337447,0.53906715,0.00043231953,0.029254682,0.0073291394,0.0056679402,0.00023983326,0.016358914,0.00038075203,0.0018331254,0.052869003],"study_design_scores_gemma":[0.03292197,0.030313753,0.92031217,0.000350649,0.007544605,0.000121554825,0.0021284472,0.0008680883,0.004670798,0.00023726861,0.00037205074,0.00015864112],"about_ca_topic_score_codex":0.00026781758,"about_ca_topic_score_gemma":0.02343648,"teacher_disagreement_score":0.38124505,"about_ca_system_score_codex":0.00019422545,"about_ca_system_score_gemma":0.0022828083,"threshold_uncertainty_score":0.9943833},"labels":[],"label_agreement":null},{"id":"W2790090568","doi":"10.1200/jco.2018.36.4_suppl.165","title":"Regional variation in the costs of treating curative gastric cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Institute of Health Services and Policy Research; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Health care; Cancer; Disease; Indirect costs; Time horizon; Stage (stratigraphy); Emergency medicine; Internal medicine; Finance","score_opus":0.1675345703168537,"score_gpt":0.5004489368483205,"score_spread":0.3329143665314668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790090568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587919,0.00020776955,0.00065010076,0.031207567,0.000790896,0.00017993718,9.695888e-7,0.000002338931,0.00816849],"genre_scores_gemma":[0.99354696,0.0003811101,0.0014840288,0.002909802,0.0015244599,0.0000025833667,5.377788e-7,0.000003456947,0.00014708356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802005,0.00029543551,0.0012345328,0.00007518819,0.00027141644,0.00010340017],"domain_scores_gemma":[0.996362,0.0017447222,0.0014287961,0.00008342145,0.00032812465,0.00005293783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024295023,0.000056564233,0.00057487964,0.00011989465,0.000019918278,0.0000031577342,0.000116301875,0.000088942455,0.00011104416],"category_scores_gemma":[0.0017738226,0.000031771244,0.00016921789,0.00028478276,0.00014158801,0.00006781913,0.000017650236,0.00035735941,0.000002479065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034211131,0.00087509956,0.64994293,0.000019215748,0.00027598738,0.00012067321,0.0013032539,0.000018901253,0.00009985904,0.001418415,0.022531442,0.31997308],"study_design_scores_gemma":[0.0043847715,0.006919367,0.9731474,0.00009915198,0.00018931532,0.00006485272,0.000452625,0.00017659993,0.000006149849,0.00028194574,0.01425132,0.0000265022],"about_ca_topic_score_codex":0.00013848415,"about_ca_topic_score_gemma":0.00024922867,"teacher_disagreement_score":0.32320443,"about_ca_system_score_codex":0.00015446993,"about_ca_system_score_gemma":0.0006025147,"threshold_uncertainty_score":0.21235594},"labels":[],"label_agreement":null},{"id":"W2790094903","doi":"10.1200/jco.2018.36.5_suppl.217","title":"Immune response to reovirus (REO) in phase I study with chemotherapy in patients with KRAS mutant metastatic colorectal cancer (mCRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Immune system; CD8; Immunology; Cytokine; Peripheral blood mononuclear cell; Antibody; Cytotoxic T cell; Chemokine; Biology","score_opus":0.04564723968173807,"score_gpt":0.47113020347126344,"score_spread":0.4254829637895254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790094903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983647,0.00012719161,0.000020605356,0.0006342629,0.00013809493,0.0006425137,0.000015322978,0.0000015121905,0.00005582617],"genre_scores_gemma":[0.9987211,0.00009669537,0.00048795922,0.00043115174,0.0001579878,0.000041544256,0.0000034536895,0.000020579559,0.00003948783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732727,0.00074124505,0.0010259417,0.00027712787,0.00031789864,0.00031052544],"domain_scores_gemma":[0.99850094,0.00021450278,0.0005161951,0.00018610114,0.0003421057,0.00024016463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020106095,0.00015407341,0.0007428105,0.00015675,0.00002915612,0.000010502426,0.0002153778,0.00010409208,0.000062171464],"category_scores_gemma":[0.0006403512,0.000097389784,0.000084956504,0.00026532644,0.00018564146,0.000010701871,0.000055277727,0.00033183862,0.0000049218806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42832515,0.011827511,0.50453687,0.0000034632371,0.0006014314,0.00055159966,0.00028048563,0.00002369618,0.008973557,3.9984067e-7,0.00012332256,0.044752534],"study_design_scores_gemma":[0.056463126,0.2042681,0.7279881,0.000040712217,0.000049716436,0.0000168785,0.00014320272,0.000004133879,0.0057364875,0.000005866508,0.005161988,0.000121672914],"about_ca_topic_score_codex":0.00040244518,"about_ca_topic_score_gemma":0.008216447,"teacher_disagreement_score":0.37186202,"about_ca_system_score_codex":0.00018363162,"about_ca_system_score_gemma":0.0015663266,"threshold_uncertainty_score":0.45849705},"labels":[],"label_agreement":null},{"id":"W2790098578","doi":"10.1200/jco.2018.36.6_suppl.438","title":"Correlation of MTOR protein expression in the tumor and its microenvironment with more aggressive pathology at cystectomy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"PI3K/AKT/mTOR pathway; Cystectomy; Immunohistochemistry; Medicine; Stroma; Protein kinase B; Pathology; Cancer research; Tumor microenvironment; Apoptosis; Bladder cancer; Internal medicine; Biology; Cancer; Tumor cells","score_opus":0.04633276023454817,"score_gpt":0.39099780697556885,"score_spread":0.34466504674102066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790098578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959374,0.0008566616,0.000043873268,0.0022744462,0.00014323913,0.00042292633,0.0000033285485,0.0000014864632,0.00031663527],"genre_scores_gemma":[0.997723,0.00014965032,0.0008233576,0.00083530217,0.00033221874,0.000012286604,9.943135e-7,0.000007883858,0.00011531872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832445,0.0003680048,0.0008515888,0.00012787005,0.00021307741,0.000115019124],"domain_scores_gemma":[0.99789095,0.00036097836,0.0014364982,0.000112543334,0.00011047354,0.0000885764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081601157,0.00008834933,0.0006149716,0.000054174703,0.000029815017,0.0000016062868,0.00007386739,0.00014136243,0.00006987551],"category_scores_gemma":[0.00045609986,0.00004284096,0.00007700197,0.00005332249,0.00029457,0.00004397984,0.000036085647,0.00034171465,0.000005154909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06483017,0.0053815623,0.784714,0.00018120748,0.00040936805,0.0087932255,0.0055066366,0.000022263464,0.08252637,0.00003963243,0.0017108362,0.045884743],"study_design_scores_gemma":[0.017383171,0.041531052,0.91760445,0.0006603253,0.00027342065,0.0034253,0.00039836686,0.00006566341,0.01379961,0.00007641124,0.0047063758,0.00007588234],"about_ca_topic_score_codex":0.0000048155703,"about_ca_topic_score_gemma":0.000023561219,"teacher_disagreement_score":0.13289043,"about_ca_system_score_codex":0.00008262145,"about_ca_system_score_gemma":0.00024709388,"threshold_uncertainty_score":0.17470035},"labels":[],"label_agreement":null},{"id":"W2790105191","doi":"10.1200/jco.2018.36.4_suppl.209","title":"KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Tolerability; Discontinuation; Hepatocellular carcinoma; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Adverse effect; Gastroenterology; Progressive disease; Surgery; Clinical trial; Immunotherapy; Phases of clinical research; Disease; Cancer","score_opus":0.04166315873030817,"score_gpt":0.3684097563228039,"score_spread":0.32674659759249575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790105191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996858,0.00034000014,0.000048568483,0.00084612524,0.00028536012,0.0004712553,0.0000020326977,0.0000109217635,0.0011377184],"genre_scores_gemma":[0.99656284,0.00015044192,0.0014340932,0.0011905127,0.0004289556,0.000005607755,0.000005004128,0.00002966005,0.00019287028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969962,0.0002767384,0.0017319219,0.0002473505,0.00041573716,0.00033200116],"domain_scores_gemma":[0.9970252,0.00034766368,0.0013785425,0.00026449765,0.0007092102,0.00027492063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011193337,0.00019755751,0.0013608485,0.00016912966,0.000039441264,0.000008025982,0.00016295098,0.00029429182,0.00016808606],"category_scores_gemma":[0.0003269546,0.000113363596,0.00023860167,0.000309149,0.0004731322,0.00014031031,0.000021425189,0.0006587239,0.000009932465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17746541,0.0014440515,0.7658839,0.000018882338,0.00025237194,0.00042263506,0.00010416863,0.0000013790345,0.00008737582,0.0000026306643,0.0002656002,0.054051556],"study_design_scores_gemma":[0.06543103,0.086961746,0.8339954,0.00024688066,0.0002299327,0.00015757528,0.00004337754,0.000041205374,0.00027100867,0.0000106578955,0.012479828,0.00013136884],"about_ca_topic_score_codex":0.00006758607,"about_ca_topic_score_gemma":0.00013867357,"teacher_disagreement_score":0.11203439,"about_ca_system_score_codex":0.00028474513,"about_ca_system_score_gemma":0.0014807064,"threshold_uncertainty_score":0.46228334},"labels":[],"label_agreement":null},{"id":"W2790210454","doi":"10.1200/jco.2018.36.6_suppl.512","title":"Between-surgeon variation in 90-day mortality after radical cystectomy for bladder cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Cystectomy; Medicine; Perioperative; Bladder cancer; Mortality rate; Surgery; Retrospective cohort study; General surgery; Urology; Cancer; Internal medicine","score_opus":0.14497182955351218,"score_gpt":0.500408627386627,"score_spread":0.35543679783311477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790210454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879781,0.00043914295,0.0016654765,0.0058428715,0.0023032234,0.00044860534,0.000026282201,0.000009120607,0.0012871571],"genre_scores_gemma":[0.9895636,0.00018173573,0.0012108911,0.0022888244,0.006523832,0.000043577427,0.0000030873744,0.000018627206,0.00016581726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968112,0.0003866814,0.0019850507,0.00022385648,0.00031970607,0.00027349536],"domain_scores_gemma":[0.9968041,0.0014204214,0.00085522706,0.00016911488,0.00042564,0.0003254553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033783712,0.00013856341,0.0013070229,0.000114136754,0.000030752282,0.000007113569,0.000104536244,0.0004647029,0.00053151086],"category_scores_gemma":[0.0015846995,0.000098133285,0.0004185318,0.00014722288,0.00023237566,0.000104744766,0.000023759101,0.00055768376,0.000014755266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048258305,0.0010422404,0.8904455,0.000033811095,0.0008285505,0.00018327763,0.00021056588,0.0000012444107,0.000063626176,0.000024666306,0.0024330902,0.0999076],"study_design_scores_gemma":[0.012283168,0.008701368,0.9159914,0.000098884244,0.00076823315,0.000025087033,0.00001215604,0.000056727564,0.00010064491,0.000600241,0.061278284,0.00008377018],"about_ca_topic_score_codex":0.0001913587,"about_ca_topic_score_gemma":0.0004342223,"teacher_disagreement_score":0.09982383,"about_ca_system_score_codex":0.0002762242,"about_ca_system_score_gemma":0.0019353189,"threshold_uncertainty_score":0.5819671},"labels":[],"label_agreement":null},{"id":"W2790214444","doi":"10.1200/jco.2018.36.6_suppl.413","title":"New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Atezolizumab; Oncology; Gastroenterology; Proportional hazards model; Neutrophil to lymphocyte ratio; Performance status; Anemia; Chemotherapy; Cancer; Overall survival; Immunotherapy; Pembrolizumab","score_opus":0.07924778264830289,"score_gpt":0.41244393023660864,"score_spread":0.33319614758830574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790214444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872462,0.00008702568,0.006356952,0.0019179684,0.0016951057,0.00095897546,0.000048221937,0.000020051037,0.0016694777],"genre_scores_gemma":[0.9609449,0.00004487943,0.033820815,0.0015611356,0.0025822893,0.000016067352,0.0000086054015,0.000051513016,0.0009697805],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971369,0.00011750425,0.0015881137,0.00030066067,0.0004309443,0.0004258985],"domain_scores_gemma":[0.9953836,0.0010140417,0.0012536899,0.0002215937,0.0015153665,0.0006116791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004601847,0.00023665269,0.0013016149,0.000102618,0.00009153298,0.000013171155,0.00018019865,0.00031555668,0.00016985275],"category_scores_gemma":[0.0026729768,0.0001519407,0.00037663916,0.00010713487,0.00016012555,0.00018694071,0.000039448645,0.00050158694,0.000022441229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051096827,0.0024329454,0.43133825,0.000060556675,0.0006068209,0.00010248577,0.0006988715,0.000029491117,0.00022541004,0.00003960554,0.0028569682,0.51051176],"study_design_scores_gemma":[0.07298587,0.19995648,0.7073646,0.00033983449,0.001323401,0.00017419455,0.00008916807,0.0021669648,0.00029739205,0.0005638255,0.014406852,0.00033139132],"about_ca_topic_score_codex":0.000031073363,"about_ca_topic_score_gemma":0.00010182897,"teacher_disagreement_score":0.51018035,"about_ca_system_score_codex":0.00023501823,"about_ca_system_score_gemma":0.00422616,"threshold_uncertainty_score":0.74970263},"labels":[],"label_agreement":null},{"id":"W2790247164","doi":"10.1200/jco.2018.36.6_suppl.546","title":"Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Internal medicine; Receiver operating characteristic; Testicular cancer; Germ cell tumors; Retroperitoneal lymph node dissection; Teratoma; Pathology; Gastroenterology","score_opus":0.026547779995863323,"score_gpt":0.387959419497817,"score_spread":0.36141163950195365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790247164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953722,0.00032007572,0.00006219369,0.0024045426,0.0007712096,0.0005499035,0.000026102569,0.0000133519325,0.0004804169],"genre_scores_gemma":[0.9881293,0.000042617525,0.0033862272,0.0075388136,0.00074483297,0.000009350115,0.0000073815722,0.000032661897,0.00010882452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714124,0.00013840891,0.0016625533,0.0002789752,0.00042177146,0.0003570496],"domain_scores_gemma":[0.9960009,0.0005766265,0.0010215995,0.00030059466,0.000704663,0.0013956262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066437124,0.00020292404,0.0010729706,0.00016571888,0.000039364142,0.000012218507,0.00017758031,0.00015962264,0.00019060023],"category_scores_gemma":[0.003705552,0.00014388816,0.0004403189,0.00019600059,0.00014892807,0.00008873029,0.000058753398,0.00038643612,0.00013367565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047878567,0.009268064,0.9678569,0.00006071895,0.0001404801,0.003351067,0.00006201446,0.000020385343,0.00007266996,0.0000036580084,0.0011348773,0.013241325],"study_design_scores_gemma":[0.017224466,0.021951454,0.95447344,0.00028220192,0.00044019197,0.000064181135,0.000019603549,0.00013342673,0.00012101775,0.00015587959,0.005010069,0.00012406631],"about_ca_topic_score_codex":0.000051824376,"about_ca_topic_score_gemma":0.0000143783745,"teacher_disagreement_score":0.013383441,"about_ca_system_score_codex":0.0002697198,"about_ca_system_score_gemma":0.0024756533,"threshold_uncertainty_score":0.58675885},"labels":[],"label_agreement":null},{"id":"W2790262846","doi":"10.1200/jco.2018.36.6_suppl.71","title":"Validation of a genomic classifier to predict adverse pathology in men diagnosed with low risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Internal medicine; Logistic regression; Prostate; Gynecology; Cohort; Oncology; Cancer","score_opus":0.07545298122376336,"score_gpt":0.4602714696668144,"score_spread":0.38481848844305105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790262846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945543,0.00022639216,0.000037360776,0.0031212356,0.00036907426,0.0005760103,0.000019714533,0.000004527692,0.0010914218],"genre_scores_gemma":[0.9939606,0.0032385637,0.0013429928,0.000367329,0.00067962264,0.000030257363,0.0000038410008,0.000015373304,0.00036142886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972268,0.00049359584,0.0015216264,0.00019983137,0.00029216547,0.00026599146],"domain_scores_gemma":[0.9967934,0.0009337826,0.0011852941,0.00016792926,0.0006098332,0.00030977468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026657335,0.00010984343,0.0009989594,0.00022589178,0.000026236386,0.0000027710362,0.0001230726,0.00022620554,0.00017057442],"category_scores_gemma":[0.0015379494,0.0000663855,0.00014082404,0.00021480491,0.00040085448,0.00007987463,0.000047611582,0.0006280076,0.000018397232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030850021,0.0012118509,0.8924427,0.000038392187,0.00028632287,0.0012844148,0.0010672869,0.000080590944,0.0020709094,0.0000045191737,0.0020821507,0.06858085],"study_design_scores_gemma":[0.020471254,0.038347084,0.9308985,0.00024264194,0.0002531486,0.00008387901,0.00034290424,0.00010180686,0.0021231552,0.00009115147,0.0069709765,0.000073523755],"about_ca_topic_score_codex":0.00012232432,"about_ca_topic_score_gemma":0.00027845445,"teacher_disagreement_score":0.06850733,"about_ca_system_score_codex":0.00032587766,"about_ca_system_score_gemma":0.0025639518,"threshold_uncertainty_score":0.454834},"labels":[],"label_agreement":null},{"id":"W2790263191","doi":"10.1200/jco.2017.35.15_suppl.e15776","title":"Prospective genomic/transcriptomic profiling of advanced pancreatic ductal adenocarcinoma (PDAC) for personalized therapy: Feasibility and preliminary results from the COMPASS study (NCT02750657).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ontario Institute for Cancer Research; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Crizotinib; Clinical endpoint; Oncology; Primary tumor; Cancer; Metastasis; Clinical trial","score_opus":0.2491851295750121,"score_gpt":0.4981605094878511,"score_spread":0.24897537991283902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790263191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98656106,0.0034456416,0.00008674144,0.0056001577,0.00048049292,0.003321352,0.000074253796,0.000006913461,0.00042335762],"genre_scores_gemma":[0.9894456,0.0013301538,0.007974015,0.00023133798,0.0007883479,0.0000569634,0.0000067217475,0.000022053413,0.00014475198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953699,0.000977478,0.0025011608,0.00042781196,0.00040939188,0.0003142366],"domain_scores_gemma":[0.9867089,0.008802868,0.0026973446,0.0006679405,0.00084436295,0.00027857636],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007397239,0.00021286482,0.0026164004,0.000057420668,0.00031657924,0.000022125672,0.0004892127,0.0003033082,0.000028431474],"category_scores_gemma":[0.011610969,0.00012356947,0.00047167155,0.000045853925,0.0013794205,0.00014079083,0.00011440985,0.0009972337,0.0000015475973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15628529,0.0026999111,0.83131593,0.000031497566,0.0013842857,0.00012485923,0.0021567766,9.970437e-7,0.0012952526,0.00005098862,0.00018681139,0.004467385],"study_design_scores_gemma":[0.056839038,0.04612045,0.8899899,0.00010276305,0.0010413007,0.000117076015,0.0038694742,0.00027444962,0.000101929334,0.0010972476,0.00035125326,0.00009512497],"about_ca_topic_score_codex":0.00014977483,"about_ca_topic_score_gemma":0.000085080916,"teacher_disagreement_score":0.09944626,"about_ca_system_score_codex":0.00019538293,"about_ca_system_score_gemma":0.0019756055,"threshold_uncertainty_score":0.99671465},"labels":[],"label_agreement":null},{"id":"W2790263900","doi":"10.1200/jco.2018.36.5_suppl.212","title":"Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Adverse effect; Cohort; Internal medicine; Oncology; Pharmacokinetics; In vivo; Pharmacology; Gastroenterology","score_opus":0.07473774142480086,"score_gpt":0.4593583504307734,"score_spread":0.3846206090059725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790263900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935853,0.000093217284,0.0000112946545,0.0024051138,0.0025760725,0.00080278976,0.0000039912757,0.000005306769,0.00051695196],"genre_scores_gemma":[0.9956656,0.00013366526,0.0013991264,0.0011563718,0.0015151319,0.000010629192,0.0000020219545,0.000016979262,0.00010043791],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99607944,0.00041755367,0.0026120527,0.00017283857,0.0004699381,0.00024819144],"domain_scores_gemma":[0.9959411,0.00054542546,0.002499388,0.00024317212,0.0005952063,0.00017570252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025073746,0.00014074206,0.0012860713,0.00010836541,0.00003589132,0.0000052671503,0.00021373547,0.00025738397,0.00010683816],"category_scores_gemma":[0.0020170058,0.00007239342,0.00041642258,0.00030994587,0.0005697209,0.00009086831,0.00003823042,0.00067256,0.0000035422793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5775222,0.0102209775,0.037258424,0.000015183927,0.0002031215,0.000019826035,0.00012961647,3.1661222e-7,0.00082300993,0.0000042983625,0.0012535175,0.37254947],"study_design_scores_gemma":[0.5426683,0.27076563,0.090240344,0.00052884425,0.00017630497,0.0000328686,0.00010087673,0.000007208042,0.0033171475,0.000037783597,0.09200671,0.00011796544],"about_ca_topic_score_codex":0.000018879582,"about_ca_topic_score_gemma":0.00007022544,"teacher_disagreement_score":0.37243152,"about_ca_system_score_codex":0.00019501307,"about_ca_system_score_gemma":0.001725574,"threshold_uncertainty_score":0.30610943},"labels":[],"label_agreement":null},{"id":"W2790376926","doi":"10.1200/jco.2018.36.6_suppl.tps154","title":"Prospective randomized trial of genomic classifier impact on treatment decisions in patients at high risk of recurrence following radical prostatectomy (G-MINOR).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Clinical trial; Nomogram; Randomized controlled trial; Prostate cancer; Prospective cohort study; Internal medicine; Radiation therapy; Oncology; Surgery; Cancer","score_opus":0.07088323914440728,"score_gpt":0.45058203479432546,"score_spread":0.37969879564991815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790376926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514997,0.00021288244,0.000012933863,0.00031007637,0.0015581417,0.0023162144,0.000044811237,0.0000031844365,0.00039179585],"genre_scores_gemma":[0.9958116,0.0025415285,0.0010266423,0.00006560403,0.00043335874,0.00006406175,0.000007101824,0.000016334028,0.000033761014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994462,0.0010611902,0.0034337472,0.0002901633,0.00048738177,0.00026548377],"domain_scores_gemma":[0.9879607,0.0077447253,0.0032648458,0.00026649248,0.00044097134,0.00032228444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003199655,0.00023446702,0.003643131,0.00023274147,0.000039720595,0.00000384512,0.000119966055,0.0002900923,0.00009463403],"category_scores_gemma":[0.006871549,0.00012164937,0.0015852491,0.00016605419,0.0005287153,0.00006266533,0.000048935384,0.00046049376,0.000010634085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5895744,0.007721835,0.35028896,0.0000035487335,0.0011646549,0.00006586496,0.00016382254,0.0000063545776,0.00001277703,0.000016133563,0.00012721382,0.050854452],"study_design_scores_gemma":[0.483347,0.08995031,0.42469597,0.0001817141,0.00073078874,0.0000041859944,0.000008921925,0.0000141142655,0.00040622381,0.00041988536,0.00019201222,0.000048869864],"about_ca_topic_score_codex":0.00012562505,"about_ca_topic_score_gemma":0.000046919562,"teacher_disagreement_score":0.10622738,"about_ca_system_score_codex":0.0017559687,"about_ca_system_score_gemma":0.0016962081,"threshold_uncertainty_score":0.8226383},"labels":[],"label_agreement":null},{"id":"W2790707728","doi":"10.1200/jco.2018.36.6_suppl.333","title":"Loss of RSPO3 as a potential mechanism of greater invasiveness in prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Downregulation and upregulation; Cancer research; Protein kinase B; PI3K/AKT/mTOR pathway; Prostate; Cancer; Signal transduction; Radiation therapy; Oncology; Internal medicine; Biology; Cell biology","score_opus":0.12650037536201875,"score_gpt":0.5013553112941292,"score_spread":0.3748549359321105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790707728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930724,0.0004523891,0.000024971274,0.004444378,0.0008177478,0.0002679769,0.00000893503,0.0000021949847,0.000909015],"genre_scores_gemma":[0.9958528,0.0022043646,0.0003927122,0.000307858,0.0005951823,0.000006417948,0.0000014204733,0.000012339606,0.00062688574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971782,0.00029084363,0.0017456912,0.00014958993,0.0004000956,0.0002355577],"domain_scores_gemma":[0.9971047,0.00033244575,0.0011959595,0.00014507357,0.0010106523,0.00021118243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019982231,0.000102275284,0.0012822228,0.00021201739,0.000016724196,0.000002508044,0.00015488196,0.00022508777,0.00037519203],"category_scores_gemma":[0.0007140796,0.00006489186,0.0002859312,0.00019949912,0.0005758148,0.000078665464,0.00007010304,0.0004951979,0.000008980093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10433951,0.005219203,0.739486,0.0005535278,0.0016907377,0.008991297,0.0018754331,0.000019799545,0.019535957,0.00093572057,0.0011476149,0.11620524],"study_design_scores_gemma":[0.0720686,0.11417285,0.6235392,0.002038502,0.0009972302,0.0013963865,0.0008919313,0.00014107965,0.16453896,0.01317119,0.006752421,0.0002916236],"about_ca_topic_score_codex":0.00021202637,"about_ca_topic_score_gemma":0.0000981348,"teacher_disagreement_score":0.145003,"about_ca_system_score_codex":0.0001451641,"about_ca_system_score_gemma":0.0031455492,"threshold_uncertainty_score":0.55800694},"labels":[],"label_agreement":null},{"id":"W2790746043","doi":"10.1200/jco.2018.36.6_suppl.433","title":"Apparent plasticity in the biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Cystectomy; Bladder cancer; Cisplatin; Medicine; Pathology; Neoadjuvant therapy; Immunohistochemistry; Chemotherapy; Cancer research; GATA3; Cancer; Oncology; Internal medicine; Biology; Breast cancer; Gene","score_opus":0.17333692287129587,"score_gpt":0.4930251903307318,"score_spread":0.3196882674594359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790746043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96162003,0.00016929265,0.00006137356,0.036145635,0.0007602081,0.00038236778,0.000006189979,0.0000046698856,0.0008502482],"genre_scores_gemma":[0.97593254,0.0007032807,0.0005722121,0.021115752,0.0015861086,0.000023752142,4.839644e-7,0.000010275664,0.00005556974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672014,0.0009267646,0.0015237753,0.00022813372,0.00030049923,0.00030070168],"domain_scores_gemma":[0.9951447,0.0037345178,0.0004824304,0.00015897492,0.0002263545,0.00025298106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027951633,0.00014937624,0.0010505075,0.00015235925,0.000030643445,0.000007291298,0.0002506115,0.00030497392,0.00040194017],"category_scores_gemma":[0.003994379,0.000077675606,0.00023601415,0.0002899632,0.00027066696,0.000040632378,0.000037362228,0.0007766547,0.000027342405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15522134,0.008331681,0.47033846,0.000015343565,0.00045736704,0.003097422,0.004915869,0.000042971158,0.0053924033,0.000044346703,0.015415471,0.33672732],"study_design_scores_gemma":[0.011747773,0.030194849,0.90717673,0.00012955042,0.00006495956,0.000117500895,0.00043857985,0.000011368421,0.0003894679,0.0002014634,0.049446296,0.00008143117],"about_ca_topic_score_codex":0.00016613452,"about_ca_topic_score_gemma":0.001184588,"teacher_disagreement_score":0.4368383,"about_ca_system_score_codex":0.00028563393,"about_ca_system_score_gemma":0.0018887423,"threshold_uncertainty_score":0.47819334},"labels":[],"label_agreement":null},{"id":"W2790775646","doi":"10.1200/jco.2018.36.5_suppl.174","title":"Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Chemotherapy; Cancer; Lung cancer; Oncology; Retrospective cohort study; Dosing; Disease; Surgery","score_opus":0.05013185496317098,"score_gpt":0.48479626476395093,"score_spread":0.43466440980077997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790775646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852533,0.00085324276,0.0000020663947,0.010553007,0.0004406367,0.0004507669,0.000004490999,0.000005406751,0.0024371105],"genre_scores_gemma":[0.9963839,0.0009980884,0.00027162282,0.0007844912,0.0014396711,0.000025232894,0.000002249048,0.000013571051,0.00008118808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827206,0.00015898235,0.0009011605,0.00020314775,0.00026379517,0.00020087983],"domain_scores_gemma":[0.99760073,0.0007699644,0.00060644926,0.00015563503,0.00015787085,0.00070933055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048650376,0.0001625627,0.000953801,0.00010733112,0.00003154785,0.000009830663,0.000043861506,0.00014450181,0.000080898695],"category_scores_gemma":[0.00021086121,0.00007344427,0.00022280929,0.00009879348,0.00027812988,0.00006346912,0.000017238146,0.000277667,0.000010790571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016428748,0.004715566,0.6229601,0.000007952265,0.00030212454,0.0017260351,0.00007097018,0.0000016875849,0.000001730464,0.00002205437,0.0013017355,0.3524613],"study_design_scores_gemma":[0.020839607,0.1709441,0.7845803,0.00059700315,0.0004885319,0.00021146824,0.000029043049,0.000027197955,0.0000593041,0.00007459415,0.022074036,0.00007484631],"about_ca_topic_score_codex":0.000020043864,"about_ca_topic_score_gemma":0.00006195653,"teacher_disagreement_score":0.35238644,"about_ca_system_score_codex":0.0007663941,"about_ca_system_score_gemma":0.0014634412,"threshold_uncertainty_score":0.29949704},"labels":[],"label_agreement":null},{"id":"W2790809143","doi":"10.1200/jco.2018.36.6_suppl.tps707","title":"A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Everolimus; Adverse effect; Internal medicine; Clinical endpoint; Tolerability; Regimen; Renal cell carcinoma; Nivolumab; Lenvatinib; Phases of clinical research; Oncology; Urology; Surgery; Randomized controlled trial; Cancer; Clinical trial; Immunotherapy","score_opus":0.1251830929051753,"score_gpt":0.43276769499447115,"score_spread":0.30758460208929583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790809143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992905,0.00046522298,0.00002705831,0.001148288,0.0012643483,0.001112211,0.000011221613,0.00000965229,0.0030569767],"genre_scores_gemma":[0.99548864,0.00014497363,0.002609256,0.00027986267,0.0010918616,0.000051135677,0.00001655461,0.000042020045,0.0002757011],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99373144,0.0010229299,0.003527431,0.00047235723,0.00073467556,0.0005111389],"domain_scores_gemma":[0.9935189,0.0024666528,0.0024958681,0.000434774,0.00065067795,0.000433164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022588724,0.00037779292,0.0024196706,0.0005199968,0.000039770475,0.000011836084,0.00022467192,0.0005608976,0.0002662583],"category_scores_gemma":[0.0012595861,0.0002630075,0.00051875634,0.0004653875,0.00045820844,0.00021344212,0.000057919642,0.0009162396,0.000022502194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85575163,0.028337426,0.06557946,0.000061319275,0.00037163383,0.0048527485,0.0010511902,0.000010034908,0.002988568,0.0000104799365,0.00044886884,0.040536657],"study_design_scores_gemma":[0.504841,0.2835596,0.20396839,0.00018033384,0.0006504802,0.00012871556,0.00015856976,0.00018968202,0.0037901006,0.000044021974,0.0023134144,0.00017568625],"about_ca_topic_score_codex":0.00019100447,"about_ca_topic_score_gemma":0.0007165852,"teacher_disagreement_score":0.3509106,"about_ca_system_score_codex":0.0012020018,"about_ca_system_score_gemma":0.0028149786,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W2790847752","doi":"10.1200/jco.2018.36.6_suppl.516","title":"Centralization of radical cystectomy for bladder cancer in a universal healthcare system: Early results from a Canadian academic center.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Retrospective cohort study; Urology; Cancer; Surgery; General surgery; Internal medicine","score_opus":0.10613560939035803,"score_gpt":0.4604713902634751,"score_spread":0.35433578087311707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790847752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805887,0.00059981743,0.00014458124,0.014531134,0.0021360514,0.00058418117,0.0005817868,0.0000072865882,0.0008264938],"genre_scores_gemma":[0.9959357,0.0004284854,0.0005446722,0.0010852845,0.0019010047,0.0000055336764,0.00001691448,0.000016022756,0.0000664082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699014,0.00031433985,0.0019557155,0.00019790776,0.00024089024,0.00030098952],"domain_scores_gemma":[0.9970994,0.00057385536,0.0010625597,0.00012828113,0.0005268915,0.00060901884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094784476,0.00011223215,0.0010282141,0.00019122327,0.000032283373,0.0000029955359,0.00014033467,0.0005394901,0.00005329113],"category_scores_gemma":[0.0007587363,0.000086942084,0.00022661727,0.00016828396,0.00018893719,0.0000788621,0.000013468181,0.0005786897,0.0000034991158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055168487,0.0009889642,0.86153144,0.00022041526,0.0013273999,0.0006801993,0.0030396937,0.000014787464,0.00020653877,0.00047391112,0.0103485305,0.06599964],"study_design_scores_gemma":[0.076290205,0.020456504,0.8117445,0.0019289828,0.0007897993,0.00013622023,0.000770997,0.0004884291,0.00028224746,0.00017452476,0.08675787,0.00017971273],"about_ca_topic_score_codex":0.10660983,"about_ca_topic_score_gemma":0.1278266,"teacher_disagreement_score":0.07640934,"about_ca_system_score_codex":0.00095599337,"about_ca_system_score_gemma":0.006196793,"threshold_uncertainty_score":0.99943715},"labels":[],"label_agreement":null},{"id":"W2790862281","doi":"10.1200/jco.2018.36.6_suppl.431","title":"Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Nausea; Population; Rash; Metastatic Urothelial Carcinoma; Cancer; Adverse effect; Gastroenterology; Clinical trial; Bladder cancer","score_opus":0.04831238446769352,"score_gpt":0.4116602642828975,"score_spread":0.36334787981520394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790862281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967609,0.0000213995,0.000056032564,0.00026329476,0.0003121303,0.0019208564,0.00001724527,0.000009920919,0.00063821796],"genre_scores_gemma":[0.994338,0.0000058651076,0.004523163,0.00024289363,0.000742363,0.000057740785,0.000003929825,0.000043758715,0.000042337633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956289,0.00048346998,0.002363336,0.00038971595,0.00079403137,0.00034052966],"domain_scores_gemma":[0.99583846,0.0004192984,0.0019178338,0.00031315518,0.0010862047,0.0004250235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019112242,0.00028263367,0.002073126,0.00023781098,0.00005577042,0.000012556433,0.00017967005,0.00015810275,0.00013445977],"category_scores_gemma":[0.00094265875,0.00016870131,0.0002067582,0.0003150668,0.00046231295,0.0002517119,0.000037077934,0.0007960524,0.0000066077578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05798905,0.023532148,0.89514524,0.00003743657,0.001021497,0.0007657498,0.0014432536,0.0000024098083,0.00008010674,0.000005854038,0.000049603677,0.019927666],"study_design_scores_gemma":[0.083268106,0.2269739,0.6855792,0.00018298923,0.0011951555,0.00015414882,0.00067428657,0.000023079721,0.0015987264,0.000022403268,0.00020043818,0.00012758437],"about_ca_topic_score_codex":0.00029308244,"about_ca_topic_score_gemma":0.0013927078,"teacher_disagreement_score":0.20956604,"about_ca_system_score_codex":0.0003979911,"about_ca_system_score_gemma":0.0041935714,"threshold_uncertainty_score":0.7439216},"labels":[],"label_agreement":null},{"id":"W2790865280","doi":"10.1200/jco.2018.36.6_suppl.tps406","title":"Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Bicalutamide; Androgen deprivation therapy; Internal medicine; Endocrinology; Leuprorelin; Testosterone (patch); Clinical endpoint; Antagonist; Androgen receptor; Prostate cancer; Oncology; Urology; Adverse effect; Hormone; Randomized controlled trial; Cancer; Luteinizing hormone; Gonadotropin-releasing hormone; Receptor","score_opus":0.1541366464985643,"score_gpt":0.5221006580994223,"score_spread":0.367964011600858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790865280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985904,0.0006697183,0.00003878617,0.0023244852,0.00017617823,0.0065662754,0.000015073102,0.000011424164,0.00033901137],"genre_scores_gemma":[0.9945227,0.0031879318,0.00073817675,0.00036775347,0.00029592417,0.00031380693,0.000010707974,0.00004901691,0.0005140108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935729,0.0017058328,0.0029149044,0.000501922,0.00083794113,0.00046652637],"domain_scores_gemma":[0.9942639,0.0011744318,0.00248183,0.00039453237,0.001300238,0.00038505116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066858227,0.00034831002,0.0036947406,0.00031153052,0.00012391331,0.00005863662,0.00047819296,0.00020164213,0.00009215997],"category_scores_gemma":[0.00058720604,0.00016868734,0.00013450164,0.00057579944,0.000985281,0.0003699403,0.00018087635,0.00095153303,0.0000030830706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73255455,0.045899488,0.17394653,0.000018971197,0.0033756504,0.001986656,0.0043492396,0.0000034545717,0.00033988658,0.0000032382134,0.0004994815,0.03702283],"study_design_scores_gemma":[0.68758756,0.2514203,0.054856654,0.00019851899,0.000739034,0.0001380425,0.0034738365,0.00015011414,0.0003110502,0.000038807808,0.00091828656,0.00016783176],"about_ca_topic_score_codex":0.0013563024,"about_ca_topic_score_gemma":0.004386962,"teacher_disagreement_score":0.2055208,"about_ca_system_score_codex":0.00047133162,"about_ca_system_score_gemma":0.0039787297,"threshold_uncertainty_score":0.7058096},"labels":[],"label_agreement":null},{"id":"W2790901263","doi":"10.1200/jco.2018.36.5_suppl.86","title":"Aspartyl (Asparaginyl) β-Hydroxylase AABH as a serum biomarker for colorectal cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Colonoscopy; Fecal occult blood; Cancer; Internal medicine; Biomarker; Oncology; Stage (stratigraphy); Blood test; Cancer screening; Metastasis; Gastroenterology","score_opus":0.07550629596610527,"score_gpt":0.45377234960615753,"score_spread":0.3782660536400523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790901263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773514,0.0033693153,0.0006339556,0.0029427784,0.012782885,0.0002662813,0.00005620498,0.0000070994533,0.0025900258],"genre_scores_gemma":[0.9676486,0.0030950985,0.0016473929,0.004003694,0.021803321,0.000031644817,0.000012067252,0.00003684383,0.001721286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730253,0.00027193484,0.0014629412,0.00034099174,0.00021141735,0.0004101764],"domain_scores_gemma":[0.99703926,0.00031058345,0.0012567315,0.00022601824,0.0007455804,0.00042185734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021945362,0.00019957863,0.00092572893,0.00007343675,0.00009512115,0.000017583256,0.00037078455,0.0006181534,0.00021051377],"category_scores_gemma":[0.002223571,0.00016086662,0.0006690978,0.00010846215,0.00047387125,0.000012063108,0.00010873655,0.00033250995,0.000026412185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017718166,0.0013202867,0.007778166,0.000037361613,0.0014461552,0.000041160863,0.00011473572,0.000022496775,0.1975162,0.00023668437,0.38438892,0.38937965],"study_design_scores_gemma":[0.0053682225,0.010365662,0.015919292,0.000020726346,0.00023028375,0.00020919248,0.000037758866,0.00007984276,0.029658092,0.00041901326,0.93749416,0.0001977536],"about_ca_topic_score_codex":0.000036668847,"about_ca_topic_score_gemma":0.00042933118,"teacher_disagreement_score":0.55310524,"about_ca_system_score_codex":0.000045244127,"about_ca_system_score_gemma":0.0022743884,"threshold_uncertainty_score":0.655995},"labels":[],"label_agreement":null},{"id":"W2790931951","doi":"10.1200/jco.2018.36.5_suppl.185","title":"Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Immune system; CD8; Gastroenterology; Neutrophil to lymphocyte ratio; Carboplatin; Inflammation; Immunology; Chemokine; Paclitaxel; Systemic inflammation; Log-rank test; Oncology; Lymphocyte; Survival analysis; Cancer; Chemotherapy; Immunotherapy","score_opus":0.04094894280871056,"score_gpt":0.378669652425957,"score_spread":0.33772070961724643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790931951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971772,0.0012125836,0.000015976697,0.0005076547,0.00028697404,0.00030870762,0.0000047666394,0.000004185791,0.00048195245],"genre_scores_gemma":[0.9986247,0.00034589123,0.00061377895,0.0001472878,0.00019616685,0.0000029439352,0.0000051944357,0.0000127151,0.000051328785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967576,0.0003967089,0.0022785347,0.0001366538,0.00028080077,0.00014967137],"domain_scores_gemma":[0.9963098,0.00083553226,0.002048315,0.00014566314,0.00055187236,0.00010881824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019005183,0.0001297078,0.0012593748,0.00019251765,0.000021084135,0.000004764567,0.00008283799,0.00025177145,0.00004870603],"category_scores_gemma":[0.00074737635,0.00008011232,0.00016629824,0.00022221729,0.0003194975,0.00010822886,0.000018027647,0.00046559479,0.000001438268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09417262,0.0013533278,0.72609776,0.0002849902,0.0015352551,0.00023283051,0.0011025531,0.0000057650313,0.027112043,0.000026127784,0.00021958018,0.14785713],"study_design_scores_gemma":[0.033747703,0.03674055,0.92461807,0.00085444725,0.00045658275,0.00031218695,0.00032913827,0.00014223692,0.0018890417,0.000043680815,0.0007620635,0.00010432547],"about_ca_topic_score_codex":0.000087743436,"about_ca_topic_score_gemma":0.0001011034,"teacher_disagreement_score":0.19852026,"about_ca_system_score_codex":0.00013888683,"about_ca_system_score_gemma":0.00056398293,"threshold_uncertainty_score":0.32668853},"labels":[],"label_agreement":null},{"id":"W2791091396","doi":"10.1200/jco.2018.36.5_suppl.7","title":"Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Immunotherapy; Breast cancer; Immune system; Tumor-infiltrating lymphocytes; FOXP3; Oncology; Internal medicine; CD8; Cancer; Immunology","score_opus":0.06041739771748082,"score_gpt":0.4064554422141759,"score_spread":0.34603804449669506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791091396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995258,0.0006125307,0.000024067953,0.0021078095,0.0010294142,0.00049105764,0.000027719598,0.000009036847,0.0004403974],"genre_scores_gemma":[0.9897639,0.00076036796,0.0013500268,0.0065547214,0.0013241563,0.000031594063,0.00000241451,0.00003242463,0.00018037567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964939,0.00029944305,0.00220331,0.00022749661,0.00043994372,0.00033595343],"domain_scores_gemma":[0.9971356,0.00035146187,0.001534855,0.00023082922,0.0005385354,0.00020875377],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018992329,0.00020207104,0.0011350954,0.00017111385,0.000039042796,0.000017773886,0.00016235614,0.00022470797,0.001051623],"category_scores_gemma":[0.0001349086,0.00012865265,0.00027420325,0.00025921312,0.00040403864,0.00019931335,0.00003121615,0.0006610423,0.0000081524295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12214526,0.0010602465,0.5819706,0.000015775862,0.00041253728,0.00022309349,0.00021784872,0.0000011486403,0.00024764644,0.0000014501804,0.00018567551,0.29351875],"study_design_scores_gemma":[0.031470064,0.019443737,0.9059252,0.0004213292,0.00008648558,0.0001165902,0.000055082604,0.000008681804,0.0001411556,0.00000762493,0.042185046,0.00013900515],"about_ca_topic_score_codex":0.00033862915,"about_ca_topic_score_gemma":0.00037347156,"teacher_disagreement_score":0.3239546,"about_ca_system_score_codex":0.0006904625,"about_ca_system_score_gemma":0.0019828894,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W2791124263","doi":"10.1200/jco.2018.36.6_suppl.320","title":"Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; University of Ottawa; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Enzalutamide; Prostate cancer; Abiraterone acetate; Oncology; Family medicine; Internal medicine; Prednisone; Cancer; Targeted therapy; Androgen deprivation therapy; Androgen receptor","score_opus":0.2442960620736737,"score_gpt":0.5179284975572653,"score_spread":0.2736324354835916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791124263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958666,0.00032117605,0.000009494305,0.0020823814,0.00058995734,0.00053119176,0.00009036504,0.0000019409815,0.0005069027],"genre_scores_gemma":[0.99555075,0.0015283036,0.001171813,0.00019172773,0.0004519416,0.000016482943,0.0000058326013,0.000014700769,0.0010684431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716204,0.00020581197,0.0018647207,0.00016445476,0.0002709372,0.00033200797],"domain_scores_gemma":[0.9968277,0.0011495485,0.0010402395,0.0001284667,0.0005583908,0.00029565245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012172277,0.00012929995,0.0013104227,0.00015543382,0.000028241886,0.00000403273,0.000092614246,0.000059335092,0.0001039529],"category_scores_gemma":[0.00030117267,0.000079041165,0.00021695036,0.00016577242,0.00013340982,0.000054277978,0.000016523014,0.00027639486,6.459897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.045809753,0.0009780313,0.772869,0.00041143142,0.0020230468,0.0037032792,0.0011245457,0.00017508473,0.003568058,0.00009108763,0.0015050463,0.16774166],"study_design_scores_gemma":[0.071607456,0.1613467,0.7093414,0.0017048075,0.0018965839,0.00019958083,0.004966346,0.0015759856,0.01727931,0.0006343184,0.029062279,0.00038522136],"about_ca_topic_score_codex":0.708936,"about_ca_topic_score_gemma":0.96725124,"teacher_disagreement_score":0.25831527,"about_ca_system_score_codex":0.007725237,"about_ca_system_score_gemma":0.05167547,"threshold_uncertainty_score":0.9960839},"labels":[],"label_agreement":null},{"id":"W2791155737","doi":"10.1200/jco.2018.36.6_suppl.tps390","title":"Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Asymptomatic; Prostate cancer; Docetaxel; Internal medicine; Placebo; Clinical endpoint; Cancer; Oncology; Randomized controlled trial; Pathology; Androgen receptor","score_opus":0.10854863363798499,"score_gpt":0.4911975984817431,"score_spread":0.3826489648437581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791155737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913281,0.0003012538,0.000107154614,0.0010985043,0.0008016129,0.006281169,0.0000104615965,0.000012088711,0.00005961457],"genre_scores_gemma":[0.9975069,0.00037828434,0.0011762693,0.000287506,0.00021067692,0.0002224291,0.000011304147,0.000029110432,0.00017747421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910525,0.0021424082,0.0051818145,0.00037379668,0.0008368906,0.00041260675],"domain_scores_gemma":[0.992249,0.0033562826,0.0027181162,0.00024212162,0.0010055775,0.0004289081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007793341,0.0002944829,0.003693338,0.00059687695,0.000075953576,0.000035130524,0.00017067564,0.00014905358,0.000060859707],"category_scores_gemma":[0.004682574,0.00018524045,0.00031425306,0.0004152255,0.00045648473,0.00027039018,0.00011516529,0.0006174586,0.000003670305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9276355,0.015474547,0.034248672,0.00023161308,0.0012063766,0.0003004441,0.0054955673,0.000009209473,0.00047780282,0.000008790086,0.0001933359,0.014718177],"study_design_scores_gemma":[0.8688854,0.076330595,0.047415238,0.0012430731,0.0013880193,0.000025297191,0.0013725781,0.0027700353,0.00028011907,0.000068396046,0.00006454085,0.00015671003],"about_ca_topic_score_codex":0.0003758533,"about_ca_topic_score_gemma":0.0015685455,"teacher_disagreement_score":0.06085605,"about_ca_system_score_codex":0.0005655134,"about_ca_system_score_gemma":0.001206,"threshold_uncertainty_score":0.7553886},"labels":[],"label_agreement":null},{"id":"W2791166535","doi":"10.1200/jco.2018.36.6_suppl.59","title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Prostate; Prostate-specific antigen; Urology; Internal medicine; Proportional hazards model; Oncology; Cancer; Gynecology; Confidence interval","score_opus":0.13382764347067863,"score_gpt":0.48366137987541946,"score_spread":0.3498337364047408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791166535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946583,0.0014357576,0.000029335155,0.006422726,0.0020288115,0.00043274014,0.00003404876,0.000009011906,0.00014170926],"genre_scores_gemma":[0.93814343,0.057051133,0.00093805493,0.0005914344,0.002728331,0.0000059512945,0.000017308617,0.000025237236,0.0004991437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957323,0.0004408132,0.0028571056,0.00029234146,0.00036092827,0.00031652083],"domain_scores_gemma":[0.9959357,0.0006264487,0.0018268925,0.00021541434,0.00092717557,0.0004683624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030155487,0.00016108993,0.0015658654,0.00016100088,0.00006533231,0.0000136660965,0.00014887493,0.00037001292,0.00019518887],"category_scores_gemma":[0.0004903281,0.000107768225,0.0002927761,0.0001931645,0.0013861054,0.00014394235,0.000085671,0.00080554374,0.000018737403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018754542,0.001650519,0.67339736,0.0001064809,0.0005268651,0.00031316595,0.0003194172,7.502659e-7,0.057851836,0.00006293452,0.0014011492,0.24561496],"study_design_scores_gemma":[0.012532106,0.018518843,0.91509736,0.0002347054,0.00013998974,0.0000672254,0.00005626079,0.000045309094,0.0033219228,0.00019546437,0.049690682,0.00010015742],"about_ca_topic_score_codex":0.000024160443,"about_ca_topic_score_gemma":0.000014749918,"teacher_disagreement_score":0.2455148,"about_ca_system_score_codex":0.00010899565,"about_ca_system_score_gemma":0.0018024975,"threshold_uncertainty_score":0.5107163},"labels":[],"label_agreement":null},{"id":"W2791191075","doi":"10.1200/jco.2018.36.5_suppl.196","title":"Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Discontinuation; Medicine; Pembrolizumab; Nivolumab; Internal medicine; Dabrafenib; Metastatic melanoma; Oncology; Pediatrics; Cancer; Immunotherapy","score_opus":0.12593417400868853,"score_gpt":0.4620217195089515,"score_spread":0.336087545500263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791191075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735258,0.00006772043,0.00015561197,0.011325825,0.00012186353,0.00006448755,0.000007468728,0.000009067657,0.014722148],"genre_scores_gemma":[0.9923198,0.00011803451,0.0017031435,0.0009658259,0.0017657221,0.000012023953,0.000006545941,0.000013148149,0.0030957423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99757594,0.000076481585,0.0017994805,0.0001800944,0.00018828723,0.00017973868],"domain_scores_gemma":[0.9964996,0.0018607976,0.00096974184,0.00022579732,0.000229798,0.00021426685],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015489896,0.00011189839,0.00069768797,0.000046300207,0.000044664714,0.00001210222,0.0003107049,0.00019691265,0.0044738757],"category_scores_gemma":[0.002129611,0.00008741784,0.00021274229,0.00015856912,0.00016411358,0.000082638224,0.000045529137,0.00048390627,0.00035344224],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050079017,0.009087996,0.0144566735,0.000041798507,0.000543374,0.00020432376,0.0008428822,0.00018234958,0.10333712,0.00019175555,0.035195906,0.83090794],"study_design_scores_gemma":[0.0067956927,0.003395523,0.011174954,0.00011493424,0.000097177166,0.00010362196,0.00012111516,0.00067241106,0.05207222,0.002021058,0.9231706,0.0002606701],"about_ca_topic_score_codex":0.000008281356,"about_ca_topic_score_gemma":0.00007672143,"teacher_disagreement_score":0.88797474,"about_ca_system_score_codex":0.00007825602,"about_ca_system_score_gemma":0.00028544187,"threshold_uncertainty_score":0.9964362},"labels":[],"label_agreement":null},{"id":"W2791198557","doi":"10.1200/jco.2018.36.6_suppl.81","title":"Perspectives of health care professionals on active surveillance for the management of prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; University of Manitoba; Sunnybrook Health Science Centre; McGill University Health Centre; University of Toronto; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Family medicine; Health care; Focus group; Cancer; Nursing; Internal medicine","score_opus":0.12455546602764003,"score_gpt":0.5459222980038902,"score_spread":0.42136683197625024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791198557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9125327,0.014185769,0.00004739282,0.06883365,0.0014906978,0.0016702791,0.000113679554,0.000003637159,0.0011222321],"genre_scores_gemma":[0.987236,0.009965185,0.0011590231,0.0010008975,0.00044669808,0.000059943533,0.000001960752,0.000009333683,0.00012092324],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979542,0.00022296014,0.0012763365,0.00014147909,0.00025402303,0.00015101716],"domain_scores_gemma":[0.99481803,0.0015673835,0.0022631325,0.00015333129,0.0011050671,0.000093026865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016254957,0.00008845043,0.0010058334,0.00004204472,0.0000551839,0.0000013613824,0.0001021169,0.000073991665,0.000038458173],"category_scores_gemma":[0.00026023327,0.000044913144,0.00029192623,0.000085159656,0.00028957965,0.000026780583,0.000029985134,0.00021320661,7.103929e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01950725,0.0036208252,0.049680967,0.0005513725,0.0028756203,0.000024137007,0.008299558,0.000012786155,0.000009717718,0.0010564557,0.008292538,0.9060688],"study_design_scores_gemma":[0.011782564,0.0632569,0.85699874,0.0014288606,0.00035511272,0.000008310533,0.029268678,0.000010179751,0.0011886774,0.0002331438,0.035397496,0.00007136425],"about_ca_topic_score_codex":0.000033506905,"about_ca_topic_score_gemma":0.00005135373,"teacher_disagreement_score":0.9059974,"about_ca_system_score_codex":0.000324461,"about_ca_system_score_gemma":0.0014538941,"threshold_uncertainty_score":0.25791457},"labels":[],"label_agreement":null},{"id":"W2791218880","doi":"10.1200/jco.2018.36.4_suppl.76","title":"Tumor platinum concentrations and pathological responses following preoperative cisplatin-containing chemotherapy in gastric or gastroesophageal junction cancer patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Fluidigm (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cisplatin; Chemotherapy; Cancer; Pathological; Perioperative; Urology; Internal medicine; Pathology; Gastroenterology; Oncology; Surgery","score_opus":0.05029274608461426,"score_gpt":0.40545242540902404,"score_spread":0.3551596793244098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791218880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251384,0.0005412835,0.00054117874,0.0002733495,0.0057658115,0.00018048151,0.00000900111,0.0000033651997,0.00017170022],"genre_scores_gemma":[0.98500675,0.000709971,0.0026834048,0.0015481991,0.009866305,0.000013000261,0.000005557021,0.0000125440265,0.00015429228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976516,0.0005027865,0.0011880173,0.0002573989,0.00015347438,0.00024672475],"domain_scores_gemma":[0.9984043,0.00033460365,0.0007313816,0.00009575004,0.0002736442,0.00016028526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013367136,0.00014357333,0.0006306954,0.00007074203,0.00008051252,0.000017532046,0.000109355264,0.00023602074,0.000063853535],"category_scores_gemma":[0.0021150752,0.000101623606,0.00017470543,0.00010917045,0.00023267267,0.000021624737,0.00004576599,0.00036645032,0.0000010704604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022470042,0.000800198,0.88211197,0.000007393515,0.00019615353,0.000021999564,0.0006108527,0.000036430803,0.015041725,0.000028858169,0.0046038534,0.0740705],"study_design_scores_gemma":[0.011299835,0.01973471,0.91559416,0.00005191405,0.00008794936,0.00008973621,0.0003345279,0.0000793962,0.000944546,0.00002901665,0.05160066,0.000153523],"about_ca_topic_score_codex":0.000016206779,"about_ca_topic_score_gemma":0.00031588148,"teacher_disagreement_score":0.07391697,"about_ca_system_score_codex":0.000058335587,"about_ca_system_score_gemma":0.0010276093,"threshold_uncertainty_score":0.41440904},"labels":[],"label_agreement":null},{"id":"W2791245831","doi":"10.1200/jco.2018.36.6_suppl.238","title":"Impact of a geriatric oncology (GO) clinic on cancer treatment plans and supportive care for older adults with genitourinary (GU) cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Geriatric oncology; Polypharmacy; Cancer; Geriatrics; Genitourinary system; Prostate cancer; Radiation therapy; Internal medicine; Malignancy; Psychiatry","score_opus":0.08016295344106074,"score_gpt":0.5011839095874145,"score_spread":0.4210209561463538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791245831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909339,0.0014709907,0.000026626758,0.0035724181,0.0014102748,0.0011176823,0.00024773873,0.000010762418,0.00120962],"genre_scores_gemma":[0.98861825,0.004234856,0.0018365724,0.0006824496,0.0039266613,0.00008606239,0.0000121875155,0.000042544296,0.0005604176],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99619615,0.0003219204,0.0023285209,0.0003987358,0.00032058454,0.00043408823],"domain_scores_gemma":[0.99158746,0.0033503587,0.0027203262,0.00027046693,0.0014918688,0.00057954807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007848764,0.00030456114,0.0024856525,0.00022213852,0.0000643679,0.000004858522,0.00015763956,0.000618964,0.0005499081],"category_scores_gemma":[0.00095839327,0.00017922194,0.00067551626,0.00016869955,0.0005763875,0.000083728584,0.000038365044,0.0006316291,0.000008794982],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10396766,0.0042043277,0.37246934,0.00021812943,0.0024526282,0.00072517083,0.00412464,0.000015901136,0.000050626564,0.0000023417585,0.013202458,0.49856678],"study_design_scores_gemma":[0.035841387,0.30946738,0.6366999,0.00056195847,0.0014137377,0.00052200566,0.0009012535,0.000035063546,0.00015718829,0.000014527769,0.014235695,0.00014987269],"about_ca_topic_score_codex":0.0006089378,"about_ca_topic_score_gemma":0.0024149385,"teacher_disagreement_score":0.4984169,"about_ca_system_score_codex":0.0011931602,"about_ca_system_score_gemma":0.0074642263,"threshold_uncertainty_score":0.9981625},"labels":[],"label_agreement":null},{"id":"W2791247819","doi":"10.1200/jco.2018.36.6_suppl.tps157","title":"SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Clinical endpoint; Metformin; Urology; Randomization; Hazard ratio; Prostate-specific antigen; Internal medicine; Cancer; Randomized controlled trial; Surgery; Oncology; Confidence interval","score_opus":0.02751522433816516,"score_gpt":0.41634363149958015,"score_spread":0.388828407161415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791247819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718668,0.023055032,0.0007158949,0.00012806106,0.0020955668,0.0019871301,0.00010866899,0.0000032351238,0.000039597697],"genre_scores_gemma":[0.93851036,0.042580225,0.012004673,0.0017469589,0.0042620976,0.00045507192,0.000034563822,0.00006548378,0.00034054145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99635375,0.00054382667,0.0021753837,0.00029999483,0.00029150856,0.0003355669],"domain_scores_gemma":[0.9955284,0.00039167167,0.002490162,0.00024676183,0.0011310654,0.00021196228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032329971,0.00022653054,0.0018623867,0.000090469046,0.00005413549,0.0000110985675,0.00024468606,0.0003278234,0.00015175508],"category_scores_gemma":[0.001521695,0.00013845392,0.00067178416,0.000094917705,0.0006027252,0.000020877505,0.000049344562,0.00024348777,8.3946975e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72404873,0.0030938683,0.0006474186,0.000030895153,0.0008544793,0.000002892358,0.00012876539,0.0000015385314,0.0010977908,0.0000023147556,0.0014521102,0.2686392],"study_design_scores_gemma":[0.60257447,0.04480968,0.0002184193,0.00003910159,0.00034091878,0.0000013802693,0.000011881372,0.000026164496,0.006932798,0.00003357871,0.34487915,0.00013243542],"about_ca_topic_score_codex":0.000008112796,"about_ca_topic_score_gemma":0.000034618817,"teacher_disagreement_score":0.34342703,"about_ca_system_score_codex":0.000037107766,"about_ca_system_score_gemma":0.00088258134,"threshold_uncertainty_score":0.5645987},"labels":[],"label_agreement":null},{"id":"W2791249363","doi":"10.1200/jco.2018.36.4_suppl.147","title":"Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interquartile range; Perioperative; Gastroesophageal Junction; Surgery; Cancer; Pathological; Esophageal cancer; Retrospective cohort study; Disease; Internal medicine; Adenocarcinoma","score_opus":0.05472872287465947,"score_gpt":0.45615367557516895,"score_spread":0.4014249527005095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791249363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312276,0.00038555523,0.0011456269,0.00348602,0.0011651014,0.00021103806,0.000014734969,0.0000031288932,0.00046601513],"genre_scores_gemma":[0.99558514,0.0009926086,0.0017308545,0.0008865875,0.0005043441,0.000005650256,9.282032e-7,0.000008430188,0.0002854577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754333,0.00020935478,0.0015986889,0.00016400067,0.0003166393,0.00016798216],"domain_scores_gemma":[0.9963724,0.00078749517,0.0017196722,0.00012303168,0.00083841995,0.00015896346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001010166,0.00012163238,0.0012179639,0.00013683097,0.000018735358,0.0000032290627,0.000095439296,0.00013744696,0.0001987211],"category_scores_gemma":[0.0009473127,0.00008357311,0.00025717643,0.00012316556,0.00031914655,0.00014523794,0.00006938447,0.0004315913,0.0000013805051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008316092,0.00034914442,0.8609261,0.00006470504,0.00032987614,0.00008159449,0.00025393575,0.0000029042722,0.0000598423,0.000028211927,0.00041648065,0.12917113],"study_design_scores_gemma":[0.0054700826,0.019664645,0.9719405,0.00038069897,0.0003083888,0.00002876419,0.00024613822,0.000020726964,0.00046992785,0.000092683345,0.0013256556,0.000051744813],"about_ca_topic_score_codex":0.00007278669,"about_ca_topic_score_gemma":0.00034468746,"teacher_disagreement_score":0.12911938,"about_ca_system_score_codex":0.000086487635,"about_ca_system_score_gemma":0.0004008485,"threshold_uncertainty_score":0.34080127},"labels":[],"label_agreement":null},{"id":"W2791359474","doi":"10.1200/jco.2018.36.6_suppl.297","title":"Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Androgen deprivation therapy; Internal medicine; Population; Febrile neutropenia; Adverse effect; Cancer; Oncology; Neutropenia; Surgery; Chemotherapy","score_opus":0.14804286026040095,"score_gpt":0.5351239183200455,"score_spread":0.38708105805964454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791359474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922935,0.000084975785,0.00068112754,0.0055662543,0.00031578232,0.00041658664,0.00004450166,0.00000766525,0.0005896235],"genre_scores_gemma":[0.9882861,0.00016467052,0.00846251,0.0008590949,0.0013206813,0.000037243557,0.00004499945,0.000011922154,0.0008128184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792546,0.00016081032,0.0011257322,0.00022351048,0.0003458886,0.00021859622],"domain_scores_gemma":[0.9957431,0.0014423727,0.0010113207,0.0001513188,0.0013617517,0.00029015087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000806953,0.000113741175,0.0010778235,0.00021770535,0.000081749415,0.000014800382,0.00007401134,0.000119535776,0.00016996403],"category_scores_gemma":[0.00047437864,0.00006674839,0.0003173171,0.00045676727,0.00028898744,0.00010566942,0.000010188296,0.00030487133,0.0000029907262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022589605,0.00055366824,0.9583089,0.000011347715,0.0018645924,0.00020464919,0.0004849043,0.00012003296,0.00019424298,0.000035686673,0.00056025217,0.015072134],"study_design_scores_gemma":[0.009504722,0.009045642,0.97330487,0.00008866018,0.0017484365,0.0000069282355,0.00020636305,0.0018167401,0.001031038,0.000121971905,0.003039469,0.00008516042],"about_ca_topic_score_codex":0.0019607793,"about_ca_topic_score_gemma":0.009158829,"teacher_disagreement_score":0.014995984,"about_ca_system_score_codex":0.0002733853,"about_ca_system_score_gemma":0.0024885056,"threshold_uncertainty_score":0.5110842},"labels":[],"label_agreement":null},{"id":"W2791471075","doi":"10.1200/jco.2018.36.6_suppl.20","title":"Genomic variations associated with prostate cancer in large cohort of African American men.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Cohort; Internal medicine","score_opus":0.07277079858176388,"score_gpt":0.479823935837381,"score_spread":0.4070531372556171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791471075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878968,0.00020782201,0.000030946383,0.0054604644,0.00018957656,0.00033148422,0.00003160618,0.0000047348285,0.0058465884],"genre_scores_gemma":[0.9968445,0.0011113507,0.00049971306,0.00030314547,0.00035714975,0.00001360641,0.000004818574,0.000013916839,0.00085180363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976351,0.00033934976,0.0012734056,0.0001433555,0.00032558484,0.00028315483],"domain_scores_gemma":[0.9965957,0.00077512214,0.0015020903,0.00012152214,0.00077889964,0.00022665679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026332808,0.00009188811,0.0011460801,0.00017600876,0.000032077834,0.0000037588538,0.000107160966,0.00011419948,0.00023546936],"category_scores_gemma":[0.0011310024,0.000055982717,0.00013650348,0.00043128588,0.00056107197,0.00005456283,0.000033764376,0.0005573434,0.000005436739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072935894,0.0016770221,0.97587764,0.000007938136,0.00083597266,0.0001780461,0.00041048092,0.000005204203,0.00026196608,0.000032636144,0.0011448362,0.012274689],"study_design_scores_gemma":[0.009504969,0.015811564,0.96859956,0.00010556592,0.0002861375,0.000020267727,0.0002648527,0.0001592909,0.00009463867,0.00008339217,0.005013947,0.0000558043],"about_ca_topic_score_codex":0.00025247282,"about_ca_topic_score_gemma":0.0012331991,"teacher_disagreement_score":0.014134542,"about_ca_system_score_codex":0.00048456338,"about_ca_system_score_gemma":0.0034089999,"threshold_uncertainty_score":0.60474193},"labels":[],"label_agreement":null},{"id":"W2791503968","doi":"10.1200/jco.2018.36.6_suppl.193","title":"Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; William Osler Health System; Western University; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Proportional hazards model; Cohort; Cancer","score_opus":0.1017387499189603,"score_gpt":0.49130339179874516,"score_spread":0.38956464187978485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791503968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837476,0.008479105,0.0000024153103,0.0059944037,0.0003096179,0.00085736363,0.0002871587,0.000010474216,0.00031188646],"genre_scores_gemma":[0.96683806,0.029771477,0.0003210151,0.0012846763,0.00041250975,0.000047180412,0.000017048169,0.000040566312,0.0012674461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950393,0.0005321032,0.0026280892,0.00037730328,0.0009111591,0.0005120712],"domain_scores_gemma":[0.99039394,0.0012937046,0.0051078917,0.00028628364,0.0024615135,0.00045664975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018292367,0.00033649712,0.002429126,0.00024845006,0.0000650963,0.000010809107,0.0002494289,0.0003003313,0.000087454566],"category_scores_gemma":[0.0016798401,0.00019722842,0.0004949859,0.0004072014,0.0013613114,0.00016823618,0.00006311471,0.0010861985,0.000007785538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22311324,0.008211435,0.3969606,0.0003444557,0.009199547,0.003927329,0.004235427,0.0002955069,0.10614249,0.000064025626,0.02343347,0.2240725],"study_design_scores_gemma":[0.03383509,0.05191042,0.8088185,0.0009268821,0.0009782435,0.00026311752,0.00029557073,0.00007426,0.093520865,0.00020318755,0.008862436,0.0003114327],"about_ca_topic_score_codex":0.0008443767,"about_ca_topic_score_gemma":0.0000963332,"teacher_disagreement_score":0.4118579,"about_ca_system_score_codex":0.0003341141,"about_ca_system_score_gemma":0.0024917147,"threshold_uncertainty_score":0.80427414},"labels":[],"label_agreement":null},{"id":"W2791520417","doi":"10.1200/jco.2018.36.6_suppl.tps383","title":"ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Abiraterone acetate; Enzalutamide; Clinical endpoint; Placebo; Performance status; Androgen receptor; Cancer; Randomized controlled trial; Pathology","score_opus":0.1433848701866493,"score_gpt":0.5219258120212307,"score_spread":0.37854094183458137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791520417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916878,0.0003411282,0.00034357415,0.005157646,0.00017114318,0.0016836065,0.000034870085,0.0000040450464,0.0005761829],"genre_scores_gemma":[0.99403733,0.0009082662,0.003919166,0.00025171053,0.00042501758,0.00006530711,0.000010649499,0.000019564734,0.00036300777],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99740005,0.00031089722,0.001403522,0.00018883668,0.00043004143,0.00026664216],"domain_scores_gemma":[0.9954786,0.001385822,0.0014393764,0.00012269722,0.0013630859,0.00021045202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025291252,0.00013561735,0.0014094976,0.00021312223,0.000029006747,0.00000641736,0.000073370305,0.000108032975,0.0000138933765],"category_scores_gemma":[0.0009842761,0.000073611096,0.00015985298,0.00024677752,0.0006010006,0.00013526434,0.000015828307,0.00043852467,0.0000013177101],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9372068,0.0065473984,0.002530421,0.00007164182,0.0011957187,0.00072407903,0.00091804087,0.000011722604,0.00081502565,0.000048763668,0.0012733015,0.048657067],"study_design_scores_gemma":[0.67463523,0.3017132,0.013284345,0.00035869094,0.0010752779,0.00014955725,0.00080667034,0.0008243667,0.0027829555,0.00047997397,0.0037720648,0.00011765613],"about_ca_topic_score_codex":0.00006598406,"about_ca_topic_score_gemma":0.00018591082,"teacher_disagreement_score":0.2951658,"about_ca_system_score_codex":0.00023035923,"about_ca_system_score_gemma":0.0030749994,"threshold_uncertainty_score":0.5454917},"labels":[],"label_agreement":null},{"id":"W2791544907","doi":"10.1200/jco.2018.36.4_suppl.211","title":"Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Ontario Institute for Cancer Research; Toronto General Hospital; University Health Network; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Precision medicine; Internal medicine; Primary tumor; Cancer; Pathology; Metastasis","score_opus":0.08227963421941238,"score_gpt":0.4189014470934742,"score_spread":0.33662181287406184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791544907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98545,0.00082742225,0.0016710741,0.0055670845,0.0052226093,0.00050477637,0.00013698923,0.000002686846,0.00061733334],"genre_scores_gemma":[0.97209775,0.0009860857,0.00558015,0.0015668757,0.019564621,0.000011546364,0.00006187867,0.000024194529,0.000106893815],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967199,0.0003066569,0.002181286,0.000335919,0.00020247168,0.0002537953],"domain_scores_gemma":[0.99286085,0.0040539987,0.001790363,0.00043093716,0.0006379323,0.00022593005],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022311842,0.0001729327,0.0008949979,0.00003259786,0.000113292386,0.000016895467,0.00053548015,0.00037915874,0.000026000662],"category_scores_gemma":[0.010558245,0.000109739514,0.00040197014,0.000057439192,0.0004911736,0.0000071643335,0.00014627085,0.00033610314,0.000008007089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64523655,0.0011380191,0.012104615,0.000010212273,0.0010413164,0.00007294316,0.0007763647,0.0001896519,0.05926281,0.00021370698,0.17789556,0.10205823],"study_design_scores_gemma":[0.1496845,0.07350126,0.06898435,0.00006125885,0.00053200556,0.000048188384,0.00021470839,0.00029834587,0.0028587214,0.0019341791,0.7016115,0.00027096205],"about_ca_topic_score_codex":0.00010440931,"about_ca_topic_score_gemma":0.00032147535,"teacher_disagreement_score":0.5237159,"about_ca_system_score_codex":0.00006855404,"about_ca_system_score_gemma":0.0009728415,"threshold_uncertainty_score":0.99777627},"labels":[],"label_agreement":null},{"id":"W2791572489","doi":"10.1200/jco.2018.36.6_suppl.374","title":"Retrospective analysis of fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Internal medicine; Androgen deprivation therapy; Cancer; Concomitant; Univariate analysis; Oncology; Surgery; Multivariate analysis; Androgen receptor","score_opus":0.13964410447729805,"score_gpt":0.4978893387357752,"score_spread":0.3582452342584771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791572489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949844,0.00030462275,0.000044305503,0.0017435491,0.00003947738,0.00038003622,0.000025483016,0.0000040354644,0.002474118],"genre_scores_gemma":[0.99708635,0.0005644127,0.0015879057,0.00009215648,0.00012551078,0.000017315278,0.000008383579,0.000013208147,0.000504737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972218,0.00032596174,0.0014706267,0.00021430149,0.00052644446,0.00024086505],"domain_scores_gemma":[0.9963834,0.00048520864,0.0013551264,0.00016642272,0.0013834594,0.0002263554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001572885,0.00014060608,0.0017673323,0.00049178314,0.000031230593,0.0000076013052,0.00009019123,0.000103654595,0.00019975498],"category_scores_gemma":[0.00039746883,0.00007142544,0.00020499277,0.0012759174,0.00059647224,0.000114045404,0.000014303574,0.0004832558,0.0000011091441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041234855,0.0012431813,0.9408855,0.00003263786,0.007937163,0.0011424834,0.00063731207,0.00015340335,0.0010397355,0.00004508682,0.00016701312,0.0054816348],"study_design_scores_gemma":[0.01423886,0.030741522,0.94751173,0.00021339416,0.0044928994,0.00003563728,0.0005350409,0.0004439211,0.0014277112,0.00005820503,0.00022024513,0.00008081784],"about_ca_topic_score_codex":0.00062195526,"about_ca_topic_score_gemma":0.0054064374,"teacher_disagreement_score":0.029498342,"about_ca_system_score_codex":0.0004620056,"about_ca_system_score_gemma":0.0026101216,"threshold_uncertainty_score":0.46302438},"labels":[],"label_agreement":null},{"id":"W2791666791","doi":"10.1200/jco.2018.36.4_suppl.204","title":"Phase II LAPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Neutropenia; Gemcitabine; Clinical endpoint; Internal medicine; Regimen; Phases of clinical research; Adverse effect; Febrile neutropenia; Induction chemotherapy; Pancreatic cancer; Nab-paclitaxel; Anemia; Gastroenterology; Progressive disease; Oncology; Surgery; Cancer; Clinical trial; Chemotherapy","score_opus":0.10133424120144549,"score_gpt":0.5064914284515502,"score_spread":0.40515718725010463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791666791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98803484,0.00039773484,0.0016061782,0.0034069733,0.001449761,0.0021064985,0.000060490318,0.0000144741625,0.0029230448],"genre_scores_gemma":[0.97733474,0.00085535157,0.015544933,0.0016190632,0.0031060758,0.00010373419,0.000017083476,0.00005291473,0.0013661315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99387676,0.00050856225,0.003681335,0.00038657244,0.00089873304,0.0006480377],"domain_scores_gemma":[0.987703,0.0045216237,0.00317635,0.00044625613,0.0033775351,0.00077522715],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042161546,0.00030946283,0.004040911,0.0002368517,0.0001532371,0.0000075345897,0.00035513644,0.0005926625,0.00040475608],"category_scores_gemma":[0.009572192,0.00019541357,0.00065967103,0.00031459623,0.0013044121,0.00020382954,0.00009851583,0.0009569198,0.000010207907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7683706,0.02053249,0.06820194,0.00019280992,0.0019541143,0.00009988682,0.00027893402,0.0000065699387,0.00026181582,0.00010268582,0.00845509,0.13154306],"study_design_scores_gemma":[0.5004495,0.42232934,0.027141398,0.00044696784,0.002201509,0.00004363494,0.0001119598,0.00038980343,0.000100326666,0.000345408,0.046244085,0.00019607288],"about_ca_topic_score_codex":0.000046669633,"about_ca_topic_score_gemma":0.00009635501,"teacher_disagreement_score":0.40179685,"about_ca_system_score_codex":0.00038014684,"about_ca_system_score_gemma":0.006803154,"threshold_uncertainty_score":0.99882734},"labels":[],"label_agreement":null},{"id":"W2791697169","doi":"10.1200/jco.2018.36.5_suppl.184","title":"Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; TIGIT; Pembrolizumab; Internal medicine; CD8; Immunophenotyping; Gastroenterology; Oncology; Immune system; Immunotherapy; Cancer; Immunology; Flow cytometry","score_opus":0.06533237155806704,"score_gpt":0.4068555114984129,"score_spread":0.3415231399403459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791697169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265885,0.002343773,0.000050101786,0.0014220465,0.00024442404,0.00012703234,0.0000032172472,0.000004526496,0.0031460505],"genre_scores_gemma":[0.99543715,0.00095591316,0.0023744253,0.0005336234,0.00041129423,0.0000011434026,0.0000015227045,0.000013737956,0.00027117695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976984,0.00022293479,0.0016255388,0.00012232552,0.00017995037,0.00015084744],"domain_scores_gemma":[0.9972394,0.00070383324,0.0014180857,0.00015664462,0.0003269761,0.00015505636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016344342,0.0001106168,0.0012846959,0.00011931779,0.000027653738,0.0000047739054,0.00009515035,0.00014132429,0.00036707846],"category_scores_gemma":[0.00030275361,0.000064434134,0.00024480122,0.00012572814,0.0005235651,0.000050622082,0.000021648175,0.00031474288,0.0000048256647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24709603,0.0021354442,0.3688362,0.00013063682,0.005274106,0.00085715234,0.00044790673,0.0000013675212,0.033101454,0.00007414291,0.0026020207,0.33944353],"study_design_scores_gemma":[0.03170041,0.0611709,0.8823457,0.00014232247,0.00094557676,0.00242892,0.00018026873,0.000056517558,0.0017359643,0.0000715847,0.019128582,0.00009329778],"about_ca_topic_score_codex":0.000049296636,"about_ca_topic_score_gemma":0.000044460063,"teacher_disagreement_score":0.51350945,"about_ca_system_score_codex":0.000046496818,"about_ca_system_score_gemma":0.0007916112,"threshold_uncertainty_score":0.40192518},"labels":[],"label_agreement":null},{"id":"W2791715186","doi":"10.1200/jco.2018.36.6_suppl.13","title":"The association between physician trust and prostate specific antigen screening: Implications for shared decision making.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Family medicine; Health Information National Trends Survey; Logistic regression; Receipt; Prostate cancer screening; Cancer screening; Cancer; Prostate-specific antigen; Prostate cancer; Internal medicine; Health care; Health information","score_opus":0.5069406588063454,"score_gpt":0.5957774695631556,"score_spread":0.08883681075681016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791715186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7987027,0.0033074184,0.011635543,0.1706161,0.0058482117,0.004089323,0.00027227035,0.00007081495,0.0054576197],"genre_scores_gemma":[0.96371794,0.0011837434,0.027890285,0.0030943626,0.0038149722,0.00008064276,0.000013538546,0.000027872087,0.00017665394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994006,0.0017990596,0.0032812934,0.00021365045,0.00027496248,0.00042507783],"domain_scores_gemma":[0.9545168,0.03666352,0.0055914777,0.00047595755,0.0025307303,0.00022149995],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.0058318065,0.00012006696,0.0007372128,0.00008860229,0.0017248685,0.00002704396,0.00056222884,0.0004757424,0.000016862028],"category_scores_gemma":[0.012223204,0.0000825634,0.00020787917,0.00020771941,0.00022614664,0.00021026735,0.00021175368,0.00122826,0.00002827187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000857103,0.00006603988,0.5892204,0.000013302957,0.000087902474,2.384225e-7,0.0009032543,4.6019838e-7,0.000011450685,0.0007414071,0.028800484,0.37929797],"study_design_scores_gemma":[0.0014360384,0.0013808364,0.5892802,0.00012679522,0.000035689707,6.375644e-7,0.0006677235,0.00004803113,0.000001114259,0.008531531,0.39844042,0.000050984796],"about_ca_topic_score_codex":0.000010668345,"about_ca_topic_score_gemma":0.000106359825,"teacher_disagreement_score":0.37924698,"about_ca_system_score_codex":0.00035817642,"about_ca_system_score_gemma":0.0010855149,"threshold_uncertainty_score":0.9995747},"labels":[],"label_agreement":null},{"id":"W2791716014","doi":"10.1200/jco.2018.36.6_suppl.196","title":"Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Trillium Health Centre; University of Alberta; Juravinski Cancer Centre; Dalhousie University; University of Manitoba; University of Calgary; Hôtel-Dieu de Québec; McMaster University; Université de Sherbrooke","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Internal medicine; Interim analysis; Enzalutamide; Cancer; Clinical endpoint; Androgen deprivation therapy; Oncology; Clinical trial; Urology; Androgen receptor","score_opus":0.1431754224399609,"score_gpt":0.4761652050253367,"score_spread":0.3329897825853758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791716014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950828,0.00070941803,0.0000022643976,0.001964937,0.00039608055,0.0011654012,0.00004181948,0.000013877139,0.00062341534],"genre_scores_gemma":[0.9945664,0.0022953264,0.00093557726,0.00017809674,0.0000819802,0.00004565396,0.00001169568,0.000040661427,0.001844624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939252,0.0007389316,0.0035263516,0.00039162388,0.0008515254,0.00056633604],"domain_scores_gemma":[0.99368334,0.0011232749,0.0027143194,0.00031267718,0.0017003439,0.00046603117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018246691,0.00031473226,0.0024399383,0.00043530902,0.000058625905,0.000016513448,0.00021489094,0.000195562,0.00023613875],"category_scores_gemma":[0.0009280849,0.00017737468,0.0002813927,0.0007568709,0.00087966584,0.0003240952,0.00007519127,0.00086192053,0.000014707576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062372796,0.002860671,0.9037668,0.00019714015,0.0013860766,0.0015909992,0.0010477396,0.000058672547,0.0010050549,0.000010769347,0.00038803503,0.025315208],"study_design_scores_gemma":[0.035033554,0.050559353,0.9081831,0.0016204674,0.00082669134,0.00003647354,0.00022110109,0.00014747422,0.0026501026,0.00007164944,0.00045943676,0.00019058655],"about_ca_topic_score_codex":0.001611504,"about_ca_topic_score_gemma":0.0033195047,"teacher_disagreement_score":0.047698684,"about_ca_system_score_codex":0.00081887876,"about_ca_system_score_gemma":0.0035575358,"threshold_uncertainty_score":0.723313},"labels":[],"label_agreement":null},{"id":"W2791757400","doi":"10.1200/jco.2018.36.6_suppl.434","title":"Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Metastatic Urothelial Carcinoma; Atezolizumab; Oncology; Progression-free survival; Neutropenia; Ramucirumab; Progressive disease; Population; Tolerability; Discontinuation; Febrile neutropenia; Gastroenterology; Pembrolizumab; Chemotherapy; Cancer; Randomized controlled trial; Adverse effect; Bladder cancer; Immunotherapy","score_opus":0.12710766081345845,"score_gpt":0.444385500738038,"score_spread":0.3172778399245796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791757400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414366,0.0005953118,0.0005621053,0.0022864789,0.0006980324,0.0009802799,0.0000635626,0.000011247201,0.000659324],"genre_scores_gemma":[0.9936281,0.00015456899,0.0016334424,0.0013932916,0.0028038686,0.000088158355,0.00001393261,0.000035049252,0.00024963263],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945102,0.0011596469,0.0030015735,0.00036665102,0.00062967365,0.0003322895],"domain_scores_gemma":[0.99449855,0.0024035398,0.0019260426,0.0004560202,0.0004198053,0.0002960593],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002870178,0.00028825368,0.0025313213,0.00025982573,0.000065182976,0.000029512443,0.0001685154,0.00027048486,0.0022035],"category_scores_gemma":[0.0015100425,0.00014059652,0.0007822894,0.0005423647,0.0004978395,0.0002034484,0.000047420068,0.0010384372,0.000032082007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8803297,0.007231791,0.08271546,0.000016902983,0.0043672733,0.0023408558,0.0012810869,0.0000031113075,0.00044801136,0.000003853303,0.00035445328,0.020907495],"study_design_scores_gemma":[0.47121146,0.07235244,0.4334328,0.00021166053,0.012021972,0.0002431099,0.00048281325,0.00021433507,0.0012662108,0.0001735229,0.008122817,0.0002668802],"about_ca_topic_score_codex":0.0006867513,"about_ca_topic_score_gemma":0.0025004284,"teacher_disagreement_score":0.40911824,"about_ca_system_score_codex":0.00026403274,"about_ca_system_score_gemma":0.002025007,"threshold_uncertainty_score":0.9987086},"labels":[],"label_agreement":null},{"id":"W2791763446","doi":"10.1200/jco.2018.36.6_suppl.513","title":"Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Bladder cancer; Medicine; Cystectomy; Transcriptome; Oncology; Gene expression profiling; Internal medicine; Radiation therapy; Microarray; Survival analysis; Biomarker; Cancer; Gene expression; Gene; Biology; Genetics","score_opus":0.15586708864566995,"score_gpt":0.4707449192174971,"score_spread":0.31487783057182717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791763446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812675,0.00040062328,0.0003287515,0.007356382,0.001495511,0.0007406751,0.000024880545,0.000013336062,0.0015130755],"genre_scores_gemma":[0.9856396,0.00045840538,0.0038692707,0.006964668,0.0027252818,0.000027528917,8.97819e-7,0.000033488483,0.0002808952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604315,0.0006621792,0.0021845812,0.00032307298,0.0004373196,0.00034972653],"domain_scores_gemma":[0.995225,0.0016879675,0.0010610188,0.00034844136,0.0009646639,0.00071290205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036631464,0.00019869638,0.0015033424,0.00021125027,0.00006087288,0.000008882092,0.00027068748,0.0003132482,0.0004358109],"category_scores_gemma":[0.0038304483,0.00014281254,0.00043279448,0.00027558667,0.00018945278,0.00008443784,0.00010342656,0.00055216975,0.00003508387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17114227,0.003964766,0.36142868,0.000055870572,0.0033524646,0.00037315354,0.0030141305,0.000103636645,0.1854987,0.000036485068,0.009220348,0.2618095],"study_design_scores_gemma":[0.012688781,0.047544174,0.86489695,0.00020589835,0.00048255557,0.00006820047,0.00025936455,0.000016585953,0.04214697,0.000154052,0.031371787,0.00016467746],"about_ca_topic_score_codex":0.00020527098,"about_ca_topic_score_gemma":0.00018392222,"teacher_disagreement_score":0.5034683,"about_ca_system_score_codex":0.00032400896,"about_ca_system_score_gemma":0.0055013555,"threshold_uncertainty_score":0.9759168},"labels":[],"label_agreement":null},{"id":"W2791783648","doi":"10.1200/jco.2018.36.15_suppl.4066","title":"Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Esophageal cancer; Cancer; Internal medicine; Radiation therapy; Adenocarcinoma; Proportional hazards model; Oncology; Gastroenterology; Surgery","score_opus":0.31973518995837774,"score_gpt":0.581728887716018,"score_spread":0.2619936977576403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791783648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812737,0.0055549745,0.00059502927,0.007897268,0.0035831276,0.0008622133,0.00011418657,0.000012637901,0.00010683505],"genre_scores_gemma":[0.99105144,0.0022200076,0.0012482876,0.000830539,0.0044335644,0.00007104629,0.000010722976,0.000019936424,0.00011445325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955527,0.0007152163,0.0021692198,0.00035580838,0.0007666075,0.0004404253],"domain_scores_gemma":[0.9921036,0.0038487695,0.0020306616,0.0003688126,0.001180956,0.0004672243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021552409,0.00022165137,0.001682854,0.000054199958,0.00015313592,0.000016891881,0.00040744085,0.00027975102,0.001199639],"category_scores_gemma":[0.0017553355,0.00011632996,0.00055697624,0.0002214976,0.0008727682,0.00014837353,0.00007018942,0.0007362711,0.0000037352668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13315812,0.0022716252,0.71962667,0.00002695085,0.00093776267,0.000078349374,0.0008762985,0.000009338411,0.00006937959,0.00006349025,0.0042381035,0.1386439],"study_design_scores_gemma":[0.03428035,0.03452675,0.9103399,0.00012292946,0.00043942276,0.000010028782,0.00075333624,0.00029663809,0.005938057,0.00019159874,0.01299599,0.00010499439],"about_ca_topic_score_codex":0.0024524743,"about_ca_topic_score_gemma":0.002994387,"teacher_disagreement_score":0.19071323,"about_ca_system_score_codex":0.0005815576,"about_ca_system_score_gemma":0.0046355175,"threshold_uncertainty_score":0.9997134},"labels":[],"label_agreement":null},{"id":"W2791795647","doi":"10.1200/jco.2018.36.6_suppl.77","title":"Overcoming miR-106a induced radioresistance in prostate cancer: Targeting senescence with KU-55933.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Radioresistance; Clonogenic assay; Prostate cancer; Cancer research; Downregulation and upregulation; Medicine; DNA damage; Prostate; Senescence; Cancer; Radiation therapy; Biology; Cell; Internal medicine; Gene; Genetics; DNA","score_opus":0.051025811229825,"score_gpt":0.42892133350598205,"score_spread":0.3778955222761571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791795647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151397,0.0014471306,0.0030054373,0.0019516323,0.0009128037,0.00026994303,0.000005085714,0.0000053273047,0.0008886742],"genre_scores_gemma":[0.9915054,0.0015989313,0.004388569,0.00080733246,0.0014311898,0.000012616075,0.000003198734,0.000030968837,0.00022179112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99675834,0.00056706823,0.0014186203,0.0003902064,0.0003965793,0.00046917805],"domain_scores_gemma":[0.9974339,0.00019106854,0.001092924,0.00026398944,0.00074696523,0.00027113716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003006901,0.00018378421,0.0007169461,0.00011813711,0.00007287004,0.000020267124,0.00039836337,0.0004180694,0.000042229243],"category_scores_gemma":[0.001976814,0.00014759715,0.00018323991,0.0002848082,0.0002950373,0.000016048654,0.00013487597,0.0009800353,0.0000050722842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009810958,0.00046002847,0.010075725,0.000038628554,0.00026753038,0.00060691015,0.00015547317,0.000232532,0.9352936,0.00007160059,0.0039106817,0.0390763],"study_design_scores_gemma":[0.017419001,0.029817276,0.023023289,0.0006841887,0.00014823244,0.00050080504,0.00045615013,0.00071628334,0.5581459,0.00038387653,0.3678788,0.0008262377],"about_ca_topic_score_codex":0.00009247467,"about_ca_topic_score_gemma":0.0009109235,"teacher_disagreement_score":0.37714776,"about_ca_system_score_codex":0.00017828541,"about_ca_system_score_gemma":0.0024857786,"threshold_uncertainty_score":0.6018837},"labels":[],"label_agreement":null},{"id":"W2791803000","doi":"10.1200/jco.2018.36.5_suppl.169","title":"Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Discontinuation; Histology; Oncology; Gastroenterology; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.06885531867939113,"score_gpt":0.4457146054494242,"score_spread":0.3768592867700331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791803000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892889,0.0006805658,0.0000691844,0.0036409264,0.0010137201,0.00020984499,0.0000045286424,0.000004821256,0.005087494],"genre_scores_gemma":[0.9920826,0.0026003097,0.003132325,0.0013155114,0.00055821077,0.0000013848498,0.0000024288488,0.000013668991,0.0002935795],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970007,0.0003407837,0.0021212904,0.00014643278,0.00022357354,0.00016723097],"domain_scores_gemma":[0.9975103,0.0006585659,0.0012229101,0.00014903473,0.0003279944,0.00013117291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003142907,0.00010436397,0.0011858471,0.000114947026,0.000019641224,0.000002920364,0.00010230937,0.00027469438,0.0005039093],"category_scores_gemma":[0.00059479824,0.00007414148,0.00023485266,0.00014729047,0.00041453924,0.0000921712,0.000022388629,0.0004441703,0.000003123738],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24766676,0.0015360115,0.09280973,0.000032404085,0.00055014674,0.00011909761,0.00025553067,0.0000021541562,0.014229267,0.00014077281,0.0023143294,0.6403438],"study_design_scores_gemma":[0.04592627,0.021226007,0.8280243,0.00017192795,0.0000698474,0.000118967924,0.00013211064,0.000086005755,0.0010028677,0.0002194057,0.10292557,0.000096662836],"about_ca_topic_score_codex":0.000046145455,"about_ca_topic_score_gemma":0.000105063555,"teacher_disagreement_score":0.73521465,"about_ca_system_score_codex":0.00009902854,"about_ca_system_score_gemma":0.0008650506,"threshold_uncertainty_score":0.55174536},"labels":[],"label_agreement":null},{"id":"W2791818089","doi":"10.1200/jco.2018.36.5_suppl.172","title":"Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; KRAS; Nivolumab; Internal medicine; Atezolizumab; Oncology; ROS1; Lung cancer; Adenocarcinoma; Cancer; Immunotherapy; Population; Microsatellite instability; Colorectal cancer","score_opus":0.04160812740707414,"score_gpt":0.44612770733337315,"score_spread":0.404519579926299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791818089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938418,0.00039913246,0.00034498048,0.00089136086,0.001225978,0.0003595293,0.0000026252878,0.0000041802277,0.0029303778],"genre_scores_gemma":[0.99483,0.0001311628,0.003889955,0.00034057946,0.0007125357,0.000010948778,0.000003215924,0.000018537408,0.00006303755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968208,0.0001443056,0.002438909,0.00016323094,0.0002360568,0.00019669392],"domain_scores_gemma":[0.9966583,0.00057443226,0.0018114311,0.00015376342,0.00063584134,0.0001661827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008887994,0.0001239549,0.00084256293,0.00017311017,0.000041698077,0.000006918219,0.00009946561,0.00018602722,0.00006019974],"category_scores_gemma":[0.0011640767,0.000094324656,0.00034172574,0.00019795734,0.00010633027,0.00010546479,0.000044085813,0.00052375864,0.0000028124682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027568853,0.0070002903,0.83263946,0.00016945109,0.0008583673,0.00019373688,0.0028568532,0.00038609368,0.028160807,0.00003251199,0.00042208107,0.12452348],"study_design_scores_gemma":[0.02599319,0.007387595,0.9157593,0.0010868723,0.000683766,0.000009493401,0.00021432438,0.00056470075,0.04624667,0.000029634417,0.0018796471,0.00014475298],"about_ca_topic_score_codex":0.00019322697,"about_ca_topic_score_gemma":0.00003581912,"teacher_disagreement_score":0.12437873,"about_ca_system_score_codex":0.0003530094,"about_ca_system_score_gemma":0.001494794,"threshold_uncertainty_score":0.38464478},"labels":[],"label_agreement":null},{"id":"W2791861582","doi":"10.1200/jco.2018.36.4_suppl.96","title":"A real-world comparison of multi-modality therapies in locally advanced gastro-esophageal junction (GEJ) cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Carboplatin; Epirubicin; Internal medicine; Proportional hazards model; Gastroenterology; Population; Oncology; Cisplatin; Chemotherapy; Surgery; Cancer; Breast cancer","score_opus":0.1359784983442094,"score_gpt":0.5003470615904421,"score_spread":0.3643685632462327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791861582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869868,0.00027547215,0.0013006717,0.0061262143,0.002182917,0.0002716414,0.0000013732584,0.000011725225,0.0028431588],"genre_scores_gemma":[0.9874703,0.00044309185,0.009371006,0.0008441845,0.0010790569,0.0000034179186,0.0000014506726,0.0000117321415,0.0007757179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963375,0.00029087887,0.0025786771,0.00018450782,0.00036456579,0.0002439039],"domain_scores_gemma":[0.9965498,0.0006431268,0.0019790186,0.00019177413,0.00045824784,0.00017802921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023755757,0.0001363016,0.001668116,0.00026620133,0.000027077707,0.000004761811,0.00016222677,0.0001650065,0.000186662],"category_scores_gemma":[0.0007971346,0.000101419166,0.00034015492,0.00033457103,0.00037875425,0.0001201166,0.000050833878,0.0007031165,0.0000066369244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008687441,0.0010896057,0.7918004,0.000044506814,0.000230104,0.000075992764,0.00029508962,0.00009641598,0.00016322998,0.0000978874,0.0023638739,0.1950555],"study_design_scores_gemma":[0.013670051,0.010663401,0.9549958,0.00012756781,0.00018765744,0.00001083897,0.00044642677,0.00096622726,0.00009883567,0.000112190784,0.018654292,0.00006672652],"about_ca_topic_score_codex":0.00057423534,"about_ca_topic_score_gemma":0.005938672,"teacher_disagreement_score":0.19498877,"about_ca_system_score_codex":0.00043335842,"about_ca_system_score_gemma":0.0009886319,"threshold_uncertainty_score":0.41357535},"labels":[],"label_agreement":null},{"id":"W2791864483","doi":"10.1200/jco.2018.36.6_suppl.28","title":"Evaluation of PUMA and NOXA expression as predictive biomarkers in prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Cytokeratin; Puma; Tissue microarray; Prostate cancer; Immunofluorescence; Medicine; Biomarker; Cancer; Pathology; Immunohistochemistry; PCA3; Prostate; Cancer research; Apoptosis; Antibody; Oncology; Biology; Internal medicine; Immunology","score_opus":0.09051054876671984,"score_gpt":0.48886174177364755,"score_spread":0.39835119300692773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791864483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961707,0.0013732448,0.00004505025,0.00050411467,0.00037921447,0.00016185822,0.0000047507465,7.66676e-7,0.001360297],"genre_scores_gemma":[0.99775934,0.0009773956,0.0005028006,0.00017493179,0.00053999695,0.0000073578385,0.0000016002806,0.0000058466203,0.000030733914],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981956,0.0004895199,0.0008275723,0.0001419031,0.00024352751,0.00010190801],"domain_scores_gemma":[0.99815047,0.000085783846,0.00082154816,0.00009034352,0.0007650757,0.00008679701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004538439,0.000065287175,0.00032087212,0.000052459152,0.000018954282,0.0000032837856,0.00008994154,0.00020643366,0.000046852125],"category_scores_gemma":[0.0023053652,0.000047949867,0.000085123465,0.000056329976,0.0002591918,0.000007935918,0.00005934494,0.0001498595,7.8890537e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008839558,0.0007833755,0.08426348,0.000019418658,0.00039518566,0.000019331397,0.00022945536,0.000054718752,0.45947278,0.000015029685,0.0029434934,0.44296417],"study_design_scores_gemma":[0.017945938,0.06312571,0.44323838,0.00043860136,0.00040587352,0.00010641614,0.00075095316,0.0015349679,0.42962536,0.0029581825,0.039587602,0.00028200966],"about_ca_topic_score_codex":0.000040142408,"about_ca_topic_score_gemma":0.00013704212,"teacher_disagreement_score":0.44268218,"about_ca_system_score_codex":0.0000278305,"about_ca_system_score_gemma":0.0010243547,"threshold_uncertainty_score":0.2759904},"labels":[],"label_agreement":null},{"id":"W2791865910","doi":"10.1200/jco.2018.36.6_suppl.621","title":"Application of Canadian hereditary renal cell carcinoma risk criteria to a population database.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Children's Hospital of Eastern Ontario; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre; Western University; McGill University; Université Laval; Centre Hospitalier de l’Université de Montréal; University of Calgary; Princess Margaret Cancer Centre; St Joseph's Health Care; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Renal cell carcinoma; Population; Genetic testing; Family history; Clinical endpoint; Database; Internal medicine; Cancer; Oncology; Clinical trial","score_opus":0.05658359369038238,"score_gpt":0.4162365608632075,"score_spread":0.35965296717282513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791865910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102956,0.00017063328,0.0051062843,0.0010320698,0.0011164531,0.00012327806,0.000085516534,0.0000012962357,0.0013348823],"genre_scores_gemma":[0.9758079,0.000062551226,0.020124108,0.00083787204,0.0030438679,0.0000047688136,0.000057669382,0.000011876746,0.000049373586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981785,0.0002575071,0.0010941349,0.00018753651,0.00013245999,0.00014988898],"domain_scores_gemma":[0.9978921,0.00009700343,0.00089277135,0.00028406756,0.00054908183,0.00028496847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014764208,0.00008019019,0.00032693092,0.0001988401,0.000046485045,0.000004283062,0.00023905929,0.000259465,0.000059089874],"category_scores_gemma":[0.00093276554,0.00007352352,0.00013277613,0.00019311527,0.00010376123,0.0000075927437,0.00005471354,0.00020325788,0.000012539792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029670561,0.0007010249,0.3077605,0.00004051679,0.0002490008,0.000048544243,0.00029388728,0.00041611085,0.22616291,0.00008357444,0.26456347,0.19671339],"study_design_scores_gemma":[0.001485899,0.006994599,0.5558563,0.000012367052,0.00012511782,0.00006459816,0.00007690727,0.00025207555,0.032907136,0.00020922942,0.40186822,0.00014757126],"about_ca_topic_score_codex":0.0115324985,"about_ca_topic_score_gemma":0.050874807,"teacher_disagreement_score":0.24809575,"about_ca_system_score_codex":0.000101532416,"about_ca_system_score_gemma":0.0013901984,"threshold_uncertainty_score":0.9950498},"labels":[],"label_agreement":null},{"id":"W2792016453","doi":"10.1200/jco.2018.36.6_suppl.89","title":"Contribution of microRNA-200b-3p to radiation therapy resistance in 22RV1 prostate cancer cells.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Clonogenic assay; microRNA; Prostate cancer; Cancer research; Biology; Cancer; Cell culture; Cell growth; Prostate; Phenotype; Medicine; Oncology; Gene; Genetics","score_opus":0.03699752903621162,"score_gpt":0.4369804443098479,"score_spread":0.3999829152736363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792016453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891315,0.0036767123,0.0025084394,0.0027615384,0.0011351655,0.00036456532,0.00001812536,0.0000020415664,0.00040189855],"genre_scores_gemma":[0.98956037,0.0068339864,0.0013190333,0.001078507,0.0009288688,0.000012207437,0.000005785679,0.00001659938,0.00024465637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974883,0.00046346307,0.00131159,0.00022661894,0.00024869523,0.00026131427],"domain_scores_gemma":[0.9975992,0.00011830911,0.000873581,0.00019848387,0.0010370192,0.00017343347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024325403,0.00010657452,0.000530866,0.0001237021,0.00002716568,0.000007225446,0.00024715887,0.0004057804,0.00004909941],"category_scores_gemma":[0.0012535742,0.00009212028,0.00019059499,0.00022253611,0.0001609056,0.0000072249427,0.00005781302,0.00037248334,0.000006428205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075186826,0.00030375356,0.00094016996,0.000006701253,0.00010689834,0.000020985128,0.00008141343,0.0000792189,0.9419249,0.000041014893,0.0062182117,0.042758],"study_design_scores_gemma":[0.004201924,0.0056564463,0.00747488,0.000046302684,0.0000147575865,0.0000059344047,0.000012722832,0.000015263895,0.71569866,0.00018551717,0.26659685,0.00009071174],"about_ca_topic_score_codex":0.00004512376,"about_ca_topic_score_gemma":0.00073112996,"teacher_disagreement_score":0.26037866,"about_ca_system_score_codex":0.00013500154,"about_ca_system_score_gemma":0.001363498,"threshold_uncertainty_score":0.37565562},"labels":[],"label_agreement":null},{"id":"W2792071348","doi":"10.1200/jco.2018.36.6_suppl.260","title":"Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Enzalutamide; Prostate cancer; Oncology; Internal medicine; PTEN; Cancer; Metastasis; Androgen deprivation therapy; Androgen receptor; PI3K/AKT/mTOR pathway; Biology","score_opus":0.062144587322816865,"score_gpt":0.4070200623173648,"score_spread":0.34487547499454796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792071348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972394,0.00011267542,0.0013511254,0.00022598806,0.00053947757,0.00035635076,0.00012680037,0.000001360932,0.00004679737],"genre_scores_gemma":[0.95505625,0.000028829952,0.043979086,0.00046672695,0.0004133751,0.000010536406,0.0000054513775,0.000024967083,0.0000147997725],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997693,0.00020449208,0.0014338688,0.00023413554,0.00019134193,0.0002431464],"domain_scores_gemma":[0.99595743,0.0008007794,0.0017919075,0.00023784787,0.0010009152,0.00021111868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016710731,0.00014331171,0.00059014274,0.00008623671,0.00007269942,0.000016543849,0.00022723456,0.00010135877,0.0000084692],"category_scores_gemma":[0.0034951922,0.00011460701,0.00019480549,0.00010366757,0.0001811363,0.000009868627,0.000070729344,0.00011320259,3.7761205e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07273358,0.0013319093,0.094732516,0.00014523695,0.00095951353,0.00008961099,0.0004272749,0.0018947263,0.80050087,0.000011646336,0.0017622198,0.025410881],"study_design_scores_gemma":[0.06878379,0.18133844,0.47305122,0.00089668453,0.0025509903,0.00017562139,0.0012612643,0.0027678746,0.20431414,0.0004588315,0.06284775,0.0015533823],"about_ca_topic_score_codex":0.000037240465,"about_ca_topic_score_gemma":0.00026263625,"teacher_disagreement_score":0.59618676,"about_ca_system_score_codex":0.00007794644,"about_ca_system_score_gemma":0.0022952713,"threshold_uncertainty_score":0.46735382},"labels":[],"label_agreement":null},{"id":"W2792097174","doi":"10.1200/jco.2017.76.0876","title":"Symptom Burden in the First Year After Cancer Diagnosis: An Analysis of Patient-Reported Outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Comorbidity; Odds ratio; Logistic regression; Observational study; Cancer; Odds; Quality of life (healthcare); Disease; Pediatrics; Internal medicine","score_opus":0.07137898609017283,"score_gpt":0.459422390448551,"score_spread":0.38804340435837814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792097174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893577,0.00034388647,0.000005480534,0.009065523,0.0010683512,0.00010207145,0.000008261006,0.0000029105645,0.00046771998],"genre_scores_gemma":[0.9942156,0.0003988875,0.00006428331,0.0043619666,0.0008774928,0.000042896,0.0000015665819,0.000007747563,0.00002955451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971506,0.00029888639,0.0018556276,0.00014275963,0.00040248432,0.0001496349],"domain_scores_gemma":[0.99669164,0.0011716251,0.0012246086,0.00029018012,0.00048267154,0.00013924438],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017770358,0.000092502276,0.0012576971,0.00023428124,0.000017326754,0.000005877028,0.0001763908,0.00021832997,0.0009567078],"category_scores_gemma":[0.001082077,0.00005137978,0.0006024923,0.0004754986,0.00020932684,0.000069276706,0.000029994548,0.00043131088,0.0000032909431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014280558,0.0006063696,0.97386086,0.0000077827435,0.001469164,0.00018131518,0.0026474786,0.000010833984,7.229381e-7,0.00000912279,0.0009056707,0.018872637],"study_design_scores_gemma":[0.0017866959,0.0042422386,0.9388188,0.00006128895,0.0031236643,0.000009995812,0.0015371415,0.00003736755,0.000008126455,0.00003377118,0.050288815,0.000052063864],"about_ca_topic_score_codex":0.0014753329,"about_ca_topic_score_gemma":0.031677626,"teacher_disagreement_score":0.049383145,"about_ca_system_score_codex":0.00009342032,"about_ca_system_score_gemma":0.00047464744,"threshold_uncertainty_score":0.99995655},"labels":[],"label_agreement":null},{"id":"W2792110199","doi":"10.1200/jco.2018.36.6_suppl.109","title":"Personalized risk stratification for patients with early prostate cancer (PRONTO): A Canadian team biomarker project.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Ontario Institute for Cancer Research; McGill University; Queen's University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Grading (engineering); Oncology; Biopsy; Cohort; Risk stratification; Prostate biopsy; Internal medicine; Cancer","score_opus":0.11807399547422467,"score_gpt":0.4874807099409833,"score_spread":0.36940671446675866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792110199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150854,0.00030490145,0.000038988797,0.0037847126,0.0005309127,0.0016274668,0.00009807544,0.0000068260015,0.0020995864],"genre_scores_gemma":[0.99335676,0.0005261356,0.0027063128,0.00039820318,0.00080224697,0.00009992411,0.000024033348,0.000022938604,0.002063425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979344,0.00021280946,0.00094748836,0.00021239971,0.00034279146,0.00035011987],"domain_scores_gemma":[0.99612135,0.00037695115,0.00095403235,0.00013845484,0.0019158395,0.00049338856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014971069,0.00012474737,0.0006694893,0.00017532853,0.0001244093,0.000019336323,0.0001060568,0.0002177014,0.000120119985],"category_scores_gemma":[0.0009152976,0.00007040375,0.00019180491,0.00017028158,0.0004293937,0.00013247482,0.000009587929,0.00041086887,0.0000073066135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028456844,0.00093564694,0.76328486,0.000032655546,0.00068274734,0.000026690403,0.0006636007,1.2754776e-7,0.000021910955,0.000020871568,0.012532787,0.19334123],"study_design_scores_gemma":[0.02153684,0.03345239,0.81377715,0.000109068395,0.00042292813,0.00001125497,0.00014994778,0.00007430794,0.000034913013,0.00011592916,0.13022156,0.00009369625],"about_ca_topic_score_codex":0.012809153,"about_ca_topic_score_gemma":0.03676128,"teacher_disagreement_score":0.19324754,"about_ca_system_score_codex":0.0005247902,"about_ca_system_score_gemma":0.009254606,"threshold_uncertainty_score":0.99636203},"labels":[],"label_agreement":null},{"id":"W2792147494","doi":"10.1200/jco.2018.36.6_suppl.200","title":"Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naïve prostate cancer (mCNPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Abiraterone acetate; Androgen deprivation therapy; Cabazitaxel; Internal medicine; Oncology; Prednisone; Population; Quality of life (healthcare); Urology; Chemotherapy; Cancer","score_opus":0.22694376382890014,"score_gpt":0.5203448045402858,"score_spread":0.2934010407113856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792147494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929099,0.0014749509,0.000006947729,0.0034823585,0.0006220404,0.0009981138,0.000028438033,0.000008983161,0.0004682608],"genre_scores_gemma":[0.9952591,0.0022857606,0.0011473682,0.00026952478,0.00018356288,0.000052560543,0.00000989441,0.00002311461,0.0007691007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953579,0.00045653997,0.0029394638,0.0003243842,0.00054307695,0.00037868877],"domain_scores_gemma":[0.9956446,0.00094126374,0.0022571287,0.00022563033,0.0005733463,0.00035802196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013590232,0.0002597342,0.0024409858,0.00030673807,0.000056728903,0.000016572481,0.000092403156,0.00018982688,0.000104451734],"category_scores_gemma":[0.0006938401,0.00015482705,0.000251733,0.0002467044,0.0005317065,0.00014438423,0.00004219972,0.0005457414,0.000007231235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022736276,0.0043981005,0.80902004,0.00009764923,0.0019657805,0.0009688244,0.0026348468,0.000081645914,0.000841369,0.000011313168,0.00042645083,0.15681767],"study_design_scores_gemma":[0.041477557,0.05964025,0.88735723,0.00032510023,0.0008597914,0.00014490729,0.0005639986,0.00043972538,0.0063568857,0.00015010714,0.0025241654,0.00016029246],"about_ca_topic_score_codex":0.00037127486,"about_ca_topic_score_gemma":0.000853333,"teacher_disagreement_score":0.15665738,"about_ca_system_score_codex":0.00061287737,"about_ca_system_score_gemma":0.0022987153,"threshold_uncertainty_score":0.6313664},"labels":[],"label_agreement":null},{"id":"W2792254250","doi":"10.1200/jco.2018.36.6_suppl.573","title":"Dissecting the expression landscape of genitourinary cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Cancer; Medicine; Gene; Bladder cancer; Genitourinary system; Kidney cancer; Cancer research; Prostate cancer; Carcinoma; Oncology; Biology; Pathology; Internal medicine; Genetics","score_opus":0.056233504106872334,"score_gpt":0.4255615949561426,"score_spread":0.36932809084927026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792254250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714076,0.0022227592,0.00018828493,0.00054234924,0.021114135,0.00005813316,0.0000030714864,0.0000016522729,0.0044620284],"genre_scores_gemma":[0.91855377,0.0013766167,0.0007916841,0.00047820984,0.078342766,0.000001629871,0.0000013177464,0.000009560161,0.000444428],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983872,0.00021854325,0.00097458955,0.00012609613,0.00014763189,0.0001459147],"domain_scores_gemma":[0.99787974,0.00023904772,0.0011014673,0.00020260029,0.00046864408,0.000108484586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016035265,0.00007984574,0.0004472723,0.000027990027,0.000058900354,0.000004240952,0.00027515882,0.00023975546,0.0000661524],"category_scores_gemma":[0.0015304963,0.000046871268,0.00029217347,0.000056077184,0.00026507635,0.000004963076,0.00010016026,0.00029313142,0.000002292495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007104381,0.0006619487,0.04409108,0.000034090244,0.00044281982,0.0000043687155,0.00043651267,0.00006588476,0.5089654,0.00009450905,0.29245624,0.14564282],"study_design_scores_gemma":[0.0016136013,0.0045605623,0.030263282,0.000028991468,0.0000726212,0.000080297745,0.0003357839,0.000011218632,0.018484011,0.000099786164,0.94437563,0.000074239775],"about_ca_topic_score_codex":0.000020499374,"about_ca_topic_score_gemma":0.000087583125,"teacher_disagreement_score":0.65191936,"about_ca_system_score_codex":0.0000127105795,"about_ca_system_score_gemma":0.0006771323,"threshold_uncertainty_score":0.1911355},"labels":[],"label_agreement":null},{"id":"W2792288841","doi":"10.1200/jco.2018.77.8001","title":"Different View on Larynx Preservation Evidence-Based Treatment Recommendations","year":2018,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Voice and Speech Disorders","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Debiopharm Group (Canada)","funders":"Università degli Studi di Milano","keywords":"Medicine; Larynx; Intensive care medicine; Surgery","score_opus":0.4875263581058109,"score_gpt":0.544442704256455,"score_spread":0.056916346150644115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792288841","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016088234,0.0007667526,0.00012680682,0.9779171,0.002826379,0.00047288023,0.000010689869,0.000014511315,0.0017766581],"genre_scores_gemma":[0.0024575621,0.011218796,0.0013777375,0.96150106,0.018543458,0.000025443323,0.00014261273,0.00004355002,0.004689786],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994953,0.0011063776,0.0027623628,0.00030223225,0.00059544516,0.00028061224],"domain_scores_gemma":[0.9890049,0.0069160163,0.002746212,0.000444317,0.0006616117,0.00022690452],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0016897161,0.00029733547,0.0022510695,0.0002601933,0.000060096823,0.00001806671,0.00025012295,0.0015203622,0.0013681111],"category_scores_gemma":[0.004967247,0.00017897093,0.0011584808,0.00011300025,0.00015555312,0.0001572995,0.000025859617,0.0027019072,0.00014737161],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013092621,0.0016815229,0.0028096847,0.00009009779,0.0005104243,0.0005416763,0.000019146008,0.0000015050367,0.0000033238425,0.0000043918994,0.8704772,0.12255175],"study_design_scores_gemma":[0.004842292,0.04819167,0.010125953,0.0018618847,0.0012681697,0.000048906022,0.000010214695,0.000043513814,0.000021002112,0.00019513787,0.93325883,0.00013240775],"about_ca_topic_score_codex":0.000019698706,"about_ca_topic_score_gemma":0.00004998707,"teacher_disagreement_score":0.122419335,"about_ca_system_score_codex":0.00056553056,"about_ca_system_score_gemma":0.0023122577,"threshold_uncertainty_score":0.9997759},"labels":[],"label_agreement":null},{"id":"W2792325188","doi":"10.1200/jco.2018.36.6_suppl.667","title":"Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; Health Sciences Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Cohort; Nephrectomy; Oncology; Metastasis; Targeted therapy; Internal medicine; Proportional hazards model; Cancer; Kidney","score_opus":0.12531369407310516,"score_gpt":0.43463918543349744,"score_spread":0.3093254913603923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792325188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966413,0.0001069134,0.000004692144,0.00023163778,0.00030058922,0.00044236946,0.0000131034285,0.0000060459242,0.0022533946],"genre_scores_gemma":[0.99778306,0.000027102327,0.0013196503,0.00036045077,0.00031183666,0.0000043056834,0.000006368852,0.000035827154,0.00015141876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947697,0.00095798733,0.0029642617,0.00027685717,0.0006614607,0.00036971862],"domain_scores_gemma":[0.9929672,0.0028722656,0.0024836063,0.00032497555,0.0008953846,0.00045657673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018426179,0.00029780547,0.0025137798,0.0002660088,0.000024698295,0.000005482865,0.00018766733,0.0001765583,0.00036068194],"category_scores_gemma":[0.0016249745,0.00015702017,0.0007553138,0.00033332108,0.00028528148,0.00007853579,0.000028013843,0.0007831715,0.000020657979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038424976,0.0075759436,0.94613475,0.000018957378,0.0004817524,0.0016165626,0.00010739634,0.000017341343,0.0009265679,0.0000017830912,0.0002544183,0.0044395276],"study_design_scores_gemma":[0.028651873,0.16987674,0.7981972,0.000052526873,0.0003087235,0.000083158295,0.000033481934,0.000021770002,0.0025252327,0.000015668296,0.00012878508,0.00010480732],"about_ca_topic_score_codex":0.0002684036,"about_ca_topic_score_gemma":0.000059317845,"teacher_disagreement_score":0.1623008,"about_ca_system_score_codex":0.00048796306,"about_ca_system_score_gemma":0.0014370668,"threshold_uncertainty_score":0.6403097},"labels":[],"label_agreement":null},{"id":"W2792325737","doi":"10.1200/jco.2018.36.6_suppl.626","title":"Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"BAP1; Medicine; Clear cell renal cell carcinoma; Renal cell carcinoma; Internal medicine; Oncology; Proportional hazards model; Cancer","score_opus":0.1003443753210771,"score_gpt":0.4106007203347001,"score_spread":0.310256345013623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792325737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947481,0.00007319656,0.00071326044,0.0019043031,0.00026356895,0.00045990208,0.000008375455,0.0000037279947,0.0018255471],"genre_scores_gemma":[0.96348906,0.000009499576,0.03514072,0.0006414991,0.0004999855,0.000007347589,0.000013330724,0.0000161112,0.00018246577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971559,0.00025255606,0.0018694177,0.00017725366,0.00037282455,0.00017202467],"domain_scores_gemma":[0.9956639,0.0007667489,0.0014510993,0.00024546788,0.0014942746,0.00037850285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010122695,0.00012404074,0.0009541396,0.00017170528,0.00003328665,0.000004957238,0.000115441726,0.00009254961,0.00012006396],"category_scores_gemma":[0.0010808599,0.00007699576,0.00019368269,0.00017555164,0.00018521563,0.000064256434,0.00003499098,0.0002921728,0.000044136395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012558679,0.0063820668,0.94175243,0.00007608156,0.0004354804,0.00021858403,0.00050603383,0.00002665703,0.0045460775,0.00007774079,0.0031452451,0.030274892],"study_design_scores_gemma":[0.0067776786,0.06310488,0.91923314,0.00004614391,0.0008782186,0.000054843284,0.000023016935,0.00003264144,0.004022692,0.00004819666,0.0057120044,0.00006652151],"about_ca_topic_score_codex":0.000011732647,"about_ca_topic_score_gemma":0.00002352742,"teacher_disagreement_score":0.056722816,"about_ca_system_score_codex":0.00017189232,"about_ca_system_score_gemma":0.0011803354,"threshold_uncertainty_score":0.3139796},"labels":[],"label_agreement":null},{"id":"W2792329419","doi":"10.1200/jco.2018.36.4_suppl.244","title":"Palliative care intervention and aggressive care at end-of-life in patients with advanced pancreatic adenocarcinoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Queen Elizabeth II Health Sciences Centre; Queen's University; Dalhousie University","funders":"","keywords":"Medicine; Palliative care; Intensive care unit; End-of-life care; Pancreatic cancer; Intensive care; Emergency department; Cancer; Emergency medicine; Internal medicine; Intensive care medicine; Nursing","score_opus":0.08607255701266446,"score_gpt":0.47465343407907945,"score_spread":0.388580877066415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792329419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316764,0.00437712,0.000038207792,0.0003181245,0.00022807448,0.00040918388,0.000008223804,0.0000030789931,0.0014503475],"genre_scores_gemma":[0.99565005,0.0005655878,0.0032279426,0.00021202577,0.0002501451,0.000007774536,0.000010618767,0.000013196575,0.00006266202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996947,0.00051872636,0.001700862,0.00020651419,0.00039258398,0.00023432753],"domain_scores_gemma":[0.99429387,0.0014945795,0.0021894732,0.00016318203,0.0015243026,0.00033461847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076653704,0.00013530564,0.001764142,0.00017606436,0.000043651322,0.0000028237725,0.00011310996,0.0003012865,0.00017045303],"category_scores_gemma":[0.0045374087,0.00008753975,0.0001762045,0.00014027534,0.0008097072,0.00008111208,0.00009467949,0.00059897365,0.0000070367237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017063057,0.0005632375,0.9180578,0.00017859516,0.00029944873,0.00018272705,0.0019893085,5.713601e-7,0.0000050954395,0.000015033127,0.00007837278,0.06156678],"study_design_scores_gemma":[0.023980396,0.048630662,0.9227038,0.00088000036,0.0004243359,0.00002075088,0.0027590916,0.000020264459,0.000023770099,0.00003135019,0.00045440265,0.00007117846],"about_ca_topic_score_codex":0.000044661818,"about_ca_topic_score_gemma":0.00042018382,"teacher_disagreement_score":0.061495602,"about_ca_system_score_codex":0.00037546086,"about_ca_system_score_gemma":0.0012341447,"threshold_uncertainty_score":0.543203},"labels":[],"label_agreement":null},{"id":"W2792431643","doi":"10.1200/jco.2018.36.6_suppl.123","title":"Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université du Québec à Chicoutimi; Hôpital Maisonneuve-Rosemont; Saint John Regional Hospital; Hôtel-Dieu de Québec; Hôpital Notre-Dame; Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University; Cégep de Rimouski; Bausch Health (Canada); Centre Hospitalier Universitaire de Sherbrooke; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Randomized controlled trial; Prostate; Radiation therapy; Dose fractionation; Urology; Nuclear medicine; Adjuvant; Concomitant; Internal medicine; Cancer","score_opus":0.10019377179591943,"score_gpt":0.5024123413044331,"score_spread":0.4022185695085137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792431643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707887,0.0022736804,0.0011042672,0.021211267,0.0023531793,0.001984098,0.000050490675,0.000010348095,0.00022396598],"genre_scores_gemma":[0.970706,0.016704524,0.0042581907,0.0014939995,0.005519208,0.00012384834,0.000032365602,0.000030648327,0.0011312385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633247,0.00054418435,0.0022508027,0.00019430157,0.00042702592,0.00025119632],"domain_scores_gemma":[0.9923272,0.0036610947,0.0026724362,0.00020452106,0.0009214539,0.0002132772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005182207,0.00013857093,0.0012930731,0.0001311707,0.00011807031,0.00001006951,0.0001527364,0.00026363053,0.00019230673],"category_scores_gemma":[0.0016223802,0.00007228453,0.0004787044,0.00018217471,0.0005280361,0.00016988737,0.000024415927,0.0007076221,0.0000029409591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4931218,0.0034205334,0.0015972682,0.000032673815,0.001104243,0.00003219923,0.00018660707,0.0000047286326,0.0022873932,0.00007387128,0.006357568,0.49178112],"study_design_scores_gemma":[0.5593358,0.11527384,0.03641109,0.000110079556,0.001011484,0.000056114637,0.00011356558,0.00044838057,0.0013815913,0.0016464442,0.28409484,0.00011674404],"about_ca_topic_score_codex":0.00011491679,"about_ca_topic_score_gemma":0.000043581793,"teacher_disagreement_score":0.49166435,"about_ca_system_score_codex":0.00041847173,"about_ca_system_score_gemma":0.0021958235,"threshold_uncertainty_score":0.38952965},"labels":[],"label_agreement":null},{"id":"W2792470458","doi":"10.1200/jco.2018.36.6_suppl.182","title":"Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Hypokalemia; Abiraterone acetate; Androgen deprivation therapy; Adverse effect; Internal medicine; Prednisone; Urology; Gastroenterology; Cancer","score_opus":0.3536237821018281,"score_gpt":0.5897643233906775,"score_spread":0.23614054128884943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792470458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785775,0.00267573,0.00021738044,0.015627649,0.0011557392,0.0012134087,0.00007837014,0.00001067223,0.00044353344],"genre_scores_gemma":[0.98754376,0.0051497496,0.0027570594,0.0011638532,0.0020146049,0.000059769663,0.000032922726,0.000027055514,0.0012512073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99452937,0.0012261743,0.0028698854,0.00032204826,0.0006233887,0.0004291153],"domain_scores_gemma":[0.99431056,0.0026708164,0.0016147944,0.00031395367,0.0007200363,0.00036984918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038193187,0.00022978387,0.0018231291,0.00014842465,0.00011980605,0.00003840245,0.00026536713,0.00020562983,0.0008172381],"category_scores_gemma":[0.0019859725,0.00012076713,0.00039510857,0.0003823456,0.0006568134,0.00023619964,0.000068521615,0.0010585072,0.000040920033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75588185,0.007199233,0.047692902,0.00006780359,0.005637758,0.0026981332,0.003203738,0.00043837694,0.0062185363,0.00003056821,0.006477259,0.16445383],"study_design_scores_gemma":[0.7111966,0.056328256,0.18700631,0.00055813557,0.0036023967,0.000119221164,0.0010401488,0.003441993,0.0030753606,0.0010697873,0.032194212,0.00036757562],"about_ca_topic_score_codex":0.0005392787,"about_ca_topic_score_gemma":0.004251092,"teacher_disagreement_score":0.16408625,"about_ca_system_score_codex":0.00052337075,"about_ca_system_score_gemma":0.0047506248,"threshold_uncertainty_score":0.8948184},"labels":[],"label_agreement":null},{"id":"W2792485007","doi":"10.1200/jco.2018.36.6_suppl.197","title":"Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Subtyping; Internal medicine; Basal (medicine); Oncology; Androgen deprivation therapy; Prostatectomy; Cancer","score_opus":0.2732079752417164,"score_gpt":0.5633154662081646,"score_spread":0.2901074909664482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792485007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979158,0.0036129623,0.0000185563,0.016087068,0.00043397656,0.00030786174,0.0000215311,0.0000037051327,0.00035637323],"genre_scores_gemma":[0.9886716,0.0077279373,0.0018265535,0.0005321358,0.000924113,0.0000090748745,0.000002942073,0.000011387483,0.00029425987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693,0.00035698205,0.0020511418,0.00020653433,0.00024490096,0.0002104565],"domain_scores_gemma":[0.9957123,0.0015658006,0.0011679188,0.00011852794,0.0010282842,0.00040720322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033062417,0.00010927408,0.0010359915,0.00010781628,0.00006850616,0.000010758276,0.00007747264,0.00015313062,0.00006921708],"category_scores_gemma":[0.0018950736,0.000071735485,0.00016274408,0.00013540756,0.00075819215,0.0001231507,0.000051649895,0.0005324674,0.0000028335005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028416075,0.0024564553,0.6469105,0.00041839306,0.0018966697,0.00044838287,0.0005872884,0.0000013034755,0.009012372,0.00087370427,0.005031093,0.30394775],"study_design_scores_gemma":[0.0102156475,0.018032357,0.9591034,0.00022555504,0.0007050393,0.00024052006,0.00018222183,0.00014021463,0.0010037888,0.0009908512,0.009069556,0.000090848596],"about_ca_topic_score_codex":0.000033001787,"about_ca_topic_score_gemma":0.000115160154,"teacher_disagreement_score":0.3121929,"about_ca_system_score_codex":0.00006516919,"about_ca_system_score_gemma":0.002295798,"threshold_uncertainty_score":0.4072647},"labels":[],"label_agreement":null},{"id":"W2792488544","doi":"10.1200/jco.2018.36.6_suppl.569","title":"Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Pathological; Germ cell tumors; Germ cell; Testicular cancer; Minimal residual disease; Cancer; Pathology; Primary tumor; Internal medicine; Oncology; Metastasis; Bone marrow","score_opus":0.045761115078409256,"score_gpt":0.4084640920409716,"score_spread":0.3627029769625624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792488544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770015,0.00038123937,0.00022320467,0.0008531741,0.00034468135,0.00043845215,0.0000126230625,0.0000038205003,0.000042638967],"genre_scores_gemma":[0.99602526,0.00008299131,0.0024571083,0.0008918169,0.00045219238,0.000015055678,0.0000016938297,0.0000187143,0.00005513648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838614,0.00008866302,0.00096401345,0.00013559009,0.0002449296,0.00018068687],"domain_scores_gemma":[0.99581033,0.001915143,0.0012700347,0.00012943188,0.00073352864,0.00014151761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065615965,0.00010883159,0.000662612,0.00006926887,0.000046286368,0.000005224548,0.00008880558,0.00010902421,0.00007098237],"category_scores_gemma":[0.0019674008,0.000052218995,0.00017185269,0.00012410623,0.00017258634,0.00005443353,0.0000145386475,0.00023928679,0.0000019951951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03412295,0.0049906364,0.87537014,0.00009261772,0.0005091823,0.00018717711,0.00010865897,0.000045431858,0.00088436255,0.000002476503,0.0001427068,0.08354365],"study_design_scores_gemma":[0.026393613,0.025802853,0.9403231,0.00020957325,0.0007423365,0.000052155963,0.000067957815,0.0006101963,0.002667865,0.000022752027,0.003038361,0.00006924147],"about_ca_topic_score_codex":0.000114770584,"about_ca_topic_score_gemma":0.00025952258,"teacher_disagreement_score":0.08347441,"about_ca_system_score_codex":0.000119379474,"about_ca_system_score_gemma":0.001188795,"threshold_uncertainty_score":0.23553047},"labels":[],"label_agreement":null},{"id":"W2792497546","doi":"10.1200/jco.2018.36.4_suppl.362","title":"Major arterial resection for stage 3 adenocarcinoma of the pancreas.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Mount Sinai Hospital; McMaster University; University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Stage (stratigraphy); Surgery; Pancreas; Pancreatic fistula; Adenocarcinoma; Cohort; Radiation therapy; Cancer; Internal medicine","score_opus":0.21027408831219635,"score_gpt":0.5222218102512969,"score_spread":0.31194772193910053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792497546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847479,0.00013600203,0.00051047327,0.0064426623,0.002314297,0.00041370065,0.000008255568,0.000003435062,0.005423266],"genre_scores_gemma":[0.9871044,0.00009163032,0.0041263457,0.00082490005,0.0052020177,0.0000076054725,8.7464247e-7,0.000011381319,0.0026308117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969319,0.00055285636,0.0018095436,0.0001316454,0.00034824174,0.00022581308],"domain_scores_gemma":[0.9942463,0.0027656131,0.0014167407,0.0002563166,0.0010956466,0.00021934972],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051315697,0.00008341925,0.0012959924,0.000085434964,0.0000779436,0.0000037415698,0.00021947404,0.00039637386,0.000408572],"category_scores_gemma":[0.010360463,0.00004594986,0.0004977975,0.00012716331,0.00081233826,0.00005180015,0.000061264545,0.00058363815,0.000011916811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07219815,0.0018708124,0.86338353,0.0001389366,0.0009938116,0.00008029087,0.00024891683,3.226981e-7,0.005076018,0.0010252112,0.03324738,0.021736639],"study_design_scores_gemma":[0.013150926,0.04459447,0.86780435,0.000092127884,0.00065172074,0.00027354452,0.00016192858,0.00014563101,0.0011011097,0.0010097009,0.07096522,0.00004925364],"about_ca_topic_score_codex":0.000030079196,"about_ca_topic_score_gemma":0.00009209388,"teacher_disagreement_score":0.059047222,"about_ca_system_score_codex":0.00010321705,"about_ca_system_score_gemma":0.0025899813,"threshold_uncertainty_score":0.9979757},"labels":[],"label_agreement":null},{"id":"W2792646568","doi":"10.1200/jco.2018.36.4_suppl.148","title":"Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Stage (stratigraphy); Perioperative; Gastroenterology; Cohort; Chemotherapy; Hazard ratio; Oncology; Surgery; Confidence interval","score_opus":0.15824394564224784,"score_gpt":0.4612998130800514,"score_spread":0.30305586743780355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792646568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789439,0.00018609554,0.0055557997,0.0066675586,0.006141949,0.00031653457,0.00000448775,0.000019085659,0.0021646298],"genre_scores_gemma":[0.9796818,0.00017913751,0.01187381,0.0015123796,0.0035246438,0.0000051000966,0.0000031841157,0.000021882122,0.0031980686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747103,0.00018747807,0.0014479026,0.00021479648,0.0003177861,0.00036100415],"domain_scores_gemma":[0.99594843,0.002137607,0.0010314252,0.00017127494,0.0003290917,0.00038219633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030575835,0.00015959579,0.0012308095,0.00026214952,0.00007374147,0.000016169935,0.00013316392,0.00023767144,0.00015802211],"category_scores_gemma":[0.003593968,0.00011740997,0.00043312687,0.00018949965,0.0002512229,0.0001219704,0.00006492457,0.0005378984,0.000008544198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016564962,0.00034106258,0.925629,0.000042371616,0.00048260897,0.0002429852,0.00004797823,0.0000023137502,0.000020367273,0.00023436313,0.005920431,0.05047152],"study_design_scores_gemma":[0.030701704,0.024471654,0.90202457,0.000017783788,0.0007819969,0.000111246656,0.00020054249,0.000090642054,0.000007832256,0.00008146326,0.04143937,0.000071206996],"about_ca_topic_score_codex":0.000013840408,"about_ca_topic_score_gemma":0.00006066561,"teacher_disagreement_score":0.05040031,"about_ca_system_score_codex":0.00021358937,"about_ca_system_score_gemma":0.0006643011,"threshold_uncertainty_score":0.47878397},"labels":[],"label_agreement":null},{"id":"W2792742267","doi":"10.1200/jco.2018.36.6_suppl.80","title":"Nuclear factor-kappa B p65 evaluation on the Canadian Prostate Cancer Biomarker Network (CPCBN) TMA-series for biomarker validation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; University of British Columbia; Princess Margaret Cancer Centre; University of Manitoba; Université de Montréal; Université Laval; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Biomarker; Prostatectomy; Cohort; Oncology; Internal medicine; Cancer; Kappa; Immunohistochemistry; Pathology; Biology","score_opus":0.3345544202130519,"score_gpt":0.5313495037804408,"score_spread":0.1967950835673889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792742267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8680767,0.0007694414,0.000010659293,0.12005264,0.003358929,0.0016476222,0.000049862218,0.000011877789,0.006022266],"genre_scores_gemma":[0.99007386,0.0009672337,0.00050821493,0.003693363,0.003107713,0.00006765373,0.000018484185,0.000033441134,0.001530026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997009,0.0005936113,0.0011435633,0.00022168976,0.0005885411,0.00044363024],"domain_scores_gemma":[0.99531627,0.0013761257,0.00077868445,0.00022972208,0.0018299083,0.00046929027],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056173876,0.00015318276,0.00064239337,0.0001421895,0.0003648625,0.0000454211,0.00018237004,0.00031667203,0.0016342851],"category_scores_gemma":[0.002741869,0.000082222316,0.00029133612,0.00024253478,0.000546984,0.00014715108,0.000028805045,0.00047596256,0.00005219397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031039102,0.00069417513,0.08490911,0.000050000373,0.0022352624,0.0001071765,0.0006745932,0.000022935688,0.00053522614,0.00096636626,0.38651747,0.49224856],"study_design_scores_gemma":[0.006516451,0.009112734,0.3589874,0.0001540268,0.0003979894,0.000040248095,0.00012925256,0.00057670823,0.00016580183,0.0016250621,0.62217736,0.00011699706],"about_ca_topic_score_codex":0.0015070294,"about_ca_topic_score_gemma":0.016873915,"teacher_disagreement_score":0.49213156,"about_ca_system_score_codex":0.00081644,"about_ca_system_score_gemma":0.0060977833,"threshold_uncertainty_score":0.9995367},"labels":[],"label_agreement":null},{"id":"W2792798255","doi":"10.1200/jco.2018.36.4_suppl.164","title":"Screening for cancer-associated dysphagia: The development of two rapid tools for use in observational studies and routine care.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Dysphagia Assessment and Management","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dysphagia; Observational study; Odynophagia; Swallowing; Gold standard (test); Physical therapy; Common Terminology Criteria for Adverse Events; MEDLINE; Adverse effect; Intensive care medicine; Surgery; Internal medicine","score_opus":0.6905311397852898,"score_gpt":0.6457674477273871,"score_spread":0.04476369205790265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792798255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802665,0.00085027126,0.0071420097,0.007838854,0.0023096718,0.0013598116,0.000017878521,0.0000059151553,0.000209099],"genre_scores_gemma":[0.88537616,0.00044271105,0.10963029,0.002985096,0.0009291483,0.00021065971,0.0000094700845,0.000014208684,0.00040229256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616116,0.00056024286,0.0026736902,0.00013492804,0.00019929835,0.00027068623],"domain_scores_gemma":[0.9775222,0.018404754,0.002460301,0.000079116624,0.0014643539,0.000069299655],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008815356,0.00009954478,0.0008827566,0.000069234084,0.00029521735,0.000007464931,0.00016551932,0.00016078033,0.000026392196],"category_scores_gemma":[0.008469,0.00006196382,0.00011859996,0.000107202235,0.00015566777,0.0002242741,0.00013672828,0.0003996291,4.779292e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028777164,0.00039226338,0.628096,0.00026316024,0.0018784101,0.0000029842365,0.006980417,0.000032044092,0.00003185578,0.0032341073,0.016619366,0.33959165],"study_design_scores_gemma":[0.013161496,0.0026046534,0.8398402,0.00040389175,0.0002889335,2.7379923e-7,0.008449351,0.00034735387,0.000021619027,0.0009677206,0.13381897,0.00009556216],"about_ca_topic_score_codex":0.000025395919,"about_ca_topic_score_gemma":0.0050172918,"teacher_disagreement_score":0.3394961,"about_ca_system_score_codex":0.00025237136,"about_ca_system_score_gemma":0.0016065065,"threshold_uncertainty_score":0.9998831},"labels":[],"label_agreement":null},{"id":"W2792841998","doi":"10.1200/jco.2018.36.6_suppl.615","title":"Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Sunnybrook Hospital; University of Manitoba; BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Calgary","funders":"","keywords":"Cabozantinib; Nivolumab; Medicine; Renal cell carcinoma; Oncology; Hazard ratio; Internal medicine; Tyrosine-kinase inhibitor; Population; Kidney cancer; Axitinib; Urology; Cancer; Immunotherapy; Sunitinib; Confidence interval","score_opus":0.1283341814706414,"score_gpt":0.41237827101512387,"score_spread":0.28404408954448246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792841998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98449934,0.00058324484,0.00004623185,0.005577533,0.0011951153,0.00046229915,0.00030533707,0.000007361537,0.0073235286],"genre_scores_gemma":[0.98422617,0.00023968221,0.01245784,0.0010080837,0.00082665426,0.000007777666,0.00008183898,0.000036001617,0.0011159254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917959,0.0012505946,0.004956031,0.0005632597,0.0009834219,0.00045082372],"domain_scores_gemma":[0.9851017,0.009267716,0.0036965152,0.0006721262,0.0007709184,0.0004910271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00512256,0.00037641946,0.0024551707,0.0004036205,0.00007082011,0.000026119234,0.0005517639,0.00016688666,0.00025292108],"category_scores_gemma":[0.0030417945,0.00023176167,0.00057313166,0.0003220515,0.0009536183,0.00020782222,0.00028529888,0.001293321,0.000022534377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024978306,0.0043288637,0.9342106,0.0000816621,0.00094261527,0.0063059293,0.0011492705,0.0000140147,0.007101182,0.0000990281,0.015647003,0.0051415563],"study_design_scores_gemma":[0.035235286,0.007961236,0.93761146,0.0001148712,0.0018215779,0.00028066194,0.0006003478,0.00033117997,0.009615844,0.00017775198,0.0060412376,0.00020853215],"about_ca_topic_score_codex":0.0032049546,"about_ca_topic_score_gemma":0.0034617342,"teacher_disagreement_score":0.012411608,"about_ca_system_score_codex":0.00025887162,"about_ca_system_score_gemma":0.0022419712,"threshold_uncertainty_score":0.9450967},"labels":[],"label_agreement":null},{"id":"W2792860007","doi":"10.1200/jco.2018.36.6_suppl.321","title":"Patterns of prostate cancer management across Canadian prostate cancer treatment specialists.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; University of Ottawa; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation oncologist; Referral; Family medicine; Cancer; Radiation therapy; Multidisciplinary approach; Palliative care; Oncology; Internal medicine; Nursing","score_opus":0.15095056708451754,"score_gpt":0.5317794849189827,"score_spread":0.3808289178344652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792860007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975667,0.0018758898,0.0000026422213,0.01508572,0.0021947045,0.00083051884,0.00025579406,0.0000075969356,0.004080104],"genre_scores_gemma":[0.95107377,0.03226435,0.00029717837,0.0011863102,0.0026960026,0.000070650734,0.000012687274,0.000032739033,0.012366337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654853,0.00019868443,0.0018148009,0.00029172347,0.00048504665,0.0006612043],"domain_scores_gemma":[0.9965555,0.00019317486,0.0011213822,0.00026700052,0.00095495314,0.0009080106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013161869,0.00021787397,0.001366715,0.00019520242,0.00010663998,0.000017153503,0.00019835071,0.00023692171,0.00091170275],"category_scores_gemma":[0.00012167289,0.0001368434,0.00041487868,0.00022026335,0.00040215332,0.000104223116,0.000060976585,0.00043166362,0.000023855151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005848268,0.0009181945,0.5913108,0.0001053375,0.0014053881,0.0014305173,0.0013031727,0.000005065536,0.0000406714,0.000037642185,0.004365675,0.3932293],"study_design_scores_gemma":[0.013585605,0.013572722,0.5710504,0.00037080146,0.00046420205,0.000054763113,0.00053368055,0.000011732342,0.00089898583,0.00009552043,0.39923388,0.00012767373],"about_ca_topic_score_codex":0.04359415,"about_ca_topic_score_gemma":0.17717573,"teacher_disagreement_score":0.39486822,"about_ca_system_score_codex":0.001722121,"about_ca_system_score_gemma":0.0049849967,"threshold_uncertainty_score":0.9982506},"labels":[],"label_agreement":null},{"id":"W2792916595","doi":"10.1200/jco.2018.36.4_suppl.217","title":"A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tremelimumab; Durvalumab; Internal medicine; Adverse effect; Clinical endpoint; Diarrhea; Gemcitabine; Gastroenterology; Randomized controlled trial; Combination therapy; Oncology; Population; Cancer; Ipilimumab; Immunotherapy; Nivolumab","score_opus":0.09852714321238622,"score_gpt":0.4710260784119542,"score_spread":0.372498935199568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792916595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960283,0.00018187673,0.000062801846,0.00040871443,0.000083326406,0.003056071,0.0000012684211,0.0000037061604,0.00017392957],"genre_scores_gemma":[0.9981615,0.00010135645,0.0014354985,0.00011160095,0.000082474544,0.000050481016,0.0000019722108,0.000020697931,0.00003444127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926883,0.0031570792,0.002882959,0.00028407524,0.00071748963,0.00027006964],"domain_scores_gemma":[0.993228,0.0038620557,0.0016701834,0.00023623816,0.0007812444,0.00022226802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007719248,0.00020093865,0.0041040815,0.0005321146,0.00003615742,0.00000720099,0.00013876181,0.00013878239,0.0000728779],"category_scores_gemma":[0.0025907822,0.00011484591,0.00011061999,0.00040710226,0.0007446841,0.00013866498,0.00003496634,0.0007150788,0.0000016283678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40597162,0.03301287,0.5550582,0.000018628421,0.0009420911,0.0004852011,0.002096593,9.279292e-7,0.0000023988969,0.0000044414915,0.000008833385,0.0023982308],"study_design_scores_gemma":[0.3998579,0.14090572,0.45615217,0.00007597396,0.00084199314,0.000049735372,0.0017519445,0.00026124582,9.040928e-7,0.00005103745,0.0000024832216,0.000048886184],"about_ca_topic_score_codex":0.00022640993,"about_ca_topic_score_gemma":0.00085344503,"teacher_disagreement_score":0.10789285,"about_ca_system_score_codex":0.00015822619,"about_ca_system_score_gemma":0.0011402782,"threshold_uncertainty_score":0.46832803},"labels":[],"label_agreement":null},{"id":"W2792993335","doi":"10.1200/jco.2018.36.6_suppl.84","title":"Long-term outcomes of stereotactic body radiotherapy for low- and intermediate-risk prostate adenocarcinoma: A multi-institutional consortium study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Internal medicine; Oncology; Prostate; Dose fractionation; Urology; Surgery; Cancer; Prostatectomy","score_opus":0.13607477495906306,"score_gpt":0.5017333499122798,"score_spread":0.36565857495321674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792993335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480486,0.0014520307,0.0003768798,0.001112463,0.0010654517,0.0011283403,0.000023516577,0.000006201037,0.000030251222],"genre_scores_gemma":[0.9955947,0.001496811,0.0015018891,0.0002855564,0.0007146044,0.000022289372,0.000003742352,0.000016328811,0.0003641089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996999,0.00031165493,0.0019025187,0.00022169985,0.0003089544,0.00025614386],"domain_scores_gemma":[0.99520236,0.0020834554,0.0014502349,0.00016912933,0.0007696923,0.000325102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023470728,0.00016183947,0.0014812658,0.00017182433,0.00007572759,0.000011404678,0.00012967129,0.0001823165,0.00005772026],"category_scores_gemma":[0.0025912425,0.00009197274,0.0003363001,0.00007932203,0.0010593017,0.00012190995,0.0000507111,0.00052581687,0.0000029860303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01669319,0.004424321,0.95514,0.00009890605,0.0018610781,0.000417318,0.0005205448,2.4280138e-7,0.00011641239,0.000007693849,0.00013969287,0.020580579],"study_design_scores_gemma":[0.040915698,0.04413954,0.9132435,0.00010091504,0.0005676561,0.0001731535,0.00013227442,0.00009719232,0.00015407479,0.000028019254,0.00037415835,0.00007386605],"about_ca_topic_score_codex":0.000013497014,"about_ca_topic_score_gemma":0.00005132468,"teacher_disagreement_score":0.04189657,"about_ca_system_score_codex":0.00015320297,"about_ca_system_score_gemma":0.0016511669,"threshold_uncertainty_score":0.39030412},"labels":[],"label_agreement":null},{"id":"W2793081366","doi":"10.1200/jco.2018.36.4_suppl.252","title":"Method of diagnosis of pancreatic adenocarcinoma: A Nova Scotia experience.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Queen Elizabeth II Health Sciences Centre; Queen's University; Dalhousie University","funders":"","keywords":"Medicine; Nova scotia; Pancreatic cancer; Adenocarcinoma; Logistic regression; Gold standard (test); Internal medicine; Epidemiology; Retrospective cohort study; Radiology; Cancer; Gastroenterology","score_opus":0.24852796021863519,"score_gpt":0.5599622150878313,"score_spread":0.31143425486919607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793081366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852573,0.0008769636,0.002256002,0.0021756438,0.0006114382,0.00025061503,0.0000033082688,0.00000397533,0.008564751],"genre_scores_gemma":[0.91202444,0.0005813999,0.085586764,0.0005404104,0.0010210796,0.0000046064224,6.169976e-7,0.000013110534,0.00022755354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945045,0.00094388006,0.0034742681,0.00020049395,0.0005772863,0.00029956998],"domain_scores_gemma":[0.9870703,0.008146609,0.0024790955,0.0003351422,0.0015450832,0.0004237571],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006203463,0.00013777635,0.0031730093,0.00024951022,0.000025443936,0.0000022845124,0.0003082759,0.00048293534,0.0020262022],"category_scores_gemma":[0.012292827,0.00009295642,0.00056534307,0.00033095657,0.0014965463,0.00008188739,0.00009986153,0.00072576595,0.000037624483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003699123,0.0019928687,0.9568033,0.00009439919,0.00066281547,0.00021298799,0.0007873158,3.4070038e-7,0.0007341569,0.00020257209,0.003399356,0.031410743],"study_design_scores_gemma":[0.007006801,0.036863565,0.9447593,0.0003078741,0.0012769952,0.00065830414,0.00074418937,0.00013589623,0.00305136,0.00050094706,0.0046145134,0.0000802166],"about_ca_topic_score_codex":0.00024962734,"about_ca_topic_score_gemma":0.00007274467,"teacher_disagreement_score":0.083330765,"about_ca_system_score_codex":0.00009189046,"about_ca_system_score_gemma":0.0026614806,"threshold_uncertainty_score":0.9988861},"labels":[],"label_agreement":null},{"id":"W2793100803","doi":"10.1200/jco.2018.36.4_suppl.136","title":"Can recurrence patterns after curative resection for gastric adenocarcinoma (GCa) inform the selection of adjuvant treatment?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Surgery; Adjuvant therapy; Lymphadenectomy; Univariate analysis; Multivariate analysis; Cancer; Internal medicine","score_opus":0.13449037816807274,"score_gpt":0.4614149838121733,"score_spread":0.32692460564410053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793100803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98687714,0.00015416005,0.0012790402,0.008886389,0.0016286323,0.00048179794,0.000009066998,0.0000050851954,0.0006786625],"genre_scores_gemma":[0.9956958,0.00047278308,0.00066632737,0.00069779454,0.001885831,0.000021085105,0.000002463364,0.000007093068,0.0005507917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813133,0.00013029472,0.0012281808,0.00011554227,0.00022356526,0.00017105463],"domain_scores_gemma":[0.9969306,0.00088246877,0.0013019447,0.00011698096,0.000660367,0.00010766621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009918073,0.00010165081,0.0006864455,0.00014440034,0.000048493283,0.0000065845,0.00009302201,0.00012633542,0.00011498238],"category_scores_gemma":[0.0010309668,0.0000549113,0.00036253862,0.00021110907,0.00015332799,0.000096347794,0.000023865154,0.00028263414,0.0000025990548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009577794,0.00030566525,0.77404994,0.000028142415,0.00035120346,0.000014774598,0.00030116487,0.000001323687,0.000011296674,0.00002884741,0.0034302298,0.21189961],"study_design_scores_gemma":[0.0049831904,0.061176796,0.90752363,0.000072507435,0.00059252593,0.00011278715,0.00032206287,0.00013749067,0.00018749462,0.000128756,0.024718612,0.000044155557],"about_ca_topic_score_codex":0.00006760159,"about_ca_topic_score_gemma":0.0010749097,"teacher_disagreement_score":0.21185546,"about_ca_system_score_codex":0.0002626519,"about_ca_system_score_gemma":0.0006262854,"threshold_uncertainty_score":0.22392178},"labels":[],"label_agreement":null},{"id":"W2793156050","doi":"10.1200/jco.2018.36.6_suppl.279","title":"The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Biobank; Malignancy; Exome sequencing; Cancer; Internal medicine; Oncology; Bioinformatics; Gene; Genetics","score_opus":0.22543862509949827,"score_gpt":0.5182232148556427,"score_spread":0.2927845897561444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793156050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9409784,0.0063805976,0.000076481134,0.035265237,0.0036591934,0.0014097366,0.000042251784,0.000015499705,0.012172592],"genre_scores_gemma":[0.973331,0.014607073,0.00612622,0.0034673787,0.0020003575,0.00010067053,0.0000043251202,0.00002495044,0.0003380552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968688,0.00051009015,0.0017845492,0.00018909379,0.00039852888,0.00024893513],"domain_scores_gemma":[0.995667,0.002248282,0.0012522641,0.00017022694,0.0005385594,0.00012366337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022608174,0.00014095071,0.0008547937,0.000049087314,0.00017595192,0.000020063986,0.000110930785,0.00008895842,0.00015331438],"category_scores_gemma":[0.0007413519,0.000073417745,0.00044728976,0.00014642818,0.0003453529,0.000094374765,0.000031545085,0.0005078871,0.000013214443],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007847848,0.0031415627,0.03954386,0.000037269012,0.002994692,0.00031094596,0.0036432755,0.000028696033,0.000056412366,0.00035507375,0.04682574,0.8952146],"study_design_scores_gemma":[0.006030291,0.01551905,0.038233884,0.000081188504,0.0009512155,0.000101236954,0.000336684,0.000073293144,0.00036378377,0.00045121406,0.9377727,0.000085477404],"about_ca_topic_score_codex":0.00015406962,"about_ca_topic_score_gemma":0.00045876036,"teacher_disagreement_score":0.89512914,"about_ca_system_score_codex":0.0002750044,"about_ca_system_score_gemma":0.0035643063,"threshold_uncertainty_score":0.6322926},"labels":[],"label_agreement":null},{"id":"W2793185495","doi":"10.1200/jco.2018.36.4_suppl.131","title":"Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroesophageal Junction; Trastuzumab; Cancer; Esophagus; Esophageal cancer; Gastroenterology; Proportional hazards model; Oncology; Surgery; Adenocarcinoma; Breast cancer","score_opus":0.06254679207656892,"score_gpt":0.46606822682872395,"score_spread":0.403521434752155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793185495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9117361,0.0013158298,0.0025821393,0.079592064,0.003845098,0.0005723977,0.0000615458,0.000014398355,0.00028044227],"genre_scores_gemma":[0.9777311,0.0008064842,0.0026340634,0.014666855,0.0031239474,0.00004373256,0.000009611298,0.00001944273,0.00096474605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997398,0.00017819519,0.0014219644,0.0002788678,0.00039414567,0.00032878786],"domain_scores_gemma":[0.9955091,0.0020098214,0.0012299514,0.00021806876,0.00076287787,0.00027020558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007816706,0.00017730272,0.0010851076,0.000038817816,0.000100727426,0.000018885756,0.00035799167,0.00017539345,0.0006212701],"category_scores_gemma":[0.0011748861,0.000103608356,0.00035245868,0.0001670669,0.00047553444,0.00015135978,0.00008281664,0.00047249373,0.0000062255717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033063826,0.00035588158,0.8255286,0.000011701115,0.00046762722,0.000032498447,0.00041256897,0.000009269827,0.000031788164,0.000067901725,0.056568198,0.11320757],"study_design_scores_gemma":[0.007788313,0.0021111204,0.84179145,0.00010971857,0.00042116485,0.0000071220147,0.0006128724,0.0001338481,0.00027345732,0.000107534644,0.14654748,0.000095899006],"about_ca_topic_score_codex":0.00030610373,"about_ca_topic_score_gemma":0.00071388145,"teacher_disagreement_score":0.113111675,"about_ca_system_score_codex":0.0003106153,"about_ca_system_score_gemma":0.00084568193,"threshold_uncertainty_score":0.6802472},"labels":[],"label_agreement":null},{"id":"W2793199699","doi":"10.1200/jco.2018.36.6_suppl.436","title":"C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Performance status; Proportional hazards model; Oncology; Gastroenterology; Discontinuation; C-reactive protein; Lactate dehydrogenase; Inflammation","score_opus":0.08753861650590891,"score_gpt":0.4555690492437165,"score_spread":0.36803043273780756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793199699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057597,0.00026109733,0.00007731811,0.00341145,0.00089334813,0.0010214952,0.0000049880673,0.000015686895,0.0037386452],"genre_scores_gemma":[0.9902614,0.00012893346,0.00364434,0.002848677,0.0019005038,0.000037422942,8.1300516e-7,0.000045850225,0.0011320724],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967947,0.0003808604,0.0018152691,0.00028597278,0.0003727573,0.0003504676],"domain_scores_gemma":[0.99689806,0.0009446221,0.0011664036,0.00023452888,0.00047149428,0.00028491102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010226952,0.0002261965,0.0014539674,0.00017272998,0.000045708992,0.000011865668,0.00019499067,0.0003787507,0.0011104479],"category_scores_gemma":[0.002756811,0.00014311525,0.00036460557,0.00023754688,0.0002589956,0.00017274423,0.000024612105,0.0008915891,0.000058675116],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07769247,0.0037145528,0.4080956,0.000031976222,0.0005588429,0.0011720735,0.0013550556,4.015284e-7,0.01573016,0.000018804758,0.0002058429,0.49142423],"study_design_scores_gemma":[0.037523463,0.07502161,0.8384439,0.00039378883,0.00011822103,0.0005965355,0.00022622976,0.0000139450985,0.008295712,0.00048690598,0.03868392,0.0001957652],"about_ca_topic_score_codex":0.000107958214,"about_ca_topic_score_gemma":0.00013688282,"teacher_disagreement_score":0.49122846,"about_ca_system_score_codex":0.00035217765,"about_ca_system_score_gemma":0.0038699603,"threshold_uncertainty_score":0.99980265},"labels":[],"label_agreement":null},{"id":"W2793288544","doi":"10.1200/jco.2018.36.6_suppl.72","title":"Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; DECIPHER; Prostate cancer; Logistic regression; Internal medicine; Odds ratio; Adjuvant therapy; Salvage therapy; Cancer; Oncology; Bioinformatics; Chemotherapy","score_opus":0.1278614806549402,"score_gpt":0.5342841960884889,"score_spread":0.4064227154335487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793288544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955629,0.00061724527,0.000021349957,0.0010242587,0.00043954307,0.0006246316,0.000023115323,0.0000062777613,0.0016806434],"genre_scores_gemma":[0.99580145,0.0018215514,0.0012519937,0.00006506836,0.0008235321,0.000015500085,0.0000053656145,0.00001844879,0.00019707106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965999,0.00044820516,0.0018026226,0.00027012904,0.00053733453,0.0003418162],"domain_scores_gemma":[0.994884,0.0027329857,0.0012097305,0.00028264103,0.0003792547,0.00051134627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022761766,0.00018199984,0.0016389634,0.00030801314,0.000055729117,0.0000068849645,0.00017027733,0.00031806185,0.00014971834],"category_scores_gemma":[0.007165359,0.00009349125,0.0010304335,0.00025238204,0.0006287415,0.000061205785,0.000046383953,0.00089636224,0.000020199024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026666706,0.0035476296,0.8546538,0.0000069036273,0.001280553,0.0019135864,0.00050153263,0.0000068771146,0.0002220422,0.000015238208,0.00083111745,0.11035403],"study_design_scores_gemma":[0.027295403,0.09825414,0.8708107,0.00037271672,0.00030698723,0.0001286346,0.000116713425,0.000043454562,0.00030004262,0.00076372334,0.0015390795,0.00006844327],"about_ca_topic_score_codex":0.00020638313,"about_ca_topic_score_gemma":0.00012226329,"teacher_disagreement_score":0.11028558,"about_ca_system_score_codex":0.0016663811,"about_ca_system_score_gemma":0.0057043275,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W2793295628","doi":"10.1200/jco.2018.36.6_suppl.277","title":"Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Statin; Proportional hazards model; Internal medicine; Oncology; Prostatectomy; Cohort; Androgen deprivation therapy; Cancer; Docetaxel; Confidence interval","score_opus":0.045118989199462826,"score_gpt":0.38118062390525204,"score_spread":0.3360616347057892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793295628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984265,0.00017258897,0.000122005215,0.00020535094,0.0007731792,0.00019223965,0.000044297438,0.0000020806024,0.00006176982],"genre_scores_gemma":[0.99347526,0.00065004814,0.00419671,0.00029640706,0.0011096286,0.0000071938007,0.000013513545,0.000018557435,0.00023269423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980519,0.00026208974,0.0010867683,0.00020591175,0.00020976864,0.00018358849],"domain_scores_gemma":[0.99731034,0.00015582315,0.0013516253,0.00014333808,0.0008848707,0.00015401522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000687256,0.00014705384,0.00074716326,0.00008794076,0.000043409105,0.000017073124,0.00008271843,0.00011460774,0.0000135808195],"category_scores_gemma":[0.00042302092,0.00008806969,0.00007933458,0.000119615164,0.00040000325,0.000026913543,0.000027769856,0.0001706192,3.699887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019667266,0.0008451525,0.9076294,0.000049729035,0.0009837055,0.000006109246,0.00033771683,0.00003864596,0.025126578,0.000033743247,0.0017270467,0.043554954],"study_design_scores_gemma":[0.009234424,0.020812707,0.9175915,0.000056620305,0.0004233234,0.000015026722,0.00011408318,0.000008429639,0.0044253357,0.000025506088,0.047148533,0.00014451885],"about_ca_topic_score_codex":0.00019808004,"about_ca_topic_score_gemma":0.002152402,"teacher_disagreement_score":0.045421485,"about_ca_system_score_codex":0.000026653444,"about_ca_system_score_gemma":0.00065277645,"threshold_uncertainty_score":0.35913777},"labels":[],"label_agreement":null},{"id":"W2793310654","doi":"10.1200/jco.2018.36.6_suppl.642","title":"Association of dividing pathologically upstaged T3a renal cell carcinoma with improved alignment of outcomes: A call for TMN revision.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Renal cell carcinoma; Stage (stratigraphy); Pathological; Cohort; Surgery; Internal medicine","score_opus":0.098306413637358,"score_gpt":0.41113100713151124,"score_spread":0.31282459349415326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793310654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931655,0.00016348845,0.0019108885,0.002703706,0.00036741747,0.00063520455,0.000016796152,0.000005665179,0.0010313435],"genre_scores_gemma":[0.96837825,0.000081196464,0.029680854,0.0006006489,0.00048452494,0.0000079528945,0.0000047478143,0.000020472362,0.0007413363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99512583,0.00054465886,0.0031660171,0.00025437583,0.0006130236,0.0002961184],"domain_scores_gemma":[0.98842686,0.0039462307,0.0054372507,0.00028397772,0.0016154839,0.00029021184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005936846,0.00020068034,0.0022692939,0.00012560324,0.00004197812,0.0000049571436,0.00019007157,0.00042961474,0.000057299345],"category_scores_gemma":[0.004666297,0.000112059985,0.0007965097,0.000120364355,0.00020154889,0.00006457961,0.00006565507,0.00046797906,0.0000027657263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015129117,0.004039814,0.91488284,0.00025040223,0.0009849707,0.0003378925,0.0004217531,0.0000066198604,0.044907127,0.000042631196,0.0031215593,0.0158753],"study_design_scores_gemma":[0.02444173,0.13854347,0.80161774,0.00025946178,0.0023687717,0.00012246065,0.00020439301,0.00011105589,0.025187697,0.00015030192,0.0068202033,0.00017273193],"about_ca_topic_score_codex":0.000014924916,"about_ca_topic_score_gemma":0.000017157065,"teacher_disagreement_score":0.13450366,"about_ca_system_score_codex":0.000459706,"about_ca_system_score_gemma":0.00092558406,"threshold_uncertainty_score":0.5586331},"labels":[],"label_agreement":null},{"id":"W2793366594","doi":"10.1200/jco.2018.36.6_suppl.276","title":"Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Cabazitaxel; Clinical trial; Oncology; Abiraterone; Internal medicine; Cost effectiveness; Cancer; Androgen deprivation therapy","score_opus":0.13089206356827762,"score_gpt":0.526600887928451,"score_spread":0.3957088243601733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793366594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98111206,0.0015172684,0.0002266172,0.015128046,0.0005332748,0.0013193431,0.00003029818,0.0000035508817,0.0001295585],"genre_scores_gemma":[0.9787758,0.009430922,0.009776239,0.0014845487,0.00041372262,0.00003806905,0.0000015406564,0.000018888955,0.000060286864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938284,0.0012608424,0.0038071491,0.00036734718,0.00046859423,0.00026765472],"domain_scores_gemma":[0.9880158,0.0080969175,0.002173022,0.00038509403,0.0009938914,0.00033531067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008611836,0.0001804433,0.0018386716,0.000105494626,0.00008809942,0.00001371559,0.00019770494,0.0004436975,0.000015645144],"category_scores_gemma":[0.0061355224,0.00009967317,0.0002262871,0.00026082128,0.0024195518,0.00011697837,0.00023280106,0.0012452169,9.165691e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006342174,0.0009342459,0.854877,0.00011259984,0.00029967734,0.000013442943,0.00044180595,0.00011183185,0.0007475294,0.0010926098,0.0001428582,0.13488422],"study_design_scores_gemma":[0.009455526,0.007486803,0.97054625,0.0005588656,0.00039656556,0.000054954417,0.00023189606,0.00071795005,0.0019418788,0.0069584013,0.0015598811,0.00009100599],"about_ca_topic_score_codex":0.00017282435,"about_ca_topic_score_gemma":0.0003941671,"teacher_disagreement_score":0.13479322,"about_ca_system_score_codex":0.00006541295,"about_ca_system_score_gemma":0.001410029,"threshold_uncertainty_score":0.891494},"labels":[],"label_agreement":null},{"id":"W2793442370","doi":"10.1200/jco.2018.36.4_suppl.163","title":"Management of metastatic gastric and esophageal cancer in older adults.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Odds ratio; Internal medicine; Chemotherapy; Cancer; Proportional hazards model; Young adult; Retrospective cohort study; Surgery","score_opus":0.08828725901406138,"score_gpt":0.5010358733959583,"score_spread":0.41274861438189697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793442370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98648417,0.00926643,0.000053927903,0.0022615131,0.00027186723,0.00028686074,0.0000043525333,0.0000021883613,0.0013686876],"genre_scores_gemma":[0.99014074,0.0046399003,0.0043570246,0.00031284385,0.00030800726,0.000008216159,4.8296243e-7,0.0000074301297,0.00022537295],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99791884,0.00018476657,0.0012474881,0.00013477403,0.00031689255,0.00019722617],"domain_scores_gemma":[0.99834794,0.00041336814,0.0005902604,0.00010357071,0.00025810144,0.0002867684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014692333,0.00008261592,0.0008666949,0.0001613571,0.000013229688,0.0000025680456,0.00007883827,0.00007340212,0.00038779338],"category_scores_gemma":[0.00022676396,0.00005420411,0.00014354294,0.00018811921,0.00025814353,0.000053822092,0.0000491527,0.00037202987,0.0000059216013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007244724,0.0020714148,0.31804943,0.000244566,0.000702411,0.00534024,0.00014715725,0.0000018926884,0.000004442289,0.00013267093,0.00059539825,0.66546565],"study_design_scores_gemma":[0.016516771,0.015524965,0.9659478,0.00042166607,0.0003075513,0.00018173369,0.0001566928,0.000054123644,0.00009282119,0.00019799295,0.00056308927,0.00003478982],"about_ca_topic_score_codex":0.000072076604,"about_ca_topic_score_gemma":0.000094188195,"teacher_disagreement_score":0.66543084,"about_ca_system_score_codex":0.00012409034,"about_ca_system_score_gemma":0.00052397716,"threshold_uncertainty_score":0.42460656},"labels":[],"label_agreement":null},{"id":"W2793539844","doi":"10.1200/jco.2018.36.6_suppl.634","title":"Comparison of tumor mutational burden (TMB) in <i>PBRM1/BAP1</i>-based subsets of advanced renal cell carcinoma (aRCC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"BAP1; Medicine; Clear cell renal cell carcinoma; Oncology; Internal medicine; Cancer research; Renal cell carcinoma; Cancer","score_opus":0.11680790066887438,"score_gpt":0.46359298274843447,"score_spread":0.3467850820795601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793539844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259245,0.0005564318,0.000099965306,0.001356443,0.0005728151,0.00030253603,0.000011608808,0.0000046012133,0.0045031398],"genre_scores_gemma":[0.9863234,0.000012080217,0.012446394,0.00036548704,0.00073691795,0.0000048346556,0.000013209861,0.000022588247,0.000075078075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99386734,0.00056201435,0.0042528636,0.0002613545,0.00075361715,0.00030278656],"domain_scores_gemma":[0.9918688,0.0026357863,0.0036778296,0.00029240662,0.0011627307,0.00036245072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002124566,0.00021017125,0.0024169332,0.00034140475,0.000024459554,0.0000029479488,0.00025327594,0.00027833154,0.00026448522],"category_scores_gemma":[0.0014365738,0.00016025659,0.00059921463,0.000285184,0.00061868463,0.00008168806,0.000049096114,0.00078621047,0.00001829757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022921357,0.0066861776,0.90510756,0.00024039735,0.00019293695,0.0018151314,0.00057820627,0.0009542097,0.039850723,0.000056777557,0.0019925172,0.019604024],"study_design_scores_gemma":[0.02137298,0.038417995,0.8216796,0.00022213126,0.0003871375,0.00021044486,0.0003245592,0.0009259976,0.11312415,0.000154697,0.003044249,0.00013608324],"about_ca_topic_score_codex":0.00006491902,"about_ca_topic_score_gemma":0.00008039255,"teacher_disagreement_score":0.08342796,"about_ca_system_score_codex":0.00026127114,"about_ca_system_score_gemma":0.002772315,"threshold_uncertainty_score":0.6535074},"labels":[],"label_agreement":null},{"id":"W2793542547","doi":"10.1200/jco.2018.36.6_suppl.242","title":"Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Germline; Prostate cancer; Internal medicine; Oncology; Androgen deprivation therapy; Cancer; Germline mutation; Androgen receptor; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.1052536716788147,"score_gpt":0.5215393664997483,"score_spread":0.4162856948209336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793542547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295104,0.00013901791,0.0000035913242,0.006022453,0.00020280224,0.00036234068,0.000004325405,0.0000033192637,0.0003111219],"genre_scores_gemma":[0.99598145,0.0006000671,0.0020803811,0.00057080784,0.00016472676,0.000017505554,0.0000027718377,0.00001171412,0.00057055795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998162,0.00013378735,0.0010984598,0.00015207136,0.0002338274,0.00021989658],"domain_scores_gemma":[0.9977679,0.00095164526,0.0005972106,0.000076503544,0.000434497,0.00017220674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008472563,0.00009676771,0.0008310628,0.00017302531,0.000030589345,0.0000057064904,0.00005329039,0.000117447125,0.0000565382],"category_scores_gemma":[0.0016732053,0.0000504562,0.00005174351,0.00024180008,0.000270821,0.00015979802,0.000031651194,0.00057944213,0.0000018040365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013546101,0.0010976025,0.79927266,0.000020498002,0.00008462327,0.000219351,0.00042901436,0.000006577711,0.00001999298,0.000002861295,0.00004798342,0.18525273],"study_design_scores_gemma":[0.03100925,0.01923777,0.9470815,0.0002681597,0.000045122306,0.00001687507,0.00022489547,0.000046919475,0.00006888167,0.00006696224,0.0018761561,0.00005752192],"about_ca_topic_score_codex":0.00007412133,"about_ca_topic_score_gemma":0.0009837801,"teacher_disagreement_score":0.1851952,"about_ca_system_score_codex":0.00030233618,"about_ca_system_score_gemma":0.0013336452,"threshold_uncertainty_score":0.251742},"labels":[],"label_agreement":null},{"id":"W2793583610","doi":"10.1200/jco.2012.30.15_suppl.e18098","title":"Prognostication in non-small cell lung cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Performance status; Cohort; Proportional hazards model; Hazard ratio; Lung cancer; Oncology; Stage (stratigraphy); Cancer; Confidence interval","score_opus":0.10929904621740563,"score_gpt":0.4721509446286103,"score_spread":0.3628518984112047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793583610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772118,0.0023417345,0.00019350539,0.0040095313,0.0018669559,0.00023529862,0.000001337408,0.0000037157818,0.014136151],"genre_scores_gemma":[0.98846644,0.0016250656,0.0037407237,0.003647682,0.002171599,0.000008281428,0.000001928455,0.000010254245,0.00032802662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978334,0.0001661596,0.0015116356,0.00009271476,0.00015637676,0.00023975805],"domain_scores_gemma":[0.9974186,0.0010517886,0.0008895334,0.00010849214,0.00017424677,0.0003573687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024233572,0.000079960846,0.00079593307,0.00009995087,0.000014261927,0.0000028265495,0.00009717266,0.00025525966,0.0003472869],"category_scores_gemma":[0.0010315139,0.00005949071,0.00020843043,0.00010297654,0.000063384214,0.0001384984,0.000023012562,0.0008373491,0.00001244198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010350976,0.0010014577,0.8651864,0.00006995117,0.00005723932,0.00006772073,0.00024273797,0.000012527772,0.00042562347,0.000013711681,0.0053551137,0.12653244],"study_design_scores_gemma":[0.0060882433,0.0019699312,0.9225825,0.000088010274,0.00020731281,0.00006525989,0.00008643431,0.00039580968,0.00026003597,0.000011970026,0.06817865,0.00006581853],"about_ca_topic_score_codex":0.000037364418,"about_ca_topic_score_gemma":0.000043634733,"teacher_disagreement_score":0.12646662,"about_ca_system_score_codex":0.0002768507,"about_ca_system_score_gemma":0.0018836682,"threshold_uncertainty_score":0.3802548},"labels":[],"label_agreement":null},{"id":"W2793615431","doi":"10.1200/jco.2018.36.4_suppl.167","title":"Patient-level costs of treating metastatic gastric cancer by treatment strategy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Institute of Health Services and Policy Research; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Cancer; Gastrectomy; Comorbidity; Health care; Indirect costs; Time horizon; Intensive care medicine; Internal medicine","score_opus":0.19853761632283498,"score_gpt":0.49031104197612707,"score_spread":0.2917734256532921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793615431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996973,0.00090777426,0.00041887327,0.0022337942,0.0009095877,0.00025715082,0.000024101546,0.0000062114527,0.0052727936],"genre_scores_gemma":[0.9926854,0.0011233237,0.0035867381,0.0007912533,0.0006753847,0.000005867807,0.0000036961692,0.000012619625,0.0011157603],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971106,0.00019538474,0.0019852472,0.00014394335,0.0003235223,0.00024127608],"domain_scores_gemma":[0.99627256,0.0008899693,0.0020339321,0.00013817246,0.00042238034,0.00024295246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008231832,0.00013875101,0.00133008,0.00013802922,0.000031838445,0.0000058097175,0.00008986397,0.00009742866,0.0005166691],"category_scores_gemma":[0.00069763244,0.00008798978,0.00039090286,0.00021480059,0.00018513126,0.00007566536,0.00002994979,0.00024063293,0.000008562918],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016973441,0.0013687998,0.1305202,0.000020059064,0.00093114487,0.00012565145,0.0000953953,0.000009207879,0.00017671353,0.0000359783,0.016646003,0.84837353],"study_design_scores_gemma":[0.045237307,0.22190958,0.58255357,0.00049198756,0.006080279,0.00036365897,0.0019193414,0.00044997432,0.0015448139,0.00023333878,0.13888839,0.00032773448],"about_ca_topic_score_codex":0.00029506534,"about_ca_topic_score_gemma":0.00016752862,"teacher_disagreement_score":0.84804577,"about_ca_system_score_codex":0.00038068937,"about_ca_system_score_gemma":0.00096445595,"threshold_uncertainty_score":0.5657165},"labels":[],"label_agreement":null},{"id":"W2793617322","doi":"10.1200/jco.2018.36.4_suppl.260","title":"Pancreatic adenocarcinoma in young adults (≤45 years old): Characteristics and clinical outcomes from a Canadian center.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Population; Adenocarcinoma; Pancreatic cancer; Family history; Internal medicine; Young adult; Medical record; Progression-free survival; Cancer; Chemotherapy; Oncology; Surgery; Oxaliplatin","score_opus":0.10148255672607129,"score_gpt":0.46251803210593695,"score_spread":0.3610354753798657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793617322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911505,0.0002024151,0.000013725439,0.0040793302,0.0014439449,0.0002745349,0.000026910571,0.000005978742,0.0028026619],"genre_scores_gemma":[0.9894435,0.0015559345,0.003661895,0.0028900946,0.002065379,0.0000034037323,0.000009791052,0.000020303796,0.00034971617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99477476,0.00087213475,0.003212285,0.00031002174,0.00034745148,0.00048336427],"domain_scores_gemma":[0.9926868,0.004252712,0.0010104773,0.0002919342,0.0004203198,0.001337752],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00444022,0.00017075811,0.0026907055,0.00027777694,0.00004762257,0.000014541691,0.00023108977,0.0007732594,0.00047042334],"category_scores_gemma":[0.011797617,0.00012893417,0.000341359,0.00014020177,0.0008308248,0.000086196276,0.00008275223,0.0015928735,0.00009471855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031389978,0.0007809468,0.9561172,0.00001265582,0.00045355366,0.0022398036,0.00028100144,5.7049e-9,0.0000020522825,0.000019714178,0.0008894475,0.036064602],"study_design_scores_gemma":[0.012685498,0.009506773,0.9727227,0.00022944664,0.00045346358,0.00037846944,0.00021251908,0.00019338625,4.2210013e-7,0.0001402897,0.0033720369,0.00010496892],"about_ca_topic_score_codex":0.021673003,"about_ca_topic_score_gemma":0.09967896,"teacher_disagreement_score":0.078005955,"about_ca_system_score_codex":0.00028081695,"about_ca_system_score_gemma":0.0033215599,"threshold_uncertainty_score":0.9965264},"labels":[],"label_agreement":null},{"id":"W2793667186","doi":"10.1200/jco.2018.36.6_suppl.273","title":"Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Biomarker; Taxane; Context (archaeology); Cohort; Prostate cancer; Cancer; Breast cancer","score_opus":0.18636542787027024,"score_gpt":0.5069247617636963,"score_spread":0.32055933389342606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793667186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365675,0.00019103609,0.00013288211,0.0030510714,0.00065438385,0.0009345364,0.000024401872,0.000012313771,0.001342625],"genre_scores_gemma":[0.9941562,0.00039194923,0.00390332,0.0004000933,0.0005320669,0.000038054233,0.000012615181,0.000031675318,0.0005340383],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9970421,0.0003492799,0.0016869312,0.00024599643,0.0003845597,0.00029113452],"domain_scores_gemma":[0.9960773,0.0010987313,0.0016096437,0.00013073033,0.0008506509,0.00023291557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016698305,0.00016880437,0.0010175687,0.00022905866,0.00011871493,0.000020571608,0.00007651039,0.00011293501,0.00026955552],"category_scores_gemma":[0.0007474535,0.00011206538,0.0004065062,0.00023865636,0.00023644681,0.00012731814,0.000014179973,0.00024366516,0.00001279288],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14835101,0.007210293,0.013388548,0.00063794834,0.005784325,0.000864892,0.0018066601,0.00039110755,0.34245425,0.00066277507,0.0032788774,0.4751693],"study_design_scores_gemma":[0.1569006,0.3245067,0.075100765,0.0027005016,0.008401884,0.0008759962,0.0028814513,0.021840751,0.3058377,0.007148421,0.09287423,0.00093101873],"about_ca_topic_score_codex":0.00018747884,"about_ca_topic_score_gemma":0.000057565372,"teacher_disagreement_score":0.47423828,"about_ca_system_score_codex":0.00056143274,"about_ca_system_score_gemma":0.0016594733,"threshold_uncertainty_score":0.45698938},"labels":[],"label_agreement":null},{"id":"W2793733549","doi":"10.1200/jco.2018.36.6_suppl.440","title":"A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Transcriptome; Oncology; Carcinoma; Subtyping; Cystectomy; Cancer; Pathology; Gene; Gene expression; Biology","score_opus":0.26102167334113796,"score_gpt":0.5434736255947905,"score_spread":0.28245195225365255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793733549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696772,0.00078981783,0.00042466435,0.020874022,0.005443826,0.0005694295,0.000008145709,0.000023586126,0.0021893107],"genre_scores_gemma":[0.96982926,0.0014920054,0.0062258807,0.008600854,0.00872125,0.000034005196,0.0000013964839,0.00006136883,0.005033972],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626803,0.00031638134,0.002066926,0.00031778723,0.00046098029,0.0005698646],"domain_scores_gemma":[0.9945112,0.0021353895,0.0013555973,0.0002787258,0.0010982286,0.00062086113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146864,0.00017309426,0.0013126467,0.00022618545,0.00008557915,0.000021749756,0.00032153793,0.000037896112,0.0005448972],"category_scores_gemma":[0.0061299456,0.00012640565,0.00062904117,0.00018744371,0.0005259183,0.0001903102,0.00012451512,0.0011031069,0.00007009428],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046421528,0.0039062388,0.18499292,0.00039526774,0.0021727001,0.03078142,0.00013678455,0.000017362821,0.038404454,0.00052491645,0.41643676,0.27580965],"study_design_scores_gemma":[0.010575472,0.019862639,0.079633705,0.000084296546,0.00040825256,0.005825268,0.00008753112,0.00020034854,0.0016275541,0.0008702696,0.8806862,0.00013845882],"about_ca_topic_score_codex":0.000020887317,"about_ca_topic_score_gemma":0.00017755725,"teacher_disagreement_score":0.46424943,"about_ca_system_score_codex":0.00015568183,"about_ca_system_score_gemma":0.0022485314,"threshold_uncertainty_score":0.733856},"labels":[],"label_agreement":null},{"id":"W2793752308","doi":"10.1200/jco.2018.36.4_suppl.349","title":"The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Calgary; McGill University; Jewish General Hospital; University of Ottawa","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Oncology; Adjuvant; Cancer; Randomized controlled trial; Gastroenterology","score_opus":0.26729468975113263,"score_gpt":0.5241850064502284,"score_spread":0.25689031669909573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793752308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709216,0.009630091,0.000006139392,0.01383573,0.00085440156,0.0043396098,0.00008866993,0.0000039742504,0.0003197965],"genre_scores_gemma":[0.97658855,0.021456284,0.00038056736,0.000351107,0.0009605454,0.00012441754,0.000010269319,0.000027888795,0.00010036605],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9799871,0.009986002,0.008110211,0.00047301457,0.000858259,0.00058544904],"domain_scores_gemma":[0.9080419,0.08508871,0.0047131283,0.00065259135,0.00087948376,0.0006242232],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.050728783,0.00034598718,0.0071343533,0.0003785434,0.00030244098,0.000023195385,0.0004228874,0.00041680742,0.00016038404],"category_scores_gemma":[0.08413544,0.00017518303,0.0005279322,0.00047468886,0.00213391,0.000119393815,0.00013230612,0.0013184801,0.0000015779094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9176399,0.0045576845,0.042731542,0.000023715527,0.003414013,0.00041117164,0.004846961,0.0000026939483,0.000037812308,0.000069533526,0.00029899308,0.025965981],"study_design_scores_gemma":[0.7214384,0.08843608,0.18215123,0.000204134,0.002317981,0.000054171593,0.0030925926,0.0005404736,0.000004970375,0.0007757102,0.00086818123,0.00011609733],"about_ca_topic_score_codex":0.12766689,"about_ca_topic_score_gemma":0.4367237,"teacher_disagreement_score":0.30905682,"about_ca_system_score_codex":0.00043377306,"about_ca_system_score_gemma":0.005005703,"threshold_uncertainty_score":0.9774745},"labels":[],"label_agreement":null},{"id":"W2793782219","doi":"10.1200/jco.2018.36.6_suppl.472","title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Bladder cancer; Willingness to pay; Cost effectiveness; Oncology; Internal medicine; Quality-adjusted life year; Cancer; Immunotherapy","score_opus":0.18572527601231326,"score_gpt":0.5304688733149896,"score_spread":0.34474359730267634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793782219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830795,0.00096879323,0.00014190796,0.0010793407,0.0018251584,0.00044662645,0.000012868035,0.00000547237,0.0072118887],"genre_scores_gemma":[0.9960485,0.0006650512,0.0007078281,0.0011122224,0.0011533757,0.00001894116,0.0000016360649,0.000018199127,0.0002742607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970677,0.0004978413,0.0017661481,0.00018420772,0.00025805904,0.00022604264],"domain_scores_gemma":[0.9963968,0.0014418049,0.0010656014,0.00017723776,0.0006760302,0.00024255001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019401979,0.00013632796,0.0016379652,0.00013959802,0.000018302235,0.0000022493423,0.00013527565,0.00029461682,0.0010259806],"category_scores_gemma":[0.0010728542,0.00009651277,0.0003317358,0.00019868725,0.00032388937,0.0001020637,0.000034083205,0.0006112742,0.000012752104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09850152,0.005965476,0.2528757,0.000275525,0.0014898027,0.000786864,0.00030656788,0.00006669504,0.0054839305,0.00016323572,0.001768485,0.63231623],"study_design_scores_gemma":[0.051700424,0.04301187,0.8466723,0.00046302093,0.0004605471,0.00025580425,0.00008868961,0.000053317548,0.010390508,0.00081141066,0.04596298,0.0001291221],"about_ca_topic_score_codex":0.00006211102,"about_ca_topic_score_gemma":0.00038709032,"teacher_disagreement_score":0.63218707,"about_ca_system_score_codex":0.0002617179,"about_ca_system_score_gemma":0.0024699233,"threshold_uncertainty_score":0.9998872},"labels":[],"label_agreement":null},{"id":"W2793819981","doi":"10.1200/jco.2018.36.6_suppl.112","title":"Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Prostatectomy; Medicine; Adjuvant; Adjuvant therapy; Salvage therapy; Prostate cancer; Anxiety; Internal medicine; Oncology; Cancer; Bioinformatics; Psychiatry; Chemotherapy; Biology","score_opus":0.1353992134906448,"score_gpt":0.5391408966939886,"score_spread":0.4037416832033438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793819981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943356,0.00060758815,0.0000065212935,0.0012749679,0.00045988074,0.00031918794,0.000007963979,0.000006537239,0.0029817421],"genre_scores_gemma":[0.99631727,0.0010376544,0.0011092407,0.00022496044,0.0007399271,0.0000037706068,0.0000029957673,0.000018394598,0.0005457782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755275,0.00025292073,0.0013194068,0.00019345655,0.00039765576,0.00028378668],"domain_scores_gemma":[0.9959587,0.002318063,0.0007287554,0.00016588523,0.00031542755,0.00051318255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001546894,0.00015076705,0.0013409978,0.00014178311,0.000047702248,0.000007062693,0.00009339093,0.00026700238,0.00017593808],"category_scores_gemma":[0.0035920893,0.00008033958,0.00060135766,0.00014613422,0.00050889276,0.000079157166,0.000038582413,0.0005726228,0.0000165651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018566247,0.0040982338,0.78900975,0.00001901737,0.0016832886,0.0015692608,0.00018374431,5.803286e-7,0.0030590417,0.0000049560185,0.0024449623,0.1793609],"study_design_scores_gemma":[0.024573497,0.11101345,0.8598946,0.00025644572,0.00043449996,0.00017546977,0.000039039172,0.00002904467,0.0009714483,0.00017389968,0.002370636,0.0000679876],"about_ca_topic_score_codex":0.000022720753,"about_ca_topic_score_gemma":0.0000062222125,"teacher_disagreement_score":0.17929292,"about_ca_system_score_codex":0.000299211,"about_ca_system_score_gemma":0.0016098936,"threshold_uncertainty_score":0.43003258},"labels":[],"label_agreement":null},{"id":"W2793863239","doi":"10.1200/jco.2018.36.4_suppl.17","title":"The prognostic role of neutrophil-to-lymphocyte ratio trends during therapy in esophageal cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Neutrophil to lymphocyte ratio; Internal medicine; Esophageal cancer; Adenocarcinoma; Esophagectomy; Gastroenterology; Biomarker; Lymphocyte; Cancer; Chemotherapy; Oncology; Disease","score_opus":0.05595299659797098,"score_gpt":0.43778567510858957,"score_spread":0.3818326785106186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793863239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908953,0.0023551208,0.000003539323,0.004388802,0.0010537182,0.00024260908,0.0000027209362,0.00000783815,0.0010503671],"genre_scores_gemma":[0.99513674,0.0013818477,0.0005235937,0.00074284314,0.0020479623,0.00002394178,4.3457126e-7,0.000019355846,0.00012328521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963796,0.00048643432,0.0022808127,0.00017726203,0.00037924584,0.00029664414],"domain_scores_gemma":[0.99622834,0.00132618,0.0013118577,0.00024331456,0.0005665399,0.00032377022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024660714,0.00013866242,0.00094071584,0.00022239491,0.000078527904,0.000009983533,0.00029922626,0.00024033512,0.00013405291],"category_scores_gemma":[0.002022586,0.00008502272,0.0003699859,0.00036500182,0.00047452183,0.00007513203,0.00006607456,0.00046583067,0.000009512572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018974757,0.0007115205,0.6412169,0.000017143426,0.00033917266,0.00030158332,0.00021249577,0.000011068579,0.0029166772,0.00005209918,0.00044366848,0.33480293],"study_design_scores_gemma":[0.007618162,0.007628362,0.97151405,0.00013514707,0.00012761302,0.000086226464,0.00008196943,0.00014342806,0.0033191072,0.00012871763,0.009144455,0.00007278947],"about_ca_topic_score_codex":0.000019452067,"about_ca_topic_score_gemma":0.000086550885,"teacher_disagreement_score":0.33473015,"about_ca_system_score_codex":0.00023020097,"about_ca_system_score_gemma":0.0017348116,"threshold_uncertainty_score":0.3467126},"labels":[],"label_agreement":null},{"id":"W2793901188","doi":"10.1200/jco.2018.36.6_suppl.686","title":"Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) <i>v</i> sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Discontinuation; Adverse effect; Sunitinib; Renal cell carcinoma; Clinical endpoint; Nivolumab; Toxicity; Gastroenterology; Clinical trial; Cancer; Immunotherapy","score_opus":0.07046305125117139,"score_gpt":0.38233359659708543,"score_spread":0.3118705453459141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793901188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943084,0.00017679369,0.00013011023,0.00076317985,0.0010069944,0.0010965855,0.00016083465,0.000008000899,0.0023490705],"genre_scores_gemma":[0.99352354,0.000310132,0.00374967,0.00020298148,0.0011110577,0.000029649776,0.000040103278,0.000040930492,0.0009919371],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99551266,0.00039892958,0.0030240044,0.0002896557,0.000438831,0.00033589298],"domain_scores_gemma":[0.9910862,0.001208942,0.0053584864,0.0005078622,0.0015695584,0.00026896675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013575024,0.0002653661,0.0019484401,0.00014041376,0.000092238726,0.0000053462727,0.00027820154,0.00037411656,0.00014363852],"category_scores_gemma":[0.0009196091,0.00015831401,0.0010805835,0.0002243736,0.00050321524,0.00012540926,0.00007084851,0.00033976897,0.000008137322],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045452863,0.0085091,0.12654193,0.00036266563,0.0010108938,0.00010733216,0.0010069999,0.000017791612,0.533125,0.000132104,0.0005370078,0.2831963],"study_design_scores_gemma":[0.02281583,0.05784634,0.4138653,0.00014813722,0.0014438097,0.00013142066,0.00013659583,0.00015005776,0.49538502,0.00013533932,0.007816138,0.00012600387],"about_ca_topic_score_codex":0.000036618603,"about_ca_topic_score_gemma":0.000043172673,"teacher_disagreement_score":0.2873234,"about_ca_system_score_codex":0.00030052094,"about_ca_system_score_gemma":0.0015259397,"threshold_uncertainty_score":0.64558583},"labels":[],"label_agreement":null},{"id":"W2793942823","doi":"10.1200/jco.2018.36.6_suppl.237","title":"Effects of a 6-month moderate-intensity exercise program on metabolic parameters and bone mineral density in men on androgen deprivation therapy for prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; Toronto Public Health; Cancer Care Ontario; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Androgen deprivation therapy; Bone mineral; Prostate cancer; Femoral neck; Randomized controlled trial; Bone density; Internal medicine; Urology; Physical therapy; Cancer; Osteoporosis","score_opus":0.062065669024254366,"score_gpt":0.42313203289953877,"score_spread":0.3610663638752844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793942823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553627,0.0009469202,0.000027390322,0.0016548049,0.0005608598,0.0012049992,0.0000035051792,0.0000072902753,0.000057953468],"genre_scores_gemma":[0.99439436,0.0028265775,0.001011473,0.0013306153,0.0003312932,0.00006171481,0.0000020637651,0.000013583882,0.000028314053],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982138,0.00019280068,0.0009792031,0.00020452822,0.00021776596,0.00019186162],"domain_scores_gemma":[0.99753743,0.00082097255,0.00077241263,0.00012134055,0.00056728674,0.00018053749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014289719,0.0001327097,0.0014344353,0.00012344764,0.000027357126,0.0000070650963,0.000056930072,0.00021865855,0.000002459512],"category_scores_gemma":[0.00082031527,0.000091105474,0.00022667911,0.00012102488,0.00018948998,0.000055315886,0.000017345337,0.0003646481,3.6367754e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123914704,0.0027602597,0.08521735,0.000109545224,0.00026049494,0.00011005358,0.00090960885,0.000017755912,0.0011638085,0.0000294111,0.00055381417,0.7849532],"study_design_scores_gemma":[0.027791942,0.06824492,0.86185867,0.00058849994,0.00046058663,0.000053556527,0.00012797481,0.0014976962,0.035426714,0.0007048175,0.003070047,0.00017457895],"about_ca_topic_score_codex":0.00033928023,"about_ca_topic_score_gemma":0.0008920245,"teacher_disagreement_score":0.7847786,"about_ca_system_score_codex":0.000074708245,"about_ca_system_score_gemma":0.0003808634,"threshold_uncertainty_score":0.37151733},"labels":[],"label_agreement":null},{"id":"W2793957208","doi":"10.1200/jco.2018.36.6_suppl.3","title":"PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Placebo; Hazard ratio; Gynecology; Randomized controlled trial; Urology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","score_opus":0.13905785457491876,"score_gpt":0.5135764442932255,"score_spread":0.3745185897183067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793957208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98777753,0.00086976873,0.000024713343,0.0024754559,0.0002804589,0.0066233794,0.000010693764,0.0000075375287,0.0019304646],"genre_scores_gemma":[0.9959574,0.0007741024,0.0008492451,0.00018264726,0.00055874564,0.00045667705,0.000004120877,0.000029837429,0.0011872549],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930856,0.0012526374,0.0039610956,0.00034439846,0.00092002656,0.00043621476],"domain_scores_gemma":[0.9926613,0.0027113312,0.002653411,0.0002719536,0.0012975658,0.00040442156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008579202,0.0002715289,0.0041965856,0.00039694933,0.00006886723,0.000022966035,0.00019813958,0.0001999229,0.00024105224],"category_scores_gemma":[0.0013897987,0.00014398665,0.0004133125,0.00041066384,0.0007890999,0.00019238463,0.000044394765,0.0009361772,0.000006776752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9509549,0.0129760485,0.021439496,0.00007907414,0.0028906972,0.0013725961,0.0022794113,0.00005081451,0.0007501783,0.000022631672,0.0002934802,0.00689063],"study_design_scores_gemma":[0.92524815,0.06513241,0.0042401045,0.00029616585,0.0018920876,0.00008444255,0.0015319707,0.00046121335,0.00055422616,0.00008071738,0.00034830594,0.00013021125],"about_ca_topic_score_codex":0.0004327997,"about_ca_topic_score_gemma":0.0023744465,"teacher_disagreement_score":0.05215636,"about_ca_system_score_codex":0.0003424496,"about_ca_system_score_gemma":0.0046949815,"threshold_uncertainty_score":0.8328696},"labels":[],"label_agreement":null},{"id":"W2793995697","doi":"10.1200/jco.2018.36.4_suppl.327","title":"Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Ontario Institute for Cancer Research; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; Queen's University; Cancer Care Ontario; Mount Sinai Hospital; Sunnybrook Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Pancreatic cancer; Chemotherapy; Oncology; Regimen; Chemotherapy regimen; Odds ratio; Cancer registry; Cancer; Surgery; Irinotecan","score_opus":0.0712720617878873,"score_gpt":0.3777327958666369,"score_spread":0.3064607340787496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793995697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899481,0.0052432134,0.000117137126,0.0023793154,0.0018127478,0.00015683127,0.000021812893,0.0000046884825,0.0003161571],"genre_scores_gemma":[0.9787253,0.01698879,0.00018398756,0.0034534133,0.00057120854,0.0000076940905,8.537362e-7,0.000015116244,0.0000535976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972562,0.00005667595,0.0021360088,0.0002594749,0.000044067103,0.00024752688],"domain_scores_gemma":[0.99670327,0.00042877608,0.002199431,0.00016182371,0.00012602103,0.00038070555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088950497,0.00014163685,0.0010312287,0.00014958996,0.000039316717,0.00005369182,0.00017864417,0.0001894428,0.00017704102],"category_scores_gemma":[0.002284554,0.00013065513,0.00015745948,0.00008701559,0.0001905158,0.0013421953,0.000037892092,0.00036351467,0.00001503194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005664115,0.00018522766,0.8667883,0.00001454368,0.00003950625,0.000007436548,0.000317726,0.00005527998,0.000005296183,0.0004505976,0.00016228668,0.13140735],"study_design_scores_gemma":[0.0021146252,0.0017381452,0.9353778,0.00013481089,0.000012930413,0.0000018472672,0.00009590371,0.00015325441,0.000012481703,0.0050780713,0.05514031,0.00013983123],"about_ca_topic_score_codex":0.00045158225,"about_ca_topic_score_gemma":0.00043583818,"teacher_disagreement_score":0.13126752,"about_ca_system_score_codex":0.00023245314,"about_ca_system_score_gemma":0.00028634164,"threshold_uncertainty_score":0.53279614},"labels":[],"label_agreement":null},{"id":"W2794093685","doi":"10.1200/jco.2018.36.4_suppl.332","title":"Amplitude-modulated radiofrequency electromagnetic fields target hepatocellular carcinoma stem cells through activation of Cav 3.2 T-type calcium channels.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electromagnetic Fields and Biological Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cancer research; Cancer; Liver cancer; Stem cell; In vivo; Cancer cell; Pathology; Internal medicine; Biology; Cell biology","score_opus":0.0618504113317616,"score_gpt":0.362949010592088,"score_spread":0.3010985992603264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794093685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926788,0.0011091753,0.0030568128,0.00072867546,0.0013659402,0.00022618256,0.0000025687332,0.0000065673103,0.0008252519],"genre_scores_gemma":[0.99340487,0.0004942107,0.002991713,0.0010472527,0.001762571,0.000003139975,0.000011252406,0.000017814797,0.00026718774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996763,0.00062147825,0.0016274147,0.00034770436,0.00023934837,0.00040105917],"domain_scores_gemma":[0.9971024,0.0003545359,0.001259187,0.00030982928,0.0007900689,0.00018397861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013413901,0.00022353783,0.0009538438,0.000052865977,0.00005871463,0.000010878995,0.0004003251,0.001102749,0.00011105851],"category_scores_gemma":[0.000644457,0.00016350688,0.0003924527,0.00020528509,0.00034956622,0.000012708847,0.00008476712,0.0006135277,0.0000066166403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015985821,0.00054957264,0.0046064574,0.000029513267,0.00016358077,0.000043170905,0.000046586294,0.000016269902,0.9803877,0.00010737815,0.003127501,0.009323686],"study_design_scores_gemma":[0.0023170589,0.13592064,0.0041752825,0.000034770623,0.00010135908,0.000096027274,0.000021636875,0.00043772682,0.83812535,0.001209572,0.017306292,0.00025427865],"about_ca_topic_score_codex":0.00006448167,"about_ca_topic_score_gemma":0.000004843164,"teacher_disagreement_score":0.14226234,"about_ca_system_score_codex":0.000034996046,"about_ca_system_score_gemma":0.0006164351,"threshold_uncertainty_score":0.85054106},"labels":[],"label_agreement":null},{"id":"W2794097131","doi":"10.1200/jco.2018.36.4_suppl.248","title":"Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Proportional hazards model; Hazard ratio; Gastroenterology; Sorafenib; Ethnic group; Hepatitis C; Hepatitis B virus; Hepatitis B; Multivariate analysis; Oncology; Confidence interval; Immunology","score_opus":0.1811713486330298,"score_gpt":0.3817156013052668,"score_spread":0.20054425267223702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794097131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743783,0.00018209913,0.00006255933,0.00095301,0.00011142561,0.00048588612,0.0000058881133,0.000012332635,0.0007489766],"genre_scores_gemma":[0.9970638,0.000022078237,0.00215495,0.00018848851,0.00041195608,0.000005435423,0.000022800215,0.00002948843,0.00010096957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996887,0.0006254094,0.0014573984,0.00029736335,0.0004284908,0.00030428905],"domain_scores_gemma":[0.9959734,0.0017954588,0.0009918086,0.00021975528,0.0005804393,0.00043913745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015824382,0.00022696349,0.0015306246,0.00019308644,0.00006706915,0.000010543822,0.000099944074,0.00039954716,0.00004652326],"category_scores_gemma":[0.000859235,0.0001406862,0.00016536823,0.00025967488,0.00038679712,0.0001889124,0.000034969864,0.0008661897,0.00000958766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01046156,0.000912589,0.98001003,0.000023658373,0.00017715976,0.0005112334,0.00012080287,3.7816724e-7,0.000004859103,0.000030700507,0.000045032026,0.0077020046],"study_design_scores_gemma":[0.0253891,0.034046296,0.93843794,0.00010414033,0.00058700197,0.000026111316,0.000024337765,0.00007341194,0.00008404846,0.00008067748,0.0009994678,0.00014746946],"about_ca_topic_score_codex":0.00006886677,"about_ca_topic_score_gemma":0.00010054115,"teacher_disagreement_score":0.041572083,"about_ca_system_score_codex":0.00015458488,"about_ca_system_score_gemma":0.0006181692,"threshold_uncertainty_score":0.5737017},"labels":[],"label_agreement":null},{"id":"W2794109715","doi":"10.1200/jco.2018.36.6_suppl.199","title":"Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; MedDRA; Adverse effect; Placebo; Oncology; Cancer; Androgen receptor; Pharmacovigilance; Pathology; Alternative medicine","score_opus":0.2899779807679661,"score_gpt":0.5905129250429935,"score_spread":0.30053494427502736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794109715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.839893,0.121912435,0.00007285771,0.031699944,0.0017490884,0.0024575556,0.00023210702,0.000009909907,0.0019730898],"genre_scores_gemma":[0.6945779,0.29886755,0.0016591705,0.0028829605,0.0013129002,0.000028128805,0.000087915534,0.000025807904,0.000557692],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99302304,0.0019426463,0.0039653704,0.00024534014,0.00056147866,0.00026213337],"domain_scores_gemma":[0.9900459,0.005954263,0.0025149607,0.00042251617,0.0007717212,0.00029063423],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016308624,0.00014037202,0.0026459014,0.00010909057,0.000029848501,0.000006581915,0.00029544238,0.00021192411,0.00027133644],"category_scores_gemma":[0.021148996,0.000083623316,0.00025972017,0.0002915985,0.00033872697,0.00016775218,0.00008699819,0.0007061001,0.0000070630913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07174844,0.007274652,0.14990526,0.01564005,0.002512824,0.0020607228,0.00026566096,0.0000018381188,0.022069125,0.00006271907,0.12122383,0.6072349],"study_design_scores_gemma":[0.08119395,0.06250466,0.44222653,0.059870165,0.0035374009,0.00017687022,0.000118969,0.0002832325,0.009091087,0.00051621377,0.340048,0.000432946],"about_ca_topic_score_codex":0.00021385965,"about_ca_topic_score_gemma":0.00038734486,"teacher_disagreement_score":0.6068019,"about_ca_system_score_codex":0.00029260025,"about_ca_system_score_gemma":0.0052404706,"threshold_uncertainty_score":0.9870963},"labels":[],"label_agreement":null},{"id":"W2794152261","doi":"10.1200/jco.2018.36.6_suppl.5","title":"Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Occupational Cancer Research Centre; Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostatectomy; Radiation therapy; Biochemical recurrence; Oncology; Hypoxia (environmental); DU145; Internal medicine; Metastasis; LNCaP; Cancer","score_opus":0.04698471439548915,"score_gpt":0.40465397876786957,"score_spread":0.35766926437238045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794152261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829798,0.005210061,0.0004501594,0.0067682425,0.0038592077,0.00037858915,0.00008906306,0.000006643918,0.00025827056],"genre_scores_gemma":[0.97075933,0.0050539984,0.012480352,0.00275078,0.007985801,0.000040836025,0.00001820513,0.00004335731,0.0008673307],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755746,0.00019344436,0.0013951734,0.00035853096,0.0001708392,0.00032452558],"domain_scores_gemma":[0.9976357,0.00021167843,0.0008124094,0.00021485233,0.00064563216,0.00047973392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019659514,0.00017934722,0.0008143806,0.00008345128,0.00006762549,0.000016937836,0.00023967758,0.00052394706,0.00004366611],"category_scores_gemma":[0.002395652,0.00013821895,0.00036389995,0.00013361845,0.00037467183,0.000009979684,0.0001301498,0.0002846594,0.0000042110732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062733507,0.0003644559,0.0029368252,0.000031725005,0.0010174979,0.000009130887,0.000090097,0.000004319352,0.3523479,0.000043453405,0.3365484,0.30033284],"study_design_scores_gemma":[0.004257081,0.0062612817,0.012833245,0.00003136248,0.00033467045,0.00013269784,0.000050103812,0.00002666556,0.019167265,0.00023416063,0.95649457,0.00017687277],"about_ca_topic_score_codex":0.000015913874,"about_ca_topic_score_gemma":0.000098370096,"teacher_disagreement_score":0.6199462,"about_ca_system_score_codex":0.000027262606,"about_ca_system_score_gemma":0.00082841574,"threshold_uncertainty_score":0.5636405},"labels":[],"label_agreement":null},{"id":"W2794154391","doi":"10.1200/jco.2018.36.6_suppl.408","title":"Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Gemcitabine; Bladder cancer; Regimen; Urology; Cystectomy; Clinical endpoint; Internal medicine; Toxicity; Cisplatin; Gastroenterology; Surgery; Oncology; Nuclear medicine; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.06305900183668589,"score_gpt":0.4121444219876597,"score_spread":0.3490854201509738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794154391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840669,0.00026940994,0.0032042204,0.0031318972,0.0013549372,0.006811636,0.0002406153,0.000026327032,0.0008940594],"genre_scores_gemma":[0.98723745,0.0006459196,0.0058440217,0.002203076,0.0028143048,0.00033028924,0.00025265562,0.000076239216,0.00059602165],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933863,0.001076791,0.0036218944,0.00053521595,0.00093880936,0.00044094244],"domain_scores_gemma":[0.9838147,0.0061815716,0.005711266,0.0003485928,0.0035501432,0.00039371528],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029681108,0.0004067018,0.0029342428,0.0002884892,0.00013750869,0.000027667294,0.00021882531,0.00047954867,0.00014823201],"category_scores_gemma":[0.008683118,0.00024127304,0.0004732575,0.0004190318,0.00046082027,0.0007302821,0.000040947198,0.00064595597,0.00000509841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93162096,0.004304991,0.0031695627,0.00010221494,0.0032133937,0.000030691655,0.0018338109,0.00018239948,0.00011834212,0.0000042461224,0.0060043405,0.049415063],"study_design_scores_gemma":[0.85542053,0.08871138,0.0440753,0.00026954195,0.00393939,0.000012086732,0.00013843755,0.0015944052,0.00060512463,0.000039205148,0.004952363,0.00024221942],"about_ca_topic_score_codex":0.00034135106,"about_ca_topic_score_gemma":0.0004937561,"teacher_disagreement_score":0.08440639,"about_ca_system_score_codex":0.0009583834,"about_ca_system_score_gemma":0.0067459126,"threshold_uncertainty_score":0.99966717},"labels":[],"label_agreement":null},{"id":"W2794194244","doi":"10.1200/jco.2018.36.6_suppl.39","title":"Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Oncology; Cancer; Incidence (geometry); Bioinformatics","score_opus":0.5071174571360112,"score_gpt":0.6738651297559975,"score_spread":0.16674767261998635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794194244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907145,0.0001115723,0.00047526273,0.00358941,0.0007999169,0.0011597244,0.00006463997,0.000010217507,0.0030747368],"genre_scores_gemma":[0.98100966,0.0061835293,0.010877947,0.0002501171,0.00069958845,0.00001838737,0.000008421809,0.000027780761,0.0009245895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9876345,0.00209088,0.007875947,0.0005772884,0.0013937096,0.00042767977],"domain_scores_gemma":[0.9690098,0.01678142,0.0064595556,0.0009986177,0.005856313,0.00089430116],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031272966,0.00026197557,0.0038643251,0.0009032724,0.00007904284,0.0000141174705,0.0005362002,0.0007590347,0.00052096223],"category_scores_gemma":[0.033913635,0.00016691953,0.0031031538,0.0013066366,0.0018265864,0.000079021986,0.0002568207,0.0018314315,0.00006620995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036476064,0.008877246,0.8418603,0.00006869839,0.029027889,0.00012511645,0.0003333979,0.00036308233,0.00066156243,0.00054273056,0.00058253866,0.0810814],"study_design_scores_gemma":[0.01108993,0.10355164,0.8689214,0.00012207459,0.01016398,0.000009899564,0.00022802639,0.0019127172,0.00014476945,0.0033481326,0.0003956153,0.000111821435],"about_ca_topic_score_codex":0.00015756542,"about_ca_topic_score_gemma":0.00021450952,"teacher_disagreement_score":0.09467439,"about_ca_system_score_codex":0.0007666811,"about_ca_system_score_gemma":0.0036959029,"threshold_uncertainty_score":0.99750835},"labels":[],"label_agreement":null},{"id":"W2794222772","doi":"10.1200/jco.2018.36.4_suppl.375","title":"Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; McMaster University; Cancer Care Ontario; Queen's University; Mount Sinai Hospital; Sunnybrook Hospital; Health Sciences Centre; Ontario Institute for Cancer Research; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Pancreatic cancer; Cancer registry; Proportional hazards model; Internal medicine; Logistic regression; Propensity score matching; Population; Cancer; Oncology; Environmental health","score_opus":0.11186073717567276,"score_gpt":0.43271185339725304,"score_spread":0.3208511162215803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794222772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748045,0.0006351181,0.00028738572,0.00044148296,0.00039780146,0.0003590524,0.00005966763,0.00000108256,0.00033794218],"genre_scores_gemma":[0.9993597,0.00018801454,0.00028567918,0.00006568265,0.000082715575,0.0000046856712,8.9003515e-7,0.0000067699716,0.000005812176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727744,0.00021704688,0.0021443837,0.0001642584,0.00005121834,0.0001456807],"domain_scores_gemma":[0.9946606,0.0013476412,0.0035285794,0.00012024397,0.00026838214,0.00007452738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027193653,0.00010042652,0.0014303158,0.000198316,0.000040292143,0.000006012491,0.00013987959,0.00010906975,0.00005588322],"category_scores_gemma":[0.0008343621,0.000084320425,0.00012705856,0.00020233214,0.00025314663,0.00029038655,0.000052644915,0.00019602153,3.0699547e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011964393,0.0002704302,0.98178136,0.000044456596,0.00014834445,7.1933147e-7,0.0005243573,0.000099865836,0.000030846488,0.005386437,0.000007502012,0.010509252],"study_design_scores_gemma":[0.0069254152,0.0031361128,0.9855837,0.00007937171,0.000045041434,0.000001015586,0.0009232263,0.00018765035,0.00007087293,0.0027220484,0.0002527927,0.00007275309],"about_ca_topic_score_codex":0.0012500967,"about_ca_topic_score_gemma":0.003351238,"teacher_disagreement_score":0.010436499,"about_ca_system_score_codex":0.00022190757,"about_ca_system_score_gemma":0.00037690267,"threshold_uncertainty_score":0.3438487},"labels":[],"label_agreement":null},{"id":"W2794270719","doi":"10.1200/jco.2018.36.4_suppl.145","title":"Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Mount Sinai Hospital; Toronto Western Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Oncology; Gastroenterology","score_opus":0.1684058235979041,"score_gpt":0.4674000224871667,"score_spread":0.2989941988892626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794270719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952219,0.00076055236,0.00008824916,0.0025425737,0.0007629703,0.00024946991,0.00009300195,0.000012959651,0.00026833126],"genre_scores_gemma":[0.99227697,0.00012151067,0.004459185,0.00034173843,0.0027031796,0.0000053647423,0.000021452975,0.000020196561,0.00005041834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995579,0.001145865,0.0022426946,0.00024202684,0.0003090984,0.00048129086],"domain_scores_gemma":[0.99485666,0.002682715,0.001289727,0.00014589484,0.00027237486,0.00075262703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017591589,0.00018635293,0.0015722022,0.00016801429,0.000093412695,0.000014480436,0.00009257466,0.00025234342,0.00022111606],"category_scores_gemma":[0.002097293,0.00013038574,0.00030105564,0.00015141684,0.00032972108,0.0001625745,0.000045090204,0.00083950406,0.000009610924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000856901,0.0004556253,0.9729459,0.00006970977,0.00031542312,0.0005048048,0.00011876355,0.0000015549716,0.000011587532,0.0005763786,0.0008203255,0.023322983],"study_design_scores_gemma":[0.007058257,0.0109443925,0.977414,0.00011648734,0.00059796654,0.00014753075,0.00018328038,0.0000068735803,0.00005505255,0.00010439021,0.0032903098,0.00008142711],"about_ca_topic_score_codex":0.00035958423,"about_ca_topic_score_gemma":0.00023282054,"teacher_disagreement_score":0.023241557,"about_ca_system_score_codex":0.000428371,"about_ca_system_score_gemma":0.0008474653,"threshold_uncertainty_score":0.53169763},"labels":[],"label_agreement":null},{"id":"W2794297331","doi":"10.1200/jco.2018.36.6_suppl.410","title":"Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Pembrolizumab; Internal medicine; Paclitaxel; Regimen; Clinical endpoint; Oncology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","score_opus":0.15059133438656336,"score_gpt":0.49691032084698405,"score_spread":0.3463189864604207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794297331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779296,0.0010367981,0.0000330084,0.009011968,0.008032629,0.0010910447,0.00016505859,0.000018311966,0.0026815603],"genre_scores_gemma":[0.97705585,0.0019813182,0.0022249517,0.006964795,0.011036153,0.000058940805,0.00001095112,0.000062936306,0.0006041133],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99341947,0.0011354693,0.0036957788,0.00046451244,0.00077820395,0.00050657726],"domain_scores_gemma":[0.99115413,0.004048733,0.0026838002,0.0005831528,0.0007836892,0.0007465042],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002242972,0.00037472954,0.0025841931,0.00017542942,0.000089345835,0.000018875959,0.000567531,0.00048759897,0.0013998516],"category_scores_gemma":[0.013180541,0.00021837662,0.0007546617,0.00044995704,0.00088615075,0.00025719462,0.00011444998,0.0014912705,0.000036806792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8393025,0.0049327477,0.028697884,0.000042203883,0.0011070173,0.00022749383,0.00060294435,0.0000052098194,0.0012203942,0.00009888555,0.014749666,0.109013066],"study_design_scores_gemma":[0.6799118,0.08436862,0.027897514,0.0006582725,0.00147345,0.0000518094,0.00023380657,0.00005452876,0.0010434554,0.00073489256,0.20329393,0.0002779437],"about_ca_topic_score_codex":0.001419178,"about_ca_topic_score_gemma":0.003270295,"teacher_disagreement_score":0.18854427,"about_ca_system_score_codex":0.0003724094,"about_ca_system_score_gemma":0.0074865683,"threshold_uncertainty_score":0.99951303},"labels":[],"label_agreement":null},{"id":"W2794329127","doi":"10.1200/jco.2018.36.4_suppl.238","title":"A sensitive biomarker panel to distinguish pancreaticobiliary malignancies from benign disease.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Biomarker; Immunohistochemistry; Pathology; Pancreas; Pancreatic cancer; Endoscopic ultrasound; Cancer; Fine-needle aspiration; Endoscopic retrograde cholangiopancreatography; Biopsy; Cytology; Internal medicine; Radiology; Pancreatitis; Biology","score_opus":0.24770767139649547,"score_gpt":0.5023424947226302,"score_spread":0.2546348233261347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794329127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711492,0.00022189143,0.0015958296,0.012618412,0.0011659489,0.0003715892,0.000037661313,0.0000191965,0.012820288],"genre_scores_gemma":[0.9717809,0.00020367082,0.015469162,0.0068800063,0.004242787,0.000009026497,0.000009141592,0.000024693523,0.0013806116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954361,0.00092090934,0.002247428,0.00034734965,0.0005968974,0.00045133958],"domain_scores_gemma":[0.988107,0.0072348076,0.0009865507,0.0003958185,0.0016896187,0.0015862023],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040034023,0.0001986062,0.0022469412,0.00017321747,0.000102587204,0.000014419744,0.0002284233,0.00038372484,0.0006392842],"category_scores_gemma":[0.031583812,0.00013693163,0.0004997285,0.00024391849,0.00091802486,0.00007641453,0.0001536554,0.00071896845,0.00028688821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021091118,0.0020085778,0.8631912,0.00003268777,0.0013160213,0.0052250326,0.00052773074,4.528746e-7,0.0015499014,0.0001835255,0.04260045,0.06227331],"study_design_scores_gemma":[0.004183941,0.0098892115,0.9364193,0.00030546295,0.0011195,0.00020102589,0.0003557069,0.00027583356,0.000102295875,0.0011553363,0.04585757,0.00013481195],"about_ca_topic_score_codex":0.00013976514,"about_ca_topic_score_gemma":0.00006495909,"teacher_disagreement_score":0.073228106,"about_ca_system_score_codex":0.00020244795,"about_ca_system_score_gemma":0.0032608798,"threshold_uncertainty_score":0.9765736},"labels":[],"label_agreement":null},{"id":"W2794337388","doi":"10.1200/jco.2018.36.6_suppl.301","title":"Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone (A) and docetaxel (D).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Abiraterone; Docetaxel; Internal medicine; Oncology; Cancer; Androgen receptor","score_opus":0.2170137957382113,"score_gpt":0.5748296015047577,"score_spread":0.35781580576654637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794337388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741256,0.0005239278,0.000035785462,0.0013231791,0.00010493354,0.00014481458,0.0000056188496,0.000002098986,0.00044709392],"genre_scores_gemma":[0.99608034,0.0027532382,0.00066108926,0.0002535909,0.00018628595,8.313558e-7,0.0000010785601,0.0000046696605,0.000058876587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982753,0.00018998847,0.0010868406,0.000121616795,0.00022023912,0.00010602605],"domain_scores_gemma":[0.9977373,0.0006006836,0.00069493405,0.00010435331,0.0006988554,0.00016390232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017068111,0.00006889676,0.00074147317,0.00008516033,0.000020683887,0.0000032635828,0.0000465172,0.0001571391,0.000043166747],"category_scores_gemma":[0.001530296,0.00004361245,0.000060104852,0.00007983852,0.0007432013,0.000083297266,0.000037124668,0.00023429534,0.000001154701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024278335,0.00245131,0.83554155,0.00039389334,0.0004376242,0.00009049731,0.0005747404,0.000008029633,0.024325294,0.00024850736,0.0007872804,0.11086291],"study_design_scores_gemma":[0.0065230746,0.023810605,0.961252,0.00017840561,0.00010575756,0.000036929796,0.00004184153,0.00010351442,0.00566682,0.00057149626,0.0016738651,0.000035728783],"about_ca_topic_score_codex":0.000019471523,"about_ca_topic_score_gemma":0.000018925024,"teacher_disagreement_score":0.12571038,"about_ca_system_score_codex":0.000030947827,"about_ca_system_score_gemma":0.00040833445,"threshold_uncertainty_score":0.2738356},"labels":[],"label_agreement":null},{"id":"W2794348724","doi":"10.1200/jco.2018.36.6_suppl.278","title":"Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Chromogranin A; Prostate cancer; Internal medicine; Biopsy; Gastroenterology; Pathology; Oncology; Cancer; Immunohistochemistry","score_opus":0.11519572686541225,"score_gpt":0.45103905666513255,"score_spread":0.3358433297997203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794348724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97303534,0.0015379596,0.000003298644,0.020149354,0.0009946438,0.0023183061,0.0017954987,0.000019131943,0.00014647805],"genre_scores_gemma":[0.92122877,0.07392617,0.0009931963,0.0010789819,0.0011552304,0.00014023193,0.00008609579,0.00010162442,0.0012897208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907294,0.0018574162,0.0046266858,0.0010017216,0.0008179934,0.0009667839],"domain_scores_gemma":[0.990614,0.0027981899,0.0038314646,0.00095937966,0.0009920523,0.0008049153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015535335,0.0005660449,0.0026363796,0.00020797818,0.00013507294,0.000053744017,0.00066517986,0.000035269353,0.00025682643],"category_scores_gemma":[0.0020071743,0.00033518628,0.00024950443,0.00048127802,0.0013927652,0.000423692,0.00043189208,0.0016788602,0.0000047993713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057844315,0.0027803977,0.8328924,0.00025647494,0.0009542066,0.010529231,0.00021898658,0.000051394316,0.0017190939,0.000002702521,0.004269242,0.08848156],"study_design_scores_gemma":[0.028197924,0.04467554,0.86399233,0.00072441506,0.0020127827,0.0010474188,0.0009894217,0.0015397364,0.001256693,0.000038875914,0.05515848,0.00036640305],"about_ca_topic_score_codex":0.007495753,"about_ca_topic_score_gemma":0.060001407,"teacher_disagreement_score":0.088115156,"about_ca_system_score_codex":0.00036807827,"about_ca_system_score_gemma":0.0049699484,"threshold_uncertainty_score":0.99991},"labels":[],"label_agreement":null},{"id":"W2794418238","doi":"10.1200/jco.2018.36.6_suppl.145","title":"Comparative effectiveness of a patient-centered prostate biopsy report in clinical prostate cancer practice.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Prostate biopsy; Prostate; Prostate cancer; Biopsy; Checklist; Gynecology; Cancer; Radiology; Internal medicine","score_opus":0.37917970834735487,"score_gpt":0.641642305559582,"score_spread":0.26246259721222714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794418238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508024,0.00021828187,0.00015512208,0.0084113125,0.0036643678,0.0012452902,0.000015005282,0.000010360478,0.0012000457],"genre_scores_gemma":[0.98570514,0.000716101,0.010230742,0.0020214347,0.0012164806,0.00002382308,0.000014598281,0.000024922292,0.000046766683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98012024,0.005201286,0.013119789,0.00046499047,0.0007390725,0.00035463605],"domain_scores_gemma":[0.9523619,0.02834902,0.013794301,0.00041252928,0.0046290304,0.0004532605],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031942457,0.00022622995,0.0031071582,0.00022843285,0.000036622514,0.000011618855,0.00018331363,0.0004369525,0.00013039201],"category_scores_gemma":[0.100241825,0.00016737175,0.000623974,0.00045795317,0.0008887534,0.0005435052,0.0001375564,0.0017943139,0.00002247221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09977738,0.009385662,0.76270044,0.0001393049,0.0010270278,0.003452087,0.00074042444,0.00001747051,0.0007699854,0.00003547613,0.0024161376,0.11953863],"study_design_scores_gemma":[0.027281549,0.04783081,0.84880733,0.0009734806,0.0010155631,0.0025513202,0.0016593956,0.00020045793,0.0007086462,0.0003980881,0.06837244,0.00020093855],"about_ca_topic_score_codex":0.0003148742,"about_ca_topic_score_gemma":0.00022125054,"teacher_disagreement_score":0.119337685,"about_ca_system_score_codex":0.0002817146,"about_ca_system_score_gemma":0.0052071195,"threshold_uncertainty_score":0.99681896},"labels":[],"label_agreement":null},{"id":"W2794426755","doi":"10.1200/jco.2018.36.6_suppl.451","title":"Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Nomogram; Nivolumab; Internal medicine; Oncology; Metastatic Urothelial Carcinoma; Clinical endpoint; Confidence interval; Urology; Statistical significance; Clinical trial; Cancer; Bladder cancer; Urothelial carcinoma; Immunotherapy","score_opus":0.12614052563275158,"score_gpt":0.45635219054460147,"score_spread":0.3302116649118499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794426755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853575,0.0007426182,0.0005783468,0.002612687,0.0033543669,0.0008279239,0.00008938064,0.000027973261,0.0064092046],"genre_scores_gemma":[0.98607385,0.00049291947,0.0045200386,0.0031411075,0.0048232274,0.000024955621,0.00001447601,0.00005405765,0.0008553666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631757,0.000297479,0.0021154464,0.0003262944,0.0004988969,0.000444321],"domain_scores_gemma":[0.9953358,0.0018315163,0.0012065273,0.00029565164,0.0007645378,0.00056592503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017820396,0.0002763741,0.0018306555,0.00014404465,0.000110273126,0.000023885292,0.00025442618,0.00035778308,0.0007743082],"category_scores_gemma":[0.0012590836,0.00018906045,0.00090530387,0.00014517234,0.00048334087,0.00014291416,0.0000342566,0.0006116063,0.000029581648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08374781,0.008211624,0.46084207,0.00006824743,0.004873917,0.001008734,0.00047550825,0.000003752197,0.0014234744,0.0006256791,0.012964709,0.4257545],"study_design_scores_gemma":[0.07502171,0.14448845,0.6484239,0.000102243874,0.0019878757,0.00055582623,0.00021026291,0.00025662678,0.0013641968,0.0039529544,0.12332576,0.0003102096],"about_ca_topic_score_codex":0.0002495126,"about_ca_topic_score_gemma":0.0003307573,"teacher_disagreement_score":0.42544428,"about_ca_system_score_codex":0.00015520348,"about_ca_system_score_gemma":0.0026647523,"threshold_uncertainty_score":0.84781325},"labels":[],"label_agreement":null},{"id":"W2794427394","doi":"10.1200/jco.2018.36.6_suppl.140","title":"When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Watchful waiting; Proportional hazards model; Regimen; Prostate biopsy; Prostate-specific antigen; Prostate; Cancer; Gynecology; Internal medicine","score_opus":0.109090738893853,"score_gpt":0.43810631017629453,"score_spread":0.3290155712824415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794427394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693585,0.00022209203,0.00046271077,0.009880644,0.0006301596,0.0009203864,0.0004625974,0.000008610229,0.00047692427],"genre_scores_gemma":[0.99281347,0.004485927,0.0008789496,0.00029271175,0.0011823924,0.00011252228,0.00003538558,0.000022521761,0.00017613295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975965,0.00025181388,0.0013836261,0.00025668752,0.00029230866,0.00021904857],"domain_scores_gemma":[0.99354917,0.0013109588,0.0031004213,0.00019560545,0.0015977494,0.00024609207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012455769,0.00015163966,0.001103709,0.000078961246,0.00006481842,0.000006715921,0.00010445535,0.00020882809,0.00004116951],"category_scores_gemma":[0.0007702782,0.00009833665,0.0002180685,0.00009910494,0.00039252033,0.00012865663,0.000019905372,0.000379738,7.1213947e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02128543,0.0014192213,0.6386143,0.00007482745,0.0010421112,0.000028770412,0.00069167966,0.000007866022,0.00024983854,0.0000090517,0.0018860364,0.33469087],"study_design_scores_gemma":[0.011930271,0.030313743,0.9440679,0.00031752777,0.0006031452,0.00003993055,0.00025151647,0.00010491269,0.008457355,0.0000783246,0.0037553706,0.00007999961],"about_ca_topic_score_codex":0.0001752492,"about_ca_topic_score_gemma":0.0014959284,"teacher_disagreement_score":0.33461088,"about_ca_system_score_codex":0.0005620184,"about_ca_system_score_gemma":0.0020910709,"threshold_uncertainty_score":0.4010052},"labels":[],"label_agreement":null},{"id":"W2794466540","doi":"10.1200/jco.2013.31.15_suppl.539","title":"Extended adjuvant tamoxifen for early breast cancer: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Number needed to treat; Adjuvant therapy; Internal medicine; Absolute risk reduction; Oncology; Odds ratio; Discontinuation; Subgroup analysis; Cancer; Confidence interval; Surgery; Relative risk; Gynecology","score_opus":0.09022888115406734,"score_gpt":0.4399383848234166,"score_spread":0.3497095036693492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794466540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98401165,0.0074307476,0.0010503144,0.0059383907,0.0006570697,0.00037388923,0.00003607005,0.0000052173164,0.00049664074],"genre_scores_gemma":[0.99284256,0.00096778286,0.0028113453,0.0014283471,0.0009959195,0.000051653842,0.000009133005,0.000018889556,0.0008743602],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99740505,0.00039845047,0.0015006118,0.0002504649,0.00017733905,0.00026805428],"domain_scores_gemma":[0.997075,0.0003672423,0.0013668046,0.00023615487,0.000621168,0.00033363161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017025744,0.00016442484,0.0018041414,0.00008712214,0.0000452786,0.000018158004,0.0003004331,0.0006005807,0.00024628945],"category_scores_gemma":[0.0004621931,0.0001013817,0.0032538786,0.00013786006,0.00013254689,0.0000110673,0.00006174097,0.00042483912,0.000016686572],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006116102,0.003351411,0.022768758,0.000042784864,0.66453725,0.00014205556,0.00009784019,0.0006619817,0.059629165,0.00021503025,0.08157567,0.16086198],"study_design_scores_gemma":[0.012973482,0.029710455,0.4148854,0.000012620214,0.39750835,0.00060641463,0.00008433424,0.0006971551,0.009932728,0.002066905,0.13064784,0.0008742891],"about_ca_topic_score_codex":0.0000642852,"about_ca_topic_score_gemma":0.00002209709,"teacher_disagreement_score":0.39211667,"about_ca_system_score_codex":0.00002024085,"about_ca_system_score_gemma":0.0005400138,"threshold_uncertainty_score":0.46322283},"labels":[],"label_agreement":null},{"id":"W2794946998","doi":"10.1200/jco.2013.31.15_suppl.6502","title":"A population-based analysis of outcomes in cancer patients who do not satisfy clinical trial eligibility criteria (CTEC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Population; Cancer; Multivariate analysis; Clinical trial; Renal function; Surgery","score_opus":0.1765682778883138,"score_gpt":0.567136430421316,"score_spread":0.3905681525330022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794946998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358284,0.00013500864,0.0000054316934,0.0038868487,0.0015281917,0.0005889589,0.000029351404,0.0000042613106,0.00023910639],"genre_scores_gemma":[0.997126,0.00027055637,0.00060692575,0.0015400088,0.0003548014,0.000032796117,0.000010058956,0.000009078794,0.000049780814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931569,0.00073453726,0.0051561804,0.00027723052,0.000467774,0.0002073405],"domain_scores_gemma":[0.99133974,0.004721036,0.0025715553,0.0002377822,0.00088535727,0.00024452488],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002674788,0.00016760004,0.0040112836,0.00032549963,0.000028480497,0.000009749185,0.00012625425,0.00035335985,0.0007653959],"category_scores_gemma":[0.009112599,0.00010493164,0.0014004896,0.00041691583,0.00017106255,0.0000922757,0.000048102098,0.00055656617,0.0000032847167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035872314,0.0048427833,0.88647133,0.00001526772,0.0022528227,0.000014183606,0.000051542862,0.00002032669,0.0000014469856,0.00000468275,0.0005263278,0.06992696],"study_design_scores_gemma":[0.062378336,0.015407562,0.9189263,0.000050053044,0.0022704725,3.6842033e-7,0.000023373294,0.0002889393,0.0000019584188,0.00009294988,0.00048127468,0.0000784205],"about_ca_topic_score_codex":0.0030509825,"about_ca_topic_score_gemma":0.0035064379,"teacher_disagreement_score":0.069848545,"about_ca_system_score_codex":0.0003340553,"about_ca_system_score_gemma":0.0007607441,"threshold_uncertainty_score":0.9992341},"labels":[],"label_agreement":null},{"id":"W2795058050","doi":"10.1200/jco.2017.76.3656","title":"Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bendamustine; Obinutuzumab; Internal medicine; Rituximab; Gastroenterology; Neutropenia; Hazard ratio; Refractory (planetary science); Follicular lymphoma; Surgery; Lymphoma; Chemotherapy; Confidence interval","score_opus":0.05563711913773614,"score_gpt":0.380538862532708,"score_spread":0.3249017433949719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795058050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965008,0.00011432637,0.000007213148,0.00097010547,0.00095535815,0.0009593908,0.000005960482,0.0000058765677,0.00048098405],"genre_scores_gemma":[0.9972869,0.00035054362,0.00039349764,0.001050146,0.00081420114,0.000028283564,0.0000064225783,0.000023445193,0.00004653759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956365,0.00067496987,0.0022006165,0.00040918353,0.00067893486,0.000399788],"domain_scores_gemma":[0.996117,0.0012994787,0.0014351975,0.00033654852,0.00057071564,0.00024103909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030652648,0.00028806945,0.0018075088,0.0002542466,0.00007024407,0.00002353466,0.00022452317,0.000339281,0.000034898963],"category_scores_gemma":[0.0010173508,0.00016089903,0.00017147086,0.00028092047,0.00031159443,0.00021111187,0.0000869161,0.00070185616,0.000007906086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02262426,0.012063706,0.8622687,0.00001768522,0.000272268,0.00075392035,0.0019867085,0.000026040363,0.0000023409157,0.000025184925,0.0005317396,0.09942744],"study_design_scores_gemma":[0.10169205,0.048312385,0.84606224,0.00033394265,0.00021861584,0.00010370047,0.00086284074,0.00009834193,0.0000049541704,0.00009015392,0.0020838089,0.00013698745],"about_ca_topic_score_codex":0.001053214,"about_ca_topic_score_gemma":0.002864201,"teacher_disagreement_score":0.09929045,"about_ca_system_score_codex":0.0028587654,"about_ca_system_score_gemma":0.0021341532,"threshold_uncertainty_score":0.74755716},"labels":[],"label_agreement":null},{"id":"W2795389053","doi":"10.1200/jco.2018.36.4_suppl.614","title":"Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Oncology; Stage (stratigraphy); Colorectal cancer; Oxaliplatin; Confidence interval; Hazard ratio; Proportional hazards model; Adjuvant; Gastroenterology; Cancer","score_opus":0.048153343294930304,"score_gpt":0.3961819419516077,"score_spread":0.3480285986566774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795389053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968036,0.00011989371,0.000029094437,0.0004758384,0.00049822073,0.0019869457,0.00002918941,0.000006270795,0.000050950537],"genre_scores_gemma":[0.9983748,0.0003080242,0.00040005316,0.0005824174,0.0002191225,0.000034187677,0.00001850408,0.00001386412,0.00004897832],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955787,0.0003653866,0.0032105793,0.00019172914,0.00036203294,0.000291588],"domain_scores_gemma":[0.9957203,0.0008998945,0.0024607994,0.00018557871,0.00052168756,0.00021172852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002109156,0.00019578495,0.0016018206,0.00029111948,0.0000352938,0.000012575924,0.00014275225,0.0003222723,0.00007027917],"category_scores_gemma":[0.0020944905,0.0001226675,0.00014278248,0.0004312851,0.00030852458,0.00031244603,0.000039132014,0.0005760642,0.0000026228238],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6198536,0.002643051,0.28677756,0.00006468493,0.00015311198,0.00014474674,0.0008561248,0.000003042885,0.00018375053,0.0000013283184,0.00019461525,0.08912439],"study_design_scores_gemma":[0.328747,0.13581987,0.5315194,0.0005602523,0.00017304475,0.0000263074,0.00019856074,0.00012303358,0.00041284994,0.000004255157,0.0023054369,0.00010996757],"about_ca_topic_score_codex":0.0010787831,"about_ca_topic_score_gemma":0.0027938725,"teacher_disagreement_score":0.29110658,"about_ca_system_score_codex":0.00030264255,"about_ca_system_score_gemma":0.0017022827,"threshold_uncertainty_score":0.5002236},"labels":[],"label_agreement":null},{"id":"W2795424799","doi":"10.1200/jco.2017.35.15_suppl.3579","title":"Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; CD8; Stage (stratigraphy); Oncology; CD20; CD3; Immune system; Gastroenterology; Immunology; Immunohistochemistry","score_opus":0.05267206944974719,"score_gpt":0.3802259054741129,"score_spread":0.3275538360243657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795424799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962947,0.00064654293,0.000009669697,0.001084026,0.0004719025,0.00034889192,0.000027742495,0.00000404831,0.0011124895],"genre_scores_gemma":[0.9968072,0.0015997807,0.00041178736,0.000106655185,0.00011883488,0.0000031444338,0.000008789366,0.000021161986,0.0009226131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656624,0.00032070844,0.002143756,0.00019060305,0.00054397795,0.00023471097],"domain_scores_gemma":[0.99033934,0.0008754882,0.0073028766,0.00036614004,0.0009671725,0.00014900685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028464631,0.0001854563,0.0019386995,0.0000805437,0.000094332434,0.000012744919,0.00023205002,0.00035482374,0.000059783804],"category_scores_gemma":[0.0009606275,0.00011659105,0.00030906068,0.00009089514,0.0005414913,0.00017746117,0.000049852468,0.0005447338,5.0013546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11317733,0.0020948348,0.8521904,0.0000801746,0.0015635752,0.00008757405,0.00012179106,9.603107e-7,0.0016498201,0.0000047182193,0.0002674828,0.028761355],"study_design_scores_gemma":[0.06719643,0.038280085,0.8892894,0.000391371,0.0006739499,0.00002271714,0.00021354151,0.000017426097,0.0010010193,0.000004395953,0.0028011003,0.00010860552],"about_ca_topic_score_codex":0.00063911895,"about_ca_topic_score_gemma":0.0005181426,"teacher_disagreement_score":0.045980904,"about_ca_system_score_codex":0.00026821232,"about_ca_system_score_gemma":0.00090331025,"threshold_uncertainty_score":0.47544453},"labels":[],"label_agreement":null},{"id":"W2795445414","doi":"10.1200/jco.2018.36.4_suppl.723","title":"KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Cancer; Oncology; Adenocarcinoma; Microsatellite instability; Gastroenterology; Immunotherapy","score_opus":0.03521878479211881,"score_gpt":0.3942529768204152,"score_spread":0.3590341920282964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795445414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611163,0.00014223694,0.00041177848,0.000993804,0.0006100802,0.00085082743,0.0000038393064,0.000020000749,0.0008557998],"genre_scores_gemma":[0.9949247,0.0007111751,0.0014854374,0.0011423643,0.0007889849,0.000036009224,0.0000144400765,0.00003738971,0.0008594469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947942,0.00048056958,0.0029547145,0.000491597,0.0006678041,0.00061115075],"domain_scores_gemma":[0.996265,0.00038748712,0.0020989787,0.0003328566,0.0005284029,0.0003872825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017825866,0.0003376445,0.0027075286,0.0011917506,0.000047515176,0.000019304349,0.00025677172,0.00028283146,0.0006784318],"category_scores_gemma":[0.0005994072,0.00022040914,0.00047899946,0.0021512087,0.00023582726,0.00027733052,0.000045509816,0.0009790037,0.000011252526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067258134,0.0015727228,0.8360516,0.000025305322,0.0009820926,0.0004986456,0.00012072237,0.00026494497,0.000005483974,0.0000024692881,0.00046684124,0.092751026],"study_design_scores_gemma":[0.04730753,0.028671319,0.92021626,0.00016372318,0.0015039213,0.00004105895,0.00008646506,0.000375941,0.000007711368,0.000009515398,0.0014670813,0.00014949971],"about_ca_topic_score_codex":0.00046146923,"about_ca_topic_score_gemma":0.0068346653,"teacher_disagreement_score":0.09260153,"about_ca_system_score_codex":0.0011890292,"about_ca_system_score_gemma":0.0011252088,"threshold_uncertainty_score":0.8988024},"labels":[],"label_agreement":null},{"id":"W2795493686","doi":"10.1200/jco.2018.36.4_suppl.619","title":"Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Hazard ratio; Oncology; Progression-free survival; Microsatellite instability; Propensity score matching; Univariate analysis; Population; Proportional hazards model; Targeted therapy; Cancer; Confidence interval; Multivariate analysis; Overall survival; Microsatellite","score_opus":0.10574584379024932,"score_gpt":0.5403080452122118,"score_spread":0.43456220142196245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795493686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037176,0.00096532726,0.000001884155,0.0059566395,0.00079246424,0.0005164778,0.000004431515,0.00000265708,0.0013883564],"genre_scores_gemma":[0.99776334,0.00087433314,0.0001817485,0.00061255676,0.0005109238,0.000036248566,8.038061e-7,0.0000086756545,0.000011365867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966148,0.0013562132,0.0013133729,0.00013692488,0.00039497827,0.00018371936],"domain_scores_gemma":[0.99345857,0.00526705,0.00090204354,0.00012849223,0.00017242524,0.00007143066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060192556,0.00013122035,0.0014034784,0.000111869274,0.000027449267,0.000003656692,0.00016750017,0.00011554254,0.00008451589],"category_scores_gemma":[0.0025514783,0.00005868162,0.0002532307,0.00021692723,0.0002900036,0.00003526171,0.00003190935,0.00056435796,0.0000017667919],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075191006,0.004363603,0.21464771,0.00003347939,0.00037218464,0.00050614984,0.0013213465,0.0000023012162,0.00037933997,0.000011637881,0.0006714456,0.7024998],"study_design_scores_gemma":[0.061161254,0.3115504,0.6199116,0.00035538743,0.00027848693,0.00006226031,0.00041815417,0.00010472711,0.0027312997,0.00018335493,0.003159107,0.000083940206],"about_ca_topic_score_codex":0.000086312924,"about_ca_topic_score_gemma":0.00094781007,"teacher_disagreement_score":0.7024159,"about_ca_system_score_codex":0.00014424871,"about_ca_system_score_gemma":0.00046746765,"threshold_uncertainty_score":0.30545422},"labels":[],"label_agreement":null},{"id":"W2795538731","doi":"10.1200/jco.2018.36.4_suppl.494","title":"The impact of lung and bone metastases on prognosis in advanced PDAC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Cohort; Adenocarcinoma; Oncology; Lung; Retrospective cohort study; Stage (stratigraphy); Disease; Gastroenterology; Surgery; Cancer","score_opus":0.10918289431401784,"score_gpt":0.5415777872694904,"score_spread":0.4323948929554725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795538731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121207,0.0021260455,0.0000019848542,0.005450423,0.00025101556,0.00017673943,0.0000036150318,0.0000014610617,0.0007766505],"genre_scores_gemma":[0.9949484,0.0038543886,0.0005171029,0.0002747577,0.00036717992,0.000006504047,3.8903008e-7,0.0000057701195,0.000025509018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982742,0.00017962683,0.0011654564,0.0000943154,0.00015694136,0.00012947722],"domain_scores_gemma":[0.99585927,0.0028137888,0.00086450705,0.00009945707,0.00021355944,0.00014943267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016079508,0.00007661876,0.0008711688,0.00006737323,0.000024870658,0.0000040192913,0.000047738406,0.00008724662,0.00005164765],"category_scores_gemma":[0.001923422,0.00003565879,0.0003069721,0.00009170441,0.0002530881,0.000038211692,0.000021386752,0.00027729242,0.0000018415111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007436576,0.002632047,0.6403743,0.000009796391,0.00051177543,0.000207963,0.000058876252,0.0000058776277,0.00006011289,0.00007697831,0.0046495036,0.34397617],"study_design_scores_gemma":[0.00733327,0.04781145,0.9363946,0.00016743402,0.00024614777,0.0001226169,0.00004398526,0.000035365912,0.00041102179,0.00016165656,0.0072399927,0.000032475655],"about_ca_topic_score_codex":0.00005336408,"about_ca_topic_score_gemma":0.00014592154,"teacher_disagreement_score":0.3439437,"about_ca_system_score_codex":0.00013798801,"about_ca_system_score_gemma":0.00053187646,"threshold_uncertainty_score":0.23026547},"labels":[],"label_agreement":null},{"id":"W2795551138","doi":"10.1200/jco.2018.36.4_suppl.476","title":"A real world multicenter study of first (1L) and second (2L) line treatment patterns and outcomes in advanced pancreatic cancer (APC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Dalhousie University; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; McMaster University; Nova Scotia Cancer Centre; University of Manitoba; Ottawa Hospital; Juravinski Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Pancreatic cancer; Performance status; Cancer; Oncology; Irinotecan","score_opus":0.1376889025046027,"score_gpt":0.5273407289432996,"score_spread":0.38965182643869695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795551138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594975,0.0002290624,0.0000055069872,0.0021194755,0.00025719416,0.0006306371,0.0000091124375,0.0000035892044,0.000795663],"genre_scores_gemma":[0.99350774,0.003513924,0.00094864605,0.00028828235,0.0003748227,0.000027439468,7.851849e-7,0.000013438427,0.001324894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968275,0.00041349375,0.002012743,0.00023811826,0.00024415646,0.00026402468],"domain_scores_gemma":[0.99473405,0.0035107243,0.000923185,0.00019125747,0.00030615248,0.0003346032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015434197,0.00016711853,0.00249656,0.0002482232,0.000041028532,0.0000050183166,0.000086848806,0.00018837802,0.00037448597],"category_scores_gemma":[0.0011288289,0.00010305894,0.0001246424,0.00011490083,0.00036546923,0.00007481298,0.00007243692,0.0004743067,0.0000020268749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006078932,0.0054193367,0.9548235,0.0000672518,0.00075301493,0.000359829,0.001424874,6.727346e-7,0.000028483599,0.0000033422077,0.00006170717,0.030979069],"study_design_scores_gemma":[0.029875694,0.05220153,0.91408354,0.00020463316,0.00065968215,0.000032876425,0.001107654,0.00032319405,0.000020209342,0.000025101312,0.00139537,0.00007053282],"about_ca_topic_score_codex":0.0016701258,"about_ca_topic_score_gemma":0.07771533,"teacher_disagreement_score":0.0760452,"about_ca_system_score_codex":0.0002149625,"about_ca_system_score_gemma":0.00052512554,"threshold_uncertainty_score":0.939114},"labels":[],"label_agreement":null},{"id":"W2795631559","doi":"10.1200/jco.2013.31.15_suppl.10551","title":"Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Regorafenib; GiST; Sunitinib; Internal medicine; Oncology; Imatinib; Placebo; CD117; Gastroenterology; Stromal cell; Cancer; Colorectal cancer; Pathology; CD34","score_opus":0.2130394538691137,"score_gpt":0.515789648152525,"score_spread":0.3027501942834113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795631559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461246,0.000025423362,0.00039689365,0.0030890766,0.00025776893,0.0011472123,0.00021455855,0.000010832894,0.00024578752],"genre_scores_gemma":[0.9601686,0.000010911909,0.038922023,0.00020484037,0.00036054154,0.00004361474,0.00019129703,0.000022466675,0.000075720665],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99048525,0.0015101675,0.0056810686,0.00047229626,0.0013088863,0.0005423064],"domain_scores_gemma":[0.98198104,0.011340318,0.00444511,0.0004641282,0.0009458111,0.00082361733],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0053665363,0.0003518973,0.003952712,0.00082398846,0.000040743547,0.000026027883,0.0002579059,0.00009733081,0.0005303905],"category_scores_gemma":[0.030167157,0.00022998589,0.0013735837,0.0005737417,0.0002513439,0.00012210563,0.000058827023,0.0011729938,0.000020154515],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52784187,0.037238058,0.38789633,0.0000395325,0.0038691498,0.008521171,0.0000842723,0.0004879437,0.0010888156,0.000013861295,0.00041032166,0.032508705],"study_design_scores_gemma":[0.23910657,0.12152718,0.6098544,0.00037620252,0.0037852305,0.00013133869,0.00011822523,0.024885101,0.000057308924,0.0000448814,0.00001498116,0.00009859726],"about_ca_topic_score_codex":0.0008621462,"about_ca_topic_score_gemma":0.00014037325,"teacher_disagreement_score":0.28873527,"about_ca_system_score_codex":0.0004996246,"about_ca_system_score_gemma":0.0020084681,"threshold_uncertainty_score":0.97800213},"labels":[],"label_agreement":null},{"id":"W2795652858","doi":"10.1200/jco.2018.36.4_suppl.409","title":"A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; London Health Sciences Centre; McMaster University; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Trametinib; KRAS; FOLFIRINOX; MEK inhibitor; Progressive disease; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Oncology; Phases of clinical research; Clinical trial; Chemotherapy; Kinase; MAPK/ERK pathway; Gastroenterology; Cancer; Irinotecan","score_opus":0.10791350907821008,"score_gpt":0.48608679272787503,"score_spread":0.37817328364966496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795652858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423385,0.00029840285,0.000028143733,0.0014260779,0.00071294303,0.0018712247,0.0000082530305,0.0000069104394,0.0014141795],"genre_scores_gemma":[0.99275464,0.00030363604,0.0053073973,0.00032079642,0.0011182328,0.000028359837,0.0000046548403,0.000022323204,0.00013994414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935901,0.0011620175,0.0037449093,0.00037234722,0.0006932683,0.00043733453],"domain_scores_gemma":[0.991715,0.0043253447,0.0020825723,0.0003826686,0.0009345255,0.0005598677],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00617344,0.00023173382,0.003573321,0.00031858508,0.00007426996,0.000006338061,0.0002174425,0.00054534146,0.0002923547],"category_scores_gemma":[0.013005794,0.00014984074,0.0003237515,0.0003324802,0.0015618529,0.00015670403,0.00010018612,0.0012019145,0.0000064526907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65990406,0.02567064,0.2869221,0.000046510075,0.0003850369,0.00016121524,0.00027988869,1.6006456e-7,0.000034712506,0.000021808075,0.00022336747,0.026350487],"study_design_scores_gemma":[0.44376376,0.31306323,0.2412799,0.00011573501,0.0005406343,0.000052799744,0.00013022649,0.00003427181,0.00001220156,0.00012911356,0.0008054533,0.00007267978],"about_ca_topic_score_codex":0.000029466475,"about_ca_topic_score_gemma":0.000046133715,"teacher_disagreement_score":0.2873926,"about_ca_system_score_codex":0.0001528219,"about_ca_system_score_gemma":0.0029395754,"threshold_uncertainty_score":0.9953081},"labels":[],"label_agreement":null},{"id":"W2795896143","doi":"10.1200/jco.2018.36.4_suppl.585","title":"Baseline characteristics as predictors of adjuvant chemotherapy (AC) discontinuations and modifications in stage III colorectal cancer (CRC) patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Capecitabine; Combination therapy; Cohort; Anemia; Regimen; Population; Univariate analysis; Colorectal cancer; Adjuvant therapy; Oncology; Cancer; Multivariate analysis; Oxaliplatin","score_opus":0.06575716322426566,"score_gpt":0.43822340233880863,"score_spread":0.37246623911454296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795896143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940502,0.00031652834,0.000039796894,0.003012474,0.0007293285,0.000288193,0.00006952259,0.0000041131257,0.0014898117],"genre_scores_gemma":[0.9948675,0.0033998268,0.00032828422,0.0004504359,0.0006102909,0.000016463586,0.000008976459,0.000010271746,0.00030794812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776393,0.0001298578,0.0016111347,0.000147645,0.00020738524,0.00014003366],"domain_scores_gemma":[0.99712217,0.00069905084,0.00117552,0.00009066728,0.0007549374,0.00015766779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077481364,0.00011078096,0.0010591411,0.00010950507,0.000043409433,0.000004252883,0.00006579999,0.00014022939,0.00019118843],"category_scores_gemma":[0.0016444913,0.00007542851,0.00014446018,0.00013660987,0.00042193587,0.00008541719,0.000032503267,0.000293813,0.0000014601275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044995,0.002248985,0.8917249,0.000014917778,0.00036567892,0.000017303177,0.00095945055,9.635557e-7,0.00015914328,0.000060085327,0.00068425905,0.09926483],"study_design_scores_gemma":[0.008355049,0.011007524,0.9670919,0.0000906303,0.00023278156,0.0000064095516,0.00020761964,0.00016138302,0.00013900743,0.000030243147,0.012618195,0.00005925601],"about_ca_topic_score_codex":0.00016122576,"about_ca_topic_score_gemma":0.0007468645,"teacher_disagreement_score":0.099205576,"about_ca_system_score_codex":0.00014758231,"about_ca_system_score_gemma":0.00077464565,"threshold_uncertainty_score":0.30758852},"labels":[],"label_agreement":null},{"id":"W2796046569","doi":"10.1200/jco.2017.35.15_suppl.tps4143","title":"Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Placebo; Internal medicine; Adverse effect; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical trial; Surgery; Cancer; Phases of clinical research; Immunotherapy; Pathology; Alternative medicine","score_opus":0.2064633325214666,"score_gpt":0.4643588554910116,"score_spread":0.257895522969545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796046569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901367,0.001551257,0.00026259615,0.001413605,0.0014531761,0.0037762837,0.00006626866,0.000014123452,0.0013260246],"genre_scores_gemma":[0.9950224,0.0002491938,0.0023212356,0.0002739554,0.0011623232,0.00013872712,0.000045148805,0.00006388713,0.0007231022],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923514,0.0010458026,0.0049549676,0.00051431457,0.0006222664,0.000511265],"domain_scores_gemma":[0.98607486,0.0036960621,0.0065479777,0.0008796069,0.0020939084,0.0007075588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004330233,0.0004432295,0.0062701567,0.00026202,0.00025949476,0.000032162658,0.0005595939,0.00061384717,0.0003069598],"category_scores_gemma":[0.007269837,0.00031654155,0.0023526007,0.00009264467,0.000579299,0.00027684908,0.00014313542,0.0009651883,0.0000132477035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54434204,0.017815452,0.38183063,0.0003163765,0.0018738277,0.003074272,0.001424244,0.0000017690342,0.0005467915,0.00002612295,0.00045102296,0.048297465],"study_design_scores_gemma":[0.8214816,0.1426866,0.012235899,0.00019228473,0.0061149057,0.00023224008,0.0020630753,0.001371911,0.0048021437,0.00015399611,0.008362631,0.0003027386],"about_ca_topic_score_codex":0.00007499455,"about_ca_topic_score_gemma":0.000108644716,"teacher_disagreement_score":0.36959472,"about_ca_system_score_codex":0.00020746252,"about_ca_system_score_gemma":0.0020010432,"threshold_uncertainty_score":0.99992865},"labels":[],"label_agreement":null},{"id":"W2796394809","doi":"10.1200/jco.2012.30.15_suppl.e18562","title":"Number needed to treat (NNT) as a measure of drug benefit: Lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (MM).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Number needed to treat; Lenalidomide; Multiple myeloma; Bortezomib; Refractory (planetary science); Thalidomide; Internal medicine; Confidence interval; Oncology; Surgery; Relative risk","score_opus":0.17794682662387246,"score_gpt":0.48414149840327464,"score_spread":0.3061946717794022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796394809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991038,0.00094227085,0.00005352477,0.0024854443,0.0011509698,0.0010222726,0.00005992106,0.000010226632,0.0032373313],"genre_scores_gemma":[0.9898697,0.0006028752,0.0065642954,0.00027422758,0.0012961752,0.000049754784,0.00001719959,0.000044396973,0.0012813429],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99527246,0.00038706308,0.0027373275,0.00026012483,0.0007304328,0.0006126217],"domain_scores_gemma":[0.9875498,0.00777501,0.0017768022,0.00042137248,0.0010947462,0.0013822771],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021035715,0.00030013628,0.0026722522,0.00023207573,0.00005680039,0.0000056231,0.00020197894,0.00043436544,0.00028416468],"category_scores_gemma":[0.008658401,0.00019931237,0.0013275195,0.00019562984,0.00020227728,0.000186974,0.000049741226,0.0003270841,0.00006216017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27688405,0.022286212,0.31522557,0.00017135075,0.004027063,0.00035701474,0.0013824176,0.000020416253,0.0052992087,0.00014905121,0.0079713,0.36622632],"study_design_scores_gemma":[0.29288283,0.12797491,0.38100994,0.00049115845,0.0041836123,0.000525945,0.0020443422,0.0001045639,0.04179914,0.00020083807,0.14831628,0.00046645102],"about_ca_topic_score_codex":0.00042247534,"about_ca_topic_score_gemma":0.000180449,"teacher_disagreement_score":0.36575988,"about_ca_system_score_codex":0.00062213687,"about_ca_system_score_gemma":0.0014429503,"threshold_uncertainty_score":0.9996921},"labels":[],"label_agreement":null},{"id":"W2796727977","doi":"10.1200/jco.2017.35.7_suppl.86","title":"Perspectives from the community setting: A retrospective chart review of nivolumab for previously treated non-small cell lung cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Nivolumab; Medicine; Discontinuation; Lung cancer; Retrospective cohort study; Cancer; Internal medicine; Stage (stratigraphy); Oncology; Surgery; Immunotherapy","score_opus":0.10272184075221755,"score_gpt":0.469878250525866,"score_spread":0.3671564097736485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796727977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9007905,0.06545951,0.000055653323,0.029202739,0.00080609974,0.0011393058,0.00006358863,0.000006459377,0.0024761003],"genre_scores_gemma":[0.87479323,0.11892262,0.0011062595,0.0033575592,0.0013517342,0.000029249715,0.000005220144,0.000021990965,0.00041211845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969518,0.0006920272,0.0017826925,0.0001570346,0.00021740583,0.00019903283],"domain_scores_gemma":[0.99091697,0.0026626894,0.004602374,0.00064701197,0.0010383489,0.00013262128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060728327,0.0001515859,0.0017135969,0.000029630919,0.00029758178,0.000014615796,0.0005756927,0.00024207169,0.00016332847],"category_scores_gemma":[0.005053353,0.000089126166,0.0010114335,0.00005963468,0.0004985625,0.00008102439,0.00007491691,0.0011879663,8.1083334e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03879324,0.0044530737,0.6887076,0.0030695866,0.0048242114,0.00007606432,0.0070514,5.10573e-7,0.0035860646,0.00002599356,0.11929985,0.13011242],"study_design_scores_gemma":[0.017200686,0.012058134,0.9277676,0.009189447,0.0021085464,0.000040230232,0.0015332318,0.000048178248,0.0006135984,0.00010593525,0.029197706,0.00013673183],"about_ca_topic_score_codex":0.0016108437,"about_ca_topic_score_gemma":0.0005636159,"teacher_disagreement_score":0.23905998,"about_ca_system_score_codex":0.0003690658,"about_ca_system_score_gemma":0.0016385402,"threshold_uncertainty_score":0.60497004},"labels":[],"label_agreement":null},{"id":"W2797665114","doi":"10.1200/jco.2017.35.7_suppl.112","title":"Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; CD47; Phagocytosis; Whole blood; Immunology; Pharmacodynamics; Immune system; Proinflammatory cytokine; Pharmacology; Internal medicine; Inflammation; Pharmacokinetics","score_opus":0.06798572663813271,"score_gpt":0.39814146338346135,"score_spread":0.3301557367453286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797665114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570227,0.0010675691,0.000008400029,0.0006670531,0.0018154657,0.0005448665,0.000013286354,0.000012451206,0.00016866956],"genre_scores_gemma":[0.99817634,0.0012500947,0.00007917121,0.00020930312,0.00012465553,0.000017481256,0.000011978499,0.00002901043,0.000101975114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937452,0.0018748656,0.003274835,0.00048751393,0.00016089536,0.00045669018],"domain_scores_gemma":[0.9828297,0.011168703,0.0052711135,0.0004005364,0.00023187016,0.000098066135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004664556,0.0003413072,0.0030112658,0.0002834068,0.00021219383,0.000025104539,0.0005645684,0.0011894954,0.00004544489],"category_scores_gemma":[0.0075939232,0.00022710487,0.00035502246,0.00013979162,0.0010215867,0.00034885854,0.00013001909,0.0017891007,0.000005594608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15072393,0.010354694,0.79284066,0.00011545822,0.0018354671,0.0009791926,0.00040184715,0.000029016877,0.03371294,0.0001401445,0.0005250866,0.008341563],"study_design_scores_gemma":[0.14109637,0.026094621,0.8229781,0.0012365067,0.00037479505,0.00004805549,0.00006761641,0.000018705823,0.0069529517,0.00015864144,0.0007367341,0.00023692579],"about_ca_topic_score_codex":0.0001495972,"about_ca_topic_score_gemma":0.0009804445,"teacher_disagreement_score":0.030137427,"about_ca_system_score_codex":0.00019529797,"about_ca_system_score_gemma":0.0005185539,"threshold_uncertainty_score":0.92610675},"labels":[],"label_agreement":null},{"id":"W2798054859","doi":"10.1200/jco.2018.36.4_suppl.560","title":"A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Colorectal cancer; Rash; Clinical endpoint; Atezolizumab; Gastroenterology; Microsatellite instability; Phases of clinical research; Adverse effect; Refractory (planetary science); Oncology; Cancer; Surgery; Chemotherapy; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.10273529988525194,"score_gpt":0.5005962849997099,"score_spread":0.39786098511445794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798054859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980418,0.0002660239,0.0000059463714,0.00036676342,0.00031602025,0.000600582,0.000020084924,0.0000023370428,0.00038040412],"genre_scores_gemma":[0.998318,0.0010601102,0.00035265036,0.00008956939,0.00014530882,0.000006552554,6.112098e-7,0.0000107746155,0.000016394166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964845,0.00060914597,0.0021635026,0.00024124881,0.00032747153,0.00017414243],"domain_scores_gemma":[0.9950035,0.0020841598,0.0019496183,0.00010716239,0.00064140715,0.00021410614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019283921,0.0001589456,0.0024571347,0.000119214055,0.00003764356,0.0000028588813,0.00006671659,0.00013091773,0.000043422788],"category_scores_gemma":[0.001434627,0.000095947995,0.00014645953,0.0001813685,0.00084364205,0.00007890787,0.00008705561,0.0004773836,3.0433276e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10362461,0.021241853,0.6562277,0.00003077397,0.0013118712,0.00007954937,0.0005726015,4.3138638e-7,0.000018375878,0.0000025325858,0.000038931634,0.21685076],"study_design_scores_gemma":[0.072113335,0.22839113,0.6974505,0.00009607887,0.0009799036,0.000022463284,0.00036301283,0.000034415843,0.00004418378,0.000009147821,0.00043863372,0.000057172238],"about_ca_topic_score_codex":0.00035021428,"about_ca_topic_score_gemma":0.0037653146,"teacher_disagreement_score":0.21679358,"about_ca_system_score_codex":0.000116810086,"about_ca_system_score_gemma":0.0007262131,"threshold_uncertainty_score":0.39126456},"labels":[],"label_agreement":null},{"id":"W2799307461","doi":"10.1200/jco.2018.36.4_suppl.562","title":"Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Western University; University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Ottawa Hospital; Queen's University; Toronto General Hospital; McMaster University; Grand River Hospital; Hotel Dieu Hospital; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Colorectal cancer; Hazard ratio; Randomized controlled trial; Stage (stratigraphy); Proportional hazards model; Internal medicine; Log-rank test; Cancer; Surgery; Confidence interval","score_opus":0.02291461175545683,"score_gpt":0.4076205361921019,"score_spread":0.3847059244366451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799307461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556565,0.00051519315,0.00006084164,0.0015236643,0.00057803764,0.001502148,0.000012377311,0.000002025748,0.00024003017],"genre_scores_gemma":[0.9982952,0.00089357427,0.00015157154,0.00033373173,0.00025759923,0.000019968833,0.0000027465992,0.0000094791385,0.00003613718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947358,0.0025718273,0.0018203184,0.00018608388,0.00051298755,0.00017302604],"domain_scores_gemma":[0.9903067,0.006960538,0.0020076123,0.00013732881,0.00036117618,0.00022668716],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012172017,0.00012781467,0.0018912716,0.00013811719,0.000031119867,0.0000065620197,0.00016014825,0.00003431554,0.000031572803],"category_scores_gemma":[0.015106618,0.000059916634,0.0002851075,0.00012988521,0.0005860407,0.000052513664,0.000045136,0.0006540851,7.0970356e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.920232,0.0011299509,0.030280108,0.0001311431,0.0008160526,0.0006125229,0.000031352793,0.000032883352,0.0000048178367,0.000022123411,0.00020005682,0.046506967],"study_design_scores_gemma":[0.7734637,0.033803523,0.18843001,0.00081134815,0.0018639616,0.000020651638,0.000003953549,0.0013578108,0.000044371838,0.000010996556,0.00013550476,0.000054149572],"about_ca_topic_score_codex":0.00003094711,"about_ca_topic_score_gemma":0.000017351837,"teacher_disagreement_score":0.1581499,"about_ca_system_score_codex":0.00004758499,"about_ca_system_score_gemma":0.00035171976,"threshold_uncertainty_score":0.9931896},"labels":[],"label_agreement":null},{"id":"W2800094508","doi":"10.1200/jco.2017.35.15_suppl.6501","title":"Cognitive technology addressing optimal cancer clinical trial matching and protocol feasibility in a community cancer practice.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Text Mining and Ontologies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IBM (Canada)","funders":"","keywords":"Medicine; Protocol (science); Population; Clinical trial; Inclusion and exclusion criteria; Breast cancer; IBM; Randomized controlled trial; Cancer; Medical physics; Family medicine; Internal medicine; Alternative medicine; Pathology","score_opus":0.4296981489753393,"score_gpt":0.6408233170785116,"score_spread":0.21112516810317228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800094508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854888,0.0004599345,0.00019999202,0.0076238336,0.0010179019,0.0046060067,0.000010517781,0.0000072353682,0.0005857778],"genre_scores_gemma":[0.98686785,0.0009504531,0.0077121663,0.0010700389,0.0015627955,0.001771433,0.0000015219947,0.000016124652,0.000047610214],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9945366,0.0023483846,0.0022832125,0.00032336896,0.00020345807,0.0003050077],"domain_scores_gemma":[0.99314713,0.0022448385,0.0034905442,0.00040597725,0.00048159415,0.00022993764],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012067097,0.00017630408,0.0011903316,0.00007911891,0.00029868365,0.0000520172,0.0006111008,0.0013103666,0.000020327638],"category_scores_gemma":[0.05062096,0.00013191486,0.00025642404,0.00005739683,0.0020080083,0.00002842615,0.00057376386,0.0029921907,9.196051e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0824953,0.0024045045,0.15224475,0.00004022884,0.00027785441,0.00012701337,0.00010455176,0.0000036030078,0.00032072965,0.000013616852,0.00043495122,0.7615329],"study_design_scores_gemma":[0.21596332,0.047778618,0.5438924,0.0010991368,0.00044821823,0.00030363334,0.0032653436,0.00006603161,0.00057176675,0.001916547,0.18411277,0.00058225327],"about_ca_topic_score_codex":0.0003554796,"about_ca_topic_score_gemma":0.0012032486,"teacher_disagreement_score":0.7609506,"about_ca_system_score_codex":0.00005416384,"about_ca_system_score_gemma":0.0020318837,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W2800600983","doi":"10.1200/jco.2018.36.4_suppl.435","title":"Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Pancreatic cancer; Internal medicine; Performance status; Oncology; Cancer; Irinotecan","score_opus":0.146758172869003,"score_gpt":0.5235647027754803,"score_spread":0.3768065299064773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800600983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995173,0.00034947714,0.00020340824,0.0023073659,0.0007844022,0.0004259443,0.000022374716,0.0000039483666,0.00073011674],"genre_scores_gemma":[0.98573685,0.0035403974,0.007736092,0.0014719717,0.0008305725,0.000014206911,0.000004091589,0.000015342228,0.00065050344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711317,0.00022270481,0.0020547821,0.00014901784,0.00023431564,0.00022599494],"domain_scores_gemma":[0.99188215,0.00457448,0.0017633762,0.00014864745,0.001367196,0.0002641658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024190035,0.00011796352,0.0022159899,0.0000977127,0.000047871104,0.0000033846386,0.00011389695,0.00027799804,0.00030197404],"category_scores_gemma":[0.007606847,0.00007547007,0.00023743956,0.00007440247,0.0004866379,0.00006906222,0.000034938497,0.00040167262,0.000002118091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007917748,0.00074800197,0.73897713,0.000060887036,0.0004104377,0.000008192775,0.00009929289,3.0580264e-8,0.0001881661,0.000018768264,0.00049025513,0.2510811],"study_design_scores_gemma":[0.014945063,0.032171905,0.93831676,0.0001216513,0.00030665178,0.000014072755,0.000044516557,0.000080112666,0.0001256849,0.00024650467,0.013565943,0.000061159175],"about_ca_topic_score_codex":0.000006692647,"about_ca_topic_score_gemma":0.00002675164,"teacher_disagreement_score":0.25101992,"about_ca_system_score_codex":0.000071253155,"about_ca_system_score_gemma":0.0011639816,"threshold_uncertainty_score":0.9106656},"labels":[],"label_agreement":null},{"id":"W2800681950","doi":"10.1200/jco.2013.31.15_suppl.tps8618","title":"A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Idelalisib; Bendamustine; Rituximab; Internal medicine; Follicular lymphoma; Lymphoma; Oncology; Ofatumumab; Clinical endpoint; Ibrutinib; Gastroenterology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","score_opus":0.09848421511876561,"score_gpt":0.4642473764283994,"score_spread":0.3657631613096338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800681950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831867,0.0007891549,0.000097364915,0.0028102435,0.00013229751,0.012789273,0.0000027442238,0.000005806131,0.00018641294],"genre_scores_gemma":[0.99715865,0.0005271404,0.0010911529,0.00025238242,0.00016119891,0.00074260816,0.000007287311,0.000019049272,0.00004055762],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405086,0.0011841132,0.0037617662,0.00029477393,0.00045019953,0.00025830907],"domain_scores_gemma":[0.98096037,0.014869205,0.0029288942,0.00020826017,0.0007910851,0.00024217478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011273601,0.0002597433,0.004000533,0.00020292922,0.00008700563,0.000029038407,0.00010960619,0.00022061501,0.000029910272],"category_scores_gemma":[0.0035503444,0.00012537221,0.00034024118,0.00016841809,0.00030623208,0.00013847784,0.000052814343,0.00032173426,8.634773e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85496193,0.031398535,0.022333523,0.00003982762,0.0017717287,0.000072519455,0.0009969707,0.000029702633,0.000025551679,0.00005088922,0.00005955643,0.08825929],"study_design_scores_gemma":[0.87598515,0.077632494,0.037480813,0.0003267332,0.003699084,0.0001689681,0.0005239458,0.0039450736,0.000036688165,0.00006833842,0.00003343101,0.00009930997],"about_ca_topic_score_codex":0.00029643925,"about_ca_topic_score_gemma":0.00014102973,"teacher_disagreement_score":0.08815998,"about_ca_system_score_codex":0.00019357592,"about_ca_system_score_gemma":0.0008220126,"threshold_uncertainty_score":0.51125306},"labels":[],"label_agreement":null},{"id":"W2800864769","doi":"10.1200/jco.2018.36.4_suppl.577","title":"Differential utilization of preventive care among colon cancer survivors compared to non-cancer patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Context (archaeology); Internal medicine; Disease; Cohort; Cancer screening; Preventive healthcare; Hazard ratio; Multivariate analysis; Confidence interval; Public health; Pathology","score_opus":0.10574947015863072,"score_gpt":0.4712014191552697,"score_spread":0.36545194899663896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800864769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931035,0.00012806298,0.0010475144,0.0002735113,0.0040416927,0.00034393228,0.000014226363,0.000007972655,0.0010396029],"genre_scores_gemma":[0.9976406,0.0001363177,0.0002636075,0.00023794758,0.0015565086,0.0000152095845,0.0000047298145,0.000013797081,0.00013127443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762166,0.00023559727,0.0014234617,0.00018156062,0.0003707375,0.00016697655],"domain_scores_gemma":[0.99579734,0.00033313833,0.0014475367,0.00011133099,0.0020497718,0.00026085725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044143255,0.00011493981,0.0010313779,0.00014658799,0.000047456935,0.0000050564818,0.00011088267,0.00025634508,0.0003608193],"category_scores_gemma":[0.00081425376,0.00008884545,0.00029928665,0.00026001254,0.0002111732,0.00007535541,0.000054389737,0.0003875834,0.0000037473078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02712457,0.0007552231,0.7933114,0.000058870166,0.0002719479,0.000005968538,0.0012080084,0.00004944788,0.00035724966,0.0000016198145,0.0015288574,0.17532684],"study_design_scores_gemma":[0.004666355,0.032417364,0.95222795,0.0003064793,0.00036711904,0.0000024427857,0.00025138343,0.00039060568,0.0040733116,0.000009488158,0.005205981,0.000081499515],"about_ca_topic_score_codex":0.0012406535,"about_ca_topic_score_gemma":0.008565891,"teacher_disagreement_score":0.17524533,"about_ca_system_score_codex":0.0002703032,"about_ca_system_score_gemma":0.0007281495,"threshold_uncertainty_score":0.47799677},"labels":[],"label_agreement":null},{"id":"W2802054964","doi":"10.1200/jco.2018.36.4_suppl.685","title":"Platinum deposition in skin as a possible mechanism for peripheral sensory neuropathy (PSN) in patients (pts) with colorectal cancer (CRC) following oxaliplatin-based therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Oxaliplatin; Medicine; FOLFOX; Internal medicine; Colorectal cancer; Gastroenterology; Peripheral neuropathy; Cancer; Cetuximab; Oncology; Urology; Endocrinology","score_opus":0.06722822838202357,"score_gpt":0.440695205084386,"score_spread":0.3734669767023624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802054964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955241,0.00008376284,0.000073370575,0.0015298068,0.0015462448,0.0007466815,0.000007889072,0.000009103557,0.00047904614],"genre_scores_gemma":[0.99222624,0.000068800895,0.0021999083,0.004391382,0.00093547074,0.00005871343,0.000008351206,0.000031039126,0.00008010698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740314,0.00041288536,0.0013375542,0.0002532784,0.00027130422,0.0003218321],"domain_scores_gemma":[0.9975335,0.0009931484,0.0008513014,0.000081869875,0.00034959623,0.00019060333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000874442,0.00018610792,0.0010646686,0.0002032808,0.000054474054,0.000009322057,0.00009173981,0.0003026375,0.00016071317],"category_scores_gemma":[0.00032183464,0.00013464296,0.00031915845,0.00020041387,0.00009913259,0.00010658774,0.000014401913,0.0005849799,0.0000031993122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10337307,0.0066603334,0.8216235,0.000026419742,0.00040806574,0.0009091425,0.000792053,0.00009528701,0.006803549,0.000038655253,0.00030749245,0.05896244],"study_design_scores_gemma":[0.11722874,0.15976481,0.7095952,0.00026645605,0.0004047982,0.000097895754,0.00012431081,0.0032432638,0.007830713,0.0002841335,0.00090678583,0.00025287885],"about_ca_topic_score_codex":0.00026883747,"about_ca_topic_score_gemma":0.0022378033,"teacher_disagreement_score":0.15310447,"about_ca_system_score_codex":0.00046621414,"about_ca_system_score_gemma":0.0015885568,"threshold_uncertainty_score":0.5490581},"labels":[],"label_agreement":null},{"id":"W2802172791","doi":"10.1200/jco.2017.77.2293","title":"Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Quality of life (healthcare); Internal medicine; Odds ratio; Hazard ratio; Cancer; Clinical trial; Performance status; Confidence interval; Chemotherapy; Oncology","score_opus":0.05406334905879762,"score_gpt":0.4881889375538155,"score_spread":0.43412558849501787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802172791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556524,0.0006382439,0.000013449304,0.001263839,0.00068434374,0.00076798326,0.00000420891,0.0000032034097,0.0010595056],"genre_scores_gemma":[0.9974751,0.001151276,0.00053631986,0.00023029567,0.00047183788,0.000027777869,0.0000016794312,0.000013632875,0.00009206794],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814814,0.00011404333,0.0012742304,0.00014728171,0.00014913313,0.00016716952],"domain_scores_gemma":[0.9970727,0.0007654733,0.0015437532,0.00016297931,0.0002881421,0.0001669538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038202864,0.00013476166,0.00091502664,0.00006974386,0.00003461828,0.0000045748784,0.0000535362,0.00013028279,0.00007611978],"category_scores_gemma":[0.00015408082,0.00006114637,0.0002509691,0.00013798359,0.00020821011,0.000052784402,0.000010208394,0.00021634686,4.6873208e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32188272,0.0031988325,0.29822743,0.000012823135,0.0031810305,0.00012973403,0.0016334096,0.00006401155,0.00028623288,0.0000022865945,0.00024189024,0.3711396],"study_design_scores_gemma":[0.42848986,0.29489827,0.2677865,0.00016605188,0.0023818132,0.00007531689,0.00034215333,0.00029568127,0.00046033424,0.00001069447,0.004990033,0.00010326698],"about_ca_topic_score_codex":0.00040637146,"about_ca_topic_score_gemma":0.00025617413,"teacher_disagreement_score":0.37103632,"about_ca_system_score_codex":0.00053209736,"about_ca_system_score_gemma":0.003334991,"threshold_uncertainty_score":0.59161305},"labels":[],"label_agreement":null},{"id":"W2802241849","doi":"10.1200/jco.2017.77.1931","title":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children’s Oncology Group AREN0533 Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital","funders":"National Institutes of Health; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Internal medicine; Histology; Wilms' tumor; Etoposide; Lung; Vincristine; Regimen; Chemotherapy; Cyclophosphamide; Lung cancer; Gastroenterology","score_opus":0.04014447159697515,"score_gpt":0.3973690894663661,"score_spread":0.35722461786939097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802241849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284077,0.0030213778,0.00032246573,0.0011553873,0.0012032222,0.0004300824,0.00003655254,0.0000046708856,0.0009854676],"genre_scores_gemma":[0.9950075,0.00079961057,0.0013085883,0.0008206786,0.0016051931,0.000018253386,0.00003489878,0.000023799115,0.00038147136],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99570704,0.001120005,0.0021702375,0.00042649405,0.000270099,0.00030611228],"domain_scores_gemma":[0.99503624,0.0005860273,0.0032120508,0.00051742775,0.00042490585,0.0002233364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015900802,0.0002462166,0.0014527523,0.000056787376,0.000104043305,0.000008042303,0.00041453782,0.00034333987,0.00011456844],"category_scores_gemma":[0.0005992021,0.00012453776,0.0004459169,0.00012473244,0.00089672825,0.000010009491,0.00008957618,0.00045108993,0.000004495277],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03624645,0.01849098,0.81615937,0.000017993762,0.015574295,0.010119947,0.0009351643,0.00022714867,0.009643069,0.00006774958,0.027933627,0.064584196],"study_design_scores_gemma":[0.023258949,0.26769364,0.21754101,0.00005427951,0.00271178,0.006336882,0.001855836,0.000045220186,0.0037499194,0.000095703916,0.47623035,0.00042644082],"about_ca_topic_score_codex":0.0007028531,"about_ca_topic_score_gemma":0.0012381304,"teacher_disagreement_score":0.5986184,"about_ca_system_score_codex":0.00018454288,"about_ca_system_score_gemma":0.0019613686,"threshold_uncertainty_score":0.5078503},"labels":[],"label_agreement":null},{"id":"W2802292825","doi":"10.1200/jco.2016.34.15_suppl.6518","title":"Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Formulary; Pharmacy; Health care; Cost effectiveness; Cost–benefit analysis; Actuarial science; Family medicine; Business; Economic growth","score_opus":0.18408650535455268,"score_gpt":0.46150149974446353,"score_spread":0.27741499438991085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802292825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9046434,0.0030353789,0.07617549,0.0059372317,0.0042583123,0.000641426,0.00093849597,0.000013528009,0.0043567093],"genre_scores_gemma":[0.9949533,0.0012940115,0.0017705926,0.0008141576,0.0008995552,0.00007497322,0.0000023906996,0.00001839631,0.00017266428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957283,0.00016128834,0.003252427,0.00037033187,0.000060546296,0.00042710628],"domain_scores_gemma":[0.992173,0.0029385255,0.003985518,0.00018760603,0.00035932707,0.0003559903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056793666,0.00019910495,0.0028729716,0.00022282713,0.000060379254,0.000028422055,0.00038659785,0.00031380035,0.0004571971],"category_scores_gemma":[0.0048943167,0.00014802557,0.0014184389,0.0003413184,0.00024733559,0.00043423942,0.00005232855,0.0002554251,0.00007691064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065173516,0.0009901609,0.54666644,0.000040155766,0.0062878397,0.000046520465,0.000067607274,0.00040192952,0.000026246877,0.06795001,0.0039041738,0.36710158],"study_design_scores_gemma":[0.011491413,0.003917688,0.66553,0.000041029623,0.00077936216,0.000023662778,0.000022958744,0.00032773084,0.000050520226,0.06376879,0.2537379,0.00030891053],"about_ca_topic_score_codex":0.00016940467,"about_ca_topic_score_gemma":0.00064955006,"teacher_disagreement_score":0.36679268,"about_ca_system_score_codex":0.000998232,"about_ca_system_score_gemma":0.000916617,"threshold_uncertainty_score":0.6036308},"labels":[],"label_agreement":null},{"id":"W2802296799","doi":"10.1200/jco.2012.30.15_suppl.596","title":"Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Hazard ratio; Internal medicine; Clinical endpoint; Breast cancer; Population; Hormone receptor; Subgroup analysis; Randomization; Oncology; Intention-to-treat analysis; Placebo; Trastuzumab; Gastroenterology; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.08460041507953373,"score_gpt":0.4613426568447472,"score_spread":0.3767422417652134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802296799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907649,0.00018116235,0.000008698076,0.0069457274,0.0005149549,0.0009807236,0.00009123923,0.000002180729,0.00051042135],"genre_scores_gemma":[0.9982447,0.0003245399,0.00014595807,0.00045387013,0.0003981865,0.00003836621,0.0000014038409,0.00002222609,0.00037075757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993043,0.0026668059,0.0025391371,0.000207403,0.0011454481,0.0003981961],"domain_scores_gemma":[0.99250513,0.00253876,0.003193845,0.00053181266,0.00096082437,0.00026962312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006492645,0.00018298432,0.0019794148,0.00024613063,0.000051774325,0.000005209359,0.0005674183,0.0003000477,0.00029234466],"category_scores_gemma":[0.0035177616,0.00007886646,0.00061305787,0.0016758796,0.00065320916,0.00011923445,0.0002140243,0.0014791831,0.0000014585395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060381114,0.0018850481,0.9103617,0.00003552536,0.0013487594,0.0000036952385,0.0040691756,0.0001280672,0.0007860938,0.000028259326,0.0004799373,0.020492617],"study_design_scores_gemma":[0.014671111,0.00631132,0.9747232,0.0004244964,0.00097283424,0.000009234601,0.0016000863,0.000028637376,0.00072720257,0.000022880506,0.00043326567,0.00007568817],"about_ca_topic_score_codex":0.0065605347,"about_ca_topic_score_gemma":0.003320874,"teacher_disagreement_score":0.064361535,"about_ca_system_score_codex":0.0010112395,"about_ca_system_score_gemma":0.0012868244,"threshold_uncertainty_score":0.99176097},"labels":[],"label_agreement":null},{"id":"W2802609110","doi":"10.1200/jco.2015.33.15_suppl.e18562","title":"Effect of FK866, NAMPT inhibitor, on small cell lung cancer cell lines.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Cell culture; Apoptosis; Programmed cell death; Viability assay; Cancer research; Nicotinamide adenine dinucleotide; Cell growth; Nicotinamide phosphoribosyltransferase; Biology; NAD+ kinase; Cisplatin; Chemotherapy; Biochemistry; Enzyme; Genetics","score_opus":0.12365408856675252,"score_gpt":0.500820750508073,"score_spread":0.3771666619413204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802609110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690955,0.004274977,0.00009648999,0.0030883676,0.0053746244,0.00034322,0.000008184531,0.000014349742,0.017704275],"genre_scores_gemma":[0.98726743,0.001896754,0.0010838874,0.0034701708,0.00518115,0.000013543176,0.0000022450267,0.000037963102,0.0010468606],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953928,0.00094014365,0.0025910113,0.00022746903,0.0005762162,0.0002723607],"domain_scores_gemma":[0.99210805,0.003547598,0.0025550271,0.00028217013,0.0008334744,0.0006737089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058535966,0.00021262949,0.0019382162,0.0001254707,0.00002165124,0.000005242556,0.00021081037,0.00057251233,0.00030430307],"category_scores_gemma":[0.0016615773,0.00014533306,0.00065326877,0.00015631066,0.00020413681,0.000080809485,0.00004239588,0.0012610488,0.000026759655],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11336922,0.011017732,0.27144852,0.0013325898,0.0011382526,0.0017670958,0.0010935771,0.0012210459,0.028879909,0.000062013256,0.38746613,0.1812039],"study_design_scores_gemma":[0.11266086,0.17709479,0.010998951,0.0015821205,0.0017726807,0.00031092542,0.00014453584,0.0005341463,0.3271743,0.0001932371,0.36705056,0.00048287082],"about_ca_topic_score_codex":0.000062516556,"about_ca_topic_score_gemma":0.000029640041,"teacher_disagreement_score":0.2982944,"about_ca_system_score_codex":0.0005730777,"about_ca_system_score_gemma":0.002773492,"threshold_uncertainty_score":0.592651},"labels":[],"label_agreement":null},{"id":"W2802679302","doi":"10.1200/jco.2018.36.4_suppl.661","title":"Detection and description of <i>ERBB2</i> amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Medicine; Internal medicine; Oncology; KRAS; Cancer; Exact test; Cancer research","score_opus":0.07487431677985841,"score_gpt":0.3847588717214613,"score_spread":0.3098845549416029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802679302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910024,0.0006854817,0.007609273,0.00005885229,0.00045222978,0.00010003912,0.000015346192,0.0000010885211,0.000075286116],"genre_scores_gemma":[0.9944036,0.000528011,0.0043400256,0.00017231319,0.00053418084,0.0000028735185,0.0000039064494,0.000010926041,0.0000041891717],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980689,0.00021749898,0.0012670702,0.00019876006,0.000106999214,0.00014075616],"domain_scores_gemma":[0.9976754,0.00023026275,0.0015428549,0.00014152737,0.00031417343,0.00009578614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013836012,0.00009619579,0.00057718536,0.00015954998,0.000039010196,0.000012058801,0.00012880049,0.00014755585,0.000010870952],"category_scores_gemma":[0.0009710347,0.00009142562,0.00020771097,0.00021516909,0.00017695293,0.000010303393,0.000071274495,0.00017769136,3.8014363e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006024953,0.00018494375,0.0841526,0.00001548587,0.00024463175,0.0000070564183,0.00005987591,0.0015535705,0.9039601,0.0000047935923,0.000028065864,0.009186379],"study_design_scores_gemma":[0.0053698095,0.0063162367,0.76375765,0.0000418839,0.0020496643,0.000098370896,0.00033383025,0.017150516,0.20173085,0.00058710674,0.0022602577,0.00030386608],"about_ca_topic_score_codex":0.0002951129,"about_ca_topic_score_gemma":0.0032960488,"teacher_disagreement_score":0.70222926,"about_ca_system_score_codex":0.000104395076,"about_ca_system_score_gemma":0.0005355206,"threshold_uncertainty_score":0.37282285},"labels":[],"label_agreement":null},{"id":"W2803060236","doi":"10.1200/jco.2018.36.4_suppl.414","title":"Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Gastroenterology; Neutropenia; Discontinuation; Progression-free survival; Surgery; Chemotherapy; Cancer","score_opus":0.1971894995990235,"score_gpt":0.521799951063017,"score_spread":0.32461045146399353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803060236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98043334,0.0015040523,0.00002489067,0.014572231,0.001290332,0.0005304873,0.000014248619,0.000006064206,0.0016243351],"genre_scores_gemma":[0.9921162,0.002431206,0.00083143375,0.0028251596,0.0014342739,0.000087168984,0.0000046212235,0.000019831075,0.00025006625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967623,0.00039176867,0.0018806168,0.00024661768,0.00036845112,0.00035028337],"domain_scores_gemma":[0.99549735,0.002446493,0.0012375276,0.00027605155,0.0003232437,0.00021933322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010105863,0.00024227085,0.0016342296,0.00016065176,0.000053838867,0.0000068518193,0.00022499802,0.00015539567,0.0007136793],"category_scores_gemma":[0.00036204513,0.00011992755,0.0003864531,0.00027202375,0.0006634629,0.0001099702,0.000035267636,0.0004367215,0.000011206975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08543109,0.019394021,0.7829882,0.000119028824,0.003931005,0.0024999103,0.0072871847,0.000024735607,0.0002843577,0.000058244645,0.0052491548,0.09273309],"study_design_scores_gemma":[0.10667845,0.17988667,0.53883696,0.00044426834,0.004358431,0.0007970344,0.0014312986,0.00013052061,0.00085125474,0.00011278622,0.16621888,0.00025343828],"about_ca_topic_score_codex":0.00044390603,"about_ca_topic_score_gemma":0.0037456525,"teacher_disagreement_score":0.24415119,"about_ca_system_score_codex":0.0004064009,"about_ca_system_score_gemma":0.0011206077,"threshold_uncertainty_score":0.7814288},"labels":[],"label_agreement":null},{"id":"W2803357164","doi":"10.1200/jco.2007.13.4569","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Family medicine","score_opus":0.14315812127373168,"score_gpt":0.5280995480127147,"score_spread":0.3849414267389831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803357164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372516,0.00045534564,0.00021980872,0.019303981,0.00391169,0.000051598072,2.277414e-7,0.0000034704863,0.038802255],"genre_scores_gemma":[0.97412515,0.00020777366,0.00076247484,0.021778675,0.002279385,2.389007e-7,1.7792061e-7,0.0000058849387,0.00084021874],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772084,0.00010880886,0.0017407902,0.000079291036,0.00020397358,0.00014632121],"domain_scores_gemma":[0.99740815,0.0014075462,0.0006293998,0.00010750883,0.00020540819,0.00024196487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071252594,0.000047953967,0.00073700177,0.00011632977,0.000006446849,0.0000016437497,0.00007130428,0.00019967793,0.00022289816],"category_scores_gemma":[0.0027657815,0.000034272343,0.00027547794,0.00013720975,0.00007052486,0.000053712505,0.000016032023,0.0008327577,0.000017673763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009814236,0.0013408945,0.48552686,0.000025010275,0.00010312402,0.008625763,0.00043674526,0.0000015231084,0.00017018698,0.00047174652,0.03191537,0.46156853],"study_design_scores_gemma":[0.0030108227,0.0039604628,0.38287434,0.000035148776,0.000039110906,0.00044579845,0.0002173437,0.0000018189692,0.00007388431,0.00038764146,0.60892427,0.00002934587],"about_ca_topic_score_codex":0.00008717713,"about_ca_topic_score_gemma":0.0010914364,"teacher_disagreement_score":0.5770089,"about_ca_system_score_codex":0.00011509085,"about_ca_system_score_gemma":0.0007662022,"threshold_uncertainty_score":0.36179638},"labels":[],"label_agreement":null},{"id":"W2803526639","doi":"10.1200/jco.2018.36.4_suppl.621","title":"Effects of proton pump inhibitors (PPIs) on FOLFOX and XELOX regimens in colorectal cancer (CRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Children's Hospital","funders":"","keywords":"FOLFOX; Medicine; Oxaliplatin; Capecitabine; Internal medicine; Colorectal cancer; Oncology; Cancer; Gastroenterology","score_opus":0.05863695940895872,"score_gpt":0.45449558851586297,"score_spread":0.3958586291069042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803526639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137527,0.0009010253,9.488287e-7,0.0032647387,0.0010744923,0.0006808939,0.0000020146827,0.0000046423797,0.0026959889],"genre_scores_gemma":[0.9959873,0.0019611483,0.0001552769,0.000633934,0.001099188,0.000043725453,2.915823e-7,0.000011763909,0.000107353255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978637,0.00021304861,0.001277619,0.00018666283,0.00025873023,0.00020024768],"domain_scores_gemma":[0.9969787,0.0015489457,0.0009385386,0.00007017437,0.0002810472,0.00018258409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091972976,0.00013987049,0.0013687271,0.00014250568,0.000034412988,0.0000032083685,0.00006160729,0.0002464485,0.000038056496],"category_scores_gemma":[0.0016136805,0.00008909521,0.0001894566,0.00014579177,0.00044304127,0.000050842802,0.000053446638,0.00050214975,0.0000032275707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03253858,0.004347641,0.79047096,0.0002929888,0.0010028438,0.00081527076,0.0010381604,0.0000014415548,0.005165495,0.00008616722,0.0033205033,0.16091992],"study_design_scores_gemma":[0.012569415,0.07141273,0.8860358,0.00053334574,0.00029849063,0.00005751266,0.00007759292,0.000011005466,0.015335676,0.00013826424,0.013445892,0.00008424617],"about_ca_topic_score_codex":0.00012496898,"about_ca_topic_score_gemma":0.0004458826,"teacher_disagreement_score":0.16083567,"about_ca_system_score_codex":0.00023173861,"about_ca_system_score_gemma":0.0006817337,"threshold_uncertainty_score":0.3633197},"labels":[],"label_agreement":null},{"id":"W2803564892","doi":"10.1200/jco.2018.78.8604","title":"Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Medicine; Breast cancer; Oncology; Taxane; Neratinib; Trastuzumab; Pertuzumab; Internal medicine; Capecitabine; Adjuvant therapy; Anthracycline; Cancer; Colorectal cancer","score_opus":0.04761808395535508,"score_gpt":0.45843001847197196,"score_spread":0.4108119345166169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803564892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745684,0.0024755297,0.00318481,0.018118905,0.0011759734,0.00029465518,0.00006992224,0.0000060937605,0.000105702304],"genre_scores_gemma":[0.91197485,0.018184133,0.059198223,0.005042134,0.005508399,0.00001650979,0.000010187006,0.00003417154,0.000031405834],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966699,0.00038372958,0.00222366,0.00031384596,0.00018124026,0.00022764067],"domain_scores_gemma":[0.9947346,0.000603659,0.002377188,0.0001627952,0.0019545401,0.00016721955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028847682,0.00018130086,0.0010015172,0.00003850784,0.000081979706,0.0000088256775,0.000177988,0.00042888935,0.000040578736],"category_scores_gemma":[0.001298419,0.0001332045,0.00038090616,0.00008486644,0.00052391103,0.000021386084,0.000053038337,0.00027621622,0.00000113194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055750962,0.0022505017,0.122115724,0.000010991603,0.0030663959,0.000008085031,0.00008370329,0.000010291769,0.005210861,0.000026366724,0.03625916,0.775207],"study_design_scores_gemma":[0.02084131,0.026160728,0.48660865,0.000029783361,0.0003773383,0.00022242182,0.000065903434,0.00010424639,0.0067047733,0.00008855592,0.4585916,0.00020466557],"about_ca_topic_score_codex":0.00007684467,"about_ca_topic_score_gemma":0.000059995007,"teacher_disagreement_score":0.7750023,"about_ca_system_score_codex":0.000036857524,"about_ca_system_score_gemma":0.0008703856,"threshold_uncertainty_score":0.5431922},"labels":[],"label_agreement":null},{"id":"W2803622815","doi":"10.1200/jco.2018.77.9736","title":"Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Trastuzumab; Mace; Internal medicine; Breast cancer; Population; Cohort; Odds ratio; Incidence (geometry); Logistic regression; Retrospective cohort study; Regimen; Cancer; Oncology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.06337906425243756,"score_gpt":0.46066046865111204,"score_spread":0.3972814043986745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803622815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917601,0.00026341676,0.00084526907,0.0033879422,0.0013886961,0.0021896865,0.000029144107,0.00001743688,0.00011834809],"genre_scores_gemma":[0.99422437,0.00035627748,0.0011568327,0.0009989798,0.002930563,0.00021171328,0.0000044736976,0.00003668652,0.00008013272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964495,0.0007514064,0.0018445164,0.00030222957,0.00032670895,0.00032564998],"domain_scores_gemma":[0.9909196,0.0039300034,0.0038763084,0.00021033217,0.0008658021,0.00019795736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011806956,0.00016384559,0.001522947,0.00018741656,0.00011358918,0.00003305153,0.00013366385,0.0001726718,0.000024753279],"category_scores_gemma":[0.003254235,0.00013374802,0.0004565479,0.0001693978,0.00007388319,0.00025078448,0.000011868782,0.0005745306,8.726823e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005868508,0.00067155977,0.8946378,0.000062809406,0.00044951364,0.000015125564,0.0009153033,0.00003091279,0.0014430091,0.0000014390533,0.00013268975,0.095771305],"study_design_scores_gemma":[0.013629205,0.002872734,0.9766661,0.00025483637,0.00027386498,0.000053759424,0.0018131013,0.0012998056,0.000340703,0.000070027534,0.0025935923,0.00013227722],"about_ca_topic_score_codex":0.0011310895,"about_ca_topic_score_gemma":0.00021240948,"teacher_disagreement_score":0.09563903,"about_ca_system_score_codex":0.0007861474,"about_ca_system_score_gemma":0.0012506859,"threshold_uncertainty_score":0.5454086},"labels":[],"label_agreement":null},{"id":"W2803821709","doi":"10.1200/jco.2018.36.4_suppl.634","title":"Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Proportional hazards model; Circulating tumor DNA; Lymph node; Cancer; Logistic regression; Gastroenterology","score_opus":0.0707007655400564,"score_gpt":0.42912591105572595,"score_spread":0.35842514551566956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803821709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952364,0.00047998247,0.001272032,0.0003761303,0.0020659782,0.00019519904,0.000020169187,0.0000024351289,0.00035165777],"genre_scores_gemma":[0.9909987,0.00020677997,0.004645041,0.00086746353,0.0032179789,0.000018438723,0.0000035644998,0.000021782069,0.000020286254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779063,0.00016323384,0.001435163,0.00022036432,0.000120751916,0.00026987673],"domain_scores_gemma":[0.99716204,0.0009894061,0.001191951,0.00010910091,0.00038120415,0.0001662784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022013409,0.0001204262,0.0006214631,0.000068487265,0.00005409037,0.000013099347,0.00019950641,0.00018182083,0.000025032066],"category_scores_gemma":[0.007519199,0.000105134204,0.00029425678,0.00008764156,0.00017622941,0.0000062549225,0.00007607351,0.000276704,0.0000015401637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007928499,0.0013716368,0.36206618,0.00010015195,0.0011800067,0.00023604213,0.00041791724,0.0014040666,0.34754768,0.0001783106,0.0067483406,0.27082115],"study_design_scores_gemma":[0.028861519,0.067168444,0.3663233,0.00031807995,0.0009726074,0.0007075722,0.000961916,0.006047345,0.1718436,0.0024855467,0.3531865,0.0011235807],"about_ca_topic_score_codex":0.00004226779,"about_ca_topic_score_gemma":0.0014166248,"teacher_disagreement_score":0.34643814,"about_ca_system_score_codex":0.000089456655,"about_ca_system_score_gemma":0.001472511,"threshold_uncertainty_score":0.90017265},"labels":[],"label_agreement":null},{"id":"W2803932097","doi":"10.1200/jco.2018.36.4_suppl.641","title":"Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Medicine; Allele; Cancer; Mutation; Genotype; Allele frequency; Mutant; Cancer research; Molecular biology; Internal medicine; Genetics; Biology; Gene","score_opus":0.050851628703648295,"score_gpt":0.43341178334557556,"score_spread":0.3825601546419273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803932097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490476,0.0002490518,0.00010905189,0.0009850939,0.0033058356,0.00010202979,0.000010553653,9.607469e-7,0.00033263667],"genre_scores_gemma":[0.99036604,0.00060931727,0.0034068942,0.00020456719,0.005374783,0.000005878964,0.0000021338733,0.000008952255,0.000021404107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984457,0.00010703153,0.001070941,0.00013320673,0.00010767803,0.00013546461],"domain_scores_gemma":[0.9985258,0.00020919806,0.0006857626,0.000075767945,0.00037983843,0.00012361254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008626504,0.00007294106,0.00042778585,0.00005990406,0.000016539161,0.000005097972,0.00015754979,0.00023888807,0.000017887916],"category_scores_gemma":[0.0016949159,0.00006328082,0.00012234322,0.00008423797,0.00010539526,0.0000041458784,0.00006627289,0.00014893663,0.0000025879415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008181495,0.0006964208,0.23341845,0.000020756073,0.00016048457,0.00006561673,0.00026429436,0.00056455925,0.6449398,0.00012585896,0.0046550664,0.10690723],"study_design_scores_gemma":[0.0032585785,0.017472481,0.3881239,0.0000657142,0.000049377308,0.00002377035,0.0001204217,0.000024485715,0.5388284,0.00015767473,0.051740255,0.00013494636],"about_ca_topic_score_codex":0.00006735759,"about_ca_topic_score_gemma":0.00042791863,"teacher_disagreement_score":0.15470546,"about_ca_system_score_codex":0.000054907945,"about_ca_system_score_gemma":0.0009297241,"threshold_uncertainty_score":0.2580517},"labels":[],"label_agreement":null},{"id":"W2804327225","doi":"10.1200/jco.2017.35.15_suppl.tps3629","title":"NRG-GI002: A phase II clinical trial platform for total neoadjuvant therapy (TNT) in rectal cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Neoadjuvant therapy; Clinical endpoint; Total mesorectal excision; Oncology; Population; FOLFOX; Internal medicine; Chemoradiotherapy; Randomized controlled trial; Radiation therapy; Cancer; Surgery; Oxaliplatin; Breast cancer","score_opus":0.4128762817880377,"score_gpt":0.611146713313172,"score_spread":0.19827043152513435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804327225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729909,0.0017730575,0.000016152482,0.013489223,0.007682882,0.0011559243,0.000018540239,0.000009087019,0.00286429],"genre_scores_gemma":[0.9823955,0.0073025716,0.00093480246,0.00122979,0.007244477,0.00008956611,0.0000030302035,0.00002397361,0.00077626755],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951228,0.00017690903,0.0036234318,0.00033631557,0.00034385786,0.0003967246],"domain_scores_gemma":[0.99316317,0.0026856656,0.0029959343,0.00033748776,0.00041772783,0.00040003023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004657398,0.00023226667,0.0028901692,0.00010266535,0.0002985157,0.00002610539,0.00028747463,0.0005270533,0.0001648221],"category_scores_gemma":[0.0074425368,0.00014654377,0.0013463042,0.000056166467,0.00044480513,0.00019962882,0.00012583061,0.0011154909,0.0000034415652],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35911852,0.0073186974,0.014816587,0.000007764338,0.0006952501,0.00042615712,0.00014372049,9.718874e-7,0.000018671968,0.000028316977,0.0040554926,0.6133698],"study_design_scores_gemma":[0.48738414,0.23802789,0.13558586,0.00013726718,0.00037836828,0.00014502279,0.00011318751,0.00012456138,0.000039174218,0.00039927446,0.13750777,0.00015749135],"about_ca_topic_score_codex":0.00014820241,"about_ca_topic_score_gemma":0.0008267197,"teacher_disagreement_score":0.61321235,"about_ca_system_score_codex":0.00032087832,"about_ca_system_score_gemma":0.0026644543,"threshold_uncertainty_score":0.8909949},"labels":[],"label_agreement":null},{"id":"W2804658719","doi":"10.1200/jco.2013.31.15_suppl.10021","title":"Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; DLCO; Pulmonary function testing; Vital capacity; Spirometry; Lung volumes; Diffusing capacity; Cyclophosphamide; Radiation therapy; Cumulative dose; Nuclear medicine; Lung; Surgery; Internal medicine; Chemotherapy; Lung function; Asthma","score_opus":0.1165004088817783,"score_gpt":0.43066234334675135,"score_spread":0.31416193446497304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804658719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544309,0.0003482987,0.00007423982,0.04173399,0.0012063639,0.00070770807,0.000008991141,0.000010825571,0.0014786961],"genre_scores_gemma":[0.9880186,0.00010757258,0.0009774311,0.008802559,0.0014555778,0.0001910381,0.000014918103,0.000021940963,0.0004103914],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975661,0.00021022857,0.001406509,0.00023027984,0.0003318782,0.0002549936],"domain_scores_gemma":[0.99569637,0.0023815066,0.0009946702,0.00017093917,0.00032033032,0.00043617713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008486187,0.0001950385,0.0011019843,0.00016765074,0.00006324901,0.000016965307,0.00006660519,0.00028199313,0.00072231324],"category_scores_gemma":[0.0008130691,0.00012104468,0.00077670877,0.000079944744,0.00008230424,0.00014275589,0.000017444683,0.00030449347,0.00009951543],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02153805,0.01823932,0.4384883,0.000039542952,0.0016135343,0.0015367077,0.000096527605,0.000052082098,0.00070867705,0.00038347283,0.031686973,0.4856168],"study_design_scores_gemma":[0.0115354145,0.044448722,0.8854817,0.0000772602,0.00039780876,0.00034656675,0.00005752529,0.00018833697,0.00008993659,0.0015013887,0.055779897,0.00009542712],"about_ca_topic_score_codex":0.000028529761,"about_ca_topic_score_gemma":0.000014459705,"teacher_disagreement_score":0.48552138,"about_ca_system_score_codex":0.00044143136,"about_ca_system_score_gemma":0.0006892153,"threshold_uncertainty_score":0.7908823},"labels":[],"label_agreement":null},{"id":"W2805054456","doi":"10.1200/jco.2018.36.18_suppl.lba5005","title":"Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prednisone; Prostate cancer; Internal medicine; Abiraterone acetate; Regimen; Oncology; Performance status; Randomization; Clinical endpoint; Cancer; Gastroenterology; Randomized controlled trial; Surgery; Androgen deprivation therapy","score_opus":0.15815292437814457,"score_gpt":0.5027045043736905,"score_spread":0.344551579995546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805054456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97286725,0.00047630366,0.000034585577,0.01885291,0.0002108542,0.0003808059,0.000032504016,0.000009428072,0.007135382],"genre_scores_gemma":[0.9931579,0.0010873745,0.0025881946,0.00036830845,0.0012581692,0.000012655986,0.0000055536707,0.000023936836,0.0014978994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972313,0.00040132622,0.0012164728,0.00024819336,0.0005374683,0.00036525674],"domain_scores_gemma":[0.99642664,0.0010046352,0.0011023945,0.00016012139,0.00068082736,0.0006253541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017964587,0.000173378,0.0013982909,0.00013202612,0.00009037119,0.000024784833,0.00010844351,0.00008944035,0.00012880661],"category_scores_gemma":[0.00043079603,0.000099769015,0.0001445914,0.00021962957,0.0011487938,0.00013272364,0.000039706174,0.0006310991,0.0000067853925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032676935,0.0011102733,0.72065824,0.00010847172,0.0034415661,0.002405959,0.001520194,0.0000033373383,0.0007367714,0.00012621238,0.0048469296,0.2323651],"study_design_scores_gemma":[0.014656102,0.045162257,0.8925962,0.00014855244,0.0010931131,0.00018293744,0.0012603281,0.000036279478,0.0002244178,0.0002786664,0.044191435,0.00016971842],"about_ca_topic_score_codex":0.0006484198,"about_ca_topic_score_gemma":0.00097129965,"teacher_disagreement_score":0.23219538,"about_ca_system_score_codex":0.00024524026,"about_ca_system_score_gemma":0.0031750463,"threshold_uncertainty_score":0.5632396},"labels":[],"label_agreement":null},{"id":"W2805079852","doi":"10.1200/jco.2018.36.15_suppl.1023","title":"Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Palbociclib; Fulvestrant; Letrozole; Adjuvant; Progression-free survival; Overall survival; Cancer; Gynecology; Metastatic breast cancer; Tamoxifen","score_opus":0.068602060323931,"score_gpt":0.4536442761604686,"score_spread":0.3850422158365376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805079852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913188,0.00623949,0.00015585673,0.001636641,0.00017294247,0.00034984524,0.000011719292,0.0000067446376,0.00010794795],"genre_scores_gemma":[0.99203527,0.0060404525,0.0012123921,0.0003471147,0.000290107,0.000008365645,0.000004269031,0.000017387943,0.00004461614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969433,0.00057264516,0.0017888946,0.00022573816,0.0002653556,0.00020407567],"domain_scores_gemma":[0.9939011,0.0033795869,0.0018612377,0.00021075869,0.00038626156,0.00026106028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013102927,0.00020697116,0.002828447,0.00026286684,0.000024764333,0.0000044416965,0.00007409764,0.00016541254,0.00006901183],"category_scores_gemma":[0.00143637,0.00011943168,0.0004378214,0.0003302376,0.00077119813,0.00006801655,0.000039166236,0.00030632224,8.092849e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016219726,0.00079686684,0.48675108,0.00005496025,0.0052512214,0.00012897965,0.0003781864,0.0000027892206,0.004243119,0.000035965044,0.000046907564,0.4860902],"study_design_scores_gemma":[0.031759817,0.11103984,0.83631593,0.0001304514,0.004184593,0.00045124075,0.00008888541,0.00015987914,0.0061611785,0.00018533753,0.009396604,0.0001262751],"about_ca_topic_score_codex":0.00006572439,"about_ca_topic_score_gemma":0.00007334266,"teacher_disagreement_score":0.48596394,"about_ca_system_score_codex":0.000112278845,"about_ca_system_score_gemma":0.00044572717,"threshold_uncertainty_score":0.48702827},"labels":[],"label_agreement":null},{"id":"W2805080829","doi":"10.1200/jco.2018.36.7_suppl.34","title":"Ascertaining cancer survivors in Ontario using the Ontario Cancer Registry and administrative data.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Cancer registry; Cohort; Survivorship curve; Concordance; Cancer; Radiation therapy; Population; Cumulative incidence; Internal medicine; Family medicine; Environmental health","score_opus":0.6584366608062311,"score_gpt":0.5960909375971968,"score_spread":0.06234572320903431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805080829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985505,0.00075413566,0.000067574954,0.00472619,0.0013876258,0.00013040028,0.0000045738325,0.0000028417614,0.0030715994],"genre_scores_gemma":[0.9908396,0.00028244004,0.003049038,0.0035465148,0.0015247911,0.0000026138398,0.0000017232945,0.00000934293,0.0007439389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732417,0.00026352686,0.0015092075,0.00026775352,0.00036063237,0.00027471667],"domain_scores_gemma":[0.99675703,0.0009106993,0.0013481976,0.0003221908,0.00040727595,0.00025458538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037284906,0.00013634667,0.00096555764,0.000056382843,0.00009068576,0.000021499478,0.00033890523,0.0002741588,0.0005254266],"category_scores_gemma":[0.0013340127,0.00008494953,0.000114429386,0.00012942044,0.0005410347,0.0002362869,0.0001502538,0.0017313844,0.0000012432519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00259624,0.00010235564,0.972609,0.0000058486366,0.00018670209,0.0003977777,0.0020663752,0.000023235565,0.000026534368,0.000021590755,0.001055062,0.02090931],"study_design_scores_gemma":[0.0022254246,0.0029326046,0.84225637,0.00040885105,0.00029408484,0.00041019384,0.0012921642,0.0002668102,0.00001574237,0.000113096685,0.14968958,0.00009506296],"about_ca_topic_score_codex":0.82419837,"about_ca_topic_score_gemma":0.9975791,"teacher_disagreement_score":0.17338073,"about_ca_system_score_codex":0.0011328674,"about_ca_system_score_gemma":0.015224517,"threshold_uncertainty_score":0.99035823},"labels":[],"label_agreement":null},{"id":"W2805105610","doi":"10.1200/jco.2018.36.7_suppl.143","title":"Implementation of an electronic patient reported outcome system in a prostate cancer urology clinic.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Prostate cancer; Context (archaeology); Gynecology; Cancer; General surgery; Internal medicine","score_opus":0.14652242965286766,"score_gpt":0.5641010602817411,"score_spread":0.41757863062887346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805105610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937648,0.00014599747,0.000043041207,0.004122745,0.0011496464,0.00057297485,0.0000050214207,0.000010329972,0.0001854112],"genre_scores_gemma":[0.995182,0.00020954144,0.00073978846,0.0029332647,0.0008748293,0.000018798692,0.000010668209,0.0000149658,0.00001619262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919083,0.0006130238,0.0065428666,0.00020577514,0.0003581366,0.0003718637],"domain_scores_gemma":[0.9928457,0.0005435707,0.0053645014,0.00019033796,0.00078706123,0.00026884145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004765879,0.00011691585,0.0013653884,0.00027502468,0.000025736423,0.0000020700613,0.00009234029,0.00017475875,0.0002914734],"category_scores_gemma":[0.00092236005,0.00008680424,0.00017084609,0.0002666575,0.0001498736,0.00012588158,0.000025079593,0.00069487514,0.0000048400802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003588169,0.00048271878,0.75857717,0.00006953123,0.00013759261,0.00023539028,0.00045848955,0.0000014714028,0.000060083043,0.000041307165,0.0007083827,0.23563966],"study_design_scores_gemma":[0.0121969115,0.06901477,0.8912187,0.000041817355,0.00034728268,0.00048184316,0.0023072532,0.000063615276,0.0001455144,0.000062522515,0.024055982,0.00006378408],"about_ca_topic_score_codex":0.0005972446,"about_ca_topic_score_gemma":0.004209282,"teacher_disagreement_score":0.23557588,"about_ca_system_score_codex":0.00036130074,"about_ca_system_score_gemma":0.003128569,"threshold_uncertainty_score":0.5549947},"labels":[],"label_agreement":null},{"id":"W2805127121","doi":"10.1200/jco.2018.36.7_suppl.98","title":"Cancer patient interest and perceptions of health behavior change programs.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Health and Food Behavior","field":"Nursing","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Smoking cessation; Logistic regression; Cancer; Environmental health; Quality of life (healthcare); Family medicine; Internal medicine; Nursing","score_opus":0.3919112222060758,"score_gpt":0.5683722767989139,"score_spread":0.17646105459283806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805127121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973347,0.0010124795,0.000008552688,0.014898577,0.0038207679,0.00047072262,0.000014165772,0.000007643915,0.0000336473],"genre_scores_gemma":[0.99294,0.0006321606,0.0017945059,0.0029084906,0.0016520256,0.00005235054,0.0000023420837,0.000011828282,0.0000063171065],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967936,0.00047659205,0.0021777793,0.00013591418,0.00016755903,0.00024849834],"domain_scores_gemma":[0.99686056,0.00022552066,0.0019001365,0.000107800035,0.00053018064,0.00037581424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00147516,0.000089973786,0.0008162371,0.00011156469,0.00009281162,0.0000069156895,0.000102702725,0.00023010057,0.00012566854],"category_scores_gemma":[0.00024416958,0.00007036721,0.00017391086,0.00010439871,0.00043064597,0.0001189776,0.00003183487,0.00050684024,0.0000047181156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006214835,0.0019972492,0.25075215,0.000037055015,0.000010353862,0.000005943643,0.0006787792,6.7698016e-9,0.000045679917,0.000009174225,0.0014791748,0.74436295],"study_design_scores_gemma":[0.0020380034,0.053041995,0.8827437,0.0002565291,0.00013269376,0.000093780545,0.00066646334,0.000003275366,0.00003452784,0.000077975346,0.060839735,0.000071328606],"about_ca_topic_score_codex":0.00030422182,"about_ca_topic_score_gemma":0.0012025756,"teacher_disagreement_score":0.7442916,"about_ca_system_score_codex":0.00013530099,"about_ca_system_score_gemma":0.00035900017,"threshold_uncertainty_score":0.28694916},"labels":[],"label_agreement":null},{"id":"W2805275869","doi":"10.1200/jco.2018.36.7_suppl.11","title":"Barriers of EQ5D-5L implementation into routine clinical practice: A multisite evaluation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of British Columbia; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multidisciplinary approach; Family medicine; Cancer registry; Population; Nursing; Health care; Environmental health","score_opus":0.6337731829820504,"score_gpt":0.6847171766675494,"score_spread":0.050943993685498956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805275869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8892835,0.0014836519,0.0071943393,0.08780371,0.0074819047,0.000834048,0.000053469634,0.000012930591,0.0058524674],"genre_scores_gemma":[0.9212616,0.00048425893,0.052424308,0.021037541,0.0046638707,0.000015694226,0.0000090351705,0.00002525922,0.000078393634],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.96789646,0.004912873,0.02601139,0.00044937505,0.00039023743,0.00033965046],"domain_scores_gemma":[0.9502464,0.016151326,0.030452339,0.0004597011,0.002079034,0.00061122316],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23798275,0.00017033261,0.0028145367,0.00033848704,0.00013639014,0.000028306224,0.0004415986,0.00052314106,0.002446696],"category_scores_gemma":[0.20180026,0.00017913555,0.00060310285,0.00023932119,0.00046677326,0.0009074521,0.00009266546,0.0007259598,0.00059458514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013552853,0.0010981334,0.78770065,0.00010532158,0.0011459773,0.000011790531,0.003320991,0.00007228247,0.0000065345394,0.021019738,0.09720063,0.08696264],"study_design_scores_gemma":[0.013677733,0.009615292,0.43259588,0.00008377418,0.00025965757,0.000055345237,0.0050712046,0.0055472236,0.000010956616,0.020737074,0.512032,0.0003138856],"about_ca_topic_score_codex":0.0005242387,"about_ca_topic_score_gemma":0.00048804836,"teacher_disagreement_score":0.41483134,"about_ca_system_score_codex":0.0006437315,"about_ca_system_score_gemma":0.002929622,"threshold_uncertainty_score":0.9984652},"labels":[],"label_agreement":null},{"id":"W2805363969","doi":"10.1200/jco.2018.36.18_suppl.lba1006","title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Clinical endpoint; Hazard ratio; Adverse effect; Oncology; Population; Randomized controlled trial; Cancer; Breast cancer; Placebo; Progression-free survival; Estrogen receptor; Confidence interval; Overall survival; Pathology","score_opus":0.03734654690843785,"score_gpt":0.40994934581902676,"score_spread":0.3726027989105889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805363969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365985,0.0006191469,0.00204773,0.0010591304,0.0006323796,0.0012548037,0.000618031,0.000020696363,0.00008823501],"genre_scores_gemma":[0.9846236,0.00045284233,0.011885368,0.002072985,0.00073524856,0.000049507686,0.00006752134,0.00007147663,0.000041429776],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99148303,0.0010232623,0.0048173578,0.0007548712,0.0012805605,0.000640911],"domain_scores_gemma":[0.9905584,0.0017229781,0.004367364,0.0006211866,0.0020005018,0.00072956836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018116436,0.0005527406,0.0047313278,0.00049826584,0.00008938895,0.000017377994,0.0004916049,0.00029259827,0.00086597615],"category_scores_gemma":[0.00047030253,0.0003550783,0.00060374313,0.0015288823,0.000854985,0.00048450188,0.00010811608,0.0012577017,0.0000074860277],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.346207,0.05063626,0.21446921,0.000069356545,0.014167136,0.0011001617,0.0015146991,0.00062426075,0.0035777267,0.0000033059396,0.00022247298,0.36740842],"study_design_scores_gemma":[0.35552537,0.2011365,0.4123382,0.0012530391,0.018017508,0.000310423,0.003674246,0.00021969364,0.0020531167,0.000071781884,0.0045250743,0.000875049],"about_ca_topic_score_codex":0.0004930017,"about_ca_topic_score_gemma":0.0018537589,"teacher_disagreement_score":0.36653337,"about_ca_system_score_codex":0.0007446855,"about_ca_system_score_gemma":0.0031993552,"threshold_uncertainty_score":0.99989015},"labels":[],"label_agreement":null},{"id":"W2805527938","doi":"10.1200/jco.2017.76.4431","title":"Financial Hardship and the Economic Effect of Childhood Cancer Survivorship","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Population; Worry; Survivorship curve; Poverty; Government (linguistics); Health care; Finance; Psychiatry; Environmental health; Economic growth; Business","score_opus":0.1531745821459396,"score_gpt":0.5152607007689682,"score_spread":0.36208611862302864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805527938","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017467313,0.9712241,0.0000038205208,0.0030219215,0.0063325907,0.0010555343,0.00005063013,0.000008848832,0.00083523145],"genre_scores_gemma":[0.001722912,0.983659,0.000116186726,0.0012935806,0.012996687,0.000027804623,0.000005484527,0.00005999525,0.00011830191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.985119,0.006522675,0.0070519405,0.00043307513,0.0005092425,0.00036406133],"domain_scores_gemma":[0.9618243,0.027036643,0.009886153,0.00057020923,0.00027837438,0.00040432846],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.029979313,0.0005026734,0.013166436,0.00021253497,0.000065784494,0.000016514103,0.00061317877,0.0014204953,0.00021142185],"category_scores_gemma":[0.018922381,0.00026156838,0.003419923,0.00015469603,0.0015936148,0.00007986186,0.00019317177,0.0029213466,0.0000345532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043501942,0.00029193817,0.0018177285,0.008481496,0.0021753549,0.00005964363,0.00022087301,4.0356647e-7,1.2197795e-8,0.0002527225,0.010662413,0.9716872],"study_design_scores_gemma":[0.012441813,0.010843783,0.0056776484,0.01367758,0.008247569,0.000629235,0.000010526216,0.0000018064541,8.2225034e-7,0.00026909518,0.94796884,0.000231278],"about_ca_topic_score_codex":0.0005499624,"about_ca_topic_score_gemma":0.0010497371,"teacher_disagreement_score":0.97145593,"about_ca_system_score_codex":0.00037561075,"about_ca_system_score_gemma":0.011789657,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W2805627633","doi":"10.1200/jco.2018.36.4_suppl.737","title":"Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; KRAS; Internal medicine; Maintenance therapy; Oncology; Clinical endpoint; Cetuximab; Colorectal cancer; Phases of clinical research; Primary tumor; Clinical trial; Cancer; Epidermal growth factor receptor; Chemotherapy; Metastasis","score_opus":0.0785497417539015,"score_gpt":0.4446956624617356,"score_spread":0.3661459207078341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805627633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960863,0.00011517877,0.000002035829,0.0010689445,0.0003823218,0.001288593,0.00018250095,0.000007102646,0.00086700293],"genre_scores_gemma":[0.9985868,0.00013716704,0.00021268091,0.000422923,0.00050940196,0.000029698493,0.000025470552,0.00002368142,0.00005219026],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961339,0.00048178327,0.0022113775,0.00031245043,0.0005452269,0.00031524381],"domain_scores_gemma":[0.991917,0.0041335206,0.0025676356,0.00023541116,0.00092961255,0.0002168115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012255682,0.00027221485,0.0024190817,0.00010865662,0.00006750617,0.000008212251,0.0001733212,0.00010735785,0.000083075436],"category_scores_gemma":[0.0019314154,0.000110899295,0.00037378684,0.00034828717,0.00067071547,0.00007959927,0.000038452512,0.0006347208,0.0000023587406],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8119452,0.01468362,0.12503068,0.000006035512,0.0023238906,0.00032369766,0.0005548354,0.000022131053,0.000011249216,0.0000013776105,0.0015893136,0.043507986],"study_design_scores_gemma":[0.31458643,0.17025271,0.51371366,0.00026749834,0.000719317,0.000012850165,0.00008381071,0.000009048121,0.00003186137,0.000005380805,0.00024906648,0.000068378555],"about_ca_topic_score_codex":0.0017065508,"about_ca_topic_score_gemma":0.0020795611,"teacher_disagreement_score":0.49735877,"about_ca_system_score_codex":0.00075385725,"about_ca_system_score_gemma":0.0025736876,"threshold_uncertainty_score":0.45656112},"labels":[],"label_agreement":null},{"id":"W2805668121","doi":"10.1200/jco.2018.36.15_suppl.553","title":"Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institutes of Health; Science Foundation Ireland; Irish Cancer Society; European Commission; Cancer Research UK","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Anastrozole; Proportional hazards model; Tamoxifen; Clinical endpoint; Gynecology; Population; Estrogen receptor; Cancer; Cohort; Lymph node; Clinical trial","score_opus":0.035816226857534515,"score_gpt":0.3960269030139362,"score_spread":0.36021067615640173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805668121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947127,0.00071254605,0.000011008658,0.0027667042,0.0004681333,0.00024353148,0.000028189119,0.0000011867271,0.0010559899],"genre_scores_gemma":[0.9979388,0.00012224285,0.00024851042,0.0007336554,0.0008998626,0.000024046954,0.0000028252746,0.000011069305,0.000018997274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763745,0.0007473656,0.00078270055,0.00018044976,0.00045963828,0.0001924177],"domain_scores_gemma":[0.9970138,0.00023294643,0.00110661,0.00015726779,0.0014107996,0.00007858957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002420732,0.00012446834,0.0005304459,0.000034765515,0.000038953778,0.0000034965378,0.00020977916,0.00023236191,0.000027826894],"category_scores_gemma":[0.00057550566,0.00006971754,0.00008644704,0.00013450437,0.0004631709,0.000008219763,0.000097941345,0.000320842,7.1056684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014961062,0.0025878272,0.6090434,0.000022493512,0.0018601816,0.000031274107,0.000590957,0.00018017189,0.015589215,0.000021396587,0.0010988596,0.35401312],"study_design_scores_gemma":[0.004828032,0.009181287,0.98320013,0.000105931416,0.0003623805,0.00014275884,0.00015369509,0.000007843857,0.001189056,0.00012224948,0.0006302771,0.00007637749],"about_ca_topic_score_codex":0.000028975006,"about_ca_topic_score_gemma":0.0004393215,"teacher_disagreement_score":0.37415668,"about_ca_system_score_codex":0.0003236583,"about_ca_system_score_gemma":0.002974347,"threshold_uncertainty_score":0.5276364},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2805678476","doi":"10.1200/jco.2018.36.7_suppl.6","title":"Patterns and predictors of attendance at a comprehensive, multi-disciplinary supportive care program for men with prostate cancer and their partners.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Attendance; Logistic regression; Prostate cancer; Family medicine; Gerontology; Demography; Cancer; Internal medicine","score_opus":0.48244723385486543,"score_gpt":0.5704298255786098,"score_spread":0.08798259172374434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805678476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852977,0.0022274717,0.00032228223,0.010051002,0.00045441458,0.0010100611,0.0004662846,0.000007676023,0.00016310549],"genre_scores_gemma":[0.9910524,0.0009176445,0.0055591436,0.001502277,0.0006774099,0.000100832425,0.000009540496,0.000022459759,0.00015827359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943681,0.0002632297,0.0047196066,0.00032800427,0.00006147602,0.0002596315],"domain_scores_gemma":[0.98993325,0.00220322,0.006902337,0.00015790905,0.00053505483,0.00026823752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005348501,0.00015277024,0.0018597937,0.000109308254,0.00010800787,0.000013175875,0.00013151269,0.00019980819,0.000028948625],"category_scores_gemma":[0.0010987781,0.00012109095,0.00013775386,0.000055804998,0.00050248916,0.00020772839,0.00008929828,0.00022654817,0.0000035104647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012769081,0.00028085918,0.9806765,0.0004653829,0.00033123634,0.0000032171727,0.006654398,0.000011691439,0.0000022790725,0.00012106655,0.0036921396,0.006484365],"study_design_scores_gemma":[0.0058634407,0.01071991,0.9297713,0.00021491121,0.000045453675,0.000027273843,0.005727147,0.0015849519,0.000013426884,0.00032508784,0.045542695,0.00016439125],"about_ca_topic_score_codex":0.00012167313,"about_ca_topic_score_gemma":0.0010520951,"teacher_disagreement_score":0.050905146,"about_ca_system_score_codex":0.00020835048,"about_ca_system_score_gemma":0.00048239273,"threshold_uncertainty_score":0.49379456},"labels":[],"label_agreement":null},{"id":"W2805689283","doi":"10.1200/jco.2017.76.5180","title":"Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children; Rigshospitalet; Lunds Universitet; Newcastle University; Aarhus Universitetshospital; Ankara Universitesi; Gentofte Hospital; University of Bern; Aarhus Universitet; National Cancer Institute; University of Toronto; Univerzita Karlova v Praze","keywords":"Survivorship curve; Medicine; Childhood cancer; Health care; Family medicine; Population; Cancer survivorship; Cancer survivor; Cancer; Pediatric cancer; Gerontology; Environmental health; Economic growth","score_opus":0.2409461504659584,"score_gpt":0.5393194386638476,"score_spread":0.29837328819788916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805689283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02856461,0.96241707,0.00013003187,0.0020230855,0.003627627,0.002135118,0.0008058731,0.000008579105,0.0002880194],"genre_scores_gemma":[0.030266987,0.9603609,0.0011484437,0.0015564708,0.0063969144,0.0000834061,0.00007024348,0.000103730876,0.000012895297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9837042,0.004491307,0.0091624195,0.0006175096,0.0013124961,0.0007120874],"domain_scores_gemma":[0.9591466,0.02659541,0.010853538,0.0011516649,0.0019163243,0.00033642273],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.014109991,0.000637074,0.01013438,0.00019030199,0.0001244095,0.00002357013,0.0019233236,0.0016518013,0.000041131945],"category_scores_gemma":[0.009267947,0.00034237507,0.0039080684,0.00062790373,0.0008404092,0.00020281268,0.0002619451,0.0031789131,0.0000023476812],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020312634,0.0010237261,0.002857522,0.016236847,0.0018335149,0.000047025835,0.03370087,0.00008690342,2.4004441e-7,0.0000754019,0.0011998686,0.9409068],"study_design_scores_gemma":[0.0062964414,0.008303608,0.0049486314,0.034548756,0.005309062,0.00010877382,0.027877795,0.000016216878,0.000005518934,0.0007046581,0.91143405,0.0004465122],"about_ca_topic_score_codex":0.0067533734,"about_ca_topic_score_gemma":0.09985205,"teacher_disagreement_score":0.9404603,"about_ca_system_score_codex":0.00057790545,"about_ca_system_score_gemma":0.009294923,"threshold_uncertainty_score":0.99990284},"labels":[],"label_agreement":null},{"id":"W2805854983","doi":"10.1200/jco.2018.36.7_suppl.20","title":"Educating primary care providers about cancer survivorship.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Psychosocial; Cancer survivorship; Cancer; Likert scale; Patient satisfaction; Gerontology; Nursing; Internal medicine; Psychology; Psychiatry","score_opus":0.1079131999386521,"score_gpt":0.4831236211258979,"score_spread":0.3752104211872458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805854983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92919546,0.0050898953,0.000053843123,0.008995456,0.012122965,0.00020016741,0.000005286171,0.000018967823,0.044317957],"genre_scores_gemma":[0.97481334,0.00082172005,0.001098733,0.010528824,0.011694901,0.000008507126,0.0000040088503,0.00002890531,0.001001053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967654,0.0003886168,0.0018633972,0.0002276334,0.00044308807,0.0003118951],"domain_scores_gemma":[0.99510574,0.0011315665,0.0014476682,0.00024425337,0.0015734703,0.00049731694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021830075,0.0001525783,0.0012891522,0.0001135139,0.000072743256,0.00001566289,0.00021450501,0.00039821226,0.00047083487],"category_scores_gemma":[0.0017837458,0.00011219464,0.0005385854,0.00020215368,0.00039264082,0.00013368118,0.000058839338,0.0010980015,0.00002978213],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026898105,0.0004416973,0.34593514,0.0002628289,0.0002794049,0.0001488875,0.0034860487,0.0000011681933,0.00015800424,0.000052670406,0.0128477365,0.6336966],"study_design_scores_gemma":[0.004430545,0.010335307,0.4497893,0.00067776104,0.0005650528,0.00027689844,0.0048901564,0.000006633373,0.00025751817,0.00013755211,0.5284285,0.00020481685],"about_ca_topic_score_codex":0.0014952843,"about_ca_topic_score_gemma":0.00929344,"teacher_disagreement_score":0.6334918,"about_ca_system_score_codex":0.00048661686,"about_ca_system_score_gemma":0.0072434437,"threshold_uncertainty_score":0.99838454},"labels":[],"label_agreement":null},{"id":"W2805859670","doi":"10.1200/jco.2018.36.7_suppl.18","title":"Breast cancer survivors' self-reported outcomes following an end of treatment group intervention.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Survivorship curve; Medicine; Psychological intervention; Feeling; Family medicine; Descriptive statistics; Patient satisfaction; Gerontology; Cancer; Physical therapy; Nursing; Psychology; Internal medicine","score_opus":0.10017089555942911,"score_gpt":0.49289944759177384,"score_spread":0.39272855203234475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805859670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903884,0.0003227302,0.000099590514,0.0035800359,0.0040267496,0.00026337907,0.000014923105,0.00002274696,0.0012814613],"genre_scores_gemma":[0.9964016,0.00052346144,0.0008635549,0.0005123207,0.0013274087,0.000010071055,0.0000032600515,0.00002042129,0.00033786544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596924,0.00041882333,0.0028031792,0.00021870826,0.00034980619,0.00024027204],"domain_scores_gemma":[0.9951958,0.0010289971,0.002421913,0.00019276941,0.0008585612,0.00030195664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022549697,0.00018612255,0.0018375565,0.00016695572,0.000059004673,0.0000053295153,0.00010792461,0.00025269,0.0005497398],"category_scores_gemma":[0.0008429264,0.00012184371,0.0011736484,0.00016671173,0.0003053345,0.00016545889,0.000051611936,0.00039284473,0.000008803349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024132982,0.0049434546,0.82402116,0.000021186099,0.0078698145,0.00027315554,0.00033317463,9.3803146e-7,0.00008723274,0.0000137095485,0.00035811926,0.15966474],"study_design_scores_gemma":[0.014569932,0.0363851,0.9365403,0.00025053765,0.0035575603,0.00039668346,0.00040170102,0.000027944045,0.000071773145,0.000089153065,0.007605797,0.00010350244],"about_ca_topic_score_codex":0.0010583361,"about_ca_topic_score_gemma":0.003334218,"teacher_disagreement_score":0.15956123,"about_ca_system_score_codex":0.00062692736,"about_ca_system_score_gemma":0.00089374423,"threshold_uncertainty_score":0.60192657},"labels":[],"label_agreement":null},{"id":"W2805860863","doi":"10.1200/jco.2017.35.15_suppl.7032","title":"Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from a randomized phase III study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Gastroenterology; Febrile neutropenia; Refractory (planetary science); Anemia; Cumulative incidence; Randomized controlled trial; Chemotherapy; Transplantation","score_opus":0.0510083162225245,"score_gpt":0.4186300855709411,"score_spread":0.3676217693484166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805860863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950408,0.0001274614,0.000414438,0.00057505746,0.00095356745,0.0024006655,0.0000423862,0.000016027536,0.00042961288],"genre_scores_gemma":[0.9956785,0.00019490572,0.0030649134,0.0004407715,0.00039504815,0.00003968717,0.000020874932,0.00007181781,0.00009347918],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911609,0.0013759597,0.004456522,0.00059153367,0.0018026499,0.00061240187],"domain_scores_gemma":[0.9872586,0.0042201,0.00478965,0.0009761055,0.0018493736,0.0009061645],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003892738,0.0004469225,0.0061962623,0.0004841417,0.000119592136,0.0000188366,0.0010050518,0.0005955226,0.00009654219],"category_scores_gemma":[0.008927808,0.0003074518,0.00072040065,0.00022023034,0.00056278927,0.00032918813,0.0003159182,0.0016076856,0.000018724193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.79533106,0.0066993553,0.17074035,0.00005277906,0.0030233096,0.0014418272,0.0028814112,0.00007845899,0.000081688835,0.000002894993,0.0005576224,0.019109262],"study_design_scores_gemma":[0.7319531,0.06646313,0.19645108,0.0007501507,0.0016679196,0.000033525455,0.001345889,0.0004810706,0.00013281991,0.000023235527,0.00047084567,0.00022726551],"about_ca_topic_score_codex":0.00032893685,"about_ca_topic_score_gemma":0.00045954547,"teacher_disagreement_score":0.06337798,"about_ca_system_score_codex":0.0039102295,"about_ca_system_score_gemma":0.0070212656,"threshold_uncertainty_score":0.9999378},"labels":[],"label_agreement":null},{"id":"W2805900669","doi":"10.1200/jco.2018.36.7_suppl.67","title":"The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; University of Calgary; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Cancer; Internal medicine; Mastectomy; Anxiety; Incidence (geometry); Psychiatry","score_opus":0.11857133554428409,"score_gpt":0.5176051289782942,"score_spread":0.39903379343401013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805900669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701166,0.00028729686,0.0000038673834,0.0016024526,0.00027410747,0.00019869982,0.000060719114,6.6384257e-7,0.0005605537],"genre_scores_gemma":[0.99870914,0.0005287619,0.000016438467,0.00036736723,0.00034184047,0.000009493663,0.0000011074388,0.000005778352,0.00002008429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695677,0.0008767894,0.0016344357,0.00008243446,0.00032474822,0.00012482381],"domain_scores_gemma":[0.99347484,0.0033600628,0.0020358125,0.00019757511,0.00082412764,0.00010758799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017958073,0.000094087496,0.001083068,0.000041897834,0.000015266369,0.000002170092,0.00013749361,0.00012313265,0.000114776325],"category_scores_gemma":[0.001073779,0.000034670556,0.00041257348,0.00015833587,0.000652757,0.0000483277,0.000016663382,0.0002795779,4.4891775e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02851817,0.0019053436,0.9401372,0.000015589738,0.00043860296,0.000027373044,0.003424358,0.0000020508762,0.000012888904,0.000009976657,0.0004062678,0.025102163],"study_design_scores_gemma":[0.00711537,0.022854237,0.9678356,0.00010358942,0.00014469154,0.0000056845424,0.001129025,0.0000018978924,0.00002556032,0.000042985663,0.0007084862,0.00003288809],"about_ca_topic_score_codex":0.004024589,"about_ca_topic_score_gemma":0.027759291,"teacher_disagreement_score":0.027698368,"about_ca_system_score_codex":0.00014075288,"about_ca_system_score_gemma":0.0015371521,"threshold_uncertainty_score":0.9899816},"labels":[],"label_agreement":null},{"id":"W2805918900","doi":"10.1200/jco.2018.36.7_suppl.97","title":"Body mass index (BMI), health behaviors, and perceptions in cancer survivors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Body mass index; Obesity; Cancer; Logistic regression; Smoking cessation; Quality of life (healthcare); Internal medicine; Alcohol consumption; Moderation; Alcohol intake; Physical therapy; Alcohol; Pathology","score_opus":0.20225864274381664,"score_gpt":0.5856274932374544,"score_spread":0.3833688504936378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805918900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93578285,0.0005158612,0.00014488302,0.06112942,0.0014810084,0.00015036172,0.000003412543,0.000006970661,0.00078521494],"genre_scores_gemma":[0.97714514,0.005756551,0.0028302285,0.011995814,0.0020546655,0.0000037766142,0.000001152188,0.00000985375,0.00020280555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723446,0.00037611797,0.0018272544,0.00013160564,0.0001965376,0.00023401303],"domain_scores_gemma":[0.99788237,0.00043222052,0.00078600144,0.00009277529,0.00028413124,0.0005225024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034562147,0.00007502577,0.0009622458,0.00019030733,0.0000623912,0.000005158069,0.00006163342,0.0002453821,0.0005805491],"category_scores_gemma":[0.00048663522,0.00005862445,0.00010977634,0.00013480349,0.00026323387,0.00006453043,0.00002066673,0.0010501026,0.000010861378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006179534,0.0006973154,0.94472253,0.000045139375,0.000016194788,0.0000692087,0.0001235203,2.0050395e-7,0.000059387316,0.0000716843,0.00559568,0.0479812],"study_design_scores_gemma":[0.0042421045,0.005437351,0.905152,0.00020933252,0.000032345964,0.00015373944,0.0002417571,0.00006065815,0.0000023578134,0.000335025,0.0840883,0.00004497299],"about_ca_topic_score_codex":0.00069412205,"about_ca_topic_score_gemma":0.0037498423,"teacher_disagreement_score":0.07849263,"about_ca_system_score_codex":0.000231821,"about_ca_system_score_gemma":0.0017849534,"threshold_uncertainty_score":0.6356605},"labels":[],"label_agreement":null},{"id":"W2806062198","doi":"10.1200/jco.2018.36.18_suppl.lba3579","title":"Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; FOLFOX; Bevacizumab; Regimen; Internal medicine; FOLFIRI; Demography; Cancer; Chemotherapy regimen; Cancer registry; Chemotherapy; Surgery; Irinotecan; Oxaliplatin","score_opus":0.09675852131450305,"score_gpt":0.3867445359728928,"score_spread":0.2899860146583898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806062198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800414,0.0005576909,0.00004101073,0.00025425557,0.00048703267,0.00017991906,0.00005088985,0.0000013521491,0.0004237092],"genre_scores_gemma":[0.9980314,0.0010363022,0.0004377866,0.00029505926,0.00012418958,0.000003192166,8.0933455e-7,0.000013053851,0.00005824905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749833,0.00006651831,0.002014894,0.00018821827,0.000041599436,0.00019043483],"domain_scores_gemma":[0.99724215,0.0005277043,0.001923806,0.000062296225,0.00012461454,0.000119437034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015836128,0.000080615435,0.001548586,0.00009497163,0.000020935508,0.000058755733,0.000105762156,0.00015589835,0.00008650476],"category_scores_gemma":[0.00058025296,0.00009872142,0.00005726144,0.00010275256,0.0003531867,0.00038003587,0.000031120377,0.00034895126,0.0000012295092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008174334,0.00048264264,0.95289415,0.000011175444,0.000060106355,0.000005212879,0.00021868548,0.000009582236,4.036824e-7,0.000060976596,0.00018597284,0.045253687],"study_design_scores_gemma":[0.007792982,0.003815239,0.9814939,0.00007501052,0.0000114552395,0.0000032539415,0.000038343886,0.00012791893,0.0000020786701,0.0006150717,0.0059189717,0.00010578413],"about_ca_topic_score_codex":0.007528745,"about_ca_topic_score_gemma":0.16614614,"teacher_disagreement_score":0.1586174,"about_ca_system_score_codex":0.00012001497,"about_ca_system_score_gemma":0.00018437843,"threshold_uncertainty_score":0.9990802},"labels":[],"label_agreement":null},{"id":"W2806064604","doi":"10.1200/jco.2018.36.18_suppl.lba4008","title":"Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Esomeprazole; Aspirin; Internal medicine; Interquartile range; Randomized controlled trial; Clinical endpoint; Gastroenterology; Proton-pump inhibitor; Esophageal cancer; Dysplasia; Cancer; Esophagus; Surgery","score_opus":0.11167045525514369,"score_gpt":0.5129507413602011,"score_spread":0.40128028610505745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806064604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98994076,0.0052166805,0.0000641355,0.0026573325,0.00040116181,0.0012634039,0.0000035410592,0.0000025533382,0.00045045294],"genre_scores_gemma":[0.9927172,0.0047543235,0.00023342433,0.0003147611,0.0019041792,0.000022115417,0.0000017307234,0.000008258961,0.000043989912],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968431,0.0009617921,0.0014632021,0.0001614065,0.00039729677,0.00017322275],"domain_scores_gemma":[0.99524546,0.0032129243,0.0009928521,0.0001305057,0.0002293544,0.00018891523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006320164,0.00011967524,0.0016764236,0.000093700706,0.000040119983,0.000009388211,0.000092186296,0.00015251238,0.00014130642],"category_scores_gemma":[0.0011852373,0.000055505654,0.00020482858,0.00012966673,0.0006814024,0.00007651639,0.000023670447,0.0005596404,6.698826e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8423569,0.002437915,0.0039919037,0.000014514427,0.0005179739,0.00019668852,0.00033061157,4.1689736e-7,0.000041200998,0.00008065665,0.00010122088,0.14993],"study_design_scores_gemma":[0.90526694,0.049103495,0.042966817,0.00009379692,0.00029640336,0.00007176017,0.000046986555,0.000015896552,0.00034969125,0.00032215816,0.0014228188,0.00004323418],"about_ca_topic_score_codex":0.000117045,"about_ca_topic_score_gemma":0.00012699718,"teacher_disagreement_score":0.14988676,"about_ca_system_score_codex":0.00007691398,"about_ca_system_score_gemma":0.0009653614,"threshold_uncertainty_score":0.25106555},"labels":[],"label_agreement":null},{"id":"W2806103948","doi":"10.1200/jco.2018.78.5204","title":"Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Germline; Mesothelioma; Medicine; Cancer research; Germline mutation; Gene; Cancer; Oncology; Genetics; Mutation; Internal medicine; Pathology; Biology","score_opus":0.11855703223085112,"score_gpt":0.4889699949414306,"score_spread":0.3704129627105795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806103948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957644,0.00072279276,0.000011320381,0.002514351,0.0003203529,0.00010009755,0.000012599384,0.0000016124252,0.0005525182],"genre_scores_gemma":[0.99669653,0.00043464827,0.0018336553,0.0005471813,0.00041516725,0.000003204126,0.0000030731746,0.0000053898916,0.00006115542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769825,0.00018566003,0.0016929957,0.00011139321,0.00020015017,0.00011156921],"domain_scores_gemma":[0.99843824,0.00055378064,0.0006422848,0.00009517444,0.0001373388,0.00013318374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011444374,0.000064472035,0.0006362025,0.00013425059,0.000009920985,9.74854e-7,0.00007367722,0.00013333865,0.0007947892],"category_scores_gemma":[0.00092666043,0.000045115026,0.00017480878,0.00015100121,0.0003645205,0.000062853265,0.000020984517,0.00021814575,0.000010227864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097062736,0.0022701414,0.96634233,0.000021328735,0.000041680007,0.00012805358,0.00005655023,0.000024518708,0.0049023735,0.000073327355,0.00010279804,0.025066253],"study_design_scores_gemma":[0.0028105974,0.0029293045,0.99092734,0.0001081401,0.00007685983,0.000028063801,0.00006517061,0.000066213295,0.0005744645,0.0018406113,0.0005330688,0.00004017317],"about_ca_topic_score_codex":0.00031398874,"about_ca_topic_score_gemma":0.0021398051,"teacher_disagreement_score":0.02502608,"about_ca_system_score_codex":0.00015250246,"about_ca_system_score_gemma":0.00073195365,"threshold_uncertainty_score":0.8702384},"labels":[],"label_agreement":null},{"id":"W2806124324","doi":"10.1200/jco.2018.36.4_suppl.426","title":"Baseline anemia in patients with biliary tract cancer (BTC) and its association with survival: A retrospective cohort study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anemia; Internal medicine; Proportional hazards model; Gastroenterology; Cohort; Hemoglobin; Cancer; Retrospective cohort study; Univariate analysis; Multivariate analysis","score_opus":0.0377582344687395,"score_gpt":0.4013489959360343,"score_spread":0.3635907614672948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806124324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691576,0.00006677507,0.000004812574,0.0012079978,0.00052964396,0.0007775389,0.000010933002,0.000009324775,0.00047722552],"genre_scores_gemma":[0.99816275,0.000094995,0.00041004192,0.00052099995,0.0007199,0.000017205299,0.0000027612434,0.000020805484,0.0000505672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966122,0.00076811103,0.0013767129,0.00026761036,0.0007534018,0.00022195824],"domain_scores_gemma":[0.9948608,0.0011633127,0.001761057,0.00013568738,0.001803721,0.00027539706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006770399,0.00014988429,0.0012174484,0.00014610671,0.000040478782,0.000008400615,0.000085082655,0.0002828065,0.00013874096],"category_scores_gemma":[0.004678189,0.000093306815,0.0000874561,0.00025678848,0.00014430532,0.00015938419,0.000031026324,0.0007548606,0.0000033082865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017130978,0.0039277957,0.9735675,0.000020255922,0.00062634953,0.00027075995,0.000108404995,6.6591446e-7,0.0000035530104,0.0000014748,0.00070151646,0.0036407697],"study_design_scores_gemma":[0.016433708,0.02182535,0.9601599,0.0001435148,0.00083371473,0.000011897838,0.00007936263,0.000042564527,0.0000142313775,0.000009654214,0.00034110737,0.000105023406],"about_ca_topic_score_codex":0.00003376088,"about_ca_topic_score_gemma":0.000527126,"teacher_disagreement_score":0.017897556,"about_ca_system_score_codex":0.0007927953,"about_ca_system_score_gemma":0.0011759194,"threshold_uncertainty_score":0.5600567},"labels":[],"label_agreement":null},{"id":"W2806145489","doi":"10.1200/jco.2018.36.18_suppl.lba9000","title":"IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Carboplatin; Atezolizumab; Paclitaxel; Internal medicine; Docetaxel; Oncology; Population; Chemotherapy; Cisplatin; Cancer; Nivolumab; Immunotherapy","score_opus":0.053843135627837414,"score_gpt":0.4520079957856368,"score_spread":0.39816486015779934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806145489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896818,0.0043063443,0.000088044,0.0012151783,0.0007982283,0.0021899163,0.000051250066,0.000017084598,0.00165219],"genre_scores_gemma":[0.9918438,0.0050294464,0.0011500231,0.0012082888,0.00041451483,0.00003872621,0.00001591013,0.000050719147,0.00024852672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98567694,0.0027981054,0.0092457915,0.0006395704,0.0010674428,0.0005721409],"domain_scores_gemma":[0.98090667,0.009990628,0.0066978545,0.00073553895,0.0012006421,0.00046868128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013595607,0.0005284454,0.009121289,0.0011735564,0.00009209454,0.000016387417,0.00040244334,0.0007392917,0.0004723084],"category_scores_gemma":[0.0072084945,0.00034956128,0.001902603,0.0016495265,0.0014979689,0.0002364259,0.00012070822,0.001204257,0.0000015219201],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84618425,0.010048503,0.015650153,0.00007304301,0.009213973,0.00038748514,0.004483425,0.000017901844,0.004506634,0.000019183448,0.00016113122,0.1092543],"study_design_scores_gemma":[0.765241,0.10676883,0.11522012,0.00031507225,0.0047498727,0.00017775699,0.0041320957,0.00050994795,0.000395301,0.00013260865,0.0019842612,0.00037308867],"about_ca_topic_score_codex":0.0015372565,"about_ca_topic_score_gemma":0.0017876719,"teacher_disagreement_score":0.10888121,"about_ca_system_score_codex":0.0004420983,"about_ca_system_score_gemma":0.0026316165,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W2806173865","doi":"10.1200/jco.2018.36.4_suppl.633","title":"The Association of <i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Internal medicine; Hazard ratio; Genotype; Colorectal cancer; Oncology; Progression-free survival; Genotyping; Gastroenterology; Cancer; Chemotherapy; Confidence interval; Biology; Gene; Genetics","score_opus":0.04723861465880604,"score_gpt":0.4243349544137173,"score_spread":0.3770963397549113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806173865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294376,0.00077698857,0.0000024000153,0.0047167763,0.00032776024,0.0004049899,0.000029250212,0.0000036057652,0.0007944568],"genre_scores_gemma":[0.99742377,0.001473662,0.0001392491,0.00054690865,0.00017936468,0.000019260126,0.000003762848,0.000009228333,0.0002048071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719685,0.0003990868,0.0016036467,0.00018405699,0.00039970916,0.00021662792],"domain_scores_gemma":[0.9944878,0.0026757533,0.0019855315,0.00008408555,0.00062214566,0.00014465442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016107127,0.00015878306,0.002043945,0.00015223828,0.00008846204,0.000013685942,0.00006716121,0.00013293477,0.000017027964],"category_scores_gemma":[0.00161009,0.000078238714,0.00025383587,0.00035598443,0.0004620031,0.00008192382,0.000033031127,0.00032962466,4.7578484e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05517724,0.0015410897,0.92480165,0.000006693152,0.004836485,0.000032587108,0.00023842955,7.779798e-7,0.000022508484,0.000009105174,0.000557835,0.012775624],"study_design_scores_gemma":[0.08060505,0.03597508,0.8769531,0.000028930486,0.0039337007,0.0000071460895,0.00012858976,0.00002324611,0.00008349586,0.00003725367,0.002152417,0.000071942624],"about_ca_topic_score_codex":0.00028931326,"about_ca_topic_score_gemma":0.007027086,"teacher_disagreement_score":0.047848485,"about_ca_system_score_codex":0.00027419708,"about_ca_system_score_gemma":0.0004690626,"threshold_uncertainty_score":0.3921279},"labels":[],"label_agreement":null},{"id":"W2806196841","doi":"10.1200/jco.2018.36.7_suppl.104","title":"Effect and moderators of exercise on fatigue in patients with cancer: Meta-analysis of individual patient data.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cancer-related fatigue; Meta-analysis; Randomized controlled trial; Physical therapy; Exercise prescription; Random effects model; Rehabilitation; Body mass index; Cancer; Internal medicine","score_opus":0.19065806810151437,"score_gpt":0.47704489170128345,"score_spread":0.2863868235997691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806196841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99836165,0.0006511325,0.00002119778,0.00025793866,0.0002805154,0.00019850829,0.00011462127,0.0000012514477,0.0001131697],"genre_scores_gemma":[0.9991985,0.00013430258,0.00021273392,0.00034975243,0.00007180104,0.000004088567,0.00001582988,0.000007895699,0.000005093564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970201,0.00046643085,0.0016134449,0.00019731709,0.0005841804,0.000118508826],"domain_scores_gemma":[0.9960772,0.0012955916,0.0016417003,0.00032057596,0.0004997209,0.00016523691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024315673,0.000117788,0.002889045,0.00031834503,0.000012122289,0.0000031441405,0.00017203562,0.00017411554,0.0001274836],"category_scores_gemma":[0.00061618857,0.00006625636,0.00041132848,0.0003872055,0.00024596305,0.00007532496,0.00007886777,0.0003773767,2.4609676e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014526176,0.0014042417,0.82198924,0.00006878475,0.036361855,0.000021347432,0.0007023949,0.00009514955,0.0000018714597,0.00000735638,0.0003978902,0.12442372],"study_design_scores_gemma":[0.007286874,0.059200544,0.7719066,0.00012934949,0.16026372,0.0000013298685,0.000118946584,0.00015570484,0.00024429525,0.000013846162,0.00058070594,0.000098083096],"about_ca_topic_score_codex":0.0002632321,"about_ca_topic_score_gemma":0.0016005486,"teacher_disagreement_score":0.12432563,"about_ca_system_score_codex":0.000040772753,"about_ca_system_score_gemma":0.0004219176,"threshold_uncertainty_score":0.27018562},"labels":[],"label_agreement":null},{"id":"W2806222490","doi":"10.1200/jco.2018.36.7_suppl.22","title":"Engaging breast cancer survivors in their survivorship care.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Survivorship curve; Psychological intervention; Breast cancer; Family medicine; Quality of life (healthcare); Health care; Gerontology; Wilcoxon signed-rank test; Patient satisfaction; Cancer; Internal medicine; Nursing; Mann–Whitney U test","score_opus":0.11606435223613785,"score_gpt":0.4604397603526909,"score_spread":0.34437540811655304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806222490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97288686,0.0016855062,0.000053539487,0.007978618,0.007428269,0.00013802385,0.000015720545,0.000015737929,0.009797714],"genre_scores_gemma":[0.98969483,0.0009243608,0.00013958603,0.0032800662,0.005746056,0.0000050423346,0.0000019237373,0.000029120627,0.00017903728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959593,0.00093127077,0.002071672,0.00025756613,0.0003898176,0.00039038304],"domain_scores_gemma":[0.9953657,0.0018285674,0.0010120359,0.00026754415,0.0010824294,0.00044375026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004835951,0.00019072156,0.0015490002,0.00024693564,0.000053978667,0.000012412876,0.0002633822,0.00045264736,0.000610305],"category_scores_gemma":[0.0010364796,0.00013433573,0.0005215998,0.0003935982,0.0003813896,0.00013254871,0.00006896871,0.0016138222,0.00002190543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029616281,0.00035371972,0.72082555,0.00004872728,0.00012943796,0.00025315996,0.0030123638,0.0000031016355,0.00006809956,0.00005450253,0.00056746753,0.27172226],"study_design_scores_gemma":[0.0043550585,0.0034631477,0.85932624,0.00032310293,0.00014575361,0.0004370134,0.0062533314,0.000034388366,0.00015763992,0.00018486733,0.12514548,0.00017397279],"about_ca_topic_score_codex":0.0063750762,"about_ca_topic_score_gemma":0.15971155,"teacher_disagreement_score":0.27154827,"about_ca_system_score_codex":0.0003663669,"about_ca_system_score_gemma":0.0022619944,"threshold_uncertainty_score":0.9637251},"labels":[],"label_agreement":null},{"id":"W2806278428","doi":"10.1200/jco.2018.36.7_suppl.1","title":"Evaluating the impact of survivorship models on health system resources and costs.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Survivorship curve; Health care; Breast cancer; Cancer; Family medicine; Cancer registry; Demography; Emergency medicine; Gerontology; Internal medicine","score_opus":0.6172811653107226,"score_gpt":0.6332038180234433,"score_spread":0.015922652712720642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806278428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875373,0.0008797627,0.00011958547,0.0053280415,0.00034097632,0.00014362602,0.0000021616022,0.000004493468,0.0056440006],"genre_scores_gemma":[0.99615455,0.00015956836,0.00088892394,0.0015333435,0.0012348434,7.4013735e-7,1.9819451e-7,0.0000066893267,0.000021125643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964652,0.0010893085,0.0016735098,0.00011686478,0.00046679605,0.0001883082],"domain_scores_gemma":[0.9938335,0.0030976047,0.0020122884,0.00017265217,0.0006008874,0.00028306656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015126057,0.00008576877,0.001031536,0.000060022358,0.00007408588,0.00000736036,0.00014198305,0.00015191853,0.000015840027],"category_scores_gemma":[0.0034325977,0.00004213643,0.00029009423,0.000112824375,0.00030047496,0.00006473518,0.000036129422,0.00059485366,0.0000027360713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03165489,0.0006091156,0.18087639,0.00013557845,0.00079722865,0.00013149159,0.0022916389,0.0012671952,0.0001487409,0.0018734594,0.0087892795,0.771425],"study_design_scores_gemma":[0.009289166,0.32374823,0.6212267,0.003074909,0.00036857475,0.0015602658,0.004057645,0.033853337,0.00003650999,0.0012629672,0.0013690247,0.0001526262],"about_ca_topic_score_codex":0.0013420302,"about_ca_topic_score_gemma":0.0001803114,"teacher_disagreement_score":0.77127236,"about_ca_system_score_codex":0.0003078813,"about_ca_system_score_gemma":0.0014276939,"threshold_uncertainty_score":0.524242},"labels":[],"label_agreement":null},{"id":"W2806346499","doi":"10.1200/jco.2018.36.7_suppl.71","title":"Facilitating patient communication through understanding their social media use: A comparison by age groups.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Social media; Demographics; Young adult; Gerontology; Quality of life (healthcare); Cancer; The Internet; Affect (linguistics); Demography; Family medicine; Internal medicine; Psychology; Nursing","score_opus":0.7098657691992568,"score_gpt":0.5986809628980633,"score_spread":0.11118480630119354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806346499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624208,0.00042512617,0.0019940708,0.018110266,0.012067216,0.0004263255,0.000012169179,0.000030147618,0.004513882],"genre_scores_gemma":[0.9892214,0.0005174034,0.005297708,0.0011149994,0.0038055999,0.000015350244,0.000008948265,0.000012118158,0.0000064913297],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924277,0.0040610596,0.0023761285,0.00015744256,0.0006117313,0.00036590316],"domain_scores_gemma":[0.9385491,0.057454176,0.0030222381,0.00014285307,0.0005613872,0.00027022147],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0073736133,0.000112809925,0.000857301,0.00006014065,0.00093664933,0.00006032413,0.0004249555,0.00054569496,0.0001002548],"category_scores_gemma":[0.057657927,0.000098825716,0.00022406394,0.0003141364,0.0018415991,0.00053552206,0.000063179534,0.0010109525,0.000015006973],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034607458,0.00090070214,0.020954909,0.000010048217,0.000090148314,0.000004777398,0.687835,7.592374e-7,0.000027728898,0.017545547,0.04337403,0.22891031],"study_design_scores_gemma":[0.0015637004,0.002349026,0.02159718,0.00007671952,0.00007712938,0.0000025595582,0.33765304,0.000028905913,0.000019910662,0.035184152,0.6012361,0.00021154371],"about_ca_topic_score_codex":0.0009623294,"about_ca_topic_score_gemma":0.0047281585,"teacher_disagreement_score":0.5578621,"about_ca_system_score_codex":0.0011964245,"about_ca_system_score_gemma":0.0015507527,"threshold_uncertainty_score":0.95027983},"labels":[],"label_agreement":null},{"id":"W2806368367","doi":"10.1200/jco.2017.35.15_suppl.3601","title":"Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Bevacizumab; FOLFIRI; Colorectal cancer; Internal medicine; Multivariate analysis; Oncology; Nuclear medicine; Gastroenterology; Radiology; Chemotherapy; Cancer; Irinotecan","score_opus":0.05780382940564195,"score_gpt":0.4582889742829536,"score_spread":0.4004851448773117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806368367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314684,0.00025841096,0.0029318843,0.002372189,0.0007082963,0.0003709058,0.00003919176,0.0000062288127,0.000166034],"genre_scores_gemma":[0.9972911,0.00028396535,0.0016619316,0.0002807327,0.0003666258,0.000007711703,0.000018443103,0.0000168114,0.000072662064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735904,0.00027940754,0.0015460079,0.00025363648,0.00029972682,0.0002621865],"domain_scores_gemma":[0.9963045,0.0010616719,0.0018597363,0.00014393283,0.0003293696,0.00030078206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002531917,0.00015077736,0.0017164664,0.00018314543,0.00014021203,0.000036044352,0.00014315992,0.00014588043,0.00004224172],"category_scores_gemma":[0.0066474024,0.00010916306,0.00037330255,0.000121085825,0.00025004882,0.00015833678,0.000029621991,0.00086447614,3.2464632e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004049487,0.000884748,0.8867348,0.000030487963,0.0017885483,0.00007310697,0.00007393425,0.00012180231,0.00093123567,0.0000064059886,0.0005396926,0.10476574],"study_design_scores_gemma":[0.022045694,0.004484478,0.9316526,0.000092707494,0.0035338684,0.000028140943,0.000036289293,0.036396217,0.00014559628,0.00007782599,0.0014045819,0.00010198062],"about_ca_topic_score_codex":0.00025923204,"about_ca_topic_score_gemma":0.00022637864,"teacher_disagreement_score":0.10466376,"about_ca_system_score_codex":0.00021064497,"about_ca_system_score_gemma":0.00044495324,"threshold_uncertainty_score":0.79580414},"labels":[],"label_agreement":null},{"id":"W2806406177","doi":"10.1200/jco.2018.36.7_suppl.112","title":"Implementation of an electronic referral smoking cessation tool into clinical practice across cancer clinics of different disease sites and institutions.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Centre for Addiction and Mental Health; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; McGill University; University of Toronto","funders":"","keywords":"Medicine; Referral; Smoking cessation; Family medicine; Cancer; Health care; Physical therapy; Internal medicine","score_opus":0.40035266448062035,"score_gpt":0.6723005316665276,"score_spread":0.27194786718590724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806406177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98625547,0.00032537457,0.0013997555,0.010174681,0.0013460908,0.00041137653,0.000029989647,0.000009825612,0.000047454],"genre_scores_gemma":[0.98307604,0.003583647,0.007564511,0.0033333425,0.0023608622,0.000008166939,0.000045797347,0.000019756511,0.000007865356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98829925,0.0015457139,0.00878904,0.00035232198,0.000702206,0.00031145077],"domain_scores_gemma":[0.9785017,0.009073602,0.008740563,0.0003447541,0.0028878022,0.00045161237],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014970313,0.00018554257,0.0014547363,0.0001245418,0.00010295572,0.000017665978,0.00018890393,0.00036636047,0.00017167507],"category_scores_gemma":[0.045616303,0.00014536752,0.00039957112,0.00022272281,0.0007985086,0.0010007038,0.00013457445,0.0011656517,0.0000017523143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009293413,0.00209402,0.556505,0.00006945338,0.0004715569,0.000021760326,0.00032447604,0.0000073027363,0.00021886722,0.0005972163,0.00033551766,0.43006137],"study_design_scores_gemma":[0.012982629,0.022758152,0.93331903,0.000119596116,0.002156856,0.00006250891,0.0023546335,0.0005301641,0.00021436534,0.0017241153,0.023633715,0.0001442066],"about_ca_topic_score_codex":0.00029068426,"about_ca_topic_score_gemma":0.0019827406,"teacher_disagreement_score":0.4299172,"about_ca_system_score_codex":0.0002516457,"about_ca_system_score_gemma":0.0046950267,"threshold_uncertainty_score":0.96242285},"labels":[],"label_agreement":null},{"id":"W2806544610","doi":"10.1200/jco.2017.76.7228","title":"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Dasatinib; Imatinib; Cumulative incidence; Internal medicine; Hematopoietic stem cell transplantation; Chemotherapy; Acute lymphocytic leukemia; Philadelphia chromosome; Transplantation; Oncology; Leukemia; Surgery; Lymphoblastic Leukemia; Myeloid leukemia; Chromosomal translocation","score_opus":0.030126736458791173,"score_gpt":0.3770404011580003,"score_spread":0.34691366469920915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806544610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920275,0.00020131712,0.00026248425,0.004333669,0.00093224715,0.0017129342,0.000069601934,0.000018718642,0.00044152112],"genre_scores_gemma":[0.98955107,0.0018354882,0.0021615261,0.0028154051,0.0034639295,0.000017902046,0.000040852745,0.00007173832,0.000042094176],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99186736,0.0010013668,0.004540141,0.0007701386,0.0010484773,0.00077249424],"domain_scores_gemma":[0.99004793,0.0025542795,0.0038197876,0.0004816466,0.002301405,0.00079497875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034045386,0.00048190326,0.0036184068,0.00057269254,0.000083369836,0.000017475051,0.0005165626,0.0012664,0.00004983515],"category_scores_gemma":[0.006580433,0.00033756002,0.0004238955,0.00057196524,0.002507446,0.00024201459,0.00025319328,0.0022725547,0.000013910509],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89828706,0.0030901784,0.06004242,0.000057860627,0.0026276833,0.0015177972,0.0018194668,0.000009386963,0.00047853947,0.00002700921,0.0038586364,0.028183958],"study_design_scores_gemma":[0.41918027,0.115830645,0.45359725,0.0012270457,0.00072110374,0.007737486,0.00035679253,0.00053821167,0.00031459008,0.00003444529,0.00020933755,0.00025281045],"about_ca_topic_score_codex":0.00040517747,"about_ca_topic_score_gemma":0.0003267432,"teacher_disagreement_score":0.47910678,"about_ca_system_score_codex":0.003377578,"about_ca_system_score_gemma":0.010202785,"threshold_uncertainty_score":0.9999077},"labels":[],"label_agreement":null},{"id":"W2806730227","doi":"10.1200/jco.2018.36.15_suppl.tps1107","title":"BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Letrozole; Medicine; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Internal medicine; Mutant; Hormone receptor; Pharmacology; Receptor; Oncology; Endocrinology; Cancer; Estrogen receptor; Biology; Genetics","score_opus":0.06887970135663998,"score_gpt":0.4446081298824254,"score_spread":0.37572842852578536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806730227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907134,0.0011186046,0.00041226487,0.002734671,0.00085184164,0.0032791647,0.00078968157,0.000034010056,0.00006633355],"genre_scores_gemma":[0.9840088,0.0008672683,0.0107258735,0.00077906944,0.0029629536,0.0003589323,0.000016310902,0.00013982413,0.00014099531],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99249333,0.0007939471,0.0040574255,0.0008420009,0.0010475738,0.00076572644],"domain_scores_gemma":[0.9888062,0.0019560826,0.0053303186,0.0005286824,0.0027086386,0.0006700787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001047008,0.00077856105,0.003943603,0.00031575543,0.0002653057,0.00002041031,0.00035131807,0.00044713705,0.00041653172],"category_scores_gemma":[0.00045219783,0.0004723087,0.00073834165,0.00042097952,0.0012905216,0.0005027448,0.00007336203,0.00074502337,0.0000035129196],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40935823,0.040084768,0.005516414,0.000079620935,0.0034601777,0.00040723145,0.0052284054,0.000023486666,0.07002686,0.000008693278,0.00013853621,0.46566755],"study_design_scores_gemma":[0.17685908,0.62281084,0.047439,0.0012761856,0.00126165,0.00041350085,0.0033982864,0.000017658253,0.14081398,0.0000818532,0.0049546584,0.00067327387],"about_ca_topic_score_codex":0.0001550676,"about_ca_topic_score_gemma":0.000344355,"teacher_disagreement_score":0.5827261,"about_ca_system_score_codex":0.000896963,"about_ca_system_score_gemma":0.001968414,"threshold_uncertainty_score":0.99977285},"labels":[],"label_agreement":null},{"id":"W2806732140","doi":"10.1200/jco.2018.36.4_suppl.418","title":"Effect of cytoreductive surgery and HIPEC on survival in comparison to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Hyperthermic intraperitoneal chemotherapy; Chemotherapy; Gallbladder cancer; Surgery; Surgical oncology; Metastasis; Internal medicine; Cancer; Oncology; Cytoreductive surgery; Gallbladder; Ovarian cancer","score_opus":0.127284127777718,"score_gpt":0.44244763919525165,"score_spread":0.3151635114175336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806732140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500155,0.001118749,0.0002762627,0.002251403,0.00071915105,0.0005378711,0.000037102494,0.000003840499,0.000054056745],"genre_scores_gemma":[0.9954811,0.00024736993,0.002636654,0.000396899,0.0011885745,0.000024712013,0.000006012564,0.0000134059255,0.0000052704972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770683,0.00039819375,0.0011411906,0.0003007379,0.0002665368,0.00018648517],"domain_scores_gemma":[0.993282,0.005373275,0.00065405515,0.00011356995,0.0003576304,0.00021943572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002320228,0.00019343357,0.0022275145,0.0001746268,0.000055168784,0.0000059686904,0.00006161529,0.00016618658,0.000006181058],"category_scores_gemma":[0.0014697247,0.00011599497,0.00022106928,0.0001350941,0.00066807296,0.00005214765,0.00003421803,0.00038034847,3.8574652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04524769,0.0006822636,0.8990901,0.000051430063,0.0009528437,0.000076498596,0.0010900795,0.0000020294851,0.00019246223,0.000013268494,0.00035289355,0.05224841],"study_design_scores_gemma":[0.011947806,0.031273272,0.95308375,0.0002166494,0.000497552,0.00003461034,0.0006019906,0.00008666621,0.0014416602,0.000019579249,0.00069170963,0.00010478091],"about_ca_topic_score_codex":0.000257653,"about_ca_topic_score_gemma":0.00069701456,"teacher_disagreement_score":0.05399359,"about_ca_system_score_codex":0.000135517,"about_ca_system_score_gemma":0.00060650904,"threshold_uncertainty_score":0.47301373},"labels":[],"label_agreement":null},{"id":"W2806800866","doi":"10.1200/jco.2018.36.15_suppl.1031","title":"Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Lapatinib; Taxane; Breast cancer; Univariate analysis; Cancer; Multivariate analysis","score_opus":0.0924004381767024,"score_gpt":0.4892809865557027,"score_spread":0.3968805483790003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806800866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891702,0.00047889384,0.00004892523,0.007942063,0.001535191,0.00067214575,0.00006515065,0.0000069930406,0.00008045899],"genre_scores_gemma":[0.99380785,0.002154015,0.0012232984,0.0017271853,0.00095995,0.000013671458,0.00000282376,0.00003371747,0.00007746055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951158,0.00042401912,0.0033062268,0.00030201173,0.0004696931,0.00038225064],"domain_scores_gemma":[0.9952009,0.0015837788,0.0021505512,0.00022929405,0.0005526165,0.00028291595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059495,0.0002685775,0.002753068,0.00031788473,0.000031210508,0.0000069034318,0.00020508177,0.00026185214,0.00033929409],"category_scores_gemma":[0.0010047156,0.00018462702,0.00032375864,0.0003046934,0.00055173784,0.00022258739,0.000053255866,0.0008877919,0.000003558504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15971236,0.01524041,0.4684873,0.0000407016,0.0004774428,0.00014210487,0.00034905592,0.000016523802,0.000064572174,0.000008115807,0.00007365398,0.35538775],"study_design_scores_gemma":[0.27726308,0.038062938,0.67900103,0.00022622803,0.00013896837,0.000120887555,0.00011490197,0.000049345606,0.00007863614,0.00038085584,0.0044334605,0.00012964832],"about_ca_topic_score_codex":0.0002108512,"about_ca_topic_score_gemma":0.001328805,"teacher_disagreement_score":0.3552581,"about_ca_system_score_codex":0.00033322992,"about_ca_system_score_gemma":0.0015168865,"threshold_uncertainty_score":0.7528871},"labels":[],"label_agreement":null},{"id":"W2806802695","doi":"10.1200/jco.2018.36.7_suppl.27","title":"Impact of immigration status on health behaviors and perceptions in cancer survivors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Wellbeing Research","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Immigration; Cancer survivorship; Survivorship curve; Cancer; Moderation; Smoking cessation; Demography; Gerontology; Quality of life (healthcare); Internal medicine; Psychology","score_opus":0.2681321552475181,"score_gpt":0.6889272776813915,"score_spread":0.4207951224338734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806802695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98773634,0.00016506326,0.000028643753,0.010216323,0.0009623154,0.0002896548,0.000019712006,0.0000033527701,0.0005785905],"genre_scores_gemma":[0.9916477,0.005746216,0.00022026272,0.0013503695,0.00090356875,0.000008722068,0.0000019775625,0.000009808472,0.00011132743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99346113,0.002918158,0.0026902708,0.00013499871,0.00027731195,0.0005181472],"domain_scores_gemma":[0.9930638,0.0039577186,0.0015943897,0.00012545925,0.0005756743,0.0006829277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009219355,0.00008237672,0.00091790676,0.00026018187,0.0001752109,0.0000020572652,0.000099712466,0.00036083814,0.0006440431],"category_scores_gemma":[0.0027874575,0.00005574951,0.000145686,0.00020794306,0.00024090923,0.00008337781,0.000036937497,0.0017985618,0.000026718128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011025612,0.0005369281,0.87062085,0.000042389427,0.000014922723,0.000004781489,0.0021345804,0.000003868755,0.000030116526,0.000042327243,0.0049398686,0.12052682],"study_design_scores_gemma":[0.0019764889,0.01739841,0.9724644,0.00020552108,0.000008510442,0.0000019669535,0.00086699286,0.0000512589,7.407692e-7,0.00016017965,0.0068263644,0.00003917235],"about_ca_topic_score_codex":0.031004053,"about_ca_topic_score_gemma":0.062246058,"teacher_disagreement_score":0.12048765,"about_ca_system_score_codex":0.00064077263,"about_ca_system_score_gemma":0.0108311735,"threshold_uncertainty_score":0.9947765},"labels":[],"label_agreement":null},{"id":"W2806902926","doi":"10.1200/jco.2018.36.7_suppl.109","title":"Feasibility pilot implementation of a low-dose CT screening program.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Internal medicine; Family history; Charlson comorbidity index; Socioeconomic status; Quartile; Cancer; Physical therapy; Family medicine; Population; Comorbidity; Confidence interval; Environmental health","score_opus":0.48701547282178576,"score_gpt":0.6208168236874386,"score_spread":0.13380135086565287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806902926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415493,0.0001286807,0.00059310166,0.0023231998,0.0005808574,0.00034152906,0.0000025564686,0.000011384214,0.0018637833],"genre_scores_gemma":[0.97140837,0.00005312904,0.025633207,0.0014312064,0.0014350128,0.000002964308,0.000001741626,0.000007912248,0.000026447542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644905,0.00028936038,0.002400065,0.00016409931,0.00047104177,0.00022637755],"domain_scores_gemma":[0.99594325,0.0005563359,0.0019425801,0.00018577962,0.001069134,0.00030291147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048540835,0.00009779631,0.0010055249,0.00008275035,0.00003972484,0.000006787136,0.0001572546,0.000090701986,0.0003625343],"category_scores_gemma":[0.0023151254,0.00007155151,0.00036154818,0.00019614532,0.0003598883,0.00015951465,0.000054444037,0.00051971915,0.000009575229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052975304,0.000832154,0.5199254,0.000028050636,0.00013317449,0.0001534424,0.000057421796,0.0000010896281,0.00033400644,0.000048665752,0.0019959898,0.47119305],"study_design_scores_gemma":[0.00884807,0.062180158,0.9139634,0.00018855912,0.000243227,0.0003890736,0.00061100966,0.00006093132,0.00069543143,0.00028619225,0.0124661755,0.00006779418],"about_ca_topic_score_codex":0.0001857453,"about_ca_topic_score_gemma":0.0003045066,"teacher_disagreement_score":0.47112525,"about_ca_system_score_codex":0.0001133692,"about_ca_system_score_gemma":0.0013871808,"threshold_uncertainty_score":0.39694962},"labels":[],"label_agreement":null},{"id":"W2806959531","doi":"10.1200/jco.2018.36.7_suppl.39","title":"The impact of a well breast cancer patient transition model of care on oncologists’ practice.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Family medicine; Breast cancer; Workload; Cancer; Thematic analysis; Nonprobability sampling; Nursing; Qualitative research; Population; Internal medicine","score_opus":0.10695712038728433,"score_gpt":0.5008333214586185,"score_spread":0.39387620107133414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806959531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421604,0.00049907196,0.00012333457,0.00914987,0.0007522013,0.00023206051,0.000058816502,0.0000031802833,0.014965416],"genre_scores_gemma":[0.99419546,0.0018770132,0.00081488374,0.0023345766,0.0007318541,0.0000029097282,0.0000019162994,0.000010309433,0.00003107907],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99711645,0.0003859631,0.0018523849,0.00012365355,0.00035068215,0.00017088767],"domain_scores_gemma":[0.99351144,0.0020799562,0.0024457297,0.00019987483,0.0015652333,0.00019773819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013950609,0.000111160414,0.0010234951,0.00006804182,0.000047103684,0.000002935036,0.00013506615,0.00026407928,0.00023408805],"category_scores_gemma":[0.001033349,0.000058631078,0.0006857783,0.0000877208,0.000514451,0.00010774457,0.000018291246,0.00068076525,0.0000032803307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1379004,0.0036474026,0.007477903,0.00010723459,0.0016590906,0.00012827969,0.0048346454,0.008868237,0.0023945034,0.00008968098,0.020730391,0.8121622],"study_design_scores_gemma":[0.044285845,0.45224133,0.37898135,0.0010845145,0.0029008763,0.0012687274,0.008402342,0.024522666,0.0030786074,0.00051480037,0.08225207,0.0004668656],"about_ca_topic_score_codex":0.00020554008,"about_ca_topic_score_gemma":0.000107874264,"teacher_disagreement_score":0.8116954,"about_ca_system_score_codex":0.0005331875,"about_ca_system_score_gemma":0.005202474,"threshold_uncertainty_score":0.92289656},"labels":[],"label_agreement":null},{"id":"W2807055868","doi":"10.1200/jco.2018.36.7_suppl.25","title":"Nutrition services for men with prostate cancer: A health professional survey.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Focus group; Cancer survivorship; Prostate cancer; Health care; Health professionals; Nursing; Gerontology; Cancer; Internal medicine","score_opus":0.23318992215911616,"score_gpt":0.5945727235667796,"score_spread":0.36138280140766343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807055868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7247178,0.0017601906,0.00032898,0.26759824,0.002660172,0.0017476986,0.00006569862,0.00002370476,0.0010975257],"genre_scores_gemma":[0.9026842,0.005433093,0.0320783,0.04961143,0.008455278,0.000101316466,0.000045276545,0.00003492434,0.0015561688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730116,0.0004218925,0.0016212481,0.00014215623,0.00026385282,0.00024967955],"domain_scores_gemma":[0.9953046,0.0010285861,0.0017439848,0.00008415832,0.0013925416,0.00044616355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005736237,0.00008401983,0.0009836281,0.00009420731,0.000119042634,0.000005977312,0.00007843442,0.00016514905,0.000102784514],"category_scores_gemma":[0.00029809366,0.000052534084,0.00011852117,0.00012357344,0.0001510328,0.00008803695,0.000014708454,0.0005153726,0.000004230931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091508076,0.0059961616,0.5144347,0.002517517,0.00030711276,0.000064541404,0.0006861369,7.1009487e-7,0.000056772235,0.00015438211,0.20346004,0.1808139],"study_design_scores_gemma":[0.020309767,0.033513024,0.51097786,0.0017747101,0.000064211614,0.00016825755,0.000278751,0.00019962741,0.000034696874,0.0005610034,0.43204942,0.000068649686],"about_ca_topic_score_codex":0.00010896802,"about_ca_topic_score_gemma":0.0007824063,"teacher_disagreement_score":0.2285894,"about_ca_system_score_codex":0.00016356635,"about_ca_system_score_gemma":0.0038102497,"threshold_uncertainty_score":0.6759219},"labels":[],"label_agreement":null},{"id":"W2807062821","doi":"10.1200/jco.2018.36.15_suppl.e12501","title":"Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis.","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Triple-negative breast cancer; Chemotherapy; Meta-analysis; Adjuvant; Stage (stratigraphy); Cancer","score_opus":0.173639070236508,"score_gpt":0.4911054341419415,"score_spread":0.31746636390543354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807062821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013495999,0.99593496,0.000010984714,0.0019780253,0.0003761252,0.00074214034,0.0007555464,0.0000027865067,0.00006445104],"genre_scores_gemma":[0.00021149313,0.99550873,0.00037888298,0.002290691,0.0011230308,0.00018481226,0.000052404976,0.00004282527,0.00020711914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993731,0.0010288829,0.004016744,0.0006761374,0.0002435828,0.00030360578],"domain_scores_gemma":[0.99266905,0.0007447481,0.0054277773,0.00046581085,0.0004651246,0.000227503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002095794,0.0005516322,0.013912693,0.00017004363,0.000038767375,0.0000130810095,0.00045205886,0.0008627235,0.00028567],"category_scores_gemma":[0.0004057475,0.00033353874,0.004476676,0.00037681125,0.0002826643,0.000009336975,0.00017744047,0.00069018104,0.000007859501],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056661974,0.00058483845,0.00025833512,0.0033397938,0.45594633,0.00011209797,0.000035743684,0.0000017490195,5.118021e-7,0.0000033622835,0.007596656,0.531554],"study_design_scores_gemma":[0.0018514202,0.0006205684,0.002620364,0.0015324204,0.48300928,0.00024246474,0.000009240646,5.140942e-7,4.433386e-7,0.000031605563,0.5098102,0.00027148452],"about_ca_topic_score_codex":0.00038565238,"about_ca_topic_score_gemma":0.0015155001,"teacher_disagreement_score":0.5312825,"about_ca_system_score_codex":0.00019253354,"about_ca_system_score_gemma":0.001257642,"threshold_uncertainty_score":0.99991167},"labels":[],"label_agreement":null},{"id":"W2807081886","doi":"10.1200/jco.2018.36.18_suppl.lba4001","title":"Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Hazard ratio; Clinical endpoint; FOLFIRINOX; Pancreatic cancer; Gastroenterology; Irinotecan; Surgery; Cancer; Randomized controlled trial; Confidence interval; Colorectal cancer","score_opus":0.12647728485526064,"score_gpt":0.4860946307585331,"score_spread":0.35961734590327243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807081886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877546,0.00018513667,0.000087749235,0.0020134386,0.0037688548,0.0035674993,0.000013659536,0.000011306093,0.0025977618],"genre_scores_gemma":[0.9940511,0.0004598711,0.0025882397,0.00022686078,0.0020635845,0.000090086476,0.000022704462,0.000031488566,0.00046605794],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908483,0.0019876258,0.0050305566,0.00041335105,0.0012178548,0.000502335],"domain_scores_gemma":[0.9860641,0.007461124,0.0033438082,0.00044351263,0.0021971725,0.0004903155],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0076924376,0.00028769052,0.0049322727,0.0004970476,0.000049146234,0.000012477372,0.0004599787,0.00046567761,0.00072949874],"category_scores_gemma":[0.02346849,0.00017704153,0.0006290222,0.0003641841,0.0016710695,0.0001960935,0.0001511637,0.0013680146,0.00001393118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8457232,0.012098896,0.1338687,0.000028241682,0.002099327,0.00033037827,0.0003061442,9.5059045e-7,0.000030106554,0.000022476761,0.0006559859,0.0048355917],"study_design_scores_gemma":[0.79844344,0.09580353,0.10238547,0.0002508917,0.0013187652,0.000024126231,0.00007969289,0.00048224922,0.000024106088,0.00004713708,0.0010135393,0.00012705149],"about_ca_topic_score_codex":0.00011144277,"about_ca_topic_score_gemma":0.00017917453,"teacher_disagreement_score":0.08370463,"about_ca_system_score_codex":0.00044888005,"about_ca_system_score_gemma":0.0034777678,"threshold_uncertainty_score":0.98475724},"labels":[],"label_agreement":null},{"id":"W2807107361","doi":"10.1200/jco.2018.36.7_suppl.178","title":"The influence of an androgen deprivation therapy educational program on dyadic quality and intimacy for prostate cancer patients and their partners.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network; Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Sexual function; Cancer; Physical therapy; Internal medicine; Nursing","score_opus":0.13966151044110736,"score_gpt":0.5452720289038523,"score_spread":0.40561051846274493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807107361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246776,0.00040047857,0.0000038046771,0.00628128,0.0003421043,0.00043566653,0.000008848277,0.0000026831099,0.0000573784],"genre_scores_gemma":[0.99663115,0.0011143541,0.00016825093,0.00153988,0.00048293508,0.000035970454,0.0000038346075,0.0000061736546,0.00001744206],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985837,0.00020978741,0.00084750605,0.0001153777,0.00014236438,0.000101310354],"domain_scores_gemma":[0.9965992,0.0013931321,0.0008757746,0.000092501614,0.0009046426,0.0001347269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017526718,0.00006939284,0.0003888219,0.00003075206,0.00006715156,0.000010049241,0.000066380555,0.00009784077,0.0000056711065],"category_scores_gemma":[0.0012521243,0.000036748756,0.000077240504,0.00006000305,0.00041403744,0.000083897045,0.000014466215,0.0001875142,1.505899e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004809818,0.00069510983,0.37876645,0.000016012766,0.00007574761,2.050024e-7,0.0005899043,8.0659174e-7,0.00006968424,0.000104225284,0.0001191311,0.6147529],"study_design_scores_gemma":[0.003585957,0.01742565,0.9501773,0.000044591652,0.000031074043,0.000004928808,0.00012954079,0.00003088668,0.0002446551,0.0018048611,0.026479712,0.000040834184],"about_ca_topic_score_codex":0.00006412264,"about_ca_topic_score_gemma":0.00044077498,"teacher_disagreement_score":0.61471206,"about_ca_system_score_codex":0.000036509296,"about_ca_system_score_gemma":0.000684298,"threshold_uncertainty_score":0.15255383},"labels":[],"label_agreement":null},{"id":"W2807154308","doi":"10.1200/jco.2018.36.30_suppl.177","title":"Cancer patient (pt) attitudes and preferences towards smoking status assessment.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; McMaster University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Logistic regression; Family medicine; Head and neck cancer; Multivariate analysis; Cancer; Internal medicine; Pathology","score_opus":0.20824757708678945,"score_gpt":0.5525156379353623,"score_spread":0.34426806084857287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807154308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97422504,0.0025223114,0.000026433292,0.0052034766,0.0019797883,0.00009037151,0.0000038625194,0.0000068225377,0.015941862],"genre_scores_gemma":[0.9837852,0.009093552,0.0027278804,0.0026304838,0.0016674456,0.000004459266,3.6070963e-7,0.000007238581,0.00008338437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791414,0.0001803609,0.0012103957,0.00014969167,0.00031476133,0.00023065707],"domain_scores_gemma":[0.9976582,0.00061751605,0.00077779905,0.00008496976,0.0005481562,0.00031337605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011659693,0.00009998083,0.0011131574,0.000060266582,0.0000691069,0.000009728225,0.000061660794,0.00016979601,0.00031301557],"category_scores_gemma":[0.0010029664,0.00006099378,0.00013750646,0.00007217513,0.00038148588,0.000084304775,0.00007453007,0.00057603576,0.0000019798204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052273745,0.00030081422,0.49836415,0.000024373454,0.0002914783,0.000047398848,0.00024969838,2.2154991e-7,0.000035861034,0.00002871366,0.0039793574,0.4961552],"study_design_scores_gemma":[0.0024318101,0.020420276,0.8053373,0.00020960812,0.00018478253,0.000040691226,0.00019882187,0.000012729631,0.00005426266,0.00013560953,0.17091738,0.000056699202],"about_ca_topic_score_codex":0.00013269593,"about_ca_topic_score_gemma":0.00036650983,"teacher_disagreement_score":0.4960985,"about_ca_system_score_codex":0.00015219972,"about_ca_system_score_gemma":0.002302477,"threshold_uncertainty_score":0.4084495},"labels":[],"label_agreement":null},{"id":"W2807238235","doi":"10.1200/jco.2018.36.18_suppl.lba1","title":"TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Internal medicine; Oncology; Chemotherapy; Randomized controlled trial; Clinical endpoint; Cancer; Hormonal therapy; Hormone therapy; Hormone receptor; Gynecology; Confidence interval","score_opus":0.07398647356347338,"score_gpt":0.4346108684949703,"score_spread":0.36062439493149695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807238235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374837,0.0016854177,0.000018188013,0.002346432,0.0013560014,0.00056725973,0.00015641867,0.000005151412,0.0001167825],"genre_scores_gemma":[0.95152676,0.044266034,0.0012957916,0.0003337346,0.0024326756,0.00007775963,0.000022679771,0.000027945276,0.000016630243],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966015,0.00056514237,0.0016932598,0.00049351767,0.00027440366,0.00037214224],"domain_scores_gemma":[0.99625796,0.0006139866,0.0017540812,0.00024248565,0.00088698,0.0002444838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008624895,0.00032996066,0.0013943643,0.00011753263,0.000067505905,0.000012371078,0.00031157586,0.00021641415,0.0000647769],"category_scores_gemma":[0.00065515377,0.0002475817,0.00025881975,0.00022060893,0.0012542651,0.0000420791,0.00013900429,0.00044403717,0.0000013868298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61008716,0.005849518,0.014724562,0.0000066427524,0.0012651415,0.000040147803,0.0003792952,0.0000015127983,0.0262883,0.0000040358677,0.00074795133,0.3406057],"study_design_scores_gemma":[0.505962,0.08359868,0.20710589,0.00012815474,0.00015833146,0.000093526716,0.00026654874,0.000014046233,0.19956693,0.00009312239,0.002616892,0.00039584065],"about_ca_topic_score_codex":0.00043478148,"about_ca_topic_score_gemma":0.00053266576,"teacher_disagreement_score":0.34020987,"about_ca_system_score_codex":0.00010385302,"about_ca_system_score_gemma":0.00064992276,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2807250715","doi":"10.1200/jco.2018.36.4_suppl.591","title":"Systematic review and meta-analysis of the effect of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Colorectal cancer; Positron emission tomography; Metastasis; PET-CT; Radiology; Meta-analysis; Cancer; Subgroup analysis; Nuclear medicine; Internal medicine","score_opus":0.04073627842637377,"score_gpt":0.43498220910821606,"score_spread":0.39424593068184227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807250715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761994,0.008536978,0.00007578429,0.0022116883,0.00009225534,0.001154153,0.000008878634,8.9944905e-7,0.00029943747],"genre_scores_gemma":[0.995941,0.0021113174,0.0010599096,0.00077734166,0.000024752346,0.000020346468,0.0000010656321,0.00000706927,0.000057206835],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99451363,0.0025711628,0.0020748964,0.00013657325,0.0005844555,0.000119309625],"domain_scores_gemma":[0.99457556,0.0020229171,0.0026658857,0.00023151693,0.00043456696,0.00006953612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009322014,0.00012023266,0.0038854517,0.00011547938,0.000028513483,0.0000041036587,0.0002690818,0.000022275433,0.00013777218],"category_scores_gemma":[0.0021022644,0.000043325024,0.0008190361,0.00047153092,0.0004616756,0.000047269998,0.00007530509,0.0005164565,2.2573312e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008554872,0.0029025632,0.18144964,0.110116035,0.68912333,0.00093409687,0.0009167731,0.0005268648,0.00005537525,0.00021932684,0.0010338293,0.0041672923],"study_design_scores_gemma":[0.0036365835,0.010631807,0.23610643,0.0036743141,0.74486154,0.000111746645,0.00007620983,0.00065953314,0.00007418014,0.000007814908,0.000094229224,0.00006558553],"about_ca_topic_score_codex":0.00010102292,"about_ca_topic_score_gemma":0.000088562985,"teacher_disagreement_score":0.106441714,"about_ca_system_score_codex":0.000035015782,"about_ca_system_score_gemma":0.00015501078,"threshold_uncertainty_score":0.32308426},"labels":[],"label_agreement":null},{"id":"W2807337207","doi":"10.1200/jco.2018.36.7_suppl.117","title":"Assessment of pulmonary function test abnormalities in adult survivors of childhood cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Pulmonary function testing; Lung cancer; Respiratory system; Cancer; Pediatrics; Vital capacity; Abnormality; Internal medicine; Lung; Diffusing capacity; Lung function","score_opus":0.057986695720455485,"score_gpt":0.4527687158180805,"score_spread":0.394782020097625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807337207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836697,0.000555605,0.000042489028,0.0018619461,0.0010744294,0.0002526231,0.00003120392,0.000004623961,0.012507378],"genre_scores_gemma":[0.9964098,0.0010848405,0.0005318887,0.00030880794,0.00141979,0.000006989806,0.00000450706,0.000017277518,0.00021609777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955111,0.00051538093,0.0027670215,0.00020344059,0.0007160057,0.00028704407],"domain_scores_gemma":[0.99357706,0.0023346222,0.0018171448,0.000246526,0.001718339,0.0003063172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029731898,0.00013842268,0.0014505647,0.0003015863,0.000026252777,0.0000027501892,0.0002092455,0.0002943271,0.00074022193],"category_scores_gemma":[0.0032426028,0.00010746294,0.00040230615,0.00033551315,0.0008238418,0.00016171769,0.00009666757,0.0009715169,0.0000040032887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020765415,0.004592412,0.90823674,0.00024886776,0.00023489252,0.0002101217,0.00007748093,0.00001544521,0.00048699,0.00024683945,0.00028649892,0.08328719],"study_design_scores_gemma":[0.00418395,0.008737905,0.98300683,0.00037733215,0.0002120483,0.00013327287,0.0006283362,0.0005920917,0.00014277989,0.00039446357,0.0015135397,0.00007741624],"about_ca_topic_score_codex":0.00061135436,"about_ca_topic_score_gemma":0.00059540465,"teacher_disagreement_score":0.083209775,"about_ca_system_score_codex":0.0003973338,"about_ca_system_score_gemma":0.004852781,"threshold_uncertainty_score":0.8608625},"labels":[],"label_agreement":null},{"id":"W2807341461","doi":"10.1200/jco.2018.36.7_suppl.137","title":"Utilization of the sexual health service from the prostate cancer supportive care program: A chart review.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Orgasm; Distress; Androgen deprivation therapy; Reproductive health; Erectile dysfunction; Prostatectomy; Family medicine; Gynecology; Cancer; Sexual dysfunction; Clinical psychology; Internal medicine; Population","score_opus":0.21488837185169027,"score_gpt":0.5444733381260389,"score_spread":0.32958496627434863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807341461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7800164,0.029314414,0.00001366875,0.18488243,0.0037259085,0.0012788441,0.00008346005,0.000011222329,0.00067361037],"genre_scores_gemma":[0.91608477,0.013577297,0.00013281025,0.06723742,0.0027483911,0.000027172828,0.00001487571,0.000016313219,0.00016096469],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969453,0.0007003504,0.001643101,0.00014423291,0.00039436168,0.00017266191],"domain_scores_gemma":[0.9949229,0.0005059492,0.0023232778,0.00027367283,0.0018072926,0.00016695952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019272019,0.000097598626,0.0009351433,0.000016780268,0.000063274034,0.0000042157353,0.00022641043,0.00013764095,0.00022159085],"category_scores_gemma":[0.0009372309,0.000045497793,0.00023874533,0.00028896893,0.00025432804,0.00004768178,0.00006460774,0.00060977606,0.000004763635],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015742033,0.0004057629,0.20122166,0.00057099405,0.00023152785,0.000010734001,0.008421382,4.7743055e-7,0.000015534,0.000013773606,0.040207576,0.7473264],"study_design_scores_gemma":[0.0022038568,0.009421191,0.40354812,0.0020015964,0.00046868014,0.00003285943,0.005368526,0.00001719362,0.00008481229,0.000048475613,0.57674253,0.000062154475],"about_ca_topic_score_codex":0.0020449797,"about_ca_topic_score_gemma":0.024166603,"teacher_disagreement_score":0.7472642,"about_ca_system_score_codex":0.0001456375,"about_ca_system_score_gemma":0.0043457486,"threshold_uncertainty_score":0.9936398},"labels":[],"label_agreement":null},{"id":"W2807637103","doi":"10.1200/jco.2018.77.8084","title":"T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":791,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"NIH Clinical Center; National Cancer Institute; National Institutes of Health; Kite Pharma; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Chimeric antigen receptor; Multiple myeloma; Minimal residual disease; Cytokine release syndrome; Antigen; Cyclophosphamide; Bone marrow; Fludarabine; Immunology; Regimen; Cancer research; Internal medicine; T cell; Oncology; Chemotherapy; Immune system","score_opus":0.1424856689320132,"score_gpt":0.4582241318970513,"score_spread":0.3157384629650381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807637103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918557,0.00013942679,0.0008930776,0.0031064535,0.0013538455,0.00072096026,0.000014524817,0.000023013074,0.0018930326],"genre_scores_gemma":[0.95644647,0.0013754534,0.03792319,0.0009845967,0.0021189665,0.0000070850338,0.000010535873,0.000057801084,0.0010758784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940622,0.0010968038,0.002996368,0.00045296625,0.00088327535,0.0005083808],"domain_scores_gemma":[0.9932472,0.0018139287,0.0014725267,0.0005508784,0.0016835239,0.0012319179],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035211917,0.00024896435,0.0017251442,0.00034952004,0.00010824026,0.000023353341,0.0005121107,0.00070035993,0.001717882],"category_scores_gemma":[0.0033178062,0.00019150459,0.00051772734,0.0004888546,0.0004915545,0.00016256902,0.00014762588,0.0010807888,0.00008814525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010209597,0.0024649638,0.023291279,0.000033177068,0.00025447842,0.000113860304,0.0004073669,0.000031351723,0.90770674,0.0000047329186,0.007632538,0.047849916],"study_design_scores_gemma":[0.009864193,0.03322637,0.24798158,0.0002179764,0.00024887288,0.00011670187,0.00025177427,0.0016355846,0.64362633,0.000041044557,0.062487647,0.00030194598],"about_ca_topic_score_codex":0.00004364363,"about_ca_topic_score_gemma":0.00001965836,"teacher_disagreement_score":0.26408044,"about_ca_system_score_codex":0.0001162619,"about_ca_system_score_gemma":0.0014348021,"threshold_uncertainty_score":0.9991947},"labels":[],"label_agreement":null},{"id":"W2808040186","doi":"10.1200/jco.2017.35.15_suppl.tps4590","title":"Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital","funders":"","keywords":"Gemcitabine; Medicine; Chemotherapy; Carboplatin; Urothelial cancer; Cisplatin; Pembrolizumab; Oncology; Docetaxel; Bladder cancer; Metastatic Urothelial Carcinoma; Internal medicine; Cancer; Urothelial carcinoma; Immunotherapy","score_opus":0.1709571782320348,"score_gpt":0.5346557741687141,"score_spread":0.3636985959366793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808040186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800108,0.00044563372,0.000102188395,0.011546703,0.0030645013,0.0012501829,0.000015143461,0.000023143306,0.0035416675],"genre_scores_gemma":[0.98398876,0.004939705,0.0028051913,0.0032724603,0.003367542,0.00006722693,0.0000024256617,0.00008701121,0.0014696865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960212,0.00027074752,0.0021618411,0.00043993385,0.0006114553,0.0004948194],"domain_scores_gemma":[0.99482685,0.00076871325,0.002793419,0.0006850687,0.00038818573,0.0005377816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014104861,0.00037448647,0.0029323408,0.00015593466,0.0001453319,0.000042987886,0.0005011708,0.0004979859,0.00071271864],"category_scores_gemma":[0.0011641086,0.00022641063,0.0004986871,0.00012689624,0.00048141487,0.00031375216,0.0000363575,0.0011632014,0.000013515232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.682035,0.0047792555,0.010764035,0.000021187221,0.00071412424,0.0006688997,0.00019099207,0.000005068084,0.00025779122,0.000005629352,0.00048175544,0.30007628],"study_design_scores_gemma":[0.7904508,0.1268554,0.019977266,0.00027259093,0.00048228318,0.00019521911,0.00008500017,0.00006460792,0.0010387538,0.000060937127,0.060272407,0.00024474662],"about_ca_topic_score_codex":0.0003476134,"about_ca_topic_score_gemma":0.0010374725,"teacher_disagreement_score":0.2998315,"about_ca_system_score_codex":0.00045282388,"about_ca_system_score_gemma":0.005292134,"threshold_uncertainty_score":0.9388019},"labels":[],"label_agreement":null},{"id":"W2810134512","doi":"10.1200/jco.2017.35.15_suppl.tps4594","title":"Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Axitinib; Medicine; Sunitinib; Avelumab; Internal medicine; Renal cell carcinoma; Tyrosine-kinase inhibitor; Oncology; Gastroenterology; Cancer; Nivolumab; Immunotherapy","score_opus":0.16769427094462616,"score_gpt":0.4735742379567842,"score_spread":0.305879967012158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810134512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824181,0.00080569607,0.000045929515,0.0033232176,0.0012668063,0.0012860248,0.000038156173,0.00001662007,0.01079942],"genre_scores_gemma":[0.9915722,0.0007820739,0.0025735688,0.0002630867,0.0022446604,0.000035200654,0.00002578743,0.00006406425,0.002439357],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99206245,0.0007204677,0.005008114,0.0006000252,0.0010026296,0.0006062855],"domain_scores_gemma":[0.98738056,0.0024320735,0.006597981,0.0012902812,0.0012242896,0.0010748147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002581376,0.000543045,0.0042093084,0.00029994608,0.00029718364,0.000034250887,0.0006061424,0.0005329657,0.0005880217],"category_scores_gemma":[0.0030407242,0.00037652577,0.0014707025,0.00011755393,0.00058275263,0.00021977967,0.0001673696,0.0010006926,0.000084489984],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20475025,0.1355453,0.12361189,0.00024306058,0.003327383,0.05805574,0.0029237813,0.00034643937,0.0040140795,0.00005630934,0.0024867216,0.46463904],"study_design_scores_gemma":[0.2167003,0.4476574,0.26988682,0.00021408619,0.0036163619,0.001714349,0.0008921268,0.00015478687,0.015953917,0.0001420591,0.04266591,0.00040187023],"about_ca_topic_score_codex":0.00030559546,"about_ca_topic_score_gemma":0.00027690796,"teacher_disagreement_score":0.46423718,"about_ca_system_score_codex":0.00090229814,"about_ca_system_score_gemma":0.0041541816,"threshold_uncertainty_score":0.9998687},"labels":[],"label_agreement":null},{"id":"W2883374837","doi":"10.1200/jco.2016.34.15_suppl.tps4152","title":"POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (g<i>BRCA</i>m).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Clinical endpoint; BRCA mutation; Oncology; Population; Regimen; Cancer; Phases of clinical research; Ovarian cancer; Surgery; Randomized controlled trial; Chemotherapy; Genetics","score_opus":0.06732688848700241,"score_gpt":0.4505925390702192,"score_spread":0.38326565058321677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883374837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817481,0.00053436076,0.0062612076,0.008169742,0.00082389935,0.0019786612,0.000037690283,0.000011116947,0.00043519863],"genre_scores_gemma":[0.9885971,0.0037969789,0.002845751,0.003377438,0.00071424467,0.00017167212,0.0000056980707,0.00004578484,0.0004453446],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915689,0.0016959178,0.0052488334,0.00034029133,0.0007566152,0.0003894415],"domain_scores_gemma":[0.9867499,0.00576575,0.005723587,0.00031545068,0.0011102004,0.00033512127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00602893,0.000296292,0.0046855505,0.0003235324,0.000030110332,0.000007914674,0.00019996583,0.00027737668,0.0003494816],"category_scores_gemma":[0.0034592655,0.00015807181,0.00073721755,0.0002783067,0.0007635668,0.0002521729,0.00001870204,0.0006588701,0.0000044127823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9007059,0.005478066,0.004434456,0.000040538096,0.0012491746,0.0001856503,0.00033657663,0.00002837901,0.00038698496,0.000074443116,0.0013008065,0.08577907],"study_design_scores_gemma":[0.96017647,0.029557975,0.0027539378,0.0012967814,0.00088625,0.00007237319,0.00006448705,0.00024030062,0.00075253024,0.0008525021,0.0031667172,0.00017970079],"about_ca_topic_score_codex":0.0001605918,"about_ca_topic_score_gemma":0.00013390444,"teacher_disagreement_score":0.08559937,"about_ca_system_score_codex":0.000522155,"about_ca_system_score_gemma":0.0022436306,"threshold_uncertainty_score":0.6445981},"labels":[],"label_agreement":null},{"id":"W2883524169","doi":"10.1200/jco.2012.30.15_suppl.2063","title":"Illness intrusiveness and subjective well-being in patients with glioblastoma multiforme.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Mood; Depression (economics); Quality of life (healthcare); Affect (linguistics); Disease; Oncology; Psychiatry; Psychology","score_opus":0.02454908464498962,"score_gpt":0.3747641222261956,"score_spread":0.350215037581206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883524169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757946,0.00012447897,0.000010493742,0.0007263857,0.0005382993,0.00020032724,7.316936e-7,0.0000030935967,0.00081676076],"genre_scores_gemma":[0.9986709,0.00007843841,0.0004509682,0.00043728235,0.00033947203,0.000005160467,8.989215e-7,0.000011475525,0.000005451017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831283,0.00018202943,0.0009430699,0.00011028102,0.00022124412,0.00023055598],"domain_scores_gemma":[0.9974901,0.001138817,0.000685426,0.000086357424,0.00026848787,0.00033083346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010707325,0.000112499554,0.0009126535,0.00015818185,0.000029789586,0.000004922951,0.000046276466,0.00018922871,0.000038071455],"category_scores_gemma":[0.000770434,0.000066372006,0.0001097017,0.00013132759,0.0001218071,0.00018479818,0.000035979567,0.0004168787,0.000007089808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049823546,0.0039906804,0.9127289,0.000011590116,0.00017895765,0.00016521028,0.00035321983,0.0000028681218,0.0000052869186,0.00008630939,0.00003773634,0.07745687],"study_design_scores_gemma":[0.018680668,0.010148633,0.9676962,0.00014284304,0.00020194674,0.00008759254,0.00017267506,0.000009094544,0.00021740062,0.00006899709,0.0024988696,0.00007509877],"about_ca_topic_score_codex":0.000012970796,"about_ca_topic_score_gemma":0.000047527927,"teacher_disagreement_score":0.077381775,"about_ca_system_score_codex":0.00014757257,"about_ca_system_score_gemma":0.00020654013,"threshold_uncertainty_score":0.27065718},"labels":[],"label_agreement":null},{"id":"W2884498415","doi":"10.1200/jco.2012.30.15_suppl.1513","title":"An alternative approach to identify women at risk for colorectal cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Lynch syndrome; Medicine; MLH1; Colorectal cancer; MSH2; Microsatellite instability; Endometrial cancer; Cancer; Oncology; Internal medicine; Gynecology; MSH6; DNA mismatch repair; Ovarian cancer; Family history; PMS2; Germline mutation; Genetics; Mutation; Gene; Biology","score_opus":0.16233450888094425,"score_gpt":0.5236089624783943,"score_spread":0.36127445359745003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884498415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892958,0.00037302164,0.0013642921,0.0007615013,0.0053516147,0.00062360975,0.000033058477,0.000010970235,0.0021861678],"genre_scores_gemma":[0.974641,0.0002737092,0.017425118,0.0017715687,0.005471756,0.00012601358,0.0000028813315,0.000032969663,0.00025495316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664766,0.00046603344,0.0016531002,0.00024656465,0.00043872505,0.0005479238],"domain_scores_gemma":[0.99458295,0.0017959351,0.0015053551,0.00018831417,0.00059254136,0.0013348836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052729985,0.00017196627,0.0013704671,0.0001270297,0.00007181931,0.000009083539,0.00029157192,0.00038435435,0.00027070838],"category_scores_gemma":[0.004255284,0.00012600193,0.0003914831,0.00014408524,0.00017264484,0.00013999389,0.00009189263,0.00075518334,0.000022640177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03258224,0.0050034802,0.77983576,0.000070268135,0.0012718601,0.000025605932,0.004590924,0.0004518052,0.007436243,0.00006257318,0.020124055,0.14854516],"study_design_scores_gemma":[0.00778315,0.033518683,0.8541233,0.00003353207,0.0004610195,0.00022368312,0.00057206483,0.00034537006,0.003181099,0.00031922213,0.0992365,0.00020240385],"about_ca_topic_score_codex":0.000037554233,"about_ca_topic_score_gemma":0.00003941163,"teacher_disagreement_score":0.14834276,"about_ca_system_score_codex":0.0014568546,"about_ca_system_score_gemma":0.0010313913,"threshold_uncertainty_score":0.51382095},"labels":[],"label_agreement":null},{"id":"W2884526250","doi":"10.1200/jco.2017.35.15_suppl.11012","title":"Pathologic complete response and survival outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy: Long-term update of NRG Oncology RTOG 9514 and 0630.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital","funders":"","keywords":"Medicine; Soft tissue sarcoma; Hazard ratio; Chemoradiotherapy; Internal medicine; Radiation therapy; Confidence interval; Oncology; Multivariate analysis; Sarcoma; Proportional hazards model; Surgery; Soft tissue; Pathology","score_opus":0.08726929626182808,"score_gpt":0.4367865716541898,"score_spread":0.34951727539236177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884526250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208814,0.0008983636,0.00007849734,0.0060676956,0.00017578388,0.00062045094,0.000019740966,0.000009204355,0.000042096697],"genre_scores_gemma":[0.99066263,0.0021098081,0.0058257855,0.00119747,0.000098575176,0.000012203274,0.0000067526234,0.00003732539,0.000049462353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960593,0.0010639798,0.0017868653,0.00038704806,0.00036563826,0.00033719192],"domain_scores_gemma":[0.9930933,0.003286027,0.0024514361,0.0004802674,0.0003129857,0.0003759489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023627516,0.00032690063,0.0037542963,0.00019900667,0.000094435505,0.000025838488,0.00022392767,0.000401694,0.00009222649],"category_scores_gemma":[0.0010322003,0.00016615597,0.00015646812,0.00008422874,0.0010761326,0.00013174597,0.0000597512,0.0005504912,0.0000012389048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11898044,0.004439326,0.727107,0.000025268282,0.0006302869,0.005709097,0.00011201765,0.0000013865932,0.00008068907,0.0000049538553,0.00003054833,0.142879],"study_design_scores_gemma":[0.08322402,0.061815158,0.85127366,0.00018129057,0.0003724376,0.0007071224,0.00003444568,0.000017090299,0.000057156878,0.000014180274,0.0021473032,0.00015615411],"about_ca_topic_score_codex":0.00006999497,"about_ca_topic_score_gemma":0.00035213857,"teacher_disagreement_score":0.14272285,"about_ca_system_score_codex":0.00020868717,"about_ca_system_score_gemma":0.00065131654,"threshold_uncertainty_score":0.6775643},"labels":[],"label_agreement":null},{"id":"W2884957349","doi":"10.1200/jco.2012.30.15_suppl.1535","title":"Genetic sequence variant (GSV) in <i>TERT-CLPTM1L </i>(5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hazard ratio; Lung cancer; Oncology; Internal medicine; Genotyping; Cancer; Proportional hazards model; Genotype; Gene; Genetics; Confidence interval; Biology","score_opus":0.04886612391995202,"score_gpt":0.3856038124766891,"score_spread":0.3367376885567371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884957349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134237,0.0062518134,0.00031583346,0.0003034037,0.00085168483,0.00022721048,0.000040752206,0.0000028921556,0.00066403765],"genre_scores_gemma":[0.98875046,0.0072675324,0.0017698442,0.00074065034,0.0012195071,0.00001318608,0.000010816524,0.000026031717,0.00020194508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684167,0.000576916,0.001598263,0.00032197408,0.00018402253,0.00047717095],"domain_scores_gemma":[0.9980307,0.00028194723,0.00075564126,0.00023492814,0.00019698282,0.00049979554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016254141,0.00022212586,0.00075941964,0.00011706789,0.000034188604,0.000016580576,0.00024687056,0.000529521,0.000055167795],"category_scores_gemma":[0.00042828912,0.00019716292,0.00018259107,0.00012433229,0.00018957997,0.000016160087,0.00011705674,0.00047691926,0.0000030046049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013563812,0.0011738022,0.9621471,0.00007389869,0.00006048381,0.00026218078,0.00011678482,0.0002397827,0.030340195,0.0000068556806,0.00062018086,0.0036023424],"study_design_scores_gemma":[0.011260338,0.002151911,0.96933943,0.00012042673,0.0001582729,0.000085387284,0.00015343998,0.0004184785,0.003864018,0.000080955615,0.011979252,0.00038807117],"about_ca_topic_score_codex":0.00029191206,"about_ca_topic_score_gemma":0.001114683,"teacher_disagreement_score":0.026476176,"about_ca_system_score_codex":0.000076186305,"about_ca_system_score_gemma":0.00096462463,"threshold_uncertainty_score":0.80400705},"labels":[],"label_agreement":null},{"id":"W2885063174","doi":"10.1200/jco.2012.30.15_suppl.1597","title":"Association of <i>p53 Arg72Pro</i> polymorphism and HPV status with the initiation, progression, and development of cervical cancer (CC): A meta-analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cervical cancer; Meta-analysis; Internal medicine; Odds ratio; Oncology; HPV infection; Human papillomavirus; Disease; Cancer; Gastroenterology; Gynecology","score_opus":0.23960845067925446,"score_gpt":0.5160739540044555,"score_spread":0.2764655033252011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885063174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9386273,0.020909712,0.00052143453,0.03639461,0.0001825878,0.00048796568,0.000019101333,0.000005073768,0.0028522257],"genre_scores_gemma":[0.9948338,0.0009124215,0.0027196174,0.0011282967,0.0002781537,0.000013940783,0.0000025185302,0.000007524508,0.000103676495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968625,0.00045721256,0.0015530697,0.000117234915,0.00076071103,0.00024932166],"domain_scores_gemma":[0.9945829,0.0019252857,0.0018717101,0.00011174236,0.0011385601,0.00036979947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005255249,0.00010013242,0.0017595966,0.00012679545,0.000049650516,0.0000061853834,0.000077211575,0.00020654031,0.0008698149],"category_scores_gemma":[0.0010157214,0.000047100217,0.00030464932,0.00030272984,0.00022437517,0.000100037185,0.000064630614,0.0005816709,6.450754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003388975,0.0022496686,0.82119894,0.00011844163,0.04680837,0.000008128043,0.0012491127,0.0000025970794,0.000042802138,0.000096445976,0.0014630379,0.123373486],"study_design_scores_gemma":[0.0051342514,0.0017178893,0.9361801,0.000006722467,0.032327227,0.000014628755,0.00016718401,0.000014345922,0.0002344734,0.00003391392,0.024115028,0.00005422445],"about_ca_topic_score_codex":0.000040090516,"about_ca_topic_score_gemma":0.00038324532,"teacher_disagreement_score":0.12331926,"about_ca_system_score_codex":0.000116139774,"about_ca_system_score_gemma":0.0015282054,"threshold_uncertainty_score":0.9523863},"labels":[],"label_agreement":null},{"id":"W2885107163","doi":"10.1200/jco.2018.79.1483","title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":978,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Surgery; Esophagectomy; Clinical endpoint; Radiation therapy; Chemoradiotherapy; Esophagus; Neoadjuvant therapy; Neutropenia; Leukopenia; Phases of clinical research; Esophageal cancer; Gastroenterology; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval","score_opus":0.19565537900381294,"score_gpt":0.5140244621430774,"score_spread":0.3183690831392645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885107163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632571,0.017545205,0.00046046544,0.004688186,0.009289654,0.004540813,0.000053973294,0.000012345644,0.0001522793],"genre_scores_gemma":[0.99034506,0.0017539344,0.0024722323,0.0017850016,0.0029698827,0.00015418079,0.00001778602,0.00006137607,0.0004405234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98866487,0.002386815,0.0068229893,0.00054101314,0.0008830409,0.0007012707],"domain_scores_gemma":[0.9421736,0.049570706,0.0052527417,0.0006919703,0.0013503334,0.00096064963],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017176045,0.00038376442,0.0072658486,0.00016419424,0.00014535221,0.000030821106,0.0006924041,0.000591922,0.0002915264],"category_scores_gemma":[0.021403566,0.00022725866,0.002939117,0.00029102562,0.0014881812,0.00019859028,0.0001689074,0.0011456147,0.000010629965],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.821167,0.021848,0.0049131373,0.00005818936,0.0008048254,0.0005085515,0.000040178213,4.92597e-7,0.000078004654,0.000003460702,0.03965347,0.11092468],"study_design_scores_gemma":[0.9212268,0.06837375,0.00068420905,0.00011546334,0.0011099053,0.00006024121,0.000039494924,0.00033156193,0.0038748854,0.000044202694,0.0039673555,0.00017210928],"about_ca_topic_score_codex":0.00009813041,"about_ca_topic_score_gemma":0.00006466891,"teacher_disagreement_score":0.110752575,"about_ca_system_score_codex":0.00032977774,"about_ca_system_score_gemma":0.0070080743,"threshold_uncertainty_score":0.9986213},"labels":[],"label_agreement":null},{"id":"W2885515490","doi":"10.1200/jco.2017.35.15_suppl.e21714","title":"Sexual function and satisfaction in Mexican young women undergoing breast cancer treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Sexual function; Prospective cohort study; Gynecology; Breast cancer; Cohort; Internal medicine; Cancer","score_opus":0.09438340854156262,"score_gpt":0.44994743122095276,"score_spread":0.35556402267939013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885515490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903823,0.00022862006,0.000023749704,0.0057102526,0.0022805424,0.000071689,0.0000042089027,0.000004106861,0.0012945418],"genre_scores_gemma":[0.9962142,0.0015248772,0.00003192893,0.00043960483,0.0014099964,0.000006178708,4.879739e-7,0.000008266059,0.00036447833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987027,0.00013241112,0.00073146785,0.00013079893,0.00014737902,0.00015525549],"domain_scores_gemma":[0.9983028,0.00036339532,0.0008633579,0.00013812321,0.00010891309,0.00022338821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009715075,0.000083485655,0.0006846751,0.00007369139,0.000075519325,0.00001993055,0.000045017146,0.00019864745,0.00014580146],"category_scores_gemma":[0.0003440669,0.00006017176,0.000087615575,0.000031477222,0.00011657363,0.0001771109,0.000020670333,0.00036893398,0.0000018525238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025491184,0.00012774815,0.649317,0.00001134455,0.000112350994,0.00006356777,0.00024043779,0.000001756686,0.000066997214,0.000016978585,0.0000861478,0.34740654],"study_design_scores_gemma":[0.006393041,0.0061298776,0.98241156,0.000060572587,0.00014763766,0.0003158666,0.001221789,0.000020824098,0.0000034250922,0.00024189733,0.0030007693,0.000052763968],"about_ca_topic_score_codex":0.003973141,"about_ca_topic_score_gemma":0.06902598,"teacher_disagreement_score":0.34735376,"about_ca_system_score_codex":0.0006365809,"about_ca_system_score_gemma":0.0010207167,"threshold_uncertainty_score":0.94796187},"labels":[],"label_agreement":null},{"id":"W2886255359","doi":"10.1200/jco.2017.35.15_suppl.5518","title":"Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with <i>BRCA</i>-mutated (<i>BRCA</i>m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Nausea; Discontinuation; Vomiting; Internal medicine; Adverse effect; Tolerability; Anemia; Oncology; Neutropenia; BRCA mutation; Gastroenterology; Chemotherapy; Ovarian cancer; Cancer","score_opus":0.07173639697451109,"score_gpt":0.4348203187221891,"score_spread":0.363083921747678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886255359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861138,0.00006631414,0.0004430232,0.0064198477,0.002583697,0.0015878855,0.00006282664,0.000029392191,0.0026932415],"genre_scores_gemma":[0.9900374,0.00036039297,0.0024636912,0.005037737,0.0012409693,0.00007256152,0.000023570286,0.00008083822,0.0006828849],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99314034,0.000799581,0.0035775052,0.0006535427,0.0010397865,0.0007892402],"domain_scores_gemma":[0.9884665,0.0011197692,0.0072206003,0.0007610889,0.0017142433,0.00071780145],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032189926,0.0004873133,0.0030741636,0.00024290936,0.00028123366,0.000024598217,0.0004819337,0.00072686444,0.00020058212],"category_scores_gemma":[0.001985732,0.00033069748,0.0004163254,0.00027290586,0.00076893513,0.0006198338,0.000090857,0.0025214665,0.000027453361],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83598566,0.010223279,0.11200272,0.000049245016,0.0017065621,0.0043603685,0.00072679477,0.00028796378,0.00030451803,0.000041945073,0.0070658005,0.027245164],"study_design_scores_gemma":[0.7874497,0.05415148,0.14294223,0.0019287606,0.00072787463,0.0003986213,0.00032387083,0.00019806721,0.0004693041,0.0001648138,0.0107605485,0.00048471824],"about_ca_topic_score_codex":0.00033691069,"about_ca_topic_score_gemma":0.00093928765,"teacher_disagreement_score":0.04853594,"about_ca_system_score_codex":0.001106371,"about_ca_system_score_gemma":0.004155589,"threshold_uncertainty_score":0.9999145},"labels":[],"label_agreement":null},{"id":"W2887254277","doi":"10.1200/jco.2018.36.4_suppl.648","title":"Clinical implications of muscle mass and quality in early-stage colorectal cancer (CRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sarcopenia; Internal medicine; Proportional hazards model; Skeletal muscle; Body mass index; Univariate analysis; Colorectal cancer; Cancer; Cohort; Stage (stratigraphy); Gastroenterology; Sarcopenic obesity; Multivariate analysis","score_opus":0.37213117773223076,"score_gpt":0.6187799639384304,"score_spread":0.24664878620619962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887254277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727855,0.00023580123,0.00013134093,0.023490025,0.00087530946,0.00017149211,0.000010530288,0.0000053427802,0.0022947127],"genre_scores_gemma":[0.9865612,0.0020409082,0.0061379443,0.003746294,0.0013920412,0.000004524957,7.4984007e-7,0.000008152442,0.00010821833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953079,0.0006559524,0.0035062134,0.00016459098,0.00017915937,0.00018617997],"domain_scores_gemma":[0.9945661,0.0026506751,0.001684154,0.00013251705,0.0005732722,0.00039331452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006924059,0.00007416334,0.0012442814,0.000114725335,0.000034934747,0.0000034063119,0.00009896415,0.0003544378,0.00019328835],"category_scores_gemma":[0.0031703766,0.000058445796,0.00021843816,0.00015299037,0.00061526755,0.000063651954,0.00003599029,0.0009473851,0.000006074164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001691772,0.0008621833,0.9458949,0.000059561713,0.000044936394,0.000018680123,0.000084124316,2.0723893e-7,0.00053974695,0.00085465435,0.00084424106,0.049105003],"study_design_scores_gemma":[0.0062931594,0.005258187,0.94314164,0.000120645156,0.0000542841,0.00001846039,0.00006958625,0.000024556866,0.00006575563,0.0009583584,0.043947164,0.00004823032],"about_ca_topic_score_codex":0.00016523963,"about_ca_topic_score_gemma":0.0006155494,"teacher_disagreement_score":0.049056772,"about_ca_system_score_codex":0.000088100955,"about_ca_system_score_gemma":0.0011825184,"threshold_uncertainty_score":0.41159695},"labels":[],"label_agreement":null},{"id":"W2888159090","doi":"10.1200/jco.2015.33.15_suppl.5523","title":"The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Ottawa Hospital; McMaster University; Cancer Care Ontario; Thunder Bay Regional Health Sciences Centre; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Cervical cancer; Oncology; Cancer; Radiology; Internal medicine","score_opus":0.10171724162074634,"score_gpt":0.483993990781262,"score_spread":0.3822767491605156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888159090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921771,0.0026719333,0.00012752732,0.002225274,0.00054737565,0.00044446395,0.0000055043292,0.000003861041,0.0017969353],"genre_scores_gemma":[0.993161,0.0011406061,0.0047024437,0.00037369633,0.00044246143,0.00006058042,5.591846e-7,0.000013919529,0.000104735926],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973804,0.00017072735,0.0016217114,0.00015755038,0.00039295902,0.00027667682],"domain_scores_gemma":[0.99322855,0.0047586807,0.0010333952,0.00015553502,0.00046605017,0.0003577687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001826857,0.0001292564,0.0012988081,0.00008860166,0.000029250607,0.0000055783994,0.00015008605,0.00006150407,0.00003405557],"category_scores_gemma":[0.0022513412,0.000059275644,0.00022693245,0.00023795041,0.00013281437,0.000058059366,0.000029162988,0.00028615404,0.0000018379004],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09250847,0.0013897495,0.06855021,0.0000112213875,0.00029144055,0.0003287561,0.00008782076,0.0001701197,0.00001519234,0.000062896994,0.000043524768,0.8365406],"study_design_scores_gemma":[0.15475406,0.25161588,0.2928816,0.00086980825,0.000721772,0.00090882095,0.0033300065,0.00056168495,0.00041560872,0.01771385,0.27597672,0.00025017906],"about_ca_topic_score_codex":0.00005158316,"about_ca_topic_score_gemma":0.00066457165,"teacher_disagreement_score":0.8362904,"about_ca_system_score_codex":0.0009816805,"about_ca_system_score_gemma":0.002320995,"threshold_uncertainty_score":0.41173455},"labels":[],"label_agreement":null},{"id":"W2888335003","doi":"10.1200/jco.2007.25.18_suppl.1047","title":"A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Pemetrexed; Doxorubicin; Neutropenia; Breast cancer; Internal medicine; Chemotherapy; Phases of clinical research; Febrile neutropenia; Oncology; Gastroenterology; Surgery; Cancer; Cisplatin","score_opus":0.11186106138756197,"score_gpt":0.5453082906213601,"score_spread":0.43344722923379814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888335003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975948,0.00024089032,0.000010351965,0.0010758764,0.00037865678,0.0005680283,0.000010512544,0.0000028497518,0.000118082804],"genre_scores_gemma":[0.99792135,0.00022880652,0.00088014605,0.0006778636,0.00016614863,0.000006647626,0.0000014875751,0.000011831784,0.00010569798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974017,0.00020776324,0.0017433375,0.00016226733,0.00027851484,0.00020641989],"domain_scores_gemma":[0.9967718,0.0012135005,0.001302859,0.00009419405,0.00036048907,0.0002571268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015547517,0.0001311986,0.0014986165,0.00024215718,0.000024393621,0.0000015328659,0.00006773714,0.000089865316,0.00027269023],"category_scores_gemma":[0.00028895534,0.000073654766,0.00009262909,0.00028518017,0.00013474477,0.00008665681,0.000033766406,0.00047363635,4.1757227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13324817,0.06426715,0.5043641,0.000027585418,0.0007206742,0.0006810005,0.0005656406,0.0000072655484,0.00015441638,0.0000015061792,0.00025783345,0.2957047],"study_design_scores_gemma":[0.14484291,0.2233606,0.6289445,0.00007309822,0.0009350237,0.0000733599,0.00047936977,0.0000061270184,0.00004908642,0.0000064826936,0.0011739165,0.00005548901],"about_ca_topic_score_codex":0.00013995988,"about_ca_topic_score_gemma":0.0022987088,"teacher_disagreement_score":0.2956492,"about_ca_system_score_codex":0.00015971404,"about_ca_system_score_gemma":0.0007139472,"threshold_uncertainty_score":0.30035543},"labels":[],"label_agreement":null},{"id":"W2888374522","doi":"10.1200/jco.2012.30.15_suppl.558","title":"Aromatase inhibitors and cardiac outcomes in women undergoing cardiac angiography after early breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Tamoxifen; Cardiology; Angiography; Odds ratio; Cancer; Disease; Gynecology","score_opus":0.03397472960994263,"score_gpt":0.38552975233338854,"score_spread":0.3515550227234459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888374522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914808,0.0031359917,0.0000040466257,0.0032642512,0.0016894647,0.00017499537,0.000027979444,0.000007900146,0.00021453055],"genre_scores_gemma":[0.9944605,0.001907311,0.0002528384,0.0013586709,0.0019543322,0.00001678035,0.0000013275692,0.000017081471,0.000031137468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773186,0.00035350467,0.001166353,0.00013851505,0.0002703315,0.00033945066],"domain_scores_gemma":[0.99773866,0.000960596,0.000547291,0.00013279686,0.0001057602,0.0005148879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002665463,0.00014034804,0.0014485292,0.00022575872,0.000023973067,0.000010659036,0.000050630522,0.0003586865,0.00002740854],"category_scores_gemma":[0.00033536347,0.00010682446,0.00082346087,0.00019611396,0.00014810062,0.0002733571,0.000030863088,0.0006565866,0.000003096902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013840168,0.00037393323,0.94629025,0.000029760839,0.0007346358,0.000050792285,0.0006838652,6.601502e-7,0.0010847956,0.000011182918,0.00049058243,0.04886555],"study_design_scores_gemma":[0.0031702337,0.001036413,0.9897911,0.00014115172,0.00024408258,0.0000559537,0.00041068852,4.2007335e-7,0.00031608125,0.000083402345,0.004645967,0.0001044856],"about_ca_topic_score_codex":0.0000681763,"about_ca_topic_score_gemma":0.000012907622,"teacher_disagreement_score":0.048761062,"about_ca_system_score_codex":0.0002462073,"about_ca_system_score_gemma":0.00043884528,"threshold_uncertainty_score":0.4356175},"labels":[],"label_agreement":null},{"id":"W2888699993","doi":"10.1200/jco.2012.30.15_suppl.1542","title":"Genetic testing referral, uptake, and results in a program for women age 40 or younger with breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Genetic counseling; BRCA mutation; Breast cancer; Genetic testing; Referral; Family history; Population; Cancer; Epidemiology; Ovarian cancer; Gynecology; Internal medicine; Family medicine; Pediatrics; Genetics","score_opus":0.14331371480795843,"score_gpt":0.4601277388476735,"score_spread":0.31681402403971504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888699993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965432,0.0007837791,0.00007301644,0.0013516954,0.00043941694,0.0003025892,0.000025553938,0.000003903433,0.00047679213],"genre_scores_gemma":[0.94357413,0.00041063945,0.05311935,0.0006756159,0.0017368227,0.000120396486,0.0000032879636,0.000021548547,0.00033822528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99794996,0.00014633693,0.0012485445,0.00019872878,0.00011265114,0.00034375157],"domain_scores_gemma":[0.9981164,0.0003439067,0.0008801328,0.00014487386,0.00029249524,0.0002222379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001993288,0.00011733775,0.00047118874,0.00005139061,0.0000343813,0.00001537353,0.00013966217,0.0002821857,0.000009695998],"category_scores_gemma":[0.0017232244,0.000077905825,0.00006481193,0.00012638132,0.00017892191,0.000014010929,0.00005076828,0.00027555757,4.7268728e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022156335,0.0012649627,0.107822716,0.000055317447,0.00031011042,0.0000768533,0.00034608858,0.00019962214,0.003290779,0.000006200044,0.0050977156,0.8593733],"study_design_scores_gemma":[0.0067374385,0.010958809,0.7205033,0.000054490876,0.000067719666,0.00066822063,0.00021957204,0.000052698164,0.00010222711,0.00004567578,0.26043403,0.00015584021],"about_ca_topic_score_codex":0.000018142415,"about_ca_topic_score_gemma":0.0002829125,"teacher_disagreement_score":0.85921746,"about_ca_system_score_codex":0.00014136195,"about_ca_system_score_gemma":0.0013207868,"threshold_uncertainty_score":0.31769073},"labels":[],"label_agreement":null},{"id":"W2888722611","doi":"10.1200/jco.2018.79.3257","title":"Prostate Cancer Radiotherapy: An Evolving Paradigm","year":2018,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Context (archaeology); Prostate; Rectal examination; Perineural invasion; Radiation therapy; Cancer; Lower urinary tract symptoms; Internal medicine; Oncology; Radiology; Urology","score_opus":0.12379741805128039,"score_gpt":0.4830681059764752,"score_spread":0.3592706879251948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888722611","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02894777,0.01688053,0.00002647275,0.9453353,0.007016736,0.00061516766,0.00005023468,0.00002231446,0.0011054568],"genre_scores_gemma":[0.0037926582,0.04167947,0.003916107,0.88082784,0.067693226,0.00005910886,0.000049408754,0.00011559317,0.0018665931],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947912,0.0006164412,0.0030286019,0.0004447697,0.00061651244,0.00050248386],"domain_scores_gemma":[0.99305695,0.0013730711,0.0037958757,0.00045607123,0.0008187408,0.0004992785],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0020785555,0.0003719106,0.003271165,0.00019906087,0.000058474518,0.00003758144,0.00029406272,0.0016619306,0.001241464],"category_scores_gemma":[0.0006769566,0.00024289476,0.000957674,0.00012126659,0.00040486152,0.00021011902,0.000035946377,0.0038404246,0.000020315669],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013739684,0.00088808395,0.029589087,0.00010555903,0.0017404818,0.006843358,0.00013849004,0.0000025533493,0.000005113386,0.0000028406787,0.84633476,0.11297573],"study_design_scores_gemma":[0.007142227,0.031011404,0.022060106,0.0006800946,0.0013051914,0.00058539555,0.000010796333,0.0000478234,0.000018017685,0.00023826527,0.9366882,0.00021249444],"about_ca_topic_score_codex":0.000082374005,"about_ca_topic_score_gemma":0.000037478574,"teacher_disagreement_score":0.11276323,"about_ca_system_score_codex":0.0010535762,"about_ca_system_score_gemma":0.0055959355,"threshold_uncertainty_score":0.9996715},"labels":[],"label_agreement":null},{"id":"W2889005127","doi":"10.1200/jco.2013.31.15_suppl.8104","title":"A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Clinical endpoint; Internal medicine; Lung cancer; Oncology; KRAS; Phases of clinical research; Chemotherapy; Cancer; Gastroenterology; Clinical trial; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.050834212854776045,"score_gpt":0.4696614283411989,"score_spread":0.4188272154864229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889005127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837966,0.00070347957,0.00015663568,0.004155018,0.001641225,0.0014367931,0.000008892,0.000011792894,0.0035064959],"genre_scores_gemma":[0.9901163,0.00029707613,0.0053930725,0.0016821774,0.0014390332,0.00014538848,0.000009921846,0.00003311308,0.0008839208],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99672216,0.00021129705,0.0021460277,0.00026512318,0.00030285967,0.00035254736],"domain_scores_gemma":[0.9962885,0.0008787779,0.0016307503,0.00019523015,0.00047928432,0.0005274725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009521473,0.0002102422,0.0014936842,0.00017680679,0.000071370676,0.000016162663,0.00013041733,0.00028204964,0.00040158906],"category_scores_gemma":[0.00049678906,0.00013636771,0.000313945,0.00021860923,0.00011682328,0.00022734163,0.000041849264,0.0010097733,0.000012365455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29704797,0.060230967,0.10611868,0.00028350006,0.002206654,0.0038529031,0.0041184104,0.00051722466,0.0030558822,0.000049353843,0.01868023,0.50383824],"study_design_scores_gemma":[0.81468844,0.13964525,0.018217402,0.0009184052,0.0018541507,0.0001533532,0.0008698867,0.0009808933,0.00050335116,0.00006160022,0.021814428,0.0002928188],"about_ca_topic_score_codex":0.0001866449,"about_ca_topic_score_gemma":0.00020247763,"teacher_disagreement_score":0.5176405,"about_ca_system_score_codex":0.00034602496,"about_ca_system_score_gemma":0.0041986196,"threshold_uncertainty_score":0.74481714},"labels":[],"label_agreement":null},{"id":"W2889564758","doi":"10.1200/jco.2017.35.15_suppl.e22526","title":"Carcinosarcoma: A single centre experience and population based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Carcinosarcoma; Incidence (geometry); Carboplatin; Cancer registry; Cancer; Referral; Population; Radiation therapy; Regimen; Surgery; Internal medicine; Chemotherapy; Carcinoma; Family medicine","score_opus":0.2526113635015154,"score_gpt":0.4923814562654765,"score_spread":0.2397700927639611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889564758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931384,0.000295347,0.000019928973,0.004519244,0.00067303155,0.000151077,0.000001053135,0.0000033242002,0.0011986148],"genre_scores_gemma":[0.9975024,0.000027212256,0.0012662826,0.00052963506,0.0005699392,0.0000011990563,4.6692458e-7,0.0000063008983,0.000096586264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980465,0.00025044876,0.0011455321,0.0001483263,0.00027601852,0.00013318648],"domain_scores_gemma":[0.9973838,0.0004717917,0.0013755506,0.00026027023,0.0002766285,0.0002319951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001633436,0.000089758374,0.0010079448,0.000052325417,0.00016552032,0.000022812414,0.00010390599,0.00009911001,0.00006180343],"category_scores_gemma":[0.004893711,0.000059160688,0.00020674082,0.000023220691,0.00013015167,0.000103971826,0.00007140535,0.0003246662,0.000002037845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007790869,0.0014109898,0.9211515,0.000010897208,0.000075486714,0.0009894136,0.00023094301,2.4028554e-7,0.0000620675,0.000019321928,0.0003275003,0.07494256],"study_design_scores_gemma":[0.005422544,0.006581149,0.98112655,0.000037570408,0.0002647303,0.000113072594,0.00096463464,0.00003752381,0.000029230689,0.000033610697,0.0053370073,0.000052394746],"about_ca_topic_score_codex":0.000053481795,"about_ca_topic_score_gemma":0.00010328298,"teacher_disagreement_score":0.07489017,"about_ca_system_score_codex":0.0000462808,"about_ca_system_score_gemma":0.00022551106,"threshold_uncertainty_score":0.5858583},"labels":[],"label_agreement":null},{"id":"W2889576382","doi":"10.1200/jco.2017.35.15_suppl.11587","title":"Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Oncology; Targeted therapy; Internal medicine; Lung cancer; Immunotherapy; Pathology; Cancer","score_opus":0.0318163345960466,"score_gpt":0.3624763704538503,"score_spread":0.3306600358578037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889576382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960139,0.0013546749,0.0017111576,0.00017238606,0.00020430124,0.00020866453,0.00004274246,0.0000012870387,0.00029092474],"genre_scores_gemma":[0.9942797,0.0006908817,0.0046301945,0.000044778557,0.00023571811,0.0000047017434,0.000073030526,0.000015797514,0.00002523536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829537,0.00016045217,0.0009813639,0.00023870917,0.00016162047,0.00016248638],"domain_scores_gemma":[0.9969244,0.00060504477,0.0015958326,0.00017883771,0.00052720454,0.00016865502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085533597,0.00013559968,0.0004948284,0.00007785211,0.000094111485,0.000037632053,0.00014746664,0.00030514004,0.0000083429195],"category_scores_gemma":[0.0014002611,0.000108539876,0.000094821255,0.000051239676,0.00018951681,0.000021907426,0.00007753127,0.00036694916,2.7705022e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031576671,0.00047612507,0.5085277,0.000026794914,0.000057095393,0.00006313208,0.00010456684,0.0007484572,0.484332,0.0000064042824,0.00085121946,0.0016488787],"study_design_scores_gemma":[0.0069685387,0.003747373,0.94249004,0.000071773684,0.00006559785,0.00005422801,0.00011959243,0.0022984492,0.043652467,0.000060007715,0.00033165223,0.00014024887],"about_ca_topic_score_codex":0.000057998983,"about_ca_topic_score_gemma":0.00011280666,"teacher_disagreement_score":0.44067952,"about_ca_system_score_codex":0.00006162834,"about_ca_system_score_gemma":0.001186563,"threshold_uncertainty_score":0.44261277},"labels":[],"label_agreement":null},{"id":"W2889584784","doi":"10.1200/jco.2018.36.30_suppl.213","title":"Does the risk of emergency department visits and hospitalizations during systemic therapy for cancer influence patient decisions regarding treatment?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Emergency department; Systemic therapy; Multinomial logistic regression; Internal medicine; Cancer; Breast cancer; Emergency medicine","score_opus":0.268674369872595,"score_gpt":0.5541663017117557,"score_spread":0.2854919318391607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889584784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859277,0.004342022,0.00015364119,0.0038771771,0.0041170637,0.0014365539,0.00007494356,0.000009691283,0.000061195446],"genre_scores_gemma":[0.95709485,0.040324308,0.0012287141,0.00032284178,0.00066996616,0.00028815796,0.0000018848391,0.000016157033,0.00005312153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99363685,0.0023017349,0.0033826148,0.0001832666,0.00023184801,0.00026366924],"domain_scores_gemma":[0.9838132,0.008280922,0.0049717515,0.000472868,0.0022606468,0.00020061359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013243359,0.00013118809,0.0007499788,0.00008846241,0.0009471693,0.0000040808854,0.0003211245,0.000251172,0.000049067912],"category_scores_gemma":[0.0075760023,0.000060037513,0.00024270175,0.00016260019,0.00014896966,0.00015251193,0.000121522,0.00045590568,0.0000030262509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010259608,0.0003091743,0.9518911,0.00005221261,0.0003122511,0.000001202566,0.00721069,0.00008874038,0.0000672901,0.0001660017,0.0005658824,0.03830945],"study_design_scores_gemma":[0.0059454897,0.009864869,0.9232641,0.00089427794,0.00028822958,0.0000076362685,0.00737374,0.00024247752,0.000114109265,0.0020203653,0.04983682,0.00014792314],"about_ca_topic_score_codex":0.00022848479,"about_ca_topic_score_gemma":0.0010183962,"teacher_disagreement_score":0.04927094,"about_ca_system_score_codex":0.0003182923,"about_ca_system_score_gemma":0.0012032908,"threshold_uncertainty_score":0.90697294},"labels":[],"label_agreement":null},{"id":"W2889588367","doi":"10.1200/jco.2017.35.15_suppl.e18336","title":"Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Discontinuation; Hazard ratio; Oncology; Toxicity; Odds ratio; Clinical trial; Adverse effect; Confidence interval","score_opus":0.046718650702489074,"score_gpt":0.41618026573376043,"score_spread":0.36946161503127134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889588367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942144,0.00042839357,0.00015759034,0.0019631048,0.00049853517,0.000107684784,0.0000074458385,6.8159034e-7,0.0026221287],"genre_scores_gemma":[0.9957545,0.0017550733,0.0014949896,0.0003556951,0.0005829446,0.0000010593786,0.000001982165,0.000008222864,0.00004553353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775237,0.00014649033,0.0016527809,0.00018892484,0.00010469015,0.0001547322],"domain_scores_gemma":[0.99676347,0.0005870459,0.0019177649,0.0003546541,0.0002121003,0.0001649413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025069413,0.00009455876,0.0008506647,0.000031170912,0.000045130368,0.0000145997265,0.00034275264,0.00028341936,0.000008077101],"category_scores_gemma":[0.007464983,0.00007966121,0.00019638365,0.000019966246,0.00035124892,0.0000062966974,0.0002469206,0.00032042043,7.008524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014450411,0.004059572,0.4845633,0.00010026613,0.00034589626,0.00009860576,0.00032379245,0.00042607103,0.033677693,0.0006027461,0.0038039042,0.45754775],"study_design_scores_gemma":[0.0072485334,0.0049873963,0.9319705,0.000043444616,0.00004477047,0.000037325583,0.000053533342,0.000092515234,0.0032770613,0.0007262943,0.051388703,0.00012995179],"about_ca_topic_score_codex":0.00006262366,"about_ca_topic_score_gemma":0.00017262947,"teacher_disagreement_score":0.4574178,"about_ca_system_score_codex":0.000028129232,"about_ca_system_score_gemma":0.0008602635,"threshold_uncertainty_score":0.8936821},"labels":[],"label_agreement":null},{"id":"W2889590535","doi":"10.1200/jco.2017.35.15_suppl.3602","title":"Differences in systemic and surgical therapy between right (R) and left (L) sided metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Colorectal cancer; Systemic therapy; Irinotecan; Internal medicine; Oncology; Cetuximab; Primary tumor; Cancer; Oxaliplatin; Proportional hazards model; Chemotherapy; Metastasis; Breast cancer","score_opus":0.17213221868915646,"score_gpt":0.4855553904047687,"score_spread":0.31342317171561224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889590535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414797,0.009029114,0.0000011492521,0.0050861724,0.00044573893,0.00021916539,0.0000066275425,0.0000034922668,0.0010605493],"genre_scores_gemma":[0.9779321,0.021229872,0.00011024178,0.00011559067,0.0004792903,0.000006174816,4.6356377e-7,0.0000073809397,0.0001188923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979592,0.00027478236,0.0011861068,0.00018891205,0.00020585893,0.00018515272],"domain_scores_gemma":[0.99593544,0.0025488972,0.0010497286,0.000099393226,0.00013636069,0.00023019106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012787576,0.0001439761,0.001938216,0.000074765056,0.00012380784,0.000026571479,0.00010420294,0.00015658946,0.0000638411],"category_scores_gemma":[0.0009126976,0.000079693826,0.0001566217,0.000025779902,0.00049055286,0.00009795592,0.000067987385,0.0004837046,7.9486927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025174664,0.00024935536,0.8957989,0.000022264088,0.0006289746,0.0009584054,0.0002105965,7.7134224e-8,0.000031743497,0.000023436021,0.000069089045,0.09948968],"study_design_scores_gemma":[0.011559742,0.0075445836,0.9764317,0.00021973572,0.00031066092,0.0006119606,0.00011952789,0.000013593955,0.00004025963,0.0002555823,0.0028146678,0.00007795127],"about_ca_topic_score_codex":0.00020615765,"about_ca_topic_score_gemma":0.00087716617,"teacher_disagreement_score":0.09941173,"about_ca_system_score_codex":0.00009488436,"about_ca_system_score_gemma":0.00046286662,"threshold_uncertainty_score":0.32498202},"labels":[],"label_agreement":null},{"id":"W2889599863","doi":"10.1200/jco.2017.35.15_suppl.tps3113","title":"INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Immunogenicity; Agonist; Immunotherapy; Pharmacokinetics; Antibody; CD28; Pharmacodynamics; Internal medicine; Oncology; Biomarker; Cytokine release syndrome; Cancer; Pharmacology; T cell; Immunology; Immune system; Chimeric antigen receptor; Adverse effect; Receptor","score_opus":0.12653220019038627,"score_gpt":0.5105342624420508,"score_spread":0.38400206225166456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889599863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783367,0.000049623348,0.0000054665124,0.00072596164,0.00016825553,0.0009857413,0.000004353248,0.0000022047723,0.00022473022],"genre_scores_gemma":[0.99903506,0.00008235072,0.0005328304,0.00025111213,0.00004710667,0.000009187332,0.000007366752,0.000016586426,0.000018419374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970352,0.0003299623,0.0018785383,0.0002404567,0.00033088046,0.00018492743],"domain_scores_gemma":[0.9959564,0.0002277011,0.0029342703,0.0003475838,0.00035359387,0.00018041738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017904518,0.00015292618,0.001620632,0.00018207794,0.00007301626,0.000036958285,0.00032452884,0.0001584856,0.000010874004],"category_scores_gemma":[0.0004950457,0.000100960606,0.000040498504,0.00011388206,0.00034472268,0.00046928664,0.00008238434,0.00057441,2.1041913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2553465,0.054511543,0.58230513,0.000024542634,0.00017820255,0.00041861364,0.0004024548,0.000001021862,0.00045587716,0.0000027598321,0.000008409718,0.10634497],"study_design_scores_gemma":[0.24493602,0.15815191,0.59592694,0.00028855496,0.00007701611,0.00004772008,0.00032940495,0.000028909446,0.00005667352,0.000011866765,0.00007188776,0.000073118026],"about_ca_topic_score_codex":0.00017906411,"about_ca_topic_score_gemma":0.0016555991,"teacher_disagreement_score":0.10627185,"about_ca_system_score_codex":0.00011617716,"about_ca_system_score_gemma":0.0010293052,"threshold_uncertainty_score":0.41170537},"labels":[],"label_agreement":null},{"id":"W2889620472","doi":"10.1200/jco.2017.35.15_suppl.10123","title":"Trastuzumab-related subclinical cardiotoxicity in patients with early stage HER2-positive breast cancer: A retrospective single-center cohort study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Ejection fraction; Internal medicine; Breast cancer; Asymptomatic; Cardiotoxicity; Cancer; Surgery; Heart failure; Chemotherapy","score_opus":0.05702956444858435,"score_gpt":0.44346861963295403,"score_spread":0.38643905518436966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889620472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919034,0.00004454133,0.0000026465195,0.002363428,0.0016344159,0.0013734476,0.00009423838,0.000010340753,0.0025734988],"genre_scores_gemma":[0.99815667,0.00020790054,0.000057530957,0.0004583467,0.0007024287,0.000026047686,0.0000061517712,0.00003087353,0.00035407557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555176,0.00076746073,0.0022374506,0.0004450056,0.00061032496,0.00038797347],"domain_scores_gemma":[0.99480337,0.0007334407,0.0027508666,0.00036906844,0.00088378723,0.00045945018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022953532,0.0002657672,0.0026688278,0.00013922919,0.00013119397,0.000030198196,0.00028919772,0.00045191156,0.00033078174],"category_scores_gemma":[0.000650672,0.00018233698,0.00049556815,0.00011871264,0.000570708,0.0002540041,0.00009620582,0.0018724945,0.000008976732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033289663,0.02725981,0.9264589,0.000007349578,0.0026935115,0.001513579,0.00029152204,0.0000037568589,0.0000052976006,0.0000034819238,0.00043941016,0.008033724],"study_design_scores_gemma":[0.05335538,0.06052835,0.8841667,0.00012899867,0.0010726352,0.000084440115,0.000056177072,0.0000048839784,0.0000062627414,0.0000116749625,0.00043849455,0.0001459701],"about_ca_topic_score_codex":0.0011006086,"about_ca_topic_score_gemma":0.0019348937,"teacher_disagreement_score":0.042292163,"about_ca_system_score_codex":0.0014141188,"about_ca_system_score_gemma":0.0012722039,"threshold_uncertainty_score":0.8135161},"labels":[],"label_agreement":null},{"id":"W2889624058","doi":"10.1200/jco.2018.36.15_suppl.10504","title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neurofibromatosis and Schwannoma Cases","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Trametinib; Cohort; Internal medicine; Neurofibromatosis; Adverse effect; Stock options; Oncology; Surgery; Gastroenterology; Pathology; MAPK/ERK pathway","score_opus":0.09482405278384176,"score_gpt":0.43430183984761417,"score_spread":0.3394777870637724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889624058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955519,0.00005182593,0.0000031624081,0.00091452687,0.001403645,0.00065241696,0.000008799217,0.00003262928,0.0013811248],"genre_scores_gemma":[0.9972692,0.000058391895,0.00056615635,0.0010015826,0.0009722583,0.0000052173455,0.000006721006,0.000056986686,0.00006349233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99381757,0.0009528044,0.0034589306,0.00044010652,0.00083120936,0.00049939886],"domain_scores_gemma":[0.99335647,0.002006488,0.0024987452,0.00037538205,0.0011519417,0.000610972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022196518,0.00031560755,0.0022061628,0.00047115594,0.000084075895,0.000029299137,0.0002942139,0.00036020108,0.00014088523],"category_scores_gemma":[0.0064992695,0.00021368878,0.00038990122,0.0010769683,0.00025628027,0.00025420016,0.0000962246,0.0011416484,0.000047711215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016597118,0.022807324,0.950284,0.000029229266,0.00017615604,0.001984146,0.00016563378,8.7520414e-7,0.00008478993,0.000009005742,0.0029564227,0.004905313],"study_design_scores_gemma":[0.03447422,0.1680796,0.79484284,0.00006222013,0.00055698195,0.00018150714,0.000091663635,0.000023287836,0.00004749557,0.000024583855,0.001453509,0.00016209825],"about_ca_topic_score_codex":0.000015268008,"about_ca_topic_score_gemma":0.000047037694,"teacher_disagreement_score":0.15544115,"about_ca_system_score_codex":0.00010644511,"about_ca_system_score_gemma":0.0013404741,"threshold_uncertainty_score":0.87139755},"labels":[],"label_agreement":null},{"id":"W2889637655","doi":"10.1200/jco.2018.36.15_suppl.8003","title":"Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Waldenstrom macroglobulinemia; Gastroenterology; Clinical endpoint; Placebo; Regimen; Macroglobulinemia; Randomized controlled trial; Surgery; Lymphoma; Pathology","score_opus":0.1359827613221785,"score_gpt":0.5320171864932534,"score_spread":0.39603442517107484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889637655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97902507,0.00041721042,0.00024160284,0.0064990534,0.0028341638,0.0015267978,0.0000075818307,0.000015875336,0.009432639],"genre_scores_gemma":[0.98650163,0.0009092546,0.0053979666,0.0011818465,0.0053344155,0.000019371662,0.000004888347,0.000038065333,0.00061256316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98798656,0.0023278873,0.007393372,0.00039886136,0.0012346794,0.00065863715],"domain_scores_gemma":[0.980419,0.013595955,0.0033631902,0.0005513248,0.0013681565,0.00070237403],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.021716848,0.00028373496,0.0063757086,0.00046238388,0.000041734726,0.000014743189,0.0005260779,0.00095216074,0.0010258118],"category_scores_gemma":[0.044656254,0.00019842482,0.0014527154,0.00045794042,0.0022870805,0.0001469134,0.00019364925,0.0019522127,0.00014487191],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9224488,0.01566112,0.00008595319,0.00008613517,0.000493134,0.002343002,0.00015658954,0.0000018764409,0.0001352613,0.000150722,0.006145965,0.052291427],"study_design_scores_gemma":[0.9301286,0.0395914,0.000048190042,0.0003012197,0.0005295853,0.0015385495,0.00008410799,0.003344083,0.00075273844,0.00054107216,0.022993254,0.00014719299],"about_ca_topic_score_codex":0.00016570637,"about_ca_topic_score_gemma":0.00007728467,"teacher_disagreement_score":0.052144233,"about_ca_system_score_codex":0.003199487,"about_ca_system_score_gemma":0.032559466,"threshold_uncertainty_score":0.9998874},"labels":[],"label_agreement":null},{"id":"W2889640189","doi":"10.1200/jco.2018.36.15_suppl.tps3126","title":"An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Nivolumab; Oncology; Internal medicine; Cancer; Androgen receptor; Immunotherapy","score_opus":0.2131296219286533,"score_gpt":0.551173903580684,"score_spread":0.33804428165203065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889640189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957359,0.00021430061,0.000010675046,0.0014703809,0.00009578668,0.0018212569,0.000012521747,0.0000047685994,0.0006344513],"genre_scores_gemma":[0.99686956,0.0003341522,0.0018329333,0.00015522915,0.0001041083,0.00009037239,0.000006947492,0.00002796682,0.00057873403],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9959969,0.00079497433,0.0019863541,0.00030014347,0.0005967438,0.00032491487],"domain_scores_gemma":[0.99667233,0.00046165724,0.0014755583,0.00024785945,0.00087526615,0.00026730928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003391738,0.00019049179,0.0015172394,0.00025788211,0.000050574043,0.00003225717,0.00027464185,0.00011199177,0.0001840522],"category_scores_gemma":[0.000308953,0.00010126588,0.00003296368,0.0005424216,0.00039813487,0.0004488578,0.000045695066,0.00064581365,0.0000022488518],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4748603,0.113031216,0.31982028,0.00020171044,0.0017824592,0.005900881,0.007133311,0.00010050859,0.0050735907,0.0000675628,0.0004670303,0.07156112],"study_design_scores_gemma":[0.29834548,0.44950894,0.24172096,0.0006804207,0.0006692156,0.00015206494,0.0059637893,0.0008979482,0.001077682,0.00017285852,0.00060675247,0.0002039013],"about_ca_topic_score_codex":0.001385919,"about_ca_topic_score_gemma":0.019943273,"teacher_disagreement_score":0.33647773,"about_ca_system_score_codex":0.00039959344,"about_ca_system_score_gemma":0.0042127213,"threshold_uncertainty_score":0.9979402},"labels":[],"label_agreement":null},{"id":"W2889642957","doi":"10.1200/jco.2017.35.15_suppl.3070","title":"Validation of the Princess Margaret immune oncology prognostic index (PM-IPI) for patients (pts) treated in immune oncology (IO) early phase trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Oncology; Progression-free survival; Gastroenterology; Surgery; Overall survival","score_opus":0.19966323785957193,"score_gpt":0.4962821865088141,"score_spread":0.2966189486492422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889642957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679996,0.00032734306,0.00006867899,0.0054537505,0.0027869125,0.0026690098,0.000023874534,0.000008647899,0.0018618209],"genre_scores_gemma":[0.9974481,0.00032206476,0.0009299947,0.00019735115,0.000725271,0.00009849736,0.000028041215,0.000039312934,0.00021138765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9884759,0.0030328836,0.007034132,0.0003906323,0.00058755395,0.0004788519],"domain_scores_gemma":[0.9756707,0.008990955,0.012794573,0.000802299,0.001412935,0.00032856973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01188864,0.00032916397,0.0045440025,0.0002963721,0.00016491443,0.000025431167,0.00081086386,0.0011238476,0.00010619731],"category_scores_gemma":[0.03442058,0.00019737284,0.0013879654,0.00017838838,0.0006972312,0.00023686673,0.00023556167,0.0013610182,0.000008028653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04117188,0.017247923,0.71098876,0.00009160062,0.000898555,0.0003724744,0.00026772326,0.000015232041,0.0014536724,0.00005507354,0.0002955454,0.22714157],"study_design_scores_gemma":[0.07829246,0.07045201,0.83568907,0.00027218834,0.0014103793,0.0001108779,0.000059567545,0.000085990876,0.0043475884,0.000387267,0.008751013,0.00014157034],"about_ca_topic_score_codex":0.00028835973,"about_ca_topic_score_gemma":0.000121873585,"teacher_disagreement_score":0.22700001,"about_ca_system_score_codex":0.0011571355,"about_ca_system_score_gemma":0.0031731867,"threshold_uncertainty_score":0.9737129},"labels":[],"label_agreement":null},{"id":"W2889659318","doi":"10.1200/jco.2017.35.15_suppl.e18275","title":"Potentially avoidable hospitalizations in patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Logistic regression; Emergency department; Odds ratio; Emergency medicine; Medical record; Population; Cancer; Hospital admission; Odds; Pediatrics; Internal medicine","score_opus":0.04840045251408476,"score_gpt":0.43883400695124714,"score_spread":0.3904335544371624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889659318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987122,0.00018398352,0.00016423507,0.005078175,0.0021138731,0.00016509651,0.0000044161948,0.0000038984326,0.005164318],"genre_scores_gemma":[0.99708515,0.000360742,0.00075466844,0.0009411175,0.00043397737,0.000004855644,0.0000021182022,0.0000118468415,0.00040549823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839014,0.00008601551,0.0009646048,0.00012134284,0.00028103095,0.00015683867],"domain_scores_gemma":[0.99732107,0.00016968515,0.0014230496,0.0002472746,0.0006333503,0.00020557971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071915326,0.00007952386,0.0007718856,0.00006549492,0.00007606964,0.00001599558,0.0001895992,0.00017024465,0.00013131306],"category_scores_gemma":[0.0013764406,0.00005419095,0.00016098646,0.000059216283,0.00014293137,0.0002004372,0.000037285303,0.0005022451,0.0000035514522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027893805,0.0007379093,0.87704504,0.000012835638,0.000081568964,0.00010080242,0.00006492656,0.000052021187,0.0000030259127,0.000043272114,0.0006168953,0.118452296],"study_design_scores_gemma":[0.010179372,0.0072135106,0.94957626,0.00017216189,0.00012420162,0.0000057388943,0.00005830345,0.00000949631,0.00000791741,0.00007743575,0.032512892,0.000062737105],"about_ca_topic_score_codex":0.0002386791,"about_ca_topic_score_gemma":0.0040047206,"teacher_disagreement_score":0.11838956,"about_ca_system_score_codex":0.00013770122,"about_ca_system_score_gemma":0.0014103483,"threshold_uncertainty_score":0.25018975},"labels":[],"label_agreement":null},{"id":"W2889659866","doi":"10.1200/jco.2018.36.15_suppl.tps598","title":"The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Overweight; Weight loss; Cancer; Hazard ratio; Internal medicine; Randomized controlled trial; Body mass index; Oncology; Obesity; Confidence interval","score_opus":0.06536582109040022,"score_gpt":0.466055785757973,"score_spread":0.4006899646675728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889659866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857763,0.005132277,0.000011152074,0.0052260575,0.0015928138,0.0019395624,0.00014153235,0.000005209703,0.00017506717],"genre_scores_gemma":[0.9687881,0.026630655,0.000082712584,0.0002081958,0.0037471957,0.00019691682,0.0000011143268,0.00003272158,0.00031242517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933404,0.0013762505,0.0036472452,0.00034964623,0.0007914758,0.0004949927],"domain_scores_gemma":[0.9897598,0.0043798923,0.0042919926,0.00040489246,0.0007946525,0.00036878834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006491596,0.00032930353,0.0036611483,0.00010063584,0.00012631498,0.000017425857,0.00028847184,0.0003044216,0.00061062985],"category_scores_gemma":[0.0005371216,0.00013899413,0.00055286527,0.00028480284,0.0019272537,0.00012691805,0.000057779303,0.00067446165,0.0000011571312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7901538,0.002501135,0.035396922,0.000019482008,0.0012098779,0.000069349786,0.0015480211,0.000006546059,0.00009861699,0.000043838885,0.00007117915,0.16888122],"study_design_scores_gemma":[0.89917856,0.041776434,0.045169238,0.0003606323,0.0011013129,0.00015590432,0.00031066893,0.00038178035,0.00018225875,0.00021854592,0.011012134,0.00015252044],"about_ca_topic_score_codex":0.0028519654,"about_ca_topic_score_gemma":0.002275256,"teacher_disagreement_score":0.1687287,"about_ca_system_score_codex":0.00063759426,"about_ca_system_score_gemma":0.0034301677,"threshold_uncertainty_score":0.71010464},"labels":[],"label_agreement":null},{"id":"W2889677173","doi":"10.1200/jco.2018.36.15_suppl.9537","title":"Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Avelumab; Medicine; Merkel cell carcinoma; Expanded access; Internal medicine; Progressive disease; Merkel cell polyomavirus; Clinical trial; Oncology; Carcinoma; Chemotherapy; Nivolumab; Cancer; Immunotherapy","score_opus":0.13064093407760075,"score_gpt":0.49024850444011536,"score_spread":0.3596075703625146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889677173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520457,0.0009027242,0.000056208515,0.00023093479,0.0007046111,0.00048726506,0.00008707567,0.0000129376485,0.0023136465],"genre_scores_gemma":[0.9950457,0.00019800702,0.003577547,0.00041978163,0.00055394165,0.00001857793,0.000018059867,0.00001617992,0.00015216663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662596,0.0002815703,0.0020446368,0.00028008348,0.00046404795,0.0003037132],"domain_scores_gemma":[0.9959696,0.0004541924,0.0020032548,0.00028097723,0.00063782255,0.0006541765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027926205,0.0002281695,0.001645955,0.00007302499,0.00004977697,0.000014621847,0.00024458757,0.00024283871,0.0007343286],"category_scores_gemma":[0.00034474029,0.00012711817,0.00045610318,0.00018802602,0.00060528563,0.00016747268,0.00005548026,0.0002585796,0.000014386077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027196541,0.034819264,0.6162243,0.00005083079,0.0012081513,0.0010415073,0.0007480626,0.0000035649894,0.00010211646,0.0000065946347,0.0008164064,0.3177827],"study_design_scores_gemma":[0.04013359,0.11988891,0.82216763,0.00011222384,0.0021253328,0.00008874585,0.00036959816,0.00015128836,0.0022960186,0.00010377346,0.012384315,0.00017854974],"about_ca_topic_score_codex":0.00019938263,"about_ca_topic_score_gemma":0.00014166739,"teacher_disagreement_score":0.31760412,"about_ca_system_score_codex":0.00022172139,"about_ca_system_score_gemma":0.0017133289,"threshold_uncertainty_score":0.80403835},"labels":[],"label_agreement":null},{"id":"W2889685701","doi":"10.1200/jco.2016.34.15_suppl.5578","title":"A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Medicine; Ovarian cancer; Paclitaxel; Cancer; Cancer research; Oncology; Internal medicine","score_opus":0.2935424440650372,"score_gpt":0.5664334602611045,"score_spread":0.2728910161960673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889685701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884862,0.00050362485,0.000029074285,0.0067046247,0.0031005512,0.0005796778,0.00010296353,0.00001109191,0.00048222154],"genre_scores_gemma":[0.9971019,0.0006010145,0.00014028272,0.0007722516,0.00082068663,0.000044404835,9.918131e-7,0.000028819064,0.0004896713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937961,0.002020986,0.0029532746,0.00036623265,0.0003952638,0.0004681245],"domain_scores_gemma":[0.9931246,0.002623287,0.003006581,0.00020900735,0.0006087729,0.00042774246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035510568,0.00029866956,0.0018960015,0.00022821876,0.00014769433,0.000009354911,0.00046542275,0.00054131524,0.00090988685],"category_scores_gemma":[0.0005084166,0.00017442326,0.00022733651,0.0003492262,0.0005545792,0.00021320963,0.00013984783,0.0013673038,0.000004231345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11567008,0.058628496,0.5928597,0.00008798665,0.0023802198,0.0018426605,0.0015055157,0.00005884029,0.03222269,0.00025823704,0.005034721,0.18945089],"study_design_scores_gemma":[0.24664605,0.19839305,0.45367354,0.0008767068,0.0015232414,0.0000818935,0.002789253,0.00016106458,0.0053924094,0.0003757094,0.089346714,0.0007403905],"about_ca_topic_score_codex":0.0003098071,"about_ca_topic_score_gemma":0.0042765485,"teacher_disagreement_score":0.1887105,"about_ca_system_score_codex":0.00029595636,"about_ca_system_score_gemma":0.0015958116,"threshold_uncertainty_score":0.9962623},"labels":[],"label_agreement":null},{"id":"W2889696341","doi":"10.1200/jco.2017.35.15_suppl.tps3621","title":"The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Ottawa; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Durvalumab; Irinotecan; Tremelimumab; Internal medicine; Oncology; Colorectal cancer; Pembrolizumab; Oxaliplatin; Cancer; Immunotherapy; Ipilimumab","score_opus":0.05437149275475614,"score_gpt":0.44329688858097105,"score_spread":0.3889253958262149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889696341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357545,0.0008360903,0.000005516733,0.0014216525,0.00086153223,0.0030977342,0.000026543143,0.000005582597,0.00016991605],"genre_scores_gemma":[0.9985307,0.0007151243,0.00021288324,0.00019289415,0.00022864014,0.0000471226,0.000003120447,0.000030449564,0.000039076058],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948826,0.0010587338,0.0028109178,0.00028456212,0.0006753407,0.00028787268],"domain_scores_gemma":[0.9921281,0.0024224934,0.0037987884,0.00042669318,0.0009670637,0.00025686057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044890135,0.00023564498,0.0029663052,0.00014022063,0.0002795731,0.000026566757,0.00030895002,0.00024181667,0.000039576465],"category_scores_gemma":[0.003844108,0.00012754435,0.0003692969,0.00009354654,0.0008674446,0.00015476145,0.00008559191,0.00076024316,5.965409e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82656646,0.006940631,0.047496963,0.000016287842,0.00096357206,0.00013742488,0.003932454,8.3705794e-7,0.0000632971,0.0000013410139,0.00014907477,0.11373167],"study_design_scores_gemma":[0.602886,0.24273838,0.14750066,0.000114829694,0.0003661675,0.000009554287,0.004066376,0.0000017302236,0.00006404834,0.000009183083,0.0021514383,0.00009160558],"about_ca_topic_score_codex":0.00019159411,"about_ca_topic_score_gemma":0.0011826275,"teacher_disagreement_score":0.23579775,"about_ca_system_score_codex":0.0003443197,"about_ca_system_score_gemma":0.0017145097,"threshold_uncertainty_score":0.5201108},"labels":[],"label_agreement":null},{"id":"W2889698651","doi":"10.1200/jco.2018.36.15_suppl.5003","title":"Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Clinical endpoint; Prostate cancer; Abiraterone; Progression-free survival; Oncology; Urology; Randomized controlled trial; Gastroenterology; Cancer; Chemotherapy; Pathology; Androgen receptor","score_opus":0.0999205760092294,"score_gpt":0.4754539768126198,"score_spread":0.37553340080339037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889698651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911366,0.00012533057,0.00017669713,0.005083287,0.00085407763,0.002033791,0.00001719521,0.000011263813,0.0005617543],"genre_scores_gemma":[0.9927165,0.00019361041,0.003755921,0.0022154194,0.0006335062,0.00014547902,0.000009988521,0.000031018815,0.00029857352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943863,0.0011219967,0.0032842876,0.00026903595,0.0006279833,0.00031037896],"domain_scores_gemma":[0.9936955,0.0013659567,0.0030811979,0.00021986032,0.0012930434,0.00034444427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044205016,0.00023003992,0.002872798,0.00020854277,0.000077937584,0.000016862026,0.00012305276,0.0001580015,0.00040905885],"category_scores_gemma":[0.0011389315,0.00012862192,0.00024279507,0.0003125669,0.00085247576,0.00020702381,0.000018696008,0.0007483887,0.000007067281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9739431,0.010111661,0.0021627466,0.000028135893,0.0009129135,0.00026310488,0.00047007567,0.000017591388,0.00021216029,0.00004598457,0.0010914949,0.01074101],"study_design_scores_gemma":[0.7871446,0.20456444,0.002994624,0.00036587866,0.00064835517,0.0000350178,0.000059826598,0.00007037318,0.00026627717,0.00015741517,0.0035713315,0.00012187501],"about_ca_topic_score_codex":0.00007440079,"about_ca_topic_score_gemma":0.00059237896,"teacher_disagreement_score":0.19445278,"about_ca_system_score_codex":0.00033754073,"about_ca_system_score_gemma":0.0032039606,"threshold_uncertainty_score":0.56836885},"labels":[],"label_agreement":null},{"id":"W2889703062","doi":"10.1200/jco.2017.35.15_suppl.6036","title":"A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Adenoid cystic carcinoma; Adverse effect; Cancer; Internal medicine; Sorafenib; Response Evaluation Criteria in Solid Tumors; Progressive disease; Oncology; Gastroenterology; Surgery; Carcinoma; Disease; Hepatocellular carcinoma","score_opus":0.0691088080318681,"score_gpt":0.4482751800529927,"score_spread":0.37916637202112463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889703062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99067336,0.004038448,0.000014747767,0.00055186753,0.0041530994,0.00036362244,0.000015750236,0.000001601043,0.00018748756],"genre_scores_gemma":[0.9954721,0.0016995884,0.000118083604,0.0001693922,0.002357917,0.000032590546,0.0000020956873,0.000021528016,0.00012673678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964598,0.0004203346,0.0021794199,0.00035423494,0.00026157292,0.00032466924],"domain_scores_gemma":[0.9963925,0.000247628,0.0022463086,0.00054578984,0.0003283953,0.00023936406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016393211,0.00019884537,0.0013787284,0.0001376113,0.00007107232,0.000015381429,0.00055746676,0.00039556625,0.00001822395],"category_scores_gemma":[0.0025662894,0.00016858132,0.0002914617,0.00008800801,0.00021263644,0.000023671131,0.00018666446,0.00059768965,0.0000012222251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044882562,0.061399624,0.4243751,0.00026826566,0.0005819527,0.002129107,0.0014287848,0.0012468592,0.11669691,0.000028100327,0.0031130791,0.34384966],"study_design_scores_gemma":[0.16126616,0.045270566,0.61472833,0.00034210106,0.00044318216,0.0001602988,0.0017853595,0.00021141111,0.009527553,0.00009409304,0.16557354,0.0005974271],"about_ca_topic_score_codex":0.0005992868,"about_ca_topic_score_gemma":0.016057603,"teacher_disagreement_score":0.34325224,"about_ca_system_score_codex":0.00008188486,"about_ca_system_score_gemma":0.0013886939,"threshold_uncertainty_score":0.896052},"labels":[],"label_agreement":null},{"id":"W2889710159","doi":"10.1200/jco.2017.35.15_suppl.7547","title":"Rapid, real-time central pathology review for E1412: A novel and successful paradigm for future National Clinical Trials Network diffuse large B cell lymphoma studies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Rituximab; Lenalidomide; Lymphoma; Internal medicine; Clinical trial; Multiple myeloma","score_opus":0.2970037648933071,"score_gpt":0.5463932405795847,"score_spread":0.24938947568627762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889710159","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63543206,0.1578462,0.00075553014,0.17958272,0.017359456,0.0068570906,0.0005051653,0.00004121639,0.0016205633],"genre_scores_gemma":[0.23412044,0.6903953,0.021636756,0.021013971,0.031991642,0.0002909862,0.0000695729,0.00006926408,0.00041204723],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916598,0.0011964177,0.0056722076,0.0004847961,0.00038027077,0.00060648157],"domain_scores_gemma":[0.96701205,0.023731586,0.007143032,0.00041950177,0.0009993206,0.00069453736],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028384918,0.00030889464,0.0055490267,0.00005822705,0.00032404196,0.00003415152,0.00031481878,0.00074772665,0.000045821653],"category_scores_gemma":[0.035792068,0.00019276778,0.0020171134,0.000048071226,0.0003353259,0.00014871698,0.00012612302,0.0003365343,0.0000063722828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021553969,0.039492235,0.09546281,0.0012845647,0.005033393,0.0008650589,0.00011774478,0.0000012204717,0.000017034161,0.0035510892,0.47097674,0.36164415],"study_design_scores_gemma":[0.13805188,0.013688031,0.27835083,0.0008643425,0.0036599066,0.0004948163,0.00004522748,0.000105110434,0.000006667652,0.0015964819,0.5629374,0.00019932535],"about_ca_topic_score_codex":0.0000031942868,"about_ca_topic_score_gemma":0.000017464396,"teacher_disagreement_score":0.5325491,"about_ca_system_score_codex":0.00024449988,"about_ca_system_score_gemma":0.0021819244,"threshold_uncertainty_score":0.9837703},"labels":[],"label_agreement":null},{"id":"W2889722712","doi":"10.1200/jco.2017.35.15_suppl.5062","title":"Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Prostatectomy; Biochemical recurrence; Oncology; Internal medicine; Cancer; Quartile; Proportional hazards model","score_opus":0.10635789916803427,"score_gpt":0.46901205146430897,"score_spread":0.3626541522962747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889722712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97648925,0.0001339665,0.000012640018,0.021227699,0.00039459296,0.00011086548,0.000006420917,0.000001929017,0.0016226565],"genre_scores_gemma":[0.9969559,0.00024799752,0.0009928084,0.00035540666,0.00044036342,0.0000010260582,8.1939106e-7,0.00000799563,0.0009976935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978251,0.00014270209,0.0013685863,0.0000839678,0.0004645599,0.00011506915],"domain_scores_gemma":[0.9928695,0.000722302,0.0047678887,0.00016645592,0.0013152143,0.00015861365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021520583,0.000067526526,0.0011508144,0.000054014286,0.000038717117,0.000004445718,0.00011873059,0.0001755239,0.00009794339],"category_scores_gemma":[0.004501487,0.00004112766,0.00022120288,0.000031696763,0.0002120194,0.0001046878,0.000028379909,0.00041586868,0.0000021334727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010849896,0.0010461229,0.94223684,0.000066516026,0.00057967036,0.00057513284,0.00014005807,0.000028274822,0.0065691955,0.000105145155,0.0042903773,0.033512797],"study_design_scores_gemma":[0.0079230955,0.007005319,0.95472646,0.00020681517,0.0004185356,0.00019545302,0.00004248995,0.00011796483,0.002508877,0.000102644204,0.026709188,0.000043143784],"about_ca_topic_score_codex":0.000054758064,"about_ca_topic_score_gemma":0.00005986902,"teacher_disagreement_score":0.033469655,"about_ca_system_score_codex":0.00009040285,"about_ca_system_score_gemma":0.0012724329,"threshold_uncertainty_score":0.5389026},"labels":[],"label_agreement":null},{"id":"W2889732469","doi":"10.1200/jco.2017.35.15_suppl.7565","title":"Results of a phase II trial of efficacy and safety of entospletinib (ENTO) in patients with lymphoplasmacytoid lymphoma/Waldenstrom's macroglubulinemia (LPL/WM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Gastroenterology; Nausea; Waldenstrom macroglobulinemia; Adverse effect; Clinical endpoint; Rash; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy","score_opus":0.06514471723858213,"score_gpt":0.4508575970605035,"score_spread":0.3857128798219214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889732469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957779,0.00009801572,0.00000826157,0.001228579,0.0005148037,0.00083356176,0.00006523361,0.0000033489623,0.0014703015],"genre_scores_gemma":[0.99714404,0.00059520564,0.0016197363,0.000070905124,0.0003957934,0.0000032657451,0.000011244811,0.000025120333,0.00013467635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921218,0.00049100886,0.0054512364,0.00034879713,0.0011804863,0.00040664815],"domain_scores_gemma":[0.9869537,0.0036735553,0.0069695557,0.00078642974,0.0011442618,0.00047249417],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055660717,0.00023582106,0.0030290429,0.0002823015,0.000069887225,0.000008816096,0.0005424978,0.0005127599,0.000056523604],"category_scores_gemma":[0.019026605,0.00016469187,0.0003965933,0.00015888056,0.0014350732,0.00013985469,0.0003494997,0.000556202,0.000001541758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8135282,0.018773708,0.021397598,0.00018768122,0.00054047385,0.00038725932,0.0003047328,0.00001332984,0.0003130048,0.000029290375,0.0005315537,0.14399317],"study_design_scores_gemma":[0.7692722,0.099585064,0.12488171,0.0007006678,0.00033649334,0.00013714243,0.0000411648,0.00024047183,0.00096003193,0.000021337515,0.0037158993,0.00010779389],"about_ca_topic_score_codex":0.00033692285,"about_ca_topic_score_gemma":0.00009436829,"teacher_disagreement_score":0.14388537,"about_ca_system_score_codex":0.0017080483,"about_ca_system_score_gemma":0.015793461,"threshold_uncertainty_score":0.9897861},"labels":[],"label_agreement":null},{"id":"W2889751375","doi":"10.1200/jco.2017.35.15_suppl.5547","title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Ovarian cancer; Population; Folate receptor; Oncology; Nausea; Phases of clinical research; Dosing; Clinical trial; Cancer; Gastroenterology; Cancer cell","score_opus":0.08919688874973307,"score_gpt":0.4818670002204941,"score_spread":0.39267011147076103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889751375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875269,0.0011010036,0.000034233035,0.009022107,0.0013568351,0.00063034566,0.00013355746,0.000009036857,0.00018596672],"genre_scores_gemma":[0.9916763,0.0056455065,0.0013965215,0.0005058825,0.0006523097,0.000015922958,0.000027107026,0.00003501696,0.000045466062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99471366,0.00075975165,0.0029864016,0.00054860674,0.0005048062,0.00048675996],"domain_scores_gemma":[0.99384695,0.0013438402,0.0035085552,0.00039584484,0.00041540232,0.00048937945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033925045,0.00035349687,0.0029188192,0.00027291547,0.00019871592,0.000056432673,0.00021934419,0.0004132311,0.00019575784],"category_scores_gemma":[0.0029564288,0.00026081936,0.0003779151,0.0001606704,0.00029432453,0.00040769347,0.00013098677,0.0011609787,0.0000046024647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050084107,0.011358494,0.6290061,0.00008865769,0.0010748655,0.0018307039,0.00047706554,0.00003742502,0.018397033,0.000018598714,0.0006270182,0.28699994],"study_design_scores_gemma":[0.07956569,0.008230483,0.9034937,0.0010048581,0.00076068885,0.00001894492,0.000065384425,0.00051652855,0.0016217745,0.000077621095,0.004393981,0.00025033124],"about_ca_topic_score_codex":0.0030094506,"about_ca_topic_score_gemma":0.00292993,"teacher_disagreement_score":0.2867496,"about_ca_system_score_codex":0.0006148386,"about_ca_system_score_gemma":0.0013719514,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W2889754370","doi":"10.1200/jco.2017.35.15_suppl.10516","title":"Temporal trends in late-onset morbidity and mortality after medulloblastoma diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Cumulative incidence; Radiation therapy; Medulloblastoma; Incidence (geometry); Late effect; Confidence interval; Odds ratio; Pediatrics; Psychosocial; Internal medicine; Chemotherapy; Surgery; Cohort; Pathology","score_opus":0.1463614847882759,"score_gpt":0.5080865464384776,"score_spread":0.3617250616502017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889754370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98630905,0.0014608796,0.0000010306239,0.0104984995,0.0011843619,0.0003871316,0.00008049723,0.0000072342737,0.00007130054],"genre_scores_gemma":[0.9973129,0.0005831209,0.00006646396,0.00101039,0.00090109283,0.00007539701,0.000006564613,0.000018804112,0.000025263722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960245,0.00048503658,0.0022815212,0.00039690878,0.00048937404,0.0003226671],"domain_scores_gemma":[0.994166,0.0021057962,0.002378694,0.0007683985,0.00020285061,0.00037823443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043411865,0.00023322749,0.0017413583,0.00006497892,0.00016895428,0.000065150314,0.00030961627,0.00034035914,0.0002198432],"category_scores_gemma":[0.0033096655,0.0001288565,0.00042854736,0.00009539428,0.0004311926,0.00019434099,0.0002105111,0.000973905,0.0000033843512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014344152,0.0070587555,0.9334149,0.00000326018,0.0009600881,0.019798325,0.0006880949,0.0000028539266,0.0000018041876,2.987938e-7,0.0014880527,0.035149198],"study_design_scores_gemma":[0.014527771,0.0033700014,0.97846943,0.00011577452,0.00071482896,0.00018336032,0.00023049691,0.000018822744,0.000011534264,0.000123966,0.0021183365,0.00011566886],"about_ca_topic_score_codex":0.01222166,"about_ca_topic_score_gemma":0.23154563,"teacher_disagreement_score":0.21932396,"about_ca_system_score_codex":0.00012510504,"about_ca_system_score_gemma":0.00055237365,"threshold_uncertainty_score":0.99435604},"labels":[],"label_agreement":null},{"id":"W2889755645","doi":"10.1200/jco.2018.36.15_suppl.11012","title":"Assessing trainee’s need and readiness for e-cancer education and training in Africa.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Competence (human resources); Medicine; The Internet; Medical education; Internet access; Learning Management; Multimedia; Psychology; Computer science; World Wide Web","score_opus":0.2883706598442693,"score_gpt":0.4732122507548923,"score_spread":0.18484159091062302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889755645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675561,0.0038143983,0.0017613241,0.0055544875,0.0023006557,0.00012053603,0.000008697585,0.0000029669545,0.018880837],"genre_scores_gemma":[0.9908602,0.0010941839,0.0047681206,0.0009792247,0.002026792,0.000008969747,4.0823778e-7,0.000011667435,0.0002503864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979611,0.000028634307,0.0016295639,0.00017400061,0.000016430593,0.00019024659],"domain_scores_gemma":[0.9975414,0.00066818,0.0014643893,0.00006311568,0.0001209869,0.0001419037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031961116,0.0000834176,0.0009005664,0.00018675694,0.00004178422,0.000046342167,0.000089722875,0.000222716,0.000041353815],"category_scores_gemma":[0.0023575157,0.00008186188,0.0000918169,0.00008355337,0.00019784183,0.00054248463,0.000017773644,0.00024169737,0.000002535358],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028910988,0.00020031042,0.09373451,0.000022300443,0.000051859555,0.0000021849708,0.0020221716,0.0000035421924,0.000013242664,0.031296354,0.0015820387,0.8707824],"study_design_scores_gemma":[0.0030382003,0.0016190722,0.5326895,0.00008088286,0.000024257288,0.000025216703,0.0012059225,0.0006846211,0.0000052722644,0.09833693,0.3621209,0.00016922694],"about_ca_topic_score_codex":0.000046522924,"about_ca_topic_score_gemma":0.00012220624,"teacher_disagreement_score":0.87061316,"about_ca_system_score_codex":0.000092183014,"about_ca_system_score_gemma":0.00066713826,"threshold_uncertainty_score":0.33382306},"labels":[],"label_agreement":null},{"id":"W2889787928","doi":"10.1200/jco.2017.35.15_suppl.e15717","title":"Epigenetic regulation of cancer self-renewal differs between endocrine tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Telomerase; Pancreatic cancer; Medicine; Cancer; Epigenetics; Thyroid cancer; Cancer research; Endocrine system; DNA methylation; Methylation; Adenocarcinoma; Oncology; Pathology; Internal medicine; Biology; Gene expression; Gene; Hormone","score_opus":0.08922450147754078,"score_gpt":0.4699659219019446,"score_spread":0.3807414204244038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889787928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489653,0.001384653,0.0007031289,0.0008455062,0.00077493687,0.00009021159,0.000008396897,0.0000021696687,0.0012944826],"genre_scores_gemma":[0.9924715,0.0025662456,0.002658587,0.000055980785,0.0020862864,0.0000022394674,0.0000074204527,0.000015057722,0.00013663694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751467,0.0002571378,0.0016447265,0.00018473332,0.00022381607,0.00017491284],"domain_scores_gemma":[0.9956449,0.00021582343,0.0031586555,0.000380441,0.00041987267,0.00018028397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014207208,0.000118969554,0.00074159197,0.000052566746,0.000085533844,0.000013582575,0.00038963422,0.00029865722,0.00003219241],"category_scores_gemma":[0.0016880317,0.0000970493,0.00033538754,0.0000267398,0.00019345699,0.000007647855,0.00011948808,0.00023656957,0.0000016242742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000331951,0.00024915277,0.79593724,0.000018841349,0.00030788546,0.0000088141705,0.000016909515,0.00013032038,0.08971213,0.00003030595,0.0001535103,0.11310293],"study_design_scores_gemma":[0.0018485367,0.0028235402,0.8547468,0.000025363466,0.00016111105,0.0000034328896,0.000005374704,0.000024327768,0.124640964,0.0010502015,0.01457432,0.00009602109],"about_ca_topic_score_codex":0.000058155234,"about_ca_topic_score_gemma":0.000074544485,"teacher_disagreement_score":0.113006905,"about_ca_system_score_codex":0.000027013713,"about_ca_system_score_gemma":0.0005782613,"threshold_uncertainty_score":0.39575556},"labels":[],"label_agreement":null},{"id":"W2889788441","doi":"10.1200/jco.2018.36.15_suppl.10033","title":"Patient-reported psychosocial needs and psychological distress: the influence on survival in geriatric oncology patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Psychosocial; Internal medicine; Lung cancer; Univariate analysis; Depression (economics); Anxiety; Cancer; Proportional hazards model; Disease; Breast cancer; Distress; Multivariate analysis; Psychiatry; Clinical psychology","score_opus":0.09241947522599955,"score_gpt":0.45985215407124236,"score_spread":0.3674326788452428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889788441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97731,0.00011266212,0.0000070955894,0.007982359,0.005125269,0.00024640185,0.0000048047814,0.0000086471,0.009202736],"genre_scores_gemma":[0.9914655,0.00040487264,0.000073189556,0.0060952217,0.0018983674,0.0000073296997,0.0000026150444,0.000012539227,0.000040382758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957843,0.0009257123,0.002283526,0.00025068445,0.00046083188,0.00029494928],"domain_scores_gemma":[0.99502957,0.002188935,0.0015966344,0.00025006832,0.0006248997,0.00030990847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023449191,0.0001661615,0.0011720909,0.00018076846,0.00007040698,0.0000122578695,0.00019042353,0.0005896232,0.000114614384],"category_scores_gemma":[0.0040824735,0.00009631847,0.00028209444,0.00045217894,0.0007523084,0.00007438288,0.000069139394,0.001393895,0.000014736644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011205678,0.0034485748,0.5774514,0.000009132886,0.000119071796,0.0002750423,0.0010412087,0.0000016352484,0.000018597353,0.0001513396,0.0043255403,0.40195277],"study_design_scores_gemma":[0.006465243,0.039111502,0.84157634,0.00004658581,0.00011688914,0.00009938767,0.0004822713,0.0000028502427,0.0000029839334,0.00035656558,0.11165012,0.00008925437],"about_ca_topic_score_codex":0.00009677144,"about_ca_topic_score_gemma":0.00071972614,"teacher_disagreement_score":0.40186352,"about_ca_system_score_codex":0.00018244106,"about_ca_system_score_gemma":0.00040260362,"threshold_uncertainty_score":0.60558575},"labels":[],"label_agreement":null},{"id":"W2889794204","doi":"10.1200/jco.2018.36.15_suppl.10089","title":"Exercise counseling in integrative oncology: Patient characteristics and effects on self-reported symptoms.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Physical therapy; Distress; Breast cancer; Cancer; Internal medicine; Clinical psychology","score_opus":0.04248562181880545,"score_gpt":0.423016045959344,"score_spread":0.38053042414053856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889794204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915274,0.00038291718,0.000028890832,0.0017685102,0.0037320675,0.0002647615,0.0000021141886,0.00001361278,0.0022797408],"genre_scores_gemma":[0.99123114,0.0019383067,0.00050796894,0.004878755,0.0013772094,0.0000073384126,0.0000023062453,0.000015428366,0.00004155794],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99685806,0.00044507015,0.0019649381,0.00021944575,0.0002962453,0.00021624433],"domain_scores_gemma":[0.9945056,0.0027359237,0.001538495,0.00015762085,0.0007203101,0.00034206966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023748223,0.0001610993,0.0016043411,0.00017500743,0.000033972632,0.000007759685,0.00007927684,0.0004754463,0.00003567112],"category_scores_gemma":[0.0027643547,0.00010913856,0.0002024472,0.00015779713,0.00021604328,0.000060193895,0.000035094796,0.0011930844,0.000010205326],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009379242,0.0017308363,0.06858843,0.000068608664,0.00036553646,0.0025714769,0.0054138643,2.1087735e-7,0.00013009136,0.000043484702,0.0017942112,0.909914],"study_design_scores_gemma":[0.018098123,0.16179635,0.49470648,0.0036055376,0.0017954656,0.0012433329,0.0024058193,0.00032218624,0.0011778694,0.00047855655,0.31396958,0.00040068218],"about_ca_topic_score_codex":0.000051884464,"about_ca_topic_score_gemma":0.00037706908,"teacher_disagreement_score":0.90951335,"about_ca_system_score_codex":0.00035318584,"about_ca_system_score_gemma":0.0013533301,"threshold_uncertainty_score":0.51834244},"labels":[],"label_agreement":null},{"id":"W2889806646","doi":"10.1200/jco.2017.35.15_suppl.e21623","title":"Quality of life and satisfaction with care in a contemporary cohort of pancreatic cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Quality of life (healthcare); Pancreatic cancer; Gemcitabine; Cohort; Palliative care; Stage (stratigraphy); Internal medicine; Triage; Cancer; Disease; Physical therapy; Emergency medicine; Nursing","score_opus":0.22548521354422768,"score_gpt":0.5388889857192649,"score_spread":0.31340377217503723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889806646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351096,0.001017467,0.000011247452,0.000990978,0.00014619422,0.00031661298,0.00000873179,0.0000012032905,0.0039965785],"genre_scores_gemma":[0.9974671,0.0014365833,0.0007621298,0.00016229558,0.00011709087,0.000006708653,0.0000014011058,0.000006445627,0.000040255763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968213,0.00050538394,0.0020711576,0.00012158051,0.00036115717,0.00011942547],"domain_scores_gemma":[0.99375653,0.0017994255,0.003156081,0.00021303142,0.00084538024,0.00022957723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028763919,0.00008176905,0.002254325,0.000095703464,0.0000345479,0.0000029465357,0.00009768593,0.00025856053,0.0000455694],"category_scores_gemma":[0.007451359,0.000052007035,0.00012227338,0.000041076826,0.00069420406,0.00010164297,0.00004304413,0.0005285033,4.2187378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011926918,0.0005600426,0.96587515,0.00023008765,0.00043291322,0.000037118374,0.00023018375,6.050363e-7,0.000037958478,0.000029569364,0.00015560296,0.02048388],"study_design_scores_gemma":[0.013785956,0.011781986,0.97323936,0.0002767086,0.00020839486,0.000008909392,0.00036127077,0.000014041989,0.000012181031,0.00005474879,0.00021301869,0.000043410262],"about_ca_topic_score_codex":0.0031021407,"about_ca_topic_score_gemma":0.002258419,"teacher_disagreement_score":0.020440469,"about_ca_system_score_codex":0.00009991206,"about_ca_system_score_gemma":0.0036482825,"threshold_uncertainty_score":0.89205116},"labels":[],"label_agreement":null},{"id":"W2889823387","doi":"10.1200/jco.2018.36.15_suppl.e22030","title":"The utility of a modified frailty index in predicting chemotherapy toxicity, response and survival for older patients (pts) with advanced pancreatic cancer receiving first-line palliative chemotherapy: A single institution experience.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Winnipeg; CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; FOLFIRINOX; Internal medicine; Gemcitabine; Irinotecan; Oxaliplatin; Chemotherapy; Pancreatic cancer; Performance status; Cancer; Oncology; Surgery; Colorectal cancer","score_opus":0.10637247261086996,"score_gpt":0.4403967638603683,"score_spread":0.33402429124949834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889823387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904495,0.00015770025,0.0033256758,0.004573944,0.00050087617,0.0008422862,0.000009198167,0.000008775063,0.00013204022],"genre_scores_gemma":[0.9964862,0.0006314512,0.0018027648,0.0006341438,0.00034032768,0.00004107353,0.0000010955024,0.000019519912,0.000043414864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685186,0.00042117294,0.0017722453,0.0002716137,0.00040124997,0.0002818694],"domain_scores_gemma":[0.9915219,0.00538662,0.0017364853,0.00022118048,0.00096465676,0.00016917591],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031876813,0.0001777777,0.0011029397,0.0000864595,0.000116907315,0.00001069469,0.00016418484,0.0002801433,0.00002927219],"category_scores_gemma":[0.009837026,0.00010897901,0.0001358137,0.00023369153,0.00087052037,0.0001736019,0.000038589547,0.00050714065,1.377296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080279656,0.0018194382,0.71637547,0.000060673177,0.00018676977,0.0000063583648,0.0043906774,0.00003615481,0.00035098597,0.0000030667384,0.000058425667,0.19643235],"study_design_scores_gemma":[0.026568817,0.015882557,0.9482501,0.0008788722,0.00006500616,0.000008509573,0.0005952942,0.004861607,0.001267396,0.00013566777,0.0013833862,0.00010279637],"about_ca_topic_score_codex":0.00009150388,"about_ca_topic_score_gemma":0.0017544944,"teacher_disagreement_score":0.23187464,"about_ca_system_score_codex":0.000250167,"about_ca_system_score_gemma":0.00082965574,"threshold_uncertainty_score":0.99850357},"labels":[],"label_agreement":null},{"id":"W2889829025","doi":"10.1200/jco.2017.35.15_suppl.4583","title":"Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Renal cell carcinoma; Univariate analysis; Internal medicine; Adverse effect; Demography; Overall survival; Latin Americans; Multivariate analysis; Oncology","score_opus":0.28258339503401864,"score_gpt":0.4477951157874429,"score_spread":0.16521172075342427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889829025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122167,0.00026232016,0.00016485942,0.0007147062,0.0018830975,0.0003194123,0.0008560102,0.0000031637637,0.0045747575],"genre_scores_gemma":[0.99723613,0.000728143,0.0007589938,0.00027948644,0.0008621106,0.0000026072898,0.00003411231,0.000028280992,0.000070117254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98868024,0.00089137786,0.009343408,0.00054152927,0.0001408937,0.0004025746],"domain_scores_gemma":[0.972364,0.0059279185,0.02010744,0.0009107793,0.00027451888,0.00041532284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019952482,0.00028174496,0.0047440077,0.00038286246,0.00007906984,0.00005910427,0.00079954835,0.00043830878,0.00010592037],"category_scores_gemma":[0.02598352,0.00021487121,0.0014139101,0.0000798461,0.00040015334,0.00064814533,0.000115146555,0.0012484286,0.000030909767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029073035,0.0023475457,0.9557894,0.000007653739,0.00049714826,0.0000772593,0.00003610992,0.0000936818,0.0000010508136,0.00056232867,0.0015460858,0.0099687185],"study_design_scores_gemma":[0.03955642,0.013650967,0.9402475,0.00008817853,0.00014844042,0.0000016280744,0.0000070537644,0.000117373485,0.0000033017393,0.0036920742,0.002267715,0.00021934026],"about_ca_topic_score_codex":0.002530963,"about_ca_topic_score_gemma":0.0004413181,"teacher_disagreement_score":0.016316198,"about_ca_system_score_codex":0.00021111564,"about_ca_system_score_gemma":0.00085337926,"threshold_uncertainty_score":0.982221},"labels":[],"label_agreement":null},{"id":"W2889831061","doi":"10.1200/jco.2016.34.15_suppl.10576","title":"Patient-reported levels of concern in the Childhood Cancer Survivor Study (CCSS).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Relative risk; Cancer; Poisson regression; Confidence interval; Demography; Childhood cancer; Environmental health; Population; Internal medicine","score_opus":0.24681736137816393,"score_gpt":0.5089009932190185,"score_spread":0.2620836318408546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889831061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96219033,0.0010965203,0.000035089073,0.033297233,0.0018598298,0.00064828986,0.000018564355,0.000008114536,0.0008460192],"genre_scores_gemma":[0.9901458,0.00049816084,0.00014307626,0.007862525,0.0012216606,0.000011943715,3.7368284e-7,0.000021700464,0.000094749936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990655,0.0022652517,0.0054224734,0.00028123704,0.0010690945,0.0003069495],"domain_scores_gemma":[0.98732156,0.006794007,0.004436217,0.0004970364,0.00068506814,0.0002661262],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010238439,0.0001942756,0.002212379,0.0001546219,0.000031582054,0.000005720159,0.00037776504,0.00029501805,0.0005113705],"category_scores_gemma":[0.009925071,0.0000953072,0.00054110837,0.00029260604,0.00034847585,0.00015644271,0.000082968094,0.0009453532,0.000008571153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023826482,0.009033498,0.8025955,0.000025800828,0.0009070409,0.00055353844,0.0056801387,0.0000034082398,0.0001363563,0.000029683571,0.004428116,0.17422427],"study_design_scores_gemma":[0.015683576,0.015757626,0.94238204,0.00035069502,0.00037979233,0.00019360038,0.0026372424,0.0000010566238,0.00009387411,0.00016788395,0.022239493,0.000113094924],"about_ca_topic_score_codex":0.00067228574,"about_ca_topic_score_gemma":0.0024019026,"teacher_disagreement_score":0.17411117,"about_ca_system_score_codex":0.00016002782,"about_ca_system_score_gemma":0.0028670996,"threshold_uncertainty_score":0.99841475},"labels":[],"label_agreement":null},{"id":"W2889839922","doi":"10.1200/jco.2018.36.15_suppl.e18538","title":"Results of a pan-Canadian approach to systems change for smoking cessation support in Canadian cancer centers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Smoking cessation; Medicine; Referral; Family medicine; Cancer; General partnership; Business","score_opus":0.6155360364767851,"score_gpt":0.6048971604436514,"score_spread":0.010638876033133737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889839922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8538156,0.00016974243,0.000984926,0.12430565,0.007590845,0.0029826986,0.0003071341,0.0000082869565,0.009835112],"genre_scores_gemma":[0.9815628,0.00010360117,0.0029509633,0.011829294,0.0033991379,0.000039118506,0.00003629673,0.00001709333,0.00006171581],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99432606,0.00032952297,0.004412942,0.00021799422,0.00029697357,0.0004164958],"domain_scores_gemma":[0.9931481,0.0020700977,0.0022193717,0.00018024794,0.0013338189,0.0010483757],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011937543,0.000105393665,0.001002919,0.00055418134,0.000036894748,0.000010005036,0.00016519046,0.00035116693,0.000042873446],"category_scores_gemma":[0.02128424,0.000089285255,0.00019255823,0.00028370292,0.000089182155,0.00018878184,0.000017653836,0.0004690262,0.00000494062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010556985,0.001125617,0.54128945,0.00019828207,0.00044272988,0.0001531388,0.0019696616,0.00006144902,0.00006640081,0.00027348584,0.08855981,0.355303],"study_design_scores_gemma":[0.011676567,0.009372581,0.38984916,0.00022742045,0.0003052337,0.00009599539,0.00097036944,0.0015475111,0.000014895134,0.00004388769,0.58578485,0.000111553585],"about_ca_topic_score_codex":0.857853,"about_ca_topic_score_gemma":0.95557225,"teacher_disagreement_score":0.49722505,"about_ca_system_score_codex":0.0011061847,"about_ca_system_score_gemma":0.008959014,"threshold_uncertainty_score":0.9966593},"labels":[],"label_agreement":null},{"id":"W2889855746","doi":"10.1200/jco.2017.35.15_suppl.e18297","title":"Strategies to minimize wastage of expensive drugs in expensive times: Cabazitaxel, a single center experience.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cabazitaxel; Vial; Medicine; Prostate cancer; Drug; Cancer; Internal medicine; Pharmacology; Androgen deprivation therapy","score_opus":0.19456911130182628,"score_gpt":0.533104279183883,"score_spread":0.33853516788205673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889855746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738462,0.0002860152,0.00002501171,0.007408285,0.0018785084,0.0003036197,0.000007181883,0.0000041762364,0.016240988],"genre_scores_gemma":[0.9938138,0.0003016154,0.0023694176,0.0019143737,0.00076445955,0.000013365828,0.0000017722839,0.000015236392,0.0008059227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969977,0.0002459365,0.0019439246,0.00023427715,0.00028078764,0.00029736361],"domain_scores_gemma":[0.99553645,0.0012252767,0.0020036204,0.00032256168,0.00054169376,0.00037038975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007486778,0.00017473714,0.0017667495,0.00018342823,0.000053248656,0.00002009878,0.00030833416,0.00027862965,0.0006814749],"category_scores_gemma":[0.0015951712,0.00013001928,0.0004017514,0.00006116037,0.0004583082,0.00026735236,0.00012836323,0.0005200288,0.000020975644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09559775,0.033766292,0.48672596,0.00021606035,0.0024562737,0.014431458,0.08077514,0.000071007176,0.05711388,0.0005856684,0.10664318,0.121617325],"study_design_scores_gemma":[0.093924075,0.08520821,0.5332837,0.0011848467,0.00090647856,0.0013182882,0.100944005,0.000050645365,0.018510334,0.0009030298,0.16306113,0.0007052171],"about_ca_topic_score_codex":0.00013391045,"about_ca_topic_score_gemma":0.00015506998,"teacher_disagreement_score":0.120912105,"about_ca_system_score_codex":0.00019775722,"about_ca_system_score_gemma":0.0012300737,"threshold_uncertainty_score":0.74616724},"labels":[],"label_agreement":null},{"id":"W2889865404","doi":"10.1200/jco.18.00606","title":"Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; American Society for Radiation Oncology","keywords":"Guideline; Medicine; Prostate cancer; Clinical Oncology; Oncology; Family medicine; Radiation oncology; Internal medicine; Cryotherapy; Professional association; Cancer; Medical physics; Radiation therapy; Surgery; Pathology","score_opus":0.09601643125784026,"score_gpt":0.5257047638460317,"score_spread":0.42968833258819145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889865404","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7344966,0.0019783082,0.0067739054,0.24761797,0.0041801482,0.0031819502,0.00039159338,0.000071554496,0.0013079704],"genre_scores_gemma":[0.25878137,0.048556693,0.5976336,0.08738829,0.0071034785,0.00020030537,0.00015212227,0.00007781773,0.00010629712],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97941506,0.0029057148,0.014898029,0.0008846885,0.0010904066,0.00080607587],"domain_scores_gemma":[0.9429241,0.019874465,0.027778579,0.0006020487,0.00787443,0.0009463695],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.034860373,0.0004763407,0.0060105138,0.00012463039,0.0001452206,0.000013619395,0.00053749635,0.0011976114,0.00016397187],"category_scores_gemma":[0.028041301,0.00034555787,0.0034442933,0.00060550874,0.0029925897,0.00026551832,0.00020118614,0.0017856618,0.0000065141003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028891036,0.015725775,0.17582111,0.000043020023,0.004539378,0.000059566155,0.00033102097,0.00014017742,0.00016937531,0.000049728213,0.15043753,0.6237923],"study_design_scores_gemma":[0.022126144,0.21661025,0.028819436,0.00004649766,0.0033011164,0.00007150008,0.000919329,0.002777329,0.00016963981,0.00019314217,0.72475,0.00021560898],"about_ca_topic_score_codex":0.00048147808,"about_ca_topic_score_gemma":0.000113184025,"teacher_disagreement_score":0.62357664,"about_ca_system_score_codex":0.0020113944,"about_ca_system_score_gemma":0.009721934,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W2889881016","doi":"10.1200/jco.2017.35.15_suppl.tps5095","title":"Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of British Columbia; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; University Health Network; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Clinical endpoint; Prostatectomy; Urology; Oncology; Prednisone; Docetaxel; Internal medicine; Androgen deprivation therapy; Randomized controlled trial; Cancer","score_opus":0.3262107862489707,"score_gpt":0.5600936919070783,"score_spread":0.23388290565810754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889881016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775531,0.0006168928,0.000006477663,0.018034998,0.00090549607,0.0005722717,0.0000056781073,0.0000050296967,0.0023000436],"genre_scores_gemma":[0.99655145,0.0007530348,0.00096178456,0.00051905995,0.00037476496,0.000020092191,0.0000025216516,0.00001819875,0.0007991171],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99553025,0.0010838176,0.0023686192,0.00022941075,0.00038243222,0.00040548318],"domain_scores_gemma":[0.99481237,0.0027043093,0.0015384624,0.0003630315,0.0002604141,0.00032139604],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0114682,0.00014268342,0.0016228886,0.00033404407,0.00008376587,0.00003462628,0.0003061106,0.00033180678,0.000083375155],"category_scores_gemma":[0.012277542,0.00009620859,0.00027267932,0.00011128186,0.0004025166,0.00020232628,0.00011694543,0.0015638069,0.000042821226],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.725199,0.002197649,0.22390352,0.00003379939,0.00013061534,0.0080794105,0.00024842343,0.00000853989,0.00073370297,0.000037953778,0.0008966615,0.038530733],"study_design_scores_gemma":[0.22593804,0.028253237,0.7253592,0.00031862213,0.000052402374,0.00014426264,0.0001308471,0.00006578492,0.00009221316,0.00038387877,0.019169789,0.00009173026],"about_ca_topic_score_codex":0.00011633049,"about_ca_topic_score_gemma":0.00026200947,"teacher_disagreement_score":0.50145566,"about_ca_system_score_codex":0.0004262012,"about_ca_system_score_gemma":0.002818199,"threshold_uncertainty_score":0.9960425},"labels":[],"label_agreement":null},{"id":"W2889887419","doi":"10.1200/jco.2019.37.15_suppl.tps4597","title":"PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Nivolumab; Perioperative; Nephrectomy; Internal medicine; Kidney cancer; Stage (stratigraphy); Blockade; Oncology; Urology; Surgery; Cancer; Immunotherapy; Kidney","score_opus":0.09170392916847256,"score_gpt":0.39466345786887347,"score_spread":0.3029595287004009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889887419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921407,0.000121466,0.000040150368,0.0002367167,0.00090383826,0.003096144,0.000001313762,0.000012722806,0.0034469147],"genre_scores_gemma":[0.9966809,0.000026098478,0.0023846894,0.00017597216,0.00028993693,0.000039560844,0.000014301629,0.00003809691,0.0003504486],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937522,0.0013777395,0.0032797619,0.00044816485,0.0007499204,0.00039220488],"domain_scores_gemma":[0.99334323,0.0030138344,0.002204694,0.0003386563,0.00074835634,0.00035123262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030823834,0.00033967907,0.0037756928,0.00026280346,0.00006458707,0.000030766823,0.00019687247,0.00024637085,0.00016090582],"category_scores_gemma":[0.0010687117,0.00022371726,0.00048866845,0.00029386132,0.00017210977,0.0003090089,0.00008687935,0.0012177676,0.000032907945],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42326552,0.0074593583,0.5657489,0.000029095194,0.00037642152,0.00039502897,0.0008073333,0.00011452132,0.00007039201,0.000007287224,0.000031092437,0.0016950736],"study_design_scores_gemma":[0.51223,0.052473724,0.4331261,0.00009688492,0.0005629679,0.00001807393,0.0005861209,0.0005234014,0.00008112558,0.00000314549,0.00017008123,0.00012842662],"about_ca_topic_score_codex":0.0001653372,"about_ca_topic_score_gemma":0.00043585847,"teacher_disagreement_score":0.13262278,"about_ca_system_score_codex":0.000892384,"about_ca_system_score_gemma":0.002060233,"threshold_uncertainty_score":0.9122925},"labels":[],"label_agreement":null},{"id":"W2889887782","doi":"10.1200/jco.2017.35.15_suppl.e21073","title":"Burden of Merkel cell carcinoma: A targeted literature review.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Merkel cell carcinoma; Incidence (geometry); Stage (stratigraphy); Epidemiology; Merkel cell polyomavirus; Disease; Cancer; Internal medicine; Oncology; Carcinoma","score_opus":0.0762835692298501,"score_gpt":0.4660225817533011,"score_spread":0.389739012523451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889887782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7287393,0.22609654,0.0000068937616,0.02022913,0.0017956909,0.00022924607,0.000017422513,0.000005777737,0.022879962],"genre_scores_gemma":[0.93292123,0.061846264,0.00074330956,0.0016911004,0.0014091348,9.0085393e-7,0.000003048635,0.000011534179,0.0013734683],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99718285,0.00023472305,0.0019924275,0.00012934522,0.0002907998,0.00016985298],"domain_scores_gemma":[0.9946638,0.00047661117,0.003370295,0.00042133773,0.0006041928,0.0004637811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016114592,0.00011628038,0.0016286877,0.00007325023,0.00006162901,0.000008709633,0.00030946135,0.000456023,0.00016582744],"category_scores_gemma":[0.005315236,0.00006938353,0.00086410285,0.000060086466,0.00025960026,0.00010593514,0.0000697748,0.0010458174,0.00001671631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015219607,0.010055565,0.2182682,0.006212297,0.0019857888,0.02444319,0.00055645156,0.000009962231,0.008710028,0.00027743066,0.4695497,0.24471179],"study_design_scores_gemma":[0.01989991,0.015495365,0.56127936,0.008094423,0.0041552405,0.001293443,0.00006482027,0.00008555975,0.0010212047,0.0004887081,0.38788086,0.00024109866],"about_ca_topic_score_codex":0.000020375837,"about_ca_topic_score_gemma":0.0000012644518,"teacher_disagreement_score":0.34301117,"about_ca_system_score_codex":0.000030357483,"about_ca_system_score_gemma":0.0012258525,"threshold_uncertainty_score":0.6363218},"labels":[],"label_agreement":null},{"id":"W2889889395","doi":"10.1200/jco.2018.36.15_suppl.2028","title":"Genomic landscape of pineoblastoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Incidence (geometry); Oncology; Germline; Genetics; Biology; Gene","score_opus":0.09425203884546483,"score_gpt":0.45623082067668447,"score_spread":0.3619787818312196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889889395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868843,0.00042870548,0.000024969857,0.0041432506,0.0008707057,0.000070122114,0.0000014230726,0.0000033288331,0.0075731776],"genre_scores_gemma":[0.9945977,0.00022786664,0.0024227127,0.00097484305,0.0017071507,8.319141e-7,5.618843e-7,0.000007694856,0.000060649254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799126,0.00011149346,0.0015183276,0.00008599541,0.00017508374,0.00011785748],"domain_scores_gemma":[0.9971897,0.00082389213,0.0011864691,0.00013922324,0.00043866027,0.00022208394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001163397,0.00006962709,0.001011222,0.0001034877,0.000014677231,0.0000019841823,0.00008629876,0.00018281404,0.0005049106],"category_scores_gemma":[0.0012087444,0.00004307513,0.00038500674,0.000081891274,0.00018493985,0.000028097465,0.000029732832,0.00025064984,0.000063717096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003361096,0.0051343828,0.78244764,0.000025949954,0.0009569737,0.00069583487,0.00010368892,0.0000029920104,0.003894944,0.00026380448,0.036507808,0.16660489],"study_design_scores_gemma":[0.00952516,0.029954031,0.85833746,0.0000733122,0.0004383822,0.00042286742,0.00004605838,0.000046778077,0.0016749769,0.0002214246,0.09921606,0.00004348107],"about_ca_topic_score_codex":0.0000041248036,"about_ca_topic_score_gemma":0.000012798782,"teacher_disagreement_score":0.16656141,"about_ca_system_score_codex":0.00003775791,"about_ca_system_score_gemma":0.0006014312,"threshold_uncertainty_score":0.55284166},"labels":[],"label_agreement":null},{"id":"W2889894882","doi":"10.1200/jco.2018.36.15_suppl.e16515","title":"Clinical validation of an ultra-deep next generation DNA sequencing approach for the detection of bladder cancer in the urine.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Urine; Cancer; Internal medicine; Incidence (geometry); Cohort; Urinary system; Urology; False positive paradox; Oncology","score_opus":0.2867035589713152,"score_gpt":0.4901314975346996,"score_spread":0.20342793856338437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889894882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829351,0.0003653613,0.012952517,0.0012661844,0.0012135432,0.0005715172,0.000004905004,0.0000029797825,0.00068789895],"genre_scores_gemma":[0.99171835,0.0005407159,0.0024714135,0.00090386835,0.0043070656,0.000024053372,0.000003701318,0.000010975297,0.000019847781],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99671155,0.00068979233,0.002038472,0.00015150766,0.00028085793,0.00012779099],"domain_scores_gemma":[0.99610096,0.0015777507,0.0014473172,0.000209388,0.00058841193,0.000076169315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005256688,0.000092120594,0.00071912934,0.000064985834,0.00005111244,0.000008071557,0.00016431033,0.00026187464,0.000054655764],"category_scores_gemma":[0.0013964616,0.00004669535,0.0003257393,0.00014489904,0.00028283306,0.00016803145,0.000007341391,0.000427788,7.319852e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008182826,0.0032627208,0.033263694,0.00007225112,0.0010003354,0.000012318938,0.0016240393,0.0006120712,0.052843004,0.000056636378,0.00031346484,0.8987566],"study_design_scores_gemma":[0.04498417,0.12324562,0.5448748,0.0002189461,0.0061033405,0.00055325753,0.005518175,0.056596268,0.20626593,0.0013789188,0.009869989,0.00039062242],"about_ca_topic_score_codex":0.00013462984,"about_ca_topic_score_gemma":0.00029989134,"teacher_disagreement_score":0.89836603,"about_ca_system_score_codex":0.000101248326,"about_ca_system_score_gemma":0.0008935283,"threshold_uncertainty_score":0.2019817},"labels":[],"label_agreement":null},{"id":"W2889899936","doi":"10.1200/jco.2018.36.15_suppl.tps5092","title":"A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Prospective cohort study; Cancer; Androgen deprivation therapy; Prostate; Tolerability; Cohort; Radiology; Nuclear medicine; Internal medicine; Adverse effect","score_opus":0.06507719558226906,"score_gpt":0.48582579872710174,"score_spread":0.4207486031448327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889899936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694073,0.00020899365,0.0000056610656,0.00046938512,0.00020241953,0.0018837524,0.000016512891,0.000004501114,0.00026801744],"genre_scores_gemma":[0.99894935,0.00035211095,0.00024222932,0.00008608744,0.00022971175,0.00004986296,0.000005327851,0.000019961482,0.00006535017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964306,0.00053036335,0.0018944519,0.00025243437,0.0006155765,0.0002766216],"domain_scores_gemma":[0.992837,0.00311731,0.0017646118,0.00019200832,0.0018907858,0.00019824927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001865924,0.00016030906,0.0011777616,0.00026995465,0.000034825152,0.0000068237027,0.00014938902,0.000031166666,0.00011903638],"category_scores_gemma":[0.0059174793,0.00009905675,0.00012853857,0.0002958696,0.00042811266,0.0002622017,0.000069475966,0.00058321626,0.0000025352103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025583716,0.021361217,0.86344886,0.000065760185,0.00033684922,0.00082325743,0.0021048011,0.000023685423,0.000018896624,0.0000010657373,0.00012621106,0.08610571],"study_design_scores_gemma":[0.08214783,0.05127512,0.8632477,0.0004806256,0.0003553761,0.000023464048,0.001462099,0.000444333,0.00028217313,0.000016164382,0.00018816344,0.000076978],"about_ca_topic_score_codex":0.00016013937,"about_ca_topic_score_gemma":0.000114091075,"teacher_disagreement_score":0.08602873,"about_ca_system_score_codex":0.0003690863,"about_ca_system_score_gemma":0.0010538643,"threshold_uncertainty_score":0.7084203},"labels":[],"label_agreement":null},{"id":"W2889905549","doi":"10.1200/jco.2017.35.15_suppl.8559","title":"Systemic therapy use and outcomes after relapse from accelerated hemithoracic radiation and surgery for malignant pleural mesothelioma (MPM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Radiation therapy; Surgery; Internal medicine; Retrospective cohort study; Chemotherapy; Oncology; Pneumonectomy; Lung cancer","score_opus":0.1781167241893634,"score_gpt":0.45142730702831013,"score_spread":0.2733105828389467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889905549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440265,0.0018112776,0.000016706746,0.0030124378,0.0005045704,0.0001951623,0.000042360938,0.0000045352704,0.000010326439],"genre_scores_gemma":[0.99422675,0.0031746882,0.00051882886,0.0015579221,0.0003779424,0.00000999432,0.00001252106,0.000012786704,0.00010857383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998438,0.00015729794,0.0009834064,0.00015009362,0.00015955909,0.00011163892],"domain_scores_gemma":[0.99551547,0.0029445956,0.0010705871,0.0001474407,0.00008464374,0.00023727569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091056497,0.00010688933,0.0008424861,0.000055767385,0.0000914693,0.00004380541,0.000056147786,0.00018669327,0.000045136367],"category_scores_gemma":[0.002237173,0.00006690197,0.00023352739,0.000013260653,0.00016815287,0.00030402132,0.000026734639,0.00018896948,0.0000033458484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084431,0.00027160757,0.93331516,0.00001982203,0.0002377135,0.00015214144,0.000021038792,5.692323e-7,0.00032636497,0.000004003741,0.0006736324,0.056534853],"study_design_scores_gemma":[0.004028933,0.0009592597,0.9915809,0.00011197913,0.00023124485,0.00014211913,0.000022869437,0.0000675631,0.00008349534,0.0002344346,0.0024650004,0.000072211216],"about_ca_topic_score_codex":0.000032112446,"about_ca_topic_score_gemma":0.000007662892,"teacher_disagreement_score":0.05826574,"about_ca_system_score_codex":0.000042316246,"about_ca_system_score_gemma":0.00015794874,"threshold_uncertainty_score":0.27281833},"labels":[],"label_agreement":null},{"id":"W2889914080","doi":"10.1200/jco.2017.35.15_suppl.e15715","title":"Overall survival (OS) achieved with gemcitabine (G) or gemcitabine-abraxane (GA) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) who received first line modified FOLFIRINOX (m-FFX) palliative chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Chemotherapy; Pancreatic cancer; Oncology; Cancer; Surgery; Irinotecan","score_opus":0.11848690342293411,"score_gpt":0.435482105195888,"score_spread":0.31699520177295387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889914080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810594,0.00026311696,0.0003435057,0.011746777,0.0005022019,0.0014350896,0.000017952423,0.00002429473,0.00460768],"genre_scores_gemma":[0.98471504,0.0026973684,0.008000808,0.001043338,0.0009647341,0.00005431129,0.000023131272,0.00009447598,0.002406766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99292696,0.00081257074,0.0032152925,0.0007543533,0.0013006666,0.0009901731],"domain_scores_gemma":[0.9886204,0.003974883,0.0039330707,0.001035316,0.0014960598,0.00094028085],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0034226975,0.0006004128,0.004963267,0.0003082917,0.00031944714,0.00005628602,0.0008445907,0.0007917361,0.00041594377],"category_scores_gemma":[0.007877206,0.00035496318,0.00040682955,0.00026590587,0.0011761128,0.00051974104,0.00019314581,0.0024427471,0.000022671413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13987218,0.0043711266,0.8405223,0.00013707388,0.0014714906,0.0021495698,0.00039430775,0.00007018602,0.000032033946,0.00004820852,0.0003425091,0.0105890315],"study_design_scores_gemma":[0.09148822,0.06170397,0.8424822,0.000815327,0.00077878276,0.00016983347,0.0001508987,0.0007407769,0.000017119864,0.00015942774,0.0011381354,0.000355307],"about_ca_topic_score_codex":0.00022528587,"about_ca_topic_score_gemma":0.0018574472,"teacher_disagreement_score":0.05733284,"about_ca_system_score_codex":0.0006293353,"about_ca_system_score_gemma":0.0031900161,"threshold_uncertainty_score":0.9998902},"labels":[],"label_agreement":null},{"id":"W2889917536","doi":"10.1200/jco.2017.35.15_suppl.e17560","title":"Randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electron Spin Resonance Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Ototoxicity; Medicine; Cisplatin; Randomized controlled trial; Adverse effect; Hearing loss; Anesthesia; Sodium hyaluronate; Surgery; Audiology; Chemotherapy; Internal medicine","score_opus":0.06476399339391428,"score_gpt":0.443562091378092,"score_spread":0.37879809798417774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889917536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98797065,0.00028653673,0.00036422643,0.0067849415,0.0010336356,0.0025008155,0.0000053244726,0.0000021464882,0.0010517401],"genre_scores_gemma":[0.9970394,0.00048348808,0.0005532014,0.0004748139,0.0010505323,0.000105913816,4.973036e-7,0.000014753046,0.0002774016],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99506307,0.0010244505,0.0031123448,0.00023118469,0.0003064794,0.000262472],"domain_scores_gemma":[0.9911487,0.003975829,0.0035620045,0.00050971843,0.0006290231,0.00017468522],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007366149,0.00018373413,0.002899134,0.000074501935,0.00015405878,0.000013643146,0.0007147239,0.0003288045,0.000012823443],"category_scores_gemma":[0.04723157,0.00010647727,0.0014991659,0.00007217912,0.00030442898,0.0000064159476,0.00015747962,0.00046790732,0.0000022025756],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8524696,0.0021658868,0.00018303671,0.000008344221,0.0010717125,0.000004563969,0.00013123835,0.000038449445,0.13824482,0.000048526006,0.00061087846,0.005022906],"study_design_scores_gemma":[0.9116367,0.030681876,0.005383273,0.00006233447,0.00060166704,0.000017077364,0.000049832473,0.000019409794,0.047316678,0.00010629009,0.003991253,0.00013359993],"about_ca_topic_score_codex":0.000024897638,"about_ca_topic_score_gemma":0.00021301777,"teacher_disagreement_score":0.090928145,"about_ca_system_score_codex":0.000026695812,"about_ca_system_score_gemma":0.0010165453,"threshold_uncertainty_score":0.96079403},"labels":[],"label_agreement":null},{"id":"W2889953739","doi":"10.1200/jco.2017.35.15_suppl.e21669","title":"Online education needs and preferences of patients with cancer and their caregivers.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Information needs; Quarter (Canadian coin); Cancer; Patient education; Family medicine; Disease; Needs assessment; Internal medicine","score_opus":0.1972120857713412,"score_gpt":0.5838443528811682,"score_spread":0.386632267109827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889953739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932099,0.00018086891,0.000022362445,0.0033036454,0.0010501144,0.0001834579,0.000032282045,0.0000016845287,0.002015661],"genre_scores_gemma":[0.9964388,0.0008679852,0.00078551227,0.0014937504,0.000306567,0.0000034563657,0.0000038062813,0.0000025121788,0.00009758781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975084,0.0003587631,0.001862801,0.00006137301,0.000102455466,0.00010620226],"domain_scores_gemma":[0.99279016,0.0009874747,0.0048314244,0.00014184855,0.0010629767,0.00018613471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020450454,0.000058512425,0.00052380277,0.000060405684,0.00025383057,0.0000068704703,0.0001436513,0.00019711968,0.00008697264],"category_scores_gemma":[0.0022387162,0.000030628387,0.00003218532,0.000028394066,0.00022523485,0.0006600947,0.000062872976,0.0006176624,6.125053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003779764,0.00023350565,0.7065358,0.00010303884,0.000016212167,6.2815204e-8,0.0020917081,1.4484776e-7,1.9829734e-7,0.000051969208,0.00071786536,0.28987148],"study_design_scores_gemma":[0.0019214565,0.0011196071,0.9291841,0.00021313269,0.000018872946,3.705418e-7,0.0029749675,0.000024298693,8.858494e-7,0.000278357,0.06423365,0.000030316487],"about_ca_topic_score_codex":0.0002651033,"about_ca_topic_score_gemma":0.00035694698,"teacher_disagreement_score":0.28984118,"about_ca_system_score_codex":0.00004031327,"about_ca_system_score_gemma":0.0027441792,"threshold_uncertainty_score":0.48680562},"labels":[],"label_agreement":null},{"id":"W2889960081","doi":"10.1200/jco.2017.35.15_suppl.8537","title":"Multi-modality therapy for stage IIIa N2 non-small cell lung cancer: Does the answer lie in the components?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Regimen; Internal medicine; Stage (stratigraphy); Chemotherapy; Oncology; Surgery","score_opus":0.1682182097630047,"score_gpt":0.5070876072570385,"score_spread":0.3388693974940338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889960081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9006071,0.0012497477,0.00012017442,0.09452407,0.0020146754,0.000962097,0.000021682368,0.000002862141,0.0004975716],"genre_scores_gemma":[0.9832828,0.007528644,0.00091219565,0.0062537338,0.0015048806,0.00009794794,0.0000019810325,0.000014455992,0.00040334312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767816,0.00035034123,0.0012715997,0.00019804784,0.00024714085,0.00025468736],"domain_scores_gemma":[0.9944409,0.0029180788,0.0017252708,0.00053488853,0.00023779254,0.0001430622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004049227,0.00015053258,0.0009900493,0.000040571605,0.00021794684,0.000042246716,0.0005528976,0.00021854893,0.0000671683],"category_scores_gemma":[0.0005058468,0.000056675995,0.00054949545,0.000036307385,0.00024335628,0.00007837193,0.000052116706,0.00072725274,0.0000018484666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031186042,0.004794716,0.95280915,0.000060782953,0.0004677602,0.00017742043,0.0006683096,0.000020028905,0.00010452104,0.000048011243,0.0052386196,0.03249208],"study_design_scores_gemma":[0.02025418,0.0030364064,0.87931085,0.0001147609,0.00030765007,0.000010042803,0.00016131226,0.00048677533,0.0001526425,0.00010238322,0.095994785,0.0000681993],"about_ca_topic_score_codex":0.0006476161,"about_ca_topic_score_gemma":0.0017730786,"teacher_disagreement_score":0.09075616,"about_ca_system_score_codex":0.00025567555,"about_ca_system_score_gemma":0.0008741943,"threshold_uncertainty_score":0.31595916},"labels":[],"label_agreement":null},{"id":"W2889975785","doi":"10.1200/jco.2018.36.15_suppl.10100","title":"Effect of pre-treatment sleep disturbance on radiation therapy (RT)-induced pain in 676 women with breast cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Breast cancer; Sleep disorder; Anxiety; Depression (economics); Internal medicine; Population; Cancer; Brief Pain Inventory; Cancer pain; Prostate cancer; Physical therapy; Mood; Randomized controlled trial; Insomnia; Chronic pain; Psychiatry","score_opus":0.035561274661817494,"score_gpt":0.4235305354207909,"score_spread":0.3879692607589734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889975785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951049,0.0003645866,0.000016668646,0.0028469777,0.00090114883,0.00031287337,0.0000060302177,0.0000053136073,0.00044148316],"genre_scores_gemma":[0.99647593,0.00080939726,0.000022146774,0.0009972557,0.0015819051,0.00003348114,0.0000011120883,0.000014351725,0.00006440188],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99732745,0.001010566,0.0010017146,0.00016884129,0.0002857608,0.00020564185],"domain_scores_gemma":[0.99653906,0.0018594937,0.0009980919,0.00017825846,0.00022211763,0.00020298093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00358588,0.0001427145,0.0012080065,0.0000935818,0.00001912094,0.0000036121817,0.00009453764,0.00021312431,0.0001235384],"category_scores_gemma":[0.00040759915,0.000078404795,0.00016741717,0.00018167376,0.00012996147,0.000053085838,0.000007786514,0.00037385343,0.0000023757893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056364127,0.0007678258,0.23700893,0.000022345688,0.00021767602,0.00006077408,0.0006665639,0.000007833624,0.00019505051,0.0000033526421,0.000121218625,0.7045643],"study_design_scores_gemma":[0.014349206,0.21378139,0.7608999,0.00021692725,0.00008091581,0.00004600372,0.00007336972,0.000049776765,0.0014372013,0.000014959314,0.00897606,0.00007431343],"about_ca_topic_score_codex":0.0004381584,"about_ca_topic_score_gemma":0.0011791324,"teacher_disagreement_score":0.70449,"about_ca_system_score_codex":0.0007650965,"about_ca_system_score_gemma":0.00075229653,"threshold_uncertainty_score":0.31972548},"labels":[],"label_agreement":null},{"id":"W2889980037","doi":"10.1200/jco.2016.34.15_suppl.e16574","title":"Pioglitazone and the risk of prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pioglitazone; Medicine; Proportional hazards model; Hazard ratio; Thiazolidinedione; Prostate cancer; Internal medicine; Cumulative incidence; Confidence interval; Cumulative dose; Cohort; Oncology; Rosiglitazone; Cancer; Diabetes mellitus; Endocrinology","score_opus":0.03175221975303665,"score_gpt":0.396235338296708,"score_spread":0.3644831185436713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889980037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754405,0.010494125,0.00022474791,0.005722845,0.0074141044,0.00010833435,0.000025276286,0.0000011441473,0.0005689435],"genre_scores_gemma":[0.88350415,0.099664085,0.0004323502,0.000659059,0.014803269,0.0000053323274,4.0723356e-7,0.000009356051,0.0009219855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811804,0.0004793369,0.0010388696,0.000120715624,0.00011644566,0.0001266018],"domain_scores_gemma":[0.9975157,0.00058068684,0.0013629178,0.00015809089,0.00026923264,0.00011341387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003023956,0.00007618111,0.0006166904,0.000021636213,0.000027119884,0.000002968447,0.00015834023,0.00018531171,0.0000219265],"category_scores_gemma":[0.0026532689,0.000033124674,0.00028106937,0.000032983542,0.0006620544,0.000004487601,0.00007079098,0.00019240641,0.0000010008091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013239004,0.0003085454,0.09981909,0.00001920835,0.00081116945,0.0000010312411,0.00015641545,0.000010079565,0.027498977,0.0006866403,0.05950698,0.7979429],"study_design_scores_gemma":[0.010304055,0.002036966,0.06981078,0.000027056067,0.00021071466,0.000032183143,0.00005128313,0.000002384773,0.0015390752,0.0010199737,0.91490203,0.00006347272],"about_ca_topic_score_codex":0.000057672187,"about_ca_topic_score_gemma":0.00012858187,"teacher_disagreement_score":0.8553951,"about_ca_system_score_codex":0.000009588337,"about_ca_system_score_gemma":0.0005712416,"threshold_uncertainty_score":0.31764022},"labels":[],"label_agreement":null},{"id":"W2889984783","doi":"10.1200/jco.2018.36.15_suppl.2065","title":"Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology’s RTOG 0614.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Apolipoprotein E; Internal medicine; Memantine; Oncology; Radiation therapy; Hazard ratio; Confidence interval; Disease; Dementia","score_opus":0.08349959232344668,"score_gpt":0.4754882555808338,"score_spread":0.3919886632573871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889984783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963984,0.000051507377,0.00022171867,0.0010495982,0.0004060398,0.00060939224,0.000056909725,0.0000077722025,0.0011986622],"genre_scores_gemma":[0.99779785,0.00008413947,0.00047614175,0.0011319352,0.00041963966,0.000008745367,0.000020936171,0.000026137535,0.00003448917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99466795,0.0011990529,0.0027618015,0.00035564008,0.0006657068,0.00034983954],"domain_scores_gemma":[0.9906849,0.0022365488,0.0037229392,0.00026627805,0.0027528848,0.00033639668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028642195,0.00026737177,0.0029588705,0.0009927629,0.000045606714,0.0000037183354,0.00015346863,0.00040806647,0.00043040264],"category_scores_gemma":[0.0037717728,0.00017756426,0.00086117524,0.0012482596,0.0007583556,0.0001817518,0.00006186928,0.0010513149,0.000009585086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1026717,0.009306587,0.7120104,0.000025612095,0.013468734,0.00009065503,0.00036708004,0.00014402307,0.00017050293,0.0000127669555,0.00047202152,0.16125992],"study_design_scores_gemma":[0.01543741,0.21532871,0.7615518,0.00015641106,0.006589403,0.000009488643,0.00022509776,0.000081917286,0.00012677081,0.00004830146,0.00033647465,0.00010819334],"about_ca_topic_score_codex":0.00037675461,"about_ca_topic_score_gemma":0.00087930117,"teacher_disagreement_score":0.20602213,"about_ca_system_score_codex":0.0006261186,"about_ca_system_score_gemma":0.0015803627,"threshold_uncertainty_score":0.72408605},"labels":[],"label_agreement":null},{"id":"W2889986295","doi":"10.1200/jco.2017.35.15_suppl.e15007","title":"Real world eligibility of treatment-refractory stage IV colorectal cancer patients for palliative intent regorafenib monotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Panitumumab; Colorectal cancer; Cetuximab; Refractory (planetary science); Oncology; Performance status; Cancer; Stage (stratigraphy)","score_opus":0.18964150691964077,"score_gpt":0.53253625672663,"score_spread":0.3428947498069892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889986295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912818,0.00043608889,0.000010469299,0.0017012277,0.0015833793,0.00075161055,0.000107520515,0.0000061182354,0.0041217846],"genre_scores_gemma":[0.99037,0.0064907,0.000634235,0.00017937862,0.00063857523,0.00006369917,0.0000053009103,0.00001879974,0.0015993159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972114,0.00015559384,0.0018768702,0.0002626965,0.00025018738,0.00024327669],"domain_scores_gemma":[0.99307585,0.00151221,0.0037793433,0.00026413667,0.0011266641,0.0002417756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084054767,0.00020850275,0.0020284639,0.000089904395,0.00014803978,0.000010663456,0.00018774363,0.00019746658,0.000097433556],"category_scores_gemma":[0.001744578,0.00012743872,0.00081284245,0.000047227335,0.0004507807,0.00011845318,0.000054925524,0.00031442312,0.0000012923001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036643088,0.0044373856,0.804598,0.000035129484,0.0019382632,0.00002499835,0.00042560307,0.0000030998215,0.00014643319,0.000035003646,0.0012677094,0.15044533],"study_design_scores_gemma":[0.021550873,0.057785016,0.87591714,0.00009531777,0.00058383937,0.0000010488798,0.0001259422,0.000038330643,0.00055826234,0.00013511676,0.04311438,0.00009476425],"about_ca_topic_score_codex":0.0010516616,"about_ca_topic_score_gemma":0.005256404,"teacher_disagreement_score":0.15035056,"about_ca_system_score_codex":0.0012469199,"about_ca_system_score_gemma":0.0016706452,"threshold_uncertainty_score":0.51968},"labels":[],"label_agreement":null},{"id":"W2890000379","doi":"10.1200/jco.2018.36.15_suppl.4088","title":"Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Sorafenib; Hepatocellular carcinoma; Cabozantinib; Systemic therapy; Gastroenterology; Progression-free survival; Placebo; Overall survival; Oncology; Cancer; Surgery; Pathology","score_opus":0.16660777477734562,"score_gpt":0.4300913041073774,"score_spread":0.2634835293300318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890000379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914375,0.00039639501,0.0000031018023,0.0029475407,0.0018528013,0.0028188012,0.0000068806326,0.0000057718617,0.0005312028],"genre_scores_gemma":[0.998036,0.0004799546,0.0001342482,0.0005556649,0.00065180095,0.0000511488,0.000007834383,0.000027853115,0.00005548874],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992234,0.0026213815,0.0036805363,0.00033093357,0.00069928897,0.00043386192],"domain_scores_gemma":[0.9917313,0.0051461156,0.0020584194,0.0004576209,0.0004289785,0.00017755733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006121551,0.00030277023,0.0023795844,0.0002707361,0.00006211431,0.000014123785,0.0005088953,0.0005095543,0.00006527629],"category_scores_gemma":[0.0042824023,0.00016125475,0.00062050374,0.00044921148,0.00038786168,0.00013465235,0.000052563606,0.0012565489,0.000015751946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27334592,0.0053471066,0.6643499,0.000016767624,0.0001315281,0.0005400584,0.0011805226,8.501102e-7,0.000063518724,0.000014367478,0.00006251877,0.054946937],"study_design_scores_gemma":[0.46241453,0.07249819,0.460301,0.00020429197,0.00020469252,0.000046137062,0.0005592241,0.00029099087,0.00027296288,0.000036040576,0.0030281185,0.0001438015],"about_ca_topic_score_codex":0.00030943612,"about_ca_topic_score_gemma":0.00050942367,"teacher_disagreement_score":0.20404889,"about_ca_system_score_codex":0.00023107331,"about_ca_system_score_gemma":0.0019411049,"threshold_uncertainty_score":0.6575778},"labels":[],"label_agreement":null},{"id":"W2890011261","doi":"10.1200/jco.2017.35.15_suppl.10558","title":"Diabetes risk in childhood cancer survivors: A population-based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Hospital for Sick Children; Institute for Clinical Evaluative Sciences; University of Toronto; Pediatric Oncology Group; Women's College Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Cancer; Hazard ratio; Population; Cancer registry; Internal medicine; Pediatrics; Confidence interval; Environmental health; Endocrinology","score_opus":0.04875401170802344,"score_gpt":0.4273763398380212,"score_spread":0.37862232812999774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890011261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97781867,0.01966281,0.0000117483105,0.0002487381,0.0018939486,0.00015707035,0.0000141129,0.0000020766138,0.00019083652],"genre_scores_gemma":[0.9878601,0.008949301,0.00021503979,0.0007792301,0.0021287221,0.000014883582,0.000004404504,0.000016760603,0.000031583626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723077,0.00067367713,0.0013863317,0.00024731184,0.00021200732,0.00024988584],"domain_scores_gemma":[0.9966038,0.00026965764,0.002297878,0.00044043458,0.00021397158,0.00017428027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033870994,0.00013977215,0.00086530746,0.00006616106,0.000108788874,0.000030675783,0.000499743,0.00033137423,0.00007404065],"category_scores_gemma":[0.00461039,0.00010895267,0.00032391885,0.00004075614,0.000085591906,0.000012654465,0.00007997782,0.00050771405,0.0000031968139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001745776,0.0009131531,0.7701411,0.0000038155617,0.0001241378,0.000007542102,0.00002122255,0.0001526631,0.00004869926,0.0000021652977,0.00025493721,0.22815599],"study_design_scores_gemma":[0.004273174,0.0021285128,0.94381833,0.000024203686,0.00010868744,4.982985e-7,0.00003902899,0.000036588917,0.0002452065,0.00015250708,0.049050584,0.00012267772],"about_ca_topic_score_codex":0.0007461759,"about_ca_topic_score_gemma":0.01038355,"teacher_disagreement_score":0.2280333,"about_ca_system_score_codex":0.000034336063,"about_ca_system_score_gemma":0.0008127108,"threshold_uncertainty_score":0.57942647},"labels":[],"label_agreement":null},{"id":"W2890013612","doi":"10.1200/jco.2016.34.15_suppl.e16577","title":"Concomitant use of glucocorticoids in patients with metastatic castration resistant prostate cancer (mCRPC) treated with oral therapies.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Concomitant; Abiraterone acetate; Hazard ratio; Prostate cancer; Proportional hazards model; Enzalutamide; Internal medicine; Urology; Population; Cancer; Confidence interval; Androgen deprivation therapy; Androgen receptor","score_opus":0.13777576950248407,"score_gpt":0.44504356195058126,"score_spread":0.3072677924480972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890013612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963403,0.00025070034,0.000030007794,0.0026293655,0.0000780503,0.0005853747,0.000028220524,0.0000042354823,0.000053787313],"genre_scores_gemma":[0.99626625,0.00089879864,0.0022769608,0.00014278578,0.0000478575,0.000017441138,0.000004551042,0.00001886488,0.00032648715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718004,0.00038659468,0.0015232348,0.00017209638,0.00048218865,0.0002558571],"domain_scores_gemma":[0.9964309,0.0009757616,0.0012958073,0.00015304613,0.00091812573,0.00022639369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091441366,0.0001442884,0.0011803802,0.00015671573,0.000019566209,0.000008018949,0.000069416914,0.00010445129,0.000083264975],"category_scores_gemma":[0.00046518157,0.00005771319,0.00011434603,0.00022617425,0.00041979205,0.00023409227,0.000013788105,0.00032972373,0.0000012625586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093386665,0.0017510167,0.829245,0.00003206158,0.0007420384,0.0005823037,0.00012184182,0.0000061637065,0.0008589197,0.000027864018,0.000089650996,0.07315651],"study_design_scores_gemma":[0.049309324,0.042279493,0.905164,0.0005579881,0.00037835585,0.000019703202,0.000078362216,0.0000069921743,0.0008227412,0.000057201745,0.001246698,0.00007911883],"about_ca_topic_score_codex":0.00020051532,"about_ca_topic_score_gemma":0.0007065534,"teacher_disagreement_score":0.07591906,"about_ca_system_score_codex":0.000351215,"about_ca_system_score_gemma":0.0022494067,"threshold_uncertainty_score":0.39903507},"labels":[],"label_agreement":null},{"id":"W2890014497","doi":"10.1200/jco.2018.36.15_suppl.4500","title":"Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Clinical endpoint; Internal medicine; Renal cell carcinoma; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Adverse effect; Surgery; Urology; Clinical trial; Disease; Cancer; Immunotherapy","score_opus":0.0781875072256028,"score_gpt":0.4026770833521769,"score_spread":0.3244895761265741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890014497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98260945,0.0015943499,0.000055078286,0.0031736933,0.00086551084,0.00064773386,0.000023914588,0.000013274177,0.011017009],"genre_scores_gemma":[0.9868951,0.003997032,0.0048584784,0.001713581,0.0017408768,0.000009004958,0.000017002152,0.00006067056,0.00070827606],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9928613,0.0006950569,0.0046755522,0.00056040153,0.00074004405,0.0004676823],"domain_scores_gemma":[0.99119633,0.0031376267,0.0033998862,0.0006990318,0.001019389,0.0005477612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002581185,0.0003689034,0.0026807096,0.00031048417,0.0000511352,0.000009602676,0.00041322445,0.0006929776,0.00042861298],"category_scores_gemma":[0.0013483049,0.00026512367,0.0008577688,0.0002998265,0.00044481375,0.00013637291,0.00007328901,0.001296548,0.0000762624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51021034,0.013338764,0.3239089,0.00006193031,0.00073881034,0.0045979386,0.0018055922,0.00023304447,0.027178012,0.000012636515,0.004622444,0.113291614],"study_design_scores_gemma":[0.08388946,0.118388236,0.7177186,0.00015558575,0.00028467688,0.00016068993,0.00012512271,0.00021868391,0.052385904,0.0003998387,0.026035247,0.00023794535],"about_ca_topic_score_codex":0.00057607517,"about_ca_topic_score_gemma":0.00020081185,"teacher_disagreement_score":0.42632085,"about_ca_system_score_codex":0.00041212628,"about_ca_system_score_gemma":0.0017759942,"threshold_uncertainty_score":0.9999801},"labels":[],"label_agreement":null},{"id":"W2890019948","doi":"10.1200/jco.2018.36.15_suppl.10055","title":"Effect of comorbidities on outcomes in colorectal cancer (CRC) survivors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Cancer; Colorectal cancer; Cohort; Diabetes mellitus; Cancer registry; Proportional hazards model; Hazard ratio; Disease; Population; Confidence interval","score_opus":0.13394694619328104,"score_gpt":0.5518254339397244,"score_spread":0.4178784877464433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890019948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905663,0.00012444699,0.0000010082389,0.002719671,0.0013768837,0.0001633422,0.000004144579,0.0000034393686,0.005040748],"genre_scores_gemma":[0.9976319,0.00049097225,0.00006312984,0.00049937546,0.00086138595,0.0000034069485,6.5162385e-7,0.0000106588495,0.00043849938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689853,0.00083705934,0.001497215,0.00011665425,0.00043115177,0.00021941382],"domain_scores_gemma":[0.99231863,0.0063655954,0.000652023,0.00010761765,0.00036822582,0.00018792404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051336465,0.000104912724,0.0017366718,0.000230573,0.000018514913,0.0000031846362,0.00015473343,0.00030773872,0.00037764825],"category_scores_gemma":[0.005410356,0.000060504884,0.0003561911,0.00016122265,0.00050877774,0.000052325806,0.000045074717,0.0009281718,0.000031898566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0147579145,0.0011520277,0.9105747,0.000060386617,0.0002800506,0.00037926738,0.00010733104,0.0000018820086,0.0010851396,0.000029737166,0.0027487476,0.068822846],"study_design_scores_gemma":[0.0082215015,0.10781856,0.86654776,0.00016098726,0.00010321902,0.000053460848,0.000047115547,0.000058535647,0.0094799325,0.00003476906,0.007417096,0.000057086632],"about_ca_topic_score_codex":0.00042092492,"about_ca_topic_score_gemma":0.0013859877,"teacher_disagreement_score":0.10666653,"about_ca_system_score_codex":0.00012259075,"about_ca_system_score_gemma":0.0008292553,"threshold_uncertainty_score":0.6477092},"labels":[],"label_agreement":null},{"id":"W2890023827","doi":"10.1200/jco.2017.35.15_suppl.e18213","title":"Accreditation of oncology education in low-and- middle income countries: Perspectives of African oncologists.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Accreditation; Medicine; Competence (human resources); Graduate medical education; Internal medicine; Medical education; Family medicine; Oncology; Psychology","score_opus":0.08429982759965596,"score_gpt":0.5378438578608855,"score_spread":0.4535440302612296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890023827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670025,0.0024070013,0.00019184785,0.012547529,0.0024858704,0.00027495358,0.000004365247,0.0000039412703,0.015081971],"genre_scores_gemma":[0.97525537,0.008385454,0.014387248,0.0005213641,0.0011826993,0.0000057542106,0.0000010542784,0.000010360304,0.00025072406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965265,0.00048346617,0.0023789008,0.00019126195,0.00023057763,0.00018933717],"domain_scores_gemma":[0.9888372,0.0043605687,0.00546694,0.00029545647,0.0008577455,0.00018212016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004113504,0.00012586442,0.0018855612,0.00025988978,0.000067449415,0.0000040918735,0.00030280315,0.00065779133,0.00013737856],"category_scores_gemma":[0.011675314,0.00009471947,0.0002377659,0.00008441111,0.0021790816,0.0002047257,0.000058256443,0.000844619,0.0000017099376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019847928,0.008391988,0.62463844,0.00046168832,0.0005426229,0.00025067356,0.005294084,0.000029700614,0.0003115575,0.0049845073,0.0008322283,0.3344146],"study_design_scores_gemma":[0.010044142,0.02886456,0.90059096,0.00069181446,0.00021304401,0.0003276066,0.0071504195,0.00004698829,0.00012746408,0.0029298004,0.048906606,0.00010657916],"about_ca_topic_score_codex":0.00005827386,"about_ca_topic_score_gemma":0.00019518702,"teacher_disagreement_score":0.33430803,"about_ca_system_score_codex":0.000447056,"about_ca_system_score_gemma":0.0085721705,"threshold_uncertainty_score":0.9970483},"labels":[],"label_agreement":null},{"id":"W2890030948","doi":"10.1200/jco.2016.34.15_suppl.e16118","title":"Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lactate dehydrogenase; Sunitinib; Internal medicine; Temsirolimus; Renal cell carcinoma; Everolimus; Progression-free survival; Proportional hazards model; Gastroenterology; Hazard ratio; Urology; Oncology; Discovery and development of mTOR inhibitors; Overall survival; PI3K/AKT/mTOR pathway; Confidence interval; Apoptosis","score_opus":0.1092548767671688,"score_gpt":0.37358715672499254,"score_spread":0.2643322799578237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890030948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958744,0.0003122623,0.00014308188,0.0016812119,0.0004318465,0.0007390974,0.00012549046,0.000011274421,0.0006813285],"genre_scores_gemma":[0.9976972,0.00044737535,0.0007348949,0.00042547673,0.00039268777,0.000021306365,0.00006497507,0.00004063984,0.00017546378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918746,0.0034338841,0.0029177351,0.00054330594,0.00076231285,0.00046816858],"domain_scores_gemma":[0.9805334,0.015323775,0.0023326345,0.00046989028,0.00068149297,0.00065880216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038384649,0.0004045815,0.0025340356,0.00038960663,0.0000655853,0.000019268908,0.00023877808,0.00028991385,0.00032897136],"category_scores_gemma":[0.0029809903,0.0001892756,0.0007375995,0.00055653177,0.0003695977,0.00019281714,0.000088719804,0.00069401826,0.000010992465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40137208,0.0031662416,0.5718561,0.000009411851,0.0040235803,0.0020665934,0.00010060986,0.000017738817,0.00019900672,0.0000015729994,0.00049588864,0.016691197],"study_design_scores_gemma":[0.24135421,0.030393578,0.7172589,0.00007987307,0.008748627,0.000026947571,0.000095262316,0.0004208994,0.00033543186,0.000031685217,0.0010686463,0.0001859858],"about_ca_topic_score_codex":0.0010431925,"about_ca_topic_score_gemma":0.00155357,"teacher_disagreement_score":0.16001785,"about_ca_system_score_codex":0.00049972825,"about_ca_system_score_gemma":0.0010644523,"threshold_uncertainty_score":0.7718435},"labels":[],"label_agreement":null},{"id":"W2890032742","doi":"10.1200/jco.2017.35.15_suppl.5524","title":"Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Cancer Care Ontario; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Cohort; Progression-free survival; Oncology; Mucositis; Phases of clinical research; Cabozantinib; Endometrial cancer; Cancer; Chemotherapy; Surgery","score_opus":0.14368234547990025,"score_gpt":0.4800996152587704,"score_spread":0.3364172697788701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890032742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596447,0.00024315435,0.0000017268975,0.00043476807,0.0008585935,0.0022959064,0.00005778834,0.0000026171745,0.00014097927],"genre_scores_gemma":[0.99935085,0.00015093602,0.000117483316,0.00006404442,0.0002255694,0.000032281503,0.0000020480643,0.000020609836,0.000036172773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99393326,0.001101031,0.003434806,0.00034646504,0.00090942706,0.00027501237],"domain_scores_gemma":[0.9909312,0.0013148631,0.006144248,0.00061032927,0.0006880576,0.00031128386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028316176,0.00025774035,0.002624345,0.000263743,0.00019208573,0.000011762294,0.00042145833,0.00013681523,0.00007279804],"category_scores_gemma":[0.004702098,0.0001368032,0.00023531808,0.00024641494,0.00044541567,0.000111228575,0.0003296772,0.0009496849,4.6875164e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048001785,0.14476213,0.7325027,0.000051075458,0.0011027859,0.00037827878,0.0013546391,0.000004918122,0.000044329176,0.000001983415,0.000079915524,0.07171543],"study_design_scores_gemma":[0.22256504,0.28460598,0.4896545,0.00020304727,0.0015433249,0.00002789954,0.0007486075,0.000021310345,0.0000904912,0.0000064603432,0.0004522416,0.000081102764],"about_ca_topic_score_codex":0.0005392463,"about_ca_topic_score_gemma":0.0020404402,"teacher_disagreement_score":0.24284822,"about_ca_system_score_codex":0.00012918875,"about_ca_system_score_gemma":0.0012265184,"threshold_uncertainty_score":0.562919},"labels":[],"label_agreement":null},{"id":"W2890043858","doi":"10.1200/jco.2017.35.15_suppl.10118","title":"Frequency and factors predictive of aberrant drug behavior in patients presenting to outpatient supportive care center at a comprehensive cancer center.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer pain; Multivariate analysis; Cancer; Internal medicine; Odds ratio; Anxiety; Palliative care; Distress; Depression (economics); Psychiatry","score_opus":0.09508279447093089,"score_gpt":0.44797533611754686,"score_spread":0.352892541646616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890043858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953573,0.00021593411,0.0000016796371,0.0005628475,0.0025946044,0.0005586008,0.00019303548,0.000002867725,0.0005131288],"genre_scores_gemma":[0.99914426,0.00017771934,0.000059287908,0.00029587848,0.00021732616,0.000014640714,0.000013278107,0.000015251582,0.000062364874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971783,0.00022699148,0.0016822804,0.00024394847,0.00041461023,0.00025382897],"domain_scores_gemma":[0.99576443,0.0003548458,0.0021065325,0.00024354304,0.0011419685,0.0003886718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031948267,0.00016053706,0.0012654525,0.00012387095,0.00007091106,0.000009265608,0.00018774194,0.0002061579,0.00006566436],"category_scores_gemma":[0.0008142012,0.00011842471,0.0003104763,0.000042036412,0.00022729061,0.00013273192,0.00022838954,0.00060734217,9.92651e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023581223,0.0011828601,0.9788672,0.000082667604,0.00013813288,0.00011570319,0.0099904025,0.0000019746856,0.0000352563,0.0000011403697,0.00038222334,0.0068443464],"study_design_scores_gemma":[0.0073892092,0.0048671826,0.9824325,0.00031620573,0.00021727395,0.0000073945926,0.0029365628,0.0000030673223,0.0001716326,0.000005419754,0.0015626425,0.0000909466],"about_ca_topic_score_codex":0.001465256,"about_ca_topic_score_gemma":0.0068986705,"teacher_disagreement_score":0.00705384,"about_ca_system_score_codex":0.00042314493,"about_ca_system_score_gemma":0.0004145358,"threshold_uncertainty_score":0.48292193},"labels":[],"label_agreement":null},{"id":"W2890046006","doi":"10.1200/jco.2018.36.15_suppl.2515","title":"A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vomiting; Nausea; Internal medicine; Tolerability; Pharmacodynamics; Hypokalemia; Gastroenterology; Pharmacokinetics; Adverse effect","score_opus":0.07626437236207907,"score_gpt":0.5230527555881498,"score_spread":0.44678838322607073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890046006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974968,0.000041416453,0.00011652656,0.00047081028,0.00046094254,0.0007681598,0.0000052896753,0.000004642781,0.0006354225],"genre_scores_gemma":[0.9958872,0.000027010297,0.0030719491,0.0005137254,0.00028474216,0.000016985263,0.0000027709325,0.000016679034,0.00017894678],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9963957,0.0002760478,0.0025346645,0.00018723276,0.00040914732,0.00019722042],"domain_scores_gemma":[0.9961545,0.0006582225,0.0018315109,0.0001831422,0.00094153965,0.00023112084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095445436,0.00013805932,0.0015441856,0.00016518694,0.000028258326,0.0000035995374,0.000102428494,0.00008316995,0.000108961205],"category_scores_gemma":[0.0015046439,0.00007541024,0.00013589636,0.00028054626,0.00020689867,0.00012950612,0.000029184303,0.00039563517,0.0000065074164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10733074,0.17334358,0.31571513,0.00008908957,0.0023848435,0.0016970843,0.003920006,0.000038520426,0.00011724322,0.0000121495505,0.0013500825,0.3940015],"study_design_scores_gemma":[0.19299203,0.54622084,0.25264025,0.00044534105,0.0015800549,0.00007723392,0.0022262922,0.000061528684,0.00014954263,0.00006200299,0.0034271204,0.00011775443],"about_ca_topic_score_codex":0.000049121096,"about_ca_topic_score_gemma":0.0005505081,"teacher_disagreement_score":0.39388376,"about_ca_system_score_codex":0.00019237067,"about_ca_system_score_gemma":0.0026649435,"threshold_uncertainty_score":0.4727495},"labels":[],"label_agreement":null},{"id":"W2890074783","doi":"10.1200/jco.2016.34.15_suppl.e23134","title":"Clinico-pathologic and molecular characteristics of patients with resected lung adenocarcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"KRAS; Medicine; Adenocarcinoma; Malignancy; Stage (stratigraphy); Internal medicine; Lung cancer; Molecular pathology; Lung; Oncology; Adjuvant therapy; Pathology; Cancer; Gastroenterology; Colorectal cancer; Gene; Biology","score_opus":0.046947412984324234,"score_gpt":0.4493518904111951,"score_spread":0.40240447742687085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890074783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605054,0.00032195536,0.0003273912,0.0023149678,0.00028810458,0.00017108329,0.000018051027,0.000004079254,0.0005038142],"genre_scores_gemma":[0.99625903,0.0003232054,0.0025418364,0.0006080836,0.00015766938,0.000002131296,0.0000039845486,0.00001028589,0.00009375718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805343,0.00017589545,0.00131195,0.00012803412,0.00020939893,0.000121311554],"domain_scores_gemma":[0.9967274,0.0008749647,0.0013913022,0.00013781585,0.00066408684,0.00020441141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006381723,0.000085977284,0.0008755854,0.00007492745,0.000017424343,0.0000024464498,0.000060884682,0.00018093412,0.00005417081],"category_scores_gemma":[0.001941792,0.000040319625,0.00013377887,0.000067243105,0.00022997387,0.00005988315,0.000026175217,0.00023208343,0.000001989126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030730036,0.0009461264,0.9306418,0.000022115722,0.0003614921,0.0006184048,0.0000414221,7.008392e-8,0.00017271776,0.00006357021,0.00024279921,0.06381648],"study_design_scores_gemma":[0.01169675,0.014900726,0.96986264,0.00014026056,0.0008800692,0.00009156921,0.000015899122,0.0000020453897,0.00005865765,0.00009705579,0.0022070627,0.00004725937],"about_ca_topic_score_codex":0.0000021165522,"about_ca_topic_score_gemma":0.0000013885999,"teacher_disagreement_score":0.06376922,"about_ca_system_score_codex":0.000067569745,"about_ca_system_score_gemma":0.0006801464,"threshold_uncertainty_score":0.23246467},"labels":[],"label_agreement":null},{"id":"W2890080134","doi":"10.1200/jco.2017.35.15_suppl.tps10129","title":"A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hôpital Notre-Dame; University of Toronto; Toronto Western Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Randomized controlled trial; Radiosurgery; Clinical trial; Adverse effect; Phases of clinical research; Nuclear medicine; Radiology; Surgery; Internal medicine","score_opus":0.18334270351052073,"score_gpt":0.5220405143617511,"score_spread":0.3386978108512304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890080134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812354,0.0005048395,0.009267788,0.002731269,0.0019611293,0.003851615,0.000020713498,0.00001599137,0.0004112695],"genre_scores_gemma":[0.98308074,0.00025662035,0.014500173,0.0008689576,0.0008081029,0.00009979414,0.000022276938,0.000044112552,0.00031922729],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993866,0.0012081378,0.0031273735,0.00041637802,0.0009939476,0.00038813797],"domain_scores_gemma":[0.987493,0.003996001,0.00635128,0.0005869742,0.0009966377,0.000576151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007021107,0.00036126055,0.004245468,0.00024223041,0.00036459442,0.00008349252,0.0004849374,0.00013122863,0.00048471382],"category_scores_gemma":[0.006221224,0.00023599126,0.0011756757,0.00007603971,0.0006046705,0.00037919116,0.00007855048,0.0006421668,0.0000027808142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8702464,0.03427759,0.062384814,0.000066955065,0.013790643,0.00033557162,0.00017734748,0.0000075018816,0.0000037890388,0.00021101152,0.0020946001,0.016403776],"study_design_scores_gemma":[0.7719538,0.11249091,0.09962625,0.00013533181,0.005465313,0.000009676657,0.0002358663,0.001240339,0.0000018409232,0.00008568982,0.008559459,0.00019549158],"about_ca_topic_score_codex":0.000019067194,"about_ca_topic_score_gemma":0.000013643634,"teacher_disagreement_score":0.09829257,"about_ca_system_score_codex":0.00027701486,"about_ca_system_score_gemma":0.0010186137,"threshold_uncertainty_score":0.96234447},"labels":[],"label_agreement":null},{"id":"W2890082473","doi":"10.1200/jco.2017.35.15_suppl.11046","title":"Influence of chemotherapy combined with radiotherapy on the time-to-development of radiation-induced sarcomas: A multicenter, retrospective analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Chemotherapy; Malignancy; Sarcoma; Retrospective cohort study; Radiation therapy; Cancer; Internal medicine; Oncology; Clinical endpoint; Cohort; Pathology; Clinical trial","score_opus":0.05404400754967848,"score_gpt":0.4163317366361691,"score_spread":0.36228772908649065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890082473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98458236,0.00007421085,0.00003705944,0.014475767,0.000061122184,0.00039928814,0.0000019860772,0.0000030113733,0.00036517807],"genre_scores_gemma":[0.9939059,0.00017566385,0.003561655,0.0021765942,0.0001051326,0.00001003467,8.5267254e-7,0.000012364633,0.000051792595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975556,0.00021530614,0.0014571621,0.00017087969,0.00045772933,0.00014329194],"domain_scores_gemma":[0.9939761,0.0016392047,0.0031858552,0.0004925466,0.00052395824,0.00018232723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018740551,0.00014255747,0.0017024184,0.0001757491,0.00008517658,0.000009420872,0.0003059693,0.00013689545,0.00013419846],"category_scores_gemma":[0.0015576101,0.000073096744,0.00036410923,0.00017273813,0.00018201645,0.00004754894,0.00002306464,0.0003296179,0.0000071555783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009807985,0.0053920923,0.886609,0.000008352127,0.006948239,0.00006415243,0.0005463314,0.00015664559,0.0016480377,0.00004956707,0.00029240036,0.08847719],"study_design_scores_gemma":[0.012611968,0.015768817,0.96148926,0.00012817758,0.00066142535,0.000007702937,0.000027602113,0.00012016537,0.007260678,0.000017836617,0.0018431052,0.00006323755],"about_ca_topic_score_codex":0.000019420933,"about_ca_topic_score_gemma":0.00003526021,"teacher_disagreement_score":0.08841395,"about_ca_system_score_codex":0.00021202287,"about_ca_system_score_gemma":0.00070191483,"threshold_uncertainty_score":0.29807988},"labels":[],"label_agreement":null},{"id":"W2890089103","doi":"10.1200/jco.2018.36.15_suppl.8568","title":"Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Placebo; Clinical endpoint; Confidence interval; Progression-free survival; Gastroenterology; Surgery; Randomized controlled trial; Overall survival; Pathology","score_opus":0.04363397691707189,"score_gpt":0.37913852378508134,"score_spread":0.33550454686800946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890089103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972739,0.000034340053,0.00001695236,0.0013614492,0.00023787768,0.000864262,0.000024301442,0.000006170793,0.000180697],"genre_scores_gemma":[0.9990285,0.00006412251,0.00046366718,0.00011653537,0.00018575031,0.00001548191,0.000030619474,0.000025015863,0.00007031361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950366,0.0010877379,0.0022243375,0.00033242546,0.0010191858,0.00029973162],"domain_scores_gemma":[0.9943253,0.002895493,0.002028714,0.0001922219,0.0003343022,0.00022401776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041703964,0.00023532711,0.0014921782,0.00040751055,0.00004115335,0.000012753386,0.0001815953,0.00025507875,0.000065272376],"category_scores_gemma":[0.0027001102,0.00015765487,0.00009507121,0.00039132228,0.00019179388,0.00026205427,0.000116894276,0.0006113931,0.000003430333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044285845,0.009730615,0.9407546,0.000053592295,0.0002512907,0.00015370996,0.00031520549,0.00005758339,0.000009419979,0.000013601642,0.00008755003,0.0042870142],"study_design_scores_gemma":[0.063742965,0.057035677,0.8774975,0.00053868035,0.00025281377,0.000006927778,0.00025001308,0.0002748736,0.000015219162,0.00014431105,0.000096802636,0.00014423246],"about_ca_topic_score_codex":0.00025361596,"about_ca_topic_score_gemma":0.0077090356,"teacher_disagreement_score":0.06325709,"about_ca_system_score_codex":0.000502551,"about_ca_system_score_gemma":0.00035132482,"threshold_uncertainty_score":0.6428979},"labels":[],"label_agreement":null},{"id":"W2890094213","doi":"10.1200/jco.2017.35.15_suppl.10040","title":"Unmet supportive care needs of older adults with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Geriatric oncology; Depression (economics); Comorbidity; Cancer; Geriatric Depression Scale; Geriatrics; Gerontology; Internal medicine; Physical therapy; Psychiatry; Anxiety; Depressive symptoms","score_opus":0.06262196663165667,"score_gpt":0.4739512200986473,"score_spread":0.4113292534669907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890094213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800272,0.00086221757,0.00007645201,0.010447783,0.0015466096,0.00031285346,0.000017732555,0.0000074710338,0.0067017027],"genre_scores_gemma":[0.99292827,0.0009137007,0.003737496,0.0008984713,0.00090650085,0.0000063225984,0.0000030139151,0.00002362675,0.0005825736],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99699396,0.00014470254,0.0019912443,0.00015550166,0.00045441088,0.0002601761],"domain_scores_gemma":[0.9919418,0.0008980417,0.004506113,0.000508185,0.0017248546,0.00042098376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086426333,0.00016244744,0.0017961585,0.00012448712,0.00006701946,0.000007796939,0.00038211193,0.00035326087,0.00025539572],"category_scores_gemma":[0.0043836813,0.000105236126,0.00038363703,0.00008279754,0.0006079297,0.0002121314,0.000076917175,0.0009854651,0.000006744957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017026031,0.0010711368,0.3864358,0.00026600205,0.00064425025,0.00088220276,0.0035761755,0.000025015499,0.00010306358,0.000037232978,0.004322742,0.58561033],"study_design_scores_gemma":[0.029558828,0.030649718,0.91179335,0.0019626182,0.0006825406,0.00037852896,0.005517619,0.000016178901,0.0010869198,0.000037937538,0.018162,0.00015376827],"about_ca_topic_score_codex":0.00011014918,"about_ca_topic_score_gemma":0.00036529137,"teacher_disagreement_score":0.58545655,"about_ca_system_score_codex":0.00015134361,"about_ca_system_score_gemma":0.0023597789,"threshold_uncertainty_score":0.5247993},"labels":[],"label_agreement":null},{"id":"W2890094313","doi":"10.1200/jco.2017.35.15_suppl.e18507","title":"Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Gastroenterology; Neutropenia; Oncology; Surgery; Leukemia; Toxicity","score_opus":0.03385748828145582,"score_gpt":0.37456946737509494,"score_spread":0.34071197909363915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890094313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981157,0.000038350037,0.00014910637,0.00016572856,0.00011548141,0.0011544585,0.00012869792,0.000007844092,0.0001246126],"genre_scores_gemma":[0.9985027,0.00045611121,0.00074197515,0.000033213786,0.00009341491,0.000020068086,0.000054396398,0.000041257645,0.0000569039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945948,0.0008076262,0.0025119702,0.0005051276,0.0011441386,0.000436329],"domain_scores_gemma":[0.9905861,0.0030432066,0.0039846725,0.0006799281,0.0011616923,0.00054442405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018462063,0.00035546446,0.00337208,0.0007100315,0.00012627618,0.000024391109,0.00042874098,0.00035727964,0.00004187871],"category_scores_gemma":[0.0002896688,0.00021093516,0.00026882032,0.00057379453,0.0006465294,0.00032113466,0.00006829556,0.0014381838,9.13723e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23803718,0.008956066,0.7309466,0.00005405728,0.007836443,0.0020760137,0.0023126404,0.00046129787,0.00002604773,0.0000028512238,0.000027054319,0.009263713],"study_design_scores_gemma":[0.25823855,0.077875935,0.65170664,0.00020656773,0.009903634,0.00001597357,0.0013045128,0.00053067226,0.000060239046,8.0864805e-7,0.000009730447,0.00014672906],"about_ca_topic_score_codex":0.004132365,"about_ca_topic_score_gemma":0.009657255,"teacher_disagreement_score":0.07923997,"about_ca_system_score_codex":0.0004785482,"about_ca_system_score_gemma":0.0020262075,"threshold_uncertainty_score":0.86016864},"labels":[],"label_agreement":null},{"id":"W2890098668","doi":"10.1200/jco.2017.35.15_suppl.e21588","title":"Impact of fertility preservation by ovarian stimulation on breast cancer outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Fertility preservation; Breast cancer; Ovarian cancer; Ovarian reserve; Oncology; Internal medicine; Stimulation; Cancer; Gynecology; Chemotherapy; Fertility; Population; Infertility; Pregnancy","score_opus":0.21665006635327236,"score_gpt":0.5572425079150906,"score_spread":0.3405924415618182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890098668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852761,0.000058914018,0.00009807648,0.012581474,0.000800938,0.00017171032,0.000026737223,0.0000035970663,0.0009824561],"genre_scores_gemma":[0.9988578,0.0000508466,0.0001556782,0.00030176455,0.00042984704,0.0000016502297,0.0000036986644,0.000005365657,0.0001933497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762917,0.0003579964,0.0014890238,0.00019161782,0.00020528279,0.0001269079],"domain_scores_gemma":[0.9952649,0.0007226977,0.0025398366,0.0005113917,0.0007882411,0.00017297332],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034433845,0.00009940711,0.001101619,0.00004130893,0.00007085683,0.0000050225335,0.000188387,0.00038591996,0.0002552253],"category_scores_gemma":[0.009875541,0.00005791985,0.0005064282,0.000029370562,0.00033348222,0.0002196764,0.000037742422,0.0006284783,0.0000035392918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039089676,0.0017287967,0.90040225,0.000010337797,0.00039846922,0.000008298665,0.00001762117,0.000022155724,0.00076117256,0.000009474702,0.0015507089,0.056001063],"study_design_scores_gemma":[0.004234651,0.005523048,0.9886852,0.000031772106,0.00015387124,0.000015432706,0.0000025798029,0.00011524465,0.00007735374,0.00050112506,0.000616893,0.00004285581],"about_ca_topic_score_codex":0.00031203462,"about_ca_topic_score_gemma":0.000020091597,"teacher_disagreement_score":0.08828295,"about_ca_system_score_codex":0.00017464817,"about_ca_system_score_gemma":0.00085426215,"threshold_uncertainty_score":0.9984647},"labels":[],"label_agreement":null},{"id":"W2890099753","doi":"10.1200/jco.2016.34.15_suppl.7045","title":"Up-regulation of <i>BAALC/MN1/MLLT11/EVI1</i> gene cluster in relation to <i>MYC</i> / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; NPM1; Internal medicine; Gene signature; Cancer research; Neuroblastoma RAS viral oncogene homolog; Gene expression; Gene; Bioinformatics; Cancer; Karyotype; Biology; Genetics; KRAS","score_opus":0.05827811660056799,"score_gpt":0.4142460874379162,"score_spread":0.3559679708373482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890099753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98034567,0.00011902576,0.0010717008,0.016137816,0.0004789366,0.0009267376,0.000011445645,0.000009590462,0.0008990611],"genre_scores_gemma":[0.98919654,0.0005832109,0.0065191463,0.0015284986,0.00067842455,0.000019113453,0.000008045119,0.000038641567,0.0014283919],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9936049,0.0012585259,0.0034400742,0.0004074688,0.00083489,0.00045416615],"domain_scores_gemma":[0.9947289,0.0023875337,0.0015219245,0.00032288724,0.00054297864,0.00049574644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072239563,0.00023373298,0.001739322,0.0005629293,0.000031975786,0.0000107068945,0.00025316956,0.000810515,0.000105224135],"category_scores_gemma":[0.004874339,0.0001518663,0.00025419012,0.000326637,0.0002474322,0.00041062656,0.00019351378,0.001269243,0.00002759571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03030656,0.0006391172,0.15923244,0.00008455917,0.0001546543,0.00029946456,0.00026586684,0.00008955037,0.73878,0.0001335201,0.0068187444,0.06319551],"study_design_scores_gemma":[0.046106927,0.0097550545,0.8807849,0.0013786298,0.00014255905,0.00033300745,0.00006243743,0.0005079889,0.037286874,0.0010196159,0.022325084,0.00029692272],"about_ca_topic_score_codex":0.00007643568,"about_ca_topic_score_gemma":0.00009877294,"teacher_disagreement_score":0.7215525,"about_ca_system_score_codex":0.0015152988,"about_ca_system_score_gemma":0.0026102427,"threshold_uncertainty_score":0.6251434},"labels":[],"label_agreement":null},{"id":"W2890118891","doi":"10.1200/jco.2017.35.15_suppl.6598","title":"Examining the relationship between cost of novel oncology drugs and their clinical benefit over time.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Drug; Internal medicine; Oncology; Pharmacology","score_opus":0.5846933505889429,"score_gpt":0.5167507478294732,"score_spread":0.06794260275946973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890118891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95481664,0.00045830017,0.0002904517,0.014889672,0.0012979141,0.00015240502,0.00010949172,0.000003445911,0.027981708],"genre_scores_gemma":[0.9936724,0.000814049,0.0006665737,0.0026511538,0.0018867413,0.0000025608788,0.0000018049619,0.000018041732,0.00028668082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947092,0.00017289704,0.004535975,0.00026949457,0.0000423179,0.00027012144],"domain_scores_gemma":[0.9729884,0.018875938,0.0072255023,0.0004633746,0.00010471822,0.0003420199],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014368455,0.00015326492,0.0019658525,0.00011697517,0.00021535519,0.000052349435,0.0007718317,0.0006110217,0.00015766163],"category_scores_gemma":[0.012441451,0.00011226322,0.00045784633,0.000049535818,0.0009230126,0.0002706158,0.00029038856,0.0014000713,0.00006601993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019794289,0.0003507152,0.88857275,0.000006739801,0.00023649,0.0000030690474,0.00015640672,0.000012098082,0.0000019102397,0.04314981,0.0013683013,0.06594374],"study_design_scores_gemma":[0.0035252543,0.0012100473,0.7863122,0.00001663973,0.000044087108,0.000012682202,0.00002861546,0.0009463282,0.0000022090749,0.025529925,0.18227121,0.00010075472],"about_ca_topic_score_codex":0.000047084715,"about_ca_topic_score_gemma":0.00002064095,"teacher_disagreement_score":0.18090291,"about_ca_system_score_codex":0.000092636365,"about_ca_system_score_gemma":0.00033262355,"threshold_uncertainty_score":0.99587715},"labels":[],"label_agreement":null},{"id":"W2890129786","doi":"10.1200/jco.2016.34.15_suppl.9509","title":"Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Regimen; Vismodegib; Adverse effect; Internal medicine; Population; Placebo; Basal cell carcinoma; Surgery; Gastroenterology; Basal cell; Pathology","score_opus":0.07855143791029871,"score_gpt":0.4039875667882645,"score_spread":0.32543612887796575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890129786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944079,0.00029881182,0.00138043,0.0011854748,0.00039636545,0.0021375394,0.000010418601,0.000003193206,0.00017984645],"genre_scores_gemma":[0.9985245,0.00017902849,0.00041390272,0.00033812725,0.00033439967,0.00005341287,0.0000020369303,0.000029142559,0.00012545775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99403805,0.0020765818,0.0026466078,0.00044943218,0.000429105,0.0003602094],"domain_scores_gemma":[0.9923864,0.004413336,0.0019198128,0.00043595,0.00058145676,0.00026304886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005416424,0.00031653818,0.0025415665,0.00013460057,0.0000760981,0.0000137807365,0.00040254171,0.00021268746,0.0000072599987],"category_scores_gemma":[0.0028974304,0.0001437218,0.00039071866,0.00011287077,0.00043624264,0.000011851228,0.0002633618,0.00042445638,0.0000014534285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7954476,0.009508218,0.18449442,0.000012660803,0.00091740035,0.000051127103,0.00043088497,0.0000695797,0.0039757797,0.000015982587,0.00023168144,0.0048446986],"study_design_scores_gemma":[0.9051629,0.025081981,0.064847216,0.00008507783,0.00045124048,0.0000082698525,0.0002718339,0.000025498952,0.003023755,0.000019971843,0.0008088799,0.00021341648],"about_ca_topic_score_codex":0.00003190114,"about_ca_topic_score_gemma":0.0001900289,"teacher_disagreement_score":0.119647205,"about_ca_system_score_codex":0.00006522888,"about_ca_system_score_gemma":0.00042687778,"threshold_uncertainty_score":0.5860805},"labels":[],"label_agreement":null},{"id":"W2890138337","doi":"10.1200/jco.2021.39.15_suppl.4532","title":"Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Regimen; Internal medicine; Randomization; Clinical trial; Phases of clinical research; Oncology; Cancer","score_opus":0.2242483104486075,"score_gpt":0.5124252516500166,"score_spread":0.28817694120140913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890138337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97330964,0.0045022573,0.000020733392,0.01078599,0.009000014,0.0007086236,0.0001990715,0.000013787809,0.0014599083],"genre_scores_gemma":[0.9781342,0.0080290865,0.0022742597,0.004795421,0.0055480595,0.00007129512,0.000031166866,0.000070625276,0.0010458772],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99384785,0.0012055959,0.0033573364,0.00044403365,0.0007163106,0.00042890207],"domain_scores_gemma":[0.98932546,0.0064833057,0.0021908437,0.0005552137,0.0007640063,0.0006811523],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015359671,0.00032861947,0.002498768,0.00011818596,0.00006436687,0.000017521948,0.00039338844,0.00049531966,0.0016308259],"category_scores_gemma":[0.021525325,0.00020062306,0.00081630907,0.00050677947,0.00039752637,0.00020716221,0.000110834204,0.0015428049,0.00001656384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82027304,0.005746971,0.014960707,0.00006127787,0.0017021389,0.00092841266,0.00041755004,0.000015961512,0.001633557,0.00007156248,0.01010519,0.1440836],"study_design_scores_gemma":[0.73402345,0.04239864,0.022386448,0.0006242697,0.0018419331,0.000044296958,0.00036075767,0.000029767454,0.0017106985,0.00036173293,0.19597192,0.00024605633],"about_ca_topic_score_codex":0.0006532999,"about_ca_topic_score_gemma":0.002683597,"teacher_disagreement_score":0.18586673,"about_ca_system_score_codex":0.00040331006,"about_ca_system_score_gemma":0.01104702,"threshold_uncertainty_score":0.9992818},"labels":[],"label_agreement":null},{"id":"W2890146145","doi":"10.1200/jco.2017.35.15_suppl.e21064","title":"Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Diarrhea; Internal medicine; Colitis; Discontinuation; Gastroenterology; Cancer","score_opus":0.1453140435504841,"score_gpt":0.4877604757531635,"score_spread":0.3424464322026794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890146145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97529846,0.0035842217,0.000011242396,0.017132748,0.0007057531,0.00019973468,0.000010553436,0.0000038693674,0.003053384],"genre_scores_gemma":[0.9783257,0.018091548,0.0004051326,0.002364631,0.0004024143,0.0000010611277,0.0000013603028,0.0000081511425,0.00039999667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970975,0.00027708465,0.0020178605,0.0001648129,0.00028234583,0.00016043184],"domain_scores_gemma":[0.99466515,0.0007130629,0.0034805443,0.00036703763,0.00055051275,0.0002236669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031217672,0.00010571522,0.0022943406,0.00013840714,0.00006767352,0.000010624487,0.00018159788,0.00024152486,0.00039199553],"category_scores_gemma":[0.0074215718,0.00006716189,0.0008754438,0.00018229178,0.00033471728,0.00009776772,0.000046953246,0.00045362127,0.0000014794256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046589453,0.003058253,0.5506406,0.0003943403,0.014335755,0.0007869197,0.00026293125,2.675937e-7,0.0029090086,0.00008240822,0.010340879,0.37059918],"study_design_scores_gemma":[0.0069883685,0.00951195,0.9541302,0.00097167987,0.004781612,0.00009220809,0.00006486249,0.000020555679,0.00020577712,0.00005318695,0.023106132,0.00007346643],"about_ca_topic_score_codex":0.00005220566,"about_ca_topic_score_gemma":0.00039273326,"teacher_disagreement_score":0.4034896,"about_ca_system_score_codex":0.00016969515,"about_ca_system_score_gemma":0.0007397621,"threshold_uncertainty_score":0.8884851},"labels":[],"label_agreement":null},{"id":"W2890150873","doi":"10.1200/jco.2016.34.15_suppl.11001","title":"Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Ifosfamide; Hazard ratio; Etoposide; Clinical endpoint; Chemotherapy; Lung cancer; Oncology; Internal medicine; Lung; Vincristine; Surgery; Urology; Randomized controlled trial; Cyclophosphamide; Confidence interval","score_opus":0.05152015427993155,"score_gpt":0.3892344495344783,"score_spread":0.3377142952545467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890150873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878228,0.00029811444,0.0006536526,0.008287902,0.00037275103,0.0023710108,0.00003058503,0.000013376186,0.00014983119],"genre_scores_gemma":[0.9903311,0.0005137852,0.007789778,0.00083086686,0.00035825235,0.00004745148,0.000060844653,0.000039517665,0.000028367067],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928494,0.0014044279,0.0042775176,0.00037967673,0.00078297727,0.00030600672],"domain_scores_gemma":[0.983703,0.010827865,0.0041266675,0.0003313294,0.0007047803,0.00030632716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056029004,0.00030972887,0.0039319447,0.00044504897,0.000038962848,0.000012992092,0.00019929027,0.00023434019,0.00009615656],"category_scores_gemma":[0.0025057355,0.00017294704,0.0005888487,0.0003882656,0.00034470417,0.00019587003,0.000028130475,0.00037137317,0.0000023486834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9210366,0.008043992,0.032595154,0.00006192037,0.002122775,0.0001829474,0.00025689404,0.00010184154,0.0013795432,0.0001617739,0.000518677,0.03353788],"study_design_scores_gemma":[0.7184143,0.011456235,0.26585838,0.0008780085,0.00085299555,0.000063375584,0.000038803017,0.00012921578,0.0016574411,0.00004310332,0.00046851262,0.00013964261],"about_ca_topic_score_codex":0.00007353935,"about_ca_topic_score_gemma":0.000023715247,"teacher_disagreement_score":0.23326324,"about_ca_system_score_codex":0.00037186846,"about_ca_system_score_gemma":0.001259335,"threshold_uncertainty_score":0.70525753},"labels":[],"label_agreement":null},{"id":"W2890158093","doi":"10.1200/jco.2017.35.15_suppl.tps2613","title":"A phase I study of oral SRA737 (formerly CCT245737) given in combination with gemcitabine plus cisplatin or gemcitabine alone in patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Gemcitabine; Cisplatin; Medicine; CHEK1; Cancer; Cancer research; DNA damage; Oncology; Cell cycle; Chemotherapy; Cell cycle checkpoint; Internal medicine; Pharmacology; DNA; Biology; Genetics","score_opus":0.047176775955044534,"score_gpt":0.42541481226459055,"score_spread":0.378238036309546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890158093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983675,0.0001086819,0.000089233334,0.0004860785,0.00031221806,0.0005020311,0.000029439723,0.0000010938314,0.00010374505],"genre_scores_gemma":[0.99813634,0.00029209343,0.001221993,0.00013406464,0.00011830547,0.000019314537,0.000017639384,0.00001970992,0.000040514962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977045,0.000137943,0.0014277674,0.00025223775,0.00025114563,0.00022642937],"domain_scores_gemma":[0.99658567,0.00020258769,0.002247345,0.00032427252,0.0005066042,0.00013350461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009058292,0.00016675223,0.0010059326,0.0001075499,0.000049327642,0.000015574891,0.00034359767,0.00019610267,0.000015128857],"category_scores_gemma":[0.0012572284,0.00011326238,0.00007652188,0.00009632592,0.0001767914,0.000028735658,0.00010147111,0.00036574499,4.0906522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07011738,0.016018791,0.76989764,0.000025824802,0.00025271432,0.00016072813,0.00022918134,0.001715855,0.0005356985,0.000009637367,0.0001712409,0.14086533],"study_design_scores_gemma":[0.1314257,0.1507539,0.7151797,0.00009711847,0.00010383056,0.000007231844,0.00021751481,0.00013188658,0.0002469117,0.00002717817,0.0016396538,0.0001694154],"about_ca_topic_score_codex":0.00035047292,"about_ca_topic_score_gemma":0.014493833,"teacher_disagreement_score":0.14069591,"about_ca_system_score_codex":0.0001193556,"about_ca_system_score_gemma":0.0010902251,"threshold_uncertainty_score":0.8087899},"labels":[],"label_agreement":null},{"id":"W2890178450","doi":"10.1200/jco.2017.35.15_suppl.5021","title":"A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Baker Hughes (Canada); BC Cancer Agency; Kelowna General Hospital; Ottawa Regional Cancer Foundation; Juravinski Cancer Centre; Queen's University; London Health Sciences Centre","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Taxane; Cancer; Adverse effect; Phases of clinical research; Randomized controlled trial; Chemotherapy; Urology; Surgery; Breast cancer","score_opus":0.1337965742926648,"score_gpt":0.5014514949699028,"score_spread":0.36765492067723804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890178450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942717,0.0007931411,0.0000065863915,0.0007390053,0.00045575676,0.0035512834,0.00013293867,0.0000017663399,0.00004781731],"genre_scores_gemma":[0.99836165,0.0006863135,0.00015494134,0.00017038398,0.0002606236,0.00022184117,0.000019996607,0.00003516623,0.00008911602],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9896367,0.004804692,0.0038411578,0.00048639337,0.00074661727,0.00048443623],"domain_scores_gemma":[0.9921929,0.00059183495,0.0050486256,0.0006400775,0.0010541982,0.00047232228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016005095,0.000305388,0.0033074785,0.000295071,0.0002450062,0.000052749703,0.000654196,0.00024019681,0.00010179761],"category_scores_gemma":[0.0053626713,0.00020574752,0.00036752757,0.00015027502,0.0004219869,0.000041283754,0.00012919617,0.0007361987,7.541452e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89745414,0.01247034,0.060358968,0.000026284426,0.0030188235,0.0002840387,0.0009456014,0.0004063259,0.002033741,0.0000019170761,0.00024307452,0.022756737],"study_design_scores_gemma":[0.73823273,0.19066739,0.06742258,0.000084483494,0.001002735,0.0000050390477,0.0010261842,0.00005125699,0.0008324364,0.000046441535,0.00036277212,0.00026597152],"about_ca_topic_score_codex":0.03783462,"about_ca_topic_score_gemma":0.67298114,"teacher_disagreement_score":0.63514656,"about_ca_system_score_codex":0.00027797153,"about_ca_system_score_gemma":0.005832309,"threshold_uncertainty_score":0.9998037},"labels":[],"label_agreement":null},{"id":"W2890185811","doi":"10.1200/jco.2018.36.15_suppl.e18089","title":"A retrospective analysis of adult head and neck rhabdomyosarcoma (HN RMS) from 1984-2017.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rhabdomyosarcoma; Univariate analysis; Retrospective cohort study; Radiation therapy; Stage (stratigraphy); Malignancy; Chemotherapy; Sarcoma; Surgery; Head and neck; Internal medicine; Multivariate analysis; Pathology","score_opus":0.08957847869580883,"score_gpt":0.4607020467742596,"score_spread":0.37112356807845076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890185811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068016,0.00084015465,0.0000558603,0.0055934396,0.0004896605,0.00012467582,0.00002092171,0.0000057972684,0.0021893329],"genre_scores_gemma":[0.989526,0.0011800544,0.006253115,0.0019363869,0.0010460343,0.0000028254549,0.0000053897575,0.000010819547,0.000039372742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690753,0.00026210275,0.0020097762,0.00025577593,0.00037316914,0.0001916167],"domain_scores_gemma":[0.99475574,0.0017879672,0.0017685475,0.00028896373,0.0010292169,0.00036955942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009298419,0.00014858875,0.002476123,0.00028261947,0.00004013269,0.000007422951,0.0001223024,0.00032311652,0.00033946134],"category_scores_gemma":[0.002748351,0.00009795142,0.00077609863,0.0003819843,0.0004521676,0.00007198814,0.00006207921,0.00047768158,0.000015520302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002378299,0.002972096,0.93614453,0.000004856131,0.0061842357,0.00052721385,0.00022823097,5.5824773e-7,0.000077748395,0.00015988332,0.0018550394,0.049467307],"study_design_scores_gemma":[0.008608665,0.015394711,0.96318686,0.00010062362,0.0064968183,0.00009455635,0.00011446597,0.00020539969,0.0001549759,0.0007377576,0.004829882,0.00007527726],"about_ca_topic_score_codex":0.00031003004,"about_ca_topic_score_gemma":0.00070910493,"teacher_disagreement_score":0.04939203,"about_ca_system_score_codex":0.00014056101,"about_ca_system_score_gemma":0.00041312416,"threshold_uncertainty_score":0.3994343},"labels":[],"label_agreement":null},{"id":"W2890208257","doi":"10.1200/jco.2018.36.15_suppl.e21577","title":"Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Adverse effect; Internal medicine; Hazard ratio; Multivariate analysis; Pneumonitis; Lactate dehydrogenase; Melanoma; Gastroenterology; Immunotherapy; Cancer; Confidence interval","score_opus":0.07655993975475398,"score_gpt":0.45488470605453935,"score_spread":0.3783247662997854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890208257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894603,0.0004044331,0.0000051389684,0.004377217,0.0027561786,0.00016847246,0.0000011291255,0.000008081943,0.0028190818],"genre_scores_gemma":[0.9970028,0.0007311159,0.0005781087,0.00080668816,0.00029940854,0.0000016611156,0.0000010155907,0.00001480287,0.0005644393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637693,0.00038346797,0.0025832045,0.0001738778,0.0002566496,0.00022586172],"domain_scores_gemma":[0.9971471,0.0009460174,0.0013022816,0.00018088473,0.00022873115,0.0001950007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032523868,0.00013692777,0.0014741082,0.00016283989,0.00003397047,0.0000018865499,0.0001269029,0.00039155295,0.00021539933],"category_scores_gemma":[0.0018931061,0.000094957846,0.00041003706,0.00017130909,0.00022416367,0.00012297831,0.000044760403,0.0007412203,0.000015040402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043685064,0.0011865817,0.7866551,0.00001753066,0.00072335434,0.0004462401,0.00023915213,6.2208636e-7,0.006336953,0.000039449165,0.0001046193,0.16056533],"study_design_scores_gemma":[0.03394854,0.013898303,0.94340163,0.00011564298,0.00011766279,0.00028075016,0.00017688329,0.00001796039,0.00019231069,0.00019196825,0.00756563,0.00009272258],"about_ca_topic_score_codex":0.000048441405,"about_ca_topic_score_gemma":0.00012370145,"teacher_disagreement_score":0.16047262,"about_ca_system_score_codex":0.00015350184,"about_ca_system_score_gemma":0.00072086556,"threshold_uncertainty_score":0.38722685},"labels":[],"label_agreement":null},{"id":"W2890218253","doi":"10.1200/jco.2018.36.15_suppl.e17522","title":"Utility of PETCT over conventional imaging in ovarian cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Surgery","score_opus":0.14091089615241048,"score_gpt":0.5202413171159773,"score_spread":0.37933042096356684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890218253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968147,0.00085491576,0.00011165723,0.018303398,0.0021979674,0.00014590527,0.000010622657,0.0000027454507,0.010225785],"genre_scores_gemma":[0.99512,0.00046779026,0.0014259693,0.0014508852,0.0014369944,0.0000027413455,0.0000010487857,0.0000066944353,0.000087867236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974948,0.00020166468,0.0017617369,0.00014096843,0.00025246805,0.00014831679],"domain_scores_gemma":[0.997417,0.0007497841,0.0011175127,0.00013250609,0.00040347036,0.00017973185],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019715065,0.000079828205,0.0009440639,0.00009405456,0.000015482236,0.0000028062925,0.000082366096,0.0001251829,0.003312054],"category_scores_gemma":[0.0008438555,0.000057618534,0.00035065433,0.00011170829,0.0003095612,0.00006918168,0.000029682653,0.00036647904,0.00000786864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019597062,0.0019989219,0.89674956,0.000016998845,0.00018410177,0.00025328636,0.000038208524,5.623612e-7,0.00004774267,0.0004042702,0.006244524,0.092102125],"study_design_scores_gemma":[0.010621936,0.00276739,0.9415233,0.00018859933,0.0002032744,0.000083410705,0.000027361033,0.00011827964,0.00019488578,0.0006476156,0.04358384,0.000040085168],"about_ca_topic_score_codex":0.0002415818,"about_ca_topic_score_gemma":0.00030831384,"teacher_disagreement_score":0.09206204,"about_ca_system_score_codex":0.00012631707,"about_ca_system_score_gemma":0.002043926,"threshold_uncertainty_score":0.99759907},"labels":[],"label_agreement":null},{"id":"W2890224043","doi":"10.1200/jco.2017.35.15_suppl.5078","title":"A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Hazard ratio; Estramustine; Internal medicine; Randomization; Oncology; Androgen suppression; Prostate cancer; Radiation therapy; Chemotherapy; Docetaxel; Urology; Adjuvant; Confidence interval; Etoposide; Cancer; Randomized controlled trial; Prostate disease","score_opus":0.08164844456432574,"score_gpt":0.5119246027542678,"score_spread":0.430276158189942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890224043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151796,0.0014766138,0.000041631116,0.005396775,0.00028464044,0.0010864153,0.00013797804,0.0000022344168,0.00005575428],"genre_scores_gemma":[0.9865129,0.011924774,0.0009452148,0.00013118224,0.0002608005,0.000049488604,0.000016079866,0.000013829932,0.00014575473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966728,0.00065112096,0.0019300552,0.0002272854,0.00030205227,0.00021669893],"domain_scores_gemma":[0.99256885,0.0025958954,0.0038556813,0.00026706068,0.0004857757,0.0002267207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058662086,0.00013430964,0.0022589662,0.00042158217,0.000072568946,0.000008626517,0.00013782518,0.0003232491,0.00007719712],"category_scores_gemma":[0.0022595664,0.000079968806,0.0003261912,0.00017815376,0.0004735683,0.00014600188,0.000035790807,0.0005469654,1.2311699e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6166106,0.0021971648,0.06589896,0.000039432165,0.002035568,0.00012048064,0.0005135104,0.000015244287,0.0013036159,0.0000023682524,0.00030133798,0.31096172],"study_design_scores_gemma":[0.544086,0.096777804,0.3450537,0.00018799798,0.0030327362,0.000019067089,0.0001808214,0.0006096961,0.0039365054,0.00013311183,0.0058942013,0.000088416724],"about_ca_topic_score_codex":0.00026119567,"about_ca_topic_score_gemma":0.00036895642,"teacher_disagreement_score":0.3108733,"about_ca_system_score_codex":0.00021085698,"about_ca_system_score_gemma":0.003681248,"threshold_uncertainty_score":0.6530376},"labels":[],"label_agreement":null},{"id":"W2890226048","doi":"10.1200/jco.2017.35.15_suppl.e15784","title":"Comparison of guidelines, BRCAPRO, and genetic counsellors estimates for the identification of BRCA1 and BRCA2 mutations in pancreatic cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; Mount Sinai Hospital; Women's College Hospital; Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Proband; Genetic counseling; Genetic testing; BRCA mutation; Oncology; Internal medicine; Cancer; Pancreatic cancer; Mutation; Breast cancer; Genetics; Biology; Gene","score_opus":0.6995114152868215,"score_gpt":0.7116406582566603,"score_spread":0.01212924296983886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890226048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664777,0.005697685,0.0013132362,0.025686545,0.00034325072,0.00040205257,0.000009691739,0.000001460778,0.00006835566],"genre_scores_gemma":[0.97699374,0.013297388,0.009169792,0.00020433318,0.00022116488,0.000013512588,9.483091e-7,0.000009209905,0.000089927475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516445,0.00016772031,0.003960737,0.00015952684,0.00041682486,0.00013076543],"domain_scores_gemma":[0.94668174,0.046406057,0.0040931166,0.00037156604,0.0022967358,0.00015078422],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011693404,0.00007622816,0.0011706224,0.000080735976,0.000093869996,0.000017439108,0.00028381814,0.00033956362,0.000012781081],"category_scores_gemma":[0.13538846,0.000048475118,0.00013738436,0.000055847755,0.0014456827,0.0000628298,0.00006320968,0.0009242966,3.4660457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001356188,0.0005687252,0.8983973,0.00041778752,0.00028040758,0.000013011056,0.00029949253,0.00023614943,0.0020755872,0.000735567,0.0005326024,0.09508713],"study_design_scores_gemma":[0.0035630492,0.0026387782,0.9609415,0.0004027705,0.0005250103,0.000029294688,0.00029839238,0.016338568,0.0005534858,0.014025845,0.00064084656,0.000042464035],"about_ca_topic_score_codex":0.00022192595,"about_ca_topic_score_gemma":0.0009235013,"teacher_disagreement_score":0.12369505,"about_ca_system_score_codex":0.000040745395,"about_ca_system_score_gemma":0.0014233809,"threshold_uncertainty_score":0.87189454},"labels":[],"label_agreement":null},{"id":"W2890226403","doi":"10.1200/jco.2018.36.15_suppl.3089","title":"Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Tumor microenvironment; Cancer research; Gene signature; Immune checkpoint; Immunology; Gene expression; Blockade; Immune system; Immunotherapy; Gene; Biology; Receptor; Internal medicine; Genetics","score_opus":0.06121968000714845,"score_gpt":0.41145483868857796,"score_spread":0.3502351586814295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890226403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983207,0.00032459578,0.00008842497,0.012945126,0.0021228024,0.00087451877,0.0000032950165,0.000020785186,0.00041344418],"genre_scores_gemma":[0.991587,0.000077904944,0.0026896086,0.0028407008,0.002131942,0.000011950119,9.1052874e-7,0.000031348736,0.00062868046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952471,0.0012689687,0.0021278171,0.00027139968,0.0007298368,0.00035483],"domain_scores_gemma":[0.9944498,0.001962123,0.0015306771,0.00048322266,0.00080618047,0.0007680195],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011241377,0.00021811991,0.0013641343,0.00020574486,0.00008038594,0.000008287433,0.00037454662,0.00073338574,0.00029787325],"category_scores_gemma":[0.008600507,0.000113537346,0.00052285136,0.00028039917,0.00024410641,0.00006885907,0.00012880583,0.0014695664,0.000050517512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14003372,0.0018034976,0.013030794,0.000044272874,0.0005216461,0.001383583,0.008501878,0.00003089146,0.7537881,0.0000065561235,0.019993141,0.060861915],"study_design_scores_gemma":[0.010426168,0.061805908,0.34033656,0.0006826382,0.00024576485,0.0006256683,0.00014578807,0.00004610117,0.37324366,0.0001246272,0.21213287,0.00018422774],"about_ca_topic_score_codex":0.000016313339,"about_ca_topic_score_gemma":0.00004493597,"teacher_disagreement_score":0.38054442,"about_ca_system_score_codex":0.00015490754,"about_ca_system_score_gemma":0.0019059404,"threshold_uncertainty_score":0.9997505},"labels":[],"label_agreement":null},{"id":"W2890234755","doi":"10.1200/jco.2017.35.15_suppl.e17081","title":"Molecular-based classification algorithm for endometrial carcinoma to categorize ovarian endometrioid carcinoma into prognostically significant groups.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Carcinoma; Oncology; MSH2; Endometrial cancer; MSH6; Serous carcinoma; Internal medicine; MLH1; Ovarian cancer; Ovarian carcinoma; Serous fluid; Immunohistochemistry; Pathology; Cancer; DNA mismatch repair; Colorectal cancer","score_opus":0.14840495081090258,"score_gpt":0.4496375149044509,"score_spread":0.30123256409354837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890234755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85216755,0.00041083127,0.10913808,0.025968248,0.0066701164,0.0032305957,0.00006473883,0.000037363512,0.0023124544],"genre_scores_gemma":[0.89706326,0.000039368388,0.09739028,0.0016583126,0.0035781828,0.00013194274,0.000024485806,0.000047478392,0.000066711815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99418956,0.0004566971,0.0032602162,0.00059036684,0.0009233478,0.0005797924],"domain_scores_gemma":[0.9859932,0.0073214057,0.0028035901,0.0007508623,0.0016526844,0.0014782468],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045896024,0.0003479032,0.0025430934,0.0007757854,0.00026571707,0.000099498524,0.0007285265,0.00064091454,0.000099638404],"category_scores_gemma":[0.044033665,0.00025422417,0.001318131,0.00055924983,0.00034007,0.00017213289,0.00011997839,0.000883705,0.00003159267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021113979,0.0038426078,0.07911554,0.00008292047,0.0006263157,0.001290859,0.000045506255,0.000005347756,0.005244874,0.0008703876,0.00056762673,0.88719404],"study_design_scores_gemma":[0.10932634,0.0864849,0.7680886,0.00010726845,0.002526215,0.00015912678,0.00010574184,0.0018169322,0.008713037,0.0021771574,0.019996138,0.0004985425],"about_ca_topic_score_codex":0.00020263817,"about_ca_topic_score_gemma":0.000015963975,"teacher_disagreement_score":0.8866955,"about_ca_system_score_codex":0.00062994304,"about_ca_system_score_gemma":0.0032772026,"threshold_uncertainty_score":0.999991},"labels":[],"label_agreement":null},{"id":"W2890235767","doi":"10.1200/jco.2017.35.15_suppl.e15114","title":"N-myristoyltransferase 2: A novel marker for colorectal cancer screening.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; University of Winnipeg","funders":"","keywords":"Medicine; Immunohistochemistry; Colorectal cancer; Internal medicine; Cancer; Gastroenterology; Adenomatous polyps; Peripheral blood mononuclear cell; Oncology; Pathology; Colonoscopy; Biology","score_opus":0.09476294080098878,"score_gpt":0.4511867652803546,"score_spread":0.3564238244793658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890235767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92631733,0.0024564867,0.022291992,0.005681736,0.040491983,0.00034572577,0.00013316769,0.0000049523633,0.002276636],"genre_scores_gemma":[0.9071348,0.0038572652,0.011535178,0.0022521622,0.073857605,0.0000364227,0.000010167378,0.00003851752,0.0012779004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980845,0.00009780493,0.0011488516,0.00024211894,0.00016186581,0.00026486785],"domain_scores_gemma":[0.99743575,0.00025818683,0.0012738279,0.00027870454,0.000475084,0.00027845253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020921673,0.00014445277,0.00079996913,0.000036809688,0.00017543505,0.000030057778,0.0004882563,0.00046820607,0.00004747182],"category_scores_gemma":[0.003137487,0.00011637713,0.0007110903,0.000018079772,0.00032215004,0.000012757424,0.00007353633,0.00035518777,0.0000014476467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022586089,0.0013597702,0.04708871,0.000042971496,0.0012714118,0.0000046192044,0.000059321068,0.000070294634,0.18154293,0.00023851749,0.23707445,0.5086609],"study_design_scores_gemma":[0.0066661807,0.0025635306,0.12929761,0.000021497666,0.00017270012,0.000051950592,0.0000190967,0.000046186105,0.0019133309,0.000052645733,0.8590618,0.000133507],"about_ca_topic_score_codex":0.000066602595,"about_ca_topic_score_gemma":0.0005010439,"teacher_disagreement_score":0.62198734,"about_ca_system_score_codex":0.000022840852,"about_ca_system_score_gemma":0.0012366676,"threshold_uncertainty_score":0.47457215},"labels":[],"label_agreement":null},{"id":"W2890237290","doi":"10.1200/jco.2016.34.15_suppl.9570","title":"Prognosticators of first line treatment for metastatic uveal melanoma (MUM).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Neutrophil to lymphocyte ratio; Retrospective cohort study; Cancer; Liver disease; Progressive disease; Surgery; Oncology; Disease; Overall survival","score_opus":0.17343131427153757,"score_gpt":0.4917184273396288,"score_spread":0.3182871130680912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890237290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788768,0.00062690896,0.0017414622,0.016155384,0.0009895448,0.0006533694,0.000026784466,0.00000857277,0.00092113053],"genre_scores_gemma":[0.981551,0.0006531109,0.01633658,0.0002898716,0.00056278874,0.000022845079,0.0000034626792,0.000016500173,0.0005638491],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971665,0.00022556337,0.002036825,0.00016850056,0.0001832482,0.00021933818],"domain_scores_gemma":[0.99086815,0.006602188,0.001609013,0.00018446993,0.00041001095,0.00032615988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013815649,0.00014733113,0.001808929,0.00011441626,0.00003026357,0.0000016058265,0.00010117548,0.0002725905,0.00013774782],"category_scores_gemma":[0.0047074533,0.00007090635,0.0007668978,0.000071539354,0.0002859151,0.00006227683,0.000020901278,0.00015846863,0.000022011733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010582483,0.010366153,0.51302683,0.000058644237,0.0035738132,0.0009348606,0.000060334438,0.0000010803103,0.00011681415,0.00048218385,0.001142134,0.45965463],"study_design_scores_gemma":[0.094151616,0.31671116,0.23016657,0.00039931654,0.008056929,0.0012238827,0.000078268225,0.000038542126,0.0033854109,0.004226095,0.34136307,0.00019911607],"about_ca_topic_score_codex":0.00000493457,"about_ca_topic_score_gemma":0.000041036248,"teacher_disagreement_score":0.45945552,"about_ca_system_score_codex":0.00019645288,"about_ca_system_score_gemma":0.0012282494,"threshold_uncertainty_score":0.5635601},"labels":[],"label_agreement":null},{"id":"W2890254030","doi":"10.1200/jco.2017.35.15_suppl.6537","title":"Comparison between Canadian and British oncology drug review recommendations and their impact on patient access.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Nice; Medicine; Excellence; Family medicine; Agency (philosophy); Internal medicine","score_opus":0.7402503551643232,"score_gpt":0.6437291264330187,"score_spread":0.09652122873130453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890254030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5681992,0.013911685,0.000048548558,0.40617102,0.0015351871,0.0004533723,0.0002957606,0.0000051037696,0.009380142],"genre_scores_gemma":[0.93777287,0.029038241,0.00066637725,0.031598024,0.00081874063,0.000009458258,0.000011870196,0.00001580902,0.00006862695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99034655,0.0010759411,0.007908253,0.00030481952,0.00005849948,0.0003059167],"domain_scores_gemma":[0.9800192,0.006449669,0.012141826,0.00035117537,0.00016618542,0.0008719367],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031115629,0.00015257833,0.0032341573,0.00019500002,0.00039264196,0.00016329795,0.00045346888,0.00029589946,0.00034882774],"category_scores_gemma":[0.020329837,0.00014564417,0.0002542175,0.000042128515,0.00022786384,0.000553255,0.00010930862,0.0007827062,0.00006963008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002897129,0.00017198174,0.5239718,0.00010368142,0.00018476852,0.000009415706,0.00025586516,0.0000038511444,1.6329981e-8,0.0005120996,0.27615634,0.19860125],"study_design_scores_gemma":[0.0008304973,0.0012928077,0.5160145,0.0004331398,0.000021669352,0.000036253063,0.00010626417,0.00007948704,1.0217256e-7,0.0033546581,0.47772598,0.00010461659],"about_ca_topic_score_codex":0.033281464,"about_ca_topic_score_gemma":0.06416577,"teacher_disagreement_score":0.374573,"about_ca_system_score_codex":0.00074739003,"about_ca_system_score_gemma":0.001535553,"threshold_uncertainty_score":0.99767035},"labels":[],"label_agreement":null},{"id":"W2890257235","doi":"10.1200/jco.2018.36.15_suppl.12008","title":"Evolution of genomic instability in metastatic cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Mutation; Cancer; Genome instability; Metastasis; Germline mutation; Medicine; Disease; Genetics; Biology; Computational biology; Gene; Pathology; DNA damage","score_opus":0.07278318245115799,"score_gpt":0.4417991866077643,"score_spread":0.3690160041566063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890257235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549997,0.0016311378,0.0006384504,0.0003933391,0.0010787835,0.00007236503,0.000012981491,5.7871125e-7,0.0006723817],"genre_scores_gemma":[0.9952924,0.0013155222,0.0020856361,0.00029130524,0.0009860529,0.0000020288835,0.0000013915135,0.0000067639194,0.00001884487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980186,0.00020892861,0.0014190204,0.00013367165,0.000091029855,0.00012871536],"domain_scores_gemma":[0.9980971,0.00027742158,0.0010142341,0.00015758017,0.00035857942,0.000095085335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00195063,0.00006898337,0.00052571145,0.000054790613,0.000013330671,0.0000024348406,0.00017825735,0.00016282928,0.000048421207],"category_scores_gemma":[0.0021413998,0.000058683934,0.000189858,0.0000676488,0.00028986618,0.0000035707928,0.00007375849,0.00019375446,0.000002943059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006122764,0.0022505706,0.6583581,0.00005712923,0.000371678,0.00003688218,0.00015340713,0.0009459045,0.1824751,0.0008421087,0.0049588177,0.14342755],"study_design_scores_gemma":[0.0046729515,0.012943626,0.86895096,0.00003163542,0.00012008201,0.000033055163,0.00013515918,0.00019538855,0.008596977,0.0023072297,0.10186829,0.00014464973],"about_ca_topic_score_codex":0.00018649182,"about_ca_topic_score_gemma":0.002078649,"teacher_disagreement_score":0.21059288,"about_ca_system_score_codex":0.00012657601,"about_ca_system_score_gemma":0.0021412955,"threshold_uncertainty_score":0.37985662},"labels":[],"label_agreement":null},{"id":"W2890261486","doi":"10.1200/jco.2017.35.15_suppl.10560","title":"Relationship between the cumulative burden (CB) of chronic health conditions (CHC) and health-related quality of life (HRQoL) among childhood cancer survivors (CCS): The St. Jude Lifetime (SJLIFE) cohort.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cohort; Quality of life (healthcare); Vitality; Hazard ratio; Health related quality of life; Internal medicine; Confidence interval; Demography; Disease","score_opus":0.23144196804082953,"score_gpt":0.521968395059174,"score_spread":0.2905264270183445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890261486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8014073,0.004303375,0.00005841669,0.19178692,0.00088434684,0.001015321,0.00019939795,0.000014324047,0.0003306485],"genre_scores_gemma":[0.9926983,0.0017484596,0.00013307214,0.0029756874,0.0022435,0.000015700187,0.000026481892,0.000039464827,0.000119309385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98541355,0.004368776,0.0081655355,0.0004106453,0.0011456126,0.0004958702],"domain_scores_gemma":[0.9609112,0.0174403,0.018809566,0.0011131618,0.00083297037,0.0008927795],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031074133,0.00031225543,0.0039014837,0.00015316723,0.00077670865,0.000028848706,0.0007870844,0.00053901254,0.00015696851],"category_scores_gemma":[0.020663718,0.00019526803,0.00077137386,0.00024447555,0.0027606813,0.00027134884,0.00023796681,0.002752593,0.000004510693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048602532,0.00057956233,0.9863903,0.00021436394,0.0013892291,0.0000038456787,0.0028691597,0.00013762101,0.0000014280158,0.0007842669,0.0037451568,0.0033990622],"study_design_scores_gemma":[0.0062976563,0.004478706,0.98341316,0.0006647965,0.0004965598,0.000021447431,0.00083546754,0.000068683876,0.0000035401147,0.0020393808,0.0015228847,0.0001577408],"about_ca_topic_score_codex":0.051663466,"about_ca_topic_score_gemma":0.024802007,"teacher_disagreement_score":0.19129106,"about_ca_system_score_codex":0.00045354516,"about_ca_system_score_gemma":0.009987336,"threshold_uncertainty_score":0.9999532},"labels":[],"label_agreement":null},{"id":"W2890273388","doi":"10.1200/jco.2017.35.15_suppl.8027","title":"Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); McGill University Health Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Daratumumab; Progressive disease; Clinical endpoint; Multiple myeloma; Cohort; Population; Neutropenia; Bortezomib; Refractory (planetary science); Surgery; Dexamethasone; Oncology; Clinical trial; Chemotherapy","score_opus":0.11709354483459519,"score_gpt":0.4371151103498414,"score_spread":0.3200215655152462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890273388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484897,0.00056039507,0.0003263295,0.0014564379,0.00030583856,0.0011111472,0.0012937607,0.0000081540375,0.00008899641],"genre_scores_gemma":[0.99532723,0.00017517513,0.0034808381,0.0002371141,0.0001993482,0.0000770117,0.00012647892,0.000052356925,0.0003244349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919441,0.0014698544,0.003843677,0.00059173716,0.0014944872,0.0006561497],"domain_scores_gemma":[0.9847559,0.00596562,0.0051533272,0.001414038,0.001381409,0.0013297381],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003312798,0.0004912161,0.0042639063,0.00073573046,0.000103927996,0.00002527129,0.0006341395,0.00047876753,0.0003637386],"category_scores_gemma":[0.013533797,0.0003072627,0.0014106646,0.00032330593,0.00091025134,0.00030934563,0.0001407642,0.0008703055,0.0000057122847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20929734,0.018770529,0.71309936,0.000104195824,0.0051585576,0.001217558,0.000040860046,0.00011111283,0.0002927584,0.0000019293275,0.0001451262,0.05176066],"study_design_scores_gemma":[0.1556408,0.025709145,0.8117698,0.00040962544,0.0034589048,0.000004088351,0.000026660153,0.0013704594,0.00087213813,0.00001598881,0.00052126864,0.0002011205],"about_ca_topic_score_codex":0.00042743556,"about_ca_topic_score_gemma":0.0027782684,"teacher_disagreement_score":0.09867044,"about_ca_system_score_codex":0.000572766,"about_ca_system_score_gemma":0.0026674415,"threshold_uncertainty_score":0.99993795},"labels":[],"label_agreement":null},{"id":"W2890280370","doi":"10.1200/jco.2017.35.15_suppl.6607","title":"Impact of intravenous cancer drug wastage on economic evaluations.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Drug; Cancer drugs; Vial; Dosing; Revenue; Body surface area; Emergency medicine; Surgery; Internal medicine; Pharmacology; Accounting","score_opus":0.17522746253136742,"score_gpt":0.5663329527005595,"score_spread":0.39110549016919205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890280370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849181,0.0006830947,0.000049014216,0.005330452,0.0036959667,0.00009618895,0.00004494527,0.0000032240114,0.005178992],"genre_scores_gemma":[0.99663264,0.001003498,0.0006409863,0.00036735233,0.00044116154,0.0000014323523,9.587972e-7,0.000008353072,0.00090361683],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969814,0.0008381068,0.0017478908,0.00016061166,0.00005133739,0.000220696],"domain_scores_gemma":[0.9940828,0.002123159,0.003114719,0.000360153,0.00023366808,0.00008549319],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048098695,0.0001268747,0.0012592336,0.00008543563,0.0001248577,0.000011725065,0.00054363796,0.00049449195,0.0024254392],"category_scores_gemma":[0.0031045019,0.00007833637,0.00079159555,0.0000192961,0.0007012386,0.00008627847,0.00008202876,0.0009129776,0.000059185404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004804668,0.002011083,0.08215359,0.000012566782,0.0024429716,0.00004377453,0.00011487416,0.00012009693,0.0059429943,0.0010637504,0.033142835,0.8681468],"study_design_scores_gemma":[0.0058388524,0.012575836,0.93177676,0.00008182451,0.00047365262,0.00007096511,0.000039402432,0.000043721644,0.0037228777,0.0018093099,0.04340984,0.0001569389],"about_ca_topic_score_codex":0.00019481579,"about_ca_topic_score_gemma":0.000108134045,"teacher_disagreement_score":0.86798984,"about_ca_system_score_codex":0.00017172322,"about_ca_system_score_gemma":0.0015449926,"threshold_uncertainty_score":0.99848646},"labels":[],"label_agreement":null},{"id":"W2890291916","doi":"10.1200/jco.2017.35.15_suppl.e18201","title":"Utilization of an electronic medical record trigger to promote palliative care consultation in ambulatory oncology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Palliative care; Ambulatory; Population; Ambulatory care; Electronic medical record; Quality of life (healthcare); Medical record; Advance care planning; Family medicine; Emergency medicine; Medical emergency; Health care; Nursing; Internal medicine","score_opus":0.40333454108048095,"score_gpt":0.6169082311020976,"score_spread":0.21357369002161664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890291916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914589,0.00089737657,0.00028918238,0.004392401,0.0006386095,0.00030982704,0.000004219422,0.0000046243194,0.0020048793],"genre_scores_gemma":[0.9896603,0.0032023233,0.0057534296,0.0007932567,0.0005101882,0.000005155778,0.000007782991,0.000012787877,0.00005474326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962294,0.0005077715,0.0023485136,0.00019577036,0.0004924263,0.00022608959],"domain_scores_gemma":[0.9934656,0.001721949,0.002814587,0.00024997577,0.0013791594,0.00036872685],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033622896,0.00012243153,0.0015918454,0.00017059449,0.00003797933,0.0000041387443,0.00027740345,0.00061987527,0.000088004395],"category_scores_gemma":[0.026865868,0.00009355978,0.00027316087,0.00012270478,0.00032488504,0.0001510569,0.00004885812,0.00089256227,0.000004670384],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007323496,0.0015432459,0.27031478,0.00011145685,0.00028080138,0.00028818497,0.0050132466,0.000012187729,0.00035024283,0.00023575568,0.00057950866,0.71394706],"study_design_scores_gemma":[0.020707855,0.04575526,0.6948755,0.0017724531,0.00039902865,0.0000348432,0.003164743,0.00052495,0.002662252,0.0008577062,0.22906843,0.00017696846],"about_ca_topic_score_codex":0.0000923081,"about_ca_topic_score_gemma":0.0010877129,"teacher_disagreement_score":0.7137701,"about_ca_system_score_codex":0.0003834464,"about_ca_system_score_gemma":0.004680643,"threshold_uncertainty_score":0.9813312},"labels":[],"label_agreement":null},{"id":"W2890301250","doi":"10.1200/jco.2016.34.15_suppl.5045","title":"Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Adenocarcinoma; Pathology; Biopsy; Prostate cancer; Carcinoma; Cancer; Immunohistochemistry; Biology; Internal medicine","score_opus":0.1062622741420373,"score_gpt":0.40624153992301626,"score_spread":0.29997926578097894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890301250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96811783,0.0041739615,0.000004189317,0.025724715,0.0008279147,0.0006699284,0.0002867258,0.000008506165,0.00018620571],"genre_scores_gemma":[0.9732444,0.023898356,0.00020118094,0.00071584916,0.00094030006,0.00003679427,0.000008964699,0.00003280543,0.00092131423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952391,0.0006838476,0.0025481696,0.00048327207,0.0004534953,0.0005921518],"domain_scores_gemma":[0.99276316,0.004217374,0.0015966941,0.00030945562,0.0006030272,0.0005102825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017877655,0.00027909753,0.0015349339,0.00014556907,0.000069463065,0.000018631012,0.0003440359,0.00017792713,0.00007850146],"category_scores_gemma":[0.0018318561,0.00013628889,0.00032550623,0.00022664662,0.0009821287,0.00014963826,0.00021974913,0.0012505087,0.000005574969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045412872,0.0008765528,0.8712534,0.00009415271,0.00024433166,0.0018594699,0.0013104584,0.000027319771,0.008702505,0.000003495038,0.001979022,0.06823646],"study_design_scores_gemma":[0.035468157,0.009430494,0.9374494,0.0013059612,0.0004321566,0.00014477018,0.0010367836,0.00009665438,0.005317227,0.00016320993,0.008953563,0.00020160525],"about_ca_topic_score_codex":0.0012579816,"about_ca_topic_score_gemma":0.0026601031,"teacher_disagreement_score":0.06803486,"about_ca_system_score_codex":0.00034605584,"about_ca_system_score_gemma":0.002541908,"threshold_uncertainty_score":0.55577},"labels":[],"label_agreement":null},{"id":"W2890315255","doi":"10.1200/jco.2016.34.15_suppl.e15154","title":"Canadian experience managing dose intensity of regorafenib in relation to safety and clinical outcome in metastatic colorectal cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Adverse effect; Colorectal cancer; Hazard ratio; Oxaliplatin; Progression-free survival; Oncology; Chemotherapy; Surgery; Clinical trial; Gastroenterology; Cancer; Confidence interval","score_opus":0.11021236492023644,"score_gpt":0.47194351392569706,"score_spread":0.3617311490054606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890315255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870836,0.00017534959,0.000013377541,0.011187992,0.00074940646,0.00028472245,0.000007416658,0.0000018413037,0.0004962586],"genre_scores_gemma":[0.99732494,0.001142505,0.0005276471,0.00084792275,0.00008093163,0.0000048219927,5.339128e-7,0.000006739727,0.0000639819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965539,0.00025771733,0.0025885731,0.00019852926,0.00018972222,0.00021155123],"domain_scores_gemma":[0.9970053,0.0014591649,0.0007663659,0.00008171005,0.00032133746,0.0003661544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019942268,0.00010648277,0.001441682,0.00024948257,0.000022805325,0.0000023300713,0.00007271505,0.0001345056,0.000042743784],"category_scores_gemma":[0.004834422,0.00006353244,0.00015952166,0.00019842762,0.00018293793,0.00010020991,0.000058644113,0.0003688438,0.0000016532899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073542614,0.00041293696,0.8556359,0.000008122884,0.00009620816,0.00019160629,0.00047531287,0.0000033104316,0.000007500914,0.00002000434,0.00006158133,0.13573329],"study_design_scores_gemma":[0.008384264,0.0063357763,0.98243177,0.00019461136,0.00010445385,0.000015320189,0.0002659067,0.000025079109,0.0000065117233,0.0000846549,0.002087513,0.00006414472],"about_ca_topic_score_codex":0.012690599,"about_ca_topic_score_gemma":0.21181779,"teacher_disagreement_score":0.19912718,"about_ca_system_score_codex":0.0008841383,"about_ca_system_score_gemma":0.0008719994,"threshold_uncertainty_score":0.99388397},"labels":[],"label_agreement":null},{"id":"W2890317544","doi":"10.1200/jco.2016.34.15_suppl.10099","title":"Improving bone health in men with prostate cancer on ADT: Results of a randomized phase II trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Randomized controlled trial; Androgen deprivation therapy; Odds ratio; Physical therapy; Osteoporosis; Bone mineral; Psychological intervention; Confidence interval; Internal medicine; Prostate cancer; Cancer; Nursing","score_opus":0.1234740438026997,"score_gpt":0.5308560331266703,"score_spread":0.4073819893239706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890317544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8954222,0.002059765,0.000039722578,0.0984179,0.00039261775,0.0020294974,0.000028291777,0.0000059264507,0.0016040343],"genre_scores_gemma":[0.9817487,0.0130179245,0.00070482795,0.0008995887,0.0006743883,0.00006198562,0.0000029989938,0.000018804874,0.0028708086],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99469316,0.0010160693,0.0033319544,0.00020967024,0.00043081216,0.00031833633],"domain_scores_gemma":[0.9922945,0.0036442778,0.0031040784,0.00017293269,0.00041606088,0.00036818092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011654251,0.00012981765,0.003020748,0.00024271323,0.00003300523,0.0000030518886,0.0000913208,0.00016250943,0.000048448586],"category_scores_gemma":[0.0056328396,0.00005356466,0.00035171834,0.00016849906,0.00037203857,0.00008147152,0.000035148216,0.00058570865,0.0000017137891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69194233,0.0037724671,0.00017320906,0.000030404633,0.0002738328,0.00025138343,0.00022228772,0.0000016630788,0.00023238035,0.000011082707,0.0015640603,0.3015249],"study_design_scores_gemma":[0.8766769,0.11574147,0.00051400857,0.0008314098,0.00014828332,0.000026372012,0.000057495046,0.000048204678,0.0003573621,0.00010535097,0.005439265,0.00005384172],"about_ca_topic_score_codex":0.00021972794,"about_ca_topic_score_gemma":0.00015214199,"teacher_disagreement_score":0.30147108,"about_ca_system_score_codex":0.0004216656,"about_ca_system_score_gemma":0.005426563,"threshold_uncertainty_score":0.9626489},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2890319629","doi":"10.1200/jco.2017.35.15_suppl.5014","title":"Post hoc analysis of a phase III study to test the association between circulating <i>methylated glutathione s transferase (mGSTP1</i>) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; GSTP1; Docetaxel; Internal medicine; Prostate cancer; Post-hoc analysis; Oncology; Cancer; Gastroenterology; Glutathione; Biology; Enzyme","score_opus":0.09317301733335843,"score_gpt":0.46971515463543945,"score_spread":0.376542137302081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890319629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954815,0.00028673428,0.00045598237,0.0029162073,0.00011817826,0.0005676383,0.00015533925,0.0000014866714,0.00001693618],"genre_scores_gemma":[0.9987763,0.00015336747,0.0007045732,0.00016059529,0.00013593273,0.000013204316,0.000010658498,0.000012529352,0.00003283934],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956984,0.0013746691,0.002085427,0.00028715824,0.00034544108,0.00020890596],"domain_scores_gemma":[0.99512553,0.0016888937,0.0019602396,0.00030805886,0.00071843807,0.00019882125],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01147027,0.00014839417,0.000976988,0.00023833812,0.0001517496,0.000050956656,0.00023643344,0.00016750803,0.0000054063003],"category_scores_gemma":[0.009281456,0.0001110828,0.00022204219,0.0003049356,0.00005956719,0.00002022652,0.0000575406,0.0003064205,3.5027966e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011586229,0.001505686,0.19750807,0.00000984817,0.0016319735,0.00004801463,0.0020431841,0.0013850718,0.75600415,0.0000021024296,0.000005702872,0.028269956],"study_design_scores_gemma":[0.008887996,0.019069143,0.95562625,0.000031760213,0.0018110051,0.0000015645834,0.0005954255,0.00017985453,0.0133082215,0.000036656344,0.00030866312,0.0001434363],"about_ca_topic_score_codex":0.00030673863,"about_ca_topic_score_gemma":0.004929827,"teacher_disagreement_score":0.7581182,"about_ca_system_score_codex":0.000102101185,"about_ca_system_score_gemma":0.0006965438,"threshold_uncertainty_score":0.9990638},"labels":[],"label_agreement":null},{"id":"W2890336344","doi":"10.1200/jco.2016.34.15_suppl.e16568","title":"Identifying candidates for prednisone to dexamethasone switch amongst patients with castration-resistant prostate cancer undergoing abiraterone therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prednisone; Prostate cancer; Docetaxel; Dexamethasone; Internal medicine; Abiraterone acetate; Cancer; Chemotherapy; Urology; Corticosteroid; Oncology; Gastroenterology; Androgen deprivation therapy","score_opus":0.13415254367498405,"score_gpt":0.47188810988483837,"score_spread":0.33773556620985434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890336344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875351,0.0007597302,0.00066133164,0.009325854,0.00048377068,0.0010963294,0.0000410002,0.000010492971,0.00008635544],"genre_scores_gemma":[0.99098974,0.0020628297,0.004338086,0.00050636305,0.00048826472,0.0000892425,0.000006872611,0.00003363587,0.0014849391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974143,0.00016148262,0.0013047063,0.00026657103,0.00046232776,0.00039060134],"domain_scores_gemma":[0.995748,0.0016326128,0.00091335754,0.00016240432,0.0010851321,0.00045853574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013651025,0.00016862781,0.0009257909,0.00014100446,0.00009323769,0.000029259101,0.00012716725,0.00016072579,0.00007814508],"category_scores_gemma":[0.00085592084,0.000079902835,0.00017798184,0.00016152691,0.00013399243,0.00022289007,0.00003124851,0.0002675359,0.0000071440554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07015362,0.0014876191,0.66507584,0.00008870001,0.0010341128,0.00012669363,0.00036543675,0.000007829954,0.0106148645,0.000018965646,0.0020609691,0.24896537],"study_design_scores_gemma":[0.057016592,0.04480556,0.8761614,0.0010526926,0.0003088498,0.000018693278,0.00016991075,0.000005956052,0.0068911067,0.0002448007,0.013126198,0.00019822572],"about_ca_topic_score_codex":0.00007715819,"about_ca_topic_score_gemma":0.0007569853,"teacher_disagreement_score":0.24876714,"about_ca_system_score_codex":0.00042477954,"about_ca_system_score_gemma":0.0024695643,"threshold_uncertainty_score":0.43809012},"labels":[],"label_agreement":null},{"id":"W2890342236","doi":"10.1200/jco.2017.35.15_suppl.5517","title":"Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Randomization; Ovarian cancer; Chemotherapy; Progression-free survival; Oncology; Complete response; Cancer; PARP inhibitor; Gastroenterology; Randomized controlled trial; Poly ADP ribose polymerase","score_opus":0.1039516384024911,"score_gpt":0.477338568951608,"score_spread":0.37338693054911687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890342236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96046567,0.000040553532,0.000101705344,0.037105203,0.00096435554,0.00079365214,0.000017908476,0.0000075284693,0.00050344714],"genre_scores_gemma":[0.9942791,0.000049551483,0.0017415975,0.0028497833,0.0009616029,0.000044847475,0.0000022643121,0.000033991255,0.000037281803],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956964,0.00094873476,0.0017447526,0.00029968817,0.0009949486,0.0003154422],"domain_scores_gemma":[0.99239844,0.0028361608,0.0029754487,0.00084618403,0.0005975377,0.00034620878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047255615,0.00022134231,0.0013011434,0.00015498679,0.00012125043,0.000021401536,0.00056793133,0.00025578676,0.00015217807],"category_scores_gemma":[0.003878606,0.00011388679,0.00021440111,0.00017365515,0.00046973888,0.00008514508,0.000051241634,0.0011010264,0.0000054496572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4335001,0.004369933,0.41877237,0.00001781807,0.00024336445,0.00009856887,0.00028361467,0.0003071716,0.00006311583,0.000023654075,0.0030352024,0.13928506],"study_design_scores_gemma":[0.076724246,0.049539935,0.8335858,0.001384865,0.000098104894,0.000010057994,0.000030096946,0.000049216942,0.00061005837,0.00001799354,0.037823908,0.00012569675],"about_ca_topic_score_codex":0.000043528085,"about_ca_topic_score_gemma":0.00056531595,"teacher_disagreement_score":0.41481343,"about_ca_system_score_codex":0.00030448977,"about_ca_system_score_gemma":0.002656441,"threshold_uncertainty_score":0.47834733},"labels":[],"label_agreement":null},{"id":"W2890354796","doi":"10.1200/jco.2018.36.15_suppl.e18851","title":"Investigating strategies to improve clinical trial opportunities in oncology in New Zealand (INSIGHT).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Cancer; Family medicine; Demographics; Randomization; Internal medicine; Demography","score_opus":0.853004071202739,"score_gpt":0.705098620075514,"score_spread":0.14790545112722497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890354796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88741404,0.00010568655,0.000065971195,0.077576295,0.0059747966,0.0007148354,0.0000016887125,0.000013975159,0.02813274],"genre_scores_gemma":[0.92560446,0.0029291096,0.021942245,0.020272784,0.020995678,0.00001638137,0.0000028928598,0.000060693266,0.00817575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9822869,0.003502298,0.011609535,0.0006161254,0.0012216237,0.0007635712],"domain_scores_gemma":[0.74781334,0.23295604,0.008138263,0.0015170262,0.0036017618,0.0059735877],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.06600933,0.00025644797,0.0034917183,0.0006109518,0.000047684305,0.000038496146,0.00069800735,0.0027087585,0.0003249372],"category_scores_gemma":[0.2669368,0.00019398807,0.0006392877,0.0005100043,0.0019356933,0.0002840499,0.0003771515,0.010393233,0.000081693455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19734575,0.008319044,0.236629,0.00010521323,0.00044504573,0.003796032,0.0027019712,0.000012516109,0.0003819201,0.008513309,0.039964415,0.5017858],"study_design_scores_gemma":[0.16539508,0.22365956,0.16862582,0.00081160327,0.00016270299,0.00014396019,0.0025719523,0.00013024845,0.000053324755,0.07558482,0.3625471,0.00031380958],"about_ca_topic_score_codex":0.00048283552,"about_ca_topic_score_gemma":0.012911693,"teacher_disagreement_score":0.501472,"about_ca_system_score_codex":0.00046519368,"about_ca_system_score_gemma":0.051818877,"threshold_uncertainty_score":0.99858594},"labels":[],"label_agreement":null},{"id":"W2890365096","doi":"10.1200/jco.2017.35.15_suppl.9085","title":"Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Pneumonitis; Adverse effect; Rash; Gastroenterology; Clinical endpoint; Nausea; Oncology; Surgery; Nivolumab; Clinical trial; Cancer; Lung; Immunotherapy","score_opus":0.07735938050308919,"score_gpt":0.45217460592540987,"score_spread":0.3748152254223207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890365096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960225,0.0001843959,0.000035543988,0.001996972,0.0004070626,0.00045310424,0.000012559341,0.0000056027184,0.0008822334],"genre_scores_gemma":[0.99476403,0.0037042978,0.00052215933,0.00052419875,0.0001922261,0.00000141497,0.000003751496,0.000019591373,0.0002683472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585825,0.0006743124,0.0026778309,0.0002455123,0.00031919903,0.00022490507],"domain_scores_gemma":[0.99385655,0.0010421157,0.004046979,0.0004286166,0.00037842075,0.00024730782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046531297,0.00017042951,0.0020032707,0.000108339475,0.000068345274,0.000013474497,0.00022935422,0.00047057684,0.00012244533],"category_scores_gemma":[0.0014135526,0.000107581756,0.0003808611,0.000083123276,0.000756859,0.00020993718,0.000045719178,0.0008849863,0.0000013439347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15075721,0.0022232023,0.5940465,0.000014131904,0.0005364151,0.00008108049,0.00003701227,7.0658086e-7,0.00006662053,0.0000023381183,0.00014017812,0.25209463],"study_design_scores_gemma":[0.06615296,0.02433061,0.8954834,0.00020444032,0.0002070222,0.000020961194,0.0000176194,0.000051633648,0.00005858083,0.000009570078,0.013365346,0.00009786918],"about_ca_topic_score_codex":0.0002298141,"about_ca_topic_score_gemma":0.00046170436,"teacher_disagreement_score":0.3014369,"about_ca_system_score_codex":0.00013760821,"about_ca_system_score_gemma":0.0010238407,"threshold_uncertainty_score":0.43870565},"labels":[],"label_agreement":null},{"id":"W2890366457","doi":"10.1200/jco.2018.36.15_suppl.e21060","title":"Real-world dose adjustment study of first-line afatinib in pts with <i>EGFR</i> mutation-positive (<i>EGFR</i>m+) advanced NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Afatinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Incidence (geometry); Medical record; Oncology; Gefitinib; Cancer; Epidermal growth factor receptor","score_opus":0.061094580241303154,"score_gpt":0.48453997645575086,"score_spread":0.4234453962144477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890366457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98125464,0.00020141553,0.00009631468,0.0031844077,0.00089085085,0.0010059315,0.000010370313,0.000010365789,0.013345716],"genre_scores_gemma":[0.99259025,0.00032223985,0.0047390135,0.0009369268,0.0008198356,0.00003162615,0.000009133958,0.000024715475,0.00052623096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627525,0.0003052898,0.002423615,0.00027522637,0.000473437,0.00024718576],"domain_scores_gemma":[0.9946511,0.0016810183,0.0020404842,0.0002556477,0.0010845673,0.00028721636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010693978,0.00019570884,0.0014577158,0.00026965878,0.000058668218,0.0000053562308,0.00013383223,0.00013954313,0.0001116541],"category_scores_gemma":[0.00066257926,0.00012682221,0.00019120195,0.00047398455,0.00025040662,0.00016773572,0.000036924535,0.0005164215,0.000009131846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054066535,0.053007144,0.5104913,0.00011145677,0.0036741449,0.0034899707,0.009918648,0.0009202014,0.00015299908,0.00038913536,0.0023661181,0.36141232],"study_design_scores_gemma":[0.056667406,0.10972188,0.82378304,0.00053570245,0.0014698376,0.00013258652,0.0025507114,0.00008655616,0.0002148666,0.00015769996,0.004534178,0.00014555892],"about_ca_topic_score_codex":0.00042458958,"about_ca_topic_score_gemma":0.00978998,"teacher_disagreement_score":0.36126676,"about_ca_system_score_codex":0.00047160036,"about_ca_system_score_gemma":0.0014459232,"threshold_uncertainty_score":0.54630387},"labels":[],"label_agreement":null},{"id":"W2890374573","doi":"10.1200/jco.2017.35.15_suppl.9018","title":"Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; T790M; Medicine; Internal medicine; Genotyping; Gastroenterology; Oncology; Aura; Progression-free survival; Epidermal growth factor receptor; Chemotherapy; Genotype; Cancer; Gefitinib; Erlotinib; Genetics","score_opus":0.23769348002614202,"score_gpt":0.5610531228271586,"score_spread":0.3233596428010166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890374573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97157484,0.0000520875,0.000014449025,0.01578551,0.00090847904,0.00041528553,0.000021101036,0.0000020382156,0.011226213],"genre_scores_gemma":[0.99769676,0.00007407502,0.0006219183,0.0009870033,0.0003682521,0.000008949289,0.0000024605692,0.0000070977962,0.00023351064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706775,0.00026482306,0.002136787,0.00009885909,0.00031981265,0.000111981775],"domain_scores_gemma":[0.99398464,0.0024955228,0.0028557496,0.00031180677,0.00025630122,0.0000959959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282593,0.00007958613,0.0010178977,0.00008387345,0.00006186178,0.0000064954907,0.00026275753,0.0001433422,0.00006838289],"category_scores_gemma":[0.006420544,0.00004428518,0.00035693694,0.000057451205,0.00032604387,0.00007191861,0.000019791474,0.0004772723,0.000010003411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24423315,0.020739574,0.5747485,0.00019189395,0.0026600533,0.0009878186,0.004033236,0.00033166193,0.00036492103,0.0077013117,0.0052325362,0.13877536],"study_design_scores_gemma":[0.093629,0.02609702,0.85621977,0.0001943217,0.0006809544,0.000064008724,0.0002947026,0.000104855586,0.000039186405,0.00073953543,0.02189073,0.00004593395],"about_ca_topic_score_codex":0.00008331226,"about_ca_topic_score_gemma":0.00005837267,"teacher_disagreement_score":0.28147125,"about_ca_system_score_codex":0.000064722146,"about_ca_system_score_gemma":0.00080570666,"threshold_uncertainty_score":0.76864547},"labels":[],"label_agreement":null},{"id":"W2890379758","doi":"10.1200/jco.2016.34.15_suppl.e21627","title":"Outpatient oncology massage self-reported outcomes in cancer patients and their caregivers.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Massage; Sadness; Anxiety; Distress; Physical therapy; Cancer; Outpatient clinic; Internal medicine; Psychiatry; Anger; Clinical psychology; Alternative medicine","score_opus":0.15373384137720922,"score_gpt":0.4895182255404701,"score_spread":0.33578438416326084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890379758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97901314,0.00029512905,0.000025954625,0.017085725,0.0019291927,0.00023661017,0.000011104477,0.0000071224663,0.0013960006],"genre_scores_gemma":[0.99545836,0.002132687,0.0002805562,0.00142236,0.00047624813,0.0000069110924,0.000001129262,0.00000862632,0.00021313425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997048,0.0003539597,0.001946017,0.00019324465,0.00023754672,0.00022123891],"domain_scores_gemma":[0.9952922,0.0025180944,0.0014403996,0.00010100635,0.00040549578,0.00024280809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014216644,0.00015196821,0.0015998068,0.00015195273,0.000030659816,0.0000016822567,0.00009508043,0.0000875126,0.00019103973],"category_scores_gemma":[0.0025938794,0.000070517184,0.00021547082,0.000071780094,0.00023624316,0.00008251326,0.000113375085,0.0004766729,0.0000026356106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075713935,0.001748906,0.7738295,0.000011098138,0.00075367175,0.00031486567,0.00072633463,1.14703404e-7,0.00004375938,0.000012280337,0.0011245233,0.22067778],"study_design_scores_gemma":[0.019339157,0.021885889,0.8591774,0.00013067177,0.00024977565,0.00003682036,0.0007692596,0.0000029063792,0.000047408972,0.00012119717,0.09816549,0.000074028554],"about_ca_topic_score_codex":0.00007581018,"about_ca_topic_score_gemma":0.000322443,"teacher_disagreement_score":0.22060375,"about_ca_system_score_codex":0.00039167434,"about_ca_system_score_gemma":0.0005548952,"threshold_uncertainty_score":0.31053033},"labels":[],"label_agreement":null},{"id":"W2890388049","doi":"10.1200/jco.2017.35.15_suppl.3529","title":"Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Internal medicine; Colorectal cancer; Cancer; Oncology; Combination therapy; Irinotecan; Gastroenterology; Pharmacology; Chemotherapy","score_opus":0.3085729750230846,"score_gpt":0.5868428381078282,"score_spread":0.2782698630847436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890388049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933388,0.00030412746,0.0000066053035,0.0012613833,0.0038864762,0.000849577,0.000057296194,0.0000053345957,0.00029040093],"genre_scores_gemma":[0.9986438,0.00045901845,0.000085688254,0.0003597047,0.00028395813,0.00006560441,0.0000042822785,0.000024626197,0.00007332561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943734,0.0017931338,0.0026270153,0.00035312175,0.00044064084,0.00041271994],"domain_scores_gemma":[0.9933691,0.0012571181,0.004164449,0.00020627202,0.0007301108,0.00027296157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031986802,0.00028132997,0.0017643764,0.0003037626,0.00026419718,0.000024227225,0.00062065053,0.00039783545,0.0002603493],"category_scores_gemma":[0.0008450465,0.00021428429,0.00020509203,0.00022235738,0.0005355958,0.0004159616,0.0001956968,0.0017768969,0.0000027574106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01697901,0.075789854,0.7941222,0.000051621235,0.00067270873,0.00047223706,0.0011910817,0.00012682211,0.0004934232,0.0000253137,0.0004978893,0.109577805],"study_design_scores_gemma":[0.14472374,0.040213767,0.805439,0.00019086742,0.00059845473,0.000015344725,0.0008155912,0.0006573003,0.0012803002,0.000115452596,0.0056722513,0.00027795142],"about_ca_topic_score_codex":0.000717649,"about_ca_topic_score_gemma":0.014193005,"teacher_disagreement_score":0.12774473,"about_ca_system_score_codex":0.0004189998,"about_ca_system_score_gemma":0.0011441682,"threshold_uncertainty_score":0.87382597},"labels":[],"label_agreement":null},{"id":"W2890388336","doi":"10.1200/jco.2017.35.15_suppl.e18322","title":"Economic aspects of nivolumab in non-small cell lung cancer (NSCLC): Lessons from real life.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Lung cancer; Internal medicine; Immunotherapy; Cancer; Oncology; Nuclear medicine","score_opus":0.11268479600938883,"score_gpt":0.40768808722392963,"score_spread":0.29500329121454083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890388336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8726024,0.002531762,0.00019384088,0.0039028162,0.004119217,0.00013514105,0.00015598758,0.0000032160187,0.1163556],"genre_scores_gemma":[0.98550814,0.011024349,0.00061685184,0.0004744849,0.0020052239,0.000005766626,0.0000014787156,0.000028818722,0.00033490988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951718,0.000056927838,0.004002501,0.00036234467,0.00003828613,0.00036813205],"domain_scores_gemma":[0.9896387,0.0006949182,0.00870169,0.0005304676,0.00009303025,0.00034121142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026124606,0.00019303127,0.0024541186,0.0002145285,0.00008584715,0.00005437849,0.0009496013,0.00056427997,0.00056755834],"category_scores_gemma":[0.0012969582,0.00020630083,0.0005702859,0.000034854882,0.00026885656,0.0005175783,0.00015169679,0.000825392,0.00009021763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075610745,0.00053375255,0.9558687,0.000029928464,0.00024628325,0.000063048305,0.00026562996,0.0003966395,0.000018125964,0.016767332,0.004265561,0.020788891],"study_design_scores_gemma":[0.006138797,0.00084722927,0.9615836,0.000093073264,0.00004991819,0.0000023855707,0.000048215068,0.0010423359,0.00005669474,0.015363591,0.014542753,0.0002314121],"about_ca_topic_score_codex":0.012051318,"about_ca_topic_score_gemma":0.009502136,"teacher_disagreement_score":0.11602069,"about_ca_system_score_codex":0.0005239113,"about_ca_system_score_gemma":0.0020222706,"threshold_uncertainty_score":0.9945275},"labels":[],"label_agreement":null},{"id":"W2890405016","doi":"10.1200/jco.2017.35.15_suppl.e18529","title":"Burden of illness in patients with acute myeloid leukemia aged ò65 years ineligible for intensive chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Internal medicine; Chemotherapy; Decitabine; Chemotherapy regimen; Pediatrics","score_opus":0.06297915824340701,"score_gpt":0.43908598297760104,"score_spread":0.37610682473419405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890405016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294364,0.00003812311,0.00012642787,0.005159458,0.00047467518,0.0005884196,0.000010507253,0.00000441365,0.0006543058],"genre_scores_gemma":[0.9920452,0.00040359903,0.0049260557,0.0013631579,0.00070398394,0.000009192423,0.000006405032,0.000036348407,0.0005060281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969352,0.0001693772,0.0018313844,0.00022715768,0.0004946091,0.00034227656],"domain_scores_gemma":[0.99348235,0.0013109802,0.002471224,0.0004795851,0.0019602494,0.00029559687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026890787,0.00015677283,0.0018454461,0.00024466077,0.000059206122,0.000015087088,0.00054690434,0.0004496177,0.000047614536],"category_scores_gemma":[0.0074091894,0.000106862826,0.00034417,0.000110034205,0.0005549347,0.00018860096,0.00012390414,0.001266512,0.000006253796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1059902,0.0013505233,0.5160014,0.00014914395,0.0023125713,0.0014750536,0.0017441593,0.000060235358,0.0011978908,0.00005812548,0.022560691,0.3471],"study_design_scores_gemma":[0.053881682,0.015383772,0.9133042,0.00027485468,0.0002694365,0.00007987552,0.0003692081,0.00013570403,0.00047406,0.00023602438,0.01544872,0.00014245452],"about_ca_topic_score_codex":0.00014316913,"about_ca_topic_score_gemma":0.000044419237,"teacher_disagreement_score":0.3973028,"about_ca_system_score_codex":0.0005817536,"about_ca_system_score_gemma":0.003793573,"threshold_uncertainty_score":0.8870027},"labels":[],"label_agreement":null},{"id":"W2890415736","doi":"10.1200/jco.2018.36.15_suppl.5039","title":"DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; MSH6; MSH2; MLH1; Medicine; Cancer; CHEK2; Cancer research; Pathology; Biology; Oncology; Internal medicine; DNA mismatch repair; Gene; Genetics; Mutation; Germline mutation; Colorectal cancer","score_opus":0.1557911161741769,"score_gpt":0.4617809647307325,"score_spread":0.3059898485565556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890415736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758035,0.0077525685,0.000006728485,0.010795175,0.0008866743,0.0018267924,0.0025959313,0.000018809144,0.0003138212],"genre_scores_gemma":[0.95487475,0.040621176,0.00090291013,0.00030243504,0.0007646708,0.00018374102,0.00029586907,0.000057787634,0.0019966648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941227,0.00085054035,0.003117983,0.0006514054,0.00069596793,0.0005614159],"domain_scores_gemma":[0.99264,0.0017307288,0.0030207573,0.00072813866,0.0013762048,0.000504144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015450648,0.00039873814,0.0017960361,0.00015732207,0.00019726045,0.000028765493,0.00038450176,0.000115376264,0.00041672678],"category_scores_gemma":[0.0009481825,0.00023021271,0.00035508486,0.00038431506,0.0012901208,0.00026943328,0.00022846521,0.00069447275,0.0000041539442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058896698,0.0068152756,0.75929105,0.0006586745,0.005089777,0.0015943701,0.0048454665,0.00011091069,0.016201854,0.000033104552,0.010663973,0.13579887],"study_design_scores_gemma":[0.040029246,0.044076923,0.8294268,0.0013978216,0.007840497,0.00024449138,0.0040544425,0.0016895467,0.014572659,0.00042219274,0.05571307,0.0005322846],"about_ca_topic_score_codex":0.01939691,"about_ca_topic_score_gemma":0.06307921,"teacher_disagreement_score":0.13526659,"about_ca_system_score_codex":0.00041300902,"about_ca_system_score_gemma":0.005747358,"threshold_uncertainty_score":0.99988914},"labels":[],"label_agreement":null},{"id":"W2890416541","doi":"10.1200/jco.2017.35.15_suppl.e18038","title":"Timeliness of adjuvant chemotherapy in patients with resected pancreatic cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Pancreatic cancer; Proportional hazards model; Chemotherapy; Cancer; Cohort; Colorectal cancer; Population; Oncology; Retrospective cohort study; Multivariate analysis; Logistic regression; Surgery; Gastroenterology","score_opus":0.13150283730635295,"score_gpt":0.5209140429233012,"score_spread":0.3894112056169483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890416541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911291,0.00022342391,0.000035262587,0.004722995,0.00026481968,0.00030669995,0.0000039284,0.000002721741,0.0033110448],"genre_scores_gemma":[0.99516344,0.0010183901,0.0025977662,0.00041338746,0.00034042477,0.0000062973404,0.0000018934182,0.000014525137,0.00044385676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969103,0.00030141883,0.0019036975,0.00015388371,0.0004823381,0.0002483622],"domain_scores_gemma":[0.9943995,0.0013683229,0.0024710295,0.00039333396,0.0011047784,0.00026302255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00279377,0.00011670547,0.0023990367,0.00014546626,0.000051643034,0.000005816235,0.00031904088,0.0003311627,0.00034242135],"category_scores_gemma":[0.0057577104,0.00006881486,0.00018003103,0.00009377526,0.0005911131,0.00010264319,0.000049090846,0.0008487402,0.000004280627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020419884,0.0021098459,0.9145037,0.000045993078,0.00038740868,0.00017007548,0.00006140226,0.0000025749796,0.000043381504,0.000010012105,0.0008459487,0.061399765],"study_design_scores_gemma":[0.02940257,0.015571568,0.95221055,0.00044299045,0.0002943287,0.000019176894,0.000030057705,0.00021267828,0.000043765514,0.00009541696,0.0016148665,0.00006205767],"about_ca_topic_score_codex":0.00018380788,"about_ca_topic_score_gemma":0.00018545247,"teacher_disagreement_score":0.061337706,"about_ca_system_score_codex":0.0001413935,"about_ca_system_score_gemma":0.0028779663,"threshold_uncertainty_score":0.6892933},"labels":[],"label_agreement":null},{"id":"W2890420786","doi":"10.1200/jco.2018.36.15_suppl.4519","title":"Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Renal cell carcinoma; Nivolumab; Medicine; Microbiome; Gut microbiome; Internal medicine; Oncology; Cancer research; Gut flora; Immunotherapy; Bioinformatics; Immunology; Cancer; Biology","score_opus":0.08613951638584051,"score_gpt":0.4532590257786263,"score_spread":0.3671195093927858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890420786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649451,0.0000712873,0.0001018895,0.0044115954,0.0007370355,0.00036159996,0.000008961975,0.0000057041043,0.029356845],"genre_scores_gemma":[0.985748,0.000046756668,0.008310465,0.0031300634,0.0013113013,0.00000546146,0.000006615772,0.000014887353,0.0014264398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962267,0.0006655088,0.0020480023,0.00025230093,0.00044358318,0.00036390297],"domain_scores_gemma":[0.9962454,0.0014117525,0.0008008756,0.0002429077,0.00078554446,0.00051352923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028335867,0.00013624164,0.0013846867,0.00034622097,0.000058276983,0.000006454115,0.0002240683,0.00042459954,0.00021142547],"category_scores_gemma":[0.0016239829,0.000103462306,0.00022435951,0.00026596736,0.00036456794,0.0000622966,0.000066345034,0.0009778773,0.00018433842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026523741,0.0047327005,0.8908214,0.00004479508,0.00008455747,0.0006131456,0.00028079658,0.0000010493578,0.0035038465,0.000050995634,0.06666362,0.006679324],"study_design_scores_gemma":[0.013038593,0.041492943,0.9117496,0.00021650107,0.00012227171,0.00003765379,0.000027697099,0.000025227244,0.000321601,0.00013042241,0.032753997,0.00008347945],"about_ca_topic_score_codex":0.00002471527,"about_ca_topic_score_gemma":0.00016064303,"teacher_disagreement_score":0.036760245,"about_ca_system_score_codex":0.0004835816,"about_ca_system_score_gemma":0.0013612518,"threshold_uncertainty_score":0.42484444},"labels":[],"label_agreement":null},{"id":"W2890444065","doi":"10.1200/jco.2018.36.15_suppl.tps6094","title":"Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Head and neck cancer; Head and neck squamous-cell carcinoma; Regimen; Oncology; Larynx; Phases of clinical research; Radiation therapy; Cancer; Urology; Surgery; Chemotherapy; Immunotherapy; Pathology","score_opus":0.06739899375646541,"score_gpt":0.43358376972508367,"score_spread":0.36618477596861826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890444065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877231,0.0011836451,0.00058977713,0.0077683055,0.0013077415,0.00095516077,0.000005878129,0.000010479272,0.0004559136],"genre_scores_gemma":[0.992481,0.00019043892,0.0011851694,0.003261674,0.0025614493,0.00001955282,0.0000061198994,0.000023768393,0.0002708514],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719816,0.0002249175,0.0017728767,0.00024108612,0.00030635198,0.0002566044],"domain_scores_gemma":[0.9960617,0.0013243945,0.0015555769,0.00024206442,0.0005923331,0.00022395937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025336,0.00017169802,0.0011122734,0.00009033971,0.00013686968,0.000019439405,0.00016092772,0.00027078303,0.000053173026],"category_scores_gemma":[0.0012877347,0.000111207555,0.0003307599,0.00016476375,0.00031062792,0.00014175514,0.00002862688,0.00048028264,0.0000049898636],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44156858,0.0072178678,0.020342287,0.000121085635,0.00032980283,0.00015107002,0.0019154428,0.000024328736,0.0046694996,0.00001104762,0.010213298,0.51343566],"study_design_scores_gemma":[0.36714005,0.18532228,0.34896928,0.000050563296,0.0009563903,0.00041880138,0.000833723,0.0036063741,0.002547183,0.00012287374,0.08977042,0.0002620684],"about_ca_topic_score_codex":0.00005255425,"about_ca_topic_score_gemma":0.0001169114,"teacher_disagreement_score":0.5131736,"about_ca_system_score_codex":0.00030657824,"about_ca_system_score_gemma":0.0015154731,"threshold_uncertainty_score":0.45349124},"labels":[],"label_agreement":null},{"id":"W2890449437","doi":"10.1200/jco.2017.35.15_suppl.tps5607","title":"FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Topotecan; Oncology; Clinical endpoint; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Carboplatin; Interim analysis; Clinical trial; Adverse effect; Cisplatin","score_opus":0.05741997394984657,"score_gpt":0.44167065880726075,"score_spread":0.3842506848574142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890449437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95767283,0.0024933617,0.000035869645,0.033600915,0.0016176355,0.003918661,0.00027417194,0.000010219573,0.00037632234],"genre_scores_gemma":[0.97503006,0.019124076,0.002053223,0.0018310788,0.0014417447,0.00028345577,0.00001245075,0.000069908616,0.0001540128],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936737,0.0011534104,0.003146297,0.0006365344,0.0008762746,0.0005138165],"domain_scores_gemma":[0.9915175,0.0039053853,0.0026658834,0.00060874585,0.00075888063,0.000543604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004897913,0.0004877857,0.0046651736,0.00016115968,0.00026469462,0.000051877352,0.00044742948,0.0002821246,0.0003198838],"category_scores_gemma":[0.0013977996,0.00025924385,0.0004971585,0.00021116751,0.00068000343,0.00020061116,0.00013299903,0.0009530828,0.0000013527798],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7378252,0.007423805,0.012391726,0.00010019693,0.003912647,0.00045530006,0.0021095492,0.000034743847,0.00023861324,0.000014619691,0.0002646149,0.23522897],"study_design_scores_gemma":[0.5958279,0.043524396,0.35324028,0.001514463,0.0023197487,0.000029739816,0.00021733493,0.000093715375,0.00014742323,0.000007876609,0.0028482117,0.00022895033],"about_ca_topic_score_codex":0.0049217613,"about_ca_topic_score_gemma":0.010095225,"teacher_disagreement_score":0.34084857,"about_ca_system_score_codex":0.0011685812,"about_ca_system_score_gemma":0.005652854,"threshold_uncertainty_score":0.999986},"labels":[],"label_agreement":null},{"id":"W2890455003","doi":"10.1200/jco.2017.35.15_suppl.e16011","title":"Standard of care for MIBC is becoming more standard.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Regimen; Guideline; Chemotherapy; Cisplatin; Chemotherapy regimen; Stage (stratigraphy); Cancer; Internal medicine; Oncology; Surgery; Pathology","score_opus":0.15935648269332112,"score_gpt":0.5357403778493247,"score_spread":0.37638389515600357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890455003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954247,0.0022617525,0.0008307589,0.029879091,0.003007327,0.000599979,0.00032464796,0.000007369288,0.00884206],"genre_scores_gemma":[0.98618615,0.0005571904,0.010011059,0.0015809794,0.0012987508,0.0000041176454,0.0000020783746,0.000018455046,0.00034120574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787205,0.000059399685,0.0014291018,0.00013527182,0.00033300137,0.0001711624],"domain_scores_gemma":[0.9958567,0.0006119422,0.0019411925,0.0003172656,0.0010259536,0.00024695956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010904426,0.000107557884,0.001687511,0.00005334135,0.00011341271,0.000011207263,0.00020985022,0.0002627171,0.00015555177],"category_scores_gemma":[0.002318219,0.000073407144,0.00068694935,0.00001860706,0.00024628913,0.00009004889,0.000043152704,0.00036753717,0.0000017394028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06320378,0.0007191773,0.24825801,0.00035861955,0.0015276414,0.0003607274,0.0017457692,0.0000022037968,0.00013164553,0.00014922295,0.026793972,0.65674925],"study_design_scores_gemma":[0.04821472,0.08417174,0.16715056,0.0005163427,0.0019111864,0.00014233719,0.0014983953,0.000011050846,0.0044600125,0.0013135553,0.69046134,0.00014878699],"about_ca_topic_score_codex":0.000024607714,"about_ca_topic_score_gemma":0.00006140255,"teacher_disagreement_score":0.6636673,"about_ca_system_score_codex":0.00017196163,"about_ca_system_score_gemma":0.0022571916,"threshold_uncertainty_score":0.4004161},"labels":[],"label_agreement":null},{"id":"W2890465007","doi":"10.1200/jco.2016.34.15_suppl.10126","title":"Opinions of palliative care physicians regarding renaming the specialty supportive care.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Palliative care; Medicine; Specialty; Referral; Family medicine; Nursing","score_opus":0.3184628074952527,"score_gpt":0.5608353604836948,"score_spread":0.24237255298844207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890465007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9477668,0.005394992,0.0019122747,0.01556664,0.0031434845,0.00037052337,0.000093855546,0.000011717198,0.025739754],"genre_scores_gemma":[0.9913157,0.003634412,0.0019885162,0.0005160877,0.0023662886,0.0000022047134,0.0000043457994,0.000014152867,0.00015824678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968258,0.00042130018,0.0019946164,0.00015593796,0.0003948236,0.00020752026],"domain_scores_gemma":[0.98954976,0.0056322096,0.0027874624,0.00022800053,0.0016570035,0.00014555856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010371075,0.00012994031,0.0015082383,0.00008634327,0.000045791272,0.000002278341,0.00021945647,0.00022786907,0.0000653725],"category_scores_gemma":[0.0076250196,0.00006359877,0.0007491964,0.00014748523,0.0005167544,0.00008329512,0.000065477885,0.00052017916,0.0000056554104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028762822,0.00052111835,0.600228,0.00018061866,0.0012101041,0.00023451698,0.020192472,0.000007644593,0.0010642912,0.0009855953,0.009853226,0.3626461],"study_design_scores_gemma":[0.010101928,0.013283963,0.52731466,0.005308834,0.0010221115,0.000019764337,0.053949054,0.0000054193933,0.008449738,0.0006554458,0.3796961,0.00019297111],"about_ca_topic_score_codex":0.000023280829,"about_ca_topic_score_gemma":0.00010319328,"teacher_disagreement_score":0.3698429,"about_ca_system_score_codex":0.00021570986,"about_ca_system_score_gemma":0.0011594783,"threshold_uncertainty_score":0.9128412},"labels":[],"label_agreement":null},{"id":"W2890466450","doi":"10.1200/jco.2017.35.15_suppl.9523","title":"Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Gastroenterology; Adverse effect; Placebo; Immunotherapy; Cancer; Pathology","score_opus":0.14229025081470043,"score_gpt":0.4783152062342483,"score_spread":0.33602495541954785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890466450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951608,0.00034082506,0.000112490095,0.0025264532,0.0003478131,0.0005209898,0.000008705556,0.0000054630664,0.0009764424],"genre_scores_gemma":[0.9944866,0.0009377126,0.0035156172,0.00029926343,0.00017620531,0.000007568974,0.0000027127317,0.00001546599,0.00055885495],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9946254,0.0006802028,0.0037566486,0.00025482534,0.00037433038,0.00030858125],"domain_scores_gemma":[0.9922328,0.0020912187,0.004954233,0.00030226406,0.00022239091,0.00019707829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010805944,0.00019362918,0.0030963789,0.00019760593,0.000082877945,0.000013730988,0.00025993795,0.00022134154,0.00015146649],"category_scores_gemma":[0.0049862936,0.00012554368,0.0003216713,0.00014365227,0.00045611593,0.00017965735,0.00010519751,0.0007344464,5.0086675e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5844187,0.007883708,0.06961145,0.00010675114,0.0011558613,0.0059459037,0.00023092006,0.000019480902,0.0021656943,0.000023520824,0.00038054815,0.32805744],"study_design_scores_gemma":[0.30271077,0.08229205,0.6085392,0.0028282586,0.000433093,0.00070267613,0.00048750226,0.00019888458,0.00036712206,0.00008311916,0.0011908498,0.00016647193],"about_ca_topic_score_codex":0.0001126219,"about_ca_topic_score_gemma":0.0013736024,"teacher_disagreement_score":0.53892773,"about_ca_system_score_codex":0.00043277777,"about_ca_system_score_gemma":0.0010907259,"threshold_uncertainty_score":0.59694195},"labels":[],"label_agreement":null},{"id":"W2890474185","doi":"10.1200/jco.2017.35.15_suppl.6579","title":"Symptom burden and hospital length of stay among patients with curable cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Depression (economics); Anxiety; Cancer; Marital status; Distress; Breast cancer; Physical therapy; Internal medicine; Psychiatry; Population","score_opus":0.04587991332804393,"score_gpt":0.42037783296415837,"score_spread":0.37449791963611445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890474185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185604,0.0004052975,0.00000911318,0.0033234158,0.0014872556,0.00012888075,0.000009222238,0.0000028659829,0.0027779185],"genre_scores_gemma":[0.997566,0.00084989885,0.00016170237,0.00015979212,0.000979401,0.0000021412416,9.63762e-7,0.000011560237,0.0002685309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998378,0.0000856183,0.0009368241,0.00012983571,0.00031901736,0.00015073146],"domain_scores_gemma":[0.9963663,0.0004070215,0.0020776421,0.00023749225,0.0006362528,0.00027526004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082843855,0.00009453082,0.0010087935,0.00004338494,0.00006227057,0.000012898723,0.00016666866,0.00019876893,0.00008642082],"category_scores_gemma":[0.0010234815,0.00005986679,0.00016069064,0.000028405171,0.00045411012,0.00018301701,0.000056335433,0.0005292312,8.645474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015143387,0.00026224364,0.8944235,0.000031038853,0.00028653367,0.0000580553,0.00029456994,0.0000018240396,0.000002757988,0.000018015997,0.0007326247,0.10237451],"study_design_scores_gemma":[0.006947604,0.01222399,0.9620406,0.00022822035,0.00033518387,0.0000079485135,0.00021453018,0.000011680086,0.000022834545,0.000052310726,0.017843518,0.00007155439],"about_ca_topic_score_codex":0.0010602959,"about_ca_topic_score_gemma":0.0011397696,"teacher_disagreement_score":0.10230295,"about_ca_system_score_codex":0.00006374072,"about_ca_system_score_gemma":0.00067835633,"threshold_uncertainty_score":0.24412967},"labels":[],"label_agreement":null},{"id":"W2890487472","doi":"10.1200/jco.2017.35.15_suppl.4071","title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Hepatocellular carcinoma; Interim analysis; Adverse effect; Gastroenterology; Sorafenib; Population; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.08252898576785439,"score_gpt":0.42888099083417397,"score_spread":0.3463520050663196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890487472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567753,0.00024446592,0.00005024186,0.0026171745,0.00059263164,0.00026256853,0.000004215676,0.000002289245,0.0005488949],"genre_scores_gemma":[0.99690855,0.0015674577,0.0006827731,0.0004666447,0.00028873538,7.732859e-7,7.5957223e-7,0.000014270324,0.00007001096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666196,0.00044345148,0.0022153084,0.00019686196,0.0003110463,0.00017136113],"domain_scores_gemma":[0.99500024,0.0009659698,0.0031414954,0.00038607628,0.00029952583,0.00020671461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004382727,0.0001303192,0.001770183,0.000085250824,0.000058421607,0.0000091152815,0.00020179528,0.00038834428,0.000054174565],"category_scores_gemma":[0.0012085806,0.000084487176,0.00038201033,0.00004889853,0.00072669436,0.00015225567,0.000045465156,0.0008050353,8.718767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105227135,0.0016532412,0.68734527,0.000015538766,0.00029075664,0.00008912545,0.000028149363,2.0323974e-7,0.000044144068,0.0000043221635,0.00006932388,0.20523281],"study_design_scores_gemma":[0.05082581,0.022383383,0.9198634,0.00012290709,0.0001473106,0.000026893233,0.000013616167,0.00008088478,0.00007317177,0.000027105592,0.00635542,0.00008007538],"about_ca_topic_score_codex":0.00014657216,"about_ca_topic_score_gemma":0.000107992615,"teacher_disagreement_score":0.23251818,"about_ca_system_score_codex":0.00009959388,"about_ca_system_score_gemma":0.0009797731,"threshold_uncertainty_score":0.34975225},"labels":[],"label_agreement":null},{"id":"W2890496731","doi":"10.1200/jco.2017.35.15_suppl.8015","title":"Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Pembrolizumab; Multiple myeloma; Oncology; Toxicity; Cancer; Immunotherapy","score_opus":0.29015573585746385,"score_gpt":0.5321339181034322,"score_spread":0.2419781822459684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890496731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075,0.0027865916,0.00036500685,0.0037287658,0.0007225938,0.0007930682,0.000024054658,0.000015439275,0.000814471],"genre_scores_gemma":[0.98595136,0.0025878637,0.009318282,0.00046818395,0.0008490191,0.000020498628,0.000011122917,0.000045949233,0.0007477415],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956395,0.0005698621,0.0021673858,0.00050327706,0.000535104,0.0005848707],"domain_scores_gemma":[0.9855246,0.009525188,0.0023354026,0.0006428223,0.0006551444,0.0013168433],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036056787,0.0003289727,0.002391423,0.0002934023,0.0004220276,0.00008652936,0.00033467868,0.00062054733,0.00007106955],"category_scores_gemma":[0.03268554,0.00022660963,0.0006148896,0.00007715138,0.0010573756,0.00037295412,0.00023430813,0.0010477786,0.00001372042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11592533,0.0029302987,0.11509424,0.00022062904,0.0028947191,0.002505576,0.00010366917,0.000005002177,0.0058118887,0.000029096453,0.0022741456,0.75220543],"study_design_scores_gemma":[0.13967243,0.011226462,0.8308418,0.00025235664,0.00093879213,0.00081918394,0.00006462383,0.0025582176,0.00034163703,0.00015901912,0.012927106,0.00019842097],"about_ca_topic_score_codex":0.00013094682,"about_ca_topic_score_gemma":0.00013054872,"teacher_disagreement_score":0.752007,"about_ca_system_score_codex":0.00023572547,"about_ca_system_score_gemma":0.0015964296,"threshold_uncertainty_score":0.97546256},"labels":[],"label_agreement":null},{"id":"W2890512508","doi":"10.1200/jco.2018.36.15_suppl.8040","title":"Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Dexamethasone; Oncology; Gastroenterology; Discontinuation","score_opus":0.17176960524995247,"score_gpt":0.5024723600516399,"score_spread":0.3307027548016874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890512508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524033,0.00055150787,0.000052918163,0.000472096,0.0011130783,0.0009933944,0.000014579614,0.000011981272,0.0015501183],"genre_scores_gemma":[0.99538594,0.00044523145,0.0027336904,0.00020835969,0.000695616,0.000019611674,0.00000566806,0.000042557356,0.00046329954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99091566,0.0018566434,0.005001022,0.00044902705,0.0011847178,0.0005929495],"domain_scores_gemma":[0.98789656,0.0060473024,0.0032868271,0.00065119733,0.0013553799,0.0007627326],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006141894,0.00031552234,0.0033112764,0.0006558334,0.00005723906,0.0000074758277,0.00044179143,0.0005553016,0.00059816404],"category_scores_gemma":[0.016471444,0.00023011786,0.00075338135,0.00049995066,0.00068766763,0.0001621297,0.00016341647,0.0015195295,0.000035768302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17576438,0.07465701,0.34863123,0.0001383711,0.0027405352,0.004930934,0.0017184792,0.000002709166,0.0062531168,0.000037950074,0.001537022,0.38358825],"study_design_scores_gemma":[0.21940246,0.17127353,0.59859794,0.0003421013,0.00062323624,0.0002550394,0.0017828058,0.00032663933,0.0029961418,0.00013558158,0.0040796157,0.00018491776],"about_ca_topic_score_codex":0.00050175824,"about_ca_topic_score_gemma":0.0010150364,"teacher_disagreement_score":0.38340333,"about_ca_system_score_codex":0.0003576158,"about_ca_system_score_gemma":0.0023362073,"threshold_uncertainty_score":0.99181324},"labels":[],"label_agreement":null},{"id":"W2890529757","doi":"10.1200/jco.2017.35.15_suppl.5587","title":"Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): A study of the Princess Margaret, Chicago, and California phase II consortia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Cabozantinib; Internal medicine; Progression-free survival; Oncology; Cohort; Cancer; Endometrial cancer; Carcinosarcoma; Everolimus; Phases of clinical research; Chemotherapy; Gastroenterology; Urology; Carcinoma","score_opus":0.2760814337365475,"score_gpt":0.539506538901688,"score_spread":0.2634251051651405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890529757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947811,0.0012694706,0.000002871253,0.0022331635,0.00058090076,0.0009839957,0.00003624942,0.000002153183,0.00011009201],"genre_scores_gemma":[0.9989879,0.00049028563,0.0001943353,0.00013342296,0.00013933847,0.000031924206,0.0000025451045,0.000011576504,0.000008632281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950487,0.0011876554,0.0026560193,0.00022412583,0.00070632115,0.0001771694],"domain_scores_gemma":[0.99391717,0.00091941335,0.0037825226,0.00050830067,0.00067277526,0.00019982427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005853991,0.00016369078,0.0016137426,0.00014015428,0.0001453226,0.000007710713,0.0002629172,0.000116744115,0.00009190549],"category_scores_gemma":[0.0048029525,0.000097281794,0.0002453432,0.00009683841,0.00040468195,0.00011198011,0.00025328674,0.0005314196,6.60845e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005003365,0.067675345,0.63237846,0.000065251435,0.0005330994,0.00036530578,0.0009800674,0.000003984467,0.00020512386,0.00001739868,0.00022337581,0.29254922],"study_design_scores_gemma":[0.11113214,0.06015425,0.8216182,0.00034625,0.0018740128,0.00014749893,0.00079958705,0.0005374816,0.00045401065,0.000140472,0.0027053012,0.00009077814],"about_ca_topic_score_codex":0.00009054354,"about_ca_topic_score_gemma":0.00060240866,"teacher_disagreement_score":0.29245844,"about_ca_system_score_codex":0.000079474325,"about_ca_system_score_gemma":0.0011546134,"threshold_uncertainty_score":0.57499295},"labels":[],"label_agreement":null},{"id":"W2890530559","doi":"10.1200/jco.2017.35.15_suppl.e18043","title":"Enrolment of adolescents and young adults with cancer (AYAWC) to clinical trials at the Children’s Hospital of Eastern Ontario (CHEO).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Pediatrics; Retrospective cohort study; Internal medicine","score_opus":0.15688100875649177,"score_gpt":0.5028108312641033,"score_spread":0.3459298225076115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890530559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755414,0.00054788386,0.000026819367,0.019826684,0.0029398354,0.0008172369,0.000025592439,0.00000354097,0.00027100093],"genre_scores_gemma":[0.9937156,0.00076311146,0.00066089054,0.0022005048,0.0022493491,0.0000074929894,0.0000016505735,0.000022302145,0.0003791431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907986,0.0014532596,0.006233704,0.0003556629,0.0008802739,0.0002785368],"domain_scores_gemma":[0.98588294,0.0022311532,0.009865094,0.0007067459,0.000665235,0.0006488438],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018227298,0.00022771413,0.0036543813,0.0000692453,0.000098775825,0.000016651185,0.0005277961,0.0003950373,0.00015254489],"category_scores_gemma":[0.01245137,0.0001276357,0.0007986904,0.000042150295,0.00084391097,0.00011113343,0.00031855973,0.0012040114,0.000005324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02409996,0.0018587675,0.9158926,0.000069653004,0.0010516038,0.000040385163,0.0017379815,0.0000020333337,0.000010620377,0.000005630165,0.0021048733,0.053125888],"study_design_scores_gemma":[0.021714445,0.020443097,0.9507303,0.0016880401,0.00091298926,0.00010124057,0.00023092846,0.0000032496632,0.0000891733,0.000021930666,0.0039385855,0.00012597378],"about_ca_topic_score_codex":0.014802178,"about_ca_topic_score_gemma":0.09985983,"teacher_disagreement_score":0.08505766,"about_ca_system_score_codex":0.00025010726,"about_ca_system_score_gemma":0.0023746055,"threshold_uncertainty_score":0.9958672},"labels":[],"label_agreement":null},{"id":"W2890544386","doi":"10.1200/jco.2017.35.15_suppl.e20019","title":"A meta-analysis of trials of etoposide plus platinum agent versus irinotecan/topotecan plus platinum agent in first-line therapy of extensive stage small cell lung cancer (ES SCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Thunder Bay Regional Health Sciences Centre; Health Sciences Centre; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Irinotecan; Topotecan; Internal medicine; Etoposide; Neutropenia; Randomized controlled trial; Oncology; Meta-analysis; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.5605280711602462,"score_gpt":0.570289572427092,"score_spread":0.009761501266845829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890544386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97405064,0.015879417,0.00017504874,0.0065829176,0.0010750953,0.0011659454,0.00022855419,0.0000057092793,0.000836698],"genre_scores_gemma":[0.9761796,0.020886037,0.0015194279,0.00029746493,0.0005100687,0.000043904063,0.0000055252094,0.000032812426,0.000525159],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.98870456,0.0015625282,0.0074953814,0.00045412924,0.0012760346,0.00050736446],"domain_scores_gemma":[0.97084457,0.012005051,0.013754067,0.00095793064,0.0020356083,0.0004027721],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0131067075,0.000372236,0.011181032,0.000764411,0.00010193987,0.000015094806,0.00075724756,0.00047313818,0.0009107659],"category_scores_gemma":[0.017574186,0.000244162,0.004219298,0.00041160377,0.00088273006,0.00012007139,0.00034781703,0.0013139481,0.0000010448163],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1869717,0.006526657,0.10191512,0.0016180468,0.6077089,0.0026421088,0.007794857,0.044339646,0.006887479,0.00014691667,0.0038697477,0.02957885],"study_design_scores_gemma":[0.1515025,0.051557057,0.45478913,0.0007821711,0.29597887,0.000022862378,0.0022984056,0.007268703,0.022468382,0.00020383198,0.012303235,0.000824837],"about_ca_topic_score_codex":0.004200682,"about_ca_topic_score_gemma":0.011296416,"teacher_disagreement_score":0.352874,"about_ca_system_score_codex":0.00088294974,"about_ca_system_score_gemma":0.004638332,"threshold_uncertainty_score":0.9972248},"labels":[],"label_agreement":null},{"id":"W2890548675","doi":"10.1200/jco.2017.35.15_suppl.10562","title":"Long-term incidence of venous thromboembolism (VTE) among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Confidence interval; Incidence (geometry); Cancer; Cohort; Hazard ratio; Childhood cancer; Pediatrics; Demography; Relative risk; Internal medicine","score_opus":0.10473240839962775,"score_gpt":0.47611997118104293,"score_spread":0.37138756278141516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890548675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97539663,0.006500864,0.00003003273,0.009915638,0.0062647485,0.0012638591,0.000105927735,0.000022836994,0.00049947517],"genre_scores_gemma":[0.9876821,0.005400196,0.00019654003,0.0017827314,0.0047238334,0.00003265619,0.000007917901,0.000077624165,0.00009640234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98726654,0.0018396849,0.0075355587,0.00074139086,0.0020147995,0.00060200813],"domain_scores_gemma":[0.97296745,0.0052440115,0.017198764,0.0022915318,0.0016421273,0.00065614557],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011873529,0.00050923304,0.005884374,0.00016728016,0.00032817657,0.000047743975,0.0020184454,0.00068830955,0.00045690167],"category_scores_gemma":[0.0146228345,0.0003496857,0.0013748207,0.00025360813,0.0016353745,0.000509955,0.0005891479,0.0025220248,0.0000056522963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012833988,0.010948715,0.94759727,0.00008363041,0.0034591735,0.0011011434,0.006755633,0.000025001164,0.000051094466,0.0000071129853,0.0013345659,0.027353246],"study_design_scores_gemma":[0.008878103,0.006913048,0.9775424,0.0014290111,0.0023525232,0.00028797533,0.0011292455,0.000005520946,0.00020854555,0.0001659993,0.00078422215,0.0003034292],"about_ca_topic_score_codex":0.07029353,"about_ca_topic_score_gemma":0.11107884,"teacher_disagreement_score":0.040785313,"about_ca_system_score_codex":0.00025286322,"about_ca_system_score_gemma":0.006546294,"threshold_uncertainty_score":0.9998955},"labels":[],"label_agreement":null},{"id":"W2890555915","doi":"10.1200/jco.2016.34.15_suppl.e21631","title":"Evaluation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) tool: Acceptability, feasibility and potential role in enhancing clinical care of men with early-stage prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Sexual function; Patient experience; Cancer; Family medicine; Thematic analysis; Prostatectomy; Gynecology; Qualitative research; Internal medicine; Health care","score_opus":0.13179739571262614,"score_gpt":0.5176480569455177,"score_spread":0.3858506612328916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890555915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98646915,0.003312643,0.000046783272,0.006270742,0.0007412998,0.0028888902,0.00012468679,0.0000051858024,0.00014060664],"genre_scores_gemma":[0.9871253,0.010627001,0.00125358,0.00033598306,0.00042382037,0.00017247521,0.0000026366329,0.000024381932,0.000034861852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99058306,0.0026608144,0.0048673786,0.00052172533,0.0010390013,0.00032799607],"domain_scores_gemma":[0.9852095,0.005420644,0.004770838,0.0004263543,0.0038995608,0.0002730992],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018852169,0.0002300014,0.0020753404,0.00007411942,0.000056636218,0.000012851257,0.0002038943,0.0003928266,0.00006160563],"category_scores_gemma":[0.008951921,0.00011662,0.00054966175,0.00017172641,0.00077825773,0.0003354208,0.00014772323,0.0007504942,2.9101608e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020741278,0.0019192899,0.67497134,0.0001099654,0.00053465745,0.00001464676,0.0005258955,0.00006190427,0.00016092026,0.000005369294,0.00004897686,0.30090576],"study_design_scores_gemma":[0.038098663,0.014126228,0.9409307,0.00069188775,0.0021773397,0.000019359972,0.0008447452,0.00015976782,0.0013333524,0.00028236644,0.0012099807,0.0001255794],"about_ca_topic_score_codex":0.00047299362,"about_ca_topic_score_gemma":0.0019607872,"teacher_disagreement_score":0.3007802,"about_ca_system_score_codex":0.0007575366,"about_ca_system_score_gemma":0.0063768723,"threshold_uncertainty_score":0.9993961},"labels":[],"label_agreement":null},{"id":"W2890555947","doi":"10.1200/jco.2018.36.15_suppl.12121","title":"Early mortality with immune checkpoint inhibitors (IOs) in solid tumors: An inconvenient truth?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Oncology; Melanoma; Cancer research","score_opus":0.09172081577637263,"score_gpt":0.45602678384590917,"score_spread":0.3643059680695365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890555947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943634,0.00021371714,0.000029699893,0.002130665,0.0015411242,0.00019522576,0.0000015239482,0.000010456746,0.0015141515],"genre_scores_gemma":[0.9954726,0.00013073959,0.00082783465,0.0011850797,0.0022943704,0.0000035902049,0.0000015177046,0.000019781106,0.000064501866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99525124,0.0004156431,0.0034009777,0.00023103914,0.000409452,0.00029164526],"domain_scores_gemma":[0.99660325,0.00041277832,0.0019081095,0.00030404827,0.00043411934,0.0003377157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057193907,0.00016389218,0.001466149,0.00017610691,0.000037498754,0.000013032782,0.00019438106,0.00032658412,0.00023454026],"category_scores_gemma":[0.0009200031,0.0001051229,0.00042612967,0.0002543291,0.00072400743,0.00019962652,0.00003932491,0.000959741,0.000013438934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.109892316,0.0077758576,0.7088623,0.000067785484,0.0013253224,0.0027104048,0.002030139,0.0000042373686,0.012836816,0.00006959763,0.0005447984,0.1538804],"study_design_scores_gemma":[0.014612003,0.05053233,0.9237606,0.00032788242,0.00013805614,0.000468112,0.00032828018,0.00003361635,0.0035263589,0.00017113221,0.0059724865,0.00012913554],"about_ca_topic_score_codex":0.00033362792,"about_ca_topic_score_gemma":0.00037727348,"teacher_disagreement_score":0.21489827,"about_ca_system_score_codex":0.0002554057,"about_ca_system_score_gemma":0.001842678,"threshold_uncertainty_score":0.42867872},"labels":[],"label_agreement":null},{"id":"W2890557090","doi":"10.1200/jco.2017.35.15_suppl.e21074","title":"Evaluation of the risk of relapse of patients with stage III cutaneous melanoma at event-free survival time points.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Melanoma; Stage (stratigraphy); Internal medicine; Cancer; Oncology; Gastroenterology; Surgery","score_opus":0.06320070647038718,"score_gpt":0.39088992281647905,"score_spread":0.3276892163460919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890557090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98747516,0.000038166723,0.00002937352,0.00092165277,0.001075014,0.0004538324,0.000026856625,0.0000027657416,0.0099771945],"genre_scores_gemma":[0.99742997,0.000082442806,0.0003335999,0.00007090975,0.00014593899,0.0000013946898,0.0000017089161,0.00001299858,0.001921025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99528205,0.0009988823,0.002040309,0.00014337299,0.0014053286,0.0001300737],"domain_scores_gemma":[0.9890381,0.0009371211,0.007407088,0.0008224794,0.0016625003,0.00013267914],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066933553,0.00011557022,0.0011526769,0.00008577247,0.000081057726,0.0000035039347,0.00042162533,0.00020073503,0.0005327409],"category_scores_gemma":[0.012033858,0.00006576167,0.00044477326,0.000059617778,0.00037450044,0.00005628601,0.0003088546,0.00044675643,0.000007912909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034881085,0.0051850146,0.8242553,0.00012387463,0.0033362098,0.00021128748,0.000290481,0.0004203859,0.0007151881,0.000112843045,0.004166851,0.12630151],"study_design_scores_gemma":[0.02294728,0.01841808,0.9464025,0.00017197974,0.0035263768,0.00016144171,0.00009382814,0.0007607668,0.00072306977,0.0004991413,0.0062051746,0.00009037162],"about_ca_topic_score_codex":0.000057158726,"about_ca_topic_score_gemma":0.00027340147,"teacher_disagreement_score":0.12621114,"about_ca_system_score_codex":0.00018725089,"about_ca_system_score_gemma":0.0006735654,"threshold_uncertainty_score":0.9962882},"labels":[],"label_agreement":null},{"id":"W2890571864","doi":"10.1200/jco.2018.36.15_suppl.3586","title":"Prognostic immune scoring of colorectal cancer liver metastasis with MHC class-I expression combined to T cell quantification.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; CD8; Immune system; Chemotherapy; Major histocompatibility complex; Tissue microarray; Metastasis; Immunohistochemistry; Internal medicine; Oncology; Gastroenterology; Pathology; Cancer; Immunology","score_opus":0.11011219782431647,"score_gpt":0.4368056017572908,"score_spread":0.3266934039329743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890571864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939809,0.0010789259,0.0004596878,0.0023849087,0.0010546646,0.00035868035,0.0000050940043,0.000007770077,0.0006694002],"genre_scores_gemma":[0.9913417,0.0006549942,0.0067481836,0.00058448495,0.0004648779,0.000012111667,0.0000015132555,0.000017461252,0.0001746431],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972793,0.00024661198,0.0017893155,0.00018220926,0.00031234502,0.00019022576],"domain_scores_gemma":[0.99599165,0.0009689039,0.0017216064,0.00018382483,0.0009168378,0.00021715635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019285441,0.00012585719,0.0010607591,0.00014205276,0.000050270573,0.0000072144576,0.0001772126,0.00018860002,0.00035509153],"category_scores_gemma":[0.0007618367,0.00007890295,0.00026031188,0.00027747412,0.00037041938,0.00008870242,0.00004034499,0.00040235708,0.0000111081845],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14316146,0.00357106,0.12234616,0.00015419257,0.0010376724,0.00013366881,0.00061929825,0.00002175136,0.6126458,0.000026653133,0.0052987863,0.110983506],"study_design_scores_gemma":[0.013927833,0.063648574,0.65947866,0.0008629799,0.00080675905,0.00012628753,0.00026276615,0.00010019535,0.22899152,0.000013135123,0.03161681,0.0001644626],"about_ca_topic_score_codex":0.00008475338,"about_ca_topic_score_gemma":0.00007918181,"teacher_disagreement_score":0.5371325,"about_ca_system_score_codex":0.00012449708,"about_ca_system_score_gemma":0.0012932626,"threshold_uncertainty_score":0.38880032},"labels":[],"label_agreement":null},{"id":"W2890572331","doi":"10.1200/jco.2017.35.15_suppl.8033","title":"Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Lenalidomide; Internal medicine; Dexamethasone; Daratumumab; Carfilzomib; Adverse effect; Gastroenterology; Toxicity","score_opus":0.08499588755638966,"score_gpt":0.4329216199730279,"score_spread":0.34792573241663827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890572331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982679,0.00019705416,0.000036535508,0.0006607058,0.00011212105,0.0003502524,0.00003229555,0.000002961304,0.0003402085],"genre_scores_gemma":[0.9968183,0.00041610023,0.0024610583,0.0000774466,0.000064666914,0.0000023081147,0.000012541236,0.000016244845,0.00013134396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634403,0.00048300513,0.0020581477,0.00028962016,0.0005434374,0.00028176422],"domain_scores_gemma":[0.99157566,0.0039550574,0.0029164716,0.00050171086,0.0005543394,0.0004967754],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001847371,0.00018700826,0.0022994287,0.0005189204,0.00009637232,0.000011062511,0.00019132542,0.000329274,0.000049951122],"category_scores_gemma":[0.009205984,0.00011368016,0.00028926358,0.00024376268,0.0007518984,0.00015311914,0.00007316169,0.0007033799,7.5171505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06930542,0.0032743723,0.81523526,0.000056599423,0.0018048872,0.00074523623,0.00011121577,0.000011071497,0.00011401102,0.0000044744106,0.000048997983,0.10928843],"study_design_scores_gemma":[0.06413384,0.03344049,0.8989475,0.00022885915,0.0013176989,0.000026685364,0.000056143297,0.0005905924,0.0000758948,0.000003151477,0.0010938465,0.000085322965],"about_ca_topic_score_codex":0.00035121047,"about_ca_topic_score_gemma":0.00225094,"teacher_disagreement_score":0.10920311,"about_ca_system_score_codex":0.00015140571,"about_ca_system_score_gemma":0.00094826386,"threshold_uncertainty_score":0.9991399},"labels":[],"label_agreement":null},{"id":"W2890576827","doi":"10.1200/jco.2018.36.15_suppl.5008","title":"A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Dosing; Oncology; Internal medicine; Cancer; Castration; Bone metastasis; Hormone","score_opus":0.22473482069133566,"score_gpt":0.5522200574403112,"score_spread":0.32748523674897556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890576827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096256,0.0006455334,0.000096323005,0.0064150407,0.00027424298,0.00094750104,0.000008864382,0.000008611182,0.00064131763],"genre_scores_gemma":[0.9939156,0.00024116688,0.0041047763,0.00065842294,0.0008536616,0.000055543762,0.000002840186,0.000016739712,0.0001512015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99423945,0.0007543496,0.0040691295,0.00024822864,0.000419941,0.0002688891],"domain_scores_gemma":[0.9926032,0.0035694714,0.00261305,0.00021198844,0.0005396901,0.000462625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071395314,0.00017410827,0.0023213828,0.00011362073,0.00006893995,0.000011548807,0.00013908667,0.00013616198,0.00011053047],"category_scores_gemma":[0.007723728,0.00012470002,0.00034801319,0.00037966188,0.00092791364,0.000115712675,0.000031876625,0.0009429763,0.000003188613],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5843974,0.039380074,0.015954452,0.0005269442,0.0032155986,0.0021736748,0.0051935236,0.00015962873,0.28848124,0.00042812113,0.0016613037,0.058428038],"study_design_scores_gemma":[0.93847215,0.010566571,0.0054552294,0.0006623337,0.0032388144,0.00033919307,0.0014559947,0.0025126056,0.031082407,0.0013375814,0.004616613,0.00026051636],"about_ca_topic_score_codex":0.00010442643,"about_ca_topic_score_gemma":0.00006984713,"teacher_disagreement_score":0.35407475,"about_ca_system_score_codex":0.0001592567,"about_ca_system_score_gemma":0.0016201702,"threshold_uncertainty_score":0.9246582},"labels":[],"label_agreement":null},{"id":"W2890579724","doi":"10.1200/jco.2016.34.15_suppl.e15126","title":"Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Bevacizumab; Irinotecan; Capecitabine; Oxaliplatin; Internal medicine; Oncology; Colorectal cancer; Angiogenesis; Chemotherapy; Placental growth factor; Metastasis; Cancer; Gastroenterology; Vascular endothelial growth factor; VEGF receptors","score_opus":0.034029302550745884,"score_gpt":0.4170639724287018,"score_spread":0.3830346698779559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890579724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901816,0.00036262537,0.00002024119,0.008407201,0.00036511358,0.00047075198,0.000027404252,0.000004906905,0.00016015761],"genre_scores_gemma":[0.99774146,0.00036687206,0.0009770219,0.00058304233,0.00006822607,0.00002291391,7.1906413e-7,0.000018333065,0.00022142945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740624,0.00029162224,0.0014680296,0.00019396206,0.0004108472,0.00022927954],"domain_scores_gemma":[0.99650383,0.0016765494,0.0009311834,0.00012602528,0.0005061389,0.0002562825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011888653,0.00015310128,0.0014691537,0.00019367672,0.000019639676,0.0000022368522,0.00011689529,0.000116071984,0.00018523201],"category_scores_gemma":[0.0017756062,0.00007620039,0.00028162327,0.00024299961,0.00016345314,0.00006621572,0.00003782849,0.00021188353,0.000005925572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24014531,0.0021445213,0.6343299,0.000015236587,0.0011929928,0.0001625035,0.0003120269,0.00000374304,0.0006913737,0.0000029085293,0.00027615848,0.12072333],"study_design_scores_gemma":[0.031611152,0.07211486,0.89297736,0.0002510186,0.0003544855,0.000029799823,0.000063149986,0.0000039679694,0.00018711339,0.00005125953,0.0022793515,0.000076502896],"about_ca_topic_score_codex":0.000051831026,"about_ca_topic_score_gemma":0.0004991811,"teacher_disagreement_score":0.25864744,"about_ca_system_score_codex":0.00065488805,"about_ca_system_score_gemma":0.0017779584,"threshold_uncertainty_score":0.31540218},"labels":[],"label_agreement":null},{"id":"W2890585143","doi":"10.1200/jco.2017.35.15_suppl.9024","title":"Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; Queen's University; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Liquid biopsy; T790M; Erlotinib; Internal medicine; Lung cancer; Oncology; Biopsy; Amplicon; STK11; Gefitinib; Concordance; Crizotinib; Cancer; Pathology; Epidermal growth factor receptor; Polymerase chain reaction; Biology; Colorectal cancer; Gene","score_opus":0.05525560385110357,"score_gpt":0.42167813700868056,"score_spread":0.366422533157577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890585143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672467,0.00086791767,0.00077399303,0.00020965132,0.00068177504,0.00041397163,0.000023960276,4.6112655e-7,0.00030360563],"genre_scores_gemma":[0.9955438,0.00033771447,0.0035756885,0.00014268428,0.00034435504,0.00002214922,0.000009770486,0.000014617782,0.000009228955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844193,0.000120867124,0.0008946019,0.00016616956,0.00022909278,0.00014733202],"domain_scores_gemma":[0.9962693,0.00014894463,0.0018177122,0.00024361814,0.0014363019,0.000084115054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026664461,0.00009580395,0.00047453024,0.00004569672,0.000039300216,0.000010746015,0.00025815665,0.00024145257,0.00000407921],"category_scores_gemma":[0.002365709,0.0000764007,0.00016778253,0.000020620373,0.000105483494,0.0000065721315,0.00007040692,0.00015874898,1.2899511e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016559409,0.002136077,0.8510739,0.00013825209,0.00060502015,0.00001320949,0.00010685288,0.008720087,0.06758199,0.00003554214,0.00080099446,0.05222863],"study_design_scores_gemma":[0.046007186,0.033970468,0.70724124,0.00027344842,0.0014887598,0.0000030078986,0.000098450444,0.003244102,0.20312509,0.00016366248,0.0039586173,0.00042598162],"about_ca_topic_score_codex":0.000033479053,"about_ca_topic_score_gemma":0.00019762339,"teacher_disagreement_score":0.1438327,"about_ca_system_score_codex":0.00007258642,"about_ca_system_score_gemma":0.00223438,"threshold_uncertainty_score":0.3963694},"labels":[],"label_agreement":null},{"id":"W2890593119","doi":"10.1200/jco.2017.35.15_suppl.e16012","title":"Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Nomogram; Oncology; Internal medicine; Docetaxel; Pazopanib; Salvage therapy; Sunitinib; Progression-free survival; Urology; Surgery; Chemotherapy; Cancer; Overall survival","score_opus":0.42450118140751847,"score_gpt":0.5525516053763351,"score_spread":0.1280504239688166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890593119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130035,0.00044850135,0.0012739279,0.008042143,0.005016443,0.002054984,0.000026586249,0.0000051434417,0.0018319337],"genre_scores_gemma":[0.98722833,0.00057640753,0.006602434,0.0015376705,0.002305139,0.00007068865,0.0000027302428,0.00004015048,0.0016364355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99378514,0.0009359599,0.0041038305,0.00029011435,0.0005595272,0.00032543502],"domain_scores_gemma":[0.9863101,0.008614369,0.0035673263,0.00043574776,0.0004126511,0.00065979356],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011477977,0.0002498582,0.006128734,0.00022120004,0.00006271568,0.000023330958,0.00042208828,0.0003236584,0.00033140474],"category_scores_gemma":[0.02471503,0.00016205551,0.0019269972,0.000084008745,0.00016490565,0.00012839749,0.00005750156,0.00055631524,0.000007649318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63434416,0.0050211963,0.08846743,0.000058830945,0.0023946462,0.00055448234,0.00043668138,0.000013022963,0.00037428408,0.00014593436,0.012215196,0.25597414],"study_design_scores_gemma":[0.55299354,0.021417463,0.3725397,0.00013612206,0.0018642282,0.000052455962,0.000042826236,0.00006602002,0.00042887742,0.0021348973,0.04813703,0.00018680932],"about_ca_topic_score_codex":0.002025157,"about_ca_topic_score_gemma":0.00028451538,"teacher_disagreement_score":0.28407228,"about_ca_system_score_codex":0.00044140566,"about_ca_system_score_gemma":0.0029030857,"threshold_uncertainty_score":0.9835002},"labels":[],"label_agreement":null},{"id":"W2890593893","doi":"10.1200/jco.2017.35.15_suppl.e14026","title":"Examining the adherence to CONSORT guidelines and the reporting of the enrollment process in clinical oncology randomized controlled trials: A review of trials published between 2013 and 2015.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université Laval","funders":"","keywords":"Generalizability theory; Medicine; Randomization; Consolidated Standards of Reporting Trials; Randomized controlled trial; Clinical trial; External validity; Sample size determination; Family medicine; Internal medicine; Statistics","score_opus":0.9503351118676293,"score_gpt":0.7353530254183969,"score_spread":0.21498208644923245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890593893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011182289,0.88434017,0.00008639656,0.10013515,0.0029041916,0.010714006,0.000064891785,0.0000029249973,0.00063406525],"genre_scores_gemma":[0.0010544232,0.98815274,0.0009940928,0.006706471,0.0022930303,0.0006229318,0.0000037201514,0.000028867536,0.00014371677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.420212,0.17755133,0.39917305,0.0014558925,0.00081693986,0.0007907957],"domain_scores_gemma":[0.026238378,0.50654006,0.46379644,0.0013216514,0.0017176595,0.00038581545],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.8996943,0.00048480558,0.09337551,0.00038687605,0.00016204808,0.00009106884,0.0016044975,0.0012351377,0.00011958529],"category_scores_gemma":[0.9592031,0.00021206748,0.0056472793,0.0002378584,0.0016810163,0.000267837,0.00038863855,0.0021487975,0.0000083333025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026966674,0.00047678908,0.008720702,0.025634037,0.007997938,0.000010456688,0.0005733224,0.0000074124155,6.911905e-9,0.0020255912,0.04515255,0.88243455],"study_design_scores_gemma":[0.18318407,0.0016164301,0.0011088392,0.047531858,0.004789074,0.00007107244,0.00025662815,0.000077672266,1.3826025e-8,0.004294192,0.7568014,0.00026875085],"about_ca_topic_score_codex":0.00036605846,"about_ca_topic_score_gemma":0.00012274091,"teacher_disagreement_score":0.8821658,"about_ca_system_score_codex":0.00023337231,"about_ca_system_score_gemma":0.009142098,"threshold_uncertainty_score":0.99647516},"labels":[],"label_agreement":null},{"id":"W2890598392","doi":"10.1200/jco.2017.35.15_suppl.e18269","title":"Reliability of administrative data for evaluating quality of systemic cancer treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Institute for Clinical Evaluative Sciences; Trillium Health Centre; University of Toronto; Health Sciences Centre; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Documentation; Cancer registry; Medical record; Reliability (semiconductor); Breast cancer; Chart; Cancer; Gold standard (test); Quality (philosophy); Statistics; Surgery; Internal medicine; Computer science","score_opus":0.9440016621577794,"score_gpt":0.7367906590685522,"score_spread":0.20721100308922713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890598392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757082,0.0016783936,0.0017442259,0.014854495,0.0022971833,0.00076011725,0.0017399025,0.0000034453135,0.0012140796],"genre_scores_gemma":[0.98530775,0.00077698805,0.012301974,0.0005257398,0.0008606422,0.000028527811,0.000012280528,0.00001371171,0.00017239824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97833955,0.0016995227,0.019142553,0.00043136478,0.0001572398,0.00022978129],"domain_scores_gemma":[0.92280006,0.020477569,0.054042846,0.0015842505,0.00087433396,0.00022096449],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.124638826,0.00014453859,0.00423828,0.00010067023,0.0001396567,0.00001962388,0.0010785236,0.00035146016,0.00012840876],"category_scores_gemma":[0.17217605,0.00013290906,0.0005124407,0.00003857257,0.00038431562,0.00058685435,0.00012183062,0.0002623761,0.00001286626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026989053,0.0024680507,0.9420435,0.0016968513,0.0012852221,0.000002489368,0.0014824144,0.00029438513,0.00008198487,0.019464431,0.007664853,0.020816946],"study_design_scores_gemma":[0.0129662445,0.0123890275,0.9211158,0.00060109346,0.0002372064,0.000014555043,0.0019393009,0.0062224283,0.000043876684,0.02306683,0.021080729,0.0003228835],"about_ca_topic_score_codex":0.0016388036,"about_ca_topic_score_gemma":0.0006495482,"teacher_disagreement_score":0.055539504,"about_ca_system_score_codex":0.0005600142,"about_ca_system_score_gemma":0.003624456,"threshold_uncertainty_score":0.90136856},"labels":[],"label_agreement":null},{"id":"W2890604647","doi":"10.1200/jco.2018.36.15_suppl.e18715","title":"Population based analysis of male patients with breast cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Male breast cancer; Breast cancer; Internal medicine; Tamoxifen; Cohort; Stage (stratigraphy); Cancer; Estrogen receptor; Cancer registry; Hormonal therapy; Gynecology; Population; Oncology","score_opus":0.08704690424708182,"score_gpt":0.4962407785667956,"score_spread":0.40919387431971377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890604647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292,0.00004376599,0.00013205162,0.0056017693,0.00039084817,0.000113859714,0.000021650934,0.0000031986144,0.0007728923],"genre_scores_gemma":[0.9949648,0.00003357091,0.0025436147,0.0016928345,0.00068190775,0.0000015616768,0.0000061594956,0.0000070256524,0.00006852839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973798,0.00020602159,0.0017595325,0.00011778457,0.00038947427,0.000147388],"domain_scores_gemma":[0.99487185,0.000708903,0.002323164,0.00014178784,0.0017309604,0.00022335011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013140378,0.00008134225,0.0015377898,0.00026090042,0.00003259137,0.0000013603646,0.0000714478,0.00015330917,0.00080060825],"category_scores_gemma":[0.00081867847,0.000049598042,0.00028519225,0.00046487487,0.00018203947,0.00005079935,0.000017894154,0.0002872812,0.0000029852986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066985176,0.00095655274,0.94653106,0.000035716883,0.0012512149,0.000014240705,0.00002222733,0.000033236374,0.0000015808214,0.0000078825,0.00061890093,0.043828897],"study_design_scores_gemma":[0.0050114747,0.0073273783,0.98253495,0.000095045674,0.003098866,0.000022874341,0.00001541554,0.00045587117,0.0000018166893,0.0000055729665,0.0013884387,0.00004231473],"about_ca_topic_score_codex":0.0002752542,"about_ca_topic_score_gemma":0.0006462556,"teacher_disagreement_score":0.043786585,"about_ca_system_score_codex":0.00013031479,"about_ca_system_score_gemma":0.0008750738,"threshold_uncertainty_score":0.87660986},"labels":[],"label_agreement":null},{"id":"W2890632219","doi":"10.1200/jco.2017.35.15_suppl.e16502","title":"Metformin to treat prostate cancer (PCa) and prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Results of a randomized double-blind placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced PCa.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Metformin; Internal medicine; Endocrinology; Insulin resistance; Hyperinsulinemia; Metabolic syndrome; Insulin; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Type 2 diabetes; Placebo; Diabetes mellitus; Randomized controlled trial; Cancer","score_opus":0.06054494848033803,"score_gpt":0.414958900850354,"score_spread":0.35441395237001594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890632219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97968626,0.015709223,0.000046881323,0.00009217386,0.00016773632,0.0041522905,0.000037959682,0.0000018112397,0.00010564432],"genre_scores_gemma":[0.97900003,0.019145014,0.000863916,0.00008441368,0.00012408716,0.00068007945,0.000011973644,0.000025822514,0.00006465489],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535,0.0007313068,0.002970957,0.000343428,0.0003031345,0.0003011907],"domain_scores_gemma":[0.992214,0.0012080306,0.005378289,0.00033208576,0.00069746387,0.0001700841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00901567,0.000245549,0.0034967274,0.00017227403,0.00007528093,0.000020668456,0.00032016452,0.0002891631,0.000004669345],"category_scores_gemma":[0.0049930764,0.00016078493,0.00036999112,0.00011010471,0.00016144838,0.000044562512,0.00008045031,0.00023823693,8.707219e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86464363,0.0017140014,0.004663158,0.00003460556,0.0022418145,0.000011556991,0.00071581564,0.00030845264,0.004055648,0.0000056440795,0.000025289639,0.12158037],"study_design_scores_gemma":[0.9452349,0.012772381,0.009773848,0.0001724102,0.0011044744,0.000008196025,0.00037267196,0.00014181802,0.02948253,0.00011366916,0.00061013637,0.0002129992],"about_ca_topic_score_codex":0.00008320124,"about_ca_topic_score_gemma":0.0005945555,"teacher_disagreement_score":0.12136737,"about_ca_system_score_codex":0.00004066612,"about_ca_system_score_gemma":0.00069997803,"threshold_uncertainty_score":0.6556619},"labels":[],"label_agreement":null},{"id":"W2890645189","doi":"10.1200/jco.2017.35.15_suppl.e21077","title":"Impact of the epigenetic modulator BORIS on sensitivity of melanoma cells to UV-induced DNA damage.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Chromatin; DNA damage; Molecular biology; Biology; Melanoma; Cell cycle; Apoptosis; Cell culture; Cell growth; Cancer research; Cell biology; DNA; Genetics","score_opus":0.06236483575700701,"score_gpt":0.42820551219557895,"score_spread":0.36584067643857193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890645189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970367,0.00004290189,0.000098456265,0.0007333396,0.0013164121,0.00012740398,0.000046980345,5.3976595e-7,0.00059725705],"genre_scores_gemma":[0.9982774,0.00017921867,0.00036281388,0.00032290857,0.0007983659,7.904107e-7,9.1735535e-7,0.00001317087,0.000044411066],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980937,0.0003185558,0.0010686055,0.00017316376,0.00017667672,0.00016925114],"domain_scores_gemma":[0.996098,0.0005658701,0.0020525458,0.0006974549,0.00037862413,0.00020750833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017692902,0.00012305994,0.000717497,0.00003572812,0.00006169416,0.000010504004,0.00043566062,0.00032035558,0.000011149593],"category_scores_gemma":[0.0047579478,0.00008087487,0.0006886293,0.00003281514,0.00017012566,0.0000035766159,0.0002328118,0.00026653963,0.0000027737617],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014766566,0.0007787855,0.087277725,0.000009249263,0.00032237158,0.000031605374,0.00003112233,0.00119104,0.8775564,0.00003128034,0.0029074275,0.028386356],"study_design_scores_gemma":[0.0011908807,0.009359126,0.7291561,0.000024718589,0.0000743429,0.00001186876,0.0000086851305,0.00004408379,0.25765952,0.000073542644,0.0023182335,0.0000789199],"about_ca_topic_score_codex":0.00013682373,"about_ca_topic_score_gemma":0.00019330137,"teacher_disagreement_score":0.64187837,"about_ca_system_score_codex":0.00004671076,"about_ca_system_score_gemma":0.0011045618,"threshold_uncertainty_score":0.5696052},"labels":[],"label_agreement":null},{"id":"W2890646471","doi":"10.1200/jco.2018.36.15_suppl.4084","title":"Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Toxicity; Internal medicine; Gastroenterology; Surgery; Urology; Randomized controlled trial; Cancer; Oncology","score_opus":0.13425940325722255,"score_gpt":0.49905968341093204,"score_spread":0.36480028015370947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890646471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96387863,0.0066681085,0.00044866206,0.01945961,0.004277636,0.0017052518,0.000015581538,0.000018385548,0.0035281344],"genre_scores_gemma":[0.9736739,0.0046961554,0.009077357,0.0042570126,0.007188154,0.00011712318,0.0000028499014,0.000032456795,0.00095499965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958961,0.00042867832,0.0027612473,0.00030337455,0.00030020438,0.00031038804],"domain_scores_gemma":[0.98842245,0.008181501,0.0018590414,0.00019125898,0.0009812503,0.00036446968],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005877276,0.00021354234,0.003426198,0.0001428922,0.00009469327,0.000012350585,0.00012657142,0.00032691116,0.00017125193],"category_scores_gemma":[0.012112134,0.00013591305,0.0009610604,0.00014936489,0.000706407,0.00012947094,0.000053343687,0.00062166434,0.0000045879415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81801444,0.0008070066,0.004960188,0.00005565551,0.0008795977,0.00006453853,0.00026005073,5.242784e-7,0.00014489067,0.000055806853,0.01088654,0.16387077],"study_design_scores_gemma":[0.8595823,0.022827247,0.029649328,0.0001412529,0.0017089522,0.00017102738,0.0001453877,0.00013151256,0.00008794371,0.0005709748,0.08483821,0.00014587949],"about_ca_topic_score_codex":0.000027011274,"about_ca_topic_score_gemma":0.00007202742,"teacher_disagreement_score":0.1637249,"about_ca_system_score_codex":0.000087924316,"about_ca_system_score_gemma":0.0010945186,"threshold_uncertainty_score":0.99620926},"labels":[],"label_agreement":null},{"id":"W2890649367","doi":"10.1200/jco.2017.35.15_suppl.6609","title":"Delivery of meaningful cancer care: Evaluating benefit and cost of cancer therapies using ASCO and ESMO frameworks.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Cancer; Breast cancer; Internal medicine; Oncology","score_opus":0.7151945709060141,"score_gpt":0.6375399019103009,"score_spread":0.07765466899571327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890649367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95979595,0.028039347,0.0002596076,0.009867893,0.0013995471,0.00022119531,0.00006933931,0.0000020172101,0.0003451122],"genre_scores_gemma":[0.9784074,0.009729517,0.008956652,0.0021016807,0.0007534332,0.0000075075554,5.1111425e-7,0.000016867689,0.00002642686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99238575,0.00036870164,0.0066644954,0.00024939948,0.00012800559,0.00020365606],"domain_scores_gemma":[0.97795326,0.0039975815,0.017057488,0.00028646865,0.00052706955,0.00017813173],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021113312,0.00012893102,0.0023168048,0.000152113,0.00018061754,0.00003586708,0.00028407466,0.0004971695,0.00014257214],"category_scores_gemma":[0.010859877,0.00013038056,0.00019137928,0.000039606868,0.00042243986,0.00039361784,0.000106191554,0.0006182929,0.0000019323925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022360939,0.00009753798,0.919927,0.0002567728,0.0004387171,0.0000019832967,0.0024420223,0.0008345335,0.000017438944,0.0031545337,0.00026029596,0.07234556],"study_design_scores_gemma":[0.004047504,0.001412573,0.9642518,0.00078935776,0.00016063631,0.000012078772,0.0021076016,0.009507046,0.000021621674,0.00988596,0.007577243,0.00022658201],"about_ca_topic_score_codex":0.0050092065,"about_ca_topic_score_gemma":0.0017969032,"teacher_disagreement_score":0.07211898,"about_ca_system_score_codex":0.00026860437,"about_ca_system_score_gemma":0.0009313579,"threshold_uncertainty_score":0.99747205},"labels":[],"label_agreement":null},{"id":"W2890657694","doi":"10.1200/jco.2017.35.15_suppl.10503","title":"Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Chemotherapy; Neurofibromatosis; Internal medicine; Oncology; Glioma; Cohort; Targeted therapy; Pathology; Cancer research; Cancer","score_opus":0.08349145367884152,"score_gpt":0.46471313919468876,"score_spread":0.38122168551584723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890657694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95640975,0.00017480609,0.000107695596,0.04220861,0.00059416704,0.00025991802,0.0000070994797,0.0000035146372,0.00023442351],"genre_scores_gemma":[0.9952328,0.00023924088,0.0026070673,0.0011303008,0.00074801984,0.000006452601,5.466879e-7,0.000012673781,0.00002287791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978928,0.0002825745,0.0012140438,0.00016072424,0.00029548994,0.00015435317],"domain_scores_gemma":[0.9965051,0.001373546,0.0008877016,0.00033392926,0.0003244018,0.0005753174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002303286,0.00010597352,0.0009577541,0.00021274324,0.00006483853,0.000018798513,0.00016380164,0.00016969745,0.000029423689],"category_scores_gemma":[0.0060189473,0.00007590048,0.00026021342,0.00009432447,0.00008347114,0.000057922174,0.000060748076,0.00023221924,0.000006986321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027013913,0.008942611,0.8481552,0.000053072145,0.0011019971,0.004331394,0.00039911814,0.00011082766,0.050143752,0.00028484946,0.008719198,0.050744038],"study_design_scores_gemma":[0.010425373,0.015847055,0.96138805,0.00005375341,0.00037556267,0.00012175931,0.000031175034,0.000023822817,0.005451704,0.000090629335,0.006120786,0.000070321184],"about_ca_topic_score_codex":0.000014006631,"about_ca_topic_score_gemma":0.00001378206,"teacher_disagreement_score":0.11323283,"about_ca_system_score_codex":0.000054758046,"about_ca_system_score_gemma":0.00058100576,"threshold_uncertainty_score":0.7205677},"labels":[],"label_agreement":null},{"id":"W2890672884","doi":"10.1200/jco.2018.36.15_suppl.tps9600","title":"A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Saskatchewan; Cancer Care Ontario; Queen's University; McMaster University; Horizon Health Network; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Clinical endpoint; Adverse effect; Internal medicine; Clinical trial; Quality of life (healthcare); Population; Randomized controlled trial; Oncology; Melanoma; Phases of clinical research; Surgery","score_opus":0.4135943830261517,"score_gpt":0.6025961119743353,"score_spread":0.18900172894818357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890672884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908162,0.00028385612,0.00008139072,0.0016763929,0.0014414066,0.005007891,0.000007751404,0.000005731908,0.00067943323],"genre_scores_gemma":[0.99641633,0.0010858853,0.00044074553,0.00045343718,0.0013553634,0.00004075859,0.0000041229805,0.000035247205,0.0001680868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9568275,0.026359808,0.014822139,0.00041671228,0.0011250443,0.00044879434],"domain_scores_gemma":[0.9609269,0.029073255,0.0069691134,0.0006069848,0.0015776065,0.0008461367],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1369045,0.00028017137,0.009901096,0.0009769445,0.00005676456,0.000014909962,0.00046696293,0.00042889506,0.002096061],"category_scores_gemma":[0.043184906,0.00018169342,0.0014476358,0.0006318744,0.0008796519,0.00014919422,0.000050317103,0.0016172768,0.00000813477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7258633,0.04916473,0.0925053,0.000022727452,0.0053163664,0.0010410809,0.003384139,0.0000032175985,0.003164916,0.000027811351,0.0005511156,0.11895532],"study_design_scores_gemma":[0.75700635,0.16248056,0.07291431,0.00007209872,0.00128714,0.00008107408,0.00421162,0.00027757246,0.00018352507,0.00018627624,0.0011714671,0.00012801522],"about_ca_topic_score_codex":0.014626968,"about_ca_topic_score_gemma":0.0714086,"teacher_disagreement_score":0.118827306,"about_ca_system_score_codex":0.00022094577,"about_ca_system_score_gemma":0.004463251,"threshold_uncertainty_score":0.99881613},"labels":[],"label_agreement":null},{"id":"W2890676324","doi":"10.1200/jco.2017.35.15_suppl.3604","title":"Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Cetuximab; Internal medicine; Oncology; Colorectal cancer; Adverse effect; Single-nucleotide polymorphism; FOLFIRI; Population; Cancer; Genotype; Oxaliplatin; Genetics","score_opus":0.09206851080191718,"score_gpt":0.4119960083812368,"score_spread":0.3199274975793196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890676324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928933,0.0031386074,0.000009722282,0.0005121057,0.00048858754,0.00035407304,0.0000226764,0.000004603731,0.0025763444],"genre_scores_gemma":[0.99658144,0.002126128,0.00036693297,0.0001783484,0.00016234172,0.000007781511,0.0000022415823,0.000018881386,0.00055590103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971694,0.00015783642,0.0018455256,0.00019168528,0.0004004607,0.0002351364],"domain_scores_gemma":[0.9942757,0.000752602,0.0035954588,0.0003283023,0.00087856577,0.0001693966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005038457,0.00020139203,0.0022811485,0.00006927667,0.00010572938,0.000007828706,0.00023043636,0.00023015111,0.00008773994],"category_scores_gemma":[0.00051431725,0.00011929078,0.00038664238,0.000056928555,0.00075036637,0.00008581508,0.0000725515,0.00039348737,0.0000016973419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01639845,0.0024250855,0.91831285,0.000059718303,0.00117959,0.00023871363,0.00032444988,0.000007943531,0.000105811625,0.000021360856,0.0001656655,0.06076034],"study_design_scores_gemma":[0.021071251,0.06437291,0.9108904,0.00019971632,0.00091523596,0.0000322279,0.00026001118,0.000046863162,0.00053807633,0.00005070241,0.001526712,0.000095890486],"about_ca_topic_score_codex":0.00017540643,"about_ca_topic_score_gemma":0.00026874334,"teacher_disagreement_score":0.06194783,"about_ca_system_score_codex":0.00014606239,"about_ca_system_score_gemma":0.0007540345,"threshold_uncertainty_score":0.48645368},"labels":[],"label_agreement":null},{"id":"W2890697824","doi":"10.1200/jco.2016.34.15_suppl.3564","title":"Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Internal medicine; Colorectal cancer; Gastroenterology; Adverse effect; Irinotecan; Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.20684317347930398,"score_gpt":0.5463825819132724,"score_spread":0.3395394084339684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890697824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956406,0.00022104921,0.00001864693,0.0010625726,0.0020213502,0.0008891489,0.000042367563,0.000007584301,0.00009669246],"genre_scores_gemma":[0.998714,0.0004644191,0.000100371064,0.00037831496,0.00019841663,0.00006028095,0.0000029159746,0.000028037119,0.000053233132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950501,0.0015033911,0.0022290603,0.0003997932,0.0004276971,0.00039001307],"domain_scores_gemma":[0.9946307,0.0014789698,0.0025718668,0.00014817658,0.00089567126,0.00027459496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016721283,0.0002794527,0.0014950045,0.0002888478,0.000072159455,0.000007861043,0.000300681,0.00042853729,0.00018639702],"category_scores_gemma":[0.00034688145,0.0001651911,0.00013081776,0.00037025928,0.00039663533,0.00034109858,0.00008272786,0.0010234358,0.0000024966548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06885166,0.048359364,0.67801017,0.000029362976,0.00030514432,0.00033228289,0.00043168696,0.000055016495,0.001925703,0.000009307051,0.00016117563,0.20152912],"study_design_scores_gemma":[0.18644425,0.07360409,0.73315126,0.0004147984,0.00027708945,0.000018106168,0.00046818022,0.00009156113,0.0024925526,0.000028741875,0.0027610254,0.00024833984],"about_ca_topic_score_codex":0.00008551061,"about_ca_topic_score_gemma":0.004020323,"teacher_disagreement_score":0.20128077,"about_ca_system_score_codex":0.00046833677,"about_ca_system_score_gemma":0.0010362224,"threshold_uncertainty_score":0.67362976},"labels":[],"label_agreement":null},{"id":"W2890699905","doi":"10.1200/jco.2017.35.15_suppl.e18148","title":"The impact of mild left ventricular dysfunction on trastuzumab use and oncologic outcomes in early stage breast cancer therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Ejection fraction; Trastuzumab; Discontinuation; Internal medicine; Heart failure; Stage (stratigraphy); Cancer; Oncology; Surgery","score_opus":0.15195770627723926,"score_gpt":0.47709520560439317,"score_spread":0.3251374993271539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890699905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943523,0.00021377466,0.000009557738,0.004514691,0.0004943863,0.00024688305,0.000008909125,0.0000030586818,0.00015645352],"genre_scores_gemma":[0.9948497,0.0041581825,0.000038311562,0.00042552018,0.0003604853,0.0000024043359,5.0701885e-7,0.000009573203,0.00015534928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809843,0.00030950323,0.0010414623,0.0001290381,0.00025751107,0.00016407145],"domain_scores_gemma":[0.996165,0.0015985608,0.0016117938,0.00024126764,0.00024029647,0.00014312651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021448089,0.0001194542,0.0010011115,0.00007935785,0.00010549407,0.000031430736,0.00013569676,0.00031431008,0.000032354114],"category_scores_gemma":[0.0014635628,0.00006075291,0.00052522344,0.000037975897,0.00022335882,0.00018884517,0.000019459789,0.0007499983,8.5875183e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006169668,0.0008964393,0.8937429,0.000005935468,0.00051779934,0.00013913812,0.00012305148,0.0000499867,0.002219701,0.000016499467,0.00018725384,0.09593158],"study_design_scores_gemma":[0.009425185,0.009329905,0.97863626,0.00007696563,0.00007158733,0.00013706337,0.00005786979,0.000030789924,0.001008981,0.00009361109,0.0010767295,0.000055070206],"about_ca_topic_score_codex":0.00049792253,"about_ca_topic_score_gemma":0.00021106543,"teacher_disagreement_score":0.095876515,"about_ca_system_score_codex":0.0003043091,"about_ca_system_score_gemma":0.00072614616,"threshold_uncertainty_score":0.32584113},"labels":[],"label_agreement":null},{"id":"W2890710292","doi":"10.1200/jco.2017.35.15_suppl.5581","title":"Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cancer; Pathology; Immunotherapy","score_opus":0.08087035136110318,"score_gpt":0.41750179391872866,"score_spread":0.33663144255762545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890710292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947114,0.00018246955,0.0000022679924,0.004062537,0.00040861897,0.00054279255,0.000011055557,0.0000026255318,0.00007623201],"genre_scores_gemma":[0.9969967,0.0019698206,0.000051501054,0.0006960008,0.00021523054,0.000013394229,0.000008203379,0.0000104507435,0.00003868901],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974804,0.00041854376,0.0015972317,0.00015320197,0.00018816278,0.00016246544],"domain_scores_gemma":[0.9968011,0.00026058976,0.0024813653,0.00025532788,0.00014413199,0.000057483863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015827084,0.00012692744,0.0010598078,0.0001339184,0.000085299376,0.000013798854,0.00023583797,0.00028229252,0.000037476944],"category_scores_gemma":[0.00041552438,0.000070109956,0.00013167992,0.00010315483,0.00031469006,0.00014217135,0.000037644015,0.00054579356,2.9386544e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4806172,0.005884933,0.27594602,0.000022944767,0.00031540607,0.00013000522,0.00044393333,0.0000013091268,0.0049031875,0.000011250171,0.000024104707,0.23169972],"study_design_scores_gemma":[0.24432895,0.033463724,0.72059876,0.00012305712,0.00011898223,0.00003256879,0.000033896853,0.000010611182,0.00008120094,0.000017832968,0.0011361436,0.000054278447],"about_ca_topic_score_codex":0.00083940505,"about_ca_topic_score_gemma":0.00037212495,"teacher_disagreement_score":0.44465274,"about_ca_system_score_codex":0.00017655532,"about_ca_system_score_gemma":0.0006094724,"threshold_uncertainty_score":0.2859001},"labels":[],"label_agreement":null},{"id":"W2890722161","doi":"10.1200/jco.2017.35.15_suppl.e18030","title":"Patterns of unavoidable and potentially avoidable hospitalizations among cancer patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Queen's University; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Multivariate analysis; Malignancy; Cancer; Palliative care; Emergency medicine; Health care; Hematologic malignancy; Internal medicine; Pediatrics","score_opus":0.20371336723941705,"score_gpt":0.5270508716774222,"score_spread":0.32333750443800513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890722161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403965,0.0006235735,0.00034066525,0.0015708396,0.000863998,0.00012621295,0.000018135896,0.0000023415012,0.0024145886],"genre_scores_gemma":[0.9926995,0.0048689228,0.0013004674,0.0002532792,0.0003525291,0.0000022199881,0.0000027371398,0.000009709649,0.00051060633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799544,0.000111920104,0.001405206,0.00010860141,0.00024767197,0.0001311662],"domain_scores_gemma":[0.9953144,0.0005579955,0.0027340532,0.0001900554,0.0010049813,0.0001984692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084974716,0.0000846774,0.0010394282,0.00006753669,0.00006773509,0.000008942872,0.00016551788,0.00021365331,0.00011986778],"category_scores_gemma":[0.004617205,0.00006168205,0.00022930458,0.000033520206,0.00025244307,0.00017591291,0.00007247485,0.0003188367,0.0000010303826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032094985,0.0007050411,0.9826659,0.00007308315,0.00026741318,0.00003371304,0.0001809456,0.000010494805,0.000060189042,0.000091742564,0.0012719672,0.014318586],"study_design_scores_gemma":[0.0041636806,0.004025118,0.9698856,0.00067506713,0.00035549325,0.0000032107387,0.00013336317,0.000032547174,0.0004924111,0.00014900335,0.020028064,0.00005646383],"about_ca_topic_score_codex":0.00047280052,"about_ca_topic_score_gemma":0.00030614808,"teacher_disagreement_score":0.018756095,"about_ca_system_score_codex":0.000042997734,"about_ca_system_score_gemma":0.00055796746,"threshold_uncertainty_score":0.5527559},"labels":[],"label_agreement":null},{"id":"W2890726222","doi":"10.1200/jco.2017.35.15_suppl.7041","title":"Emotion and Symptom-focused Engagement (EASE): A randomized pilot trial of an integrated psychosocial and palliative care intervention for individuals with acute leukemia (AL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychosocial; Palliative care; Randomized controlled trial; Population; Distress; Physical therapy; Clinical endpoint; Quality of life (healthcare); Intervention (counseling); Psychological intervention; Clinical psychology; Psychiatry; Internal medicine; Nursing","score_opus":0.11748264553029597,"score_gpt":0.4836153645537564,"score_spread":0.36613271902346045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890726222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300784,0.0002162352,0.0019234208,0.002108112,0.0012728721,0.0012535915,0.000035489196,0.000005651875,0.00017678029],"genre_scores_gemma":[0.9958473,0.00061189843,0.0024525337,0.00031333385,0.00066667685,0.000039075825,0.00002093654,0.000013977484,0.000034300145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968537,0.0009912779,0.0015468907,0.00019829297,0.0002789792,0.00013082605],"domain_scores_gemma":[0.99440575,0.0014518787,0.0030456397,0.00017029655,0.00071279163,0.00021364697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051943683,0.00014101708,0.0018191296,0.00010089611,0.00011306144,0.00003481941,0.00012267144,0.00021855992,0.00001839085],"category_scores_gemma":[0.0030148267,0.000089892914,0.00037353343,0.00003687883,0.00042949134,0.00017289199,0.00003790254,0.0005455241,1.5359706e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.817576,0.00065615977,0.0061189346,0.00008361302,0.0014014856,0.000028063001,0.002295307,4.5068685e-7,0.000025073332,0.0000903421,0.00020224412,0.1715223],"study_design_scores_gemma":[0.8740068,0.07000117,0.04629658,0.0004896182,0.0024045007,0.000018533237,0.0021417807,0.00007237675,0.000057818754,0.0003710093,0.0040394478,0.00010035616],"about_ca_topic_score_codex":0.00017913128,"about_ca_topic_score_gemma":0.00067809824,"teacher_disagreement_score":0.17142196,"about_ca_system_score_codex":0.00014995228,"about_ca_system_score_gemma":0.00081329094,"threshold_uncertainty_score":0.36657268},"labels":[],"label_agreement":null},{"id":"W2890738870","doi":"10.1200/jco.2017.35.15_suppl.10058","title":"Temporal treatments and outcomes following acute myocardial infarction among cancer survivors: A population-based study, 1995-2013.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency; St. Michael's Hospital; Baker Hughes (Canada); Institute for Clinical Evaluative Sciences; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Myocardial infarction; Internal medicine; Percutaneous coronary intervention; Confounding; Prostate cancer; Population; Propensity score matching; Cancer; Cardiology","score_opus":0.08747889048920449,"score_gpt":0.47476045773724335,"score_spread":0.38728156724803886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890738870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281055,0.000054961354,0.000038264,0.004518213,0.0019903162,0.00039965528,0.0000041741073,0.0000107156675,0.00017317383],"genre_scores_gemma":[0.99777097,0.00009902255,0.00038074394,0.0007715648,0.00081382814,0.000011663802,0.0000061475,0.000015909383,0.00013017154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978324,0.00028537022,0.001171325,0.00018775245,0.00036793688,0.00015520774],"domain_scores_gemma":[0.99729425,0.0005105226,0.0015521252,0.00024565973,0.0001554497,0.00024198314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017658486,0.00014630558,0.0013030949,0.00010159098,0.00019682026,0.000039761642,0.00010132556,0.0003152196,0.000017705874],"category_scores_gemma":[0.0009532415,0.000105527884,0.0006477795,0.000041067415,0.00008188984,0.00028160587,0.000027657628,0.00047370573,0.0000013767801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070665625,0.00063409755,0.95900464,0.000005311882,0.0023249185,0.00015054065,0.000110641515,0.000009891645,0.00023278322,0.000001315045,0.00006361139,0.0367556],"study_design_scores_gemma":[0.012641718,0.0033555098,0.98145825,0.00006085623,0.001478637,0.000014467237,0.000098445176,0.00005656508,0.00009377454,0.00006194306,0.00059004803,0.00008981856],"about_ca_topic_score_codex":0.004418245,"about_ca_topic_score_gemma":0.0028919785,"teacher_disagreement_score":0.036665782,"about_ca_system_score_codex":0.00020614488,"about_ca_system_score_gemma":0.00047397564,"threshold_uncertainty_score":0.66790944},"labels":[],"label_agreement":null},{"id":"W2890739427","doi":"10.1200/jco.2018.36.15_suppl.9027","title":"Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; T790M; Medicine; Internal medicine; Oncology; Lung cancer; Clinical trial; Acquired resistance; Gastroenterology; Cancer; Epidermal growth factor receptor; Gefitinib; Erlotinib","score_opus":0.09850696491913635,"score_gpt":0.5246477761164255,"score_spread":0.4261408111972892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890739427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811382,0.000059949958,0.00004060485,0.014719725,0.00067990413,0.00048819225,0.000009216587,0.000002681976,0.0028614865],"genre_scores_gemma":[0.9958647,0.000031358348,0.0018974742,0.0012728041,0.0005442043,0.000012910489,7.16539e-7,0.00000782068,0.0003680474],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99687666,0.00066424045,0.0019127653,0.000104775354,0.0003163939,0.00012514392],"domain_scores_gemma":[0.99422735,0.003786571,0.0011441559,0.00018614244,0.0005095179,0.00014623521],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00310485,0.000072139046,0.0007605774,0.0001515087,0.000026259462,0.0000033413307,0.0001599775,0.0001512154,0.00010038979],"category_scores_gemma":[0.008988893,0.000042214662,0.0002470527,0.00027841105,0.00028061692,0.000061385355,0.000016998492,0.0003222936,0.000020625414],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87728226,0.0074304147,0.035266116,0.00003514464,0.0009553453,0.00031033647,0.01166147,0.000045382614,0.0016175861,0.0005082349,0.00613541,0.05875231],"study_design_scores_gemma":[0.0857962,0.09951436,0.7605327,0.00022249494,0.0006505623,0.00009986519,0.00081897277,0.000032592903,0.0004110106,0.00046477726,0.0514017,0.00005476503],"about_ca_topic_score_codex":0.00006558539,"about_ca_topic_score_gemma":0.000047166355,"teacher_disagreement_score":0.791486,"about_ca_system_score_codex":0.00007800159,"about_ca_system_score_gemma":0.0020287423,"threshold_uncertainty_score":0.99935883},"labels":[],"label_agreement":null},{"id":"W2890760483","doi":"10.1200/jco.2016.34.15_suppl.11585","title":"Prognostic and predictive effects of <i>TP53</i> mutation in patients with <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Stage (stratigraphy); Oncology; Demographics; Cancer; Biology","score_opus":0.013517193474923658,"score_gpt":0.3810150777036595,"score_spread":0.36749788422873586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890760483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641466,0.00044192476,0.00060188153,0.0008564486,0.00038270134,0.00075940765,0.000013015136,0.0000039390657,0.00052599586],"genre_scores_gemma":[0.998262,0.0003158393,0.00085596286,0.00032595225,0.00012715028,0.000026647676,0.0000042233637,0.000014359513,0.00006789082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998323,0.0001473089,0.0010071278,0.00015601587,0.00021129509,0.00015520427],"domain_scores_gemma":[0.9964562,0.0016998624,0.0010906042,0.00008057992,0.00048311087,0.00018964492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036293626,0.00011362274,0.0007642362,0.00011139899,0.000017173401,0.0000028457266,0.000048713522,0.00015515635,0.000011340254],"category_scores_gemma":[0.00063540536,0.0000587378,0.00008882833,0.00012768141,0.00012984902,0.000099683486,0.000016890297,0.00023711582,8.084788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003943021,0.0018572821,0.9514748,0.0001651823,0.0003791395,0.000192212,0.00037278325,0.000021366784,0.0001884949,0.0000026106911,0.00021875254,0.04118435],"study_design_scores_gemma":[0.0330012,0.018310515,0.94520146,0.0011604253,0.00147491,0.0000141583705,0.00003528478,0.00005227732,0.00047109713,0.000029092133,0.0001861711,0.00006343526],"about_ca_topic_score_codex":0.000033351393,"about_ca_topic_score_gemma":0.0000389874,"teacher_disagreement_score":0.041120917,"about_ca_system_score_codex":0.00020166763,"about_ca_system_score_gemma":0.0012727753,"threshold_uncertainty_score":0.23952581},"labels":[],"label_agreement":null},{"id":"W2890761658","doi":"10.1200/jco.2017.35.15_suppl.e18295","title":"Market capitalism in cancer pharmaceuticals.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Formulary; Medicine; Health care; Actuarial science; Family medicine; Business; Economics","score_opus":0.8166737936824948,"score_gpt":0.6758299591783014,"score_spread":0.14084383450419347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890761658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6580189,0.004739967,0.0001840634,0.28163186,0.007783475,0.00027168685,0.00005298235,0.0000068046015,0.0473103],"genre_scores_gemma":[0.9621968,0.0039257403,0.0021211028,0.027190704,0.0030404383,0.000016016538,6.658907e-7,0.000021046639,0.0014874348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98689103,0.0008530982,0.011531504,0.00027943408,0.00010881914,0.0003360979],"domain_scores_gemma":[0.9802909,0.004459139,0.014279482,0.00043535983,0.00014599183,0.00038913518],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07230992,0.00012453263,0.0025049753,0.00022016287,0.00012666646,0.000060235525,0.00071225676,0.00039416572,0.002362489],"category_scores_gemma":[0.042915136,0.00012962703,0.0003543525,0.0000442951,0.0002525515,0.00061828014,0.00009393968,0.0008498399,0.00040884843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003277089,0.00079611264,0.7612494,0.000092437396,0.00021401445,0.000086439104,0.00042055696,0.000043895732,0.0000011946331,0.022475114,0.19622643,0.018066682],"study_design_scores_gemma":[0.0031483276,0.00036682072,0.5356372,0.00006314817,0.0000129387,0.000015625292,0.00010814378,0.0010401997,0.0000010684785,0.016763922,0.4427183,0.00012430949],"about_ca_topic_score_codex":0.00076409365,"about_ca_topic_score_gemma":0.0006812432,"teacher_disagreement_score":0.304178,"about_ca_system_score_codex":0.0005360126,"about_ca_system_score_gemma":0.0010203198,"threshold_uncertainty_score":0.99854946},"labels":[],"label_agreement":null},{"id":"W2890785873","doi":"10.1200/jco.2017.35.15_suppl.5506","title":"Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Placebo; Clinical endpoint; Chemotherapy; Ovarian cancer; Log-rank test; Oncology; Survival analysis; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.1606985941140904,"score_gpt":0.49588457906669337,"score_spread":0.335185984952603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890785873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655836,0.00037410064,0.000003453554,0.027587576,0.001819776,0.00029789,0.000017485021,0.0000015729994,0.0043145125],"genre_scores_gemma":[0.9924762,0.005077382,0.0008345465,0.0003985742,0.0010667689,0.0000043764067,7.885091e-7,0.00001072859,0.0001305941],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99669254,0.00023490733,0.0024660255,0.00017726583,0.00028430772,0.00014493628],"domain_scores_gemma":[0.9942279,0.0014837257,0.0035308865,0.0003261328,0.00024682548,0.0001845729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034694476,0.00010986329,0.0018872677,0.00008599367,0.00002533038,0.0000064082237,0.0001546689,0.00031687977,0.000063562264],"category_scores_gemma":[0.0031143161,0.00007676422,0.00032243744,0.00003936306,0.00026606288,0.00006089436,0.000033745582,0.00045989893,4.0296587e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50211215,0.006472278,0.23154226,0.00007469054,0.0010893428,0.00046910316,0.00032325395,0.000006862315,0.00025289351,0.0005598676,0.00195242,0.25514486],"study_design_scores_gemma":[0.3346093,0.018751469,0.6368999,0.00026537175,0.00023233933,0.000018136905,0.000020668731,0.00001648301,0.00022790136,0.00039177563,0.008518252,0.000048440703],"about_ca_topic_score_codex":0.00076272717,"about_ca_topic_score_gemma":0.0004742679,"teacher_disagreement_score":0.40535763,"about_ca_system_score_codex":0.00010307099,"about_ca_system_score_gemma":0.0013842128,"threshold_uncertainty_score":0.37283522},"labels":[],"label_agreement":null},{"id":"W2890790704","doi":"10.1200/jco.2018.36.15_suppl.6614","title":"A value framework analysis of the Canadian Cancer Trials Group.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Kingston General Hospital; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Cancer; Clinical endpoint; Sample size determination; Internal medicine; Oncology; Surrogate endpoint; Statistical significance; Breast cancer; Statistics","score_opus":0.7965816731755393,"score_gpt":0.6509179693506371,"score_spread":0.14566370382490224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890790704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72081333,0.0031182964,0.0042752875,0.24857304,0.013608215,0.00057253346,0.0003531006,0.0000069005296,0.008679283],"genre_scores_gemma":[0.95169544,0.00035062167,0.0060499953,0.03809965,0.003621102,0.000009063721,0.0000014129408,0.000013718251,0.00015899079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97952145,0.0032259105,0.01653968,0.00024976349,0.00015739248,0.00030581033],"domain_scores_gemma":[0.9576784,0.017138455,0.02373576,0.00049769564,0.00044520962,0.00050448056],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.13947189,0.000118707816,0.0045681405,0.00062740024,0.00016321368,0.000025233043,0.00063158356,0.0006145632,0.0016823806],"category_scores_gemma":[0.12259298,0.000093939256,0.0013777463,0.0007394279,0.00038558323,0.0001621538,0.00004555973,0.00070235104,0.00012097294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022613141,0.00036460592,0.73121524,0.00004141733,0.005626794,0.0000039781157,0.0013147565,0.0005807031,0.0000011121538,0.20483747,0.049354147,0.0064336676],"study_design_scores_gemma":[0.001133302,0.00086187857,0.6310363,0.00007798699,0.0006349613,0.0000035241292,0.00018293597,0.002253431,0.000001755445,0.045882266,0.31780043,0.00013124586],"about_ca_topic_score_codex":0.071206875,"about_ca_topic_score_gemma":0.34633937,"teacher_disagreement_score":0.2751325,"about_ca_system_score_codex":0.0009409471,"about_ca_system_score_gemma":0.0037499098,"threshold_uncertainty_score":0.9992302},"labels":[],"label_agreement":null},{"id":"W2890803263","doi":"10.1200/jco.2016.34.15_suppl.4123","title":"Overall survival of patients with pancreatic adenocarcinoma and <i>BRCA1</i> or <i>BRCA2</i> germline mutation.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Toronto General Hospital; University of Toronto; University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Germline mutation; Pancreatic cancer; Adenocarcinoma; Stage (stratigraphy); Cancer; Gastroenterology; Mutation","score_opus":0.03288781087764063,"score_gpt":0.3430829090600471,"score_spread":0.3101950981824065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890803263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688494,0.0006865646,0.0008051075,0.00084270485,0.00042127594,0.0000998662,0.00004215836,0.0000012870379,0.0002161175],"genre_scores_gemma":[0.99467057,0.0018869509,0.0019376975,0.0007198435,0.00057720253,0.0000018479045,0.000007735779,0.000015861715,0.00018231776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821824,0.0001473562,0.001131698,0.00017791455,0.00017456713,0.00015020992],"domain_scores_gemma":[0.997094,0.00092772243,0.0011601235,0.00016972619,0.0004699197,0.00017855619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007120111,0.00011618163,0.00063895993,0.000035469657,0.000020854339,0.000005784085,0.00014141397,0.00020941481,0.00003192003],"category_scores_gemma":[0.001844844,0.000062193554,0.00012269053,0.000039492807,0.000226651,0.0000082584675,0.000072719165,0.00012509237,0.0000013564979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013593805,0.0010852647,0.9142417,0.000037690956,0.0005369613,0.00009363316,0.000031681946,0.000023070597,0.0039602,0.00020500614,0.0046243593,0.06156667],"study_design_scores_gemma":[0.016331632,0.02334844,0.90764606,0.00007050031,0.0002622054,0.00006663699,0.000023991473,0.0000044291446,0.0016795058,0.00032189075,0.050053433,0.0001912488],"about_ca_topic_score_codex":0.0000069833704,"about_ca_topic_score_gemma":0.00006994915,"teacher_disagreement_score":0.06137542,"about_ca_system_score_codex":0.000022239217,"about_ca_system_score_gemma":0.00071484246,"threshold_uncertainty_score":0.25361797},"labels":[],"label_agreement":null},{"id":"W2890809656","doi":"10.1200/jco.2018.36.15_suppl.e15071","title":"Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Royal Victoria Hospital; McGill University Health Centre; Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Melanoma; Immune system; Immunotherapy; Oncology; Eosinophil; Immune checkpoint; Pembrolizumab; Cancer research; Immunology; Internal medicine","score_opus":0.05367705653353559,"score_gpt":0.370737021129612,"score_spread":0.3170599645960764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890809656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979951,0.000066624394,0.00008498789,0.0004835214,0.0008298912,0.00018506033,0.000015845539,0.0000062599934,0.0003327257],"genre_scores_gemma":[0.99658215,0.00024465504,0.0017413908,0.00039518377,0.0008409961,0.000001222679,0.000031635078,0.000016249705,0.00014651561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970295,0.00009656473,0.0023445217,0.00013160327,0.00025851533,0.00013932917],"domain_scores_gemma":[0.99608576,0.0002710474,0.0026330024,0.0001605397,0.00071168545,0.00013797382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064347807,0.000121611825,0.0010476877,0.000092824914,0.000028227532,0.000004655139,0.00009965709,0.0003030733,0.00034415358],"category_scores_gemma":[0.0003883665,0.00007470309,0.00031344738,0.00013437269,0.00032842383,0.00010108738,0.000020471005,0.0003375555,0.000011870137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081183,0.0035720952,0.4081694,0.00002021236,0.0011646792,0.00020267912,0.00032981957,1.2146572e-7,0.30507302,9.658075e-7,0.00011444479,0.2001696],"study_design_scores_gemma":[0.01878106,0.03818292,0.88501316,0.00024035979,0.00028892976,0.00016003328,0.000039112452,0.000049803824,0.047899656,0.0000049764717,0.009253686,0.000086323234],"about_ca_topic_score_codex":0.00011745734,"about_ca_topic_score_gemma":0.00004482459,"teacher_disagreement_score":0.47684377,"about_ca_system_score_codex":0.00012400192,"about_ca_system_score_gemma":0.00049579865,"threshold_uncertainty_score":0.37682402},"labels":[],"label_agreement":null},{"id":"W2890810711","doi":"10.1200/jco.2018.36.15_suppl.4090","title":"Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Etiology; Sorafenib; Gastroenterology; Cabozantinib; Placebo; Incidence (geometry); Cancer; Pathology","score_opus":0.18898254622279195,"score_gpt":0.43087232621092614,"score_spread":0.24188977998813418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890810711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946424,0.000029772358,0.000018440607,0.0014326863,0.0010419302,0.0012467573,0.000006134962,0.000004695498,0.0015772207],"genre_scores_gemma":[0.9978617,0.000016192365,0.0009176062,0.00061854406,0.0005086032,0.000022098915,0.000013860943,0.000021114432,0.000020315047],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955102,0.0010316543,0.0022177873,0.0002539103,0.00067178893,0.000314625],"domain_scores_gemma":[0.99422574,0.0035954788,0.0013409609,0.0003336727,0.00030201164,0.00020216522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030203643,0.00023121339,0.0017766223,0.00024419458,0.00003284234,0.0000071253507,0.0002480185,0.00032892727,0.00006489647],"category_scores_gemma":[0.0025255748,0.00012813299,0.0004339131,0.00031530534,0.00033343417,0.00007611575,0.000023324148,0.0008339545,0.000008762083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36344826,0.008043105,0.61064947,0.0000132088235,0.000070335795,0.0015584254,0.00014326566,0.0000022536663,0.000010946411,0.000009090617,0.00007983562,0.01597182],"study_design_scores_gemma":[0.47422147,0.15447402,0.36707672,0.00009330514,0.00028432647,0.0000067274696,0.00007392636,0.0006683065,0.00019546684,0.00000807427,0.0027990239,0.00009864008],"about_ca_topic_score_codex":0.000052635467,"about_ca_topic_score_gemma":0.00019003823,"teacher_disagreement_score":0.24357274,"about_ca_system_score_codex":0.00013033292,"about_ca_system_score_gemma":0.0010478189,"threshold_uncertainty_score":0.5225112},"labels":[],"label_agreement":null},{"id":"W2890817079","doi":"10.1200/jco.2017.35.15_suppl.11607","title":"A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Biomarker; Breast cancer; Triple-negative breast cancer; Oncology; Cancer; Melanoma; Ovarian cancer; Internal medicine; Cancer research; Immunotherapy; Biology","score_opus":0.5247670049047602,"score_gpt":0.5941794047374243,"score_spread":0.069412399832664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890817079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98184204,0.0012384607,0.000008428363,0.013777447,0.0014846561,0.001184925,0.000011446839,0.00001490374,0.00043770892],"genre_scores_gemma":[0.9973373,0.0003823298,0.00027726075,0.001477921,0.00042254152,0.0000247355,0.000004142842,0.00001350009,0.000060282302],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9898346,0.004579598,0.004009787,0.00038997433,0.0009776966,0.00020834037],"domain_scores_gemma":[0.97819644,0.0113163795,0.007158104,0.0012509958,0.0018368068,0.00024127841],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02572631,0.00022437386,0.0019909288,0.000088574336,0.00042678165,0.000016023496,0.0005122675,0.00050273235,0.00011276119],"category_scores_gemma":[0.14652212,0.000120266195,0.0006449607,0.0001295821,0.0018956916,0.0001445488,0.00021795857,0.0016261323,0.0000032068306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71609557,0.027126562,0.1210025,0.000010578811,0.0036729048,0.001995075,0.0017284455,0.000006856746,0.008616276,0.000017959552,0.0044769505,0.11525036],"study_design_scores_gemma":[0.06302256,0.13875502,0.79107255,0.00024061775,0.001202201,0.00038244738,0.0015698994,0.000055200984,0.00023946355,0.0005583742,0.0027985391,0.00010309975],"about_ca_topic_score_codex":0.00010122973,"about_ca_topic_score_gemma":0.000114473136,"teacher_disagreement_score":0.67007005,"about_ca_system_score_codex":0.00059238944,"about_ca_system_score_gemma":0.0036514343,"threshold_uncertainty_score":0.8916277},"labels":[],"label_agreement":null},{"id":"W2890828988","doi":"10.1200/jco.2018.36.15_suppl.e16265","title":"A stage versus stage survival analysis of small bowel and colon adenocarcinomas using the SEER database.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Colorectal cancer; Gastroenterology; Univariate analysis; Adenocarcinoma; Multivariate analysis; Oncology; Survival analysis; T-stage; Cancer","score_opus":0.38723454753340275,"score_gpt":0.5274973115644233,"score_spread":0.1402627640310205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890828988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962001,0.0002533221,0.0006596222,0.0015643229,0.00033194895,0.00016001063,0.000034587396,0.0000031567038,0.0007929282],"genre_scores_gemma":[0.9915827,0.00011576395,0.0073327166,0.00016849293,0.00044284447,9.0495627e-7,0.000005764523,0.000009846445,0.00034096205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972606,0.0005900848,0.0012726511,0.00017749783,0.0004341136,0.00026508354],"domain_scores_gemma":[0.9942649,0.003309708,0.0010869086,0.000278269,0.00065372046,0.00040647297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038896308,0.00011784569,0.0011640606,0.00017635878,0.00006255357,0.000010188002,0.00015872579,0.0000884392,0.00021976812],"category_scores_gemma":[0.0044653714,0.000066731685,0.00038762137,0.00034024153,0.00070641865,0.000056132674,0.00013046346,0.0006309321,0.0000030540807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026352784,0.0014971625,0.9592967,0.00004820445,0.0049631298,0.0026144378,0.0001298631,0.00003310102,0.0014178274,0.00026421706,0.0002215511,0.003161041],"study_design_scores_gemma":[0.01074216,0.036861684,0.9382358,0.000059100443,0.0048283986,0.00021815274,0.0007406495,0.00397256,0.0001872279,0.000016367036,0.0040691565,0.00006872027],"about_ca_topic_score_codex":0.00023262187,"about_ca_topic_score_gemma":0.0007284937,"teacher_disagreement_score":0.035364524,"about_ca_system_score_codex":0.000110908855,"about_ca_system_score_gemma":0.001034541,"threshold_uncertainty_score":0.5345789},"labels":[],"label_agreement":null},{"id":"W2890829740","doi":"10.1200/jco.2017.35.15_suppl.6067","title":"Resource utilization in patients with head and neck cancer: Analysis of CCTG HN6 (NCT00820248).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; Hôpital Maisonneuve-Rosemont; Queen's University","funders":"","keywords":"Medicine; Head and neck cancer; Head and neck squamous-cell carcinoma; Internal medicine; Cancer","score_opus":0.6322084171309365,"score_gpt":0.5876787781340351,"score_spread":0.04452963899690132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890829740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823834,0.0008606102,0.00019761136,0.014466828,0.00040148894,0.00017162935,0.000055972134,0.000002107679,0.0014603998],"genre_scores_gemma":[0.9958978,0.0005522151,0.0011742013,0.0020584336,0.0002186905,0.000004154672,0.000005567929,0.000010512324,0.000078407575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99175096,0.00045269707,0.007253409,0.000249099,0.0001144381,0.00017941106],"domain_scores_gemma":[0.9832308,0.0018461568,0.014166537,0.00035784545,0.00021344649,0.000185164],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018987725,0.000100757,0.0025046074,0.00049509975,0.00008848694,0.000028601253,0.00029428976,0.00024663203,0.00012678238],"category_scores_gemma":[0.011390173,0.000095599775,0.00019783064,0.00017862076,0.00019565794,0.00036332323,0.00005514391,0.00033179452,0.000009711781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003696975,0.00037129474,0.9894231,0.000037043497,0.0005044456,0.0000018549088,0.00022014476,0.00042127128,3.234817e-8,0.0016381375,0.001126428,0.00588654],"study_design_scores_gemma":[0.0038844955,0.0012978627,0.9634298,0.00007839281,0.000136587,5.958388e-7,0.00008010832,0.001977962,1.9789768e-7,0.00070201914,0.028324544,0.00008741694],"about_ca_topic_score_codex":0.0007593292,"about_ca_topic_score_gemma":0.0026029649,"teacher_disagreement_score":0.027198117,"about_ca_system_score_codex":0.00024050896,"about_ca_system_score_gemma":0.00042911392,"threshold_uncertainty_score":0.99693733},"labels":[],"label_agreement":null},{"id":"W2890837116","doi":"10.1200/jco.18.00374","title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Immunosuppression; Internal medicine; Intensive care medicine; Antibiotic prophylaxis; Neutropenia; Immunology; Chemotherapy; Antibiotics; Pathology","score_opus":0.09569353173144673,"score_gpt":0.5292164824563593,"score_spread":0.4335229507249126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890837116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002515822,0.97442853,0.00013536638,0.00684819,0.0119709615,0.00304238,0.0001551593,0.0000373264,0.00086626917],"genre_scores_gemma":[0.00007878841,0.97251976,0.017027756,0.0048777424,0.0051033455,0.000052715415,0.00007149849,0.00008438583,0.00018400066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889074,0.0012767538,0.008416275,0.00058364973,0.0004399931,0.00037593395],"domain_scores_gemma":[0.9789765,0.004052703,0.009778429,0.000443063,0.006193373,0.00055593264],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004566975,0.00046072892,0.0062158788,0.00015413418,0.00013959093,0.000032246684,0.0003175279,0.0016726878,0.00016949595],"category_scores_gemma":[0.010814541,0.0002621726,0.001541983,0.00028307148,0.00053887157,0.0002642661,0.00014366917,0.003062105,0.000026935424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054927226,0.0029296787,0.0011639331,0.0017608689,0.0029887639,0.00013672456,0.000011530892,2.1877047e-7,1.5559398e-7,0.000014290204,0.13754381,0.8479573],"study_design_scores_gemma":[0.013521222,0.030116074,0.0006496636,0.008103664,0.012014173,0.00104829,0.0000069076946,0.0000018343898,5.1167376e-7,0.0000120869045,0.9342631,0.0002624565],"about_ca_topic_score_codex":0.000019202918,"about_ca_topic_score_gemma":0.000017020036,"teacher_disagreement_score":0.8476948,"about_ca_system_score_codex":0.00024638866,"about_ca_system_score_gemma":0.0075366097,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W2890860192","doi":"10.1200/jco.2018.36.15_suppl.e18617","title":"Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Proportional hazards model; Percentile; Medicaid; Breast cancer; Internal medicine; Demography; Population; Survival analysis; Cancer; Multivariate analysis; Metastatic breast cancer; Oncology; Gynecology; Health care; Environmental health; Statistics","score_opus":0.1593955461301674,"score_gpt":0.4502000907970359,"score_spread":0.29080454466686845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890860192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536467,0.00010491473,0.00005635951,0.0011785609,0.0020928148,0.00019044145,0.0007785483,0.0000012336654,0.00023244321],"genre_scores_gemma":[0.9974376,0.00061255397,0.00054104446,0.0012277629,0.00014640404,0.0000031934374,0.0000057033003,0.00001434736,0.000011389051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925788,0.00017168073,0.006571906,0.00024354339,0.000092771916,0.00034128525],"domain_scores_gemma":[0.99295115,0.0018820765,0.00419029,0.00015190455,0.00043297085,0.00039157434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027786207,0.00015609416,0.0034954355,0.00040651113,0.000018658746,0.000010265362,0.00026931489,0.00012986893,0.00005862342],"category_scores_gemma":[0.004620389,0.000150305,0.00013190496,0.0003479968,0.00016555964,0.00016661827,0.00009761477,0.0004611772,0.0000060722987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017905468,0.0007397543,0.97721547,0.000025479005,0.0001084769,0.000006228034,0.00037831668,0.00025253455,6.9791304e-7,0.0002425027,0.00021937948,0.01902061],"study_design_scores_gemma":[0.0035510976,0.0018331333,0.9886166,0.000102426755,0.000014729923,9.321524e-7,0.0004127485,0.00047171838,0.0000039793663,0.00035803445,0.0044902973,0.0001443454],"about_ca_topic_score_codex":0.33927348,"about_ca_topic_score_gemma":0.54289216,"teacher_disagreement_score":0.20361869,"about_ca_system_score_codex":0.0004171486,"about_ca_system_score_gemma":0.0015824243,"threshold_uncertainty_score":0.6651263},"labels":[],"label_agreement":null},{"id":"W2890864638","doi":"10.1200/jco.2017.35.15_suppl.3516","title":"Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Vitamin D and neurology; Hazard ratio; FOLFOX; Proportional hazards model; Cetuximab; Colorectal cancer; Cancer; Confidence interval; Oxaliplatin","score_opus":0.09333574250023492,"score_gpt":0.4243236335858297,"score_spread":0.3309878910855948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890864638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963829,0.00036500205,0.0000029257262,0.0018847848,0.00012526715,0.00037856845,0.00004943843,0.0000036248127,0.0008074897],"genre_scores_gemma":[0.99834746,0.00067821593,0.00033061794,0.00025337227,0.00008047559,0.000012086268,0.000002995228,0.000013978258,0.00028079923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752456,0.00014612901,0.0015120184,0.00025919755,0.00032107794,0.00023701231],"domain_scores_gemma":[0.996311,0.00047479614,0.0022898805,0.00023180465,0.0005012961,0.00019122064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008741675,0.00018945844,0.002659076,0.00019203586,0.00008753788,0.000013451114,0.00014844778,0.00021766275,0.00006788113],"category_scores_gemma":[0.0005033246,0.00011693734,0.00033693435,0.00021050696,0.00036699514,0.00012350058,0.00006258156,0.0003667018,4.2667926e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008247919,0.0024285587,0.88928473,0.00003206745,0.0027912797,0.0003214599,0.00030388386,0.0000029314988,0.000024264404,0.0000030407966,0.000053435724,0.096506424],"study_design_scores_gemma":[0.027217321,0.027471181,0.94134146,0.00011396703,0.002568032,0.000009063847,0.00014984186,0.00012085142,0.0001993305,0.000004883119,0.0007048505,0.00009921602],"about_ca_topic_score_codex":0.00023518036,"about_ca_topic_score_gemma":0.002141227,"teacher_disagreement_score":0.096407205,"about_ca_system_score_codex":0.00021166448,"about_ca_system_score_gemma":0.00043853204,"threshold_uncertainty_score":0.47685665},"labels":[],"label_agreement":null},{"id":"W2890892063","doi":"10.1200/jco.2018.36.15_suppl.11007","title":"Creation of a high-fidelity simulation tool to teach competency in radiation oncology treatment plan evaluation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Likert scale; DICOM; Medical physics; Action plan; Plan (archaeology); Conformity; Medical education; Radiology; Psychology","score_opus":0.1328424372123982,"score_gpt":0.576173018798992,"score_spread":0.4433305815865938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890892063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97983575,0.00026946136,0.007944034,0.0063236007,0.0020405329,0.00069703825,0.0000044993017,0.0000075655316,0.0028775122],"genre_scores_gemma":[0.96379995,0.00043922948,0.031154312,0.0020052583,0.0024829458,0.00001361739,0.000013178288,0.000009871173,0.00008162562],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954308,0.0011551485,0.002676159,0.00021235424,0.00035119537,0.00017429258],"domain_scores_gemma":[0.99292886,0.0038610925,0.0018714489,0.00020269043,0.000971553,0.00016433063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057633743,0.00012519429,0.0013875881,0.00027837345,0.00004403951,0.0000022579932,0.00010470898,0.000523117,0.00035670714],"category_scores_gemma":[0.006306887,0.00009124827,0.0002013556,0.00022933619,0.00026513843,0.00013564517,0.000014516646,0.00039643398,0.000015758666],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010653345,0.003201938,0.08941642,0.000009004838,0.00020649716,0.000045107234,0.0006705267,0.008644018,0.0004125037,0.00042371365,0.00053949247,0.8857774],"study_design_scores_gemma":[0.02097722,0.0746539,0.75423026,0.0000697924,0.0003827359,0.000100873476,0.000134217,0.01325392,0.00020552234,0.0031687976,0.13271417,0.000108593675],"about_ca_topic_score_codex":0.000044906654,"about_ca_topic_score_gemma":0.00022098924,"teacher_disagreement_score":0.8856688,"about_ca_system_score_codex":0.001530922,"about_ca_system_score_gemma":0.003264594,"threshold_uncertainty_score":0.75503886},"labels":[],"label_agreement":null},{"id":"W2890907759","doi":"10.1200/jco.2017.35.15_suppl.e22505","title":"Limb salvage surgery in pediatric and AYA patients with osteosarcoma: The incidence of venous thrombosis (VT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Medicine; Amputation; Incidence (geometry); Surgery; Osteosarcoma; Venous thrombosis; Sarcoma; Retrospective cohort study; Thrombosis","score_opus":0.1063530403173477,"score_gpt":0.4247975552246514,"score_spread":0.3184445149073037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890907759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925833,0.0012170927,0.0000011543622,0.005361098,0.0003566725,0.00017601244,0.0000021763576,0.0000017598755,0.0003007334],"genre_scores_gemma":[0.9952231,0.003671078,0.00031175918,0.00045876086,0.00031601297,0.000004104416,7.017957e-7,0.000009454914,0.0000050264907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779147,0.0002469962,0.0013433136,0.00013249491,0.00032236148,0.0001633764],"domain_scores_gemma":[0.991426,0.005644384,0.0022078203,0.00030650775,0.0002615669,0.00015373308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020775464,0.000104377126,0.0012466925,0.00010519939,0.00007277364,0.000012100338,0.00017163262,0.00016116879,0.00001509414],"category_scores_gemma":[0.0042669345,0.000052612195,0.00022117251,0.0000684236,0.00029111706,0.00011096724,0.000082702565,0.00046189217,0.0000030555545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093508617,0.004140829,0.94359595,0.00002360768,0.00011544408,0.0003820855,0.00006786488,5.289272e-7,0.0000010533372,0.000010813395,0.0004583142,0.050268404],"study_design_scores_gemma":[0.004592847,0.0072650537,0.98683,0.00010435239,0.00045222457,0.00006280366,0.000032964497,0.0000024685305,0.000010803254,0.00008070225,0.0005172116,0.00004858185],"about_ca_topic_score_codex":0.000076985234,"about_ca_topic_score_gemma":0.00016247042,"teacher_disagreement_score":0.050219823,"about_ca_system_score_codex":0.000054667616,"about_ca_system_score_gemma":0.0006052247,"threshold_uncertainty_score":0.5108227},"labels":[],"label_agreement":null},{"id":"W2890914022","doi":"10.1200/jco.2017.35.15_suppl.e18234","title":"Early integration of palliative care in Ontario cancer settings.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Palliative care; Medicine; Multidisciplinary approach; Advance care planning; Family medicine; Quality of life (healthcare); Cancer; Nursing; Internal medicine","score_opus":0.43080330387943533,"score_gpt":0.5984238571150413,"score_spread":0.16762055323560598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890914022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936826,0.0010487443,0.000042675205,0.002347102,0.0007974202,0.00009551225,0.0000040993577,0.0000013636094,0.006294809],"genre_scores_gemma":[0.99374276,0.0012636604,0.0039860057,0.00035271622,0.00036835443,0.0000018878325,0.0000016305388,0.0000059429867,0.00027704696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781984,0.00013649567,0.0015968017,0.000101253376,0.00023360175,0.00011201421],"domain_scores_gemma":[0.9950391,0.00079961726,0.0029398918,0.00016639728,0.0009428128,0.00011218632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010156188,0.000083485764,0.0012211625,0.00008401788,0.000023177025,0.000004371937,0.0001730797,0.000264616,0.000094728115],"category_scores_gemma":[0.0054595084,0.000057799738,0.00028911317,0.000035588902,0.00021649175,0.000110275854,0.000036091013,0.0008490881,0.0000019338079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018112316,0.00022062499,0.92835635,0.000033543794,0.00013712433,0.00009644726,0.0062826755,0.000003896909,0.00024173249,0.000057830075,0.00044553573,0.062313005],"study_design_scores_gemma":[0.004068174,0.0050463965,0.95607513,0.0014858177,0.00015100284,0.0000019473755,0.0012627856,0.0000082444,0.001113516,0.00016181228,0.030578876,0.00004629894],"about_ca_topic_score_codex":0.018531179,"about_ca_topic_score_gemma":0.13412687,"teacher_disagreement_score":0.1155957,"about_ca_system_score_codex":0.00033561763,"about_ca_system_score_gemma":0.002111283,"threshold_uncertainty_score":0.9880045},"labels":[],"label_agreement":null},{"id":"W2890915407","doi":"10.1200/jco.2017.35.15_suppl.tps8052","title":"CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Nivolumab; Internal medicine; Pembrolizumab; Lenalidomide; Dexamethasone; Oncology; Refractory (planetary science); Progressive disease; Multiple myeloma; Immunotherapy; Chemotherapy; Cancer","score_opus":0.2646944539655388,"score_gpt":0.5483476067111028,"score_spread":0.283653152745564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890915407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938953,0.0004370958,0.00004454634,0.0014801316,0.0005222424,0.0016114197,0.00002403867,0.0000045743895,0.0019806742],"genre_scores_gemma":[0.99045146,0.0017194245,0.0072144927,0.00008725797,0.00021191011,0.000029902172,0.000009596902,0.000024208319,0.00025172456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931051,0.0019260454,0.0038029696,0.0002877963,0.00055919494,0.0003188787],"domain_scores_gemma":[0.9850574,0.008147089,0.0048134513,0.00062741555,0.00074742635,0.0006071887],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011587492,0.00020103187,0.0038715266,0.00032915885,0.00011811645,0.000034108245,0.00061563856,0.00043623286,0.00008240732],"category_scores_gemma":[0.051319413,0.00014502613,0.00030464228,0.0001013025,0.0012540244,0.00043829443,0.00027460902,0.00096083607,0.000003654359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8186882,0.034891695,0.014596632,0.000050897623,0.00074899604,0.00056259916,0.00011272448,0.0000011571124,0.0015747485,0.00020827734,0.0001113829,0.12845267],"study_design_scores_gemma":[0.8968255,0.04312288,0.055969484,0.0002248366,0.00040798806,0.00009418373,0.00007751113,0.0011685123,0.00054758566,0.00065459457,0.0008072532,0.00009968617],"about_ca_topic_score_codex":0.00058553484,"about_ca_topic_score_gemma":0.00037978828,"teacher_disagreement_score":0.128353,"about_ca_system_score_codex":0.00014600092,"about_ca_system_score_gemma":0.0017766404,"threshold_uncertainty_score":0.9566717},"labels":[],"label_agreement":null},{"id":"W2890922887","doi":"10.1200/jco.2017.35.15_suppl.e21529","title":"Hospitalizations in elderly glioblastoma patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Emergency department; Emergency medicine; Ambulatory; Cohort; Acute care; Ambulatory care; Observational study; Health care; Internal medicine","score_opus":0.07517939111903714,"score_gpt":0.4692487179722566,"score_spread":0.39406932685321944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890922887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725044,0.00011273889,0.000040932053,0.012156615,0.0020537314,0.00019317362,0.0000024912865,0.0000056744657,0.012930257],"genre_scores_gemma":[0.9971255,0.0004647031,0.00027856763,0.0010726014,0.00069324335,0.0000035090343,7.6348977e-7,0.000010528373,0.00035060066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977549,0.00012387705,0.0015652853,0.00012362146,0.00025814326,0.00017419634],"domain_scores_gemma":[0.9963528,0.000637849,0.0018885685,0.00019447347,0.000737764,0.00018854188],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001104268,0.000091339185,0.00092180754,0.0001359859,0.000100134406,0.000012649106,0.00016253615,0.00022783091,0.00010276475],"category_scores_gemma":[0.013352059,0.00006908353,0.00027787988,0.00006610946,0.00030590728,0.00017705362,0.00007638225,0.00068396656,0.000027255768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016971307,0.0017820959,0.85871124,0.000008940458,0.00018987445,0.00023318481,0.000079992555,0.0000027640247,0.000002797002,0.00005410571,0.008785291,0.1284526],"study_design_scores_gemma":[0.011754538,0.024848277,0.92587024,0.00016748112,0.00017985569,0.000033526132,0.00007375191,0.000019571591,0.000012734062,0.00032557792,0.036653385,0.00006105344],"about_ca_topic_score_codex":0.000015403848,"about_ca_topic_score_gemma":0.00016546102,"teacher_disagreement_score":0.12839155,"about_ca_system_score_codex":0.00017603462,"about_ca_system_score_gemma":0.0006414986,"threshold_uncertainty_score":0.9949589},"labels":[],"label_agreement":null},{"id":"W2890940212","doi":"10.1200/jco.2017.35.15_suppl.e20563","title":"Clinical outcomes after whole genome sequencing in patients with metastatic non-small cell lung cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Canada's Michael Smith Genome Sciences Centre; Genome British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Adenocarcinoma; Regimen; Liquid biopsy; Cohort; Cancer; KRAS; Colorectal cancer","score_opus":0.048172609641067024,"score_gpt":0.4034643979642133,"score_spread":0.3552917883231463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890940212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673045,0.0005098475,0.00029307525,0.0005262952,0.0012353434,0.00020494191,0.000041156225,0.0000011097192,0.00045777846],"genre_scores_gemma":[0.9923293,0.000945766,0.0041204616,0.0016600449,0.0007277979,0.000011430747,0.00000898837,0.000024973484,0.00017122708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721825,0.00019100231,0.001835359,0.00029561538,0.00017206231,0.00028770068],"domain_scores_gemma":[0.9964012,0.00041503462,0.002114734,0.00046005708,0.00033752728,0.00027143324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001891088,0.00017574806,0.0010332274,0.00005254694,0.00006549057,0.00003924842,0.0004902532,0.00029314248,0.000023050026],"category_scores_gemma":[0.0015278141,0.00012768139,0.0003820749,0.000027478234,0.00021503339,0.000013427109,0.00020858049,0.00057580543,0.000004570069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014629223,0.00046104964,0.9909971,0.000019309191,0.00021149736,0.00012445742,0.000026468952,0.00029450917,0.00014113424,0.0000015114805,0.0003660958,0.00589399],"study_design_scores_gemma":[0.008080159,0.003722081,0.9727864,0.000040112845,0.00020574628,0.0000037014413,0.000024065599,0.00004556304,0.00004527834,0.000026346444,0.014849844,0.00017065488],"about_ca_topic_score_codex":0.00010598508,"about_ca_topic_score_gemma":0.0012189497,"teacher_disagreement_score":0.018210607,"about_ca_system_score_codex":0.00013805872,"about_ca_system_score_gemma":0.0022177116,"threshold_uncertainty_score":0.5206696},"labels":[],"label_agreement":null},{"id":"W2890966188","doi":"10.1200/jco.2018.36.15_suppl.10005","title":"Randomized trial of a symptom monitoring intervention for hospitalized patients with cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Intervention (counseling); Cancer; Physical therapy; Internal medicine","score_opus":0.08092567291742726,"score_gpt":0.48218469184212137,"score_spread":0.4012590189246941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890966188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985445,0.00019189894,0.0008356491,0.00070276647,0.0072119315,0.0008140658,0.000005543687,0.000004507796,0.0003791992],"genre_scores_gemma":[0.9949188,0.00018414926,0.0008835288,0.00011865317,0.0037135032,0.00003947564,0.0000020157813,0.000012433792,0.00012740534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971452,0.00033608504,0.0019870838,0.00010995537,0.00029641265,0.00012530753],"domain_scores_gemma":[0.99432343,0.001579664,0.0023326715,0.000108945635,0.0015089541,0.00014631466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003147354,0.00008796378,0.0018478463,0.0000764954,0.000020032938,0.0000041325397,0.00009104852,0.00019053946,0.000073171555],"category_scores_gemma":[0.0031907938,0.0000530995,0.00087798946,0.00008193739,0.00026141445,0.00006696502,0.000017735303,0.00024873007,6.954428e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8834662,0.0010943069,0.050614703,0.000047735248,0.0006072487,0.0000034947955,0.00017259434,3.3864893e-7,0.000004745001,0.00001775751,0.00026834675,0.06370256],"study_design_scores_gemma":[0.9155527,0.048621163,0.029572044,0.0004459259,0.0009706599,0.0000027731348,0.000073009316,0.000011940668,0.00014132512,0.00013712877,0.0044185175,0.00005286049],"about_ca_topic_score_codex":0.00011882838,"about_ca_topic_score_gemma":0.000086332635,"teacher_disagreement_score":0.0636497,"about_ca_system_score_codex":0.00009617605,"about_ca_system_score_gemma":0.0005649246,"threshold_uncertainty_score":0.38199085},"labels":[],"label_agreement":null},{"id":"W2890975237","doi":"10.1200/jco.2017.35.15_suppl.e21677","title":"Use of granulocyte colony stimulating factor (GCSF) in patients receiving highly myelosuppressive chemotherapy for breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Waterloo","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Breast cancer; Cohort; Cancer; Febrile neutropenia; Chemotherapy; Incidence (geometry); Population; Granulocyte colony-stimulating factor; Oncology; Surgery","score_opus":0.17069218748319226,"score_gpt":0.4872451574340433,"score_spread":0.316552969950851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890975237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922077,0.000028965023,0.000054939035,0.005406846,0.0016091276,0.00040797872,0.00006115151,0.0000040799664,0.00021918479],"genre_scores_gemma":[0.99672353,0.00033984016,0.0012747634,0.0007354885,0.0007690872,0.000011893433,0.0000013569721,0.000019203626,0.00012484306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760616,0.00013391708,0.0016753156,0.00016075066,0.0002215873,0.0002022948],"domain_scores_gemma":[0.9941573,0.0015651068,0.0030395086,0.00023912099,0.00081433187,0.00018459329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066168734,0.00011696297,0.0012720877,0.00009377007,0.000099969744,0.00001882179,0.00018104044,0.0002540183,0.00009832276],"category_scores_gemma":[0.0024753797,0.00008800147,0.00036968678,0.000050877123,0.00018198403,0.0002809944,0.00003880116,0.0005543898,8.905114e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006786565,0.00074433145,0.8266611,0.00003618572,0.00017354276,0.000015628513,0.00006965078,0.000064894986,0.00065888127,0.000010292114,0.00082107505,0.16395785],"study_design_scores_gemma":[0.014855572,0.005342937,0.9714527,0.00033413802,0.00014645974,0.000019925556,0.000009810301,0.00009971415,0.00040495847,0.000048304544,0.0072091282,0.00007634321],"about_ca_topic_score_codex":0.00019697985,"about_ca_topic_score_gemma":0.00028250387,"teacher_disagreement_score":0.1638815,"about_ca_system_score_codex":0.00021065406,"about_ca_system_score_gemma":0.0009835779,"threshold_uncertainty_score":0.35885957},"labels":[],"label_agreement":null},{"id":"W2890978982","doi":"10.1200/jco.2018.36.15_suppl.3538","title":"Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Capecitabine; Oxaliplatin; Bevacizumab; Irinotecan; Colorectal cancer; Proportional hazards model; Perioperative; Radiology; Internal medicine; Chemotherapy; Oncology; Cancer","score_opus":0.10096094359669039,"score_gpt":0.48798117943028163,"score_spread":0.38702023583359124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890978982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849953,0.00014319658,0.0006212778,0.01116911,0.00109829,0.00013793509,0.0000029910907,0.000007317982,0.0018245463],"genre_scores_gemma":[0.9852589,0.00023470317,0.0094577605,0.0040523503,0.0008103304,0.0000010097713,0.0000017915103,0.00001847753,0.0001647211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965677,0.00051573553,0.0020933447,0.00015585244,0.0004881939,0.00017915027],"domain_scores_gemma":[0.99258125,0.004063431,0.002353677,0.0002203769,0.00055437087,0.0002268821],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047073024,0.00012481051,0.0015977144,0.00021054795,0.000034605848,0.000003350659,0.00017114566,0.0001627727,0.00062555715],"category_scores_gemma":[0.01005158,0.00008259854,0.00054858834,0.00015959695,0.000644363,0.000043353448,0.00002162027,0.0009729186,0.00000839463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025403429,0.008041118,0.5922426,0.00026493147,0.002402391,0.00065719057,0.000248135,0.00036978335,0.0084851645,0.0012634391,0.022862857,0.337759],"study_design_scores_gemma":[0.02204222,0.07066757,0.8123657,0.00037309589,0.0007819408,0.00025353392,0.000072396164,0.006333667,0.0063731354,0.00046551423,0.0801177,0.00015348445],"about_ca_topic_score_codex":0.00006909933,"about_ca_topic_score_gemma":0.000024691393,"teacher_disagreement_score":0.3376055,"about_ca_system_score_codex":0.00007657086,"about_ca_system_score_gemma":0.0010541005,"threshold_uncertainty_score":0.9982872},"labels":[],"label_agreement":null},{"id":"W2890984843","doi":"10.1200/jco.2017.35.15_suppl.e17089","title":"Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"CHEK1; Olaparib; Kinase; Cancer research; Synthetic lethality; Cell cycle; Aurora kinase; Cell cycle checkpoint; Ovarian cancer; Cancer; Medicine; Biology; DNA repair; Gene; Genetics; Poly ADP ribose polymerase","score_opus":0.09044699779686242,"score_gpt":0.4583855588175047,"score_spread":0.36793856102064226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890984843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947189,0.00036749727,0.00010627382,0.0030597388,0.0009940604,0.000069712085,0.0000065656154,0.000001095644,0.00067612145],"genre_scores_gemma":[0.9960903,0.0017752973,0.0003419232,0.00032574005,0.001389729,0.0000024096817,0.0000029334817,0.000009199317,0.00006248419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982921,0.00027282746,0.0010102461,0.0001938183,0.00008378264,0.00014723591],"domain_scores_gemma":[0.99799407,0.00019959199,0.0013136157,0.00024220049,0.00011455168,0.0001360027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001806126,0.00009902632,0.00053920835,0.000043702745,0.00006952921,0.000026871725,0.00023613285,0.00039357698,0.000011904795],"category_scores_gemma":[0.0022615946,0.00008236281,0.00016509698,0.000017779379,0.00021447605,0.00001559596,0.00014440353,0.00045648465,0.000001288386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007142067,0.00036176562,0.70070076,0.000023454513,0.00016824776,0.00006700581,0.000041573876,0.000013617575,0.050507717,0.00003677512,0.0010842858,0.24628061],"study_design_scores_gemma":[0.0029376817,0.0026433656,0.8673862,0.00011422494,0.00012327106,0.00007865112,0.00008801083,0.00002463301,0.019769568,0.00027571505,0.10637943,0.00017924487],"about_ca_topic_score_codex":0.0002257487,"about_ca_topic_score_gemma":0.00063600775,"teacher_disagreement_score":0.24610136,"about_ca_system_score_codex":0.00003788037,"about_ca_system_score_gemma":0.00035456684,"threshold_uncertainty_score":0.3358658},"labels":[],"label_agreement":null},{"id":"W2890999691","doi":"10.1200/jco.2017.35.15_suppl.e21633","title":"Characteristics and predictors of pain in patients with newly diagnosed and relapsed acute leukemia (AL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Disease; Population; Malignancy; Distress; Cancer","score_opus":0.03640134964645151,"score_gpt":0.3862062775824498,"score_spread":0.34980492793599827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890999691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970323,0.000029639486,0.000021002346,0.0019308383,0.0004921158,0.00014043618,0.000006148163,0.0000021160179,0.00034542286],"genre_scores_gemma":[0.9975318,0.0009477578,0.00043933155,0.00080429274,0.00021935739,0.0000019903123,0.0000015268367,0.000008248623,0.000045752127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849117,0.00016050613,0.0009869795,0.0001055641,0.00015110595,0.000104651175],"domain_scores_gemma":[0.99721485,0.00076589617,0.0014554695,0.00015736294,0.0002058081,0.00020062483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013304251,0.00007688991,0.00085793657,0.000065466884,0.00004575855,0.000009476374,0.00007428957,0.0001603411,0.000013891483],"category_scores_gemma":[0.0023088208,0.000050403876,0.00006824874,0.00002925917,0.00030799833,0.000115400515,0.00003799747,0.0005399706,4.161844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034139857,0.00037022834,0.9427731,0.000016644086,0.00015841376,0.00017325093,0.000045038294,3.8940874e-7,0.000029557947,0.000011636568,0.000983899,0.052023824],"study_design_scores_gemma":[0.015559143,0.016411548,0.957331,0.00015296935,0.00028749162,0.00003373475,0.000012717972,0.000009360273,0.000008057093,0.000024177189,0.010125559,0.000044213546],"about_ca_topic_score_codex":0.000026642265,"about_ca_topic_score_gemma":0.000054615906,"teacher_disagreement_score":0.05197961,"about_ca_system_score_codex":0.000070519076,"about_ca_system_score_gemma":0.0006132047,"threshold_uncertainty_score":0.27640408},"labels":[],"label_agreement":null},{"id":"W2891007196","doi":"10.1200/jco.2016.34.15_suppl.e18190","title":"Ovarian cancer pathway map development as an approach to identifying priority areas for quality improvement in Ontario.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multidisciplinary approach; Quality management; Reimbursement; Stakeholder; Specialty; Working group; Identification (biology); Knowledge translation; Quality (philosophy); Health care; Process management; Nursing; Family medicine; Operations management; Knowledge management; Business; Public relations; Political science; Management system; Engineering; Computer science","score_opus":0.5713299334557643,"score_gpt":0.6141441214806601,"score_spread":0.04281418802489578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891007196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537659,0.000021518705,0.022510659,0.020203184,0.0020092262,0.0010330391,0.000006198861,0.000009942353,0.0004403222],"genre_scores_gemma":[0.8788519,0.000031830208,0.110652864,0.008456886,0.001164808,0.00008766733,0.000009582916,0.000022988166,0.0007214834],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99139845,0.0005644303,0.006649781,0.00041951967,0.0005954777,0.0003723463],"domain_scores_gemma":[0.99079657,0.0044197524,0.0028027475,0.0002940765,0.0009829304,0.00070395385],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020708539,0.00017696177,0.0013771818,0.00015801407,0.000054204527,0.000018278844,0.00023533682,0.00033904865,0.0002542072],"category_scores_gemma":[0.01902783,0.00011544166,0.00031345405,0.00010376155,0.00006371162,0.00036892245,0.00011062265,0.000763148,0.00001928548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009048779,0.0036592532,0.24226244,0.00005959515,0.0002410541,0.000043247226,0.00065231236,0.000004906907,0.0019573316,0.0003582262,0.00079912925,0.74091375],"study_design_scores_gemma":[0.01628839,0.0059246314,0.8023897,0.00016999588,0.00015489463,0.000028335151,0.0005780565,0.000012806897,0.0004308464,0.0015928637,0.172258,0.00017152216],"about_ca_topic_score_codex":0.010803356,"about_ca_topic_score_gemma":0.1093628,"teacher_disagreement_score":0.7407422,"about_ca_system_score_codex":0.0018896707,"about_ca_system_score_gemma":0.011119045,"threshold_uncertainty_score":0.9957838},"labels":[],"label_agreement":null},{"id":"W2891010170","doi":"10.1200/jco.2018.36.15_suppl.4112","title":"A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Erlotinib; Surgery; Perioperative; Phases of clinical research; Urology; Internal medicine; Oncology; Cancer; Chemotherapy; Randomized controlled trial","score_opus":0.09613788876951203,"score_gpt":0.48138346970380697,"score_spread":0.38524558093429495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891010170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334127,0.00064351637,0.000108438704,0.0009593127,0.00037654192,0.004155536,0.000035810757,0.000009783503,0.00036977234],"genre_scores_gemma":[0.9909058,0.00033436416,0.0062962235,0.0002560663,0.0014121693,0.00011251647,0.0000113302385,0.000037068017,0.0006344371],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947997,0.00086073496,0.0026864181,0.00048988324,0.00066466135,0.000498601],"domain_scores_gemma":[0.98994887,0.0047371155,0.0017743359,0.00034698664,0.0025685313,0.00062416756],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003430486,0.00030847493,0.003741369,0.00020477634,0.00024803545,0.00001948663,0.00021705632,0.00039824302,0.00011165606],"category_scores_gemma":[0.008786148,0.00019580133,0.0001933062,0.00023180878,0.0011208131,0.00024846316,0.00017426482,0.0007974219,0.0000019068087],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5044053,0.018555604,0.4666131,0.00011829088,0.00200092,0.00014472778,0.002609355,5.7287536e-7,0.00022069545,0.000034214958,0.00048022481,0.004816976],"study_design_scores_gemma":[0.2476658,0.37491933,0.3739406,0.00013082648,0.0017287314,0.00011744767,0.00082671666,0.00024909133,0.000019964873,0.00005006397,0.0002469661,0.00010448719],"about_ca_topic_score_codex":0.0001263632,"about_ca_topic_score_gemma":0.00016953761,"teacher_disagreement_score":0.35636374,"about_ca_system_score_codex":0.00014497309,"about_ca_system_score_gemma":0.0024484794,"threshold_uncertainty_score":0.9995633},"labels":[],"label_agreement":null},{"id":"W2891023817","doi":"10.1200/jco.2016.34.15_suppl.e15580","title":"Population-based analysis of hospital readmissions within 1 year of esophagectomy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; University of British Columbia; Institute for Clinical Evaluative Sciences; Centre for Addiction and Mental Health","funders":"","keywords":"Medicine; Esophagectomy; Hospital readmission; Comorbidity; Odds ratio; Population; Retrospective cohort study; Esophageal cancer; Emergency medicine; Internal medicine; Surgery; Cancer; Environmental health","score_opus":0.07312906529011805,"score_gpt":0.45307726344882043,"score_spread":0.3799481981587024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891023817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932518,0.00011559014,0.00050898397,0.004873527,0.00064890494,0.00007504697,0.000014756468,0.0000048436777,0.00050655083],"genre_scores_gemma":[0.99253005,0.000041073992,0.006485114,0.00038096716,0.0002729827,7.0997436e-7,0.0000038462053,0.000008315507,0.00027692705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965391,0.00035207125,0.0025501684,0.00013665289,0.00029618418,0.00012578053],"domain_scores_gemma":[0.99341005,0.002782246,0.0027266287,0.00022910116,0.00057083956,0.0002811116],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021893352,0.00009014297,0.0018631292,0.00037703884,0.000014158089,8.360787e-7,0.00013143837,0.00034042684,0.00056586956],"category_scores_gemma":[0.008788974,0.000048111087,0.00085583807,0.00039957688,0.00020235928,0.000048191796,0.000024932968,0.000324138,0.0000067916967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013381271,0.0015278207,0.9842977,0.00001820107,0.0009785517,0.00026613302,0.000051009047,0.000041523326,0.0008482513,0.00035317687,0.00042730203,0.009852218],"study_design_scores_gemma":[0.0041054566,0.011095392,0.9810188,0.00009002769,0.002247193,0.000015332675,0.000028461813,0.000093268856,0.0005244397,0.00043085436,0.00030334372,0.00004742985],"about_ca_topic_score_codex":0.000023673285,"about_ca_topic_score_gemma":0.000017716968,"teacher_disagreement_score":0.009804788,"about_ca_system_score_codex":0.00004509084,"about_ca_system_score_gemma":0.00084787514,"threshold_uncertainty_score":0.9995604},"labels":[],"label_agreement":null},{"id":"W2891027171","doi":"10.1200/jco.2016.34.15_suppl.e21501","title":"Acceptance of illness of advanced cancer patients in palliative care center in Kuwait.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Cancer; Quality of life (healthcare); Disease; Family medicine; Breast cancer; Nursing; Internal medicine","score_opus":0.22868591656455964,"score_gpt":0.5651216046004621,"score_spread":0.3364356880359025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891027171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955937,0.0016602129,0.000027164333,0.0008849858,0.0007450513,0.0001485119,0.000030539195,0.0000011447397,0.0009086646],"genre_scores_gemma":[0.9901527,0.008401572,0.0009981544,0.0002495913,0.00014525121,0.0000040835407,0.0000014592163,0.000008644273,0.000038549417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681234,0.0002536535,0.0023471469,0.0001323865,0.00028926574,0.00016519471],"domain_scores_gemma":[0.9949737,0.0018005384,0.002170157,0.00011732157,0.0008316475,0.000106608066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058016175,0.000102574835,0.0015641745,0.00015516703,0.00000450077,4.2843482e-7,0.0001548488,0.00022366733,0.000088481196],"category_scores_gemma":[0.004142987,0.00006141644,0.0002506254,0.0001780751,0.00022437518,0.000100346995,0.000040206316,0.0003326141,0.0000011217314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003442637,0.00090068026,0.82188493,0.00008474704,0.000073357354,0.000032439857,0.0019506377,0.000008377395,0.00038356034,0.000014599196,0.00013415731,0.17108986],"study_design_scores_gemma":[0.015910944,0.0041617993,0.9594719,0.0033261185,0.00004802501,5.942798e-7,0.0015581192,0.0000020654581,0.003911394,0.0000875526,0.011454664,0.00006685842],"about_ca_topic_score_codex":0.00007740889,"about_ca_topic_score_gemma":0.0007966196,"teacher_disagreement_score":0.171023,"about_ca_system_score_codex":0.00023112792,"about_ca_system_score_gemma":0.00061684835,"threshold_uncertainty_score":0.49598417},"labels":[],"label_agreement":null},{"id":"W2891033814","doi":"10.1200/jco.2017.35.15_suppl.9052","title":"A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Cancer; Oncology; Taxane; Paclitaxel; Breast cancer","score_opus":0.23669700405385305,"score_gpt":0.5656816634140758,"score_spread":0.3289846593602227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891033814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924311,0.00066990795,0.000047998583,0.00089931104,0.0018048041,0.0009525639,0.000025734149,0.00000772804,0.003160865],"genre_scores_gemma":[0.9968543,0.0011528278,0.0004109781,0.0004898123,0.00051542075,0.000036191992,0.0000017323979,0.0000324875,0.0005062372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951574,0.0011125995,0.0025269575,0.00040288613,0.00026505886,0.0005350797],"domain_scores_gemma":[0.99230313,0.0016385972,0.004638338,0.00041066707,0.00053517165,0.0004741059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033202027,0.00032992926,0.0020317466,0.00019055637,0.00024663942,0.000025603871,0.000891904,0.00056749943,0.00016990145],"category_scores_gemma":[0.0005883789,0.00024164308,0.00033895887,0.0001546027,0.00050684647,0.00026186812,0.00015831951,0.002204031,0.0000056229283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01881865,0.057487316,0.8520978,0.000121975914,0.0006638316,0.002573091,0.001185667,0.00020298855,0.002726772,0.0000051016855,0.001560162,0.06255664],"study_design_scores_gemma":[0.2029681,0.09298329,0.67679536,0.0003365496,0.0019768013,0.00015190554,0.0021387152,0.0022962727,0.003234927,0.00004154104,0.016474599,0.00060192967],"about_ca_topic_score_codex":0.00031324817,"about_ca_topic_score_gemma":0.0016992075,"teacher_disagreement_score":0.18414946,"about_ca_system_score_codex":0.00018947515,"about_ca_system_score_gemma":0.0011515865,"threshold_uncertainty_score":0.98539186},"labels":[],"label_agreement":null},{"id":"W2891041569","doi":"10.1200/jco.2017.35.15_suppl.e18241","title":"Predicting the failure of randomized clinical trials in radiation oncology: What can we learn?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Juravinski Cancer Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Interim analysis; Radiation therapy; Odds ratio; Internal medicine; Clinical trial; Sample size determination; Oncology","score_opus":0.2574327202892108,"score_gpt":0.48480846683634793,"score_spread":0.2273757465471371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891041569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86613363,0.00909898,0.0005314661,0.10002811,0.011756503,0.00075470377,0.000029222607,0.00000601917,0.011661352],"genre_scores_gemma":[0.94623977,0.0484482,0.0006288777,0.0013849848,0.0030540451,0.000011254189,0.0000011278574,0.000017123943,0.00021461403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98216534,0.0030519245,0.0140932845,0.0002954667,0.000081005506,0.0003129922],"domain_scores_gemma":[0.9411313,0.027992155,0.029955875,0.00048698433,0.00020714036,0.00022657329],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15430859,0.00016735667,0.007120247,0.00021096104,0.00013838318,0.00012502624,0.0008669291,0.0008723381,0.00017593004],"category_scores_gemma":[0.19641148,0.000118734075,0.0019353223,0.00006767209,0.00093102833,0.0008994443,0.000118789736,0.0016173704,0.00002748005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024845175,0.00065826887,0.37054542,0.000019263607,0.0006873976,0.00003339679,0.00083468633,0.00014500541,0.0000014143217,0.016544947,0.0034333374,0.58225167],"study_design_scores_gemma":[0.2118386,0.0039869766,0.32806835,0.00024585667,0.00030612713,0.00003245579,0.0011032516,0.002313139,0.000011209109,0.08246208,0.36932838,0.00030358694],"about_ca_topic_score_codex":0.00029953846,"about_ca_topic_score_gemma":0.00082869816,"teacher_disagreement_score":0.5819481,"about_ca_system_score_codex":0.00023840804,"about_ca_system_score_gemma":0.001283136,"threshold_uncertainty_score":0.87081724},"labels":[],"label_agreement":null},{"id":"W2891051877","doi":"10.1200/jco.2017.35.15_suppl.3555","title":"Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer (CRC): An analysis of NCIC CTG CO.17 and CO.20.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Cetuximab; Internal medicine; Quality of life (healthcare); Colorectal cancer; Adverse effect; Placebo; Oncology; Multivariate analysis; Proportional hazards model; Clinical trial; Progression-free survival; Cancer; Overall survival","score_opus":0.16131797049969265,"score_gpt":0.5208069018835222,"score_spread":0.35948893138382954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891051877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948692,0.0029308752,0.00000736992,0.00073353644,0.00016237123,0.000817088,0.00021079075,0.000004090033,0.00026473566],"genre_scores_gemma":[0.99386317,0.0052332045,0.0003628036,0.00017080494,0.00015505473,0.000094530114,0.000015048048,0.000012745361,0.000092643684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998012,0.00018716707,0.0011334363,0.00025884082,0.00020776036,0.00020080454],"domain_scores_gemma":[0.99592644,0.0018481319,0.0015432904,0.00014517202,0.0002802271,0.0002567147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066666823,0.00019436219,0.0022915096,0.0002058571,0.00010255531,0.000016846137,0.000087515284,0.0001567639,0.0000801459],"category_scores_gemma":[0.0012947143,0.00011858261,0.00034667677,0.00008204276,0.0004979527,0.00012649542,0.000021510647,0.00023107055,1.5543208e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024332767,0.0026139873,0.8563546,0.000028691835,0.008907949,0.00032989346,0.0019215798,0.000006940358,0.0007381672,0.0000031605437,0.000058458547,0.1047038],"study_design_scores_gemma":[0.013941949,0.05700988,0.9224256,0.000043331274,0.0035095734,0.00002295826,0.00041742154,0.00039226888,0.0004563743,0.00005696864,0.0016367694,0.00008689274],"about_ca_topic_score_codex":0.0003985708,"about_ca_topic_score_gemma":0.003132947,"teacher_disagreement_score":0.10461691,"about_ca_system_score_codex":0.00029107262,"about_ca_system_score_gemma":0.00091048673,"threshold_uncertainty_score":0.48356587},"labels":[],"label_agreement":null},{"id":"W2891062831","doi":"10.1200/jco.2017.35.15_suppl.tps6090","title":"KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Population; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Placebo; Chemoradiotherapy; Head and neck cancer; Radiation therapy; Cancer; Surgery; Pathology; Immunotherapy; Alternative medicine","score_opus":0.04883037949348787,"score_gpt":0.3914537141748603,"score_spread":0.3426233346813724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891062831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990685,0.0007080672,0.000051832736,0.0045968913,0.00062774925,0.00031134713,0.0000013337477,0.0000057440416,0.0030120357],"genre_scores_gemma":[0.99753124,0.0005748734,0.0011257594,0.00040930597,0.00023884309,0.000006975245,0.0000061918527,0.000019091638,0.00008773958],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975537,0.00023313874,0.0014527888,0.00023291934,0.00030225766,0.0002251803],"domain_scores_gemma":[0.9965803,0.00093084894,0.0018462274,0.0002529997,0.0002197698,0.0001698753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018872956,0.00016122493,0.0010131324,0.00020885603,0.00006464208,0.000030275634,0.00015711114,0.00039031982,0.000019670886],"category_scores_gemma":[0.0013261422,0.0001310771,0.00013942488,0.00012632496,0.00024727162,0.00040632152,0.000028336242,0.00075724965,0.0000022333807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3706916,0.002452431,0.3527015,0.000113901966,0.000060833983,0.00068857544,0.00038608207,0.00009534676,0.0017011645,0.000032617136,0.00018290349,0.2708931],"study_design_scores_gemma":[0.21824431,0.01579903,0.7620551,0.00009897425,0.000064963264,0.00012666853,0.000083876446,0.0007825069,0.00046316057,0.00006242559,0.0021037161,0.000115283314],"about_ca_topic_score_codex":0.00027906455,"about_ca_topic_score_gemma":0.0010422562,"teacher_disagreement_score":0.4093536,"about_ca_system_score_codex":0.0004613354,"about_ca_system_score_gemma":0.0012039278,"threshold_uncertainty_score":0.53451693},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2891071236","doi":"10.1200/jco.2018.36.30_suppl.6","title":"Predicting acute care use following the initiation of systemic therapy for solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Regimen; Lung cancer; Cancer; Logistic regression; Emergency department; Cancer registry","score_opus":0.3930160466540462,"score_gpt":0.5854689857293168,"score_spread":0.1924529390752706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891071236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943395,0.001923658,0.0008520436,0.00075235864,0.0014268559,0.00027530975,0.000009397653,0.0000053995223,0.00041544446],"genre_scores_gemma":[0.99283916,0.0015123999,0.0027308094,0.0008193507,0.0020510885,0.0000043969158,0.0000032911971,0.000012215826,0.000027263886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726844,0.00027730007,0.0019710194,0.0000955474,0.0002510102,0.00013667898],"domain_scores_gemma":[0.991484,0.004734625,0.0022204968,0.0001434601,0.0013263281,0.000091078975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002107144,0.000086129025,0.001162568,0.00006895531,0.00004469722,0.0000044809453,0.00013932705,0.00020173535,0.000008369345],"category_scores_gemma":[0.0069175866,0.000048786143,0.00059948326,0.00009073319,0.00016108713,0.000116406074,0.000022006609,0.00032416696,0.000001116389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060981666,0.00035632995,0.9321212,0.00013925294,0.0018602711,0.00009711107,0.008493328,0.000009909333,0.0054797484,0.00007885327,0.0014741152,0.043791674],"study_design_scores_gemma":[0.060025297,0.15331535,0.59643215,0.01621184,0.0059831063,0.00081111013,0.036863472,0.0012817051,0.050163783,0.0009299755,0.07748373,0.000498456],"about_ca_topic_score_codex":0.000015402606,"about_ca_topic_score_gemma":0.000015108588,"teacher_disagreement_score":0.33568907,"about_ca_system_score_codex":0.000066511086,"about_ca_system_score_gemma":0.0007807733,"threshold_uncertainty_score":0.8281497},"labels":[],"label_agreement":null},{"id":"W2891080378","doi":"10.1200/jco.2017.35.15_suppl.e17076","title":"Performance of preoperative plasma HE4 and CA-125 levels in predicting ovarian cancer mortality in women with epithelial ovarian cancer (EOC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Cohort; Internal medicine; Receiver operating characteristic; Oncology; Biomarker; Ovarian cancer; Debulking; Cancer; Youden's J statistic","score_opus":0.115120202585895,"score_gpt":0.45080555876250455,"score_spread":0.33568535617660955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891080378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196637,0.00025415848,0.000003396998,0.005671616,0.00063405297,0.00037952315,0.000056271187,0.0000028696868,0.0010317347],"genre_scores_gemma":[0.99537915,0.0026154793,0.0007492811,0.00040482776,0.0006774224,0.00007689624,6.1142276e-7,0.000016666438,0.000079686004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970255,0.00024535184,0.0017770191,0.00029440635,0.00032456446,0.0003331642],"domain_scores_gemma":[0.9966642,0.00056563184,0.0019177329,0.00028804847,0.00027377007,0.00029057972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025343315,0.00019004468,0.0016704546,0.00012256425,0.00008261687,0.00001971142,0.00017915208,0.0002843883,0.00021560292],"category_scores_gemma":[0.0007016494,0.00012630415,0.00009421703,0.00010078386,0.00036374654,0.00029341024,0.00007416623,0.0008384051,8.3025003e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061837304,0.0010270559,0.9173049,0.000085594664,0.0005717124,0.0004020676,0.0012160186,0.00024157103,0.000051189796,0.000022958404,0.000036541303,0.07285671],"study_design_scores_gemma":[0.021192947,0.0076029073,0.9676537,0.0010700154,0.00025730525,0.00006242363,0.00019459898,0.0009065821,0.00025346776,0.00003166125,0.0006628617,0.00011151348],"about_ca_topic_score_codex":0.0037658024,"about_ca_topic_score_gemma":0.010319657,"teacher_disagreement_score":0.0727452,"about_ca_system_score_codex":0.00062323984,"about_ca_system_score_gemma":0.0031947396,"threshold_uncertainty_score":0.57586104},"labels":[],"label_agreement":null},{"id":"W2891084787","doi":"10.1200/jco.2017.35.15_suppl.e15110","title":"Colorectal cancer sidedeness and its association with survival and tumor biology in operable patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Stage (stratigraphy); Proportional hazards model; Oncology; Cancer; Log-rank test; Gastroenterology; Multivariate analysis; Chemotherapy; Clinical trial","score_opus":0.09090771574152283,"score_gpt":0.46111776135502863,"score_spread":0.3702100456135058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891084787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923341,0.00090395776,5.648577e-7,0.0036741032,0.0006886993,0.00015608108,0.000006259891,0.0000019537097,0.0022342794],"genre_scores_gemma":[0.99701196,0.0022358873,0.00009465369,0.00025219476,0.0002562037,0.000009167574,7.310009e-7,0.000006026418,0.00013320222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987947,0.00014625044,0.0006357069,0.00014111455,0.00012871453,0.00015353881],"domain_scores_gemma":[0.99768823,0.0007485532,0.0010279306,0.00005228309,0.000361387,0.000121627985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010632053,0.000089354166,0.0009936505,0.000045500514,0.00010250701,0.000014514903,0.000056157114,0.00014403129,0.000021070691],"category_scores_gemma":[0.0024582644,0.00005367914,0.00005360714,0.000028163937,0.000119061704,0.000108019725,0.00006293164,0.00033624072,5.8809894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035149197,0.00038860226,0.9639954,0.00001188435,0.00025364425,0.000115880095,0.00007446698,8.095364e-7,0.000047932677,0.00003444628,0.00006847041,0.03149357],"study_design_scores_gemma":[0.010831363,0.010136924,0.9758372,0.00006285101,0.00016773131,0.000032070173,0.000074588046,0.000026142488,0.000059663886,0.00004879807,0.002666056,0.000056618246],"about_ca_topic_score_codex":0.00027655103,"about_ca_topic_score_gemma":0.002538532,"teacher_disagreement_score":0.031436954,"about_ca_system_score_codex":0.00022821878,"about_ca_system_score_gemma":0.00047388102,"threshold_uncertainty_score":0.29429495},"labels":[],"label_agreement":null},{"id":"W2891090525","doi":"10.1200/jco.2017.35.15_suppl.10059","title":"Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Metformin; Randomized controlled trial; Breast cancer; Clinical endpoint; IGFBP3; Cancer; Insulin","score_opus":0.09636518564126115,"score_gpt":0.479374396606075,"score_spread":0.3830092109648139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891090525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915408,0.00013407266,0.000018327994,0.0042507104,0.0025057858,0.0010621871,0.000043914333,0.0000048217416,0.0004394184],"genre_scores_gemma":[0.9971358,0.0016510338,0.00003322553,0.00018373647,0.00079297234,0.000038408627,0.0000018005588,0.000015315869,0.00014768465],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99602437,0.0015294098,0.001487873,0.00022783542,0.0005004209,0.00023007505],"domain_scores_gemma":[0.9900656,0.006028025,0.0030462726,0.00029450696,0.00033953742,0.00022606623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075431354,0.00019864259,0.0029883266,0.00015997197,0.00013864865,0.000021599593,0.00026568153,0.00026758277,0.00007998189],"category_scores_gemma":[0.005225016,0.00009602069,0.0007403721,0.00012207015,0.00088790036,0.0002606494,0.00011111811,0.0008894265,6.6041474e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77775574,0.008289883,0.002779504,0.000028333045,0.0008390105,0.000073623705,0.0005426846,0.0000014629535,0.00023524376,0.00014789532,0.000063624684,0.20924303],"study_design_scores_gemma":[0.904396,0.020071035,0.068939306,0.00014747198,0.0010756749,0.000035710542,0.00034796045,0.0013468897,0.00083857926,0.000046801837,0.0026349972,0.00011956907],"about_ca_topic_score_codex":0.0058963113,"about_ca_topic_score_gemma":0.010427332,"teacher_disagreement_score":0.20912346,"about_ca_system_score_codex":0.00011894181,"about_ca_system_score_gemma":0.001004186,"threshold_uncertainty_score":0.8913498},"labels":[],"label_agreement":null},{"id":"W2891093729","doi":"10.1200/jco.2017.35.15_suppl.6591","title":"Estimating the optimal rate of adjuvant chemotherapy utilization in stage III colon cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer registry; Colorectal cancer; Cancer; Population; Stage (stratigraphy); Adjuvant chemotherapy; Internal medicine; Benchmarking; Medical record; Oncology; Environmental health","score_opus":0.23347155479766216,"score_gpt":0.5293438185457285,"score_spread":0.2958722637480664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891093729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541194,0.00035589118,0.0005013491,0.010374457,0.0012313249,0.00019730457,0.0000043098453,0.0000025299128,0.0019208709],"genre_scores_gemma":[0.99126226,0.0011337094,0.0036168236,0.0028671403,0.0006535884,0.0000034199334,0.0000013578998,0.00001043594,0.0004512545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976473,0.00024150584,0.0016802094,0.00011552079,0.000166127,0.00014933881],"domain_scores_gemma":[0.9955226,0.0009101907,0.002953525,0.00025553346,0.0002474345,0.00011069302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038534603,0.000087337336,0.0010712164,0.000053113996,0.00007880562,0.000010278946,0.0002660983,0.00019124454,0.00031999784],"category_scores_gemma":[0.0022888922,0.00005343016,0.00021505638,0.000045522796,0.00030983175,0.00014740859,0.000040250063,0.0006804765,0.0000010021431],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012518596,0.0007213778,0.21660376,0.000094531664,0.00030365004,0.00027514208,0.0006731031,0.0043448517,0.002150314,0.000101479956,0.0021605378,0.7600527],"study_design_scores_gemma":[0.02137966,0.0055614365,0.9029467,0.00027757537,0.0001484439,0.000044135424,0.00018978317,0.040661443,0.0010411746,0.00008271747,0.027574053,0.00009288664],"about_ca_topic_score_codex":0.00020857579,"about_ca_topic_score_gemma":0.0002628946,"teacher_disagreement_score":0.75995976,"about_ca_system_score_codex":0.00013427618,"about_ca_system_score_gemma":0.0020177553,"threshold_uncertainty_score":0.35794112},"labels":[],"label_agreement":null},{"id":"W2891105830","doi":"10.1200/jco.2018.36.15_suppl.12031","title":"Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Cancer; Clinical endpoint; Randomization; Breast cancer; Oncology; Progression-free survival; Exemestane; Gastroenterology; Randomized controlled trial; Gynecology; Chemotherapy; Aromatase; Estrogen receptor","score_opus":0.034244122088055357,"score_gpt":0.4042840549857932,"score_spread":0.37003993289773784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891105830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201334,0.00056274614,0.00001877437,0.0057025827,0.00016688657,0.0010859619,0.0000533372,0.000009340942,0.00038701494],"genre_scores_gemma":[0.99629164,0.0011694293,0.0006719266,0.0011581059,0.00057672674,0.00004980356,0.000004118951,0.000039571136,0.000038681035],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99620277,0.0010998866,0.0014273855,0.00031950057,0.0005608753,0.0003895719],"domain_scores_gemma":[0.9953986,0.0012624696,0.0019962376,0.00030863704,0.0008602643,0.00017381094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016356055,0.00029309202,0.0018310981,0.00021019987,0.000039451803,0.0000067565397,0.00025041,0.0001912799,0.00011603658],"category_scores_gemma":[0.0003291843,0.00014940582,0.00020710751,0.0005908721,0.00056794577,0.00032628782,0.000031822892,0.0011073644,0.0000021365702],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48460865,0.0048687547,0.16001251,0.0000077149725,0.0003507861,0.00006879735,0.00038185867,0.000028370041,0.003462895,0.0000094251345,0.000025303487,0.34617493],"study_design_scores_gemma":[0.1624989,0.077900484,0.754133,0.00029885303,0.000107203334,0.00010439683,0.00024613037,0.000009456547,0.0026918428,0.000041803298,0.0018360955,0.0001318359],"about_ca_topic_score_codex":0.0002840585,"about_ca_topic_score_gemma":0.00086940615,"teacher_disagreement_score":0.5941205,"about_ca_system_score_codex":0.00041581318,"about_ca_system_score_gemma":0.0010581707,"threshold_uncertainty_score":0.6092593},"labels":[],"label_agreement":null},{"id":"W2891106916","doi":"10.1200/jco.2017.35.15_suppl.e15148","title":"Prognostic impact of tumour laterality in early-stage colon cancer: A population-based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Descending colon; Splenic flexure; Internal medicine; Cancer; Laterality; Stage (stratigraphy); Cohort; Population; Gastroenterology; Ascending colon; Proportional hazards model; Oncology; Cecum; Cancer registry; Sigmoid colon; Colonoscopy; Rectum","score_opus":0.1664535650667288,"score_gpt":0.5408234269066992,"score_spread":0.37436986183997034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891106916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968826,0.00015413396,0.0000011070332,0.0017213261,0.00043797202,0.0004423019,0.00001207084,0.0000030981666,0.00034534762],"genre_scores_gemma":[0.99939615,0.00007465784,0.000100006604,0.00008679082,0.00023785853,0.0000135065875,9.4947916e-7,0.00000774791,0.0000823357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765635,0.00025014923,0.0015431582,0.00013748575,0.00024880498,0.00016406154],"domain_scores_gemma":[0.99633235,0.00085323065,0.0021499377,0.0001887675,0.0003235873,0.00015214233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014784983,0.00011393295,0.0014858574,0.00008935443,0.0000676215,0.000010830596,0.00013746579,0.0001294013,0.00007834437],"category_scores_gemma":[0.003081759,0.00007038325,0.00041977302,0.000057248842,0.00009372775,0.0000814116,0.000043242082,0.00042540685,0.0000010715517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00728728,0.0033097232,0.9785726,0.00002311322,0.0004442131,0.00053945964,0.00017935075,0.00008113454,0.000019709049,0.000002561702,0.00005549497,0.009485357],"study_design_scores_gemma":[0.010164301,0.029469589,0.9596134,0.00012357248,0.00030707903,0.000005780617,0.000042334446,0.00008188238,0.0000065018608,0.00003832835,0.00009422758,0.00005302911],"about_ca_topic_score_codex":0.00991274,"about_ca_topic_score_gemma":0.008001136,"teacher_disagreement_score":0.026159866,"about_ca_system_score_codex":0.00042046007,"about_ca_system_score_gemma":0.0014058261,"threshold_uncertainty_score":0.9966803},"labels":[],"label_agreement":null},{"id":"W2891107628","doi":"10.1200/jco.2017.35.15_suppl.e21591","title":"Impact of perioperative blood transfusion on survival among women with breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Blood transfusion and management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Breast cancer; Perioperative; Blood transfusion; Cancer; Internal medicine; Population; Subgroup analysis; Oncology; Meta-analysis; Surgery","score_opus":0.07605661122505082,"score_gpt":0.465114862922694,"score_spread":0.3890582516976432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891107628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98324883,0.000024176477,0.000035010467,0.0055457973,0.0005245966,0.00023747739,0.000011226356,0.0000047066164,0.010368163],"genre_scores_gemma":[0.99707246,0.0014772454,0.0001707336,0.00032952253,0.0005090599,0.0000055217465,3.9433326e-7,0.000014522929,0.00042055192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978535,0.00025738188,0.0011199309,0.00016443184,0.00039441974,0.00021031451],"domain_scores_gemma":[0.9973193,0.00034568895,0.0011956724,0.00028928785,0.0004420278,0.00040807106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021132075,0.00014215046,0.001393519,0.00008706929,0.000100524936,0.000013698397,0.0002122576,0.00019721226,0.00085648557],"category_scores_gemma":[0.00033744719,0.000076496864,0.0003812287,0.000049894705,0.00039623518,0.00012836567,0.000025319474,0.000734257,0.0000025210397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043601263,0.0058894614,0.8173554,0.000047546007,0.0025623452,0.0007685894,0.00082099397,0.000053018615,0.001004012,0.000099133664,0.00022724703,0.12757097],"study_design_scores_gemma":[0.019163338,0.04181819,0.9366735,0.00023277738,0.0005778748,0.00013955247,0.00025632363,0.000013778047,0.000085702384,0.0000071244026,0.00095722737,0.00007458265],"about_ca_topic_score_codex":0.0004231981,"about_ca_topic_score_gemma":0.000498607,"teacher_disagreement_score":0.12749638,"about_ca_system_score_codex":0.0001024832,"about_ca_system_score_gemma":0.001120004,"threshold_uncertainty_score":0.93779165},"labels":[],"label_agreement":null},{"id":"W2891110398","doi":"10.1200/jco.2017.35.15_suppl.e20567","title":"Whole genome and transcriptome sequencing of lung cancer: Options for personalized cancer treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; BC Cancer Agency","funders":"","keywords":"KRAS; Medicine; ROS1; Lung cancer; Adenocarcinoma; CDKN2A; Oncology; Transcriptome; Cancer; Targeted therapy; Cancer research; Internal medicine; Bioinformatics; Colorectal cancer; Biology; Gene; Genetics; Gene expression","score_opus":0.10765919603407609,"score_gpt":0.46355180045953365,"score_spread":0.35589260442545756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891110398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98073006,0.014053916,0.00058183743,0.0030118432,0.0008818752,0.0001830042,0.0003140143,9.981272e-7,0.00024245404],"genre_scores_gemma":[0.95164394,0.04383983,0.0019639973,0.00038519886,0.0014987887,0.000028760447,0.000010380575,0.000015497624,0.00061361253],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988087,0.000053081305,0.0007629817,0.00015794218,0.0000686835,0.00014860771],"domain_scores_gemma":[0.99807763,0.00019415823,0.0011255089,0.00017830709,0.00027298013,0.00015141023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057307543,0.00009961162,0.0006119546,0.000029763916,0.00011401745,0.00001778904,0.00018575495,0.00021685382,0.000021640984],"category_scores_gemma":[0.0005293117,0.00008055607,0.0003318966,0.000012656876,0.0002603901,0.00000795644,0.00003325479,0.000107598506,1.35015e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037875962,0.00058506586,0.06255865,0.00012046617,0.001860698,0.00002907633,0.00041988894,0.00063009973,0.8562973,0.0006774396,0.0027144675,0.070319265],"study_design_scores_gemma":[0.01484687,0.009662149,0.07092683,0.00008634323,0.0010659465,0.000049452425,0.00017130956,0.00038490054,0.006524375,0.00031822248,0.8956975,0.00026610773],"about_ca_topic_score_codex":0.00020773191,"about_ca_topic_score_gemma":0.0006007327,"teacher_disagreement_score":0.892983,"about_ca_system_score_codex":0.00010553062,"about_ca_system_score_gemma":0.0015284711,"threshold_uncertainty_score":0.32849813},"labels":[],"label_agreement":null},{"id":"W2891124641","doi":"10.1200/jco.2017.35.15_suppl.e16025","title":"Concurrent chemoradiotherapy (CRT) for bladder cancer: Practice patterns and outcomes in the general population.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Bladder cancer; Carboplatin; Cancer registry; Cystectomy; Internal medicine; Proportional hazards model; Cancer; Population; Hazard ratio; Cisplatin; Oncology; Chemoradiotherapy; Surgery; Urology; Chemotherapy; Confidence interval","score_opus":0.16789627523740164,"score_gpt":0.5547314183440867,"score_spread":0.38683514310668504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891124641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92074937,0.00093692093,0.00013379588,0.0757366,0.00155389,0.0004032556,0.000016190847,0.0000023389882,0.0004676533],"genre_scores_gemma":[0.9840322,0.0029913224,0.0010550463,0.010075196,0.001631235,0.000023276312,0.0000018643093,0.000010519859,0.00017932056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847955,0.00017555791,0.00089560286,0.00012115694,0.00019159762,0.00013652338],"domain_scores_gemma":[0.9969649,0.0013491163,0.0012181129,0.00018586463,0.00017152724,0.00011049092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014603463,0.00009517524,0.000854022,0.00003292234,0.00008603782,0.000028778702,0.00015554136,0.00014378603,0.000042064905],"category_scores_gemma":[0.0017876802,0.000050818264,0.00020955912,0.000014900469,0.00008953009,0.00015362051,0.000015975287,0.00036990788,6.047191e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077028753,0.0006693162,0.77062494,0.000011919927,0.00031886602,0.00006881219,0.00015165226,0.0000015663067,0.000004763652,0.0000877923,0.0012309899,0.22605911],"study_design_scores_gemma":[0.012702123,0.0035243253,0.92537093,0.00003099307,0.0003751996,0.0001389401,0.00008303365,0.000053685653,0.000008320353,0.0001567642,0.05750576,0.000049951126],"about_ca_topic_score_codex":0.0006379053,"about_ca_topic_score_gemma":0.0003910863,"teacher_disagreement_score":0.22600915,"about_ca_system_score_codex":0.000085974214,"about_ca_system_score_gemma":0.00042607888,"threshold_uncertainty_score":0.21401493},"labels":[],"label_agreement":null},{"id":"W2891125250","doi":"10.1200/jco.2017.35.15_suppl.e20062","title":"Risk stratification of lung cancer patients at initial presentation: A retrospective cohort study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Retrospective cohort study; Cohort; Lung cancer; Internal medicine; Multivariate analysis; Weight loss; Cancer; Chest pain; Pediatrics; Surgery; Obesity","score_opus":0.10760864113668546,"score_gpt":0.5412639535393668,"score_spread":0.4336553124026814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891125250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385,0.00012040895,0.0000065856098,0.0013550326,0.0013835834,0.00065138814,0.000023501108,0.000002222364,0.0026072676],"genre_scores_gemma":[0.9976817,0.0011037448,0.00012286681,0.00008061945,0.00085349975,0.000033902834,0.0000040070686,0.0000076155384,0.000112080386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975905,0.00022293237,0.0014875737,0.00016325948,0.00044062588,0.00009512539],"domain_scores_gemma":[0.99387324,0.00050578953,0.004241346,0.00027061946,0.00095738686,0.00015159858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001202243,0.000083277046,0.0009759654,0.0000453769,0.00011385787,0.000010782404,0.00011686235,0.00013114317,0.00027832505],"category_scores_gemma":[0.002362061,0.000058643633,0.0002608228,0.000032308853,0.00015983188,0.000117137744,0.00004838608,0.00033789972,0.0000026496075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023234445,0.0053879963,0.96828765,0.000010160446,0.0011022986,0.000051315805,0.0001867247,0.000004023808,0.0000041126796,0.0000126640725,0.0031294823,0.019500125],"study_design_scores_gemma":[0.0105303405,0.011625134,0.97549933,0.00005411156,0.001526263,0.0000057022844,0.000043884193,0.000030480818,0.00009987434,0.00006150959,0.0004806106,0.000042733933],"about_ca_topic_score_codex":0.0005663171,"about_ca_topic_score_gemma":0.0011283852,"teacher_disagreement_score":0.019457392,"about_ca_system_score_codex":0.0005281193,"about_ca_system_score_gemma":0.0006591269,"threshold_uncertainty_score":0.30474642},"labels":[],"label_agreement":null},{"id":"W2891134412","doi":"10.1200/jco.2017.35.15_suppl.e18041","title":"Predictors of treatment attrition in patients with metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Cancer; Internal medicine; Colorectal cancer; Attrition; Confidence interval; Logistic regression; Population; Cohort; Oncology; Disease","score_opus":0.12147348051258006,"score_gpt":0.46590522076023044,"score_spread":0.3444317402476504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891134412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961907,0.00035033046,0.0000019126128,0.0011984736,0.00065983884,0.00030835936,0.000019280697,0.0000021614908,0.0012688932],"genre_scores_gemma":[0.9982858,0.000925784,0.00038447126,0.00007519023,0.00021862876,0.000016890908,0.0000025524373,0.000008236092,0.00008246408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982504,0.00011122629,0.0011403653,0.00012402254,0.00023315685,0.00014081612],"domain_scores_gemma":[0.9972309,0.0004274692,0.0017065614,0.00012564863,0.0003723097,0.00013712645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004563719,0.000115419265,0.0013759313,0.00008294025,0.000053892138,0.000005081203,0.00008287918,0.00009147966,0.00006115294],"category_scores_gemma":[0.00068663206,0.0000631881,0.00022946442,0.00004500842,0.00026422564,0.00009715139,0.000025514964,0.00020721578,9.957106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013657161,0.0031280804,0.9149497,0.00001706767,0.0011208844,0.0001181281,0.00012848874,0.0000076519955,0.000008981047,0.0000049724167,0.00016442299,0.066694416],"study_design_scores_gemma":[0.023417953,0.06437568,0.9084899,0.00013539464,0.0007713927,0.000010080271,0.00005186283,0.0000073580936,0.00006644449,0.000022024822,0.0026054112,0.00004650798],"about_ca_topic_score_codex":0.00029648043,"about_ca_topic_score_gemma":0.0014921492,"teacher_disagreement_score":0.06664791,"about_ca_system_score_codex":0.00052060076,"about_ca_system_score_gemma":0.0010254183,"threshold_uncertainty_score":0.2576736},"labels":[],"label_agreement":null},{"id":"W2891142232","doi":"10.1200/jco.2018.36.15_suppl.5537","title":"Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Placebo; Oncology; Adverse effect; Population; Clinical trial; Pathology","score_opus":0.21567490903444042,"score_gpt":0.5013908320503578,"score_spread":0.2857159230159174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891142232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462646,0.00006216329,0.000018287845,0.003149649,0.00050918414,0.0011856598,0.000012554656,0.0000024038181,0.00043364623],"genre_scores_gemma":[0.99763024,0.00003375275,0.00039032716,0.0011454365,0.0007310398,0.00002983344,0.000009359678,0.000014731781,0.000015281688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923581,0.0030698583,0.002690849,0.0002728101,0.0013790069,0.00022939316],"domain_scores_gemma":[0.99383616,0.002360417,0.0017337471,0.00029450603,0.0015840486,0.00019114153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018023128,0.00016254678,0.0011440841,0.00029458725,0.000031537787,0.0000049645946,0.00015498948,0.00018236265,0.00019206447],"category_scores_gemma":[0.007240306,0.000092891656,0.000101290934,0.00041586367,0.00037119357,0.00011148089,0.000042517433,0.0009035063,0.0000050107715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0846799,0.0065499824,0.8878132,0.000012662969,0.00008295823,0.00025258106,0.0028871344,0.000059883576,0.000011658453,0.000013418209,0.0005869228,0.017049689],"study_design_scores_gemma":[0.052967746,0.031618822,0.91186047,0.00037309184,0.00033729756,0.000032951506,0.0009719578,0.0011734486,0.000040715848,0.00016088749,0.00037123042,0.00009139779],"about_ca_topic_score_codex":0.000138842,"about_ca_topic_score_gemma":0.007289037,"teacher_disagreement_score":0.031712156,"about_ca_system_score_codex":0.00086788513,"about_ca_system_score_gemma":0.0033961514,"threshold_uncertainty_score":0.8667846},"labels":[],"label_agreement":null},{"id":"W2891144912","doi":"10.1200/jco.2018.36.15_suppl.5561","title":"Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Institute of Cancer Research; Ontario Institute for Cancer Research; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Carboplatin; Medicine; Serous fluid; Oncology; Internal medicine; Ovarian cancer; Debulking; Chemotherapy; Olaparib; Exome; Exome sequencing; Cancer; Cancer research; Mutation; Cisplatin; Gene; Biology; Genetics","score_opus":0.10834185372273678,"score_gpt":0.43558367804775394,"score_spread":0.32724182432501714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891144912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659946,0.00010556704,0.0007871901,0.03123655,0.0008971814,0.0007534287,0.000014859215,0.000013097258,0.00019754139],"genre_scores_gemma":[0.96122664,0.00007198717,0.019855846,0.01785915,0.00080527505,0.000059856015,0.000004194475,0.00004058945,0.00007648174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648213,0.00028484376,0.002054624,0.00037041417,0.00041843503,0.00038954784],"domain_scores_gemma":[0.99661463,0.0009310312,0.0008606588,0.00026890158,0.00071067765,0.00061409886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287907,0.00023593147,0.0014026992,0.0002906987,0.000046612848,0.000017083816,0.00019096998,0.00021244194,0.00038301648],"category_scores_gemma":[0.0019314784,0.00017348772,0.00031665657,0.000333425,0.00008404401,0.00005291353,0.00004701421,0.00045722618,0.000030986987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0467356,0.007364717,0.8435741,0.000045359604,0.00048467368,0.0013049503,0.0002626457,0.00033986024,0.0010605706,0.0000337973,0.001371366,0.097422324],"study_design_scores_gemma":[0.025378358,0.032790925,0.9238384,0.0004902425,0.00023886736,0.000020895035,0.000013878496,0.00033994473,0.0055541093,0.00006046788,0.011085807,0.00018811716],"about_ca_topic_score_codex":0.00012594774,"about_ca_topic_score_gemma":0.0006718551,"teacher_disagreement_score":0.09723421,"about_ca_system_score_codex":0.000536127,"about_ca_system_score_gemma":0.0016198673,"threshold_uncertainty_score":0.7074624},"labels":[],"label_agreement":null},{"id":"W2891147617","doi":"10.1200/jco.2017.35.15_suppl.10047","title":"Evaluation of adolescents and young adults (AYA) attitudes towards participation in cancer clinical trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Logistic regression; Young adult; Descriptive statistics; Demographics; Cohort; Clinical trial; Cancer; Family medicine; Gerontology; Demography; Internal medicine","score_opus":0.5754906372886499,"score_gpt":0.664847985884529,"score_spread":0.08935734859587907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891147617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98501515,0.0012213893,0.000032851214,0.009087862,0.0037165992,0.00046647363,0.000005679317,0.0000038519506,0.00045011946],"genre_scores_gemma":[0.9934383,0.002880996,0.00051096076,0.00077975565,0.0023507546,0.000010628384,0.0000012917734,0.000012227517,0.000015058813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98495716,0.006160773,0.0069887964,0.00028304488,0.0013957075,0.00021451058],"domain_scores_gemma":[0.9871114,0.0022634373,0.008079913,0.00039015178,0.0017520646,0.0004030429],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.10954236,0.00013323508,0.0026916284,0.00011659723,0.00005207897,0.000017383836,0.00022616917,0.00050211453,0.00008679788],"category_scores_gemma":[0.13798453,0.0001014384,0.0005072986,0.00005610962,0.00042218834,0.00023460026,0.00008988503,0.0009897148,0.0000025464926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042906846,0.0016116159,0.61037624,0.00008062706,0.00020836739,0.000014835736,0.00024547917,0.0000057827488,0.000011601272,0.0000075659477,0.0002845337,0.38286266],"study_design_scores_gemma":[0.026521187,0.0043343916,0.96461755,0.0015752307,0.0012646365,0.000017205588,0.00009720293,0.0006747704,0.000041504973,0.000253731,0.0005190867,0.00008347745],"about_ca_topic_score_codex":0.0009176608,"about_ca_topic_score_gemma":0.0057936856,"teacher_disagreement_score":0.38277918,"about_ca_system_score_codex":0.00019863436,"about_ca_system_score_gemma":0.003544853,"threshold_uncertainty_score":0.9169135},"labels":[],"label_agreement":null},{"id":"W2891155889","doi":"10.1200/jco.2017.35.15_suppl.e20089","title":"Adjuvant chemotherapy outcome in unselected single-center non-small cell lung cancer (NSCLC) population.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Vinorelbine; Chemotherapy; Internal medicine; Stage (stratigraphy); Regimen; Lung cancer; Oncology; Population; Chemotherapy regimen; Adjuvant; Cancer; Surgery; Cisplatin","score_opus":0.10915799173742291,"score_gpt":0.4726053867581045,"score_spread":0.3634473950206816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891155889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97990113,0.00074852206,0.000031907384,0.014712634,0.0018077515,0.00035144383,0.0000042679344,0.0000060934426,0.002436235],"genre_scores_gemma":[0.9923649,0.0012486122,0.0012548841,0.0035198082,0.0011525443,0.0000147182045,0.0000044560798,0.000023837936,0.00041622677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722683,0.00012476333,0.0019367507,0.00021347361,0.00023659984,0.00026160275],"domain_scores_gemma":[0.99655735,0.00048632835,0.002103998,0.0003152495,0.00026411423,0.00027295496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009779553,0.00015771469,0.0014444679,0.00010380947,0.00006541968,0.000023980461,0.00021154112,0.0003068871,0.00020961522],"category_scores_gemma":[0.0005080888,0.00010753314,0.0004170387,0.000056022756,0.00007289655,0.00010602172,0.000033640175,0.000651902,0.000007147692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001447878,0.0036902823,0.9398768,0.000047864487,0.00022574257,0.00039794185,0.00007711703,0.000010964376,0.0000523374,0.0000047588524,0.0029664438,0.051201895],"study_design_scores_gemma":[0.023757888,0.0034282869,0.9617882,0.0003542171,0.0002956238,0.000048912058,0.0000110148,0.0001398479,0.0001253562,0.000027949285,0.009925762,0.000096946686],"about_ca_topic_score_codex":0.00040899104,"about_ca_topic_score_gemma":0.0011113953,"teacher_disagreement_score":0.051104948,"about_ca_system_score_codex":0.0008422897,"about_ca_system_score_gemma":0.0007664885,"threshold_uncertainty_score":0.4385074},"labels":[],"label_agreement":null},{"id":"W2891159956","doi":"10.1200/jco.2018.36.15_suppl.e15052","title":"Characterization of two potential immunotherapeutics in tumor infiltrating lymphocytes (TILs) using flow cytometry and Meso Scale Discovery.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Flow cytometry; Tumor-infiltrating lymphocytes; CD8; IL-2 receptor; CD28; T cell; Cancer research; Cytokine; Medicine; Immunophenotyping; Molecular biology; Proinflammatory cytokine; Immune system; Immunotherapy; Immunology; Biology; Inflammation","score_opus":0.06901335600157942,"score_gpt":0.438163824961048,"score_spread":0.36915046895946857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891159956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957577,0.00039746528,0.002278369,0.00041917607,0.0009252041,0.00011351248,0.0000051474917,0.000003257827,0.0001001674],"genre_scores_gemma":[0.9913496,0.00059363357,0.0058785095,0.0011658722,0.0009720176,5.135952e-7,0.000002201423,0.000013857091,0.000023801716],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99729544,0.00023268243,0.0019633307,0.00012556871,0.00022344224,0.00015951258],"domain_scores_gemma":[0.9976535,0.00034772587,0.0015503305,0.000114366725,0.00025570273,0.000078388235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020328984,0.000106445856,0.0008978612,0.00020741766,0.000034742396,0.000016500579,0.00008835006,0.0001637121,0.00006351027],"category_scores_gemma":[0.00034129928,0.00008066439,0.00021767506,0.0002482034,0.0004276102,0.00024422488,0.000031335723,0.00030519062,6.2911965e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011830831,0.00050713064,0.11188228,0.00003481189,0.00022829621,0.00006020153,0.00023440518,0.000005960299,0.7753967,0.0000043199616,0.0000054362463,0.09980964],"study_design_scores_gemma":[0.027198182,0.010850489,0.88991314,0.0006894524,0.00037916258,0.0014625706,0.00031957764,0.007684965,0.05941752,0.00010143442,0.0017929879,0.00019053834],"about_ca_topic_score_codex":0.000053733685,"about_ca_topic_score_gemma":0.000032678832,"teacher_disagreement_score":0.7780309,"about_ca_system_score_codex":0.00014856266,"about_ca_system_score_gemma":0.00096544327,"threshold_uncertainty_score":0.32893983},"labels":[],"label_agreement":null},{"id":"W2891163403","doi":"10.1200/jco.2016.34.15_suppl.tps8580","title":"Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lanreotide; Clinical endpoint; Internal medicine; Randomization; Placebo; Performance status; Randomized controlled trial; Gastroenterology; Oncology; Surgery; Chemotherapy; Pathology","score_opus":0.05461933923490235,"score_gpt":0.4524517521008514,"score_spread":0.39783241286594906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891163403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98771393,0.0003089381,0.00012225102,0.00710994,0.00028606897,0.003912496,0.0000036852832,0.000007488277,0.0005352276],"genre_scores_gemma":[0.9981902,0.00052258023,0.00028614348,0.00039931494,0.00032185228,0.00003442978,0.0000012621813,0.000022431588,0.00022179073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99297273,0.0019366128,0.0036601354,0.00027558135,0.00076951104,0.00038539816],"domain_scores_gemma":[0.9803129,0.016064474,0.0024206443,0.0003184956,0.0005076306,0.00037585534],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065157395,0.00022023992,0.003706631,0.00024219358,0.00004396117,0.000009999545,0.00028597307,0.000048526315,0.00007781647],"category_scores_gemma":[0.012286044,0.00008642714,0.00036256446,0.00019653032,0.00064920704,0.00017069584,0.000116324074,0.00096391013,0.0000030592282],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83916986,0.005624969,0.13778608,0.000016027667,0.0007287027,0.0013194463,0.000053495478,0.000016158003,0.000016680418,0.00002742236,0.00017346228,0.015067687],"study_design_scores_gemma":[0.89162654,0.02226176,0.08373047,0.00018456177,0.0005832373,0.0002110461,0.00008400369,0.000049836985,0.000020204885,0.000030731262,0.0011347997,0.00008280631],"about_ca_topic_score_codex":0.000040621624,"about_ca_topic_score_gemma":0.00018026406,"teacher_disagreement_score":0.0540556,"about_ca_system_score_codex":0.000089415735,"about_ca_system_score_gemma":0.0007557807,"threshold_uncertainty_score":0.9960339},"labels":[],"label_agreement":null},{"id":"W2891179139","doi":"10.1200/jco.2018.36.15_suppl.e15137","title":"Immunotherapy efficacy and toxicity in a real-world elderly population.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Toxicity; Population; Immunotherapy; Oncology; Internal medicine; Pharmacology; Cancer; Environmental health","score_opus":0.23109806734966992,"score_gpt":0.5420036895177022,"score_spread":0.31090562216803225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891179139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864716,0.0002517544,0.000023177508,0.008082093,0.00036995328,0.00019587282,7.060803e-7,0.000006542786,0.004598278],"genre_scores_gemma":[0.99037385,0.0036811845,0.0033146369,0.0009787705,0.0013838006,0.0000020183234,4.93507e-7,0.000009729419,0.00025551073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971808,0.00043997864,0.0017005358,0.00014740448,0.00031633067,0.00021494784],"domain_scores_gemma":[0.99570197,0.0028800007,0.0006747659,0.00014894025,0.000367552,0.00022674793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038082502,0.00009062144,0.0011084259,0.00023196712,0.000046769863,0.000008322974,0.00010055565,0.00016697627,0.0001487518],"category_scores_gemma":[0.0065763374,0.00006162612,0.00015343314,0.000212097,0.00037204646,0.00008328778,0.000053313302,0.0007399864,0.000009384395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004703037,0.00095730164,0.5320485,0.0000109262,0.00015500166,0.00007505594,0.00017028014,7.5008995e-7,0.0013020233,0.000051865096,0.0019239428,0.45860133],"study_design_scores_gemma":[0.010246616,0.012182162,0.95913726,0.00010406853,0.000026127398,0.000030655654,0.00003376867,0.00006476977,0.00007384232,0.00019170782,0.017858537,0.000050508923],"about_ca_topic_score_codex":0.000286548,"about_ca_topic_score_gemma":0.0013900691,"teacher_disagreement_score":0.4585508,"about_ca_system_score_codex":0.00013403907,"about_ca_system_score_gemma":0.0003570472,"threshold_uncertainty_score":0.7872965},"labels":[],"label_agreement":null},{"id":"W2891187747","doi":"10.1200/jco.18.00407","title":"Guideline for the Management of <i>Clostridium Difficile</i> Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Fidaxomicin; Clostridium difficile; Guideline; Hematopoietic stem cell transplantation; Intensive care medicine; Population; Transplantation; Pediatric cancer; Randomized controlled trial; Cancer; Pediatrics; Internal medicine; Vancomycin; Antibiotics; Pathology","score_opus":0.03703784133326699,"score_gpt":0.3923241802123301,"score_spread":0.35528633887906313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891187747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964648,0.000492694,0.0010410002,0.001039161,0.00042633814,0.00044111095,0.0000056493727,0.0000023208504,0.00008695219],"genre_scores_gemma":[0.98107946,0.017531503,0.0004617307,0.0003479218,0.0005289596,0.000011504027,0.0000010405985,0.0000075419293,0.000030342328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986423,0.000056821398,0.00096141885,0.00010981376,0.00013487047,0.000094750874],"domain_scores_gemma":[0.99885166,0.00013927087,0.0006531672,0.000067296234,0.00021289825,0.000075683645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007746088,0.000071201306,0.00039916628,0.000071999304,0.000036394107,0.0000038796375,0.000037534228,0.00008448325,0.0000074368345],"category_scores_gemma":[0.0000122851625,0.000041353374,0.000064626096,0.00012641656,0.00010494117,0.000046453402,0.000012338674,0.00021302533,3.3995704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033819063,0.0006168798,0.96646976,0.00020135574,0.00012127797,0.000008472301,0.00006398026,0.00002151484,0.000043179632,0.000012917712,0.0006454036,0.028413361],"study_design_scores_gemma":[0.010889566,0.0053158095,0.9806806,0.00026497364,0.001318568,0.00017939409,0.000026489732,0.000021356582,0.0003390563,0.000022896378,0.00089425046,0.000047045673],"about_ca_topic_score_codex":0.00005659616,"about_ca_topic_score_gemma":0.00010424721,"teacher_disagreement_score":0.028366316,"about_ca_system_score_codex":0.000040793253,"about_ca_system_score_gemma":0.00015477973,"threshold_uncertainty_score":0.16863416},"labels":[],"label_agreement":null},{"id":"W2891191100","doi":"10.1200/jco.2017.35.15_suppl.10029","title":"Do elderly and young patients derive similar relative survival benefits from novel oncology drugs? A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Confidence interval; Clinical trial; Randomized controlled trial; Clinical endpoint; Publication bias; Subgroup analysis; Relative survival; Cancer; Cancer registry","score_opus":0.8350348266645607,"score_gpt":0.6174323078995919,"score_spread":0.21760251876496883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891191100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006126844,0.9852203,0.00026129876,0.00806378,0.001422905,0.0024275156,0.0013971543,0.000007783302,0.0011379985],"genre_scores_gemma":[0.00012224223,0.99087465,0.002923776,0.005072825,0.00048209736,0.00014095003,0.00006393733,0.000059087466,0.00026042885],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.95963126,0.0066838856,0.031851485,0.001069422,0.00030051285,0.00046345388],"domain_scores_gemma":[0.8887412,0.030534636,0.078234755,0.0010766798,0.00068451185,0.00072820456],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.086048774,0.00070468825,0.052532103,0.0007062263,0.0002429829,0.00013300212,0.000958228,0.0017279942,0.00027953595],"category_scores_gemma":[0.06938024,0.00056800083,0.0049444423,0.00025516888,0.0003703527,0.0006988271,0.00029174867,0.0019402343,0.00016914227],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007041802,0.0016817916,0.0014828602,0.40589312,0.53872037,0.00004518151,0.0011388058,0.000005470015,8.496851e-10,0.010522533,0.004726327,0.035713136],"study_design_scores_gemma":[0.001801115,0.0018124381,0.001029796,0.014268322,0.50127965,0.000042663123,0.00012692981,0.000021436093,6.3464956e-10,0.0019213909,0.477119,0.00057724334],"about_ca_topic_score_codex":0.00024972466,"about_ca_topic_score_gemma":0.0003602935,"teacher_disagreement_score":0.47239268,"about_ca_system_score_codex":0.0008289557,"about_ca_system_score_gemma":0.00171482,"threshold_uncertainty_score":0.9996771},"labels":[],"label_agreement":null},{"id":"W2891194456","doi":"10.1200/jco.2017.35.15_suppl.9045","title":"Recurrent versus de novo metastatic NSCLC: Impact on outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cohort; Oncology; Chemotherapy; Radiation therapy; Retrospective cohort study; Performance status; Cancer; Stage (stratigraphy); Disease; Lung cancer; Surgery","score_opus":0.2901324808872659,"score_gpt":0.6029319645217727,"score_spread":0.31279948363450677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891194456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593061,0.0002737748,0.000017050963,0.028113384,0.0039766147,0.00015716824,0.0000059990994,0.000005117123,0.00814475],"genre_scores_gemma":[0.99505836,0.0009073686,0.0014367566,0.0015901385,0.0008443919,0.0000049318883,0.0000010532798,0.000012727627,0.0001442837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979022,0.0001900493,0.0012108188,0.00014467235,0.000315636,0.00023661506],"domain_scores_gemma":[0.9943504,0.0027824696,0.001753804,0.00039860635,0.0001998515,0.0005148723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002031854,0.00014114426,0.0014176699,0.00006583151,0.000078173514,0.000022188566,0.00020837283,0.00014371463,0.00024816633],"category_scores_gemma":[0.005901514,0.0000751964,0.00096140103,0.000023060915,0.0001325285,0.00007762208,0.000039261868,0.0006716906,0.000064167514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01835296,0.005416223,0.59639907,0.000020958358,0.0028896392,0.002879571,0.00005109587,0.000013455478,0.000003180725,0.00020737466,0.013602041,0.3601644],"study_design_scores_gemma":[0.026937904,0.04063677,0.9068014,0.00016019655,0.001256023,0.0001778606,0.000017058113,0.00001820972,0.000022706781,0.0002013072,0.023703517,0.00006705404],"about_ca_topic_score_codex":0.000040233637,"about_ca_topic_score_gemma":0.000057375117,"teacher_disagreement_score":0.36009735,"about_ca_system_score_codex":0.0008974277,"about_ca_system_score_gemma":0.0018438972,"threshold_uncertainty_score":0.706509},"labels":[],"label_agreement":null},{"id":"W2891197019","doi":"10.1200/jco.2017.35.15_suppl.6600","title":"Are surrogate endpoints unbiased metrics compared to hazard ratio for death? An evaluation of clinical benefit scores (CBS) in the American Society of Clinical Oncology (ASCO) value framework.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; University of Calgary; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Hazard ratio; Internal medicine; Clinical endpoint; Clinical Oncology; Oncology; Clinical trial; Progression-free survival; Randomized controlled trial; Confidence interval; Cancer; Overall survival","score_opus":0.8654856141165033,"score_gpt":0.6718629996983625,"score_spread":0.19362261441814077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891197019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94063115,0.00033282707,0.008320713,0.044458725,0.004150379,0.0014971487,0.00022953509,0.000007389039,0.00037215967],"genre_scores_gemma":[0.92564094,0.00066287856,0.053027924,0.018027462,0.002505483,0.00006286058,0.000014536138,0.000036617097,0.000021305885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95408845,0.009219664,0.03444552,0.00089419715,0.000732677,0.00061951054],"domain_scores_gemma":[0.8426312,0.07448377,0.07828763,0.0015815969,0.002294475,0.0007212824],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3327429,0.00030926513,0.008352228,0.00043719978,0.00024585394,0.00007146304,0.0018585443,0.0010763381,0.000088441775],"category_scores_gemma":[0.29670125,0.00027980792,0.001974715,0.000357394,0.0009679234,0.0005624055,0.00018167833,0.0017651002,0.000042839027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020961512,0.0030469552,0.94023895,0.00010893891,0.00054215745,0.0000053283566,0.0006388388,0.002420881,9.773651e-7,0.0071703536,0.008076909,0.03565357],"study_design_scores_gemma":[0.0085460525,0.007340431,0.9064961,0.0001767717,0.00021846872,0.0000070399856,0.0015046506,0.04049236,0.0000035282023,0.022029039,0.012946703,0.00023885728],"about_ca_topic_score_codex":0.0007097544,"about_ca_topic_score_gemma":0.0026732364,"teacher_disagreement_score":0.111457184,"about_ca_system_score_codex":0.0006020121,"about_ca_system_score_gemma":0.00385213,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W2891207456","doi":"10.1200/jco.2017.35.15_suppl.4007","title":"Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Gemcitabine; Erlotinib; Capecitabine; Internal medicine; Pancreatic cancer; Adenocarcinoma; Gastroenterology; Stage (stratigraphy); Randomized controlled trial; Chemotherapy; Oncology; Cancer; Colorectal cancer; Epidermal growth factor receptor","score_opus":0.22802393153807055,"score_gpt":0.5543225874790554,"score_spread":0.32629865594098484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891207456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850576,0.0001506539,0.00029610537,0.009109367,0.00050410454,0.0031861286,0.000112873786,0.0000038760704,0.001579271],"genre_scores_gemma":[0.99177396,0.00013065866,0.0069394335,0.0002804064,0.00039816415,0.000082783525,0.000026343658,0.000019401861,0.00034884023],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9910424,0.0023628324,0.004996149,0.0002642719,0.0009980691,0.0003362742],"domain_scores_gemma":[0.96779776,0.016624313,0.010496405,0.0008230739,0.003987648,0.0002708015],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020313961,0.00019294173,0.003970473,0.00016995851,0.00027156592,0.0000054344714,0.0005842715,0.00041365967,0.000089462985],"category_scores_gemma":[0.11094398,0.000089193694,0.00073391915,0.00018382359,0.00158141,0.00010829281,0.00018656356,0.0008364014,0.0000011362318],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8302482,0.0067267856,0.10603996,0.0001530145,0.0014760196,0.00001974574,0.0007925384,0.00001917324,0.0014635015,0.00009365799,0.0028621238,0.050105304],"study_design_scores_gemma":[0.3787802,0.11846227,0.49625716,0.00075547287,0.0029124047,0.00003759226,0.0001897363,0.001203662,0.00032526653,0.0004010223,0.0006018057,0.00007342276],"about_ca_topic_score_codex":0.00011956704,"about_ca_topic_score_gemma":0.0001278968,"teacher_disagreement_score":0.451468,"about_ca_system_score_codex":0.00017493863,"about_ca_system_score_gemma":0.003586254,"threshold_uncertainty_score":0.89654493},"labels":[],"label_agreement":null},{"id":"W2891210203","doi":"10.1200/jco.2018.36.15_suppl.10561","title":"Cardiac outcomes in childhood cancer survivors (CCS): A population-based study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Toronto General Hospital; Hospital for Sick Children; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Cumulative incidence; Population; Coronary artery disease; Myocardial infarction; Internal medicine; Incidence (geometry); Heart failure; Cancer; Cancer registry; Cohort; Cardiology","score_opus":0.08415394058232088,"score_gpt":0.4758722954247155,"score_spread":0.3917183548423946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891210203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165934,0.000089272944,0.00002973636,0.005138883,0.0020033242,0.0003669893,0.0000033428673,0.000009723695,0.0006993745],"genre_scores_gemma":[0.9945955,0.0000521085,0.00041953597,0.0028663864,0.0019476975,0.0000074378477,0.0000019742133,0.000015583979,0.000093727154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708277,0.0005267167,0.0016740294,0.00016775756,0.00037220467,0.00017650602],"domain_scores_gemma":[0.9972932,0.0011352296,0.00086191396,0.00017819437,0.00033251077,0.00019900006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003028412,0.0001185652,0.001511297,0.000171567,0.00003508071,0.0000065048775,0.000098543256,0.00030419734,0.00011741254],"category_scores_gemma":[0.0018942266,0.00008704237,0.00052857614,0.00020379458,0.00007182947,0.00007607922,0.000014611791,0.0006900703,0.0000080472155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069379644,0.0020371508,0.9511281,0.0000061721266,0.00032242635,0.000048843387,0.0002654854,0.000018540075,0.0002845402,0.0000072216294,0.00014195254,0.045045733],"study_design_scores_gemma":[0.0074288105,0.0057488354,0.9832557,0.0000594085,0.00020301441,0.000008109654,0.00021689734,0.000023645705,0.00045097613,0.00009227294,0.0024316665,0.00008068043],"about_ca_topic_score_codex":0.0007922792,"about_ca_topic_score_gemma":0.0022853767,"teacher_disagreement_score":0.04496505,"about_ca_system_score_codex":0.00024353914,"about_ca_system_score_gemma":0.0012055105,"threshold_uncertainty_score":0.3549485},"labels":[],"label_agreement":null},{"id":"W2891211996","doi":"10.1200/jco.2018.36.15_suppl.10532","title":"Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Induction chemotherapy; Bonferroni correction; Oncology; Neuroblastoma; Cog; Univariate analysis; Univariate; Logistic regression; Clinical endpoint; Stage (stratigraphy); Chemotherapy; Multivariate analysis; Clinical trial; Multivariate statistics; Statistics; Biology","score_opus":0.04990366565574631,"score_gpt":0.422558036838731,"score_spread":0.37265437118298467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891211996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98471135,0.00002406922,0.00010610993,0.012635882,0.0018602735,0.0005438404,0.00001594974,0.000010780172,0.000091732145],"genre_scores_gemma":[0.99492985,0.00017020709,0.00091338117,0.0010694177,0.002791657,0.0000102426475,0.000005363937,0.000026305384,0.00008355573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940277,0.0022972461,0.002428467,0.00033802647,0.00058180164,0.00032676925],"domain_scores_gemma":[0.99301326,0.0037408788,0.0019595374,0.0004167649,0.00040459138,0.00046494152],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033521252,0.00018051077,0.0013689708,0.00026070664,0.00005632036,0.00000775813,0.00028358444,0.0004038325,0.00018208625],"category_scores_gemma":[0.009563199,0.00010735877,0.0003721307,0.0003386754,0.00053327915,0.000087800996,0.000112439884,0.0014340793,0.000022332626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17710915,0.007089101,0.68410957,0.0000044095586,0.001250808,0.003090479,0.0003413427,0.0000035985177,0.011470554,0.000006980507,0.008239964,0.107284054],"study_design_scores_gemma":[0.014986244,0.06960764,0.904481,0.000056292756,0.0002579879,0.0009541115,0.000032373908,0.000008772745,0.0011283238,0.00013707619,0.008287986,0.00006222311],"about_ca_topic_score_codex":0.0003966913,"about_ca_topic_score_gemma":0.0004343721,"teacher_disagreement_score":0.22037141,"about_ca_system_score_codex":0.00020308729,"about_ca_system_score_gemma":0.0013034913,"threshold_uncertainty_score":0.99877965},"labels":[],"label_agreement":null},{"id":"W2891227713","doi":"10.1200/jco.2017.35.15_suppl.10502","title":"A high-risk genetic profile for premature menopause (PM) in childhood cancer survivors (CCS) exposed to gonadotoxic therapy: A report from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oncology; Single-nucleotide polymorphism; Internal medicine; Cohort; Population; SNP; Odds ratio; Genotype; Genetics; Biology; Gene","score_opus":0.03653410305298986,"score_gpt":0.3940896106472354,"score_spread":0.35755550759424554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891227713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524475,0.007639703,0.000077691846,0.0025338256,0.0018134312,0.0022173158,0.0004373227,0.0000047232334,0.000031212054],"genre_scores_gemma":[0.98623294,0.0070685293,0.0027152144,0.0011130498,0.0022102895,0.000456613,0.000019237037,0.000057058758,0.00012709721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566203,0.0007688672,0.0022067113,0.0006358194,0.000376296,0.00035028716],"domain_scores_gemma":[0.9939849,0.0009249978,0.0033402648,0.0009553637,0.00055063603,0.00024383218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035278955,0.00029887373,0.0012625749,0.000073920026,0.00020755419,0.00005118152,0.000877105,0.00050301984,0.0000586882],"category_scores_gemma":[0.004202764,0.00020671845,0.000256347,0.00010615778,0.00025518087,0.000021215335,0.0002604187,0.0006565567,9.176121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002165129,0.0023507886,0.94176686,0.000014591292,0.0020527337,0.000063970176,0.0011227656,0.0005641437,0.005749008,0.0000011981721,0.0077494485,0.036399394],"study_design_scores_gemma":[0.006298958,0.0052021565,0.96735626,0.00007234223,0.00031280098,0.00003255355,0.00024715986,0.00001568465,0.0035933724,0.00010482101,0.016569432,0.00019444311],"about_ca_topic_score_codex":0.0036241387,"about_ca_topic_score_gemma":0.028044093,"teacher_disagreement_score":0.03620495,"about_ca_system_score_codex":0.00010805605,"about_ca_system_score_gemma":0.002603403,"threshold_uncertainty_score":0.98969156},"labels":[],"label_agreement":null},{"id":"W2891249056","doi":"10.1200/jco.2018.36.15_suppl.9580","title":"Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Melanoma; CTL*; Receiver operating characteristic; Oncology; Hazard ratio; Proportional hazards model; Multiplex; Immune system; Survival analysis; CD8; Cancer research; Internal medicine; Pathology; Immunology; Biology; Confidence interval; Bioinformatics","score_opus":0.1376824661390942,"score_gpt":0.5206512406025781,"score_spread":0.3829687744634839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891249056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592745,0.0013387635,0.000046031466,0.0015220479,0.00033444076,0.0006643377,0.000014277385,0.0000022751437,0.0001503818],"genre_scores_gemma":[0.9954785,0.0012757417,0.0026900722,0.00035465392,0.00011227943,0.000010691731,0.0000017601061,0.000011774473,0.00006449403],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99619704,0.0008529029,0.0018725144,0.00023315843,0.00058234273,0.00026201684],"domain_scores_gemma":[0.9967685,0.0011959103,0.0011209246,0.00019623262,0.000485205,0.00023322753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009928826,0.00013202454,0.0010890401,0.00028556783,0.000057900048,0.0000053979597,0.00017983004,0.00011021904,0.00018144333],"category_scores_gemma":[0.004171197,0.00009953607,0.00014966601,0.00015396603,0.00073510484,0.00008720475,0.0001967484,0.00043253467,0.000007664913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023367496,0.0011935649,0.07886372,0.000035564168,0.0012810574,0.00017284133,0.0023222303,0.000018967325,0.8602224,0.000011161712,0.00056442665,0.031946566],"study_design_scores_gemma":[0.012657854,0.019578645,0.9574865,0.00018821753,0.00020115134,0.00005748876,0.0011402147,0.0011163703,0.0059243897,0.00008452926,0.0014733227,0.0000913342],"about_ca_topic_score_codex":0.00031853473,"about_ca_topic_score_gemma":0.0007549341,"teacher_disagreement_score":0.8786228,"about_ca_system_score_codex":0.0005469436,"about_ca_system_score_gemma":0.0009488261,"threshold_uncertainty_score":0.49936134},"labels":[],"label_agreement":null},{"id":"W2891251835","doi":"10.1200/jco.2018.36.15_suppl.10506","title":"Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with <i>BRAF</i> V600–mutant relapsed refractory low-grade glioma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Dabrafenib; Trametinib; Internal medicine; Adverse effect; Refractory (planetary science); Pilocytic astrocytoma; Glioma; Discontinuation; Oncology; Gastroenterology; Astrocytoma; Cancer; Cancer research","score_opus":0.05443035417168518,"score_gpt":0.41155083201273956,"score_spread":0.3571204778410544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891251835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973872,0.00022077464,0.000002516212,0.00093458546,0.00053698214,0.0007059695,0.000046616387,0.0000073295305,0.0001580687],"genre_scores_gemma":[0.9981801,0.00030971717,0.00043579505,0.00024690936,0.0007805447,0.000004710166,0.00001589934,0.000022486855,0.000003856712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947892,0.000600732,0.0033939495,0.00037997225,0.00057769776,0.0002584402],"domain_scores_gemma":[0.99186766,0.004159204,0.002686792,0.00035601523,0.0004910975,0.00043921138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017021123,0.00022047131,0.0017969871,0.00032433166,0.00004626565,0.000007680284,0.00015355436,0.0003080424,0.00004529238],"category_scores_gemma":[0.0033841785,0.00013623413,0.00016555194,0.0004136573,0.0002346329,0.00011910076,0.00007370485,0.0007051821,0.000005630033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10758512,0.12912954,0.7260314,0.000018507944,0.00063589035,0.0024935796,0.0011221879,0.0000049669266,0.0002486665,0.0000034649422,0.0005656652,0.032160968],"study_design_scores_gemma":[0.22424752,0.08585887,0.68722314,0.00012765634,0.0008203586,0.000020817593,0.0001383178,0.00001008108,0.000112156325,0.000015505224,0.0013358154,0.000089800895],"about_ca_topic_score_codex":0.00009229603,"about_ca_topic_score_gemma":0.0002498845,"teacher_disagreement_score":0.11666239,"about_ca_system_score_codex":0.00013083847,"about_ca_system_score_gemma":0.00059036195,"threshold_uncertainty_score":0.55554664},"labels":[],"label_agreement":null},{"id":"W2891255953","doi":"10.1200/jco.2017.35.15_suppl.e22535","title":"Efficacy of bevacizumab and temozolomide in locally advanced and metastatic hemangiopericytoma (HPC) and malignant solitary fibrous tumor (SFT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Population; Regimen; Solitary fibrous tumor; Temozolomide; Cancer; Progression-free survival; Lung cancer; Internal medicine; Surgery; Oncology; Radiation therapy; Chemotherapy","score_opus":0.09811153632288673,"score_gpt":0.462811491498051,"score_spread":0.3646999551751643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891255953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873207,0.007532614,0.00001693024,0.0042607347,0.00023129873,0.00030002,0.0000040026976,0.00000548621,0.00032820238],"genre_scores_gemma":[0.9886538,0.0020755234,0.008559181,0.00044376325,0.00018342312,0.0000036216582,4.2353062e-7,0.000017481087,0.00006277944],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99711466,0.00022595201,0.0019245046,0.00025562852,0.00023007226,0.00024919724],"domain_scores_gemma":[0.9945632,0.0030452507,0.0016004833,0.00026904303,0.00020709076,0.00031490234],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020133245,0.00017882377,0.002178053,0.00013643643,0.000082052684,0.000011344931,0.00012578384,0.00010446502,0.000011170013],"category_scores_gemma":[0.011414451,0.00012649012,0.00015306172,0.000049372567,0.0010110278,0.00015746112,0.00022330205,0.0005049515,0.000001496971],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038566887,0.0024108163,0.42227027,0.0009485176,0.001397523,0.035617992,0.0015042672,0.000011638998,0.0030645814,0.0002702995,0.0008631259,0.4930741],"study_design_scores_gemma":[0.024469135,0.014897842,0.94893694,0.0006090635,0.00054171536,0.0072629675,0.0006782299,0.0000953368,0.00022546627,0.00051962066,0.0016250088,0.00013866187],"about_ca_topic_score_codex":0.000053509335,"about_ca_topic_score_gemma":0.000095524105,"teacher_disagreement_score":0.5266667,"about_ca_system_score_codex":0.00005167685,"about_ca_system_score_gemma":0.00040600184,"threshold_uncertainty_score":0.99691284},"labels":[],"label_agreement":null},{"id":"W2891257014","doi":"10.1200/jco.2017.35.15_suppl.10064","title":"Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; Ontario Clinical Oncology Group; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Neurocognitive; Medicine; Prospective cohort study; Cohort; Distress; Cancer; Internal medicine; Clinical psychology; Psychiatry; Cognition","score_opus":0.1436877634208372,"score_gpt":0.4990582177761629,"score_spread":0.35537045435532566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891257014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876848,0.00019228277,0.00004052534,0.00421902,0.0010047825,0.0008354249,0.000014417198,0.000009333698,0.005999454],"genre_scores_gemma":[0.99756217,0.0008232381,0.00010281818,0.00021620445,0.0009052627,0.000075372016,7.792837e-7,0.000014377388,0.00029980537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976354,0.00023596166,0.001161115,0.00038199173,0.00032784897,0.00025768494],"domain_scores_gemma":[0.99656904,0.0007624703,0.0014507502,0.00019213281,0.0007714471,0.0002541383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009095201,0.00018584906,0.0012667967,0.00011713836,0.0002067,0.000027232742,0.00013062003,0.00018722888,0.000077518576],"category_scores_gemma":[0.0033915218,0.00011681957,0.00015506553,0.000104124876,0.0008052532,0.00019937572,0.00011156467,0.0014498121,0.0000050825847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026330704,0.0054110815,0.92400396,0.000015530184,0.00053706573,0.0014351307,0.00028001596,0.0000013378644,0.0000026320376,0.000004977607,0.00041983623,0.04155775],"study_design_scores_gemma":[0.027606677,0.044170618,0.9247777,0.00042721003,0.0006600905,0.0005085267,0.0014988051,0.0000091796355,0.0000017008172,0.000052663105,0.00017495612,0.00011189387],"about_ca_topic_score_codex":0.0002415366,"about_ca_topic_score_gemma":0.0062317965,"teacher_disagreement_score":0.04144586,"about_ca_system_score_codex":0.0001604745,"about_ca_system_score_gemma":0.0002506814,"threshold_uncertainty_score":0.6298793},"labels":[],"label_agreement":null},{"id":"W2891282311","doi":"10.1200/jco.2017.35.15_suppl.e20588","title":"A phase IV study using multi-omics to identify mechanisms of response and resistance to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients with distinct progression free survival outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital Notre-Dame; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; ALK inhibitor; Progression-free survival; Adenocarcinoma; Cancer; Chemotherapy; Progressive disease","score_opus":0.09242738899590684,"score_gpt":0.5440280215783889,"score_spread":0.45160063258248206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891282311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937985,0.00006786983,0.0021937112,0.0014768544,0.0007684589,0.0015749185,0.00004704413,0.0000037737796,0.0000688589],"genre_scores_gemma":[0.9577324,0.000014072372,0.041792702,0.00021957202,0.000064560125,0.000032492906,0.00000148534,0.000024403584,0.00011835471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728566,0.00030773372,0.0014875962,0.00029775905,0.0003901665,0.00023108345],"domain_scores_gemma":[0.9960607,0.0007414172,0.0017902253,0.0004270853,0.00058955397,0.0003909893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019578577,0.00017780115,0.0012954033,0.00016276541,0.00011804324,0.000021953758,0.0002518715,0.000127112,0.0000068469794],"category_scores_gemma":[0.003168253,0.000117076714,0.0001186662,0.000100476354,0.000080741345,0.0001362776,0.00015344449,0.00035296663,4.1055924e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04555809,0.009814774,0.9316971,0.00005474422,0.00024271739,0.00032774167,0.0010301406,0.00002304111,0.0009750995,0.0000029314888,0.000030091573,0.010243549],"study_design_scores_gemma":[0.06988272,0.014727992,0.91326296,0.00058870926,0.0006434454,0.0000024656445,0.00041382216,0.00005382601,0.00015973518,0.000020427047,0.00013353025,0.00011037233],"about_ca_topic_score_codex":0.000130156,"about_ca_topic_score_gemma":0.0023761261,"teacher_disagreement_score":0.03959899,"about_ca_system_score_codex":0.00031939798,"about_ca_system_score_gemma":0.0012277236,"threshold_uncertainty_score":0.47742498},"labels":[],"label_agreement":null},{"id":"W2891308616","doi":"10.1200/jco.2016.34.15_suppl.10090","title":"Cancer patients' interest and preferences for an inpatient smoking cessation program (SCP).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Smoking cessation; Cancer; Logistic regression; Feeling; Internal medicine; Thematic analysis; Family medicine; Qualitative research","score_opus":0.2461960793081947,"score_gpt":0.5131489395659122,"score_spread":0.26695286025771753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891308616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274784,0.000050457616,0.00014101852,0.002001543,0.0031945903,0.00033705402,0.000009835837,0.000013583506,0.0015040584],"genre_scores_gemma":[0.9970211,0.00047020134,0.0010609785,0.0003757471,0.00095028686,0.000035839243,0.000001257526,0.0000073884607,0.000077200086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975541,0.00056905136,0.0012061597,0.00016068608,0.00028736424,0.00022259759],"domain_scores_gemma":[0.9941882,0.003238247,0.0015325703,0.0000686606,0.0007095246,0.00026278498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034194856,0.00007779568,0.00044937932,0.00006565245,0.00013397961,0.00003361398,0.00024932803,0.00028140517,0.000051582323],"category_scores_gemma":[0.00635356,0.00004605432,0.00010916714,0.00007365255,0.0004702714,0.00051799224,0.000040599156,0.0002041424,8.9294025e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115874405,0.00047598215,0.4142871,0.000004304766,0.000027210517,7.66967e-7,0.00089464354,2.8041455e-7,0.0000029914784,0.00049824733,0.0010690937,0.58262354],"study_design_scores_gemma":[0.0028056188,0.010491318,0.6305505,0.000113635884,0.00007580902,7.2050284e-7,0.0016053796,0.000007750246,0.000020796597,0.0068169557,0.34742028,0.00009124938],"about_ca_topic_score_codex":0.00021148048,"about_ca_topic_score_gemma":0.0045162896,"teacher_disagreement_score":0.5825323,"about_ca_system_score_codex":0.00014492862,"about_ca_system_score_gemma":0.0009195441,"threshold_uncertainty_score":0.7606263},"labels":[],"label_agreement":null},{"id":"W2891331437","doi":"10.1200/jco.2018.36.15_suppl.2062","title":"Neurological death in patients with EGFR-mutant non-small cell lung cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Radiosurgery; Incidence (geometry); Exact test; Cause of death; Internal medicine; Cancer; Mortality rate; Surgery; Disease; Radiation therapy","score_opus":0.05322073428816949,"score_gpt":0.4530012459895872,"score_spread":0.3997805117014177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891331437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903734,0.00012961517,0.00010368685,0.0028459204,0.0008595027,0.0002934268,0.000004296477,0.0000053352,0.005384863],"genre_scores_gemma":[0.99296296,0.00014294355,0.00241866,0.0034536715,0.00084041717,0.000007611075,0.0000022485897,0.000013306742,0.00015816305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980821,0.00013412807,0.0011449124,0.00018330112,0.00022641887,0.00022913655],"domain_scores_gemma":[0.99791735,0.0004102008,0.0007912417,0.00013044356,0.0004652939,0.00028548768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005471753,0.00011806615,0.0008423538,0.00008949341,0.000035745656,0.0000057960774,0.00010824822,0.00021945659,0.00016825812],"category_scores_gemma":[0.00028587706,0.00006613697,0.00015428843,0.00013163671,0.00013198605,0.0000614333,0.000029387358,0.0006024439,0.000009405423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041462225,0.0024471804,0.9767867,0.000013480423,0.00015963962,0.00040478402,0.00010958721,0.000014109849,0.000008314105,0.000012506411,0.00075028726,0.015147203],"study_design_scores_gemma":[0.016601099,0.031855177,0.9416972,0.00007652722,0.0005552341,0.000027733773,0.000016039729,0.00014002786,0.000021613465,0.000030542695,0.008913334,0.000065495],"about_ca_topic_score_codex":0.00005301072,"about_ca_topic_score_gemma":0.00012055918,"teacher_disagreement_score":0.035089508,"about_ca_system_score_codex":0.00019497554,"about_ca_system_score_gemma":0.0016985339,"threshold_uncertainty_score":0.30131263},"labels":[],"label_agreement":null},{"id":"W2891333639","doi":"10.1200/jco.2018.36.15_suppl.10513","title":"Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; AIDS Vancouver","funders":"","keywords":"Medicine; Anxiety; Somatization; Depression (economics); Quality of life (healthcare); Population; Cancer; Physical therapy; Internal medicine; Psychiatry","score_opus":0.1112602167752333,"score_gpt":0.5128691900782826,"score_spread":0.4016089733030493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891333639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823981,0.0018918795,0.0000070939727,0.010706332,0.00298842,0.001207335,0.00011442816,0.000018675073,0.0006677344],"genre_scores_gemma":[0.98948014,0.0036260379,0.00023658338,0.0020268494,0.004475816,0.000034274653,0.000007114341,0.00005482027,0.000058342986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877468,0.0021654922,0.007248707,0.0007372023,0.0015398869,0.0005619251],"domain_scores_gemma":[0.98454,0.0052362415,0.0067954203,0.0011993395,0.0016606548,0.00056838145],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009146682,0.0004676501,0.004545504,0.0002791984,0.00007126832,0.000012416336,0.0009328446,0.0007125415,0.0010179455],"category_scores_gemma":[0.0100721745,0.00027603068,0.0015038576,0.00075184705,0.000876064,0.00015651925,0.00018238228,0.0023516554,0.000012140775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010865121,0.018984511,0.9170827,0.000026494177,0.0016553199,0.00046855377,0.006705688,0.00006564354,0.000046932862,0.0000057208695,0.006350953,0.037742354],"study_design_scores_gemma":[0.014890082,0.033943824,0.94598913,0.0012975754,0.0007703305,0.00014258304,0.0016080525,0.000012299555,0.00005611606,0.00015804282,0.0008957788,0.00023617386],"about_ca_topic_score_codex":0.05407063,"about_ca_topic_score_gemma":0.02692957,"teacher_disagreement_score":0.037506178,"about_ca_system_score_codex":0.00034576055,"about_ca_system_score_gemma":0.0033295131,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W2891337611","doi":"10.1200/jco.2017.35.15_suppl.tps3098","title":"A phase I single arm, open label clinical trial evaluating safety of MAGE-A10<sup>c796</sup>T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Context (archaeology); Melanoma; Internal medicine; Cyclophosphamide; Oncology; Head and neck cancer; Immunotherapy; Cancer; Chemotherapy; Urology; Surgery; Cancer research","score_opus":0.28683108458539314,"score_gpt":0.5290232871734059,"score_spread":0.24219220258801272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891337611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939446,0.0015643071,0.00009571295,0.0011102328,0.0013401974,0.0013492872,0.00003552816,0.000009849326,0.00055028475],"genre_scores_gemma":[0.98740476,0.0012783192,0.008496108,0.00070208387,0.00025072828,0.00002976219,0.000008730539,0.000050458442,0.0017790273],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9871674,0.005825115,0.0057351445,0.00050763565,0.00018299634,0.0005816949],"domain_scores_gemma":[0.98035794,0.012314008,0.0060838144,0.0006918225,0.0004182582,0.00013413506],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015052902,0.00038543475,0.0038382497,0.00022154559,0.0003374717,0.00007344747,0.0013048064,0.00062777,0.00069027295],"category_scores_gemma":[0.025567349,0.00023122107,0.0003621512,0.00015530536,0.001609441,0.0006279943,0.0003935776,0.0018441926,0.000022708113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6871691,0.013772483,0.001626511,0.000028156981,0.00084704923,0.00047536445,0.00030803442,0.000013155449,0.004505511,0.00003653269,0.00012150301,0.2910966],"study_design_scores_gemma":[0.5781294,0.38573644,0.011152544,0.0006413965,0.00047079392,0.0011035833,0.0005996229,0.00008175952,0.0016685006,0.00015697867,0.019907463,0.00035153734],"about_ca_topic_score_codex":0.0001255411,"about_ca_topic_score_gemma":0.00035698913,"teacher_disagreement_score":0.37196395,"about_ca_system_score_codex":0.000093815186,"about_ca_system_score_gemma":0.0042261635,"threshold_uncertainty_score":0.9826407},"labels":[],"label_agreement":null},{"id":"W2891338044","doi":"10.1200/jco.2018.36.15_suppl.4535","title":"Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nomogram; Oncology; Cystectomy; Internal medicine; Bladder cancer; Urology; Adjuvant; Cisplatin; Proportional hazards model; Overall survival; Chemotherapy; Cancer","score_opus":0.2348426878479415,"score_gpt":0.5021674275938941,"score_spread":0.2673247397459526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891338044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97353107,0.00037313637,0.0072158366,0.0052926918,0.008046409,0.0036590584,0.00008516968,0.000039753075,0.0017568641],"genre_scores_gemma":[0.92713416,0.00077551097,0.04501018,0.0044769836,0.020810446,0.00014150754,0.000006578771,0.0001581183,0.0014865163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9846443,0.003540184,0.008764525,0.0009840267,0.0012771466,0.00078981277],"domain_scores_gemma":[0.9817347,0.0097694695,0.0040309927,0.0010531361,0.0020414665,0.001370267],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01401109,0.00065823173,0.0063729137,0.00021851067,0.00013980569,0.000034481858,0.00077449117,0.0017123417,0.0015825045],"category_scores_gemma":[0.0123350965,0.0003827496,0.002253521,0.00029325302,0.003103721,0.00025488806,0.00014437566,0.0023153296,0.000041107476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8252801,0.007585133,0.12886547,0.0000649842,0.003163498,0.0006870899,0.00046418144,6.442227e-7,0.000045101944,0.000033584252,0.0075805984,0.026229639],"study_design_scores_gemma":[0.48182318,0.3382842,0.12047278,0.00029272845,0.0028561796,0.00069169246,0.00034394328,0.00016723719,0.0005120535,0.00017709979,0.053910762,0.0004681679],"about_ca_topic_score_codex":0.00005671741,"about_ca_topic_score_gemma":0.00018504701,"teacher_disagreement_score":0.34345692,"about_ca_system_score_codex":0.00019939504,"about_ca_system_score_gemma":0.010911084,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W2891344194","doi":"10.1200/jco.2017.35.15_suppl.e16551","title":"Variation in radiation oncology referral and adjuvant radiotherapy use following prostatectomy: A population-based study of health system performance.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Referral; Internal medicine; Cohort; Population; Radiation therapy; Cancer registry; Cancer; Surgery; Oncology; Family medicine","score_opus":0.11904155010840642,"score_gpt":0.5260919580161537,"score_spread":0.40705040790774727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891344194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923519,0.00072011695,0.000830517,0.0030046462,0.002243746,0.0007841511,0.0000012598558,0.000009639519,0.00005400722],"genre_scores_gemma":[0.99012613,0.00083396636,0.007796008,0.0006814054,0.00050973543,0.000011357796,0.0000028108543,0.000017114824,0.000021446309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99520874,0.0012449996,0.0028458252,0.00021960954,0.00026864867,0.0002121569],"domain_scores_gemma":[0.99260396,0.0018223097,0.004953959,0.0002939911,0.00017054786,0.00015525927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006830426,0.00014035733,0.002124535,0.00025784984,0.00018503371,0.000012065793,0.00014882538,0.00039652732,0.000007722726],"category_scores_gemma":[0.0019141258,0.00010404873,0.00017803753,0.00008733074,0.00010256393,0.00039176675,0.000017155844,0.000738324,3.2506753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052990587,0.0017526199,0.7695154,0.000062342726,0.00020227316,0.000119955155,0.00076983083,0.0004368742,0.00004334591,0.00002445203,0.000019407911,0.22175446],"study_design_scores_gemma":[0.028203927,0.035702936,0.92857194,0.00022521892,0.00011281953,0.000087363565,0.0002841523,0.004521101,0.0000026001496,0.000018878744,0.00219268,0.00007640095],"about_ca_topic_score_codex":0.00026378664,"about_ca_topic_score_gemma":0.00027301387,"teacher_disagreement_score":0.22167806,"about_ca_system_score_codex":0.0010763551,"about_ca_system_score_gemma":0.0020341992,"threshold_uncertainty_score":0.42429844},"labels":[],"label_agreement":null},{"id":"W2891362692","doi":"10.1200/jco.2018.36.15_suppl.5514","title":"QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; BRCA mutation; Phases of clinical research; Ovarian cancer; Population; Oncology; Chemotherapy; Progressive disease; Refractory (planetary science); Adverse effect; Gastroenterology; Placebo; Cancer; Clinical trial; Pathology","score_opus":0.21810407177131452,"score_gpt":0.529958972689591,"score_spread":0.3118549009182765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891362692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97301394,0.00009630474,0.00012366375,0.019868117,0.0013295179,0.0024984248,0.000009512068,0.000016911961,0.0030436292],"genre_scores_gemma":[0.9717104,0.00021345227,0.0055579487,0.019452116,0.0016469258,0.000093697614,0.0000035668868,0.000079934645,0.0012419496],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321824,0.0013327394,0.0033693563,0.00061807066,0.0009408922,0.00052070146],"domain_scores_gemma":[0.9930713,0.00089136936,0.0027158326,0.00057163765,0.0020377964,0.00071207253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006129586,0.00034551753,0.002534106,0.00034227618,0.00011135127,0.000045443503,0.00055827096,0.0003625383,0.0008697845],"category_scores_gemma":[0.0017257705,0.00024935466,0.00015669451,0.000548423,0.00038386625,0.0002820635,0.000106018895,0.0012959428,0.00003786092],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31907657,0.12816662,0.16920888,0.000025517065,0.001723646,0.0005296059,0.006261349,0.000016119839,0.0009675659,0.000015453072,0.041361563,0.33264711],"study_design_scores_gemma":[0.38526708,0.3803872,0.14404833,0.000933339,0.00046383767,0.00006494993,0.000596943,0.000115050614,0.0006877379,0.00021496916,0.08683809,0.00038249872],"about_ca_topic_score_codex":0.00019054458,"about_ca_topic_score_gemma":0.0012126197,"teacher_disagreement_score":0.3322646,"about_ca_system_score_codex":0.0012956769,"about_ca_system_score_gemma":0.0030016142,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W2891363159","doi":"10.1200/jco.2017.35.15_suppl.e18237","title":"Baseline characteristics as predictors of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; FOLFOX; Capecitabine; Anemia; Cohort; Univariate analysis; Cancer; Colorectal cancer; Population; Oncology; Gastroenterology; Multivariate analysis; Oxaliplatin","score_opus":0.08234248336522221,"score_gpt":0.48125398293434235,"score_spread":0.39891149956912014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891363159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900018,0.00031704723,0.0000046443615,0.0035538098,0.0034106253,0.00029196969,0.00006838272,0.0000052614487,0.002346483],"genre_scores_gemma":[0.9890398,0.0064688004,0.0001382299,0.0016434834,0.0016658272,0.000010200812,0.000011779124,0.000019254705,0.0010026591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968506,0.00022808464,0.0022099195,0.00017167753,0.00030001462,0.00023967693],"domain_scores_gemma":[0.9949022,0.00094935624,0.0031822317,0.0001865389,0.00051379454,0.0002658736],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014797249,0.00016614945,0.0018489956,0.00013186697,0.000051568335,0.00000813483,0.00023755334,0.00034409857,0.0012582927],"category_scores_gemma":[0.0017867729,0.00012130093,0.0003549865,0.000050452843,0.00044151445,0.0001534926,0.000057263107,0.0007134481,0.0000042894576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017343642,0.0041065123,0.9055763,0.00004532427,0.00050639245,0.00028188393,0.00035807522,0.0000028725947,0.0007270492,0.000020660727,0.0027035824,0.06832769],"study_design_scores_gemma":[0.024818417,0.017396329,0.91191244,0.00014469601,0.00032874796,0.0000184082,0.00006759354,0.00006375873,0.0015048033,0.000025686228,0.04362776,0.00009132745],"about_ca_topic_score_codex":0.00031226748,"about_ca_topic_score_gemma":0.00035581252,"teacher_disagreement_score":0.068236366,"about_ca_system_score_codex":0.00026646888,"about_ca_system_score_gemma":0.0017613709,"threshold_uncertainty_score":0.9996547},"labels":[],"label_agreement":null},{"id":"W2891380948","doi":"10.1200/jco.2018.36.15_suppl.e17010","title":"Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Cancer; Oncology; Internal medicine; Enzalutamide; Androgen deprivation therapy; Placebo; Gynecology; Androgen receptor; Confidence interval; Pathology","score_opus":0.12220646471505014,"score_gpt":0.507304079551666,"score_spread":0.38509761483661586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891380948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913881,0.002125785,0.000022847806,0.0039261747,0.000779753,0.0011238018,0.00047196372,0.000011791724,0.000149824],"genre_scores_gemma":[0.9934175,0.0034208698,0.0013094851,0.00016625425,0.0008203536,0.00010547499,0.000029175764,0.000053289503,0.00067758217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297154,0.0010498308,0.00379849,0.0004921889,0.0010012352,0.0006867336],"domain_scores_gemma":[0.99255157,0.0016157003,0.003187694,0.00038312536,0.0013745383,0.0008873595],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033150106,0.00040292752,0.0021127625,0.0005327622,0.00012049453,0.000043376014,0.00026256984,0.00017417011,0.0006677958],"category_scores_gemma":[0.002462921,0.0002593273,0.0007926226,0.0005972583,0.000743537,0.00031936137,0.000065559245,0.0013068648,0.000016929458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2022252,0.007216766,0.5750814,0.00091229327,0.005722756,0.006409553,0.003916812,0.0051852977,0.01045732,0.00014719658,0.002923622,0.17980176],"study_design_scores_gemma":[0.02340048,0.044241454,0.9245214,0.0019332964,0.0016002965,0.000042734267,0.0005751694,0.00096778094,0.0007814077,0.0007386551,0.0008919339,0.0003054067],"about_ca_topic_score_codex":0.005140656,"about_ca_topic_score_gemma":0.0040832204,"teacher_disagreement_score":0.34943998,"about_ca_system_score_codex":0.0012727267,"about_ca_system_score_gemma":0.008905499,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W2891394568","doi":"10.1200/jco.2018.36.15_suppl.e21072","title":"Detection of <i>EGFR</i> mutations in cfDNA and development of resistance.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; T790M; Oncology; Lung cancer; Cohort; Cancer; Adenocarcinoma","score_opus":0.08581517410043638,"score_gpt":0.4951139988762518,"score_spread":0.4092988247758154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891394568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408406,0.0003100307,0.00079616293,0.00089580053,0.0003128795,0.00009249185,0.0000013870194,0.0000014689605,0.0035057254],"genre_scores_gemma":[0.9842715,0.000101715916,0.015203049,0.00014552122,0.00014152407,0.0000018871194,7.6205487e-7,0.000003641317,0.00013037816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983615,0.00006840252,0.0013247371,0.000062944375,0.00012010242,0.00006228792],"domain_scores_gemma":[0.9982677,0.0004034683,0.00084090146,0.00005433162,0.00035715682,0.00007643831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007786956,0.000041472747,0.00048497476,0.00010476524,0.000019425273,9.3923245e-7,0.000028134978,0.000095291165,0.00002291527],"category_scores_gemma":[0.0006416614,0.00002994782,0.000060938448,0.00010134715,0.00017991629,0.000043296302,0.000009679759,0.00014472993,0.0000012588902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051879506,0.0030650797,0.15334803,0.00016017191,0.00082175795,0.00009483257,0.0049382653,0.0000056329445,0.010523089,0.00021179605,0.0005653677,0.821078],"study_design_scores_gemma":[0.0090890005,0.0058493977,0.91539764,0.0002290687,0.00032573484,0.000054750926,0.0008289378,0.000011904566,0.009242093,0.00053358095,0.058388148,0.00004974563],"about_ca_topic_score_codex":0.000010037541,"about_ca_topic_score_gemma":0.0005637527,"teacher_disagreement_score":0.8210283,"about_ca_system_score_codex":0.000093183044,"about_ca_system_score_gemma":0.0012386371,"threshold_uncertainty_score":0.2197289},"labels":[],"label_agreement":null},{"id":"W2891420311","doi":"10.1200/jco.2016.34.15_suppl.e15025","title":"Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; CancerCare Manitoba; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Cetuximab; Internal medicine; Oncology; Proportional hazards model; Multivariate analysis; Cancer; Panitumumab; Refractory (planetary science); Chemotherapy; Progression-free survival; Univariate analysis","score_opus":0.08152849494958646,"score_gpt":0.4152980487856483,"score_spread":0.3337695538360618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891420311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964334,0.0013690544,0.000021047073,0.0016261028,0.00018331215,0.00028464623,0.000037749058,0.000004377549,0.00004031257],"genre_scores_gemma":[0.9937347,0.005616512,0.00017659628,0.00020357307,0.00014317043,0.0000072647595,0.0000025465254,0.0000128948905,0.00010275358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970051,0.00058129244,0.0016027029,0.00025536143,0.00034227286,0.00021328112],"domain_scores_gemma":[0.9911921,0.006590577,0.0013275199,0.00012287786,0.0004995909,0.00026733836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001450148,0.0001682235,0.002426081,0.0004874424,0.000029625231,0.0000075320804,0.000068216905,0.00022655384,0.00008366869],"category_scores_gemma":[0.0075921384,0.000094837524,0.00037779362,0.00037919398,0.0006280911,0.00016905039,0.00003369701,0.0004475915,6.118194e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015254082,0.00066750793,0.9686515,0.00001936524,0.0025384123,0.0003715103,0.00034516447,0.000004548808,0.0013773212,0.000005792067,0.00028760865,0.010477237],"study_design_scores_gemma":[0.0062002544,0.013114649,0.9724184,0.00026225962,0.0054332386,0.00031436599,0.00032374114,0.00019451033,0.00042585045,0.00004070859,0.0011792942,0.00009269311],"about_ca_topic_score_codex":0.00026985418,"about_ca_topic_score_gemma":0.00043136353,"teacher_disagreement_score":0.012447141,"about_ca_system_score_codex":0.00022544639,"about_ca_system_score_gemma":0.0010576431,"threshold_uncertainty_score":0.90890473},"labels":[],"label_agreement":null},{"id":"W2891421611","doi":"10.1200/jco.2018.36.15_suppl.8560","title":"Long-term survival following trimodality therapy vs. medical management of malignant pleural mesothelioma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Cohort; Mesothelioma; Radiation therapy; Retrospective cohort study; Surgery; Hazard ratio; Decortication; Chemotherapy; Palliative care; Internal medicine","score_opus":0.12309691917520853,"score_gpt":0.4761118440743171,"score_spread":0.3530149248991086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891421611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915645,0.00040099112,0.00018296452,0.003391019,0.0018779719,0.00015172547,0.0000049096884,0.0000069836897,0.0024189302],"genre_scores_gemma":[0.9951516,0.0012363998,0.0006641372,0.0015788936,0.0011113121,0.0000020098116,0.0000055127,0.000013056907,0.00023710009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636364,0.00034652976,0.0019141966,0.00017452681,0.0010024082,0.00019867372],"domain_scores_gemma":[0.9976802,0.0006670069,0.0008951241,0.0001839685,0.00010705952,0.0004666452],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029259094,0.0001282176,0.0010869099,0.00006873308,0.000037771963,0.000003809522,0.00022299493,0.00022909207,0.0010901219],"category_scores_gemma":[0.00042653782,0.000081695805,0.0007752966,0.00010146675,0.00042113205,0.00007757044,0.00008272757,0.0003178371,0.000030990555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01118068,0.0031278722,0.888896,0.000047009486,0.0012114557,0.0015525961,0.000025251959,5.4568136e-7,0.0001390886,0.00029963162,0.0005811413,0.09293873],"study_design_scores_gemma":[0.008586045,0.008478817,0.97876316,0.00021856306,0.0003737137,0.00008118517,0.00003742495,0.000014506397,0.00021131619,0.0002701536,0.0028888378,0.00007627274],"about_ca_topic_score_codex":0.000009032535,"about_ca_topic_score_gemma":0.0000064404626,"teacher_disagreement_score":0.09286246,"about_ca_system_score_codex":0.000082361235,"about_ca_system_score_gemma":0.00047939873,"threshold_uncertainty_score":0.99982303},"labels":[],"label_agreement":null},{"id":"W2891429405","doi":"10.1200/jco.2016.34.15_suppl.6082","title":"A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of head and neck (LASCCHN).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Oncology; Internal medicine; Radiation therapy; Taxane; Systemic therapy; Head and neck squamous-cell carcinoma; Induction chemotherapy; MEDLINE; Head and neck cancer; Cancer; Breast cancer","score_opus":0.07549374423689996,"score_gpt":0.38904257728516434,"score_spread":0.31354883304826436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891429405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276305,0.013071103,0.001236184,0.0025548723,0.000070808564,0.00014189593,0.0000022980869,0.0000013324615,0.00015847464],"genre_scores_gemma":[0.9920748,0.001642014,0.0056418832,0.0005379822,0.000065922184,0.0000016482302,1.414221e-7,0.000010522536,0.000025105312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973122,0.0006026791,0.0015652906,0.00013796479,0.00024614457,0.00013576123],"domain_scores_gemma":[0.9936889,0.003820162,0.0019660944,0.00015692392,0.00026841264,0.00009950594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026407184,0.00010972386,0.002535046,0.0001423744,0.000015524985,0.0000019467927,0.000108755215,0.00012972819,0.000014884284],"category_scores_gemma":[0.0010948429,0.000046489462,0.00043100276,0.00027462022,0.0005358808,0.000048005884,0.000026067106,0.00041195672,3.7232873e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049327933,0.00037116505,0.9352134,0.00019550939,0.015682545,0.000105207146,0.0014718093,0.0030831285,0.0061996556,0.00030773962,0.000028313525,0.032408744],"study_design_scores_gemma":[0.023803774,0.019417103,0.8880732,0.0008442977,0.06102958,0.00056177075,0.0011124905,0.0035438666,0.0005061494,0.00052558305,0.00038110907,0.00020109868],"about_ca_topic_score_codex":0.000068574365,"about_ca_topic_score_gemma":0.00007331529,"teacher_disagreement_score":0.04714021,"about_ca_system_score_codex":0.000049732946,"about_ca_system_score_gemma":0.0005529794,"threshold_uncertainty_score":0.19744752},"labels":[],"label_agreement":null},{"id":"W2891434425","doi":"10.1200/jco.2017.35.15_suppl.10505","title":"ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age—A report from the Children Oncology Group.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Children's Hospital","funders":"","keywords":"Medicine; Medulloblastoma; Neurocognitive; Prospective cohort study; Regimen; Cohort; Internal medicine; Pediatrics; Hazard ratio; Interim analysis; Oncology; Surgery; Clinical trial; Confidence interval; Pathology","score_opus":0.13454917068950778,"score_gpt":0.4890555801361913,"score_spread":0.35450640944668355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891434425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941636,0.0005879261,0.000049708568,0.0025184483,0.0006184215,0.0019712248,0.00005150093,0.0000028201591,0.00003635037],"genre_scores_gemma":[0.9977332,0.00057521317,0.0009177294,0.000118022086,0.0005055038,0.00009719534,0.000016934455,0.000021312917,0.0000148837535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587274,0.00048060025,0.0027273241,0.00028283108,0.00038262235,0.00025389928],"domain_scores_gemma":[0.9866279,0.00784383,0.0043947157,0.0007498695,0.0002047047,0.00017899476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027354269,0.00021255942,0.0023281095,0.00010819854,0.00014850254,0.000012245244,0.0004682171,0.00019706813,0.000025101346],"category_scores_gemma":[0.0031500312,0.000105223335,0.00079625717,0.00008343785,0.00049305,0.00006689129,0.000098599085,0.00036912406,0.0000013501442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049583265,0.04771355,0.7338455,0.0000037828415,0.0046293545,0.0016105816,0.0008031085,0.00001810593,0.00008947541,0.0000077242585,0.00027031903,0.2060502],"study_design_scores_gemma":[0.04665372,0.106946275,0.8402123,0.00007489358,0.004118751,0.00045361262,0.00043267757,0.000043993707,0.0001178758,0.00010023986,0.0007800091,0.00006569333],"about_ca_topic_score_codex":0.0013167687,"about_ca_topic_score_gemma":0.0028505141,"teacher_disagreement_score":0.2059845,"about_ca_system_score_codex":0.00018980564,"about_ca_system_score_gemma":0.0007216156,"threshold_uncertainty_score":0.4290883},"labels":[],"label_agreement":null},{"id":"W2891436279","doi":"10.1200/jco.2017.35.15_suppl.5553","title":"Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Carboplatin; Tolerability; Bevacizumab; Neutropenia; Internal medicine; Adverse effect; Phases of clinical research; Pembrolizumab; Dosing; Oncology; Gastroenterology; Pharmacology; Chemotherapy; Cancer; Cisplatin; Immunotherapy","score_opus":0.07562984281282185,"score_gpt":0.46037880139180154,"score_spread":0.38474895857897967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891436279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858262,0.0002610609,0.000023418686,0.010562448,0.00088835193,0.0022082187,0.000067691486,0.000016631966,0.00014595992],"genre_scores_gemma":[0.9968699,0.00036994182,0.0015973267,0.0004565425,0.00043060386,0.000063898806,0.000069080714,0.0000667617,0.000075936216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99298954,0.0011494105,0.0034986248,0.0006861717,0.001065741,0.0006105243],"domain_scores_gemma":[0.991873,0.00196825,0.0042034416,0.000595394,0.0010026074,0.00035730575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047760196,0.0004861914,0.0026261515,0.00025063913,0.000535473,0.00009906879,0.00047278134,0.00033767708,0.00021398693],"category_scores_gemma":[0.0027502994,0.00026964277,0.0002539738,0.00035072566,0.0002891232,0.00047870216,0.0001673089,0.0017191482,0.000004636248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12801903,0.022066055,0.76384014,0.00003223738,0.001416623,0.0010186903,0.002986924,0.000110712645,0.00016559793,0.000013006083,0.00019087493,0.080140084],"study_design_scores_gemma":[0.24091443,0.08724163,0.66590035,0.0011327703,0.0011545437,0.000032579028,0.00057460886,0.0023440563,0.000091133144,0.000042557902,0.00031628448,0.00025508547],"about_ca_topic_score_codex":0.004673832,"about_ca_topic_score_gemma":0.009164442,"teacher_disagreement_score":0.1128954,"about_ca_system_score_codex":0.0011876251,"about_ca_system_score_gemma":0.002758173,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W2891440744","doi":"10.1200/jco.2016.34.15_suppl.7510","title":"Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gene signature; Mantle cell lymphoma; Oncology; Biopsy; Gene expression; Log-rank test; Gene expression profiling; Pathology; Lymph node; Cancer research; Lymphoma; Internal medicine; Gene; Survival analysis; Biology","score_opus":0.07063665507013846,"score_gpt":0.3815942314998427,"score_spread":0.31095757642970423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891440744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961747,0.0005574464,0.00020299209,0.0018242901,0.00044991894,0.00060343836,0.000007833953,0.0000041591493,0.00017523648],"genre_scores_gemma":[0.99683475,0.00013978129,0.0025043914,0.00019108491,0.00024217823,0.00001500906,0.0000016345463,0.000013032914,0.000058131143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698615,0.0003286571,0.001884973,0.00018658109,0.00039325305,0.0002203567],"domain_scores_gemma":[0.9966972,0.0012849817,0.0014244275,0.00019337208,0.00026232074,0.00013770662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011371297,0.00014636364,0.00094097055,0.00011730566,0.000020488966,0.000009797123,0.00015133053,0.00037174742,0.00001324348],"category_scores_gemma":[0.0020332912,0.00006960301,0.00022501359,0.00019351165,0.000132358,0.00020545442,0.000050905368,0.0002054099,0.0000034263467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040419307,0.007644817,0.6641638,0.00006351882,0.00007641298,0.00054965605,0.00022672991,0.00013458681,0.2530695,0.000017819277,0.00026581393,0.069745384],"study_design_scores_gemma":[0.026584078,0.0037799696,0.50405973,0.0009820353,0.00016093599,0.00019426372,0.000068312926,0.00018698844,0.46274674,0.0002218827,0.000885348,0.00012974958],"about_ca_topic_score_codex":0.00000767622,"about_ca_topic_score_gemma":0.000027032207,"teacher_disagreement_score":0.20967723,"about_ca_system_score_codex":0.00034834456,"about_ca_system_score_gemma":0.0013824626,"threshold_uncertainty_score":0.28672564},"labels":[],"label_agreement":null},{"id":"W2891448606","doi":"10.1200/jco.2017.35.15_suppl.10519","title":"Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Dexrazoxane; Medicine; Cardiotoxicity; Doxorubicin; Cardioprotection; Internal medicine; Cardiology; Cardiac function curve; Chemotherapy; Urology; Body surface area; Heart failure; Etoposide; Cancer; Surgery; Breast cancer; Anthracycline; Myocardial infarction","score_opus":0.13308597080684256,"score_gpt":0.4037456443433846,"score_spread":0.2706596735365421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891448606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95616806,0.0005998336,0.025129836,0.004535811,0.0066780024,0.0063519585,0.00033142758,0.000034624707,0.00017045438],"genre_scores_gemma":[0.9889096,0.00024373345,0.002550336,0.00049545924,0.0070604878,0.0003765831,0.00007785732,0.00006837878,0.00021755033],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99594665,0.00057128107,0.0020442116,0.00050793594,0.0004088333,0.00052110193],"domain_scores_gemma":[0.99265075,0.002917053,0.0021194103,0.0007245127,0.0013323043,0.0002559773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0065165604,0.0003524934,0.0026644894,0.00021063564,0.00070282543,0.00008949826,0.00028034791,0.0009467576,0.000005820009],"category_scores_gemma":[0.003777606,0.00026116168,0.0024610432,0.00013575055,0.00027697135,0.00024832232,0.00005390077,0.0010928806,0.0000014643534],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04119004,0.00045433597,0.035069503,0.00056650775,0.004904678,0.000030104238,0.00031898153,0.00074897095,0.53965247,0.0002353473,0.0016840112,0.37514505],"study_design_scores_gemma":[0.035961084,0.030210625,0.4215806,0.00046559342,0.004529734,0.00055080507,0.0010271722,0.0022932217,0.08103275,0.0030070988,0.41855615,0.00078514044],"about_ca_topic_score_codex":0.0009411258,"about_ca_topic_score_gemma":0.0007543086,"teacher_disagreement_score":0.4586197,"about_ca_system_score_codex":0.00051007693,"about_ca_system_score_gemma":0.00064124406,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W2891448801","doi":"10.1200/jco.2016.34.15_suppl.tps9110","title":"A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Internal medicine; Oncology; Regimen; Hazard ratio; Clinical endpoint; Phases of clinical research; Taxane; Progression-free survival; Chemotherapy; Cancer; Randomized controlled trial; Confidence interval; Breast cancer","score_opus":0.04533389530143748,"score_gpt":0.44474085606756897,"score_spread":0.39940696076613147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891448801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521446,0.00017843783,0.00049499254,0.0010212027,0.00042462136,0.0024077033,0.000058761005,0.0000090687845,0.0001907258],"genre_scores_gemma":[0.9937646,0.00027706244,0.004856932,0.00021925748,0.000078284604,0.00011394545,0.000015044475,0.000047972997,0.00062693947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953635,0.0005303749,0.0025390445,0.0004477181,0.00069929444,0.00042011077],"domain_scores_gemma":[0.9930168,0.0025016048,0.0025853373,0.00028796552,0.0012674198,0.00034088065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010080937,0.00035806626,0.002300221,0.00050120277,0.000049182407,0.000011913678,0.000211232,0.00017003935,0.00025062336],"category_scores_gemma":[0.0010557207,0.00016233577,0.00015845214,0.0009027657,0.00019042456,0.00035111356,0.000047517842,0.00055462384,0.0000025745794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54845065,0.0820131,0.24229139,0.00019567498,0.002469951,0.0027734286,0.0018799156,0.00017614945,0.000103084814,0.0000041713433,0.00015401938,0.11948847],"study_design_scores_gemma":[0.44866163,0.21403778,0.33095637,0.0013201095,0.002508835,0.000031560066,0.0018187867,0.00014785689,0.00017062592,0.000006051921,0.000121064324,0.00021932978],"about_ca_topic_score_codex":0.0003581369,"about_ca_topic_score_gemma":0.010072211,"teacher_disagreement_score":0.13202468,"about_ca_system_score_codex":0.00097042747,"about_ca_system_score_gemma":0.0048921406,"threshold_uncertainty_score":0.8678447},"labels":[],"label_agreement":null},{"id":"W2891456907","doi":"10.1200/jco.2018.36.15_suppl.8523","title":"The population-based impact of adjuvant chemotherapy (CTx) on outcomes in AJCC6 stage IB non-small cell lung cancer (NSCLC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cohort; Proportional hazards model; Population; Stage (stratigraphy); Logistic regression; Lung cancer; Adjuvant; non-small cell lung cancer (NSCLC)","score_opus":0.062116778918097415,"score_gpt":0.4921375919807623,"score_spread":0.4300208130626649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891456907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892194,0.00048586077,0.000020320082,0.008407833,0.0009181666,0.00035860838,0.000011783677,0.0000035475928,0.00087195693],"genre_scores_gemma":[0.9952518,0.0011123569,0.00036799564,0.0022750478,0.0006737865,0.000012534072,0.0000018548457,0.000019418043,0.00028524912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973908,0.00020465629,0.0017099807,0.00016284475,0.00029445492,0.0002372506],"domain_scores_gemma":[0.9949022,0.0027642169,0.0015726911,0.00025853523,0.00030125768,0.00020111882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015034339,0.00015797856,0.0012891911,0.000102115526,0.00004215637,0.0000072426405,0.00015457415,0.00021337847,0.0002627766],"category_scores_gemma":[0.0004511353,0.00007721128,0.0006734571,0.00011556864,0.00011810148,0.000033982153,0.000014322364,0.00047396604,0.0000046861587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037123335,0.0023070697,0.9650507,0.00002659781,0.00041466046,0.00005981988,0.00008491146,0.00019353414,0.00002897783,0.000012492628,0.0017217704,0.026387151],"study_design_scores_gemma":[0.014405606,0.014709869,0.9674136,0.0002487759,0.00021117169,0.0000027908065,0.000022063015,0.0005670434,0.00035295627,0.000025820036,0.0019717172,0.00006859968],"about_ca_topic_score_codex":0.0012649209,"about_ca_topic_score_gemma":0.0018507207,"teacher_disagreement_score":0.026318552,"about_ca_system_score_codex":0.0009233687,"about_ca_system_score_gemma":0.002236195,"threshold_uncertainty_score":0.39669138},"labels":[],"label_agreement":null},{"id":"W2891464456","doi":"10.1200/jco.2018.36.15_suppl.5545","title":"Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Confidence interval; Loss of heterozygosity; Cutoff; Proportional hazards model; Biology; Allele; Genetics; Gene","score_opus":0.04563241925470352,"score_gpt":0.3631921090438925,"score_spread":0.31755968978918897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891464456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991702,0.00007720062,0.0002874127,0.000046503024,0.0001571737,0.00009283797,0.000033525932,3.38841e-7,0.00013481003],"genre_scores_gemma":[0.99913627,0.00010222481,0.0005684942,0.00006906476,0.00009524562,0.0000014833898,0.000015723164,0.000006344562,0.0000051385477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759406,0.00036870423,0.001587181,0.0001755345,0.0001546612,0.00011986218],"domain_scores_gemma":[0.99741125,0.000113730064,0.0016639637,0.00022275366,0.0005170967,0.00007117761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010383861,0.00009140407,0.0008465611,0.0002009596,0.000011342517,0.0000015133436,0.00016614863,0.00021878777,0.000022907205],"category_scores_gemma":[0.0002098194,0.00007281031,0.0002278187,0.00019118036,0.00035412482,0.0000081041335,0.00005811387,0.0002170688,3.924316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042576613,0.0012517547,0.9812206,0.000011716667,0.00042581087,0.000007330291,0.00030275126,0.00014098789,0.008261995,0.000018662284,0.000038801412,0.004061941],"study_design_scores_gemma":[0.003045671,0.0059217,0.9865449,0.000026384574,0.0002056231,0.0000014297502,0.00019265973,0.00007764593,0.0036727495,0.00001321637,0.00023059719,0.00006739718],"about_ca_topic_score_codex":0.00005575059,"about_ca_topic_score_gemma":0.0009376562,"teacher_disagreement_score":0.0053243386,"about_ca_system_score_codex":0.000060810853,"about_ca_system_score_gemma":0.00045303837,"threshold_uncertainty_score":0.29691184},"labels":[],"label_agreement":null},{"id":"W2891482688","doi":"10.1200/jco.2018.36.15_suppl.e18539","title":"Access to smoking cessation resources for cancer patients across Canada and systemic barriers to implementing change in systems process.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Smoking cessation; Family medicine; General partnership; Accreditation; Cancer; Tobacco control; Public health; Health care; Environmental health; Nursing; Economic growth; Business; Medical education","score_opus":0.24949472947910467,"score_gpt":0.5460664894281079,"score_spread":0.2965717599490032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891482688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995214,0.00022777256,0.000050945582,0.0023694502,0.0013835388,0.00066689897,0.000021942335,0.0000032125479,0.000062236446],"genre_scores_gemma":[0.9917587,0.000030341032,0.00007693175,0.006225949,0.0018164017,0.00007203552,0.0000010289292,0.000010101324,0.000008535193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974599,0.00010775429,0.0014928816,0.00019326844,0.00038802504,0.00035816152],"domain_scores_gemma":[0.9970375,0.0003770329,0.0009822005,0.00007268599,0.00097329094,0.0005573375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002953586,0.00009568445,0.0007493938,0.00006790213,0.00010212172,0.000038766248,0.00017798171,0.00013005153,0.000012605766],"category_scores_gemma":[0.0035853724,0.00007482573,0.000054019947,0.00021912812,0.00003653452,0.00021037177,0.00008112911,0.00023165204,1.8797604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015119326,0.000020974832,0.9545653,0.00013343485,0.000047638798,0.000019509804,0.0021944328,0.000036647856,0.00000822232,0.0000015598406,0.0009244016,0.040535953],"study_design_scores_gemma":[0.0036734587,0.0045456477,0.94875,0.0015799018,0.00008959287,0.000035778754,0.0041018813,0.00020451631,0.00004739549,0.000006866105,0.036852505,0.0001124235],"about_ca_topic_score_codex":0.19238146,"about_ca_topic_score_gemma":0.65660286,"teacher_disagreement_score":0.46422142,"about_ca_system_score_codex":0.000564499,"about_ca_system_score_gemma":0.0013771083,"threshold_uncertainty_score":0.81299657},"labels":[],"label_agreement":null},{"id":"W2891531514","doi":"10.1200/jco.2017.35.15_suppl.8041","title":"Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Carfilzomib; Lenalidomide; Internal medicine; Neurotoxicity; Progression-free survival; Multiple myeloma; Bortezomib; Dexamethasone; Refractory (planetary science); Clinical endpoint; Gastroenterology; Oncology; Urology; Toxicity; Clinical trial; Chemotherapy","score_opus":0.15279300443406846,"score_gpt":0.4796246044408957,"score_spread":0.32683160000682726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891531514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834186,0.00013620779,0.0000043460836,0.00034535644,0.00016039942,0.000691638,0.000018022141,0.000004572443,0.0002976199],"genre_scores_gemma":[0.9987516,0.00023102631,0.0006491831,0.00009524913,0.0001514572,0.000011092696,0.000012904465,0.000024909597,0.00007258902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950281,0.001286573,0.0025361124,0.0003044455,0.0004924557,0.000352334],"domain_scores_gemma":[0.9936779,0.0021953827,0.0027858457,0.00034342232,0.0004685988,0.0005288086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027765483,0.0002447681,0.0029616968,0.00027514962,0.000076014534,0.000022989629,0.0001966342,0.00027290275,0.00004159803],"category_scores_gemma":[0.0066903858,0.00014028877,0.00020238772,0.00012889646,0.00060571294,0.00026626,0.000060198003,0.0010609382,0.0000017696573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18722796,0.00646545,0.7674901,0.000026866594,0.00029340104,0.0022902142,0.00015274878,0.0000062101176,0.00019151396,0.0000014357971,0.00007040535,0.035783667],"study_design_scores_gemma":[0.2075779,0.05534506,0.7355241,0.0002321405,0.00014872914,0.0000634446,0.0000823168,0.0003492958,0.00020271998,0.0000036153285,0.0003781314,0.000092542425],"about_ca_topic_score_codex":0.0004333126,"about_ca_topic_score_gemma":0.0010084015,"teacher_disagreement_score":0.04887961,"about_ca_system_score_codex":0.00019778043,"about_ca_system_score_gemma":0.0010070037,"threshold_uncertainty_score":0.80095},"labels":[],"label_agreement":null},{"id":"W2891548023","doi":"10.1200/jco.2017.35.15_suppl.e17034","title":"Clinical trial of biopsies in oncology: Patient-reported impact (BIOPSY).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Biopsy; Anxiety; Hospital Anxiety and Depression Scale; Clinical trial; Cancer; Internal medicine; Surgery; Psychiatry","score_opus":0.29710052910956075,"score_gpt":0.4956030712720882,"score_spread":0.19850254216252744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891548023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94944024,0.00070779136,0.00006672643,0.003044943,0.008367812,0.00026102498,0.000037916685,0.0000047088724,0.03806885],"genre_scores_gemma":[0.99354166,0.0024509109,0.0014544697,0.0006005896,0.0017752597,0.000004473251,0.0000014552204,0.000021685704,0.00014949929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98824173,0.00022833819,0.010675694,0.00036896067,0.00008155519,0.00040374088],"domain_scores_gemma":[0.975357,0.0018433686,0.021375766,0.0006847335,0.00035744565,0.00038171824],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013066791,0.00021135113,0.0039411252,0.0003216678,0.000085222746,0.00004336224,0.0008149044,0.001047439,0.0002953292],"category_scores_gemma":[0.03312827,0.00018530822,0.0014734704,0.00008950181,0.00082699826,0.0006325695,0.00017192111,0.0012806058,0.00006624696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037351172,0.0030393293,0.7061603,0.000009830858,0.00047681382,0.00028810088,0.0001275133,0.000029101504,0.0000037847356,0.0029629967,0.0036916488,0.24585938],"study_design_scores_gemma":[0.060395252,0.019792683,0.7887469,0.000041902265,0.00004804533,0.00006188263,0.000058485777,0.00007645633,0.0000062394292,0.014635619,0.11593251,0.00020405579],"about_ca_topic_score_codex":0.00053816073,"about_ca_topic_score_gemma":0.00017800306,"teacher_disagreement_score":0.24565533,"about_ca_system_score_codex":0.00035204226,"about_ca_system_score_gemma":0.0018210354,"threshold_uncertainty_score":0.9750161},"labels":[],"label_agreement":null},{"id":"W2891550266","doi":"10.1200/jco.2017.35.15_suppl.3613","title":"Impact of adjuvant treatment in elderly patients with locally advanced rectal cancer: A population-based retrospective study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Queen's University; Dalhousie University","funders":"","keywords":"Medicine; Internal medicine; Mucositis; Proportional hazards model; Retrospective cohort study; Colorectal cancer; Population; Multivariate analysis; Stage (stratigraphy); Surgery; Cancer; Chemotherapy","score_opus":0.05744211580907657,"score_gpt":0.45878212768338117,"score_spread":0.40134001187430457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891550266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983606,0.000074481584,0.000004544115,0.00048718677,0.00025775237,0.00049428554,0.000011092886,0.000003044839,0.00030703493],"genre_scores_gemma":[0.99944144,0.000033919998,0.00022136793,0.000045064295,0.00019766897,0.000009152596,0.000002989813,0.000011195855,0.00003720849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978068,0.00017370906,0.0013309859,0.00018173386,0.00033597328,0.00017078599],"domain_scores_gemma":[0.9964041,0.00033472275,0.0022076902,0.00021974163,0.0006163482,0.00021740387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000580898,0.0001445766,0.0015817382,0.000118823715,0.000050281422,0.0000066055904,0.00012515787,0.00013464766,0.00005764404],"category_scores_gemma":[0.0013727697,0.00007994027,0.00042630185,0.00008256526,0.000109024644,0.00010716966,0.000020480247,0.0004113511,7.622154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024023168,0.005647272,0.8312945,0.0000060609914,0.00027240248,0.00029254754,0.000085538464,0.000121460514,0.00001500692,0.0000012015342,0.000009511332,0.13823134],"study_design_scores_gemma":[0.024065075,0.17519031,0.80014,0.00013784037,0.00021548432,0.000007687162,0.000044117565,0.00008210355,0.0000071538257,0.000028589533,0.000019013294,0.000062595784],"about_ca_topic_score_codex":0.0022669884,"about_ca_topic_score_gemma":0.007317598,"teacher_disagreement_score":0.16954304,"about_ca_system_score_codex":0.00091165124,"about_ca_system_score_gemma":0.0020710195,"threshold_uncertainty_score":0.40833914},"labels":[],"label_agreement":null},{"id":"W2891562940","doi":"10.1200/jco.2018.36.15_suppl.6562","title":"Financial toxicity associated with conflict-induced cross-border travel for cancer care: Experience of Iraqi patients in Lebanon.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Context (archaeology); Family medicine; Population; Cancer; Thematic analysis; Qualitative research; Environmental health; Internal medicine; Geography","score_opus":0.12543270979001225,"score_gpt":0.45930058710662536,"score_spread":0.3338678773166131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891562940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917105,0.00042501435,0.00047277423,0.00024512227,0.0020528808,0.00027162212,0.00015788684,0.0000031594398,0.0046610343],"genre_scores_gemma":[0.9973164,0.0002395974,0.00042547096,0.0010646279,0.000709701,0.000019666903,0.0000029305781,0.000020599538,0.00020096476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960757,0.00004680036,0.0031417345,0.00029609737,0.000070127324,0.00036953617],"domain_scores_gemma":[0.99407816,0.00060697016,0.004141451,0.00016621829,0.0008587184,0.0001484697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015934407,0.00016960243,0.0017727999,0.00016790559,0.00006262117,0.000018983063,0.0003015807,0.0005192485,0.00022208341],"category_scores_gemma":[0.0056431196,0.00015591361,0.00029831243,0.00019018332,0.0004387872,0.00036841203,0.000037006568,0.00042430309,0.0000065613026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024685794,0.0009442431,0.96194154,0.000019088018,0.00010332886,0.000005456765,0.0022174323,0.00003273292,0.000025209185,0.0029062568,0.0005441002,0.028792046],"study_design_scores_gemma":[0.0083770305,0.00781857,0.9485032,0.00006258338,0.00001765331,0.0000012109448,0.00009579315,0.00006520634,0.00047465588,0.00092972064,0.033453092,0.00020131],"about_ca_topic_score_codex":0.00048726203,"about_ca_topic_score_gemma":0.0027143038,"teacher_disagreement_score":0.03290899,"about_ca_system_score_codex":0.0004006445,"about_ca_system_score_gemma":0.0010236464,"threshold_uncertainty_score":0.6755749},"labels":[],"label_agreement":null},{"id":"W2891567177","doi":"10.1200/jco.2015.33.15_suppl.e20560","title":"Association between physical activity (actigraphy) and symptom burden in advanced cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Actigraphy; Hospital Anxiety and Depression Scale; Internal medicine; Anxiety; Depression (economics); Quality of life (healthcare); Cancer; Physical therapy; Lung cancer; Psychiatry","score_opus":0.09209866868071535,"score_gpt":0.4673537239723891,"score_spread":0.37525505529167374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891567177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172133,0.0001814414,0.0000083724935,0.005771483,0.0011478498,0.00010855921,0.0000059490117,0.000005124396,0.0010499138],"genre_scores_gemma":[0.9974408,0.0002774249,0.000052638723,0.00031046072,0.0017823364,0.000003869967,0.0000013813813,0.000008255517,0.00012282374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835163,0.0003119381,0.00065406825,0.00013509109,0.00038459632,0.00016266532],"domain_scores_gemma":[0.9967098,0.00136594,0.0010382297,0.00007449743,0.00046985733,0.00034167056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014578324,0.00008853698,0.0010269715,0.00009230456,0.000012277181,0.0000055338382,0.00006198701,0.00026075533,0.000009794011],"category_scores_gemma":[0.0022173543,0.000068062924,0.00020330152,0.00015563784,0.000052855958,0.00015781065,0.00002984039,0.00084444636,0.0000020549646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010543845,0.000420622,0.7559094,0.00000933402,0.00014116899,0.000013589934,0.00039425073,0.0000037059986,0.000017001943,0.0000033166016,0.0006613949,0.24137186],"study_design_scores_gemma":[0.007037834,0.0042443066,0.9590136,0.00006279789,0.000260637,0.000002243129,0.0001590648,0.000023290107,0.00004397042,0.00017828862,0.02890829,0.00006567938],"about_ca_topic_score_codex":0.00037575696,"about_ca_topic_score_gemma":0.0006380439,"teacher_disagreement_score":0.24130619,"about_ca_system_score_codex":0.00046805787,"about_ca_system_score_gemma":0.00077848835,"threshold_uncertainty_score":0.3668746},"labels":[],"label_agreement":null},{"id":"W2891568037","doi":"10.1200/jco.2017.35.15_suppl.10524","title":"A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Ependymoma; Refractory (planetary science); Internal medicine; Sarcoma; Gastroenterology; Oncology; Cancer; Surgery; Pathology; Nivolumab; Immunotherapy","score_opus":0.07854338184453231,"score_gpt":0.4758854040754624,"score_spread":0.3973420222309301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891568037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666303,0.00012436147,0.0000025669103,0.0005761951,0.00054308824,0.0007734698,0.0000051036377,0.0000062901086,0.0013058821],"genre_scores_gemma":[0.99775845,0.00085005554,0.00020358124,0.00009813987,0.0006660997,0.000007944263,0.0000021424,0.00003595532,0.0003776633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947899,0.00056458847,0.0029633513,0.00033212028,0.00094074034,0.00040927524],"domain_scores_gemma":[0.993124,0.00089961913,0.0036035492,0.0005832686,0.0012763109,0.00051322806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028296437,0.00022736694,0.0022833415,0.00044554623,0.00014858092,0.000024991643,0.00042674615,0.00034239027,0.00018901794],"category_scores_gemma":[0.0053611295,0.00015437671,0.00023661253,0.00017951854,0.0003686391,0.0002631665,0.00021158718,0.0017403956,0.0000044496637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047191627,0.030246234,0.8425703,0.000066563276,0.0002715158,0.0013693097,0.0008336008,0.000002261749,0.00013088518,0.0000044514873,0.0002737453,0.077039495],"study_design_scores_gemma":[0.11780428,0.18226214,0.6983367,0.00009706019,0.0003246899,0.00012580647,0.00036071727,0.00006584344,0.000025506675,0.000034499597,0.00044455242,0.00011820056],"about_ca_topic_score_codex":0.00026922772,"about_ca_topic_score_gemma":0.00060122524,"teacher_disagreement_score":0.15201591,"about_ca_system_score_codex":0.0002092682,"about_ca_system_score_gemma":0.0014107183,"threshold_uncertainty_score":0.7561249},"labels":[],"label_agreement":null},{"id":"W2891578028","doi":"10.1200/jco.2016.34.15_suppl.e20640","title":"Effect of molecular profile in non-small cell lung carcinoma on the development of brain metastases.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Western Hospital; Princess Margaret Cancer Centre; Centre Integre de Sante et de Services Sociaux de Laval","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; KRAS; Univariate analysis; Adenocarcinoma; Histology; Stage (stratigraphy); Performance status; Gastroenterology; Cancer; Multivariate analysis","score_opus":0.04085546704490309,"score_gpt":0.4418191791213141,"score_spread":0.400963712076411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891578028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991922,0.00017635219,0.00029340637,0.003796805,0.0001985989,0.0003878155,0.0000048901466,0.0000011407618,0.0032189449],"genre_scores_gemma":[0.99665654,0.00001720367,0.0026554542,0.00039777128,0.00006197052,0.000013202422,0.0000011137494,0.000008279862,0.00018845765],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99770755,0.0004785023,0.0013974473,0.00009727543,0.00019932576,0.000119908436],"domain_scores_gemma":[0.9945673,0.0040616775,0.0009791394,0.0001381653,0.00015397665,0.00009975034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031373834,0.000087517496,0.0008231567,0.00009437301,0.000012540915,9.988429e-7,0.00010111805,0.00010739676,0.00008759941],"category_scores_gemma":[0.0013923586,0.000036377347,0.00024402344,0.00008854641,0.00008424191,0.000020815476,0.000025063311,0.0002202988,0.0000048648812],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081744585,0.004780386,0.42729968,0.00045362316,0.0015007938,0.000838252,0.0012292665,0.000020246516,0.049266286,0.000249518,0.0045402143,0.5016473],"study_design_scores_gemma":[0.036262065,0.042694937,0.5320211,0.00092577375,0.0014569942,0.000054021628,0.00017340155,0.000041800962,0.37760767,0.000082143604,0.008541003,0.00013905877],"about_ca_topic_score_codex":0.000008831006,"about_ca_topic_score_gemma":0.000012301963,"teacher_disagreement_score":0.50150824,"about_ca_system_score_codex":0.0001535331,"about_ca_system_score_gemma":0.001503327,"threshold_uncertainty_score":0.26668376},"labels":[],"label_agreement":null},{"id":"W2891579537","doi":"10.1200/jco.2018.36.15_suppl.4032","title":"Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Discontinuation; Adverse effect; Nausea; Vomiting; Internal medicine; Tolerability; Oncology; Blockade; Gastroenterology; Cancer; Surgery; Immunotherapy; Nivolumab","score_opus":0.051781930594670164,"score_gpt":0.433290098603136,"score_spread":0.3815081680084658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891579537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970656,0.00015390686,0.00009646326,0.0013166445,0.00068622536,0.0002006426,0.0000049938744,0.0000029710905,0.00047257703],"genre_scores_gemma":[0.9950609,0.0011457877,0.001909457,0.0011592397,0.0006676255,6.5256927e-7,6.7411014e-7,0.000012455964,0.000043209617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967468,0.00046856905,0.0021277128,0.00017967231,0.00029336437,0.0001839126],"domain_scores_gemma":[0.99655026,0.0009377156,0.0017549684,0.00016654548,0.00039258137,0.00019790547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003559561,0.00011632214,0.0014241803,0.00009915204,0.0000234413,0.000003117793,0.000101536105,0.00028916026,0.00012825821],"category_scores_gemma":[0.0005667576,0.00007458615,0.0002682214,0.00014276148,0.0008842254,0.000098652694,0.00002258537,0.0006810018,0.0000010785852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15810035,0.001066832,0.5925855,0.000008141288,0.00032419834,0.000027662805,0.000043406886,4.1789824e-7,0.000030005394,0.0000022932898,0.00017920278,0.247632],"study_design_scores_gemma":[0.043862782,0.054457158,0.8958923,0.0001075558,0.000111649286,0.000024585039,0.000018561806,0.000025662315,0.000059130853,0.000014046046,0.0053723194,0.00005425813],"about_ca_topic_score_codex":0.00010860352,"about_ca_topic_score_gemma":0.0003224354,"teacher_disagreement_score":0.30330682,"about_ca_system_score_codex":0.00020598767,"about_ca_system_score_gemma":0.0015446668,"threshold_uncertainty_score":0.32579654},"labels":[],"label_agreement":null},{"id":"W2891583838","doi":"10.1200/jco.2016.34.15_suppl.e21677","title":"Outpatient management of pulmonary embolism in cancer patients: A matched-cohort analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pulmonary embolism; Hazard ratio; Internal medicine; Confidence interval; Cancer; Cohort; Surgery","score_opus":0.06440227917690212,"score_gpt":0.4345484908610899,"score_spread":0.37014621168418776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891583838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714757,0.00037617018,0.00018875771,0.005362877,0.0009766044,0.0004407549,0.0000065511595,0.000005313606,0.005495391],"genre_scores_gemma":[0.9882893,0.009043355,0.0008391301,0.0011875661,0.00023599164,0.000027268861,0.0000024340782,0.000014401374,0.00036057713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954668,0.0002524464,0.0031905575,0.0002486922,0.00056979206,0.0002716699],"domain_scores_gemma":[0.9964906,0.00047559777,0.0020806775,0.00027562925,0.00042981122,0.00024768684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024981138,0.00015066586,0.0025637157,0.000444084,0.00001482627,0.0000031020083,0.0002115072,0.00022820759,0.00041796803],"category_scores_gemma":[0.00032165676,0.000088424946,0.0007347302,0.00043475282,0.00012900973,0.00010682817,0.00013446836,0.00030957346,0.000012980756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007550698,0.009473071,0.75372696,0.00008146026,0.0035298346,0.00031797838,0.00007203824,0.000035177418,0.000012551048,0.00032308375,0.0015529577,0.23011981],"study_design_scores_gemma":[0.004769353,0.0030032117,0.97174567,0.00038637908,0.0038502696,0.000003552346,0.00011079063,0.000027576167,0.000021717584,0.00021497333,0.015773818,0.00009268795],"about_ca_topic_score_codex":0.000105672356,"about_ca_topic_score_gemma":0.00006364235,"teacher_disagreement_score":0.23002711,"about_ca_system_score_codex":0.0003015907,"about_ca_system_score_gemma":0.00023683996,"threshold_uncertainty_score":0.45764565},"labels":[],"label_agreement":null},{"id":"W2891585716","doi":"10.1200/jco.2017.35.15_suppl.tps5608","title":"Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Clinical trial; Cancer","score_opus":0.18879572078453033,"score_gpt":0.5059444769074753,"score_spread":0.317148756122945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891585716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182994,0.00007138415,0.00009766541,0.0109161325,0.0024894162,0.0043271794,0.000029753752,0.0000072631283,0.00023127983],"genre_scores_gemma":[0.99533004,0.0002580879,0.0014873728,0.001700318,0.00075051014,0.00007020286,0.0000056622134,0.00003667435,0.0003611437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99172395,0.0028436184,0.0039804494,0.00038169432,0.00071835663,0.00035193845],"domain_scores_gemma":[0.98660135,0.003655517,0.0077133775,0.0006836072,0.0010339944,0.00031215142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074283895,0.00029222222,0.0040701316,0.0001322326,0.00028027708,0.00003971035,0.0006383494,0.00037415826,0.000100664525],"category_scores_gemma":[0.005007326,0.0001608004,0.00028469643,0.00013653365,0.00066337746,0.00028411255,0.00021067458,0.0016836659,0.0000034706925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87987626,0.06855939,0.010390281,0.000010384873,0.0014675029,0.00051086687,0.0024434908,0.000043532735,0.00006752838,0.000032585674,0.0011063409,0.035491854],"study_design_scores_gemma":[0.9086906,0.06388432,0.023668624,0.00041761526,0.0009395244,0.000032553387,0.0007231546,0.00025466966,0.000096939235,0.00007226685,0.0010635853,0.00015616756],"about_ca_topic_score_codex":0.0015231844,"about_ca_topic_score_gemma":0.0015339414,"teacher_disagreement_score":0.035335686,"about_ca_system_score_codex":0.0003464701,"about_ca_system_score_gemma":0.0018259315,"threshold_uncertainty_score":0.73147845},"labels":[],"label_agreement":null},{"id":"W2891591185","doi":"10.1200/jco.2017.35.15_suppl.tps5097","title":"A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Population; Internal medicine; Oncology; Randomized controlled trial; Prostate; Cancer; Clinical endpoint; Urology; Androgen receptor","score_opus":0.0972456130784421,"score_gpt":0.49013676786294486,"score_spread":0.39289115478450276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891591185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957513,0.00026197234,0.000006317576,0.0015966765,0.00035612893,0.0013455724,0.000005773329,0.0000030221622,0.0006732229],"genre_scores_gemma":[0.9979842,0.001337307,0.0001792647,0.00010193338,0.00013977522,0.00002928209,0.000001667012,0.000015513624,0.00021108128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962242,0.0010013686,0.0017766898,0.0001968995,0.0005491181,0.00025168742],"domain_scores_gemma":[0.9927334,0.0029778455,0.00298777,0.00028080962,0.00080886885,0.0002112735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038080662,0.00014021576,0.002621489,0.00014410702,0.00006764498,0.000012982074,0.0002042479,0.00014952058,0.000041322903],"category_scores_gemma":[0.005313318,0.00007501323,0.00023415443,0.00008874625,0.0004948506,0.00016492096,0.00007303046,0.0007386931,0.000001207584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41808033,0.0031637955,0.55392164,0.000027769041,0.00069802144,0.00018494888,0.00040408847,0.000019180266,0.0000027419978,0.0000021693602,0.00003340185,0.023461873],"study_design_scores_gemma":[0.44640753,0.011828343,0.54082984,0.0002029487,0.00015354334,0.0000029633418,0.00026084125,0.000023990797,0.000026467287,0.000056512366,0.00015958813,0.000047431826],"about_ca_topic_score_codex":0.0004475936,"about_ca_topic_score_gemma":0.0018921989,"teacher_disagreement_score":0.02832719,"about_ca_system_score_codex":0.00028241848,"about_ca_system_score_gemma":0.00248582,"threshold_uncertainty_score":0.6360922},"labels":[],"label_agreement":null},{"id":"W2891610084","doi":"10.1200/jco.2018.36.15_suppl.e22057","title":"Impact of prostate cancer treatments on exercise behaviors of men attending an exercise counselling service implemented as standard care.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Prostate cancer; Physical therapy; Physical activity; Cancer; Internal medicine","score_opus":0.09207065390470909,"score_gpt":0.5200323341862576,"score_spread":0.4279616802815485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891610084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968533,0.00078846945,0.0000077808245,0.00029181878,0.0009285575,0.00045802857,0.00015434324,0.000008553001,0.00050913886],"genre_scores_gemma":[0.9938952,0.005086863,0.00020871288,0.00018402675,0.00047799214,0.000012078001,0.000017751212,0.000032974363,0.0000844212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963801,0.00020925004,0.0021874027,0.0002464565,0.00066144706,0.0003153699],"domain_scores_gemma":[0.99450123,0.0003020912,0.0022104415,0.0003056599,0.0022099377,0.0004706429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014395973,0.00021648638,0.0019114722,0.0001975038,0.000051565934,0.0000071800555,0.00019459288,0.00026453627,0.00058828114],"category_scores_gemma":[0.00009895221,0.00015058546,0.0005782106,0.00027024187,0.00017887146,0.00013774408,0.000025983056,0.00045880597,0.0000043908085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06955867,0.0022323723,0.6030167,0.00022251967,0.0008971958,0.00025320504,0.011691737,0.00006295774,0.002180854,0.0000061867445,0.0009679592,0.30890968],"study_design_scores_gemma":[0.048308387,0.25322357,0.6377619,0.00584924,0.009324935,0.00015372715,0.015113382,0.000113084396,0.020526545,0.00021025962,0.008808806,0.00060619914],"about_ca_topic_score_codex":0.0036866046,"about_ca_topic_score_gemma":0.0020018686,"teacher_disagreement_score":0.30830348,"about_ca_system_score_codex":0.00056183065,"about_ca_system_score_gemma":0.0023506521,"threshold_uncertainty_score":0.6441266},"labels":[],"label_agreement":null},{"id":"W2891614702","doi":"10.1200/jco.2017.35.15_suppl.10566","title":"Human papillomavirus (HPV)-associated malignancies as subsequent malignant neoplasms (SMN) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cumulative incidence; Population; Cancer; Incidence (geometry); Epidemiology; Rectum; Oncology; Internal medicine; Confidence interval; Gynecology; Cervix; HPV infection; Hazard ratio; Cervical cancer; Cohort","score_opus":0.10277357425882899,"score_gpt":0.4582296336392546,"score_spread":0.3554560593804256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891614702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766084,0.0068318327,4.4126654e-7,0.011945142,0.002698416,0.00109146,0.00010880106,0.000012877211,0.0007026527],"genre_scores_gemma":[0.9870881,0.009787173,0.000033872875,0.0015125731,0.0011042434,0.00013278742,0.000010791845,0.00004673606,0.00028373377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927049,0.0008787462,0.004390589,0.0005446491,0.0009688585,0.00051225035],"domain_scores_gemma":[0.9887355,0.0017797194,0.0074183936,0.0010037023,0.00066805695,0.00039464817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049097976,0.00038353557,0.0032615573,0.00012572324,0.00028960846,0.000050227416,0.00068183866,0.00044313568,0.0006293639],"category_scores_gemma":[0.003656561,0.00023249381,0.0009055387,0.00017773415,0.0004268183,0.00019194189,0.00022072384,0.0011734846,0.0000073595347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008246391,0.015018526,0.9530327,0.000011351297,0.002673399,0.0048102736,0.0014629787,0.000029150502,0.00008819477,0.00002133927,0.0021733926,0.019854078],"study_design_scores_gemma":[0.015964583,0.008560909,0.9657305,0.00073028216,0.0015518237,0.00015631187,0.00079042045,0.0000024655635,0.00032600475,0.00020771015,0.0057684793,0.00021050502],"about_ca_topic_score_codex":0.14774011,"about_ca_topic_score_gemma":0.28605628,"teacher_disagreement_score":0.13831617,"about_ca_system_score_codex":0.00073743943,"about_ca_system_score_gemma":0.00378167,"threshold_uncertainty_score":0.9480822},"labels":[],"label_agreement":null},{"id":"W2891622971","doi":"10.1200/jco.2018.36.15_suppl.e22035","title":"Symptom assessment of oldest old cancer patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Anxiety; Population; Distress; Depression (economics); Physical therapy; Cancer; Internal medicine; Psychiatry; Clinical psychology","score_opus":0.1046562143260261,"score_gpt":0.5219166599979091,"score_spread":0.41726044567188303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891622971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780927,0.00019438237,0.000075336764,0.0029757628,0.005425095,0.00010194662,0.000007343216,0.000004573705,0.013122883],"genre_scores_gemma":[0.9923614,0.0005113583,0.00061635533,0.003265873,0.002749786,0.0000026226721,0.0000015782155,0.000011548528,0.00047945324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729323,0.00020090754,0.0017997209,0.00012479012,0.00042104413,0.00016028751],"domain_scores_gemma":[0.9958719,0.0007298105,0.0015855496,0.00016420899,0.0013703891,0.00027811737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015885335,0.0000903175,0.0011093296,0.00008347414,0.000020806765,0.000003214234,0.00013875763,0.0002576262,0.0007939329],"category_scores_gemma":[0.00078930485,0.00006250051,0.00039816072,0.00014560677,0.00028203602,0.000060531085,0.00004354813,0.00056974683,0.0000069556654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008820653,0.001392961,0.8847809,0.000035643374,0.00025069705,0.000032132128,0.00015845215,9.0313114e-7,0.00008077389,0.00021876134,0.00824765,0.103919074],"study_design_scores_gemma":[0.004493939,0.01652783,0.8375812,0.00015639974,0.00030202046,0.00001623991,0.0000828108,0.000022767797,0.000137141,0.000078135025,0.14054468,0.00005682102],"about_ca_topic_score_codex":0.00020406165,"about_ca_topic_score_gemma":0.0006794967,"teacher_disagreement_score":0.13229702,"about_ca_system_score_codex":0.00018563679,"about_ca_system_score_gemma":0.0019158748,"threshold_uncertainty_score":0.86930084},"labels":[],"label_agreement":null},{"id":"W2891642191","doi":"10.1200/jco.2017.35.15_suppl.e21517","title":"Systematic reviews and meta-analyses in geriatric oncology.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Geriatric oncology; Internal medicine; Lung cancer; Cancer; Oncology; Incidence (geometry); Clinical trial; Systematic review; Meta-analysis; Survivorship curve; MEDLINE; Gerontology; Family medicine","score_opus":0.6218982079971925,"score_gpt":0.6189552378079196,"score_spread":0.00294297018927292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891642191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63171387,0.122796506,0.0003031941,0.18340558,0.0068730405,0.005235984,0.000007699445,0.000030372328,0.04963377],"genre_scores_gemma":[0.95923483,0.016729075,0.014002682,0.005285407,0.0014474896,0.00004327787,7.242645e-7,0.000025920255,0.0032305855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9915598,0.0020378402,0.0056439643,0.00021689678,0.0003206777,0.00022082664],"domain_scores_gemma":[0.98459524,0.006678497,0.007361631,0.0006206903,0.0003469679,0.0003969906],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015214431,0.00018117252,0.0074410397,0.00021675906,0.00006527232,0.000026122147,0.0003717951,0.00048321963,0.0002186097],"category_scores_gemma":[0.08735951,0.00009741067,0.0012165275,0.00008485172,0.00030963047,0.0002022178,0.00011536058,0.0011817194,0.00006140865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011873392,0.020083439,0.1652128,0.06477238,0.08767119,0.038661756,0.002418159,0.000037784623,0.001572546,0.00086097996,0.20141582,0.40541974],"study_design_scores_gemma":[0.028545605,0.029837525,0.48813424,0.003497998,0.14143513,0.007852742,0.0003700816,0.00022862984,0.000052281906,0.0017604061,0.2977892,0.00049616233],"about_ca_topic_score_codex":0.00004200486,"about_ca_topic_score_gemma":0.00018774165,"teacher_disagreement_score":0.4049236,"about_ca_system_score_codex":0.00016339382,"about_ca_system_score_gemma":0.00084599975,"threshold_uncertainty_score":0.920328},"labels":[],"label_agreement":null},{"id":"W2891651027","doi":"10.1200/jco.2018.36.15_suppl.8566","title":"Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Placebo; Gastroenterology; Clinical endpoint; Pemetrexed; Confidence interval; Combination therapy; Phases of clinical research; Progression-free survival; Surgery; Urology; Chemotherapy; Randomized controlled trial; Cisplatin; Pathology","score_opus":0.04242951230717217,"score_gpt":0.37571430927929367,"score_spread":0.3332847969721215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891651027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974626,0.00007612265,0.000005482886,0.0014150806,0.00013686685,0.0007807416,0.000009319132,0.0000029189284,0.00011091464],"genre_scores_gemma":[0.99920386,0.000054733075,0.00031643876,0.00017775883,0.00011137181,0.000015989242,0.000005919765,0.000016232547,0.00009767164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971275,0.0004170847,0.0015717067,0.00023451542,0.0004593122,0.00018991607],"domain_scores_gemma":[0.9977059,0.00078735134,0.001062545,0.0001620514,0.0001373833,0.00014480033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011116681,0.00018243778,0.0009485418,0.00023581072,0.00004937632,0.000005596771,0.000115972456,0.00009943855,0.0000742736],"category_scores_gemma":[0.0006851834,0.000096358766,0.00009570118,0.00030024827,0.00027427508,0.00012564626,0.000068175155,0.0003157966,0.0000015819412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034130327,0.01675197,0.92294663,0.000021161577,0.000112411864,0.00022673601,0.0009234275,0.00008606642,0.000029383176,0.0000061168616,0.000036051028,0.024729691],"study_design_scores_gemma":[0.061698217,0.12073255,0.81543785,0.00048409414,0.00016584009,0.000048602895,0.00068686955,0.0003723176,0.00006125665,0.000027323827,0.00020205959,0.00008298767],"about_ca_topic_score_codex":0.00022877069,"about_ca_topic_score_gemma":0.00508197,"teacher_disagreement_score":0.10750878,"about_ca_system_score_codex":0.00035884438,"about_ca_system_score_gemma":0.0003164685,"threshold_uncertainty_score":0.39293966},"labels":[],"label_agreement":null},{"id":"W2891651298","doi":"10.1200/jco.2018.36.15_suppl.5583","title":"A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Gene signature; Serous fluid; Proportional hazards model; Oncology; Hazard ratio; Internal medicine; Ovarian cancer; Gene expression profiling; Regression; Gene expression; Cancer; Gene; Confidence interval; Biology; Statistics","score_opus":0.03935416924213644,"score_gpt":0.39609708697568974,"score_spread":0.3567429177335533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891651298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988056,0.00031741947,0.008866242,0.00085174,0.0012762555,0.00052923366,0.000032635904,0.0000033966262,0.000067060544],"genre_scores_gemma":[0.9890759,0.00016530915,0.008316632,0.0005708732,0.001647547,0.000029343553,0.00003793574,0.000035544745,0.000120931],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762386,0.00038921452,0.00093960256,0.0003338332,0.00036099003,0.00035248138],"domain_scores_gemma":[0.99778116,0.00022396898,0.0007402791,0.00022474966,0.00080351817,0.00022635618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012676279,0.0001589359,0.00060682715,0.00008470798,0.00004907077,0.000013486825,0.00029561084,0.00068299676,0.00004402791],"category_scores_gemma":[0.0014078467,0.0001163415,0.00018169846,0.00011198149,0.00015559311,0.000009491836,0.00010867372,0.0006242687,0.0000017573127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08533563,0.0072341897,0.09468696,0.00012173274,0.0014118222,0.00028893468,0.00013465557,0.0018612873,0.68604994,0.00016255242,0.016167846,0.10654447],"study_design_scores_gemma":[0.07155407,0.11856249,0.33134454,0.0004240274,0.0003318551,0.00005195043,0.00004545013,0.00017561413,0.40051782,0.0010624888,0.07509411,0.0008355722],"about_ca_topic_score_codex":0.000040421855,"about_ca_topic_score_gemma":0.00039162877,"teacher_disagreement_score":0.28553212,"about_ca_system_score_codex":0.00009600924,"about_ca_system_score_gemma":0.0013655943,"threshold_uncertainty_score":0.52678967},"labels":[],"label_agreement":null},{"id":"W2891655951","doi":"10.1200/jco.2016.34.15_suppl.e21650","title":"Predictive impact of quality of life measurements in chemotherapy treated advanced pancreatic cancer patients at a single Canadian cancer institution.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; CancerCare Manitoba","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Pancreatic cancer; Cancer; Quality of life (healthcare); Performance status; Cancer registry; Clinical endpoint; Oncology; Surgery; Clinical trial","score_opus":0.24312195315376908,"score_gpt":0.529300531704876,"score_spread":0.28617857855110695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891655951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952614,0.0005776865,0.000022429505,0.0017919721,0.00025054082,0.00046888075,0.00008524068,0.0000029537327,0.0015389342],"genre_scores_gemma":[0.9969369,0.0020482407,0.00027123015,0.000376963,0.00015430292,0.000022094346,0.0000024886363,0.000012871588,0.00017491174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537265,0.00074217,0.0027895651,0.00019088679,0.0005495443,0.0003551667],"domain_scores_gemma":[0.99386966,0.0014922355,0.0022387765,0.00018728912,0.0014903158,0.0007217184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025830676,0.00015517826,0.0024264434,0.00029013876,0.000029613799,0.0000012369105,0.00015863837,0.00038620504,0.0006558545],"category_scores_gemma":[0.008347042,0.000088002555,0.00040424595,0.0002625236,0.00051414064,0.0001150972,0.000025759009,0.00034295194,0.0000027736924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018778801,0.0022092583,0.9417786,0.000048239825,0.0011712018,0.00001302665,0.00015752777,0.000023287586,0.0039055406,0.0000035357778,0.00045043533,0.03146052],"study_design_scores_gemma":[0.025182908,0.01275366,0.9602738,0.00057994213,0.00024609113,0.000003956962,0.000024983357,0.000026423379,0.0004659692,0.000045431352,0.00032193624,0.00007492121],"about_ca_topic_score_codex":0.057469018,"about_ca_topic_score_gemma":0.08276009,"teacher_disagreement_score":0.031385597,"about_ca_system_score_codex":0.0036314274,"about_ca_system_score_gemma":0.013331618,"threshold_uncertainty_score":0.99927914},"labels":[],"label_agreement":null},{"id":"W2891656079","doi":"10.1200/jco.2017.35.15_suppl.e18024","title":"Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intestinal and Peritoneal Adhesions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ambulatory; Colorectal cancer; Population; Gynecologic cancer; Cancer; Prospective cohort study; Bowel management; Intensive care medicine; Surgery; Internal medicine","score_opus":0.10508348258293516,"score_gpt":0.4806179454144649,"score_spread":0.37553446283152975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891656079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942481,0.000099725235,0.00009664704,0.00210086,0.0010308938,0.00078291073,0.000015443216,0.00001403455,0.0016114014],"genre_scores_gemma":[0.94166464,0.00070080406,0.056223497,0.00008730622,0.0005297485,0.0001343902,0.0000018376461,0.000013955961,0.000643852],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99747145,0.00012604054,0.001602937,0.00022815217,0.00027419598,0.0002972197],"domain_scores_gemma":[0.99480253,0.0007768929,0.003224509,0.00028181713,0.0005863536,0.00032791466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016123563,0.00015421986,0.0011530903,0.000050494284,0.00023391818,0.000010646495,0.00023780041,0.00025910788,0.00008031607],"category_scores_gemma":[0.0010330006,0.00009041936,0.00029081365,0.00004250874,0.00049621816,0.0001146976,0.00008112163,0.0006293281,0.000002123432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031319078,0.0036164436,0.1677577,0.00035545352,0.0007899873,0.0007824776,0.00015450813,0.0001133198,0.0007537839,0.00025928346,0.0003006329,0.7937973],"study_design_scores_gemma":[0.007346968,0.051662613,0.9317595,0.00034258768,0.00042525158,0.00018346786,0.000649619,0.00025374902,0.00022740664,0.00087712903,0.0061642993,0.000107434316],"about_ca_topic_score_codex":0.000016488926,"about_ca_topic_score_gemma":0.000044234414,"teacher_disagreement_score":0.7936899,"about_ca_system_score_codex":0.00016550728,"about_ca_system_score_gemma":0.0005611376,"threshold_uncertainty_score":0.36871943},"labels":[],"label_agreement":null},{"id":"W2891676222","doi":"10.1200/jco.2018.36.15_suppl.e15146","title":"Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Syk; Medicine; Splenectomy; Rituximab; Immune thrombocytopenia; Placebo; Thrombopoietin; Internal medicine; Platelet; Gastroenterology; Immunology; Spleen; Tyrosine kinase; Receptor; Lymphoma; Pathology","score_opus":0.10227411756076644,"score_gpt":0.4816816468334611,"score_spread":0.37940752927269467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891676222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97929513,0.016442152,0.000029418567,0.0022941942,0.00030356474,0.0014659726,0.00014107779,0.0000042373613,0.000024221601],"genre_scores_gemma":[0.9925157,0.005459269,0.0015472239,0.0001421648,0.00015726923,0.000042876985,0.000026489697,0.000022158138,0.00008685325],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99423444,0.00090450636,0.003879492,0.00027706308,0.00037364644,0.0003308527],"domain_scores_gemma":[0.9883938,0.006563319,0.003547447,0.00041699273,0.00092050876,0.00015796043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040672515,0.00028678437,0.0053938082,0.00044229516,0.00007675974,0.000005720239,0.00023069615,0.00023891618,0.00010521077],"category_scores_gemma":[0.0021842634,0.00015522637,0.0018526297,0.0005268973,0.0007960262,0.000120038094,0.000038776878,0.00024156657,9.455738e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7600341,0.029633319,0.0067394334,0.000095169,0.04498976,0.0002828318,0.0057063177,0.000077888246,0.007621133,0.00002194074,0.0003409008,0.14445725],"study_design_scores_gemma":[0.59285045,0.34445122,0.014721366,0.0005187145,0.020551387,0.00006296439,0.0083054295,0.0041603674,0.01001936,0.000093637726,0.0040173107,0.00024777715],"about_ca_topic_score_codex":0.000121562705,"about_ca_topic_score_gemma":0.00067339523,"teacher_disagreement_score":0.3148179,"about_ca_system_score_codex":0.00036709098,"about_ca_system_score_gemma":0.00092628924,"threshold_uncertainty_score":0.6329948},"labels":[],"label_agreement":null},{"id":"W2891679676","doi":"10.1200/jco.2018.36.15_suppl.3584","title":"Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; Chemotherapy; Metastasis; Internal medicine; Gastroenterology; Cancer; Tissue microarray; Pathological; Oncology; Pathology","score_opus":0.1283321538426467,"score_gpt":0.4910790270639583,"score_spread":0.3627468732213116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891679676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955658,0.00025329023,0.0001047052,0.0022048776,0.0002215219,0.00011481022,0.0000051685333,0.0000050628823,0.0015248157],"genre_scores_gemma":[0.9946251,0.00030417502,0.0031166594,0.00090758083,0.00092414947,0.0000037532084,0.0000020192442,0.000008617798,0.00010797539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670666,0.0006374455,0.0019879073,0.00014377006,0.0003546988,0.00016952104],"domain_scores_gemma":[0.9961096,0.0013843902,0.0013746384,0.00010181918,0.0007855501,0.00024399562],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002351081,0.00009150274,0.001209021,0.0002619462,0.000021290665,0.0000030011195,0.000103117505,0.00026914282,0.0010706374],"category_scores_gemma":[0.006566046,0.000060953764,0.00041083744,0.0003383722,0.0003509178,0.0000804348,0.00004445905,0.00065345474,0.00001524222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023005715,0.010156487,0.59771883,0.00019846972,0.001276494,0.002931956,0.000784079,0.0000539655,0.21464913,0.00019787152,0.029497804,0.11952919],"study_design_scores_gemma":[0.009905176,0.01657368,0.91533613,0.001763414,0.0007150344,0.00022625433,0.00017951467,0.0011185637,0.043818805,0.0002126574,0.010026656,0.00012408232],"about_ca_topic_score_codex":0.000058920174,"about_ca_topic_score_gemma":0.00023841798,"teacher_disagreement_score":0.31761733,"about_ca_system_score_codex":0.00009633349,"about_ca_system_score_gemma":0.0011120931,"threshold_uncertainty_score":0.9998425},"labels":[],"label_agreement":null},{"id":"W2891681718","doi":"10.1200/jco.2016.34.15_suppl.6569","title":"Adjuvant chemotherapy for stage II colon cancer: Practice patterns and effectiveness in the general population.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"Medicine; Cancer registry; Internal medicine; Colorectal cancer; Lymphovascular invasion; Population; Cancer; Poisson regression; Stage (stratigraphy); Proportional hazards model; Oncology; Disease; Metastasis","score_opus":0.09798228825450694,"score_gpt":0.5150648917791182,"score_spread":0.41708260352461124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891681718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95943475,0.0009958444,0.00011202519,0.038445182,0.00046030295,0.00040670205,0.0000125764045,0.0000020870025,0.00013056],"genre_scores_gemma":[0.9909768,0.004733934,0.00041976353,0.0030500272,0.0006375348,0.0000451313,6.7334264e-7,0.000006907322,0.0001292347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861604,0.00034708684,0.00066410744,0.000112641035,0.00014063047,0.000119523655],"domain_scores_gemma":[0.9944372,0.0046450337,0.00059728656,0.00006707131,0.0001913219,0.00006208365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022669933,0.00007776148,0.00069881877,0.000035293844,0.000055716337,0.000003945229,0.000052471347,0.00010320434,0.00002203683],"category_scores_gemma":[0.0015406008,0.00003309018,0.0001355777,0.000042176427,0.00006108983,0.00008091613,0.000019070116,0.00017435304,1.9496372e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012842226,0.0007750457,0.61840093,0.000027037562,0.0002790873,0.000087139444,0.0002451322,0.0000019839101,0.00009280879,0.00010959576,0.00044051596,0.3666985],"study_design_scores_gemma":[0.013109668,0.0142327715,0.8954047,0.00010170044,0.00017993734,0.00006429123,0.00011557126,0.000010182202,0.000030371333,0.00013978171,0.07657185,0.000039164857],"about_ca_topic_score_codex":0.0002624052,"about_ca_topic_score_gemma":0.00063009054,"teacher_disagreement_score":0.36665934,"about_ca_system_score_codex":0.00019174576,"about_ca_system_score_gemma":0.0002521482,"threshold_uncertainty_score":0.18443543},"labels":[],"label_agreement":null},{"id":"W2891684664","doi":"10.1200/jco.2018.36.15_suppl.e13088","title":"Comparison of triple negative (TN) and HER2 positive (HER2+) invasive lobular carcinomas (ILCs) to a matched cohort of invasive ductal carcinomas.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Confidence interval; Cohort; Stage (stratigraphy); Estrogen receptor; Cancer; HER2 negative; Triple-negative breast cancer; Prospective cohort study; Metastatic breast cancer; Biology","score_opus":0.05888482131693445,"score_gpt":0.40536396037670924,"score_spread":0.3464791390597748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891684664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957231,0.0010443511,0.00010336333,0.0012453072,0.00059047336,0.00037022072,0.0000588835,0.000002273677,0.0008619985],"genre_scores_gemma":[0.99549586,0.00033970803,0.0028143157,0.0005276986,0.0007251838,0.000010268887,0.000011000635,0.000020622863,0.000055357355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679327,0.00047883557,0.0018307791,0.00036513398,0.00027033576,0.0002616624],"domain_scores_gemma":[0.9952753,0.00085621414,0.0020022502,0.00025303912,0.0013424237,0.0002707264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085381034,0.00023893382,0.0017919332,0.00009935587,0.00006041142,0.000005787197,0.00025707833,0.00037580726,0.000026176172],"category_scores_gemma":[0.0027504123,0.00019475169,0.0003405891,0.00015114958,0.0009514294,0.00001326017,0.00028185276,0.00029654396,0.0000040529644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058730193,0.0011514379,0.95225227,0.000040809227,0.0019869558,0.00008901197,0.002015925,0.000008284739,0.031007364,0.000040092385,0.0031434316,0.0023913716],"study_design_scores_gemma":[0.0041760853,0.017805437,0.8028511,0.000079080695,0.00047223284,0.00013373335,0.0018154188,0.0000033969345,0.1717463,0.00015778556,0.00059871696,0.0001607382],"about_ca_topic_score_codex":0.0003709694,"about_ca_topic_score_gemma":0.0012231976,"teacher_disagreement_score":0.14940122,"about_ca_system_score_codex":0.00008973113,"about_ca_system_score_gemma":0.0011637434,"threshold_uncertainty_score":0.7941743},"labels":[],"label_agreement":null},{"id":"W2891692504","doi":"10.1200/jco.2016.34.15_suppl.8039","title":"Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Ixazomib; Multiple myeloma; Placebo; Internal medicine; Dexamethasone; Oncology; Refractory (planetary science); Carfilzomib; Pathology","score_opus":0.08530791326686953,"score_gpt":0.4407067113779121,"score_spread":0.3553987981110426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891692504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762,0.0001721105,0.000018467794,0.0009931175,0.00013861225,0.0008754651,0.000026903088,0.000005107594,0.00015024624],"genre_scores_gemma":[0.996264,0.001564486,0.0018227582,0.00012454181,0.0001222781,0.0000072797216,0.0000044304547,0.00003287038,0.000057379122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944895,0.0011933929,0.002851315,0.0003239151,0.0006925119,0.0004493826],"domain_scores_gemma":[0.9874473,0.009193787,0.0019800514,0.00033183204,0.00051082444,0.00053617486],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035230957,0.00027837703,0.0023541097,0.0004944184,0.00002298201,0.0000043425807,0.00020164154,0.00042185947,0.00015012494],"category_scores_gemma":[0.009090627,0.00013863861,0.00038359585,0.0002495137,0.00043726814,0.00017538336,0.000063265354,0.0009300587,0.000006307814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24365348,0.006331333,0.53377277,0.000017677563,0.00042095457,0.00022695669,0.00009185535,0.000013246178,0.00057091576,0.0000018131224,0.00009020123,0.21480878],"study_design_scores_gemma":[0.18797046,0.07082808,0.7395256,0.000580774,0.000057311543,0.000028942944,0.000017681126,0.00003255417,0.00039170368,0.000013769864,0.00045619032,0.00009692515],"about_ca_topic_score_codex":0.00024695497,"about_ca_topic_score_gemma":0.00025946245,"teacher_disagreement_score":0.21471184,"about_ca_system_score_codex":0.0004753313,"about_ca_system_score_gemma":0.0014782809,"threshold_uncertainty_score":0.99925625},"labels":[],"label_agreement":null},{"id":"W2891694121","doi":"10.1200/jco.2017.35.15_suppl.9522","title":"Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Cohort; Expanded access; Oncology; Cancer; Immunotherapy","score_opus":0.0642788692201449,"score_gpt":0.4571803772239324,"score_spread":0.3929015080037875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891694121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980201,0.00007692061,0.000044166245,0.00063177774,0.0003564451,0.00044035216,0.000007690827,0.0000059800886,0.0004165396],"genre_scores_gemma":[0.9977839,0.00015431014,0.0017117191,0.00017890155,0.000096449934,0.0000092952705,0.00002833586,0.000015589847,0.00002147278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678797,0.00040631593,0.0018038092,0.00023926316,0.0005236937,0.00023893839],"domain_scores_gemma":[0.9954785,0.00048111685,0.0029980156,0.00042500952,0.00044076293,0.0001765704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017540461,0.00016269593,0.0017556386,0.00032638936,0.000042751693,0.000029747505,0.00038488174,0.00027399007,0.0000764716],"category_scores_gemma":[0.000489537,0.00010744207,0.00026559582,0.00027477316,0.00028339037,0.00066633016,0.000047980582,0.0005679007,3.7288993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088956535,0.0062756827,0.74775785,0.000011310255,0.0009058914,0.00005321292,0.00013228414,0.000026785527,0.000023991392,0.0000042727897,0.000012074131,0.15584008],"study_design_scores_gemma":[0.07356782,0.02964808,0.8953498,0.00017112038,0.00049606356,0.00000330504,0.000100535355,0.00015149773,0.000045525525,0.000053539483,0.00029792514,0.0001147918],"about_ca_topic_score_codex":0.00086518266,"about_ca_topic_score_gemma":0.0063521382,"teacher_disagreement_score":0.1557253,"about_ca_system_score_codex":0.00024005327,"about_ca_system_score_gemma":0.00068199536,"threshold_uncertainty_score":0.43813604},"labels":[],"label_agreement":null},{"id":"W2891697957","doi":"10.1200/jco.2018.36.34_suppl.190","title":"Symptom burden in hospitalized patients with curable and incurable cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Depression (economics); Palliative care; Anxiety; Internal medicine; Cancer; Distress; Psychiatry","score_opus":0.03941322034355473,"score_gpt":0.4049154279957251,"score_spread":0.3655022076521704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891697957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989243,0.0003354857,0.00001151656,0.0026358236,0.001114316,0.00014078977,0.0000020801724,0.0000047923822,0.006512222],"genre_scores_gemma":[0.9964997,0.00037454988,0.0004368597,0.0014312534,0.0009771655,0.0000026553769,0.0000013076486,0.000011825121,0.00026467777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823034,0.00014804045,0.0010082908,0.00014876407,0.00026956818,0.00019498056],"domain_scores_gemma":[0.99797827,0.0004216367,0.0006634417,0.00012296386,0.0005519283,0.0002617337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011107472,0.00009584494,0.000932521,0.0000946012,0.000026097869,0.000008001188,0.00008579152,0.00020917812,0.00017381167],"category_scores_gemma":[0.0007327906,0.00006220597,0.00009633671,0.00016271207,0.000278383,0.00012556254,0.000030985622,0.0005248316,0.0000061107917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005147543,0.0002804303,0.95174515,0.000023464083,0.00011613893,0.00010663615,0.0005092478,0.0000016819273,0.0000056408107,0.000034263685,0.0023706537,0.03965914],"study_design_scores_gemma":[0.014036587,0.018968202,0.85552585,0.00023326867,0.00013800857,0.00004031205,0.00023110483,0.000028416525,0.000013784145,0.00018882206,0.11050446,0.00009119834],"about_ca_topic_score_codex":0.0009304041,"about_ca_topic_score_gemma":0.0021511517,"teacher_disagreement_score":0.10813381,"about_ca_system_score_codex":0.00021199431,"about_ca_system_score_gemma":0.0012296571,"threshold_uncertainty_score":0.25366858},"labels":[],"label_agreement":null},{"id":"W2891720308","doi":"10.1200/jco.2017.35.15_suppl.7001","title":"Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Clinical endpoint; Anemia; Internal medicine; Gastroenterology; Ruxolitinib; Randomized controlled trial; Surgery; Bone marrow","score_opus":0.13005416151927524,"score_gpt":0.4476270528897659,"score_spread":0.31757289137049066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891720308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018097,0.00023270793,0.000006527447,0.0013256395,0.0005468139,0.0025118366,0.000017106735,0.0000075544417,0.0051708315],"genre_scores_gemma":[0.99471456,0.0021975543,0.0018175645,0.00020887665,0.0005037433,0.00010292053,0.000019186413,0.000038347498,0.00039726438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994502,0.000928577,0.0031190554,0.00036740044,0.00068807293,0.0003948663],"domain_scores_gemma":[0.98837286,0.004660297,0.0049304194,0.00056196516,0.0010256876,0.00044879297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032241398,0.00034513717,0.0045854338,0.00019739887,0.00011332698,0.000033728873,0.0002720972,0.00036828365,0.00043683965],"category_scores_gemma":[0.004434114,0.00018064777,0.0006159909,0.000122012156,0.00070068054,0.00022772286,0.000040323514,0.0006751805,0.000022362748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7529768,0.027191428,0.18356703,0.00002036687,0.0015232932,0.00021504665,0.00008322611,0.0000027234655,0.000005448614,0.000031798074,0.00036479678,0.034018047],"study_design_scores_gemma":[0.76508653,0.18420495,0.046002526,0.0004012401,0.000983601,0.000014719434,0.000024731124,0.000015052059,0.00038922994,0.00001421983,0.002728456,0.00013473733],"about_ca_topic_score_codex":0.00014253765,"about_ca_topic_score_gemma":0.00009418887,"teacher_disagreement_score":0.15701352,"about_ca_system_score_codex":0.00017409622,"about_ca_system_score_gemma":0.001604313,"threshold_uncertainty_score":0.7366602},"labels":[],"label_agreement":null},{"id":"W2891723502","doi":"10.1200/jco.2017.35.15_suppl.3058","title":"Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Centre Hospitalier de l’Université de Montréal; Kingston General Hospital; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; McMaster University; Juravinski Cancer Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Durvalumab; Adverse effect; Nivolumab; Immunotherapy; Cancer","score_opus":0.06334241880670663,"score_gpt":0.4143125597281582,"score_spread":0.3509701409214516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891723502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819141,0.0004965361,0.00005643725,0.009929777,0.0009795655,0.0004159943,0.0000027443214,0.000019899995,0.0061849216],"genre_scores_gemma":[0.99235606,0.0011136987,0.002308557,0.0011943185,0.00057096954,0.000005222779,0.000003550317,0.000051300918,0.0023963002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957642,0.00026521136,0.0027029954,0.00028805662,0.00062480813,0.00035472232],"domain_scores_gemma":[0.992856,0.0005338334,0.0051570944,0.00069717236,0.0004355323,0.0003203371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033333967,0.00027078966,0.001793938,0.00012816228,0.00022114892,0.000014127457,0.00044908657,0.0003427635,0.0006491221],"category_scores_gemma":[0.00078627374,0.00015835876,0.0006707804,0.000121824625,0.00064778293,0.0002891206,0.00004398818,0.0013479657,0.000023532775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31728438,0.0038085626,0.33755335,0.000060386024,0.005679293,0.0037744765,0.00037336734,0.000022474258,0.0021341634,0.00003917193,0.0019009307,0.32736942],"study_design_scores_gemma":[0.112382665,0.028668284,0.8157372,0.0005562708,0.0005146486,0.0029851734,0.00018436268,0.000039297618,0.00037823906,0.000088384826,0.038249187,0.00021632125],"about_ca_topic_score_codex":0.00008937342,"about_ca_topic_score_gemma":0.00008838893,"teacher_disagreement_score":0.4781838,"about_ca_system_score_codex":0.0002618087,"about_ca_system_score_gemma":0.002132932,"threshold_uncertainty_score":0.7107432},"labels":[],"label_agreement":null},{"id":"W2891731991","doi":"10.1200/jco.2016.34.15_suppl.e21569","title":"Implementation of a disease specific survivorship program for men with prostate cancer and their partners.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Survivorship curve; Family medicine; Quality of life (healthcare); Androgen deprivation therapy; Cancer; Gynecology; Internal medicine; Oncology; Physical therapy; Nursing","score_opus":0.12946858940903713,"score_gpt":0.49720260460266513,"score_spread":0.367734015193628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891731991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98314273,0.00088306,0.00023595023,0.014436775,0.00033403345,0.00067940535,0.000044969885,0.000007188771,0.00023586539],"genre_scores_gemma":[0.9964302,0.0019456923,0.0004265508,0.00029248325,0.0006040661,0.000069251866,0.0000026063174,0.000014044397,0.0002150587],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984117,0.00013717449,0.0009753702,0.00014138261,0.00016696365,0.00016740446],"domain_scores_gemma":[0.99714786,0.0009844847,0.0009528462,0.00010750965,0.00047803728,0.000329237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014522842,0.00009648677,0.000713911,0.000053774922,0.000018734625,0.000005164034,0.00005776195,0.000081219056,0.00006833489],"category_scores_gemma":[0.00016744442,0.00004460621,0.00018702219,0.00007090405,0.00020487746,0.0000800375,0.000015702048,0.00014006869,3.2818724e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016648112,0.00029395532,0.37087974,0.000077783574,0.00018062346,0.000015964173,0.00035479275,1.9286486e-7,0.000108507826,0.00009702813,0.0016225615,0.60972077],"study_design_scores_gemma":[0.016516808,0.022751445,0.7284384,0.0003176821,0.00036615657,0.00002436307,0.0020865449,0.0000067804444,0.00058423035,0.00069471565,0.22809665,0.000116266165],"about_ca_topic_score_codex":0.00011120791,"about_ca_topic_score_gemma":0.0020691175,"teacher_disagreement_score":0.6096045,"about_ca_system_score_codex":0.000066678745,"about_ca_system_score_gemma":0.001089347,"threshold_uncertainty_score":0.19324547},"labels":[],"label_agreement":null},{"id":"W2891736313","doi":"10.1200/jco.18.00626","title":"The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clinical Oncology; Brachytherapy; Genitourinary system; Radium; Radium-223; Cancer; Family medicine; Oncology; Internal medicine; Gynecology; Prostate cancer; Radiation therapy; Bone metastasis","score_opus":0.12933760369264186,"score_gpt":0.5088845969933284,"score_spread":0.3795469933006866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891736313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580223,0.0012929434,0.009901756,0.028682997,0.0012280159,0.00064253854,0.000043798922,0.000035793204,0.00014987083],"genre_scores_gemma":[0.6768194,0.03535313,0.23768477,0.034095895,0.015440577,0.000113396716,0.0000067729275,0.0001304598,0.00035563987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909399,0.002853783,0.004447595,0.00054440304,0.000556195,0.0006581068],"domain_scores_gemma":[0.9751671,0.011055695,0.0109935105,0.0008516041,0.0016272909,0.0003047766],"candidate_categories":["sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008093033,0.00048788064,0.0034721654,0.00002506561,0.00075646356,0.00008914797,0.0012965946,0.00020430858,0.000062902494],"category_scores_gemma":[0.00037031202,0.00023931004,0.0034402916,0.00040381026,0.019082947,0.0002537101,0.00034877786,0.0029840104,0.0000012157919],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005697346,0.0006572688,0.19083345,0.00000797028,0.0029966827,0.000005121843,0.0037890188,0.000019684143,0.00027001355,0.00015050847,0.10194139,0.69363153],"study_design_scores_gemma":[0.006681662,0.012010909,0.14777645,0.000043345168,0.00057790475,0.00004007761,0.00943409,0.0012901284,0.00014222505,0.0014402529,0.82016313,0.00039984693],"about_ca_topic_score_codex":0.011323848,"about_ca_topic_score_gemma":0.002044406,"teacher_disagreement_score":0.7182217,"about_ca_system_score_codex":0.00032440136,"about_ca_system_score_gemma":0.0026465582,"threshold_uncertainty_score":0.99931616},"labels":[],"label_agreement":null},{"id":"W2891754170","doi":"10.1200/jco.2016.34.15_suppl.e22003","title":"Imaging of metastatic medulloblastoma in the molecular era.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Medicine; Metastasis; Oncology; Neuroimaging; Pathology; Internal medicine; Cancer","score_opus":0.07717745242740441,"score_gpt":0.4607548551192846,"score_spread":0.3835774026918802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891754170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95019925,0.0007837495,0.00014779712,0.04752303,0.00024429377,0.00010756719,0.0000011520941,0.0000014042048,0.0009917364],"genre_scores_gemma":[0.9957026,0.00021004894,0.001733692,0.0022232777,0.000112766626,0.0000034606494,1.5942229e-7,0.0000059638105,0.000007998868],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99756,0.00046619284,0.0014760667,0.00008351175,0.00028502563,0.00012916684],"domain_scores_gemma":[0.9953346,0.0033334051,0.00089072617,0.00015150335,0.00018048014,0.00010928627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027711163,0.0000712469,0.0008292396,0.00010979947,0.000008012105,0.0000022435124,0.00012614178,0.00005461096,0.00008399655],"category_scores_gemma":[0.0029661485,0.000028423572,0.0003611796,0.00010774934,0.00014361324,0.000045132616,0.00001994872,0.0002496248,0.00000906541],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014032911,0.0063037556,0.4683986,0.000025522286,0.000645174,0.009780547,0.00017514346,0.0000061275127,0.008035524,0.0023371761,0.0035086002,0.49938053],"study_design_scores_gemma":[0.022586288,0.009515784,0.9340413,0.00041315652,0.0009363266,0.0015165526,0.000295273,0.000029257533,0.004518161,0.003560304,0.022507077,0.00008048815],"about_ca_topic_score_codex":0.000007481284,"about_ca_topic_score_gemma":0.000012666528,"teacher_disagreement_score":0.49930006,"about_ca_system_score_codex":0.000052282358,"about_ca_system_score_gemma":0.00042366277,"threshold_uncertainty_score":0.35509712},"labels":[],"label_agreement":null},{"id":"W2891759256","doi":"10.1200/jco.2017.35.15_suppl.7503","title":"A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Rituximab; Cyclophosphamide; Obinutuzumab; Gastroenterology; Randomized controlled trial; Interim analysis; Regimen; IGHV@; Lenalidomide; Oncology; Leukemia; Surgery; Multiple myeloma; Chemotherapy; Lymphoma","score_opus":0.07279910882673507,"score_gpt":0.4713194874257098,"score_spread":0.3985203785989747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891759256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935566,0.0020219686,0.00017641677,0.00051674835,0.0010091253,0.0020026295,0.00006388167,0.000020771906,0.0006318291],"genre_scores_gemma":[0.98623145,0.011791907,0.00089772185,0.000090882546,0.00065610243,0.000072892704,0.000023937588,0.000050047463,0.00018508275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889201,0.002043729,0.0067476113,0.0006991147,0.0009807827,0.0006086541],"domain_scores_gemma":[0.98093325,0.010044524,0.006587461,0.0011467705,0.0006476012,0.00064036535],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072377343,0.0004380643,0.004731849,0.0003508097,0.00020490932,0.00008046897,0.00084857055,0.0007011069,0.00013392842],"category_scores_gemma":[0.018681917,0.000324392,0.0006077441,0.0002620659,0.001546111,0.000316914,0.0003219294,0.0016739517,0.000014394248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7127039,0.013985381,0.036998726,0.0006045661,0.008268531,0.0059980312,0.0036564544,0.0029087279,0.0036526306,0.0001813233,0.0016177465,0.20942397],"study_design_scores_gemma":[0.7613896,0.015435393,0.09068237,0.0010103051,0.0016689403,0.00014631043,0.00030079982,0.12818252,0.00009771506,0.00067732227,0.00017614829,0.00023257421],"about_ca_topic_score_codex":0.029818105,"about_ca_topic_score_gemma":0.012481467,"teacher_disagreement_score":0.2091914,"about_ca_system_score_codex":0.03900868,"about_ca_system_score_gemma":0.049037367,"threshold_uncertainty_score":0.9999208},"labels":[],"label_agreement":null},{"id":"W2891759897","doi":"10.1200/jco.2017.35.15_suppl.e18242","title":"Patterns of futile care for comorbidities in colorectal cancer patients near the end of life.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; End-of-life care; Internal medicine; Retrospective cohort study; Medical prescription; Population; Cohort; Cause of death; Psychological intervention; Palliative care; Intensive care medicine; Disease; Emergency medicine","score_opus":0.10717762261401868,"score_gpt":0.45029964971011965,"score_spread":0.34312202709610096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891759897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595827,0.00035459604,0.000025145378,0.0012428649,0.0016833349,0.00023543288,0.000042958844,0.0000018920618,0.00045548438],"genre_scores_gemma":[0.9988136,0.00020248332,0.00016904272,0.00017777427,0.0005941088,0.000011619114,0.0000019099316,0.000007750787,0.000021656711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982116,0.00012920583,0.0012322053,0.00008781497,0.00022217103,0.00011699852],"domain_scores_gemma":[0.9958236,0.0011805496,0.002135813,0.00013265265,0.00063181337,0.00009555359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000930814,0.000070694725,0.0009018199,0.000048043596,0.00008852733,0.000008510546,0.0001831743,0.00018617028,0.00005069471],"category_scores_gemma":[0.0033826472,0.000044438642,0.0003205879,0.000030159614,0.00032339813,0.000060706145,0.000050018054,0.00041047798,2.9237853e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01775673,0.0003567569,0.8691286,0.000099434044,0.000116198025,0.0000063369785,0.00077675073,0.000022168984,0.00005591779,0.000009946772,0.00041204598,0.111259125],"study_design_scores_gemma":[0.0065509146,0.024551785,0.95943016,0.00017115398,0.00013257079,0.0000063176685,0.0006036748,0.00013011576,0.0010253855,0.000038560607,0.0073192385,0.000040139],"about_ca_topic_score_codex":0.0010486321,"about_ca_topic_score_gemma":0.0041113202,"teacher_disagreement_score":0.11121899,"about_ca_system_score_codex":0.000092496346,"about_ca_system_score_gemma":0.0013482615,"threshold_uncertainty_score":0.4049589},"labels":[],"label_agreement":null},{"id":"W2891762167","doi":"10.1200/jco.2018.36.15_suppl.e18623","title":"Baseline demographics and disparities in cancer registration trials: An analysis of U.S. Food and Drug Administration approved drugs in 2015 and 2016.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Demographics; Population; Cancer; Internal medicine; Food and drug administration; Demography; Environmental health","score_opus":0.07796101687764148,"score_gpt":0.44532908625694434,"score_spread":0.3673680693793029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891762167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940832,0.0035394765,0.00031961384,0.0017422751,0.0001580948,0.00009058144,0.000036344685,5.1949667e-7,0.00002988077],"genre_scores_gemma":[0.98006314,0.018344223,0.00091264513,0.00025945026,0.00038509397,0.0000034401257,0.000017292443,0.000004691744,0.000010037696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769926,0.00051996653,0.0014257428,0.00018060133,0.000082184175,0.00009227422],"domain_scores_gemma":[0.9977404,0.00083598256,0.0010117145,0.000100287645,0.00019960428,0.00011205157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061588865,0.000081292805,0.00073708943,0.00016571615,0.000016945929,0.000014251951,0.00005856517,0.00022688106,0.000003241594],"category_scores_gemma":[0.002958666,0.00006875386,0.000088461275,0.0001292294,0.00030350828,0.000013106356,0.000032523883,0.0001567737,1.5099985e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058532623,0.0009850655,0.88501424,0.000051192827,0.0007277601,0.000008157754,0.00036471718,0.00009683238,0.0055960137,0.00063046545,0.001523571,0.099148735],"study_design_scores_gemma":[0.0081752185,0.016000088,0.95524174,0.000078972706,0.0012871097,0.000017296425,0.00080516364,0.005692537,0.0025737514,0.0015703504,0.008283625,0.0002741356],"about_ca_topic_score_codex":0.0003314174,"about_ca_topic_score_gemma":0.03634833,"teacher_disagreement_score":0.0988746,"about_ca_system_score_codex":0.000013597634,"about_ca_system_score_gemma":0.0005265641,"threshold_uncertainty_score":0.9812358},"labels":[],"label_agreement":null},{"id":"W2891773217","doi":"10.1200/jco.2017.35.15_suppl.4574","title":"Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Sunnybrook Hospital","funders":"","keywords":"Medicine; Pazopanib; Renal cell carcinoma; Adverse effect; Sunitinib; Internal medicine; Dosing; Urology","score_opus":0.09640312324605789,"score_gpt":0.39568890662049133,"score_spread":0.29928578337443346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891773217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975259,0.00028311895,0.000024875802,0.0006032218,0.00015910548,0.0005345727,0.000009981046,0.0000026490945,0.0008566278],"genre_scores_gemma":[0.99749285,0.00014411594,0.00201966,0.00015879488,0.00012623683,0.0000030376566,0.000012501995,0.000017195463,0.000025596652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970036,0.000568741,0.0016009016,0.00026090903,0.0003780908,0.00018776968],"domain_scores_gemma":[0.99260026,0.0041123643,0.0023469874,0.00033627165,0.00026173747,0.0003424043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010881037,0.00019220571,0.0016351532,0.00014025053,0.000065863045,0.000014835405,0.0001465319,0.00016346184,0.000012595762],"category_scores_gemma":[0.0013619674,0.00012374774,0.00013789814,0.000046017965,0.00036438936,0.000109082896,0.000049058857,0.0006156785,0.0000026328073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04278635,0.0071480386,0.87784576,0.0001571062,0.00029134683,0.00082587276,0.00030399888,0.000023845929,0.0007088137,0.00005049632,0.000055180706,0.06980317],"study_design_scores_gemma":[0.046536043,0.025165774,0.9251991,0.00024051234,0.00071100367,0.000022351578,0.00003559636,0.00007358261,0.0016588297,0.00005189294,0.00021271252,0.0000925993],"about_ca_topic_score_codex":0.00014915451,"about_ca_topic_score_gemma":0.000045201472,"teacher_disagreement_score":0.069710575,"about_ca_system_score_codex":0.00011281183,"about_ca_system_score_gemma":0.0003316272,"threshold_uncertainty_score":0.50462866},"labels":[],"label_agreement":null},{"id":"W2891785187","doi":"10.1200/jco.2017.35.15_suppl.e18331","title":"Nivolumab in the treatment of metastatic renal cell carcinoma: A cost-utility analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Everolimus; Quality-adjusted life year; Renal cell carcinoma; Oncology; Cost–utility analysis; Quality of life (healthcare); Cost effectiveness; Cohort; Internal medicine; Clinical trial; Cost–benefit analysis; Cancer; Immunotherapy; Risk analysis (engineering); Nursing","score_opus":0.23907608985782514,"score_gpt":0.4828454824997873,"score_spread":0.24376939264196218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891785187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886005,0.001094261,0.000067601926,0.002907829,0.0002671118,0.0004652682,0.000007574267,0.0000018198051,0.006588024],"genre_scores_gemma":[0.99716,0.00043639733,0.0016281878,0.00021661531,0.0002752131,0.0000118269245,0.0000041563353,0.000008890954,0.00025872228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99527055,0.0010478111,0.002673101,0.0002334934,0.0005184995,0.00025656566],"domain_scores_gemma":[0.9928182,0.0023839425,0.0033066892,0.00088534347,0.00034462544,0.00026119893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039283712,0.00018654193,0.002625138,0.0002352596,0.00007795356,0.000015831894,0.00039833406,0.0001804942,0.00012828987],"category_scores_gemma":[0.0012300615,0.00009636492,0.001600825,0.00018384944,0.0004176148,0.00008416281,0.000033621433,0.0004977302,0.000008463782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005386202,0.013391969,0.90945387,0.000035526675,0.001820403,0.004854703,0.0006286202,0.00003116899,0.00013261495,0.000018570005,0.00052865245,0.063717715],"study_design_scores_gemma":[0.013555461,0.028100464,0.9425688,0.000014965807,0.0069596996,0.00018641244,0.00023489623,0.00026725218,0.00061693246,0.00012707905,0.0073042964,0.000063741434],"about_ca_topic_score_codex":0.00046167674,"about_ca_topic_score_gemma":0.0006688666,"teacher_disagreement_score":0.06365397,"about_ca_system_score_codex":0.00032592763,"about_ca_system_score_gemma":0.0012260927,"threshold_uncertainty_score":0.39296475},"labels":[],"label_agreement":null},{"id":"W2891785344","doi":"10.1200/jco.2018.36.15_suppl.6055","title":"Prognostic role of pretreatment plasma EBV DNA on stage III nasopharyngeal carcinoma staged by AJCC/UICC 8<sup>th</sup> edition TNM staging classification.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Stage (stratigraphy); Oncology; Internal medicine; Proportional hazards model; Cancer; Chemotherapy; Cancer staging; Cohort; Radiation therapy; Gastroenterology","score_opus":0.09119959686260101,"score_gpt":0.4166935414322467,"score_spread":0.32549394456964564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891785344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877735,0.00053151394,0.00006182056,0.0041099424,0.0008707752,0.0004968185,0.00005930417,0.000021333117,0.006074992],"genre_scores_gemma":[0.99448204,0.00045950443,0.0008521724,0.00093718775,0.0024821057,0.000021895115,0.000020666239,0.000029254406,0.00071517995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956494,0.00047345966,0.0024623282,0.0003479257,0.00067946257,0.00038745315],"domain_scores_gemma":[0.9941527,0.0024870015,0.001825437,0.0002925098,0.0008013106,0.00044104134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019371003,0.0002476471,0.0017844578,0.00017484454,0.00013728913,0.000010598151,0.00018522314,0.00035248668,0.00028386185],"category_scores_gemma":[0.00227899,0.00018065757,0.0003806938,0.00018374907,0.0005041072,0.00014601873,0.000059543156,0.00089713966,0.000030997795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028011477,0.011944363,0.67178977,0.0002991013,0.0021816879,0.0006189055,0.0036861994,0.000029990699,0.010204531,0.00057461736,0.066420555,0.20423883],"study_design_scores_gemma":[0.030593654,0.11617114,0.7322464,0.00067820895,0.0012761757,0.00010883929,0.0034792344,0.0026077745,0.010690302,0.00020124657,0.1015793,0.0003677421],"about_ca_topic_score_codex":0.000036596055,"about_ca_topic_score_gemma":0.000025110077,"teacher_disagreement_score":0.20387109,"about_ca_system_score_codex":0.00043301188,"about_ca_system_score_gemma":0.0014383292,"threshold_uncertainty_score":0.73670024},"labels":[],"label_agreement":null},{"id":"W2891798328","doi":"10.1200/jco.2018.36.15_suppl.8000","title":"Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Carfilzomib; Internal medicine; Clinical endpoint; Lenalidomide; Regimen; Interim analysis; Multiple myeloma; Tolerability; Neutropenia; Dexamethasone; Gastroenterology; Adverse effect; Randomized controlled trial; Toxicity","score_opus":0.08809992328939925,"score_gpt":0.4424007583133508,"score_spread":0.35430083502395154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891798328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949231,0.00019934522,0.000026559372,0.001512639,0.000585706,0.0020881162,0.000022161343,0.000008649931,0.0006337117],"genre_scores_gemma":[0.99637043,0.00011374991,0.0025054582,0.00029538907,0.00042795108,0.000016192891,0.000006412648,0.000031409214,0.00023297337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913989,0.0030676231,0.0035917442,0.00042252455,0.0010682956,0.0004509509],"domain_scores_gemma":[0.9848087,0.009760358,0.0031103839,0.000544887,0.0012325812,0.00054312375],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077846996,0.00028738385,0.0031754454,0.0002933787,0.000108760876,0.000016273007,0.0003083453,0.00035780133,0.00003241206],"category_scores_gemma":[0.02758004,0.00014920377,0.00041256048,0.0004048007,0.0013289349,0.00019901089,0.00016673742,0.0014299856,0.000004974367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60700685,0.00952931,0.34317312,0.00002023871,0.00081736705,0.0002816193,0.0007803494,0.0000023637708,0.000073442694,0.000001546658,0.00029753562,0.03801626],"study_design_scores_gemma":[0.48131928,0.048547413,0.4681053,0.00022005122,0.00040381873,0.000024252791,0.00027941083,0.00020660616,0.000081616105,0.000013926505,0.00071801967,0.00008032861],"about_ca_topic_score_codex":0.0003671212,"about_ca_topic_score_gemma":0.0005661684,"teacher_disagreement_score":0.12568758,"about_ca_system_score_codex":0.00035176225,"about_ca_system_score_gemma":0.001852191,"threshold_uncertainty_score":0.9806111},"labels":[],"label_agreement":null},{"id":"W2891803428","doi":"10.1200/jco.2018.36.15_suppl.10509","title":"Subsequent malignant neoplasms (SMNs) among non-irradiated survivors of childhood cancer treated with chemotherapy in the Childhood Cancer Survivor Study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Oncology; Anthracycline; Population; Cancer; Incidence (geometry); Chemotherapy; Cumulative dose; Cohort; Breast cancer","score_opus":0.06399970264894177,"score_gpt":0.4226527542472576,"score_spread":0.35865305159831584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891803428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98535687,0.00068912265,0.000016963104,0.010134976,0.0013480112,0.0016912274,0.000033534605,0.000025445554,0.0007038244],"genre_scores_gemma":[0.9905178,0.0016011287,0.0002286178,0.0049997508,0.0023950476,0.00007010467,0.000006129001,0.00008920841,0.00009220237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99017376,0.0022044955,0.004782408,0.0006386049,0.0014746268,0.0007260962],"domain_scores_gemma":[0.99084055,0.0023686357,0.0043039178,0.0008056076,0.0011298457,0.00055143767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009562729,0.0005427811,0.0036759295,0.00040198522,0.00011610144,0.000027464988,0.00084634614,0.00057724223,0.0004468761],"category_scores_gemma":[0.0010722905,0.00031686045,0.00066512113,0.0012017345,0.0010465645,0.00022917002,0.00007285826,0.0018920144,0.000009070984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006118331,0.012081985,0.9519568,0.000051236646,0.0019624503,0.0003472819,0.012702894,0.000058294,0.00006987759,0.000008356796,0.0009494802,0.013692992],"study_design_scores_gemma":[0.023633517,0.027077446,0.94115555,0.00076104695,0.000787569,0.00016165426,0.003797546,0.00004641752,0.000352496,0.000028389723,0.001871317,0.00032704635],"about_ca_topic_score_codex":0.02838873,"about_ca_topic_score_gemma":0.12964113,"teacher_disagreement_score":0.1012524,"about_ca_system_score_codex":0.0003801406,"about_ca_system_score_gemma":0.004327148,"threshold_uncertainty_score":0.99992836},"labels":[],"label_agreement":null},{"id":"W2891822390","doi":"10.1200/jco.2017.35.15_suppl.e17049","title":"Survival outcomes in patients with platinum-resistant (PL-R) ovarian cancer (OC): The Princess Margaret Cancer Centre (PM) experience.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Ovarian cancer; Confidence interval; Oncology; Cancer; Proportional hazards model; Clinical trial; Gynecology; Surgery","score_opus":0.09802903731853926,"score_gpt":0.45625268877028374,"score_spread":0.3582236514517445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891822390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9478711,0.00024124702,0.000004394148,0.04736776,0.0025108382,0.00041381034,0.000029124516,0.000004852816,0.0015569032],"genre_scores_gemma":[0.99644935,0.0006730689,0.00033252058,0.0013740045,0.0007469297,0.00003919807,0.0000019542279,0.000021682976,0.00036129713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968845,0.00026336208,0.001575396,0.0002893766,0.0006334207,0.0003539377],"domain_scores_gemma":[0.9955021,0.0009191068,0.002347409,0.00051611295,0.00040724373,0.000307999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011105144,0.0002164467,0.0015603085,0.000059885188,0.00017782237,0.000048142814,0.00043800464,0.00022913962,0.00060937385],"category_scores_gemma":[0.0008873325,0.000104188664,0.0002443371,0.000071984476,0.0003635788,0.00018173442,0.00009961526,0.0007323331,0.0000042392485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004461894,0.0019076335,0.9456387,0.000014454519,0.0005705775,0.00032569995,0.000414776,0.0000119775395,0.000001091339,0.0001450868,0.00072667084,0.04578141],"study_design_scores_gemma":[0.019001804,0.0027542126,0.9495617,0.0002998655,0.0003179074,0.000003875149,0.00020312871,0.000007749741,0.000011838343,0.000047041012,0.027673844,0.0001170406],"about_ca_topic_score_codex":0.0020113934,"about_ca_topic_score_gemma":0.010917185,"teacher_disagreement_score":0.048578274,"about_ca_system_score_codex":0.00048345613,"about_ca_system_score_gemma":0.0017455762,"threshold_uncertainty_score":0.6672216},"labels":[],"label_agreement":null},{"id":"W2891829898","doi":"10.1200/jco.2018.36.15_suppl.e17026","title":"A population-based analysis of the effectiveness of docetaxel for castration-sensitive prostate cancer (CSPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Neutropenia; Febrile neutropenia; Population; Androgen deprivation therapy; Adverse effect; Oncology; Surgery; Cancer; Urology; Chemotherapy","score_opus":0.11679375847145256,"score_gpt":0.5280941466882085,"score_spread":0.41130038821675596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891829898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969518,0.0001483747,0.00025379643,0.0014720481,0.00040475852,0.0005260496,0.00005573118,0.000001491808,0.00018592797],"genre_scores_gemma":[0.9988059,0.00006741627,0.00058498146,0.0001484516,0.00026834826,0.000014093838,0.0000097593065,0.0000065778113,0.00009452043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773395,0.000611263,0.0011313917,0.00011246521,0.00028574778,0.00012517498],"domain_scores_gemma":[0.99243826,0.0040916833,0.0013329305,0.00013639318,0.0019054262,0.00009531348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031503756,0.000073194984,0.0011566607,0.00017160278,0.000039614708,0.0000025083084,0.000078912744,0.00013505912,0.00003369998],"category_scores_gemma":[0.0022237385,0.000038746482,0.00065380713,0.0004697669,0.00032201587,0.000040433057,0.000014510009,0.00021698777,3.278577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028217522,0.00086449593,0.9511219,0.00015600683,0.003785781,0.0000134997135,0.00011537902,0.00045476772,0.0025234884,0.00010121858,0.000099962046,0.012545961],"study_design_scores_gemma":[0.0071941274,0.0064414614,0.97207904,0.00019350907,0.0029618803,0.0000041036574,0.00004050464,0.0012001484,0.009391045,0.00019820832,0.00026166212,0.0000343178],"about_ca_topic_score_codex":0.0002335876,"about_ca_topic_score_gemma":0.00039241815,"teacher_disagreement_score":0.021023395,"about_ca_system_score_codex":0.0001528933,"about_ca_system_score_gemma":0.0021006407,"threshold_uncertainty_score":0.37264466},"labels":[],"label_agreement":null},{"id":"W2891830669","doi":"10.1200/jco.2016.34.15_suppl.6626","title":"FDG-PET/CT in small cell lung cancer (SCLC): A value analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiology; Lung cancer; Nuclear medicine; Oncology","score_opus":0.050245488409703463,"score_gpt":0.46887313749560877,"score_spread":0.41862764908590533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891830669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95453084,0.0010855361,0.002695659,0.036503375,0.0011943526,0.00010892716,0.0000014586212,0.000009123784,0.0038707193],"genre_scores_gemma":[0.9833104,0.0024736691,0.0061335615,0.00556014,0.0012143982,0.0000033839208,6.847094e-7,0.000018901175,0.0012848574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962666,0.0005790739,0.0023013258,0.00023552307,0.00029341673,0.00032407718],"domain_scores_gemma":[0.99480206,0.0028837086,0.0013776693,0.00020664008,0.0002067844,0.00052313454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056690974,0.00013884886,0.0018470022,0.0003871399,0.000024384193,0.000008084682,0.00023521706,0.00007518607,0.00044223355],"category_scores_gemma":[0.0055273953,0.000076515025,0.0007809041,0.00039370838,0.00019269405,0.00006979178,0.000057094294,0.0014261178,0.000011479638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007395101,0.0009117514,0.85735255,0.00003822883,0.00092337694,0.0075033405,0.000042637395,0.0003345785,0.00056368386,0.00012004992,0.0046955426,0.12677476],"study_design_scores_gemma":[0.021486802,0.0033659872,0.81791097,0.0006003636,0.0046214717,0.001451755,0.000060269176,0.017761867,0.0001226459,0.00058349816,0.13176984,0.00026456322],"about_ca_topic_score_codex":0.0001812413,"about_ca_topic_score_gemma":0.00011171792,"teacher_disagreement_score":0.12707429,"about_ca_system_score_codex":0.00025561967,"about_ca_system_score_gemma":0.0014992002,"threshold_uncertainty_score":0.66172075},"labels":[],"label_agreement":null},{"id":"W2891848997","doi":"10.1200/jco.2018.36.15_suppl.11511","title":"Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; GiST; Stromal tumor; Internal medicine; Oncology; Drug; Stromal cell; Imatinib; Cancer research; Gastroenterology; Pharmacology","score_opus":0.10079463350486198,"score_gpt":0.4806631851111028,"score_spread":0.3798685516062408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891848997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974373,0.000020221603,0.000025693786,0.00067826046,0.000120680525,0.00087169645,0.000011722532,0.0000032687412,0.00083117554],"genre_scores_gemma":[0.99520946,0.0000025228674,0.0043372163,0.00008365473,0.00028900572,0.000012867023,0.0000054156276,0.000011399678,0.000048471014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944859,0.0012388215,0.0028837067,0.00019216748,0.00090522575,0.00029415567],"domain_scores_gemma":[0.9934152,0.0023292084,0.0023828952,0.00025009108,0.0013685558,0.00025405004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004333478,0.00014919433,0.0012367704,0.00021740823,0.00004019601,0.0000060945167,0.00025975253,0.000036675166,0.00011821012],"category_scores_gemma":[0.008267766,0.00008488756,0.00027960242,0.0002637217,0.00040965163,0.00007376083,0.00005627796,0.0007374506,0.000007711366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07281414,0.067775205,0.8432239,0.00007838745,0.00025181824,0.005347429,0.0010586914,0.000004032851,0.0008470095,0.000030270397,0.0011415477,0.0074275145],"study_design_scores_gemma":[0.049142558,0.275907,0.6696774,0.00028687486,0.0002465455,0.00089582993,0.0033187717,0.000108868066,0.00022661731,0.000083434796,0.00006195959,0.00004416512],"about_ca_topic_score_codex":0.00011071495,"about_ca_topic_score_gemma":0.00017923108,"teacher_disagreement_score":0.2081318,"about_ca_system_score_codex":0.00013593257,"about_ca_system_score_gemma":0.0011684216,"threshold_uncertainty_score":0.9897885},"labels":[],"label_agreement":null},{"id":"W2891851554","doi":"10.1200/jco.2017.35.15_suppl.10031","title":"Accrual of older adults to Canadian Cancer Trials Group (CCTG) led trials: A retrospective analysis from 1990 to 2015.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital","funders":"","keywords":"Medicine; Accrual; Clinical trial; Internal medicine; Cancer; Lung cancer; Randomized controlled trial","score_opus":0.7027000625205989,"score_gpt":0.7196269273348241,"score_spread":0.01692686481422523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891851554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85062736,0.00041708676,0.0004710816,0.14142184,0.0038043924,0.0011864273,0.00031535025,0.0000071269255,0.0017493301],"genre_scores_gemma":[0.9780885,0.0015870524,0.007301059,0.0062337457,0.0060121333,0.000033284196,0.000007368742,0.000033392334,0.00070344855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98156255,0.0048743524,0.01021762,0.0007072551,0.0019642138,0.00067401025],"domain_scores_gemma":[0.8097415,0.16139384,0.013284283,0.0022056487,0.0076395124,0.005735221],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.12671185,0.00027384132,0.009588653,0.0009519058,0.00018247846,0.000066302695,0.0013840704,0.0018178695,0.0027952949],"category_scores_gemma":[0.7416226,0.0001885874,0.002992159,0.0005722798,0.0005190655,0.00016080844,0.00032327432,0.0045159026,0.000068399924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06426081,0.0027185755,0.68198276,0.00007466178,0.020243602,0.0012504761,0.0013849797,0.00004553288,0.0006045706,0.00086769846,0.057213377,0.16935295],"study_design_scores_gemma":[0.016287697,0.011254005,0.94635886,0.00073028833,0.00493056,0.0000060720827,0.00026947173,0.00005165987,0.00014045941,0.0035127618,0.01627164,0.00018653178],"about_ca_topic_score_codex":0.16993798,"about_ca_topic_score_gemma":0.74587584,"teacher_disagreement_score":0.6149108,"about_ca_system_score_codex":0.0011332864,"about_ca_system_score_gemma":0.012959555,"threshold_uncertainty_score":0.999478},"labels":[],"label_agreement":null},{"id":"W2891861352","doi":"10.1200/jco.2016.34.15_suppl.e14577","title":"Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Immunovaccine (Canada); University Health Network","funders":"","keywords":"Medicine; Survivin; ELISPOT; Immunogenicity; Adjuvant; Immune system; Immunology; Ovarian cancer; Immunotherapy; Adverse effect; Vaccination; Oncology; CD8; Internal medicine; Cancer","score_opus":0.09811844666618247,"score_gpt":0.44765003389164687,"score_spread":0.3495315872254644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891861352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989156,0.006663479,0.0004872364,0.001335214,0.001212889,0.0010632847,0.0000618002,0.000005231271,0.000014834823],"genre_scores_gemma":[0.99128395,0.006987628,0.00065855234,0.000060628838,0.000067977184,0.00007160406,0.0000030793353,0.000025515437,0.000841032],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99547017,0.0014400859,0.0025297874,0.00021610064,0.00009723888,0.00024664265],"domain_scores_gemma":[0.99293894,0.0032946079,0.002858986,0.00035563495,0.0005230395,0.000028794677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014385784,0.0002602929,0.0016819284,0.00017331932,0.00011311695,0.000005639444,0.00031071444,0.0004053244,0.00022280813],"category_scores_gemma":[0.0003543492,0.00012493112,0.0006032639,0.00013703713,0.00042071636,0.00015027025,0.00003183754,0.00015549577,8.6445294e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06974976,0.012415208,0.008640433,0.000016554532,0.00214923,0.0000037272976,0.0016396772,0.000002069603,0.35447428,0.00010129215,0.00001069194,0.5507971],"study_design_scores_gemma":[0.19997439,0.22444011,0.2881415,0.0002711657,0.0011015097,0.00017446459,0.0013324796,0.000047121197,0.24873939,0.00011429875,0.035359155,0.0003044223],"about_ca_topic_score_codex":0.00019750943,"about_ca_topic_score_gemma":0.0001480174,"teacher_disagreement_score":0.55049264,"about_ca_system_score_codex":0.00021362322,"about_ca_system_score_gemma":0.0010870093,"threshold_uncertainty_score":0.5094543},"labels":[],"label_agreement":null},{"id":"W2891862100","doi":"10.1200/jco.2017.35.15_suppl.e15008","title":"Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) in the treatment of metastatic colorectal cancer: Systematic review and metanalysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bevacizumab; Medicine; Panitumumab; Cetuximab; Internal medicine; Oncology; Colorectal cancer; Observational study; Adverse effect; Hazard ratio; Meta-analysis; Cochrane Library; Chemotherapy; Cancer; Confidence interval","score_opus":0.1491967215175082,"score_gpt":0.504894761262827,"score_spread":0.3556980397453188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891862100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8462065,0.1515151,0.0000031564796,0.001149972,0.00006314269,0.00085350446,0.00001939646,7.8564113e-7,0.0001884798],"genre_scores_gemma":[0.85238856,0.14727582,0.00019861438,0.00006556624,0.000024865953,0.00003617472,6.064798e-7,0.000003490747,0.0000062806935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969327,0.00096817,0.0016300103,0.00015531477,0.00020384784,0.000109957764],"domain_scores_gemma":[0.99319255,0.0040317243,0.0022599052,0.00015110536,0.00028633117,0.00007840778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002295762,0.00016338883,0.00496432,0.000071757,0.00009629814,0.000009094842,0.00008760684,0.000058597325,0.000006144892],"category_scores_gemma":[0.0010317541,0.00007689485,0.00026508427,0.00006352527,0.0006605639,0.00007512216,0.0000389418,0.00016496354,9.602276e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024607094,0.0076365545,0.8038458,0.08637127,0.029399924,0.00067514344,0.0066670454,0.0000068807194,0.00020920683,0.000377125,0.00004535416,0.040158555],"study_design_scores_gemma":[0.009675527,0.01766918,0.94735736,0.006309655,0.017533386,0.00023534283,0.0007930508,0.0000435116,0.00009545045,0.0001568343,0.000060910206,0.00006978509],"about_ca_topic_score_codex":0.00027035116,"about_ca_topic_score_gemma":0.0009256225,"teacher_disagreement_score":0.14351152,"about_ca_system_score_codex":0.00010784335,"about_ca_system_score_gemma":0.00026304246,"threshold_uncertainty_score":0.339351},"labels":[],"label_agreement":null},{"id":"W2891875586","doi":"10.1200/jco.2018.36.15_suppl.e22134","title":"Using patient reported outcomes (PROs) to hear the patient: Are we listening?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Anxiety; Population; Medical prescription; Breast cancer; Family medicine; Cancer; Physical therapy; Internal medicine; Psychiatry; Nursing","score_opus":0.6126924899811849,"score_gpt":0.6333406400587146,"score_spread":0.020648150077529737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891875586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87292147,0.00007327313,0.00091816473,0.12136189,0.0036521512,0.00046894402,0.0000029028017,0.000013099096,0.00058813096],"genre_scores_gemma":[0.92937607,0.0000691434,0.022987816,0.04523057,0.0022190874,0.000003538242,0.0000013419738,0.000025371233,0.00008705973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99099076,0.0007977625,0.006922412,0.00025980055,0.000740657,0.00028863954],"domain_scores_gemma":[0.9827911,0.0071925838,0.006905332,0.00046481518,0.0021202848,0.00052584347],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061425036,0.00016289258,0.0013388392,0.00012053659,0.00012667582,0.000021227854,0.000175326,0.0002759625,0.0002565458],"category_scores_gemma":[0.074980125,0.00009218811,0.00057182286,0.00027135387,0.0002566458,0.00016937304,0.0001674572,0.0010852796,0.000046275665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008246285,0.0023880007,0.4602247,0.000022080076,0.00084515056,0.0011344629,0.001192532,0.0000661211,0.00034551672,0.000039437047,0.057750486,0.46774524],"study_design_scores_gemma":[0.00573461,0.03159101,0.2822685,0.00022792822,0.0010592494,0.0014933015,0.0026456153,0.0005051497,0.00013206972,0.0004004597,0.6737732,0.00016887208],"about_ca_topic_score_codex":0.00008078953,"about_ca_topic_score_gemma":0.000104433864,"teacher_disagreement_score":0.61602277,"about_ca_system_score_codex":0.00020713171,"about_ca_system_score_gemma":0.0012803896,"threshold_uncertainty_score":0.93281174},"labels":[],"label_agreement":null},{"id":"W2891880958","doi":"10.1200/jco.18.00659","title":"Reply to D.M. Green","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine","score_opus":0.059871478377918466,"score_gpt":0.44339779910408145,"score_spread":0.383526320726163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891880958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588791,0.00032676646,0.00067517074,0.017089477,0.002667601,0.000063864965,0.0000014648808,0.000002998963,0.02029353],"genre_scores_gemma":[0.95322037,0.00047272435,0.0028306006,0.031688463,0.0079054115,0.000001124283,0.0000012211748,0.000012386933,0.0038677244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998481,0.00015215947,0.0009525918,0.00014384915,0.00012452826,0.00014588855],"domain_scores_gemma":[0.9985798,0.00007384551,0.00054520974,0.00015731229,0.00036968497,0.000274137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001326194,0.000069184796,0.00037834412,0.000037658312,0.000029399573,0.0000041060716,0.0002308043,0.00028836462,0.000050988347],"category_scores_gemma":[0.0010773136,0.000046327685,0.0002556579,0.00007377681,0.00016749577,0.0000025461566,0.00007067573,0.00027366471,0.0000718806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004913453,0.0003979186,0.0064422064,0.000007411177,0.0005537184,0.00014506716,0.000075583564,0.000034364977,0.042092945,0.00008178044,0.4626812,0.48257434],"study_design_scores_gemma":[0.0010214489,0.014715853,0.007053497,0.000013810092,0.00003443231,0.00013518675,0.000017435148,0.0000035036524,0.0069947643,0.00018245845,0.9697601,0.00006746615],"about_ca_topic_score_codex":0.000024207591,"about_ca_topic_score_gemma":0.000024879184,"teacher_disagreement_score":0.50707895,"about_ca_system_score_codex":0.00001805828,"about_ca_system_score_gemma":0.00055881194,"threshold_uncertainty_score":0.22241321},"labels":[],"label_agreement":null},{"id":"W2891881749","doi":"10.1200/jco.2018.36.15_suppl.10065","title":"Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont","funders":"","keywords":"Medicine; Pregnancy; Trastuzumab; Breast cancer; Lapatinib; Internal medicine; Gestation; Cancer; Gynecology; Obstetrics","score_opus":0.06382796730366658,"score_gpt":0.3910603095119024,"score_spread":0.3272323422082358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891881749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956613,0.0012613069,0.000020238269,0.001980643,0.0003443954,0.0005489895,0.00006967583,0.0000087143935,0.00010473831],"genre_scores_gemma":[0.9959044,0.0012891764,0.0006772239,0.0006876183,0.0012168535,0.000020927864,0.000010067894,0.000029282162,0.00016445543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542385,0.0010503778,0.0021879352,0.00046026488,0.000496429,0.00038112103],"domain_scores_gemma":[0.9929643,0.004384146,0.0016672469,0.00025078477,0.0003194562,0.00041403386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023161413,0.0003029057,0.0026317595,0.0001888218,0.00014613812,0.0000444819,0.00014416111,0.00035232565,0.00006527243],"category_scores_gemma":[0.0019286774,0.00016118634,0.00034935618,0.00039072632,0.00049770065,0.00017342858,0.00011345304,0.0008268904,0.000002552171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011339277,0.0007501123,0.87950355,0.000019627076,0.0038545532,0.00033570614,0.0018260152,0.0000037107022,0.000027214875,0.0000014453581,0.0000924864,0.102246284],"study_design_scores_gemma":[0.037999373,0.0090724025,0.946357,0.0007815918,0.0045704544,0.00011305146,0.0004409103,0.000058299884,0.000033844633,0.000023983917,0.00039160324,0.00015744753],"about_ca_topic_score_codex":0.0026634408,"about_ca_topic_score_gemma":0.008267661,"teacher_disagreement_score":0.10208884,"about_ca_system_score_codex":0.0006791602,"about_ca_system_score_gemma":0.0014355894,"threshold_uncertainty_score":0.6572988},"labels":[],"label_agreement":null},{"id":"W2891887155","doi":"10.1200/jco.18.00242","title":"National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Achieve Life Sciences (Canada)","funders":"AstraZeneca","keywords":"Medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Cancer; Oncology; Internal medicine; Family medicine; Medical physics","score_opus":0.4241682816083695,"score_gpt":0.5935647420298819,"score_spread":0.16939646042151235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891887155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93856823,0.0013943359,0.00020561292,0.04722469,0.010580048,0.0010127975,0.00014369827,0.000017488937,0.000853079],"genre_scores_gemma":[0.97153145,0.005334015,0.0026461629,0.0073203733,0.01276195,0.00012824647,0.000010777004,0.000033926557,0.00023307816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.992332,0.0012836213,0.0050238846,0.00046407554,0.00050470605,0.00039170578],"domain_scores_gemma":[0.98875153,0.0060566138,0.0038181415,0.0001486454,0.0007959633,0.00042910723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02117581,0.00027093076,0.0031239134,0.00026283102,0.00009238865,0.000022301325,0.00016525046,0.00037146622,0.00047937446],"category_scores_gemma":[0.0034804114,0.00019337484,0.0006324108,0.00021765874,0.00048998214,0.00018908337,0.000059089834,0.001130485,0.0000027272515],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03302797,0.0029027865,0.37648535,0.00007426592,0.002386619,0.0007569823,0.00016955072,0.000055157117,0.0001424039,0.00026864436,0.008761339,0.57496893],"study_design_scores_gemma":[0.034993973,0.006893303,0.8651371,0.00091355393,0.002032024,0.0017386765,0.00005061773,0.0005453727,0.000026407926,0.0011397921,0.08627906,0.0002501051],"about_ca_topic_score_codex":0.00049768446,"about_ca_topic_score_gemma":0.003717464,"teacher_disagreement_score":0.57471883,"about_ca_system_score_codex":0.0006991447,"about_ca_system_score_gemma":0.0032599536,"threshold_uncertainty_score":0.78855973},"labels":[],"label_agreement":null},{"id":"W2891887641","doi":"10.1200/jco.2017.35.15_suppl.7550","title":"Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Adverse effect; Pharmacokinetics; Biosimilar; Pharmacodynamics; Gastroenterology; Diffuse large B-cell lymphoma; Prednisone; Tolerability; Lymphoma","score_opus":0.187153099149315,"score_gpt":0.4910621316563976,"score_spread":0.3039090325070826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891887641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98621124,0.00018172667,0.000009009486,0.0044409414,0.00084585673,0.0014863837,0.000010152503,0.0000027809667,0.0068118996],"genre_scores_gemma":[0.9962874,0.00030085744,0.0011081372,0.00023834515,0.0009715505,0.000012921663,0.000009121371,0.000013588817,0.0010580804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99482834,0.0008434468,0.0028262609,0.0002575491,0.000882038,0.00036236245],"domain_scores_gemma":[0.9919465,0.0025628859,0.0034672045,0.0004024322,0.0012705673,0.0003503659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006049646,0.00019875882,0.00414418,0.00020079216,0.00010143191,0.000020921632,0.00041935703,0.00030700155,0.00006040403],"category_scores_gemma":[0.0034912403,0.00011025769,0.0005357516,0.00010321174,0.0009280215,0.00018802956,0.00015047095,0.0008881393,0.000020474077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89071065,0.067148075,0.03705081,0.00007161814,0.00042096002,0.00021248216,0.00016942021,4.8413364e-7,0.000010548946,0.00011542255,0.0006958418,0.0033936787],"study_design_scores_gemma":[0.88631403,0.017561374,0.087259926,0.00013667266,0.00026202732,0.000018462135,0.000031935364,0.000032233715,0.00020697925,0.000082871746,0.007992656,0.000100805824],"about_ca_topic_score_codex":0.00008057107,"about_ca_topic_score_gemma":0.000063641644,"teacher_disagreement_score":0.050209112,"about_ca_system_score_codex":0.00007546305,"about_ca_system_score_gemma":0.0018639745,"threshold_uncertainty_score":0.4496178},"labels":[],"label_agreement":null},{"id":"W2891915117","doi":"10.1200/jco.2017.35.15_suppl.10075","title":"Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Logistic regression; Internal medicine; Confidence interval; Cancer; Pediatrics","score_opus":0.2852841711799342,"score_gpt":0.5313693095904174,"score_spread":0.24608513841048318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891915117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815154,0.0003117469,0.000004189465,0.0006358648,0.00029529736,0.0005161946,0.000020046711,0.0000050536337,0.00006008149],"genre_scores_gemma":[0.99940205,0.00018935649,0.00009644922,0.00006819926,0.00020263079,0.0000071897616,0.0000037005475,0.000015126043,0.000015283409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99619085,0.0009927412,0.0018469426,0.00023798131,0.0005205699,0.00021088937],"domain_scores_gemma":[0.9911437,0.0039141504,0.0038539022,0.00034823568,0.00045869907,0.0002813379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033454273,0.0001864803,0.0016374968,0.000078406345,0.00013755118,0.000023079563,0.0002605709,0.00031628227,0.000025175497],"category_scores_gemma":[0.007083318,0.00009675979,0.00042058955,0.000100348174,0.0010316089,0.0001385418,0.00007424245,0.0009664046,3.5102008e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065286545,0.0065413234,0.98648083,0.000009304794,0.0009847011,0.00087895576,0.00063585234,0.000028306764,0.0000016273239,0.0000031492755,0.00003904903,0.0037440096],"study_design_scores_gemma":[0.010835341,0.013099335,0.97141165,0.00021039532,0.0025356493,0.000009824781,0.0015338865,0.00014807345,0.0000010887171,0.00009518707,0.000028417597,0.00009115757],"about_ca_topic_score_codex":0.004635515,"about_ca_topic_score_gemma":0.0072600353,"teacher_disagreement_score":0.015069212,"about_ca_system_score_codex":0.00006408,"about_ca_system_score_gemma":0.0006698836,"threshold_uncertainty_score":0.8479905},"labels":[],"label_agreement":null},{"id":"W2891916139","doi":"10.1200/jco.2016.34.15_suppl.e16554","title":"The impact of multiple prostate biopsies on radical prostatectomy outcomes: A population-based analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; St Joseph's Health Care; Western University","funders":"","keywords":"Medicine; Prostatectomy; Urology; Biopsy; Prostate; Cohort; Prostate cancer; Population; Prostate biopsy; Surgery; Urinary system; Transurethral resection of the prostate; Internal medicine; Cancer","score_opus":0.08506118024202386,"score_gpt":0.4794264236325432,"score_spread":0.3943652433905193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891916139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697096,0.00024555495,0.000062319436,0.0118928235,0.00024155909,0.0004074424,0.000039322935,0.000007953811,0.00013205405],"genre_scores_gemma":[0.9983106,0.0005669222,0.00050589046,0.00036051727,0.00015048865,0.00001939726,0.0000050805943,0.000010896835,0.00007020209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655294,0.00036979702,0.0022397072,0.00017999265,0.00040535873,0.00025221996],"domain_scores_gemma":[0.9875659,0.009301947,0.0020771087,0.00028942619,0.0004432848,0.0003223315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020997734,0.00016575694,0.0016854401,0.00020494599,0.00005797472,0.000009117964,0.0001302823,0.00017115094,0.000058426],"category_scores_gemma":[0.005855817,0.0000584832,0.0016108862,0.0002932618,0.0002852851,0.000060198276,0.000015251045,0.00031732206,0.000006759146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006424642,0.001889736,0.91234154,0.000008890171,0.003126625,0.00011014192,0.000021314432,0.00024496164,0.00004198029,0.000032204152,0.00051834295,0.075239606],"study_design_scores_gemma":[0.012948703,0.01790585,0.9657375,0.000121737474,0.0009984492,0.000011857083,0.000014075448,0.00024850288,0.00017446865,0.00021292236,0.0015607635,0.00006512937],"about_ca_topic_score_codex":0.0001286873,"about_ca_topic_score_gemma":0.000052926367,"teacher_disagreement_score":0.07517447,"about_ca_system_score_codex":0.00043271558,"about_ca_system_score_gemma":0.0014418532,"threshold_uncertainty_score":0.7010383},"labels":[],"label_agreement":null},{"id":"W2891920301","doi":"10.1200/jco.2017.35.15_suppl.4053","title":"Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Esophageal cancer; Internal medicine; Chemoradiotherapy; Carboplatin; Gastroenterology; Regimen; Cancer; Esophagectomy; Radiation therapy; Adenocarcinoma; Surgery; Oncology; Chemotherapy; Cisplatin","score_opus":0.46849327326668205,"score_gpt":0.6292209848304746,"score_spread":0.16072771156379256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891920301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837631,0.0066612707,0.0011068154,0.0029194788,0.0037965963,0.0008142241,0.0000966484,0.000013467792,0.0008284239],"genre_scores_gemma":[0.9705805,0.0006461203,0.023954693,0.0002497467,0.0040239044,0.00002381296,0.0000092187765,0.000042048883,0.0004699399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545974,0.00023446916,0.0026073107,0.00034088516,0.0008326772,0.0005249434],"domain_scores_gemma":[0.9913954,0.0026108238,0.0038400483,0.0004671962,0.00096623803,0.0007202823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021480802,0.00027776315,0.0027211176,0.00015716632,0.0002899601,0.000035072902,0.00041566812,0.0004143995,0.00051033375],"category_scores_gemma":[0.0037293383,0.00019294381,0.00088975986,0.00009392859,0.00062971015,0.00023501036,0.00007723355,0.0010153358,0.0000040363416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20849976,0.0054409546,0.55748254,0.00042601099,0.003878567,0.0022949786,0.00027312772,0.0004277317,0.00096042885,0.00027746533,0.008476165,0.21156228],"study_design_scores_gemma":[0.11711588,0.112139255,0.7468164,0.00044188052,0.0021139104,0.0006067643,0.00021610389,0.009963175,0.004143536,0.00023748844,0.0058827423,0.00032289716],"about_ca_topic_score_codex":0.00026757215,"about_ca_topic_score_gemma":0.0002880744,"teacher_disagreement_score":0.21123938,"about_ca_system_score_codex":0.0007732718,"about_ca_system_score_gemma":0.0053721294,"threshold_uncertainty_score":0.95299274},"labels":[],"label_agreement":null},{"id":"W2891920787","doi":"10.1200/jco.2018.36.15_suppl.6520","title":"Opioid use in long term cancer survivors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Opioid; National Death Index; Cancer; Retrospective cohort study; Cohort; Internal medicine; Oxycodone; Hazard ratio; Confidence interval","score_opus":0.15149114116033563,"score_gpt":0.4918304771177776,"score_spread":0.340339335957442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891920787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873538,0.000732536,0.00007959674,0.0029364375,0.006355635,0.00010425083,0.0000030260849,0.0000071058935,0.0024276173],"genre_scores_gemma":[0.98825127,0.0015125506,0.00024809205,0.004445195,0.0046355603,0.0000031889613,0.0000011436963,0.000015765387,0.0008872222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972831,0.00030110305,0.0017128347,0.00016623823,0.00029574474,0.00024094908],"domain_scores_gemma":[0.9969946,0.0011155446,0.0008181924,0.00019126474,0.00054803485,0.00033234555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022167047,0.00010838469,0.0011584088,0.000147499,0.00002131486,0.000010964864,0.00015218678,0.00035937008,0.00070680387],"category_scores_gemma":[0.0017033555,0.00007869282,0.0003363917,0.00020365202,0.0002746816,0.00015478529,0.000048779064,0.0009255412,0.000026316378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002266523,0.00044013382,0.85007215,0.00002207839,0.00008249498,0.00057200214,0.00026446892,5.730565e-7,0.000051709387,0.000023260804,0.0019945786,0.14421006],"study_design_scores_gemma":[0.0034358797,0.0043786224,0.8943502,0.0001997681,0.00010944769,0.00013065505,0.00006785086,0.0000096578515,0.000091119065,0.00006477648,0.09708677,0.00007527685],"about_ca_topic_score_codex":0.0023933207,"about_ca_topic_score_gemma":0.106672086,"teacher_disagreement_score":0.14413479,"about_ca_system_score_codex":0.00020493097,"about_ca_system_score_gemma":0.00161796,"threshold_uncertainty_score":0.9096288},"labels":[],"label_agreement":null},{"id":"W2891923862","doi":"10.1200/jco.2017.35.15_suppl.e20065","title":"Real-world data evaluating the value of PET-CT for mediastinal staging in patients diagnosed with non-small cell lung cancer in an area with high prevalence of granulomatous diseases: The LACOG-0114 study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Lung cancer; Mediastinoscopy; Mediastinum; Radiology; Standardized uptake value; Nuclear medicine; Internal medicine; Positron emission tomography","score_opus":0.09365035847660579,"score_gpt":0.4875902462018383,"score_spread":0.3939398877252325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891923862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670744,0.000088727924,0.00014457526,0.0015735687,0.0002973667,0.0011008574,0.000035406225,0.0000027123306,0.000049349317],"genre_scores_gemma":[0.9966197,0.00025880334,0.0025475542,0.00021729457,0.00027862808,0.000030499377,0.0000062767326,0.000024633277,0.000016616588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617624,0.00078979606,0.0017713559,0.00030686834,0.0006813709,0.00027436134],"domain_scores_gemma":[0.98896074,0.0058233007,0.0037722744,0.0008090407,0.00043825692,0.000196409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008139696,0.00016600156,0.0012347655,0.00012140531,0.000114231414,0.000020929649,0.0010799309,0.000027323324,0.0000117309955],"category_scores_gemma":[0.0066202506,0.000078027355,0.00009676435,0.00013276751,0.000596232,0.0001768759,0.00019208566,0.0010888315,6.1275664e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051293685,0.002501481,0.9669183,0.00029195883,0.00013076783,0.00032548935,0.0006413513,0.0015918164,0.000010256042,0.000005347494,0.00005682245,0.022397058],"study_design_scores_gemma":[0.016759612,0.011710756,0.91682774,0.001224373,0.0010125438,0.000014436687,0.00055253983,0.051774733,0.00000367166,0.000026463647,0.000011638777,0.000081489234],"about_ca_topic_score_codex":0.0019212954,"about_ca_topic_score_gemma":0.0031499192,"teacher_disagreement_score":0.050182916,"about_ca_system_score_codex":0.00009163855,"about_ca_system_score_gemma":0.0016354219,"threshold_uncertainty_score":0.79255366},"labels":[],"label_agreement":null},{"id":"W2891924922","doi":"10.1200/jco.2017.35.15_suppl.tps11625","title":"WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine; Liquid biopsy; Personalized medicine; Precision medicine; Biopsy; Bioinformatics; Pathology","score_opus":0.050982798086367805,"score_gpt":0.4077705009773873,"score_spread":0.3567877028910195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891924922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757236,0.000034510267,0.00016775103,0.0017336296,0.00016948409,0.00013464282,0.0000149964935,5.9362617e-7,0.00017204788],"genre_scores_gemma":[0.99706304,0.00010536593,0.0010372609,0.0016066736,0.00016311542,0.000004696812,0.0000043838886,0.0000068308536,0.0000086377195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987947,0.00015563096,0.0006294613,0.00015201894,0.00017073315,0.00009746407],"domain_scores_gemma":[0.9981276,0.0004426112,0.0008038685,0.0002580132,0.00029572885,0.000072199095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001388101,0.00008535961,0.00042779793,0.00009895949,0.000051172825,0.000027118802,0.0003291351,0.00006263289,0.000012987873],"category_scores_gemma":[0.00099386,0.000053746353,0.0001011912,0.000076514574,0.00013643349,0.000009611505,0.000057973026,0.00015517893,2.153534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008170293,0.0021660817,0.94724035,0.0000030045003,0.0011631607,0.000049041155,0.0002506838,0.014144149,0.010566694,0.00009264245,0.000045790657,0.016108083],"study_design_scores_gemma":[0.002425354,0.0112974625,0.98015237,0.000011793284,0.00024688337,0.000005910861,0.00033178064,0.0014183105,0.0025968512,0.000022565366,0.0014108778,0.00007981912],"about_ca_topic_score_codex":0.000028331806,"about_ca_topic_score_gemma":0.0016826104,"teacher_disagreement_score":0.032912012,"about_ca_system_score_codex":0.00002272281,"about_ca_system_score_gemma":0.0004837052,"threshold_uncertainty_score":0.21917127},"labels":[],"label_agreement":null},{"id":"W2891929823","doi":"10.1200/jco.2017.35.15_suppl.10573","title":"Predictors of specialized pediatric palliative care involvement and impact on patterns of end-of-life care in children with cancer: A population-based study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Southlake Regional Health Center; Pediatric Oncology Group; Children's Hospital of Western Ontario; Children's Hospital of Eastern Ontario; Institute for Clinical Evaluative Sciences; Hospital for Sick Children","funders":"","keywords":"Medicine; Palliative care; Odds ratio; Confidence interval; Cancer; Population; Retrospective cohort study; Cancer registry; Emergency medicine; End-of-life care; Cohort; Pediatrics; Internal medicine; Nursing","score_opus":0.18972230577644741,"score_gpt":0.5260706253980901,"score_spread":0.3363483196216427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891929823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969497,0.0018930798,0.0000068861887,0.00016847206,0.00025610093,0.00050356076,0.00014977933,0.0000017614361,0.00007070996],"genre_scores_gemma":[0.9971788,0.0018594146,0.00026335655,0.00006721144,0.00059490197,0.0000052947084,0.000016016958,0.000012630287,0.0000023546704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968539,0.0003164827,0.0019849034,0.00017281633,0.0005275654,0.00014433506],"domain_scores_gemma":[0.9932541,0.0011099327,0.00437708,0.00025212087,0.0008067215,0.0002000121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069856393,0.00016604605,0.0019966026,0.00024866895,0.000026506894,0.000003130936,0.00018710057,0.00018356026,0.000046945665],"category_scores_gemma":[0.0020205325,0.00010500735,0.0002865357,0.000094661234,0.00013398343,0.0000573433,0.000041140254,0.00039897687,9.542008e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064501166,0.0010774832,0.9827913,0.00020692292,0.0006876872,0.000022407447,0.0035289717,0.00018805073,0.000004660598,0.0000031939974,0.000021790742,0.0050174207],"study_design_scores_gemma":[0.016771127,0.025448944,0.95308214,0.0008166304,0.00072003674,5.112693e-7,0.0029254402,0.000006913873,0.000103876126,0.000005196544,0.000044051943,0.00007513466],"about_ca_topic_score_codex":0.0037348385,"about_ca_topic_score_gemma":0.003965194,"teacher_disagreement_score":0.029709157,"about_ca_system_score_codex":0.00021631923,"about_ca_system_score_gemma":0.0019926217,"threshold_uncertainty_score":0.5645984},"labels":[],"label_agreement":null},{"id":"W2891943773","doi":"10.1200/jco.2017.35.15_suppl.5044","title":"Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Dementia; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Publication bias; Internal medicine; Systematic review; Oncology; Relative risk; Confidence interval; Cancer; MEDLINE; Disease","score_opus":0.4182014348188262,"score_gpt":0.568332147441062,"score_spread":0.15013071262223576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891943773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005512015,0.99376935,0.000002176027,0.0018830108,0.000072012495,0.0036420778,0.00003687978,0.0000014403212,0.000041838066],"genre_scores_gemma":[0.00048510378,0.9984349,0.000060621926,0.0004923426,0.00008858359,0.00035009618,0.0000046173122,0.000012491101,0.00007121648],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99314004,0.0020435597,0.0041534696,0.00023102418,0.00029350966,0.0001384135],"domain_scores_gemma":[0.9859845,0.0029476206,0.010293093,0.00032321655,0.00036139486,0.00009017502],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005985015,0.0002856742,0.015929595,0.00022507198,0.00005560486,0.00001167472,0.0001392274,0.00024633878,0.000035619065],"category_scores_gemma":[0.0018900989,0.000116167874,0.0026010028,0.00022324012,0.00022584811,0.000051854196,0.000027018606,0.00049896113,7.030469e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017516431,0.0008596145,0.0036315625,0.12063184,0.4840837,0.00007668966,0.00018747778,1.9358798e-7,5.596872e-9,0.0000018445288,0.00012172273,0.39023018],"study_design_scores_gemma":[0.002043604,0.0054418542,0.0022052068,0.01588889,0.8346039,0.00010997418,0.000021591093,7.5151723e-7,4.27707e-8,0.0000154535,0.13959332,0.000075385586],"about_ca_topic_score_codex":0.000064661726,"about_ca_topic_score_gemma":0.00018361922,"teacher_disagreement_score":0.3901548,"about_ca_system_score_codex":0.00013320139,"about_ca_system_score_gemma":0.0006946055,"threshold_uncertainty_score":0.99867994},"labels":[],"label_agreement":null},{"id":"W2891963848","doi":"10.1200/jco.2017.35.15_suppl.e18329","title":"Patients’ willingness to pay for blood-based <i>EGFR</i> <i>T790M</i> testing: Results from a Canadian validation study of circulating DNA <i>T790M</i> testing.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Regional Municipality of Durham; Health Sciences Centre; Mount Sinai Hospital; McGill University Health Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Concordance; T790M; Internal medicine; Willingness to pay; Circulating tumor DNA; Oncology; Lung cancer; Liquid biopsy; Cancer; Circulating tumor cell; Gefitinib; Epidermal growth factor receptor; Metastasis","score_opus":0.12285510482468687,"score_gpt":0.3962301796292797,"score_spread":0.27337507480459283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891963848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956449,0.000032888016,0.00039379435,0.0009161493,0.0014345045,0.00059311185,0.0003805438,0.0000036495946,0.0006004453],"genre_scores_gemma":[0.9864453,0.000011738748,0.010113634,0.0015020047,0.0017784229,0.000016191703,0.00008061897,0.000034994326,0.00001710308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963429,0.0001990292,0.0024042032,0.0004422427,0.0002640765,0.00034754656],"domain_scores_gemma":[0.99026847,0.0030257627,0.0036314214,0.000653075,0.0018845323,0.0005367362],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023588892,0.00021108643,0.0008701786,0.000075979384,0.00026705876,0.000065145774,0.00065914635,0.00036665503,0.000002092638],"category_scores_gemma":[0.056750186,0.00017829909,0.00025060287,0.000093503586,0.000095163574,0.000013419134,0.00013208699,0.0003182096,0.0000013430177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023830796,0.002973045,0.9099692,0.0000263762,0.00031310235,0.000058415542,0.00014591405,0.003909031,0.016843082,0.0000046072837,0.002748414,0.060625695],"study_design_scores_gemma":[0.033642508,0.04466249,0.8566591,0.00025226767,0.00093579554,0.000013267392,0.00016659369,0.0007518223,0.016924134,0.00029103237,0.045058485,0.0006425104],"about_ca_topic_score_codex":0.010687486,"about_ca_topic_score_gemma":0.018814893,"teacher_disagreement_score":0.059983186,"about_ca_system_score_codex":0.00007476617,"about_ca_system_score_gemma":0.0028247917,"threshold_uncertainty_score":0.9990892},"labels":[],"label_agreement":null},{"id":"W2891981628","doi":"10.1200/jco.2017.35.15_suppl.5000","title":"Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Prostatectomy; Oncology; Metastasis; Cancer; Retrospective cohort study; Cohort; Prostate; Prostate biopsy","score_opus":0.17988952275501133,"score_gpt":0.49409810977178814,"score_spread":0.3142085870167768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891981628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821306,0.0004526328,0.0071197147,0.0027029603,0.0009736042,0.0004256576,0.000011856136,0.000006479552,0.00009405428],"genre_scores_gemma":[0.8215416,0.005002303,0.17231132,0.00033128515,0.0007485464,0.000012003631,0.000005058595,0.000017778335,0.000030077901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995417,0.00042705893,0.0034810242,0.00031231533,0.00018280024,0.00017978749],"domain_scores_gemma":[0.986147,0.00265868,0.010299085,0.0002414864,0.00035195515,0.0003017825],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018877443,0.00014258045,0.0013495785,0.00009528251,0.00026508092,0.00003435003,0.0001854417,0.00032994902,0.0000047095955],"category_scores_gemma":[0.021113407,0.00010424863,0.00022269633,0.000030573698,0.000644471,0.000124434,0.00012064965,0.0012426883,6.9924096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009731446,0.00034070367,0.5632083,0.000048046564,0.000119963086,0.0000082884,0.00012154849,0.000020512425,0.0015016866,0.000052117983,0.000042566666,0.43356314],"study_design_scores_gemma":[0.010650565,0.0030775066,0.9641279,0.00016671684,0.0005447245,0.000072860195,0.00009788353,0.013025904,0.00003737852,0.0005150132,0.0075806202,0.00010290666],"about_ca_topic_score_codex":0.000048148475,"about_ca_topic_score_gemma":0.000025891746,"teacher_disagreement_score":0.43346024,"about_ca_system_score_codex":0.000080054655,"about_ca_system_score_gemma":0.0009772112,"threshold_uncertainty_score":0.9871322},"labels":[],"label_agreement":null},{"id":"W2891990387","doi":"10.1200/jco.2018.36.15_suppl.e18891","title":"The cost and cost-effectiveness of a pediatric cancer unit (PCU) in the context of universal health coverage (UHC): A report from the Childhood Cancer 2030 Network.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Activity-based costing; Unit cost; Context (archaeology); Per capita; Cost database; Cost effectiveness; Emergency medicine; Demography; Pediatrics; Environmental health; Population; Database","score_opus":0.13558156842080146,"score_gpt":0.48791260278695714,"score_spread":0.35233103436615565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891990387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436346,0.011083895,0.000116758514,0.041369658,0.0020306015,0.0012944888,0.0000705431,0.0000043923305,0.0003950124],"genre_scores_gemma":[0.96942335,0.01822543,0.00005116261,0.008162259,0.0040646736,0.000023186914,0.0000044693356,0.000018343224,0.000027093047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914837,0.0043417676,0.002900038,0.0002591587,0.00065573835,0.00035960053],"domain_scores_gemma":[0.97165173,0.0225368,0.0044213263,0.000460537,0.00069739186,0.00023223144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018992204,0.00018647316,0.001760912,0.000060544604,0.00015698139,0.000012226871,0.00046828677,0.00025310312,0.00005999396],"category_scores_gemma":[0.0043104137,0.000093963055,0.00032669146,0.00044428697,0.0009302901,0.00008760431,0.00011705793,0.0014120471,9.746923e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008191279,0.001038122,0.8905662,0.000080646416,0.0007914873,0.00015975926,0.004156764,0.000058218837,0.0000046654204,0.00024239298,0.016267093,0.078443415],"study_design_scores_gemma":[0.008860624,0.004224656,0.91142774,0.00045659594,0.00041843022,0.00014207285,0.0017963571,0.000027262628,0.0000071644013,0.000384133,0.07217092,0.00008404038],"about_ca_topic_score_codex":0.014538195,"about_ca_topic_score_gemma":0.034298994,"teacher_disagreement_score":0.07835937,"about_ca_system_score_codex":0.00025510654,"about_ca_system_score_gemma":0.0066616186,"threshold_uncertainty_score":0.9989697},"labels":[],"label_agreement":null},{"id":"W2891993411","doi":"10.1200/jco.2016.34.15_suppl.e18054","title":"Comparing cervical cancer stage at diagnosis in immigrant women and long-term residents.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Juravinski Cancer Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Immigration; Cervical cancer; Cohort; Stage (stratigraphy); Socioeconomic status; Cancer; Demography; Retrospective cohort study; Odds ratio; Cohort study; Gynecology; Internal medicine; Population; Environmental health","score_opus":0.1983455501720531,"score_gpt":0.516193621608926,"score_spread":0.3178480714368729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891993411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98234415,0.0018338123,0.000010808319,0.014079542,0.0003630284,0.0001478812,0.000004417379,0.0000047752424,0.0012115972],"genre_scores_gemma":[0.9842767,0.012552303,0.000045777684,0.0013369913,0.00077414874,0.000023662114,3.9248042e-7,0.000013893947,0.00097614125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689275,0.00033001555,0.0016634354,0.00022485091,0.0004779293,0.0004110095],"domain_scores_gemma":[0.9955877,0.002785326,0.0004824281,0.00015672352,0.00024958458,0.0007382133],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028233067,0.0001150005,0.0013810085,0.00015941937,0.00003304633,0.000009499006,0.0001657059,0.0002691942,0.005596034],"category_scores_gemma":[0.0018314063,0.000064846536,0.00019625954,0.00012619274,0.00029440122,0.00010121204,0.0002151126,0.0007651611,0.00002144221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006607615,0.00048657847,0.7955684,0.000079548845,0.00009874819,0.00082714984,0.00013705977,5.69489e-7,0.000072340794,0.000015235125,0.00063474936,0.19547199],"study_design_scores_gemma":[0.012464052,0.003431362,0.97609663,0.00015994343,0.000046250825,0.00007282399,0.00003798402,0.000008670068,0.00007500182,0.00012535026,0.0074036983,0.000078256526],"about_ca_topic_score_codex":0.00031242956,"about_ca_topic_score_gemma":0.0057736887,"teacher_disagreement_score":0.19539373,"about_ca_system_score_codex":0.00092150434,"about_ca_system_score_gemma":0.0007191978,"threshold_uncertainty_score":0.995313},"labels":[],"label_agreement":null},{"id":"W2891994975","doi":"10.1200/jco.2018.36.15_suppl.3069","title":"Can body composition (BC) be predictive for outcomes and severe toxicities (ST) in metastatic solid tumors patients (pts) treated with checkpoint inhibitor (CPI)? An analysis of 145 patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Discontinuation; Multivariate analysis; Internal medicine; Chemotherapy; Surgery; Oncology; Gastroenterology; Nuclear medicine","score_opus":0.05574704513382154,"score_gpt":0.41707895198082,"score_spread":0.36133190684699845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891994975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791235,0.000023359073,0.000024815008,0.001025475,0.00013693677,0.0005401197,0.00025543832,0.0000043541627,0.00007713188],"genre_scores_gemma":[0.9982139,0.00007217908,0.0008231359,0.0005874418,0.000120115634,0.000027660679,0.0001293534,0.000014048409,0.000012165035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720144,0.00022682695,0.0018428835,0.00022120855,0.00032189334,0.00018575833],"domain_scores_gemma":[0.99619853,0.0009349841,0.0015718054,0.00013290305,0.00091010524,0.0002516714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006335219,0.00016941286,0.0020149304,0.0003489626,0.000038497572,0.000007648683,0.00005758855,0.000117507436,0.000037208873],"category_scores_gemma":[0.00042826348,0.000106040294,0.00032813358,0.00023005281,0.00029572638,0.00013796441,0.000023193297,0.0002062442,1.9007176e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008083512,0.0070945807,0.9770651,0.000035300283,0.0031399683,0.000030961815,0.0005329055,0.000043372504,0.000012394187,0.000013193149,0.00013371969,0.0038150232],"study_design_scores_gemma":[0.018849574,0.07547065,0.89880747,0.00015920064,0.0050837523,0.000006603826,0.00037731533,0.0005782485,0.0004746867,0.00003798085,0.000068056215,0.00008647837],"about_ca_topic_score_codex":0.00040063594,"about_ca_topic_score_gemma":0.002431648,"teacher_disagreement_score":0.07825762,"about_ca_system_score_codex":0.00035689873,"about_ca_system_score_gemma":0.00038851175,"threshold_uncertainty_score":0.43241978},"labels":[],"label_agreement":null},{"id":"W2891996081","doi":"10.1200/jco.2017.35.15_suppl.6032","title":"A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Cancer; Adverse effect; Head and neck cancer; Nausea; Response Evaluation Criteria in Solid Tumors; Internal medicine; Tolerability; Salivary gland cancer; Radiation therapy; Phases of clinical research; Oncology; Gastroenterology; Surgery; Toxicity","score_opus":0.10204527226987137,"score_gpt":0.5201254061705319,"score_spread":0.41808013390066057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891996081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953947,0.0016065678,0.0000027198369,0.001625368,0.0008121874,0.000402765,0.00001772901,0.0000013844767,0.0001365675],"genre_scores_gemma":[0.9972734,0.0017011594,0.000100886115,0.00010008907,0.0006224546,0.00004801581,0.0000013194084,0.000020682412,0.00013197896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660933,0.00045866804,0.0019256781,0.00036607412,0.00031199312,0.00032822668],"domain_scores_gemma":[0.99704975,0.00027523978,0.0015961487,0.0004405804,0.00036424433,0.0002740343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017164774,0.0001751169,0.0011524728,0.00014872299,0.000090934685,0.000017807259,0.0004375933,0.00037922815,0.000018266417],"category_scores_gemma":[0.002763058,0.00014893622,0.00016540506,0.00009617646,0.0003426596,0.000025942392,0.0002461181,0.00072804006,8.849696e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03541356,0.04385269,0.5355496,0.0002400434,0.000384391,0.003412773,0.0009979622,0.00061339576,0.11682791,0.0000070073843,0.0022639106,0.26043674],"study_design_scores_gemma":[0.25544524,0.12575181,0.470278,0.0014982178,0.00020792685,0.00018184616,0.0019621812,0.00077165465,0.06260068,0.000051654926,0.0803821,0.00086869963],"about_ca_topic_score_codex":0.0014799724,"about_ca_topic_score_gemma":0.05797418,"teacher_disagreement_score":0.25956804,"about_ca_system_score_codex":0.00014973404,"about_ca_system_score_gemma":0.0014509165,"threshold_uncertainty_score":0.95921534},"labels":[],"label_agreement":null},{"id":"W2892010000","doi":"10.1200/jco.2018.36.15_suppl.e18607","title":"Clinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Medicaid; Lung cancer; Percentile; Health insurance; Proportional hazards model; Internal medicine; Cancer; Demography; Health care; Family medicine","score_opus":0.06857732494023797,"score_gpt":0.42968676139533396,"score_spread":0.36110943645509597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892010000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487984,0.0003622768,0.00006369809,0.0008592308,0.0027769988,0.00024216491,0.00035832435,0.0000013162655,0.0004561678],"genre_scores_gemma":[0.996691,0.0011149566,0.00058694836,0.000988323,0.00058238197,0.0000029364373,0.0000012588902,0.000011863466,0.000020370806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670506,0.00007039214,0.002762449,0.00019155149,0.000054427666,0.00021612104],"domain_scores_gemma":[0.9955015,0.000585019,0.0029975073,0.00014027831,0.0005410066,0.00023469134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016743091,0.00010160635,0.0011509046,0.00009669695,0.000057257384,0.000015247796,0.00019061539,0.0001620363,0.000049649345],"category_scores_gemma":[0.002633582,0.00008392348,0.00015366603,0.00010835434,0.00018155976,0.00020335977,0.00014780715,0.0002471291,0.0000023420691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049410993,0.0000845247,0.8713794,0.000028155204,0.0000657335,3.474138e-7,0.0005982638,0.0000015303152,0.0000091389265,0.0003933997,0.00017007503,0.12677534],"study_design_scores_gemma":[0.0019224485,0.0030963414,0.9800884,0.000052486674,0.00002796818,6.722307e-7,0.00036954184,0.000009975581,0.00003013554,0.00013055622,0.01418281,0.0000886786],"about_ca_topic_score_codex":0.00042567708,"about_ca_topic_score_gemma":0.0006746278,"teacher_disagreement_score":0.12668666,"about_ca_system_score_codex":0.00011869712,"about_ca_system_score_gemma":0.00044063228,"threshold_uncertainty_score":0.34223002},"labels":[],"label_agreement":null},{"id":"W2892012428","doi":"10.1200/jco.2016.34.15_suppl.3546","title":"IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; McGill University Health Centre; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Hazard ratio; Gastroenterology; Colorectal cancer; Clinical endpoint; Progression-free survival; Randomized controlled trial; KRAS; Chemotherapy; Surgery; Oncology; Confidence interval; Cancer","score_opus":0.073541251622984,"score_gpt":0.4775817518546719,"score_spread":0.4040405002316879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892012428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770653,0.00021442228,0.00023862795,0.00032624052,0.00025690635,0.0009792564,0.00004663238,0.0000020245943,0.00022938315],"genre_scores_gemma":[0.99728507,0.0010631862,0.0009780827,0.00012052932,0.00025913425,0.00009666575,0.000007297495,0.000023337436,0.00016668749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99620396,0.0010157067,0.0017031701,0.00028681965,0.00046700094,0.00032336076],"domain_scores_gemma":[0.996392,0.00087154546,0.0017765242,0.0001926992,0.0004911587,0.00027607108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019945903,0.00020264769,0.0018633318,0.0001277347,0.000025429394,0.000007665914,0.00023674832,0.00020158457,0.00010622078],"category_scores_gemma":[0.0023408325,0.00008897912,0.00032019554,0.0001483824,0.0005216763,0.000019485136,0.00006101495,0.00029138924,0.0000024404374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9011503,0.004246862,0.01998707,0.000013052325,0.0013964744,0.000148289,0.000034915047,0.000004389964,0.00078613363,0.000004340048,0.00020869495,0.07201949],"study_design_scores_gemma":[0.895893,0.09471848,0.0022842137,0.00012375443,0.00036566422,0.000036480676,0.000021759797,0.0000060351367,0.0036911285,0.000044354605,0.002681735,0.00013342024],"about_ca_topic_score_codex":0.00022493306,"about_ca_topic_score_gemma":0.0034091342,"teacher_disagreement_score":0.09047162,"about_ca_system_score_codex":0.00013709707,"about_ca_system_score_gemma":0.0031708926,"threshold_uncertainty_score":0.56250274},"labels":[],"label_agreement":null},{"id":"W2892013444","doi":"10.1200/jco.2017.35.15_suppl.e20579","title":"Does blood sugar impact on metastatic non-small cell lung cancer (NSCLC) outcome?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Metastasis; Comorbidity; Lung cancer; Oncology; Population; Cancer","score_opus":0.1286326449183823,"score_gpt":0.5229970537044597,"score_spread":0.39436440878607737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892013444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97652406,0.000805262,0.00001528092,0.015329671,0.0029107116,0.000299925,0.000019045523,0.0000052573496,0.0040907767],"genre_scores_gemma":[0.99062634,0.0033299932,0.0010322555,0.0022475047,0.0017923706,0.000016109087,0.0000011461536,0.000024086854,0.00093021966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717027,0.00015439096,0.0018302717,0.00022591361,0.00032169675,0.00029745465],"domain_scores_gemma":[0.9942551,0.0017479863,0.0026828106,0.00047920196,0.00028410178,0.0005507953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001637419,0.00020944538,0.001938867,0.00009223079,0.00011082111,0.000035541674,0.00027013404,0.0001971571,0.0006064661],"category_scores_gemma":[0.0012094267,0.00009232644,0.0011375119,0.000033071952,0.00014049475,0.00008417287,0.00005952963,0.0008261517,0.000025152493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020106535,0.004622508,0.9475642,0.00006716439,0.001741581,0.0016424838,0.000063585176,0.000032528438,0.00003711467,0.000011833122,0.0056853583,0.03652103],"study_design_scores_gemma":[0.017594658,0.01348374,0.95594084,0.0002828887,0.004017376,0.00007991341,0.00003116209,0.000043595217,0.0005228918,0.000059314232,0.007828665,0.00011494033],"about_ca_topic_score_codex":0.00047099259,"about_ca_topic_score_gemma":0.00041489102,"teacher_disagreement_score":0.03640609,"about_ca_system_score_codex":0.00029463085,"about_ca_system_score_gemma":0.001760061,"threshold_uncertainty_score":0.6640378},"labels":[],"label_agreement":null},{"id":"W2892039209","doi":"10.1200/jco.2016.34.15_suppl.e17551","title":"A Retrospective Review of the Multidisciplinary Management of Medullary Thyroid Cancer.","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Medullary thyroid cancer; Thyroid cancer; Radiation therapy; Stage (stratigraphy); Retrospective cohort study; Cancer; Sorafenib; Population; Surgery; Internal medicine","score_opus":0.15203710360763825,"score_gpt":0.5357997698883847,"score_spread":0.3837626662807465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892039209","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006998599,0.9888532,0.00000290438,0.0047058673,0.0019601767,0.0012804596,0.00007755151,0.0000032542246,0.0030466125],"genre_scores_gemma":[0.0001543306,0.9975383,0.00051636726,0.00039206212,0.00084954087,0.00008061336,0.0000028209183,0.000035883324,0.00043003858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923131,0.0008580518,0.005579207,0.0003048424,0.00072193344,0.00022289225],"domain_scores_gemma":[0.98625433,0.0013266485,0.01088002,0.00065951596,0.000649452,0.00023001667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031612022,0.0003333264,0.008256656,0.000103665625,0.00002917458,0.0000015012921,0.00051791384,0.00048195582,0.00027766652],"category_scores_gemma":[0.00076153013,0.00014109585,0.0040171337,0.00031808342,0.0003816518,0.00003932988,0.000309231,0.0010163974,0.0000085681795],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025874493,0.0015787055,0.0011041426,0.07185531,0.004562472,0.00029904343,0.000010314225,6.318743e-8,2.0231305e-7,0.00018877692,0.011382654,0.9087596],"study_design_scores_gemma":[0.0022206048,0.0040872768,0.0077713504,0.35917056,0.010063129,0.0001701971,0.00000888944,5.5162833e-8,0.0000015537004,0.00007968309,0.6163422,0.00008451131],"about_ca_topic_score_codex":0.000009673171,"about_ca_topic_score_gemma":0.000006732326,"teacher_disagreement_score":0.9086751,"about_ca_system_score_codex":0.0008665919,"about_ca_system_score_gemma":0.0035098316,"threshold_uncertainty_score":0.62262905},"labels":[],"label_agreement":null},{"id":"W2892092015","doi":"10.1200/jco.2017.35.15_suppl.6514","title":"Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Interquartile range; Adverse effect; Internal medicine; Clinical endpoint","score_opus":0.974756710608536,"score_gpt":0.7922291530621699,"score_spread":0.18252755754636607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892092015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721488,0.00030978594,0.0006220337,0.016513655,0.0019990664,0.0004892448,0.000005297257,0.0000010279317,0.007911092],"genre_scores_gemma":[0.98856145,0.00014361997,0.009388864,0.00016642665,0.00083537254,0.0000042502843,9.3721894e-7,0.000005008504,0.00089408807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.7302319,0.034833834,0.22819613,0.0010882651,0.0052847248,0.00036516105],"domain_scores_gemma":[0.28148115,0.13918269,0.56729996,0.005756229,0.0055673313,0.00071266375],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.65187675,0.0001567966,0.013467997,0.0003726511,0.00012128634,0.0003645953,0.0020634658,0.00041869777,0.00060983846],"category_scores_gemma":[0.92143804,0.00007545662,0.002634113,0.0003257788,0.000376393,0.00040605638,0.00023208348,0.00084501447,0.000068382884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026538914,0.0037580377,0.5016568,0.000022997443,0.00038694724,0.000051871415,0.00027429257,0.0000127093335,0.000044744313,0.00063401245,0.07676104,0.38985765],"study_design_scores_gemma":[0.1355638,0.009078065,0.5086512,0.0001375152,0.00071494584,0.000060696795,0.0008035758,0.0027219625,0.000026960886,0.010851062,0.331202,0.00018821182],"about_ca_topic_score_codex":0.000016108157,"about_ca_topic_score_gemma":0.00009313389,"teacher_disagreement_score":0.44875073,"about_ca_system_score_codex":0.000028575252,"about_ca_system_score_gemma":0.0009976004,"threshold_uncertainty_score":0.92064536},"labels":[],"label_agreement":null},{"id":"W2892097654","doi":"10.1200/jco.2017.35.15_suppl.e18168","title":"The validity of algorithms using health administrative data in identifying cancer-related events in adolescents and young adults: A population-based study using the IMPACT cohort.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; St. Michael's Hospital; Canadian Partnership Against Cancer; Hospital for Sick Children; Pediatric Oncology Group","funders":"","keywords":"Medicine; Cancer; Cohort; Population; Record linkage; Diagnosis code; Algorithm; Cancer registry; Oncology; Internal medicine; Environmental health; Computer science","score_opus":0.4041400078385652,"score_gpt":0.5956005280646292,"score_spread":0.19146052022606397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892097654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995799,0.00030619072,0.00006310186,0.0018197058,0.0010239289,0.0009601829,0.000021391586,0.0000025709535,0.000003897371],"genre_scores_gemma":[0.99887717,0.00021855671,0.0006005384,0.0000864963,0.00019502513,0.0000023383204,0.0000039628767,0.000013162984,0.0000027336994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944517,0.0016465536,0.0028681662,0.00025799303,0.00050639565,0.00026918197],"domain_scores_gemma":[0.9928735,0.0012898186,0.0046933778,0.0006750096,0.00028071008,0.00018760152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010337308,0.00014920076,0.0011984311,0.00010452736,0.00024231622,0.000024867988,0.00056410243,0.00017856121,0.000004252751],"category_scores_gemma":[0.0076155774,0.000084528176,0.00013507977,0.00013636675,0.00017580412,0.00026924294,0.00018289294,0.0011779971,1.3169455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012823683,0.0016181238,0.9856378,0.000045337987,0.00020187766,0.000093953226,0.00059523963,0.00016280955,0.0000049907608,3.0195412e-7,0.000008780871,0.010348415],"study_design_scores_gemma":[0.010181223,0.0025572847,0.94579595,0.001970248,0.00018144897,0.00007187784,0.000988273,0.03814097,0.0000017707258,0.0000450501,0.000002938045,0.00006295093],"about_ca_topic_score_codex":0.01987804,"about_ca_topic_score_gemma":0.023258891,"teacher_disagreement_score":0.039841834,"about_ca_system_score_codex":0.0006711922,"about_ca_system_score_gemma":0.0030700236,"threshold_uncertainty_score":0.9945641},"labels":[],"label_agreement":null},{"id":"W2892110441","doi":"10.1200/jco.2016.34.15_suppl.8010","title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Pembrolizumab; Multiple myeloma; Internal medicine; Tolerability; Dexamethasone; Population; Refractory (planetary science); Adverse effect; Oncology; Toxicity; Cancer; Immunotherapy","score_opus":0.10145107000851554,"score_gpt":0.43749800026940094,"score_spread":0.3360469302608854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892110441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289834,0.0004450929,0.0017788522,0.0041170944,0.00009307951,0.00054165145,0.000013800298,0.000006378377,0.0001056983],"genre_scores_gemma":[0.9913832,0.0012829712,0.0066871056,0.00021459367,0.00017297134,0.000013466822,0.000008460369,0.000016630473,0.0002205861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970015,0.00051532325,0.001513293,0.00029678934,0.0003549021,0.00031813871],"domain_scores_gemma":[0.9867181,0.011282279,0.0009019094,0.00017878579,0.00040342196,0.0005154749],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028675585,0.0001695918,0.0015580184,0.00041690446,0.000057079462,0.00001117127,0.00008841258,0.00028401968,0.000040746043],"category_scores_gemma":[0.00908262,0.00009176492,0.00024073831,0.0002377326,0.00035541318,0.00018355771,0.000045364042,0.0004969942,0.0000026586292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11307969,0.0026040159,0.47710124,0.00004284334,0.0013748511,0.0005514331,0.00005677021,0.0000073753577,0.0005459137,0.00005133638,0.000102322934,0.40448222],"study_design_scores_gemma":[0.14986837,0.018431198,0.8265627,0.00018185523,0.0007475051,0.00019617255,0.000030171082,0.00059036503,0.000080908336,0.00012436564,0.0030969284,0.000089466776],"about_ca_topic_score_codex":0.000030747768,"about_ca_topic_score_gemma":0.00031993818,"teacher_disagreement_score":0.40439275,"about_ca_system_score_codex":0.00021797136,"about_ca_system_score_gemma":0.0007910024,"threshold_uncertainty_score":0.9992643},"labels":[],"label_agreement":null},{"id":"W2892113537","doi":"10.1200/jco.2017.35.15_suppl.e18219","title":"Utility of PET/CT in primary identification and management of cancers of unknown primary.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Alberta","funders":"","keywords":"Medicine; Concordance; Lymph node; PET-CT; Radiology; Nuclear medicine; Retrospective cohort study; Cancer; Positron emission tomography; Internal medicine","score_opus":0.12879361867085246,"score_gpt":0.48496028727329393,"score_spread":0.3561666686024415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892113537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891789,0.0010245498,0.000009978916,0.0022210027,0.00038121437,0.0002170928,0.0000060495026,7.9466656e-7,0.0069604334],"genre_scores_gemma":[0.9864996,0.012201187,0.0010192904,0.00009931392,0.00006164834,0.0000036320826,0.0000017011682,0.000004280348,0.00010936268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749994,0.00009959715,0.001950574,0.00012414392,0.00024125114,0.000084477346],"domain_scores_gemma":[0.99590427,0.00041894993,0.0030774483,0.00029391356,0.00021584891,0.000089593974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019375255,0.00006741476,0.0011394891,0.00007366165,0.000016114745,0.00000261317,0.00012561337,0.000032084077,0.000040455496],"category_scores_gemma":[0.00031113307,0.000050357867,0.0002083605,0.00004032317,0.0003428194,0.00007196335,0.00006859413,0.00018833423,3.5401075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021214285,0.002086992,0.7532222,0.0006621724,0.00045215426,0.00039419436,0.000030922845,0.000003549836,0.00014305177,0.00018960574,0.0006691431,0.24002454],"study_design_scores_gemma":[0.0063093607,0.0020650898,0.98577523,0.00044945962,0.00043279494,0.000060936633,0.000037377697,0.0000148895815,0.0005732073,0.0001630566,0.0040884567,0.000030143463],"about_ca_topic_score_codex":0.00026497574,"about_ca_topic_score_gemma":0.00024731597,"teacher_disagreement_score":0.23999439,"about_ca_system_score_codex":0.00017735355,"about_ca_system_score_gemma":0.00070612703,"threshold_uncertainty_score":0.20535341},"labels":[],"label_agreement":null},{"id":"W2892126810","doi":"10.1200/jco.2018.36.15_suppl.7042","title":"Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Azacitidine; Internal medicine; Gastroenterology; Neutropenia; Febrile neutropenia; Myeloid leukemia; Toxicity","score_opus":0.04641121958465396,"score_gpt":0.38688004272316784,"score_spread":0.3404688231385139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892126810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926341,0.000074946496,0.00005376474,0.004534093,0.00072180486,0.0006563539,0.000013502392,0.0000164418,0.0012949788],"genre_scores_gemma":[0.98966295,0.00041353935,0.0051396284,0.0024982335,0.0019236173,0.000026429481,0.0000123452,0.00004867848,0.00027457497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951875,0.00039232423,0.002630364,0.00044142336,0.00085142674,0.000496964],"domain_scores_gemma":[0.9942947,0.0016082275,0.0018650845,0.00033039786,0.0012377539,0.0006638475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013942977,0.00037253712,0.0023702325,0.0002798511,0.000087090666,0.00002497916,0.00018941358,0.00044680512,0.0004295258],"category_scores_gemma":[0.0013232732,0.00018728396,0.00027199084,0.00039629437,0.0005620534,0.00026857766,0.00007039558,0.0011677099,0.00005796388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053642206,0.004144709,0.9039304,0.000026451455,0.0014481237,0.006449404,0.0002501617,0.00000621447,0.000118844575,0.00007155256,0.0040417304,0.0258702],"study_design_scores_gemma":[0.04658999,0.12649055,0.8020273,0.00074210967,0.0009984017,0.0011698938,0.000105995576,0.000017271192,0.004071618,0.0000793419,0.017436245,0.00027130745],"about_ca_topic_score_codex":0.00005439972,"about_ca_topic_score_gemma":0.0011118492,"teacher_disagreement_score":0.122345835,"about_ca_system_score_codex":0.00077915675,"about_ca_system_score_gemma":0.004163176,"threshold_uncertainty_score":0.7637219},"labels":[],"label_agreement":null},{"id":"W2892130770","doi":"10.1200/jco.2018.36.15_suppl.e18900","title":"A population-based comparison of cancer and non-cancer related healthcare costs.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Health care; Population; Cancer; Context (archaeology); Total cost; Incidence (geometry); Disease; Indirect costs; Environmental health; Emergency medicine; Internal medicine; Accounting; Business","score_opus":0.629545018262372,"score_gpt":0.636246734717579,"score_spread":0.006701716455207007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892130770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90381086,0.0049423906,0.0002299045,0.08737584,0.0026206577,0.00025632314,0.000060257153,0.000007550594,0.0006961877],"genre_scores_gemma":[0.9849933,0.0006783198,0.0033901336,0.009790606,0.0010597182,0.000011745889,0.0000033237452,0.000016587563,0.000056256664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98718345,0.0005827012,0.011638206,0.0002558675,0.000113203394,0.00022657642],"domain_scores_gemma":[0.9808134,0.003909896,0.014329139,0.00020359267,0.0004393798,0.00030459234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02076526,0.00011896839,0.0026808924,0.0002422271,0.000088799796,0.000011811704,0.0001991364,0.00043237177,0.00038483096],"category_scores_gemma":[0.0063819205,0.00012265342,0.0002223693,0.00016288125,0.00017895819,0.00018689041,0.00002857194,0.0005080126,0.00005976441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018196927,0.00030511306,0.9809184,0.00012265469,0.00015296554,9.331705e-7,0.00046280707,0.00008655924,7.6927813e-7,0.0029501363,0.0061050816,0.0087126065],"study_design_scores_gemma":[0.0031014727,0.0022327555,0.949065,0.00021534713,0.000038107253,0.0000025245952,0.00022946707,0.010576675,0.000004193516,0.002763169,0.031638123,0.00013314922],"about_ca_topic_score_codex":0.004512829,"about_ca_topic_score_gemma":0.0031941673,"teacher_disagreement_score":0.08118242,"about_ca_system_score_codex":0.000679676,"about_ca_system_score_gemma":0.001364142,"threshold_uncertainty_score":0.7640216},"labels":[],"label_agreement":null},{"id":"W2892143167","doi":"10.1200/jco.2016.34.15_suppl.e20534","title":"Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Gemcitabine; Lung cancer; Chemotherapy; Carboplatin; Proportional hazards model; Relative risk; Cisplatin; Confidence interval","score_opus":0.09988383138418304,"score_gpt":0.494027381386435,"score_spread":0.39414355000225193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892143167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873347,0.0018361527,0.004800672,0.0042747343,0.0005868946,0.0004962371,0.0002832248,0.0000031592851,0.00038418607],"genre_scores_gemma":[0.9885434,0.00418139,0.0053237025,0.0007906866,0.00067182473,0.0000151563945,0.0000066420084,0.000018795132,0.00044839608],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99651235,0.00023769196,0.0026919085,0.000187481,0.00020564791,0.00016491144],"domain_scores_gemma":[0.9906381,0.00487678,0.0035414596,0.00019097766,0.00055010995,0.00020259383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021696645,0.00013421466,0.003585473,0.00020627723,0.000024801335,0.0000039323963,0.00010883639,0.00025937418,0.00036210465],"category_scores_gemma":[0.0011638062,0.000073884294,0.0009734608,0.00015830806,0.00012727057,0.00005986872,0.000017644954,0.0001605989,3.9445388e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018738696,0.0070712366,0.2845664,0.00027331384,0.07181194,0.0001109329,0.0023511143,0.000100747166,0.0339964,0.000110967914,0.0039282944,0.57693994],"study_design_scores_gemma":[0.06503318,0.010489352,0.850317,0.00040873737,0.05733746,0.0000061014143,0.00024451906,0.00042882859,0.003844131,0.00045211124,0.01128084,0.0001577296],"about_ca_topic_score_codex":0.00030748927,"about_ca_topic_score_gemma":0.00015703608,"teacher_disagreement_score":0.5767822,"about_ca_system_score_codex":0.00014074828,"about_ca_system_score_gemma":0.0017494981,"threshold_uncertainty_score":0.3964792},"labels":[],"label_agreement":null},{"id":"W2892144284","doi":"10.1200/jco.2016.34.15_suppl.e21054","title":"Second-line drug regimens in metastatic melanoma patients based on BRAF mutation status: A Canadian real-world retrospective study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Metastatic melanoma; Oncology; Melanoma; Internal medicine; Retrospective cohort study; Targeted therapy; Metastasis; Mutation; Immunotherapy; Cancer; Cancer research; Gene","score_opus":0.042917849054351455,"score_gpt":0.374787704850302,"score_spread":0.3318698557959505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892144284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929556,0.000022443846,0.000052821462,0.0009640118,0.0007592545,0.00031270814,0.00005702253,0.0000028661718,0.004873259],"genre_scores_gemma":[0.99720263,0.000048939764,0.00051634747,0.0011026196,0.00033916897,0.000009530134,0.000017548522,0.000020039797,0.0007431935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667764,0.0009122342,0.0014882397,0.00031640832,0.00025488247,0.00035060433],"domain_scores_gemma":[0.9973829,0.0004512939,0.0010664404,0.00026388717,0.00038308927,0.0004524221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022310424,0.0001670639,0.00072656636,0.00029275945,0.000039692204,0.000008701528,0.00019551806,0.00016501403,0.00015998993],"category_scores_gemma":[0.0023790332,0.000111736816,0.00020674178,0.00014662772,0.00008460228,0.000012263623,0.00003140434,0.0003413225,0.000015622625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026291653,0.002531265,0.9688539,0.000009125864,0.00022335185,0.0006789541,0.00015129389,0.000039622457,0.001132022,0.000106759595,0.0047447383,0.018899824],"study_design_scores_gemma":[0.010488318,0.021782303,0.9485196,0.000044738714,0.00006541816,0.000008058931,0.00010868128,0.000027806733,0.0006464988,0.00023463275,0.017911445,0.00016249563],"about_ca_topic_score_codex":0.0023490118,"about_ca_topic_score_gemma":0.3174242,"teacher_disagreement_score":0.3150752,"about_ca_system_score_codex":0.0003268171,"about_ca_system_score_gemma":0.002163551,"threshold_uncertainty_score":0.695031},"labels":[],"label_agreement":null},{"id":"W2892151154","doi":"10.1200/jco.2018.36.15_suppl.e20561","title":"Impact of different risk factors on survival of malignant pleural mesothelioma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Asbestos; Mesothelioma; Internal medicine; Risk factor; Chemotherapy; Body mass index; Proportional hazards model; Cancer; Surgery; Gastroenterology; Oncology; Pathology","score_opus":0.11659260849655531,"score_gpt":0.4723705712630698,"score_spread":0.3557779627665145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892151154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981876,0.000047771864,0.00001272183,0.00020628714,0.00060145033,0.000074939744,0.00005945218,0.0000023867058,0.00080740335],"genre_scores_gemma":[0.9990064,0.00021044098,0.000106261694,0.000076345576,0.00051217765,3.1788673e-7,0.000004680925,0.000009392714,0.00007397438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975564,0.00028345126,0.0015094265,0.00010408667,0.00041507947,0.00013155652],"domain_scores_gemma":[0.99626726,0.0014675623,0.0016950188,0.00013798592,0.0001443307,0.00028787018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064577494,0.00011560361,0.0010990283,0.00009778994,0.000018649236,0.0000012444192,0.00010627431,0.00014939015,0.00066500885],"category_scores_gemma":[0.001363641,0.000059615628,0.00085315044,0.00005951892,0.0003922384,0.000036574304,0.00003379057,0.00028326883,0.000011722146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008823374,0.003389888,0.9789699,0.000012914331,0.00057031785,0.000026578593,0.000038921247,0.000014575212,0.0012030653,0.000044171,0.0005744828,0.006331858],"study_design_scores_gemma":[0.002867019,0.04499252,0.9501227,0.00006721323,0.00036523252,0.000015905636,0.00004308655,0.000033311844,0.0009496391,0.0002696799,0.00022497465,0.000048675887],"about_ca_topic_score_codex":0.000056894354,"about_ca_topic_score_gemma":0.000009109852,"teacher_disagreement_score":0.041602634,"about_ca_system_score_codex":0.00010048999,"about_ca_system_score_gemma":0.00028745632,"threshold_uncertainty_score":0.728138},"labels":[],"label_agreement":null},{"id":"W2892156748","doi":"10.1200/jco.2017.35.15_suppl.e18158","title":"Hyperglycemia and survival in solid tumors: A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Meta-analysis; Confidence interval; Internal medicine; Subgroup analysis; Diabetes mellitus; Random effects model; Oncology; Adverse effect; Endocrinology","score_opus":0.28690273092007024,"score_gpt":0.5266745490457977,"score_spread":0.23977181812572745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892156748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024154868,0.9980846,0.00001231752,0.000262428,0.00066427415,0.0006399646,0.000027986267,0.0000013799026,0.0002828818],"genre_scores_gemma":[0.000058168098,0.99702626,0.00020351839,0.00071397773,0.0012473756,0.00004543035,0.000014059222,0.00002703586,0.000664148],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99187887,0.0021511058,0.005011869,0.00046370525,0.00023660366,0.00025785537],"domain_scores_gemma":[0.9910988,0.0007102884,0.006958473,0.0006561773,0.00025780246,0.00031844506],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008840531,0.00040250295,0.021905148,0.00020229208,0.000043582764,0.000034387504,0.0005250469,0.0008843051,0.000026369595],"category_scores_gemma":[0.006721108,0.00024401571,0.0041472698,0.00013480346,0.00025405764,0.000009563963,0.00023825628,0.0009309464,0.0000029150324],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016412417,0.00047208465,0.000028509648,0.5973243,0.27209127,0.0001943368,0.0000158409,0.0000010739244,0.000002430336,0.000048718954,0.0029815768,0.12667572],"study_design_scores_gemma":[0.00039836072,0.00045662597,0.000019100022,0.004990432,0.43277478,0.00032574456,0.0000034335815,2.6910897e-7,9.858821e-8,0.00001140631,0.56086403,0.0001557529],"about_ca_topic_score_codex":0.000014241814,"about_ca_topic_score_gemma":0.00017698215,"teacher_disagreement_score":0.59233385,"about_ca_system_score_codex":0.000026282116,"about_ca_system_score_gemma":0.0014558859,"threshold_uncertainty_score":0.9950672},"labels":[],"label_agreement":null},{"id":"W2892170684","doi":"10.1200/jco.2017.35.15_suppl.e16503","title":"Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Statin; Oncology; Internal medicine; Cohort; Abiraterone; Cancer; Androgen receptor; Urology; Androgen deprivation therapy","score_opus":0.0748665733548037,"score_gpt":0.39710103159926446,"score_spread":0.32223445824446073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892170684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979313,0.00023670262,0.000027684047,0.00033878008,0.001117113,0.00024778795,0.000060317037,0.0000018130019,0.00003850195],"genre_scores_gemma":[0.9947365,0.0015764592,0.0018970564,0.00020736731,0.0010713822,0.000012994928,0.000013379301,0.000023036964,0.00046180643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979806,0.0003171917,0.0009963063,0.00025403316,0.00021442083,0.00023745233],"domain_scores_gemma":[0.9973912,0.00016700878,0.0015441685,0.00024501755,0.00045361524,0.00019894975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009307094,0.00017457527,0.0008061204,0.000042923508,0.00008398551,0.00006978499,0.00015915181,0.00012524148,0.000014947833],"category_scores_gemma":[0.00073035766,0.00009956646,0.00006493618,0.00004188846,0.0003279811,0.000048473205,0.00004566162,0.0002779232,4.7834936e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048254866,0.0007058689,0.91876364,0.000033871132,0.00051296345,0.000031752326,0.00011917148,0.00016150388,0.0038005456,0.000011325318,0.0008715769,0.026732896],"study_design_scores_gemma":[0.01645044,0.009109064,0.9442504,0.00006147339,0.00019343983,0.000014070615,0.00007301483,0.000008190021,0.00033245323,0.000010057053,0.02934344,0.00015397428],"about_ca_topic_score_codex":0.00043262614,"about_ca_topic_score_gemma":0.0127710095,"teacher_disagreement_score":0.031804428,"about_ca_system_score_codex":0.000032738164,"about_ca_system_score_gemma":0.0010755389,"threshold_uncertainty_score":0.7126523},"labels":[],"label_agreement":null},{"id":"W2892185075","doi":"10.1200/jco.2017.35.15_suppl.tps3105","title":"A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Triple-negative breast cancer; Immunotherapy; Phases of clinical research; Antigen; Immune system; Neutropenia; Metastatic breast cancer; Cancer; Breast cancer; Clinical trial; Immunology; Chemotherapy","score_opus":0.09115560599467787,"score_gpt":0.4964976122619084,"score_spread":0.40534200626723055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892185075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669135,0.0002456636,0.000023152934,0.0004978616,0.0001439675,0.0022708836,0.00011332731,0.0000015573754,0.000012245681],"genre_scores_gemma":[0.99733543,0.00044596195,0.0016746896,0.00006129703,0.00011074299,0.0002542184,0.000020445115,0.000028928644,0.00006825629],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99782646,0.00021896126,0.0009880462,0.0003998582,0.00028648856,0.0002802171],"domain_scores_gemma":[0.99735874,0.00015576821,0.0016064569,0.0002929358,0.00026525464,0.00032083353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050275406,0.00025020808,0.0010764095,0.00007223698,0.0001817395,0.000036908703,0.0002673575,0.00007382332,0.000007287522],"category_scores_gemma":[0.0002954406,0.00013311356,0.00013335352,0.000042879605,0.00014492308,0.000047343055,0.00011667284,0.00017341888,1.0718217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37291938,0.044689853,0.13536167,0.000034298922,0.0020909836,0.00022136218,0.00035098032,0.00003258167,0.0005765251,3.2910944e-7,0.000020198626,0.44370183],"study_design_scores_gemma":[0.43928733,0.44553262,0.10862834,0.0004897544,0.00059714,0.000009098009,0.00043709602,0.0001987683,0.0041363216,0.000009539036,0.0004545219,0.00021946598],"about_ca_topic_score_codex":0.00037148834,"about_ca_topic_score_gemma":0.0046679927,"teacher_disagreement_score":0.44348237,"about_ca_system_score_codex":0.00020242923,"about_ca_system_score_gemma":0.0009906207,"threshold_uncertainty_score":0.54282135},"labels":[],"label_agreement":null},{"id":"W2892188128","doi":"10.1200/jco.2017.35.15_suppl.e19037","title":"Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Fludarabine; Rituximab; Internal medicine; Cyclophosphamide; Confidence interval; Regimen; Surgery; Lymphoma; Gastroenterology; Leukemia; Oncology; Chemotherapy","score_opus":0.09444569567659457,"score_gpt":0.43694260700121706,"score_spread":0.3424969113246225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892188128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965872,0.00016239528,0.00005229124,0.0013247716,0.00045854226,0.0006046248,0.0000074652303,0.000006272862,0.0007964438],"genre_scores_gemma":[0.99694806,0.00070954754,0.0007932864,0.00006870854,0.0010749922,0.000009075715,0.00000648651,0.000031617517,0.00035822357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958349,0.00019539215,0.0024388656,0.00029445317,0.00076272705,0.00047367765],"domain_scores_gemma":[0.9930772,0.0022950708,0.0026994331,0.0007199166,0.00073874195,0.00046962034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015144715,0.00024007366,0.0022249206,0.00022974936,0.00008681816,0.000019387891,0.0004703516,0.00045269637,0.0001525346],"category_scores_gemma":[0.0056497403,0.00014770651,0.0003669579,0.00012832586,0.00067927106,0.00017701201,0.00013724476,0.0006831325,0.000028589859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03669617,0.002711879,0.80063456,0.0004612312,0.0014319521,0.004473897,0.00032982233,0.008819036,0.00003139349,0.000034858596,0.0014712987,0.14290388],"study_design_scores_gemma":[0.34453294,0.08282412,0.52677155,0.0014193174,0.00072311575,0.00055304286,0.000065100074,0.01920913,0.00016555356,0.000045930894,0.023446204,0.00024402587],"about_ca_topic_score_codex":0.00132475,"about_ca_topic_score_gemma":0.0028361278,"teacher_disagreement_score":0.30783677,"about_ca_system_score_codex":0.059145015,"about_ca_system_score_gemma":0.08177311,"threshold_uncertainty_score":0.94446677},"labels":[],"label_agreement":null},{"id":"W2892194924","doi":"10.1200/jco.2018.36.15_suppl.e18760","title":"Defining non-inferiority margins for quality of surgical resection for rectal cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Colorectal cancer; Total mesorectal excision; Randomized controlled trial; Resection margin; Surgery; Psychological intervention; General surgery; Laparoscopy; Resection; Cancer; Internal medicine","score_opus":0.25275356249967096,"score_gpt":0.5855453852691554,"score_spread":0.3327918227694845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892194924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987198,0.00030053675,0.0007158668,0.0035356702,0.0032943133,0.00061532424,0.000051031246,0.000009124133,0.0042801523],"genre_scores_gemma":[0.9870403,0.00042706038,0.008697264,0.0002553247,0.003244957,0.00005169506,0.0000056057397,0.0000193806,0.000258438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961047,0.0003184506,0.0026914075,0.0002485831,0.0003458175,0.00029103685],"domain_scores_gemma":[0.9881607,0.0076192366,0.0020819756,0.00016960011,0.0016287926,0.00033967625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056600086,0.00014360629,0.002000294,0.00009936439,0.00007206236,0.000005234141,0.00012555323,0.0004675863,0.00013214923],"category_scores_gemma":[0.0064027375,0.00010507057,0.0010493469,0.00018154785,0.0003553366,0.000089420835,0.000045909503,0.00048133885,0.0000034203122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29138827,0.003503784,0.46866634,0.0003529021,0.0014007072,0.00011531015,0.00017941608,0.000004441568,0.0007624206,0.0012663079,0.005903379,0.22645672],"study_design_scores_gemma":[0.03446839,0.10690267,0.680972,0.0002406855,0.00059319916,0.00019439816,0.00007486105,0.00029255307,0.0018006172,0.0011669046,0.17313248,0.00016126932],"about_ca_topic_score_codex":0.00012956772,"about_ca_topic_score_gemma":0.000590148,"teacher_disagreement_score":0.2569199,"about_ca_system_score_codex":0.0004068721,"about_ca_system_score_gemma":0.0019555031,"threshold_uncertainty_score":0.76651376},"labels":[],"label_agreement":null},{"id":"W2892202190","doi":"10.1200/jco.2018.36.15_suppl.7534","title":"Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Brentuximab vedotin; Neutropenia; Internal medicine; ABVD; Dacarbazine; Febrile neutropenia; Chemotherapy regimen; Surgery; Gastroenterology; Chemotherapy; Lymphoma; Hodgkin lymphoma; Vincristine; Cyclophosphamide","score_opus":0.03357932821953199,"score_gpt":0.38376293910968273,"score_spread":0.35018361089015076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892202190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959083,0.00009847032,0.00015232373,0.0022971828,0.00051432237,0.00052325154,0.000005409934,0.000014970893,0.00048572445],"genre_scores_gemma":[0.98560655,0.00010996852,0.010195749,0.0035639296,0.00030826204,0.000015992986,0.000005255758,0.00003846422,0.00015580762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967883,0.00020787492,0.0017354216,0.00032719408,0.0005470269,0.0003941885],"domain_scores_gemma":[0.9954881,0.0014806947,0.0018194269,0.00030573548,0.0005212978,0.00038471862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009005436,0.00027372324,0.0019113517,0.00016841007,0.00004825776,0.000017361723,0.00017551567,0.0002578359,0.000111306865],"category_scores_gemma":[0.0010426767,0.00015006863,0.0002598118,0.00020803121,0.0002573185,0.0001904773,0.000040025414,0.00031202403,0.000016554133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017211955,0.0062457873,0.7004156,0.000015001115,0.0003387579,0.00064190675,0.00011860074,0.000012349761,0.000004444964,0.00002018198,0.00020438129,0.27477103],"study_design_scores_gemma":[0.15906622,0.04191012,0.7952205,0.0001790424,0.00019079432,0.00003170839,0.00009996712,0.000048223115,0.000073433155,0.00001971087,0.0030215646,0.00013869739],"about_ca_topic_score_codex":0.00013365883,"about_ca_topic_score_gemma":0.0004045487,"teacher_disagreement_score":0.27463233,"about_ca_system_score_codex":0.0007190034,"about_ca_system_score_gemma":0.0020262063,"threshold_uncertainty_score":0.61196214},"labels":[],"label_agreement":null},{"id":"W2892202359","doi":"10.1200/jco.2018.36.15_suppl.5576","title":"Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; Progression-free survival; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Overall survival","score_opus":0.2564612880490028,"score_gpt":0.5040262150334156,"score_spread":0.2475649269844128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892202359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97414875,0.0028216224,0.0006985791,0.013879446,0.0049732593,0.0027611358,0.00052908965,0.000016927124,0.00017116925],"genre_scores_gemma":[0.9799144,0.010216588,0.006344091,0.0013253395,0.0013956251,0.00065725273,0.000056690882,0.000043922897,0.00004608967],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98834884,0.0031233465,0.006438759,0.0006142375,0.0009073398,0.00056745275],"domain_scores_gemma":[0.96334547,0.027404891,0.0068768812,0.00050771283,0.0014044761,0.0004605549],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017477086,0.0004447167,0.008387282,0.00065217965,0.00008704601,0.000024232746,0.00043377632,0.0006628932,0.0014537009],"category_scores_gemma":[0.029900972,0.00027419606,0.0028264537,0.0006751156,0.00049369136,0.00018040382,0.00017336727,0.00077492534,0.00000229072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4198123,0.0068271514,0.16184084,0.00005516572,0.01503557,0.00014497773,0.0008061733,0.00033678653,0.00008022062,0.00014732638,0.0005277338,0.39438576],"study_design_scores_gemma":[0.5275798,0.024026945,0.42725876,0.00052570883,0.00802683,0.0000073294154,0.00015786856,0.0015145628,0.00058764603,0.0009610742,0.009062725,0.00029075408],"about_ca_topic_score_codex":0.0015546815,"about_ca_topic_score_gemma":0.024752386,"teacher_disagreement_score":0.394095,"about_ca_system_score_codex":0.0006254471,"about_ca_system_score_gemma":0.0023024878,"threshold_uncertainty_score":0.99997103},"labels":[],"label_agreement":null},{"id":"W2892202751","doi":"10.1200/jco.2017.35.15_suppl.e18312","title":"The impact of pricing strategy on the cost of oral anti-cancer drugs during dose reductions.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Drug; Cancer drugs; Pharmacology","score_opus":0.2176923478335994,"score_gpt":0.46512882769962327,"score_spread":0.24743647986602388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892202751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771487,0.0007912784,0.000019748371,0.0041085696,0.001390004,0.00014175814,0.00003632053,0.0000017393579,0.016361887],"genre_scores_gemma":[0.99308234,0.0057119993,0.000048393744,0.00009289631,0.0006492625,0.0000034234258,1.7664185e-7,0.0000125901615,0.00039893156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690455,0.00007549644,0.0025762524,0.0001486238,0.00005333549,0.0002417398],"domain_scores_gemma":[0.99031055,0.00090454094,0.008015219,0.00045054735,0.00020564107,0.000113525675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042704684,0.00012028778,0.0011855236,0.00008500581,0.00029114223,0.00005290407,0.00069350883,0.00019982923,0.00016888928],"category_scores_gemma":[0.0031117285,0.00007083649,0.00066816027,0.000057532652,0.00061666814,0.000320103,0.00007237159,0.000650319,0.000015161093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004592617,0.0017819104,0.576667,0.000047338264,0.0022569937,0.00002009331,0.00067757646,0.009628189,0.00044358967,0.098430775,0.011764541,0.29368937],"study_design_scores_gemma":[0.0019151605,0.0016968886,0.9783989,0.000046989782,0.000025649733,0.000007850535,0.0001225595,0.00018520755,0.00024710214,0.007892481,0.009366031,0.00009518317],"about_ca_topic_score_codex":0.0006952767,"about_ca_topic_score_gemma":0.00005402252,"teacher_disagreement_score":0.4017319,"about_ca_system_score_codex":0.00020812968,"about_ca_system_score_gemma":0.0005988516,"threshold_uncertainty_score":0.37252545},"labels":[],"label_agreement":null},{"id":"W2892205551","doi":"10.1200/jco.2017.35.15_suppl.5548","title":"A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre","funders":"","keywords":"Medicine; Taxane; Internal medicine; Ovarian cancer; Cancer; Paclitaxel; Oncology; Tolerability; Adverse effect; Gastroenterology; Breast cancer","score_opus":0.3722542817996232,"score_gpt":0.6021979240114069,"score_spread":0.2299436422117837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892205551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925289,0.0004249114,0.000013116983,0.0021506352,0.0013637394,0.0005650563,0.00003429596,0.000007804829,0.002911547],"genre_scores_gemma":[0.99764925,0.0006953623,0.00045597806,0.00038680734,0.00041626717,0.000019562081,0.0000015071313,0.00002197518,0.00035330118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949378,0.0015602167,0.0024835442,0.00032462864,0.0002825998,0.0004112349],"domain_scores_gemma":[0.992812,0.0014584617,0.0045389817,0.00036245576,0.00045659742,0.0003715165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003901729,0.00024876095,0.0017493495,0.00015768743,0.0002387566,0.000022740927,0.00068559765,0.00044995223,0.00024466254],"category_scores_gemma":[0.0012508566,0.00017569821,0.00021448125,0.00013968292,0.0005724018,0.00026990855,0.00011417098,0.0017704489,0.0000038857283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06727559,0.056565832,0.6887164,0.00005887289,0.001389885,0.0036614393,0.001057497,0.000086810964,0.004131398,0.00011905897,0.001361204,0.17557602],"study_design_scores_gemma":[0.14456193,0.096224904,0.70658904,0.0002897778,0.0009511357,0.00012495025,0.0016972837,0.00026571768,0.0008004297,0.00021864935,0.04791261,0.0003635494],"about_ca_topic_score_codex":0.00028761104,"about_ca_topic_score_gemma":0.0027333002,"teacher_disagreement_score":0.17521246,"about_ca_system_score_codex":0.0001610767,"about_ca_system_score_gemma":0.0009501183,"threshold_uncertainty_score":0.7691818},"labels":[],"label_agreement":null},{"id":"W2892206270","doi":"10.1200/jco.2016.34.15_suppl.6603","title":"Identifying opportunities to improve quality of cancer care: An evaluation of the use of diagnostic imaging in women curatively treated for early breast cancer (EBC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; Health Sciences Centre; Credit Valley Hospital; University Health Network; University of Toronto; Trillium Health Centre","funders":"","keywords":"Medicine; Breast cancer; Population; Medical imaging; Cancer; Cancer registry; Stage (stratigraphy); Comorbidity; Medical record; Radiology; Emergency medicine; Internal medicine","score_opus":0.3407535757868888,"score_gpt":0.5214422280734277,"score_spread":0.18068865228653885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892206270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960695,0.00077264063,0.00009198694,0.0019213322,0.00040006987,0.00031925834,0.00041506244,8.412552e-7,0.000009294886],"genre_scores_gemma":[0.99839574,0.0009188381,0.00017840044,0.00018227649,0.00019337592,0.00010073237,0.0000018610043,0.000010582759,0.00001819202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972565,0.0007019907,0.0014449059,0.00017243563,0.0002622295,0.00016191042],"domain_scores_gemma":[0.99476033,0.001234638,0.0019205862,0.00018021153,0.0018206175,0.000083607825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017803921,0.000110647954,0.00067065295,0.0000583671,0.000023501107,0.000003716146,0.00017265536,0.00011057497,0.000014668104],"category_scores_gemma":[0.0032967,0.00006399125,0.00019958962,0.000062161525,0.00025174295,0.000030144865,0.00007796884,0.0000776822,5.0807223e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029852928,0.00033004084,0.6249018,0.00003854106,0.0003089289,0.0000010023405,0.00090398424,0.00007780362,0.045440175,0.000009053182,0.00008621115,0.3249172],"study_design_scores_gemma":[0.0047097304,0.0010974243,0.9769252,0.0002084452,0.0002245847,0.0000022311779,0.00080748793,0.000006643499,0.015523342,0.00008278639,0.00033769087,0.00007444692],"about_ca_topic_score_codex":0.0018298208,"about_ca_topic_score_gemma":0.0029513796,"teacher_disagreement_score":0.35202342,"about_ca_system_score_codex":0.00027415814,"about_ca_system_score_gemma":0.0014183281,"threshold_uncertainty_score":0.39466962},"labels":[],"label_agreement":null},{"id":"W2892215224","doi":"10.1200/jco.2016.34.15_suppl.5509","title":"Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; KRAS; Serous fluid; Internal medicine; Oncology; Neuroblastoma RAS viral oncogene homolog; HRAS; Gynecology; Cancer; Pathology","score_opus":0.10776116559958537,"score_gpt":0.46327436090044927,"score_spread":0.3555131953008639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892215224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98708457,0.00028223425,0.0018703877,0.008486523,0.0014606393,0.00048683575,0.000027696517,0.0000039882784,0.00029715043],"genre_scores_gemma":[0.9879067,0.00047230805,0.0103745945,0.00070470583,0.0004270688,0.000044737168,0.0000028169336,0.00001058447,0.000056477133],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977995,0.00014357123,0.0016082549,0.00012415607,0.00019117583,0.00013331158],"domain_scores_gemma":[0.99568385,0.0017431072,0.0016048015,0.00010352175,0.00072854833,0.00013618478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009273229,0.000090864545,0.0009536312,0.00006745922,0.000016242719,0.0000022831482,0.000075729215,0.00020783252,0.00018219149],"category_scores_gemma":[0.0037122555,0.000044681772,0.00043610614,0.00005266096,0.00008467462,0.000061292405,0.000015946527,0.00015124834,0.0000032453238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020365147,0.0029983402,0.23663576,0.00007107491,0.0005342507,0.00005628968,0.000041573327,0.0000052564374,0.0044715274,0.00057143107,0.0007048977,0.7518731],"study_design_scores_gemma":[0.04012145,0.051181052,0.8391456,0.0007068085,0.0016580306,0.000022602118,0.000067488545,0.00007709806,0.052763876,0.0039390204,0.010167618,0.00014937186],"about_ca_topic_score_codex":0.0000056622375,"about_ca_topic_score_gemma":0.0000106816315,"teacher_disagreement_score":0.7517237,"about_ca_system_score_codex":0.0002513077,"about_ca_system_score_gemma":0.0010117295,"threshold_uncertainty_score":0.4444185},"labels":[],"label_agreement":null},{"id":"W2892218252","doi":"10.1200/jco.2017.35.15_suppl.e15137","title":"Phosphorylated signal transducer and activator of transcription–3 (p-STAT3) expression concordance in paired primary and metastatic colorectal cancers (mCRC): Updated analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Toronto","funders":"","keywords":"Concordance; Medicine; Immunohistochemistry; STAT3; Tissue microarray; Colorectal cancer; Oncology; Metastasis; Primary tumor; Internal medicine; Correlation; Pathology; Gastroenterology; Cancer; Gene; Biology","score_opus":0.08082416252872952,"score_gpt":0.4181913557883962,"score_spread":0.3373671932596667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892218252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950703,0.002377584,0.00006201501,0.0015068328,0.00023532637,0.0002589601,0.000022600352,0.000004414046,0.00046197147],"genre_scores_gemma":[0.9956059,0.0029884074,0.0010392745,0.00022418004,0.000065274864,0.000008604112,0.0000054470424,0.000010050862,0.000052899417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750173,0.0002626362,0.0015513881,0.00023870985,0.00025968003,0.00018584552],"domain_scores_gemma":[0.997243,0.00063242466,0.0015132503,0.00013500727,0.00024543382,0.00023089924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011906539,0.00016706929,0.0021857147,0.00016178329,0.00009663953,0.000012417852,0.00010061837,0.00016057923,0.000098664554],"category_scores_gemma":[0.00034976169,0.00011452089,0.0003096105,0.00015023944,0.0005978387,0.00019670621,0.000029566772,0.00046396113,1.7943022e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06265395,0.0021337366,0.6946309,0.00018896397,0.0077593056,0.0010331447,0.0021089537,0.00006716422,0.050187718,0.000019132644,0.00061988237,0.17859712],"study_design_scores_gemma":[0.014151235,0.007931307,0.969701,0.00014880172,0.0024904397,0.000050970717,0.0003202907,0.00029271393,0.0034252338,0.00006608932,0.0013147322,0.00010720843],"about_ca_topic_score_codex":0.00031833304,"about_ca_topic_score_gemma":0.00089139084,"teacher_disagreement_score":0.27507004,"about_ca_system_score_codex":0.00021882931,"about_ca_system_score_gemma":0.00090874924,"threshold_uncertainty_score":0.46700263},"labels":[],"label_agreement":null},{"id":"W2892218953","doi":"10.1200/jco.2017.35.15_suppl.4530","title":"Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Discontinuation; Docetaxel; Quality of life (healthcare); Internal medicine; Urothelial cancer; Cancer; Proportional hazards model; Oncology; Bladder cancer","score_opus":0.17778016552948103,"score_gpt":0.5218018808113934,"score_spread":0.3440217152819124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892218953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793824,0.0022796735,0.000068721965,0.014974576,0.0009433851,0.001177851,0.000069994974,0.000010531232,0.0010928875],"genre_scores_gemma":[0.9904043,0.004501655,0.0019725957,0.0020768852,0.00050655374,0.00003826685,0.0000057101374,0.00004572519,0.00044827492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99299675,0.00053608423,0.0052780034,0.00033092586,0.00043730103,0.00042091432],"domain_scores_gemma":[0.98927253,0.0013453589,0.007614124,0.0005568972,0.0007347364,0.0004763258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033712003,0.00026754313,0.004253644,0.00015726654,0.00007917211,0.0000074766263,0.0004056685,0.00055631355,0.00017530182],"category_scores_gemma":[0.004554659,0.00019980008,0.0009299546,0.00011570993,0.00042528647,0.0001569592,0.000043426742,0.00070906215,0.0000021589376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22070973,0.005979842,0.43041602,0.0007568105,0.0017332006,0.00004915184,0.0006830012,0.0000449429,0.0022267606,0.0001129358,0.001607803,0.3356798],"study_design_scores_gemma":[0.116712876,0.023068687,0.85042095,0.0006576385,0.00033944234,0.000037263086,0.00005949893,0.00006790743,0.0022718469,0.000605283,0.0055745053,0.00018411262],"about_ca_topic_score_codex":0.0025733258,"about_ca_topic_score_gemma":0.0010256548,"teacher_disagreement_score":0.4200049,"about_ca_system_score_codex":0.00039568226,"about_ca_system_score_gemma":0.0054556676,"threshold_uncertainty_score":0.96781206},"labels":[],"label_agreement":null},{"id":"W2892219840","doi":"10.1200/jco.2018.36.15_suppl.e21095","title":"Prognosis of thoracic radiation-induced metastatic NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Cancer; Radiation therapy; Group B; Population; Breast cancer; Internal medicine; Prostate cancer; Surgery; Oncology","score_opus":0.2300115919040708,"score_gpt":0.5574967752262217,"score_spread":0.3274851833221508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892219840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567224,0.00067835377,0.00007054273,0.009312882,0.0011269158,0.00022474569,0.0000027593628,0.0000047319118,0.0029068259],"genre_scores_gemma":[0.9919952,0.00067484914,0.004695763,0.0011902335,0.0013622852,0.000007634498,0.0000011591518,0.00001031776,0.000062512896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972971,0.00025315574,0.0018929767,0.00011988607,0.00029931098,0.00013755453],"domain_scores_gemma":[0.99555963,0.0016269847,0.0017701816,0.0001444567,0.0006480856,0.00025068576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018846305,0.00008974846,0.001223131,0.00011477167,0.000023184195,0.0000039428637,0.000084870626,0.00013230318,0.00035830494],"category_scores_gemma":[0.002269941,0.000058141257,0.00046970948,0.00016101623,0.0001620559,0.00006609509,0.00001971911,0.00029818676,0.000030873485],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002166682,0.0037553024,0.15591863,0.000038595274,0.0010347799,0.00017084093,0.00012757668,6.8417984e-7,0.00023811958,0.00010173849,0.005616652,0.8308304],"study_design_scores_gemma":[0.008857833,0.06265413,0.84774405,0.00033482636,0.002795198,0.00031112827,0.00013507342,0.00006220382,0.010991666,0.00049629185,0.065507755,0.00010984178],"about_ca_topic_score_codex":0.000027155762,"about_ca_topic_score_gemma":0.00003311912,"teacher_disagreement_score":0.83072054,"about_ca_system_score_codex":0.00011384494,"about_ca_system_score_gemma":0.0013802735,"threshold_uncertainty_score":0.3923188},"labels":[],"label_agreement":null},{"id":"W2892222821","doi":"10.1200/jco.2017.35.15_suppl.tps8055","title":"A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Lenalidomide; Clinical endpoint; Internal medicine; Regimen; Dexamethasone; Population; Multiple myeloma; Cohort; Oncology; Phases of clinical research; Surgery; Chemotherapy; Clinical trial","score_opus":0.13688062233079704,"score_gpt":0.4809013942419234,"score_spread":0.34402077191112634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892222821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683267,0.000027947774,0.00010437841,0.000618833,0.00011641004,0.002042444,0.0000071641202,0.000007645969,0.00024250793],"genre_scores_gemma":[0.9945845,0.00005954346,0.004906662,0.000106951346,0.000104527644,0.000060310165,0.000008790185,0.000043199045,0.00012550586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945994,0.001054687,0.0022393372,0.0004253922,0.001201323,0.00047984213],"domain_scores_gemma":[0.99164426,0.0029891543,0.0031752645,0.0006284982,0.0010343473,0.00052847265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029623173,0.0003113822,0.0026051542,0.00044910307,0.00010372231,0.000032269916,0.00039038513,0.00025984237,0.00004736345],"category_scores_gemma":[0.007899335,0.00016660886,0.00013244984,0.00028647258,0.00048553717,0.0004527436,0.00008909961,0.0011741464,0.000004488357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20722127,0.05451841,0.65465546,0.000041291692,0.00056267425,0.004078636,0.00049325713,0.000034632896,0.000012848033,0.000001474529,0.000017213377,0.07836286],"study_design_scores_gemma":[0.29243246,0.1550477,0.5505934,0.00041970238,0.00021240825,0.000074432,0.00051465083,0.00047633145,0.000050751885,0.0000056326453,0.000068088455,0.00010448014],"about_ca_topic_score_codex":0.0012378572,"about_ca_topic_score_gemma":0.020916857,"teacher_disagreement_score":0.10406208,"about_ca_system_score_codex":0.00042530126,"about_ca_system_score_gemma":0.002616569,"threshold_uncertainty_score":0.99694884},"labels":[],"label_agreement":null},{"id":"W2892229061","doi":"10.1200/jco.2017.35.15_suppl.e21004","title":"Generalizability of clinical trials in metastatic melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Ipilimumab; Clinical trial; Internal medicine; Population; Vemurafenib; Cancer; Cohort; Oncology; Melanoma; Metastatic melanoma; Immunotherapy","score_opus":0.6925201321336265,"score_gpt":0.6835808158821697,"score_spread":0.00893931625145683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892229061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778595,0.00036799084,0.000107598935,0.011744023,0.0021221275,0.00043778218,0.0000054004977,0.0000033466997,0.0073522152],"genre_scores_gemma":[0.9866888,0.0019399675,0.0069029084,0.00093232625,0.0021956945,0.000004244964,0.0000013266332,0.000019596348,0.0013151583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97424954,0.011413026,0.012960004,0.0002915282,0.00076218654,0.00032370258],"domain_scores_gemma":[0.9454775,0.039949115,0.011562429,0.0011690303,0.0010481664,0.0007937476],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1735477,0.00014610976,0.0067372792,0.00019444275,0.0000432931,0.000016989909,0.0006001253,0.00052170845,0.0026622915],"category_scores_gemma":[0.25850177,0.00009482343,0.0021685176,0.00009072712,0.0009693655,0.00013502344,0.00015399266,0.0020528617,0.00001884176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016100885,0.0034336739,0.54722786,0.000060306218,0.00072434347,0.0008175017,0.000045231547,0.000005158607,0.0013623997,0.00012465133,0.0028239184,0.42727408],"study_design_scores_gemma":[0.028205799,0.016402354,0.8611443,0.00010659679,0.0004978968,0.00018852369,0.000058150443,0.0002545104,0.00044232103,0.0023717005,0.09023451,0.00009332591],"about_ca_topic_score_codex":0.0001329965,"about_ca_topic_score_gemma":0.00017722856,"teacher_disagreement_score":0.42718074,"about_ca_system_score_codex":0.000111418696,"about_ca_system_score_gemma":0.0037703891,"threshold_uncertainty_score":0.9982494},"labels":[],"label_agreement":null},{"id":"W2892242225","doi":"10.1200/jco.2017.35.15_suppl.e16065","title":"Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Queen Elizabeth II Health Sciences Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Nephrectomy; Anemia; Kidney cancer; Cancer; Histology; Oncology; Gastroenterology; Kidney","score_opus":0.16145747959391302,"score_gpt":0.451637824812956,"score_spread":0.290180345219043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892242225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948349,0.0001166821,0.000057115736,0.002205364,0.00042679388,0.0008839903,0.000006362496,0.000012675924,0.0014561182],"genre_scores_gemma":[0.9895893,0.000081382546,0.008336605,0.0014016876,0.00031009637,0.000014293659,0.000007371561,0.0000543333,0.00020497425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936066,0.0010307602,0.003475947,0.00052209466,0.0008309241,0.00053363555],"domain_scores_gemma":[0.99127847,0.0024904446,0.0036167467,0.0008423832,0.0008348437,0.0009371173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037017115,0.00040808113,0.0035645524,0.0002938729,0.00014265676,0.000039722392,0.0005078949,0.0003642806,0.00006233543],"category_scores_gemma":[0.0023604988,0.00021653179,0.00070882717,0.00018018764,0.00037230502,0.0002457443,0.00011067121,0.0016324838,0.000024602621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031833615,0.0051031034,0.9227006,0.000017894161,0.00066279894,0.0019831967,0.000075817836,0.00001802511,0.0000359751,0.000002649048,0.00020109571,0.037365235],"study_design_scores_gemma":[0.046776623,0.06737823,0.8837528,0.00012020733,0.0006290253,0.00004714984,0.00010131702,0.000012272887,0.00031885135,0.0000171672,0.0006386991,0.00020760843],"about_ca_topic_score_codex":0.0002611245,"about_ca_topic_score_gemma":0.00021770154,"teacher_disagreement_score":0.06227513,"about_ca_system_score_codex":0.00035706488,"about_ca_system_score_gemma":0.0014522093,"threshold_uncertainty_score":0.882991},"labels":[],"label_agreement":null},{"id":"W2892245423","doi":"10.1200/jco.2016.34.15_suppl.tps8574","title":"Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Nintedanib; Internal medicine; Clinical endpoint; Placebo; Docetaxel; Phases of clinical research; Oncology; Bevacizumab; Maintenance therapy; Pemetrexed; Progression-free survival; Gastroenterology; Chemotherapy; Surgery; Clinical trial; Cisplatin; Pathology","score_opus":0.05603232695569429,"score_gpt":0.400165441583721,"score_spread":0.34413311462802676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892245423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911476,0.00024414322,0.00087755057,0.0018072535,0.0011308619,0.0038889658,0.000294879,0.00002079079,0.00058795355],"genre_scores_gemma":[0.9932932,0.00017166282,0.0011665897,0.0003754797,0.00021537878,0.00023659568,0.00007231619,0.00006566483,0.004403083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934093,0.00062184717,0.0035401238,0.0005847852,0.0011885955,0.0006553638],"domain_scores_gemma":[0.98818386,0.006572239,0.0035115045,0.00039312156,0.0006514459,0.00068782415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033794171,0.00047063167,0.0032474452,0.0002141374,0.000151321,0.00001685681,0.00044276065,0.00032708852,0.00044143683],"category_scores_gemma":[0.004108072,0.0002518565,0.0009840716,0.0002700886,0.0005871601,0.0003202485,0.00014310525,0.00046762935,0.000011027835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88580906,0.020131277,0.026017817,0.000038251514,0.0022301618,0.00011921174,0.0000965655,0.0000078871335,0.0016275853,0.000032429372,0.05993393,0.003955849],"study_design_scores_gemma":[0.9003463,0.08615918,0.0020453557,0.0004088876,0.0022436974,0.00003142485,0.0004047743,0.00012193235,0.0004740492,0.000055159657,0.0073974677,0.00031180945],"about_ca_topic_score_codex":0.000076007076,"about_ca_topic_score_gemma":0.000093849245,"teacher_disagreement_score":0.0660279,"about_ca_system_score_codex":0.0003943136,"about_ca_system_score_gemma":0.0006368228,"threshold_uncertainty_score":0.9999934},"labels":[],"label_agreement":null},{"id":"W2892255893","doi":"10.1200/jco.2018.36.15_suppl.4540","title":"Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Proportional hazards model; Gene; ARID1A; Exon; Cancer; Genetics; Mutation; Biology","score_opus":0.04896137684477809,"score_gpt":0.3893823247653211,"score_spread":0.340420947920543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892255893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99730486,0.00007940023,0.0004372302,0.00090885954,0.0005605068,0.00011117657,0.000022044436,0.0000010648433,0.0005748898],"genre_scores_gemma":[0.99464166,0.000058837915,0.0037073023,0.0006961785,0.000804989,0.000004560559,0.0000044556296,0.000013718299,0.00006827387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788886,0.00024003742,0.0013943379,0.00015115004,0.00015693872,0.00016869593],"domain_scores_gemma":[0.9969385,0.0007639967,0.001683688,0.0001450129,0.00037276538,0.00009598649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001552736,0.000099608056,0.0006536428,0.00006942546,0.00003188085,0.000010410806,0.00015234626,0.00008339732,0.000027955839],"category_scores_gemma":[0.0035865298,0.00007909702,0.00019128762,0.000067860885,0.00010811266,0.0000067364267,0.000050255203,0.00021617889,0.000003226105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067561975,0.00057274,0.95642775,0.000012719008,0.0003626401,0.00008901846,0.000085567284,0.00036295695,0.03648073,0.00012095364,0.0008741508,0.0039351257],"study_design_scores_gemma":[0.00749381,0.010525177,0.9501148,0.000034830024,0.00035603362,0.00017454119,0.00014735214,0.00038816393,0.013560434,0.00041823112,0.016556893,0.00022973192],"about_ca_topic_score_codex":0.00005620491,"about_ca_topic_score_gemma":0.00096432416,"teacher_disagreement_score":0.022920294,"about_ca_system_score_codex":0.000103391016,"about_ca_system_score_gemma":0.0013673814,"threshold_uncertainty_score":0.429367},"labels":[],"label_agreement":null},{"id":"W2892256324","doi":"10.1200/jco.2019.37.15_suppl.3123","title":"Phase 1b study of selinexor, a first-in-class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Doxorubicin; Febrile neutropenia; Adverse effect; Anemia; Phases of clinical research; Metastatic breast cancer; Gastroenterology; Clinical endpoint; Surgery; Toxicity; Breast cancer; Oncology; Chemotherapy; Cancer; Clinical trial","score_opus":0.019593328464661264,"score_gpt":0.3483013990197485,"score_spread":0.3287080705550872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892256324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886906,0.000025882775,0.00008740869,0.00010851225,0.00019315247,0.0006256654,0.0000029031337,0.0000015651713,0.00008587197],"genre_scores_gemma":[0.9982278,0.000025161175,0.0015059744,0.00013837616,0.000048606526,0.0000035110713,0.000008625525,0.00002149476,0.000020454376],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99740744,0.00033442205,0.0015761559,0.00024403377,0.00027228196,0.00016564604],"domain_scores_gemma":[0.9976713,0.00022304509,0.0014124465,0.00016387332,0.0004596094,0.000069691356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008295592,0.00015179724,0.0009671723,0.00017609802,0.000012573883,0.0000038248827,0.00014351135,0.00018073834,0.000017378872],"category_scores_gemma":[0.00035613388,0.000102281825,0.000062017876,0.00027352158,0.00009520581,0.000025314484,0.000041934607,0.00041709287,0.0000012162778],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1654602,0.06315079,0.68773,0.00015181185,0.0005057617,0.0002972341,0.0011222957,0.002652569,0.021814995,0.00002070957,0.00029758853,0.056796018],"study_design_scores_gemma":[0.17871521,0.41006282,0.40096715,0.0002750903,0.00016051356,0.00006475509,0.0022032135,0.0006197815,0.0023954224,0.00005167934,0.0041921483,0.0002921974],"about_ca_topic_score_codex":0.00004726764,"about_ca_topic_score_gemma":0.0020184934,"teacher_disagreement_score":0.34691203,"about_ca_system_score_codex":0.00007577431,"about_ca_system_score_gemma":0.00036840496,"threshold_uncertainty_score":0.4170932},"labels":[],"label_agreement":null},{"id":"W2892262946","doi":"10.1200/jco.2017.35.15_suppl.10565","title":"Mental healthcare use and severe psychiatric diagnoses in adult survivors of childhood cancer: A population-based study using health services data.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; Institute for Clinical Evaluative Sciences; Centre for Addiction and Mental Health; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Mental health; Hazard ratio; Emergency department; Population; Cohort; Cancer registry; Confidence interval; Psychiatry; Cohort study; Pediatrics; Internal medicine","score_opus":0.19696346907355347,"score_gpt":0.5300768381444735,"score_spread":0.33311336907092004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892262946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96753037,0.0016131713,0.0000044979283,0.02832146,0.0016192803,0.0007496649,0.00014899949,0.0000073228607,0.000005242132],"genre_scores_gemma":[0.98907137,0.0017673508,0.0026658166,0.005582374,0.00086127355,0.000003313891,0.000021121059,0.00002509499,0.0000022836794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936294,0.0013274313,0.0036678896,0.0004096949,0.00066937704,0.00029621978],"domain_scores_gemma":[0.9903811,0.001861872,0.006026129,0.0008295716,0.00041169894,0.0004896063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050119543,0.00020691178,0.0022799706,0.00024910455,0.00019854771,0.000036637903,0.00052377366,0.00023938571,0.00001529615],"category_scores_gemma":[0.0024200398,0.00017246675,0.00018687411,0.0001569179,0.000111835674,0.0005328069,0.00020456294,0.000877329,3.764774e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014806049,0.0039835544,0.97562,0.00042275767,0.0002093863,0.000045153993,0.0016048221,0.000037365393,4.795126e-7,0.000006662341,0.00008790017,0.016501334],"study_design_scores_gemma":[0.0124463625,0.00642226,0.97681534,0.0010750777,0.00020389518,0.000051663654,0.0022926813,0.0003269644,5.474553e-7,0.000044587025,0.00019337068,0.00012725889],"about_ca_topic_score_codex":0.13992612,"about_ca_topic_score_gemma":0.31293967,"teacher_disagreement_score":0.17301355,"about_ca_system_score_codex":0.00025539118,"about_ca_system_score_gemma":0.0036080398,"threshold_uncertainty_score":0.8658012},"labels":[],"label_agreement":null},{"id":"W2892271101","doi":"10.1200/jco.2017.35.15_suppl.5534","title":"Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Chemotherapy; Ovarian cancer; Randomization; Randomized controlled trial; Oncology; Progression-free survival; BRCA mutation; Surgery; Cancer; Gastroenterology","score_opus":0.2896326746587832,"score_gpt":0.5637847703547282,"score_spread":0.274152095695945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892271101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98097384,0.0019577025,0.00008035169,0.009236553,0.0032283252,0.00022343351,0.000027108636,0.0000038957364,0.0042688036],"genre_scores_gemma":[0.9833952,0.012576694,0.001128911,0.00037567804,0.0018920178,0.000009330964,0.000002201836,0.000015622309,0.0006043177],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965893,0.00014877849,0.002555599,0.00016904701,0.00035472374,0.00018252751],"domain_scores_gemma":[0.9926133,0.0007169187,0.005225538,0.00050190854,0.0006531245,0.00028920808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012562162,0.00013873348,0.0018774559,0.0001047505,0.000052614614,0.000005973414,0.00024983293,0.00032203656,0.0009667142],"category_scores_gemma":[0.0006905,0.000096498225,0.0007005233,0.000044227356,0.00044927732,0.0000930646,0.000031189633,0.000362211,0.000008036907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008143665,0.0034856321,0.48228386,0.000056967903,0.000917993,0.00018073521,0.00014185243,0.0000071720033,0.001213351,0.00023143386,0.0012981104,0.50203925],"study_design_scores_gemma":[0.021682115,0.021246757,0.9182663,0.00051920454,0.0006153059,0.0001425235,0.000014913046,0.000011354003,0.00565059,0.00047230974,0.031293336,0.000085295665],"about_ca_topic_score_codex":0.00011354782,"about_ca_topic_score_gemma":0.00020594602,"teacher_disagreement_score":0.50195396,"about_ca_system_score_codex":0.0003342086,"about_ca_system_score_gemma":0.0015962541,"threshold_uncertainty_score":0.99994653},"labels":[],"label_agreement":null},{"id":"W2892272740","doi":"10.1200/jco.2016.34.15_suppl.e16540","title":"Effect of abiraterone acetate (AA) and enzalutamide (EZ) administration on chemotherapy-naïve metastatic castration-resistant prostate cancer (CN-mCRPC) patient’s symptom burden.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Multivariate analysis; Abiraterone acetate; Univariate analysis; Cancer; Chemotherapy; Oncology; Androgen deprivation therapy","score_opus":0.0626399407867444,"score_gpt":0.47133645379068634,"score_spread":0.40869651300394194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892272740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863009,0.0006899023,0.00001238972,0.011303309,0.0008010799,0.0005541769,0.000034951172,0.000008040785,0.0002952485],"genre_scores_gemma":[0.9953982,0.0024981766,0.00028859483,0.00077168696,0.0004765321,0.000029963041,0.0000037215516,0.000021626982,0.0005114726],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9967756,0.0006673106,0.0017721335,0.0002338872,0.00031838982,0.00023266923],"domain_scores_gemma":[0.9946959,0.002790682,0.0018031674,0.00013750623,0.00028848185,0.0002842441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014869863,0.00021106952,0.0013770235,0.000119904136,0.000036373072,0.000008266493,0.00007261838,0.00017367642,0.00029094552],"category_scores_gemma":[0.0005174746,0.00011548426,0.000258403,0.00009016384,0.0002800155,0.00012045594,0.00001623793,0.00033131588,0.000007467432],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06798438,0.0015506038,0.018352536,0.00021250594,0.0016052986,0.0005707519,0.0005215422,0.000018108578,0.085047126,0.000045884583,0.0018599535,0.8222313],"study_design_scores_gemma":[0.09359007,0.39285463,0.27423576,0.0012892395,0.0045144204,0.0006383683,0.00015184678,0.00007866859,0.19529805,0.00039003015,0.036521524,0.00043738243],"about_ca_topic_score_codex":0.000047424135,"about_ca_topic_score_gemma":0.00010440045,"teacher_disagreement_score":0.8217939,"about_ca_system_score_codex":0.00020764797,"about_ca_system_score_gemma":0.0010784538,"threshold_uncertainty_score":0.47093114},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2892287506","doi":"10.1200/jco.2016.34.15_suppl.e21669","title":"Early palliative care: Attitudes and opinions of palliative care physicians.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palliative care; Referral; Logistic regression; Family medicine; Multivariate analysis; Cancer; Nursing; Internal medicine","score_opus":0.3084399886090278,"score_gpt":0.563526140174335,"score_spread":0.2550861515653072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892287506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98188007,0.009937099,0.0004416758,0.0041191727,0.0007746958,0.00019032402,0.000070654176,0.000007050027,0.0025792327],"genre_scores_gemma":[0.9840686,0.010213061,0.0043776203,0.00043436128,0.0007938817,0.0000030005713,0.0000041039875,0.000014966346,0.00009044426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972368,0.00028986426,0.001716606,0.00019488139,0.00036334887,0.00019848389],"domain_scores_gemma":[0.9919024,0.0040802364,0.001966529,0.00017544747,0.0016487716,0.0002266293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005020107,0.00016090725,0.0017525756,0.00010851157,0.000029128321,0.0000029392493,0.00015639026,0.00030471722,0.0000435784],"category_scores_gemma":[0.0035561637,0.00009561737,0.00047395364,0.00012814,0.00063853903,0.00010695598,0.000065615604,0.00043874595,0.000005862216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013980967,0.00041021846,0.8729135,0.00020149234,0.0006901977,0.00007278198,0.0061210915,9.816504e-7,0.0005798281,0.00046229115,0.0009535034,0.11619604],"study_design_scores_gemma":[0.0067638694,0.01125703,0.9344842,0.0027059747,0.00035810412,0.000002568866,0.0037364801,0.0000011335675,0.0016453924,0.00028260247,0.038654096,0.000108590255],"about_ca_topic_score_codex":0.000043746128,"about_ca_topic_score_gemma":0.000054185006,"teacher_disagreement_score":0.116087444,"about_ca_system_score_codex":0.00013295868,"about_ca_system_score_gemma":0.00078903476,"threshold_uncertainty_score":0.4257317},"labels":[],"label_agreement":null},{"id":"W2892289693","doi":"10.1200/jco.2017.35.15_suppl.4534","title":"Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"KRAS; ARID1A; Medicine; CDKN2A; Bladder cancer; Cancer research; Oncology; Copy-number variation; Cancer; Gene; Internal medicine; Bioinformatics; Biology; Mutation; Colorectal cancer; Genetics; Genome","score_opus":0.09577273611006674,"score_gpt":0.4675657469478829,"score_spread":0.37179301083781613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892289693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776984,0.00036211143,0.000025646697,0.0110748345,0.001661552,0.00030064996,0.000021107036,0.000009631296,0.008846058],"genre_scores_gemma":[0.9934818,0.0005025318,0.0006718353,0.003378466,0.0014077344,0.000020217916,0.0000041211356,0.000031018848,0.0005022628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973271,0.00020998922,0.0016435653,0.00025760685,0.00027011905,0.0002916491],"domain_scores_gemma":[0.9970521,0.0005749395,0.0015436226,0.00037642234,0.00017315669,0.00027978868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010902978,0.00018323255,0.0011881797,0.00015390862,0.00015982345,0.00004379261,0.00026275552,0.00013848285,0.0005897693],"category_scores_gemma":[0.0012285755,0.00013283895,0.00037388722,0.00005410934,0.00015959222,0.00015782111,0.00005336836,0.00085008965,0.00005690172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063020126,0.0036720554,0.82382447,0.000061674844,0.0013522321,0.007198475,0.00041949324,0.00038192145,0.0027404819,0.00025079257,0.0030483496,0.15074806],"study_design_scores_gemma":[0.016396027,0.0052088886,0.96183354,0.00032596482,0.00048395962,0.00069782254,0.00010258618,0.001247311,0.00015070173,0.0008128643,0.012554071,0.00018624784],"about_ca_topic_score_codex":0.00033950078,"about_ca_topic_score_gemma":0.001122223,"teacher_disagreement_score":0.15056182,"about_ca_system_score_codex":0.00029023757,"about_ca_system_score_gemma":0.0018675498,"threshold_uncertainty_score":0.64575595},"labels":[],"label_agreement":null},{"id":"W2892290548","doi":"10.1200/jco.2017.35.15_suppl.6504","title":"Post-discharge transitions of care for hospitalized patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Constipation; Logistic regression; Anxiety; Depression (economics); Cancer; Hospital Anxiety and Depression Scale; Quality of life (healthcare); Proportional hazards model; Hospital discharge; Internal medicine; Physical therapy; Emergency medicine; Nursing; Psychiatry","score_opus":0.04774962478174776,"score_gpt":0.45436998530943545,"score_spread":0.4066203605276877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892290548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950124,0.000563817,0.00016791768,0.0059003737,0.0017826407,0.00039000597,0.00018788906,0.000003898791,0.0015022476],"genre_scores_gemma":[0.9971107,0.00027005246,0.0013083885,0.0006924028,0.00046428363,0.000016664791,0.0000140499005,0.000015220501,0.00010824198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984115,0.00006037271,0.0010190306,0.00012184428,0.00023975437,0.00014751997],"domain_scores_gemma":[0.9954849,0.00029292074,0.0017143424,0.00024219346,0.0020511544,0.00021450648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003877491,0.000094414405,0.0011507344,0.00004638199,0.00009387208,0.000005920599,0.00016923957,0.00018172353,0.0000728217],"category_scores_gemma":[0.0009668422,0.000061971325,0.0004775392,0.000027906126,0.00019847749,0.00013239103,0.000014780137,0.00031596873,6.09699e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046278995,0.0018856536,0.60190403,0.000452763,0.0007721728,0.000049121765,0.0021974067,0.000010714244,0.00019034556,0.00023249871,0.0008444932,0.34518176],"study_design_scores_gemma":[0.025812663,0.038831368,0.8771505,0.00039772794,0.0007701503,0.000008118831,0.00072186906,0.000003986776,0.00016111259,0.00006294909,0.055976156,0.00010341797],"about_ca_topic_score_codex":0.00010116113,"about_ca_topic_score_gemma":0.0017162912,"teacher_disagreement_score":0.34507835,"about_ca_system_score_codex":0.00007695073,"about_ca_system_score_gemma":0.0011771261,"threshold_uncertainty_score":0.2527117},"labels":[],"label_agreement":null},{"id":"W2892293944","doi":"10.1200/jco.2018.36.15_suppl.3056","title":"Initial safety assessment of MAGE-A10<sup>c796</sup>TCR T-cells in two clinical trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T-cell receptor; Clinical trial; Cancer research; Oncology; Internal medicine; T cell; Immunology; Immune system","score_opus":0.3952715896467518,"score_gpt":0.6543995209197939,"score_spread":0.2591279312730421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892293944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94292855,0.00016990895,0.0009142434,0.008599244,0.0037540046,0.0008753873,0.00002114209,0.000014840042,0.042722657],"genre_scores_gemma":[0.97190076,0.0020715368,0.00953853,0.0031898837,0.011605019,0.0000059615586,0.00000588102,0.000051051484,0.0016313902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9738367,0.010814581,0.01292299,0.00047271207,0.0013337503,0.0006192764],"domain_scores_gemma":[0.96057546,0.031327862,0.0047214753,0.00068172434,0.0016322848,0.0010611733],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09385996,0.0002792867,0.0057576452,0.0004823428,0.000048498798,0.000017843642,0.0005817597,0.0009081968,0.009557629],"category_scores_gemma":[0.028914476,0.00020208706,0.0019693598,0.0004652893,0.0015412866,0.00015330991,0.00024351681,0.004357689,0.00009728172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054651264,0.010308318,0.15067944,0.000083037834,0.0013727364,0.0022456157,0.00022277185,0.00007067919,0.0056734052,0.00035636174,0.016980128,0.7573562],"study_design_scores_gemma":[0.113721475,0.08623229,0.29574803,0.0005136931,0.0009894496,0.0006574937,0.00048345397,0.0047884146,0.0016057505,0.0013774083,0.49347523,0.00040734178],"about_ca_topic_score_codex":0.00006827153,"about_ca_topic_score_gemma":0.000121921665,"teacher_disagreement_score":0.7569489,"about_ca_system_score_codex":0.0004042691,"about_ca_system_score_gemma":0.00696723,"threshold_uncertainty_score":0.99866235},"labels":[],"label_agreement":null},{"id":"W2892309170","doi":"10.1200/jco.2018.36.15_suppl.tps3120","title":"An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cancer; Biomarker; Lung cancer; PD-L1; Oncology; Internal medicine; Immunotherapy","score_opus":0.10984176389203318,"score_gpt":0.48741888138114337,"score_spread":0.37757711748911016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892309170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994198,0.0005344235,0.0000101889045,0.00064447604,0.0012532583,0.0028544161,0.000017759203,0.00003085409,0.0004566283],"genre_scores_gemma":[0.99398535,0.000728941,0.0020277882,0.0023035516,0.0007259543,0.00004167145,0.000015937965,0.000073558265,0.00009722702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99418485,0.0013096189,0.002656551,0.0006565835,0.00059687847,0.0005955207],"domain_scores_gemma":[0.99457544,0.000718977,0.00251587,0.0005600171,0.0010351624,0.00059451914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039011613,0.0004218897,0.0021349108,0.00029869017,0.00019017253,0.00006790709,0.00071685057,0.00044287433,0.00017040884],"category_scores_gemma":[0.0002676789,0.00028216268,0.00015690638,0.0004723228,0.00038750764,0.0003812335,0.00009567697,0.0010516972,0.0000030612473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21210377,0.07128179,0.49626014,0.000021661575,0.0007058632,0.00029403524,0.0017265312,0.0000032163855,0.0016175766,3.0698754e-7,0.00054121413,0.21544388],"study_design_scores_gemma":[0.21349496,0.24254909,0.5372589,0.00048645938,0.0002538902,0.000010449638,0.0007349531,0.0017424724,0.0003254503,8.480084e-7,0.0028839854,0.0002585343],"about_ca_topic_score_codex":0.0006924058,"about_ca_topic_score_gemma":0.0017033996,"teacher_disagreement_score":0.21518534,"about_ca_system_score_codex":0.0003744747,"about_ca_system_score_gemma":0.0019927307,"threshold_uncertainty_score":0.99996305},"labels":[],"label_agreement":null},{"id":"W2892311857","doi":"10.1200/jco.2018.36.15_suppl.2500","title":"Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Lapatinib; Trastuzumab; Internal medicine; Oncology; Adverse effect; Cancer; Breast cancer","score_opus":0.2772677226377683,"score_gpt":0.5580802764934101,"score_spread":0.2808125538556418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892311857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863534,0.00068310107,0.000121480676,0.004199671,0.0015360407,0.00035005456,0.000007791392,0.00001443604,0.006734009],"genre_scores_gemma":[0.9938654,0.0008010548,0.002849951,0.00048287972,0.0016778318,0.000004262501,0.000002349788,0.000037563612,0.00027874045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943783,0.0012238533,0.0026224162,0.0003623405,0.0008664144,0.0005466665],"domain_scores_gemma":[0.9944823,0.0016786974,0.0018048821,0.00042007965,0.00107064,0.00054342666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049111717,0.00020751361,0.0020691662,0.00038803654,0.000049645518,0.00001559486,0.00033022623,0.0006010054,0.0007649817],"category_scores_gemma":[0.004693663,0.00016192737,0.00044024416,0.00065608154,0.0009804006,0.0001561314,0.00012121087,0.0017797173,0.000023591687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02141426,0.0072501507,0.42268378,0.00027193013,0.0005414296,0.002181062,0.0007797768,0.000029358007,0.23308824,0.000012627592,0.011988714,0.29975864],"study_design_scores_gemma":[0.0123000285,0.045369867,0.7668623,0.0017320989,0.00019131837,0.00031111072,0.00023307701,0.0005305505,0.058678754,0.0001252479,0.11341407,0.00025162325],"about_ca_topic_score_codex":0.0008580101,"about_ca_topic_score_gemma":0.0008587572,"teacher_disagreement_score":0.34417847,"about_ca_system_score_codex":0.0012930656,"about_ca_system_score_gemma":0.004775215,"threshold_uncertainty_score":0.84710264},"labels":[],"label_agreement":null},{"id":"W2892330548","doi":"10.1200/jco.2017.35.15_suppl.3057","title":"Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Université de Montréal; Hôpital Notre-Dame; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Atezolizumab; Adverse effect; Internal medicine; Melanoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy; Pembrolizumab; Cancer research","score_opus":0.1440716241624101,"score_gpt":0.5033347753420615,"score_spread":0.3592631511796514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892330548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97748965,0.0005174027,0.00006287359,0.01548111,0.0016902373,0.0002361425,0.000006359688,0.0000068579047,0.004509364],"genre_scores_gemma":[0.990221,0.0053574634,0.0017241011,0.0016244788,0.0006029404,0.0000012392115,0.0000020719824,0.000017715154,0.00044899082],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950584,0.0009114195,0.0032140568,0.00026039965,0.00028678478,0.00026889218],"domain_scores_gemma":[0.9932446,0.0024715608,0.0032907892,0.00041766113,0.0002100015,0.00036537385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009505594,0.00016655392,0.0022188956,0.00013286398,0.000105676256,0.000030384337,0.00028819955,0.0004226656,0.0002826458],"category_scores_gemma":[0.0053358823,0.00011703504,0.00061182864,0.00007748629,0.000812043,0.00021874165,0.00010285501,0.0013904482,0.0000130646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084652305,0.0017590353,0.24267748,0.000021387952,0.0010216275,0.0014135911,0.000037630176,4.1123118e-7,0.0002382363,0.000039960385,0.0017939978,0.66634434],"study_design_scores_gemma":[0.02939174,0.010933585,0.8147432,0.000107330525,0.00037391408,0.0006339374,0.000045539397,0.000098855955,0.0000586222,0.00011267841,0.14339723,0.000103350554],"about_ca_topic_score_codex":0.00014129108,"about_ca_topic_score_gemma":0.00035787144,"teacher_disagreement_score":0.666241,"about_ca_system_score_codex":0.00013632844,"about_ca_system_score_gemma":0.0014903287,"threshold_uncertainty_score":0.63879347},"labels":[],"label_agreement":null},{"id":"W2892333922","doi":"10.1200/jco.2018.36.15_suppl.6587","title":"Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Public Health Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Liquid biopsy; Biopsy; Internal medicine; Oncology","score_opus":0.0740725888490928,"score_gpt":0.41440988568009185,"score_spread":0.34033729683099906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892333922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786906,0.018562362,0.000017853006,0.0009559068,0.0013336136,0.00017337898,0.00006320268,0.000001910789,0.00020116431],"genre_scores_gemma":[0.97020996,0.026777636,0.00077872927,0.00078010303,0.0013332134,0.000012730938,0.000006494232,0.000013018267,0.000088091256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985253,0.000093664414,0.00088177616,0.0002434251,0.00006868067,0.00018710627],"domain_scores_gemma":[0.9975545,0.0005063855,0.00091458485,0.00010507939,0.00070409704,0.00021536154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003134249,0.00012673186,0.00050091994,0.00003930864,0.00007689706,0.000011714266,0.00008912603,0.00027044897,0.000027331509],"category_scores_gemma":[0.000759877,0.00009828171,0.00012999991,0.0000401556,0.00047354214,0.0000047610965,0.00015940725,0.00010672839,4.6994654e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026042081,0.0015826483,0.33546323,0.00017911449,0.0054795006,0.000059632577,0.0009604775,0.00001614091,0.2085415,0.00006472328,0.07214794,0.34946302],"study_design_scores_gemma":[0.007311745,0.023372717,0.07413765,0.00010591216,0.0007957517,0.0001296926,0.0002558513,0.000056966328,0.042415544,0.00014848093,0.85097045,0.0002992218],"about_ca_topic_score_codex":0.00007222783,"about_ca_topic_score_gemma":0.0018109732,"teacher_disagreement_score":0.77882254,"about_ca_system_score_codex":0.000027767426,"about_ca_system_score_gemma":0.0007139453,"threshold_uncertainty_score":0.40078115},"labels":[],"label_agreement":null},{"id":"W2892335150","doi":"10.1200/jco.2017.35.15_suppl.e18052","title":"An exploration of how a countries' HTA process can affect patient access.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reimbursement; Internal medicine; Hematology; Oncology; Family medicine; Health care","score_opus":0.7948069652598819,"score_gpt":0.6385099456784047,"score_spread":0.15629701958147724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892335150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87910426,0.00032865125,0.0024032623,0.113305695,0.002597501,0.0003863939,0.00007575633,0.0000072956677,0.0017911814],"genre_scores_gemma":[0.99177897,0.00037927588,0.0010540991,0.0055302717,0.00117367,0.00001588289,0.0000044149688,0.000017469132,0.000045942965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99054813,0.0008015138,0.007951708,0.00028665218,0.0001703774,0.00024164],"domain_scores_gemma":[0.96859366,0.0023799615,0.027580941,0.0005790635,0.0005357121,0.00033069178],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03387445,0.0001352295,0.0023321204,0.00021350895,0.00019675081,0.00015414153,0.0008561716,0.0003536325,0.00012477126],"category_scores_gemma":[0.03243927,0.00013528281,0.00027468894,0.000054546035,0.00025273548,0.0032118636,0.00006379163,0.00043783354,0.00004242794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011791722,0.0025815393,0.8963697,0.0007364627,0.0005728745,0.000044887984,0.00585597,0.0008857141,0.00000459067,0.034803733,0.031532355,0.025433006],"study_design_scores_gemma":[0.009909658,0.019819597,0.6674582,0.0004190391,0.00011698124,0.000050903007,0.0037643937,0.004641915,0.00009127144,0.088939995,0.20405951,0.00072853663],"about_ca_topic_score_codex":0.00023168151,"about_ca_topic_score_gemma":0.0005692746,"teacher_disagreement_score":0.22891149,"about_ca_system_score_codex":0.00028721747,"about_ca_system_score_gemma":0.0015472767,"threshold_uncertainty_score":0.99482954},"labels":[],"label_agreement":null},{"id":"W2892335295","doi":"10.1200/jco.2017.35.15_suppl.e14637","title":"Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Children's Hospital of Eastern Ontario; Queen's University; McMaster University; Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; Juravinski Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Oncolytic virus; Immunology; Immune system; Internal medicine","score_opus":0.09307991895084566,"score_gpt":0.49132386903773057,"score_spread":0.3982439500868849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892335295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942956,0.002955196,0.0003414327,0.0007389246,0.00033377216,0.00094181753,0.00003408666,0.000008882132,0.00035029146],"genre_scores_gemma":[0.9949038,0.0019600654,0.0017839294,0.00032750875,0.0005179221,0.00003534529,0.0000094106,0.00009417519,0.0003678701],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9931033,0.0015458269,0.0030089556,0.0007845383,0.00075592246,0.0008014147],"domain_scores_gemma":[0.99402785,0.0006156382,0.0031264275,0.0010712823,0.00056480785,0.0005939978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0051843366,0.00051639887,0.002327502,0.00034268136,0.00026882498,0.00010645779,0.0011937775,0.00046757882,0.00010006124],"category_scores_gemma":[0.002041069,0.00040878146,0.00034651073,0.00020537198,0.00061162026,0.00011550601,0.00032151814,0.0016843283,0.000006580377],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12445205,0.02093542,0.08844183,0.00022530381,0.0016589949,0.0016090656,0.0006679837,0.00053906674,0.48071188,0.000003294284,0.00045504572,0.28030008],"study_design_scores_gemma":[0.2233668,0.45323056,0.10404031,0.0010049375,0.0017143181,0.0010870359,0.0019762006,0.0012957095,0.20339018,0.0007590608,0.0063111787,0.0018237223],"about_ca_topic_score_codex":0.00007404895,"about_ca_topic_score_gemma":0.0029651716,"teacher_disagreement_score":0.4322951,"about_ca_system_score_codex":0.00012165682,"about_ca_system_score_gemma":0.0018600193,"threshold_uncertainty_score":0.9998364},"labels":[],"label_agreement":null},{"id":"W2892340132","doi":"10.1200/jco.2018.36.15_suppl.tps3621","title":"Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy: A randomized controlled phase III trial—(ACTIVE-2 SAKK 41/14).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Colorectal cancer; Oncology; Tolerability; Chemotherapy; Cancer; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Clinical trial; Progressive disease; Adverse effect","score_opus":0.061365754386437536,"score_gpt":0.4669973376078926,"score_spread":0.40563158322145504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892340132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851377,0.00009284252,0.00021308097,0.0037023015,0.0014428602,0.005410553,0.000021396569,0.00001891183,0.0005842635],"genre_scores_gemma":[0.99580956,0.000340361,0.0003411594,0.00087473576,0.0019850524,0.0004849179,0.0000059519725,0.000035300178,0.00012293668],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944306,0.0019147829,0.002163903,0.00037164846,0.0007228247,0.00039625878],"domain_scores_gemma":[0.9870504,0.007173284,0.0036074098,0.00017898814,0.0015893609,0.0004005332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036485307,0.00033735193,0.0074834004,0.00018170748,0.00006358561,0.000017783525,0.00016773891,0.0002867864,0.0002531014],"category_scores_gemma":[0.0047264933,0.0001912366,0.0012511238,0.00038625678,0.00085043063,0.00017949427,0.000031127645,0.0013190942,0.0000038700487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.759231,0.018488163,0.0035705545,0.00002083033,0.0026039274,0.00006120049,0.0012999522,0.0000034383017,0.000008135781,0.000006031927,0.00017775566,0.21452902],"study_design_scores_gemma":[0.8895776,0.081464514,0.023403902,0.00025229077,0.0018323455,0.0000036749977,0.00011392398,0.0007931739,0.00021200403,0.000119283715,0.0020456566,0.00018158961],"about_ca_topic_score_codex":0.00025948902,"about_ca_topic_score_gemma":0.0032368554,"teacher_disagreement_score":0.21434744,"about_ca_system_score_codex":0.00049833296,"about_ca_system_score_gemma":0.0018488868,"threshold_uncertainty_score":0.77984023},"labels":[],"label_agreement":null},{"id":"W2892348984","doi":"10.1200/jco.2018.36.15_suppl.e17005","title":"The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Discontinuation; Chemotherapy; Toxicity; Internal medicine; Oncology; Cancer; Neutropenia; Androgen deprivation therapy; Febrile neutropenia; Urology","score_opus":0.1890748277089229,"score_gpt":0.5159057343590882,"score_spread":0.32683090665016523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892348984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824584,0.000578498,0.000011080978,0.015831528,0.00019732528,0.00043485296,0.0000038381772,0.0000010057729,0.00048343567],"genre_scores_gemma":[0.99324334,0.005531026,0.00021454625,0.00068236294,0.00020086787,0.000007929672,4.898375e-7,0.000006742813,0.000112691116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976461,0.0006905494,0.0012436867,0.00008779168,0.00018157107,0.00015028795],"domain_scores_gemma":[0.99481636,0.003061014,0.0012838247,0.00009021554,0.0006731105,0.00007544493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055315206,0.00007601669,0.00080558006,0.00007144531,0.000044045864,0.0000059436325,0.00006753758,0.00007936188,0.0000149344105],"category_scores_gemma":[0.0013299703,0.000033212327,0.00011960418,0.00016737056,0.0009064429,0.000067375855,0.000024034054,0.00045000005,5.4110944e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17557278,0.0021070458,0.07110741,0.00025741974,0.0035300392,0.0005456045,0.014880186,0.000024939342,0.042399775,0.00093345915,0.00073708675,0.68790424],"study_design_scores_gemma":[0.10188577,0.02864729,0.7327208,0.00088050787,0.0009402201,0.00027398992,0.0043760915,0.0024785707,0.12017777,0.005204229,0.0022378021,0.00017697697],"about_ca_topic_score_codex":0.00010833708,"about_ca_topic_score_gemma":0.00024337815,"teacher_disagreement_score":0.6877273,"about_ca_system_score_codex":0.00006621781,"about_ca_system_score_gemma":0.0012435735,"threshold_uncertainty_score":0.33398265},"labels":[],"label_agreement":null},{"id":"W2892361194","doi":"10.1200/jco.2017.35.15_suppl.10501","title":"Age-associated vulnerability to treatment-related late cardiotoxicity: A report from the Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Coronary artery disease; Cardiotoxicity; Internal medicine; Cancer; Relative risk; Population; Incidence (geometry); Cumulative incidence; Confidence interval; Cohort; Toxicity","score_opus":0.14259630072283283,"score_gpt":0.48506790070300254,"score_spread":0.34247159998016974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892361194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97484535,0.00028780886,0.000014121649,0.019773442,0.0023182726,0.0010997077,0.000026815687,0.000023997054,0.0016104702],"genre_scores_gemma":[0.99389607,0.00047548048,0.00009159733,0.0028677043,0.0017043245,0.000027652122,0.000009240291,0.000028047194,0.00089985837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950287,0.0012638943,0.0024556338,0.0003974755,0.0005619866,0.00029231005],"domain_scores_gemma":[0.99312246,0.0020394176,0.0028954595,0.00096077693,0.00053957466,0.00044231382],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006437862,0.00023597415,0.0022937225,0.00005293182,0.00034627618,0.000056864832,0.00036571393,0.00054718053,0.00013884976],"category_scores_gemma":[0.011913433,0.00014143556,0.0010653982,0.00011867181,0.00022779139,0.00015657199,0.0000831967,0.0012136764,0.000013247167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023663142,0.0078089666,0.7946845,0.0000039015795,0.008051201,0.004697891,0.002704438,0.0000697187,0.004032716,0.000002321416,0.0026887192,0.17288929],"study_design_scores_gemma":[0.013052311,0.006788421,0.9598539,0.00008899421,0.0013988878,0.00015173391,0.00023068557,0.000011982467,0.001225714,0.00019236685,0.016870596,0.00013440051],"about_ca_topic_score_codex":0.0035328574,"about_ca_topic_score_gemma":0.0046592127,"teacher_disagreement_score":0.17275488,"about_ca_system_score_codex":0.0006458253,"about_ca_system_score_gemma":0.0017174802,"threshold_uncertainty_score":0.99640965},"labels":[],"label_agreement":null},{"id":"W2892367125","doi":"10.1200/jco.2017.35.15_suppl.6545","title":"Exploring the time delay between regulatory approval and health techonology assessments (HTAs) of oncology therapies in France, Germany, England, Scotland, Canada, and Australia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Oncology; Health care; Economic growth","score_opus":0.696622928924642,"score_gpt":0.5648463011343657,"score_spread":0.1317766277902762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892367125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94173664,0.0010505229,0.00007931716,0.055464737,0.0010327904,0.00027464173,0.000041460906,0.0000025327884,0.00031738498],"genre_scores_gemma":[0.99301636,0.0014416503,0.0016536447,0.0029353711,0.0007707231,0.0000140610755,0.000001991817,0.000013805576,0.00015238106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906593,0.0011113932,0.0074764336,0.00029722333,0.000116913136,0.00033876556],"domain_scores_gemma":[0.9837285,0.0042951917,0.011238863,0.00039559847,0.00009498859,0.0002468502],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.045643445,0.00014865088,0.0026257955,0.00019744088,0.0001982419,0.000027102406,0.000457949,0.00028569435,0.00003319523],"category_scores_gemma":[0.0028014772,0.00012790672,0.00010570754,0.00004955507,0.00045794694,0.0004071538,0.00011918031,0.0008243531,0.000010429292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007369164,0.00011238064,0.9678443,0.0000728871,0.00023291058,0.000011845793,0.0005326392,0.000010703166,9.967554e-7,0.0015070997,0.0018971242,0.02770344],"study_design_scores_gemma":[0.0028255214,0.0012622597,0.88999015,0.000057792062,0.00001471734,0.00003429942,0.0001938581,0.00007838231,7.745354e-7,0.0022588882,0.103185326,0.0000980167],"about_ca_topic_score_codex":0.07665068,"about_ca_topic_score_gemma":0.12578194,"teacher_disagreement_score":0.1012882,"about_ca_system_score_codex":0.00046257224,"about_ca_system_score_gemma":0.0020426908,"threshold_uncertainty_score":0.9827109},"labels":[],"label_agreement":null},{"id":"W2892372577","doi":"10.1200/jco.2017.35.15_suppl.4084","title":"Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Sunnybrook Hospital; Princess Margaret Cancer Centre; University of Calgary; University Health Network; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Proportional hazards model; Hazard ratio; Survival analysis; Liver cancer; Internal medicine; Cancer; Gastroenterology; Oncology; Confidence interval","score_opus":0.11353319818788302,"score_gpt":0.37065935299072295,"score_spread":0.25712615480283996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892372577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670255,0.0000832457,0.0000016073433,0.001588868,0.00052875606,0.00057617313,0.00011181004,0.0000035257935,0.00040347563],"genre_scores_gemma":[0.9988641,0.000038722614,0.00044333108,0.00028044177,0.00026358332,0.0000031114175,0.00006593242,0.000021184953,0.000019576715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642897,0.0007537929,0.0017437673,0.0003396137,0.00039562577,0.00033821177],"domain_scores_gemma":[0.9943224,0.0022208379,0.001836018,0.0005312414,0.00038607972,0.0007034202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039760745,0.00023368152,0.0018863344,0.00019957534,0.00010305526,0.000022480046,0.00020464105,0.00030499027,0.000018797786],"category_scores_gemma":[0.0058390494,0.00015126346,0.00024159257,0.000059085352,0.00027436696,0.00017207889,0.00008743485,0.00087966514,0.000006309846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057840034,0.0008471878,0.91863316,0.00003992368,0.00024164755,0.0027756735,0.00016068351,3.9033213e-7,0.000045429784,0.0000024673454,0.000102607315,0.019310817],"study_design_scores_gemma":[0.0476091,0.021201042,0.92819476,0.00040850652,0.00049251947,0.0000064469405,0.000031730073,0.0008378621,0.00062150374,0.0000066021453,0.00047117248,0.000118772376],"about_ca_topic_score_codex":0.030043138,"about_ca_topic_score_gemma":0.019627104,"teacher_disagreement_score":0.020353856,"about_ca_system_score_codex":0.00019184928,"about_ca_system_score_gemma":0.000747158,"threshold_uncertainty_score":0.99826217},"labels":[],"label_agreement":null},{"id":"W2892376413","doi":"10.1200/jco.2018.36.15_suppl.8533","title":"The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Demographics; Exon; Oncology; Stage (stratigraphy); Smoking history; Epidermal growth factor receptor; Exome; Exome sequencing; Mutation; Cancer; Gene; Genetics; Biology; Demography","score_opus":0.038393804658525356,"score_gpt":0.4377770137652252,"score_spread":0.39938320910669983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892376413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97877043,0.0030767045,0.000084931446,0.0034592508,0.0018428733,0.0005606639,0.000004577825,0.0000032883681,0.012197266],"genre_scores_gemma":[0.9971764,0.00040541188,0.0002634194,0.000931956,0.0006346794,0.00002286354,5.8758843e-7,0.000016960023,0.0005477114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769634,0.00041545733,0.001275093,0.00012769287,0.0003088461,0.00017657295],"domain_scores_gemma":[0.9943215,0.0030736409,0.0017935712,0.00026187746,0.00042814913,0.00012124874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022789626,0.00011932775,0.0008113878,0.00005386006,0.000067119196,0.0000028021557,0.00020213675,0.00017078125,0.00018454445],"category_scores_gemma":[0.0010912889,0.00005240379,0.00042223933,0.000080325626,0.00041077897,0.00002445148,0.0000353584,0.00053062564,0.000003420877],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029530123,0.00515308,0.29406744,0.00097249355,0.009055129,0.0010535151,0.005022171,0.00012866418,0.057505433,0.0014145715,0.06106559,0.5350318],"study_design_scores_gemma":[0.040136855,0.13823764,0.24904047,0.0025638014,0.011997127,0.00017174859,0.00054275064,0.0010158088,0.17011552,0.0001624064,0.38564122,0.00037464447],"about_ca_topic_score_codex":0.00007304931,"about_ca_topic_score_gemma":0.000028808166,"teacher_disagreement_score":0.5346572,"about_ca_system_score_codex":0.0004950797,"about_ca_system_score_gemma":0.0022350505,"threshold_uncertainty_score":0.39648837},"labels":[],"label_agreement":null},{"id":"W2892397412","doi":"10.1200/jco.2018.36.30_suppl.260","title":"Safety and clinical efficacy of programmed cell death 1 antibodies (PD-1 Ab) in patients with advanced non-small cell lung cancer (NSCLC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Lung cancer; Pembrolizumab; Gastroenterology; Pneumonitis; Hazard ratio; Atezolizumab; Adverse effect; Clinical trial; Cancer; Proportional hazards model; Oncology; Surgery; Lung; Immunotherapy; Confidence interval","score_opus":0.039853733966512164,"score_gpt":0.42258185502727835,"score_spread":0.3827281210607662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892397412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513763,0.0012291849,0.000087573346,0.0006902646,0.0009681039,0.0006495938,0.0000069187818,0.000006188685,0.0012245466],"genre_scores_gemma":[0.9864505,0.005712235,0.0062435986,0.0008708891,0.0005823454,0.0000029418438,0.0000032238675,0.00002450987,0.00010974929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955497,0.0003263692,0.0031880708,0.00029301725,0.00031539664,0.00032748512],"domain_scores_gemma":[0.9947794,0.0016722946,0.0023604936,0.00022501132,0.00066917925,0.00029358655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026892903,0.00020069764,0.0017903448,0.00013361582,0.00004011486,0.0000066560883,0.00017429328,0.000405714,0.00007050081],"category_scores_gemma":[0.00057904783,0.00012866344,0.0003731887,0.00019620833,0.0006623669,0.00008901858,0.00005760219,0.0008442077,0.0000014420042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081543274,0.0033700755,0.75097424,0.00008321916,0.00027901228,0.000039042745,0.00013939968,0.0000017978801,0.00010975248,9.3041854e-7,0.00025139944,0.16320786],"study_design_scores_gemma":[0.05926115,0.033030275,0.8973853,0.00050060864,0.00040627734,0.000008870242,0.000065110384,0.000048506823,0.0002389436,0.0000030991428,0.008921592,0.00013029],"about_ca_topic_score_codex":0.00007722122,"about_ca_topic_score_gemma":0.00021490816,"teacher_disagreement_score":0.16307756,"about_ca_system_score_codex":0.00013374804,"about_ca_system_score_gemma":0.0016006328,"threshold_uncertainty_score":0.5246743},"labels":[],"label_agreement":null},{"id":"W2892442860","doi":"10.1200/jco.2018.36.30_suppl.53","title":"Improving radiotherapy quality of care: Examining practice patterns in regional centers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Palliative care; Cancer; Life expectancy; Quality of life (healthcare); Radiation therapy; Medical prescription; Prospective cohort study; Internal medicine; Population","score_opus":0.17526520505937593,"score_gpt":0.573836238202545,"score_spread":0.3985710331431691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892442860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97238207,0.0035399173,0.010331369,0.008355556,0.0032654786,0.0001927037,0.0000025476247,0.000007887077,0.0019224463],"genre_scores_gemma":[0.91724694,0.0044438425,0.06303987,0.010640733,0.004550929,0.0000017819094,0.0000014468889,0.000018485342,0.00005597191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953287,0.0011621815,0.0027621945,0.0002000661,0.00032518187,0.00022166903],"domain_scores_gemma":[0.9883426,0.007053282,0.0034946792,0.00022043222,0.00071077433,0.00017825508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00567817,0.00012215314,0.0015377068,0.00015019425,0.000033154814,0.000002633475,0.00019657613,0.00047152236,0.00012682125],"category_scores_gemma":[0.006839313,0.00009045014,0.0002792867,0.0001328817,0.000627502,0.00021436486,0.00002572058,0.0010958689,0.0000018204287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022191342,0.0017486829,0.4917006,0.000084068844,0.0003526351,0.00047378984,0.0014329259,0.0000075629932,0.0019545765,0.00020413141,0.00068204786,0.47916767],"study_design_scores_gemma":[0.024670305,0.053565037,0.69578356,0.00031678076,0.00017013049,0.0012363999,0.0031739122,0.00008619426,0.0002405965,0.00013747346,0.22044402,0.00017556926],"about_ca_topic_score_codex":0.000059618913,"about_ca_topic_score_gemma":0.000095771546,"teacher_disagreement_score":0.47899207,"about_ca_system_score_codex":0.00034299897,"about_ca_system_score_gemma":0.0013829697,"threshold_uncertainty_score":0.8187791},"labels":[],"label_agreement":null},{"id":"W2892443679","doi":"10.1200/jco.2018.36.30_suppl.246","title":"Evolving best practice for take-home cancer drugs in Ontario.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario","funders":"","keywords":"Medicine; Best practice; Pharmacy; Delphi method; Pharmacist; Family medicine; Preparedness; Patient safety; Nursing; Government (linguistics); SAFER; Medical education; Health care","score_opus":0.43400094444135134,"score_gpt":0.6510217887452475,"score_spread":0.21702084430389618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892443679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76080275,0.0003469092,0.0005895598,0.09212737,0.0060892045,0.00070214225,0.000003002266,0.000023237828,0.13931581],"genre_scores_gemma":[0.96455747,0.0005962642,0.025854196,0.0016998511,0.003915033,0.00002968869,1.813703e-7,0.000014772411,0.0033325644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99595594,0.0011287051,0.0016611301,0.00017685858,0.00065100973,0.00042634067],"domain_scores_gemma":[0.98243535,0.013666679,0.0014341713,0.00013279871,0.0020367838,0.00029422343],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024359332,0.00007821543,0.0006608014,0.00016653062,0.00016343988,0.000042054562,0.0006159819,0.0004661906,0.00078690675],"category_scores_gemma":[0.03948163,0.00006638538,0.00023008273,0.00025857534,0.0008244335,0.0005487134,0.00007996552,0.0013310841,0.00003145085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057905796,0.0057804203,0.26384756,0.000024424598,0.00029908997,0.00034614123,0.024132742,0.000010085322,0.00010925987,0.009106139,0.17583077,0.5147228],"study_design_scores_gemma":[0.0014160037,0.0051466026,0.019506492,0.000076922435,0.000042085656,0.000009057922,0.004107392,0.000028723292,0.000013192302,0.005641171,0.96392167,0.00009067257],"about_ca_topic_score_codex":0.09372229,"about_ca_topic_score_gemma":0.60913444,"teacher_disagreement_score":0.78809094,"about_ca_system_score_codex":0.0013555165,"about_ca_system_score_gemma":0.011132584,"threshold_uncertainty_score":0.9944734},"labels":[],"label_agreement":null},{"id":"W2892488632","doi":"10.1200/jco.2018.36.30_suppl.268","title":"An interprofessional pathway for patients initiating treatment with palbociclib: Optimization of toxicity monitoring.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neutropenia; Palbociclib; Toxicity; Internal medicine; Breast cancer; Cancer; Metastatic breast cancer","score_opus":0.10546826391672033,"score_gpt":0.4904770058813342,"score_spread":0.3850087419646139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892488632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762441,0.000041431413,0.021977685,0.00039155464,0.0009653765,0.00024184037,0.000009273729,0.000007848527,0.0001209242],"genre_scores_gemma":[0.8677758,0.000027772256,0.13042891,0.00019469402,0.0015239582,0.000008296432,0.0000046318996,0.000016520373,0.000019430508],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99809295,0.00016189004,0.0012562247,0.00012980719,0.00022040769,0.0001386995],"domain_scores_gemma":[0.9958472,0.00092703855,0.0017490753,0.00012269214,0.0011742339,0.00017975063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064130116,0.000104224426,0.0007885324,0.000065355925,0.00004328817,0.0000027219428,0.00008261515,0.00016486683,0.000039069517],"category_scores_gemma":[0.0006602577,0.00006259738,0.00016111854,0.00006853746,0.00020178898,0.00016806778,0.000013785454,0.0001961553,5.9068543e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027653,0.004015854,0.54749405,0.000027192411,0.0003047485,0.0000128337215,0.0005042398,0.0002914915,0.0005172329,0.000015137258,0.000011228117,0.41915298],"study_design_scores_gemma":[0.05532763,0.46736896,0.45292908,0.0013554773,0.0005510484,0.00010758378,0.0012932528,0.003246857,0.012072068,0.00047489195,0.0050020227,0.00027110163],"about_ca_topic_score_codex":0.000003737433,"about_ca_topic_score_gemma":0.0000051899433,"teacher_disagreement_score":0.46335313,"about_ca_system_score_codex":0.00018717161,"about_ca_system_score_gemma":0.0010080681,"threshold_uncertainty_score":0.25526467},"labels":[],"label_agreement":null},{"id":"W2892576229","doi":"10.1200/jco.2018.36.30_suppl.192","title":"Financial toxicity among patients with lung cancer in a publicly funded health care system.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Logistic regression; Cohort; Lung cancer; Medicaid; Health care; Quality of life (healthcare); Internal medicine; Cancer; Finance; Emergency medicine; Nursing","score_opus":0.064399338631188,"score_gpt":0.3824552573934795,"score_spread":0.3180559187622915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892576229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815462,0.0018596775,0.0005098267,0.0016576205,0.00315383,0.0002773736,0.000102830636,0.000009846752,0.010882787],"genre_scores_gemma":[0.99534553,0.00024317639,0.00052429433,0.002023886,0.0017459999,0.000009796738,0.0000022483441,0.00002177938,0.000083295745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956722,0.00010573847,0.0033548977,0.00033102834,0.000076337434,0.00045979032],"domain_scores_gemma":[0.9943778,0.00022121228,0.00445083,0.00021579902,0.0004309678,0.00030338508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026058718,0.00017370006,0.0018611427,0.00028093928,0.00008942394,0.00003802993,0.00035100826,0.00037961235,0.00018814707],"category_scores_gemma":[0.001227609,0.0001532952,0.0002478814,0.0002461805,0.00028481404,0.0005733848,0.000058099253,0.0006908332,0.000026988717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079175556,0.0002948624,0.966832,0.000047955065,0.00006349204,0.000011337825,0.00042867468,0.000026592315,2.942358e-8,0.0074098655,0.0042393515,0.019854102],"study_design_scores_gemma":[0.004852622,0.004069586,0.95486176,0.00013152842,0.000012347832,0.0000026910768,0.000112723756,0.00013935803,0.0000012535463,0.00042173956,0.035218455,0.00017592777],"about_ca_topic_score_codex":0.002233368,"about_ca_topic_score_gemma":0.017339602,"teacher_disagreement_score":0.030979102,"about_ca_system_score_codex":0.0014221782,"about_ca_system_score_gemma":0.0014866297,"threshold_uncertainty_score":0.9675905},"labels":[],"label_agreement":null},{"id":"W2892595004","doi":"10.1200/jco.2018.36.30_suppl.157","title":"A tale of 2,000 charts: Measuring provider response to patient-reported outcome measures.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Audit; Psychological intervention; Psychosocial; Anxiety; Intervention (counseling); Family medicine; Physical therapy; Psychiatry","score_opus":0.587045078270556,"score_gpt":0.5926294228956958,"score_spread":0.005584344625139792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892595004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652712,0.00005925116,0.00123301,0.029862292,0.0022167135,0.00052937627,0.000004834315,0.000015791298,0.0008075632],"genre_scores_gemma":[0.9765161,0.000026708696,0.0127587905,0.008871856,0.0016130703,0.0000058950613,0.0000012395329,0.000027626273,0.00017867079],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98724955,0.0013983056,0.009712804,0.00028120642,0.0010628832,0.00029525108],"domain_scores_gemma":[0.9802944,0.008627937,0.006128713,0.00045244052,0.003811946,0.00068455766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022663452,0.00016594124,0.0017275229,0.00027625277,0.000046597623,0.000009522895,0.00019448501,0.00034003487,0.0004208269],"category_scores_gemma":[0.24040279,0.00012393961,0.00055809313,0.0003074875,0.00028276548,0.00024237468,0.0001145287,0.0009181721,0.000057723457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1045268,0.0032785723,0.36472654,0.000054222746,0.0008874814,0.00080554903,0.0007334086,0.0000124747685,0.016532151,0.000013568499,0.014964014,0.49346521],"study_design_scores_gemma":[0.015222865,0.053931985,0.5701842,0.00024685916,0.001074879,0.0010140254,0.0007928436,0.000061013245,0.002546274,0.00017013375,0.3545516,0.00020332097],"about_ca_topic_score_codex":0.000071526476,"about_ca_topic_score_gemma":0.000085475236,"teacher_disagreement_score":0.49326187,"about_ca_system_score_codex":0.00022208388,"about_ca_system_score_gemma":0.0024597647,"threshold_uncertainty_score":0.78547454},"labels":[],"label_agreement":null},{"id":"W2892612339","doi":"10.1200/jco.2018.36.30_suppl.45","title":"Using standardized electronic pathology data to identify practice variation, potential impact to patient outcomes, and quality improvement initiatives.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Trillium Health Centre; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Lynch syndrome; Psychological intervention; Guideline; Colorectal cancer; Family medicine; Endometrial cancer; Prostate cancer; Cancer; Internal medicine; Nursing; Pathology","score_opus":0.5252144668557951,"score_gpt":0.6839167250167637,"score_spread":0.1587022581609686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892612339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88601226,0.000054433673,0.075465076,0.03579622,0.001707046,0.0007630485,0.000067821486,0.000011303384,0.0001228169],"genre_scores_gemma":[0.89624435,0.00014645918,0.070199065,0.03202744,0.0013241976,0.0000036733047,0.000023222583,0.00002392667,0.000007651812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9894243,0.0023321211,0.0063820863,0.0005317942,0.00086079736,0.0004688877],"domain_scores_gemma":[0.97988355,0.009244002,0.0054897075,0.0007882303,0.0036917685,0.00090273],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025989678,0.0002164807,0.0016609088,0.00022392858,0.000109071305,0.000045372144,0.0002982056,0.00030204278,0.00023536521],"category_scores_gemma":[0.16768914,0.00016198879,0.00026490304,0.00028525008,0.00015840851,0.0009262791,0.0005740485,0.0010529313,0.000025409858],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09433632,0.007942537,0.08881168,0.000061182334,0.005442718,0.0010260667,0.0023104036,0.00015527093,0.04783909,0.00051285344,0.015262649,0.7362992],"study_design_scores_gemma":[0.01666312,0.061413534,0.8497647,0.000052203613,0.0020400377,0.0008040259,0.0012687885,0.00039370195,0.00013126523,0.000571803,0.06662295,0.00027384944],"about_ca_topic_score_codex":0.00037449092,"about_ca_topic_score_gemma":0.00021404383,"teacher_disagreement_score":0.760953,"about_ca_system_score_codex":0.00074760505,"about_ca_system_score_gemma":0.0050236103,"threshold_uncertainty_score":0.9007555},"labels":[],"label_agreement":null},{"id":"W2892641446","doi":"10.1200/jco.2018.36.30_suppl.101","title":"Active identification of patients appropriate for palliative care: Impact on use of palliative care and home care resources.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Sinai Health System; Ontario Stroke Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Family medicine; Propensity score matching; Intervention (counseling); Curative care; Health care; Ambulatory care; Nursing; Internal medicine","score_opus":0.30532328489630955,"score_gpt":0.5522447707738959,"score_spread":0.24692148587758633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892641446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965094,0.0013993608,0.00019275602,0.00014552906,0.0005484185,0.0005776679,0.0004025785,0.0000041233648,0.0002201937],"genre_scores_gemma":[0.99553055,0.0012838865,0.002461664,0.00012880574,0.0004941381,0.0000077460045,0.000051777068,0.000021983102,0.000019445002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964471,0.0003603184,0.0022611949,0.0002610067,0.0004671533,0.00020321128],"domain_scores_gemma":[0.98553246,0.0034626801,0.004429887,0.0002358046,0.0061166203,0.00022252493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055015966,0.00020537498,0.0017762822,0.00021079004,0.00004347002,0.0000060250404,0.00015746131,0.0004031938,0.000014141474],"category_scores_gemma":[0.0066201645,0.00014001288,0.0005854146,0.00017723224,0.0005889743,0.0001318673,0.000053428354,0.00044121203,0.000001385226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022495015,0.0007446795,0.825339,0.00055536017,0.0010469923,0.000009501899,0.054006394,0.000021018019,0.0004789621,0.000038153572,0.00035850413,0.09490642],"study_design_scores_gemma":[0.008525641,0.03891568,0.92220134,0.00089167774,0.00068255974,4.8172933e-7,0.013412196,0.000024510386,0.008732958,0.00014038234,0.0063490625,0.00012349177],"about_ca_topic_score_codex":0.0000677107,"about_ca_topic_score_gemma":0.000048754042,"teacher_disagreement_score":0.09686236,"about_ca_system_score_codex":0.00033430458,"about_ca_system_score_gemma":0.0006340245,"threshold_uncertainty_score":0.79254335},"labels":[],"label_agreement":null},{"id":"W2892672945","doi":"10.1200/jco.2018.36.30_suppl.99","title":"Imaging progression-free survival: How much does it matter to patients?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Progression-free survival; Quality of life (healthcare); Asymptomatic; Internal medicine; Clinical endpoint; Oncology; Clinical trial; Chemotherapy","score_opus":0.035589810378700654,"score_gpt":0.41298622714132277,"score_spread":0.37739641676262214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892672945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95398706,0.0001286307,0.00081242295,0.036690038,0.004770594,0.00013667365,0.000019826297,0.0000026331543,0.0034520973],"genre_scores_gemma":[0.97249395,0.00027350374,0.0072086193,0.014135714,0.0054675085,0.000004467196,0.000007245908,0.000024815015,0.00038416273],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998242,0.00016818964,0.00089703285,0.00023167733,0.0002177605,0.00024329839],"domain_scores_gemma":[0.99750835,0.0003255516,0.000746276,0.00034694438,0.00076607586,0.00030677696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013060132,0.00012335529,0.00047303844,0.000051156847,0.00005212803,0.000033271983,0.0004490558,0.00020882112,0.00011397045],"category_scores_gemma":[0.0043368605,0.00008193133,0.00024033878,0.000056683413,0.00018596985,0.000006865516,0.00034488112,0.00023762048,0.0000397956],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011478427,0.0006341639,0.46920657,0.000008080107,0.00010982173,0.000028658793,0.000053189306,0.0000025734423,0.0029989264,0.00003550584,0.4373099,0.08846478],"study_design_scores_gemma":[0.0027009621,0.005099417,0.13079596,0.00003165326,0.000053918826,0.000015305053,0.00008716255,0.00000783208,0.0031971626,0.00050573057,0.8573394,0.00016553595],"about_ca_topic_score_codex":0.000008394924,"about_ca_topic_score_gemma":0.00019390609,"teacher_disagreement_score":0.4200295,"about_ca_system_score_codex":0.00003352112,"about_ca_system_score_gemma":0.000425109,"threshold_uncertainty_score":0.519194},"labels":[],"label_agreement":null},{"id":"W2892738222","doi":"10.1200/jco.2018.36.30_suppl.200","title":"Routine collection of EQ-5D-5L derived utility scores in a brain metastases clinic: Correlation with health-related quality of life (FACT-Br).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brain metastasis; Quality of life (healthcare); Radiation therapy; Cancer; Population; Lung cancer; Breast cancer; Metastasis; Internal medicine; Family medicine; Nursing; Environmental health","score_opus":0.6429333884766342,"score_gpt":0.549566297760139,"score_spread":0.09336709071649518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892738222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597903,0.0010351402,0.005059003,0.031244922,0.0013174104,0.0005775652,0.000098350916,0.0000097346065,0.0008675639],"genre_scores_gemma":[0.98951966,0.00020128745,0.005610843,0.004178776,0.000339795,0.00000768397,0.000012824464,0.000019244744,0.000109903085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96658075,0.005749507,0.0266727,0.00041852702,0.00023314242,0.0003453714],"domain_scores_gemma":[0.9435147,0.01790156,0.03706403,0.0004133441,0.0007131105,0.00039325908],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.12365283,0.00019471612,0.00486873,0.00053869514,0.000093375216,0.000010763835,0.0002938346,0.0004939924,0.0007239434],"category_scores_gemma":[0.08319801,0.000189045,0.0004257301,0.0005412716,0.0006233902,0.00041500476,0.000053810465,0.0007642116,0.000074930824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039906725,0.0016200736,0.9776125,0.00024469517,0.00039597633,0.0000020104023,0.0015697442,0.00016974009,0.000005588241,0.0026181673,0.01004878,0.0017220562],"study_design_scores_gemma":[0.008280418,0.008034612,0.9732066,0.0001910639,0.000026995325,0.0000121194835,0.0009512363,0.002523889,0.000009633671,0.004085226,0.0025116624,0.00016658148],"about_ca_topic_score_codex":0.0035622425,"about_ca_topic_score_gemma":0.0056548044,"teacher_disagreement_score":0.040454824,"about_ca_system_score_codex":0.00048498512,"about_ca_system_score_gemma":0.0035914234,"threshold_uncertainty_score":0.9245246},"labels":[],"label_agreement":null},{"id":"W2892873949","doi":"10.1200/jco.2018.36.30_suppl.77","title":"Assessment of language needs and resource use among Canadian immigrant patients with cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Immigration; Language barrier; Limited English proficiency; Interpreter; Health care; Cancer; Population; Family medicine; Demographics; First language; Gerontology; Demography; Environmental health; Linguistics; Pathology; Internal medicine","score_opus":0.12608345482710723,"score_gpt":0.5593030284076734,"score_spread":0.4332195735805662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892873949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898534,0.00009285394,0.000017396002,0.0031587952,0.0006886138,0.00018078306,0.000020320846,0.0000044143076,0.0059834197],"genre_scores_gemma":[0.9949164,0.00010470498,0.001244437,0.0030219026,0.00040349347,0.0000075818807,0.0000028445709,0.0000111594345,0.0002874857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960089,0.0017925276,0.0016754816,0.000084884916,0.000195592,0.00024262349],"domain_scores_gemma":[0.9927194,0.0035225744,0.0019921218,0.00025197046,0.0011177069,0.000396194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029067385,0.00007524361,0.0005978999,0.0001516728,0.00023317996,0.0000038567982,0.00022470696,0.0003012054,0.00016581513],"category_scores_gemma":[0.001675695,0.000050340528,0.00006782254,0.00012467607,0.0003270525,0.00007791626,0.00006290246,0.001289641,0.0000022423594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030771978,0.00008413997,0.9825141,0.000030015763,0.00005399078,0.0000047532967,0.004193532,0.0000014134849,0.0000012413947,0.00018313703,0.002846405,0.009779563],"study_design_scores_gemma":[0.0014539872,0.003132867,0.94556665,0.00049369386,0.000042889234,0.0000014110728,0.005294051,0.000067577916,8.2634364e-7,0.000015083709,0.04388143,0.000049499842],"about_ca_topic_score_codex":0.13752142,"about_ca_topic_score_gemma":0.3120941,"teacher_disagreement_score":0.17457266,"about_ca_system_score_codex":0.00023089942,"about_ca_system_score_gemma":0.0031413622,"threshold_uncertainty_score":0.8682219},"labels":[],"label_agreement":null},{"id":"W2892891221","doi":"10.1200/jco.2018.36.30_suppl.220","title":"Development and initial psychometric validation of the advisor experience survey.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Confirmatory factor analysis; Exploratory factor analysis; Likert scale; Structural equation modeling; Delphi method; Scale (ratio); Construct validity; Construct (python library); Psychology; Public engagement; Medicine; Applied psychology; Psychometrics; Clinical psychology; Developmental psychology; Public relations; Computer science","score_opus":0.48488189930686143,"score_gpt":0.6414973307558779,"score_spread":0.15661543144901646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892891221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843813,0.00010859822,0.00016470884,0.0046152365,0.0051913857,0.00016232344,0.0000025690617,0.0000032919818,0.00537057],"genre_scores_gemma":[0.9850583,0.00019519417,0.00328827,0.010214458,0.0010143509,0.000004463164,7.418701e-7,0.0000062052873,0.00021802016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99453783,0.0020443075,0.0028134277,0.0001071821,0.00028960148,0.00020766801],"domain_scores_gemma":[0.9899897,0.0062610027,0.0026111081,0.00015253687,0.0008141929,0.00017146391],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008737149,0.000070871465,0.00069541566,0.00012733822,0.00024175788,0.0000020831933,0.00025864012,0.00030540486,0.00026442687],"category_scores_gemma":[0.009869477,0.000040546252,0.00009706806,0.0003354385,0.0002680453,0.00010411001,0.0001327982,0.0007795299,0.000020608959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007616812,0.00019227556,0.83194894,0.000036384172,0.00003518635,0.0000022553054,0.0024609081,7.653636e-8,0.000018727134,0.00009389578,0.015521571,0.14892808],"study_design_scores_gemma":[0.001263401,0.0008488096,0.7460558,0.000028885415,0.000012187408,0.0000046282435,0.0002972749,8.654658e-7,0.00008876904,0.00010737482,0.25125927,0.000032789954],"about_ca_topic_score_codex":0.000043806584,"about_ca_topic_score_gemma":0.00026564623,"teacher_disagreement_score":0.23573768,"about_ca_system_score_codex":0.00015128488,"about_ca_system_score_gemma":0.0055485195,"threshold_uncertainty_score":0.9984708},"labels":[],"label_agreement":null},{"id":"W2892955820","doi":"10.1200/jco.2018.36.30_suppl.221","title":"Development of a person-centered patient portal in oncology using stakeholder co-design.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Patient portal; Medicine; Stakeholder; Health care; Workload; Medical emergency; Nursing; Computer science; Public relations","score_opus":0.6156617692443381,"score_gpt":0.5593203835344321,"score_spread":0.05634138570990599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892955820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313825,0.00007621915,0.0023011358,0.0019282481,0.00093474024,0.00035043893,0.0000019274219,0.0000042960332,0.0012647547],"genre_scores_gemma":[0.9032682,0.000036914895,0.09349904,0.002489206,0.0006740638,0.0000025305994,0.0000042388765,0.000012206352,0.000013566778],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99488306,0.00045186625,0.00379975,0.00016014291,0.00041098855,0.00029420725],"domain_scores_gemma":[0.99539876,0.0008068532,0.0028359555,0.00011169181,0.00052923296,0.0003175305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004047559,0.000119024124,0.0013273604,0.0002911856,0.00003695495,0.00000196187,0.00009052869,0.0002630346,0.00048068317],"category_scores_gemma":[0.0013219282,0.00008934759,0.00014450018,0.00017016713,0.00021749605,0.00007921745,0.000023302851,0.00057380606,0.0000065565046],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008649177,0.0041661486,0.14646778,0.000086393426,0.00035284943,0.0011365806,0.0077401428,0.0000043849595,0.0036261003,0.000027090702,0.009402068,0.8183413],"study_design_scores_gemma":[0.04120996,0.09362599,0.56340957,0.00051585864,0.0004220397,0.0018141711,0.015213345,0.0004409446,0.004481959,0.000061682826,0.27855733,0.00024715762],"about_ca_topic_score_codex":0.000029741164,"about_ca_topic_score_gemma":0.0001492269,"teacher_disagreement_score":0.81809413,"about_ca_system_score_codex":0.0003634311,"about_ca_system_score_gemma":0.0059367693,"threshold_uncertainty_score":0.99969864},"labels":[],"label_agreement":null},{"id":"W2892968865","doi":"10.1200/jco.2018.36.30_suppl.73","title":"Underutilization of GnRH analogues (G) and exemestane (E) in young patients with early-stage breast cancer (BC) in Ontario.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Tamoxifen; Exemestane; Breast cancer; Population; Internal medicine; Gynecology; Adjuvant; Oncology; Adjuvant therapy; Stage (stratigraphy); Cancer; Oophorectomy; Surgery; Hysterectomy","score_opus":0.06466246384608657,"score_gpt":0.41658067563930484,"score_spread":0.35191821179321825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892968865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982491,0.00009876135,0.000184703,0.0006126315,0.0002869824,0.0001543234,0.000005342314,0.0000026693372,0.00040545186],"genre_scores_gemma":[0.9978355,0.00014964858,0.0014488479,0.00025939848,0.00016694574,0.000002218525,0.000002355867,0.000012392579,0.00012268068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800134,0.00013814284,0.0012875394,0.00015062183,0.00025281528,0.0001695419],"domain_scores_gemma":[0.9979533,0.00026453106,0.0010229673,0.000105145366,0.00052442483,0.00012960672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000723441,0.00010510107,0.0008988087,0.00017587366,0.000012819329,0.0000031133118,0.0000706722,0.00017254328,0.00014266401],"category_scores_gemma":[0.00019593388,0.00007332777,0.000058226367,0.00018713999,0.0004028549,0.00018514012,0.000025379437,0.0005090394,6.435358e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009040446,0.0006804729,0.9604511,0.000019004565,0.00007977822,0.00005533702,0.00064383115,0.000018526962,0.000025290221,0.000032239794,0.000007087655,0.02894687],"study_design_scores_gemma":[0.011387789,0.0057056486,0.9811814,0.00033357574,0.00006313122,0.00005573,0.00016507976,0.000025200552,0.000017123351,0.00016983273,0.0008334347,0.00006204586],"about_ca_topic_score_codex":0.019159947,"about_ca_topic_score_gemma":0.43517566,"teacher_disagreement_score":0.4160157,"about_ca_system_score_codex":0.0003975881,"about_ca_system_score_gemma":0.0011874922,"threshold_uncertainty_score":0.98737156},"labels":[],"label_agreement":null},{"id":"W2893082622","doi":"10.1200/jco.2018.36.30_suppl.103","title":"Impact of novel chronic lymphocytic leukemia drugs on public spending.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Ibrutinib; Chronic lymphocytic leukemia; Bendamustine; Obinutuzumab; Population; Ofatumumab; Rituximab; Fludarabine; Alemtuzumab; Leukemia; Internal medicine; Lymphoma; Environmental health; Chemotherapy; Cyclophosphamide; Transplantation","score_opus":0.20370372919790636,"score_gpt":0.5267540615955266,"score_spread":0.32305033239762027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893082622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774703,0.00026832276,0.00017972302,0.0008007379,0.00139779,0.00026725416,0.0000059815916,0.000017406386,0.019592501],"genre_scores_gemma":[0.9917003,0.00040788503,0.0011969771,0.00053658546,0.0054447493,0.0000023469195,0.0000028941347,0.000044815308,0.0006634512],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99396384,0.0003568822,0.0033949728,0.0003496933,0.0012110345,0.00072355627],"domain_scores_gemma":[0.9903282,0.004254339,0.002472127,0.0006411507,0.001266577,0.0010375958],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060484237,0.00026356432,0.0022928643,0.0005158837,0.00006207722,0.000019171148,0.0005927977,0.0006961295,0.0012170207],"category_scores_gemma":[0.011221144,0.00017353872,0.001400399,0.0005218619,0.001280817,0.00019279693,0.00018267054,0.00133358,0.0002471015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07122121,0.011009452,0.043330785,0.0007152035,0.010109826,0.0043738517,0.0010431847,0.0011195021,0.013855709,0.0043698344,0.07535419,0.76349723],"study_design_scores_gemma":[0.34526855,0.33825624,0.1600677,0.0014309555,0.0011216026,0.009913634,0.00020994946,0.069058664,0.0024081469,0.00045960705,0.07112891,0.00067602476],"about_ca_topic_score_codex":0.00036119457,"about_ca_topic_score_gemma":0.00005036174,"teacher_disagreement_score":0.7628212,"about_ca_system_score_codex":0.14322068,"about_ca_system_score_gemma":0.25077146,"threshold_uncertainty_score":0.999696},"labels":[],"label_agreement":null},{"id":"W2893103876","doi":"10.1200/jco.2018.36.30_suppl.187","title":"Defining a patient-reported outcome measure (PROM) selection process: What criteria should be considered when choosing a PROM for routine symptom assessment in clinical practice?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; Queen's University; Windsor Regional Hospital; McGill University; Juravinski Cancer Centre","funders":"","keywords":"Prom; Medicine; Patient-reported outcome; Usability; Reliability (semiconductor); Medical physics; Physical therapy; Computer science; Quality of life (healthcare); Nursing","score_opus":0.2542732604837206,"score_gpt":0.5486111306380751,"score_spread":0.2943378701543545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893103876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93999434,0.0007165128,0.0022388578,0.046718594,0.0075789825,0.0013274669,0.000006038535,0.00004419261,0.001375014],"genre_scores_gemma":[0.9586302,0.00014328367,0.02504366,0.013769442,0.002259969,0.000058338974,0.000010609749,0.000046534158,0.00003796375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99004894,0.0013271279,0.0067820917,0.0005241336,0.0008449576,0.0004727255],"domain_scores_gemma":[0.9847063,0.005581589,0.005187873,0.0002805906,0.00374731,0.0004963666],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014845025,0.00027716235,0.0023558545,0.0002320317,0.00010534926,0.000100804114,0.00016254693,0.0008842951,0.00014764135],"category_scores_gemma":[0.040122487,0.00021670977,0.0006755408,0.00029833513,0.00026895324,0.00084539666,0.00006259738,0.002246394,0.0000030999288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019689234,0.004301182,0.73917496,0.0002091379,0.0010943442,0.0005151238,0.0029732601,0.000003616309,0.00011816491,0.0001254188,0.0037755729,0.22802],"study_design_scores_gemma":[0.060184266,0.111626945,0.6355596,0.0038845344,0.005291276,0.005254218,0.020417525,0.0026499785,0.0002890936,0.0029232493,0.15093353,0.0009857714],"about_ca_topic_score_codex":0.0001008458,"about_ca_topic_score_gemma":0.0012487428,"teacher_disagreement_score":0.22703423,"about_ca_system_score_codex":0.00048663674,"about_ca_system_score_gemma":0.00565197,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W2893178393","doi":"10.1200/jco.2018.36.30_suppl.36","title":"Cancer survival outcomes in Ontario, Canada: Significant unexplained variation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Cancer Care South East; Queen's University","funders":"","keywords":"Medicine; Cancer registry; Cancer; Colorectal cancer; Proportional hazards model; Cohort; Prostate cancer; Lung cancer; Breast cancer; Socioeconomic status; Demography; Internal medicine; Oncology; Population; Environmental health","score_opus":0.31103441094530004,"score_gpt":0.49716017721942923,"score_spread":0.1861257662741292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893178393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97329366,0.00007004623,0.0001265694,0.015921408,0.003836666,0.00010366124,0.000002760339,0.0000037184454,0.0066414988],"genre_scores_gemma":[0.99112797,0.000046227346,0.0014597898,0.0052376958,0.0011836041,0.000002673011,8.689998e-7,0.000007376376,0.0009338015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968709,0.00022233311,0.0019664676,0.00015459109,0.00053169153,0.00025405877],"domain_scores_gemma":[0.9967421,0.0011270074,0.0010232234,0.00013626968,0.00064945937,0.00032192693],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027577246,0.00010813786,0.001316134,0.00007722493,0.00003411406,0.000005889545,0.00016416963,0.00021256793,0.00120183],"category_scores_gemma":[0.002969949,0.00007564925,0.00019095195,0.00013962678,0.00011885597,0.00009405196,0.000031993473,0.0008805018,0.000005308881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019843047,0.00023145184,0.9803926,0.000003576645,0.00017740185,0.0007156047,0.00013838586,0.000026297717,0.00006349047,0.00014512842,0.009377232,0.006744557],"study_design_scores_gemma":[0.003934407,0.003179647,0.92507243,0.00006441377,0.00011657107,0.000039030583,0.00013863933,0.00004467047,0.000019342662,0.00014813223,0.067170985,0.00007173927],"about_ca_topic_score_codex":0.9419163,"about_ca_topic_score_gemma":0.99718785,"teacher_disagreement_score":0.05779375,"about_ca_system_score_codex":0.0015655598,"about_ca_system_score_gemma":0.022065518,"threshold_uncertainty_score":0.9997112},"labels":[],"label_agreement":null},{"id":"W2893189908","doi":"10.1200/jco.2018.36.30_suppl.42","title":"A descriptive analysis of clinician input and feedback into the CADTH pan-Canadian Oncology Drug Review process.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Family medicine; Reimbursement; Cancer; Breast cancer; Internal medicine; Health care; Oncology","score_opus":0.5509671481621732,"score_gpt":0.5776254028922917,"score_spread":0.026658254730118514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893189908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67884785,0.028387573,0.00031197944,0.27818698,0.0023135694,0.0007427599,0.00007148426,0.000007311385,0.011130467],"genre_scores_gemma":[0.9022782,0.018761368,0.0024585803,0.07488187,0.0013686614,0.000016968213,0.000004850284,0.000020032514,0.00020949461],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98280746,0.002249201,0.014028997,0.0003986872,0.00014422159,0.000371429],"domain_scores_gemma":[0.97322065,0.008458222,0.016381664,0.00044257153,0.0008828978,0.0006139766],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.086469375,0.00018015779,0.004585355,0.0006788847,0.00017086425,0.000020857795,0.0005981102,0.00043187477,0.0005007403],"category_scores_gemma":[0.039493065,0.00014804164,0.0006294028,0.0007567978,0.00087350124,0.0002995084,0.00006773177,0.00083798263,0.000204425],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006677877,0.0013684747,0.60819054,0.0013127065,0.008634027,0.00004149536,0.029673481,0.00004717769,9.3479497e-7,0.02039925,0.19245397,0.13721015],"study_design_scores_gemma":[0.0019066674,0.003789666,0.3049111,0.0005178651,0.001107033,0.000028387592,0.004196287,0.0011958409,0.000001004667,0.014500081,0.6675759,0.00027019085],"about_ca_topic_score_codex":0.014528751,"about_ca_topic_score_gemma":0.14207137,"teacher_disagreement_score":0.47512192,"about_ca_system_score_codex":0.00077229616,"about_ca_system_score_gemma":0.004377367,"threshold_uncertainty_score":0.9920336},"labels":[],"label_agreement":null},{"id":"W2893197549","doi":"10.1200/jco.2018.36.30_suppl.40","title":"Tiers of service: Outpatient medical oncology services for British Columbia, Canada.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health; Spinal Cord Injury BC","funders":"","keywords":"Medicine; General partnership; Service (business); Health care; Family medicine; Nursing; Business; Political science; Marketing","score_opus":0.07371395506120224,"score_gpt":0.36796245009870066,"score_spread":0.2942484950374984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893197549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574235,0.0011919558,0.0005608444,0.010511166,0.008340711,0.00023906807,0.00023683537,0.0000052389187,0.021490647],"genre_scores_gemma":[0.97581464,0.0006862835,0.0021664884,0.01785998,0.00275756,0.000007654941,0.000005636009,0.000024750427,0.00067699695],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.994911,0.00007315566,0.0042881668,0.00025766596,0.00011208277,0.00035793765],"domain_scores_gemma":[0.9925686,0.0010792249,0.004878641,0.00018892785,0.0007890845,0.00049547973],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004403148,0.00010612351,0.0019887602,0.0000675575,0.00007831603,0.00003104124,0.00060074625,0.00069897494,0.0012893766],"category_scores_gemma":[0.0029424576,0.00014608158,0.00033502112,0.00013005816,0.00030594546,0.00020588371,0.00008589182,0.0005136413,0.000022602087],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014255414,0.0016682692,0.41534135,0.00023410133,0.0008058981,0.00012096214,0.00054407696,0.000017841641,0.000001851321,0.0041535767,0.21211535,0.3635712],"study_design_scores_gemma":[0.0037381207,0.006221623,0.13655634,0.00006502431,0.000035526882,0.000053742504,0.00016516501,0.00036340585,0.0000031862028,0.008540569,0.8441045,0.00015274993],"about_ca_topic_score_codex":0.5154865,"about_ca_topic_score_gemma":0.9693991,"teacher_disagreement_score":0.6319892,"about_ca_system_score_codex":0.00048059167,"about_ca_system_score_gemma":0.005580097,"threshold_uncertainty_score":0.9996236},"labels":[],"label_agreement":null},{"id":"W2893237370","doi":"10.1200/jco.2018.36.30_suppl.2","title":"Can administrative data improve the performance of clinical trial economic analyses?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Ontario Institute for Cancer Research; Sunnybrook Hospital; Institute for Clinical Evaluative Sciences; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Confidence interval; Cetuximab; Randomized controlled trial; Economic evaluation; Emergency medicine; Internal medicine; Cancer; Colorectal cancer","score_opus":0.9126761815013912,"score_gpt":0.7028486602167052,"score_spread":0.20982752128468596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893237370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384887,0.0003495945,0.00019845113,0.04509522,0.010150167,0.0005367622,0.00034981666,0.000006185354,0.0048250537],"genre_scores_gemma":[0.9763229,0.0006684604,0.003035656,0.007668119,0.01198759,0.000008154611,0.000013966286,0.000020584921,0.00027458527],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.969987,0.0024196024,0.02651885,0.000561694,0.00015755108,0.00035534892],"domain_scores_gemma":[0.94807154,0.017656354,0.0321821,0.0013231331,0.00035502925,0.00041184088],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.13560095,0.00019382195,0.0040843445,0.00017953986,0.00014105254,0.00003528945,0.001703444,0.00053709495,0.0006028634],"category_scores_gemma":[0.046302114,0.00015428248,0.00067055464,0.00012354339,0.0010397877,0.0005535854,0.0002550138,0.0010623242,0.00046778822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07910004,0.0063708397,0.47368222,0.00034214888,0.0070266603,0.00003458999,0.0024934714,0.00023365195,0.000012274722,0.0389861,0.31058997,0.081128016],"study_design_scores_gemma":[0.083062254,0.06497212,0.23527582,0.00012646156,0.00041048083,0.000070705326,0.0018097977,0.034944236,0.00004861509,0.009444598,0.56913155,0.0007033564],"about_ca_topic_score_codex":0.0003052671,"about_ca_topic_score_gemma":0.00075263064,"teacher_disagreement_score":0.25854158,"about_ca_system_score_codex":0.00027837337,"about_ca_system_score_gemma":0.0050851167,"threshold_uncertainty_score":0.9617313},"labels":[],"label_agreement":null},{"id":"W2893312979","doi":"10.1200/jco.2018.36.30_suppl.197","title":"Comparison of health utility values from EQ-5D-3L and EQ-5D-5L in patients with breast cancer in different health states.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"EQ-5D; Medicine; Breast cancer; Cancer; Demography; Internal medicine; Disease; Health related quality of life","score_opus":0.6078438354652338,"score_gpt":0.5560102824382559,"score_spread":0.0518335530269779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893312979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440999,0.002152138,0.0003679009,0.05136941,0.001042504,0.00044839398,0.00044162772,0.0000042954425,0.000073796575],"genre_scores_gemma":[0.99051094,0.0008639312,0.0011240455,0.0069871657,0.00046518038,0.0000073245255,0.000013753842,0.00001728581,0.000010396327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9822588,0.0022140949,0.014458687,0.0004334968,0.00018643809,0.0004484911],"domain_scores_gemma":[0.9815112,0.0034295055,0.014127126,0.00028342314,0.00024038092,0.0004084005],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.029703788,0.0001939749,0.0045708874,0.00032516828,0.00007311979,0.00001651769,0.0002554339,0.00025258807,0.00028149103],"category_scores_gemma":[0.0022228141,0.00017025626,0.00013224913,0.00016441186,0.00034842876,0.00026728294,0.000071542374,0.00071173854,0.000017157563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071819354,0.0016920875,0.96881527,0.00011772538,0.00008005427,5.790991e-7,0.001997574,0.00004165613,2.5741869e-8,0.00017072195,0.0034020848,0.022964058],"study_design_scores_gemma":[0.00586888,0.004151519,0.9800207,0.0003069868,0.000006854814,0.0000011118618,0.00066823734,0.0025783256,2.4341387e-7,0.0037224987,0.0025439535,0.00013067492],"about_ca_topic_score_codex":0.010223882,"about_ca_topic_score_gemma":0.013377596,"teacher_disagreement_score":0.046410985,"about_ca_system_score_codex":0.0011258835,"about_ca_system_score_gemma":0.0016606877,"threshold_uncertainty_score":0.9991241},"labels":[],"label_agreement":null},{"id":"W2893322250","doi":"10.1200/jco.2018.36.30_suppl.184","title":"Experience and outcomes of the Acute Leukemia Shared-Care Program.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Retrospective cohort study; Intervention (counseling); Patient satisfaction; Health care; Patient experience; Family medicine; Emergency medicine; Nursing; Internal medicine","score_opus":0.11186251145139145,"score_gpt":0.5253788766302638,"score_spread":0.41351636517887236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893322250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899341,0.00011810121,0.000010466897,0.0037118436,0.0013273797,0.0001588543,0.000002015472,0.000005578852,0.0047316817],"genre_scores_gemma":[0.9958142,0.00017137421,0.0013307148,0.0017906143,0.0006112229,0.0000057760035,1.7224686e-7,0.0000055336363,0.00027037377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986098,0.000092666785,0.0009275633,0.00009002965,0.00017628822,0.00010367101],"domain_scores_gemma":[0.99819595,0.0003066815,0.00074447517,0.00015976634,0.00045382272,0.00013931438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003743819,0.000062691666,0.0006442429,0.000029652678,0.000050560026,0.0000055743462,0.00013091319,0.00014006582,0.00012526283],"category_scores_gemma":[0.0007360384,0.000031631705,0.00026755815,0.000095629606,0.00057723164,0.000070114234,0.00006780183,0.00042445678,0.0000039899905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057934714,0.00025067537,0.8509539,0.000012343012,0.00021297352,0.000037149788,0.0006680801,2.1577421e-7,0.000357021,0.00008467504,0.0023405056,0.14450316],"study_design_scores_gemma":[0.00215067,0.0072806147,0.87469745,0.000045311128,0.00028388848,0.0002694693,0.00032122168,0.0000030512708,0.00052333705,0.00005756828,0.11433611,0.000031329528],"about_ca_topic_score_codex":0.0000104976025,"about_ca_topic_score_gemma":0.00002823864,"teacher_disagreement_score":0.14447184,"about_ca_system_score_codex":0.0000784382,"about_ca_system_score_gemma":0.0009482258,"threshold_uncertainty_score":0.2126834},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2893550988","doi":"10.1200/jco.2018.36.30_suppl.233","title":"Lessons learned from the investigation of a sustained increase in paclitaxel hypersensitivity reactions (P-HSR) at a large community oncology practice: A mystery not fully solved.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Medicine; Premedication; Compounding; Protocol (science); Anesthesia; Oncology; Pharmacology; Alternative medicine","score_opus":0.24896799413529722,"score_gpt":0.4966592168383393,"score_spread":0.24769122270304209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893550988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86766696,0.00007880021,0.00018681491,0.12828937,0.00047546922,0.00034348495,0.000033867203,0.000015910135,0.0029093085],"genre_scores_gemma":[0.98093295,0.00041399186,0.0041498323,0.013341482,0.0009528149,0.000005418391,0.000016361766,0.00002774395,0.00015942915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98628813,0.00958533,0.0030215983,0.00025208123,0.00047407014,0.0003787745],"domain_scores_gemma":[0.9522893,0.040554643,0.0044447086,0.0007083395,0.0015603509,0.00044270192],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021269234,0.00021365324,0.0018285788,0.00018711072,0.00023782723,0.00001015952,0.0002830728,0.0010284481,0.00012588335],"category_scores_gemma":[0.06748184,0.00015212432,0.00048083332,0.00042040303,0.0013203522,0.00026665762,0.00023139591,0.004292141,0.00002435794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21993403,0.03756382,0.25684515,0.0002390125,0.005417395,0.004719869,0.037128557,0.000035714053,0.22202437,0.0015198872,0.029802693,0.18476951],"study_design_scores_gemma":[0.040971875,0.026861722,0.72942436,0.0006721894,0.0017528804,0.0022145577,0.021950126,0.0010257055,0.0038141666,0.0042022816,0.16675426,0.00035588467],"about_ca_topic_score_codex":0.0025058892,"about_ca_topic_score_gemma":0.008483802,"teacher_disagreement_score":0.4725792,"about_ca_system_score_codex":0.0011075486,"about_ca_system_score_gemma":0.003871959,"threshold_uncertainty_score":0.998005},"labels":[],"label_agreement":null},{"id":"W2893562808","doi":"10.1200/jco.2018.36.30_suppl.94","title":"Inclusion of health-related quality-of-life data in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Reimbursement; Medicine; Quality of life (healthcare); Economic evaluation; Inclusion (mineral); Family medicine; Quality-adjusted life year; Clinical trial; Health care; Cost effectiveness; Internal medicine; Nursing","score_opus":0.7944834876836229,"score_gpt":0.641942368348441,"score_spread":0.15254111933518189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893562808","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003613719,0.7593135,0.000014048973,0.23305401,0.0024795393,0.0028391974,0.00082305976,0.0000023679606,0.0011128552],"genre_scores_gemma":[0.00055792177,0.9545474,0.0010862551,0.04297534,0.00041461052,0.00007842859,0.00016543717,0.000050809507,0.00012379029],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8808547,0.030905636,0.08536946,0.0011613708,0.00065647124,0.0010523353],"domain_scores_gemma":[0.8462198,0.04418334,0.10327359,0.003201273,0.0010482607,0.0020737296],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.31444123,0.0005281607,0.024598699,0.0013146712,0.0001873322,0.00000518279,0.0035294904,0.00095266744,0.00084456976],"category_scores_gemma":[0.16639578,0.0004308501,0.0011174226,0.001473947,0.00035173137,0.00021161282,0.00143853,0.0027902576,0.00008803629],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000983257,0.0011560665,0.0026547213,0.09427572,0.00049636443,0.00003063887,0.00071118964,0.000008068175,1.505936e-8,0.0017709001,0.54121923,0.35757875],"study_design_scores_gemma":[0.0011919308,0.000874127,0.0027613407,0.118267424,0.00018326753,0.000027777549,0.00031076788,0.00002143692,1.2209783e-8,0.00042616657,0.8756591,0.00027666043],"about_ca_topic_score_codex":0.85345554,"about_ca_topic_score_gemma":0.9712458,"teacher_disagreement_score":0.3573021,"about_ca_system_score_codex":0.011510966,"about_ca_system_score_gemma":0.16467483,"threshold_uncertainty_score":0.99981433},"labels":[],"label_agreement":null},{"id":"W2893595884","doi":"10.1200/jco.2018.36.30_suppl.16","title":"Quality of care during active surveillance in low-risk prostate cancer patients: A population-based approach.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Population; Benchmarking; Prostate cancer; Health care; MEDLINE; Quality management; Cancer registry; Family medicine; Watchful waiting; Cancer; Intensive care medicine; Environmental health; Internal medicine; Operations management","score_opus":0.2328897678498223,"score_gpt":0.5786830667521957,"score_spread":0.3457932989023734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893595884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700004,0.00006548849,0.00013991572,0.0013509074,0.000735234,0.00043954924,0.000053910375,0.0000058703085,0.00020906312],"genre_scores_gemma":[0.9946391,0.00016135699,0.0036729495,0.00068352424,0.0007785144,0.000008111486,0.000031895357,0.000015550675,0.000008974657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915818,0.0015026799,0.00598563,0.00023047796,0.00050122075,0.00019820269],"domain_scores_gemma":[0.98349726,0.00667484,0.007109729,0.00019861972,0.002334111,0.00018546083],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056539527,0.00012266428,0.0013926594,0.00014386492,0.00003612906,0.000004063739,0.000116070325,0.00025140014,0.00008473881],"category_scores_gemma":[0.057083137,0.00009536625,0.00031929035,0.00025363726,0.00017532824,0.0001806232,0.00003977167,0.00087180483,0.0000026706196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0170178,0.0016319057,0.9208382,0.00014904025,0.0001012309,0.0000075246044,0.00034619367,0.00026151357,0.00003306692,0.0000032863682,0.000057428897,0.059552826],"study_design_scores_gemma":[0.016485004,0.00517553,0.97659534,0.00013409302,0.00009131793,0.0000024375288,0.0006201836,0.0002916768,0.0000863168,0.000053170003,0.00038013564,0.00008479491],"about_ca_topic_score_codex":0.0016639739,"about_ca_topic_score_gemma":0.0034650357,"teacher_disagreement_score":0.05946803,"about_ca_system_score_codex":0.00043604933,"about_ca_system_score_gemma":0.0016316614,"threshold_uncertainty_score":0.9508594},"labels":[],"label_agreement":null},{"id":"W2893613554","doi":"10.1200/jco.2018.36.30_suppl.27","title":"Representativeness of oncology clinical trials in Alberta.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Cohort; Population; Cancer; Comorbidity; Logistic regression","score_opus":0.9138878559671506,"score_gpt":0.8102880672203882,"score_spread":0.10359978874676246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893613554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88673407,0.0002145786,0.00041861425,0.054249913,0.005518748,0.000593746,0.0000037982575,0.0000067111273,0.052259844],"genre_scores_gemma":[0.97229403,0.0041236514,0.01112825,0.004411385,0.006092254,0.000006768219,0.0000016339127,0.00003088355,0.0019111456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.93673587,0.03099858,0.029010577,0.0007318775,0.001843187,0.0006799009],"domain_scores_gemma":[0.14769933,0.8275295,0.015415925,0.0011693935,0.0065606707,0.0016252006],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.32822517,0.00020012123,0.007970245,0.00041457274,0.00003608852,0.0000076096785,0.0007454369,0.003129218,0.001022864],"category_scores_gemma":[0.80988073,0.00013677344,0.002132616,0.0005406251,0.003943579,0.00013449945,0.00035021937,0.008712906,0.00011317236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04445684,0.010326759,0.58532816,0.00013833531,0.0009821602,0.0013133279,0.00036253998,0.0000034384543,0.0003039878,0.006402336,0.0070126397,0.34336945],"study_design_scores_gemma":[0.03762764,0.121006265,0.5916383,0.00086211314,0.00065014,0.00039982094,0.00059308007,0.00015089668,0.00073716696,0.055865396,0.19026138,0.00020776987],"about_ca_topic_score_codex":0.0003259409,"about_ca_topic_score_gemma":0.002668444,"teacher_disagreement_score":0.7965309,"about_ca_system_score_codex":0.00025579266,"about_ca_system_score_gemma":0.014541853,"threshold_uncertainty_score":0.9998903},"labels":[],"label_agreement":null},{"id":"W2893725430","doi":"10.1200/jco.2018.36.30_suppl.191","title":"The impact of routine ESAS use on receiving palliative care services: Results of a population-based retrospective matched cohort analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University; Health Sciences Centre; Sunnybrook Hospital; Ontario Institute for Cancer Research; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Retrospective cohort study; Cohort; Propensity score matching; Cancer; Emergency medicine; Cohort study; Population; Family medicine; Intensive care medicine; Internal medicine; Nursing","score_opus":0.23952682546363677,"score_gpt":0.5606786819047199,"score_spread":0.32115185644108313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893725430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997481,0.00024810826,0.00008809756,0.0007095158,0.00025840962,0.00020057695,0.00007073634,0.0000050061285,0.0009385482],"genre_scores_gemma":[0.9966672,0.00045471673,0.0021131507,0.0001987603,0.00047552172,0.0000013877293,0.00003341878,0.000012384585,0.0000434608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953031,0.000673136,0.0030685717,0.00020925913,0.0005539455,0.00019201824],"domain_scores_gemma":[0.9820492,0.008340886,0.005454911,0.000383824,0.0035894206,0.00018173845],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030640175,0.00016548937,0.0023420672,0.0002305885,0.000050167484,0.000006083437,0.00021018245,0.0003045646,0.000036341746],"category_scores_gemma":[0.014000138,0.00009202184,0.0011717121,0.00064848916,0.00030595754,0.0000773107,0.000032189233,0.0005550231,0.0000017434351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013590937,0.00045891386,0.97839886,0.000037991613,0.0035335245,0.0000198188,0.0019174356,0.0004689673,0.00007919857,0.000021889762,0.0001920836,0.001280387],"study_design_scores_gemma":[0.005288697,0.0151701,0.9741578,0.0007404588,0.0017462987,0.0000012275964,0.0011162368,0.00083881675,0.0004773742,0.000103716826,0.00028856983,0.00007071362],"about_ca_topic_score_codex":0.0026618915,"about_ca_topic_score_gemma":0.0015982616,"teacher_disagreement_score":0.014711186,"about_ca_system_score_codex":0.00042946776,"about_ca_system_score_gemma":0.000792576,"threshold_uncertainty_score":0.9943054},"labels":[],"label_agreement":null},{"id":"W2893741950","doi":"10.1200/jco.2018.36.30_suppl.54","title":"Pathology quality improvement in British Columbia using performance measurement and knowledge mobilization.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer; Provincial Health Services Authority; Royal Jubilee Hospital; University of British Columbia; Island Health","funders":"","keywords":"Medicine; Data collection; Data quality; Health care; Documentation; Benchmarking; Quality management; Medical physics; Operations management; Computer science; Statistics; Metric (unit)","score_opus":0.5554200309743909,"score_gpt":0.6004611995022975,"score_spread":0.04504116852790663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893741950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954519,0.0002789447,0.0010762468,0.0012716667,0.0012784547,0.00032057657,0.0000017834557,0.0000058994888,0.00031452987],"genre_scores_gemma":[0.98684543,0.0007204588,0.0088567585,0.002277423,0.001231067,0.000003478776,0.0000014750686,0.000012387414,0.000051522977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932767,0.0008291278,0.0050398926,0.000240218,0.0003976815,0.00021636652],"domain_scores_gemma":[0.9937379,0.0016587152,0.0022092734,0.00016106994,0.0019913616,0.00024169592],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021797584,0.00007923634,0.0010259103,0.000069179405,0.00006360613,0.00002871621,0.000089512854,0.0002757687,0.00019956093],"category_scores_gemma":[0.024986202,0.00009514741,0.00013920055,0.00017143834,0.00035462412,0.0002205387,0.00009431255,0.000651007,0.0000061447286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055815995,0.0012490499,0.5208338,0.000045753768,0.00005693311,0.000071994466,0.00006831619,0.000003034691,0.0012148048,0.0000022487604,0.001020856,0.47487503],"study_design_scores_gemma":[0.009923494,0.013457908,0.957864,0.00017112956,0.000205537,0.0005965788,0.00042334475,0.0012555728,0.00004888595,0.00018190275,0.015773041,0.00009860574],"about_ca_topic_score_codex":0.0015826924,"about_ca_topic_score_gemma":0.052087303,"teacher_disagreement_score":0.47477645,"about_ca_system_score_codex":0.00035995545,"about_ca_system_score_gemma":0.0023327114,"threshold_uncertainty_score":0.9832268},"labels":[],"label_agreement":null},{"id":"W2893784792","doi":"10.1200/jco.2018.36.30_suppl.74","title":"Reducing the impact of distance on hematopoietic cell therapy patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Receipt; Medicine; Hematopoietic cell; Family medicine; Health care; Nursing; Economic growth","score_opus":0.11274739216809417,"score_gpt":0.40259352305747415,"score_spread":0.28984613088938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893784792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9443072,0.0010471235,0.0003915948,0.00092263357,0.0016564174,0.00010604351,0.000023444392,0.0000026600019,0.0515429],"genre_scores_gemma":[0.99646926,0.001193122,0.0002036731,0.0007656608,0.0011340041,0.0000013118828,4.9215066e-7,0.000015250135,0.0002172007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968776,0.000071650866,0.0026091752,0.00017090443,0.00004838545,0.0002222868],"domain_scores_gemma":[0.9941865,0.000797428,0.0043575573,0.00028176844,0.00023974151,0.00013697984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026219958,0.00012418971,0.0011412381,0.00009172628,0.0000596079,0.000015264255,0.00040113658,0.00020508094,0.0004005274],"category_scores_gemma":[0.0013368893,0.00007993511,0.0006608332,0.0001126042,0.0003788286,0.00016993271,0.000029486455,0.00045900926,0.000116167896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046143103,0.0041273152,0.725311,0.00001914324,0.0004856475,0.000010997195,0.001476436,0.00028293606,0.000018616967,0.032182544,0.052776594,0.1786945],"study_design_scores_gemma":[0.004577076,0.021701459,0.79811585,0.000042312473,0.000013496552,0.0000055583,0.000043528384,0.00012066014,0.00015431373,0.028517032,0.14652473,0.00018396878],"about_ca_topic_score_codex":0.00010135808,"about_ca_topic_score_gemma":0.00000729261,"teacher_disagreement_score":0.17851053,"about_ca_system_score_codex":0.00017289014,"about_ca_system_score_gemma":0.00033454734,"threshold_uncertainty_score":0.43854943},"labels":[],"label_agreement":null},{"id":"W2893817455","doi":"10.1200/jco.2018.36.30_suppl.173","title":"Understanding what drives patients with cancer to visit the emergency department: A qualitative study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Psychological intervention; Medicine; Emergency department; Qualitative research; Anxiety; Family medicine; MEDLINE; Psychiatry","score_opus":0.29573093313788995,"score_gpt":0.5536257403957086,"score_spread":0.2578948072578186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893817455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843063,0.00010564683,0.0006133294,0.010508612,0.0025795803,0.00046717684,0.0000023627783,0.000005230886,0.0014117789],"genre_scores_gemma":[0.9958908,0.00037843967,0.00015119562,0.0021518818,0.0012004961,0.000018779172,4.5703433e-7,0.00001132566,0.00019665374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977866,0.00052763947,0.0010281052,0.00014408556,0.0003456864,0.00016790623],"domain_scores_gemma":[0.99759704,0.0006424067,0.00074410054,0.0001417358,0.0006272264,0.00024747103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001369969,0.00009686674,0.00061167503,0.00007020858,0.000141299,0.000016107766,0.00011611991,0.00007061185,0.0006013436],"category_scores_gemma":[0.00038718196,0.000047987993,0.00015791698,0.00023416786,0.00017244364,0.00020443751,0.000038886068,0.00040845215,0.000022774728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010203378,0.004536456,0.90448576,0.000010971586,0.0018966037,0.000071323535,0.032743976,0.000012459818,0.000015605849,0.00040843492,0.020552335,0.025062682],"study_design_scores_gemma":[0.008723762,0.072401725,0.81754184,0.00016409524,0.00091551366,0.00002106778,0.05021397,0.0000020773696,0.000016651251,0.0006407678,0.049238846,0.000119660785],"about_ca_topic_score_codex":0.000026117767,"about_ca_topic_score_gemma":0.000997717,"teacher_disagreement_score":0.08694392,"about_ca_system_score_codex":0.00023765137,"about_ca_system_score_gemma":0.0005799921,"threshold_uncertainty_score":0.658429},"labels":[],"label_agreement":null},{"id":"W2894047329","doi":"10.1200/jco.2018.36.30_suppl.195","title":"Development of a PREM for acute leukemia and/or stem cell transplantation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Population; Transplantation; Delphi method; Patient experience; Family medicine; Internal medicine; Health care","score_opus":0.12825152021405328,"score_gpt":0.46417547875813275,"score_spread":0.33592395854407947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894047329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259406,0.00016460141,0.0038575232,0.0006731612,0.0010237108,0.00016129737,0.0000067778797,0.0000035625912,0.0015152942],"genre_scores_gemma":[0.9726746,0.00055233866,0.02418733,0.0008996789,0.00080812344,0.000004878525,0.0000017864425,0.000009477023,0.000861792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820596,0.00006531845,0.001364371,0.00009432874,0.00016155883,0.00010848871],"domain_scores_gemma":[0.99776435,0.0008225002,0.00075632375,0.000066921806,0.00041687128,0.00017304003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012930179,0.0000667472,0.0007304303,0.00005269297,0.000026340347,0.000002432731,0.00006890551,0.00019031033,0.00005036046],"category_scores_gemma":[0.00008275683,0.000042873544,0.00016684164,0.000054309734,0.00011569693,0.00004083711,0.000010750635,0.00021040796,0.0000021073106],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049510423,0.0006925275,0.011400369,0.0005719565,0.0009513816,0.00023107765,0.009034248,8.43196e-7,0.0030221948,0.00009903754,0.004428308,0.92005765],"study_design_scores_gemma":[0.032369282,0.051827956,0.15888129,0.00058335764,0.003071939,0.0010881015,0.0027514517,0.000105407446,0.029877989,0.00018240516,0.71899784,0.00026295212],"about_ca_topic_score_codex":0.000004574638,"about_ca_topic_score_gemma":0.00030761995,"teacher_disagreement_score":0.9197947,"about_ca_system_score_codex":0.00009256385,"about_ca_system_score_gemma":0.0028550476,"threshold_uncertainty_score":0.5064732},"labels":[],"label_agreement":null},{"id":"W2894060912","doi":"10.1200/jco.2018.36.30_suppl.39","title":"Expansion of high-quality specialized services: The gynecologic oncology experience in Ontario hospitals.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Multidisciplinary approach; Medicine; Gynecologic oncology; Credibility; Capacity building; Medical education; Nursing; Oncology; Political science","score_opus":0.4607970685245562,"score_gpt":0.6066684481307844,"score_spread":0.14587137960622815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894060912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97605896,0.000056438075,0.00018921393,0.016790397,0.0036041897,0.00044354534,0.0000018315457,0.0000074544996,0.002847949],"genre_scores_gemma":[0.97771347,0.0002576556,0.008992491,0.011249553,0.0016365966,0.000008254048,0.000004639497,0.000012606296,0.00012473162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9883336,0.0020930676,0.008331211,0.0003044179,0.00062759547,0.00031011453],"domain_scores_gemma":[0.97159934,0.018971791,0.0071096276,0.00047941357,0.001555808,0.00028400077],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016964862,0.00017274181,0.002169156,0.00013351635,0.000058775888,0.000008612984,0.0004439149,0.00060416956,0.0020874804],"category_scores_gemma":[0.028047495,0.000104609186,0.0004512131,0.00027997635,0.00085008336,0.0002799149,0.00018779193,0.0016163874,0.00003964974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019535348,0.0038878918,0.73400706,0.000047117916,0.00026306717,0.0004306225,0.004779992,0.000012230857,0.0013037843,0.00073804986,0.0021994342,0.23279542],"study_design_scores_gemma":[0.011363851,0.022315456,0.87315,0.00007568944,0.00021881486,0.000118898344,0.0032452676,0.00002432624,0.00025299675,0.0023429329,0.08679576,0.00009601833],"about_ca_topic_score_codex":0.023672447,"about_ca_topic_score_gemma":0.20177786,"teacher_disagreement_score":0.23269941,"about_ca_system_score_codex":0.000712092,"about_ca_system_score_gemma":0.0051029725,"threshold_uncertainty_score":0.9988248},"labels":[],"label_agreement":null},{"id":"W2894171415","doi":"10.1200/jco.2018.36.30_suppl.41","title":"Pan-Canadian Oncology Drug Review (pCODR): A unique model to support harmonization of cancer drug funding decisions in Canada.","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Harmonization; Concordance; Cancer drugs; Family medicine; Drug; Actuarial science; Pharmacology; Business; Internal medicine","score_opus":0.7783201006569027,"score_gpt":0.6289006342464639,"score_spread":0.1494194664104388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894171415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003330602,0.95110947,0.0005737974,0.039764524,0.0035985303,0.0016295563,0.00069223234,0.0000043395726,0.002294484],"genre_scores_gemma":[0.00036883148,0.963465,0.004874504,0.029530317,0.0009977513,0.000115815164,0.000037880392,0.00006702843,0.0005429248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9637714,0.0030559734,0.031498555,0.00068617705,0.00025286723,0.0007349983],"domain_scores_gemma":[0.9554238,0.012989938,0.028726092,0.0006700927,0.000735424,0.0014546735],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07788384,0.00042241835,0.01289727,0.0013497412,0.000093601586,0.000018535668,0.001184082,0.0008118182,0.0006920811],"category_scores_gemma":[0.0438702,0.00043156877,0.00094456755,0.000788614,0.0001245467,0.00027904418,0.00014204776,0.0016144507,0.00025893247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000037031805,0.00023681406,0.0027322418,0.0069082845,0.00038148992,0.00005606351,0.0002782444,0.0003221648,5.6632476e-9,0.0016293874,0.51879674,0.46862152],"study_design_scores_gemma":[0.00066114374,0.00040376402,0.00034980458,0.019018246,0.00023961569,0.000034602388,0.000072029005,0.0005097575,2.509625e-8,0.00095857325,0.9774107,0.00034176285],"about_ca_topic_score_codex":0.7736059,"about_ca_topic_score_gemma":0.9897339,"teacher_disagreement_score":0.46827975,"about_ca_system_score_codex":0.016142322,"about_ca_system_score_gemma":0.13131575,"threshold_uncertainty_score":0.9998136},"labels":[],"label_agreement":null},{"id":"W2894254476","doi":"10.1200/jco.2018.36.30_suppl.151","title":"Assessment of scheduled pharmacy follow-up for patients receiving oral chemotherapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacist; Pharmacy; Psychological intervention; Chemotherapy; Patient education; Audit; Intervention (counseling); Intensive care medicine; Physical therapy; Family medicine; Internal medicine; Nursing","score_opus":0.18655034475399465,"score_gpt":0.5783130633114408,"score_spread":0.39176271855744615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894254476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861733,0.00008948936,0.00029943942,0.004186213,0.004985388,0.00042030003,0.0000055268506,0.000006806818,0.0038335605],"genre_scores_gemma":[0.976986,0.00042210546,0.016698852,0.0029851557,0.002307847,0.000009426743,0.0000054733796,0.0000191258,0.00056603894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731094,0.0002282799,0.0018380457,0.0001579189,0.00024581296,0.0002190031],"domain_scores_gemma":[0.99522156,0.0014971165,0.0017787104,0.000116143296,0.0011355961,0.00025085217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002046539,0.00012615585,0.0013711845,0.00010868155,0.000038623017,0.00000352567,0.0001353445,0.00018193662,0.0007814909],"category_scores_gemma":[0.0010131703,0.000090569265,0.00059670454,0.000110632085,0.0002233161,0.00008517161,0.000028426737,0.00040247294,0.0000049782657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014894804,0.006399454,0.6115912,0.000047681344,0.0013318346,0.000018991055,0.00010156231,6.040763e-7,0.0016312696,0.000045500725,0.02083575,0.34310132],"study_design_scores_gemma":[0.09314562,0.061916754,0.6003961,0.00008315239,0.0011779204,0.000030073943,0.000027461112,0.00026986425,0.0018653595,0.00025114065,0.24073268,0.00010385545],"about_ca_topic_score_codex":0.000011311747,"about_ca_topic_score_gemma":0.000024310775,"teacher_disagreement_score":0.34299746,"about_ca_system_score_codex":0.00018193343,"about_ca_system_score_gemma":0.0016408216,"threshold_uncertainty_score":0.85567766},"labels":[],"label_agreement":null},{"id":"W2894286942","doi":"10.1200/jco.2018.36.30_suppl.71","title":"Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba; University of Winnipeg","funders":"","keywords":"FOLFIRINOX; Medicine; Irinotecan; Oxaliplatin; Gemcitabine; Internal medicine; Chemotherapy; Toxicity; Pancreatic cancer; Oncology; Nausea; Gastroenterology; Surgery; Cancer; Colorectal cancer","score_opus":0.08036436431117458,"score_gpt":0.4728333609264149,"score_spread":0.3924689966152404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894286942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927161,0.00027075812,0.00017743584,0.0055221487,0.0002488621,0.00038191915,0.000009037759,0.000005763579,0.0006679959],"genre_scores_gemma":[0.9889905,0.0054568993,0.0039615063,0.0007573675,0.00041819253,0.000011586722,0.00000194865,0.00001853811,0.0003834689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974215,0.00021520635,0.0015425832,0.00019628009,0.0003661129,0.0002583262],"domain_scores_gemma":[0.995208,0.0022340098,0.0013008438,0.00020167104,0.00073557487,0.00031986606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008924284,0.00017074807,0.0022397798,0.000108793116,0.000054596127,0.0000044431185,0.00010742826,0.0002513249,0.000296784],"category_scores_gemma":[0.001247129,0.00009371326,0.00018776054,0.00009790772,0.0004530379,0.00008172029,0.000033352542,0.00033952566,0.0000029500181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005057879,0.0021364111,0.75015754,0.000042704018,0.0008638911,0.00003921116,0.00018051482,6.5336525e-7,0.00001881334,0.00000427059,0.00007397039,0.24142411],"study_design_scores_gemma":[0.022790466,0.08265071,0.89078283,0.00024989477,0.00065281714,0.000038518763,0.000060450802,0.000051667274,0.00010218393,0.00005302934,0.0024910693,0.0000763594],"about_ca_topic_score_codex":0.00013815716,"about_ca_topic_score_gemma":0.0005552173,"teacher_disagreement_score":0.24134776,"about_ca_system_score_codex":0.00018956816,"about_ca_system_score_gemma":0.000916522,"threshold_uncertainty_score":0.38215157},"labels":[],"label_agreement":null},{"id":"W2894291846","doi":"10.1200/jco.2018.36.30_suppl.205","title":"Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Cancer; Proportional hazards model; Pancreatic cancer; Cohort; Comorbidity; Cancer registry; Performance status","score_opus":0.0915211924685493,"score_gpt":0.37563156738197645,"score_spread":0.28411037491342717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894291846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844356,0.00013059757,0.000039428007,0.0009279047,0.0016129575,0.00023102543,0.00004889954,0.000011070055,0.0125624845],"genre_scores_gemma":[0.9974991,0.00021043031,0.00045298765,0.0011586697,0.00029079473,0.000009910632,0.0000035356188,0.000034268476,0.0003402956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956197,0.00010307024,0.003412572,0.0003357295,0.00011244495,0.00041647837],"domain_scores_gemma":[0.98829913,0.0007706756,0.009903168,0.00025311243,0.00051902985,0.00025490604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001714295,0.00022518655,0.002457304,0.00030000033,0.000058816036,0.000023010445,0.00024927067,0.00025278545,0.00020671412],"category_scores_gemma":[0.003152692,0.00017109423,0.00020908797,0.00035877436,0.00030131242,0.00044312736,0.000039425588,0.0005982681,0.000023283246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00248828,0.00082235725,0.98291075,0.0000046646164,0.00041693088,0.000049431168,0.00008284491,0.00006340341,8.2357126e-8,0.0006269823,0.0003555698,0.0121786995],"study_design_scores_gemma":[0.009458276,0.0061967536,0.9745653,0.00013048774,0.00005583715,0.0000011158584,0.000046806137,0.00002279229,0.000001664051,0.0011097098,0.008175009,0.00023622146],"about_ca_topic_score_codex":0.0005076025,"about_ca_topic_score_gemma":0.011103117,"teacher_disagreement_score":0.013063474,"about_ca_system_score_codex":0.0006065127,"about_ca_system_score_gemma":0.000508252,"threshold_uncertainty_score":0.697702},"labels":[],"label_agreement":null},{"id":"W2894298745","doi":"10.1200/jco.2018.36.30_suppl.295","title":"Development of the CCRU kit squad: Centralization of biospecimen “kit” management.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Workflow; Protocol (science); Vendor; Pathology; Computer science; Database; Alternative medicine; Business","score_opus":0.059016912509143794,"score_gpt":0.40468118685913584,"score_spread":0.34566427434999203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894298745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911297,0.0002361842,0.0016519139,0.00049062114,0.0013935803,0.000105815845,0.000005759454,7.609611e-7,0.0049856417],"genre_scores_gemma":[0.98593277,0.0008062307,0.011845465,0.0005240347,0.0006866089,9.2414143e-7,0.000003706502,0.000008153029,0.0001921134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981896,0.000090956906,0.0013399152,0.00010833175,0.00015324376,0.00011791892],"domain_scores_gemma":[0.9979701,0.000091602284,0.0013523063,0.0001891322,0.00032458804,0.000072272436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009477907,0.0000707915,0.00034455047,0.000030899686,0.00003071205,0.000003263094,0.0002902873,0.0001746594,0.000050427276],"category_scores_gemma":[0.00046529406,0.00004920095,0.00018986796,0.00007652945,0.00021227146,0.0000025854847,0.0001615095,0.00010140977,0.0000027548358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048110364,0.004754708,0.13134031,0.0002126325,0.0027339896,0.000031452248,0.00083913706,0.00027310767,0.22432686,0.009334327,0.083727404,0.53761506],"study_design_scores_gemma":[0.0023311526,0.0021931445,0.11900396,0.00004581265,0.00011884278,0.000010489978,0.0001108354,0.000015840096,0.10779623,0.00037796254,0.76790273,0.00009299143],"about_ca_topic_score_codex":0.0000029681196,"about_ca_topic_score_gemma":0.00005845779,"teacher_disagreement_score":0.6841753,"about_ca_system_score_codex":0.000029384611,"about_ca_system_score_gemma":0.0005477329,"threshold_uncertainty_score":0.20063566},"labels":[],"label_agreement":null},{"id":"W2894305723","doi":"10.1200/jco.2018.36.30_suppl.188","title":"Evaluation of the implementation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) across the province of Ontario.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Formative assessment; Medicine; Prom; EPIC; Prostate cancer; Family medicine; Cancer; Internal medicine; Psychology; Obstetrics","score_opus":0.45545880240924475,"score_gpt":0.6818553382830012,"score_spread":0.2263965358737564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894305723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576817,0.00012848176,0.00035296485,0.03634298,0.0028717888,0.0023795068,0.000040051287,0.0000025706809,0.00019991753],"genre_scores_gemma":[0.99180394,0.00018316369,0.0027668101,0.003907921,0.001178226,0.00003432219,0.0000038644857,0.000016895696,0.00010487751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98607075,0.003522641,0.00822792,0.00024162586,0.0016943078,0.00024275453],"domain_scores_gemma":[0.9569168,0.016742311,0.01629991,0.000553888,0.009374098,0.000112969195],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0527927,0.00014755645,0.0011411675,0.000035349833,0.00013343115,0.000010010676,0.0004785506,0.00027725587,0.00016682765],"category_scores_gemma":[0.056473978,0.00007100698,0.0007795094,0.0002377484,0.0010322788,0.00031627016,0.00021143036,0.0010515873,9.884212e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011507935,0.0016570521,0.60327667,0.00005815397,0.0010029984,0.0000017482228,0.0019812668,0.00007377223,0.00074082124,0.00005698912,0.0051511847,0.37449142],"study_design_scores_gemma":[0.017721789,0.008537932,0.91806626,0.00016585855,0.0038715757,0.00005384723,0.0027664558,0.0004792094,0.002179878,0.00080134557,0.04528207,0.00007378988],"about_ca_topic_score_codex":0.0042782086,"about_ca_topic_score_gemma":0.05703537,"teacher_disagreement_score":0.37441763,"about_ca_system_score_codex":0.0004773226,"about_ca_system_score_gemma":0.017663132,"threshold_uncertainty_score":0.9879058},"labels":[],"label_agreement":null},{"id":"W2894316538","doi":"10.1200/jco.2018.36.30_suppl.212","title":"Improving patient-centered oral chemotherapy at an academic cancer center.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Patient education; Family medicine; Likert scale; Patient satisfaction; PDCA; Quality management; Nursing; Service (business)","score_opus":0.172892096806572,"score_gpt":0.4288187333832802,"score_spread":0.2559266365767082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894316538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817812,0.0013559109,0.00045941575,0.002787246,0.005941333,0.0001181846,0.00006216481,0.0000113261585,0.0074832505],"genre_scores_gemma":[0.98306125,0.002581702,0.0012649761,0.008859125,0.0036954435,0.0000036501863,0.0000022052805,0.000033384695,0.0004982626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958191,0.000076407916,0.003321531,0.00032144305,0.00005474224,0.00040675965],"domain_scores_gemma":[0.9944411,0.00017618357,0.004529459,0.00023703711,0.00020755484,0.0004086459],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021563054,0.00017151679,0.0013723657,0.00014248311,0.00009213167,0.000023799688,0.00044470277,0.0005241372,0.0014254207],"category_scores_gemma":[0.00085824984,0.0001619283,0.00038568175,0.00009028825,0.00031100397,0.000636823,0.00009189093,0.000750256,0.00021949703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021413222,0.00059835,0.47077212,0.000009248673,0.00018225753,0.000018185552,0.00048264166,0.000006474908,0.0000808277,0.002104848,0.01371565,0.5098881],"study_design_scores_gemma":[0.0061114677,0.0071548,0.18088228,0.000032154054,0.000021046268,0.00004064273,0.000047680354,0.0005428128,0.00016631295,0.0044601397,0.8002702,0.00027045907],"about_ca_topic_score_codex":0.00020668976,"about_ca_topic_score_gemma":0.00031247872,"teacher_disagreement_score":0.7865546,"about_ca_system_score_codex":0.0005136788,"about_ca_system_score_gemma":0.0003671088,"threshold_uncertainty_score":0.9994874},"labels":[],"label_agreement":null},{"id":"W2894329622","doi":"10.1200/jco.2018.36.30_suppl.185","title":"The influence of patient-reported adverse events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Public Health Ontario","funders":"","keywords":"Medicine; Nausea; Common Terminology Criteria for Adverse Events; Internal medicine; Lung cancer; Vomiting; Constipation; Rash; Quality of life (healthcare); Adverse effect; Cancer","score_opus":0.10923004756912373,"score_gpt":0.3927858307219786,"score_spread":0.28355578315285485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894329622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870529,0.008148566,0.000026399854,0.0020332923,0.0012246391,0.00061171106,0.000114479335,0.0000035261612,0.00078446645],"genre_scores_gemma":[0.9839324,0.013702724,0.00015558531,0.0019863695,0.00014219653,0.000012087016,0.0000019239924,0.000020545789,0.00004618497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915543,0.00030215146,0.0071363873,0.0004346948,0.0000963518,0.00047609027],"domain_scores_gemma":[0.9850496,0.00093264086,0.012796566,0.00033074236,0.0004212558,0.00046918052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064074644,0.00023783125,0.002247135,0.00019073724,0.00012781993,0.000008512651,0.00029986497,0.0003691624,0.000051795225],"category_scores_gemma":[0.0015839475,0.00020147224,0.00025428773,0.0002117387,0.0004692113,0.00021816009,0.00012662074,0.0008024282,0.0000022189786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015630192,0.0007178729,0.9796535,0.00023187321,0.00010970742,0.000001804052,0.0008471555,0.00022979546,0.0000018195373,0.00019236743,0.00060209935,0.015849035],"study_design_scores_gemma":[0.005721626,0.0031308017,0.9876863,0.00029790378,0.000023955388,8.0148203e-7,0.00009478569,0.00044794485,0.000012389027,0.0008923419,0.0015214883,0.00016967331],"about_ca_topic_score_codex":0.011860689,"about_ca_topic_score_gemma":0.0070104916,"teacher_disagreement_score":0.015679361,"about_ca_system_score_codex":0.00045598374,"about_ca_system_score_gemma":0.0023437678,"threshold_uncertainty_score":0.9947194},"labels":[],"label_agreement":null},{"id":"W2894392060","doi":"10.1200/jco.2018.36.30_suppl.100","title":"How nonrandomized trials (NRT) inform pan-Canadian Oncology Drug Review (pCODR) expert review committee (pERC) recommendations in blood cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; University of Waterloo; McMaster University; Impact; Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Reimbursement; Randomized controlled trial; Clinical trial; Quality of life (healthcare); Cancer; Cancer drugs; Intensive care medicine; Health care; Family medicine; Surgery; Internal medicine; Nursing","score_opus":0.7279657384608857,"score_gpt":0.631861927244846,"score_spread":0.09610381121603973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894392060","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031198256,0.20730291,0.00028391366,0.77089894,0.008336347,0.0019266735,0.0001443963,0.0000120368795,0.007974975],"genre_scores_gemma":[0.0057925833,0.6659229,0.011985957,0.309229,0.005937143,0.00024677144,0.000025166175,0.000036665984,0.0008238842],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9613419,0.008279615,0.028965147,0.00051789224,0.00019928212,0.0006961581],"domain_scores_gemma":[0.9374447,0.029594896,0.030031348,0.0008112213,0.00094574114,0.0011721299],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23532544,0.00032164183,0.010704306,0.0006190719,0.00018567753,0.000057697525,0.0008713133,0.0006310505,0.0034251055],"category_scores_gemma":[0.16775078,0.0003028465,0.0011869067,0.0004519886,0.0003131773,0.0008015978,0.00008267694,0.0013485567,0.0005851776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033859446,0.0006314131,0.0032827249,0.0009581819,0.0004626518,0.00002004998,0.00044923992,9.804405e-7,3.7536924e-7,0.0014092184,0.906453,0.08599358],"study_design_scores_gemma":[0.013908806,0.0015357559,0.0013943164,0.0055037686,0.00018283432,0.000057256315,0.00021169113,0.00008191454,7.8535896e-7,0.0018380691,0.9749919,0.00029286975],"about_ca_topic_score_codex":0.013649259,"about_ca_topic_score_gemma":0.09387847,"teacher_disagreement_score":0.46166995,"about_ca_system_score_codex":0.0019876927,"about_ca_system_score_gemma":0.007409857,"threshold_uncertainty_score":0.99994236},"labels":[],"label_agreement":null},{"id":"W2894435598","doi":"10.1200/jco.2018.36.30_suppl.255","title":"Developing a standard approach to immune checkpoint inhibitor toxicity management in Ontario.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Patient safety; Health care; Multidisciplinary approach; Best practice; Pathology","score_opus":0.16921011393515303,"score_gpt":0.3859399597052832,"score_spread":0.2167298457701302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894435598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8152642,0.0002749879,0.026068062,0.00233214,0.0024930688,0.00021547209,0.0000061133787,0.000005455353,0.15334049],"genre_scores_gemma":[0.9286813,0.0002198749,0.06720383,0.0020536573,0.0009722481,0.000007456604,6.5819165e-7,0.000016184531,0.00084478187],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9953025,0.00005520326,0.0039408114,0.00028834163,0.000058395228,0.00035472706],"domain_scores_gemma":[0.9973469,0.00014491103,0.0019212974,0.00020249965,0.00014626795,0.0002381584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069633382,0.00014287625,0.0015229507,0.00031157758,0.000045628956,0.000031318108,0.00036292864,0.00027227966,0.000198261],"category_scores_gemma":[0.0009707694,0.00014171825,0.0003066361,0.00018036018,0.0001368673,0.00026607938,0.00014906231,0.00063052785,0.00018227348],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006647912,0.002290214,0.3125464,0.00008443109,0.0009606695,0.00019986363,0.0038429047,0.00026376313,0.000027024296,0.33757102,0.0074800486,0.32808572],"study_design_scores_gemma":[0.0029709002,0.002583652,0.5459235,0.00005020855,0.000010752344,0.00001425224,0.000115527306,0.000034874436,0.00005801334,0.03140557,0.41663134,0.00020146478],"about_ca_topic_score_codex":0.0018299379,"about_ca_topic_score_gemma":0.010706436,"teacher_disagreement_score":0.4091513,"about_ca_system_score_codex":0.001653522,"about_ca_system_score_gemma":0.0007839144,"threshold_uncertainty_score":0.59744424},"labels":[],"label_agreement":null},{"id":"W2894506678","doi":"10.1200/jco.2018.36.30_suppl.25","title":"Identifying potentially preventable emergency department (PPED) visits among patients with cancer in Ontario.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Emergency department; Ambulatory; Cancer; Emergency medicine; Ambulatory care; Health care; Internal medicine","score_opus":0.2564972184699313,"score_gpt":0.5535578732620259,"score_spread":0.2970606547920946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894506678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920568,0.00006153948,0.0009631521,0.0021635836,0.003319883,0.00049579015,0.000004198078,0.0000069533144,0.0009281302],"genre_scores_gemma":[0.98972327,0.00021470337,0.006982177,0.0011968433,0.0011449005,0.0000098740475,0.000012209094,0.000022926652,0.000693109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336576,0.00042810783,0.004917616,0.00027772726,0.0006846198,0.00032616942],"domain_scores_gemma":[0.99385804,0.0008106263,0.0034350012,0.00020835572,0.0013215905,0.0003664129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004235698,0.00016125095,0.0010874425,0.0001552645,0.00005561746,0.000012070607,0.00016995409,0.00024582152,0.003945898],"category_scores_gemma":[0.0038551998,0.00011666646,0.00027276578,0.00020810791,0.00011847438,0.00051431265,0.000090196496,0.0010877379,0.000031516956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047724806,0.002163886,0.9146216,0.000013633206,0.00031823618,0.00012622033,0.0001120766,0.000018118271,0.000021800855,0.000005206068,0.0035636183,0.07426315],"study_design_scores_gemma":[0.011790038,0.010737033,0.95571125,0.00017847582,0.0006089518,0.00002225459,0.00008249498,0.00003219405,0.000023614637,0.00017587173,0.020526135,0.00011170983],"about_ca_topic_score_codex":0.00982512,"about_ca_topic_score_gemma":0.40190926,"teacher_disagreement_score":0.39208415,"about_ca_system_score_codex":0.0006124149,"about_ca_system_score_gemma":0.0030072841,"threshold_uncertainty_score":0.99696463},"labels":[],"label_agreement":null},{"id":"W2894519075","doi":"10.1200/jco.2018.36.30_suppl.148","title":"Improving support for smoking cessation in medical oncology patients: A quality improvement initiative.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Trillium Health Centre; University of Toronto","funders":"","keywords":"Medicine; Smoking cessation; Referral; Family medicine; Psychological intervention; Intervention (counseling); Nursing","score_opus":0.1813620592666873,"score_gpt":0.5181388366743152,"score_spread":0.33677677740762785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894519075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98039484,0.00003532947,0.0026510954,0.0067400336,0.003123097,0.00047748885,0.000011057754,0.00000857144,0.0065584667],"genre_scores_gemma":[0.97169775,0.00011335656,0.0033669563,0.022322034,0.0023931686,0.000017205759,0.000020423593,0.000015484418,0.000053596257],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9945643,0.00050039496,0.003808134,0.0002515652,0.00055811525,0.0003175101],"domain_scores_gemma":[0.9922205,0.0033741763,0.002717589,0.00015689184,0.0011002887,0.0004305396],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010384553,0.00013405987,0.0014433481,0.00018676241,0.00005013791,0.0000064757432,0.00018616083,0.0006380315,0.0008784515],"category_scores_gemma":[0.015203053,0.000102872196,0.00035514755,0.0001224563,0.00032406702,0.0002207725,0.000073780044,0.0010177505,0.0000046785317],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008404742,0.002184687,0.13090426,0.00007516446,0.00017244836,0.00009726753,0.00038554997,4.782543e-7,0.00013614894,0.000079112404,0.0023970571,0.8551631],"study_design_scores_gemma":[0.06650885,0.09670893,0.5678741,0.00013331725,0.00026007107,0.000066455614,0.0006473376,0.0007352424,0.00046873753,0.0005152109,0.26586762,0.00021416918],"about_ca_topic_score_codex":0.00006399885,"about_ca_topic_score_gemma":0.00040170283,"teacher_disagreement_score":0.85494894,"about_ca_system_score_codex":0.000906927,"about_ca_system_score_gemma":0.0074897935,"threshold_uncertainty_score":0.9981368},"labels":[],"label_agreement":null},{"id":"W289544031","doi":"10.1200/jco.2014.32.15_suppl.5010","title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":231,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Pazopanib; Sunitinib; Renal cell carcinoma; Internal medicine; Peripheral edema; Urology; Oncology; Gastroenterology; Surgery; Adverse effect; Immunotherapy; Cancer","score_opus":0.07842517922211807,"score_gpt":0.37313754177960434,"score_spread":0.2947123625574863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W289544031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945035,0.000070399044,0.00014105783,0.0011825635,0.00028483573,0.0006807652,0.0000037236034,0.00000971978,0.0031234578],"genre_scores_gemma":[0.99380773,0.000046278405,0.004805939,0.00075103453,0.00020594762,0.000016165654,0.00002327962,0.00004903546,0.00029459145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99415267,0.0013249608,0.0028159453,0.00040124013,0.0008172119,0.0004879972],"domain_scores_gemma":[0.9940204,0.0023359144,0.0021327843,0.00035633682,0.0006787616,0.00047578439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031141918,0.00033572732,0.002310209,0.00053139305,0.000041850348,0.00001819575,0.00023868585,0.0002826304,0.00013173596],"category_scores_gemma":[0.0012401192,0.00019741298,0.00023912798,0.00047957854,0.0002543717,0.00022114978,0.000053843713,0.0013776006,0.000024840985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02768623,0.01003029,0.9256878,0.00011705358,0.00016276288,0.0032715623,0.0002572041,0.000115231596,0.00005571321,0.000058476886,0.00036385024,0.03219383],"study_design_scores_gemma":[0.06623832,0.08890201,0.8408151,0.00031600404,0.00050040754,0.00034433333,0.00020575237,0.00026098808,0.00037623727,0.00006693967,0.0017735519,0.00020034667],"about_ca_topic_score_codex":0.00018290602,"about_ca_topic_score_gemma":0.0011383959,"teacher_disagreement_score":0.08487269,"about_ca_system_score_codex":0.0006376236,"about_ca_system_score_gemma":0.0018603029,"threshold_uncertainty_score":0.80502677},"labels":[],"label_agreement":null},{"id":"W2895446891","doi":"10.1200/jco.2014.32.15_suppl.4009","title":"A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dysphagia; Nausea; Radiation therapy; Vomiting; Quality of life (healthcare); Chemoradiotherapy; Concomitant; Clinical endpoint; Esophageal cancer; Palliative care; Internal medicine; Toxicity; Randomized controlled trial; Cancer; Surgery","score_opus":0.10745577387733762,"score_gpt":0.5137101380998058,"score_spread":0.4062543642224682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895446891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935873,0.0023603358,0.00009871981,0.0013634925,0.00008934389,0.0024566269,0.000009746803,0.0000042942474,0.000030119058],"genre_scores_gemma":[0.99697345,0.0012088383,0.0007905645,0.00072369585,0.00014172506,0.0001007231,0.000004089968,0.000019353265,0.000037528902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99352175,0.002299017,0.0030039106,0.00026411942,0.00064157514,0.00026965048],"domain_scores_gemma":[0.9932605,0.0036854558,0.0019706816,0.00025206569,0.000457212,0.00037408175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056771836,0.0002111295,0.003734853,0.0002086471,0.000027014989,0.0000065904937,0.00017265695,0.00011302467,0.000113547394],"category_scores_gemma":[0.0022773964,0.00010549417,0.00021838628,0.0004009971,0.00028539452,0.000088259825,0.000019788748,0.000546654,3.0965487e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4589322,0.005746061,0.50945383,0.000039887087,0.0005657361,0.000040379622,0.0006677557,0.00009074862,0.000019617806,0.0000066765,0.000029757759,0.02440734],"study_design_scores_gemma":[0.45552263,0.02617293,0.517563,0.000092660885,0.00011730315,0.0000023019663,0.00011472069,0.0002520508,0.0000688735,0.000008679704,0.000034243054,0.0000506295],"about_ca_topic_score_codex":0.0010105267,"about_ca_topic_score_gemma":0.0033707668,"teacher_disagreement_score":0.024356712,"about_ca_system_score_codex":0.00038520913,"about_ca_system_score_gemma":0.0011627931,"threshold_uncertainty_score":0.43019274},"labels":[],"label_agreement":null},{"id":"W2895587916","doi":"10.1200/jco.2007.25.18_suppl.4006","title":"Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Colorectal cancer; Quartile; Proportional hazards model; Internal medicine; Cancer; Hazard ratio; Lymph node; Lymph; Metastasis; Gastroenterology; Oncology; Urology; Confidence interval; Pathology","score_opus":0.10443047500784192,"score_gpt":0.4592210023204857,"score_spread":0.35479052731264377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895587916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970673,0.00021349816,0.000500322,0.0008879802,0.0004348836,0.00013033803,0.0000314321,0.0000025882139,0.0007317082],"genre_scores_gemma":[0.99757874,0.000116919735,0.0014291288,0.00052171695,0.00023001952,0.0000011026766,0.00000458938,0.000009997006,0.00010778262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511147,0.00038103783,0.0036115167,0.00019178078,0.00049643184,0.00020775002],"domain_scores_gemma":[0.99450517,0.00228184,0.002006273,0.000183791,0.00068609574,0.00033680449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046197963,0.00013810184,0.002709321,0.000750054,0.0000072176244,0.0000021552896,0.0001987006,0.00017723834,0.00041932773],"category_scores_gemma":[0.0026683547,0.00010112897,0.00075321883,0.0007570391,0.00018640196,0.00009350602,0.000060561404,0.0003448127,6.739284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020276533,0.002787597,0.9409668,0.00009609604,0.002262857,0.0002490473,0.0013476938,0.00013589268,0.013010944,0.000066329834,0.0001143456,0.018685853],"study_design_scores_gemma":[0.0047288844,0.014375934,0.97386247,0.00015120328,0.0021318907,0.00001962228,0.0006876885,0.0015519013,0.0021958726,0.0000674208,0.00014967406,0.00007743787],"about_ca_topic_score_codex":0.0008256475,"about_ca_topic_score_gemma":0.00352151,"teacher_disagreement_score":0.03289566,"about_ca_system_score_codex":0.00017304135,"about_ca_system_score_gemma":0.00084845675,"threshold_uncertainty_score":0.45913446},"labels":[],"label_agreement":null},{"id":"W2895620575","doi":"10.1200/jco.18.00140","title":"Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"National Cancer Institute; Biogen; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; National Institute on Aging; ACADIA Pharmaceuticals; Eli Lilly and Company","keywords":"Medicine; Breast cancer; Cognition; Cancer; Internal medicine; Neuropsychology; Hormone therapy; Dementia; Longitudinal study; Hormonal therapy; Oncology; Disease; Psychiatry","score_opus":0.06155092313415968,"score_gpt":0.4563994688259394,"score_spread":0.39484854569177974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895620575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98380524,0.0009061313,0.000010239897,0.011880602,0.0014646496,0.00094897905,0.000014143103,0.000019498673,0.00095052517],"genre_scores_gemma":[0.9927494,0.0021544094,0.000034598466,0.0037080485,0.0010561955,0.000092305185,3.420761e-7,0.000031454507,0.00017322824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958625,0.0009532436,0.0017600578,0.00034855693,0.00066794996,0.00040770962],"domain_scores_gemma":[0.9916251,0.005181135,0.001651738,0.00013652892,0.0011997895,0.00020576364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041614473,0.0002795034,0.0016596236,0.00020847101,0.00019358734,0.000026325295,0.00019143327,0.0002711111,0.00038124714],"category_scores_gemma":[0.0013199305,0.00014882941,0.00019391176,0.0004621231,0.00088566885,0.00021941228,0.00011484659,0.0017045026,0.000002848065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013789549,0.002012027,0.9499058,0.000023911105,0.0025498488,0.0002948816,0.012453889,0.0000057809184,0.0000013979254,0.0000033311258,0.00030427042,0.031065913],"study_design_scores_gemma":[0.010528081,0.0072970027,0.9631393,0.0018227204,0.0021095928,0.0001971938,0.0144668445,0.000038613754,0.0000018106808,0.000027961469,0.00019863508,0.00017224172],"about_ca_topic_score_codex":0.0070096264,"about_ca_topic_score_gemma":0.092496574,"teacher_disagreement_score":0.08548695,"about_ca_system_score_codex":0.00035128216,"about_ca_system_score_gemma":0.0013163589,"threshold_uncertainty_score":0.9996028},"labels":[],"label_agreement":null},{"id":"W2896703180","doi":"10.1200/jco.18.01097","title":"Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Vanderbilt University; Virginia Commonwealth University; University of Ottawa; Cedars-Sinai Medical Center; GlaxoSmithKline; Massachusetts General Hospital; University of Washington; Bristol-Myers Squibb; Vanderbilt University Medical Center; Wake Forest University; Amgen","keywords":"Medicine; Guideline; Prostate cancer; Medical physics; Radiation therapy; Cancer; Prostate; Gynecology; Oncology; Internal medicine; Pathology","score_opus":0.1976066805520311,"score_gpt":0.5285539743962889,"score_spread":0.3309472938442578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896703180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92725575,0.008786784,0.0014034767,0.06011181,0.0014748111,0.00088513433,0.00002314696,0.00001607728,0.000042984873],"genre_scores_gemma":[0.9306709,0.03546132,0.013996852,0.016237218,0.0034067067,0.000093052564,0.000023871895,0.000026030551,0.00008401705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736434,0.00026063892,0.001720281,0.00022360786,0.0002376531,0.00019345444],"domain_scores_gemma":[0.9951314,0.0016126054,0.0014589701,0.000141839,0.0012936506,0.00036154516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026533592,0.00013250993,0.00090235565,0.00009481803,0.00006884219,0.000015792279,0.00006852017,0.00020342162,0.00017724388],"category_scores_gemma":[0.0018758489,0.000087427376,0.00021885804,0.000101939724,0.00021711955,0.00031691475,0.000009414935,0.00026880522,0.0000026874525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020667225,0.001367999,0.08898558,0.000019090216,0.00032177748,0.000033458604,0.00004149332,0.000048856946,0.00032429738,0.000018620607,0.012149306,0.8760223],"study_design_scores_gemma":[0.03556227,0.098365046,0.24798694,0.00036366528,0.0004838581,0.00005786262,0.000041722444,0.004387945,0.003301973,0.0003582719,0.6089621,0.00012835416],"about_ca_topic_score_codex":0.000090440095,"about_ca_topic_score_gemma":0.00004426509,"teacher_disagreement_score":0.87589395,"about_ca_system_score_codex":0.0002728334,"about_ca_system_score_gemma":0.00258764,"threshold_uncertainty_score":0.45903623},"labels":[],"label_agreement":null},{"id":"W2898835023","doi":"10.1200/jco.2018.79.0147","title":"Prognostication in Kidney Cancer: Recent Advances and Future Directions","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Disease; Renal cell carcinoma; Kidney cancer; Cancer; Clinical trial; Oncology; Internal medicine; Localized disease; Systemic therapy; Bioinformatics; Prostate cancer","score_opus":0.1885659619419373,"score_gpt":0.5265841929566255,"score_spread":0.3380182310146882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898835023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116617,0.9886004,0.0000016842339,0.005432204,0.0031583232,0.00061843323,0.000008952224,0.0000060686402,0.0020573714],"genre_scores_gemma":[0.000006114036,0.99098164,0.0013771873,0.00039829567,0.006998106,0.000050497343,0.000013354161,0.000023003731,0.00015178355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957568,0.00065436674,0.0028843847,0.0002734058,0.0002470057,0.00018405181],"domain_scores_gemma":[0.99458486,0.0014662833,0.0028009324,0.00018297535,0.000435881,0.00052905193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017408652,0.00022702987,0.0036192145,0.00024757223,0.000028082059,0.0000071888785,0.00010777247,0.0007067031,0.00012701744],"category_scores_gemma":[0.003158704,0.00013566444,0.00053760473,0.00028522135,0.00019307606,0.00007622573,0.000037828584,0.0012585004,0.0000130219],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026588832,0.0006505863,0.0014661752,0.0028649783,0.000299442,0.00024596695,0.000020208505,2.1468313e-8,3.009729e-8,0.000008175344,0.002526742,0.9916518],"study_design_scores_gemma":[0.0015353804,0.005203827,0.003286391,0.008310962,0.0028124985,0.0009644341,0.000014130183,6.6576604e-7,2.567386e-7,0.000042592736,0.97773135,0.00009751558],"about_ca_topic_score_codex":0.000007349795,"about_ca_topic_score_gemma":0.0000522994,"teacher_disagreement_score":0.99155426,"about_ca_system_score_codex":0.0005722684,"about_ca_system_score_gemma":0.0052128853,"threshold_uncertainty_score":0.9247434},"labels":[],"label_agreement":null},{"id":"W2899304092","doi":"10.1200/jco.18.00313","title":"Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Cardiotoxicity; Medicine; Myeloid leukemia; Overall survival; Internal medicine; Oncology; Clinical trial; Chemotherapy; Pediatrics","score_opus":0.11453359950520818,"score_gpt":0.4899605696626425,"score_spread":0.3754269701574343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899304092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432105,0.00024793445,0.0000051132038,0.0025519687,0.0007967269,0.001410996,0.000064965854,0.000013007444,0.0005882491],"genre_scores_gemma":[0.99589825,0.0010340948,0.000051613697,0.0014293806,0.0014935833,0.000013295292,0.000048645565,0.000013751278,0.000017380155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991699,0.0031071603,0.004050157,0.00041262514,0.0004330947,0.00029799962],"domain_scores_gemma":[0.9861725,0.009471829,0.0032734475,0.0005183302,0.00029183438,0.00027208813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0090608625,0.00029999582,0.0029372887,0.00012436396,0.0000852008,0.0000144172645,0.00031653285,0.0009823444,0.00005766082],"category_scores_gemma":[0.006902764,0.00013749453,0.0015255845,0.0002805795,0.0008917642,0.00011181025,0.000043656742,0.0016064733,0.000006383615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024786687,0.002827489,0.9155394,0.0000017243445,0.0023201394,0.00024834267,0.00037416868,0.0000031816558,0.0001663944,0.000009921142,0.0009370146,0.052785538],"study_design_scores_gemma":[0.061615285,0.04696239,0.8883665,0.00007433593,0.0009659617,0.0008569319,0.000072168994,0.000021258356,0.00039521835,0.000098461845,0.00046414873,0.00010730531],"about_ca_topic_score_codex":0.00069916225,"about_ca_topic_score_gemma":0.00028436363,"teacher_disagreement_score":0.052678235,"about_ca_system_score_codex":0.00035923728,"about_ca_system_score_gemma":0.0011367709,"threshold_uncertainty_score":0.8263752},"labels":[],"label_agreement":null},{"id":"W2900683197","doi":"10.1200/jco.18.00537","title":"Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712—A Randomized Phase II Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Gemcitabine; Bladder cancer; Regimen; Urology; Cystectomy; Clinical endpoint; Fluorouracil; Surgery; Chemoradiotherapy; Internal medicine; Radiation therapy; Cancer; Gastroenterology; Randomized controlled trial","score_opus":0.12176141321705831,"score_gpt":0.4691346344075544,"score_spread":0.3473732211904961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900683197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466875,0.0014694455,0.020296907,0.017005589,0.005950832,0.006916674,0.00011891947,0.00006452214,0.0014895671],"genre_scores_gemma":[0.9666922,0.002286491,0.006867297,0.0044425693,0.016425524,0.00053977274,0.00011987617,0.0000946828,0.002531582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934279,0.0011183908,0.0035695774,0.0005293724,0.0008402838,0.0005144909],"domain_scores_gemma":[0.9860754,0.0071320278,0.004088898,0.00037247952,0.001789618,0.0005415862],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005148747,0.00041570776,0.0031287014,0.00025975122,0.00028742387,0.00004256606,0.0002626979,0.0006491131,0.00088034477],"category_scores_gemma":[0.011400023,0.00026030254,0.0007652757,0.00036790955,0.00045166304,0.00074999646,0.000052413023,0.0007666476,0.000014847609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7742079,0.0019221833,0.00014267427,0.0000450274,0.0021517305,0.0000817198,0.0012747966,0.0001672581,0.00024162431,0.000041211017,0.010307946,0.20941594],"study_design_scores_gemma":[0.8508933,0.09134068,0.0015524451,0.00018837987,0.004191597,0.00006995471,0.0001703531,0.005283093,0.0007387885,0.00023225289,0.045064062,0.00027508708],"about_ca_topic_score_codex":0.00024891185,"about_ca_topic_score_gemma":0.00057399814,"teacher_disagreement_score":0.20914085,"about_ca_system_score_codex":0.0009405654,"about_ca_system_score_gemma":0.009307646,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W2901292094","doi":"10.1200/jco.18.00896","title":"Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Pregabalin; Neuropathic pain; Head and neck cancer; Randomized controlled trial; Radiation therapy; Head and neck; Cancer; Gabapentin; Cancer pain; Surgery; Anesthesia; Internal medicine; Alternative medicine","score_opus":0.03760009475940908,"score_gpt":0.4626852405136183,"score_spread":0.42508514575420925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901292094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987406,0.0010769392,0.00001578216,0.0030512006,0.0014932288,0.0043301955,0.0000018694249,0.0000055530895,0.00015119216],"genre_scores_gemma":[0.9962778,0.0008704338,0.0005350952,0.0014580745,0.00071493484,0.00008139587,6.7781104e-7,0.000020470085,0.0000410793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9858985,0.009982695,0.0032951757,0.00019952747,0.0003929748,0.00023115035],"domain_scores_gemma":[0.9783533,0.018039297,0.0028465928,0.00015469585,0.00031195863,0.00029410503],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025273863,0.00018450581,0.005392539,0.00016706718,0.000022349761,0.000003034743,0.00007215361,0.00032026018,0.00006605682],"category_scores_gemma":[0.0104603125,0.00009104535,0.00042742756,0.00014379265,0.00045120367,0.000037980957,0.000010459396,0.0007599328,0.0000011314886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73264635,0.0019277147,0.08241121,0.000054699663,0.00051508064,0.000064431675,0.000058036974,0.0000062619492,0.0000018053656,0.0000037344141,0.00007391502,0.18223675],"study_design_scores_gemma":[0.6789895,0.2965007,0.022631645,0.0006189106,0.00046477982,0.00000786249,0.000001180749,0.0003787628,0.000011642909,0.000014675731,0.00033647142,0.000043789667],"about_ca_topic_score_codex":0.00006542454,"about_ca_topic_score_gemma":0.000047238398,"teacher_disagreement_score":0.294573,"about_ca_system_score_codex":0.00029590895,"about_ca_system_score_gemma":0.001320616,"threshold_uncertainty_score":0.997875},"labels":[],"label_agreement":null},{"id":"W2901314939","doi":"10.1200/jco.18.01160","title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":630,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Guideline; Tolerability; Oncology; Internal medicine; Adjuvant therapy; Cancer; Aromatase inhibitor; Adjuvant; Clinical trial; Gynecology; Randomized controlled trial; Aromatase; Adverse effect; Pathology","score_opus":0.045589835450751494,"score_gpt":0.4509187382371283,"score_spread":0.4053289027863768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901314939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89467233,0.0069739297,0.003712516,0.08872784,0.0030917926,0.00082456693,0.00044938756,0.000019913423,0.0015277187],"genre_scores_gemma":[0.86263454,0.0438328,0.05537627,0.019969728,0.01768398,0.0001287675,0.000050559924,0.0000859363,0.00023740958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567145,0.0006001514,0.0024989676,0.00047009013,0.00029228083,0.00046704602],"domain_scores_gemma":[0.9928729,0.001069413,0.002631086,0.00032320377,0.0027392574,0.00036414605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033490658,0.00028290885,0.0013425704,0.000039829636,0.00013988481,0.000016022583,0.0003420599,0.0003462549,0.00007263617],"category_scores_gemma":[0.001832324,0.00018484888,0.00036447242,0.00010879309,0.00075216126,0.000027922182,0.000119450444,0.0004479875,0.000011015417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13889962,0.0028935333,0.011499859,0.000005390828,0.0043030535,0.000069255286,0.00008436433,0.0000064231263,0.0015513604,0.000034535184,0.118113786,0.7225388],"study_design_scores_gemma":[0.020365695,0.04197117,0.10173323,0.000027535134,0.0002746544,0.00040840864,0.00017517689,0.0000066392795,0.00086091424,0.00008429019,0.83386374,0.00022853416],"about_ca_topic_score_codex":0.000060891773,"about_ca_topic_score_gemma":0.000099636876,"teacher_disagreement_score":0.7223103,"about_ca_system_score_codex":0.00015424746,"about_ca_system_score_gemma":0.0016512247,"threshold_uncertainty_score":0.7537918},"labels":[],"label_agreement":null},{"id":"W2902050784","doi":"10.1200/jco.2018.36.34_suppl.64","title":"Oncologists and medical assistance in dying: Where do we stand?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Odds ratio; Univariate analysis; Descriptive statistics; Multivariate analysis; Confidence interval; Internal medicine","score_opus":0.398220800426062,"score_gpt":0.6034953037608263,"score_spread":0.20527450333476427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902050784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9206687,0.038064957,0.00028513765,0.029138695,0.0012414558,0.00009769139,0.0000018942588,0.000006504608,0.01049496],"genre_scores_gemma":[0.9287679,0.06097475,0.0070415484,0.001083036,0.0018324443,0.0000013200171,2.223444e-7,0.000010820258,0.00028794404],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966961,0.00041256173,0.0020183746,0.00016857802,0.00050112477,0.00020326977],"domain_scores_gemma":[0.9938689,0.0039046432,0.0011456825,0.00013531478,0.0005218128,0.00042366085],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004397497,0.00010833686,0.0014813673,0.00011199089,0.000019622963,0.000005350711,0.00015628435,0.00055756804,0.00034309356],"category_scores_gemma":[0.012628117,0.00007290639,0.0001760493,0.00015343206,0.00085461274,0.00007383542,0.00006097273,0.0009610499,0.000008609128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004310225,0.0009498438,0.6985757,0.000115477815,0.00017299276,0.0017963153,0.00064753427,3.3841954e-7,0.0000717348,0.0003547254,0.015325693,0.27767944],"study_design_scores_gemma":[0.0077101085,0.012153079,0.1460607,0.0023826272,0.00009838699,0.00019897128,0.00058129226,0.000056509904,0.00006727582,0.0007585437,0.82985395,0.00007857003],"about_ca_topic_score_codex":0.000014910439,"about_ca_topic_score_gemma":0.00028201818,"teacher_disagreement_score":0.8145282,"about_ca_system_score_codex":0.00014271979,"about_ca_system_score_gemma":0.0019516384,"threshold_uncertainty_score":0.9956889},"labels":[],"label_agreement":null},{"id":"W2902090583","doi":"10.1200/jco.2018.36.34_suppl.191","title":"A comparison of the attitudes about the legalization of marijuana use for medical purposes by cancer patients in two cancer centers located in a legalized and a non-legalized state.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Anxiety; Cancer; Psychological intervention; Legalization; Family medicine; Depression (economics); Demography; Psychiatry; Internal medicine","score_opus":0.1053460587616877,"score_gpt":0.5411559694508912,"score_spread":0.4358099106892035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902090583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98304844,0.00089246756,0.000085203195,0.014625807,0.0005353547,0.0007451929,0.000037660622,0.0000014293109,0.000028424693],"genre_scores_gemma":[0.99709475,0.0015737931,0.000051304465,0.0008056291,0.00013870302,0.000041844407,0.000003964533,0.0000138272735,0.00027618484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960963,0.00055609964,0.002263274,0.0001663045,0.0006684718,0.00024953],"domain_scores_gemma":[0.9968251,0.00044309272,0.0013744071,0.00015216049,0.0010230404,0.00018221213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025680496,0.00011692367,0.0012335498,0.00013195327,0.00003648889,0.000013417432,0.0002481487,0.00017719743,0.00009484133],"category_scores_gemma":[0.0039312583,0.00006138919,0.0002058736,0.00033084815,0.000828658,0.00010797681,0.000090850444,0.000622176,1.11239196e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00962142,0.0019986075,0.9433831,0.00012357035,0.00016859028,0.0000052751366,0.00054912764,0.000029939174,0.00038768435,0.000019771129,0.027824486,0.015888413],"study_design_scores_gemma":[0.020320235,0.0031386241,0.938643,0.0007247862,0.00011034119,0.0000042253564,0.00011430488,0.0025196625,0.0005773298,0.000018267545,0.033768237,0.000060988565],"about_ca_topic_score_codex":0.01104747,"about_ca_topic_score_gemma":0.0460582,"teacher_disagreement_score":0.03501073,"about_ca_system_score_codex":0.00019703218,"about_ca_system_score_gemma":0.0024080651,"threshold_uncertainty_score":0.99553806},"labels":[],"label_agreement":null},{"id":"W2902357265","doi":"10.1200/jco.2018.36.34_suppl.92","title":"The effect of palliative care consults on deprescribing in palliative cancer patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Alberta Children's Hospital; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Deprescribing; Medicine; Palliative care; Pill; Polypharmacy; Quality of life (healthcare); Cancer; Retrospective cohort study; Drug; Emergency medicine; Intensive care medicine; Internal medicine; Nursing; Psychiatry","score_opus":0.2750761008600258,"score_gpt":0.573436494000642,"score_spread":0.2983603931406162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902357265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915686,0.0025338382,0.0000125439465,0.00094192964,0.0012055774,0.0002863986,0.000015580177,0.0000027869726,0.0034327307],"genre_scores_gemma":[0.99539876,0.0032153844,0.00029715858,0.00043255967,0.0006013943,0.0000068662216,0.0000023135697,0.000011191957,0.000034394998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648786,0.000805084,0.0019319131,0.00015967035,0.0004036557,0.00021184688],"domain_scores_gemma":[0.9832189,0.012878625,0.0021313892,0.00015711713,0.0014640426,0.000149938],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016291043,0.0001453361,0.0014498718,0.00009912978,0.00004048499,0.0000028777813,0.00018451887,0.0002620283,0.000029911438],"category_scores_gemma":[0.017063702,0.000077745135,0.00034798752,0.00019006176,0.00061085087,0.000043317337,0.00004657913,0.0007395476,0.000005655075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010504407,0.00027331972,0.905922,0.000057758596,0.00031808706,0.000035878762,0.002485912,0.000008758665,0.000046798268,0.00003805408,0.00087252696,0.0794365],"study_design_scores_gemma":[0.014302638,0.04789432,0.9016592,0.0022172001,0.00027334562,6.315329e-7,0.0011120477,0.000029476601,0.00797902,0.00006475173,0.024383025,0.00008434877],"about_ca_topic_score_codex":0.00012245403,"about_ca_topic_score_gemma":0.00048640638,"teacher_disagreement_score":0.079352155,"about_ca_system_score_codex":0.00023916533,"about_ca_system_score_gemma":0.0006369683,"threshold_uncertainty_score":0.991216},"labels":[],"label_agreement":null},{"id":"W2902423257","doi":"10.1200/jco.2018.36.34_suppl.88","title":"Barriers to providing palliative care to patients with advanced cancer: A province-wide survey of oncology clinicians’ perceptions.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Referral; Family medicine; Palliative care; Perception; Nursing; Oncology; Psychology","score_opus":0.271130871578523,"score_gpt":0.5588176183394057,"score_spread":0.2876867467608827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902423257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287826,0.00029727916,0.0005003126,0.0030239255,0.0011369411,0.00079045945,0.00008571199,0.00000859743,0.0012785358],"genre_scores_gemma":[0.97537804,0.00070350786,0.01891609,0.004299536,0.0005819443,0.000019913066,0.000009618615,0.000027934466,0.00006339375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99519336,0.000863603,0.0027338762,0.00033715938,0.00052506814,0.0003469233],"domain_scores_gemma":[0.9857178,0.0042951666,0.0024243142,0.00026182627,0.006319959,0.0009809617],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002203502,0.00021592148,0.002337557,0.00024432482,0.00006391665,0.0000038938915,0.000288844,0.00037738154,0.0001753708],"category_scores_gemma":[0.032524753,0.00015055809,0.00028932365,0.0004413358,0.00047174984,0.00011497542,0.00009359346,0.0006695448,0.000013525055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014941768,0.00046677256,0.8331456,0.00006624125,0.00031704624,0.000030042793,0.004240149,0.000041198397,0.00006112143,0.000005076062,0.0020632786,0.14462169],"study_design_scores_gemma":[0.006794277,0.07068801,0.85021776,0.0011084725,0.00027964302,0.0000016021406,0.0031873411,0.0000065638565,0.00029714475,0.000008994173,0.06726957,0.0001406276],"about_ca_topic_score_codex":0.00052831805,"about_ca_topic_score_gemma":0.009008195,"teacher_disagreement_score":0.14448105,"about_ca_system_score_codex":0.0006508777,"about_ca_system_score_gemma":0.00769069,"threshold_uncertainty_score":0.99793476},"labels":[],"label_agreement":null},{"id":"W2902425806","doi":"10.1200/jco.2018.36.34_suppl.168","title":"Clinical and demographic variables of young adult (YA) patients referred to inpatient supportive care.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Cohort; Distress; Retrospective cohort study; Cancer; Internal medicine; Depression (economics); Psychiatry; Clinical psychology","score_opus":0.069196023932038,"score_gpt":0.4452860064241422,"score_spread":0.3760899824921042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902425806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896644,0.0001784893,0.00012327413,0.001107893,0.0053580618,0.00023892867,0.000016812457,0.0000065781805,0.0033055919],"genre_scores_gemma":[0.99389434,0.0004889709,0.0016061676,0.0024923717,0.0014472759,0.0000034426866,0.000005746202,0.000016503252,0.000045183624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951588,0.00053606473,0.0033252474,0.00026656582,0.00047434762,0.00023895479],"domain_scores_gemma":[0.99253786,0.001438466,0.0017600099,0.00024196795,0.0033524,0.0006693014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022328785,0.00014656958,0.0016048123,0.00019370689,0.000037753794,0.0000056609915,0.00015833396,0.0004747149,0.000084158426],"category_scores_gemma":[0.0073833037,0.000107385786,0.0004586066,0.0002568873,0.0005858455,0.00007651985,0.00011035413,0.000729538,0.0000063921916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063269897,0.0009187701,0.89735377,0.000047051497,0.00024379912,0.000039912527,0.0010942362,1.9726315e-7,0.000015552107,0.00007150686,0.0031991182,0.09068909],"study_design_scores_gemma":[0.006658445,0.046994954,0.92706406,0.00022652862,0.00043917316,0.000035857614,0.0010335535,0.0000067490146,0.00005699797,0.00014993036,0.017230142,0.000103630264],"about_ca_topic_score_codex":0.000160006,"about_ca_topic_score_gemma":0.0015664004,"teacher_disagreement_score":0.09058546,"about_ca_system_score_codex":0.00006411051,"about_ca_system_score_gemma":0.0010489111,"threshold_uncertainty_score":0.88390374},"labels":[],"label_agreement":null},{"id":"W2902460563","doi":"10.1200/jco.18.01580","title":"Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Genentech; Universiteit van Amsterdam","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Minimal residual disease; Hazard ratio; Gastroenterology; Neutropenia; Refractory (planetary science); Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Lymphoma; Confidence interval","score_opus":0.07805887314922061,"score_gpt":0.4367975780317877,"score_spread":0.3587387048825671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902460563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559176,0.0012424699,0.0000035832252,0.000908493,0.0007902609,0.0013333235,0.000013614474,0.0000078150215,0.00010867601],"genre_scores_gemma":[0.9981108,0.0004722024,0.00010006696,0.00012276307,0.0008873806,0.000024454575,0.000005523119,0.000030434729,0.0002464123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936304,0.0012736486,0.0034248675,0.0003775554,0.0008948582,0.0003986526],"domain_scores_gemma":[0.99300826,0.0029628498,0.0022322387,0.00055836694,0.00078992755,0.00044837888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037409046,0.00025103302,0.001936567,0.0002474426,0.000072063805,0.000009564206,0.00035247672,0.00034986256,0.0000819676],"category_scores_gemma":[0.005897944,0.00015559467,0.0004001611,0.00032041487,0.001258484,0.00012827241,0.00016755996,0.0006178998,0.0000056977556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5912629,0.03890676,0.18919946,0.001143184,0.0066547072,0.005756216,0.012245804,0.00032738905,0.029561553,0.00014227885,0.0020168433,0.12278295],"study_design_scores_gemma":[0.55653477,0.14363213,0.28466958,0.0005452648,0.0019319371,0.00032079703,0.0011278382,0.0073140715,0.0023173841,0.000087644774,0.0013010909,0.0002175033],"about_ca_topic_score_codex":0.0011439183,"about_ca_topic_score_gemma":0.001724289,"teacher_disagreement_score":0.12256545,"about_ca_system_score_codex":0.031943206,"about_ca_system_score_gemma":0.1123347,"threshold_uncertainty_score":0.97177297},"labels":[],"label_agreement":null},{"id":"W2902586695","doi":"10.1200/jco.2018.36.34_suppl.91","title":"Evaluation of a multi-disciplinary, systematic approach to palliative care for patients undergoing active treatment for head and neck cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Feeding tube; Head and neck cancer; Palliative care; Cancer; Medical record; Dysphagia; Radiation therapy; Emergency medicine; Internal medicine; Surgery; Nursing","score_opus":0.41415960825678755,"score_gpt":0.5788368683227693,"score_spread":0.1646772600659817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902586695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922931,0.0014340011,0.0010808287,0.00096289854,0.00062232977,0.0031900806,0.00003490739,0.0000026487876,0.00037918487],"genre_scores_gemma":[0.98367286,0.00028544056,0.01498151,0.00016009674,0.00051448535,0.00033966833,0.0000034290572,0.000011076029,0.00003144766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978802,0.0002587241,0.0012364363,0.000170746,0.00030602174,0.00014784711],"domain_scores_gemma":[0.9934086,0.002022374,0.0011181813,0.00008542936,0.0032004796,0.00016490051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016230312,0.00011097139,0.0015505431,0.00006854226,0.000081648264,0.0000027490305,0.000046930425,0.00013237279,0.0000021973037],"category_scores_gemma":[0.0047966843,0.00006873134,0.00024074345,0.0000615718,0.000093603565,0.00004186252,0.000025712798,0.000088311994,3.5119237e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046699923,0.014973088,0.15789434,0.021899588,0.008020843,0.000004686814,0.09018306,0.00017295663,0.000099838726,0.00009198737,0.0014347313,0.65852493],"study_design_scores_gemma":[0.09696402,0.31820732,0.53849757,0.009935211,0.00814672,0.0000068887366,0.01778067,0.008747698,0.00031440973,0.00028139143,0.00090434315,0.00021373293],"about_ca_topic_score_codex":0.000019946257,"about_ca_topic_score_gemma":0.0006650082,"teacher_disagreement_score":0.65831125,"about_ca_system_score_codex":0.0007842459,"about_ca_system_score_gemma":0.0017764944,"threshold_uncertainty_score":0.57424253},"labels":[],"label_agreement":null},{"id":"W2902616141","doi":"10.1200/jco.2018.36.34_suppl.227","title":"Exercise counseling in integrative cancer care: Effects on patient self-reported symptoms and quality of life.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Physical therapy; Distress; Breast cancer; Cancer; Psychological distress; Mental health; Clinical psychology; Psychiatry; Internal medicine; Nursing","score_opus":0.07231725780933197,"score_gpt":0.4663099392163322,"score_spread":0.3939926814070002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902616141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925992,0.0031214813,0.000017096698,0.0008655462,0.0022328736,0.00022823701,0.000003538929,0.000006421256,0.00092563883],"genre_scores_gemma":[0.99511105,0.002280567,0.0001778913,0.0016933233,0.0007008026,0.000007799817,9.593226e-7,0.000009947874,0.000017655513],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99671084,0.0005054166,0.002103998,0.00017749963,0.00035323712,0.00014899446],"domain_scores_gemma":[0.99465615,0.0021946526,0.0017117811,0.00014878734,0.0010162055,0.00027245193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019627316,0.0001224367,0.0015244004,0.00011648826,0.000019489162,0.0000035377966,0.000066577726,0.00028926082,0.00003328054],"category_scores_gemma":[0.0028214431,0.000081029066,0.00022273605,0.00015983703,0.00019074307,0.000045759745,0.00002486311,0.0006952555,0.0000013880995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01810929,0.0012112345,0.4334902,0.00037852483,0.0006383202,0.00019906159,0.01798215,0.000004472296,0.00029507224,0.00006348294,0.0009369007,0.5266913],"study_design_scores_gemma":[0.021870283,0.06293653,0.8711136,0.004643214,0.001242248,0.00005104358,0.009146335,0.00007512589,0.0034890343,0.00019463565,0.024912814,0.00032515437],"about_ca_topic_score_codex":0.0010429786,"about_ca_topic_score_gemma":0.0042813895,"teacher_disagreement_score":0.5263661,"about_ca_system_score_codex":0.00022290375,"about_ca_system_score_gemma":0.0015660712,"threshold_uncertainty_score":0.33777347},"labels":[],"label_agreement":null},{"id":"W2902656167","doi":"10.1200/jco.2018.36.34_suppl.135","title":"Outpatient acupuncture effects on patient self-reported symptoms in oncology care: A retrospective analysis of real-world data.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acupuncture Treatment Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Acupuncture; Physical therapy; Internal medicine; Distress; Breast cancer; Head and neck cancer; Cancer; Alternative medicine","score_opus":0.09702222555283777,"score_gpt":0.5091989531285582,"score_spread":0.41217672757572044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902656167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877629,0.0002522724,0.000019191997,0.0035985329,0.0010778834,0.0008930341,0.000027028656,0.000020442067,0.0063486835],"genre_scores_gemma":[0.9943149,0.000758783,0.0026399926,0.0012404877,0.00088522845,0.000016817912,0.00005356567,0.000021976983,0.000068267385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930371,0.0013585022,0.0034186568,0.00059258967,0.0011303733,0.000462777],"domain_scores_gemma":[0.9853157,0.007379352,0.0039709914,0.000941236,0.0019599416,0.00043278505],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030743007,0.00040879007,0.005451811,0.0013146469,0.00005676632,0.0000059305053,0.00037910146,0.00046700417,0.00006979366],"category_scores_gemma":[0.012137982,0.00018858042,0.00093047885,0.0017951815,0.00063554564,0.00009962268,0.0003539087,0.0016215735,0.000010525966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010279897,0.0051230765,0.87116146,0.000064294225,0.021361101,0.002786826,0.0019495385,0.000013054845,0.000043980133,0.00005673882,0.0055534756,0.08160656],"study_design_scores_gemma":[0.0068341736,0.10461751,0.85485727,0.00014591689,0.011152014,0.000039609073,0.00028726945,0.000108092165,0.00021776019,0.00005395599,0.021564987,0.00012144258],"about_ca_topic_score_codex":0.0002523692,"about_ca_topic_score_gemma":0.0062726373,"teacher_disagreement_score":0.099494435,"about_ca_system_score_codex":0.0024210664,"about_ca_system_score_gemma":0.0020426116,"threshold_uncertainty_score":0.9961832},"labels":[],"label_agreement":null},{"id":"W2902672529","doi":"10.1200/jco.18.01624","title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; Institute of Cancer Research; Jewish General Hospital","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Public Health Agency; MacroGenics; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Genomic Health","keywords":"Letrozole; Palbociclib; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Urology; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.14846606869792917,"score_gpt":0.5541645440786152,"score_spread":0.405698475380686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902672529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862159,0.00043560125,0.000100241254,0.008637832,0.0016923322,0.0027119848,0.000028003722,0.000013150994,0.00016494139],"genre_scores_gemma":[0.9899292,0.00037969823,0.0020972455,0.0025364002,0.0047532916,0.00020579745,0.000005529632,0.00003611048,0.000056708916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920538,0.0028789458,0.0035786985,0.00038364765,0.0006869244,0.0004179516],"domain_scores_gemma":[0.9935607,0.0030084532,0.0020285333,0.00022918219,0.00078598724,0.00038716657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010036178,0.0002584928,0.0030379724,0.00034652159,0.00007740027,0.000013741028,0.00023091199,0.00029490548,0.0010804157],"category_scores_gemma":[0.0036501056,0.00018766848,0.0004905905,0.0004223569,0.00033164545,0.00022210946,0.00006935349,0.0011782276,0.000025031763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5968614,0.0055863312,0.0035788966,0.0000017825931,0.0003575138,0.00014096267,0.002015172,0.000019574243,0.0006915145,0.00000942425,0.00009838524,0.39063898],"study_design_scores_gemma":[0.8181682,0.16226143,0.015893463,0.0002977987,0.00016882553,0.000101470796,0.0009026687,0.000069937945,0.00013810776,0.00036914696,0.0014776763,0.00015125272],"about_ca_topic_score_codex":0.00038101748,"about_ca_topic_score_gemma":0.00029235217,"teacher_disagreement_score":0.39048773,"about_ca_system_score_codex":0.0005966565,"about_ca_system_score_gemma":0.0019511017,"threshold_uncertainty_score":0.99983275},"labels":[],"label_agreement":null},{"id":"W2902717985","doi":"10.1200/jco.2018.36.34_suppl.187","title":"Total relaxation: A Buddhist mindfulness-based intervention pilot studies in laypersons and cancer patients.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mindfulness; Cancer; Breast cancer; Intervention (counseling); Physical therapy; Feeling; Adverse effect; Internal medicine; Clinical psychology; Psychiatry; Psychology","score_opus":0.2924090359902144,"score_gpt":0.5562065556839323,"score_spread":0.2637975196937179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902717985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990558,0.0011459893,0.00008885901,0.0054557086,0.002160488,0.00013592132,0.0000034801267,0.0000030081778,0.00044848994],"genre_scores_gemma":[0.99686635,0.000116432995,0.0003408747,0.00083124824,0.0016515595,0.000009428492,0.0000017040778,0.0000050788194,0.00017732497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811566,0.00021907606,0.0012300203,0.00012586756,0.00019365869,0.00011570437],"domain_scores_gemma":[0.99740344,0.0010413412,0.00084363855,0.000054118664,0.0005587438,0.0000987299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012962427,0.00008768447,0.0007908894,0.00012512042,0.00004819134,0.0000022206011,0.00004439223,0.00002691022,0.00018641636],"category_scores_gemma":[0.0031957694,0.000058529247,0.00012426937,0.00010069966,0.00056802295,0.000066877124,0.000047181853,0.00034784296,0.0000024484948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039965026,0.0019188019,0.74127626,0.000062565916,0.0003909422,0.00009726143,0.00044212292,0.0000010367812,0.000011894567,0.00005169136,0.0029310312,0.2488199],"study_design_scores_gemma":[0.019864267,0.06360169,0.89772695,0.00072127837,0.00029721286,0.000035835303,0.0015004668,0.000065614484,0.00015311313,0.00020387779,0.015756061,0.00007366058],"about_ca_topic_score_codex":0.00006538417,"about_ca_topic_score_gemma":0.0005130039,"teacher_disagreement_score":0.24874623,"about_ca_system_score_codex":0.0001355218,"about_ca_system_score_gemma":0.00018300244,"threshold_uncertainty_score":0.3825865},"labels":[],"label_agreement":null},{"id":"W2902915027","doi":"10.1200/jco.2018.36.34_suppl.203","title":"Association of impairments in activities of daily living (ADLs) with symptom burden, health care utilization, and survival among hospitalized patients with advanced cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Activities of daily living; Comorbidity; Bathing; Cancer; Quality of life (healthcare); Depression (economics); Internal medicine; Physical therapy; Charlson comorbidity index; Performance status","score_opus":0.028522420539070597,"score_gpt":0.4049875585745656,"score_spread":0.376465138035495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902915027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978464,0.00048589424,0.000044282602,0.000547641,0.0005837773,0.00024927608,0.000016087253,0.0000040405353,0.00022255021],"genre_scores_gemma":[0.9984642,0.0008523988,0.00023202859,0.00015533982,0.00022688246,0.0000046678397,0.0000046271225,0.00001478548,0.000045017154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975291,0.00037154625,0.0012675598,0.00014972009,0.00049951,0.00018255728],"domain_scores_gemma":[0.99487,0.00075278233,0.002892786,0.00010746736,0.0012232843,0.0001536987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001201214,0.00011354633,0.0012318504,0.0001208087,0.00002933452,0.000004084114,0.000070415896,0.00016868941,0.00002903348],"category_scores_gemma":[0.0007259449,0.0000796602,0.00008553465,0.00020991352,0.00021921887,0.00017578655,0.000028381,0.0003012416,7.349309e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037633346,0.0003638923,0.9622846,0.00014838342,0.00023012573,0.000006489935,0.0055205845,0.000010751198,0.0000046266614,0.0000026890139,0.000081276696,0.02758323],"study_design_scores_gemma":[0.008134975,0.02199558,0.9636264,0.0010098373,0.00014518865,0.000002685744,0.0045693424,0.0000129385,0.00002638992,0.0000046138935,0.00040253543,0.00006951783],"about_ca_topic_score_codex":0.0011965737,"about_ca_topic_score_gemma":0.015067585,"teacher_disagreement_score":0.027513713,"about_ca_system_score_codex":0.00044006153,"about_ca_system_score_gemma":0.0014942391,"threshold_uncertainty_score":0.8408066},"labels":[],"label_agreement":null},{"id":"W2903040004","doi":"10.1200/jco.2018.36.34_suppl.216","title":"Prediction of hospitalizations in patients with cancer age 70 and older receiving chemotherapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Medicine; Chemotherapy; Multivariate analysis; Internal medicine; Cancer; Univariate analysis; Population; Exact test; Disease; Surgery","score_opus":0.0690542074008144,"score_gpt":0.4530315156451838,"score_spread":0.3839773082443694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903040004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962221,0.00017357402,0.000038843948,0.0019111186,0.00061434705,0.00016059206,0.000004602041,0.000002589424,0.00087226235],"genre_scores_gemma":[0.9970762,0.00088050595,0.0005005129,0.00082771434,0.000554906,0.0000031360507,0.0000025524018,0.0000075370185,0.00014691173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998888,0.00008232856,0.00074504054,0.000085038955,0.000114598355,0.00008500712],"domain_scores_gemma":[0.9987312,0.00023550709,0.00060240075,0.000051429644,0.0002886531,0.000090822025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004122196,0.000057448156,0.0005293172,0.00008306405,0.000014524606,0.0000015891147,0.000031284857,0.00013004176,0.0002845451],"category_scores_gemma":[0.0001556384,0.00003801581,0.00005562569,0.000110158624,0.00020622609,0.000060333623,0.000009331921,0.00020062775,4.702623e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002562988,0.0015679683,0.9540503,0.00001338696,0.00019358876,0.000015906508,0.00034866668,0.0000018495357,0.000048925045,0.000005464094,0.002213588,0.038977366],"study_design_scores_gemma":[0.01534873,0.017039884,0.9603409,0.000119735385,0.00020332877,0.0000074644895,0.000020822328,0.000019432344,0.0000612382,0.0000320527,0.0067791296,0.000027251739],"about_ca_topic_score_codex":0.000039886294,"about_ca_topic_score_gemma":0.00014876759,"teacher_disagreement_score":0.038950115,"about_ca_system_score_codex":0.00008123294,"about_ca_system_score_gemma":0.00035263188,"threshold_uncertainty_score":0.31155694},"labels":[],"label_agreement":null},{"id":"W2903048052","doi":"10.1200/jco.2018.36.34_suppl.226","title":"An association between tobacco smoking, daily opioid use, pain response and the risk for aberrant opioid use behaviors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Opioid; Anxiety; Internal medicine; Smoking cessation; Morphine; Tobacco use; Cancer pain; Cancer; Psychiatry; Physical therapy; Population","score_opus":0.0996389485349773,"score_gpt":0.43802334097669204,"score_spread":0.33838439244171475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903048052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914468,0.0001660137,0.00083247904,0.0051248726,0.0019342727,0.00038757868,0.000054254244,0.000012727545,0.00004097921],"genre_scores_gemma":[0.9900341,0.0005331426,0.0010790261,0.003914179,0.0039937445,0.000012230781,0.0000084290905,0.000023838558,0.00040130067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99372286,0.003609447,0.0017494687,0.00022493843,0.00041516637,0.00027813812],"domain_scores_gemma":[0.97106683,0.025087966,0.002226158,0.00029849834,0.0009687974,0.00035177497],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029793467,0.00014722273,0.0012152246,0.00009670152,0.00015342423,0.00006553636,0.00018677677,0.0005875879,0.00004490143],"category_scores_gemma":[0.03099697,0.00009101973,0.00046511242,0.0001175667,0.00034595237,0.00028205715,0.00004284246,0.0010099637,0.0000023151629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022405306,0.00023789662,0.88873863,0.0000069741786,0.00030667303,0.000021149213,0.0010102467,3.779667e-7,0.0000358728,0.000024957035,0.0067500416,0.08046187],"study_design_scores_gemma":[0.008996081,0.012047087,0.7846183,0.000054228865,0.0012145538,0.000019509082,0.00029658206,0.00003398125,0.00003006886,0.00028623512,0.19231714,0.000086218846],"about_ca_topic_score_codex":0.0006431535,"about_ca_topic_score_gemma":0.0020491178,"teacher_disagreement_score":0.1855671,"about_ca_system_score_codex":0.00028240756,"about_ca_system_score_gemma":0.0009353443,"threshold_uncertainty_score":0.9990318},"labels":[],"label_agreement":null},{"id":"W2903089052","doi":"10.1200/jco.2018.36.34_suppl.196","title":"Examination of the Screener and Opioid Assessment for Patients with Pain-Short Form (SOAPP-SF) in an oncology palliative medicine clinic.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Logistic regression; Internal medicine; Observational study; Population; Cancer pain; Opioid; Cancer; Emergency medicine","score_opus":0.12893512822241984,"score_gpt":0.4891677460635716,"score_spread":0.3602326178411518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903089052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892847,0.0000381371,0.0021827281,0.004034128,0.0005771725,0.00083209603,0.0000024848755,0.0000037442896,0.0030447915],"genre_scores_gemma":[0.98612106,0.00023315342,0.009246539,0.0032500932,0.0009465223,0.000013678838,0.000009565065,0.000013991248,0.00016537518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622494,0.0009383853,0.0020163814,0.00020746303,0.00040759938,0.00020521991],"domain_scores_gemma":[0.992767,0.0041679097,0.001626684,0.00021083171,0.0010420758,0.00018553469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011955573,0.00013717075,0.0012016975,0.00016636547,0.000049886607,0.0000035744656,0.0001978022,0.00029940362,0.000059462232],"category_scores_gemma":[0.0039598,0.00007105737,0.00013367378,0.00017690752,0.00068939116,0.00013366838,0.00006693849,0.00053028244,5.4622535e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026969488,0.0015749552,0.7761338,0.000045774275,0.00014205952,0.000009385456,0.0003519935,7.037178e-7,0.000012613134,0.00019554397,0.0013513324,0.2174849],"study_design_scores_gemma":[0.011639959,0.07252762,0.8872976,0.00021911983,0.00031341182,0.0000012642623,0.0005548975,0.00057213195,0.0000064023493,0.0005743498,0.026225924,0.000067377034],"about_ca_topic_score_codex":0.0000093852095,"about_ca_topic_score_gemma":0.00034056936,"teacher_disagreement_score":0.21741752,"about_ca_system_score_codex":0.00017386972,"about_ca_system_score_gemma":0.0006376771,"threshold_uncertainty_score":0.47405365},"labels":[],"label_agreement":null},{"id":"W2903097628","doi":"10.1200/jco.2018.36.34_suppl.210","title":"Preliminary validation of the Edmonton Symptom Assessment Scale – Acute Leukemia (ESAS-AL) in patients with acute leukemia (AL).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Constipation; Itching; Anxiety; Physical therapy; Internal medicine; Psychiatry; Surgery","score_opus":0.0379535662499178,"score_gpt":0.4291157522819904,"score_spread":0.3911621860320726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903097628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98648995,0.000028153823,0.00018035396,0.008486559,0.00093052874,0.00074143976,0.000013406021,0.000011042395,0.003118558],"genre_scores_gemma":[0.9888004,0.0002518424,0.006223494,0.0035307356,0.0006204068,0.000012293953,0.00001586582,0.00004312058,0.00050183653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938429,0.00096049136,0.0028996821,0.00038371162,0.0014143039,0.00049893826],"domain_scores_gemma":[0.99329746,0.0014586569,0.0025871457,0.0006483979,0.0016014756,0.00040689387],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0042442707,0.00026506613,0.0016939894,0.00028509359,0.00009182069,0.000015943422,0.00065862795,0.0005534147,0.00013095747],"category_scores_gemma":[0.0011120971,0.00015277193,0.0004406714,0.0005440611,0.000879691,0.00032295618,0.00032437127,0.0023633086,0.000020353653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021874638,0.0018014505,0.91154236,0.0000398592,0.0013144553,0.00034412916,0.00032178962,0.000054459586,0.0015045016,0.00003544589,0.03398754,0.02717938],"study_design_scores_gemma":[0.018414447,0.03325322,0.9345888,0.0003391965,0.00078911614,0.00020465963,0.00008277551,0.00060798903,0.0015182903,0.00008673742,0.009968152,0.00014663843],"about_ca_topic_score_codex":0.000073116564,"about_ca_topic_score_gemma":0.00005614034,"teacher_disagreement_score":0.03145177,"about_ca_system_score_codex":0.0038847353,"about_ca_system_score_gemma":0.011788542,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W2903106796","doi":"10.1200/jco.2018.36.34_suppl.173","title":"Comparison of health care-related social media and Internet usage between patients treated with curative and palliative intent.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Social media; Palliative care; Logistic regression; Family medicine; Cancer; Internal medicine; Nursing","score_opus":0.39789722368677033,"score_gpt":0.5977436023445198,"score_spread":0.1998463786577495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903106796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050623,0.00032460233,0.000022970475,0.0064432207,0.001719552,0.00037482308,0.0000066791745,0.000005897997,0.00059601513],"genre_scores_gemma":[0.99805987,0.00021347281,0.00048994285,0.00017141405,0.0010410935,0.0000060315415,0.000005378587,0.0000074149925,0.0000054056254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994965,0.0023351517,0.0019423774,0.00015159862,0.00038235265,0.00022352382],"domain_scores_gemma":[0.9844752,0.010254584,0.0036775477,0.000041826803,0.0012379412,0.00031287604],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003058068,0.00009652201,0.0011916987,0.00009245202,0.00019718791,0.000010931078,0.00013521395,0.0003374917,0.00003116016],"category_scores_gemma":[0.011945481,0.00007269981,0.00006458346,0.00022576429,0.002039505,0.00014724956,0.000034111028,0.0005652027,0.0000017272397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021439622,0.0001712222,0.6703515,0.00000851414,0.0000663295,4.1478503e-7,0.18220255,1.213679e-8,1.2864905e-7,0.00018669563,0.00040945134,0.14638877],"study_design_scores_gemma":[0.0019587872,0.007593556,0.95580536,0.000080387625,0.000075618314,1.8590934e-7,0.0272214,0.0000025336913,0.000006116731,0.00026477585,0.0069286297,0.00006265949],"about_ca_topic_score_codex":0.0011886065,"about_ca_topic_score_gemma":0.0037613078,"teacher_disagreement_score":0.28545386,"about_ca_system_score_codex":0.0003202097,"about_ca_system_score_gemma":0.0017036849,"threshold_uncertainty_score":0.99637735},"labels":[],"label_agreement":null},{"id":"W2903268770","doi":"10.1200/jco.2018.36.34_suppl.209","title":"CACHEXIO: Evaluation of body composition changes and immunotherapy in patients with metastatic cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Lung cancer; Incidence (geometry); Adipose tissue; Adverse effect; Chemotherapy; Cancer; Gastroenterology; Progressive disease","score_opus":0.15653522290311092,"score_gpt":0.5169057084751956,"score_spread":0.3603704855720846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903268770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521667,0.0010701205,0.0000092155,0.0030741002,0.00022981825,0.00025486862,0.000003576502,8.97365e-7,0.0001407172],"genre_scores_gemma":[0.99763334,0.0010208905,0.00061149,0.00053014315,0.00018188059,0.000010690255,0.0000026780144,0.000005261999,0.0000036181846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986323,0.00023945916,0.00066980836,0.00007689697,0.00031174428,0.00006976338],"domain_scores_gemma":[0.998031,0.00032622498,0.00081987394,0.00006369849,0.0006950675,0.00006410803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015972918,0.000056560966,0.0006313451,0.00007706106,0.000011639256,0.000001998229,0.000024732384,0.00005590922,0.000104483435],"category_scores_gemma":[0.00012595329,0.000034734618,0.000052049756,0.00006833642,0.00013204158,0.00003876196,0.000006414731,0.00013224005,5.134667e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054541323,0.002186862,0.6649419,0.000013103272,0.00037215016,0.000007726374,0.0001516519,0.000005336089,0.00008437475,0.000009984972,0.00013207948,0.3266407],"study_design_scores_gemma":[0.023454197,0.029623719,0.9449017,0.00019382534,0.0006172044,0.000009250603,0.000028691471,0.000112254565,0.00029031467,0.000061057326,0.0006780545,0.000029701061],"about_ca_topic_score_codex":0.00014319064,"about_ca_topic_score_gemma":0.00063070556,"teacher_disagreement_score":0.326611,"about_ca_system_score_codex":0.00018863863,"about_ca_system_score_gemma":0.00051119726,"threshold_uncertainty_score":0.14164366},"labels":[],"label_agreement":null},{"id":"W2903272877","doi":"10.1200/jco.2018.36.34_suppl.111","title":"Feasibility of a massive online open course to teach skills in primary palliative care for a global audience.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palliative care; Medicine; Bachelor; Family medicine; Nursing; Primary care; Medical education","score_opus":0.3838922869031976,"score_gpt":0.6320067988272428,"score_spread":0.24811451192404516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903272877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98769444,0.00066855445,0.00051191216,0.0059299855,0.0006472811,0.00091172045,0.00013802458,0.000002841205,0.0034952227],"genre_scores_gemma":[0.93102854,0.00034796973,0.06465931,0.0030316373,0.00081173395,0.000009167478,0.000011661449,0.000008777711,0.00009117499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965071,0.00034496185,0.002339014,0.00025213207,0.00031786133,0.00023893756],"domain_scores_gemma":[0.9926766,0.002524796,0.0018340782,0.00022599171,0.0024154945,0.00032299754],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023497627,0.00013777686,0.002165813,0.000069880094,0.000022238055,0.000003684799,0.00041128747,0.00029658,0.00003979737],"category_scores_gemma":[0.01438705,0.00009789659,0.00038227096,0.0002614567,0.00045650054,0.00009341872,0.0001883151,0.00040676343,0.0000028300492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011902544,0.003992092,0.9205442,0.0001226743,0.00023876503,0.00008714554,0.0024200669,0.000006605031,0.00010446667,0.00010533039,0.0031050686,0.05737105],"study_design_scores_gemma":[0.011047603,0.03277137,0.9212518,0.0011556305,0.00026184932,0.000008260862,0.003460907,0.000015946403,0.00017538205,0.0007247572,0.029034188,0.0000923123],"about_ca_topic_score_codex":0.00006699229,"about_ca_topic_score_gemma":0.0009674697,"teacher_disagreement_score":0.0641474,"about_ca_system_score_codex":0.00058704347,"about_ca_system_score_gemma":0.003506009,"threshold_uncertainty_score":0.9939152},"labels":[],"label_agreement":null},{"id":"W2903278833","doi":"10.1200/jco.18.01583","title":"Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Simon Fraser University; University Health Network; Spinal Cord Injury BC","funders":"National Cancer Institute; Medical Research Council; Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre","keywords":"BCL6; Germinal center; Diffuse large B-cell lymphoma; Lymphoma; Medicine; Biology; Oncology; Cancer research; B cell; Genetics; Internal medicine; Antibody","score_opus":0.057047727094527635,"score_gpt":0.392159535548267,"score_spread":0.33511180845373933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903278833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911204,0.001302673,0.00011104783,0.00119817,0.0017987582,0.0002506952,0.000027795835,0.000012808373,0.0041776756],"genre_scores_gemma":[0.9916321,0.0006034633,0.003452854,0.001509881,0.002179553,0.000008573307,0.000017559058,0.000031227435,0.0005647776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959488,0.0002986203,0.0024377024,0.0003306922,0.00056266703,0.00042152507],"domain_scores_gemma":[0.9948759,0.0012115157,0.002310542,0.00037485998,0.00066781614,0.00055937713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001307663,0.0002796323,0.001792674,0.00014722529,0.00008160604,0.000012411794,0.00026043723,0.0006519896,0.00027078285],"category_scores_gemma":[0.00036694,0.0001726282,0.0008917786,0.00015011292,0.00029456033,0.0001109093,0.00015265757,0.00040017723,0.000055113906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03285717,0.16138446,0.70941806,0.00019794953,0.00056663656,0.004402655,0.00042501316,4.586535e-7,0.010939714,0.000097155775,0.042818733,0.036892004],"study_design_scores_gemma":[0.27000895,0.032395452,0.44636112,0.0005074883,0.0014869622,0.001397992,0.00012922216,0.000053493102,0.047008682,0.00015024062,0.20015468,0.00034569544],"about_ca_topic_score_codex":0.000023724206,"about_ca_topic_score_gemma":0.00003468333,"teacher_disagreement_score":0.2630569,"about_ca_system_score_codex":0.00020370513,"about_ca_system_score_gemma":0.0009003233,"threshold_uncertainty_score":0.7039574},"labels":[],"label_agreement":null},{"id":"W2903425560","doi":"10.1200/jco.2018.36.34_suppl.204","title":"Changes in symptom burden associated with exposure to outpatient palliative care in an integrated health system.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Advance care planning; Palliative care; Population; Cancer; Physical therapy; Family medicine; Internal medicine; Nursing","score_opus":0.2929536710100551,"score_gpt":0.5479608867626838,"score_spread":0.25500721575262875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903425560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289733,0.00073612697,0.000053486972,0.0049211737,0.0005398047,0.00036819544,0.000015431995,0.00000993036,0.00045849563],"genre_scores_gemma":[0.9956172,0.0002772533,0.0019083784,0.0015038507,0.0006241762,0.000008154452,0.000014067379,0.000015878633,0.000031056956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996184,0.0010759656,0.0018771198,0.00020875526,0.00037063292,0.00028354122],"domain_scores_gemma":[0.99503523,0.0012292869,0.0016234888,0.00015492324,0.0015671044,0.00038999185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023780803,0.00015428271,0.001904227,0.00032188348,0.000019950394,0.0000045890206,0.0001571138,0.0003448699,0.000018649254],"category_scores_gemma":[0.004137849,0.00010039298,0.0001084973,0.0004549979,0.00014512183,0.00006078547,0.000030695155,0.0007663827,0.000004561609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050907955,0.00075335184,0.9338909,0.00009713799,0.00017446165,0.00025129828,0.025410576,0.000045543657,0.000021623184,0.000021607739,0.00032458975,0.033918165],"study_design_scores_gemma":[0.009098495,0.14139263,0.78868747,0.0077841356,0.00008344625,0.000006936261,0.0407032,0.000061220584,0.00011453625,0.000006640003,0.011936522,0.00012476838],"about_ca_topic_score_codex":0.00039549475,"about_ca_topic_score_gemma":0.026905812,"teacher_disagreement_score":0.1452034,"about_ca_system_score_codex":0.0010781905,"about_ca_system_score_gemma":0.0018549858,"threshold_uncertainty_score":0.9908506},"labels":[],"label_agreement":null},{"id":"W2903506287","doi":"10.1200/jco.2018.36.34_suppl.208","title":"FIT: Functional and imaging testing for patients with metastatic cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cancer; Cachexia; Internal medicine; Clinical endpoint; Malignancy; Response Evaluation Criteria in Solid Tumors; Anorexia; Performance status; Clinical trial; Physical therapy; Oncology; Phases of clinical research","score_opus":0.1216903745679661,"score_gpt":0.4797659609511657,"score_spread":0.3580755863831996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903506287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98024905,0.00020030724,0.0070419475,0.010641517,0.0010677696,0.00015442798,0.0000022516454,0.0000072242756,0.0006355322],"genre_scores_gemma":[0.92244726,0.000027262351,0.07114862,0.004340257,0.0019304941,0.0000034986933,0.0000014719666,0.000014378498,0.0000867517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857885,0.00008288679,0.00084548525,0.00012411913,0.00021447764,0.00015416635],"domain_scores_gemma":[0.99541116,0.0026163547,0.0008112367,0.00005757108,0.0008468089,0.0002568586],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017875931,0.000076187695,0.0006099887,0.00006481666,0.00007117154,0.000009754383,0.000048269474,0.000044494707,0.00005159577],"category_scores_gemma":[0.01004126,0.00004643548,0.000089425586,0.00007440792,0.00033105488,0.000076551,0.000020519681,0.00049276196,0.0000011781468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012403968,0.00026762177,0.60785884,0.000023275921,0.00013016765,0.000026693584,0.000022843815,0.0000078583735,0.000022733304,0.00002494935,0.0028697334,0.3875049],"study_design_scores_gemma":[0.012072301,0.011443995,0.9202518,0.00020328298,0.00053261995,0.00024370762,0.000033956912,0.009921742,0.0000040338473,0.0003888088,0.044830665,0.000073107854],"about_ca_topic_score_codex":0.000012157909,"about_ca_topic_score_gemma":0.0000037161321,"teacher_disagreement_score":0.3874318,"about_ca_system_score_codex":0.000044932116,"about_ca_system_score_gemma":0.00067888957,"threshold_uncertainty_score":0.9982976},"labels":[],"label_agreement":null},{"id":"W2903507940","doi":"10.1200/jco.2018.36.34_suppl.167","title":"Development and evaluation of an innovative creative arts program on a tertiary palliative care unit.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Art Therapy and Mental Health","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital; Covenant Health","funders":"","keywords":"Medicine; Gratitude; Palliative care; The arts; Feeling; Grief; Psychosocial; Scale (ratio); Art therapy; Nursing; Psychology; Social psychology; Psychiatry; Visual arts; Physical therapy","score_opus":0.47692531762646473,"score_gpt":0.5681275510962586,"score_spread":0.09120223346979384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903507940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763507,0.00009205168,0.0000039465353,0.00033293062,0.0005169572,0.00032786038,0.0000042064507,0.000005524361,0.022365775],"genre_scores_gemma":[0.99523383,0.00003094883,0.0027896632,0.0010120169,0.0008335038,0.000011626535,0.000005998314,0.0000066592265,0.00007576725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773765,0.00054743566,0.0011597656,0.00011419474,0.00032363142,0.00011734709],"domain_scores_gemma":[0.99609864,0.0003778182,0.0012235809,0.000064778964,0.0021207621,0.00011440222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028280576,0.00009067781,0.0004591007,0.00008848442,0.00015165978,0.000009915278,0.00007721468,0.000093941315,0.00024551022],"category_scores_gemma":[0.00026226311,0.00006053549,0.000049433485,0.000040780404,0.0005739089,0.0001542969,0.000021934871,0.0002838381,0.0000049300174],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013920575,0.0013551782,0.0017333156,0.000015048405,0.00013340882,0.0000055967093,0.12885617,6.5580514e-7,0.0000075109488,0.005422513,0.00009665339,0.8609819],"study_design_scores_gemma":[0.0075769895,0.07511603,0.3125313,0.00036184333,0.00016188603,0.0000070173364,0.09886032,0.00014603848,0.001702469,0.0026630294,0.500665,0.0002080856],"about_ca_topic_score_codex":0.000016827893,"about_ca_topic_score_gemma":0.001093403,"teacher_disagreement_score":0.8607738,"about_ca_system_score_codex":0.00010880346,"about_ca_system_score_gemma":0.0011852138,"threshold_uncertainty_score":0.2688165},"labels":[],"label_agreement":null},{"id":"W2903517856","doi":"10.1200/jco.2012.30.27_suppl.25","title":"Metformin and breast cancer risk: A meta-analysis and critical literature review.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Metformin; Breast cancer; Meta-analysis; Internal medicine; Cochrane Library; Observational study; Hazard ratio; Odds ratio; Cancer; Oncology; Cohort study; Cohort; Publication bias; Glycemic; Confidence interval; Insulin","score_opus":0.08398438369483965,"score_gpt":0.4740763750984211,"score_spread":0.3900919914035814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903517856","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11375756,0.884168,0.00014090164,0.0012993772,0.00038145372,0.00005963928,0.00007563797,0.0000012170718,0.00011615944],"genre_scores_gemma":[0.19170882,0.8001388,0.0016224429,0.004951792,0.0014881042,0.000008440889,0.0000040557366,0.000008710622,0.00006885674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751174,0.00071821955,0.0011495758,0.00019928279,0.0001727002,0.00024845774],"domain_scores_gemma":[0.9977983,0.00041147994,0.0007835544,0.00018484535,0.0003769325,0.00044486413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043294667,0.00015047204,0.0017795324,0.00006807246,0.000041954507,0.000016710072,0.00012248657,0.0003525575,0.00024418216],"category_scores_gemma":[0.002069205,0.00009268742,0.001040494,0.00016753975,0.0002139929,0.000022785749,0.000079677564,0.0004870385,0.0000011621185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070857827,0.00074988854,0.08182625,0.00034385544,0.08483435,0.000038346232,0.00009402894,0.000002056803,0.00037384903,0.00026935432,0.02269968,0.80805975],"study_design_scores_gemma":[0.0009868208,0.0007873315,0.05856217,0.000048393875,0.1611862,0.00036104955,0.000020086805,0.0000060263806,0.00026649472,0.00017971332,0.77739316,0.00020253018],"about_ca_topic_score_codex":0.000009634234,"about_ca_topic_score_gemma":0.000035534642,"teacher_disagreement_score":0.8078572,"about_ca_system_score_codex":0.000008875273,"about_ca_system_score_gemma":0.00018084889,"threshold_uncertainty_score":0.37796834},"labels":[],"label_agreement":null},{"id":"W2903873307","doi":"10.1200/jco.18.00885","title":"Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"National Institute for Health and Care Research","keywords":"Medicine; Interquartile range; Hepatocellular carcinoma; Internal medicine; Hazard ratio; Gastroenterology; Human immunodeficiency virus (HIV); Liver cancer; Cancer; Proportional hazards model; Immunology; Confidence interval","score_opus":0.06908172650292099,"score_gpt":0.39575274550692824,"score_spread":0.32667101900400725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903873307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946094,0.00035643348,0.0000048352454,0.0013934079,0.001312495,0.00025639698,0.000011460532,0.0000046602527,0.0020508745],"genre_scores_gemma":[0.99827373,0.00007758194,0.00006960395,0.00097462075,0.00050080573,0.0000016321477,0.0000017749467,0.000006400517,0.00009385955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675906,0.00050329755,0.002001866,0.00016125709,0.00043564115,0.00013886213],"domain_scores_gemma":[0.99521136,0.0012067902,0.0024311591,0.00024040636,0.00079247175,0.0001178101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002335763,0.000107759115,0.0009870304,0.00005358,0.000024567575,0.0000015309494,0.0001497196,0.0002445386,0.000029348847],"category_scores_gemma":[0.007424672,0.0000654729,0.0003375703,0.00012889018,0.00044103997,0.00005783095,0.000038679496,0.0006765084,0.0000067757783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012355023,0.002400101,0.97223645,0.0000065955633,0.0003861161,0.00007735554,0.00062223506,0.000045443227,0.00029779787,0.00002375211,0.008465682,0.0030834589],"study_design_scores_gemma":[0.012707511,0.018477134,0.9620736,0.00006959489,0.00043698438,0.000009285582,0.00028252706,0.00042904276,0.00007258536,0.00012116859,0.005265096,0.000055421562],"about_ca_topic_score_codex":0.0016999058,"about_ca_topic_score_gemma":0.00035108524,"teacher_disagreement_score":0.016077032,"about_ca_system_score_codex":0.00072396547,"about_ca_system_score_gemma":0.0017936847,"threshold_uncertainty_score":0.88885623},"labels":[],"label_agreement":null},{"id":"W2904444972","doi":"10.1200/jco.2018.78.2276","title":"T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":992,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Clinical endpoint; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; KRAS; Clinical trial; Phases of clinical research; Immunotherapy; Colorectal cancer","score_opus":0.0401353546324534,"score_gpt":0.39514115414317325,"score_spread":0.35500579951071987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904444972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742335,0.00037479668,0.000020350686,0.00061265106,0.000368212,0.0008077048,0.000020377493,0.000017700957,0.00035488405],"genre_scores_gemma":[0.99523336,0.00018241456,0.0026823527,0.00046652314,0.0011409271,0.000031596504,0.000028809249,0.000031316416,0.00020272372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639183,0.00031262,0.0019446422,0.00036186207,0.0005744076,0.00041465703],"domain_scores_gemma":[0.9963824,0.0006542663,0.0016390572,0.0002048858,0.0007176774,0.00040171712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012940537,0.0002435736,0.0011217988,0.00013116375,0.00010681629,0.000027104632,0.00017015541,0.00035465756,0.000081251834],"category_scores_gemma":[0.00072384893,0.00015003872,0.00019607395,0.00022543268,0.0005888455,0.00017639682,0.00005785758,0.00067980646,0.0000035245885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19243583,0.0027878222,0.7453531,0.000072567054,0.00029442483,0.0004915149,0.0010264545,0.00001635311,0.013759069,4.1721958e-7,0.0027325186,0.041029923],"study_design_scores_gemma":[0.08046674,0.03153595,0.86304355,0.00076382497,0.00015538989,0.00021347008,0.00016046005,0.00011518547,0.017623885,0.00000820556,0.005725017,0.00018832787],"about_ca_topic_score_codex":0.00009138678,"about_ca_topic_score_gemma":0.000058411857,"teacher_disagreement_score":0.117690444,"about_ca_system_score_codex":0.00030716238,"about_ca_system_score_gemma":0.0017887414,"threshold_uncertainty_score":0.6118401},"labels":[],"label_agreement":null},{"id":"W2905529840","doi":"10.1200/jco.18.01585","title":"<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":471,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; Foundation Medicine; Pharmacyclics; Genentech; Incyte; Five Prime Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Exelixis; Alexion Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Stop Cancer","keywords":"Medicine; T790M; Internal medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Cancer; Cancer research; Gefitinib","score_opus":0.18107480095245018,"score_gpt":0.5113336326705391,"score_spread":0.3302588317180889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905529840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9171441,0.0026880642,0.00008458042,0.07166685,0.0025681204,0.0007512537,0.000018153303,0.000022885206,0.005055993],"genre_scores_gemma":[0.9626956,0.0032701304,0.0012612521,0.027112726,0.0037142728,0.000023941077,4.3237117e-7,0.000056304154,0.0018653275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99476814,0.00050171744,0.0028758927,0.00049300416,0.0006821204,0.00067914085],"domain_scores_gemma":[0.9935991,0.003147676,0.0009527082,0.0003777224,0.00065288454,0.0012698767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032720002,0.00030888658,0.0026425,0.00021100817,0.00010963763,0.000023057775,0.000371719,0.00022633538,0.00023250844],"category_scores_gemma":[0.0027201865,0.00017970189,0.00075621356,0.00021713295,0.0008194145,0.00011110608,0.00022305067,0.0016744965,0.000024768866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004857719,0.0007756505,0.9334382,0.00011642088,0.0007612116,0.0011915094,0.00029617615,7.07167e-7,0.000105216,0.000019824214,0.01597982,0.04245757],"study_design_scores_gemma":[0.011645173,0.016503695,0.7178852,0.00014180652,0.00087612885,0.00045481583,0.00020866771,0.0000429232,0.0004584961,0.000053066662,0.25155148,0.00017855612],"about_ca_topic_score_codex":0.00025217116,"about_ca_topic_score_gemma":0.0009147424,"teacher_disagreement_score":0.23557167,"about_ca_system_score_codex":0.0002802634,"about_ca_system_score_gemma":0.0020137664,"threshold_uncertainty_score":0.73280305},"labels":[],"label_agreement":null},{"id":"W2906394325","doi":"10.1200/jco.2012.30.15_suppl.5026","title":"Brief family history questionnaire for identification of Lynch syndrome in women with newly diagnosed endometrial cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Family history; Endometrial cancer; Lynch syndrome; Medical history; Population; Gynecology; Logistic regression; Family medicine; Medical record; Cancer; Internal medicine","score_opus":0.1041072345341725,"score_gpt":0.4270942662869386,"score_spread":0.3229870317527661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906394325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868567,0.0042372486,0.0006151854,0.001063743,0.0047648903,0.00046520412,0.000005683406,0.000005549788,0.00015682998],"genre_scores_gemma":[0.9952692,0.00073530676,0.0019901334,0.0006987635,0.0010761687,0.00007991773,0.0000010492091,0.000020158013,0.00012934058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965403,0.0002867217,0.0023311786,0.0001538764,0.00039272528,0.0002951847],"domain_scores_gemma":[0.9944488,0.0023353032,0.0021769337,0.00016999399,0.0005450825,0.0003239131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004481129,0.00011922749,0.001286277,0.00027819487,0.000013610677,0.0000023927441,0.00015256194,0.0003266748,0.000088556015],"category_scores_gemma":[0.0076562567,0.00009043399,0.00018965673,0.0002206675,0.00024792016,0.00012967263,0.000020850817,0.0005135222,0.0000019668375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0477476,0.0041718595,0.6487582,0.00030324145,0.0006243947,0.00017163802,0.0013510359,0.00022953033,0.0065654665,0.000105953746,0.00939272,0.28057837],"study_design_scores_gemma":[0.016454775,0.015789563,0.9362016,0.0002109382,0.00020137131,0.00014045447,0.00012577775,0.00002632224,0.00018689642,0.000079586105,0.030492892,0.000089837275],"about_ca_topic_score_codex":0.00010470909,"about_ca_topic_score_gemma":0.000075080825,"teacher_disagreement_score":0.2874434,"about_ca_system_score_codex":0.002076488,"about_ca_system_score_gemma":0.0030779145,"threshold_uncertainty_score":0.91658074},"labels":[],"label_agreement":null},{"id":"W2906445288","doi":"10.1200/jco.18.01279","title":"Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; U.S. Army; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; AstraZeneca; Celgene; Sanofi; Duke Clinical Research Institute; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Docetaxel; Oncology; Proportional hazards model; Regimen; Clinical endpoint; Gynecology; Cancer; Urology; Confidence interval; Clinical trial","score_opus":0.22113449729156442,"score_gpt":0.5174372183398704,"score_spread":0.296302721048306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906445288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025044508,0.9690404,0.000006485021,0.001020422,0.0001572543,0.001610401,0.00013116394,0.000008040705,0.002981356],"genre_scores_gemma":[0.0019036958,0.9931407,0.001045386,0.000048670365,0.00044783918,0.000030844523,0.00003148886,0.00005134799,0.0033000237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521416,0.0007507922,0.0026717575,0.00034997895,0.00067182205,0.00034150004],"domain_scores_gemma":[0.99319434,0.0012106334,0.003715631,0.0002487236,0.0011558733,0.0004748013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021222695,0.00038323345,0.005482224,0.00023133686,0.000040407005,0.000020272186,0.00015185105,0.00031396703,0.00013114286],"category_scores_gemma":[0.0002831446,0.000174145,0.00044618256,0.0002812551,0.0010220249,0.00011436742,0.000041113628,0.0010300954,0.0000039793704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07814853,0.0042314767,0.029714856,0.031987604,0.028966384,0.008131862,0.0005630743,0.000009948968,0.000010322209,0.000058632577,0.0076684016,0.8105089],"study_design_scores_gemma":[0.034345906,0.08502337,0.015058642,0.027758967,0.023108026,0.0011888063,0.00021727751,0.000019027277,0.000008223707,0.000053064276,0.8127562,0.00046251583],"about_ca_topic_score_codex":0.00009048683,"about_ca_topic_score_gemma":0.00024167664,"teacher_disagreement_score":0.8100464,"about_ca_system_score_codex":0.00028342148,"about_ca_system_score_gemma":0.008388137,"threshold_uncertainty_score":0.9972334},"labels":[],"label_agreement":null},{"id":"W2906531899","doi":"10.1200/jco.18.00790","title":"Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Tumor marker; Internal medicine; Germ cell tumors; Oncology; Pathology; Cancer; Chemotherapy","score_opus":0.016821693350867688,"score_gpt":0.33766041159528404,"score_spread":0.32083871824441634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906531899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970715,0.0014947603,0.000039332495,0.00048253752,0.00039118037,0.00039342337,0.000014990761,0.00000769123,0.00010460914],"genre_scores_gemma":[0.99833316,0.00014072965,0.00060174684,0.0004165073,0.00046355478,0.000005251485,0.000010457181,0.000021715152,0.000006868974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971187,0.00040478745,0.0016491174,0.0002971304,0.000294251,0.00023600372],"domain_scores_gemma":[0.9960735,0.0006874927,0.0024998977,0.00025711235,0.00018528997,0.00029670156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011597686,0.00017759117,0.0009947153,0.000081238744,0.00004839631,0.000008322526,0.00012774923,0.00014724952,0.00001568638],"category_scores_gemma":[0.0011611766,0.00010359075,0.00021667933,0.00011252363,0.00048209692,0.00008304258,0.00006490768,0.00052819174,0.0000033529643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013479487,0.0022701789,0.9404483,0.0000092153205,0.00026835123,0.0031385308,0.00004265474,3.240337e-7,0.00029545682,4.4726488e-7,0.00028380292,0.03976324],"study_design_scores_gemma":[0.02073207,0.011842666,0.9594393,0.00034139518,0.0009605692,0.006102055,0.00008597032,0.000029700814,0.00017020933,0.000019984553,0.0001834521,0.000092678],"about_ca_topic_score_codex":0.0007094772,"about_ca_topic_score_gemma":0.00019535654,"teacher_disagreement_score":0.03967056,"about_ca_system_score_codex":0.00019180043,"about_ca_system_score_gemma":0.00072656013,"threshold_uncertainty_score":0.4224308},"labels":[],"label_agreement":null},{"id":"W2906729146","doi":"10.1200/jco.2014.32.15_suppl.6513","title":"Impact of duration of adjuvant therapy (AT) on cancer survival.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Proportional hazards model; Discontinuation; Cancer; Cohort; Population; Stage (stratigraphy); Logistic regression; Hazard ratio; Surgery; Oncology; Colorectal cancer; Confidence interval; Oxaliplatin","score_opus":0.21761892523337503,"score_gpt":0.5501208074755597,"score_spread":0.3325018822421847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906729146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909744,0.000898612,0.000011239335,0.001987045,0.0007511234,0.000105123974,0.000005647069,0.000001944923,0.005264865],"genre_scores_gemma":[0.99403477,0.004870958,0.00010087109,0.00026105987,0.0005498724,0.0000024737021,8.467736e-7,0.000006767574,0.00017236614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793804,0.00022268358,0.0014033646,0.00008622635,0.0002507038,0.00009900869],"domain_scores_gemma":[0.9963021,0.0013577665,0.0016688604,0.0001049769,0.0004575549,0.00010874298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012165318,0.00008731082,0.0013502173,0.00006142336,0.000018613937,8.8708504e-7,0.00005599279,0.00012811382,0.00025796122],"category_scores_gemma":[0.0011100008,0.00004606087,0.0005443048,0.00006817958,0.00012577431,0.000026440817,0.000016868917,0.00022118397,0.0000019148924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02099556,0.0018800047,0.6030924,0.000015092721,0.0012024741,0.000018917008,0.00015332173,0.000041536063,0.0014788195,0.00005217813,0.0023133927,0.36875632],"study_design_scores_gemma":[0.0076565016,0.057161286,0.92593205,0.00006883235,0.00015458453,0.000013018034,0.000020648671,0.000030192368,0.00062070525,0.000084891915,0.008222329,0.000034947374],"about_ca_topic_score_codex":0.00015555257,"about_ca_topic_score_gemma":0.00019425688,"teacher_disagreement_score":0.36872137,"about_ca_system_score_codex":0.00022129179,"about_ca_system_score_gemma":0.0006308019,"threshold_uncertainty_score":0.28244945},"labels":[],"label_agreement":null},{"id":"W2906780340","doi":"10.1200/jco.2014.32.15_suppl.e15571","title":"Surgical ischemia and detection of clear cell renal cell carcinoma biomarkers.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clear cell renal cell carcinoma; Biomarker; Perioperative; Nephrectomy; Renal cell carcinoma; Ischemia; Clear cell; Cohort; Pathology; Internal medicine; Oncology; Kidney; Surgery; Biology","score_opus":0.05748911722807229,"score_gpt":0.3719757220900661,"score_spread":0.31448660486199376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906780340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98137546,0.00088226266,0.00012819793,0.0007519759,0.00042154908,0.00012551567,0.0000010197904,0.0000057110396,0.016308313],"genre_scores_gemma":[0.99621004,0.00025141262,0.0022361202,0.00017442719,0.0008217989,0.00000118118,0.0000011930582,0.000018327986,0.00028551693],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99670184,0.00051846396,0.0019796807,0.00022096219,0.00036489032,0.00021418066],"domain_scores_gemma":[0.9955326,0.0018620272,0.0015735936,0.00021333083,0.00032795983,0.00049054023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027968024,0.00015740067,0.001353703,0.00014476888,0.000030220715,0.000005198374,0.000101278274,0.00046551073,0.00007633961],"category_scores_gemma":[0.0006566749,0.0001091959,0.0005119899,0.00011451739,0.00027704122,0.00006190222,0.000059475482,0.00073323207,0.000012987783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041702673,0.0054694875,0.2948206,0.00053181563,0.00060613756,0.003663058,0.00021035052,0.00000994054,0.34987065,0.00004476004,0.003902468,0.29916805],"study_design_scores_gemma":[0.026282992,0.06661829,0.4819127,0.000081140104,0.0012604416,0.0028335436,0.00012194671,0.00043361238,0.3343665,0.00012325349,0.0857565,0.00020906822],"about_ca_topic_score_codex":0.000026854575,"about_ca_topic_score_gemma":0.0000056389654,"teacher_disagreement_score":0.298959,"about_ca_system_score_codex":0.000106334155,"about_ca_system_score_gemma":0.00042203514,"threshold_uncertainty_score":0.44528794},"labels":[],"label_agreement":null},{"id":"W2906804973","doi":"10.1200/jco.2014.32.15_suppl.9523","title":"Palliative radiotherapy for bone metastases: Population-based utilization near end of life in a Canadian province.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palliative care; Genitourinary system; Radiation therapy; Population; Internal medicine; Life expectancy; Pelvis; Lung cancer; Surgery","score_opus":0.13247052916745036,"score_gpt":0.4625070546024163,"score_spread":0.330036525434966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906804973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483034,0.0006439692,0.027113385,0.021050766,0.0006548932,0.0015013919,0.00005192197,0.000007953842,0.00067232706],"genre_scores_gemma":[0.95430446,0.000053513842,0.039461046,0.005853123,0.00021711289,0.000009906494,0.000035487767,0.000016295044,0.000049033548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964712,0.00058392773,0.002264607,0.00014836043,0.00031470833,0.00021715858],"domain_scores_gemma":[0.9947577,0.0023568266,0.0017957551,0.00016574508,0.00032960196,0.00059434836],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056085736,0.0001076498,0.0013154845,0.00029391254,0.000025067338,0.0000072440735,0.00010111839,0.00014230386,0.00024748506],"category_scores_gemma":[0.014782672,0.000085696054,0.00031896125,0.0001489663,0.00010570092,0.00007333903,0.0000066031357,0.00024188249,0.000001330813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008377547,0.0023201276,0.8417172,0.00039193238,0.00053270464,0.0000951952,0.0001014516,0.0015212977,0.000017014012,0.002381306,0.003927145,0.13861707],"study_design_scores_gemma":[0.020474853,0.0076924236,0.8091617,0.00014347941,0.000520157,0.0000028283087,0.00007311019,0.05253862,0.0000084404455,0.00066161965,0.108617246,0.00010549472],"about_ca_topic_score_codex":0.008773894,"about_ca_topic_score_gemma":0.044133574,"teacher_disagreement_score":0.13851157,"about_ca_system_score_codex":0.00024963115,"about_ca_system_score_gemma":0.00576843,"threshold_uncertainty_score":0.9998679},"labels":[],"label_agreement":null},{"id":"W2906827916","doi":"10.1200/jco.2014.32.15_suppl.5522","title":"Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Cisplatin; Medicine; Nuclear export signal; In vivo; Cancer; Cancer research; Apoptosis; Ovarian cancer; Refractory (planetary science); In vitro; Pharmacokinetics; Pharmacology; Oncology; Internal medicine; Chemotherapy; Biology; Cell nucleus; Biochemistry; Nucleus","score_opus":0.03223171022178561,"score_gpt":0.3593790091952818,"score_spread":0.3271472989734962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906827916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980396,0.000051371484,0.000042479212,0.00036162458,0.0009802022,0.0002052224,0.000012726684,0.0000027712651,0.0003040029],"genre_scores_gemma":[0.9976094,0.00013811876,0.0009846553,0.00033596405,0.00086713827,0.0000018993787,0.0000024310693,0.000027970314,0.000032430016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99558675,0.0009798304,0.00252902,0.00035632518,0.00032820358,0.0002198519],"domain_scores_gemma":[0.99498147,0.0005137642,0.003487143,0.00030503247,0.00053362345,0.00017898215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028045918,0.00019380539,0.0011730371,0.000058087582,0.00005160683,0.0000088847855,0.00025168704,0.00070584053,0.000022439408],"category_scores_gemma":[0.0028105062,0.00012353083,0.0003112259,0.00012970036,0.0006249995,0.000025680114,0.00014329144,0.0009899688,5.469363e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0191297,0.0015236228,0.90666395,0.000024792756,0.00026341242,0.000005387103,0.0000697685,0.000010263464,0.012026158,0.00002363597,0.0011955857,0.05906369],"study_design_scores_gemma":[0.0066125295,0.020800594,0.95611364,0.000066688044,0.00014139585,0.000008588023,0.000031379812,0.000023889115,0.0017137926,0.00005486709,0.014297811,0.00013483582],"about_ca_topic_score_codex":0.00008641936,"about_ca_topic_score_gemma":0.00032532387,"teacher_disagreement_score":0.05892886,"about_ca_system_score_codex":0.000038430826,"about_ca_system_score_gemma":0.0006930404,"threshold_uncertainty_score":0.54440886},"labels":[],"label_agreement":null},{"id":"W2906898167","doi":"10.1200/jco.2013.31.15_suppl.3534","title":"Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care South East; Princess Margaret Cancer Centre; Ottawa Hospital; McMaster University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Hazard ratio; Internal medicine; Colorectal cancer; Oncology; Systemic therapy; Cancer; Induction chemotherapy; Clinical trial; Maintenance therapy; Confidence interval; Radiation therapy; Chemotherapy; Breast cancer","score_opus":0.7982382956893898,"score_gpt":0.5909382153687214,"score_spread":0.20730008032066838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906898167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9126723,0.07192459,0.0006155534,0.005450902,0.0013631834,0.007553513,0.00034022814,0.000011141205,0.00006858577],"genre_scores_gemma":[0.98895097,0.0018450125,0.0024089105,0.0011913441,0.00033392222,0.0051880595,0.00002027486,0.000025571306,0.000035919642],"study_design_codex":"meta_analysis","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9686395,0.0082340455,0.021914791,0.0005638933,0.00023498671,0.0004128145],"domain_scores_gemma":[0.8654732,0.10727648,0.025566503,0.0003605071,0.0011101324,0.00021319566],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.053221684,0.0003996542,0.02351432,0.0004827416,0.00009017725,0.00013566548,0.00049874646,0.00032533077,0.0014171626],"category_scores_gemma":[0.03191106,0.0002470649,0.0058138166,0.00026127815,0.00023547141,0.000429523,0.00003798186,0.0004151625,0.000012009982],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31713402,0.0014549746,0.09154152,0.00058641954,0.49957842,0.000026215665,0.031947233,0.03855197,0.000015400505,0.00048750898,0.0005313526,0.018144976],"study_design_scores_gemma":[0.73201406,0.009581814,0.024265649,0.0006606221,0.1807994,0.0000029790467,0.032404505,0.01796423,0.000029897441,0.00050314225,0.0011891267,0.00058454333],"about_ca_topic_score_codex":0.20424758,"about_ca_topic_score_gemma":0.2131776,"teacher_disagreement_score":0.41488007,"about_ca_system_score_codex":0.0031449492,"about_ca_system_score_gemma":0.005005044,"threshold_uncertainty_score":0.99999815},"labels":[],"label_agreement":null},{"id":"W2906924309","doi":"10.1200/jco.2014.32.15_suppl.e20524","title":"Interobserver variation in predicting fracture risk in patients with long bone metastatic lesions.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pathologic fracture; Orthopedic surgery; Internal medicine; Surgery; Radiology","score_opus":0.05526922012185403,"score_gpt":0.3998482788889992,"score_spread":0.3445790587671452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906924309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99024224,0.000050586892,0.0064472943,0.0022783438,0.00032964823,0.00032828507,0.0000017445816,0.0000057161083,0.000316114],"genre_scores_gemma":[0.9856902,0.000038071368,0.011657072,0.0023968122,0.00015107139,0.0000035090804,0.0000059746417,0.000015392297,0.000041924435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954996,0.0012349,0.002370146,0.00019174728,0.00050597487,0.00019761012],"domain_scores_gemma":[0.9949273,0.0020826329,0.00228596,0.00020316482,0.00025955544,0.00024141165],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071957754,0.00012928182,0.0011863223,0.000296362,0.000017404527,0.000008963459,0.00011308321,0.00013059635,0.0001229519],"category_scores_gemma":[0.013472051,0.00008577089,0.00016602164,0.00020697601,0.000061131366,0.0002038017,0.000045852288,0.0011422373,0.000008169705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004729234,0.0029270346,0.94924396,0.000059417158,0.00017660578,0.00023243364,0.00014370293,0.0005000155,5.5168834e-7,0.000018312037,0.0003827239,0.04158602],"study_design_scores_gemma":[0.022602966,0.0059542693,0.96682274,0.00030409673,0.0006002607,0.0000092791215,0.000068060406,0.0020593759,4.3306534e-7,0.00033045793,0.0011778645,0.000070216054],"about_ca_topic_score_codex":0.000045203164,"about_ca_topic_score_gemma":0.00015598131,"teacher_disagreement_score":0.0415158,"about_ca_system_score_codex":0.00012529355,"about_ca_system_score_gemma":0.00029910175,"threshold_uncertainty_score":0.9948379},"labels":[],"label_agreement":null},{"id":"W2906959486","doi":"10.1200/jco.2014.32.15_suppl.8581","title":"Efficacy, safety, and cost efficiency of rituximab, gemcitabine, dexamethasone, and oxaliplatin (RGDOx) in B-cell NHL: Report of the prospective multicentric trial NCT01019863.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Hôpital de l'Enfant-Jésus; BC Cancer Agency; Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Neutropenia; Rituximab; Internal medicine; Regimen; Gemcitabine; Gastroenterology; Surgery; Febrile neutropenia; Toxicity; Chemotherapy; Lymphoma","score_opus":0.061327356409881684,"score_gpt":0.4378011206439991,"score_spread":0.37647376423411744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906959486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925157,0.00047961037,0.0002109577,0.0012546711,0.0006147249,0.0013457158,0.000003500443,0.000003826089,0.0035713052],"genre_scores_gemma":[0.99671334,0.00052701304,0.00198228,0.00012332092,0.00041451803,0.0000047151193,9.0730043e-7,0.000018024892,0.00021588765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936468,0.0010769985,0.0038305179,0.0003228415,0.00078991026,0.0003329099],"domain_scores_gemma":[0.9830183,0.012656257,0.0029614938,0.00041200986,0.0006407844,0.00031115592],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011565605,0.000171424,0.0021263692,0.00022341202,0.00004010136,0.0000067379947,0.00025671892,0.00043343758,0.000037761547],"category_scores_gemma":[0.04313209,0.000104868595,0.00031598608,0.0004605539,0.0010300054,0.00006865301,0.00024518653,0.0012370402,0.0000021016372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4785828,0.030266184,0.34086737,0.00096042914,0.00069577736,0.0021586225,0.0014240509,0.00027570233,0.0023660737,0.0007897861,0.0013397689,0.14027344],"study_design_scores_gemma":[0.6460386,0.015661364,0.32249966,0.0003089225,0.00041564534,0.0018259089,0.00014021462,0.007050565,0.000852522,0.00021637375,0.0048517627,0.00013848297],"about_ca_topic_score_codex":0.00022021552,"about_ca_topic_score_gemma":0.00009204222,"teacher_disagreement_score":0.16745579,"about_ca_system_score_codex":0.001298409,"about_ca_system_score_gemma":0.007844554,"threshold_uncertainty_score":0.99778},"labels":[],"label_agreement":null},{"id":"W2907019586","doi":"10.1200/jco.2014.32.15_suppl.6568","title":"Socioeconomic status and lifestyle behaviors in cancer survivors.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Socioeconomic status; Lung cancer; Logistic regression; Cancer; Population; Confounding; Smoking cessation; Disease; Demography; Multivariate analysis; Internal medicine; Gerontology; Environmental health; Pathology","score_opus":0.06752983944173513,"score_gpt":0.4552186938004624,"score_spread":0.3876888543587273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907019586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904064,0.0009703449,0.000014306742,0.004652998,0.00224128,0.000070881884,0.000002482573,0.0000046778077,0.0016366083],"genre_scores_gemma":[0.9931202,0.0027097014,0.0001467439,0.002674776,0.0011232949,0.000003611915,8.6428633e-7,0.0000127436215,0.00020806264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780834,0.00032796114,0.001366215,0.00014390236,0.00013404472,0.00021956372],"domain_scores_gemma":[0.9975071,0.0011689382,0.00070354814,0.000108670734,0.00013477585,0.00037699382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026890931,0.000091491966,0.0010952592,0.00010530305,0.000016978478,0.0000063875186,0.000070657334,0.0002938858,0.00025335266],"category_scores_gemma":[0.000704976,0.00007190716,0.00020299635,0.000051103063,0.00016292497,0.00007321173,0.000033224205,0.0008033996,0.000009656699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056219316,0.00025816646,0.84688526,0.00001706597,0.00003646698,0.000041500247,0.00026480595,0.0000042571046,0.000022553526,0.00006282506,0.0005068129,0.15133809],"study_design_scores_gemma":[0.0035317028,0.002932801,0.84979576,0.000045478286,0.00012035377,0.00004202595,0.00027175026,0.000032937347,0.000013452759,0.00019320268,0.14295147,0.00006905614],"about_ca_topic_score_codex":0.0028845696,"about_ca_topic_score_gemma":0.031369735,"teacher_disagreement_score":0.15126903,"about_ca_system_score_codex":0.00017978402,"about_ca_system_score_gemma":0.0009861025,"threshold_uncertainty_score":0.98630524},"labels":[],"label_agreement":null},{"id":"W2907129893","doi":"10.1200/jco.2014.32.15_suppl.2078","title":"A phase II study of whole brain radiotherapy with simultaneous integrated boost using volumetric modulated arc therapy for 1 to 10 brain metastases.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Radiosurgery; Brain metastasis; Clinical endpoint; Radiation therapy; Nuclear medicine; Lung cancer; Primary tumor; Oncology; Metastasis; Internal medicine; Surgery; Cancer; Clinical trial","score_opus":0.1168901751515622,"score_gpt":0.4477374966414164,"score_spread":0.3308473214898542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907129893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374424,0.00006793815,0.059783168,0.0016224546,0.000365635,0.0006315588,0.000053968703,0.000015206612,0.000017673121],"genre_scores_gemma":[0.96661305,0.0000089087935,0.031039033,0.001895656,0.00028194886,0.0000053720623,0.0000052063274,0.000027469501,0.00012337776],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99541616,0.0015139005,0.0020755273,0.0002959113,0.00041361857,0.00028488148],"domain_scores_gemma":[0.99053246,0.0065271747,0.0015307616,0.00024797046,0.0008828329,0.00027878638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006151627,0.00020646943,0.0016699998,0.00027441743,0.00013433553,0.00003425056,0.00038518978,0.00014933852,0.00043420924],"category_scores_gemma":[0.0033578125,0.00012882287,0.00027387377,0.000564862,0.00015537284,0.00016849098,0.000022265296,0.00028669756,0.0000063087946],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04127082,0.022289846,0.00024428876,0.000024884805,0.0007282315,0.0001763486,0.0010669712,0.012512991,0.7739832,0.000046709596,0.0021736075,0.1454821],"study_design_scores_gemma":[0.12063545,0.61840886,0.00069468236,0.00013978776,0.00056692166,0.00038643557,0.00080539874,0.05142966,0.028612396,0.00062781264,0.17704633,0.000646286],"about_ca_topic_score_codex":0.000120296965,"about_ca_topic_score_gemma":0.00015357764,"teacher_disagreement_score":0.7453708,"about_ca_system_score_codex":0.000060512128,"about_ca_system_score_gemma":0.0005134983,"threshold_uncertainty_score":0.5253244},"labels":[],"label_agreement":null},{"id":"W2907244787","doi":"10.1200/jco.18.00474","title":"Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; McGill University; McGill University Health Centre; Ottawa Hospital; University of Manitoba; Université Laval; Toronto General Hospital; SickKids Foundation; University of Toronto; Dalhousie University; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"PMS2; Medicine; MSH6; DNA mismatch repair; Lynch syndrome; MSH2; Cancer; MLH1; Cancer research; Internal medicine; Colorectal cancer","score_opus":0.09735795156169769,"score_gpt":0.4197024419549971,"score_spread":0.32234449039329943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907244787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730779,0.0012521388,0.00771989,0.0051252036,0.009747059,0.00065897335,0.00004630267,0.000019776866,0.0023527683],"genre_scores_gemma":[0.9787377,0.00023535018,0.017852236,0.0012771346,0.0014490165,0.000029954721,0.000006099553,0.00001186567,0.00040063364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666214,0.00021793149,0.0020878229,0.0002441956,0.00057990226,0.00020798977],"domain_scores_gemma":[0.97208095,0.025240231,0.0013411143,0.00027116688,0.0008785518,0.0001880031],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033430995,0.00013990514,0.0011258903,0.00007393815,0.000054069365,0.000003962672,0.00018554354,0.0003902911,0.0017132601],"category_scores_gemma":[0.011458922,0.000085068765,0.0008811195,0.00012934647,0.0007167387,0.000050812865,0.000059913003,0.0006696105,0.000053782373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008016911,0.0020262226,0.8241487,0.00012998669,0.0010927955,0.000069212816,0.000098230565,0.0018292696,0.0013808239,0.00096004084,0.14417185,0.016075967],"study_design_scores_gemma":[0.008084488,0.017448656,0.730141,0.00020233617,0.0011601798,0.00026588477,0.00016424063,0.0020682137,0.0010862673,0.00091077754,0.2383211,0.00014688166],"about_ca_topic_score_codex":0.000028450615,"about_ca_topic_score_gemma":0.00002646908,"teacher_disagreement_score":0.09414924,"about_ca_system_score_codex":0.00017893557,"about_ca_system_score_gemma":0.0033856833,"threshold_uncertainty_score":0.99919933},"labels":[],"label_agreement":null},{"id":"W2907322496","doi":"10.1200/jco.2014.32.15_suppl.e17674","title":"Does the side of surgery and treatment have an effect on cardiovascular measurements in breast cancer survivors?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Surgery; Blood pressure; Side effect (computer science); Hormone therapy; Cancer; Breast cancer; Internal medicine","score_opus":0.17804367442507127,"score_gpt":0.47283594077418845,"score_spread":0.29479226634911715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907322496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926101,0.0007782441,0.0000022253619,0.004578013,0.0012902204,0.00023743455,0.0000050035696,0.0000028029297,0.0004959356],"genre_scores_gemma":[0.995735,0.002335839,0.00002169619,0.00073208637,0.00110098,0.00001555141,0.0000012734367,0.0000112080015,0.00004638871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641055,0.0018307606,0.0011061173,0.0001719547,0.00030713083,0.00017350582],"domain_scores_gemma":[0.99450606,0.004320934,0.00062469003,0.0001966015,0.00015699661,0.00019469924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005687118,0.00014294533,0.0018504516,0.00011161037,0.000025414154,0.0000036126771,0.00006870887,0.00018169911,0.000055618475],"category_scores_gemma":[0.0004414831,0.000058040194,0.00064778555,0.000067038825,0.00017773676,0.00004628766,0.000014817477,0.0003240495,0.0000011550575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00438128,0.0012269812,0.6812646,0.000018317247,0.001260299,0.000063428524,0.00007440258,0.000041928743,0.00014186658,0.0000017780199,0.0001007694,0.31142437],"study_design_scores_gemma":[0.00924233,0.012233969,0.9627492,0.00010232014,0.0013809906,0.00011592046,0.00003284973,0.000031543404,0.0006488667,0.000030102728,0.01337099,0.000060923274],"about_ca_topic_score_codex":0.001876626,"about_ca_topic_score_gemma":0.0038640904,"teacher_disagreement_score":0.31136346,"about_ca_system_score_codex":0.00022415652,"about_ca_system_score_gemma":0.00046367277,"threshold_uncertainty_score":0.283691},"labels":[],"label_agreement":null},{"id":"W2907342474","doi":"10.1200/jco.2014.32.15_suppl.6594","title":"Comparison of RCC surveillance guidelines: Competing tradeoffs.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiation exposure; Guideline; Renal cell carcinoma; Nephrectomy; Risk assessment; Nuclear medicine; Medical physics; Oncology; Internal medicine; Pathology; Kidney","score_opus":0.34462978616178547,"score_gpt":0.5469357402240312,"score_spread":0.20230595406224577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907342474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787804,0.0010500288,0.00088865956,0.007998595,0.0010612117,0.0001237597,0.0000011720626,0.000008893483,0.010087303],"genre_scores_gemma":[0.9791933,0.00016252494,0.018036969,0.0009920961,0.001489514,8.0104263e-7,0.0000023077137,0.000015364434,0.00010713152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937011,0.00073664624,0.004710542,0.0001640751,0.00048289722,0.0002047339],"domain_scores_gemma":[0.9906379,0.004369804,0.0033995002,0.000250106,0.0010026834,0.00034003388],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062271967,0.00014125819,0.0026443808,0.00010163192,0.000023780181,0.0000037693403,0.0001835827,0.00028209976,0.000093856135],"category_scores_gemma":[0.009523175,0.00009418968,0.00065075944,0.00011754249,0.00020273215,0.000038882252,0.00003872192,0.0007261844,0.00001818684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019208532,0.00163104,0.83963364,0.00006891921,0.00028163544,0.0001231082,0.00009714751,0.00011406477,0.0010241133,0.00013616003,0.0068411184,0.1481282],"study_design_scores_gemma":[0.009291293,0.02314944,0.82080656,0.00021295939,0.00032196238,0.00045841341,0.00024160185,0.0020445813,0.0012563384,0.00013924783,0.14196184,0.00011576363],"about_ca_topic_score_codex":0.000016255653,"about_ca_topic_score_gemma":0.000019937906,"teacher_disagreement_score":0.14801243,"about_ca_system_score_codex":0.00009843348,"about_ca_system_score_gemma":0.00064324884,"threshold_uncertainty_score":0.99882},"labels":[],"label_agreement":null},{"id":"W2907383822","doi":"10.1200/jco.2014.32.15_suppl.e14527","title":"Is laparoscopic resection in select T4 colorectal lesions comparable to open resection for achieving adequate margins?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Contraindication; Surgery; Laparoscopy; Population; Colorectal cancer; Resection margin; Retrospective cohort study; Odds ratio; Logistic regression; Cancer; Internal medicine; Resection","score_opus":0.2622564082595478,"score_gpt":0.5358981935057573,"score_spread":0.27364178524620947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907383822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98093504,0.00009025506,0.00053333706,0.008313815,0.0018233038,0.0011188488,0.000004101941,0.000011341879,0.007169941],"genre_scores_gemma":[0.99161625,0.000095612195,0.004515153,0.001726989,0.0009005431,0.00009390224,0.000003852698,0.000024228042,0.0010234908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962989,0.0007526372,0.0018924717,0.00034777014,0.00032672595,0.0003814654],"domain_scores_gemma":[0.9943746,0.0036724014,0.00085706287,0.00019081254,0.00042988025,0.00047524483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049718465,0.00016451733,0.0016808121,0.0002790524,0.0001059369,0.00003325062,0.0002790472,0.00036298824,0.00020429894],"category_scores_gemma":[0.005503988,0.00012838338,0.00035207428,0.00050486444,0.00007136918,0.00020336107,0.00014558533,0.0009176822,0.000031366155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18927231,0.0056940666,0.60688365,0.00013177571,0.0007701856,0.0002336812,0.00060705515,0.0004563283,0.0016723946,0.00038790386,0.03001538,0.16387524],"study_design_scores_gemma":[0.02076196,0.09164091,0.79891574,0.00039463973,0.00022340109,0.00017807448,0.000096974785,0.0013810855,0.0012301774,0.00054095715,0.084478,0.00015805404],"about_ca_topic_score_codex":0.00020099343,"about_ca_topic_score_gemma":0.0016992929,"teacher_disagreement_score":0.1920321,"about_ca_system_score_codex":0.0007325798,"about_ca_system_score_gemma":0.000840116,"threshold_uncertainty_score":0.6589185},"labels":[],"label_agreement":null},{"id":"W2907451490","doi":"10.1200/jco.2018.36.4_suppl.824","title":"A phase II trial of the effect of perindopril on hand foot syndrome (HFSR) incidence and severity in patients receiving regorafenib with refractory metastatic colorectal carcinoma (mCRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Regorafenib; Perindopril; Clinical endpoint; Interim analysis; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Colorectal cancer; Surgery; Oncology; Clinical trial; Blood pressure; Cancer","score_opus":0.03779630698213137,"score_gpt":0.3952876897858462,"score_spread":0.35749138280371484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907451490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998124,0.000049810904,0.000006060409,0.00035198347,0.000548147,0.00073910377,0.0000042066827,0.0000028727384,0.00017380314],"genre_scores_gemma":[0.99928063,0.000029674527,0.00036991396,0.00012827647,0.00014794433,0.000004002041,5.417734e-7,0.000017413753,0.000021599273],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99573654,0.0013310834,0.0019578175,0.00022303355,0.00055341446,0.00019813282],"domain_scores_gemma":[0.9928451,0.0038349018,0.002530617,0.0002602953,0.00034678483,0.00018231181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043034307,0.00017910119,0.0018925968,0.00014582454,0.00006231761,0.0000042932784,0.00019087417,0.00029568013,0.000039011262],"category_scores_gemma":[0.008263866,0.00009997103,0.00026156078,0.00025876943,0.0010346471,0.00009725708,0.000086788925,0.0011849231,6.112012e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5287485,0.008043444,0.41622797,0.00011502817,0.00043768203,0.0003053915,0.00080007117,0.0000031072725,0.002358663,0.0000016705045,0.00008375219,0.04287475],"study_design_scores_gemma":[0.17555432,0.32204366,0.49436775,0.00044067664,0.00029007692,0.0002904606,0.00001901052,0.00004400273,0.0067368033,0.000016404449,0.00012935106,0.000067491594],"about_ca_topic_score_codex":0.000042473,"about_ca_topic_score_gemma":0.00012986042,"teacher_disagreement_score":0.35319418,"about_ca_system_score_codex":0.00019347668,"about_ca_system_score_gemma":0.0007972345,"threshold_uncertainty_score":0.9893217},"labels":[],"label_agreement":null},{"id":"W2907477020","doi":"10.1200/jco.2014.32.15_suppl.6570","title":"Urban and rural differences in outcomes of head and neck cancer (HNC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Residence; Population; Cancer; Demography; Proportional hazards model; Multivariate analysis; Rural area; Gerontology; Internal medicine; Environmental health; Pathology","score_opus":0.14179818434177854,"score_gpt":0.49522726926325594,"score_spread":0.3534290849214774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907477020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98285055,0.0024212268,0.0000026568798,0.012938781,0.00046848174,0.000055203003,0.0000016092199,0.0000017173082,0.0012597732],"genre_scores_gemma":[0.9939182,0.0037968494,0.00032001734,0.0014602859,0.00034949795,0.0000015524517,9.633927e-8,0.0000040339382,0.00014948804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835646,0.00015366785,0.0011448468,0.00008219643,0.00013789463,0.000124941],"domain_scores_gemma":[0.9976241,0.001524782,0.00052416156,0.00005818904,0.00010557223,0.00016318631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010515719,0.00007762685,0.00168551,0.00006718305,0.00001570183,0.0000023039129,0.00004561035,0.00013996531,0.000022658667],"category_scores_gemma":[0.0015909723,0.000045395293,0.00009973193,0.000047533686,0.0002580887,0.000041434872,0.00003665513,0.00038303266,3.98179e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006266495,0.0002152652,0.9158599,0.000033032975,0.00009655024,0.00001593238,0.00022921347,1.0713265e-7,0.000029672017,0.00007610378,0.0012752443,0.08154236],"study_design_scores_gemma":[0.00579211,0.007356845,0.9756196,0.00020502148,0.000090857015,0.00002157676,0.00014199,0.000033227538,0.000008559235,0.00020502225,0.01048311,0.00004205299],"about_ca_topic_score_codex":0.00016243862,"about_ca_topic_score_gemma":0.0007121278,"teacher_disagreement_score":0.08150031,"about_ca_system_score_codex":0.000025250465,"about_ca_system_score_gemma":0.00024872343,"threshold_uncertainty_score":0.19046575},"labels":[],"label_agreement":null},{"id":"W2907496901","doi":"10.1200/jco.2018.36.4_suppl.854","title":"Variation in the use of adjuvant chemotherapy following neoadjuvant radiotherapy and surgery for rectal cancer in a publicly-insured health care system.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Colorectal cancer; Radiation therapy; Internal medicine; Retrospective cohort study; Cancer; Logistic regression; Health care; Chemoradiotherapy; Chemotherapy; Oncology; Surgery","score_opus":0.1769613705762693,"score_gpt":0.48231024110888937,"score_spread":0.30534887053262005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907496901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822057,0.0039075008,0.00014547879,0.011775299,0.001152623,0.00075555756,0.000010153732,0.0000055643645,0.000042131076],"genre_scores_gemma":[0.99303913,0.0015434698,0.002159837,0.0025022817,0.0006902215,0.000036836085,0.0000021542262,0.000017415397,0.000008656465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963167,0.0008070088,0.002119462,0.00020460863,0.0003055607,0.0002466588],"domain_scores_gemma":[0.9932771,0.004723018,0.001400527,0.00015193401,0.00029913938,0.00014828869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004451085,0.00012991898,0.0018124062,0.0002182914,0.00003259675,0.000012383294,0.000090472284,0.00023482648,0.00001678693],"category_scores_gemma":[0.0015125067,0.000079141566,0.00041852478,0.00031495732,0.00010407776,0.00014156528,0.000011271414,0.00035684902,1.5405658e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01520532,0.00090677873,0.61897564,0.000155542,0.00041184216,0.00016167428,0.0037145307,0.000010730404,0.000073578834,0.000034437933,0.00089170295,0.3594582],"study_design_scores_gemma":[0.013478733,0.010013921,0.9540238,0.0005733053,0.000084609135,0.0001129926,0.00046576397,0.0005347762,0.000016966846,0.000018682756,0.020600477,0.000076008146],"about_ca_topic_score_codex":0.001059992,"about_ca_topic_score_gemma":0.0028417176,"teacher_disagreement_score":0.35938218,"about_ca_system_score_codex":0.0008448785,"about_ca_system_score_gemma":0.001956284,"threshold_uncertainty_score":0.3470364},"labels":[],"label_agreement":null},{"id":"W2907600475","doi":"10.1200/jco.2014.32.15_suppl.11026","title":"The use of whole-genome sequencing in therapeutic for decision making in patients with advanced malignancies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Ion semiconductor sequencing; KRAS; Oncology; Internal medicine; Cancer; Colorectal cancer; Bioinformatics; DNA sequencing; Gene; Biology; Genetics","score_opus":0.0724228581644367,"score_gpt":0.3866799241158889,"score_spread":0.3142570659514522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907600475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911697,0.00034354822,0.009878191,0.00015792495,0.000304109,0.00016650003,0.000008039578,4.0455373e-7,0.00002430727],"genre_scores_gemma":[0.9916303,0.00024912762,0.0073785316,0.0005834758,0.00013437726,0.000004239345,0.0000026757232,0.000010605057,0.0000066257076],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984041,0.00012414878,0.0010828472,0.00012443634,0.00010662621,0.00015783429],"domain_scores_gemma":[0.9963071,0.0023631607,0.00086449005,0.00015805343,0.00026306938,0.00004412547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014561558,0.00007519128,0.00039943086,0.000046072048,0.000022923057,0.000009210352,0.00017272725,0.0001544545,8.0093434e-7],"category_scores_gemma":[0.0036262956,0.000047426263,0.000114853625,0.00006272614,0.00009034699,0.0000067960186,0.000046156394,0.00016830955,2.0050076e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013949069,0.00048381084,0.38775122,0.000020499423,0.000103644175,0.000008107893,0.00007035722,0.0303172,0.011564163,0.0004583226,0.00014764452,0.55512595],"study_design_scores_gemma":[0.009356181,0.01598351,0.81134415,0.00019976812,0.000045389424,0.000005853724,0.000068544316,0.0005471315,0.00030317262,0.0018500407,0.16013099,0.00016523976],"about_ca_topic_score_codex":0.0000048058787,"about_ca_topic_score_gemma":0.00036904836,"teacher_disagreement_score":0.5549607,"about_ca_system_score_codex":0.000099237004,"about_ca_system_score_gemma":0.00056603,"threshold_uncertainty_score":0.43412763},"labels":[],"label_agreement":null},{"id":"W2907626779","doi":"10.1200/jco.2014.32.15_suppl.2089","title":"Comparison of hypofractionated radiation with temozolomide to the current standard of care in the treatment of glioblastoma: Results from a single institution.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Concomitant; Temozolomide; Univariate analysis; Radiation therapy; Adjuvant; Glioblastoma; Clinical endpoint; Proportional hazards model; Internal medicine; Retrospective cohort study; Dose fractionation; Multivariate analysis; Surgery; Nuclear medicine; Oncology; Clinical trial","score_opus":0.09017045558002997,"score_gpt":0.4541654660188654,"score_spread":0.3639950104388355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907626779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122006,0.0013782352,0.00008590074,0.00633986,0.00035318758,0.00035540928,0.000048724585,0.0000016121892,0.0002170366],"genre_scores_gemma":[0.9987896,0.00031134734,0.0005776068,0.000088166766,0.00021098497,0.0000073160863,0.000010078933,0.0000041291373,7.6535486e-7],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971717,0.000445213,0.0018162832,0.00010945564,0.00037139293,0.00008593806],"domain_scores_gemma":[0.9945046,0.0031831446,0.0015435786,0.00020185074,0.0004903723,0.00007645836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090888166,0.00009115265,0.001099355,0.00011558878,0.000023558961,0.0000026883297,0.00009458347,0.000090198955,0.0000051950637],"category_scores_gemma":[0.001500307,0.000039899714,0.00020194962,0.00020337297,0.00013023523,0.00004113183,0.000008751578,0.000206817,0.0000010458133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043906577,0.01374299,0.1806114,0.000023366638,0.00042838012,0.000030869054,0.0033005648,0.0034093822,0.00026051345,0.000106304804,0.0010397222,0.7531399],"study_design_scores_gemma":[0.028217113,0.1559513,0.6515683,0.00035233013,0.0008213358,0.0000174033,0.0013448679,0.0002267055,0.010237786,0.000052876847,0.1511523,0.00005768763],"about_ca_topic_score_codex":0.00013097085,"about_ca_topic_score_gemma":0.001132646,"teacher_disagreement_score":0.7530822,"about_ca_system_score_codex":0.00026126532,"about_ca_system_score_gemma":0.00051114144,"threshold_uncertainty_score":0.17961161},"labels":[],"label_agreement":null},{"id":"W2907694304","doi":"10.1200/jco.2014.32.15_suppl.e17556","title":"Absolute risk and cost of management of toxicities of newly approved anticancer drugs: A meta-analysis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine; Drug; Toxicity; Adverse effect; Relative risk; Placebo; Pharmacology; Internal medicine; Meta-analysis; Oncology; Confidence interval; Pathology; Alternative medicine","score_opus":0.166550402184465,"score_gpt":0.3895969750296335,"score_spread":0.22304657284516846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907694304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89097375,0.014185853,0.027568838,0.0019827683,0.00094895886,0.00043071646,0.00027256194,0.0000046361347,0.063631915],"genre_scores_gemma":[0.9847375,0.008071094,0.006388524,0.00034173194,0.00013401541,0.000004472558,7.425617e-7,0.00001034522,0.00031155857],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99513316,0.00011379128,0.0042948034,0.00020653877,0.000071312716,0.00018039596],"domain_scores_gemma":[0.98994976,0.0010497455,0.00839382,0.00027392164,0.00019756256,0.00013519244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060346723,0.000132272,0.004159084,0.00029386498,0.000019623722,0.0000073471165,0.0002815123,0.00020589867,0.00022713815],"category_scores_gemma":[0.0007713478,0.00011307691,0.0014688156,0.00019835724,0.00041813034,0.00017328463,0.00007870882,0.00028468488,0.0000039812808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029231373,0.0023026885,0.17177449,0.0004838697,0.22470376,0.000012705145,0.0012132637,0.0046186377,0.000016146909,0.35216638,0.0033921916,0.2363927],"study_design_scores_gemma":[0.009692581,0.0066373907,0.6133508,0.00004548242,0.051208526,0.0000060905795,0.0006417909,0.004090467,0.00015902481,0.083220005,0.2304457,0.0005021126],"about_ca_topic_score_codex":0.00026154265,"about_ca_topic_score_gemma":0.000079141326,"teacher_disagreement_score":0.44157633,"about_ca_system_score_codex":0.00004206269,"about_ca_system_score_gemma":0.000098490105,"threshold_uncertainty_score":0.46111426},"labels":[],"label_agreement":null},{"id":"W2907731149","doi":"10.1200/jco.2018.36.4_suppl.794","title":"The impact of chronic kidney disease in locally advanced rectal cancer patients treated with neoadjuvant chemoradiation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; St. John’s Health Sciences Centre; University of Calgary; Dr. H. Bliss Murphy Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Renal function; Internal medicine; Capecitabine; Kidney disease; Colorectal cancer; Hazard ratio; Neoadjuvant therapy; Proportional hazards model; Oncology; Urology; Cancer; Breast cancer; Confidence interval","score_opus":0.03800606589371769,"score_gpt":0.43714673547962385,"score_spread":0.39914066958590616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907731149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607414,0.00062816456,0.000004461394,0.0014360514,0.00043366972,0.00038535724,0.000015220004,0.0000057443062,0.0010171962],"genre_scores_gemma":[0.99800134,0.0009118661,0.00010134352,0.00023965862,0.0005981576,0.00001728745,0.0000057124207,0.000017744853,0.000106891755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731994,0.00025842208,0.0015683987,0.0001953234,0.00037771228,0.0002802124],"domain_scores_gemma":[0.9957674,0.0009820511,0.0014787044,0.00019609867,0.000868764,0.0007069374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007296518,0.00016308809,0.001099231,0.00008712664,0.000041255036,0.0000055431296,0.00014953394,0.00015192376,0.00019254789],"category_scores_gemma":[0.002924984,0.00007844685,0.0003951876,0.0003417067,0.00045674312,0.00010681883,0.00003329999,0.0004765751,0.000006227369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047438126,0.002149207,0.75607866,0.000011084576,0.0003807072,0.00018989175,0.000031248364,0.00011853773,0.00003374892,0.0000031489428,0.0004809061,0.19308472],"study_design_scores_gemma":[0.022794046,0.05365037,0.91896856,0.0002926945,0.00021176119,0.000015954249,0.0000058269707,0.00060397654,0.000105414816,0.000039635077,0.0032357953,0.00007598017],"about_ca_topic_score_codex":0.0002731461,"about_ca_topic_score_gemma":0.00036130968,"teacher_disagreement_score":0.19300874,"about_ca_system_score_codex":0.0014086862,"about_ca_system_score_gemma":0.006561722,"threshold_uncertainty_score":0.99907017},"labels":[],"label_agreement":null},{"id":"W2907871591","doi":"10.1200/jco.2014.32.15_suppl.e14627","title":"Treatment patterns and progression-free survival (PFS) in first-line metastatic colorectal (mCRC) patients (pts) on an oxaliplatin-based chemotherapy (OX-t): A Canadian retrospective chart review.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Bevacizumab; Oxaliplatin; FOLFIRI; FOLFOX; Internal medicine; Progression-free survival; Colorectal cancer; Irinotecan; Oncology; Retrospective cohort study; Chemotherapy; Capecitabine; Surgery; Cancer","score_opus":0.07739181201287954,"score_gpt":0.46429319807991426,"score_spread":0.3869013860670347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907871591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97710276,0.00033350557,0.0000057887232,0.020078711,0.0008347234,0.00092195737,0.000049577353,0.000008496992,0.00066447054],"genre_scores_gemma":[0.9887827,0.0035812282,0.00043999718,0.00638419,0.00064100686,0.00004578595,0.000043332366,0.000027355263,0.000054420925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966671,0.0007882738,0.0015111965,0.00033343353,0.00035434176,0.00034565097],"domain_scores_gemma":[0.99618644,0.0015259376,0.0010156704,0.00022671015,0.00027610757,0.00076912646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018573961,0.00025805758,0.0018748526,0.0002217221,0.000062159575,0.000008087652,0.00014130659,0.0002150286,0.0003923278],"category_scores_gemma":[0.0013349856,0.00017166686,0.00027487148,0.00015009397,0.00013226333,0.000068419184,0.000016286313,0.00056340237,0.000006842207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006803028,0.0069972896,0.83814734,0.00009490036,0.00033191993,0.00035289963,0.00015805027,0.000007007229,0.0000095584655,0.000019980449,0.0011968128,0.14588122],"study_design_scores_gemma":[0.040784337,0.10332817,0.8327283,0.00061111694,0.000489044,0.00004204132,0.000017040957,0.00040237958,0.000053073934,0.00009601277,0.021304935,0.00014352474],"about_ca_topic_score_codex":0.0037431428,"about_ca_topic_score_gemma":0.10911316,"teacher_disagreement_score":0.1457377,"about_ca_system_score_codex":0.0009977871,"about_ca_system_score_gemma":0.0012773041,"threshold_uncertainty_score":0.90714324},"labels":[],"label_agreement":null},{"id":"W2907944812","doi":"10.1200/jco.2018.36.4_suppl.797","title":"Potential drug cost impact of nivolumab (N) in Canada in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Nivolumab; Colorectal cancer; Oncology; Internal medicine; Context (archaeology); Immunotherapy; Chemotherapy; DNA mismatch repair; Cancer; Pembrolizumab","score_opus":0.24620073453541463,"score_gpt":0.49623566838754346,"score_spread":0.2500349338521288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907944812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375457,0.0003546348,0.000060786395,0.003236306,0.0016079434,0.0005008243,0.00016552776,0.0000033155998,0.00031607557],"genre_scores_gemma":[0.9969196,0.000071196955,0.0011235876,0.0015390182,0.0002742792,0.000014783336,0.000005100544,0.000019519684,0.000032920932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98765314,0.0010081854,0.010357796,0.00032641817,0.00022574383,0.00042869206],"domain_scores_gemma":[0.98770225,0.0022819894,0.009083669,0.000224649,0.00040400674,0.0003034199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019606825,0.00017315219,0.0026902128,0.00036168116,0.000042153624,0.000010410858,0.00030417723,0.00014536631,0.0004565382],"category_scores_gemma":[0.0054213414,0.00015835006,0.00031327183,0.0002955477,0.00019059423,0.00025924225,0.000046388494,0.0005410504,0.00003032891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011969572,0.0008040787,0.984653,0.000048483278,0.00020186548,0.00001969492,0.00038840933,0.0019285828,4.272914e-7,0.000086972854,0.009821542,0.0008499828],"study_design_scores_gemma":[0.007080045,0.00290707,0.984028,0.000109107845,0.000025812144,0.000007720588,0.00037279076,0.0028993438,0.000001961049,0.00032314882,0.0020852126,0.00015981677],"about_ca_topic_score_codex":0.53264594,"about_ca_topic_score_gemma":0.85620356,"teacher_disagreement_score":0.32355762,"about_ca_system_score_codex":0.004561612,"about_ca_system_score_gemma":0.010395401,"threshold_uncertainty_score":0.9992597},"labels":[],"label_agreement":null},{"id":"W2907986520","doi":"10.1200/jco.2018.36.4_suppl.849","title":"Social and contextual factors and their relationship with the use of palliative chemotherapy in patients with metastatic colorectal cancer (mCRC): A retrospective cohort study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Colorectal cancer; Cohort; Oncology; Cancer; Palliative care; Retrospective cohort study; Logistic regression; Gastroenterology","score_opus":0.3396661062608113,"score_gpt":0.5176457647511129,"score_spread":0.17797965849030162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907986520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983941,0.00010828211,0.00004322431,0.00082830945,0.00005587992,0.00050631625,0.0000145609065,0.0000017552894,0.000047580448],"genre_scores_gemma":[0.99913263,0.00014505743,0.00037106065,0.00021609967,0.000106334046,0.000005695745,0.0000012601895,0.00000978186,0.00001205024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828666,0.00042815073,0.00078739447,0.00013523678,0.00025486544,0.00010770812],"domain_scores_gemma":[0.9942191,0.0034929246,0.0012797137,0.00005813635,0.0008740273,0.000076076634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009147396,0.0001230583,0.0012177572,0.00006927921,0.000043600507,0.000004661767,0.000050736802,0.0000954678,0.000014970296],"category_scores_gemma":[0.0015832596,0.000054103693,0.00006906647,0.00016278663,0.0009498921,0.0000935088,0.000017323982,0.00044572641,8.052337e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010940795,0.0008181649,0.9727745,0.000008216781,0.0010162075,0.0000067463984,0.012978544,6.5505503e-7,0.00000492543,0.00002829073,0.0001158189,0.0013071132],"study_design_scores_gemma":[0.010821291,0.025647439,0.95871913,0.00013200499,0.0003053541,0.0000014051583,0.00388082,0.000010252714,0.000041582865,0.00004489062,0.00034062203,0.00005522649],"about_ca_topic_score_codex":0.00018636264,"about_ca_topic_score_gemma":0.001988893,"teacher_disagreement_score":0.024829274,"about_ca_system_score_codex":0.00010214223,"about_ca_system_score_gemma":0.000389506,"threshold_uncertainty_score":0.3499917},"labels":[],"label_agreement":null},{"id":"W2908002421","doi":"10.1200/jco.2014.32.15_suppl.e14576","title":"The impact of dose reduction on survival for colon cancer patients treated with adjuvant FOLFOX.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Oxaliplatin; FOLFOX; Colorectal cancer; Internal medicine; Gastroenterology; Cancer; Chemotherapy; Stage (stratigraphy); Surgery","score_opus":0.1290869723939355,"score_gpt":0.5346742928818136,"score_spread":0.40558732048787804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908002421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479425,0.0001242771,0.000011577973,0.0023562592,0.0013580867,0.00039697927,0.000011940851,0.0000039934803,0.0009426423],"genre_scores_gemma":[0.9976186,0.000555202,0.00007825774,0.00016195874,0.0011949157,0.000018668401,0.0000061521123,0.00001333741,0.00035291177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981341,0.00032994593,0.0010479856,0.00011863711,0.00018997173,0.00017936555],"domain_scores_gemma":[0.9952304,0.002345836,0.0015036971,0.000105281324,0.0006365115,0.0001782761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013213595,0.00011412312,0.0009851345,0.000058098474,0.000054384876,0.0000031746524,0.00008136192,0.00017715892,0.0000549433],"category_scores_gemma":[0.0006568996,0.000051803683,0.00043144205,0.00008786178,0.0001827234,0.00003625617,0.000009162208,0.00033785042,0.0000016039382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1806961,0.01028105,0.4467251,0.000027811935,0.0025476154,0.000020903588,0.00011699075,0.00025943396,0.0010053521,0.00006714164,0.02568319,0.3325693],"study_design_scores_gemma":[0.034716252,0.21324848,0.72592723,0.00007683928,0.0010444167,0.000030235733,0.000021702253,0.00013895132,0.00060578046,0.000100623634,0.024019914,0.000069589376],"about_ca_topic_score_codex":0.00016028101,"about_ca_topic_score_gemma":0.000110789515,"teacher_disagreement_score":0.3324997,"about_ca_system_score_codex":0.00028883162,"about_ca_system_score_gemma":0.0009250586,"threshold_uncertainty_score":0.21124929},"labels":[],"label_agreement":null},{"id":"W2908014039","doi":"10.1200/jco.2018.36.4_suppl.786","title":"Impact of age and frailty on survival in older adults with squamous cell carcinoma of the anus.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anal cancer; Internal medicine; Cancer; Retrospective cohort study; Population; Toxicity; Adverse effect; Stage (stratigraphy); Radiation therapy; Logistic regression; Common Terminology Criteria for Adverse Events; Surgery","score_opus":0.06835623918342212,"score_gpt":0.40343536592506873,"score_spread":0.33507912674164664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908014039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941749,0.00011271104,0.0000020953994,0.00058608205,0.00025243036,0.0001422568,0.000003883586,0.0000011630933,0.004724495],"genre_scores_gemma":[0.9991711,0.000017393457,0.00007533525,0.00021321856,0.00041178908,4.794237e-7,3.5240677e-7,0.0000081047765,0.00010224779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980722,0.00026643154,0.0011176703,0.00012360312,0.0002715553,0.00014853111],"domain_scores_gemma":[0.99727744,0.0011020898,0.0009872246,0.00015311145,0.0003096473,0.00017046278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010277278,0.00010424376,0.0010269374,0.00008734254,0.000015173046,0.0000016829226,0.000119511635,0.00019035021,0.00007016733],"category_scores_gemma":[0.0008354073,0.000048828184,0.00033132947,0.00016077624,0.0004911685,0.000036886497,0.000049584003,0.00061328267,0.0000010240491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016282506,0.0017699259,0.96975875,0.000051904353,0.000038365524,0.000429467,0.0004832787,0.0000023284613,0.00050938287,0.000013731932,0.00027767767,0.01038266],"study_design_scores_gemma":[0.009546038,0.05706696,0.9321429,0.0001292807,0.00009446099,0.0001202869,0.0001608643,0.000033474906,0.00049828325,0.00004478704,0.00011640586,0.000046258378],"about_ca_topic_score_codex":0.00024243153,"about_ca_topic_score_gemma":0.00060054025,"teacher_disagreement_score":0.055297032,"about_ca_system_score_codex":0.00005681817,"about_ca_system_score_gemma":0.00070781,"threshold_uncertainty_score":0.2664442},"labels":[],"label_agreement":null},{"id":"W2908065842","doi":"10.1200/jco.2014.32.15_suppl.3612","title":"Surveillance for asymptomatic recurrence in resected stage III colon cancer (CC): Does it result in a more favorable outcome?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oxaliplatin; Capecitabine; Stage (stratigraphy); Asymptomatic; Internal medicine; Colorectal cancer; Surgery; Log-rank test; Cancer; Chemotherapy; Gastroenterology; Proportional hazards model","score_opus":0.13776916414397633,"score_gpt":0.5149679254030469,"score_spread":0.3771987612590706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908065842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97510517,0.00058652903,0.000037997383,0.020741617,0.0012512183,0.00056180585,0.000022630988,0.000007834509,0.0016851791],"genre_scores_gemma":[0.9945685,0.0014076657,0.000897764,0.0015009686,0.00040154753,0.00007684245,0.0000031298066,0.000013506908,0.0011300426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605167,0.00044278003,0.0026109894,0.00026037017,0.0002915828,0.0003425971],"domain_scores_gemma":[0.99310565,0.0048005865,0.0013056388,0.00017632857,0.0004382182,0.00017355257],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004491594,0.00016483391,0.0020584527,0.00018244017,0.000042680083,0.000008829246,0.00015847565,0.00026195464,0.000044696713],"category_scores_gemma":[0.010620372,0.00009866228,0.0002555192,0.00029423964,0.00016680517,0.00007932611,0.000052129195,0.0007090909,0.0000018078081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013995308,0.002442985,0.9258665,0.00015358634,0.00019418453,0.0001703627,0.00062450743,0.000046276327,0.000031316296,0.00003740353,0.0032932905,0.053144295],"study_design_scores_gemma":[0.039970107,0.010357785,0.8921552,0.00043248595,0.000086268585,0.000015335552,0.00049630454,0.0008918941,0.00002584037,0.00024525024,0.055188082,0.00013547666],"about_ca_topic_score_codex":0.00049964635,"about_ca_topic_score_gemma":0.033807263,"teacher_disagreement_score":0.053008817,"about_ca_system_score_codex":0.00053758454,"about_ca_system_score_gemma":0.000927619,"threshold_uncertainty_score":0.99771357},"labels":[],"label_agreement":null},{"id":"W2908125496","doi":"10.1200/jco.2014.32.15_suppl.10556","title":"Predictive ability of blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in gastrointestinal stromal tumors (GIST).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"GiST; Medicine; Hazard ratio; Internal medicine; Proportional hazards model; Univariate analysis; Lymphocyte; Gastroenterology; Multivariate analysis; Neutrophil to lymphocyte ratio; Oncology; Univariate; Platelet; Confidence interval; Multivariate statistics; Stromal cell","score_opus":0.03865870961522595,"score_gpt":0.3774403603547332,"score_spread":0.3387816507395073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908125496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593025,0.000119197655,0.000614547,0.0016049066,0.0003531541,0.00056774734,0.000015349446,0.000015538146,0.00077929057],"genre_scores_gemma":[0.9798534,0.000034447243,0.018260453,0.0010565676,0.0007373548,0.0000149778025,0.0000020473738,0.000026299593,0.000014483046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941032,0.00090034667,0.003589204,0.00042271262,0.00055396056,0.00043058424],"domain_scores_gemma":[0.9936807,0.0025116012,0.001656794,0.00035221325,0.0007012298,0.001097463],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005119925,0.0002618489,0.0019842347,0.0003650028,0.000041077135,0.000011694774,0.0002838167,0.0002633007,0.000055237382],"category_scores_gemma":[0.012413002,0.00021705526,0.00038683528,0.00029092794,0.0005325804,0.00012732299,0.00018463522,0.00073344295,0.00000981861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0473266,0.0026723063,0.902574,0.00021288791,0.000378059,0.0017915528,0.00019049729,0.00027788075,0.009191192,0.00013151899,0.00035767947,0.034895826],"study_design_scores_gemma":[0.016318973,0.02844051,0.9482871,0.0007303953,0.00039186396,0.0018873152,0.000099696925,0.0011139489,0.0014905244,0.00021046071,0.00087168266,0.00015748217],"about_ca_topic_score_codex":0.000027278174,"about_ca_topic_score_gemma":0.000023105791,"teacher_disagreement_score":0.04571314,"about_ca_system_score_codex":0.00033578477,"about_ca_system_score_gemma":0.0024914832,"threshold_uncertainty_score":0.9959059},"labels":[],"label_agreement":null},{"id":"W2908141617","doi":"10.1200/jco.2014.32.15_suppl.9572","title":"Feasibility of neurocognitove and psychological assessments in allogeneic stem cell transplantation: A pilot study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Medicine; Psychosocial; Anxiety; Depression (economics); Transplantation; Distress; Psychiatry; Cognition; Clinical psychology; Internal medicine","score_opus":0.32697394660703516,"score_gpt":0.5404806055651553,"score_spread":0.21350665895812015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908141617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509835,0.00012186731,0.00021497207,0.00094554434,0.000558629,0.0005702559,0.0000030764588,0.0000051801667,0.0024821048],"genre_scores_gemma":[0.99770975,0.0006680265,0.00047163002,0.0008536447,0.00023704795,0.0000069945777,5.990852e-7,0.000008580825,0.00004371957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959585,0.0011470387,0.002146247,0.00025396884,0.00032548583,0.00016873857],"domain_scores_gemma":[0.995606,0.0025988999,0.0011410817,0.00012131434,0.0003431563,0.00018953625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003553448,0.000131775,0.0013580137,0.00012466333,0.000022119273,0.000003423486,0.00009185474,0.00014345133,0.000033263237],"category_scores_gemma":[0.00066224596,0.000093790906,0.00014768941,0.00014973989,0.00023068838,0.000062613086,0.000034656718,0.0008287259,0.0000026767116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01499558,0.014968437,0.9206632,0.00006882172,0.00014818512,0.00027475072,0.00014559098,0.000004625922,0.00041716805,0.0000036413232,0.00010040099,0.048209608],"study_design_scores_gemma":[0.02056272,0.1338963,0.8442059,0.000072410214,0.00041750344,0.00016799335,0.0003051413,0.000014980654,0.000033900153,0.000112538786,0.00015020205,0.00006036331],"about_ca_topic_score_codex":0.000009309009,"about_ca_topic_score_gemma":0.00007102127,"teacher_disagreement_score":0.118927866,"about_ca_system_score_codex":0.00006944418,"about_ca_system_score_gemma":0.00020180912,"threshold_uncertainty_score":0.38246822},"labels":[],"label_agreement":null},{"id":"W2908205637","doi":"10.1200/jco.2018.36.4_suppl.807","title":"Adjuvant therapy use and outcomes of stage II and III colorectal cancer (CRC): Comparison of young and elderly patients (pts) in a large, contemporary, population-based Canadian database.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Cohort; Colorectal cancer; Internal medicine; Proportional hazards model; Cancer; Comorbidity; Stage (stratigraphy); Population; Incidence (geometry); Life expectancy; Gerontology; Oncology","score_opus":0.1474130293842703,"score_gpt":0.4674537969861372,"score_spread":0.3200407676018669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908205637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973701,0.00091841875,0.0000033528202,0.0006083029,0.0003565625,0.00041836145,0.00017250168,0.0000025036543,0.00014985182],"genre_scores_gemma":[0.99879515,0.00042154678,0.0002910567,0.00036759634,0.0000628087,0.0000057931115,0.000020661086,0.0000117663,0.000023605922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736243,0.00026291353,0.0017090603,0.00020123657,0.00026620505,0.00019813942],"domain_scores_gemma":[0.99655396,0.0012904921,0.001224849,0.000108209526,0.00041300413,0.00040949965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009084295,0.00014835369,0.0016926845,0.00021483884,0.000049956147,0.000006285766,0.00006187871,0.00021293397,0.00007771148],"category_scores_gemma":[0.0010115175,0.00010520148,0.00010297686,0.00013048192,0.00028989874,0.00017910596,0.00004390214,0.00034212178,1.3301367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007201375,0.0012753735,0.9760454,0.00002410629,0.00021981593,0.000050464278,0.00031135805,0.0000010106792,0.00003399043,0.000013601505,0.000120749086,0.014702734],"study_design_scores_gemma":[0.02305742,0.019265829,0.95523286,0.00013814576,0.00008685751,0.000005598157,0.000090406815,0.0002755544,0.000078254125,0.000009456719,0.0016797055,0.00007993009],"about_ca_topic_score_codex":0.06390437,"about_ca_topic_score_gemma":0.28125843,"teacher_disagreement_score":0.21735406,"about_ca_system_score_codex":0.00017176333,"about_ca_system_score_gemma":0.0012143138,"threshold_uncertainty_score":0.94232917},"labels":[],"label_agreement":null},{"id":"W2908207357","doi":"10.1200/jco.2014.32.15_suppl.6505","title":"Measuring compliance to oral antineoplastic agents: A comparison between administrative data and medical records.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Concordance; Medical record; Medical prescription; Cohort; Internal medicine; Pharmacy; Colorectal cancer; Regimen; Cancer; Population; Cancer registry; Emergency medicine; Family medicine","score_opus":0.5937050769355431,"score_gpt":0.49828333697721716,"score_spread":0.09542173995832592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908207357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9383687,0.0005909023,0.03260034,0.010003955,0.0025265205,0.00014864473,0.0001083154,0.000010429149,0.015642235],"genre_scores_gemma":[0.98992634,0.00033685373,0.0058800713,0.0020175637,0.0017112195,0.0000013472385,0.000004968095,0.00001570396,0.000105939136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956115,0.00014562809,0.0034638625,0.0003817199,0.00010024578,0.00029707208],"domain_scores_gemma":[0.9940776,0.0021562057,0.0025592328,0.00034121683,0.00012945094,0.00073629426],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008133442,0.00015265656,0.0020785069,0.00012586894,0.00006391374,0.00004273328,0.0007837904,0.00032925376,0.000222324],"category_scores_gemma":[0.019578937,0.00014653239,0.00013474181,0.0001072036,0.00020484228,0.00035389373,0.00027226543,0.0007741881,0.00017009102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029209274,0.00022816689,0.7541522,0.000017401731,0.00015690278,0.000018642007,0.000091865324,0.000011899465,3.2437137e-7,0.003002997,0.012058888,0.22996865],"study_design_scores_gemma":[0.0018929013,0.003123357,0.5681539,0.0000850843,0.000030180074,0.000023785511,0.00003257489,0.0025877752,0.0000018121995,0.0032874055,0.4206205,0.00016069431],"about_ca_topic_score_codex":0.000060193615,"about_ca_topic_score_gemma":0.00023892942,"teacher_disagreement_score":0.40856162,"about_ca_system_score_codex":0.00008266708,"about_ca_system_score_gemma":0.0004085291,"threshold_uncertainty_score":0.9886796},"labels":[],"label_agreement":null},{"id":"W2908214045","doi":"10.1200/jco.2014.32.15_suppl.4031","title":"A comparison between 5-fluorouracil/mitomycin (FM) and capecitabine/mitomycin (CM) in combination with radiation (RT) for squamous cell carcinoma (SCC) of the anal canal.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Anal cancer; Anal canal; Internal medicine; Fluorouracil; Log-rank test; Cohort; Surgery; Radiation therapy; Stage (stratigraphy); Retrospective cohort study; Mitomycin C; Cancer; Gastroenterology; Survival analysis; Rectum; Colorectal cancer","score_opus":0.06260871274923978,"score_gpt":0.38555020959686565,"score_spread":0.32294149684762585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908214045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993833,0.00029429203,0.00032709425,0.004020105,0.00031149326,0.00041242634,0.000006674038,0.000003729535,0.00079116237],"genre_scores_gemma":[0.99812585,0.0000150396845,0.0007025395,0.00029853111,0.0007390798,0.000004806891,0.0000068300856,0.00001448794,0.00009282632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968152,0.00048656153,0.0018751619,0.00019917729,0.0003980635,0.00022583663],"domain_scores_gemma":[0.9943865,0.003026201,0.0017356097,0.00015628303,0.00045552492,0.00023991296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026081132,0.00016371727,0.0015205456,0.00018897229,0.000052590356,0.000008189116,0.00015581222,0.00028911693,0.00001130341],"category_scores_gemma":[0.0016377779,0.0000943872,0.0002977681,0.00025685868,0.00018976847,0.000089214394,0.000042322397,0.00077794224,6.4127187e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023786463,0.0006863802,0.95266545,0.000095622,0.00003957451,0.000017114135,0.00018632946,0.00003360207,0.0003389038,0.00008366869,0.0006769913,0.04279774],"study_design_scores_gemma":[0.0147561,0.018809002,0.95738494,0.000051043666,0.00043630178,0.00005460578,0.00022388082,0.002999842,0.0010241452,0.00020700971,0.00395351,0.000099638855],"about_ca_topic_score_codex":0.00058106636,"about_ca_topic_score_gemma":0.0018637839,"teacher_disagreement_score":0.042698104,"about_ca_system_score_codex":0.00018027062,"about_ca_system_score_gemma":0.00071353035,"threshold_uncertainty_score":0.38489982},"labels":[],"label_agreement":null},{"id":"W2908296452","doi":"10.1200/jco.2018.36.4_suppl.tps876","title":"NRG-GI002: A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Colorectal cancer; Total mesorectal excision; Capecitabine; Neoadjuvant therapy; Clinical endpoint; FOLFOX; Internal medicine; Oncology; Chemoradiotherapy; Population; Cancer; Phases of clinical research; Surgery; Randomized controlled trial; Oxaliplatin; Clinical trial; Breast cancer","score_opus":0.5393947318110343,"score_gpt":0.6072542489257051,"score_spread":0.06785951711467086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908296452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98971987,0.0003077918,0.00027063664,0.0020868233,0.0054880306,0.0012366344,0.000009584221,0.000017518756,0.00086313125],"genre_scores_gemma":[0.9752826,0.00032852087,0.011654267,0.0011312199,0.01143543,0.000023045432,0.000005466743,0.000037479494,0.00010196638],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993974,0.00044967112,0.004323993,0.00039291792,0.0004170326,0.00044240654],"domain_scores_gemma":[0.9880651,0.0077944146,0.0024713809,0.00019157048,0.000995591,0.0004819284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005453104,0.00024065792,0.0022893713,0.00018585399,0.00013077025,0.00001498801,0.000129751,0.0006623288,0.00017315042],"category_scores_gemma":[0.01473794,0.0001748382,0.0007933864,0.0004092499,0.0003750886,0.00020365603,0.0000764792,0.0010011453,0.000004455532],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35715535,0.0062233796,0.0248243,0.000011543212,0.00036087626,0.00046314625,0.0001217944,0.000025679234,0.00050877896,0.000011597829,0.0003048938,0.6099887],"study_design_scores_gemma":[0.5840979,0.33761656,0.043211848,0.00052194326,0.0005565775,0.001056605,0.00006997816,0.018729504,0.00040368573,0.00056297064,0.0128706535,0.0003017474],"about_ca_topic_score_codex":0.000108675,"about_ca_topic_score_gemma":0.00018103023,"teacher_disagreement_score":0.6096869,"about_ca_system_score_codex":0.00065600115,"about_ca_system_score_gemma":0.0035330325,"threshold_uncertainty_score":0.9935613},"labels":[],"label_agreement":null},{"id":"W2908320450","doi":"10.1200/jco.2014.32.15_suppl.8585","title":"Mantle cell lymphoma: Toll-like receptors (TLRs) and B-cell receptor (BCR) gene expression analysis for identification of a distinct BCR-activated subset, with germinal center signature and indolent biology.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"breakpoint cluster region; Germinal center; Mantle cell lymphoma; B-cell receptor; Cancer research; B cell; Biology; Gene expression profiling; Syk; Medicine; Gene expression; Gene; Immunology; Receptor; Lymphoma; Internal medicine; Genetics; Tyrosine kinase; Antibody","score_opus":0.03338232921223511,"score_gpt":0.3595329396474885,"score_spread":0.3261506104352534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908320450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969691,0.00059152505,0.00093201885,0.0006074501,0.0004469184,0.00032689268,0.00003234005,0.000006082847,0.00008764326],"genre_scores_gemma":[0.99422354,0.0007737363,0.0042859265,0.00020946309,0.00028195253,0.000018346576,0.00007095154,0.000016331058,0.00011978528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973063,0.00038478838,0.0015637625,0.00033938518,0.00020284465,0.00020290798],"domain_scores_gemma":[0.995607,0.001400759,0.0021343064,0.00020441186,0.0003560541,0.00029747933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001391255,0.00019652644,0.0013917481,0.00021050301,0.00006047347,0.000011486503,0.000095147574,0.0004351031,0.000038596194],"category_scores_gemma":[0.00035856597,0.0001186577,0.00032833894,0.00017711267,0.0002267567,0.00007925059,0.000046568664,0.00021224603,0.0000015126144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010735191,0.008172249,0.8423659,0.00015978666,0.0011428072,0.000042796903,0.0002177988,0.0000071252575,0.07631096,0.000010015522,0.001956313,0.058879018],"study_design_scores_gemma":[0.045276146,0.019154819,0.74273473,0.00021326017,0.004044982,0.00014149382,0.0002555633,0.00025194164,0.15962768,0.000053194024,0.027979612,0.00026661198],"about_ca_topic_score_codex":0.000013732624,"about_ca_topic_score_gemma":0.0000149037205,"teacher_disagreement_score":0.09963123,"about_ca_system_score_codex":0.00011986794,"about_ca_system_score_gemma":0.00022939473,"threshold_uncertainty_score":0.48387206},"labels":[],"label_agreement":null},{"id":"W2908462842","doi":"10.1200/jco.2014.32.15_suppl.e15544","title":"FGFR1 overexpression and anti-FGFR compound sensitivity in renal cell carcinoma.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ponatinib; Medicine; Renal cell carcinoma; Fibroblast growth factor receptor 1; Cancer; Immunohistochemistry; Cancer research; Internal medicine; Pathology; Fibroblast growth factor; Receptor; Dasatinib","score_opus":0.08799213177184954,"score_gpt":0.40445891446828625,"score_spread":0.3164667826964367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908462842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898233,0.000336258,0.00010648261,0.0018778658,0.00037917247,0.00014977217,0.000001176831,0.0000053230456,0.0073206825],"genre_scores_gemma":[0.99519897,0.00013926985,0.0027974632,0.00089675625,0.0008026931,8.6526205e-7,0.000002103421,0.000015257012,0.0001466526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653184,0.00096125156,0.0016669194,0.00024357677,0.0003473467,0.00024905126],"domain_scores_gemma":[0.9953616,0.0026944517,0.0010780165,0.00021172357,0.0002029059,0.00045129412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040016053,0.00016557414,0.0015673457,0.00015433677,0.000033658453,0.000009516944,0.00006603662,0.00036494373,0.000036545116],"category_scores_gemma":[0.0011272755,0.00011357144,0.00028703365,0.000089265704,0.00020497703,0.00009390397,0.00008255128,0.0010309427,0.000011989876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029467046,0.002040768,0.92368364,0.0000756076,0.000058422345,0.0041653924,0.00010043947,0.000034337292,0.038138278,0.000042979143,0.00205479,0.026658626],"study_design_scores_gemma":[0.01034654,0.007530775,0.96476877,0.00015262286,0.00016474964,0.001564483,0.000039484534,0.0004303534,0.0052548656,0.00015671467,0.009489478,0.00010114873],"about_ca_topic_score_codex":0.00006553912,"about_ca_topic_score_gemma":0.00004007343,"teacher_disagreement_score":0.04108513,"about_ca_system_score_codex":0.00016163003,"about_ca_system_score_gemma":0.00048735517,"threshold_uncertainty_score":0.4631309},"labels":[],"label_agreement":null},{"id":"W2908507660","doi":"10.1200/jco.2014.32.15_suppl.6611","title":"The impact of PET-CT on staging, management, and prognostication of small-cell lung cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiology; PET-CT; Cancer staging; Nuclear medicine; Positron emission tomography; Cancer; Internal medicine","score_opus":0.04262662154480008,"score_gpt":0.47041617589763496,"score_spread":0.4277895543528349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908507660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863895,0.00050001155,0.0009328057,0.0045391745,0.0003242285,0.00015892703,7.2230466e-7,0.000002902771,0.0071516987],"genre_scores_gemma":[0.9939334,0.0026314557,0.0025829084,0.00033509068,0.00028329136,0.0000017310844,5.7060396e-7,0.000009169049,0.00022240933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981335,0.00028547613,0.0011531628,0.00009595876,0.00020160437,0.00013034049],"domain_scores_gemma":[0.99530846,0.0026575148,0.0015461592,0.0001388417,0.00017833474,0.00017066576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037763054,0.00007482636,0.0006372945,0.0000701616,0.000033278717,0.0000054082648,0.00013019648,0.000030655705,0.000016034088],"category_scores_gemma":[0.0033525382,0.000039885846,0.00021636357,0.00006770076,0.00023857811,0.00002217548,0.000035521738,0.0006317381,4.4227895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009890548,0.00066636095,0.6202326,0.0001700695,0.0004485685,0.00008945828,0.000051383442,0.00025907782,0.00016714592,0.00068090763,0.004529126,0.3717163],"study_design_scores_gemma":[0.006373739,0.009274981,0.9393463,0.00043724457,0.0006776255,0.00016773853,0.00006841078,0.03202226,0.00007728146,0.0006720867,0.010813059,0.00006928231],"about_ca_topic_score_codex":0.000051929204,"about_ca_topic_score_gemma":0.0000024431058,"teacher_disagreement_score":0.371647,"about_ca_system_score_codex":0.000048272308,"about_ca_system_score_gemma":0.00029364764,"threshold_uncertainty_score":0.40135434},"labels":[],"label_agreement":null},{"id":"W2908583831","doi":"10.1200/jco.2013.31.15_suppl.5517","title":"A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Temsirolimus; Neutropenia; Internal medicine; Gastroenterology; Adverse effect; Phases of clinical research; Cancer; Hypokalemia; Tolerability; Bevacizumab; Toxicity; Surgery; Chemotherapy; PI3K/AKT/mTOR pathway","score_opus":0.07515892749311999,"score_gpt":0.41698013271736123,"score_spread":0.34182120522424125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908583831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209493,0.0005129868,0.000003853401,0.0047735614,0.0003357815,0.0021762224,0.000052630094,0.0000033697727,0.000046682464],"genre_scores_gemma":[0.9987771,0.00024610516,0.00016703118,0.00032844546,0.00029673334,0.000118222466,6.144035e-7,0.000019916793,0.00004583142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600506,0.00058526953,0.0023120237,0.000340267,0.00045846074,0.00029893444],"domain_scores_gemma":[0.9963693,0.0005717346,0.00199936,0.00031049098,0.00028063636,0.0004684631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012721529,0.00023919402,0.001836238,0.00013854743,0.00007942999,0.000011233904,0.00017387363,0.0001619905,0.00023840883],"category_scores_gemma":[0.0003360866,0.00012792014,0.000109532404,0.00018479626,0.0002611711,0.00007417179,0.0001786318,0.0007023742,7.0892406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052493926,0.112659276,0.4763863,0.000072021714,0.0019355693,0.00021783168,0.0144370105,0.000012219725,0.000060303748,0.0000053451035,0.0003412488,0.34137893],"study_design_scores_gemma":[0.21908526,0.22112231,0.5453978,0.00042301838,0.0011869986,0.00008189001,0.009963747,0.00010538027,0.00002050538,0.000031766835,0.0024509225,0.0001303751],"about_ca_topic_score_codex":0.0021211754,"about_ca_topic_score_gemma":0.0027330297,"teacher_disagreement_score":0.34124854,"about_ca_system_score_codex":0.00018556566,"about_ca_system_score_gemma":0.0011611726,"threshold_uncertainty_score":0.52164316},"labels":[],"label_agreement":null},{"id":"W2909334052","doi":"10.1200/jco.18.00766","title":"Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Cilag; National Cancer Institute; Pharmacyclics; Genentech; Servier; Incyte; Celgene; LAM Therapeutics; Adaptive Biotechnologies; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Kite Pharma; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Cohort; Internal medicine; Refractory (planetary science); Transplantation; Surgery; Adverse effect; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Cancer; Immunotherapy","score_opus":0.07914781576734928,"score_gpt":0.4257238446997092,"score_spread":0.34657602893235995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909334052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950873,0.00014174901,0.0001237168,0.0006695402,0.001421113,0.0022727498,0.000047597732,0.000014675947,0.00022153021],"genre_scores_gemma":[0.99594855,0.00013854662,0.0020896813,0.0008709481,0.00032072898,0.00010428223,0.000035682322,0.000033061024,0.00045849502],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618196,0.00024651192,0.0025318272,0.00033950317,0.00031230046,0.00038791506],"domain_scores_gemma":[0.9940827,0.0035210024,0.0014630572,0.00022819868,0.0004304396,0.00027459487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001583478,0.00022337881,0.0017838632,0.00022895528,0.00008355767,0.000013654044,0.00015754031,0.0003807417,0.0000696894],"category_scores_gemma":[0.0012458132,0.00014922873,0.0005376448,0.00013838321,0.000042541553,0.00017437435,0.000033499775,0.00023839773,0.000010880496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06389696,0.43220052,0.40863237,0.0001455779,0.00036765102,0.0005509694,0.00089055975,0.00000323753,0.0000447575,0.000012570146,0.0015987424,0.09165609],"study_design_scores_gemma":[0.46124384,0.2834924,0.23568879,0.00014599136,0.00082161574,0.00004428047,0.00034972225,0.00016483363,0.000096627096,0.00003371333,0.017779186,0.00013903347],"about_ca_topic_score_codex":0.000015996298,"about_ca_topic_score_gemma":0.00012738013,"teacher_disagreement_score":0.39734688,"about_ca_system_score_codex":0.0005440255,"about_ca_system_score_gemma":0.0011897687,"threshold_uncertainty_score":0.6085371},"labels":[],"label_agreement":null},{"id":"W2910245285","doi":"10.1200/jco.18.00149","title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1716,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Tolerability; Clinical endpoint; Chemotherapy regimen; Surgery; Cancer; Confidence interval; Randomized controlled trial; Immunotherapy; Adverse effect","score_opus":0.06235330001325926,"score_gpt":0.4207660967554982,"score_spread":0.3584127967422389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910245285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615425,0.00026405405,0.0007487654,0.0010414886,0.00062321336,0.0009131513,0.00003169732,0.0000072859857,0.00021608041],"genre_scores_gemma":[0.9933583,0.0002205901,0.004803628,0.00091285387,0.00019412179,0.000020943715,0.00002513931,0.000032543845,0.000431885],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99656236,0.000117343174,0.0024109501,0.0002676988,0.00038885267,0.0002528068],"domain_scores_gemma":[0.994031,0.00074320164,0.003880802,0.00029701588,0.0008973403,0.0001506003],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001234685,0.00020865227,0.0022184371,0.00034246116,0.000023405895,0.0000047541344,0.00017885286,0.00027695403,0.0010463966],"category_scores_gemma":[0.00016847008,0.00012375865,0.00088531006,0.0005441471,0.00019715026,0.00008308437,0.000012494471,0.00038229438,7.94325e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7264834,0.0012470911,0.22946067,0.0003552974,0.006082542,0.000050960974,0.00014183926,0.001272324,0.01565949,0.0000012825619,0.00043951062,0.018805582],"study_design_scores_gemma":[0.23734902,0.08075658,0.6128643,0.0008317154,0.011465649,0.00004459859,0.00031892903,0.009887537,0.039129943,0.000004630272,0.006972005,0.000375071],"about_ca_topic_score_codex":0.00007450489,"about_ca_topic_score_gemma":0.00019208282,"teacher_disagreement_score":0.48913437,"about_ca_system_score_codex":0.00024177422,"about_ca_system_score_gemma":0.0030009018,"threshold_uncertainty_score":0.9998668},"labels":[],"label_agreement":null},{"id":"W2911268138","doi":"10.1200/jco.2019.37.4_suppl.37","title":"The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Data collection; Stakeholder; Delegation; Family medicine; Multidisciplinary approach; Resource (disambiguation); Medical education; Nursing; Medical physics","score_opus":0.3152761806428403,"score_gpt":0.5415469088368896,"score_spread":0.2262707281940493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911268138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906997,0.0009567968,0.00026168954,0.004928174,0.0018814985,0.00037579788,0.000044200926,0.0000033068336,0.0008488153],"genre_scores_gemma":[0.99233794,0.004640402,0.0022509855,0.00035061268,0.00024621782,0.0000041916123,0.000010732361,0.00001018713,0.00014873933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99431336,0.00030127773,0.0047273454,0.00029343308,0.000115428666,0.0002491599],"domain_scores_gemma":[0.9930529,0.00223712,0.0038312592,0.00037710514,0.00035790182,0.00014370134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01826188,0.00010137429,0.0011251033,0.00013842086,0.00013778724,0.000046769816,0.00027013212,0.00024024988,0.00004006697],"category_scores_gemma":[0.0045330315,0.00007713565,0.00014657283,0.00012816057,0.00036134326,0.0005810728,0.00028953943,0.00083547144,0.0000031895174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051768176,0.00035464857,0.84464204,0.000011327827,0.00017741065,0.0000064138267,0.000049923394,0.0000024894446,7.238894e-7,0.014692228,0.0015913991,0.1379537],"study_design_scores_gemma":[0.0044377465,0.0066411914,0.95073473,0.000017920158,0.000027694157,0.000020158139,0.00019546208,0.0015337757,0.0000012318054,0.008405499,0.027909057,0.000075525],"about_ca_topic_score_codex":0.00020328854,"about_ca_topic_score_gemma":0.00028946146,"teacher_disagreement_score":0.13787818,"about_ca_system_score_codex":0.000117070515,"about_ca_system_score_gemma":0.00084054685,"threshold_uncertainty_score":0.63292396},"labels":[],"label_agreement":null},{"id":"W2911275531","doi":"10.1200/jco.2019.37.4_suppl.491","title":"Impact of cardiac comorbidity on use and outcomes of adjuvant chemotherapy (ADJ) for colorectal cancer (CRC): A real-world population-based study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Heart failure; Oxaliplatin; Colorectal cancer; Comorbidity; Population; Myocardial infarction; Proportional hazards model; Regimen; Ejection fraction; Cancer","score_opus":0.12540960435311918,"score_gpt":0.5088728840238295,"score_spread":0.38346327967071026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911275531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971458,0.00018847077,0.0000013047816,0.0008410343,0.00066730217,0.0009285778,0.00008290311,0.0000038574262,0.00014076082],"genre_scores_gemma":[0.99864846,0.00057830027,0.00026351985,0.0001973837,0.00017121251,0.000016799035,0.0000040566265,0.000014783279,0.00010548191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781865,0.00018541985,0.0014103808,0.00016609783,0.00027105698,0.00014841644],"domain_scores_gemma":[0.9939852,0.0037555643,0.0014917596,0.00013532364,0.0004943734,0.0001378028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009228267,0.0001552137,0.002499009,0.00012910401,0.00002545665,0.000003705657,0.000060273036,0.000119655626,0.00006835827],"category_scores_gemma":[0.0007544253,0.00009073743,0.00077123224,0.00010555741,0.00008232961,0.000052695057,0.000018322222,0.00024166967,3.3973618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019123968,0.0028028297,0.9504234,0.000033483204,0.0022314892,0.000007447477,0.00013419308,0.0000444026,0.000095306765,0.000008897437,0.00039428787,0.02470028],"study_design_scores_gemma":[0.011998488,0.05073774,0.93588924,0.000069232956,0.00059351773,0.0000013389993,0.000063604515,0.000056891946,0.00007438751,0.00002087706,0.00042678518,0.00006791267],"about_ca_topic_score_codex":0.0027762935,"about_ca_topic_score_gemma":0.0017981392,"teacher_disagreement_score":0.04793491,"about_ca_system_score_codex":0.0003141718,"about_ca_system_score_gemma":0.0008186619,"threshold_uncertainty_score":0.4196944},"labels":[],"label_agreement":null},{"id":"W2911387963","doi":"10.1200/jco.2019.37.4_suppl.351","title":"Survival and cost associated with chemotherapy and chemoradiotherapy among resected pancreas cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Ontario Institute for Cancer Research; Health Sciences Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Log-rank test; Pancreatic cancer; Chemoradiotherapy; Pancreaticoduodenectomy; Cancer; Surgery; Pancreatectomy; Internal medicine; Chemotherapy; Survival analysis; Pancreas","score_opus":0.08101139602023859,"score_gpt":0.45729766037278596,"score_spread":0.37628626435254736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911387963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991844,0.00047754025,0.000010851794,0.0034066082,0.00027642402,0.00050886796,0.000004700201,0.000008607951,0.0034624268],"genre_scores_gemma":[0.9923869,0.0043127504,0.0004559901,0.0011890006,0.00034382285,0.000008209578,0.000004436366,0.000024813327,0.0012740751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975174,0.0004909006,0.0010630735,0.00021925129,0.00042305823,0.00028628708],"domain_scores_gemma":[0.99479383,0.0028926414,0.0010080248,0.00013632336,0.00071382616,0.00045532326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027894173,0.00014747519,0.0020804533,0.000100051744,0.000041299176,0.000011499607,0.00009110808,0.00044598902,0.00036577252],"category_scores_gemma":[0.0020144288,0.00009174728,0.00010876994,0.00015650883,0.00055403425,0.00009824035,0.00002655163,0.00093522604,0.0000026716166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007428566,0.00094710937,0.96121305,0.00002246063,0.00091773615,0.00007439184,0.00010524555,3.3820064e-7,0.00010897811,0.00001886007,0.0009682296,0.028195012],"study_design_scores_gemma":[0.029485462,0.015325483,0.9485911,0.00017079944,0.00026467768,0.000045172128,0.00008083739,0.00018194503,0.000020645133,0.00003944532,0.0056997607,0.00009463418],"about_ca_topic_score_codex":0.00012438465,"about_ca_topic_score_gemma":0.0001874062,"teacher_disagreement_score":0.028100377,"about_ca_system_score_codex":0.00017265743,"about_ca_system_score_gemma":0.0012365594,"threshold_uncertainty_score":0.40631437},"labels":[],"label_agreement":null},{"id":"W2911447682","doi":"10.1200/jco.2019.37.4_suppl.627","title":"Obesity and its impact on outcomes in stage III colon cancer (CC) patients receiving adjuvant chemotherapy (AC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Underweight; Body mass index; Internal medicine; Overweight; Cohort; Obesity; Population; Proportional hazards model; Cancer; Confounding; Colorectal cancer; Cancer registry; Gastroenterology; Surgery","score_opus":0.11831101877602838,"score_gpt":0.5426206500762337,"score_spread":0.4243096313002053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911447682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98796314,0.0003281557,0.0000013020568,0.009363874,0.0011694185,0.00033855686,0.000005025896,0.00000548388,0.0008250645],"genre_scores_gemma":[0.98598075,0.0029475805,0.00018042604,0.010088628,0.0002513421,0.0000022211268,0.0000010510886,0.000011829239,0.0005361744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976507,0.0002565314,0.0014648424,0.00014936847,0.00025314564,0.00022543207],"domain_scores_gemma":[0.99703074,0.0013212337,0.0010188717,0.000096912394,0.00021665062,0.00031560793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021266877,0.00011363618,0.0014434444,0.0001448893,0.000025415877,0.000005173431,0.00007330716,0.00025675585,0.00036872656],"category_scores_gemma":[0.00079291454,0.000073795774,0.00019475886,0.00008190413,0.000036150785,0.00008322148,0.00002201036,0.0010197018,0.000014230455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004116743,0.0033916982,0.9634006,0.00006889468,0.00006473308,0.000047422796,0.00012629408,0.0000040190844,0.000041218642,0.00001620546,0.0007590677,0.02796313],"study_design_scores_gemma":[0.037050784,0.008439601,0.9460513,0.00037594084,0.00002632163,0.000009756138,0.000039783987,0.00012492805,0.00003160892,0.000042213287,0.007743284,0.000064472864],"about_ca_topic_score_codex":0.0000575703,"about_ca_topic_score_gemma":0.00008786207,"teacher_disagreement_score":0.03293404,"about_ca_system_score_codex":0.00036071308,"about_ca_system_score_gemma":0.0006155551,"threshold_uncertainty_score":0.44301537},"labels":[],"label_agreement":null},{"id":"W2911550866","doi":"10.1200/jco.2019.37.4_suppl.tps724","title":"CO.28: <i>N</i>eoadjuvant Chemotherapy, <i>E</i>xcision and <i>O</i>bservation (<i>NEO</i>) for early rectal cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Lakeridge Health; University Health Network; Hôpital Saint-François d'Assise; University of Manitoba; Providence Health Care; Ottawa Hospital; Queen's University; St. Paul's Hospital; CancerCare Manitoba","funders":"","keywords":"Medicine; Microsurgery; FOLFOX; Colorectal cancer; Surgery; Total mesorectal excision; Pelvic exenteration; Radiation therapy; Chemotherapy; Rectal examination; Anal canal; Rectum; Cancer; Prostate; Internal medicine; Oxaliplatin","score_opus":0.11130154495267135,"score_gpt":0.4808824684034279,"score_spread":0.36958092345075655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911550866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464876,0.0011218078,0.00013943818,0.008506319,0.0019256362,0.0008240261,0.000016634005,0.000017939563,0.00279942],"genre_scores_gemma":[0.9817356,0.0034071074,0.005754354,0.0066701025,0.0012934668,0.000028554918,0.0000071720447,0.000040104595,0.0010635329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968883,0.00019035347,0.0018640893,0.0003239238,0.00043776416,0.0002955832],"domain_scores_gemma":[0.9949091,0.0024746389,0.0014517531,0.0001983631,0.0005493805,0.0004167581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002112542,0.00020368201,0.001708326,0.00009310044,0.000046334248,0.000017058692,0.00013420882,0.0004397621,0.00021173635],"category_scores_gemma":[0.0008840362,0.00014415629,0.0005535779,0.00015980507,0.0001349678,0.00019957985,0.00003027009,0.00064782734,0.00002167834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02873105,0.0013930849,0.53109115,0.00007948128,0.00050934294,0.00011511582,0.00014846567,0.000004148314,0.0021978074,0.00003781817,0.0068073673,0.4288852],"study_design_scores_gemma":[0.030825898,0.03425504,0.6376441,0.00023330277,0.00034602318,0.00026062346,0.00003624321,0.00018841006,0.0012665252,0.0004889486,0.29427868,0.00017619343],"about_ca_topic_score_codex":0.00005696231,"about_ca_topic_score_gemma":0.000026743206,"teacher_disagreement_score":0.42870897,"about_ca_system_score_codex":0.0002416231,"about_ca_system_score_gemma":0.0009203482,"threshold_uncertainty_score":0.5878523},"labels":[],"label_agreement":null},{"id":"W2911639050","doi":"10.1200/jco.2019.37.4_suppl.299","title":"Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Oxaliplatin; Pancreatic cancer; Irinotecan; Internal medicine; Oncology; Population; Surgery; Cancer; Colorectal cancer","score_opus":0.083741180831066,"score_gpt":0.4561542741868971,"score_spread":0.37241309335583106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911639050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934305,0.00040530934,0.00004545178,0.001939158,0.00044331056,0.00077370484,0.000017972201,0.000012088112,0.0070199436],"genre_scores_gemma":[0.9922698,0.0004847373,0.0034028501,0.0003936306,0.00025475674,0.00002057743,0.000011944736,0.00003779312,0.0031238715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956423,0.00042044977,0.0022047423,0.0002998401,0.0009319604,0.0005006918],"domain_scores_gemma":[0.9906617,0.0046459795,0.0019681489,0.00041703053,0.0017971427,0.0005100451],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017450945,0.00026628716,0.0038199078,0.00023421888,0.000043435808,0.00000700711,0.00026010527,0.00042617295,0.0010505234],"category_scores_gemma":[0.0024315862,0.00014180316,0.0003289312,0.00035534136,0.00046761014,0.00016095932,0.00006513746,0.0010421744,0.000030762265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07078945,0.0020057082,0.9186783,0.00011747524,0.002899493,0.00018198106,0.00006705734,0.00003756183,0.000018157247,0.00004550389,0.00071559317,0.0044437447],"study_design_scores_gemma":[0.06756879,0.058798283,0.866872,0.00022985548,0.0018316658,0.000028120874,0.0001470504,0.00016565048,0.00002305573,0.00001900683,0.0041807126,0.00013578519],"about_ca_topic_score_codex":0.00040011355,"about_ca_topic_score_gemma":0.00031454428,"teacher_disagreement_score":0.056792572,"about_ca_system_score_codex":0.00037986843,"about_ca_system_score_gemma":0.0043289806,"threshold_uncertainty_score":0.9998627},"labels":[],"label_agreement":null},{"id":"W2911649012","doi":"10.1200/jco.2019.37.4_suppl.697","title":"Wait times for colorectal cancer patients in a universal healthcare system over a decade: Is it sustainable?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Colorectal cancer; Incidence (geometry); Cancer registry; Cancer; Population; Stage (stratigraphy); Internal medicine","score_opus":0.05311210044616391,"score_gpt":0.4328645370080496,"score_spread":0.37975243656188573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911649012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022305,0.00024399399,0.00003570225,0.005574711,0.0015152892,0.00067361945,0.000009762848,0.000011487864,0.0017123765],"genre_scores_gemma":[0.9959971,0.00011466053,0.0002206581,0.0016257345,0.00060141605,0.000016010443,0.0000022337008,0.000016949047,0.0014052615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757075,0.00021799476,0.0013638486,0.0002177796,0.00030854662,0.0003210845],"domain_scores_gemma":[0.99663633,0.0010537344,0.0010432056,0.000091744754,0.00090636767,0.00026861194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015110959,0.0001225735,0.0011352961,0.00021483166,0.000041274594,0.000008113225,0.00010670581,0.0004503503,0.00014477123],"category_scores_gemma":[0.00086562004,0.00009681427,0.0003762004,0.00023834605,0.00005175037,0.00013098304,0.000043020973,0.0007429389,0.000008538569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0960093,0.0008421106,0.849016,0.00063511566,0.00030359763,0.00022435925,0.0008045472,0.000034646266,0.000023866745,0.00048554022,0.01818599,0.033434946],"study_design_scores_gemma":[0.028585142,0.08702018,0.78057873,0.00066664215,0.00027922512,0.00011256637,0.0036340305,0.0028098158,0.00012597795,0.00008517084,0.09591088,0.00019165363],"about_ca_topic_score_codex":0.0009176717,"about_ca_topic_score_gemma":0.00060541666,"teacher_disagreement_score":0.08617807,"about_ca_system_score_codex":0.0014150911,"about_ca_system_score_gemma":0.0025823487,"threshold_uncertainty_score":0.45809758},"labels":[],"label_agreement":null},{"id":"W2911731790","doi":"10.1200/jco.2019.37.4_suppl.313","title":"An updated retrospective review of the safety and efficacy of sorafenib for recurrent hepatocellular carcinoma post-liver transplantation.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Liver transplantation; Toxicity; Immunosuppression; Adverse effect; Calcineurin; Tacrolimus; Oncology; Retrospective cohort study; Gastroenterology; Surgery; Transplantation","score_opus":0.03749607391930446,"score_gpt":0.3830962415238641,"score_spread":0.3456001676045597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911731790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98791254,0.009900718,0.0003400183,0.00053758384,0.00068003114,0.00042320832,0.000085310494,0.0000010936703,0.00011950158],"genre_scores_gemma":[0.9835814,0.014720887,0.00076360547,0.00062189065,0.00024031254,0.0000019672611,0.000030225401,0.000011721289,0.000027960363],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99770063,0.00042193217,0.0013931539,0.0001927434,0.00017545432,0.00011611095],"domain_scores_gemma":[0.99695706,0.00026219647,0.0016292796,0.0002523028,0.00081210653,0.00008704994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018897711,0.0001042377,0.0007504539,0.000024573954,0.00002182086,0.000002097015,0.00027375427,0.00024349993,0.00005241599],"category_scores_gemma":[0.00063749717,0.00006982153,0.00038447123,0.00006538225,0.00017457124,0.0000077089635,0.000030813957,0.00025554403,5.3545097e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050701875,0.0028261836,0.4200807,0.004817467,0.0015725804,0.00006191681,0.0003907154,0.000107100575,0.45287856,0.0008225484,0.005102705,0.060637653],"study_design_scores_gemma":[0.017037906,0.053025223,0.7565949,0.0019260659,0.0013629317,0.00026358338,0.000057952373,0.0003776176,0.10523242,0.00019113281,0.06354902,0.00038125145],"about_ca_topic_score_codex":0.000006895615,"about_ca_topic_score_gemma":0.000008489691,"teacher_disagreement_score":0.34764615,"about_ca_system_score_codex":0.000032145534,"about_ca_system_score_gemma":0.0006292952,"threshold_uncertainty_score":0.28472394},"labels":[],"label_agreement":null},{"id":"W2911802772","doi":"10.1200/jco.2019.37.4_suppl.350","title":"Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Cancer Care Ontario; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Stage (stratigraphy); Percutaneous ethanol injection; Percutaneous; Radiation therapy; Liver cancer; Internal medicine; Surgery; Nuclear medicine; Radiofrequency ablation; Ablation","score_opus":0.10840011985109764,"score_gpt":0.37279884469893204,"score_spread":0.2643987248478344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911802772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724376,0.0005310558,0.000112444584,0.00081434223,0.00018149811,0.0005688795,0.000023425388,0.000022725211,0.0005018689],"genre_scores_gemma":[0.997446,0.0004556741,0.00062822376,0.00063952775,0.0004561916,0.000009442384,0.000099532495,0.000027054373,0.00023834126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964103,0.0007242418,0.0017130093,0.00035785834,0.0004989789,0.00029562679],"domain_scores_gemma":[0.9956151,0.0009102829,0.002107313,0.00041970974,0.00044926297,0.0004982878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085265026,0.00026191975,0.0022110932,0.00045496243,0.00005846779,0.00002835202,0.00016761389,0.00017037927,0.00032463577],"category_scores_gemma":[0.00020879915,0.00017040582,0.0009091198,0.0011046982,0.00020814991,0.00022073473,0.000023094986,0.0007350758,0.00007042682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006309249,0.0010846686,0.95809674,0.000006113218,0.0077477335,0.0019430434,0.00013214137,0.000012340854,0.00011754352,0.000009465314,0.000016377839,0.024524583],"study_design_scores_gemma":[0.014237064,0.018277071,0.9508476,0.000016186503,0.0072492654,0.000039476156,0.000043141685,0.0026609232,0.00021250828,0.0000033537037,0.0062464117,0.00016694849],"about_ca_topic_score_codex":0.002676912,"about_ca_topic_score_gemma":0.00036959667,"teacher_disagreement_score":0.024357634,"about_ca_system_score_codex":0.00025319727,"about_ca_system_score_gemma":0.0014725969,"threshold_uncertainty_score":0.6948948},"labels":[],"label_agreement":null},{"id":"W2912000079","doi":"10.1200/jco.2019.37.4_suppl.401","title":"Outcomes of stereotactic body radiotherapy for unresectable hepatocellular carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Place Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cyberknife; Internal medicine; Proportional hazards model; Toxicity; Gastroenterology; Radiation therapy; Radiosurgery; Nuclear medicine; Radiology","score_opus":0.17274628825799643,"score_gpt":0.422807365827653,"score_spread":0.25006107756965656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912000079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922737,0.0016966845,0.00021637899,0.002521276,0.0012043179,0.0008276892,0.000006172283,0.000007551565,0.0012462399],"genre_scores_gemma":[0.99242765,0.00029324676,0.004517671,0.0007376173,0.00047565764,0.000010263983,0.000005572715,0.00003177774,0.0015005587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659884,0.0003064612,0.002256726,0.00020366217,0.0003519909,0.00028234182],"domain_scores_gemma":[0.99417543,0.003008037,0.0016709546,0.00031076215,0.0005227516,0.00031207595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002599789,0.0001799759,0.0024023452,0.00017794261,0.000023710667,0.000006877371,0.0001808789,0.0003832617,0.00043855933],"category_scores_gemma":[0.0010192546,0.000120205514,0.001257523,0.00012566354,0.00009591709,0.00011623085,0.000024923327,0.00046231752,0.000018394927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042708945,0.0015124814,0.98253864,0.00012500635,0.0012834038,0.00026787314,0.000069236565,5.3844525e-7,0.0017524466,0.00012281985,0.0008216937,0.007234942],"study_design_scores_gemma":[0.02466961,0.034345835,0.8670852,0.000072360315,0.001132361,0.0002234151,0.00006467611,0.00238488,0.0028505805,0.0001975763,0.0668181,0.00015535735],"about_ca_topic_score_codex":0.000029693161,"about_ca_topic_score_gemma":0.000002479471,"teacher_disagreement_score":0.115453415,"about_ca_system_score_codex":0.00013225779,"about_ca_system_score_gemma":0.0011594569,"threshold_uncertainty_score":0.49018386},"labels":[],"label_agreement":null},{"id":"W2912027461","doi":"10.1200/jco.2019.37.4_suppl.102","title":"Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Irinotecan; Internal medicine; Chemotherapy; Oncology; Cancer; Combination therapy; Progression-free survival; Performance status; Combination chemotherapy; Response Evaluation Criteria in Solid Tumors; Surgery; Progressive disease; Colorectal cancer","score_opus":0.1429087468151546,"score_gpt":0.4956412227019849,"score_spread":0.3527324758868303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912027461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272424,0.000094696516,0.000044458684,0.00305403,0.0022262288,0.0014443519,0.00003265162,0.000010505825,0.00036882993],"genre_scores_gemma":[0.9761469,0.0069457274,0.004646591,0.0013356691,0.0005160847,0.00005987612,0.000015340947,0.000034822668,0.01029899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953198,0.00029743518,0.0033259885,0.00038561237,0.00027843314,0.00039272915],"domain_scores_gemma":[0.9923794,0.0049033174,0.0018849383,0.00025379853,0.00021797465,0.00036056642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014763323,0.0002906051,0.0029903697,0.0003460459,0.000028797518,0.000013664144,0.00012041027,0.00015162895,0.0005289788],"category_scores_gemma":[0.0010065294,0.00016672262,0.0007427558,0.00020138647,0.0000658832,0.00014746771,0.00005026354,0.00036221865,0.000007193324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068139154,0.0023404309,0.66354805,0.00004802755,0.00087122095,0.00007457,0.000037126694,0.000014757438,6.234959e-7,0.0000051725797,0.0002049033,0.32604122],"study_design_scores_gemma":[0.05631666,0.053066693,0.8692014,0.00012873515,0.0011280024,0.0000089493715,0.0001018745,0.00008584832,0.0000036472409,0.000028400478,0.01980743,0.00012232785],"about_ca_topic_score_codex":0.00034781022,"about_ca_topic_score_gemma":0.012000973,"teacher_disagreement_score":0.32591888,"about_ca_system_score_codex":0.0009166047,"about_ca_system_score_gemma":0.00089660153,"threshold_uncertainty_score":0.67987514},"labels":[],"label_agreement":null},{"id":"W2912094423","doi":"10.1200/jco.2019.37.4_suppl.327","title":"Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Hepatocellular carcinoma; Sorafenib; Gastroenterology; Cancer; Progressive disease; Clinical endpoint; Clinical trial; Oncology; Immunotherapy; Disease","score_opus":0.029937500286940696,"score_gpt":0.3545736872949904,"score_spread":0.3246361870080497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912094423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937174,0.0012982439,0.0000067009673,0.0013267806,0.00074967765,0.0004425833,0.0000043459604,0.000007233899,0.002447082],"genre_scores_gemma":[0.99623585,0.0010593015,0.0008453287,0.0014346335,0.00019829908,0.0000030080516,0.0000057126495,0.000025388446,0.00019250081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698,0.0002129064,0.0018280891,0.00026144958,0.00037170626,0.00034585033],"domain_scores_gemma":[0.99760073,0.00036067938,0.0012488608,0.00023139874,0.0002684421,0.0002898589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013237932,0.00018243633,0.0013974104,0.00015622212,0.000030089132,0.000009501267,0.000121464785,0.00031807114,0.00021542881],"category_scores_gemma":[0.00032889255,0.00012437084,0.00023903177,0.00018692693,0.0002044746,0.0001722795,0.000041576994,0.00088676583,0.000013220516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04032399,0.0011350492,0.88874286,0.000059417678,0.00018674244,0.00023098546,0.0001350612,0.0000034213258,0.00014178963,0.000007846827,0.0002157883,0.06881702],"study_design_scores_gemma":[0.048562117,0.025176264,0.89324486,0.000275474,0.00010285905,0.0001630048,0.00014146602,0.00007757273,0.00011554643,0.00002234834,0.031980082,0.00013838027],"about_ca_topic_score_codex":0.00010320681,"about_ca_topic_score_gemma":0.000051875817,"teacher_disagreement_score":0.06867864,"about_ca_system_score_codex":0.00025984208,"about_ca_system_score_gemma":0.00083992264,"threshold_uncertainty_score":0.50716954},"labels":[],"label_agreement":null},{"id":"W2912102267","doi":"10.1200/jco.2019.37.4_suppl.650","title":"Implementing DPYD*2A genotyping in clinical practice, the Quebec experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cegep de Saint Jerome; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"DPYD; Medicine; Mucositis; Internal medicine; Chemotherapy; Gastroenterology; Neutropenia; Genotyping; Diarrhea; Rash; Surgery; Pharmacogenetics; Genotype","score_opus":0.14892020592865957,"score_gpt":0.5519050690895535,"score_spread":0.40298486316089394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912102267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538082,0.0014096659,0.000018791177,0.018279646,0.0022358675,0.00031196795,5.7016825e-7,0.000005299689,0.023930032],"genre_scores_gemma":[0.9883017,0.0014907756,0.0017809224,0.0061598346,0.0014041603,0.000007760628,5.395624e-7,0.000010794975,0.0008435294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99524146,0.00060602283,0.0032410945,0.0002096775,0.0003555529,0.00034616428],"domain_scores_gemma":[0.9907917,0.006551022,0.0019091981,0.00021035594,0.0003749285,0.00016283465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008325499,0.00012213839,0.0013220039,0.00006866133,0.000071933115,0.000014751931,0.00017415495,0.00020617743,0.0003156978],"category_scores_gemma":[0.0083239805,0.000065615684,0.00050654187,0.00016282928,0.00019503308,0.00017735946,0.0001577399,0.0011690746,0.000040667568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034200144,0.0010179599,0.6120644,0.000009396993,0.00038677308,0.00040671646,0.0009409659,0.000002589818,0.00001532479,0.000226995,0.0016085237,0.3799003],"study_design_scores_gemma":[0.0043335063,0.0046635703,0.5517818,0.000048716105,0.00015722931,0.00014607368,0.0032900674,0.000027555301,0.0000041259864,0.000054951033,0.4354442,0.000048239246],"about_ca_topic_score_codex":0.0006025937,"about_ca_topic_score_gemma":0.0032494348,"teacher_disagreement_score":0.4338357,"about_ca_system_score_codex":0.0002348347,"about_ca_system_score_gemma":0.001442327,"threshold_uncertainty_score":0.9965184},"labels":[],"label_agreement":null},{"id":"W2912271356","doi":"10.1200/jco.2019.37.4_suppl.670","title":"Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Adverse effect; Nausea; Population; Gastroenterology; Cancer; Oncology; Surgery; Nivolumab; Immunotherapy","score_opus":0.03658901201206075,"score_gpt":0.3932580590738272,"score_spread":0.35666904706176644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912271356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971523,0.00027107695,0.000021390511,0.0011903165,0.00059513474,0.00042904238,0.000007654308,0.0000037909851,0.00032923825],"genre_scores_gemma":[0.99646074,0.0014347497,0.00094711274,0.00091997447,0.00015135636,6.46103e-7,0.0000022972538,0.000016526477,0.00006662108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995511,0.0006873475,0.0030237508,0.00025536955,0.00032297583,0.00019959004],"domain_scores_gemma":[0.9953565,0.001725157,0.0021346463,0.00027327336,0.00032258022,0.0001878668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005083466,0.0001526193,0.002096997,0.000117522344,0.000015897172,0.0000049934424,0.0001286052,0.0003899387,0.0001507504],"category_scores_gemma":[0.0005654133,0.00009869351,0.00037562722,0.00017762372,0.0005108129,0.00013701993,0.000034962253,0.00095836585,0.0000027134831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14451304,0.002503679,0.65186226,0.000030121826,0.00027613624,0.000017438504,0.00004723681,0.0000013974951,0.00017993376,0.000006294237,0.000017673134,0.20054479],"study_design_scores_gemma":[0.048673782,0.02916485,0.9146847,0.00025932805,0.00008624328,0.000023557153,0.000026774147,0.00001194579,0.00012229482,0.00004001976,0.006812466,0.0000940262],"about_ca_topic_score_codex":0.00010769457,"about_ca_topic_score_gemma":0.00009556141,"teacher_disagreement_score":0.26282245,"about_ca_system_score_codex":0.00015546073,"about_ca_system_score_gemma":0.0010765748,"threshold_uncertainty_score":0.4163676},"labels":[],"label_agreement":null},{"id":"W2912528378","doi":"10.1200/jco.2019.37.4_suppl.612","title":"The impact of socioeconomic factors on outcomes of patients with locally advanced rectal cancer (LARC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Calgary; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Multivariate analysis; Colorectal cancer; Socioeconomic status; Internal medicine; Univariate analysis; Demographics; Cancer; Demography; Population","score_opus":0.18484675303368095,"score_gpt":0.5802165012339738,"score_spread":0.3953697482002929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912528378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498874,0.000040550312,0.000021108732,0.003312641,0.00093661924,0.00038850063,0.000019678684,0.000002694913,0.00028944088],"genre_scores_gemma":[0.99839705,0.00023303342,0.00048777883,0.00063466775,0.00014808554,0.0000016718733,0.000004948419,0.000016794833,0.000075958334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950904,0.00034912856,0.0038616306,0.00014288543,0.00037614105,0.00017978571],"domain_scores_gemma":[0.9774427,0.015453408,0.005774527,0.00023417514,0.0009193124,0.00017587257],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002787314,0.00013612455,0.0015008037,0.00006728993,0.00002309906,0.0000034622476,0.00017595988,0.00019156717,0.0003987301],"category_scores_gemma":[0.009410345,0.00006348995,0.0006731512,0.000059995225,0.00021456095,0.0001545047,0.000036663543,0.00078024616,0.0000114692175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015020102,0.0010543722,0.90306216,0.000010290556,0.00089086907,0.0000031143632,0.000046969722,0.00035048558,0.000047997644,0.000013060215,0.0006019508,0.07889863],"study_design_scores_gemma":[0.013004527,0.033113442,0.95175904,0.000054167438,0.00025549802,0.000002542887,0.00021924033,0.000046323818,0.000050299404,0.0000787827,0.0013569102,0.00005919759],"about_ca_topic_score_codex":0.00013565412,"about_ca_topic_score_gemma":0.00011783124,"teacher_disagreement_score":0.078839436,"about_ca_system_score_codex":0.00027464904,"about_ca_system_score_gemma":0.0023496817,"threshold_uncertainty_score":0.9989338},"labels":[],"label_agreement":null},{"id":"W2912552045","doi":"10.1200/jco.2019.37.4_suppl.495","title":"Utility of restaging patients with stage II/III rectal cancer following neoadjuvant chemo/XRT: A systematic review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Colorectal cancer; Neoadjuvant therapy; Cancer; Chemotherapy; Oncology; Internal medicine; Radiology; Breast cancer","score_opus":0.06694085340421353,"score_gpt":0.45334841328569914,"score_spread":0.3864075598814856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912552045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98656166,0.005288958,0.000008953735,0.0008914399,0.0011524544,0.0015012089,0.000009303875,0.000011085463,0.0045749596],"genre_scores_gemma":[0.9960989,0.0012762952,0.0005078369,0.0010540187,0.00013304854,0.000018427338,0.0000035839219,0.000023364317,0.0008845246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448675,0.0005200812,0.003504589,0.00029361917,0.00089518534,0.0002997574],"domain_scores_gemma":[0.9933513,0.0016720889,0.0035157504,0.00040030864,0.0006936611,0.00036692174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003218194,0.0002241599,0.004256412,0.00009506893,0.00003720712,0.000004457127,0.00020857801,0.0002274649,0.0005894743],"category_scores_gemma":[0.00321401,0.00013119071,0.0009154794,0.00029060562,0.00011035908,0.00015245049,0.00010999588,0.0008251488,0.000009787664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008693507,0.0025347606,0.95498323,0.024711523,0.001806751,0.0004882376,0.00014991194,0.0000031869736,0.000028228516,0.0000066756566,0.00046275478,0.006131235],"study_design_scores_gemma":[0.037958857,0.033144366,0.78348416,0.1350159,0.0056745126,0.00010855957,0.00017197055,0.00013868939,0.00017049792,0.0000331814,0.0037652294,0.00033406971],"about_ca_topic_score_codex":0.00006286861,"about_ca_topic_score_gemma":0.000043647742,"teacher_disagreement_score":0.17149906,"about_ca_system_score_codex":0.00030940384,"about_ca_system_score_gemma":0.0015164437,"threshold_uncertainty_score":0.645433},"labels":[],"label_agreement":null},{"id":"W2912666850","doi":"10.1200/jco.2019.37.4_suppl.321","title":"Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Regimen; Clinical endpoint; Progressive disease; Gastroenterology; Temozolomide; Adverse effect; Retrospective cohort study; Surgery; Chemotherapy; Clinical trial","score_opus":0.07521099663434302,"score_gpt":0.4828652562034394,"score_spread":0.4076542595690964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912666850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484595,0.0034017707,0.0000059160398,0.040613856,0.0018697698,0.0010389385,0.000002669365,0.000018597044,0.004589003],"genre_scores_gemma":[0.9557151,0.027553843,0.0012948063,0.012651472,0.000793452,0.000009878961,0.0000018832657,0.00003906439,0.0019404821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938592,0.0009431757,0.003381869,0.00041161166,0.0007926729,0.0006115076],"domain_scores_gemma":[0.9939377,0.002725465,0.0018036895,0.00044074818,0.00049311557,0.00059929834],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019563062,0.00023338947,0.0027535988,0.0002914625,0.00002145592,0.000008905623,0.00035856047,0.0000390949,0.0005651284],"category_scores_gemma":[0.012699731,0.00016624184,0.0006590241,0.0003953236,0.00022432336,0.0002681744,0.00013413242,0.0030505282,0.00021235683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011178331,0.003932627,0.86619824,0.00055018323,0.00022897084,0.066424675,0.00002459603,0.000022470322,0.0021758834,0.00010073615,0.029927853,0.019235447],"study_design_scores_gemma":[0.042135425,0.035289984,0.56089514,0.0021032211,0.00028709008,0.018083457,0.000108265034,0.00019895172,0.0010531717,0.00045290275,0.33911833,0.0002740834],"about_ca_topic_score_codex":0.00003578155,"about_ca_topic_score_gemma":0.00009661694,"teacher_disagreement_score":0.30919048,"about_ca_system_score_codex":0.0002875596,"about_ca_system_score_gemma":0.0009096083,"threshold_uncertainty_score":0.99924946},"labels":[],"label_agreement":null},{"id":"W2912712830","doi":"10.1200/jco.2019.37.4_suppl.162","title":"Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Perioperative; Surgery; Salvage therapy; Curative treatment; Chemotherapy; Internal medicine; Disease","score_opus":0.08515997921965614,"score_gpt":0.4819853560264239,"score_spread":0.39682537680676777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912712830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869798,0.003866966,0.00009581985,0.0074333,0.00068683503,0.0004926217,0.000010936685,0.0000050888198,0.00042866237],"genre_scores_gemma":[0.9952599,0.0003018569,0.0019693465,0.0009789243,0.00057020196,0.000018671813,0.0000025272955,0.000011932543,0.00088664494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980606,0.00025299971,0.0009803659,0.00018393202,0.00028563797,0.00023650094],"domain_scores_gemma":[0.99652463,0.0020397112,0.00054238265,0.00013037414,0.00040570932,0.000357192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018401548,0.000108669105,0.0010497224,0.000088814115,0.000025732024,0.000009341507,0.00006251752,0.000167377,0.00014385338],"category_scores_gemma":[0.0015068356,0.000067806664,0.00032741288,0.000058112553,0.00011567134,0.00011183483,0.00003287401,0.00053304964,0.000018600515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019311316,0.00037418102,0.96332234,0.000045906167,0.00030575416,0.00046354855,0.000045902598,9.385148e-7,0.000008245837,0.000042449312,0.0009754327,0.015103976],"study_design_scores_gemma":[0.011075748,0.03784467,0.9476899,0.000031067844,0.00007171106,0.00023291366,0.000052500727,0.000030880637,0.000042820986,0.00027628106,0.0026105638,0.00004097154],"about_ca_topic_score_codex":0.000009122775,"about_ca_topic_score_gemma":0.0000602125,"teacher_disagreement_score":0.037470486,"about_ca_system_score_codex":0.0001458305,"about_ca_system_score_gemma":0.0006692552,"threshold_uncertainty_score":0.27650756},"labels":[],"label_agreement":null},{"id":"W2912731586","doi":"10.1200/jco.2019.37.4_suppl.352","title":"Provider-volume associated with variable receipt of therapy and outcomes for noncurative pancreas adenocarcinoma: A population-based analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; Institute for Clinical Evaluative Sciences; Queen's University; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Population; Multivariate analysis; Receipt; Internal medicine; Retrospective cohort study; Cohort; Cancer registry; Comorbidity; Adenocarcinoma; Cancer; Emergency medicine","score_opus":0.11289468655560884,"score_gpt":0.4537656775262124,"score_spread":0.3408709909706035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912731586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938216,0.0003024603,0.0010881755,0.0031219847,0.00012431537,0.0007916047,0.00001387237,0.0000059092563,0.0007300806],"genre_scores_gemma":[0.9835118,0.00008448651,0.014349095,0.0008700993,0.00010860032,0.000016754826,0.000021037278,0.000014229989,0.0010238674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688196,0.00050024176,0.0017823668,0.00021208178,0.00038520084,0.00023816421],"domain_scores_gemma":[0.98653096,0.00971949,0.002151348,0.00019515536,0.0011562221,0.0002468195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004449724,0.00014042931,0.0031684004,0.00025305783,0.000039317674,0.0000061690835,0.00011113737,0.0003984684,0.00025873186],"category_scores_gemma":[0.0071122986,0.00008285192,0.0004101586,0.0003806315,0.00018905525,0.00008734888,0.000016715663,0.0005165722,0.0000018617043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007544192,0.0011404924,0.98329306,0.00003905271,0.0049793515,0.000022450473,0.000071846145,0.000039081868,0.000025115734,0.00019963337,0.0002520298,0.0023936732],"study_design_scores_gemma":[0.01696969,0.022616658,0.95185995,0.000078159195,0.0027781837,0.000015913907,0.00009122867,0.004428773,0.00000621867,0.000433863,0.00064279995,0.00007856248],"about_ca_topic_score_codex":0.00014824684,"about_ca_topic_score_gemma":0.00008518163,"teacher_disagreement_score":0.03143313,"about_ca_system_score_codex":0.0001384764,"about_ca_system_score_gemma":0.0027732446,"threshold_uncertainty_score":0.85146},"labels":[],"label_agreement":null},{"id":"W2912820618","doi":"10.1200/jco.2019.37.4_suppl.tps176","title":"A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Capecitabine; Tolerability; Peptide vaccine; Immunogenicity; Oncology; Internal medicine; HER2/neu; Cancer; Trastuzumab; Phases of clinical research; Chemotherapy; Monoclonal antibody; Breast cancer; Antibody; Epitope; Cancer research; Immunology; Adverse effect; Colorectal cancer","score_opus":0.10382909989289561,"score_gpt":0.46260139783792614,"score_spread":0.3587722979450305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912820618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647915,0.00020365049,0.000012450113,0.0011564272,0.00021473286,0.0017479275,0.000021240763,0.0000037469342,0.00016066484],"genre_scores_gemma":[0.9918116,0.00011024428,0.0037744362,0.0006321045,0.00015339136,0.000015224948,0.000003850871,0.000039727453,0.00345946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950563,0.0007879796,0.0025151116,0.0003643762,0.00089405716,0.00038219496],"domain_scores_gemma":[0.99462104,0.0019563967,0.0021082896,0.00037304775,0.0006493254,0.0002919031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019262059,0.0002940516,0.0023936124,0.00017398967,0.00008618889,0.00001744821,0.00047489905,0.00014477476,0.00088198064],"category_scores_gemma":[0.0009953082,0.00013045841,0.0001552565,0.00042483516,0.00018558523,0.00029417308,0.00032752397,0.0010554154,0.0000023681725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32961446,0.024049554,0.59212726,0.00021020687,0.0008697034,0.00044223445,0.0010637385,0.000061238425,0.0007535326,0.000003688846,0.00043009844,0.050374273],"study_design_scores_gemma":[0.16430394,0.14264522,0.6894005,0.00047080297,0.00029765387,0.000219456,0.0012126722,0.00046196047,0.00015121086,0.000012250156,0.00069718156,0.00012711887],"about_ca_topic_score_codex":0.00025374658,"about_ca_topic_score_gemma":0.00061363034,"teacher_disagreement_score":0.1653105,"about_ca_system_score_codex":0.00014761795,"about_ca_system_score_gemma":0.0015892348,"threshold_uncertainty_score":0.96570694},"labels":[],"label_agreement":null},{"id":"W2913035205","doi":"10.1200/jco.2019.37.4_suppl.tps466","title":"Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Celiac plexus; Clinical endpoint; Pancreatic cancer; Radiosurgery; Cancer pain; Cancer; Radiation therapy; Surgery; Randomized controlled trial; Internal medicine","score_opus":0.11410617297672038,"score_gpt":0.5193187368560871,"score_spread":0.4052125638793667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913035205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853744,0.00011099071,0.00044091293,0.0043218583,0.0057194205,0.001649043,0.000018313023,0.000008131927,0.0023569122],"genre_scores_gemma":[0.9737722,0.0008197337,0.01222187,0.009903967,0.0010448005,0.00011305836,0.000053905937,0.000031146436,0.0020392747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958908,0.000490873,0.0026043751,0.00026078147,0.0005142791,0.00023891886],"domain_scores_gemma":[0.9960477,0.0014060651,0.001639504,0.00022851439,0.0003635162,0.00031475432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077056536,0.00013920087,0.0011864232,0.00029788318,0.000020428935,0.00000893395,0.00023985039,0.00012486435,0.00077165297],"category_scores_gemma":[0.0036156224,0.000110975525,0.00044041188,0.00011458301,0.00004776798,0.00026884646,0.00006688348,0.00035647157,0.000007781395],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18044765,0.022796378,0.03756313,0.000112341644,0.0006871786,0.00020763252,0.000052808904,0.00007682372,0.000010464051,0.0003139149,0.0112167625,0.7465149],"study_design_scores_gemma":[0.42269394,0.051186215,0.07126015,0.00018956389,0.000499993,0.0000026277646,0.00024013058,0.0018690905,0.0000031835802,0.0005938445,0.4513086,0.00015267037],"about_ca_topic_score_codex":0.000004324329,"about_ca_topic_score_gemma":0.000006781885,"teacher_disagreement_score":0.7463622,"about_ca_system_score_codex":0.00023643258,"about_ca_system_score_gemma":0.0004131678,"threshold_uncertainty_score":0.8449059},"labels":[],"label_agreement":null},{"id":"W2913043131","doi":"10.1200/jco.2019.37.4_suppl.537","title":"Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Ottawa","funders":"","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; Cetuximab; Medicine; Internal medicine; Sanger sequencing; Oncology; Exon; Predictive marker; Colorectal cancer; Cancer; Mutation; Biology; Gene; Genetics","score_opus":0.18211864501253242,"score_gpt":0.5038699796930456,"score_spread":0.3217513346805132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913043131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773957,0.0010870601,0.000054895932,0.004114239,0.0009053357,0.0024716246,0.0000055574674,0.0000060526613,0.013959497],"genre_scores_gemma":[0.9965112,0.0003588883,0.0006317241,0.0015900839,0.00058746827,0.000077027966,0.0000024879143,0.000009781763,0.00023133686],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99695253,0.0006246945,0.001778784,0.00019088965,0.00025192543,0.0002011545],"domain_scores_gemma":[0.9803801,0.017961217,0.0011673525,0.000111255875,0.000248795,0.00013125253],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0059883203,0.00014048866,0.0021626581,0.00009419001,0.00006028588,0.000014192661,0.00009006486,0.00017024792,0.000049243878],"category_scores_gemma":[0.011172866,0.0000719523,0.000456802,0.000111029534,0.0002751512,0.00006480738,0.00002915226,0.00036249674,0.0000019429112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9230423,0.0039183474,0.0027208726,0.00001878265,0.001144818,0.00018865652,0.0006557825,0.0000014736238,0.00016806448,0.000012829394,0.0017074718,0.0664206],"study_design_scores_gemma":[0.90919894,0.07663823,0.0033300328,0.00010916089,0.0009234381,0.00022585373,0.0010857453,0.000182762,0.00004121428,0.00042455358,0.0077713793,0.000068719615],"about_ca_topic_score_codex":0.00003131186,"about_ca_topic_score_gemma":0.000022048309,"teacher_disagreement_score":0.07271988,"about_ca_system_score_codex":0.00015117288,"about_ca_system_score_gemma":0.00065015425,"threshold_uncertainty_score":0.99715644},"labels":[],"label_agreement":null},{"id":"W2913103808","doi":"10.1200/jco.2019.37.4_suppl.396","title":"A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Waterloo; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gemcitabine; Folinic acid; Internal medicine; Oncology; Pancreatic cancer; Erlotinib; Capecitabine; Meta-analysis; Randomized controlled trial; Adjuvant therapy; Randomization; Cancer; Fluorouracil; Colorectal cancer","score_opus":0.3707025740204211,"score_gpt":0.5469295356664763,"score_spread":0.17622696164605517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913103808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779304,0.015525515,0.00004902822,0.002909174,0.00034310654,0.00051920064,0.000005538187,0.0000045383845,0.0027134963],"genre_scores_gemma":[0.9888997,0.007488805,0.0011113608,0.0011386725,0.0003058631,0.000022556744,0.0000029297526,0.000013449922,0.0010166622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929299,0.0019002692,0.003957632,0.00023504726,0.0006118076,0.00036539225],"domain_scores_gemma":[0.98791796,0.00803307,0.0025428787,0.0003921119,0.00082974514,0.00028426334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009981562,0.00015961514,0.009157331,0.00050601875,0.000017105465,0.0000035567116,0.00026824084,0.00050054694,0.0026203846],"category_scores_gemma":[0.0026181976,0.00009282909,0.0020356565,0.0012029478,0.00020655242,0.00005864071,0.000046644058,0.0011578357,0.000015105758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007033892,0.0008938142,0.8535,0.000055582008,0.13219264,0.0002890964,0.00012685204,0.0007403856,0.000300134,0.00006439129,0.0010186317,0.00378459],"study_design_scores_gemma":[0.00861814,0.014456409,0.81797934,0.00011298122,0.15371808,0.00012531006,0.00016120325,0.003050955,0.00001143636,0.00021917449,0.0014526133,0.000094338524],"about_ca_topic_score_codex":0.00031921073,"about_ca_topic_score_gemma":0.00030185838,"teacher_disagreement_score":0.035520636,"about_ca_system_score_codex":0.0002074024,"about_ca_system_score_gemma":0.0030667188,"threshold_uncertainty_score":0.9982914},"labels":[],"label_agreement":null},{"id":"W2913109842","doi":"10.1200/jco.2019.37.4_suppl.247","title":"A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Capecitabine; Oxaliplatin; Oncology; Adjuvant therapy; Gallbladder cancer; Adjuvant; Surgery; Colorectal cancer; Cancer","score_opus":0.5089441776066193,"score_gpt":0.5601738382747834,"score_spread":0.051229660668164145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913109842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011312545,0.9945196,0.000021349864,0.0012532696,0.00043265696,0.0035298525,0.00008159335,0.0000042482543,0.00014610184],"genre_scores_gemma":[0.0000565366,0.9964913,0.000536734,0.001865126,0.0005373722,0.00018542161,0.000019311488,0.00003371431,0.00027445142],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9893028,0.0019810356,0.0076546296,0.0003813186,0.0004144333,0.00026575365],"domain_scores_gemma":[0.9736441,0.013265622,0.011298342,0.00047716135,0.0010877841,0.0002270021],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.007891385,0.00042675855,0.043923035,0.00032445727,0.000034914105,0.0000071755194,0.0002799386,0.0005536811,0.00010100945],"category_scores_gemma":[0.0048886524,0.00020714515,0.0130321765,0.00080459856,0.00018909104,0.0000628897,0.000054048716,0.0010885553,0.0000016631715],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033356322,0.00026806744,0.00005172522,0.4492534,0.4996202,0.000056217694,0.000040347026,0.0000010266515,3.2187828e-8,0.000008837908,0.0066723702,0.043694217],"study_design_scores_gemma":[0.0011677596,0.004908978,0.00036036145,0.050743364,0.71521586,0.00013592684,0.000015376814,0.0000037824211,1.9729814e-8,0.000009714229,0.22731228,0.00012659421],"about_ca_topic_score_codex":0.000019378193,"about_ca_topic_score_gemma":0.000045393394,"teacher_disagreement_score":0.39851004,"about_ca_system_score_codex":0.00020552844,"about_ca_system_score_gemma":0.0034994476,"threshold_uncertainty_score":0.99685204},"labels":[],"label_agreement":null},{"id":"W2913218375","doi":"10.1200/jco.2019.37.4_suppl.188","title":"Integrative molecular profiling and response to chemotherapy on the COMPASS trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University Health Network; Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Oncology; Population; Cohort; Biopsy; Pathology","score_opus":0.05060127767840055,"score_gpt":0.4247411236847193,"score_spread":0.3741398460063187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913218375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827156,0.00019290764,0.0003527156,0.0144741,0.00075738487,0.00034190484,0.0000039127794,0.0000010485628,0.0011603963],"genre_scores_gemma":[0.984942,0.00033684156,0.0014227072,0.012598184,0.00048749012,0.000005721234,0.0000010568815,0.000011821492,0.00019417031],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844205,0.0004557707,0.0007040115,0.00016241972,0.00011636627,0.00011938383],"domain_scores_gemma":[0.9974058,0.0016000164,0.0004735837,0.00019936096,0.00018694738,0.00013427348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029402156,0.00009674624,0.00044339793,0.00003422253,0.0000232169,0.000014899669,0.00019259179,0.00018574792,0.000019989895],"category_scores_gemma":[0.0040853405,0.000056872323,0.00018577339,0.00004741732,0.00007776912,0.0000017953994,0.00006223383,0.00032224442,0.000010704886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54694366,0.0011532393,0.0037246617,0.00000803079,0.00055156817,0.00006849164,0.00024909034,0.00037043737,0.37330624,0.0033167768,0.019805085,0.05050274],"study_design_scores_gemma":[0.057027444,0.09397014,0.009877808,0.00006877406,0.000077362376,0.000056137033,0.0006163372,0.0000960861,0.09708987,0.0011806315,0.7396353,0.00030408893],"about_ca_topic_score_codex":0.0000023652678,"about_ca_topic_score_gemma":0.000005331824,"teacher_disagreement_score":0.7198302,"about_ca_system_score_codex":0.000029823845,"about_ca_system_score_gemma":0.00058720034,"threshold_uncertainty_score":0.48908296},"labels":[],"label_agreement":null},{"id":"W2913241831","doi":"10.1200/jco.2019.37.4_suppl.662","title":"Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Likert scale; Colorectal cancer; Resection; Hepatectomy; Internal medicine; Test (biology); General surgery; Surgery; Cancer; Oncology","score_opus":0.12933923914528347,"score_gpt":0.4094063674513154,"score_spread":0.280067128306032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913241831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975379,0.00090147805,0.00032730258,0.00031395667,0.00027736792,0.00032149995,0.000025919475,0.000005837867,0.00028871564],"genre_scores_gemma":[0.99691296,0.00025621394,0.0023120895,0.00022731328,0.00015140892,0.000005240585,0.000022565528,0.00001416668,0.0000980498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681467,0.00095412735,0.0014446679,0.00019654175,0.0004056875,0.0001843346],"domain_scores_gemma":[0.99204624,0.005033952,0.001581599,0.00016644745,0.00092536135,0.00024639373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030917232,0.00013940207,0.0019734933,0.0002858206,0.000020502179,0.0000052585506,0.00009750447,0.00026546876,0.0007177522],"category_scores_gemma":[0.0013838628,0.000086151056,0.00071864406,0.00057419797,0.00014882871,0.00005612814,0.000015818996,0.0004944932,0.000014481065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021258514,0.0016340042,0.9563576,0.000053396005,0.0051073157,0.001318792,0.00003969901,0.0011547823,0.00021150179,0.0000020476489,0.00011439793,0.012747947],"study_design_scores_gemma":[0.012466956,0.071770415,0.86951184,0.000109486624,0.01074541,0.00014699789,0.000049258917,0.030713873,0.001832416,0.000003129375,0.0025085828,0.00014164577],"about_ca_topic_score_codex":0.00071537466,"about_ca_topic_score_gemma":0.002096414,"teacher_disagreement_score":0.08684577,"about_ca_system_score_codex":0.00017935758,"about_ca_system_score_gemma":0.0021493707,"threshold_uncertainty_score":0.7858884},"labels":[],"label_agreement":null},{"id":"W2913253641","doi":"10.1200/jco.2019.37.4_suppl.382","title":"Efficacy and tolerability of sorafenib in unresectable/advanced hepatocellular carcinoma patients: Real-life experience in a Hong Kong tertiary liver cancer institute.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Tolerability; Internal medicine; Cirrhosis; Liver cancer; Liver function; Hepatitis B; Gastroenterology; Population; Oncology; Adverse effect; Surgery","score_opus":0.15559305188483183,"score_gpt":0.40550228366684804,"score_spread":0.2499092317820162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913253641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960534,0.0016931873,0.000007014524,0.0005351308,0.0005907452,0.0008098693,0.000003335863,0.000005016879,0.00030231755],"genre_scores_gemma":[0.997193,0.0018882175,0.00043883332,0.00028407935,0.0001291602,0.000020914678,0.0000042931592,0.000015557893,0.000025992085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959825,0.00049071136,0.0025222772,0.00034377674,0.00035162407,0.0003090985],"domain_scores_gemma":[0.9969953,0.0010540562,0.0010402987,0.00025868893,0.00030639567,0.00034526963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001536081,0.00019620253,0.0017788494,0.00024920722,0.000019190038,0.0000060997763,0.00015699575,0.00036119038,0.00012298227],"category_scores_gemma":[0.0017242187,0.00015049354,0.00024140203,0.0003083643,0.00027385863,0.00038204066,0.000091537986,0.0007366555,0.000003714763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00493306,0.0024186706,0.9666228,0.00013919781,0.00006637769,0.00067593355,0.0008303658,0.000015291816,0.0005485902,0.000017362769,0.000012736547,0.023719603],"study_design_scores_gemma":[0.019394904,0.0042094025,0.9728825,0.00035282562,0.00009628114,0.000017311157,0.00015243211,0.0016727874,0.00055750017,0.000016925023,0.0005212146,0.00012592075],"about_ca_topic_score_codex":0.0010215522,"about_ca_topic_score_gemma":0.0003544333,"teacher_disagreement_score":0.023593683,"about_ca_system_score_codex":0.00027340162,"about_ca_system_score_gemma":0.0012330767,"threshold_uncertainty_score":0.61369485},"labels":[],"label_agreement":null},{"id":"W2913281659","doi":"10.1200/jco.2019.37.4_suppl.tps718","title":"Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Nivolumab; Bevacizumab; Irinotecan; Colorectal cancer; Oncology; Internal medicine; Oxaliplatin; Immunotherapy; Progression-free survival; Phases of clinical research; Clinical trial; Cancer; Chemotherapy","score_opus":0.16423734793000058,"score_gpt":0.5189681292614418,"score_spread":0.3547307813314412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913281659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985883,0.0076432433,0.0000114398,0.0004345936,0.0013472206,0.002941308,0.0010901976,0.0000043393757,0.00064465706],"genre_scores_gemma":[0.99515027,0.0032190545,0.0012273554,0.000018487259,0.00014799375,0.00008516978,0.000019485495,0.000027871418,0.00010431431],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9952063,0.00019976018,0.0033435987,0.0003136452,0.0006602925,0.0002764346],"domain_scores_gemma":[0.99118507,0.0018024506,0.003767676,0.0002902481,0.0027511308,0.00020345097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076260924,0.0002957613,0.005842413,0.00016289005,0.00007891922,0.0000044341004,0.00028768266,0.00018076811,0.00016974448],"category_scores_gemma":[0.00063400884,0.00019857248,0.0005928697,0.0002124795,0.00029109465,0.00009199418,0.00017342028,0.00022793296,2.6597598e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7763872,0.021398684,0.017879836,0.0010283323,0.009230008,0.00012022981,0.016413579,0.00022487553,0.0002605542,0.000031330914,0.00034585892,0.15667948],"study_design_scores_gemma":[0.28438252,0.6779175,0.0026185631,0.00033435653,0.004637348,0.000009144456,0.020940207,0.000042711497,0.0035327112,0.000015449781,0.0054531563,0.00011637331],"about_ca_topic_score_codex":0.0006600416,"about_ca_topic_score_gemma":0.010478248,"teacher_disagreement_score":0.65651876,"about_ca_system_score_codex":0.0014014941,"about_ca_system_score_gemma":0.0038568145,"threshold_uncertainty_score":0.809755},"labels":[],"label_agreement":null},{"id":"W2913380162","doi":"10.1200/jco.2019.37.4_suppl.665","title":"Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Colorectal cancer; Cohort; Cancer; Surgery; Resection; Population; Hepatectomy; Internal medicine","score_opus":0.07944958598568663,"score_gpt":0.4608492941564335,"score_spread":0.38139970817074687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913380162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929396,0.0006308713,0.000045493533,0.0006802678,0.0033711232,0.0018927933,0.000029623248,0.000014500407,0.00039573753],"genre_scores_gemma":[0.99759567,0.00019340261,0.0007644031,0.00027862587,0.0007983999,0.000091207716,0.000011912671,0.000020907439,0.00024548382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734426,0.000328448,0.0014144345,0.00027213088,0.00040813582,0.0002326015],"domain_scores_gemma":[0.99175066,0.0060324823,0.001124741,0.00013768254,0.00075998285,0.00019446465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017902635,0.0001701104,0.0015892129,0.000118852426,0.000092623064,0.000010922266,0.000087914384,0.00019310277,0.00036629618],"category_scores_gemma":[0.0036084135,0.00011758286,0.0005110801,0.00013945677,0.00006319546,0.00007026413,0.00002699188,0.0004577128,0.000009764679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.113119975,0.0032260204,0.8326915,0.000051701572,0.0027620287,0.00037326996,0.00013075086,0.0012614054,0.00002607952,0.0000053112203,0.0005896494,0.045762338],"study_design_scores_gemma":[0.033225775,0.14026849,0.8148394,0.000056032008,0.0023809331,0.000030027284,0.00046144333,0.0021562744,0.00003389303,0.000009792122,0.0064058406,0.00013204549],"about_ca_topic_score_codex":0.00056969706,"about_ca_topic_score_gemma":0.0040101735,"teacher_disagreement_score":0.13704248,"about_ca_system_score_codex":0.0009370651,"about_ca_system_score_gemma":0.0014473252,"threshold_uncertainty_score":0.47948897},"labels":[],"label_agreement":null},{"id":"W2913433184","doi":"10.1200/jco.2019.37.4_suppl.309","title":"Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomes—Final results of a prospective clinical trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Celiac plexus; Pancreatic cancer; Clinical endpoint; Brief Pain Inventory; Palliative care; Plexus; Neurolysis; Radiation therapy; Prospective cohort study; Surgery; Cancer; Clinical trial; Internal medicine; Chronic pain","score_opus":0.2813686330321332,"score_gpt":0.48145285450585046,"score_spread":0.20008422147371724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913433184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886782,0.000503113,0.000026748638,0.0040308572,0.0027253598,0.0007617237,0.000008333543,0.0000067875217,0.0032588562],"genre_scores_gemma":[0.9930278,0.0019005613,0.001110948,0.001572947,0.0011539416,0.000011052845,0.000004042544,0.000015036253,0.0012036583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993389,0.00087693485,0.004641152,0.0003375056,0.0004944581,0.00026093575],"domain_scores_gemma":[0.9853139,0.010794705,0.002988172,0.00022200603,0.00041225893,0.0002689426],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0094667785,0.0001832448,0.0028333927,0.00025706657,0.000019683026,0.000007768957,0.0001117181,0.00039978803,0.00012152471],"category_scores_gemma":[0.01370747,0.00012836081,0.0006190326,0.0002389646,0.00030017085,0.00011548549,0.00006764842,0.0011613114,0.000009173151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16258001,0.0027088234,0.822027,0.000054220833,0.0005609302,0.00017489535,0.00008739018,0.000015071802,0.000039272167,0.00007594053,0.0027840456,0.008892365],"study_design_scores_gemma":[0.1393169,0.013445303,0.837041,0.00024531127,0.00037700284,0.000007047415,0.0001377285,0.000116876814,0.000008522171,0.00030215166,0.008903416,0.0000986853],"about_ca_topic_score_codex":0.000043236218,"about_ca_topic_score_gemma":0.00005836969,"teacher_disagreement_score":0.023263106,"about_ca_system_score_codex":0.0002107331,"about_ca_system_score_gemma":0.0012801136,"threshold_uncertainty_score":0.9946005},"labels":[],"label_agreement":null},{"id":"W2913477419","doi":"10.1200/jco.2019.37.4_suppl.428","title":"Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Cancer Care Ontario; Credit Valley Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Univariate analysis; Internal medicine; Liver disease; Gastroenterology; Liver cancer; Portal vein thrombosis; Hepatitis C; Hepatitis B; Radiology; Multivariate analysis; Portal vein","score_opus":0.1399601682685083,"score_gpt":0.3767698923414292,"score_spread":0.23680972407292092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913477419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243003,0.0021768038,0.00018010441,0.002762747,0.0006767632,0.0012014164,0.000002295984,0.000011436057,0.0005584229],"genre_scores_gemma":[0.9944532,0.0009039452,0.0020297314,0.0013446478,0.0008114571,0.000022256763,0.000016451813,0.000036195663,0.00038210204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729514,0.0003387388,0.0014596393,0.0002513712,0.00039237688,0.00026275773],"domain_scores_gemma":[0.99630535,0.001336267,0.0011993686,0.00030185748,0.00051237934,0.00034476712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023888808,0.00018822661,0.0014316228,0.00014723644,0.00004236492,0.000015521216,0.00013376363,0.0003549546,0.00023917526],"category_scores_gemma":[0.0004445498,0.00011602417,0.0008454067,0.00013936503,0.00007129585,0.00015831647,0.000017357504,0.00050272146,0.00005030742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073112343,0.0011102878,0.94253707,0.00005064368,0.0009206013,0.00063306076,0.00006421268,5.217187e-7,0.0005362938,0.00004575633,0.00056023296,0.04623008],"study_design_scores_gemma":[0.037104633,0.05969766,0.7364407,0.00008662077,0.0010627472,0.00076224946,0.00005364298,0.00187244,0.0031838585,0.00013228721,0.15940072,0.00020240173],"about_ca_topic_score_codex":0.000016032003,"about_ca_topic_score_gemma":0.0000020367315,"teacher_disagreement_score":0.20609634,"about_ca_system_score_codex":0.00013285338,"about_ca_system_score_gemma":0.0013665867,"threshold_uncertainty_score":0.47313285},"labels":[],"label_agreement":null},{"id":"W2913498395","doi":"10.1200/jco.2019.37.4_suppl.171","title":"Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Dysphagia; Malnutrition; Weight loss; Univariate analysis; Performance status; Gastroenterology; Esophageal cancer; Quality of life (healthcare); Cancer; Anorexia; Body mass index; Lung cancer; Nausea; Surgery; Multivariate analysis; Obesity","score_opus":0.03957735685969444,"score_gpt":0.3666720646715879,"score_spread":0.3270947078118935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913498395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923653,0.0032574113,0.00019221545,0.00021451432,0.005879475,0.00026161477,0.000010125179,0.0000012986886,0.0009468395],"genre_scores_gemma":[0.9927439,0.00042714362,0.0019734406,0.00029649018,0.004192566,0.0000060243387,0.0000070382625,0.000013135739,0.00034023446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973663,0.00044193646,0.0015996406,0.00020280595,0.00018710358,0.0002022117],"domain_scores_gemma":[0.99777126,0.00047059517,0.0011907886,0.00018552764,0.00024827285,0.00013357677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017203918,0.00011462602,0.00085091556,0.00008894713,0.0000095932055,0.0000040202017,0.00021670797,0.00023953494,0.000053276814],"category_scores_gemma":[0.00097486895,0.00009720333,0.000325129,0.00010044682,0.00011429271,0.000008515147,0.00004463234,0.00036823805,0.000008527879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007617853,0.005558556,0.6211334,0.00052033865,0.00014924476,0.000039647806,0.00017444084,0.00075322133,0.3144133,0.00021338176,0.021265905,0.028160734],"study_design_scores_gemma":[0.020814473,0.02133039,0.66047615,0.00005613718,0.00034772063,0.0001497667,0.0003110882,0.00010901318,0.026432391,0.0005996784,0.269024,0.00034920475],"about_ca_topic_score_codex":0.000028666027,"about_ca_topic_score_gemma":0.0000516516,"teacher_disagreement_score":0.2879809,"about_ca_system_score_codex":0.000026524778,"about_ca_system_score_gemma":0.000985083,"threshold_uncertainty_score":0.39638367},"labels":[],"label_agreement":null},{"id":"W2913676144","doi":"10.1200/jco.2019.37.4_suppl.384","title":"Symptom burden of patients with advanced pancreas cancer (APC): A provincial cancer institute observational study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Internal medicine; Nausea; Cancer; Cohort","score_opus":0.13158364951803597,"score_gpt":0.3949832483492032,"score_spread":0.2633995988311672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913676144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901219,0.0007244514,0.00006276934,0.0010797366,0.0036155155,0.0005428271,0.00018592719,0.00000583284,0.0036610682],"genre_scores_gemma":[0.9968088,0.00050400686,0.00045654434,0.00062033924,0.0011782934,0.00002590057,0.0000047731032,0.00002518551,0.0003761559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960377,0.000056549565,0.003155179,0.00032600196,0.00013680234,0.0002877248],"domain_scores_gemma":[0.99330956,0.00033752577,0.0052941614,0.00023891567,0.00061189587,0.0002079247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014849722,0.00019225542,0.0019670883,0.00016473526,0.00004103356,0.00001567022,0.00039847952,0.00026253963,0.0007291793],"category_scores_gemma":[0.0008730037,0.00016294495,0.00029426374,0.00017937903,0.00017629896,0.0008289146,0.00005729184,0.00054953946,0.000041336647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024131234,0.0009592068,0.96185553,0.000024272984,0.00040286357,0.0000060211037,0.00028218582,0.002725536,0.0000017103055,0.0033286095,0.00034623314,0.027654687],"study_design_scores_gemma":[0.00862435,0.005004977,0.9215489,0.000066575434,0.00006222156,0.0000010456639,0.00008376462,0.000105312974,0.0000029097694,0.0014891741,0.062813595,0.00019718712],"about_ca_topic_score_codex":0.0011860499,"about_ca_topic_score_gemma":0.000678043,"teacher_disagreement_score":0.062467363,"about_ca_system_score_codex":0.00034940868,"about_ca_system_score_gemma":0.0018551961,"threshold_uncertainty_score":0.7984002},"labels":[],"label_agreement":null},{"id":"W2913822346","doi":"10.1200/jco.2019.37.4_suppl.444","title":"Impact of an inter-professional clinic on pancreatic cancer outcomes: The Princess Margaret Cancer Centre (PM) experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Referral; Pancreatic cancer; Stage (stratigraphy); Psychosocial; Cancer; Internal medicine; Radiation therapy; Family medicine","score_opus":0.17306891316998554,"score_gpt":0.5840669568285217,"score_spread":0.4109980436585362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913822346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985358,0.00026085108,0.000008174354,0.0087126335,0.0022892645,0.00053267425,0.000016395503,0.000006613191,0.0028153772],"genre_scores_gemma":[0.9902868,0.001383264,0.0003081531,0.0021975338,0.000837454,0.00002318193,0.0000028494972,0.000021810925,0.0049388967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99458313,0.0012663826,0.0026831073,0.00028738048,0.0007493431,0.00043064883],"domain_scores_gemma":[0.98964167,0.006438692,0.002215951,0.00048595492,0.00070157304,0.0005161808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038609973,0.0002210314,0.002702434,0.0001356959,0.0000604816,0.000007537002,0.000538687,0.00049985066,0.010027966],"category_scores_gemma":[0.003010457,0.00010109229,0.0008514016,0.00018644863,0.0005759764,0.00013633103,0.000115601135,0.001775876,0.00007027772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076824785,0.0022095463,0.9609534,0.00004701731,0.0010839787,0.00011269171,0.0007862646,0.000012762892,0.00007917835,0.000030842413,0.0030787063,0.023923092],"study_design_scores_gemma":[0.007186539,0.014883852,0.971389,0.0005197418,0.00044751074,0.000056312914,0.0011044028,0.0003207691,0.000018463092,0.00012652783,0.003846828,0.00010007654],"about_ca_topic_score_codex":0.0005257766,"about_ca_topic_score_gemma":0.00022698352,"teacher_disagreement_score":0.023823015,"about_ca_system_score_codex":0.00045195938,"about_ca_system_score_gemma":0.0062033553,"threshold_uncertainty_score":0.99943054},"labels":[],"label_agreement":null},{"id":"W2913846253","doi":"10.1200/jco.2019.37.4_suppl.654","title":"The impact of psychosocial distress on survival in patients diagnosed with gastrointestinal (GI) malignancies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Psychosocial; Depression (economics); Anxiety; Cancer; Internal medicine; Proportional hazards model; Distress; Prospective cohort study; Colorectal cancer; Psychiatry; Clinical psychology","score_opus":0.06192144007442394,"score_gpt":0.36952861760746153,"score_spread":0.30760717753303757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913846253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98375463,0.00012054431,0.00004488967,0.00048871356,0.0011938651,0.00016176557,0.000056218527,0.0000019476672,0.014177438],"genre_scores_gemma":[0.99903435,0.00020711248,0.00014054583,0.00013075546,0.00034882396,0.0000021494009,0.0000016520225,0.000015023824,0.000119601704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688613,0.00008825229,0.0024517726,0.00018960354,0.00007648071,0.00030776107],"domain_scores_gemma":[0.9941994,0.0016000107,0.0036608097,0.00020872141,0.00018357733,0.00014750569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024513525,0.00014334884,0.0013184675,0.00010586332,0.00003284808,0.000020272857,0.00036732104,0.00014821457,0.00012426502],"category_scores_gemma":[0.001971545,0.00009370003,0.00044350987,0.00012364842,0.0002104892,0.00017964997,0.000030696578,0.000598536,0.000060544975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034561171,0.0008460627,0.9803686,0.000004705698,0.000072231196,0.000013328237,0.000048625014,0.0002529667,5.7646093e-7,0.0047461293,0.001122306,0.009068309],"study_design_scores_gemma":[0.006167775,0.013974401,0.9739331,0.00007604692,0.0000059013087,0.0000042466595,0.00003738487,0.00004074643,7.8715436e-7,0.0023449243,0.003313027,0.00010164122],"about_ca_topic_score_codex":0.0002531744,"about_ca_topic_score_gemma":0.00016957286,"teacher_disagreement_score":0.015279718,"about_ca_system_score_codex":0.0002882167,"about_ca_system_score_gemma":0.00041822353,"threshold_uncertainty_score":0.38209763},"labels":[],"label_agreement":null},{"id":"W2913866957","doi":"10.1200/jco.2019.37.4_suppl.353","title":"Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Cirrhosis; Gastroenterology; Liver function; Hepatitis C; Liver cancer; Oncology","score_opus":0.15136912326912558,"score_gpt":0.3749005118042736,"score_spread":0.223531388535148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913866957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954024,0.0007847026,0.000006400964,0.002000468,0.0005704279,0.0008219323,0.000022656142,0.0000030307556,0.00038798613],"genre_scores_gemma":[0.9904703,0.0073694154,0.00096140173,0.00031532522,0.00028897604,0.000015187726,0.000017697814,0.0000256905,0.0005360092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714214,0.00018930984,0.0020002294,0.00021356651,0.00021339033,0.00024137332],"domain_scores_gemma":[0.99618906,0.0017396348,0.0012360602,0.00021014856,0.00034703364,0.00027808532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085108896,0.00019084569,0.0019562603,0.00013674742,0.000019449692,0.0000036407257,0.000092767135,0.00014141781,0.00007574125],"category_scores_gemma":[0.00034307485,0.00013074327,0.00028557997,0.00016851518,0.000060643804,0.000052035713,0.000020991163,0.00027067307,0.0000025956006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053213467,0.00083151803,0.91679984,0.00006853217,0.00021043223,0.0007158241,0.00005853241,0.0000016912691,0.00034563307,0.000024058374,0.000082744016,0.07553986],"study_design_scores_gemma":[0.01690103,0.01996684,0.90369093,0.00010257974,0.00023344714,0.000051557057,0.00003476702,0.0013507312,0.0013246614,0.000030232855,0.056204233,0.00010900669],"about_ca_topic_score_codex":0.055140264,"about_ca_topic_score_gemma":0.16981356,"teacher_disagreement_score":0.1146733,"about_ca_system_score_codex":0.00044718376,"about_ca_system_score_gemma":0.0035356153,"threshold_uncertainty_score":0.9511516},"labels":[],"label_agreement":null},{"id":"W2913874229","doi":"10.1200/jco.2019.37.4_suppl.481","title":"CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Hôpital Charles-Le Moyne; University of Saskatchewan; Université de Montréal; Nova Scotia Cancer Centre; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; McGill University; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; BC Cancer Agency; Moncton Hospital","funders":"","keywords":"Medicine; Tremelimumab; Irinotecan; Internal medicine; Hazard ratio; Refractory (planetary science); Durvalumab; Oxaliplatin; Oncology; Colorectal cancer; Gastroenterology; Clinical endpoint; Randomized controlled trial; Cancer; Confidence interval; Immunotherapy; Ipilimumab; Nivolumab","score_opus":0.05959807721354623,"score_gpt":0.4340736936208993,"score_spread":0.3744756164073531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913874229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937831,0.0008054925,0.0000016574209,0.00017470376,0.0015716883,0.003148395,0.000014046114,0.000008419018,0.00049249973],"genre_scores_gemma":[0.9989529,0.00042493976,0.00015170124,0.0001169387,0.0002113323,0.000032033793,0.000011463913,0.00003618638,0.000062478735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405473,0.0012156349,0.0034284855,0.00035609043,0.000648095,0.000296974],"domain_scores_gemma":[0.99256647,0.0030417112,0.0031529744,0.00026056555,0.00072465884,0.000253619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028721683,0.00026983736,0.003936735,0.00027348258,0.000049088998,0.000006335103,0.00016335877,0.00035364542,0.00013893032],"category_scores_gemma":[0.0017768405,0.00017996391,0.00048068396,0.00021898648,0.00043712487,0.00016682746,0.000054654774,0.00088352105,0.000003079795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9014241,0.018052343,0.02658985,0.00005112264,0.0011613497,0.00026671734,0.0033588507,0.0000046921164,0.0002581239,6.5659043e-7,0.00008574305,0.048746467],"study_design_scores_gemma":[0.62370235,0.333113,0.03687076,0.000118928816,0.000657355,0.000020306588,0.0047436845,0.0000133155245,0.00008885805,0.0000015002404,0.00055335637,0.00011660392],"about_ca_topic_score_codex":0.00020744021,"about_ca_topic_score_gemma":0.00041767658,"teacher_disagreement_score":0.31506068,"about_ca_system_score_codex":0.0005921019,"about_ca_system_score_gemma":0.0022003162,"threshold_uncertainty_score":0.7338716},"labels":[],"label_agreement":null},{"id":"W2913987637","doi":"10.1200/jco.18.00915","title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":264,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cégep de l'Outaouais; McGill University","funders":"Verastem Oncology","keywords":"Medicine; Internal medicine; Refractory (planetary science); Neutropenia; Tolerability; Rituximab; Adverse effect; Lymphoma; Gastroenterology; Nausea; Oncology; Surgery; Chemotherapy","score_opus":0.04454469984713691,"score_gpt":0.4284871544306216,"score_spread":0.38394245458348464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913987637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687576,0.00008915374,0.0000020478767,0.00043526836,0.0007609208,0.00084623223,0.0000049762243,0.0000040533905,0.0009815666],"genre_scores_gemma":[0.9986864,0.000089996036,0.00034462812,0.0005749844,0.00018767577,0.000011423297,0.0000045574884,0.000019932468,0.00008040371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579614,0.00034099136,0.0026892638,0.00026381642,0.0006615297,0.00024825518],"domain_scores_gemma":[0.99555266,0.0010482802,0.0022464471,0.0003426114,0.0004949244,0.00031508468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015332849,0.00019707334,0.002074997,0.0002503086,0.000024455612,0.0000045524175,0.00017016107,0.00028001412,0.00014157382],"category_scores_gemma":[0.0005660027,0.000118914606,0.00028733493,0.00020244076,0.00008742577,0.00012896708,0.00009193931,0.0003845569,0.000019134044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017837515,0.117370434,0.72459716,0.000019673682,0.00050385616,0.0004921565,0.0005186934,0.000009377929,0.00000822459,0.0000039874376,0.0003571791,0.13828173],"study_design_scores_gemma":[0.13513392,0.21662168,0.64505327,0.0001843674,0.00028006654,0.000020177735,0.00033498215,0.000020367084,0.000018263103,0.0000056337662,0.0022559802,0.00007128847],"about_ca_topic_score_codex":0.0000928511,"about_ca_topic_score_gemma":0.00010592304,"teacher_disagreement_score":0.13821045,"about_ca_system_score_codex":0.0005007269,"about_ca_system_score_gemma":0.0013965749,"threshold_uncertainty_score":0.4849197},"labels":[],"label_agreement":null},{"id":"W2914115087","doi":"10.1200/jco.2019.37.4_suppl.273","title":"Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Ontario Institute for Cancer Research; Vancouver General Hospital; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre; Genome British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFIRINOX; KRAS; Oncology; Internal medicine; Pancreatic cancer; Adenocarcinoma; Cancer; PTEN; Cancer research; Colorectal cancer; Genetics; Biology","score_opus":0.09350536448579719,"score_gpt":0.42970206085676715,"score_spread":0.33619669637096994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914115087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630326,0.0011754307,0.0007932047,0.0002668533,0.00087329454,0.00027506377,0.000050645947,0.0000014755494,0.00026079518],"genre_scores_gemma":[0.99243945,0.0020917964,0.0044991793,0.0003018365,0.0004217406,0.000004337275,0.000053421893,0.0000146983075,0.00017356407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945313,0.0005492909,0.0041669696,0.00029183546,0.00027842633,0.00018223195],"domain_scores_gemma":[0.9924248,0.0012724964,0.0046835714,0.00037072226,0.0010625811,0.00018586755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024868094,0.00014720771,0.0019817164,0.00019158622,0.000024558114,0.0000068765107,0.00024745901,0.00030239747,0.00014189607],"category_scores_gemma":[0.0023775962,0.00012266205,0.0011098712,0.0002640385,0.00025291514,0.0000110016235,0.0000885892,0.0003449573,0.0000069962302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030487513,0.0017558784,0.8517226,0.00010788889,0.007833926,0.00004130755,0.000057911428,0.0056526475,0.123502426,0.0003117656,0.0022944747,0.0036704117],"study_design_scores_gemma":[0.002928655,0.008841671,0.9724605,0.000025574778,0.0038353843,0.000042345768,0.0002513469,0.0008398708,0.0017299514,0.00029782884,0.008591482,0.00015540764],"about_ca_topic_score_codex":0.000049153918,"about_ca_topic_score_gemma":0.00003052869,"teacher_disagreement_score":0.121772476,"about_ca_system_score_codex":0.00004352566,"about_ca_system_score_gemma":0.0016566702,"threshold_uncertainty_score":0.50020134},"labels":[],"label_agreement":null},{"id":"W2914171716","doi":"10.1200/jco.2019.37.4_suppl.128","title":"Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Nivolumab; Proportional hazards model; Internal medicine; Hazard ratio; Oncology; Cancer; Population; Overall survival; Confidence interval; Immunotherapy","score_opus":0.10667430785080925,"score_gpt":0.5017733909166542,"score_spread":0.39509908306584496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914171716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98683625,0.0008233507,0.008238824,0.00022784834,0.0012449042,0.0023018157,0.00006151467,0.000010799546,0.00025466245],"genre_scores_gemma":[0.98618263,0.00019758337,0.01281064,0.0000948646,0.00018915103,0.00003131143,0.000016054428,0.000023669505,0.00045407374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957554,0.0006210114,0.002483394,0.00031906433,0.00050046365,0.00032070407],"domain_scores_gemma":[0.99053997,0.004709624,0.0027546454,0.0002300843,0.0014978922,0.00026779645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011957694,0.00027791254,0.0041207466,0.00036082897,0.00003867272,0.0000056533054,0.00015307606,0.00016068514,0.00013487386],"category_scores_gemma":[0.00079833006,0.00018685435,0.00074095285,0.0005084686,0.00014016575,0.00016408363,0.000049550075,0.00040587818,0.000004879675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3679816,0.0030580142,0.4406858,0.0013837693,0.0049270093,0.00012152208,0.0025524981,0.05343103,0.0008872253,0.000104577346,0.0013406272,0.12352631],"study_design_scores_gemma":[0.092709064,0.38564637,0.49629754,0.0015257463,0.0047403644,0.00003850255,0.0052306647,0.00149927,0.0023139587,0.00012342345,0.009611973,0.0002631307],"about_ca_topic_score_codex":0.00006738945,"about_ca_topic_score_gemma":0.00011469304,"teacher_disagreement_score":0.38258836,"about_ca_system_score_codex":0.0013012413,"about_ca_system_score_gemma":0.0017564514,"threshold_uncertainty_score":0.7619699},"labels":[],"label_agreement":null},{"id":"W2914445643","doi":"10.1200/jco.18.00969","title":"Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Cumulative incidence; Medulloblastoma; Incidence (geometry); Radiation therapy; Late effect; Pediatrics; Cancer; Chemotherapy; Internal medicine; Surgery; Cohort; Pathology","score_opus":0.09363611086461766,"score_gpt":0.461136151399589,"score_spread":0.3675000405349714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914445643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262446,0.00088486704,0.0000041661606,0.0030570533,0.0022789836,0.0009730537,0.00003651733,0.000014834683,0.00012608277],"genre_scores_gemma":[0.99747336,0.0006511311,0.00006522697,0.00072146347,0.0009940518,0.000036221947,0.000004816928,0.000024604647,0.000029130899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545306,0.0006770388,0.0024438032,0.00042953767,0.0006558124,0.00034073013],"domain_scores_gemma":[0.99051607,0.0058532697,0.0022309574,0.0005693539,0.00037988546,0.0004504678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055423593,0.00024582812,0.0019415657,0.00003974033,0.0000993437,0.000034099994,0.00024438827,0.00034898578,0.00020226053],"category_scores_gemma":[0.0029853103,0.00013334687,0.00050801336,0.00017177868,0.00030434265,0.00013739632,0.00016677882,0.0010238329,0.000014002277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054192916,0.005697559,0.9734969,0.0000071357395,0.0021704128,0.004508793,0.0006772388,0.000018323144,0.000015479325,0.0000020789087,0.0005422407,0.012321877],"study_design_scores_gemma":[0.011047408,0.004452371,0.9807649,0.00011344483,0.0010796826,0.00013317354,0.000762971,0.000039055783,0.000032568045,0.00012482295,0.0013256453,0.00012395883],"about_ca_topic_score_codex":0.01456566,"about_ca_topic_score_gemma":0.11757514,"teacher_disagreement_score":0.10300948,"about_ca_system_score_codex":0.00011589628,"about_ca_system_score_gemma":0.00068823464,"threshold_uncertainty_score":0.9919964},"labels":[],"label_agreement":null},{"id":"W2914477651","doi":"10.1200/jco.2019.37.4_suppl.164","title":"Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lymphovascular invasion; Stage (stratigraphy); Resection margin; Cancer; Radiation therapy; Proportional hazards model; Surgery; Chemotherapy; T-stage; Retrospective cohort study; Neoadjuvant therapy; Internal medicine; Adjuvant therapy; Oncology; Resection; Metastasis; Breast cancer","score_opus":0.0347930521195405,"score_gpt":0.4382697299276947,"score_spread":0.4034766778081542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914477651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978257,0.00014173181,0.000065693705,0.00079298136,0.00044381426,0.0006145567,0.0000135389055,0.0000015526438,0.00010043558],"genre_scores_gemma":[0.9976497,0.0001552346,0.0012634834,0.00050203205,0.00025044527,0.000009597875,0.0000035224905,0.000010508288,0.00015544638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836695,0.00010074266,0.0010221147,0.00012248571,0.00021021851,0.00017748434],"domain_scores_gemma":[0.9981189,0.00041338458,0.00087180495,0.000094346746,0.00039543476,0.0001061551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066283194,0.00009501997,0.0009837748,0.00014259198,0.0000065499466,0.000003504635,0.00007047097,0.000116938194,0.00016988639],"category_scores_gemma":[0.00017047845,0.000055142224,0.00034525595,0.000113293616,0.000058014604,0.0000777876,0.000016833395,0.00033693507,0.0000012916448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09674019,0.0009208199,0.8662316,0.00002418532,0.0003267647,0.000025996582,0.00004280386,0.000020399591,0.00003375419,0.0000015782441,0.0004430176,0.03518885],"study_design_scores_gemma":[0.027183546,0.09179884,0.8804316,0.00014582265,0.000090166315,0.0000039958195,0.000012681594,0.000011620286,0.000020930398,0.000012775859,0.00025312637,0.000034927147],"about_ca_topic_score_codex":0.00007198608,"about_ca_topic_score_gemma":0.00010983171,"teacher_disagreement_score":0.090878025,"about_ca_system_score_codex":0.00025427426,"about_ca_system_score_gemma":0.0006620378,"threshold_uncertainty_score":0.22486345},"labels":[],"label_agreement":null},{"id":"W2914549406","doi":"10.1200/jco.2019.37.4_suppl.439","title":"Undertreatment of noncurative pancreatic adenocarcinoma?: A population-based analysis of patterns of care.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Queen's University; Ontario Institute for Cancer Research; Health Sciences Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Comorbidity; Multivariate analysis; Internal medicine; Palliative care; Population; Pancreatic cancer; Cancer; Socioeconomic status; Adenocarcinoma; Odds ratio; Health care; Emergency medicine; Nursing","score_opus":0.11388457765141684,"score_gpt":0.4923129725475892,"score_spread":0.37842839489617236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914549406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958315,0.0006107482,0.00037248497,0.00060366053,0.0001371923,0.00035828547,0.00002894353,0.0000021750832,0.0020550268],"genre_scores_gemma":[0.99674284,0.00021038325,0.002654656,0.00014198018,0.00007115019,0.0000036886968,0.000025503166,0.000009991248,0.00013982662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951707,0.0006947095,0.0031879782,0.00017350439,0.0005884571,0.00018462294],"domain_scores_gemma":[0.98883915,0.0061289454,0.0033431125,0.00033295,0.0011398698,0.0002159746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016642351,0.00013468107,0.004127642,0.00055420917,0.0000136565795,0.0000012735721,0.00016166021,0.00034095158,0.0008244145],"category_scores_gemma":[0.0017362824,0.0000906165,0.0010768408,0.00044544434,0.00018052616,0.000044806242,0.000033622946,0.00040750284,0.0000039729684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039115585,0.0016537406,0.984302,0.00028227837,0.006311299,0.00006344507,0.00038373566,0.00019874108,0.00017331466,0.00020713994,0.000018936369,0.002493799],"study_design_scores_gemma":[0.007232027,0.023573618,0.9557138,0.00024102753,0.010387888,0.0000136046465,0.0010057645,0.0013970259,0.0002634509,0.00006826564,0.000046119054,0.0000573831],"about_ca_topic_score_codex":0.00059859036,"about_ca_topic_score_gemma":0.00021779785,"teacher_disagreement_score":0.028588187,"about_ca_system_score_codex":0.00023804656,"about_ca_system_score_gemma":0.0024116668,"threshold_uncertainty_score":0.90267605},"labels":[],"label_agreement":null},{"id":"W2914549990","doi":"10.1200/jco.2019.37.4_suppl.tps721","title":"A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Capecitabine; Colorectal cancer; Neoadjuvant therapy; Total mesorectal excision; Clinical endpoint; Oncology; Internal medicine; Chemoradiotherapy; Population; FOLFOX; Cancer; Clinical trial; Surgery; Oxaliplatin; Breast cancer","score_opus":0.43149053426285416,"score_gpt":0.5759043177590171,"score_spread":0.1444137834961629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914549990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897173,0.00043576435,0.00008640221,0.0016693901,0.0054566665,0.0017416569,0.000011085745,0.000015762054,0.0008659716],"genre_scores_gemma":[0.9870486,0.00047052067,0.006984099,0.00094089477,0.0043014167,0.000022167707,0.000007637031,0.000038841245,0.00018581681],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940403,0.0004270209,0.004275037,0.0003996272,0.00043570407,0.0004222947],"domain_scores_gemma":[0.9871441,0.009115261,0.0024871768,0.00020204032,0.0006287812,0.00042261113],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005116899,0.00024143579,0.0025746804,0.00018885182,0.00006940527,0.000014256137,0.00012635134,0.0006688482,0.00019196104],"category_scores_gemma":[0.008502254,0.00017586754,0.0009135615,0.000356525,0.00014256584,0.00022063161,0.00007255845,0.0011767725,0.000006960532],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35648313,0.008822007,0.072647676,0.000022417213,0.00039281417,0.00043804853,0.00009367453,0.00016416427,0.00059129455,0.0000136501085,0.00015156511,0.5601796],"study_design_scores_gemma":[0.6663784,0.2572465,0.042918436,0.00052615284,0.0004251362,0.00079444103,0.00006891068,0.021313986,0.00014854815,0.0003443824,0.0095563345,0.00027882314],"about_ca_topic_score_codex":0.00008936065,"about_ca_topic_score_gemma":0.000064538726,"teacher_disagreement_score":0.55990076,"about_ca_system_score_codex":0.00068702607,"about_ca_system_score_gemma":0.0034157326,"threshold_uncertainty_score":0.99984956},"labels":[],"label_agreement":null},{"id":"W2914573001","doi":"10.1200/jco.2019.37.4_suppl.635","title":"Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nivolumab; Discontinuation; Internal medicine; Ipilimumab; Microsatellite instability; Oncology; Adverse effect; Clinical endpoint; Colorectal cancer; Progressive disease; Cancer; Disease; Gastroenterology; Clinical trial; Immunotherapy","score_opus":0.043043324367019395,"score_gpt":0.38159065969065203,"score_spread":0.3385473353236326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914573001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190444,0.0027058462,0.000003801965,0.00062731165,0.0019960646,0.0019635742,0.00003807992,0.00004366795,0.00071718893],"genre_scores_gemma":[0.995761,0.0019505343,0.00044145333,0.0005746665,0.00020809963,0.00008171847,0.000032880067,0.00006154059,0.00088810286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99352837,0.0007016291,0.0034358017,0.0007477881,0.00082512037,0.00076129026],"domain_scores_gemma":[0.99466145,0.0012341798,0.0020658602,0.00044297974,0.0010933378,0.0005021705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018625811,0.0005223898,0.003515615,0.0002927549,0.00009912491,0.00002810347,0.0002671108,0.0003683751,0.0004368131],"category_scores_gemma":[0.0007540188,0.00034030888,0.00090029754,0.00058702845,0.00041589572,0.00024382188,0.00014661474,0.0011853095,0.000041714968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046849925,0.0080298,0.89204013,0.00026646702,0.0015938272,0.000883092,0.0009847387,0.00003950757,0.00011899584,0.0000062820804,0.000283947,0.048903283],"study_design_scores_gemma":[0.057475533,0.043556463,0.8941353,0.00096744625,0.0013160502,0.00014309121,0.00023727206,0.000052409196,0.00018125496,0.000023615674,0.0015906707,0.00032087078],"about_ca_topic_score_codex":0.0006975484,"about_ca_topic_score_gemma":0.006844301,"teacher_disagreement_score":0.048582412,"about_ca_system_score_codex":0.0018606136,"about_ca_system_score_gemma":0.0023037335,"threshold_uncertainty_score":0.9999049},"labels":[],"label_agreement":null},{"id":"W2914624644","doi":"10.1200/jco.2019.37.4_suppl.438","title":"Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Gastroenterology; Sorafenib; Overall survival; Surgery","score_opus":0.12293025405465818,"score_gpt":0.3751913513005263,"score_spread":0.2522610972458681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914624644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923279,0.0025477742,0.0000052691576,0.0017353776,0.0007541984,0.000476284,0.000005895069,0.0000061295873,0.0021411586],"genre_scores_gemma":[0.99605685,0.00052495836,0.00038037408,0.00040506735,0.0008261417,0.000012075481,0.000004677281,0.000024807641,0.0017650719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699235,0.00040177428,0.0017474886,0.00020224058,0.0004036634,0.00025246033],"domain_scores_gemma":[0.9968399,0.0011325487,0.0010956126,0.00039207697,0.00026759494,0.00027229774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010147671,0.00018906056,0.0016131416,0.00011283757,0.000019829784,0.0000081817925,0.00015488813,0.00036152874,0.0022124175],"category_scores_gemma":[0.00023250199,0.00010359529,0.0011832853,0.00014551888,0.00018696861,0.00007173109,0.000040696832,0.000360409,0.00025287803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034572168,0.0019104986,0.9536923,0.000025359317,0.00054064457,0.0019339486,0.00021492403,4.4848323e-7,0.00019313605,0.00003121472,0.0009015589,0.037098724],"study_design_scores_gemma":[0.009118884,0.021711096,0.7582418,0.000037647857,0.00084587815,0.0002438948,0.000061352075,0.000289926,0.00058836554,0.00004875192,0.20872699,0.00008546081],"about_ca_topic_score_codex":0.000032741376,"about_ca_topic_score_gemma":0.000011141481,"teacher_disagreement_score":0.20782542,"about_ca_system_score_codex":0.00015800212,"about_ca_system_score_gemma":0.00091172877,"threshold_uncertainty_score":0.9986997},"labels":[],"label_agreement":null},{"id":"W2914777901","doi":"10.1200/jco.2019.37.4_suppl.422","title":"Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Regorafenib; Sorafenib; Hepatocellular carcinoma; Cabozantinib; Internal medicine; Ramucirumab; Clinical trial; Pazopanib; Generalizability theory; Oncology; Cancer; Hazard ratio; Confidence interval; Colorectal cancer; Sunitinib","score_opus":0.08459065596358865,"score_gpt":0.37009405777981935,"score_spread":0.2855034018162307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914777901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077326,0.0004901658,0.00014798994,0.0011150818,0.0014065674,0.0004946374,0.000037417078,0.00000640784,0.005528448],"genre_scores_gemma":[0.9965946,0.00040289052,0.0013693909,0.0007974846,0.00036273274,0.000018401613,0.0000032914897,0.000024573896,0.0004266401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953345,0.000082307975,0.0036356333,0.00045383815,0.000058615682,0.00043507514],"domain_scores_gemma":[0.9959622,0.00089956704,0.0023419873,0.00029993884,0.00020826099,0.00028807085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041683256,0.00019272974,0.0018853954,0.000301487,0.00003812441,0.00003190982,0.0002715382,0.0003279922,0.00020517582],"category_scores_gemma":[0.001452228,0.00018790753,0.0004142249,0.0001647112,0.00016883224,0.00051946234,0.000081103,0.0005340228,0.0000811986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002686371,0.00050281145,0.9769706,0.000026160707,0.000038727914,0.000017130129,0.00010033316,0.000016779744,0.0000030424374,0.007329949,0.0003403678,0.011967696],"study_design_scores_gemma":[0.009162092,0.0019857127,0.8997581,0.000020230202,0.000013365264,0.000002645412,0.000028661625,0.0008134584,0.000017977838,0.01584376,0.07214875,0.00020527623],"about_ca_topic_score_codex":0.00026327564,"about_ca_topic_score_gemma":0.000515879,"teacher_disagreement_score":0.07721256,"about_ca_system_score_codex":0.00023299271,"about_ca_system_score_gemma":0.00031352066,"threshold_uncertainty_score":0.7662647},"labels":[],"label_agreement":null},{"id":"W2914793375","doi":"10.1200/jco.2019.37.4_suppl.487","title":"Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Oncology; Colorectal cancer; Pathological; Single Center; Proportional hazards model; Cancer","score_opus":0.10841255057620021,"score_gpt":0.46988815888058444,"score_spread":0.36147560830438424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914793375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98651206,0.0004596507,0.000027749858,0.0068994695,0.0032755095,0.002334953,0.00027692318,0.000028123599,0.00018554526],"genre_scores_gemma":[0.99058187,0.00045351763,0.0020421615,0.003151733,0.0013908255,0.000079939404,0.000044001492,0.000041174208,0.0022147538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930272,0.001084649,0.0038634918,0.0007366451,0.0006845127,0.0006035172],"domain_scores_gemma":[0.9881208,0.0064731184,0.0028116347,0.0004685745,0.0012218484,0.0009040347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004647589,0.00041589336,0.0034789008,0.00013959024,0.00020078511,0.000033248692,0.00034762992,0.0008864052,0.0003844513],"category_scores_gemma":[0.0071539925,0.0002352144,0.0013565265,0.00022041977,0.00045123138,0.00013416848,0.00020818468,0.0018216263,0.000030676278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04265369,0.0074180043,0.86953855,0.000054174485,0.00065213745,0.00028595395,0.000118110824,0.000009942158,0.000047034846,0.000036897574,0.0030799673,0.07610555],"study_design_scores_gemma":[0.019698448,0.16685297,0.7615006,0.00017355282,0.001309821,0.000039064016,0.00010277817,0.000018593504,0.00004550954,0.00007877304,0.049977493,0.00020239249],"about_ca_topic_score_codex":0.00019548042,"about_ca_topic_score_gemma":0.0007377969,"teacher_disagreement_score":0.15943496,"about_ca_system_score_codex":0.00035519592,"about_ca_system_score_gemma":0.00239368,"threshold_uncertainty_score":0.9591765},"labels":[],"label_agreement":null},{"id":"W2914875903","doi":"10.1200/jco.2019.37.4_suppl.416","title":"Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McMaster University; Alberta Health Services; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Saskatchewan; Dr. H. Bliss Murphy Cancer Centre; Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Internal medicine; Pancreatic cancer; Logistic regression; Chemotherapy; Gastroenterology; Cancer; Surgery; Oncology","score_opus":0.090392913208182,"score_gpt":0.45672998045514934,"score_spread":0.36633706724696735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914875903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952674,0.00024162352,0.000014859329,0.001800821,0.00026972438,0.0007175246,0.000010221778,0.000009720306,0.0016680999],"genre_scores_gemma":[0.9976629,0.0004783259,0.00020030724,0.00065846054,0.00012227062,0.000014055556,0.000023950708,0.000025742394,0.0008140096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960173,0.000753134,0.0018525171,0.0002949746,0.00048370793,0.0005983635],"domain_scores_gemma":[0.99317473,0.0039458317,0.0012123398,0.0002398697,0.0006156239,0.00081159035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025139572,0.00022133927,0.0033151072,0.000643446,0.00003692692,0.0000111999125,0.00020786334,0.0005025543,0.0009017949],"category_scores_gemma":[0.0033633583,0.00014011723,0.00041819995,0.0008607942,0.00021181657,0.00011005465,0.000020579373,0.0012319966,0.000013575403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031866846,0.0011768336,0.9843466,0.000027746799,0.0051683066,0.0007932936,0.0001828217,0.000046703215,0.000048221158,0.0000026788598,0.000029207617,0.004990886],"study_design_scores_gemma":[0.01602896,0.0060869204,0.9731153,0.00033613786,0.0032419737,0.000014103102,0.00016809946,0.00065149687,0.000011478092,0.000004668472,0.00020702218,0.00013379056],"about_ca_topic_score_codex":0.009255581,"about_ca_topic_score_gemma":0.21891402,"teacher_disagreement_score":0.20965843,"about_ca_system_score_codex":0.0010535733,"about_ca_system_score_gemma":0.0050159055,"threshold_uncertainty_score":0.9973419},"labels":[],"label_agreement":null},{"id":"W2914878635","doi":"10.1200/jco.2019.37.4_suppl.400","title":"Treatment sequencing in MPC, insights from a 3˚ care center.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Irinotecan; FOLFIRINOX; Internal medicine; Capecitabine; Retrospective cohort study; Progression-free survival; Pancreatic cancer; Gastroenterology; Adverse effect; Overall survival; Cancer; Surgery; Colorectal cancer","score_opus":0.05513639993918503,"score_gpt":0.3986432633940565,"score_spread":0.34350686345487147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914878635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926478,0.002340202,0.000035136884,0.00020730784,0.00139868,0.00009490122,0.000014664599,0.0000010123657,0.003260244],"genre_scores_gemma":[0.99464256,0.0026429852,0.000897314,0.00070774945,0.0010057319,0.0000017369172,0.000021878142,0.000010109125,0.00006995595],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985484,0.00012939658,0.0009338403,0.00017667278,0.0000841702,0.00012752137],"domain_scores_gemma":[0.9987495,0.0002899286,0.0005318551,0.0001777959,0.00012613535,0.00012478165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016192734,0.00009656428,0.0005369644,0.000040889612,0.000011076592,0.0000075992853,0.00014537736,0.00028288303,0.000025798618],"category_scores_gemma":[0.0003594132,0.000073776064,0.00025037958,0.00003398132,0.00003673343,0.0000034867378,0.000055476663,0.00019521284,0.000016991366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004408764,0.001115407,0.74851483,0.000023858003,0.00059772516,0.0008145819,0.0016198468,0.0025533189,0.07781756,0.00023390098,0.0017865672,0.16051361],"study_design_scores_gemma":[0.018824307,0.02630418,0.13280547,0.00007908894,0.00010903157,0.00008445278,0.0017079681,0.0001790274,0.0126908785,0.0006093826,0.80629003,0.00031618145],"about_ca_topic_score_codex":0.00018760192,"about_ca_topic_score_gemma":0.0011817947,"teacher_disagreement_score":0.80450344,"about_ca_system_score_codex":0.000428621,"about_ca_system_score_gemma":0.0018014039,"threshold_uncertainty_score":0.31956133},"labels":[],"label_agreement":null},{"id":"W2914959582","doi":"10.1200/jco.2019.37.4_suppl.297","title":"Symptom burden at the end of life for neuroendocrine tumors: A population-based analysis of patient-reported outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Toronto; Sunnybrook Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; University of Manitoba; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Nausea; Anxiety; Appetite; Population; Cohort; Poisson regression; Quality of life (healthcare); Multivariate analysis; Internal medicine; Pediatrics; Psychiatry","score_opus":0.06950746429008718,"score_gpt":0.4555268555661157,"score_spread":0.3860193912760285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914959582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861595,0.00012388268,0.000022080783,0.012377343,0.000442835,0.0006663936,0.000022379458,0.0000064144897,0.00017916091],"genre_scores_gemma":[0.99733776,0.000040854673,0.00064157264,0.0013716746,0.00017449501,0.000009522602,0.000017804954,0.000021129083,0.00038519918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99389714,0.0004944511,0.0041776355,0.00024349676,0.0008826321,0.00030461806],"domain_scores_gemma":[0.9827264,0.010626306,0.004844583,0.00051228906,0.0009454409,0.00034498284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011799525,0.00016046246,0.0027102898,0.00047402372,0.000029695677,0.000004172244,0.00027671197,0.000027545118,0.0005131112],"category_scores_gemma":[0.021585738,0.000092626586,0.0015079124,0.00057521986,0.00024504404,0.00007899827,0.000098587625,0.00054836256,0.0000039391884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063307863,0.00080892874,0.9816594,0.00009214632,0.0021283778,0.00058733113,0.000014700612,0.0028721537,0.0004813526,0.00003300511,0.00050662085,0.0044851974],"study_design_scores_gemma":[0.0098485,0.01365268,0.9608504,0.00005893795,0.0024744824,0.00023649809,0.00007977659,0.0019264389,0.00059559604,0.00009000061,0.010101102,0.00008559098],"about_ca_topic_score_codex":0.00014971507,"about_ca_topic_score_gemma":0.000112783266,"teacher_disagreement_score":0.020809002,"about_ca_system_score_codex":0.00010272279,"about_ca_system_score_gemma":0.001192989,"threshold_uncertainty_score":0.98665583},"labels":[],"label_agreement":null},{"id":"W2915015389","doi":"10.1200/jco.2019.37.4_suppl.303","title":"Real-world outcomes among patients (pts) treated with gemcitabine (GEM)-based therapy post-FOLFIRINOX (FFOX) failure in advanced pancreatic cancer (APC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Regimen; Proportional hazards model; FOLFIRINOX; Gastroenterology; Hazard ratio; Population; Chemotherapy regimen; Pancreatic cancer; Oncology; Overall survival; Chemotherapy; Cancer; Confidence interval; Irinotecan","score_opus":0.06045049066184131,"score_gpt":0.45083884128358886,"score_spread":0.39038835062174754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915015389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885288,0.00013963298,0.00000899246,0.00542115,0.00036133008,0.0012154191,0.0000111798045,0.000023042938,0.004290446],"genre_scores_gemma":[0.99082726,0.0010807911,0.002532512,0.0023017684,0.00023772453,0.00005704262,0.000020034468,0.00005180955,0.0028910537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448574,0.0008545383,0.0027639535,0.00043037278,0.00082327455,0.0006421386],"domain_scores_gemma":[0.99155986,0.004280659,0.001843814,0.00047312133,0.0012518658,0.00059069647],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023280338,0.00035700065,0.003807131,0.00055637816,0.000049500763,0.000013261105,0.00032781702,0.00052902097,0.0013055025],"category_scores_gemma":[0.0016707731,0.0002098548,0.0004662755,0.00056290015,0.00041229976,0.00022506855,0.000047622158,0.0016492646,0.00005386643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018962367,0.003118171,0.9530901,0.000060770257,0.0007582263,0.00048348127,0.00007568853,0.000067406276,0.00012910414,0.000018322484,0.00048011303,0.022756284],"study_design_scores_gemma":[0.04970821,0.024270205,0.9211894,0.00041625713,0.0004125939,0.000015869935,0.000102812235,0.00026584507,0.00004137625,0.000027611106,0.0033495026,0.00020031595],"about_ca_topic_score_codex":0.0013447704,"about_ca_topic_score_gemma":0.0052732183,"teacher_disagreement_score":0.031900663,"about_ca_system_score_codex":0.0006369251,"about_ca_system_score_gemma":0.0032465225,"threshold_uncertainty_score":0.99960744},"labels":[],"label_agreement":null},{"id":"W2915045132","doi":"10.1200/jco.18.00884","title":"Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"Janssen Pharmaceuticals; Amgen; Pfizer; Bristol-Myers Squibb; Juno Therapeutics; National Cancer Institute; Incyte","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Minimal residual disease; Oncology; Cog; Cohort; Leukemia","score_opus":0.029235141052143497,"score_gpt":0.3617810082818976,"score_spread":0.3325458672297541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915045132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149454,0.00013127038,0.0012693239,0.0038327451,0.0012721455,0.0011578371,0.000107893226,0.0000237723,0.0007104628],"genre_scores_gemma":[0.9926126,0.00045409572,0.0026931928,0.0021492222,0.0010530397,0.000019836658,0.000047856545,0.00006835458,0.00090182276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99178207,0.00083072006,0.004850938,0.0006014606,0.0013500538,0.0005847612],"domain_scores_gemma":[0.98597413,0.0073534134,0.004734914,0.00073127047,0.00066563603,0.0005406063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039042556,0.0003995118,0.0031180028,0.00022992768,0.00007426193,0.000020446305,0.0007085601,0.00095667987,0.00019198073],"category_scores_gemma":[0.00075205695,0.00019573019,0.00080099364,0.00025337728,0.000731134,0.00021271822,0.00013894736,0.0020514047,0.00007838954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044242278,0.003961751,0.87914157,0.00025608364,0.006384779,0.0071763555,0.00090285315,0.00010740314,0.02661481,0.000101586746,0.001096038,0.03001447],"study_design_scores_gemma":[0.060396053,0.038375597,0.84684306,0.00026915103,0.0067537557,0.035058457,0.00045726207,0.00037677737,0.010104351,0.00020440729,0.00071862416,0.00044251882],"about_ca_topic_score_codex":0.00038558393,"about_ca_topic_score_gemma":0.00010224712,"teacher_disagreement_score":0.034413844,"about_ca_system_score_codex":0.001599758,"about_ca_system_score_gemma":0.007216355,"threshold_uncertainty_score":0.99841183},"labels":[],"label_agreement":null},{"id":"W2915057376","doi":"10.1200/jco.2019.37.4_suppl.101","title":"The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Nivolumab; Cancer; Drug; Context (archaeology); Oncology; Internal medicine; Pharmacy; Intensive care medicine; Lung cancer; Immunotherapy; Pharmacology; Family medicine","score_opus":0.032326147812433495,"score_gpt":0.33713391955829014,"score_spread":0.30480777174585666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915057376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946413,0.0014925122,0.00007575035,0.00047414334,0.002393993,0.00038457036,0.0001119552,0.00000146889,0.00042430486],"genre_scores_gemma":[0.99665487,0.0023717969,0.00020316728,0.000255474,0.00021055245,0.000015655074,0.0000022077868,0.000021901684,0.00026439904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960514,0.000104642175,0.0030040103,0.0002554859,0.00011677236,0.00046769774],"domain_scores_gemma":[0.99497896,0.0005450666,0.0038666483,0.00020121066,0.00021677821,0.0001913524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001582025,0.00018862812,0.0015662478,0.00022015651,0.000036021862,0.000017189079,0.00033605253,0.00010608337,0.00047122262],"category_scores_gemma":[0.00047341624,0.00012635927,0.00024039992,0.00032315796,0.00011142099,0.00042907338,0.000040444465,0.0007446315,0.000009938182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005720131,0.0002874297,0.90218085,0.000011397535,0.00013981939,0.000023665096,0.000036729853,0.021001203,4.915091e-7,0.000050557017,0.0011521414,0.06939561],"study_design_scores_gemma":[0.009928891,0.0027899102,0.9833932,0.00007317248,0.000023421808,0.000005146688,0.000076189666,0.00073339784,0.0000010630968,0.00028933398,0.0025590216,0.0001272357],"about_ca_topic_score_codex":0.2964536,"about_ca_topic_score_gemma":0.6705825,"teacher_disagreement_score":0.3741289,"about_ca_system_score_codex":0.0030855546,"about_ca_system_score_gemma":0.0073099704,"threshold_uncertainty_score":0.99831766},"labels":[],"label_agreement":null},{"id":"W2915177933","doi":"10.1200/jco.18.02031","title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Prostate cancer; Castration; Asymptomatic; Prostate; Oncology; Cancer; Internal medicine; Urology; Gynecology; Surgery; Hormone","score_opus":0.14487688439168125,"score_gpt":0.5227371279460361,"score_spread":0.3778602435543549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915177933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251944,0.0006406716,0.0000039721626,0.0030642673,0.00082135946,0.0021708563,0.00001629273,0.000006645495,0.0007564767],"genre_scores_gemma":[0.9946714,0.0009618908,0.001674663,0.00023013471,0.00026968538,0.00006834662,0.0000064792634,0.00002194227,0.0020954416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942113,0.0005497544,0.0039623654,0.00022250843,0.00070821977,0.00034580866],"domain_scores_gemma":[0.9942904,0.002290983,0.0023317018,0.00023426053,0.00053809973,0.0003145368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037385263,0.00018601735,0.0023149487,0.0003083441,0.000021542337,0.000012533794,0.00017665235,0.0001848223,0.00055466266],"category_scores_gemma":[0.0018364603,0.000106675725,0.00039321365,0.0003666196,0.00020901556,0.00018692695,0.00003784421,0.00066970236,0.000017857597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8751309,0.017804494,0.018653471,0.0010820541,0.001545449,0.0018539651,0.0010429984,0.000033174252,0.007071116,0.000054222455,0.0008482173,0.07487995],"study_design_scores_gemma":[0.7991571,0.16821201,0.024295961,0.001603655,0.0010344009,0.00018961645,0.0008133495,0.00086279796,0.0013724223,0.00029937312,0.0019636066,0.00019573396],"about_ca_topic_score_codex":0.000053695407,"about_ca_topic_score_gemma":0.00014670087,"teacher_disagreement_score":0.15040751,"about_ca_system_score_codex":0.00032255484,"about_ca_system_score_gemma":0.007903221,"threshold_uncertainty_score":0.9977211},"labels":[],"label_agreement":null},{"id":"W2915328041","doi":"10.1200/jco.18.02433","title":"Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Lights and Shadows","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Ipsen; Pfizer; Breast Cancer Research Foundation","keywords":"Medicine; Adjuvant; Breast cancer; Oncology; Hormone receptor; Internal medicine; Cancer; Systemic therapy; Hormone; Gynecology","score_opus":0.020962797451660447,"score_gpt":0.33935481780003623,"score_spread":0.31839202034837577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915328041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291784,0.005352233,0.000010243082,0.0007473974,0.0003431197,0.00025563766,0.00008182199,0.0000027158057,0.00028901064],"genre_scores_gemma":[0.9906566,0.0081807505,0.0002957856,0.00009350322,0.0005627154,0.00002464759,0.0000043718974,0.00001763457,0.00016399649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816406,0.00020791983,0.0009504023,0.00026386586,0.00018140543,0.0002323408],"domain_scores_gemma":[0.9978953,0.00017085901,0.001206844,0.00017532894,0.00036011633,0.0001915298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037475006,0.00019296061,0.0011305297,0.000042698157,0.000030299629,0.000006146365,0.000114659495,0.00022712909,0.000026317117],"category_scores_gemma":[0.0000314552,0.00011780078,0.000109898014,0.000055983695,0.00019218329,0.000011004304,0.000052438274,0.00012993049,0.0000046181185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05051002,0.002871546,0.72014385,0.0000684711,0.006031156,0.00009759826,0.0016138832,0.00004374838,0.07280375,0.000035775356,0.0006871451,0.14509302],"study_design_scores_gemma":[0.012139734,0.06385086,0.91534674,0.00015195654,0.0003458442,0.0005691711,0.00043397755,0.0000018527701,0.0022134595,0.000017562654,0.0047442825,0.00018455538],"about_ca_topic_score_codex":0.00013091044,"about_ca_topic_score_gemma":0.00006460462,"teacher_disagreement_score":0.19520287,"about_ca_system_score_codex":0.00021704503,"about_ca_system_score_gemma":0.0006424358,"threshold_uncertainty_score":0.48037764},"labels":[],"label_agreement":null},{"id":"W2915708315","doi":"10.1200/jco.18.01998","title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Dosing; Oncology; Melanoma; Internal medicine; Metastatic melanoma; Clinical trial; Cancer; Immunotherapy; Cancer research","score_opus":0.09565285910935743,"score_gpt":0.4600113664279852,"score_spread":0.36435850731862773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915708315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956155,0.0001561804,0.000032430784,0.0016464846,0.00064590335,0.0016736486,0.000017159373,0.000002332161,0.00021036035],"genre_scores_gemma":[0.9984789,0.000048399084,0.0010363044,0.00022933324,0.00013369201,0.000013251164,0.000030578638,0.000011717345,0.000017810882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964825,0.0006484829,0.0019280184,0.00017466521,0.0006254528,0.0001408722],"domain_scores_gemma":[0.9945594,0.0020607575,0.0023424742,0.00019538248,0.0007939041,0.00004806863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008597998,0.00010187951,0.0008664901,0.00010118634,0.000018959401,0.0000049825067,0.00010507274,0.0001471254,0.000021229502],"category_scores_gemma":[0.0016028619,0.00005657599,0.00014130567,0.00018233735,0.00010663801,0.00014006515,0.000010681057,0.00037236614,5.9741467e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81770813,0.003783114,0.020895462,0.000007635762,0.00022711519,0.000004620863,0.00033332917,0.00010476991,0.00022756297,0.000005107991,0.00008388896,0.15661928],"study_design_scores_gemma":[0.69307095,0.07319672,0.23105824,0.0003574982,0.00032615365,0.0000030096085,0.00015773908,0.00088439975,0.00012291531,0.00015109047,0.00061232643,0.000058955768],"about_ca_topic_score_codex":0.00010554326,"about_ca_topic_score_gemma":0.0005789916,"teacher_disagreement_score":0.21016277,"about_ca_system_score_codex":0.00037809336,"about_ca_system_score_gemma":0.0013515545,"threshold_uncertainty_score":0.29799116},"labels":[],"label_agreement":null},{"id":"W2916451481","doi":"10.1200/jco.18.01042","title":"First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Cegep de Saint Jerome","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; Eisai; Pfizer; Moderna; Incyte; Agios Pharmaceuticals; Syndax Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; University of Pennsylvania; Amgen; Jounce Therapeutics; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Cancer; Immunotherapy; Clinical trial","score_opus":0.03760860318418664,"score_gpt":0.4112338146753233,"score_spread":0.37362521149113664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916451481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824386,0.004496241,0.000037551938,0.010401442,0.0011328824,0.00087658345,0.000013574139,0.000013058943,0.0005900281],"genre_scores_gemma":[0.9909428,0.0027364208,0.0017907995,0.0026724937,0.00027739396,0.00003587153,0.0000101607575,0.000035563502,0.0014985303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641705,0.0001658135,0.002277111,0.00034778315,0.000394304,0.0003979339],"domain_scores_gemma":[0.99635273,0.0013432765,0.0015084445,0.00018965386,0.00027508847,0.0003307871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019459985,0.00025616653,0.0016261567,0.00018957048,0.00004817901,0.000022403688,0.00019039375,0.00033953326,0.00021813343],"category_scores_gemma":[0.0005544803,0.00018924347,0.00041009576,0.00021484018,0.00021406633,0.00014941511,0.0000567187,0.0007464845,0.000009714373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058297772,0.0016177436,0.8195168,0.0004007319,0.0016267882,0.0007272246,0.000553528,0.00018506982,0.0055275434,0.000007683411,0.0022665616,0.1092726],"study_design_scores_gemma":[0.18524867,0.020765383,0.7137217,0.0011960049,0.00092700165,0.0007462597,0.0009973526,0.005190222,0.0018014973,0.00017682865,0.06857041,0.00065866974],"about_ca_topic_score_codex":0.0004957749,"about_ca_topic_score_gemma":0.00036474105,"teacher_disagreement_score":0.12695089,"about_ca_system_score_codex":0.0005188244,"about_ca_system_score_gemma":0.0022906363,"threshold_uncertainty_score":0.7717125},"labels":[],"label_agreement":null},{"id":"W2917537905","doi":"10.1200/jco.18.00605","title":"First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Rituximab; Vincristine; Bendamustine; Mantle cell lymphoma; CHOP; Internal medicine; Hazard ratio; Prednisone; Cyclophosphamide; Oncology; Gastroenterology; Lymphoma; Surgery; Chemotherapy; Confidence interval","score_opus":0.06547427927673023,"score_gpt":0.37185667375765874,"score_spread":0.3063823944809285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917537905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944083,0.000103678045,0.000003992024,0.00077622215,0.0014872134,0.0019470096,0.00009204274,0.0000085464,0.0011729624],"genre_scores_gemma":[0.9968568,0.00038655923,0.0009215875,0.0001535688,0.00031208788,0.000029310831,0.000014541388,0.000047158697,0.001278393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945493,0.00035715874,0.0031054716,0.0004840318,0.001099575,0.00040451263],"domain_scores_gemma":[0.99096984,0.003157403,0.0037852146,0.00079405337,0.0009174628,0.0003760443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008610602,0.00043995355,0.0030492756,0.00017180626,0.00007454252,0.000011107905,0.0003455385,0.00031893974,0.00015827981],"category_scores_gemma":[0.00061526074,0.00017629398,0.000600382,0.00039315387,0.00027231258,0.000105093204,0.00011410758,0.00018215513,0.000024091718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42242858,0.08021083,0.45398152,0.00008239836,0.0023331542,0.00088337524,0.0006494746,0.00007006493,0.0000029661508,0.0000046979903,0.0004548262,0.03889813],"study_design_scores_gemma":[0.34146184,0.1701364,0.48037776,0.00028168707,0.0016907292,0.00005752575,0.00032645685,0.00003297683,0.0002371454,0.000001226631,0.0052817552,0.00011447946],"about_ca_topic_score_codex":0.0003474299,"about_ca_topic_score_gemma":0.0014133817,"teacher_disagreement_score":0.08992557,"about_ca_system_score_codex":0.0010362292,"about_ca_system_score_gemma":0.003593068,"threshold_uncertainty_score":0.718906},"labels":[],"label_agreement":null},{"id":"W2917684283","doi":"10.1200/jco.2015.33.15_suppl.1544","title":"Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Multiplex ligation-dependent probe amplification; Sanger sequencing; Breast cancer; Medicine; Nonsense mutation; Germline mutation; Cancer research; Exome sequencing; Mutation; Cancer; Exon; Exome; Somatic cell; Internal medicine; Oncology; Gene; Genetics; Biology; Missense mutation","score_opus":0.09120939041578294,"score_gpt":0.45986588970284975,"score_spread":0.3686564992870668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917684283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903702,0.00024672312,0.00013271725,0.006709057,0.0016279734,0.00017923555,0.000032344593,0.000008924937,0.0006927947],"genre_scores_gemma":[0.9924154,0.000044824657,0.0045853076,0.0011582758,0.0016775483,0.000011480033,0.0000057676193,0.000019948826,0.000081440434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688226,0.0003467565,0.0019605532,0.00016643209,0.00042295922,0.00022103068],"domain_scores_gemma":[0.99594367,0.0011731345,0.0015695249,0.00012588016,0.0007438329,0.00044397975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093603594,0.00013734723,0.0011990764,0.00013269405,0.000021607702,0.0000063045477,0.00013984386,0.00018640571,0.00021819644],"category_scores_gemma":[0.0020145245,0.00010269462,0.00021075833,0.00017773296,0.00027990487,0.00025101056,0.00003410191,0.0008561539,0.000024903908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004523846,0.0017289722,0.8869779,0.00001110452,0.00023809528,0.00035152587,0.0016600214,0.00015626353,0.000030626255,0.000012876055,0.00037370628,0.10393508],"study_design_scores_gemma":[0.014926011,0.0027698996,0.9743725,0.00026793385,0.00018744082,0.00025074353,0.0016026773,0.0001150799,0.000034361216,0.003651326,0.0017233543,0.00009864097],"about_ca_topic_score_codex":0.0008063858,"about_ca_topic_score_gemma":0.00088492996,"teacher_disagreement_score":0.10383644,"about_ca_system_score_codex":0.0006645453,"about_ca_system_score_gemma":0.0025729528,"threshold_uncertainty_score":0.45643076},"labels":[],"label_agreement":null},{"id":"W2917815963","doi":"10.1200/jco.18.01250","title":"Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Germ cell tumors; Stage (stratigraphy); Oncology; Germ cell; Gynecology; Internal medicine; Chemotherapy","score_opus":0.10138828570044812,"score_gpt":0.47320571849421916,"score_spread":0.37181743279377105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917815963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924936,0.0010775956,0.0000057730604,0.00050495245,0.0010288692,0.0003278698,0.000030190145,0.000006471009,0.004524676],"genre_scores_gemma":[0.9959739,0.0010726734,0.0011197203,0.00021707054,0.0003334499,0.000001933289,0.000005398992,0.0000200915,0.0012557594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946366,0.0005689846,0.003935956,0.00024096991,0.00041459716,0.00020288881],"domain_scores_gemma":[0.98856276,0.0055598137,0.0046148743,0.00043243507,0.0003585968,0.00047151782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015332481,0.00018122591,0.0028290735,0.00009652106,0.0000125940305,0.000002252536,0.00012926415,0.00032775445,0.00022120948],"category_scores_gemma":[0.002404194,0.00011300953,0.0013713647,0.00009524834,0.00020343828,0.000034154036,0.000027552105,0.0003695706,0.00006476873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00836588,0.01609996,0.93293035,0.00009396112,0.00055273925,0.0018177626,0.000029415018,0.00002550714,0.00007422895,0.00005417327,0.0002900484,0.039665952],"study_design_scores_gemma":[0.020635374,0.074733496,0.8950427,0.00013523079,0.00043362175,0.00015397632,0.00005202587,0.00006622481,0.00024908566,0.000029213923,0.008390414,0.000078595614],"about_ca_topic_score_codex":0.000032868174,"about_ca_topic_score_gemma":0.000006514968,"teacher_disagreement_score":0.058633532,"about_ca_system_score_codex":0.00010796158,"about_ca_system_score_gemma":0.0019068401,"threshold_uncertainty_score":0.4608395},"labels":[],"label_agreement":null},{"id":"W2918069808","doi":"10.1200/jco.18.01765","title":"Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; BC Children's Hospital; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"National Cancer Institute","keywords":"Medicine; Ependymoma; Radiation therapy; Surgery; Chemotherapy; Medulloblastoma; Pathology","score_opus":0.17085446517604938,"score_gpt":0.4465413640004253,"score_spread":0.2756868988243759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918069808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98282844,0.00074124546,0.00095447997,0.0074851764,0.00343257,0.0043199356,0.00013418258,0.000022871316,0.000081122256],"genre_scores_gemma":[0.9797073,0.0007869291,0.010736518,0.0018151604,0.006237121,0.0002610961,0.00026543328,0.00006867676,0.00012174709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560654,0.00024576383,0.0027583106,0.00042608546,0.000452668,0.00051065785],"domain_scores_gemma":[0.98657346,0.00856167,0.002501086,0.00027327638,0.0016932033,0.0003973321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036170501,0.00031521384,0.0019506265,0.00031268163,0.00016365961,0.00005274181,0.00022080964,0.00064179295,0.000098501376],"category_scores_gemma":[0.003017674,0.0002348101,0.0008258241,0.00021507475,0.00008688475,0.00033369428,0.000030178942,0.0004234673,0.0000060951083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17397965,0.007801765,0.3810287,0.0006273232,0.0029593199,0.0002488062,0.0004017109,0.00003865624,0.005546115,0.004755073,0.047075137,0.37553775],"study_design_scores_gemma":[0.13679183,0.0701284,0.6213874,0.00005396169,0.0006467746,0.00043648627,0.00007399297,0.0023578617,0.0017533503,0.0016897859,0.16436532,0.0003147963],"about_ca_topic_score_codex":0.00002774845,"about_ca_topic_score_gemma":0.00004606694,"teacher_disagreement_score":0.37522295,"about_ca_system_score_codex":0.00020452405,"about_ca_system_score_gemma":0.0012675112,"threshold_uncertainty_score":0.95752776},"labels":[],"label_agreement":null},{"id":"W2920048684","doi":"10.1200/jco.2019.37.7_suppl.3","title":"SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; SABR volatility model; Prostate; Urology; Internal medicine; Prospective cohort study; Clinical trial; Prostate-specific antigen; Oncology; Cancer; Surgery; Gastroenterology","score_opus":0.14388872262186886,"score_gpt":0.545312926737813,"score_spread":0.4014242041159441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920048684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892505,0.0015564337,0.000016852344,0.0062594167,0.0009962503,0.0014237732,0.000045238987,0.000010118299,0.0004414233],"genre_scores_gemma":[0.98750246,0.007920405,0.002058978,0.000627781,0.0011606442,0.000032944852,0.0000063528537,0.000026437005,0.0006639748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297404,0.0023392735,0.0034181245,0.00043014376,0.00049966865,0.0003387601],"domain_scores_gemma":[0.98626274,0.009673733,0.002827133,0.00020280444,0.0005913127,0.00044226774],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011511702,0.0002152556,0.0035536014,0.0001831438,0.0000417753,0.000021758575,0.00012158631,0.00034428423,0.00016918099],"category_scores_gemma":[0.008862983,0.00011546419,0.00036614074,0.00021517255,0.0003562239,0.00020073424,0.000050522223,0.0020382232,0.000017984363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043095157,0.0008724653,0.86468303,0.000012368371,0.0015264851,0.00015386769,0.00026858292,0.000022855325,0.000021146674,0.000035895788,0.00018494081,0.0891232],"study_design_scores_gemma":[0.07215936,0.017595977,0.90610343,0.00015237446,0.0006405588,0.00002755803,0.00018648063,0.000114471906,0.000042094012,0.0013592466,0.0014978896,0.000120542],"about_ca_topic_score_codex":0.0011125132,"about_ca_topic_score_gemma":0.0009719129,"teacher_disagreement_score":0.089002654,"about_ca_system_score_codex":0.00044046418,"about_ca_system_score_gemma":0.003609516,"threshold_uncertainty_score":0.9994858},"labels":[],"label_agreement":null},{"id":"W2920799111","doi":"10.1200/jco.2019.37.7_suppl.159","title":"Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; PALB2; Prostatectomy; Cancer; Germline mutation; Gene; Mutation","score_opus":0.07643932083146604,"score_gpt":0.4478475139241071,"score_spread":0.37140819309264106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920799111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965768,0.00033581414,0.0000048345664,0.0013535594,0.00043196356,0.000785292,0.00005667999,0.0000080403115,0.00044700957],"genre_scores_gemma":[0.99633145,0.00038576123,0.0020583933,0.00016750825,0.0001595742,0.000019590725,0.000037073296,0.00002033208,0.0008202906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965321,0.0003300503,0.0020667866,0.00021138364,0.0005993424,0.00026032727],"domain_scores_gemma":[0.9964831,0.00075076893,0.0013639634,0.00020522904,0.00092856423,0.00026838886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014958265,0.00014365857,0.0011713781,0.00023818143,0.000025009094,0.0000058340183,0.00010559545,0.00012792661,0.00020652478],"category_scores_gemma":[0.00063597015,0.0000871872,0.0002477375,0.0003138787,0.00023517765,0.00016817062,0.000028924072,0.00060590176,0.0000071697564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015695244,0.0030868677,0.9733946,0.0001572515,0.0009057637,0.0004661062,0.00043272047,0.00029719295,0.0011886315,0.000012196227,0.0005004114,0.0038630248],"study_design_scores_gemma":[0.025392825,0.023561858,0.947233,0.00027707536,0.0004862562,0.000019673378,0.0002292983,0.00016609953,0.00069183804,0.000044634533,0.0018104155,0.000087026216],"about_ca_topic_score_codex":0.000095453484,"about_ca_topic_score_gemma":0.00028886454,"teacher_disagreement_score":0.026161587,"about_ca_system_score_codex":0.00030534194,"about_ca_system_score_gemma":0.0032381474,"threshold_uncertainty_score":0.57443345},"labels":[],"label_agreement":null},{"id":"W2920807851","doi":"10.1200/jco.2019.37.7_suppl.8","title":"A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Cohort; Veterans Affairs; Internal medicine; Proportional hazards model; Oncology; Capra; Population; Prostate cancer; Cancer","score_opus":0.06329346366512623,"score_gpt":0.3944528811715529,"score_spread":0.3311594175064267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920807851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918174,0.00015871183,0.000013803529,0.0036749751,0.0002477879,0.00095339667,0.000025227964,0.000012183299,0.0030964902],"genre_scores_gemma":[0.9965276,0.0006425928,0.0017597706,0.00057516946,0.00015158766,0.000042134536,0.0000065194854,0.000021848085,0.0002727649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964682,0.00035466652,0.0022701537,0.000287755,0.00031340905,0.00030584758],"domain_scores_gemma":[0.9956387,0.0013363216,0.0021959152,0.00023648607,0.0002734768,0.00031908235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001471358,0.00020128071,0.0024947098,0.00021687531,0.000014846639,0.0000056336216,0.0001329188,0.00025331564,0.00013711546],"category_scores_gemma":[0.0005093715,0.00011338304,0.0003615426,0.0002609831,0.0004148745,0.000089439374,0.000038584112,0.00077804533,0.000008190581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011175729,0.0038219085,0.9331727,0.0000327051,0.00068972324,0.000362246,0.00010884792,0.00001902599,0.0015060271,0.000015903988,0.00026392748,0.048831247],"study_design_scores_gemma":[0.022217283,0.07344995,0.8972476,0.00010761927,0.000415854,0.00012571916,0.00044283213,0.00027272222,0.00035141082,0.000042478634,0.0052394,0.00008711576],"about_ca_topic_score_codex":0.00015865856,"about_ca_topic_score_gemma":0.00010144904,"teacher_disagreement_score":0.06962804,"about_ca_system_score_codex":0.00077316636,"about_ca_system_score_gemma":0.0019267799,"threshold_uncertainty_score":0.46236262},"labels":[],"label_agreement":null},{"id":"W2920819127","doi":"10.1200/jco.2015.33.15_suppl.e15173","title":"Pancreatic neuroendocrine tumors (pNET) in adolescent and young adult (AYA) population: A multi-institutional study of characteristics and outcomes.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Neuroendocrine tumors; Internal medicine; Population; Gastroenterology; Everolimus; Oncology; Pancreatic cancer; Cancer","score_opus":0.1530237532525875,"score_gpt":0.47934176185187355,"score_spread":0.32631800859928606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920819127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968441,0.00016034862,0.000012501452,0.0020504054,0.00042667094,0.00044393545,0.0000034228635,0.0000056047465,0.00005300022],"genre_scores_gemma":[0.9978016,0.00033486186,0.0011239657,0.00043239866,0.00022293477,0.000005045927,0.0000020545272,0.000011939099,0.00006522366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963303,0.00047451005,0.002216963,0.00020972475,0.00054130115,0.00022715527],"domain_scores_gemma":[0.99713564,0.00067053083,0.0010272493,0.00014794164,0.0005001268,0.00051853707],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00087388995,0.00015195158,0.0016046624,0.00022763027,0.000024097642,0.0000082317065,0.00010155801,0.000019936582,0.0000061288047],"category_scores_gemma":[0.013187872,0.000103871,0.00009597312,0.00013952305,0.00023878847,0.00014909617,0.00011610504,0.00085484196,0.0000011718472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024797048,0.0037200106,0.9741347,0.00007378907,0.00006236135,0.012422251,0.00006604673,0.000009192216,0.000019743677,0.000032898963,0.00006807865,0.006911258],"study_design_scores_gemma":[0.018363519,0.011315571,0.9634599,0.00013152097,0.00011727634,0.005459248,0.00038672992,0.00036653006,0.0000050433728,0.00003976933,0.00028836235,0.00006649956],"about_ca_topic_score_codex":0.0001684292,"about_ca_topic_score_gemma":0.00039300468,"teacher_disagreement_score":0.015883815,"about_ca_system_score_codex":0.00009707058,"about_ca_system_score_gemma":0.0005054762,"threshold_uncertainty_score":0.99512446},"labels":[],"label_agreement":null},{"id":"W2920842687","doi":"10.1200/jco.2019.37.7_suppl.662","title":"Mechanisms underlying the association between sarcopenia and poor oncologic outcomes in clear cell renal cell carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Sarcopenia; Clear cell renal cell carcinoma; Internal medicine; Cohort; Oncology; Renal cell carcinoma","score_opus":0.2037874505641023,"score_gpt":0.48037889945328854,"score_spread":0.27659144888918624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920842687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9606309,0.0001970211,0.00007867302,0.032796316,0.00078550854,0.00032801146,0.0000018250705,0.0000064512246,0.005175324],"genre_scores_gemma":[0.98615557,0.00024290278,0.0036343609,0.0087063955,0.00020961327,0.0000018955913,0.0000012730134,0.000011791173,0.0010361826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966886,0.00073250674,0.0017988613,0.00016152504,0.0003503548,0.0002681281],"domain_scores_gemma":[0.99306417,0.0047782827,0.001630937,0.000114070666,0.00017638903,0.00023614363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070813037,0.000105978455,0.0012366452,0.00013112977,0.00005894113,0.000013998616,0.00013517585,0.00043341646,0.00013236496],"category_scores_gemma":[0.0009121099,0.000065152606,0.00021189761,0.00011357272,0.00004590562,0.00008324538,0.00005831967,0.0015811246,0.000052955063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070057163,0.00049629563,0.9888003,0.00007255173,0.000043128624,0.00009652551,0.00012010782,0.0000024332278,0.0011792122,0.00016514972,0.001235509,0.007088213],"study_design_scores_gemma":[0.009995376,0.0069845673,0.96530885,0.000052250387,0.00015960567,0.000028492312,0.00036018208,0.000058701113,0.00009226383,0.002129107,0.014764219,0.000066380155],"about_ca_topic_score_codex":0.00002840418,"about_ca_topic_score_gemma":0.00003412251,"teacher_disagreement_score":0.025524713,"about_ca_system_score_codex":0.00046169048,"about_ca_system_score_gemma":0.000822681,"threshold_uncertainty_score":0.68692875},"labels":[],"label_agreement":null},{"id":"W2920844027","doi":"10.1200/jco.2015.33.15_suppl.e16096","title":"Regional differences in cardiovascular status and events in prostate cancer patients treated with a gonadotrophin-releasing hormone agonist vs antagonist: Results of a pooled analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Incidence (geometry); Myocardial infarction; Proportional hazards model; Cumulative incidence; Cancer; Gynecology; Cohort","score_opus":0.09186731443337066,"score_gpt":0.4082371779295669,"score_spread":0.3163698634961962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920844027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99152786,0.0065487,0.0000019074203,0.0013587398,0.00006783261,0.00037351844,0.000029360179,0.0000028892366,0.00008921081],"genre_scores_gemma":[0.98974025,0.009763067,0.00020018601,0.00007605232,0.000078817335,0.0000117099935,0.000028793997,0.000011463216,0.00008967426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625456,0.0006107321,0.0017876908,0.0002810312,0.0007260414,0.0003399178],"domain_scores_gemma":[0.9972962,0.0004047326,0.0009996959,0.00016268973,0.000691081,0.00044555738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001599898,0.0001654307,0.0022293122,0.0004848094,0.000023907625,0.0000069303023,0.000090818896,0.00016537549,0.0000024345954],"category_scores_gemma":[0.0007619269,0.00009829601,0.00032657915,0.00072774035,0.00033297774,0.000107356,0.00004138635,0.00061492884,3.6029795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072465435,0.0018219943,0.91043705,0.000026952404,0.0033228945,0.00061833754,0.0004103496,0.0000685853,0.000018765642,0.0000014597224,0.000061364655,0.010746828],"study_design_scores_gemma":[0.05001187,0.013611682,0.9334773,0.00020779048,0.0016456343,0.000021663574,0.00017050403,0.00013670143,0.0000114530785,0.00003997322,0.00057695585,0.00008846098],"about_ca_topic_score_codex":0.002615596,"about_ca_topic_score_gemma":0.00051760895,"teacher_disagreement_score":0.023040276,"about_ca_system_score_codex":0.00048731078,"about_ca_system_score_gemma":0.0023286813,"threshold_uncertainty_score":0.41309804},"labels":[],"label_agreement":null},{"id":"W2920859248","doi":"10.1200/jco.2015.33.15_suppl.e13021","title":"Clinical outcomes of patients with gliomas treated with bevacizumab in British Columbia (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Temozolomide; Internal medicine; Progression-free survival; Cancer; Glioma; Etoposide; Lomustine; Oncology; Radiation therapy; Chemotherapy; Cyclophosphamide; Vincristine","score_opus":0.0844184738330545,"score_gpt":0.41985977813496095,"score_spread":0.33544130430190644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920859248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976662,0.0001219936,0.0000034566588,0.00087098277,0.00031274243,0.0003629966,0.000011889859,0.000007447849,0.000642315],"genre_scores_gemma":[0.99711365,0.00008825715,0.0020631682,0.00044957752,0.00015029921,0.000007128463,0.000009845867,0.000022381117,0.00009569888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953234,0.00045742953,0.0031075932,0.00024471415,0.0006159739,0.00025089836],"domain_scores_gemma":[0.9941802,0.0017529518,0.0020416297,0.00023630189,0.0011587255,0.00063021615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020545837,0.00013611249,0.0026139992,0.000115245115,0.000018204622,0.00001961951,0.00014084132,0.00037269085,0.00009203942],"category_scores_gemma":[0.0027533676,0.00010568755,0.00038468846,0.00028776168,0.0003492792,0.000111109606,0.000039217837,0.000629329,0.0000066681546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044006114,0.013954901,0.92851627,0.000010911253,0.00083718373,0.0030866796,0.000021521742,0.000005257747,2.6949837e-7,0.0000023446983,0.0029900072,0.046174027],"study_design_scores_gemma":[0.06257649,0.047398817,0.88534135,0.00020080798,0.0006642489,0.00016124701,0.00007868599,0.000005523881,0.0000033604065,0.000040749695,0.0034350168,0.00009368043],"about_ca_topic_score_codex":0.0024643287,"about_ca_topic_score_gemma":0.030416388,"teacher_disagreement_score":0.058175873,"about_ca_system_score_codex":0.00017556852,"about_ca_system_score_gemma":0.0014057378,"threshold_uncertainty_score":0.98727596},"labels":[],"label_agreement":null},{"id":"W2920861638","doi":"10.1200/jco.2015.33.15_suppl.3531","title":"Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Metformin; Internal medicine; FOLFOX; Proportional hazards model; Cohort; Cancer; Diabetes mellitus; Cetuximab; Hazard ratio; Colorectal cancer; Oncology; Gastroenterology; Oxaliplatin; Insulin; Endocrinology; Confidence interval","score_opus":0.16620528320427766,"score_gpt":0.4149939038659656,"score_spread":0.24878862066168791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920861638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983061,0.015810436,0.000036015117,0.00019656193,0.00053132797,0.00017325042,0.00011533926,0.0000028790644,0.000073168056],"genre_scores_gemma":[0.9768253,0.020761497,0.0013156277,0.0002864184,0.00064077723,0.000006083569,0.000045690256,0.00001801427,0.00010058737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714977,0.00065133435,0.0013337297,0.00035029647,0.0002726904,0.00024216303],"domain_scores_gemma":[0.9965677,0.0011889588,0.0012510287,0.00020265742,0.0004697213,0.00031990372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002895563,0.00016480112,0.00086203945,0.0000543245,0.00003954822,0.000026752778,0.00016643974,0.00041980948,0.0000057410425],"category_scores_gemma":[0.0054078605,0.00012493174,0.00006527358,0.00013070094,0.00020886058,0.00004547458,0.0000724767,0.0005801467,5.2627684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006001588,0.00027763704,0.87272173,0.0000074820728,0.000089055495,0.000007976752,0.00018458895,0.000011125699,0.00005055633,0.0000050833405,0.0009367494,0.11970644],"study_design_scores_gemma":[0.02451257,0.0032393266,0.88769203,0.0000943373,0.0000765383,0.0000012169568,0.000089068286,0.000015377398,0.0003267514,0.00011274988,0.08367537,0.00016465526],"about_ca_topic_score_codex":0.00034781542,"about_ca_topic_score_gemma":0.0021612782,"teacher_disagreement_score":0.11954178,"about_ca_system_score_codex":0.00006902148,"about_ca_system_score_gemma":0.000764363,"threshold_uncertainty_score":0.64741045},"labels":[],"label_agreement":null},{"id":"W2920874600","doi":"10.1200/jco.2019.37.7_suppl.234","title":"Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Confidence interval; Placebo; Brief Pain Inventory; Randomized controlled trial; Clinical endpoint; Quality of life (healthcare); Urology; Oncology; Surgery; Cancer; Physical therapy; Pathology","score_opus":0.1149465555236373,"score_gpt":0.4599041896610921,"score_spread":0.3449576341374548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920874600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943683,0.00037149913,0.000003965954,0.003778308,0.000077010845,0.0012291585,0.000016737205,0.0000046942237,0.00015032367],"genre_scores_gemma":[0.9987823,0.00021283876,0.0004868622,0.00021026553,0.000015132265,0.000021738666,0.00003483837,0.000019617763,0.00021640696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954265,0.00082869356,0.0025717954,0.00023313664,0.00063548086,0.00030444443],"domain_scores_gemma":[0.99584794,0.00060790504,0.0023082157,0.00016384733,0.0007867212,0.0002853777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024685143,0.00016869068,0.0018823026,0.00026964807,0.000021858063,0.000008184275,0.00008393524,0.00013036838,0.00006574019],"category_scores_gemma":[0.00025889295,0.00008918515,0.00007459599,0.0005035139,0.0002177589,0.00019749414,0.00001303601,0.00073861924,0.0000026507973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09488462,0.0038728684,0.8942316,0.00022147832,0.00043519892,0.00011267495,0.00038751712,0.0002914921,0.000049421105,0.000029087358,0.000031732015,0.0054522716],"study_design_scores_gemma":[0.074475005,0.047203574,0.87706983,0.0006622156,0.00008967679,0.0000072378953,0.00022628697,0.000056168934,0.000044762957,0.000029416182,0.000049755305,0.000086093634],"about_ca_topic_score_codex":0.0023062297,"about_ca_topic_score_gemma":0.00613304,"teacher_disagreement_score":0.043330707,"about_ca_system_score_codex":0.0005829712,"about_ca_system_score_gemma":0.004687003,"threshold_uncertainty_score":0.8314542},"labels":[],"label_agreement":null},{"id":"W2920893311","doi":"10.1200/jco.18.01100","title":"RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; ECOG-ACRIN Cancer Research Group; American College of Radiology Imaging Network; Merck KGaA; Sanofi; Genentech; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; European Organisation for Research and Treatment of Cancer; GlaxoSmithKline","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Oncology; Internal medicine; Cancer; Placebo; Lung cancer; Clinical trial; Progressive disease; Pathology","score_opus":0.07568698635110496,"score_gpt":0.4649794050065792,"score_spread":0.38929241865547426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920893311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003273,0.00012353712,0.00078078645,0.006933595,0.00072395906,0.0009681126,0.00036441392,0.0000045093484,0.00006833726],"genre_scores_gemma":[0.9855031,0.00012570882,0.0033433922,0.00963064,0.00051768665,0.00011849452,0.00016493781,0.000027479435,0.00056857505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996836,0.0006587374,0.0013616914,0.00045883624,0.00040311474,0.0002816213],"domain_scores_gemma":[0.99626434,0.0005211643,0.0010022129,0.00038640248,0.0015194346,0.0003064445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003076897,0.00020819176,0.0010505432,0.00020717915,0.000054396034,0.000013082195,0.00027668956,0.0002596808,0.00016869431],"category_scores_gemma":[0.0035942446,0.0001653412,0.000532236,0.00036678536,0.000044275854,0.000010692864,0.000102629165,0.00015700946,0.000024102197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17785156,0.0027924199,0.5088548,0.000020733734,0.012804754,0.000013548079,0.0002521238,0.0021669825,0.048780452,0.0000020633736,0.03326355,0.21319702],"study_design_scores_gemma":[0.01396492,0.008328756,0.8514609,0.00003236747,0.0024205095,0.0000035330456,0.00006764437,0.00018519381,0.007936252,0.000005973405,0.11535532,0.00023863456],"about_ca_topic_score_codex":0.00012033606,"about_ca_topic_score_gemma":0.00046254921,"teacher_disagreement_score":0.3426061,"about_ca_system_score_codex":0.00028395397,"about_ca_system_score_gemma":0.0010738971,"threshold_uncertainty_score":0.6742419},"labels":[],"label_agreement":null},{"id":"W2920901744","doi":"10.1200/jco.2015.33.15_suppl.e14584","title":"Subjective sleep problems and objective circadian disruption: Impact on outcomes in patients with metastatic colorectal cancer (MCC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Circadian rhythm; Medicine; Actigraphy; Proportional hazards model; Logistic regression; Internal medicine; Hazard ratio; Sleep (system call); Oncology; Confidence interval","score_opus":0.0761175645398896,"score_gpt":0.4333763361226617,"score_spread":0.3572587715827721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920901744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962147,0.00021912929,0.000014861799,0.0013218952,0.0009091514,0.0003949939,0.000016644757,0.0000052051732,0.0009034089],"genre_scores_gemma":[0.9988403,0.000058104593,0.00009387394,0.00070228614,0.00023115541,0.000016239273,0.0000031617483,0.00001656921,0.000038316473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977894,0.00040034647,0.0009718834,0.00019655874,0.0004188796,0.00022295075],"domain_scores_gemma":[0.9969631,0.0010008696,0.000807041,0.00009123832,0.00060940225,0.0005283791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013674885,0.00016686956,0.0013847561,0.00018000918,0.000020494486,0.000009997879,0.000068705085,0.00016535583,0.000042295767],"category_scores_gemma":[0.001057868,0.00009408703,0.00021102719,0.0002002966,0.00017969531,0.00014137458,0.00002153391,0.0008377422,0.0000034976663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0130579425,0.0012038236,0.95942485,0.000014206031,0.00051555847,0.00013107367,0.0019918713,0.000102972845,0.0000010878481,0.000011638682,0.000063309286,0.02348166],"study_design_scores_gemma":[0.014854467,0.035606667,0.9477965,0.000106438856,0.00026705084,0.000042314037,0.00064394524,0.000029474468,0.000006071451,0.00018283576,0.00036262014,0.000101565245],"about_ca_topic_score_codex":0.00085242855,"about_ca_topic_score_gemma":0.0067177005,"teacher_disagreement_score":0.034402844,"about_ca_system_score_codex":0.0006221982,"about_ca_system_score_gemma":0.0014329578,"threshold_uncertainty_score":0.38367578},"labels":[],"label_agreement":null},{"id":"W2920928707","doi":"10.1200/jco.2015.33.15_suppl.e18029","title":"Comparison of patient characteristics and chromosomal abnormalities by first-line treatment in chronic lymphoid leukemia (CLL) patients in Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Fludarabine; Bendamustine; Medicine; Chlorambucil; Chronic lymphocytic leukemia; Internal medicine; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.10036165327814958,"score_gpt":0.43092141650057314,"score_spread":0.33055976322242353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920928707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712706,0.0012202967,0.000002087708,0.0004892851,0.00049574475,0.0003215451,0.00003097984,0.0000022365125,0.00031076968],"genre_scores_gemma":[0.99805033,0.0012957944,0.00011161509,0.00018998668,0.00025145037,0.000008102978,0.000024752488,0.000016801947,0.00005113763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486023,0.00035792135,0.0034717524,0.00020918026,0.0007004407,0.0004004634],"domain_scores_gemma":[0.99577177,0.0015565965,0.0014786393,0.0001996128,0.00042496997,0.00056840066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011319965,0.00019137286,0.0020899042,0.00015910875,0.000016897875,0.000005463041,0.00014663441,0.00027546374,0.000035737456],"category_scores_gemma":[0.0022069637,0.00014312583,0.00011869471,0.00016451898,0.00022985757,0.00008944886,0.00009668493,0.00053715287,0.000002087757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004326127,0.002067916,0.92115116,0.00012534458,0.0001308119,0.00073964725,0.00081059436,0.0002614313,0.000017459577,0.0000062712716,0.0023136842,0.068049535],"study_design_scores_gemma":[0.15993409,0.071652375,0.70160574,0.00067851425,0.00021734218,0.00049592275,0.0013158505,0.020009357,0.0009551713,0.000039197428,0.042776674,0.0003197457],"about_ca_topic_score_codex":0.37830153,"about_ca_topic_score_gemma":0.5756969,"teacher_disagreement_score":0.21954541,"about_ca_system_score_codex":0.09465982,"about_ca_system_score_gemma":0.12035523,"threshold_uncertainty_score":0.9088156},"labels":[],"label_agreement":null},{"id":"W2921002154","doi":"10.1200/jco.2019.37.7_suppl.516","title":"Comprehensive and epidemiological characterization of urachal adenocarcinoma: A pan-Canadian collaboration.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Urinary and Genital Oncology Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Regional Municipality of Durham; University of Ottawa; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Stage (stratigraphy); Bladder cancer; Disease; Malignancy; Epidemiology; Internal medicine; Oncology; Cancer","score_opus":0.13745494707212133,"score_gpt":0.44362195078668104,"score_spread":0.30616700371455974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921002154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785562,0.001074642,0.000014586663,0.01742891,0.00079928146,0.00024984565,0.000012485467,0.0000034476247,0.0018605617],"genre_scores_gemma":[0.99395835,0.0008172505,0.0009975685,0.003412553,0.0004572487,0.0000019180238,0.000008614459,0.000005955418,0.00034055856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973552,0.0005077755,0.0016786373,0.00015315443,0.00013454349,0.00017065238],"domain_scores_gemma":[0.99542063,0.0021433246,0.0012481043,0.000105837746,0.0007698583,0.00031222755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013774621,0.000108236774,0.0016122165,0.00013259379,0.000038314363,0.0000027709536,0.00007373686,0.00042284682,0.00012795578],"category_scores_gemma":[0.002103498,0.00007423131,0.00019354992,0.00013768679,0.0003346773,0.000119979435,0.00004255605,0.0005526389,0.000029795729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002687118,0.0005434489,0.9802055,0.000051529063,0.00037002296,0.0003414257,0.00016794243,0.0000016729755,0.0027037137,0.00040972146,0.0009497222,0.011568223],"study_design_scores_gemma":[0.0031752074,0.018264582,0.917968,0.000029512477,0.00019834588,0.0005526296,0.00034887742,0.00003616207,0.0000306531,0.00019230382,0.059146874,0.00005687992],"about_ca_topic_score_codex":0.00009108837,"about_ca_topic_score_gemma":0.00023273526,"teacher_disagreement_score":0.062237486,"about_ca_system_score_codex":0.000074641044,"about_ca_system_score_gemma":0.0012337221,"threshold_uncertainty_score":0.3261382},"labels":[],"label_agreement":null},{"id":"W2921002359","doi":"10.1200/jco.2015.33.15_suppl.e17693","title":"Validation of heart failure prediction tool in cardio-oncology breast cancer population.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Population; Trastuzumab; Framingham Risk Score; Oncology; Heart failure; Cardiomyopathy; Cancer; Disease","score_opus":0.1036673671391026,"score_gpt":0.4485284319079394,"score_spread":0.3448610647688368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921002359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98326445,0.00012694403,0.0001845101,0.014441548,0.0012846411,0.00022627239,0.000013611431,0.000008268546,0.00044976122],"genre_scores_gemma":[0.9950865,0.00015870541,0.0019018524,0.00084004644,0.001948638,0.0000058499345,0.000012858148,0.000011373399,0.000034174474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968266,0.0005503368,0.0019468958,0.00013988074,0.0003976512,0.0001386232],"domain_scores_gemma":[0.99737835,0.0004385743,0.001140022,0.00013384651,0.00073497527,0.0001742381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039647124,0.00009408048,0.0012388898,0.00017940231,0.000014837911,0.0000037768439,0.000065574095,0.0005715796,0.000053104395],"category_scores_gemma":[0.0013309559,0.000077444456,0.00035898064,0.0002122874,0.00008647799,0.00020622532,0.000016519783,0.0006804878,0.0000031719796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004337946,0.0010783542,0.86141133,0.000049295817,0.00034719708,0.000057725843,0.0003828338,0.0016023669,0.022352602,0.000081665174,0.011568097,0.096730605],"study_design_scores_gemma":[0.012956454,0.004857344,0.9404441,0.0001894275,0.0003191835,0.0012221157,0.0003788533,0.00016660278,0.008958873,0.0007333159,0.029678546,0.00009516201],"about_ca_topic_score_codex":0.00015021424,"about_ca_topic_score_gemma":0.00007851184,"teacher_disagreement_score":0.09663544,"about_ca_system_score_codex":0.00062657514,"about_ca_system_score_gemma":0.0019116355,"threshold_uncertainty_score":0.44085455},"labels":[],"label_agreement":null},{"id":"W2921010571","doi":"10.1200/jco.2015.33.15_suppl.574","title":"A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FRAX; Medicine; Osteoporosis; Bone mineral; Trabecular bone score; Internal medicine; Breast cancer; Cancer; Osteoporotic fracture; Quantitative computed tomography","score_opus":0.050912777449077684,"score_gpt":0.40251755489457614,"score_spread":0.35160477744549845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921010571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357855,0.0006828094,0.00062635686,0.0034421254,0.00023811961,0.0010748161,0.00031645643,0.000013191136,0.000027585924],"genre_scores_gemma":[0.9847682,0.00041247334,0.011860283,0.0024846303,0.00030186918,0.000028811575,0.00008027997,0.000044987406,0.000018475499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950064,0.0007808876,0.0025315082,0.00043496874,0.0007794962,0.00046675207],"domain_scores_gemma":[0.9940142,0.0005309434,0.0027670753,0.0003136371,0.00086490024,0.0015092177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021321962,0.00035904357,0.002564993,0.00032572966,0.00006698819,0.000015376556,0.00013379766,0.00070108735,0.00003093234],"category_scores_gemma":[0.0010160506,0.0002277731,0.0002547069,0.00038033767,0.0002087989,0.00021898576,0.000057745197,0.0019441241,0.000004115969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01922431,0.0043701236,0.89554065,0.0000782627,0.0004877417,0.0009173601,0.00043292376,0.000107019325,0.0000026905875,3.5599405e-7,0.0022168963,0.07662169],"study_design_scores_gemma":[0.048122972,0.01548009,0.9320165,0.0005939827,0.0012888506,0.00035226645,0.00024045717,0.00046356628,0.000027540736,0.000038073355,0.0011911498,0.00018453832],"about_ca_topic_score_codex":0.005234857,"about_ca_topic_score_gemma":0.00051277544,"teacher_disagreement_score":0.076437145,"about_ca_system_score_codex":0.00024144795,"about_ca_system_score_gemma":0.0011870303,"threshold_uncertainty_score":0.92883176},"labels":[],"label_agreement":null},{"id":"W2921016615","doi":"10.1200/jco.2019.37.15_suppl.e16123","title":"Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"CDKN2A; Genetics; Copy number analysis; BAP1; Transcriptome; Biology; Exon; Gene; Copy-number variation; Cancer research; Genome; Medicine; Gene expression","score_opus":0.089101991097599,"score_gpt":0.42876174340638024,"score_spread":0.3396597523087812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921016615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943123,0.0010587835,0.00041565794,0.0024229519,0.00030613996,0.00015457407,0.000011242887,0.0000041715616,0.0013141712],"genre_scores_gemma":[0.9961608,0.00005546081,0.0021087746,0.0007805238,0.00024961136,9.614519e-7,0.000005364602,0.0000109448465,0.0006275492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996551,0.00030803104,0.0023657023,0.00018877408,0.000369447,0.00021705445],"domain_scores_gemma":[0.99672955,0.001172555,0.001133772,0.0001968766,0.00030980972,0.00045743765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019852037,0.00013172616,0.0023601819,0.00031606018,0.000016560318,0.000004465672,0.00013296286,0.00017681785,0.0007238967],"category_scores_gemma":[0.0006427967,0.00008763508,0.0008561032,0.00041458828,0.0002476092,0.000081323546,0.000030833136,0.00069807033,0.000031664436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012890132,0.004083725,0.91914725,0.000397189,0.010256133,0.013563472,0.0009135041,0.00025819693,0.008205387,0.0009671964,0.00052473386,0.028793063],"study_design_scores_gemma":[0.0066592945,0.010355406,0.9674918,0.000030286628,0.005643387,0.0028204664,0.00019811177,0.00043168565,0.000085151194,0.00028382702,0.005903417,0.00009717884],"about_ca_topic_score_codex":0.000015552767,"about_ca_topic_score_gemma":0.000011089241,"teacher_disagreement_score":0.048344523,"about_ca_system_score_codex":0.00003747092,"about_ca_system_score_gemma":0.00067353906,"threshold_uncertainty_score":0.7926161},"labels":[],"label_agreement":null},{"id":"W2921037661","doi":"10.1200/jco.2019.37.7_suppl.146","title":"Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Cancer; Cancer research; Transcriptome; Internal medicine; Gene; Biology; Genetics; Gene expression; Androgen receptor","score_opus":0.10582980403252615,"score_gpt":0.4651932925895905,"score_spread":0.35936348855706435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921037661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883544,0.004208329,0.0000014856013,0.0058455,0.00024348678,0.0005528563,0.000015367244,0.000002558416,0.00077604275],"genre_scores_gemma":[0.99080276,0.0051428764,0.0027021924,0.00020993024,0.00008439396,0.000011984283,0.0000020819846,0.000011440448,0.0010323395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744517,0.00026186442,0.0015809707,0.00017919201,0.0003142889,0.00021851026],"domain_scores_gemma":[0.99743396,0.00089540187,0.0010375403,0.00009725565,0.00032965242,0.00020618069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018245406,0.00010594947,0.0011136377,0.0001696222,0.000017831413,0.0000066331486,0.00008919027,0.000110632354,0.00008597518],"category_scores_gemma":[0.00050397636,0.000072105395,0.00016535695,0.0001717203,0.00023926696,0.00010465786,0.000030449713,0.00049890723,0.0000039988195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019380387,0.0009976058,0.9359823,0.00042328003,0.00057836086,0.00078121637,0.0006370267,0.000029315492,0.019649751,0.00017302379,0.00060189527,0.020765861],"study_design_scores_gemma":[0.016716052,0.008261089,0.9639339,0.00051359483,0.0003240822,0.00004040662,0.0005833741,0.000049936993,0.0016986731,0.00051493273,0.007269093,0.00009488957],"about_ca_topic_score_codex":0.000087284716,"about_ca_topic_score_gemma":0.00064792036,"teacher_disagreement_score":0.0279516,"about_ca_system_score_codex":0.0002575148,"about_ca_system_score_gemma":0.0025426492,"threshold_uncertainty_score":0.45105505},"labels":[],"label_agreement":null},{"id":"W2921079290","doi":"10.1200/jco.2019.37.7_suppl.186","title":"Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Prostate cancer; Regimen; Docetaxel; Oncology; Prednisone; Abiraterone acetate; Progression-free survival; Proportional hazards model; Cancer; Androgen deprivation therapy; Chemotherapy; Confidence interval","score_opus":0.10637759293864724,"score_gpt":0.5081206529327078,"score_spread":0.40174305999406057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921079290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679324,0.00040661727,0.0000041504077,0.025081323,0.000274062,0.00067501917,0.000015208089,0.0000073832034,0.005603807],"genre_scores_gemma":[0.9924365,0.0018754491,0.002513681,0.0006965472,0.00020745728,0.000021422939,0.0000038434378,0.000025807696,0.0022192919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958866,0.00065004954,0.002216295,0.0003310139,0.0005155548,0.0004004479],"domain_scores_gemma":[0.99590665,0.0015235463,0.0014217197,0.00022124177,0.00032296812,0.0006038436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028839533,0.00020227711,0.0022197352,0.0002195827,0.000034737935,0.000021880247,0.00013245008,0.0001302008,0.00012965499],"category_scores_gemma":[0.00068822724,0.00011401941,0.00026560982,0.00030058256,0.0006549617,0.0001496481,0.000044321107,0.0011713514,0.000011408429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011345464,0.0011325355,0.87382305,0.000046467056,0.0007777593,0.0015236039,0.00039546573,0.000005389896,0.000044187553,0.000031405412,0.00037292734,0.11050173],"study_design_scores_gemma":[0.016252061,0.022647966,0.9481392,0.00014454534,0.00035962195,0.00015051017,0.0024797488,0.000053277192,0.0000106315365,0.000094504954,0.009540624,0.00012733428],"about_ca_topic_score_codex":0.0005634175,"about_ca_topic_score_gemma":0.0025452273,"teacher_disagreement_score":0.11037439,"about_ca_system_score_codex":0.00026642636,"about_ca_system_score_gemma":0.0033931488,"threshold_uncertainty_score":0.60193},"labels":[],"label_agreement":null},{"id":"W2921090392","doi":"10.1200/jco.18.02158","title":"Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University; London Health Sciences Centre; Alberta Cancer Foundation","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Docetaxel; Hazard ratio; Radiation therapy; Internal medicine; Oncology; Androgen suppression; Chemotherapy; Randomized controlled trial; Urology; Cancer; Confidence interval","score_opus":0.025023422093902622,"score_gpt":0.4323725354707703,"score_spread":0.4073491133768677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921090392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97852457,0.0056188838,0.0003539386,0.008128798,0.0007630724,0.0065115234,0.000034123437,0.0000079176625,0.000057176232],"genre_scores_gemma":[0.9531053,0.041874822,0.002418477,0.0012341853,0.0007530562,0.00044268463,0.000009193556,0.00004443486,0.00011790372],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954469,0.0015825644,0.002029538,0.00030961097,0.0003441752,0.00028717594],"domain_scores_gemma":[0.98295057,0.01256056,0.0035840562,0.00026004255,0.00037804258,0.0002667428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006830789,0.0002783718,0.004469786,0.0000817516,0.00006146276,0.000011865832,0.00012717197,0.00030207308,0.00011949834],"category_scores_gemma":[0.0006291177,0.000109274355,0.000531259,0.000114658746,0.00064066245,0.000084214225,0.0000175726,0.0005614033,4.9925677e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73740023,0.0019237117,0.009872267,0.00008725716,0.003187769,0.00006372003,0.00024717802,0.00003954271,0.00015358617,0.000015724163,0.0007227137,0.24628629],"study_design_scores_gemma":[0.74209327,0.21957207,0.00038847292,0.00026046784,0.0024244688,0.00012093834,0.000032525855,0.00024681413,0.0036798343,0.00005964135,0.031025765,0.00009574955],"about_ca_topic_score_codex":0.00013566762,"about_ca_topic_score_gemma":0.000034124587,"teacher_disagreement_score":0.24619055,"about_ca_system_score_codex":0.00020698053,"about_ca_system_score_gemma":0.0016470376,"threshold_uncertainty_score":0.44560787},"labels":[],"label_agreement":null},{"id":"W2921091729","doi":"10.1200/jco.2019.37.15_suppl.e16553","title":"IMPACT of putative chemopreventative agents on prostate cancer diagnosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University Health Network; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Internal medicine; Metformin; Population; Proportional hazards model; Disease; Diabetes mellitus; Oncology; Cause of death; Insulin; Endocrinology","score_opus":0.06440651341254248,"score_gpt":0.49352775586982395,"score_spread":0.42912124245728145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921091729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895699,0.0009783388,0.000013788046,0.0003994786,0.0076798988,0.00021747354,0.00006890275,0.0000013013173,0.0010708955],"genre_scores_gemma":[0.9843805,0.0072099194,0.00026327532,0.00078187586,0.006509513,0.00002077294,0.0000108373315,0.000017560747,0.0008057347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997916,0.0002908358,0.0011888925,0.00020602514,0.0002017574,0.00019650323],"domain_scores_gemma":[0.9972073,0.0002886357,0.0017509707,0.00016156197,0.0004066058,0.00018496352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010591188,0.00014184002,0.00090774824,0.00005583508,0.00001444536,0.0000042255942,0.00019906527,0.0002590451,0.0002211487],"category_scores_gemma":[0.0007732389,0.0000991304,0.0007092088,0.00007553836,0.00014155326,0.0000088533325,0.00005784631,0.00035621077,0.000012182729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0097251665,0.0023737052,0.67452663,0.000040143204,0.001992133,0.000003914011,0.00060666376,0.0011460675,0.02214357,0.00004384534,0.12631162,0.16108656],"study_design_scores_gemma":[0.006364739,0.017140547,0.6756717,0.00005317222,0.00013677403,0.0000139818985,0.00011614994,0.000009715581,0.008266068,0.00018445935,0.29189247,0.00015023655],"about_ca_topic_score_codex":0.000069275615,"about_ca_topic_score_gemma":0.000021348642,"teacher_disagreement_score":0.16558084,"about_ca_system_score_codex":0.00006820342,"about_ca_system_score_gemma":0.0013517645,"threshold_uncertainty_score":0.40424204},"labels":[],"label_agreement":null},{"id":"W2921096034","doi":"10.1200/jco.2015.33.15_suppl.e17035","title":"Impact of total cisplatin dose on outcomes in locally advanced oropharyngeal squamous cell carcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Mucositis; Cisplatin; Nausea; Internal medicine; Chemoradiotherapy; Radiation therapy; Stage (stratigraphy); Vomiting; Hazard ratio; Oncology; Gastroenterology; Chemotherapy; Surgery; Confidence interval","score_opus":0.12595774379769184,"score_gpt":0.48789602781771524,"score_spread":0.36193828402002337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921096034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887875,0.0005561935,0.0000064796973,0.0015255318,0.0009613216,0.00016957914,0.0000050730805,0.0000044961116,0.007983823],"genre_scores_gemma":[0.9977873,0.00007874029,0.000801354,0.0006164033,0.000396045,0.0000020879534,7.945387e-7,0.000014701856,0.0003025964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661446,0.0002751984,0.0022680673,0.00016380174,0.00040971406,0.00026875164],"domain_scores_gemma":[0.9957728,0.0020012183,0.0011237239,0.00017395314,0.0004295692,0.00049874326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018067952,0.00016373338,0.0024992302,0.00016249108,0.0000127578005,0.0000021716444,0.00010916947,0.00026310614,0.00005645953],"category_scores_gemma":[0.003920344,0.000100220044,0.00059368834,0.0001416694,0.00014940313,0.000075899,0.000051232306,0.0009280749,0.000014334889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023649897,0.004580913,0.9068849,0.000040142706,0.00011416493,0.0016731168,0.00046256083,0.00039344066,0.00042472142,0.000008816643,0.003380987,0.05838635],"study_design_scores_gemma":[0.028740982,0.08941682,0.880671,0.00005629904,0.00009908329,0.00010407563,0.00015136195,0.00007921446,0.00011341866,0.00005468843,0.0004292968,0.00008376115],"about_ca_topic_score_codex":0.00010500722,"about_ca_topic_score_gemma":0.000067252935,"teacher_disagreement_score":0.0848359,"about_ca_system_score_codex":0.00037607164,"about_ca_system_score_gemma":0.00298927,"threshold_uncertainty_score":0.5302837},"labels":[],"label_agreement":null},{"id":"W2921112225","doi":"10.1200/jco.2019.37.7_suppl.457","title":"Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Concordance; Medicine; Liquid biopsy; KRAS; ARID1A; Renal cell carcinoma; Bladder cancer; Pathology; Biopsy; Carcinoma; Circulating tumor DNA; Cancer; Oncology; Cancer research; Internal medicine; Gene; Mutation; Biology; Colorectal cancer; Genetics","score_opus":0.05577374403521592,"score_gpt":0.39043677043665426,"score_spread":0.33466302640143836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921112225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976708,0.0008911119,0.00026303506,0.00019694779,0.00044726062,0.00021114491,0.000019319208,9.674541e-7,0.0002993677],"genre_scores_gemma":[0.99277997,0.00021303636,0.006126618,0.00026783952,0.0005652284,0.0000021806004,0.0000054001425,0.000017157521,0.00002259878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977244,0.0001988694,0.0015755171,0.0002068037,0.00011255525,0.00018184025],"domain_scores_gemma":[0.9975952,0.0006748059,0.0012997886,0.00016412546,0.00014136292,0.00012471159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016327508,0.00011472901,0.0009298173,0.000059872753,0.000013097561,0.0000072850044,0.00017607104,0.00014776313,0.000012488662],"category_scores_gemma":[0.0011704424,0.00010384773,0.00014059638,0.00005473963,0.00011895861,0.000005734952,0.00010804354,0.0002957931,0.0000028979425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042137978,0.000106304324,0.6792586,0.000057159443,0.00008634716,0.00005192348,0.000044979544,0.00018756918,0.31004113,0.00007175867,0.000032635817,0.009640218],"study_design_scores_gemma":[0.009271622,0.0086670155,0.88073564,0.000085951724,0.0002059291,0.0001823891,0.00029207714,0.00026715492,0.09152786,0.0008708483,0.007592712,0.0003008121],"about_ca_topic_score_codex":0.00004396524,"about_ca_topic_score_gemma":0.000043163138,"teacher_disagreement_score":0.2185133,"about_ca_system_score_codex":0.000038327533,"about_ca_system_score_gemma":0.0009998757,"threshold_uncertainty_score":0.42347875},"labels":[],"label_agreement":null},{"id":"W2921119383","doi":"10.1200/jco.2019.37.7_suppl.523","title":"Excellent outcomes in bilateral testicular germ cell tumors over four decades.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Testicular cancer; Stage (stratigraphy); Histology; Orchiectomy; Surgery; Cancer; Median follow-up; Urology; Internal medicine; Gastroenterology; Chemotherapy","score_opus":0.07944387660892757,"score_gpt":0.44480306698274386,"score_spread":0.36535919037381626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921119383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952986,0.0007046617,0.000010814531,0.0017058076,0.00086679606,0.0002681029,0.00000230329,0.000008223497,0.0011346849],"genre_scores_gemma":[0.99562365,0.00012614096,0.0015077462,0.0016983338,0.00024329578,0.0000025374757,0.0000015779053,0.00001926359,0.0007774705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712443,0.00019804933,0.0018353523,0.0002034502,0.00037310118,0.0002656042],"domain_scores_gemma":[0.9965433,0.001472639,0.0011571166,0.00022280595,0.00014432606,0.00045980985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008797004,0.0001646374,0.0014823755,0.00014409334,0.000012819912,0.000008563932,0.00012288116,0.00025015662,0.00043869225],"category_scores_gemma":[0.0015249564,0.00010195176,0.00069269456,0.000100191435,0.0000648457,0.000076448414,0.00005286265,0.000629427,0.00015328168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075651996,0.003402236,0.98200405,0.000041243886,0.00018281309,0.00607666,0.000019505975,0.000045246103,0.00007631653,0.00001846076,0.00033144976,0.007045518],"study_design_scores_gemma":[0.0142882345,0.005993624,0.9737903,0.000128325,0.00036434986,0.00022963276,0.000021860336,0.00018046726,0.00002829598,0.00025162403,0.004627521,0.00009580157],"about_ca_topic_score_codex":0.000046115285,"about_ca_topic_score_gemma":0.000010568415,"teacher_disagreement_score":0.013531715,"about_ca_system_score_codex":0.00017474583,"about_ca_system_score_gemma":0.0009798936,"threshold_uncertainty_score":0.48033726},"labels":[],"label_agreement":null},{"id":"W2921151092","doi":"10.1200/jco.2019.37.7_suppl.280","title":"Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University","funders":"","keywords":"Wnt signaling pathway; Cancer research; Prostate cancer; Carcinogenesis; Biology; Cancer; Signal transduction; Cell biology","score_opus":0.10598788587465319,"score_gpt":0.48312061680180146,"score_spread":0.3771327309271483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921151092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046504,0.0006403323,0.000046288416,0.0062932773,0.00042463862,0.00033115412,0.0000029666298,0.000004756293,0.0017915483],"genre_scores_gemma":[0.9939358,0.0024922362,0.0018690306,0.00041538203,0.00047329423,0.0000033736032,0.0000030394267,0.000013845189,0.00079395645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746424,0.00025605602,0.0014842023,0.00018145841,0.00040191464,0.0002121588],"domain_scores_gemma":[0.99638647,0.0016536943,0.0010870029,0.00013295027,0.0005223456,0.00021755887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016431703,0.00011241452,0.0011689055,0.00008230712,0.000026934038,0.000006684507,0.000097516335,0.00023836143,0.00014074444],"category_scores_gemma":[0.0008513674,0.00007015692,0.00026476558,0.00013038759,0.00033964636,0.00016487073,0.000052732557,0.0005955965,0.000010934136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026162138,0.0031497842,0.8511187,0.00038803162,0.0011442939,0.00062732626,0.0010477396,0.000042877244,0.030385297,0.00073711324,0.0010822535,0.08411444],"study_design_scores_gemma":[0.035455886,0.057377644,0.807599,0.0008531753,0.00064816314,0.00045794976,0.0008052752,0.000110810244,0.05360218,0.0043848753,0.038434554,0.0002704944],"about_ca_topic_score_codex":0.000019158953,"about_ca_topic_score_gemma":0.0000024935193,"teacher_disagreement_score":0.08384395,"about_ca_system_score_codex":0.00011785297,"about_ca_system_score_gemma":0.0019179138,"threshold_uncertainty_score":0.34022966},"labels":[],"label_agreement":null},{"id":"W2921155986","doi":"10.1200/jco.2019.37.7_suppl.42","title":"Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; DECIPHER; Prostate cancer; Subtyping; Oncology; Androgen deprivation therapy; Internal medicine; Hazard ratio; Transcriptome; Cancer; Bioinformatics; Gene; Biology; Confidence interval; Gene expression; Genetics","score_opus":0.12030030968046344,"score_gpt":0.4970611933775088,"score_spread":0.37676088369704536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921155986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995692,0.00016961998,0.0000040784225,0.0022246747,0.00028964,0.0015183099,0.000008720274,0.0000013462105,0.00009159866],"genre_scores_gemma":[0.99862224,0.00013240393,0.00055527966,0.0004203849,0.000051537,0.000037703114,0.0000016965759,0.000013994184,0.0001647767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957754,0.0011387782,0.0019148778,0.00019753561,0.0006860487,0.00028735804],"domain_scores_gemma":[0.99679387,0.0015179542,0.00097551756,0.00022009872,0.0003248014,0.00016777715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054957187,0.0001268481,0.0010894107,0.00029128755,0.000017975795,0.000012668479,0.00018548516,0.000112762165,0.000039362552],"category_scores_gemma":[0.001554543,0.00006871479,0.00015194654,0.00039144795,0.00011361048,0.00010819966,0.000031797077,0.0005770048,0.0000073013753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4005929,0.0017282008,0.5810371,0.0000749366,0.000102926606,0.0012058355,0.0009535902,0.00010114562,0.0016923405,0.000003872653,0.000045461904,0.012461681],"study_design_scores_gemma":[0.095921606,0.034357164,0.8671792,0.00058786006,0.00012454482,0.000018652663,0.00058507605,0.0000287232,0.00066472293,0.00005892219,0.00039875842,0.00007476153],"about_ca_topic_score_codex":0.000118275915,"about_ca_topic_score_gemma":0.00091470225,"teacher_disagreement_score":0.3046713,"about_ca_system_score_codex":0.0002878031,"about_ca_system_score_gemma":0.0020730111,"threshold_uncertainty_score":0.36774325},"labels":[],"label_agreement":null},{"id":"W2921168318","doi":"10.1200/jco.2019.37.7_suppl.411","title":"FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Hazard ratio; Fibroblast growth factor receptor 3; Meta-analysis; Oncology; Internal medicine; Urothelial carcinoma; Carcinoma; Mutation; Carcinogenesis; Proportional hazards model; Gastroenterology; Cancer; Confidence interval; Bladder cancer; Fibroblast growth factor; Receptor; Biology; Genetics; Gene","score_opus":0.18605412222159087,"score_gpt":0.4832615048870897,"score_spread":0.29720738266549884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921168318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003173638,0.99372464,0.000005409942,0.00033453997,0.00013033046,0.005260866,0.000038019487,0.000004386966,0.00018444093],"genre_scores_gemma":[0.0042031826,0.9931119,0.00023852877,0.0017988576,0.00012034369,0.00021833132,0.000037436188,0.000045660327,0.00022572237],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9915658,0.0019147209,0.0052334447,0.00040393387,0.00064977235,0.00023228985],"domain_scores_gemma":[0.9901846,0.0020440933,0.006653037,0.000385187,0.00038314392,0.00034993066],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0028748375,0.00043196688,0.023163065,0.00054358714,0.000019073384,0.000013665134,0.00020180029,0.00056896213,0.0002116875],"category_scores_gemma":[0.0028533703,0.0002072878,0.0032083173,0.00056416047,0.000109320885,0.00008569053,0.000042715084,0.0012153292,0.000059930575],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056476105,0.002287506,0.010183745,0.7339948,0.23871525,0.00079468277,0.00004215647,2.2178692e-7,7.3453843e-10,0.000008391356,0.00011527917,0.01329322],"study_design_scores_gemma":[0.004324476,0.011393675,0.005940735,0.021014603,0.9457982,0.0003165637,0.0000044076455,3.3063563e-7,5.5729767e-9,0.0000073840606,0.011036575,0.0001630511],"about_ca_topic_score_codex":0.000021946635,"about_ca_topic_score_gemma":0.000013167397,"teacher_disagreement_score":0.71298015,"about_ca_system_score_codex":0.0002478788,"about_ca_system_score_gemma":0.004087967,"threshold_uncertainty_score":0.9913391},"labels":[],"label_agreement":null},{"id":"W2921196529","doi":"10.1200/jco.2019.37.7_suppl.161","title":"A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; St. Joseph’s Healthcare Hamilton; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cohort; Prostate cancer; Androgen deprivation therapy; Internal medicine; Retrospective cohort study; Oncology; Guideline; Cancer; Pathology","score_opus":0.14723141278242588,"score_gpt":0.4637936837074555,"score_spread":0.31656227092502964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921196529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792755,0.0002785726,0.000005693734,0.00062029564,0.00020429716,0.0007906703,0.000016997785,0.000001352998,0.0001545599],"genre_scores_gemma":[0.9986797,0.00042798521,0.0006496137,0.00006934421,0.000043876098,0.000018901024,0.000004321885,0.0000080434875,0.000098193676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977946,0.00021902197,0.0010833764,0.00016932092,0.00058375124,0.0001499152],"domain_scores_gemma":[0.9980341,0.00026152912,0.00089907227,0.000084934116,0.0006028967,0.00011744722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011583788,0.00009333964,0.0007572068,0.00010919202,0.000026755906,0.000008907579,0.00004135554,0.000051546158,0.00003739756],"category_scores_gemma":[0.00013845648,0.000059054084,0.000049803468,0.00022439014,0.00006113275,0.00016150648,0.000026642856,0.00037774403,2.575902e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008078516,0.0013829602,0.9650756,0.000094189854,0.0005663932,0.0003900443,0.00010495787,0.000052218038,0.00015513694,0.000007306449,0.000029097775,0.02406358],"study_design_scores_gemma":[0.014794614,0.009267012,0.97368306,0.00020426742,0.00027330537,0.0000090362255,0.0012920453,0.000056507142,0.00010845758,0.000024666948,0.0002345269,0.0000525136],"about_ca_topic_score_codex":0.04512481,"about_ca_topic_score_gemma":0.36555204,"teacher_disagreement_score":0.32042724,"about_ca_system_score_codex":0.0010768842,"about_ca_system_score_gemma":0.0033934512,"threshold_uncertainty_score":0.9612338},"labels":[],"label_agreement":null},{"id":"W2921199143","doi":"10.1200/jco.2015.33.15_suppl.6562","title":"Utility of surveillance following curative intent resection of metastases.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Colorectal cancer; Stage (stratigraphy); Perioperative; Cancer; Internal medicine; Population; Surgery; Proportional hazards model; Chemotherapy","score_opus":0.3202193344151429,"score_gpt":0.5342160388243958,"score_spread":0.21399670440925295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921199143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756516,0.0019333452,0.00019175911,0.0020058956,0.0014289689,0.00012467847,0.000008541881,0.000002486327,0.006739147],"genre_scores_gemma":[0.998291,0.00031730812,0.0010247816,0.00010674474,0.00017395483,0.0000013114253,0.000001018394,0.000003929275,0.00007991822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742323,0.00040373017,0.0016611036,0.00009612743,0.00032021958,0.00009559703],"domain_scores_gemma":[0.9960549,0.0012047963,0.0014506205,0.00010238561,0.0010293147,0.0001580182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003358725,0.000074459385,0.0014669208,0.0000632602,0.00001348052,0.0000010875788,0.00005831112,0.00010062839,0.00003207833],"category_scores_gemma":[0.007861186,0.000045710094,0.0005230661,0.00012852339,0.00017772343,0.00005850585,0.000042781114,0.00030474245,8.467142e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024378162,0.0026295122,0.8463047,0.000045160265,0.0025650521,0.00023791162,0.0006176889,0.0000074415148,0.00016140263,0.000054825665,0.007085487,0.11591265],"study_design_scores_gemma":[0.013464713,0.059407417,0.88535523,0.00014557836,0.00066586235,0.000094894225,0.0019701496,0.000066751156,0.0011328042,0.0005765822,0.037047736,0.00007226214],"about_ca_topic_score_codex":0.00008607188,"about_ca_topic_score_gemma":0.00037589806,"teacher_disagreement_score":0.11584039,"about_ca_system_score_codex":0.00008978693,"about_ca_system_score_gemma":0.0009740703,"threshold_uncertainty_score":0.9411141},"labels":[],"label_agreement":null},{"id":"W2921222181","doi":"10.1200/jco.2013.31.15_suppl.e20622","title":"Quality-of-care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis-induced by androgen deprivation therapy (ADT): Results of a chart audit.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Osteoporosis; Vitamin D and neurology; Referral; Prostate cancer; Physical therapy; FRAX; vitamin D deficiency; Bone mineral; Hip fracture; Internal medicine; Pediatrics; Cancer; Family medicine; Osteoporotic fracture","score_opus":0.161976080279255,"score_gpt":0.5146142643139257,"score_spread":0.3526381840346706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921222181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119186,0.00070345047,0.000010786228,0.0048668412,0.00018951099,0.0029069055,0.000082793085,0.0000024687763,0.00004540588],"genre_scores_gemma":[0.99556,0.0023719992,0.0013506141,0.0002732027,0.00012946824,0.00014644883,0.000036467587,0.000012716821,0.00011908564],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958478,0.00039707148,0.002968462,0.00018902463,0.0003929489,0.0002046947],"domain_scores_gemma":[0.9937654,0.0010856449,0.0026995605,0.0001561414,0.0019628706,0.00033035746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015270977,0.000111982845,0.0013049048,0.00011864867,0.000028879347,0.0000034802792,0.00006939392,0.0002415427,0.00001705722],"category_scores_gemma":[0.002127348,0.000074546086,0.00024950417,0.00012325449,0.00006964944,0.00009996292,0.000019593223,0.00016000228,7.7614754e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034361083,0.0033561052,0.16193809,0.00034224853,0.00021390054,5.872796e-7,0.0017803191,0.0000011359582,0.023003906,0.00000384568,0.0021219836,0.7728768],"study_design_scores_gemma":[0.049786836,0.14606774,0.74915355,0.00032633127,0.000099387995,0.0000021275455,0.0005873123,0.00001632479,0.043080755,0.00009242894,0.010696603,0.00009059475],"about_ca_topic_score_codex":0.00043159997,"about_ca_topic_score_gemma":0.00018833118,"teacher_disagreement_score":0.7727862,"about_ca_system_score_codex":0.00015729887,"about_ca_system_score_gemma":0.0012428259,"threshold_uncertainty_score":0.3039901},"labels":[],"label_agreement":null},{"id":"W2921242005","doi":"10.1200/jco.2019.37.7_suppl.568","title":"Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Ottawa Hospital; University of British Columbia; London Health Sciences Centre; McMaster University; Juravinski Cancer Centre; Dalhousie University; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Nivolumab; Axitinib; Renal cell carcinoma; Hazard ratio; Internal medicine; Cancer; Kidney cancer; Ipilimumab; Oncology; Urology; Gastroenterology; Sunitinib; Immunotherapy; Confidence interval","score_opus":0.05934665579512874,"score_gpt":0.3556969391781236,"score_spread":0.29635028338299485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921242005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830956,0.00093520386,0.0000031565116,0.005917807,0.0014091973,0.0008432881,0.00011729578,0.000005453454,0.0024590534],"genre_scores_gemma":[0.9967523,0.00014312664,0.00061740703,0.0017852412,0.00054581533,0.000017667875,0.00004129011,0.000019329269,0.00007778794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938621,0.00077697646,0.004168301,0.00021360294,0.0006292633,0.00034976652],"domain_scores_gemma":[0.9937626,0.0018504418,0.002710469,0.00042325826,0.00053856,0.000714631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034123526,0.00023361137,0.0015470757,0.00029342505,0.00003746894,0.000017942297,0.0002482336,0.00034059334,0.00019642538],"category_scores_gemma":[0.0015055123,0.00013367464,0.00058512395,0.0002818501,0.00013973219,0.00020847273,0.000037963022,0.0010675857,0.000057784768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073265895,0.0015855045,0.8732039,0.0002560826,0.0011819619,0.0017645239,0.0051018214,0.0006223405,0.0021548409,0.000026064852,0.0112836845,0.029553402],"study_design_scores_gemma":[0.030536238,0.005392836,0.93955475,0.00040944343,0.0003337288,0.00006390549,0.0005390317,0.0002480092,0.005071652,0.000011619606,0.01770934,0.00012946717],"about_ca_topic_score_codex":0.07146903,"about_ca_topic_score_gemma":0.022398945,"teacher_disagreement_score":0.06635085,"about_ca_system_score_codex":0.0013493047,"about_ca_system_score_gemma":0.007355864,"threshold_uncertainty_score":0.9982715},"labels":[],"label_agreement":null},{"id":"W2921242416","doi":"10.1200/jco.2019.37.7_suppl.206","title":"Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"DU145; Unfolded protein response; Endoplasmic reticulum; Medicine; Downregulation and upregulation; Antibody; Cancer research; Prostate cancer; Cell culture; Cell; Molecular biology; Cancer; LNCaP; Immunology; Cell biology; Biology; Biochemistry; Internal medicine; Gene","score_opus":0.031992266772243004,"score_gpt":0.42724423948903445,"score_spread":0.39525197271679147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921242416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940239,0.0013387145,0.0001584959,0.0022772502,0.0014135442,0.00027409094,0.000021921298,0.000004478216,0.00048758058],"genre_scores_gemma":[0.98827016,0.0011746635,0.007974501,0.001465544,0.000307753,0.000005346576,0.000029280236,0.00002620843,0.0007465691],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99747854,0.00022963328,0.0013907502,0.0003283126,0.00024473405,0.0003280048],"domain_scores_gemma":[0.99741447,0.00017723124,0.0014112241,0.00018065733,0.00032578895,0.0004906484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015265817,0.00016859303,0.0006382362,0.000026957136,0.000051269333,0.000021323867,0.0002546513,0.00027164727,0.000031302072],"category_scores_gemma":[0.0011577167,0.00012286092,0.00024741015,0.000088616536,0.00008710012,0.000011642401,0.00016535068,0.0004215528,0.000017449098],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048515448,0.00057132845,0.29903114,0.000057627447,0.000055639543,0.000017261918,0.000042440795,0.00069833116,0.68205,0.0000030372237,0.012424278,0.0045637568],"study_design_scores_gemma":[0.021613248,0.02612244,0.05031152,0.000983456,0.00031796048,0.00008750389,0.00066827744,0.001996465,0.3441044,0.0001331236,0.55245405,0.0012075277],"about_ca_topic_score_codex":0.000027972666,"about_ca_topic_score_gemma":0.000004257497,"teacher_disagreement_score":0.5400298,"about_ca_system_score_codex":0.000030540115,"about_ca_system_score_gemma":0.0007543007,"threshold_uncertainty_score":0.50101227},"labels":[],"label_agreement":null},{"id":"W2921252344","doi":"10.1200/jco.2019.37.7_suppl.201","title":"Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Saskatchewan; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Doubling time; Progression-free survival; Internal medicine; Cancer; Clinical endpoint; Metastasis; Urology; Population; Log-rank test; Prostate; Survival analysis; Overall survival; Clinical trial","score_opus":0.11677330585184705,"score_gpt":0.4777341261483805,"score_spread":0.3609608202965335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921252344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878517,0.0010420383,0.000007967804,0.005202312,0.0016641787,0.0007541293,0.00008017904,0.0000053096874,0.0033922072],"genre_scores_gemma":[0.9942261,0.0022214213,0.0010537357,0.0002167346,0.0003757814,0.000017023458,0.00001129952,0.000025265534,0.0018526533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949692,0.00063815474,0.0027480163,0.0002688182,0.00097433134,0.0004014928],"domain_scores_gemma":[0.99482954,0.002112124,0.0015696001,0.00034951934,0.0007364524,0.0004027437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046512387,0.00019758481,0.002154885,0.00026023143,0.00002219755,0.000011945951,0.0002922866,0.00019733285,0.0005633835],"category_scores_gemma":[0.0022178353,0.00013174977,0.00047290215,0.0002885263,0.00023645461,0.000189695,0.00009239319,0.0009901784,0.000021780634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07537113,0.0059527764,0.86768955,0.0007715337,0.0028752708,0.003378629,0.00082717615,0.00026537274,0.009087404,0.00062396,0.0027260166,0.030431153],"study_design_scores_gemma":[0.05901644,0.03310603,0.8955671,0.000644641,0.0006837588,0.00010570464,0.00073486345,0.00021752845,0.0008709133,0.0017850084,0.0070665916,0.00020142006],"about_ca_topic_score_codex":0.0005760303,"about_ca_topic_score_gemma":0.000725259,"teacher_disagreement_score":0.030229732,"about_ca_system_score_codex":0.00033671525,"about_ca_system_score_gemma":0.0055790334,"threshold_uncertainty_score":0.98969656},"labels":[],"label_agreement":null},{"id":"W2921257975","doi":"10.1200/jco.2019.37.7_suppl.233","title":"Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Prostate cancer; Confidence interval; Oncology; Proportional hazards model; Urinary system; Metastasis; Cancer; Gastroenterology","score_opus":0.08263281353558231,"score_gpt":0.4836826978408333,"score_spread":0.40104988430525096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921257975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098337,0.001062467,3.6472295e-7,0.0058987355,0.00041917182,0.001379563,0.000024772116,0.0000066357616,0.00022492543],"genre_scores_gemma":[0.99176514,0.0037147782,0.00016513688,0.00012123958,0.0002131503,0.000025397452,0.0000091119455,0.000018672217,0.003967398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955744,0.00069780217,0.0025722114,0.00033451986,0.00049090595,0.00033014835],"domain_scores_gemma":[0.9950102,0.0028720156,0.0013333944,0.00013944635,0.0002725771,0.00037237964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035776198,0.00020533659,0.001851246,0.00017360604,0.00004833148,0.00002795347,0.000071488255,0.0003371711,0.000099057164],"category_scores_gemma":[0.0007862615,0.00012530739,0.00025419562,0.0001445602,0.00016527626,0.00019251781,0.000051409148,0.0008616616,0.000012568532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041400595,0.0037521073,0.9527046,0.000028199265,0.0029970414,0.0005449851,0.00036832262,0.0000021388812,0.000026146405,0.000004658886,0.00008862108,0.035343096],"study_design_scores_gemma":[0.031881053,0.050437883,0.91518456,0.00007945913,0.0011399969,0.00003681048,0.00024481936,0.000044707413,0.000004342604,0.0000977939,0.0007453626,0.00010323893],"about_ca_topic_score_codex":0.00016066806,"about_ca_topic_score_gemma":0.0002388233,"teacher_disagreement_score":0.046685774,"about_ca_system_score_codex":0.00065343553,"about_ca_system_score_gemma":0.0014911289,"threshold_uncertainty_score":0.51098865},"labels":[],"label_agreement":null},{"id":"W2921270519","doi":"10.1200/jco.2019.37.7_suppl.250","title":"Preliminary results of a two stage phase II study of <sup>18</sup>F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Probe Development and Commercialization; University Health Network; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Stage (stratigraphy); Clinical endpoint; Nuclear medicine; Ablative case; SABR volatility model; Biochemical recurrence; Radiation therapy; Salvage therapy; Radiology; Urology; Cancer; Surgery; Clinical trial; Internal medicine; Chemotherapy","score_opus":0.22843948182652438,"score_gpt":0.5566189419865039,"score_spread":0.32817946015997945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921270519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266535,0.0018858856,0.0000068134946,0.0017071152,0.00035119735,0.002933852,0.00020988847,0.0000066023863,0.00023326992],"genre_scores_gemma":[0.9919481,0.0051765116,0.0008444234,0.00017226825,0.00040469068,0.000071287526,0.000020048412,0.000032293232,0.0013303597],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9928788,0.0009348953,0.0046334323,0.00042006426,0.000675315,0.00045752543],"domain_scores_gemma":[0.98736936,0.0077284994,0.0029931508,0.00036194245,0.0012197345,0.00032733748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007547876,0.00024555568,0.0028275142,0.00043242666,0.00004967987,0.0000064981045,0.0002857076,0.00019884363,0.00017012356],"category_scores_gemma":[0.0036071364,0.00015862136,0.00057628687,0.00043763814,0.00034078586,0.00019499636,0.00012631461,0.0011172206,0.0000018324547],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61798656,0.05756539,0.1853229,0.0003247709,0.0025070526,0.001235431,0.006382119,0.0019368711,0.0014044995,0.000022922626,0.001135601,0.12417587],"study_design_scores_gemma":[0.3163685,0.63585514,0.027900023,0.00068186026,0.0005198402,0.000050695216,0.006166019,0.0019575844,0.0021744526,0.0001960218,0.007921786,0.00020809867],"about_ca_topic_score_codex":0.00026069477,"about_ca_topic_score_gemma":0.000090205205,"teacher_disagreement_score":0.57828975,"about_ca_system_score_codex":0.00021257278,"about_ca_system_score_gemma":0.0031618262,"threshold_uncertainty_score":0.64683914},"labels":[],"label_agreement":null},{"id":"W2921281835","doi":"10.1200/jco.2020.38.6_suppl.102","title":"KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Western University","funders":"","keywords":"Medicine; Abiraterone; Enzalutamide; Cohort; Nausea; Prostate cancer; Cancer; Rash; Pembrolizumab; Internal medicine; Oncology; Immunotherapy","score_opus":0.10977388063207714,"score_gpt":0.43686790981130014,"score_spread":0.327094029179223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921281835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852097,0.0009309907,0.000017717688,0.010206886,0.00038317507,0.0014415714,0.0002253028,0.00003508059,0.0015495855],"genre_scores_gemma":[0.9939948,0.0019136786,0.0009869353,0.0018189412,0.0003317579,0.000058028654,0.00015422539,0.000069693866,0.0006719898],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99248016,0.0010179238,0.003917625,0.0006633081,0.0011202857,0.00080070406],"domain_scores_gemma":[0.9942128,0.0008391785,0.002129789,0.00033362448,0.0013453895,0.0011392311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002087368,0.00044584755,0.0028064921,0.00029041365,0.000081497274,0.000043144322,0.00032958077,0.00035863527,0.00020596737],"category_scores_gemma":[0.0018152316,0.0002765075,0.0003379962,0.0008481732,0.00049823476,0.00031093592,0.000101469595,0.001957471,0.000036290432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5481081,0.004455159,0.38999206,0.00035925803,0.003396873,0.014423774,0.0014656191,0.0011708821,0.0017786234,0.000014633988,0.0070950272,0.027739964],"study_design_scores_gemma":[0.21837878,0.070706725,0.68646526,0.00089955254,0.0019274363,0.00019701794,0.000574671,0.0014482077,0.0020210673,0.00006739911,0.01675645,0.00055745884],"about_ca_topic_score_codex":0.00061364286,"about_ca_topic_score_gemma":0.0006875538,"teacher_disagreement_score":0.32972935,"about_ca_system_score_codex":0.0013158304,"about_ca_system_score_gemma":0.0060296413,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W2921297874","doi":"10.1200/jco.2019.37.7_suppl.205","title":"Prostate cancer-derived anti-GRP78 autoantibodies compromise the blood-brain barrier and accelerate atherosclerosis progression <i>in vivo</i>.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"In vivo; Medicine; Cancer research; In vitro; Blood–brain barrier; Pathology; Cell biology; Biology; Endocrinology; Biochemistry; Central nervous system","score_opus":0.03547056075995012,"score_gpt":0.39220885420087503,"score_spread":0.3567382934409249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921297874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251217,0.001937111,0.0000039282445,0.0043140138,0.0005493054,0.00030761102,0.000021719146,0.0000035129726,0.00035060666],"genre_scores_gemma":[0.9908054,0.006628974,0.00028846745,0.0015837918,0.00030197925,0.0000138113455,0.0000028954444,0.000017153623,0.00035752027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781555,0.00043012938,0.0010441504,0.0002757604,0.00017810363,0.00025629502],"domain_scores_gemma":[0.9982487,0.00031128668,0.00087313954,0.00021078301,0.000148257,0.00020785865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011941876,0.00016463698,0.0006535924,0.000035161895,0.00006132511,0.000033515058,0.000239516,0.0002546995,0.000066060085],"category_scores_gemma":[0.00058546674,0.0000966292,0.00021952891,0.00005879735,0.00029448816,0.000013673354,0.0001519494,0.00038705408,0.0000024515045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012025328,0.0005111278,0.5650266,0.00004436197,0.000173082,0.000041382784,0.00010937726,0.00015007354,0.42188337,0.000025358542,0.0021918747,0.0086409],"study_design_scores_gemma":[0.021914711,0.009164066,0.7285528,0.000522006,0.00034949605,0.00011374065,0.00047209984,0.00070378615,0.12888254,0.00020748116,0.10854942,0.0005678478],"about_ca_topic_score_codex":0.000021951511,"about_ca_topic_score_gemma":0.00003984136,"teacher_disagreement_score":0.29300082,"about_ca_system_score_codex":0.000011248752,"about_ca_system_score_gemma":0.00044101127,"threshold_uncertainty_score":0.39404243},"labels":[],"label_agreement":null},{"id":"W2921298565","doi":"10.1200/jco.2015.33.15_suppl.e14696","title":"Utilization of capecitabine-oxaliplatin (CAPOX) versus infusional 5-fluorouracil and oxaliplatin (FFOX) in the adjuvant treatment (AT) of resected high-risk colon cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oxaliplatin; Colorectal cancer; Internal medicine; Capecitabine; Mucositis; Cancer; Gastroenterology; Surgery; Chemotherapy","score_opus":0.2621284959251986,"score_gpt":0.4857470963016,"score_spread":0.2236186003764014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921298565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092674,0.0032118636,0.000002835791,0.0033039886,0.0007049834,0.00034694554,0.000047048656,0.0000031539942,0.0014524597],"genre_scores_gemma":[0.99418944,0.0046825116,0.00050796894,0.00009836323,0.0003645058,0.000017619726,0.000010513979,0.000008922801,0.00012014392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967166,0.00059045514,0.0018602237,0.00016821844,0.0004953501,0.00016915206],"domain_scores_gemma":[0.9941375,0.003042446,0.0018702424,0.00014814691,0.00063775905,0.00016389384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017664561,0.00015822476,0.001427318,0.00011862805,0.000047739428,0.0000031264385,0.000094805764,0.00021684104,0.000090195506],"category_scores_gemma":[0.0030740777,0.00008694585,0.00019158209,0.00023736563,0.0002794406,0.00005950547,0.00006733367,0.00032961447,8.7967226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078839585,0.003448891,0.62279564,0.000050778377,0.0011170903,0.00027061533,0.0044038626,0.00018517453,0.00051998225,0.00013875564,0.0038100197,0.28441963],"study_design_scores_gemma":[0.041803166,0.0616681,0.88536096,0.00014080045,0.0009053821,0.00006987508,0.0013756907,0.00034597088,0.00061135925,0.00022753804,0.0073974025,0.00009374074],"about_ca_topic_score_codex":0.0025847338,"about_ca_topic_score_gemma":0.008162227,"teacher_disagreement_score":0.2843259,"about_ca_system_score_codex":0.00053622935,"about_ca_system_score_gemma":0.0013110458,"threshold_uncertainty_score":0.4554715},"labels":[],"label_agreement":null},{"id":"W2921313886","doi":"10.1200/jco.2013.31.15_suppl.e15599","title":"A cytokine and angiogenic factor (CAF) analysis in plasma in testicular germ cell tumor patients (TGCTs).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Cytokine; Medicine; Chemotherapy; Cancer research; Oncology; Germ cell tumors; Internal medicine","score_opus":0.04158294709014045,"score_gpt":0.36499567965818747,"score_spread":0.32341273256804703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921313886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979061,0.0003392181,0.000022074073,0.001113362,0.00015240944,0.00023570318,0.0000036038084,0.000003957751,0.00022359184],"genre_scores_gemma":[0.99686295,0.00013413624,0.0019522948,0.00080895,0.00017861786,0.0000042457427,0.0000041809217,0.000013619367,0.000040998915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685436,0.00027627806,0.0020664905,0.00021556279,0.0003095795,0.00027774274],"domain_scores_gemma":[0.99737525,0.00084398675,0.0009795818,0.00016329819,0.00025140806,0.0003864701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010659161,0.00015162124,0.0016560594,0.00053641974,0.000015080013,0.000011838341,0.000116173,0.00021292974,0.0001976837],"category_scores_gemma":[0.0024462568,0.000105369094,0.00072385476,0.00053358544,0.000102496015,0.00011433458,0.00006043141,0.0006784444,0.00002347919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025518,0.002179164,0.98829216,0.000025552587,0.00030656045,0.0011645374,0.00007344356,0.000044271383,0.00029704307,0.0000053633157,0.00010488852,0.0072518215],"study_design_scores_gemma":[0.0113089895,0.003642332,0.98214537,0.000069461305,0.0005996836,0.00010388335,0.000050929284,0.0006730626,0.00008679228,0.00012321511,0.0010932403,0.000103047016],"about_ca_topic_score_codex":0.00016425387,"about_ca_topic_score_gemma":0.00016457013,"teacher_disagreement_score":0.01105381,"about_ca_system_score_codex":0.00013984862,"about_ca_system_score_gemma":0.00050639,"threshold_uncertainty_score":0.4296827},"labels":[],"label_agreement":null},{"id":"W2921357372","doi":"10.1200/jco.2019.37.15_suppl.tps4590","title":"A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Internal medicine; Carboplatin; Gemcitabine; Cetuximab; Chemotherapy; Cancer; Cisplatin; Ipilimumab; Immunotherapy; Nivolumab","score_opus":0.04679858788516644,"score_gpt":0.42469434791247646,"score_spread":0.37789576002731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921357372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917246,0.00052925915,0.00011422112,0.0010734258,0.0001703575,0.0062474045,0.00005143446,0.0000060771595,0.00008319668],"genre_scores_gemma":[0.99544793,0.0019973519,0.0019591162,0.00033757385,0.0000302563,0.00011843885,0.00001591891,0.000050414455,0.000042967247],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99553007,0.000658948,0.0021645403,0.0004684512,0.0008438616,0.00033411995],"domain_scores_gemma":[0.9957557,0.0009280853,0.0019756565,0.00025602707,0.00090955145,0.00017502699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017524466,0.0003806213,0.003683119,0.0002369084,0.000038984588,0.000023945538,0.00023441516,0.00019522436,0.00009669387],"category_scores_gemma":[0.00023137941,0.00023679712,0.00008807481,0.0005012287,0.00033350443,0.00036409154,0.00004587303,0.00049376965,2.033424e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6865274,0.022351798,0.21363865,0.00015788239,0.0010366231,0.00005607142,0.0026019944,0.00010391032,0.000018583962,0.0000046588502,0.000005691455,0.07349677],"study_design_scores_gemma":[0.75638396,0.1691383,0.07065171,0.0008198601,0.0004329397,0.000009030927,0.0017115499,0.00040619052,0.00015990237,0.00003323924,0.00006608666,0.00018724514],"about_ca_topic_score_codex":0.0019844417,"about_ca_topic_score_gemma":0.022777973,"teacher_disagreement_score":0.1467865,"about_ca_system_score_codex":0.0008370661,"about_ca_system_score_gemma":0.0016546717,"threshold_uncertainty_score":0.99505377},"labels":[],"label_agreement":null},{"id":"W2921385405","doi":"10.1200/jco.2019.37.7_suppl.74","title":"MiR-34a to enhance the radiosensitivity of 22RV1 and 22RV1-radiation resistance prostate cancer cell lines.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Prostate cancer; Radiosensitivity; Cancer research; Clonogenic assay; microRNA; Radioresistance; Survivin; Oncology; Biochemical recurrence; Medicine; Cancer; Radiation therapy; Biology; Cell culture; Internal medicine; Gene; Genetics; Prostatectomy","score_opus":0.023336079997537704,"score_gpt":0.4206889374638469,"score_spread":0.39735285746630916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921385405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869747,0.005156509,0.0010351323,0.0042982455,0.0008163664,0.00040266817,0.000017029015,0.0000020820085,0.0012972385],"genre_scores_gemma":[0.9912312,0.004782723,0.00096162147,0.0011665523,0.0005312724,0.000008474774,0.0000031073923,0.000019214862,0.0012958222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765605,0.0005154898,0.001017412,0.00027628586,0.00030103192,0.00023370348],"domain_scores_gemma":[0.99768573,0.00035035246,0.00095285196,0.00030453913,0.0005169432,0.00018955451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025113933,0.0001241595,0.00056352036,0.000040872146,0.000036947218,0.00001092733,0.0002389026,0.00032578257,0.000033604203],"category_scores_gemma":[0.0010555806,0.00008988455,0.00019874959,0.00012363824,0.0001382275,0.000010301165,0.00012388165,0.00045665415,0.000005675705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026417477,0.0001894298,0.00038675955,0.00004488861,0.00012569767,0.000018015893,0.00009398438,0.0003257468,0.9611341,0.000022769309,0.0050404454,0.029976446],"study_design_scores_gemma":[0.001892341,0.0038566391,0.006601277,0.000069237896,0.0000674207,0.000025100504,0.00006750675,0.00008960659,0.8195291,0.000093887924,0.16755606,0.0001518029],"about_ca_topic_score_codex":0.00005813264,"about_ca_topic_score_gemma":0.0003829675,"teacher_disagreement_score":0.16251561,"about_ca_system_score_codex":0.00007180084,"about_ca_system_score_gemma":0.0009801016,"threshold_uncertainty_score":0.36653855},"labels":[],"label_agreement":null},{"id":"W2921415341","doi":"10.1200/jco.2019.37.7_suppl.38","title":"Do elderly men (&gt;75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Genome British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"DECIPHER; Medicine; Internal medicine; Cancer; Logistic regression; Prostate cancer; Oncology; Prostate; Population; Basal (medicine); Bioinformatics; Biology","score_opus":0.0976612869611432,"score_gpt":0.4959094721567694,"score_spread":0.3982481851956262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921415341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883069,0.0067616845,0.0000040502136,0.0027404567,0.0005746119,0.0006104613,0.000012233667,0.000007101811,0.0009824906],"genre_scores_gemma":[0.99335,0.004761443,0.00024376766,0.00016821404,0.00040761504,0.00001647421,0.000004383695,0.000023720006,0.0010243678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967738,0.00028242148,0.0017768595,0.0002627103,0.0005609862,0.00034327226],"domain_scores_gemma":[0.995134,0.0013875747,0.0022925301,0.00021936394,0.00047365855,0.00049285573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096807576,0.00019576898,0.0019917525,0.00012897285,0.000036463138,0.000016857854,0.00016796855,0.00032631523,0.0002236176],"category_scores_gemma":[0.00071752636,0.000113465954,0.00029538147,0.0001202015,0.00050307414,0.0001145189,0.00010072264,0.0009955197,0.0000059174763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005979923,0.0013492149,0.870527,0.00013110788,0.00061467447,0.0007166027,0.00066047837,0.0000066006596,0.00094509794,0.000020342914,0.0022030487,0.1168459],"study_design_scores_gemma":[0.014597306,0.0198736,0.9599933,0.000732226,0.0003716379,0.00003648871,0.0004631254,0.00015139891,0.00061542384,0.00017630735,0.0028768787,0.000112288995],"about_ca_topic_score_codex":0.00005020489,"about_ca_topic_score_gemma":0.00006263604,"teacher_disagreement_score":0.11673361,"about_ca_system_score_codex":0.00019704046,"about_ca_system_score_gemma":0.0006927914,"threshold_uncertainty_score":0.46270072},"labels":[],"label_agreement":null},{"id":"W2921417738","doi":"10.1200/jco.2019.37.7_suppl.435","title":"Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Nivolumab; Durvalumab; Atezolizumab; Internal medicine; Pembrolizumab; Metastatic Urothelial Carcinoma; Oncology; Proportional hazards model; Cancer; Urothelial carcinoma; Bladder cancer; Immunotherapy","score_opus":0.09772049846714904,"score_gpt":0.4903594484353953,"score_spread":0.3926389499682463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921417738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290246,0.0004340862,0.000116832285,0.0042327177,0.0012760198,0.0005574088,0.000020871548,0.000005099516,0.00045449293],"genre_scores_gemma":[0.9972929,0.00022975195,0.0005709719,0.00055470463,0.00081377587,0.000010753168,0.0000047742456,0.00002114387,0.00050125463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969761,0.0003093132,0.0019171876,0.00016156516,0.00041542258,0.0002204105],"domain_scores_gemma":[0.9919643,0.0050781253,0.0019159744,0.00025417033,0.00049402536,0.00029343975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018058975,0.00016278938,0.0018571944,0.00018465551,0.000025783995,0.00000469772,0.00015644435,0.00015971872,0.00020723426],"category_scores_gemma":[0.0024394747,0.000090107365,0.0009887598,0.0001091792,0.00028175884,0.000065229055,0.000014819817,0.0005419912,0.000015159608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042140514,0.00439941,0.8548126,0.00017313022,0.0022945378,0.000108666165,0.0003644651,0.00008401774,0.0004296394,0.00019233281,0.008780435,0.08622026],"study_design_scores_gemma":[0.019915696,0.06320812,0.880702,0.00022777809,0.0010217293,0.0003064999,0.00018210341,0.00007732246,0.00016959517,0.00003973491,0.034041762,0.00010766825],"about_ca_topic_score_codex":0.00005011281,"about_ca_topic_score_gemma":0.000014426332,"teacher_disagreement_score":0.08611259,"about_ca_system_score_codex":0.00017903105,"about_ca_system_score_gemma":0.0043108943,"threshold_uncertainty_score":0.7647341},"labels":[],"label_agreement":null},{"id":"W2921423014","doi":"10.1200/jco.2019.37.7_suppl.126","title":"Radiogenomic characterization of multifocal prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Magnetic resonance imaging; Radiogenomics; Prostatectomy; ATRX; Prostate; Cancer; Pathology; Radiology; Internal medicine; Gene; Mutation; Biology; Radiomics","score_opus":0.04538494451729355,"score_gpt":0.4470190684444935,"score_spread":0.4016341239272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921423014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885032,0.00017530471,0.00029469814,0.008175604,0.001984816,0.00016541698,0.0000025383476,0.000004853148,0.0006935743],"genre_scores_gemma":[0.99326843,0.00129787,0.0022188225,0.0016807299,0.00091694505,0.0000010997752,0.0000044387957,0.00001463252,0.00059705676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759346,0.00019454942,0.0017211153,0.00011399912,0.00023690362,0.00013995651],"domain_scores_gemma":[0.9971334,0.0005080978,0.0017455949,0.00011602807,0.00026926745,0.00022761119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022995002,0.00007703287,0.0011058747,0.00009462728,0.0000121536805,0.0000035637383,0.00011002986,0.00017479794,0.0002462684],"category_scores_gemma":[0.0014918181,0.00005389226,0.00029061103,0.0000837379,0.0001322543,0.00006948308,0.000026058322,0.00083505723,0.000016092623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002055856,0.0005088647,0.48513508,0.00008111536,0.00022298373,0.00009755395,0.00014930656,0.000071284965,0.09742376,0.00005604298,0.00033942904,0.4138587],"study_design_scores_gemma":[0.009530398,0.005743276,0.86255884,0.0002602293,0.00024910909,0.00028805653,0.000037644433,0.0075925956,0.0008578284,0.000054492208,0.11274211,0.00008544403],"about_ca_topic_score_codex":0.000017021564,"about_ca_topic_score_gemma":8.895517e-7,"teacher_disagreement_score":0.41377327,"about_ca_system_score_codex":0.000075962904,"about_ca_system_score_gemma":0.0010224625,"threshold_uncertainty_score":0.36279547},"labels":[],"label_agreement":null},{"id":"W2921436941","doi":"10.1200/jco.2019.37.7_suppl.47","title":"MRI-guided prostate brachytherapy dose escalation to the dominant intraprostatic lesions: A retrospective analysis of urinary toxicity and biochemical response.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Prostate; Urology; Magnetic resonance imaging; Nuclear medicine; Androgen deprivation therapy; External beam radiotherapy; Retrospective cohort study; Radiation therapy; Prostate brachytherapy; Urinary system; Radiology; Surgery; Internal medicine; Cancer","score_opus":0.07230739240007582,"score_gpt":0.46380061786436805,"score_spread":0.3914932254642922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921436941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93978554,0.0003861035,0.00022146464,0.05846588,0.0003613051,0.00069003046,0.000013983369,0.00000460765,0.00007105718],"genre_scores_gemma":[0.99033874,0.0025760764,0.0039841193,0.0027296213,0.00022994536,0.000014888113,0.000002279895,0.000013935941,0.000110381545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959002,0.0009087502,0.0022326137,0.0002859869,0.00046868442,0.00020376925],"domain_scores_gemma":[0.99135315,0.0057204263,0.0016366527,0.00036062568,0.0006381566,0.0002909872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069400687,0.00014413489,0.0017318341,0.0003649691,0.000037052792,0.000009231319,0.00016319209,0.0002694037,0.00013968628],"category_scores_gemma":[0.0043729967,0.00008585983,0.0004787834,0.0008419822,0.00025532296,0.00008588579,0.00007800646,0.00072138896,0.0000070454134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057665486,0.003144443,0.87840766,0.00006450838,0.0027334392,0.00018538177,0.0015014098,0.00023869575,0.024077503,0.000086845095,0.011555789,0.020338828],"study_design_scores_gemma":[0.00577872,0.021162532,0.96250826,0.0001717755,0.0015640928,0.0001549046,0.0001904286,0.0009905712,0.0024215705,0.0002489392,0.004716494,0.000091680275],"about_ca_topic_score_codex":0.000017918348,"about_ca_topic_score_gemma":0.00002012859,"teacher_disagreement_score":0.08410062,"about_ca_system_score_codex":0.00028384937,"about_ca_system_score_gemma":0.00083757716,"threshold_uncertainty_score":0.5235202},"labels":[],"label_agreement":null},{"id":"W2921438191","doi":"10.1200/jco.2015.33.15_suppl.e12546","title":"Biochemical and imaging surveillance for Li-Fraumeni syndrome: The “Toronto Protocol” at 11 years.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Asymptomatic; Cancer; Germline mutation; Li–Fraumeni syndrome; Observational study; Pediatrics; Internal medicine; Mutation","score_opus":0.09600205207830861,"score_gpt":0.46008666560619177,"score_spread":0.3640846135278831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921438191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587477,0.0021736643,0.00063589634,0.018503342,0.001754838,0.016138034,0.000009490891,0.000025826474,0.0020112013],"genre_scores_gemma":[0.98879546,0.00011095166,0.004712325,0.0028211116,0.0014818492,0.001622933,0.0000033646004,0.000045991655,0.00040603883],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977503,0.00023672095,0.0012812688,0.00019199945,0.0003070054,0.00023275103],"domain_scores_gemma":[0.99703574,0.001030311,0.0008772169,0.00022630727,0.00038856632,0.0004418435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039421204,0.000116844094,0.0008658335,0.000028688515,0.000032595148,0.000010436074,0.00015643197,0.00025859257,0.000040734267],"category_scores_gemma":[0.0041165636,0.000074911106,0.00028995032,0.000058537535,0.00027380427,0.000063695115,0.00008808474,0.00049040304,0.000006700355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030451074,0.0027288378,0.19420627,0.0002896504,0.0011593348,0.0051289797,0.000727131,0.000022366343,0.0111061,0.00030699561,0.5272941,0.22657914],"study_design_scores_gemma":[0.01743627,0.0065562096,0.068565674,0.0001010716,0.0001707112,0.007021919,0.00011351461,0.00025075104,0.00037470885,0.0002750752,0.8990046,0.00012952724],"about_ca_topic_score_codex":0.00003354837,"about_ca_topic_score_gemma":0.00013641582,"teacher_disagreement_score":0.37171045,"about_ca_system_score_codex":0.00044287325,"about_ca_system_score_gemma":0.0011564769,"threshold_uncertainty_score":0.49282086},"labels":[],"label_agreement":null},{"id":"W2921445811","doi":"10.1200/jco.2020.38.15_suppl.5056","title":"Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sperm and Testicular Function","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Cisplatin; Medicine; Semen; Testicular cancer; Urology; Sperm; Semen quality; Azoospermia; Gastroenterology; Internal medicine; Chemotherapy; Andrology; Infertility; Pregnancy; Biology","score_opus":0.1362802667045879,"score_gpt":0.42374329845475533,"score_spread":0.2874630317501674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921445811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658895,0.0004483284,0.000103276994,0.0015500459,0.00028654333,0.00014218556,0.0000057460525,0.0000033849524,0.00087153167],"genre_scores_gemma":[0.9961328,0.00025359384,0.0031536897,0.00026705483,0.00016180685,0.000001155427,0.0000019824695,0.000008724767,0.000019209285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969627,0.0001957036,0.0022792066,0.00012787644,0.00031566888,0.0001188318],"domain_scores_gemma":[0.9950416,0.0018495788,0.0021738159,0.00011015457,0.00064582075,0.00017904327],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010093375,0.00009346136,0.001449723,0.00008883652,0.0000069633857,6.484949e-7,0.00010083136,0.0002055319,0.00015310688],"category_scores_gemma":[0.010366945,0.00006998635,0.00030297742,0.00032638188,0.00019146728,0.000053093507,0.000027581864,0.00042868292,0.0000010127291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004010835,0.0008376577,0.93766737,0.0002056444,0.0002399783,0.00021754808,0.0003002713,0.0012900552,0.032372948,0.000027217322,0.000121124394,0.022709353],"study_design_scores_gemma":[0.008850333,0.017847225,0.96148163,0.0005392668,0.0005575642,0.00006758958,0.00055608526,0.0020990616,0.0071472484,0.00004807637,0.0007284929,0.00007742339],"about_ca_topic_score_codex":0.00014550805,"about_ca_topic_score_gemma":0.0000902488,"teacher_disagreement_score":0.025225699,"about_ca_system_score_codex":0.00005137192,"about_ca_system_score_gemma":0.0007319474,"threshold_uncertainty_score":0.99796915},"labels":[],"label_agreement":null},{"id":"W2921472048","doi":"10.1200/jco.2015.33.15_suppl.2594","title":"NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; University of Toronto; University Health Network; Ottawa Hospital; CancerCare Manitoba; Hospital for Sick Children; Baker Hughes (Canada); McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Interior Health; BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Queen's University","funders":"","keywords":"Medicine; Sunitinib; Temsirolimus; Internal medicine; Cohort; Oncology; Clinical trial; Cancer; Surgery","score_opus":0.3306211071058806,"score_gpt":0.5534815828749803,"score_spread":0.22286047576909968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921472048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897107,0.001463866,0.0000050413437,0.004314431,0.0018199881,0.00051401975,0.000010240421,0.0000064300475,0.0021552753],"genre_scores_gemma":[0.9943151,0.0013097704,0.001315825,0.0014628787,0.0013558338,0.00002203506,0.0000044626927,0.00001931554,0.00019478965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954382,0.0005067971,0.0030997058,0.00020130363,0.00047542853,0.00027853367],"domain_scores_gemma":[0.99367577,0.0029198078,0.0020493015,0.00024150852,0.0005263801,0.0005872609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028988894,0.0001725448,0.0022683041,0.00022940904,0.000024395917,0.000003831584,0.00016996426,0.0003953058,0.00017830596],"category_scores_gemma":[0.008295688,0.00010948766,0.00046565285,0.0002714623,0.00017850453,0.000089569694,0.0000637057,0.00080302294,0.000008585142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50721115,0.02949239,0.023068389,0.000039105857,0.0004799599,0.0063200947,0.00047676396,0.000026921005,0.000072348485,0.00005501221,0.0062831948,0.42647466],"study_design_scores_gemma":[0.6627816,0.19491227,0.01842247,0.0004104459,0.0006029462,0.0006034143,0.0008203487,0.000052554333,0.00026438164,0.0002932713,0.12068605,0.00015026597],"about_ca_topic_score_codex":0.00012193667,"about_ca_topic_score_gemma":0.0004037133,"teacher_disagreement_score":0.4263244,"about_ca_system_score_codex":0.00049819355,"about_ca_system_score_gemma":0.005836472,"threshold_uncertainty_score":0.9997995},"labels":[],"label_agreement":null},{"id":"W2921483392","doi":"10.1200/jco.2019.37.7_suppl.610","title":"Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Sunitinib; Renal cell carcinoma; Internal medicine; Thrombocytosis; Clear cell renal cell carcinoma; Anemia; Database; Oncology","score_opus":0.10083678117430452,"score_gpt":0.43539819432713356,"score_spread":0.33456141315282906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921483392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558784,0.00007449176,0.00018921486,0.0024284692,0.0020214058,0.0009775098,0.00019635422,0.000012895744,0.008511809],"genre_scores_gemma":[0.98958606,0.00064443407,0.00637848,0.0011738514,0.00055344414,0.000020624908,0.00020603115,0.000056385463,0.0013806819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98892903,0.001844934,0.0064929007,0.00058530195,0.001674804,0.0004730495],"domain_scores_gemma":[0.97616345,0.012968416,0.008032475,0.00085976697,0.0012702293,0.00070564967],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007879884,0.00044689103,0.0033127116,0.00027542602,0.00008678548,0.000026373167,0.00072484266,0.00028180334,0.0007753756],"category_scores_gemma":[0.0025613427,0.00024242359,0.0012037695,0.00026636772,0.00072352646,0.00027261022,0.00028244412,0.0024216867,0.000031572134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056596347,0.007769487,0.9724694,0.00007531416,0.0016522341,0.00056752295,0.000046393856,0.00006821764,0.00003406965,0.000075460426,0.005848444,0.0057338607],"study_design_scores_gemma":[0.030655013,0.024126602,0.92828614,0.00014561067,0.002322979,0.000073899464,0.00015709642,0.00053595525,0.00013701743,0.000039143222,0.013309529,0.00021104567],"about_ca_topic_score_codex":0.0010275077,"about_ca_topic_score_gemma":0.0015684683,"teacher_disagreement_score":0.044183254,"about_ca_system_score_codex":0.00039996585,"about_ca_system_score_gemma":0.0016801839,"threshold_uncertainty_score":0.9998798},"labels":[],"label_agreement":null},{"id":"W2921492570","doi":"10.1200/jco.2019.37.7_suppl.253","title":"Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Retrospective cohort study; Abiraterone; Cohort; Cancer; Abiraterone acetate; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.17222980574543542,"score_gpt":0.5145880124233151,"score_spread":0.34235820667787964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921492570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962397,0.00017016906,0.000009306739,0.00052543054,0.00019820547,0.0026036205,0.000033207576,0.000009254003,0.00021110897],"genre_scores_gemma":[0.9964535,0.0008729058,0.0009954467,0.00009788845,0.000109385255,0.00013237502,0.000007010377,0.00003859168,0.0012928912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953006,0.00054447295,0.002288785,0.00054083805,0.0009329263,0.00039236754],"domain_scores_gemma":[0.9948692,0.0007899684,0.002295318,0.00032442197,0.0011974617,0.00052366935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010346636,0.00035288557,0.0026399286,0.00016789405,0.000072814546,0.000026012745,0.00012915151,0.000099106626,0.00010096081],"category_scores_gemma":[0.000114797425,0.00014211885,0.00011944736,0.00037069875,0.0007048098,0.00021860904,0.00003426999,0.00066253264,0.0000020153152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1214075,0.010486069,0.8525661,0.00008161877,0.0021844825,0.0011496273,0.0021227691,0.00002581072,0.00001934498,0.0000071894847,0.000023326955,0.009926107],"study_design_scores_gemma":[0.07481454,0.27270907,0.6482459,0.0003100589,0.0008839668,0.000067256886,0.0024592902,0.000021197102,0.000040246876,0.0000018116111,0.00031177193,0.00013488907],"about_ca_topic_score_codex":0.0007308767,"about_ca_topic_score_gemma":0.009980572,"teacher_disagreement_score":0.262223,"about_ca_system_score_codex":0.000646044,"about_ca_system_score_gemma":0.0030781536,"threshold_uncertainty_score":0.5795438},"labels":[],"label_agreement":null},{"id":"W2921510308","doi":"10.1200/jco.2019.37.7_suppl.295","title":"A survey to determine patients’ (pts) opinions of a clinical trial (CT) comparing intermittent (int) versus continuous (cont) androgen receptor signaling inhibitor (ARSi) therapy for the treatment of advanced prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Quality of life (healthcare); Abiraterone acetate; Randomized controlled trial; Cancer; Clinical trial; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.28283184826699775,"score_gpt":0.5139859629778228,"score_spread":0.2311541147108251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921510308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862674,0.0021668621,0.000012015993,0.0013003434,0.00590654,0.004170172,0.0001297548,0.0000060563757,0.00004087648],"genre_scores_gemma":[0.9889141,0.008859309,0.00051684823,0.00014380403,0.0010934959,0.00014875669,0.00003992645,0.000030367655,0.00025339224],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99412477,0.0007643647,0.003955852,0.00033385438,0.00045445742,0.00036671766],"domain_scores_gemma":[0.98478097,0.010554991,0.002625527,0.0003218786,0.0013286959,0.00038796995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038685051,0.00023230459,0.0028635329,0.00012546832,0.000052501957,0.000010414067,0.00026687773,0.00018236235,0.00008118472],"category_scores_gemma":[0.0027709925,0.00012663305,0.0010902936,0.00017790572,0.00025966883,0.0000781399,0.000059278158,0.00043879487,0.0000045295233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3948763,0.0044625425,0.26250625,0.000028452243,0.0012191758,0.000010579584,0.0002519492,0.000031098643,0.00015977667,0.0000013732039,0.000626589,0.33582592],"study_design_scores_gemma":[0.47184297,0.30414075,0.16481744,0.00042714618,0.00045443603,0.0000048777915,0.00034961835,0.00018353977,0.0026576067,0.000008129797,0.054949764,0.00016372683],"about_ca_topic_score_codex":0.0001611729,"about_ca_topic_score_gemma":0.00022534138,"teacher_disagreement_score":0.3356622,"about_ca_system_score_codex":0.00034256055,"about_ca_system_score_gemma":0.0019814128,"threshold_uncertainty_score":0.5163946},"labels":[],"label_agreement":null},{"id":"W2921510652","doi":"10.1200/jco.2019.37.7_suppl.476","title":"Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Atezolizumab; Medicine; Internal medicine; Proportional hazards model; Oncology; Avelumab; Hazard ratio; Metastatic Urothelial Carcinoma; Cancer; Confidence interval; Immunotherapy; Urothelial carcinoma; Bladder cancer; Nivolumab","score_opus":0.08776305482482193,"score_gpt":0.3905054433023566,"score_spread":0.30274238847753465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921510652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518144,0.000051413863,0.00065811694,0.0006326229,0.0016156276,0.0013007584,0.00024152863,0.000011081255,0.00030740217],"genre_scores_gemma":[0.996084,0.000027854705,0.0025960023,0.0003116203,0.00045370075,0.000027954207,0.000032651424,0.000052498894,0.0004137416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603105,0.00037659364,0.0022697668,0.00030876216,0.00065976253,0.00035405045],"domain_scores_gemma":[0.9932871,0.0027736716,0.0019746528,0.00024660045,0.0013441631,0.0003738268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079759874,0.00028612715,0.0022370266,0.00014560173,0.00003880512,0.000011121168,0.00018189273,0.0002466591,0.00017321663],"category_scores_gemma":[0.0024516063,0.00017377388,0.00056401396,0.00010959414,0.00012859875,0.00013503348,0.00005148184,0.000589549,0.000009297102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028276702,0.0047408002,0.95001507,0.00027220257,0.0013171873,0.000057986013,0.00049591606,0.00015080486,0.0007113018,0.000021121557,0.0003226334,0.013618275],"study_design_scores_gemma":[0.044106223,0.055564158,0.89242613,0.00037350133,0.0022608638,0.00003714561,0.00017213801,0.0031606532,0.0010321027,0.00013767579,0.00047746373,0.00025192925],"about_ca_topic_score_codex":0.00003461966,"about_ca_topic_score_gemma":0.00004772485,"teacher_disagreement_score":0.057588924,"about_ca_system_score_codex":0.00019324539,"about_ca_system_score_gemma":0.0019530933,"threshold_uncertainty_score":0.7086293},"labels":[],"label_agreement":null},{"id":"W2921550149","doi":"10.1200/jco.2019.37.7_suppl.270","title":"Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive prostate cancer (mCSPC): A single institution experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Toxicity; Internal medicine; Febrile neutropenia; Neutropenia; Androgen deprivation therapy; Oncology; Surgery; Cancer; Urology","score_opus":0.2666221390067654,"score_gpt":0.5529440095559734,"score_spread":0.28632187054920805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921550149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930947,0.0014160555,0.00006624151,0.0034643991,0.00043052304,0.0010494106,0.000015932848,0.0000023074901,0.00046042597],"genre_scores_gemma":[0.99285424,0.0057185,0.0006794,0.00011674324,0.00019195379,0.000024235294,0.0000017425144,0.00000787977,0.0004053059],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980046,0.00028665093,0.0011165154,0.0001443953,0.0002601613,0.00018767022],"domain_scores_gemma":[0.9942539,0.0037623164,0.0012220935,0.00014981588,0.00050077745,0.00011110376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013628723,0.00011452853,0.0009713059,0.0000708878,0.000071934584,0.000014244293,0.00007150738,0.000066964356,0.00002107059],"category_scores_gemma":[0.0004322504,0.00004856338,0.0002399744,0.00015865268,0.0006409639,0.00013006583,0.000019456433,0.00022231838,5.148036e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03443048,0.010799802,0.16794488,0.00041620745,0.0043717367,0.0003475971,0.013600917,0.0005752501,0.055474482,0.00042232315,0.00022230252,0.711394],"study_design_scores_gemma":[0.05503511,0.07700723,0.7386952,0.0009926152,0.0034593935,0.00023846088,0.009392665,0.0021191277,0.098129936,0.00037024918,0.014330273,0.000229741],"about_ca_topic_score_codex":0.00019182096,"about_ca_topic_score_gemma":0.00016648197,"teacher_disagreement_score":0.7111643,"about_ca_system_score_codex":0.00022825674,"about_ca_system_score_gemma":0.0014531541,"threshold_uncertainty_score":0.2577833},"labels":[],"label_agreement":null},{"id":"W2921560039","doi":"10.1200/jco.2019.37.7_suppl.350","title":"Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Bladder cancer; Cohort; Pembrolizumab; Cystectomy; Internal medicine; Clinical endpoint; Urology; Cancer; Carcinoma in situ; Discontinuation; Surgery; Oncology; Clinical trial; Immunotherapy","score_opus":0.062360026302152996,"score_gpt":0.43040390942938983,"score_spread":0.36804388312723685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921560039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895701,0.00014043956,0.00024068722,0.0030058874,0.003158997,0.0027241223,0.00032946488,0.0000116581,0.0008186488],"genre_scores_gemma":[0.9903524,0.00045411327,0.0028819956,0.0032576504,0.0017268655,0.00010470829,0.000018443649,0.00006514227,0.0011386701],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493366,0.000564933,0.002711474,0.0004928549,0.0007848264,0.0005122632],"domain_scores_gemma":[0.99080676,0.0034925833,0.0027379205,0.00045385645,0.0017721516,0.0007367225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014236342,0.0003647257,0.0027460842,0.0002839592,0.00009568948,0.000010477342,0.00030575535,0.0005050846,0.0006428751],"category_scores_gemma":[0.0039064893,0.00024379592,0.00076417666,0.00028991533,0.00020609098,0.00017219683,0.00011079801,0.0008565728,0.000038009446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75362325,0.013118501,0.017988894,0.00008671405,0.0026422332,0.00015139759,0.00050031586,0.00013464759,0.00035575664,0.00003229703,0.007799536,0.20356648],"study_design_scores_gemma":[0.506713,0.41101906,0.03451626,0.0002494832,0.002183591,0.00003710814,0.00013033205,0.000018305087,0.0010736247,0.00013848254,0.043663684,0.00025710423],"about_ca_topic_score_codex":0.00046593693,"about_ca_topic_score_gemma":0.0003901718,"teacher_disagreement_score":0.39790055,"about_ca_system_score_codex":0.0004654258,"about_ca_system_score_gemma":0.0051557655,"threshold_uncertainty_score":0.9941709},"labels":[],"label_agreement":null},{"id":"W2921577079","doi":"10.1200/jco.2019.37.7_suppl.531","title":"Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Germ cell tumors; Rhabdomyosarcoma; Sarcoma; Malignancy; Mediastinum; Neuroblastoma; Internal medicine; Chemotherapy; Oncology; Radiology; Surgery; Pathology","score_opus":0.03462674166731124,"score_gpt":0.3872642208955436,"score_spread":0.35263747922823235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921577079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942938,0.0021616723,0.000008695664,0.0007136532,0.00048407813,0.00035403506,0.000018665834,0.000013813813,0.0019516003],"genre_scores_gemma":[0.9938261,0.00022160664,0.0039340504,0.0012639837,0.00021268347,0.000002952621,0.000011379583,0.000028903016,0.00049833866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955707,0.0005241888,0.002823246,0.00027372263,0.0005274285,0.00028070598],"domain_scores_gemma":[0.9882765,0.0067373016,0.0037763868,0.00023198433,0.00037148327,0.00060637214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019587488,0.0002408631,0.0028406654,0.00011534081,0.000029933637,0.000009094286,0.00015233034,0.00040321617,0.00017381497],"category_scores_gemma":[0.003792425,0.00014386991,0.0006620445,0.00010327601,0.00034751976,0.00009709306,0.000076238466,0.00095903006,0.000014690631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018484475,0.004300678,0.964662,0.00021156254,0.0010911055,0.0020414519,0.000047364534,0.0000017244914,0.000039056406,0.000012309803,0.0006658833,0.025078375],"study_design_scores_gemma":[0.017138895,0.015896995,0.963006,0.0006115489,0.0017179056,0.0011095075,0.00009376793,0.00001974911,0.000022411523,0.00012117851,0.00013293063,0.0001291084],"about_ca_topic_score_codex":0.000007817128,"about_ca_topic_score_gemma":0.0000100987345,"teacher_disagreement_score":0.024949266,"about_ca_system_score_codex":0.00008407425,"about_ca_system_score_gemma":0.0028532424,"threshold_uncertainty_score":0.58668447},"labels":[],"label_agreement":null},{"id":"W2921579584","doi":"10.1200/jco.2019.37.7_suppl.526","title":"Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Cohort; Oncology; Internal medicine; Stage (stratigraphy); Chemotherapy","score_opus":0.05841168889898268,"score_gpt":0.3936973225472163,"score_spread":0.3352856336482336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921579584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987622,0.00011835737,0.0000042956653,0.00025095444,0.00017830689,0.0002836529,0.00000330671,0.0000016382647,0.00039729278],"genre_scores_gemma":[0.9966954,0.000068629364,0.0029805778,0.00014045,0.000036391903,0.000002730646,0.000002286768,0.000009279381,0.00006426046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979436,0.00025273376,0.0012679409,0.00012418715,0.0002986896,0.00011284581],"domain_scores_gemma":[0.9965927,0.0014677619,0.0014907141,0.00011614315,0.00018923188,0.0001434428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009282393,0.00009070244,0.0009637744,0.000113881964,0.000008352167,0.0000041460867,0.000049344388,0.00008209334,0.00009018295],"category_scores_gemma":[0.00039557304,0.00005304049,0.00011290658,0.00006735249,0.000055181765,0.000096317635,0.000024391074,0.00029633852,0.000006696427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032497286,0.0039487137,0.98582,0.000049208767,0.00007507395,0.0001543141,0.00010068092,0.000014468209,0.00018650644,0.0000049372857,0.00007076077,0.006325614],"study_design_scores_gemma":[0.020880839,0.01574201,0.958417,0.00018864774,0.0001797174,0.000013020598,0.00007273446,0.0000150191245,0.0034355796,0.000022589182,0.0009860004,0.000046859746],"about_ca_topic_score_codex":0.000016920241,"about_ca_topic_score_gemma":0.0000046038117,"teacher_disagreement_score":0.02740301,"about_ca_system_score_codex":0.000053223124,"about_ca_system_score_gemma":0.00026177044,"threshold_uncertainty_score":0.21629284},"labels":[],"label_agreement":null},{"id":"W2921604675","doi":"10.1200/jco.2019.37.7_suppl.422","title":"Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Pembrolizumab; Adverse effect; Concomitant; Common Terminology Criteria for Adverse Events; Internal medicine; Randomized controlled trial; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical trial; Surgery; Phases of clinical research; Cancer; Immunotherapy","score_opus":0.12270569597161524,"score_gpt":0.4737296795899862,"score_spread":0.35102398361837095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921604675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990898,0.00093858683,0.00013717978,0.0029800013,0.0019325276,0.0016984259,0.000036256566,0.0000050837257,0.001373925],"genre_scores_gemma":[0.99533266,0.0011096884,0.002122207,0.0004695387,0.0008197997,0.000013275198,0.000006570188,0.000026908436,0.000099332676],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920888,0.0020013952,0.0047863163,0.0003234107,0.00055419223,0.00024589375],"domain_scores_gemma":[0.986608,0.010231771,0.002274106,0.00024792596,0.0002953506,0.00034281518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006419094,0.00023597559,0.004380251,0.00019233799,0.000019214816,0.000009182362,0.00013003567,0.00027246692,0.00014357328],"category_scores_gemma":[0.0020711352,0.00014251788,0.00075738045,0.00013643166,0.0006222965,0.00013799946,0.000013569963,0.00094148156,0.0000034101608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.956468,0.00482138,0.020757329,0.000038154634,0.0018477441,0.00055112917,0.00021847388,0.000007212293,0.000039225615,0.00010218964,0.00006966361,0.015079529],"study_design_scores_gemma":[0.8799072,0.089394055,0.025889384,0.00009491017,0.0017469547,0.00027641596,0.00006420865,0.00050898234,0.000021992804,0.00012682694,0.0018546113,0.00011447701],"about_ca_topic_score_codex":0.000064564745,"about_ca_topic_score_gemma":0.000036148595,"teacher_disagreement_score":0.08457267,"about_ca_system_score_codex":0.00007329284,"about_ca_system_score_gemma":0.0036296498,"threshold_uncertainty_score":0.6438843},"labels":[],"label_agreement":null},{"id":"W2921617928","doi":"10.1200/jco.2015.33.15_suppl.3538","title":"Population-based assessment of surrogate endpoints (SE) in stage I-III colon (CCa) and rectal cancers (RCa).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Stage (stratigraphy); Proportional hazards model; Surrogate endpoint; Population; Oncology; Multivariate analysis; Surgery; Cancer; Gastroenterology; Confidence interval","score_opus":0.2045610785715725,"score_gpt":0.5339820698945421,"score_spread":0.32942099132296965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921617928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923152,0.00048548172,0.000015590176,0.0022282917,0.00074558373,0.00020261151,0.0000086136815,0.0000038730846,0.0039947648],"genre_scores_gemma":[0.997319,0.00032690153,0.0015784734,0.00038981115,0.00018079084,0.000005342707,0.0000036809001,0.000008104467,0.0001879284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976026,0.00027449967,0.0014968321,0.0001453515,0.00032461932,0.00015611754],"domain_scores_gemma":[0.9970949,0.001100299,0.0011232132,0.00008953638,0.00033724128,0.0002547964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021861945,0.00010870849,0.0013696776,0.00012677496,0.000020279404,0.0000037494015,0.00005431,0.00016197398,0.000055309618],"category_scores_gemma":[0.0012069708,0.00007714793,0.00016555659,0.0001235379,0.00013069667,0.00006105352,0.000033039683,0.0004098462,4.908988e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060854936,0.00073962257,0.9702932,0.00003246106,0.0002229278,0.00035152253,0.00020880392,0.00017545026,0.00003313998,0.000041846568,0.00046660483,0.021348879],"study_design_scores_gemma":[0.01653655,0.016091852,0.96133,0.00011362351,0.00017332897,0.000027071104,0.0004073023,0.0006050854,0.000037064066,0.000089220295,0.0045239087,0.00006499023],"about_ca_topic_score_codex":0.0013282214,"about_ca_topic_score_gemma":0.0047546923,"teacher_disagreement_score":0.021283887,"about_ca_system_score_codex":0.0008285461,"about_ca_system_score_gemma":0.0027405876,"threshold_uncertainty_score":0.48616844},"labels":[],"label_agreement":null},{"id":"W2921618481","doi":"10.1200/jco.2015.33.15_suppl.e16087","title":"Evaluation of a genomic classifier in primary tumor and lymph node metastases in pre- and post-radical prostatectomy tissue specimens from patients with lymph node positive prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Concordance; Lymph node; Prostate; Biopsy; Biochemical recurrence; Stage (stratigraphy); Cancer; Lymph; Metastasis; Internal medicine; Pathology; Oncology; Urology","score_opus":0.0833392777891157,"score_gpt":0.43414709949767055,"score_spread":0.35080782170855485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921618481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929993,0.0035811763,0.0000030293768,0.0018489676,0.00013675334,0.0010206937,0.00014622955,0.0000028598304,0.00026097748],"genre_scores_gemma":[0.99699163,0.0008314539,0.0014831972,0.00041662922,0.00013005316,0.0000380917,0.00004999842,0.00001973394,0.00003923344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963238,0.0008444568,0.0013973461,0.00029672906,0.0008658692,0.00027177602],"domain_scores_gemma":[0.9967007,0.0007596264,0.0008712463,0.00012311939,0.0011559626,0.00038936455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003586248,0.00017170284,0.0012358958,0.00023857472,0.000019376857,0.000011755395,0.00007651909,0.00015674692,0.000030935877],"category_scores_gemma":[0.0009977836,0.000109303706,0.000058882273,0.00015347391,0.0004687918,0.000185442,0.000076169614,0.00043578,0.0000013099637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034344718,0.0019634955,0.9007173,0.000054981032,0.00037775826,0.00041379282,0.0009077522,0.000048447033,0.0017140682,0.0000025253537,0.00004622703,0.05940894],"study_design_scores_gemma":[0.055306073,0.00595228,0.93642175,0.0004028738,0.0005882224,0.000052618812,0.00018790198,0.00021893583,0.00043684087,0.00018750901,0.00014398943,0.00010100418],"about_ca_topic_score_codex":0.0006920997,"about_ca_topic_score_gemma":0.00015854478,"teacher_disagreement_score":0.059307937,"about_ca_system_score_codex":0.0011945133,"about_ca_system_score_gemma":0.0062439684,"threshold_uncertainty_score":0.9993897},"labels":[],"label_agreement":null},{"id":"W2921633401","doi":"10.1200/jco.2019.37.7_suppl.543","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Clinical endpoint; Temsirolimus; Internal medicine; Interim analysis; Oncology; Tolerability; Discontinuation; Phases of clinical research; Adverse effect; Clinical trial; Discovery and development of mTOR inhibitors","score_opus":0.18107808368130654,"score_gpt":0.4758328862607582,"score_spread":0.29475480257945164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921633401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851268,0.0012189483,0.0005174337,0.0022399013,0.0027757033,0.0040483824,0.000032148087,0.000036293823,0.0040044216],"genre_scores_gemma":[0.9875417,0.0007443691,0.005289016,0.001530843,0.0014370432,0.000116930314,0.000043263783,0.00011740878,0.0031794747],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915118,0.00091721007,0.0048712855,0.00075317355,0.0010992417,0.0008472748],"domain_scores_gemma":[0.98258334,0.010588487,0.003500069,0.00080217986,0.0014404815,0.0010854414],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036320197,0.00064433133,0.004251489,0.00036288076,0.00014693946,0.000034597666,0.00056835153,0.00047020148,0.0014783089],"category_scores_gemma":[0.002799318,0.00042208994,0.0015347587,0.00035094333,0.00026999385,0.0002513223,0.00012232002,0.0015561869,0.00014684061],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8223227,0.02268683,0.0026367484,0.00020816662,0.0020886862,0.008010604,0.00072427717,0.0004652753,0.0011169764,0.00005048183,0.0017833856,0.13790585],"study_design_scores_gemma":[0.4989007,0.43980372,0.010102744,0.00014698206,0.002044996,0.0010082399,0.0014127211,0.0006297932,0.0023370658,0.000115238494,0.043068238,0.00042956395],"about_ca_topic_score_codex":0.00006768928,"about_ca_topic_score_gemma":0.0001275808,"teacher_disagreement_score":0.41711688,"about_ca_system_score_codex":0.00075595506,"about_ca_system_score_gemma":0.00631843,"threshold_uncertainty_score":0.9998231},"labels":[],"label_agreement":null},{"id":"W2921680685","doi":"10.1200/jco.2019.37.7_suppl.230","title":"Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"GDF15 and Related Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; GDF15; Oncology; Prostate cancer; Internal medicine; Cohort; Proportional hazards model; Chemotherapy; Cancer; Cytokine; Biomarker","score_opus":0.07299526728642265,"score_gpt":0.45398563281952786,"score_spread":0.3809903655331052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921680685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936408,0.00016847372,0.0000071816926,0.004774385,0.00018342154,0.0006407563,0.0000044977,0.0000027038027,0.0005778146],"genre_scores_gemma":[0.99455446,0.0003260581,0.004753882,0.00017816482,0.000054730186,0.000005911843,0.0000015569844,0.000012062427,0.00011318646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951959,0.0009851446,0.0030879013,0.00019755655,0.00037294143,0.00016054173],"domain_scores_gemma":[0.9937566,0.003058446,0.0022848963,0.00012438913,0.0005451642,0.00023053396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008095364,0.00011655639,0.0013615789,0.00022272007,0.000013875316,0.0000059459203,0.000075902375,0.00020853356,0.000041040923],"category_scores_gemma":[0.0033217664,0.00007358137,0.00018899863,0.00030563693,0.00020618197,0.00011089877,0.000021751699,0.000473702,0.0000016033972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.109527536,0.0008335612,0.8515429,0.00019585271,0.0007490281,0.00026805722,0.0003691468,0.00020758883,0.01701586,0.000009970464,0.00010119272,0.019179298],"study_design_scores_gemma":[0.01227695,0.02785804,0.95507365,0.0009499643,0.0005913402,0.00018438455,0.0012246891,0.00023038937,0.0010641237,0.000044303666,0.00041637194,0.00008578957],"about_ca_topic_score_codex":0.00012628047,"about_ca_topic_score_gemma":0.00005462141,"teacher_disagreement_score":0.10353075,"about_ca_system_score_codex":0.00007463738,"about_ca_system_score_gemma":0.0020690039,"threshold_uncertainty_score":0.39767048},"labels":[],"label_agreement":null},{"id":"W2921684231","doi":"10.1200/jco.2019.37.7_suppl.257","title":"Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Glucuronidation; Metabolite; Pharmacokinetics; Prostate cancer; ADME; Medicine; Androgen receptor; Pharmacology; Sulfation; Internal medicine; Endocrinology; Chemistry; Cancer; In vitro; Biochemistry; Microsome","score_opus":0.29043854511582246,"score_gpt":0.5270321079671706,"score_spread":0.23659356285134814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921684231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95856166,0.0012270665,0.000019485808,0.037436157,0.0015026226,0.0009868799,0.00012718858,0.000004159119,0.000134791],"genre_scores_gemma":[0.99215066,0.003072368,0.0013803421,0.0003464173,0.0022048645,0.000031202144,0.000054568944,0.00001870996,0.00074087776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619144,0.00076543307,0.0019878917,0.00023245598,0.000583989,0.00023880709],"domain_scores_gemma":[0.99552774,0.0018890515,0.0016105496,0.00023282108,0.0005005827,0.00023926889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030888596,0.00014971543,0.001178073,0.00007702684,0.00008074673,0.000020889167,0.00015424633,0.00017786384,0.0005830947],"category_scores_gemma":[0.0010083437,0.000081699225,0.00041853831,0.00016062267,0.00024590746,0.00013723648,0.000035307887,0.00068047486,0.000019285526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63203204,0.008037,0.009961429,0.0001262957,0.0026594705,0.00089623366,0.0021344482,0.000076420445,0.07068568,0.00014239282,0.0156065915,0.257642],"study_design_scores_gemma":[0.6591784,0.10862983,0.007023304,0.00073362334,0.0022532186,0.00014785687,0.0016914887,0.0005465347,0.01885452,0.0015627525,0.19903141,0.00034709097],"about_ca_topic_score_codex":0.00017334033,"about_ca_topic_score_gemma":0.00037980446,"teacher_disagreement_score":0.25729492,"about_ca_system_score_codex":0.00022055823,"about_ca_system_score_gemma":0.0034080835,"threshold_uncertainty_score":0.6384478},"labels":[],"label_agreement":null},{"id":"W2921696120","doi":"10.1200/jco.2019.37.7_suppl.479","title":"Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Durvalumab; Histology; Nivolumab; Atezolizumab; Internal medicine; Oncology; Urothelial carcinoma; Urology; Bladder cancer; Cancer; Immunotherapy","score_opus":0.09284589838312211,"score_gpt":0.43653079119132965,"score_spread":0.3436848928082075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921696120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929154,0.0003745029,0.000012471311,0.0020849372,0.0023539774,0.00048144886,0.000019675013,0.0000083272,0.0017492564],"genre_scores_gemma":[0.9981375,0.00006608164,0.00068700715,0.0002432022,0.00045877046,0.000011279491,0.000002903217,0.000037325855,0.00035594485],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99526143,0.0010275713,0.0026335127,0.00026340567,0.0004921412,0.00032191165],"domain_scores_gemma":[0.9929159,0.0034980124,0.0023597085,0.0003865414,0.00046675146,0.0003730854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002690626,0.00025998204,0.0024100025,0.0002663141,0.000026587562,0.0000043409773,0.00019137512,0.00032000782,0.0005935062],"category_scores_gemma":[0.0026534228,0.00015257139,0.0012257458,0.00018783276,0.00029205545,0.00007971084,0.000038474165,0.001010037,0.00005706601],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8231644,0.00451406,0.13568015,0.00006333085,0.0032594923,0.0019074923,0.00028160578,0.00008201652,0.0046693604,0.000039129154,0.0015087521,0.024830196],"study_design_scores_gemma":[0.051590376,0.1968664,0.7432182,0.00012785077,0.0013518397,0.0007766428,0.00015518055,0.000014267327,0.0025505137,0.000048099857,0.0031554217,0.00014520698],"about_ca_topic_score_codex":0.000112499736,"about_ca_topic_score_gemma":0.000029378265,"teacher_disagreement_score":0.771574,"about_ca_system_score_codex":0.00056682737,"about_ca_system_score_gemma":0.0046003843,"threshold_uncertainty_score":0.81608844},"labels":[],"label_agreement":null},{"id":"W2921697223","doi":"10.1200/jco.2019.37.7_suppl.564","title":"Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Discontinuation; Nivolumab; Internal medicine; Ipilimumab; Sunitinib; Gastroenterology; Oncology; Cancer; Immunotherapy","score_opus":0.04489977160114744,"score_gpt":0.33908855315619607,"score_spread":0.29418878155504863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921697223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957492,0.00035530093,0.0000786308,0.00067813427,0.0005750011,0.0012395668,0.00012826629,0.000011629533,0.0011843173],"genre_scores_gemma":[0.9948697,0.00060131855,0.0030004745,0.000113781105,0.00025551402,0.00003915388,0.00009136193,0.00005978834,0.00096888334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945621,0.0006947924,0.0029708997,0.0005981221,0.0006976115,0.00047646937],"domain_scores_gemma":[0.99339193,0.0021934428,0.0024043955,0.00067480013,0.00078495935,0.000550481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001024258,0.00046281476,0.0026997877,0.00037782325,0.000048394875,0.000020555406,0.00026651032,0.00039156622,0.00029007866],"category_scores_gemma":[0.0009805594,0.00028765734,0.00044407844,0.00030749998,0.00021758574,0.00030900622,0.00016040257,0.0007105575,0.000027059908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092349924,0.0042410595,0.85399425,0.000089481044,0.00027644594,0.0007612077,0.0006160687,0.0001238681,0.00024017264,0.0000030507938,0.000046330348,0.047258127],"study_design_scores_gemma":[0.09520158,0.07641,0.82371455,0.00039507102,0.0009608326,0.000060778053,0.0005833078,0.00021540002,0.0015137864,0.00006429318,0.00063781015,0.00024256714],"about_ca_topic_score_codex":0.0014424104,"about_ca_topic_score_gemma":0.0071626888,"teacher_disagreement_score":0.07216894,"about_ca_system_score_codex":0.0009620906,"about_ca_system_score_gemma":0.0009861541,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W2921709383","doi":"10.1200/jco.2019.37.7_suppl.141","title":"Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Clinical endpoint; Hypokalemia; Interim analysis; Internal medicine; Adverse effect; Placebo; Prostate cancer; MedDRA; Hazard ratio; Gastroenterology; Urology; Androgen deprivation therapy; Confidence interval; Randomized controlled trial; Cancer","score_opus":0.09064761430012958,"score_gpt":0.4504710675112411,"score_spread":0.35982345321111153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921709383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961986,0.00016708396,0.000081479084,0.0005979964,0.000086308646,0.002762785,0.000076849465,0.000008339737,0.000020535663],"genre_scores_gemma":[0.99684465,0.00086007424,0.0016770383,0.00015837503,0.000059237344,0.00010702343,0.000082785264,0.000028020288,0.00018279832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99573785,0.0006932171,0.002038398,0.00039882638,0.00078458333,0.00034711964],"domain_scores_gemma":[0.99566823,0.0007195802,0.0019116438,0.0003051775,0.0010645407,0.0003308463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152631,0.00026428443,0.0022218588,0.00062363694,0.000046004847,0.000020219517,0.00015846684,0.0001232518,0.00020290271],"category_scores_gemma":[0.00022488507,0.00015009409,0.00019492769,0.0012688172,0.00012799642,0.00024343946,0.000029422754,0.0005479136,0.000004883815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09742198,0.011279521,0.8231933,0.000021558266,0.007680543,0.00035547308,0.0014655304,0.0051927576,0.00021097748,0.0000010388029,0.00004108997,0.05313621],"study_design_scores_gemma":[0.14779305,0.08713059,0.7605113,0.000107178384,0.0029653588,0.0000044378285,0.00036603643,0.0004686681,0.00046450653,0.000006752533,0.000058137834,0.0001240153],"about_ca_topic_score_codex":0.0014958337,"about_ca_topic_score_gemma":0.0043185856,"teacher_disagreement_score":0.07585107,"about_ca_system_score_codex":0.0003313106,"about_ca_system_score_gemma":0.0014416262,"threshold_uncertainty_score":0.6120659},"labels":[],"label_agreement":null},{"id":"W2921712318","doi":"10.1200/jco.2019.37.7_suppl.584","title":"First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University; University of Manitoba; Princess Margaret Cancer Centre; Sunnybrook Hospital; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Hazard ratio; Internal medicine; Ipilimumab; Proportional hazards model; Oncology; Cohort; Urology; Gastroenterology; Cancer; Confidence interval; Immunotherapy","score_opus":0.0989817461027572,"score_gpt":0.381779474156885,"score_spread":0.28279772805412784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921712318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96882623,0.0034120716,0.00015315713,0.019649485,0.0027691075,0.0012159502,0.00023322455,0.000017336793,0.0037234446],"genre_scores_gemma":[0.9874669,0.000848391,0.0069088717,0.0024175004,0.0007789444,0.000039431252,0.00042112617,0.00006389843,0.0010549686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98931843,0.0023764165,0.005645642,0.0007775091,0.0012552353,0.0006267483],"domain_scores_gemma":[0.9770813,0.016058855,0.004521118,0.0009705005,0.0009126462,0.000455553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0070510814,0.00054738513,0.0026667318,0.0004424479,0.00011373654,0.00004723971,0.0009731552,0.00040258863,0.0006943774],"category_scores_gemma":[0.002732674,0.0003569313,0.0008965581,0.00035457866,0.0004991228,0.00039359822,0.00036883538,0.0022257369,0.00014921965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3036205,0.048964534,0.44386512,0.00060423184,0.005045006,0.03786116,0.009705989,0.0028029254,0.045810986,0.00042118205,0.05286219,0.048436195],"study_design_scores_gemma":[0.10075267,0.07352669,0.7511491,0.00036903354,0.003141749,0.0015767675,0.0025730608,0.004513397,0.010982009,0.0010774136,0.049714625,0.0006234747],"about_ca_topic_score_codex":0.0008670004,"about_ca_topic_score_gemma":0.0004964535,"teacher_disagreement_score":0.307284,"about_ca_system_score_codex":0.0010776041,"about_ca_system_score_gemma":0.003198857,"threshold_uncertainty_score":0.99988824},"labels":[],"label_agreement":null},{"id":"W2921718523","doi":"10.1200/jco.2015.33.15_suppl.6582","title":"Association between Oncologic Drugs Advisory Committee (ODAC) members’ financial conflicts of interest (FCOIs) and recommendations for drug approval by the U.S. Food and Drug Administration (FDA).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Waiver; Voting; Drug; Family medicine; Food and drug administration; Advisory committee; Conflict of interest; Pharmacology; Political science; Law; Public administration","score_opus":0.6928399515032594,"score_gpt":0.608665257823911,"score_spread":0.08417469367934838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921718523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8443048,0.000877857,0.00005780559,0.15095991,0.0019453369,0.0005824901,0.00023356358,0.00001240327,0.0010258417],"genre_scores_gemma":[0.9893559,0.00081526645,0.00043036952,0.00734224,0.0013641893,0.000027664493,0.000036878988,0.000013907964,0.00061354664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99360955,0.00323689,0.0023228347,0.0002476445,0.00021368028,0.00036941725],"domain_scores_gemma":[0.9805024,0.015142912,0.0027467485,0.00011750142,0.0007398077,0.0007506039],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015767416,0.00020472932,0.0010774537,0.00007618763,0.0002467008,0.000020794112,0.00031353824,0.001152847,0.000079541824],"category_scores_gemma":[0.0070271366,0.00015391501,0.00021135069,0.00012777178,0.000527225,0.0002274105,0.000117520794,0.0032557163,0.0000030001463],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005941132,0.002090604,0.10224799,0.00016913166,0.0011959412,0.0000143676525,0.004096337,0.000014402728,0.00016240549,0.00349734,0.654089,0.22648138],"study_design_scores_gemma":[0.009323394,0.006023841,0.007619583,0.000037699327,0.00094299234,0.00003705081,0.0018558509,0.00019590465,0.0012425126,0.0042566783,0.9682755,0.00018898505],"about_ca_topic_score_codex":0.000020811925,"about_ca_topic_score_gemma":0.000217659,"teacher_disagreement_score":0.31418654,"about_ca_system_score_codex":0.00021795576,"about_ca_system_score_gemma":0.0013053365,"threshold_uncertainty_score":0.9990438},"labels":[],"label_agreement":null},{"id":"W2921738033","doi":"10.1200/jco.2019.37.7_suppl.518","title":"Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Immature teratoma; Germ cell tumors; Mediastinum; Malignancy; Proportional hazards model; Internal medicine; Chemotherapy; Oncology; Surgery; Radiology","score_opus":0.0369654525681171,"score_gpt":0.41601554658198664,"score_spread":0.3790500940138695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921738033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942704,0.0032014393,0.000003942558,0.00090410776,0.00081025116,0.000243969,0.000013273267,0.000006745395,0.0005458835],"genre_scores_gemma":[0.9922517,0.0003209355,0.005706227,0.0012686928,0.0002077378,0.0000013366998,0.0000039696647,0.000019126206,0.0002202986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958125,0.0004957243,0.002973798,0.0002479684,0.00026944428,0.00020061679],"domain_scores_gemma":[0.9926736,0.004259601,0.0023352783,0.00022618481,0.00013510851,0.00037022456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013928621,0.00017325842,0.0022184248,0.00011492487,0.000016391858,0.000010621997,0.00011355522,0.0003269064,0.00019706418],"category_scores_gemma":[0.0022646817,0.00011321689,0.00059511035,0.00007504655,0.0001425995,0.000108224245,0.00007282571,0.0009604982,0.00002292085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011133546,0.002546356,0.96808165,0.000096047705,0.00039286105,0.0021277356,0.00007324662,0.0000038296425,0.00012624903,0.000015229515,0.00019477376,0.025228681],"study_design_scores_gemma":[0.016293952,0.004929437,0.9758316,0.0004402855,0.00068495853,0.00015478767,0.000074275944,0.00008415921,0.000046119578,0.0010617212,0.0003055585,0.000093104594],"about_ca_topic_score_codex":0.000037659975,"about_ca_topic_score_gemma":0.000025264293,"teacher_disagreement_score":0.025135577,"about_ca_system_score_codex":0.000049273156,"about_ca_system_score_gemma":0.0010660464,"threshold_uncertainty_score":0.4616851},"labels":[],"label_agreement":null},{"id":"W2921758445","doi":"10.1200/jco.2015.33.15_suppl.6592","title":"Nationwide utilization of cardiac imaging in patients undergoing cardiotoxic chemotherapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cardiotoxicity; Chemotherapy; Internal medicine; Breast cancer; Cancer; Oncology; Anthracycline; Acute leukemia; Trastuzumab; Metastatic breast cancer; Population; Prostate cancer; Leukemia","score_opus":0.12013701395829691,"score_gpt":0.4367872051822162,"score_spread":0.3166501912239193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921758445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207807,0.00039982045,0.0004162022,0.0014780891,0.001038895,0.00022877894,0.0000016051382,0.0000069274834,0.0043515945],"genre_scores_gemma":[0.9964966,0.0005364519,0.0013305886,0.0010083887,0.0005649891,0.0000014433865,0.0000058469795,0.000016252146,0.00003941785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715084,0.00037723352,0.0017147729,0.00013096438,0.00048528746,0.00014089714],"domain_scores_gemma":[0.996911,0.00066522846,0.001213064,0.0001395446,0.0008668722,0.0002042782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003465625,0.000099211175,0.0011015759,0.00021123284,0.000013389427,0.000004965981,0.0000820272,0.00023651325,0.000010307414],"category_scores_gemma":[0.0037267052,0.00008551482,0.00042256014,0.00023221837,0.00009387089,0.00017819699,0.000017062985,0.0004254946,0.0000022878194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014612615,0.000739235,0.74950105,0.000032638403,0.00018902429,0.000014704246,0.00037704618,0.00008514335,0.002257846,0.000055788125,0.0009425157,0.24434377],"study_design_scores_gemma":[0.017734388,0.0034586703,0.94863164,0.0002442765,0.00017198756,0.000031012736,0.00043667416,0.0001839933,0.016167792,0.0007889618,0.012030114,0.00012046382],"about_ca_topic_score_codex":0.000011577691,"about_ca_topic_score_gemma":0.000009005337,"teacher_disagreement_score":0.24422331,"about_ca_system_score_codex":0.0002905768,"about_ca_system_score_gemma":0.0016168605,"threshold_uncertainty_score":0.44614837},"labels":[],"label_agreement":null},{"id":"W2921789044","doi":"10.1200/jco.2019.37.7_suppl.544","title":"Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Renal cell carcinoma; Subgroup analysis; Axitinib; Sunitinib; Clinical endpoint; Temsirolimus; Progression-free survival; Discontinuation; Gastroenterology; Randomized controlled trial; Urology; Oncology; Confidence interval; Overall survival","score_opus":0.10929191523843512,"score_gpt":0.4221614423895783,"score_spread":0.3128695271511432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921789044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954993,0.00053650734,0.0003373502,0.0021766762,0.0018986736,0.00086835393,0.00007959809,0.000017182925,0.0045356946],"genre_scores_gemma":[0.98250264,0.0001319544,0.014189692,0.0008505139,0.00096633914,0.000029381517,0.00015482279,0.000056835324,0.0011178397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923727,0.00076433364,0.0046231537,0.000682748,0.0008490936,0.00070797553],"domain_scores_gemma":[0.9844004,0.010531139,0.0029111838,0.00068129716,0.0007358537,0.0007401602],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032796974,0.00046199668,0.0044992347,0.0007652632,0.00005540026,0.000023196124,0.0004567778,0.0007625954,0.00091704616],"category_scores_gemma":[0.0025376547,0.00034789785,0.0025385127,0.00060548534,0.00019195718,0.00020051909,0.00012485243,0.0015780819,0.00010859966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09443502,0.0035149725,0.852489,0.000097252385,0.0040497086,0.0031221695,0.00045101563,0.0010459853,0.0024500566,0.00010255429,0.001129042,0.037113238],"study_design_scores_gemma":[0.08759815,0.023977263,0.8703052,0.00008206948,0.0045490153,0.000055057033,0.00052803487,0.0009854176,0.0017345212,0.00018687906,0.00965213,0.00034625866],"about_ca_topic_score_codex":0.00026555164,"about_ca_topic_score_gemma":0.00071347924,"teacher_disagreement_score":0.03676698,"about_ca_system_score_codex":0.0009881693,"about_ca_system_score_gemma":0.0023275383,"threshold_uncertainty_score":0.99999624},"labels":[],"label_agreement":null},{"id":"W2921803816","doi":"10.1200/jco.2020.38.6_suppl.103","title":"KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Enzalutamide; Prednisone; Abiraterone; Cohort; Internal medicine; Prostate cancer; Cancer; Pembrolizumab; Pneumonitis; Oncology; Lung","score_opus":0.11685923084650794,"score_gpt":0.4364121771567669,"score_spread":0.31955294631025893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921803816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876145,0.0014814523,0.000014154622,0.008211198,0.00023168116,0.0015675153,0.00025899822,0.000029446715,0.0005910336],"genre_scores_gemma":[0.99152565,0.0045364015,0.0013154722,0.001281476,0.00023966076,0.0000615908,0.00009958024,0.0000615815,0.00087858207],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.993494,0.0008475886,0.0033934084,0.0006626846,0.0008953332,0.0007070287],"domain_scores_gemma":[0.9949008,0.0009056459,0.0018256682,0.00027782423,0.0010050444,0.0010849965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001780539,0.00043175952,0.0026775226,0.00021341362,0.000085377615,0.0000514178,0.00024009982,0.0003282896,0.00016235124],"category_scores_gemma":[0.0018694509,0.00024558097,0.00020087013,0.00069651264,0.0005684363,0.00032601517,0.00011214887,0.0015364357,0.000012172276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6849584,0.0033785307,0.26495233,0.0004556524,0.0027807788,0.010915934,0.0014961144,0.0003920473,0.0011535989,0.000008020219,0.0033988408,0.026109768],"study_design_scores_gemma":[0.25665095,0.083541915,0.642525,0.0009979522,0.0020809593,0.00035964954,0.00067619386,0.001691726,0.0012958518,0.000051135743,0.009611201,0.00051747647],"about_ca_topic_score_codex":0.00050061324,"about_ca_topic_score_gemma":0.0008771022,"teacher_disagreement_score":0.42830744,"about_ca_system_score_codex":0.00081391033,"about_ca_system_score_gemma":0.0050602416,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W2921821362","doi":"10.1200/jco.2019.37.7_suppl.217","title":"Immunogenomic landscape of neuroendocrine small cell prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Adenocarcinoma; Prostatectomy; Immunohistochemistry; Prostate; Chromogranin A; Pathology; Cancer; Cancer research; Oncology; Internal medicine","score_opus":0.09115831815454796,"score_gpt":0.45057301926428595,"score_spread":0.359414701109738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921821362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828105,0.005100687,0.0000013725071,0.00447517,0.0011577562,0.0003250721,0.000008322065,0.0000045617558,0.0061165416],"genre_scores_gemma":[0.98075324,0.012009863,0.00037910554,0.00045623299,0.0004321163,0.000003840107,0.0000034142872,0.000017521927,0.0059446404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763364,0.00019190315,0.0015294624,0.0001471204,0.00024427564,0.00025359026],"domain_scores_gemma":[0.9973183,0.00068247976,0.0011648779,0.00019224001,0.00040169683,0.00024037423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092127314,0.00010675451,0.0012049663,0.00011955151,0.000014996901,0.000004167717,0.00016460347,0.000090930465,0.00055036024],"category_scores_gemma":[0.0002507049,0.00006680971,0.00039387782,0.000121564415,0.00011192432,0.000049288537,0.00006507538,0.0007390655,0.000044880806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020141684,0.0019106376,0.88201404,0.00026047096,0.0004951587,0.001241646,0.000117801676,0.00005080667,0.015442589,0.000017318333,0.0037527839,0.07455507],"study_design_scores_gemma":[0.05424218,0.05647495,0.66783017,0.0003177043,0.0007043323,0.0007097615,0.00031309077,0.00015473337,0.017861327,0.00016881093,0.2010281,0.00019481685],"about_ca_topic_score_codex":0.00003783481,"about_ca_topic_score_gemma":0.000010434277,"teacher_disagreement_score":0.21418384,"about_ca_system_score_codex":0.000092818365,"about_ca_system_score_gemma":0.0023341458,"threshold_uncertainty_score":0.6026059},"labels":[],"label_agreement":null},{"id":"W2921854614","doi":"10.1200/jco.2019.37.7_suppl.521","title":"Patient-reported psychosocial distress in adolescents and young adults with germ cell tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Psychosocial; Medicine; Anxiety; Subclinical infection; Anger; Distress; Young adult; Depression (economics); Clinical psychology; Testicular Germ Cell Tumor; Psychiatry; Cancer; Testicular cancer; Internal medicine","score_opus":0.025820206544212347,"score_gpt":0.37942270807721257,"score_spread":0.3536025015330002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921854614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975447,0.00056919194,0.0000033686124,0.0003468576,0.00052190415,0.00027446417,0.000003149666,0.00000452087,0.000731852],"genre_scores_gemma":[0.9990517,0.00010992665,0.00026587615,0.0003314996,0.00017713016,0.0000020546747,0.0000033624815,0.000012058046,0.000046418514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980193,0.00012564166,0.0012400924,0.00017517613,0.00027515748,0.00016464212],"domain_scores_gemma":[0.99780947,0.00013347498,0.0014345003,0.0001234336,0.00016869788,0.00033040013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002907038,0.00011006117,0.0008451968,0.000058372287,0.000013470049,0.0000061117908,0.000044831,0.00015062708,0.000026999985],"category_scores_gemma":[0.00041686094,0.000069385365,0.00016457675,0.0000759491,0.00007781818,0.000058415924,0.00002226389,0.00042479532,0.000008282075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072667315,0.0036520457,0.9362075,0.000080452264,0.00010400507,0.0030812498,0.00008778108,0.0000012317454,0.000009128761,0.0000021156893,0.00007732996,0.049430437],"study_design_scores_gemma":[0.0217132,0.009680775,0.96650976,0.0008036173,0.00025400447,0.00042771507,0.00014222079,0.000023907904,0.000005833511,0.000024426909,0.0003476968,0.00006683398],"about_ca_topic_score_codex":0.000052952124,"about_ca_topic_score_gemma":0.000060597285,"teacher_disagreement_score":0.049363606,"about_ca_system_score_codex":0.000066084525,"about_ca_system_score_gemma":0.00047769136,"threshold_uncertainty_score":0.2829453},"labels":[],"label_agreement":null},{"id":"W2921863528","doi":"10.1200/jco.2019.37.7_suppl.7","title":"Hypofractionated, accelerated radiotherapy to the prostate bed: Five-year outcomes of a prospective phase I/II study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Barrie Urology Group; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Prospective cohort study; Urinary system; Surgery; Quality of life (healthcare); Toxicity; Urology; Internal medicine; Cancer","score_opus":0.09585297146166652,"score_gpt":0.49539008670381546,"score_spread":0.39953711524214897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921863528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97283685,0.00034056383,0.000012532766,0.023260301,0.0011216943,0.0019419058,0.000016215336,0.000008289242,0.00046162982],"genre_scores_gemma":[0.99420935,0.00069548417,0.0007011594,0.0030737203,0.00033624336,0.000045913155,0.000002195902,0.000019357476,0.00091659086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971767,0.00028733647,0.001710614,0.00022266919,0.00040643595,0.00019622907],"domain_scores_gemma":[0.9961061,0.001212347,0.0013775186,0.00026735125,0.00080127857,0.00023540943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017987398,0.00015679249,0.0015456314,0.00011385682,0.00005342781,0.0000094193865,0.00016421852,0.00013368542,0.00035110742],"category_scores_gemma":[0.0008831963,0.00008033768,0.00037570554,0.00024263166,0.000080621656,0.00013661396,0.00005012519,0.0006075633,0.0000304151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015166569,0.022907186,0.855357,0.000013740709,0.0028210091,0.00021498733,0.0014381682,0.000065604174,0.00026772197,0.00006261051,0.0051876865,0.09649773],"study_design_scores_gemma":[0.04446985,0.15265611,0.7599206,0.00005770291,0.00041707276,0.000050347495,0.0010113933,0.000028849008,0.00042573095,0.000094869785,0.040781125,0.000086363245],"about_ca_topic_score_codex":0.000046045636,"about_ca_topic_score_gemma":0.000022953443,"teacher_disagreement_score":0.12974893,"about_ca_system_score_codex":0.0003038422,"about_ca_system_score_gemma":0.0010365772,"threshold_uncertainty_score":0.38443798},"labels":[],"label_agreement":null},{"id":"W2921866173","doi":"10.1200/jco.2019.37.7_suppl.315","title":"The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Androgen receptor; Internal medicine; Oncology; Androgen; Androgen deprivation therapy; Overall survival; Urology; Cancer; Hormone","score_opus":0.045850744046622226,"score_gpt":0.39754535761622006,"score_spread":0.35169461356959786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921866173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651086,0.00025404262,4.2670965e-7,0.0015395493,0.00014532065,0.0014244599,0.000021294623,0.0000037369146,0.00010032184],"genre_scores_gemma":[0.9983627,0.000359995,0.00010029226,0.00006380116,0.00007259319,0.000024458546,0.0000074932727,0.000018476838,0.0009901974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970114,0.00050066196,0.0013111299,0.00021092255,0.000707012,0.00025884522],"domain_scores_gemma":[0.99613553,0.001254413,0.0015044442,0.00011931784,0.00084068335,0.00014558641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031172538,0.0001569552,0.0012391148,0.00007883715,0.00006583259,0.000020807282,0.00008309613,0.00014142464,0.0000512208],"category_scores_gemma":[0.00038382868,0.000073996904,0.00009797085,0.0001796883,0.00010269534,0.00011148096,0.0000197123,0.00047420827,0.0000010256331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019077921,0.0013301711,0.97348285,0.000031278934,0.0015934164,0.000033621047,0.0008555125,0.00002986646,0.00024516153,7.687858e-7,0.000063250416,0.0032561906],"study_design_scores_gemma":[0.023586988,0.015346802,0.95902175,0.00014774967,0.0002373415,0.0000014778176,0.0010479862,0.00001545915,0.00018769727,0.0000024704152,0.00032320505,0.00008106303],"about_ca_topic_score_codex":0.0002489197,"about_ca_topic_score_gemma":0.00060437655,"teacher_disagreement_score":0.014461082,"about_ca_system_score_codex":0.0004472537,"about_ca_system_score_gemma":0.0009019454,"threshold_uncertainty_score":0.3017506},"labels":[],"label_agreement":null},{"id":"W2921869013","doi":"10.1200/jco.2019.37.7_suppl.566","title":"Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Renal cell carcinoma; Underweight; Proportional hazards model; Overweight; Body mass index; Oncology; Gastroenterology; Confidence interval","score_opus":0.09813768646173032,"score_gpt":0.44327081788098144,"score_spread":0.3451331314192511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921869013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930885,0.00026144023,0.00001898602,0.0018980049,0.0005857174,0.00087665877,0.00001119037,0.00000641889,0.003253123],"genre_scores_gemma":[0.9963331,0.000094893534,0.0018346497,0.00022041853,0.00022617483,0.000013263458,0.0000055366418,0.000040693893,0.0012312275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99354386,0.0006492858,0.004238619,0.0003803329,0.0006891207,0.00049880147],"domain_scores_gemma":[0.9937154,0.0023839334,0.0022869436,0.0005991111,0.00031639994,0.00069823145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021903084,0.0004196439,0.0039484887,0.0005947876,0.000017450706,0.000008394685,0.00025995428,0.0003245096,0.00048498405],"category_scores_gemma":[0.00085717137,0.00023954907,0.0021120335,0.00028416078,0.00009952476,0.00007570422,0.00006490714,0.0009174505,0.00013910228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012143413,0.007387764,0.94113064,0.00004983888,0.0010220151,0.0024776724,0.00014066872,0.0007725109,0.028534314,0.0000056005065,0.00008948188,0.006246094],"study_design_scores_gemma":[0.021548467,0.106591664,0.8576982,0.00010518107,0.0006147424,0.00020751877,0.000103814426,0.00011842882,0.012354969,0.000063792795,0.00043995713,0.0001532842],"about_ca_topic_score_codex":0.0004797527,"about_ca_topic_score_gemma":0.00004026152,"teacher_disagreement_score":0.0992039,"about_ca_system_score_codex":0.0019305685,"about_ca_system_score_gemma":0.0023449955,"threshold_uncertainty_score":0.9768528},"labels":[],"label_agreement":null},{"id":"W2921882662","doi":"10.1200/jco.2019.37.7_suppl.237","title":"Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Incidence (geometry); Adverse effect; MedDRA; Clinical trial; Oncology; Cancer; Androgen receptor; Pathology","score_opus":0.35448445688229574,"score_gpt":0.5752077519366866,"score_spread":0.22072329505439087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921882662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727447,0.014365167,0.0000059929685,0.008217237,0.0013539939,0.0012737192,0.00039238232,0.0000022458098,0.0016445768],"genre_scores_gemma":[0.82375246,0.17253605,0.000619349,0.0006835529,0.0012322564,0.000008625865,0.00013108608,0.000020306175,0.001016297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932873,0.0011633735,0.00460159,0.00022315436,0.0005186678,0.00020590014],"domain_scores_gemma":[0.99304724,0.0024024886,0.0033795447,0.00038721092,0.0005816436,0.00020185224],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011025428,0.00012847864,0.0026350527,0.00012202834,0.000010593402,0.0000015623003,0.00033014503,0.00019896487,0.0010884531],"category_scores_gemma":[0.0069161872,0.00008094234,0.0003461014,0.00021836342,0.00014961949,0.00018550837,0.00011281393,0.0007242617,0.000007677422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14822753,0.0100385165,0.53315765,0.011309135,0.0027960837,0.0009005912,0.0002939996,0.00001730082,0.019946573,0.00012738664,0.059568126,0.2136171],"study_design_scores_gemma":[0.08033945,0.025078442,0.5730925,0.041374005,0.0016750729,0.000078068486,0.00045801591,0.00006624891,0.0026150327,0.00025797103,0.27466014,0.00030500916],"about_ca_topic_score_codex":0.00012698938,"about_ca_topic_score_gemma":0.00036670992,"teacher_disagreement_score":0.21509202,"about_ca_system_score_codex":0.0002807945,"about_ca_system_score_gemma":0.004664629,"threshold_uncertainty_score":0.9998247},"labels":[],"label_agreement":null},{"id":"W2921911282","doi":"10.1200/jco.2019.37.7_suppl.429","title":"Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Avelumab; Medicine; Metastatic Urothelial Carcinoma; Javelin; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Chemotherapy; Urothelial carcinoma; Phases of clinical research; Immunotherapy; Cancer; Pembrolizumab; Bladder cancer","score_opus":0.11009727768758071,"score_gpt":0.4788035239572756,"score_spread":0.3687062462696949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921911282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179155,0.000100391146,0.0000030059743,0.006375285,0.0003591698,0.0011251097,0.000019731346,0.0000034881496,0.00022228327],"genre_scores_gemma":[0.9979532,0.000053612916,0.00016274166,0.0008080797,0.00024521345,0.000026316899,0.0000015143559,0.0000150178475,0.0007343266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99500346,0.0021721155,0.0019112508,0.00021290421,0.00043302172,0.00026726056],"domain_scores_gemma":[0.99294007,0.0056105247,0.0009854044,0.00019040477,0.00012218137,0.0001514207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006058601,0.00017486833,0.0017719278,0.0001998263,0.000029797122,0.000017949567,0.00012290194,0.00013351285,0.00006325798],"category_scores_gemma":[0.002094108,0.00008929131,0.00025431125,0.00015338486,0.00004348437,0.00010965146,0.000022664917,0.000618292,0.00002725265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013600406,0.0065979725,0.96717584,0.000007586067,0.0005312067,0.0011389303,0.002105919,0.0000022420231,0.000049984104,0.0000016877184,0.000048378974,0.008739831],"study_design_scores_gemma":[0.0660398,0.051444218,0.879313,0.00002517436,0.000731091,0.00006124762,0.001206619,0.000015207956,0.000034452554,0.00007829474,0.0009805049,0.000070366994],"about_ca_topic_score_codex":0.00053212536,"about_ca_topic_score_gemma":0.00035642556,"teacher_disagreement_score":0.087862834,"about_ca_system_score_codex":0.0006857318,"about_ca_system_score_gemma":0.0015260263,"threshold_uncertainty_score":0.36411938},"labels":[],"label_agreement":null},{"id":"W2921914635","doi":"10.1200/jco.2019.37.7_suppl.17","title":"Genomic validation of three-tiered sub-classification of high-risk prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Oncology; Prostate-specific antigen; Internal medicine; DECIPHER; Risk assessment; Bioinformatics; Biology","score_opus":0.14036873691157623,"score_gpt":0.47122851877000627,"score_spread":0.33085978185843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921914635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456143,0.00094046805,0.000048813345,0.0027249656,0.0008185389,0.0004343014,0.000022285212,0.0000034950529,0.000445673],"genre_scores_gemma":[0.99233615,0.0062668463,0.00067726505,0.00004784558,0.00031151957,0.0000057758307,0.000011556024,0.000012510412,0.0003305229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970775,0.00026758644,0.0019922887,0.00014253079,0.00036434137,0.00015572242],"domain_scores_gemma":[0.99488205,0.00091667706,0.0030287793,0.00019720406,0.000822272,0.00015300742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023732984,0.00008719357,0.0010860643,0.000139469,0.000016785303,0.000002890116,0.00012351105,0.00022326212,0.00016505044],"category_scores_gemma":[0.00084043713,0.00005770038,0.00027168661,0.00015081643,0.00019050634,0.00008577166,0.00003052577,0.0005076091,0.000015506997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00884185,0.00078969944,0.8255481,0.00011410651,0.00048411996,0.000016202013,0.00009760021,0.000072102834,0.03164101,0.00008294384,0.0005094099,0.13180284],"study_design_scores_gemma":[0.010703355,0.010757718,0.95245355,0.00013813969,0.00039181768,0.000014976462,0.00007022963,0.00018986162,0.022127021,0.0009502302,0.0021502208,0.000052892286],"about_ca_topic_score_codex":0.00016069962,"about_ca_topic_score_gemma":0.000040366856,"teacher_disagreement_score":0.13174994,"about_ca_system_score_codex":0.0002175198,"about_ca_system_score_gemma":0.002194808,"threshold_uncertainty_score":0.38934955},"labels":[],"label_agreement":null},{"id":"W2921920097","doi":"10.1200/jco.2019.37.7_suppl.1","title":"PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Cohort; External beam radiotherapy; Dose fractionation; Toxicity; Randomized controlled trial; Urology; Radiosurgery; Prostate cancer; Nuclear medicine; Internal medicine; Cancer; Brachytherapy","score_opus":0.09406648063087258,"score_gpt":0.5172467262077756,"score_spread":0.423180245576903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921920097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818853,0.000635326,0.004981333,0.0034480842,0.0022165284,0.0066707134,0.00007023642,0.000016448084,0.00007604581],"genre_scores_gemma":[0.98688185,0.005819101,0.0027209679,0.0011935129,0.0007047009,0.00049868494,0.0000990832,0.000040769097,0.0020413275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99228597,0.0013122334,0.0045690434,0.00046797885,0.0009637981,0.0004009648],"domain_scores_gemma":[0.9887379,0.0051394245,0.003606772,0.0002512757,0.0017894511,0.00047517856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0066601504,0.00032492503,0.0066850088,0.0012039928,0.00006286543,0.000052077103,0.0002866151,0.0003833605,0.0017913191],"category_scores_gemma":[0.0013018996,0.00020529995,0.0018201363,0.00069076073,0.00020164566,0.0005764585,0.000026830676,0.00085150765,0.0000020983869],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9272337,0.007537476,0.01360959,0.000026489986,0.034366485,0.00015339801,0.00021934419,0.0039015107,0.007232395,0.00003621907,0.00016343003,0.005519957],"study_design_scores_gemma":[0.83924896,0.015429019,0.00947135,0.00012812325,0.0037787694,0.000043816464,0.000051378633,0.1294929,0.00036339147,0.00006434947,0.0017541071,0.00017386563],"about_ca_topic_score_codex":0.00018797816,"about_ca_topic_score_gemma":0.00010733438,"teacher_disagreement_score":0.12559138,"about_ca_system_score_codex":0.0012497626,"about_ca_system_score_gemma":0.0032855,"threshold_uncertainty_score":0.9991212},"labels":[],"label_agreement":null},{"id":"W2921928260","doi":"10.1200/jco.2015.33.15_suppl.e17688","title":"A study of effects of concomitant administration of proton pump inhibitors (PPIs) and capecitabine (cape) on survival in early stage colorectal cancer (CRC) patients (pts).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Alberta Health Services; University of Alberta; CancerCare Manitoba","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Cancer; Stage (stratigraphy); Oxaliplatin; Colorectal cancer; Concomitant; Overall survival; Oncology; Gastroenterology","score_opus":0.08833392676926104,"score_gpt":0.4340082781896324,"score_spread":0.34567435142037134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921928260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679923,0.00023871462,4.855944e-7,0.00023780842,0.000776993,0.0015019703,0.000012450021,0.0000022300014,0.0004301168],"genre_scores_gemma":[0.999469,0.00023073152,0.00003923179,0.000030694177,0.0001512099,0.000044442895,0.0000012702004,0.0000107313645,0.000022730865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652535,0.00045266032,0.0021612581,0.00017636098,0.00053607806,0.00014829627],"domain_scores_gemma":[0.9955415,0.0014293512,0.002035024,0.00009588731,0.0007042532,0.00019397712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280457,0.0001543751,0.0018516583,0.00015240168,0.000014155881,0.000002439104,0.000070075446,0.00017680644,0.0000076273086],"category_scores_gemma":[0.002158546,0.00010328545,0.00014118686,0.00016284894,0.00021164391,0.00007104787,0.000051376395,0.00038236415,2.4854558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034792937,0.01229629,0.94065595,0.00019578467,0.00048174273,0.0002070695,0.0021391185,0.0000061281603,0.00029132425,0.000009518104,0.000039084087,0.008885086],"study_design_scores_gemma":[0.028101506,0.19016172,0.7773774,0.00025303251,0.000248733,0.00000464051,0.001038348,0.000007893265,0.002606481,0.000012917242,0.00012852231,0.000058762584],"about_ca_topic_score_codex":0.00065080565,"about_ca_topic_score_gemma":0.0024337715,"teacher_disagreement_score":0.17786543,"about_ca_system_score_codex":0.00023224887,"about_ca_system_score_gemma":0.0010200044,"threshold_uncertainty_score":0.42118585},"labels":[],"label_agreement":null},{"id":"W2921940659","doi":"10.1200/jco.2019.37.7_suppl.144","title":"Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Adverse effect; Abiraterone acetate; Internal medicine; Placebo; Enzalutamide; Randomized controlled trial; Androgen deprivation therapy; Oncology; Cancer; Androgen receptor; Confidence interval","score_opus":0.05830491259392324,"score_gpt":0.42172842444029973,"score_spread":0.3634235118463765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921940659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673986,0.0002997747,0.0000014856553,0.0011644388,0.00007874587,0.0016218472,0.000050623534,0.0000017539629,0.00004145985],"genre_scores_gemma":[0.9978158,0.0017785019,0.00024166555,0.000048303482,0.00002607008,0.000030278658,0.000019648487,0.000012971418,0.000026752989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957432,0.000971783,0.0018638693,0.00024944567,0.0009318285,0.00023985934],"domain_scores_gemma":[0.9956751,0.0014842963,0.0018451486,0.00033149507,0.0005351682,0.00012880834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033254537,0.0001699021,0.0016722176,0.0003572376,0.000035112356,0.000009117192,0.00020016424,0.000099716,0.000066271874],"category_scores_gemma":[0.00026659365,0.00007598984,0.00011339551,0.00093288935,0.00027436716,0.00010367028,0.00003520321,0.0006085524,2.900059e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06456374,0.006475596,0.9167384,0.000048892467,0.0024545004,0.00018785868,0.0016148778,0.0010618814,0.00002372777,0.000006644543,0.000018195222,0.0068056746],"study_design_scores_gemma":[0.043192197,0.04806888,0.9057071,0.00022302965,0.0010840504,0.0000033509823,0.0014278964,0.00010590255,0.000029183286,0.000016484431,0.00006948462,0.000072394134],"about_ca_topic_score_codex":0.001672668,"about_ca_topic_score_gemma":0.044433605,"teacher_disagreement_score":0.042760935,"about_ca_system_score_codex":0.00016786419,"about_ca_system_score_gemma":0.001135082,"threshold_uncertainty_score":0.973003},"labels":[],"label_agreement":null},{"id":"W2921945934","doi":"10.1200/jco.2019.37.7_suppl.2","title":"A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Clinical endpoint; Clinical trial; Randomized controlled trial; Pelvis; Internal medicine; Radiology; Cancer","score_opus":0.11740091288418172,"score_gpt":0.5057142715991796,"score_spread":0.38831335871499784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921945934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857197,0.0013506794,0.00001349788,0.007163018,0.0011183915,0.0012751496,0.0000018949538,0.000006796622,0.0033508986],"genre_scores_gemma":[0.9953458,0.0012800719,0.00069778576,0.0005143796,0.00063168444,0.000040517498,0.0000057782336,0.000015315793,0.0014686793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964928,0.000590572,0.0019697477,0.00019429295,0.00046881227,0.000283788],"domain_scores_gemma":[0.9963618,0.0017686198,0.0011166747,0.00011656847,0.0003851344,0.00025123594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005196502,0.00012983574,0.0022501496,0.00019130704,0.000022923206,0.000014031563,0.00011432451,0.00002477023,0.00030918038],"category_scores_gemma":[0.0008319283,0.00007324751,0.0004473767,0.00015436023,0.0002858671,0.00013838561,0.00003675148,0.0009952711,0.000019521052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7760899,0.0008674351,0.21231076,0.00003400714,0.00030281628,0.003247952,0.000031956075,0.000039859224,0.000031719952,0.00004498765,0.0003356871,0.0066629243],"study_design_scores_gemma":[0.972603,0.0044556167,0.014683312,0.00040762417,0.00023783032,0.0011204898,0.000091721224,0.0012729521,0.000042851378,0.00018151275,0.004821833,0.00008125912],"about_ca_topic_score_codex":0.00008393256,"about_ca_topic_score_gemma":0.00004728697,"teacher_disagreement_score":0.19762745,"about_ca_system_score_codex":0.00027223132,"about_ca_system_score_gemma":0.0030706043,"threshold_uncertainty_score":0.544712},"labels":[],"label_agreement":null},{"id":"W2921946378","doi":"10.1200/jco.2019.37.7_suppl.425","title":"Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Javelin; Chemotherapy; Urology; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Urothelial carcinoma; Bladder cancer; Immunotherapy; Nivolumab","score_opus":0.0944301480800086,"score_gpt":0.4722891942763653,"score_spread":0.3778590461963567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921946378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970119,0.00014889754,0.00013929329,0.0007495466,0.00022451613,0.0014947619,0.000050464507,0.000003020741,0.00017761403],"genre_scores_gemma":[0.9982098,0.00007206976,0.000885732,0.00048083338,0.00017407215,0.000018585386,0.000012200046,0.000017739203,0.00012901689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686265,0.0005620822,0.0017802521,0.00024397865,0.0003365256,0.0002144956],"domain_scores_gemma":[0.99642444,0.0018589769,0.0010561367,0.00027186004,0.00022334613,0.00016526102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019588189,0.0001749433,0.0021692065,0.00022710276,0.000026500691,0.000008454984,0.00013979427,0.00006834118,0.00010227242],"category_scores_gemma":[0.00034408388,0.000093995324,0.00051393645,0.0003402226,0.00011420607,0.00005395198,0.000018388802,0.0002887722,0.0000036357078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1921399,0.03294018,0.5834766,0.000042420143,0.01748002,0.001883067,0.004720997,0.00031108258,0.00019496809,0.00003884174,0.00014842418,0.16662352],"study_design_scores_gemma":[0.26396737,0.13430484,0.58061486,0.00004109252,0.015041744,0.00019469405,0.0018509714,0.00062171643,0.00010919617,0.000037544298,0.003088162,0.00012779263],"about_ca_topic_score_codex":0.0002347541,"about_ca_topic_score_gemma":0.0005152006,"teacher_disagreement_score":0.16649573,"about_ca_system_score_codex":0.00013869519,"about_ca_system_score_gemma":0.0012473833,"threshold_uncertainty_score":0.38330182},"labels":[],"label_agreement":null},{"id":"W2921967070","doi":"10.1200/jco.2019.37.7_suppl.81","title":"The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Prostatectomy; PTEN; Hypoxia (environmental); Oncology; Biomarker; Metastasis; Biochemical recurrence; Internal medicine; Cancer; Pathology; Biology; Genetics","score_opus":0.09635114724034834,"score_gpt":0.5072047743489597,"score_spread":0.4108536271086114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921967070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711984,0.007961063,0.0000010749294,0.018110197,0.000715064,0.0003665368,0.0000029924634,0.0000019631384,0.001642713],"genre_scores_gemma":[0.9774849,0.020747975,0.00033672462,0.00074001506,0.00016365315,0.000005206112,5.41429e-7,0.000008287435,0.00051270955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965669,0.00061634916,0.0021081853,0.00016148135,0.0003190207,0.0002280609],"domain_scores_gemma":[0.9945384,0.0036018377,0.0011112043,0.0001519454,0.00035930733,0.00023727585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005501299,0.000091441325,0.0011070755,0.000069277594,0.000022727645,0.000007891323,0.00014879,0.00015219262,0.00005198912],"category_scores_gemma":[0.002322217,0.00004641891,0.00026037998,0.00011953189,0.0010347225,0.000056137607,0.000061024282,0.000980264,0.000004586872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00943782,0.00056992605,0.88690156,0.00005001234,0.0003506264,0.0011803316,0.000053599877,0.0000044253115,0.0009686455,0.00024811077,0.00051367347,0.099721275],"study_design_scores_gemma":[0.017478,0.019131606,0.9298666,0.00037816213,0.00021382587,0.00032235892,0.00036356092,0.00009965284,0.00077594,0.0017560238,0.029525677,0.00008860033],"about_ca_topic_score_codex":0.000079113895,"about_ca_topic_score_gemma":0.00009101148,"teacher_disagreement_score":0.09963267,"about_ca_system_score_codex":0.00008295127,"about_ca_system_score_gemma":0.0031071105,"threshold_uncertainty_score":0.55118805},"labels":[],"label_agreement":null},{"id":"W2921980052","doi":"10.1200/jco.2015.33.15_suppl.e17734","title":"Predictors of attrition in the treatment of metastatic colorectal cancer (MCRC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Colorectal cancer; Attrition; Cancer; Internal medicine; Logistic regression; Confounding; Population; Disease; Proportional hazards model; Medical record; Cohort study; Oncology","score_opus":0.2627255436798661,"score_gpt":0.5101945243127587,"score_spread":0.24746898063289258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921980052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902621,0.004230007,0.0000036940733,0.002977548,0.00072700024,0.00026948898,0.000012969456,0.0000015203706,0.0015157011],"genre_scores_gemma":[0.9948313,0.0042917416,0.00031820583,0.00014740664,0.0003381865,0.000018997785,0.0000015725267,0.000004856001,0.00004770387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976675,0.0003368893,0.0014857072,0.00008344723,0.00031631882,0.000110137575],"domain_scores_gemma":[0.99704516,0.0013463756,0.0010491615,0.000076177064,0.00037411568,0.00010898918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012667088,0.00008991751,0.0012899673,0.00008718044,0.000010985524,0.0000013199823,0.00007035608,0.00008563791,0.000032560325],"category_scores_gemma":[0.0007835281,0.00004394545,0.00032955201,0.00015600509,0.00021494328,0.00003751064,0.000009782694,0.00016441097,7.389856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014791352,0.011316949,0.8576975,0.00004189269,0.0017942508,0.00039707578,0.0038224778,0.000043384232,0.00012673269,0.000044404424,0.0026114003,0.10731259],"study_design_scores_gemma":[0.017904202,0.105259776,0.8455904,0.00009413436,0.0013724436,0.000116261646,0.0018659642,0.000029261544,0.0004227039,0.00021113036,0.027085923,0.000047796144],"about_ca_topic_score_codex":0.00025008275,"about_ca_topic_score_gemma":0.00078402646,"teacher_disagreement_score":0.107264794,"about_ca_system_score_codex":0.00029604597,"about_ca_system_score_gemma":0.0011258284,"threshold_uncertainty_score":0.19971712},"labels":[],"label_agreement":null},{"id":"W2922002660","doi":"10.1200/jco.2019.37.7_suppl.98","title":"Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Prednisone; Neoadjuvant therapy; Adverse effect; Internal medicine; Neutropenia; Randomized controlled trial; Febrile neutropenia; Hazard ratio; Surgery; Oncology; Urology; Cancer; Chemotherapy; Confidence interval; Androgen deprivation therapy; Breast cancer","score_opus":0.21133374720830636,"score_gpt":0.5171035825473507,"score_spread":0.30576983533904434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922002660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848302,0.00045450227,0.000011579142,0.005139485,0.0020249966,0.00084051554,0.000019131037,0.000005746215,0.006673867],"genre_scores_gemma":[0.9799002,0.0008662568,0.0010790153,0.00032549293,0.001254102,0.000006686371,0.0000051939487,0.000017015123,0.016546061],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99576247,0.00050642673,0.0026970303,0.00021242394,0.0005481272,0.00027352085],"domain_scores_gemma":[0.99495023,0.00212551,0.001523976,0.00025342897,0.000792853,0.0003540141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003176586,0.00013960805,0.0018897743,0.0001341102,0.000023139599,0.000008670009,0.00018092408,0.00036722486,0.00029929672],"category_scores_gemma":[0.0029083744,0.00007272283,0.00042998823,0.00015523448,0.00026949664,0.00012989748,0.00006317685,0.0009370678,0.0000757467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94544524,0.0023310804,0.0062206183,0.00005448956,0.00079394825,0.0014456416,0.00070266996,0.000012539242,0.0006557996,0.000030956417,0.0061095706,0.036197457],"study_design_scores_gemma":[0.57219696,0.3208453,0.06668279,0.00033921024,0.00046650917,0.00027146767,0.0004212821,0.00007577227,0.0016446785,0.00010682047,0.036806222,0.00014297913],"about_ca_topic_score_codex":0.000060882237,"about_ca_topic_score_gemma":0.000031601474,"teacher_disagreement_score":0.37324828,"about_ca_system_score_codex":0.00024251519,"about_ca_system_score_gemma":0.0046481113,"threshold_uncertainty_score":0.824555},"labels":[],"label_agreement":null},{"id":"W2922010177","doi":"10.1200/jco.2019.37.7_suppl.tps346","title":"Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; PARP inhibitor; Veliparib; Oncology; Internal medicine; Cyclophosphamide; Clinical endpoint; Cancer; Cancer research; Clinical trial; Chemotherapy; Poly ADP ribose polymerase; DNA; Biology","score_opus":0.18840276535886388,"score_gpt":0.5044325240745496,"score_spread":0.3160297587156857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922010177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057555,0.0010981911,0.00015534431,0.003929967,0.002450952,0.0015069561,0.000093799514,0.000014491348,0.00017473013],"genre_scores_gemma":[0.98348135,0.0012606119,0.010926385,0.0017450883,0.0009154133,0.00007932337,0.000009966568,0.000030497078,0.0015513847],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954504,0.00029478446,0.003371388,0.00025550375,0.00037526278,0.00025270382],"domain_scores_gemma":[0.99265975,0.0025790737,0.003405449,0.00025469545,0.00082822586,0.00027279067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003387318,0.0001586338,0.0018144804,0.00015111905,0.00005072711,0.000007705437,0.0001095595,0.00024551948,0.0004491436],"category_scores_gemma":[0.0019937002,0.00012070449,0.0011362041,0.00014609275,0.00022384158,0.00015148275,0.000022934479,0.0004483069,0.0000049779064],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90862906,0.009725011,0.006761783,0.0001864141,0.0015169982,0.00008572484,0.0004958949,0.00033162677,0.027439523,0.00064354483,0.016846083,0.027338361],"study_design_scores_gemma":[0.4238098,0.11313837,0.0050601214,0.0003306027,0.00081242813,0.00006674397,0.00021916785,0.00049802853,0.0032045534,0.00020521354,0.45248035,0.00017461684],"about_ca_topic_score_codex":0.000043903845,"about_ca_topic_score_gemma":0.00003165833,"teacher_disagreement_score":0.48481923,"about_ca_system_score_codex":0.00050165213,"about_ca_system_score_gemma":0.004192624,"threshold_uncertainty_score":0.74375343},"labels":[],"label_agreement":null},{"id":"W2922015761","doi":"10.1200/jco.2019.37.7_suppl.377","title":"Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Gastroenterology; Cancer; Anemia; Chemotherapy; Bladder cancer; Oncology; Adverse effect","score_opus":0.07501301366022906,"score_gpt":0.45484002772730087,"score_spread":0.3798270140670718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922015761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963653,0.00012949033,0.000004368239,0.0006076521,0.00094716327,0.00089736114,0.00016862006,0.0000045608076,0.0008754561],"genre_scores_gemma":[0.9981794,0.000062294945,0.00064583163,0.0005654871,0.0003476361,0.0000143670195,0.000011896364,0.000023815765,0.0001493179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602,0.00040394446,0.0024894422,0.00026387433,0.0006057211,0.00021699474],"domain_scores_gemma":[0.9959288,0.0011705221,0.0019778819,0.0002830641,0.00040521764,0.0002344945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010333625,0.00018522861,0.0019133689,0.00014914018,0.000014035315,0.00000519404,0.00016582348,0.0001824719,0.00045934232],"category_scores_gemma":[0.00085980166,0.00011185618,0.00021264829,0.00018233102,0.000074816955,0.000109403685,0.000027012602,0.00084695994,0.000013588602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1411001,0.025897624,0.7864201,0.000029657527,0.0015086017,0.00040714815,0.0011891372,0.000059652317,0.000039630824,0.0000027812166,0.0007428658,0.042602707],"study_design_scores_gemma":[0.18577258,0.07268797,0.7374518,0.00026002937,0.0010938226,0.0000095731375,0.0005282773,0.000021886422,0.00007797275,0.00003721455,0.0019598182,0.00009905587],"about_ca_topic_score_codex":0.0009344109,"about_ca_topic_score_gemma":0.0004750524,"teacher_disagreement_score":0.048968296,"about_ca_system_score_codex":0.00017262688,"about_ca_system_score_gemma":0.0021027878,"threshold_uncertainty_score":0.5029476},"labels":[],"label_agreement":null},{"id":"W2922029403","doi":"10.1200/jco.2019.37.7_suppl.511","title":"Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Taxane; Medicine; Docetaxel; Carboplatin; Oncology; Internal medicine; Regimen; Chemotherapy; Paclitaxel; Cancer; Cisplatin; Breast cancer","score_opus":0.13331974767200436,"score_gpt":0.5799691032745201,"score_spread":0.44664935560251573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922029403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97746193,0.009872675,0.00006536433,0.0040750485,0.0039574355,0.0038034325,0.000016300775,0.0000067315846,0.0007411037],"genre_scores_gemma":[0.99429834,0.00088403607,0.0009055111,0.0022113346,0.00054818194,0.00006778495,0.000011733815,0.000018638937,0.0010544449],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99521077,0.00024410561,0.0036884728,0.00017872897,0.00043422764,0.0002437078],"domain_scores_gemma":[0.9903621,0.0027092937,0.00505296,0.00027979445,0.0011411333,0.00045470012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002853738,0.0001430402,0.003028416,0.00007893845,0.000030919964,0.0000048881298,0.00016683583,0.00027334914,0.0002449586],"category_scores_gemma":[0.0062969574,0.00010285407,0.0006679963,0.00012924879,0.00009914198,0.00009657164,0.000017199309,0.000453215,0.000018575362],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7154788,0.008433183,0.02095118,0.23012911,0.00046656196,0.000042160344,0.000211865,0.000061044884,0.00036972945,0.0000949466,0.012347484,0.011413983],"study_design_scores_gemma":[0.77130055,0.16504617,0.019908838,0.025753904,0.0041817506,0.00006694916,0.00036177834,0.0012656208,0.00056444836,0.00014496807,0.01104296,0.00036207098],"about_ca_topic_score_codex":0.000014902674,"about_ca_topic_score_gemma":0.000012504459,"teacher_disagreement_score":0.2043752,"about_ca_system_score_codex":0.00024927882,"about_ca_system_score_gemma":0.0027742046,"threshold_uncertainty_score":0.7538501},"labels":[],"label_agreement":null},{"id":"W2922033790","doi":"10.1200/jco.18.01764","title":"Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Cancer; Heart failure; Heart disease; Anthracycline; Cumulative incidence; Internal medicine; Disease; Incidence (geometry); Cardiac toxicity; Pediatrics; Cardiology; Chemotherapy; Breast cancer; Cohort","score_opus":0.0458068344492423,"score_gpt":0.42218554085162036,"score_spread":0.376378706402378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922033790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416494,0.0013149795,0.000002600186,0.0012306196,0.0019662606,0.0008896505,0.000033177872,0.000008342184,0.0003894289],"genre_scores_gemma":[0.993469,0.0050919023,0.000028192315,0.00071371906,0.00056688604,0.0000136185745,0.000003835043,0.000025756506,0.00008706166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940927,0.0022534172,0.002459285,0.00031595086,0.0006281394,0.0002505129],"domain_scores_gemma":[0.99514073,0.0011779164,0.0025046836,0.00052088586,0.00044995753,0.0002058256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060543995,0.0002020313,0.0027202962,0.00033234368,0.00004304075,0.000008524001,0.00031505778,0.00049183966,0.00034236713],"category_scores_gemma":[0.0007058679,0.00012447937,0.0014897652,0.0012210637,0.00012609942,0.0001413357,0.00004164703,0.0015971115,0.0000027082654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079669134,0.0044252016,0.913244,0.0000056985778,0.00756204,0.000009057602,0.0029861694,0.0014749105,0.0012316722,0.000005315648,0.00002241291,0.06823682],"study_design_scores_gemma":[0.0092388075,0.004219764,0.98012626,0.00008430612,0.0029092445,0.00000547705,0.0013463228,0.00014106334,0.0010604444,0.00004800471,0.0006969356,0.00012336696],"about_ca_topic_score_codex":0.006258463,"about_ca_topic_score_gemma":0.012423034,"teacher_disagreement_score":0.068113446,"about_ca_system_score_codex":0.00023613921,"about_ca_system_score_gemma":0.0016333814,"threshold_uncertainty_score":0.9460966},"labels":[],"label_agreement":null},{"id":"W2922056055","doi":"10.1200/jco.2019.37.7_suppl.581","title":"Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Randomized controlled trial; Diarrhea; Adverse effect; Gastroenterology","score_opus":0.04543029092802406,"score_gpt":0.3627115971951943,"score_spread":0.3172813062671702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922056055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938661,0.00008218759,0.000006307005,0.0016181422,0.00071669836,0.001927472,0.000026530966,0.000017180242,0.0017393981],"genre_scores_gemma":[0.9943688,0.000114227325,0.0012469782,0.00045293226,0.00013359335,0.000043056723,0.000039728842,0.000077688535,0.0035229789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930681,0.0006504335,0.0041128434,0.00065335195,0.00074319285,0.0007720794],"domain_scores_gemma":[0.994624,0.0015194705,0.0020673634,0.00059248455,0.00042149288,0.0007751795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012906365,0.00056818017,0.003826036,0.0006255265,0.000045198194,0.000007809596,0.0003317886,0.0005305851,0.0003981509],"category_scores_gemma":[0.0008433439,0.00034529323,0.0006648776,0.00055769633,0.000121226585,0.00030069868,0.00010899215,0.001131215,0.00014940153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053704336,0.010165798,0.8929677,0.00006938109,0.00032910137,0.0047303773,0.0005696846,0.00064535026,0.00008394902,0.0000035340206,0.000052488474,0.036678325],"study_design_scores_gemma":[0.10530933,0.07277044,0.81855726,0.00044213442,0.00036212313,0.00014566179,0.00024457747,0.00008269672,0.00044625718,0.000018530274,0.0013346303,0.00028634875],"about_ca_topic_score_codex":0.00022579991,"about_ca_topic_score_gemma":0.002171119,"teacher_disagreement_score":0.07441041,"about_ca_system_score_codex":0.0016611847,"about_ca_system_score_gemma":0.001461445,"threshold_uncertainty_score":0.9998999},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2922095471","doi":"10.1200/jco.2019.37.7_suppl.93","title":"Concordance of systematic and fusion biopsy with surgical pathology.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concordance; Prostatectomy; Biopsy; Prostate cancer; Prostate biopsy; Radiology; Urology; Cancer; Internal medicine","score_opus":0.07453023238399618,"score_gpt":0.4291876933821388,"score_spread":0.3546574609981426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922095471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993243,0.002957862,0.00001525768,0.001832653,0.00041231627,0.00035037182,0.0000022347467,0.000002811067,0.0011835399],"genre_scores_gemma":[0.995475,0.0024693066,0.001479199,0.00029905757,0.0001447211,0.0000048327006,6.989198e-7,0.000007120939,0.000120050136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781513,0.00024409239,0.0015036613,0.00012640438,0.00019983017,0.00011088839],"domain_scores_gemma":[0.9960037,0.0018188916,0.0015545272,0.00014926988,0.00028946484,0.00018416853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016014372,0.000086895016,0.0018053823,0.00005258657,0.000009756711,0.000002448781,0.000054228494,0.00016525401,0.000058948557],"category_scores_gemma":[0.00042248156,0.00004469369,0.00016970932,0.00006617545,0.00018803414,0.000042363834,0.000026323067,0.00030180838,0.000007921441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054201754,0.0015784897,0.97468424,0.003405557,0.00043132703,0.004891706,0.000103297374,0.0000036921465,0.00025794475,0.00038459976,0.00018405865,0.008654895],"study_design_scores_gemma":[0.033764236,0.08534023,0.8467391,0.010262922,0.0013595179,0.017331038,0.00037543703,0.000066495115,0.00040575,0.00020409354,0.004007655,0.00014348517],"about_ca_topic_score_codex":0.00000439943,"about_ca_topic_score_gemma":0.0000025629947,"teacher_disagreement_score":0.12794511,"about_ca_system_score_codex":0.000052428528,"about_ca_system_score_gemma":0.00047693716,"threshold_uncertainty_score":0.18225558},"labels":[],"label_agreement":null},{"id":"W2922100235","doi":"10.1200/jco.2019.37.7_suppl.262","title":"Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biopsy; Prostate; Proportional hazards model; Prostate-specific antigen; Urology; Hazard ratio; Prostate biopsy; Internal medicine; Confidence interval; Gynecology; Cancer; Oncology","score_opus":0.03825013097930663,"score_gpt":0.3542684730054825,"score_spread":0.31601834202617585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922100235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836256,0.0004527124,1.7604022e-7,0.009605992,0.0003553732,0.004125305,0.0005891302,0.000010027829,0.0012356709],"genre_scores_gemma":[0.9946433,0.003330134,0.0001011916,0.00071617065,0.0002336989,0.00017359594,0.000026184947,0.000052520176,0.00072324293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99507594,0.0008690004,0.002135382,0.00062757597,0.00076415046,0.0005279387],"domain_scores_gemma":[0.990984,0.003565985,0.0036556895,0.00072426896,0.0008312007,0.00023880781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026045418,0.00040034048,0.0019670643,0.00009184836,0.0001110795,0.000020706324,0.0004642643,0.00016397127,0.000032178257],"category_scores_gemma":[0.000634387,0.00018321321,0.00019771606,0.0005282728,0.00047882766,0.00022188091,0.00016033802,0.0013947495,0.0000061828305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08614014,0.0022195233,0.88829887,0.000042424654,0.0011431379,0.00041483136,0.0028990058,0.0011269132,0.00021173558,7.300349e-7,0.00054682116,0.016955873],"study_design_scores_gemma":[0.029629506,0.029858977,0.93534017,0.00063475803,0.0002496018,0.00007042407,0.0019427591,0.00014386453,0.0007136889,0.0000149201605,0.0011865741,0.00021473823],"about_ca_topic_score_codex":0.0041390904,"about_ca_topic_score_gemma":0.020703057,"teacher_disagreement_score":0.056510635,"about_ca_system_score_codex":0.00087721366,"about_ca_system_score_gemma":0.004244914,"threshold_uncertainty_score":0.9971666},"labels":[],"label_agreement":null},{"id":"W2922115950","doi":"10.1200/jco.2019.37.7_suppl.220","title":"Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"LNCaP; Prostate cancer; Androgen receptor; Potency; In vivo; ADME; Pharmacology; Medicine; IC50; Tolerability; Cancer research; Pharmacokinetics; Cancer; In vitro; Internal medicine; Chemistry; Biology; Biochemistry; Adverse effect","score_opus":0.12400454156004478,"score_gpt":0.4240479212813577,"score_spread":0.3000433797213129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922115950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916937,0.0030299465,0.000010429885,0.0040194304,0.000347137,0.00068392645,0.000011594052,0.0000039951024,0.00019985266],"genre_scores_gemma":[0.99296314,0.0034666122,0.0026452953,0.00018399711,0.00047855132,0.000023124809,0.000008369389,0.000013583026,0.00021734474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975994,0.00031955994,0.0012797763,0.00024795398,0.0003111888,0.00024211689],"domain_scores_gemma":[0.998321,0.0002198807,0.0006357463,0.00013316312,0.0004140317,0.0002761674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019590443,0.00013449685,0.0009088043,0.00011797442,0.000034804096,0.0000220745,0.00005932047,0.00019838837,0.00010518496],"category_scores_gemma":[0.00013952542,0.000080024714,0.00011374247,0.00015718506,0.00017431729,0.00035088384,0.00002588419,0.00061027025,0.000002106312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053747583,0.002681994,0.5029567,0.00023552276,0.0006885758,0.00089427084,0.0020153832,0.00013763378,0.20695348,0.00016033938,0.00038045723,0.22914805],"study_design_scores_gemma":[0.16580328,0.11888702,0.6090832,0.0012839314,0.0015745967,0.0013400958,0.005191752,0.01437475,0.051091805,0.0030628236,0.027061198,0.0012455347],"about_ca_topic_score_codex":0.00022137963,"about_ca_topic_score_gemma":0.0007703385,"teacher_disagreement_score":0.22790252,"about_ca_system_score_codex":0.0002230485,"about_ca_system_score_gemma":0.0027860086,"threshold_uncertainty_score":0.49422595},"labels":[],"label_agreement":null},{"id":"W2922126493","doi":"10.1200/jco.2019.37.7_suppl.46","title":"The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Biomarker; Prostatectomy; Oncology; Internal medicine; Biomarker discovery; Proportional hazards model; Cohort; Prostate; Cancer; Pathology; Gene; Biology; Proteomics; Genetics","score_opus":0.11123965375314998,"score_gpt":0.5247581897498865,"score_spread":0.41351853599673655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922126493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222314,0.001814809,8.4637134e-7,0.003974098,0.00058473105,0.0006428928,0.0000071739923,0.00000314019,0.0007491377],"genre_scores_gemma":[0.99627256,0.003148347,0.00006819424,0.00014744735,0.00017853768,0.000011052128,0.0000020287123,0.000011648009,0.00016019198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706084,0.00052379776,0.0015866008,0.00015009407,0.00036471552,0.00031398222],"domain_scores_gemma":[0.99602103,0.0021591336,0.0010350103,0.00018136142,0.00033949397,0.00026398624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003162346,0.000121924575,0.0011108686,0.00011551072,0.000024806972,0.000008397963,0.00016231668,0.00018589196,0.00006850076],"category_scores_gemma":[0.0016970598,0.00005521838,0.00050451234,0.00023310457,0.00033366555,0.000057586272,0.000037480706,0.00082600565,0.000011343715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040291715,0.0012554587,0.87944674,0.000036526315,0.00087840774,0.00032749117,0.00005243995,0.000088348104,0.00045036493,0.000012625697,0.0011465795,0.076013274],"study_design_scores_gemma":[0.016626606,0.04105545,0.9388584,0.00030749547,0.000101218,0.00006248453,0.00007299145,0.00036745763,0.0006474761,0.00019713721,0.0016401062,0.0000631626],"about_ca_topic_score_codex":0.00019338897,"about_ca_topic_score_gemma":0.00010779307,"teacher_disagreement_score":0.07595011,"about_ca_system_score_codex":0.0004354499,"about_ca_system_score_gemma":0.0038861313,"threshold_uncertainty_score":0.68938303},"labels":[],"label_agreement":null},{"id":"W2922151518","doi":"10.1200/jco.2019.37.7_suppl.tps340","title":"PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Olaparib; Prostate cancer; Internal medicine; Clinical endpoint; Population; Oncology; Prednisone; Enzalutamide; Placebo; Hazard ratio; Cancer; Urology; Randomized controlled trial; Pathology; Confidence interval","score_opus":0.10858592777829928,"score_gpt":0.4756403416663116,"score_spread":0.3670544138880123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922151518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897708,0.0003785823,0.000045955727,0.004063197,0.00035959974,0.0052527967,0.00001169336,0.000005026933,0.0001123352],"genre_scores_gemma":[0.9970889,0.0008202283,0.00091439695,0.0007615349,0.00017993928,0.00010616675,0.000007535038,0.000025381367,0.00009593048],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99443936,0.001358815,0.0030502998,0.00023593823,0.0007004936,0.00021511967],"domain_scores_gemma":[0.9912137,0.004147522,0.003392901,0.0002248634,0.00086434936,0.00015669735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069234143,0.00020668276,0.0024404528,0.000107080494,0.000053269516,0.0000144646065,0.00011559289,0.00011082555,0.00020356236],"category_scores_gemma":[0.0010966903,0.0000933799,0.00016706002,0.00022124794,0.00049790286,0.0001402796,0.000016773627,0.0006983704,0.0000016554936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9618908,0.0041364795,0.0070821075,0.00004675663,0.0009811423,0.00003086371,0.00069792476,0.0004164058,0.0002365168,0.00003169398,0.00002685754,0.02442242],"study_design_scores_gemma":[0.8058321,0.1777753,0.014503447,0.0005092219,0.00043940172,0.000019024674,0.00007384716,0.00028764817,0.00010937019,0.000085445405,0.0002729857,0.00009221455],"about_ca_topic_score_codex":0.00008918019,"about_ca_topic_score_gemma":0.00013243184,"teacher_disagreement_score":0.17363882,"about_ca_system_score_codex":0.00014020684,"about_ca_system_score_gemma":0.0023370138,"threshold_uncertainty_score":0.41457623},"labels":[],"label_agreement":null},{"id":"W2922152917","doi":"10.1200/jco.2019.37.7_suppl.143","title":"Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Circulating tumor cell; Surrogate endpoint; Clinical endpoint; Oncology; Internal medicine; Clinical trial; Biomarker; Prostate-specific antigen; Overall survival; Urology; Phases of clinical research; Cancer; Metastasis","score_opus":0.3094984787866785,"score_gpt":0.5928363546640458,"score_spread":0.2833378758773673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922152917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919376,0.00022871654,0.00045547294,0.0033686685,0.00074055465,0.0023329668,0.00031648754,0.0000031659777,0.00061638944],"genre_scores_gemma":[0.99016464,0.0001828856,0.008553069,0.00018175277,0.00032599826,0.00014053608,0.000052968724,0.000019771154,0.00037837296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948609,0.00065493956,0.0034884796,0.00022155969,0.0004729447,0.00030118471],"domain_scores_gemma":[0.9901611,0.006479949,0.0021829149,0.00010789244,0.00084663986,0.0002214789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011397132,0.00014766901,0.0022829347,0.0001247246,0.000046497837,0.00000920476,0.00008556541,0.00010624061,0.00038702652],"category_scores_gemma":[0.0017828306,0.00010064662,0.0007546422,0.00012850265,0.00009836108,0.0001132884,0.0000150464575,0.00041635692,0.0000014396094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35468382,0.057046514,0.18932205,0.006849952,0.0072943773,0.0023404262,0.0031888182,0.003774322,0.2747515,0.004573091,0.0016615673,0.094513535],"study_design_scores_gemma":[0.5717684,0.17873761,0.19291598,0.001741907,0.0040919795,0.00030082767,0.0032992384,0.009419582,0.014369339,0.009059118,0.01365289,0.00064312917],"about_ca_topic_score_codex":0.00005947196,"about_ca_topic_score_gemma":0.00009395833,"teacher_disagreement_score":0.26038218,"about_ca_system_score_codex":0.00032575018,"about_ca_system_score_gemma":0.00678327,"threshold_uncertainty_score":0.99884737},"labels":[],"label_agreement":null},{"id":"W2922165125","doi":"10.1200/jco.2019.37.15_suppl.5072","title":"Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of British Columbia; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Incidence (geometry); Prostate cancer; Cohort; Oncology; KRAS; Germline mutation; Microsatellite instability; Cancer; Mutation; Gastroenterology; Genetics; Gene; Biology; Microsatellite; Colorectal cancer; Allele","score_opus":0.02801651428252136,"score_gpt":0.4044923736696856,"score_spread":0.3764758593871642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922165125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767184,0.00039031007,0.000051678515,0.00066679576,0.0009126214,0.00018320052,0.00003440941,0.0000012672543,0.00008784874],"genre_scores_gemma":[0.9941591,0.0041247853,0.00044806325,0.0008854817,0.00018146001,0.0000029252524,0.000010250323,0.000012786323,0.00017512105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751157,0.0001637057,0.0017985713,0.00021845724,0.0001758648,0.0001318365],"domain_scores_gemma":[0.9963409,0.00057079096,0.0019210558,0.00020500558,0.000803935,0.0001583412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013400487,0.00010445582,0.00071048294,0.000037069214,0.000018692102,0.00000952259,0.00018561892,0.00023877372,0.000020938334],"category_scores_gemma":[0.0018994234,0.00007312174,0.00017656658,0.000057553094,0.00023635112,0.000009657735,0.00009229718,0.00025710277,0.0000037231075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012750328,0.00048738462,0.9734483,0.0000116805895,0.00025498826,0.0000055337728,0.000021304839,0.000056373538,0.00069960754,0.000018201328,0.0009678381,0.022753797],"study_design_scores_gemma":[0.004153674,0.0061170803,0.9688564,0.000021996051,0.0001269138,0.000007955772,0.000032726603,0.00002332728,0.00059849926,0.00007274709,0.019891232,0.00009745606],"about_ca_topic_score_codex":0.000038270533,"about_ca_topic_score_gemma":0.00018429868,"teacher_disagreement_score":0.022656342,"about_ca_system_score_codex":0.00002271349,"about_ca_system_score_gemma":0.0008878889,"threshold_uncertainty_score":0.2981818},"labels":[],"label_agreement":null},{"id":"W2922177938","doi":"10.1200/jco.2019.37.7_suppl.664","title":"Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Clear cell renal cell carcinoma; BAP1; Internal medicine; PTEN; Proportional hazards model; Oncology; Renal cell carcinoma; Cancer; PI3K/AKT/mTOR pathway; Biology; Genetics","score_opus":0.09942283151706245,"score_gpt":0.4268646399002469,"score_spread":0.3274418083831845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922177938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319386,0.0014782652,0.000009928583,0.0002946464,0.0010221769,0.00040839714,0.0000034162344,0.0000036761207,0.00358562],"genre_scores_gemma":[0.9938534,0.0014742796,0.0034997845,0.00038282547,0.00038423575,0.0000016230154,0.0000013481005,0.000025650776,0.00037684743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99302745,0.0010166176,0.004810883,0.0003979766,0.00039888217,0.00034822052],"domain_scores_gemma":[0.9928191,0.003112408,0.0028298637,0.00038597372,0.00030292428,0.0005497325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004942293,0.00022609349,0.0028359445,0.00021830182,0.00001628469,0.0000060961447,0.00025146015,0.0006175408,0.00016624277],"category_scores_gemma":[0.0009972809,0.00016481528,0.0006784791,0.00014672079,0.00037040235,0.00008452315,0.00014713132,0.0014292656,0.00006564488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009703646,0.0022062038,0.94414663,0.00014073175,0.00005003935,0.0014315096,0.00007171511,0.000005395686,0.0017944144,0.000003179565,0.00032857686,0.040117934],"study_design_scores_gemma":[0.020203216,0.037585113,0.93377566,0.00016603927,0.00036068808,0.00042434369,0.00009146963,0.00042047785,0.0021090799,0.00006434701,0.0046640267,0.00013554146],"about_ca_topic_score_codex":0.000059162678,"about_ca_topic_score_gemma":0.000048525322,"teacher_disagreement_score":0.039982393,"about_ca_system_score_codex":0.00018600626,"about_ca_system_score_gemma":0.0017113243,"threshold_uncertainty_score":0.6720972},"labels":[],"label_agreement":null},{"id":"W2922191218","doi":"10.1200/jco.2019.37.7_suppl.428","title":"Avelumab treatment in metastatic urothelial carcinoma: Post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Javelin; Response Evaluation Criteria in Solid Tumors; Oncology; Adverse effect; Urology; Neutropenia; Gastroenterology; Chemotherapy; Phases of clinical research; Cancer; Urothelial carcinoma; Immunotherapy; Bladder cancer; Nivolumab","score_opus":0.145055644120517,"score_gpt":0.4980796812358861,"score_spread":0.3530240371153691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922191218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643046,0.0002491422,0.000024609337,0.001444998,0.0004926406,0.0010312813,0.00008513545,0.0000029326402,0.00023882506],"genre_scores_gemma":[0.99817044,0.000115642295,0.0007428002,0.0006142474,0.0002151266,0.000025493428,0.000015488034,0.00001534662,0.00008544598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946695,0.001434395,0.0029459228,0.0002496378,0.00045906115,0.0002414753],"domain_scores_gemma":[0.9960023,0.0016169745,0.0015932157,0.00036802902,0.00026551573,0.00015393493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002582866,0.00019609714,0.0025069828,0.0006378236,0.000028361592,0.000007543584,0.00019903368,0.0001111318,0.0003320485],"category_scores_gemma":[0.0007716523,0.00011038901,0.0007584574,0.0007242314,0.00008445903,0.00008040583,0.000025179059,0.0005777847,0.000016795575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0150421485,0.02745379,0.91647416,0.000012646055,0.0031837416,0.0013648589,0.002677213,0.0005615294,0.000047772362,0.000042646276,0.00003982384,0.03309968],"study_design_scores_gemma":[0.052656937,0.07344501,0.8618752,0.000022495225,0.008445978,0.00006452053,0.0024388349,0.00055462134,0.000020870068,0.00014718372,0.00024728128,0.000081102495],"about_ca_topic_score_codex":0.0037168893,"about_ca_topic_score_gemma":0.0067330766,"teacher_disagreement_score":0.054598983,"about_ca_system_score_codex":0.00033944356,"about_ca_system_score_gemma":0.0016566388,"threshold_uncertainty_score":0.56188494},"labels":[],"label_agreement":null},{"id":"W2922202278","doi":"10.1200/jco.2019.37.7_suppl.546","title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Renal cell carcinoma; Internal medicine; Chromophobe cell; Clinical endpoint; Population; Surgery; Oncology; Gastroenterology; Clear cell; Cancer; Clinical trial; Immunotherapy","score_opus":0.059357984523098505,"score_gpt":0.38132261727029954,"score_spread":0.32196463274720105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922202278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980665,0.00095692836,0.0007710579,0.0038894264,0.002229064,0.0016208659,0.000089825044,0.00002446986,0.009753325],"genre_scores_gemma":[0.97081286,0.0010529947,0.018225744,0.0020443231,0.0022692352,0.000026270227,0.00007358045,0.00010577065,0.0053892443],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.992925,0.00036778644,0.0045046005,0.0007870186,0.0007601501,0.0006554804],"domain_scores_gemma":[0.9880801,0.005800323,0.0035262827,0.00087665097,0.0008574486,0.00085919024],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024360872,0.00048582398,0.0032046447,0.00022629643,0.000088475026,0.00002206143,0.00046927572,0.00087584904,0.0003533146],"category_scores_gemma":[0.0010163867,0.00036006086,0.001593878,0.0001804882,0.0001685838,0.00018360456,0.00009388346,0.0014550145,0.00022514109],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6010265,0.012652549,0.25688246,0.00042745317,0.0017834109,0.0034344129,0.0008781425,0.0032004218,0.042453676,0.00001789062,0.032619424,0.044623706],"study_design_scores_gemma":[0.20414239,0.116518654,0.51766944,0.0002736877,0.0017643317,0.0002429974,0.00021790815,0.0034162994,0.033960767,0.00036453758,0.12078761,0.00064135314],"about_ca_topic_score_codex":0.00020074552,"about_ca_topic_score_gemma":0.000052437324,"teacher_disagreement_score":0.39688405,"about_ca_system_score_codex":0.00059742597,"about_ca_system_score_gemma":0.0018411056,"threshold_uncertainty_score":0.99988514},"labels":[],"label_agreement":null},{"id":"W2922253981","doi":"10.1200/jco.2019.37.7_suppl.431","title":"Impact of bone metastasis on clinical outcomes in metastatic urothelial bladder cancer (mUC) for patients treated with first-line platinum-based chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Proportional hazards model; Oncology; Bone metastasis; Metastasis; Cancer; Progressive disease; Bladder cancer; Progression-free survival; Surgery; Urology","score_opus":0.1107324041417388,"score_gpt":0.4820809997094317,"score_spread":0.3713485955676929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922253981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579257,0.0000827339,0.00007963136,0.0017802661,0.0004843544,0.0013073396,0.00021768805,0.000008479389,0.0002469185],"genre_scores_gemma":[0.99460185,0.00029575988,0.0028425336,0.0016562794,0.0002776368,0.000056654884,0.000015600946,0.0000572015,0.00019647511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490863,0.00039593232,0.003469913,0.00034543336,0.0005232482,0.00035682923],"domain_scores_gemma":[0.9900064,0.0061500366,0.002539572,0.00030991598,0.00064659986,0.0003474737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017483798,0.00033109135,0.0036569275,0.00027331884,0.000023026843,0.000006523938,0.00014912318,0.00030086807,0.000753595],"category_scores_gemma":[0.0020879246,0.00018190275,0.0014983371,0.00022904342,0.00018025302,0.00008934331,0.000014961068,0.00065733603,0.000010240709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05945334,0.012023509,0.88130075,0.00005886872,0.0037491997,0.000065416556,0.000038468646,0.00038318144,0.0000114990235,0.000003089788,0.00057228946,0.042340398],"study_design_scores_gemma":[0.08432153,0.114395596,0.7978384,0.0002271509,0.0014652408,0.000010498761,0.000011533526,0.00016454044,0.00011913039,0.000032185704,0.0012678392,0.00014639462],"about_ca_topic_score_codex":0.00030974075,"about_ca_topic_score_gemma":0.00033126253,"teacher_disagreement_score":0.10237209,"about_ca_system_score_codex":0.00029518508,"about_ca_system_score_gemma":0.0030083056,"threshold_uncertainty_score":0.82513374},"labels":[],"label_agreement":null},{"id":"W2922256160","doi":"10.1200/jco.2019.37.15_suppl.e16024","title":"First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Internal medicine; Nivolumab; Durvalumab; Gastroenterology; Oncology; Urology; Cancer; Immunotherapy","score_opus":0.08396877193433286,"score_gpt":0.43964204991986605,"score_spread":0.35567327798553316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922256160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799708,0.0006000319,0.00039349106,0.0075471103,0.0049292217,0.0009188189,0.00002624648,0.000019195248,0.0055950494],"genre_scores_gemma":[0.98458797,0.00031898837,0.0059235953,0.002748465,0.0039280527,0.000019409255,0.0000065101517,0.00004236804,0.0024246436],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99670005,0.00010638533,0.002208926,0.00027714664,0.00036629502,0.00034117544],"domain_scores_gemma":[0.99597484,0.0016302438,0.0012564579,0.0002549353,0.00046468832,0.00041884067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012125344,0.00021122934,0.001689026,0.00013153971,0.000050105566,0.000008948252,0.00017014485,0.0004147748,0.00038622637],"category_scores_gemma":[0.0013860724,0.00014738375,0.0008236426,0.00012776215,0.00009587108,0.00013956384,0.00004208524,0.00065017707,0.00010278054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06293315,0.0049525467,0.64208233,0.00036948553,0.0012729026,0.0005913702,0.0003504505,0.0004361098,0.0027094912,0.000327245,0.028194334,0.25578058],"study_design_scores_gemma":[0.088337846,0.07517004,0.1564587,0.0003181324,0.001029076,0.00054295425,0.00015340529,0.00042442183,0.0032305273,0.0018269928,0.67216974,0.00033813794],"about_ca_topic_score_codex":0.000025572741,"about_ca_topic_score_gemma":0.000029783094,"teacher_disagreement_score":0.64397544,"about_ca_system_score_codex":0.00018998356,"about_ca_system_score_gemma":0.0015994773,"threshold_uncertainty_score":0.6010135},"labels":[],"label_agreement":null},{"id":"W2922292408","doi":"10.1200/jco.2019.37.7_suppl.256","title":"Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Cabazitaxel; Prostate cancer; Oncology; Internal medicine; Regimen; Retrospective cohort study; Taxane; Combination therapy; Abiraterone acetate; Cancer; Chemotherapy; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.1340544811949481,"score_gpt":0.49896898248693994,"score_spread":0.3649145012919919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922292408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954055,0.00006608279,9.345341e-7,0.0018483191,0.00027272708,0.0021605266,0.000071105474,0.0000032373214,0.0001715784],"genre_scores_gemma":[0.99789673,0.0004242133,0.00023983038,0.00007703136,0.00007402141,0.000098124874,0.0000080324935,0.000016916123,0.001165102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972588,0.00028302163,0.0016320401,0.0002476491,0.00033265955,0.0002458699],"domain_scores_gemma":[0.997342,0.0007800035,0.001081225,0.00015053278,0.000470874,0.00017534784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097042625,0.00016391261,0.0015666151,0.00023661078,0.000025856438,0.000009356326,0.000062892344,0.00007428876,0.000044787703],"category_scores_gemma":[0.00028185302,0.00009204591,0.00022276159,0.00013027719,0.000073103816,0.000090943526,0.000027706685,0.00027898655,8.9609495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011353084,0.0046380814,0.9703762,0.000088008725,0.0009896572,0.00017190751,0.0020210044,0.0000054005263,0.000032363616,0.000010344771,0.00003443943,0.010279503],"study_design_scores_gemma":[0.04047476,0.05381659,0.90351754,0.0001165062,0.00047065376,0.0000053999383,0.0011871656,0.000029291028,0.00006040872,0.00007503652,0.00017821153,0.000068446425],"about_ca_topic_score_codex":0.0014965634,"about_ca_topic_score_gemma":0.0077540865,"teacher_disagreement_score":0.06685868,"about_ca_system_score_codex":0.000583116,"about_ca_system_score_gemma":0.0008755108,"threshold_uncertainty_score":0.43269622},"labels":[],"label_agreement":null},{"id":"W2922329974","doi":"10.1200/jco.2019.37.7_suppl.tps342","title":"TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Internal medicine; Clinical endpoint; Urology; Oncology; Enzalutamide; Progression-free survival; Cancer; Chemotherapy; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.20163990613291013,"score_gpt":0.48499839965607117,"score_spread":0.283358493523161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922329974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914417,0.00019953745,0.000023900771,0.002927915,0.00009517222,0.005185824,0.000047681522,0.000018977935,0.000059255297],"genre_scores_gemma":[0.9946689,0.00027637678,0.0024768615,0.001862127,0.0000989793,0.0002577682,0.000008102858,0.000063969084,0.00028689348],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99402434,0.002048668,0.002268785,0.0006402643,0.0006167462,0.00040117744],"domain_scores_gemma":[0.9946236,0.0018006455,0.0020630648,0.0004502311,0.00055271306,0.00050976337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076141027,0.00037790995,0.002187153,0.00032459156,0.00008921753,0.00005126363,0.0002475787,0.00013042142,0.000118879376],"category_scores_gemma":[0.000616219,0.00024482742,0.00007645552,0.0003966285,0.00030337708,0.00034758943,0.000056946257,0.00070808,8.626233e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72455484,0.028165078,0.029474037,0.000106865584,0.0009053544,0.00096815685,0.0027582822,0.00013712041,0.2010811,0.000010117584,0.00017356474,0.011665483],"study_design_scores_gemma":[0.24227205,0.53138393,0.2124747,0.0010852523,0.00029878944,0.00014880797,0.00076160056,0.00066048634,0.009655983,0.000025947356,0.00088419486,0.00034823385],"about_ca_topic_score_codex":0.00015457858,"about_ca_topic_score_gemma":0.00080677815,"teacher_disagreement_score":0.5032189,"about_ca_system_score_codex":0.0002554141,"about_ca_system_score_gemma":0.0027104756,"threshold_uncertainty_score":0.99837726},"labels":[],"label_agreement":null},{"id":"W2922347809","doi":"10.1200/jco.2019.37.7_suppl.569","title":"Systematic review and REMARK scoring of renal cell carcinoma (RCC) prognostic circulating biomarker manuscripts.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Biomarker; Internal medicine; Oncology; Blinding; MEDLINE; Clear cell renal cell carcinoma; Cancer; Hazard ratio; Kidney cancer; Clinical trial; Confidence interval","score_opus":0.11932958410922478,"score_gpt":0.3960013679252129,"score_spread":0.2766717838159881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922347809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94790536,0.0445463,0.000025248199,0.000830903,0.00047614958,0.0012906858,0.0000014109127,0.0000060231314,0.0049179066],"genre_scores_gemma":[0.9951405,0.0017748959,0.0017905738,0.0007077742,0.00016228885,0.0000085944,0.0000018134099,0.000024507377,0.00038907485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99399155,0.0007793437,0.004216251,0.00026444095,0.00049397635,0.0002544206],"domain_scores_gemma":[0.9924053,0.0025690792,0.003750948,0.00038209214,0.00052705087,0.00036553745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050166007,0.00020880207,0.0035743734,0.00015834611,0.000023742616,0.0000073073566,0.00015323468,0.00024341977,0.00008273054],"category_scores_gemma":[0.004234254,0.00013554335,0.00063683157,0.000175348,0.00012263976,0.000096607975,0.00008408658,0.00061031326,0.000023301473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011663744,0.0014537445,0.6168735,0.36531222,0.0012015409,0.002835057,0.000110900866,0.000004134854,0.0071060807,0.000038532347,0.0008122158,0.0030856754],"study_design_scores_gemma":[0.0087184915,0.017545285,0.8607725,0.09284817,0.012606757,0.00584293,0.00015190107,0.0001832474,0.0007455158,0.00008380647,0.00024019131,0.00026119142],"about_ca_topic_score_codex":0.000011489169,"about_ca_topic_score_gemma":0.0000016459362,"teacher_disagreement_score":0.27246407,"about_ca_system_score_codex":0.00016776874,"about_ca_system_score_gemma":0.00066268176,"threshold_uncertainty_score":0.5527297},"labels":[],"label_agreement":null},{"id":"W2922348154","doi":"10.1200/jco.2019.37.7_suppl.478","title":"Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Randomized controlled trial; Internal medicine; Checklist; Prostate cancer; Oncology; Consolidated Standards of Reporting Trials; Disease; Clinical trial; Cancer; Physical therapy","score_opus":0.6371573398874049,"score_gpt":0.5905948463226594,"score_spread":0.04656249356474551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922348154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95547414,0.00989687,0.00028998387,0.028367171,0.0016059848,0.0035508573,0.00009674837,0.0000062999707,0.0007119218],"genre_scores_gemma":[0.99321896,0.0007541,0.0023826396,0.003127686,0.00026443313,0.00006417611,0.0000055723704,0.000027214555,0.00015519296],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.82405907,0.026803052,0.14757128,0.00063221785,0.00038119045,0.000553209],"domain_scores_gemma":[0.6569951,0.10292922,0.2383838,0.00051888986,0.0005855335,0.0005874183],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.549112,0.00028100703,0.036276605,0.0007498675,0.000047868285,0.000020284662,0.00029623,0.00039439742,0.0003994043],"category_scores_gemma":[0.49639997,0.00023622141,0.0020279654,0.00023986601,0.0003789977,0.0003391175,0.00006972287,0.00084362313,0.000026047728],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.423657,0.0030645782,0.53428555,0.0019289701,0.0036106682,0.00003638802,0.00399441,0.00036121384,0.00003592493,0.023706567,0.0018418774,0.003476852],"study_design_scores_gemma":[0.87768435,0.0040698485,0.09642896,0.00031225517,0.00025569153,0.0000499467,0.0013889802,0.00487594,0.000008561741,0.01404209,0.0005824687,0.00030090834],"about_ca_topic_score_codex":0.0023547045,"about_ca_topic_score_gemma":0.00017671449,"teacher_disagreement_score":0.45402735,"about_ca_system_score_codex":0.0003394273,"about_ca_system_score_gemma":0.0048564337,"threshold_uncertainty_score":0.97803086},"labels":[],"label_agreement":null},{"id":"W2922348865","doi":"10.1200/jco.2019.37.7_suppl.202","title":"Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Taxane; Internal medicine; Cancer; Oncology; Cancer research; Breast cancer","score_opus":0.07907273652936153,"score_gpt":0.44528852209238573,"score_spread":0.3662157855630242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922348865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739087,0.0003826791,0.0000028965715,0.0004848771,0.00032940527,0.0012263578,0.000047670885,0.0000057320326,0.00012950927],"genre_scores_gemma":[0.9982067,0.00026394342,0.0010902784,0.00022365901,0.0000990222,0.000019020898,0.0000073452948,0.00001860391,0.00007145356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995322,0.00054555276,0.0031023887,0.0002625067,0.0005705381,0.00019703616],"domain_scores_gemma":[0.9947407,0.001034239,0.0030174504,0.00025293566,0.0007582436,0.00019640393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021949657,0.00016746437,0.0016129947,0.00024070666,0.000026115968,0.0000030695007,0.00009522771,0.00013156238,0.000043955723],"category_scores_gemma":[0.0006440596,0.00011620018,0.00016915335,0.00025027274,0.00020068337,0.00013769775,0.000039321396,0.0004903297,8.1330063e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34892726,0.045552183,0.57965946,0.00028401127,0.0013912547,0.00032155946,0.003001165,0.00053207885,0.005837517,0.0000092906275,0.0007967041,0.013687502],"study_design_scores_gemma":[0.1420886,0.30351135,0.55144054,0.00041481273,0.00046015767,0.000022090187,0.0004502492,0.00005273194,0.0009355097,0.000029835162,0.0004951766,0.00009892044],"about_ca_topic_score_codex":0.00013833279,"about_ca_topic_score_gemma":0.00035830238,"teacher_disagreement_score":0.2579592,"about_ca_system_score_codex":0.00013930914,"about_ca_system_score_gemma":0.0014534501,"threshold_uncertainty_score":0.47385058},"labels":[],"label_agreement":null},{"id":"W2922362450","doi":"10.1200/jco.2019.37.7_suppl.454","title":"Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Methylation; CpG site; DNA methylation; Medicine; Cystectomy; Bladder cancer; Biomarker; Bisulfite sequencing; Methylated DNA immunoprecipitation; Internal medicine; Cancer; Oncology; Liquid biopsy; Differentially methylated regions; Cell-free fetal DNA; Cancer research; Molecular biology; DNA; Gene; Biology; Gene expression; Genetics","score_opus":0.05001349509028416,"score_gpt":0.39549508723748905,"score_spread":0.34548159214720486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922362450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905872,0.0002193404,0.000024287547,0.0033011546,0.0012278805,0.00087411737,0.000029097328,0.0000094875695,0.0037274433],"genre_scores_gemma":[0.99405676,0.00013562515,0.0015707419,0.0036131009,0.00034412442,0.000017849115,0.0000062984464,0.000030141693,0.00022533974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967097,0.0004029674,0.0016022138,0.00035620513,0.00058085663,0.00034804156],"domain_scores_gemma":[0.99628365,0.0010897452,0.0010003689,0.00032228467,0.00083800167,0.0004659466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009629433,0.00022558543,0.0014186894,0.00018958807,0.000033281358,0.000010748115,0.00024839392,0.0003118006,0.0004435254],"category_scores_gemma":[0.0015575171,0.00014823039,0.0002216758,0.00034372526,0.00009060342,0.0001798168,0.000080890364,0.0009827806,0.000034707547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059253424,0.0020023347,0.9440555,0.000037171165,0.00048137803,0.00034323937,0.0008377286,0.00021388983,0.00036493802,0.0000050055028,0.0015163437,0.04421713],"study_design_scores_gemma":[0.026205795,0.02760887,0.9419733,0.00044770347,0.0003774918,0.000021973778,0.00021270728,0.000024141591,0.00041279147,0.00004904058,0.002497713,0.00016846553],"about_ca_topic_score_codex":0.00014648709,"about_ca_topic_score_gemma":0.00027262024,"teacher_disagreement_score":0.044048663,"about_ca_system_score_codex":0.00041123093,"about_ca_system_score_gemma":0.0028622278,"threshold_uncertainty_score":0.60446596},"labels":[],"label_agreement":null},{"id":"W2922411602","doi":"10.1200/jco.2019.37.7_suppl.44","title":"Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Logistic regression; Internal medicine; Microarray; Gene expression profiling; Gene; Cancer; Gene expression; Biology; Genetics","score_opus":0.17067420117990623,"score_gpt":0.5098196829870763,"score_spread":0.33914548180717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922411602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975707,0.0011882192,0.000007998594,0.018609893,0.0010878625,0.00048643653,0.0000060702646,0.0000062113813,0.002900319],"genre_scores_gemma":[0.99245,0.00044423083,0.00072806637,0.0020280122,0.0006096029,0.0000057123907,0.000004530344,0.000016570008,0.0037132674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739134,0.0002297858,0.0015327282,0.00019539411,0.00035963388,0.00029109354],"domain_scores_gemma":[0.99752367,0.0008263332,0.00044114242,0.00020482113,0.00018392556,0.00082009094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002261006,0.00010853994,0.0010377847,0.00024206366,0.000013824386,0.0000072257567,0.0001766586,0.00019291938,0.00081726344],"category_scores_gemma":[0.0018337873,0.00006938138,0.00036556437,0.00018766447,0.00009401685,0.000068544556,0.00007459534,0.0006251077,0.00034299403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018639142,0.00075130136,0.92260855,0.000047203586,0.00020241232,0.0010417526,0.000024466777,0.000013950304,0.00025918844,0.00001196866,0.008007315,0.04839277],"study_design_scores_gemma":[0.00996528,0.008124379,0.8879701,0.00015559947,0.00010602927,0.000035420035,0.000034286277,0.000053588596,0.00001671368,0.00009456839,0.093383454,0.00006060277],"about_ca_topic_score_codex":0.00001315707,"about_ca_topic_score_gemma":0.000013527843,"teacher_disagreement_score":0.085376136,"about_ca_system_score_codex":0.0004299255,"about_ca_system_score_gemma":0.0019710371,"threshold_uncertainty_score":0.8948462},"labels":[],"label_agreement":null},{"id":"W2922414225","doi":"10.1200/jco.2015.33.15_suppl.e14517","title":"A retrospective analysis of the role of proton pump inhibitors on colorectal cancer disease survival.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Cancer; Proportional hazards model; Oncology; Retrospective cohort study; Univariate analysis; Multivariate analysis; Cancer registry; Disease","score_opus":0.04088949249448092,"score_gpt":0.3967581265120193,"score_spread":0.3558686340175384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922414225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054617,0.0010035473,0.0000118321905,0.0004934222,0.006541298,0.00021848206,0.000050569484,0.0000012120491,0.0011334432],"genre_scores_gemma":[0.9923696,0.00066186907,0.000037569072,0.0001814003,0.0066288174,0.000013762646,0.0000032552296,0.000009573739,0.00009418543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976143,0.0004885474,0.001203882,0.00018383564,0.0003678435,0.00014159158],"domain_scores_gemma":[0.99685663,0.000117401854,0.001791224,0.00022630239,0.00074888655,0.0002595468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017857918,0.000109536806,0.00096737605,0.00009158513,0.000019798425,0.0000031889192,0.00026940246,0.00024000929,0.000019553583],"category_scores_gemma":[0.0028846436,0.000069207854,0.0008610115,0.00029865923,0.00028964874,0.000005131234,0.000092344984,0.00031183564,4.4009022e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007942278,0.0012410072,0.9477712,0.000013843404,0.0022507105,8.57872e-7,0.00013954852,0.0008103418,0.026576294,0.00020207484,0.003850119,0.009201715],"study_design_scores_gemma":[0.0026365165,0.003967198,0.7380765,0.000030717423,0.0015905914,0.0000020495352,0.00018215517,0.000077035744,0.024949545,0.0003583334,0.22801633,0.00011301361],"about_ca_topic_score_codex":0.00010253582,"about_ca_topic_score_gemma":0.00038793602,"teacher_disagreement_score":0.22416621,"about_ca_system_score_codex":0.000069612855,"about_ca_system_score_gemma":0.0019419688,"threshold_uncertainty_score":0.34533963},"labels":[],"label_agreement":null},{"id":"W2922424266","doi":"10.1200/jco.2019.37.7_suppl.36","title":"Impact of compliance on outcomes for patients on active surveillance for prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Logistic regression; Biopsy; Exact test; Cancer; Prospective cohort study; Surgery; Internal medicine","score_opus":0.6609600576795013,"score_gpt":0.6309098276290325,"score_spread":0.030050230050468807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922424266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800825,0.000099361234,0.00020579042,0.013041944,0.003041648,0.0013945269,0.0013193709,0.0000042293914,0.00081063516],"genre_scores_gemma":[0.99277854,0.00015873615,0.0013313392,0.004839577,0.00043688048,0.000056305184,0.000012054143,0.000024112946,0.00036245116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916055,0.00034358585,0.0073497705,0.0003022822,0.00010406192,0.00029477323],"domain_scores_gemma":[0.96852297,0.017130865,0.013362561,0.00025310265,0.00054751715,0.00018295889],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015767405,0.00015608539,0.002954427,0.00016971173,0.000045530516,0.000009920537,0.00027992576,0.00024016628,0.000103917824],"category_scores_gemma":[0.020259783,0.00013633592,0.00083052326,0.00006821143,0.000069002235,0.00017869158,0.000018372783,0.00030236563,0.000103424274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031313442,0.0010714934,0.97343856,0.00016524635,0.00036349377,1.9700403e-7,0.00014937097,0.0008396853,4.552274e-7,0.0027559283,0.010771569,0.0073126396],"study_design_scores_gemma":[0.007958729,0.017943047,0.94879436,0.00012237573,0.000008979855,4.04191e-7,0.000045066212,0.00083370233,0.0000015644538,0.0042222394,0.019935241,0.00013430181],"about_ca_topic_score_codex":0.00013362248,"about_ca_topic_score_gemma":0.00006856794,"teacher_disagreement_score":0.02464423,"about_ca_system_score_codex":0.0007862894,"about_ca_system_score_gemma":0.0008127444,"threshold_uncertainty_score":0.987993},"labels":[],"label_agreement":null},{"id":"W2922462283","doi":"10.1200/jco.2015.33.15_suppl.1534","title":"Evaluation of rapid whole-body magnetic resonance as screening strategy for early cancer detection in 57 Brazilian Li-Fraumeni syndrome patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Magnetic resonance imaging; Li–Fraumeni syndrome; Breast MRI; Lesion; Breast cancer; Pathological; Germline mutation; Cancer; Radiology; Biopsy; Mutation; Pathology; Internal medicine; Mammography; Gene; Genetics","score_opus":0.17463464607409332,"score_gpt":0.46840619564239866,"score_spread":0.2937715495683053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922462283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911119,0.0047096037,0.0005243457,0.0009817206,0.001241183,0.00080313196,0.000010295888,0.000007001535,0.0006108316],"genre_scores_gemma":[0.9980001,0.0002242582,0.0010067587,0.00028103666,0.00033427906,0.000038816925,0.000004773758,0.000027361937,0.00008264226],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953942,0.0007876932,0.0022768884,0.00024464214,0.001037397,0.00025920867],"domain_scores_gemma":[0.99486554,0.00048182523,0.0016145782,0.0001995183,0.002510591,0.00032792948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007916815,0.00014573097,0.0010666847,0.00026010635,0.000023263876,0.000007651793,0.00013918395,0.0005018638,0.000087127824],"category_scores_gemma":[0.0056950715,0.00012899004,0.00030856446,0.00029640694,0.0001607412,0.0001611139,0.000029955712,0.00084597233,0.000007181261],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062025297,0.00083919626,0.014632971,0.000026918211,0.000118957636,0.000080412094,0.00013529429,0.0012395097,0.00094397215,0.000005985375,0.0003750945,0.97539914],"study_design_scores_gemma":[0.045892686,0.08317409,0.8413885,0.0005699901,0.0011871563,0.00022131068,0.0001505698,0.007825771,0.0009995692,0.0007531916,0.017656658,0.0001804968],"about_ca_topic_score_codex":0.00020914178,"about_ca_topic_score_gemma":0.00039419282,"teacher_disagreement_score":0.97521865,"about_ca_system_score_codex":0.0006300709,"about_ca_system_score_gemma":0.0035546857,"threshold_uncertainty_score":0.6817944},"labels":[],"label_agreement":null},{"id":"W2922491707","doi":"10.1200/jco.2015.33.15_suppl.e15179","title":"Streptozocin-based treatment in advanced neuroendocrine tumors (NETs): A single institution experience.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Nausea; Concomitant; Vomiting; Neuroendocrine tumors; Streptozocin; Diabetes mellitus; Endocrinology; Streptozotocin","score_opus":0.20523619322374817,"score_gpt":0.5049903876999093,"score_spread":0.29975419447616114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922491707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666465,0.00028480423,0.000043200023,0.009198845,0.00091788,0.00040627105,0.000001789227,0.00002108767,0.002461476],"genre_scores_gemma":[0.99435294,0.00014631054,0.0033233934,0.0014170833,0.0004501546,0.000021582104,0.0000023573937,0.000019145029,0.00026704484],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958812,0.0005505238,0.0021971043,0.0002968639,0.00062580407,0.00044851087],"domain_scores_gemma":[0.99631935,0.001093581,0.0010044901,0.00027084115,0.0004212637,0.0008904561],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006882195,0.00019565874,0.001418844,0.00032111938,0.00002556573,0.00001056602,0.0001916409,0.0000265841,0.000063701395],"category_scores_gemma":[0.010042683,0.00013826013,0.00032393087,0.0003390999,0.00035701532,0.00025871219,0.0000464718,0.00076748204,0.000020805657],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03403644,0.017942503,0.4716679,0.000050249168,0.0001092316,0.17103514,0.0002539405,0.0044247624,0.0038712935,0.00010789435,0.0018710467,0.2946296],"study_design_scores_gemma":[0.08802697,0.23215382,0.12336157,0.00039565944,0.00015829703,0.012617911,0.0016307062,0.0012024277,0.019358689,0.0005230249,0.520174,0.00039690308],"about_ca_topic_score_codex":0.000060166465,"about_ca_topic_score_gemma":0.00019821918,"teacher_disagreement_score":0.518303,"about_ca_system_score_codex":0.0007623142,"about_ca_system_score_gemma":0.0037365928,"threshold_uncertainty_score":0.99829614},"labels":[],"label_agreement":null},{"id":"W2922497097","doi":"10.1200/jco.2019.37.7_suppl.605","title":"Patterns of response of organ specific metastasis in patients with metastatic renal cell cancer (mRCC) treated with an immune checkpoint inhibitor (CPI) post tyrosine kinase inhibitor (TKI).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tyrosine-kinase inhibitor; Nivolumab; Oncology; Cohort; Renal cell carcinoma; Cancer; Immunotherapy","score_opus":0.04800085762007966,"score_gpt":0.35058926734152746,"score_spread":0.3025884097214478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922497097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976761,0.00049217866,0.000010612678,0.00055640243,0.00024714836,0.00083750265,0.000098939105,0.0000060501493,0.000075118456],"genre_scores_gemma":[0.99632,0.00014032923,0.0029834292,0.00012078158,0.0001650382,0.000009473549,0.00003808308,0.000060245424,0.00016259022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99320835,0.0013128812,0.0037884729,0.0004089991,0.0009059775,0.0003753118],"domain_scores_gemma":[0.9924478,0.0011897653,0.0038255728,0.0005548753,0.0015209458,0.0004610285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002731853,0.00037370258,0.0030356855,0.0005235294,0.000020294186,0.0000086314285,0.00021660332,0.00023118439,0.00054993614],"category_scores_gemma":[0.00042070824,0.000220411,0.00042616087,0.00046728062,0.0002262978,0.00022086992,0.00006355945,0.0008474242,0.00001039444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20060335,0.010380951,0.72025585,0.00020051505,0.0007175584,0.0010514422,0.00025800866,0.00007104591,0.062271934,0.000002166793,0.00003757386,0.004149618],"study_design_scores_gemma":[0.034749426,0.102476165,0.7124804,0.00069401786,0.0009113311,0.00006808547,0.00027542922,0.0000065083873,0.14794768,0.000002363053,0.00022792682,0.00016065821],"about_ca_topic_score_codex":0.0003593151,"about_ca_topic_score_gemma":0.00018788413,"teacher_disagreement_score":0.16585392,"about_ca_system_score_codex":0.00050181954,"about_ca_system_score_gemma":0.0017034353,"threshold_uncertainty_score":0.89881},"labels":[],"label_agreement":null},{"id":"W2922525744","doi":"10.1200/jco.2019.37.7_suppl.434","title":"The cost of obesity in radical cystectomy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Cystectomy; Overweight; Body mass index; Obesity; Population; Internal medicine; Bladder cancer; Cancer; Environmental health","score_opus":0.08849562201145696,"score_gpt":0.4670757647496304,"score_spread":0.3785801427381735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922525744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829992,0.0006410484,0.000019668538,0.004776336,0.0012244988,0.00026279376,0.0000014711486,0.0000021398128,0.010072832],"genre_scores_gemma":[0.9973573,0.00063416077,0.00027627233,0.0008666981,0.00038564028,0.0000017022737,3.0027184e-7,0.000006206759,0.00047170598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976965,0.0003128388,0.0014936641,0.00008651449,0.0002666422,0.00014384113],"domain_scores_gemma":[0.9966668,0.002093608,0.0007576583,0.00015940837,0.00016239796,0.00016011314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024288888,0.00006606081,0.0009554087,0.00004820588,0.000014728979,0.000002397362,0.00013797318,0.00021277477,0.00015993536],"category_scores_gemma":[0.0012600207,0.000034457928,0.0003070228,0.00009647455,0.00018369925,0.000036234385,0.000027669625,0.00068668823,0.000034210232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005266482,0.0014290876,0.8956607,0.000019978956,0.00019753705,0.00023036814,0.000050399754,0.000004228422,0.000100285935,0.00018790478,0.0015424745,0.09531054],"study_design_scores_gemma":[0.01332234,0.008985155,0.8574573,0.00008387009,0.000119361386,0.00020832579,0.00006663108,0.000025567982,0.00015368043,0.00033493605,0.119209275,0.000033554363],"about_ca_topic_score_codex":0.0000488766,"about_ca_topic_score_gemma":0.00008209099,"teacher_disagreement_score":0.1176668,"about_ca_system_score_codex":0.00010800429,"about_ca_system_score_gemma":0.0013757932,"threshold_uncertainty_score":0.29833567},"labels":[],"label_agreement":null},{"id":"W2922528063","doi":"10.1200/jco.2019.37.7_suppl.464","title":"Comparison of investigator-initiated and industry-initiated trials in Canada and other countries.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Cancer; Internal medicine","score_opus":0.8248956025783694,"score_gpt":0.6858585221441569,"score_spread":0.13903708043421248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922528063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98612404,0.00054129056,0.0000020746163,0.010311915,0.0005736968,0.0002889387,0.000013243247,0.000002535851,0.0021422927],"genre_scores_gemma":[0.99034023,0.0006663171,0.00044984475,0.0081973765,0.00023238361,0.0000013201703,0.0000010003541,0.000015430229,0.0000960727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897891,0.0026371374,0.006203132,0.00022163201,0.0008841204,0.0002648711],"domain_scores_gemma":[0.74696445,0.24233511,0.006589934,0.0004431568,0.0019202867,0.001747088],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.041760586,0.00013033226,0.0037107426,0.00016866546,0.000016193924,0.000008761277,0.00017150382,0.0014644079,0.00042002933],"category_scores_gemma":[0.24309675,0.00009365988,0.00014671127,0.00020263295,0.0006915854,0.00006522807,0.000102664344,0.006295675,0.0000037377738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027277207,0.0003215312,0.9915699,0.00014399536,0.00020903935,0.00016175499,0.00008208792,0.000005444647,0.00007913363,0.00071929407,0.001437696,0.0025424135],"study_design_scores_gemma":[0.016214477,0.008338387,0.9489975,0.000923345,0.00020529519,0.00007377911,0.00083868357,0.0002690182,0.00039919376,0.0039944774,0.019620892,0.00012496804],"about_ca_topic_score_codex":0.110911466,"about_ca_topic_score_gemma":0.44277483,"teacher_disagreement_score":0.33186337,"about_ca_system_score_codex":0.00024062872,"about_ca_system_score_gemma":0.02688308,"threshold_uncertainty_score":0.9998319},"labels":[],"label_agreement":null},{"id":"W2922530774","doi":"10.1200/jco.2019.37.7_suppl.62","title":"Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Bromodomain; Prostate cancer; Cancer research; BET inhibitor; Cancer; Mutant; Medicine; Downregulation and upregulation; Molecular biology; Epigenetics; Biology; Internal medicine; Genetics; Gene","score_opus":0.0355274068530394,"score_gpt":0.4001736102346286,"score_spread":0.3646462033815892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922530774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975512,0.00065287686,0.00003859071,0.0007593236,0.0006584256,0.00019517509,0.000025874304,0.0000012239992,0.000117278534],"genre_scores_gemma":[0.9981126,0.0008618402,0.000489509,0.00006973345,0.0003324645,0.0000021568396,0.000004872828,0.000012652267,0.00011414802],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979726,0.00018801996,0.001317883,0.00019487801,0.00017205926,0.0001545805],"domain_scores_gemma":[0.9975277,0.00019505175,0.0017811204,0.00014504307,0.00025153143,0.000099511766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013143687,0.00010901297,0.0007772293,0.00008954422,0.000008777423,0.0000029121152,0.000092598246,0.0004433543,0.000016989154],"category_scores_gemma":[0.00045892445,0.00009335421,0.00017103333,0.00012715498,0.00017827054,0.000012242925,0.000080856276,0.0003528162,5.3890693e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005755154,0.0005897973,0.0998148,0.00005682801,0.00017390886,0.0000078824005,0.00008793413,0.0012118146,0.84412247,0.000009065302,0.00030650236,0.04786383],"study_design_scores_gemma":[0.01469695,0.013440265,0.72746795,0.00021146801,0.00014283782,0.00010597429,0.00007407676,0.00063667964,0.23316361,0.00009697542,0.009733054,0.00023012882],"about_ca_topic_score_codex":0.00013801374,"about_ca_topic_score_gemma":0.00038632928,"teacher_disagreement_score":0.6276532,"about_ca_system_score_codex":0.000052457322,"about_ca_system_score_gemma":0.0010710119,"threshold_uncertainty_score":0.38068742},"labels":[],"label_agreement":null},{"id":"W2922677067","doi":"10.1200/jco.2019.37.7_suppl.182","title":"CCN3/NOV as a functional driver and prognostic biomarker of prostate cancer bone metastasis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Connective Tissue Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; McGill University Health Centre; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Bone metastasis; Metastasis; LNCaP; Cancer research; Immunohistochemistry; Tissue microarray; In vivo; Pathology; Ex vivo; Cancer; Internal medicine; Biology","score_opus":0.09780035776442682,"score_gpt":0.45280081116013543,"score_spread":0.3550004533957086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922677067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471253,0.002362825,0.00004117063,0.0014169138,0.000533722,0.00024666972,0.000015200139,0.0000016277933,0.0006693366],"genre_scores_gemma":[0.9973916,0.0009344397,0.00033442696,0.00025222404,0.00026043164,0.0000073251526,0.0000053883987,0.00001397038,0.0008002149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788266,0.0003856942,0.0010044555,0.00023742931,0.00028723362,0.00020250259],"domain_scores_gemma":[0.997589,0.00057953637,0.0008222817,0.0001505489,0.0006605645,0.00019805142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018855304,0.00011379417,0.0006518057,0.00009228656,0.000020979054,0.0000074485024,0.00012884845,0.00024050829,0.0003891747],"category_scores_gemma":[0.0027564522,0.00008591958,0.0002311293,0.00009781877,0.00026906224,0.000010754888,0.00015672695,0.00034988474,0.000016541126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055071856,0.000816592,0.6920802,0.000066008855,0.0009657165,0.000076698125,0.000040785937,0.000010924131,0.18268298,0.00011011053,0.0035077503,0.11413508],"study_design_scores_gemma":[0.005741483,0.009364324,0.81997913,0.000045408833,0.0001583409,0.0002163477,0.0000687961,0.000024522084,0.009070487,0.00028882673,0.15489541,0.00014689953],"about_ca_topic_score_codex":0.000029159715,"about_ca_topic_score_gemma":0.000039795126,"teacher_disagreement_score":0.17361249,"about_ca_system_score_codex":0.00002778043,"about_ca_system_score_gemma":0.0010995776,"threshold_uncertainty_score":0.426119},"labels":[],"label_agreement":null},{"id":"W2923415241","doi":"10.1200/jco.18.02105","title":"Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Calgary","funders":"","keywords":"Medicine; Real world evidence; Internal medicine","score_opus":0.17525855241652183,"score_gpt":0.5119333615079049,"score_spread":0.3366748090913831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923415241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929176,0.0008529375,0.000007828401,0.0017897586,0.0008655253,0.00037237615,0.0000032287078,0.0000038201897,0.0031869542],"genre_scores_gemma":[0.9980475,0.00088039646,0.00034858673,0.00034963049,0.00028672826,0.0000056325557,0.0000014153038,0.0000070604215,0.000073102005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643433,0.0012886166,0.001490355,0.0001832858,0.00045747985,0.00014591774],"domain_scores_gemma":[0.96868616,0.029742246,0.001002991,0.00023759382,0.00021337609,0.000117649055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040100217,0.00010580122,0.0012726755,0.000099723744,0.000012947891,0.0000032081982,0.00024609073,0.0001772096,0.00019749976],"category_scores_gemma":[0.003621989,0.00005905152,0.0003994355,0.00030625734,0.00022457448,0.000102145415,0.00005497234,0.000735662,0.00003596531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011302159,0.0016189519,0.96285474,0.000047380257,0.00017437787,0.00077662576,0.00012604275,0.000047227324,0.000507143,0.00016148316,0.00010788593,0.022275958],"study_design_scores_gemma":[0.005096525,0.007438991,0.9836828,0.00084330543,0.0001235513,0.00007514529,0.000056202512,0.000040585648,0.0001353579,0.00048986665,0.0019680967,0.000049557042],"about_ca_topic_score_codex":0.00039705585,"about_ca_topic_score_gemma":0.00019563186,"teacher_disagreement_score":0.028453631,"about_ca_system_score_codex":0.00025023965,"about_ca_system_score_gemma":0.0010189039,"threshold_uncertainty_score":0.43361205},"labels":[],"label_agreement":null},{"id":"W2923453543","doi":"10.1200/jco.18.02403","title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":616,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Diffuse large B-cell lymphoma; Rituximab; Population; CHOP; Hazard ratio; Cyclophosphamide; Gastroenterology; Oncology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia; Confidence interval","score_opus":0.03015399178565479,"score_gpt":0.38829917842144357,"score_spread":0.35814518663578876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923453543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914711,0.00197169,0.000024055378,0.0009888334,0.0010399561,0.0015176898,0.000024148647,0.000006271807,0.0029562402],"genre_scores_gemma":[0.9924,0.0048251026,0.001066521,0.00079585693,0.00043309334,0.000022236654,0.0000100354855,0.000024546423,0.00042261317],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99420696,0.00064948865,0.003937433,0.00037890824,0.0004307862,0.00039640983],"domain_scores_gemma":[0.9917858,0.0046742894,0.0025387695,0.00027155803,0.00024590545,0.0004836365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042218277,0.00030281142,0.0049192198,0.00021642593,0.000033561908,0.000015389754,0.00013371593,0.00047653404,0.000092494396],"category_scores_gemma":[0.0012665129,0.00020171324,0.0006560002,0.00013097018,0.00032912876,0.00012551203,0.00012987693,0.00041050356,0.000012518367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8507441,0.10545584,0.025564903,0.00015373917,0.00030194974,0.0011122159,0.0002454925,4.276998e-7,0.00015931288,0.00003811615,0.00072882086,0.015495024],"study_design_scores_gemma":[0.9567341,0.018880017,0.016670214,0.00024164544,0.000936233,0.00032722726,0.00012701494,0.0004647571,0.00053630635,0.000059659997,0.00486553,0.00015727768],"about_ca_topic_score_codex":0.00009312084,"about_ca_topic_score_gemma":0.000019956047,"teacher_disagreement_score":0.10598996,"about_ca_system_score_codex":0.00018933379,"about_ca_system_score_gemma":0.0010143267,"threshold_uncertainty_score":0.8225627},"labels":[],"label_agreement":null},{"id":"W2926245852","doi":"10.1200/jco.18.00622","title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Lung cancer; Toxicity; Nuclear medicine; Oncology; Dose fractionation; Internal medicine; Radiology","score_opus":0.04541880917222,"score_gpt":0.4418866063995124,"score_spread":0.39646779722729236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926245852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839666,0.0022963928,0.00031374887,0.007984578,0.002842162,0.0020716991,0.000012680216,0.0000084154835,0.0005037579],"genre_scores_gemma":[0.98090523,0.012578257,0.0029926181,0.0013663408,0.0016751823,0.00003562309,0.000009537267,0.000032900443,0.00040431618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964749,0.00034133493,0.0023131869,0.0003092745,0.00025404457,0.00030722763],"domain_scores_gemma":[0.9918679,0.004384774,0.002653042,0.0002296634,0.0005060464,0.00035858862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019961302,0.00020437667,0.002232315,0.00012110983,0.00004349229,0.000010143203,0.00013128103,0.00051986886,0.00021179493],"category_scores_gemma":[0.00064618234,0.0001457089,0.0005805094,0.00011620119,0.00011776478,0.000112551024,0.000027017652,0.00068597205,0.0000032636221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6210048,0.01658685,0.23893179,0.00058530894,0.0048270216,0.00018433365,0.00035749658,0.00022063516,0.0016071213,0.00005006406,0.00484602,0.11079855],"study_design_scores_gemma":[0.5627654,0.091239296,0.24215195,0.0005835699,0.003795944,0.00014370387,0.00012965649,0.0027219616,0.000779582,0.000024461235,0.09543736,0.00022708497],"about_ca_topic_score_codex":0.00010140415,"about_ca_topic_score_gemma":0.000059513513,"teacher_disagreement_score":0.11057147,"about_ca_system_score_codex":0.0012178562,"about_ca_system_score_gemma":0.0034596708,"threshold_uncertainty_score":0.6137307},"labels":[],"label_agreement":null},{"id":"W2928272073","doi":"10.1200/jco.18.02096","title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Multiple myeloma; Randomized controlled trial; Evidence-based medicine; Systematic review; MEDLINE; Intensive care medicine; Evidence-based practice; Family medicine; Quality of life (healthcare); Clinical trial; Oncology; Internal medicine; Alternative medicine; Nursing; Pathology","score_opus":0.20892787530049778,"score_gpt":0.5413060471164012,"score_spread":0.3323781718159034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928272073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97697175,0.0017792387,0.00012916363,0.013490269,0.0011411385,0.00066024443,0.000010056037,0.00000911314,0.005809056],"genre_scores_gemma":[0.9247008,0.005998571,0.06617981,0.0011561902,0.0012089616,0.000004742594,0.000008679785,0.000022969798,0.00071926607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9929564,0.0009404433,0.0048658224,0.0003082922,0.000610421,0.00031862836],"domain_scores_gemma":[0.9856548,0.009116032,0.002754642,0.00038473864,0.0012534991,0.00083634193],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0046660136,0.0001994559,0.0025586914,0.0001548401,0.000029388846,0.000008439392,0.000113451344,0.00045363398,0.00024828952],"category_scores_gemma":[0.023138775,0.00012114778,0.0007888899,0.000114216455,0.0003002549,0.0001734337,0.000078971214,0.0006783625,0.00009241917],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014111787,0.0093355,0.48398095,0.000035008437,0.0015878519,0.0016642464,0.00005543043,0.0000031708414,0.00038056474,0.00004231622,0.0028339932,0.4859692],"study_design_scores_gemma":[0.047387443,0.07581912,0.48731148,0.000073178904,0.00069928216,0.0015191233,0.00023673421,0.000673329,0.00028301898,0.00006279131,0.38583598,0.00009851284],"about_ca_topic_score_codex":0.00007763817,"about_ca_topic_score_gemma":0.000020768857,"teacher_disagreement_score":0.48587066,"about_ca_system_score_codex":0.00017394742,"about_ca_system_score_gemma":0.0018077743,"threshold_uncertainty_score":0.9850897},"labels":[],"label_agreement":null},{"id":"W2935776045","doi":"10.1200/jco.2015.33.15_suppl.e20522","title":"Geriatric preoperative assessment of elderly patients with gastrointestinal cancer: Clinical factors and prognostic implication.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Univariate analysis; Gastrointestinal cancer; Medical record; Delirium; Internal medicine; Retrospective cohort study; Surgery; Multivariate analysis; Intensive care medicine","score_opus":0.133141524036513,"score_gpt":0.4941518546437067,"score_spread":0.3610103306071937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935776045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969176,0.0001784154,0.00016085978,0.0009126441,0.0004014538,0.00056014745,0.00001308981,0.0000075830053,0.00084817846],"genre_scores_gemma":[0.98835766,0.00014183173,0.010973809,0.00012229737,0.00033280035,0.000015632446,0.000005942344,0.000014705283,0.000035338428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961885,0.000511029,0.0023249267,0.00025421884,0.00052037946,0.00020095381],"domain_scores_gemma":[0.99210805,0.002989202,0.0022149421,0.00015390002,0.0017881456,0.00074579025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016555967,0.00017548431,0.0016293625,0.00009157305,0.000024740162,0.000008342598,0.0001118922,0.00016339678,0.000042928838],"category_scores_gemma":[0.004114739,0.000098603756,0.00024294766,0.00019511476,0.00033988053,0.00012535046,0.000060709546,0.0007276807,0.0000010273566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004041853,0.0029935017,0.96723425,0.000020770312,0.00032332333,0.000068864276,0.000039617265,0.000008029253,0.0000024409962,0.000019007455,0.00023952813,0.025008827],"study_design_scores_gemma":[0.012766628,0.08722475,0.8981305,0.0001387908,0.00059370603,0.00011856098,0.00005962419,0.0000399917,0.0000054498396,0.000045909834,0.00080229,0.00007380614],"about_ca_topic_score_codex":0.00005116585,"about_ca_topic_score_gemma":0.00003868461,"teacher_disagreement_score":0.08423125,"about_ca_system_score_codex":0.00026717165,"about_ca_system_score_gemma":0.0039461013,"threshold_uncertainty_score":0.70002145},"labels":[],"label_agreement":null},{"id":"W2935820515","doi":"10.1200/jco.19.00281","title":"Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Oxaliplatin; Guideline; Oncology; Colorectal cancer; Adjuvant; Internal medicine; Cancer; Stage (stratigraphy); Clinical Practice; Adjuvant therapy; Family medicine; Pathology","score_opus":0.43743843882417877,"score_gpt":0.637752291713975,"score_spread":0.2003138528897962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935820515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016526065,0.9830464,0.00028407582,0.0024023848,0.006518365,0.0033174958,0.0001263802,0.0000162677,0.0026360063],"genre_scores_gemma":[0.0003587548,0.9804847,0.011660347,0.0019333662,0.00449442,0.00011199689,0.00008158906,0.00008857634,0.0007862168],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9802895,0.002125492,0.015715266,0.0006031522,0.00084286643,0.00042370876],"domain_scores_gemma":[0.9421912,0.031461157,0.02262477,0.0005027831,0.0027032522,0.00051682733],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.016261404,0.00053749495,0.013100802,0.0002447742,0.00005765855,0.000014671091,0.00040958318,0.0019365806,0.00032409467],"category_scores_gemma":[0.024204662,0.00034616713,0.004306103,0.0003057803,0.00027778148,0.00022123253,0.00011031348,0.0025117307,0.0000143509815],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027990205,0.0025161896,0.00077297736,0.0018285763,0.004085307,0.000345997,0.000029083112,0.0000055727432,7.424974e-7,0.00006186831,0.0054297023,0.9569338],"study_design_scores_gemma":[0.020488808,0.056920756,0.00049024634,0.00504017,0.0073161083,0.0003282728,0.00005354075,0.000055685778,0.000001599305,0.00002014898,0.909047,0.00023766812],"about_ca_topic_score_codex":0.00009426535,"about_ca_topic_score_gemma":0.0000507294,"teacher_disagreement_score":0.9566961,"about_ca_system_score_codex":0.00084456627,"about_ca_system_score_gemma":0.014322772,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W2935992323","doi":"10.1200/jco.2015.33.15_suppl.7066","title":"Digital <i>Fusion-Gene</i> expression profiling in acute leukemia (AL): Clinical validation of throughput molecular technology in laboratory medicine.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fusion gene; Chromosomal translocation; Medicine; Concordance; Gene expression profiling; breakpoint cluster region; ABL; Fusion transcript; Oncology; Cancer research; Gene expression; Computational biology; Gene; Bioinformatics; Internal medicine; Biology; Genetics; Tyrosine kinase","score_opus":0.10116976483108321,"score_gpt":0.4765078047867848,"score_spread":0.3753380399557016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935992323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98006696,0.0006677813,0.0005970545,0.015636928,0.0009087581,0.0004464229,0.000006494683,0.000018375651,0.0016512288],"genre_scores_gemma":[0.98155814,0.0012281449,0.014727914,0.0017712638,0.0005956869,0.000009819922,0.000016477381,0.00003758576,0.000054941193],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9913445,0.0010566752,0.0057318583,0.00043799193,0.0009903342,0.0004386348],"domain_scores_gemma":[0.9927854,0.0023996388,0.0024014967,0.00049005944,0.0013665227,0.0005568756],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012071541,0.00023052271,0.0025840746,0.00083926966,0.000018060051,0.000008984077,0.0005005136,0.0012775153,0.00002808705],"category_scores_gemma":[0.02854583,0.00016592354,0.00030539383,0.0011226628,0.0009364967,0.00042541025,0.00031900153,0.003346436,0.000019066802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012732178,0.0025940312,0.8036315,0.000079163896,0.00033275838,0.008975797,0.00025728683,0.0004023437,0.10196432,0.00017711308,0.013140363,0.055713173],"study_design_scores_gemma":[0.2214386,0.11189192,0.11446077,0.0054207835,0.001290804,0.0037913558,0.0074729747,0.0046357084,0.41846967,0.013512001,0.096136525,0.0014788823],"about_ca_topic_score_codex":0.000014191154,"about_ca_topic_score_gemma":0.000004765289,"teacher_disagreement_score":0.6891707,"about_ca_system_score_codex":0.0010398985,"about_ca_system_score_gemma":0.008810888,"threshold_uncertainty_score":0.99895287},"labels":[],"label_agreement":null},{"id":"W2937134473","doi":"10.1200/jco.2015.33.15_suppl.10075","title":"Longitudinal smoking patterns in survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) update.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Population; Demography; Cancer; Pediatrics; Internal medicine; Environmental health","score_opus":0.17479615493533263,"score_gpt":0.48468377574810523,"score_spread":0.3098876208127726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937134473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979192,0.0031495455,0.000060374216,0.011029336,0.0051539317,0.00087871205,0.0000649755,0.000029966826,0.0004411334],"genre_scores_gemma":[0.99138254,0.0021834662,0.00032559605,0.0025596207,0.003379011,0.000035498564,0.000007299572,0.000079497535,0.00004747029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98742926,0.0023271227,0.006936641,0.0006903978,0.0018744355,0.000742167],"domain_scores_gemma":[0.98966,0.0021880108,0.004997668,0.0006881729,0.0013029716,0.001163159],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014997344,0.00049660355,0.004748016,0.00048558766,0.00005747965,0.000023978699,0.0007605338,0.000640948,0.0003770605],"category_scores_gemma":[0.0053869723,0.0004079611,0.00088981655,0.0007733645,0.00029105946,0.00034670875,0.00029110475,0.0027726833,0.000010543762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025746375,0.013538815,0.9429806,0.00009368477,0.0014572467,0.00059499685,0.005136589,0.0002001651,0.000004808214,0.000018796325,0.0012895989,0.032110065],"study_design_scores_gemma":[0.02365633,0.011688217,0.9535917,0.00088077236,0.00087771815,0.0002039416,0.0044044373,0.000022422208,0.00004583135,0.00016379877,0.004114173,0.00035064737],"about_ca_topic_score_codex":0.021914804,"about_ca_topic_score_gemma":0.09302387,"teacher_disagreement_score":0.07110906,"about_ca_system_score_codex":0.00069522735,"about_ca_system_score_gemma":0.007367813,"threshold_uncertainty_score":0.9998372},"labels":[],"label_agreement":null},{"id":"W2937305232","doi":"10.1200/jco.2015.33.15_suppl.e11559","title":"Long-term consequences of ovarian ablation for premenopausal breast cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; University of British Columbia","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Population; Gynecology; Oncology; Aromatase inhibitor; Internal medicine; Cancer; Obstetrics","score_opus":0.08784071211632306,"score_gpt":0.4447684368637817,"score_spread":0.35692772474745865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937305232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948405,0.001185113,0.00084520644,0.0014639951,0.0010967602,0.00014750812,0.000015304162,0.0000018767113,0.00040376172],"genre_scores_gemma":[0.9966604,0.00044477146,0.0015369641,0.00018086718,0.001066889,0.0000041550365,0.00000898141,0.000008661784,0.00008827701],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99839914,0.00022680065,0.0009953578,0.000118137315,0.0001304954,0.00013007873],"domain_scores_gemma":[0.99778354,0.00018424341,0.0011821168,0.00009647687,0.0005574304,0.0001962161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017942035,0.00008060518,0.0004600664,0.000031695246,0.00001914308,0.000004533927,0.00015416864,0.0004070682,0.000010234207],"category_scores_gemma":[0.0007402734,0.00005826446,0.00018604186,0.000041917752,0.00022495355,0.0000071484537,0.000030231475,0.00020319369,0.0000011524226],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02139022,0.0016906024,0.36560357,0.00009609062,0.0017770008,0.00010812742,0.00009138408,0.0005887926,0.44727236,0.00057481474,0.012455403,0.14835162],"study_design_scores_gemma":[0.03511003,0.09335008,0.6456802,0.0003338706,0.0014682617,0.0024654332,0.00014016512,0.00022984501,0.18429005,0.0022783529,0.033973478,0.0006802489],"about_ca_topic_score_codex":0.000013510943,"about_ca_topic_score_gemma":0.000014901872,"teacher_disagreement_score":0.2800766,"about_ca_system_score_codex":0.000025894922,"about_ca_system_score_gemma":0.0015581566,"threshold_uncertainty_score":0.31396827},"labels":[],"label_agreement":null},{"id":"W2937974648","doi":"10.1200/jco.2015.33.15_suppl.e19065","title":"Early and late brain metastases in EGFR wild type and EGFR mutation positive non small cell lung cancer: Implications for survival.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Retrospective cohort study; Cohort; Radiation therapy; Gastroenterology; Pathology; Cancer","score_opus":0.10206436964531386,"score_gpt":0.5015900971370302,"score_spread":0.39952572749171633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937974648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974922,0.0019273919,0.0005687542,0.020899298,0.0003864676,0.00043353066,0.000039473758,0.000003640334,0.00081944227],"genre_scores_gemma":[0.9928038,0.0007064654,0.004485042,0.0013299002,0.00026049497,0.00002138159,0.000017712619,0.000011992698,0.00036322046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988148,0.00014036628,0.00071314664,0.00013541471,0.00007426387,0.00012199502],"domain_scores_gemma":[0.9971827,0.0014328769,0.0005143091,0.00006466649,0.00055602216,0.0002494092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067229,0.00008117379,0.00055749697,0.000090566355,0.000032095046,0.000011006489,0.000036022466,0.00012316501,0.000004253254],"category_scores_gemma":[0.0009229377,0.00006057675,0.000066652734,0.00011931483,0.00007009198,0.000099215606,0.000016260994,0.00021152242,5.904511e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043721246,0.0015702349,0.8230553,0.000106811814,0.00092445326,0.00015336454,0.0024255286,0.00015753586,0.00068382605,0.0005503885,0.0050051184,0.1609953],"study_design_scores_gemma":[0.012443074,0.0067670704,0.9711188,0.00008088321,0.0010407333,0.000057467896,0.00022965527,0.00024106223,0.000045188626,0.00074493716,0.0071596974,0.00007144326],"about_ca_topic_score_codex":0.00035501414,"about_ca_topic_score_gemma":0.00048815823,"teacher_disagreement_score":0.16092387,"about_ca_system_score_codex":0.00017771889,"about_ca_system_score_gemma":0.0013542383,"threshold_uncertainty_score":0.2470248},"labels":[],"label_agreement":null},{"id":"W2939833210","doi":"10.1200/jco.2015.33.15_suppl.10020","title":"Temporal trends in health status among adults in the Childhood Cancer Survivor Study (CCSS).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Anxiety; Cancer; Confidence interval; Pediatrics; Internal medicine; Psychiatry","score_opus":0.20267816921273626,"score_gpt":0.5297678227729743,"score_spread":0.327089653560238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939833210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93943363,0.002706975,0.000004265224,0.05440387,0.0019222402,0.0005734171,0.00000911862,0.000011553555,0.00093490665],"genre_scores_gemma":[0.9830265,0.0007269521,0.00023462938,0.013933082,0.0019060905,0.000019423134,0.000005876704,0.00002710937,0.0001203335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98772377,0.004755671,0.005358504,0.00036420216,0.0011877648,0.0006100704],"domain_scores_gemma":[0.99323785,0.0022081216,0.0029184732,0.00042573357,0.00032817147,0.00088164594],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.025124501,0.00024162128,0.0025648098,0.00047666387,0.000036621626,0.000016723394,0.00042569145,0.00031203774,0.000118159405],"category_scores_gemma":[0.004745644,0.00015498126,0.00038520753,0.0008193039,0.00021710621,0.00022929574,0.000081736885,0.002570357,0.0000070665023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035866231,0.010223049,0.89445543,0.000025335234,0.00013801015,0.00041647724,0.017682146,0.000044203833,6.0592e-8,0.000007157873,0.013198657,0.060222864],"study_design_scores_gemma":[0.026566293,0.022076162,0.9044851,0.00031180208,0.000065286324,0.000060122064,0.014891451,0.000031128286,2.4131018e-7,0.00006174143,0.031323478,0.00012721472],"about_ca_topic_score_codex":0.031653978,"about_ca_topic_score_gemma":0.20798679,"teacher_disagreement_score":0.17633282,"about_ca_system_score_codex":0.00063680136,"about_ca_system_score_gemma":0.0056970264,"threshold_uncertainty_score":0.99993974},"labels":[],"label_agreement":null},{"id":"W2939988319","doi":"10.1200/jco.2015.33.15_suppl.e20094","title":"Evolution of BRAF gene mutation testing and treatment options in BRAF mutation carriers in Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dabrafenib; Vemurafenib; Trametinib; Medicine; Ipilimumab; Oncology; Internal medicine; Melanoma; Mutation; Cancer; Metastatic melanoma; Immunotherapy; Cancer research; Gene; MAPK/ERK pathway; Genetics","score_opus":0.09995703269657306,"score_gpt":0.37960054990944736,"score_spread":0.2796435172128743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939988319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984683,0.00045167972,0.0002424448,0.0002058978,0.00030738124,0.00008064595,0.000005807638,6.1868127e-7,0.00023725424],"genre_scores_gemma":[0.9962554,0.00008572845,0.0033975,0.000055008837,0.00017955362,0.0000026851505,0.000007690542,0.000004340017,0.000012111807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985318,0.0002526622,0.00090706535,0.000108049986,0.000099770725,0.00010062397],"domain_scores_gemma":[0.9987985,0.00023418132,0.0005817701,0.000063736414,0.00019252548,0.00012931267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009450303,0.00006228113,0.00032503117,0.000068625974,0.000010419867,0.000002094128,0.00004848536,0.00014742515,0.0000013102039],"category_scores_gemma":[0.0023698343,0.000053400297,0.000042329397,0.000085749285,0.000045048662,0.0000072573903,0.000016462336,0.00011347961,1.883528e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012164142,0.0006151538,0.76365286,0.000016568274,0.00010120306,0.0005836108,0.00030893556,0.012326359,0.05256103,0.0000924832,0.00037365584,0.16815175],"study_design_scores_gemma":[0.0082699675,0.010787523,0.96833414,0.000035743975,0.00006126948,0.00047035192,0.0012650875,0.0022393744,0.0060929614,0.00068403303,0.0016278515,0.00013170844],"about_ca_topic_score_codex":0.100697465,"about_ca_topic_score_gemma":0.5643015,"teacher_disagreement_score":0.463604,"about_ca_system_score_codex":0.00036922615,"about_ca_system_score_gemma":0.0051724934,"threshold_uncertainty_score":0.91757816},"labels":[],"label_agreement":null},{"id":"W2939993825","doi":"10.1200/jco.2015.33.15_suppl.9578","title":"Cardiac care after myocardial infarction in cancer survivors: A population-based study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; St. Michael's Hospital; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myocardial infarction; Psychological intervention; Internal medicine; Cohort; Cancer; Population; Emergency medicine; Surgery","score_opus":0.11510652901787895,"score_gpt":0.4685050866469929,"score_spread":0.353398557629114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939993825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938427,0.00061159173,0.000029981838,0.0019436292,0.0026481864,0.00039072812,0.000004312238,0.000009100943,0.0005197561],"genre_scores_gemma":[0.99551904,0.00006343259,0.00026328914,0.0015177391,0.0025651078,0.00002469515,0.0000066544694,0.000015449148,0.00002460534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707276,0.0007352482,0.0014010383,0.00016325191,0.0004711823,0.00015652299],"domain_scores_gemma":[0.9978113,0.00047781863,0.00062203413,0.00015362889,0.0006439867,0.00029122288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027064849,0.0001141395,0.0011660743,0.00018189684,0.000016412001,0.000008440902,0.00006198899,0.00036417213,0.000031228523],"category_scores_gemma":[0.0013556522,0.00009245704,0.0005851244,0.00020779052,0.000037525708,0.000115273935,0.000014303691,0.000748934,0.0000046677364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003667286,0.00065361144,0.95375,0.000016008167,0.00025164604,0.00010358061,0.00093218556,0.00034760372,0.00012866376,0.0000016912816,0.00017025378,0.039977428],"study_design_scores_gemma":[0.008752844,0.0048776376,0.97513074,0.000079121695,0.0003076791,0.0000107852275,0.001549852,0.000028481225,0.00012485443,0.000040828712,0.009007737,0.000089439316],"about_ca_topic_score_codex":0.0013410415,"about_ca_topic_score_gemma":0.0025717323,"teacher_disagreement_score":0.039887987,"about_ca_system_score_codex":0.00071216753,"about_ca_system_score_gemma":0.00207123,"threshold_uncertainty_score":0.37702888},"labels":[],"label_agreement":null},{"id":"W2941651034","doi":"10.1200/jco.19.00441","title":"Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology","keywords":"Medicine; Context (archaeology); Clinical trial; Radiation therapy; Disease; Cancer; Systemic therapy; Stage (stratigraphy); Intensive care medicine; Oncology; Internal medicine","score_opus":0.16038123513863095,"score_gpt":0.521495729756904,"score_spread":0.361114494618273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941651034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825599,0.0026202626,0.00000703832,0.007924615,0.0011665702,0.00046676848,0.0000050243825,0.0000018714618,0.0052479547],"genre_scores_gemma":[0.9772473,0.020495918,0.000989364,0.0005891368,0.00054232834,0.00001059262,0.000002199931,0.000007051046,0.00011611553],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99627084,0.0003887861,0.0026947395,0.00016456013,0.00033961842,0.00014147273],"domain_scores_gemma":[0.99651283,0.0013150315,0.001498744,0.00021192725,0.0003669016,0.00009458191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003124595,0.00010042119,0.0015752283,0.00007662363,0.000015212895,0.0000015142977,0.00016022011,0.00017648604,0.00006610223],"category_scores_gemma":[0.00025670187,0.0000537723,0.00044037233,0.00012331728,0.00017375482,0.00004478622,0.000039784634,0.00040649268,0.0000075026037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007241987,0.00415426,0.40126354,0.00015143087,0.0008440223,0.000047557303,0.000343089,0.00002001931,0.00033168492,0.00078937004,0.0013342621,0.5834788],"study_design_scores_gemma":[0.0082803,0.027157214,0.90745133,0.00042349726,0.0002661955,0.000031105417,0.0009965042,0.0001350186,0.00008656777,0.00014643525,0.054979205,0.000046601304],"about_ca_topic_score_codex":0.00009591769,"about_ca_topic_score_gemma":0.0000399214,"teacher_disagreement_score":0.5834322,"about_ca_system_score_codex":0.00017070422,"about_ca_system_score_gemma":0.0009698674,"threshold_uncertainty_score":0.21927707},"labels":[],"label_agreement":null},{"id":"W2942550491","doi":"10.1200/jco.19.00321","title":"FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Astellas Pharma","keywords":"Medicine; Transplantation; Randomized controlled trial; Placebo; Internal medicine; Oncology; Alternative medicine; Pathology","score_opus":0.05451053573607225,"score_gpt":0.4402787948149593,"score_spread":0.38576825907888707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942550491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.917205,0.0004648297,0.0005929636,0.06932624,0.0031135876,0.0028730545,0.0000069093744,0.000014786111,0.006402663],"genre_scores_gemma":[0.9576126,0.002863907,0.00405612,0.024937583,0.0046094838,0.00011410364,0.000003548012,0.000038447328,0.0057642595],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907795,0.0028957648,0.0045559253,0.00034251946,0.0009626056,0.0004636513],"domain_scores_gemma":[0.97941554,0.016896429,0.0018412614,0.0003256318,0.00090710353,0.00061406195],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.020376317,0.00024028632,0.0050375247,0.00023422598,0.000032831515,0.000019612884,0.00029236384,0.0015315822,0.0025495489],"category_scores_gemma":[0.013033801,0.00014161893,0.002254177,0.00017946764,0.0005026797,0.000111548514,0.00004772127,0.0044401903,0.0005351832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9758183,0.0006160912,0.0009186159,0.00006627953,0.0011492597,0.0017972884,0.00022314463,0.000004593341,0.0002155817,0.00010137858,0.0131949205,0.0058945427],"study_design_scores_gemma":[0.9524499,0.007865611,0.0007731713,0.00017531253,0.0010594472,0.0008396607,0.00005207275,0.00032285377,0.00009247471,0.0003789584,0.03585442,0.00013609976],"about_ca_topic_score_codex":0.000009803795,"about_ca_topic_score_gemma":0.000008263925,"teacher_disagreement_score":0.044388656,"about_ca_system_score_codex":0.0003193649,"about_ca_system_score_gemma":0.0045936606,"threshold_uncertainty_score":0.9997646},"labels":[],"label_agreement":null},{"id":"W2943339517","doi":"10.1200/jco.18.01358","title":"Cognitive Implications of Ototoxicity in Pediatric Patients With Embryonal Brain Tumors","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Ototoxicity; Medicine; Cognitive impairment; Cognition; Hearing loss; Audiology; Pediatrics; Oncology; Chemotherapy; Internal medicine; Psychiatry; Cisplatin","score_opus":0.10152839505850057,"score_gpt":0.43531961681642606,"score_spread":0.33379122175792547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943339517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940438,0.000010562447,0.00010728782,0.001053507,0.00033698892,0.00033905415,0.000014424628,0.000004852449,0.0040894956],"genre_scores_gemma":[0.99698013,0.000036559035,0.00062809733,0.0020426412,0.00020657542,0.000002998092,7.672638e-7,0.000015000966,0.00008724887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996129,0.0007617036,0.0021352738,0.0002662859,0.0004365067,0.0002712484],"domain_scores_gemma":[0.98926467,0.007576965,0.0022658973,0.00017957769,0.0004829782,0.00022993411],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00194151,0.00011952499,0.0008429926,0.00023201156,0.000026301166,0.0000076917195,0.000360608,0.000214045,0.00010257713],"category_scores_gemma":[0.015440037,0.00009337071,0.00016353012,0.0004690051,0.00022545972,0.0001266991,0.000106781226,0.0009600498,0.000046893023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076366204,0.0016175399,0.9905381,0.000016184717,0.000008815539,0.000021179401,0.00007833486,0.00007191827,0.0007878945,0.00013483326,0.00019414599,0.0057673557],"study_design_scores_gemma":[0.0044000153,0.0058935476,0.9879006,0.000036488258,0.000031075637,0.000020408364,0.000027970107,0.00003620703,0.00065440347,0.00033745333,0.00056419085,0.000097652235],"about_ca_topic_score_codex":0.00000580537,"about_ca_topic_score_gemma":0.000029367287,"teacher_disagreement_score":0.013498527,"about_ca_system_score_codex":0.000073818475,"about_ca_system_score_gemma":0.0015246028,"threshold_uncertainty_score":0.99285334},"labels":[],"label_agreement":null},{"id":"W2944301866","doi":"10.1200/jco.19.00201","title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Ignyta; University of Texas MD Anderson Cancer Center; Genentech","keywords":"Medicine; Clinical endpoint; Radiation therapy; Lung cancer; Randomized controlled trial; Surgery; Systemic therapy; Progression-free survival; Internal medicine; Cancer; Chemotherapy","score_opus":0.1064471531521062,"score_gpt":0.4624029523308717,"score_spread":0.3559557991787655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944301866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883633,0.00058897515,0.0030279541,0.0013862748,0.000711524,0.0058033788,0.00007724518,0.000005526695,0.00003580018],"genre_scores_gemma":[0.98940915,0.0043739146,0.004341793,0.0011594525,0.00015275476,0.00027973374,0.000032653603,0.000021296459,0.00022926644],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961058,0.0004364156,0.0025137332,0.00030986386,0.00040101242,0.00023316586],"domain_scores_gemma":[0.9905652,0.0042374544,0.003152526,0.00023362572,0.0016137395,0.00019744383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023493178,0.00024460958,0.002736353,0.00011320792,0.0000627821,0.000008158986,0.00015078837,0.00014797982,0.00006461731],"category_scores_gemma":[0.00084364903,0.000115989926,0.00048472921,0.00016336577,0.00030555643,0.00012917195,0.000022992002,0.00032947093,0.000001287204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5925357,0.0374123,0.32332128,0.00009001806,0.0026208223,0.00008683627,0.0005917093,0.00014147145,0.0000111275685,0.0000052262585,0.00030167846,0.04288187],"study_design_scores_gemma":[0.6895117,0.092964046,0.21429947,0.00041738368,0.00092887186,0.000008179347,0.00010274054,0.000991313,0.00020544136,0.0000046941104,0.00046308347,0.0001030611],"about_ca_topic_score_codex":0.00007586949,"about_ca_topic_score_gemma":0.00014599226,"teacher_disagreement_score":0.10902183,"about_ca_system_score_codex":0.00040958734,"about_ca_system_score_gemma":0.0027802705,"threshold_uncertainty_score":0.49320805},"labels":[],"label_agreement":null},{"id":"W2945661283","doi":"10.1200/jco.19.00315","title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Dacarbazine; Adverse effect; Neutropenia; Clinical endpoint; Tolerability; Rash; Oncology; Surgery; Cancer; Chemotherapy; Clinical trial; Immunotherapy","score_opus":0.07774469496044747,"score_gpt":0.46104854099773945,"score_spread":0.38330384603729195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945661283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962885,0.0007859219,0.000024184865,0.006186897,0.0007985705,0.0017578166,0.000012359998,0.000007683936,0.00079770276],"genre_scores_gemma":[0.99528986,0.0010194688,0.00072884274,0.0021292889,0.00037500536,0.00004018405,0.0000051675534,0.000019452487,0.00039272022],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964218,0.00048593496,0.0021445435,0.00029960944,0.00033743356,0.00031063528],"domain_scores_gemma":[0.9904756,0.0075616017,0.0012280452,0.00031864177,0.00017292779,0.00024319628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036567464,0.00020406501,0.0017047416,0.000111223584,0.00008643019,0.000016364482,0.00020474022,0.00024013723,0.00009649243],"category_scores_gemma":[0.0025153358,0.00011534323,0.0004197076,0.00015077763,0.00012076304,0.00012532622,0.000073958065,0.0003359856,0.000012055688],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026370998,0.06983307,0.11323563,0.000040752777,0.0005510481,0.001720516,0.0010259104,0.000039512353,0.00003837027,0.00034902373,0.0021135309,0.7846816],"study_design_scores_gemma":[0.22489326,0.08504176,0.5792916,0.00008723456,0.00045208455,0.00014051268,0.0010182579,0.00015529568,0.000012882119,0.00009064213,0.108713366,0.00010310638],"about_ca_topic_score_codex":0.00003394136,"about_ca_topic_score_gemma":0.000122413,"teacher_disagreement_score":0.7845785,"about_ca_system_score_codex":0.0002940984,"about_ca_system_score_gemma":0.0008573591,"threshold_uncertainty_score":0.47035605},"labels":[],"label_agreement":null},{"id":"W2946833429","doi":"10.1200/jco.2019.37.15_suppl.6500","title":"Effect of montelukast and rupatadine on rituximab infusion time, rate, severity of reactions, and cost of administration.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Royal Victoria Regional Health Centre; Barrie Urology Group","funders":"","keywords":"Medicine; Rituximab; Diphenhydramine; Montelukast; Internal medicine; Gastroenterology; Anesthesia; Asthma; Lymphoma","score_opus":0.04399686101824434,"score_gpt":0.4408276135542058,"score_spread":0.39683075253596145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946833429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231315,0.00007545219,0.000009157524,0.00071870314,0.00035553682,0.0003264805,0.000014798645,0.0000033182696,0.006183392],"genre_scores_gemma":[0.99852,0.00053195463,0.00041254956,0.00008227846,0.0001286404,0.0000012412524,0.0000043501955,0.000008457453,0.00031053674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974068,0.00044997488,0.0016996844,0.00012998033,0.00022048097,0.00009312036],"domain_scores_gemma":[0.9927283,0.0046022693,0.0019571926,0.00017466651,0.00035433323,0.00018324904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002995402,0.00010191439,0.0014080639,0.00015910866,0.000017042908,0.0000019781805,0.000052864914,0.000282342,0.000035319077],"category_scores_gemma":[0.004067783,0.00007576906,0.00018408458,0.00011588208,0.00021367267,0.00012362217,0.000033775428,0.00062130677,0.0000074930667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022205204,0.00959085,0.17327255,0.0011976368,0.001004656,0.00019238087,0.00012673115,0.000036121455,0.16375786,0.00028451724,0.0012278657,0.6271036],"study_design_scores_gemma":[0.02192683,0.036129285,0.8957042,0.0007445891,0.0007135578,0.0008588012,0.000102350445,0.00037169294,0.018201767,0.000052952295,0.02508502,0.000108939064],"about_ca_topic_score_codex":0.000030081586,"about_ca_topic_score_gemma":0.000010289242,"teacher_disagreement_score":0.72243166,"about_ca_system_score_codex":0.000050928586,"about_ca_system_score_gemma":0.00058516255,"threshold_uncertainty_score":0.48698097},"labels":[],"label_agreement":null},{"id":"W2946835497","doi":"10.1200/jco.2019.37.15_suppl.6026","title":"Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Docetaxel; Oncology; Internal medicine; Population; Radiation therapy; Clinical endpoint; Clinical trial; Cancer","score_opus":0.12327658474516984,"score_gpt":0.49281692595415894,"score_spread":0.3695403412089891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946835497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790396,0.016186127,0.000028564893,0.0033039195,0.0005780988,0.00063477305,0.00007558716,0.000004947427,0.00014839838],"genre_scores_gemma":[0.99293804,0.00522905,0.0007114269,0.00044804226,0.00040039662,0.000010437167,0.000011522912,0.000016488779,0.00023459375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974488,0.00020614537,0.0016287463,0.00025692474,0.00022233206,0.00023701992],"domain_scores_gemma":[0.99576074,0.0018383847,0.0011759446,0.00016665322,0.00040890515,0.0006493809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006444709,0.0001883296,0.0017803613,0.00014421929,0.00005128735,0.000007762497,0.00005793256,0.00014022348,0.000030473182],"category_scores_gemma":[0.0012524005,0.00012568058,0.00038228175,0.000076653625,0.00014459266,0.00009079754,0.000032297834,0.00024408477,0.0000022026984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15848665,0.007660277,0.15840277,0.00070184225,0.00045515667,0.0002222154,0.00085260184,0.000014394475,0.0021929205,0.000016844842,0.001943661,0.6690507],"study_design_scores_gemma":[0.12880065,0.23516612,0.6052356,0.00015733506,0.0019034183,0.00007781845,0.0002147316,0.0007364905,0.00082772877,0.000108976725,0.026580364,0.00019081747],"about_ca_topic_score_codex":0.000045303572,"about_ca_topic_score_gemma":0.00005229678,"teacher_disagreement_score":0.66885984,"about_ca_system_score_codex":0.00019896578,"about_ca_system_score_gemma":0.0017031515,"threshold_uncertainty_score":0.51251054},"labels":[],"label_agreement":null},{"id":"W2946837939","doi":"10.1200/jco.2019.37.15_suppl.5029","title":"Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Abiraterone; Enzalutamide; Prednisone; Prostate cancer; Internal medicine; Cancer; Cohort; Oncology","score_opus":0.08929796729595767,"score_gpt":0.4626246529269634,"score_spread":0.37332668563100574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946837939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446493,0.0009343659,0.0000023537968,0.0009340959,0.0003571401,0.0028976516,0.00007608271,0.000007729491,0.00032563158],"genre_scores_gemma":[0.9961759,0.0014247826,0.00024683977,0.00018641514,0.000080814854,0.000063758605,0.000007524036,0.000039315393,0.0017746469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454945,0.0010401455,0.0025668803,0.00043472368,0.00091391074,0.0004949154],"domain_scores_gemma":[0.9954929,0.00096585765,0.0019352877,0.00040575463,0.0008276071,0.00037261506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023569348,0.0003149939,0.002302294,0.00019494114,0.00006234918,0.000022961569,0.00025743188,0.00019016762,0.0001392646],"category_scores_gemma":[0.0007316937,0.00014834708,0.00020411969,0.00050189765,0.0004926494,0.00020733362,0.00012121441,0.0010961972,0.000004280274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20218037,0.010953573,0.767766,0.00028022207,0.0016169052,0.0011370108,0.001009368,0.00009860679,0.00068872917,0.000003619749,0.00013940116,0.014126218],"study_design_scores_gemma":[0.18841425,0.06549771,0.7420066,0.0006481334,0.0011580893,0.00011515577,0.0007103768,0.0002405668,0.00055149687,0.00003084217,0.00046547514,0.0001613087],"about_ca_topic_score_codex":0.0005426959,"about_ca_topic_score_gemma":0.0013708301,"teacher_disagreement_score":0.05454414,"about_ca_system_score_codex":0.00063098595,"about_ca_system_score_gemma":0.004149475,"threshold_uncertainty_score":0.7360991},"labels":[],"label_agreement":null},{"id":"W2946841075","doi":"10.1200/jco.2019.37.15_suppl.511","title":"NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Trastuzumab; Cancer research; Cancer","score_opus":0.059799797295934556,"score_gpt":0.3923305171100879,"score_spread":0.33253071981415333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946841075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914685,0.0040916232,0.00006384906,0.0028825272,0.0007338235,0.00046268388,0.00001532809,0.000006608262,0.00027506307],"genre_scores_gemma":[0.99541545,0.0014629755,0.0010079701,0.0014339824,0.00043465642,0.000015805183,0.000008155533,0.000018499264,0.00020250765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954097,0.0025571329,0.0012981069,0.00028948011,0.00021426276,0.00023128868],"domain_scores_gemma":[0.9938291,0.0038146405,0.0016828009,0.00019579998,0.00033272474,0.00014498139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005459445,0.00020335872,0.0018601775,0.000058959125,0.00005241721,0.000013307978,0.00017413739,0.00045426187,0.000025201934],"category_scores_gemma":[0.005705948,0.000118612064,0.00041819407,0.00006596956,0.0004676392,0.000006778947,0.0001076038,0.00038946478,0.000004468621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9772077,0.0006064742,0.006342726,0.000004724395,0.0012421238,0.00022030038,0.000047913618,0.000036668167,0.0051164147,0.000021471069,0.0008428446,0.0083106235],"study_design_scores_gemma":[0.8638506,0.025225934,0.087280005,0.0000668969,0.00060566026,0.00025157272,0.00012067805,0.000022835175,0.000361276,0.00025196196,0.021716839,0.00024576427],"about_ca_topic_score_codex":0.0000070827105,"about_ca_topic_score_gemma":0.00003621471,"teacher_disagreement_score":0.113357134,"about_ca_system_score_codex":0.00003964594,"about_ca_system_score_gemma":0.00052217586,"threshold_uncertainty_score":0.68309647},"labels":[],"label_agreement":null},{"id":"W2946845225","doi":"10.1200/jco.2019.37.15_suppl.6522","title":"Enhancing community capacity to improve cancer care delivery and the effect on patient-reported outcomes, healthcare utilization and total costs of care.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Intervention (counseling); Health care; Cancer; Physical therapy; Family medicine; Internal medicine; Nursing","score_opus":0.14291115111775504,"score_gpt":0.47558118666275634,"score_spread":0.3326700355450013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946845225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462295,0.0020044835,0.000011290055,0.0016641986,0.0008477435,0.0005693481,0.000010660058,0.0000038534567,0.00026547015],"genre_scores_gemma":[0.99671847,0.00020674079,0.00015426597,0.002789237,0.00011187768,0.00000541842,0.0000017569827,0.000007225083,0.0000050050467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714404,0.0010005945,0.001246705,0.00012864632,0.0003298692,0.00015012585],"domain_scores_gemma":[0.9950204,0.0026905774,0.0010943235,0.0002040739,0.0007588425,0.00023181784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020276036,0.00011489477,0.0011909463,0.00005774684,0.000077512144,0.000006498879,0.00007549159,0.00020753706,0.0000075006933],"category_scores_gemma":[0.0030455925,0.000066495784,0.0001788877,0.00008511611,0.00015303976,0.00006680366,0.00007821547,0.0009650023,7.086432e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010781269,0.000059052527,0.77592933,0.00021817653,0.00016932005,0.000026304082,0.0029975902,0.000024501327,0.00038369495,0.00004599369,0.00004013856,0.20932461],"study_design_scores_gemma":[0.011445584,0.04569396,0.9331133,0.00088278385,0.0003654433,0.00011003954,0.0062420927,0.000033550754,0.001590831,0.000020942698,0.00040885003,0.00009265696],"about_ca_topic_score_codex":0.00424039,"about_ca_topic_score_gemma":0.0026972918,"teacher_disagreement_score":0.20923196,"about_ca_system_score_codex":0.00030985847,"about_ca_system_score_gemma":0.00047439348,"threshold_uncertainty_score":0.6410229},"labels":[],"label_agreement":null},{"id":"W2946850150","doi":"10.1200/jco.2019.37.15_suppl.1086","title":"Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Confidence interval; Progressive disease; Cancer; Hazard ratio; Breast cancer; Disease; Oncology; Surgery","score_opus":0.03563998643533165,"score_gpt":0.42339137601618504,"score_spread":0.38775138958085337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946850150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877048,0.003022888,0.000006144832,0.007165166,0.00072845427,0.0006068073,0.000021803447,0.000010826746,0.0007330738],"genre_scores_gemma":[0.9908029,0.0048907176,0.00059395574,0.0024518762,0.00038900683,0.00002320794,0.0000029880987,0.000030385188,0.00081495673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970316,0.00034172632,0.0017286564,0.00025536318,0.00035695886,0.00028567368],"domain_scores_gemma":[0.9965038,0.0008713738,0.0016419325,0.00023983217,0.00043321468,0.0003098888],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010820011,0.00020504615,0.0015281386,0.00017231533,0.00002539749,0.000009115441,0.00017005026,0.00023357922,0.00094116124],"category_scores_gemma":[0.000249092,0.00012244681,0.00045756967,0.0003487915,0.0002787878,0.00019249953,0.000016019703,0.00080834277,0.00001367808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19523822,0.0013867264,0.5747299,0.000022312806,0.0006015486,0.0005487945,0.00009829676,0.00002817029,0.00081491284,0.0000053608405,0.00019518952,0.22633055],"study_design_scores_gemma":[0.05106142,0.010271212,0.9270616,0.00064658676,0.00017145103,0.00023571127,0.00017453567,0.000057335514,0.00013919297,0.000041771862,0.009984801,0.00015434698],"about_ca_topic_score_codex":0.00019900406,"about_ca_topic_score_gemma":0.00012080849,"teacher_disagreement_score":0.35233173,"about_ca_system_score_codex":0.00039084905,"about_ca_system_score_gemma":0.0025653564,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2946854933","doi":"10.1200/jco.2019.37.15_suppl.5513","title":"Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Carboplatin; Internal medicine; Adverse effect; Gemcitabine; Cohort; Toxicity; Oncology; Ovarian cancer; Chemotherapy; Phases of clinical research; Surgery; Cancer; Cisplatin","score_opus":0.12335326585438619,"score_gpt":0.46977216359482143,"score_spread":0.3464188977404352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946854933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98966956,0.00010475582,0.0000062170784,0.0066638016,0.00038207657,0.0018219004,0.000012428403,0.000007991946,0.0013312723],"genre_scores_gemma":[0.9931891,0.00013702472,0.0028074896,0.0031011698,0.0003373275,0.000060618295,0.0000062613476,0.000048282876,0.00031272395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965008,0.00035283837,0.001774294,0.0004463926,0.00058336725,0.00034233215],"domain_scores_gemma":[0.99649966,0.0005422273,0.0016240337,0.0004171739,0.0004534007,0.00046351508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001621725,0.00026787232,0.0019684175,0.00012954824,0.000064899774,0.000032933367,0.00036330076,0.00015001428,0.0009053336],"category_scores_gemma":[0.00016416139,0.00015295586,0.0000772754,0.0002740393,0.00009074233,0.00032471106,0.00008458781,0.00077755976,0.000008583864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072814606,0.07295845,0.68213123,0.0000190918,0.0010640324,0.00110193,0.00036264322,0.000027807366,0.00002159901,0.000037218142,0.00068188366,0.16877949],"study_design_scores_gemma":[0.16346198,0.31505314,0.50663596,0.00027560283,0.00035562547,0.000036556943,0.00017085501,0.000028427652,0.000019539102,0.00002388596,0.013801551,0.00013686417],"about_ca_topic_score_codex":0.0005958206,"about_ca_topic_score_gemma":0.0029947977,"teacher_disagreement_score":0.24209468,"about_ca_system_score_codex":0.00053367583,"about_ca_system_score_gemma":0.0025395781,"threshold_uncertainty_score":0.99127686},"labels":[],"label_agreement":null},{"id":"W2946857908","doi":"10.1200/jco.2019.37.15_suppl.tps5604","title":"Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Radioimmunotherapy; Fallopian tube; Tolerability; Response Evaluation Criteria in Solid Tumors; Oncology; Urology; Ovarian carcinoma; Radiation therapy; Internal medicine; Gastroenterology; Ovarian cancer; Chemotherapy; Phases of clinical research; Adverse effect; Immunotherapy; Surgery; Nivolumab; Cancer; Antibody; Immunology","score_opus":0.06220732014825342,"score_gpt":0.4392053871118035,"score_spread":0.3769980669635501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946857908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872631,0.00026180592,0.00033170596,0.0074493657,0.0010196433,0.0006164053,0.000030078025,0.000008216515,0.0030197084],"genre_scores_gemma":[0.97097206,0.00055351673,0.025481958,0.0015581355,0.0011743772,0.0000069272187,0.000011000047,0.000038583712,0.0002034493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950087,0.000647149,0.0029623916,0.0003577585,0.00066252466,0.00036148113],"domain_scores_gemma":[0.99491686,0.0023212654,0.0017027059,0.0003430693,0.00034327846,0.00037282612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030750334,0.00025274762,0.0026977912,0.00020833207,0.000037140413,0.000011384716,0.00015221456,0.00039697337,0.00036259214],"category_scores_gemma":[0.00031716973,0.0001566774,0.0003743279,0.00023448335,0.00022976274,0.00014063819,0.000039125065,0.0010889397,0.000002725463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16504072,0.018259255,0.6716816,0.00035339288,0.0022271043,0.015578183,0.00069645495,0.00018969495,0.00591188,0.000813688,0.0007020974,0.118545964],"study_design_scores_gemma":[0.10523363,0.08454442,0.7901258,0.00054508843,0.0004733333,0.0011440039,0.00024530813,0.00083018054,0.00016034972,0.000027975728,0.01648717,0.00018277054],"about_ca_topic_score_codex":0.00013668544,"about_ca_topic_score_gemma":0.00023108935,"teacher_disagreement_score":0.1184442,"about_ca_system_score_codex":0.0010276088,"about_ca_system_score_gemma":0.0069511835,"threshold_uncertainty_score":0.9986785},"labels":[],"label_agreement":null},{"id":"W2946858619","doi":"10.1200/jco.2019.37.15_suppl.e15701","title":"Comprehensive characterization of pseudomyxoma peritonei.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"GNAS complex locus; KRAS; Pseudomyxoma peritonei; Medicine; Stromal cell; Neuroblastoma RAS viral oncogene homolog; Pathology; Deep sequencing; Cancer research; Internal medicine; Biology; Cancer; Gene; Appendix; Colorectal cancer; Genetics; Genome","score_opus":0.10254429420385829,"score_gpt":0.45151573837171055,"score_spread":0.34897144416785225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946858619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99277693,0.00012846128,0.0000118480375,0.0034834554,0.001213103,0.00016550963,0.000003015097,0.0000032957448,0.0022143584],"genre_scores_gemma":[0.9964416,0.000562589,0.00091531145,0.0013587673,0.0004897752,0.0000013713153,0.0000055524324,0.0000073119263,0.0002177104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792063,0.00015170404,0.001511144,0.00009684441,0.0002212479,0.000098421515],"domain_scores_gemma":[0.99698365,0.0007823213,0.0014328307,0.00013576957,0.0005062891,0.00015916917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045715537,0.00007723796,0.0012082085,0.000068314686,0.000009407012,0.0000025914217,0.00006533345,0.0001984781,0.0003133843],"category_scores_gemma":[0.00028689086,0.00005056399,0.00039480164,0.000067067595,0.00007792862,0.00006731073,0.000024239915,0.00020444432,0.00006278625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029287618,0.003922659,0.8578656,0.0000739225,0.00057442783,0.00038149202,0.000094131676,0.000001882883,0.028413136,0.00030615905,0.0006162176,0.10482166],"study_design_scores_gemma":[0.008391126,0.011270732,0.90561706,0.000092120084,0.00021241636,0.0003658886,0.000046562687,0.000028293392,0.0017839308,0.00003153049,0.07212146,0.000038863465],"about_ca_topic_score_codex":0.000005471196,"about_ca_topic_score_gemma":5.5188406e-7,"teacher_disagreement_score":0.10478279,"about_ca_system_score_codex":0.000075290416,"about_ca_system_score_gemma":0.0006266743,"threshold_uncertainty_score":0.34313387},"labels":[],"label_agreement":null},{"id":"W2946863309","doi":"10.1200/jco.2019.37.15_suppl.5079","title":"CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Urology; Prostate cancer; Nomogram; Stage (stratigraphy); Neoadjuvant therapy; Androgen deprivation therapy; Biopsy; Survival analysis; Internal medicine; Gynecology; Surgery; Oncology; Cancer; Breast cancer","score_opus":0.06574906304178667,"score_gpt":0.4462995836944603,"score_spread":0.38055052065267364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946863309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845866,0.0021300835,0.00007135247,0.008502723,0.0004067866,0.002622472,0.000028036135,0.00003307596,0.0016188726],"genre_scores_gemma":[0.94551665,0.039239008,0.007981679,0.0020705448,0.00095856696,0.0001577018,0.000018034496,0.00010948955,0.003948331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923626,0.0008361552,0.003686655,0.000752332,0.0014110334,0.0009511991],"domain_scores_gemma":[0.9928775,0.0020667864,0.0025901208,0.0004917255,0.0009502682,0.0010236037],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004838177,0.00050440145,0.0035316152,0.0002064674,0.00007790345,0.000040149625,0.00042836176,0.00066287577,0.00079649786],"category_scores_gemma":[0.00069994514,0.00023771918,0.00038368226,0.0005948957,0.0010815075,0.00029073659,0.00008906677,0.0034398115,0.000055184384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2922983,0.002296948,0.59522694,0.000075398915,0.0010074027,0.0025808678,0.00022465922,0.00009097033,0.00010467124,0.000013418685,0.001141464,0.104938954],"study_design_scores_gemma":[0.23497723,0.18681195,0.47499427,0.001705457,0.0006899125,0.0009340127,0.00050625874,0.0013008054,0.0005970085,0.00030517168,0.0964755,0.00070241344],"about_ca_topic_score_codex":0.00055011467,"about_ca_topic_score_gemma":0.00037673392,"teacher_disagreement_score":0.184515,"about_ca_system_score_codex":0.0006598806,"about_ca_system_score_gemma":0.010766596,"threshold_uncertainty_score":0.9988593},"labels":[],"label_agreement":null},{"id":"W2946868463","doi":"10.1200/jco.2019.37.15_suppl.1034","title":"Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Baker Hughes (Canada); University Health Network; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Pertuzumab; Internal medicine; Taxane; Metastatic breast cancer; Trastuzumab emtansine; Breast cancer; Oncology; Regimen; Chemotherapy; Stage (stratigraphy); Cancer; Surgery","score_opus":0.07790662826635882,"score_gpt":0.4466586246627598,"score_spread":0.368751996396401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946868463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968121,0.0007148467,0.00012652158,0.0009109186,0.00072543416,0.0002933689,0.0004071118,0.000001585137,0.000008089744],"genre_scores_gemma":[0.9953872,0.002181343,0.0016253531,0.000411184,0.00031699255,0.00001310465,0.00003501132,0.000013308288,0.0000165084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963873,0.0005444694,0.0020628555,0.00036441762,0.00042252356,0.00021845203],"domain_scores_gemma":[0.9956021,0.00083650026,0.001760396,0.00033750196,0.0010650359,0.0003985149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011364251,0.00020920031,0.0015334612,0.00013943166,0.000024141253,0.0000049285654,0.00029726495,0.00012743607,0.000070421265],"category_scores_gemma":[0.0018301419,0.00013848142,0.00053133763,0.00026505947,0.00036585075,0.000022310413,0.0001187363,0.0002618929,0.000004892755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08671891,0.0037306077,0.89787567,0.00004192711,0.0024833218,0.000035999205,0.000017890681,0.0005198263,0.000080582795,0.00000605491,0.00009908942,0.008390105],"study_design_scores_gemma":[0.011552953,0.0061255107,0.98017937,0.00017647004,0.0011593004,8.542932e-7,0.000013658379,0.00003849887,0.000020014792,0.0000028203497,0.0005947339,0.00013578837],"about_ca_topic_score_codex":0.0000744625,"about_ca_topic_score_gemma":0.00018625057,"teacher_disagreement_score":0.08230371,"about_ca_system_score_codex":0.00007785404,"about_ca_system_score_gemma":0.0021440522,"threshold_uncertainty_score":0.5647109},"labels":[],"label_agreement":null},{"id":"W2946874178","doi":"10.1200/jco.2019.37.15_suppl.5024","title":"Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Randomized controlled trial; Randomization; Placebo; Androgen deprivation therapy; Cancer; Oncology; Urology; Pathology","score_opus":0.053887843042956025,"score_gpt":0.4069688485368145,"score_spread":0.35308100549385846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946874178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997623,0.00094695936,0.000008539943,0.00044732296,0.000080913676,0.0007591348,0.00004973651,0.0000021114984,0.00008224858],"genre_scores_gemma":[0.9955317,0.0037517783,0.00052589364,0.000053420004,0.000019863419,0.0000053341105,0.000047596608,0.000013979662,0.000050451974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962966,0.00035211522,0.0024079648,0.0002078443,0.0005330405,0.0002024356],"domain_scores_gemma":[0.99527645,0.0012900553,0.0023087342,0.0001818251,0.00079152355,0.00015140435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016515006,0.00014504927,0.0018076677,0.00047487157,0.000019903691,0.0000046861933,0.00009625031,0.00016457993,0.00008073805],"category_scores_gemma":[0.00038097147,0.00009172503,0.000227468,0.0007446241,0.0003067517,0.00012616697,0.000026478821,0.0003956898,5.1696844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066858426,0.0016328754,0.8863805,0.00014252096,0.003526977,0.00009619653,0.0011631438,0.0015125679,0.0038623186,0.000023677752,0.000005674669,0.034795105],"study_design_scores_gemma":[0.03410509,0.018394731,0.9442808,0.0003322285,0.001138061,0.000005596517,0.00021800437,0.0005779031,0.00077799713,0.000024497023,0.00006880194,0.00007627773],"about_ca_topic_score_codex":0.00026279996,"about_ca_topic_score_gemma":0.0009407793,"teacher_disagreement_score":0.0579003,"about_ca_system_score_codex":0.00022785873,"about_ca_system_score_gemma":0.0013437885,"threshold_uncertainty_score":0.37404382},"labels":[],"label_agreement":null},{"id":"W2946878839","doi":"10.1200/jco.2019.37.15_suppl.5520","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Adverse effect; Gastroenterology; Nausea; Ovarian cancer; Combination therapy; Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.035629440572361115,"score_gpt":0.3737685522482352,"score_spread":0.33813911167587407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946878839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634696,0.0002950622,0.000012222388,0.011092222,0.00068633485,0.001360252,0.000039038456,0.000008492164,0.0001594372],"genre_scores_gemma":[0.99690807,0.0002713179,0.0015614927,0.0008509911,0.0002175035,0.000030446408,0.00004133473,0.000036955047,0.000081860686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956252,0.0005742121,0.0022581303,0.0004470452,0.00070018845,0.0003952314],"domain_scores_gemma":[0.9956246,0.0016615465,0.0017577484,0.00027535812,0.0004757568,0.00020500411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024769676,0.00029598572,0.0018054704,0.00017189092,0.00009708898,0.000031259693,0.00023271197,0.00022147271,0.00023201441],"category_scores_gemma":[0.00049971906,0.000165749,0.00017289301,0.0003866256,0.00011398703,0.0002412739,0.000072903706,0.0011925687,0.000011521031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03223474,0.008484757,0.9397995,0.000021329193,0.0006857658,0.00035161126,0.0014001911,0.00006419415,0.00004318664,0.00004399261,0.00081990036,0.01605082],"study_design_scores_gemma":[0.091394156,0.048813067,0.8544345,0.00089425547,0.00043377827,0.00000916574,0.00055457937,0.000134641,0.000030186106,0.00008059986,0.0030477825,0.00017327124],"about_ca_topic_score_codex":0.0018191519,"about_ca_topic_score_gemma":0.0043634293,"teacher_disagreement_score":0.085365005,"about_ca_system_score_codex":0.00074296904,"about_ca_system_score_gemma":0.0014793767,"threshold_uncertainty_score":0.6759048},"labels":[],"label_agreement":null},{"id":"W2946881657","doi":"10.1200/jco.2019.37.15_suppl.4068","title":"Prognostic significance of sarcopenia in metastatic esophageal squamous cell carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcopenia; Internal medicine; Dysphagia; Gastroenterology; Anorexia; Body mass index; Esophageal cancer; Nausea; Cancer; Weight loss; Oncology; Surgery; Obesity","score_opus":0.13624260456218404,"score_gpt":0.4707593959202165,"score_spread":0.3345167913580325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946881657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902985,0.0011312593,0.000056054014,0.0035411282,0.00085745275,0.00048365453,0.00000224732,0.0000037885768,0.0036259242],"genre_scores_gemma":[0.9881844,0.000090018446,0.008991298,0.0020582727,0.0002767765,0.000003554671,0.0000011641283,0.00001238968,0.00038210626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996058,0.0005114162,0.0027442018,0.00014721874,0.00031060097,0.00022856645],"domain_scores_gemma":[0.9941924,0.0034886908,0.0015623443,0.00014928465,0.0003118011,0.00029547335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003546032,0.000094483374,0.001515774,0.00019606561,0.000011313524,0.0000027715175,0.00013525937,0.00015671412,0.0004027079],"category_scores_gemma":[0.0019000274,0.000072251176,0.00024639117,0.00018735658,0.000109605615,0.00006644951,0.00002549457,0.001012844,0.000057382254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002867904,0.0027165874,0.9821061,0.00075427187,0.000021470692,0.0011141559,0.00013001183,0.00002136047,0.000990259,0.00011630276,0.00131787,0.0078437],"study_design_scores_gemma":[0.018323405,0.015251152,0.95592225,0.00018588126,0.0001816733,0.0002478857,0.00019312942,0.00024840783,0.0006392779,0.0005042516,0.008222229,0.00008047709],"about_ca_topic_score_codex":0.000025814626,"about_ca_topic_score_gemma":0.00001559199,"teacher_disagreement_score":0.026183877,"about_ca_system_score_codex":0.00010658791,"about_ca_system_score_gemma":0.0019371302,"threshold_uncertainty_score":0.44093692},"labels":[],"label_agreement":null},{"id":"W2946884430","doi":"10.1200/jco.2019.37.15_suppl.6525","title":"Clinical outcomes and cost-effectiveness of breast cancer screening for childhood cancer survivors treated with chest radiation: A comparative modeling study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Mammography; Breast cancer screening; Cancer; Cohort; Oncology; Internal medicine","score_opus":0.12431458936501587,"score_gpt":0.48416037574638526,"score_spread":0.3598457863813694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946884430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936578,0.0007033074,0.003587113,0.00033286284,0.0005501228,0.0010353351,0.00007616945,0.0000029828936,0.0000542942],"genre_scores_gemma":[0.9968539,0.0005634625,0.0017826655,0.00017105447,0.000474342,0.00009112821,0.000010666302,0.0000215491,0.00003126162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702793,0.0007807016,0.0014924697,0.00033545104,0.00018568525,0.00017776254],"domain_scores_gemma":[0.9961123,0.0013515189,0.0013626263,0.0001882447,0.0008425086,0.00014281945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003043082,0.00017593769,0.0013217642,0.00006375546,0.00004661831,0.0000100243415,0.00018263953,0.00029132975,0.000017692768],"category_scores_gemma":[0.00030914042,0.00012509165,0.00028089585,0.000110868794,0.00017087077,0.000017185039,0.00005732214,0.00034015134,3.5529646e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053274697,0.0009158033,0.9334748,0.000027704662,0.0016885513,0.0000024764265,0.000117386066,0.018844752,0.00022986668,0.0000050523336,0.000042374144,0.039323796],"study_design_scores_gemma":[0.012477621,0.006752529,0.9758491,0.00008751554,0.00039048123,0.000024440234,0.0004818839,0.0025306982,0.0002383832,0.000012784209,0.0009963675,0.00015818159],"about_ca_topic_score_codex":0.00028150843,"about_ca_topic_score_gemma":0.0010515993,"teacher_disagreement_score":0.042374346,"about_ca_system_score_codex":0.00007494454,"about_ca_system_score_gemma":0.0013667768,"threshold_uncertainty_score":0.51010895},"labels":[],"label_agreement":null},{"id":"W2946889769","doi":"10.1200/jco.2019.37.15_suppl.1040","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA-</i>mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Letrozole; Breast cancer; Oncology; Cohort; Regimen; Palbociclib; Cancer; Metastatic breast cancer; Estrogen receptor; Tamoxifen","score_opus":0.04594670903478027,"score_gpt":0.4199377363683728,"score_spread":0.3739910273335925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946889769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896103,0.00035185996,0.00004437201,0.00565608,0.0008523542,0.0019351438,0.00021606639,0.000039137172,0.0012946872],"genre_scores_gemma":[0.9939159,0.0010592884,0.0014062485,0.0026572559,0.0005437003,0.000059304624,0.00003947433,0.000107774846,0.00021105733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924984,0.0012404566,0.0038061335,0.0007897616,0.0009421961,0.00072303746],"domain_scores_gemma":[0.9908598,0.0023980401,0.0037338727,0.0004679622,0.002011685,0.0005286314],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015476277,0.0006155806,0.0031316401,0.00034687095,0.000098541226,0.000025088202,0.00045964436,0.00032607946,0.0004435975],"category_scores_gemma":[0.0009029121,0.0004241827,0.00041837056,0.0005535154,0.0004780933,0.0007811596,0.00014518113,0.0024097918,0.00002742538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22724655,0.016443843,0.6109777,0.000034922286,0.002235649,0.00060859066,0.0044836057,0.00031137775,0.0011735718,0.0000274503,0.00048729542,0.13596945],"study_design_scores_gemma":[0.10947354,0.061124317,0.8236007,0.00045456423,0.00013315662,0.0001445222,0.0012842589,0.000011839611,0.00050115923,0.000072659015,0.0028123318,0.00038694544],"about_ca_topic_score_codex":0.00065620133,"about_ca_topic_score_gemma":0.0009101126,"teacher_disagreement_score":0.212623,"about_ca_system_score_codex":0.0011431464,"about_ca_system_score_gemma":0.0010577901,"threshold_uncertainty_score":0.9998917},"labels":[],"label_agreement":null},{"id":"W2946893188","doi":"10.1200/jco.2019.37.15_suppl.2602","title":"Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Common Terminology Criteria for Adverse Events; Pharmacokinetics; Leukopenia; Refractory (planetary science); Cancer; Internal medicine; Gastroenterology; Pharmacology; Pathology; Urology; Toxicity","score_opus":0.06102023954126988,"score_gpt":0.42982169381317836,"score_spread":0.36880145427190847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946893188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976655,0.00040177107,0.00016641557,0.0010733021,0.0002114445,0.0003330525,0.0000028927477,0.000002975305,0.0001426342],"genre_scores_gemma":[0.9955111,0.00032212932,0.0038358343,0.000088292516,0.00018323217,0.0000037053119,0.0000022186002,0.000009680961,0.000043796546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759436,0.00014908034,0.0017740304,0.00014910201,0.00022164897,0.000111760375],"domain_scores_gemma":[0.99562144,0.001438024,0.0020878124,0.00011993797,0.00061697816,0.00011582824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010554972,0.00011500627,0.0011806025,0.00015771008,0.00003816896,0.0000022166835,0.000063644824,0.00015438843,0.000105357896],"category_scores_gemma":[0.0010018139,0.00007612816,0.00012111305,0.000191362,0.0002734666,0.00026754534,0.000055439275,0.00051721133,2.5311766e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07724231,0.0033151794,0.50661176,0.00090465136,0.0006235586,0.000035897978,0.0024554643,0.00007843703,0.39844134,0.00025319523,0.00007317627,0.009965018],"study_design_scores_gemma":[0.012347243,0.026747229,0.9368704,0.0014819887,0.00041404663,0.00037142594,0.0006309991,0.00031013868,0.020459266,0.0001032714,0.00017863863,0.00008538417],"about_ca_topic_score_codex":0.00011514772,"about_ca_topic_score_gemma":0.00006159769,"teacher_disagreement_score":0.4302586,"about_ca_system_score_codex":0.00011973778,"about_ca_system_score_gemma":0.0011492014,"threshold_uncertainty_score":0.31044164},"labels":[],"label_agreement":null},{"id":"W2946902624","doi":"10.1200/jco.2019.37.15_suppl.e20091","title":"Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Circulating tumor cell; Medicine; Flow cytometry; Cancer; Antibody; Lung cancer; Stage (stratigraphy); Cancer research; Pathology; Oncology; Internal medicine; Andrology; Metastasis; Immunology; Biology","score_opus":0.1469994223230298,"score_gpt":0.44997912313238814,"score_spread":0.3029797008093583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946902624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127483,0.002109005,0.000098789744,0.00035758625,0.0041756416,0.00031932263,0.000045485525,0.000006478521,0.0016128763],"genre_scores_gemma":[0.99264234,0.0010256007,0.0037522381,0.0015531636,0.00088629103,0.0000025393272,0.0000066896378,0.000029740264,0.000101369405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957628,0.00034149602,0.0028575922,0.00029492134,0.0004459462,0.00029719042],"domain_scores_gemma":[0.9939105,0.001373645,0.0033634508,0.00032180236,0.00063636387,0.0003942472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016826327,0.0001885328,0.0020645624,0.00010869484,0.000025625985,0.000007761541,0.00021687518,0.0002885808,0.0008334857],"category_scores_gemma":[0.00048915035,0.00014297587,0.00091007596,0.00013633443,0.00010500045,0.000078162746,0.00009019447,0.000900808,0.00002515952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017123689,0.0018852807,0.9378688,0.00025128177,0.00052433554,0.00011513363,0.00012500101,0.00021981978,0.020126196,0.0000064090236,0.0013549073,0.035810504],"study_design_scores_gemma":[0.02515876,0.008741043,0.86852366,0.0007350381,0.0024157055,0.000038063794,0.0001760402,0.0006998314,0.035278924,0.00003866021,0.05783875,0.0003555365],"about_ca_topic_score_codex":0.0005440067,"about_ca_topic_score_gemma":0.00023689769,"teacher_disagreement_score":0.06934512,"about_ca_system_score_codex":0.00019492987,"about_ca_system_score_gemma":0.0013761923,"threshold_uncertainty_score":0.9126084},"labels":[],"label_agreement":null},{"id":"W2946903222","doi":"10.1200/jco.2019.37.15_suppl.6629","title":"Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Cancer registry; Population; Retrospective cohort study; Health care; Cancer; Cohort; Chemotherapy; Stage (stratigraphy); Internal medicine; Gerontology; Environmental health","score_opus":0.07248009870838056,"score_gpt":0.33867548948500853,"score_spread":0.26619539077662796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946903222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97287893,0.0019945442,0.000027514625,0.0012664513,0.0010203522,0.0003538307,0.000023485509,7.0168284e-7,0.022434173],"genre_scores_gemma":[0.99503106,0.002438198,0.00030788526,0.0009769886,0.0001373659,0.000019204756,0.0000014189769,0.0000112399175,0.0010766542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974296,0.000045877572,0.0020299766,0.00018045102,0.000045787503,0.00026828426],"domain_scores_gemma":[0.99712795,0.0006734966,0.0018680668,0.00018624336,0.000052656473,0.000091616246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010221673,0.00013488198,0.0014453703,0.00011351324,0.000015063871,0.000011367089,0.00027466752,0.00016237938,0.000198845],"category_scores_gemma":[0.00008019892,0.00009610361,0.00015961102,0.000097079734,0.000080299265,0.00015199771,0.000013484439,0.00045330924,0.0000040529117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072888285,0.00060770515,0.9883341,0.000016412756,0.000052296316,0.00009469995,0.0009352525,0.0018565798,0.0000010322105,0.0007876757,0.0005607801,0.006024579],"study_design_scores_gemma":[0.00562083,0.0025414347,0.86260915,0.000057057485,0.000016488293,0.0000040610666,0.00023461528,0.000071702045,0.000007873772,0.00034630045,0.12837802,0.00011249256],"about_ca_topic_score_codex":0.76385367,"about_ca_topic_score_gemma":0.991453,"teacher_disagreement_score":0.22759934,"about_ca_system_score_codex":0.0014409253,"about_ca_system_score_gemma":0.0029746995,"threshold_uncertainty_score":0.52769893},"labels":[],"label_agreement":null},{"id":"W2946904359","doi":"10.1200/jco.2019.37.15_suppl.e15726","title":"Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Peripheral blood mononuclear cell; Internal medicine; Oncology; Immune system; Gastroenterology; Immunology; Immunotherapy; Biology","score_opus":0.0708954678070737,"score_gpt":0.424349866591526,"score_spread":0.3534543987844523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946904359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718535,0.00072847103,0.000041969553,0.0007281526,0.00043116725,0.00022237014,0.000019787158,0.0000013791556,0.00064138154],"genre_scores_gemma":[0.9983216,0.00029792794,0.00047707593,0.00016126221,0.00032103682,0.0000057769016,0.000007341565,0.00001093525,0.0003970728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762213,0.0005709568,0.0011504433,0.00019930002,0.00024842605,0.00020876294],"domain_scores_gemma":[0.99850315,0.00031736054,0.0005045842,0.00022977983,0.00021627863,0.00022887306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018746275,0.00009434557,0.0006249433,0.00013356663,0.000011745107,0.0000046138443,0.00019920761,0.0002500844,0.00007631974],"category_scores_gemma":[0.0020261502,0.00007565013,0.0002474671,0.000113283386,0.00007707751,0.000007836578,0.00009506737,0.00029948977,0.00002169392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080132194,0.00075884804,0.8584827,0.000025405063,0.0003181027,0.00029077503,0.000099634,0.00016881672,0.05330413,0.000015154909,0.0018730751,0.004531149],"study_design_scores_gemma":[0.010524621,0.028962873,0.94669,0.000044462955,0.000048881822,0.00023950724,0.000089013316,0.000038072158,0.0026375628,0.00007187202,0.010586574,0.000066557215],"about_ca_topic_score_codex":0.00007291929,"about_ca_topic_score_gemma":0.00011687004,"teacher_disagreement_score":0.08820728,"about_ca_system_score_codex":0.00013435041,"about_ca_system_score_gemma":0.0015768128,"threshold_uncertainty_score":0.30849227},"labels":[],"label_agreement":null},{"id":"W2946906089","doi":"10.1200/jco.2019.37.15_suppl.2542","title":"Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Oncology; Response Evaluation Criteria in Solid Tumors; Biomarker; Confidence interval; Clinical trial; Circulating tumor DNA; Cancer; Phases of clinical research; Immunotherapy","score_opus":0.032600876827548704,"score_gpt":0.3558608983958778,"score_spread":0.3232600215683291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946906089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997204,0.00014662242,0.0001719396,0.00015309735,0.000418867,0.00026706432,0.00002909489,0.0000035505693,0.0016057583],"genre_scores_gemma":[0.998268,0.00007997318,0.00042161168,0.0008641396,0.0002305697,0.000007012202,0.00004210354,0.000027512368,0.000059059337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706215,0.0002720184,0.001646368,0.00040069985,0.00028953888,0.00032925254],"domain_scores_gemma":[0.9968503,0.00038571501,0.0017021568,0.00029029613,0.0005009841,0.000270565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008997172,0.00021661649,0.0011120586,0.00023638328,0.000032628275,0.000023086832,0.00025205401,0.0002544363,0.00007388763],"category_scores_gemma":[0.0015525788,0.0001704381,0.0005052699,0.00034266117,0.00012867419,0.000011756046,0.00011559225,0.00036053002,0.000015140836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012316607,0.003095346,0.9531415,0.000022382277,0.0022536623,0.0004732065,0.000078773395,0.0058728806,0.01614755,0.000016381833,0.00021804323,0.0063636773],"study_design_scores_gemma":[0.015878402,0.031611897,0.94168466,0.00009462852,0.001069158,0.0001296553,0.00014484527,0.00097423675,0.0028769365,0.00007602121,0.0051195095,0.00034003396],"about_ca_topic_score_codex":0.000092665265,"about_ca_topic_score_gemma":0.00031833787,"teacher_disagreement_score":0.028516553,"about_ca_system_score_codex":0.00026567324,"about_ca_system_score_gemma":0.0013081912,"threshold_uncertainty_score":0.6950264},"labels":[],"label_agreement":null},{"id":"W2946907024","doi":"10.1200/jco.2019.37.15_suppl.3110","title":"Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in <i>EGFR</i>-mutated lung adenocarcinoma (LUAD).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adenocarcinoma; Biopsy; Pathological; Lung; Pathology; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.04465612019417261,"score_gpt":0.44195616162485457,"score_spread":0.397300041430682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946907024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993146,0.0027883376,0.000025093703,0.0014275825,0.0012995878,0.00066114153,0.000009138663,0.000010089561,0.0006329984],"genre_scores_gemma":[0.99249965,0.0022177922,0.0038332334,0.0010784917,0.00028770493,0.000010026685,0.0000074960008,0.000018227824,0.000047400477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947799,0.0006601648,0.0036163758,0.00031603206,0.00035247652,0.00027506644],"domain_scores_gemma":[0.99558985,0.0016095173,0.0018089215,0.00023907813,0.00033257186,0.0004200361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012380802,0.00018725039,0.0018076889,0.000175315,0.000024651938,0.0000072889825,0.00012357079,0.00046698883,0.00013894588],"category_scores_gemma":[0.0010897757,0.00012382664,0.00044583657,0.00017568158,0.0003292817,0.00008499125,0.0000793009,0.0008269649,0.000009124858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018280591,0.0025903662,0.9518989,0.00004981678,0.00056134147,0.001048013,0.00040508318,0.000028823859,0.00047496855,0.000012436426,0.00044230395,0.04065991],"study_design_scores_gemma":[0.014419802,0.026674017,0.9523945,0.0001647972,0.00084928103,0.00034388644,0.00035854484,0.00011690702,0.0000874687,0.00009145594,0.0043969974,0.00010234497],"about_ca_topic_score_codex":0.000022283566,"about_ca_topic_score_gemma":0.000013176345,"teacher_disagreement_score":0.040557563,"about_ca_system_score_codex":0.00015916592,"about_ca_system_score_gemma":0.0010780663,"threshold_uncertainty_score":0.5049504},"labels":[],"label_agreement":null},{"id":"W2946909477","doi":"10.1200/jco.2019.37.15_suppl.5580","title":"Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Ovarian cancer; Cancer; Immunotherapy; Clinical trial","score_opus":0.0830174930603624,"score_gpt":0.4858528766404057,"score_spread":0.40283538358004334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946909477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768226,0.0015601418,0.000016417229,0.015252678,0.004719767,0.00045349795,0.0000063695493,0.000005768843,0.0011627204],"genre_scores_gemma":[0.9894996,0.0032384235,0.0034007952,0.0021804443,0.0013595932,0.00001818422,0.000001657477,0.000028274168,0.00027298473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924699,0.00039032524,0.0061609256,0.0003056803,0.0003884753,0.00028468258],"domain_scores_gemma":[0.9950613,0.0010895217,0.0028696782,0.0003478102,0.0003237831,0.00030791556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004237926,0.00019901535,0.0028969953,0.00015854904,0.0000099640465,0.0000052758764,0.00016865935,0.00053888,0.0013419844],"category_scores_gemma":[0.00079257134,0.00014029063,0.0013063843,0.0001939096,0.00019304623,0.000118492826,0.00005714247,0.0011705175,0.000030077612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00922108,0.0030769368,0.8002347,0.00005328073,0.00048691005,0.00036087772,0.000065137785,0.00002193134,0.00024249093,0.000032457825,0.0001363031,0.1860679],"study_design_scores_gemma":[0.033234995,0.010827441,0.92694205,0.00042693075,0.00026888007,0.000055366207,0.000052890642,0.000023862667,0.00065906346,0.000113712864,0.027279336,0.000115462775],"about_ca_topic_score_codex":0.00015367419,"about_ca_topic_score_gemma":0.00012114224,"teacher_disagreement_score":0.18595244,"about_ca_system_score_codex":0.0003687374,"about_ca_system_score_gemma":0.0015895707,"threshold_uncertainty_score":0.9995709},"labels":[],"label_agreement":null},{"id":"W2946909981","doi":"10.1200/jco.2019.37.15_suppl.e23034","title":"Treatment approaches and survival outcomes of older patients with locally advanced esophageal cancer (LAEC) in Ireland.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Esophageal cancer; Radiation therapy; Cancer; Cancer registry; Chemoradiotherapy; Population; Adjuvant; Stage (stratigraphy); Univariate analysis; Surgery; Proportional hazards model; Multivariate analysis; Oncology","score_opus":0.08414246832239562,"score_gpt":0.43669911680591855,"score_spread":0.3525566484835229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946909981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947243,0.0021618956,0.000011181977,0.0014743109,0.0002587144,0.0005329135,0.000007975516,0.000002798558,0.0008259409],"genre_scores_gemma":[0.9975301,0.00084795564,0.0009825571,0.00014060152,0.00008497726,0.000014895463,0.0000036475597,0.000013167176,0.00038209456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780256,0.00020258885,0.0011446067,0.00019757957,0.0004218489,0.00023084223],"domain_scores_gemma":[0.99771917,0.0009214083,0.0006966336,0.00014699275,0.00021408123,0.0003017031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058839103,0.0001513376,0.0016237629,0.000112439484,0.000012195813,0.0000035231383,0.000073277166,0.0001590071,0.00008102362],"category_scores_gemma":[0.00021534105,0.00007960618,0.00018325172,0.00009863957,0.00015315977,0.00008923953,0.000029322766,0.00038183163,0.0000034435325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008517655,0.0029103043,0.84513915,0.000043558604,0.00051928737,0.00028094245,0.00009282583,0.000040071995,0.000001067387,0.000031947737,0.0000120358545,0.14241116],"study_design_scores_gemma":[0.04364794,0.032433487,0.9232045,0.00009013381,0.0001634355,0.00001453804,0.0000664043,0.00003554891,0.000029534096,0.000027440497,0.000231646,0.00005539542],"about_ca_topic_score_codex":0.000108721295,"about_ca_topic_score_gemma":0.00030572468,"teacher_disagreement_score":0.14235575,"about_ca_system_score_codex":0.00027152014,"about_ca_system_score_gemma":0.001138814,"threshold_uncertainty_score":0.3246246},"labels":[],"label_agreement":null},{"id":"W2946910439","doi":"10.1200/jco.2019.37.15_suppl.e14595","title":"Muscle wasting, visceral and subcutaneous adiposity, inflammation, nutritional deficiencies, and metastatic esophageal cancer (MEC) prognosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sarcopenia; Internal medicine; Cachexia; Wasting; Hazard ratio; Proportional hazards model; Cancer; Body mass index; Skeletal muscle; Gastroenterology; Adipose tissue; Oncology; Confidence interval","score_opus":0.11541234393414355,"score_gpt":0.4602772202881578,"score_spread":0.34486487635401425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946910439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97742504,0.0034669756,0.00004186271,0.017621815,0.0005688666,0.0003062545,0.0000062062854,0.000010747722,0.0005522334],"genre_scores_gemma":[0.985347,0.002107859,0.008450173,0.0031614327,0.0007494152,0.0000065180398,0.0000032402193,0.000010574047,0.00016384105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975821,0.00021922775,0.0014925619,0.0001727148,0.00031956998,0.00021385841],"domain_scores_gemma":[0.99706554,0.0011782455,0.00087836897,0.00006756814,0.00042043693,0.0003898634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019000083,0.00010476955,0.0008592795,0.00013170936,0.00007928547,0.00002009743,0.000062022664,0.00014702092,0.00024169995],"category_scores_gemma":[0.0007297254,0.00008186805,0.00011845853,0.00010011197,0.00018788438,0.00012317984,0.000043586584,0.0006671483,0.000008050356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020637305,0.0013672088,0.85082865,0.0011080949,0.00025194627,0.0009900733,0.0002793796,0.000017484304,0.0012293739,0.0019675067,0.002817611,0.13707893],"study_design_scores_gemma":[0.011184103,0.008255927,0.9297062,0.0005997928,0.00043578693,0.0046098228,0.0001319079,0.001168578,0.000075936434,0.0015451696,0.042146903,0.00013984511],"about_ca_topic_score_codex":0.000018306777,"about_ca_topic_score_gemma":0.000029343719,"teacher_disagreement_score":0.13693908,"about_ca_system_score_codex":0.0000945512,"about_ca_system_score_gemma":0.0008736075,"threshold_uncertainty_score":0.3338482},"labels":[],"label_agreement":null},{"id":"W2946917538","doi":"10.1200/jco.2019.37.15_suppl.e20676","title":"Effect of body mass index and age on survival in patients with advanced lung cancer treated with anti-PD-1 immune checkpoint inhibitors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Hazard ratio; Proportional hazards model; Lung cancer; Oncology; Cancer; Confidence interval; Overweight; Retrospective cohort study; Univariate analysis; Multivariate analysis","score_opus":0.015824066699492417,"score_gpt":0.3729389510020911,"score_spread":0.3571148843025987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946917538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973913,0.00020755784,0.000004236426,0.00026281585,0.0004676079,0.00055703364,0.0000057845577,0.000004320732,0.0010993601],"genre_scores_gemma":[0.99914557,0.00027590565,0.00011821951,0.00022106527,0.00013287608,0.000004882218,0.000006717712,0.000021662665,0.00007309782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973136,0.00038889394,0.0014959372,0.00021922932,0.0003682218,0.0002140771],"domain_scores_gemma":[0.9969398,0.0011418642,0.0013565657,0.00017747954,0.00019644012,0.00018784907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015078598,0.00018518537,0.0020545316,0.00016189004,0.000013704208,0.0000039815827,0.00008436374,0.00024011522,0.00010325724],"category_scores_gemma":[0.00031058316,0.00010435859,0.00016189345,0.0001548264,0.00016549349,0.00012323115,0.000023296543,0.00090371806,0.0000010156475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06652714,0.000531153,0.9050258,0.00016557235,0.00033125,0.00021497087,0.00003715037,0.00015745609,0.0012673505,0.0000013577467,0.00002429812,0.025716495],"study_design_scores_gemma":[0.05257887,0.05712483,0.887312,0.0006022853,0.00019301186,0.000008996183,0.000020383033,0.00011817518,0.0015105262,0.0000010047455,0.00042793134,0.000102007616],"about_ca_topic_score_codex":0.00008811761,"about_ca_topic_score_gemma":0.000048546848,"teacher_disagreement_score":0.05659368,"about_ca_system_score_codex":0.00023571373,"about_ca_system_score_gemma":0.0006748959,"threshold_uncertainty_score":0.425562},"labels":[],"label_agreement":null},{"id":"W2946919252","doi":"10.1200/jco.2019.37.15_suppl.e18214","title":"Socioeconomic contributions to clinical outcome by HPV status in squamous cell carcinomas of the head and neck (SCCHN): An analysis of NCDB.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Socioeconomic status; Residence; Demography; Stage (stratigraphy); Internal medicine; Cancer; Demographics; Oncology; Environmental health; Population","score_opus":0.08186424534813325,"score_gpt":0.4918483483844827,"score_spread":0.40998410303634947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946919252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078476,0.000649957,0.000010899291,0.006782662,0.0007291716,0.00025113017,0.00008222458,0.0000023868479,0.00070679403],"genre_scores_gemma":[0.996915,0.0004033959,0.00023218514,0.0021010456,0.00018145134,0.0000019326299,0.0000027415147,0.000008365986,0.00015390909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950058,0.00060277665,0.003720164,0.0002138682,0.0001965823,0.00026082803],"domain_scores_gemma":[0.99403197,0.0033426618,0.0015937662,0.00029113534,0.00036509096,0.00037536654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036993634,0.0001192878,0.0031295805,0.00017890964,0.000025784093,0.0000029409528,0.00016774518,0.00032469063,0.00012316337],"category_scores_gemma":[0.002426468,0.00007584094,0.00072936167,0.00022733332,0.0003042246,0.000055603185,0.0000944778,0.00081319164,0.000005849192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015548243,0.0013828884,0.99106646,0.000026748885,0.00039493042,0.000010970063,0.00021401691,0.00004386327,0.00018612815,0.000033007,0.001118675,0.0039674896],"study_design_scores_gemma":[0.0088374065,0.01226176,0.9682755,0.000021211468,0.0011239816,0.0000058200712,0.00032856123,0.00017766487,0.00007464362,0.000032398864,0.008793914,0.00006712103],"about_ca_topic_score_codex":0.0003104544,"about_ca_topic_score_gemma":0.0011139694,"teacher_disagreement_score":0.02279094,"about_ca_system_score_codex":0.00020421355,"about_ca_system_score_gemma":0.0010881195,"threshold_uncertainty_score":0.35329583},"labels":[],"label_agreement":null},{"id":"W2946930604","doi":"10.1200/jco.2019.37.15_suppl.5586","title":"Mismatch repair deficiency as a predictor of adjuvant radiotherapy response in endometrioid endometrial carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Endometrial cancer; Hazard ratio; Internal medicine; Radiation therapy; Oncology; Adjuvant; External beam radiotherapy; Proportional hazards model; Brachytherapy; Retrospective cohort study; Carcinoma; Cancer; Confidence interval","score_opus":0.07251138207104028,"score_gpt":0.432397180909754,"score_spread":0.3598857988387137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946930604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715764,0.0047379606,0.000035579076,0.0013198262,0.0043701124,0.00065911986,0.0000066410857,0.000013395613,0.0016997027],"genre_scores_gemma":[0.99098927,0.00094296585,0.0062356377,0.0007046481,0.0007429096,0.0000060832454,7.0547424e-7,0.000028490667,0.00034929847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930124,0.0014283257,0.0039638416,0.0003262864,0.0009008429,0.00036828133],"domain_scores_gemma":[0.9820554,0.014402295,0.002186795,0.00043047365,0.00053862797,0.0003864036],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011106483,0.00019883993,0.00266164,0.0010201903,0.000013606384,0.000004348937,0.00032901327,0.00060058414,0.0010211004],"category_scores_gemma":[0.037404012,0.00014685953,0.0009907532,0.0009818225,0.00027013524,0.000073002164,0.0000650948,0.0012438693,0.000024891402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17200053,0.0021439716,0.78729093,0.00008824922,0.00022227735,0.00064402656,0.00042066808,0.00006155175,0.020735199,0.000021273616,0.001290021,0.015081289],"study_design_scores_gemma":[0.043518122,0.10622383,0.8194664,0.00015845029,0.00017979405,0.0007883539,0.00021066458,0.00015541675,0.0021985339,0.00012242861,0.026834043,0.0001439333],"about_ca_topic_score_codex":0.000054780525,"about_ca_topic_score_gemma":0.000010287579,"teacher_disagreement_score":0.1284824,"about_ca_system_score_codex":0.0006068964,"about_ca_system_score_gemma":0.0054746554,"threshold_uncertainty_score":0.9998921},"labels":[],"label_agreement":null},{"id":"W2946935240","doi":"10.1200/jco.2019.37.15_suppl.e17554","title":"Changes in the proportion of squamous cell carcinoma in head and neck cancer in the United States and Canada, 1995-2015.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Head and neck cancer; Cancer; Incidence (geometry); Larynx; Population; Head and neck; Head and neck squamous-cell carcinoma; Internal medicine; Cohort; Cancer registry; Epidemiology; Basal cell; Demography; Surgery","score_opus":0.07670651852911921,"score_gpt":0.4246644428863203,"score_spread":0.34795792435720113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946935240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95960444,0.0021397471,1.0118391e-7,0.037551846,0.0001887044,0.00024012552,0.0000038777216,4.529025e-7,0.00027072817],"genre_scores_gemma":[0.99295866,0.0031300709,0.00001474756,0.003735182,0.00012287412,0.0000056968947,0.00000109298,0.0000037517852,0.000027931172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835974,0.00035977463,0.00083027733,0.00008979592,0.00021699088,0.00014341947],"domain_scores_gemma":[0.9980079,0.0013291566,0.00043510465,0.000078459445,0.00009744773,0.000051926127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021464732,0.000069329406,0.00070319715,0.000105731466,0.000012235462,0.0000023578718,0.00007334001,0.00009689262,0.000012661572],"category_scores_gemma":[0.00034841037,0.00003394007,0.000028565528,0.00015893363,0.00010415843,0.000024440802,0.000020408756,0.00056155614,1.2300121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008829987,0.0002745192,0.9883296,0.00008296204,0.00000846571,0.00018789044,0.0019233365,0.00001740224,0.000034292825,0.000007619805,0.0013017947,0.006949127],"study_design_scores_gemma":[0.004828932,0.0052138087,0.9735669,0.000096682335,0.000033182063,0.000038843118,0.0029222318,0.0001084675,0.000027711092,0.000031147734,0.013096953,0.000035144058],"about_ca_topic_score_codex":0.26288462,"about_ca_topic_score_gemma":0.9127899,"teacher_disagreement_score":0.64990526,"about_ca_system_score_codex":0.00010254748,"about_ca_system_score_gemma":0.0009963734,"threshold_uncertainty_score":0.7420239},"labels":[],"label_agreement":null},{"id":"W2946941944","doi":"10.1200/jco.2019.37.15_suppl.5560","title":"Effect of estrogen and progesterone receptor expression on progression-free and overall survival outcomes in low-grade serous ovarian cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Dalhousie University; Vancouver General Hospital; Centre Hospitalier de l’Université de Montréal; University of Calgary; Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Immunohistochemistry; Internal medicine; Progesterone receptor; Oncology; Ovarian cancer; Estrogen receptor; Tissue microarray; Serous fluid; Proportional hazards model; Gynecology; Progression-free survival; Population; Estrogen; Stage (stratigraphy); Cancer; Breast cancer; Overall survival","score_opus":0.04703348005093867,"score_gpt":0.44751143145926464,"score_spread":0.400477951408326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946941944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892105,0.0009854435,9.3778027e-7,0.008260109,0.0010577478,0.0006225891,0.000009676877,0.000004488224,0.00013793167],"genre_scores_gemma":[0.99688303,0.0013402554,0.0010798565,0.00030131792,0.00029323134,0.000023216884,0.0000017995208,0.000016422715,0.00006084545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974565,0.00054707046,0.0012328553,0.00023884872,0.00033797752,0.00018678364],"domain_scores_gemma":[0.9958919,0.00254561,0.0010005493,0.00022388101,0.00007904249,0.0002589775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018941032,0.00016827851,0.0017706017,0.00009387522,0.000015504236,0.000007445686,0.00009747819,0.00028839317,0.00006436082],"category_scores_gemma":[0.0008389675,0.00009589668,0.00017173467,0.0000560548,0.00010150298,0.00007674215,0.00007983077,0.0005092742,0.000002318294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070148213,0.0016794126,0.8944725,0.0001890568,0.00022233154,0.00013737503,0.000060111597,0.0000048793236,0.00038906588,0.000042339016,0.00024693646,0.09554121],"study_design_scores_gemma":[0.033319414,0.04629689,0.9140266,0.0016641399,0.00021964952,0.0000486614,0.000016872345,0.000016738397,0.0025682037,0.00005913171,0.0016753213,0.000088387635],"about_ca_topic_score_codex":0.000050252038,"about_ca_topic_score_gemma":0.000027059581,"teacher_disagreement_score":0.09545282,"about_ca_system_score_codex":0.00012605432,"about_ca_system_score_gemma":0.0003663758,"threshold_uncertainty_score":0.39105532},"labels":[],"label_agreement":null},{"id":"W2946942811","doi":"10.1200/jco.2019.37.15_suppl.tps10066","title":"A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with <i>RET</i>-altered cancers.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Medullary thyroid cancer; Oncology; Internal medicine; Cancer; Thyroid cancer","score_opus":0.03912156607813211,"score_gpt":0.4619869757031472,"score_spread":0.42286540962501507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946942811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962899,0.00013224235,0.0000044605836,0.0004553261,0.00094413967,0.0008430783,0.0000098177225,0.000004379316,0.0013166328],"genre_scores_gemma":[0.9983246,0.000092501796,0.0004618508,0.0003970088,0.0005828424,0.0000113712995,0.0000048501524,0.00001588868,0.00010909849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972702,0.00025952002,0.0016714851,0.00020697745,0.0004043461,0.00018746643],"domain_scores_gemma":[0.99666387,0.0006141693,0.0016731808,0.00016305615,0.0006820649,0.00020363984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067811593,0.00013084803,0.0012675938,0.00022562577,0.000017374292,0.0000037416014,0.00008963818,0.00015741984,0.00003859045],"category_scores_gemma":[0.00042743658,0.00008324077,0.0001481555,0.0003774779,0.000051565163,0.00012433068,0.000023629515,0.0006263472,0.0000058878327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012469145,0.031417932,0.94362557,0.0000326472,0.0005929765,0.00015470259,0.0013247225,0.00002735727,0.000010882358,0.0000040553036,0.0013610154,0.008978989],"study_design_scores_gemma":[0.13578427,0.15020911,0.71056145,0.00007256194,0.0011852981,0.000013729664,0.00049258675,0.000014344712,0.000015658668,0.000025271911,0.001543857,0.00008185131],"about_ca_topic_score_codex":0.00016467471,"about_ca_topic_score_gemma":0.0003014962,"teacher_disagreement_score":0.23306412,"about_ca_system_score_codex":0.00052128755,"about_ca_system_score_gemma":0.0033886477,"threshold_uncertainty_score":0.60113156},"labels":[],"label_agreement":null},{"id":"W2946951304","doi":"10.1200/jco.2019.37.15_suppl.6062","title":"Tumor volume, circulating tumor cells, and cfDNA changes during radiotherapy in patients with head and neck cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Circulating tumor cell; Head and neck cancer; Radiation therapy; Cancer; Head and neck squamous-cell carcinoma; Prospective cohort study; Internal medicine; Oncology; Nuclear medicine; Pathology; Metastasis","score_opus":0.01913560605055093,"score_gpt":0.3344534505440395,"score_spread":0.3153178444934886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946951304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971352,0.001803381,0.0000066868397,0.00042761108,0.00041132674,0.00014238876,0.000011477406,0.0000010895182,0.0000608298],"genre_scores_gemma":[0.9956343,0.0019349277,0.0009430603,0.0009344931,0.0004942031,0.0000026446387,0.0000022350052,0.000016197606,0.000037922455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890023,0.00007254041,0.00056471396,0.00019830909,0.00009297374,0.0001712019],"domain_scores_gemma":[0.9989512,0.00011232956,0.0005973264,0.000102603066,0.00010162065,0.00013493627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038675396,0.000104924045,0.0005004553,0.00004361029,0.000023537796,0.000013238017,0.000080313184,0.00011219276,0.00001520028],"category_scores_gemma":[0.00015348836,0.000084270614,0.000050495342,0.000040283812,0.000077834426,0.0000057339935,0.000053463682,0.00023239749,4.561218e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013886344,0.00018321759,0.9790659,0.000029513245,0.00006357505,0.00003223812,0.000036775535,0.0001590312,0.0067876587,0.000002998912,0.000120191806,0.012130274],"study_design_scores_gemma":[0.0077698817,0.006219928,0.97024965,0.00006784949,0.000022978631,0.000033366065,0.00002955339,0.00009112474,0.0007224947,0.000009054189,0.014661283,0.00012283782],"about_ca_topic_score_codex":0.00005334951,"about_ca_topic_score_gemma":0.00037298826,"teacher_disagreement_score":0.014541091,"about_ca_system_score_codex":0.000044156983,"about_ca_system_score_gemma":0.0002777651,"threshold_uncertainty_score":0.3436456},"labels":[],"label_agreement":null},{"id":"W2946966384","doi":"10.1200/jco.2019.37.15_suppl.e20704","title":"Clinical haematological biomarkers: Derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) and their relationship to survival outcomes in non small cell lung cancer (NSCLC) treated with immunotherapy: A multicenter review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Retrospective cohort study; Lung cancer; Immunotherapy; Lymphocyte; non-small cell lung cancer (NSCLC); Biomarker; Oncology; Cancer; Neutrophil to lymphocyte ratio; Gastroenterology; Cohort","score_opus":0.051536857699354434,"score_gpt":0.3863202218278438,"score_spread":0.33478336412848936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946966384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98332655,0.0039406554,0.0005643898,0.0074315434,0.00058730494,0.00396444,0.00002980731,0.000024769606,0.00013052108],"genre_scores_gemma":[0.9818414,0.004353892,0.004917279,0.008255239,0.0002795631,0.0002178556,0.000015054491,0.000061295774,0.000058424965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99263424,0.0016619682,0.003925456,0.0007532148,0.00047454602,0.00055059744],"domain_scores_gemma":[0.99017113,0.0062465887,0.0014324678,0.0004031335,0.0006967821,0.0010499037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00411489,0.0005092251,0.0031359333,0.00045691023,0.00009588036,0.000049414575,0.00030231904,0.0006698893,0.000104362996],"category_scores_gemma":[0.0031601775,0.0003367009,0.00045962335,0.0005056486,0.00030731776,0.00019659699,0.00017156868,0.00093330257,0.000025492995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030505817,0.0017660935,0.95650864,0.0005302084,0.0008489673,0.0006429323,0.00015561456,0.000026643567,0.00053810194,0.000010129893,0.00029911046,0.008167749],"study_design_scores_gemma":[0.030117005,0.005406366,0.9574461,0.0032833612,0.00044066444,0.0002202458,0.00010588472,0.0011627285,0.00016338832,0.000015094703,0.0012692277,0.0003699629],"about_ca_topic_score_codex":0.00004431293,"about_ca_topic_score_gemma":0.00013525569,"teacher_disagreement_score":0.007797786,"about_ca_system_score_codex":0.0004543458,"about_ca_system_score_gemma":0.0018038336,"threshold_uncertainty_score":0.9999085},"labels":[],"label_agreement":null},{"id":"W2946969181","doi":"10.1200/jco.2019.37.15_suppl.e16056","title":"Delivery of bleomycin among patients with testicular cancer: A population-based study of pulmonary monitoring and toxicity.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Alberta Health Services; Queen's University","funders":"","keywords":"Medicine; Bleomycin; Testicular cancer; Etoposide; Pulmonary function testing; Pulmonary toxicity; Chemotherapy; Medical record; Internal medicine; Population; Surgery; Lung","score_opus":0.03782181552380954,"score_gpt":0.3878335032877829,"score_spread":0.35001168776397334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946969181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887,0.0004394942,0.00000410691,0.000056968995,0.00020354686,0.00039429893,0.0000046820546,0.0000029143382,0.000023959197],"genre_scores_gemma":[0.9992417,0.000029708843,0.0005838937,0.000034113957,0.00008736707,0.0000031751565,0.0000022385357,0.000010177444,0.000007617929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982097,0.00013473337,0.0010805911,0.00012861847,0.0003486115,0.000097740245],"domain_scores_gemma":[0.9968064,0.00081235386,0.0014636168,0.00013624558,0.00059133733,0.00019005938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030114874,0.000096172116,0.0009289613,0.000086858745,0.000014640136,0.0000020624477,0.00005315156,0.00009903418,0.000020088737],"category_scores_gemma":[0.00056918606,0.00006194672,0.00013055615,0.000095955904,0.000047827692,0.00006412103,0.000021573038,0.00019561917,3.9571253e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023807061,0.0076479325,0.97528565,0.000082415245,0.0004550494,0.00017460505,0.000022741746,0.000465842,0.000052237563,3.692619e-7,0.0000020117338,0.013430447],"study_design_scores_gemma":[0.011124186,0.016923446,0.9699776,0.00041625608,0.0011265811,0.0000064231776,0.000093842486,0.00022622959,0.000044921508,0.0000066371194,0.0000041039575,0.00004974878],"about_ca_topic_score_codex":0.00029203432,"about_ca_topic_score_gemma":0.000017204118,"teacher_disagreement_score":0.013380699,"about_ca_system_score_codex":0.00006244331,"about_ca_system_score_gemma":0.00042781926,"threshold_uncertainty_score":0.25261137},"labels":[],"label_agreement":null},{"id":"W2946973054","doi":"10.1200/jco.2019.37.15_suppl.2620","title":"Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; KRAS; Oncology; Internal medicine; Lung cancer; Clinical trial; Stage (stratigraphy); Cohort; Cancer; Clinical endpoint; Bioinformatics; Colorectal cancer","score_opus":0.14259807258460055,"score_gpt":0.40341643479304795,"score_spread":0.2608183622084474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946973054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843963,0.0052890657,0.004155322,0.0033625858,0.0017894538,0.0005209801,0.000016720322,0.000004283102,0.00046533823],"genre_scores_gemma":[0.97958744,0.0014506144,0.0062839296,0.010277514,0.0022551422,0.000011872083,0.000027743861,0.000049290917,0.000056470264],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99673903,0.00052202196,0.0016355168,0.00038524088,0.0002280052,0.00049018924],"domain_scores_gemma":[0.995978,0.00048734443,0.001763933,0.00043870398,0.0009356493,0.00039637586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024437124,0.00025698968,0.00077922543,0.00009434283,0.00044051738,0.0001448344,0.00056892645,0.00043592314,0.000013566405],"category_scores_gemma":[0.00045036754,0.00017115209,0.00036450513,0.00012652123,0.00014259749,0.00002393273,0.00017279215,0.0010054746,0.000001915585],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050902483,0.00010297974,0.03389159,0.00013790543,0.0005934709,0.000047221307,0.009088356,0.34501103,0.5651857,0.00021317686,0.005830403,0.03938912],"study_design_scores_gemma":[0.007842267,0.0051605953,0.0030412432,0.00031673154,0.0005721795,0.00024203022,0.023281777,0.89790696,0.020593068,0.00016700584,0.039808,0.0010681306],"about_ca_topic_score_codex":0.08827108,"about_ca_topic_score_gemma":0.5567624,"teacher_disagreement_score":0.55289596,"about_ca_system_score_codex":0.0027375463,"about_ca_system_score_gemma":0.02273991,"threshold_uncertainty_score":0.98280025},"labels":[],"label_agreement":null},{"id":"W2946979972","doi":"10.1200/jco.2019.37.15_suppl.tps6092","title":"Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nasopharyngeal carcinoma; Immunotherapy; Cancer; Cancer research; Oncology; Internal medicine; Radiation therapy; Immunology","score_opus":0.04064699943115404,"score_gpt":0.37605686815655204,"score_spread":0.335409868725398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946979972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896346,0.0011579883,0.000019670078,0.0020892972,0.0007608016,0.0006452222,0.000013418048,0.000012432955,0.0056666085],"genre_scores_gemma":[0.9973849,0.0004382637,0.00047404555,0.001255297,0.00014954666,0.0000119816,0.000024886232,0.00003718227,0.00022388327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952758,0.00081313134,0.0024471437,0.00037164017,0.0005974861,0.000494827],"domain_scores_gemma":[0.9957328,0.0014137005,0.0018783729,0.00021600786,0.00043286188,0.00032629154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020694027,0.00027908004,0.002095296,0.00045586648,0.00003496402,0.000016646989,0.00020736645,0.0004372346,0.00021738766],"category_scores_gemma":[0.0011531598,0.0002154433,0.0003213411,0.0005723232,0.00015981785,0.00028092662,0.000043980028,0.0018970898,0.00004233727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04568962,0.0052941698,0.87699807,0.00012409198,0.00046598894,0.00252655,0.00092986913,0.00028216938,0.0005491423,0.00019875064,0.0013840623,0.06555751],"study_design_scores_gemma":[0.104484655,0.043485668,0.84646654,0.0005577534,0.0004089821,0.00029689056,0.00068466197,0.0019178671,0.00021212749,0.00058127014,0.000619587,0.0002839661],"about_ca_topic_score_codex":0.00049875723,"about_ca_topic_score_gemma":0.0013304269,"teacher_disagreement_score":0.06527354,"about_ca_system_score_codex":0.0009712434,"about_ca_system_score_gemma":0.0022643185,"threshold_uncertainty_score":0.8785523},"labels":[],"label_agreement":null},{"id":"W2946983074","doi":"10.1200/jco.2019.37.15_suppl.tps5600","title":"ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Oncology; Internal medicine; Carboplatin; Trabectedin; Pembrolizumab; Bevacizumab; Clinical endpoint; Phases of clinical research; Clinical trial; Chemotherapy; Surgery; Cancer; Immunotherapy; Cisplatin; Soft tissue sarcoma","score_opus":0.12831326470956897,"score_gpt":0.44998987546242525,"score_spread":0.32167661075285625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946983074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984356,0.0022697158,0.00017563681,0.0013892286,0.0012426757,0.009869414,0.0002929424,0.00002009272,0.00038428314],"genre_scores_gemma":[0.9940277,0.0032229272,0.001312036,0.00020585753,0.0005891207,0.00046701473,0.000029774676,0.00009986753,0.000045711153],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910531,0.0010413883,0.0049953703,0.00077569694,0.0015831417,0.00055128825],"domain_scores_gemma":[0.98282397,0.007487229,0.0064595845,0.0009459821,0.0017935748,0.0004896779],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027199276,0.0007758103,0.0077863415,0.0004924153,0.00013233602,0.000021646072,0.000387537,0.0005081332,0.0010350136],"category_scores_gemma":[0.00023778636,0.0004673166,0.0014026122,0.0005247695,0.0004701896,0.00013867511,0.000039279228,0.00077687023,0.0000041643502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7707009,0.07540669,0.07291027,0.00008792191,0.01060023,0.00058899465,0.0059138113,0.0040882053,0.000040920317,0.000018039274,0.000025338586,0.05961869],"study_design_scores_gemma":[0.60615104,0.37862226,0.005393606,0.0003250509,0.002289082,0.0000068682857,0.0031428905,0.00026284147,0.0019269541,0.0000044201497,0.0016412078,0.00023379183],"about_ca_topic_score_codex":0.0031655033,"about_ca_topic_score_gemma":0.0055874554,"teacher_disagreement_score":0.30321556,"about_ca_system_score_codex":0.0010070221,"about_ca_system_score_gemma":0.0067948443,"threshold_uncertainty_score":0.99987817},"labels":[],"label_agreement":null},{"id":"W2946991330","doi":"10.1200/jco.2019.37.15_suppl.1079","title":"Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Cohort; Internal medicine; Oncology; Cancer; Basal (medicine); Log-rank test; Overall survival","score_opus":0.04564204003399749,"score_gpt":0.4018103288116963,"score_spread":0.35616828877769885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946991330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98745203,0.00013360762,0.000008881712,0.010648825,0.00038465357,0.0011356799,0.00012975693,0.000008050768,0.000098495846],"genre_scores_gemma":[0.99590075,0.0000295757,0.0006215131,0.0031749487,0.00015167837,0.000021277316,0.00002298763,0.00003062596,0.000046669236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966068,0.0008783977,0.001417405,0.00028287125,0.00048724865,0.00032723902],"domain_scores_gemma":[0.99505377,0.0027332685,0.0013416476,0.00021271233,0.00033636033,0.0003222621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020276776,0.00024367019,0.0013245674,0.00012545256,0.000040174687,0.000022028678,0.0001402913,0.00013257632,0.00046411844],"category_scores_gemma":[0.00054202415,0.00011150128,0.000205862,0.00024367435,0.00021962984,0.00011236245,0.000051062725,0.00084258924,0.000006695239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024298695,0.003469778,0.9843674,0.000034977238,0.0007951966,0.0002272956,0.00006167139,0.000012915889,0.000007481334,0.00010538565,0.0005956851,0.00789238],"study_design_scores_gemma":[0.014077301,0.008833052,0.9712181,0.00021916405,0.0009135598,0.00046511457,0.00019035055,0.000046935333,0.000003989032,0.00006144735,0.003851068,0.00011989501],"about_ca_topic_score_codex":0.00017265527,"about_ca_topic_score_gemma":0.00017244369,"teacher_disagreement_score":0.013149241,"about_ca_system_score_codex":0.00016962776,"about_ca_system_score_gemma":0.0013780037,"threshold_uncertainty_score":0.50817716},"labels":[],"label_agreement":null},{"id":"W2946992161","doi":"10.1200/jco.2019.37.15_suppl.3137","title":"The whole genome landscape of adult metastatic sarcoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Kelowna General Hospital; University of British Columbia; Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Sarcoma; Medicine; Copy number analysis; Copy-number variation; CDKN2A; Metastasis; Clear-cell sarcoma; Transcriptome; Cancer research; Cancer; Genome; Biology; Gene; Pathology; Genetics; Internal medicine; Gene expression","score_opus":0.08046725359385948,"score_gpt":0.43339263867414307,"score_spread":0.3529253850802836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946992161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97683287,0.002957899,0.000008959886,0.014835565,0.0007132275,0.00018902382,0.000004271731,0.0000028901293,0.0044553],"genre_scores_gemma":[0.99479556,0.0015010815,0.0014349443,0.0015256715,0.00031136826,0.0000028269687,0.0000020725558,0.000009736649,0.00041674532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974673,0.00026859745,0.0017045859,0.00009862875,0.00030208798,0.0001588344],"domain_scores_gemma":[0.99353904,0.0042913924,0.0013229264,0.00023041814,0.00043484554,0.00018135492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001688889,0.00008620148,0.0011238632,0.000055626162,0.000024788938,0.000005375848,0.00015067526,0.00010320763,0.00019494003],"category_scores_gemma":[0.0015971985,0.000041573854,0.0005297936,0.00008683626,0.00010787845,0.000039205253,0.000035762983,0.00041019288,0.00011927194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00284654,0.0046233865,0.8293625,0.00004454845,0.001658126,0.0006399388,0.000105204985,0.000015645486,0.00043958917,0.0010019722,0.0056996928,0.15356283],"study_design_scores_gemma":[0.010354117,0.0120644085,0.7636452,0.000067799374,0.0006696053,0.00040045156,0.00031545904,0.000056653935,0.00007652282,0.0005629966,0.2117337,0.000053137006],"about_ca_topic_score_codex":0.0000069369353,"about_ca_topic_score_gemma":0.000014396172,"teacher_disagreement_score":0.206034,"about_ca_system_score_codex":0.00004097561,"about_ca_system_score_gemma":0.00056008686,"threshold_uncertainty_score":0.21344566},"labels":[],"label_agreement":null},{"id":"W2946993394","doi":"10.1200/jco.2019.37.15_suppl.e16038","title":"Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Rash; Adverse effect; Cancer; Lung cancer; Oncology; Gastroenterology","score_opus":0.028234575770547898,"score_gpt":0.3466008892436285,"score_spread":0.3183663134730806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946993394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969891,0.0001485842,0.0000063376942,0.0007758975,0.0006236321,0.000983482,0.000013997951,0.000010239481,0.00044877332],"genre_scores_gemma":[0.9982195,0.00013791947,0.0006997637,0.00023934689,0.000116653835,0.000011977851,0.000017793242,0.000046625486,0.0005104214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99129146,0.00074536446,0.006345461,0.000335966,0.0009084976,0.00037326282],"domain_scores_gemma":[0.9893834,0.0016134684,0.007475888,0.00034585546,0.000957116,0.0002242809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005948207,0.00030270166,0.0026820556,0.0002952351,0.00003047049,0.0000044068206,0.00020765506,0.0004969639,0.00024542576],"category_scores_gemma":[0.0009615298,0.00017652623,0.0008475496,0.0005125122,0.00023979551,0.00021631963,0.000038151396,0.0013487375,0.000013591378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11908585,0.0034528198,0.8649791,0.00004618539,0.002413632,0.000115983705,0.00010534932,0.00006781475,0.00012210601,0.0000030899034,0.00003763586,0.009570448],"study_design_scores_gemma":[0.08143011,0.045159735,0.87049276,0.00060754,0.0011428236,0.000054415435,0.00016412933,0.000033711647,0.00026988838,0.00001155541,0.00044780227,0.00018553295],"about_ca_topic_score_codex":0.0003330813,"about_ca_topic_score_gemma":0.0001962878,"teacher_disagreement_score":0.041706912,"about_ca_system_score_codex":0.00057599746,"about_ca_system_score_gemma":0.0015440244,"threshold_uncertainty_score":0.7198531},"labels":[],"label_agreement":null},{"id":"W2946994391","doi":"10.1200/jco.2019.37.15_suppl.4028","title":"Perioperative chemotherapy alone versus preoperative chemoradiotherapy for locally advanced distal esophageal and gastroesophageal junction cancer: A 10-year review of the British Columbia (BC) Cancer Registry.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Surrey Place Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Perioperative; Cancer; Chemoradiotherapy; Cohort; Esophageal cancer; Adenocarcinoma; Surgery; Internal medicine; Cancer registry; Chemotherapy; Oncology","score_opus":0.10012901348788239,"score_gpt":0.4864971553933123,"score_spread":0.3863681419054299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946994391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00073023717,0.9916437,0.000024621242,0.0011036826,0.0014539897,0.0043675187,0.00041451943,0.000008104991,0.0002535946],"genre_scores_gemma":[0.00025982107,0.98820204,0.0011835361,0.0007999359,0.0015590673,0.0004996252,0.000059115762,0.000085499116,0.007351356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944652,0.0007517928,0.0029803396,0.0006041765,0.00073684676,0.0004616798],"domain_scores_gemma":[0.9926213,0.0012346292,0.0039906944,0.0004487901,0.0012423475,0.0004622618],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016884961,0.00042895233,0.0069519845,0.000059201015,0.00019312395,0.00010016725,0.0003979057,0.0005769209,0.0011630345],"category_scores_gemma":[0.0013437867,0.00032496476,0.0019083585,0.0003584057,0.00068714004,0.00015264773,0.000079172605,0.0014913083,0.0000024764188],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006311633,0.00071110035,0.0011629568,0.026473604,0.002689513,0.0001730544,0.00002921459,0.0000018523227,4.955926e-7,0.000003438786,0.013794513,0.94864863],"study_design_scores_gemma":[0.033800334,0.027577009,0.0028808122,0.0886994,0.0044036084,0.0004149589,0.00003589834,0.000010372393,0.0000061793053,0.000005156594,0.8418906,0.00027567067],"about_ca_topic_score_codex":0.0013531772,"about_ca_topic_score_gemma":0.0038420171,"teacher_disagreement_score":0.94837296,"about_ca_system_score_codex":0.0012141742,"about_ca_system_score_gemma":0.012622633,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W2946995821","doi":"10.1200/jco.2019.37.15_suppl.e13021","title":"Confirmation of germline variants identified by tumor testing: A population-based study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; HRAS; Neuroblastoma RAS viral oncogene homolog; Oncology; KRAS; Internal medicine; PDGFRA; SDHD; SDHB; Cancer; Genetic testing; Germline; Population; PTEN; Colorectal cancer; Germline mutation; GiST; Genetics; Mutation; Stromal cell; Biology","score_opus":0.06173140254786654,"score_gpt":0.4108980837037009,"score_spread":0.3491666811558344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946995821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761987,0.00013667227,0.00048960623,0.00024934034,0.00096771645,0.00019045692,0.000018642671,0.0000015225928,0.000326198],"genre_scores_gemma":[0.9975616,0.000017439936,0.0012846432,0.00063280226,0.0003912686,0.0000017394755,0.000024895853,0.000010255374,0.00007538052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977932,0.0001984358,0.0015903112,0.00014610103,0.00016583502,0.000106118016],"domain_scores_gemma":[0.996592,0.0007879851,0.0018613877,0.00018817525,0.00046968219,0.000100771336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015960516,0.000084096326,0.00054890616,0.00004451853,0.000016916225,0.0000089177,0.00017426632,0.00015365932,0.000049839215],"category_scores_gemma":[0.004058236,0.0000728049,0.00016487285,0.0000690655,0.00002984965,0.000004701841,0.000040736184,0.00018008874,0.000005985365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012980326,0.002115921,0.92389435,0.000025340225,0.00017885747,0.000020534038,0.000017437402,0.0011467392,0.05908041,0.000030557712,0.0045131925,0.007678645],"study_design_scores_gemma":[0.00840051,0.015053928,0.95721114,0.000035841866,0.00016270168,0.00002305275,0.00008599658,0.00090745714,0.003405893,0.00016232053,0.014384704,0.00016645384],"about_ca_topic_score_codex":0.00006509271,"about_ca_topic_score_gemma":0.000042569423,"teacher_disagreement_score":0.055674516,"about_ca_system_score_codex":0.000023766854,"about_ca_system_score_gemma":0.00070310483,"threshold_uncertainty_score":0.48583803},"labels":[],"label_agreement":null},{"id":"W2946996357","doi":"10.1200/jco.2019.37.15_suppl.6085","title":"Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Lymphovascular invasion; Internal medicine; Cumulative incidence; Incidence (geometry); Proportional hazards model; Oncology; Framingham Risk Score; Cancer; Disease; Metastasis","score_opus":0.13319114756522787,"score_gpt":0.4152466557838499,"score_spread":0.282055508218622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946996357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773157,0.00045300723,0.00029852137,0.0006153958,0.0002824903,0.00036601038,0.000028692677,0.0000023820426,0.00022194898],"genre_scores_gemma":[0.98706883,0.00019182159,0.012365261,0.00015829138,0.00010956254,0.000014022533,0.000026427022,0.000008193783,0.00005760387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979678,0.00008105113,0.0015308614,0.00013467956,0.00017454602,0.00011110176],"domain_scores_gemma":[0.99787694,0.0010197539,0.00072337734,0.00009062323,0.0001558222,0.00013348277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013383046,0.000089405956,0.0009146343,0.00010926337,0.000013657514,0.0000032542268,0.000041237592,0.00011203487,0.000020931726],"category_scores_gemma":[0.00035598138,0.000057648045,0.00015490131,0.000054525393,0.000040039387,0.00006607609,0.000020594167,0.00016211782,0.0000010002798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003764514,0.0016484519,0.9886943,0.000099257086,0.00023254372,0.00008009385,0.00021334592,0.000089580375,0.000039792176,0.00022319738,0.00033954912,0.004575387],"study_design_scores_gemma":[0.018441776,0.0067528137,0.96748495,0.00019285898,0.00044592537,0.00014114646,0.00012138046,0.0029308773,0.0011995691,0.00046893192,0.0017560063,0.0000637685],"about_ca_topic_score_codex":0.000011387618,"about_ca_topic_score_gemma":0.000023431949,"teacher_disagreement_score":0.02120934,"about_ca_system_score_codex":0.00007814387,"about_ca_system_score_gemma":0.00073720055,"threshold_uncertainty_score":0.23508191},"labels":[],"label_agreement":null},{"id":"W2946997709","doi":"10.1200/jco.2019.37.15_suppl.9048","title":"Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Repeated measures design; Quality of life (healthcare); Tremelimumab; Chemotherapy; Population; Oncology; Nuclear medicine; Gastroenterology; Surgery; Cancer; Immunotherapy; Ipilimumab","score_opus":0.08890860114174669,"score_gpt":0.4595490581262037,"score_spread":0.370640456984457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946997709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846277,0.00027896222,0.00006244418,0.009847711,0.0014887799,0.00058174564,0.000027145687,0.000013604115,0.003071875],"genre_scores_gemma":[0.9922462,0.0003003708,0.0055005383,0.0012174967,0.00020948879,0.000009551404,0.000038159356,0.000028480516,0.000449698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596965,0.00018922273,0.0028097166,0.00030169758,0.00048110416,0.00024860929],"domain_scores_gemma":[0.9927909,0.004046307,0.0021884416,0.00034715148,0.00035916828,0.00026805612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089902314,0.00020368448,0.001711704,0.00014994253,0.0000298983,0.000010619549,0.00010521329,0.00012001698,0.0002988464],"category_scores_gemma":[0.0027753897,0.000120971505,0.0003356893,0.00019836043,0.000094868505,0.00013073142,0.000020374131,0.00058202335,0.00003876259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17875266,0.011538331,0.5137828,0.00006093323,0.008995,0.0069782347,0.0015639842,0.0011512346,0.00005409894,0.00005595833,0.0026480341,0.27441877],"study_design_scores_gemma":[0.23501888,0.037926815,0.6887835,0.00036541463,0.0021888302,0.00021961555,0.0006055096,0.0002947622,0.000046897618,0.0002240351,0.03411691,0.00020881004],"about_ca_topic_score_codex":0.00038114958,"about_ca_topic_score_gemma":0.00078525435,"teacher_disagreement_score":0.27420995,"about_ca_system_score_codex":0.00040220853,"about_ca_system_score_gemma":0.0020142614,"threshold_uncertainty_score":0.49330747},"labels":[],"label_agreement":null},{"id":"W2947004267","doi":"10.1200/jco.2019.37.15_suppl.5549","title":"How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Proportional hazards model; Prospective cohort study; Internal medicine; Cohort; Ovarian cancer; Cancer; Receiver operating characteristic; Oncology; Gynecology","score_opus":0.07482746390600016,"score_gpt":0.425299448468368,"score_spread":0.35047198456236783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947004267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9130355,0.0014429935,0.00005088556,0.08399258,0.0006121888,0.00068071735,0.000015654485,0.0000031074,0.00016634726],"genre_scores_gemma":[0.99502003,0.0022123442,0.0010748232,0.00076858007,0.0005455323,0.000047623354,0.0000018099416,0.000018695946,0.0003105669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825495,0.00015066874,0.0009146726,0.00019586328,0.00023648281,0.00024735538],"domain_scores_gemma":[0.99404204,0.0040665823,0.0013166183,0.0001774091,0.00026853243,0.0001288456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001390138,0.00014500799,0.0013711812,0.000064058215,0.000024513485,0.00001728698,0.00011785514,0.00014897095,0.0000777739],"category_scores_gemma":[0.00074805407,0.00007651491,0.00015907378,0.00008852358,0.00015849716,0.000109508146,0.000034436245,0.00043406285,0.0000022292438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011466196,0.002339892,0.5139886,0.00019111249,0.0011628781,0.00011023238,0.0008067291,0.00012332306,0.00009558973,0.00010959949,0.0016790365,0.4679268],"study_design_scores_gemma":[0.023279032,0.023491759,0.9195572,0.0012222682,0.0006271629,0.00006531783,0.00061548845,0.0009967966,0.00011338801,0.0003883473,0.029499141,0.00014405743],"about_ca_topic_score_codex":0.000041529456,"about_ca_topic_score_gemma":0.00024385029,"teacher_disagreement_score":0.46778274,"about_ca_system_score_codex":0.00023670931,"about_ca_system_score_gemma":0.0009422598,"threshold_uncertainty_score":0.31201875},"labels":[],"label_agreement":null},{"id":"W2947005140","doi":"10.1200/jco.2019.37.15_suppl.e14220","title":"MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada); Université de Montréal","funders":"","keywords":"IL-2 receptor; Cytotoxic T cell; Cancer research; CD8; Interleukin 2; Cytokine; Immunotherapy; Tumor microenvironment; Medicine; T cell; In vivo; Immune system; Immunology; Molecular biology; Biology; In vitro; Biochemistry","score_opus":0.0849344890506948,"score_gpt":0.4362207527314609,"score_spread":0.3512862636807661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947005140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909386,0.00022986597,9.0293565e-7,0.0028148578,0.0004444087,0.0005672785,0.0000010214883,0.0000027114659,0.0050003766],"genre_scores_gemma":[0.9958007,0.00023918318,0.000117302356,0.0019200847,0.000509611,0.0000053278372,0.0000012033651,0.000020847932,0.0013857741],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99549395,0.0018530892,0.0016385876,0.00018802399,0.0005717583,0.00025462027],"domain_scores_gemma":[0.9959546,0.0027762298,0.00063339947,0.00039089657,0.00007841348,0.00016648861],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00779793,0.00014477452,0.0013652198,0.00016734851,0.000013565036,0.000007660464,0.00040815995,0.00019084734,0.0012653456],"category_scores_gemma":[0.0010014072,0.000070903705,0.00041957383,0.00010958639,0.0002819042,0.000073370684,0.000058653535,0.001588927,0.00008125099],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05256158,0.0072917473,0.19809401,0.00025507066,0.00022187908,0.0010709658,0.0007078281,0.000044023225,0.6299804,0.000009873305,0.0010416002,0.10872105],"study_design_scores_gemma":[0.04390281,0.38051337,0.25680417,0.0006877083,0.0003106825,0.0014208797,0.00092045096,0.00027785296,0.13601623,0.000054640226,0.17884992,0.00024127148],"about_ca_topic_score_codex":0.000023025033,"about_ca_topic_score_gemma":0.000018359657,"teacher_disagreement_score":0.49396414,"about_ca_system_score_codex":0.00015721214,"about_ca_system_score_gemma":0.00035190454,"threshold_uncertainty_score":0.9996476},"labels":[],"label_agreement":null},{"id":"W2947006117","doi":"10.1200/jco.2019.37.15_suppl.5012","title":"Diagnostic performance of <sup>18</sup>F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prospective cohort study; Cohort; Prostate cancer; Nuclear medicine; Biopsy; Histopathology; Radiology; Cancer; Internal medicine; Pathology","score_opus":0.07746961558481354,"score_gpt":0.4646073883673265,"score_spread":0.387137772782513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947006117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990403,0.00045384566,0.0000014826102,0.00085925957,0.00027825625,0.007683588,0.0000389359,0.000010207641,0.00027143632],"genre_scores_gemma":[0.99763507,0.0010593762,0.0002114219,0.00020765571,0.00020430394,0.0003250249,0.000013845507,0.000053589938,0.00028971673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99219036,0.0016411183,0.003666733,0.0005478679,0.0012488056,0.0007051049],"domain_scores_gemma":[0.98967946,0.006015555,0.002251518,0.00050105253,0.0012673713,0.00028503977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004203223,0.00041669904,0.0027186435,0.0005471735,0.00006126124,0.000024262386,0.00048261177,0.00006435512,0.00047409866],"category_scores_gemma":[0.004098404,0.0002147242,0.00031554364,0.00092622696,0.0004578872,0.00041906882,0.00013434749,0.0017335721,0.000010783244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22343203,0.028527426,0.7299926,0.0002461693,0.0006918664,0.002073542,0.0045449464,0.0012339681,0.000010414865,0.0000016253708,0.0002643422,0.00898105],"study_design_scores_gemma":[0.39723492,0.10645919,0.47822022,0.0012998226,0.0009769327,0.000121663856,0.007926705,0.0070456844,0.00008813602,0.000017980476,0.00036543174,0.0002433001],"about_ca_topic_score_codex":0.000522932,"about_ca_topic_score_gemma":0.00039005646,"teacher_disagreement_score":0.2517724,"about_ca_system_score_codex":0.0006901928,"about_ca_system_score_gemma":0.002532731,"threshold_uncertainty_score":0.8756199},"labels":[],"label_agreement":null},{"id":"W2947012155","doi":"10.1200/jco.2019.37.15_suppl.tps3170","title":"Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistance—A compLEEment-1 Canadian correlative sub-study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Grand River Hospital; Université Laval; University of Alberta; BC Cancer Agency; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Oncology; Proteome; Internal medicine; Population; Proteomics; Cancer; Letrozole; Metastatic breast cancer; Biomarker; Bioinformatics; Biology; Tamoxifen; Genetics","score_opus":0.05483441910059244,"score_gpt":0.4019711863863359,"score_spread":0.34713676728574344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947012155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332047,0.00011249286,0.0032267666,0.0010391014,0.0002172082,0.0017908158,0.00016011181,0.0000043102505,0.00012875514],"genre_scores_gemma":[0.9961705,0.000025685016,0.0032908435,0.0002464102,0.00012522853,0.000016538459,0.0000060438706,0.000017685446,0.00010105551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607027,0.00091602246,0.0019567173,0.00032272527,0.00047413167,0.00026013554],"domain_scores_gemma":[0.9950521,0.00091573776,0.0023238037,0.00029801362,0.0009999638,0.0004103951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015205228,0.00020113705,0.0025018025,0.00042454785,0.000035968933,0.0000060266557,0.00011689247,0.00020204247,0.000035909838],"category_scores_gemma":[0.0007108091,0.0001519197,0.0004037865,0.00032931246,0.00022481983,0.00021718006,0.000099404846,0.0006778302,0.0000015400151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023822088,0.0011852665,0.90122706,0.00015521493,0.003102848,0.00019672293,0.0018736392,0.00032035698,0.06309561,0.000027066944,0.000025960588,0.0049681785],"study_design_scores_gemma":[0.0076656514,0.010458077,0.96800154,0.00060636294,0.0009886931,0.000026943388,0.0027164037,0.000095851006,0.008987937,0.00010083628,0.00022343318,0.00012829085],"about_ca_topic_score_codex":0.003738108,"about_ca_topic_score_gemma":0.016960511,"teacher_disagreement_score":0.066774465,"about_ca_system_score_codex":0.00038783514,"about_ca_system_score_gemma":0.0015593835,"threshold_uncertainty_score":0.9464363},"labels":[],"label_agreement":null},{"id":"W2947017063","doi":"10.1200/jco.2019.37.15_suppl.e17035","title":"Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcopenia; Taxane; Internal medicine; Chemotherapy; Geriatric oncology; Cancer; Oncology; Chemotherapy regimen; Surgery; Gastroenterology; Breast cancer","score_opus":0.05346899142032963,"score_gpt":0.43050897078696615,"score_spread":0.3770399793666365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947017063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864086,0.00011164821,0.000028552466,0.0120183425,0.00032713785,0.00041687503,0.000004093803,0.0000048398897,0.0006799333],"genre_scores_gemma":[0.98422277,0.00027485457,0.004962981,0.010174061,0.00025234267,0.0000029960468,0.0000013946125,0.000016562959,0.00009204156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977335,0.00018565053,0.0014467153,0.00015280186,0.00030348258,0.0001778478],"domain_scores_gemma":[0.9972359,0.00072507997,0.0013901708,0.0001208674,0.00029185685,0.00023610289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016066376,0.00010298876,0.0011360269,0.00013180565,0.000015892441,0.000003816136,0.00007835588,0.00023944615,0.00072679925],"category_scores_gemma":[0.00042997496,0.00007187288,0.00009480216,0.0001349428,0.000106590094,0.00007085936,0.000010821812,0.0006763661,0.0000023231328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015239238,0.0012365221,0.9420772,0.00014060905,0.00007197547,0.000016039097,0.00013175297,0.000005571514,0.00022378509,0.000011440922,0.0003099142,0.04053596],"study_design_scores_gemma":[0.04501529,0.010244915,0.9366438,0.00083558785,0.00003420193,0.000012534735,0.000032261432,0.000117162504,0.00025060843,0.000068524634,0.00668007,0.00006508097],"about_ca_topic_score_codex":0.000055705874,"about_ca_topic_score_gemma":0.00005386121,"teacher_disagreement_score":0.04047088,"about_ca_system_score_codex":0.0001299366,"about_ca_system_score_gemma":0.0012820578,"threshold_uncertainty_score":0.7957942},"labels":[],"label_agreement":null},{"id":"W2947022664","doi":"10.1200/jco.2019.37.15_suppl.6509","title":"The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; McMaster University; Ontario Institute for Cancer Research; Institute for Clinical Evaluative Sciences; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Retrospective cohort study; Propensity score matching; Proportional hazards model; Cancer; Cohort; Internal medicine; Comorbidity; Cohort study; Population; Survival analysis","score_opus":0.08710106740873273,"score_gpt":0.4617616227388621,"score_spread":0.3746605553301294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947022664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553406,0.000037737733,0.000027062635,0.0014722726,0.0005193953,0.000266782,0.000045799625,0.00000403244,0.0020928676],"genre_scores_gemma":[0.99838716,0.00013763666,0.00037522928,0.00046207383,0.00022777254,7.9646327e-7,0.000032354,0.0000118532635,0.00036511404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954702,0.0006017696,0.0030205268,0.00019284768,0.0005338154,0.00018082107],"domain_scores_gemma":[0.98769206,0.0070598666,0.0038272347,0.0004462606,0.00078243564,0.00019213966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005141414,0.00013604733,0.0023801725,0.00019592786,0.00002413155,0.0000064633696,0.0001686641,0.00026203756,0.0002108283],"category_scores_gemma":[0.006660866,0.00007474284,0.0015476615,0.00031598454,0.000121925135,0.00008865843,0.000021946056,0.0007436129,0.0000035207966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032587636,0.0006331635,0.9562439,0.000010428234,0.0033088943,0.000023273786,0.000041515395,0.0046373545,0.00016549863,0.000058162623,0.0009576009,0.0013326069],"study_design_scores_gemma":[0.012162228,0.012763765,0.97071475,0.000044120774,0.0009603156,0.0000050361314,0.000024149007,0.002625909,0.000045552053,0.00007652507,0.0005153385,0.00006229991],"about_ca_topic_score_codex":0.0017371601,"about_ca_topic_score_gemma":0.0002670981,"teacher_disagreement_score":0.020425407,"about_ca_system_score_codex":0.00051024667,"about_ca_system_score_gemma":0.0015852295,"threshold_uncertainty_score":0.79741603},"labels":[],"label_agreement":null},{"id":"W2947026438","doi":"10.1200/jco.2019.37.15_suppl.6000","title":"Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Population; Head and neck squamous-cell carcinoma; Pembrolizumab; Internal medicine; Interim analysis; Cisplatin; Oncology; Head and neck cancer; Urology; Nuclear medicine; Radiation therapy; Randomized controlled trial; Surgery; Cancer; Chemotherapy; Immunotherapy","score_opus":0.18097689072096435,"score_gpt":0.4906753055908003,"score_spread":0.30969841486983596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947026438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977633,0.00047535024,0.000068826295,0.0021061643,0.0009093439,0.018297708,0.000035893223,0.0000035943788,0.00047011283],"genre_scores_gemma":[0.9968789,0.00030060252,0.0006707556,0.00067248207,0.00046481285,0.0006580906,0.000006148642,0.000021263322,0.00032693215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949431,0.00052449235,0.0035092356,0.00027284762,0.00049539894,0.00025493526],"domain_scores_gemma":[0.9918463,0.0030665887,0.0039233896,0.00042117946,0.0005637101,0.00017879314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029563224,0.00022166164,0.0024944367,0.0002870047,0.000049151033,0.0000086378595,0.0002933016,0.00027814286,0.00040627338],"category_scores_gemma":[0.0010373964,0.00012853589,0.0018341598,0.0005164907,0.00032184774,0.000070907394,0.000041364732,0.00057769223,0.0000013931065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89593726,0.008069726,0.009284534,0.00024163057,0.0013667891,0.000018954399,0.00018114156,0.000017867917,0.0014577961,0.00002182714,0.0009655537,0.082436904],"study_design_scores_gemma":[0.6317196,0.20180285,0.077050336,0.00011609033,0.0023350876,0.000060469825,0.000087148605,0.0006318841,0.0018048729,0.00015022738,0.08409066,0.00015077199],"about_ca_topic_score_codex":0.00005265082,"about_ca_topic_score_gemma":0.00007366473,"teacher_disagreement_score":0.26421767,"about_ca_system_score_codex":0.00010381353,"about_ca_system_score_gemma":0.0016241582,"threshold_uncertainty_score":0.5241542},"labels":[],"label_agreement":null},{"id":"W2947026458","doi":"10.1200/jco.2019.37.15_suppl.tps602","title":"Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Université Laval; Jewish General Hospital; BC Cancer Agency; Health Sciences Centre; Hôtel-Dieu de Québec; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Radiation therapy; Mastectomy; Oncology; Breast-conserving surgery; Population; Internal medicine; Axillary Lymph Node Dissection; Cancer; Biomarker; Randomized controlled trial; Confidence interval; Sentinel lymph node","score_opus":0.031727497421856474,"score_gpt":0.39928660661024395,"score_spread":0.36755910918838747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947026458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880509,0.0026854773,0.00015297993,0.006316665,0.0017436633,0.0006188658,0.00008272938,0.0000037921386,0.00034497157],"genre_scores_gemma":[0.985872,0.010434878,0.0009702788,0.0010658352,0.001453926,0.000039215818,0.000011042675,0.00003468032,0.000118197335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954873,0.0013776143,0.0022260367,0.00033690452,0.00029635994,0.00027581328],"domain_scores_gemma":[0.9951465,0.0014686249,0.0025523086,0.00024970548,0.00043877686,0.00014404682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00304601,0.00023820017,0.0022214781,0.00012360103,0.00002383859,0.000006374623,0.00026696702,0.0005012186,0.00012879568],"category_scores_gemma":[0.0007371221,0.00016628238,0.0010091409,0.00013483329,0.000492824,0.000012716615,0.00007463019,0.00043254357,0.000004475263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9119112,0.0018497419,0.053047128,0.000015382586,0.0022736136,0.000033315064,0.00008250224,0.00006743244,0.00223309,0.000019099241,0.0025158164,0.025951665],"study_design_scores_gemma":[0.82465273,0.0034293807,0.16417441,0.0001237342,0.00033205704,0.00011872781,0.000058335452,0.00007866676,0.00044039518,0.000117897674,0.006279612,0.0001940385],"about_ca_topic_score_codex":0.00033902618,"about_ca_topic_score_gemma":0.00015080963,"teacher_disagreement_score":0.11112728,"about_ca_system_score_codex":0.00014023698,"about_ca_system_score_gemma":0.0012139255,"threshold_uncertainty_score":0.67807984},"labels":[],"label_agreement":null},{"id":"W2947029248","doi":"10.1200/jco.2019.37.15_suppl.5044","title":"Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Prostate cancer; Enzalutamide; Quality of life (healthcare); Internal medicine; Placebo; Androgen deprivation therapy; Proportional hazards model; Oncology; Cancer; Physical therapy; Chronic pain; Pathology","score_opus":0.18634195898994688,"score_gpt":0.5224271293812304,"score_spread":0.3360851703912835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947029248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671466,0.008045714,0.00000604089,0.023249429,0.00012187571,0.0013631119,0.00001759657,0.0000041605244,0.00004550126],"genre_scores_gemma":[0.995258,0.0029884237,0.00060389994,0.000930465,0.00008751163,0.000019883892,0.0000055057926,0.000014482585,0.00009186742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99268776,0.0039722202,0.002279601,0.0002352167,0.0005549194,0.0002702907],"domain_scores_gemma":[0.9899604,0.007201401,0.0019871863,0.00018329076,0.00036032728,0.00030744847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012890042,0.00014311892,0.0018979426,0.000091822745,0.000033195593,0.000007713836,0.00010228299,0.00010997275,0.000022576358],"category_scores_gemma":[0.002754737,0.00006602561,0.0001322137,0.0002194952,0.00039559658,0.00008413185,0.00006157532,0.0010478005,0.000002104089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05890074,0.0020957242,0.84889036,0.000079188365,0.0009768377,0.0002411611,0.005033508,0.000023546134,0.00022867261,0.000008200056,0.0002281825,0.08329389],"study_design_scores_gemma":[0.020574288,0.02290994,0.95008296,0.0004564928,0.00015021898,0.000015097774,0.005079158,0.00012045182,0.000037823025,0.00022066715,0.0002844966,0.00006839569],"about_ca_topic_score_codex":0.0022501983,"about_ca_topic_score_gemma":0.0014050545,"teacher_disagreement_score":0.10119262,"about_ca_system_score_codex":0.00018392428,"about_ca_system_score_gemma":0.0033588891,"threshold_uncertainty_score":0.5958525},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2947030501","doi":"10.1200/jco.2019.37.15_suppl.5011","title":"Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Copy-number variation; Gene; Cancer; Medicine; Oncology; Cancer research; Biology; Genetics; Internal medicine; Genome; Androgen receptor","score_opus":0.07740954457735694,"score_gpt":0.4699141394071012,"score_spread":0.39250459482974426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947030501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373734,0.000892862,0.0000043874807,0.0037845296,0.00020014131,0.0010307046,0.00008350212,0.0000076169795,0.00025893524],"genre_scores_gemma":[0.9964883,0.0004572346,0.0011753957,0.0005370509,0.00006333841,0.00007631396,0.000025713654,0.000024164332,0.0011525372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609137,0.0005590362,0.00181376,0.00037467616,0.0007481981,0.00041295498],"domain_scores_gemma":[0.9958574,0.0013074838,0.0012405429,0.00015204227,0.0010620157,0.00038052548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021112477,0.00020634003,0.0017272324,0.00032717673,0.00004960017,0.000041022446,0.0001347984,0.00012935261,0.0002421442],"category_scores_gemma":[0.0012875464,0.00013206807,0.00025968926,0.000904711,0.00016649676,0.00020682851,0.000047713496,0.0005842315,0.0000117097225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01590433,0.0015028875,0.9744216,0.00008493191,0.002999514,0.0007233931,0.00025919286,0.00007311342,0.00079308747,0.000008742701,0.0005609056,0.002668277],"study_design_scores_gemma":[0.0136207715,0.0042370833,0.97606754,0.0003420719,0.0021674794,0.000012051687,0.00021550113,0.000043682932,0.0012027294,0.000048092374,0.0018910761,0.00015192847],"about_ca_topic_score_codex":0.00016217692,"about_ca_topic_score_gemma":0.0031929857,"teacher_disagreement_score":0.0032474787,"about_ca_system_score_codex":0.00045267143,"about_ca_system_score_gemma":0.0015544321,"threshold_uncertainty_score":0.538558},"labels":[],"label_agreement":null},{"id":"W2947046925","doi":"10.1200/jco.2019.37.15_suppl.6045","title":"Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mucositis; Internal medicine; Gastroenterology; Fusobacterium; Roseburia; Veillonella; Prevotella; Fusobacterium nucleatum; Oncology; Radiation therapy; Periodontitis; Bacteroides; Biology; Porphyromonas gingivalis; Streptococcus","score_opus":0.04152127884742903,"score_gpt":0.39415077100068824,"score_spread":0.3526294921532592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947046925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98197764,0.002357997,4.4966413e-7,0.0043312907,0.0004973536,0.00023629381,0.0000036395538,0.0000023978369,0.0105929095],"genre_scores_gemma":[0.9969869,0.00033335816,0.0004784896,0.001553371,0.00010050934,0.0000019112008,4.6857633e-7,0.0000126754185,0.00053231936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770564,0.00035571383,0.0013496097,0.00017429504,0.00021412782,0.00020061173],"domain_scores_gemma":[0.9972609,0.0013610083,0.0008333111,0.00017425658,0.00021382779,0.0001566586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001250404,0.00012599392,0.0013599057,0.00008440154,0.000020997808,0.000003045182,0.00015957643,0.00026287712,0.000103668375],"category_scores_gemma":[0.00070468284,0.00007424559,0.00028993763,0.0001392831,0.00030739207,0.00005372,0.00011905405,0.00065613666,0.000010384094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009803839,0.0017627977,0.7943783,0.00013872946,0.00010969678,0.00040125346,0.00043426757,0.000002743122,0.11569549,0.00008473247,0.0033182797,0.07386991],"study_design_scores_gemma":[0.01219246,0.008030183,0.93710506,0.00010071605,0.000105116014,0.00043672774,0.0002457187,0.000034616227,0.00037349766,0.00018271482,0.041121118,0.00007209854],"about_ca_topic_score_codex":0.00006820328,"about_ca_topic_score_gemma":0.00013617889,"teacher_disagreement_score":0.14272676,"about_ca_system_score_codex":0.00007929958,"about_ca_system_score_gemma":0.0012402554,"threshold_uncertainty_score":0.30276474},"labels":[],"label_agreement":null},{"id":"W2947047617","doi":"10.1200/jco.2019.37.15_suppl.10060","title":"Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from St. Jude lifetime cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Thyroid cancer; Confidence interval; Cumulative incidence; Odds ratio; Population; Internal medicine; Cancer; Cohort; Hazard ratio; Oncology; Demography","score_opus":0.016113532701212824,"score_gpt":0.3611058840890232,"score_spread":0.34499235138781037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947047617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93873996,0.057297617,0.000011097792,0.00075395714,0.0018590937,0.0006322655,0.0006167076,0.000005493148,0.00008380727],"genre_scores_gemma":[0.9394116,0.05621127,0.00018213018,0.0012219534,0.0026265944,0.00006881222,0.000035888075,0.000041436007,0.00020034987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954486,0.0006968638,0.0024100868,0.0006317637,0.00045669946,0.00035598167],"domain_scores_gemma":[0.99561936,0.00024086582,0.002458462,0.00055420835,0.00058965187,0.0005374757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016318676,0.00030280263,0.0013949877,0.00008393698,0.000054057364,0.000018575965,0.0003357043,0.00047923453,0.0004913485],"category_scores_gemma":[0.00068565994,0.00024974762,0.0005518546,0.00010050091,0.00022351524,0.000017539869,0.00018499943,0.00056157884,0.00000413852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025255303,0.0032338486,0.98208416,0.000022013524,0.002009344,0.00011204238,0.0001401797,0.00006738761,0.002564721,4.6183342e-7,0.0034593886,0.0037809014],"study_design_scores_gemma":[0.00745982,0.0044003893,0.97214866,0.000078938174,0.0011118408,0.00004535805,0.00014791812,0.000006695505,0.0010279684,0.00007483984,0.013217303,0.00028026616],"about_ca_topic_score_codex":0.0026943919,"about_ca_topic_score_gemma":0.0043776627,"teacher_disagreement_score":0.009935519,"about_ca_system_score_codex":0.000076795965,"about_ca_system_score_gemma":0.002626073,"threshold_uncertainty_score":0.99999547},"labels":[],"label_agreement":null},{"id":"W2947052398","doi":"10.1200/jco.2019.37.15_suppl.3080","title":"Whole transcriptome sequencing in metastatic cancer: A review of expression outliers in 113 metastatic breast cancer patients.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"CDKN2A; PTEN; Breast cancer; Transcriptome; Clinical significance; Medicine; Cancer; Gene expression profiling; Metastatic breast cancer; Oncology; Computational biology; Bioinformatics; Gene; Biology; Internal medicine; Gene expression; Genetics; PI3K/AKT/mTOR pathway","score_opus":0.1396057508204198,"score_gpt":0.47635573075887033,"score_spread":0.33674997993845057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947052398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033661274,0.9935814,0.000019115954,0.00024117029,0.0014596361,0.00074532966,0.00051458064,9.720264e-7,0.0000716367],"genre_scores_gemma":[0.0009480889,0.9970925,0.0004989477,0.0009351846,0.0002933064,0.000068927424,0.000071220646,0.00004805965,0.000043781878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928091,0.0010574792,0.0050674267,0.0004106267,0.00031791913,0.0003374183],"domain_scores_gemma":[0.99370956,0.00074336625,0.004627539,0.00032347743,0.00039295034,0.00020309754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002835341,0.0003649658,0.0051917853,0.00024870565,0.000012643231,0.000007664025,0.00051300117,0.00041987372,0.00007444874],"category_scores_gemma":[0.0014757691,0.0002722532,0.0012447591,0.0002901495,0.00012746989,0.000012877839,0.00010780316,0.0009831664,0.0000034231175],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003123454,0.00074296544,0.0009940976,0.042833775,0.00053824997,0.00007601051,0.000045106455,0.00014879518,0.00013968072,0.0000039234196,0.0030940315,0.951071],"study_design_scores_gemma":[0.002964064,0.0016896162,0.00033975852,0.07606941,0.0018039809,0.000046178087,0.000030937565,0.000006457235,0.000015011859,0.000017839186,0.91671336,0.0003033975],"about_ca_topic_score_codex":0.0002165853,"about_ca_topic_score_gemma":0.0003964444,"teacher_disagreement_score":0.95076764,"about_ca_system_score_codex":0.000610165,"about_ca_system_score_gemma":0.008959192,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W2947055368","doi":"10.1200/jco.2019.37.15_suppl.10009","title":"Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; ROS1; Response Evaluation Criteria in Solid Tumors; Internal medicine; Crizotinib; Refractory (planetary science); ALK inhibitor; Anaplastic lymphoma kinase; Oncology; Progressive disease; Cancer; Disease; Adenocarcinoma; Lung cancer","score_opus":0.13766374804919101,"score_gpt":0.4875379488064219,"score_spread":0.34987420075723086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947055368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973788,0.000039255538,0.0000103715865,0.00055498444,0.00060735986,0.0012714805,0.000008004736,0.000006725553,0.00012298393],"genre_scores_gemma":[0.9991349,0.000072201576,0.000093232484,0.0001294293,0.00051491003,0.000006969238,0.0000010404259,0.00001831221,0.000029019095],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.996132,0.0010679822,0.0015333139,0.00026748047,0.0005914971,0.00040769024],"domain_scores_gemma":[0.9963849,0.0011854351,0.0014360162,0.00022482089,0.00019647574,0.000572321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021133975,0.00017856869,0.0016322657,0.00019086366,0.00004008738,0.000013523302,0.00019516435,0.00014315445,0.00001724401],"category_scores_gemma":[0.0019045052,0.00009025472,0.0002021453,0.0002209576,0.00012652266,0.00012364649,0.00012026121,0.0012631607,0.0000059748468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5596575,0.019220278,0.29797548,0.00016123206,0.0004278639,0.0016218347,0.00015238793,0.000009349488,0.00095598184,0.000004669697,0.00015012058,0.119663306],"study_design_scores_gemma":[0.17518683,0.09637174,0.7245962,0.0015134292,0.00017063653,0.0011137697,0.00014995117,0.00006598055,0.0006141098,0.0000018939324,0.00012902342,0.0000864264],"about_ca_topic_score_codex":0.000044315777,"about_ca_topic_score_gemma":0.00006849493,"teacher_disagreement_score":0.42662072,"about_ca_system_score_codex":0.00031583532,"about_ca_system_score_gemma":0.0016423323,"threshold_uncertainty_score":0.5487875},"labels":[],"label_agreement":null},{"id":"W2947059432","doi":"10.1200/jco.2019.37.15_suppl.6569","title":"Clinical impact of the Mexican healthcare system \"Seguro Popular\" on breast cancer survival.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Health care; Cohort; Healthcare system; Clinical endpoint; Retrospective cohort study; Family medicine; Social security; Cancer; Internal medicine; Clinical trial; Economic growth","score_opus":0.20167313497239467,"score_gpt":0.5231600957105342,"score_spread":0.32148696073813954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947059432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85347784,0.00011976112,0.000005723492,0.12622112,0.01185528,0.00027474813,0.000022787463,0.000014875769,0.008007854],"genre_scores_gemma":[0.9590294,0.00018866258,0.000029406676,0.03351472,0.0071255104,0.0000023657612,0.0000016122898,0.000019975772,0.00008837841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99289054,0.0011488778,0.004677489,0.00027058885,0.00044748734,0.00056503265],"domain_scores_gemma":[0.9898667,0.0021421032,0.00640931,0.00046600564,0.0009487343,0.00016718541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013898657,0.00020874116,0.0024058733,0.00013381497,0.00009042121,0.00002183139,0.0007973339,0.0005927296,0.00020189382],"category_scores_gemma":[0.0038443152,0.00011059807,0.0015123966,0.0003835132,0.0002338109,0.0002489057,0.00023478393,0.0014452748,0.00010127573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009441281,0.00037769758,0.8604473,0.00019444386,0.00020914113,0.000010932918,0.000005266585,0.00061731687,0.0000012524677,0.0165223,0.10169621,0.018974023],"study_design_scores_gemma":[0.001656185,0.00090383855,0.75197655,0.0001823716,0.0000741373,0.000028490034,0.00012590188,0.00073060667,4.2320405e-8,0.00030098934,0.24393402,0.00008688385],"about_ca_topic_score_codex":0.014622588,"about_ca_topic_score_gemma":0.0005547497,"teacher_disagreement_score":0.14223781,"about_ca_system_score_codex":0.00029939183,"about_ca_system_score_gemma":0.0015356671,"threshold_uncertainty_score":0.9919391},"labels":[],"label_agreement":null},{"id":"W2947059980","doi":"10.1200/jco.2019.37.15_suppl.10023","title":"Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Induction chemotherapy; Etoposide; Chemotherapy; Germ cell tumors; Bleomycin; Cisplatin; Internal medicine; Oncology; Complete response; Surgery","score_opus":0.041706340526872346,"score_gpt":0.40367735054528825,"score_spread":0.3619710100184159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947059980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662167,0.00082633516,0.0000051585976,0.0018913285,0.00017391313,0.00026244821,0.000019783554,0.0000024988815,0.00019683823],"genre_scores_gemma":[0.9981086,0.000174568,0.00034380957,0.00045413614,0.00008045064,0.0000011251695,0.0000041668336,0.000013565172,0.0008195343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977616,0.00034508272,0.0013044182,0.00011775257,0.00032630167,0.00014481126],"domain_scores_gemma":[0.9963248,0.0009025289,0.0021746324,0.00022313918,0.00018476258,0.00019014749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001283232,0.00010035118,0.0009000557,0.00004962454,0.000015451022,0.0000017789725,0.00008419796,0.00013035373,0.00027735325],"category_scores_gemma":[0.00057046954,0.000047758374,0.00030959936,0.000079032965,0.00022471668,0.000034904693,0.000025094785,0.00029333643,0.000009175359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019077512,0.0019398412,0.96392727,0.000020620739,0.00045266727,0.000057846664,0.000050341194,0.000007377764,0.0028978288,0.0000035884545,0.00056282285,0.011002307],"study_design_scores_gemma":[0.010534151,0.016407836,0.9674305,0.000058052756,0.00047941797,0.00026656254,0.00005771295,0.000002908394,0.002494853,0.000014931053,0.0022085507,0.000044555803],"about_ca_topic_score_codex":0.00005125474,"about_ca_topic_score_gemma":0.000005658426,"teacher_disagreement_score":0.014467995,"about_ca_system_score_codex":0.00009834081,"about_ca_system_score_gemma":0.0007440969,"threshold_uncertainty_score":0.30368233},"labels":[],"label_agreement":null},{"id":"W2947061444","doi":"10.1200/jco.2019.37.15_suppl.2580","title":"Patient survival with immune checkpoint inhibitors and targeted agents in phase 1 trials: A propensity score weighted analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Propensity score matching; Regimen; Oncology; Clinical trial; Univariate analysis; Multivariate analysis","score_opus":0.10280761896088547,"score_gpt":0.4077101492047787,"score_spread":0.30490253024389324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947061444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737287,0.00088231254,0.00010824829,0.00041644523,0.000722933,0.00028992808,0.000013687067,0.0000013127853,0.00019226564],"genre_scores_gemma":[0.9976762,0.0009892589,0.0006238972,0.0003107195,0.0003324879,0.0000030458173,0.000025322059,0.000011332335,0.000027732078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644226,0.0006179063,0.0023165673,0.00025769303,0.00018235811,0.00018322469],"domain_scores_gemma":[0.99696445,0.00043295842,0.0019324941,0.00020439089,0.00027700546,0.0001886929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041538877,0.00014088988,0.0016222383,0.00012938415,0.000019724383,0.0000153021,0.00011730207,0.00028145235,0.000042312742],"category_scores_gemma":[0.0020791413,0.000095001116,0.00040609235,0.00020130284,0.0001066709,0.0000067990695,0.00011274496,0.00036482455,0.0000021828735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02488001,0.004145377,0.8590835,0.00003255148,0.0033615367,0.0003532651,0.00015801983,0.00060268736,0.04291266,0.000029777779,0.0008863572,0.06355431],"study_design_scores_gemma":[0.044663332,0.05090039,0.8135783,0.000108594504,0.0016866989,0.00008176995,0.00024361558,0.00071965525,0.024503484,0.00013770146,0.06283113,0.0005453315],"about_ca_topic_score_codex":0.0000668187,"about_ca_topic_score_gemma":0.0003486924,"teacher_disagreement_score":0.06300898,"about_ca_system_score_codex":0.000045449797,"about_ca_system_score_gemma":0.00072583836,"threshold_uncertainty_score":0.3874033},"labels":[],"label_agreement":null},{"id":"W2947063341","doi":"10.1200/jco.2019.37.15_suppl.10052","title":"Cost-effectiveness of screening guidelines to prevent heart failure in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Guideline; Quality-adjusted life year; Cost effectiveness; Cancer; Anthracycline; Quality of life (healthcare); Pediatrics; Internal medicine; Breast cancer; Pathology","score_opus":0.14188312476143325,"score_gpt":0.49067017350493647,"score_spread":0.3487870487435032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947063341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792998,0.0010909449,0.00017629957,0.015550842,0.0013481998,0.0024433408,0.000022395723,0.000007716097,0.00006050704],"genre_scores_gemma":[0.9932929,0.0003706369,0.00088579854,0.003607576,0.0016775687,0.00007893537,0.000006210991,0.000029909712,0.000050456954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994278,0.001585509,0.002866373,0.00036710472,0.0006474524,0.0002555652],"domain_scores_gemma":[0.9935859,0.00330577,0.0015549816,0.00041893157,0.00090198114,0.00023245646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009763745,0.0002076997,0.0021029836,0.00011961892,0.000034802535,0.00001037521,0.00024607743,0.00034040443,0.00017587529],"category_scores_gemma":[0.003821273,0.00013506741,0.0005667856,0.0003616557,0.00006533413,0.00013474979,0.00008200798,0.001100786,0.00000399138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023191837,0.003930653,0.94664687,0.000033007753,0.0011800433,0.00011817541,0.0011636683,0.0013647323,0.0073725716,0.0000017776136,0.0018307439,0.034038544],"study_design_scores_gemma":[0.008166215,0.0035937885,0.96114916,0.0012122835,0.0003134715,0.00012587941,0.0011202821,0.000018136638,0.0059105908,0.000036282137,0.018220048,0.00013385597],"about_ca_topic_score_codex":0.0073909815,"about_ca_topic_score_gemma":0.015565094,"teacher_disagreement_score":0.033904687,"about_ca_system_score_codex":0.00021727351,"about_ca_system_score_gemma":0.001888693,"threshold_uncertainty_score":0.9992189},"labels":[],"label_agreement":null},{"id":"W2947066317","doi":"10.1200/jco.2019.37.15_suppl.e15171","title":"Current treatment strategies and patterns of recurrence in locally advanced colon cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Cohort; Cancer; Surgery; Population; Retrospective cohort study; Proportional hazards model; Stage (stratigraphy); Chemotherapy; Oncology; Internal medicine","score_opus":0.10673629691833653,"score_gpt":0.47914403603584943,"score_spread":0.3724077391175129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947066317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933855,0.003928091,0.000011088931,0.0012854076,0.0007743552,0.0001758141,0.0000040155273,0.0000018357866,0.00043391302],"genre_scores_gemma":[0.9910599,0.008479641,0.00011080719,0.00010373388,0.00018756988,0.0000033871925,8.394354e-7,0.0000042290126,0.000049867416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982914,0.00012799782,0.0011733371,0.00012707147,0.0001533982,0.00012682352],"domain_scores_gemma":[0.9982043,0.0006295408,0.0007625595,0.00007315685,0.0001814077,0.00014903666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005590764,0.00008936049,0.0010399825,0.00007652063,0.0000064523597,0.0000035878445,0.00005972638,0.00011319941,0.00007499102],"category_scores_gemma":[0.00022189986,0.000057671215,0.00017059747,0.00007398164,0.00007722383,0.00009365756,0.000025425745,0.00039194745,0.0000020966604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003229884,0.00072437397,0.5286364,0.00007045198,0.000038918966,0.00009335889,0.000102770064,0.000026446389,0.00044981795,0.000085874795,0.000013314111,0.46652842],"study_design_scores_gemma":[0.008199554,0.03574262,0.9449934,0.000585236,0.0000994482,0.000070243805,0.0005003052,0.0001288459,0.00020564003,0.00021819356,0.009192972,0.00006354873],"about_ca_topic_score_codex":0.00008298501,"about_ca_topic_score_gemma":0.0006481063,"teacher_disagreement_score":0.46646485,"about_ca_system_score_codex":0.00012865078,"about_ca_system_score_gemma":0.0015150658,"threshold_uncertainty_score":0.26876616},"labels":[],"label_agreement":null},{"id":"W2947067229","doi":"10.1200/jco.2019.37.15_suppl.5528","title":"Comparative benefit of interstitial needles in addition to intracavitary applicators in the treatment of locally advanced cervical cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of British Columbia, Okanagan Campus; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Brachytherapy; Cervical cancer; Nuclear medicine; Rectum; Radiation treatment planning; Cumulative dose; Cancer; Surgery; Radiology; Radiation therapy; Internal medicine","score_opus":0.08949431611392374,"score_gpt":0.4815628766745558,"score_spread":0.39206856056063205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947067229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301267,0.00070658943,0.0000144499145,0.0046779355,0.00033007233,0.000603356,0.000025922223,0.0000011873302,0.0006278251],"genre_scores_gemma":[0.9966481,0.0017191614,0.00056113006,0.0007547399,0.00024156296,0.000056167002,0.000005667205,0.0000053720946,0.000008154643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997728,0.00013733884,0.0016394061,0.0001414407,0.00022338242,0.0001304544],"domain_scores_gemma":[0.99724096,0.0016134506,0.00073954073,0.00014077092,0.00015030536,0.00011499227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047603558,0.000108575376,0.0014497074,0.00014313609,0.000005785744,0.0000015541076,0.00011217892,0.0001393263,0.0001782904],"category_scores_gemma":[0.00006984044,0.00006354753,0.00027102718,0.0001968505,0.00009830464,0.000043649845,0.000015194585,0.000261369,0.000005495718],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02098857,0.01721837,0.45518166,0.00006480971,0.00045969535,0.00019526252,0.0038901877,0.0024108859,0.00033203486,0.00038217462,0.0006995828,0.49817675],"study_design_scores_gemma":[0.013505185,0.054835923,0.91788006,0.00048958394,0.00020002613,0.000029852568,0.0020427997,0.00008096773,0.0009427352,0.00019505886,0.009730477,0.00006731414],"about_ca_topic_score_codex":0.00047630546,"about_ca_topic_score_gemma":0.0027305656,"teacher_disagreement_score":0.49810946,"about_ca_system_score_codex":0.0004418023,"about_ca_system_score_gemma":0.00047895242,"threshold_uncertainty_score":0.2591393},"labels":[],"label_agreement":null},{"id":"W2947071545","doi":"10.1200/jco.2019.37.15_suppl.e18096","title":"Generating real-world evidence: Using automated data extraction to replace manual chart review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Data extraction; Medical record; Clinical trial; Lung cancer; Cancer; MEDLINE; Internal medicine; Intensive care medicine","score_opus":0.25496319891806163,"score_gpt":0.6008652848898383,"score_spread":0.34590208597177663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947071545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404155,0.002671642,0.0014586322,0.047911085,0.004743379,0.00047629818,0.0000020080322,0.00006570965,0.0022557455],"genre_scores_gemma":[0.5105413,0.034410406,0.34902254,0.08610604,0.013457843,0.0000045420425,0.000040339084,0.0001172044,0.006299751],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954269,0.00070760545,0.0027101838,0.0003503943,0.00054816867,0.00025676363],"domain_scores_gemma":[0.9941992,0.002208248,0.0020449301,0.0006299045,0.00039762605,0.0005200538],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014941928,0.00013691872,0.001473815,0.0001686929,0.000053543907,0.000019366073,0.00037122006,0.00017962653,0.0003533532],"category_scores_gemma":[0.02353619,0.00010123796,0.00021777324,0.00027834816,0.00006296164,0.00034383644,0.00018497343,0.0017146659,0.000082396495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027598087,0.0009361392,0.15593933,0.001117125,0.00053848926,0.0017274143,0.00011983885,0.0017378984,0.023047138,0.00005841351,0.402748,0.40927044],"study_design_scores_gemma":[0.0035366442,0.004338375,0.07074504,0.010347668,0.0009385188,0.0026213839,0.000069429196,0.5050103,0.00005175074,0.000015431151,0.40208736,0.0002380854],"about_ca_topic_score_codex":0.000085469146,"about_ca_topic_score_gemma":0.000013554242,"teacher_disagreement_score":0.5032724,"about_ca_system_score_codex":0.00021112089,"about_ca_system_score_gemma":0.0013833215,"threshold_uncertainty_score":0.984689},"labels":[],"label_agreement":null},{"id":"W2947071917","doi":"10.1200/jco.2019.37.15_suppl.6046","title":"Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive chemoradiotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Carboplatin; Nasopharyngeal carcinoma; Internal medicine; Cisplatin; Adjuvant; Oncology; Chemoradiotherapy; Cohort; Chemotherapy; Median follow-up; Gastroenterology; Stage (stratigraphy); Radiation therapy","score_opus":0.05751148577035272,"score_gpt":0.44134735523684837,"score_spread":0.38383586946649567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947071917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932796,0.0016423614,0.000010852761,0.00075272925,0.00008734748,0.000349571,0.000005816306,0.0000047112553,0.0038670173],"genre_scores_gemma":[0.99589133,0.0018569246,0.0014391937,0.0005641035,0.00013084487,0.0000035328449,0.0000015383929,0.000023602233,0.00008892075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975703,0.00027415893,0.001453742,0.00021916593,0.00024844432,0.00023418506],"domain_scores_gemma":[0.99598074,0.002137819,0.0011356731,0.0001349393,0.00038142578,0.00022937576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010915475,0.00020179265,0.002694774,0.00014911659,0.000014982078,0.0000033103868,0.00007591021,0.00025573085,0.00009923229],"category_scores_gemma":[0.00040591508,0.000119933255,0.00029029994,0.00020775592,0.00031162598,0.000111858455,0.000018688062,0.0007004416,0.0000018991922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044202253,0.0010212936,0.78359044,0.000040210634,0.00054077816,0.00045510344,0.0008332942,0.000030672727,0.0010730623,0.000014871434,0.00006803192,0.16812997],"study_design_scores_gemma":[0.046997543,0.05575535,0.8953708,0.00034464736,0.00010322171,0.00027526915,0.00017690753,0.00026461194,0.00024459814,0.000035367815,0.00032530143,0.000106425236],"about_ca_topic_score_codex":0.00008804498,"about_ca_topic_score_gemma":0.00004751614,"teacher_disagreement_score":0.16802354,"about_ca_system_score_codex":0.00020976659,"about_ca_system_score_gemma":0.001481267,"threshold_uncertainty_score":0.4890736},"labels":[],"label_agreement":null},{"id":"W2947072656","doi":"10.1200/jco.2019.37.15_suppl.1037","title":"Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Cohort; Pertuzumab; Population; Randomized controlled trial; Metastatic breast cancer; Breast cancer; Cancer; Cancer registry; Trastuzumab; Retrospective cohort study; Oncology","score_opus":0.12778230212331326,"score_gpt":0.5199624051973608,"score_spread":0.39218010307404755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947072656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951288,0.0001579462,0.00017583944,0.002772878,0.00074288505,0.0009524303,0.000013535799,0.000008512975,0.000047158097],"genre_scores_gemma":[0.9930822,0.0001088631,0.005552458,0.000950776,0.0001975257,0.000024146093,0.0000026234045,0.000039196326,0.00004217739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927665,0.0008277769,0.004965326,0.00030108783,0.00077447895,0.000364837],"domain_scores_gemma":[0.98754424,0.005470995,0.005665675,0.0003749823,0.00065408484,0.0002900064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052444553,0.00025922633,0.0058769383,0.000251085,0.000016528402,0.0000047818944,0.00023894623,0.00025147494,0.00034304833],"category_scores_gemma":[0.0009935931,0.00014490035,0.0004368839,0.00032399816,0.00033470092,0.00015827284,0.000021742053,0.0010746629,0.0000017026762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17794767,0.0043707797,0.77774245,0.000053886153,0.0015657031,0.00003131941,0.00015436587,0.0010439194,0.000023520986,0.000006980616,0.000005674588,0.03705372],"study_design_scores_gemma":[0.13980477,0.022023104,0.8367144,0.00032603,0.00027823224,0.000035925765,0.00024815323,0.000111350426,0.000015629195,0.00003234267,0.0002829181,0.00012712929],"about_ca_topic_score_codex":0.00035222826,"about_ca_topic_score_gemma":0.0003072476,"teacher_disagreement_score":0.058971953,"about_ca_system_score_codex":0.00045469144,"about_ca_system_score_gemma":0.002809844,"threshold_uncertainty_score":0.5908864},"labels":[],"label_agreement":null},{"id":"W2947072948","doi":"10.1200/jco.2019.37.15_suppl.4004","title":"Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Mallinckrodt; Clinical trial; Placebo; Phases of clinical research; Internal medicine; Surgery; Family medicine; Hepatocellular carcinoma; Alternative medicine; Pathology","score_opus":0.1730982922476607,"score_gpt":0.43972418757607973,"score_spread":0.266625895328419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947072948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379504,0.0015366116,0.000017630262,0.0005438473,0.0006543341,0.0026844046,0.00010010228,0.000006302365,0.0006617372],"genre_scores_gemma":[0.99771875,0.00030157322,0.0009495029,0.0001815064,0.00034614035,0.000037599722,0.00005337317,0.000043925844,0.00036760292],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9932284,0.0006451166,0.0048052315,0.00043482793,0.0005020551,0.00038440066],"domain_scores_gemma":[0.9918345,0.0024481865,0.0034654287,0.0004874819,0.0014291214,0.00033526545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024054286,0.00031542405,0.0034599605,0.00037769205,0.00002722931,0.000004900955,0.00027619943,0.00051138684,0.00019826477],"category_scores_gemma":[0.0012700775,0.00023525216,0.00093760627,0.0002885126,0.0001468462,0.00014325554,0.000057009103,0.00078677404,0.0000076177867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12883155,0.016103705,0.80298465,0.0002548474,0.0005256461,0.00088842487,0.0024667457,0.000008221622,0.0028340116,0.000004910118,0.00016445601,0.04493283],"study_design_scores_gemma":[0.31531587,0.45634896,0.18560176,0.00031457414,0.00095133804,0.00011304283,0.0055338093,0.0010284077,0.024489626,0.000060208928,0.0099398615,0.00030252786],"about_ca_topic_score_codex":0.00007553955,"about_ca_topic_score_gemma":0.0001112586,"teacher_disagreement_score":0.6173829,"about_ca_system_score_codex":0.00018597374,"about_ca_system_score_gemma":0.0016854573,"threshold_uncertainty_score":0.95933044},"labels":[],"label_agreement":null},{"id":"W2947085892","doi":"10.1200/jco.2019.37.15_suppl.e20574","title":"Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; Lung cancer; DNA methylation; Medicine; Brain metastasis; Oncology; Lung; Metastasis; Pathology; Adenocarcinoma; Cancer research; Internal medicine; Cancer; Biology; Gene expression; Gene; Genetics","score_opus":0.06494350395087325,"score_gpt":0.4981648071657933,"score_spread":0.43322130321492003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947085892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865873,0.0027679857,0.001290993,0.0066759717,0.00035907843,0.00044514274,0.000010812886,0.0000041888006,0.0018585663],"genre_scores_gemma":[0.97392124,0.0005376978,0.023761066,0.0013752162,0.00014727916,0.0000074025625,0.0000053960584,0.000013633523,0.00023105979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809426,0.00021003168,0.0011879611,0.00013042617,0.00026149163,0.00011582428],"domain_scores_gemma":[0.9967076,0.0013223839,0.0013503592,0.00010346595,0.00036398318,0.00015220937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015390196,0.000092881666,0.0011154322,0.000101988335,0.000017773791,0.0000041455096,0.000044023436,0.00007908216,0.000100688994],"category_scores_gemma":[0.00045401836,0.000053524724,0.00015330252,0.00012102112,0.00009397084,0.00012867848,0.000016671886,0.00031206108,0.0000011309111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00879415,0.0023792358,0.5273414,0.0010314456,0.009823055,0.00044669866,0.0009328778,0.00055014814,0.01417031,0.0014392385,0.0008166265,0.43227476],"study_design_scores_gemma":[0.067095086,0.052148815,0.81045055,0.0014734226,0.023251249,0.001358605,0.0015448837,0.0032741278,0.007709132,0.00089778117,0.030350298,0.00044606533],"about_ca_topic_score_codex":0.00003434419,"about_ca_topic_score_gemma":0.000018017368,"teacher_disagreement_score":0.4318287,"about_ca_system_score_codex":0.00015595218,"about_ca_system_score_gemma":0.0019898824,"threshold_uncertainty_score":0.3529966},"labels":[],"label_agreement":null},{"id":"W2947087421","doi":"10.1200/jco.2019.37.15_suppl.2537","title":"Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fludarabine; Immunology; Cyclophosphamide; Adoptive cell transfer; Cytokine release syndrome; Internal medicine; T cell; Immune system; Chemotherapy; Chimeric antigen receptor","score_opus":0.09368089686190016,"score_gpt":0.47088243630873095,"score_spread":0.37720153944683077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947087421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377096,0.00033231464,0.000051937695,0.0025709572,0.0011888875,0.0008589033,0.0000071830095,0.000013557976,0.0012053108],"genre_scores_gemma":[0.9900032,0.0014771229,0.0037158355,0.0008983666,0.0016058245,0.000005613916,0.0000025425134,0.00005579962,0.002235694],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9929581,0.0024422018,0.0028412484,0.00045198147,0.0008928934,0.000413533],"domain_scores_gemma":[0.9774435,0.019600537,0.0011903758,0.00050205924,0.000480907,0.00078262354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014595335,0.00026770445,0.0026188218,0.0003699135,0.000032636566,0.000017145494,0.00027162768,0.0006287878,0.00075609726],"category_scores_gemma":[0.004788677,0.00017099452,0.00060157216,0.0002663097,0.00031850385,0.00007653858,0.00008999495,0.001458908,0.000100344885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38725182,0.002390506,0.17533763,0.00017745429,0.0007703345,0.0010101732,0.00013229804,0.000052305746,0.12304532,0.000015194423,0.005678646,0.30413833],"study_design_scores_gemma":[0.032656964,0.3279675,0.481502,0.00039223992,0.00035120055,0.0007755192,0.000056076242,0.000118603304,0.028601715,0.000008754611,0.12733117,0.00023826025],"about_ca_topic_score_codex":0.0000074406116,"about_ca_topic_score_gemma":0.0000061084797,"teacher_disagreement_score":0.35459486,"about_ca_system_score_codex":0.00023997792,"about_ca_system_score_gemma":0.0013319758,"threshold_uncertainty_score":0.82787347},"labels":[],"label_agreement":null},{"id":"W2947093201","doi":"10.1200/jco.2019.37.15_suppl.6599","title":"Online advertising and marketing claims by providers of proton beam therapy: Are they guideline based?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diverse Approaches in Healthcare and Education Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario; London Health Sciences Centre","funders":"","keywords":"Medicine; Guideline; Family medicine; Radiation therapy; Internal medicine; Pathology","score_opus":0.18713243790744322,"score_gpt":0.4956056501914282,"score_spread":0.308473212283985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947093201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97733766,0.0015394702,0.000036492584,0.019216169,0.00062166766,0.00058814284,0.0000057788247,0.000006376911,0.00064823334],"genre_scores_gemma":[0.98217046,0.0023029195,0.007933079,0.006791428,0.00055722304,0.0000043703503,0.0000060035572,0.000015076041,0.00021943757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996743,0.0004094162,0.0022007797,0.00017458023,0.00030132814,0.00017087419],"domain_scores_gemma":[0.9942671,0.002533883,0.0020990404,0.00016345622,0.0007432971,0.0001932253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005619833,0.000113556816,0.0011359398,0.00008756571,0.000031304728,0.000004959147,0.00009551478,0.00022771672,0.000089443245],"category_scores_gemma":[0.003687174,0.00007596522,0.00021079254,0.000077515,0.00015262165,0.00008840277,0.00004390378,0.0006046999,0.0000024972576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004087735,0.0017915948,0.84498215,0.00033460066,0.00024026776,0.000017201475,0.00023133235,0.0000106926445,0.00019731165,0.0000032795149,0.014006322,0.13409752],"study_design_scores_gemma":[0.013732678,0.01530871,0.6584284,0.0012173633,0.00031469038,0.0001415261,0.00962729,0.0005027473,0.0004533813,0.00016528717,0.29988682,0.00022116107],"about_ca_topic_score_codex":0.000039730643,"about_ca_topic_score_gemma":0.000005191562,"teacher_disagreement_score":0.2858805,"about_ca_system_score_codex":0.00006792898,"about_ca_system_score_gemma":0.0010506954,"threshold_uncertainty_score":0.44141582},"labels":[],"label_agreement":null},{"id":"W2947096198","doi":"10.1200/jco.2019.37.15_suppl.5521","title":"Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ozmosis Research (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Oncology; PARP inhibitor; BRCA mutation; Progression-free survival; Ovarian cancer; Clinical trial; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy","score_opus":0.15581672792770404,"score_gpt":0.5288553929845182,"score_spread":0.37303866505681416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947096198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96030456,0.000557149,0.00023362973,0.021376854,0.013398041,0.002386422,0.00017673607,0.00001999152,0.0015466373],"genre_scores_gemma":[0.9834078,0.0011315937,0.0019069073,0.0037358182,0.009292261,0.00006288646,0.000043812106,0.00005254111,0.0003664073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9853333,0.0018792246,0.010372421,0.00062696455,0.0012369696,0.00055108423],"domain_scores_gemma":[0.9862539,0.0052877115,0.005858805,0.0005215319,0.0012977048,0.0007803202],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012463906,0.00038951339,0.004397187,0.0004320704,0.00009912933,0.000013988902,0.00045547617,0.0013044741,0.003036553],"category_scores_gemma":[0.0047223195,0.00031763347,0.0015898118,0.0004885338,0.0007263889,0.00035349952,0.00008927967,0.002793902,0.000018704162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8862453,0.04064291,0.0066759526,0.00007583853,0.0007688312,0.00026593133,0.00029272927,0.000028678749,0.0026214689,0.00031768277,0.0054197866,0.056644857],"study_design_scores_gemma":[0.72395223,0.17211814,0.0040138625,0.00043148044,0.00047177964,0.00009201471,0.00007353837,0.00016256132,0.00047629324,0.00041706627,0.09755078,0.00024025883],"about_ca_topic_score_codex":0.00007266093,"about_ca_topic_score_gemma":0.00013265651,"teacher_disagreement_score":0.16229312,"about_ca_system_score_codex":0.00033059705,"about_ca_system_score_gemma":0.010325395,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W2947096842","doi":"10.1200/jco.2019.37.15_suppl.6624","title":"Evaluating the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) value frameworks for Food and Drug Administration (FDA) approved checkpoint inhibitors (CIs).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interquartile range; Clinical trial; Oncology; Internal medicine; Concordance; Food and drug administration; Pharmacology","score_opus":0.5719839373035693,"score_gpt":0.5992712751077521,"score_spread":0.0272873378041828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947096842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83555037,0.0008641289,0.0035431182,0.15654337,0.0019158463,0.0008342382,0.000049719347,0.000008508317,0.00069066737],"genre_scores_gemma":[0.9162407,0.0028909084,0.053825963,0.02439801,0.002500484,0.000022993574,0.000007758428,0.00004386779,0.00006932123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9727146,0.0054352544,0.02024319,0.0006940573,0.00045486906,0.0004580349],"domain_scores_gemma":[0.9243261,0.044419877,0.02971921,0.0004565585,0.0005531905,0.0005250596],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21318401,0.0002623332,0.0049314206,0.00010227318,0.00014130038,0.000026774995,0.00059868867,0.0012802593,0.00007890588],"category_scores_gemma":[0.038270343,0.00022426774,0.0013637576,0.00018342439,0.0016582293,0.00024895646,0.00026585843,0.0025993162,0.000014223883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071482407,0.0073394165,0.3033046,0.0023006506,0.005062309,0.000009297544,0.013159647,0.00045661573,0.00010034673,0.038058076,0.11576341,0.5072974],"study_design_scores_gemma":[0.030748896,0.13089384,0.29996318,0.00070127967,0.000561122,0.00021030314,0.021228809,0.12594007,0.000058320285,0.02648925,0.36226237,0.0009425474],"about_ca_topic_score_codex":0.00012136117,"about_ca_topic_score_gemma":0.00013555492,"teacher_disagreement_score":0.5063548,"about_ca_system_score_codex":0.00033458218,"about_ca_system_score_gemma":0.004329368,"threshold_uncertainty_score":0.99970174},"labels":[],"label_agreement":null},{"id":"W2947105388","doi":"10.1200/jco.2019.37.15_suppl.1013","title":"Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Cohort; Oncology; Breast cancer; Tolerability; Phases of clinical research; Paclitaxel; Cancer; Gastroenterology; Adverse effect; Toxicity; Clinical trial; Pembrolizumab","score_opus":0.11011647550504756,"score_gpt":0.505768883853412,"score_spread":0.39565240834836446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947105388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806274,0.0006396491,0.00009080395,0.009068756,0.0011679637,0.007245701,0.0006706668,0.000027964532,0.00046107123],"genre_scores_gemma":[0.9832806,0.0024147837,0.0026290026,0.0012068762,0.00061789906,0.00058692455,0.00006556133,0.00009474938,0.009103624],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.993668,0.0006804912,0.0030369929,0.00072505313,0.0010447861,0.0008446569],"domain_scores_gemma":[0.9891112,0.0044297185,0.0025367786,0.00049476465,0.0024186696,0.0010088657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019301565,0.00057964644,0.0034947258,0.00029992335,0.00024336242,0.000029347706,0.00032423472,0.00030653863,0.0010466069],"category_scores_gemma":[0.0021783384,0.00030946237,0.00074441277,0.00045940033,0.00042721216,0.00032268622,0.00010640655,0.00086557365,0.00005557182],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47881556,0.100278005,0.057542704,0.00024434895,0.008356477,0.0011206778,0.0011312971,0.00013573213,0.00003720195,0.000023004754,0.0027601907,0.3495548],"study_design_scores_gemma":[0.34972778,0.5713697,0.02193212,0.00041428188,0.0030444746,0.00024305136,0.0012420748,0.00020732815,0.00010269192,0.00015522224,0.051227212,0.00033407443],"about_ca_topic_score_codex":0.00026173276,"about_ca_topic_score_gemma":0.0007944539,"teacher_disagreement_score":0.4710917,"about_ca_system_score_codex":0.0014262745,"about_ca_system_score_gemma":0.006238477,"threshold_uncertainty_score":0.99993575},"labels":[],"label_agreement":null},{"id":"W2947110407","doi":"10.1200/jco.2019.37.15_suppl.tps11634","title":"Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective cardio-oncology study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Ejection fraction; Prospective cohort study; Population; Cardiology; Cancer; Quality of life (healthcare); Heart failure; Physical therapy","score_opus":0.15381152840877702,"score_gpt":0.43451680460036834,"score_spread":0.28070527619159136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947110407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360144,0.0013283697,0.00032127576,0.0021390165,0.0007310162,0.0011082978,0.000011306425,0.000012826057,0.00074647245],"genre_scores_gemma":[0.99535805,0.002330916,0.0003447831,0.00047354083,0.0013357896,0.000035426405,0.0000010897186,0.000025162488,0.00009524884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971535,0.00056387007,0.0012302923,0.00036678123,0.0004361559,0.00024937745],"domain_scores_gemma":[0.9977243,0.0007830477,0.00066580425,0.0002103576,0.0002762247,0.00034029764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026353116,0.0002117702,0.0020931398,0.00013082575,0.000064147665,0.000013642613,0.000060188384,0.00041892624,0.00003868269],"category_scores_gemma":[0.00026723975,0.0001404279,0.0006545166,0.00012472816,0.00014291887,0.00015743756,0.00006476026,0.00065070053,0.0000016573921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003887823,0.00088504516,0.92513084,0.000042469328,0.00501371,0.00033191356,0.0011528236,0.000044125147,0.00043066937,0.0000090973535,0.00002520555,0.063046284],"study_design_scores_gemma":[0.023898544,0.01296696,0.9537607,0.00021183281,0.0020575551,0.0018439661,0.0026596158,0.00008779058,0.00017332593,0.00023282637,0.0019624624,0.00014444986],"about_ca_topic_score_codex":0.00010594717,"about_ca_topic_score_gemma":0.00011427889,"teacher_disagreement_score":0.06290183,"about_ca_system_score_codex":0.0012248971,"about_ca_system_score_gemma":0.0009527016,"threshold_uncertainty_score":0.57264835},"labels":[],"label_agreement":null},{"id":"W2947110460","doi":"10.1200/jco.2019.37.15_suppl.6627","title":"A weighted criterion-based approach to value assessment of oncology drugs.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of British Columbia; Baker Hughes (Canada); Centre for Advancing Health Outcomes; University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Reimbursement; Internal medicine; Oncology; Cancer; Stakeholder; Quality of life (healthcare); Family medicine; Health care","score_opus":0.5290182037926451,"score_gpt":0.5917653646179457,"score_spread":0.06274716082530063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947110460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7730511,0.0004743601,0.030534562,0.08238243,0.006018233,0.0011015924,0.00007991923,0.000017830687,0.10633999],"genre_scores_gemma":[0.8483422,0.00007030216,0.1157025,0.034524877,0.000965142,0.000021913029,0.0000075401617,0.00002890003,0.00033666645],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98143715,0.002110716,0.015389955,0.00044903724,0.00023206166,0.0003810575],"domain_scores_gemma":[0.9753846,0.0098771155,0.013312664,0.00048582687,0.000417248,0.00052252563],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07074786,0.00018879298,0.0042663747,0.00055147806,0.000048474998,0.000019389532,0.00059464073,0.0006082147,0.0005972981],"category_scores_gemma":[0.0087280115,0.0001907171,0.0006450416,0.00025811675,0.00013343788,0.00024753864,0.00008186639,0.00082608813,0.00052262883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018129768,0.013958062,0.47396523,0.0012736659,0.0014475968,0.000027868397,0.0031250236,0.008968557,0.000052235275,0.36754414,0.10150871,0.026315935],"study_design_scores_gemma":[0.010249703,0.013347777,0.18084362,0.00016481835,0.000068254965,0.000030073386,0.0011474683,0.049641706,0.0000072445528,0.010285388,0.73378,0.00043391445],"about_ca_topic_score_codex":0.00014478505,"about_ca_topic_score_gemma":0.000012197809,"teacher_disagreement_score":0.63227135,"about_ca_system_score_codex":0.0011106188,"about_ca_system_score_gemma":0.0037300433,"threshold_uncertainty_score":0.99962187},"labels":[],"label_agreement":null},{"id":"W2947112132","doi":"10.1200/jco.2019.37.15_suppl.5536","title":"Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the British Columbia (BC) cancer experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Stage (stratigraphy); Ovarian cancer; Cancer; Adjuvant therapy; Population; Lymph node; Dissection (medical); Internal medicine; Cohort; Surgery; Retrospective cohort study; Oncology","score_opus":0.08360401372582288,"score_gpt":0.45040053471250646,"score_spread":0.3667965209866836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947112132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402634,0.049887415,6.4509084e-7,0.0060997885,0.001442195,0.0005841448,0.00001844736,0.000001802125,0.0017021985],"genre_scores_gemma":[0.6389145,0.35676965,0.00019944523,0.0027536768,0.00020363177,0.00001750925,5.2846576e-7,0.000011510289,0.0011295243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663067,0.00037981436,0.002230886,0.00018769727,0.00039727133,0.00017368334],"domain_scores_gemma":[0.99639606,0.00052354607,0.002288826,0.00028041255,0.00034787497,0.00016326405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015103784,0.00009252683,0.0017367402,0.000025560268,0.000028103344,0.000011001472,0.00022043151,0.0002024211,0.0045893556],"category_scores_gemma":[0.0003441742,0.000069716414,0.00050004444,0.00020177483,0.00014734693,0.000061867715,0.000047489182,0.00052456907,0.0000023871232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076281995,0.0017680462,0.7244207,0.00062892423,0.00012383497,0.0000822208,0.00012530458,0.000008708688,0.00017660193,0.0000037847303,0.009013138,0.26288587],"study_design_scores_gemma":[0.0096905455,0.005524969,0.7689391,0.010177598,0.00014103312,0.000022270075,0.00011043295,0.000009700114,0.00033887135,0.0000183604,0.20496291,0.00006424899],"about_ca_topic_score_codex":0.02077907,"about_ca_topic_score_gemma":0.0070321104,"teacher_disagreement_score":0.30688223,"about_ca_system_score_codex":0.00023561607,"about_ca_system_score_gemma":0.002514385,"threshold_uncertainty_score":0.9963206},"labels":[],"label_agreement":null},{"id":"W2947114193","doi":"10.1200/jco.2019.37.15_suppl.e15506","title":"Relationship between PET response and pathologic response in distal esophageal/gastroesophageal junction cancers: A provincial population-based analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Surrey Place Centre","funders":"","keywords":"Medicine; Esophageal cancer; Perioperative; Internal medicine; Neoadjuvant therapy; Adenocarcinoma; Population; Cancer; Complete response; Chemotherapy; Oncology; Gastroenterology; Nuclear medicine; Surgery; Breast cancer","score_opus":0.08927403208406293,"score_gpt":0.4588524818933175,"score_spread":0.3695784498092546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947114193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475384,0.00047533718,0.00014422339,0.0038167837,0.00023431754,0.00049122615,0.000025407511,0.000012709951,0.0000461685],"genre_scores_gemma":[0.9973572,0.000013955257,0.0015512907,0.0003947905,0.00039095333,0.000013724655,0.000033953558,0.000015405218,0.00022871578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937115,0.0031158372,0.0019173785,0.00034075862,0.00058156817,0.00033297253],"domain_scores_gemma":[0.9887411,0.009177409,0.0011080576,0.0002483367,0.00024279831,0.00048230216],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010128832,0.00017917244,0.0015209453,0.0007779611,0.0000621917,0.000019702484,0.00011042966,0.00027177486,0.00011232976],"category_scores_gemma":[0.0100691095,0.00013357202,0.0004698171,0.000659718,0.00014532884,0.00017527815,0.000039262195,0.0012061243,0.00001560502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107037894,0.0003946854,0.88565046,0.000026221838,0.00021175506,0.0039839055,0.000047274687,0.0003360673,0.000010135915,0.000018623685,0.000040579067,0.0022423912],"study_design_scores_gemma":[0.011307523,0.023901433,0.96322745,0.000039177634,0.0006877514,0.00012837877,0.000045154844,0.00032120672,0.0000071151862,0.00018664845,0.00007293979,0.00007520779],"about_ca_topic_score_codex":0.0002628421,"about_ca_topic_score_gemma":0.00041322442,"teacher_disagreement_score":0.09573037,"about_ca_system_score_codex":0.0012542373,"about_ca_system_score_gemma":0.0036249415,"threshold_uncertainty_score":0.9982695},"labels":[],"label_agreement":null},{"id":"W2947114791","doi":"10.1200/jco.2019.37.15_suppl.e14536","title":"Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of British Columbia; St. Boniface Hospital; CancerCare Manitoba","funders":"","keywords":"Medicine; Cohort; Malignancy; Excretion; Internal medicine; Spermidine; Spermine; Polyamine; Gastroenterology; Biology; Biochemistry","score_opus":0.08677341771380294,"score_gpt":0.4257135534131903,"score_spread":0.33894013569938736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947114791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958389,0.0002336474,0.0006202053,0.0007679924,0.00054364366,0.00026374857,0.000011603862,0.0000024363499,0.0017178642],"genre_scores_gemma":[0.997788,0.00032127867,0.000644551,0.00022206493,0.00050780067,0.0000057340158,0.000014637526,0.000015167642,0.000480761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979263,0.0003725289,0.0009629127,0.0001987474,0.0003789747,0.0001605633],"domain_scores_gemma":[0.9977582,0.00017413581,0.0008894861,0.00028823855,0.0007460993,0.0001438101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028447593,0.000122047146,0.00069566304,0.00006109923,0.00001949116,0.000004254324,0.00022796412,0.00027854912,0.00009858747],"category_scores_gemma":[0.0007624185,0.000086898974,0.00027465075,0.00012867004,0.00013067786,0.000011376094,0.00003022839,0.00028332885,0.000010486808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030943945,0.0008570434,0.018407073,0.000014720416,0.00039399907,0.000003904905,0.000033020588,0.00026206113,0.8928178,0.00010377392,0.00088958355,0.08312265],"study_design_scores_gemma":[0.035900056,0.018588958,0.19833447,0.00006941433,0.0016486952,0.00019305813,0.00023120659,0.00095995306,0.57731456,0.00028330646,0.1659814,0.00049491104],"about_ca_topic_score_codex":0.000008249699,"about_ca_topic_score_gemma":0.00003219857,"teacher_disagreement_score":0.3155032,"about_ca_system_score_codex":0.000020422587,"about_ca_system_score_gemma":0.0011639633,"threshold_uncertainty_score":0.3543637},"labels":[],"label_agreement":null},{"id":"W2947117188","doi":"10.1200/jco.2019.37.15_suppl.e18251","title":"Population kinetics of progression free survival (PFS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Kingston Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Proportional hazards model; Population; Medicine; Oncology; Internal medicine; Survival analysis; Phase (matter); Hazard ratio; Confidence interval; Physics","score_opus":0.04484391223899619,"score_gpt":0.4095451009139515,"score_spread":0.3647011886749553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947117188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915388,0.0003788362,0.0012471498,0.0004720672,0.0020697983,0.00010932983,0.0000042420256,0.0000014750761,0.0041782605],"genre_scores_gemma":[0.99167633,0.00025595483,0.006760543,0.0002356326,0.00088078855,4.344859e-7,0.000013629636,0.000008989353,0.00016770033],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978301,0.0001581653,0.0015903427,0.00009454012,0.00019822663,0.00012862422],"domain_scores_gemma":[0.99749523,0.00016331162,0.0017363535,0.00025724573,0.00024305511,0.00010478663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016846177,0.000082285,0.0005654486,0.000033930115,0.0000098278815,0.000004589889,0.0002751039,0.0004278049,0.000039681614],"category_scores_gemma":[0.0006441015,0.000060436032,0.00026231032,0.0000445104,0.00006421512,0.000005241095,0.0001277673,0.0002721133,0.000005726873],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044855876,0.0018678105,0.28777948,0.0001350025,0.00055821403,0.00001761838,0.00007668316,0.0011506531,0.07175834,0.0016255125,0.017627127,0.61291796],"study_design_scores_gemma":[0.01496852,0.047463957,0.5613323,0.00021489753,0.00025539158,0.00014248623,0.00019989659,0.0014288239,0.01259668,0.0065078777,0.3543682,0.000520958],"about_ca_topic_score_codex":0.0000035002781,"about_ca_topic_score_gemma":0.000015764132,"teacher_disagreement_score":0.612397,"about_ca_system_score_codex":0.000012448237,"about_ca_system_score_gemma":0.00014678734,"threshold_uncertainty_score":0.3299623},"labels":[],"label_agreement":null},{"id":"W2947120195","doi":"10.1200/jco.2019.37.15_suppl.5539","title":"Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Adverse effect; Internal medicine; Neutropenia; Nausea; Placebo; Vomiting; Anemia; Surgery; Oncology; Gastroenterology; Chemotherapy","score_opus":0.04655180867685195,"score_gpt":0.4359048671981457,"score_spread":0.38935305852129376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947120195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932672,0.00015717033,0.0003819546,0.0029779233,0.0011772489,0.0013819975,0.000013006352,0.000011611804,0.0006319061],"genre_scores_gemma":[0.9925413,0.000715326,0.0029840993,0.0029593667,0.00042694458,0.00007232964,0.000010113503,0.000033309054,0.00025721267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963219,0.00039459582,0.0020416963,0.00036684633,0.00052593206,0.0003490388],"domain_scores_gemma":[0.9952055,0.001119729,0.0024579572,0.00023285382,0.00061038625,0.0003735596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014027603,0.00022917717,0.0016010229,0.0001954113,0.000036387373,0.0000053786744,0.00013019539,0.00030030086,0.00022171534],"category_scores_gemma":[0.00074052287,0.00015175853,0.00016334471,0.00027738197,0.00019594081,0.00035951778,0.000023903034,0.0009629588,0.000012170121],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5816995,0.005913096,0.23599328,0.00005480715,0.0004417805,0.0008546471,0.00056485576,0.0003893976,0.000119695396,0.00004967628,0.00068583555,0.17323342],"study_design_scores_gemma":[0.75282025,0.05398756,0.18107326,0.00095819304,0.00022838073,0.00013636221,0.00034441304,0.00019765433,0.000049310744,0.00012575761,0.009880317,0.00019856471],"about_ca_topic_score_codex":0.00009424126,"about_ca_topic_score_gemma":0.0004236359,"teacher_disagreement_score":0.17303485,"about_ca_system_score_codex":0.00049659965,"about_ca_system_score_gemma":0.0018874703,"threshold_uncertainty_score":0.61885333},"labels":[],"label_agreement":null},{"id":"W2947121907","doi":"10.1200/jco.2019.37.15_suppl.5021","title":"PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Regimen; Internal medicine; Abiraterone acetate; Prednisone; Logistic regression; Odds ratio; Oncology; Docetaxel; Cancer; Gynecology; Androgen deprivation therapy","score_opus":0.07261390822757398,"score_gpt":0.47254360320337413,"score_spread":0.39992969497580017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947121907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740933,0.0010706615,0.000003288119,0.023004804,0.00008345247,0.00059921085,0.000011644838,0.0000033570516,0.0011302937],"genre_scores_gemma":[0.993834,0.002607869,0.0012009672,0.0004457637,0.000099017874,0.000012517156,0.0000025526672,0.000015223524,0.0017820579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975283,0.0006321112,0.0010656025,0.00022886068,0.0003022661,0.00024284226],"domain_scores_gemma":[0.9971013,0.0014956361,0.0006170451,0.000109115805,0.000369925,0.00030697056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031742416,0.00014051858,0.0010340149,0.00018561269,0.000028500303,0.000021408085,0.000055923054,0.00011784923,0.00008498719],"category_scores_gemma":[0.0007297537,0.000080842205,0.00007062923,0.00018726497,0.00036279846,0.00015859144,0.00004183593,0.00064871734,0.000004058123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14564149,0.0005973526,0.8311932,0.00010448149,0.0005315734,0.0016717844,0.0014203133,0.00003169229,0.0016565425,0.000018770887,0.0003458251,0.016786963],"study_design_scores_gemma":[0.02203555,0.020121282,0.9523907,0.0002725332,0.00023912358,0.00021520755,0.0019474709,0.00019666315,0.0002129851,0.00028913293,0.0019873232,0.00009204876],"about_ca_topic_score_codex":0.00007467193,"about_ca_topic_score_gemma":0.00070879183,"teacher_disagreement_score":0.123605944,"about_ca_system_score_codex":0.000189676,"about_ca_system_score_gemma":0.0025252067,"threshold_uncertainty_score":0.44796082},"labels":[],"label_agreement":null},{"id":"W2947136960","doi":"10.1200/jco.2019.37.15_suppl.6550","title":"Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cabazitaxel; Vial; Medicine; Taxane; Prostate cancer; Internal medicine; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.1360054522753275,"score_gpt":0.4651577656908596,"score_spread":0.3291523134155321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947136960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911893,0.002749783,0.0000682386,0.0052273646,0.001427712,0.00042122396,0.000102143546,0.0000060736697,0.0008785321],"genre_scores_gemma":[0.9878717,0.00068308733,0.0057610436,0.0010831741,0.000091172995,0.000006519704,0.0000023942584,0.000019219488,0.004481666],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956663,0.00119814,0.0023392076,0.000298905,0.00010371928,0.0003937206],"domain_scores_gemma":[0.9943793,0.003387779,0.0014893971,0.00020947985,0.00033673563,0.000197336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003697183,0.00021696264,0.001964255,0.0001539749,0.00004710101,0.00001205152,0.0002556973,0.00034131098,0.00069568807],"category_scores_gemma":[0.0012004755,0.00014189225,0.00036097338,0.00017623938,0.0004172672,0.00009710542,0.00011100694,0.0008388484,0.000027863032],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023262307,0.0029763589,0.059280902,0.00044442294,0.0027553258,0.00064858055,0.0018121647,0.000094161136,0.5796012,0.00078643346,0.018930096,0.30940804],"study_design_scores_gemma":[0.04929459,0.044368878,0.16651306,0.0011905732,0.00421945,0.0010629143,0.006537766,0.000109505,0.13370647,0.0011854033,0.59039384,0.0014175498],"about_ca_topic_score_codex":0.00014556991,"about_ca_topic_score_gemma":0.00027679797,"teacher_disagreement_score":0.57146376,"about_ca_system_score_codex":0.00007207819,"about_ca_system_score_gemma":0.00066620664,"threshold_uncertainty_score":0.76172966},"labels":[],"label_agreement":null},{"id":"W2947141225","doi":"10.1200/jco.2020.38.15_suppl.e18549","title":"Phase II study: Induction chemotherapy &amp; transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): An update and retrospective review of non-study patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Dr. Cyrus and Myrtle Katzen Cancer Research Center, George Washington University","keywords":"Medicine; Docetaxel; Neck dissection; Regimen; Induction chemotherapy; Surgery; Carboplatin; Quality of life (healthcare); Stage (stratigraphy); Internal medicine; Radiation therapy; Chemotherapy; Cisplatin; Cancer; Oncology","score_opus":0.132247104912551,"score_gpt":0.4616501318745257,"score_spread":0.32940302696197465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947141225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98937297,0.0033134047,0.000044542066,0.0047043925,0.00042817157,0.0019784488,0.00003253055,0.000007867971,0.000117663825],"genre_scores_gemma":[0.9843522,0.010371542,0.00059245003,0.0040890346,0.0004910106,0.000049378938,0.000013824276,0.00002693174,0.000013639321],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9964044,0.00043860893,0.002236248,0.00036854285,0.0003277476,0.00022442474],"domain_scores_gemma":[0.99630886,0.0007162943,0.0014316831,0.00015246993,0.0009176382,0.00047303556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013605533,0.00024039696,0.0033085719,0.00007566257,0.00009208192,0.0000034573911,0.000076595934,0.00014457991,0.000055921453],"category_scores_gemma":[0.0014098199,0.00016910254,0.00044732608,0.00017368824,0.00014294006,0.00014104984,0.000023216253,0.00042501837,0.0000015409379],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06085358,0.07584285,0.18291007,0.00074524124,0.00069516787,0.0002410568,0.0058273585,8.4541375e-7,0.00018800449,0.0000025507711,0.0016111303,0.67108214],"study_design_scores_gemma":[0.08332001,0.68030465,0.22667314,0.00028700585,0.0013986558,0.000019365654,0.0013237174,0.000007749015,0.00023239083,0.000019667308,0.006243463,0.00017020825],"about_ca_topic_score_codex":0.00003367969,"about_ca_topic_score_gemma":0.00006767111,"teacher_disagreement_score":0.67091197,"about_ca_system_score_codex":0.00020644115,"about_ca_system_score_gemma":0.0011717859,"threshold_uncertainty_score":0.68958014},"labels":[],"label_agreement":null},{"id":"W2947143352","doi":"10.1200/jco.2019.37.15_suppl.3571","title":"Outcomes of salvage surgery for anal squamous cell carcinoma: A systematic review and meta-analysis.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; McGill University; University of Toronto","funders":"","keywords":"Medicine; Meta-analysis; Cochrane Library; Internal medicine; Chemoradiotherapy; Subgroup analysis; Oncology; Surgery; MEDLINE; Radiation therapy","score_opus":0.40636974513660945,"score_gpt":0.5111833983470542,"score_spread":0.10481365321044472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947143352","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016661015,0.9961754,0.000022052825,0.00086068164,0.00031476057,0.002147884,0.0000781985,0.0000041563426,0.00023027697],"genre_scores_gemma":[0.01034265,0.9860942,0.00027298517,0.0015765706,0.00022180594,0.00006137299,0.000023521528,0.000039478284,0.0013674678],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9866833,0.0017427491,0.0103604,0.0003953053,0.00052356353,0.00029468475],"domain_scores_gemma":[0.95997036,0.025571592,0.012719546,0.00051768427,0.0007964496,0.00042436973],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.010824321,0.00050463754,0.057582963,0.00065809477,0.000024547984,0.00000849538,0.0002984505,0.00074183516,0.0001578661],"category_scores_gemma":[0.009715686,0.00025196216,0.027589602,0.0005609323,0.0001602507,0.000058023375,0.00010170522,0.0011293935,0.0000088696115],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011929902,0.00062644563,0.00087947946,0.9052342,0.08807989,0.00024448882,0.0000060706866,1.0633151e-7,3.1843506e-8,0.000011973264,0.0017262894,0.0030717216],"study_design_scores_gemma":[0.0008034137,0.0032662333,0.0007629869,0.006266688,0.9394267,0.00041293426,0.00000985865,0.0000026304235,8.676314e-8,0.000010555082,0.048845254,0.00019262388],"about_ca_topic_score_codex":0.000010783643,"about_ca_topic_score_gemma":0.000014939714,"teacher_disagreement_score":0.8989675,"about_ca_system_score_codex":0.00010687106,"about_ca_system_score_gemma":0.002548398,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W2947153295","doi":"10.1200/jco.2019.37.15_suppl.e14060","title":"Revisiting the ethics of phase 1 oncology trials in the era of precision medicine: A systematic review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Allison University; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Clinical trial; Oncology; Internal medicine; Adverse effect; Meta-analysis","score_opus":0.17746584155271336,"score_gpt":0.5472240729682935,"score_spread":0.36975823141558006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947153295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8250965,0.09778655,0.0006799689,0.069431186,0.0022389933,0.0021962698,0.000020735044,0.0000012422612,0.0025485554],"genre_scores_gemma":[0.8953514,0.09444575,0.0005364865,0.008254707,0.0013624814,0.00001078013,0.00000501758,0.000010363533,0.000022982815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862167,0.0070565958,0.0060676984,0.00015421513,0.0003636837,0.00014106324],"domain_scores_gemma":[0.9597328,0.03210129,0.0070520183,0.00044756837,0.0006050541,0.00006130427],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.074513294,0.0001108334,0.0027712856,0.000041050218,0.000021219046,0.0000033675894,0.00060747185,0.00043781186,0.00003649495],"category_scores_gemma":[0.14276583,0.00005089,0.0005830139,0.00013463807,0.00023615905,0.0000037779878,0.00009365228,0.0011027514,0.0000021223987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027696937,0.00956923,0.012640239,0.19177018,0.0050123814,0.00041700172,0.007554893,0.00085407373,0.16925836,0.009796483,0.08777993,0.4776503],"study_design_scores_gemma":[0.072536685,0.16412476,0.008473955,0.2241595,0.010708869,0.0017018752,0.008157903,0.0005233895,0.0069763307,0.0067292647,0.49493533,0.0009721315],"about_ca_topic_score_codex":0.000016779191,"about_ca_topic_score_gemma":0.000021265289,"teacher_disagreement_score":0.47667816,"about_ca_system_score_codex":0.0000327134,"about_ca_system_score_gemma":0.0014284626,"threshold_uncertainty_score":0.9529833},"labels":[],"label_agreement":null},{"id":"W2947154035","doi":"10.1200/jco.2019.37.15_suppl.2585","title":"Measuring the long-term “tail of curve” survival benefits in oncology trials: A comparison of the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Immunotherapy; Clinical Oncology; Cancer","score_opus":0.3083587440940593,"score_gpt":0.4576854135794311,"score_spread":0.14932666948537182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947154035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785264,0.006522542,0.0001417402,0.0052997083,0.004669258,0.00050255645,0.000038971564,0.0000020232544,0.0042967754],"genre_scores_gemma":[0.992527,0.0054693404,0.0005790131,0.00058627484,0.00075648644,0.0000052296655,4.994842e-7,0.000020180958,0.000055954628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98620117,0.001525344,0.011420767,0.00033693874,0.00017412641,0.00034167414],"domain_scores_gemma":[0.95874786,0.024907362,0.01524636,0.00060000323,0.00034899206,0.00014941122],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04488071,0.00021536728,0.0058818813,0.000156289,0.00005696723,0.000018361785,0.0011149134,0.0008889168,0.00013044743],"category_scores_gemma":[0.023561927,0.00012400866,0.0013695973,0.00024482943,0.0012918876,0.0001891664,0.00030724634,0.001988215,0.000011848803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003474345,0.00081777276,0.88111275,0.00004337733,0.00034252193,0.0000016385143,0.0004189983,0.0007324025,0.0000016551993,0.043944035,0.00007462095,0.06903587],"study_design_scores_gemma":[0.00866446,0.0023120595,0.961928,0.00022194049,0.00013921609,0.000008972589,0.00017809903,0.00034342965,0.000027169423,0.023193378,0.002859494,0.00012377965],"about_ca_topic_score_codex":0.00035865288,"about_ca_topic_score_gemma":0.001210244,"teacher_disagreement_score":0.08081524,"about_ca_system_score_codex":0.00011555042,"about_ca_system_score_gemma":0.00075021206,"threshold_uncertainty_score":0.984663},"labels":[],"label_agreement":null},{"id":"W2947158459","doi":"10.1200/jco.2019.37.15_suppl.4052","title":"The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Western University; Cancer Care Ontario; Ottawa Regional Cancer Foundation; London Health Sciences Centre","funders":"","keywords":"Medicine; Epirubicin; Esophagus; Esophageal cancer; Radiation therapy; Clinical endpoint; Dysphagia; Internal medicine; Neoadjuvant therapy; Surgery; Chemotherapy; Randomized controlled trial; Chemoradiotherapy; Adverse effect; Quality of life (healthcare); Stage (stratigraphy); Gastroenterology; Cancer; Breast cancer","score_opus":0.2981304060792845,"score_gpt":0.572361625842314,"score_spread":0.2742312197630295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947158459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672091,0.024196308,0.0000018693364,0.0049744467,0.0020201192,0.00081421033,0.0000122502615,0.0000027019237,0.00076901034],"genre_scores_gemma":[0.9766026,0.022050949,0.00012081576,0.00022515074,0.00073431095,0.000022414106,0.000001571174,0.00001251337,0.0002296896],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99444187,0.0010211162,0.003356168,0.0001872682,0.000690637,0.0003029554],"domain_scores_gemma":[0.9900855,0.0064682867,0.0023019125,0.0003342301,0.0004479507,0.00036213658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004348006,0.00015886337,0.0023077382,0.00010489267,0.00002338766,0.000004046534,0.00022457723,0.00022473845,0.0003205194],"category_scores_gemma":[0.0024537616,0.000078701676,0.00081173895,0.00015651023,0.0003636174,0.000058356156,0.000038053728,0.0006113459,0.000009278911],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5520464,0.0039885994,0.20338006,0.000025731548,0.0011045383,0.0001637749,0.00016698531,0.000026363774,0.000082327,0.00015954878,0.0002688411,0.2385868],"study_design_scores_gemma":[0.37646213,0.13270213,0.48320928,0.000094577656,0.000117070194,0.00000878735,0.0002967917,0.00002682113,0.0007373767,0.0001466344,0.0061287796,0.00006961895],"about_ca_topic_score_codex":0.0010909181,"about_ca_topic_score_gemma":0.0008932408,"teacher_disagreement_score":0.27982923,"about_ca_system_score_codex":0.0004930553,"about_ca_system_score_gemma":0.005205452,"threshold_uncertainty_score":0.92342484},"labels":[],"label_agreement":null},{"id":"W2947165750","doi":"10.1200/jco.2019.37.15_suppl.4552","title":"5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Atezolizumab; Durvalumab; Medicine; Avelumab; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Proportional hazards model; Hazard ratio; Urothelial carcinoma; Cancer; Nivolumab; Immunotherapy; Bladder cancer; Confidence interval","score_opus":0.08777987752887684,"score_gpt":0.3847421826644194,"score_spread":0.29696230513554256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947165750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945312,0.00007672463,0.0013686706,0.0006308973,0.0016653731,0.0013127528,0.00014540013,0.000008026772,0.0002609463],"genre_scores_gemma":[0.9957733,0.0000161548,0.0031417676,0.0002986144,0.0005153613,0.000017501072,0.000017182118,0.00004519084,0.00017491782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658436,0.00019446318,0.0020288955,0.00026119393,0.00061945117,0.0003116471],"domain_scores_gemma":[0.99443513,0.0021993597,0.0017359672,0.00023270163,0.0010748006,0.00032201433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067650137,0.0002466837,0.0019969423,0.00011815256,0.000032639186,0.000008233184,0.0001601872,0.00021015698,0.00013194421],"category_scores_gemma":[0.00150405,0.00014501125,0.0005322501,0.00008084979,0.000120697674,0.000120599856,0.000044002758,0.0005330097,0.000006572059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019691152,0.002938317,0.9611967,0.0001713467,0.0007632341,0.000024400726,0.0001925036,0.000056091187,0.00022410975,0.000027013884,0.00009059714,0.014624526],"study_design_scores_gemma":[0.029429907,0.040113147,0.92667973,0.00019875017,0.0012052377,0.000014186257,0.000054770637,0.0015474444,0.00016360592,0.00025782693,0.00019124556,0.00014414467],"about_ca_topic_score_codex":0.000019048974,"about_ca_topic_score_gemma":0.000107289765,"teacher_disagreement_score":0.037174832,"about_ca_system_score_codex":0.00015102996,"about_ca_system_score_gemma":0.0017034728,"threshold_uncertainty_score":0.5913387},"labels":[],"label_agreement":null},{"id":"W2947171618","doi":"10.1200/jco.2019.37.15_suppl.594","title":"Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Chemotherapy; Digital polymerase chain reaction; Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Stage (stratigraphy); Cancer; Neoadjuvant therapy; Exome; Exome sequencing; Mutation; Gene; Polymerase chain reaction; Biology","score_opus":0.023447588355615518,"score_gpt":0.35297013002762667,"score_spread":0.32952254167201117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947171618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593514,0.0007716005,0.0000131639645,0.0023353607,0.0005526456,0.00030079042,0.000048385216,0.000001682899,0.000041199535],"genre_scores_gemma":[0.9947282,0.0013067039,0.00038979313,0.0029431244,0.0005450985,0.000009321777,0.0000010011313,0.000022192664,0.000054536573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815613,0.00011434837,0.0010404494,0.0003096254,0.00012509098,0.0002543701],"domain_scores_gemma":[0.9980878,0.0007230756,0.00063364336,0.00013212976,0.00016748445,0.00025582142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064683787,0.00015975501,0.00077442615,0.00009365972,0.000021181133,0.000023811852,0.00008986991,0.00021044454,0.00008553419],"category_scores_gemma":[0.0011166009,0.00013478546,0.00016369006,0.00007968805,0.000078044344,0.000011090354,0.00009987397,0.00029223802,0.0000027437688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030676078,0.00021783201,0.9378273,0.00004773271,0.00012583609,0.00019937374,0.0002873682,0.000015846992,0.016978739,0.0000014538496,0.00027043384,0.04096049],"study_design_scores_gemma":[0.003319662,0.0011148496,0.9901719,0.0001389033,0.00002876357,0.00028154216,0.000083608764,0.000034251436,0.0020668483,0.00003262708,0.0025495146,0.00017750647],"about_ca_topic_score_codex":0.000048945734,"about_ca_topic_score_gemma":0.0001909892,"teacher_disagreement_score":0.052344635,"about_ca_system_score_codex":0.00006377191,"about_ca_system_score_gemma":0.00069622044,"threshold_uncertainty_score":0.5496391},"labels":[],"label_agreement":null},{"id":"W2947183813","doi":"10.1200/jco.2019.37.15_suppl.1501","title":"Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Risk assessment; Framingham Risk Score; Breast cancer; Single-nucleotide polymorphism; Gynecology; Demography; Internal medicine; Cancer; Disease; Genetics; Genotype","score_opus":0.046458437407426716,"score_gpt":0.4521005864186666,"score_spread":0.40564214901123985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947183813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941175,0.0022608556,0.0002847814,0.0013037347,0.0009192331,0.0008052748,0.00019818818,0.0000024975357,0.0001079285],"genre_scores_gemma":[0.98249465,0.014796923,0.00050725474,0.00095247925,0.001101635,0.000023203964,0.000004258844,0.000025896841,0.00009370378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962611,0.0013291893,0.0014866483,0.00030755813,0.00033631516,0.00027916738],"domain_scores_gemma":[0.99552095,0.0013050811,0.0018355941,0.0005660367,0.00049251737,0.0002798427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021893976,0.00021815312,0.0006984641,0.00006578086,0.00008024387,0.000020211672,0.00055620214,0.00021060997,0.00033796235],"category_scores_gemma":[0.0018560245,0.00010853095,0.0010768505,0.00012615415,0.00018516686,0.0000063833904,0.00010986599,0.00048545856,0.000021832106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24844466,0.004560021,0.4644919,0.000014364958,0.002057118,0.00002683859,0.00013840283,0.00564421,0.014271986,0.000027556904,0.014931205,0.24539173],"study_design_scores_gemma":[0.026036981,0.022630278,0.9430187,0.00006255346,0.00025295222,0.000048809477,0.00004344436,0.00005992043,0.0013659782,0.00084523315,0.005481337,0.0001538304],"about_ca_topic_score_codex":0.0002639314,"about_ca_topic_score_gemma":0.0001885062,"teacher_disagreement_score":0.47852677,"about_ca_system_score_codex":0.00005175395,"about_ca_system_score_gemma":0.0015177364,"threshold_uncertainty_score":0.44257635},"labels":[],"label_agreement":null},{"id":"W2947186615","doi":"10.1200/jco.2019.37.15_suppl.e17122","title":"Does mismatch repair (MMR) deficiency have prognostic significance in low-risk endometrioid endometrial cancers?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health; Lions Gate Hospital; BC Cancer Agency; Université de Montréal; Women's Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Endometrial cancer; Oncology; Internal medicine; Hazard ratio; Proportional hazards model; Lynch syndrome; Cohort; Population; Retrospective cohort study; DNA mismatch repair; Cancer; Gynecology; Confidence interval","score_opus":0.057382826510830855,"score_gpt":0.4082444049480249,"score_spread":0.350861578437194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947186615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98314345,0.0011533767,0.000073117844,0.0010552454,0.009778645,0.001113775,0.000011992294,0.000027358565,0.0036430352],"genre_scores_gemma":[0.9882598,0.0017832686,0.0068227304,0.00070775714,0.0017518352,0.000025066573,0.000001436823,0.0000360073,0.00061211846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929981,0.0009398822,0.0039540837,0.0005307871,0.0009807334,0.0005964087],"domain_scores_gemma":[0.9810787,0.014418962,0.0028773895,0.00044698297,0.00066930003,0.00050867436],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007278495,0.00028016802,0.002507078,0.000712588,0.000036930178,0.000015267571,0.00039864128,0.0006664194,0.0008952094],"category_scores_gemma":[0.04928081,0.000166347,0.0009418473,0.00095211976,0.0003333775,0.00012156262,0.00010132215,0.0023350155,0.00007975438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008945702,0.0013229748,0.95647615,0.00014126426,0.00019926939,0.0005295981,0.00021004735,0.00033043,0.0010379485,0.000010415295,0.0010632426,0.029732948],"study_design_scores_gemma":[0.036737464,0.04624147,0.87230325,0.00064644596,0.0006498073,0.00029953945,0.0007884772,0.0005370191,0.0025082543,0.00063879485,0.03820065,0.00044884032],"about_ca_topic_score_codex":0.00025866058,"about_ca_topic_score_gemma":0.00031996382,"teacher_disagreement_score":0.08417293,"about_ca_system_score_codex":0.0011984847,"about_ca_system_score_gemma":0.005627744,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W2947188549","doi":"10.1200/jco.2019.37.15_suppl.e16036","title":"Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Concordance; Liquid biopsy; KRAS; ARID1A; Pathology; Cancer; Oncology; Urothelial cancer; Bladder cancer; Internal medicine; Colorectal cancer; Gene; Mutation; Biology","score_opus":0.023735408177790233,"score_gpt":0.3471638519235148,"score_spread":0.32342844374572455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947188549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985681,0.00027356832,0.00010583073,0.00016842283,0.00041062597,0.00025979616,0.000031672156,0.0000011500741,0.00018078995],"genre_scores_gemma":[0.9962108,0.00017965536,0.0028506084,0.00048307754,0.00020512143,0.00000491009,0.0000070446617,0.000023551478,0.000035189158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980547,0.00010899073,0.0012317917,0.00021685057,0.00018206063,0.00020560423],"domain_scores_gemma":[0.99772125,0.0003006883,0.0013825523,0.00018462303,0.00029618156,0.00011467505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070733833,0.00014053851,0.0008840657,0.00006331599,0.000014478839,0.000007739661,0.00021426147,0.000114116076,0.000046875815],"category_scores_gemma":[0.00035300312,0.000102651014,0.000105045,0.000085491345,0.00015172796,0.0000080567015,0.000060314153,0.00026968584,0.000003601892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005804575,0.0005661487,0.9357989,0.00006038172,0.00028413394,0.00007166663,0.00008238604,0.0023613453,0.04726886,0.000032589604,0.00014293716,0.0075261057],"study_design_scores_gemma":[0.019925626,0.021472495,0.93416435,0.00018143006,0.00019553688,0.00006496832,0.00013251939,0.000072689414,0.012982313,0.00006664782,0.010433657,0.00030778092],"about_ca_topic_score_codex":0.000095548836,"about_ca_topic_score_gemma":0.00025536996,"teacher_disagreement_score":0.034286544,"about_ca_system_score_codex":0.00007622648,"about_ca_system_score_gemma":0.0014291308,"threshold_uncertainty_score":0.4185987},"labels":[],"label_agreement":null},{"id":"W2947194115","doi":"10.1200/jco.2019.37.15_suppl.tps3152","title":"A phase I study of [<sup>225</sup>Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; General Fusion (Canada); Juravinski Cancer Centre","funders":"","keywords":"Radioimmunotherapy; Medicine; Cancer research; Pharmacokinetics; Nuclear medicine; Radionuclide therapy; Antibody; Radiation therapy; Monoclonal antibody; Internal medicine; Immunology","score_opus":0.08850344923798618,"score_gpt":0.49329569765641157,"score_spread":0.40479224841842537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947194115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973537,0.000139555,0.00004167295,0.0006855004,0.00010487533,0.0005833975,0.0000034800914,0.0000072422713,0.0010805845],"genre_scores_gemma":[0.9980802,0.00005038559,0.0007643184,0.0006440666,0.0003158993,0.000009501172,0.0000033077442,0.000021605416,0.00011070418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627554,0.0002688649,0.0025380081,0.00023627537,0.0004353083,0.0002459809],"domain_scores_gemma":[0.9965052,0.001072733,0.0014731848,0.00032777208,0.0003326844,0.00028843575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014324328,0.00016587025,0.0016998257,0.00010122654,0.000029812034,0.0000075816943,0.00022301027,0.00021990402,0.00026710492],"category_scores_gemma":[0.00053289655,0.00011407842,0.00022321289,0.000228168,0.0001841958,0.00012358499,0.00003097254,0.0011876237,0.000009795813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03728709,0.08441421,0.80118865,0.00012264728,0.00078602735,0.0002973177,0.001228274,0.0005888863,0.0071544237,0.000018959363,0.0005912798,0.06632223],"study_design_scores_gemma":[0.28220245,0.11229138,0.58049583,0.0008259598,0.0007893144,0.00024893504,0.0018437966,0.001928709,0.0039940085,0.00011611518,0.014835025,0.00042843976],"about_ca_topic_score_codex":0.000005620614,"about_ca_topic_score_gemma":7.491365e-7,"teacher_disagreement_score":0.24491538,"about_ca_system_score_codex":0.000109144756,"about_ca_system_score_gemma":0.0006469587,"threshold_uncertainty_score":0.51597},"labels":[],"label_agreement":null},{"id":"W2947197208","doi":"10.1200/jco.2019.37.15_suppl.e20506","title":"Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Proportional hazards model; Cohort; Population; Adverse effect; Pembrolizumab; Cancer; Gastroenterology; Oncology; Confidence interval; Immunotherapy","score_opus":0.05864685892664957,"score_gpt":0.4779817900254512,"score_spread":0.41933493109880166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947197208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755858,0.0053927284,0.00030465279,0.010211323,0.0038489276,0.0011725598,0.000008208678,0.000007682526,0.0034680932],"genre_scores_gemma":[0.9511991,0.024908883,0.01216935,0.008608946,0.0017040673,0.00002034188,0.0000035372896,0.00004305535,0.0013426896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946265,0.0005082785,0.00385907,0.000367385,0.00027733436,0.0003614163],"domain_scores_gemma":[0.98550683,0.011001954,0.002421046,0.00026376557,0.0004728803,0.00033350708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075637777,0.00020198322,0.0019594955,0.00013112673,0.000036060723,0.00001189604,0.00019501388,0.0006355663,0.00018187615],"category_scores_gemma":[0.0037607385,0.00014934315,0.00066736556,0.00016013972,0.00017851913,0.00020921303,0.00005234015,0.0013664181,0.000006672197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29781172,0.0034693908,0.21221866,0.0002819759,0.0008104541,0.00021019319,0.00031075318,0.00006216735,0.0014700585,0.000019143665,0.005779417,0.47755605],"study_design_scores_gemma":[0.10076344,0.018064307,0.4940814,0.00043636435,0.000562719,0.00017838637,0.0002192018,0.00037101793,0.0000850103,0.00002267545,0.3850369,0.00017856609],"about_ca_topic_score_codex":0.000044128654,"about_ca_topic_score_gemma":0.00007854453,"teacher_disagreement_score":0.4773775,"about_ca_system_score_codex":0.0002826488,"about_ca_system_score_gemma":0.0029979006,"threshold_uncertainty_score":0.60900366},"labels":[],"label_agreement":null},{"id":"W2947197349","doi":"10.1200/jco.2019.37.15_suppl.6006","title":"A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy versus trans-oral robotic surgery (ORATOR).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; Cancer Care Ontario; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Transoral robotic surgery; Clinical endpoint; Swallowing; Quality of life (healthcare); Dysphagia; Randomized controlled trial; Radiation therapy; Surgery; Stage (stratigraphy); Tonsil; Internal medicine; Neck dissection; Adverse effect; Oncology; Carcinoma","score_opus":0.13445006556543737,"score_gpt":0.45256334936562354,"score_spread":0.31811328380018616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947197349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98267233,0.0020258892,0.00018690509,0.0039635557,0.00901182,0.0015923923,0.000010028891,0.0000058409355,0.0005312287],"genre_scores_gemma":[0.99562544,0.00051806855,0.00056429574,0.0008904464,0.0015824636,0.00002040313,0.0000011137981,0.000026711736,0.00077107025],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99511415,0.0010189674,0.002974734,0.00020095486,0.00038813447,0.00030307617],"domain_scores_gemma":[0.98296136,0.014166108,0.001983558,0.00026299912,0.00038695615,0.00023903522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006020622,0.00019007633,0.0047485423,0.00010421593,0.00007095037,0.000005021214,0.00019597614,0.00032821952,0.00020845249],"category_scores_gemma":[0.0027876697,0.00010565809,0.0024710565,0.00015172006,0.00034815638,0.00007621545,0.000025491672,0.00066986814,0.0000020896566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9792665,0.0043803905,0.0024287095,0.000106789994,0.00044284613,0.000060023947,0.0003434616,0.000016634252,0.00046148975,0.000019417173,0.003149916,0.009323807],"study_design_scores_gemma":[0.9031558,0.07310071,0.001358984,0.000045349887,0.0008884744,0.0000134343845,0.00006550422,0.00019270505,0.0003695075,0.000018530192,0.020692263,0.00009871505],"about_ca_topic_score_codex":0.00003300866,"about_ca_topic_score_gemma":0.000015331216,"teacher_disagreement_score":0.07611069,"about_ca_system_score_codex":0.00012105266,"about_ca_system_score_gemma":0.0025093837,"threshold_uncertainty_score":0.44515392},"labels":[],"label_agreement":null},{"id":"W2947198747","doi":"10.1200/jco.2019.37.15_suppl.e18021","title":"Using a video to introduce fertility preservation to women with cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Health and Technologies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Readability; Medicine; Fertility preservation; Infertility; Fertility; Gynecology; Family medicine; Perception; Patient education; Health literacy; Psychology; Population","score_opus":0.2518106421615643,"score_gpt":0.5432225064804259,"score_spread":0.2914118643188616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947198747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9418815,0.000090339185,0.000546045,0.055658568,0.000820943,0.0005134671,8.857345e-7,0.000016370423,0.00047188674],"genre_scores_gemma":[0.9725954,0.000041957424,0.020174908,0.0061046886,0.0008072577,0.000013715564,1.5503e-7,0.000009623964,0.00025231033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785197,0.00015190328,0.0011867324,0.00026265252,0.00027885943,0.0002678687],"domain_scores_gemma":[0.9973955,0.00039617336,0.0006595849,0.00034174294,0.00078686234,0.00042009485],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003173937,0.000086456654,0.0009838487,0.0001365627,0.00002370863,0.0000052032096,0.00014516442,0.00019055244,0.00011707697],"category_scores_gemma":[0.009201771,0.000054318352,0.00006676507,0.00031946524,0.000061009796,0.00013331108,0.00007100014,0.00065471896,0.000024120922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042116985,0.00076248264,0.7531853,0.00011524664,0.00019371127,0.00006319014,0.00032027616,0.00047106133,0.004649609,0.000076435004,0.0038121731,0.19423357],"study_design_scores_gemma":[0.002291699,0.023916906,0.861017,0.00010694562,0.00004658463,0.00005696176,0.0002022996,0.0000492206,0.00052409543,0.00026646216,0.11145945,0.00006240793],"about_ca_topic_score_codex":0.00007974654,"about_ca_topic_score_gemma":0.00003346875,"teacher_disagreement_score":0.19417116,"about_ca_system_score_codex":0.00049252296,"about_ca_system_score_gemma":0.0019523561,"threshold_uncertainty_score":0.99914414},"labels":[],"label_agreement":null},{"id":"W2947202175","doi":"10.1200/jco.2019.37.15_suppl.9514","title":"Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Ipilimumab; Discontinuation; Metastatic melanoma; Internal medicine; Melanoma; Tolerability; Toxicity; Oncology; Surgery; Cancer; Adverse effect; Immunotherapy; Cancer research","score_opus":0.05677921057621099,"score_gpt":0.4489293667916658,"score_spread":0.3921501562154548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947202175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905531,0.0009624462,0.00006638887,0.0012570675,0.002185921,0.00049141253,0.000037978796,0.000012103806,0.0044335835],"genre_scores_gemma":[0.99497193,0.0020786421,0.0008889243,0.0011794518,0.000452864,0.0000063581156,0.000014922172,0.00003180889,0.0003750702],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9931315,0.00057217956,0.0046029664,0.0003990987,0.0008665731,0.00042767668],"domain_scores_gemma":[0.9936608,0.0018326712,0.0030339276,0.00051348517,0.0006322208,0.0003268625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047578467,0.00027907226,0.0039848797,0.00084953505,0.00002855903,0.000011873305,0.00039082387,0.00057564536,0.0012782008],"category_scores_gemma":[0.001250469,0.00021389044,0.0016196676,0.00091324735,0.00032443836,0.00020998488,0.00008802785,0.0012608212,0.000017499924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43696696,0.0019284111,0.42426223,0.00009741171,0.008288861,0.0010226384,0.00028082458,0.0006003319,0.004885264,0.00005467375,0.00057840516,0.12103398],"study_design_scores_gemma":[0.09893372,0.027657969,0.84871995,0.00026300916,0.0032326502,0.00025425444,0.00025236874,0.0010214609,0.00084940396,0.00012714883,0.018401502,0.0002865479],"about_ca_topic_score_codex":0.00020107476,"about_ca_topic_score_gemma":0.00036749558,"teacher_disagreement_score":0.42445773,"about_ca_system_score_codex":0.0008233792,"about_ca_system_score_gemma":0.0032669099,"threshold_uncertainty_score":0.99963474},"labels":[],"label_agreement":null},{"id":"W2947205286","doi":"10.1200/jco.2019.37.15_suppl.e18352","title":"Social values and cancer funding priorities: Empirical evidence for cancer policy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Allocative efficiency; Respondent; Population; Medicine; Preference; Randomized controlled trial; Health care; Preference elicitation; Public health; Social psychology; Actuarial science; Psychology; Nursing; Environmental health; Economics; Microeconomics","score_opus":0.8855700493985477,"score_gpt":0.7001810517017222,"score_spread":0.18538899769682549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947205286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74237424,0.009354442,0.00053361844,0.24337372,0.0030985873,0.00043597558,0.00006378541,0.000008646844,0.0007569804],"genre_scores_gemma":[0.9248843,0.0078902235,0.003652562,0.048264842,0.013030863,0.00006849306,0.0000010849583,0.000038380866,0.0021692435],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910618,0.00057946326,0.0075252187,0.00033939347,0.00011879551,0.00037529995],"domain_scores_gemma":[0.9777249,0.014320828,0.007268607,0.0001443091,0.00025594674,0.00028539612],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03502085,0.00013963044,0.0024136023,0.00024891895,0.00013342247,0.000044744058,0.00027187492,0.00041906018,0.00031828828],"category_scores_gemma":[0.0253333,0.00014286165,0.00038773558,0.0001205339,0.00017224917,0.0005463869,0.0000626614,0.00048492005,0.00007690486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053212105,0.00017012907,0.8881768,0.00045422895,0.00033801183,0.0000022053262,0.0024985508,0.00007586192,0.0000035333458,0.020759454,0.07142967,0.015559449],"study_design_scores_gemma":[0.0038924152,0.001935172,0.4002191,0.0003238064,0.00005786627,0.000015028104,0.0009646343,0.0016682179,0.0000015891627,0.046624184,0.5440039,0.00029404234],"about_ca_topic_score_codex":0.0006140936,"about_ca_topic_score_gemma":0.0001587372,"teacher_disagreement_score":0.48795766,"about_ca_system_score_codex":0.0010104812,"about_ca_system_score_gemma":0.002908935,"threshold_uncertainty_score":0.9936491},"labels":[],"label_agreement":null},{"id":"W2947205964","doi":"10.1200/jco.2019.37.15_suppl.1577","title":"Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Genetic testing; Psychosocial; Breast cancer; Anxiety; Distress; BRCA mutation; Genetic counseling; Depression (economics); Cancer; Mastectomy; Gynecology; Oncology; Internal medicine; Clinical psychology; Psychiatry; Genetics","score_opus":0.05387189787112014,"score_gpt":0.39881693803793555,"score_spread":0.34494504016681543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947205964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964587,0.0010353284,0.000050508384,0.0015943206,0.0003892417,0.00020405815,0.000075153795,0.0000023115285,0.00019035002],"genre_scores_gemma":[0.99343216,0.00036558145,0.004497735,0.00092464965,0.0003342672,0.000028750032,0.0000065702,0.00002295171,0.0003873184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982945,0.0001633925,0.0010161503,0.00020809754,0.00014530288,0.00017257346],"domain_scores_gemma":[0.99615955,0.0014659864,0.001486746,0.00015386962,0.0006243332,0.000109518485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010290581,0.000117522526,0.0007227565,0.000040485917,0.000031562682,0.0000053598374,0.00016137383,0.00029428347,0.00012052913],"category_scores_gemma":[0.0018880523,0.00008526146,0.00017670197,0.00007302971,0.00017410288,0.0000055923724,0.000078541736,0.00016434446,0.0000023936268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006729755,0.00023834828,0.94613874,0.000018596622,0.0006104185,0.000004557216,0.000023727722,0.00025028922,0.0078970855,0.0000015808552,0.0040291934,0.040114474],"study_design_scores_gemma":[0.004579333,0.005306094,0.97852993,0.000056805544,0.00021122897,0.00008454931,0.000017702163,0.000113563474,0.0018686969,0.000036973357,0.009075555,0.00011954781],"about_ca_topic_score_codex":0.0000092852315,"about_ca_topic_score_gemma":0.000060294893,"teacher_disagreement_score":0.03999493,"about_ca_system_score_codex":0.00010692834,"about_ca_system_score_gemma":0.000949048,"threshold_uncertainty_score":0.34768614},"labels":[],"label_agreement":null},{"id":"W2947213749","doi":"10.1200/jco.2019.37.15_suppl.5055","title":"Complex biologic heterogeneity of <i>de novo</i> hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Cohort; Randomized controlled trial; Prostate cancer; Population; Oncology; Progression-free survival; Exact test; Cancer; Overall survival","score_opus":0.27531638913711065,"score_gpt":0.5496829417536255,"score_spread":0.2743665526165149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947213749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173886,0.004226145,0.00000818605,0.0021149276,0.00022607026,0.0015074372,0.00007052215,0.000007577164,0.00010030473],"genre_scores_gemma":[0.99654764,0.0016514771,0.0013436992,0.00015494988,0.00011790977,0.00003978692,0.000008817114,0.000018095772,0.000117652504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996034,0.0008273024,0.0021367439,0.0002586751,0.00038300687,0.00036022067],"domain_scores_gemma":[0.9959169,0.0011505827,0.0017482592,0.000203112,0.00058180856,0.00039935278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019745945,0.00019849946,0.002379146,0.00022096519,0.0000315482,0.000007925245,0.00015052423,0.00021362846,0.00003280824],"category_scores_gemma":[0.00048091882,0.000119737575,0.00031435874,0.00023332855,0.00043929374,0.00007416151,0.00006525457,0.00044447574,0.0000050180843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069785304,0.0028999206,0.8493406,0.00035900157,0.0018818973,0.00032905347,0.0016960421,0.0000504045,0.033863895,0.000013757776,0.00024092162,0.03953917],"study_design_scores_gemma":[0.04278068,0.21063933,0.72530836,0.0006701403,0.0014458747,0.00062987476,0.0013165482,0.00021919103,0.014441622,0.000107038635,0.0021966053,0.0002447192],"about_ca_topic_score_codex":0.00009927494,"about_ca_topic_score_gemma":0.000059463215,"teacher_disagreement_score":0.2077394,"about_ca_system_score_codex":0.00029852265,"about_ca_system_score_gemma":0.0017735253,"threshold_uncertainty_score":0.48827565},"labels":[],"label_agreement":null},{"id":"W2947217282","doi":"10.1200/jco.2019.37.15_suppl.1002","title":"Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Capecitabine; Medicine; Lapatinib; Internal medicine; Neratinib; Metastatic breast cancer; Gastroenterology; Clinical endpoint; Randomized controlled trial; Breast cancer; Oncology; Cancer; Trastuzumab; Colorectal cancer","score_opus":0.05348833309670203,"score_gpt":0.41720628720842934,"score_spread":0.3637179541117273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947217282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871031,0.00057530386,0.000006867646,0.007186586,0.0012313211,0.003318217,0.00010093917,0.000023913186,0.00045375768],"genre_scores_gemma":[0.9942057,0.0005614221,0.0013808067,0.0015958596,0.00091247953,0.00020914857,0.00017423696,0.000051727413,0.00090858457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941281,0.0015965316,0.0027196896,0.00043524872,0.00070517475,0.0004152447],"domain_scores_gemma":[0.9858708,0.010044122,0.0024326816,0.0002814739,0.0010516937,0.00031923817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024609037,0.00039161666,0.0034241013,0.00017517363,0.000072349045,0.000022999424,0.00022908147,0.000242123,0.0027983545],"category_scores_gemma":[0.0011839892,0.0001960187,0.0004368319,0.00045349408,0.00037983907,0.00020797097,0.000036423113,0.0011073065,0.000017585886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8797773,0.010376354,0.09410197,0.000016958063,0.003344326,0.00019749915,0.00035153553,0.0000700431,0.000025334524,0.000009401588,0.003600608,0.008128633],"study_design_scores_gemma":[0.86936176,0.031520087,0.09092001,0.00028662707,0.0032630437,0.000043129054,0.000113008035,0.00039436843,0.000019608911,0.000008648581,0.0038731052,0.00019663754],"about_ca_topic_score_codex":0.0013082749,"about_ca_topic_score_gemma":0.0017275976,"teacher_disagreement_score":0.021143733,"about_ca_system_score_codex":0.00048404804,"about_ca_system_score_gemma":0.0018716542,"threshold_uncertainty_score":0.9981132},"labels":[],"label_agreement":null},{"id":"W2947218961","doi":"10.1200/jco.2019.37.15_suppl.5519","title":"Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Common Terminology Criteria for Adverse Events; Pembrolizumab; Internal medicine; Ovarian cancer; Tolerability; Neutropenia; Adverse effect; Fallopian tube cancer; Oncology; Topotecan; Bevacizumab; Gastroenterology; Progression-free survival; Surgery; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.07024901414033385,"score_gpt":0.42144278812756775,"score_spread":0.3511937739872339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947218961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97410876,0.00119311,0.00002994603,0.016748847,0.0018294897,0.00090297585,0.000098996534,0.000011993797,0.00507589],"genre_scores_gemma":[0.987903,0.0013877011,0.0071128607,0.0014787283,0.001399733,0.000043672848,0.000018557554,0.000034826462,0.00062090065],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99667615,0.00018231037,0.0020662574,0.0003962666,0.00036339587,0.0003156243],"domain_scores_gemma":[0.9958105,0.0015434634,0.001503424,0.00027417956,0.0004314603,0.00043698848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013933762,0.00022961073,0.0017682277,0.00010086272,0.000050156854,0.000023409713,0.00011956356,0.00031256804,0.000094893134],"category_scores_gemma":[0.0005055175,0.00014700885,0.00028516536,0.00009633034,0.0001535791,0.00010033256,0.000050294537,0.00068169273,0.0000036408053],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41154274,0.005391611,0.1503171,0.00083489623,0.0028911226,0.0016193204,0.00071420206,0.000057202546,0.0008306614,0.00082025543,0.01236138,0.4126195],"study_design_scores_gemma":[0.065792404,0.08641828,0.7293237,0.0011836936,0.0008858054,0.00043891015,0.000116527066,0.00019612514,0.0001226203,0.00009937772,0.11519948,0.00022310471],"about_ca_topic_score_codex":0.00008233253,"about_ca_topic_score_gemma":0.00031518305,"teacher_disagreement_score":0.57900655,"about_ca_system_score_codex":0.00049160497,"about_ca_system_score_gemma":0.002746461,"threshold_uncertainty_score":0.5994847},"labels":[],"label_agreement":null},{"id":"W2947222604","doi":"10.1200/jco.2019.37.15_suppl.e13503","title":"Comparison of two dose calculation methods of intra-arterial carboplatin in the treatment of recurrent glioblastoma multiforme.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Carboplatin; Toxicity; Neutropenia; Dosing; Glioblastoma; Body surface area; Clinical endpoint; Internal medicine; Area under the curve; Oncology; Incidence (geometry); Chemotherapy; Retrospective cohort study; Urology; Surgery; Clinical trial; Cisplatin","score_opus":0.1690650732593063,"score_gpt":0.5644332061742287,"score_spread":0.39536813291492234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947222604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970404,0.000403313,0.000043686072,0.0008717728,0.00095126114,0.000459696,0.00000536328,0.0000011002876,0.0002234114],"genre_scores_gemma":[0.9924126,0.00020010614,0.0071099643,0.00003831058,0.00021931161,0.000006231054,0.0000031308753,0.000006670741,0.0000036618221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955113,0.0009047502,0.0030326354,0.000120735036,0.00030118224,0.00012941283],"domain_scores_gemma":[0.99263203,0.004133213,0.0026745803,0.00021375457,0.00025640498,0.00009002942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020603524,0.00012211573,0.001970713,0.00016491632,0.000008252021,0.000001902953,0.000098004675,0.00018663061,0.000081452934],"category_scores_gemma":[0.0006742837,0.000060190898,0.00051976606,0.00016538388,0.00011639642,0.000038829847,0.000013338208,0.00022431697,0.0000021427081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011010965,0.021247039,0.48791727,0.000058775324,0.00052471063,0.000041440726,0.0019932657,0.00031776016,0.012140858,0.000120977806,0.000118222655,0.4645087],"study_design_scores_gemma":[0.037597246,0.101323076,0.8228205,0.00023929711,0.0008975946,0.000048974052,0.0005301033,0.002813658,0.029578108,0.0001138522,0.003962723,0.00007485531],"about_ca_topic_score_codex":0.000073817166,"about_ca_topic_score_gemma":0.0001930973,"teacher_disagreement_score":0.46443385,"about_ca_system_score_codex":0.00013851482,"about_ca_system_score_gemma":0.00032633392,"threshold_uncertainty_score":0.24545135},"labels":[],"label_agreement":null},{"id":"W2947224002","doi":"10.1200/jco.19.03166","title":"Long-Term Incidence and Predictors of Significant Hearing Loss Requiring Hearing Assistive Devices Among Childhood Cancer Survivors: A Population-Based Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; Hotel Dieu Hospital; Institute for Clinical Evaluative Sciences; Hospital for Sick Children; Kingston Health Sciences Centre; Queen's University","funders":"Ontario Ministry of Health and Long-Term Care; Pediatric Oncology Group of Ontario; Cancer Care Ontario","keywords":"Medicine; Cumulative incidence; Incidence (geometry); Hearing loss; Hazard ratio; Population; Pediatrics; Late effect; Relative risk; Cancer; Confidence interval; Internal medicine; Audiology; Cohort; Environmental health","score_opus":0.16099830392871006,"score_gpt":0.4383941194037265,"score_spread":0.27739581547501646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947224002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973634,0.000107565575,0.00042302374,0.0008816574,0.00072467694,0.00042212798,0.000005787293,0.000025342631,0.0000464356],"genre_scores_gemma":[0.9978877,0.00008976783,0.0004887557,0.0007811343,0.00070816674,0.000006339312,3.9711648e-7,0.000032504406,0.0000052395294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99410677,0.001264886,0.0029172201,0.0005542904,0.00077529956,0.00038155474],"domain_scores_gemma":[0.991758,0.004381451,0.0027430449,0.00023432098,0.00030183836,0.0005813734],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028840632,0.00023591617,0.0013482516,0.00016384193,0.00013926353,0.00005722945,0.00049976585,0.00024863143,0.000029106512],"category_scores_gemma":[0.013720603,0.00020649291,0.00021850191,0.00041621245,0.00033048986,0.0003164535,0.00029935787,0.0012180589,0.000001996998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003964104,0.00070086244,0.9890503,0.000067721776,0.0000688596,0.00028403325,0.00082554197,0.002451571,0.0016177152,0.0000038085518,0.000004017517,0.004529106],"study_design_scores_gemma":[0.0018586738,0.0040072263,0.99089426,0.0002727321,0.00014620613,0.00001612045,0.00017986413,0.0010296346,0.0013853287,0.000010917313,0.000020345286,0.00017867226],"about_ca_topic_score_codex":0.00077152776,"about_ca_topic_score_gemma":0.0017046427,"teacher_disagreement_score":0.01083654,"about_ca_system_score_codex":0.00014374619,"about_ca_system_score_gemma":0.0010858554,"threshold_uncertainty_score":0.99458724},"labels":[],"label_agreement":null},{"id":"W2947225939","doi":"10.1200/jco.2019.37.15_suppl.e21054","title":"Melanoma nodal management in Ontario following ASCO/SSO guidelines.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"","keywords":"Medicine; Sentinel lymph node; Guideline; Melanoma; Lymph node; Wide local excision; Dissection (medical); Biopsy; Population; Stage (stratigraphy); Surgery; Cancer; General surgery; Internal medicine; Breast cancer; Pathology","score_opus":0.12725113422356116,"score_gpt":0.44809935742205426,"score_spread":0.3208482231984931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947225939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8916394,0.00009398416,0.00013418318,0.005361331,0.005184166,0.00035757548,1.4745899e-7,0.000011826332,0.09721735],"genre_scores_gemma":[0.9623607,0.00011948907,0.008549588,0.005416771,0.0005076182,0.0000031270974,0.0000012823148,0.000017302507,0.023024134],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622285,0.0001538079,0.0026944147,0.00022176669,0.00045578842,0.00025137223],"domain_scores_gemma":[0.9981256,0.0003447094,0.00086544454,0.0002486812,0.00017156418,0.00024400928],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033531166,0.00013837239,0.0012462072,0.00028565447,0.000018099856,0.000011122428,0.00017020195,0.0002478199,0.0010706639],"category_scores_gemma":[0.00053452334,0.00010640056,0.00067165244,0.00013847458,0.000029397586,0.00007903138,0.00010353593,0.00096340326,0.0002585712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056113945,0.002231549,0.53081363,0.00006715074,0.0017301012,0.019876432,0.00020763962,0.00017559387,0.00017302031,0.00061654043,0.019878665,0.41861826],"study_design_scores_gemma":[0.009222346,0.004917211,0.34718776,0.00012433217,0.0002847696,0.0006878942,0.00023838658,0.00011323334,0.000009772568,0.00017565052,0.6369394,0.000099241624],"about_ca_topic_score_codex":0.0010797207,"about_ca_topic_score_gemma":0.011788911,"teacher_disagreement_score":0.6170607,"about_ca_system_score_codex":0.0005974323,"about_ca_system_score_gemma":0.0006605271,"threshold_uncertainty_score":0.99984246},"labels":[],"label_agreement":null},{"id":"W2947234394","doi":"10.1200/jco.2019.37.15_suppl.1018","title":"In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Letrozole; Breast cancer; Oncology; Anastrozole; Hazard ratio; Palbociclib; Tamoxifen; Cancer; Progression-free survival; Population; Aromatase inhibitor; Metastatic breast cancer; Chemotherapy; Confidence interval","score_opus":0.053760651211555203,"score_gpt":0.43821853841543934,"score_spread":0.38445788720388413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947234394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969974,0.00044393408,0.00009550263,0.0009984607,0.00019329684,0.0010514181,0.000021686228,0.000006616651,0.00019168037],"genre_scores_gemma":[0.9966744,0.0004195472,0.0014268287,0.001044953,0.000287044,0.000049113572,0.000012926415,0.00003261819,0.00005256643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955834,0.000673539,0.0023228622,0.00034430178,0.0007358052,0.00034008475],"domain_scores_gemma":[0.99462575,0.0012908701,0.002907455,0.00037606657,0.0006318004,0.00016806446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018383464,0.00026664688,0.0025281485,0.00043234645,0.000028727718,0.0000070101923,0.00029101298,0.0002299069,0.0002786846],"category_scores_gemma":[0.00013953981,0.00013332652,0.0002747333,0.0010150865,0.00021749502,0.00034802486,0.000025443347,0.00090194534,9.417576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44169945,0.0043707187,0.4722499,0.000009166718,0.0013266199,0.00010968258,0.0004892016,0.0013545313,0.0018566721,0.0000029820546,0.000008722303,0.07652238],"study_design_scores_gemma":[0.32610506,0.04393484,0.62689155,0.0002946643,0.00079313375,0.000030561954,0.00044049564,0.00008719533,0.0004971303,0.000017812328,0.00076428644,0.00014324472],"about_ca_topic_score_codex":0.00016048153,"about_ca_topic_score_gemma":0.0004311023,"teacher_disagreement_score":0.15464167,"about_ca_system_score_codex":0.00029319953,"about_ca_system_score_gemma":0.00091916294,"threshold_uncertainty_score":0.5436898},"labels":[],"label_agreement":null},{"id":"W2947234519","doi":"10.1200/jco.2021.39.15_suppl.2004","title":"EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University; McMaster University; Hôpital Notre-Dame; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Dacarbazine; Concomitant; Interim analysis; Radiation therapy; Chemotherapy; Phases of clinical research; Progression-free survival; Randomized controlled trial; Clinical trial; Glioma; Chemoradiotherapy; Chemotherapy regimen; Quality of life (healthcare); Surgery; Cancer research","score_opus":0.036947379224883434,"score_gpt":0.378806078346372,"score_spread":0.34185869912148853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947234519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223524,0.0002963971,0.00020888318,0.0049275146,0.00068224827,0.0015027969,0.000014592345,0.00001462634,0.00011770666],"genre_scores_gemma":[0.99344015,0.00021816952,0.004479587,0.0014053523,0.00025563923,0.000060376973,0.00006582763,0.00006292551,0.000011982011],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99381936,0.0009354511,0.0033527985,0.00051708735,0.0009085972,0.0004667313],"domain_scores_gemma":[0.99090147,0.0044920216,0.0027893397,0.0004947519,0.0008925797,0.00042984722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021168962,0.0004180422,0.0031992514,0.00064814277,0.000040175466,0.00001970288,0.00021982534,0.0005642441,0.00017650891],"category_scores_gemma":[0.0015170985,0.0002973117,0.0005016853,0.00088866294,0.0003510462,0.00014700966,0.000019222554,0.0009073702,0.0000025501852],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6585711,0.058230855,0.22582686,0.000043595574,0.0007459316,0.0024545977,0.00008265719,0.00034134486,0.0003170222,0.000017868784,0.00052211643,0.052846026],"study_design_scores_gemma":[0.7348941,0.12443034,0.13178505,0.00041889906,0.000410358,0.000023287894,0.00006710632,0.00034888845,0.0065085804,0.000028065939,0.00086189713,0.00022342536],"about_ca_topic_score_codex":0.00010078097,"about_ca_topic_score_gemma":0.0005579399,"teacher_disagreement_score":0.0940418,"about_ca_system_score_codex":0.0006898457,"about_ca_system_score_gemma":0.00413609,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W2947248861","doi":"10.1200/jco.2019.37.15_suppl.e20512","title":"Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; ACE inhibitor; Proportional hazards model; Angiotensin-converting enzyme; Oncology; Cancer; Blood pressure","score_opus":0.021934325573529898,"score_gpt":0.3237520985914816,"score_spread":0.30181777301795165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947248861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995639,0.000829645,0.0000065674094,0.0019787191,0.0004730481,0.00086224574,0.000010777643,0.000024728934,0.00017526651],"genre_scores_gemma":[0.9980575,0.0002432878,0.00045071906,0.0004664116,0.0004187779,0.0000096996955,0.000025205145,0.00006190071,0.00026652505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951771,0.0008270925,0.002039,0.00045752205,0.00095777865,0.0005415083],"domain_scores_gemma":[0.99441046,0.0012905591,0.0025155877,0.00040750141,0.00095172867,0.00042417325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002528573,0.00038371337,0.002300287,0.00024884287,0.00007518418,0.000032459047,0.0001931993,0.0004965368,0.00007866203],"category_scores_gemma":[0.0016953711,0.00023693676,0.00026823083,0.00033244403,0.0003702326,0.0002955379,0.000065251326,0.0011573606,0.0000022577333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13122989,0.0013615225,0.8602148,0.00005749394,0.00084818306,0.00040838224,0.0002886435,0.000023062596,0.00034029715,0.0000014696406,0.0005160042,0.004710203],"study_design_scores_gemma":[0.05686498,0.02232321,0.91514355,0.0021624472,0.00063287764,0.00013044744,0.00023463287,0.0004966402,0.00055616256,0.000003711684,0.0011556249,0.0002957158],"about_ca_topic_score_codex":0.00080830936,"about_ca_topic_score_gemma":0.00061100535,"teacher_disagreement_score":0.07436491,"about_ca_system_score_codex":0.00081684295,"about_ca_system_score_gemma":0.0025294207,"threshold_uncertainty_score":0.9662001},"labels":[],"label_agreement":null},{"id":"W2947251340","doi":"10.1200/jco.2019.37.15_suppl.e18027","title":"Staging the development and implementation of a Coordinated Cancer Care Model using risk-based survivorship care: A deliberative discussion among multiple stakeholders.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École Nationale d'Administration Publique; Santé Montérégie; Centre intégré de santé et de services sociaux de la Montérégie-Centre; Université de Montréal","funders":"","keywords":"Survivorship curve; Medicine; Context (archaeology); Health care; Nursing; Population; Family medicine; Environmental health","score_opus":0.1685628618791216,"score_gpt":0.458370667818484,"score_spread":0.2898078059393624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947251340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953308,0.0006731217,0.0020988712,0.0007675029,0.0005921037,0.00044879806,0.000026499854,0.0000055993423,0.000056714805],"genre_scores_gemma":[0.9975469,0.000074797164,0.0019134217,0.00029023155,0.00011492612,0.00000874011,0.0000097894645,0.00001826267,0.000022901766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728745,0.0005155569,0.0014468279,0.00019127862,0.00036275582,0.00019613907],"domain_scores_gemma":[0.996267,0.0008225402,0.0017029593,0.00014287492,0.00089376123,0.00017082122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015710627,0.00014446263,0.00083991606,0.00010096639,0.000089770205,0.000011705027,0.00009949412,0.0001772311,0.000037921473],"category_scores_gemma":[0.000274962,0.000076844815,0.00020381353,0.00015202671,0.00013546943,0.00011172167,0.000047104288,0.00063331355,2.8279246e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013367372,0.00007780318,0.8842365,0.00014443397,0.00017101632,0.000010320542,0.021110741,0.004353077,0.00019709973,0.0000034838936,0.00002481914,0.08833398],"study_design_scores_gemma":[0.015443014,0.0027312743,0.7953033,0.0006294007,0.000812184,0.000007684163,0.15932846,0.020571344,0.0036078559,0.000029518016,0.0012920033,0.00024399527],"about_ca_topic_score_codex":0.0029624854,"about_ca_topic_score_gemma":0.036135063,"teacher_disagreement_score":0.13821772,"about_ca_system_score_codex":0.0003967345,"about_ca_system_score_gemma":0.0031220852,"threshold_uncertainty_score":0.98145294},"labels":[],"label_agreement":null},{"id":"W2947257322","doi":"10.1200/jco.2019.37.15_suppl.tps5598","title":"DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bevacizumab; Olaparib; Oncology; Internal medicine; BRCA mutation; Ovarian cancer; Cancer; PARP inhibitor; Chemotherapy; Maintenance therapy; Surgery","score_opus":0.022389126519296698,"score_gpt":0.3849379027665236,"score_spread":0.3625487762472269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947257322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894393,0.000928908,0.000070761314,0.006509884,0.00071404985,0.0026177245,0.000018178484,0.0000049940386,0.00019155708],"genre_scores_gemma":[0.9914147,0.0063758385,0.00097343134,0.0008937267,0.000096754535,0.00012041492,0.000016253716,0.000027647024,0.00008118678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99547875,0.000703704,0.00270739,0.00038720018,0.0004240786,0.00029885097],"domain_scores_gemma":[0.9934624,0.0033877685,0.0023704404,0.00019775353,0.00033208466,0.00024956715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003008659,0.0002591682,0.0034528486,0.00021709842,0.00002384363,0.000012995993,0.00010237448,0.0003419089,0.000087074724],"category_scores_gemma":[0.0016461154,0.00017649237,0.00027019586,0.00024381682,0.00026885388,0.00021939033,0.000029230305,0.0006163454,7.7075515e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7922277,0.010837142,0.107107215,0.000053386233,0.00048290912,0.00013251582,0.0003619379,0.000011107532,0.00008213278,0.00015666265,0.0003860937,0.08816121],"study_design_scores_gemma":[0.86008006,0.028042274,0.108967826,0.00054003607,0.00035410057,0.000016911134,0.00007276726,0.0002673594,0.000081711405,0.0003078576,0.0011229133,0.0001461943],"about_ca_topic_score_codex":0.00043389155,"about_ca_topic_score_gemma":0.0006723644,"teacher_disagreement_score":0.08801501,"about_ca_system_score_codex":0.0003780123,"about_ca_system_score_gemma":0.00094003754,"threshold_uncertainty_score":0.71971494},"labels":[],"label_agreement":null},{"id":"W2947258108","doi":"10.1200/jco.2019.37.15_suppl.e13571","title":"Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Clinique Neuro-Outaouais","funders":"","keywords":"Medicine; Temozolomide; Avelumab; Radiation therapy; Internal medicine; Interim analysis; Adverse effect; Oncology; Gastroenterology; Surgery; Clinical trial; Nivolumab; Cancer; Immunotherapy","score_opus":0.0695240831331027,"score_gpt":0.4440116371999934,"score_spread":0.3744875540668907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947258108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864073,0.0002497733,0.0000022093059,0.009951075,0.0012912593,0.00067490584,0.000001036878,0.0000059272547,0.0014165372],"genre_scores_gemma":[0.99695647,0.00018648572,0.00023990216,0.0019511294,0.0005184158,0.000013850758,4.6092634e-7,0.000014546251,0.000118754026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665344,0.00046423395,0.0020470761,0.000183914,0.0004053135,0.00024601968],"domain_scores_gemma":[0.99379146,0.004391234,0.0010557504,0.00029577746,0.00023041952,0.00023536482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029988985,0.00014101512,0.001343975,0.00015074236,0.000028344013,0.000011365634,0.00020148497,0.0002319058,0.00031577845],"category_scores_gemma":[0.002440066,0.00007208023,0.00045300476,0.00021919065,0.00008724846,0.00008361388,0.00006581362,0.00090128294,0.0001843122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024286758,0.010798039,0.88048214,0.000007701066,0.00034126814,0.002885865,0.00036248312,0.00004422174,0.000046649886,0.000034928606,0.0024003854,0.10016762],"study_design_scores_gemma":[0.034513716,0.028592039,0.9104261,0.00007574498,0.00024152675,0.00021598845,0.0010737807,0.00012956785,0.00004820888,0.00006303654,0.024554327,0.00006598515],"about_ca_topic_score_codex":0.0000625937,"about_ca_topic_score_gemma":0.0005669962,"teacher_disagreement_score":0.100101635,"about_ca_system_score_codex":0.00017662763,"about_ca_system_score_gemma":0.000713115,"threshold_uncertainty_score":0.39156762},"labels":[],"label_agreement":null},{"id":"W2947261505","doi":"10.1200/jco.2019.37.15_suppl.e14245","title":"Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Target lesion; Radiology; Cancer; Oncology; Clinical trial; Immunotherapy; Phases of clinical research; Internal medicine; Nuclear medicine","score_opus":0.09063345437569931,"score_gpt":0.49285659727015474,"score_spread":0.40222314289445543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947261505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478275,0.00009329542,0.000013029649,0.0010763345,0.00033824693,0.0036567724,0.0000023302232,0.000005160427,0.00003207794],"genre_scores_gemma":[0.998789,0.000026058293,0.00080827007,0.00023382997,0.000043192387,0.000067295936,0.0000015434346,0.000023349765,0.000007473701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99181473,0.003565672,0.0030570466,0.00040016614,0.0008597885,0.00030260303],"domain_scores_gemma":[0.9857858,0.011081296,0.0022057467,0.0003897459,0.0003725137,0.00016493135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010357459,0.0002534615,0.001982238,0.00046795158,0.000051618797,0.000020257758,0.0002023905,0.000138106,0.000026477275],"category_scores_gemma":[0.0048326766,0.00014688648,0.00021362638,0.0005718214,0.00012921766,0.00015572131,0.00013247076,0.0009622302,0.0000020849166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07997276,0.11311603,0.7878297,0.000026505853,0.0003547143,0.0013827911,0.0028017769,0.00040167876,0.00039789773,0.0000016354679,0.000003748567,0.013710738],"study_design_scores_gemma":[0.17247435,0.15559079,0.66558933,0.00035326954,0.00031755914,0.000023603909,0.0019836924,0.003463137,0.0001141367,0.000005242868,0.0000030883969,0.00008177138],"about_ca_topic_score_codex":0.00023796319,"about_ca_topic_score_gemma":0.00026015486,"teacher_disagreement_score":0.122240365,"about_ca_system_score_codex":0.0004248128,"about_ca_system_score_gemma":0.00095683686,"threshold_uncertainty_score":0.5989857},"labels":[],"label_agreement":null},{"id":"W2947262464","doi":"10.1200/jco.2019.37.15_suppl.5007","title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Denosumab; Data monitoring committee; Interim analysis; Internal medicine; Oncology; Prostate cancer; Population; Clinical trial; Cancer; Osteoporosis; Androgen receptor","score_opus":0.18276435438651864,"score_gpt":0.5078856986522432,"score_spread":0.3251213442657246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947262464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942929,0.00093913847,0.00018661581,0.002366376,0.00064731983,0.000817136,0.0000045571205,0.0000098355895,0.0007361298],"genre_scores_gemma":[0.9965715,0.0008729199,0.0005205578,0.0012556418,0.00060115673,0.000009518735,0.000035636232,0.000018725643,0.000114360766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99406606,0.002370477,0.0022747943,0.00036311007,0.0005101851,0.0004153728],"domain_scores_gemma":[0.9925708,0.0050153825,0.0015254021,0.00031014107,0.00019729442,0.00038093372],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012764211,0.00022117526,0.0020121376,0.00026415024,0.00013151493,0.00005317131,0.0002743275,0.00035348974,0.00014486705],"category_scores_gemma":[0.0033645362,0.00013205562,0.0003999567,0.0004195863,0.0001749823,0.00023535336,0.00010168629,0.0023582499,0.000006173199],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72037077,0.0029776695,0.20113187,0.00007855603,0.0034681638,0.0013763882,0.002133782,0.00030998213,0.0016905703,0.000011376132,0.0012440629,0.06520684],"study_design_scores_gemma":[0.6051097,0.035658594,0.31275672,0.00039248093,0.0033840493,0.00020168601,0.0052412893,0.009652962,0.00058795616,0.000122991,0.026470322,0.00042127495],"about_ca_topic_score_codex":0.00031879934,"about_ca_topic_score_gemma":0.00036307616,"teacher_disagreement_score":0.11526106,"about_ca_system_score_codex":0.00031081194,"about_ca_system_score_gemma":0.00069297064,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2947265946","doi":"10.1200/jco.2019.37.15_suppl.2507","title":"Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Pharmacodynamics; Pharmacokinetics; Lymphoma; Gastroenterology; Oncology; Cancer; Immunotherapy","score_opus":0.061459076868332324,"score_gpt":0.4461295254891137,"score_spread":0.38467044862078137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947265946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979578,0.00008410881,0.00001245479,0.00035436067,0.00036278786,0.00096041855,0.0000025512293,0.0000038588187,0.00026163983],"genre_scores_gemma":[0.99870044,0.000100992904,0.00058637623,0.00041184685,0.000050163133,0.000010295709,0.0000042578654,0.000020434582,0.00011516841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609435,0.0004023076,0.0025262865,0.0002178861,0.0005300686,0.0002291187],"domain_scores_gemma":[0.99640113,0.0007345208,0.0021506867,0.00021440018,0.00036683804,0.00013240776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017194847,0.00016902578,0.0017108833,0.00032120047,0.000013811829,0.000005094504,0.0001483052,0.00011273003,0.00012700945],"category_scores_gemma":[0.00041949033,0.000098282304,0.00012390039,0.00044164967,0.00015254632,0.00019113277,0.00002164572,0.00045815663,0.0000035621074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23393944,0.046674322,0.62394685,0.00007856126,0.00038881096,0.0007117438,0.00074411393,0.000097883734,0.00007518802,0.000003620024,0.000097228185,0.09324224],"study_design_scores_gemma":[0.21947807,0.23267077,0.54494697,0.0004914854,0.00013953912,0.00009353078,0.0013523892,0.00008743888,0.00007039791,0.000017463848,0.0005559422,0.00009601072],"about_ca_topic_score_codex":0.00007033488,"about_ca_topic_score_gemma":0.0008092428,"teacher_disagreement_score":0.18599644,"about_ca_system_score_codex":0.00032221602,"about_ca_system_score_gemma":0.0012776583,"threshold_uncertainty_score":0.4007836},"labels":[],"label_agreement":null},{"id":"W2947266573","doi":"10.1200/jco.2019.37.15_suppl.e14125","title":"Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier universitaire de Québec","funders":"","keywords":"Nivolumab; Pembrolizumab; Medicine; Discontinuation; Adverse effect; Population; Melanoma; Internal medicine; Renal cell carcinoma; Lung cancer; Cancer; Oncology; Immunotherapy","score_opus":0.04672971601381915,"score_gpt":0.3583926393468246,"score_spread":0.31166292333300544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947266573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072504,0.00018814072,0.0000030152432,0.0076150126,0.00036253387,0.00012470479,0.0000029337405,0.000001609539,0.0009770215],"genre_scores_gemma":[0.9962981,0.0017045864,0.00032833,0.0011633472,0.000081116166,1.11240745e-7,3.8543763e-7,0.000006341595,0.00041771602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979645,0.00036398627,0.0012196475,0.000118173244,0.00019175834,0.00014195264],"domain_scores_gemma":[0.9972834,0.0014293656,0.0008743249,0.00011715653,0.00014247678,0.00015326646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013907007,0.00007723339,0.00095492136,0.00013840871,0.000012176377,0.000002526567,0.00009119095,0.00019954647,0.00004890621],"category_scores_gemma":[0.00178731,0.00006367486,0.00013776707,0.00009511919,0.000093914845,0.00011919677,0.000030477935,0.00071813416,4.7110882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019897023,0.00027276995,0.95245725,0.00003772857,0.00013508927,0.0005149745,0.00014233863,0.000010124545,0.00025589054,0.000047519938,0.0034585076,0.022770789],"study_design_scores_gemma":[0.016204651,0.003172879,0.95116895,0.00019790421,0.00004586412,0.00008571693,0.000369692,0.000104075974,0.00000812087,0.000006894576,0.028574469,0.000060805094],"about_ca_topic_score_codex":0.7036803,"about_ca_topic_score_gemma":0.8366692,"teacher_disagreement_score":0.13298891,"about_ca_system_score_codex":0.0005979805,"about_ca_system_score_gemma":0.0071014888,"threshold_uncertainty_score":0.99852735},"labels":[],"label_agreement":null},{"id":"W2947267775","doi":"10.1200/jco.2019.37.15_suppl.tps2664","title":"Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Microbiome; Metagenomics; Internal medicine; Pembrolizumab; Feces; Adverse effect; Randomized controlled trial; Oncology; Immunotherapy; Gastroenterology; Immunology; Bioinformatics; Cancer; Biology; Microbiology","score_opus":0.05768376519729694,"score_gpt":0.4426608200986469,"score_spread":0.3849770549013499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947267775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694663,0.00015767026,0.000011203488,0.00011947786,0.0015576078,0.0011364673,0.000015215282,0.000001428039,0.00005427726],"genre_scores_gemma":[0.9986475,0.000101336474,0.0003802876,0.0006626797,0.00014865103,0.0000025964234,0.000005360527,0.00002084493,0.000030744104],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9951286,0.0015367988,0.0025201233,0.0003235444,0.00022060689,0.00027036548],"domain_scores_gemma":[0.99677086,0.00046290236,0.0017214532,0.00043255187,0.00048195603,0.00013026927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033903657,0.00019258405,0.0014298491,0.0001726524,0.000019041154,0.0000047618937,0.00040572014,0.00045759373,0.000018065311],"category_scores_gemma":[0.0003650171,0.00014936573,0.00037161505,0.00016066308,0.000059984304,0.0000058116307,0.00010033508,0.00043989212,0.000011824238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010121487,0.010390603,0.3888415,0.00011330485,0.00037912405,0.0000051626034,0.00024302838,0.000047955262,0.5813422,0.0000024309043,0.00016130549,0.008351912],"study_design_scores_gemma":[0.023654997,0.10640862,0.83575827,0.0001331661,0.00008370141,0.0000070779483,0.00010989793,0.0000025026661,0.030253015,0.000010451454,0.0034202696,0.00015803982],"about_ca_topic_score_codex":0.000024082216,"about_ca_topic_score_gemma":0.00013998528,"teacher_disagreement_score":0.55108917,"about_ca_system_score_codex":0.00011764366,"about_ca_system_score_gemma":0.0006516166,"threshold_uncertainty_score":0.60909575},"labels":[],"label_agreement":null},{"id":"W2947269143","doi":"10.1200/jco.2019.37.15_suppl.4570","title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Renal cell carcinoma; Internal medicine; Clear cell renal cell carcinoma; Clinical endpoint; Oncology; Surgery; Urology; Gastroenterology; Cancer; Clinical trial; Immunotherapy","score_opus":0.06056821045133883,"score_gpt":0.38968190688245813,"score_spread":0.3291136964311193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947269143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824113,0.00084753527,0.00018209039,0.003635481,0.0013357132,0.0016839394,0.000029145554,0.00002187069,0.009852923],"genre_scores_gemma":[0.98417354,0.000945816,0.0085142115,0.0014471032,0.0009045461,0.000025912985,0.00005602931,0.000081292674,0.0038515774],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9929217,0.00050381944,0.0046279933,0.0006669464,0.0006215458,0.00065796834],"domain_scores_gemma":[0.99221736,0.0029364747,0.0028278243,0.0006712488,0.0007113636,0.00063572405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034408874,0.00041705446,0.002879125,0.00036248172,0.000054265114,0.000015562284,0.00038711212,0.0008047216,0.00020793226],"category_scores_gemma":[0.0008773236,0.00031423048,0.0010631807,0.00029431822,0.00014498566,0.00017729161,0.00007552513,0.0015086236,0.00011993403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57503515,0.012069557,0.34149805,0.00042707106,0.00068069104,0.0037173685,0.00047256515,0.005832315,0.0137910275,0.000041173826,0.01897583,0.027459202],"study_design_scores_gemma":[0.17106311,0.09214886,0.5920263,0.00018269938,0.00063001906,0.00037595423,0.00010760208,0.002394706,0.010130731,0.00023359052,0.13027224,0.00043420837],"about_ca_topic_score_codex":0.00006788191,"about_ca_topic_score_gemma":0.00009663935,"teacher_disagreement_score":0.40397203,"about_ca_system_score_codex":0.0007231172,"about_ca_system_score_gemma":0.0016997242,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W2947269397","doi":"10.1200/jco.2019.37.15_suppl.6639","title":"A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Atezolizumab; Medicine; Docetaxel; Metastatic Urothelial Carcinoma; Cost effectiveness; Taxane; Oncology; Chemotherapy; Cost-effectiveness analysis; Quality-adjusted life year; Internal medicine; Cancer; Bladder cancer; Immunotherapy; Breast cancer; Urothelial carcinoma; Pembrolizumab","score_opus":0.2139740202085181,"score_gpt":0.4899264956342296,"score_spread":0.27595247542571144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947269397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468476,0.0006079545,0.000037589143,0.0011477809,0.0003287051,0.0005591703,0.00007173921,0.0000016353667,0.0025606842],"genre_scores_gemma":[0.99832207,0.00024659908,0.00042876415,0.0005251983,0.00014622445,0.000008312137,0.000006791503,0.000008336093,0.000307682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960595,0.0007277756,0.002494564,0.00016961436,0.00037212673,0.0001764205],"domain_scores_gemma":[0.9956852,0.0020253502,0.0015225089,0.00034997615,0.0002850613,0.00013189552],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018434931,0.0001431051,0.0025790446,0.0002804008,0.000010500233,0.0000024278174,0.00016598085,0.00014627402,0.001263818],"category_scores_gemma":[0.00037493007,0.000075108874,0.0011155909,0.0004710821,0.00016367805,0.00004773956,0.000016034013,0.000296826,0.0000074258323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013884254,0.009354726,0.90131956,0.00007837688,0.006326764,0.00034600552,0.0012520571,0.00006727403,0.00023563113,0.000051303712,0.0001290078,0.066955045],"study_design_scores_gemma":[0.021604633,0.03477526,0.92531186,0.000027188344,0.0073987474,0.000084457286,0.00045420404,0.00047256213,0.00064476964,0.00014996903,0.009015465,0.00006090878],"about_ca_topic_score_codex":0.00029654696,"about_ca_topic_score_gemma":0.0006405025,"teacher_disagreement_score":0.06689414,"about_ca_system_score_codex":0.00015904485,"about_ca_system_score_gemma":0.0015137647,"threshold_uncertainty_score":0.99964917},"labels":[],"label_agreement":null},{"id":"W2947269449","doi":"10.1200/jco.2019.37.15_suppl.10026","title":"Frailty among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer; Population; Late effect; Gerontology; Demography; Pediatrics; Internal medicine; Environmental health","score_opus":0.08884448426099217,"score_gpt":0.4508535062062902,"score_spread":0.36200902194529805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947269449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582977,0.0032193775,0.000015993039,0.025558434,0.009236557,0.0013952951,0.000048704595,0.000032133168,0.002195758],"genre_scores_gemma":[0.98134434,0.0016119372,0.0002180125,0.007559179,0.0066599646,0.000045679015,0.0000107749465,0.00007144808,0.0024786426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99176145,0.0012956759,0.0044873697,0.0006390646,0.0012628357,0.0005535996],"domain_scores_gemma":[0.987376,0.005886529,0.0040822634,0.0010761776,0.0009493704,0.0006296645],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00582368,0.0003892549,0.0028742473,0.000111456466,0.00010252749,0.00003508678,0.00075955153,0.00066609913,0.0034584894],"category_scores_gemma":[0.0073255342,0.000229859,0.0009391575,0.00036242054,0.00032991986,0.00030814673,0.0002328336,0.0032937676,0.00011332161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085431564,0.005540185,0.93120974,0.000011288121,0.0021145944,0.0013558487,0.0017676102,0.00005301101,0.000024860274,0.0000020840732,0.023449747,0.033616737],"study_design_scores_gemma":[0.011273977,0.0054649743,0.8883349,0.000343156,0.0010181343,0.0003442432,0.0011174025,0.000026790507,0.000024599489,0.00007509536,0.091753215,0.00022355482],"about_ca_topic_score_codex":0.02106245,"about_ca_topic_score_gemma":0.047647968,"teacher_disagreement_score":0.068303466,"about_ca_system_score_codex":0.00030891722,"about_ca_system_score_gemma":0.0039321333,"threshold_uncertainty_score":0.9990057},"labels":[],"label_agreement":null},{"id":"W2947277775","doi":"10.1200/jco.2019.37.15_suppl.e18297","title":"A population-based study of medical cannabis utilization in patients with cancer in the pre-legalization era.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; College of Physicians and Surgeons of Ontario; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Cannabis; Medical cannabis; Medical record; Legalization; Cancer registry; Cancer; Logistic regression; Population; Family medicine; Multivariate analysis; Internal medicine; Environmental health; Psychiatry","score_opus":0.07067512665734292,"score_gpt":0.4809109788595038,"score_spread":0.41023585220216086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947277775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98051625,0.000053680375,0.00002085405,0.01823342,0.0002707526,0.00078971847,0.0000021075316,0.0000015631916,0.00011162316],"genre_scores_gemma":[0.99880296,0.000023983559,0.000018410132,0.0008546315,0.00012734569,0.000017052107,0.000007097635,0.000009483921,0.00013902191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958351,0.00077519106,0.0016379538,0.00014019913,0.0014592144,0.00015229754],"domain_scores_gemma":[0.9981211,0.00017113218,0.0008121449,0.00017032141,0.0005998045,0.0001255259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004057362,0.00008068371,0.00076594885,0.0002464291,0.000013572872,0.000006395877,0.00019499658,0.00023002154,0.00042118208],"category_scores_gemma":[0.0020204089,0.00004404887,0.0000881169,0.00050484587,0.000048238096,0.00007660625,0.000020713882,0.00079492555,7.163857e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042808787,0.0055250996,0.968683,0.000042611362,0.00003677312,0.000033470445,0.00044769404,0.0011034829,8.2761517e-7,0.000024327506,0.0016199292,0.018201903],"study_design_scores_gemma":[0.016347015,0.013207106,0.9660013,0.00016263036,0.000049247523,0.0000028449738,0.00034467352,0.001615356,0.0000013509692,0.000010882572,0.0022152623,0.000042335847],"about_ca_topic_score_codex":0.0019054626,"about_ca_topic_score_gemma":0.009013636,"teacher_disagreement_score":0.018286692,"about_ca_system_score_codex":0.00019250532,"about_ca_system_score_gemma":0.0027384441,"threshold_uncertainty_score":0.502982},"labels":[],"label_agreement":null},{"id":"W2947279348","doi":"10.1200/jco.2019.37.15_suppl.1097","title":"Measuring on-treatment genome-wide tumor copy number alterations in cell-free DNA (cfDNA) in plasma is highly prognostic in metastatic breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Oncology; Genome instability; Cancer; Cell-free fetal DNA; Internal medicine; Circulating tumor cell; Tumor progression; Metastasis; Copy-number variation; Genome; Gene; DNA; Biology; DNA damage; Genetics","score_opus":0.053305796756423135,"score_gpt":0.36415443894673827,"score_spread":0.31084864219031516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947279348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946472,0.00029797357,0.000022428123,0.0028764347,0.0006925032,0.00035743887,0.000076555836,0.0000015111721,0.0010279788],"genre_scores_gemma":[0.99532664,0.0015931425,0.0009402205,0.0015995867,0.00034147478,0.00003471161,0.000010755465,0.000022988861,0.00013048753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734557,0.00026152213,0.0015716715,0.00032114645,0.00018013919,0.00031992816],"domain_scores_gemma":[0.9976948,0.001008091,0.00070085115,0.00028762256,0.00013499819,0.00017365704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093408825,0.00019618466,0.0008476317,0.0001342886,0.000018835133,0.000019570214,0.0002858694,0.00017893776,0.000095234434],"category_scores_gemma":[0.00082246866,0.00016440207,0.00021840518,0.00014413989,0.00006178359,0.000010475234,0.00008999085,0.00040432255,0.000032341322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020902895,0.0024777208,0.9808493,0.000029773748,0.00012173094,0.00039487437,0.00014036572,0.0058715907,0.0023921714,0.000040540304,0.0009039906,0.004687603],"study_design_scores_gemma":[0.024863513,0.009320271,0.9268941,0.00024684748,0.00015053558,0.00019884369,0.00020202478,0.0005723228,0.008072047,0.00055219,0.028438037,0.0004892564],"about_ca_topic_score_codex":0.0002800149,"about_ca_topic_score_gemma":0.005090659,"teacher_disagreement_score":0.05395524,"about_ca_system_score_codex":0.00042510912,"about_ca_system_score_gemma":0.0017216527,"threshold_uncertainty_score":0.6704122},"labels":[],"label_agreement":null},{"id":"W2947285993","doi":"10.1200/jco.2019.37.15_suppl.5025","title":"Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Androgen deprivation therapy; Internal medicine; Prostate cancer; Proportional hazards model; Oncology; Cancer","score_opus":0.04823765635962641,"score_gpt":0.40657250111632176,"score_spread":0.35833484475669536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947285993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997694,0.00064211735,0.000006992088,0.0005337898,0.00008086009,0.0008834372,0.000015509131,0.000004314058,0.0001389935],"genre_scores_gemma":[0.99730086,0.0017550485,0.00054703496,0.0001767239,0.00007045242,0.000014981347,0.00001543191,0.000019133038,0.000100348574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977194,0.00021818285,0.0011413245,0.00020511987,0.0004969685,0.00021900733],"domain_scores_gemma":[0.9975091,0.00060144876,0.0011127973,0.00012934272,0.0004600616,0.00018725039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079346984,0.00015494696,0.0010053945,0.00018999712,0.000025594645,0.00001104271,0.00007093137,0.00014504032,0.000048619797],"category_scores_gemma":[0.00017285938,0.00008174545,0.000077156525,0.00021094517,0.00019440273,0.00017439474,0.000015256478,0.00045608214,9.0762643e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03785898,0.000811141,0.9351621,0.00006961822,0.00063385814,0.0001207954,0.0005739056,0.00028605608,0.0007043107,0.0000027855613,0.000024413204,0.023752013],"study_design_scores_gemma":[0.03501523,0.026987815,0.9354254,0.00038702518,0.00017804,0.000019792082,0.00020737274,0.00009314259,0.0012323548,0.000014994114,0.0003571955,0.000081648126],"about_ca_topic_score_codex":0.00018596389,"about_ca_topic_score_gemma":0.0003858896,"teacher_disagreement_score":0.026176674,"about_ca_system_score_codex":0.00024619143,"about_ca_system_score_gemma":0.0016002889,"threshold_uncertainty_score":0.33334824},"labels":[],"label_agreement":null},{"id":"W2947287592","doi":"10.1200/jco.2019.37.15_suppl.3561","title":"Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Colorectal cancer; Cancer; Stage (stratigraphy); Oncology; Internal medicine","score_opus":0.1663466852735201,"score_gpt":0.5275581294484417,"score_spread":0.3612114441749216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947287592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794995,0.00043185268,0.000081029575,0.013040696,0.0044752797,0.00040029243,0.000003084209,0.0000050991803,0.0020631363],"genre_scores_gemma":[0.99020696,0.002109546,0.00073992147,0.0034999393,0.0015452921,0.0000028897412,0.0000016242278,0.000016227126,0.0018776169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588114,0.0008571301,0.002503075,0.00018731072,0.00039956742,0.0001717565],"domain_scores_gemma":[0.9939149,0.0031912744,0.0021801903,0.00017166196,0.00028696744,0.00025502016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00651961,0.000106233485,0.0013311177,0.000057284426,0.000036366895,0.000008155188,0.00018814193,0.00040727603,0.00034222216],"category_scores_gemma":[0.010352555,0.000059498823,0.0004589128,0.00011904035,0.00037241206,0.00006525782,0.00008850407,0.0018308742,0.0000039658407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03923713,0.0012052252,0.6351526,0.000076222736,0.00041163975,0.00007189151,0.0001306934,0.00010030541,0.00036975383,0.00022015821,0.0074171275,0.31560728],"study_design_scores_gemma":[0.0825749,0.012090654,0.6390816,0.00025923495,0.00047252138,0.000077700075,0.000061853665,0.009086396,0.00009803093,0.00021065758,0.25588194,0.00010452899],"about_ca_topic_score_codex":0.000027771921,"about_ca_topic_score_gemma":0.000015312831,"teacher_disagreement_score":0.31550273,"about_ca_system_score_codex":0.000052257798,"about_ca_system_score_gemma":0.0013843126,"threshold_uncertainty_score":0.9979837},"labels":[],"label_agreement":null},{"id":"W2947288491","doi":"10.1200/jco.2019.37.15_suppl.e23142","title":"The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Concordance; Palliative care; Advance care planning; Family medicine; Health care; Descriptive statistics; Cancer; Disease; Cross-sectional study; Internal medicine; Nursing","score_opus":0.23867509514881322,"score_gpt":0.5683137586030486,"score_spread":0.3296386634542353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947288491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897682,0.0070362864,0.000022171487,0.00063110754,0.0012013875,0.00082835817,0.000011568057,0.000003919355,0.0004970182],"genre_scores_gemma":[0.9957925,0.0017974196,0.0014643564,0.00043111187,0.00037616747,0.000018164907,0.000003787104,0.000014470953,0.00010199272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775934,0.00034666,0.0012538821,0.00016908773,0.00028397748,0.00018702858],"domain_scores_gemma":[0.9930517,0.003608591,0.0013337453,0.0001236032,0.0017432901,0.00013909116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010046267,0.00011389159,0.0009370846,0.000048149137,0.00008280105,0.000014100001,0.000110323774,0.000143725,0.000016363667],"category_scores_gemma":[0.0026618151,0.00006721154,0.00023400485,0.000057358768,0.000117539304,0.00016770634,0.000056016735,0.00052590424,0.0000012650972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017062483,0.00029953223,0.77808917,0.00011952673,0.00030641013,0.000016408223,0.0064975144,0.000004467944,0.00004897341,0.0000058687287,0.0003002525,0.21260561],"study_design_scores_gemma":[0.012423614,0.022091014,0.7843066,0.0005014099,0.00059878634,0.0000017839681,0.07074261,0.000008378462,0.00020274379,0.000021643955,0.10900948,0.00009195023],"about_ca_topic_score_codex":0.000042803043,"about_ca_topic_score_gemma":0.00011023057,"teacher_disagreement_score":0.21251366,"about_ca_system_score_codex":0.00015824435,"about_ca_system_score_gemma":0.0009963721,"threshold_uncertainty_score":0.31866336},"labels":[],"label_agreement":null},{"id":"W2947289475","doi":"10.1200/jco.2019.37.15_suppl.e13586","title":"Clinical outcomes in patients with melanoma brain metastases at a tertiary cancer center.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Melanoma; Asymptomatic; Single Center; Cancer; Retrospective cohort study; Internal medicine; Radiation therapy; Brain metastasis; Oncology; Medical record; Immunotherapy; Stage (stratigraphy); Gastroenterology; Surgery; Metastasis","score_opus":0.06488818833078144,"score_gpt":0.4543036014782888,"score_spread":0.3894154131475074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947289475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715705,0.00020122707,0.0000072992875,0.010409,0.001308084,0.00046403648,0.00004102217,0.0000062788454,0.0004059976],"genre_scores_gemma":[0.9847585,0.00017524492,0.0029454916,0.010768804,0.0002970478,0.0000068888207,0.000018030689,0.000024941673,0.0010050682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995034,0.0009940107,0.0028909538,0.00029672228,0.00047415792,0.000310153],"domain_scores_gemma":[0.9935482,0.003838035,0.0016357768,0.00029706027,0.00024400669,0.00043691712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033126138,0.00020627565,0.0024155392,0.00013439191,0.000020316731,0.000006225853,0.00015209096,0.000267175,0.00085526693],"category_scores_gemma":[0.0014206815,0.00011140993,0.00075138436,0.00010832497,0.00015967761,0.00011047694,0.000094811774,0.0008234565,0.000067895875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007992899,0.0072262455,0.92245483,0.00002077989,0.0013497702,0.0006400696,0.000019694779,0.000005627007,9.109104e-7,0.000013379716,0.0042855525,0.05599025],"study_design_scores_gemma":[0.03940547,0.020025954,0.8838413,0.0001316068,0.00044921998,0.00006316779,0.00001927823,0.0000069221987,0.0000032059002,0.000020759277,0.055934444,0.00009868571],"about_ca_topic_score_codex":0.00005605729,"about_ca_topic_score_gemma":0.000274938,"teacher_disagreement_score":0.055891562,"about_ca_system_score_codex":0.00022516517,"about_ca_system_score_gemma":0.00076803664,"threshold_uncertainty_score":0.93645734},"labels":[],"label_agreement":null},{"id":"W2947290136","doi":"10.1200/jco.2019.37.15_suppl.552","title":"Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Osteonecrosis of the jaw; Breast cancer; Zoledronic acid; Bisphosphonate; Internal medicine; Cancer; Bisphosphonate-associated osteonecrosis of the jaw; Oncology; Surgery; Osteoporosis","score_opus":0.0731254339666774,"score_gpt":0.41550900848091543,"score_spread":0.34238357451423806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947290136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98416764,0.00013457352,1.553103e-7,0.013395336,0.0010194768,0.0010338059,0.00018406849,0.0000035325213,0.00006140833],"genre_scores_gemma":[0.997625,0.0002957034,0.000027171542,0.0014869601,0.000035806308,0.00004964541,0.0000012835138,0.000023056702,0.000455363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624664,0.00072254916,0.0018355713,0.00021674705,0.000606141,0.00037234466],"domain_scores_gemma":[0.99418646,0.0017586147,0.0028863414,0.00029284644,0.0005303215,0.00034540874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019181465,0.00020455506,0.0018711478,0.00008062826,0.000043629825,0.000005116999,0.0002349858,0.00021999645,0.00041184956],"category_scores_gemma":[0.0008876928,0.00008233779,0.00024757444,0.00051909714,0.00019120968,0.00008462638,0.00007247601,0.0006895048,0.0000016418327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092240795,0.003330797,0.8849248,0.000047601363,0.0012753037,0.00001618217,0.0003831848,0.0001066699,0.000064017724,0.0000044563285,0.0003205274,0.01728564],"study_design_scores_gemma":[0.04269155,0.009752151,0.9438543,0.0015047437,0.00058259757,0.00003736887,0.00027099697,0.0000015838019,0.00041151498,0.000019781344,0.00079203927,0.00008141168],"about_ca_topic_score_codex":0.009709877,"about_ca_topic_score_gemma":0.019185062,"teacher_disagreement_score":0.058929436,"about_ca_system_score_codex":0.00068558287,"about_ca_system_score_gemma":0.0041752453,"threshold_uncertainty_score":0.99871224},"labels":[],"label_agreement":null},{"id":"W2947290708","doi":"10.1200/jco.2019.37.15_suppl.10056","title":"Emergency department (ED) visits and hospitalizations in survivors of childhood cancer in the Childhood Cancer Survivor Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hospital for Sick Children","funders":"","keywords":"Medicine; Interquartile range; Emergency department; Relative risk; Pediatrics; Poisson regression; Confidence interval; Cancer; Childhood cancer; Underweight; Cancer registry; Rate ratio; Internal medicine; Population; Body mass index; Overweight; Psychiatry","score_opus":0.05200854528586643,"score_gpt":0.44729589211840276,"score_spread":0.3952873468325363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947290708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97949046,0.005395815,0.000008113383,0.010739592,0.0023798784,0.0013701825,0.00003256393,0.0000071755417,0.00057623984],"genre_scores_gemma":[0.98836607,0.009199604,0.00009343873,0.0015182999,0.0006920599,0.000042178683,0.000003751338,0.000030419613,0.000054196942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99249154,0.0017279654,0.004136847,0.00039469628,0.00087208115,0.0003768829],"domain_scores_gemma":[0.9950256,0.0017595672,0.0021609124,0.0004229003,0.00037629175,0.00025472732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075305863,0.00026415926,0.0021701166,0.00029453833,0.000040490308,0.000009523532,0.0004040312,0.00030408468,0.0005104775],"category_scores_gemma":[0.0018293597,0.00018188394,0.00036260384,0.0006495293,0.00011541503,0.00018080646,0.00011348573,0.0011689381,0.0000063149328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005040637,0.0083240615,0.9713848,0.00007002063,0.00041915386,0.00005956176,0.0074352007,0.0001637986,0.000006804816,0.00006758455,0.0006756202,0.010889331],"study_design_scores_gemma":[0.00900391,0.006644038,0.97761256,0.00031808842,0.0002841965,0.0000345981,0.0035468072,0.000023150838,0.00000765068,0.00017273393,0.0021808231,0.00017144126],"about_ca_topic_score_codex":0.004408717,"about_ca_topic_score_gemma":0.062267095,"teacher_disagreement_score":0.057858378,"about_ca_system_score_codex":0.00017323194,"about_ca_system_score_gemma":0.0017722695,"threshold_uncertainty_score":0.95484406},"labels":[],"label_agreement":null},{"id":"W2947297019","doi":"10.1200/jco.2019.37.15_suppl.e18018","title":"Barriers to accessing healthcare services: A multidisciplinary approach towards improving pancreatic cancer survival in a Canadian province.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Atlantic School of Theology; Nova Scotia Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Referral; Pancreatic cancer; Multidisciplinary approach; Health care; Cancer; Lung cancer; Family medicine; Emergency medicine; Medical emergency; Internal medicine","score_opus":0.1426392188335489,"score_gpt":0.5035522278638204,"score_spread":0.36091300903027146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947297019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728085,0.0006211112,0.000048970905,0.01710208,0.0009592025,0.0010240746,0.000011350078,0.000009264591,0.0074154846],"genre_scores_gemma":[0.9877815,0.00026634775,0.007006721,0.0035078223,0.0007585221,0.00003570918,0.0000042122892,0.00003089678,0.0006082401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949472,0.0008986599,0.0023093969,0.00040126112,0.0005705715,0.0008729149],"domain_scores_gemma":[0.99408495,0.0010221164,0.0008726494,0.00031953896,0.0005394194,0.0031612974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074024457,0.0002143875,0.002605815,0.0005316547,0.0000981204,0.00002343568,0.00041308583,0.0006413466,0.00030959735],"category_scores_gemma":[0.0026385211,0.00015662148,0.00029098825,0.0004282636,0.00014042766,0.00020613178,0.00015346831,0.0017617844,0.00002766942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027291588,0.00027582972,0.9479792,0.0005660653,0.0001787406,0.0006301991,0.0009443569,0.00004920276,0.0000787534,0.000034705667,0.00007579386,0.04645801],"study_design_scores_gemma":[0.006729814,0.006424925,0.970496,0.0006342551,0.00024320568,0.00019858962,0.0033729721,0.007768937,0.0000057716284,0.00006182471,0.0038864787,0.00017723737],"about_ca_topic_score_codex":0.24376573,"about_ca_topic_score_gemma":0.3401563,"teacher_disagreement_score":0.09639056,"about_ca_system_score_codex":0.0018492044,"about_ca_system_score_gemma":0.051138982,"threshold_uncertainty_score":0.9542402},"labels":[],"label_agreement":null},{"id":"W2947300494","doi":"10.1200/jco.2019.37.15_suppl.1516","title":"Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cardiomyopathy; Genome-wide association study; Locus (genetics); Odds ratio; 1000 Genomes Project; Minor allele frequency; Internal medicine; Oncology; Genetics; Allele frequency; Allele; Single-nucleotide polymorphism; Biology; Genotype; Heart failure; Gene","score_opus":0.09676967644697249,"score_gpt":0.4266509189368534,"score_spread":0.32988124248988093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947300494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958998,0.00019330463,0.0008187762,0.0005994108,0.0005553244,0.0014551099,0.00019132021,0.000013465779,0.00027350365],"genre_scores_gemma":[0.99758905,0.0000639171,0.0012968762,0.0005884686,0.00034548622,0.000008537454,0.000012033042,0.000047328907,0.000048301434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892706,0.0025135507,0.0054415865,0.0005799236,0.0016650723,0.0005292389],"domain_scores_gemma":[0.9837352,0.004141585,0.00911257,0.0005757679,0.001992851,0.00044204204],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.022703156,0.0003370357,0.0046123588,0.00059147674,0.0000469281,0.000015976822,0.00041612837,0.000449921,0.000039405157],"category_scores_gemma":[0.01715427,0.00028527656,0.00076328317,0.0012840659,0.00013074724,0.00022580172,0.00015343944,0.0018320758,0.0000027981657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002073459,0.0050579887,0.9737578,0.00014323405,0.0026824332,0.000058782087,0.006088805,0.00876854,0.0010165371,0.0000015709783,0.000005828353,0.00034499564],"study_design_scores_gemma":[0.018539902,0.0068258294,0.9650244,0.00047017337,0.0016009383,0.0000134333995,0.0064064637,0.0007835318,0.000028797258,0.000017852422,0.000050972187,0.00023771822],"about_ca_topic_score_codex":0.011727483,"about_ca_topic_score_gemma":0.014449838,"teacher_disagreement_score":0.016466444,"about_ca_system_score_codex":0.0022568353,"about_ca_system_score_gemma":0.0045575765,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2947303166","doi":"10.1200/jco.2019.37.15_suppl.6513","title":"Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Administration.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Food and drug administration; Cancer drugs; Clinical Oncology; Cancer; Randomized controlled trial; Internal medicine; Drug; Clinical research; Oncology; Pharmacology","score_opus":0.4202416281277462,"score_gpt":0.5449675164172438,"score_spread":0.12472588828949766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947303166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87962496,0.0026354273,0.0001887312,0.11410461,0.001808111,0.0003568328,0.00019079958,0.0000055297496,0.0010850006],"genre_scores_gemma":[0.9691806,0.004193091,0.0013517678,0.023537088,0.00085378805,0.000012300518,0.000018789357,0.000022217433,0.00083035335],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98505235,0.0011083863,0.013107151,0.000334042,0.00014537376,0.00025267748],"domain_scores_gemma":[0.9700139,0.015583582,0.013443595,0.00034904206,0.00033800848,0.00027184156],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0470855,0.00015284542,0.0024373485,0.0001345758,0.0000692132,0.00002940839,0.0004044865,0.00035808288,0.00030928134],"category_scores_gemma":[0.007154376,0.00012603722,0.00036862277,0.00016533335,0.00034210243,0.0002869783,0.000068334186,0.00076306326,0.00007836267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010819505,0.0018070287,0.6917181,0.0003223135,0.0013170452,0.0000026520356,0.0026854966,0.00041046532,0.0000018625666,0.04571462,0.23662882,0.018309642],"study_design_scores_gemma":[0.0068169204,0.0057351342,0.1223945,0.000122064535,0.000085331216,0.000023720828,0.0032588753,0.0031976122,0.000007889999,0.023737855,0.8343305,0.0002895758],"about_ca_topic_score_codex":0.00069351634,"about_ca_topic_score_gemma":0.00035567765,"teacher_disagreement_score":0.5977017,"about_ca_system_score_codex":0.00015882464,"about_ca_system_score_gemma":0.0008809507,"threshold_uncertainty_score":0.981226},"labels":[],"label_agreement":null},{"id":"W2947306414","doi":"10.1200/jco.2019.37.15_suppl.tps3166","title":"A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Cancer; Mdm2; Oncology; Internal medicine; Clinical trial; Phases of clinical research; Primary tumor; Pharmacology; Metastasis; Adverse effect; Apoptosis; Biology","score_opus":0.09282442175627433,"score_gpt":0.49550978428126174,"score_spread":0.40268536252498743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947306414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995847,0.000057786925,0.00009627852,0.00044233172,0.0006826156,0.00254798,0.000015688252,0.000007705591,0.000302642],"genre_scores_gemma":[0.9945219,0.00009080353,0.0044396194,0.0006990345,0.00008882643,0.000021211637,0.0000146557195,0.000040600444,0.00008333193],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99430376,0.0007271457,0.0036379322,0.00035761634,0.0006590414,0.00031452713],"domain_scores_gemma":[0.99381506,0.0009710821,0.0034470365,0.00038632675,0.0010565091,0.00032397264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018283065,0.00023306234,0.0024573428,0.00027486088,0.000028061444,0.0000151596705,0.0003573487,0.00019508324,0.00013517504],"category_scores_gemma":[0.002922766,0.00015207379,0.00016025588,0.00041580404,0.000119553886,0.0002981043,0.00014451458,0.0010896992,0.000018923365],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.289151,0.19849491,0.29958647,0.00029693785,0.0019857914,0.0028853198,0.0018322652,0.0010233038,0.0044633313,0.000022516599,0.00039596102,0.19986217],"study_design_scores_gemma":[0.45559272,0.3057044,0.2310399,0.0011794923,0.0010747821,0.00012134015,0.0013175871,0.0020514326,0.00045991395,0.00002252539,0.0011686182,0.00026726915],"about_ca_topic_score_codex":0.00008671939,"about_ca_topic_score_gemma":0.0005707965,"teacher_disagreement_score":0.19959489,"about_ca_system_score_codex":0.0002922719,"about_ca_system_score_gemma":0.0017146476,"threshold_uncertainty_score":0.62013894},"labels":[],"label_agreement":null},{"id":"W2947314711","doi":"10.1200/jco.2020.38.6_suppl.50","title":"Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; Cancer","score_opus":0.20144469297215994,"score_gpt":0.4925169662479288,"score_spread":0.29107227327576884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947314711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295396,0.00033240035,0.000011700494,0.0028763034,0.0002817941,0.00330247,0.00014423866,0.000017657952,0.0000794535],"genre_scores_gemma":[0.9954405,0.0023801045,0.00083736185,0.00027610498,0.00021138818,0.00015603215,0.000016994796,0.000051790452,0.00062972703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929028,0.0011415894,0.0037693325,0.0006925039,0.0009645634,0.00052917015],"domain_scores_gemma":[0.9938029,0.0016611896,0.0025944794,0.0003002281,0.00083616923,0.0008050049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014419403,0.0004646593,0.0038933698,0.00022797615,0.000083394516,0.000031260028,0.00019661285,0.00019215354,0.000097859236],"category_scores_gemma":[0.0009141166,0.00022340938,0.00024734327,0.0005261819,0.00062573,0.00022313598,0.00008658031,0.000988485,0.0000022142947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18946633,0.016116645,0.7700929,0.00012398761,0.0033419796,0.002041128,0.0029076952,0.00008274742,0.0000318265,0.000004911924,0.00013379808,0.015656061],"study_design_scores_gemma":[0.12720732,0.21312277,0.6560594,0.0002528883,0.0012519632,0.000025272577,0.001487102,0.00012433369,0.00004946192,0.0000067162605,0.00024307004,0.00016969655],"about_ca_topic_score_codex":0.0013294313,"about_ca_topic_score_gemma":0.020149415,"teacher_disagreement_score":0.19700612,"about_ca_system_score_codex":0.0012777377,"about_ca_system_score_gemma":0.0050884075,"threshold_uncertainty_score":0.9977303},"labels":[],"label_agreement":null},{"id":"W2947320935","doi":"10.1200/jco.2019.37.15_suppl.3512","title":"CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; University of Toronto; Hôpital Charles-Le Moyne; University of Saskatchewan; Université de Montréal; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; McGill University; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Moncton Hospital","funders":"","keywords":"Medicine; Hazard ratio; Durvalumab; Internal medicine; Confidence interval; Clinical endpoint; Tremelimumab; Gastroenterology; Microsatellite instability; Immunotherapy; Randomized controlled trial; Oncology; Cancer; Microsatellite; Allele; Genetics; Nivolumab; Biology","score_opus":0.04624605588599972,"score_gpt":0.4041748008360857,"score_spread":0.357928744950086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947320935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829197,0.00041509356,0.0000018163562,0.000049956692,0.00013908975,0.0009618194,0.00011570183,0.0000033809301,0.000021194142],"genre_scores_gemma":[0.9994412,0.00020320286,0.00022369284,0.000012136249,0.0000342583,0.0000052509395,0.000059770227,0.000016659464,0.000003794467],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99575335,0.0007532799,0.002585034,0.00031887062,0.0003626697,0.00022681238],"domain_scores_gemma":[0.9952461,0.0014118883,0.0024317107,0.00016576961,0.0005508552,0.00019364478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017208093,0.00021852257,0.0023540934,0.00053574133,0.000025723182,0.000007957434,0.00007465275,0.0002084578,0.00008427894],"category_scores_gemma":[0.0008209632,0.00015585512,0.0002980156,0.0005364323,0.0004944438,0.00016529068,0.00003552364,0.0005215769,2.5982192e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70248914,0.0030679456,0.26069602,0.00009582189,0.0018623782,0.00015195349,0.0028847589,0.000013263733,0.005507631,8.273055e-8,0.0000033363235,0.02322765],"study_design_scores_gemma":[0.32552463,0.15630654,0.51311624,0.00007070891,0.0013324734,0.000031903106,0.0018576548,0.00029111648,0.0013529108,0.0000016954939,0.0000143077605,0.000099812016],"about_ca_topic_score_codex":0.0014506262,"about_ca_topic_score_gemma":0.0016857174,"teacher_disagreement_score":0.3769645,"about_ca_system_score_codex":0.000584177,"about_ca_system_score_gemma":0.0016363157,"threshold_uncertainty_score":0.6355587},"labels":[],"label_agreement":null},{"id":"W2947326095","doi":"10.1200/jco.2019.37.15_suppl.1517","title":"Gliomas in the context of Li-Fraumeni syndrome: An international cohort.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Children's Hospital of Western Ontario; Hospital for Sick Children","funders":"","keywords":"Medicine; Context (archaeology); Asymptomatic; Cohort; Li–Fraumeni syndrome; Cancer; Internal medicine; Retrospective cohort study; Oncology; Natural history; Family history; Germline mutation; Pediatrics; Mutation; Gene","score_opus":0.07178894839877802,"score_gpt":0.44976429112271377,"score_spread":0.37797534272393574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947326095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364216,0.00020321048,0.000040171686,0.005927961,0.0022941674,0.00026818347,0.0000033434746,0.0000034418156,0.0076173344],"genre_scores_gemma":[0.99610794,0.0002305423,0.00046927706,0.002729857,0.00032403914,0.000002396897,0.0000037193279,0.000011513786,0.00012071584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682564,0.00044646568,0.0019358315,0.00014435197,0.0005069191,0.00014079247],"domain_scores_gemma":[0.9967966,0.0011037601,0.0013229876,0.00027894677,0.00035562573,0.00014207915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00412705,0.00008951406,0.000990103,0.00018127615,0.000008370197,0.0000054172465,0.00036075793,0.00033044958,0.00039884585],"category_scores_gemma":[0.0019416236,0.00005719861,0.0003464328,0.00016703602,0.000148382,0.00011442586,0.000041512434,0.0010909613,0.000038186347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008197767,0.005258826,0.86423856,0.00004788984,0.0012724977,0.005857277,0.0009338442,0.000099699966,0.005162975,0.0022025967,0.0043857987,0.10234226],"study_design_scores_gemma":[0.01261899,0.019087974,0.87552017,0.0001879007,0.00024672988,0.0050778664,0.0006577236,0.00028910142,0.000261709,0.00027977346,0.085683115,0.00008896128],"about_ca_topic_score_codex":0.00003890695,"about_ca_topic_score_gemma":0.00006109857,"teacher_disagreement_score":0.1022533,"about_ca_system_score_codex":0.0001425284,"about_ca_system_score_gemma":0.0009806646,"threshold_uncertainty_score":0.47397447},"labels":[],"label_agreement":null},{"id":"W2947330283","doi":"10.1200/jco.2019.37.15_suppl.6511","title":"Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neutropenia; Lenalidomide; Internal medicine; Adverse effect; Follicular lymphoma; Bendamustine; Gastroenterology; Area under the curve; Rituximab; Surgery; Toxicity; Lymphoma; Multiple myeloma","score_opus":0.07840256986650905,"score_gpt":0.403790824738665,"score_spread":0.32538825487215595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947330283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956222,0.00059854146,0.000233175,0.0018434691,0.00024899346,0.00029684723,0.000007863,0.0000029226521,0.0011459563],"genre_scores_gemma":[0.99394494,0.0009813027,0.004135639,0.0006729477,0.00011116391,0.000007156187,0.000003657664,0.000012295035,0.00013087277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995927,0.0002513706,0.0027061298,0.00029806845,0.0005045304,0.00031290588],"domain_scores_gemma":[0.9950244,0.0022930657,0.0017698596,0.00029989803,0.0003635939,0.00024920003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003071675,0.00018811085,0.0028780273,0.0008317702,0.0000102697595,0.000005969252,0.00018505829,0.000305303,0.000080102196],"category_scores_gemma":[0.0014989696,0.00011850059,0.0007964412,0.0014806418,0.00013259923,0.00012393338,0.000061906074,0.0003421467,0.000006354268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009569972,0.0086041745,0.9636855,0.000038143597,0.0017984408,0.0022411763,0.000034565637,0.00060052436,0.00009169532,0.00015618381,0.00014121355,0.013038414],"study_design_scores_gemma":[0.05067354,0.0074728657,0.93692833,0.00025195815,0.0013295498,0.0002502334,0.00008494716,0.00050459325,0.00043837496,0.0000365851,0.0019202012,0.00010879489],"about_ca_topic_score_codex":0.00039784174,"about_ca_topic_score_gemma":0.0012863026,"teacher_disagreement_score":0.041103568,"about_ca_system_score_codex":0.00068900327,"about_ca_system_score_gemma":0.0013171452,"threshold_uncertainty_score":0.48323137},"labels":[],"label_agreement":null},{"id":"W2947330567","doi":"10.1200/jco.2019.37.15_suppl.10017","title":"Comparing late mortality risks among childhood cancer survivors: A report from the Childhood Cancer Survivor Study and British Childhood Cancer Survivor Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Cancer; Pediatrics; Standardized mortality ratio; Demography; Internal medicine","score_opus":0.16225776193381872,"score_gpt":0.4781971440603974,"score_spread":0.3159393821265787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947330567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709955,0.008296391,0.000013387644,0.0057506827,0.009300863,0.004472402,0.00026398958,0.00011008632,0.0007967253],"genre_scores_gemma":[0.98336613,0.0049969386,0.00009698364,0.0037147955,0.0070250584,0.00022596645,0.000029189923,0.00019947137,0.00034544594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9806686,0.0047328304,0.00856121,0.0019207181,0.0028296676,0.0012869649],"domain_scores_gemma":[0.9820221,0.005605715,0.0077245575,0.0018465738,0.0013806947,0.0014203652],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017916,0.0010301946,0.0070340782,0.00024150853,0.00047092157,0.00026721568,0.0013542231,0.0009029243,0.0011229431],"category_scores_gemma":[0.0043789363,0.00081845035,0.0013416517,0.0008498558,0.00074120186,0.0007037528,0.00083870714,0.005300134,0.00002666601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010295353,0.015722794,0.9435976,0.00006654886,0.008120559,0.0013749946,0.010081801,0.00022019923,0.0000056997073,0.0000022068732,0.0014162643,0.018361775],"study_design_scores_gemma":[0.021836072,0.005189558,0.9570286,0.0011898482,0.0038483797,0.00034550412,0.0068684635,0.000085614556,0.000007759808,0.00012596976,0.002635261,0.00083891547],"about_ca_topic_score_codex":0.5202891,"about_ca_topic_score_gemma":0.73935443,"teacher_disagreement_score":0.21906532,"about_ca_system_score_codex":0.0005989413,"about_ca_system_score_gemma":0.0050810357,"threshold_uncertainty_score":0.9997902},"labels":[],"label_agreement":null},{"id":"W2947332272","doi":"10.1200/jco.2019.37.15_suppl.9576","title":"Comprehensive genomic profiling reveals distinct patterns of driver mutations and chromosomal alterations in acral and mucosal melanomas.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Mucosal melanoma; Medicine; Melanoma; Survival analysis; Proportional hazards model; Oncology; Pathology; Cancer research; Internal medicine","score_opus":0.058307030348577316,"score_gpt":0.3924512714534622,"score_spread":0.3341442411048849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947332272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972334,0.00011431604,0.00010512697,0.0011547155,0.00045052732,0.0003145027,0.000006996332,0.0000038971166,0.00061654055],"genre_scores_gemma":[0.99721974,0.00013644535,0.0018538791,0.00034479122,0.00021048325,0.0000022874844,0.0000045450142,0.000007700255,0.00022015069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822646,0.0001814685,0.0012201496,0.00013601502,0.00012533579,0.000110580666],"domain_scores_gemma":[0.9981917,0.0007723126,0.00065894576,0.0000881976,0.00015341515,0.00013540086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004889586,0.00008143672,0.0007383436,0.00013759654,0.000022066002,0.0000070007886,0.0000427912,0.00012007047,0.0000905271],"category_scores_gemma":[0.00029051973,0.00006501946,0.00010308415,0.000052721865,0.00007661272,0.000059630103,0.000055362467,0.00036963113,0.00000489082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010990095,0.00049918325,0.97053915,0.00015897027,0.00020730884,0.00048316407,0.00036641417,0.000033825858,0.010921938,0.00041063054,0.000062477106,0.0152179105],"study_design_scores_gemma":[0.0045690173,0.0040309033,0.98646164,0.00008518844,0.00014207425,0.0010098666,0.00045057456,0.00059961603,0.00009650095,0.0001254505,0.0023680378,0.00006114885],"about_ca_topic_score_codex":0.000018839219,"about_ca_topic_score_gemma":0.000063448526,"teacher_disagreement_score":0.015922453,"about_ca_system_score_codex":0.00005446639,"about_ca_system_score_gemma":0.00016865954,"threshold_uncertainty_score":0.26514167},"labels":[],"label_agreement":null},{"id":"W2947334480","doi":"10.1200/jco.2019.37.15_suppl.tps5597","title":"CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Durvalumab; Cervical cancer; Internal medicine; Clinical endpoint; Oncology; Cancer; Radiation therapy; Chemoradiotherapy; Urology; Randomized controlled trial; Nivolumab; Immunotherapy","score_opus":0.05282560527458163,"score_gpt":0.4371832909920048,"score_spread":0.3843576857174232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947334480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228483,0.00296077,0.000094716066,0.0015253772,0.0006998143,0.0023282378,0.000002843909,0.0000064174214,0.000097007796],"genre_scores_gemma":[0.99474424,0.0038436076,0.0005535428,0.0005763906,0.00017274129,0.000045569966,0.000001297565,0.000026784921,0.000035813297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960888,0.00041746456,0.002355436,0.00034318777,0.00047119934,0.00032388876],"domain_scores_gemma":[0.99569327,0.002099571,0.0014458207,0.00019998687,0.0002402372,0.0003211189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003626851,0.00025821378,0.003640527,0.0001476654,0.00003089303,0.00001207322,0.00012921132,0.00022193197,0.00011401365],"category_scores_gemma":[0.0001818371,0.00015317612,0.00022592668,0.00021506977,0.00047254836,0.00013315766,0.00003626361,0.00075321115,4.2919353e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.841618,0.0040412447,0.027703384,0.000062965184,0.0029357262,0.00022027851,0.0012846836,0.000036959067,0.00033961172,0.000001990911,0.000009975208,0.121745184],"study_design_scores_gemma":[0.9156161,0.04765339,0.032551553,0.000597435,0.00060729834,0.00007144914,0.0010588486,0.00017875586,0.000060123326,0.0000011241113,0.0014356134,0.0001683094],"about_ca_topic_score_codex":0.00017301788,"about_ca_topic_score_gemma":0.00044482254,"teacher_disagreement_score":0.121576875,"about_ca_system_score_codex":0.00035063075,"about_ca_system_score_gemma":0.0011819953,"threshold_uncertainty_score":0.6246341},"labels":[],"label_agreement":null},{"id":"W2947348468","doi":"10.1200/jco.2019.37.15_suppl.e23107","title":"The efficacy and safety of exercise in metastatic solid cancer: A meta-analysis of randomized control trials.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Randomized controlled trial; Physical therapy; Meta-analysis; Aerobic exercise; Internal medicine","score_opus":0.1716563639250635,"score_gpt":0.5013317512700025,"score_spread":0.329675387344939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947348468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.935771,0.0513125,0.00024476394,0.009522482,0.0011437542,0.0015289144,0.000040924493,0.0000024316332,0.00043323456],"genre_scores_gemma":[0.9842568,0.014995643,0.00012508409,0.00035991342,0.000078554986,0.000018126577,9.0838967e-7,0.000007304509,0.00015768857],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9891045,0.003969849,0.0062004467,0.00014415842,0.00042945507,0.00015160712],"domain_scores_gemma":[0.94543105,0.04837987,0.005215407,0.00024204905,0.00057112105,0.00016048561],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.038102157,0.00012427845,0.014329041,0.00025854167,0.000013838462,0.000004530605,0.00014915607,0.00015796315,0.00044443752],"category_scores_gemma":[0.014530122,0.000057384877,0.0045411717,0.00037855215,0.00033452344,0.00003977794,0.000025614558,0.00052477355,7.6516835e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72031516,0.00073694246,0.008967921,0.000108237466,0.23720534,0.0000360092,0.00053031556,0.0005690138,0.00007986494,0.00019797313,0.00012668081,0.031126563],"study_design_scores_gemma":[0.39853105,0.0020277554,0.022812262,0.000087839355,0.5728144,0.0000092804,0.000341789,0.00073401537,0.000041389776,0.00022875707,0.0023024436,0.00006901491],"about_ca_topic_score_codex":0.00037171578,"about_ca_topic_score_gemma":0.000865288,"teacher_disagreement_score":0.33560908,"about_ca_system_score_codex":0.00004540772,"about_ca_system_score_gemma":0.0009806992,"threshold_uncertainty_score":0.9937709},"labels":[],"label_agreement":null},{"id":"W2947369739","doi":"10.1200/jco.2019.37.15_suppl.5075","title":"Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Taxane; Circulating tumor cell; Androgen receptor; Biomarker; EPIC; Oncology; Medicine; Context (archaeology); Internal medicine; Cancer; Biology; Prostate cancer; Breast cancer; Metastasis; Genetics","score_opus":0.059591003087976886,"score_gpt":0.4095917832058968,"score_spread":0.3500007801179199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947369739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557817,0.000039276914,0.00008047954,0.0029036934,0.00013214536,0.0010924144,0.00013253547,0.0000036607219,0.000037652637],"genre_scores_gemma":[0.9898268,0.0000792552,0.009834371,0.00018930234,0.000030398089,0.000020407193,0.000005054997,0.000009688192,0.000004698868],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99613094,0.0006492602,0.0024965985,0.00019330333,0.0004036263,0.00012626415],"domain_scores_gemma":[0.99667895,0.0009429143,0.0015943293,0.00018047012,0.00045725732,0.00014607601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036456534,0.000105867824,0.001084839,0.00018377184,0.000013157894,0.0000023219036,0.0001155114,0.00014611018,0.000050947205],"category_scores_gemma":[0.0027741985,0.00007268416,0.00017067186,0.0003736492,0.00025330286,0.00008369847,0.000065160544,0.00031144827,2.6421583e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006770095,0.002527501,0.42705867,0.00053931924,0.00031834785,0.000008126158,0.0015376991,0.00016944026,0.52666175,0.0001538228,0.0002238791,0.03403138],"study_design_scores_gemma":[0.004814015,0.005231351,0.8927543,0.0010230412,0.00020280009,0.000010293118,0.0005930499,0.0011366628,0.09352687,0.00009815621,0.0005389853,0.00007047242],"about_ca_topic_score_codex":0.00021500057,"about_ca_topic_score_gemma":0.00013028499,"teacher_disagreement_score":0.46569565,"about_ca_system_score_codex":0.00018206828,"about_ca_system_score_gemma":0.00056064804,"threshold_uncertainty_score":0.33211753},"labels":[],"label_agreement":null},{"id":"W2947376429","doi":"10.1200/jco.2019.37.15_suppl.10012","title":"A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cog; Medicine; Internal medicine; Oncology; Overall survival; Artificial intelligence; Computer science","score_opus":0.11599326307350759,"score_gpt":0.4771272656687701,"score_spread":0.3611340025952625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947376429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883367,0.00026877172,0.000063754225,0.0044495836,0.002098022,0.0019904436,0.000025553552,0.000040589006,0.0027266005],"genre_scores_gemma":[0.99609387,0.00038892654,0.00050617626,0.0010247845,0.0017135905,0.00003262814,0.000030589144,0.000040110546,0.0001693349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98959994,0.0049362574,0.0037183135,0.00064318965,0.00062241877,0.00047988808],"domain_scores_gemma":[0.9851136,0.008067703,0.0046458505,0.0009230022,0.0006470925,0.00060271187],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00608375,0.00029118,0.002369185,0.00017963717,0.00013099368,0.000024360428,0.0005239346,0.0005499871,0.00017630389],"category_scores_gemma":[0.0071661985,0.00016497099,0.0007215004,0.00030819,0.00035944706,0.00012780406,0.0001853245,0.0024923098,0.00035516624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009835404,0.0068080355,0.9246157,0.000017716318,0.0021690908,0.004430435,0.00008135494,0.0000024364713,0.0008950946,0.000072594135,0.0038523723,0.047219757],"study_design_scores_gemma":[0.017035084,0.060709916,0.8972303,0.00008993557,0.0015116417,0.0034623577,0.00043795345,0.00009593804,0.000017554787,0.00007978329,0.019216703,0.00011281904],"about_ca_topic_score_codex":0.00024604614,"about_ca_topic_score_gemma":0.00012277927,"teacher_disagreement_score":0.053901877,"about_ca_system_score_codex":0.00031094067,"about_ca_system_score_gemma":0.0017053965,"threshold_uncertainty_score":0.99980897},"labels":[],"label_agreement":null},{"id":"W2947377968","doi":"10.1200/jco.2019.37.15_suppl.9561","title":"Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Gastroenterology; Adverse effect; Melanoma; Rash; Immunotherapy; Cancer","score_opus":0.018448734506566245,"score_gpt":0.327820990103751,"score_spread":0.30937225559718473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947377968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771094,0.00032221407,0.000032801334,0.00079688674,0.00036986553,0.0004507863,0.000004359727,0.0000034462073,0.00030869746],"genre_scores_gemma":[0.9980782,0.00046745906,0.000814948,0.00038386032,0.000029084917,0.0000015459444,0.0000098209275,0.000021141339,0.00019389068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700814,0.0004191304,0.001861738,0.00018870854,0.0003575972,0.00016468651],"domain_scores_gemma":[0.99707055,0.00081949425,0.0016316602,0.00015824188,0.00021009258,0.00010996206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025137626,0.00017110254,0.0012605555,0.00014596534,0.000018024097,0.000002445853,0.000066236156,0.0001756211,0.00022293265],"category_scores_gemma":[0.0002115583,0.0001059345,0.00017137018,0.00013953114,0.00018767177,0.00013351357,0.000016048247,0.0005406974,0.0000011793958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18475506,0.0012751926,0.7829176,0.000048838676,0.0008686264,0.00003212809,0.0001539684,0.0000942174,0.00013405917,0.0000089890445,0.000013890278,0.029697392],"study_design_scores_gemma":[0.07779602,0.034674544,0.8856844,0.00042313573,0.00019538582,0.000049004837,0.00014875722,0.0005377982,0.0000139908625,0.000017923387,0.00035532308,0.00010373192],"about_ca_topic_score_codex":0.00006195577,"about_ca_topic_score_gemma":0.000027182126,"teacher_disagreement_score":0.10695904,"about_ca_system_score_codex":0.00012377185,"about_ca_system_score_gemma":0.00039104174,"threshold_uncertainty_score":0.43198836},"labels":[],"label_agreement":null},{"id":"W2947381343","doi":"10.1200/jco.2019.37.15_suppl.1041","title":"Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Population; Letrozole; Breast cancer; Interim analysis; Hazard ratio; Cancer; Chemotherapy regimen; Adverse effect; Oncology; Confidence interval; Clinical trial; Tamoxifen","score_opus":0.12992821335902252,"score_gpt":0.5039471352598323,"score_spread":0.37401892190080976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947381343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981476,0.00070510095,0.000026071591,0.0072509376,0.0009132257,0.0010348976,0.00014342827,0.0000030877068,0.00010847009],"genre_scores_gemma":[0.9983141,0.0003492466,0.00025108893,0.0005497081,0.0004513381,0.00001627738,0.0000096623035,0.00001665691,0.000041935607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99490756,0.0010291196,0.003064105,0.0002193963,0.0005809675,0.00019885032],"domain_scores_gemma":[0.9921175,0.0028294814,0.0039951047,0.00059919566,0.00038802094,0.00007069831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014576886,0.00018768474,0.0016139161,0.00006749228,0.000036104913,0.0000035185362,0.00045554395,0.00013577788,0.00013305772],"category_scores_gemma":[0.00038977075,0.00008398024,0.0004199955,0.00024840646,0.00027672056,0.00010453116,0.000059498903,0.0005077093,0.0000015027985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12686187,0.026198154,0.37525618,0.00004509062,0.0016547472,0.00004382568,0.012903607,0.0027390444,0.006205142,0.000048196624,0.00021157885,0.44783258],"study_design_scores_gemma":[0.08244193,0.027340233,0.8740312,0.00033591824,0.0004988083,0.000048425303,0.007352756,0.00021621127,0.0003057355,0.00017697515,0.0071683126,0.000083508065],"about_ca_topic_score_codex":0.0019792046,"about_ca_topic_score_gemma":0.002672599,"teacher_disagreement_score":0.498775,"about_ca_system_score_codex":0.00043323514,"about_ca_system_score_gemma":0.0004911428,"threshold_uncertainty_score":0.3424615},"labels":[],"label_agreement":null},{"id":"W2947385567","doi":"10.1200/jco.2019.37.15_suppl.3573","title":"Chemoradiotherapy for anal cancer: A population-based study of treatment interruption, treatment completion, and associated outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Chemoradiotherapy; Proportional hazards model; Hazard ratio; Cancer registry; Internal medicine; Population; Anal cancer; Cancer; Surgery; Urology; Oncology; Confidence interval","score_opus":0.19686097664842014,"score_gpt":0.5061143188030429,"score_spread":0.30925334215462275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947385567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611086,0.00014436802,0.000019883873,0.0026628666,0.00036907964,0.0006335197,0.000013146854,0.0000047165004,0.000041589134],"genre_scores_gemma":[0.9987727,0.000086583874,0.00022280474,0.00042456758,0.00020035342,0.000016469601,0.00001122509,0.000009340993,0.00025596176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981454,0.00015226363,0.0013072039,0.00013854759,0.00014936378,0.0001072467],"domain_scores_gemma":[0.99724495,0.0010282448,0.0011422525,0.00008959378,0.00035455215,0.00014037547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056839344,0.00011777983,0.0016601254,0.00010135449,0.000024688437,0.0000037687864,0.000041051393,0.0001217637,0.00010594929],"category_scores_gemma":[0.00027478393,0.00007073414,0.0003978733,0.000077318604,0.000030435152,0.000028585335,0.000005545999,0.00010834613,6.285706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004041996,0.0053472235,0.9627209,0.0000127539815,0.00082677836,0.000011931883,0.00018632779,0.000060266644,0.00010859313,0.00000707858,0.000048209004,0.026627984],"study_design_scores_gemma":[0.028370164,0.10115563,0.86719674,0.000032789914,0.00051413866,0.0000087896215,0.0001695883,0.00094436423,0.000016180258,0.000026425603,0.0015144736,0.000050732804],"about_ca_topic_score_codex":0.0006141416,"about_ca_topic_score_gemma":0.0013052485,"teacher_disagreement_score":0.09580841,"about_ca_system_score_codex":0.0007398869,"about_ca_system_score_gemma":0.00061123044,"threshold_uncertainty_score":0.28844544},"labels":[],"label_agreement":null},{"id":"W2947388394","doi":"10.1200/jco.2019.37.15_suppl.2009","title":"NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; Hôtel-Dieu de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Neurocognitive; Internal medicine; Clinical endpoint; Randomized controlled trial; Cumulative incidence; Radiosurgery; Oncology; Radiation therapy; Confidence interval; Surgery; Cohort; Cognition","score_opus":0.0558983452086749,"score_gpt":0.43508885214524395,"score_spread":0.3791905069365691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947388394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681814,0.00010187339,0.0007168625,0.02517236,0.001496312,0.0037909327,0.00009941924,0.00001284438,0.0004280305],"genre_scores_gemma":[0.9866004,0.00006604655,0.00084419176,0.011083703,0.0008882835,0.0001225928,0.000047777135,0.000042545256,0.00030448413],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929841,0.0019096519,0.0033411826,0.0005210111,0.00075078744,0.00049327314],"domain_scores_gemma":[0.9890934,0.0067829075,0.002365884,0.00024388384,0.0011001208,0.000413793],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044820867,0.00032849188,0.0030481915,0.00085947086,0.000035972567,0.000008818593,0.00019497833,0.00033999223,0.00035128545],"category_scores_gemma":[0.009427959,0.000255698,0.00036880307,0.00089589047,0.00021150481,0.00028599106,0.00009581799,0.0013914328,0.000026090984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83426887,0.012712704,0.024856195,0.00006238108,0.00087883504,0.00033273993,0.0007868127,0.00040529872,0.00054520613,0.00000966533,0.019382095,0.10575921],"study_design_scores_gemma":[0.48404768,0.26437956,0.20685385,0.00066065637,0.00039223197,0.00003889404,0.00050009514,0.00008702097,0.00009356721,0.0000566648,0.042663425,0.00022634966],"about_ca_topic_score_codex":0.000072751776,"about_ca_topic_score_gemma":0.0005780256,"teacher_disagreement_score":0.3502212,"about_ca_system_score_codex":0.00088063226,"about_ca_system_score_gemma":0.0017819392,"threshold_uncertainty_score":0.9999895},"labels":[],"label_agreement":null},{"id":"W2947390505","doi":"10.1200/jco.2019.37.15_suppl.6575","title":"Diagnostic and treatment delays in young women with breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Breastfeeding; Obstetrics; Gynecology; Pregnancy; Cancer; Prospective cohort study; Cohort; Young adult; Cohort study; Pediatrics; Internal medicine","score_opus":0.053611685920124816,"score_gpt":0.4353962318566222,"score_spread":0.38178454593649735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947390505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423826,0.0003715377,0.000003428989,0.0038531588,0.00047563502,0.00015946357,0.0000056811864,0.0000023679718,0.00089049677],"genre_scores_gemma":[0.9942978,0.0044328077,0.00010557667,0.0004970384,0.00046468133,0.0000074764257,3.2293426e-7,0.000008726506,0.00018554568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987452,0.000072427385,0.00076643395,0.000114632865,0.00013214222,0.00016916676],"domain_scores_gemma":[0.99793696,0.0011612393,0.00046216798,0.00008263931,0.000090790425,0.0002661848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005565261,0.000084502164,0.0009314479,0.00006678796,0.000008967075,0.0000043426053,0.000037865146,0.00013302448,0.00028028787],"category_scores_gemma":[0.00020381351,0.000046926747,0.0000710205,0.00007073699,0.00007800291,0.00005777182,0.00001239775,0.00034432052,0.0000059125423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047100643,0.0004982036,0.8463612,0.000008693911,0.00013825986,0.00034137993,0.0002532414,0.00001871535,0.000014914394,0.000006903781,0.00010729892,0.14754114],"study_design_scores_gemma":[0.010762527,0.018801104,0.9618806,0.00011731578,0.000109064444,0.000918035,0.0002631253,0.000025786358,0.000002557859,0.000022916149,0.00704565,0.000051295363],"about_ca_topic_score_codex":0.00063986477,"about_ca_topic_score_gemma":0.0018270405,"teacher_disagreement_score":0.14748983,"about_ca_system_score_codex":0.0005089344,"about_ca_system_score_gemma":0.0010256703,"threshold_uncertainty_score":0.30689555},"labels":[],"label_agreement":null},{"id":"W2947393171","doi":"10.1200/jco.2019.37.15_suppl.e23083","title":"Development of a comprehensive prognostic model of lymphedema risk for breast cancer survivors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lymphedema; Breast cancer; Radiation therapy; Proportional hazards model; Supraclavicular lymph nodes; Oncology; Lymph node; Cohort; Secondary lymphedema; Cancer; Internal medicine; Stage (stratigraphy); Surgery","score_opus":0.15001493885184553,"score_gpt":0.4566072008022727,"score_spread":0.30659226195042716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947393171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585813,0.0005540897,0.0013976789,0.0004042114,0.0008210897,0.00048324227,0.000056916146,0.0000034578875,0.00042116165],"genre_scores_gemma":[0.98401535,0.00017713362,0.015117816,0.00027088515,0.0002806435,0.000010675961,0.0000017079336,0.0000126217055,0.0001131665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645495,0.00017167762,0.0027337682,0.00013110685,0.0003522633,0.00015622572],"domain_scores_gemma":[0.9922051,0.0029467605,0.0030651763,0.0001424705,0.0013888174,0.00025169388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013530061,0.000108914326,0.001840148,0.000081019054,0.00001662689,0.0000016445115,0.00012231013,0.00019714734,0.00009152668],"category_scores_gemma":[0.0011624321,0.00007130189,0.00045725526,0.00007221898,0.00010730495,0.00004669515,0.000035208857,0.000040373376,0.000005670709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009447653,0.0028294888,0.9105868,0.0011569231,0.001282826,0.0000146306475,0.0004415222,0.0007521395,0.0011269404,0.00014436898,0.00057314493,0.0716436],"study_design_scores_gemma":[0.019569952,0.0036002803,0.9630367,0.0009927251,0.0013548177,0.000114958486,0.00096594257,0.0074354424,0.00028150674,0.00028562229,0.0022316913,0.00013035462],"about_ca_topic_score_codex":0.000037679893,"about_ca_topic_score_gemma":0.000046263795,"teacher_disagreement_score":0.07151324,"about_ca_system_score_codex":0.000104122366,"about_ca_system_score_gemma":0.0058621042,"threshold_uncertainty_score":0.99977374},"labels":[],"label_agreement":null},{"id":"W2947393358","doi":"10.1200/jco.2013.31.15_suppl.6535","title":"Use and impact of chemotherapy-free intervals in metastatic colorectal cancer in routine practice.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Irinotecan; Oxaliplatin; Bevacizumab; Colorectal cancer; Internal medicine; Chemotherapy; Population; Cancer registry; Cancer; Oncology; Proportional hazards model; Surgery","score_opus":0.13189274433192127,"score_gpt":0.5105341346530632,"score_spread":0.3786413903211419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947393358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778886,0.0016073383,0.0000027895107,0.009598973,0.00019577918,0.00031283326,0.0000063363295,0.000001805995,0.00048531478],"genre_scores_gemma":[0.99302477,0.0046072025,0.001512977,0.0006720102,0.00010976575,0.000014662262,3.5091014e-7,0.000009265055,0.00004897036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754524,0.00032121385,0.001667754,0.000122907,0.0001731425,0.00016974623],"domain_scores_gemma":[0.99503493,0.0031888692,0.0011564506,0.00009330307,0.00038375065,0.00014271897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014936103,0.000117758434,0.0015335411,0.00015303251,0.000008408547,0.000007967952,0.000076921926,0.00011030489,0.00028442574],"category_scores_gemma":[0.007078451,0.000070027,0.00025922622,0.00016290571,0.00016391823,0.00027426187,0.000056543646,0.0004798851,0.0000011310083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008921639,0.0020774384,0.86123925,0.000022275666,0.0009676496,0.00025395985,0.0006762177,0.000014488013,0.00029821557,0.000008087538,0.0011775115,0.12434325],"study_design_scores_gemma":[0.012287182,0.017263984,0.9685388,0.0001477634,0.00021851344,0.0001508175,0.00033008386,0.00012049294,0.00005574875,0.00020547913,0.0006273963,0.00005372906],"about_ca_topic_score_codex":0.0037076818,"about_ca_topic_score_gemma":0.0023346744,"teacher_disagreement_score":0.12428953,"about_ca_system_score_codex":0.00033791587,"about_ca_system_score_gemma":0.00076877547,"threshold_uncertainty_score":0.8474078},"labels":[],"label_agreement":null},{"id":"W2947399181","doi":"10.1200/jco.2019.37.15_suppl.4530","title":"Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Bladder cancer; Cystectomy; Pembrolizumab; Internal medicine; Urology; Carcinoma in situ; Cancer; Surgery; Oncology; Immunotherapy","score_opus":0.04361577754928139,"score_gpt":0.3796368207711966,"score_spread":0.33602104322191517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947399181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98748577,0.00017745642,0.0004344547,0.0042443373,0.0043140454,0.001953935,0.00059243134,0.000024266403,0.0007732968],"genre_scores_gemma":[0.98263,0.00041162485,0.004140409,0.009249687,0.0015911852,0.00010021481,0.00009346358,0.000101652564,0.0016817286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484134,0.0005671677,0.002385577,0.0007137463,0.00081774074,0.00067443226],"domain_scores_gemma":[0.9908495,0.003580774,0.0020857642,0.0005686152,0.0019002989,0.0010150794],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095182157,0.00048384382,0.002727784,0.00027138588,0.00011142633,0.000028884142,0.000405972,0.00068560353,0.0013978952],"category_scores_gemma":[0.0025441807,0.0003288483,0.0007488979,0.00035215847,0.00017068346,0.00023651429,0.00012613308,0.0011772788,0.00023408525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22083983,0.005440312,0.4351757,0.00008614065,0.007695883,0.0006549837,0.0012380817,0.00034610712,0.000948886,0.000028796574,0.061787125,0.26575816],"study_design_scores_gemma":[0.12802765,0.10790681,0.68227386,0.0003635202,0.0034309335,0.00003900165,0.00040206808,0.00005046499,0.001164513,0.00031214915,0.07551645,0.00051260577],"about_ca_topic_score_codex":0.0031347913,"about_ca_topic_score_gemma":0.0021684896,"teacher_disagreement_score":0.26524556,"about_ca_system_score_codex":0.00074079126,"about_ca_system_score_gemma":0.004622179,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W2947403106","doi":"10.1200/jco.2019.37.15_suppl.522","title":"Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Mount Sinai Hospital; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Meta-analysis; Hazard ratio; Breast cancer; Oncology; Randomized controlled trial; Adjuvant; Cochrane Library; Adjuvant therapy; Subgroup analysis; Cancer; Gynecology; Confidence interval","score_opus":0.16269906664943268,"score_gpt":0.46906344444713344,"score_spread":0.30636437779770076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947403106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000065771404,0.9973562,0.000013507702,0.00043258414,0.000105583626,0.0011727748,0.0007640673,0.0000014985103,0.00008806127],"genre_scores_gemma":[0.0012615791,0.9974296,0.00023527612,0.00061452144,0.00014568899,0.00008565997,0.00007121119,0.00003786046,0.000118618096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99390036,0.0013948205,0.003601412,0.00047325867,0.00040164366,0.00022848413],"domain_scores_gemma":[0.9903074,0.0005902697,0.007521392,0.00048367286,0.000913354,0.00018391051],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.001607148,0.00045847354,0.016818853,0.00011854833,0.000022894577,0.000008663567,0.00034098953,0.0005221301,0.00008843768],"category_scores_gemma":[0.00037891098,0.00024178656,0.0034581982,0.00022488057,0.00024029888,0.000011382808,0.00015409227,0.00047532984,0.0000042618044],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004159471,0.0014367043,0.00053034065,0.25820565,0.7181337,0.000019814066,0.000026256379,0.0000016192233,1.2245148e-7,0.000009019395,0.00047179314,0.020749044],"study_design_scores_gemma":[0.001272192,0.0028451453,0.001617797,0.020816656,0.9469475,0.000071593415,0.000010725908,4.5581494e-8,2.3983168e-7,0.000002456655,0.026169214,0.0002464286],"about_ca_topic_score_codex":0.000027886943,"about_ca_topic_score_gemma":0.000059960854,"teacher_disagreement_score":0.237389,"about_ca_system_score_codex":0.00012066998,"about_ca_system_score_gemma":0.0010503744,"threshold_uncertainty_score":0.9977775},"labels":[],"label_agreement":null},{"id":"W2947404045","doi":"10.1200/jco.2019.37.15_suppl.505","title":"Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Internal medicine; Proportional hazards model; Cancer; Gynecology; Prospective cohort study; Hazard ratio; Confidence interval","score_opus":0.031886027855897954,"score_gpt":0.3706999652819637,"score_spread":0.33881393742606575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947404045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927644,0.00047622115,0.000025608955,0.0044217836,0.0004450768,0.0008628663,0.0009826154,0.0000017860198,0.000019651316],"genre_scores_gemma":[0.9979891,0.0011365128,0.00005013639,0.0003808831,0.00025409655,0.0001171528,0.000025880532,0.000016775415,0.000029471465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977937,0.00017676632,0.0012126991,0.0003165839,0.00023865348,0.00026161282],"domain_scores_gemma":[0.99833196,0.0002442356,0.000757406,0.00018451341,0.00037443,0.0001074735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006422689,0.00019923068,0.00090334733,0.00009109021,0.000025793097,0.0000066020093,0.00019061397,0.0001805467,0.000021442936],"category_scores_gemma":[0.000079904436,0.00011749757,0.00014659042,0.0001749972,0.00015084473,0.000017794151,0.0000416827,0.0002691534,2.0613597e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096036196,0.0012129394,0.86378026,0.0000308471,0.00025939103,0.000006281331,0.00015146809,0.00019915051,0.00020442551,0.000002910501,0.00015693936,0.03795921],"study_design_scores_gemma":[0.05550276,0.0052092886,0.9373686,0.00018949839,0.00015818981,0.000022391912,0.000058602018,0.000030875868,0.00007922408,0.000021753927,0.001251297,0.00010756167],"about_ca_topic_score_codex":0.0004842316,"about_ca_topic_score_gemma":0.0022385828,"teacher_disagreement_score":0.07358831,"about_ca_system_score_codex":0.00011337914,"about_ca_system_score_gemma":0.00031652756,"threshold_uncertainty_score":0.47914118},"labels":[],"label_agreement":null},{"id":"W2947404224","doi":"10.1200/jco.2019.37.15_suppl.10036","title":"Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Germ cell tumors; Chemotherapy; Internal medicine; Confidence interval; Oncology","score_opus":0.04817798237975705,"score_gpt":0.4030604489564392,"score_spread":0.35488246657668215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947404224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385315,0.0004080842,0.00012490212,0.0027990616,0.00049365865,0.0013070182,0.000098559896,0.000008945939,0.000906613],"genre_scores_gemma":[0.99334705,0.00002877039,0.0036535333,0.0008457623,0.0007031416,0.000028416105,0.000042269417,0.000025255513,0.0013258075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964301,0.00017665519,0.002393648,0.00026510732,0.0005365985,0.00019789756],"domain_scores_gemma":[0.99321723,0.0014406522,0.0041725636,0.00035392767,0.0005137596,0.0003018601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012610287,0.00017415281,0.001202969,0.000050713617,0.000026270609,0.000011525713,0.0002517034,0.00018709608,0.00033638216],"category_scores_gemma":[0.0022952582,0.000088140376,0.000645857,0.000051007355,0.0001655467,0.0000691111,0.00006233076,0.0004150606,0.00002586602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047410494,0.0030085584,0.9870932,0.00003607198,0.0009772344,0.0012686744,0.000040812723,0.0000072151715,0.00028742765,0.00003704758,0.0006070067,0.0018956724],"study_design_scores_gemma":[0.016145429,0.010331662,0.9658076,0.00023873577,0.0011928561,0.0009630784,0.00006150496,0.00003853233,0.0005151842,0.00029743774,0.004312939,0.00009501735],"about_ca_topic_score_codex":0.0001442196,"about_ca_topic_score_gemma":0.000011746888,"teacher_disagreement_score":0.021285607,"about_ca_system_score_codex":0.00009529294,"about_ca_system_score_gemma":0.0017556193,"threshold_uncertainty_score":0.3683149},"labels":[],"label_agreement":null},{"id":"W2947405348","doi":"10.1200/jco.2019.37.15_suppl.4578","title":"Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; University of Manitoba; Princess Margaret Cancer Centre; BC Cancer Agency; Dalhousie University; University of Calgary","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Proportional hazards model; Internal medicine; Cohort; Nephrectomy; Surgery; Oncology; Expanded access; Urology; Kidney","score_opus":0.061423392041514924,"score_gpt":0.3531500393208842,"score_spread":0.29172664727936926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947405348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98764193,0.00010769925,0.000044305292,0.00026274414,0.00031884978,0.0010990027,0.000014075715,0.000019297699,0.010492101],"genre_scores_gemma":[0.9915773,0.00002598847,0.006962734,0.00050479505,0.00038466233,0.000019241566,0.000042534964,0.00006917722,0.00041352597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951296,0.00088975736,0.0021745546,0.00043773477,0.0008811494,0.00048724463],"domain_scores_gemma":[0.99214685,0.0025582404,0.00265082,0.0003559737,0.0014699203,0.00081822154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010312579,0.00041277547,0.0024720347,0.00030531656,0.000052858442,0.000023769535,0.00022540452,0.00028950666,0.0003171885],"category_scores_gemma":[0.0005674454,0.00023643722,0.0004886493,0.0003616781,0.00041195715,0.00029240444,0.000048612932,0.0012293616,0.000054381773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031130932,0.0043499367,0.9488353,0.000051915642,0.0010547815,0.007790204,0.0002691399,0.00008506976,0.00016894583,0.000007033369,0.0003783177,0.0058784015],"study_design_scores_gemma":[0.054173246,0.080341116,0.8601562,0.00016396341,0.0021372433,0.00047653556,0.00032513862,0.000019359373,0.0010372576,0.000017995688,0.0009219081,0.00023008494],"about_ca_topic_score_codex":0.00015812683,"about_ca_topic_score_gemma":0.00008358039,"teacher_disagreement_score":0.088679165,"about_ca_system_score_codex":0.0004039978,"about_ca_system_score_gemma":0.0023432632,"threshold_uncertainty_score":0.964163},"labels":[],"label_agreement":null},{"id":"W2947417651","doi":"10.1200/jco.2019.37.15_suppl.e17068","title":"Increasing potency and safety of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Ovarian cancer; Doxorubicin; Cancer research; Cancer cell; Peptide; Cancer; Medicine; Pharmacology; Receptor; Cell culture; Biology; Internal medicine; Biochemistry; Chemotherapy","score_opus":0.07427144066241295,"score_gpt":0.44060203216285887,"score_spread":0.3663305915004459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947417651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96977067,0.02670258,0.00050676527,0.0015655631,0.00040914153,0.00068441377,0.00011117223,0.0000016330425,0.00024805125],"genre_scores_gemma":[0.86637783,0.12877223,0.0037291895,0.00022327763,0.00060591544,0.00002942376,0.000023015667,0.000016934262,0.00022217711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802667,0.0002621802,0.0010549327,0.0002220544,0.00020942095,0.00022475836],"domain_scores_gemma":[0.9975787,0.0006987847,0.0010664559,0.00020359928,0.00030598158,0.00014647207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086620305,0.00014290346,0.000816347,0.000029582994,0.00004002452,0.0000053539893,0.00017468234,0.00024039568,0.00009479366],"category_scores_gemma":[0.0003191891,0.0000820389,0.0003419963,0.00009512298,0.0002149504,0.000010214613,0.00003143568,0.00014729488,3.4749272e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05781158,0.002633079,0.16142428,0.000065824715,0.0044295774,0.0000035967569,0.0006695417,0.0002599783,0.07065144,0.000046460726,0.0016842285,0.7003204],"study_design_scores_gemma":[0.082731485,0.068568885,0.19701923,0.00019710141,0.00084083364,0.000042446904,0.0009062606,0.00078842125,0.07510503,0.00046326406,0.57281893,0.0005180924],"about_ca_topic_score_codex":0.003743733,"about_ca_topic_score_gemma":0.00028802175,"teacher_disagreement_score":0.69980234,"about_ca_system_score_codex":0.000089126115,"about_ca_system_score_gemma":0.002212719,"threshold_uncertainty_score":0.56594294},"labels":[],"label_agreement":null},{"id":"W2947426122","doi":"10.1200/jco.2019.37.15_suppl.6595","title":"Incidence and outcome of interval breast cancer among women participating in the provincial population based screening program in Manitoba, Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Breast cancer; Cancer; Cancer registry; Hazard ratio; Confidence interval; Odds ratio; Population; Internal medicine; Gynecology; Breast cancer screening; Oncology; Incidence (geometry); Demography; Obstetrics; Mammography; Environmental health","score_opus":0.18841969922009527,"score_gpt":0.4799339508962928,"score_spread":0.29151425167619754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947426122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699926,0.00005510337,0.000017173128,0.0022325136,0.00023993051,0.00035371564,0.0000035416788,0.0000024259396,0.00009636015],"genre_scores_gemma":[0.9972919,0.000007604494,0.00095176994,0.001470093,0.00023181495,0.0000357342,8.166902e-7,0.0000059603235,0.000004267168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681526,0.0003788192,0.00194856,0.00013647792,0.0004661746,0.00025471507],"domain_scores_gemma":[0.99750024,0.0008576341,0.00121813,0.00010350447,0.00018850801,0.00013197065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004325674,0.00009275986,0.00087492476,0.00009152011,0.000017500437,0.000009073579,0.00015453796,0.0001398543,0.000043361753],"category_scores_gemma":[0.0015205542,0.000060786046,0.00008548409,0.00020416548,0.000072999836,0.00016518969,0.00004053481,0.0007609497,1.9102262e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014179816,0.00014745905,0.89630294,0.000046722686,0.00001797462,0.00015592083,0.00023381003,0.0003289709,0.0000060915977,0.0000055635414,0.000025632326,0.101310946],"study_design_scores_gemma":[0.00256012,0.0019591283,0.9897459,0.0004908851,0.00003951341,0.00005442078,0.001395853,0.003548541,0.000002563312,0.000019504576,0.00012648293,0.000057095313],"about_ca_topic_score_codex":0.39538255,"about_ca_topic_score_gemma":0.83717257,"teacher_disagreement_score":0.44178998,"about_ca_system_score_codex":0.00048138722,"about_ca_system_score_gemma":0.0014701426,"threshold_uncertainty_score":0.60864365},"labels":[],"label_agreement":null},{"id":"W2947430416","doi":"10.1200/jco.2019.37.15_suppl.e18347","title":"Real-world demographic and clinical characteristics of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in the United States (US).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Internal medicine; Lymphoma; Comorbidity; International Prognostic Index; Diagnosis code; Oncology; Population","score_opus":0.035913725050773004,"score_gpt":0.37627531164420264,"score_spread":0.34036158659342963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947430416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974133,0.00008284895,0.0000018486112,0.0012182996,0.00039055548,0.00043985678,0.00002567201,0.0000046036,0.00042301908],"genre_scores_gemma":[0.9889073,0.007562331,0.00029319146,0.0029456422,0.00018034312,0.000005975913,0.00004651982,0.000017707764,0.000041015595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954844,0.00085080334,0.0027487318,0.0002239487,0.00041966562,0.0002724163],"domain_scores_gemma":[0.98866814,0.008152105,0.0021864485,0.00029601023,0.00041384075,0.00028343056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029153388,0.00018591696,0.001721623,0.00029026822,0.000027897519,0.000011338306,0.0001787226,0.00026756356,0.000027421873],"category_scores_gemma":[0.0009793855,0.00009537987,0.00034535475,0.0003910566,0.00026273416,0.00006740773,0.000056209316,0.00045769304,0.000007176379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004055911,0.05252862,0.92804205,0.000044974833,0.00029095574,0.0006122981,0.00015892614,3.662873e-7,6.590328e-7,0.00006383993,0.00044822876,0.013753145],"study_design_scores_gemma":[0.08468486,0.017888183,0.8795419,0.00016325341,0.0005431747,0.000025118525,0.0001591191,0.00007444119,0.0000031392592,0.000032381035,0.016799383,0.00008505326],"about_ca_topic_score_codex":0.00019449781,"about_ca_topic_score_gemma":0.00039857536,"teacher_disagreement_score":0.080628954,"about_ca_system_score_codex":0.0000846255,"about_ca_system_score_gemma":0.0005193525,"threshold_uncertainty_score":0.3889478},"labels":[],"label_agreement":null},{"id":"W2947430871","doi":"10.1200/jco.2019.37.15_suppl.3035","title":"Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Colorectal cancer; Oncology; Adiponectin; Cancer; Hazard ratio; Confounding; Prospective cohort study; Cohort; Progression-free survival; Insulin; Chemotherapy; Insulin resistance; Confidence interval","score_opus":0.08814053796606491,"score_gpt":0.4175538381733434,"score_spread":0.3294133002072785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947430871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959549,0.0009708986,0.000014590875,0.0013351425,0.0004281937,0.00084435026,0.0003217092,0.000009992036,0.00012025969],"genre_scores_gemma":[0.9962226,0.0014599026,0.0018468193,0.00019738883,0.0001834211,0.000014547456,0.00003104461,0.000021768834,0.000022477821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958372,0.0005157374,0.0024507835,0.00036600063,0.0005415712,0.00028872004],"domain_scores_gemma":[0.9940698,0.0021396258,0.0026055628,0.00015876252,0.0004516141,0.0005746049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018116343,0.00022010531,0.0017867252,0.00017517369,0.000045854045,0.000014208906,0.000116282165,0.0002780622,0.000025799256],"category_scores_gemma":[0.004346643,0.0001480091,0.00017399184,0.00030665015,0.00025266333,0.00027640845,0.00006693543,0.0010418372,0.0000022426245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010015132,0.0011392278,0.9775775,0.00008481041,0.00049243384,0.00021749869,0.00046625355,0.00000397733,0.001680957,0.000026340995,0.000050225215,0.0082456255],"study_design_scores_gemma":[0.0144142825,0.006997284,0.97612333,0.00049701694,0.0005421654,0.000015662925,0.0001378681,0.00021021426,0.0005112211,0.00020006474,0.00020052546,0.00015033815],"about_ca_topic_score_codex":0.00061219494,"about_ca_topic_score_gemma":0.00042824855,"teacher_disagreement_score":0.008095288,"about_ca_system_score_codex":0.00019708321,"about_ca_system_score_gemma":0.0016705705,"threshold_uncertainty_score":0.6035636},"labels":[],"label_agreement":null},{"id":"W2947433692","doi":"10.1200/jco.2020.38.15_suppl.tps6596","title":"ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–Phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Northeast Cancer Centre; Health Sciences North","funders":"","keywords":"Mucositis; Medicine; Head and neck cancer; Chemoradiotherapy; Placebo; Cisplatin; Radiation therapy; Internal medicine; Cancer; Gastroenterology; Chemotherapy; Surgery; Urology; Oncology; Pathology","score_opus":0.1208178825276187,"score_gpt":0.5027613591483789,"score_spread":0.3819434766207602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947433692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144644,0.00076711096,0.00014234852,0.015148785,0.00085979904,0.0015927274,0.0000093814215,0.0000070485157,0.000026364227],"genre_scores_gemma":[0.97156155,0.0014026016,0.023232885,0.002702914,0.00095600076,0.000080968726,0.000007869299,0.000030918534,0.000024282028],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966464,0.00027396847,0.0021574474,0.00030719367,0.00029034383,0.000324655],"domain_scores_gemma":[0.99732345,0.00062072097,0.0012548756,0.0001085584,0.0002022059,0.00049020693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012116986,0.00018022482,0.0018297266,0.0001172394,0.000030694973,0.000007251071,0.000078123856,0.00020099115,0.000035044293],"category_scores_gemma":[0.00064540334,0.00013393554,0.00013702046,0.00024431525,0.000117362804,0.0001776407,0.000015222566,0.00067835284,8.254385e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43361664,0.0028153912,0.09537122,0.00014026603,0.00010860385,0.00030372184,0.00032903254,0.00010841746,0.000018227973,0.0000017642643,0.00036244938,0.46682426],"study_design_scores_gemma":[0.62775147,0.17823769,0.18656187,0.0006786469,0.00020168761,0.00010098201,0.00014578097,0.000677974,0.000050702158,0.000039622075,0.005406667,0.00014687965],"about_ca_topic_score_codex":0.00012214419,"about_ca_topic_score_gemma":0.0006623666,"teacher_disagreement_score":0.4666774,"about_ca_system_score_codex":0.00086449954,"about_ca_system_score_gemma":0.0017250681,"threshold_uncertainty_score":0.5461733},"labels":[],"label_agreement":null},{"id":"W2947440045","doi":"10.1200/jco.2019.37.15_suppl.554","title":"Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Exome sequencing; Internal medicine; Cancer; Digital polymerase chain reaction; Copy number analysis; Exome; Chemotherapy; Population; Cohort; Mutation; Copy-number variation; Genetics; Gene; Genome; Biology; Polymerase chain reaction","score_opus":0.046394274262798976,"score_gpt":0.45771201654683535,"score_spread":0.4113177422840364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947440045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879767,0.000336672,0.000009409659,0.010058078,0.00058348884,0.00039349584,0.000018409288,0.0000031356935,0.0006206231],"genre_scores_gemma":[0.994627,0.0010671327,0.00076735055,0.002116489,0.00079889194,0.000019938105,3.6492878e-7,0.000030558243,0.00057228975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997049,0.0001887107,0.0017366457,0.00022760939,0.00042342595,0.00037462063],"domain_scores_gemma":[0.99799275,0.00038685906,0.0005677921,0.00022531734,0.00034581852,0.0004814444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028968037,0.00013830357,0.0015571548,0.00018742618,0.000009122995,0.000007306344,0.00016509993,0.00037822503,0.0012829154],"category_scores_gemma":[0.00030443963,0.00010347181,0.0001801572,0.00019503303,0.00015995969,0.00007381281,0.0000712528,0.0010369682,0.000012857438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013811044,0.00049669965,0.8064897,0.00012929508,0.00018351935,0.00019348598,0.0024206068,0.00003355118,0.00096879754,0.0000041854073,0.00036765158,0.17490144],"study_design_scores_gemma":[0.010251316,0.011162822,0.96856856,0.00023780852,0.00003252509,0.00048981747,0.00057322707,0.000056829656,0.00008908042,0.00007590703,0.0083757965,0.0000862987],"about_ca_topic_score_codex":0.00014637077,"about_ca_topic_score_gemma":0.0010126142,"teacher_disagreement_score":0.17481513,"about_ca_system_score_codex":0.0014080259,"about_ca_system_score_gemma":0.0031421082,"threshold_uncertainty_score":0.99963003},"labels":[],"label_agreement":null},{"id":"W2947442453","doi":"10.1200/jco.2019.37.15_suppl.e18273","title":"Lack of clinician knowledge of human papillomavirus (HPV) vaccination to prevent HPV-related cancers in men: An interview study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vaccination; Cervical cancer; Family medicine; HPV vaccines; Human papillomavirus; Health care; Cancer; Public health; Disease; HPV infection; Gynecology; Nursing; Immunology; Internal medicine","score_opus":0.29104063080584003,"score_gpt":0.5963573114512065,"score_spread":0.3053166806453665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947442453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605473,0.00080388144,0.000004197751,0.0015704741,0.0006241223,0.0008843483,0.0000027574683,0.000004252176,0.035558667],"genre_scores_gemma":[0.9979562,0.00051579234,0.00008581919,0.0005029654,0.00029798018,0.000007719038,0.0000022493405,0.000018224235,0.00061306084],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99335897,0.0014684243,0.0042208587,0.00025812426,0.00044419526,0.00024943257],"domain_scores_gemma":[0.99566096,0.0010787109,0.0015095967,0.00033033206,0.0010079542,0.00041243972],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009708357,0.00013857246,0.0022207324,0.00035711483,0.000015807587,0.0000038660237,0.0003526603,0.00032580763,0.0066664317],"category_scores_gemma":[0.0014250956,0.00010419909,0.00041525112,0.0004545996,0.00007464873,0.000106942905,0.0001404813,0.0011587603,0.000034990495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046072723,0.011204256,0.1630244,0.00031681758,0.0003899244,0.00005819377,0.0018623737,0.000039004943,0.0003478761,0.000103265535,0.0009037692,0.81714284],"study_design_scores_gemma":[0.01171619,0.06496589,0.9167009,0.00013324601,0.00018177356,0.000009240766,0.0012315164,0.000113090675,0.00023437402,0.00030460226,0.0043213167,0.00008784861],"about_ca_topic_score_codex":0.0003289289,"about_ca_topic_score_gemma":0.0032325347,"teacher_disagreement_score":0.817055,"about_ca_system_score_codex":0.0005117859,"about_ca_system_score_gemma":0.0017263634,"threshold_uncertainty_score":0.9942416},"labels":[],"label_agreement":null},{"id":"W2947444428","doi":"10.1200/jco.2019.37.15_suppl.5023","title":"Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Incidence (geometry); Cancer; Urology; Oncology","score_opus":0.08928748551687671,"score_gpt":0.42942383229262193,"score_spread":0.3401363467757452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947444428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966303,0.000951824,0.000013496715,0.0012938862,0.00017815645,0.00078732055,0.00001870337,0.0000038546586,0.00012247569],"genre_scores_gemma":[0.9949328,0.0035646653,0.0009348074,0.00024882215,0.00011644746,0.000011740634,0.000020266949,0.000017775115,0.00015269894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732536,0.00032748724,0.0014546836,0.00019446769,0.0004750729,0.00022294116],"domain_scores_gemma":[0.9967411,0.0013750204,0.0010684477,0.0001422199,0.00049643114,0.00017673508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016826397,0.00014222576,0.0010556938,0.00018648893,0.000029556451,0.000011036338,0.00007974383,0.00012421647,0.00008030739],"category_scores_gemma":[0.0004887711,0.000087747176,0.00010978607,0.00018408863,0.00021150327,0.00016026433,0.00002526033,0.00047190188,0.0000023418045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037794646,0.0013843345,0.8686858,0.00012615857,0.00040110867,0.00012217944,0.0006218376,0.00024791964,0.0006590672,0.0000151259055,0.00009821288,0.08984363],"study_design_scores_gemma":[0.052080527,0.016752843,0.9278311,0.0004534715,0.00014006422,0.000022121521,0.0002557097,0.0004506374,0.0007701259,0.000051349045,0.0010941245,0.00009791834],"about_ca_topic_score_codex":0.00018268115,"about_ca_topic_score_gemma":0.0003101624,"teacher_disagreement_score":0.089745715,"about_ca_system_score_codex":0.00025638062,"about_ca_system_score_gemma":0.0017944418,"threshold_uncertainty_score":0.3578226},"labels":[],"label_agreement":null},{"id":"W2947449715","doi":"10.1200/jco.2019.37.15_suppl.2599","title":"A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Ottawa; University of Alberta; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nausea; Avelumab; Adverse effect; Vomiting; Oncology; Gastroenterology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.047685911572707365,"score_gpt":0.39437321195440667,"score_spread":0.3466873003816993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947449715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964267,0.00005020588,0.000018520359,0.001773716,0.00045842232,0.0009780588,0.0000011715986,0.0000025110417,0.0002906946],"genre_scores_gemma":[0.998197,0.000022051054,0.0007131849,0.000881506,0.000041938194,0.0000063687185,6.231122e-7,0.000012890058,0.00012441666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763507,0.00028408924,0.0013235743,0.00015296717,0.0004385247,0.00016574828],"domain_scores_gemma":[0.997465,0.0005034344,0.0013372686,0.00020756463,0.0003945348,0.00009218653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013081843,0.000109088076,0.000905383,0.00013650033,0.000023342809,0.000004734644,0.00018476523,0.000114452596,0.00005572972],"category_scores_gemma":[0.0003609193,0.000055982364,0.00012968128,0.00026703742,0.00008882941,0.000079938894,0.0000389273,0.000413129,0.0000028271568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039208066,0.0043960973,0.9013287,0.000023974846,0.00029052893,0.000028122968,0.0013314362,0.000049442708,0.0005426477,0.0000038727007,0.000080051796,0.05271708],"study_design_scores_gemma":[0.04602148,0.06167794,0.88943607,0.0004253974,0.00013090062,0.000018581015,0.0007212872,0.0000108622135,0.00015142947,0.00002054829,0.0013170486,0.00006845041],"about_ca_topic_score_codex":0.00006581252,"about_ca_topic_score_gemma":0.00040648394,"teacher_disagreement_score":0.05728184,"about_ca_system_score_codex":0.0002146003,"about_ca_system_score_gemma":0.00064140145,"threshold_uncertainty_score":0.22828946},"labels":[],"label_agreement":null},{"id":"W2947454850","doi":"10.1200/jco.2019.37.15_suppl.e14585","title":"Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; KRAS; PTEN; Serous fluid; CDKN2A; Clear cell; Carcinosarcoma; ARID1A; Oncology; Endometrial cancer; Internal medicine; Germ cell tumors; Cancer research; Cancer; PI3K/AKT/mTOR pathway; Carcinoma; Chemotherapy; Colorectal cancer; Biology","score_opus":0.15547059204170982,"score_gpt":0.4855170319560759,"score_spread":0.33004643991436605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947454850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912822,0.000131307,0.00002781913,0.003619116,0.00077107706,0.0005586225,0.000006739563,0.0000027339875,0.0036003883],"genre_scores_gemma":[0.9965234,0.000103083905,0.0011507195,0.00200342,0.00016907667,0.0000086311875,0.0000036013598,0.0000066882844,0.000031395248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967739,0.00030567814,0.0021456596,0.00022947551,0.00037117247,0.00017412653],"domain_scores_gemma":[0.9948423,0.0028517675,0.0015620815,0.00031298053,0.00023176444,0.00019910155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029241988,0.000118850134,0.0022412182,0.00030821707,0.00000803486,0.0000030398928,0.00011952121,0.00033994613,0.0009806614],"category_scores_gemma":[0.0022656263,0.00007799072,0.001118476,0.00045509255,0.00007858141,0.000040005994,0.000018844903,0.00058226875,0.000009028161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11156982,0.006163996,0.8569585,0.000034153847,0.0013070257,0.00077339046,0.000025261157,0.002725198,0.000021598249,0.00008641202,0.00023259592,0.02010206],"study_design_scores_gemma":[0.15446532,0.049262177,0.79163873,0.00008245974,0.0017701156,0.0000063400894,0.000044045704,0.0010627758,0.00010995663,0.00019189995,0.0012932924,0.000072870826],"about_ca_topic_score_codex":0.00008642972,"about_ca_topic_score_gemma":0.0002403634,"teacher_disagreement_score":0.06531974,"about_ca_system_score_codex":0.0008724072,"about_ca_system_score_gemma":0.0028223149,"threshold_uncertainty_score":0.9999326},"labels":[],"label_agreement":null},{"id":"W2947469974","doi":"10.1200/jco.2019.37.15_suppl.500","title":"Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Internal medicine; Oncology; Trastuzumab emtansine; Taxane; Docetaxel; Breast cancer; Regimen; Chemotherapy; Carboplatin; Cancer; Cisplatin","score_opus":0.17629281528993362,"score_gpt":0.5137821301172162,"score_spread":0.33748931482728256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947469974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614625,0.0005350732,0.0000138027135,0.0347909,0.0012109741,0.0012200132,0.00038811678,0.0000151606,0.00036349113],"genre_scores_gemma":[0.9941573,0.0015592267,0.00031207505,0.0016613106,0.0019130361,0.000019147677,0.000023654004,0.000058727317,0.00029552006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992639,0.0012897287,0.0037680555,0.0007191418,0.0009526671,0.0006314124],"domain_scores_gemma":[0.9887299,0.008062184,0.0015433498,0.0004163123,0.000614609,0.0006336715],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003970052,0.00042902646,0.0027486496,0.00020047989,0.00014174898,0.000051067655,0.0004008832,0.00047474814,0.0012168195],"category_scores_gemma":[0.002666686,0.00027398628,0.00033284942,0.00029016822,0.00063265115,0.00022083899,0.00014248688,0.0028057164,0.000012802249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2141978,0.008102491,0.49348944,0.00006747232,0.001399631,0.001587486,0.004596338,0.0000074505083,0.0010868117,0.000013848994,0.0054704566,0.2699808],"study_design_scores_gemma":[0.14098868,0.029831447,0.8226999,0.0002707746,0.0002669458,0.00024970167,0.0015049983,0.0001654012,0.000060889004,0.00002584607,0.0036919566,0.00024343781],"about_ca_topic_score_codex":0.003923988,"about_ca_topic_score_gemma":0.0026742436,"teacher_disagreement_score":0.3292105,"about_ca_system_score_codex":0.0010283509,"about_ca_system_score_gemma":0.0021820762,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W2947471957","doi":"10.1200/jco.2019.37.15_suppl.e20611","title":"A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Curcumin; Lung cancer; Cancer; Population; Pharmacology; Sorafenib; Erlotinib; Oncology; Internal medicine; Epidermal growth factor receptor","score_opus":0.03614944452226873,"score_gpt":0.44511968807369545,"score_spread":0.40897024355142675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947471957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886758,0.0005067988,0.0036199447,0.0012654478,0.0016779592,0.0033146904,0.000109393884,0.0000031850657,0.00082681444],"genre_scores_gemma":[0.9919269,0.00040906703,0.0046564653,0.00041466096,0.0016767104,0.00026524952,0.000042119827,0.000031255804,0.0005775511],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664825,0.00015352057,0.0022408285,0.0004308238,0.00023932816,0.0002872477],"domain_scores_gemma":[0.9956474,0.0005031908,0.0024584439,0.00037225927,0.0006956634,0.00032306783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002172996,0.00019661088,0.0012894729,0.000064334774,0.000044382916,0.00001444098,0.00068479084,0.0005167347,0.000058178237],"category_scores_gemma":[0.0012115302,0.00015684981,0.00049603597,0.0001720746,0.00024120926,0.000014869123,0.00028066547,0.0004189953,0.0000038031499],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15754561,0.0117323445,0.014735498,0.0001855196,0.0007480587,0.000026946656,0.00011167438,0.0001138019,0.75073344,0.00013829354,0.011475135,0.052453697],"study_design_scores_gemma":[0.37014705,0.06729021,0.002991144,0.00016473744,0.00070030696,0.00003070712,0.00017410949,0.00063178287,0.33101422,0.00029565868,0.22610308,0.00045699306],"about_ca_topic_score_codex":0.000037748676,"about_ca_topic_score_gemma":0.000043954886,"teacher_disagreement_score":0.41971922,"about_ca_system_score_codex":0.00015688514,"about_ca_system_score_gemma":0.0029882723,"threshold_uncertainty_score":0.639615},"labels":[],"label_agreement":null},{"id":"W2947481805","doi":"10.1200/jco.2019.37.15_suppl.10005","title":"Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children’s Oncology Group (COG).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Discontinuation; Hazard ratio; Internal medicine; Cumulative incidence; Confidence interval; Asparaginase; Context (archaeology); Cog; Randomization; Incidence (geometry); Clinical trial; Pediatrics; Lymphoblastic Leukemia; Leukemia; Cohort","score_opus":0.09600367879032529,"score_gpt":0.4987552018245681,"score_spread":0.40275152303424283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947481805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861831,0.00012383783,0.00006911321,0.009829046,0.0007960425,0.0007100548,0.000014246443,0.0000067917763,0.0022677567],"genre_scores_gemma":[0.99579394,0.00012585605,0.00086787203,0.0019462446,0.001079068,0.0000071488735,0.000028511566,0.000026484802,0.00012484791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933857,0.0010951125,0.0040253797,0.000331747,0.0007801722,0.00038193638],"domain_scores_gemma":[0.9858706,0.009576844,0.0032742848,0.0005999184,0.00033250815,0.00034582586],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00677546,0.00020692096,0.0022442439,0.00021183421,0.00001901399,0.000009270547,0.0004389463,0.00059517974,0.0003744884],"category_scores_gemma":[0.014395286,0.00010994427,0.0008941234,0.00022209327,0.00026333283,0.00013296393,0.00012961961,0.0021761197,0.00007945553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006814592,0.0048541143,0.9437285,0.0000045323627,0.00092309417,0.0019118958,0.00023270606,0.000073897136,0.00016936912,0.00004562506,0.0036913815,0.037550278],"study_design_scores_gemma":[0.01969735,0.0290023,0.94651353,0.00011956377,0.00030719777,0.0015870314,0.0000688452,0.00019247095,0.000014764306,0.0002553284,0.0021506362,0.000090999645],"about_ca_topic_score_codex":0.000896361,"about_ca_topic_score_gemma":0.00018759159,"teacher_disagreement_score":0.037459277,"about_ca_system_score_codex":0.0013839244,"about_ca_system_score_gemma":0.004795281,"threshold_uncertainty_score":0.99390686},"labels":[],"label_agreement":null},{"id":"W2947482799","doi":"10.1200/jco.2019.37.15_suppl.9014","title":"A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Lung cancer; Gastroenterology; Interim analysis; Response Evaluation Criteria in Solid Tumors; Biomarker; Phases of clinical research; Progression-free survival; Stage (stratigraphy); Oncology; Randomized controlled trial; Cancer; Immunotherapy; Clinical trial; Overall survival","score_opus":0.03816719068031371,"score_gpt":0.40792299775776353,"score_spread":0.3697558070774498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947482799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873433,0.0017584242,0.00007706542,0.00015515054,0.0019132299,0.008419235,0.00003456804,0.000020271478,0.00027875378],"genre_scores_gemma":[0.9978328,0.00033673758,0.00022868555,0.00020253423,0.00024875428,0.000136757,0.0000138058,0.000065662025,0.000934311],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934505,0.0010265955,0.0038263914,0.00052636035,0.000698847,0.00047125464],"domain_scores_gemma":[0.98886216,0.005155126,0.0039612446,0.0004308013,0.0012536905,0.00033698394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045388867,0.00041807548,0.0042845695,0.0002736375,0.00010704829,0.000026085925,0.00025711127,0.00034691612,0.0001943133],"category_scores_gemma":[0.00087077694,0.00027438675,0.0006570784,0.00027466138,0.000276561,0.00021599987,0.000081673395,0.0006851032,0.0000024835606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8686751,0.023066219,0.089876235,0.00033950416,0.0039189872,0.00008533798,0.0019509185,0.000018678222,0.00030047397,5.539975e-7,0.00127646,0.010491491],"study_design_scores_gemma":[0.8598092,0.11260597,0.018411163,0.00022607775,0.004175437,0.000010335483,0.0016644263,0.0013258267,0.000037838687,0.0000015823287,0.0014642284,0.00026787637],"about_ca_topic_score_codex":0.0009020496,"about_ca_topic_score_gemma":0.0006314191,"teacher_disagreement_score":0.08953975,"about_ca_system_score_codex":0.0005806678,"about_ca_system_score_gemma":0.0017395384,"threshold_uncertainty_score":0.99997085},"labels":[],"label_agreement":null},{"id":"W2947494310","doi":"10.1200/jco.2019.37.15_suppl.3094","title":"A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Medicine; Tolerability; Toxicity; Pharmacokinetics; Dosing; Internal medicine; Prostate cancer; Adverse effect; Phases of clinical research; Gastroenterology; Urology; Cancer","score_opus":0.03546129956307053,"score_gpt":0.4211166670666374,"score_spread":0.3856553675035669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947494310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647844,0.0006938605,0.000015208297,0.00062526815,0.0011359827,0.0003039115,0.0000099558665,9.404482e-7,0.00073642045],"genre_scores_gemma":[0.99635154,0.0018915167,0.00042489392,0.00033560733,0.0008896456,0.000010014501,0.0000046212576,0.0000150801725,0.00007709818],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772274,0.00012054274,0.001568696,0.00021916324,0.0001560511,0.00021281734],"domain_scores_gemma":[0.99792266,0.00033315312,0.001236756,0.00020465204,0.00017661767,0.00012618219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011074644,0.00012488833,0.0008988468,0.00009494589,0.000018032622,0.000004143049,0.0002104938,0.0003109244,0.000035590787],"category_scores_gemma":[0.0007496083,0.000100429635,0.00020241525,0.00011515043,0.00011015524,0.0000074493537,0.00008508707,0.00039529873,9.961034e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5264957,0.022677623,0.15825856,0.0001853071,0.0005193412,0.0005133762,0.00041406995,0.011583338,0.14696069,0.00041257465,0.00339712,0.1285823],"study_design_scores_gemma":[0.5095701,0.28844443,0.026211744,0.00038860334,0.00012079147,0.000047675298,0.00018408005,0.00011333233,0.023929548,0.00034215083,0.15020102,0.0004465122],"about_ca_topic_score_codex":0.00010353718,"about_ca_topic_score_gemma":0.003425244,"teacher_disagreement_score":0.2657668,"about_ca_system_score_codex":0.00007849287,"about_ca_system_score_gemma":0.0015055384,"threshold_uncertainty_score":0.40954015},"labels":[],"label_agreement":null},{"id":"W2947496453","doi":"10.1200/jco.2019.37.15_suppl.541","title":"Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Tolerability; Adverse effect; Internal medicine; Clinical endpoint; Dosing; VO2 max; Cancer; Surgery; Heart rate; Blood pressure","score_opus":0.031577592902537734,"score_gpt":0.35310982591609197,"score_spread":0.3215322330135542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947496453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128306,0.00051192584,0.00009199495,0.00043173038,0.0037861962,0.0036278376,0.0000032293192,0.000008631263,0.00025539577],"genre_scores_gemma":[0.99703735,0.00034188345,0.00019290649,0.0006954383,0.0013022238,0.00007975974,0.000004076359,0.000034458695,0.00031191215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943284,0.0016586287,0.0026682774,0.0002974445,0.0007373212,0.00030996557],"domain_scores_gemma":[0.99210864,0.00484845,0.001890127,0.0002690913,0.00062799273,0.0002557165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006853623,0.000243789,0.0067504356,0.00023036642,0.00003604961,0.000005903628,0.000118883574,0.00041486532,0.00013293752],"category_scores_gemma":[0.0020104612,0.00013421923,0.0018693057,0.00025237256,0.00014114531,0.00010163788,0.000029798488,0.0009201278,0.0000056560334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712287,0.0014658523,0.008610151,0.00013189416,0.003293692,0.000109103006,0.000389202,0.0012343529,0.00007163183,0.0000015925034,0.000077437595,0.013386388],"study_design_scores_gemma":[0.9404759,0.02990183,0.02396841,0.0010953553,0.002766417,0.000036965295,0.000115617935,0.00068975595,0.0000406059,0.00000241337,0.0007701981,0.00013653337],"about_ca_topic_score_codex":0.00029601908,"about_ca_topic_score_gemma":0.00020363981,"teacher_disagreement_score":0.030752806,"about_ca_system_score_codex":0.00040075864,"about_ca_system_score_gemma":0.002020036,"threshold_uncertainty_score":0.5473301},"labels":[],"label_agreement":null},{"id":"W2947501186","doi":"10.1200/jco.2019.37.15_suppl.e17105","title":"Clinical outcomes of postoperative intraperitoneal chemotherapy for patients with early-stage high-grade serous ovarian cancer (HGSC) treated at British Columbia cancer agency.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Chemotherapy; Ovarian cancer; Retrospective cohort study; Stage (stratigraphy); Internal medicine; Oncology; Serous fluid; Cohort; Cancer; Surgery","score_opus":0.04794476041468461,"score_gpt":0.41216069356467455,"score_spread":0.36421593314998996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947501186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883546,0.00028744276,0.0000087620965,0.00752922,0.0019738663,0.001388671,0.00030901385,0.000011451795,0.00013693077],"genre_scores_gemma":[0.98630285,0.0029856307,0.002272709,0.004735474,0.00055026246,0.00008844058,0.000024588731,0.00005640167,0.0029836656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995636,0.000313475,0.0027703103,0.0004461508,0.00046377216,0.00037031967],"domain_scores_gemma":[0.9943239,0.0016483506,0.002271451,0.00028697768,0.0010301997,0.00043910058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000917759,0.00023110076,0.0029516849,0.000053666725,0.000070862436,0.000032444874,0.00018717344,0.000529711,0.0021194383],"category_scores_gemma":[0.00030720164,0.00019316621,0.0007557908,0.00015239826,0.00028714098,0.00013331529,0.00003974632,0.0006065953,0.0000057474017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064747897,0.0056334175,0.88797873,0.000038786537,0.0031519146,0.00015096221,0.00012475289,0.000011291838,0.000011737691,0.000007962376,0.004877276,0.09153835],"study_design_scores_gemma":[0.048655294,0.031000145,0.8917635,0.00023942464,0.00084731536,0.000020358488,0.000020385762,0.000011601905,0.000036866306,0.000018067689,0.027212987,0.00017406447],"about_ca_topic_score_codex":0.020587822,"about_ca_topic_score_gemma":0.033586577,"teacher_disagreement_score":0.09136428,"about_ca_system_score_codex":0.00054286816,"about_ca_system_score_gemma":0.0017767097,"threshold_uncertainty_score":0.99879277},"labels":[],"label_agreement":null},{"id":"W2947502981","doi":"10.1200/jco.2019.37.15_suppl.9584","title":"An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Adverse effect; Incidence (geometry); Internal medicine; Stage (stratigraphy); Clinical endpoint; Melanoma; Oncology; Clinical trial; Surgery; Cancer","score_opus":0.06504591594462274,"score_gpt":0.4566494913299082,"score_spread":0.39160357538528545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947502981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981808,0.000090237634,0.000014126434,0.0007794664,0.00043083128,0.0002926627,0.000013673476,0.0000074682957,0.0001907065],"genre_scores_gemma":[0.9970481,0.0009855125,0.00054225733,0.0006163764,0.00016500484,0.0000012393477,0.000019394862,0.000014116475,0.0006080466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99453294,0.0011295453,0.0033461016,0.0002545278,0.00050702406,0.00022986786],"domain_scores_gemma":[0.9914011,0.004062662,0.0035565447,0.00025880206,0.0004594622,0.00026143895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008383447,0.00013861271,0.0022663283,0.00042213572,0.000018080496,0.0000036092563,0.00015299393,0.0006065898,0.0004964359],"category_scores_gemma":[0.0030596482,0.00008786324,0.00047511738,0.0007811562,0.00013763149,0.00015146002,0.00002695285,0.000878699,0.000004696889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09451724,0.0024593426,0.8893131,0.000022020185,0.0036235347,0.00015879699,0.0001435489,0.000040280644,0.0008412485,0.0000016872701,0.00010899394,0.008770179],"study_design_scores_gemma":[0.040809613,0.02294206,0.9305799,0.000121330144,0.0014796088,0.00001583564,0.00031224146,0.0013383598,0.000034153974,0.0000020873974,0.0022716399,0.000093151815],"about_ca_topic_score_codex":0.0001998645,"about_ca_topic_score_gemma":0.0013905856,"teacher_disagreement_score":0.053707626,"about_ca_system_score_codex":0.00029345145,"about_ca_system_score_gemma":0.0013112988,"threshold_uncertainty_score":0.5435625},"labels":[],"label_agreement":null},{"id":"W2947511888","doi":"10.1200/jco.2019.37.15_suppl.4030","title":"A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Capecitabine; Tolerability; Immunogenicity; HER2/neu; Internal medicine; Trastuzumab; Cancer; Oncology; Peptide vaccine; Chemotherapy; Gastroenterology; Breast cancer; Adjuvant; Antibody; Immunology; Epitope; Adverse effect; Colorectal cancer","score_opus":0.07432630902825714,"score_gpt":0.4537691023314801,"score_spread":0.37944279330322295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947511888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722993,0.00017423966,0.000020243866,0.00088910264,0.00038980175,0.0011326205,0.0000114567565,0.0000043255955,0.00014830282],"genre_scores_gemma":[0.99614215,0.00008075167,0.0016374488,0.0006037478,0.0002234923,0.000007951791,0.000003117468,0.000032229145,0.0012691277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994746,0.0008224584,0.002677526,0.00030306357,0.001070937,0.00037997792],"domain_scores_gemma":[0.9945061,0.0019179136,0.0022319928,0.00037983133,0.00068903796,0.0002751031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016715295,0.00025314474,0.002248877,0.00021326863,0.00004773126,0.000007723237,0.0003713755,0.00014094397,0.00059459865],"category_scores_gemma":[0.00093456946,0.00011719439,0.00035206167,0.0004346955,0.00017755732,0.00017537871,0.0001188572,0.0012213307,0.000004370726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19947243,0.018217308,0.75711524,0.00019334919,0.00072742644,0.00038764306,0.0006216722,0.00020984128,0.00049340504,0.000003039703,0.00035597317,0.02220265],"study_design_scores_gemma":[0.092857845,0.10925408,0.79495776,0.00036227205,0.00025796428,0.0001351314,0.0009321195,0.00028098284,0.00021614159,0.000012165,0.00063990755,0.00009360596],"about_ca_topic_score_codex":0.00012925784,"about_ca_topic_score_gemma":0.00019849774,"teacher_disagreement_score":0.10661458,"about_ca_system_score_codex":0.00017792977,"about_ca_system_score_gemma":0.0017138874,"threshold_uncertainty_score":0.65104383},"labels":[],"label_agreement":null},{"id":"W2947522903","doi":"10.1200/jco.2019.37.15_suppl.e12100","title":"Comparative efficacy of neoadjuvant to adjuvant chemotherapy for the treatment of early-stage HER2 negative breast cancer: A population-based analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Chemotherapy; Stage (stratigraphy); Cancer; Population; Neoadjuvant therapy; Surgery","score_opus":0.06254262448780375,"score_gpt":0.4487971389834127,"score_spread":0.386254514495609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947522903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480224,0.0007482024,0.00055527914,0.0027317812,0.00031764145,0.00058401556,0.00022146881,0.0000016182945,0.000037733742],"genre_scores_gemma":[0.9970079,0.00087350624,0.0012576295,0.00040043186,0.0003179308,0.00003191539,0.000014527689,0.000011641197,0.00008450889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979655,0.00019996963,0.0012623746,0.00022560492,0.00018012716,0.00016639516],"domain_scores_gemma":[0.99575454,0.0015813626,0.0017383408,0.00026818892,0.00055334996,0.0001042155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044849623,0.00017426178,0.0015987841,0.000082182385,0.00003660647,0.0000037941306,0.00019731863,0.00015057992,0.00005413531],"category_scores_gemma":[0.000116517884,0.000101057725,0.0009167734,0.00020694874,0.00012844852,0.000004755624,0.00002020205,0.00008727305,0.000001159343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0239453,0.0034371454,0.8842242,0.000017446973,0.011094536,0.0000027295218,0.0008030774,0.016529074,0.00092299347,0.00002410516,0.00037118729,0.0586282],"study_design_scores_gemma":[0.010075751,0.011730235,0.96760637,0.000023900144,0.0011374574,0.0000019862603,0.00018890845,0.00023263675,0.0037741575,0.00001153783,0.0051236097,0.00009343898],"about_ca_topic_score_codex":0.001357957,"about_ca_topic_score_gemma":0.0013074977,"teacher_disagreement_score":0.083382174,"about_ca_system_score_codex":0.00011300058,"about_ca_system_score_gemma":0.0005446186,"threshold_uncertainty_score":0.41210145},"labels":[],"label_agreement":null},{"id":"W2947529777","doi":"10.1200/jco.2019.37.15_suppl.tps5609","title":"NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Oncology; Ovarian cancer; Clinical endpoint; Endometrial cancer; Randomized controlled trial; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","score_opus":0.21656716718570007,"score_gpt":0.4681063172353258,"score_spread":0.25153915004962574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947529777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897263,0.0016626731,0.00016104974,0.0027337067,0.0022724003,0.0030070047,0.0000096061685,0.000010536291,0.00041671525],"genre_scores_gemma":[0.9973121,0.000955571,0.0005080074,0.0005984389,0.0003801032,0.000114975286,0.0000031577254,0.000028354149,0.000099277386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99130255,0.0028980316,0.0041014017,0.00035946342,0.0009477477,0.00039077943],"domain_scores_gemma":[0.98667,0.008135397,0.0039440203,0.0002933739,0.0006262471,0.00033095406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013413241,0.00028906955,0.004602538,0.000432872,0.00008519793,0.00002645737,0.00024265853,0.0001576635,0.0003174983],"category_scores_gemma":[0.0041325246,0.000158096,0.00052693236,0.0005620355,0.0006693681,0.00017639753,0.000091340946,0.0010605125,0.0000025107388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9294261,0.024578592,0.0050384197,0.0001401064,0.00295406,0.0001366646,0.0067718388,0.00019065714,0.0010382136,0.00005776162,0.00021174565,0.029455893],"study_design_scores_gemma":[0.8796871,0.1077991,0.0023063333,0.00062476395,0.001761932,0.0001645729,0.0040985635,0.0010995946,0.0001559842,0.000111053625,0.0020157464,0.00017529391],"about_ca_topic_score_codex":0.00009426274,"about_ca_topic_score_gemma":0.00013465401,"teacher_disagreement_score":0.083220504,"about_ca_system_score_codex":0.00095700286,"about_ca_system_score_gemma":0.0010925512,"threshold_uncertainty_score":0.6446968},"labels":[],"label_agreement":null},{"id":"W2947530291","doi":"10.1200/jco.2019.37.15_suppl.9506","title":"Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cabozantinib; Internal medicine; Oncology; Melanoma; Progression-free survival; Chemotherapy; Cancer; Gastroenterology; Cancer research","score_opus":0.07792512973015793,"score_gpt":0.4421275705548288,"score_spread":0.3642024408246709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947530291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240327,0.000614574,0.000015879801,0.0012034497,0.0023501005,0.00082744577,0.0000040879977,0.000003141582,0.0025780506],"genre_scores_gemma":[0.9960995,0.0013437057,0.0019472354,0.00019388061,0.00019216737,0.0000043274777,0.0000036245694,0.000015424497,0.00020013501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99503654,0.0012556469,0.0029974987,0.00018966151,0.0003194725,0.00020118077],"domain_scores_gemma":[0.9864165,0.010388055,0.0026012561,0.00018227966,0.00024557448,0.00016632536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058593783,0.00017041707,0.004472722,0.00017964165,0.000009742879,0.000002416797,0.000112835,0.00042555385,0.00027566636],"category_scores_gemma":[0.0039936635,0.0001143582,0.00071535894,0.00011348783,0.00042131467,0.00007814773,0.00003536483,0.0006801007,0.000007726316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.855862,0.003152945,0.12799035,0.000049937204,0.0020420193,0.00025219913,0.00015113247,0.000004687702,0.00012730858,0.00030111137,0.000050460007,0.010015823],"study_design_scores_gemma":[0.9199373,0.027517023,0.04937107,0.000100488745,0.0011736351,0.00009427214,0.00009700499,0.00012881386,0.00018316066,0.0005459198,0.00077410485,0.00007717699],"about_ca_topic_score_codex":0.000054538083,"about_ca_topic_score_gemma":0.000038009857,"teacher_disagreement_score":0.07861928,"about_ca_system_score_codex":0.000056130542,"about_ca_system_score_gemma":0.0010537872,"threshold_uncertainty_score":0.47810766},"labels":[],"label_agreement":null},{"id":"W2947532401","doi":"10.1200/jco.2019.37.15_suppl.e12019","title":"Impact of treatment on patient-reported pain and fatigue in early breast cancer patients receiving adjuvant radiotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Univariate analysis; Quality of life (healthcare); Radiation therapy; Chemotherapy; Stage (stratigraphy); Cancer; Oncology; Multivariate analysis","score_opus":0.07559023904211747,"score_gpt":0.45038486610846706,"score_spread":0.3747946270663496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947532401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767226,0.00020996323,0.000014186454,0.0008548155,0.0003600723,0.0005084615,0.000012412729,0.0000032202029,0.00036459503],"genre_scores_gemma":[0.9982306,0.00054359966,0.0004473227,0.0005992691,0.00008687675,0.0000051070724,0.000002857276,0.000015894371,0.00006852584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655074,0.00066410855,0.0020765346,0.00018745703,0.00033436346,0.0001868119],"domain_scores_gemma":[0.9959879,0.0012269376,0.002067303,0.00018727666,0.0002395942,0.00029102436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019477748,0.00015195353,0.0014104807,0.00021396759,0.0000086998325,0.000004801672,0.000063145584,0.00012667086,0.00030774885],"category_scores_gemma":[0.0011684884,0.00009474651,0.0003708303,0.000118590004,0.00006716114,0.000081090126,0.000017453456,0.00029434418,0.0000017021001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005597457,0.00301714,0.64206606,0.000025600417,0.0005787819,0.000104500155,0.00019489067,0.000059427693,0.00003202004,0.0000017850036,0.00022613519,0.3480962],"study_design_scores_gemma":[0.01738554,0.05656764,0.92455536,0.00032887375,0.0002384127,0.000015525386,0.00005126002,0.00036267898,0.0000030755687,0.000018100447,0.00040344129,0.00007010043],"about_ca_topic_score_codex":0.0003074387,"about_ca_topic_score_gemma":0.00002781499,"teacher_disagreement_score":0.3480261,"about_ca_system_score_codex":0.00048880547,"about_ca_system_score_gemma":0.0007901185,"threshold_uncertainty_score":0.38636506},"labels":[],"label_agreement":null},{"id":"W2947533513","doi":"10.1200/jco.2019.37.15_suppl.e20667","title":"Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Progressive disease; Response Evaluation Criteria in Solid Tumors; Histology; Stage (stratigraphy); Metastasis; Disease; Cancer","score_opus":0.039780566048534166,"score_gpt":0.3993018404263666,"score_spread":0.35952127437783243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947533513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195,0.003096526,3.5014867e-7,0.0029610335,0.0010769059,0.0007403302,0.000023707245,0.0000055730675,0.00014561138],"genre_scores_gemma":[0.9974835,0.0013279244,0.00010982198,0.0006120074,0.00024036983,0.000011517794,0.00000803101,0.000018584411,0.0001882529],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99550086,0.0008694086,0.0027753895,0.00023916413,0.00038907,0.00022610422],"domain_scores_gemma":[0.99509245,0.0019100866,0.0021538127,0.0002498285,0.00024056631,0.00035325316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028659115,0.00020298059,0.0015376956,0.0002898385,0.000021495107,0.000005970742,0.00008983938,0.0002250038,0.00017321887],"category_scores_gemma":[0.002617832,0.00012833033,0.00063187256,0.00017191705,0.00032250263,0.00009576242,0.000039350973,0.0004247881,0.00000784445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4731587,0.0064974516,0.46269348,0.000055648637,0.0008246624,0.00054763944,0.0003169216,0.000007152589,0.0033006095,0.000005116619,0.0002829858,0.05230963],"study_design_scores_gemma":[0.034840386,0.08773282,0.860577,0.00063422084,0.0003744921,0.000039509014,0.00015848732,0.0000087257295,0.0024380973,0.000028612942,0.013062882,0.00010479904],"about_ca_topic_score_codex":0.00006824573,"about_ca_topic_score_gemma":0.000008891418,"teacher_disagreement_score":0.4383183,"about_ca_system_score_codex":0.0004145003,"about_ca_system_score_gemma":0.001774875,"threshold_uncertainty_score":0.52331585},"labels":[],"label_agreement":null},{"id":"W2947545307","doi":"10.1200/jco.2019.37.15_suppl.6078","title":"Impact of antiviral prophylaxis in HSV positive patients treated with concurrent chemoradiotherapy for head and neck cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Mucositis; Medicine; Head and neck cancer; Internal medicine; Chemoradiotherapy; Incidence (geometry); Radiation therapy; Cancer; Surgery; Gastroenterology","score_opus":0.0651689364119741,"score_gpt":0.4803281901546786,"score_spread":0.41515925374270446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947545307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976904,0.00069003185,0.0000038445232,0.0005832163,0.00022882661,0.0005026617,0.000022902348,0.000001771631,0.0002763411],"genre_scores_gemma":[0.99840695,0.0009412308,0.00022202678,0.00019829164,0.00017142923,0.000005989309,0.0000019527624,0.000010324664,0.000041787694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985195,0.00009417337,0.00094567705,0.00013249069,0.00014473656,0.00016342729],"domain_scores_gemma":[0.99803925,0.0005726906,0.00077719096,0.000061771185,0.0004323515,0.00011675714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043371523,0.00010942391,0.0017290337,0.0000758244,0.000011293328,0.0000020856435,0.000041871717,0.000139944,0.000017967148],"category_scores_gemma":[0.00023309927,0.000060764723,0.00021231237,0.00010361387,0.00014324079,0.000059074508,0.000010351235,0.00031665943,3.900107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015844243,0.0012884074,0.8361706,0.000051189523,0.00034785832,0.000016988586,0.00019098316,0.0000015496976,0.00018352525,0.0000027447772,0.00018866516,0.14571323],"study_design_scores_gemma":[0.02737578,0.1418909,0.8295331,0.00036554332,0.00007121933,0.000010907511,0.000021289356,0.0000357773,0.00016434438,0.0000042779484,0.00047309717,0.000053744257],"about_ca_topic_score_codex":0.00015959179,"about_ca_topic_score_gemma":0.00009718744,"teacher_disagreement_score":0.14565948,"about_ca_system_score_codex":0.00020136268,"about_ca_system_score_gemma":0.00092227093,"threshold_uncertainty_score":0.24779135},"labels":[],"label_agreement":null},{"id":"W2947547256","doi":"10.1200/jco.2019.37.15_suppl.e12002","title":"Clinical practice patterns on the use of adjuvant bisphosphonate for early breast cancer: A Canadian perspective.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Breast cancer; Zoledronic acid; Internal medicine; Oncology; Guideline; Adjuvant; Bisphosphonate; Demographics; Family medicine; Cancer; Osteoporosis","score_opus":0.21490745780618845,"score_gpt":0.5219799413298709,"score_spread":0.30707248352368244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947547256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8787704,0.00020355724,0.000012588872,0.117302746,0.0021990654,0.000692226,0.00012517539,0.0000034581617,0.0006907924],"genre_scores_gemma":[0.9728048,0.0014069376,0.0012501649,0.023625609,0.0003965779,0.000011026981,0.0000016397842,0.00002116207,0.00048211942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963972,0.00053287187,0.0021901007,0.00021987065,0.00032465308,0.00033528454],"domain_scores_gemma":[0.9841135,0.011192548,0.0021299801,0.00028089932,0.0014463092,0.0008367586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032484157,0.00013461676,0.0013571631,0.00009497044,0.000048988997,0.0000084358035,0.00014641491,0.00037693162,0.00024666378],"category_scores_gemma":[0.007270317,0.00007491369,0.00060777867,0.000102072605,0.00013109896,0.00013679851,0.000019859115,0.0011790324,0.000037294987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016184153,0.0020185446,0.8722017,0.000025718991,0.0008869694,0.00030907607,0.00014605075,0.0000054196057,0.0000016027361,0.0007024719,0.0073857205,0.1001326],"study_design_scores_gemma":[0.0075513455,0.015367137,0.81251967,0.00018120803,0.0004950706,0.00028586513,0.0002099157,0.00005647258,0.0000032757127,0.000096405354,0.16317655,0.00005710706],"about_ca_topic_score_codex":0.1227045,"about_ca_topic_score_gemma":0.042214017,"teacher_disagreement_score":0.15579084,"about_ca_system_score_codex":0.0004480755,"about_ca_system_score_gemma":0.007067821,"threshold_uncertainty_score":0.9985612},"labels":[],"label_agreement":null},{"id":"W2947547484","doi":"10.1200/jco.2019.37.15_suppl.9577","title":"Prediction of distant melanoma recurrence from primary tumor digital H&amp;E images using deep learning.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Cohort; Melanoma; Hazard ratio; Proportional hazards model; Artificial intelligence; Deep learning; Convolutional neural network; Internal medicine; Confidence interval; Computer science; Cancer research","score_opus":0.0936605936633298,"score_gpt":0.38124786233482677,"score_spread":0.287587268671497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947547484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73040617,0.00033338423,0.26335868,0.00024807325,0.004434391,0.00008283521,0.000007891728,0.000019438978,0.001109129],"genre_scores_gemma":[0.95534366,0.00012369233,0.043706935,0.00012017926,0.0006428902,7.370887e-7,0.0000020765424,0.000009219031,0.000050635],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996844,0.0003800198,0.0018648345,0.0002747423,0.00045589686,0.00018050043],"domain_scores_gemma":[0.9943476,0.0020007521,0.0028449462,0.00028551614,0.00037472695,0.0001464633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017127941,0.00011552755,0.00079766504,0.00010260667,0.00003856429,0.00004922133,0.0006111141,0.0001770032,0.000041585125],"category_scores_gemma":[0.001396873,0.000094632494,0.00028360842,0.00020488995,0.0001467991,0.0010107914,0.00020946414,0.0008968472,0.000024056531],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010051095,0.0006523666,0.2687859,0.000037904923,0.00019311365,0.0000863799,0.00033550456,0.0013380685,0.004381588,0.00012831933,0.0005307181,0.72252506],"study_design_scores_gemma":[0.0065318523,0.020576334,0.8026262,0.0004779179,0.00019868875,0.0007510833,0.00016477992,0.04868437,0.0015240022,0.010985319,0.1070005,0.0004789557],"about_ca_topic_score_codex":0.000019124644,"about_ca_topic_score_gemma":0.0000046389437,"teacher_disagreement_score":0.7220461,"about_ca_system_score_codex":0.00026858377,"about_ca_system_score_gemma":0.00074671797,"threshold_uncertainty_score":0.38964048},"labels":[],"label_agreement":null},{"id":"W2947559705","doi":"10.1200/jco.2019.37.15_suppl.3095","title":"A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Cancer; Bioavailability; Cervical cancer; Internal medicine; Pharmacology; Ovarian cancer; CHEK1; Oncology; Adverse effect; Cell cycle; Cell cycle checkpoint","score_opus":0.04307739164022831,"score_gpt":0.43836247018055424,"score_spread":0.3952850785403259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947559705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353665,0.0002793826,0.000035455578,0.004215499,0.00059103844,0.0010616382,0.00000372557,0.0000070110864,0.00026961506],"genre_scores_gemma":[0.99763876,0.00017788343,0.0014091553,0.00032566086,0.0002967284,0.000035285644,0.0000044686058,0.000031214044,0.00008086199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99625754,0.00029284685,0.0023430604,0.0002900143,0.00047801115,0.0003385318],"domain_scores_gemma":[0.9964205,0.00075240596,0.0020428968,0.00022723527,0.00037683663,0.00018011866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017822264,0.00021576716,0.0021748415,0.00043759338,0.000020739313,0.0000035930043,0.00017233595,0.00026559277,0.000098583674],"category_scores_gemma":[0.00051896734,0.0001514707,0.00015020753,0.0005438652,0.00026039672,0.0003851409,0.000041748997,0.0011805985,0.0000016564092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.675197,0.020517169,0.16731729,0.00017513645,0.00017896057,0.0008494177,0.0007322447,0.00185759,0.0024749609,0.00011033132,0.00002602533,0.13056387],"study_design_scores_gemma":[0.65812325,0.17725766,0.15798052,0.0017147753,0.00008807395,0.000093195325,0.0002941782,0.00015180188,0.0006259621,0.0003207408,0.0031660956,0.0001837305],"about_ca_topic_score_codex":0.0002555614,"about_ca_topic_score_gemma":0.0061091464,"teacher_disagreement_score":0.15674049,"about_ca_system_score_codex":0.00064328546,"about_ca_system_score_gemma":0.0018369863,"threshold_uncertainty_score":0.6176796},"labels":[],"label_agreement":null},{"id":"W2947561786","doi":"10.1200/jco.2019.37.15_suppl.e18322","title":"Implementation of malignant bowel obstruction multidisciplinary case conferences (MCCs) to improve clinical decision making in malignant bowel obstruction (MBO) in gynecologic oncology.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intestinal and Peritoneal Adhesions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bowel obstruction; Gynecologic oncology; Ovarian cancer; Colorectal cancer; General surgery; Cancer; Surgery; Internal medicine","score_opus":0.11295317720063716,"score_gpt":0.501789195893384,"score_spread":0.38883601869274687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947561786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905056,0.000083779916,0.00020384802,0.0023513532,0.0054546786,0.00091077684,0.000012209508,0.000011122745,0.0004666813],"genre_scores_gemma":[0.97867346,0.00029098825,0.019720327,0.000542841,0.00066661777,0.000018961282,0.000005872654,0.000019451807,0.000061477665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909759,0.001080762,0.0064786174,0.00053497,0.0004637029,0.0004660293],"domain_scores_gemma":[0.98913443,0.0064899656,0.0031366523,0.0002822213,0.0005891376,0.00036760542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007362307,0.00027056827,0.0021562576,0.0005556736,0.00006522765,0.000012037931,0.00023873638,0.0008610178,0.00045455698],"category_scores_gemma":[0.0045075784,0.00019472261,0.0005488804,0.00038248228,0.00024067213,0.00024047015,0.00020299522,0.0016411631,0.000042275213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006595187,0.0014891939,0.63971454,0.00005566747,0.000063749016,0.0049850876,0.0003702899,0.00012564257,0.00265094,0.00012320511,0.000113751055,0.34371272],"study_design_scores_gemma":[0.008893534,0.03473455,0.9388304,0.0006361701,0.00017476846,0.0060573337,0.0061490056,0.0011191603,0.00036600474,0.0017656318,0.0010729433,0.0002005047],"about_ca_topic_score_codex":0.00049157615,"about_ca_topic_score_gemma":0.003524774,"teacher_disagreement_score":0.3435122,"about_ca_system_score_codex":0.00058284146,"about_ca_system_score_gemma":0.002354023,"threshold_uncertainty_score":0.79405576},"labels":[],"label_agreement":null},{"id":"W2947564188","doi":"10.1200/jco.2019.37.15_suppl.6530","title":"Association of providers’ prescribing patterns with postsurgical opioid use among cancer patients undergoing curative-intent surgery.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Medicine; Opioid; Medical prescription; Logistic regression; Cancer surgery; Population; Morphine; Internal medicine; Anesthesia; Cancer; Surgery; Pharmacology","score_opus":0.0801336874473683,"score_gpt":0.38509113424384717,"score_spread":0.30495744679647885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947564188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947558,0.00007690563,0.00006387048,0.0023410923,0.0021637937,0.0003018666,0.0000117244235,0.000006838798,0.00027811856],"genre_scores_gemma":[0.9977663,0.00044349182,0.0000641598,0.000814341,0.00033740757,0.0000047914873,0.0000067422284,0.000018634986,0.0005441251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662924,0.00045888877,0.0018071977,0.00019057706,0.0006763156,0.00023776926],"domain_scores_gemma":[0.99026865,0.0048872773,0.0030901728,0.00013730164,0.0013790652,0.0002375529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016582484,0.00013501375,0.0013865515,0.000111353285,0.000021488413,0.000016526194,0.000088503584,0.00029873993,0.00021077995],"category_scores_gemma":[0.002867462,0.000090084184,0.00046849335,0.00012367066,0.00006396723,0.00035505887,0.000040528837,0.0007560268,0.0000032248092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031256685,0.0006976963,0.9861409,0.00010831148,0.00053876743,0.000055570003,0.00051947363,0.000025450687,0.00001943424,0.000007015063,0.001397217,0.0073645064],"study_design_scores_gemma":[0.00474214,0.005788624,0.9824167,0.0010111874,0.00034285992,0.000012996889,0.00046497257,0.00004940179,0.000104712526,0.00000923278,0.0049556987,0.00010146158],"about_ca_topic_score_codex":0.00080907205,"about_ca_topic_score_gemma":0.0045478726,"teacher_disagreement_score":0.007263045,"about_ca_system_score_codex":0.0005141459,"about_ca_system_score_gemma":0.0016704694,"threshold_uncertainty_score":0.36735263},"labels":[],"label_agreement":null},{"id":"W2947568083","doi":"10.1200/jco.2019.37.15_suppl.503","title":"Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Breast cancer; Oncology; Chemotherapy; Adjuvant; Cancer; Gastroenterology","score_opus":0.042866685598706426,"score_gpt":0.4001449851761654,"score_spread":0.357278299577459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947568083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625987,0.0021969453,0.0000027613055,0.0008335861,0.00025754626,0.00025294663,0.00013746977,9.510832e-7,0.000057900317],"genre_scores_gemma":[0.97570664,0.023841426,0.000068443325,0.0001305199,0.00021418523,0.0000117439495,0.0000047713443,0.000010208252,0.000012070155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743605,0.000412792,0.0015859692,0.00025836538,0.0001495083,0.0001573089],"domain_scores_gemma":[0.99738985,0.00064188405,0.0015687089,0.00015920006,0.00015237766,0.00008796777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020870047,0.00014449227,0.0010555353,0.00005552351,0.000015975887,0.000004228082,0.0001406549,0.00033204287,0.000010638158],"category_scores_gemma":[0.00038755254,0.000086935055,0.00025882968,0.000093111565,0.00051230745,0.00001082234,0.000063032996,0.0004726452,2.7696544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011148421,0.00083969894,0.92027587,0.0000133672065,0.0003744,0.0000047217513,0.000114251925,0.000027791544,0.0007573267,0.0000053781832,0.00021909837,0.06621965],"study_design_scores_gemma":[0.0122252675,0.0060932008,0.9807273,0.00009367244,0.00008442981,0.000020435124,0.00003327889,0.000021355147,0.0003721743,0.00011475509,0.00015016836,0.00006396534],"about_ca_topic_score_codex":0.0010346557,"about_ca_topic_score_gemma":0.00040401964,"teacher_disagreement_score":0.06615569,"about_ca_system_score_codex":0.000045332967,"about_ca_system_score_gemma":0.00033586234,"threshold_uncertainty_score":0.35451087},"labels":[],"label_agreement":null},{"id":"W2947568997","doi":"10.1200/jco.2019.37.15_suppl.10016","title":"Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Cumulative incidence; Confidence interval; Incidence (geometry); Relative risk; Population; Internal medicine; Standardized mortality ratio; Absolute risk reduction; Pediatrics; Cancer; Surgery; Cohort","score_opus":0.08578644839533864,"score_gpt":0.47690605348205656,"score_spread":0.39111960508671795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947568997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257326,0.0005287908,0.000010411946,0.004890867,0.00059716054,0.0009751793,0.000031216714,0.000004589364,0.00038852406],"genre_scores_gemma":[0.9957459,0.0022002428,0.00005367909,0.0015240912,0.0003551781,0.000018280582,0.0000056702474,0.00002013734,0.000076832475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938141,0.0015283901,0.0031023794,0.00030797755,0.00076957163,0.00047757907],"domain_scores_gemma":[0.9925389,0.0050004395,0.0015296349,0.00036637843,0.00025169834,0.00031289068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009373111,0.00018910441,0.0020640427,0.00030050852,0.000031785334,0.000009653049,0.00036373117,0.00030122433,0.00014626891],"category_scores_gemma":[0.0013172263,0.00011870641,0.00023514955,0.00047779674,0.00035399583,0.00013132252,0.00012304388,0.0014396535,0.000011669517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094619906,0.0022135933,0.9880594,0.00011547514,0.00084860175,0.0005874301,0.0013918625,0.00031521393,0.000089906476,0.000067293164,0.0002960271,0.0050690225],"study_design_scores_gemma":[0.019634249,0.012612007,0.9647226,0.00024240106,0.00028032518,0.00021705213,0.0006610904,0.0008822488,0.000005767504,0.00016714584,0.00048505273,0.00009005975],"about_ca_topic_score_codex":0.008397115,"about_ca_topic_score_gemma":0.024338588,"teacher_disagreement_score":0.023336774,"about_ca_system_score_codex":0.0024484755,"about_ca_system_score_gemma":0.016656596,"threshold_uncertainty_score":0.9982061},"labels":[],"label_agreement":null},{"id":"W2947570200","doi":"10.1200/jco.2019.37.15_suppl.e15747","title":"Role of neoadjuvant therapy (NAT) in pancreatic adenocarcinoma (PAC): A single center experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Saint-Luc; Université de Montréal; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; FOLFIRINOX; Proportional hazards model; Confidence interval; Univariate analysis; Surgery; Internal medicine; Subgroup analysis; Neoadjuvant therapy; Oncology; Multivariate analysis; Cancer; Oxaliplatin; Colorectal cancer","score_opus":0.13412143525967796,"score_gpt":0.4710290248389366,"score_spread":0.33690758957925865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947570200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806052,0.002680418,0.0000120655895,0.0016702526,0.00039034267,0.0003871881,0.0000016667801,0.000004438094,0.014248448],"genre_scores_gemma":[0.9948723,0.0014560928,0.0016978853,0.0010839353,0.0003569437,0.00000686951,0.0000013900913,0.000015653608,0.00050896726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958287,0.0005984413,0.0025297964,0.00020811391,0.0004819956,0.00035295117],"domain_scores_gemma":[0.9954299,0.0023878817,0.0012059544,0.00029384374,0.00036427772,0.00031818214],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027029505,0.00014120067,0.0024482885,0.00024881822,0.00001513496,0.0000043880955,0.00025311398,0.00043025616,0.0010033442],"category_scores_gemma":[0.0018835986,0.000093746974,0.00041076413,0.00020517316,0.00034216454,0.00010573103,0.00006170672,0.00095411454,0.000052622054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006160751,0.0034434772,0.95254475,0.000026625303,0.00020503098,0.00030456492,0.0009403706,0.0000015648956,0.005271465,0.00007074466,0.00033376177,0.030696878],"study_design_scores_gemma":[0.016046172,0.025946176,0.940622,0.00023674198,0.000088217144,0.0005616876,0.0015924941,0.00024415052,0.0003780424,0.0004365792,0.013763354,0.000084395426],"about_ca_topic_score_codex":0.00006362608,"about_ca_topic_score_gemma":0.00002507935,"teacher_disagreement_score":0.030612482,"about_ca_system_score_codex":0.00018223508,"about_ca_system_score_gemma":0.0015170428,"threshold_uncertainty_score":0.9999099},"labels":[],"label_agreement":null},{"id":"W2947572398","doi":"10.1200/jco.2019.37.15_suppl.e18238","title":"Impact of rates of referral and systemic therapy on 1-year outcomes in metastatic NSCLC: A real-world population based study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Referral; Hazard ratio; Lung cancer; Cancer; Cancer registry; Stage (stratigraphy); Charlson comorbidity index; Cohort; Population; Proportional hazards model; Oncology; Comorbidity; Confidence interval; Family medicine","score_opus":0.10064309205383193,"score_gpt":0.482684941827976,"score_spread":0.38204184977414407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947572398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991523,0.00016673874,0.0000069270527,0.00008471244,0.00022504281,0.00022916071,0.00001152148,5.142911e-7,0.0001231054],"genre_scores_gemma":[0.99909323,0.0004750899,0.00022818413,0.0000940556,0.000068990244,0.0000017169184,0.000005179542,0.000008980784,0.00002458818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805886,0.00032198266,0.0012838992,0.00012527766,0.000116401316,0.00009357743],"domain_scores_gemma":[0.9976681,0.0007797752,0.0011825367,0.00016133895,0.00014531422,0.00006297512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013429003,0.00009174978,0.0008585061,0.00011670744,0.0000059789363,0.0000035119192,0.00009968638,0.000101756,0.000015141149],"category_scores_gemma":[0.00068169454,0.000062388615,0.00023764622,0.00006590814,0.00002952535,0.0000037783589,0.000023501772,0.00016065389,5.693113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028772885,0.0009572632,0.987938,0.0000133778785,0.0002036574,0.0000054823104,0.000026161955,0.00076834275,0.0041056075,0.0000283791,0.000040029,0.0030364166],"study_design_scores_gemma":[0.006186482,0.019489685,0.973663,0.00003890311,0.00003901483,0.0000026602606,0.000059645212,0.000051867988,0.00030735714,0.00005789097,0.00004724761,0.000056298268],"about_ca_topic_score_codex":0.00039647604,"about_ca_topic_score_gemma":0.0005061714,"teacher_disagreement_score":0.018532421,"about_ca_system_score_codex":0.000045382527,"about_ca_system_score_gemma":0.0004669459,"threshold_uncertainty_score":0.2544134},"labels":[],"label_agreement":null},{"id":"W2947581034","doi":"10.1200/jco.2019.37.15_suppl.e15645","title":"Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Discontinuation; Hepatitis C virus; Gastroenterology; Proportional hazards model; Oncology; Hepatitis C; Retrospective cohort study; Liver cancer; Surgery; Immunology; Virus","score_opus":0.10120502116706723,"score_gpt":0.4821976755227777,"score_spread":0.3809926543557105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947581034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496704,0.000051363422,0.0000031366194,0.0003154413,0.00019718392,0.0005708136,0.000006819176,0.0000025577212,0.0038856613],"genre_scores_gemma":[0.99897826,0.00011651298,0.0004863623,0.00012214828,0.000114559276,0.0000034501581,0.0000042036595,0.00001957336,0.0001549562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969497,0.00040360534,0.0016303454,0.00017883416,0.0005632188,0.00027431172],"domain_scores_gemma":[0.99680626,0.0011028936,0.0009726951,0.00027954968,0.000491273,0.00034732363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010640944,0.00014252446,0.0016298067,0.00025291485,0.0000089149635,0.0000025939942,0.00012337726,0.00024156983,0.00031603125],"category_scores_gemma":[0.0010731422,0.00008012504,0.00043391107,0.00018222694,0.00010621503,0.00008156545,0.00002404156,0.0006742536,0.000057282854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017444033,0.004277612,0.8483293,0.000015346846,0.000206699,0.0005049301,0.00005273257,0.000051990908,0.000052172996,0.0000054332086,0.00007162838,0.12898813],"study_design_scores_gemma":[0.025489092,0.14562798,0.8258603,0.000100183766,0.00005319023,0.000007204873,0.000011396728,0.00017333242,0.0000660772,0.000012457814,0.0025418412,0.000056944573],"about_ca_topic_score_codex":0.00014602723,"about_ca_topic_score_gemma":0.00003823015,"teacher_disagreement_score":0.14135036,"about_ca_system_score_codex":0.0007301059,"about_ca_system_score_gemma":0.0024967322,"threshold_uncertainty_score":0.44290957},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2947587841","doi":"10.1200/jco.2019.37.15_suppl.e18378","title":"Do the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale measure <i>Absolute</i> or <i>Relative</i> clinical benefit?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Confidence interval; Mean difference; Clinical trial; Oncology","score_opus":0.12238274238753583,"score_gpt":0.40547733883787174,"score_spread":0.2830945964503359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947587841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93358284,0.008637955,0.0008894984,0.019307606,0.00874627,0.0006157599,0.00007627348,0.0000112263315,0.028132567],"genre_scores_gemma":[0.95964307,0.019777926,0.0048022186,0.010914844,0.0036507377,0.000009001304,0.0000012158116,0.00005226669,0.0011487212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9874953,0.0006423794,0.010484513,0.0006361833,0.00020740615,0.00053424196],"domain_scores_gemma":[0.966556,0.021697117,0.009898713,0.00087275845,0.00050877826,0.00046663938],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.034065902,0.00034302517,0.004633201,0.000112903675,0.0001536944,0.00008195613,0.001237958,0.0014855228,0.0005341501],"category_scores_gemma":[0.017856404,0.00019972079,0.0019303686,0.00026127283,0.0019334784,0.0005467464,0.00034058967,0.0036521165,0.00025880992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072759087,0.0008735039,0.6604675,0.000025574489,0.00088299764,0.000015114222,0.0002583851,0.00013002084,2.3791469e-7,0.23191975,0.0031051561,0.095045835],"study_design_scores_gemma":[0.010934454,0.00435448,0.5944646,0.0001482444,0.00022472299,0.000053700507,0.00013008958,0.00033868745,0.0000014318981,0.20205879,0.18701555,0.00027523367],"about_ca_topic_score_codex":0.00014035127,"about_ca_topic_score_gemma":0.00017345816,"teacher_disagreement_score":0.18391038,"about_ca_system_score_codex":0.00008417622,"about_ca_system_score_gemma":0.00079971954,"threshold_uncertainty_score":0.99981076},"labels":[],"label_agreement":null},{"id":"W2947599368","doi":"10.1200/jco.2019.37.15_suppl.tps9599","title":"ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Internal medicine; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Progressive disease; Combination therapy; Phases of clinical research; Adjuvant therapy; Randomized controlled trial; Gastroenterology; Immunotherapy; Clinical trial; Chemotherapy; Cancer; Cancer research","score_opus":0.02516898557946562,"score_gpt":0.3730638883808516,"score_spread":0.34789490280138596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947599368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578613,0.00081652025,0.00001643667,0.00014769228,0.0004947131,0.002659612,0.0000033998986,0.000010325228,0.00006518064],"genre_scores_gemma":[0.9992579,0.00017992475,0.00021526225,0.00013117933,0.000008749274,0.00007893672,0.000012701649,0.000035471876,0.00007986653],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99317956,0.0033953828,0.0024553672,0.00035412054,0.00023463208,0.0003809272],"domain_scores_gemma":[0.99393904,0.0029533354,0.0023931698,0.00033960043,0.00033413392,0.00004069879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029534944,0.00033648484,0.0032582032,0.00047790588,0.00005158161,0.000010098137,0.00030426343,0.0003635825,0.00013534057],"category_scores_gemma":[0.00036851925,0.0001709822,0.00023688216,0.00037177757,0.00033002126,0.00030412362,0.000038891576,0.0010267333,0.000008849219],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8101145,0.030180143,0.11531681,0.000015392005,0.0010929549,0.00019052492,0.0016185998,0.000064671214,0.0014948935,0.0000033014035,0.0000037929763,0.03990442],"study_design_scores_gemma":[0.5523433,0.13088715,0.31410694,0.0005663245,0.000105881016,0.000023974504,0.0008144506,0.000011534795,0.00077758543,0.000006990393,0.00018458247,0.00017130106],"about_ca_topic_score_codex":0.000026860356,"about_ca_topic_score_gemma":0.000086862856,"teacher_disagreement_score":0.2577712,"about_ca_system_score_codex":0.0001148659,"about_ca_system_score_gemma":0.00056808355,"threshold_uncertainty_score":0.6972451},"labels":[],"label_agreement":null},{"id":"W2947606778","doi":"10.1200/jco.2019.37.15_suppl.9013","title":"KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Université de Sherbrooke","funders":"","keywords":"Pemetrexed; Medicine; Placebo; Oncology; Internal medicine; Pembrolizumab; Carboplatin; Docetaxel; Cisplatin; Chemotherapy; Cancer; Immunotherapy; Alternative medicine","score_opus":0.07164292177969342,"score_gpt":0.40844652258449093,"score_spread":0.33680360080479754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947606778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884267,0.002821524,0.00029445943,0.0056708474,0.0002724879,0.0018478282,0.000012059485,0.000011197629,0.00022691434],"genre_scores_gemma":[0.989855,0.0011466637,0.0063120327,0.0018852891,0.00029605156,0.000046893187,0.000009152551,0.00004477698,0.00040417246],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698955,0.0002778181,0.0016429828,0.00031478418,0.00045745057,0.00031740277],"domain_scores_gemma":[0.99491984,0.002149862,0.0019172115,0.00030427118,0.00048414269,0.00022470343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023566915,0.00029057133,0.0018268119,0.00013063844,0.0000620478,0.00002706209,0.00016963584,0.00027579552,0.000223455],"category_scores_gemma":[0.00031606844,0.00013577867,0.00025820764,0.00022514444,0.0006173302,0.00016111707,0.000045062643,0.00070601853,0.0000014190255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8330375,0.00081574,0.010318985,0.00022578672,0.0015683245,0.00012757197,0.00059367594,0.000017457625,0.0030861115,0.000007143005,0.000837148,0.14936455],"study_design_scores_gemma":[0.5310026,0.21587832,0.17751026,0.0020373922,0.0027228564,0.00438672,0.0016254876,0.0059357127,0.006215976,0.000120268385,0.051772,0.000792444],"about_ca_topic_score_codex":0.000028329963,"about_ca_topic_score_gemma":0.00006716596,"teacher_disagreement_score":0.30203494,"about_ca_system_score_codex":0.00012922222,"about_ca_system_score_gemma":0.0016069725,"threshold_uncertainty_score":0.5536893},"labels":[],"label_agreement":null},{"id":"W2947614825","doi":"10.1200/jco.2019.37.15_suppl.5514","title":"Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, phase II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Ovarian cancer; Debulking; Taxane; Chemotherapy; Internal medicine; Surgery; Cisplatin; Gastroenterology; Cancer; Breast cancer","score_opus":0.07083881081287317,"score_gpt":0.4701139727208219,"score_spread":0.3992751619079487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947614825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9344354,0.0010751188,0.000013224388,0.05776151,0.0030563406,0.0014817939,0.0000057261773,0.0000065898685,0.0021642614],"genre_scores_gemma":[0.983786,0.005142425,0.0011871383,0.007432571,0.0017979678,0.00006179902,0.000002132301,0.000026053707,0.0005639479],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953982,0.00086238654,0.0028316288,0.0002827701,0.00034721868,0.00027779525],"domain_scores_gemma":[0.9952537,0.0024298115,0.0014186302,0.00022774971,0.00031972514,0.00035041198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041807224,0.0002061985,0.003455271,0.00017069426,0.000036344074,0.000015373276,0.00013922068,0.0004152852,0.0016039163],"category_scores_gemma":[0.0009744927,0.00013224213,0.00084413664,0.00018093284,0.00020088021,0.00013524064,0.000030069737,0.0010019497,0.000032526266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8283013,0.011022864,0.0067777843,0.000009790212,0.0010872934,0.0007238442,0.0006585882,0.0000072887933,0.00018228701,0.00029869875,0.0012701348,0.1496601],"study_design_scores_gemma":[0.88906056,0.061472762,0.017383497,0.0001634849,0.0004155792,0.00010578232,0.000065667984,0.000050407834,0.0001786852,0.00016271048,0.030825809,0.00011507492],"about_ca_topic_score_codex":0.00031085563,"about_ca_topic_score_gemma":0.000084392865,"teacher_disagreement_score":0.14954503,"about_ca_system_score_codex":0.0003685062,"about_ca_system_score_gemma":0.002532988,"threshold_uncertainty_score":0.99930876},"labels":[],"label_agreement":null},{"id":"W2947628210","doi":"10.1200/jco.2019.37.15_suppl.e18361","title":"Predictors of financial toxicity among head and neck cancer patients: A prospective cohort study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck cancer; Cohort; Prospective cohort study; Cancer; Internal medicine; Demography","score_opus":0.043303819223111294,"score_gpt":0.35141505309165455,"score_spread":0.3081112338685433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947628210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875063,0.0004739359,0.00001980193,0.00018532138,0.0030151075,0.0005925291,0.000059990893,0.0000042401066,0.008142831],"genre_scores_gemma":[0.9979008,0.0006424164,0.000108185675,0.00042514864,0.0006251459,0.000011313837,8.138884e-7,0.000014981648,0.00027122255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996332,0.00006457216,0.0029988114,0.0003007909,0.00007330948,0.00023049673],"domain_scores_gemma":[0.9950597,0.00034079028,0.0039388677,0.00017088548,0.00028728685,0.00020244265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023771331,0.00014840104,0.001972072,0.00014434142,0.000032901702,0.000014054355,0.00022243055,0.00031810976,0.00023410616],"category_scores_gemma":[0.001928971,0.00013714103,0.0002803549,0.00011751671,0.00021672394,0.00043185428,0.000081183025,0.000558249,0.00002210338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065841957,0.001422058,0.99192554,0.000015626674,0.0002235837,0.000004099112,0.0002559601,0.000024432016,5.556162e-7,0.0013736737,0.0008990737,0.0031969775],"study_design_scores_gemma":[0.0051296507,0.009114304,0.9732615,0.00003351125,0.000044262117,0.0000012385675,0.000027987006,0.000028108238,0.00000507224,0.0021230965,0.010096641,0.00013466652],"about_ca_topic_score_codex":0.0004150831,"about_ca_topic_score_gemma":0.0004136805,"teacher_disagreement_score":0.018664079,"about_ca_system_score_codex":0.00023471647,"about_ca_system_score_gemma":0.00043756515,"threshold_uncertainty_score":0.5592449},"labels":[],"label_agreement":null},{"id":"W2947633439","doi":"10.1200/jco.2019.37.15_suppl.5518","title":"A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Oncology; Olaparib; BRCA mutation; Ovarian cancer; Cancer; Progression-free survival; Placebo; Chemotherapy; Pathology","score_opus":0.04141560706164391,"score_gpt":0.3808206048477158,"score_spread":0.33940499778607186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947633439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922252,0.00027140835,0.00014880128,0.002127646,0.00070476584,0.004342505,0.000048853897,0.0000021069225,0.00012868659],"genre_scores_gemma":[0.99795496,0.0005872137,0.00035741695,0.00032760145,0.00042772925,0.00026685436,0.000009360592,0.000023259945,0.00004557051],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957357,0.00072690647,0.002559739,0.00035740357,0.00030218693,0.0003180694],"domain_scores_gemma":[0.99604374,0.0009433658,0.002277265,0.00026890068,0.00026285625,0.00020386382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046475395,0.00024439226,0.0023441731,0.00016237961,0.0000667106,0.00002100077,0.00029103478,0.00028138122,0.000027317936],"category_scores_gemma":[0.0010891578,0.00014830711,0.0001875992,0.00020775814,0.00023977838,0.0000139037575,0.00013800607,0.00053089904,2.2767212e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9814071,0.0053369557,0.0008439054,0.000018556868,0.00045038047,0.000014326374,0.00031049328,0.00055593956,0.0038368239,0.00008542306,0.000033734203,0.007106329],"study_design_scores_gemma":[0.91249454,0.08205244,0.00037558406,0.00014749292,0.00015933737,0.00000839907,0.00007205361,0.0005469645,0.00051383284,0.000085283755,0.0033630843,0.00018098232],"about_ca_topic_score_codex":0.00019946296,"about_ca_topic_score_gemma":0.0027416172,"teacher_disagreement_score":0.076715484,"about_ca_system_score_codex":0.00014624548,"about_ca_system_score_gemma":0.0018900691,"threshold_uncertainty_score":0.6047788},"labels":[],"label_agreement":null},{"id":"W2947636245","doi":"10.1200/jco.2019.37.15_suppl.6081","title":"Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Post-hoc analysis; Lenvatinib; Refractory (planetary science); Progression-free survival; Oncology; Gastroenterology; Cancer; Overall survival; Confidence interval; Thyroid cancer","score_opus":0.039799942864473185,"score_gpt":0.3822262406669829,"score_spread":0.3424262978025097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947636245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954957,0.0015723935,8.096588e-7,0.0013380122,0.0005756001,0.00067002623,0.00005024836,0.000009965746,0.00028724718],"genre_scores_gemma":[0.9889229,0.007997117,0.00017125523,0.0024864457,0.00014025408,0.00004356324,0.000011353017,0.00002885013,0.00019823774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950678,0.00070657255,0.0029363763,0.00041269194,0.0004466842,0.00042990386],"domain_scores_gemma":[0.9910825,0.005192196,0.0025003743,0.00027857657,0.0005161161,0.00043024097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009771133,0.0003448063,0.0027867001,0.00019624301,0.000040296083,0.0000067820597,0.00013884912,0.00033028887,0.00033347763],"category_scores_gemma":[0.0016055238,0.0002207418,0.00028022318,0.00018885739,0.00026629795,0.0001603335,0.00010210499,0.00096927676,0.000023771336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01544754,0.0056943046,0.94485307,0.00007114634,0.0005809222,0.00029815515,0.0003670161,0.0007344529,0.0014595949,0.000007056872,0.00031633023,0.030170402],"study_design_scores_gemma":[0.031695224,0.06662635,0.8937474,0.00047192958,0.00030462307,0.000056804154,0.00012651432,0.00029732674,0.000971841,0.000004560569,0.0055240276,0.00017343464],"about_ca_topic_score_codex":0.0002790136,"about_ca_topic_score_gemma":0.00058203173,"teacher_disagreement_score":0.06093204,"about_ca_system_score_codex":0.0010024735,"about_ca_system_score_gemma":0.0011162204,"threshold_uncertainty_score":0.90015894},"labels":[],"label_agreement":null},{"id":"W2947642691","doi":"10.1200/jco.2019.37.15_suppl.8502","title":"Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Metformin; Carboplatin; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Lung cancer; Chemoradiotherapy; Chemotherapy; Response Evaluation Criteria in Solid Tumors; non-small cell lung cancer (NSCLC); Paclitaxel; Phases of clinical research; Randomized controlled trial; Cisplatin; Insulin","score_opus":0.04920128483287982,"score_gpt":0.4557763617730748,"score_spread":0.40657507694019496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947642691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9432341,0.050510094,0.0007631022,0.00005689714,0.0036140047,0.00091444276,0.000013815429,0.0000020645055,0.0008914793],"genre_scores_gemma":[0.9478994,0.04830756,0.0014979321,0.0004949017,0.0016024424,0.00004032074,0.000011086197,0.00003126666,0.000115083356],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99070334,0.0007114216,0.007537741,0.0003489436,0.00034518505,0.00035335697],"domain_scores_gemma":[0.9860306,0.0006990587,0.012094824,0.00031911072,0.00064773427,0.00020871808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008873436,0.00025242742,0.003916333,0.00012759633,0.000021780348,0.0000054148522,0.0003759285,0.0005751428,0.00021876761],"category_scores_gemma":[0.003825304,0.00019382466,0.0011517147,0.00014480195,0.00027140492,0.000018011,0.0000794104,0.0006158426,6.726089e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47678745,0.0035715655,0.0015617581,0.00017133792,0.0005780761,0.0000362153,0.00019998723,0.00031740582,0.056341656,0.000014788577,0.0004581599,0.45996162],"study_design_scores_gemma":[0.82785654,0.0125429565,0.00010870052,0.00020865689,0.000343176,0.0000136426415,0.000094250114,0.0004079528,0.12569036,0.00003699823,0.032450788,0.00024600938],"about_ca_topic_score_codex":0.000038112034,"about_ca_topic_score_gemma":0.0000565019,"teacher_disagreement_score":0.4597156,"about_ca_system_score_codex":0.000060094255,"about_ca_system_score_gemma":0.0032734901,"threshold_uncertainty_score":0.790394},"labels":[],"label_agreement":null},{"id":"W2947643418","doi":"10.1200/jco.2019.37.15_suppl.3505","title":"NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Veliparib; Clinical endpoint; Colorectal cancer; Internal medicine; Population; Total mesorectal excision; Hazard ratio; Neoadjuvant therapy; Surgery; Oncology; Randomized controlled trial; Cancer; Confidence interval; Breast cancer","score_opus":0.3052111821451899,"score_gpt":0.5732453887775554,"score_spread":0.2680342066323655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947643418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810207,0.0016873478,0.0000145651165,0.0018432592,0.0099529615,0.0019046861,0.000028554714,0.000030488662,0.0035174622],"genre_scores_gemma":[0.99056894,0.0015877056,0.0017016492,0.0014976915,0.0042972174,0.00004881023,0.000014452599,0.000066752385,0.00021675925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895303,0.000726695,0.007119986,0.0007969438,0.0010549625,0.00077106646],"domain_scores_gemma":[0.9908677,0.0040693358,0.0032233456,0.00045307825,0.00044141448,0.0009451317],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051333574,0.0004991708,0.0039734314,0.0002997629,0.00011620221,0.000025538195,0.00036698396,0.0010760598,0.0010508609],"category_scores_gemma":[0.0031334865,0.0003691825,0.001661942,0.00043234017,0.00048516947,0.00044418353,0.0002436074,0.0027159587,0.000034494733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7037447,0.024784556,0.0066147735,0.000014081836,0.0006442546,0.0028637906,0.000326712,0.0001601558,0.0005691235,0.00001347036,0.000231022,0.26003337],"study_design_scores_gemma":[0.68204755,0.27136326,0.010790489,0.00059063936,0.00024792957,0.00083775097,0.0003021151,0.0015865847,0.0011440867,0.00006796219,0.0305998,0.0004218015],"about_ca_topic_score_codex":0.00016974586,"about_ca_topic_score_gemma":0.00022680359,"teacher_disagreement_score":0.25961158,"about_ca_system_score_codex":0.0014737279,"about_ca_system_score_gemma":0.0047188126,"threshold_uncertainty_score":0.999876},"labels":[],"label_agreement":null},{"id":"W2947644019","doi":"10.1200/jco.2019.37.15_suppl.9022","title":"A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PALB2; FANCA; Population; CHEK2; Cancer; Internal medicine; Oncology; Carboplatin; Cancer research; Chemotherapy; Fanconi anemia; DNA repair; Mutation; Germline mutation; Gene; Cisplatin; Genetics","score_opus":0.034810740560160626,"score_gpt":0.42832962319926315,"score_spread":0.3935188826391025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947644019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994145,0.00041155936,0.000030701838,0.0004761719,0.0015195668,0.0025432585,0.000025915633,0.000021226613,0.00082663127],"genre_scores_gemma":[0.9986898,0.000071425064,0.00018032332,0.0004651289,0.00017716213,0.0000464656,0.000008541098,0.00003685006,0.00032432878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993909,0.0011708785,0.0032147616,0.00046716558,0.00086508424,0.0003731222],"domain_scores_gemma":[0.9933321,0.0012551278,0.0034431822,0.00039821235,0.001315905,0.0002554571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003181413,0.00026905505,0.001944778,0.00040616578,0.00007542734,0.000007329398,0.00023656627,0.00032294486,0.00028556603],"category_scores_gemma":[0.0005421787,0.00020285469,0.00030253537,0.0004517046,0.00017270661,0.00023168189,0.000088183835,0.0013396734,0.000006038074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023484834,0.10596542,0.8624721,0.00008915488,0.0002658013,0.0004260626,0.0023571937,0.0002117497,0.00017185064,0.000008794966,0.0010036172,0.003543428],"study_design_scores_gemma":[0.12902819,0.25653678,0.6114205,0.0001767628,0.00051653234,0.000020236565,0.001386159,0.0002884102,0.00018451907,0.000017233962,0.00023515728,0.00018950575],"about_ca_topic_score_codex":0.000244903,"about_ca_topic_score_gemma":0.0003065105,"teacher_disagreement_score":0.2510516,"about_ca_system_score_codex":0.0009117255,"about_ca_system_score_gemma":0.0017239245,"threshold_uncertainty_score":0.8272174},"labels":[],"label_agreement":null},{"id":"W2947648853","doi":"10.1200/jco.2021.39.6_suppl.276","title":"Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Dalhousie University; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Axitinib; Nivolumab; Internal medicine; Ipilimumab; Oncology; Renal cell carcinoma; Hazard ratio; Population; Cancer; Sunitinib; Immunotherapy; Confidence interval","score_opus":0.14275147815557596,"score_gpt":0.4227383730812307,"score_spread":0.27998689492565476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947648853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94623965,0.0021044237,0.00009838298,0.046817943,0.0019542605,0.00030834207,0.00015332863,0.0000063171988,0.0023173317],"genre_scores_gemma":[0.99013007,0.0015373076,0.005015149,0.0022253243,0.00042252822,0.000010310855,0.00021622403,0.000023135086,0.00041995267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99261546,0.0014258536,0.0045376685,0.000371017,0.00077047275,0.00027950114],"domain_scores_gemma":[0.9792441,0.015541632,0.0033108396,0.0005670237,0.0011229119,0.00021346634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004585856,0.0002566413,0.0021040733,0.00019428198,0.000052571922,0.00001618342,0.00046304052,0.0002866525,0.00036925063],"category_scores_gemma":[0.00788332,0.00015834963,0.0006665591,0.00023569881,0.0004009573,0.00016324641,0.00021738304,0.0011418776,0.00001432112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024741037,0.015406465,0.8932505,0.0000660651,0.0027563113,0.010533386,0.0019494409,0.00014506403,0.0096395565,0.00027594613,0.008893733,0.03234248],"study_design_scores_gemma":[0.042867642,0.008408299,0.90443534,0.00013844232,0.0010184506,0.0004528612,0.001425547,0.00034421458,0.008434808,0.0008006199,0.03151593,0.00015784522],"about_ca_topic_score_codex":0.00046402213,"about_ca_topic_score_gemma":0.0013895516,"teacher_disagreement_score":0.04459262,"about_ca_system_score_codex":0.0004978556,"about_ca_system_score_gemma":0.002444544,"threshold_uncertainty_score":0.943764},"labels":[],"label_agreement":null},{"id":"W2947650008","doi":"10.1200/jco.2019.37.15_suppl.524","title":"De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Cardiotoxicity; Chemotherapy; Stage (stratigraphy); Cancer; Confidence interval","score_opus":0.16155229738912746,"score_gpt":0.4780084247341706,"score_spread":0.31645612734504314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947650008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012384017,0.99601173,0.000029807277,0.00078315625,0.00022395112,0.000751199,0.0008445248,0.000004114201,0.00011309724],"genre_scores_gemma":[0.011026178,0.9870289,0.00022517357,0.00072254654,0.0005659765,0.00010255547,0.0000648914,0.00005526332,0.0002085157],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9913645,0.002755876,0.0044258414,0.0007052127,0.00028481326,0.00046380705],"domain_scores_gemma":[0.9921844,0.0010199298,0.005709687,0.0003615259,0.00042855335,0.0002958741],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026206223,0.0006351132,0.013689095,0.00022310052,0.00006706622,0.000023453149,0.00043599695,0.0009601982,0.0002417225],"category_scores_gemma":[0.00062576536,0.0004172743,0.0046495637,0.00033086055,0.00021041074,0.000017034661,0.00023484236,0.001238095,0.0000058871206],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038037615,0.0011405519,0.014007918,0.02507232,0.45005807,0.0002896679,0.0001324271,0.000012767856,0.000012607322,0.000030091342,0.001401716,0.5074615],"study_design_scores_gemma":[0.0023026257,0.002485599,0.029352691,0.0041931868,0.8143342,0.0010266437,0.000043366388,0.000001230163,0.000003521679,0.000006389435,0.14544548,0.00080506183],"about_ca_topic_score_codex":0.00033546297,"about_ca_topic_score_gemma":0.0002194363,"teacher_disagreement_score":0.5066564,"about_ca_system_score_codex":0.00045062392,"about_ca_system_score_gemma":0.001696951,"threshold_uncertainty_score":0.9998279},"labels":[],"label_agreement":null},{"id":"W2947651192","doi":"10.1200/jco.2019.37.15_suppl.3052","title":"Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clear cell renal cell carcinoma; DNA methylation; Cancer research; Methylation; Medicine; CpG site; Renal cell carcinoma; Computational biology; Epigenomics; Biology; Oncology; DNA; Gene; Genetics; Gene expression","score_opus":0.018643684046578436,"score_gpt":0.30692787385592873,"score_spread":0.2882841898093503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947651192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953765,0.0016384615,0.0003403984,0.00035722883,0.0006007503,0.0002921149,0.0000072411945,0.0000056798476,0.0013815762],"genre_scores_gemma":[0.99137396,0.00054145034,0.007496093,0.00016111157,0.0002134307,0.0000035032826,0.000026274645,0.00003502416,0.0001491317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697727,0.00045248037,0.0015212256,0.0004183439,0.00030141778,0.00032924453],"domain_scores_gemma":[0.9970959,0.00031479495,0.0015202176,0.000433945,0.0004757304,0.00015940536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016547574,0.00022528748,0.0007904248,0.00022051066,0.000046439647,0.000016367945,0.0003636377,0.000887475,0.00002537493],"category_scores_gemma":[0.00044698935,0.00018185646,0.00014078841,0.00022039647,0.00018606297,0.000023989647,0.00019893268,0.0007578908,0.000008288539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004373289,0.0013987584,0.526313,0.00007832045,0.000107995744,0.000047828806,0.00022789539,0.000805263,0.45311502,0.00004100459,0.00033761724,0.013154016],"study_design_scores_gemma":[0.026711257,0.051031575,0.54707205,0.00006506189,0.0002005401,0.000011551475,0.00045367045,0.00017038634,0.3660046,0.0017851843,0.005929829,0.0005642877],"about_ca_topic_score_codex":0.000043441905,"about_ca_topic_score_gemma":0.000048489357,"teacher_disagreement_score":0.08711041,"about_ca_system_score_codex":0.00009945838,"about_ca_system_score_gemma":0.0006523743,"threshold_uncertainty_score":0.7415891},"labels":[],"label_agreement":null},{"id":"W2947653952","doi":"10.1200/jco.2019.37.15_suppl.1031","title":"Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Taxane; Breast cancer; Oncology; Cancer; Endocrinology","score_opus":0.13666957168465982,"score_gpt":0.5087187885674074,"score_spread":0.37204921688274756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947653952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97338,0.00032481123,0.000016360902,0.023915462,0.00054061884,0.0010406664,0.000023586088,0.0000045291977,0.0007539249],"genre_scores_gemma":[0.9950174,0.0026671053,0.00031005728,0.001078446,0.00057399744,0.00002956345,0.0000035359617,0.000015974594,0.00030391314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99482566,0.001602643,0.0023543972,0.00029279903,0.00049314887,0.00043133998],"domain_scores_gemma":[0.9893736,0.008891229,0.0009957822,0.00021410054,0.0002157376,0.00030954322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010092311,0.00020102062,0.0026612815,0.00023445049,0.000047847418,0.000017276097,0.0002067043,0.0003547316,0.00040457206],"category_scores_gemma":[0.0027730847,0.00012071742,0.00017647463,0.00032706102,0.00037553825,0.00014050078,0.00007952866,0.0018689446,0.000007945173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28914434,0.0071074762,0.6474075,0.00012899979,0.0005504646,0.0012922573,0.0008131624,0.000007993874,0.00009226606,0.00006121639,0.0007160353,0.05267833],"study_design_scores_gemma":[0.27417442,0.027453516,0.6916272,0.00021059497,0.000429574,0.00080594094,0.00073833956,0.0016437385,0.000004736389,0.00025127025,0.0025478208,0.00011285081],"about_ca_topic_score_codex":0.0005709571,"about_ca_topic_score_gemma":0.0025825417,"teacher_disagreement_score":0.052565478,"about_ca_system_score_codex":0.0002169313,"about_ca_system_score_gemma":0.0024863384,"threshold_uncertainty_score":0.8119738},"labels":[],"label_agreement":null},{"id":"W2947663188","doi":"10.1200/jco.2019.37.15_suppl.4569","title":"KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Cohort; Chromophobe cell; Pembrolizumab; Renal cell carcinoma; Internal medicine; Population; Clinical endpoint; Histology; Urology; Oncology; Clear cell; Surgery; Cancer; Clinical trial; Immunotherapy","score_opus":0.05779333220240377,"score_gpt":0.39268583742607055,"score_spread":0.33489250522366676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947663188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978568,0.0013126472,0.0009365366,0.0030221706,0.0020894865,0.0017553766,0.000015198604,0.000025494926,0.012275048],"genre_scores_gemma":[0.9757169,0.0010856806,0.01145973,0.002175634,0.0018659137,0.000038118964,0.000020639409,0.000116885545,0.0075204996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938379,0.00033172604,0.0037041951,0.0006580784,0.00074722164,0.0007208867],"domain_scores_gemma":[0.9915169,0.0030576284,0.0028728137,0.00074298086,0.00092732854,0.00088233134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023595428,0.00048503376,0.0031968488,0.00026778708,0.00009411412,0.000021092123,0.0004494961,0.00080959714,0.000582194],"category_scores_gemma":[0.000555399,0.00035828643,0.001752969,0.0002038571,0.00018134443,0.00019321806,0.000087861976,0.0014428163,0.0002431868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20835613,0.014259005,0.635801,0.0009737363,0.0014902911,0.0031482927,0.0004660214,0.0019716476,0.04588577,0.000055239158,0.021261148,0.06633172],"study_design_scores_gemma":[0.14356743,0.16307862,0.4736185,0.00022641754,0.0019046791,0.0007692149,0.00015994468,0.0022800677,0.035219062,0.00030076964,0.17817314,0.0007021342],"about_ca_topic_score_codex":0.000036953687,"about_ca_topic_score_gemma":0.000021887165,"teacher_disagreement_score":0.16218248,"about_ca_system_score_codex":0.000642211,"about_ca_system_score_gemma":0.0020243113,"threshold_uncertainty_score":0.99988693},"labels":[],"label_agreement":null},{"id":"W2947664767","doi":"10.1200/jco.2019.37.15_suppl.4500","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Clinical endpoint; Internal medicine; Axitinib; Oncology; Everolimus; Urology; Surgery; Clinical trial","score_opus":0.10725753453450605,"score_gpt":0.42692863951810667,"score_spread":0.31967110498360063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947664767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049425,0.0006934351,0.00002239079,0.0038658034,0.00131001,0.0030743247,0.00004847293,0.000008240547,0.0004830462],"genre_scores_gemma":[0.99744374,0.00054938253,0.00034763763,0.0010888673,0.00027660443,0.00006480582,0.000012572847,0.000047971283,0.00016843977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99274117,0.0020903493,0.0034819732,0.00040636762,0.00080496,0.00047515967],"domain_scores_gemma":[0.9793314,0.016076917,0.0031453585,0.00067656505,0.00046837554,0.00030138443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052472414,0.0004228741,0.0028766552,0.00024780058,0.000108161235,0.000025041414,0.00066271477,0.0002655042,0.00012193651],"category_scores_gemma":[0.002958346,0.0002097423,0.0010791857,0.0002672973,0.0004363542,0.000120563986,0.00015238917,0.001427798,0.000010817508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25632405,0.025036747,0.6883807,0.00023833982,0.0017963336,0.0012967983,0.003757617,0.000055794153,0.00046015956,0.00009469334,0.00075735745,0.02180138],"study_design_scores_gemma":[0.25449303,0.13413568,0.60354125,0.000077864235,0.0013126476,0.00027609608,0.0025844288,0.00032653662,0.00087240885,0.00029049203,0.001899444,0.00019013185],"about_ca_topic_score_codex":0.00020769381,"about_ca_topic_score_gemma":0.00029440052,"teacher_disagreement_score":0.109098926,"about_ca_system_score_codex":0.00024791033,"about_ca_system_score_gemma":0.0013062158,"threshold_uncertainty_score":0.85530424},"labels":[],"label_agreement":null},{"id":"W2947681396","doi":"10.1200/jco.2019.37.15_suppl.e20505","title":"Model-driven metronomic vinorelbine in heavily pre-treated metastatic NSCLC and PM patients: Results of a phase I/II study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Vinorelbine; Neutropenia; Response Evaluation Criteria in Solid Tumors; non-small cell lung cancer (NSCLC); Phases of clinical research; Toxicity; Dosing; Internal medicine; Lung cancer; Pemetrexed; Population; Oncology; Surgery; Nuclear medicine; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.07419922990392695,"score_gpt":0.4936330278500683,"score_spread":0.41943379794614133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947681396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732643,0.0001489443,0.000038119033,0.00078592007,0.00021011586,0.00074428227,0.000034839082,0.00000373145,0.00070764235],"genre_scores_gemma":[0.99672616,0.0001080094,0.0025878812,0.00020635438,0.00005816188,0.0000073321653,0.000014315959,0.000011674871,0.00028011456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693567,0.00024749126,0.0022647793,0.00019233213,0.00021106172,0.00014865588],"domain_scores_gemma":[0.9972347,0.0007125593,0.0013645029,0.00017143636,0.00032497876,0.00019183499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010153258,0.00012138879,0.0013714981,0.00020956893,0.000018736999,0.0000033371512,0.00007796392,0.000099750105,0.000036970974],"category_scores_gemma":[0.00077950367,0.00008022279,0.00017897329,0.00014055493,0.00007649256,0.00012124879,0.00004539507,0.00034988107,0.0000031970196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043041196,0.0602833,0.7663585,0.00006733176,0.002681774,0.00019429496,0.0025147286,0.0019332884,0.0003437837,0.00003689357,0.0009098314,0.121635064],"study_design_scores_gemma":[0.20498803,0.16988729,0.61232847,0.00021176673,0.0024683424,0.000025683628,0.0005148716,0.007923455,0.000039463826,0.00010371615,0.001386873,0.00012200374],"about_ca_topic_score_codex":0.00013866853,"about_ca_topic_score_gemma":0.000118972224,"teacher_disagreement_score":0.16194683,"about_ca_system_score_codex":0.00020936222,"about_ca_system_score_gemma":0.0008170068,"threshold_uncertainty_score":0.32713902},"labels":[],"label_agreement":null},{"id":"W2947692688","doi":"10.1200/jco.2019.37.15_suppl.e14006","title":"A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Adverse effect; Internal medicine; Cancer; Antibody; Gastroenterology; Oncology; Immunology","score_opus":0.0930166138414748,"score_gpt":0.4811636294540753,"score_spread":0.3881470156126005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947692688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958448,0.00046121902,0.000025974005,0.0013564155,0.0012344262,0.0006998076,0.0000012386387,0.000005206619,0.00037092017],"genre_scores_gemma":[0.99802536,0.0006076587,0.00032775063,0.00060159835,0.00028424652,0.0000017825648,0.0000013613418,0.000012003949,0.00013821918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699736,0.00047759793,0.0018255634,0.00017362958,0.00036693015,0.00015893595],"domain_scores_gemma":[0.9968671,0.0007968916,0.001678898,0.0002669048,0.00024523493,0.00014492327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026837343,0.00012032757,0.0010268235,0.00008613498,0.00003907198,0.000008561094,0.00014238297,0.00025053334,0.00007569468],"category_scores_gemma":[0.00037981512,0.000066466215,0.0003585815,0.00017427566,0.00013996783,0.000090293164,0.00005556387,0.00056872336,0.000003215576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038715847,0.022287032,0.5826309,0.00007860104,0.00037819782,0.000113976865,0.0007467657,0.000007343074,0.103925005,0.000005371787,0.00029417584,0.25081682],"study_design_scores_gemma":[0.0684919,0.059511248,0.86331993,0.00012597808,0.00042890248,0.00012978507,0.00088923,0.00020064226,0.00091234763,0.00002494578,0.0058846595,0.00008045616],"about_ca_topic_score_codex":0.000055323086,"about_ca_topic_score_gemma":0.000017324768,"teacher_disagreement_score":0.28068903,"about_ca_system_score_codex":0.000052009815,"about_ca_system_score_gemma":0.00054653146,"threshold_uncertainty_score":0.27104133},"labels":[],"label_agreement":null},{"id":"W2947694391","doi":"10.1200/jco.2019.37.15_suppl.2002","title":"Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Univariate analysis; Proportional hazards model; Glioma; IDH1; Subgroup analysis; Multivariate analysis; Confidence interval; Gene; Cancer research; Biology; Mutation; Genetics","score_opus":0.034846486336773626,"score_gpt":0.37747089829965613,"score_spread":0.3426244119628825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947694391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912111,0.000699166,0.000035863068,0.006117538,0.0007206849,0.0007014001,0.00008462474,0.000005630371,0.00042398286],"genre_scores_gemma":[0.99823844,0.0005475307,0.00063260645,0.00036807015,0.00012313429,0.00001400845,0.000015871026,0.000021171403,0.000039167095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935416,0.0014901218,0.0036817875,0.0003044581,0.000724758,0.00025729736],"domain_scores_gemma":[0.987567,0.003658357,0.0069422144,0.0007667994,0.0008348098,0.0002308006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027005796,0.00027479487,0.0035914702,0.00040090657,0.000039738887,0.0000042671913,0.00040751067,0.0005198241,0.00014868686],"category_scores_gemma":[0.0014963781,0.00012471882,0.0020820864,0.0011740132,0.00064083625,0.000056525612,0.00010599372,0.000676724,0.0000051483144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007228961,0.014675249,0.92639595,0.000040103194,0.031145526,0.00035807036,0.0009467654,0.0049396283,0.0064542675,0.0010279204,0.00041421773,0.006373344],"study_design_scores_gemma":[0.018862523,0.036523398,0.8945904,0.00016409963,0.024065528,0.000064107895,0.00059881416,0.0012302491,0.022470037,0.0005402303,0.0007837226,0.000106926724],"about_ca_topic_score_codex":0.0003807086,"about_ca_topic_score_gemma":0.0002478327,"teacher_disagreement_score":0.031805582,"about_ca_system_score_codex":0.00035424597,"about_ca_system_score_gemma":0.001335455,"threshold_uncertainty_score":0.5085886},"labels":[],"label_agreement":null},{"id":"W2947696102","doi":"10.1200/jco.2019.37.15_suppl.e16518","title":"A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Androgen deprivation therapy; Internal medicine; Androgen deficiency; Geriatric Depression Scale; Adverse effect; Urology; Cancer; Androgen; Endocrinology; Hormone","score_opus":0.08323762863015056,"score_gpt":0.4713934125413345,"score_spread":0.38815578391118394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947696102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950606,0.0009647196,0.000003848777,0.0012537539,0.00017781272,0.0022409423,0.000044114557,0.000007089281,0.00024709024],"genre_scores_gemma":[0.99663264,0.0017053506,0.0004012721,0.000099945806,0.00015591618,0.00006732693,0.0000048157895,0.000026257976,0.0009064766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952942,0.0006536806,0.002541939,0.00044556143,0.0006789128,0.00038567136],"domain_scores_gemma":[0.9958783,0.0010010768,0.0019385456,0.0003421161,0.00050162955,0.00033835674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034358667,0.00023908928,0.0021980656,0.00021572415,0.000037522906,0.00001632658,0.00016424851,0.00018473511,0.000038409096],"category_scores_gemma":[0.00037346166,0.00012880654,0.00010977565,0.00039144745,0.00023829873,0.00019967656,0.00013155176,0.0008880945,0.0000020086302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44745275,0.015382012,0.47353444,0.00037826208,0.001158323,0.0038493755,0.004357287,0.00017218335,0.0014997568,0.000001943099,0.00033950785,0.05187417],"study_design_scores_gemma":[0.13997066,0.30154285,0.55058986,0.000771804,0.00052490475,0.0006183441,0.004727564,0.0001318026,0.00010628056,0.0000117443715,0.00083066395,0.00017352267],"about_ca_topic_score_codex":0.00039519923,"about_ca_topic_score_gemma":0.0005254739,"teacher_disagreement_score":0.3074821,"about_ca_system_score_codex":0.0005137753,"about_ca_system_score_gemma":0.0036710498,"threshold_uncertainty_score":0.6512285},"labels":[],"label_agreement":null},{"id":"W2947704037","doi":"10.1200/jco.2019.37.15_suppl.e16501","title":"Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Univariate analysis; Cancer; Internal medicine; Proportional hazards model; Oncology; Chemotherapy; Retrospective cohort study; Urology; Multivariate analysis","score_opus":0.07848670944788415,"score_gpt":0.4537076069597042,"score_spread":0.37522089751182003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947704037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944185,0.00008771975,0.0000012173793,0.0020758102,0.00096656283,0.0008777145,0.000014579116,0.000005537947,0.0015523693],"genre_scores_gemma":[0.99800354,0.00019735888,0.00015362068,0.0007185491,0.0001869467,0.0000065901286,0.000009542437,0.000019911213,0.0007039379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970177,0.00061840354,0.0011156374,0.00026032503,0.0006249968,0.00036297002],"domain_scores_gemma":[0.996344,0.001627118,0.00080678484,0.00016866704,0.0007290514,0.00032439557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002276867,0.00019140028,0.0018716326,0.00015942274,0.000023307295,0.000010517068,0.00008726076,0.00014780955,0.00008644423],"category_scores_gemma":[0.0006333015,0.000102683276,0.0002473704,0.00016331286,0.0001643019,0.000117239855,0.000033334883,0.0012737594,0.00004702096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11566975,0.0018109118,0.86075383,0.000070380745,0.0006480115,0.0016605012,0.000100561956,0.00007771395,0.0000466358,0.000013511727,0.00024524433,0.018902915],"study_design_scores_gemma":[0.045251887,0.075501546,0.877588,0.0003363654,0.00023200257,0.000033011496,0.00005286124,0.000039199316,0.0002289922,0.000033965196,0.000606741,0.00009547448],"about_ca_topic_score_codex":0.00013143172,"about_ca_topic_score_gemma":0.00010579216,"teacher_disagreement_score":0.07369064,"about_ca_system_score_codex":0.00044923514,"about_ca_system_score_gemma":0.0015338009,"threshold_uncertainty_score":0.5533921},"labels":[],"label_agreement":null},{"id":"W2947706358","doi":"10.1200/jco.20.03692","title":"Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"","keywords":"Medicine; Gastroenterology; Asparaginase; Lymphoblastic lymphoma; Internal medicine; Dosing; Surgery; Lymphoblastic Leukemia; Leukemia; Immunology","score_opus":0.05017809689090002,"score_gpt":0.4072225850133072,"score_spread":0.3570444881224072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947706358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452853,0.0006450757,0.00008032925,0.0035158617,0.00027168854,0.00025848168,0.000043404834,0.0000057291068,0.0006509188],"genre_scores_gemma":[0.9936318,0.0024176335,0.0028781581,0.0004721002,0.00038402365,0.0000022827012,0.0000092572645,0.000024885361,0.00017987969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938262,0.0007544039,0.0038871455,0.00040685528,0.00070299517,0.000422361],"domain_scores_gemma":[0.986841,0.00925542,0.0018923617,0.00037094127,0.00088124553,0.0007589978],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029168269,0.00023137577,0.002577193,0.00030736922,0.000027995451,0.000008987475,0.0002028957,0.0006347283,0.00006184631],"category_scores_gemma":[0.026532186,0.00017794177,0.00025833817,0.00042604876,0.00080830546,0.00012684787,0.0002958465,0.0011477108,0.0000034093027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18938576,0.054262456,0.29984313,0.0021118585,0.006830235,0.11124327,0.0046679853,0.00055338396,0.089282975,0.00085932604,0.033178724,0.20778091],"study_design_scores_gemma":[0.17681952,0.022305666,0.7663136,0.0010700291,0.0014828071,0.014816071,0.0003582244,0.0016918654,0.011546766,0.00032947832,0.0029793002,0.00028668303],"about_ca_topic_score_codex":0.000108040134,"about_ca_topic_score_gemma":0.00015557844,"teacher_disagreement_score":0.46647048,"about_ca_system_score_codex":0.0005726848,"about_ca_system_score_gemma":0.009419203,"threshold_uncertainty_score":0.99619645},"labels":[],"label_agreement":null},{"id":"W2947710003","doi":"10.1200/jco.2019.37.15_suppl.1582","title":"Unselected germline screening in pancreatic adenocarcinoma yields high rates of pathogenic and likely pathogenic variants (PV) in hereditary cancer susceptibility genes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; CHEK2; Cancer; Genetic testing; CDKN2A; Population; Oncology; Germline; Internal medicine; Lynch syndrome; Germline mutation; Family history; Pancreatic cancer; KRAS; Colorectal cancer; Mutation; Genetics; Gene; DNA mismatch repair; Biology","score_opus":0.04094712006365024,"score_gpt":0.3619862126938999,"score_spread":0.32103909263024966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947710003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854235,0.013178527,0.000114188704,0.00037411993,0.0006174419,0.0002179786,0.00004410873,0.00000146065,0.000028676868],"genre_scores_gemma":[0.9881038,0.00907786,0.0017775453,0.0004007208,0.00056642777,0.0000059054105,0.00002038812,0.000020132686,0.000027184024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968133,0.00042701155,0.0019633786,0.0003553286,0.00015471593,0.00028625378],"domain_scores_gemma":[0.9975265,0.00076251925,0.001017389,0.00026265156,0.0002659576,0.00016498346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020064458,0.0001753015,0.0010841015,0.00011854159,0.0000152006605,0.0000073456963,0.00022918463,0.0005514985,0.000069204376],"category_scores_gemma":[0.001091283,0.00015589107,0.00021242147,0.00018201221,0.00015644633,0.000011115181,0.0001322564,0.00051564607,0.0000012018537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019814225,0.00041195218,0.8936815,0.000043483175,0.00012792066,0.00012985145,0.000036868,0.0005460805,0.08231918,0.000014557295,0.000115973075,0.020591209],"study_design_scores_gemma":[0.0049202503,0.004050503,0.9875618,0.000087307984,0.00009251186,0.000073435025,0.000058630852,0.00037369708,0.001922818,0.000213034,0.00048296188,0.00016304474],"about_ca_topic_score_codex":0.0005477152,"about_ca_topic_score_gemma":0.0031184382,"teacher_disagreement_score":0.0938803,"about_ca_system_score_codex":0.000052619882,"about_ca_system_score_gemma":0.0012718285,"threshold_uncertainty_score":0.63570535},"labels":[],"label_agreement":null},{"id":"W2947719708","doi":"10.1200/jco.2019.37.15_suppl.9069","title":"Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Pemetrexed; Nivolumab; Pembrolizumab; Ipilimumab; Erlotinib; Internal medicine; Oncology; Carboplatin; Atezolizumab; Lung cancer; Cancer; Chemotherapy; Immunotherapy; Epidermal growth factor receptor; Cisplatin","score_opus":0.1224058409726355,"score_gpt":0.5188490254552658,"score_spread":0.3964431844826303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947719708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797047,0.00070747733,0.000013872284,0.010111031,0.0012953131,0.0004883531,0.0000034211494,0.000015278818,0.007660564],"genre_scores_gemma":[0.9931769,0.0013473955,0.0016286487,0.0008618379,0.0009582112,0.0000044462045,0.000001823098,0.00003170043,0.0019890605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922588,0.0007138268,0.005402692,0.0003007611,0.00092100294,0.00040290126],"domain_scores_gemma":[0.98903906,0.0054401834,0.0033068953,0.0004623933,0.0012511028,0.0005003685],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077733295,0.0002304864,0.0040462585,0.00020758882,0.000031022097,0.0000064243795,0.00029953188,0.00048182614,0.00029262624],"category_scores_gemma":[0.008587902,0.00012617192,0.0013325869,0.00026978666,0.00078871474,0.00012748758,0.00017041697,0.0019875807,0.000076925884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011075904,0.0022795484,0.950718,0.00008567076,0.0024736645,0.00043842543,0.00007430218,0.000004448322,0.00042273916,0.00003126887,0.0023776002,0.030018464],"study_design_scores_gemma":[0.021073414,0.040155683,0.9165014,0.00039487737,0.0005973766,0.0001531656,0.00024243096,0.000014591793,0.0005357002,0.000049813854,0.020159468,0.0001221014],"about_ca_topic_score_codex":0.00010655476,"about_ca_topic_score_gemma":0.000043180487,"teacher_disagreement_score":0.037876137,"about_ca_system_score_codex":0.0002579966,"about_ca_system_score_gemma":0.002416255,"threshold_uncertainty_score":0.9997632},"labels":[],"label_agreement":null},{"id":"W2947721471","doi":"10.1200/jco.2019.37.15_suppl.3535","title":"Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and immunogenicity in metastatic colorectal carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Coastal Health; Canada's Michael Smith Genome Sciences Centre; Pancreas Centre (Canada)","funders":"","keywords":"Endogenous retrovirus; Colorectal cancer; Biology; Cancer research; Epigenetics; Transcriptome; Gene expression; Cancer; Medicine; Gene; Genetics; Genome","score_opus":0.08713091754391102,"score_gpt":0.3852378193336241,"score_spread":0.2981069017897131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947721471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914781,0.0064387643,0.0011510864,0.00019143458,0.00030901926,0.0002600002,0.000016519056,0.0000022826623,0.00015281],"genre_scores_gemma":[0.9953266,0.0013102498,0.002764824,0.00009230115,0.00040802083,0.0000032065673,0.000039387924,0.000016762198,0.000038663635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99593836,0.0010976915,0.0021258711,0.00033733985,0.00025538995,0.00024535914],"domain_scores_gemma":[0.9972043,0.0006975055,0.0012789221,0.00025526228,0.00036799957,0.00019599464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021393183,0.00017995948,0.0012804555,0.00024080159,0.000042098218,0.000015166333,0.0002107002,0.0004105605,0.000028306295],"category_scores_gemma":[0.0005354609,0.00015358263,0.000473813,0.00028956158,0.00013172647,0.000010118316,0.00007388278,0.00041701228,0.0000032289377],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051227806,0.00007944676,0.4757167,0.000014998408,0.00037584282,0.000015420477,0.00006988734,0.00050724455,0.5113747,0.0000025440966,0.0000032262515,0.011327657],"study_design_scores_gemma":[0.003259011,0.0044882824,0.92503685,0.0000147479295,0.00059276586,0.000014424374,0.000066008855,0.00012079655,0.063320264,0.00035181953,0.0025676524,0.00016738706],"about_ca_topic_score_codex":0.000040767613,"about_ca_topic_score_gemma":0.000048735536,"teacher_disagreement_score":0.4493201,"about_ca_system_score_codex":0.000045568137,"about_ca_system_score_gemma":0.00031328996,"threshold_uncertainty_score":0.62629175},"labels":[],"label_agreement":null},{"id":"W2947731597","doi":"10.1200/jco.2019.37.15_suppl.10002","title":"Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Induction chemotherapy; Internal medicine; Minimal residual disease; Oncology; Myeloid leukemia; Chemotherapy; Regimen; Chemotherapy regimen; Leukemia; Surgery","score_opus":0.03208573921117659,"score_gpt":0.3784880680724489,"score_spread":0.3464023288612723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947731597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941002,0.00011972332,0.001165071,0.002668072,0.0003305578,0.001524572,0.000028492439,0.000007965663,0.000055311324],"genre_scores_gemma":[0.9956733,0.00087954465,0.0021390386,0.00047668812,0.0005298166,0.000014189494,0.000057867637,0.000038537135,0.00019101572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952616,0.0009795564,0.002749618,0.00033344718,0.00046983888,0.0002059213],"domain_scores_gemma":[0.987609,0.0048601185,0.0061397557,0.00046796107,0.0007758683,0.00014729207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005825273,0.00020908433,0.0021290688,0.00018102952,0.000051980507,0.0000044510875,0.0002505895,0.000658587,0.000020590303],"category_scores_gemma":[0.0010800485,0.00011604815,0.00036443112,0.00020932624,0.00040587512,0.0001067798,0.00007422321,0.0012583315,0.0000013646118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03356933,0.0007862368,0.80088127,0.00007062373,0.001716378,0.00001172247,0.0004286411,0.00011149179,0.006561832,0.000027616881,0.0010920824,0.15474279],"study_design_scores_gemma":[0.023324432,0.07686384,0.8822238,0.00011241462,0.0013790507,0.0005178653,0.00009812672,0.00017972793,0.01423344,0.000054729055,0.0009130168,0.00009957722],"about_ca_topic_score_codex":0.00046841017,"about_ca_topic_score_gemma":0.000024102912,"teacher_disagreement_score":0.15464321,"about_ca_system_score_codex":0.00045439985,"about_ca_system_score_gemma":0.001027521,"threshold_uncertainty_score":0.5466894},"labels":[],"label_agreement":null},{"id":"W2947734198","doi":"10.1200/jco.2019.37.15_suppl.e23005","title":"A survey of healthcare professionals and oncology patients at the McGill University Health Centre reveals enthusiasm towards establishing a post-mortem rapid tissue donation program.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Health professionals; Enthusiasm; Health care; Tissue Donation; Donation; Family medicine; Oncology; Cancer; Nursing; Internal medicine; Transplantation; Organ donation","score_opus":0.2610996805437228,"score_gpt":0.5447314232199774,"score_spread":0.2836317426762546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947734198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94904786,0.001713345,0.0000031718737,0.046932835,0.00083479384,0.0008391906,0.00028421945,0.0000064614032,0.0003380953],"genre_scores_gemma":[0.990753,0.0036460464,0.0015517918,0.0033131337,0.00013215978,0.0000010437019,0.00007140281,0.000012315437,0.0005191289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941791,0.0029571864,0.0018896736,0.00022164416,0.000496759,0.00025561382],"domain_scores_gemma":[0.98891145,0.004556522,0.003558763,0.0001841771,0.0024444754,0.00034463708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064886566,0.00013462009,0.001668989,0.00013070938,0.0000761222,0.000001931834,0.0001787997,0.0003763435,0.00008544838],"category_scores_gemma":[0.0062307897,0.00008572038,0.00019443946,0.0002382326,0.00018353418,0.00014356332,0.00015849192,0.00069383666,0.00000344732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039046078,0.0016914731,0.55048674,0.000300886,0.00020784649,0.00003949867,0.001666705,0.000001018172,0.000035959463,0.00003854509,0.0059519745,0.43567473],"study_design_scores_gemma":[0.0050303047,0.01607587,0.768268,0.0007224622,0.00008402282,0.0000198627,0.0013550882,0.000009418383,0.00004533775,0.000014182961,0.20831297,0.0000624556],"about_ca_topic_score_codex":0.002178237,"about_ca_topic_score_gemma":0.0030914354,"teacher_disagreement_score":0.4356123,"about_ca_system_score_codex":0.00065590587,"about_ca_system_score_gemma":0.0022833203,"threshold_uncertainty_score":0.74592876},"labels":[],"label_agreement":null},{"id":"W2947737786","doi":"10.1200/jco.2019.37.15_suppl.6532","title":"The effects of immunotherapy and novel therapies on medical oncology work load in a Canadian province.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Workload; Subspecialty; Internal medicine; Disease; Lung cancer; Oncology; Cancer; Family medicine","score_opus":0.04221241713544121,"score_gpt":0.35083249318852855,"score_spread":0.30862007605308733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947737786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583361,0.00926083,0.000041190586,0.012763283,0.002899475,0.0002399598,0.000005162647,0.0000018349446,0.01645215],"genre_scores_gemma":[0.9856865,0.009977828,0.00015210058,0.0034717952,0.00032708579,0.0000040309124,1.6830127e-7,0.000013361831,0.00036714654],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971264,0.00009686411,0.0021944838,0.00017784188,0.000071829214,0.00033257488],"domain_scores_gemma":[0.9933069,0.004244519,0.0018891653,0.00018588484,0.00008070687,0.0002928421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006260062,0.00011580221,0.0013125144,0.00016117553,0.000038525497,0.000015319027,0.00036714456,0.0005083482,0.00012847844],"category_scores_gemma":[0.004524373,0.00008430535,0.00020524733,0.000103758524,0.0003058974,0.000116462434,0.000030024028,0.0008165265,0.000042335847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020619591,0.00059534085,0.50862837,0.00002635506,0.00025350624,0.000060784627,0.000456422,0.000010457306,0.00001013574,0.078601465,0.0016537001,0.40764153],"study_design_scores_gemma":[0.0045172274,0.0050497064,0.46475434,0.00009210826,0.000004510883,0.000013724152,0.00003785099,0.00003745487,0.0000044873755,0.0065544797,0.518843,0.000091140064],"about_ca_topic_score_codex":0.010012735,"about_ca_topic_score_gemma":0.054312244,"teacher_disagreement_score":0.51718926,"about_ca_system_score_codex":0.0005705922,"about_ca_system_score_gemma":0.0037908023,"threshold_uncertainty_score":0.99657965},"labels":[],"label_agreement":null},{"id":"W2947741267","doi":"10.1200/jco.2019.37.15_suppl.6047","title":"Impact of tobacco smoking on radiotherapy outcomes in 1875 HPV-positive oropharynx cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Radiation therapy; Univariate analysis; Proportional hazards model; Regimen; Population; Multivariate analysis; Cancer; Oncology","score_opus":0.07932926845632539,"score_gpt":0.5054970214550458,"score_spread":0.42616775299872045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947741267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923934,0.0007978138,0.0000034525453,0.0014583621,0.0014136585,0.00021827777,0.000006846002,0.0000030178933,0.0037051977],"genre_scores_gemma":[0.99562234,0.002243084,0.00017893717,0.0015424002,0.00029104992,0.0000025072961,6.287766e-7,0.00001432285,0.00010475484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973691,0.00027278828,0.0016786105,0.00014844305,0.00031517007,0.00021587082],"domain_scores_gemma":[0.9961618,0.002038942,0.0011735184,0.00012711115,0.00033682218,0.00016181744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001127292,0.00013698052,0.0023401263,0.00016048997,0.0000135485025,0.0000024056449,0.0000986494,0.00022420057,0.00047052343],"category_scores_gemma":[0.001319311,0.00008132418,0.0006167554,0.00013220165,0.00008900109,0.00007227316,0.00001916047,0.00074936886,0.000004804795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042601046,0.0019931814,0.8970049,0.000012229025,0.0007583576,0.000060256865,0.00024342487,0.00004436453,0.00008424377,0.00001981503,0.0006622056,0.09485693],"study_design_scores_gemma":[0.014123665,0.03608193,0.94692606,0.00023830234,0.00008783415,0.0000073215624,0.000040542098,0.0000073346914,0.00007789537,0.000022546828,0.0023158772,0.00007069332],"about_ca_topic_score_codex":0.00019150281,"about_ca_topic_score_gemma":0.00007210753,"teacher_disagreement_score":0.09478624,"about_ca_system_score_codex":0.00058229023,"about_ca_system_score_gemma":0.0013233889,"threshold_uncertainty_score":0.5151902},"labels":[],"label_agreement":null},{"id":"W2947748070","doi":"10.1200/jco.2019.37.15_suppl.5015","title":"Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Conventional PCI; Myocardial infarction; Percutaneous coronary intervention; Randomized controlled trial; Agonist; Cardiology; Oncology; Cancer; Receptor","score_opus":0.06547726952186192,"score_gpt":0.42900697231901963,"score_spread":0.3635297027971577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947748070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930678,0.0022634172,0.000006084315,0.0007371527,0.0008431204,0.0021243547,0.000004579321,0.0000058536425,0.00094766304],"genre_scores_gemma":[0.9949044,0.004104616,0.00031572813,0.00010196568,0.00028263815,0.000043515,0.000007659614,0.000016833805,0.00022263968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664277,0.0006951297,0.0015881008,0.00025554534,0.00052973494,0.0002887337],"domain_scores_gemma":[0.9972036,0.0010406702,0.0008940266,0.00018992602,0.00037448548,0.0002972817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004116603,0.00015754801,0.0033557424,0.00012756992,0.000041789,0.000019057097,0.00009421824,0.00017784718,0.000030025256],"category_scores_gemma":[0.000869255,0.00008993815,0.00055358495,0.00014733372,0.0005102154,0.00015931505,0.000054777185,0.00090254215,0.0000026915482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5149784,0.00058031874,0.46814454,0.000041008498,0.00071198464,0.00016291396,0.000062517705,0.00006136776,0.000003166349,0.0000028780655,0.000030808715,0.015220085],"study_design_scores_gemma":[0.6328343,0.0065235724,0.35805172,0.00019114738,0.00036667843,0.000011071959,0.000042349817,0.000118393895,0.000016078062,0.000022779614,0.0017523667,0.000069554946],"about_ca_topic_score_codex":0.00028170942,"about_ca_topic_score_gemma":0.00014765751,"teacher_disagreement_score":0.11785589,"about_ca_system_score_codex":0.00024741082,"about_ca_system_score_gemma":0.0013096327,"threshold_uncertainty_score":0.39211467},"labels":[],"label_agreement":null},{"id":"W2947749725","doi":"10.1200/jco.2019.37.15_suppl.tps2646","title":"A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Oncology; Tolerability; Immunotherapy; Cancer; Adverse effect","score_opus":0.028566372420013322,"score_gpt":0.4017550666596621,"score_spread":0.3731886942396488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947749725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809045,0.00008829652,0.00007947699,0.00050829287,0.00012711984,0.0009892397,0.000001872469,0.000002001448,0.00011328308],"genre_scores_gemma":[0.9988859,0.00006124873,0.00031185948,0.000613091,0.000048547245,0.000015112908,0.000016185637,0.000018223147,0.000029802675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976733,0.0005459514,0.00093447906,0.000307195,0.0003161282,0.00022299458],"domain_scores_gemma":[0.99845505,0.0001932037,0.0006360463,0.00017018415,0.0004530698,0.000092447466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011164037,0.00017096857,0.0006200506,0.00014676627,0.0000316454,0.00001610039,0.00017471633,0.000121356505,0.00001178895],"category_scores_gemma":[0.00035058192,0.00010184959,0.000044098117,0.00022339755,0.00007994481,0.000033191696,0.00006245572,0.0003925952,0.0000015699296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038479127,0.012612288,0.93838286,0.000019501567,0.00013744953,0.00013187292,0.00087835663,0.0016930065,0.0040511372,0.000011424097,0.00005672526,0.0035462468],"study_design_scores_gemma":[0.16241828,0.09080491,0.7434124,0.00025886387,0.00009616951,0.000023345061,0.0011480759,0.000571506,0.00063972204,0.000021373362,0.00036866247,0.00023670508],"about_ca_topic_score_codex":0.00014981229,"about_ca_topic_score_gemma":0.0015043116,"teacher_disagreement_score":0.19497047,"about_ca_system_score_codex":0.00010815074,"about_ca_system_score_gemma":0.00036574568,"threshold_uncertainty_score":0.41533056},"labels":[],"label_agreement":null},{"id":"W2947750174","doi":"10.1200/jco.2019.37.15_suppl.529","title":"The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Cancer Care Ontario; Université Laval; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Statistics Canada","funders":"","keywords":"Medicine; Sex hormone-binding globulin; Metformin; Placebo; Internal medicine; Breast cancer; Testosterone (patch); Endocrinology; Cancer; Gynecology; Oncology; Hormone; Insulin; Androgen","score_opus":0.02049513219298395,"score_gpt":0.3981167886882116,"score_spread":0.37762165649522766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947750174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900836,0.00644106,0.0000074685954,0.00007643815,0.0015948152,0.0015646537,0.00007336582,7.8974733e-7,0.00015786041],"genre_scores_gemma":[0.9726897,0.026663,0.000046042314,0.000112070666,0.00032047738,0.00012234431,0.000011955086,0.0000152492885,0.000019190344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951068,0.0015491953,0.0024636178,0.00023023588,0.00036222042,0.000287916],"domain_scores_gemma":[0.99514425,0.0027691573,0.0015616367,0.0002177674,0.00019071986,0.000116446296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008609256,0.00019484817,0.0022701279,0.00018978548,0.000014477482,0.0000058269443,0.0002783655,0.00035118646,0.000058949397],"category_scores_gemma":[0.0020091159,0.00011552427,0.00046906108,0.00018593093,0.00013292316,0.000014937217,0.000051375377,0.0004175784,0.000001420218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63240683,0.00062892644,0.0014099696,0.000012659972,0.00014398652,0.0000035963665,0.000055590877,0.00007616171,0.0009204612,0.0000027522797,0.00019479988,0.3641443],"study_design_scores_gemma":[0.92691827,0.040195324,0.0034414416,0.0001301591,0.00009839701,0.0000013586341,0.000057945457,0.000062813655,0.020016517,0.000035372654,0.008905497,0.0001368877],"about_ca_topic_score_codex":0.00008205138,"about_ca_topic_score_gemma":0.00038726302,"teacher_disagreement_score":0.36400738,"about_ca_system_score_codex":0.00010345398,"about_ca_system_score_gemma":0.0005582148,"threshold_uncertainty_score":0.4710943},"labels":[],"label_agreement":null},{"id":"W2947750347","doi":"10.1200/jco.2019.37.15_suppl.5551","title":"Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Oncology; Ovarian cancer; Placebo; BRCA mutation; Progression-free survival; Cancer; Chemotherapy; Pathology","score_opus":0.09327385480056455,"score_gpt":0.49854041473171123,"score_spread":0.4052665599311467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947750347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862246,0.00029604815,0.0011385557,0.006825823,0.002841176,0.0022531932,0.000051083774,0.000006083248,0.00036341845],"genre_scores_gemma":[0.99007577,0.00081612973,0.001351472,0.0065000937,0.00072709663,0.00012122292,0.000022073027,0.000023965214,0.00036217156],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99533534,0.00053042435,0.0031361931,0.00025387472,0.00044851087,0.00029565688],"domain_scores_gemma":[0.9865822,0.009087345,0.0032166806,0.00025778392,0.00068973756,0.00016623968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034597036,0.00016618198,0.0015605789,0.00011602152,0.000032576394,0.000007813676,0.00028184376,0.00033288097,0.00037268698],"category_scores_gemma":[0.006555063,0.000098271055,0.00044713763,0.00024489805,0.00017232077,0.00017836374,0.000018136063,0.0007385461,0.000006956945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6256917,0.011865123,0.0024591943,0.00006504293,0.00031852318,0.00008563999,0.00065531797,0.00018646421,0.000980619,0.00018370272,0.043418918,0.31408972],"study_design_scores_gemma":[0.8279894,0.0506786,0.01422487,0.00039433673,0.00023194226,0.000033231958,0.0002286447,0.00020027328,0.00030833972,0.00062775344,0.104946114,0.00013650145],"about_ca_topic_score_codex":0.000047040437,"about_ca_topic_score_gemma":0.00008373698,"teacher_disagreement_score":0.31395322,"about_ca_system_score_codex":0.00031177292,"about_ca_system_score_gemma":0.0016465536,"threshold_uncertainty_score":0.7847496},"labels":[],"label_agreement":null},{"id":"W2947752713","doi":"10.1200/jco.2019.37.15_suppl.5003","title":"Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; Princess Margaret Cancer Centre; Baker Hughes (Canada); University of Alberta; Dalhousie University; Regional Municipality of Durham; Lakeridge Health; Juravinski Cancer Centre; University of Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; BC Cancer Agency; Jewish General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Cabazitaxel; Docetaxel; Progression-free survival; Oncology; Abiraterone acetate; Prostate cancer; Randomized controlled trial; Abiraterone; Androgen receptor; Gastroenterology; Urology; Androgen deprivation therapy; Overall survival; Chemotherapy; Cancer","score_opus":0.09457267435545368,"score_gpt":0.4400768584416765,"score_spread":0.3455041840862228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947752713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957904,0.0005090117,0.000046984842,0.00074092177,0.0016393478,0.0008939786,0.00014259928,0.000002763339,0.00023397456],"genre_scores_gemma":[0.99560064,0.00093524606,0.0023602613,0.0004413102,0.00040505434,0.000020491838,0.00006747979,0.000024487215,0.00014502813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99424195,0.0010625167,0.0037668818,0.0003903023,0.000270378,0.00026794427],"domain_scores_gemma":[0.9931639,0.0032368614,0.0026649996,0.00032318287,0.00040536007,0.00020571458],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003954204,0.00021956435,0.0022337546,0.000108105734,0.000028947361,0.000013607538,0.00037361807,0.00031136733,0.00011305054],"category_scores_gemma":[0.009461152,0.00015702791,0.00042770297,0.00015676138,0.00017025947,0.000011945616,0.00020532921,0.00046024745,0.000008711772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9502143,0.013607691,0.0019192968,0.000013881758,0.0018931286,0.00023917804,0.0004105586,0.0005836844,0.01553672,0.000014475152,0.0035488417,0.01201823],"study_design_scores_gemma":[0.8832407,0.09347891,0.0023525243,0.00005818503,0.0009803239,0.000015815009,0.0009511448,0.00040939657,0.0042963997,0.00012717792,0.0138139585,0.00027548056],"about_ca_topic_score_codex":0.0004314141,"about_ca_topic_score_gemma":0.0016155463,"teacher_disagreement_score":0.07987122,"about_ca_system_score_codex":0.00006267519,"about_ca_system_score_gemma":0.0012054503,"threshold_uncertainty_score":0.9988826},"labels":[],"label_agreement":null},{"id":"W2947759305","doi":"10.1200/jco.2019.37.15_suppl.9504","title":"United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Discontinuation; Ipilimumab; Adverse effect; Placebo; Adjuvant; Hazard ratio; Randomized controlled trial; Intention-to-treat analysis; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy; Pathology","score_opus":0.1243248276908649,"score_gpt":0.49600989343293717,"score_spread":0.3716850657420723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947759305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909097,0.00019384809,0.00024013319,0.0013490749,0.0033425915,0.0036604146,0.00004552241,0.000028315993,0.0002304124],"genre_scores_gemma":[0.99159074,0.0011915658,0.0012075296,0.00028311793,0.00097602134,0.0000713998,0.000072006085,0.00007702867,0.004530603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9885586,0.0036541205,0.0057349214,0.00050559593,0.00094537786,0.00060136913],"domain_scores_gemma":[0.95972496,0.032745287,0.003908312,0.00072421686,0.0022539455,0.00064325565],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013028889,0.00038215576,0.006072917,0.0008625466,0.00006169707,0.000023837034,0.00064190465,0.00055394496,0.0072599812],"category_scores_gemma":[0.017288236,0.00023595938,0.0011136543,0.0006014834,0.0005131989,0.00015828334,0.00025221403,0.0021367846,0.000042427357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9213307,0.014099493,0.0007656218,0.000091081405,0.0054227235,0.00045009673,0.0010882571,0.000039894745,0.0028463388,0.00002331105,0.003107153,0.05073534],"study_design_scores_gemma":[0.71991444,0.25951698,0.0008889875,0.00018963397,0.001652406,0.00006346353,0.0024352514,0.002190805,0.00053292763,0.00014823847,0.012290572,0.00017627004],"about_ca_topic_score_codex":0.0006872066,"about_ca_topic_score_gemma":0.00064406445,"teacher_disagreement_score":0.24541749,"about_ca_system_score_codex":0.0004218579,"about_ca_system_score_gemma":0.0016348154,"threshold_uncertainty_score":0.9936475},"labels":[],"label_agreement":null},{"id":"W2947773829","doi":"10.1200/jco.2019.37.15_suppl.5504","title":"Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Radical Hysterectomy; Hysterectomy; Odds ratio; Surgery; Stage (stratigraphy); Abdominal surgery; Cervical cancer; Lymphovascular invasion; Radical surgery; Cancer; Multivariate analysis; Retrospective cohort study; Adjuvant therapy; Internal medicine; Metastasis","score_opus":0.12220136213634544,"score_gpt":0.44906298153096724,"score_spread":0.32686161939462177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947773829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975946,0.0004046678,0.000008696686,0.0004927253,0.000664395,0.0003470038,0.000048311656,0.000003876487,0.0004357307],"genre_scores_gemma":[0.9975848,0.00040080227,0.0013670097,0.00034863653,0.00019733714,0.0000134063275,0.000029217728,0.000010465666,0.00004830989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99620676,0.0003415093,0.002241302,0.00031994222,0.0006146771,0.00027579645],"domain_scores_gemma":[0.99227244,0.0048568975,0.0015220514,0.00016332287,0.0007738597,0.00041142793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008473381,0.00021930621,0.0026276724,0.0005756535,0.000022913477,0.0000057427824,0.00018525003,0.0003337265,0.000728693],"category_scores_gemma":[0.0032174638,0.00012906303,0.0006572009,0.001361575,0.00035508038,0.00012363493,0.000046806585,0.00071214855,0.00001324224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07770421,0.004978307,0.892609,0.00005565802,0.0033634414,0.00080186763,0.000054249944,0.0000871469,0.00005421447,0.000012249036,0.000032910626,0.020246722],"study_design_scores_gemma":[0.06401846,0.026678061,0.9045059,0.00029485853,0.003419366,0.000035655587,0.000046926547,0.0002718199,0.00020297566,0.0000044763306,0.00040252524,0.000118957774],"about_ca_topic_score_codex":0.0005869104,"about_ca_topic_score_gemma":0.0023527057,"teacher_disagreement_score":0.021699753,"about_ca_system_score_codex":0.0005674997,"about_ca_system_score_gemma":0.002885955,"threshold_uncertainty_score":0.79786766},"labels":[],"label_agreement":null},{"id":"W2947775394","doi":"10.1200/jco.19.00934","title":"Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pembrolizumab; Overall survival; Lung cancer; Safety profile; Phases of clinical research; Survival rate; Cancer; Lung","score_opus":0.043142148027036545,"score_gpt":0.41046673368768,"score_spread":0.36732458566064347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947775394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949187,0.00021024927,0.000029526573,0.0013058098,0.0009149317,0.0018515184,0.00015322045,0.0000095617615,0.000606453],"genre_scores_gemma":[0.99621344,0.00030298793,0.00058253465,0.0011756493,0.0006551133,0.000024757146,0.00004631916,0.000037215934,0.00096199295],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970221,0.0003070209,0.0016060671,0.0003336384,0.00043778145,0.00029338777],"domain_scores_gemma":[0.9940013,0.0028603072,0.0018614607,0.0003607323,0.00071879337,0.00019737585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013032042,0.00022876759,0.0013186085,0.00005239204,0.000065186054,0.000016433092,0.00024983738,0.00021376908,0.00014628078],"category_scores_gemma":[0.00032999556,0.00010953471,0.0002923182,0.00013279502,0.00011848277,0.000106476735,0.000028803035,0.0006702083,0.0000039863207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5069,0.008801681,0.46186993,0.000018085047,0.001502027,0.00006349218,0.00034647324,0.000059909617,0.00012948478,5.651299e-7,0.0024625026,0.017845837],"study_design_scores_gemma":[0.31975245,0.08178364,0.583197,0.0001826613,0.00092204503,0.0000050776102,0.00037360657,0.00012387834,0.000040511266,0.0000028350664,0.013472104,0.00014416239],"about_ca_topic_score_codex":0.0005998812,"about_ca_topic_score_gemma":0.00067401817,"teacher_disagreement_score":0.18714756,"about_ca_system_score_codex":0.00021608344,"about_ca_system_score_gemma":0.0012272329,"threshold_uncertainty_score":0.44666958},"labels":[],"label_agreement":null},{"id":"W2947784673","doi":"10.1200/jco.2019.37.15_suppl.tps4156","title":"NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Cisplatin; Internal medicine; Gallbladder cancer; Oncology; Cancer; Adverse effect; Phases of clinical research; Gastroenterology; Chemotherapy","score_opus":0.10157063427803416,"score_gpt":0.4550929416456283,"score_spread":0.35352230736759416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947784673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707056,0.0017962281,0.000041480755,0.0092495475,0.00063528796,0.0005602402,0.000008450313,0.0000032708122,0.0006349439],"genre_scores_gemma":[0.99519646,0.002312995,0.001567017,0.00030792324,0.00031132842,0.000023326682,0.000003867948,0.000012039953,0.00026506855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816656,0.00006351302,0.0013044631,0.00014425356,0.00017745956,0.00014372078],"domain_scores_gemma":[0.9967012,0.0017046134,0.0010580943,0.00011902983,0.00032149622,0.00009558563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005798738,0.00011036717,0.0013627701,0.00010517323,0.000014927598,0.0000016663396,0.00005810695,0.00014503876,0.00005432754],"category_scores_gemma":[0.0003077854,0.000067651556,0.00028274025,0.00011352228,0.00007425346,0.00007300929,0.000008939575,0.00020641508,0.000001539979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013089806,0.003941889,0.7553334,0.000102706756,0.00031472385,0.00008426245,0.00044464602,0.0001881582,0.00015516453,0.00003059547,0.00041488337,0.22589976],"study_design_scores_gemma":[0.03877396,0.071007155,0.8701545,0.00023417408,0.0003178707,0.000052729527,0.00019995126,0.000188337,0.00025070127,0.00013291847,0.018618757,0.00006891534],"about_ca_topic_score_codex":0.000058402016,"about_ca_topic_score_gemma":0.00065471604,"teacher_disagreement_score":0.22583084,"about_ca_system_score_codex":0.0002583752,"about_ca_system_score_gemma":0.0007198674,"threshold_uncertainty_score":0.27587506},"labels":[],"label_agreement":null},{"id":"W2947788704","doi":"10.1200/jco.2019.37.15_suppl.9076","title":"Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after comprehensive genomic profiling (CGP): A real-world study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Internal medicine; Profiling (computer programming); Oncology","score_opus":0.03462381057021498,"score_gpt":0.371582246900044,"score_spread":0.336958436329829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947788704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984602,0.00034355122,0.000045046625,0.000043635944,0.00033669276,0.00069800415,0.00003094135,8.494342e-7,0.00004108759],"genre_scores_gemma":[0.99436057,0.0037109298,0.0015219594,0.00010070524,0.000116860414,0.000033226523,0.00001108012,0.000015509437,0.00012913324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983501,0.00012772894,0.0010622432,0.00024209211,0.000080916274,0.00013695915],"domain_scores_gemma":[0.9981351,0.0002439124,0.0009823919,0.00019822919,0.00034550807,0.00009486714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025235652,0.00012388005,0.0005416189,0.00008552759,0.000016400685,0.000011595557,0.00008667472,0.00011973104,0.000008586952],"category_scores_gemma":[0.000060816732,0.000097221426,0.00010603951,0.00006465956,0.00005829016,0.000010906981,0.00005773839,0.00015393291,0.0000010538039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031560806,0.0014322539,0.9698651,0.000027287086,0.00015459342,0.0000083260675,0.00014328127,0.0037734762,0.016494786,0.0000028765169,0.000026143822,0.0049157995],"study_design_scores_gemma":[0.007881469,0.01159429,0.97608185,0.00004201141,0.00017815102,0.0000015295966,0.00013478629,0.0001917998,0.0017440723,0.0000042475904,0.0020356283,0.000110158864],"about_ca_topic_score_codex":0.00019076846,"about_ca_topic_score_gemma":0.0021502236,"teacher_disagreement_score":0.0147507135,"about_ca_system_score_codex":0.00015920572,"about_ca_system_score_gemma":0.0006370439,"threshold_uncertainty_score":0.39645746},"labels":[],"label_agreement":null},{"id":"W2947797291","doi":"10.1200/jco.2019.37.15_suppl.e16105","title":"Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia","funders":"","keywords":"BAP1; Medicine; Clear cell renal cell carcinoma; Renal cell carcinoma; Cancer research; Kidney cancer; Germline; Germline mutation; CHEK2; PALB2; Oncology; CDKN2A; Cancer; Internal medicine; Gene; Mutation; Biology; Genetics","score_opus":0.022543275187793355,"score_gpt":0.3153364688915254,"score_spread":0.292793193703732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947797291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983779,0.00014691874,0.00018456367,0.00002775224,0.00038294256,0.00012679277,0.0000055059068,6.008789e-7,0.00074701506],"genre_scores_gemma":[0.9983691,0.00003408874,0.0011777339,0.00020397881,0.00017089682,9.3732416e-7,0.0000043409045,0.000013697554,0.000025216554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828386,0.00016021455,0.0011074755,0.00015605603,0.00014819582,0.00014421676],"domain_scores_gemma":[0.9979419,0.00026154373,0.0013119435,0.00015008418,0.00023891404,0.000095574746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008145366,0.000090241505,0.0005129595,0.00006099056,0.00001147853,0.0000044127746,0.00012573796,0.00011980093,0.000015970722],"category_scores_gemma":[0.00037268063,0.00007203346,0.00016227158,0.00006808757,0.00005351348,0.000005322911,0.000049702925,0.00027456458,0.0000036711954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057929326,0.0017565989,0.7923933,0.00008569983,0.000084660634,0.000053887812,0.00006208582,0.0020997413,0.18668829,0.0000070103506,0.00014979571,0.01082596],"study_design_scores_gemma":[0.013975844,0.033116493,0.86592674,0.00003438952,0.00014107783,0.000019565874,0.00011776048,0.00020379951,0.0809181,0.000059174825,0.005290167,0.00019688901],"about_ca_topic_score_codex":0.000023075336,"about_ca_topic_score_gemma":0.000056964447,"teacher_disagreement_score":0.10577019,"about_ca_system_score_codex":0.000040697407,"about_ca_system_score_gemma":0.00053147774,"threshold_uncertainty_score":0.2937439},"labels":[],"label_agreement":null},{"id":"W2947802634","doi":"10.1200/jco.2019.37.15_suppl.4095","title":"A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Adverse effect; FGF19; Internal medicine; Pharmacokinetics; Gastroenterology; Liver function; Oncology; Pharmacodynamics; Dosing; Receptor","score_opus":0.08834159242637876,"score_gpt":0.4301059335035991,"score_spread":0.3417643410772203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947802634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981694,0.00014766464,0.000016889646,0.000099758625,0.00058602425,0.0006957259,0.000008962713,0.0000023365692,0.0002732163],"genre_scores_gemma":[0.99907815,0.000052135656,0.00021600761,0.00013373788,0.0002989091,0.000008338513,0.000011971089,0.000031232845,0.00016954176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950146,0.0010558863,0.0026267846,0.00037260394,0.00054072303,0.00038940192],"domain_scores_gemma":[0.9967943,0.00052941486,0.0013835606,0.000464496,0.00053747237,0.0002907472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002394493,0.0002114576,0.001314493,0.00024102039,0.000021034464,0.000010791533,0.00060264394,0.0004677767,0.00014041016],"category_scores_gemma":[0.0024616355,0.00015638776,0.00035214997,0.0002476182,0.00013605517,0.00001845268,0.00026314263,0.00080444606,0.000025638496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008195218,0.01331088,0.9553705,0.000057511275,0.00018600514,0.00022196636,0.00020874187,0.000010951699,0.013710831,0.000003084228,0.0005403492,0.008183958],"study_design_scores_gemma":[0.042109184,0.14843735,0.7995527,0.0000615648,0.00008118153,0.000039970513,0.00046579866,0.0003467725,0.0049122865,0.000024599529,0.0037397733,0.00022883352],"about_ca_topic_score_codex":0.00009216484,"about_ca_topic_score_gemma":0.00011273103,"teacher_disagreement_score":0.15581782,"about_ca_system_score_codex":0.00008561979,"about_ca_system_score_gemma":0.0010464839,"threshold_uncertainty_score":0.6377308},"labels":[],"label_agreement":null},{"id":"W2947804460","doi":"10.1200/jco.2019.37.15_suppl.1562","title":"Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Underweight; Internal medicine; Overweight; Body mass index; Lung cancer; Hazard ratio; Proportional hazards model; Oncology; Gastroenterology; Confidence interval","score_opus":0.032015233309086705,"score_gpt":0.3904214898331603,"score_spread":0.35840625652407354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947804460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98968416,0.0011100487,0.0002944932,0.0006512329,0.0073126974,0.0003105352,0.00010703769,0.0000019216386,0.0005278811],"genre_scores_gemma":[0.99319357,0.0019609327,0.00008050082,0.00042177204,0.0037820253,0.000014723049,0.000030089908,0.000015934704,0.0005004427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968051,0.0006793111,0.001608331,0.00033158698,0.00032286346,0.0002528415],"domain_scores_gemma":[0.9959619,0.0014647706,0.0017476361,0.00024877625,0.00042235936,0.00015456374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022928764,0.00018789222,0.0011296689,0.0001963183,0.0000374015,0.000016428286,0.00037454983,0.0004919189,0.0001167995],"category_scores_gemma":[0.000940734,0.000116002695,0.0005012179,0.00021282569,0.00016610307,0.000020230666,0.00014397873,0.00073018315,4.8268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009950689,0.00023516541,0.9914064,0.00003453048,0.0015815811,6.1166554e-7,0.000069659014,0.0008079535,0.0018834212,0.0000152551565,0.0015757055,0.0013946957],"study_design_scores_gemma":[0.0052530067,0.00039850787,0.9842618,0.000051745246,0.0015715411,4.919448e-7,0.000047679285,0.00087432616,0.00016607312,0.000030630566,0.007194543,0.00014966584],"about_ca_topic_score_codex":0.0007677257,"about_ca_topic_score_gemma":0.003114288,"teacher_disagreement_score":0.007144563,"about_ca_system_score_codex":0.000112667905,"about_ca_system_score_gemma":0.0008078375,"threshold_uncertainty_score":0.47304526},"labels":[],"label_agreement":null},{"id":"W2947804662","doi":"10.1200/jco.2019.37.15_suppl.e16058","title":"Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Behavioral Risk Factor Surveillance System; Renal function; Internal medicine; Physical therapy; Medical record; Population; Environmental health","score_opus":0.08652499422483131,"score_gpt":0.4938337333037047,"score_spread":0.40730873907887344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947804662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98870295,0.00063090475,0.000008303974,0.00772379,0.0015634494,0.0007079821,0.000022281361,0.000022643158,0.0006176885],"genre_scores_gemma":[0.9904229,0.0022501878,0.00071456435,0.0059826532,0.0001178338,0.000003821118,0.000010197774,0.000033401106,0.00046442638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99338484,0.00063024944,0.0045934697,0.00033896317,0.0006046985,0.0004477564],"domain_scores_gemma":[0.9903913,0.0024941629,0.0054725544,0.00037017037,0.00034807986,0.0009236955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004233228,0.00029530263,0.0036084026,0.00025475156,0.000055178978,0.0000052294845,0.00014457083,0.00034782072,0.0008510195],"category_scores_gemma":[0.0014703016,0.00018660272,0.0009635131,0.00018270526,0.00018100553,0.00014291631,0.000054087872,0.0012008869,0.0000095262085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013306384,0.0015885794,0.9653158,0.00011206335,0.0028651406,0.00015329139,0.00036443432,0.00039920074,0.000011787971,0.000013406897,0.001121015,0.026724646],"study_design_scores_gemma":[0.0131925745,0.023118181,0.9596904,0.0002315784,0.00030762405,0.000093523835,0.00009885915,0.0003169618,0.0000024779185,0.000019259092,0.0027886224,0.0001399546],"about_ca_topic_score_codex":0.004716596,"about_ca_topic_score_gemma":0.000866786,"teacher_disagreement_score":0.026584692,"about_ca_system_score_codex":0.0010137599,"about_ca_system_score_gemma":0.007157206,"threshold_uncertainty_score":0.9984713},"labels":[],"label_agreement":null},{"id":"W2947812531","doi":"10.1200/jco.2019.37.15_suppl.e20082","title":"Prognostic impact of paraneoplastic syndromes in patients with small cell lung cancer, real-world data.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Immunotherapy; Chemotherapy; Limbic encephalitis; Cancer; Small-cell carcinoma; Lung cancer; Oncology; Small Cell Lung Carcinoma; Gastroenterology; Antibody; Autoantibody; Immunology","score_opus":0.1043215460163125,"score_gpt":0.46344252461151825,"score_spread":0.35912097859520575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947812531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761075,0.00046742894,0.0000037174589,0.00036574426,0.00047923825,0.0005105897,0.000034288925,0.0000029432617,0.00052532984],"genre_scores_gemma":[0.9977204,0.0012127077,0.000678124,0.00010341514,0.00015046698,0.0000067967985,0.000016550995,0.00001614706,0.00009535959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975775,0.00015283204,0.0015442375,0.00021619134,0.00028944423,0.00021982077],"domain_scores_gemma":[0.99490964,0.0025813917,0.0016820871,0.0003190804,0.0002663486,0.00024145556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007541956,0.00014055989,0.0016549146,0.00017243017,0.0000080016425,0.0000042234624,0.00017547421,0.00010336992,0.00019526717],"category_scores_gemma":[0.0004284034,0.00008100943,0.00022670538,0.00021737063,0.00009002828,0.00007799203,0.000055372704,0.00047828312,0.0000066861826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005470944,0.0047275866,0.9753617,0.00011949209,0.00056948955,0.0002431393,0.000028969751,0.00026841203,0.0000015050733,0.0000035203836,0.0009064664,0.012298744],"study_design_scores_gemma":[0.016109426,0.027400065,0.9542996,0.00064650516,0.0008540728,0.000020416428,0.000009435147,0.00014778023,0.0000042617394,0.000005772093,0.0004300991,0.00007251949],"about_ca_topic_score_codex":0.0012990582,"about_ca_topic_score_gemma":0.002959972,"teacher_disagreement_score":0.02267248,"about_ca_system_score_codex":0.0003896648,"about_ca_system_score_gemma":0.0025290656,"threshold_uncertainty_score":0.44864535},"labels":[],"label_agreement":null},{"id":"W2947813932","doi":"10.1200/jco.2019.37.15_suppl.e18236","title":"Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Placebo; Visual analogue scale; Randomized controlled trial; Internal medicine; Nuclear medicine; Physical therapy; Pathology","score_opus":0.03457543385275431,"score_gpt":0.3263448571101933,"score_spread":0.291769423257439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947813932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981375,0.00001039208,0.000017387389,0.00011406564,0.00027057526,0.0010003536,0.0000050717485,0.000004710626,0.00043996578],"genre_scores_gemma":[0.9997669,0.000002473711,0.000025934187,0.000109497574,0.000054859724,0.0000115115645,0.000010214149,0.000007342742,0.000011298265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956862,0.0005928955,0.0022631881,0.00015963052,0.0011224075,0.00017567979],"domain_scores_gemma":[0.9957581,0.00055078877,0.002606058,0.00023349964,0.0007136647,0.00013786931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002191221,0.0001717576,0.0015768151,0.000330378,0.00003756102,0.000014747336,0.00009832,0.00012302719,0.00001873489],"category_scores_gemma":[0.0004068685,0.00008420442,0.00035466003,0.00043951123,0.00009008407,0.00028762314,0.000041947067,0.00041324281,0.0000026868172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008151604,0.0043449528,0.97285116,0.000093153154,0.0024278895,0.00006128302,0.0015336596,0.00011193694,0.0000040015216,0.000017562656,0.0000075835455,0.010395233],"study_design_scores_gemma":[0.012971965,0.016308952,0.9618849,0.000102181955,0.0034960972,0.0000064733727,0.0048771934,0.0002087543,0.0000031207478,0.0000046291143,0.00005644909,0.000079294616],"about_ca_topic_score_codex":0.00026224038,"about_ca_topic_score_gemma":0.00011891662,"teacher_disagreement_score":0.011964,"about_ca_system_score_codex":0.00022879885,"about_ca_system_score_gemma":0.00030063116,"threshold_uncertainty_score":0.34337565},"labels":[],"label_agreement":null},{"id":"W2947823476","doi":"10.1200/jco.2019.37.15_suppl.4079","title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Biliary tract cancer; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Cancer; Immunotherapy; Gemcitabine","score_opus":0.16147508083098983,"score_gpt":0.46010494319948825,"score_spread":0.2986298623684984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947823476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9220807,0.031584937,0.00004706104,0.039618704,0.0036803144,0.00087087776,0.00006971908,0.000021012473,0.0020266573],"genre_scores_gemma":[0.97862107,0.006556573,0.0027608396,0.007207389,0.0033100895,0.000014357041,0.000013825804,0.00004291876,0.0014729439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950286,0.0004390377,0.0029639371,0.00058370415,0.0005086218,0.00047609577],"domain_scores_gemma":[0.9803082,0.015911419,0.0018885126,0.0006023732,0.000920108,0.00036939516],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033602407,0.00034181162,0.0026418932,0.00013214212,0.00013873605,0.000019872197,0.00035886327,0.00043820232,0.00004508106],"category_scores_gemma":[0.010082937,0.00020030997,0.00083738257,0.00021668329,0.000509428,0.00018274553,0.00025615722,0.0013072975,0.000030530522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14420317,0.001643621,0.50915134,0.00029712048,0.005627995,0.000701272,0.004632774,0.000037144713,0.0007480994,0.00025162156,0.18028466,0.1524212],"study_design_scores_gemma":[0.054681033,0.016738066,0.76949996,0.00030127796,0.0012937115,0.00027135827,0.0024708994,0.00009949116,0.00007418456,0.0010819867,0.15323645,0.00025161088],"about_ca_topic_score_codex":0.000056414163,"about_ca_topic_score_gemma":0.00011044685,"teacher_disagreement_score":0.26034862,"about_ca_system_score_codex":0.000215761,"about_ca_system_score_gemma":0.0013409015,"threshold_uncertainty_score":0.99825555},"labels":[],"label_agreement":null},{"id":"W2947828388","doi":"10.1200/jco.2019.37.15_suppl.tps601","title":"KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Breast cancer; Epirubicin; Placebo; Oncology; Chemotherapy; Neoadjuvant therapy; Anthracycline; Cancer; Gastroenterology; Urology; Pathology; Immunotherapy","score_opus":0.036272967628889555,"score_gpt":0.38653736965506713,"score_spread":0.3502644020261776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947828388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320424,0.00056675996,0.00012244817,0.0017317934,0.0005653462,0.003316188,0.00044046185,0.000010468636,0.000042277436],"genre_scores_gemma":[0.99367094,0.0037658114,0.0009739081,0.00031638594,0.00074607565,0.0002454962,0.000050740713,0.0000748178,0.00015581395],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99518126,0.0011367418,0.0021569016,0.000668398,0.00038977718,0.00046694474],"domain_scores_gemma":[0.99316156,0.0015673974,0.003564838,0.000353341,0.0010585429,0.00029429415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013625179,0.00053150236,0.003232697,0.000120627265,0.00015662934,0.00002434525,0.00035504968,0.0003308112,0.00018718836],"category_scores_gemma":[0.00025837278,0.00035068666,0.0005497971,0.00012508927,0.0005841146,0.000040101437,0.00010919399,0.0005852014,0.0000020381765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85850054,0.0054101036,0.108816184,0.000027852866,0.0056566605,0.000017640066,0.00053366757,0.0000248239,0.0023769175,0.000045434936,0.00024081804,0.018349359],"study_design_scores_gemma":[0.7972684,0.068225704,0.11529228,0.000066256696,0.00053481275,0.000048331975,0.00040148865,0.000009325379,0.017333984,0.000040971412,0.00042798,0.00035046824],"about_ca_topic_score_codex":0.0014872364,"about_ca_topic_score_gemma":0.00029046694,"teacher_disagreement_score":0.0628156,"about_ca_system_score_codex":0.00012246204,"about_ca_system_score_gemma":0.0006067261,"threshold_uncertainty_score":0.9998945},"labels":[],"label_agreement":null},{"id":"W2947829857","doi":"10.1200/jco.2019.37.15_suppl.4012","title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Nivolumab; Sorafenib; Gastroenterology; Hepatocellular carcinoma; Clinical endpoint; Randomized controlled trial; Adverse effect; Cancer; Immunotherapy","score_opus":0.047177588256687567,"score_gpt":0.3612129806940574,"score_spread":0.31403539243736983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947829857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404055,0.0005133669,0.000011043717,0.0020432058,0.0014170307,0.0006221249,0.00001451714,0.000011769522,0.0013264104],"genre_scores_gemma":[0.9961723,0.0010691363,0.0006801333,0.0014344098,0.00025131268,0.000004532975,0.00003911979,0.00002955473,0.00031946637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587405,0.00040643875,0.002560232,0.00032764624,0.0005490692,0.0002825896],"domain_scores_gemma":[0.9959422,0.0008951198,0.0020988614,0.00035975783,0.00051681773,0.00018729444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020625656,0.00020661809,0.0014091717,0.00017586666,0.000030143712,0.000011795518,0.00022095467,0.0004069723,0.00018682955],"category_scores_gemma":[0.0004429129,0.00014249737,0.0003565376,0.00024590222,0.0001487727,0.00021416813,0.00002886856,0.00087198237,0.000028160572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17986237,0.0027718905,0.6433387,0.000012763801,0.00026294414,0.00013864176,0.00025628303,0.000008314402,0.0009249151,0.0000072236285,0.00038684954,0.17202914],"study_design_scores_gemma":[0.1474484,0.04053158,0.7951231,0.00020452017,0.00006183172,0.00001896476,0.00011144142,0.00027832016,0.0005891951,0.00008373069,0.015403648,0.00014523366],"about_ca_topic_score_codex":0.00023353621,"about_ca_topic_score_gemma":0.0000656693,"teacher_disagreement_score":0.17188391,"about_ca_system_score_codex":0.0004180789,"about_ca_system_score_gemma":0.0009850803,"threshold_uncertainty_score":0.58108747},"labels":[],"label_agreement":null},{"id":"W2947836162","doi":"10.1200/jco.2019.37.15_suppl.5522","title":"Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Dysgeusia; Internal medicine; Clinical endpoint; Adverse effect; Anemia; Oncology; Placebo; Population; Nausea; BRCA mutation; Clinical trial; Surgery; Cancer; Ovarian cancer; Pathology","score_opus":0.08156899300859487,"score_gpt":0.4479196416337377,"score_spread":0.3663506486251428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947836162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996889,0.000055599055,0.000015809153,0.0013495455,0.0005554617,0.0008421107,0.00020208456,0.0000022253453,0.00008816525],"genre_scores_gemma":[0.9991689,0.00003144615,0.00009882264,0.0005565322,0.0000728938,0.000003690801,0.000049740927,0.000010470416,0.0000075485495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508524,0.0020267845,0.0019131006,0.0002841726,0.00054762437,0.00014308398],"domain_scores_gemma":[0.99131674,0.0047977436,0.00269237,0.00073356915,0.00035745703,0.00010211001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036349753,0.0001628329,0.0018780163,0.00013275765,0.000032427168,0.0000044113995,0.0003112241,0.00015233364,0.000051999832],"category_scores_gemma":[0.0015195147,0.00006908082,0.00020828561,0.00044267136,0.00029030783,0.00009745854,0.00013640574,0.00086259155,0.0000012554171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059662156,0.002844578,0.9221982,0.000007368104,0.0017503841,0.000034076857,0.0005334635,0.00002584074,0.000049317692,0.000005196337,0.00026078123,0.012628654],"study_design_scores_gemma":[0.045717496,0.03985663,0.9112468,0.00029944992,0.0015163661,0.0000031302873,0.0005018489,0.0003380985,0.0001925304,0.000007479644,0.00025824172,0.00006194298],"about_ca_topic_score_codex":0.00006513543,"about_ca_topic_score_gemma":0.0001701556,"teacher_disagreement_score":0.03701205,"about_ca_system_score_codex":0.00012241853,"about_ca_system_score_gemma":0.0003750626,"threshold_uncertainty_score":0.37475792},"labels":[],"label_agreement":null},{"id":"W2947837169","doi":"10.1200/jco.2020.38.6_suppl.tps383","title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostatectomy; Urology; Prostate cancer; Placebo; Internal medicine; Randomization; Antiandrogen; Biopsy; Prostate-specific antigen; Randomized controlled trial; Oncology; Gastroenterology; Cancer; Pathology","score_opus":0.08701395422269277,"score_gpt":0.4446149494255303,"score_spread":0.35760099520283756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947837169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96502686,0.000824092,0.0008410159,0.006147801,0.0007206082,0.026304256,0.000046054767,0.000030010982,0.000059333866],"genre_scores_gemma":[0.9878477,0.0044768774,0.0035381485,0.00090129115,0.00081578374,0.002163162,0.000045374356,0.0000812061,0.0001304531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99060607,0.0016514586,0.0048307627,0.0006806235,0.00151718,0.0007139229],"domain_scores_gemma":[0.9902381,0.0033982939,0.0036061683,0.00033798805,0.001339548,0.0010799319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049160547,0.0005037175,0.0058684847,0.00039589943,0.00009614852,0.000032775275,0.00038025252,0.00053371035,0.0001665559],"category_scores_gemma":[0.0052914512,0.00027456362,0.0007093238,0.00083677564,0.0006639602,0.00029652932,0.000106519605,0.001706878,0.0000070603587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8790337,0.004406915,0.0029352817,0.00011201125,0.0025910346,0.00046568448,0.0009127561,0.001349837,0.000052212246,0.000009888301,0.0001309921,0.10799971],"study_design_scores_gemma":[0.8887145,0.104653545,0.00040130998,0.0004403167,0.00093230006,0.000009204472,0.00013224389,0.001126755,0.0007018959,0.000034484554,0.0025852048,0.00026825428],"about_ca_topic_score_codex":0.00023124907,"about_ca_topic_score_gemma":0.00021920686,"teacher_disagreement_score":0.10773146,"about_ca_system_score_codex":0.0010022204,"about_ca_system_score_gemma":0.010560282,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W2947840610","doi":"10.1200/jco.2019.37.15_suppl.4005","title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) <i>(</i>Alliance A021202<i>)</i>.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Pazopanib; Internal medicine; Hazard ratio; Regorafenib; Neuroendocrine tumors; Gastroenterology; Placebo; Randomization; Progression-free survival; Randomized controlled trial; Urology; Cancer; Confidence interval; Chemotherapy; Colorectal cancer; Pathology","score_opus":0.05478446337088199,"score_gpt":0.4539388293389862,"score_spread":0.3991543659681042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947840610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042344,0.00023541629,0.000004132182,0.0012527345,0.001273115,0.004835437,0.000008477213,0.000009428759,0.001957819],"genre_scores_gemma":[0.99739754,0.00013489621,0.0013968917,0.00018984375,0.0005350338,0.00007116001,0.0000043399414,0.000033148484,0.00023715178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934555,0.0013174688,0.0031620748,0.0003915585,0.0011801693,0.00049321],"domain_scores_gemma":[0.9893184,0.005441636,0.003233785,0.00033405854,0.0012342547,0.00043789842],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002990123,0.00025512264,0.0039167004,0.00021391994,0.000031237785,0.0000075525068,0.00031544434,0.00007211335,0.00015562595],"category_scores_gemma":[0.013604477,0.00015904703,0.0005707844,0.0003747586,0.0007418518,0.00026070044,0.00012883174,0.0017509813,0.000010533793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90164834,0.009959564,0.08149265,0.0000718885,0.0003539026,0.0024391804,0.00006673799,0.000017343218,0.000045272875,0.000059332262,0.00021722214,0.0036285918],"study_design_scores_gemma":[0.80209225,0.1822305,0.013598493,0.0002720387,0.00022370751,0.00008523467,0.00008925888,0.000026960342,0.00040309786,0.00010942203,0.0007562648,0.000112769405],"about_ca_topic_score_codex":0.000012306383,"about_ca_topic_score_gemma":0.000019576626,"teacher_disagreement_score":0.17227094,"about_ca_system_score_codex":0.0002178694,"about_ca_system_score_gemma":0.0023178111,"threshold_uncertainty_score":0.99470437},"labels":[],"label_agreement":null},{"id":"W2947842052","doi":"10.1200/jco.2019.37.15_suppl.e12567","title":"Associations with response to poly (ADP-ribose) polymerase (PARP) inhibitors in metastatic breast cancer: Results of a meta-regression analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; BRCA mutation; Oncology; Breast cancer; Internal medicine; Metastatic breast cancer; Chemotherapy; Germline; Meta-analysis; Cancer; Germline mutation; PARP inhibitor; Mutation; Poly ADP ribose polymerase; Polymerase; Genetics; Biology","score_opus":0.11975684818303342,"score_gpt":0.4893155801934462,"score_spread":0.3695587320104128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947842052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94178885,0.0009832273,0.00014295294,0.055492636,0.0005559818,0.00038570786,0.00031391767,0.000008544674,0.0003281642],"genre_scores_gemma":[0.99276114,0.00020137074,0.0030914184,0.0029923862,0.00040839298,0.000016989476,0.000009930131,0.000022244642,0.00049614743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925848,0.0019496105,0.003981757,0.0003260825,0.00085399474,0.0003037493],"domain_scores_gemma":[0.98885375,0.0052688285,0.004151755,0.0003940237,0.0008481239,0.00048350397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008845587,0.00022778439,0.0037205494,0.0010303581,0.000028508874,0.000008301128,0.00019491804,0.00025365973,0.0004097585],"category_scores_gemma":[0.0027595176,0.00013511619,0.0010688532,0.0017076744,0.00014590278,0.00016775445,0.000039737944,0.00089732104,0.000013979472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37305838,0.0070554903,0.5180879,0.000060090268,0.03628292,0.0009637873,0.0015327759,0.003975429,0.01755219,0.00005924618,0.011668934,0.029702831],"study_design_scores_gemma":[0.039125793,0.014974401,0.91615707,0.00050659984,0.01334658,0.00022221237,0.0003165582,0.00014422006,0.0036054507,0.00008100789,0.011258219,0.00026190066],"about_ca_topic_score_codex":0.00053244253,"about_ca_topic_score_gemma":0.00061627576,"teacher_disagreement_score":0.3980691,"about_ca_system_score_codex":0.0005505191,"about_ca_system_score_gemma":0.003359521,"threshold_uncertainty_score":0.5959646},"labels":[],"label_agreement":null},{"id":"W2947849684","doi":"10.1200/jco.2019.37.15_suppl.e17030","title":"Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcopenia; Taxane; Internal medicine; Cancer; Chemotherapy; Oncology; Breast cancer; Proportional hazards model","score_opus":0.0631211389098044,"score_gpt":0.4319822986129038,"score_spread":0.3688611597030994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947849684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051344,0.000081889666,0.000021135767,0.007432479,0.00076073984,0.000344674,0.0000088578345,0.000004021068,0.000832783],"genre_scores_gemma":[0.99293596,0.00016040137,0.00333031,0.0030506758,0.0004027742,0.000002527776,0.0000020473392,0.0000151981685,0.000100104444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758345,0.00027135608,0.001488219,0.0001434469,0.00033542508,0.0001780894],"domain_scores_gemma":[0.9969337,0.0010759431,0.0013265321,0.000107698455,0.00031599618,0.00024011178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020554846,0.00009538976,0.0011663992,0.00013395495,0.000015810661,0.000003615035,0.000074126525,0.00022093288,0.00053517503],"category_scores_gemma":[0.0007168897,0.00006605486,0.000093113995,0.00011637575,0.00010745743,0.00006408947,0.000014915107,0.00070536823,0.000003602985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016178913,0.0009172765,0.95528686,0.00013432624,0.00006567989,0.00002897865,0.00010760956,0.0000070570377,0.0001283644,0.000019617399,0.00014033426,0.026984997],"study_design_scores_gemma":[0.043558016,0.00977974,0.9383849,0.0007861037,0.000051246865,0.000011423926,0.000040572686,0.00008914656,0.000067141526,0.00006287077,0.007108233,0.000060616123],"about_ca_topic_score_codex":0.000101449674,"about_ca_topic_score_gemma":0.0001019044,"teacher_disagreement_score":0.027379103,"about_ca_system_score_codex":0.0001027438,"about_ca_system_score_gemma":0.0015402265,"threshold_uncertainty_score":0.5859791},"labels":[],"label_agreement":null},{"id":"W2947849849","doi":"10.1200/jco.2019.37.15_suppl.e15597","title":"The impact of geography and center volume on access to care and outcomes in advanced hepatocellular carcinoma (HCC): A retrospective population based study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Population; Liver disease; Sorafenib; Liver cancer; Hepatitis B; Gastroenterology; Cancer; Hepatitis C; Surgery","score_opus":0.045606782079829426,"score_gpt":0.4379082440342711,"score_spread":0.39230146195444165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947849849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977069,0.00020246109,0.0000028381273,0.0008709908,0.0003007973,0.0006861351,0.00000953205,0.0000018391232,0.00021850115],"genre_scores_gemma":[0.9991706,0.000059626353,0.00011128733,0.0005652325,0.000063156374,0.0000036922547,0.000002510735,0.000008217921,0.000015670468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823856,0.00024567597,0.0010020247,0.00016889497,0.0002078971,0.00013693297],"domain_scores_gemma":[0.99811417,0.0007319574,0.00061862456,0.00016268119,0.00020735794,0.0001652211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087842013,0.00010553752,0.001054863,0.00017177552,0.00002749917,0.000010607754,0.000098328645,0.000110071276,0.000021874757],"category_scores_gemma":[0.00059494853,0.000059806163,0.00025387495,0.00010006085,0.000043952285,0.000107879256,0.000042570882,0.0004460639,9.371459e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006614474,0.00042444534,0.97174454,0.000016351156,0.00011984885,0.000046590245,0.00018511525,0.000055743294,0.000024949692,0.0000013081125,0.00003831598,0.02072831],"study_design_scores_gemma":[0.010840857,0.026742592,0.9614356,0.00004562868,0.000050549756,0.0000062841164,0.00032163752,0.0002852309,0.000005031711,0.000016050513,0.00019733218,0.00005316917],"about_ca_topic_score_codex":0.00036812722,"about_ca_topic_score_gemma":0.00023630074,"teacher_disagreement_score":0.026318146,"about_ca_system_score_codex":0.00023645512,"about_ca_system_score_gemma":0.00032269824,"threshold_uncertainty_score":0.24388245},"labels":[],"label_agreement":null},{"id":"W2947850872","doi":"10.1200/jco.2019.37.15_suppl.e16062","title":"Utilization of mental health services among survivors of testicular cancer: A population-based study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Orchiectomy; Testicular cancer; Mental health; Cohort; Cancer registry; Population; Seminoma; Distress; Cancer; Emergency medicine; Gynecology; Surgery; Internal medicine; Psychiatry; Chemotherapy; Environmental health","score_opus":0.07620055100182839,"score_gpt":0.4791347674127212,"score_spread":0.40293421641089283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947850872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738187,0.001063752,0.000018302499,0.0005291841,0.00046530884,0.00048346285,0.00001472404,0.0000043205287,0.00003909724],"genre_scores_gemma":[0.9989503,0.00009707475,0.0005555664,0.0002703677,0.00007750167,0.000002121032,0.00001813795,0.00000988499,0.000019031093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997377,0.00030068323,0.001719748,0.00011877024,0.00037731958,0.00010651827],"domain_scores_gemma":[0.99596566,0.00054266147,0.0027724395,0.00014959264,0.0003561399,0.0002134784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087684044,0.0000890224,0.0011186235,0.000094528405,0.000017579798,0.0000019476042,0.00007554347,0.000097626886,0.00013828065],"category_scores_gemma":[0.00032932247,0.00006227403,0.0002814199,0.00014287762,0.000039158283,0.00005479164,0.000017304086,0.00014980555,0.0000020667103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097035925,0.004878019,0.97884476,0.00023343987,0.00036085374,0.000026372572,0.00009252839,0.00029635805,0.000011167654,0.0000076258675,0.000015153894,0.014263375],"study_design_scores_gemma":[0.007852198,0.012116586,0.9773624,0.00046016896,0.00042620246,0.0000059129843,0.00024141396,0.0013670414,0.000014796045,0.00001810727,0.000097122276,0.000038075108],"about_ca_topic_score_codex":0.0026109386,"about_ca_topic_score_gemma":0.00079055596,"teacher_disagreement_score":0.0142252995,"about_ca_system_score_codex":0.000111221714,"about_ca_system_score_gemma":0.001147627,"threshold_uncertainty_score":0.39469758},"labels":[],"label_agreement":null},{"id":"W2947865574","doi":"10.1200/jco.2019.37.15_suppl.533","title":"Influence of competing risks on estimates of recurrence risk and breast cancer-specific mortality in analyses of the Early Breast Cancer Trialists Collaborative Group.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Breast cancer; Medicine; Relative risk; Cancer; Epidemiology; Internal medicine; Incidence (geometry); Cumulative incidence; Oncology; Absolute risk reduction; Demography; Confidence interval; Cohort","score_opus":0.106162191758528,"score_gpt":0.47761207753335144,"score_spread":0.37144988577482346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947865574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621636,0.0023124048,0.000004755247,0.00038278714,0.0003186546,0.00018299566,0.0005328392,8.4801064e-7,0.000048371734],"genre_scores_gemma":[0.9925964,0.0070000812,0.00018560776,0.000047180307,0.0001532518,0.000006896747,0.0000016224877,0.0000075213356,0.0000014250418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971306,0.00064826215,0.0015943028,0.00023576252,0.00024325,0.00014787928],"domain_scores_gemma":[0.99458975,0.0008791291,0.0035143085,0.00022896615,0.0007224403,0.000065411674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013060848,0.00015506611,0.0011577699,0.000056703368,0.000029211647,0.0000039606384,0.00024915705,0.00019495087,0.000012033553],"category_scores_gemma":[0.0006033941,0.000098808305,0.0002094727,0.00026067306,0.0006097044,0.000013681417,0.00011929932,0.00032616893,1.9040729e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003892289,0.0004687166,0.97297704,0.000039009665,0.0004988955,0.0000025446436,0.00013697003,0.0023952897,0.0089020785,0.000021118214,0.000028184228,0.010637847],"study_design_scores_gemma":[0.003474716,0.0012432162,0.98957145,0.0003444173,0.00021092272,0.000013567833,0.00013833244,0.000017235916,0.0047653024,0.000071087976,0.00006844965,0.00008129533],"about_ca_topic_score_codex":0.0032531428,"about_ca_topic_score_gemma":0.0012731698,"teacher_disagreement_score":0.016594399,"about_ca_system_score_codex":0.0000602535,"about_ca_system_score_gemma":0.0005735089,"threshold_uncertainty_score":0.49178007},"labels":[],"label_agreement":null},{"id":"W2947872006","doi":"10.1200/jco.2019.37.15_suppl.e16091","title":"Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in forty-three countries.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; Kidney Foundation of Canada","funders":"","keywords":"Medicine; Psychosocial; Family medicine; Quality of life (healthcare); Cancer; Renal cell carcinoma; Kidney cancer; Internal medicine; Nursing; Psychiatry","score_opus":0.08904162561845069,"score_gpt":0.33962377416890577,"score_spread":0.2505821485504551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947872006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891599,0.0025147963,0.00007680024,0.00015945232,0.0010503333,0.0002488993,0.0005003843,0.0000017851404,0.006287638],"genre_scores_gemma":[0.99660164,0.0024534252,0.0006173627,0.00018895479,0.00008911457,0.0000051912434,0.000007489076,0.000008866015,0.000027967655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421585,0.000082613624,0.0050649084,0.00031758597,0.00008575151,0.0002333124],"domain_scores_gemma":[0.9918028,0.001013181,0.0065697995,0.0002831166,0.00017898392,0.00015207966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020684153,0.00014072932,0.0016042112,0.00013652946,0.000014231071,0.000011086087,0.00023444263,0.00027133638,0.00010557593],"category_scores_gemma":[0.0013434486,0.00013817413,0.00020447516,0.00015186962,0.0001978068,0.0002572541,0.0001278752,0.00026744898,0.000009700732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022035202,0.0003358438,0.98191285,0.000019294745,0.000108525244,0.000042001822,0.0005797367,0.00016885123,0.0000013147968,0.00054537004,0.00068474736,0.013397934],"study_design_scores_gemma":[0.0052660974,0.0027830868,0.96877843,0.00007209524,0.000021387945,0.0000037243515,0.0001922643,0.00010244134,0.00003680748,0.0032433274,0.019365443,0.00013490146],"about_ca_topic_score_codex":0.005912361,"about_ca_topic_score_gemma":0.0012881322,"teacher_disagreement_score":0.018680695,"about_ca_system_score_codex":0.0001786399,"about_ca_system_score_gemma":0.00023307263,"threshold_uncertainty_score":0.8937761},"labels":[],"label_agreement":null},{"id":"W2947877747","doi":"10.1200/jco.2019.37.15_suppl.e18215","title":"Impact of the addition of bevacizumab (Bev) to chemotherapy on survival in metastatic colorectal cancer (MCRC): A real-world population-based analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Oxaliplatin; Oncology; Colorectal cancer; Irinotecan; Proportional hazards model; Cohort; Population; Chemotherapy; Multivariate analysis; Cancer","score_opus":0.07961893963974925,"score_gpt":0.49263509719442966,"score_spread":0.4130161575546804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947877747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959118,0.000055776152,0.000005018193,0.0021177898,0.00041540345,0.00039089046,0.000051604915,0.0000021281871,0.0010496028],"genre_scores_gemma":[0.99907863,0.000120757366,0.00020426484,0.0003625922,0.00011494275,0.000010279499,0.0000067757856,0.000009410443,0.00009232512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973149,0.00036219173,0.0016216941,0.00015115847,0.00040175967,0.00014832239],"domain_scores_gemma":[0.9959707,0.0018775439,0.0015392373,0.00015972399,0.00034279865,0.00010995134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011016137,0.00012896433,0.0019442413,0.00034965234,0.000017198121,0.000002237161,0.00010726879,0.00008623707,0.0006531178],"category_scores_gemma":[0.00065259833,0.00006945757,0.0010177522,0.0008635887,0.000065261185,0.000032396772,0.000017707825,0.00031703393,0.0000015929166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016633496,0.0014927705,0.9596029,0.000018497994,0.0026071516,0.000012329032,0.00013332309,0.0036122447,0.0001549782,0.000021624634,0.00023420315,0.015476494],"study_design_scores_gemma":[0.007513273,0.014304343,0.9762662,0.000112572896,0.0010091582,0.0000018235612,0.00004609363,0.00034255462,0.00012770873,0.00005344688,0.00016845534,0.00005437712],"about_ca_topic_score_codex":0.0032921555,"about_ca_topic_score_gemma":0.01802135,"teacher_disagreement_score":0.016663305,"about_ca_system_score_codex":0.0006978784,"about_ca_system_score_gemma":0.001210446,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W2947885749","doi":"10.1200/jco.2019.37.15_suppl.3028","title":"Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (<i>DPYD)</i> genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Toronto; Lawson Health Research Institute; Cancer Care Ontario; Western University","funders":"","keywords":"DPYD; Medicine; Capecitabine; Dihydropyrimidine dehydrogenase; Internal medicine; Prospective cohort study; Adverse effect; Chemotherapy; Oncology; Cohort; Common Terminology Criteria for Adverse Events; Fluorouracil; Pharmacogenetics; Genotype; Cancer; Colorectal cancer; Thymidylate synthase","score_opus":0.03903251721696833,"score_gpt":0.4040380503552473,"score_spread":0.365005533138279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947885749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952027,0.00017826728,0.0000042776005,0.000672518,0.0006085841,0.0028356772,0.000017160053,0.00000583329,0.00047494014],"genre_scores_gemma":[0.9990311,0.00007761485,0.00040487308,0.00020064632,0.00018928602,0.00003058529,0.0000012672359,0.000026262685,0.000038308448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974924,0.00015770597,0.001478917,0.00026992973,0.00038537395,0.00021571256],"domain_scores_gemma":[0.99442285,0.0022407547,0.0020552103,0.0002623523,0.00085644925,0.00016237023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011262903,0.00022676756,0.0017390014,0.00007561995,0.000057921323,0.0000020566285,0.00014701538,0.00015205758,0.000024157822],"category_scores_gemma":[0.00286228,0.000121289915,0.00063541316,0.00019527141,0.00017129583,0.00005490479,0.000055390814,0.000378571,0.0000010569981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010727061,0.009831357,0.9718014,0.000036374076,0.0019469316,0.000024256024,0.00029609358,0.00014262623,0.00044237406,0.0000031319314,0.0002095926,0.0045388006],"study_design_scores_gemma":[0.018736789,0.17497192,0.8038649,0.00013423868,0.00060242123,0.0000070551055,0.00023016435,0.00022986846,0.0010397717,0.000050566825,0.000039101924,0.000093188035],"about_ca_topic_score_codex":0.00017056026,"about_ca_topic_score_gemma":0.000029142117,"teacher_disagreement_score":0.16793649,"about_ca_system_score_codex":0.000457138,"about_ca_system_score_gemma":0.0008659282,"threshold_uncertainty_score":0.49460593},"labels":[],"label_agreement":null},{"id":"W2947888157","doi":"10.1200/jco.2019.37.15_suppl.6065","title":"Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Contraindication; Durvalumab; Internal medicine; Common Terminology Criteria for Adverse Events; Cancer; Head and neck cancer; Adverse effect; Head and neck squamous-cell carcinoma; Tolerability; Oncology; Clinical endpoint; Surgery; Clinical trial; Pathology","score_opus":0.02629450861956823,"score_gpt":0.4376512528046826,"score_spread":0.41135674418511436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947888157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935248,0.0009204324,0.00027097776,0.004152024,0.000116800686,0.0007341377,0.000014500904,0.0000026932516,0.00026366234],"genre_scores_gemma":[0.99310917,0.00084891694,0.0046332646,0.0012264219,0.000073296076,0.000017475773,0.000008305653,0.000014835366,0.0000683233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839485,0.000071588314,0.00087192905,0.00019219969,0.0003265348,0.00014292377],"domain_scores_gemma":[0.99784005,0.00042316638,0.0009753785,0.000102160324,0.00040272,0.00025652375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035497345,0.00012726507,0.0010130488,0.00010135171,0.000019137662,0.0000037265615,0.000046686873,0.00009511664,0.000052606778],"category_scores_gemma":[0.00008721087,0.00006828255,0.000039909148,0.00011915118,0.00018261107,0.00010046547,0.000009089913,0.0002664976,3.3981777e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023667997,0.00074538426,0.77653867,0.00003827549,0.00042462055,0.000023615921,0.00041690393,0.00016489309,0.000018366909,0.00006224043,0.000038064572,0.19786097],"study_design_scores_gemma":[0.060337182,0.033173814,0.896549,0.00088934595,0.00026858697,0.000043482025,0.00008768593,0.000057760975,0.000004850695,0.000008467097,0.008500862,0.00007900651],"about_ca_topic_score_codex":0.00005701726,"about_ca_topic_score_gemma":0.000503715,"teacher_disagreement_score":0.19778197,"about_ca_system_score_codex":0.00019231677,"about_ca_system_score_gemma":0.0014293918,"threshold_uncertainty_score":0.27844816},"labels":[],"label_agreement":null},{"id":"W2947888232","doi":"10.1200/jco.2019.37.15_suppl.3142","title":"Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Capecitabine; Medicine; Epirubicin; Docetaxel; Triple-negative breast cancer; Internal medicine; Oncology; Cyclophosphamide; Breast cancer; Gene signature; Chemotherapy; Adjuvant; Cancer; Colorectal cancer; Gene expression","score_opus":0.04443171687605387,"score_gpt":0.47001652870276767,"score_spread":0.4255848118267138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947888232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97055525,0.0006185509,0.000005431532,0.023485009,0.0034762437,0.0013367197,0.000016282655,0.0000047077006,0.00050180603],"genre_scores_gemma":[0.99385476,0.00040455925,0.0003401302,0.0029035269,0.0010415906,0.000033168162,0.0000010461698,0.000019439796,0.0014017643],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99567133,0.00131862,0.0021956784,0.00022767698,0.00031883435,0.00026787719],"domain_scores_gemma":[0.98819256,0.009709457,0.0013467856,0.00017714364,0.0002611196,0.00031296382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028800885,0.00018526813,0.002374167,0.00038910226,0.000012971545,0.0000022808213,0.00016309478,0.00032912803,0.0006741364],"category_scores_gemma":[0.0025130871,0.00012255652,0.0005470646,0.00031555028,0.000111481604,0.00003856602,0.000043928598,0.0011418454,0.000033801643],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8863322,0.0054114684,0.0073787835,0.00008352502,0.00045618354,0.00067550095,0.00045482162,0.00012728994,0.018344985,0.000010790314,0.0013533359,0.07937113],"study_design_scores_gemma":[0.27871433,0.10642036,0.6015903,0.00042081697,0.00044480906,0.0001504555,0.00004731682,0.000010187956,0.0035074893,0.000114881295,0.008469926,0.00010919003],"about_ca_topic_score_codex":0.00014897811,"about_ca_topic_score_gemma":0.0001393021,"teacher_disagreement_score":0.60761786,"about_ca_system_score_codex":0.00041185357,"about_ca_system_score_gemma":0.0019291359,"threshold_uncertainty_score":0.7381321},"labels":[],"label_agreement":null},{"id":"W2947890783","doi":"10.1200/jco.2019.37.15_suppl.tps5095","title":"High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Asymptomatic; Androgen deprivation therapy; Androgen receptor; Internal medicine; Oncology; Disease; Circulating tumor cell; Homologous recombination; Cancer; Endocrinology; Cancer research; Metastasis; Biology; DNA; Genetics","score_opus":0.08331740267119467,"score_gpt":0.4405109860249789,"score_spread":0.35719358335378426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947890783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988353,0.0022197298,0.000003815281,0.0071069323,0.00026506252,0.0006085967,0.000006437385,0.0000052876126,0.0014311494],"genre_scores_gemma":[0.99383986,0.002833005,0.0013110818,0.00023551293,0.000070886614,0.000018830828,0.0000041731496,0.000015330545,0.0016713171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758637,0.00032502128,0.0012139531,0.00023018988,0.0003478051,0.0002966456],"domain_scores_gemma":[0.99770534,0.0008077678,0.0007786459,0.00012996845,0.00033651467,0.00024174726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002098474,0.00013687147,0.0010649693,0.00020201522,0.000028842152,0.000014587452,0.00008648188,0.00013327523,0.00012299613],"category_scores_gemma":[0.0003203982,0.000079016834,0.00007807304,0.00022124847,0.00021965794,0.00015633118,0.000034715224,0.0007192521,0.000009974816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06491538,0.006159921,0.63574415,0.00049808074,0.0007866252,0.008495325,0.0011055979,0.00021530426,0.004723493,0.00035021163,0.0011155403,0.27589035],"study_design_scores_gemma":[0.042976122,0.05240818,0.8995499,0.0004003702,0.0003725198,0.00069133576,0.0006097046,0.00016467996,0.00038662364,0.0010131885,0.0012700169,0.0001573729],"about_ca_topic_score_codex":0.00030044976,"about_ca_topic_score_gemma":0.00028711164,"teacher_disagreement_score":0.27573296,"about_ca_system_score_codex":0.0003185922,"about_ca_system_score_gemma":0.0019527789,"threshold_uncertainty_score":0.3464146},"labels":[],"label_agreement":null},{"id":"W2947894548","doi":"10.1200/jco.2019.37.15_suppl.e12556","title":"New docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Docetaxel; Cancer research; Triple-negative breast cancer; Medicine; Gene silencing; In vivo; Survivin; Cancer; Apoptosis; Breast cancer; Biology; Internal medicine; Biochemistry","score_opus":0.04427647179821066,"score_gpt":0.41146423793898645,"score_spread":0.3671877661407758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947894548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402977,0.010505142,0.0026821743,0.007664628,0.035683468,0.001341544,0.00035205027,0.000004553608,0.0014687423],"genre_scores_gemma":[0.88823104,0.041721016,0.0032222671,0.0021922912,0.055356346,0.000043300788,0.000016021262,0.000045788274,0.009171952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791294,0.00019552585,0.0013119844,0.00021425937,0.00014767791,0.000217587],"domain_scores_gemma":[0.9965955,0.0009194761,0.0015711031,0.00022507372,0.0004965813,0.0001922707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000788774,0.00015770241,0.0009890597,0.000031805983,0.000038016846,0.000007142951,0.00023238565,0.0002692893,0.0001092063],"category_scores_gemma":[0.00035774958,0.00009335536,0.0008022342,0.00005586185,0.00017019006,0.000007953198,0.000028148866,0.00017740334,0.000004287948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037397135,0.0020827053,0.01587166,0.000037797447,0.0041372273,0.00000222284,0.00055708585,0.000635934,0.048428833,0.00041267037,0.111372136,0.7790646],"study_design_scores_gemma":[0.015161984,0.015079612,0.06240507,0.000032698124,0.00059931795,0.00006525679,0.00022428317,0.000048913877,0.013092351,0.0002723417,0.89287263,0.00014552244],"about_ca_topic_score_codex":0.00024650517,"about_ca_topic_score_gemma":0.00040721582,"teacher_disagreement_score":0.7815005,"about_ca_system_score_codex":0.00005937968,"about_ca_system_score_gemma":0.0020389198,"threshold_uncertainty_score":0.3806921},"labels":[],"label_agreement":null},{"id":"W2947918745","doi":"10.1200/jco.2019.37.15_suppl.tps597","title":"NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Letrozole; Anastrozole; Internal medicine; Randomization; Goserelin; Breast cancer; Cancer; Oncology; Metastatic breast cancer; Adjuvant; Randomized controlled trial; Tamoxifen","score_opus":0.07142779416144623,"score_gpt":0.473287293458567,"score_spread":0.4018594992971208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947918745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907476,0.0017539237,0.000016350205,0.0040391525,0.0009501848,0.0018944193,0.00019399283,0.000022909462,0.00038150937],"genre_scores_gemma":[0.99357504,0.0031631659,0.00058183813,0.0009941148,0.0009964113,0.00008196153,0.000017517716,0.00007769076,0.0005122756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99293005,0.0014380397,0.0036771519,0.0005919014,0.00077686977,0.00058598706],"domain_scores_gemma":[0.99203104,0.0024123513,0.003524623,0.00040469234,0.0011087293,0.0005185662],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013021932,0.00052286516,0.003795918,0.00034939332,0.00006679388,0.0000130178905,0.0003453752,0.00033614028,0.0020199688],"category_scores_gemma":[0.00044782757,0.0003666315,0.0006557614,0.00038995725,0.0004124349,0.00050688407,0.00008896377,0.0014849721,0.00003972575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15137991,0.04532681,0.27014014,0.000040892228,0.00510747,0.0010072339,0.0123019675,0.000033230008,0.04076853,0.000106113905,0.00028739704,0.47350028],"study_design_scores_gemma":[0.15118839,0.11623946,0.7201489,0.00024039,0.00027483475,0.00032336797,0.0027865695,0.0000063981074,0.005527506,0.00018339716,0.002746741,0.00033405598],"about_ca_topic_score_codex":0.003197316,"about_ca_topic_score_gemma":0.0004733253,"teacher_disagreement_score":0.47316623,"about_ca_system_score_codex":0.0012719021,"about_ca_system_score_gemma":0.0017319339,"threshold_uncertainty_score":0.9998786},"labels":[],"label_agreement":null},{"id":"W2947922688","doi":"10.1200/jco.2019.37.15_suppl.e20594","title":"Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Myeloid; Oncology; Immunotherapy; Population; Proportional hazards model; Lymphocyte; Immunology; Confounding; Cancer; Gastroenterology","score_opus":0.014262838401212603,"score_gpt":0.34053839713564865,"score_spread":0.32627555873443603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947922688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430907,0.0018813838,0.0000034485693,0.00029382302,0.0009726269,0.0015613742,0.000041430583,0.000011806273,0.000925029],"genre_scores_gemma":[0.997613,0.0006187386,0.0010145723,0.00027724443,0.00024811507,0.00004852228,0.000011319701,0.00004843101,0.00012006185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954965,0.00054407906,0.0025705723,0.00039143662,0.0005781124,0.0004193165],"domain_scores_gemma":[0.99334294,0.0011219142,0.0035431911,0.00026278177,0.0012854976,0.0004436728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012117663,0.00031103494,0.0019320324,0.0002533574,0.000031421143,0.000010963659,0.0002248679,0.00039565976,0.00014972402],"category_scores_gemma":[0.00095300394,0.00021600367,0.00028442097,0.00026121037,0.00037424662,0.00022013557,0.00012511651,0.00088701164,0.000005421756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057784352,0.0021918444,0.9189614,0.00040493574,0.0007488375,0.0005003675,0.00045287804,0.000020478323,0.0017419034,0.0000012109326,0.00020714376,0.016984634],"study_design_scores_gemma":[0.03778118,0.015380349,0.93930817,0.001686788,0.00067410205,0.000020649086,0.00023658054,0.00013720324,0.0040961076,0.000016152979,0.00044457856,0.0002181705],"about_ca_topic_score_codex":0.00004713288,"about_ca_topic_score_gemma":0.000027186103,"teacher_disagreement_score":0.020346725,"about_ca_system_score_codex":0.00024493778,"about_ca_system_score_gemma":0.0025716345,"threshold_uncertainty_score":0.8808374},"labels":[],"label_agreement":null},{"id":"W2947923256","doi":"10.1200/jco.2019.37.15_suppl.6610","title":"A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Premedication; Dexamethasone; Chemotherapy; Randomized controlled trial; Randomization; Anesthesia; Surgery; Internal medicine","score_opus":0.1421217506752672,"score_gpt":0.4744485448073466,"score_spread":0.33232679413207944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947923256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866359,0.00026577633,0.0032554972,0.0030567178,0.001668972,0.004204626,0.0000015370083,0.000062510175,0.00084846746],"genre_scores_gemma":[0.973612,0.00016330466,0.020675275,0.0036867135,0.00095988484,0.00006156902,0.000006577456,0.000059228543,0.00077543966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928822,0.0013806627,0.0041496544,0.00044843837,0.00075816497,0.00038088424],"domain_scores_gemma":[0.98527646,0.009544202,0.0038077177,0.0005115524,0.0005251687,0.00033491745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013768439,0.0003003931,0.004595175,0.00020505962,0.00006849094,0.000020714066,0.00032040305,0.00039975697,0.00019365178],"category_scores_gemma":[0.006987814,0.00020141594,0.0013450471,0.00029805783,0.00014782298,0.00016454775,0.0000635729,0.0011592377,0.000019736879],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8670955,0.010558891,0.032689694,0.000110987625,0.007813601,0.000101779406,0.0014157824,0.000057272217,0.00502266,0.000011290897,0.0023712805,0.07275129],"study_design_scores_gemma":[0.9252726,0.02306087,0.02784517,0.0004518936,0.0020788715,0.00009848943,0.0005706649,0.009409166,0.00095619145,0.00022162232,0.009748536,0.00028592066],"about_ca_topic_score_codex":0.00002045821,"about_ca_topic_score_gemma":0.000028854347,"teacher_disagreement_score":0.07246537,"about_ca_system_score_codex":0.000366938,"about_ca_system_score_gemma":0.0010419462,"threshold_uncertainty_score":0.8365571},"labels":[],"label_agreement":null},{"id":"W2947926317","doi":"10.1200/jco.2019.37.15_suppl.6614","title":"Impact of specialist palliative care delivered over three months prior to death on a colorectal cancer patient’s risk of experiencing aggressive end-of-life care.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Palliative care; End-of-life care; Colorectal cancer; Intensive care unit; Cohort; Retrospective cohort study; Population; Emergency medicine; Rapid response team; Cancer; Logistic regression; Quality of life (healthcare); Cohort study; Emergency department; Cancer registry; Internal medicine; Nursing","score_opus":0.18209864675123713,"score_gpt":0.5263835279459649,"score_spread":0.3442848811947278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947926317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916154,0.0049497704,0.000025571831,0.000074783726,0.001009689,0.00058973156,0.00029853545,0.000003688334,0.0014328347],"genre_scores_gemma":[0.99521786,0.0023878536,0.001661389,0.00016401484,0.00052255986,0.000008686081,0.0000066379316,0.000023478673,0.000007546745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562687,0.000379851,0.00271327,0.00026876232,0.00073131477,0.0002799587],"domain_scores_gemma":[0.9872392,0.0031346886,0.006536865,0.0002533864,0.0024272846,0.0004085712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048096292,0.0002508317,0.002772798,0.0002158824,0.00002618743,0.000002732872,0.00024300307,0.00037830364,0.0004113016],"category_scores_gemma":[0.007889601,0.00017208606,0.0011073181,0.00021955311,0.00026008583,0.00008398537,0.00009605748,0.00064589427,0.000003355993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019309504,0.0006302721,0.90536076,0.00013302974,0.0012041049,0.00009152014,0.028393973,0.00053250766,0.0012242818,0.00001996205,0.00033999913,0.042760093],"study_design_scores_gemma":[0.008248194,0.04387047,0.9255821,0.0023888065,0.000525449,0.0000033085914,0.010898526,0.000041615247,0.0071156663,0.000021074457,0.0011522482,0.00015253537],"about_ca_topic_score_codex":0.0027306199,"about_ca_topic_score_gemma":0.0015571797,"teacher_disagreement_score":0.0432402,"about_ca_system_score_codex":0.00070253905,"about_ca_system_score_gemma":0.0036478036,"threshold_uncertainty_score":0.944516},"labels":[],"label_agreement":null},{"id":"W2947926728","doi":"10.1200/jco.2019.37.15_suppl.e18269","title":"Delay in diagnosis and treatment of gastrointestinal cancer in Nepal.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Referral; Gastrointestinal cancer; Cancer; Disease; Colorectal cancer; Stage (stratigraphy); Pediatrics; Internal medicine; Family medicine","score_opus":0.1332647710073407,"score_gpt":0.40261163495991253,"score_spread":0.26934686395257185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947926728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891258,0.0038071885,0.000022101725,0.0016423865,0.0006061501,0.000118011674,0.000019622974,9.696965e-7,0.0046577984],"genre_scores_gemma":[0.98729223,0.011158346,0.0009559043,0.00024868653,0.00021099232,0.0000072712623,2.2806742e-7,0.000007982537,0.00011837979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972121,0.00003977561,0.0023804477,0.0001618219,0.000021473623,0.00018439033],"domain_scores_gemma":[0.99723417,0.00074155314,0.0017759246,0.00009473936,0.000045042852,0.000108568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012602002,0.000092408816,0.0013963835,0.00022185307,0.0000057280013,0.0000057628627,0.00010584007,0.00013766432,0.0003545299],"category_scores_gemma":[0.0006042522,0.000084565916,0.0001741455,0.00009142482,0.000085344276,0.00017499863,0.000020055611,0.00023355833,0.000020858735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038520843,0.000524047,0.9180313,0.0000071645695,0.000024399853,0.000038097864,0.00008987184,0.00020250316,0.0000019937343,0.0022482285,0.000104834064,0.07834238],"study_design_scores_gemma":[0.004355113,0.005010246,0.9541559,0.000075861215,0.000007078701,0.00002608371,0.00003589752,0.00029906153,0.000005537543,0.0032712454,0.03268156,0.00007641028],"about_ca_topic_score_codex":0.00094107207,"about_ca_topic_score_gemma":0.00187733,"teacher_disagreement_score":0.07826597,"about_ca_system_score_codex":0.00028673236,"about_ca_system_score_gemma":0.0002863769,"threshold_uncertainty_score":0.3881854},"labels":[],"label_agreement":null},{"id":"W2947929331","doi":"10.1200/jco.2019.37.15_suppl.5576","title":"DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE<sup>1</sup> trial): T cell responses and tumor infiltration correlate with tumor regression.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada); Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Survivin; Immune system; T cell; Tumor microenvironment; Internal medicine; Oncology; Cyclophosphamide; Clinical trial; Chemotherapy; Ovarian cancer; Cancer; Urology; Immunology","score_opus":0.034451568998529906,"score_gpt":0.3608689255516176,"score_spread":0.3264173565530877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947929331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900603,0.0071456837,0.000020450734,0.00070514646,0.00065382465,0.0013200128,0.00002458391,0.0000083312725,0.00006162189],"genre_scores_gemma":[0.9894013,0.008965859,0.0004356121,0.00038764096,0.000071824354,0.000056861427,0.0000064546557,0.00003256843,0.000641911],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9947343,0.0025164103,0.0018101885,0.00038763968,0.00016641802,0.00038507654],"domain_scores_gemma":[0.9922188,0.00476417,0.002371433,0.0003545697,0.00021767848,0.00007334766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020247628,0.00038961106,0.0018313545,0.00021179667,0.00011319275,0.000022920274,0.00025664456,0.00027975216,0.00009152481],"category_scores_gemma":[0.00034647837,0.00016827187,0.0001517758,0.00023156183,0.00073784287,0.00024522524,0.00003431393,0.0008833238,0.0000044161147],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86377746,0.0024471735,0.051160786,0.00004608983,0.0005335241,0.00036647994,0.0031136097,0.0001028729,0.0067336764,0.000014044497,0.000036980495,0.0716673],"study_design_scores_gemma":[0.29326627,0.2876813,0.3703485,0.0021053588,0.0006474888,0.0029079826,0.0063726716,0.00005925734,0.011093439,0.00003139847,0.02490381,0.00058251776],"about_ca_topic_score_codex":0.00017852489,"about_ca_topic_score_gemma":0.00032459534,"teacher_disagreement_score":0.5705112,"about_ca_system_score_codex":0.00012093102,"about_ca_system_score_gemma":0.0016112282,"threshold_uncertainty_score":0.68619275},"labels":[],"label_agreement":null},{"id":"W2947938912","doi":"10.1200/jco.2019.37.15_suppl.1546","title":"A comparison of risk factors for cigarette and e-cigarette use in the United States adult population.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Human Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Electronic cigarette; Population; Logistic regression; Cigarette smoking; National Health and Nutrition Examination Survey; Public health; Demography; Environmental health; Internal medicine","score_opus":0.18558688028487416,"score_gpt":0.507813811878341,"score_spread":0.3222269315934668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947938912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588907,0.00011630564,0.00002999787,0.003246411,0.00030241837,0.00036076028,0.000025340838,0.000002727738,0.00002698723],"genre_scores_gemma":[0.9945244,0.00017733708,0.00024812904,0.004801681,0.00018899594,0.0000018555671,0.00003625317,0.0000072351695,0.000014069951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971929,0.00046829897,0.0018480343,0.00010119251,0.0002352859,0.00015426552],"domain_scores_gemma":[0.98762554,0.010116454,0.001486409,0.00013647269,0.00037626553,0.00025883704],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020157346,0.00008028222,0.00097241974,0.00015799984,0.000027197933,0.0000063094926,0.00008332257,0.00020073642,0.000036744943],"category_scores_gemma":[0.010932198,0.000045431723,0.00019082862,0.00011326795,0.000082632854,0.00007330315,0.000013075538,0.00071482774,7.64098e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034005695,0.00060689595,0.98932403,0.000063251144,0.000056284283,0.000011436826,0.00080697716,0.00007634242,7.4744247e-7,0.000108234526,0.0030068166,0.002538384],"study_design_scores_gemma":[0.0061678924,0.005322013,0.9788672,0.0000800141,0.00023852747,0.0000071462837,0.0012048883,0.0016583672,0.0000025164645,0.00040515207,0.0060038166,0.000042482978],"about_ca_topic_score_codex":0.00031268285,"about_ca_topic_score_gemma":0.00016706731,"teacher_disagreement_score":0.010456878,"about_ca_system_score_codex":0.00003580994,"about_ca_system_score_gemma":0.00028493165,"threshold_uncertainty_score":0.99739915},"labels":[],"label_agreement":null},{"id":"W2947945506","doi":"10.1200/jco.2019.37.15_suppl.9080","title":"Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; T790M; Osimertinib; Erlotinib; Digital polymerase chain reaction; Internal medicine; Oncology; Gefitinib; Lung cancer; Circulating tumor DNA; Liquid biopsy; Cell-free fetal DNA; KRAS; Cancer; Epidermal growth factor receptor; Polymerase chain reaction; Biology; Gene","score_opus":0.04919784682892617,"score_gpt":0.3806111399036394,"score_spread":0.33141329307471323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947945506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977195,0.00014534201,0.0001730684,0.0005288722,0.00047913278,0.00021208425,0.000010800475,0.0000013150623,0.0007298339],"genre_scores_gemma":[0.9975371,0.000054858876,0.0013969084,0.00089534756,0.0000901655,0.0000023974922,0.0000046824557,0.000010743311,0.000007844213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976835,0.00008575933,0.0017534214,0.00017573423,0.00014921238,0.00015235887],"domain_scores_gemma":[0.9976258,0.00047004683,0.0012784593,0.00024534736,0.0002468,0.00013351062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001108369,0.00010025496,0.0006089681,0.00008624349,0.000017515342,0.0000088901015,0.00015718472,0.00018746911,0.000011822444],"category_scores_gemma":[0.004680465,0.000084825,0.00015193076,0.00010728842,0.000048347305,0.0000072936914,0.00013371084,0.00020826772,0.0000023069413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069262733,0.0003960572,0.776535,0.000038876187,0.00012490955,0.00003383162,0.0002395262,0.0020545777,0.14846152,0.00023689834,0.00015473974,0.07103147],"study_design_scores_gemma":[0.0055514937,0.0077065835,0.9594019,0.0001462119,0.00006734652,0.00010827323,0.00038680504,0.000978762,0.014880402,0.00032105783,0.0102013275,0.00024985222],"about_ca_topic_score_codex":0.00004823476,"about_ca_topic_score_gemma":0.00012101979,"teacher_disagreement_score":0.18286692,"about_ca_system_score_codex":0.00005511157,"about_ca_system_score_gemma":0.00043268967,"threshold_uncertainty_score":0.5603292},"labels":[],"label_agreement":null},{"id":"W2947946663","doi":"10.1200/jco.2019.37.15_suppl.5010","title":"Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone; Rash; Nausea; Prostate cancer; Cohort; Internal medicine; Cancer; Oncology","score_opus":0.08409594014976089,"score_gpt":0.4644896020229624,"score_spread":0.3803936618732015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947946663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416095,0.0005773097,0.0000026230798,0.0010514806,0.0005999778,0.0027335556,0.00006246796,0.000008632414,0.00080302433],"genre_scores_gemma":[0.9973285,0.0005947693,0.0001728695,0.00024354056,0.000106075306,0.000060820996,0.0000103765615,0.000043962587,0.0014390711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936968,0.001263449,0.0029204618,0.00042833248,0.0011395433,0.0005514038],"domain_scores_gemma":[0.99488413,0.00091051974,0.002251541,0.0004950455,0.0010866923,0.00037209256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002787823,0.00032126036,0.0023944299,0.00026240989,0.000059082173,0.00001868505,0.0003525302,0.0002035161,0.00017588664],"category_scores_gemma":[0.00068681553,0.00016307853,0.0003384856,0.0006021893,0.00043305213,0.00019327432,0.000111750116,0.0013761547,0.000011896341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12062965,0.012903394,0.84872234,0.00018808234,0.0016461612,0.0011698597,0.0008338524,0.00022810842,0.0008759749,0.0000054864317,0.00021270377,0.012584372],"study_design_scores_gemma":[0.16158491,0.055947177,0.7781969,0.0005896569,0.001058833,0.00006240423,0.00062309427,0.00019197517,0.00082180527,0.000040450384,0.00071555696,0.00016728227],"about_ca_topic_score_codex":0.00067637756,"about_ca_topic_score_gemma":0.0011376075,"teacher_disagreement_score":0.0705255,"about_ca_system_score_codex":0.0010028003,"about_ca_system_score_gemma":0.004893202,"threshold_uncertainty_score":0.868033},"labels":[],"label_agreement":null},{"id":"W2947954703","doi":"10.1200/jco.2019.37.15_suppl.tps5093","title":"A phase III, multicenter study to assess the diagnostic performance and clinical impact of <sup>18</sup>F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Nuclear medicine; Recurrent prostate cancer; Positron emission tomography; Cancer; Glutamate carboxypeptidase II; Radiology; Internal medicine; Prostatectomy","score_opus":0.13288894220568048,"score_gpt":0.5381535805383449,"score_spread":0.40526463833266446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947954703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592304,0.0004222653,0.0000015967324,0.0010385355,0.00016578703,0.0021329245,0.00001767566,0.0000034041313,0.00029479648],"genre_scores_gemma":[0.99567354,0.0036564914,0.00012742753,0.00010165149,0.00015904356,0.000030548585,0.0000022798329,0.000016667665,0.00023233179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955777,0.0008287672,0.002441898,0.0002933697,0.00050997257,0.00034829913],"domain_scores_gemma":[0.9905152,0.0067349197,0.0013194706,0.00029639422,0.0007652003,0.00036881378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004598715,0.00019234729,0.0018461057,0.00017842713,0.000028057812,0.000009948445,0.00024540306,0.000047285575,0.00020032373],"category_scores_gemma":[0.0028893661,0.00009150575,0.00025072577,0.00035314934,0.00040742566,0.00015512464,0.000114884206,0.0012024587,0.0000035242674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043768067,0.010501395,0.9239715,0.00007318671,0.00085769396,0.00089218904,0.00084924296,0.00022903651,0.0000319657,6.799335e-7,0.00050823647,0.018316839],"study_design_scores_gemma":[0.06689472,0.09356241,0.8340773,0.00061814603,0.00039977377,0.00013401403,0.0014426926,0.002531506,0.000059299746,0.0000042413326,0.00018422701,0.00009167879],"about_ca_topic_score_codex":0.0003592555,"about_ca_topic_score_gemma":0.00017980178,"teacher_disagreement_score":0.08989417,"about_ca_system_score_codex":0.00022352758,"about_ca_system_score_gemma":0.0025194518,"threshold_uncertainty_score":0.5224152},"labels":[],"label_agreement":null},{"id":"W2947957162","doi":"10.1200/jco.2019.37.15_suppl.10051","title":"Long term morbidity and mortality among survivors of infant neuroblastoma: A report from the Childhood Cancer Survivor Study (CCSS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cumulative incidence; Hazard ratio; Incidence (geometry); Confidence interval; Standardized mortality ratio; Proportional hazards model; Internal medicine; Cancer; Neuroblastoma; Pediatrics; Cohort","score_opus":0.09157472567337363,"score_gpt":0.46170517463895444,"score_spread":0.3701304489655808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947957162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645656,0.00035213804,0.0000029841478,0.0009687878,0.0010974495,0.00082714786,0.000020264437,0.000008096872,0.00026654388],"genre_scores_gemma":[0.99835235,0.0005908679,0.000027959195,0.0003807062,0.00047776825,0.000008547989,0.0000028108775,0.000020253177,0.00013873595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953058,0.0010641818,0.0022457398,0.00034608482,0.00076306774,0.00027517544],"domain_scores_gemma":[0.9934453,0.0031334455,0.0020518182,0.0005312378,0.00040533516,0.00043285653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032190816,0.00018554446,0.0016425076,0.00007703953,0.000045983015,0.000013400337,0.00023428812,0.0001805761,0.00020442682],"category_scores_gemma":[0.002635199,0.00010334754,0.00038276962,0.00016506367,0.00035079132,0.0001619715,0.00019300601,0.0011876315,0.00000654465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016248587,0.004608165,0.9825268,0.00001949065,0.0012903734,0.0047623515,0.0001571219,0.0000041447247,0.0001332715,6.447593e-7,0.0003146097,0.0045581902],"study_design_scores_gemma":[0.0077576484,0.010329324,0.9802957,0.00009201064,0.0005824227,0.00036422693,0.00009388433,0.000014122396,0.00011361325,0.000018333574,0.0002647111,0.00007397299],"about_ca_topic_score_codex":0.005685568,"about_ca_topic_score_gemma":0.012322261,"teacher_disagreement_score":0.006636693,"about_ca_system_score_codex":0.00005538383,"about_ca_system_score_gemma":0.0011078074,"threshold_uncertainty_score":0.8594916},"labels":[],"label_agreement":null},{"id":"W2947959256","doi":"10.1200/jco.2019.37.15_suppl.e13145","title":"Differences in MSI phenotype between cancer types using a new PCR-based pan-cancer biomarker panel.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Microsatellite instability; Colorectal cancer; Biomarker; Cancer; Lynch syndrome; Oncology; Internal medicine; DNA mismatch repair; Allele; Gene; Genetics; Biology; Microsatellite","score_opus":0.38391276096217125,"score_gpt":0.503423433720265,"score_spread":0.11951067275809374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947959256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878422,0.0023415424,0.00007886055,0.004911554,0.003551895,0.00029607196,0.0000067763967,0.000008795016,0.0009623127],"genre_scores_gemma":[0.99295205,0.0005407803,0.0024740587,0.0017397272,0.0017869006,0.000004650867,9.574644e-7,0.000027614791,0.00047324767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965941,0.0003588711,0.0019203931,0.00028692756,0.000485173,0.00035453806],"domain_scores_gemma":[0.9955897,0.0022066245,0.0013139925,0.00021106751,0.00031141378,0.00036725038],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013936448,0.00020321846,0.0018468095,0.0002070688,0.000019895766,0.000011233611,0.00025249357,0.0005470623,0.0025794383],"category_scores_gemma":[0.0012433246,0.00014191255,0.00035460532,0.00031649877,0.00017000701,0.000072412986,0.000046808902,0.001005303,0.000029815723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025306593,0.00026264536,0.85608107,0.00004586212,0.00027619934,0.000049741906,0.000060162398,0.00007815199,0.0027086413,0.000002492838,0.000982128,0.13692224],"study_design_scores_gemma":[0.0066092047,0.0038587204,0.9738053,0.00043628758,0.00042783548,0.00001227976,0.000037954043,0.00047831977,0.00061265373,0.00017561269,0.0133830905,0.00016276026],"about_ca_topic_score_codex":0.0007987981,"about_ca_topic_score_gemma":0.00049321936,"teacher_disagreement_score":0.13675947,"about_ca_system_score_codex":0.0004836813,"about_ca_system_score_gemma":0.006525864,"threshold_uncertainty_score":0.9991062},"labels":[],"label_agreement":null},{"id":"W2947960158","doi":"10.1200/jco.2019.37.15_suppl.e16508","title":"Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Zoledronic acid; Concomitant; Internal medicine; Prostate cancer; Denosumab; Prednisone; Gastroenterology; Androgen deprivation therapy; Urology; Cancer; Oncology; Osteoporosis","score_opus":0.06569301104753747,"score_gpt":0.4377551408867463,"score_spread":0.37206212983920883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947960158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833812,0.0010063144,0.000028079048,0.013444367,0.00032488178,0.0016444615,0.00010849777,0.000008276619,0.000053907377],"genre_scores_gemma":[0.9927321,0.0036060363,0.0023430365,0.00024037644,0.0003470468,0.00006982786,0.00014542718,0.00003297644,0.000483193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967902,0.00022845562,0.0017920877,0.00035699585,0.0005364935,0.00029577763],"domain_scores_gemma":[0.99621123,0.00079954625,0.0016635942,0.00023069273,0.0008196592,0.00027526767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016622575,0.00021661221,0.001264811,0.00024739592,0.000039114737,0.000028429613,0.00011843851,0.00019720229,0.000108725784],"category_scores_gemma":[0.00048518687,0.0001401286,0.00018976677,0.00015628485,0.00032216072,0.00031963002,0.0000299241,0.00045876717,0.000002774291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4581096,0.011151217,0.4594513,0.00037933147,0.0013434959,0.00071278383,0.0010090581,0.0007246394,0.0250344,0.000022169033,0.0009845532,0.041077483],"study_design_scores_gemma":[0.18074295,0.089953706,0.69381726,0.0011915229,0.0004712672,0.00006869228,0.00036877065,0.001639802,0.02169813,0.00008331336,0.009667151,0.00029745884],"about_ca_topic_score_codex":0.00022577157,"about_ca_topic_score_gemma":0.00047398312,"teacher_disagreement_score":0.27736664,"about_ca_system_score_codex":0.00025248737,"about_ca_system_score_gemma":0.0012002419,"threshold_uncertainty_score":0.5714278},"labels":[],"label_agreement":null},{"id":"W2947969924","doi":"10.1200/jco.2019.37.15_suppl.5541","title":"Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Placebo; Internal medicine; Chemotherapy; Oncology; Response Evaluation Criteria in Solid Tumors; Ovarian cancer; Surgery; Progressive disease; Tolerability; Urology; Cancer; Adverse effect; Pathology","score_opus":0.024357977983577105,"score_gpt":0.3886728951364615,"score_spread":0.36431491715288444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947969924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99080294,0.000697997,0.000021876862,0.006611269,0.0002883835,0.0014568673,0.000019967003,0.0000039014894,0.000096786185],"genre_scores_gemma":[0.9949151,0.000787116,0.0006446737,0.003339857,0.000142815,0.000109516484,0.000011099558,0.000019829504,0.000029937144],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971263,0.0004242162,0.0014594084,0.00032749848,0.0003347888,0.00032778806],"domain_scores_gemma":[0.99508965,0.003355843,0.0009979084,0.00017152865,0.00014698601,0.00023806073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013252061,0.00020329189,0.0012991843,0.00010659417,0.000023198496,0.000021270498,0.000077996854,0.0001809033,0.00014589787],"category_scores_gemma":[0.0004955505,0.000114398754,0.00012268439,0.00018514073,0.00015626213,0.00012581065,0.000013618246,0.0006389064,0.0000014753223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3305706,0.009753391,0.42814982,0.000026702619,0.00015898078,0.0011498965,0.000438009,0.000057787092,0.0000045860816,0.00002862411,0.00046322422,0.22919837],"study_design_scores_gemma":[0.5045735,0.022558216,0.46514007,0.00024220324,0.000105134575,0.000027883418,0.0000723883,0.0001582283,0.0000062408208,0.000028270731,0.0069987355,0.000089132765],"about_ca_topic_score_codex":0.00020444214,"about_ca_topic_score_gemma":0.00040458792,"teacher_disagreement_score":0.22910923,"about_ca_system_score_codex":0.00027019155,"about_ca_system_score_gemma":0.00089318235,"threshold_uncertainty_score":0.46650457},"labels":[],"label_agreement":null},{"id":"W2947974803","doi":"10.1200/jco.2019.37.15_suppl.3579","title":"Population-based screening for <i>BRAF</i> V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; Lions Gate Hospital; Genome British Columbia; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Colorectal cancer; Cohort; Population; Cancer; Immunohistochemistry","score_opus":0.14706015144104456,"score_gpt":0.48835239648233053,"score_spread":0.34129224504128597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947974803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853864,0.00018621622,0.00058392953,0.009699799,0.0023561448,0.0014710802,0.00001688528,0.000010931878,0.00028862947],"genre_scores_gemma":[0.94137293,0.000020209365,0.05184616,0.005774355,0.00069184654,0.00010605778,0.000007012348,0.000035299454,0.0001460996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959493,0.00035532567,0.0025247894,0.00031509437,0.00047146188,0.00038401262],"domain_scores_gemma":[0.9935437,0.0041296124,0.0012378885,0.00015489121,0.00050962274,0.00042430355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033556898,0.00019076382,0.001860214,0.00026644644,0.000027624817,0.000010585768,0.00020893458,0.00030170454,0.0002975486],"category_scores_gemma":[0.0051703737,0.00014903309,0.00051183946,0.00033652183,0.00006077642,0.00007591179,0.000039406525,0.0007826347,0.0000131656225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010740482,0.00071956,0.9049941,0.000108189124,0.00018875033,0.00005860391,0.000068694004,0.0029465083,0.0015134085,0.000012364412,0.0029784348,0.075670905],"study_design_scores_gemma":[0.0126011465,0.020543162,0.9456973,0.00036699174,0.0003219425,0.000052031024,0.00006309816,0.0013740554,0.0011676688,0.00012797884,0.017503286,0.00018132785],"about_ca_topic_score_codex":0.0001568484,"about_ca_topic_score_gemma":0.000763889,"teacher_disagreement_score":0.07548958,"about_ca_system_score_codex":0.0004561685,"about_ca_system_score_gemma":0.0023911593,"threshold_uncertainty_score":0.61897933},"labels":[],"label_agreement":null},{"id":"W2947975377","doi":"10.1200/jco.2019.37.15_suppl.2021","title":"Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Temozolomide; Internal medicine; Adverse effect; Ataxia; Common Terminology Criteria for Adverse Events; Phases of clinical research; Clinical endpoint; Glioma; Toxicity; Surgery; Clinical trial; Radiation therapy","score_opus":0.08167081924197511,"score_gpt":0.46734422815304844,"score_spread":0.3856734089110733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947975377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941695,0.00045234177,0.000005733044,0.0029350137,0.0003964249,0.0018457399,0.00002915707,0.0000064773167,0.00015962325],"genre_scores_gemma":[0.9936595,0.00064407144,0.0042575663,0.0011240563,0.00022035514,0.000026136779,0.00000844969,0.000029479668,0.000030390178],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99506795,0.0008301514,0.0029039707,0.00047815908,0.00043910337,0.0002806444],"domain_scores_gemma":[0.9932493,0.0033476092,0.0021766939,0.00047579972,0.00026080327,0.0004898248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024449038,0.00025792635,0.0024481618,0.00022626028,0.000028118135,0.000030499576,0.00033112496,0.000263567,0.00010631015],"category_scores_gemma":[0.000792827,0.00016528633,0.00013199548,0.00017747743,0.00012231655,0.00024282494,0.00011667785,0.000600482,0.000004454376],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28481337,0.15495127,0.38329962,0.000017255366,0.0016573285,0.004913329,0.0015891081,0.000037360867,0.0030361046,0.000007716056,0.0005837393,0.16509381],"study_design_scores_gemma":[0.39449462,0.21385112,0.3869518,0.00021102968,0.00038647297,0.00007453437,0.0012211839,0.00052485894,0.00029265543,0.000023378638,0.0018457791,0.00012253434],"about_ca_topic_score_codex":0.0008016096,"about_ca_topic_score_gemma":0.0023565667,"teacher_disagreement_score":0.16497128,"about_ca_system_score_codex":0.00020415531,"about_ca_system_score_gemma":0.00055146444,"threshold_uncertainty_score":0.6740181},"labels":[],"label_agreement":null},{"id":"W2947981934","doi":"10.1200/jco.2019.37.15_suppl.10022","title":"Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Young adult; Germ cell tumors; Pediatrics; Internal medicine; Chemotherapy","score_opus":0.025611251660999347,"score_gpt":0.3350378673689782,"score_spread":0.30942661570797886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947981934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630964,0.0008523518,0.00008558155,0.0011751923,0.00048271072,0.00063501653,0.000089241534,0.000011062131,0.00035921173],"genre_scores_gemma":[0.9961429,0.00018210718,0.0025405954,0.00055913784,0.00031736668,0.0000047826898,0.000051665684,0.000030470908,0.0001709599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961328,0.00026327948,0.0022387083,0.0003864063,0.00071332284,0.00026546305],"domain_scores_gemma":[0.9941143,0.00089206896,0.003838745,0.00035692652,0.00041567482,0.0003823296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008584774,0.0002843774,0.0016340272,0.000072908755,0.00004121193,0.000022028076,0.00024603322,0.00014333751,0.00013568065],"category_scores_gemma":[0.00034167425,0.00013630942,0.00038548437,0.00007358546,0.00039769243,0.000100086225,0.00008352456,0.00054770824,0.000008599563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009295257,0.003929696,0.9765575,0.000046899146,0.000856819,0.007351475,0.00011018516,0.0000126800505,0.00010238314,0.000013850524,0.00015233066,0.0015709364],"study_design_scores_gemma":[0.01897931,0.005115707,0.9685215,0.0007090014,0.0012126532,0.004544823,0.00037507582,0.00006434215,0.00007740329,0.000023371878,0.00021940887,0.00015740236],"about_ca_topic_score_codex":0.00041792242,"about_ca_topic_score_gemma":0.00013307315,"teacher_disagreement_score":0.009684052,"about_ca_system_score_codex":0.00009030892,"about_ca_system_score_gemma":0.00088859856,"threshold_uncertainty_score":0.5558537},"labels":[],"label_agreement":null},{"id":"W2947988059","doi":"10.1200/jco.2019.37.15_suppl.4535","title":"Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Oncology; Proportional hazards model; Cohort; Logistic regression; Cancer; Gastroenterology","score_opus":0.11342934441014209,"score_gpt":0.4429583004609353,"score_spread":0.32952895605079324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947988059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985692,0.005983262,0.000044009517,0.003635313,0.0028422603,0.000740217,0.00024953764,0.000009398945,0.0008039746],"genre_scores_gemma":[0.98375803,0.0028750063,0.0022102115,0.009970838,0.00095649913,0.000019906262,0.000056595516,0.0000432895,0.000109643646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99431294,0.0011748082,0.0031335077,0.0006119493,0.00033794477,0.00042886502],"domain_scores_gemma":[0.98961973,0.0072229616,0.001848337,0.0004906191,0.00029961238,0.0005187521],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012708063,0.00032348945,0.0026959574,0.00016543745,0.000047617512,0.000014862344,0.00028159592,0.000681719,0.00094382046],"category_scores_gemma":[0.00043865654,0.00024023445,0.00047313378,0.00011044581,0.00037495402,0.00010105903,0.00016119379,0.0016828505,0.000050546674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004815526,0.0042046453,0.9356066,0.000060965853,0.00070877513,0.0021724387,0.00026449907,0.000027904725,0.0020865723,0.000018849147,0.002875101,0.047158152],"study_design_scores_gemma":[0.037482027,0.011823721,0.8896753,0.000056325196,0.0010227815,0.0001442744,0.0003314816,0.00033202494,0.000044166827,0.00019276865,0.058691237,0.00020386792],"about_ca_topic_score_codex":0.0020457893,"about_ca_topic_score_gemma":0.0014285026,"teacher_disagreement_score":0.055816136,"about_ca_system_score_codex":0.0004614528,"about_ca_system_score_gemma":0.00411667,"threshold_uncertainty_score":0.9999694},"labels":[],"label_agreement":null},{"id":"W2947989730","doi":"10.1200/jco.2019.37.15_suppl.2033","title":"A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Temozolomide; Disulfiram; Internal medicine; Radiation therapy; Glioblastoma; Toxicity; Phases of clinical research; Oncology; Adjuvant; Urology; Nuclear medicine; Surgery; Gastroenterology; Pharmacology; Cancer research","score_opus":0.07891149560424808,"score_gpt":0.451144864605638,"score_spread":0.3722333690013899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947989730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952622,0.0013990877,0.00001106538,0.0017445649,0.00034525123,0.0011773871,0.0000070945603,0.000003851671,0.00004946949],"genre_scores_gemma":[0.9977457,0.0013617378,0.00024120009,0.00038168495,0.00021525072,0.000024523382,0.0000021549245,0.000012878207,0.000014893068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822676,0.00014725201,0.0011097294,0.00018021572,0.000203838,0.0001321754],"domain_scores_gemma":[0.9958934,0.0024239335,0.0010846131,0.00012009416,0.00025020487,0.00022771755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000877628,0.00012759275,0.0011998687,0.00010081376,0.000034560195,0.000008314353,0.000047531965,0.00013149432,0.000028998644],"category_scores_gemma":[0.00050533726,0.000073375464,0.00013194414,0.0000728774,0.000105417836,0.00008060312,0.000022401106,0.00021127905,0.0000010760054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013085986,0.020809388,0.48409852,0.000028517336,0.00080162275,0.000105826926,0.0005350679,0.000004427823,0.0003618576,0.00005474753,0.0010127996,0.47910124],"study_design_scores_gemma":[0.168453,0.3631625,0.4521794,0.00010378438,0.00059700146,0.00009293927,0.00052259216,0.00018871452,0.00028027993,0.000039313447,0.014292142,0.00008836363],"about_ca_topic_score_codex":0.000013137905,"about_ca_topic_score_gemma":0.000038804457,"teacher_disagreement_score":0.47901288,"about_ca_system_score_codex":0.00004097997,"about_ca_system_score_gemma":0.00026513543,"threshold_uncertainty_score":0.29921648},"labels":[],"label_agreement":null},{"id":"W2947991887","doi":"10.1200/jco.2019.37.15_suppl.e23025","title":"Delirium incidence, risk factors, and treatment in older adults receiving chemotherapy: A scoping review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Delirium; Medicine; CINAHL; MEDLINE; Incidence (geometry); Psychological intervention; Data extraction; Intensive care medicine; Psychiatry","score_opus":0.052569868598610035,"score_gpt":0.44264840915947606,"score_spread":0.39007854056086605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947991887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98431855,0.0065721297,0.000024363586,0.0066774576,0.0005564445,0.00090587145,0.0000016029376,0.00000505557,0.0009385484],"genre_scores_gemma":[0.88982445,0.075707085,0.00053253403,0.033632614,0.00020815662,0.000004631403,0.0000025657519,0.00001821643,0.00006974063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971747,0.0004836682,0.0017138921,0.00021537974,0.00020822002,0.000204157],"domain_scores_gemma":[0.99164313,0.0032530248,0.0013954521,0.00014576425,0.0033579315,0.0002047017],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018154341,0.00016082329,0.0016995817,0.0001623093,0.000017479637,0.0000045571496,0.00006949551,0.0002489998,0.00021339984],"category_scores_gemma":[0.034014627,0.00010440513,0.0003317094,0.0001399104,0.00010620746,0.00009801424,0.000026628648,0.00074045634,0.000013074548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015733878,0.00050840754,0.89593655,0.00033670795,0.00014690345,0.00016119925,0.00038714233,5.7262486e-7,0.000024015339,0.0000015478399,0.0010266498,0.099896945],"study_design_scores_gemma":[0.012675469,0.009643363,0.9345446,0.03960636,0.00025086442,0.0001585246,0.0015355976,0.00003306177,0.00007145573,0.000019987145,0.001340495,0.00012018956],"about_ca_topic_score_codex":0.000100110505,"about_ca_topic_score_gemma":0.00022581598,"teacher_disagreement_score":0.09977675,"about_ca_system_score_codex":0.00019117382,"about_ca_system_score_gemma":0.0010046813,"threshold_uncertainty_score":0.9741223},"labels":[],"label_agreement":null},{"id":"W2947993621","doi":"10.1200/jco.2019.37.15_suppl.tps5603","title":"ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Carboplatin; Oncology; Tolerability; Internal medicine; Olaparib; BRCA mutation; Debulking; Placebo; Chemotherapy; Gynecology; Surgery; Cancer; Adverse effect; Immunotherapy; Pathology","score_opus":0.07951074915557566,"score_gpt":0.45804426383334607,"score_spread":0.3785335146777704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947993621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984636,0.0005777472,0.00093647774,0.0032059988,0.00079757784,0.009433621,0.000070712806,0.0000147230285,0.00032710584],"genre_scores_gemma":[0.9918376,0.004314971,0.0014460701,0.00049339404,0.0006925392,0.00068210217,0.0000111566615,0.000056183046,0.00046597727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939962,0.0005473863,0.004083753,0.00046200512,0.0005108168,0.0003998263],"domain_scores_gemma":[0.98684657,0.0053426595,0.0057757,0.00037900632,0.0013011412,0.00035491568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002446315,0.0004145897,0.007292719,0.00026100085,0.00006239382,0.000009053909,0.00019048937,0.00037169177,0.00031796785],"category_scores_gemma":[0.00049104955,0.00025154912,0.00078218087,0.00022031968,0.0004695091,0.00016591598,0.00001968544,0.00051759975,0.0000022621653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9123033,0.013270389,0.0005642347,0.00008058929,0.0053146565,0.000075866934,0.0014350566,0.0009714399,0.0015082015,0.00004091555,0.00007981036,0.06435552],"study_design_scores_gemma":[0.8948741,0.09354519,0.00032105047,0.0003222116,0.0019252114,0.00014692242,0.0005673067,0.0016229639,0.0024850278,0.000111149,0.0038801958,0.0001986545],"about_ca_topic_score_codex":0.0001607256,"about_ca_topic_score_gemma":0.0003059497,"teacher_disagreement_score":0.0802748,"about_ca_system_score_codex":0.00058671046,"about_ca_system_score_gemma":0.0022608603,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W2947997956","doi":"10.1200/jco.2020.38.4_suppl.650","title":"Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A multicenter analysis from the CHORD consortium.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Saskatchewan; BC Cancer Agency; Nova Scotia Cancer Centre; Moncton Hospital; Dalhousie University; Dr. H. Bliss Murphy Cancer Centre; Health Sciences Centre; CancerCare Manitoba; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Chemotherapy regimen; Gastroenterology; Cancer; Logistic regression; Oncology; Surgery","score_opus":0.19888104100285148,"score_gpt":0.4854780213107208,"score_spread":0.28659698030786934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947997956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98762447,0.0005079782,0.0002124803,0.01038929,0.00024871438,0.00056412705,0.00003096673,0.000012784037,0.00040921266],"genre_scores_gemma":[0.99620336,0.00075168035,0.00047672176,0.0019736895,0.00045547742,0.00002454734,0.000024260993,0.00002131991,0.00006895415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99473965,0.0014988713,0.0023269763,0.00033541475,0.0006690628,0.000430037],"domain_scores_gemma":[0.9815711,0.015821356,0.001213164,0.0002300413,0.00055115623,0.00061317795],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023270648,0.00022495858,0.0032045948,0.00012901399,0.000058386282,0.000015427535,0.00031951323,0.0003994025,0.0005869188],"category_scores_gemma":[0.017759651,0.00011747358,0.0005385416,0.00076345954,0.000474081,0.000101418824,0.000071759045,0.0017918046,0.000006689518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061578862,0.0011312618,0.9803873,0.000013480365,0.0065469337,0.00068171154,0.0006482627,0.000063670705,0.00011636431,0.0000031777458,0.00016122237,0.0040887357],"study_design_scores_gemma":[0.009045243,0.0051529715,0.97435755,0.00020113758,0.008087135,0.0000044512194,0.00073409145,0.0017374741,0.000012959225,0.000011618643,0.0005374467,0.00011792091],"about_ca_topic_score_codex":0.00023624423,"about_ca_topic_score_gemma":0.0031715774,"teacher_disagreement_score":0.015432587,"about_ca_system_score_codex":0.00028198608,"about_ca_system_score_gemma":0.0021347103,"threshold_uncertainty_score":0.99051416},"labels":[],"label_agreement":null},{"id":"W2948001735","doi":"10.1200/jco.2019.37.15_suppl.6641","title":"Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Population; Negotiation; Cost–benefit analysis; Quality-adjusted life year; Actuarial science; Marginal cost; Cost effectiveness; Economics; Environmental health","score_opus":0.6448411428074864,"score_gpt":0.5710485489788962,"score_spread":0.07379259382859016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948001735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92824155,0.0030743002,0.0004889143,0.065737,0.0011939897,0.0003895694,0.000051094597,0.0000089506875,0.0008146144],"genre_scores_gemma":[0.9823698,0.0009762746,0.0062443977,0.0092967795,0.0009882986,0.000005142143,0.000014540975,0.000017647619,0.00008711335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9863401,0.0012411663,0.0115485815,0.00034358475,0.00015674753,0.0003698352],"domain_scores_gemma":[0.98158044,0.0060692257,0.011727613,0.00020669005,0.00008429492,0.00033173352],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07358685,0.0001375661,0.0024255386,0.0004808687,0.00008675598,0.00004590815,0.00026785754,0.00027490946,0.000093194554],"category_scores_gemma":[0.014313362,0.00015432428,0.00017725123,0.00022661405,0.00004403743,0.00069649133,0.000079658515,0.00077391666,0.000105695326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028789127,0.000116777024,0.97534037,0.00012959338,0.000059755315,9.2221535e-7,0.00087034446,0.00042103571,7.1404806e-8,0.0120932255,0.00091440504,0.010024702],"study_design_scores_gemma":[0.0020079992,0.0006294302,0.97524625,0.00020195582,0.000007707752,0.000008752011,0.000470183,0.00094557315,6.2153376e-8,0.00468084,0.015669968,0.00013128198],"about_ca_topic_score_codex":0.0008095498,"about_ca_topic_score_gemma":0.00031371563,"teacher_disagreement_score":0.05927349,"about_ca_system_score_codex":0.000756234,"about_ca_system_score_gemma":0.00088081416,"threshold_uncertainty_score":0.99398947},"labels":[],"label_agreement":null},{"id":"W2948008600","doi":"10.1200/jco.2019.37.15_suppl.9036","title":"SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Interim analysis; Paclitaxel; Phases of clinical research; Adverse effect; Adenocarcinoma; Cancer; Chemotherapy; Randomized controlled trial","score_opus":0.028746556915911256,"score_gpt":0.4411868270330542,"score_spread":0.4124402701171429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948008600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396485,0.0004119441,0.0000537358,0.0004994508,0.0006495259,0.001751538,0.000028263476,0.000005763039,0.0026349323],"genre_scores_gemma":[0.996938,0.000107955166,0.0018851516,0.00030477415,0.00018479805,0.000036426034,0.0000114243585,0.0000355923,0.0004958767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969072,0.00025142467,0.001673431,0.0003418673,0.0005120467,0.00031407434],"domain_scores_gemma":[0.9957367,0.00084459374,0.0019419726,0.00028067417,0.000883104,0.0003129606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005894404,0.00025416442,0.0018758175,0.00018023193,0.000037894024,0.000008015893,0.00016326063,0.00019717276,0.00012913231],"category_scores_gemma":[0.0001361797,0.00015627196,0.00018671261,0.00030433654,0.00011438701,0.00019102692,0.00003781626,0.00084973016,0.00000561907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13416576,0.029026203,0.80482185,0.00010946,0.0022243941,0.00059391896,0.0028565729,0.0015713358,0.000045885517,0.0000031663608,0.00018502206,0.024396423],"study_design_scores_gemma":[0.31208804,0.12118536,0.56114733,0.0005164739,0.0022364443,0.000013323522,0.0020669755,0.00016213869,0.00006860064,0.0000023894172,0.00034517393,0.0001677464],"about_ca_topic_score_codex":0.00032108522,"about_ca_topic_score_gemma":0.0008523793,"teacher_disagreement_score":0.24367452,"about_ca_system_score_codex":0.00061254343,"about_ca_system_score_gemma":0.0030789452,"threshold_uncertainty_score":0.6372585},"labels":[],"label_agreement":null},{"id":"W2948010379","doi":"10.1200/jco.2019.37.15_suppl.e17093","title":"Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Randomized controlled trial; Checklist; Ovarian cancer; Cochrane Library; Meta-analysis; MEDLINE; Chemotherapy; Surgery; Oncology; Internal medicine; Cancer","score_opus":0.33519821354455426,"score_gpt":0.5253226495820315,"score_spread":0.1901244360374772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948010379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032186112,0.9837626,0.000012142335,0.010132685,0.0009839585,0.004555614,0.00018665906,0.000010320861,0.000034159293],"genre_scores_gemma":[0.00017808234,0.99160504,0.000989365,0.0056826607,0.0004890442,0.00066471176,0.000044394306,0.000054205815,0.00029248983],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99067104,0.0017880652,0.0060886606,0.0006629624,0.0004303261,0.00035893495],"domain_scores_gemma":[0.9781321,0.013703938,0.006879344,0.00046211787,0.00035847124,0.00046397216],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.007460947,0.0006519547,0.044477005,0.0003256853,0.00008046465,0.000025172,0.00018062747,0.00089886977,0.00015889372],"category_scores_gemma":[0.002197911,0.00033881894,0.012711001,0.00035820706,0.00018123827,0.00009739296,0.00008637277,0.0008558329,0.0000033452081],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036471803,0.0010025286,0.0010281849,0.36900875,0.5621339,0.00031277232,0.00002183678,2.991737e-7,1.06955945e-7,0.000008273976,0.0012734152,0.06484518],"study_design_scores_gemma":[0.0026217012,0.0021605538,0.0022189014,0.016717343,0.86657536,0.00037107142,0.000005521567,8.8013485e-7,1.8179978e-7,0.000012800838,0.1090659,0.00024978357],"about_ca_topic_score_codex":0.000059426096,"about_ca_topic_score_gemma":0.00003895816,"teacher_disagreement_score":0.3522914,"about_ca_system_score_codex":0.0011466553,"about_ca_system_score_gemma":0.0036708075,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null},{"id":"W2948022903","doi":"10.1200/jco.2019.37.15_suppl.e12588","title":"Retrospective study of neuroendocrine breast cancer cases from a single institution in Québec.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Fleurimont; Université de Sherbrooke","funders":"","keywords":"Medicine; Breast cancer; Retrospective cohort study; Oncology; Cohort; Internal medicine; Cancer; Pathological; Population; Neuroendocrine tumors; Disease; Pathology","score_opus":0.1080650241086576,"score_gpt":0.4776723023119165,"score_spread":0.3696072782032589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948022903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926009,0.0002585973,0.0000013980068,0.005155787,0.0008859555,0.00045555417,0.000014705408,0.0000065403574,0.0006205386],"genre_scores_gemma":[0.99850506,0.00029544352,0.00011590975,0.00038293866,0.0005275577,0.0000055745777,6.018598e-7,0.000014035972,0.00015287646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965756,0.00050274126,0.0019026219,0.00024549337,0.0005342683,0.00023925448],"domain_scores_gemma":[0.99659526,0.0011987557,0.001248666,0.00022812554,0.0004989112,0.00023029468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047618584,0.00012345213,0.0015256576,0.00023134965,0.00001434308,0.0000045209226,0.00017562123,0.000020310585,0.00039350538],"category_scores_gemma":[0.004390155,0.00008968812,0.00019994356,0.0002739673,0.00017257377,0.00020556171,0.000093262584,0.0011058575,0.000012395174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00933763,0.007946036,0.9467631,0.00002050908,0.00013374451,0.021047868,0.000059657283,0.00007414101,0.0016294952,0.000008713422,0.00031500554,0.012664082],"study_design_scores_gemma":[0.013447593,0.03436408,0.9439642,0.00012900915,0.00010932937,0.0038215125,0.00049306446,0.000033582706,0.00022421697,0.000056190496,0.0032958349,0.00006138792],"about_ca_topic_score_codex":0.01370776,"about_ca_topic_score_gemma":0.031886335,"teacher_disagreement_score":0.026418041,"about_ca_system_score_codex":0.00042021324,"about_ca_system_score_gemma":0.0018739683,"threshold_uncertainty_score":0.99286},"labels":[],"label_agreement":null},{"id":"W2948248276","doi":"10.1200/jco.2019.37.18_suppl.lba9015","title":"Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Incidence (geometry); Clinical trial; Immunotherapy; Cancer","score_opus":0.04006387445179824,"score_gpt":0.3833419232587135,"score_spread":0.34327804880691526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948248276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954372,0.000104607614,0.000051797528,0.0012957703,0.0008962858,0.0006783063,0.000096492964,0.00001408888,0.0014254694],"genre_scores_gemma":[0.994888,0.0002705151,0.0017593291,0.001107576,0.00059072516,0.000005275935,0.00013580907,0.000037598154,0.0012051413],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970377,0.00019540048,0.0017138128,0.0003174657,0.00044317075,0.00029245016],"domain_scores_gemma":[0.9946612,0.0022227264,0.0018329246,0.00030879863,0.00071508996,0.00025921914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008850321,0.00021097974,0.0014576241,0.00008554235,0.000035606998,0.000012830997,0.00017694809,0.00033418226,0.00020725424],"category_scores_gemma":[0.00056823675,0.000121779456,0.0003565863,0.00010247559,0.00016436812,0.00015857008,0.000021671844,0.0005588457,0.000015978505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5712428,0.002219412,0.38091373,0.000021113283,0.0010012604,0.00009871761,0.000053062184,0.00001236777,0.0001263329,0.0000037802236,0.0011093428,0.04319808],"study_design_scores_gemma":[0.17516464,0.057223,0.75653666,0.00029936925,0.0003234938,0.000020468347,0.000033961926,0.000012447528,0.00004691589,0.000011854709,0.010185353,0.0001418321],"about_ca_topic_score_codex":0.00011109383,"about_ca_topic_score_gemma":0.000117229065,"teacher_disagreement_score":0.39607817,"about_ca_system_score_codex":0.000190184,"about_ca_system_score_gemma":0.0008025095,"threshold_uncertainty_score":0.4966022},"labels":[],"label_agreement":null},{"id":"W2948321946","doi":"10.1200/jco.19.00014","title":"Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"Genentech; MorphoSys; National Cancer Institute; Celgene","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Internal medicine; Cumulative incidence; Aggressive lymphoma; Incidence (geometry); Oncology; Rituximab; Cohort","score_opus":0.021605431312223554,"score_gpt":0.3417026623509291,"score_spread":0.3200972310387056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948321946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959124,0.0002315202,0.0000020438242,0.0008490624,0.00018102133,0.00035008587,0.0000035956039,0.000008171149,0.002462131],"genre_scores_gemma":[0.9964728,0.00045013207,0.00073008944,0.0015587437,0.00009480559,0.0000046940454,0.000007941131,0.000025531355,0.00065527775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780923,0.00018263479,0.0012160294,0.00019913052,0.00033045732,0.00026251195],"domain_scores_gemma":[0.99750125,0.00070868526,0.0010569857,0.00024325305,0.00027301157,0.00021683417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000610068,0.00017674062,0.0013522791,0.00012103695,0.000018679544,0.000008120339,0.00010064652,0.00025306913,0.00011548343],"category_scores_gemma":[0.00011023331,0.000090509,0.00021054293,0.0001592517,0.00007118192,0.000101615675,0.000019029925,0.0002606424,0.000053770906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019531293,0.04442396,0.9143636,0.000013781334,0.00038755298,0.0005685415,0.000064730106,0.0000022833071,0.000011650471,0.000010714218,0.00023932807,0.020382516],"study_design_scores_gemma":[0.19537556,0.03457422,0.7612676,0.00016059272,0.00019160876,0.000039974973,0.000029227094,0.000008805446,0.00013139268,0.0000074421096,0.0081299795,0.0000836066],"about_ca_topic_score_codex":0.000031873114,"about_ca_topic_score_gemma":0.000026587622,"teacher_disagreement_score":0.17584427,"about_ca_system_score_codex":0.0002847492,"about_ca_system_score_gemma":0.0007144544,"threshold_uncertainty_score":0.36908498},"labels":[],"label_agreement":null},{"id":"W2948365327","doi":"10.1200/jco.2019.37.18_suppl.lba3","title":"ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Anthracycline; Population; Neutropenia; Dexrazoxane; Doxorubicin; Randomization; Placebo; Phases of clinical research; Urology; Randomized controlled trial; Oncology; Surgery; Gastroenterology; Toxicity; Chemotherapy; Cancer; Breast cancer; Pathology","score_opus":0.06501265917635984,"score_gpt":0.43745745383217993,"score_spread":0.3724447946558201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948365327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843522,0.001716993,0.00004004654,0.0018393738,0.0033516318,0.0059463475,0.000011328552,0.000013754205,0.002728371],"genre_scores_gemma":[0.99631274,0.0007969318,0.0011471817,0.0004908342,0.0007575855,0.0001554281,0.000025054707,0.000044611374,0.00026963372],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912674,0.0012199014,0.005358537,0.0005017448,0.001104613,0.0005478],"domain_scores_gemma":[0.9831178,0.010392138,0.004534005,0.0005295649,0.0009218549,0.00050464354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00592749,0.00045448742,0.0072542536,0.00044955965,0.000047447797,0.000020280564,0.000319549,0.0006490832,0.00027758905],"category_scores_gemma":[0.0033970086,0.00027506935,0.0012026947,0.00036424253,0.00036089588,0.00027484144,0.0000773576,0.0013967039,0.000054391985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89370596,0.027460173,0.010357198,0.00003823786,0.0018781092,0.00066620123,0.0001685492,0.000088702,0.000064387576,0.00009474614,0.0005647083,0.06491303],"study_design_scores_gemma":[0.8906994,0.09628259,0.0019651328,0.0003404087,0.0018279867,0.00006080647,0.00015096918,0.00008115343,0.00017574444,0.000054331707,0.008139698,0.0002218237],"about_ca_topic_score_codex":0.00007001128,"about_ca_topic_score_gemma":0.00011648396,"teacher_disagreement_score":0.06882241,"about_ca_system_score_codex":0.00043816285,"about_ca_system_score_gemma":0.0018725815,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","score_opus":0.1404453096150034,"score_gpt":0.5111550693327782,"score_spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948405934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96343225,0.0004641885,0.000019589037,0.033400454,0.0010406079,0.0010818272,0.0001749524,0.00001132262,0.00037478414],"genre_scores_gemma":[0.9958166,0.0005235019,0.00020363594,0.0016438952,0.0015675627,0.00001644173,0.00000855366,0.000040886607,0.00017893394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99429977,0.0011462411,0.0027559667,0.00045156112,0.00086497545,0.00048151385],"domain_scores_gemma":[0.9911066,0.006241063,0.001151577,0.0003616072,0.00063507224,0.00050403323],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034261756,0.0002881139,0.0025935643,0.000157617,0.000095294214,0.000030109359,0.00040178062,0.00033146844,0.0027928618],"category_scores_gemma":[0.0023542023,0.00016612884,0.000360578,0.0002320464,0.0003952222,0.00016385982,0.0001707346,0.002491365,0.00002720403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009358034,0.0045532277,0.8904425,0.000021629387,0.00066073687,0.00077374565,0.0010581682,0.0000019722563,0.00049058284,0.000020141308,0.00215957,0.090459675],"study_design_scores_gemma":[0.047185685,0.019012177,0.9301007,0.00022165896,0.0002506569,0.0001361813,0.0013637769,0.000080059865,0.00003176516,0.00007322067,0.0013865205,0.00015763615],"about_ca_topic_score_codex":0.0029565115,"about_ca_topic_score_gemma":0.0031674004,"teacher_disagreement_score":0.09030204,"about_ca_system_score_codex":0.0007087806,"about_ca_system_score_gemma":0.0023228468,"threshold_uncertainty_score":0.9998099},"labels":[],"label_agreement":null},{"id":"W2948772049","doi":"10.1200/jco.2019.37.18_suppl.lba2","title":"Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ottawa Hospital","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Oncology; Internal medicine; Clinical endpoint; Prostate cancer; Hazard ratio; Cancer; Androgen receptor; Randomized controlled trial; Confidence interval","score_opus":0.12377839788157827,"score_gpt":0.5153794555294441,"score_spread":0.3916010576478658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948772049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98737675,0.00081219594,0.00043325132,0.0013059888,0.0013486418,0.0075725005,0.000850062,0.0000065993754,0.00029402517],"genre_scores_gemma":[0.9880626,0.005775794,0.004351687,0.00016779384,0.0006282491,0.0001645829,0.00012120828,0.000039763105,0.0006882766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99218625,0.002089023,0.0039773574,0.00037827433,0.0010556203,0.0003134677],"domain_scores_gemma":[0.98310214,0.007876496,0.0046359776,0.000273725,0.003823012,0.00028867155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00855493,0.00029462724,0.0055865985,0.0002747385,0.000033917288,0.00001484915,0.00023286279,0.00022061323,0.00009626341],"category_scores_gemma":[0.004203348,0.00015235253,0.00081381307,0.00020208396,0.0007335661,0.00027002353,0.000040732724,0.00062099803,4.8474095e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9627644,0.0054413364,0.00017764643,0.00009611615,0.0059588836,0.00011873008,0.00347984,0.00004918157,0.0022345711,0.00008166197,0.00020609243,0.019391565],"study_design_scores_gemma":[0.76296127,0.22861809,0.00010494076,0.00029504253,0.0009879391,0.000015987842,0.0012961657,0.00031141014,0.0032102163,0.00007297898,0.0020059966,0.000119968725],"about_ca_topic_score_codex":0.00015366594,"about_ca_topic_score_gemma":0.0002031065,"teacher_disagreement_score":0.22317675,"about_ca_system_score_codex":0.00027625295,"about_ca_system_score_gemma":0.005596391,"threshold_uncertainty_score":0.99277574},"labels":[],"label_agreement":null},{"id":"W2948947061","doi":"10.1200/jco.18.02238","title":"Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Chemotherapy; Ovarian cancer; Oncology; Complete response; Internal medicine; Cancer","score_opus":0.08218152378833052,"score_gpt":0.43926064476605997,"score_spread":0.3570791209777294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948947061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430346,0.00012766091,0.00006766291,0.052979764,0.0016862454,0.0018924132,0.000008869251,0.00000553612,0.00019724188],"genre_scores_gemma":[0.9643627,0.0001444743,0.00039031054,0.033588074,0.0012704975,0.0001669501,0.0000018886719,0.000027951572,0.000047174624],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9944699,0.0020436635,0.0020524026,0.00030641616,0.000731753,0.00039588023],"domain_scores_gemma":[0.9947463,0.0031189504,0.001156845,0.0004535793,0.00035149918,0.00017278187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007995066,0.00022395191,0.0011482232,0.00019665858,0.00002941366,0.000020771717,0.00036880968,0.00028457918,0.00066723046],"category_scores_gemma":[0.0008968971,0.000105853345,0.00029406644,0.0005267288,0.00017616466,0.00008857192,0.000018092629,0.001530396,0.000025136706],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7062255,0.0023589388,0.234462,0.0000045125244,0.000094598356,0.00006478202,0.0008835577,0.000135596,0.00003466101,0.00000981074,0.0026576088,0.053068403],"study_design_scores_gemma":[0.21350248,0.03053394,0.61928993,0.0002722278,0.00002208455,0.00000878192,0.00007451654,0.00003724728,0.000037055812,0.000027670438,0.136089,0.00010507322],"about_ca_topic_score_codex":0.000047704867,"about_ca_topic_score_gemma":0.00060928403,"teacher_disagreement_score":0.49272305,"about_ca_system_score_codex":0.00041364777,"about_ca_system_score_gemma":0.0019844119,"threshold_uncertainty_score":0.73057055},"labels":[],"label_agreement":null},{"id":"W2948961541","doi":"10.1200/jco.2019.37.15_suppl.11554","title":"Functional impairment on admission and associated symptom burden and health outcomes among hospitalized patients with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Activities of daily living; Comorbidity; Cancer; Functional impairment; Physical therapy; Internal medicine; Quality of life (healthcare); Charlson comorbidity index; Bathing","score_opus":0.04057101021562927,"score_gpt":0.416983170461441,"score_spread":0.37641216024581176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948961541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98425,0.00029722,0.0000039778665,0.013590165,0.0013125493,0.00032600726,0.000007138155,0.000008039393,0.00020490788],"genre_scores_gemma":[0.9954099,0.00064439204,0.00006609137,0.003262937,0.00020584515,0.0000047850135,0.000007479929,0.000012967135,0.00038562296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981513,0.00016974364,0.00090393063,0.00018483489,0.00041431468,0.00017585781],"domain_scores_gemma":[0.9974728,0.0005021947,0.0011742787,0.00009343995,0.00029908,0.00045820957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010172811,0.00012512364,0.001107404,0.00006647148,0.000039180184,0.0000071969707,0.000039830986,0.00017620806,0.00014381399],"category_scores_gemma":[0.00034341493,0.00007459308,0.0001325732,0.00006692828,0.000076125485,0.000081954924,0.000027786193,0.0004904862,0.0000017688167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042654737,0.00040808006,0.93448776,0.000025823878,0.00023802633,0.0000120159075,0.00014984558,0.000011101873,0.0000013754004,0.0000067486367,0.00094979984,0.05944393],"study_design_scores_gemma":[0.019162698,0.030934056,0.9442168,0.0003588541,0.00009915619,0.0000054376824,0.00013244258,0.000017275917,0.0000012208322,0.000021383492,0.0049751354,0.0000755353],"about_ca_topic_score_codex":0.00021613349,"about_ca_topic_score_gemma":0.0002870218,"teacher_disagreement_score":0.05936839,"about_ca_system_score_codex":0.00029766813,"about_ca_system_score_gemma":0.00088223076,"threshold_uncertainty_score":0.30418175},"labels":[],"label_agreement":null},{"id":"W2949246094","doi":"10.1200/jco.19.00107","title":"Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Sunitinib; Nomogram; Sorafenib; TNM staging system; Stage (stratigraphy); Kidney cancer; Internal medicine; Cancer; Prospective cohort study; Cancer staging; Oncology; Clinical trial; Clear cell renal cell carcinoma; Staging system; Hepatocellular carcinoma","score_opus":0.36815285276110676,"score_gpt":0.4716899339327549,"score_spread":0.10353708117164812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949246094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883418,0.00033115927,0.0013694506,0.0007038644,0.00054527115,0.0009431108,0.0000047543263,0.000010940482,0.007749637],"genre_scores_gemma":[0.9815648,0.00009193547,0.017728254,0.000095679745,0.0003602812,0.000037714395,0.0000068922077,0.000018089133,0.00009635374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660665,0.00037930117,0.002060606,0.00022272114,0.00053973665,0.00019096168],"domain_scores_gemma":[0.98916805,0.00606627,0.0031488072,0.00015879984,0.0012679776,0.00019012023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023905057,0.0001390328,0.0011620678,0.0001527503,0.00003926877,0.000008368582,0.000091247624,0.00019738963,0.000030504607],"category_scores_gemma":[0.0058681886,0.0000917116,0.00027888635,0.00023670934,0.00012250435,0.00016069578,0.000019053325,0.00071065343,0.000004161906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07490392,0.002002365,0.86228466,0.00010275278,0.00061625475,0.00014965402,0.00044904754,0.025893532,0.00028781593,0.00052137783,0.000058828977,0.032729775],"study_design_scores_gemma":[0.23092175,0.19661081,0.51229,0.004742548,0.004606592,0.00047146174,0.0008903982,0.04250946,0.0039768247,0.0021519628,0.0004285462,0.0003996422],"about_ca_topic_score_codex":0.000033247685,"about_ca_topic_score_gemma":0.000026783347,"teacher_disagreement_score":0.34999466,"about_ca_system_score_codex":0.00028968204,"about_ca_system_score_gemma":0.0036475698,"threshold_uncertainty_score":0.70251936},"labels":[],"label_agreement":null},{"id":"W2949517930","doi":"10.1200/jco.2006.24.18_suppl.4638","title":"Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Placebo; Prostate cancer; Bone pain; Zoledronic acid; Cancer; Malignancy; Internal medicine; Surgery; Physical therapy; Chronic pain; Pathology","score_opus":0.04802439274774274,"score_gpt":0.45338614372281066,"score_spread":0.40536175097506794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949517930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595124,0.000943583,0.000005921929,0.0009836005,0.00017218577,0.0017263296,0.000029112785,0.0000027925869,0.0001852302],"genre_scores_gemma":[0.99897,0.00033350528,0.00008838416,0.00013787419,0.000291418,0.00006905041,0.000010117044,0.000015444659,0.0000842432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99546987,0.0013218008,0.002227043,0.00017353304,0.000464395,0.00034337203],"domain_scores_gemma":[0.9955592,0.0025161055,0.0013289957,0.00011803961,0.00029261113,0.00018504943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005766633,0.00016107269,0.0019902817,0.00035013893,0.000013479463,0.0000050932936,0.000083464976,0.00015788001,0.000105434214],"category_scores_gemma":[0.0016643432,0.00008386036,0.00045286815,0.00024947713,0.00016902164,0.00008380427,0.000012170055,0.00081041164,0.0000015579872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6184879,0.005776623,0.34587774,0.000018441531,0.0003125524,0.0004511733,0.000027448328,0.00026622505,0.000043177075,0.0000013299032,0.00036337995,0.028374037],"study_design_scores_gemma":[0.6260676,0.07236197,0.3007349,0.0002185274,0.00016504609,0.000005563754,0.000011280683,0.00007181551,0.000055188797,0.000044465654,0.00020787893,0.00005576734],"about_ca_topic_score_codex":0.00039007136,"about_ca_topic_score_gemma":0.00058100035,"teacher_disagreement_score":0.06658535,"about_ca_system_score_codex":0.00066027103,"about_ca_system_score_gemma":0.003417872,"threshold_uncertainty_score":0.6063158},"labels":[],"label_agreement":null},{"id":"W2949754698","doi":"10.1200/jco.2012.30.15_suppl.5010","title":"Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"PTEN; KRAS; Neuroblastoma RAS viral oncogene homolog; Medicine; Temsirolimus; PI3K/AKT/mTOR pathway; Cancer research; Selumetinib; PDGFRA; Oncology; Internal medicine; CDKN2A; Cancer; Discovery and development of mTOR inhibitors; Genetics; Biology; Signal transduction","score_opus":0.18033303618569202,"score_gpt":0.4885293930350842,"score_spread":0.3081963568493922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949754698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967148,0.000907388,0.000031538086,0.00061085727,0.00084406644,0.00020883132,0.0000022163988,0.000002227599,0.0006781201],"genre_scores_gemma":[0.9969619,0.0001679865,0.0016239638,0.00038676104,0.0008003915,0.000006094748,6.5185844e-7,0.000013722196,0.00003850884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966375,0.00032561438,0.0023106965,0.0001035352,0.00039007698,0.00023252537],"domain_scores_gemma":[0.99649894,0.0010795635,0.0017311358,0.00013265954,0.0002419415,0.00031573695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024561936,0.00011416655,0.0015578318,0.00026156942,0.000007758284,0.0000017994953,0.000050857892,0.00024444202,0.00009212428],"category_scores_gemma":[0.002009778,0.000069177564,0.0003214489,0.00020632034,0.00012646991,0.00010567415,0.000026200554,0.00052507344,0.0000057882653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070020314,0.0016928812,0.9643818,0.0000381663,0.00013038609,0.0016338886,0.000058511567,0.000012197128,0.0014080313,0.000012012391,0.00005385393,0.02357622],"study_design_scores_gemma":[0.01753446,0.01429393,0.9529181,0.00017013962,0.0004591033,0.0006495471,0.00003812802,0.000009187227,0.012682226,0.000018994973,0.0011581029,0.000068057016],"about_ca_topic_score_codex":0.00006676314,"about_ca_topic_score_gemma":0.000065122345,"teacher_disagreement_score":0.023508163,"about_ca_system_score_codex":0.00026218756,"about_ca_system_score_gemma":0.00063200213,"threshold_uncertainty_score":0.28209794},"labels":[],"label_agreement":null},{"id":"W2949974727","doi":"10.1200/jco.2012.30.15_suppl.6058","title":"Treatment and treatment outcomes of advanced NSCLC patients in routine clinical care: Results of the retrospective LUCEOR study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Erlotinib; Pemetrexed; Docetaxel; Gemcitabine; Lung cancer; Internal medicine; Adenocarcinoma; Stage (stratigraphy); KRAS; Cancer; Performance status; Oncology; Chemotherapy; Epidermal growth factor receptor","score_opus":0.07741247070655305,"score_gpt":0.5155121252538329,"score_spread":0.4380996545472799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949974727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947255,0.00040695365,8.5868004e-7,0.0014751981,0.0011126786,0.0008481773,0.000036379784,0.0000024263368,0.0013918102],"genre_scores_gemma":[0.99835163,0.00054167316,0.0005290546,0.00010619445,0.00022374371,0.000012790949,0.0000039224856,0.000010392347,0.00022059723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960458,0.0005329743,0.0028183374,0.00017084458,0.00025127365,0.00018072332],"domain_scores_gemma":[0.9952351,0.0017733412,0.0021301156,0.000261789,0.00039126465,0.00020838504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009905332,0.00015501081,0.0017851102,0.00007789621,0.000028170123,0.0000017098089,0.00007635693,0.00016923659,0.000006563231],"category_scores_gemma":[0.0026764793,0.00007341309,0.00047451234,0.00012861592,0.00019588818,0.00007912771,0.00003894547,0.00024744868,8.1915437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050656823,0.01686609,0.8754475,0.000005449293,0.00084694894,0.000014433579,0.0024193805,0.0000029068253,0.0000020823234,0.000021729446,0.000030614927,0.09927718],"study_design_scores_gemma":[0.060253263,0.053497884,0.8817838,0.000044771114,0.0012423231,0.000007729845,0.0014321627,9.617617e-7,0.000028335768,0.00001660467,0.0016465113,0.00004566837],"about_ca_topic_score_codex":0.00022204779,"about_ca_topic_score_gemma":0.00035706625,"teacher_disagreement_score":0.09923151,"about_ca_system_score_codex":0.0007242908,"about_ca_system_score_gemma":0.0007509209,"threshold_uncertainty_score":0.3204189},"labels":[],"label_agreement":null},{"id":"W2950864878","doi":"10.1200/jco.2013.31.15_suppl.6022","title":"A phase II study of dasatanib (BMS 354825) in recurrent or metastatic <i>ckit</i>-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Dasatinib; Internal medicine; Gastroenterology; Nausea; Progressive disease; Response Evaluation Criteria in Solid Tumors; Vomiting; Stage (stratigraphy); Chemotherapy; Surgery; Imatinib","score_opus":0.1292075495369981,"score_gpt":0.4666290240801813,"score_spread":0.3374214745431832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950864878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995633,0.0013014132,0.000025914775,0.0012083855,0.0006427389,0.00097448577,0.000011617705,0.0000082905735,0.0001941209],"genre_scores_gemma":[0.99641883,0.0007809342,0.001824211,0.00046917226,0.00036775737,0.00005301107,0.000007711854,0.000030053146,0.00004830802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942414,0.00073253794,0.0037619816,0.00037031207,0.00051388115,0.00037988243],"domain_scores_gemma":[0.99367607,0.0030715524,0.0020927365,0.00032066353,0.0002891307,0.00054982404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002462839,0.0003046471,0.002762397,0.000303069,0.00007336032,0.000022658796,0.00020278846,0.00016064802,0.00030755586],"category_scores_gemma":[0.001866747,0.00017634574,0.00029185676,0.00026855705,0.00017107565,0.00022613251,0.00015736924,0.00077011844,0.000009263352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024202751,0.14291635,0.6824996,0.0003599489,0.0018019767,0.017903686,0.003528188,0.000022720918,0.0005518184,0.00002031237,0.0034870214,0.12270561],"study_design_scores_gemma":[0.096210614,0.25869972,0.63434803,0.001576233,0.0017206296,0.0022255776,0.0032343601,0.00045498952,0.00025018552,0.00025645693,0.0007327449,0.00029046828],"about_ca_topic_score_codex":0.00022842166,"about_ca_topic_score_gemma":0.00009403817,"teacher_disagreement_score":0.12241514,"about_ca_system_score_codex":0.00012110964,"about_ca_system_score_gemma":0.0008025582,"threshold_uncertainty_score":0.71911705},"labels":[],"label_agreement":null},{"id":"W2951890881","doi":"10.1200/jco.18.01608","title":"Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Seminoma; Teratoma; Germ cell tumors; Cumulative incidence; Incidence (geometry); Immature teratoma; Internal medicine; Chemotherapy; Oncology; Surgery; Transplantation","score_opus":0.03348144968460822,"score_gpt":0.41825171039187625,"score_spread":0.38477026070726805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951890881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988981,0.00015889121,0.0000016296714,0.00014735032,0.000085810534,0.0003886404,0.000011229721,0.0000019451768,0.00030639485],"genre_scores_gemma":[0.99967414,0.00002158706,0.00016257308,0.00008550215,0.000018557444,0.0000015582405,0.000002744182,0.000010087536,0.000023241046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978409,0.00025897712,0.0013018321,0.00012225793,0.00034730588,0.00012875062],"domain_scores_gemma":[0.9953837,0.0017106679,0.0021110924,0.00020239134,0.0003591457,0.00023300547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004542517,0.00011440837,0.0009208105,0.00008381001,0.000009158054,0.0000015685098,0.00010071816,0.00008353335,0.000094765186],"category_scores_gemma":[0.001489571,0.000052416723,0.00037382712,0.00014340061,0.000100082994,0.00006772987,0.000023646953,0.00035513434,0.0000066384573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014209426,0.004899986,0.97656083,0.00002250985,0.0002553415,0.00018487971,0.00004857802,0.0006657789,0.000012224357,0.000035119985,0.000011662217,0.0030936738],"study_design_scores_gemma":[0.012557136,0.034979597,0.95132,0.000467088,0.00026144777,0.000004836056,0.000018724617,0.00014515399,0.000019766636,0.00017520742,0.000006018057,0.000045055756],"about_ca_topic_score_codex":0.000021895752,"about_ca_topic_score_gemma":0.000002369439,"teacher_disagreement_score":0.030079609,"about_ca_system_score_codex":0.0001507627,"about_ca_system_score_gemma":0.0012514963,"threshold_uncertainty_score":0.22201006},"labels":[],"label_agreement":null},{"id":"W2952164772","doi":"10.1200/jco.19.00948","title":"Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"National Comprehensive Cancer Network; American Society of Clinical Oncology","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Guideline; Disease; Adjuvant therapy; Cancer; Lymph node; Systemic therapy; Stage (stratigraphy); Hormone therapy; Clinical trial; Hormonal therapy; Chemotherapy; Gynecology; Pathology","score_opus":0.024441167467496236,"score_gpt":0.37759405045548083,"score_spread":0.3531528829879846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952164772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056846,0.007731861,0.000009370391,0.00043361174,0.00058305764,0.0004478206,0.00020925495,4.2080632e-7,0.000016117992],"genre_scores_gemma":[0.99723375,0.0022649094,0.00017304128,0.00020871013,0.000073972304,0.000018007226,0.0000022654874,0.0000097829525,0.000015540789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796426,0.0001672879,0.0013596296,0.00017459142,0.00020133663,0.00013286812],"domain_scores_gemma":[0.9975215,0.00017155579,0.0015455697,0.00025010432,0.0004512954,0.00005994416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040901417,0.0001219365,0.000668827,0.000026991258,0.000028432783,0.0000025762279,0.00025423485,0.000112055575,0.000027282125],"category_scores_gemma":[0.00015208182,0.00006123017,0.00030154435,0.00005077555,0.00010586428,0.0000067019364,0.00017248825,0.00014842302,4.5976556e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003322401,0.00022670689,0.957088,0.000037828308,0.0002608077,6.259128e-7,0.00053475593,0.0015737271,0.0033102366,0.000005762593,0.00009735468,0.0335418],"study_design_scores_gemma":[0.004071863,0.0010644043,0.9820577,0.0004941202,0.00013092942,0.0000044896015,0.0009093023,0.000015853208,0.006145877,0.000042354313,0.0049916073,0.000071507064],"about_ca_topic_score_codex":0.0045321747,"about_ca_topic_score_gemma":0.015832888,"teacher_disagreement_score":0.03347029,"about_ca_system_score_codex":0.00016305642,"about_ca_system_score_gemma":0.001375233,"threshold_uncertainty_score":0.88351226},"labels":[],"label_agreement":null},{"id":"W2952770461","doi":"10.1200/jco.2019.37.15_suppl.11578","title":"Single-fraction stereotactic versus standard conventional multifraction radiation for predominantly non-spine bone metastases: A randomized phase II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dose fractionation; Clinical endpoint; Radiation therapy; Brief Pain Inventory; Randomized controlled trial; Surgery; Nuclear medicine; Chronic pain","score_opus":0.11265081926722466,"score_gpt":0.4805233411517183,"score_spread":0.36787252188449365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952770461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93862057,0.00034316935,0.03890804,0.005832698,0.009816435,0.005455047,0.00004755596,0.000020766647,0.00095572794],"genre_scores_gemma":[0.9721378,0.00033827062,0.023078034,0.00089397246,0.0017577639,0.00011538011,0.0001421144,0.000040188217,0.0014964831],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99354655,0.0010761007,0.0039949017,0.00031520467,0.00080777035,0.0002594568],"domain_scores_gemma":[0.9858786,0.0066202674,0.005857067,0.00027704085,0.0009840204,0.00038300973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013073053,0.0002230088,0.003066337,0.00033640262,0.000080885206,0.000028075052,0.00010611703,0.00024111425,0.0007987358],"category_scores_gemma":[0.02349234,0.00017251298,0.0015956355,0.00014741773,0.00014616881,0.00050570746,0.000038202124,0.00057533535,0.000028650451],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.855179,0.010241235,0.000029876446,0.00015163803,0.0020178428,0.000086384774,0.00003176369,0.000016748778,0.00041029247,0.00012623238,0.0043394016,0.1273696],"study_design_scores_gemma":[0.7958355,0.08824428,0.00021109218,0.00010364037,0.005343574,0.00003944401,0.00017038916,0.0037555392,0.00012982222,0.0001667256,0.10587695,0.00012306908],"about_ca_topic_score_codex":0.0000052014902,"about_ca_topic_score_gemma":0.0000033086044,"teacher_disagreement_score":0.12724653,"about_ca_system_score_codex":0.00045946235,"about_ca_system_score_gemma":0.0012088992,"threshold_uncertainty_score":0.9847332},"labels":[],"label_agreement":null},{"id":"W2952789992","doi":"10.1200/jco.2013.31.15_suppl.5055","title":"Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Internal medicine; Adverse effect; Docetaxel; Interim analysis; Mitoxantrone; Febrile neutropenia; Surgery; Cancer; Toxicity; Neutropenia; Clinical trial; Chemotherapy; Androgen deprivation therapy","score_opus":0.12189504773126325,"score_gpt":0.48449588118517356,"score_spread":0.3626008334539103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952789992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929562,0.00025658484,0.000043797412,0.0014845356,0.00013388944,0.004917218,0.000053764656,0.000033631353,0.000120330056],"genre_scores_gemma":[0.9883793,0.0003818907,0.009795682,0.00027951234,0.00008622345,0.00074247475,0.000043783246,0.000036001667,0.00025513122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956361,0.00045802933,0.0024664619,0.00044541972,0.0005461622,0.00044780024],"domain_scores_gemma":[0.9939335,0.00075407,0.0024950425,0.0002260153,0.0018531061,0.000738293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007086554,0.0003500066,0.002697271,0.00045692816,0.000083584535,0.00010751688,0.00019810729,0.00016627702,0.00017021333],"category_scores_gemma":[0.00031671807,0.00019978943,0.0003134789,0.000974192,0.00037072873,0.0006364438,0.00008711424,0.0005563944,0.0000015530878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04512462,0.009743596,0.73451525,0.00021974255,0.00985843,0.00023983468,0.0008662623,0.00051917846,0.0002518988,0.0000059065287,0.00041124993,0.198244],"study_design_scores_gemma":[0.022179116,0.0816861,0.87871313,0.00044844655,0.011178392,0.000051397197,0.00013137767,0.0010352697,0.00011986306,0.0000045906413,0.004235422,0.00021689956],"about_ca_topic_score_codex":0.0037531003,"about_ca_topic_score_gemma":0.004827638,"teacher_disagreement_score":0.19802712,"about_ca_system_score_codex":0.0004688147,"about_ca_system_score_gemma":0.0015835183,"threshold_uncertainty_score":0.81471765},"labels":[],"label_agreement":null},{"id":"W2953034563","doi":"10.1200/jco.19.00502","title":"Management of Stage II Germ Cell Tumors: Be Sure, Be Patient, Be Safe","year":2019,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Stage (stratigraphy); Germ cell; Cancer research; Oncology; Internal medicine; Chemotherapy; Genetics; Biology; Gene","score_opus":0.10867866285450115,"score_gpt":0.43248548885187105,"score_spread":0.3238068259973699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953034563","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3124901,0.004388263,0.000028316328,0.65191066,0.0047130296,0.0015188968,0.00047929815,0.000024248286,0.024447165],"genre_scores_gemma":[0.16470039,0.002722276,0.004812216,0.7940403,0.0050960267,0.000016879236,0.00038249456,0.00014986406,0.028079528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99374837,0.0005116809,0.003780444,0.00040972303,0.0011088046,0.0004409543],"domain_scores_gemma":[0.9902992,0.0018291321,0.006369336,0.0006327472,0.00051289506,0.0003566916],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010791989,0.00039904309,0.003169322,0.00021636182,0.000043542117,0.000009280293,0.00033893008,0.0011605169,0.00086038973],"category_scores_gemma":[0.0006751036,0.00027872494,0.0017474672,0.00012133754,0.00021730091,0.00006899488,0.0002496301,0.0026398976,0.000028944609],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017511728,0.0056572687,0.020376911,0.0013734394,0.0031814093,0.04605727,0.000046958543,0.0000086235195,0.000003411136,0.00002344468,0.90282685,0.018693242],"study_design_scores_gemma":[0.009672788,0.021338707,0.038460918,0.00070006674,0.004178393,0.00018631213,0.00006261551,0.000005532949,0.000014302317,0.000048562113,0.92512774,0.00020408464],"about_ca_topic_score_codex":0.00003345865,"about_ca_topic_score_gemma":0.000003210395,"teacher_disagreement_score":0.14778972,"about_ca_system_score_codex":0.00025224226,"about_ca_system_score_gemma":0.001559684,"threshold_uncertainty_score":0.9999665},"labels":[],"label_agreement":null},{"id":"W2953393211","doi":"10.1200/jco.2013.31.15_suppl.e12522","title":"Diabetes, insulin resistance, and metabolic syndrome in women at high risk for breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Metabolic syndrome; Waist; Breast cancer; Insulin resistance; Population; Internal medicine; Diabetes mellitus; Family history; Type 2 diabetes; Cancer; Endocrinology; Gynecology; Body mass index; Environmental health","score_opus":0.020346348419961014,"score_gpt":0.33721047704355595,"score_spread":0.3168641286235949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953393211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8591287,0.1390407,0.000010862428,0.0006333318,0.00080126687,0.00020556748,0.00010245333,0.0000021716933,0.00007491995],"genre_scores_gemma":[0.8170462,0.1790036,0.0007970728,0.0017326693,0.0009585875,0.00010391819,0.000004325701,0.000021308939,0.00033230355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973681,0.0003737199,0.0014017792,0.00029124052,0.0001487283,0.00041644112],"domain_scores_gemma":[0.9976656,0.00034010765,0.0011720923,0.00020070691,0.00029328003,0.00032824275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021574332,0.00016529673,0.0011432444,0.00007862393,0.000049958442,0.00001540585,0.00023789717,0.0004274157,0.00018125864],"category_scores_gemma":[0.0008226587,0.000128887,0.00020927606,0.000098582525,0.000192747,0.000016847294,0.00009990912,0.00035626628,0.0000053846375],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018525166,0.00042278983,0.08829715,0.000053965658,0.00051709637,0.000012594154,0.000049805465,0.00002396625,0.0014761416,0.000087507826,0.012988674,0.8942178],"study_design_scores_gemma":[0.004529735,0.0010258802,0.5456889,0.000023811557,0.00007950543,0.000014909833,0.000024161298,0.000008791646,0.00036717835,0.0011478228,0.4469557,0.00013355879],"about_ca_topic_score_codex":0.000056446133,"about_ca_topic_score_gemma":0.00036430915,"teacher_disagreement_score":0.8940842,"about_ca_system_score_codex":0.00007004524,"about_ca_system_score_gemma":0.00047122722,"threshold_uncertainty_score":0.52558595},"labels":[],"label_agreement":null},{"id":"W2953463995","doi":"10.1200/jco.2019.37.15_suppl.7553","title":"Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Clinical endpoint; Surgery; Follicular lymphoma; Progression-free survival; Refractory (planetary science); Lymphoma; Chemotherapy; Clinical trial","score_opus":0.04862068216639961,"score_gpt":0.3738936953132423,"score_spread":0.3252730131468427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953463995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965878,0.00029011135,0.00000925112,0.00047710055,0.00057914876,0.0005924743,0.0000099114195,0.000013121869,0.0014410946],"genre_scores_gemma":[0.9965121,0.0004923443,0.00084985263,0.0007514316,0.00021571915,0.00001054398,0.000024282412,0.000040458224,0.0011032618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961554,0.000320675,0.0021521011,0.00032369464,0.00073454826,0.0003136191],"domain_scores_gemma":[0.9937915,0.0015976289,0.0027332983,0.00044339962,0.0009568799,0.000477247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008168666,0.00028225424,0.0024037983,0.00016350059,0.000033479122,0.0000092404725,0.00018663605,0.00043902296,0.00042344464],"category_scores_gemma":[0.0005950038,0.00013702494,0.0005180738,0.00021571595,0.00020651634,0.00016405247,0.000040917024,0.0003154188,0.000058615562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054481775,0.010022048,0.87026757,0.000065712746,0.0017692008,0.0024312437,0.000061282924,0.0000032312246,0.000028562725,0.000016573293,0.0008932754,0.0599595],"study_design_scores_gemma":[0.09941826,0.09856808,0.79268426,0.0004797886,0.001478858,0.00033259526,0.00004098208,0.0000050933427,0.00031068537,0.000003701676,0.0065437085,0.00013395889],"about_ca_topic_score_codex":0.00004303569,"about_ca_topic_score_gemma":0.00008701645,"teacher_disagreement_score":0.08854604,"about_ca_system_score_codex":0.00046373968,"about_ca_system_score_gemma":0.0021760121,"threshold_uncertainty_score":0.5587715},"labels":[],"label_agreement":null},{"id":"W2953537665","doi":"10.1200/jco.2019.37.15_suppl.7558","title":"Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Tocilizumab; Internal medicine; Cohort; Clinical endpoint; Transplantation; Surgery; Gastroenterology; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.05713734364355888,"score_gpt":0.37900502988949414,"score_spread":0.32186768624593526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953537665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932294,0.0001804908,0.0000149772395,0.00058416056,0.00043714614,0.00071024586,0.000024584977,0.000008671421,0.004810333],"genre_scores_gemma":[0.9896913,0.00033661246,0.0014721446,0.0007390367,0.0002642623,0.0000044241465,0.000016241203,0.00006171001,0.0074142353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940822,0.0008376484,0.0028751248,0.00042305686,0.0012403812,0.0005415817],"domain_scores_gemma":[0.99247974,0.0030009763,0.0022859173,0.000683172,0.0010349263,0.0005152952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004048295,0.00026669903,0.0020041722,0.0003849089,0.000026130368,0.000012720624,0.00034276166,0.0005949585,0.00049253256],"category_scores_gemma":[0.0012222618,0.00017002721,0.00033657503,0.00033927136,0.00028845674,0.0003131566,0.00013387424,0.0014883436,0.00005384078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29692957,0.025407065,0.6404943,0.00010716412,0.0003715831,0.00083036383,0.00035303252,0.000024790324,0.0013048836,0.0000038045857,0.0017201089,0.03245335],"study_design_scores_gemma":[0.129765,0.12902473,0.6943882,0.00032202192,0.00014424801,0.00006531575,0.0001229537,0.000034822013,0.00046770027,0.0000055318965,0.045506198,0.00015324944],"about_ca_topic_score_codex":0.00004139466,"about_ca_topic_score_gemma":0.000053201577,"teacher_disagreement_score":0.16716455,"about_ca_system_score_codex":0.00033570838,"about_ca_system_score_gemma":0.0021629673,"threshold_uncertainty_score":0.69335085},"labels":[],"label_agreement":null},{"id":"W2953647905","doi":"10.1200/jco.2013.31.15_suppl.9519","title":"Outcomes of prognostic disclosure: Effects on advanced cancer patients’ prognostic understanding, mental health, and relationship with their oncologist.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Life expectancy; Cohort; Depression (economics); Anxiety; Cancer; Distress; Hospital Anxiety and Depression Scale; Oncology; Psychiatry; Clinical psychology; Population","score_opus":0.31253634446334844,"score_gpt":0.5243403467513906,"score_spread":0.2118040022880422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953647905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866159,0.0014106899,0.000106091706,0.010111322,0.00048543647,0.0008287836,0.000008478127,0.0000066035286,0.00042671635],"genre_scores_gemma":[0.9954116,0.0013162018,0.0019010352,0.0011571705,0.0001187281,0.000020466838,0.0000064976925,0.000013647077,0.000054702454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975005,0.0003982396,0.0014362406,0.00015514168,0.0003165102,0.00019336116],"domain_scores_gemma":[0.98748845,0.0097036045,0.002042176,0.00010482571,0.00034664923,0.00031429593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007420937,0.00015120863,0.0014379469,0.00010416934,0.00004588736,0.000003892636,0.00007867422,0.0001777017,0.000018593491],"category_scores_gemma":[0.0079827085,0.00008187666,0.00016966574,0.00012135091,0.0003480903,0.00010318778,0.000025229192,0.00052729313,0.0000014155847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016557439,0.0011750568,0.97425556,0.00019724667,0.0003218669,0.000011699104,0.00078731996,0.0000053805143,0.0000071106806,0.00021888544,0.00095307094,0.020411061],"study_design_scores_gemma":[0.008264789,0.04721325,0.9394141,0.0016543287,0.00016517022,0.000008170072,0.0008780029,0.00001240446,0.000044002958,0.0006727951,0.0015983366,0.000074688214],"about_ca_topic_score_codex":0.00003098746,"about_ca_topic_score_gemma":0.00007074859,"teacher_disagreement_score":0.04603819,"about_ca_system_score_codex":0.00028123855,"about_ca_system_score_gemma":0.000899381,"threshold_uncertainty_score":0.95566237},"labels":[],"label_agreement":null},{"id":"W2953748643","doi":"10.1200/jco.2006.24.18_suppl.533","title":"Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Epirubicin; Breast cancer; Anthracycline; Internal medicine; Cyclophosphamide; Hazard ratio; Chemotherapy; Tissue microarray; Oncology; Cancer; Gynecology; Gastroenterology; Confidence interval","score_opus":0.02351475919426307,"score_gpt":0.3650299615452188,"score_spread":0.3415152023509557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953748643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969107,0.00041123206,0.0006102524,0.00084410777,0.00028411995,0.00073190266,0.000028795655,0.0000012949741,0.0001775813],"genre_scores_gemma":[0.99801826,0.00027246296,0.0006745511,0.00043214008,0.00047577056,0.00007427077,0.000004257063,0.000013678793,0.00003459434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974635,0.00048090282,0.0013883205,0.00023180316,0.00018046933,0.00025495878],"domain_scores_gemma":[0.9983948,0.00036487516,0.00079935626,0.00009808251,0.00019625877,0.00014663847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022372399,0.00014360955,0.0013153607,0.00011383456,0.000022558332,0.0000071201553,0.00012837788,0.00020239879,0.000009185613],"category_scores_gemma":[0.0002487832,0.00010640056,0.000100908044,0.000113786526,0.00016078001,0.000008688653,0.00008968385,0.00030804225,1.2709665e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96006894,0.0013559316,0.011025149,0.000015456415,0.00031677238,0.000051216066,0.000311311,0.0015434168,0.020024678,0.00010151175,0.000031063446,0.005154551],"study_design_scores_gemma":[0.8231751,0.033024557,0.13661298,0.00027758023,0.00027993156,0.00011516979,0.00021650098,0.0006346432,0.0040301695,0.00074967847,0.0006348024,0.0002488761],"about_ca_topic_score_codex":0.00030714826,"about_ca_topic_score_gemma":0.0008045782,"teacher_disagreement_score":0.13689384,"about_ca_system_score_codex":0.00012397539,"about_ca_system_score_gemma":0.00078002596,"threshold_uncertainty_score":0.4338889},"labels":[],"label_agreement":null},{"id":"W2953850267","doi":"10.1200/jco.2019.37.15_suppl.8035","title":"Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Lenalidomide; Population; Multiple myeloma; Clinical endpoint; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.04693400693711868,"score_gpt":0.402716890099325,"score_spread":0.3557828831622063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953850267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985333,0.00009435537,0.0000202714,0.00023389523,0.00004413088,0.0007951099,0.000017649612,0.000002310907,0.00025899085],"genre_scores_gemma":[0.9981193,0.0005326309,0.0012301303,0.00004056788,0.000023257011,0.000003845786,0.000016925142,0.000015768652,0.000017602912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972309,0.0004403749,0.001411318,0.00021925809,0.0004441364,0.00025400816],"domain_scores_gemma":[0.99426806,0.0041625113,0.0008891634,0.00016537537,0.00023350041,0.0002814095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013067613,0.00017221984,0.0015593894,0.00036085487,0.000014649605,0.000005064626,0.00008360358,0.00020723815,0.000022168757],"category_scores_gemma":[0.001240211,0.0001000084,0.00011362062,0.00023097137,0.00021739285,0.00012100794,0.000020936475,0.0006272085,0.0000013160018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14523675,0.005512189,0.8088286,0.000078999794,0.00030791384,0.0005949542,0.00020259504,0.00010074279,0.0001800123,0.000007561044,0.000013538206,0.038936175],"study_design_scores_gemma":[0.16069615,0.058820724,0.7792071,0.0006739878,0.00008528915,0.000045029847,0.000035438417,0.00018778023,0.00014111605,0.000014608812,0.000025103418,0.00006764853],"about_ca_topic_score_codex":0.00034610127,"about_ca_topic_score_gemma":0.0006196226,"teacher_disagreement_score":0.053308535,"about_ca_system_score_codex":0.00016235297,"about_ca_system_score_gemma":0.00051564653,"threshold_uncertainty_score":0.40782243},"labels":[],"label_agreement":null},{"id":"W2953981643","doi":"10.1200/jco.2019.37.15_suppl.7505","title":"Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Tolerability; Follicular lymphoma; Adverse effect; Gastroenterology; Febrile neutropenia; Surgery; Lymphoma; Chemotherapy","score_opus":0.04840317173428456,"score_gpt":0.40444398275506743,"score_spread":0.3560408110207829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953981643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966584,0.00085884647,0.000009459683,0.0005356331,0.0006547969,0.00064664875,0.000013041045,0.000006728217,0.00061648584],"genre_scores_gemma":[0.9977493,0.0006158886,0.00063623383,0.0006340531,0.00018986066,0.000011777256,0.00001920652,0.000024865882,0.00011878746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99485266,0.0005775971,0.0032744496,0.00039146488,0.0005926964,0.00031111366],"domain_scores_gemma":[0.99401057,0.0017874432,0.0029321637,0.0004085422,0.0004423957,0.00041887953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017766954,0.00028169583,0.0035108386,0.00071203517,0.000036246427,0.000011387752,0.0001776781,0.0004582054,0.00016188834],"category_scores_gemma":[0.0013563766,0.00018143369,0.00092511927,0.0005826404,0.00019477383,0.00019964605,0.00010063092,0.00043786893,0.000008795534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29868233,0.035259485,0.540847,0.00005725793,0.0085302815,0.0007669301,0.00043845907,0.000038268787,0.00013833783,0.00008360373,0.00043443358,0.11472361],"study_design_scores_gemma":[0.43265644,0.114483304,0.4383671,0.00028892234,0.00505692,0.000049034225,0.00015335334,0.0002549942,0.000105758605,0.000027360866,0.008400159,0.00015666107],"about_ca_topic_score_codex":0.00018141571,"about_ca_topic_score_gemma":0.00010974052,"teacher_disagreement_score":0.13397412,"about_ca_system_score_codex":0.0011820481,"about_ca_system_score_gemma":0.0021375332,"threshold_uncertainty_score":0.7398651},"labels":[],"label_agreement":null},{"id":"W2954132446","doi":"10.1200/jco.2019.37.15_suppl.e18505","title":"A retrospective, real-world population-based analysis of treatment patterns and outcomes in adult patients with relapsed/refractory acute myeloid leukemia in Alberta, Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cancer registry; Cohort; Relative survival; Population; Relative risk; Refractory (planetary science); Medical record; Cancer; Retrospective cohort study; Pediatrics; Confidence interval","score_opus":0.022238132854649432,"score_gpt":0.37009089599570305,"score_spread":0.3478527631410536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954132446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972845,0.0000061839355,0.000003345879,0.0016565399,0.00014886205,0.00040274113,0.000033685512,0.000002153179,0.00046203507],"genre_scores_gemma":[0.9980485,0.00017399121,0.00039636562,0.0006876379,0.000044083397,0.0000063705957,0.000046492652,0.00001951824,0.0005770841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617094,0.00040570748,0.0022332054,0.0003047388,0.0005896049,0.0002958154],"domain_scores_gemma":[0.994629,0.0027226922,0.0015343011,0.00030968137,0.00050991256,0.0002943829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086514844,0.00019935664,0.0026728124,0.0009590778,0.000015176208,0.000004676045,0.0001349169,0.0002523846,0.00010852164],"category_scores_gemma":[0.0012056519,0.00012800242,0.00026877312,0.00078052253,0.000073835225,0.00010274756,0.00003188767,0.00090598245,0.0000011999956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005273833,0.0007602298,0.988184,0.000021311142,0.0018889823,0.00022854154,0.00008116112,0.0004326051,0.000004194975,0.000016600505,0.00005721998,0.003051368],"study_design_scores_gemma":[0.021715453,0.008530507,0.96675205,0.00010627807,0.0010900357,0.0000032525995,0.000045941368,0.0014523339,0.000005443685,0.000007046774,0.00018528532,0.00010636137],"about_ca_topic_score_codex":0.7597864,"about_ca_topic_score_gemma":0.97118586,"teacher_disagreement_score":0.21139944,"about_ca_system_score_codex":0.010001446,"about_ca_system_score_gemma":0.009017727,"threshold_uncertainty_score":0.9966002},"labels":[],"label_agreement":null},{"id":"W2954170173","doi":"10.1200/jco.2013.31.15_suppl.e16086","title":"The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgren deprivation therapy in British Columbia, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Framingham Risk Score; Risk factor; Internal medicine; Radiation therapy; Cancer; Coronary artery disease; Disease","score_opus":0.04512691384684178,"score_gpt":0.39178600714049616,"score_spread":0.3466590932936544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954170173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933118,0.004022062,0.0000012846026,0.0016648374,0.0001528482,0.00067122513,0.000011603399,0.0000017734309,0.00016252299],"genre_scores_gemma":[0.92577696,0.07328363,0.000089290435,0.00007246248,0.00006952551,0.000031118492,0.0000014319684,0.000009179353,0.0006663769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762017,0.0005083543,0.0011164706,0.00013166186,0.00038786998,0.00023549906],"domain_scores_gemma":[0.99684846,0.0016850082,0.0008421079,0.00011024808,0.00036845182,0.00014573736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015670831,0.00006698649,0.0007105845,0.000038560323,0.0000442795,0.000024512718,0.000118777265,0.00011402913,0.00006929492],"category_scores_gemma":[0.0008158951,0.000047072557,0.00008742088,0.00020263412,0.00021798766,0.00010408981,0.000021630845,0.00059679965,2.2175209e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008502724,0.00019635649,0.86816597,0.00004036964,0.00018484432,0.00005553449,0.00011535131,0.000024832414,0.00001803392,2.7216313e-7,0.0011109385,0.12923723],"study_design_scores_gemma":[0.007414265,0.0032090428,0.9859616,0.0002894165,0.000052063293,0.0000089741425,0.0003983796,0.000060444963,0.00006514697,0.00009568591,0.0023954937,0.000049494418],"about_ca_topic_score_codex":0.7531492,"about_ca_topic_score_gemma":0.94053143,"teacher_disagreement_score":0.18738227,"about_ca_system_score_codex":0.00049149705,"about_ca_system_score_gemma":0.0066881557,"threshold_uncertainty_score":0.998943},"labels":[],"label_agreement":null},{"id":"W2954187556","doi":"10.1200/jco.2019.37.15_suppl.8005","title":"Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Population; Internal medicine; Adverse effect; Refractory (planetary science); Phases of clinical research; Daratumumab; Gastroenterology; Surgery; Clinical trial; Multiple myeloma; Lenalidomide","score_opus":0.08786617734048409,"score_gpt":0.44924676918679557,"score_spread":0.3613805918463115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954187556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939643,0.00004944746,0.0000059793397,0.00023334776,0.0006066916,0.0045431703,0.000018826013,0.0000033129327,0.0005749021],"genre_scores_gemma":[0.9989337,0.00018460533,0.0005830372,0.000047362046,0.00008253463,0.000017433436,0.000009968345,0.000021998201,0.00011936015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942349,0.0014749997,0.002898882,0.00031200168,0.00079101743,0.00028820123],"domain_scores_gemma":[0.9889086,0.0070557557,0.00257694,0.00044383568,0.0006907382,0.00032415558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002971888,0.00021905341,0.0027695016,0.00014794958,0.00006971785,0.000018317845,0.0003759035,0.00030012702,0.00006675114],"category_scores_gemma":[0.007070061,0.000120971636,0.00014997595,0.00027529773,0.00042954835,0.00016444363,0.00019554708,0.0010580817,0.0000037230907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75998014,0.038545255,0.15191735,0.000051145023,0.0008944697,0.00080933917,0.0003537973,0.000005144219,0.00011420237,0.0000032532178,0.000029120501,0.04729676],"study_design_scores_gemma":[0.5435831,0.1803714,0.27478525,0.00017865408,0.0003411538,0.000093681614,0.00019735965,0.00017512485,0.000039565042,0.0000030776469,0.00016221718,0.00006940493],"about_ca_topic_score_codex":0.00020695956,"about_ca_topic_score_gemma":0.0015875028,"teacher_disagreement_score":0.21639706,"about_ca_system_score_codex":0.00024009714,"about_ca_system_score_gemma":0.0025855058,"threshold_uncertainty_score":0.8464034},"labels":[],"label_agreement":null},{"id":"W2954202342","doi":"10.1200/jco.2019.37.15_suppl.7518","title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Dosing; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Lymphoma; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.045135116611655604,"score_gpt":0.3907390396098182,"score_spread":0.3456039229981626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954202342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927292,0.0002595177,0.00007835965,0.0015205202,0.00042025122,0.0005783346,0.0000027233073,0.000010177788,0.004400936],"genre_scores_gemma":[0.9955553,0.00097200845,0.0013456232,0.0006439245,0.00018508344,0.0000039076317,0.000002203736,0.000046353154,0.0012456187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995664,0.00065357884,0.002240214,0.00035242093,0.0007183193,0.00037146147],"domain_scores_gemma":[0.9942112,0.0028589012,0.0017273064,0.00036551012,0.00042342342,0.00041367792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034325302,0.00021386695,0.0018297819,0.00049422646,0.00003188336,0.000012502733,0.00020968332,0.0004287735,0.00065287825],"category_scores_gemma":[0.00084764266,0.00016241481,0.00025739678,0.00041681423,0.0002888008,0.00019063949,0.00010173528,0.0016677268,0.000016699243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10079091,0.009918978,0.3964956,0.000715451,0.0007514464,0.014117634,0.00025107837,0.0005708289,0.14046982,0.000021088961,0.00088595535,0.33501118],"study_design_scores_gemma":[0.07329665,0.065922506,0.82095945,0.00095965626,0.0003128399,0.0063147373,0.0003676218,0.0082146,0.0027812137,0.00012054059,0.020417402,0.00033278778],"about_ca_topic_score_codex":0.00015204164,"about_ca_topic_score_gemma":0.000045582303,"teacher_disagreement_score":0.42446384,"about_ca_system_score_codex":0.00039923834,"about_ca_system_score_gemma":0.0015454702,"threshold_uncertainty_score":0.7245536},"labels":[],"label_agreement":null},{"id":"W2954391632","doi":"10.1200/jco.2019.37.15_suppl.tps7063","title":"MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Interim analysis; Clinical endpoint; Oncology; Refractory (planetary science); Population; Phases of clinical research; Hematopoietic stem cell transplantation; Transplantation; Gastroenterology; Clinical trial","score_opus":0.07389082348103082,"score_gpt":0.4581241315676492,"score_spread":0.3842333080866184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954391632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466836,0.00005369414,0.000053509273,0.0009008787,0.001098748,0.0021273894,0.000009511541,0.000012355189,0.0010755438],"genre_scores_gemma":[0.99033046,0.00054395694,0.006468746,0.0009953602,0.0007968417,0.000017814407,0.000025998328,0.000054864937,0.0007659692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99006414,0.002611849,0.005259947,0.0003992409,0.0011748394,0.0004899754],"domain_scores_gemma":[0.98496085,0.008669976,0.0040637823,0.00057335093,0.0010910719,0.00064094237],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01330753,0.0002811102,0.0050667888,0.0005570942,0.000028756145,0.000012422099,0.00044443514,0.00081378914,0.00047821464],"category_scores_gemma":[0.011744953,0.000160768,0.0006463268,0.00040624998,0.0005361874,0.00040551744,0.000089730616,0.0030022415,0.000040388844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9466321,0.0075810924,0.01170525,0.00005375253,0.0008655928,0.00071162067,0.00020144234,0.000012293882,0.00046952715,0.000013671824,0.0007025842,0.031051109],"study_design_scores_gemma":[0.861858,0.11793214,0.014197381,0.00027922404,0.00060041127,0.00006690298,0.00011566827,0.00037427296,0.0001124257,0.00004083527,0.0042682174,0.0001545014],"about_ca_topic_score_codex":0.00005959082,"about_ca_topic_score_gemma":0.000047866102,"teacher_disagreement_score":0.11035105,"about_ca_system_score_codex":0.0011004676,"about_ca_system_score_gemma":0.010187019,"threshold_uncertainty_score":0.99929786},"labels":[],"label_agreement":null},{"id":"W2954396039","doi":"10.1200/jco.2013.31.15_suppl.5058","title":"Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Docetaxel; Oncology; Ketoconazole; Chemotherapy; Lactate dehydrogenase; Urology; Logistic regression; Prostate-specific antigen; Cancer; Androgen deprivation therapy","score_opus":0.11061810259442041,"score_gpt":0.45901309900368137,"score_spread":0.34839499640926097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954396039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808427,0.0003475291,0.00012259695,0.016552601,0.00016607706,0.0009503413,0.000030435694,0.0000048711636,0.0009828319],"genre_scores_gemma":[0.99022686,0.00050995237,0.0067905723,0.00047749453,0.00011412596,0.000075490294,0.0000032319047,0.000022109378,0.0017801501],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964592,0.0005657297,0.0018694849,0.00022587222,0.00054385606,0.00033588358],"domain_scores_gemma":[0.995658,0.0017726745,0.0009861597,0.00018083898,0.0009336909,0.0004686823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032465004,0.00016370695,0.0012978365,0.00029922108,0.000026463582,0.0000126603545,0.00014592725,0.00013505902,0.00033100325],"category_scores_gemma":[0.0012860729,0.000097381395,0.000161199,0.00035520957,0.000315905,0.00022296357,0.00004210836,0.0006392855,0.000016067219],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7413746,0.00419407,0.09000299,0.00019901752,0.0025486008,0.0013972371,0.0017711562,0.00093605235,0.10717302,0.000018958423,0.0070352824,0.04334901],"study_design_scores_gemma":[0.030586718,0.056566656,0.9059232,0.0004659856,0.0003722543,0.000111104506,0.0016407435,0.00025900267,0.0018667978,0.000097310396,0.0019876214,0.000122609],"about_ca_topic_score_codex":0.0003132359,"about_ca_topic_score_gemma":0.00022305938,"teacher_disagreement_score":0.81592023,"about_ca_system_score_codex":0.00037275674,"about_ca_system_score_gemma":0.003613823,"threshold_uncertainty_score":0.6410767},"labels":[],"label_agreement":null},{"id":"W2954523493","doi":"10.1200/jco.19.03107","title":"Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Placebo; Internal medicine; Adverse effect; Nausea; Population; Cohort; Clinical endpoint; Surgery; Randomized controlled trial; Pathology","score_opus":0.08038333448786252,"score_gpt":0.4210685781791244,"score_spread":0.3406852436912619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954523493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860938,0.0001227786,0.0001737496,0.0075207828,0.0012312691,0.0043661185,0.000015859125,0.0000053329577,0.00047027555],"genre_scores_gemma":[0.99670035,0.00015821631,0.0008049308,0.0018197171,0.00030400686,0.00015651272,0.000007996672,0.000017891676,0.00003035519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921573,0.0014411643,0.005341207,0.00027656907,0.0004963347,0.0002874356],"domain_scores_gemma":[0.99222076,0.0030265448,0.0038205874,0.00019757092,0.00036330035,0.00037126287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002148404,0.00024879078,0.0057167863,0.00021868244,0.000014841435,0.000005523978,0.00012534959,0.00025691997,0.00010860486],"category_scores_gemma":[0.0038855693,0.00014350683,0.00087155285,0.00019935983,0.00025428244,0.00007719506,0.00002349594,0.00072120136,0.000001916185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87725025,0.015520278,0.08183074,0.000013640474,0.00064280606,0.0002545855,0.00081990735,0.000020625459,0.0000067707874,0.000031348245,0.00016566219,0.023443365],"study_design_scores_gemma":[0.8987293,0.08312267,0.016100107,0.00018297712,0.00036071092,0.000008699817,0.00010721557,0.00025104324,0.000020251717,0.00006514673,0.0009470151,0.000104838735],"about_ca_topic_score_codex":0.000056610552,"about_ca_topic_score_gemma":0.000071734656,"teacher_disagreement_score":0.067602396,"about_ca_system_score_codex":0.0004985733,"about_ca_system_score_gemma":0.0017387314,"threshold_uncertainty_score":0.5852039},"labels":[],"label_agreement":null},{"id":"W2954564366","doi":"10.1200/jco.2019.37.15_suppl.7058","title":"Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Monocytosis; Myelofibrosis; Discontinuation; Interleukin-3 receptor; Phases of clinical research; Gastroenterology; Anagrelide; Clinical trial; Oncology; Leukemia; Bone marrow; Platelet; Essential thrombocythemia","score_opus":0.08061642482235527,"score_gpt":0.43866887677173166,"score_spread":0.3580524519493764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954564366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388725,0.00006047062,0.000014393387,0.001083915,0.003304744,0.0010875518,0.00015989046,0.000009425347,0.0003923862],"genre_scores_gemma":[0.99287736,0.0013965783,0.0032594693,0.000823243,0.0013986817,0.000012401634,0.00006491294,0.000035293484,0.0001320701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98960936,0.0017014785,0.0070109107,0.0005412153,0.00078435254,0.00035270583],"domain_scores_gemma":[0.9746578,0.016885499,0.0067173643,0.0005136014,0.0006691736,0.0005566075],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051223277,0.00031765673,0.0037254135,0.00024532923,0.000031029762,0.000012413099,0.00024950563,0.0007325511,0.00033396843],"category_scores_gemma":[0.01327851,0.00017854627,0.00069761544,0.00022485924,0.00031237784,0.00020783953,0.00009430519,0.0020396472,0.00005632501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4173985,0.018466972,0.4812882,0.000011997541,0.00064784486,0.00022698098,0.000096436364,0.0000062376403,0.000004093473,0.000006961704,0.0010531498,0.0807926],"study_design_scores_gemma":[0.34376544,0.1414848,0.5090673,0.00036652514,0.00047883482,0.000004124704,0.000040583127,0.000019857416,0.00003834186,0.000045539302,0.0045873253,0.00010134502],"about_ca_topic_score_codex":0.00015047647,"about_ca_topic_score_gemma":0.00025771148,"teacher_disagreement_score":0.123017825,"about_ca_system_score_codex":0.00023987023,"about_ca_system_score_gemma":0.0020271216,"threshold_uncertainty_score":0.9950331},"labels":[],"label_agreement":null},{"id":"W2954734607","doi":"10.1200/jco.2007.25.18_suppl.17010","title":"Access to care and patient satisfaction for surgically-treated breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital; Dalhousie University","funders":"","keywords":"Medicine; Interquartile range; Breast cancer; Patient satisfaction; Prospective cohort study; Confidence interval; Concordance; Cancer; Multivariate analysis; Cohort; Surgery; Internal medicine","score_opus":0.055892018427716045,"score_gpt":0.4559170115933588,"score_spread":0.4000249931656428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954734607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455625,0.0011328092,0.00032901985,0.0027291891,0.0007395523,0.00019278386,0.00005045474,0.0000027128901,0.0002672465],"genre_scores_gemma":[0.9959081,0.00089233083,0.0010288304,0.001306646,0.0008253103,0.000013621811,0.0000038797866,0.0000108749955,0.000010428387],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987018,0.000065643835,0.000771879,0.00018080881,0.00010398246,0.00017585585],"domain_scores_gemma":[0.99836516,0.00027708116,0.00050791283,0.000084432206,0.00055664557,0.0002087408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041914615,0.00010420391,0.0004424484,0.00004285577,0.00005509907,0.000010266053,0.00007566167,0.00021175257,0.000012883885],"category_scores_gemma":[0.00028067813,0.00007602864,0.00016775835,0.000052231346,0.0000690452,0.000007401996,0.00008228802,0.00011750331,6.3757034e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040467437,0.00010553621,0.41665798,0.000008095463,0.00020835467,0.000015089736,0.000059522532,0.000015746815,0.0006158942,0.0000045153065,0.0024420754,0.57582045],"study_design_scores_gemma":[0.002421246,0.0034067717,0.92512894,0.000021329046,0.00010737026,0.000098559474,0.00017628305,5.262207e-7,0.0014492008,0.000019446634,0.067086816,0.00008349464],"about_ca_topic_score_codex":0.0001347575,"about_ca_topic_score_gemma":0.0014680353,"teacher_disagreement_score":0.57573694,"about_ca_system_score_codex":0.00008121817,"about_ca_system_score_gemma":0.00023562604,"threshold_uncertainty_score":0.3100358},"labels":[],"label_agreement":null},{"id":"W2954789649","doi":"10.1200/jco.2019.37.15_suppl.tps7571","title":"POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Vincristine; Rituximab; Internal medicine; Diffuse large B-cell lymphoma; Oncology; Phases of clinical research; Cyclophosphamide; Bendamustine; Surgery; Chemotherapy; Lymphoma","score_opus":0.08224978446287155,"score_gpt":0.45607575900181024,"score_spread":0.3738259745389387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954789649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957596,0.00017677198,0.0000012601804,0.00047131683,0.0010178526,0.00078637287,0.0000065909235,0.0000068720988,0.0017733646],"genre_scores_gemma":[0.99911684,0.00009047302,0.00025766887,0.00023633517,0.00019312426,0.0000058761916,0.0000070439005,0.000021906964,0.000070712114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610525,0.00042464052,0.0023180342,0.00027626503,0.0005884728,0.0002873595],"domain_scores_gemma":[0.99522746,0.0017538694,0.0018353646,0.0003285124,0.0004956449,0.0003591603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009064447,0.00021653333,0.002101892,0.00027330365,0.000022420481,0.000007306723,0.00016498435,0.00031485458,0.00013571783],"category_scores_gemma":[0.0010727593,0.00013577974,0.00029104072,0.00030378878,0.000093510775,0.00011886793,0.000056813522,0.00063833874,0.000036594254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07566394,0.05890941,0.83347505,0.000016103237,0.0010515354,0.0008041917,0.00037499852,0.000019984449,0.000012411677,0.000019915096,0.00018712398,0.029465362],"study_design_scores_gemma":[0.25584102,0.1526225,0.5888867,0.00011156992,0.00046848838,0.000025730968,0.00046668126,0.000039754977,0.000019993595,0.00000518706,0.0014362298,0.00007612651],"about_ca_topic_score_codex":0.0004074195,"about_ca_topic_score_gemma":0.00026709822,"teacher_disagreement_score":0.24458833,"about_ca_system_score_codex":0.00078924594,"about_ca_system_score_gemma":0.0018071351,"threshold_uncertainty_score":0.5536937},"labels":[],"label_agreement":null},{"id":"W2954836703","doi":"10.1200/jco.2019.37.15_suppl.8016","title":"Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Multiple myeloma; Lenalidomide; Internal medicine; Dexamethasone; Daratumumab; Health related quality of life; Visual analogue scale; Surgery; Disease","score_opus":0.1049742725139085,"score_gpt":0.43223732366070045,"score_spread":0.32726305114679194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954836703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935242,0.00049093814,0.00018531078,0.0025211768,0.0001874026,0.0029283615,0.00010960841,0.0000068975723,0.000046115183],"genre_scores_gemma":[0.9943387,0.00057247566,0.004439476,0.0002969758,0.00007567175,0.00006520433,0.00007645367,0.000029450423,0.00010558446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950547,0.0005021931,0.0031648846,0.00037080212,0.0004000377,0.00050739],"domain_scores_gemma":[0.9878789,0.008722505,0.0018389008,0.0002042205,0.00066001574,0.00069543323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032899375,0.00024866383,0.0024248473,0.0002529094,0.000052432933,0.000012070195,0.00010363348,0.00032902393,0.000018967183],"category_scores_gemma":[0.0044664145,0.00016387751,0.00025205148,0.00017077467,0.00019693565,0.0001397893,0.000036620986,0.00047272962,9.2758796e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2593577,0.0024324113,0.6956799,0.00061255094,0.00086461194,0.00006235644,0.00018482233,0.000011826319,0.00033896227,0.000016219108,0.00016238843,0.040276296],"study_design_scores_gemma":[0.28932607,0.06255938,0.6451938,0.00027769516,0.00018803607,0.000012586519,0.00039573247,0.0009131319,0.0003189164,0.000036819652,0.0006388545,0.00013892967],"about_ca_topic_score_codex":0.0007284596,"about_ca_topic_score_gemma":0.0011135779,"teacher_disagreement_score":0.060126968,"about_ca_system_score_codex":0.00021919455,"about_ca_system_score_gemma":0.0010982436,"threshold_uncertainty_score":0.6682731},"labels":[],"label_agreement":null},{"id":"W2954921349","doi":"10.1200/jco.2019.37.15_suppl.9075","title":"Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Lung cancer; Interim analysis; Clinical endpoint; Gastroenterology; Pneumonitis; Surgery; Lung; Clinical trial","score_opus":0.02964891069922355,"score_gpt":0.4736541712863544,"score_spread":0.44400526058713086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954921349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944256,0.0004743388,0.000008193877,0.00038160686,0.001397565,0.0025751584,0.0000741975,0.000008640316,0.00065468834],"genre_scores_gemma":[0.9987117,0.000038738646,0.000089149566,0.00034128176,0.00024526665,0.000052815,0.000019820034,0.000034722412,0.00046651438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560046,0.0004139724,0.002442936,0.00040981782,0.0007753316,0.0003574625],"domain_scores_gemma":[0.9951585,0.0006766077,0.0023814372,0.00029839287,0.0011292044,0.00035589305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053615,0.00029068408,0.0019593737,0.00028424675,0.00009581911,0.00000863477,0.00021851766,0.00020099705,0.00028306927],"category_scores_gemma":[0.00022620933,0.00018943117,0.00022825821,0.00033844647,0.000095247015,0.00021317603,0.00009824007,0.00096051674,0.0000051494967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01826845,0.1415849,0.8206567,0.000111952475,0.0009924481,0.00026688798,0.006633372,0.0002560643,0.000016910351,0.0000025167885,0.0005934014,0.010616352],"study_design_scores_gemma":[0.133861,0.2968972,0.5622137,0.00017304,0.0022793734,0.0000043363134,0.0034907148,0.00008518565,0.00005204255,0.0000043197374,0.0007658914,0.00017318112],"about_ca_topic_score_codex":0.0002461526,"about_ca_topic_score_gemma":0.00048976776,"teacher_disagreement_score":0.25844306,"about_ca_system_score_codex":0.0006242558,"about_ca_system_score_gemma":0.0021168366,"threshold_uncertainty_score":0.77247787},"labels":[],"label_agreement":null},{"id":"W2954966588","doi":"10.1200/jco.2019.37.15_suppl.8018","title":"Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Ibrutinib; Anemia; Internal medicine; Placebo; Visual analogue scale; Waldenstrom macroglobulinemia; Quality of life (healthcare); Refractory (planetary science); Randomized controlled trial; Gastroenterology; Surgery; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.07737395609271454,"score_gpt":0.4418125535232706,"score_spread":0.36443859743055607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954966588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833967,0.00014289161,0.000012523068,0.0079138605,0.001257329,0.0005885376,0.000019189067,0.000020745936,0.006648228],"genre_scores_gemma":[0.9899828,0.0001347431,0.005975953,0.0024792356,0.0005366821,0.0000047433878,0.00002580521,0.000039219976,0.0008208579],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99150723,0.0004338961,0.0057274285,0.00052006554,0.0012137778,0.0005976021],"domain_scores_gemma":[0.98993695,0.004748183,0.0031558138,0.0007128445,0.00093572243,0.0005104994],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039575743,0.00027923935,0.0028394733,0.00030853032,0.00002592663,0.000021123966,0.00032679757,0.00074618246,0.00035608895],"category_scores_gemma":[0.0100688515,0.00017475174,0.0003953236,0.00056649605,0.0003263969,0.00014999011,0.00018663892,0.0023813203,0.00021369665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.088775896,0.007487143,0.69968057,0.00008692826,0.0014919498,0.032123785,0.0004790015,0.00009416737,0.0005579676,0.000070757786,0.008247043,0.16090478],"study_design_scores_gemma":[0.47603768,0.029246107,0.42143056,0.00083469786,0.00039629423,0.004106386,0.00056594715,0.001788496,0.00068167754,0.00037551194,0.06410074,0.00043588938],"about_ca_topic_score_codex":0.00076214183,"about_ca_topic_score_gemma":0.00022255474,"teacher_disagreement_score":0.3872618,"about_ca_system_score_codex":0.0041592442,"about_ca_system_score_gemma":0.024068037,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W2955160320","doi":"10.1200/jco.2013.31.15_suppl.531","title":"Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Anastrozole; Internal medicine; Clinical endpoint; Breast cancer; Population; Interim analysis; Oncology; Placebo; Cancer; Gastroenterology; Randomized controlled trial; Tamoxifen; Pathology","score_opus":0.031222375686134878,"score_gpt":0.4148741344509979,"score_spread":0.383651758764863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955160320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901281,0.00036876064,0.00009713767,0.007181797,0.00024725375,0.0019152318,0.0000032637597,0.0000074080262,0.000051069535],"genre_scores_gemma":[0.9967962,0.0002713354,0.0010293028,0.0013656059,0.00020583802,0.00025074664,5.974216e-7,0.000032299893,0.000048099155],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99544674,0.0011546862,0.002272697,0.00025209016,0.0005349405,0.00033886783],"domain_scores_gemma":[0.9950032,0.0013917283,0.002448135,0.00023499099,0.0007408939,0.00018105103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002349871,0.00024000561,0.0023747373,0.00021182203,0.00004244501,0.000007832685,0.0002145242,0.00011157095,0.00015787421],"category_scores_gemma":[0.00031563625,0.00012212482,0.00015610555,0.0004463576,0.00040417621,0.00034446304,0.000051232593,0.0010827288,6.1219504e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5761476,0.021110835,0.053227168,0.000024255976,0.00065251807,0.00014400989,0.004796501,0.0016546489,0.0035401576,0.00001280099,0.000013380186,0.33867612],"study_design_scores_gemma":[0.77248996,0.048986807,0.16807452,0.00064045645,0.00010659636,0.00021302338,0.007826984,0.00010676925,0.0007443997,0.00022813289,0.00043209965,0.00015027863],"about_ca_topic_score_codex":0.00046774955,"about_ca_topic_score_gemma":0.0005825081,"teacher_disagreement_score":0.33852586,"about_ca_system_score_codex":0.0005054233,"about_ca_system_score_gemma":0.0011932581,"threshold_uncertainty_score":0.4980106},"labels":[],"label_agreement":null},{"id":"W2955264692","doi":"10.1200/jco.2019.37.15_suppl.7059","title":"Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Chronic myelomonocytic leukemia; Refractory (planetary science); Internal medicine; Gastroenterology; Vomiting; Interleukin-3 receptor; Malignancy; Stage (stratigraphy); Leukemia; Oncology; Bone marrow; Myelodysplastic syndromes","score_opus":0.1029157698071348,"score_gpt":0.465666030387402,"score_spread":0.3627502605802672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955264692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181384,0.00018857032,0.000036095837,0.0012164557,0.0026378066,0.0012743794,0.000040438805,0.000014747302,0.0027776521],"genre_scores_gemma":[0.99254125,0.00081053283,0.0024159236,0.00059442257,0.0030617137,0.000006091166,0.000052672134,0.00006186865,0.00045549657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98646635,0.002038236,0.008761157,0.0006844062,0.0013909782,0.0006588723],"domain_scores_gemma":[0.9758456,0.015643662,0.0057647154,0.00094156613,0.0009798333,0.0008246321],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012262535,0.00034656958,0.004049348,0.00046289014,0.000034239572,0.000014792125,0.00064704346,0.001335511,0.00030589988],"category_scores_gemma":[0.020773016,0.00023958174,0.0008989115,0.00046542924,0.0006281986,0.000327495,0.00021459261,0.005453803,0.00014245228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64275146,0.008443925,0.12916863,0.000051462688,0.0007239355,0.0006812632,0.00011282883,0.000057833506,0.00011350173,0.000013329013,0.003481964,0.21439989],"study_design_scores_gemma":[0.5737791,0.14781618,0.2500665,0.0005276967,0.00036970226,0.000020716394,0.000076838216,0.00053548237,0.000051272105,0.00005969562,0.026495403,0.00020142297],"about_ca_topic_score_codex":0.00018857859,"about_ca_topic_score_gemma":0.00013063491,"teacher_disagreement_score":0.21419847,"about_ca_system_score_codex":0.0030745456,"about_ca_system_score_gemma":0.019393349,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W2955650241","doi":"10.1200/jco.18.02257","title":"Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?","year":2019,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Urothelial cancer; Medicine; Cancer; Randomized controlled trial; Immunotherapy; Bladder cancer; Oncology; Internal medicine","score_opus":0.20257949305617207,"score_gpt":0.5056114660832302,"score_spread":0.3030319730270581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955650241","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006051501,0.019062119,0.00035687446,0.9585539,0.01581747,0.003880856,0.00020031935,0.000013591692,0.0015096832],"genre_scores_gemma":[0.00070365716,0.048489578,0.00081138645,0.86238086,0.07507186,0.00030986566,0.000021621363,0.00012867758,0.012082521],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879388,0.004486607,0.006065665,0.00035818527,0.0007172438,0.00043345266],"domain_scores_gemma":[0.9485856,0.039420262,0.010324098,0.00052795483,0.001002836,0.00013923884],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.016563706,0.00045272376,0.0116462195,0.0001412162,0.000081412676,0.000034853892,0.0005365352,0.0024320506,0.00090994925],"category_scores_gemma":[0.008174968,0.00020762409,0.006759447,0.0000874162,0.0004539545,0.000066261455,0.000034374487,0.0047533265,0.00003919349],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2484742,0.0002819108,0.00046665894,0.0001286491,0.0063431966,0.00025357874,0.000044078733,0.0000017265371,0.0000066020216,0.000004544571,0.6990204,0.044974465],"study_design_scores_gemma":[0.30434242,0.0047268267,0.00020129132,0.00038833314,0.0048332717,0.00014787585,0.000024591714,0.000007906855,0.000009109276,0.00037789595,0.6848063,0.00013422171],"about_ca_topic_score_codex":0.00009800489,"about_ca_topic_score_gemma":0.000023297802,"teacher_disagreement_score":0.0961731,"about_ca_system_score_codex":0.00032484176,"about_ca_system_score_gemma":0.0064105084,"threshold_uncertainty_score":0.9992222},"labels":[],"label_agreement":null},{"id":"W2955655006","doi":"10.1200/jco.2019.37.15_suppl.8038","title":"Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Tolerability; Oncology; Gastroenterology; Multiple myeloma; Adverse effect","score_opus":0.0812774770851059,"score_gpt":0.4335409812033129,"score_spread":0.352263504118207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955655006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978571,0.0004965361,0.00005268347,0.0005318566,0.00013134032,0.0005408571,0.00005037613,0.0000045468114,0.0003347234],"genre_scores_gemma":[0.9944452,0.0012721112,0.0038967323,0.00017815318,0.00006432251,0.0000027679687,0.000021803968,0.00002045008,0.0000984771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943911,0.0015029468,0.0028397986,0.0003585339,0.00059169345,0.00031596713],"domain_scores_gemma":[0.9847887,0.011699807,0.0022348615,0.00041558142,0.00037058617,0.00049045804],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004163915,0.00021931226,0.0028910039,0.0009631536,0.00003310556,0.0000056564227,0.00015605542,0.00044954804,0.00031702642],"category_scores_gemma":[0.010138425,0.00014289378,0.00042439,0.0008077037,0.0003820512,0.00006127892,0.000068657726,0.001030788,0.000004522071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13367707,0.0030521997,0.7890071,0.0000620387,0.0023683046,0.0003972659,0.00006402004,0.00033785644,0.002090453,0.0000042960555,0.000054900138,0.068884484],"study_design_scores_gemma":[0.07176959,0.02220453,0.89316607,0.00020150367,0.0016936228,0.00003098993,0.0000719176,0.009528721,0.00049950305,0.000009054851,0.000723571,0.00010094738],"about_ca_topic_score_codex":0.00020486649,"about_ca_topic_score_gemma":0.00055408006,"teacher_disagreement_score":0.10415894,"about_ca_system_score_codex":0.00015301732,"about_ca_system_score_gemma":0.0009224062,"threshold_uncertainty_score":0.9981996},"labels":[],"label_agreement":null},{"id":"W2955662388","doi":"10.1200/jco.2019.37.15_suppl.7011","title":"Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Gastroenterology; Leukocytosis; Adverse effect; Febrile neutropenia; Anemia; Hypokalemia; Nausea; Chemotherapy","score_opus":0.05347255513071011,"score_gpt":0.4111684294296463,"score_spread":0.35769587429893623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955662388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791984,0.00017946617,0.00062658434,0.01576983,0.0013422068,0.0015852985,0.000015758953,0.000024772828,0.0012576876],"genre_scores_gemma":[0.9846466,0.00086675707,0.008210222,0.0031796906,0.0018535441,0.000049020302,0.000028212964,0.00007947024,0.0010864902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939106,0.00057438685,0.003312566,0.0004973497,0.0009862655,0.00071882847],"domain_scores_gemma":[0.9889504,0.0066773845,0.0020044497,0.00044105703,0.0012183085,0.0007084426],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0057181036,0.00033299444,0.0025900658,0.0005668112,0.000060195278,0.000034067354,0.0004414652,0.0008806116,0.00022463457],"category_scores_gemma":[0.0050934036,0.00023591169,0.000569339,0.0004930444,0.00035101213,0.0004115109,0.00012511786,0.0026611397,0.00010272022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1517612,0.010054664,0.38967884,0.0008076264,0.0039191903,0.021230798,0.0012011088,0.0005862454,0.088760294,0.0018432948,0.08729842,0.24285834],"study_design_scores_gemma":[0.27203092,0.1465478,0.39617774,0.0016496503,0.0015949071,0.004326916,0.0011543209,0.0070174662,0.013561267,0.0020358686,0.15293065,0.0009725011],"about_ca_topic_score_codex":0.00007552298,"about_ca_topic_score_gemma":0.00021020198,"teacher_disagreement_score":0.24188583,"about_ca_system_score_codex":0.002282478,"about_ca_system_score_gemma":0.007838614,"threshold_uncertainty_score":0.99963975},"labels":[],"label_agreement":null},{"id":"W2955782666","doi":"10.1200/jco.2019.37.15_suppl.e19050","title":"Real-world treatment patterns among patients (pts) diagnosed with primary mediastinal large B-cell lymphoma (PMBCL) in the United States (US).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Discontinuation; Interquartile range; Internal medicine; Lymphoma; Medical diagnosis; Pathology","score_opus":0.039437693541047605,"score_gpt":0.3656568904139013,"score_spread":0.3262191968728537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955782666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994016,0.00006403704,0.0000041626467,0.0014862937,0.000493596,0.0007574526,0.00002906311,0.00001040086,0.003138996],"genre_scores_gemma":[0.9930776,0.0024827933,0.00024543094,0.0033781338,0.00034895702,0.000041107654,0.00016029073,0.000028002522,0.00023770992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959181,0.0007523464,0.0019253279,0.00029955184,0.0006619108,0.00044277334],"domain_scores_gemma":[0.99239886,0.005004781,0.0015596957,0.00035537902,0.00032161147,0.0003596722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015460675,0.00028989537,0.001572396,0.00031234504,0.000046238038,0.000020233365,0.00022849397,0.00022035086,0.00016361255],"category_scores_gemma":[0.00024823128,0.00013995907,0.0003957381,0.00034739447,0.00012491592,0.00011985117,0.000048529684,0.0003568936,0.000047991784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033353723,0.035684835,0.93547505,0.00003649124,0.00033221842,0.0031480794,0.00060344476,0.000024898676,7.742837e-7,0.000016014896,0.00090511364,0.020437706],"study_design_scores_gemma":[0.07752866,0.030083636,0.86886215,0.0002256077,0.0005072108,0.000057885314,0.0003880336,0.000075941214,0.000017732087,0.00001221839,0.022116931,0.00012395694],"about_ca_topic_score_codex":0.0021234518,"about_ca_topic_score_gemma":0.0037981202,"teacher_disagreement_score":0.07419329,"about_ca_system_score_codex":0.001008996,"about_ca_system_score_gemma":0.0010773891,"threshold_uncertainty_score":0.5707365},"labels":[],"label_agreement":null},{"id":"W2955832334","doi":"10.1200/jco.2012.30.15_suppl.e19015","title":"Newmouse models of melanoma metastasis and differences in brain tropism and metastatic growth pattern.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Melanoma; Penetrance; Ex vivo; In vivo; Tropism; Pathology; Cancer research; Immunology; Biology; Phenotype","score_opus":0.1191218802357078,"score_gpt":0.36762794819786415,"score_spread":0.24850606796215635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955832334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117637,0.0016649207,0.0057401215,0.0009567553,0.00011967781,0.000055632147,0.00000627858,0.0000052452733,0.0002750294],"genre_scores_gemma":[0.9947734,0.0014332873,0.0034894827,0.00017584005,0.000107103144,0.0000030812564,3.8460408e-7,0.0000090661115,0.000008342395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998607,0.00015861893,0.00094583025,0.00006082418,0.0000908293,0.0001369412],"domain_scores_gemma":[0.9974686,0.00201021,0.00026543907,0.000061387946,0.000039767234,0.00015457613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009157869,0.000081590944,0.00071041036,0.00008720814,0.000011750272,0.000005929186,0.000083498315,0.00009005139,0.000017304408],"category_scores_gemma":[0.0002642925,0.00005857722,0.000078258076,0.0000619376,0.0000964516,0.00018343447,0.000017314796,0.0002826965,7.7753214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015456678,0.001309572,0.6664713,0.00022215079,0.0008893926,0.000030093575,0.0025015199,0.00021066738,0.002519241,0.0056927116,0.0007455061,0.31925327],"study_design_scores_gemma":[0.0046834806,0.0018035443,0.9659737,0.0000694174,0.00048204124,0.0002885092,0.0006285708,0.008396196,0.00025054128,0.013850183,0.0033018102,0.00027204634],"about_ca_topic_score_codex":0.000025217134,"about_ca_topic_score_gemma":0.000045424607,"teacher_disagreement_score":0.3189812,"about_ca_system_score_codex":0.000013871619,"about_ca_system_score_gemma":0.000039006198,"threshold_uncertainty_score":0.23887098},"labels":[],"label_agreement":null},{"id":"W2955919420","doi":"10.1200/jco.2019.37.15_suppl.e18531","title":"Intensive minimal residual disease monitoring to drive early intervention after allogeneic hematopoietic stem cell transplant for pediatric acute leukemia.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Minimal residual disease; Hematopoietic stem cell transplantation; Internal medicine; Leukemia; Bone marrow; Transplantation; Oncology; Myeloid leukemia","score_opus":0.059789456338762106,"score_gpt":0.41691488435006385,"score_spread":0.35712542801130176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955919420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920584,0.0006038545,0.0006058947,0.0036560455,0.0019406452,0.0010035498,0.000037302354,0.000014790053,0.00007953328],"genre_scores_gemma":[0.99102694,0.0005029574,0.0027068849,0.0009967226,0.0029911185,0.00005244675,0.000005944554,0.000051558873,0.0016654476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995493,0.00040367697,0.002510819,0.00042068306,0.00063055195,0.0005412613],"domain_scores_gemma":[0.9939606,0.002125823,0.0010109079,0.0003260792,0.0014060914,0.0011704812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024444282,0.00024758425,0.0015489232,0.00037529116,0.00003710785,0.000023424493,0.0003537695,0.0004437346,0.00008108108],"category_scores_gemma":[0.0007152058,0.00018901582,0.0010618342,0.00020723123,0.00009042779,0.00017380215,0.00012638448,0.0013359501,0.00017139871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09748396,0.0012301465,0.8674152,0.00077197544,0.001026402,0.0062125954,0.0018462148,0.000052190047,0.0026820693,0.000016850165,0.0064094276,0.0148529755],"study_design_scores_gemma":[0.02482416,0.042206567,0.9197676,0.0006260433,0.003485617,0.00052875694,0.0013067571,0.00011425325,0.0023809816,0.00010418565,0.004259832,0.00039521442],"about_ca_topic_score_codex":0.000009522497,"about_ca_topic_score_gemma":0.000003697548,"teacher_disagreement_score":0.0726598,"about_ca_system_score_codex":0.0008298761,"about_ca_system_score_gemma":0.002401661,"threshold_uncertainty_score":0.7707841},"labels":[],"label_agreement":null},{"id":"W2956011050","doi":"10.1200/jco.2012.30.15_suppl.9088","title":"Risk of rash with nilotinib: A systematic review of the literature and meta-analysis.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Nilotinib; Medicine; Rash; Incidence (geometry); Internal medicine; Relative risk; GiST; Confidence interval; Meta-analysis; Adverse effect; Odds ratio; Imatinib; Myeloid leukemia","score_opus":0.22331938847786797,"score_gpt":0.4993376894450839,"score_spread":0.2760183009672159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956011050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044030166,0.9972361,0.000005409467,0.0003858108,0.00017703201,0.0018203207,0.00006350776,0.000002407574,0.00026542987],"genre_scores_gemma":[0.00023383289,0.9975138,0.0009784895,0.00049558154,0.000229555,0.000029408333,0.0000088794495,0.000031481173,0.0004790055],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98482156,0.005489128,0.008438831,0.00025630734,0.00078382844,0.00021034146],"domain_scores_gemma":[0.964862,0.0074776243,0.025510058,0.00097261334,0.00086961675,0.0003080791],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.011938114,0.0004345315,0.03365839,0.00024265205,0.000021776874,0.0000051121456,0.00041991394,0.0007611873,0.00018606198],"category_scores_gemma":[0.008349805,0.00015092595,0.010450626,0.0009078087,0.0003187669,0.000059096696,0.0001157809,0.0021617908,0.000004043482],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006676466,0.0005019581,0.00019552888,0.65139353,0.33826065,0.000066887216,0.00003502573,1.2171371e-7,6.9460473e-9,0.000010418797,0.00021212328,0.0092569655],"study_design_scores_gemma":[0.0011603682,0.0014588161,0.00012912786,0.20994894,0.718979,0.001223998,0.000004680492,2.598048e-7,7.846635e-8,0.000007543805,0.06701246,0.000074750016],"about_ca_topic_score_codex":0.0000070410533,"about_ca_topic_score_gemma":0.000011989827,"teacher_disagreement_score":0.4414446,"about_ca_system_score_codex":0.00026885525,"about_ca_system_score_gemma":0.0037168742,"threshold_uncertainty_score":0.99961},"labels":[],"label_agreement":null},{"id":"W2956031825","doi":"10.1200/jco.2019.37.15_suppl.8025","title":"A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; McGill University Health Centre; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Daratumumab; Internal medicine; Regimen; Population; Multiple myeloma; Tolerability; Cohort; Progressive disease; Quality of life (healthcare); Oncology; Surgery; Adverse effect; Disease; Nursing","score_opus":0.15176227673606202,"score_gpt":0.484319824326145,"score_spread":0.332557547590083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956031825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931001,0.0028088908,0.00002304567,0.0021605766,0.00046352518,0.00084250164,0.000058904996,0.000010991466,0.0005314804],"genre_scores_gemma":[0.99431306,0.001187546,0.0033002736,0.00046790595,0.0001324129,0.000020431049,0.00004145295,0.000038103095,0.000498839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98604125,0.003653473,0.008185814,0.0005012233,0.000984139,0.0006340798],"domain_scores_gemma":[0.9802266,0.011443024,0.0058428356,0.00074376893,0.00069581426,0.0010479705],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0076876944,0.00036182933,0.0069590523,0.0014305308,0.000035461995,0.000007703693,0.00028113418,0.0007082587,0.0006703249],"category_scores_gemma":[0.013436961,0.00025571446,0.0021056111,0.0013023155,0.00038039306,0.00016261246,0.00008920569,0.0012681795,0.00004765202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10579382,0.009205472,0.83167654,0.00017476086,0.009138828,0.000890516,0.0004329882,0.0001944575,0.0014191503,0.000020900297,0.00008482348,0.04096772],"study_design_scores_gemma":[0.079149805,0.018787771,0.89789325,0.00032325293,0.0012053185,0.000047834135,0.00024472,0.0010106687,0.00023244922,0.000042947348,0.00089899724,0.00016298292],"about_ca_topic_score_codex":0.002195903,"about_ca_topic_score_gemma":0.002676297,"teacher_disagreement_score":0.06621669,"about_ca_system_score_codex":0.00091753964,"about_ca_system_score_gemma":0.004201456,"threshold_uncertainty_score":0.9999895},"labels":[],"label_agreement":null},{"id":"W2956547457","doi":"10.1200/jco.2019.37.8_suppl.82","title":"Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Pembrolizumab; Nivolumab; Lung cancer; Adverse effect; Internal medicine; Cancer; Medical record; Pneumonitis; Pediatrics; Lung; Immunotherapy","score_opus":0.030311993426305844,"score_gpt":0.38111122616167636,"score_spread":0.3507992327353705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956547457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965681,0.000046690024,0.000009578037,0.0010457268,0.0009573746,0.00038837938,0.000011782182,0.0000068191675,0.0009655457],"genre_scores_gemma":[0.99703187,0.0006566648,0.00024160306,0.0005702968,0.00013395914,0.0000032757487,0.000028069126,0.000021796943,0.0013124482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706334,0.0001883247,0.0020434447,0.00014640646,0.00039661588,0.00016184499],"domain_scores_gemma":[0.9954892,0.00023368945,0.00329633,0.00018940357,0.000652692,0.0001387236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009178986,0.00013075919,0.0011278451,0.0001548106,0.000017866678,0.0000013020364,0.00011220582,0.00020387057,0.00087556656],"category_scores_gemma":[0.00007584609,0.00007653254,0.00027407522,0.00031651088,0.00012622289,0.0001435415,0.000016840499,0.00048206415,0.000007887622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0641482,0.0011593429,0.91000295,0.00004153036,0.0010556218,0.000025367786,0.0000711804,0.0000071940262,0.004072244,0.0000070685983,0.00005262272,0.019356694],"study_design_scores_gemma":[0.026023159,0.014164923,0.9509106,0.00050740456,0.00035913874,0.000013499184,0.000023653958,0.000014964968,0.00036573707,0.0000034013574,0.007524543,0.000088976056],"about_ca_topic_score_codex":0.00011924005,"about_ca_topic_score_gemma":0.00009055648,"teacher_disagreement_score":0.040907666,"about_ca_system_score_codex":0.00017428507,"about_ca_system_score_gemma":0.0013674758,"threshold_uncertainty_score":0.958684},"labels":[],"label_agreement":null},{"id":"W2956596053","doi":"10.1200/jco.2013.31.15_suppl.8552","title":"Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma (DLBCL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; CHOP; Chemotherapy; Internal medicine; Lymphoma; Chemotherapy regimen; Stage (stratigraphy); Cancer registry; Cancer; Diffuse large B-cell lymphoma; Surgery; Oncology","score_opus":0.0423084318410865,"score_gpt":0.3972867599556561,"score_spread":0.3549783281145696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956596053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977069,0.00005139416,0.000017473323,0.00083988917,0.00016302243,0.00043548792,0.00011355451,0.0000026951132,0.0006695807],"genre_scores_gemma":[0.99828047,0.00027661404,0.0007068518,0.0005266534,0.00013847342,0.000013234667,0.000021680804,0.000017175073,0.000018877481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971066,0.00029656666,0.0018086308,0.00015741063,0.0004617148,0.00016905282],"domain_scores_gemma":[0.9926434,0.003378641,0.00249016,0.00021149658,0.0009905949,0.00028568672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004908291,0.00016646115,0.0017089619,0.00013321725,0.000013226609,0.0000032748817,0.00011523897,0.0002173236,0.0005120645],"category_scores_gemma":[0.00091443135,0.00009467061,0.00050546206,0.00014278243,0.000094326075,0.00010865027,0.000026198626,0.00012843304,0.000027485097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062518795,0.074625425,0.8812959,0.000011856063,0.0008751116,0.000017939063,0.00028831535,0.0000049502996,0.00011354853,0.0000087324015,0.0014270331,0.035079297],"study_design_scores_gemma":[0.06453753,0.048546754,0.8836797,0.00016325367,0.00027041,0.000001349667,0.000036336183,0.000018002916,0.0022343716,0.000048194535,0.00039611448,0.000067964604],"about_ca_topic_score_codex":0.00022581947,"about_ca_topic_score_gemma":0.000016554099,"teacher_disagreement_score":0.05828565,"about_ca_system_score_codex":0.00023404817,"about_ca_system_score_gemma":0.00066982274,"threshold_uncertainty_score":0.5606747},"labels":[],"label_agreement":null},{"id":"W2956632142","doi":"10.1200/jco.2019.37.15_suppl.tps7574","title":"ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Surgery; Lymphoma","score_opus":0.06626956772329211,"score_gpt":0.43779992131585477,"score_spread":0.37153035359256265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956632142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955854,0.00020009592,0.000017596516,0.0007133671,0.0006841616,0.0017685592,0.000016795337,0.000010482884,0.0010035307],"genre_scores_gemma":[0.9949698,0.0015781942,0.00034029176,0.0010604897,0.00047722404,0.000017093607,0.0000084309595,0.00006383398,0.0014846327],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99318147,0.0012279763,0.0032779705,0.0004676955,0.0012643896,0.00058051955],"domain_scores_gemma":[0.9931058,0.002322363,0.0024555917,0.00065138075,0.00093471754,0.00053012004],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00460251,0.00032191875,0.002558953,0.00042985915,0.000047385845,0.000013574492,0.0004478048,0.00045166127,0.002433643],"category_scores_gemma":[0.0011046675,0.00021124478,0.00048276727,0.00035669198,0.00016852237,0.00014874217,0.0001339335,0.0013780762,0.00008990548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108765565,0.16545409,0.6046799,0.000046321547,0.0007417425,0.0006251482,0.00094158243,0.000023596125,0.00063548016,0.0000021129772,0.0003426662,0.11774179],"study_design_scores_gemma":[0.38246784,0.23936288,0.35239485,0.00012805105,0.00021948123,0.000025755244,0.00054409186,0.0002146079,0.0006555377,0.000017806256,0.023796316,0.00017275817],"about_ca_topic_score_codex":0.00036871812,"about_ca_topic_score_gemma":0.00044475996,"teacher_disagreement_score":0.2737023,"about_ca_system_score_codex":0.0003477061,"about_ca_system_score_gemma":0.0011815467,"threshold_uncertainty_score":0.9984783},"labels":[],"label_agreement":null},{"id":"W2956756279","doi":"10.1200/jco.2019.37.8_suppl.85","title":"Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Combination therapy; Ipilimumab; Nivolumab; Internal medicine; Adverse effect; Pneumonitis; Pembrolizumab; Cancer; Infliximab; Melanoma; Surgery; Immunotherapy","score_opus":0.07641191059100924,"score_gpt":0.4351657891211862,"score_spread":0.35875387853017693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956756279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174094,0.0011225913,0.000030350504,0.0008808706,0.0044537005,0.0013987976,0.000037142927,0.000013606863,0.00032200755],"genre_scores_gemma":[0.9982295,0.00078212767,0.00020368882,0.00022836427,0.0003015727,0.000013686151,0.00010021139,0.000045709254,0.00009514573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940165,0.0003987815,0.004469876,0.00026811857,0.00056209165,0.00028462854],"domain_scores_gemma":[0.9927469,0.0013616411,0.004569237,0.0003447002,0.00082390965,0.00015362677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017354597,0.00027018014,0.0023659414,0.00021671785,0.00005242617,0.000004098019,0.00027625167,0.0006239928,0.00018891005],"category_scores_gemma":[0.00041000912,0.0002024613,0.0015921597,0.00016190566,0.0001364911,0.00012372807,0.00003255026,0.00070242584,0.000012741144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123506516,0.0034364352,0.7710037,0.00009188411,0.0019008156,0.00000474792,0.0010153624,0.000010641372,0.0017934329,0.000012465277,0.00008714756,0.09713685],"study_design_scores_gemma":[0.11954555,0.09465206,0.77463,0.00040883545,0.00025390115,0.0000017781377,0.0006341506,0.000037534348,0.0057103145,0.000032198357,0.003928614,0.00016506058],"about_ca_topic_score_codex":0.00007397342,"about_ca_topic_score_gemma":0.000008226957,"teacher_disagreement_score":0.09697179,"about_ca_system_score_codex":0.00044883104,"about_ca_system_score_gemma":0.00047839587,"threshold_uncertainty_score":0.82561326},"labels":[],"label_agreement":null},{"id":"W2956909849","doi":"10.1200/jco.2019.37.15_suppl.7056","title":"A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Ruxolitinib; Anemia; Gastroenterology; Oncology; Bone marrow","score_opus":0.0526204380176043,"score_gpt":0.4045944892902081,"score_spread":0.3519740512726038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956909849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655885,0.000050643983,0.0000052407095,0.00093476137,0.000106751155,0.0021341108,0.000012637093,0.000004919385,0.00019208797],"genre_scores_gemma":[0.99606377,0.000026528358,0.003185406,0.00026077946,0.00018155607,0.000060379032,0.0000046109176,0.000025827037,0.00019113303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591213,0.00055151485,0.0022513028,0.00035742603,0.0006329691,0.0002946729],"domain_scores_gemma":[0.996161,0.0009831162,0.0017444453,0.00023213017,0.00050021795,0.00037910196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014163054,0.00026419465,0.0022750332,0.00020332176,0.00004466523,0.000011349102,0.00009962331,0.00022606128,0.00017177984],"category_scores_gemma":[0.0005118786,0.00013681535,0.00012091554,0.00021892427,0.00019765414,0.00015901864,0.000065144966,0.0006351738,0.0000040707687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090908565,0.06472824,0.81587905,0.00009130945,0.00051628775,0.0010149439,0.0007503835,0.0000024040337,0.0001916186,0.000015080887,0.00010027042,0.025801852],"study_design_scores_gemma":[0.110909544,0.37914395,0.507484,0.00066287495,0.0003106167,0.000119094504,0.00044942732,0.00000957564,0.00041795627,0.000012752088,0.00037111214,0.00010904268],"about_ca_topic_score_codex":0.000040539,"about_ca_topic_score_gemma":0.00025191222,"teacher_disagreement_score":0.31441572,"about_ca_system_score_codex":0.00011643599,"about_ca_system_score_gemma":0.0010174903,"threshold_uncertainty_score":0.55791676},"labels":[],"label_agreement":null},{"id":"W2956962822","doi":"10.1200/jco.2019.37.15_suppl.10536","title":"Medical oncology trainees’ perceptions of their education and preparedness for independent practice.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Innovations in Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University; Queen's University","funders":"","keywords":"Preparedness; Medicine; Competence (human resources); Medical education; Modalities; Family medicine; Graduate medical education; Accreditation; Psychology","score_opus":0.08057229869127426,"score_gpt":0.546164416665306,"score_spread":0.46559211797403177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956962822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94277894,0.00022527743,0.0013911411,0.043978848,0.0043203942,0.00051928,0.0000025628462,0.000006072623,0.006777452],"genre_scores_gemma":[0.963274,0.0004929443,0.026109077,0.00787392,0.0017837189,0.000023254117,0.000015031392,0.00001484521,0.0004131864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962956,0.00040137809,0.0024621717,0.00017903658,0.0005038325,0.00015799109],"domain_scores_gemma":[0.9905429,0.0043766648,0.002234352,0.00022632022,0.0023342597,0.0002855138],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00870086,0.00010181703,0.0010619775,0.0002234253,0.000032795364,0.0000042787674,0.00016842182,0.0007393027,0.0006295479],"category_scores_gemma":[0.036055837,0.00007286158,0.00022185994,0.00019295388,0.00032065986,0.00017166861,0.00004024648,0.0010443634,0.000007695118],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021397285,0.0075774016,0.01286401,0.00014351294,0.0002837185,0.00000963365,0.0027866715,0.0000022928593,0.00033308507,0.0025175342,0.020541739,0.95080066],"study_design_scores_gemma":[0.01173653,0.025853118,0.12350501,0.00040500987,0.0007058593,0.00324584,0.039522868,0.000836926,0.000042489864,0.0021331822,0.79185534,0.00015780969],"about_ca_topic_score_codex":0.0000091056845,"about_ca_topic_score_gemma":0.000008024189,"teacher_disagreement_score":0.9506429,"about_ca_system_score_codex":0.0002754641,"about_ca_system_score_gemma":0.012432082,"threshold_uncertainty_score":0.9931665},"labels":[],"label_agreement":null},{"id":"W2957076795","doi":"10.1200/jco.19.00525","title":"Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Neurocognitive; Pediatrics; Regimen; Non-Hodgkin's lymphoma; Relative risk; Late effect; Internal medicine; Cancer; Lymphoma; Psychiatry; Confidence interval; Cognition","score_opus":0.06839217710615138,"score_gpt":0.4419009932977658,"score_spread":0.3735088161916144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957076795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536881,0.0073311143,0.0000127337835,0.034191355,0.0023168225,0.0021012935,0.00006766835,0.0000138837095,0.00027706756],"genre_scores_gemma":[0.97065854,0.0019442234,0.00078675244,0.024299394,0.0013342256,0.0001793017,0.000015625483,0.000046707024,0.0007352544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995173,0.00068282144,0.002862707,0.0004107414,0.0004683104,0.00040245877],"domain_scores_gemma":[0.9917618,0.004188033,0.0027410425,0.00055529026,0.00032116668,0.00043266758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00457477,0.00030559464,0.0025784331,0.00007001411,0.00007116239,0.000027521855,0.00027341858,0.00039310294,0.00014762835],"category_scores_gemma":[0.0004647447,0.00015488628,0.0010318956,0.000111198,0.00008114753,0.00009290382,0.00006483034,0.00037723363,0.00002264268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076804184,0.014620646,0.9299196,0.000017679535,0.0017368919,0.001678757,0.00090413867,0.0000034887598,0.0000066654266,0.0000019166255,0.0107309325,0.032698836],"study_design_scores_gemma":[0.05648118,0.011647751,0.8827752,0.00012143924,0.00029732342,0.00019202217,0.00038280754,0.000013262735,0.000020976311,0.00009146848,0.0478453,0.00013127022],"about_ca_topic_score_codex":0.0022224828,"about_ca_topic_score_gemma":0.0004095452,"teacher_disagreement_score":0.048800763,"about_ca_system_score_codex":0.00055860577,"about_ca_system_score_gemma":0.0070809573,"threshold_uncertainty_score":0.998548},"labels":[],"label_agreement":null},{"id":"W2957103174","doi":"10.1200/jco.2019.37.15_suppl.7005","title":"ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nilotinib; Imatinib; Gastroenterology; Imatinib mesylate; Surgery; Myeloid leukemia","score_opus":0.05632872461739119,"score_gpt":0.39284762659985123,"score_spread":0.33651890198246004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957103174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923472,0.0016318465,0.000015474528,0.0014414438,0.0011291124,0.0014036953,0.000047633406,0.000030295027,0.0019533413],"genre_scores_gemma":[0.99154806,0.0013599638,0.0012890383,0.0007557022,0.001496589,0.000046594927,0.00009467833,0.000098050754,0.0033113468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9911952,0.00078466476,0.005224904,0.0009256226,0.0008668909,0.0010027123],"domain_scores_gemma":[0.99260354,0.0020555889,0.0029592747,0.0012050383,0.0004038792,0.00077268254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027203048,0.0006527633,0.0033430967,0.00064313354,0.00004975343,0.000022310123,0.0005256218,0.000975456,0.0009981225],"category_scores_gemma":[0.0021087169,0.00045321515,0.0005838717,0.00056318083,0.00026693355,0.00043656543,0.00019849076,0.0022081297,0.00014865765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13961133,0.016073396,0.40967444,0.00044858048,0.0011632595,0.0074417386,0.00082120334,0.0013921377,0.001544276,0.000013838517,0.0020665005,0.4197493],"study_design_scores_gemma":[0.35901672,0.15701027,0.3739283,0.0024367156,0.0005157919,0.0004190928,0.00009694705,0.0009623485,0.0006210442,0.00004785328,0.10442854,0.00051638455],"about_ca_topic_score_codex":0.00034914393,"about_ca_topic_score_gemma":0.0035038644,"teacher_disagreement_score":0.4192329,"about_ca_system_score_codex":0.03914784,"about_ca_system_score_gemma":0.021868274,"threshold_uncertainty_score":0.9999151},"labels":[],"label_agreement":null},{"id":"W2958377888","doi":"10.1200/jco.2013.31.15_suppl.1593","title":"A retrospective study on the role of diabetes and metformin in colorectal cancer disease progression.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care South East","funders":"","keywords":"Medicine; Colorectal cancer; Diabetes mellitus; Population; Cancer registry; Cancer; Internal medicine; Retrospective cohort study; Epidemiology; Disease; Incidence (geometry); Type 2 diabetes; Mortality rate; Oncology; Endocrinology","score_opus":0.03011663354908976,"score_gpt":0.3969060724367998,"score_spread":0.36678943888771004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958377888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9557374,0.04318655,5.293156e-7,0.00024831694,0.0002606026,0.00032211447,0.000005633826,8.788794e-7,0.00023793695],"genre_scores_gemma":[0.9928284,0.0062316596,0.000051003837,0.00037660843,0.0004238641,0.0000672886,6.214141e-7,0.000008282239,0.000012253343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982455,0.00043370668,0.00081737427,0.00016288419,0.0001807057,0.0001598686],"domain_scores_gemma":[0.9985667,0.00020988093,0.0007274114,0.000116962794,0.00022620076,0.00015285112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015023723,0.00009805331,0.00056392926,0.000040235915,0.00002430504,0.000007787538,0.00017230246,0.0001383758,0.00006333304],"category_scores_gemma":[0.0016433023,0.000054206197,0.0001428461,0.00007103646,0.00019498133,0.000008241979,0.000074363066,0.00031169778,0.0000012551126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047901925,0.0010410781,0.7526603,0.00000428813,0.00015070497,0.0000035804092,0.00010243069,0.0000032950409,0.0044496097,0.000054977947,0.00045869383,0.24059203],"study_design_scores_gemma":[0.001888928,0.0061243232,0.97124124,0.000035091947,0.0000819302,7.5272794e-7,0.0005450215,0.00003261945,0.006044145,0.0012597743,0.01266734,0.000078830155],"about_ca_topic_score_codex":0.000014210898,"about_ca_topic_score_gemma":0.000051310883,"teacher_disagreement_score":0.2405132,"about_ca_system_score_codex":0.000023200364,"about_ca_system_score_gemma":0.0003857296,"threshold_uncertainty_score":0.22104646},"labels":[],"label_agreement":null},{"id":"W2958498622","doi":"10.1200/jco.2019.37.15_suppl.9087","title":"Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Hazard ratio; Lung cancer; Chemotherapy; Oncology; Meta-analysis; Subgroup analysis; Progression-free survival; Adverse effect; Randomized controlled trial; Cancer; Confidence interval; Immunotherapy","score_opus":0.17338429771949004,"score_gpt":0.5051865838041146,"score_spread":0.3318022860846246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958498622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73260266,0.006726552,0.12074488,0.12741838,0.0022967928,0.0049537253,0.000028888337,0.00003163135,0.0051964847],"genre_scores_gemma":[0.90128523,0.0011655673,0.078323275,0.015431506,0.0018602045,0.000030761024,0.000015543976,0.000049488226,0.0018383985],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99081856,0.002832336,0.0052437773,0.0002573974,0.00056123844,0.0002866858],"domain_scores_gemma":[0.9468725,0.04486155,0.0067376303,0.0002741157,0.00089665496,0.0003575606],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.039864756,0.00021103182,0.017494034,0.00028231865,0.000031326825,0.000011810351,0.00020788994,0.0003251082,0.0010908906],"category_scores_gemma":[0.027840834,0.00009659092,0.0076237586,0.0004594757,0.00035419982,0.00006604054,0.000023202469,0.0010264504,0.0000027766014],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6411333,0.0007756676,0.0013144747,0.000033940938,0.33550772,0.0000935268,0.00011296084,0.0013536674,0.000048480826,0.00026598407,0.0027982288,0.01656206],"study_design_scores_gemma":[0.44006914,0.013945986,0.004639001,0.000070970666,0.51454425,0.00020761252,0.000049887312,0.0150381,0.00002597609,0.00041185113,0.0108550275,0.00014219631],"about_ca_topic_score_codex":0.000025456115,"about_ca_topic_score_gemma":0.000009986642,"teacher_disagreement_score":0.20106415,"about_ca_system_score_codex":0.000058185327,"about_ca_system_score_gemma":0.0012567332,"threshold_uncertainty_score":0.99982226},"labels":[],"label_agreement":null},{"id":"W2958564469","doi":"10.1200/jco.2006.24.18_suppl.7503","title":"Phase II study of rituximab + CHOP followed by <sup>90</sup>Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Mantle cell lymphoma; Neutropenia; Vincristine; Febrile neutropenia; Gastroenterology; CHOP; International Prognostic Index; Ibritumomab tiuxetan; Cyclophosphamide; Lymphoma; Radioimmunotherapy; Chemotherapy; Immunology","score_opus":0.03392994213060223,"score_gpt":0.3841714004314493,"score_spread":0.3502414583008471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958564469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955308,0.00031710457,0.000005429073,0.00027467927,0.00023776587,0.0026232742,0.000026857071,0.000018077113,0.0009660191],"genre_scores_gemma":[0.9987077,0.000055465604,0.0003008212,0.00027451996,0.00025744297,0.000069774665,0.00006071181,0.00005071858,0.00022282638],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99222165,0.0018225139,0.0039912728,0.0006306791,0.00080381415,0.00053006574],"domain_scores_gemma":[0.99473655,0.0010372893,0.002472914,0.0004784271,0.0007777108,0.00049712666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016555764,0.000469316,0.0037852693,0.00029527012,0.00011551186,0.00002106384,0.0003197407,0.00042880737,0.00008133064],"category_scores_gemma":[0.00028406834,0.0003097522,0.00032235542,0.0004201854,0.00022786578,0.0002854249,0.0001262743,0.00051326293,0.000014485441],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02036651,0.42970467,0.5208405,0.000012762853,0.00062291266,0.0022240405,0.0010912893,0.00003178644,0.000010399677,0.0000022770766,0.0010873112,0.02400552],"study_design_scores_gemma":[0.31193012,0.38007692,0.30272102,0.00007204164,0.0012687009,0.00005647291,0.0020864077,0.000120819794,0.000031877084,0.0000051281986,0.0014639732,0.00016651458],"about_ca_topic_score_codex":0.000948105,"about_ca_topic_score_gemma":0.0018573843,"teacher_disagreement_score":0.2915636,"about_ca_system_score_codex":0.00086213474,"about_ca_system_score_gemma":0.001426426,"threshold_uncertainty_score":0.99993545},"labels":[],"label_agreement":null},{"id":"W2958693056","doi":"10.1200/jco.2019.37.15_suppl.e19509","title":"Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Population; Bortezomib; Incidence (geometry); Internal medicine; Cohort; Regimen; Environmental health","score_opus":0.14077603666368246,"score_gpt":0.45669606844115956,"score_spread":0.3159200317774771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958693056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350375,0.000039700783,0.0000060322454,0.0032107737,0.0013710255,0.0014643301,0.00020619237,0.0000061050796,0.00019207003],"genre_scores_gemma":[0.9977203,0.000026703263,0.00096710597,0.00065338804,0.00031232496,0.000045308447,0.000087860884,0.000028038976,0.00015893899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224794,0.0010249385,0.0045706555,0.00044964973,0.0011926115,0.0005141948],"domain_scores_gemma":[0.96406955,0.032873742,0.0016465402,0.0006313015,0.0002731201,0.0005057405],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032046759,0.00028905665,0.0023556615,0.00035329317,0.000060716393,0.000022837754,0.00047241035,0.0002662927,0.00015054058],"category_scores_gemma":[0.016696753,0.00018938717,0.00055855705,0.0003475981,0.000058100904,0.00025419155,0.00015559702,0.001040315,0.000036495552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00854133,0.0021122731,0.97405785,0.000010193227,0.0008286864,0.0009987401,0.0005546767,0.00014378957,0.000018981065,0.0000011896016,0.00034507102,0.012387233],"study_design_scores_gemma":[0.03546056,0.002191307,0.96040416,0.0003342084,0.00020307743,0.0000010036214,0.00033850496,0.0005006607,0.00008057572,0.00003478898,0.0002944356,0.00015670646],"about_ca_topic_score_codex":0.97874904,"about_ca_topic_score_gemma":0.9922867,"teacher_disagreement_score":0.031848807,"about_ca_system_score_codex":0.00081359874,"about_ca_system_score_gemma":0.0032199349,"threshold_uncertainty_score":0.991586},"labels":[],"label_agreement":null},{"id":"W2958818878","doi":"10.1200/jco.2019.37.15_suppl.11501","title":"A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Thunder Bay Regional Health Sciences Centre; University of Alberta; McMaster University; London Health Sciences Centre; Western University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Denosumab; Prostate cancer; Clinical endpoint; Adverse effect; Bone pain; Internal medicine; Breast cancer; Randomized controlled trial; Bone metastasis; Osteoporosis; Oncology; Urology; Cancer","score_opus":0.13759170277359867,"score_gpt":0.4364494815565148,"score_spread":0.29885777878291614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958818878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942416,0.0001997257,0.0000074727636,0.0013658751,0.0013278229,0.0025150515,0.00014525549,0.00001056172,0.00018661468],"genre_scores_gemma":[0.9970757,0.00018908644,0.001674534,0.00021887886,0.00018579485,0.000053456864,0.00010540786,0.000034062276,0.000463131],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99310637,0.0011231679,0.004255972,0.00034532743,0.00077932526,0.0003898582],"domain_scores_gemma":[0.99183786,0.0028386035,0.0040731113,0.00024296471,0.0005613017,0.00044613017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022884463,0.00030040153,0.003715607,0.0002147875,0.00004830031,0.000016866841,0.00011220194,0.00030809373,0.0005659934],"category_scores_gemma":[0.0012024518,0.00017083898,0.00038812,0.00021528285,0.00020672426,0.00025093515,0.000030635176,0.00068827876,0.000011413759],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8796444,0.0051194476,0.10544503,0.00007523818,0.0012858681,0.00080036646,0.000118435164,0.000036266403,0.000018249078,0.000004098657,0.00018644563,0.007266134],"study_design_scores_gemma":[0.6379319,0.030907862,0.32922214,0.0003130564,0.0009304671,0.000044172797,0.00008698532,0.00014850567,0.00001762698,0.000016149028,0.00026893418,0.00011219656],"about_ca_topic_score_codex":0.0013501771,"about_ca_topic_score_gemma":0.005981497,"teacher_disagreement_score":0.24171253,"about_ca_system_score_codex":0.00034873327,"about_ca_system_score_gemma":0.004594939,"threshold_uncertainty_score":0.8151224},"labels":[],"label_agreement":null},{"id":"W2958944135","doi":"10.1200/jco.2019.37.8_suppl.100","title":"CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Southlake Regional Health Center","funders":"","keywords":"Medicine; Dosing; Interim analysis; Nivolumab; Internal medicine; Safety profile; Pharmacokinetics; Randomized controlled trial; Gastroenterology; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.07353088413689789,"score_gpt":0.4558853785881979,"score_spread":0.3823544944513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958944135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896701,0.0022989735,0.000009529612,0.0010642156,0.0030393666,0.0010347064,0.000015969144,0.000010843709,0.0028563263],"genre_scores_gemma":[0.99344474,0.0041525806,0.0005861539,0.0004009068,0.00061852235,0.00001549804,0.000005985178,0.000034494733,0.00074109173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99377394,0.0005631758,0.004425616,0.0003118369,0.0005207173,0.00040472424],"domain_scores_gemma":[0.99398065,0.0016440854,0.0032796757,0.0004446139,0.0003911076,0.00025990108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003254562,0.000265177,0.0028582213,0.00029276175,0.000016906873,0.0000055514383,0.00028750798,0.0006453362,0.0008272304],"category_scores_gemma":[0.0014558225,0.00019940537,0.0011290322,0.00029786504,0.00034627324,0.00019448993,0.000053858326,0.0008783173,0.000013658052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80064803,0.004803677,0.007103477,0.00010052044,0.0007042387,0.0002733605,0.0002431902,0.0000068598533,0.011083733,0.0000037671955,0.00056563545,0.17446348],"study_design_scores_gemma":[0.7893275,0.11017343,0.04999927,0.00082590774,0.00076503,0.00008919811,0.00028990116,0.00012673925,0.0020623014,0.00003442441,0.04604936,0.00025693045],"about_ca_topic_score_codex":0.00015263612,"about_ca_topic_score_gemma":0.00026816773,"teacher_disagreement_score":0.17420655,"about_ca_system_score_codex":0.00032857122,"about_ca_system_score_gemma":0.0015913419,"threshold_uncertainty_score":0.9057593},"labels":[],"label_agreement":null},{"id":"W2959140111","doi":"10.1200/jco.2012.30.15_suppl.4633","title":"Use of miRNA profiling in metastatic renal cell carcinoma to reveal a tumor suppressor effect for mir-215.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre; York University; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"microRNA; Renal cell carcinoma; Metastasis; Medicine; Gene expression profiling; Cancer research; Microarray; Microarray analysis techniques; Oncology; Kidney cancer; Cancer; Gene expression; Gene; Internal medicine; Biology; Genetics","score_opus":0.11175262464860275,"score_gpt":0.4475576906747265,"score_spread":0.33580506602612376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959140111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270153,0.00065115426,0.0048323674,0.00034078775,0.0006301977,0.0007245381,0.00002904949,0.0000015907701,0.000088797045],"genre_scores_gemma":[0.96784765,0.0000286442,0.030858682,0.00045269672,0.0005630025,0.00004300269,0.000011135758,0.00003223375,0.00016293932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99635154,0.00090432406,0.0017094711,0.00024453035,0.00029910414,0.00049102877],"domain_scores_gemma":[0.99700135,0.0010226503,0.0009143213,0.00026805548,0.00037803157,0.00041559676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004846092,0.00016686515,0.0009742268,0.00017662821,0.000023652488,0.000009288069,0.00029967842,0.00029162937,0.000016586502],"category_scores_gemma":[0.005897181,0.00013589994,0.00051122805,0.00014642948,0.00008416018,0.000015754531,0.00015144126,0.00055741484,0.0000036069712],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007894798,0.0007612596,0.003103849,0.000121611396,0.00013507833,0.000068906695,0.000040394607,0.00025585655,0.9800328,0.000019358638,0.003280941,0.004285131],"study_design_scores_gemma":[0.005209475,0.018246733,0.004888019,0.000051527564,0.00015885226,0.00011544305,0.000026524716,0.00010993399,0.94024426,0.000033594104,0.030758932,0.0001567018],"about_ca_topic_score_codex":0.000025748534,"about_ca_topic_score_gemma":0.00003243192,"teacher_disagreement_score":0.03978855,"about_ca_system_score_codex":0.0000742799,"about_ca_system_score_gemma":0.00089529203,"threshold_uncertainty_score":0.70599025},"labels":[],"label_agreement":null},{"id":"W2959574201","doi":"10.1200/jco.2012.30.15_suppl.2547","title":"Predictive model for survival and toxicity in early-phase trials in hematology.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen's University; Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Clinical trial; Logistic regression; Univariate analysis; Hazard ratio; Toxicity; Oncology; Multivariate analysis; Confidence interval","score_opus":0.3488600469914042,"score_gpt":0.4811285454781857,"score_spread":0.13226849848678146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959574201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767365,0.0026210009,0.014227427,0.0014805463,0.0015725855,0.00025916108,0.00006913925,0.0000024634348,0.003031184],"genre_scores_gemma":[0.99556786,0.00097448856,0.0022346985,0.00045436725,0.0006839042,0.000012317277,7.549949e-7,0.000011466814,0.0000601503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946545,0.00019279082,0.0046161115,0.00017215802,0.000025345838,0.00033912985],"domain_scores_gemma":[0.99291205,0.003650683,0.0030468947,0.00009846287,0.000059446967,0.00023243084],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022960106,0.000112333284,0.0028423325,0.00025253664,0.000018934788,0.000011038529,0.00014732899,0.00045511228,0.000026734217],"category_scores_gemma":[0.01579746,0.0001062866,0.0003253677,0.00007324977,0.0001267669,0.0005151252,0.00003886212,0.00048936025,0.000007387775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046032104,0.0020007861,0.8801918,0.000022282284,0.00012037019,0.000011651761,0.00078747654,0.00035834126,0.000004241237,0.08811711,0.0010731549,0.022709595],"study_design_scores_gemma":[0.033698168,0.0061825477,0.7293095,0.000059759255,0.000053075473,0.000030270336,0.00019593695,0.032562997,0.000030644078,0.18038309,0.017133923,0.00036009916],"about_ca_topic_score_codex":0.000055360044,"about_ca_topic_score_gemma":0.00016470633,"teacher_disagreement_score":0.15088229,"about_ca_system_score_codex":0.00016306243,"about_ca_system_score_gemma":0.00025608,"threshold_uncertainty_score":0.9924929},"labels":[],"label_agreement":null},{"id":"W2960004176","doi":"10.1200/jco.2013.31.15_suppl.1550","title":"The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ethnic group; Demography; Population; Family history; Cancer; Family medicine; Genetic testing; Internal medicine","score_opus":0.03389240711542911,"score_gpt":0.36197133520266933,"score_spread":0.3280789280872402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960004176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637794,0.00038709276,0.000049297785,0.0020427655,0.00033200355,0.0005381165,0.0000023097161,0.0000025758293,0.00026789212],"genre_scores_gemma":[0.9827303,0.000014498366,0.016236851,0.0003769217,0.00018486872,0.00028407105,0.0000062180375,0.000015015156,0.00015124341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982393,0.00012631564,0.0009764302,0.00022347405,0.00016106255,0.0002734238],"domain_scores_gemma":[0.9981473,0.00064190075,0.0005736479,0.00018255947,0.0003465328,0.0001080219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054948597,0.00010499083,0.00027340237,0.000042525324,0.00011416796,0.0000375294,0.0002988639,0.0001698563,0.000020297462],"category_scores_gemma":[0.0018762657,0.000076245924,0.00007923575,0.00008913402,0.00016354797,0.000014481416,0.00008280266,0.00041312148,7.5447446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016368364,0.00022393852,0.8670911,0.00000770293,0.00005315288,0.000041265786,0.0009767967,0.0010294591,0.00012046271,0.0000029449245,0.0036998005,0.12658969],"study_design_scores_gemma":[0.0017277758,0.00241437,0.86307126,0.00002857059,0.000016377957,0.000043652435,0.0011294956,0.00021216091,0.00004363721,0.000027446275,0.13117848,0.00010675895],"about_ca_topic_score_codex":0.23555125,"about_ca_topic_score_gemma":0.9907031,"teacher_disagreement_score":0.7551518,"about_ca_system_score_codex":0.00081750803,"about_ca_system_score_gemma":0.004472383,"threshold_uncertainty_score":0.7933816},"labels":[],"label_agreement":null},{"id":"W2960915348","doi":"10.1200/jco.2019.37.8_suppl.17","title":"Evaluating the value of checkpoint inhibitor therapy using the ASCO and ESMO frameworks.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Oncology; Internal medicine; Randomized controlled trial; Hazard ratio; Oncology; Clinical trial; Lung cancer; Cancer; Confidence interval","score_opus":0.25488307659853415,"score_gpt":0.47259352919499287,"score_spread":0.21771045259645871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960915348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826032,0.0051502516,0.0005912932,0.0056964336,0.0024191586,0.00018566316,0.0000050964286,0.0000019132233,0.0033470145],"genre_scores_gemma":[0.99099916,0.0024295826,0.0024521374,0.0028488226,0.0011516362,0.000001351614,1.3072676e-7,0.000014172403,0.00010297656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968166,0.0001586857,0.00260346,0.00016697044,0.00006305533,0.00019127161],"domain_scores_gemma":[0.9933902,0.0021028835,0.004021472,0.00026011665,0.00014059541,0.00008474743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009880121,0.00010957577,0.001093648,0.00006398265,0.0000684856,0.000029330891,0.00033603937,0.00041160977,0.00019087196],"category_scores_gemma":[0.0027751792,0.00006522674,0.0003662496,0.00009319732,0.0002938419,0.00021034126,0.00007685882,0.0011471728,0.000020768346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023166125,0.00068941043,0.5511205,0.00004174941,0.0008571537,0.000008045457,0.0019674925,0.0045483964,0.0003038345,0.1265132,0.0012264845,0.31040713],"study_design_scores_gemma":[0.0071166707,0.010781626,0.7133766,0.00015808802,0.00008047831,0.00007897656,0.00055156363,0.020873416,0.0001941981,0.14580852,0.10064753,0.000332345],"about_ca_topic_score_codex":0.00010051113,"about_ca_topic_score_gemma":0.000006979827,"teacher_disagreement_score":0.3100748,"about_ca_system_score_codex":0.00008074855,"about_ca_system_score_gemma":0.00039554838,"threshold_uncertainty_score":0.49839586},"labels":[],"label_agreement":null},{"id":"W2961552355","doi":"10.1200/jco.2019.37.15_suppl.e18511","title":"The impact of infection on health-related quality of life (HRQoL) in patients with Philadelphia negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph- R/R BCP ALL) in a randomized, open-label, phase 3 study (TOWER).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Refractory (planetary science); Gastroenterology; Surgery","score_opus":0.12288685829993361,"score_gpt":0.4977854336949149,"score_spread":0.3748985753949813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961552355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930572,0.00009146826,0.000020952033,0.0012048589,0.00046123913,0.0047648414,0.00001983014,0.000006891644,0.00037274117],"genre_scores_gemma":[0.9986292,0.0005246511,0.00018655376,0.00034380305,0.000077062934,0.000040317158,0.000008956737,0.000043190692,0.0001462487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9823103,0.0074159005,0.007995934,0.00046203536,0.0012524464,0.0005634094],"domain_scores_gemma":[0.955768,0.03300225,0.008891958,0.00059094524,0.0011594028,0.00058744097],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019648485,0.00036495784,0.005662156,0.00053423434,0.00004987294,0.000017671498,0.0005385226,0.0005604939,0.00012278698],"category_scores_gemma":[0.029868154,0.00018115259,0.0004590486,0.00083791604,0.0006473422,0.00031597156,0.00020911678,0.0022658838,0.000014281442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8512394,0.037018172,0.10230089,0.000083247905,0.0022608272,0.00011332307,0.0010649877,0.00044508718,0.000064158885,0.000006852237,0.00083059137,0.0045724604],"study_design_scores_gemma":[0.5885579,0.14425743,0.26490527,0.00042514253,0.00024516598,0.000015631233,0.00017789935,0.0011834073,0.0000114049835,0.00006904758,0.000034323646,0.00011735064],"about_ca_topic_score_codex":0.002927505,"about_ca_topic_score_gemma":0.00062851503,"teacher_disagreement_score":0.26268148,"about_ca_system_score_codex":0.004220059,"about_ca_system_score_gemma":0.023036959,"threshold_uncertainty_score":0.99960256},"labels":[],"label_agreement":null},{"id":"W2961780105","doi":"10.1200/jco.2013.31.15_suppl.1523","title":"Variation in the efficacy of low-dose computed tomographic lung screening based on risk of lung cancer mortality in the National Lung Screening Trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer; National Lung Screening Trial; Lung cancer screening; Internal medicine; Lung; Cancer; Mortality rate","score_opus":0.10361332852679908,"score_gpt":0.47553806492449285,"score_spread":0.37192473639769374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961780105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956627,0.00034711807,0.00084192597,0.0073759737,0.00039332974,0.0011768311,0.000011207322,0.000003332957,0.00028402786],"genre_scores_gemma":[0.9956616,0.00028305507,0.0013830565,0.0019490396,0.00064419815,0.000060991217,0.000006536197,0.000009617899,0.000001882222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942782,0.001946449,0.0024710577,0.0001979005,0.00091517816,0.0001912012],"domain_scores_gemma":[0.98443645,0.0121944975,0.0025416776,0.00021466901,0.0005246417,0.00008803649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009379722,0.00014660117,0.0010779706,0.00028737966,0.000045479952,0.000012906874,0.00026509605,0.00022767231,0.00008822891],"category_scores_gemma":[0.003148037,0.000078625206,0.00051107357,0.0005465609,0.00013014117,0.00010498838,0.000023547942,0.00095576566,3.5390374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011160555,0.0049792076,0.96185327,0.00007465027,0.0006711692,0.00003756126,0.00037955417,0.011831695,0.000009987688,0.0001112023,0.0011574622,0.0077337124],"study_design_scores_gemma":[0.054056622,0.0025633231,0.86019266,0.000647893,0.0006258501,0.0000048369448,0.000053202915,0.08167534,0.0000062651206,0.00006430381,0.000053980842,0.000055719145],"about_ca_topic_score_codex":0.0012346798,"about_ca_topic_score_gemma":0.00028423063,"teacher_disagreement_score":0.10166059,"about_ca_system_score_codex":0.00023480292,"about_ca_system_score_gemma":0.0008436811,"threshold_uncertainty_score":0.41523793},"labels":[],"label_agreement":null},{"id":"W2961804252","doi":"10.1200/jco.2013.31.15_suppl.7532","title":"Performance of a prognostic genomic signature for early-stage NSCLC in matched fresh frozen and RNA-stabilized tissue.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Concordance; Medicine; Tissue microarray; Stage (stratigraphy); Oncology; Gene signature; Cancer; Internal medicine; Tissue bank; Pathology; Gene; Bioinformatics; Gene expression; Biology; Genetics","score_opus":0.03358895518565838,"score_gpt":0.38342967423754654,"score_spread":0.3498407190518882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961804252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964571,0.000606471,0.0012127316,0.00072135526,0.00008434572,0.00059223804,0.000012770997,0.0000028928082,0.00031006924],"genre_scores_gemma":[0.98265517,0.0007511756,0.015839908,0.00031168544,0.00015308961,0.00006817853,0.000012693514,0.0000138109945,0.00019431056],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982948,0.00014768979,0.0011188955,0.00020054626,0.000065842876,0.00017224293],"domain_scores_gemma":[0.9984215,0.0002476726,0.0008049527,0.00018336072,0.00023531685,0.000107185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010055559,0.000109848675,0.00058542675,0.000051597148,0.000021859581,0.0000057500974,0.00020999354,0.0005441707,0.00005374685],"category_scores_gemma":[0.00066776795,0.00008613297,0.00015157185,0.00005226062,0.00020454574,0.000006557944,0.000086373315,0.00030866903,0.0000017604017],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008290235,0.00044867946,0.10016615,0.00005239031,0.00009555254,0.0000052041073,0.00003315982,0.000019612053,0.85398406,0.000072231254,0.0020774417,0.04221649],"study_design_scores_gemma":[0.008899395,0.023133367,0.7288674,0.000101086756,0.00015854825,0.00006669337,0.00012187705,0.0005216813,0.14206727,0.0011945086,0.09445816,0.00040998514],"about_ca_topic_score_codex":0.000024317987,"about_ca_topic_score_gemma":0.00003497681,"teacher_disagreement_score":0.7119168,"about_ca_system_score_codex":0.000012812822,"about_ca_system_score_gemma":0.00024874008,"threshold_uncertainty_score":0.41971427},"labels":[],"label_agreement":null},{"id":"W2962751967","doi":"10.1200/jco.2013.31.15_suppl.5013","title":"A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Internal medicine; Proportional hazards model; Prostate cancer; Hazard ratio; Prednisone; Oncology; Placebo; Chemotherapy; Univariate analysis; Gastroenterology; Cancer; Androgen deprivation therapy; Multivariate analysis; Confidence interval; Pathology","score_opus":0.09891359559826622,"score_gpt":0.42143479666516726,"score_spread":0.322521201066901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962751967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944292,0.00025563597,0.00016698972,0.0023600042,0.00014863495,0.0024306253,0.00005385745,0.00001266444,0.000142396],"genre_scores_gemma":[0.993433,0.00024414223,0.0041873204,0.0002489132,0.00016140711,0.00055805617,0.000026604568,0.00004678017,0.0010938032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964732,0.00028649718,0.001718452,0.00034298262,0.00062670076,0.0005521651],"domain_scores_gemma":[0.9961487,0.0008028098,0.0011000265,0.00016901092,0.0013528022,0.00042667243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011871085,0.0002710255,0.0014259674,0.00018029475,0.000055906243,0.00004296665,0.00011504064,0.000151937,0.00008402547],"category_scores_gemma":[0.00047462637,0.00014548529,0.00017157379,0.00019981955,0.00023350434,0.00038876434,0.000028610839,0.00067970366,0.000005104203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070211776,0.0027574317,0.91135937,0.00023501071,0.0010865459,0.00044948008,0.00046369358,0.0015508101,0.00013730134,0.000006422527,0.00020442983,0.011537713],"study_design_scores_gemma":[0.063310355,0.033187922,0.8864639,0.0006905523,0.0009911156,0.000028157048,0.00015895705,0.014566982,0.00006476741,0.00014756006,0.00017985533,0.00020991429],"about_ca_topic_score_codex":0.00020855099,"about_ca_topic_score_gemma":0.0010084917,"teacher_disagreement_score":0.03043049,"about_ca_system_score_codex":0.00040184296,"about_ca_system_score_gemma":0.0023378953,"threshold_uncertainty_score":0.5932718},"labels":[],"label_agreement":null},{"id":"W2962962686","doi":"10.1200/jco.2013.31.15_suppl.e19031","title":"Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Oncology; Internal medicine; Lung cancer; Chemotherapy; Cost effectiveness; Epidermal growth factor receptor; Cancer","score_opus":0.07104813067741954,"score_gpt":0.4856174590540123,"score_spread":0.41456932837659277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962962686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985934,0.0019530577,0.0003325616,0.0046610893,0.00097410387,0.00068251544,0.000031573047,0.000004120541,0.0015016461],"genre_scores_gemma":[0.98685354,0.005630351,0.005479875,0.0006733981,0.000555776,0.00006444829,0.000012491282,0.000017919063,0.00071218185],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99797785,0.00005472471,0.0014961624,0.00018878655,0.00010431203,0.00017814619],"domain_scores_gemma":[0.9955352,0.0022659407,0.001407271,0.00015276892,0.000388017,0.00025083346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000545532,0.00013308167,0.0013597414,0.00018113782,0.000041412983,0.0000075001494,0.000090031084,0.00018477044,0.0006388787],"category_scores_gemma":[0.00030741363,0.0000924694,0.000507056,0.00012412103,0.00008686135,0.0001012231,0.00001888974,0.00022786277,0.0000037482328],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028959457,0.003343104,0.42177704,0.00021541856,0.021691922,0.000049251586,0.0013031093,0.0063954922,0.0010805026,0.0001313612,0.005091932,0.5099614],"study_design_scores_gemma":[0.11079071,0.04276206,0.7667498,0.00016731358,0.01654989,0.000016972543,0.00046772358,0.013998399,0.0007335028,0.00020207679,0.047265593,0.00029596357],"about_ca_topic_score_codex":0.00030471568,"about_ca_topic_score_gemma":0.00043533568,"teacher_disagreement_score":0.5096654,"about_ca_system_score_codex":0.00019455607,"about_ca_system_score_gemma":0.0012017048,"threshold_uncertainty_score":0.6995273},"labels":[],"label_agreement":null},{"id":"W2963041253","doi":"10.1200/jco.19.00647","title":"Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Astellas Pharma; Syndax Pharmaceuticals; GlaxoSmithKline; Genentech; AstraZeneca; Pfizer","keywords":"Medicine; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Oncology; Chemotherapy; Cyclophosphamide; Cancer; Fluorouracil; Surgery; Confidence interval; Colorectal cancer","score_opus":0.022785496661625056,"score_gpt":0.36578986413210784,"score_spread":0.3430043674704828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963041253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937488,0.0003202366,0.000008743978,0.003097756,0.0015366204,0.00084717036,0.000059496717,0.000001491734,0.00037967582],"genre_scores_gemma":[0.9971584,0.0014480948,0.00020226702,0.00018473197,0.0007836675,0.000036727142,0.0000022738639,0.000019652218,0.00016415572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99671537,0.0007120676,0.0017348315,0.000231008,0.0003598566,0.00024686556],"domain_scores_gemma":[0.99634695,0.0005985731,0.0022351681,0.00031156445,0.00040923947,0.00009852724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024058206,0.0001825587,0.0021067306,0.000053004984,0.000018924413,0.0000041171083,0.00028960104,0.00028129705,0.00023213724],"category_scores_gemma":[0.00045378352,0.00009989469,0.00045877392,0.00012446217,0.00045690176,0.000008706482,0.00007853036,0.00030717516,0.0000014795593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9858087,0.0008831774,0.003918189,0.0000111265,0.0013011859,0.000005669621,0.00014097693,0.000024083754,0.0002953256,0.00001562226,0.0006000951,0.006995886],"study_design_scores_gemma":[0.9598114,0.015615013,0.019263262,0.0000611594,0.0002090572,0.0000099718,0.0001266613,0.0000015086321,0.0006287902,0.000032711614,0.004138185,0.00010228157],"about_ca_topic_score_codex":0.00010113179,"about_ca_topic_score_gemma":0.00014300607,"teacher_disagreement_score":0.025997266,"about_ca_system_score_codex":0.00014091002,"about_ca_system_score_gemma":0.0014163229,"threshold_uncertainty_score":0.40735874},"labels":[],"label_agreement":null},{"id":"W2963208685","doi":"10.1200/jco.2006.24.18_suppl.3564","title":"Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oxaliplatin; Neurotoxicity; Internal medicine; Bolus (digestion); Gastroenterology; Colorectal cancer; Logistic regression; Surgery; Cancer; Toxicity","score_opus":0.09326442666147912,"score_gpt":0.4403192307235135,"score_spread":0.34705480406203437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963208685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97831714,0.0000056002305,0.0000014520929,0.00086194853,0.00045436065,0.018354796,0.000021419208,0.0000040065975,0.001979283],"genre_scores_gemma":[0.99796003,0.0000024852784,0.000271322,0.00026324947,0.00019976475,0.000983028,0.0000039105257,0.000015664504,0.00030056344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569976,0.00044039768,0.0028713515,0.0002179086,0.0005333394,0.0002372535],"domain_scores_gemma":[0.99351346,0.0010546407,0.0043233973,0.00027442802,0.0006888906,0.00014518818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082879415,0.00017886498,0.0013888505,0.00011352541,0.000041238218,0.0000020563564,0.00015452784,0.00023893335,0.00012105478],"category_scores_gemma":[0.0005854756,0.00008586676,0.00021790105,0.00033216,0.000420103,0.0000716584,0.00007384942,0.0007155633,6.3546673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38194692,0.009070849,0.6035675,0.000048123646,0.00024946878,0.00046824035,0.000114140865,0.000072818264,0.000104750114,0.000006209965,0.001377401,0.0029735838],"study_design_scores_gemma":[0.12202753,0.1349727,0.72807735,0.000104441526,0.00034614082,0.00003486167,0.000042037944,0.000010692153,0.0011570184,0.000005410654,0.01315333,0.00006850304],"about_ca_topic_score_codex":0.00028911457,"about_ca_topic_score_gemma":0.0012518351,"teacher_disagreement_score":0.2599194,"about_ca_system_score_codex":0.00019123586,"about_ca_system_score_gemma":0.0022990447,"threshold_uncertainty_score":0.40784067},"labels":[],"label_agreement":null},{"id":"W2963368473","doi":"10.1200/jco.19.01186","title":"Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Dalhousie University; Queen Elizabeth II Health Sciences Centre; McMaster University","funders":"Multinational Association of Supportive Care in Cancer; American Society of Clinical Oncology","keywords":"Medicine; Guideline; Osteonecrosis of the jaw; Clinical Practice; Clinical Oncology; Dentistry; Internal medicine; Cancer; Family medicine; Pathology; Osteoporosis; Bisphosphonate","score_opus":0.34220778302573757,"score_gpt":0.6267017555927451,"score_spread":0.28449397256700754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963368473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010187337,0.9530473,0.00002382902,0.02710474,0.01058737,0.0015118223,0.000026302481,0.000011693468,0.007585088],"genre_scores_gemma":[0.00017157852,0.98342973,0.006609781,0.0073620756,0.00059166056,0.000012691081,0.00003669218,0.000063736064,0.0017220764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9743661,0.0042638616,0.019345015,0.00046743194,0.001142925,0.00041466366],"domain_scores_gemma":[0.9460982,0.023797724,0.026131872,0.001122967,0.0019137677,0.00093545474],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.019693494,0.0004364785,0.010070439,0.00020910309,0.00006749374,0.0000073408596,0.0007070682,0.0029805978,0.0003833633],"category_scores_gemma":[0.06441922,0.00022251104,0.004479105,0.0004821871,0.0005873457,0.00012881802,0.00021209358,0.0053182067,0.00032440352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007846866,0.0031552296,0.001838339,0.0022217245,0.0029321252,0.00020000558,0.000015944064,3.3997858e-7,2.8079679e-8,0.00006753494,0.0498375,0.93894655],"study_design_scores_gemma":[0.0074588154,0.007754506,0.003214995,0.0077320132,0.019150237,0.0020072502,0.000024079029,0.000006625697,8.130149e-8,0.00006167937,0.9524478,0.00014194852],"about_ca_topic_score_codex":0.00013760237,"about_ca_topic_score_gemma":0.00003768288,"teacher_disagreement_score":0.93880457,"about_ca_system_score_codex":0.00033926466,"about_ca_system_score_gemma":0.02098034,"threshold_uncertainty_score":0.9983137},"labels":[],"label_agreement":null},{"id":"W2963646129","doi":"10.1200/jco.2006.24.18_suppl.6517","title":"Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Gastroenterology; Rituximab; Febrile neutropenia; Toxicity; Chronic lymphocytic leukemia; Myelodysplastic syndromes; Immunology; Leukemia; Oncology; Bone marrow; Multiple myeloma; Lymphoma","score_opus":0.04624101192510237,"score_gpt":0.40455273321319996,"score_spread":0.3583117212880976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963646129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963632,0.0009147113,0.000046327255,0.0011342195,0.00033770746,0.000606386,0.0000029903563,0.000037533835,0.0005569217],"genre_scores_gemma":[0.9944026,0.0005476641,0.0023915188,0.0007763898,0.0006783375,0.000015975362,0.0000120065415,0.000108486594,0.0010670349],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99176747,0.0019191197,0.0033617576,0.0005897808,0.0015710179,0.00079083414],"domain_scores_gemma":[0.9897608,0.0056520244,0.002311178,0.0006346836,0.0009794848,0.00066178513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005947747,0.0004152656,0.0023159632,0.00055253494,0.00007686567,0.000027288137,0.00045473,0.0009166356,0.00013413362],"category_scores_gemma":[0.0068325615,0.00023321556,0.00029570717,0.00073270407,0.0006554657,0.0002988165,0.00012750571,0.0021311394,0.00003402289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8661143,0.0037094108,0.017749824,0.00037442602,0.0009130106,0.040383633,0.00017403201,0.00439347,0.008007767,0.00008113237,0.0077379914,0.05036098],"study_design_scores_gemma":[0.4941845,0.17277592,0.26923537,0.003808083,0.00086814613,0.0034616725,0.00020828912,0.0019629532,0.010456848,0.00028335492,0.04193659,0.0008182837],"about_ca_topic_score_codex":0.0011222014,"about_ca_topic_score_gemma":0.00039387154,"teacher_disagreement_score":0.37192982,"about_ca_system_score_codex":0.093390256,"about_ca_system_score_gemma":0.18000248,"threshold_uncertainty_score":0.9510254},"labels":[],"label_agreement":null},{"id":"W2963767023","doi":"10.1200/jco.2012.30.15_suppl.e13049","title":"Efficacy endpoints (EEPs) in melanoma randomized controlled adjuvant trials (RCATs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Disease; Clinical endpoint; Melanoma; Randomized controlled trial; Oncology; Internal medicine; Cancer research","score_opus":0.15599121139306332,"score_gpt":0.4835816662308455,"score_spread":0.32759045483778215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963767023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95191073,0.0021645208,0.0005074856,0.00810333,0.0073879547,0.0023407608,9.931777e-7,0.000021730246,0.027562464],"genre_scores_gemma":[0.99012405,0.001220439,0.0013361534,0.002590619,0.0030209098,0.000027791924,0.0000012941742,0.000018242072,0.0016605089],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866313,0.004959538,0.007413567,0.00016227805,0.00046342204,0.00036993236],"domain_scores_gemma":[0.9698963,0.024544442,0.004464769,0.00023109047,0.0002403218,0.00062303036],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05203809,0.00019215833,0.009339158,0.00039365815,0.00002573435,0.000010745873,0.00014122135,0.00039388926,0.0012147012],"category_scores_gemma":[0.072971255,0.00011053131,0.0024277368,0.0001422224,0.00016832548,0.00009651519,0.00005126818,0.0009819659,0.00012761637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8301899,0.0037370212,0.0039872527,0.000018149714,0.001599173,0.00085865264,0.00018633265,0.000007428456,0.00015392351,0.00044268725,0.0034928957,0.15532658],"study_design_scores_gemma":[0.8701176,0.003798298,0.018951537,0.00009647655,0.001957881,0.0016927033,0.00016391583,0.000098541095,0.00006955635,0.0002078329,0.10272892,0.000116749485],"about_ca_topic_score_codex":0.000011306737,"about_ca_topic_score_gemma":0.00001635413,"teacher_disagreement_score":0.15520982,"about_ca_system_score_codex":0.00018037303,"about_ca_system_score_gemma":0.0005225127,"threshold_uncertainty_score":0.99969834},"labels":[],"label_agreement":null},{"id":"W2964176267","doi":"10.1200/jco.2006.24.18_suppl.6003","title":"A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Nova Scotia; Ontario Clinical Oncology Group; Cancer Care Ontario; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Randomized controlled trial; Cancer; Clinical trial; Stage (stratigraphy); Physical therapy; Hormonal therapy; Internal medicine; Nursing","score_opus":0.09229991992787431,"score_gpt":0.39403862755300467,"score_spread":0.30173870762513033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964176267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720853,0.0013787602,0.0015262697,0.0010015973,0.006370218,0.0019326328,0.00033692247,0.0000059182,0.015362363],"genre_scores_gemma":[0.9943761,0.00024224646,0.00058774836,0.000817251,0.0026307423,0.00009280523,0.0000067452042,0.00003310095,0.001213234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99016106,0.00014747451,0.008889622,0.00033593277,0.000111582034,0.0003542988],"domain_scores_gemma":[0.9845686,0.0021629862,0.012151197,0.00029596972,0.0006155217,0.00020570136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005528021,0.00025899784,0.009142993,0.0003100443,0.00005148848,0.000031164247,0.00039863487,0.00034171046,0.000087867695],"category_scores_gemma":[0.0020886254,0.00022196543,0.002905298,0.0001249102,0.00029429747,0.00028394046,0.00006239427,0.00042603657,0.000005823268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8284951,0.0007090679,0.15337092,0.00007060242,0.0011855051,0.000050612263,0.0001947147,0.00012946654,0.000009308135,0.005400077,0.0013445774,0.009040047],"study_design_scores_gemma":[0.648823,0.001474671,0.34297645,0.00005155206,0.00021503758,0.0000066648545,0.000036494424,0.000022660077,0.000012121892,0.0015509959,0.004652944,0.00017737038],"about_ca_topic_score_codex":0.0014463738,"about_ca_topic_score_gemma":0.0007321788,"teacher_disagreement_score":0.18960555,"about_ca_system_score_codex":0.00029064785,"about_ca_system_score_gemma":0.0011921172,"threshold_uncertainty_score":0.90514874},"labels":[],"label_agreement":null},{"id":"W2964293338","doi":"10.1200/jco.2009.27.15_suppl.6574","title":"Adjuvant hormone strategies in postmenopausal women with breast cancer: An economic evaluation based on the EBCTCG meta-analyses","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Adjuvant; Adverse effect; Oncology; Internal medicine; Gynecology; Letrozole; Meta-analysis; Cancer","score_opus":0.7382551979556331,"score_gpt":0.6110005545397625,"score_spread":0.12725464341587056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964293338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8601537,0.0014286436,0.00027239718,0.13476166,0.0004324041,0.00050321186,0.000112777154,0.000008532423,0.0023266976],"genre_scores_gemma":[0.9730478,0.00025167884,0.0008545486,0.02497787,0.0007567353,0.000065488726,0.0000051750885,0.000017468294,0.00002322268],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9872208,0.0028961627,0.008811418,0.00042742738,0.00024245678,0.0004017101],"domain_scores_gemma":[0.9849957,0.004858526,0.009118196,0.0004626643,0.00024764272,0.00031726563],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.080602534,0.00023713298,0.0032980929,0.000399929,0.00009694801,0.00008672913,0.00047399098,0.0002686859,0.0014308214],"category_scores_gemma":[0.002827369,0.00016110757,0.0002994297,0.00016233887,0.00014296138,0.0008036054,0.00001444329,0.00070632226,0.00011914332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017334158,0.010031492,0.055710264,0.00010212047,0.010594356,0.00012444983,0.0045906384,0.70839155,0.000058282123,0.10150601,0.028493343,0.06306331],"study_design_scores_gemma":[0.0067684692,0.01831485,0.86757517,0.000039338942,0.00067927357,0.000044863664,0.002991551,0.06459585,0.0000016667168,0.033682827,0.0049124444,0.00039368164],"about_ca_topic_score_codex":0.00053884723,"about_ca_topic_score_gemma":0.0008860927,"teacher_disagreement_score":0.8118649,"about_ca_system_score_codex":0.0018109189,"about_ca_system_score_gemma":0.0037552582,"threshold_uncertainty_score":0.99948204},"labels":[],"label_agreement":null},{"id":"W2964312447","doi":"10.1200/jco.2019.37.15_suppl.11001","title":"STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Surgery; Perioperative; Radiation therapy; Randomized controlled trial; Sarcoma","score_opus":0.09832768031246383,"score_gpt":0.440757608906021,"score_spread":0.34242992859355714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964312447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357116,0.0007335008,0.000050769475,0.00072460255,0.0018801352,0.002937167,0.000015976393,0.000008368241,0.0000782954],"genre_scores_gemma":[0.9972791,0.00058934453,0.0011630433,0.00028500296,0.0005003921,0.00008327562,0.000021743037,0.000036911526,0.0000411715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938106,0.0012284004,0.0037048897,0.00031486832,0.00063255633,0.0003086985],"domain_scores_gemma":[0.9656895,0.02968621,0.0029986086,0.00030682777,0.0009900555,0.00032879188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048526246,0.00026723024,0.006516087,0.00023466536,0.000044475823,0.000011640487,0.000116940704,0.00025171434,0.0002253418],"category_scores_gemma":[0.0029860365,0.00015283562,0.0012401354,0.00017399322,0.00023181613,0.00014216313,0.000022863358,0.00046669852,0.000002499632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53869814,0.027937615,0.40941027,0.000026745343,0.003732694,0.00021680554,0.0002522956,0.000008656568,0.0000060768343,0.000005650554,0.0010781765,0.018626882],"study_design_scores_gemma":[0.73991865,0.061657928,0.19502638,0.00016336948,0.0016401478,0.000032384993,0.00041052973,0.00011163063,0.000047291873,0.000005140344,0.00084346277,0.00014309451],"about_ca_topic_score_codex":0.00006980608,"about_ca_topic_score_gemma":0.000043596036,"teacher_disagreement_score":0.21438387,"about_ca_system_score_codex":0.00028704174,"about_ca_system_score_gemma":0.0020037652,"threshold_uncertainty_score":0.6232456},"labels":[],"label_agreement":null},{"id":"W2964348195","doi":"10.1200/jco.2006.24.18_suppl.10063","title":"Active <i>c</i>-Src has prognostic and therapeutic value in ER-negative breast cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Proto-oncogene tyrosine-protein kinase Src; Oncology; Internal medicine; Tissue microarray; Trastuzumab; Immunohistochemistry; Chemotherapy; Grading (engineering); Tamoxifen; Immunostaining; Cancer; Pathology; Receptor","score_opus":0.12691142869742486,"score_gpt":0.48829145841286997,"score_spread":0.36138002971544514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964348195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96417063,0.0014406018,0.000009047009,0.030398192,0.0008069206,0.00031325198,0.000012256853,0.0000062059903,0.0028428773],"genre_scores_gemma":[0.99421746,0.0008529957,0.00033339782,0.0027841302,0.0014579833,0.000015292735,9.900042e-7,0.000013152374,0.00032460637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790204,0.00038830488,0.0011431581,0.00017322507,0.00017346161,0.00021979032],"domain_scores_gemma":[0.99617356,0.0025671893,0.0007949429,0.000064860746,0.00022348671,0.00017594361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078920386,0.00013455129,0.0010704402,0.00012074761,0.000034015815,0.0000069303505,0.0000663958,0.00025656776,0.00039437166],"category_scores_gemma":[0.00022896458,0.00009234859,0.00019303987,0.0001506887,0.00036720393,0.00007033838,0.000024524461,0.0007990501,0.0000057534985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01644721,0.0056441845,0.7301234,0.000036891386,0.0007989577,0.0011921795,0.0003764065,0.000085522435,0.0007606064,0.00021992589,0.005067593,0.23924714],"study_design_scores_gemma":[0.015176323,0.006600805,0.9632576,0.000095346986,0.00073695666,0.0007237671,0.00007643117,0.00010601099,0.00016810288,0.0017737292,0.011201589,0.00008329796],"about_ca_topic_score_codex":0.0007065653,"about_ca_topic_score_gemma":0.0006526481,"teacher_disagreement_score":0.23916385,"about_ca_system_score_codex":0.00027285927,"about_ca_system_score_gemma":0.0016123522,"threshold_uncertainty_score":0.4318093},"labels":[],"label_agreement":null},{"id":"W2964353176","doi":"10.1200/jco.2012.30.15_suppl.tps6640","title":"An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Essential thrombocythemia; Internal medicine; Polycythemia vera; Clinical endpoint; Constitutional symptoms; Anemia; International Prognostic Scoring System; Gastroenterology; Phases of clinical research; Bone marrow; Clinical trial; Myelodysplastic syndromes; Disease","score_opus":0.12906822328021123,"score_gpt":0.4904048516542319,"score_spread":0.3613366283740207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964353176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918757,0.0001402864,0.000072711,0.00312852,0.00086081197,0.0034112218,0.00015017769,0.000027504173,0.00033307847],"genre_scores_gemma":[0.98352057,0.00022761659,0.012092405,0.0031741573,0.0006342202,0.000089408364,0.0000894088,0.00010572473,0.00006648518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99104345,0.0017742495,0.0042433194,0.000785101,0.001239456,0.00091442524],"domain_scores_gemma":[0.9870941,0.0050830296,0.003543831,0.00090401,0.0018529933,0.001522047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034693093,0.0007228852,0.003843269,0.00028384445,0.00041751703,0.00030451472,0.0010597174,0.00039607292,0.00029618441],"category_scores_gemma":[0.0025662028,0.0003908766,0.0003243802,0.0004885494,0.00057628256,0.0016742721,0.0008712393,0.0010181498,0.00001040822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081798494,0.044329748,0.8145267,0.0001198557,0.0019518781,0.00012966676,0.0018732739,0.0000032462067,0.003009956,0.000016787626,0.00027602646,0.051964372],"study_design_scores_gemma":[0.053941753,0.0732638,0.86500883,0.00056116766,0.0023041952,0.00020110277,0.0013723383,0.000011739214,0.0019735224,0.0000034003024,0.0009737489,0.00038439388],"about_ca_topic_score_codex":0.00022655605,"about_ca_topic_score_gemma":0.00017814168,"teacher_disagreement_score":0.05157998,"about_ca_system_score_codex":0.00042479858,"about_ca_system_score_gemma":0.0020581502,"threshold_uncertainty_score":0.9998543},"labels":[],"label_agreement":null},{"id":"W2964423432","doi":"10.1200/jco.2012.30.15_suppl.e14695","title":"Practice patterns in the treatment of locally advanced resectable esophageal carcinoma: A national survey of Canadian thoracic surgeons.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Esophageal cancer; Neoadjuvant therapy; Chemotherapy; Cardiothoracic surgery; Radiation therapy; Esophagectomy; General surgery; Randomized controlled trial; Cancer; Surgery; Oncology; Internal medicine; Breast cancer","score_opus":0.23331599484364487,"score_gpt":0.5250597233696197,"score_spread":0.29174372852597485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964423432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852652,0.006930587,0.000009008885,0.004280954,0.00030171746,0.00038456175,0.00006459426,0.0000012234069,0.0027621435],"genre_scores_gemma":[0.9963375,0.0022198772,0.0005904015,0.00048970606,0.0002463454,0.000013403731,0.000016229473,0.000009817329,0.00007674458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523383,0.0018956733,0.0016225612,0.000120022094,0.00074102427,0.00038688484],"domain_scores_gemma":[0.98871225,0.008240369,0.0010577689,0.00018686027,0.0012740141,0.0005287286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0093268575,0.00011726376,0.001023568,0.00044425653,0.000030290546,0.0000038881767,0.00015815516,0.00017685833,0.000111039386],"category_scores_gemma":[0.007250008,0.00006834916,0.00025194784,0.0005045802,0.00013956575,0.00018013026,0.000013668472,0.00048055142,0.000004805511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007116899,0.0054606977,0.95636755,0.000031515257,0.00026585747,0.000976943,0.00038309547,0.000016922522,0.000004579457,0.00007752577,0.0004857797,0.028812634],"study_design_scores_gemma":[0.005519301,0.018072434,0.9699831,0.000042673608,0.00013153048,0.0002837151,0.00023180805,0.000012266888,0.00014062217,0.000027640826,0.0055149803,0.000039897128],"about_ca_topic_score_codex":0.116263784,"about_ca_topic_score_gemma":0.18832448,"teacher_disagreement_score":0.0720607,"about_ca_system_score_codex":0.00069516833,"about_ca_system_score_gemma":0.0074433284,"threshold_uncertainty_score":0.99818355},"labels":[],"label_agreement":null},{"id":"W2964428585","doi":"10.1200/jco.2012.30.15_suppl.e14532","title":"A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Proportional hazards model; Oncology; Ascites; Multivariate analysis; Univariate analysis; Cancer","score_opus":0.09879951293393349,"score_gpt":0.3561440377530366,"score_spread":0.2573445248191031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964428585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985609,0.00034071764,0.00004000079,0.0001376279,0.00010436252,0.00064127165,0.000009393706,0.000007676563,0.00015804332],"genre_scores_gemma":[0.997914,0.000029821771,0.001766013,0.00008978067,0.00008211966,0.000010492028,0.00004980375,0.000027175905,0.000030793857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650544,0.00042230912,0.0019454644,0.0002167102,0.0005077098,0.00040238144],"domain_scores_gemma":[0.99586064,0.001073455,0.0016988188,0.0002451519,0.0006128926,0.0005090667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096745614,0.00025405662,0.0024601675,0.00059399003,0.000023062092,0.000004745204,0.00011631269,0.00028756587,0.000106461186],"category_scores_gemma":[0.00063709443,0.00014103405,0.0005720199,0.0008700514,0.00017953118,0.00021298377,0.000025701742,0.00053545745,0.0000032877685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010687058,0.007104134,0.97460115,0.000038294544,0.00303702,0.0003217993,0.00036021488,0.0000085175025,0.00003241902,0.0000030392255,0.000010321916,0.003796022],"study_design_scores_gemma":[0.017476257,0.018001808,0.9545333,0.00011179897,0.008311373,0.000007684348,0.00011286609,0.0005295344,0.00045497745,7.7670967e-7,0.00032279463,0.00013683258],"about_ca_topic_score_codex":0.00005715962,"about_ca_topic_score_gemma":0.00004944688,"teacher_disagreement_score":0.020067865,"about_ca_system_score_codex":0.00016380247,"about_ca_system_score_gemma":0.00040368747,"threshold_uncertainty_score":0.5751202},"labels":[],"label_agreement":null},{"id":"W2964448195","doi":"10.1200/jco.2012.30.15_suppl.9043","title":"Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: Comparison of autologous and nonautologous breast reconstruction.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Breast reconstruction; Mastectomy; Patient satisfaction; Surgery; Confounding; Multivariate analysis; Univariate analysis; Reconstructive surgery; Body mass index; Breast surgery; Implant; Cancer; Internal medicine","score_opus":0.07494465749358026,"score_gpt":0.39342220940561234,"score_spread":0.3184775519120321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964448195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602854,0.00034737616,0.000052974265,0.0009908833,0.0020369797,0.0002711807,0.0000060276607,0.000011737891,0.00025428846],"genre_scores_gemma":[0.99750435,0.00006356538,0.0018866741,0.00006218492,0.00045815427,0.0000031588274,0.0000046415107,0.000011797336,0.000005446606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579865,0.0008229803,0.0025979572,0.00017192742,0.00031679927,0.000291697],"domain_scores_gemma":[0.99502903,0.0010814703,0.003070112,0.00017775918,0.0003892193,0.0002523869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002130207,0.00017872304,0.0014710994,0.00025148658,0.00006256275,0.000009429729,0.0000747536,0.00050080527,0.00006882629],"category_scores_gemma":[0.00032239966,0.000102379214,0.0001852154,0.00024190138,0.00074698305,0.00026707153,0.000021194315,0.0011648774,0.0000018909985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022098364,0.0003371382,0.5271417,0.000024041132,0.00015313325,0.00008501723,0.00028869888,8.1211766e-7,0.000033126216,0.00001478588,0.000012299108,0.4696994],"study_design_scores_gemma":[0.002332287,0.0018175796,0.59344083,0.00012736699,0.00024775663,0.40118128,0.0007252341,0.0000147095325,0.000017624745,0.000019996334,0.000011322173,0.000063990934],"about_ca_topic_score_codex":0.00021168301,"about_ca_topic_score_gemma":0.00084597134,"teacher_disagreement_score":0.46963543,"about_ca_system_score_codex":0.00008157527,"about_ca_system_score_gemma":0.00060126995,"threshold_uncertainty_score":0.5060877},"labels":[],"label_agreement":null},{"id":"W2964501256","doi":"10.1200/jco.2012.30.15_suppl.9591","title":"Bleomycin-associated lung toxicity in childhood cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; DLCO; Pulmonary function testing; Pulmonary toxicity; Spirometry; Bleomycin; Internal medicine; Lung cancer; Diffusing capacity; Univariate analysis; Lung; Asymptomatic; Gastroenterology; Lung volumes; Surgery; Chemotherapy; Asthma","score_opus":0.07018806024973309,"score_gpt":0.5064385911034055,"score_spread":0.4362505308536724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964501256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98107636,0.0023381843,0.000024812283,0.0071997927,0.0020905943,0.00017031496,0.000006057671,0.0000074699083,0.00708642],"genre_scores_gemma":[0.9938614,0.0009706631,0.0004137442,0.003059314,0.0012568308,0.000006478596,0.0000032224857,0.000011866634,0.00041648917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773777,0.00026110708,0.0014031557,0.000094118375,0.00022537408,0.00027846222],"domain_scores_gemma":[0.99754685,0.0007703149,0.0009396498,0.0000952587,0.00028554883,0.00036240567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020223258,0.00009649625,0.0010015757,0.00010273938,0.000028152424,0.0000037307648,0.00007289038,0.00027397522,0.00032098332],"category_scores_gemma":[0.002174872,0.00006596659,0.00027857345,0.00018253172,0.00005719207,0.00019135384,0.000021317506,0.0006678541,0.000010040739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029192507,0.004638258,0.9537001,0.000009007455,0.00055668724,0.00008290812,0.0005124697,0.000013125535,0.000027922075,0.000061386054,0.002680535,0.037425637],"study_design_scores_gemma":[0.0070068515,0.001523999,0.9698221,0.00010200044,0.0005937233,0.000055468707,0.0001179998,0.000020961896,0.000037020734,0.000076246535,0.020581847,0.00006175568],"about_ca_topic_score_codex":0.00039645983,"about_ca_topic_score_gemma":0.0011412245,"teacher_disagreement_score":0.03736388,"about_ca_system_score_codex":0.0005533505,"about_ca_system_score_gemma":0.0016461082,"threshold_uncertainty_score":0.35145423},"labels":[],"label_agreement":null},{"id":"W2964510318","doi":"10.1200/jco.2013.31.15_suppl.e22191","title":"Recombinant growth/differentiation factor-5 enhances cell proliferation and tendogenic differentiation of human periodontal ligament stem cells in vitro.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Periodontal Regeneration and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Periodontal ligament stem cells; Decorin; Alkaline phosphatase; Growth differentiation factor; Aggrecan; Mesenchymal stem cell; Cell growth; Andrology; Stem cell; Follistatin; Cellular differentiation; Molecular biology; Cell biology; Immunology; Chemistry; Biology; Medicine; Extracellular matrix; Pathology; Biochemistry; Proteoglycan; Bone morphogenetic protein; Enzyme","score_opus":0.06999164507618352,"score_gpt":0.3723412318055861,"score_spread":0.3023495867294026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964510318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979591,0.00027564366,0.00007429294,0.0005305074,0.0005767503,0.00043401722,0.000002602167,0.000004593711,0.00014252498],"genre_scores_gemma":[0.9983759,0.00067147054,0.00034233672,0.00011618147,0.00014975872,0.000014890708,0.000011012166,0.0000099726985,0.0003084765],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971903,0.00028934807,0.0019185435,0.00017108947,0.00028558518,0.00014515355],"domain_scores_gemma":[0.99777126,0.00018365959,0.0014797609,0.00009032015,0.00029138944,0.00018360656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041335996,0.00013778107,0.0009598966,0.00018019692,0.000041538908,0.000021744145,0.000059626705,0.00023357295,0.000093109404],"category_scores_gemma":[0.00008892476,0.00009584496,0.00022709375,0.00007202406,0.000067364424,0.00022150353,0.000026506383,0.00031558736,0.000007787547],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071876653,0.0028403888,0.19228956,0.000074008254,0.00013132619,0.000021745409,0.00046132435,6.5074045e-7,0.7569417,0.0000213977,0.00005022472,0.04644891],"study_design_scores_gemma":[0.006086317,0.005416587,0.62418234,0.00007384171,0.000118446405,0.000028263159,0.00014929127,0.00020937003,0.3635441,0.00007427822,0.000045737863,0.0000714139],"about_ca_topic_score_codex":0.000062165476,"about_ca_topic_score_gemma":0.00007992669,"teacher_disagreement_score":0.4318928,"about_ca_system_score_codex":0.00017813452,"about_ca_system_score_gemma":0.00021379962,"threshold_uncertainty_score":0.3908444},"labels":[],"label_agreement":null},{"id":"W2964521989","doi":"10.1200/jco.2009.27.15_suppl.9607","title":"The predictive accuracy of survival between patient-reported versus clinician-reported pain in a cohort of 1,214 patients with metastatic cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cancer; Cohort; Prostate cancer; Breast cancer; Cancer pain; Logistic regression; Wilcoxon signed-rank test; Internal medicine; Performance status; Colorectal cancer; Randomized controlled trial; Lung cancer; Physical therapy; Mann–Whitney U test","score_opus":0.14912415074415636,"score_gpt":0.5031426434159173,"score_spread":0.35401849267176094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964521989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494314,0.00038166926,0.000037867325,0.001925619,0.0012343732,0.00075458037,0.00002445573,0.0000052086025,0.00069306773],"genre_scores_gemma":[0.99821097,0.0007520834,0.00031814844,0.0003380968,0.00031084564,0.000013234958,0.000016077767,0.000013242961,0.00002730641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931286,0.0011821986,0.0045546438,0.00021995387,0.00063465926,0.00027996258],"domain_scores_gemma":[0.9792557,0.012157419,0.0069085998,0.00024011123,0.0011981996,0.00023999145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051166317,0.00018649711,0.002223981,0.00014911089,0.00003400066,0.000003052135,0.00016211628,0.00021569029,0.00006836723],"category_scores_gemma":[0.008175467,0.000106602725,0.00039538433,0.00035319745,0.0003529643,0.000095163625,0.000027757116,0.00081306393,5.232785e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038424734,0.003154392,0.74202126,0.000013426932,0.0029810045,0.00020355737,0.0001342683,0.000027198905,0.00001584272,0.00000433711,0.0005912518,0.2124287],"study_design_scores_gemma":[0.028936395,0.07205961,0.892288,0.00013749787,0.0030858058,0.000008763439,0.00013332268,0.00003098017,0.00008115977,0.00009475047,0.0030652564,0.000078415695],"about_ca_topic_score_codex":0.00020420403,"about_ca_topic_score_gemma":0.00036125444,"teacher_disagreement_score":0.21235028,"about_ca_system_score_codex":0.00023771376,"about_ca_system_score_gemma":0.002642792,"threshold_uncertainty_score":0.97873884},"labels":[],"label_agreement":null},{"id":"W2964600451","doi":"10.1200/jco.2007.25.18_suppl.2522","title":"Evaluation of Cockcroft-Gault (CG) and abbreviated modified diet in renal disease (MDRD) formulae in dosing of cancer drugs other than carboplatin","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Renal function; Concordance; Carboplatin; Urology; Cancer; Creatinine; Internal medicine; Population; Chemotherapy; Cisplatin","score_opus":0.16108371904726282,"score_gpt":0.5006183896202324,"score_spread":0.3395346705729696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964600451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445456,0.0026726408,0.000052070605,0.0007948771,0.0002982328,0.00031164422,0.000011932075,0.000001920275,0.0014021217],"genre_scores_gemma":[0.99811864,0.00064966106,0.0003734241,0.000596791,0.00021930099,0.000003352373,0.00000338721,0.000011637629,0.000023809678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959854,0.00048003913,0.0025982596,0.0001566701,0.00058348646,0.0001961567],"domain_scores_gemma":[0.99625504,0.0012542193,0.0016055658,0.00012817016,0.0005217619,0.00023522544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010588019,0.0001133518,0.0011866685,0.00026092926,0.000011557915,0.000002160591,0.00008033883,0.00023570596,0.00013563177],"category_scores_gemma":[0.0022234647,0.0000869942,0.00019210025,0.00019050369,0.0001679691,0.000106836866,0.000025957943,0.0005791311,2.285652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030995768,0.000953292,0.66113937,0.00015666644,0.0002592906,0.000107337226,0.0010189732,0.0013999538,0.004521156,0.000028696953,0.000109094166,0.29931042],"study_design_scores_gemma":[0.020680727,0.002250526,0.9653017,0.00055466086,0.0004591847,0.0000071271297,0.00018107034,0.00908934,0.00053073314,0.00030475185,0.0005585025,0.00008170976],"about_ca_topic_score_codex":0.00074177375,"about_ca_topic_score_gemma":0.002723526,"teacher_disagreement_score":0.30416232,"about_ca_system_score_codex":0.0003732053,"about_ca_system_score_gemma":0.0024289954,"threshold_uncertainty_score":0.43089333},"labels":[],"label_agreement":null},{"id":"W2964631730","doi":"10.1200/jco.2013.31.15_suppl.e13013","title":"Using ANG4043, a brain-penetrant anti-HER2 mab, to increase survival in a murine intracranial breast tumor model.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada)","funders":"","keywords":"Transcytosis; Medicine; Brain tumor; Blood–brain barrier; Radioimmunotherapy; Receptor; Breast cancer; LRP1; Cancer research; Human brain; Monoclonal antibody; Internal medicine; Pharmacology; Immunology; Antibody; Pathology; Central nervous system; Cancer; Lipoprotein; LDL receptor","score_opus":0.14273372103139548,"score_gpt":0.4914529120257182,"score_spread":0.34871919099432275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964631730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772691,0.00009656537,0.00023072974,0.019342694,0.0012180044,0.00050640415,0.000012224733,0.000011189703,0.0013130711],"genre_scores_gemma":[0.98057723,0.00007872584,0.008146255,0.008890821,0.002113799,0.000010171306,0.0000027138146,0.000028841658,0.00015146605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962057,0.0005135183,0.0022316873,0.00027491816,0.00033266217,0.0004415211],"domain_scores_gemma":[0.9964731,0.0013453679,0.0007919771,0.00017306996,0.0003877405,0.0008287954],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022326375,0.00021915036,0.0018826581,0.0002485656,0.000033886095,0.000014256961,0.00019366424,0.00026026685,0.0018828398],"category_scores_gemma":[0.0009175703,0.00016563066,0.00040417307,0.0002842185,0.00013865509,0.00017430002,0.00008231324,0.0010188658,0.000047702506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044062454,0.025655523,0.67986125,0.0001641279,0.0014450477,0.021845927,0.0005930996,0.0028674316,0.036066912,0.00016370785,0.028093887,0.15918064],"study_design_scores_gemma":[0.03486862,0.013201091,0.9128385,0.00019204458,0.000622306,0.007742995,0.000108213215,0.024555415,0.000092773196,0.00059926335,0.0048851063,0.00029368207],"about_ca_topic_score_codex":0.0015282196,"about_ca_topic_score_gemma":0.0005643343,"teacher_disagreement_score":0.23297726,"about_ca_system_score_codex":0.00035915046,"about_ca_system_score_gemma":0.002060852,"threshold_uncertainty_score":0.9990296},"labels":[],"label_agreement":null},{"id":"W2964685420","doi":"10.1200/jco.2012.30.15_suppl.6030","title":"Longitudinal changes in health care utilization by adult survivors of childhood cancer in the Childhood Cancer Survivor Study (CCSS).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"","keywords":"Medicine; Cancer; Health care; Confidence interval; Cancer survivor; Incidence (geometry); Relative risk; Young adult; Childhood cancer; Pediatrics; Gerontology; Internal medicine","score_opus":0.14942772379033417,"score_gpt":0.5010216382202349,"score_spread":0.35159391442990073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964685420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92770475,0.032133993,0.000014675919,0.03622966,0.0023946394,0.0012359506,0.00007700152,0.000011608457,0.00019772597],"genre_scores_gemma":[0.9756665,0.012120781,0.00008951061,0.009778243,0.002203594,0.000058683218,0.000013211191,0.000043723558,0.000025704416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9893983,0.0037054266,0.0045153564,0.00039959038,0.0012536487,0.0007276557],"domain_scores_gemma":[0.9923503,0.0023613353,0.0036832753,0.00045400485,0.000672518,0.00047860798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0116801,0.00034500723,0.0028307226,0.00036871055,0.0000740368,0.000011792947,0.00051318505,0.00041649,0.00024185266],"category_scores_gemma":[0.0030664941,0.00024082509,0.00038228088,0.00084495073,0.00022112069,0.0002721346,0.00009552006,0.001880336,0.000003020833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009948948,0.010864341,0.909612,0.0001906864,0.00030338834,0.000024888279,0.03456885,0.000033754204,0.0000040368955,0.000023719902,0.0027699089,0.040609527],"study_design_scores_gemma":[0.009705009,0.00802425,0.9517612,0.00064266706,0.00021694179,0.000047293124,0.019921055,0.0000063212256,0.00003060782,0.000011995313,0.00943904,0.00019363027],"about_ca_topic_score_codex":0.02149661,"about_ca_topic_score_gemma":0.25357035,"teacher_disagreement_score":0.23207372,"about_ca_system_score_codex":0.0005735922,"about_ca_system_score_gemma":0.002982018,"threshold_uncertainty_score":0.9850193},"labels":[],"label_agreement":null},{"id":"W2964756619","doi":"10.1200/jco.2012.30.15_suppl.e14108","title":"Feasibility and challenges of a biopsy-driven and biomarker discovery clinical trial in metastatic colorectal cancer to identify signatures of clinical resistance.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Quebec - Clinical Research Organization in Cancer","funders":"","keywords":"Medicine; FOLFOX; Colorectal cancer; FOLFIRI; Oncology; Liquid biopsy; Clinical trial; Bevacizumab; Biopsy; Internal medicine; Metastasis; Cancer; Irinotecan; Oxaliplatin; Chemotherapy","score_opus":0.22433287519558345,"score_gpt":0.5146895476029856,"score_spread":0.29035667240740215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964756619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738973,0.022418812,0.00005665122,0.0011513741,0.0019703407,0.00034599632,0.00006336166,9.397443e-7,0.00009525773],"genre_scores_gemma":[0.9541234,0.042323276,0.0022559569,0.00022985152,0.0010315735,0.000007956,0.0000025015102,0.000013285448,0.000012228745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942228,0.001151788,0.003832258,0.0003392425,0.00020519819,0.00024868213],"domain_scores_gemma":[0.9936581,0.0034070292,0.002083285,0.00021736327,0.00026638078,0.00036779343],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008813099,0.000159745,0.0016878769,0.00008981161,0.000017905748,0.00000935647,0.0002093369,0.0005354911,0.000008236732],"category_scores_gemma":[0.0119272405,0.00012556989,0.0004530742,0.00008900325,0.00062007306,0.000021381213,0.00023383951,0.00046719355,2.8724014e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15159346,0.0039785225,0.7739721,0.0001629175,0.0008367774,0.00003633658,0.00012964172,0.00001606412,0.0076317396,0.0003683677,0.0014944766,0.059779614],"study_design_scores_gemma":[0.025959523,0.0069898996,0.9573313,0.000082292434,0.00023417908,0.0000134521415,0.00012597677,0.000008406318,0.00044238902,0.00029755238,0.008372391,0.00014261251],"about_ca_topic_score_codex":0.000035904905,"about_ca_topic_score_gemma":0.0010999436,"teacher_disagreement_score":0.18335925,"about_ca_system_score_codex":0.000028657347,"about_ca_system_score_gemma":0.0009145678,"threshold_uncertainty_score":0.9963957},"labels":[],"label_agreement":null},{"id":"W2964764956","doi":"10.1200/jco.2009.27.15_suppl.e16050","title":"Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Hazard ratio; Log-rank test; Multivariate analysis; Survival analysis; Prostate cancer; Oncology; Retrospective cohort study; Cancer; Gastroenterology; Confidence interval","score_opus":0.14197966551182978,"score_gpt":0.5245196824229064,"score_spread":0.3825400169110766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964764956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939699,0.002012393,5.08102e-7,0.0016795255,0.0004794673,0.0003038118,0.00004623001,0.0000034892666,0.0015046349],"genre_scores_gemma":[0.98027927,0.01862179,0.00006826061,0.00022955153,0.000347427,0.0000054735538,0.000009347321,0.000012425774,0.00042648788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968264,0.00031138145,0.0018076303,0.00015736929,0.0006219114,0.0002753251],"domain_scores_gemma":[0.9955522,0.001402859,0.0017511882,0.00018460899,0.0007230584,0.0003860944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012416366,0.00014688412,0.0015326914,0.00016724477,0.000025390847,0.0000026316304,0.00014055996,0.00025998647,0.00016670689],"category_scores_gemma":[0.0014434926,0.000084325926,0.0007439963,0.00015864638,0.00024431988,0.00007932742,0.00003734934,0.0006570383,0.000005772917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027607247,0.0069193873,0.7940816,0.000021515049,0.00060271256,0.0003121453,0.00016732143,0.000017351049,0.0006945632,0.000005284993,0.010183348,0.15938753],"study_design_scores_gemma":[0.013774489,0.08719919,0.89294857,0.00012655226,0.0002049489,0.0000051685956,0.000014340772,0.000003497268,0.00042221698,0.00007952497,0.0051598568,0.00006163926],"about_ca_topic_score_codex":0.000087854765,"about_ca_topic_score_gemma":0.00002638267,"teacher_disagreement_score":0.15932588,"about_ca_system_score_codex":0.00061309873,"about_ca_system_score_gemma":0.0014416077,"threshold_uncertainty_score":0.34387115},"labels":[],"label_agreement":null},{"id":"W2964766142","doi":"10.1200/jco.2013.31.15_suppl.9596","title":"Risk and predictors of suicide in colorectal cancer patients: A SEER analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Univariate analysis; Cancer; Epidemiology; Population; Cohort; Rectum; Retrospective cohort study; Oncology; Gastroenterology; Multivariate analysis","score_opus":0.05093667596738357,"score_gpt":0.3535594919609312,"score_spread":0.3026228159935477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964766142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937352,0.0015074521,0.00010463987,0.00052076246,0.0008560237,0.00012545464,0.00006470556,0.0000019442036,0.0030837993],"genre_scores_gemma":[0.9955224,0.0034810486,0.00032074162,0.00033513492,0.0002655374,0.0000066244784,0.0000012218452,0.000008746044,0.000058589536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963229,0.00007693051,0.0031772824,0.0001819945,0.000040202416,0.00020071166],"domain_scores_gemma":[0.9948795,0.0007071236,0.003941074,0.000086564665,0.00019903449,0.00018674125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020898022,0.00010347252,0.0017651293,0.0003845208,0.000017658214,0.000012572757,0.00016900331,0.000285166,0.00045784935],"category_scores_gemma":[0.0026421682,0.000093040966,0.00035676095,0.00026163532,0.00019041603,0.0003607501,0.00004516143,0.00047088394,0.000018813806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017483125,0.0003451038,0.9839094,0.0000050281183,0.00047414744,0.0000020416421,0.00013563214,0.0001767636,0.0000014866588,0.00062389125,0.00087011245,0.013281543],"study_design_scores_gemma":[0.002248327,0.001492566,0.9849482,0.0000109204875,0.00011410147,7.4900277e-7,0.0000270188,0.00038866999,0.0000070175047,0.004584415,0.00608737,0.000090638285],"about_ca_topic_score_codex":0.002468687,"about_ca_topic_score_gemma":0.0011946625,"teacher_disagreement_score":0.013190905,"about_ca_system_score_codex":0.00014281624,"about_ca_system_score_gemma":0.00020337322,"threshold_uncertainty_score":0.501313},"labels":[],"label_agreement":null},{"id":"W2964821736","doi":"10.1200/jco.2013.31.15_suppl.e20598","title":"Results from a structured interprofessional palliative care rehabilitation program in oncology.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Élisabeth Bruyère Hospital; University of Ottawa; Canadian Hospice Palliative Care Association","funders":"","keywords":"Medicine; Palliative care; Rehabilitation; Physical therapy; Cancer; Quality of life (healthcare); Internal medicine; Nursing","score_opus":0.08352360179104192,"score_gpt":0.5052795452841927,"score_spread":0.4217559434931508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964821736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97360903,0.00038376488,0.000018900206,0.01918727,0.0031207022,0.00058266637,0.000020435995,0.000013605003,0.0030636508],"genre_scores_gemma":[0.9834196,0.0000843138,0.013432775,0.0017548046,0.001146317,0.00003729349,0.000029792713,0.000012137605,0.000082939936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957213,0.00087095756,0.0026115442,0.00024544174,0.00034859625,0.00020219009],"domain_scores_gemma":[0.9908972,0.006120392,0.0015224821,0.00018644688,0.0009695846,0.00030392627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013213007,0.00013151653,0.0012481667,0.00014135054,0.000021997394,0.000008671712,0.00015639495,0.0006503538,0.00054635655],"category_scores_gemma":[0.007783317,0.00008918244,0.0003908517,0.00017886897,0.00021843273,0.00012986065,0.00005775784,0.001572494,0.000034629786],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013675672,0.0011807914,0.24752788,0.000027935059,0.00013431313,0.00023552965,0.009047233,0.000005479828,0.00007769943,0.00002106788,0.006862127,0.7212043],"study_design_scores_gemma":[0.0112530645,0.020941788,0.9101134,0.0003462793,0.00009380336,0.000012841121,0.016177006,0.00006949089,0.000014909731,0.0021577005,0.038731728,0.00008799421],"about_ca_topic_score_codex":0.0008007267,"about_ca_topic_score_gemma":0.0066029015,"teacher_disagreement_score":0.7211163,"about_ca_system_score_codex":0.0006154102,"about_ca_system_score_gemma":0.0026350603,"threshold_uncertainty_score":0.93179196},"labels":[],"label_agreement":null},{"id":"W2964824480","doi":"10.1200/jco.2013.31.15_suppl.7596","title":"Can hippocampus be spared in patients with small cell lung carcinoma (SCLC) during cranial radiation therapy (CRT)?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Radiation therapy; Internal medicine; Oncology; Conventional PCI; Lung cancer; Cohort; Chemotherapy; Radiology","score_opus":0.05252542477904314,"score_gpt":0.34636593406208427,"score_spread":0.2938405092830411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964824480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365485,0.00029283398,0.000011367256,0.0047313804,0.0004896851,0.00054595,0.000004016355,0.0000052669716,0.00026465592],"genre_scores_gemma":[0.9955593,0.0002147373,0.002205115,0.0014149764,0.00049929897,0.00000940358,0.000009731159,0.000020005327,0.00006742775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975375,0.00039040367,0.0013571176,0.00018017544,0.000280194,0.00025459216],"domain_scores_gemma":[0.99766445,0.00055812194,0.0010193965,0.00016508704,0.00026514445,0.00032781003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077190675,0.00015042895,0.0009633685,0.00012865847,0.000034066965,0.000011164637,0.0000929539,0.00021210901,0.00021413986],"category_scores_gemma":[0.00027041367,0.00009361063,0.00021810934,0.000105652325,0.00006824835,0.00008117763,0.000018804481,0.000581409,0.00000652414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00379362,0.0025422338,0.9251751,0.000019304485,0.00016531456,0.0003259014,0.0001744473,0.000018083216,0.00003038554,0.000003311772,0.00037628214,0.067376025],"study_design_scores_gemma":[0.039653618,0.013093375,0.9458176,0.000035915415,0.00015764708,0.00003725278,0.000055639106,0.000037331276,0.00006297359,0.00007281814,0.00089130446,0.00008455244],"about_ca_topic_score_codex":0.00025457877,"about_ca_topic_score_gemma":0.00013203883,"teacher_disagreement_score":0.06729147,"about_ca_system_score_codex":0.00026647866,"about_ca_system_score_gemma":0.0006781329,"threshold_uncertainty_score":0.38173306},"labels":[],"label_agreement":null},{"id":"W2964828849","doi":"10.1200/jco.2013.31.15_suppl.4578","title":"Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Nephrectomy; Targeted therapy; Oncology; Disease; Demographics; Systemic therapy; Surgery; Cancer; Kidney; Breast cancer","score_opus":0.07836846042718823,"score_gpt":0.3691284710228253,"score_spread":0.29076001059563705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964828849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574804,0.0008023808,0.0000027238184,0.0024122335,0.00019848568,0.0005655156,0.000016408623,0.0000022470576,0.00025194357],"genre_scores_gemma":[0.998029,0.00026994591,0.0011869988,0.00027225085,0.00010739743,0.000009151299,0.000008169993,0.000017487591,0.000099581215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951236,0.0016682614,0.002319706,0.00020175331,0.00048435095,0.0002022947],"domain_scores_gemma":[0.9925075,0.0046981294,0.0018433966,0.00032887145,0.00041209554,0.000210015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017720355,0.00020343637,0.0016670908,0.000115850584,0.00002037784,0.0000052752002,0.00015602725,0.00024617164,0.000119438046],"category_scores_gemma":[0.00055481587,0.00009432204,0.0003191548,0.00013641226,0.00023101945,0.00008038593,0.000029870807,0.0006310515,0.0000042810584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03914465,0.003851837,0.94469565,0.000010750382,0.00024731064,0.00038383476,0.0006716405,0.000009194434,0.001393055,0.0000020817429,0.000079144185,0.009510867],"study_design_scores_gemma":[0.026360797,0.053748496,0.91768855,0.000035211375,0.00027834854,0.000020090372,0.00017883077,0.000015595391,0.0010944423,0.000049758008,0.0004588546,0.00007103867],"about_ca_topic_score_codex":0.00067023624,"about_ca_topic_score_gemma":0.000068922214,"teacher_disagreement_score":0.049896657,"about_ca_system_score_codex":0.00015266512,"about_ca_system_score_gemma":0.0005512489,"threshold_uncertainty_score":0.3846341},"labels":[],"label_agreement":null},{"id":"W2964838365","doi":"10.1200/jco.2019.37.15_suppl.11522","title":"Acupuncture versus cognitive behavioral therapy for cognitive impairment in cancer survivors with insomnia: Implications for personalized medicine.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Acupuncture; Cognition; Insomnia; Randomized controlled trial; Physical therapy; Internal medicine; Psychiatry; Alternative medicine","score_opus":0.21182875920888392,"score_gpt":0.5373651103020832,"score_spread":0.32553635109319934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964838365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688789,0.0015001377,0.00053375005,0.022110404,0.0018243134,0.004437023,0.00018383321,0.000014821835,0.0005168151],"genre_scores_gemma":[0.99087435,0.002644975,0.00042141214,0.0035919081,0.0012218663,0.0006881767,0.000048005993,0.000048378013,0.00046092374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969882,0.00023268785,0.0016348771,0.0003897634,0.00033277593,0.000421729],"domain_scores_gemma":[0.985881,0.009681166,0.0015344055,0.00011192633,0.002509048,0.00028245797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017666434,0.00032950795,0.0022133891,0.00024550816,0.00007803223,0.00000648648,0.00012061065,0.0003968285,0.00024869086],"category_scores_gemma":[0.0018501586,0.00018493336,0.0005697517,0.00028688466,0.00057795184,0.00012801425,0.00002951694,0.00084798934,0.000004004254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29089454,0.005606907,0.5882112,0.00010520514,0.0031038704,0.0000423323,0.0020395615,0.000009510256,0.00012016992,0.000087035274,0.003659438,0.10612023],"study_design_scores_gemma":[0.16484018,0.13611276,0.6703442,0.00101567,0.0023725068,0.000070702015,0.005804947,0.000021559903,0.00004984478,0.00015152455,0.018980145,0.00023600485],"about_ca_topic_score_codex":0.00016152213,"about_ca_topic_score_gemma":0.0012933612,"teacher_disagreement_score":0.13050586,"about_ca_system_score_codex":0.0005008797,"about_ca_system_score_gemma":0.0020963321,"threshold_uncertainty_score":0.7541363},"labels":[],"label_agreement":null},{"id":"W2964860937","doi":"10.1200/jco.2013.31.15_suppl.e12505","title":"An analysis of the temporal, age, and gender trends in human papillomavirus virus (HPV)-related versus non-HPV-related head and neck cancers (HNC) in Alberta, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Incidence (geometry); Cervix; Anal cancer; Cancer registry; Population; Cancer; Head and neck cancer; Cervical cancer; Gynecology; Internal medicine; Oncology","score_opus":0.09346906454284695,"score_gpt":0.445928627416164,"score_spread":0.35245956287331703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964860937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177766,0.00085531897,2.561027e-7,0.003663216,0.00051052397,0.00014617595,0.000006016103,0.0000022900097,0.0030385444],"genre_scores_gemma":[0.99754906,0.0011484704,0.000054036405,0.000906899,0.00007449167,0.0000053515228,0.0000047088856,0.000013641489,0.0002433161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963738,0.00041561647,0.0023403896,0.00026285666,0.00030611065,0.0003012759],"domain_scores_gemma":[0.9973457,0.0009095163,0.0010362718,0.0002298532,0.00014263536,0.00033601516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010757206,0.0001866906,0.0021638656,0.00040247984,0.00006283804,0.000007564382,0.00015075596,0.0003677009,0.00034538645],"category_scores_gemma":[0.000367317,0.00012118068,0.00023326783,0.0008065269,0.00037292787,0.00011326616,0.000048869017,0.0010055094,5.814172e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017277928,0.0006348966,0.94157004,0.000024937639,0.002371602,0.00047137516,0.0014976762,0.00023236219,0.00029316658,0.000039914703,0.0033859785,0.047750235],"study_design_scores_gemma":[0.01181837,0.0035821698,0.98020005,0.00005566554,0.0009905711,0.000017000755,0.00030862834,0.0008687164,0.000016398972,0.00008033301,0.0019454857,0.000116631774],"about_ca_topic_score_codex":0.69145083,"about_ca_topic_score_gemma":0.96838087,"teacher_disagreement_score":0.27693006,"about_ca_system_score_codex":0.0004481925,"about_ca_system_score_gemma":0.0015867923,"threshold_uncertainty_score":0.49416047},"labels":[],"label_agreement":null},{"id":"W2964966490","doi":"10.1200/jco.2013.31.15_suppl.9550","title":"Local tumor control and survival outcomes of percutaneous radiofrequency ablation plus post-ablation chemotherapy for lung tumors in nonsurgical patients: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Radiofrequency ablation; Ablation; Chemotherapy; Brachytherapy; Percutaneous; Surgery; Lung; Radiology; Radiation therapy; Internal medicine","score_opus":0.05191714346333999,"score_gpt":0.4331676939418489,"score_spread":0.3812505504785089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964966490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848446,0.00068532384,0.0038453722,0.008888693,0.00022083303,0.0010518658,0.000034012042,0.0000053732992,0.0004239051],"genre_scores_gemma":[0.9957443,0.000067858186,0.0025773433,0.0013791841,0.00007693266,0.00002241438,0.000019117833,0.000012665335,0.00010021957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693143,0.00019664422,0.0022246204,0.00018283552,0.00029539887,0.00016905906],"domain_scores_gemma":[0.9945373,0.0027598483,0.0014285247,0.00012200913,0.00095521985,0.000197085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012376041,0.00014626209,0.0028907766,0.00024606354,0.000026424521,0.0000094521665,0.000064869695,0.00016844145,0.00027010706],"category_scores_gemma":[0.0012617749,0.000089791494,0.0011088168,0.00017930244,0.00014649707,0.00016662334,0.000007461262,0.0002863417,0.0000012497642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055543566,0.0034147394,0.8595972,0.00007490861,0.08765188,0.00019843693,0.00058821077,0.0015431137,0.0000749366,0.0003368401,0.00025529345,0.04071006],"study_design_scores_gemma":[0.019016054,0.005601413,0.90826374,0.000009855201,0.057735037,0.000093597846,0.00015491125,0.008428406,0.000003876534,0.00021983901,0.00037732563,0.000095941934],"about_ca_topic_score_codex":0.00027294442,"about_ca_topic_score_gemma":0.000090649024,"teacher_disagreement_score":0.048666522,"about_ca_system_score_codex":0.0002598291,"about_ca_system_score_gemma":0.0007443494,"threshold_uncertainty_score":0.36615908},"labels":[],"label_agreement":null},{"id":"W2965042402","doi":"10.1200/jco.2012.30.15_suppl.3082","title":"A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Tolerability; Nausea; Vomiting; Internal medicine; Pharmacokinetics; Gastroenterology; Adverse effect; Toxicity; Oncology; Pharmacology; Cancer","score_opus":0.07258309049514548,"score_gpt":0.4835584636050948,"score_spread":0.4109753731099493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965042402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791265,0.00009153243,0.000010702763,0.0004555358,0.000489027,0.00087581156,0.0000053426656,0.000006301166,0.00015312707],"genre_scores_gemma":[0.99849665,0.000029009007,0.0006796503,0.0003987045,0.00030857587,0.000020447449,0.000023983132,0.000022435112,0.000020535883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963291,0.0006584269,0.0020493984,0.0002023986,0.00042013227,0.00034048708],"domain_scores_gemma":[0.9968739,0.00051410863,0.001612452,0.00016613674,0.0004382853,0.0003951201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001804409,0.0001988215,0.0017206768,0.00035711788,0.000020322655,0.000003439385,0.00010975601,0.00017457905,0.00009864436],"category_scores_gemma":[0.00031403697,0.00012989057,0.000097597826,0.00036091483,0.00015699449,0.00040064604,0.00003076937,0.0008005569,0.000002047898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06151166,0.12185087,0.7865595,0.000022304905,0.00020503957,0.00038815592,0.0008351589,0.000047808146,0.000086046086,0.000007910978,0.000106831416,0.028378708],"study_design_scores_gemma":[0.16436672,0.21874067,0.61519957,0.0000825048,0.0003267112,0.000037477996,0.00040857852,0.00003895564,0.000108324704,0.000013006355,0.00058437296,0.00009309961],"about_ca_topic_score_codex":0.000075808726,"about_ca_topic_score_gemma":0.0007411373,"teacher_disagreement_score":0.17135993,"about_ca_system_score_codex":0.00029155728,"about_ca_system_score_gemma":0.000864164,"threshold_uncertainty_score":0.5296784},"labels":[],"label_agreement":null},{"id":"W2965046842","doi":"10.1200/jco.2013.31.15_suppl.4524","title":"Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Nomogram; Medicine; Internal medicine; Oncology; Hazard ratio; Anemia; Overall survival; Progression-free survival; Confidence interval","score_opus":0.1046274200903648,"score_gpt":0.49395154282305276,"score_spread":0.38932412273268796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965046842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815417,0.00025528378,0.0008131681,0.013997127,0.0010856899,0.0011765852,0.000018268976,0.0000070633096,0.0011051485],"genre_scores_gemma":[0.9881691,0.00010753346,0.0064918576,0.0035108086,0.0010745365,0.00006533079,0.0000010973663,0.000022517605,0.0005572197],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979014,0.00018356334,0.0012582327,0.00016601053,0.00023117417,0.0002596553],"domain_scores_gemma":[0.99629414,0.0015993157,0.0009563333,0.00024760238,0.000597644,0.00030495776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001216276,0.00014709664,0.0011980023,0.00006466119,0.000048701357,0.000007553118,0.00020104197,0.00019874194,0.0004266901],"category_scores_gemma":[0.000925593,0.00007845636,0.0005670233,0.00010041719,0.00014675554,0.000100005556,0.000033419376,0.0004348892,0.000016470818],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018702187,0.0025411833,0.026840646,0.000037545593,0.00054152106,0.000031174044,0.00018234708,0.000027762308,0.012813323,0.000045788944,0.004107073,0.9341295],"study_design_scores_gemma":[0.030784959,0.07957045,0.77125454,0.000064658394,0.0003779736,0.0001596321,0.0000725427,0.00017856201,0.015823139,0.0011600133,0.1004021,0.00015140734],"about_ca_topic_score_codex":0.000050746687,"about_ca_topic_score_gemma":0.00005156886,"teacher_disagreement_score":0.933978,"about_ca_system_score_codex":0.00006996874,"about_ca_system_score_gemma":0.0010880161,"threshold_uncertainty_score":0.46719572},"labels":[],"label_agreement":null},{"id":"W2965053910","doi":"10.1200/jco.2012.30.15_suppl.8587","title":"A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Docetaxel; Medicine; Tolerability; Clinical endpoint; Internal medicine; Phases of clinical research; Oncology; Melanoma; Gastroenterology; Survivin; Survival rate; Progression-free survival; Surgery; Chemotherapy; Adverse effect; Clinical trial; Cancer; Cancer research","score_opus":0.28348017463377767,"score_gpt":0.5572430561771021,"score_spread":0.27376288154332445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965053910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932772,0.00060636614,0.0000194236,0.000968119,0.0013839054,0.0014731529,0.000017171318,0.0000075754733,0.0022471044],"genre_scores_gemma":[0.9895561,0.00044179033,0.0010958604,0.00093770784,0.0007294333,0.000035461915,0.000004646872,0.000029759874,0.007169248],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995361,0.0008053636,0.002591457,0.0002695605,0.00043908542,0.00053356437],"domain_scores_gemma":[0.994414,0.0020617247,0.0022735463,0.00028515124,0.00034238887,0.000623214],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037903308,0.00025522133,0.0026426306,0.00028617197,0.000064483815,0.000010836473,0.00039044372,0.00028508014,0.001124736],"category_scores_gemma":[0.000766563,0.00014157503,0.00014261143,0.00036988079,0.0001952102,0.00040848725,0.00025323048,0.0011576525,0.0000073731544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33772662,0.32877254,0.2951405,0.00012023379,0.0022552924,0.0050886194,0.0047798716,0.000021113008,0.0010183336,0.00002432618,0.0032744068,0.02177816],"study_design_scores_gemma":[0.5718801,0.32656002,0.051285885,0.00015924111,0.0013659864,0.00019963947,0.0031902771,0.00021440306,0.0002963662,0.0000037696052,0.04464622,0.00019811718],"about_ca_topic_score_codex":0.0006526505,"about_ca_topic_score_gemma":0.003927561,"teacher_disagreement_score":0.24385461,"about_ca_system_score_codex":0.0004010287,"about_ca_system_score_gemma":0.002429325,"threshold_uncertainty_score":0.99978834},"labels":[],"label_agreement":null},{"id":"W2965079697","doi":"10.1200/jco.2013.31.15_suppl.e19520","title":"Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma (DLBCL) in clinical trials.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Internal medicine; Clinical trial; Comorbidity; Oncology; Malignancy; Refractory (planetary science); Lymphoma; Surgery","score_opus":0.09385969368676302,"score_gpt":0.4560352599266496,"score_spread":0.3621755662398866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965079697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252415,0.00026016118,0.000018897808,0.0039311084,0.0014189968,0.0010393789,0.000016651082,0.0000050132826,0.0007856712],"genre_scores_gemma":[0.9935637,0.0005653705,0.0018418127,0.0034440416,0.000454465,0.000037597532,0.0000058282167,0.000020041554,0.000067127345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9900981,0.0019224096,0.0066612447,0.0003099345,0.00063203694,0.00037625845],"domain_scores_gemma":[0.9881055,0.005855225,0.003354533,0.00033431713,0.00068822084,0.0016622265],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0097694285,0.0002260218,0.003509912,0.0002215907,0.000026782056,0.000010368951,0.00020369102,0.00043300993,0.00037504575],"category_scores_gemma":[0.015354121,0.00012766769,0.0009250767,0.00020455937,0.00013244865,0.000103444756,0.000091099646,0.00043697353,0.00006293183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084799435,0.056720752,0.7419196,0.000021147816,0.00035653677,0.00015814127,0.00009583268,0.0000012543288,0.0000025720985,0.000024177887,0.006655895,0.18556415],"study_design_scores_gemma":[0.14926483,0.033824716,0.78511745,0.00016982216,0.00041138087,0.000009430832,0.000110858426,0.00001868667,0.000034375404,0.00004114809,0.030897873,0.000099429526],"about_ca_topic_score_codex":0.00004038355,"about_ca_topic_score_gemma":0.00004719199,"teacher_disagreement_score":0.18546471,"about_ca_system_score_codex":0.000389807,"about_ca_system_score_gemma":0.002193759,"threshold_uncertainty_score":0.99293995},"labels":[],"label_agreement":null},{"id":"W2965089209","doi":"10.1200/jco.2013.31.15_suppl.e14598","title":"Palliative chemotherapy in advanced colorectal cancer patients age 80 or older.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Discontinuation; Internal medicine; Cancer; Cancer registry; Population; Surgery","score_opus":0.0835400269780549,"score_gpt":0.4760355871633287,"score_spread":0.3924955601852738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965089209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887409,0.0006472128,0.0000030124427,0.0055520595,0.0010074757,0.0005464687,0.0000035489193,0.000006513525,0.0034927719],"genre_scores_gemma":[0.9910506,0.0040200884,0.0008987213,0.0028993518,0.0004163832,0.00006423342,0.0000017144725,0.00001550185,0.00063342944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764884,0.00014374334,0.001508279,0.00018258291,0.00026780574,0.0002487463],"domain_scores_gemma":[0.99726987,0.0010056667,0.00096111494,0.0000725044,0.00047058443,0.00022025836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041064827,0.00015515811,0.0014514546,0.00008475676,0.00003154096,0.000006856644,0.00009735462,0.0002146572,0.0010018258],"category_scores_gemma":[0.0011001256,0.00008822843,0.00028038071,0.00017015918,0.00015402705,0.00011577256,0.00003474035,0.000561081,0.000016332393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008930119,0.0027455676,0.5787851,0.00001537207,0.00037477544,0.00026656679,0.00054268737,0.000002271183,0.00006714769,0.000003990046,0.0036191272,0.40464726],"study_design_scores_gemma":[0.020929977,0.018043987,0.9458917,0.00014049676,0.000091436785,0.000008371645,0.00021540112,0.000011897487,0.00008919163,0.000092645605,0.0143976975,0.00008722084],"about_ca_topic_score_codex":0.00014677622,"about_ca_topic_score_gemma":0.0009332731,"teacher_disagreement_score":0.40456003,"about_ca_system_score_codex":0.00046268626,"about_ca_system_score_gemma":0.000814803,"threshold_uncertainty_score":0.99991137},"labels":[],"label_agreement":null},{"id":"W2965135759","doi":"10.1200/jco.2013.31.15_suppl.e20619","title":"Tumor-related symptoms (TRS) assessment in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with gefitinib or erlotinib: Preliminary results of an observational study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Erlotinib; Internal medicine; Lung cancer; Proportional hazards model; Oncology; Performance status; McNemar's test; Cancer; Epidermal growth factor receptor","score_opus":0.06981059494776864,"score_gpt":0.45693360202099204,"score_spread":0.3871230070732234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965135759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954018,0.000053024214,0.000014162666,0.00081081537,0.00022484448,0.0020672693,0.000032232558,0.000012247081,0.0013836337],"genre_scores_gemma":[0.9930462,0.00004288794,0.005637163,0.00039965662,0.00011534466,0.000143313,0.000060225528,0.00003642454,0.0005187806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581593,0.000328352,0.002685298,0.00034923226,0.0005349677,0.00028622098],"domain_scores_gemma":[0.9943623,0.000974186,0.0026720155,0.00026458828,0.0013831991,0.0003437031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007903194,0.0002455023,0.00137907,0.00018218608,0.000048414073,0.000010992679,0.00016673096,0.00018086635,0.00014901145],"category_scores_gemma":[0.00025623335,0.00013559386,0.0001297858,0.0003634166,0.00012544956,0.00032443213,0.000032315187,0.00072658877,0.0000023239384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032312535,0.017507954,0.9202297,0.000052369425,0.00087362685,0.00040069997,0.0006024022,0.0011716164,0.000024925306,0.0000035275098,0.000231557,0.026589138],"study_design_scores_gemma":[0.07066052,0.12291108,0.80328053,0.00049347675,0.0010281065,0.000028895254,0.00066119526,0.00065027253,0.000024681454,0.0000050537933,0.0001305608,0.00012561512],"about_ca_topic_score_codex":0.0005214346,"about_ca_topic_score_gemma":0.00040598345,"teacher_disagreement_score":0.11694911,"about_ca_system_score_codex":0.00046253417,"about_ca_system_score_gemma":0.0043151113,"threshold_uncertainty_score":0.7654822},"labels":[],"label_agreement":null},{"id":"W2965166345","doi":"10.1200/jco.2012.30.15_suppl.e19566","title":"External validation of the simple prognostic score in a palliative care clinic at a comprehensive cancer center.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Log-rank test; Palliative care; Breast cancer; Internal medicine; Performance status; Clinical endpoint; Overall survival; Surgery; Oncology; Clinical trial","score_opus":0.24885206055586007,"score_gpt":0.5152777528009552,"score_spread":0.26642569224509516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965166345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442905,0.0013300714,0.00005463073,0.0018420556,0.001128249,0.0005495146,0.000015818372,0.0000028083816,0.0006477765],"genre_scores_gemma":[0.996472,0.00035502488,0.0007793204,0.00179455,0.00044881404,0.00001136773,0.0000047813937,0.000012070243,0.00012207395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962037,0.00078779645,0.0021434408,0.00012667243,0.0005002896,0.00023809652],"domain_scores_gemma":[0.99473137,0.0018046572,0.0024695955,0.00019925117,0.0005363674,0.00025876623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013595461,0.00011907717,0.00102848,0.00009020618,0.000025260819,0.0000031586549,0.00018073413,0.00013170941,0.00059790356],"category_scores_gemma":[0.0034135533,0.000072974195,0.00045578636,0.00015499591,0.00019051299,0.00009548563,0.00014664103,0.0005639122,0.000014850697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023378925,0.0015912092,0.9816421,0.00019718948,0.00020560613,0.000060520037,0.0006982159,0.000019547679,0.000059826125,0.00001658916,0.0014504372,0.011720865],"study_design_scores_gemma":[0.007977484,0.0016670611,0.980575,0.00048038986,0.00062910776,0.000015323956,0.00078001944,0.000032748776,0.00010328202,0.00009932399,0.0075811627,0.000059097227],"about_ca_topic_score_codex":0.00002171192,"about_ca_topic_score_gemma":0.00004420203,"teacher_disagreement_score":0.011661767,"about_ca_system_score_codex":0.00025628493,"about_ca_system_score_gemma":0.00065070216,"threshold_uncertainty_score":0.65466243},"labels":[],"label_agreement":null},{"id":"W2965178062","doi":"10.1200/jco.2012.30.15_suppl.6043","title":"Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Clinical endpoint; Breast cancer; Randomized controlled trial; Publication bias; Selection bias; Protocol (science); Reporting bias; Toxicity; Meta-analysis; Oncology; Cancer; MEDLINE; Alternative medicine; Pathology","score_opus":0.92882046466475,"score_gpt":0.7182021969669887,"score_spread":0.21061826769776126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965178062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944266,0.00063414744,0.0011795665,0.0015719151,0.00065648585,0.0010166373,0.000008031545,4.645968e-7,0.00050616794],"genre_scores_gemma":[0.992729,0.00042341018,0.0059974487,0.00021268838,0.0004296093,0.000026400452,1.8676783e-7,0.000007044055,0.00017419424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.5319846,0.19445242,0.2671434,0.0009945291,0.0046313186,0.0007937443],"domain_scores_gemma":[0.19323535,0.5446665,0.25732237,0.0012079313,0.0029008612,0.0006669488],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.8788815,0.00018912808,0.028984735,0.0004443476,0.000016637408,0.0000290023,0.00058866484,0.00034468345,0.0009814161],"category_scores_gemma":[0.84547335,0.000074603486,0.002954031,0.00058214273,0.0003849266,0.0002340648,0.00008518843,0.00056340476,0.000004013981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06809904,0.0014836346,0.7067532,0.00007675503,0.00081174297,0.000014366655,0.0005388939,0.000055857687,0.000038935905,0.00010668688,0.00085822,0.22116265],"study_design_scores_gemma":[0.14083715,0.0019016458,0.8481374,0.00038261397,0.00084030343,0.00010342041,0.00074503815,0.00078440504,0.000035744448,0.0024745578,0.0036228574,0.00013490503],"about_ca_topic_score_codex":0.000039529663,"about_ca_topic_score_gemma":0.00016879404,"teacher_disagreement_score":0.35021412,"about_ca_system_score_codex":0.00006152335,"about_ca_system_score_gemma":0.0009574159,"threshold_uncertainty_score":0.9999318},"labels":[],"label_agreement":null},{"id":"W2965188025","doi":"10.1200/jco.2012.30.15_suppl.6066","title":"Utility of positron emission tomography (PET) scans on the management of cancers of unknown primary.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Concordance; Positron emission tomography; Nuclear medicine; Primary tumor; Lymph node; Radiology; PET-CT; Cancer; Stage (stratigraphy); Metastasis; Internal medicine","score_opus":0.10406582998626833,"score_gpt":0.45294115300404053,"score_spread":0.3488753230177722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965188025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778119,0.001599403,0.00001578228,0.003857969,0.0006084742,0.00024700406,0.0000073977235,0.0000017662104,0.01585035],"genre_scores_gemma":[0.9953567,0.00299244,0.0008577927,0.0004850138,0.00021429567,0.0000039538977,0.0000012701147,0.0000066822154,0.000081894585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974436,0.00021733771,0.0016760483,0.000097391625,0.00040487526,0.00016074801],"domain_scores_gemma":[0.99640113,0.0011047906,0.0018158694,0.00024929087,0.00023288027,0.00019604167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002105129,0.00009788458,0.0010746802,0.0000842237,0.000017302822,9.74535e-7,0.0001335012,0.000098152,0.00021603733],"category_scores_gemma":[0.00013587881,0.00005242228,0.00061857514,0.00015829735,0.00024449232,0.0000397803,0.00004609096,0.0003081368,7.2441964e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007228289,0.0080649555,0.7850525,0.0003585247,0.002260229,0.000051732208,0.0001548385,0.00001135631,0.0003450567,0.0011992778,0.009766677,0.18550661],"study_design_scores_gemma":[0.003887943,0.00783202,0.95826626,0.0006331862,0.0010995643,0.000021170488,0.000119216544,0.0000079295105,0.003133123,0.0000980227,0.024861196,0.0000403723],"about_ca_topic_score_codex":0.000103423714,"about_ca_topic_score_gemma":0.000020436377,"teacher_disagreement_score":0.18546624,"about_ca_system_score_codex":0.00015490096,"about_ca_system_score_gemma":0.00047728114,"threshold_uncertainty_score":0.23654571},"labels":[],"label_agreement":null},{"id":"W2965208661","doi":"10.1200/jco.2007.25.18_suppl.6542","title":"Descriptive study on the lost productivity in breast cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Cancer; Quality of life (healthcare); Cohort; Disease; Metastatic breast cancer; Stage (stratigraphy); Productivity; Family medicine; Gerontology; Pediatrics; Gynecology; Physical therapy; Internal medicine; Nursing","score_opus":0.1641680172333427,"score_gpt":0.4021810958168167,"score_spread":0.238013078583474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965208661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763106,0.0001658171,0.000048950435,0.0070059323,0.0027387908,0.00027888804,0.00003168287,0.0000021265837,0.013417231],"genre_scores_gemma":[0.9969768,0.00014703663,0.00003402171,0.0016040892,0.0010639459,0.000003663174,1.7882647e-7,0.000012608471,0.00015768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676895,0.0001076922,0.0025406554,0.00023913397,0.00006081659,0.0002827555],"domain_scores_gemma":[0.9960324,0.00093514833,0.002524011,0.00018437425,0.00018419258,0.00013988289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00912476,0.00012224965,0.0010269445,0.0001785202,0.000043355754,0.000017020175,0.00030851862,0.00018284221,0.00021690091],"category_scores_gemma":[0.0023733082,0.00008870682,0.00021374924,0.00017658818,0.00014656466,0.00027421836,0.000047598383,0.00087988656,0.000118083626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011592438,0.0032617087,0.96530634,0.0000016414299,0.00008199715,0.000022145165,0.000525874,0.000016915663,5.698541e-7,0.0040128212,0.0018669481,0.02374377],"study_design_scores_gemma":[0.002417496,0.0027876801,0.9733346,0.00001561113,0.000010134615,0.0000036417248,0.00031644487,0.000006199227,0.0000036984948,0.004188739,0.016816212,0.000099521974],"about_ca_topic_score_codex":0.00032512328,"about_ca_topic_score_gemma":0.00075205095,"teacher_disagreement_score":0.023644246,"about_ca_system_score_codex":0.00055068784,"about_ca_system_score_gemma":0.0002918604,"threshold_uncertainty_score":0.38227183},"labels":[],"label_agreement":null},{"id":"W2965233712","doi":"10.1200/jco.2009.27.15_suppl.e19058","title":"Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Brain metastasis; Lung cancer; Oncology; Internal medicine; Cancer; Brain tumor; Metastasis; Pathology","score_opus":0.0587584564734445,"score_gpt":0.4711835553795538,"score_spread":0.4124250989061093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965233712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923368,0.0010430954,0.00014575025,0.004880802,0.0002446389,0.00027232736,0.00006693205,0.0000029447617,0.0010067137],"genre_scores_gemma":[0.9914321,0.00038512386,0.0060270666,0.00162015,0.00023054333,0.0000040891086,0.00001330161,0.000008249994,0.00027941522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984072,0.00009517884,0.0010990406,0.00013198522,0.00014641958,0.00012021893],"domain_scores_gemma":[0.99761933,0.0007717516,0.0010226072,0.000111163135,0.00024587451,0.00022924358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022245651,0.000117795134,0.0010548278,0.00006218026,0.000022787708,0.000004077336,0.000046351783,0.00010659451,0.00007889075],"category_scores_gemma":[0.00015600299,0.00006354389,0.00019084361,0.00005696531,0.00006652016,0.000056325804,0.000008431621,0.00017400041,8.3845447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020431185,0.0030384834,0.90006715,0.0000127890735,0.0007985495,0.000100074794,0.00022121746,0.000017166964,0.000032588792,0.00000780474,0.0006470904,0.09301396],"study_design_scores_gemma":[0.023146974,0.022494271,0.9433479,0.000072486866,0.0028942178,0.00000740538,0.00006546896,0.00002431378,0.00010867484,0.00003407221,0.007743588,0.000060667535],"about_ca_topic_score_codex":0.00020881396,"about_ca_topic_score_gemma":0.000095982636,"teacher_disagreement_score":0.09295329,"about_ca_system_score_codex":0.00016844514,"about_ca_system_score_gemma":0.00082355307,"threshold_uncertainty_score":0.2591245},"labels":[],"label_agreement":null},{"id":"W2965274063","doi":"10.1200/jco.2006.24.18_suppl.3081","title":"A phase I study of the pan-Bcl2 family inhibitor GX15–070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Adverse effect; Gastroenterology; Refractory (planetary science); Internal medicine; Pharmacology; Tolerability","score_opus":0.0772347158560779,"score_gpt":0.45532943602886095,"score_spread":0.37809472017278306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965274063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623924,0.00007633805,0.000002812281,0.00068978337,0.0006637185,0.0010965923,0.000005419331,0.000009189478,0.0012168885],"genre_scores_gemma":[0.9975151,0.00003460103,0.00016906162,0.0006852668,0.00092163903,0.000012996693,0.0000027887122,0.00004085424,0.0006177389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99244523,0.0011287107,0.0040546297,0.0003457017,0.0015658964,0.00045982387],"domain_scores_gemma":[0.9928695,0.0024903796,0.0028528192,0.00056330627,0.00087328145,0.00035072296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003037291,0.00025802338,0.002064434,0.00030291625,0.00006202527,0.000013851564,0.00046259185,0.0004159115,0.000069497815],"category_scores_gemma":[0.0049904995,0.00013174483,0.00033712288,0.00055603316,0.00041735507,0.00015014721,0.00024477483,0.0012673689,0.00001290207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25830656,0.17842515,0.43045533,0.00022156123,0.00074873515,0.008952457,0.0018176057,0.000052261723,0.0010799863,0.000013426587,0.008931716,0.110995226],"study_design_scores_gemma":[0.26365504,0.18157357,0.54741555,0.00054637576,0.00025634386,0.00028532528,0.0014974572,0.00012787752,0.00015945801,0.000036851005,0.0043034656,0.00014268344],"about_ca_topic_score_codex":0.0006083096,"about_ca_topic_score_gemma":0.0006867945,"teacher_disagreement_score":0.11696025,"about_ca_system_score_codex":0.0049772495,"about_ca_system_score_gemma":0.034143243,"threshold_uncertainty_score":0.9988425},"labels":[],"label_agreement":null},{"id":"W2965308822","doi":"10.1200/jco.2009.27.15_suppl.6627","title":"Characterization of published errors in high-impact oncology journals","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Citation; Clinical Oncology; Statistics; Internal medicine; Library science; Cancer; Computer science; Mathematics","score_opus":0.8010223464168651,"score_gpt":0.6690094960107177,"score_spread":0.1320128504061474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965308822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711463,0.00023120354,0.002424534,0.02002346,0.0016577803,0.00024270464,0.0000052585033,0.0000011565144,0.004267614],"genre_scores_gemma":[0.99282026,0.00028868302,0.0037574386,0.0018564387,0.00068397104,0.0000011716307,0.0000023453217,0.000006562132,0.0005831141],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.89875877,0.03640741,0.058911726,0.0006056326,0.004906509,0.00040993522],"domain_scores_gemma":[0.8980349,0.020920254,0.07372016,0.0015855967,0.005106287,0.00063284836],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3557225,0.00023557057,0.011943184,0.0013022325,0.000035759243,0.00018765558,0.0020540396,0.0006198977,0.010940055],"category_scores_gemma":[0.25343615,0.00010587153,0.003974365,0.0017749928,0.00013287169,0.00092599227,0.0000688727,0.0011815929,0.0001791586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000818306,0.0027307363,0.2696748,0.000010922446,0.0005467635,0.00027035575,0.00039457413,0.00034669015,0.004530171,0.00081020675,0.030709745,0.6891567],"study_design_scores_gemma":[0.0018440686,0.0052216914,0.9093535,0.00005371227,0.00021463168,0.00015000298,0.00012134086,0.00043111196,0.000038378384,0.012459962,0.07001342,0.000098158795],"about_ca_topic_score_codex":0.000009657696,"about_ca_topic_score_gemma":0.000042279426,"teacher_disagreement_score":0.68905854,"about_ca_system_score_codex":0.00019129367,"about_ca_system_score_gemma":0.0018249823,"threshold_uncertainty_score":0.98996407},"labels":[],"label_agreement":null},{"id":"W2965320815","doi":"10.1200/jco.2007.25.18_suppl.17005","title":"Time to treat: A system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis in a community hospital","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto East General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Referral; Lung cancer; Cancer; Pediatrics; Radiological weapon; Surgery; Emergency medicine; Internal medicine; Family medicine","score_opus":0.15395276471591696,"score_gpt":0.4924760550776181,"score_spread":0.33852329036170115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965320815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986595,0.0003513235,0.00023091419,0.009792621,0.0002947914,0.00039312785,0.00000619598,0.000008045643,0.0023280175],"genre_scores_gemma":[0.9939097,0.000038370465,0.002331289,0.0028279491,0.00082276884,0.0000073345027,9.1900324e-7,0.000013676538,0.00004795708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630713,0.0008952311,0.0019193674,0.00014485432,0.00045166953,0.00028174277],"domain_scores_gemma":[0.9911399,0.0068824035,0.0009603998,0.00026502437,0.0003607057,0.0003915771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008005034,0.00013628251,0.0012505819,0.00017755556,0.00007871838,0.000009951828,0.00028389084,0.0002549772,0.00011223355],"category_scores_gemma":[0.005027601,0.000088659384,0.00028192298,0.00033405694,0.00009319085,0.00007653945,0.0000783716,0.0010289778,0.000026521753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03606514,0.003120783,0.5626285,0.000106188345,0.0005196595,0.0019673891,0.005265536,0.00090999773,0.0034037852,0.000059118032,0.018952949,0.36700097],"study_design_scores_gemma":[0.006247099,0.02818353,0.9484261,0.0071986876,0.00074122526,0.00011731024,0.0025408124,0.00054007734,0.0020514873,0.000066793036,0.003657787,0.00022906491],"about_ca_topic_score_codex":0.0036982375,"about_ca_topic_score_gemma":0.00057509786,"teacher_disagreement_score":0.38579765,"about_ca_system_score_codex":0.0009320056,"about_ca_system_score_gemma":0.00066237594,"threshold_uncertainty_score":0.6018871},"labels":[],"label_agreement":null},{"id":"W2965340556","doi":"10.1200/jco.2006.24.18_suppl.7014","title":"Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Radiosurgery; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Adverse effect; Neurocognitive; Brain metastasis; Gastroenterology; Cancer; Oncology; Radiation therapy; Randomized controlled trial; Metastasis; Confidence interval","score_opus":0.032662869314627904,"score_gpt":0.39587852073723445,"score_spread":0.36321565142260653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965340556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97631687,0.00026347896,0.00012630557,0.018604467,0.00021357829,0.004243334,0.00007592579,0.000012449205,0.00014359954],"genre_scores_gemma":[0.9915964,0.000031276602,0.0043198005,0.0029689742,0.00048720284,0.00012458011,0.00011806522,0.00004110776,0.00031259158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943387,0.0012887208,0.0029005632,0.00045402336,0.000609664,0.00040831167],"domain_scores_gemma":[0.99377143,0.0019076178,0.0032063955,0.00030568382,0.00050511205,0.0003037318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042065196,0.00032158685,0.0020621188,0.00030059673,0.000044790475,0.000015112566,0.00019163334,0.00030337885,0.000060839386],"category_scores_gemma":[0.0008644269,0.00017994437,0.0002975,0.0004405793,0.00015906958,0.00012311019,0.00004010037,0.0007656076,0.000004901414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8287749,0.033015147,0.027915748,0.00006327535,0.00037966328,0.0006688163,0.00021561976,0.00046146952,0.00037323695,0.0000021616115,0.012801556,0.0953284],"study_design_scores_gemma":[0.6085,0.27957368,0.10034211,0.0002888571,0.00051158486,0.000024435745,0.000016655244,0.00065448333,0.00041426168,0.000015421152,0.009467789,0.00019069017],"about_ca_topic_score_codex":0.00012835284,"about_ca_topic_score_gemma":0.0001162772,"teacher_disagreement_score":0.24655855,"about_ca_system_score_codex":0.0001518795,"about_ca_system_score_gemma":0.0015417455,"threshold_uncertainty_score":0.7337919},"labels":[],"label_agreement":null},{"id":"W2965347800","doi":"10.1200/jco.2006.24.18_suppl.14544","title":"Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Placebo; Bone pain; Performance status; Internal medicine; Physical therapy; Cancer; Chronic pain","score_opus":0.02284726653465142,"score_gpt":0.3886034970333,"score_spread":0.3657562304986486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965347800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707705,0.00020093987,0.000032971635,0.0009561974,0.00022925845,0.00066119834,0.00002439924,0.000006228978,0.0008117744],"genre_scores_gemma":[0.99732363,0.00009735517,0.0007977581,0.00153181,0.0001054493,0.000022094124,0.000019509042,0.00002181526,0.00008058878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952793,0.0014267215,0.0019609847,0.00020885223,0.00079153886,0.0003325974],"domain_scores_gemma":[0.9950344,0.0024656912,0.0018031648,0.00022021642,0.00024042683,0.00023612972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007084189,0.00019991434,0.0015480467,0.00032062503,0.000018375555,0.000004796738,0.00009849218,0.00008608838,0.00015172493],"category_scores_gemma":[0.002088694,0.00011929105,0.00025131405,0.00022786763,0.00015385674,0.00008504343,0.000019231513,0.0006458926,0.000006133331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058729813,0.0058581824,0.6716187,0.00041268492,0.000158957,0.00039891675,0.000009998273,0.0022722008,0.000011712671,0.000009875014,0.0013828615,0.25913608],"study_design_scores_gemma":[0.042868428,0.16232495,0.7839303,0.00088353566,0.00074049045,0.000002466143,0.000011683294,0.0027849688,0.00033086163,0.000011727706,0.0059857,0.00012487642],"about_ca_topic_score_codex":0.000039816,"about_ca_topic_score_gemma":0.000041444626,"teacher_disagreement_score":0.2590112,"about_ca_system_score_codex":0.00022180051,"about_ca_system_score_gemma":0.00089128915,"threshold_uncertainty_score":0.48645476},"labels":[],"label_agreement":null},{"id":"W2965353248","doi":"10.1200/jco.2019.37.15_suppl.11604","title":"Phase 2 trial of Symptom screening with Targeted Early Palliative care (STEP) for patients with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University Health Network; Kingston Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nausea; Quality of life (healthcare); Clinical endpoint; Palliative care; Anxiety; Randomized controlled trial; Cancer; Physical therapy; Outpatient clinic; Clinical trial; Internal medicine; Lung cancer","score_opus":0.06337400976069466,"score_gpt":0.45862716969506206,"score_spread":0.3952531599343674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965353248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953249,0.00039454649,0.0009145859,0.00042252822,0.0013635174,0.001140901,0.00006142899,0.000006598177,0.00037097486],"genre_scores_gemma":[0.99407035,0.00009907537,0.0046184883,0.0003779929,0.0006722744,0.000026346237,0.000017932134,0.00002702711,0.00009052371],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997529,0.00015560591,0.001391984,0.00020917684,0.0004899172,0.00022437402],"domain_scores_gemma":[0.9940679,0.0012707816,0.0022467226,0.00017774726,0.001980178,0.00025663385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055592984,0.00015686244,0.0016118807,0.00008745652,0.000025992395,0.0000047197723,0.00013072827,0.00023189702,0.00007129869],"category_scores_gemma":[0.0005188289,0.000095353214,0.00035188274,0.0001602982,0.00012114551,0.00011717938,0.000018716764,0.0005421301,9.690915e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54072535,0.0016635243,0.31679782,0.00011170087,0.00061891763,0.000020665162,0.0007408871,0.000034953417,0.00002517404,0.000012131524,0.00011104241,0.13913786],"study_design_scores_gemma":[0.4973844,0.31447867,0.16754726,0.00072583155,0.0008035728,0.0000026525838,0.001335062,0.000032860844,0.0001384503,0.000007983349,0.017387794,0.00015546351],"about_ca_topic_score_codex":0.00009535346,"about_ca_topic_score_gemma":0.00047255008,"teacher_disagreement_score":0.31281513,"about_ca_system_score_codex":0.00011547698,"about_ca_system_score_gemma":0.0015436055,"threshold_uncertainty_score":0.38883913},"labels":[],"label_agreement":null},{"id":"W2965372017","doi":"10.1200/jco.2013.31.15_suppl.6041","title":"Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); University Health Network; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Hôpital Notre-Dame; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre","funders":"","keywords":"Medicine; PTEN; Oncology; Internal medicine; Clinical endpoint; Immunohistochemistry; Clinical trial; PI3K/AKT/mTOR pathway; Apoptosis; Biology","score_opus":0.09366372852937581,"score_gpt":0.5018475318425942,"score_spread":0.4081838033132184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965372017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967452,0.00014971374,0.000113986396,0.00045488193,0.0005865079,0.0013069862,0.000060696155,0.0000015962422,0.00058039493],"genre_scores_gemma":[0.99724424,0.000061933744,0.0024252753,0.00005400531,0.00013753775,0.000019712083,0.000036235047,0.000009064441,0.0000119772085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99571985,0.00068987336,0.0025213908,0.00013952113,0.0008166159,0.00011272602],"domain_scores_gemma":[0.9933444,0.0011238661,0.0032765924,0.00014939487,0.0019645256,0.00014117738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025219298,0.00010217567,0.0012427042,0.00018153567,0.000014684171,0.0000017953179,0.00008826363,0.00011909563,0.00040565204],"category_scores_gemma":[0.0035925356,0.000066341454,0.00025916935,0.00016445483,0.00019486807,0.00012456984,0.000023863005,0.00029887102,0.0000012150872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31902772,0.058531605,0.034894764,0.000052171585,0.0036029047,0.000019512161,0.00070726254,0.000326422,0.00015757786,0.0000080259915,0.0011362799,0.58153576],"study_design_scores_gemma":[0.41225258,0.15909514,0.42097065,0.0004111979,0.0052646077,0.0000034383195,0.0002793859,0.0012199527,0.00007879737,0.00026971838,0.0001053461,0.000049200677],"about_ca_topic_score_codex":0.0001501417,"about_ca_topic_score_gemma":0.000021277223,"teacher_disagreement_score":0.5814865,"about_ca_system_score_codex":0.00018552496,"about_ca_system_score_gemma":0.0022792008,"threshold_uncertainty_score":0.44416055},"labels":[],"label_agreement":null},{"id":"W2965515377","doi":"10.1200/jco.2013.31.15_suppl.9555","title":"A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Grip strength; Quality of life (healthcare); Activities of daily living; Prospective cohort study; Physical therapy; Docetaxel; Clinical trial; Cancer; Internal medicine","score_opus":0.05138347619113666,"score_gpt":0.416311259775333,"score_spread":0.36492778358419636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965515377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914024,0.00029432413,0.0000112555335,0.0050257095,0.0002793735,0.0024348893,0.000001152491,0.0000142677545,0.0005366133],"genre_scores_gemma":[0.99441165,0.00019657312,0.0021476715,0.001960798,0.00033475348,0.00012804291,1.5947874e-7,0.00003988731,0.0007804571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706095,0.00026942696,0.0016952626,0.0003142843,0.0003608166,0.00029923074],"domain_scores_gemma":[0.9963881,0.0015356716,0.0012625665,0.0001712808,0.00039234755,0.00025004387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013532103,0.00020520772,0.0014999327,0.00019379296,0.000029831392,0.000022383656,0.00010630224,0.00020520418,0.00017107936],"category_scores_gemma":[0.0013170894,0.00012201022,0.00009260006,0.00023117325,0.00016161497,0.00021430201,0.000041583513,0.0009217241,0.000006476543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038240224,0.0030068231,0.9257231,0.000063749576,0.00038441387,0.0002135667,0.005642129,0.0000060149946,0.000014844459,0.0000017251509,0.00019166626,0.060928],"study_design_scores_gemma":[0.041490797,0.019406317,0.9340496,0.00050187187,0.00014377745,0.00016519746,0.0038377082,0.000049934355,0.000011309861,0.00005334749,0.0001592963,0.00013084963],"about_ca_topic_score_codex":0.00038497266,"about_ca_topic_score_gemma":0.0012306069,"teacher_disagreement_score":0.060797147,"about_ca_system_score_codex":0.0002001629,"about_ca_system_score_gemma":0.0010183501,"threshold_uncertainty_score":0.49754325},"labels":[],"label_agreement":null},{"id":"W2965541018","doi":"10.1200/jco.2012.30.15_suppl.9003","title":"Cluster-randomized trial of early palliative care for patients with metastatic cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Palliative care; Randomized controlled trial; Cancer; Intervention (counseling); Physical therapy; Breast cancer; Internal medicine; Performance status; Nursing","score_opus":0.3331163641902894,"score_gpt":0.5776682672945262,"score_spread":0.24455190310423686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965541018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925921,0.0024156747,0.0011651668,0.00064630364,0.0014953932,0.0011924382,0.000036375583,0.0000026166756,0.00045394193],"genre_scores_gemma":[0.9764847,0.0010774173,0.020944603,0.00036022614,0.001024082,0.000034284392,0.0000076273113,0.000015106997,0.00005194624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99634194,0.0006224586,0.002338698,0.00009828677,0.00039139503,0.00020723576],"domain_scores_gemma":[0.9833547,0.0111235855,0.0033941015,0.0001127006,0.0017618422,0.00025308868],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023861094,0.00012988051,0.003097623,0.00009216999,0.000017854636,0.0000018261247,0.00010379191,0.0001660803,0.00003849338],"category_scores_gemma":[0.010910926,0.00007294908,0.00073333184,0.00009314056,0.0002968026,0.00010590482,0.000020365504,0.00034201264,0.0000010456131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7976556,0.0015300579,0.1805626,0.00015207156,0.0013571029,0.0000045606557,0.002040948,0.000004663209,0.000002669198,0.000048103306,0.00040606203,0.016235583],"study_design_scores_gemma":[0.90868706,0.037815083,0.037405454,0.00065436075,0.0026217208,0.0000010349346,0.0006907235,0.000010392682,0.000094833376,0.00010613697,0.011832627,0.00008056693],"about_ca_topic_score_codex":0.00005623027,"about_ca_topic_score_gemma":0.00002898622,"teacher_disagreement_score":0.14315714,"about_ca_system_score_codex":0.00009681334,"about_ca_system_score_gemma":0.0008980381,"threshold_uncertainty_score":0.9974206},"labels":[],"label_agreement":null},{"id":"W2965591646","doi":"10.1200/jco.2012.30.15_suppl.6572","title":"Treatment outcomes in patients older than age 60 with acute myeloid leukemia (AML) in the nonclinical trial setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Induction chemotherapy; Chemotherapy; Cohort; Cytarabine; Population; Multivariate analysis; Leukemia; Oncology; Surgery","score_opus":0.09302125964452963,"score_gpt":0.4642829151428726,"score_spread":0.371261655498343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965591646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305327,0.00006359554,0.000010201505,0.012761806,0.0010377996,0.0012262302,0.0000055366645,0.000008217082,0.0018333567],"genre_scores_gemma":[0.9918531,0.0003231102,0.0017940189,0.003431757,0.001987481,0.000039714156,0.0000114158165,0.000035185338,0.000524216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922443,0.002044536,0.0035968192,0.00030162875,0.0010170148,0.0007956875],"domain_scores_gemma":[0.98679656,0.010381618,0.0015068119,0.0004882182,0.00024198467,0.00058483554],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0085700285,0.0003046752,0.0025447581,0.0003048565,0.00004933473,0.00001916539,0.00047808903,0.0007087061,0.00007921307],"category_scores_gemma":[0.00605755,0.00014354356,0.0006703516,0.00035203138,0.00038540887,0.00024177654,0.00011064353,0.002843377,0.000048929025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09095435,0.007701508,0.8579038,0.000008666448,0.00053747016,0.0043786773,0.00085344334,0.000003024411,0.0000042215,0.000015508114,0.0015241187,0.036115214],"study_design_scores_gemma":[0.18240617,0.03561414,0.76966804,0.00005565519,0.00035325444,0.0002265146,0.0002517459,0.000014197166,0.000005913306,0.00002147031,0.011267526,0.00011534753],"about_ca_topic_score_codex":0.00010901256,"about_ca_topic_score_gemma":0.00021070322,"teacher_disagreement_score":0.09145182,"about_ca_system_score_codex":0.0020049717,"about_ca_system_score_gemma":0.004058146,"threshold_uncertainty_score":0.9994571},"labels":[],"label_agreement":null},{"id":"W2965677361","doi":"10.1200/jco.2012.30.15_suppl.3567","title":"Implications of generating genetic test results for colon cancer in the international, population-based colon cancer family registry.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"MUTYH; Medicine; Cancer registry; Lynch syndrome; Population; Genetic testing; Family medicine; PMS2; Genetic counseling; MSH6; Colorectal cancer; MSH2; Cancer; Gynecology; Oncology; Internal medicine; Germline mutation; Genetics; Mutation; Environmental health; Gene; Biology; DNA mismatch repair","score_opus":0.199543281423688,"score_gpt":0.5133340790186534,"score_spread":0.31379079759496536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965677361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97020596,0.0011266961,0.00017705257,0.024834175,0.002202702,0.00052833,0.00019304059,0.000004057473,0.00072797656],"genre_scores_gemma":[0.9836517,0.00039484934,0.009903368,0.0038405382,0.0019687165,0.00012742948,0.000022816157,0.000015179166,0.00007538869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685174,0.0001929548,0.002208664,0.00016119822,0.00035339943,0.00023204437],"domain_scores_gemma":[0.99141467,0.0052148225,0.0022588142,0.0002346873,0.00073519896,0.000141792],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026049572,0.00011584628,0.00068540836,0.000106604995,0.00004630588,0.00000816601,0.00032337595,0.00027719382,0.00004742319],"category_scores_gemma":[0.008500792,0.0000797025,0.0002458988,0.00019259834,0.000112067355,0.00004991664,0.00002705074,0.00047972,7.858683e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020645855,0.0009742904,0.92894965,0.00003695008,0.00010231217,0.000004638995,0.0001763646,0.0032854562,0.007902451,0.000024562483,0.01953098,0.03694776],"study_design_scores_gemma":[0.0046858266,0.002505916,0.9600763,0.00011707802,0.00020539957,0.000023295894,0.000086952,0.0011672098,0.0003363654,0.00009353217,0.030627225,0.00007494866],"about_ca_topic_score_codex":0.00043556184,"about_ca_topic_score_gemma":0.0014452699,"teacher_disagreement_score":0.03687281,"about_ca_system_score_codex":0.00051826687,"about_ca_system_score_gemma":0.0019781832,"threshold_uncertainty_score":0.99985105},"labels":[],"label_agreement":null},{"id":"W2965677442","doi":"10.1200/jco.2013.31.15_suppl.5089","title":"The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Internal medicine; Oncology; ERCC1; Cancer; DNA repair","score_opus":0.07133883111346599,"score_gpt":0.46307350364163186,"score_spread":0.39173467252816585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965677442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266786,0.006030759,0.0000016660582,0.008077927,0.00018524501,0.0009839884,0.0000031047837,0.0000023984944,0.0020470407],"genre_scores_gemma":[0.99005324,0.0064348974,0.0028179686,0.00025835066,0.00014257629,0.00007066996,8.05129e-7,0.0000106495,0.00021085016],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99704236,0.0003576717,0.0017216544,0.00012296061,0.00047880114,0.0002765321],"domain_scores_gemma":[0.9960057,0.0019537045,0.0010700554,0.00019477449,0.000648882,0.0001268811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022425505,0.00009766566,0.0006737346,0.0000708805,0.000044622026,0.000008014176,0.00027379714,0.000101690915,0.000041634587],"category_scores_gemma":[0.0007008368,0.000042241063,0.00017864123,0.0002728769,0.00048543466,0.00006249637,0.000066821034,0.00065301446,0.0000037589614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003396805,0.0009045334,0.1826932,0.00012400425,0.00033400176,0.00021867159,0.00034189515,0.000051786417,0.0014246339,0.00008202326,0.00017004528,0.8102584],"study_design_scores_gemma":[0.009210715,0.009491149,0.9621924,0.00046882502,0.00019828138,0.00008744064,0.0023294447,0.00018463709,0.0008456804,0.002007769,0.012924348,0.000059277223],"about_ca_topic_score_codex":0.00011107911,"about_ca_topic_score_gemma":0.000024713461,"teacher_disagreement_score":0.81019914,"about_ca_system_score_codex":0.00009745972,"about_ca_system_score_gemma":0.0009104049,"threshold_uncertainty_score":0.28370592},"labels":[],"label_agreement":null},{"id":"W2965677886","doi":"10.1200/jco.2006.24.18_suppl.7161","title":"Identifying patients with non-small cell lung cancer (NSCLC) unlikely to benefit from erlotinib: An exploratory analysis of National Cancer of Institute of Canada Clinical Trials Group BR.21","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Lung cancer; Oncology; Proportional hazards model; Anemia; Weight loss; Erlotinib Hydrochloride; Placebo; Cancer; Clinical trial; Post-hoc analysis; Performance status; Epidermal growth factor receptor; Obesity; Pathology","score_opus":0.13256866154944452,"score_gpt":0.4964888718721104,"score_spread":0.36392021032266586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965677886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950487,0.000591042,0.0006190227,0.00053296454,0.0017368194,0.00045179803,0.00059499516,0.000002863698,0.0004218127],"genre_scores_gemma":[0.9937677,0.00022658583,0.0042521125,0.0006800106,0.0008253335,0.000024252095,0.00009861417,0.000020233958,0.00010519722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928397,0.00044964714,0.0052976958,0.00030540823,0.0008932803,0.00021425054],"domain_scores_gemma":[0.9893279,0.002049919,0.005641481,0.00022486769,0.0023607854,0.00039503945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032912793,0.00018932574,0.0030488789,0.0003478236,0.000043476553,0.0000061394176,0.00021711075,0.00025287722,0.00019967902],"category_scores_gemma":[0.0010292202,0.00013345215,0.0006573314,0.0005926769,0.00014182045,0.00019563093,0.000041090512,0.00040247047,2.8153846e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040121432,0.0032562646,0.9696851,0.00006288195,0.006286368,0.0000334751,0.00028892158,0.00578706,0.00018577723,0.000044457454,0.002108792,0.008248772],"study_design_scores_gemma":[0.013045475,0.0030621407,0.97103006,0.0003306223,0.009915379,7.1508674e-7,0.00017180851,0.00023813215,0.00018769862,0.0000477252,0.0018493421,0.00012088845],"about_ca_topic_score_codex":0.12689085,"about_ca_topic_score_gemma":0.53329504,"teacher_disagreement_score":0.4064042,"about_ca_system_score_codex":0.0005827439,"about_ca_system_score_gemma":0.011450684,"threshold_uncertainty_score":0.9941535},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2965693298","doi":"10.1200/jco.2006.24.18_suppl.20020","title":"Risk of malignancy associated with chronic lymphocytic leukemia: A population based Canadian study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Malignancy; Cancer registry; Cancer; Internal medicine; Confidence interval; Incidence (geometry); Population; Leukemia; Hematologic malignancy; Oncology","score_opus":0.053940034701942016,"score_gpt":0.4055751703828912,"score_spread":0.3516351356809492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965693298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687916,0.00029753422,0.000059320057,0.0002844552,0.00031643943,0.0005642318,0.000011213905,0.0000124790495,0.0015751495],"genre_scores_gemma":[0.9982495,0.00004859031,0.00044480874,0.00021418885,0.0006815988,0.000006842405,0.000016056782,0.000033640583,0.00030478774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99451876,0.001016538,0.0027834033,0.00025802627,0.0009289714,0.0004942873],"domain_scores_gemma":[0.99256086,0.0029525685,0.0026086743,0.00035533964,0.0009517009,0.00057083106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053254208,0.0001903793,0.001777421,0.0004138496,0.00007198443,0.000009967197,0.00023797064,0.0005169826,0.00016428459],"category_scores_gemma":[0.0060856207,0.0001323458,0.00038889694,0.0005034788,0.0001969838,0.000094991316,0.000028780565,0.00097116956,0.000011474396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003651618,0.0013677517,0.97038424,0.000064811895,0.0009224522,0.003907714,0.000044924527,0.009656393,0.000025356652,0.000038441343,0.001723161,0.008213153],"study_design_scores_gemma":[0.07622056,0.026965413,0.87598383,0.0003224585,0.0010909174,0.00027857255,0.000058553,0.018128581,0.000038816524,0.000116395844,0.0006670714,0.00012884624],"about_ca_topic_score_codex":0.34214875,"about_ca_topic_score_gemma":0.4511732,"teacher_disagreement_score":0.10902444,"about_ca_system_score_codex":0.1327391,"about_ca_system_score_gemma":0.23364687,"threshold_uncertainty_score":0.87059015},"labels":[],"label_agreement":null},{"id":"W2965787995","doi":"10.1200/jco.2007.25.18_suppl.17042","title":"Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Cancer; Clinical trial; Population; Poisson regression; Internal medicine; Relative risk; Cancer registry; Rate ratio; Oncology; Confidence interval","score_opus":0.7830844675564056,"score_gpt":0.7290294410543422,"score_spread":0.0540550265020634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965787995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772836,0.00007117075,0.00002518099,0.0056776498,0.00063090335,0.016069826,0.000020568743,0.0000033350227,0.0002177424],"genre_scores_gemma":[0.9940203,0.0014440027,0.00033658394,0.0009271067,0.00060743623,0.002329638,0.0000036885833,0.000021589138,0.00030967648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98033273,0.0043929587,0.013572896,0.00038977797,0.00092925405,0.000382399],"domain_scores_gemma":[0.9148089,0.07331917,0.008389943,0.0002744147,0.0027193138,0.0004882133],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.16697402,0.00015610663,0.0033284167,0.00026258786,0.000022589937,0.000012586328,0.00021091742,0.0012641348,0.000170308],"category_scores_gemma":[0.118714005,0.00010402753,0.00034888656,0.0002903447,0.0005971174,0.000089915295,0.00007977548,0.005742608,0.0000011850937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021794392,0.0020334974,0.85575044,0.00013524418,0.0002645625,0.0003299808,0.000311967,0.000004127982,0.00017995006,0.000045232686,0.00005951916,0.11909111],"study_design_scores_gemma":[0.018284703,0.006286415,0.9703088,0.001899644,0.0002334379,0.000015308824,0.00021194838,0.000024215775,0.00008402475,0.00037649935,0.0021843717,0.00009066934],"about_ca_topic_score_codex":0.004422446,"about_ca_topic_score_gemma":0.38883883,"teacher_disagreement_score":0.38441637,"about_ca_system_score_codex":0.0013903208,"about_ca_system_score_gemma":0.012633979,"threshold_uncertainty_score":0.99655116},"labels":[],"label_agreement":null},{"id":"W2965843521","doi":"10.1200/jco.2007.25.18_suppl.4086","title":"Encouraging results from a phase I study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Febrile neutropenia; Mucositis; Internal medicine; Capecitabine; Irinotecan; Anemia; Gastroenterology; Adverse effect; Toxicity; Oxaliplatin; Colorectal cancer; FOLFIRI; Diarrhea; Phases of clinical research; Surgery; Cancer","score_opus":0.09401981366279662,"score_gpt":0.4577378627403398,"score_spread":0.3637180490775432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965843521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668115,0.0006615912,0.0000107409305,0.0012222725,0.00032443972,0.0006549748,0.00003670873,0.0000047623057,0.00040337248],"genre_scores_gemma":[0.99789226,0.0010177265,0.0005425385,0.00025338732,0.00023668393,0.000011217584,0.0000059294925,0.00001577249,0.000024477662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964178,0.00019451641,0.0024131718,0.00026808388,0.0004641257,0.00024225381],"domain_scores_gemma":[0.99490684,0.0025948533,0.001679904,0.00012110269,0.0004711448,0.00022615865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018095116,0.00019868667,0.0017393728,0.00019043592,0.000049116134,0.000005485964,0.00008625121,0.00010414441,0.00006306127],"category_scores_gemma":[0.0011903743,0.00011944071,0.00012414911,0.00024709303,0.00017765154,0.00008101192,0.000043580963,0.0005500682,5.2768235e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11629835,0.018456616,0.54820794,0.000009578417,0.0011625978,0.00076543057,0.0034428802,0.000027942442,0.000041011568,0.0000011142429,0.000055558263,0.31153098],"study_design_scores_gemma":[0.11537091,0.14978372,0.73151577,0.00012972741,0.00038838907,0.000020374164,0.0016039583,0.000041658932,0.00011208183,0.000030470359,0.00091367005,0.00008930681],"about_ca_topic_score_codex":0.0024709932,"about_ca_topic_score_gemma":0.015887652,"teacher_disagreement_score":0.3114417,"about_ca_system_score_codex":0.00024363294,"about_ca_system_score_gemma":0.0005068102,"threshold_uncertainty_score":0.88656825},"labels":[],"label_agreement":null},{"id":"W2965906848","doi":"10.1200/jco.2013.31.15_suppl.e17525","title":"Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Incidence (geometry); Adverse effect; Internal medicine; Clinical endpoint; Cancer; Randomized controlled trial; Disease","score_opus":0.28502760163649826,"score_gpt":0.45134766851708896,"score_spread":0.1663200668805907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965906848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902206,0.0004598475,0.0002440347,0.0014356261,0.0055199754,0.00047552606,0.00009759714,0.0000019907495,0.0015447945],"genre_scores_gemma":[0.9920332,0.0039253994,0.0010612579,0.0015644461,0.0010600616,0.0000222939,0.000003501252,0.000017379814,0.00031247796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9891376,0.00019391243,0.010074093,0.00026810475,0.00005039527,0.0002759225],"domain_scores_gemma":[0.98704237,0.0021151074,0.009851035,0.00015153328,0.0005477259,0.00029225327],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01041406,0.00015300153,0.0037372205,0.00015970139,0.000024421011,0.000023757619,0.00023400795,0.00054450775,0.00035185454],"category_scores_gemma":[0.019773075,0.00013668758,0.00064761855,0.000052996435,0.00018407089,0.00033987567,0.00005391655,0.0007830091,0.000020657226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090640516,0.0009045551,0.87259614,0.000026524649,0.00010981492,0.0000018373293,0.0000967702,0.0000018176527,6.4947847e-7,0.0017891541,0.003704677,0.11986164],"study_design_scores_gemma":[0.0077158203,0.002536657,0.937966,0.000078453144,0.000041757445,0.0000014980824,0.000018556608,0.00013760968,0.0000020099476,0.004944941,0.046421506,0.00013522281],"about_ca_topic_score_codex":0.009783651,"about_ca_topic_score_gemma":0.015807312,"teacher_disagreement_score":0.11972642,"about_ca_system_score_codex":0.00026424683,"about_ca_system_score_gemma":0.000825796,"threshold_uncertainty_score":0.99681026},"labels":[],"label_agreement":null},{"id":"W2965917854","doi":"10.1200/jco.2006.24.18_suppl.13536","title":"Trends in rectal cancer survival in relation to the local control strategy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Relative survival; Cancer registry; Colorectal cancer; Radiation therapy; Rectum; Cancer; Population; Surgery; Stage (stratigraphy); Oncology; Internal medicine","score_opus":0.11852044355504315,"score_gpt":0.4568708125000743,"score_spread":0.3383503689450311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965917854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628711,0.0003272242,0.00012770633,0.027111663,0.0007140242,0.0000868911,0.0000020466503,0.0000028306843,0.008756525],"genre_scores_gemma":[0.99668944,0.000036891306,0.000039345472,0.0011519174,0.0015191463,0.000004017979,0.0000013602755,0.000006290427,0.00055160146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752975,0.00042179873,0.0015148348,0.000118606804,0.0002334873,0.000181551],"domain_scores_gemma":[0.9982213,0.0010401106,0.00041535654,0.00006906926,0.00012681041,0.00012737272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026130248,0.00008074373,0.0007934001,0.00020332674,0.000014951208,0.000004553491,0.000087440814,0.00021917284,0.00015306985],"category_scores_gemma":[0.00050794345,0.000047053887,0.00023911534,0.0003618081,0.000083053914,0.000051643397,0.000015921656,0.00094671565,0.0000074668733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007516792,0.00069734734,0.6121557,0.000004030664,0.000034706558,0.000982007,0.00005297583,0.0039059904,0.00012568897,0.00030902654,0.002506001,0.37170976],"study_design_scores_gemma":[0.006056065,0.005009812,0.974736,0.000040733372,0.00005531467,0.0001007816,0.00009835754,0.001248606,0.000006243748,0.00029446784,0.0123041915,0.000049438215],"about_ca_topic_score_codex":0.0010134401,"about_ca_topic_score_gemma":0.024789922,"teacher_disagreement_score":0.37166032,"about_ca_system_score_codex":0.00023634513,"about_ca_system_score_gemma":0.0005902491,"threshold_uncertainty_score":0.9930051},"labels":[],"label_agreement":null},{"id":"W2965944618","doi":"10.1200/jco.2012.30.15_suppl.9537","title":"Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children’s Oncology Group.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Sarcoma; Internal medicine; Surgery; Radiation therapy; Chemotherapy; Ewing's sarcoma; Propensity score matching; Oncology; Pathology","score_opus":0.08709575836182411,"score_gpt":0.43512263392851314,"score_spread":0.34802687556668904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965944618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944574,0.0023266098,0.00046430182,0.0014257354,0.0003970029,0.00055476563,0.0000074581963,0.000002602155,0.00036411005],"genre_scores_gemma":[0.99775904,0.00008335585,0.0012908315,0.00047419465,0.00035112954,0.000014746245,0.000014088605,0.000011791977,8.277107e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99405277,0.0016455759,0.0029650955,0.00014610877,0.000968853,0.00022157341],"domain_scores_gemma":[0.9912001,0.004163534,0.0032815984,0.00024896915,0.00093301636,0.00017277448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009776136,0.00013725836,0.001806127,0.000092003764,0.000019520767,0.0000032760327,0.00010311074,0.00029996893,0.0000955767],"category_scores_gemma":[0.0025606598,0.000071808594,0.00032970685,0.000122058715,0.00035734123,0.0001439533,0.000029246177,0.00053986214,0.0000016708284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005247627,0.008851304,0.82298315,0.000004740267,0.0008592944,0.0001109188,0.00014211975,0.00006562102,0.0000078664625,0.000062156796,0.00016999133,0.16149521],"study_design_scores_gemma":[0.04325856,0.010077741,0.94230443,0.0001520359,0.0023999456,0.00018387301,0.00044939027,0.00010258913,0.00003065956,0.00026951873,0.0007143316,0.00005693832],"about_ca_topic_score_codex":0.0003514441,"about_ca_topic_score_gemma":0.00025650804,"teacher_disagreement_score":0.16143827,"about_ca_system_score_codex":0.0003471833,"about_ca_system_score_gemma":0.0017814985,"threshold_uncertainty_score":0.33882332},"labels":[],"label_agreement":null},{"id":"W2965985902","doi":"10.1200/jco.2012.30.15_suppl.4019","title":"Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Internal medicine; Phases of clinical research; Epidermal growth factor receptor; Oncology; Clinical endpoint; Neutropenia; Progression-free survival; Gastroenterology; Cancer; Chemotherapy; Clinical trial","score_opus":0.14879445957526555,"score_gpt":0.4710229762490449,"score_spread":0.32222851667377933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965985902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857983,0.005849029,0.00014884096,0.0026459119,0.0025254963,0.002576997,0.00021271828,0.000020277648,0.00022240556],"genre_scores_gemma":[0.9782014,0.010819792,0.00827701,0.00024620662,0.002112213,0.000100787554,0.000031421685,0.00007037104,0.00014081388],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9856636,0.003956827,0.007575005,0.00057758595,0.0011634526,0.0010635223],"domain_scores_gemma":[0.9650831,0.027155837,0.004867195,0.0003482025,0.0011859904,0.001359658],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011316644,0.0006250393,0.0090821255,0.000790922,0.00014131008,0.000017044567,0.00033342335,0.0008025338,0.0010780699],"category_scores_gemma":[0.037217777,0.00045907203,0.0008924824,0.0005565627,0.0018117649,0.00047691274,0.00024358445,0.0021434014,0.0000061607993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92707956,0.013461473,0.024321726,0.000644567,0.0036239638,0.00015946364,0.0027488226,0.0000027900749,0.007543753,0.0001918378,0.0005821408,0.01963992],"study_design_scores_gemma":[0.92512256,0.05914839,0.006656385,0.00053973496,0.003844627,0.0001682416,0.0008235978,0.0005725409,0.0016324451,0.0001431591,0.00093983696,0.00040847814],"about_ca_topic_score_codex":0.00045579983,"about_ca_topic_score_gemma":0.000058238722,"teacher_disagreement_score":0.045686916,"about_ca_system_score_codex":0.00044648466,"about_ca_system_score_gemma":0.003920777,"threshold_uncertainty_score":0.9998351},"labels":[],"label_agreement":null},{"id":"W2966026722","doi":"10.1200/jco.2013.31.15_suppl.4130","title":"Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Gallbladder cancer; Stage (stratigraphy); Proportional hazards model; Neutrophil to lymphocyte ratio; Hepatocellular carcinoma; Cancer; Overall survival","score_opus":0.11835553367590042,"score_gpt":0.45098503127777334,"score_spread":0.33262949760187294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966026722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705077,0.0048369253,0.000009370786,0.02029475,0.0015455988,0.0004404662,0.0000034112197,0.000011260553,0.00235052],"genre_scores_gemma":[0.989803,0.002521738,0.0003552398,0.004865324,0.001961886,0.00003929339,0.0000011987536,0.000020514906,0.0004317604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678254,0.00027154008,0.0020603526,0.00023020906,0.00033778942,0.0003175748],"domain_scores_gemma":[0.9963425,0.0016901304,0.00096026214,0.0001751895,0.00045304105,0.0003789226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073121866,0.00017995734,0.0015086932,0.00017471387,0.000034188404,0.000015788475,0.00015849256,0.00031069663,0.0008148276],"category_scores_gemma":[0.0025589985,0.00012048801,0.0004681717,0.00019410625,0.00017445606,0.00021031508,0.000052322554,0.001011875,0.00010195699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010847104,0.0012597368,0.8722217,0.000043962922,0.00023517579,0.0010899331,0.00035763485,0.000008289729,0.00045704027,0.000016193511,0.007802553,0.11542308],"study_design_scores_gemma":[0.0074637206,0.006146647,0.9584009,0.00012314216,0.00022691116,0.00041751913,0.00016667102,0.00006526285,0.00006985482,0.00018890528,0.026616346,0.000114098846],"about_ca_topic_score_codex":0.0005461408,"about_ca_topic_score_gemma":0.00023860582,"teacher_disagreement_score":0.11530898,"about_ca_system_score_codex":0.000375599,"about_ca_system_score_gemma":0.0029464888,"threshold_uncertainty_score":0.89217913},"labels":[],"label_agreement":null},{"id":"W2966105499","doi":"10.1200/jco.2013.31.15_suppl.e22159","title":"NSCLC driver mutations in the Quebec population: Epidemiologic and clinical evaluation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Population; Internal medicine; Cohort; Cancer; Disease; Pathology; Colorectal cancer; Environmental health","score_opus":0.20462822897206867,"score_gpt":0.5768968645618086,"score_spread":0.3722686355897399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966105499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94961375,0.00058927614,0.00020578338,0.043968253,0.00072812673,0.00058297365,0.000001114415,0.0000043942077,0.004306335],"genre_scores_gemma":[0.9877098,0.00030402603,0.005825195,0.005190952,0.0007162754,0.000024521445,0.0000104252495,0.000005152214,0.00021361452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957166,0.0015333137,0.0022084892,0.00014292097,0.00027192227,0.00012676364],"domain_scores_gemma":[0.9917587,0.006412865,0.0010210639,0.00014853964,0.0004920911,0.00016673401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071377116,0.00008156176,0.00075329526,0.00007989719,0.000053752938,0.000012978169,0.000089688416,0.00024218664,0.00040609576],"category_scores_gemma":[0.008268736,0.0000422509,0.0002577267,0.00012743892,0.00017224491,0.00016968838,0.00001720135,0.00061100075,0.000031860138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008729155,0.0005482164,0.5902105,0.0000030688957,0.00015381209,0.00003553326,0.0001404573,0.000022239292,6.9184466e-7,0.0005027652,0.004448766,0.40384665],"study_design_scores_gemma":[0.005026556,0.0021673434,0.97777873,0.000032774667,0.00072162575,0.00013680969,0.00038538603,0.0007233485,9.259504e-8,0.0052111014,0.0077754674,0.00004074746],"about_ca_topic_score_codex":0.0010648916,"about_ca_topic_score_gemma":0.0011713746,"teacher_disagreement_score":0.4038059,"about_ca_system_score_codex":0.00015542987,"about_ca_system_score_gemma":0.0010778822,"threshold_uncertainty_score":0.98990464},"labels":[],"label_agreement":null},{"id":"W2966148971","doi":"10.1200/jco.2007.25.18_suppl.15598","title":"The impact of varying rectal contours on rectal dose in prostate cancer patients treated with hypofractionated radiation","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Rectum; Medicine; Prostate; Radiation therapy; Prostate cancer; Nuclear medicine; Colorectal cancer; Contouring; Cancer; Rectal examination; Radiology; Urology; Surgery; Internal medicine","score_opus":0.08003228879996803,"score_gpt":0.5004281065897211,"score_spread":0.4203958177897531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966148971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961613,0.00040267018,0.000001170382,0.0012375178,0.0002814438,0.00042021825,0.0000071482646,0.0000043076166,0.0014842687],"genre_scores_gemma":[0.99747133,0.0019255681,0.000040388506,0.00008809736,0.00022993388,0.000006099863,0.000009011773,0.00001255794,0.00021701913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770916,0.00027522387,0.0012478448,0.00012374096,0.00037951232,0.00026453164],"domain_scores_gemma":[0.9954421,0.002413538,0.0012190273,0.00008584583,0.0006324658,0.00020701025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023865134,0.00010973464,0.0006569197,0.00018431195,0.000050101695,0.000006228104,0.000069818234,0.00015437481,0.000030962445],"category_scores_gemma":[0.00137486,0.000050536393,0.00021204722,0.0003007128,0.00017040664,0.00012949471,0.000010297889,0.0007864803,0.0000017636023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07960672,0.0015235018,0.6783653,0.0000053440185,0.00039042428,0.00026124416,0.00009998194,0.000096147145,0.0002202383,0.000002120312,0.00034926113,0.23907971],"study_design_scores_gemma":[0.020959383,0.03162516,0.945537,0.0001466344,0.00008247754,0.000035843364,0.000055172954,0.0000897775,0.0008162364,0.000024035957,0.00057810405,0.000050209786],"about_ca_topic_score_codex":0.00055867084,"about_ca_topic_score_gemma":0.00015582313,"teacher_disagreement_score":0.26717165,"about_ca_system_score_codex":0.0009088133,"about_ca_system_score_gemma":0.0016931155,"threshold_uncertainty_score":0.34169096},"labels":[],"label_agreement":null},{"id":"W2966212079","doi":"10.1200/jco.2006.24.18_suppl.4637","title":"Blood-based biomarkers for detecting aggressive prostate cancer at time of biopsy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Biopsy; Cancer; Stage (stratigraphy); Prostate; Prostate biopsy; Oncology; PCA3; Internal medicine; Pathology; Biology","score_opus":0.08479941927181094,"score_gpt":0.47610155031681495,"score_spread":0.391302131045004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966212079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919402,0.0026982948,0.000030252484,0.0038360944,0.00042550257,0.0004651964,0.000033463035,0.000007228033,0.0005637699],"genre_scores_gemma":[0.9914468,0.0004535024,0.004525563,0.0003004987,0.0009519704,0.000029303694,0.000010520209,0.000026322294,0.002255505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751765,0.00016226052,0.0015741785,0.00016427465,0.00029832238,0.00028329113],"domain_scores_gemma":[0.99425375,0.0021722151,0.0024902634,0.00011909388,0.0007600628,0.0002046308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017567916,0.000116904455,0.001034094,0.00015711582,0.000055811463,0.000004209195,0.00009992754,0.00024409892,0.0001502103],"category_scores_gemma":[0.0015916679,0.00007418921,0.0005140975,0.00015991434,0.00031716906,0.000043613578,0.00003087571,0.00032192285,0.000004893267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072747745,0.0036666791,0.64522606,0.00048733223,0.0028682856,0.0023189536,0.00010392075,0.00013990483,0.07883336,0.00001112296,0.012167607,0.18142901],"study_design_scores_gemma":[0.15232363,0.0737276,0.4425651,0.0023842803,0.0050417366,0.0011685153,0.00015802411,0.0024750708,0.25693774,0.00097310764,0.061705112,0.00054008374],"about_ca_topic_score_codex":0.0000729681,"about_ca_topic_score_gemma":0.000034210254,"teacher_disagreement_score":0.20266096,"about_ca_system_score_codex":0.00022406987,"about_ca_system_score_gemma":0.002028489,"threshold_uncertainty_score":0.35984522},"labels":[],"label_agreement":null},{"id":"W2966212106","doi":"10.1200/jco.2012.30.15_suppl.tps5600","title":"A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Juravinski Cancer Centre; London Health Sciences Centre; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Tolerability; Chemoradiotherapy; Clinical endpoint; Radiation therapy; Hazard ratio; Cetuximab; Clinical trial; Adverse effect; Confidence interval; Cancer","score_opus":0.12596640886276894,"score_gpt":0.4789210780127829,"score_spread":0.35295466915001394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966212106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950475,0.0012091539,0.0007774648,0.00041279203,0.0007860659,0.0017060508,0.00001927189,0.0000063033026,0.00003540602],"genre_scores_gemma":[0.99736845,0.0008148907,0.0012322603,0.00019478526,0.00031764177,0.00002289221,0.000006874693,0.000027584445,0.000014608809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99404186,0.0015133413,0.0031060781,0.00028920782,0.00080369454,0.00024578942],"domain_scores_gemma":[0.99018836,0.0043118056,0.004134796,0.0002001942,0.00091342314,0.0002514147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004698112,0.00025648868,0.0026820225,0.00017656753,0.00008965782,0.000009862537,0.0000965978,0.000244682,0.00004233695],"category_scores_gemma":[0.0009835759,0.00013754857,0.00012977823,0.00030541673,0.0003687269,0.0003543363,0.000023129314,0.00093000865,8.018724e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30038485,0.014534439,0.58224416,0.00005022008,0.000514758,0.000017907256,0.0010282494,0.00008034145,0.0001229533,0.000014329947,0.000057998335,0.10094981],"study_design_scores_gemma":[0.2814329,0.13704456,0.57930815,0.00011655479,0.00031989615,0.000009662768,0.0007344852,0.00011486012,0.00005013727,0.0000015941351,0.0007681502,0.000099047844],"about_ca_topic_score_codex":0.000105998406,"about_ca_topic_score_gemma":0.00050141016,"teacher_disagreement_score":0.12251013,"about_ca_system_score_codex":0.0003332163,"about_ca_system_score_gemma":0.0010359845,"threshold_uncertainty_score":0.56090677},"labels":[],"label_agreement":null},{"id":"W2966235733","doi":"10.1200/jco.2013.31.15_suppl.e16013","title":"5-alpha reductase inhibitors and risk of male breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"","keywords":"Medicine; Finasteride; Dutasteride; Lumpectomy; 5 Alpha-Reductase Inhibitor; Breast cancer; Gynecomastia; Cancer; Diagnosis code; Internal medicine; Mastectomy; Radiation therapy; Gynecology; Database; Oncology; Population; Prostate cancer; Prostate","score_opus":0.0737685976068938,"score_gpt":0.4675086077154653,"score_spread":0.3937400101085715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966235733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656539,0.0022905332,0.0000045146044,0.0292555,0.0010489458,0.00021118189,0.000017142625,0.0000042378024,0.001514057],"genre_scores_gemma":[0.98258406,0.011814838,0.0020688479,0.0009966177,0.0021548553,0.0000061124933,3.9867982e-7,0.000011299562,0.00036296854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670625,0.00035187165,0.0023237008,0.00013938597,0.00026659566,0.00021216927],"domain_scores_gemma":[0.9946719,0.0014465536,0.0024346625,0.00014238847,0.0007951631,0.0005093522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023248564,0.00011039946,0.0014578236,0.00010011283,0.00004058783,0.0000030154756,0.00008181768,0.00024822805,0.00073878403],"category_scores_gemma":[0.0024865326,0.00007284614,0.00023159724,0.00010401263,0.00045528775,0.00009504832,0.00006896025,0.00086949556,0.000014668364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012884574,0.0006059943,0.7383487,0.00012231234,0.00027795433,0.00008696483,0.000090192974,0.0000011949859,0.00012983804,0.000016314403,0.034523927,0.2245081],"study_design_scores_gemma":[0.0042767753,0.003961177,0.9752697,0.00019781374,0.0004468894,0.002373698,0.00024873324,0.000026845872,0.00003658531,0.00014983516,0.012954158,0.000057823363],"about_ca_topic_score_codex":0.0007598871,"about_ca_topic_score_gemma":0.00006164695,"teacher_disagreement_score":0.23692092,"about_ca_system_score_codex":0.000073634066,"about_ca_system_score_gemma":0.0011735565,"threshold_uncertainty_score":0.8089167},"labels":[],"label_agreement":null},{"id":"W2966320079","doi":"10.1200/jco.2012.30.15_suppl.tps4686","title":"A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Oncology; Renal cell carcinoma; Clear cell renal cell carcinoma; Biomarker; Phases of clinical research; Clinical trial; Urology; Adverse effect","score_opus":0.11395758188849721,"score_gpt":0.47421493936191306,"score_spread":0.36025735747341586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966320079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775196,0.00034285366,0.00002168057,0.00075484655,0.0011168636,0.00065125746,0.0000065452705,0.000004448721,0.009349554],"genre_scores_gemma":[0.99274105,0.00010599698,0.0061221854,0.00035101423,0.00045937867,0.000028951776,0.000014345122,0.000030986645,0.00014609793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931421,0.001249758,0.004039115,0.0003059289,0.00069075124,0.0005723025],"domain_scores_gemma":[0.99363476,0.0018733277,0.0031005465,0.00032144363,0.00045050945,0.0006194129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004360414,0.0002896453,0.002762687,0.000512457,0.000028690929,0.0000031082743,0.00020393917,0.0005562156,0.00017374867],"category_scores_gemma":[0.0008616283,0.0001933261,0.00046371846,0.00038427892,0.0002568932,0.0002307929,0.00010603538,0.0012911974,0.000005525741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2875815,0.07802853,0.45377442,0.000055967805,0.00018844432,0.0009867232,0.0002652113,0.000011448949,0.0009564326,0.000017536579,0.00034464864,0.17778914],"study_design_scores_gemma":[0.3143391,0.18419331,0.4940133,0.00009251005,0.00027807464,0.00008044264,0.00009603734,0.00003221916,0.0004938344,0.000008744088,0.0062613613,0.00011106594],"about_ca_topic_score_codex":0.00004241427,"about_ca_topic_score_gemma":0.0000777364,"teacher_disagreement_score":0.17767806,"about_ca_system_score_codex":0.001324412,"about_ca_system_score_gemma":0.0032493784,"threshold_uncertainty_score":0.78836095},"labels":[],"label_agreement":null},{"id":"W2966320885","doi":"10.1200/jco.2012.30.15_suppl.6087","title":"Involvement of low- and middle-income countries (LMCs) in oncology randomized controlled trials (RCTs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychological intervention; Clinical trial; Randomized controlled trial; Internal medicine; Logistic regression; Family medicine; Nursing","score_opus":0.5963000178050898,"score_gpt":0.648985585811387,"score_spread":0.0526855680062972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966320885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94285095,0.00922392,0.000119737626,0.03636423,0.003096985,0.002193395,0.000004834053,0.000007484576,0.006138451],"genre_scores_gemma":[0.96050775,0.028201215,0.0044814334,0.0040901005,0.0020938765,0.000047661648,0.0000011885384,0.000022281185,0.00055451103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.95709074,0.018015057,0.02188945,0.0003414833,0.001904417,0.00075885834],"domain_scores_gemma":[0.25377208,0.7281386,0.013175987,0.0005039084,0.0030351337,0.001374263],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.36459574,0.00024671247,0.018370768,0.0005039198,0.00003657912,0.000011706814,0.00032875367,0.0018893143,0.0005202507],"category_scores_gemma":[0.6306447,0.00013973429,0.0021287007,0.00020722917,0.0022378156,0.0001700035,0.00022082985,0.004600989,0.000018312485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8702637,0.0047203796,0.10000471,0.0008708511,0.0026440336,0.00031790425,0.0006018852,0.0000037140942,0.00008436671,0.015080045,0.00025899,0.005149418],"study_design_scores_gemma":[0.9236581,0.014434002,0.029784927,0.0025076056,0.0017999512,0.0001403081,0.0004753683,0.00008913946,0.00017096296,0.018324168,0.008456066,0.00015941744],"about_ca_topic_score_codex":0.00003902525,"about_ca_topic_score_gemma":0.00017542078,"teacher_disagreement_score":0.7101236,"about_ca_system_score_codex":0.00035110247,"about_ca_system_score_gemma":0.0061991406,"threshold_uncertainty_score":0.99943477},"labels":[],"label_agreement":null},{"id":"W2966354200","doi":"10.1200/jco.19.01461","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1475,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; BC Cancer Agency","funders":"","keywords":"Medicine; Edoxaban; Rivaroxaban; Apixaban; Cancer; Intensive care medicine; Guideline; Randomized controlled trial; Venous thromboembolism; Cochrane Library; Low molecular weight heparin; Ambulatory; Internal medicine; Warfarin; Heparin; Thrombosis","score_opus":0.13493177512110585,"score_gpt":0.5122619900840704,"score_spread":0.3773302149629645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966354200","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060589155,0.98313934,0.000008428559,0.0027770966,0.003264813,0.0030775403,0.000036569043,0.000012872669,0.0016244263],"genre_scores_gemma":[0.00023261977,0.9893634,0.0047930405,0.003063905,0.0022485605,0.00005765707,0.000044702447,0.000089727015,0.0001064006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882721,0.0015714893,0.008234879,0.000700772,0.0007332655,0.00048752615],"domain_scores_gemma":[0.9864454,0.0034447343,0.007988037,0.00060115143,0.0009429668,0.000577658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00577233,0.0006034144,0.014501257,0.00029283346,0.00004940663,0.000028462906,0.0003137464,0.0012605588,0.00011079031],"category_scores_gemma":[0.0034335125,0.00034115714,0.0012263454,0.00028769564,0.00030791305,0.000205195,0.0001776506,0.0022539513,0.000055278146],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013106695,0.018576419,0.0050978074,0.0016717958,0.0038938164,0.00075007556,0.00003516863,0.0000028372692,2.1357294e-9,0.000046213452,0.007928836,0.9606864],"study_design_scores_gemma":[0.010222939,0.0634374,0.042373624,0.0052409316,0.012886784,0.00011460219,0.000024814583,0.0000018742376,1.2148193e-8,0.000012132466,0.8654127,0.0002721492],"about_ca_topic_score_codex":0.00022288001,"about_ca_topic_score_gemma":0.000106799955,"teacher_disagreement_score":0.96041423,"about_ca_system_score_codex":0.0007607941,"about_ca_system_score_gemma":0.006260064,"threshold_uncertainty_score":0.99990404},"labels":[],"label_agreement":null},{"id":"W2966390396","doi":"10.1200/jco.2007.25.18_suppl.6601","title":"Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Nomogram; Internal medicine; Odds ratio; Clinical trial; Confidence interval; Statistical significance; Bootstrapping (finance); Surgery; Oncology","score_opus":0.11376492601828507,"score_gpt":0.5547181847297264,"score_spread":0.44095325871144136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966390396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942973,0.00012008783,0.0003946345,0.0010447621,0.0020693857,0.0014476199,0.000030264282,0.0000071363697,0.00058877165],"genre_scores_gemma":[0.99375916,0.00016078756,0.0036210294,0.001846738,0.000416934,0.000013534138,0.000031687392,0.000023685869,0.00012644396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877996,0.0015122471,0.009350153,0.0003180728,0.0006237332,0.00039620223],"domain_scores_gemma":[0.99252987,0.0023450728,0.0035295873,0.00027100998,0.00056629337,0.0007581422],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01829783,0.00021202819,0.0032823354,0.0005194266,0.00003088663,0.0000024368007,0.00021867028,0.0005541899,0.00015896231],"category_scores_gemma":[0.01908824,0.00015565722,0.001010679,0.00050456414,0.00010254669,0.00012869878,0.00008414841,0.000924441,0.0000121933135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030184157,0.02984079,0.6984451,0.000020333853,0.0008547301,0.00097036257,0.00035566321,0.00006167251,0.000062235704,0.0000053913463,0.0007735767,0.23842598],"study_design_scores_gemma":[0.13629805,0.052615482,0.7990373,0.00023766184,0.0007080534,0.000015221885,0.00011690526,0.000059534876,0.00004201404,0.00006522963,0.010694418,0.000110151654],"about_ca_topic_score_codex":0.000074285475,"about_ca_topic_score_gemma":0.0001636362,"teacher_disagreement_score":0.23831584,"about_ca_system_score_codex":0.00042419764,"about_ca_system_score_gemma":0.0015860788,"threshold_uncertainty_score":0.98917437},"labels":[],"label_agreement":null},{"id":"W2966405440","doi":"10.1200/jco.2013.31.15_suppl.e17526","title":"Development of a practice consensus statement of the management of locally advanced breast cancer: Expert consensus and systematic review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Lumpectomy; Systematic review; Breast cancer; Randomized controlled trial; Protocol (science); Medical physics; Mastectomy; Evidence-based medicine; Expert opinion; MEDLINE; Surgery; Intensive care medicine; Alternative medicine; Cancer; Pathology; Internal medicine","score_opus":0.1921468993927352,"score_gpt":0.577384572303625,"score_spread":0.38523767291088984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966405440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70953536,0.0347839,0.0005420151,0.22476235,0.001977664,0.010954454,0.000028555203,0.000025384186,0.017390301],"genre_scores_gemma":[0.8588839,0.04666554,0.09269824,0.0013105051,0.00006629156,0.00011417902,1.3711902e-7,0.000013948643,0.00024721603],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.992299,0.0021366782,0.0041886237,0.00012890046,0.0010372628,0.00020954254],"domain_scores_gemma":[0.98711187,0.0046665315,0.0057183052,0.00022847163,0.002109528,0.00016531433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015300133,0.000095109535,0.0013128681,0.000060902883,0.00006544658,0.000006260377,0.00048135867,0.0001293841,0.00007638216],"category_scores_gemma":[0.005143464,0.000058158053,0.0001727603,0.0002314837,0.00094887323,0.000065073815,0.000184902,0.00033353714,0.00000167475],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043994985,0.008267406,0.005318165,0.19532846,0.008177602,0.00042214157,0.018176775,0.00006906824,0.0025844688,0.012623135,0.054757167,0.68987614],"study_design_scores_gemma":[0.020886106,0.009371082,0.072287604,0.48092133,0.0048203836,0.0008701077,0.20605437,0.00020873087,0.002919393,0.004773054,0.19555908,0.0013287422],"about_ca_topic_score_codex":0.00037066443,"about_ca_topic_score_gemma":0.00017888896,"teacher_disagreement_score":0.6885474,"about_ca_system_score_codex":0.00021296232,"about_ca_system_score_gemma":0.0023854314,"threshold_uncertainty_score":0.6157578},"labels":[],"label_agreement":null},{"id":"W2966439920","doi":"10.1200/jco.2013.31.15_suppl.tps7609","title":"Cabazitaxel (Cbz) versus topotecan in patients (pts) with small cell lung cancer (SCLC) that has progressed during or after first-line treatment with platinum-based chemotherapy: A randomized phase II study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Taxane; Topotecan; Internal medicine; Oncology; Chemotherapy; Regimen; Chemotherapy regimen; Gemcitabine; Refractory (planetary science); Surgery; Cancer; Breast cancer","score_opus":0.10857136224346695,"score_gpt":0.44816974150394057,"score_spread":0.33959837926047365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966439920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871073,0.00059104024,0.00003083067,0.0069749183,0.00028419943,0.0048667337,0.0000084861995,0.000017531342,0.00011897344],"genre_scores_gemma":[0.9954906,0.0005332196,0.0016628639,0.00035997047,0.00041623146,0.0010426467,0.0000030166257,0.00005279174,0.00043863425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960588,0.0005442726,0.0017063064,0.00040722894,0.00073943794,0.0005439396],"domain_scores_gemma":[0.9948818,0.002241728,0.0014320463,0.00030728383,0.0006842022,0.0004529368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012714602,0.00037373384,0.0028479137,0.00023408054,0.00012827315,0.000032219064,0.0001808781,0.00019985967,0.00050179067],"category_scores_gemma":[0.0006465898,0.00018035715,0.00032557343,0.0002423488,0.0004745952,0.00014237792,0.00006345502,0.0008080662,0.0000027239064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6313841,0.016966427,0.32887724,0.00011836119,0.0015017841,0.00089556276,0.0012776718,0.000070190195,0.0000058798078,4.6279492e-8,0.00011556153,0.018787192],"study_design_scores_gemma":[0.71648544,0.15770817,0.12271114,0.00048339792,0.0009436562,0.0000082905035,0.0002661052,0.0003656844,0.00014672522,0.0000012064135,0.0007023205,0.00017788546],"about_ca_topic_score_codex":0.00071170577,"about_ca_topic_score_gemma":0.008634385,"teacher_disagreement_score":0.2061661,"about_ca_system_score_codex":0.0013049112,"about_ca_system_score_gemma":0.002841747,"threshold_uncertainty_score":0.7354751},"labels":[],"label_agreement":null},{"id":"W2966449194","doi":"10.1200/jco.2013.31.15_suppl.e12535","title":"U.S. Preventive Services Task Force (USPSTF) recommendations on PSA screening (PSAS) for prostate cancer (PC): Are they justified?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Prostate cancer; Randomization; Relative risk; Internal medicine; Cancer; Gynecology; Confidence interval","score_opus":0.10614149030414731,"score_gpt":0.462237872594196,"score_spread":0.3560963822900487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966449194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8420541,0.0016263331,0.00042966224,0.14943098,0.0024853921,0.0024251514,0.00021842263,0.000026662687,0.0013032791],"genre_scores_gemma":[0.9729719,0.0068016704,0.0063453126,0.009837175,0.0016420992,0.00050923525,0.000048257676,0.000039472896,0.0018048448],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972768,0.00021074853,0.0016769591,0.00027470183,0.00024208841,0.00031871913],"domain_scores_gemma":[0.994187,0.0021050284,0.0022491303,0.00019473926,0.0008883365,0.00037577224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001184666,0.00019072375,0.0011647572,0.000105556435,0.000111382724,0.000027772881,0.00015423674,0.00023116826,0.00024753503],"category_scores_gemma":[0.000527341,0.00012614494,0.00049853715,0.00008636366,0.000070910646,0.00023312782,0.00004615714,0.00057755655,0.00002634816],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003930845,0.002876022,0.13233969,0.00023925994,0.0016297462,0.000080922815,0.0006417612,0.00019098513,0.0000735702,0.00013609028,0.04860742,0.8092537],"study_design_scores_gemma":[0.021643152,0.026976181,0.4452591,0.0028263195,0.0019943498,0.00006885758,0.0018190658,0.0007457237,0.0004674817,0.0040099984,0.4938706,0.00031920098],"about_ca_topic_score_codex":0.00017822748,"about_ca_topic_score_gemma":0.00032928112,"teacher_disagreement_score":0.8089345,"about_ca_system_score_codex":0.0002590981,"about_ca_system_score_gemma":0.0005969679,"threshold_uncertainty_score":0.5144041},"labels":[],"label_agreement":null},{"id":"W2966499265","doi":"10.1200/jco.2007.25.18_suppl.3075","title":"A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Juravinski Cancer Centre; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Stage (stratigraphy); Cancer; Lung cancer; Oncology; Gastroenterology; Surgery","score_opus":0.09855500290436692,"score_gpt":0.4778238329673635,"score_spread":0.3792688300629966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966499265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964491,0.00046303205,0.00050833425,0.00039732835,0.00028050767,0.0016215688,0.00007545114,0.0000015633389,0.00020309373],"genre_scores_gemma":[0.996207,0.000631174,0.0010721746,0.0005034898,0.00022327028,0.000030338899,0.000013622658,0.000026926065,0.0012920339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966569,0.00047414887,0.0015735225,0.0003815671,0.00041795048,0.0004959057],"domain_scores_gemma":[0.9968395,0.000564092,0.0009585597,0.00039737072,0.0006195415,0.00062092376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027515728,0.00021533325,0.0008725156,0.000105970226,0.00007403907,0.000029025237,0.0008286555,0.00014532692,0.00007513479],"category_scores_gemma":[0.0008265319,0.000121030185,0.00011995723,0.00029630648,0.00006812836,0.000021650741,0.00054075336,0.0005080332,0.000002064837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08456418,0.028937643,0.87154955,0.00004410467,0.0005814037,0.00047240357,0.00017620529,0.00029832928,0.00089366245,9.83695e-7,0.0010059029,0.01147566],"study_design_scores_gemma":[0.10060446,0.026463386,0.86365837,0.00015368959,0.00025936664,0.0000037167626,0.0005002382,0.00014791507,0.0011729429,0.0000020738053,0.006809001,0.00022482518],"about_ca_topic_score_codex":0.0012957895,"about_ca_topic_score_gemma":0.032290213,"teacher_disagreement_score":0.030994423,"about_ca_system_score_codex":0.00020543908,"about_ca_system_score_gemma":0.002371602,"threshold_uncertainty_score":0.98536795},"labels":[],"label_agreement":null},{"id":"W2966549507","doi":"10.1200/jco.2007.25.18_suppl.19649","title":"Quality of life and survival in patients receiving chemotherapy for advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Chemotherapy; Lung cancer; Internal medicine; Clinical endpoint; Cancer; Clinical trial; Surgery","score_opus":0.08999110794584979,"score_gpt":0.46830363874297365,"score_spread":0.37831253079712385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966549507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941757,0.0006199724,0.00085202866,0.0009701615,0.0011270114,0.00035611587,0.0000059524,0.00000225308,0.0018908267],"genre_scores_gemma":[0.9891772,0.0013744789,0.006004376,0.002862432,0.00047498473,0.0000029662167,0.0000020916582,0.000014726073,0.00008670354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967456,0.0001579849,0.0025121567,0.00016302975,0.00020089158,0.00022034338],"domain_scores_gemma":[0.9943062,0.0031654236,0.00174009,0.00011230583,0.0003945372,0.00028143867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055292547,0.00010614543,0.0014443038,0.0001000546,0.000017230723,0.0000021766539,0.00009432315,0.0002610265,0.000057818903],"category_scores_gemma":[0.0019620545,0.0000843064,0.00025585815,0.00008373819,0.00009143942,0.000079596204,0.000020819607,0.00051736395,1.6088855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015669798,0.0006254547,0.772722,0.00016922678,0.00008675497,0.0000051963343,0.00019915318,0.000011505425,0.0006720636,0.0000029727973,0.00029926433,0.20953658],"study_design_scores_gemma":[0.036519703,0.003882711,0.9543672,0.000096880685,0.000043318243,9.689378e-7,0.00013861866,0.00007531181,0.00027943985,0.000017751638,0.004499127,0.00007892926],"about_ca_topic_score_codex":0.000056896442,"about_ca_topic_score_gemma":0.0004041121,"teacher_disagreement_score":0.20945765,"about_ca_system_score_codex":0.00018217092,"about_ca_system_score_gemma":0.0015547468,"threshold_uncertainty_score":0.3437915},"labels":[],"label_agreement":null},{"id":"W2966656938","doi":"10.1200/jco.2013.31.15_suppl.9547","title":"Population-based patterns of palliative systemic therapy use in elderly patients with metastatic colorectal cancer (mCRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; BC Cancer Agency","funders":"","keywords":"Medicine; Systemic therapy; Colorectal cancer; Bevacizumab; Internal medicine; Cancer; Adverse effect; Proportional hazards model; Population; Chemotherapy; Confounding; Oncology; Breast cancer","score_opus":0.10003882640486521,"score_gpt":0.4305683970322123,"score_spread":0.33052957062734706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966656938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979489,0.00033569444,0.000026743159,0.00066549843,0.00031704843,0.00064165395,0.000019163122,0.0000034940085,0.0000418107],"genre_scores_gemma":[0.99845976,0.0004078136,0.0005351176,0.00041482833,0.00008422403,0.0000516209,0.000006855541,0.000013011453,0.000026747464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749994,0.00028576062,0.0015703399,0.00014338862,0.0003356121,0.00016497997],"domain_scores_gemma":[0.99563676,0.0017842649,0.0015728431,0.00008370989,0.0007921842,0.00013020713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039295253,0.00014095799,0.0014590648,0.00012407365,0.000020975394,0.0000066941616,0.000068204004,0.00010486676,0.00020110808],"category_scores_gemma":[0.0005270479,0.000078217025,0.00021053002,0.00013028178,0.00006583651,0.00012163376,0.0000114525055,0.00033065118,0.0000019653837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005406819,0.0017231997,0.94837093,0.00003831666,0.0006448911,0.000045854344,0.00016942872,0.00008665477,0.000015781932,0.0000036161275,0.000060330967,0.0434342],"study_design_scores_gemma":[0.016371466,0.022766303,0.9598742,0.00035483544,0.00020593095,0.0000039220586,0.00013660194,0.00006527459,0.000026422784,0.000022213888,0.000102679434,0.00007014834],"about_ca_topic_score_codex":0.002821873,"about_ca_topic_score_gemma":0.002912059,"teacher_disagreement_score":0.04336405,"about_ca_system_score_codex":0.00031143226,"about_ca_system_score_gemma":0.00069767534,"threshold_uncertainty_score":0.42658466},"labels":[],"label_agreement":null},{"id":"W2966660064","doi":"10.1200/jco.2012.30.15_suppl.e18535","title":"Expression of mTOR in diffuse large B-cell lymphoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Univariate analysis; Diffuse large B-cell lymphoma; PI3K/AKT/mTOR pathway; Internal medicine; Oncology; Lymphoma; Stage (stratigraphy); Immunohistochemistry; Pathology; Multivariate analysis; Biology; Apoptosis","score_opus":0.09019162548205864,"score_gpt":0.44342162345375746,"score_spread":0.35322999797169885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966660064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211925,0.0017476567,0.00001156387,0.0010032973,0.00092436734,0.00010620425,0.0000027086674,0.0000029418331,0.0040819948],"genre_scores_gemma":[0.99550885,0.00094356894,0.001753676,0.0008589569,0.00076429703,0.0000033371837,0.0000013477974,0.000009477144,0.0001564955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997306,0.00027446033,0.0018206133,0.00008979577,0.000260614,0.0002485315],"domain_scores_gemma":[0.99657744,0.00152939,0.0012230985,0.00015874296,0.0001315656,0.0003797721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020703035,0.00009674437,0.0011785508,0.000109619956,0.000012380115,0.0000017197208,0.00008733808,0.00029786595,0.00011005017],"category_scores_gemma":[0.0012198711,0.000059075937,0.0003935176,0.000082767445,0.00006141054,0.0001051244,0.00005011649,0.00019968102,0.00002614689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018874151,0.09763429,0.8606356,0.000032127573,0.000063515785,0.00031318117,0.00019097084,2.9004596e-7,0.00067925407,0.000093003044,0.004655831,0.033814557],"study_design_scores_gemma":[0.07266112,0.004482208,0.83581334,0.00015219089,0.00018329358,0.0001185989,0.00012003264,0.000007582519,0.005267214,0.000041271625,0.0810989,0.00005421963],"about_ca_topic_score_codex":0.000011033354,"about_ca_topic_score_gemma":0.0000060543407,"teacher_disagreement_score":0.09315208,"about_ca_system_score_codex":0.00017999586,"about_ca_system_score_gemma":0.0005508953,"threshold_uncertainty_score":0.24090469},"labels":[],"label_agreement":null},{"id":"W2966662961","doi":"10.1200/jco.2012.30.15_suppl.6513","title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Nilotinib; Internal medicine; Adverse effect; Gastroenterology; Imatinib; Neutropenia; Myeloid leukemia; Imatinib mesylate; Pharmacology; Chemotherapy","score_opus":0.07884208343562826,"score_gpt":0.4232277760321592,"score_spread":0.34438569259653096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966662961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180657,0.0016055191,0.00017212874,0.001770209,0.001789774,0.0023423391,0.00005740808,0.00006845231,0.000387587],"genre_scores_gemma":[0.9918825,0.00033811948,0.002607846,0.0011023219,0.003162901,0.00006793567,0.00007623064,0.0001595016,0.0006026684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99003965,0.0007536983,0.005367717,0.00084823364,0.0012977354,0.0016929617],"domain_scores_gemma":[0.9911127,0.0018074521,0.0030896617,0.00092185807,0.0010046903,0.0020636152],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032687099,0.0008809371,0.003975546,0.00068732863,0.00015841919,0.00004990937,0.0005982782,0.0008125251,0.0013719974],"category_scores_gemma":[0.0030308226,0.00053116184,0.00057329267,0.0012809894,0.00038180067,0.0005975313,0.00021289931,0.0025931774,0.00012001634],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4270932,0.030667445,0.038777515,0.0003975083,0.0019848805,0.015596102,0.0004733061,0.00033207267,0.009036599,0.000023097,0.004570654,0.4710476],"study_design_scores_gemma":[0.5236711,0.30428287,0.08987735,0.0019528024,0.002502469,0.0025785137,0.00012052571,0.0017369139,0.006200239,0.00002203235,0.06574042,0.001314748],"about_ca_topic_score_codex":0.0003480326,"about_ca_topic_score_gemma":0.0055712354,"teacher_disagreement_score":0.46973288,"about_ca_system_score_codex":0.015668465,"about_ca_system_score_gemma":0.015713943,"threshold_uncertainty_score":0.999714},"labels":[],"label_agreement":null},{"id":"W2966718823","doi":"10.1200/jco.2009.27.15_suppl.9520","title":"Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Bone mineral; Clinical endpoint; Urology; Internal medicine; Androgen deprivation therapy; Osteoporosis; Breast cancer; Prostate cancer; Bone resorption; Oncology; Bone remodeling; Randomized controlled trial; Cancer","score_opus":0.03100336082667111,"score_gpt":0.412952024838892,"score_spread":0.3819486640122209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966718823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114966,0.00086025207,0.000003167026,0.0072639813,0.000056611272,0.00042648407,0.000003316497,0.0000043554655,0.00023218778],"genre_scores_gemma":[0.9929691,0.00531655,0.00021235064,0.0012535609,0.00013613349,0.000013477447,9.520261e-7,0.000011404789,0.00008647518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980955,0.0003010873,0.0009076501,0.00016599998,0.00027125364,0.00025850884],"domain_scores_gemma":[0.9976867,0.0007784123,0.0009681039,0.00009235194,0.00018106695,0.00029335427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012928828,0.000147451,0.0011986732,0.000112367685,0.000030362027,0.000004221426,0.000031981665,0.000163609,0.000013055722],"category_scores_gemma":[0.00010354755,0.000078256424,0.000050727274,0.00013873214,0.00009157229,0.00009361701,0.0000059075296,0.00048783136,4.914959e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19410852,0.0009087328,0.51075596,0.000039884068,0.00022589565,0.00041179455,0.00023547713,0.000056265544,0.00015668667,0.0000028101365,0.00015608236,0.2929419],"study_design_scores_gemma":[0.03656278,0.084788665,0.87746286,0.00033002364,0.00012497803,0.00036493497,0.000025240179,0.00004567076,0.00009481786,0.000034972236,0.00010234479,0.00006268638],"about_ca_topic_score_codex":0.0006391126,"about_ca_topic_score_gemma":0.0010602283,"teacher_disagreement_score":0.36670694,"about_ca_system_score_codex":0.0004318036,"about_ca_system_score_gemma":0.0013782649,"threshold_uncertainty_score":0.31912044},"labels":[],"label_agreement":null},{"id":"W2966733378","doi":"10.1200/jco.2006.24.18_suppl.4051","title":"Use of lymph node ratio improves staging and selection criteria for adjuvant therapy of gastric cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lymph node; Hazard ratio; Cancer; Internal medicine; Proportional hazards model; Surveillance, Epidemiology, and End Results; Population; Epidemiology; Oncology; Stage (stratigraphy); Cancer staging; Adjuvant therapy; Confidence interval; Cancer registry","score_opus":0.13963462480922817,"score_gpt":0.46454709443190095,"score_spread":0.3249124696226728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966733378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927034,0.000728172,0.0031869374,0.0025836304,0.00051481527,0.00020129308,0.000005288567,0.0000034121376,0.00007307049],"genre_scores_gemma":[0.98719996,0.002440075,0.008608449,0.0006483672,0.0007876354,0.0000046078612,0.0000013716314,0.00000921645,0.0003003407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981993,0.0000792705,0.0013595896,0.00009460545,0.00014847002,0.00011879674],"domain_scores_gemma":[0.9973179,0.0008100374,0.0013778857,0.000052655214,0.00038022784,0.00006127439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009009913,0.00007583659,0.0008575919,0.0001426966,0.000017131308,0.0000061233495,0.00004447028,0.00009546416,0.000036862184],"category_scores_gemma":[0.00045218068,0.000053244108,0.00020624073,0.00011491093,0.00008432466,0.00011370889,0.000014982674,0.0001338382,7.238366e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005011288,0.0004983347,0.6768751,0.00010106721,0.0002815827,0.000008179246,0.0000366103,0.00006340915,0.019967472,0.0000778622,0.004900823,0.29217824],"study_design_scores_gemma":[0.008202682,0.0041819713,0.96965605,0.00006307404,0.000257124,0.000020598924,0.00003946605,0.0009803303,0.0010352281,0.00014465832,0.015374433,0.000044411514],"about_ca_topic_score_codex":0.00023390271,"about_ca_topic_score_gemma":0.000036238584,"teacher_disagreement_score":0.2927809,"about_ca_system_score_codex":0.00006473223,"about_ca_system_score_gemma":0.0004299165,"threshold_uncertainty_score":0.21712317},"labels":[],"label_agreement":null},{"id":"W2966744080","doi":"10.1200/jco.19.00286","title":"Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Internal medicine; Hazard ratio; Adipose tissue; Body mass index; Cancer; Incidence (geometry); Confidence interval","score_opus":0.03357990002935072,"score_gpt":0.3770372714990963,"score_spread":0.3434573714697456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966744080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444914,0.001920754,0.00036525037,0.0017144382,0.0009836793,0.00024918557,0.000057567777,0.00000886947,0.0002510966],"genre_scores_gemma":[0.9931316,0.004953793,0.000080133934,0.00035903708,0.0013210512,0.0000029465052,0.000010528515,0.000012815696,0.00012814513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797666,0.00041827024,0.0008989994,0.0001971566,0.00035225987,0.00015662375],"domain_scores_gemma":[0.99788594,0.0004460207,0.0006257967,0.00022723209,0.0003148175,0.00050020544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026995735,0.000109251356,0.0010973071,0.000042103293,0.000035330093,0.000009172167,0.00006378316,0.00028636062,0.00013117136],"category_scores_gemma":[0.0007522096,0.000082745675,0.0006327653,0.00009455315,0.00015908954,0.00013805671,0.000023480385,0.00071521534,0.000010210061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017395671,0.00027689475,0.6887877,0.000047507536,0.0014643142,0.00015577467,0.00004229308,0.00012094075,0.0005359965,0.000020937596,0.00042474995,0.30638334],"study_design_scores_gemma":[0.0045176134,0.0010236483,0.9555281,0.0001147057,0.0014133477,0.00020361171,0.00004920282,0.00011859359,0.0005265226,0.00010732076,0.03630845,0.00008892959],"about_ca_topic_score_codex":0.00034511893,"about_ca_topic_score_gemma":0.000062520936,"teacher_disagreement_score":0.3062944,"about_ca_system_score_codex":0.000120080476,"about_ca_system_score_gemma":0.00058504404,"threshold_uncertainty_score":0.33742708},"labels":[],"label_agreement":null},{"id":"W2966774409","doi":"10.1200/jco.2012.30.15_suppl.e17539","title":"NY-ESO-1 as a predictive and prognostic marker in NSCLC.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; KRAS; Immunohistochemistry; Chemotherapy; Internal medicine; Predictive marker; Oncology; Pathological; Pathology; Stage (stratigraphy); Cancer; Colorectal cancer; Biology","score_opus":0.1043965764766866,"score_gpt":0.45681844037371455,"score_spread":0.35242186389702795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966774409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676197,0.007904362,0.000017771612,0.00644299,0.000941887,0.00018157641,9.944993e-7,0.0000051019792,0.0168856],"genre_scores_gemma":[0.9945415,0.0009149841,0.00056223635,0.0021390477,0.0015679549,0.000005579086,4.2696237e-7,0.0000092320415,0.0002589939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981038,0.00022596757,0.0011104832,0.000109436754,0.00020886051,0.0002414698],"domain_scores_gemma":[0.9970728,0.0018311142,0.000495468,0.00008434037,0.00016847279,0.0003478139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021734098,0.000096792755,0.00093659404,0.0001037206,0.00002041185,0.000003917912,0.000054953143,0.00020993766,0.00007135454],"category_scores_gemma":[0.0049152877,0.000065651424,0.00017988964,0.00009755427,0.00018869017,0.00012445042,0.000060277285,0.00074487674,0.000012637723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035583684,0.00083163846,0.94222236,0.00002051478,0.00023352343,0.00032083262,0.0004792089,1.6560976e-7,0.000015207081,0.000045347733,0.004684532,0.047588285],"study_design_scores_gemma":[0.0050545526,0.007914644,0.9538689,0.0001190076,0.00029738405,0.0008077272,0.0003942142,0.000011008669,0.0000056291888,0.00016086087,0.031310227,0.000055827044],"about_ca_topic_score_codex":0.000015975023,"about_ca_topic_score_gemma":0.000023817995,"teacher_disagreement_score":0.047532458,"about_ca_system_score_codex":0.00008538557,"about_ca_system_score_gemma":0.000513873,"threshold_uncertainty_score":0.5884414},"labels":[],"label_agreement":null},{"id":"W2966868180","doi":"10.1200/jco.2012.30.15_suppl.9067","title":"<i>Clostridium difficile</i>-associated diarrhea in cancer patients treated with fidaxomicin or vancomycin.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Fidaxomicin; Diarrhea; Internal medicine; Clostridium difficile; Gastroenterology; Vancomycin; Colorectal cancer; Cancer; Population; Antibiotics","score_opus":0.11160773125492533,"score_gpt":0.4457797029378046,"score_spread":0.33417197168287927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966868180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932145,0.0005880878,0.000003323059,0.0027061608,0.00090269156,0.0004935529,0.00002756268,0.000019624289,0.0020445366],"genre_scores_gemma":[0.99502176,0.0015716468,0.00014124981,0.0008559952,0.001366043,0.000017132934,0.000016682727,0.000050297756,0.0009592148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99443144,0.000649182,0.0028472834,0.0002850242,0.0008872732,0.00089981675],"domain_scores_gemma":[0.9936253,0.002630283,0.0015674292,0.00027030453,0.00091615,0.0009905274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026936147,0.0003130229,0.002277846,0.0003472793,0.000059064325,0.0000135094,0.00025086643,0.0005493356,0.000679793],"category_scores_gemma":[0.0053620734,0.00018638304,0.00041498014,0.00079560955,0.00023449525,0.00021024607,0.00008475833,0.0020296655,0.000035099863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01852452,0.014329975,0.9338992,0.000045891302,0.00045083676,0.0006191624,0.000105127685,0.000014879713,0.00074007374,0.000005420908,0.010046232,0.021218665],"study_design_scores_gemma":[0.036596775,0.02790846,0.88554657,0.0005886972,0.0006580748,0.00017818031,0.00016702538,0.00006857061,0.0122826705,0.0000044178214,0.03564855,0.00035200972],"about_ca_topic_score_codex":0.00031698556,"about_ca_topic_score_gemma":0.0005845832,"teacher_disagreement_score":0.048352648,"about_ca_system_score_codex":0.0010805569,"about_ca_system_score_gemma":0.0026162404,"threshold_uncertainty_score":0.88179994},"labels":[],"label_agreement":null},{"id":"W2966944913","doi":"10.1200/jco.2009.27.15_suppl.3552","title":"Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Erlotinib; Rash; Mucositis; Epidermal growth factor receptor; Internal medicine; Neutropenia; Toxicity; Pharmacology; Oncology; Cancer; Colorectal cancer","score_opus":0.08132331328723262,"score_gpt":0.5071893561485397,"score_spread":0.425866042861307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966944913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880813,0.00026306586,0.000033575117,0.009391489,0.00062825787,0.0005103028,0.000008952521,0.000014244397,0.0010688225],"genre_scores_gemma":[0.99495995,0.00017288307,0.0018783798,0.002237043,0.00063344033,0.0000073832175,0.000007866047,0.000013600278,0.000089471876],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965565,0.00033931786,0.002320485,0.0002394509,0.00028336686,0.00026083706],"domain_scores_gemma":[0.9971513,0.0008965556,0.0011492305,0.00011521355,0.0003019346,0.0003857266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011437841,0.00016928515,0.0014992993,0.00018279393,0.00006469963,0.0000134108905,0.000054615735,0.0001760695,0.00011227776],"category_scores_gemma":[0.0017836494,0.00012552446,0.00019503267,0.00017159845,0.000109682725,0.00024914663,0.000024686446,0.0008222177,0.000007471571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018155443,0.059008066,0.33285135,0.00005800837,0.00095768395,0.009061008,0.0062111267,0.00002994562,0.002015153,0.00036569446,0.0029407989,0.5683457],"study_design_scores_gemma":[0.12252947,0.112868086,0.755841,0.0003256389,0.0005714085,0.0008258312,0.0027867458,0.000051160274,0.00034296417,0.00061904953,0.0030149461,0.0002236755],"about_ca_topic_score_codex":0.000011428926,"about_ca_topic_score_gemma":0.00001672838,"teacher_disagreement_score":0.568122,"about_ca_system_score_codex":0.0002140583,"about_ca_system_score_gemma":0.0009513605,"threshold_uncertainty_score":0.5118739},"labels":[],"label_agreement":null},{"id":"W2967034948","doi":"10.1200/jco.2007.25.18_suppl.3594","title":"A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Pharmacokinetics; Erlotinib; Pharmacodynamics; Toxicity; Internal medicine; Adverse effect; Gastroenterology; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.07361737481403348,"score_gpt":0.5449734878466853,"score_spread":0.47135611303265185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967034948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959854,0.00082568644,0.00016680273,0.0011719752,0.00044543284,0.0006750577,0.000008358573,0.000006892477,0.0007144198],"genre_scores_gemma":[0.99713606,0.0007441246,0.0011952047,0.00042045748,0.00020501498,0.0000067667957,0.0000028004645,0.00001475695,0.00027480486],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99711186,0.00020096207,0.0020160696,0.0002006677,0.0002608209,0.00020959525],"domain_scores_gemma":[0.997001,0.0011000383,0.001245609,0.000096238284,0.00028019267,0.00027691695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019615788,0.00014263252,0.0010117576,0.00023810823,0.000033942677,0.000005947528,0.00006368443,0.00012220259,0.000042359217],"category_scores_gemma":[0.00048182125,0.000107758875,0.0000997719,0.00019306253,0.00014760025,0.00016727082,0.00003423651,0.00046592555,8.62442e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026019663,0.029265344,0.22654215,0.00017372373,0.0009775651,0.0019638638,0.0038260831,0.00018082974,0.029818766,0.000038609516,0.0001580595,0.68103534],"study_design_scores_gemma":[0.11310177,0.05170869,0.8246305,0.00016631659,0.0014034994,0.00021831281,0.0036964444,0.0009347645,0.00034901415,0.00006145201,0.0035988968,0.0001303532],"about_ca_topic_score_codex":0.000046100435,"about_ca_topic_score_gemma":0.00013720745,"teacher_disagreement_score":0.680905,"about_ca_system_score_codex":0.000113461436,"about_ca_system_score_gemma":0.00043704905,"threshold_uncertainty_score":0.4394279},"labels":[],"label_agreement":null},{"id":"W2967139641","doi":"10.1200/jco.2012.30.15_suppl.e18120","title":"Impact of local and systemic treatment on survival and on brain relapse of patients with localized or metastatic non-small cell lung cancer who develop brain metastasis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Brain metastasis; Medicine; Metastasis; Internal medicine; Oncology; sync; Stage (stratigraphy); Cancer","score_opus":0.07815820625922221,"score_gpt":0.43076006713305715,"score_spread":0.35260186087383494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967139641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956843,0.0013608579,0.0007942391,0.0010170564,0.00024853362,0.00069444237,0.00009572417,0.0000032247037,0.000101604404],"genre_scores_gemma":[0.99493355,0.0006960726,0.0036144706,0.00047625357,0.00010250258,0.000013371743,0.000010470073,0.000031589523,0.000121713696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959062,0.0010696482,0.0020121245,0.00024245268,0.00042790032,0.00034167877],"domain_scores_gemma":[0.9897066,0.006963167,0.0020954714,0.00022332955,0.0003983613,0.0006130719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027880438,0.00031963363,0.0028211272,0.00019235225,0.00003300674,0.0000052645432,0.000075826654,0.00018042166,0.00007927804],"category_scores_gemma":[0.0010936463,0.00015428742,0.00035768954,0.00019366473,0.00027630915,0.000079594174,0.000034807894,0.0003764443,0.0000011552937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05832095,0.01285971,0.80452186,0.000575541,0.0074301013,0.00037214745,0.0006863851,0.00024642775,0.000047321886,0.00008098336,0.0017015751,0.11315701],"study_design_scores_gemma":[0.06381101,0.13335177,0.79396963,0.00102755,0.004893143,0.00022532934,0.0004944418,0.00017450177,0.00035863096,0.000009696219,0.0014538614,0.00023041196],"about_ca_topic_score_codex":0.00021405755,"about_ca_topic_score_gemma":0.00010608503,"teacher_disagreement_score":0.12049206,"about_ca_system_score_codex":0.00041618306,"about_ca_system_score_gemma":0.0015849079,"threshold_uncertainty_score":0.6291658},"labels":[],"label_agreement":null},{"id":"W2967321104","doi":"10.1200/jco.2009.27.15_suppl.e19537","title":"DNA methylation status of Smurf2 promoter in patients with multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; DNA methylation; Multiple myeloma; Methylation; Cancer research; SMAD; Bone marrow; Epigenetics; Molecular biology; Internal medicine; Transforming growth factor; Gene; Biology; Gene expression; Genetics","score_opus":0.027834403804632857,"score_gpt":0.37101571539864237,"score_spread":0.3431813115940095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967321104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843365,0.00016603131,0.00042084823,0.00032731416,0.00025753025,0.00014242671,0.0000031318966,0.0000013398057,0.00024771577],"genre_scores_gemma":[0.99689764,0.00010405354,0.0025540702,0.00013547631,0.00025557406,7.2029064e-7,0.000017753815,0.0000074912964,0.000027208063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980941,0.0002293385,0.0011875712,0.00013823679,0.00018458598,0.00016616462],"domain_scores_gemma":[0.9980806,0.00010564855,0.001212973,0.00013316987,0.00035861623,0.00010898118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076324603,0.00008373692,0.0004393058,0.00007645924,0.000010493617,0.0000027593917,0.0000895395,0.00033240792,0.00001053717],"category_scores_gemma":[0.0009320366,0.00006323392,0.00012783676,0.00009859372,0.000064758846,0.000009847185,0.000017491042,0.00023131288,8.6183934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006884559,0.0011737066,0.54586065,0.0000073414412,0.00011579893,0.000005140361,0.000052218824,0.0012587124,0.024014305,0.000008902128,0.00034850993,0.42027017],"study_design_scores_gemma":[0.0063066683,0.012744957,0.96381843,0.000025920634,0.00003623996,0.0000042699635,0.000008385636,0.00008102236,0.008703107,0.000094257804,0.008103767,0.00007295628],"about_ca_topic_score_codex":0.0000061266305,"about_ca_topic_score_gemma":0.000079791986,"teacher_disagreement_score":0.42019722,"about_ca_system_score_codex":0.000058763486,"about_ca_system_score_gemma":0.00048118574,"threshold_uncertainty_score":0.25786045},"labels":[],"label_agreement":null},{"id":"W2967546340","doi":"10.1200/jco.2013.31.15_suppl.e20650","title":"The psychological projective test Wartegg-Zeichentest: A contribution to the knowledge of patient with cancer—The experience of two Italian centers.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Personality; Psychological distress; Test (biology); Clinical psychology; Distress; Internal medicine; Psychiatry; Anxiety; Nursing; Psychology","score_opus":0.07026673809298416,"score_gpt":0.47375493788848766,"score_spread":0.4034881997955035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967546340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745614,0.0007195495,0.000093589486,0.021778855,0.0011930132,0.00072260463,0.000008347718,0.000003470663,0.00091918436],"genre_scores_gemma":[0.9972641,0.00028978204,0.000054270058,0.0017725289,0.00045152917,0.00009115195,5.623541e-7,0.00000684491,0.000069219226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975123,0.000478236,0.0013334149,0.00015029241,0.00030729285,0.00021845687],"domain_scores_gemma":[0.9937634,0.002983299,0.0012715803,0.00027279215,0.0015313313,0.00017760294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014350713,0.000112341455,0.0006891607,0.00003480553,0.000081104685,0.000009209836,0.0003094936,0.000113348935,0.0000775872],"category_scores_gemma":[0.0027501718,0.00004000303,0.00025868363,0.00026796001,0.0006030582,0.00005404594,0.00006210008,0.00061974203,0.0000060729876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01162964,0.0058554974,0.5260065,0.00004234718,0.0006515547,0.00006492683,0.026524886,0.000022542807,0.0008518084,0.0007891191,0.016851384,0.41070974],"study_design_scores_gemma":[0.008163236,0.05925613,0.7195926,0.00053812907,0.00042335028,0.00044372393,0.019304229,0.00011522632,0.0010437925,0.00030033922,0.19065353,0.00016574399],"about_ca_topic_score_codex":0.00070549385,"about_ca_topic_score_gemma":0.0033985209,"teacher_disagreement_score":0.410544,"about_ca_system_score_codex":0.00013095181,"about_ca_system_score_gemma":0.0005352397,"threshold_uncertainty_score":0.3292411},"labels":[],"label_agreement":null},{"id":"W2967569980","doi":"10.1200/jco.19.01492","title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Nivolumab; Adverse effect; Transplantation; Oncology; Lymphoma; Anaplastic large-cell lymphoma; Gastroenterology; Surgery; CD30; Cancer; Immunotherapy","score_opus":0.043628263859766474,"score_gpt":0.38423082836358635,"score_spread":0.34060256450381987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967569980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99166065,0.0010588394,0.00003365277,0.0038916399,0.0010056978,0.0015268773,0.00004803556,0.000014812777,0.00075976085],"genre_scores_gemma":[0.995369,0.0004595938,0.0010482923,0.001984849,0.00076252606,0.000024823828,0.00003613006,0.0000337687,0.0002809969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996359,0.0004603419,0.001964479,0.00036964304,0.0004926401,0.00035393416],"domain_scores_gemma":[0.9896281,0.0075115133,0.0017591905,0.00037347147,0.00033450927,0.00039326554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026548128,0.00026865388,0.0019428367,0.00005953384,0.00016570983,0.000018314326,0.0002215499,0.00026228657,0.00010955352],"category_scores_gemma":[0.00089567027,0.00014083504,0.00035177675,0.00009636751,0.0001727664,0.000116541596,0.00013953495,0.00046612287,0.00002103298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18663481,0.26031098,0.31918213,0.00007475218,0.0024062193,0.0011348259,0.0012476551,0.0000024327346,0.00015989835,0.00004839817,0.0077059236,0.22109197],"study_design_scores_gemma":[0.3349209,0.13629009,0.4898044,0.00011680613,0.0013398023,0.000113256865,0.0003933049,0.00004841363,0.00002847464,0.00002130996,0.03681727,0.00010594808],"about_ca_topic_score_codex":0.000031418593,"about_ca_topic_score_gemma":0.000042751235,"teacher_disagreement_score":0.22098602,"about_ca_system_score_codex":0.00031256347,"about_ca_system_score_gemma":0.0016929755,"threshold_uncertainty_score":0.57430863},"labels":[],"label_agreement":null},{"id":"W2967809711","doi":"10.1200/jco.2006.24.18_suppl.666","title":"Cardiovascular risk profile of breast cancer patients treated with anthracycline-taxane containing adjuvant chemotherapy and/or trastuzumab","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Trastuzumab; Anthracycline; Ejection fraction; Oncology; Taxane; Cancer; Chemotherapy; Cardiology; Gastroenterology; Heart failure","score_opus":0.018253614914466972,"score_gpt":0.3377077644033332,"score_spread":0.31945414948886625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967809711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934414,0.0042157006,0.00018646824,0.00015794736,0.0014726183,0.00019925956,0.00010849946,0.0000035378023,0.00021456814],"genre_scores_gemma":[0.9812417,0.009717839,0.0007786843,0.0001862476,0.007896526,0.000008994115,0.000017477305,0.000025755351,0.00012679669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976431,0.00030165145,0.0013222403,0.00025998778,0.00025030426,0.00022273012],"domain_scores_gemma":[0.99742556,0.00013246122,0.0015472828,0.00019629867,0.0005491126,0.00014926247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010186838,0.00017943564,0.0013007872,0.000053813725,0.00004274054,0.000006548784,0.00014039889,0.0003119749,0.00004413464],"category_scores_gemma":[0.00022529958,0.00011302409,0.0004468694,0.00008684924,0.00027611316,0.0000107663955,0.00003048312,0.00031104803,4.0022024e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020037865,0.0018173689,0.56233734,0.000037854268,0.001936372,0.0000072621324,0.00005268122,0.00020404924,0.004513681,0.000005354267,0.006489745,0.4025604],"study_design_scores_gemma":[0.017119488,0.009758863,0.7816551,0.000064284905,0.0006272759,0.00012372223,0.00008227915,0.000024019142,0.0023193099,0.000007835048,0.18802798,0.0001899016],"about_ca_topic_score_codex":0.00055360707,"about_ca_topic_score_gemma":0.00032716244,"teacher_disagreement_score":0.4023705,"about_ca_system_score_codex":0.000033339427,"about_ca_system_score_gemma":0.00073749974,"threshold_uncertainty_score":0.46089885},"labels":[],"label_agreement":null},{"id":"W2968235903","doi":"10.1200/jco.2013.31.15_suppl.e15094","title":"Recurrent anal squamous carcinoma: Is HPV a risk factor?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Saint-Luc; Hôtel-Dieu de Montréal; Hôpital Notre-Dame; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Anal cancer; Internal medicine; Anal Carcinoma; Radiation therapy; Retrospective cohort study; Cancer; Stage (stratigraphy); Risk factor; Multivariate analysis; Cohort; Oncology; Gastroenterology","score_opus":0.11984754505454558,"score_gpt":0.43150471664970524,"score_spread":0.31165717159515965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968235903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818692,0.0010108752,0.000034377736,0.008459937,0.0015554384,0.00019802671,0.000009702595,0.000011529765,0.0068509215],"genre_scores_gemma":[0.9935297,0.0003235635,0.0006294235,0.0026406238,0.0022794332,0.0000035099397,0.0000011949269,0.000015317939,0.0005772574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964361,0.00037661847,0.0022062177,0.00022354568,0.00044291597,0.00031455336],"domain_scores_gemma":[0.9952409,0.0015237146,0.0016122579,0.00019668884,0.00071544334,0.00071099406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011651947,0.00017569916,0.0014910266,0.00015364864,0.000054277083,0.00001471518,0.00018756531,0.00038168876,0.0031754312],"category_scores_gemma":[0.0031916688,0.00011274137,0.0010110713,0.00017435307,0.00019334542,0.00013014679,0.00007761642,0.0017007294,0.0002511167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017132371,0.0012691573,0.4929791,0.000025403448,0.00016662499,0.0005623981,0.00020215387,5.1977815e-7,0.00016675779,0.00002240869,0.03198657,0.47090566],"study_design_scores_gemma":[0.0045872913,0.021128386,0.92565334,0.000021732129,0.0003340493,0.000585839,0.00014348628,0.00027959835,0.00011536027,0.0005629445,0.046472587,0.00011536452],"about_ca_topic_score_codex":0.0001539986,"about_ca_topic_score_gemma":0.00006215776,"teacher_disagreement_score":0.4707903,"about_ca_system_score_codex":0.00015867421,"about_ca_system_score_gemma":0.0010601337,"threshold_uncertainty_score":0.9977358},"labels":[],"label_agreement":null},{"id":"W2968254700","doi":"10.1200/jco.2013.31.15_suppl.e15034","title":"The management of dysphagia in esophageal adenocarcinoma patients undergoing neoadjuvant chemotherapy: Can invasive tube feeding be avoided?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Dysphagia; Neoadjuvant therapy; Interquartile range; Chemotherapy; Internal medicine; Body mass index; Esophageal cancer; Surgery; Cancer","score_opus":0.05605770101970628,"score_gpt":0.37108550303551097,"score_spread":0.3150278020158047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968254700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96976733,0.00054453127,0.000024399831,0.025409287,0.0011281676,0.0005171171,7.8866066e-7,0.000005477035,0.0026029034],"genre_scores_gemma":[0.99131,0.002247292,0.0013381044,0.003903079,0.0003166679,0.000008284332,0.0000015555626,0.000017367543,0.0008576749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658304,0.00017877233,0.002258777,0.00017563943,0.00048348168,0.00032028006],"domain_scores_gemma":[0.99588346,0.0018714967,0.0015365515,0.00020464629,0.00029852698,0.00020530444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017951645,0.00015233622,0.0010224608,0.00016135782,0.000054385426,0.000017995393,0.00029524232,0.00015484961,0.00014099087],"category_scores_gemma":[0.00069514825,0.00009598389,0.00032872532,0.00023331807,0.00016230448,0.000121781864,0.00013142543,0.00065095065,0.000007103473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078672555,0.00050795317,0.8456585,0.00011320531,0.0007152887,0.0002526698,0.00023183327,0.000013841217,0.00000864011,0.00024170667,0.008820363,0.14264928],"study_design_scores_gemma":[0.012447792,0.003984259,0.9784916,0.00021030057,0.00025852295,0.000017627563,0.001087277,0.000038107355,0.000035906225,0.00048271043,0.0028738203,0.00007208891],"about_ca_topic_score_codex":0.00010726293,"about_ca_topic_score_gemma":0.00020034357,"teacher_disagreement_score":0.14257719,"about_ca_system_score_codex":0.00028901317,"about_ca_system_score_gemma":0.00044404707,"threshold_uncertainty_score":0.39141092},"labels":[],"label_agreement":null},{"id":"W2968292138","doi":"10.1200/jco.2009.27.15_suppl.e15083","title":"Safety of bevacizumab when given perioperatively for colorectal cancer with liver metastases: McGill University pilot study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Bevacizumab; FOLFIRI; Oxaliplatin; Surgery; Colorectal cancer; Perioperative; Regimen; Chemotherapy; Internal medicine; Cancer","score_opus":0.1280333742136724,"score_gpt":0.42578412209931515,"score_spread":0.29775074788564276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968292138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923421,0.0005256197,0.00007074786,0.004459755,0.00021563486,0.0008611129,0.00019115132,0.0000065364743,0.0013272999],"genre_scores_gemma":[0.9946562,0.0008036338,0.0034921216,0.0003946132,0.00019722681,0.0000041981925,0.000001906218,0.000008310727,0.00044179123],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99809796,0.00028493622,0.00097486295,0.0002020298,0.00026384342,0.00017636786],"domain_scores_gemma":[0.996901,0.00093027856,0.00096127787,0.00008918556,0.0009326122,0.00018564724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092498446,0.00015520671,0.0016497794,0.00008625982,0.00012040341,0.0000022373777,0.00011796747,0.000074482865,0.00012196001],"category_scores_gemma":[0.0004370614,0.00009547113,0.0002707003,0.00011175941,0.00016818743,0.00010560914,0.000034769302,0.00031932333,8.1473405e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5538973,0.030610377,0.07873718,0.00006711016,0.009595181,0.0022434732,0.002841164,0.0000699663,0.000412046,0.0002975209,0.005116114,0.31611255],"study_design_scores_gemma":[0.03060271,0.3940082,0.51128536,0.00007609434,0.002423784,0.00009217038,0.0018900428,0.000022632512,0.00011308897,0.00003679069,0.059338264,0.0001108609],"about_ca_topic_score_codex":0.0002254666,"about_ca_topic_score_gemma":0.0020670125,"teacher_disagreement_score":0.5232946,"about_ca_system_score_codex":0.0005129566,"about_ca_system_score_gemma":0.0010794767,"threshold_uncertainty_score":0.38931996},"labels":[],"label_agreement":null},{"id":"W2968399040","doi":"10.1200/jco.2012.30.15_suppl.3632","title":"Surgical resection and peri-operative chemotherapy for colorectal cancer (CRC) liver metastases in routine clinical practice: A population-based outcomes study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Perioperative; Cancer; Cancer registry; Chemotherapy; Population; Surgery; Resection; General surgery; Internal medicine; Oncology","score_opus":0.16923922585168827,"score_gpt":0.5636428029485436,"score_spread":0.39440357709685536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968399040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863565,0.0023518656,0.000019857607,0.008941374,0.001125438,0.0009273953,0.000012175233,0.000007256002,0.00025816742],"genre_scores_gemma":[0.993122,0.0014509164,0.0025773875,0.0013598141,0.0012924853,0.00008315773,0.000004425381,0.000016965136,0.00009285025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961003,0.0009785305,0.0021098156,0.00023047098,0.00031485304,0.00026602313],"domain_scores_gemma":[0.98895353,0.009055076,0.0011045154,0.00008645143,0.0005240277,0.00027636922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005564174,0.00018292743,0.0018703248,0.0001168894,0.00008721457,0.000012437599,0.000054369182,0.00023898236,0.00011007922],"category_scores_gemma":[0.0068612606,0.000112448506,0.00041809623,0.00014057678,0.00014655718,0.00022812172,0.000031098076,0.0006216245,0.0000010538827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034537785,0.008293364,0.8906718,0.000014157213,0.0010709965,0.00015882915,0.00046985145,0.000006954617,0.0000018384113,0.000030683845,0.0003864904,0.06435724],"study_design_scores_gemma":[0.02820097,0.029934298,0.92286354,0.00003531077,0.0008082987,0.00010013232,0.00090917834,0.00013943962,0.000009986736,0.000010445946,0.01688875,0.00009964338],"about_ca_topic_score_codex":0.00046207415,"about_ca_topic_score_gemma":0.001859364,"teacher_disagreement_score":0.06425761,"about_ca_system_score_codex":0.0003305733,"about_ca_system_score_gemma":0.0006706118,"threshold_uncertainty_score":0.82140654},"labels":[],"label_agreement":null},{"id":"W2968566719","doi":"10.1200/jco.2013.31.15_suppl.e16082","title":"Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Université de Montréal; Université Laval; Sanofi (Canada); Sunnybrook Health Science Centre; University of Toronto; Moncton Hospital; Grand River Hospital; London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Cabazitaxel; Prostate cancer; Adverse effect; Internal medicine; Neutropenia; Febrile neutropenia; Prednisone; Surgery; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.16341291541713204,"score_gpt":0.5157864465834574,"score_spread":0.35237353116632536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968566719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97829664,0.001120447,0.0000018342663,0.015295095,0.0011205705,0.0005502861,0.000012999437,0.00000615286,0.0035959668],"genre_scores_gemma":[0.9936752,0.0012053808,0.00075828034,0.0023835155,0.00040139866,0.00007774229,0.0000068131785,0.000015023567,0.0014766783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996908,0.00035325,0.001915741,0.00020235605,0.00023518567,0.00038547485],"domain_scores_gemma":[0.9972624,0.00054477254,0.0008818648,0.00012795489,0.00045331073,0.0007297024],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00094383257,0.00015853519,0.0011429713,0.00030005182,0.00004304302,0.000015639276,0.00011242023,0.00020375311,0.0026605772],"category_scores_gemma":[0.0006340946,0.000113191876,0.00022498291,0.00028243838,0.00018010633,0.00022515214,0.000013947764,0.00070024224,0.000042830372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009242513,0.0040904437,0.7135941,0.0001048502,0.0013349205,0.008583664,0.004280312,0.00011791119,0.012074957,0.000100966616,0.044784382,0.201691],"study_design_scores_gemma":[0.016876264,0.012004269,0.9110472,0.00015337154,0.0005831189,0.00041701595,0.0009846233,0.00019844451,0.0005996366,0.0003326854,0.056614123,0.00018923556],"about_ca_topic_score_codex":0.10678059,"about_ca_topic_score_gemma":0.25187436,"teacher_disagreement_score":0.20150177,"about_ca_system_score_codex":0.00083842146,"about_ca_system_score_gemma":0.0051774196,"threshold_uncertainty_score":0.99825114},"labels":[],"label_agreement":null},{"id":"W2968569151","doi":"10.1200/jco.19.00570","title":"Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Hospital for Sick Children; Trillium Health Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Relative risk; Population; Leukemia; Cohort; Pediatrics; Retrospective cohort study; Childhood leukemia; Cohort study; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Confidence interval; Lymphoblastic Leukemia","score_opus":0.16491033015754916,"score_gpt":0.5222401100001124,"score_spread":0.3573297798425632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968569151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970774,0.00014196073,0.0005037898,0.00038770333,0.00042915568,0.0012882077,0.000082577775,0.0000047887906,0.00008442058],"genre_scores_gemma":[0.9968428,0.00022121196,0.0023170684,0.00014261094,0.00038273286,0.0000068235317,0.000032564334,0.000019005542,0.000035206365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946605,0.0011105405,0.003057437,0.0002991906,0.0006373394,0.00023498466],"domain_scores_gemma":[0.9913443,0.0036727998,0.003397105,0.0007029988,0.00052805356,0.00035478515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003183943,0.00016398571,0.002177304,0.00023343768,0.000038002327,0.00000492277,0.00020035858,0.00025895095,0.0001927979],"category_scores_gemma":[0.0025057008,0.00011153564,0.00035131827,0.00023768871,0.00015778853,0.00011782201,0.00008259477,0.0006062826,0.0000062107724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003315119,0.011447073,0.97527945,0.000052353138,0.0014569587,0.00016968585,0.00019206108,0.00018493237,0.000007291924,0.0000018350802,0.000048450733,0.007844777],"study_design_scores_gemma":[0.017025707,0.063581035,0.9164861,0.00015863597,0.001052955,0.00016202313,0.00013673474,0.0012608995,0.000012611685,0.000010217023,0.00004965786,0.000063417676],"about_ca_topic_score_codex":0.0010982079,"about_ca_topic_score_gemma":0.0006143992,"teacher_disagreement_score":0.05879336,"about_ca_system_score_codex":0.002206974,"about_ca_system_score_gemma":0.01989257,"threshold_uncertainty_score":0.9856637},"labels":[],"label_agreement":null},{"id":"W2968747111","doi":"10.1200/jco.2012.30.15_suppl.7093","title":"NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Cisplatin; Chemotherapy; Oncology; Cancer","score_opus":0.15381927137870718,"score_gpt":0.5391692761335148,"score_spread":0.38535000475480763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968747111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165267,0.0032736112,0.00004217538,0.0031780212,0.00046505054,0.0006711295,0.0000042792362,0.0000028607258,0.00071023416],"genre_scores_gemma":[0.9953871,0.0025275561,0.0009228749,0.00046170707,0.00051201,0.00002218943,0.0000010709292,0.000013946997,0.00015158611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967724,0.00055333576,0.0017741537,0.00015650137,0.00041658978,0.00032700234],"domain_scores_gemma":[0.9953115,0.0025544467,0.0012769597,0.00012232213,0.0004647299,0.00027001544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045431624,0.00013149783,0.0014476196,0.00031816625,0.000021432257,0.000004992461,0.000095909636,0.00022918919,0.000046853293],"category_scores_gemma":[0.0035061715,0.00008875845,0.00011795854,0.00024411018,0.00029575982,0.0001591791,0.00007204422,0.0011321527,7.19905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1671258,0.007075992,0.7895759,0.0003470813,0.00025650844,0.00054227817,0.0016277342,0.000025626843,0.0009675989,0.00010726013,0.00068039657,0.03166784],"study_design_scores_gemma":[0.3700261,0.035342462,0.5881613,0.0008068272,0.00037703634,0.000065218075,0.0008376878,0.00036759966,0.000809457,0.00008385236,0.0029717626,0.00015068041],"about_ca_topic_score_codex":0.00026549186,"about_ca_topic_score_gemma":0.0010464992,"teacher_disagreement_score":0.2029003,"about_ca_system_score_codex":0.0003410506,"about_ca_system_score_gemma":0.0016482545,"threshold_uncertainty_score":0.4918703},"labels":[],"label_agreement":null},{"id":"W2968841384","doi":"10.1200/jco.2012.30.15_suppl.e14154","title":"Hepatic resection for colorectal cancer metastasis: A retrospective review of the Ottawa Hospital Cancer Centre over 7 years.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Hazard ratio; Perioperative; Univariate analysis; Metastasis; Retrospective cohort study; Primary tumor; Cancer; Surgery; Chemotherapy; Internal medicine; Oncology; Multivariate analysis; Confidence interval","score_opus":0.22208241860216965,"score_gpt":0.47924843243954884,"score_spread":0.2571660138373792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968841384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004987964,0.9867948,0.0000022106199,0.0015147664,0.0038373424,0.0025003864,0.00016598302,0.000005292568,0.00019120646],"genre_scores_gemma":[0.004589079,0.99157834,0.00026735375,0.00036558099,0.0026856149,0.00020667005,0.000016573616,0.000052929387,0.00023782822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940919,0.0012314048,0.0035134584,0.00028017856,0.00055041624,0.00033264217],"domain_scores_gemma":[0.9906796,0.0015945582,0.0063331174,0.00027197838,0.00083424285,0.00028650594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038052744,0.00033177348,0.0060118726,0.00011895193,0.000042982574,0.0000057795696,0.0002659978,0.0007219635,0.00059629],"category_scores_gemma":[0.0029560435,0.00017936008,0.004324164,0.0003810143,0.00018982694,0.00008578782,0.000073633775,0.0013037886,0.000005909695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043211933,0.0011110447,0.10178156,0.03183327,0.0043487204,0.000058983613,0.00004946485,1.722753e-8,3.221495e-7,0.000018893359,0.013630624,0.846735],"study_design_scores_gemma":[0.0019202782,0.0051005348,0.015562726,0.059622806,0.031328756,0.00007266606,0.0000068693803,0.0000025490097,0.0000054467523,0.000016143966,0.88621205,0.00014917094],"about_ca_topic_score_codex":0.00010969822,"about_ca_topic_score_gemma":0.0002185571,"teacher_disagreement_score":0.8725814,"about_ca_system_score_codex":0.0009817368,"about_ca_system_score_gemma":0.0041792765,"threshold_uncertainty_score":0.74138576},"labels":[],"label_agreement":null},{"id":"W2969366123","doi":"10.1200/jco.2007.25.18_suppl.6590","title":"Adjuvant chemotherapy in non-small cell lung cancer (NSCLC): Referral and utilization patterns","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Wedge resection; Chemotherapy; Oncology; Stage (stratigraphy); Cancer; Pneumonectomy; Referral; Adenocarcinoma; Surgery; Family medicine","score_opus":0.13701736829608982,"score_gpt":0.49230391234362497,"score_spread":0.3552865440475351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969366123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896505,0.0028824327,0.0006612432,0.0048436113,0.0006845634,0.00021020125,0.0000022026286,0.0000030418757,0.0010622335],"genre_scores_gemma":[0.9791575,0.015908586,0.0006142458,0.003401976,0.00078369305,0.0000046358023,0.0000016244749,0.00001272512,0.00011500636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816453,0.00006483647,0.001289516,0.00014410075,0.00015285212,0.0001841449],"domain_scores_gemma":[0.9983175,0.00054934947,0.00067532586,0.000089069676,0.00013703569,0.00023176051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015055803,0.00009834237,0.0008170506,0.00010535435,0.00001442567,0.0000047432313,0.000048833183,0.00022511721,0.00014470394],"category_scores_gemma":[0.000113771595,0.00006912099,0.00015988118,0.00007964875,0.000043889762,0.00004318058,0.000016451118,0.00043255516,0.0000011763306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015014847,0.0011842783,0.74895084,0.000035686655,0.0000763801,0.00035744114,0.00020415905,0.0000042977454,0.000054821066,0.000007300437,0.0009426934,0.24668062],"study_design_scores_gemma":[0.013792075,0.0036737458,0.972432,0.0002658633,0.00017665394,0.000057893776,0.00009594467,0.00010605118,0.00045065576,0.000035203444,0.008852991,0.000060924573],"about_ca_topic_score_codex":0.00021596513,"about_ca_topic_score_gemma":0.0015964838,"teacher_disagreement_score":0.2466197,"about_ca_system_score_codex":0.00026572245,"about_ca_system_score_gemma":0.0005108255,"threshold_uncertainty_score":0.28186724},"labels":[],"label_agreement":null},{"id":"W2969366525","doi":"10.1200/jco.2019.37.15_suppl.11570","title":"Temporal trends among survivors of rhabdomyosarcoma: A report from the Childhood Cancer Survivor Study (CCSS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hazard ratio; Cumulative incidence; Confidence interval; Rhabdomyosarcoma; Internal medicine; Incidence (geometry); Cancer registry; Cancer; Gastroenterology; Pediatrics; Cohort; Sarcoma; Pathology","score_opus":0.0860948152913508,"score_gpt":0.4472715063787215,"score_spread":0.3611766910873707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969366525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984885,0.002973318,0.0000021986295,0.007857864,0.0023245248,0.0004376629,0.000016831227,0.000008789943,0.0014938548],"genre_scores_gemma":[0.9967713,0.00046235826,0.00022836983,0.00094554335,0.0010910309,0.000017185834,0.00000832616,0.00002516613,0.00045076138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994574,0.0008409352,0.0033527012,0.0003063269,0.0006811505,0.0002448634],"domain_scores_gemma":[0.9906771,0.0046633366,0.0033797503,0.0005763428,0.0004189336,0.00028452292],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003916685,0.00020957511,0.00231613,0.00011839835,0.000039268245,0.000009383131,0.00029080815,0.00027683325,0.0010458388],"category_scores_gemma":[0.0013831786,0.000110004075,0.00091475056,0.0002686141,0.00020191136,0.00010803514,0.00009650546,0.0008792705,0.000014893285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010839846,0.012538531,0.9228924,0.0000048879233,0.0018114919,0.0021658374,0.0003565057,0.0000056101812,0.000005841738,0.000004765959,0.004715597,0.05441457],"study_design_scores_gemma":[0.011153129,0.0083419345,0.9554386,0.000103770515,0.0011379374,0.00022674337,0.000731212,0.0000098010705,0.000021683169,0.000035896497,0.022705382,0.00009387211],"about_ca_topic_score_codex":0.0076878467,"about_ca_topic_score_gemma":0.0071261004,"teacher_disagreement_score":0.054320697,"about_ca_system_score_codex":0.00011197662,"about_ca_system_score_gemma":0.0010704217,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W2969495338","doi":"10.1200/jco.2007.25.18_suppl.6605","title":"Lack of effect of prophylactic hematopoeitic colony stimulating factors in cancer patients and stem cell transplant recipients on short term survival: A meta-analysis of randomized trials","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University Health Network","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Meta-analysis; Transplantation; Relative risk; Placebo; Regimen; Randomization; Hematopoietic stem cell transplantation; Confidence interval; Surgery","score_opus":0.35736335933728486,"score_gpt":0.5352004301034438,"score_spread":0.1778370707661589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969495338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790144,0.00025863686,0.000045908288,0.00007358994,0.0004707789,0.0009621059,0.000027215405,0.000001937256,0.00025839393],"genre_scores_gemma":[0.9996411,0.00016263642,0.00005086098,0.00004587058,0.000047969916,0.000012396111,0.0000026199343,0.000011573352,0.000024926021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990278,0.0030371146,0.005805627,0.00018314767,0.00052645314,0.00016964899],"domain_scores_gemma":[0.96724784,0.02807547,0.003953185,0.00013749863,0.00041322186,0.00017280297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0193691,0.0001715872,0.010799048,0.00051591534,0.000015307882,0.0000024132173,0.00008611135,0.00024435951,0.00009428615],"category_scores_gemma":[0.002856271,0.0000944743,0.0027336588,0.00041452592,0.00020094615,0.000049597,0.000014377784,0.00050014333,1.4805521e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12827922,0.001722532,0.8387018,0.00023285668,0.027722532,0.000027635231,0.00024199569,0.0002447258,0.0014640823,0.0000047485732,0.0000031164298,0.0013547787],"study_design_scores_gemma":[0.10766412,0.016731856,0.6375253,0.00012887086,0.22396487,0.0000036930294,0.00003480204,0.000040527735,0.0138030965,0.0000073992546,0.00000818941,0.0000872324],"about_ca_topic_score_codex":0.00012799544,"about_ca_topic_score_gemma":0.00019081889,"teacher_disagreement_score":0.20117643,"about_ca_system_score_codex":0.000101851445,"about_ca_system_score_gemma":0.00028939365,"threshold_uncertainty_score":0.7382013},"labels":[],"label_agreement":null},{"id":"W2969500357","doi":"10.1200/jco.2007.25.18_suppl.14128","title":"Phase I study of ECO-4601, a novel Ras pathway inhibitor","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pharmacology; Toxicity; Pharmacokinetics; In vivo; Glioma; Internal medicine; Oncology; Cancer research; Biology","score_opus":0.11264781821538802,"score_gpt":0.47609142826215056,"score_spread":0.3634436100467625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969500357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797382,0.00026560502,0.017458422,0.00018620999,0.001755246,0.00023464567,0.000012146781,0.0000015804843,0.00034795376],"genre_scores_gemma":[0.9941488,0.000113751914,0.0028609897,0.00070314255,0.0020232087,0.0000031313475,0.0000031693708,0.000015721987,0.00012809895],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976642,0.00008781919,0.0017181775,0.0001723835,0.00016862659,0.00018875297],"domain_scores_gemma":[0.99751,0.0003056256,0.0013793277,0.00018332321,0.0004427927,0.00017891303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040083383,0.00010558615,0.0006521663,0.00006159079,0.00002705338,0.000004205593,0.0002045221,0.0003141722,0.000012481537],"category_scores_gemma":[0.00060441013,0.00008409623,0.00035308415,0.000058455767,0.00006928455,0.0000032959836,0.000055354132,0.00024444566,7.051431e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008717443,0.016481003,0.0005110725,0.00001147213,0.00046851125,0.00003214181,0.00013488973,0.000013549739,0.757256,0.00022060919,0.0006856033,0.21546775],"study_design_scores_gemma":[0.047064293,0.15787378,0.0013398193,0.000020301824,0.0002234984,0.000078384066,0.00086060044,0.00002352842,0.24850848,0.00029225607,0.54352146,0.00019359736],"about_ca_topic_score_codex":0.0000057133907,"about_ca_topic_score_gemma":0.000102831094,"teacher_disagreement_score":0.54283583,"about_ca_system_score_codex":0.000022591868,"about_ca_system_score_gemma":0.0006346432,"threshold_uncertainty_score":0.3429345},"labels":[],"label_agreement":null},{"id":"W2969576995","doi":"10.1200/jco.2007.25.18_suppl.10553","title":"Matrix metalloproteinase 2 (<i>MMP2</i>) polymorphism, <i>Helicobacter pylori</i> (HP) infection and esophageal adenocarcinoma (EA) risk","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Genotype; Odds ratio; MMP2; Genotyping; Medicine; CagA; Gastroenterology; Internal medicine; Immunology; Biology; Cancer; Gene; Genetics; Metastasis","score_opus":0.04857886659053407,"score_gpt":0.39029820692816697,"score_spread":0.3417193403376329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969576995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856109,0.0027429534,0.0009197699,0.007255239,0.0023466249,0.0003743529,0.00000831763,0.00004704333,0.0006948139],"genre_scores_gemma":[0.98539376,0.00277967,0.004148414,0.0041658543,0.0030391428,0.0000053119606,0.000003906355,0.00004776543,0.00041614758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402195,0.0007305621,0.0036190525,0.00043668135,0.000515335,0.0006764356],"domain_scores_gemma":[0.9934825,0.0017050094,0.0027839122,0.0003396908,0.00077143963,0.00091749546],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0076080784,0.00036659156,0.0022576207,0.00043490742,0.00014899175,0.000018858684,0.00017372913,0.00092096184,0.000093313545],"category_scores_gemma":[0.004204434,0.00027856164,0.00068963016,0.00031880016,0.000667686,0.0002972766,0.00017948859,0.0029792886,0.000060116425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074181096,0.0010121089,0.93489563,0.000032245007,0.0018516777,0.0031584697,0.0001540374,0.0000021683345,0.00083114416,0.00003871004,0.001690882,0.048914805],"study_design_scores_gemma":[0.011573621,0.016222104,0.93493855,0.0000631649,0.0019907972,0.0042917477,0.000059700953,0.000014248772,0.00040350066,0.00013279571,0.030149156,0.00016061524],"about_ca_topic_score_codex":0.00013871698,"about_ca_topic_score_gemma":0.00017263545,"teacher_disagreement_score":0.04875419,"about_ca_system_score_codex":0.00022897168,"about_ca_system_score_gemma":0.0004989952,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W2969586929","doi":"10.1200/jco.2007.25.18_suppl.6541","title":"Trends in the quality of abstracts of articles describing randomized controlled cancer trials (RCTs) from 1975–2004","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Consolidated Standards of Reporting Trials; Clinical endpoint; Family medicine; Sample size determination; Confidence interval; Descriptive statistics; Scale (ratio); Quality Score; Internal medicine; Statistics","score_opus":0.939348455631671,"score_gpt":0.7084923521184733,"score_spread":0.23085610351319774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969586929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836693,0.0038415527,0.0034369796,0.0034014718,0.0009701519,0.00059065636,0.000009284307,4.8217817e-7,0.0040801675],"genre_scores_gemma":[0.9955987,0.00024666227,0.002865102,0.0006074467,0.0004303029,0.000007659469,4.558856e-7,0.000004045713,0.00023964429],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.40998065,0.31997442,0.2562455,0.0009235641,0.012227,0.0006488697],"domain_scores_gemma":[0.17142758,0.68786234,0.13587397,0.0015196638,0.0030390956,0.00027736832],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.86516947,0.00018824512,0.030832836,0.0005589457,0.000028274995,0.00006290428,0.0014102224,0.0002908712,0.0039771823],"category_scores_gemma":[0.66988283,0.00006193818,0.0109047415,0.00087552634,0.00033299232,0.00015345821,0.000042575102,0.0005709898,0.000019066307],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27822933,0.0024383673,0.06167549,0.000025490464,0.0050705993,0.000074753116,0.0022827452,0.0010922095,0.0016442694,0.0018109679,0.0096346745,0.6360211],"study_design_scores_gemma":[0.5557663,0.0010381136,0.3921682,0.0002575973,0.005006515,0.00001306307,0.0035538292,0.00089327845,0.00041348295,0.032208227,0.008470876,0.00021052014],"about_ca_topic_score_codex":0.00039531023,"about_ca_topic_score_gemma":0.001624476,"teacher_disagreement_score":0.63581055,"about_ca_system_score_codex":0.000038544727,"about_ca_system_score_gemma":0.00053362915,"threshold_uncertainty_score":0.9990008},"labels":[],"label_agreement":null},{"id":"W2969587751","doi":"10.1200/jco.2013.31.15_suppl.5048","title":"The ELDORADO study: A phase II randomised study of concurrent weekly docetaxel, IMRT, and ltadt in patients with high-risk prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Prostatectomy; Urology; Randomized controlled trial; Radiation therapy; Prostate; Clinical endpoint; Internal medicine; Chemotherapy; Androgen deprivation therapy; Hazard ratio; Nomogram; Oncology; Cancer; Confidence interval","score_opus":0.05951183498378078,"score_gpt":0.4611538331424246,"score_spread":0.4016419981586438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969587751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920884,0.0011948164,9.519018e-7,0.0024256434,0.00042379793,0.003815186,0.000009112729,0.0000034743703,0.000038611564],"genre_scores_gemma":[0.99684924,0.0025372556,0.000034065637,0.00006259104,0.00017049561,0.00013111657,0.0000016165154,0.000013929832,0.00019971468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584335,0.00093168265,0.002141796,0.00021587538,0.0005816545,0.0002856124],"domain_scores_gemma":[0.99472266,0.0021668437,0.0018000535,0.0001915231,0.000812834,0.00030610914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002917554,0.00016305661,0.0015081965,0.00011543735,0.00012218046,0.000017211565,0.00015419944,0.00009972709,0.00004927851],"category_scores_gemma":[0.0012945763,0.00007282005,0.00011238638,0.00019244157,0.00033633685,0.00012366954,0.00009322286,0.0009453807,0.0000014175791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074179135,0.025648385,0.7065064,0.000016249696,0.0009027768,0.0001000774,0.0012900586,0.000004749599,0.0000062412455,0.0000018131548,0.0005529968,0.19079117],"study_design_scores_gemma":[0.30610055,0.150396,0.5406662,0.00006434115,0.00040057325,0.0000029499415,0.0015743821,0.000017565597,0.000006591045,0.000031493317,0.0006892416,0.000050049814],"about_ca_topic_score_codex":0.00071565475,"about_ca_topic_score_gemma":0.0004817256,"teacher_disagreement_score":0.23192142,"about_ca_system_score_codex":0.00014244662,"about_ca_system_score_gemma":0.0010479497,"threshold_uncertainty_score":0.41072613},"labels":[],"label_agreement":null},{"id":"W2969597105","doi":"10.1200/jco.2019.37.15_suppl.11549","title":"Pilot randomized trial of a transdisciplinary geriatric intervention for older adults with cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Intervention (counseling); Quality of life (healthcare); Palliative care; Randomized controlled trial; Cancer; Geriatric oncology; Lung cancer; Geriatrics; Physical therapy; Confidence interval; Feeling; Clinical trial; Comorbidity; Internal medicine; Nursing; Psychiatry","score_opus":0.0656393241852573,"score_gpt":0.45550797953275857,"score_spread":0.38986865534750126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969597105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841944,0.0005377898,0.0014027109,0.006057669,0.0039557484,0.0031445543,0.000009765268,0.000008100015,0.0006892691],"genre_scores_gemma":[0.99221545,0.00048593432,0.0042851097,0.00027198088,0.0015378959,0.00007551021,0.0000054143056,0.000024321931,0.0010983843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99514484,0.0005689435,0.0035014024,0.00020588512,0.00037848204,0.00020046285],"domain_scores_gemma":[0.98999643,0.0057107965,0.0031314264,0.00019401776,0.00075823924,0.0002091025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005271548,0.0001495249,0.003048069,0.00016735948,0.00001597516,0.0000038915364,0.00016658638,0.00022728548,0.00038541816],"category_scores_gemma":[0.0028457588,0.00008996388,0.0013772368,0.00014435276,0.0002079525,0.0001110442,0.000022398206,0.00061349676,0.0000050974313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93113303,0.0042913486,0.0008252321,0.000420299,0.0007666084,0.000033578588,0.0005366972,0.000017307828,0.000037401795,0.000021376838,0.0013199053,0.0605972],"study_design_scores_gemma":[0.8853209,0.103000626,0.007398227,0.0012840747,0.0012631414,0.00010824332,0.00025848925,0.00023024424,0.000056540972,0.00015942927,0.0008350732,0.00008498085],"about_ca_topic_score_codex":0.00003524095,"about_ca_topic_score_gemma":0.00005902106,"teacher_disagreement_score":0.09870928,"about_ca_system_score_codex":0.00009209769,"about_ca_system_score_gemma":0.0011119412,"threshold_uncertainty_score":0.42200586},"labels":[],"label_agreement":null},{"id":"W2969622176","doi":"10.1200/jco.2012.30.15_suppl.e13123","title":"Effect of VAL-083, a novel N7 alkylating agent, on growth of temolozomide-resistant primary adult glioblastoma multiforme (GBM) cells providing a new potential treatment option for GBM.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Celator Pharmaceuticals (Canada); University of British Columbia","funders":"","keywords":"Temozolomide; Cancer research; Medicine; Neurosphere; Growth inhibition; Cell culture; Brain tumor; Cancer stem cell; Glioblastoma; Dacarbazine; Cancer; In vitro; Oncology; Internal medicine; Pathology; Biology; Melanoma; Adult stem cell","score_opus":0.06421470740754004,"score_gpt":0.41185186376458166,"score_spread":0.3476371563570416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969622176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954492,0.00027982445,0.0006814305,0.0010366979,0.0010809986,0.0012690022,0.000027101958,0.0000099940235,0.0001657464],"genre_scores_gemma":[0.98723185,0.00017948997,0.011212954,0.00021316795,0.0010342294,0.00003412397,0.000007948612,0.0000345099,0.000051733972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99575377,0.00033361898,0.0027792193,0.0002448347,0.00047013458,0.00041840135],"domain_scores_gemma":[0.99116486,0.004316531,0.0033244125,0.00021045547,0.00046353778,0.0005202147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024334341,0.00029661323,0.002165089,0.00026086532,0.00005608971,0.000007308205,0.000118256685,0.00038106833,0.000018504266],"category_scores_gemma":[0.0023329186,0.00018355716,0.0013273228,0.00013549587,0.00010265083,0.00014559177,0.00004339825,0.00030600402,0.000005328911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10269221,0.031453166,0.08250753,0.001074256,0.0039284085,0.00028583856,0.00056643743,0.00021540199,0.45774958,0.00037901566,0.0014848165,0.31766334],"study_design_scores_gemma":[0.09914473,0.29304072,0.117126055,0.0015715428,0.0056900806,0.0003472081,0.0001094954,0.00093674817,0.48008597,0.000062443774,0.0015740197,0.00031099288],"about_ca_topic_score_codex":0.00008603269,"about_ca_topic_score_gemma":0.000015761703,"teacher_disagreement_score":0.31735235,"about_ca_system_score_codex":0.0005781927,"about_ca_system_score_gemma":0.00070437335,"threshold_uncertainty_score":0.74852437},"labels":[],"label_agreement":null},{"id":"W2969680081","doi":"10.1200/jco.2019.37.15_suppl.10540","title":"Implementing a quality improvement curriculum for medical oncology residents: A pilot study at the Ottawa Hospital Cancer Centre.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Curriculum; Medical education; Quality management; Oncology; Internal medicine; Family medicine; Psychology","score_opus":0.07339718549655401,"score_gpt":0.5588066826063433,"score_spread":0.48540949710978926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969680081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93119895,0.0010844424,0.00037155638,0.055312764,0.008798345,0.002021669,0.0000118527205,0.000014722773,0.0011857178],"genre_scores_gemma":[0.9731871,0.0016323241,0.0023098276,0.014349592,0.005864193,0.00009345192,0.000005494492,0.00003893317,0.0025190986],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922864,0.0013791658,0.0043097897,0.0004388151,0.00088975264,0.0006960921],"domain_scores_gemma":[0.9858586,0.008628917,0.0038858869,0.00039945435,0.0007421272,0.0004850008],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018796777,0.0002423035,0.0022083889,0.00008256716,0.00021689516,0.000008871224,0.0005188141,0.00042337814,0.0027386935],"category_scores_gemma":[0.007496079,0.000134462,0.00058709836,0.00014568669,0.0004400963,0.00012330283,0.0002691568,0.0015647843,0.00002947028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007439891,0.014806727,0.7349126,0.000054776992,0.0015884622,0.00028282267,0.00045584067,0.0000053757303,0.00018020514,0.00030731744,0.031877883,0.20808811],"study_design_scores_gemma":[0.036231406,0.16274884,0.23682655,0.0000920879,0.0005890576,0.00016021602,0.0032133565,0.00006623024,0.000027736834,0.00037632996,0.5594814,0.00018678734],"about_ca_topic_score_codex":0.00025809594,"about_ca_topic_score_gemma":0.004048601,"teacher_disagreement_score":0.5276035,"about_ca_system_score_codex":0.0012171516,"about_ca_system_score_gemma":0.0034968175,"threshold_uncertainty_score":0.99817294},"labels":[],"label_agreement":null},{"id":"W2969682716","doi":"10.1200/jco.2019.37.15_suppl.11602","title":"The development of a nomogram to determine the risk for inappropriate opioid use in cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nomogram; Cancer pain; Opioid; Depression (economics); Logistic regression; Cancer; Anxiety; Distress; Internal medicine; Psychiatry; Clinical psychology","score_opus":0.11134642870758955,"score_gpt":0.4409136362468026,"score_spread":0.32956720753921304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969682716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949521,0.00016703659,0.00009635579,0.0018701443,0.0021890174,0.0005976685,0.0000063837083,0.0000015855956,0.00011971754],"genre_scores_gemma":[0.9963779,0.0002778163,0.0016651177,0.0011042799,0.0003036602,0.000036879286,9.307885e-7,0.000009904509,0.00022353485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756014,0.00020808283,0.0017064346,0.0001093812,0.00023954234,0.00017644132],"domain_scores_gemma":[0.9947671,0.0032865214,0.0011328041,0.00016870825,0.0005171162,0.00012771827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032580737,0.00008061029,0.0006859725,0.000053983946,0.00003646381,0.0000073195174,0.00019638885,0.00013713857,0.000021869037],"category_scores_gemma":[0.0026857979,0.000037375325,0.00025354774,0.00012902846,0.00006733719,0.00004019097,0.000059898422,0.0004782354,0.0000033847916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037073162,0.0003615772,0.5659485,0.000020490825,0.00009550665,0.0000021985004,0.0009663543,0.000010713926,0.00001640761,0.000009302384,0.00038277745,0.42847887],"study_design_scores_gemma":[0.003933353,0.004853343,0.69977397,0.0000917245,0.000085673964,0.000002379703,0.0002821908,0.00004270201,0.00008896303,0.00006102032,0.29073977,0.000044899356],"about_ca_topic_score_codex":0.0002077656,"about_ca_topic_score_gemma":0.013389461,"teacher_disagreement_score":0.42843398,"about_ca_system_score_codex":0.00014881496,"about_ca_system_score_gemma":0.0013830756,"threshold_uncertainty_score":0.74716336},"labels":[],"label_agreement":null},{"id":"W2969902400","doi":"10.1200/jco.2019.37.15_suppl.e22525","title":"Is PAX3-FOXO1 associated with worse outcome in adults with rhabdomyosarcoma (RMS)?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"FOXO transcription factor regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Alveolar rhabdomyosarcoma; PAX3; Rhabdomyosarcoma; Fusion gene; Internal medicine; Oncology; Sarcoma; Pathology; Biology; Gene","score_opus":0.055931290216250124,"score_gpt":0.3887353169908545,"score_spread":0.3328040267746044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969902400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967255,0.00010040393,0.00017069453,0.001523808,0.00038970757,0.00019986073,0.0000058677642,0.000004663785,0.00087948435],"genre_scores_gemma":[0.9971555,0.00005443628,0.00087455026,0.0012501315,0.00018810609,0.0000025083282,0.000016287127,0.000018124027,0.00044035367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974835,0.0003364298,0.0013985203,0.00025263644,0.00029617661,0.00023275761],"domain_scores_gemma":[0.99786913,0.00021925489,0.0011921071,0.0002263281,0.00033145666,0.00016171743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013969183,0.00015702455,0.0007663921,0.000090811176,0.00001731511,0.000009372931,0.0002149388,0.00048129112,0.00010853522],"category_scores_gemma":[0.00051972206,0.000104649516,0.00021533876,0.00014706867,0.00013722571,0.000017062745,0.000025603546,0.0005447004,0.000018577199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059844037,0.0006597524,0.98424256,0.0000138361465,0.00020151019,0.00006793318,0.00007315214,0.00015713765,0.0024979066,0.00002187623,0.0005466451,0.005533291],"study_design_scores_gemma":[0.012265603,0.012967937,0.95302427,0.00013800351,0.000057260833,0.000069824324,0.00009854589,0.00007145212,0.0006183465,0.000037145175,0.02047184,0.00017978257],"about_ca_topic_score_codex":0.000013073069,"about_ca_topic_score_gemma":0.00036977214,"teacher_disagreement_score":0.031218296,"about_ca_system_score_codex":0.00006270342,"about_ca_system_score_gemma":0.0004595849,"threshold_uncertainty_score":0.42674834},"labels":[],"label_agreement":null},{"id":"W2969945852","doi":"10.1200/jco.2012.30.15_suppl.e14048","title":"Patterns of peri-operative systemic therapy in liver-limited metastatic colorectal cancer (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Capecitabine; Colorectal cancer; Internal medicine; Regimen; Oxaliplatin; Liver function; Chemotherapy; Surgery; Chemotherapy regimen; Gastroenterology; Cancer; Oncology","score_opus":0.1606040956075382,"score_gpt":0.48632576129585636,"score_spread":0.3257216656883182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969945852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845068,0.012477202,0.0000143521165,0.00091307994,0.001063432,0.00033839082,0.000014638724,0.000003913448,0.00066818635],"genre_scores_gemma":[0.9838468,0.01470027,0.00026733163,0.0005234406,0.00052203523,0.00002801573,0.0000014218617,0.000012734537,0.000097952616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709123,0.00050292374,0.0017571249,0.00012210371,0.00027396219,0.00025267777],"domain_scores_gemma":[0.9967807,0.0013700181,0.0011455268,0.00008329963,0.00041305524,0.00020740162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014468959,0.00015088778,0.0018221925,0.00013120174,0.00002594208,0.0000031395487,0.00008784241,0.00014440382,0.0003196062],"category_scores_gemma":[0.0006850181,0.00009072568,0.00036472265,0.00014249944,0.00011140297,0.000115704825,0.00003440853,0.0005060323,0.000004042513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006734327,0.00274153,0.84862804,0.000057041416,0.0012929179,0.00026215363,0.0025483677,0.0000093081035,0.000998509,0.00003021255,0.00018231648,0.13651526],"study_design_scores_gemma":[0.010190677,0.018264566,0.96501845,0.0002777228,0.00039872588,0.0003394228,0.0015096121,0.000038860493,0.00075523957,0.0000080443515,0.0031093322,0.000089363115],"about_ca_topic_score_codex":0.00028970547,"about_ca_topic_score_gemma":0.00047522085,"teacher_disagreement_score":0.1364259,"about_ca_system_score_codex":0.0003510425,"about_ca_system_score_gemma":0.0008015185,"threshold_uncertainty_score":0.3699686},"labels":[],"label_agreement":null},{"id":"W2970021941","doi":"10.1200/jco.2019.37.15_suppl.11003","title":"Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Gastroenterology; Surgery","score_opus":0.02045692337153105,"score_gpt":0.338526687649502,"score_spread":0.31806976427797096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970021941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767333,0.0006622165,0.00008459461,0.0003727841,0.0003207946,0.00021712786,0.000005815842,9.243499e-7,0.00066239724],"genre_scores_gemma":[0.99710774,0.0014493696,0.0010710654,0.00014082147,0.00016159531,0.0000010292003,0.000008215703,0.000014957927,0.00004519498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973725,0.0003263057,0.0016602003,0.00023422604,0.0002120842,0.00019468939],"domain_scores_gemma":[0.99777055,0.0005658103,0.0011032479,0.00019588415,0.00023597706,0.00012850332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018665324,0.00013155995,0.0007684806,0.00013074168,0.000014338834,0.000005336085,0.00015242297,0.0003549877,0.000017766593],"category_scores_gemma":[0.0010519621,0.000099073266,0.00013384555,0.00013006663,0.00012597888,0.000009447188,0.00008781947,0.00037297246,0.0000028579946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068474165,0.0012675357,0.9394192,0.000026985286,0.00006912559,0.000014345719,0.00006193567,0.00046449856,0.00435684,0.000039162045,0.000044164644,0.047388807],"study_design_scores_gemma":[0.01596754,0.017672189,0.93003273,0.00008346924,0.000029649826,0.000004592835,0.000035969144,0.00006614201,0.0037064657,0.00007842288,0.032193188,0.00012962648],"about_ca_topic_score_codex":0.000020984244,"about_ca_topic_score_gemma":0.00029222664,"teacher_disagreement_score":0.047259178,"about_ca_system_score_codex":0.000036183625,"about_ca_system_score_gemma":0.0003685767,"threshold_uncertainty_score":0.40400904},"labels":[],"label_agreement":null},{"id":"W2970060261","doi":"10.1200/jco.2012.30.15_suppl.e15201","title":"Retrospective mathematical analysis of serial prostate specific antigen (PSA) measurements for patients with M0 prostate cancer treated with intermittent androgen suppression (IAS).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Androgen; Cancer; Prostate; Androgen suppression; Oncology; Internal medicine; Hormone","score_opus":0.1363414104488418,"score_gpt":0.45210160383356635,"score_spread":0.31576019338472455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970060261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691767,0.0004133697,0.00006937675,0.00055214885,0.00026646856,0.0014397902,0.00011686504,0.000007755288,0.00021658448],"genre_scores_gemma":[0.9964859,0.0006653102,0.002108607,0.00004570828,0.00035177695,0.00005880388,0.000056334888,0.000031911466,0.00019565965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965602,0.00024817913,0.001606972,0.0002590135,0.0008669099,0.00045873557],"domain_scores_gemma":[0.995511,0.0003035662,0.0016637612,0.00022223058,0.0018132142,0.00048624194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017192549,0.00022355947,0.0019595844,0.00030194587,0.000065157285,0.000012434759,0.00012964057,0.00020167737,0.00015110905],"category_scores_gemma":[0.00033929426,0.000112408015,0.0004289535,0.00045832206,0.00031852847,0.00020750746,0.0000421755,0.00040284038,0.0000016552375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071295656,0.0044281497,0.9073178,0.00008567921,0.0071490295,0.000035613735,0.00047302266,0.000014497938,0.00047082079,0.0000059319905,0.00047094355,0.008252842],"study_design_scores_gemma":[0.024445355,0.023772262,0.94322634,0.0003834952,0.0042682076,0.000013108027,0.000115312614,0.00004978991,0.0025119127,0.000025247005,0.001055031,0.00013396345],"about_ca_topic_score_codex":0.000015981828,"about_ca_topic_score_gemma":0.000015608743,"teacher_disagreement_score":0.0468503,"about_ca_system_score_codex":0.00043926467,"about_ca_system_score_gemma":0.0006968178,"threshold_uncertainty_score":0.45838657},"labels":[],"label_agreement":null},{"id":"W2970212472","doi":"10.1200/jco.2009.27.15_suppl.e22235","title":"HIV/AIDS pandemic (AP) in Africa: Chronicle of a missed opportunity","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Island University; University of British Columbia","funders":"","keywords":"Medicine; Nigerians; Seroprevalence; Population; Demography; Transmission (telecommunications); Human immunodeficiency virus (HIV); Serology; Pandemic; Immunology; Traditional medicine; Virology; Internal medicine; Environmental health; Coronavirus disease 2019 (COVID-19); Disease; Antibody","score_opus":0.1613096685731705,"score_gpt":0.40298693216566916,"score_spread":0.24167726359249866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970212472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791582,0.0075286822,0.000042224197,0.003084834,0.0012777607,0.000096921875,0.0000063452444,0.000011429387,0.008793602],"genre_scores_gemma":[0.9954345,0.0017862786,0.00034039063,0.00078471313,0.00016339417,8.451647e-7,0.000001818331,0.0000058212913,0.0014822064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962315,0.0007922416,0.0024043215,0.00016266968,0.00006458391,0.00034469456],"domain_scores_gemma":[0.99632263,0.0016361016,0.001580275,0.00016430036,0.000205662,0.00009102222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032581117,0.00014096234,0.0015513466,0.00015863046,0.000049191716,0.0000020850973,0.00032197876,0.00066430616,0.00026416747],"category_scores_gemma":[0.0026747426,0.000096484495,0.00042525856,0.00016281792,0.0004429181,0.00007437044,0.00006368573,0.0012963312,0.000044034707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00842669,0.009289899,0.23677121,0.00004382683,0.0011678907,0.0005187184,0.0017342442,0.000030602416,0.2305061,0.0016448112,0.07350386,0.43636215],"study_design_scores_gemma":[0.021530151,0.031588953,0.36597764,0.00016317797,0.00034670456,0.0005050965,0.0014639078,0.000006115631,0.004316887,0.0040874025,0.56966734,0.00034661152],"about_ca_topic_score_codex":0.000018377596,"about_ca_topic_score_gemma":0.000032114378,"teacher_disagreement_score":0.4961635,"about_ca_system_score_codex":0.000090408656,"about_ca_system_score_gemma":0.0010724424,"threshold_uncertainty_score":0.5631986},"labels":[],"label_agreement":null},{"id":"W2970304599","doi":"10.1200/jco.2013.31.15_suppl.9032","title":"Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Baker Hughes (Canada); Ottawa Hospital; BC Cancer Agency; Queen's University; Hôpital Notre-Dame; Royal Victoria Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dacarbazine; Internal medicine; Rash; Gastroenterology; Adverse effect; Phases of clinical research; Nausea; Population; Neutropenia; Melanoma; Hazard ratio; Surgery; Toxicity; Oncology; Chemotherapy; Confidence interval","score_opus":0.11078690434279748,"score_gpt":0.4519686521981819,"score_spread":0.3411817478553844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970304599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549025,0.00022263247,0.000016349542,0.0010824286,0.001173817,0.0018776004,0.000006775831,0.000003472209,0.00012668823],"genre_scores_gemma":[0.99819565,0.00024095165,0.0010450953,0.00021741878,0.000089705,0.000025178739,0.000006397711,0.0000165725,0.00016305136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99130666,0.0016755562,0.005962095,0.00024728183,0.0005630581,0.00024532466],"domain_scores_gemma":[0.9891529,0.0046434873,0.004955233,0.0002969378,0.00074910815,0.00020230378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063268715,0.00021480414,0.0036511938,0.00035733916,0.000026424796,0.000005656775,0.00024403966,0.00016969038,0.00028610745],"category_scores_gemma":[0.0060342564,0.000112890535,0.0005387774,0.00036433834,0.00035264998,0.00011921781,0.000067168985,0.00080739544,0.000002717767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7464124,0.041515183,0.0066070235,0.000047227204,0.001439394,0.00012707707,0.0013269725,0.0000020625357,0.00004031897,0.0000013787471,0.000976386,0.2015046],"study_design_scores_gemma":[0.63922787,0.221543,0.13604449,0.0005984695,0.00070124835,0.000037637506,0.00056482485,0.000030034107,0.00003976746,0.00003080694,0.001090006,0.00009188474],"about_ca_topic_score_codex":0.00023269137,"about_ca_topic_score_gemma":0.0002741611,"teacher_disagreement_score":0.20141272,"about_ca_system_score_codex":0.0001680292,"about_ca_system_score_gemma":0.0012541773,"threshold_uncertainty_score":0.7224004},"labels":[],"label_agreement":null},{"id":"W2970319198","doi":"10.1200/jco.19.01663","title":"Reply to T. Sio et al","year":2019,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine","score_opus":0.13226715639094522,"score_gpt":0.5159244080582108,"score_spread":0.3836572516672656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970319198","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012299272,0.0038375529,0.0000634697,0.9241928,0.04304109,0.0006412814,0.0000335456,0.000008407981,0.015882578],"genre_scores_gemma":[0.004955455,0.010329774,0.0034978907,0.93954796,0.02836693,0.000016552494,0.000020963704,0.00007869005,0.0131857935],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899807,0.001745268,0.0058086175,0.0006553615,0.0010579637,0.00075209857],"domain_scores_gemma":[0.9766804,0.016169896,0.004552158,0.00074791285,0.0009419031,0.00090770633],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0076689455,0.000493838,0.005230483,0.00026447763,0.000041260835,0.00003071219,0.00050832523,0.0017016557,0.002560323],"category_scores_gemma":[0.008310037,0.00033891926,0.0022177333,0.00018581428,0.00023895664,0.00012454396,0.00020389876,0.006721417,0.0032395578],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023543013,0.0026731743,0.04350014,0.00014782061,0.0024759904,0.012075683,0.0001009811,0.00003895162,0.0000048349925,0.00009231795,0.8519307,0.084605135],"study_design_scores_gemma":[0.00982733,0.04994338,0.06934432,0.0022934466,0.0022559788,0.0009834543,0.000028673892,0.000008347409,0.000008659845,0.00008602518,0.86496764,0.00025276435],"about_ca_topic_score_codex":0.00016388515,"about_ca_topic_score_gemma":0.000051351693,"teacher_disagreement_score":0.08435237,"about_ca_system_score_codex":0.0022582607,"about_ca_system_score_gemma":0.008555113,"threshold_uncertainty_score":0.9999063},"labels":[],"label_agreement":null},{"id":"W2970343731","doi":"10.1200/jco.2007.25.18_suppl.6612","title":"The utilization of new oncology drugs: A global perspective","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vintage; Cancer; Cancer drugs; Drug; Demography; Environmental health; Internal medicine; Pharmacology; Geography","score_opus":0.3505697983439747,"score_gpt":0.5386506553253644,"score_spread":0.18808085698138965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970343731","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3065338,0.009470615,0.008585136,0.062360674,0.007055943,0.0002652997,0.000047491303,0.000010871763,0.60567015],"genre_scores_gemma":[0.9885485,0.003849465,0.0013317389,0.0042842277,0.0016462844,5.543704e-7,4.859049e-7,0.000009600898,0.00032912826],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958754,0.00009993268,0.0035207474,0.00016693491,0.000048704962,0.00028828395],"domain_scores_gemma":[0.99314636,0.0023717505,0.0037271185,0.00016442873,0.0002305096,0.00035983126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0088026,0.000100018035,0.0010632302,0.000089607376,0.000059717797,0.00001425818,0.000402858,0.00034250502,0.00015650257],"category_scores_gemma":[0.0042246617,0.000078992314,0.00046858925,0.00020165074,0.00029726556,0.00012327074,0.00007141875,0.00053632545,0.00008424875],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010986257,0.00048000875,0.014870202,0.0000034527695,0.0002567594,0.000015809694,0.0004025397,0.000028846871,0.0000017941629,0.7701917,0.01193628,0.20071395],"study_design_scores_gemma":[0.00216357,0.001699768,0.036826853,0.0000044431536,0.000023912007,0.000028254899,0.0004653458,0.00024686023,0.0000134080665,0.23269199,0.7257651,0.000070507755],"about_ca_topic_score_codex":0.00017885369,"about_ca_topic_score_gemma":0.00021074727,"teacher_disagreement_score":0.7138288,"about_ca_system_score_codex":0.00068931095,"about_ca_system_score_gemma":0.0010495546,"threshold_uncertainty_score":0.50576204},"labels":[],"label_agreement":null},{"id":"W2970355953","doi":"10.1200/jco.2019.37.15_suppl.11626","title":"The importance of altruism to biomarker development for pancreatic cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biomarker; Pancreatic cancer; Cancer; Internal medicine; Oncology","score_opus":0.6108952837150997,"score_gpt":0.6792200162125077,"score_spread":0.068324732497408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970355953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401376,0.0007778279,0.00024068814,0.053577114,0.0017978548,0.00064811046,0.0000022823258,0.0000033130727,0.0028152105],"genre_scores_gemma":[0.9553975,0.0027724681,0.026816225,0.00805702,0.0007871828,0.00003729078,8.2820395e-7,0.00002610251,0.0061053797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946829,0.00024948388,0.0037255134,0.00020050726,0.00082699367,0.00031461567],"domain_scores_gemma":[0.934035,0.061248384,0.0018769811,0.0003817179,0.0020411771,0.0004167529],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026493823,0.00009812527,0.0013135788,0.00007124196,0.00005299942,0.0000065648624,0.00042350107,0.0004947561,0.00016753587],"category_scores_gemma":[0.08176992,0.000053778735,0.00042848467,0.00016452732,0.00027348546,0.000033777953,0.00011940275,0.0015203205,0.000030623873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011265909,0.00078492716,0.66998345,0.0002864404,0.00088581484,0.000045911216,0.00013916077,0.000006906769,0.00063656375,0.0028967361,0.012875941,0.30019224],"study_design_scores_gemma":[0.005044875,0.009683746,0.56894463,0.00047669513,0.00015011261,0.000030783463,0.00015805864,0.00007105823,0.00040303575,0.0065225535,0.40843177,0.00008267024],"about_ca_topic_score_codex":0.000009210768,"about_ca_topic_score_gemma":0.00027324524,"teacher_disagreement_score":0.39555585,"about_ca_system_score_codex":0.00020142835,"about_ca_system_score_gemma":0.0072454964,"threshold_uncertainty_score":0.9983825},"labels":[],"label_agreement":null},{"id":"W2970378515","doi":"10.1200/jco.19.00354","title":"Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Memorial University of Newfoundland; McMaster University; Mount Sinai Hospital; Children's Hospital of Eastern Ontario; University of Ottawa; Hospital for Sick Children; William Osler Health System; Public Health Ontario; SickKids Foundation; Western University; University of Toronto; London Health Sciences Centre; North York General Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Institute for Clinical Evaluative Sciences; Cancer Care Ontario","keywords":"Medicine; Population; Family medicine; Environmental health","score_opus":0.3134563980709659,"score_gpt":0.5391712230483912,"score_spread":0.22571482497742523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970378515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980861,0.00029503292,0.0000059881636,0.00019452293,0.00033446497,0.0009368671,0.00012077115,0.000004477211,0.000021762373],"genre_scores_gemma":[0.9969819,0.0000051146394,0.0013918834,0.0013924445,0.00018861816,0.0000050621893,0.000015538704,0.000016138845,0.000003296026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963193,0.0009807892,0.0014714962,0.00032155972,0.0006481401,0.00025870756],"domain_scores_gemma":[0.9905466,0.005670017,0.0017996451,0.0003325921,0.0012680278,0.0003831566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002674975,0.00016780329,0.001559981,0.000082143364,0.000107220374,0.0000133157355,0.00017821707,0.00010194466,0.000059508093],"category_scores_gemma":[0.0046387133,0.00011316999,0.000034842145,0.00020709021,0.00005594072,0.00021151292,0.00012780927,0.0009908691,4.5185246e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006364178,0.00093723566,0.98889834,0.00005907976,0.0006096882,0.00010637298,0.000120411576,0.0002677704,0.0000043900436,1.9216675e-7,0.00009763005,0.0025347224],"study_design_scores_gemma":[0.016282354,0.013625722,0.9681785,0.00047095696,0.00021895912,0.0000013909948,0.00022905476,0.00032259643,0.0000020795128,0.0000023265002,0.0005677978,0.0000982517],"about_ca_topic_score_codex":0.9113797,"about_ca_topic_score_gemma":0.9663132,"teacher_disagreement_score":0.054933477,"about_ca_system_score_codex":0.0016017961,"about_ca_system_score_gemma":0.02813001,"threshold_uncertainty_score":0.9773796},"labels":[],"label_agreement":null},{"id":"W2970527692","doi":"10.1200/jco.2009.27.15_suppl.8091","title":"Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"IGFBP3; Medicine; Vimentin; Internal medicine; Adenocarcinoma; Cancer research; Oncology; Cancer; Receptor; Immunohistochemistry; Growth factor","score_opus":0.0588162865371973,"score_gpt":0.4344179792031088,"score_spread":0.37560169266591154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970527692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780656,0.0012942576,0.010324491,0.0063041793,0.0024325652,0.00027683508,0.000017555387,0.000004099411,0.0012804013],"genre_scores_gemma":[0.9774015,0.0005912488,0.0053897477,0.012504204,0.003932696,0.0000052885775,0.000007619083,0.000014471738,0.00015323151],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770486,0.00033202648,0.0012278268,0.0002704565,0.00016387975,0.00030092165],"domain_scores_gemma":[0.99827147,0.0003435095,0.0005446644,0.0002255593,0.00031419512,0.000300582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024192457,0.00014739364,0.00084638,0.00009482153,0.000026435222,0.000011311767,0.00017446453,0.00039239798,0.000009743105],"category_scores_gemma":[0.0041761585,0.00012820524,0.00051059003,0.0001006794,0.00006376062,0.000008094981,0.000047210637,0.00032503073,0.0000041647213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052941167,0.0012934902,0.00076349266,0.000011913793,0.00012635606,0.00014874068,0.000037089325,0.0006994982,0.30373693,0.00026768856,0.03996774,0.647653],"study_design_scores_gemma":[0.005080526,0.007989622,0.024918728,0.000034522025,0.00008091545,0.00014455171,0.00003117442,0.00004306678,0.024392867,0.00055126264,0.93652344,0.00020934117],"about_ca_topic_score_codex":0.000012008032,"about_ca_topic_score_gemma":0.00014513193,"teacher_disagreement_score":0.89655566,"about_ca_system_score_codex":0.00003538053,"about_ca_system_score_gemma":0.0008202385,"threshold_uncertainty_score":0.5228058},"labels":[],"label_agreement":null},{"id":"W2970537945","doi":"10.1200/jco.2013.31.15_suppl.6504","title":"Association between high-cost imaging and hospice use at the end of life of cancer patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Quartile; Lung cancer; Cancer; Prostate cancer; Logistic regression; Colorectal cancer; End-of-life care; Breast cancer; Internal medicine; Radiology; Oncology; Palliative care; Confidence interval","score_opus":0.08680114941924325,"score_gpt":0.4460771846718315,"score_spread":0.3592760352525882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970537945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.936967,0.00048301535,0.0000052673713,0.061379246,0.0007369571,0.00023429595,0.000022381128,0.0000018277128,0.00017000975],"genre_scores_gemma":[0.99146396,0.00430949,0.00038926856,0.002868926,0.00078335346,0.000008531319,0.0000023836944,0.000010107393,0.0001640091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972505,0.0002917834,0.0018091704,0.00010438716,0.00040257082,0.00014158894],"domain_scores_gemma":[0.9871144,0.008023436,0.0035397797,0.00012983853,0.0009949212,0.00019758014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016875776,0.00007823769,0.0009994776,0.000054120916,0.000024251487,0.0000056325966,0.00010585902,0.00018503038,0.0005371364],"category_scores_gemma":[0.0054694167,0.000048203117,0.000181555,0.00008558221,0.0002100787,0.00015196581,0.00007384886,0.0004804047,0.00000466277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018505973,0.00025583376,0.8898733,0.000023542787,0.00038213385,0.0000017294959,0.000067425375,0.000004116595,0.000036576334,0.000003951345,0.055578634,0.053587675],"study_design_scores_gemma":[0.0037070108,0.0013850583,0.94554025,0.000091257796,0.00064553326,0.0000011877762,0.000025437741,0.000009986306,0.00020712728,0.0000565838,0.04829196,0.000038605984],"about_ca_topic_score_codex":0.0012641496,"about_ca_topic_score_gemma":0.00027476143,"teacher_disagreement_score":0.058510322,"about_ca_system_score_codex":0.0003349952,"about_ca_system_score_gemma":0.0005358816,"threshold_uncertainty_score":0.6547798},"labels":[],"label_agreement":null},{"id":"W2970567162","doi":"10.1200/jco.2006.24.18_suppl.8570","title":"Direct decompressive surgery with post-operative radiotherapy (S + RT) versus radiotherapy (RT) alone for the treatment of metastatic epidural spinal cord compression (MESCC): A cost-utility analysis using Ontario health economic data","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Ambulatory; Palliative care; Emergency medicine; Surgery; Physical therapy; Nursing","score_opus":0.29842837328388555,"score_gpt":0.5277730706481465,"score_spread":0.22934469736426094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970567162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508813,0.00649597,0.033539597,0.0056256433,0.00096029625,0.0021583936,0.000275944,0.00001086767,0.00005198693],"genre_scores_gemma":[0.92079747,0.0026964536,0.07397468,0.0013989607,0.00065314025,0.000036968886,0.00026877713,0.000045619785,0.00012791461],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939491,0.0014202122,0.0032764277,0.00049572217,0.0004507527,0.00040774827],"domain_scores_gemma":[0.9849706,0.009034496,0.0043590167,0.0008628437,0.00038942057,0.0003835694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004352792,0.00034474852,0.0042560673,0.00031604595,0.0001530062,0.000028450819,0.0003670968,0.00010173101,0.00037031795],"category_scores_gemma":[0.0004246271,0.00019468414,0.0010999975,0.00022065167,0.00044046296,0.00022668402,0.000038838243,0.00032887675,6.87379e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44447455,0.013977341,0.15057135,0.00019234068,0.044717718,0.00053019833,0.0005495929,0.0077478485,0.00007198862,0.000041363186,0.0074255336,0.32970017],"study_design_scores_gemma":[0.06687959,0.08778538,0.6791091,0.00027816987,0.023068126,0.00014185734,0.00080366177,0.08188904,0.00006137504,0.000032460404,0.059534643,0.00041662905],"about_ca_topic_score_codex":0.009591107,"about_ca_topic_score_gemma":0.020574642,"teacher_disagreement_score":0.52853775,"about_ca_system_score_codex":0.0014995551,"about_ca_system_score_gemma":0.0055444897,"threshold_uncertainty_score":0.99729735},"labels":[],"label_agreement":null},{"id":"W2970626564","doi":"10.1200/jco.2007.25.18_suppl.6574","title":"Cost-utility of adjuvant trastuzumab in Her-2/neu positive breast cancer: A Canadian perspective","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Breast cancer; Hazard ratio; Internal medicine; Oncology; Cohort; Quality-adjusted life year; Willingness to pay; Cost effectiveness; Cancer; Gynecology; Demography; Chemotherapy; Confidence interval","score_opus":0.0626734023369507,"score_gpt":0.4506877942075541,"score_spread":0.3880143918706034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970626564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868152,0.0020721236,0.000107659136,0.0058980766,0.00069227157,0.00020726335,0.00020078394,0.000001659315,0.0040049264],"genre_scores_gemma":[0.99752456,0.0007817096,0.00030108058,0.0007548722,0.0005962023,0.000004695835,0.000004655791,0.000011692219,0.000020513186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766856,0.00025572657,0.0013145275,0.0002475722,0.00016934339,0.000344289],"domain_scores_gemma":[0.9975491,0.00034589745,0.0008542869,0.00014994142,0.00075849897,0.00034225316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018107778,0.00015199059,0.0008889434,0.000121883946,0.000036614878,0.000002909087,0.0001976963,0.00034281562,0.00005723527],"category_scores_gemma":[0.0006364131,0.00012413107,0.00031454748,0.000139837,0.00033942048,0.000007646007,0.000051536692,0.00043593778,0.000001401086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009165298,0.0018777773,0.7890407,0.000010692566,0.001019631,0.00048637413,0.0008742372,0.00003237071,0.00077644706,0.000115265844,0.0018736325,0.19472758],"study_design_scores_gemma":[0.0036709707,0.0018726586,0.987896,0.0000452039,0.000104877196,0.00023935482,0.0017698008,0.0000053739354,0.00090506894,0.00014619826,0.0032375092,0.000106973064],"about_ca_topic_score_codex":0.05920178,"about_ca_topic_score_gemma":0.44490033,"teacher_disagreement_score":0.38569856,"about_ca_system_score_codex":0.0005526441,"about_ca_system_score_gemma":0.003345751,"threshold_uncertainty_score":0.9470631},"labels":[],"label_agreement":null},{"id":"W2970783342","doi":"10.1200/jco.2013.31.15_suppl.e16044","title":"Impact of a genomic classifier of metastatic risk on treatment recommendations post-radical prostatectomy: Report from the DECIDE study group.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Oncology; Internal medicine; Metastasis; Population; Cancer","score_opus":0.20661035193145635,"score_gpt":0.5353371366803238,"score_spread":0.3287267847488674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970783342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914905,0.00035218865,0.000039920167,0.006116719,0.00031152988,0.001338158,0.00007270293,0.0000043141363,0.00027398262],"genre_scores_gemma":[0.996247,0.0012771029,0.001746327,0.00015723259,0.00027774673,0.00004427723,0.00004042951,0.000018230561,0.00019164756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995068,0.0012490518,0.002791104,0.00022031844,0.0004358076,0.00023567905],"domain_scores_gemma":[0.98929167,0.0065991627,0.0026925448,0.00041533567,0.00066777744,0.00033353092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002632008,0.0001785432,0.0016237147,0.00013617439,0.00005715811,0.000009977589,0.00018109218,0.00013367807,0.0007783473],"category_scores_gemma":[0.0026636948,0.00007607901,0.00086182373,0.00014528871,0.00033751162,0.00008613863,0.000047812675,0.0007612885,0.000024552894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010681015,0.015832594,0.8131486,0.00000741027,0.0062181544,0.00088851305,0.0006637036,0.000012444568,0.0010995732,0.0000056456925,0.0031794608,0.14826289],"study_design_scores_gemma":[0.014332616,0.07960068,0.9014808,0.00005649957,0.00110145,0.00015634477,0.0008521143,0.000037918897,0.000070973154,0.0004714283,0.001784287,0.00005488033],"about_ca_topic_score_codex":0.00231428,"about_ca_topic_score_gemma":0.0001855095,"teacher_disagreement_score":0.148208,"about_ca_system_score_codex":0.0006026897,"about_ca_system_score_gemma":0.002592846,"threshold_uncertainty_score":0.85223573},"labels":[],"label_agreement":null},{"id":"W2970789858","doi":"10.1200/jco.18.02365","title":"Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Ochsner Health; European Hematology Association; American Society of Clinical Oncology","keywords":"Immune system; Follicular lymphoma; Medicine; Immunology; Vincristine; Immune checkpoint; Lymphoma; Immunophenotyping; Rituximab; Immunotherapy; Cancer research; Cyclophosphamide; Internal medicine; Flow cytometry; Chemotherapy","score_opus":0.04676229437823062,"score_gpt":0.40194868731780287,"score_spread":0.3551863929395722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970789858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443793,0.00054667186,0.0000022085019,0.0035545367,0.00054536946,0.0004528364,0.0000032294017,0.000005957627,0.00045125108],"genre_scores_gemma":[0.9982454,0.00015384851,0.000838999,0.00051812216,0.00012716318,0.000010307159,0.000011870436,0.000013396705,0.00008089659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967392,0.0003392328,0.0021005033,0.00017745246,0.00046983812,0.00017374348],"domain_scores_gemma":[0.99621207,0.000630059,0.0023071063,0.00020071182,0.00036745783,0.00028258146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016118824,0.00014091097,0.001379761,0.000122921,0.000015752725,0.0000073545657,0.00009263298,0.00025395985,0.000059528425],"category_scores_gemma":[0.0015261956,0.00008390581,0.00032066315,0.00021544224,0.00010700838,0.00013002647,0.000024067587,0.00026632438,0.000006864389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015097808,0.009637593,0.941738,0.000039034956,0.00055154116,0.0014817194,0.00027808346,0.000043303582,0.0010686062,0.00009296069,0.00045290485,0.029518418],"study_design_scores_gemma":[0.026201135,0.019434953,0.9490399,0.0010114876,0.000436048,0.000075654665,0.000109409615,0.00030897552,0.0028469237,0.00013454442,0.0003146723,0.000086319546],"about_ca_topic_score_codex":0.000028801358,"about_ca_topic_score_gemma":0.000019786034,"teacher_disagreement_score":0.029432097,"about_ca_system_score_codex":0.00032130713,"about_ca_system_score_gemma":0.0024365778,"threshold_uncertainty_score":0.43223843},"labels":[],"label_agreement":null},{"id":"W2970842314","doi":"10.1200/jco.2012.30.15_suppl.e14524","title":"Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Ampulla of Vater; Gallbladder cancer; Regimen; Gemcitabine; Gastroenterology; Gallbladder; Biliary tract; Biliary tract cancer; Retrospective cohort study; Oncology; Surgery; Carcinoma","score_opus":0.1321334407743957,"score_gpt":0.4651347063316184,"score_spread":0.3330012655572227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970842314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807652,0.015656967,0.000002418506,0.0020778533,0.0006353185,0.00039144765,0.000016593518,0.0000041146914,0.0004500538],"genre_scores_gemma":[0.99447995,0.0035450913,0.00028592246,0.0008350158,0.0007834695,0.000006982947,5.26e-7,0.000011951057,0.000051074418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745065,0.00022548884,0.0016391759,0.00018582858,0.00024359731,0.00025524737],"domain_scores_gemma":[0.99763,0.00062624965,0.0010300393,0.00016618361,0.00031933197,0.00022819897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003393589,0.00013324445,0.0017448118,0.00010687261,0.000022469723,0.0000019564252,0.00007852398,0.00018311941,0.0001460785],"category_scores_gemma":[0.001151801,0.0000940998,0.00024893534,0.00017154467,0.00012831959,0.00015439178,0.00004550178,0.00076766347,5.7752334e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00475319,0.0065464987,0.94586545,0.00003757535,0.00024852497,0.0000335421,0.0015260567,0.0000012234381,0.00007341764,0.000012180575,0.00022287195,0.040679436],"study_design_scores_gemma":[0.01904135,0.010164949,0.9673468,0.00007570617,0.00018030162,0.00006485779,0.0009778601,0.0000033047393,0.000076150456,0.00006437972,0.0019300038,0.00007434014],"about_ca_topic_score_codex":0.000040321127,"about_ca_topic_score_gemma":0.0010755918,"teacher_disagreement_score":0.040605098,"about_ca_system_score_codex":0.00024271714,"about_ca_system_score_gemma":0.000425771,"threshold_uncertainty_score":0.38372782},"labels":[],"label_agreement":null},{"id":"W2970897919","doi":"10.1200/jco.2019.37.15_suppl.11580","title":"Patient level factors associated with chronic opioid use in cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Opioid; Chronic pain; Depression (economics); Internal medicine; Logistic regression; Anxiety; Lung cancer; Prospective cohort study; Medical prescription; Population; Cohort; Physical therapy; Psychiatry","score_opus":0.16453940571424808,"score_gpt":0.4288126859610614,"score_spread":0.26427328024681335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970897919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595505,0.00023810075,0.000004166521,0.0004886855,0.0026344853,0.00023645243,0.000020747762,0.000005411528,0.0004168986],"genre_scores_gemma":[0.9979522,0.00018821387,0.000023496797,0.0012528825,0.00024471758,0.0000036577167,0.000010310491,0.000017879449,0.0003066299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975023,0.0002508227,0.0014093665,0.00016684772,0.0004287693,0.0002418831],"domain_scores_gemma":[0.9965008,0.0012943781,0.0012843099,0.00013615785,0.00054316485,0.0002411963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006617743,0.00012932948,0.0011537616,0.00011549679,0.000013102861,0.000007378874,0.00008961157,0.0003239047,0.00037792636],"category_scores_gemma":[0.0013497672,0.00008127627,0.0002589986,0.00018727276,0.00007489503,0.00014464499,0.000032466705,0.0009817407,0.0000073473984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00136122,0.0012206021,0.9706888,0.000017094397,0.00019210602,0.000056201574,0.00035739274,0.000033402477,0.000015025833,0.0000061731307,0.00078060734,0.025271373],"study_design_scores_gemma":[0.008121555,0.018494265,0.94531506,0.00033166766,0.00012108141,0.0000033584995,0.00013859497,0.0000166993,0.00004419475,0.000009649082,0.027309058,0.00009482295],"about_ca_topic_score_codex":0.000795933,"about_ca_topic_score_gemma":0.017425776,"teacher_disagreement_score":0.026528452,"about_ca_system_score_codex":0.0009890011,"about_ca_system_score_gemma":0.0024559747,"threshold_uncertainty_score":0.9723992},"labels":[],"label_agreement":null},{"id":"W2970953840","doi":"10.1200/jco.2012.30.15_suppl.5032","title":"Application of micro-RNA (miRNA) expression profiles for prognostication in low-risk endometrial carcinoma (LEC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Queen's University; Ottawa Hospital","funders":"","keywords":"Medicine; microRNA; Endometrial cancer; Internal medicine; Adjuvant therapy; Oncology; Histology; Adjuvant; Carcinoma; Cancer recurrence; Stage (stratigraphy); Cancer; Pathology; Gastroenterology; Gene","score_opus":0.09956840553026254,"score_gpt":0.45525760813347266,"score_spread":0.35568920260321013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970953840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252367,0.0013631325,0.0028943815,0.0007859069,0.0010064179,0.0010764876,0.000016390422,0.000005256787,0.00032838085],"genre_scores_gemma":[0.98504376,0.0003547354,0.01187991,0.0001443942,0.0024477108,0.000076958975,0.000011905828,0.000014044186,0.000026548438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967287,0.00033453124,0.002223516,0.00015552301,0.0003112778,0.0002464069],"domain_scores_gemma":[0.9917253,0.0049599586,0.002404901,0.00016180199,0.00044966617,0.0002983627],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003322155,0.00011769371,0.0011854339,0.00030943248,0.000024536039,0.000003025754,0.00012707603,0.00034216346,0.000036949725],"category_scores_gemma":[0.0125142895,0.00007922606,0.0004141585,0.0003840893,0.00009690904,0.00013124576,0.00003239905,0.00044211053,0.0000063412313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014050729,0.003870836,0.74060047,0.00011342419,0.000102063634,0.0000055069636,0.00007306282,0.0000028466188,0.014662104,0.00006726122,0.00022966231,0.22622205],"study_design_scores_gemma":[0.033698846,0.010842497,0.8889492,0.00016277132,0.0005452991,0.000031262032,0.00007195615,0.00006654783,0.05810621,0.00044116497,0.0069883163,0.00009594374],"about_ca_topic_score_codex":0.00003448519,"about_ca_topic_score_gemma":0.000004893486,"teacher_disagreement_score":0.2261261,"about_ca_system_score_codex":0.0001770835,"about_ca_system_score_gemma":0.0004839865,"threshold_uncertainty_score":0.9958037},"labels":[],"label_agreement":null},{"id":"W2971024745","doi":"10.1200/jco.2019.37.15_suppl.10505","title":"Humanism in global oncology curricula: An emerging priority.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Curriculum; Humanism; Medicine; Compassion; Medical education; Psychology; Pedagogy; Political science","score_opus":0.12346339578936136,"score_gpt":0.544806111290039,"score_spread":0.4213427155006776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971024745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9599668,0.0005273859,0.000024669196,0.007770025,0.0051839473,0.00023067174,0.000002071337,0.0000119473725,0.02628251],"genre_scores_gemma":[0.98624665,0.00045789115,0.0021431616,0.009517573,0.0014745954,0.0000014226865,0.0000029161477,0.000009544204,0.00014625659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948866,0.000798111,0.003143796,0.00024474834,0.0003967466,0.00053000427],"domain_scores_gemma":[0.9959961,0.0010750823,0.0014230295,0.00023123548,0.00038677483,0.0008877655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007079749,0.00014399966,0.0020719648,0.00013510363,0.000028882418,0.0000053059925,0.00018917232,0.0007024906,0.00033783994],"category_scores_gemma":[0.0023692306,0.00010886208,0.0004323186,0.00025338974,0.00012074224,0.00017062972,0.000057661506,0.0014626422,0.00013732757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025667513,0.0024968924,0.7372992,0.00004588897,0.000050473715,0.002509984,0.00006363687,0.000013220506,0.00002488085,0.0016252153,0.003360062,0.2499438],"study_design_scores_gemma":[0.007153064,0.0146496305,0.68170965,0.000104825274,0.000072033574,0.0011379843,0.00024175532,0.00013585182,0.0000017539062,0.001431315,0.29327005,0.00009209084],"about_ca_topic_score_codex":0.000105465406,"about_ca_topic_score_gemma":0.00024967693,"teacher_disagreement_score":0.28991,"about_ca_system_score_codex":0.0006775475,"about_ca_system_score_gemma":0.0040370636,"threshold_uncertainty_score":0.71615773},"labels":[],"label_agreement":null},{"id":"W2971112654","doi":"10.1200/jco.18.01972","title":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Stollery Children's Hospital; Dalhousie University; BC Children's Hospital","funders":"National Institutes of Health; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Vincristine; Internal medicine; Regimen; Wilms' tumor; Etoposide; Stage (stratigraphy); Surgery; Chemotherapy; Cyclophosphamide; Gastroenterology","score_opus":0.03223088172101514,"score_gpt":0.39476463422391217,"score_spread":0.36253375250289704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971112654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968035,0.0014151874,0.00009081838,0.00040518073,0.000602105,0.0005686235,0.000007016561,0.0000013955673,0.00010613877],"genre_scores_gemma":[0.9972985,0.0016321656,0.0005667671,0.00031222845,0.00010713948,0.000010352994,0.000013963353,0.000010765889,0.00004811435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970939,0.00043609666,0.001894555,0.0002811597,0.00012569249,0.0001685644],"domain_scores_gemma":[0.99690163,0.00035559677,0.0022585099,0.00016715696,0.00021072436,0.00010637808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002103801,0.00013334805,0.0011726421,0.000098301534,0.00002242346,0.0000028833344,0.000141335,0.0003915505,0.00000912839],"category_scores_gemma":[0.00034041036,0.00010085994,0.0001841904,0.000064597225,0.00029543592,0.0000110749315,0.00006465975,0.00033358115,1.9683368e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01377545,0.0024193537,0.9411163,0.000050289782,0.00060419826,0.00012448838,0.00018456354,0.000062880055,0.023668746,0.00003379517,0.00034301923,0.017616937],"study_design_scores_gemma":[0.029422248,0.09486931,0.866237,0.00005881696,0.0001568807,0.001106852,0.00041340722,0.00003602991,0.0036780701,0.00056508335,0.003272311,0.00018400037],"about_ca_topic_score_codex":0.00011204447,"about_ca_topic_score_gemma":0.0001555545,"teacher_disagreement_score":0.092449956,"about_ca_system_score_codex":0.000053710384,"about_ca_system_score_gemma":0.00046435543,"threshold_uncertainty_score":0.4112949},"labels":[],"label_agreement":null},{"id":"W2971160789","doi":"10.1200/jco.2019.37.15_suppl.11561","title":"Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Centre for Addiction and Mental Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Survivorship curve; Smoking cessation; Cancer survivorship; Cancer; Head and neck cancer; Physical therapy; Demography; Internal medicine","score_opus":0.24760946900617004,"score_gpt":0.47110898258554024,"score_spread":0.2234995135793702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971160789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666203,0.0070231273,0.00001642283,0.0037285613,0.0012483209,0.0004515838,0.00018793202,0.0000028450993,0.0006791834],"genre_scores_gemma":[0.9844017,0.012473322,0.0001562779,0.002544807,0.00035815843,0.000011133557,0.0000013710322,0.0000138691685,0.000039365674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956957,0.00017036425,0.0033666864,0.00032217035,0.00005340381,0.0003916548],"domain_scores_gemma":[0.9950433,0.00044437184,0.003911073,0.00018947592,0.000075213924,0.00033658333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055093234,0.00017340574,0.0026608603,0.00023870586,0.00003949432,0.000012608119,0.00015995839,0.00032295746,0.00017708464],"category_scores_gemma":[0.0008165895,0.00015942854,0.0002942196,0.00013325423,0.00016293496,0.00030502756,0.000059216443,0.0007087699,0.000009900595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005471062,0.0006569748,0.78520155,0.00003947094,0.00002245489,0.0000034136908,0.00025615472,0.000005979356,3.9165516e-7,0.0010387399,0.0004034576,0.21182431],"study_design_scores_gemma":[0.003111339,0.010131176,0.9732424,0.00010353198,0.0000047720573,0.000007638529,0.000019649638,0.000075636584,7.7649077e-7,0.0017497598,0.011429155,0.00012417433],"about_ca_topic_score_codex":0.015688803,"about_ca_topic_score_gemma":0.00797493,"teacher_disagreement_score":0.21170014,"about_ca_system_score_codex":0.00047198095,"about_ca_system_score_gemma":0.0012841497,"threshold_uncertainty_score":0.9908658},"labels":[],"label_agreement":null},{"id":"W2971223929","doi":"10.1200/jco.2019.37.15_suppl.11029","title":"Clinical characteristics of nonosteogenic, non-Ewing’s sarcoma of the bone: Experience at the Toronto Sarcoma Program.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcoma; Leiomyosarcoma; Undifferentiated Pleomorphic Sarcoma; Bone Sarcoma; Osteosarcoma; Chemotherapy; Internal medicine; Oncology; Doxorubicin; Cohort; Fibrosarcoma; Surgery; Soft tissue sarcoma; Pathology","score_opus":0.08180432522435054,"score_gpt":0.45676724853445455,"score_spread":0.374962923310104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971223929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98874396,0.0016814355,0.0000030248877,0.0040807803,0.0026869527,0.0008112567,0.000009773842,0.000005762243,0.001977068],"genre_scores_gemma":[0.99480706,0.0014062298,0.0011796802,0.0014846546,0.0007185443,0.000017533195,0.0000022195377,0.000021556549,0.00036249936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936596,0.0006530806,0.0044682287,0.00026680378,0.00064839213,0.00030386623],"domain_scores_gemma":[0.9894625,0.0047057634,0.0041715717,0.00080158625,0.0005743384,0.00028423406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003345504,0.0002067268,0.0022970885,0.00003118173,0.000058691596,0.0000076201386,0.00052950706,0.000420258,0.0004868268],"category_scores_gemma":[0.002529713,0.00009844789,0.0016330231,0.000119241115,0.00073911337,0.00009125995,0.00033020237,0.0007367246,0.000028609833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019319182,0.0049325796,0.734368,0.000030698808,0.00035961816,0.000102603735,0.0002627853,2.5149194e-7,0.00028901687,0.00003375398,0.0012728799,0.2564159],"study_design_scores_gemma":[0.0063981377,0.012111233,0.91603655,0.00020473509,0.00053730456,0.0003635789,0.00035657635,0.000035518442,0.000658098,0.000021188298,0.06319153,0.00008554678],"about_ca_topic_score_codex":0.00008192025,"about_ca_topic_score_gemma":0.00012735963,"teacher_disagreement_score":0.25633034,"about_ca_system_score_codex":0.00022458893,"about_ca_system_score_gemma":0.00095886685,"threshold_uncertainty_score":0.5330412},"labels":[],"label_agreement":null},{"id":"W2971274411","doi":"10.1200/jco.2019.37.15_suppl.11617","title":"Advanced cancer patients’ changes in terminal illness understanding (TIU) and their psychological well-being.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Worry; Life expectancy; Medicine; Expectancy theory; Cancer; Clinical psychology; Internal medicine; Psychology; Psychiatry; Social psychology; Anxiety; Population","score_opus":0.3187578809222997,"score_gpt":0.5531106680249157,"score_spread":0.23435278710261603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971274411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893085,0.0008930157,0.00005449831,0.0032350386,0.0012117246,0.00014696614,0.0000020573252,0.000003671155,0.005144572],"genre_scores_gemma":[0.99150854,0.0059441016,0.0004918965,0.0016033752,0.00033468893,0.0000024240326,0.0000011801995,0.0000087262415,0.00010507488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823785,0.0002037505,0.001033035,0.00017023816,0.00016929675,0.00018580497],"domain_scores_gemma":[0.99694514,0.0017882929,0.0008368892,0.00009327261,0.00017415831,0.0001622208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010274576,0.00011649044,0.0011968742,0.00012829535,0.00001536634,0.000003152794,0.00009744175,0.00027244398,0.00017286447],"category_scores_gemma":[0.0010397113,0.00007104713,0.00015129158,0.00011139487,0.00018323651,0.000070335176,0.000039218256,0.0006129512,0.000003773966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030977959,0.0007196117,0.88949907,0.0000549034,0.00008446308,0.00008692199,0.0010128922,0.0000037414795,0.00020035454,0.00015348897,0.00026503432,0.10482175],"study_design_scores_gemma":[0.01944967,0.024360806,0.8682872,0.0019782148,0.0001300765,0.00007109454,0.0051393667,0.000079313715,0.00052306254,0.0023107445,0.07745064,0.0002197808],"about_ca_topic_score_codex":0.000009698132,"about_ca_topic_score_gemma":0.00007503487,"teacher_disagreement_score":0.10460197,"about_ca_system_score_codex":0.000155796,"about_ca_system_score_gemma":0.0001416754,"threshold_uncertainty_score":0.2897218},"labels":[],"label_agreement":null},{"id":"W2971374060","doi":"10.1200/jco.2019.37.15_suppl.11581","title":"Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate cancer pain.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tramadol; Opioid; Clinical endpoint; Randomized controlled trial; Morphine; Cancer pain; Analgesic; Brief Pain Inventory; Breakthrough Pain; Pain ladder; Anesthesia; Cancer; Physical therapy; Chronic pain; Internal medicine","score_opus":0.06872234156710566,"score_gpt":0.43006451680746854,"score_spread":0.3613421752403629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971374060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968916,0.000059286205,0.00049783546,0.0006877343,0.00083096506,0.00081708055,0.0000054683815,0.0000030418137,0.00020694375],"genre_scores_gemma":[0.9987901,0.000021328811,0.00022815392,0.00081142073,0.000089864196,0.000007403871,0.000001914055,0.000014038268,0.00003579386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941889,0.0035132465,0.0014604202,0.00016243522,0.0004725747,0.00020243294],"domain_scores_gemma":[0.99031365,0.0073958095,0.0015582481,0.00020994297,0.00041085665,0.00011149561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009874821,0.00014955542,0.0018355731,0.00011959222,0.000016076074,0.00000400253,0.0002122109,0.00021063544,0.00004340582],"category_scores_gemma":[0.0028441693,0.000082265295,0.00028680408,0.00018828921,0.00017471307,0.00006835437,0.000030935913,0.0007933687,0.0000021300891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09497782,0.0023205227,0.8862578,0.00013436947,0.00043464772,0.00001585816,0.00010613491,0.0024200163,0.00006751196,0.00006138821,0.00025558335,0.012948326],"study_design_scores_gemma":[0.046963245,0.029746544,0.91566414,0.0005964484,0.00027970257,1.3479458e-7,0.00006564944,0.0060135094,0.000069688256,0.00009577536,0.00042963916,0.0000755297],"about_ca_topic_score_codex":0.00014913414,"about_ca_topic_score_gemma":0.00011337668,"teacher_disagreement_score":0.048014577,"about_ca_system_score_codex":0.00014709838,"about_ca_system_score_gemma":0.0004446877,"threshold_uncertainty_score":0.34468362},"labels":[],"label_agreement":null},{"id":"W2971479975","doi":"10.1200/jco.2007.25.18_suppl.17014","title":"Trends in chemotherapy (CT) utilization for colorectal cancer: A provincial population-based analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Internal medicine; Cohort; Stage (stratigraphy); Population; Adjuvant chemotherapy; Adjuvant; Oncology; Surgery; Gastroenterology; Breast cancer","score_opus":0.1240964432152481,"score_gpt":0.5087640819030738,"score_spread":0.38466763868782566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971479975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993615,0.00043076713,0.0010711484,0.0034939728,0.00048659614,0.0002302042,0.000009746134,0.000006789548,0.00065577705],"genre_scores_gemma":[0.99670094,0.000145689,0.0015214162,0.0007753016,0.0006920819,0.000015343083,0.000019464684,0.000009662838,0.00012007398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978366,0.00007258419,0.0015331259,0.00015361601,0.00021604521,0.00018805933],"domain_scores_gemma":[0.9975099,0.0010428433,0.00095177605,0.000059303533,0.0003022753,0.00013388705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017719474,0.00010492803,0.0012685993,0.0005198496,0.000039593557,0.000004209393,0.000053972944,0.00013293367,0.00014821485],"category_scores_gemma":[0.00069832354,0.00007425754,0.0006573924,0.0006985488,0.00005288828,0.000043005624,0.000006953051,0.00022756097,2.6318045e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009350205,0.0007926654,0.5987167,0.0000062660915,0.0006196544,0.000052796153,0.000040932377,0.0001173384,0.00001057546,0.000017308646,0.00020884199,0.3900667],"study_design_scores_gemma":[0.010252554,0.007328521,0.9710363,0.000019167128,0.0011243146,0.000008721078,0.000043211912,0.0014770925,0.00007692605,0.000052795094,0.008516883,0.00006351145],"about_ca_topic_score_codex":0.0004890783,"about_ca_topic_score_gemma":0.019898243,"teacher_disagreement_score":0.3900032,"about_ca_system_score_codex":0.0005891854,"about_ca_system_score_gemma":0.0007220185,"threshold_uncertainty_score":0.9979861},"labels":[],"label_agreement":null},{"id":"W2971732632","doi":"10.1200/jco.2019.37.15_suppl.11588","title":"Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Chemotherapy; Clinical trial; Cancer; Oncology","score_opus":0.7697258075137854,"score_gpt":0.6321900021730763,"score_spread":0.13753580534070908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971732632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619327,0.004796472,0.00011196794,0.027565159,0.0044239517,0.00062485586,0.00001510535,0.000006836118,0.00052295125],"genre_scores_gemma":[0.97448707,0.010713174,0.0011264582,0.0122643635,0.0009494179,0.000022644994,0.0000021109263,0.000018471916,0.0004163045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9516471,0.005447402,0.041877616,0.00052327843,0.00012218056,0.00038243333],"domain_scores_gemma":[0.93754077,0.017151758,0.044636853,0.00030334308,0.00010349053,0.00026375923],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.27245238,0.00019608371,0.006187294,0.00037286727,0.000033276898,0.000019328387,0.00030904816,0.00071050384,0.0008482046],"category_scores_gemma":[0.07048416,0.00017099197,0.00064897625,0.00017334991,0.00015737272,0.00024474558,0.000058564696,0.0011583669,0.00007759616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004977485,0.00058089074,0.978194,0.00004349904,0.00017519348,0.000018137547,0.0005161894,0.00007596466,0.0000050949584,0.00047208043,0.0012878161,0.018133402],"study_design_scores_gemma":[0.0076211863,0.0015779508,0.950783,0.00014154043,0.000009366913,0.000012455998,0.00076438335,0.0016231971,0.0000012906082,0.00476983,0.03250589,0.00018989925],"about_ca_topic_score_codex":0.0007141843,"about_ca_topic_score_gemma":0.00058541034,"teacher_disagreement_score":0.20196822,"about_ca_system_score_codex":0.00049932295,"about_ca_system_score_gemma":0.0010967653,"threshold_uncertainty_score":0.93734556},"labels":[],"label_agreement":null},{"id":"W2971880201","doi":"10.1200/jco.2019.37.15_suppl.11540","title":"Prognostic factors among older adults with advanced non-small cell lung cancer (NSCLC): A multisite cohort study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Cohort; Oncology; Population; Quality of life (healthcare); non-small cell lung cancer (NSCLC); Performance status; Proportional hazards model; Cancer","score_opus":0.02517728441168255,"score_gpt":0.3799202275765152,"score_spread":0.3547429431648327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971880201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234474,0.00048246092,0.00008092052,0.00025101166,0.0016775646,0.0027407093,0.000006747862,0.000017099966,0.0023987682],"genre_scores_gemma":[0.99587697,0.00041152618,0.0011691968,0.0010274661,0.00052088406,0.000040999636,0.000006498188,0.00004608231,0.00090037205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627066,0.00026817937,0.0020711021,0.00044784148,0.0005303719,0.00041187525],"domain_scores_gemma":[0.99484813,0.0016301374,0.0019630804,0.00034315174,0.00062779017,0.00058771094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013096081,0.0002897284,0.0021520979,0.00015291029,0.000046106998,0.00001307559,0.00024434188,0.00034486194,0.00080849195],"category_scores_gemma":[0.00047257726,0.00018401018,0.00042137297,0.00017842076,0.0001362085,0.0002364211,0.00006135541,0.0015535217,0.000016072505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063386275,0.002126016,0.9684227,0.00017751276,0.0007141996,0.00059338036,0.0010974854,0.00014133229,0.0000717019,2.0832644e-7,0.00051884825,0.019797962],"study_design_scores_gemma":[0.03016201,0.016292034,0.94836724,0.000645455,0.00096839457,0.000039282855,0.0013074981,0.0006191281,0.000064915024,3.9182814e-7,0.0013225953,0.00021103783],"about_ca_topic_score_codex":0.00019385235,"about_ca_topic_score_gemma":0.00056279846,"teacher_disagreement_score":0.023823382,"about_ca_system_score_codex":0.00032407587,"about_ca_system_score_gemma":0.0023218743,"threshold_uncertainty_score":0.885242},"labels":[],"label_agreement":null},{"id":"W2971956393","doi":"10.1200/jco.2019.37.15_suppl.e23164","title":"Bridging the information gap: A scoping review of radiation oncology patient education scholarship.","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Scholarship; Inclusion (mineral); Medical education; Psychological intervention; Curriculum; Categorization; Radiation oncology; Psychology; Nursing; Internal medicine; Pedagogy; Computer science; Political science; Radiation therapy","score_opus":0.1992272672653339,"score_gpt":0.6134676465077424,"score_spread":0.41424037924240853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971956393","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025245212,0.983853,0.00048080637,0.003056979,0.007613358,0.0021577394,0.000004695796,0.0000069486964,0.0028012586],"genre_scores_gemma":[0.000012463145,0.982894,0.0024673087,0.011909574,0.0025601676,0.000039535927,0.00004194357,0.000022129927,0.000052858108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98942566,0.0024601663,0.007241384,0.00018343439,0.00046612267,0.00022321129],"domain_scores_gemma":[0.9755792,0.006362484,0.016514882,0.0004287894,0.0009248152,0.0001897994],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008634324,0.00027093204,0.0059054424,0.0003015155,0.00006546403,0.000007742772,0.0003737846,0.0011786851,0.00013069337],"category_scores_gemma":[0.014000533,0.00015307653,0.001512089,0.0003509073,0.00029283614,0.0004693325,0.000060439845,0.0027694085,0.00005282303],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023125346,0.00051664445,0.000060871706,0.05855256,0.00038242902,0.000012599327,0.000068268884,0.0000019084823,6.619618e-8,0.00005954327,0.0055998038,0.93451405],"study_design_scores_gemma":[0.0008307059,0.0050647575,0.00006222129,0.24343221,0.0020422428,0.0011836604,0.000020932572,0.0000028793538,3.884059e-7,0.000036450423,0.7472292,0.000094359995],"about_ca_topic_score_codex":0.0000021007913,"about_ca_topic_score_gemma":0.000001910269,"teacher_disagreement_score":0.9344197,"about_ca_system_score_codex":0.000952135,"about_ca_system_score_gemma":0.028832981,"threshold_uncertainty_score":0.99953127},"labels":[],"label_agreement":null},{"id":"W2971992992","doi":"10.1200/jco.2019.37.15_suppl.10514","title":"Implementation of competency-based medical education in a Canadian medical oncology training program: Lessons from our first year.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Innovations in Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Competence (human resources); Rubric; Medical education; Medicine; Psychology; Pedagogy","score_opus":0.11356320296162473,"score_gpt":0.5718052586625867,"score_spread":0.458242055700962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971992992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7560933,0.000059372906,0.00007730316,0.23712488,0.003436411,0.00043862942,0.000004336802,0.000008299138,0.002757441],"genre_scores_gemma":[0.9552389,0.0000843248,0.031440053,0.011701198,0.001389236,0.000024097997,0.000064909415,0.000018204244,0.00003907105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942015,0.000513064,0.003416151,0.00023965436,0.0012476743,0.00038195384],"domain_scores_gemma":[0.99511546,0.0011139037,0.001624195,0.00023209318,0.00089344423,0.0010209046],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008345187,0.0001353154,0.0013082454,0.00057041843,0.000032492808,0.000005846544,0.00034010166,0.0010794908,0.0049012173],"category_scores_gemma":[0.018244358,0.000113653245,0.00022899843,0.00050039735,0.00019137487,0.000092459864,0.000029227755,0.0019527874,0.000046137746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002968099,0.002244326,0.30758145,0.000040787447,0.00008568328,0.00010160868,0.00042470067,0.0000032103105,0.00000666262,0.0018110132,0.009577651,0.6778261],"study_design_scores_gemma":[0.014296006,0.0085527105,0.72744244,0.00087532954,0.0001898187,0.00022740559,0.0130973,0.0019983738,0.000019930998,0.0009862413,0.23214713,0.00016732216],"about_ca_topic_score_codex":0.026141567,"about_ca_topic_score_gemma":0.28296167,"teacher_disagreement_score":0.67765874,"about_ca_system_score_codex":0.00092103577,"about_ca_system_score_gemma":0.22707997,"threshold_uncertainty_score":0.99600846},"labels":[],"label_agreement":null},{"id":"W2972043980","doi":"10.1200/jco.2013.31.15_suppl.11110","title":"The role of Pirh2 C-terminal residues and ubiquitin lysine chains in ubiquitination mechanism.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ubiquitin; Ubiquitin ligase; Lysine; Ubiquitin-conjugating enzyme; Ubiquitin-Protein Ligases; Cell biology; Mutant; Biology; Chemistry; Biochemistry; Amino acid; Gene","score_opus":0.035598041358222345,"score_gpt":0.37508881407023464,"score_spread":0.3394907727120123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972043980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900842,0.0033120033,0.000034674227,0.0037979065,0.0006799373,0.00013163587,0.0000016783833,0.000003987174,0.001953983],"genre_scores_gemma":[0.996593,0.0013992045,0.00017320506,0.00031231288,0.000098212106,0.0000042083702,0.0000013357327,0.00000739144,0.0014111212],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964196,0.001343188,0.0018431928,0.00011327928,0.000054055025,0.00022667083],"domain_scores_gemma":[0.9949245,0.0032809074,0.0012984067,0.00012861428,0.00033298793,0.000034593977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033944664,0.000104149345,0.0007350276,0.00014144708,0.000065145,0.000010953116,0.0002512964,0.00037961392,0.0002129037],"category_scores_gemma":[0.0027364704,0.00006393851,0.0001668674,0.000070891554,0.0004402043,0.00012546728,0.00009615593,0.0006988486,0.00004970191],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068559544,0.001181501,0.009551763,0.00002164353,0.00037748448,0.00005285702,0.00087724853,0.0000013679393,0.31402552,0.031736042,0.0026756765,0.6326429],"study_design_scores_gemma":[0.011751434,0.028305437,0.4399038,0.00030989983,0.0001972879,0.0017238994,0.006953769,0.00011860354,0.2812391,0.028843723,0.20029785,0.00035521042],"about_ca_topic_score_codex":0.00007667747,"about_ca_topic_score_gemma":0.000120145305,"teacher_disagreement_score":0.63228774,"about_ca_system_score_codex":0.00003590406,"about_ca_system_score_gemma":0.0003072363,"threshold_uncertainty_score":0.32760084},"labels":[],"label_agreement":null},{"id":"W2972072773","doi":"10.1200/jco.2013.31.15_suppl.e20562","title":"Intra-arterial infusion of irinotecan loaded microparticles (IAIRIM) for symptomatic and unresectable colorectal cancer (UCRC): Preliminary report.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Colonoscopy; Abdominal pain; Radiology; Surgery; Anemia; Angiography; Cancer; Internal medicine","score_opus":0.12285375231448063,"score_gpt":0.39726007835558114,"score_spread":0.2744063260411005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972072773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924893,0.00074535666,0.000068862886,0.0051139886,0.0006629225,0.0007761058,0.0000048246443,0.000008394257,0.00013027704],"genre_scores_gemma":[0.9953362,0.00024301754,0.0033952992,0.00022758554,0.0006553623,0.000054391425,0.0000043930613,0.000016252396,0.00006751154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708855,0.00022043493,0.0020818776,0.000174698,0.00020355545,0.00023089307],"domain_scores_gemma":[0.996005,0.0015788124,0.0014643397,0.00012599477,0.0005135495,0.0003122983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012862614,0.00013587269,0.0012252679,0.00009876238,0.000042304513,0.000012058532,0.00008233522,0.00030746826,0.0002592423],"category_scores_gemma":[0.0017120744,0.000094028255,0.00032569666,0.00009002474,0.00023391764,0.0001274841,0.000050581006,0.00027956432,0.000004146381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008524379,0.0019339697,0.6698257,0.00024584145,0.0005815315,0.00056275283,0.00029272528,0.0000013749342,0.17232347,0.000013991053,0.004713863,0.14098045],"study_design_scores_gemma":[0.016066054,0.050810177,0.8130531,0.0003732989,0.0014981707,0.0017095407,0.00017717562,0.0016440513,0.11007446,0.00056567864,0.0038496128,0.00017873368],"about_ca_topic_score_codex":0.0001475594,"about_ca_topic_score_gemma":0.000025771818,"teacher_disagreement_score":0.1432274,"about_ca_system_score_codex":0.000076616845,"about_ca_system_score_gemma":0.0008082546,"threshold_uncertainty_score":0.3834361},"labels":[],"label_agreement":null},{"id":"W2972163358","doi":"10.1200/jco.2012.30.15_suppl.tps5116","title":"A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cervical cancer; Carboplatin; Radiation therapy; Oncology; Internal medicine; Cancer; Randomized controlled trial; Chemotherapy; Cisplatin; Clinical trial; Gynecology","score_opus":0.1291107507496379,"score_gpt":0.49412237180277674,"score_spread":0.36501162105313883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972163358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759412,0.0015355443,0.0004424627,0.013316819,0.004287336,0.0037618414,0.000020172385,0.000012784039,0.00068185217],"genre_scores_gemma":[0.9848769,0.0009289903,0.0025844907,0.005193687,0.005732077,0.00030830313,0.000031721775,0.00003406683,0.00030977328],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954634,0.0003146194,0.0029381667,0.00024934352,0.0006305659,0.00040393867],"domain_scores_gemma":[0.9936342,0.0028974337,0.0021561736,0.0002749943,0.0004000111,0.0006371361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027617905,0.0002602646,0.002785214,0.0001377826,0.0000757434,0.000010392779,0.00019589589,0.0003347521,0.00016140105],"category_scores_gemma":[0.0021507912,0.0001512843,0.0013689261,0.0003664035,0.00008545097,0.000175031,0.000026080668,0.00032956654,0.000009174271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6091179,0.011194324,0.0005658957,0.000023115483,0.00092495146,0.000009366491,0.0002799748,0.00002404996,0.0005037493,0.000011122703,0.0006574254,0.37668812],"study_design_scores_gemma":[0.8596761,0.07977495,0.0049744537,0.00008342194,0.0015498275,0.000013854066,0.00011082681,0.000077080076,0.0018938171,0.0000832525,0.051625367,0.00013703137],"about_ca_topic_score_codex":0.00010809563,"about_ca_topic_score_gemma":0.000027959528,"teacher_disagreement_score":0.3765511,"about_ca_system_score_codex":0.0009949643,"about_ca_system_score_gemma":0.0019528021,"threshold_uncertainty_score":0.61691946},"labels":[],"label_agreement":null},{"id":"W2972255002","doi":"10.1200/jco.2007.25.18_suppl.19552","title":"Efficacy of an oncology palliative care clinic for improving symptom management and patient satisfaction","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palliative care; Nausea; Distress; Patient satisfaction; Anxiety; Physical therapy; Internal medicine; Cancer; Cancer pain; Surgery; Psychiatry; Nursing","score_opus":0.2509900129655008,"score_gpt":0.5644376930104934,"score_spread":0.3134476800449926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972255002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285555,0.0017776459,0.0015626635,0.00042534387,0.0010257685,0.00047261157,0.000007633294,0.0000059800636,0.0018668146],"genre_scores_gemma":[0.957282,0.0014761976,0.04019755,0.0005163359,0.00047519698,0.0000038071746,0.0000044852654,0.000013901404,0.00003050411],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963967,0.00023701282,0.0026820377,0.00020282411,0.00026798193,0.00021339947],"domain_scores_gemma":[0.99055177,0.005374952,0.0028095108,0.00015042385,0.0008343016,0.00027904322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022119314,0.00013266852,0.0014330731,0.00017721552,0.000031657168,0.0000024433134,0.00007841962,0.00038125602,0.000025871916],"category_scores_gemma":[0.0027280357,0.000100016965,0.00036844262,0.000096249765,0.00022473995,0.000082937724,0.00004927625,0.0004544344,0.0000013306226],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009199619,0.0007885045,0.1873599,0.00022700212,0.00041495464,0.00011612288,0.0019749373,0.0000052774226,0.00018824518,0.00007888963,0.0001764186,0.7994701],"study_design_scores_gemma":[0.014447252,0.05172526,0.88131696,0.00038128483,0.0008698672,0.000021839343,0.008886032,0.000034088083,0.00094341865,0.00019598633,0.04107644,0.00010155926],"about_ca_topic_score_codex":0.000031425177,"about_ca_topic_score_gemma":0.00009350523,"teacher_disagreement_score":0.79936856,"about_ca_system_score_codex":0.00022935764,"about_ca_system_score_gemma":0.0004511616,"threshold_uncertainty_score":0.40785736},"labels":[],"label_agreement":null},{"id":"W2972299169","doi":"10.1200/jco.2019.37.15_suppl.11532","title":"Goals of care designation associated with improved survival and indicators of quality end-of-life care in pancreatic cancer (PC) patients (pts) undergoing palliative chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Alberta Health Services; University of Alberta","funders":"","keywords":"Medicine; Palliative care; Cohort; Population; Cancer; Quality of life (healthcare); Retrospective cohort study; Chemotherapy; Internal medicine; Family medicine; Nursing","score_opus":0.16213747062610356,"score_gpt":0.5028634579877341,"score_spread":0.34072598736163057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972299169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996179,0.002488967,0.00004078734,0.0001835929,0.00020860607,0.00035175032,0.000042045427,0.0000024570318,0.000502822],"genre_scores_gemma":[0.99616843,0.0028451167,0.00075327046,0.00013372752,0.00005698921,0.000003122083,0.000014449615,0.000014890096,0.000010027868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603105,0.0007970864,0.0023728875,0.00016938813,0.00047124925,0.00015834485],"domain_scores_gemma":[0.98770446,0.005657733,0.00492145,0.0001264283,0.0014500098,0.00013989443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016055747,0.00014658732,0.002275546,0.00020493982,0.000010708251,0.0000015293715,0.00011038068,0.00033621737,0.000043591557],"category_scores_gemma":[0.006304832,0.000105029634,0.00020964112,0.0002818141,0.00024697938,0.000079267054,0.000026518606,0.00040069918,1.5976087e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005040785,0.0005747246,0.97548723,0.0005956019,0.00072303007,0.0000029677985,0.004992363,0.0000196398,0.0005052545,0.00003270628,0.0000071413497,0.012018528],"study_design_scores_gemma":[0.0162543,0.010968643,0.9583538,0.0022638892,0.00028123352,1.6701556e-7,0.009048003,0.000016659124,0.0026081856,0.000033061828,0.00008162829,0.00009043691],"about_ca_topic_score_codex":0.0004467966,"about_ca_topic_score_gemma":0.0016533592,"teacher_disagreement_score":0.017133465,"about_ca_system_score_codex":0.0003766431,"about_ca_system_score_gemma":0.002418957,"threshold_uncertainty_score":0.75479287},"labels":[],"label_agreement":null},{"id":"W2972493815","doi":"10.1200/jco.2019.37.15_suppl.11557","title":"Association of obesity with breast cancer outcome in relation to cancer subtypes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Statistics Canada; University of Toronto; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Internal medicine; Confidence interval; Obesity; Meta-analysis; Oncology; Cancer; Cochrane Library; Gynecology","score_opus":0.07448705368808801,"score_gpt":0.47084115561779405,"score_spread":0.39635410192970605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972493815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826261,0.00009876837,0.000017830942,0.01550478,0.0009843726,0.00016860888,0.000010444914,0.0000023472605,0.00058677985],"genre_scores_gemma":[0.99692017,0.00034963735,0.0001938351,0.0011948702,0.00042849377,0.0000022433783,6.149129e-7,0.000007822529,0.00090233306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806947,0.000110187066,0.0012852219,0.00010316467,0.0003069292,0.00012504008],"domain_scores_gemma":[0.997337,0.0004927705,0.0015112279,0.00008718821,0.00042810768,0.00014369367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016464961,0.0000659094,0.0009564828,0.00010449767,0.0000069903563,0.0000020841821,0.000058333873,0.00024201158,0.0004931888],"category_scores_gemma":[0.00044612386,0.000043285243,0.0001478309,0.00017687239,0.000021394098,0.00008287722,0.000014403488,0.00057997956,0.000010058098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031405967,0.0003333263,0.9780793,0.000022086442,0.00012912146,0.000014398265,0.00009675292,0.00029362526,0.00009431094,0.000013115083,0.0010974569,0.016685873],"study_design_scores_gemma":[0.0043794382,0.0019962122,0.98400116,0.00014758842,0.00016277898,0.000014677907,0.00003355077,0.000034336346,0.000018541507,0.000017676557,0.009146701,0.000047366902],"about_ca_topic_score_codex":0.0016020485,"about_ca_topic_score_gemma":0.003849135,"teacher_disagreement_score":0.016638506,"about_ca_system_score_codex":0.00080956926,"about_ca_system_score_gemma":0.001167158,"threshold_uncertainty_score":0.5400071},"labels":[],"label_agreement":null},{"id":"W2972616208","doi":"10.1200/jco.2019.37.15_suppl.11510","title":"Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Common Terminology Criteria for Adverse Events; Cabazitaxel; Androgen deprivation therapy; Internal medicine; Docetaxel; Chemotherapy; Cancer; Adverse effect; Oncology; Toxicity; Gynecology; Androgen receptor","score_opus":0.17855848709716127,"score_gpt":0.5171520446218073,"score_spread":0.33859355752464604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972616208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754164,0.0026219229,0.000039549835,0.019424515,0.00037715104,0.0019571064,0.000035595847,0.0000056064337,0.00012212804],"genre_scores_gemma":[0.9846915,0.009402939,0.0031192307,0.0010676924,0.00049366616,0.00023446618,0.000009102833,0.000029296827,0.00095212646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706215,0.00052983203,0.0012026599,0.0003336353,0.00047097937,0.00040075558],"domain_scores_gemma":[0.99685836,0.0018539584,0.00046596423,0.00013801454,0.0004750743,0.00020864101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008364225,0.00013696178,0.00073231,0.00021201678,0.00015003885,0.00005525201,0.00011344679,0.00012386941,0.00013624919],"category_scores_gemma":[0.0011095931,0.00008442269,0.000102318176,0.00029778684,0.00013275917,0.00021186145,0.00006669587,0.0007265941,9.863577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010985883,0.00082274445,0.46257293,0.00048757548,0.0008287383,0.000060812126,0.004556079,0.00009326499,0.05905248,0.000071018585,0.0067340466,0.45373443],"study_design_scores_gemma":[0.039106596,0.015224874,0.875074,0.003279572,0.00047059727,0.00010093608,0.0072029326,0.0039060488,0.008445986,0.00094786455,0.045863423,0.0003771155],"about_ca_topic_score_codex":0.00026489285,"about_ca_topic_score_gemma":0.0003170357,"teacher_disagreement_score":0.4533573,"about_ca_system_score_codex":0.00053982047,"about_ca_system_score_gemma":0.0012478799,"threshold_uncertainty_score":0.34426573},"labels":[],"label_agreement":null},{"id":"W2972633283","doi":"10.1200/jco.2013.31.15_suppl.6033","title":"A preliminary cost-effectiveness analysis of human papillomavirus vaccination in males for the prevention of oropharyngeal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vaccination; Vaccine efficacy; Cervical cancer; Cost effectiveness; Human papillomavirus; Cancer prevention; Cervix; Cancer; Cost-effectiveness analysis; Demography; Gynecology; Internal medicine; Immunology","score_opus":0.2569652183625575,"score_gpt":0.5790179191164118,"score_spread":0.3220527007538543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972633283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948544,0.0013775518,0.0004988416,0.001447185,0.00017136283,0.001018765,0.000007178088,0.0000013289145,0.00062338804],"genre_scores_gemma":[0.9982938,0.0010535754,0.00013348389,0.000091218026,0.00022544908,0.00011200745,0.000004516203,0.000006633953,0.00007927135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973256,0.0005315392,0.0015909658,0.000113632464,0.00030263758,0.00013563866],"domain_scores_gemma":[0.99289834,0.004680436,0.0010966202,0.00013102047,0.0010935214,0.00010006773],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003758486,0.0000687918,0.001319021,0.00027065873,0.000025507656,0.0000031598533,0.00014840672,0.00018126547,0.0014046476],"category_scores_gemma":[0.0015398102,0.00004129219,0.00061269227,0.00043341608,0.00010564689,0.00008824697,0.000039526712,0.000402978,7.0057365e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0100850705,0.0016908345,0.2874626,0.0002873869,0.0014615586,0.000009836288,0.00008445067,0.00026361097,0.0018395312,0.00013399543,0.0001833198,0.6964978],"study_design_scores_gemma":[0.0058228844,0.014495101,0.9742352,0.000057521473,0.001680274,0.0000037681903,0.000107096064,0.0019503837,0.00076705415,0.00057803857,0.00026888167,0.000033840857],"about_ca_topic_score_codex":0.0005495615,"about_ca_topic_score_gemma":0.0007453524,"teacher_disagreement_score":0.69646394,"about_ca_system_score_codex":0.00017227192,"about_ca_system_score_gemma":0.0006102656,"threshold_uncertainty_score":0.9995082},"labels":[],"label_agreement":null},{"id":"W2972664697","doi":"10.1200/jco.19.00917","title":"Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Sherbrooke","funders":"","keywords":"Medicine; Toxicity; Internal medicine; Ovarian cancer; Adverse effect; Nausea; Vomiting; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.12231099046240816,"score_gpt":0.478143250639471,"score_spread":0.3558322601770628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972664697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863674,0.0003975748,0.00004135152,0.006420068,0.0045950655,0.00087716855,0.000054660486,0.0000104695455,0.001236239],"genre_scores_gemma":[0.99552923,0.0011265911,0.00034884128,0.0008347723,0.0011570039,0.000026877387,0.000006661936,0.000021569602,0.000948476],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994226,0.0010316096,0.0033993567,0.0003903192,0.0005718721,0.0003808672],"domain_scores_gemma":[0.99223185,0.0028113048,0.0036331064,0.00057264295,0.0005041662,0.00024696317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036626605,0.00026954646,0.003224113,0.0002757904,0.000031169435,0.000010643452,0.00034753318,0.00038933332,0.0009001686],"category_scores_gemma":[0.0020393843,0.00014846564,0.0011977324,0.001037014,0.00033691953,0.00008143393,0.00005876318,0.00085851137,0.0000130815915],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6206474,0.0048442474,0.29909027,0.00003679469,0.0066251005,0.00008251366,0.00035828416,0.00032273246,0.001462967,0.00008805745,0.0011923427,0.065249346],"study_design_scores_gemma":[0.36016476,0.056237932,0.5431153,0.00040653028,0.002460925,0.000051559935,0.00009145407,0.0027707557,0.0004928984,0.00006201235,0.03384318,0.00030268167],"about_ca_topic_score_codex":0.00036158162,"about_ca_topic_score_gemma":0.0028768617,"teacher_disagreement_score":0.26048258,"about_ca_system_score_codex":0.001477472,"about_ca_system_score_gemma":0.0031948155,"threshold_uncertainty_score":0.9856215},"labels":[],"label_agreement":null},{"id":"W2972743900","doi":"10.1200/jco.2019.37.15_suppl.e21525","title":"Late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cancer; Relative risk; Interquartile range; Population; Demography; Cohort; Pediatrics; Confidence interval; Internal medicine; Environmental health","score_opus":0.06258722319529918,"score_gpt":0.4229073959037962,"score_spread":0.36032017270849703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972743900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97746617,0.0076050735,0.0000014109069,0.0093904855,0.003216226,0.0007555675,0.000021443844,0.000008825403,0.001534802],"genre_scores_gemma":[0.994202,0.0022619565,0.000055579163,0.0014768376,0.0016663012,0.000026024767,0.0000025615648,0.000027328597,0.00028138183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949099,0.00061566936,0.003174856,0.00036074364,0.0006247225,0.0003141376],"domain_scores_gemma":[0.9940534,0.002233343,0.002552341,0.00049112947,0.00047623747,0.00019353407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035886082,0.0002266237,0.0024977396,0.00012540352,0.00003858184,0.00000879332,0.00035963394,0.0002676111,0.00029520504],"category_scores_gemma":[0.0014863538,0.00013411636,0.0006099968,0.00037241328,0.00016143198,0.00009708982,0.00014625592,0.0014666414,0.000009362187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013788382,0.0026234763,0.9669848,0.000018248325,0.00146444,0.00069276174,0.0027673906,0.00003672918,0.000037820835,0.0000017740706,0.0011659362,0.022827774],"study_design_scores_gemma":[0.016734868,0.0037349372,0.9674769,0.00030883736,0.00059115695,0.00012005602,0.0012195692,0.000006973689,0.000032336364,0.0000490189,0.009599346,0.0001259753],"about_ca_topic_score_codex":0.014925641,"about_ca_topic_score_gemma":0.031664673,"teacher_disagreement_score":0.0227018,"about_ca_system_score_codex":0.00018282427,"about_ca_system_score_gemma":0.002325517,"threshold_uncertainty_score":0.9916341},"labels":[],"label_agreement":null},{"id":"W2972996301","doi":"10.1200/jco.2019.37.15_suppl.11559","title":"Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research; Toronto General Hospital; University Health Network; Health Sciences North; Northeast Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Logistic regression; Christian ministry; Vendor; Demography; Cancer; Physical therapy; Internal medicine; Pathology","score_opus":0.08799793800231909,"score_gpt":0.431932958562066,"score_spread":0.3439350205597469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972996301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98609614,0.003792957,0.0000031410416,0.006959834,0.0007059196,0.0002320635,0.0000038099427,0.0000039113916,0.0022022428],"genre_scores_gemma":[0.98819596,0.007612673,0.000517398,0.0030271816,0.00033009212,0.0000024186268,0.0000017153643,0.000008872259,0.00030368395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780416,0.00027581025,0.0013493111,0.00024339833,0.00015626871,0.00017102799],"domain_scores_gemma":[0.9974965,0.0013171993,0.00062670885,0.00013684145,0.00016129346,0.00026145994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002596561,0.000113188915,0.0011259379,0.00009293051,0.000022849083,0.000012980788,0.00005580102,0.0003043282,0.0004912328],"category_scores_gemma":[0.0009982144,0.000085813655,0.00008780434,0.00008449511,0.00018171103,0.00026138156,0.00005628073,0.0007559223,0.0000023236414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020242669,0.00012721757,0.82609385,0.00007254216,0.000056899196,0.000036471974,0.00016143233,0.0000033110784,0.00009166729,0.000019724574,0.0004481771,0.17086442],"study_design_scores_gemma":[0.007864025,0.0022318382,0.95453763,0.00011751739,0.00007925997,0.00007342499,0.00014504576,0.0002757875,0.000010957651,0.00008633156,0.034495894,0.000082290724],"about_ca_topic_score_codex":0.0006637695,"about_ca_topic_score_gemma":0.004843582,"teacher_disagreement_score":0.17078213,"about_ca_system_score_codex":0.00016909915,"about_ca_system_score_gemma":0.00084979687,"threshold_uncertainty_score":0.53786546},"labels":[],"label_agreement":null},{"id":"W2973896058","doi":"10.1200/jco.2013.31.15_suppl.4060","title":"Prognostic value of an immune score combining intra- and peritumoral T-cell subset density in patients with pancreatic adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; CD8; Immune system; Gastroenterology; Internal medicine; T cell; Tissue microarray; Adenocarcinoma; Proportional hazards model; Univariate analysis; FOXP3; Pathology; Immunohistochemistry; Oncology; Cancer; Multivariate analysis; Immunology","score_opus":0.03771683548251378,"score_gpt":0.34086053746602357,"score_spread":0.3031437019835098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973896058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823004,0.0005985173,0.0000064064197,0.00047197862,0.00020640958,0.00038413788,0.0000015030781,0.0000033687054,0.00009761865],"genre_scores_gemma":[0.9976551,0.00011621033,0.0017082535,0.00039996486,0.000086850996,0.0000033266635,0.0000038753437,0.000012570578,0.00001387321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997487,0.00033404073,0.0016051623,0.00014448895,0.00024523103,0.00018407805],"domain_scores_gemma":[0.9975826,0.0006203169,0.001123058,0.00014906884,0.00032829025,0.00019666899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013375108,0.000120063414,0.0011895576,0.00010728225,0.000022870203,0.0000085751035,0.000100211015,0.0001822695,0.00006838552],"category_scores_gemma":[0.0005119947,0.00007897271,0.00012650274,0.00012473448,0.0003522708,0.00015619172,0.00002700189,0.000557398,0.000001219397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011721356,0.0019081988,0.973058,0.000067226356,0.00013084945,0.00009875121,0.0002004617,0.0000015157893,0.0006094315,0.0000059463027,0.00004574732,0.012152512],"study_design_scores_gemma":[0.019131657,0.029753145,0.94980377,0.0002900733,0.00022025299,0.00011841783,0.00021817634,0.00009409888,0.00020055774,0.00005988464,0.000030728446,0.0000792301],"about_ca_topic_score_codex":0.00020838139,"about_ca_topic_score_gemma":0.0000379348,"teacher_disagreement_score":0.027844945,"about_ca_system_score_codex":0.00006966798,"about_ca_system_score_gemma":0.0005758014,"threshold_uncertainty_score":0.3220414},"labels":[],"label_agreement":null},{"id":"W2974137581","doi":"10.1200/jco.19.00572","title":"Effect of Psychological Intervention on Fear of Cancer Recurrence: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Chicoutimi; University of Ottawa; McGill University; Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Cancer; Cancer recurrence; Intervention (counseling); Oncology; Internal medicine; Psychiatry","score_opus":0.4090180138687211,"score_gpt":0.6402869928910684,"score_spread":0.23126897902234728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974137581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013518299,0.9970738,0.0000099292865,0.0002773432,0.00071406714,0.0015081195,0.000045678233,0.0000022199793,0.00023360137],"genre_scores_gemma":[0.0008346578,0.9982418,0.00002943946,0.00039839468,0.00013460354,0.00006757981,0.000007888369,0.0000147173805,0.00027092145],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9863903,0.0058539533,0.00679744,0.00030698677,0.0005157906,0.0001355616],"domain_scores_gemma":[0.98041123,0.0067658285,0.011657585,0.0004765944,0.00050276,0.00018600277],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.014094569,0.0003113489,0.03262394,0.00033492938,0.000007955224,0.0000035738606,0.00027405852,0.00072668126,0.0005445128],"category_scores_gemma":[0.005477541,0.00014447459,0.013725302,0.000554837,0.00015873372,0.000028655459,0.00005256233,0.0014004576,0.000007442631],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036462973,0.00039284895,0.000050253344,0.73096514,0.10943164,0.000027492251,0.0000074328386,1.7283345e-7,1.4035992e-8,0.000007867985,0.00031272398,0.15843977],"study_design_scores_gemma":[0.0007968979,0.019890703,0.000040607632,0.12338739,0.8310899,0.00010922607,0.0000041225944,5.5907446e-7,2.073853e-7,0.0000037033587,0.024592418,0.00008426275],"about_ca_topic_score_codex":0.00003897577,"about_ca_topic_score_gemma":0.000046516903,"teacher_disagreement_score":0.7216583,"about_ca_system_score_codex":0.00010597315,"about_ca_system_score_gemma":0.00036463878,"threshold_uncertainty_score":0.996152},"labels":[],"label_agreement":null},{"id":"W2974273453","doi":"10.1200/jco.2019.37.15_suppl.e21502","title":"Effective targeted antitumor activity of the antimicrobial agent taurolidine against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation and tumor xenograft studies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Lethbridge; Alberta Children's Hospital","funders":"","keywords":"Neuroblastoma; Medicine; In vivo; Cancer research; Refractory (planetary science); Bioluminescence imaging; In vitro; Cytotoxicity; Cell culture; Pathology; Oncology; Pharmacology; Biology; Transfection","score_opus":0.034760146458718374,"score_gpt":0.3618701006542097,"score_spread":0.3271099541954913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974273453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615246,0.00035581275,0.000476577,0.00047775378,0.0020294252,0.0004043498,0.000012282799,0.0000025344814,0.000088828325],"genre_scores_gemma":[0.9967367,0.00088566757,0.00042751577,0.0013997067,0.00046576597,0.0000033906642,0.0000022417344,0.000019672101,0.000059342972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980109,0.0004691516,0.0008867587,0.00025430435,0.00018943675,0.0001894696],"domain_scores_gemma":[0.9974012,0.00027642297,0.0016341098,0.00024354034,0.0003390542,0.00010570799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013452894,0.00016566366,0.00081464567,0.000054600205,0.00005400332,0.0000070565325,0.00021243969,0.00022387705,0.000005870851],"category_scores_gemma":[0.00062344386,0.00011364023,0.00037583924,0.00009521176,0.00021011605,0.000012867677,0.00022710762,0.0004854966,0.000001400059],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017840575,0.00056843914,0.004088488,0.000040419873,0.000360031,0.000015896621,0.00004579525,0.00044858936,0.9858507,0.000007915152,0.0005360883,0.0062535945],"study_design_scores_gemma":[0.0073736254,0.0143516455,0.14320241,0.00009229432,0.00017814884,0.00010349008,0.000051885636,0.0007544285,0.8144287,0.00016977724,0.019050462,0.00024312317],"about_ca_topic_score_codex":0.0000046530963,"about_ca_topic_score_gemma":0.000012067819,"teacher_disagreement_score":0.17142197,"about_ca_system_score_codex":0.000047428588,"about_ca_system_score_gemma":0.0003781298,"threshold_uncertainty_score":0.4634114},"labels":[],"label_agreement":null},{"id":"W2974979812","doi":"10.1200/jco.18.02057","title":"Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Malignancy; Germ cell tumors; False positive paradox; Biomarker; Germ cell; Internal medicine; Blinding; Oncology; Predictive value of tests; Testicular Germ Cell Tumor; Predictive value; Gastroenterology; Pathology; Seminoma; Chemotherapy; Clinical trial; Gene; Biology","score_opus":0.10457348927246797,"score_gpt":0.42913647895508633,"score_spread":0.3245629896826184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974979812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756397,0.0026878226,0.0005462755,0.004723812,0.0024827078,0.000809752,0.00002657216,0.000018177629,0.0011409076],"genre_scores_gemma":[0.9871704,0.0008484295,0.008269502,0.0012229981,0.00083510706,0.000018520512,0.000009009575,0.000043924803,0.0015821203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623305,0.00027707402,0.0021327573,0.0003659569,0.0004487936,0.0005423602],"domain_scores_gemma":[0.9931859,0.0032257608,0.0024483865,0.00042099055,0.00032146802,0.00039753236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018318294,0.00027108518,0.0013244691,0.00007282795,0.00013096056,0.000037156147,0.00031259246,0.00039475498,0.00016979546],"category_scores_gemma":[0.0006910786,0.00015015953,0.0010059939,0.00015252318,0.00015584439,0.000116302595,0.00011644263,0.00048854767,0.00015671384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029367534,0.0139747495,0.74413496,0.0014565006,0.0015934656,0.0063214307,0.0010955796,0.00004356126,0.037874375,0.00087079505,0.03940713,0.1238599],"study_design_scores_gemma":[0.028145688,0.009297302,0.6115631,0.00084928673,0.0006511897,0.0006181989,0.00054429966,0.00014695681,0.016031124,0.0009571379,0.3308279,0.00036787297],"about_ca_topic_score_codex":0.000006542568,"about_ca_topic_score_gemma":0.000005598371,"teacher_disagreement_score":0.29142076,"about_ca_system_score_codex":0.00025548218,"about_ca_system_score_gemma":0.0016318868,"threshold_uncertainty_score":0.6123328},"labels":[],"label_agreement":null},{"id":"W2976800398","doi":"10.1200/jco.19.00738","title":"Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Leydig cell; Diabetes mellitus; Testosterone (patch); Internal medicine; Retrospective cohort study; Adverse effect; Cyclophosphamide; Psychosocial; Cohort; Luteinizing hormone; Endocrinology; Hormone; Chemotherapy","score_opus":0.057343225641015634,"score_gpt":0.41771151039476684,"score_spread":0.3603682847537512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976800398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818375,0.0009763415,0.00002283067,0.00820294,0.0043441,0.0011135,0.000020335212,0.000011232436,0.0034711987],"genre_scores_gemma":[0.99340886,0.000493734,0.00021454641,0.0029952265,0.0021981345,0.000012503162,0.000010247656,0.000032300846,0.0006344308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913928,0.0016071013,0.005163131,0.00043310164,0.0011043149,0.00029957746],"domain_scores_gemma":[0.98901135,0.004957199,0.004517504,0.0007234064,0.0004943744,0.00029614914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013295227,0.00022515257,0.0027084819,0.00013486943,0.000034263696,0.000010209136,0.00038971833,0.00040014353,0.001194575],"category_scores_gemma":[0.0032616695,0.00015170319,0.0006189151,0.00032443512,0.00017105909,0.00013662815,0.0001265754,0.0018255787,0.000040115552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029900225,0.0060047386,0.978902,0.000027641981,0.0007388096,0.00039374502,0.001059178,0.00006737332,0.000051113413,0.0000029263354,0.005130608,0.0046318467],"study_design_scores_gemma":[0.009679655,0.009014604,0.95906514,0.00020872097,0.0007205789,0.00017854267,0.001946462,0.000015491845,0.00002825313,0.00008610295,0.01892328,0.00013318594],"about_ca_topic_score_codex":0.008929328,"about_ca_topic_score_gemma":0.01117845,"teacher_disagreement_score":0.019836875,"about_ca_system_score_codex":0.0002152982,"about_ca_system_score_gemma":0.0029809005,"threshold_uncertainty_score":0.9997185},"labels":[],"label_agreement":null},{"id":"W2977021423","doi":"10.1200/jco.19.00701","title":"Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Germ cell tumors; Radiation therapy; Oncology; Germ cell; Radiation oncology; Internal medicine; Chemotherapy","score_opus":0.04688865113456902,"score_gpt":0.4227588621979017,"score_spread":0.3758702110633327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977021423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932704,0.00010257347,0.000037847607,0.0012283676,0.00079131237,0.0044691553,0.000023432869,0.000009183427,0.00006770282],"genre_scores_gemma":[0.99754244,0.000045138815,0.0011201643,0.0006867452,0.00043962625,0.00009172129,0.00002676814,0.00003160928,0.000015799933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99501705,0.0012380395,0.0026955071,0.000295481,0.00048853416,0.00026539035],"domain_scores_gemma":[0.9893603,0.005641463,0.0038043922,0.00031285477,0.0005777955,0.00030322556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036659185,0.00022687537,0.002414233,0.00027703505,0.00005478213,0.0000066471503,0.00016286646,0.00033611764,0.00009989469],"category_scores_gemma":[0.0013034404,0.0001390849,0.000648849,0.00016995126,0.00014825918,0.00008306543,0.000023883282,0.00039727514,0.000004974595],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50064796,0.16013928,0.26059765,0.000010329085,0.00052214455,0.00011744548,0.00011795204,0.000008985585,0.00008796589,0.0000031453217,0.00029283663,0.07745432],"study_design_scores_gemma":[0.39576864,0.38192698,0.21830308,0.000028039953,0.00039675413,0.000010790648,0.00003446571,0.000034421886,0.00016813294,0.0000074709296,0.00325712,0.000064097214],"about_ca_topic_score_codex":0.000014636661,"about_ca_topic_score_gemma":0.000007431429,"teacher_disagreement_score":0.2217877,"about_ca_system_score_codex":0.00025095785,"about_ca_system_score_gemma":0.002201073,"threshold_uncertainty_score":0.5671718},"labels":[],"label_agreement":null},{"id":"W2977259025","doi":"10.1200/jco.2012.30.15_suppl.551","title":"Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Adverse effect; Tolerability; Rash; Breast cancer; Population; Aromatase inhibitor; Placebo; Oncology; Cancer; Aromatase","score_opus":0.054556429554377686,"score_gpt":0.4282402993348184,"score_spread":0.3736838697804407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977259025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995716,0.0009296508,0.000726629,0.0007279826,0.001030472,0.00037540196,0.0001006769,0.000006193748,0.00038699305],"genre_scores_gemma":[0.9901344,0.0006483031,0.0073538776,0.0005437561,0.000845151,0.00001826731,0.0000019402062,0.0000402729,0.00041404067],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963714,0.00015775,0.0024050714,0.00016722854,0.0004763425,0.00042222865],"domain_scores_gemma":[0.9936169,0.001548673,0.0035201004,0.00025289398,0.00068256917,0.00037889744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018291381,0.00018010123,0.002374892,0.00013412317,0.000016336518,0.0000011722867,0.00020918029,0.0002860726,0.00024105719],"category_scores_gemma":[0.000653986,0.00013197381,0.00048246724,0.00016016857,0.00049790845,0.0002378754,0.000047793554,0.00049553206,9.249495e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15423909,0.0025046407,0.22149757,0.00040938178,0.002253227,0.000041954496,0.0016726493,0.0002814148,0.007470098,0.00019037821,0.00036439757,0.6090752],"study_design_scores_gemma":[0.037370566,0.011385344,0.8977505,0.0005459036,0.00046835924,0.00018933232,0.000496292,0.000009099514,0.00081354595,0.00032271733,0.050503936,0.00014439478],"about_ca_topic_score_codex":0.00004604544,"about_ca_topic_score_gemma":0.00006217899,"teacher_disagreement_score":0.67625296,"about_ca_system_score_codex":0.0003122788,"about_ca_system_score_gemma":0.0010986554,"threshold_uncertainty_score":0.53817356},"labels":[],"label_agreement":null},{"id":"W2977374750","doi":"10.1200/jco.2013.31.15_suppl.e15044","title":"Patterns of recurrence after neoadjuvant docetaxel, cisplatin, and 5FU combined with resection and extended lymphadenectomy for locally advanced esophagogastric adenocarcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Docetaxel; Neoadjuvant therapy; Lymphadenectomy; Esophagus; Regimen; Cisplatin; Adenocarcinoma; Lymph; Chemotherapy; Internal medicine; Radiology; Surgery; Lymph node; Cancer; Pathology","score_opus":0.04308734708550322,"score_gpt":0.37954437596851054,"score_spread":0.3364570288830073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977374750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194014,0.0015838614,0.0021851559,0.0031881933,0.0003738723,0.0006457409,0.0000033337856,0.000005900813,0.000073816205],"genre_scores_gemma":[0.9915111,0.0010085384,0.00637049,0.00059902156,0.00025337897,0.00003150858,0.0000018997474,0.000013101191,0.00021094858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786806,0.000109326305,0.0013356052,0.00021798567,0.00025966286,0.00020935983],"domain_scores_gemma":[0.9968891,0.0010248334,0.0011886411,0.00013975987,0.0005064014,0.00025127165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083637726,0.00014670938,0.0011077168,0.00018241892,0.000027620834,0.000013387952,0.00008378798,0.00015071483,0.000059995837],"category_scores_gemma":[0.00073471526,0.00009637975,0.00014411447,0.00013162773,0.0001321969,0.00020608022,0.000055924134,0.0002998209,9.982384e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01503085,0.0003551796,0.7356427,0.00018166566,0.00021626412,0.00010228501,0.000049000046,0.0000037747568,0.000032745316,0.000045869474,0.00038013936,0.24795957],"study_design_scores_gemma":[0.02179034,0.036347136,0.9392322,0.0002562443,0.000418774,0.00024471775,0.0001630389,0.0001905534,0.000042369724,0.0003121183,0.00092178804,0.00008073182],"about_ca_topic_score_codex":0.00002069084,"about_ca_topic_score_gemma":0.00004604003,"teacher_disagreement_score":0.24787883,"about_ca_system_score_codex":0.000055798104,"about_ca_system_score_gemma":0.0002853763,"threshold_uncertainty_score":0.39302522},"labels":[],"label_agreement":null},{"id":"W2977857941","doi":"10.1200/jco.2006.24.18_suppl.4048","title":"Improving the quality of surgery for gastric cancer—Are surgeons aware of the relevant quality indicators?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer; Logistic regression; Epidemiology; General surgery; Surgery; Lymph node; Stage (stratigraphy); Internal medicine","score_opus":0.19814884953599785,"score_gpt":0.48714274900415133,"score_spread":0.28899389946815346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977857941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97879195,0.00056104263,0.00064263435,0.017661553,0.0017507006,0.00036499984,0.00003558634,0.000005350108,0.00018618752],"genre_scores_gemma":[0.99753946,0.0003132139,0.00022499947,0.0008612354,0.00074633985,0.000008829609,0.0000019363888,0.000011319381,0.00029266512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99406147,0.0008076671,0.004159669,0.00015500185,0.000570467,0.00024573272],"domain_scores_gemma":[0.97817975,0.012255596,0.008566234,0.0003557179,0.000539278,0.00010340942],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012313773,0.00012477532,0.001852785,0.00015834825,0.00006695092,0.000004794026,0.00029782119,0.00020327888,0.00004796365],"category_scores_gemma":[0.00994119,0.000062621446,0.0014248105,0.00044440743,0.00035313508,0.000053634863,0.00010111952,0.0005862802,3.200119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013074699,0.00048464639,0.9382075,0.00025624793,0.0002289625,0.00000626591,0.000021347623,0.000016771251,0.00006969256,0.00023740894,0.012842819,0.046320833],"study_design_scores_gemma":[0.0024075878,0.0005080954,0.983385,0.00010997823,0.0004518235,0.0000102664,0.0002786355,0.00001820028,0.00010073502,0.00024651716,0.012426814,0.000056342833],"about_ca_topic_score_codex":0.0017191687,"about_ca_topic_score_gemma":0.0010503596,"teacher_disagreement_score":0.04626449,"about_ca_system_score_codex":0.00015038955,"about_ca_system_score_gemma":0.0018468912,"threshold_uncertainty_score":0.9983985},"labels":[],"label_agreement":null},{"id":"W2978891187","doi":"10.1200/jco.2017.35.15_suppl.e21634","title":"Early palliative care interventions in patients with hematologic malignancies prior to hematopoietic cell transplantation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Psychological intervention; Transplantation; Anxiety; Performance status; Internal medicine; Cancer; Physical therapy; Psychiatry","score_opus":0.27624125039141467,"score_gpt":0.5269590569472232,"score_spread":0.25071780655580855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978891187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959316,0.0005328146,0.0003948812,0.00117993,0.000304759,0.00026181198,0.000011823247,0.0000036259614,0.0013786993],"genre_scores_gemma":[0.9904443,0.00038796556,0.008728993,0.0002567379,0.00007968935,0.00000555188,0.0000035022308,0.000009023819,0.00008424681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977656,0.0001515658,0.0015126403,0.00014068813,0.00027126356,0.00015826417],"domain_scores_gemma":[0.9964555,0.00072762545,0.0016493099,0.00019804073,0.0007784669,0.00019108376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000544762,0.00011305077,0.0011671192,0.00012625076,0.000051286424,0.000010007095,0.00021672585,0.00017819963,0.000036660003],"category_scores_gemma":[0.0016991522,0.00007392028,0.0003454687,0.00006612733,0.0001760326,0.00011545362,0.000030230523,0.00039561288,0.00001157608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002421148,0.000887472,0.9893167,0.00037640275,0.00009041298,0.00029854733,0.003769334,0.000005068539,0.000012414307,0.00005578187,0.00011754124,0.0026491892],"study_design_scores_gemma":[0.007847397,0.010540822,0.9757955,0.0030240135,0.00024537503,0.000006787356,0.0011098516,5.3894337e-7,0.00036809916,0.0000858797,0.0009000354,0.00007567613],"about_ca_topic_score_codex":0.000030043819,"about_ca_topic_score_gemma":0.00012968118,"teacher_disagreement_score":0.013521164,"about_ca_system_score_codex":0.00008013331,"about_ca_system_score_gemma":0.00036403834,"threshold_uncertainty_score":0.30143815},"labels":[],"label_agreement":null},{"id":"W2979191802","doi":"10.1200/jco.2013.31.15_suppl.5010","title":"Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Progression-free survival; Hazard ratio; Oncology; Enzalutamide; Population; Urology; Chemotherapy; Gastroenterology; Cancer; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.11890364267247432,"score_gpt":0.44364225741656615,"score_spread":0.3247386147440918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979191802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867862,0.00088656216,0.00004147626,0.010447674,0.00018039213,0.0012996246,0.0002757037,0.000004421579,0.00007796836],"genre_scores_gemma":[0.9867219,0.00079413294,0.011902236,0.00024207981,0.00013892855,0.00003887093,0.00006228845,0.0000220055,0.00007760171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953307,0.00059568527,0.0027009246,0.00028574455,0.00081957964,0.00026736234],"domain_scores_gemma":[0.9922492,0.0036493465,0.0018571065,0.00030717315,0.0015299699,0.00040722213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029841564,0.00019156869,0.0014126354,0.00035414536,0.000036927362,0.000010539236,0.00018290883,0.00017739327,0.000090387446],"category_scores_gemma":[0.0036719546,0.00011402607,0.00016352815,0.00051137165,0.0003666333,0.00016901654,0.000059656482,0.0006174133,0.0000015492055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046843294,0.0021255857,0.8982882,0.00007923312,0.0004892722,0.000073738775,0.0004614364,0.000041358184,0.00021215393,0.000010292748,0.00086125475,0.05051419],"study_design_scores_gemma":[0.042539746,0.01319223,0.94198173,0.00061542715,0.00029413306,0.0000044908707,0.00019292954,0.000109525354,0.00019112372,0.00048664675,0.00029128825,0.00010073486],"about_ca_topic_score_codex":0.000733967,"about_ca_topic_score_gemma":0.0014112596,"teacher_disagreement_score":0.050413456,"about_ca_system_score_codex":0.00011699588,"about_ca_system_score_gemma":0.001456492,"threshold_uncertainty_score":0.46498483},"labels":[],"label_agreement":null},{"id":"W2979518299","doi":"10.1200/jco.2012.30.15_suppl.e12034","title":"Implementation of a population-based breast screening program for high-risk women in Ontario: The Ontario Breast Screening Program (OBSP) High-Risk Program.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; University of Toronto; Cancer Care Ontario; North York General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Genetic counseling; Mammography; Genetic testing; Referral; Population; Family medicine; Breast cancer screening; Risk assessment; Breast MRI; Gynecology; Cancer; Oncology; Internal medicine; Environmental health; Genetics","score_opus":0.04716487413701081,"score_gpt":0.4149079795361841,"score_spread":0.36774310539917326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979518299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940969,0.00009603074,0.0025237252,0.0006619297,0.00067115604,0.0018307702,0.000073401345,0.000017095465,0.000028995988],"genre_scores_gemma":[0.85994166,0.000018371215,0.13824691,0.00016298793,0.0007923627,0.0005658323,0.00019016024,0.000034997232,0.000046684774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954825,0.00065750384,0.0024312644,0.00034085085,0.000381718,0.00070616376],"domain_scores_gemma":[0.9949429,0.00055227586,0.0032874034,0.00035093728,0.00057702657,0.00028945884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005412962,0.00026094826,0.0008565583,0.00013779347,0.00015153688,0.000040733597,0.00039892143,0.00047565202,0.00010657325],"category_scores_gemma":[0.00046257893,0.00019869761,0.0004442742,0.00021720493,0.00020027222,0.000042872027,0.00009920979,0.0009176466,8.874889e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012420089,0.0011167825,0.5431994,0.000009104086,0.00027736026,0.0000014872543,0.00022707257,0.0006328061,0.00003503099,0.000011863217,0.000138359,0.45310873],"study_design_scores_gemma":[0.0067149997,0.008950298,0.9593896,0.000039059265,0.000294944,0.00007024301,0.0005508978,0.00014547487,0.00017371372,0.00015646948,0.023306755,0.00020753506],"about_ca_topic_score_codex":0.16849883,"about_ca_topic_score_gemma":0.6559504,"teacher_disagreement_score":0.4874516,"about_ca_system_score_codex":0.0008010745,"about_ca_system_score_gemma":0.0025164774,"threshold_uncertainty_score":0.8370382},"labels":[],"label_agreement":null},{"id":"W2980147869","doi":"10.1200/jco.2012.30.15_suppl.4525","title":"Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Confidence interval; Progression-free survival; Internal medicine; Pearson product-moment correlation coefficient; Clinical endpoint; Chemotherapy; Oncology; Clinical trial; Statistics","score_opus":0.14119004843249544,"score_gpt":0.4662632227507314,"score_spread":0.32507317431823596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980147869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949134,0.0015928452,0.00022999418,0.0004237306,0.0009370126,0.0010924143,0.00023964317,0.000005043163,0.00056589104],"genre_scores_gemma":[0.99594396,0.00044505773,0.0023186202,0.00011411921,0.0006835408,0.000028656112,0.000055474196,0.00003384894,0.00037669358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930791,0.0012523821,0.004331141,0.00026251457,0.00071925105,0.00035560815],"domain_scores_gemma":[0.98854226,0.004675985,0.0051928465,0.00044980363,0.000788848,0.00035028704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072220694,0.00025555654,0.0043656183,0.00037406912,0.00003576911,0.0000026785626,0.0002387525,0.00044079934,0.00085030304],"category_scores_gemma":[0.0025390408,0.00016050384,0.0010875989,0.00028255652,0.00024301762,0.00023294661,0.0000645304,0.00034046764,7.9878464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16056646,0.0044860863,0.79574364,0.000061813684,0.0023476046,0.000019163796,0.0004268705,0.00045155262,0.0030212807,0.000034106644,0.00011289203,0.03272853],"study_design_scores_gemma":[0.058907837,0.03967518,0.8918838,0.000112642425,0.003094421,0.00001257881,0.00013723926,0.0006014197,0.0036171554,0.00008376111,0.0017313069,0.00014266209],"about_ca_topic_score_codex":0.00011540588,"about_ca_topic_score_gemma":0.002314514,"teacher_disagreement_score":0.101658635,"about_ca_system_score_codex":0.00027108614,"about_ca_system_score_gemma":0.00094883284,"threshold_uncertainty_score":0.9310222},"labels":[],"label_agreement":null},{"id":"W2980319508","doi":"10.1200/jco.2019.37.27_suppl.209","title":"Improving patient experience in health care and oncology: A scoping review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"CINAHL; PsycINFO; Medicine; Psychological intervention; MEDLINE; Systematic review; Grey literature; Family medicine; Health care; Randomized controlled trial; Nursing; Internal medicine","score_opus":0.31094497994409787,"score_gpt":0.6437382146078634,"score_spread":0.33279323466376554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980319508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538209,0.027978204,0.00003682289,0.008548237,0.005751836,0.0020137879,0.0000035997136,0.000013076009,0.0018335459],"genre_scores_gemma":[0.93271416,0.029890299,0.0050243386,0.031808753,0.00042990161,0.000074791446,0.0000019134611,0.00002085685,0.000034982422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98824424,0.004538728,0.0061023952,0.0002899234,0.00033992136,0.0004847849],"domain_scores_gemma":[0.9860551,0.0063192565,0.0063811378,0.00023720195,0.00053617166,0.0004711319],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0057671927,0.000138278,0.0018843453,0.00016461738,0.00017089029,0.000002312431,0.00016880113,0.00049391744,0.0002714292],"category_scores_gemma":[0.007242667,0.00010978404,0.00014805642,0.00018798879,0.000102146456,0.00022367037,0.000160647,0.0025597354,0.000052389518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002773813,0.00006225092,0.68733186,0.0055592577,0.000007851125,0.00002745839,0.005864235,0.0000040451127,0.000004466591,0.00003852474,0.0006427926,0.30017987],"study_design_scores_gemma":[0.011536046,0.041668896,0.65360117,0.14416575,0.00004402752,0.00011663611,0.04123789,0.00011803148,0.0000046864275,0.00012594597,0.10694733,0.00043356718],"about_ca_topic_score_codex":0.00047831095,"about_ca_topic_score_gemma":0.0011225061,"teacher_disagreement_score":0.2997463,"about_ca_system_score_codex":0.0013606016,"about_ca_system_score_gemma":0.009493379,"threshold_uncertainty_score":0.9997414},"labels":[],"label_agreement":null},{"id":"W2980349656","doi":"10.1200/jco.2019.37.27_suppl.38","title":"Contemporary analysis of bone mineral density in men initiating androgen deprivation therapy for prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Bone mineral; Internal medicine; Cohort; Odds ratio; Osteoporosis; Oncology; Cancer","score_opus":0.18803754257333605,"score_gpt":0.507475812743782,"score_spread":0.3194382701704459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980349656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384356,0.00173262,0.000022513395,0.0029191542,0.00015789727,0.0005788658,0.000011898311,0.0000024621645,0.0007310269],"genre_scores_gemma":[0.99646723,0.0020062376,0.00067484763,0.0004345099,0.00016592708,0.000013053496,0.000021278418,0.000007977437,0.00020894455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766415,0.00021205601,0.0016048703,0.00013460248,0.00023362448,0.00015067155],"domain_scores_gemma":[0.99676806,0.0011820751,0.0012874685,0.00010461174,0.0005433424,0.000114428185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027871986,0.00007793999,0.001424579,0.0003151675,0.000014171513,0.000003579175,0.000059880786,0.00016346446,0.000043835837],"category_scores_gemma":[0.00066102005,0.000051243624,0.00040319376,0.00036746997,0.00007309338,0.0000973939,0.000020399626,0.00031486223,6.7339585e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016228816,0.00067227875,0.9377169,0.000038910668,0.0017236301,0.00008485836,0.0002547089,0.00005494953,0.0024822073,0.000008243531,0.00055416155,0.040180314],"study_design_scores_gemma":[0.022918215,0.008443718,0.9627425,0.000087122025,0.00042984754,0.000011210182,0.00018950904,0.0018122244,0.0014953048,0.00013159118,0.0016792972,0.00005944056],"about_ca_topic_score_codex":0.00011462997,"about_ca_topic_score_gemma":0.00006772814,"teacher_disagreement_score":0.040120874,"about_ca_system_score_codex":0.00014328244,"about_ca_system_score_gemma":0.001606081,"threshold_uncertainty_score":0.28491187},"labels":[],"label_agreement":null},{"id":"W2980365282","doi":"10.1200/jco.2019.37.27_suppl.237","title":"Preventing complications: Hepatitis B screening in cancer patients undergoing systemic therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hepatology; Hepatitis B virus; Internal medicine; Referral; Hepatitis B; Psychological intervention; Adverse effect; Immunology; Family medicine; Virus","score_opus":0.15947457546614904,"score_gpt":0.47565300132697547,"score_spread":0.31617842586082645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980365282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926359,0.0020043303,0.000114710856,0.0018338136,0.0009201253,0.000416784,0.0000025510512,0.00000879874,0.0020629994],"genre_scores_gemma":[0.98683167,0.008765184,0.0021903568,0.0016822417,0.00034664775,0.000012773964,0.0000017181605,0.000017031709,0.00015240579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658257,0.00040625897,0.0023168658,0.0001674773,0.00031166262,0.0002151776],"domain_scores_gemma":[0.9951305,0.002368765,0.001717183,0.00014535392,0.00050943886,0.00012876904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019122387,0.00010776417,0.0011752278,0.0001452983,0.00003741073,0.0000069442453,0.00012922175,0.00018791734,0.00010110916],"category_scores_gemma":[0.0026023749,0.00008347939,0.00024910146,0.000161721,0.000051095212,0.00013104205,0.000058043268,0.00067711214,0.000033910354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026239088,0.0006002323,0.89545625,0.00005482083,0.00019254342,0.000026043286,0.00013495122,0.000038664148,0.0000457413,0.000026010914,0.0004119263,0.10275044],"study_design_scores_gemma":[0.0068552895,0.0032674242,0.98189986,0.0013763191,0.00005374844,0.000038072823,0.000054328928,0.00019678143,0.000011346621,0.000067950976,0.0061045885,0.000074274496],"about_ca_topic_score_codex":0.0005522871,"about_ca_topic_score_gemma":0.0016506416,"teacher_disagreement_score":0.10267617,"about_ca_system_score_codex":0.00020849536,"about_ca_system_score_gemma":0.00079789694,"threshold_uncertainty_score":0.34041908},"labels":[],"label_agreement":null},{"id":"W2980372944","doi":"10.1200/jco.2019.37.27_suppl.40","title":"Trends in the use of novel hormonal agents at the end of life in metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; McGill University","funders":"Réseau de cancérologie Rossy","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Hormonal therapy; Cancer; Abiraterone acetate; Cohort; Internal medicine; Abiraterone; Odds ratio; Quality of life (healthcare); Logistic regression; Oncology; Androgen receptor","score_opus":0.38431432571456825,"score_gpt":0.5256426408285975,"score_spread":0.1413283151140292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980372944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852519,0.0009865855,0.0000014688866,0.012841996,0.00020845364,0.00031604702,0.00004083905,6.2278764e-7,0.00035206255],"genre_scores_gemma":[0.99672073,0.0012726482,0.00026285197,0.0006051144,0.00008226599,0.000010205052,0.000006997469,0.000006997328,0.0010321687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686694,0.00045223415,0.0018393609,0.00011466535,0.00053757074,0.00018921518],"domain_scores_gemma":[0.9957835,0.002565239,0.0011581628,0.00017196032,0.0002179046,0.00010321327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028419795,0.00009060672,0.00089595205,0.0001778312,0.000016566708,0.00000535355,0.00016189214,0.0000904796,0.00031394814],"category_scores_gemma":[0.0008477785,0.00004034139,0.00024269552,0.0003267647,0.00031488453,0.00008964934,0.000040852283,0.0005884848,0.0000019275722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03584485,0.0053760177,0.8707858,0.00014568979,0.00085260527,0.00047724968,0.0020471434,0.0011698252,0.005645107,0.00013186903,0.005956438,0.07156746],"study_design_scores_gemma":[0.014523827,0.0063775075,0.96818745,0.00013255981,0.00016010036,0.000038197606,0.00037263255,0.0003630655,0.00013583596,0.0000328812,0.009634115,0.000041844905],"about_ca_topic_score_codex":0.00050055294,"about_ca_topic_score_gemma":0.0021988961,"teacher_disagreement_score":0.097401686,"about_ca_system_score_codex":0.00018615603,"about_ca_system_score_gemma":0.001808105,"threshold_uncertainty_score":0.34375122},"labels":[],"label_agreement":null},{"id":"W2980432548","doi":"10.1200/jco.2019.37.27_suppl.163","title":"Outcomes and care patterns for advanced pancreatic cancer patients treated in tertiary vs regional/community cancer centres in Northern Alberta.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Gemcitabine; Tertiary care; Pancreatic cancer; FOLFIRINOX; Internal medicine; Cancer registry; Cancer; Multivariate analysis; Palliative care; Chemotherapy; Retrospective cohort study; Cohort; Logistic regression; Oncology; Irinotecan; Colorectal cancer; Nursing","score_opus":0.08104810426513241,"score_gpt":0.4717553708744969,"score_spread":0.3907072666093645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980432548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930209,0.00086912053,0.0000016707597,0.0047016754,0.00029309667,0.00083640724,0.00001738266,0.0000033707015,0.00025636604],"genre_scores_gemma":[0.9949501,0.002699544,0.00017301388,0.0015696043,0.00011110121,0.00007379364,0.000016714457,0.000020421183,0.0003856998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996752,0.0007646431,0.0016855185,0.00019467127,0.00025204782,0.00035107372],"domain_scores_gemma":[0.99241877,0.005909157,0.0007700507,0.00019966983,0.00045200516,0.00025037862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010722014,0.00017198038,0.0019957698,0.00019926263,0.000038349845,0.000004659719,0.0001689573,0.00035798587,0.00010893839],"category_scores_gemma":[0.002003613,0.000116620366,0.00022091014,0.000107785985,0.00013324825,0.00010362685,0.00006310499,0.0010911525,0.0000036159538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006122075,0.001357821,0.957058,0.00021023421,0.00025386305,0.00004057561,0.0010522263,0.0000128197335,0.000013405805,0.0000040213813,0.00009135942,0.033783562],"study_design_scores_gemma":[0.023644255,0.005014397,0.9676894,0.00061010296,0.00024235583,0.0000087136905,0.0008816412,0.00009087013,0.000006867482,0.000045541332,0.0016627538,0.00010311794],"about_ca_topic_score_codex":0.011880624,"about_ca_topic_score_gemma":0.14968406,"teacher_disagreement_score":0.13780344,"about_ca_system_score_codex":0.00065765745,"about_ca_system_score_gemma":0.001067082,"threshold_uncertainty_score":0.99469936},"labels":[],"label_agreement":null},{"id":"W2980434329","doi":"10.1200/jco.2019.37.27_suppl.173","title":"Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Family medicine; Physical therapy; Oncology","score_opus":0.28193811797287255,"score_gpt":0.4881283344098445,"score_spread":0.20619021643697194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980434329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897698,0.00037239154,0.00012181959,0.0022270628,0.0020224692,0.00036674883,9.596342e-7,0.0000067104947,0.0051120324],"genre_scores_gemma":[0.9677336,0.000115632545,0.029765736,0.0018763647,0.0003377885,0.000008229164,0.0000011890254,0.000013603061,0.00014783055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960621,0.00018703984,0.0030067323,0.00017365567,0.0003703314,0.0002001118],"domain_scores_gemma":[0.9900674,0.0046173967,0.00343488,0.00014556981,0.0015064301,0.00022829996],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004960686,0.00011668473,0.0013888074,0.000102207596,0.000032503493,0.0000043677496,0.00008796531,0.00031710713,0.000028261858],"category_scores_gemma":[0.012820131,0.00008315642,0.0001951772,0.000112408794,0.00010063762,0.00013096788,0.00005021109,0.0006033837,0.0000035952742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041268426,0.000532901,0.4088505,0.00013901213,0.00026882335,0.000065357766,0.00060304994,0.0000058240826,0.0002630289,0.000021247935,0.00016885114,0.58495456],"study_design_scores_gemma":[0.007224601,0.022577465,0.19255571,0.00018267444,0.00047911698,0.0009502263,0.0016871046,0.00007937057,0.0007341716,0.00002692339,0.7733862,0.00011648474],"about_ca_topic_score_codex":0.000021913069,"about_ca_topic_score_gemma":0.000070138994,"teacher_disagreement_score":0.7732173,"about_ca_system_score_codex":0.00017537715,"about_ca_system_score_gemma":0.002805844,"threshold_uncertainty_score":0.9954953},"labels":[],"label_agreement":null},{"id":"W2980443431","doi":"10.1200/jco.2019.37.27_suppl.264","title":"Increasing screening for latent tuberculosis in patients with hematologic malignancy: A quality improvement project.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Checklist; Tuberculosis; Contact tracing; Population; Latent tuberculosis; Intensive care medicine; Emergency medicine; Internal medicine; Disease; Environmental health; Mycobacterium tuberculosis","score_opus":0.16658575834244702,"score_gpt":0.49395677610326283,"score_spread":0.3273710177608158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980443431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913492,0.000106706524,0.00022318197,0.0063750404,0.00026046112,0.0012629542,0.0000060703296,0.000008204212,0.00040814304],"genre_scores_gemma":[0.97797734,0.00010935462,0.018454581,0.0031593938,0.00020074379,0.000026102862,0.000010700514,0.00001789796,0.00004386983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994706,0.0011000687,0.002943417,0.0003106563,0.00042363125,0.0005162514],"domain_scores_gemma":[0.9925718,0.0046832045,0.001534985,0.00023434137,0.00066707056,0.00030859793],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010852404,0.00016785937,0.0022226882,0.00023758912,0.000030014698,0.0000073228184,0.00016220217,0.0004050875,0.00004653142],"category_scores_gemma":[0.010238156,0.00010000334,0.00044397614,0.00018788144,0.00011743268,0.00012701977,0.00007828745,0.0009356409,0.000008591147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022903696,0.0018472507,0.92731184,0.0001424743,0.00035917386,0.000048618575,0.000034589742,0.000016058668,0.0001322512,0.000098242934,0.000543617,0.046562172],"study_design_scores_gemma":[0.019170366,0.032313105,0.9445408,0.00028658618,0.00011745537,0.000070316404,0.00008861616,0.00019284482,0.00003153724,0.00015420736,0.0029209356,0.00011323421],"about_ca_topic_score_codex":0.00024308999,"about_ca_topic_score_gemma":0.00010657214,"teacher_disagreement_score":0.04644894,"about_ca_system_score_codex":0.0002259633,"about_ca_system_score_gemma":0.0009143316,"threshold_uncertainty_score":0.998099},"labels":[],"label_agreement":null},{"id":"W2980480216","doi":"10.1200/jco.2019.37.27_suppl.185","title":"Partnering with patients and caregivers to improve systemic treatment regimen information.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Formulary; Focus group; Regimen; Usability; Relevance (law); Medical physics; Medical education; Nursing; Surgery; Computer science","score_opus":0.16302233799854993,"score_gpt":0.5130157703368733,"score_spread":0.34999343233832336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980480216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911727,0.000022939703,0.00022886926,0.005956211,0.00076794496,0.00060029345,0.0000036795702,0.000006101774,0.0012412847],"genre_scores_gemma":[0.9928706,0.00013033135,0.0037183173,0.0028187172,0.00028004922,0.000005003611,0.000005827171,0.000007880464,0.00016324126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970052,0.00014707523,0.0023020625,0.000116076175,0.00029092302,0.00013864144],"domain_scores_gemma":[0.9949939,0.0019900757,0.0018311634,0.00014733909,0.0006879774,0.00034952746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001562612,0.000099359066,0.0008150185,0.000094873416,0.000019645488,0.000012711197,0.000057353216,0.00013287143,0.000042978227],"category_scores_gemma":[0.0037169182,0.000061671344,0.000116731,0.00007684914,0.000038190738,0.0004200661,0.000035870722,0.0002843662,0.00006127537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009184088,0.0005306916,0.5284074,0.000065058775,0.00043600425,0.000048051454,0.00062457426,0.000068626745,0.00007978912,0.00003570815,0.00273028,0.45778972],"study_design_scores_gemma":[0.053667597,0.13044734,0.46818212,0.00030622628,0.0010863905,0.00050560635,0.0042741476,0.00028553122,0.00006962735,0.000025727608,0.34093192,0.00021775243],"about_ca_topic_score_codex":0.000054195363,"about_ca_topic_score_gemma":0.000017946875,"teacher_disagreement_score":0.45757195,"about_ca_system_score_codex":0.00028413,"about_ca_system_score_gemma":0.0009064332,"threshold_uncertainty_score":0.4449767},"labels":[],"label_agreement":null},{"id":"W2980534320","doi":"10.1200/jco.18.01967","title":"Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Pharmaceuticals; National Cancer Institute; Medical Research Council; Takeda Oncology; Canadian Cancer Society Research Institute; National Institutes of Health; Ipsen; Astellas Pharma; National Health and Medical Research Council; Cancer Research UK; National Institute for Health and Care Research; American College of Radiology Imaging Network; NRG Oncology; Bristol-Myers Squibb; National Cancer Research Institute; Cancer Research Institute; NIHR Cambridge Biomedical Research Centre; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Breast Cancer Research Foundation; Sanofi; Oncosuisse; Pfizer","keywords":"Exemestane; Medicine; Tamoxifen; Breast cancer; Internal medicine; Oncology; Gynecology; Estrogen receptor; Population; Adjuvant; Proportional hazards model; Cancer","score_opus":0.042460935220968596,"score_gpt":0.3827609241418298,"score_spread":0.34029998892086116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980534320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931798,0.00144978,0.00022008289,0.0028195637,0.0013534295,0.00044095024,0.00045388265,0.000002695215,0.00007982601],"genre_scores_gemma":[0.992552,0.0007755526,0.004704142,0.00089871534,0.00085795316,0.00005387384,0.0000435972,0.00001620298,0.000097979086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99750763,0.00013927404,0.0014814978,0.00041361182,0.00015559662,0.00030237276],"domain_scores_gemma":[0.9977,0.00083562464,0.0008636711,0.0002407764,0.0001762407,0.00018368887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089297723,0.0001796661,0.00084533513,0.00004275748,0.000029200368,0.000013494667,0.00022625217,0.0001618257,0.0000302243],"category_scores_gemma":[0.0012762734,0.0001336586,0.000111918656,0.00004670373,0.00010482019,0.000011778405,0.0001839542,0.00021989217,0.0000063039156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08268752,0.0027644555,0.17999582,0.00003420808,0.0025626156,0.00009155235,0.001828809,0.000076866854,0.10214344,0.00004401094,0.007528302,0.6202424],"study_design_scores_gemma":[0.030534284,0.021913784,0.6822555,0.00012723234,0.00012127395,0.000008581755,0.0007220033,0.000047195943,0.0019380727,0.0015693925,0.2604285,0.00033417976],"about_ca_topic_score_codex":0.0002758774,"about_ca_topic_score_gemma":0.0006268548,"teacher_disagreement_score":0.6199082,"about_ca_system_score_codex":0.00009718301,"about_ca_system_score_gemma":0.0002843875,"threshold_uncertainty_score":0.54504395},"labels":[],"label_agreement":null},{"id":"W2980581080","doi":"10.1200/jco.2019.37.27_suppl.306","title":"Quality improvements in palliative radiotherapy at end of life: The FutRE Study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Baker Hughes (Canada); University of Calgary; University of Alberta","funders":"Alberta Health Services","keywords":"Medicine; Radiation therapy; Palliative care; Quality of life (healthcare); Medical prescription; Descriptive statistics; Cancer; Radiation oncologist; Internal medicine","score_opus":0.11922961990181132,"score_gpt":0.5661398768806911,"score_spread":0.4469102569788798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980581080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865081,0.00204853,0.000109801076,0.007089933,0.0018232684,0.0006299694,0.0000025376803,0.0000033126425,0.0017845973],"genre_scores_gemma":[0.98741496,0.0025310223,0.0019381744,0.0059821527,0.00097233045,0.000005031077,6.444568e-7,0.000013523136,0.001142165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951011,0.001324727,0.002814502,0.00018769981,0.00037303817,0.00019894964],"domain_scores_gemma":[0.9903922,0.0061937305,0.002725477,0.0003034564,0.00022842165,0.0001567199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066798427,0.00013178191,0.001896352,0.00008417962,0.00003158518,0.0000016896304,0.00027612835,0.00034536526,0.0008112801],"category_scores_gemma":[0.0019044193,0.000070601,0.00045540993,0.00015668523,0.00042037296,0.00007505871,0.000046319485,0.0010911498,0.000009560713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013589881,0.0039980235,0.9040606,0.00002201238,0.0008762971,0.000076357544,0.00091035507,0.000035617955,0.0006237228,0.00010297405,0.0009469529,0.07475718],"study_design_scores_gemma":[0.023092652,0.025139026,0.8901209,0.0000330756,0.00007530033,0.00002333412,0.00095547154,0.00003216898,0.000029384557,0.00030391794,0.060126815,0.000067929366],"about_ca_topic_score_codex":0.000024276804,"about_ca_topic_score_gemma":0.00015820606,"teacher_disagreement_score":0.074689254,"about_ca_system_score_codex":0.00036174906,"about_ca_system_score_gemma":0.0011803375,"threshold_uncertainty_score":0.8882948},"labels":[],"label_agreement":null},{"id":"W2980646093","doi":"10.1200/jco.2019.37.27_suppl.25","title":"Neoadjuvant chemoradiation (NCRT) for esophageal (EC) or gastroesophageal junction cancer (GEJC): A Canadian single institution real-world experience using the CROSS trial regimen.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Regimen; Surgery; Clinical trial; Esophageal cancer; Cancer; Stage (stratigraphy); Internal medicine","score_opus":0.21122527353872333,"score_gpt":0.523147152003058,"score_spread":0.3119218784643346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980646093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98873144,0.0007766785,0.00025424574,0.0029870113,0.004717752,0.0016802332,0.000015808546,0.000012777697,0.00082402764],"genre_scores_gemma":[0.9910658,0.00028776698,0.0014508569,0.0011407908,0.0043813996,0.00007729751,0.000010932579,0.000024625058,0.0015605115],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965346,0.00029925082,0.0017215523,0.00032418367,0.0005677277,0.00055268104],"domain_scores_gemma":[0.99612164,0.00084968883,0.0013311256,0.00028734058,0.0006577614,0.0007524683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024069143,0.00020180794,0.0010707005,0.00023846222,0.00022742183,0.000051137136,0.0002159182,0.00027436827,0.00033264697],"category_scores_gemma":[0.0013673635,0.00011930127,0.00045924928,0.00033393042,0.0003017356,0.0003411529,0.000031881213,0.000745288,0.000012209428],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5329287,0.003203084,0.2159703,0.00015941157,0.0011387307,0.0025959504,0.0011931407,0.0027534822,0.0005850384,0.0008131902,0.0030308184,0.23562813],"study_design_scores_gemma":[0.40404513,0.11571791,0.39020777,0.0006035486,0.001580978,0.0011929095,0.000859707,0.010868927,0.0032059818,0.00046026695,0.07069628,0.0005605877],"about_ca_topic_score_codex":0.020556992,"about_ca_topic_score_gemma":0.042006098,"teacher_disagreement_score":0.23506755,"about_ca_system_score_codex":0.002897604,"about_ca_system_score_gemma":0.0115239825,"threshold_uncertainty_score":0.99407977},"labels":[],"label_agreement":null},{"id":"W2980653308","doi":"10.1200/jco.2019.37.27_suppl.282","title":"Quality improvement of lung cancer patient selection using clinic-based spirometry.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer screening; Spirometry; Lung cancer; Incidence (geometry); Cohort; Internal medicine; Cancer; National Lung Screening Trial; Physical therapy; Asthma","score_opus":0.12607493906433184,"score_gpt":0.5377986476318326,"score_spread":0.41172370856750073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980653308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941563,0.0005085033,0.00015015663,0.0019779585,0.0022169615,0.00039244755,0.0000062179856,0.0000046489436,0.00058677833],"genre_scores_gemma":[0.994489,0.00035630018,0.0026217217,0.0019583423,0.00048724882,0.0000064221854,0.0000013390516,0.000013025018,0.000066590284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608016,0.00023244655,0.0028639287,0.00019381529,0.00044957656,0.0001800432],"domain_scores_gemma":[0.99448436,0.0012083054,0.0032747977,0.0001737364,0.0006383035,0.00022050305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022128501,0.00012029674,0.0014742853,0.00012459604,0.000019633204,0.0000037620168,0.000071386086,0.0002512125,0.0010007567],"category_scores_gemma":[0.0006531897,0.000081970305,0.0006273372,0.00017853873,0.0000634975,0.000059482063,0.000025966867,0.00047399657,0.0000060434645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002705532,0.0033717947,0.8963294,0.00018188424,0.0007140916,0.000028714892,0.000028590805,0.00015401837,0.0013995513,0.000010158009,0.000901063,0.094175175],"study_design_scores_gemma":[0.016766261,0.03887287,0.92609334,0.0005323622,0.0011778288,0.000021081778,0.00006773245,0.0011635416,0.004976383,0.000034381716,0.010162758,0.00013144048],"about_ca_topic_score_codex":0.00027567413,"about_ca_topic_score_gemma":0.00004881732,"teacher_disagreement_score":0.09404373,"about_ca_system_score_codex":0.0009943953,"about_ca_system_score_gemma":0.0025821954,"threshold_uncertainty_score":0.99991244},"labels":[],"label_agreement":null},{"id":"W2980687415","doi":"10.1200/jco.2019.37.27_suppl.89","title":"Intensity of end-of-life (EOL) cancer care in Western Washington (WA) versus Alberta (AB), Canada (CA).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Alberta Health Services","funders":"National Institutes of Health","keywords":"Medicine; Cancer; Cancer registry; Colorectal cancer; Population; Prostate cancer; Lung cancer; Internal medicine; Environmental health","score_opus":0.09739586803536292,"score_gpt":0.3709182599522036,"score_spread":0.2735223919168407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980687415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715418,0.0030397752,0.000008256535,0.0020226832,0.006608287,0.00011571332,0.00007759885,0.0000011768956,0.016584702],"genre_scores_gemma":[0.99667037,0.0015377809,0.000115976094,0.0009184371,0.00042656096,0.0000015828159,0.00000242808,0.00001643498,0.00031042605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958039,0.00005468986,0.0035526876,0.00023393202,0.00007348107,0.00028133707],"domain_scores_gemma":[0.9937317,0.0012791908,0.004237295,0.00024709365,0.00027509188,0.00022967476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013845863,0.00014759663,0.002306434,0.0001630398,0.000014797251,0.0000070999936,0.00041534664,0.00034939588,0.00060960144],"category_scores_gemma":[0.0024823265,0.00014802685,0.0003341513,0.00012026514,0.00013857379,0.00024891802,0.000088424174,0.000667616,0.000027876558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025444054,0.0001399331,0.982977,0.000056610992,0.00016193802,0.000011364279,0.0002831499,0.00046099452,0.000003313583,0.0017842358,0.0020812468,0.009495854],"study_design_scores_gemma":[0.006511008,0.002255346,0.74403363,0.00009299,0.000028202474,0.000003304238,0.0002989657,0.00010071522,0.00003576196,0.00054676045,0.24590227,0.00019101324],"about_ca_topic_score_codex":0.43293205,"about_ca_topic_score_gemma":0.84701526,"teacher_disagreement_score":0.41408318,"about_ca_system_score_codex":0.00067507126,"about_ca_system_score_gemma":0.0036063872,"threshold_uncertainty_score":0.6674708},"labels":[],"label_agreement":null},{"id":"W2980696228","doi":"10.1200/jco.2019.37.27_suppl.102","title":"Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Exon; Lung cancer; Oncology; Mutation; Proportional hazards model; Retrospective cohort study; Confidence interval; Genetics; Gene; Biology","score_opus":0.0670128601008478,"score_gpt":0.47414937560977394,"score_spread":0.40713651550892616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980696228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940311,0.000964634,0.0001636241,0.003495553,0.00011987232,0.0008821817,0.000020599264,0.000008311807,0.00031413007],"genre_scores_gemma":[0.9946035,0.0004086636,0.0040171593,0.00071177824,0.00003943772,0.000030769734,0.000046262732,0.000015685078,0.00012674641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820155,0.00018575603,0.0009064697,0.0002404905,0.00027345738,0.00019230643],"domain_scores_gemma":[0.9978207,0.00054012606,0.00091976515,0.000120484234,0.00029443917,0.00030451437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042590618,0.00015897883,0.0010330772,0.00014512152,0.00008307982,0.000015346426,0.000038161583,0.00009246851,0.000026633455],"category_scores_gemma":[0.00011002898,0.00008714697,0.000050712257,0.00015402111,0.0001639731,0.00021706843,0.000014855569,0.00034674376,6.8131686e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002621252,0.0014320825,0.97512585,0.000078889185,0.0006097347,0.000059180562,0.00079740916,0.00017420587,4.933771e-7,0.000028108303,0.000058064907,0.019014735],"study_design_scores_gemma":[0.02557282,0.009516478,0.9624366,0.0004351906,0.00070837204,0.00006478999,0.00045361917,0.00034117032,0.0000010179265,0.000034407592,0.00034993712,0.00008556112],"about_ca_topic_score_codex":0.000755291,"about_ca_topic_score_gemma":0.0025908314,"teacher_disagreement_score":0.022951568,"about_ca_system_score_codex":0.00043758377,"about_ca_system_score_gemma":0.0018571017,"threshold_uncertainty_score":0.35537502},"labels":[],"label_agreement":null},{"id":"W2980765487","doi":"10.1200/jco.19.00761","title":"Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada); Genome British Columbia","funders":"","keywords":"Medicine; Breast cancer; Cumulative incidence; Breast-conserving surgery; Oncology; Internal medicine; Hazard ratio; Radiation therapy; Adjuvant radiotherapy; Incidence (geometry); Stage (stratigraphy); Adjuvant; Cancer; Mastectomy; Cohort; Confidence interval","score_opus":0.08591532500103477,"score_gpt":0.40364243709251607,"score_spread":0.3177271120914813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980765487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778421,0.0015506331,0.0007050308,0.015991388,0.002771567,0.0007605925,0.00033467825,0.000006424844,0.000037600388],"genre_scores_gemma":[0.9882831,0.0017531465,0.00093921355,0.0038479005,0.004287711,0.0002528317,0.000020595555,0.00005170443,0.0005637902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720234,0.0002645346,0.0016006444,0.00038528483,0.00015347263,0.00039372646],"domain_scores_gemma":[0.9944115,0.0029546153,0.0015386043,0.00031356444,0.0006181065,0.00016357616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016643186,0.000270898,0.0011602278,0.00006174803,0.0001011386,0.000022365593,0.00024274617,0.00039243032,0.000063279665],"category_scores_gemma":[0.00031610817,0.00016535472,0.0012783572,0.0000577599,0.00023931827,0.000014396127,0.000062495106,0.00023447988,0.0000027588924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03262938,0.00061957183,0.88060516,0.000032994918,0.0028494496,0.000012744305,0.00013295846,0.00007755478,0.0010291554,0.000015765409,0.005282856,0.07671242],"study_design_scores_gemma":[0.010573016,0.0037259683,0.8915263,0.000081991806,0.0004955547,0.00036812673,0.00032716215,0.00026689496,0.00020521261,0.00006490707,0.09211457,0.00025032644],"about_ca_topic_score_codex":0.00010834028,"about_ca_topic_score_gemma":0.00020000846,"teacher_disagreement_score":0.08683171,"about_ca_system_score_codex":0.00021854177,"about_ca_system_score_gemma":0.0014883272,"threshold_uncertainty_score":0.674297},"labels":[],"label_agreement":null},{"id":"W2980773289","doi":"10.1200/jco.2019.37.27_suppl.124","title":"A population-based study of medical cannabis utilization in patients with cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"College of Physicians and Surgeons of Ontario; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Cannabis; Medical cannabis; Cancer registry; Medical record; Cancer; Logistic regression; Multivariate analysis; Population; Internal medicine; Psychiatry; Environmental health","score_opus":0.09057153369578522,"score_gpt":0.4921326997077508,"score_spread":0.40156116601196556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980773289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867794,0.000056334902,0.000008640586,0.012074072,0.00041607695,0.00051140226,0.0000022598679,0.0000023536154,0.00014949635],"genre_scores_gemma":[0.9988426,0.000021612746,0.00004188382,0.0006109893,0.00016134662,0.000007545659,0.0000046968394,0.000011679283,0.00029764767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960934,0.00037267766,0.0017442427,0.00014858488,0.0014745427,0.00016656233],"domain_scores_gemma":[0.9975579,0.00015203285,0.00097135187,0.00016370018,0.0008604449,0.00029460355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002694946,0.00008390524,0.0010929976,0.00023069959,0.000012050401,0.0000036314011,0.00015629658,0.0002614571,0.000849196],"category_scores_gemma":[0.0019843813,0.0000528633,0.00012781317,0.000327084,0.000054435885,0.00005575227,0.000028916527,0.00074142584,0.000001995687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057832897,0.006301391,0.94902253,0.000048623886,0.00007894777,0.00005466716,0.00007859936,0.000203723,0.0000011997785,0.00000993464,0.0023564657,0.03606062],"study_design_scores_gemma":[0.02304271,0.028081886,0.94406503,0.0001582096,0.00006862361,0.0000031101567,0.00017700192,0.00046484312,0.0000031227892,0.0000062292183,0.0038813206,0.000047896752],"about_ca_topic_score_codex":0.00132924,"about_ca_topic_score_gemma":0.0025589415,"teacher_disagreement_score":0.036012724,"about_ca_system_score_codex":0.00021113832,"about_ca_system_score_gemma":0.0039151157,"threshold_uncertainty_score":0.92981005},"labels":[],"label_agreement":null},{"id":"W2980780905","doi":"10.1200/jco.19.00129","title":"Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Chemotherapy; Oncology; Cohort; Cancer; Internal medicine; Childhood cancer","score_opus":0.05100056926619262,"score_gpt":0.43474274464712476,"score_spread":0.38374217538093214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980780905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425983,0.00036974912,0.00001248576,0.0034269225,0.00046572124,0.00085718156,0.0000045618463,0.0000022182396,0.0006013023],"genre_scores_gemma":[0.99329805,0.0049548084,0.00023407637,0.0010039976,0.00036759884,0.000009052704,4.4108455e-7,0.000014493115,0.0001174684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959066,0.0011335473,0.0018530979,0.00019383685,0.0006777795,0.00023514671],"domain_scores_gemma":[0.99351263,0.0045186006,0.0012268273,0.00027435133,0.00029188418,0.00017572746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010045788,0.000119856726,0.0014230163,0.00011881351,0.000018282472,0.0000063465504,0.00026263774,0.0002291573,0.00017080175],"category_scores_gemma":[0.0018940704,0.0000612429,0.00020810573,0.0001972268,0.00019803284,0.000051837204,0.00005571075,0.0011030636,0.000007958052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028539624,0.0030624839,0.9704737,0.000018713703,0.0007200601,0.00028008333,0.00093243783,0.000017106633,0.000072888164,0.000013678555,0.00050070195,0.021054149],"study_design_scores_gemma":[0.019001411,0.014572358,0.96235913,0.00007796788,0.0003159926,0.00029117786,0.0009804324,0.00016385023,0.000046184552,0.00006330806,0.0020723988,0.000055761426],"about_ca_topic_score_codex":0.0009447329,"about_ca_topic_score_gemma":0.0006226884,"teacher_disagreement_score":0.020998387,"about_ca_system_score_codex":0.00025486434,"about_ca_system_score_gemma":0.002789612,"threshold_uncertainty_score":0.49486518},"labels":[],"label_agreement":null},{"id":"W2980788967","doi":"10.1200/jco.2019.37.27_suppl.143","title":"Racial/ethnic disparities in childhood cancer survival in the United States: Mediation effects of health insurance coverage and area-level social deprivation.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hazard ratio; Ethnic group; Medicaid; Health equity; Demography; Mediation; Cancer; Gerontology; Proportional hazards model; Public health; Health care; Confidence interval; Internal medicine","score_opus":0.24068901714432447,"score_gpt":0.49560230637173763,"score_spread":0.2549132892274132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980788967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98749244,0.0014758854,0.0001283573,0.0100009,0.00054045,0.00028766846,0.000008792767,0.0000019801041,0.00006352644],"genre_scores_gemma":[0.9877219,0.006320985,0.00008862186,0.005578397,0.00026478732,0.0000052056785,0.000008890367,0.0000053962194,0.000005810024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688894,0.0008982324,0.0015324368,0.0001106555,0.00039320753,0.00017652188],"domain_scores_gemma":[0.99508995,0.003290569,0.0012894438,0.00007426831,0.00018890356,0.00006687697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046328884,0.000084485866,0.0009862117,0.00014400975,0.000025949977,0.000005158372,0.00011364001,0.00017819696,0.0000102482545],"category_scores_gemma":[0.002685357,0.0000568864,0.00009726098,0.0003508565,0.00010166491,0.00012825707,0.000023927007,0.00075221475,5.5074247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009030172,0.00032464738,0.93631214,0.00010162414,0.000041923482,0.000029506127,0.0024162363,0.00023002723,0.000012035498,0.00011334846,0.00017041451,0.059345055],"study_design_scores_gemma":[0.006454537,0.0024187195,0.98898846,0.00032923318,0.000019908815,0.000012070196,0.0005498067,0.000115078365,0.0000051396337,0.0006619476,0.00039776292,0.000047350226],"about_ca_topic_score_codex":0.0012601377,"about_ca_topic_score_gemma":0.0022981984,"teacher_disagreement_score":0.059297703,"about_ca_system_score_codex":0.0001701737,"about_ca_system_score_gemma":0.0011052433,"threshold_uncertainty_score":0.32680404},"labels":[],"label_agreement":null},{"id":"W2980789446","doi":"10.1200/jco.2019.37.27_suppl.210","title":"Utilizaton of patient reported outcomes measures (PROM) to characterize symptom burden and adherence associated with oral oncolytic therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prom; Nausea; Patient-reported outcome; Internal medicine; Observational study; Confidence interval; Tolerability; Vomiting; Physical therapy; Adverse effect; Quality of life (healthcare)","score_opus":0.12815848778523778,"score_gpt":0.4335398399811503,"score_spread":0.30538135219591256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980789446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536705,0.00034612324,0.000046727975,0.0029208234,0.00051554973,0.00053221965,0.0000040880605,0.000014131037,0.00025327026],"genre_scores_gemma":[0.9965598,0.00019124619,0.0012228834,0.0016187382,0.00014507506,0.000006952296,0.0000019149054,0.000025761186,0.00022762378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648935,0.00031026383,0.0021387092,0.00024171273,0.00058355695,0.00023642827],"domain_scores_gemma":[0.9942644,0.0012381253,0.0029683765,0.00026460696,0.0009291412,0.0003353096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016484276,0.00018914747,0.0020991948,0.00011792332,0.000019911608,0.0000067877054,0.00013294833,0.0002564134,0.00012656944],"category_scores_gemma":[0.0025649702,0.00011422994,0.00022345434,0.00019149476,0.00015759682,0.0001231426,0.00004449085,0.00055685436,0.000003914471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011655501,0.00068695063,0.6113727,0.000019727284,0.0012015149,0.00019112976,0.00052814506,0.0000146848215,0.0036033904,0.0000107697815,0.000031189113,0.37068427],"study_design_scores_gemma":[0.01269523,0.037198383,0.93234617,0.00047702747,0.0002362808,0.00028991565,0.00027796396,0.00001779201,0.00048447252,0.00009560368,0.0157452,0.00013596112],"about_ca_topic_score_codex":0.00003287349,"about_ca_topic_score_gemma":0.00002466717,"teacher_disagreement_score":0.3705483,"about_ca_system_score_codex":0.00016030156,"about_ca_system_score_gemma":0.0011403454,"threshold_uncertainty_score":0.46581617},"labels":[],"label_agreement":null},{"id":"W2980793753","doi":"10.1200/jco.2019.37.27_suppl.248","title":"Medication reconciliation practices in ambulatory cancer care across Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pharmacy; Family medicine; Pharmacist; Ambulatory; Ambulatory care; Nursing; Health care","score_opus":0.4049392683717622,"score_gpt":0.6261904058613822,"score_spread":0.22125113748962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980793753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717543,0.0015465923,0.000003855374,0.020495526,0.0034415524,0.00019285375,0.0000037104835,0.000002905331,0.0025587077],"genre_scores_gemma":[0.9883113,0.0014196886,0.0003188648,0.00909851,0.000642867,0.0000025683983,0.0000033249748,0.0000070482365,0.00019585322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997385,0.0003159389,0.0015482232,0.00013503399,0.0004445295,0.00017125905],"domain_scores_gemma":[0.9926071,0.0031242603,0.003491321,0.00012025685,0.00040544756,0.0002515714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002728327,0.00007510768,0.00070998183,0.000024701872,0.000018564755,0.000005168496,0.000103018916,0.00022608844,0.0003525161],"category_scores_gemma":[0.0061563044,0.000054286254,0.00014505078,0.00010189556,0.00004371793,0.00027314437,0.000024812754,0.0010870403,0.000013028875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014952119,0.0002009177,0.87508035,0.00007858396,0.00009937278,0.000064459244,0.00035745132,0.00003947242,0.000046088513,0.000006613304,0.0017479365,0.12078357],"study_design_scores_gemma":[0.0039210403,0.0009971809,0.59675604,0.000074974145,0.00010344759,0.0000278841,0.00095275,0.0004680952,0.000032811844,0.000008205251,0.396612,0.00004558449],"about_ca_topic_score_codex":0.034116924,"about_ca_topic_score_gemma":0.21797238,"teacher_disagreement_score":0.39486405,"about_ca_system_score_codex":0.0005893926,"about_ca_system_score_gemma":0.0051303734,"threshold_uncertainty_score":0.97231495},"labels":[],"label_agreement":null},{"id":"W2980832598","doi":"10.1200/jco.2019.37.27_suppl.207","title":"Feasibility of collecting survey-based patient-reported outcome measures (PROMs) from patients living with advanced cancer: Emerging findings from the Living with Colorectal Cancer study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research; Alberta Health","keywords":"Medicine; Patient-reported outcome; Family medicine; Cancer; Colorectal cancer; Population; Language barrier; Quality of life (healthcare); Gerontology; Nursing; Internal medicine; Environmental health","score_opus":0.1287889939105006,"score_gpt":0.42683518311227625,"score_spread":0.2980461892017756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980832598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966225,0.00028542022,0.00013069015,0.00023495468,0.0014649748,0.0011131702,0.000036558,0.00002610863,0.00008559474],"genre_scores_gemma":[0.9985874,0.000033683013,0.00074797956,0.0002842593,0.00024977434,0.0000379886,0.0000042061165,0.00003973739,0.0000149159905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99403137,0.0013545665,0.0026639255,0.000509142,0.0011048703,0.00033614435],"domain_scores_gemma":[0.98216295,0.01148182,0.003981755,0.0003308968,0.0018012899,0.00024131102],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042313915,0.0002876478,0.0019789943,0.0001242401,0.00015941424,0.000023192635,0.00023323452,0.00024155417,0.00018973331],"category_scores_gemma":[0.0095619345,0.0001674162,0.00030779885,0.00059568527,0.00016728211,0.0001725862,0.00008631706,0.0013109589,9.4178307e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030502317,0.0015506684,0.93690956,0.000019747451,0.000907035,0.000022436741,0.0012495223,0.0011092029,0.00024778463,4.44894e-8,0.00003706172,0.027444605],"study_design_scores_gemma":[0.008830975,0.04172956,0.94515204,0.0010557574,0.0007150254,0.0000070841984,0.0015280427,0.0005234515,0.00022454823,0.0000020405732,0.000045100125,0.00018639096],"about_ca_topic_score_codex":0.013484675,"about_ca_topic_score_gemma":0.0366823,"teacher_disagreement_score":0.040178888,"about_ca_system_score_codex":0.0006847718,"about_ca_system_score_gemma":0.0024359673,"threshold_uncertainty_score":0.99878097},"labels":[],"label_agreement":null},{"id":"W2980834768","doi":"10.1200/jco.2019.37.27_suppl.204","title":"Examining patient and visit characteristics associated with the cancer patient experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"Cancer Care Ontario","keywords":"Medicine; Logistic regression; Cancer; Quartile; Lung cancer; Internal medicine; Demography; Confidence interval","score_opus":0.2726054434819119,"score_gpt":0.5471580565574651,"score_spread":0.2745526130755532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980834768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981667,0.0001485615,0.000019418401,0.00403036,0.0044604973,0.0004961528,0.000015131797,0.000010952887,0.0010022356],"genre_scores_gemma":[0.992275,0.000275166,0.00016706123,0.006737611,0.00036477417,0.000042175652,0.0000018758286,0.000016684537,0.00011967261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945289,0.0020927563,0.0023944718,0.00019983959,0.0004462925,0.0003377499],"domain_scores_gemma":[0.9856426,0.008252483,0.004842181,0.00019938378,0.0007920096,0.000271327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002076709,0.00012831375,0.0008782618,0.00005988174,0.0002872117,0.000005932084,0.00015586318,0.00038263013,0.0005624479],"category_scores_gemma":[0.0032698896,0.00006999887,0.00007278608,0.00012776216,0.00015324516,0.00013834953,0.00010767177,0.0018677625,0.000027808572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049672986,0.000071777504,0.9153755,0.00001959692,0.00007131307,0.000018676139,0.0064489823,0.000007449017,0.000012677183,0.00002773354,0.001377401,0.0760722],"study_design_scores_gemma":[0.0014876411,0.0063859317,0.94869494,0.0003624134,0.000042879466,0.000007533565,0.0075566005,0.00006497717,0.0000025399845,0.000018842566,0.035290234,0.000085487525],"about_ca_topic_score_codex":0.0000882426,"about_ca_topic_score_gemma":0.00014819572,"teacher_disagreement_score":0.07598672,"about_ca_system_score_codex":0.00034686778,"about_ca_system_score_gemma":0.0013817458,"threshold_uncertainty_score":0.81146026},"labels":[],"label_agreement":null},{"id":"W2980846478","doi":"10.1200/jco.2019.37.27_suppl.120","title":"Costs after incident breast cancer diagnosis among high-deductible health plan members.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Deductible; Breast cancer; Health care; Proxy (statistics); Health plan; Cancer; Demography; Family medicine; Internal medicine; Actuarial science","score_opus":0.07506552261457548,"score_gpt":0.3797991385671448,"score_spread":0.3047336159525693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980846478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661947,0.0035888597,0.000041209052,0.01622728,0.0076049836,0.00022133045,0.00022009524,0.000009169191,0.005892403],"genre_scores_gemma":[0.9816365,0.008340334,0.00037519963,0.0067857825,0.0021042717,0.000034477092,0.000002320857,0.000031442894,0.00068965566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954488,0.00009859528,0.0035651396,0.0003515717,0.00007932424,0.0004565639],"domain_scores_gemma":[0.9936126,0.0005575314,0.00486984,0.00027896266,0.0001589771,0.0005221153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035152927,0.00019468878,0.0021370752,0.00023062597,0.000047992515,0.00004393306,0.00037557125,0.00039678716,0.0059040026],"category_scores_gemma":[0.0004910238,0.00018450807,0.00048633502,0.00014119927,0.00016897728,0.0006646074,0.00008845908,0.00085509784,0.0004964261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005793675,0.00037156584,0.93495953,0.000020641462,0.00018170236,0.00002851472,0.00012028157,0.000088942594,1.6948563e-7,0.0036245533,0.024305418,0.035719283],"study_design_scores_gemma":[0.002234171,0.0013220563,0.83034164,0.00007271365,0.000017346894,0.00003377828,0.000050487077,0.000031541145,0.0000025471522,0.0023989573,0.16331609,0.00017869436],"about_ca_topic_score_codex":0.00526103,"about_ca_topic_score_gemma":0.0019097861,"teacher_disagreement_score":0.13901067,"about_ca_system_score_codex":0.0010284919,"about_ca_system_score_gemma":0.0009285098,"threshold_uncertainty_score":0.9950047},"labels":[],"label_agreement":null},{"id":"W2980868009","doi":"10.1200/jco.2019.37.27_suppl.247","title":"Safety culture interventions in cancer care: A systematic review.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"CINAHL; Medicine; Psychological intervention; PsycINFO; MEDLINE; Patient safety; Health care; Systematic review; Cochrane Library; Family medicine; Safety culture; Oncology; Nursing; Meta-analysis; Internal medicine","score_opus":0.6096315297170734,"score_gpt":0.6239080428714168,"score_spread":0.014276513154343418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980868009","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11846322,0.6409005,0.0010493277,0.19099867,0.014199349,0.0050515383,0.00022453166,0.000028433678,0.029084438],"genre_scores_gemma":[0.7205471,0.12740338,0.0052418658,0.13669954,0.002689612,0.0002256686,0.000022462606,0.00008026648,0.0070901117],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.977997,0.0016528377,0.01974923,0.00025700018,0.000112717426,0.00023119032],"domain_scores_gemma":[0.9811822,0.0030470728,0.014960429,0.0003395842,0.00026566608,0.00020503954],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05133602,0.0001294101,0.0046758624,0.00022116862,0.000031954245,0.000014959487,0.00040186386,0.0003223639,0.0009061996],"category_scores_gemma":[0.026301078,0.000117497424,0.0009113357,0.00019118146,0.00004893148,0.0003183621,0.00004873857,0.0007616349,0.001182695],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029048615,0.0016831161,0.32673168,0.50740063,0.0010604633,0.000040863335,0.004159032,0.00031956212,7.987813e-7,0.043052245,0.11417417,0.0010869495],"study_design_scores_gemma":[0.015658434,0.007074885,0.17749855,0.3406276,0.0006418223,0.00016445105,0.0063288216,0.00080757274,6.9570183e-7,0.012068317,0.43808615,0.0010426961],"about_ca_topic_score_codex":0.00015862299,"about_ca_topic_score_gemma":0.00050079776,"teacher_disagreement_score":0.60208386,"about_ca_system_score_codex":0.0010702905,"about_ca_system_score_gemma":0.00077497173,"threshold_uncertainty_score":0.999595},"labels":[],"label_agreement":null},{"id":"W2980889392","doi":"10.1200/jco.2012.30.15_suppl.1555","title":"Variants of uncertain significance in BRCA testing: Impact on risk perception, worry, prevention, and counseling.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Medicine; Worry; Genetic testing; Prophylactic Mastectomy; Likert scale; Genetic counseling; Breast cancer; Risk perception; Internal medicine; Recall; Gynecology; Family medicine; Oncology; Cancer; Mastectomy; Perception; Anxiety; Psychiatry; Psychology","score_opus":0.08892078532963305,"score_gpt":0.45834055289103653,"score_spread":0.3694197675614035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980889392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683577,0.00084393925,0.00095867086,0.00026611902,0.0005381964,0.00010720799,0.000009374862,0.0000014958379,0.00043921242],"genre_scores_gemma":[0.99020714,0.0011635209,0.0074441796,0.00023158568,0.00086481293,0.0000038481426,0.0000032483597,0.000011683304,0.00006999556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761117,0.00059493224,0.0012885082,0.00015833354,0.00015721645,0.00018983467],"domain_scores_gemma":[0.99721694,0.00071131345,0.0013931635,0.00016334545,0.00036556443,0.00014966684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004097436,0.000107913846,0.00047774502,0.000076235,0.000028487508,0.0000050845247,0.00014293804,0.00030456303,0.000050803428],"category_scores_gemma":[0.0045330445,0.000084061976,0.0001603787,0.0001347561,0.00017220875,0.000011640408,0.00003090159,0.00038882066,0.0000031012921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015915576,0.0012711888,0.8587394,0.000016174785,0.0001936697,0.000007070056,0.00027612422,0.0025105411,0.012898791,0.000018970146,0.004422637,0.11805392],"study_design_scores_gemma":[0.0020168438,0.005872066,0.9843354,0.000051923875,0.00007432984,0.00006795482,0.00017945656,0.00016258513,0.00036182677,0.00050182146,0.0062721795,0.00010357088],"about_ca_topic_score_codex":0.00003941146,"about_ca_topic_score_gemma":0.00003649217,"teacher_disagreement_score":0.12559608,"about_ca_system_score_codex":0.00011004953,"about_ca_system_score_gemma":0.0012124223,"threshold_uncertainty_score":0.54268056},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2980891303","doi":"10.1200/jco.2019.37.27_suppl.228","title":"“I had already made up my mind.” The impact of prior experience and health care perceptions on decision making in women with early-stage breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Qualitative research; Cancer; Gynecology; Internal medicine","score_opus":0.3162692870586157,"score_gpt":0.607356925978179,"score_spread":0.29108763891956335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980891303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057984,0.00058381975,0.000018393706,0.0069549917,0.00070119073,0.00090012565,0.00005427901,0.0000051758275,0.0002021872],"genre_scores_gemma":[0.99567044,0.0008671252,0.0010740979,0.0020490922,0.0001659207,0.00007039992,9.990491e-7,0.00001978711,0.00008214818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937238,0.0023572175,0.0027832265,0.0002421726,0.00040868745,0.0004848669],"domain_scores_gemma":[0.9895426,0.005530599,0.0034103529,0.00058332755,0.0006050133,0.00032809222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002272948,0.00016151735,0.001090357,0.00018353756,0.00030016064,0.000007241071,0.00052201067,0.0003321664,0.00042747697],"category_scores_gemma":[0.00071596587,0.000091655165,0.00013093378,0.00024570356,0.00024654588,0.0001907978,0.00018540384,0.0022398783,0.000015867132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052111405,0.00018607048,0.821331,0.00006851103,0.000031171432,0.0000041479334,0.06750139,0.00011721061,0.000010383024,0.00002157003,0.00018991473,0.10532745],"study_design_scores_gemma":[0.003285205,0.007212748,0.91963434,0.0013143913,0.000007850199,0.000016048361,0.067412,0.000070485126,2.89513e-7,0.000031946318,0.00093739724,0.000077304845],"about_ca_topic_score_codex":0.00227098,"about_ca_topic_score_gemma":0.0016044247,"teacher_disagreement_score":0.10525014,"about_ca_system_score_codex":0.0017295743,"about_ca_system_score_gemma":0.005579345,"threshold_uncertainty_score":0.9897518},"labels":[],"label_agreement":null},{"id":"W2980921211","doi":"10.1200/jco.2019.37.27_suppl.66","title":"Implementation of an enhanced recovery program framework in medical oncology.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Distress; Gynecologic oncology; Cancer; Population; Internal medicine; Emergency medicine","score_opus":0.07519397820941076,"score_gpt":0.5480234165275073,"score_spread":0.47282943831809654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980921211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879388,0.00015705462,0.00018389203,0.004474512,0.0032264222,0.00035294416,0.0000018542568,0.000008321333,0.0036561957],"genre_scores_gemma":[0.9907823,0.00057477097,0.0047689755,0.0028146557,0.0009813793,0.000009355798,0.000004808144,0.000012172627,0.000051562754],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958495,0.0006204921,0.002568647,0.00017743134,0.00057055894,0.00021338479],"domain_scores_gemma":[0.99544966,0.0021122114,0.0015267908,0.00019527081,0.00034831822,0.0003677622],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0050637494,0.00009838382,0.0014383963,0.00015208812,0.000008253441,0.0000035121802,0.00018598305,0.00080683536,0.0020406395],"category_scores_gemma":[0.0020241407,0.00007499467,0.00035387964,0.00022128354,0.0001269465,0.00013002042,0.000040579445,0.0014344734,0.000015627738],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039679343,0.0019134787,0.10605339,0.00004704097,0.00010859385,0.00022412192,0.0004137698,0.000003184807,0.00016682326,0.000110042885,0.00024411938,0.8867475],"study_design_scores_gemma":[0.018835949,0.13107027,0.7397581,0.00061794947,0.00027279518,0.00035178618,0.006056775,0.000075205826,0.0011989397,0.0026927781,0.098875895,0.00019357441],"about_ca_topic_score_codex":0.00019418553,"about_ca_topic_score_gemma":0.003247512,"teacher_disagreement_score":0.88655394,"about_ca_system_score_codex":0.00023510767,"about_ca_system_score_gemma":0.0040529263,"threshold_uncertainty_score":0.9988716},"labels":[],"label_agreement":null},{"id":"W2980981515","doi":"10.1200/jco.2019.37.27_suppl.255","title":"Developing a standardized approach to cancer medication-related infusion reaction prevention and management in Ontario.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Regional Health Centre; Kingston Health Sciences Centre; St. Michael's Hospital; Cancer Care Ontario; Grand River Hospital; HalTech; Health Sciences Centre; Southlake Regional Health Center; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Discontinuation; Grading (engineering); Patient education; MEDLINE; Health care; Multidisciplinary approach; Quality management; Patient safety; Intensive care medicine; Family medicine; Medical emergency; Surgery; Management system; Operations management","score_opus":0.31777311217174664,"score_gpt":0.5556588099123194,"score_spread":0.23788569774057278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980981515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789882,0.00011209535,0.0004973159,0.007883987,0.000933479,0.0005291403,2.1334101e-7,0.0000040147434,0.011051584],"genre_scores_gemma":[0.9807434,0.0018393263,0.013884657,0.0023951065,0.00008238041,0.000009827168,0.0000030462913,0.000006864472,0.0010353816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794406,0.00021982331,0.0012972713,0.00013526119,0.00029292487,0.00011069203],"domain_scores_gemma":[0.9983979,0.00047683343,0.00075569545,0.000071983275,0.00011677307,0.00018080449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029748604,0.000067112545,0.0005888085,0.00014187145,0.000015748197,0.0000048355046,0.00005016533,0.00016246315,0.00014617576],"category_scores_gemma":[0.00048706576,0.000048147027,0.0000922292,0.00012044053,0.00002391076,0.00014624227,0.00004501543,0.00067321,0.000011779025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068900376,0.000985173,0.70818084,0.00012081301,0.0004249559,0.00004066381,0.00048098233,0.00003760823,0.00018669727,0.00083415624,0.00039368548,0.2814244],"study_design_scores_gemma":[0.008752526,0.0015761467,0.81222403,0.00024286486,0.00021514011,0.000042544852,0.00012380672,0.00026855487,0.000008506815,0.00037090864,0.17612033,0.000054612476],"about_ca_topic_score_codex":0.0004797982,"about_ca_topic_score_gemma":0.0012269389,"teacher_disagreement_score":0.2813698,"about_ca_system_score_codex":0.00048078562,"about_ca_system_score_gemma":0.00086207164,"threshold_uncertainty_score":0.29248},"labels":[],"label_agreement":null},{"id":"W2981024493","doi":"10.1200/jco.2019.37.27_suppl.179","title":"Living with advanced colorectal cancer: How prepared are informal caregivers to care for their loved ones?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research; Alberta Health","keywords":"Preparedness; Medicine; Family caregivers; Feeling; Palliative care; Likert scale; Caregiver stress; Family medicine; Caregiver burden; Nursing; Gerontology; Psychology; Disease; Dementia","score_opus":0.14139873635944747,"score_gpt":0.489829257431982,"score_spread":0.3484305210725346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981024493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930873,0.0011914967,0.00016564067,0.0019996949,0.0011455845,0.0006157379,0.00003414187,0.000010264809,0.0017501436],"genre_scores_gemma":[0.9917859,0.000809643,0.005674373,0.00080726773,0.00062019087,0.000016128784,0.0000041118406,0.000019274801,0.00026309822],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826276,0.000101461344,0.00092389056,0.00017755618,0.00027144502,0.00026289801],"domain_scores_gemma":[0.9937831,0.002650016,0.0015831962,0.00014903895,0.0015087498,0.00032587178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059368054,0.00016119725,0.0016280684,0.00010810278,0.000029868803,0.0000070484875,0.00017560563,0.00025351683,0.000045605295],"category_scores_gemma":[0.0025343953,0.000104071354,0.0003950904,0.00013309982,0.00010186127,0.00017781014,0.000051701234,0.00041758598,0.000003565167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019490074,0.00030398922,0.8620582,0.00038634634,0.00081696245,0.000068729445,0.014131167,0.00052988465,0.0008005244,0.000014723588,0.0021955085,0.09920385],"study_design_scores_gemma":[0.016251763,0.055877443,0.3857975,0.004287859,0.00053173234,0.00006882225,0.07307664,0.00012144015,0.0022550756,0.000006854073,0.46142897,0.00029588907],"about_ca_topic_score_codex":0.000023756882,"about_ca_topic_score_gemma":0.000513368,"teacher_disagreement_score":0.47626072,"about_ca_system_score_codex":0.0002279996,"about_ca_system_score_gemma":0.0015837156,"threshold_uncertainty_score":0.42439064},"labels":[],"label_agreement":null},{"id":"W2981029468","doi":"10.1200/jco.2019.37.27_suppl.291","title":"Real world implementation of patient report outcomes: Sustainability constraints and impact on patients health outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Mary's Hospital Centre; McGill University","funders":"Partenariat Canadien Contre Le Cancer; Réseau de cancérologie Rossy","keywords":"Medicine; General partnership; Patient experience; Distress; Anxiety; Quality of life (healthcare); Dashboard; Family medicine; Scale (ratio); Health care; Nursing; Physical therapy; Psychiatry; Database","score_opus":0.21398758080176375,"score_gpt":0.63221175862507,"score_spread":0.41822417782330623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981029468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97806156,0.000008016824,0.000030353693,0.019177247,0.0011274997,0.0011136596,0.000023090568,0.0000073570804,0.00045122544],"genre_scores_gemma":[0.99350387,0.00007849696,0.001675406,0.004520033,0.00011153167,0.0000033191548,0.000033641878,0.000016754346,0.000056967507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890468,0.00086867023,0.008692549,0.00030295775,0.00078828057,0.0003007253],"domain_scores_gemma":[0.9792148,0.008543114,0.009565405,0.00037507628,0.0017764136,0.00052517536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009580262,0.00020054092,0.002302116,0.00024789793,0.000031267195,0.000007866683,0.00009376419,0.00017396701,0.0004970109],"category_scores_gemma":[0.019590087,0.00012916476,0.00063732656,0.00017209972,0.00022675461,0.00021603599,0.00007704756,0.00083035376,0.0000066210005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019005258,0.0016393618,0.75290823,0.000052892025,0.00029403053,0.00007195458,0.000114049704,0.0000071929862,0.0000018816495,0.0000622603,0.0011856921,0.24176191],"study_design_scores_gemma":[0.013264675,0.028651062,0.95354944,0.00004547994,0.00019446781,0.000067929606,0.0016567092,0.000009014108,0.0000062427043,0.00038674002,0.0020815544,0.00008665527],"about_ca_topic_score_codex":0.0009487904,"about_ca_topic_score_gemma":0.0002898519,"teacher_disagreement_score":0.24167526,"about_ca_system_score_codex":0.00090808404,"about_ca_system_score_gemma":0.0052149342,"threshold_uncertainty_score":0.9886683},"labels":[],"label_agreement":null},{"id":"W2981050237","doi":"10.1200/jco.2019.37.27_suppl.127","title":"Barriers and facilitators to the implementation of routine ototoxicity screening for head and neck cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Western University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hearing loss; Ototoxicity; Head and neck cancer; Family medicine; Context (archaeology); Audiologist; Audiology; Surgery; Radiation therapy","score_opus":0.09406699898844101,"score_gpt":0.500741311641605,"score_spread":0.40667431265316395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981050237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888065,0.00031737986,0.00007587596,0.009859564,0.0003805785,0.0004531446,0.000027929249,0.0000014151184,0.00007761403],"genre_scores_gemma":[0.9958286,0.0002981499,0.0011795142,0.0024551593,0.00018806025,0.000009323172,6.596824e-7,0.0000045894576,0.000035933754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986371,0.00008878249,0.0009135156,0.00009885841,0.00014189503,0.00011989492],"domain_scores_gemma":[0.9982153,0.0007742712,0.00047496412,0.00005528985,0.00028035152,0.00019982534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013604977,0.00006250481,0.0007268193,0.000037519585,0.000039203307,0.000002490484,0.00003962212,0.00007012798,0.000050279872],"category_scores_gemma":[0.0010803387,0.000036095204,0.00010316084,0.00005150665,0.00007529288,0.00004495757,0.000036491067,0.00018177411,3.7948107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015488763,0.000037455113,0.8576542,0.0000351219,0.00012607095,7.0298637e-7,0.00050160533,0.0000024177766,0.00005777451,0.000015247653,0.0016767042,0.13834381],"study_design_scores_gemma":[0.0077733877,0.016254514,0.9332243,0.00008099228,0.000108410495,0.0000032670412,0.0012605016,0.00002462249,0.00012232097,0.000018286473,0.041093033,0.00003637151],"about_ca_topic_score_codex":0.00012314398,"about_ca_topic_score_gemma":0.00035614963,"teacher_disagreement_score":0.13830745,"about_ca_system_score_codex":0.00003846797,"about_ca_system_score_gemma":0.00030788878,"threshold_uncertainty_score":0.14719197},"labels":[],"label_agreement":null},{"id":"W2981053384","doi":"10.1200/jco.2019.37.27_suppl.57","title":"A systematic approach for high-quality care in complex malignant hematology.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Cancer Care Ontario; Mount Sinai Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Workload; Mentorship; Turnaround time; Health care; Family medicine; Operations management; Medical education","score_opus":0.20271204659714345,"score_gpt":0.4221021300084165,"score_spread":0.21939008341127306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981053384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572288,0.005916666,0.0071136383,0.0014977445,0.0025281585,0.0012009278,0.00008803086,0.000009299565,0.02441675],"genre_scores_gemma":[0.98803556,0.0002129772,0.00998503,0.0011847408,0.00034085053,0.000024026931,0.0000071339496,0.000018486631,0.0001911959],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.993606,0.00016374027,0.0055828225,0.00029043359,0.00004242512,0.00031463237],"domain_scores_gemma":[0.9929821,0.0014520283,0.0049580224,0.00027303759,0.0001800089,0.00015482842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065991962,0.00014788701,0.003477548,0.00020454393,0.00002545234,0.000019310257,0.0003855913,0.00045086158,0.00012641061],"category_scores_gemma":[0.0028370458,0.0001311933,0.0005455927,0.00009371779,0.00009413271,0.0002120206,0.000048413443,0.0004371234,0.00010930794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018345333,0.0011504424,0.32311866,0.007087072,0.00042210927,0.000027653588,0.0006859892,0.0004203744,0.0000084392295,0.65859103,0.002686761,0.0039669164],"study_design_scores_gemma":[0.030261796,0.012395152,0.78875446,0.0011256008,0.00014180358,0.00016303567,0.0032945126,0.0020738526,0.00002708281,0.1178887,0.042844035,0.0010299952],"about_ca_topic_score_codex":0.00009720685,"about_ca_topic_score_gemma":0.000069574504,"teacher_disagreement_score":0.54070234,"about_ca_system_score_codex":0.00030289777,"about_ca_system_score_gemma":0.00035710394,"threshold_uncertainty_score":0.5349908},"labels":[],"label_agreement":null},{"id":"W2981063609","doi":"10.1200/jco.2019.37.27_suppl.287","title":"Tailoring implementation for a cancer self-management support intervention for patients starting chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Interprofessional Education and Collaboration","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Regional Health Centre; Cancer Care Ontario; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Facilitator; Respondent; Intervention (counseling); Stakeholder; Focus group; Workflow; Implementation research; Nursing; Randomized controlled trial; Qualitative property; Psychological intervention; Knowledge management; Medical education; Public relations; Psychology; Business; Marketing","score_opus":0.1215414145350195,"score_gpt":0.6217911930193033,"score_spread":0.5002497784842838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981063609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97400105,0.000015909964,0.0030667903,0.00705564,0.01265476,0.0022058703,0.000019266408,0.000012716389,0.0009679721],"genre_scores_gemma":[0.9746635,0.000085027525,0.014052958,0.0063006193,0.0014737698,0.0004707882,0.0000441754,0.000022536242,0.0028866043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967326,0.00033892816,0.0023776216,0.00013943158,0.00018819736,0.00022322044],"domain_scores_gemma":[0.9942246,0.0012443826,0.0029590065,0.00008001737,0.0013990108,0.00009299583],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037243324,0.00008153531,0.0004459389,0.000097180746,0.00015081531,0.0000061131896,0.00011881957,0.00017544195,0.0011441748],"category_scores_gemma":[0.00038554997,0.0000650138,0.00025502857,0.000082341634,0.000009671956,0.00021365422,0.000029257148,0.00031372058,0.000027820248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070847655,0.0017707756,0.33925343,0.0005937637,0.00045687353,5.268306e-7,0.003400044,0.000012622183,0.00006206874,0.0028598884,0.07452167,0.56998354],"study_design_scores_gemma":[0.023850597,0.007740342,0.17652406,0.0003083056,0.00017152204,2.0201196e-7,0.011544951,0.00034571288,0.000040507446,0.0022211305,0.77712315,0.00012950596],"about_ca_topic_score_codex":0.000016195192,"about_ca_topic_score_gemma":0.00011771057,"teacher_disagreement_score":0.7026015,"about_ca_system_score_codex":0.00041442586,"about_ca_system_score_gemma":0.0013617296,"threshold_uncertainty_score":0.9997689},"labels":[],"label_agreement":null},{"id":"W2981064702","doi":"10.1200/jco.19.01507","title":"Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North","funders":"","keywords":"Mucositis; Medicine; Head and neck cancer; Placebo; Cisplatin; Radiation therapy; Oncology; Internal medicine; Randomized controlled trial; Head and neck; Cancer; Surgery; Chemotherapy; Pathology","score_opus":0.25883005353953864,"score_gpt":0.5843787431077885,"score_spread":0.32554868956824984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981064702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647899,0.0019645973,0.00018541985,0.021019442,0.006322139,0.0055291723,0.00004199299,0.0000052587925,0.00014203727],"genre_scores_gemma":[0.9780648,0.002130137,0.01398273,0.0027979978,0.0024658146,0.00020779388,0.000004593201,0.00003318087,0.00031294915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961782,0.00039402582,0.0024591892,0.00031350253,0.000325967,0.00032913318],"domain_scores_gemma":[0.99213123,0.005108126,0.0013214197,0.00017689407,0.00038262608,0.00087968406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036880434,0.0002056558,0.0033036764,0.000148885,0.00003616248,0.00001010511,0.00009760039,0.0003179889,0.00016167334],"category_scores_gemma":[0.0010159237,0.00014579856,0.00034994178,0.00012136443,0.00015425662,0.0000757953,0.00003676587,0.00046001424,0.0000031745824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74035513,0.0013807864,0.00040179578,0.00010209743,0.00050916814,0.000042216092,0.00022494527,0.000020434383,0.000050143735,0.000038362094,0.003014981,0.2538599],"study_design_scores_gemma":[0.8469357,0.118806146,0.0005057801,0.00032409644,0.00056385365,0.00013757881,0.000043277825,0.00015946559,0.00015374323,0.000024743587,0.03223331,0.00011230789],"about_ca_topic_score_codex":0.00018668233,"about_ca_topic_score_gemma":0.00020159244,"teacher_disagreement_score":0.2537476,"about_ca_system_score_codex":0.00048916735,"about_ca_system_score_gemma":0.00212187,"threshold_uncertainty_score":0.5945493},"labels":[],"label_agreement":null},{"id":"W2981075766","doi":"10.1200/jco.2019.37.27_suppl.285","title":"Primary non-adherence to adjuvant endocrine therapy in older women with breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; St Mary's Hospital Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Breast cancer; Polypharmacy; Internal medicine; Charlson comorbidity index; Cancer; Medical prescription; Lumpectomy; Adjuvant; Oncology; Adjuvant therapy; Gynecology; Comorbidity; Mastectomy; Pharmacology","score_opus":0.08720868989193134,"score_gpt":0.462311436297406,"score_spread":0.3751027464054747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981075766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794772,0.0001904948,0.0000791716,0.01412289,0.00058274256,0.0004068843,0.0000020022242,0.0000052407804,0.005133359],"genre_scores_gemma":[0.9756245,0.0012661992,0.0012262163,0.018205578,0.0005296242,0.000037444664,6.840579e-7,0.000011832188,0.0030978983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976789,0.00012231282,0.0013307977,0.00020318189,0.00038662596,0.00027822197],"domain_scores_gemma":[0.99769056,0.00042370666,0.0008123058,0.00023235299,0.00036567342,0.0004753825],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001256167,0.00011693498,0.0012080405,0.00010249586,0.000010990384,0.0000049251435,0.00022721203,0.00011938027,0.0038829772],"category_scores_gemma":[0.00016994306,0.00007068991,0.000088840185,0.0002465681,0.00008131238,0.00009727397,0.000030481968,0.00076224044,0.00034032078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008051193,0.0010459387,0.5519733,0.00003203787,0.00008209548,0.00025484388,0.00017435831,0.000012619399,0.0007331205,0.000007959524,0.0047225077,0.43291005],"study_design_scores_gemma":[0.011669502,0.018308224,0.94203997,0.00042229457,0.000016179218,0.0004440088,0.00018184508,0.000019692527,0.000035205623,0.000035271958,0.026744448,0.000083377854],"about_ca_topic_score_codex":0.00004639366,"about_ca_topic_score_gemma":0.000017686898,"teacher_disagreement_score":0.43282667,"about_ca_system_score_codex":0.00022892545,"about_ca_system_score_gemma":0.0026650613,"threshold_uncertainty_score":0.99702764},"labels":[],"label_agreement":null},{"id":"W2981103591","doi":"10.1200/jco.2019.37.27_suppl.39","title":"From guidelines to practice: Patient-focused and evidence-informed update of antiemetic recommendations in Ontario.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Health Sciences Centre; University of Toronto; Kingston General Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Antiemetic; Formulary; Intensive care medicine; Chemotherapy-induced nausea and vomiting; Dosing; Olanzapine; Nausea; Vomiting; Evidence-based medicine; Psychiatry; Alternative medicine; Family medicine; Anesthesia; Pharmacology; Schizophrenia (object-oriented programming)","score_opus":0.2664990445735684,"score_gpt":0.5448651961643827,"score_spread":0.2783661515908143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981103591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9212478,0.0001799262,0.000101424026,0.07573918,0.0012705532,0.0002925623,0.000001203255,0.0000028520858,0.0011645018],"genre_scores_gemma":[0.8994038,0.00081722706,0.08934841,0.00978014,0.0002590966,0.0000023308885,0.0000027077758,0.000008464198,0.00037783172],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996493,0.00023517603,0.0027378805,0.00013771994,0.0002644663,0.00013175553],"domain_scores_gemma":[0.9928507,0.004422229,0.0017149127,0.00017981569,0.0006432366,0.00018907798],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030702231,0.000081567,0.00091719825,0.00019893011,0.00001116492,0.000007804616,0.0001024412,0.00013632396,0.00036823997],"category_scores_gemma":[0.021071201,0.0000599292,0.00012946091,0.00013202043,0.000038381568,0.00024392478,0.000092125185,0.00051329436,0.000029275841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068065342,0.001110306,0.5087203,0.000055749017,0.00037403108,0.00015364242,0.0009992829,0.000026490314,0.00018816847,0.00007527521,0.044183787,0.43730646],"study_design_scores_gemma":[0.0070262025,0.011087198,0.33767667,0.0011880054,0.00036783717,0.000035042143,0.00095684355,0.00006562919,0.00007772148,0.0003249248,0.64110553,0.00008836623],"about_ca_topic_score_codex":0.0029997278,"about_ca_topic_score_gemma":0.0057214703,"teacher_disagreement_score":0.59692174,"about_ca_system_score_codex":0.0001524895,"about_ca_system_score_gemma":0.0013298934,"threshold_uncertainty_score":0.98717475},"labels":[],"label_agreement":null},{"id":"W2981130163","doi":"10.1200/jco.2019.37.27_suppl.6","title":"Why do payers refuse to fund \"effective\" therapies?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; University of Toronto; Western University","funders":"","keywords":"Medicine; Clinical trial; Family medicine; Internal medicine","score_opus":0.6146696784020019,"score_gpt":0.5891292027185676,"score_spread":0.025540475683434316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981130163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8210395,0.0013296609,0.0024017617,0.15706141,0.006075477,0.00071511744,0.000025900428,0.0000138316655,0.011337332],"genre_scores_gemma":[0.82144725,0.00038943524,0.010037583,0.16490185,0.0023852687,0.00002202271,0.0000015551241,0.00003922918,0.0007758005],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876021,0.0014594139,0.010029855,0.00039684415,0.00014356677,0.00036821194],"domain_scores_gemma":[0.9791266,0.010852374,0.0087958705,0.00045251212,0.00023495314,0.0005377215],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.0608064,0.00016697303,0.0028721597,0.000356357,0.000060094844,0.000045514247,0.00047222164,0.00043450255,0.001665597],"category_scores_gemma":[0.01851776,0.00016304413,0.00053686916,0.00018830724,0.00008194648,0.0004236052,0.00007030186,0.0007532458,0.004772891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010596382,0.0012917817,0.48299563,0.00016924404,0.00094319845,0.000028692793,0.002202999,0.00039762922,0.000014797752,0.10629676,0.37521878,0.029380849],"study_design_scores_gemma":[0.0024996328,0.0033343537,0.17341378,0.00005112677,0.000012268075,0.000018228538,0.0004774366,0.00008226162,0.0000013445103,0.0153130675,0.8046297,0.00016681023],"about_ca_topic_score_codex":0.00011240605,"about_ca_topic_score_gemma":0.00006727148,"teacher_disagreement_score":0.4294109,"about_ca_system_score_codex":0.00060066924,"about_ca_system_score_gemma":0.00052256876,"threshold_uncertainty_score":0.999247},"labels":[],"label_agreement":null},{"id":"W2981161292","doi":"10.1200/jco.2019.37.27_suppl.232","title":"Radiation Oncology Incident Learning System (RO-ILS): Increasing stakeholder participation for safety and quality improvement.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiology practices and education","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Stakeholder; Medical education; Medical physics; Medical emergency; Political science; Public relations","score_opus":0.25761404363045853,"score_gpt":0.5348861658546337,"score_spread":0.27727212222417513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981161292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889813,0.00026822637,0.0012128062,0.005466913,0.0022227995,0.0005115358,0.0000013865651,0.0000119046,0.0013231469],"genre_scores_gemma":[0.99424756,0.0005255899,0.0027049785,0.0010180129,0.001292919,0.000008973413,0.000013215463,0.000012509204,0.00017625271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537337,0.0014754169,0.0025036153,0.00020628222,0.00020018424,0.00024112679],"domain_scores_gemma":[0.988106,0.007184347,0.0038264645,0.0001291344,0.00047837442,0.0002756671],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01739675,0.00010508571,0.0011575476,0.000103013364,0.00008719015,0.000013089319,0.000061954786,0.0004428857,0.00004700522],"category_scores_gemma":[0.010974756,0.00008247289,0.00018389997,0.00006938639,0.000079492194,0.00026967083,0.000025132034,0.00075516925,0.000009979812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012627983,0.0005595997,0.59992874,0.00017709521,0.00028642564,0.00001134033,0.00050399185,0.00014984603,0.001522811,0.00065298425,0.00021685667,0.3833623],"study_design_scores_gemma":[0.009955419,0.018313693,0.85914236,0.000082656836,0.0005597095,0.0002599924,0.0028281654,0.0019518546,0.0000633467,0.00007847437,0.1066658,0.00009853647],"about_ca_topic_score_codex":0.000107766115,"about_ca_topic_score_gemma":0.000024522373,"teacher_disagreement_score":0.38326377,"about_ca_system_score_codex":0.00065175584,"about_ca_system_score_gemma":0.0012960472,"threshold_uncertainty_score":0.99735624},"labels":[],"label_agreement":null},{"id":"W2981184917","doi":"10.1200/jco.2019.37.27_suppl.19","title":"Adherence to clinical practice guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults with cancer receiving their first cycle of highly emetogenic chemotherapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; American Cancer Society","keywords":"Medicine; Guideline; Chemotherapy-induced nausea and vomiting; Nausea; Vomiting; Internal medicine; Cancer; Odds ratio; Chemotherapy regimen; Regimen; Retrospective cohort study; Chemotherapy; Cohort; Oncology; Antiemetic","score_opus":0.11044288938849475,"score_gpt":0.4860357187912971,"score_spread":0.37559282940280236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981184917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718641,0.0012007309,0.00023378526,0.024871802,0.00053412217,0.001256206,0.000011279852,0.000005637408,0.000022317314],"genre_scores_gemma":[0.9755564,0.008027292,0.010078888,0.0053900206,0.00087670423,0.000012323349,0.0000012347355,0.000030867894,0.000026319834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949893,0.0004296588,0.003611887,0.0003407337,0.00039868493,0.0002297402],"domain_scores_gemma":[0.9905978,0.003623538,0.0038111776,0.00029294004,0.001472915,0.00020166843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008658961,0.00019364042,0.0016799344,0.00009511261,0.00003825572,0.000010114255,0.00022776656,0.00029176736,0.000017029994],"category_scores_gemma":[0.006834338,0.0001206658,0.00030589747,0.00020648124,0.00015486132,0.0001867167,0.00006616033,0.00069502025,4.053522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019923,0.0009231138,0.8140448,0.00020080614,0.0012734734,0.0000028815841,0.0011969089,0.000011829637,0.00029970382,0.000004833951,0.00036734954,0.1617513],"study_design_scores_gemma":[0.020673241,0.015096272,0.95756257,0.0031472289,0.00053157925,0.00014774418,0.00089978107,0.00024278801,0.00049244164,0.000037119906,0.0010333842,0.00013584194],"about_ca_topic_score_codex":0.0005122319,"about_ca_topic_score_gemma":0.0013684594,"teacher_disagreement_score":0.16161546,"about_ca_system_score_codex":0.000061796556,"about_ca_system_score_gemma":0.00087574753,"threshold_uncertainty_score":0.8181835},"labels":[],"label_agreement":null},{"id":"W2981221787","doi":"10.1200/jco.2019.37.27_suppl.136","title":"Barriers to fertility preservation (FP) in a prospective pan-Canadian study of young women with breast cancer (YWBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; Mount Sinai Hospital; Health Sciences Centre; Sunnybrook Hospital; Women's College Hospital; CReATe Fertility Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Referral; Fertility preservation; Fertility; Breast cancer; Family medicine; Oncofertility; Gynecology; Cancer; Demography; Population; Internal medicine; Environmental health","score_opus":0.05682178690790654,"score_gpt":0.4202291544197904,"score_spread":0.36340736751188385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981221787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357986,0.000038843602,0.000003848959,0.0038193555,0.00047046106,0.0010998901,0.000008015499,0.000002985726,0.0009767208],"genre_scores_gemma":[0.99891746,0.000010649811,0.00008524564,0.000594258,0.00018950834,0.00003268596,3.552093e-7,0.000007606974,0.00016225941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724025,0.00057310244,0.0013784099,0.00031692986,0.0002298846,0.0002614395],"domain_scores_gemma":[0.9972227,0.0003218262,0.0006769745,0.00030149307,0.00087088195,0.0006061234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043233815,0.000110385845,0.0012117095,0.00016478027,0.000024811283,0.0000026552034,0.00014940591,0.00024499613,0.0003515993],"category_scores_gemma":[0.0032763174,0.000070865404,0.000078550554,0.00029268282,0.00014761412,0.00015736811,0.00003306402,0.00077200483,0.0000053373105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076088525,0.0012890485,0.91307086,0.000018445386,0.0002862378,0.000052993302,0.002377305,0.000022917726,0.00016089568,0.0000035834175,0.00005306281,0.0065761534],"study_design_scores_gemma":[0.005879968,0.021614762,0.96911776,0.000048078644,0.000068796675,0.000039073166,0.002597973,0.000010505117,0.000022146016,0.00012276937,0.00041455607,0.000063613974],"about_ca_topic_score_codex":0.011966698,"about_ca_topic_score_gemma":0.07691875,"teacher_disagreement_score":0.07020856,"about_ca_system_score_codex":0.0007677126,"about_ca_system_score_gemma":0.0036201722,"threshold_uncertainty_score":0.9946127},"labels":[],"label_agreement":null},{"id":"W2981254457","doi":"10.1200/jco.2007.25.18_suppl.10582","title":"Can we identify a group of breast cancer patients with a good prognosis despite four or more positive (4+) axillary nodes using a tissue microarray (TMA)?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Biomarker; Axillary lymph nodes; Immunohistochemistry; Proportional hazards model; Univariate analysis; Estrogen receptor; Tissue microarray; Stage (stratigraphy); Cancer; Pathology; Multivariate analysis","score_opus":0.04671597237235373,"score_gpt":0.4111796573106953,"score_spread":0.3644636849383415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981254457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958285,0.00094621134,0.00039942717,0.00195791,0.0004015747,0.00025740112,0.00015477408,0.0000033959536,0.000050804483],"genre_scores_gemma":[0.99260575,0.00063875347,0.005469082,0.0005679383,0.0006316854,0.000008173225,0.000012094293,0.00003273931,0.000033783293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974939,0.00019689757,0.0013572451,0.0003074026,0.00029969076,0.00034482536],"domain_scores_gemma":[0.99666274,0.00026443013,0.0018174774,0.0001594783,0.0008790678,0.00021679148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007664757,0.00023990363,0.0009491162,0.000096056676,0.00007347857,0.000009984417,0.00021756758,0.00034756586,0.000020202966],"category_scores_gemma":[0.00020984316,0.00015611247,0.00025952925,0.00017635307,0.00038312585,0.0000153624,0.00012250197,0.00029444302,5.327672e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01480719,0.0022286125,0.90106374,0.000051356492,0.0020267558,0.0002546764,0.00024709126,0.00001867313,0.013167663,0.000003873196,0.00015857951,0.06597176],"study_design_scores_gemma":[0.0063632117,0.0057110004,0.9767442,0.0002916216,0.00065027137,0.000451628,0.00025078183,0.0000021333312,0.007890848,0.000014902902,0.0014277882,0.00020161597],"about_ca_topic_score_codex":0.000296289,"about_ca_topic_score_gemma":0.0014888805,"teacher_disagreement_score":0.07568043,"about_ca_system_score_codex":0.00016004586,"about_ca_system_score_gemma":0.00078334555,"threshold_uncertainty_score":0.6366082},"labels":[],"label_agreement":null},{"id":"W2981289814","doi":"10.1200/jco.2019.37.27_suppl.194","title":"Performance of the patient reported CAPLET2.0 physical functioning assessment tool.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Physical therapy; Breast cancer; Genitourinary system; Disease; Internal medicine; Cancer","score_opus":0.4995544089956703,"score_gpt":0.5435481863713953,"score_spread":0.043993777375725074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981289814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97480726,0.000109175904,0.00016604878,0.012668182,0.004745499,0.0002836791,0.0000074126333,0.0000044848002,0.0072082635],"genre_scores_gemma":[0.9923033,0.000064694505,0.0018934758,0.0046082963,0.0007816068,0.0000058546375,9.865414e-7,0.000011983541,0.00032981415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98818547,0.0007210334,0.010469258,0.00022736948,0.00019304841,0.00020382265],"domain_scores_gemma":[0.9785006,0.0036012745,0.017096197,0.00041243443,0.00027309917,0.000116386866],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02823804,0.00010643343,0.0018938311,0.00010425641,0.00006873816,0.000012292095,0.0002812824,0.00019795037,0.00028734168],"category_scores_gemma":[0.008976993,0.00008523431,0.00051005126,0.00013771545,0.000107014486,0.00029617827,0.00007632743,0.00068253896,0.000164155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014073722,0.0006729706,0.9762412,0.0000932243,0.00023899948,0.0000022670768,0.00037113138,0.0019961172,0.000013229664,0.0074714366,0.0076891715,0.0050695655],"study_design_scores_gemma":[0.0017323301,0.003113222,0.8947718,0.00008957996,0.000031499403,0.000032956406,0.00030269942,0.011409173,0.000008294353,0.0016840011,0.08670386,0.000120557255],"about_ca_topic_score_codex":0.000048417944,"about_ca_topic_score_gemma":0.000007756203,"teacher_disagreement_score":0.08146932,"about_ca_system_score_codex":0.00040513955,"about_ca_system_score_gemma":0.0011881201,"threshold_uncertainty_score":0.9993708},"labels":[],"label_agreement":null},{"id":"W2981559551","doi":"10.1200/jco.2012.30.15_suppl.6548","title":"Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Etoposide; Gastroenterology; Salvage therapy; Cyclophosphamide; International Prognostic Index; Refractory (planetary science); Oncology; Urology; Chemotherapy; Surgery; Lymphoma","score_opus":0.10193094109642926,"score_gpt":0.44710194953217297,"score_spread":0.3451710084357437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981559551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97730833,0.00338276,0.00017282623,0.0077165994,0.007483945,0.00068852043,0.000010820164,0.000019637946,0.0032165379],"genre_scores_gemma":[0.97926867,0.002277815,0.0074086455,0.0051771016,0.005068917,0.000047936534,0.000015276733,0.000045849807,0.00068979413],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99545467,0.00031161858,0.00290564,0.00030214534,0.00047237254,0.0005535601],"domain_scores_gemma":[0.9879833,0.0045060962,0.0045990366,0.00034353285,0.0017104555,0.0008576188],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026949411,0.00029868828,0.0020683117,0.00018982847,0.000111344794,0.000013982512,0.00016286912,0.0008060073,0.00013104452],"category_scores_gemma":[0.0094327675,0.00020502292,0.0011301195,0.00016405775,0.00022946576,0.00034900475,0.00006238399,0.0005509201,0.00008980893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016042944,0.008883068,0.24116786,0.00007188544,0.0018981537,0.0016066039,0.0005352924,0.000010453625,0.00053760887,0.0004539448,0.092138976,0.63665324],"study_design_scores_gemma":[0.033491004,0.022713713,0.74679035,0.00037638878,0.0015534349,0.0024350556,0.0004810815,0.000040204617,0.00194171,0.0004242275,0.18952262,0.0002302215],"about_ca_topic_score_codex":0.000038406233,"about_ca_topic_score_gemma":0.000009779677,"teacher_disagreement_score":0.636423,"about_ca_system_score_codex":0.0007493118,"about_ca_system_score_gemma":0.0016424158,"threshold_uncertainty_score":0.9989112},"labels":[],"label_agreement":null},{"id":"W2981596283","doi":"10.1200/jco.2009.27.15_suppl.e17567","title":"The geography of ASCO Annual Meetings: Nationality of abstracts and recent trends","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multinational corporation; Nationality; Medicine; China; Demography; Family medicine; Library science; Geography; Political science; Immigration; Sociology; Law","score_opus":0.2521881393282255,"score_gpt":0.6042519960027785,"score_spread":0.352063856674553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981596283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7982763,0.00078292406,0.000013676906,0.09021328,0.0004998564,0.000105031766,0.000007573973,0.0000077816485,0.11009359],"genre_scores_gemma":[0.993567,0.004094956,0.0016835487,0.00026480135,0.00030666636,6.006917e-7,1.560076e-7,0.0000019098832,0.00008038178],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956463,0.0010894124,0.0018835593,0.000089783796,0.001111765,0.00017917818],"domain_scores_gemma":[0.9887863,0.006893797,0.002042825,0.0000977894,0.0020139485,0.00016536783],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032849975,0.00004976766,0.000466606,0.00010946463,0.000108512286,0.000010604732,0.00039688835,0.00027283744,0.000045694178],"category_scores_gemma":[0.022099478,0.000032533088,0.00021370823,0.00031216862,0.001105619,0.00011613068,0.00003670209,0.0005911995,3.9667958e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005906922,0.0007637454,0.03378504,0.0000040139275,0.00007364263,0.000014748196,0.00062768324,0.0000053579947,0.000042587664,0.0062324353,0.011716708,0.9461433],"study_design_scores_gemma":[0.00046950308,0.0019397356,0.68756527,0.000018032439,0.000018382714,0.0000044842395,0.00054760807,0.0000014439058,0.000059875816,0.015821494,0.29352322,0.00003096155],"about_ca_topic_score_codex":0.00019783707,"about_ca_topic_score_gemma":0.0003849012,"teacher_disagreement_score":0.9461124,"about_ca_system_score_codex":0.00007465631,"about_ca_system_score_gemma":0.0014531121,"threshold_uncertainty_score":0.9958845},"labels":[],"label_agreement":null},{"id":"W2981761085","doi":"10.1200/jco.2013.31.15_suppl.e14686","title":"The impact of multidisciplinary cancer conferences (MCC) on the treatment of metastatic rectal cancer (MRC) at the Ottawa Hospital Cancer Centre (TOHCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Radiation therapy; Cancer; Chemotherapy; Colorectal cancer; Oncology; Surgery; Internal medicine","score_opus":0.12749414835558057,"score_gpt":0.49420997586498006,"score_spread":0.36671582750939946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981761085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95600575,0.0068772715,7.342382e-7,0.032716036,0.0016102357,0.0011350252,0.000100759215,0.0000056626354,0.0015485077],"genre_scores_gemma":[0.978482,0.019029338,0.000044951634,0.00019695645,0.0006275445,0.00020127335,0.0000025017623,0.000024025927,0.0013913895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547315,0.000953225,0.0022029919,0.0002762252,0.0006620304,0.0004323527],"domain_scores_gemma":[0.98550385,0.010051146,0.002895456,0.00040046248,0.00082257926,0.0003265119],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011797462,0.0003285479,0.0018132421,0.00005790257,0.0001871455,0.000015822337,0.0003744888,0.00019458255,0.0035581477],"category_scores_gemma":[0.0009097047,0.000110347195,0.0014250533,0.00024034033,0.0010731211,0.00008315484,0.00008887536,0.00058076734,0.00001727971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008696773,0.0057076695,0.63953584,0.00002838668,0.00685832,0.00013370893,0.0014931399,0.00042042567,0.00024247689,0.0000730162,0.011489073,0.32532117],"study_design_scores_gemma":[0.00787767,0.037569482,0.93782437,0.00028695143,0.0013751315,0.00003871187,0.001017285,0.0004039205,0.0010384661,0.00031991582,0.012096856,0.00015123066],"about_ca_topic_score_codex":0.010683955,"about_ca_topic_score_gemma":0.007249702,"teacher_disagreement_score":0.32516992,"about_ca_system_score_codex":0.0014420702,"about_ca_system_score_gemma":0.0032878655,"threshold_uncertainty_score":0.9973527},"labels":[],"label_agreement":null},{"id":"W2982569105","doi":"10.1200/jco.2009.27.15_suppl.e16523","title":"Dysgerminoma of the ovary 35 years on: A single institutional experience","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Dysgerminoma; Etoposide; Stage (stratigraphy); Surgery; Gynecology; Chemotherapy; Internal medicine; Ovary","score_opus":0.18146171759083105,"score_gpt":0.4757151947880696,"score_spread":0.2942534771972386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982569105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768724,0.000281431,0.0000125253355,0.0138182,0.0011092768,0.00009118323,0.0000017092636,0.0000024318376,0.0078108325],"genre_scores_gemma":[0.99207574,0.00013041121,0.001128654,0.0058620977,0.0007044666,0.0000014540424,2.6555418e-7,0.0000029251707,0.000094009796],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99839187,0.00010194942,0.0010174632,0.00009777226,0.00029226468,0.00009865622],"domain_scores_gemma":[0.99833393,0.000508257,0.0007386237,0.00016421001,0.00012024875,0.00013473883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004898213,0.00006424658,0.00057737605,0.00004188146,0.000024454524,0.0000027741362,0.00012197418,0.00013499937,0.000115803516],"category_scores_gemma":[0.000790621,0.000036331305,0.00036278737,0.00009851329,0.00021666048,0.000043879027,0.000017712617,0.0003368157,0.000006574464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003669435,0.014826871,0.17926866,0.000011340012,0.00033267456,0.002087312,0.0004995673,0.000061252074,0.0007232342,0.004950541,0.007995524,0.7855736],"study_design_scores_gemma":[0.0036151232,0.0122301215,0.91625136,0.00014500295,0.00010439075,0.00035545308,0.00003127492,0.000005429756,0.00050796114,0.0004006122,0.06632084,0.000032409764],"about_ca_topic_score_codex":0.0000035994653,"about_ca_topic_score_gemma":0.0000022919987,"teacher_disagreement_score":0.7855412,"about_ca_system_score_codex":0.00014005153,"about_ca_system_score_gemma":0.0010972251,"threshold_uncertainty_score":0.19464304},"labels":[],"label_agreement":null},{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","score_opus":0.13532950797617835,"score_gpt":0.49091004164502033,"score_spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983284890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931742,0.0019878151,0.000002274912,0.0010518968,0.0016095774,0.0017698791,0.000030025843,0.000011322877,0.0003630102],"genre_scores_gemma":[0.99657595,0.0017529853,0.0006027542,0.0005501934,0.00015036597,0.00003017022,0.0000071782115,0.000027813161,0.00030257864],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9936345,0.0009558199,0.004162657,0.00042427346,0.00046302634,0.00035970582],"domain_scores_gemma":[0.99492556,0.0013984713,0.0025915534,0.0004199415,0.00040956933,0.00025491609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003820299,0.00027674585,0.0029881997,0.00025145826,0.000056778706,0.000015084491,0.0003741621,0.0002678471,0.0004275306],"category_scores_gemma":[0.000507247,0.00018949957,0.00048947334,0.00040988703,0.0002532552,0.00018825477,0.00013887882,0.0007231069,0.000008112178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30828568,0.27554083,0.109711416,0.0001365581,0.0032452112,0.00075984723,0.003551851,0.000030292704,0.030067269,0.000016059486,0.00036786028,0.26828712],"study_design_scores_gemma":[0.391169,0.46919036,0.0983146,0.0003664415,0.0011430394,0.00025912223,0.0023708676,0.00018207573,0.00162534,0.00004792332,0.03506525,0.00026599792],"about_ca_topic_score_codex":0.0019762977,"about_ca_topic_score_gemma":0.0015043253,"teacher_disagreement_score":0.26802114,"about_ca_system_score_codex":0.00097004947,"about_ca_system_score_gemma":0.0031735327,"threshold_uncertainty_score":0.7727568},"labels":[],"label_agreement":null},{"id":"W2984359187","doi":"10.1200/jco.19.02105","title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; DNA mismatch repair; Phases of clinical research; Gastroenterology; Immunotherapy; Toxicity; Clinical trial; Colorectal cancer","score_opus":0.05014804818147979,"score_gpt":0.40843849878294725,"score_spread":0.35829045060146747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984359187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933583,0.00026665296,0.0000025006925,0.0015375016,0.002451107,0.0018644328,0.00009989101,0.000013877851,0.00040573368],"genre_scores_gemma":[0.9978804,0.00011757981,0.0008676644,0.00059049757,0.00041343036,0.000010784913,0.000014916809,0.000032239797,0.00007250044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929946,0.0009657486,0.0042018774,0.0005489761,0.0008981131,0.00039068318],"domain_scores_gemma":[0.98959166,0.005573061,0.0028536823,0.0007330751,0.0009717714,0.00027676986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037008524,0.0002898436,0.0023017868,0.00013539653,0.00005176086,0.00000864569,0.00044979225,0.00040385753,0.0002131111],"category_scores_gemma":[0.0040122913,0.00016528806,0.00048191095,0.0004384656,0.00039941672,0.00008133762,0.00021788407,0.0015911255,0.000010847059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26821867,0.022170497,0.67979044,0.000021255077,0.0004554187,0.000072464856,0.0020560848,0.00031213064,0.00019400826,0.0000023611492,0.0004281314,0.026278546],"study_design_scores_gemma":[0.1083497,0.1363562,0.7496374,0.00019452718,0.00037412453,0.000008612674,0.00037237088,0.000048147373,0.00022652805,0.000021744721,0.0042790365,0.00013160045],"about_ca_topic_score_codex":0.0009471729,"about_ca_topic_score_gemma":0.00094933604,"teacher_disagreement_score":0.15986896,"about_ca_system_score_codex":0.00068016007,"about_ca_system_score_gemma":0.0028190443,"threshold_uncertainty_score":0.6912737},"labels":[],"label_agreement":null},{"id":"W2984671704","doi":"10.1200/jco.2009.27.15_suppl.7027","title":"Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Regimen; Phases of clinical research; Clinical trial","score_opus":0.1223123378830397,"score_gpt":0.4804999839927469,"score_spread":0.3581876461097072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984671704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903055,0.0005224082,0.000031951167,0.0053931023,0.0018443431,0.001532944,0.00016121997,0.000041939773,0.00016661244],"genre_scores_gemma":[0.98684937,0.00052490144,0.003931527,0.0033750425,0.004612056,0.000012186759,0.00028848933,0.00006775493,0.00033865636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99022704,0.00089706486,0.0058632204,0.0010299196,0.001122271,0.00086047215],"domain_scores_gemma":[0.99199486,0.0020578464,0.00258526,0.0014441656,0.0005016942,0.0014162041],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034783506,0.000581573,0.0034773555,0.00048723022,0.00014964466,0.000040843533,0.0009920541,0.00066897715,0.0009910151],"category_scores_gemma":[0.008325221,0.00037820172,0.0003959731,0.0006344304,0.00018620184,0.00049659895,0.00038881565,0.0020914027,0.0000470885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.55924004,0.014235483,0.0007025861,0.00003259164,0.0003862515,0.024005627,0.00041925535,0.00015389943,0.0029337264,0.0000044621656,0.0044082557,0.3934778],"study_design_scores_gemma":[0.5813718,0.3556069,0.016001403,0.0011459826,0.0011157125,0.00059991656,0.0001504178,0.003106364,0.00084740657,0.000065049964,0.039442692,0.00054636376],"about_ca_topic_score_codex":0.000738582,"about_ca_topic_score_gemma":0.0041550207,"teacher_disagreement_score":0.39293143,"about_ca_system_score_codex":0.008788622,"about_ca_system_score_gemma":0.014660254,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W2984927918","doi":"10.1200/jco.19.00172","title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":772,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Seagen (Canada); Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Exelixis; Karyopharm Therapeutics; MEI Pharma; Astex Pharmaceuticals; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Kite Pharma; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bendamustine; Rituximab; Neutropenia; Hazard ratio; Cohort; Diffuse large B-cell lymphoma; Transplantation; Gastroenterology; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval","score_opus":0.06801833353446632,"score_gpt":0.4233675724693748,"score_spread":0.35534923893490844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984927918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854438,0.000961564,0.0000023062526,0.0025989204,0.0016429778,0.00025290166,0.0000030704955,0.000009594343,0.009084875],"genre_scores_gemma":[0.99163026,0.0011456998,0.00088317686,0.0035050602,0.00057392713,0.000004158208,0.0000029816279,0.000022834893,0.002231885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963262,0.00040227684,0.0023353614,0.00023908592,0.0003661171,0.000330931],"domain_scores_gemma":[0.99468195,0.0030312282,0.0013936557,0.00031004418,0.00017859944,0.00040454525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017713167,0.00017240981,0.0017128628,0.00018949642,0.000020920208,0.000007734182,0.00016369819,0.0005401575,0.0004663332],"category_scores_gemma":[0.0019155804,0.00010375655,0.00053082674,0.00016730915,0.00006186616,0.00008588007,0.00006375115,0.00054569816,0.0003472771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018400589,0.093996525,0.7667812,0.0000669388,0.0003347149,0.007812946,0.00025291607,0.000002027659,0.000243529,0.0001855405,0.008129993,0.103793055],"study_design_scores_gemma":[0.1362647,0.020747615,0.6246415,0.0001577057,0.0001967162,0.0003366221,0.0001754876,0.00006541247,0.000101312595,0.00006105538,0.21715072,0.000101167614],"about_ca_topic_score_codex":0.00003192472,"about_ca_topic_score_gemma":0.00007299961,"teacher_disagreement_score":0.20902072,"about_ca_system_score_codex":0.00069380074,"about_ca_system_score_gemma":0.0027758006,"threshold_uncertainty_score":0.5106022},"labels":[],"label_agreement":null},{"id":"W2986063948","doi":"10.1200/jco.19.01382","title":"Long-Term Mental Health Outcomes in Mothers and Siblings of Children With Cancer: A Population-Based, Matched Cohort Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Addiction and Mental Health; Institute for Clinical Evaluative Sciences; Hospital for Sick Children; Public Health Ontario; Pediatric Oncology Group; University of Toronto","funders":"","keywords":"Medicine; Sibling; Population; Mental health; Cohort; Cancer registry; Psychiatry; Cancer; Socioeconomic status; Pediatrics; Environmental health; Psychology; Internal medicine","score_opus":0.06113520221668656,"score_gpt":0.4721090524822765,"score_spread":0.41097385026558997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986063948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814324,0.0002941718,0.000009506589,0.016693892,0.0003835694,0.0011418536,0.000009360788,0.000006269926,0.000029017912],"genre_scores_gemma":[0.9948748,0.0002060843,0.00059372047,0.0040927026,0.00016014684,0.000004955995,0.000005760424,0.000019986506,0.000041843454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960954,0.0004817954,0.0024333287,0.00022956473,0.0005679413,0.00019196782],"domain_scores_gemma":[0.996197,0.0008430774,0.0023586794,0.00020358682,0.00013156638,0.00026612726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004088817,0.00014643041,0.0023593653,0.00020982121,0.000019691912,0.0000055805563,0.000121273864,0.00014232962,0.000096676886],"category_scores_gemma":[0.00035715182,0.00010182935,0.00017971681,0.00016120127,0.00009639858,0.00008280283,0.000029791816,0.0006011318,0.0000014506793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027784726,0.002615403,0.9883666,0.000065525666,0.0006363853,0.00001448442,0.0007606021,0.00004422069,0.0000022174543,0.0000023114371,0.0000719173,0.004641858],"study_design_scores_gemma":[0.018070718,0.013801105,0.9671034,0.0002970255,0.00015086244,0.000041393523,0.00040390686,0.000019173305,0.0000026481953,0.0000075555663,0.000016660166,0.0000855219],"about_ca_topic_score_codex":0.004010089,"about_ca_topic_score_gemma":0.007115999,"teacher_disagreement_score":0.021263175,"about_ca_system_score_codex":0.0002508186,"about_ca_system_score_gemma":0.0015738216,"threshold_uncertainty_score":0.6062082},"labels":[],"label_agreement":null},{"id":"W2989421973","doi":"10.1200/jco.19.01907","title":"Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; University of Toronto; McGill University Health Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Congressionally Directed Medical Research Programs; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research; Všeobecná Fakultní Nemocnice v Praze; Uppsala Universitet; Medical Research Council; lékařská fakulta Univerzity Karlovy; Manchester Biomedical Research Centre; National Institutes of Health; Direction Générale de l’offre de Soins; National Institute for Health and Care Research; Vlaamse regering; Sahlgrenska Universitetssjukhuset; Lietuvos Mokslo Taryba; National Health and Medical Research Council; Oulun Yliopisto; Universiti Malaya; National Cancer Institute; Ministerstvo Zdravotnictví Ceské Republiky; Kuopion Yliopistollinen Sairaala; National Medical Research Council; NIH Office of the Director; University of Toronto; Ministero dell’Istruzione, dell’Università e della Ricerca; Lunds Universitet; Ministero della Salute; Cancer Australia; National Breast Cancer Foundation; National Institute on Minority Health and Health Disparities; European Commission; Akademiska Sjukhuset; Academy of Finland; Univerzita Karlova v Praze; Breast Cancer Research Foundation; Government of Canada; University of Cambridge; Fondation du cancer du sein du Québec; Wellcome Trust; Cancer Research UK; Myriad Genetics; Dipartimenti di Eccellenza; Institut National Du Cancer; Yayasan Sime Darby; Susan G. Komen; Associazione Italiana per la Ricerca sul Cancro; Genome Canada; Itä-Suomen Yliopisto; University of Miami","keywords":"PALB2; Medicine; Germline; Cancer; Germline mutation; Genetics; Oncology; Internal medicine; Mutation; Gene; Biology","score_opus":0.08842016761594139,"score_gpt":0.4625440728670899,"score_spread":0.37412390525114847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989421973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960695,0.00027766402,0.00010601579,0.00030006218,0.0020357328,0.00019569953,0.00002897467,0.0000032658847,0.0009831033],"genre_scores_gemma":[0.996861,0.0006726959,0.00083826465,0.000560799,0.0007842527,0.000009370133,0.000018002866,0.000021255002,0.00023437709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731946,0.0004922828,0.0014235461,0.00026598686,0.0003405743,0.00015812767],"domain_scores_gemma":[0.99648654,0.0002454391,0.0018898265,0.00029335142,0.0009452886,0.00013957535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016069051,0.00013264352,0.00065986585,0.000086920045,0.00002499566,0.000009684,0.00046610285,0.0003274611,0.00013227496],"category_scores_gemma":[0.0010562966,0.000100330515,0.00018373513,0.00012174003,0.00014853575,0.000019600975,0.00009110059,0.0004007311,0.000003589741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039808284,0.005281748,0.9265454,0.0000088617335,0.002778893,0.000051941333,0.00049802556,0.004434209,0.019334104,0.000026247459,0.0010343507,0.03602543],"study_design_scores_gemma":[0.0133936955,0.037085023,0.9233574,0.000061912004,0.00040680516,0.00006190571,0.0022834481,0.00031542176,0.0011577115,0.00007834821,0.021530919,0.00026738754],"about_ca_topic_score_codex":0.000053187603,"about_ca_topic_score_gemma":0.00056788744,"teacher_disagreement_score":0.035758045,"about_ca_system_score_codex":0.00010612607,"about_ca_system_score_gemma":0.0019549776,"threshold_uncertainty_score":0.40913597},"labels":[],"label_agreement":null},{"id":"W2989569227","doi":"10.1200/jco.2019.37.31_suppl.53","title":"Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Confidence interval; Palliative care; Tertiary care; Odds ratio; Cancer; Internal medicine; Anorexia; Distress","score_opus":0.18966072096250805,"score_gpt":0.527298057180123,"score_spread":0.33763733621761494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989569227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964473,0.001191335,0.0000043733385,0.0011874945,0.0003895274,0.0001830866,0.000080464844,8.130411e-7,0.0005156014],"genre_scores_gemma":[0.9895848,0.0093210405,0.0001854729,0.0005873789,0.00026098738,0.0000017265602,0.000009494359,0.0000069349585,0.000042148324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976843,0.0002892856,0.0015431262,0.00009592288,0.00026984705,0.000117541764],"domain_scores_gemma":[0.9956107,0.0017053576,0.0017521395,0.00012628293,0.0007241038,0.00008139813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057713577,0.00009450804,0.0012648728,0.000079037534,0.0000073125484,0.0000015724121,0.00014967675,0.00018092776,0.00003495738],"category_scores_gemma":[0.00093871856,0.00005529537,0.0001860412,0.0000765407,0.00018099097,0.000048663274,0.00005160996,0.0004471511,9.217645e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016209241,0.00032147265,0.96180785,0.00016559911,0.00034495938,0.00004528617,0.0050435355,8.6974694e-7,0.000063170985,0.000011129944,0.0001115854,0.030463623],"study_design_scores_gemma":[0.0053453124,0.0046214815,0.9702303,0.0013166912,0.00028961297,0.0000021239011,0.0016094754,0.000016145244,0.00011645344,0.000021885906,0.016385583,0.000044954697],"about_ca_topic_score_codex":0.000071775015,"about_ca_topic_score_gemma":0.00004107841,"teacher_disagreement_score":0.030418668,"about_ca_system_score_codex":0.000043554843,"about_ca_system_score_gemma":0.000361233,"threshold_uncertainty_score":0.22548798},"labels":[],"label_agreement":null},{"id":"W2989569936","doi":"10.1200/jco.2019.37.31_suppl.27","title":"A prototype mobile application to improve communication about symptom management.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Education and Validation","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Usability; Distress; Quality of life (healthcare); Population; Fast track; Intervention (counseling); Emergency department; Physical therapy; Psychiatry; Nursing; Clinical psychology; Surgery","score_opus":0.11867391456795587,"score_gpt":0.572145106957478,"score_spread":0.45347119238952216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989569936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83064914,0.0001241759,0.0019283317,0.03486131,0.0048960485,0.0043789526,0.0000017353738,0.000035387264,0.123124935],"genre_scores_gemma":[0.9866472,0.0006644807,0.0049559716,0.0036722024,0.00067679724,0.00016719359,0.000002875129,0.000007749101,0.0032055501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972123,0.00091056194,0.0012771379,0.00012843555,0.0003023783,0.00016922233],"domain_scores_gemma":[0.99683964,0.00097055297,0.0011622552,0.0002515113,0.00047999487,0.00029606538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008279057,0.00005441276,0.00035012106,0.00009814843,0.0001194118,0.00002542458,0.00038460197,0.0002088482,0.00030742201],"category_scores_gemma":[0.00096172997,0.000047952148,0.00010994691,0.00024438716,0.00007249679,0.00019926435,0.000039373557,0.0003418561,0.0005691704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004416344,0.00091177045,0.033271212,0.000042389507,0.000053782012,0.0000010148443,0.004535073,0.000044191787,0.00006349102,0.03628467,0.008512243,0.91583854],"study_design_scores_gemma":[0.00068671483,0.001263742,0.06294426,0.000024662999,0.000019500705,7.1532463e-7,0.0017786135,0.00003759624,0.0000060662223,0.00091808743,0.9322674,0.000052639],"about_ca_topic_score_codex":0.00014684838,"about_ca_topic_score_gemma":0.00012273427,"teacher_disagreement_score":0.92375517,"about_ca_system_score_codex":0.00022306172,"about_ca_system_score_gemma":0.001101606,"threshold_uncertainty_score":0.7315724},"labels":[],"label_agreement":null},{"id":"W2989619070","doi":"10.1200/jco.2019.37.31_suppl.39","title":"Four-year overview of enrollment and participation in research studies conducted at the Prostate Cancer Supportive Care (PCSC) Program.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Family medicine; Referral; Prostate cancer; Observational study; Cancer; Physical therapy; Internal medicine","score_opus":0.86258930804316,"score_gpt":0.7547647075826633,"score_spread":0.10782460046049669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989619070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96605235,0.0038059775,4.6383124e-7,0.02815072,0.0005026295,0.0013049669,0.000006690202,0.0000030701594,0.00017312584],"genre_scores_gemma":[0.9866371,0.011358021,0.0005887544,0.0009677966,0.00020314608,0.000050894323,0.000005150819,0.0000103112425,0.00017878947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371195,0.0017010277,0.003530794,0.00019272463,0.00062581646,0.00023769135],"domain_scores_gemma":[0.98448217,0.010644068,0.0021282416,0.00018078522,0.0024217505,0.00014298323],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013078738,0.00009060103,0.0010640677,0.0001029351,0.000035231235,0.0000060947013,0.00008614821,0.00014866443,0.00023052703],"category_scores_gemma":[0.02245507,0.00005215751,0.00015020951,0.00025165678,0.00039782922,0.0001401073,0.00015916968,0.0009333953,0.000010175677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006391195,0.0008166187,0.7580769,0.00026874096,0.00037179847,0.00006325429,0.0023384194,0.000021327227,0.0002931478,0.00004398631,0.0025656368,0.22874895],"study_design_scores_gemma":[0.012392137,0.019186102,0.9141132,0.00040985006,0.0003934985,0.000030357443,0.014465107,0.00006545087,0.00021931439,0.00032428582,0.038332585,0.00006806761],"about_ca_topic_score_codex":0.00019165328,"about_ca_topic_score_gemma":0.0017897156,"teacher_disagreement_score":0.22868088,"about_ca_system_score_codex":0.00036045004,"about_ca_system_score_gemma":0.0015710618,"threshold_uncertainty_score":0.9857792},"labels":[],"label_agreement":null},{"id":"W2989620365","doi":"10.1200/jco.2019.37.31_suppl.141","title":"Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Health and Risk Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anxiety; Teachable moment; Depression (economics); Mental health; Logistic regression; Quality of life (healthcare); Psychiatry; Clinical psychology; Internal medicine; Psychology","score_opus":0.039313171160273414,"score_gpt":0.4785345088116123,"score_spread":0.43922133765133886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989620365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838424,0.00035962003,0.0000047402827,0.00014335204,0.0006427021,0.00017529739,0.000013254423,0.0000017404864,0.00027505783],"genre_scores_gemma":[0.9948115,0.0045846705,0.00016191028,0.00013498256,0.0002636645,8.9931865e-7,0.0000021999347,0.000007760695,0.000032451157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980436,0.0002050224,0.0012425839,0.000103976534,0.00028640826,0.00011840843],"domain_scores_gemma":[0.9976678,0.00047385244,0.0009983848,0.0001509374,0.00039152242,0.00031751904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010642477,0.00007460868,0.001117504,0.000090328904,0.00001412065,9.281087e-7,0.00004902115,0.00028021945,0.00023103025],"category_scores_gemma":[0.00070966105,0.00004319849,0.0008186904,0.00006523215,0.00009659701,0.000042014948,0.00002292877,0.00054604025,0.0000033099589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016462969,0.0011610037,0.90988094,0.000037165755,0.00016063525,0.000004224189,0.000079493126,0.000023313882,0.00032253918,0.0000010003141,0.00054247805,0.08614091],"study_design_scores_gemma":[0.005392123,0.012189352,0.9800605,0.00014956082,0.00033742917,0.00003362947,0.000038415066,0.000009022939,0.00004382314,0.0000036714353,0.0017067823,0.000035664925],"about_ca_topic_score_codex":0.000224158,"about_ca_topic_score_gemma":0.000016038462,"teacher_disagreement_score":0.08610525,"about_ca_system_score_codex":0.00008735628,"about_ca_system_score_gemma":0.0009581177,"threshold_uncertainty_score":0.25296193},"labels":[],"label_agreement":null},{"id":"W2989644539","doi":"10.1200/jco.2019.37.31_suppl.4","title":"Timing is everything: Improving the frequency, timeliness, and effectiveness of goals of care conversations for oncology patients in Manitoba.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Advance care planning; Curriculum; Referral; Exact test; Documentation; Conversation; Family medicine; Palliative care; Internal medicine; Nursing; Psychology","score_opus":0.2359460379876279,"score_gpt":0.5357218496633563,"score_spread":0.2997758116757284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989644539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462646,0.00017840188,0.00041650533,0.0025311676,0.0010522775,0.0010072673,0.000018888468,0.0000022843944,0.00016674866],"genre_scores_gemma":[0.9919694,0.0001501301,0.0065582716,0.0010597141,0.00022374568,0.000007685702,0.000012295037,0.000013192977,0.000005563943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947319,0.0008999254,0.0037636145,0.00017981888,0.00027406932,0.00015065417],"domain_scores_gemma":[0.96380484,0.030320426,0.003757977,0.00018329638,0.0018409916,0.00009249487],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008382451,0.000106655985,0.0013602973,0.00012717208,0.000025312935,0.0000037032476,0.00014117446,0.00032004542,0.000040215622],"category_scores_gemma":[0.02691073,0.0000729149,0.0002816506,0.00012968718,0.00018344597,0.00019502756,0.00007519299,0.00060167315,0.0000024272545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004988286,0.00076180213,0.8995457,0.0005569783,0.00018728587,0.000008174722,0.0005448781,0.000027391772,0.0011872279,0.000091027294,0.00018560087,0.09191564],"study_design_scores_gemma":[0.021877395,0.019435534,0.9493507,0.00039438435,0.00074381544,0.00003174239,0.0038726465,0.00072397414,0.0006568027,0.0007744372,0.0020471856,0.0000913406],"about_ca_topic_score_codex":0.00041119623,"about_ca_topic_score_gemma":0.00029650072,"teacher_disagreement_score":0.09182429,"about_ca_system_score_codex":0.00023785091,"about_ca_system_score_gemma":0.0017709748,"threshold_uncertainty_score":0.981286},"labels":[],"label_agreement":null},{"id":"W2989768237","doi":"10.1200/jco.2009.27.15_suppl.6594","title":"Direct and indirect economic evaluation of upfront and sequential adjuvant treatment in postmenopausal women with breast cancer based on the BIG 1–98 trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Letrozole; Breast cancer; Tamoxifen; Economic evaluation; Clinical trial; Adverse effect; Time horizon; Relative risk; Oncology; Internal medicine; Cancer; Finance; Confidence interval; Economics","score_opus":0.5046445275212649,"score_gpt":0.5332362237312084,"score_spread":0.028591696209943507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989768237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965878,0.00078593235,0.000012570369,0.030502386,0.0007276574,0.0007629388,0.00009682406,0.0000030020965,0.0012306828],"genre_scores_gemma":[0.99517566,0.00048146694,0.0001658344,0.0033656766,0.00072541536,0.000052512783,0.0000018508166,0.0000103348975,0.000021272303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9925552,0.0017393302,0.0050265007,0.00030108995,0.00014232598,0.00023553225],"domain_scores_gemma":[0.99068344,0.003571367,0.0052577783,0.00019330451,0.00010701956,0.00018709847],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.043750737,0.00015591751,0.002024347,0.00027367793,0.000052827167,0.000022567552,0.00012128067,0.00019645109,0.00022933022],"category_scores_gemma":[0.0019785594,0.00011157398,0.00009079047,0.00006914477,0.00013962723,0.00014959187,0.000012250965,0.0002424083,0.000009055972],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14385541,0.0075674863,0.3453079,0.00012378278,0.0018195071,0.000041718384,0.0055614617,0.015475836,0.000030259464,0.005061854,0.0031384686,0.4720163],"study_design_scores_gemma":[0.059985545,0.024586502,0.8997826,0.00010920728,0.00011279404,0.00002416559,0.00039909923,0.00958364,0.000007543663,0.0024777066,0.0027337845,0.0001974309],"about_ca_topic_score_codex":0.0006011901,"about_ca_topic_score_gemma":0.0010291786,"teacher_disagreement_score":0.5544747,"about_ca_system_score_codex":0.0018167451,"about_ca_system_score_gemma":0.002433403,"threshold_uncertainty_score":0.98465985},"labels":[],"label_agreement":null},{"id":"W2989878039","doi":"10.1200/jco.2019.37.31_suppl.71","title":"Understanding of palliative care among members of the public.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Referral; Reading (process); Palliative care; Test (biology); Family medicine; Public health; Quality of life (healthcare); Nursing; Law","score_opus":0.603688968366755,"score_gpt":0.5682839398920376,"score_spread":0.03540502847471738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989878039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746219,0.000913538,0.00015097612,0.002611134,0.001249964,0.00015283964,0.000005701995,0.0000021236467,0.020291835],"genre_scores_gemma":[0.9975719,0.0008141506,0.00093282224,0.0002977652,0.0002170114,4.168633e-7,8.918701e-7,0.000008612809,0.000156432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718344,0.0003318867,0.001812174,0.00009954677,0.00043345647,0.00013949204],"domain_scores_gemma":[0.99249905,0.0033362713,0.0029562693,0.00019655502,0.00087136,0.00014050257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014075071,0.00009024131,0.0013768584,0.00009765855,0.000014828183,0.0000018057516,0.00021575324,0.00027245813,0.00019007814],"category_scores_gemma":[0.005037825,0.00005183218,0.0006317271,0.00019521461,0.00047053825,0.000078471974,0.000063720785,0.0005896201,0.0000020015245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066468096,0.00023564322,0.9921982,0.00014454036,0.00048492022,0.000018381663,0.0017575789,0.000024082225,0.00021304534,0.0013178822,0.0013028696,0.0016381231],"study_design_scores_gemma":[0.010218083,0.010496344,0.88983494,0.0023317994,0.00072336313,0.0000110684805,0.033139702,0.000097750126,0.0029559177,0.0012034479,0.048857987,0.00012957651],"about_ca_topic_score_codex":0.000026664069,"about_ca_topic_score_gemma":0.00008359164,"teacher_disagreement_score":0.10236329,"about_ca_system_score_codex":0.000204117,"about_ca_system_score_gemma":0.0010416585,"threshold_uncertainty_score":0.6031111},"labels":[],"label_agreement":null},{"id":"W2989979018","doi":"10.1200/jco.2019.37.31_suppl.108","title":"Evaluating patient out-of-pocket (OOP) costs associated with attendance at a prostate cancer supportive care program.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Attendance; Prostate cancer; Family medicine; Gerontology; Physical therapy; Cancer; Internal medicine","score_opus":0.5690260150260753,"score_gpt":0.6023355934126317,"score_spread":0.03330957838655635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989979018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824786,0.0021058596,0.00002042003,0.009146732,0.002608092,0.0013565416,0.00027169663,0.000014243699,0.001997773],"genre_scores_gemma":[0.98992264,0.00021230799,0.0035381373,0.0052978643,0.00036251146,0.000087197404,0.000021964695,0.00003824392,0.00051913096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98627025,0.0013323769,0.011188992,0.00045021088,0.0003004616,0.00045769624],"domain_scores_gemma":[0.969007,0.004881735,0.024375482,0.00031190063,0.0011007378,0.0003231586],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025250088,0.00021128225,0.003081984,0.00018028042,0.00008195705,0.00002084884,0.00029398093,0.00036757058,0.00064305234],"category_scores_gemma":[0.0156724,0.00019287785,0.0003806243,0.00017688413,0.00018683691,0.00032435366,0.00009156967,0.00067163137,0.00023790488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010178882,0.0008726811,0.9473021,0.00023650628,0.00063546404,0.000016797752,0.0060419943,0.00057797134,0.0000059910403,0.00034072972,0.006410199,0.036541667],"study_design_scores_gemma":[0.015761126,0.04058287,0.84161377,0.0015583361,0.00019886009,0.000024621555,0.007732992,0.0032503568,0.000037183043,0.000981349,0.08749316,0.00076536473],"about_ca_topic_score_codex":0.00021245422,"about_ca_topic_score_gemma":0.0012637688,"teacher_disagreement_score":0.105688326,"about_ca_system_score_codex":0.0023452425,"about_ca_system_score_gemma":0.0022328123,"threshold_uncertainty_score":0.99261904},"labels":[],"label_agreement":null},{"id":"W2990001733","doi":"10.1200/jco.2019.37.31_suppl.104","title":"Age-related differences in cannabis use by cancer patients referred for supportive care.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cannabis; Anxiety; Depression (economics); Nausea; Young adult; Cancer; Psychiatry; Internal medicine","score_opus":0.10931778602255135,"score_gpt":0.4748538883453778,"score_spread":0.3655361023228264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990001733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831778,0.00045342234,0.0000026036123,0.013238672,0.0018470074,0.0006512322,0.000054475415,0.0000046158125,0.00057018665],"genre_scores_gemma":[0.98469466,0.00045693276,0.00007429822,0.0009390871,0.00022304048,0.000033468856,0.000025655483,0.000020628246,0.0135322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996515,0.0002868747,0.002109631,0.00024753207,0.00046590046,0.00037509156],"domain_scores_gemma":[0.9967797,0.00042376778,0.0010781395,0.00015531397,0.0011578477,0.00040526953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012572303,0.00014174968,0.0014795983,0.00017653817,0.000023899844,0.000015865842,0.0001770284,0.0004645137,0.0003864917],"category_scores_gemma":[0.003665421,0.00009626088,0.00043816972,0.0001825393,0.00018481076,0.00013550383,0.00004918984,0.0010366462,0.000008637698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043805814,0.0012219958,0.74311185,0.000068974914,0.00018208171,0.00010297537,0.00042045323,0.0000023638147,0.00017064057,0.000015363239,0.21519144,0.03513126],"study_design_scores_gemma":[0.011622435,0.013378323,0.7716902,0.00010507083,0.00009636358,0.000008839084,0.00033319127,0.00002847032,0.0000613765,0.000044589404,0.20253739,0.00009378265],"about_ca_topic_score_codex":0.00054256746,"about_ca_topic_score_gemma":0.0004852073,"teacher_disagreement_score":0.035037477,"about_ca_system_score_codex":0.00043276392,"about_ca_system_score_gemma":0.0023305332,"threshold_uncertainty_score":0.45037696},"labels":[],"label_agreement":null},{"id":"W2990077508","doi":"10.1200/jco.2019.37.31_suppl.37","title":"Development and implementation of “advanced cancer shared care letters” to improve shared care between oncologists and family physicians.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Alberta Health","keywords":"Medicine; Palliative care; CLARITY; Family medicine; Shared care; Advance care planning; Cancer; Ambulatory care; Nursing; Health care; Internal medicine; Primary care","score_opus":0.2197810844318932,"score_gpt":0.5690071395950113,"score_spread":0.34922605516311805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990077508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891664,0.0005704734,0.00012219853,0.008411057,0.00088102627,0.00090870145,0.000079013495,0.000008014959,0.000102853985],"genre_scores_gemma":[0.9576709,0.00025531425,0.03491034,0.0063628186,0.0006879397,0.000019887748,0.000054201708,0.000021722344,0.000016874388],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99520713,0.00021928453,0.0035893428,0.00034277022,0.0003924143,0.00024907477],"domain_scores_gemma":[0.9935887,0.002218101,0.0026916354,0.00017599764,0.0010294286,0.00029612656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015077863,0.00018021403,0.0014589151,0.00013178053,0.000040684456,0.000014818006,0.00012934457,0.00021331439,0.0000859489],"category_scores_gemma":[0.0017449508,0.00015097039,0.00017057873,0.00013698747,0.00008794709,0.00029141223,0.00014803236,0.00054813735,0.0000064500236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012229787,0.00008719629,0.29280388,0.0001643936,0.00022133398,0.000017693097,0.0026459694,0.000009969195,0.013241026,0.0000033987956,0.0008092031,0.688773],"study_design_scores_gemma":[0.011684636,0.006844491,0.90371543,0.00020116397,0.00047135798,0.000008555666,0.021211015,0.000004994486,0.0014523098,0.000008424038,0.05424986,0.0001477823],"about_ca_topic_score_codex":0.00019818606,"about_ca_topic_score_gemma":0.0006149867,"teacher_disagreement_score":0.68862516,"about_ca_system_score_codex":0.00041442562,"about_ca_system_score_gemma":0.0016108474,"threshold_uncertainty_score":0.6156394},"labels":[],"label_agreement":null},{"id":"W2990184042","doi":"10.1200/jco.2019.37.31_suppl.102","title":"Integration of electronic patient-reported outcomes into clinical workflows within the Epic electronic medical record.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Workflow; Electronic medical record; Phone; EPIC; Medical record; Medical emergency; Internal medicine; Database; Computer science","score_opus":0.07037778295952211,"score_gpt":0.3940859737962316,"score_spread":0.3237081908367095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990184042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97717136,0.0016427028,0.0011427304,0.00800438,0.0054241666,0.00027698744,0.000003234959,0.000008919832,0.006325529],"genre_scores_gemma":[0.992331,0.0024082365,0.00070949504,0.0033869017,0.000718577,0.00000561116,0.0000021841338,0.000025949153,0.00041199685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98982817,0.00033640984,0.008822791,0.00036197098,0.00016980537,0.00048085963],"domain_scores_gemma":[0.9862029,0.0028527528,0.0099171745,0.00047078432,0.0002738389,0.00028254572],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014873613,0.00021212533,0.0025532371,0.00018048685,0.000051061576,0.000021767251,0.00069694687,0.0007978353,0.0010412369],"category_scores_gemma":[0.014146189,0.00014846714,0.0010653194,0.0002198515,0.0003381229,0.00034672825,0.00009644878,0.002463253,0.00020505555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010830516,0.00076565327,0.69055945,0.000009989887,0.00069011596,0.000015272453,0.00022731435,0.000051402374,0.000003707774,0.09282914,0.0020796256,0.21168531],"study_design_scores_gemma":[0.0064700656,0.01452839,0.50472647,0.000091988295,0.00012454689,0.000069593545,0.00021303199,0.0016806306,0.000017327893,0.21596822,0.25574294,0.00036678283],"about_ca_topic_score_codex":0.00020248354,"about_ca_topic_score_gemma":0.00079164223,"teacher_disagreement_score":0.2536633,"about_ca_system_score_codex":0.0003894087,"about_ca_system_score_gemma":0.002755514,"threshold_uncertainty_score":0.99987197},"labels":[],"label_agreement":null},{"id":"W2990301018","doi":"10.1200/jco.2019.37.31_suppl.107","title":"Two-year review of the electronic Patient Reported Outcome (ePRO) system in the Prostate Clinic at the Vancouver Prostate Centre (VPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Family medicine; Pediatrics; Cancer; Internal medicine","score_opus":0.19938723215426776,"score_gpt":0.5294304678932011,"score_spread":0.33004323573893335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990301018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9237509,0.0023325908,0.0000038305175,0.06388627,0.003249172,0.0035377108,0.000007835545,0.000009319344,0.0032223957],"genre_scores_gemma":[0.9680201,0.0052396455,0.00017582117,0.024988694,0.00040572844,0.000019226201,0.000006372202,0.000028896815,0.0011155133],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98327315,0.0036963862,0.011102365,0.00033370272,0.0011545016,0.0004398755],"domain_scores_gemma":[0.9748455,0.011096196,0.011826892,0.001009325,0.0010832419,0.00013879767],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031153817,0.00021194904,0.001813924,0.00005785942,0.000063681415,0.000009181659,0.00047795623,0.0002083278,0.0004115371],"category_scores_gemma":[0.03036047,0.000087622626,0.0009656736,0.00043401774,0.00022983892,0.00014610357,0.00021733266,0.0023794477,0.00008862962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081048645,0.0019935295,0.85452497,0.0021329923,0.0006655095,0.00029706667,0.000615026,0.00003424923,0.00007275536,0.00024832145,0.08935715,0.041953564],"study_design_scores_gemma":[0.023840686,0.013946119,0.24285185,0.0062056403,0.0027768575,0.0011947864,0.008209394,0.00011397185,0.000055208686,0.00035900815,0.7001685,0.00027800206],"about_ca_topic_score_codex":0.000081185186,"about_ca_topic_score_gemma":0.00082053005,"teacher_disagreement_score":0.6116731,"about_ca_system_score_codex":0.0005621938,"about_ca_system_score_gemma":0.0026133624,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W2990602488","doi":"10.1200/jco.2012.30.15_suppl.4099","title":"A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Temsirolimus; Internal medicine; Hepatocellular carcinoma; Bevacizumab; Adverse effect; Gastroenterology; Phases of clinical research; Clinical endpoint; Toxicity; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Oncology; Surgery; Chemotherapy; Clinical trial","score_opus":0.12613804617967855,"score_gpt":0.39287452382002586,"score_spread":0.2667364776403473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990602488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644583,0.0011221567,0.000011802588,0.00056035805,0.0005365442,0.00085569394,0.0000062050485,0.0000052825403,0.00045614666],"genre_scores_gemma":[0.9973822,0.00016679087,0.0016091489,0.0001766455,0.00056057377,0.000013058096,0.000009632044,0.000023144097,0.000058806094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634695,0.00041790382,0.0022568435,0.000188215,0.00043793392,0.00035213112],"domain_scores_gemma":[0.9966444,0.0007365911,0.0015367744,0.0002146111,0.0003259232,0.00054171274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020610706,0.00020366079,0.0019664904,0.00022753049,0.0000383831,0.0000036148838,0.000098323784,0.0003608806,0.00005156406],"category_scores_gemma":[0.00090221874,0.0001342256,0.00033263152,0.00018937174,0.0001970602,0.00020966429,0.00005776458,0.0006304117,0.0000028494476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14864625,0.017518623,0.7566588,0.00003760136,0.00018856139,0.00023204695,0.00020575635,1.1589655e-7,0.00005085664,0.00001736599,0.000060381397,0.07638364],"study_design_scores_gemma":[0.4129892,0.16020338,0.41895676,0.000104397164,0.00065911026,0.00006643411,0.000054033037,0.00010796017,0.00031269965,0.00002519032,0.006395035,0.0001258174],"about_ca_topic_score_codex":0.000016410087,"about_ca_topic_score_gemma":0.0000051053203,"teacher_disagreement_score":0.33770204,"about_ca_system_score_codex":0.000113981936,"about_ca_system_score_gemma":0.0006000248,"threshold_uncertainty_score":0.54735607},"labels":[],"label_agreement":null},{"id":"W2990602950","doi":"10.1200/jco.19.01307","title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1819,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Hazard ratio; Internal medicine; Sorafenib; Interim analysis; Adverse effect; Population; Randomized controlled trial; Intention-to-treat analysis; Hepatocellular carcinoma; Subgroup analysis; Surgery; Gastroenterology; Confidence interval; Cancer; Immunotherapy; Pathology","score_opus":0.12343014531554675,"score_gpt":0.40153048589316315,"score_spread":0.2781003405776164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990602950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905853,0.0007912428,0.000012467667,0.00088762864,0.000994008,0.0051838285,0.000003673034,0.000011132195,0.0015306679],"genre_scores_gemma":[0.9974744,0.00039673757,0.00035311433,0.000787123,0.00051239884,0.00009881734,0.000037766054,0.00004747091,0.00029221573],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321926,0.0011235132,0.0040577636,0.00044750437,0.00066672044,0.00048523658],"domain_scores_gemma":[0.99457693,0.002013534,0.0020988546,0.00038268528,0.00047189646,0.00045610647],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045092483,0.0003755119,0.004492629,0.0005286865,0.00002710509,0.000016674298,0.0002370723,0.0006402436,0.0010051301],"category_scores_gemma":[0.00061453145,0.00023799019,0.0009813989,0.0004032616,0.00019509511,0.0002532421,0.000043725107,0.0015025114,0.00005510644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5373001,0.0065707117,0.4414122,0.000016477881,0.00023932582,0.0009859481,0.00012375132,0.000003561692,0.000013760174,0.000015759864,0.000017037506,0.013301363],"study_design_scores_gemma":[0.88943064,0.07901433,0.027903236,0.00012698481,0.00030680755,0.00006029303,0.000041585423,0.0006670605,0.00023513306,0.00008777357,0.0019124459,0.00021371043],"about_ca_topic_score_codex":0.00007795037,"about_ca_topic_score_gemma":0.000049301252,"teacher_disagreement_score":0.41350898,"about_ca_system_score_codex":0.00028291528,"about_ca_system_score_gemma":0.0020320634,"threshold_uncertainty_score":0.9999081},"labels":[],"label_agreement":null},{"id":"W2990695360","doi":"10.1200/jco.2019.37.31_suppl.9","title":"Factors associated with improvement in uncontrolled cancer pain without increasing opioid daily dose among patients seen by an inpatient palliative care team.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Opioid; Cancer pain; Palliative care; Psychological intervention; Cancer; Morphine; Medical prescription; Emergency medicine; Anesthesia; Internal medicine; Psychiatry; Nursing","score_opus":0.1509670726560498,"score_gpt":0.4791203808962307,"score_spread":0.3281533082401809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990695360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771583,0.00044733225,0.000026988551,0.0001486361,0.00047929774,0.0007114498,0.00004588608,0.000008451724,0.00041615622],"genre_scores_gemma":[0.99831676,0.0002581776,0.00028191015,0.00083028787,0.00014559859,0.000012462629,0.000070188704,0.000027342187,0.00005725496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529207,0.0012941839,0.0021761323,0.00027815904,0.0006352402,0.00032421315],"domain_scores_gemma":[0.99229676,0.0029197566,0.0030357016,0.0001771377,0.0011992292,0.000371406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026144742,0.0002536571,0.0022269415,0.00015765721,0.000028672464,0.0000086917835,0.00017416241,0.00039249958,0.000056862496],"category_scores_gemma":[0.0056088637,0.00015723053,0.00026371528,0.00020009972,0.00015516512,0.00018916371,0.000045496297,0.0009013838,8.98878e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005438092,0.0016792213,0.9717252,0.000046590354,0.0006218314,0.000015443442,0.004066913,0.00004833348,0.00019116692,7.675064e-7,0.00021346855,0.015952937],"study_design_scores_gemma":[0.027438682,0.028632987,0.9362438,0.0014167684,0.00029046633,1.0974145e-7,0.0040395693,0.00020926604,0.00022999666,0.000011690445,0.0013220317,0.00016467742],"about_ca_topic_score_codex":0.0011301246,"about_ca_topic_score_gemma":0.0020167923,"teacher_disagreement_score":0.035481483,"about_ca_system_score_codex":0.00094201445,"about_ca_system_score_gemma":0.0012471129,"threshold_uncertainty_score":0.6714739},"labels":[],"label_agreement":null},{"id":"W2990740129","doi":"10.1200/jco.2019.37.31_suppl.117","title":"Pharmacogenetic (PGx) guided cancer pain management in an oncology palliative medicine (PM) clinic.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer pain; Opioid; Internal medicine; Cancer; CYP2D6; Pharmacogenetics; McNemar's test; Pain assessment; Oncology; Physical therapy; Pain management; Genotype","score_opus":0.4763321080730114,"score_gpt":0.6492114431055761,"score_spread":0.1728793350325647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990740129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329379,0.006594631,0.000101152225,0.014278692,0.016522562,0.0010043931,0.000022761857,0.000027804677,0.028510101],"genre_scores_gemma":[0.89232385,0.04321627,0.0023707727,0.05516506,0.0047474946,0.0000735594,0.00001198115,0.000073025534,0.0020179895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9824676,0.009618035,0.0057285246,0.00068430457,0.0005931987,0.00090833945],"domain_scores_gemma":[0.9875782,0.0065489267,0.0036224069,0.00037399726,0.0006919813,0.0011844483],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.028135711,0.00048084938,0.002886609,0.000537941,0.00009162165,0.000011408956,0.0012143797,0.0012703983,0.013341583],"category_scores_gemma":[0.0011566142,0.00038051192,0.000546334,0.00053627946,0.0006149386,0.00020968787,0.00024835096,0.0037455878,0.0003335458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062231147,0.00450247,0.19898884,0.00009661788,0.0015369905,0.0014341158,0.0009345039,0.0026369775,0.005780406,0.00026836264,0.04534935,0.73224825],"study_design_scores_gemma":[0.028402915,0.007137584,0.06204839,0.000080995254,0.0011078794,0.000037021495,0.0005115245,0.0043184278,0.00054431125,0.0016984283,0.89369375,0.00041880165],"about_ca_topic_score_codex":0.000038426402,"about_ca_topic_score_gemma":0.000117221614,"teacher_disagreement_score":0.8483444,"about_ca_system_score_codex":0.00042086653,"about_ca_system_score_gemma":0.001483633,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W2990783514","doi":"10.1200/jco.2019.37.31_suppl.110","title":"High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dexamethasone; Cancer; Internal medicine; Cancer-related fatigue; Population; Randomized controlled trial; Gastroenterology","score_opus":0.07842051092284937,"score_gpt":0.4724424980559814,"score_spread":0.394021987133132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990783514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232274,0.00013824944,0.0000985613,0.0017450084,0.0014847518,0.004093847,0.000018157061,0.000016870745,0.00008180812],"genre_scores_gemma":[0.99804443,0.0001325062,0.0006107273,0.00026843816,0.0004355621,0.00029832695,0.0000063280204,0.000040541392,0.0001631153],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966182,0.0005615275,0.0014331646,0.0004083677,0.00061140215,0.00036733146],"domain_scores_gemma":[0.99369395,0.0026417235,0.0021334626,0.000283839,0.00089681824,0.00035021026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022391803,0.00028342594,0.0038869905,0.0001718831,0.000051695813,0.0000101065925,0.0001793148,0.0002777678,0.000100892416],"category_scores_gemma":[0.00043514697,0.00016645271,0.00045333634,0.00040253368,0.00018837294,0.00024436638,0.000044689543,0.0012393746,0.0000015012303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7951076,0.0242262,0.06735481,0.00006647544,0.0012763477,0.000050706476,0.0011319545,0.0006395421,0.00003476575,0.000012794327,0.000035071625,0.11006374],"study_design_scores_gemma":[0.8613845,0.08323899,0.05201406,0.00038197511,0.0013670528,0.000004946838,0.00023120892,0.0003781548,0.00014202586,0.000026481217,0.00062498753,0.00020562853],"about_ca_topic_score_codex":0.000934065,"about_ca_topic_score_gemma":0.004026618,"teacher_disagreement_score":0.10985811,"about_ca_system_score_codex":0.00043286014,"about_ca_system_score_gemma":0.0024092176,"threshold_uncertainty_score":0.6787745},"labels":[],"label_agreement":null},{"id":"W2990814876","doi":"10.1200/jco.19.01348","title":"Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Lung cancer; Paclitaxel; Placebo; Internal medicine; Quality of life (healthcare); Oncology; Cancer; Chemotherapy; Pathology; Immunotherapy; Cisplatin; Nursing","score_opus":0.07244520924970478,"score_gpt":0.46937271443790735,"score_spread":0.3969275051882026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990814876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386823,0.00060320925,0.000103164006,0.0020828152,0.00032027287,0.0017823435,0.00004208752,0.00001165478,0.001186234],"genre_scores_gemma":[0.99060017,0.000115668125,0.0065358058,0.00128393,0.00008984759,0.000039794268,0.000015460404,0.00005664402,0.001262683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99418676,0.0006444821,0.0035595987,0.00039339793,0.00075518206,0.00046055857],"domain_scores_gemma":[0.9914666,0.0018172386,0.0047217333,0.00038161574,0.00097201904,0.0006408389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017143512,0.0003328776,0.0035230655,0.00023577159,0.00005310301,0.0000104957835,0.00017194422,0.00022600945,0.00026731673],"category_scores_gemma":[0.00072560995,0.0001571799,0.00020490242,0.0004937727,0.00024807852,0.00018373817,0.000031690965,0.0009949019,0.0000045557545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09400023,0.0045431196,0.8940866,0.00066573225,0.0015762872,0.0001680119,0.0012255048,0.0005034114,0.0000044647036,0.000014417098,0.00018008573,0.0030321428],"study_design_scores_gemma":[0.10707459,0.071689144,0.81702834,0.0009049514,0.0015449479,0.00008108446,0.00093814003,0.00026244513,0.0000060384423,0.000008654587,0.0002450892,0.00021660072],"about_ca_topic_score_codex":0.002733272,"about_ca_topic_score_gemma":0.006912347,"teacher_disagreement_score":0.07705828,"about_ca_system_score_codex":0.00068558595,"about_ca_system_score_gemma":0.015074904,"threshold_uncertainty_score":0.99050874},"labels":[],"label_agreement":null},{"id":"W2990818960","doi":"10.1200/jco.2019.37.31_suppl.18","title":"Characteristics of caregiving: A prospective, observational study of lung cancer patients and their informal caregivers.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Southlake Regional Health Center; Toronto Metropolitan University","funders":"","keywords":"Medicine; Lung cancer; Caregiver burden; Observational study; Social support; Family caregivers; Cancer; Population; Family medicine; Physical therapy; Gerontology; Internal medicine; Disease; Psychology","score_opus":0.08402284467628574,"score_gpt":0.4182878049689438,"score_spread":0.33426496029265806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990818960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723935,0.00014416152,0.000005213538,0.00022436994,0.0013224869,0.00034732383,0.000023159018,0.0000020223335,0.00069188426],"genre_scores_gemma":[0.99924225,0.00017353376,0.000025915144,0.00019410165,0.00024969748,0.0000034856503,0.000002961218,0.000007414958,0.00010063645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979628,0.000102469545,0.0014224858,0.00010285197,0.00030540078,0.00010402254],"domain_scores_gemma":[0.9959549,0.00062753225,0.0018209292,0.00010663929,0.0013691371,0.000120873934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067094516,0.00009278888,0.0011434619,0.000078881996,0.000013608826,0.0000026726689,0.00009326065,0.0001519854,0.00007674503],"category_scores_gemma":[0.00060737156,0.00006351205,0.00017332727,0.000103173275,0.000093161594,0.000112542955,0.000061372935,0.0004108428,2.8744816e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024275654,0.0011648304,0.97848487,0.00013522455,0.00033502255,0.0000067652413,0.005622487,0.0000020670186,0.000023559556,0.000023999013,0.00016547364,0.011608163],"study_design_scores_gemma":[0.0068570795,0.01233809,0.975483,0.00012593278,0.00020334365,0.000006771677,0.0028494482,0.000042702763,0.000024736793,0.0000073385563,0.002008779,0.00005276708],"about_ca_topic_score_codex":0.00020948108,"about_ca_topic_score_gemma":0.00032223508,"teacher_disagreement_score":0.011555396,"about_ca_system_score_codex":0.00008848371,"about_ca_system_score_gemma":0.0009815604,"threshold_uncertainty_score":0.2589946},"labels":[],"label_agreement":null},{"id":"W2990858591","doi":"10.1200/jco.19.00845","title":"Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children’s Oncology Group (ACNS1221)","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Children's Hospital","funders":"National Cancer Institute; Genentech; National Institute of Neurological Disorders and Stroke; Eli Lilly and Company","keywords":"Medicine; Medulloblastoma; Internal medicine; Regimen; Chemotherapy; Prospective cohort study; Histology; Oncology; Surgery; Pediatrics; Pathology","score_opus":0.045839262895501776,"score_gpt":0.41968437768173084,"score_spread":0.37384511478622906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990858591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973168,0.00018123552,0.0000034186407,0.0005312884,0.0007232329,0.0010805215,0.000011357262,0.000002863132,0.00014933175],"genre_scores_gemma":[0.9990668,0.00007371576,0.0005173136,0.00014573947,0.00013105631,0.0000121268995,0.000005086764,0.00002062569,0.000027478869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397475,0.00080017955,0.0040820437,0.000270454,0.00062583975,0.0002467455],"domain_scores_gemma":[0.9921823,0.0021565717,0.004711443,0.00049380347,0.00026288294,0.00019299485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003067288,0.00018715701,0.0027026231,0.00030222468,0.000020184876,0.000002102616,0.00030807804,0.00029227976,0.00011635222],"category_scores_gemma":[0.0026807946,0.000118246564,0.00065498345,0.00034798143,0.0003204268,0.00007726447,0.00017495474,0.0007625712,0.0000041491553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031769574,0.06675659,0.9116956,0.000022653567,0.0018102955,0.0013448584,0.0005497133,0.00004175606,0.00079595274,0.000023533175,0.00017853895,0.013603543],"study_design_scores_gemma":[0.038704447,0.10367981,0.85344523,0.00017648433,0.001392615,0.0018487715,0.00025589962,0.000011426243,0.00021717213,0.00004915661,0.00014865714,0.00007032217],"about_ca_topic_score_codex":0.00020906066,"about_ca_topic_score_gemma":0.00031072195,"teacher_disagreement_score":0.058250368,"about_ca_system_score_codex":0.00015894923,"about_ca_system_score_gemma":0.0008932365,"threshold_uncertainty_score":0.4821955},"labels":[],"label_agreement":null},{"id":"W2990868732","doi":"10.1200/jco.2019.37.31_suppl.11","title":"Proactive versus reactive feeding tube (FT) placement in head and neck cancer patients (HNC pts) receiving chemoradiation (CRT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Mucositis; Swallowing; Cetuximab; Head and neck cancer; Feeding tube; Surgery; Head and neck; Weight loss; Cancer; Radiation therapy; Internal medicine; Colorectal cancer","score_opus":0.15652432186145765,"score_gpt":0.5098062298844098,"score_spread":0.3532819080229522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990868732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868797,0.00031554248,0.0000016492849,0.006222051,0.0031178154,0.00069740997,0.0000048291213,0.0000054065795,0.00275558],"genre_scores_gemma":[0.9959872,0.0009097679,0.0012917211,0.0008508101,0.000759384,0.000022343032,0.0000032318044,0.000017557139,0.00015798131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972958,0.00021474391,0.0015517003,0.0002615667,0.00037368332,0.00030253478],"domain_scores_gemma":[0.996316,0.00146938,0.0014159059,0.00011168262,0.0003492258,0.00033777114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015360647,0.00014650973,0.0010997214,0.00014144061,0.00002962355,0.0000066227744,0.00006393808,0.00029277152,0.000112745234],"category_scores_gemma":[0.0013209316,0.00011376357,0.000119657714,0.00014993966,0.00006050109,0.00021834586,0.000043023072,0.00091237173,0.0000137848065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023449201,0.0016100521,0.83165413,0.00006401192,0.00027956555,0.000041525887,0.0006324374,0.000035502046,0.00004043313,0.000007929216,0.00064402865,0.14154121],"study_design_scores_gemma":[0.036881596,0.026232183,0.92874056,0.0003882674,0.00019195466,0.00001360525,0.00031842603,0.00021381126,0.00015759922,0.000030836058,0.0067364443,0.00009473179],"about_ca_topic_score_codex":0.00027621086,"about_ca_topic_score_gemma":0.0002963021,"teacher_disagreement_score":0.14144649,"about_ca_system_score_codex":0.0031086295,"about_ca_system_score_gemma":0.0017430694,"threshold_uncertainty_score":0.81289583},"labels":[],"label_agreement":null},{"id":"W2991050915","doi":"10.1200/jco.2019.37.31_suppl.147","title":"Symptom monitoring and the uncertain threat of disease recurrence: A deductive thematic analysis with adolescent and young adult (AYA) cancer survivors.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Stanford Maternal and Child Health Research Institute; American Psychological Foundation","keywords":"Worry; Anxiety; Medicine; Survivorship curve; Thematic analysis; Psychological intervention; Disease; Clinical psychology; Cancer; Quality of life (healthcare); Perception; Cognition; Qualitative research; Psychiatry; Psychology","score_opus":0.06766227979513618,"score_gpt":0.4441707733883531,"score_spread":0.3765084935932169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991050915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840808,0.003367973,0.000106650215,0.011012819,0.00085189316,0.00043049228,0.000008323008,0.000005091838,0.00013594811],"genre_scores_gemma":[0.99295,0.0052084536,0.0005993712,0.00048367854,0.0006571484,0.000009438121,9.127273e-7,0.0000138433925,0.00007710424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626684,0.0008838987,0.001733066,0.00027519188,0.0006361468,0.00020484658],"domain_scores_gemma":[0.9934512,0.0030203003,0.002060605,0.00031409488,0.000738991,0.00041483503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037580098,0.00018453482,0.0021991176,0.00014483984,0.000046141504,0.000013750422,0.00016228577,0.00014358504,0.000032529682],"category_scores_gemma":[0.0022302754,0.00008951292,0.00038797694,0.00036787297,0.0006932284,0.000117181895,0.000070889655,0.00077504595,9.116699e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010816186,0.0004885435,0.97423446,0.0003191688,0.0023732814,0.000024911735,0.0022285036,0.00005731032,0.0000050985886,0.00014903308,0.00004378445,0.009259728],"study_design_scores_gemma":[0.009388823,0.0022706508,0.9769555,0.0015573992,0.0051007094,0.000044446097,0.003683691,0.00034947507,0.000019604591,0.0004337792,0.00007209466,0.00012385657],"about_ca_topic_score_codex":0.0012313356,"about_ca_topic_score_gemma":0.0009292313,"teacher_disagreement_score":0.01052914,"about_ca_system_score_codex":0.000108317196,"about_ca_system_score_gemma":0.0010481708,"threshold_uncertainty_score":0.3650231},"labels":[],"label_agreement":null},{"id":"W2991211980","doi":"10.1200/jco.2019.37.31_suppl.101","title":"Digital Supportive Care Awareness and Navigation (D-SCAN): Results of a pilot randomized trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Randomized controlled trial; Intervention (counseling); Physical therapy; Family medicine; Internal medicine; Nursing","score_opus":0.07786868795704698,"score_gpt":0.4493250119278196,"score_spread":0.3714563239707726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991211980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98481363,0.00048649928,0.00004148432,0.0012212812,0.0024417364,0.00061119196,0.000030706073,0.0000050733056,0.010348419],"genre_scores_gemma":[0.998193,0.00024291863,0.00008320714,0.00024744548,0.00067345565,0.0000046074742,0.000022227878,0.000010307672,0.000522833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99626154,0.00044039547,0.0026608407,0.00016453506,0.00034704388,0.00012564509],"domain_scores_gemma":[0.9923363,0.004060351,0.002351034,0.00015610954,0.00087774365,0.00021848214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032193565,0.00010570236,0.0022594735,0.00008518332,0.000014463784,0.000009808074,0.00008213994,0.00022084087,0.000041370124],"category_scores_gemma":[0.0046465835,0.00007044046,0.0005270878,0.00009820079,0.00024049627,0.00013340174,0.000036500856,0.00048609902,0.0000046919213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.937461,0.00043993414,0.0109441755,0.000095445655,0.00023338204,0.00007387634,0.0007518899,0.0000020357345,0.00003511877,0.000038057773,0.00028545532,0.04963962],"study_design_scores_gemma":[0.9505309,0.028163237,0.008488334,0.00029076138,0.00043255673,0.00010589597,0.0017719395,0.000014829431,0.00011880226,0.00018138517,0.009822309,0.00007906566],"about_ca_topic_score_codex":0.000102883896,"about_ca_topic_score_gemma":0.000069712005,"teacher_disagreement_score":0.049560554,"about_ca_system_score_codex":0.000080032354,"about_ca_system_score_gemma":0.0017024301,"threshold_uncertainty_score":0.55627304},"labels":[],"label_agreement":null},{"id":"W2991390609","doi":"10.1200/jco.2019.37.31_suppl.100","title":"Effects of Tai Chi and Qi Gong group class participation on self-reported symptoms in cancer patients and caregivers: A preliminary report.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Duncan Family Institute for Cancer Prevention and Risk Assessment","keywords":"Medicine; Psychosocial; Distress; Wilcoxon signed-rank test; Exact test; Physical therapy; Mann–Whitney U test; Cancer; Internal medicine; Clinical psychology; Psychiatry","score_opus":0.033088579063057545,"score_gpt":0.4066341637440207,"score_spread":0.37354558468096316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991390609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966655,0.00055417453,0.000003087704,0.00057268573,0.0013769856,0.00035416943,0.0000013938508,0.000005405218,0.00046660597],"genre_scores_gemma":[0.9987446,0.0005015918,0.00004440475,0.00044214263,0.0001940256,0.000010102342,0.0000030635615,0.0000103590555,0.00004970822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976317,0.00026248838,0.0014838187,0.00019880186,0.00028289002,0.00014026761],"domain_scores_gemma":[0.99650383,0.0012571318,0.0016662662,0.00011605218,0.0002621572,0.00019454538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010611288,0.0001046982,0.0009374155,0.00011560173,0.000011927232,0.0000035470978,0.000041871306,0.00027328663,0.00001435729],"category_scores_gemma":[0.0012794292,0.00007917953,0.00012681901,0.00010618273,0.000082105646,0.000090023,0.000037079222,0.00048477194,5.821437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049037463,0.0013668006,0.9594474,0.00025170742,0.00031797093,0.0006907856,0.00079341704,0.000005830474,0.00009413164,0.00002262949,0.00018462319,0.031920973],"study_design_scores_gemma":[0.008703576,0.022267956,0.9656835,0.00045961002,0.0005336877,0.00009849519,0.00012971526,0.00010437368,0.00010146231,0.000030544226,0.0018163477,0.00007071215],"about_ca_topic_score_codex":0.00036755667,"about_ca_topic_score_gemma":0.0004815556,"teacher_disagreement_score":0.03185026,"about_ca_system_score_codex":0.00014648109,"about_ca_system_score_gemma":0.00036110144,"threshold_uncertainty_score":0.32288474},"labels":[],"label_agreement":null},{"id":"W2991588978","doi":"10.1200/jco.19.01706","title":"Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Medulloblastoma; Medicine; Radiation therapy; Proton therapy; Radiology; Cancer research","score_opus":0.04817309746620441,"score_gpt":0.4173505307887448,"score_spread":0.3691774333225404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991588978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922116,0.0015241299,0.0025910914,0.0033428236,0.0013150591,0.0018317745,0.000005192014,0.000022580372,0.000146165],"genre_scores_gemma":[0.9700108,0.0014874991,0.017352816,0.008060249,0.002022091,0.00007997725,0.0000029325495,0.00006078386,0.0009228148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966655,0.00031727832,0.0020078802,0.00026908107,0.00042862035,0.00031167115],"domain_scores_gemma":[0.9936866,0.0040827184,0.0011873697,0.00027073672,0.000399718,0.0003728651],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020375594,0.00024140697,0.0021447267,0.0003002195,0.000036102796,0.000018677061,0.0001995711,0.00041755103,0.001646705],"category_scores_gemma":[0.00088691956,0.00014679832,0.0007341066,0.00024166626,0.00014121653,0.0001592729,0.000009167586,0.00071126485,0.000021750175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07664175,0.0017014752,0.89963096,0.00010307217,0.0010558155,0.00007938839,0.00072257314,0.000041810683,0.00044742838,0.000010979398,0.0023171438,0.017247615],"study_design_scores_gemma":[0.063366435,0.07402433,0.52296627,0.00008448402,0.0005074728,0.0006106137,0.00020055292,0.0015585369,0.0007505083,0.00005308462,0.33551234,0.00036540529],"about_ca_topic_score_codex":0.0000035790626,"about_ca_topic_score_gemma":0.000004570456,"teacher_disagreement_score":0.3766647,"about_ca_system_score_codex":0.00021881984,"about_ca_system_score_gemma":0.0013782535,"threshold_uncertainty_score":0.9992659},"labels":[],"label_agreement":null},{"id":"W2991603022","doi":"10.1200/jco.2019.37.31_suppl.96","title":"Routine Edmonton Symptom Assessment System (ESAS) scores in epithelioid malignant pleural mesothelioma (eMPM) patients undergoing palliative systemic therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Depression (economics); Palliative care; Internal medicine; Nausea; Systemic therapy; Anxiety; Physical therapy; Cancer","score_opus":0.05404607827884408,"score_gpt":0.40819955210618863,"score_spread":0.3541534738273446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991603022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951086,0.0008754767,0.000033800374,0.0006533754,0.0011332451,0.00057338324,0.000017874745,0.000013986665,0.0015902427],"genre_scores_gemma":[0.99728733,0.0008613976,0.00049295777,0.0007366185,0.00038494743,0.000010388958,0.000017866112,0.000026651262,0.00018182358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955811,0.0006382671,0.0024937587,0.0002812604,0.00071337126,0.0002922705],"domain_scores_gemma":[0.99565274,0.0018233076,0.0018130575,0.00021017785,0.0001879898,0.00031270413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016688866,0.00022637735,0.0014682711,0.0001987336,0.00003644679,0.000013217712,0.00019000386,0.00025391008,0.00013998758],"category_scores_gemma":[0.00039572944,0.00014297236,0.0004677901,0.00014691005,0.00007902804,0.00016410723,0.0000689559,0.00054050406,0.0000815187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004078329,0.0020388246,0.98852456,0.00019411018,0.00032161106,0.00020958355,0.00007228604,0.00021221502,0.00030706287,0.00026980252,0.00012977495,0.0036418275],"study_design_scores_gemma":[0.014590185,0.0103012575,0.9716473,0.001529658,0.00014595415,0.000084259525,0.0005970899,0.0005791756,0.00004505287,0.000060587707,0.00027907093,0.0001404142],"about_ca_topic_score_codex":0.000046156412,"about_ca_topic_score_gemma":0.000021898648,"teacher_disagreement_score":0.016877279,"about_ca_system_score_codex":0.0011972737,"about_ca_system_score_gemma":0.00089566654,"threshold_uncertainty_score":0.5830244},"labels":[],"label_agreement":null},{"id":"W2991613512","doi":"10.1200/jco.2019.37.31_suppl.34","title":"Results from a focus group evaluating TrialTALK, a designed conversation to facilitate cancer treatment shared decision making.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"University of Wisconsin Carbone Cancer Center","keywords":"Conversation; Focus group; Medicine; Feeling; Preference; Group decision-making; Psychology; Social psychology; Communication; Statistics","score_opus":0.22076747539074723,"score_gpt":0.48990192276260963,"score_spread":0.26913444737186243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991613512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859518,0.00064692425,0.0079201255,0.0019229832,0.0025857303,0.00049899385,0.00014677104,0.000004593711,0.0003220867],"genre_scores_gemma":[0.9575782,0.0003828279,0.039741255,0.00076916884,0.001237762,0.000029054065,0.000035043016,0.00001795113,0.00020875789],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964499,0.00064345147,0.0019852412,0.00040663168,0.00031252534,0.00020227756],"domain_scores_gemma":[0.99570894,0.0018945058,0.0014412621,0.00031371386,0.00047331027,0.00016826345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028958775,0.00015776635,0.00070594175,0.00008265235,0.00003763779,0.00002131592,0.00023962004,0.00037460108,0.00022438039],"category_scores_gemma":[0.005386617,0.0001239886,0.00035573423,0.000114003335,0.000047530888,0.000012717606,0.000076196804,0.00019079185,0.00005497139],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036145844,0.00037227978,0.0031541751,0.0000034465834,0.0004966313,0.000019069692,0.00080035685,0.003713967,0.05489343,0.0000035449682,0.00611123,0.89428604],"study_design_scores_gemma":[0.1374894,0.1510272,0.17002034,0.00065863156,0.001335083,0.000080862344,0.0015180121,0.0056226286,0.022522548,0.0032562867,0.5051996,0.0012693732],"about_ca_topic_score_codex":0.00019154615,"about_ca_topic_score_gemma":0.0007052245,"teacher_disagreement_score":0.89301664,"about_ca_system_score_codex":0.0005120601,"about_ca_system_score_gemma":0.0017958429,"threshold_uncertainty_score":0.64486724},"labels":[],"label_agreement":null},{"id":"W2991646687","doi":"10.1200/jco.2019.37.31_suppl.122","title":"Comprehensive geriatric assessment in lung cancer and hematologic malignancy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Malignancy; Internal medicine; Cancer; Hematologic malignancy; Oncology; Geriatric oncology","score_opus":0.08234384787226012,"score_gpt":0.4969523623421854,"score_spread":0.4146085144699253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991646687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97765213,0.005536352,0.000023532772,0.010391417,0.0017458402,0.0004356044,0.0000021800647,0.0000064512465,0.004206503],"genre_scores_gemma":[0.9867545,0.008642328,0.00095528533,0.002806823,0.00040052496,0.000010641362,5.8775885e-7,0.000010702464,0.00041863328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744767,0.00024274849,0.0016487826,0.00019276129,0.00024615022,0.0002218784],"domain_scores_gemma":[0.9963478,0.0018236006,0.0011585982,0.000092926195,0.00041054867,0.00016653235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010185655,0.00012984256,0.001644387,0.00017554419,0.000020581629,0.000004761699,0.000065981694,0.00026125982,0.00027526455],"category_scores_gemma":[0.00049183547,0.000091677124,0.00020888988,0.0001820193,0.0001346612,0.00007763001,0.00008120053,0.001058602,0.000009158569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014660853,0.0006346587,0.97594166,0.00016575638,0.00043766486,0.0006194439,0.000073666386,0.000022670043,0.00014166984,0.00007213528,0.0034522864,0.016972318],"study_design_scores_gemma":[0.0121262735,0.005320919,0.96657944,0.0003774065,0.0003458393,0.00043688272,0.00028898238,0.00022925461,0.000012453445,0.00014791428,0.014041837,0.00009278757],"about_ca_topic_score_codex":0.00003470676,"about_ca_topic_score_gemma":0.000028762937,"teacher_disagreement_score":0.01687953,"about_ca_system_score_codex":0.00033034373,"about_ca_system_score_gemma":0.0011701386,"threshold_uncertainty_score":0.45991576},"labels":[],"label_agreement":null},{"id":"W2991767072","doi":"10.1200/jco.2013.31.15_suppl.4503","title":"Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): A large multicenter study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphovascular invasion; Internal medicine; Oncology; Disease; Clinical trial; Surgery; Cancer; Metastasis","score_opus":0.03420720959611032,"score_gpt":0.39603228389111295,"score_spread":0.3618250742950026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991767072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979964,0.000024553025,0.000044182394,0.00035653517,0.00022709701,0.0011439257,0.000025252955,0.0000067067654,0.00017537877],"genre_scores_gemma":[0.99857634,0.00005437677,0.00059202366,0.0004528875,0.00011469347,0.000015452577,0.000025410955,0.000023296443,0.00014549117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962677,0.0007517941,0.0020464503,0.0002651047,0.0004333352,0.0002356348],"domain_scores_gemma":[0.99512607,0.0010536445,0.0024766014,0.0002698432,0.0007191138,0.00035473643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011484119,0.00017470203,0.0014212275,0.000121067846,0.000024714684,0.000008227712,0.00011811343,0.00019764765,0.00015713423],"category_scores_gemma":[0.0016106084,0.00010300787,0.00021622419,0.00016609616,0.00014270407,0.0002027092,0.00005048276,0.000624217,0.000021527025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021506054,0.025587516,0.93517286,0.000029174265,0.0007514493,0.0006965404,0.000118854965,0.0000014996957,0.000008721896,0.0000035648625,0.000020491969,0.016103297],"study_design_scores_gemma":[0.046224043,0.034463793,0.91807646,0.0001687872,0.00035629448,0.000010242185,0.00023244243,0.000043465447,0.0000046905475,0.0000030744784,0.00032616185,0.000090555506],"about_ca_topic_score_codex":0.000058803238,"about_ca_topic_score_gemma":0.0001633492,"teacher_disagreement_score":0.024717988,"about_ca_system_score_codex":0.00009434403,"about_ca_system_score_gemma":0.0005533036,"threshold_uncertainty_score":0.42005393},"labels":[],"label_agreement":null},{"id":"W2992477198","doi":"10.1200/jco.19.02031","title":"Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Squamous cell cancer; Identification (biology); Oncology; Internal medicine; Head and neck cancer; Radiology; Pathology; Radiation therapy; Surgery","score_opus":0.10677442910588242,"score_gpt":0.43988699574339496,"score_spread":0.33311256663751254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992477198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966992,0.001084922,0.0009476266,0.00039412023,0.00040989142,0.00031259673,0.000001750099,0.0000016527567,0.00014822536],"genre_scores_gemma":[0.9952365,0.00021151143,0.004316347,0.00004373097,0.00010099187,0.000003883094,0.00000397431,0.0000052122336,0.00007781309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979363,0.00013321021,0.0015457224,0.00012524876,0.00016788623,0.00009161586],"domain_scores_gemma":[0.99751073,0.0009114648,0.001050958,0.000070286034,0.00038740388,0.00006912703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001418228,0.00007008126,0.0008624749,0.000101062455,0.000021094538,0.0000014956133,0.000034634893,0.00014605583,0.000012400818],"category_scores_gemma":[0.0012295409,0.000050240003,0.0001647007,0.00006053204,0.000090128175,0.000067236106,0.000015345104,0.00022800457,0.0000011393109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004372525,0.001958577,0.9075672,0.00030471486,0.000044378226,0.000021687203,0.00047703256,0.00066124165,0.034602262,0.000029519006,0.000019757597,0.04994113],"study_design_scores_gemma":[0.014634522,0.013619734,0.9604568,0.000094889765,0.00013555914,0.000033093016,0.00016587385,0.0034145925,0.00687163,0.000027830807,0.000505453,0.000040024326],"about_ca_topic_score_codex":0.000022535382,"about_ca_topic_score_gemma":0.000028036007,"teacher_disagreement_score":0.052889623,"about_ca_system_score_codex":0.00009056456,"about_ca_system_score_gemma":0.0003468115,"threshold_uncertainty_score":0.20487279},"labels":[],"label_agreement":null},{"id":"W2992567672","doi":"10.1200/jco.19.01959","title":"Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; HER2 negative; Oncology; Internal medicine; Cancer; Metastatic breast cancer","score_opus":0.021523932836251827,"score_gpt":0.3560801933331106,"score_spread":0.33455626049685877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992567672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967748,0.0002961936,0.000053753367,0.0011065725,0.00038629895,0.00042758175,0.00028740184,0.0000026244877,0.0006648037],"genre_scores_gemma":[0.9982233,0.0005322333,0.00045529567,0.0003408275,0.0003304155,0.000031963544,0.000004563871,0.00002286852,0.000058516445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997384,0.00070289033,0.0008975689,0.00037975318,0.00029337668,0.0003423763],"domain_scores_gemma":[0.9955954,0.0011000445,0.0018947808,0.00023810608,0.00093588844,0.00023578425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009679727,0.0002809051,0.0010075341,0.000046737772,0.00008783565,0.000014029,0.0002756739,0.000284855,0.000039004273],"category_scores_gemma":[0.0010186977,0.0001560212,0.00028408397,0.00017840626,0.0009956666,0.000026596103,0.00020379294,0.0005356936,0.0000015919894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006226977,0.0005079646,0.98249906,0.000018325309,0.0021111658,0.000022640126,0.0007598921,0.0001467649,0.001846012,0.000004080783,0.00021204293,0.0056450875],"study_design_scores_gemma":[0.0040749484,0.0057385815,0.9855612,0.00029400896,0.00028688574,0.0002696998,0.00039268204,0.000016628603,0.003097517,0.000072473194,0.000016480984,0.00017892277],"about_ca_topic_score_codex":0.0006855988,"about_ca_topic_score_gemma":0.00045198246,"teacher_disagreement_score":0.0054661646,"about_ca_system_score_codex":0.00030859202,"about_ca_system_score_gemma":0.0015965283,"threshold_uncertainty_score":0.636236},"labels":[],"label_agreement":null},{"id":"W2992651382","doi":"10.1200/jco.2012.30.15_suppl.9529","title":"A longitudinal study of anthracycline cardiotoxicity in pediatric Ewing sarcoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Cardiotoxicity; Sarcoma; Cohort; Anthracycline; Cardiomyopathy; Internal medicine; Retrospective cohort study; Odds ratio; Cardiac function curve; Surgery; Chemotherapy; Heart failure; Cancer; Pathology; Breast cancer","score_opus":0.18670895301698526,"score_gpt":0.5044399077065077,"score_spread":0.31773095468952245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992651382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468035,0.0011523813,0.000037603957,0.00042964274,0.0018524628,0.00024122666,0.0000012567886,0.0000043629166,0.0016007118],"genre_scores_gemma":[0.99460685,0.0004997813,0.0006263662,0.0001490558,0.004084316,0.0000017152859,4.1676842e-7,0.000013083231,0.000018390356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995588,0.00059029757,0.002922369,0.00013874593,0.00046139437,0.00029916698],"domain_scores_gemma":[0.9958152,0.0017810232,0.0015386118,0.00021171817,0.00027287213,0.00038053008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072862157,0.00012364092,0.0024251996,0.00026326935,0.00002049685,0.000002837769,0.000115804214,0.00022696378,0.00005244641],"category_scores_gemma":[0.0036168448,0.00009048026,0.00066221535,0.00031967828,0.00009464302,0.00014724457,0.00008534084,0.0011419521,0.000005811474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014383155,0.010707413,0.9772901,0.00003334133,0.00020146201,0.0006384592,0.0002825326,0.000008237454,0.00004937784,0.000015050738,0.00039763923,0.0089380955],"study_design_scores_gemma":[0.010254793,0.010406046,0.97652596,0.000034640645,0.0007454987,0.0005525042,0.00044503043,0.00000805676,0.000032237313,0.0000341545,0.00088845775,0.00007260593],"about_ca_topic_score_codex":0.000079279846,"about_ca_topic_score_gemma":0.00005221623,"teacher_disagreement_score":0.00886549,"about_ca_system_score_codex":0.00010862855,"about_ca_system_score_gemma":0.0005368925,"threshold_uncertainty_score":0.49612775},"labels":[],"label_agreement":null},{"id":"W2992699933","doi":"10.1200/jco.2009.27.15_suppl.5139","title":"A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Adverse effect; Taxane; Prostate cancer; Progression-free survival; Gastroenterology; Nausea; Chemotherapy; Surgery; Cancer; Oncology; Clinical trial; Breast cancer","score_opus":0.0965500528240619,"score_gpt":0.5084327799756414,"score_spread":0.4118827271515795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992699933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536777,0.0004865112,0.0000016956118,0.0024791008,0.00020978224,0.0012170615,0.000022623473,0.000003971117,0.00021148082],"genre_scores_gemma":[0.9980031,0.00018851989,0.0005313128,0.00076242484,0.0001909623,0.00005550809,0.0000050629956,0.000012753858,0.00025032298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642,0.00042059817,0.002252101,0.00022372344,0.00043076294,0.00025280874],"domain_scores_gemma":[0.99686813,0.00033082117,0.0017867599,0.00014790722,0.0006200488,0.00024633002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010072768,0.00018188797,0.001640788,0.00019699858,0.00003186972,0.000005825523,0.00008893493,0.00011122651,0.00015524146],"category_scores_gemma":[0.00021398821,0.00011406469,0.0001632239,0.00021436714,0.00013214444,0.00013073032,0.000019074863,0.0006134309,7.5758925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2119554,0.15251802,0.50561106,0.000060670747,0.0011110966,0.0027614047,0.0027087438,0.00003206125,0.00021219501,0.000003147205,0.0013089684,0.12171722],"study_design_scores_gemma":[0.11113487,0.3372251,0.54846156,0.00017088752,0.0011502175,0.00002273685,0.0002652305,0.000025842948,0.00007609866,0.000032311556,0.0013516246,0.00008351159],"about_ca_topic_score_codex":0.00010020572,"about_ca_topic_score_gemma":0.001633002,"teacher_disagreement_score":0.1847071,"about_ca_system_score_codex":0.00021237537,"about_ca_system_score_gemma":0.0013233847,"threshold_uncertainty_score":0.4651423},"labels":[],"label_agreement":null},{"id":"W2993254305","doi":"10.1200/jco.2013.31.15_suppl.e17517","title":"Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement; Centre hospitalier universitaire de Québec; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Thrombosis; Complication; Catheter; Incidence (geometry); Surgery","score_opus":0.04699067112446827,"score_gpt":0.3712115822345325,"score_spread":0.32422091111006424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993254305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978119,0.00014268846,0.0000034845177,0.000818766,0.00023856065,0.00050781685,0.0000056608174,0.0000038163166,0.0004673083],"genre_scores_gemma":[0.9967117,0.0023802186,0.00056180556,0.00019942153,0.000028410008,0.000007506789,0.0000013720887,0.000010884566,0.00009871064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976645,0.00020462617,0.0015880218,0.0001498233,0.0002203494,0.00017267946],"domain_scores_gemma":[0.9970275,0.0009096933,0.0014850942,0.00016218051,0.00023085755,0.00018467536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006510001,0.00014001748,0.0017232102,0.00013196228,0.000018887986,0.0000050974,0.00007799424,0.00017789181,0.00020219068],"category_scores_gemma":[0.00062962004,0.00007268343,0.00022205383,0.00008319943,0.00016715053,0.0001080493,0.0000358341,0.00026063586,0.000004972282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013740866,0.0074902726,0.97850174,0.000032502343,0.00074852305,0.0000075740954,0.00032973138,0.0000070923093,0.0000030778524,0.000025441639,0.0003594646,0.012357197],"study_design_scores_gemma":[0.007030886,0.02830129,0.9628929,0.00013845136,0.000797504,0.0000018884806,0.00011504719,0.0000065849645,0.000013941819,0.000090484165,0.0005451733,0.000065837194],"about_ca_topic_score_codex":0.00038829082,"about_ca_topic_score_gemma":0.00004058639,"teacher_disagreement_score":0.020811018,"about_ca_system_score_codex":0.000107287626,"about_ca_system_score_gemma":0.00018373408,"threshold_uncertainty_score":0.29639444},"labels":[],"label_agreement":null},{"id":"W2993731040","doi":"10.1200/jco.19.01226","title":"Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Late effect; Lung cancer; Radiation therapy; Pediatrics; Internal medicine","score_opus":0.08235248453382123,"score_gpt":0.4471668856926012,"score_spread":0.36481440115878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993731040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790833,0.00783774,0.0000034570226,0.008963335,0.002583661,0.0012198198,0.00006510281,0.0000137781635,0.000229806],"genre_scores_gemma":[0.9889905,0.007034149,0.0001585085,0.002026134,0.0016128022,0.000023225888,0.0000026091973,0.00003743791,0.00011464761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99222404,0.0014046628,0.0043847733,0.00061068323,0.0010138493,0.00036197758],"domain_scores_gemma":[0.98841846,0.0063785976,0.00370634,0.00059757155,0.00047389197,0.00042516645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009495781,0.00031325902,0.002647361,0.00018534217,0.000051957137,0.000019878626,0.000390074,0.0004311346,0.00023850621],"category_scores_gemma":[0.0062948572,0.00020597313,0.00032730823,0.0003864901,0.0004228747,0.0002297475,0.00024304727,0.0017462769,0.0000021022047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012281332,0.003002285,0.978499,0.00010975663,0.00091694586,0.0001523789,0.006839921,0.00001444701,0.000029163055,0.0000038822814,0.0004339098,0.008770164],"study_design_scores_gemma":[0.009837485,0.005180935,0.9780929,0.000931495,0.00070978457,0.0001599588,0.0023611754,0.000014326835,0.000026412064,0.00012969632,0.0023689957,0.00018680701],"about_ca_topic_score_codex":0.01450837,"about_ca_topic_score_gemma":0.031149223,"teacher_disagreement_score":0.016640853,"about_ca_system_score_codex":0.00012292153,"about_ca_system_score_gemma":0.0026557369,"threshold_uncertainty_score":0.9920541},"labels":[],"label_agreement":null},{"id":"W2994173645","doi":"10.1200/jco.2013.31.15_suppl.8040","title":"Clinical trial risk reduction in non-small cell lung cancer though the use of biomarkers and receptor-targeted therapies.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Drug development; Oncology; Phases of clinical research; Internal medicine; Lung cancer; Drug; Biomarker; Intensive care medicine; Pharmacology","score_opus":0.07440477371839342,"score_gpt":0.3998501672316342,"score_spread":0.32544539351324075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994173645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198014,0.0030951416,0.00023592371,0.0013889354,0.0028035904,0.00041216906,0.000014487052,0.0000010748274,0.00006856971],"genre_scores_gemma":[0.9338474,0.05708455,0.0062550213,0.00048652932,0.0022177228,0.000017717008,0.000004569031,0.000017138573,0.00006935235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996729,0.00074433145,0.0020223667,0.00022097745,0.00010787656,0.00017544371],"domain_scores_gemma":[0.9958908,0.0014340935,0.0020211933,0.00022335238,0.00028946687,0.0001410714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027707822,0.00012191648,0.0006536669,0.00004746371,0.000034798464,0.000019059828,0.00020199206,0.0004973149,0.000047751502],"category_scores_gemma":[0.002502005,0.00008056304,0.00033556018,0.00008487067,0.00031258893,0.000011017527,0.00009193346,0.00055691367,0.0000011572062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049273062,0.0022454467,0.33756956,0.000037621056,0.0012347955,0.000012306674,0.00027532893,0.000508784,0.026173854,0.00002197157,0.081162155,0.5014851],"study_design_scores_gemma":[0.09963339,0.024147335,0.5423517,0.00011373804,0.00069338863,0.00004056949,0.00060325,0.0010613281,0.006519149,0.0005458066,0.32376346,0.0005268751],"about_ca_topic_score_codex":0.00048586016,"about_ca_topic_score_gemma":0.00020436506,"teacher_disagreement_score":0.5009582,"about_ca_system_score_codex":0.000033014785,"about_ca_system_score_gemma":0.00074611825,"threshold_uncertainty_score":0.38357478},"labels":[],"label_agreement":null},{"id":"W2994649246","doi":"10.1200/jco.2012.30.15_suppl.6512","title":"BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Bosutinib; Cumulative incidence; Imatinib; Adverse effect; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Cohort; Dasatinib","score_opus":0.055493534638035254,"score_gpt":0.40123744529537675,"score_spread":0.3457439106573415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994649246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903626,0.002593526,0.000035346435,0.00056556956,0.0050700475,0.0016438562,0.000042498654,0.000023219873,0.000989675],"genre_scores_gemma":[0.9923958,0.0011874324,0.0015893106,0.00042747514,0.0039772703,0.00009160837,0.00006366449,0.00009507838,0.00017234843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908894,0.0008933719,0.0052969023,0.0005317873,0.0012253409,0.0011632101],"domain_scores_gemma":[0.9901587,0.00328807,0.004150386,0.0007707096,0.00056193717,0.0010702441],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034214738,0.00058943813,0.003623244,0.00037967257,0.00006661611,0.000015888376,0.00047189646,0.0010114203,0.0018980382],"category_scores_gemma":[0.003949798,0.0004268372,0.0009882826,0.00044770987,0.00056699436,0.0005460547,0.00018169082,0.002175112,0.00015189889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.60468924,0.01592872,0.1382242,0.00021194675,0.002267261,0.0011985388,0.0005363901,0.00008789648,0.000089434536,0.000035180576,0.005203524,0.23152766],"study_design_scores_gemma":[0.735822,0.10135441,0.12654717,0.0005621282,0.0016622904,0.00007380624,0.000097046555,0.00013515216,0.00023644461,0.000017396525,0.03312331,0.00036880188],"about_ca_topic_score_codex":0.00016487933,"about_ca_topic_score_gemma":0.00051123044,"teacher_disagreement_score":0.23115885,"about_ca_system_score_codex":0.009474489,"about_ca_system_score_gemma":0.014059614,"threshold_uncertainty_score":0.9998183},"labels":[],"label_agreement":null},{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","score_opus":0.11634704752836855,"score_gpt":0.5119909698977256,"score_spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994917610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792491,0.00015078193,0.0003948582,0.013836232,0.0006837374,0.0052722716,0.000078236575,0.000013858769,0.00032093402],"genre_scores_gemma":[0.9853699,0.0036775086,0.0043085134,0.003983763,0.0014332408,0.0003539623,0.000007446339,0.0000786366,0.0007870182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932959,0.0017272197,0.0030848156,0.0005645449,0.00069019437,0.0006373273],"domain_scores_gemma":[0.978784,0.016363325,0.0030673041,0.00027397208,0.0008435893,0.00066778046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072255502,0.0003804981,0.006812479,0.00023918707,0.00007073997,0.000028588642,0.0002978554,0.0005492732,0.0006504876],"category_scores_gemma":[0.0030574563,0.00019295144,0.0003261389,0.0003337946,0.0010322432,0.00020511427,0.0000549136,0.0022542744,0.0000032074852],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8663756,0.003339153,0.023943312,0.00011207422,0.0015480513,0.00037937606,0.0008076338,0.000030260633,0.000061562176,0.0000047625867,0.0049753534,0.098422825],"study_design_scores_gemma":[0.87484634,0.10620879,0.005531505,0.0007299162,0.000787838,0.0008107586,0.00083051296,0.0007684319,0.00015079178,0.00004537087,0.009049068,0.00024065896],"about_ca_topic_score_codex":0.001440587,"about_ca_topic_score_gemma":0.01289879,"teacher_disagreement_score":0.10286963,"about_ca_system_score_codex":0.0009853957,"about_ca_system_score_gemma":0.011968663,"threshold_uncertainty_score":0.99363256},"labels":[],"label_agreement":null},{"id":"W2995072671","doi":"10.1200/jco.19.01162","title":"Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":578,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Cetuximab; Esophagitis; Chemoradiotherapy; Internal medicine; Lung cancer; Clinical endpoint; Radiation therapy; Oncology; Toxicity; Gastroenterology; Cancer; Nuclear medicine; Surgery; Urology; Colorectal cancer; Randomized controlled trial","score_opus":0.07859151254591569,"score_gpt":0.4694509944018558,"score_spread":0.3908594818559401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995072671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98673254,0.001331756,0.00027311398,0.0045308773,0.002849317,0.0017920977,0.00012869717,0.000013621991,0.002347964],"genre_scores_gemma":[0.98068005,0.005241942,0.0075861537,0.0010253779,0.0014056538,0.000090719914,0.000017662367,0.00007041938,0.0038820475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956796,0.00023934705,0.0025341853,0.00048112826,0.0005433062,0.00052240526],"domain_scores_gemma":[0.99100274,0.0037315064,0.0032442592,0.00048776175,0.0010545328,0.00047918808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023081813,0.00032870748,0.0036950072,0.00015877653,0.000053372387,0.000014830501,0.0002927999,0.00055767957,0.00058714615],"category_scores_gemma":[0.00039982196,0.00019426171,0.0005161701,0.00020755501,0.0002361145,0.00013142698,0.000053257078,0.00079590466,0.0000044606227],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5992382,0.006122624,0.34955737,0.0007367393,0.0033182374,0.00081401493,0.00039307243,0.00018936377,0.00044124923,0.000024880155,0.008088555,0.031075664],"study_design_scores_gemma":[0.56743234,0.26565155,0.09170005,0.0012410997,0.0037919783,0.00015173276,0.00027918365,0.0003112301,0.006980813,0.000010155245,0.06203505,0.0004147827],"about_ca_topic_score_codex":0.0003502452,"about_ca_topic_score_gemma":0.0021447612,"teacher_disagreement_score":0.25952893,"about_ca_system_score_codex":0.0018901501,"about_ca_system_score_gemma":0.009181073,"threshold_uncertainty_score":0.99643594},"labels":[],"label_agreement":null},{"id":"W2995242987","doi":"10.1200/jco.19.02768","title":"Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Guideline; Biomarker discovery; Biomarker; Management of prostate cancer; Prostatectomy; Oncology; Medical physics; Cancer; Internal medicine; Pathology; Proteomics","score_opus":0.18783738929560062,"score_gpt":0.5500242530253391,"score_spread":0.36218686372973846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995242987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029761987,0.99046135,0.000012188397,0.0042841192,0.0024388174,0.0014809965,0.00004778012,0.000007655474,0.00096949615],"genre_scores_gemma":[0.000038246682,0.9956888,0.0013940983,0.0018115758,0.00072734925,0.00008894899,0.000043853128,0.000066776236,0.00014036149],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903702,0.00085060357,0.0074672108,0.0004391928,0.00047021956,0.00040253898],"domain_scores_gemma":[0.9916376,0.0015749439,0.0053950283,0.00040125623,0.00049828616,0.00049290695],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004022999,0.00043548457,0.009091143,0.0003945544,0.0000152251005,0.000011460473,0.00027238543,0.0009979989,0.00016786595],"category_scores_gemma":[0.0016615991,0.00026940496,0.002348092,0.00037392054,0.00018516526,0.000062138344,0.00009274544,0.0016455898,0.000049145197],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010306902,0.0013419575,0.0014970107,0.0037905965,0.003256393,0.0043888763,0.000008889523,0.000011141376,2.1355919e-7,0.000014872948,0.012230748,0.9724286],"study_design_scores_gemma":[0.009323863,0.0072068702,0.00016600062,0.019356819,0.005713154,0.00037064907,0.00000971611,0.00001260706,0.0000015787159,0.000038269474,0.957595,0.00020548374],"about_ca_topic_score_codex":0.00011484674,"about_ca_topic_score_gemma":0.000034687484,"teacher_disagreement_score":0.9722231,"about_ca_system_score_codex":0.0013107855,"about_ca_system_score_gemma":0.012184684,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2995682899","doi":"10.1200/jco.19.02748","title":"Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Lung cancer; Stage (stratigraphy); Positron emission tomography; Magnetic resonance imaging; Radiology; Randomized controlled trial; Medical physics; Internal medicine; Pathology","score_opus":0.14893239327123653,"score_gpt":0.5650323579464293,"score_spread":0.4160999646751927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995682899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9016781,0.018780204,0.00016311515,0.06574206,0.0034517585,0.0006227694,0.000019094474,0.000014669233,0.009528265],"genre_scores_gemma":[0.96419376,0.019611996,0.0011836074,0.0114954375,0.0019788577,0.000028896771,0.0000019851047,0.000025290366,0.00148015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584085,0.00060465187,0.0022769866,0.00025390423,0.0006642333,0.00035935378],"domain_scores_gemma":[0.9935605,0.0024385415,0.001255586,0.00023293888,0.0021788669,0.00033355286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00419608,0.00017613043,0.0017808615,0.00011136922,0.00002968564,0.0000098775945,0.00018764431,0.00025011334,0.0016834709],"category_scores_gemma":[0.0039878627,0.00010632324,0.00056068995,0.00016539727,0.00027078096,0.00012717886,0.00010830263,0.0013661055,0.00006490022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014959411,0.0006860932,0.8467899,0.000046457666,0.0015976202,0.0005160897,0.0002468149,0.000013715899,0.00013610937,0.000046822126,0.069977224,0.06498377],"study_design_scores_gemma":[0.0102551095,0.009152634,0.6217261,0.00024070583,0.000097096345,0.000094735406,0.00019027133,0.00017636591,0.00006847803,0.000103750644,0.35777,0.0001247762],"about_ca_topic_score_codex":0.00008119062,"about_ca_topic_score_gemma":0.0001459798,"teacher_disagreement_score":0.28779277,"about_ca_system_score_codex":0.00045642394,"about_ca_system_score_gemma":0.0027167585,"threshold_uncertainty_score":0.99922913},"labels":[],"label_agreement":null},{"id":"W2995810532","doi":"10.1200/jco.2012.30.15_suppl.9524","title":"Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children's Oncology Group.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Vincristine; Lymphoma; Cyclophosphamide; Lymph node; Chemotherapy; Prednisone; Nodular sclerosis; Surgery; Internal medicine; Hodgkin lymphoma","score_opus":0.07159168697889091,"score_gpt":0.4260902205038798,"score_spread":0.3544985335249889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995810532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864253,0.0072776987,0.000026309523,0.0029946775,0.0014093746,0.0005727729,0.000026613763,0.000013349405,0.0012539314],"genre_scores_gemma":[0.9795119,0.012047319,0.0020972774,0.00023739498,0.0058056586,0.00003829152,0.000036727623,0.000030702893,0.00019470333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99441415,0.0010502351,0.0030500498,0.00034175953,0.0006643488,0.00047948558],"domain_scores_gemma":[0.98881257,0.005951809,0.0037090285,0.0005379165,0.0003615572,0.0006271027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025510977,0.00031335294,0.0024784664,0.000137793,0.00009528499,0.000010458329,0.00018648499,0.0006002596,0.00022574863],"category_scores_gemma":[0.0010045662,0.00014922537,0.00088924513,0.00026844558,0.00034261533,0.00014750082,0.000064535605,0.0002695652,0.000024033956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019304637,0.017719414,0.79640263,0.000008243232,0.0016230418,0.008091718,0.00021135769,0.000004481425,0.000013272193,0.00006814961,0.001369262,0.15518379],"study_design_scores_gemma":[0.04505731,0.046657953,0.7924218,0.000036731017,0.0026869862,0.013612879,0.00013469602,0.000009323055,0.00024263738,0.000019154108,0.098997794,0.00012272774],"about_ca_topic_score_codex":0.0011692955,"about_ca_topic_score_gemma":0.00021693656,"teacher_disagreement_score":0.15506107,"about_ca_system_score_codex":0.0016439573,"about_ca_system_score_gemma":0.0029238546,"threshold_uncertainty_score":0.60852337},"labels":[],"label_agreement":null},{"id":"W2995817903","doi":"10.1200/jco.19.01203","title":"Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Antioxidant Activity and Oxidative Stress","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Internal medicine; Breast cancer; Proportional hazards model; Chemotherapy; Oncology; Cancer; Clinical trial; Cyclophosphamide; Vitamin E; Confidence interval; Antioxidant","score_opus":0.09548220185741739,"score_gpt":0.4520751477476196,"score_spread":0.3565929458902022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995817903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956171,0.000030180698,0.000010017526,0.0026423528,0.00089015375,0.0007085762,0.000050431205,0.0000031546545,0.000048056314],"genre_scores_gemma":[0.997814,0.00072412344,0.00045567134,0.0004813939,0.00038239002,0.0000050159088,0.0000060503844,0.000015820782,0.00011552313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581546,0.0008505251,0.002443797,0.00025663184,0.00041611594,0.00021745401],"domain_scores_gemma":[0.9943005,0.003186987,0.0017269747,0.0001517031,0.00042089119,0.00021295523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022453736,0.00018066625,0.0026050138,0.000118155025,0.000024665824,0.000007701802,0.000104059705,0.00027112188,0.00034874387],"category_scores_gemma":[0.000865816,0.0001080551,0.0003331018,0.00011893529,0.00031070082,0.00027985135,0.000059373524,0.0009397267,0.0000013067246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.242134,0.0043735625,0.74653834,0.000027347362,0.00067439064,0.000048293365,0.00008840433,0.000004698779,0.00005567016,0.00001159085,0.000041767988,0.0060019307],"study_design_scores_gemma":[0.2022952,0.017254068,0.77964747,0.000118431424,0.00014858182,0.000008819594,0.00012283422,0.000012767672,0.000024325074,0.0000057239417,0.00027357807,0.00008822013],"about_ca_topic_score_codex":0.0001022593,"about_ca_topic_score_gemma":0.0004584561,"teacher_disagreement_score":0.039838817,"about_ca_system_score_codex":0.000078427845,"about_ca_system_score_gemma":0.00052699563,"threshold_uncertainty_score":0.44063592},"labels":[],"label_agreement":null},{"id":"W2996419897","doi":"10.1200/jco.2013.31.15_suppl.e17596","title":"The risk of debilitating falls (DF) in Manitobans living with cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cancer; Hazard ratio; Cancer registry; Internal medicine; Population; Incidence (geometry); Confidence interval; Retrospective cohort study; Cumulative incidence; Surgery; Cohort","score_opus":0.32957689745598817,"score_gpt":0.6322318217824598,"score_spread":0.3026549243264717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996419897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97467977,0.0009103847,0.000059781258,0.015967604,0.0019295192,0.0004278227,0.0000023850678,0.0000038636504,0.0060188794],"genre_scores_gemma":[0.9932261,0.0026304692,0.0017997747,0.0009143563,0.0010828011,0.000035391557,5.9165828e-8,0.000011940057,0.00029909707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9843909,0.01099261,0.0038776507,0.00011485327,0.00027484822,0.0003491177],"domain_scores_gemma":[0.88722014,0.104990646,0.0064946506,0.0001799153,0.000897248,0.00021740035],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.025281157,0.000087867105,0.0009409754,0.00005864561,0.00027589523,0.0000064031647,0.000253918,0.00035459903,0.00025503436],"category_scores_gemma":[0.032721996,0.000042733118,0.00013380183,0.00014636811,0.00013758655,0.00023915136,0.00005455213,0.0027674283,0.000030154884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001777685,0.000117097195,0.85288423,0.0000911445,0.0000831683,0.0000090516405,0.0029057458,0.00002355159,0.0000069718308,0.00015444237,0.001897944,0.14164889],"study_design_scores_gemma":[0.0009783356,0.0024986619,0.9003327,0.00091316155,0.00004035954,0.000008124221,0.021923088,0.000113060545,3.6802572e-7,0.00038171993,0.07275947,0.00005095265],"about_ca_topic_score_codex":0.015196136,"about_ca_topic_score_gemma":0.05819151,"teacher_disagreement_score":0.14159794,"about_ca_system_score_codex":0.00016439545,"about_ca_system_score_gemma":0.0033578165,"threshold_uncertainty_score":0.99953324},"labels":[],"label_agreement":null},{"id":"W2996677572","doi":"10.1200/jco.19.01904","title":"Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Northeast Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Urology; Randomized controlled trial; Internal medicine; Hazard ratio; Oncology; Neoadjuvant therapy; Clinical endpoint; Incidence (geometry); Cancer; Confidence interval; Breast cancer","score_opus":0.05816555287264927,"score_gpt":0.4380329039485728,"score_spread":0.3798673510759235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996677572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249525,0.008611142,0.00025010735,0.0018745874,0.000805384,0.005812951,0.0000030920892,0.000006029269,0.00014145477],"genre_scores_gemma":[0.9546694,0.04204117,0.0012547219,0.0011664663,0.00045445873,0.00028148387,0.0000021908927,0.0000221936,0.00010792531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945487,0.00081728015,0.0037764763,0.00021969165,0.00041854737,0.00021933886],"domain_scores_gemma":[0.99210197,0.0030796516,0.003996703,0.00018739812,0.0004419138,0.00019234669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005727192,0.00019638923,0.0059332447,0.00019339936,0.000014756648,0.000008568688,0.00010128909,0.00020844542,0.0002181911],"category_scores_gemma":[0.0006212954,0.000103251405,0.00081419735,0.00016993319,0.00019335815,0.00011644254,0.000009051153,0.0004705422,9.896531e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9187212,0.00364106,0.022611279,0.000023428249,0.0018500373,0.00024687103,0.0003804667,0.00023225043,0.0015967651,0.000025831096,0.00004339981,0.050627425],"study_design_scores_gemma":[0.9522639,0.041477773,0.00059844326,0.0005107839,0.00044503823,0.000062826555,0.00006132221,0.0007253356,0.0021414822,0.00012400767,0.0014954939,0.00009357762],"about_ca_topic_score_codex":0.0001771585,"about_ca_topic_score_gemma":0.00002408164,"teacher_disagreement_score":0.05053385,"about_ca_system_score_codex":0.00048701421,"about_ca_system_score_gemma":0.0038548014,"threshold_uncertainty_score":0.6838252},"labels":[],"label_agreement":null},{"id":"W2996931187","doi":"10.1200/jco.2009.27.15_suppl.6573","title":"Importance of stratification when measuring quality of care: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; Juravinski Cancer Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer registry; Health care; Residence; Population; Family medicine; Gerontology; Environmental health; Demography","score_opus":0.7470213079471119,"score_gpt":0.6511175842341949,"score_spread":0.095903723712917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996931187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824832,0.00013304863,0.00025282448,0.014513848,0.00033471914,0.0014897665,0.000015017829,0.000011343228,0.00076623337],"genre_scores_gemma":[0.99358344,0.000057319434,0.005660631,0.00032118708,0.0003075913,0.00002250064,0.0000029630105,0.0000055663227,0.000038784416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98769915,0.004939121,0.005249495,0.00031866872,0.0014817142,0.00031183616],"domain_scores_gemma":[0.9790793,0.010823864,0.0071696644,0.0005698427,0.002152827,0.00020447122],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08163731,0.000097070195,0.0011609454,0.00006798845,0.00024041593,0.00003908535,0.00082655577,0.00021062288,0.0000078844105],"category_scores_gemma":[0.04475227,0.00006791088,0.0002921519,0.00020511395,0.00036706,0.0002882873,0.000025759593,0.00072503276,1.3619659e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019324167,0.0052158805,0.715283,0.000045850735,0.00022783279,0.00007279706,0.14268291,0.000048223057,0.00028012777,0.00042317747,0.0052825715,0.11111349],"study_design_scores_gemma":[0.0023265693,0.03470894,0.91246593,0.00016366625,0.000040029005,0.0000019987945,0.040814072,0.0000051622355,0.00007070256,0.0042422256,0.0050599463,0.00010076117],"about_ca_topic_score_codex":0.07726097,"about_ca_topic_score_gemma":0.37898955,"teacher_disagreement_score":0.30172858,"about_ca_system_score_codex":0.0012121871,"about_ca_system_score_gemma":0.022031896,"threshold_uncertainty_score":0.9835123},"labels":[],"label_agreement":null},{"id":"W2997220156","doi":"10.1200/jco.19.02393","title":"Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity","year":2019,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Biomarker; Randomized controlled trial; Value (mathematics); Oncology; Internal medicine; Statistics; Genetics; Biology","score_opus":0.2707149978191177,"score_gpt":0.477529410803239,"score_spread":0.20681441298412134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997220156","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10710417,0.0059920796,0.13246949,0.68678766,0.053804185,0.011333817,0.00059124804,0.000017493681,0.0018998571],"genre_scores_gemma":[0.012580168,0.018677885,0.07795018,0.8133154,0.07389644,0.00014809183,0.00077796256,0.00025981286,0.002394092],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872343,0.004136347,0.007236665,0.00055268547,0.00044523692,0.00039476992],"domain_scores_gemma":[0.963401,0.025398571,0.009125884,0.0006726508,0.0010862772,0.000315592],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021263272,0.0003810068,0.0050558685,0.00013719796,0.000040270534,0.000018641034,0.00077649864,0.0043905317,0.00007124374],"category_scores_gemma":[0.059071247,0.00029291454,0.0037199573,0.000056627425,0.0006784999,0.00000609933,0.00021818034,0.0019680052,0.0000039001266],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44114327,0.0007801453,0.000016806844,0.00006665395,0.0008978964,0.000049301863,0.000004104163,0.000017691124,0.0014466302,0.0000053466515,0.5477181,0.007854051],"study_design_scores_gemma":[0.36993396,0.013790482,0.000031344567,0.000109850116,0.0009407595,0.000019403147,0.0000052191417,0.000079086596,0.0011222914,0.00034574745,0.6133934,0.00022842089],"about_ca_topic_score_codex":0.000009817277,"about_ca_topic_score_gemma":0.0000015490424,"teacher_disagreement_score":0.12652771,"about_ca_system_score_codex":0.00005295262,"about_ca_system_score_gemma":0.0071047046,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W2997351648","doi":"10.1200/jco.19.01381","title":"Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Ipilimumab; Discontinuation; Adverse effect; Internal medicine; Hazard ratio; Melanoma; Adjuvant; Cancer; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Surgery; Confidence interval; Immunotherapy","score_opus":0.07986884141034623,"score_gpt":0.4345343013265612,"score_spread":0.35466545991621495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997351648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149793,0.00004030747,0.00027347083,0.0008194627,0.005542998,0.0014532997,0.000022973454,0.000031699416,0.0003178494],"genre_scores_gemma":[0.9950069,0.00021840057,0.0012141668,0.00033805802,0.0010582845,0.000023720424,0.000015722935,0.00004418792,0.0020805558],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9945805,0.00062364235,0.003446538,0.00043787484,0.0005268017,0.0003846598],"domain_scores_gemma":[0.99153924,0.0029801626,0.0037722026,0.00053908007,0.00072981406,0.0004394794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019242589,0.00028821343,0.002802189,0.00039581893,0.000056902794,0.000013514257,0.00037342624,0.00020536411,0.0008657285],"category_scores_gemma":[0.0028849754,0.0001967703,0.0005478544,0.0003757323,0.00021121121,0.00010005908,0.00019284188,0.0010844921,0.000052176063],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57117003,0.022647463,0.008788956,0.00008286562,0.0029886714,0.0010838404,0.0005201195,0.000031310872,0.00044482923,0.000018515162,0.006769174,0.3854542],"study_design_scores_gemma":[0.22285526,0.65870106,0.058501065,0.00009404041,0.0022655465,0.0002464554,0.0035521977,0.00048517346,0.00015494562,0.000020204934,0.052868765,0.00025527683],"about_ca_topic_score_codex":0.0004933681,"about_ca_topic_score_gemma":0.005340248,"teacher_disagreement_score":0.6360536,"about_ca_system_score_codex":0.00036285745,"about_ca_system_score_gemma":0.0005522617,"threshold_uncertainty_score":0.947912},"labels":[],"label_agreement":null},{"id":"W2997569907","doi":"10.1200/jco.19.02456","title":"Ethical and Policy Issues for Seamless Phase I Oncology Trials","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; Phase (matter); Internal medicine; Family medicine","score_opus":0.18104306078522953,"score_gpt":0.5865204832438125,"score_spread":0.4054774224585829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997569907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95182675,0.0022718103,0.0013818673,0.040173545,0.0023439133,0.00041057894,0.000054186115,0.0000027735696,0.0015345814],"genre_scores_gemma":[0.9532475,0.010338772,0.008221708,0.018059403,0.009451989,0.000011955904,0.00002065575,0.000029434497,0.0006185752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967464,0.00069918844,0.0019674657,0.00023782393,0.00012150248,0.0002275853],"domain_scores_gemma":[0.99376076,0.0038687442,0.0014800528,0.00018656238,0.00040033465,0.00030354958],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008887671,0.00012887878,0.0014576218,0.00007308385,0.000032937365,0.000016521279,0.00020939848,0.0012098956,0.000036363683],"category_scores_gemma":[0.021132974,0.00009964841,0.00048154706,0.00004657354,0.00018430194,0.000003931172,0.00011251774,0.0006147525,0.000006538341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021907782,0.0025714533,0.0040403837,0.00008435801,0.0010135783,0.00006891257,0.00014757225,0.00008900063,0.07648819,0.008642225,0.1281122,0.7568343],"study_design_scores_gemma":[0.013510376,0.027320333,0.00082558923,0.000013271539,0.00012992998,0.00009568949,0.000074390475,0.000048020775,0.0029005678,0.0023296957,0.95263475,0.000117354844],"about_ca_topic_score_codex":0.000017027172,"about_ca_topic_score_gemma":0.000037381236,"teacher_disagreement_score":0.82452255,"about_ca_system_score_codex":0.000052072995,"about_ca_system_score_gemma":0.0026244828,"threshold_uncertainty_score":0.98711246},"labels":[],"label_agreement":null},{"id":"W2997738375","doi":"10.1200/jco.2012.30.15_suppl.2098","title":"Effects of lazaroid U-74389G liposomes in a glioblastoma mouse model.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lipid peroxidation; Glioblastoma; Malondialdehyde; Nuclear medicine; Liposome; Bioluminescence imaging; Immunohistochemistry; Pharmacology; Luciferase; Andrology; Pathology; Internal medicine; Oxidative stress; Cancer research; Cell culture; Biology; Biochemistry","score_opus":0.03189152955792377,"score_gpt":0.3845091545092429,"score_spread":0.3526176249513191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997738375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989481,0.007184327,0.00036325658,0.00022249823,0.0022364263,0.00010921044,0.0000036451777,0.0000021992169,0.00039746866],"genre_scores_gemma":[0.9883387,0.0048232535,0.001654318,0.0006571963,0.004052157,0.0000046090227,9.16137e-7,0.000017303773,0.00045154782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977094,0.00032093297,0.0013589028,0.00013857265,0.00017920906,0.0002929957],"domain_scores_gemma":[0.9980774,0.00032915108,0.0009782973,0.00017340221,0.00017396254,0.00026781377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017311295,0.00012758186,0.0008865687,0.00010123054,0.000013533056,0.0000031412023,0.00023265817,0.00046999523,0.000010059207],"category_scores_gemma":[0.0018790606,0.000102494334,0.0004125671,0.000082984865,0.00014332277,0.000013896738,0.00009396785,0.00040984838,0.0000032669097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062610493,0.0043170517,0.014517182,0.00013425341,0.00040979643,0.000018085535,0.00028084582,0.00068494293,0.862351,0.00029286282,0.01471367,0.09601926],"study_design_scores_gemma":[0.014469477,0.011901916,0.03991249,0.00008399783,0.00033457958,0.00016006072,0.00009412838,0.00024516354,0.51299465,0.0003770898,0.41902348,0.00040292996],"about_ca_topic_score_codex":0.000008690236,"about_ca_topic_score_gemma":0.000052731775,"teacher_disagreement_score":0.4043098,"about_ca_system_score_codex":0.000023248267,"about_ca_system_score_gemma":0.00059220335,"threshold_uncertainty_score":0.41795975},"labels":[],"label_agreement":null},{"id":"W2998506404","doi":"10.1200/jco.2012.30.15_suppl.6632","title":"Post hoc analysis of relationship between baseline white blood cell count and renal and hepatic function and response in a randomized phase III trial of decitabine in patients age 65 or older with acute myeloid leukemia.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Creatinine; Blood urea nitrogen; Internal medicine; Renal function; White blood cell; Gastroenterology; Decitabine; Post-hoc analysis; Cytarabine; Absolute neutrophil count; Urology; Myeloid leukemia; Neutropenia; Chemotherapy","score_opus":0.05565027784404605,"score_gpt":0.40686781763520424,"score_spread":0.3512175397911582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998506404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997485,0.00036444177,0.0002929156,0.00082878134,0.000068687266,0.00090744044,0.000030579744,0.0000023875502,0.000019781219],"genre_scores_gemma":[0.9964281,0.0007016253,0.0023756868,0.00015679069,0.00018506845,0.000011210339,0.000033264772,0.000015855961,0.000092402195],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9922056,0.0032361771,0.0035055466,0.0002256789,0.00055475807,0.0002722013],"domain_scores_gemma":[0.976737,0.020068051,0.0020893225,0.00019369667,0.0005191536,0.00039278288],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021296132,0.0001818258,0.0034944005,0.0012185513,0.000027396285,0.000007217618,0.00007717665,0.00039699813,0.000034736244],"category_scores_gemma":[0.014271906,0.00011245898,0.00022949073,0.0008127819,0.0004955635,0.0002189638,0.000067071946,0.0010237243,2.362171e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5814532,0.0015114946,0.41361985,0.000034264933,0.0010264198,0.00009919141,0.0003452302,0.00000558934,0.000153209,0.0000019310182,0.000019975352,0.0017296283],"study_design_scores_gemma":[0.4812208,0.023009615,0.48991522,0.00009120419,0.0052856146,0.00002021308,0.000075408345,0.00027991916,0.000016410064,0.000010460221,0.000018593446,0.00005652461],"about_ca_topic_score_codex":0.00008025591,"about_ca_topic_score_gemma":0.00015536121,"teacher_disagreement_score":0.10023241,"about_ca_system_score_codex":0.00024484168,"about_ca_system_score_gemma":0.0016376687,"threshold_uncertainty_score":0.9940313},"labels":[],"label_agreement":null},{"id":"W2998689694","doi":"10.1200/jco.2013.31.15_suppl.5042","title":"NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Interior Health; Cancer Care South East; London Health Sciences Centre; Queen's University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Nausea; Oncology; Adverse effect; Phases of clinical research; Docetaxel; Cancer; Neutropenia; Gastroenterology; Toxicity; Clinical trial","score_opus":0.08646921911035348,"score_gpt":0.4616130974416957,"score_spread":0.3751438783313422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998689694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978577,0.00037874698,0.00002649574,0.00027500323,0.00061945606,0.0007612567,0.000029872077,0.0000021471492,0.000049332546],"genre_scores_gemma":[0.9982112,0.00016321623,0.00096055836,0.00022995794,0.0002371952,0.00006734214,0.000010109648,0.000022138061,0.00009826678],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99620384,0.00055127864,0.0022602999,0.00030024495,0.00041149766,0.0002728574],"domain_scores_gemma":[0.99624014,0.00024531267,0.0021927087,0.00024893912,0.0008666996,0.00020617757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012646088,0.00019761216,0.00094537187,0.000109396984,0.000043829477,0.000012378974,0.00028014873,0.00018149371,0.00018713092],"category_scores_gemma":[0.0009389801,0.0001271648,0.00014424654,0.00018802445,0.00015751332,0.000022549093,0.00008605496,0.0004972329,0.0000018933757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098298505,0.0673506,0.4744679,0.00019975862,0.0030384008,0.00030961697,0.0022389374,0.0017485884,0.028257329,0.000011454969,0.008354486,0.31572443],"study_design_scores_gemma":[0.0820213,0.45273542,0.44376114,0.00036389756,0.0007069496,0.000026096282,0.0012009438,0.000108654625,0.002958299,0.00011589044,0.01541966,0.0005817437],"about_ca_topic_score_codex":0.00020047608,"about_ca_topic_score_gemma":0.0020901556,"teacher_disagreement_score":0.38538483,"about_ca_system_score_codex":0.00010696276,"about_ca_system_score_gemma":0.00182702,"threshold_uncertainty_score":0.51856303},"labels":[],"label_agreement":null},{"id":"W2999400187","doi":"10.1200/jco.19.02309","title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1497,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Breast cancer; Oncology; Estrogen receptor; Cancer; Internal medicine; Progesterone receptor; Gynecology; Estrogen; Pathology","score_opus":0.08838685065811515,"score_gpt":0.42489571817795796,"score_spread":0.3365088675198428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999400187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9327103,0.0038964532,0.00005417067,0.06276616,0.00030174034,0.000101334794,0.000041266594,0.0000045255542,0.00012403747],"genre_scores_gemma":[0.97626984,0.003542361,0.011699843,0.0061064283,0.002331645,0.000009400525,0.000010366039,0.000020444892,0.000009691522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788696,0.00018286385,0.0013751069,0.00024353963,0.000119804485,0.00019174822],"domain_scores_gemma":[0.9984148,0.00015135304,0.0008410718,0.000091645976,0.00027255836,0.00022856961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007484445,0.00013678997,0.00066664524,0.0000205725,0.000030411693,0.000007699227,0.0001509961,0.0002074767,0.000021715681],"category_scores_gemma":[0.0010119269,0.00010669614,0.00011109174,0.00009308114,0.00015280633,0.000008382361,0.00014787137,0.000304389,0.000003791618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025694983,0.00040761702,0.7424225,0.000020661402,0.00037690747,0.000083591396,0.00005086324,0.00006736319,0.006757555,0.00001703791,0.012409838,0.23481655],"study_design_scores_gemma":[0.011962934,0.0060532326,0.63790834,0.00012150793,0.00026792474,0.0005757645,0.00019969644,0.00014280077,0.0017330614,0.00007450331,0.34061363,0.00034660977],"about_ca_topic_score_codex":0.00005945677,"about_ca_topic_score_gemma":0.000054941258,"teacher_disagreement_score":0.3282038,"about_ca_system_score_codex":0.00003894541,"about_ca_system_score_gemma":0.00058399484,"threshold_uncertainty_score":0.43509424},"labels":[],"label_agreement":null},{"id":"W2999424170","doi":"10.1200/jco.2013.31.15_suppl.e17587","title":"Keeping guidelines current: A six-month evaluation of Wiki-based lung cancer guidelines.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Guideline; Referral; Family medicine; The Internet; Public health; Breast cancer; Lung cancer; Medical education; World Wide Web; Cancer; Nursing; Pathology; Internal medicine","score_opus":0.7066311733473374,"score_gpt":0.6978410650472993,"score_spread":0.008790108300038124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999424170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8104396,0.0110484045,0.000404008,0.13582382,0.039248053,0.0015511478,0.0000032364906,0.000017567274,0.0014641847],"genre_scores_gemma":[0.95238256,0.005681192,0.013486303,0.0048003295,0.023260191,0.00032878117,0.0000034512434,0.000026426304,0.000030788153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905402,0.0027457476,0.0046334886,0.00018558168,0.0015629703,0.00033203053],"domain_scores_gemma":[0.97021997,0.0082561355,0.0051638666,0.00017087368,0.015742455,0.00044670806],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029981038,0.000115184135,0.00094063935,0.00016829916,0.00016449348,0.000019438647,0.0004075585,0.00041206513,0.0010093588],"category_scores_gemma":[0.19717804,0.00009818406,0.00033463404,0.00041412032,0.00038399274,0.00033947185,0.000026804722,0.000606423,0.000013051446],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006983355,0.00031387352,0.096308514,0.000032747714,0.00004205958,6.4006366e-7,0.0012758396,0.00050924026,0.000010963429,0.00016063357,0.0439939,0.85728174],"study_design_scores_gemma":[0.005120771,0.0010650504,0.28899717,0.000800392,0.00075383234,0.0000014786397,0.0021873484,0.028860563,0.000022831002,0.0034719703,0.6684508,0.00026781438],"about_ca_topic_score_codex":0.008583456,"about_ca_topic_score_gemma":0.0041338997,"teacher_disagreement_score":0.85701394,"about_ca_system_score_codex":0.0008155038,"about_ca_system_score_gemma":0.020490408,"threshold_uncertainty_score":0.99990386},"labels":[],"label_agreement":null},{"id":"W3000281526","doi":"10.1200/jco.19.01731","title":"Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Framing (construction); Urothelial cancer; Clinical Oncology; Oncology; Internal medicine; Cancer","score_opus":0.20458011642438761,"score_gpt":0.4975481715894315,"score_spread":0.2929680551650439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000281526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9346598,0.0014473493,0.0006918889,0.060779586,0.00097486953,0.0004204812,0.00009782886,0.000013905373,0.0009143105],"genre_scores_gemma":[0.9559699,0.0012797344,0.009531369,0.030167023,0.0029893047,0.000018873228,0.000012662026,0.000017755849,0.0000133209405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959631,0.000821927,0.0021892237,0.00031263178,0.00046186527,0.00025125736],"domain_scores_gemma":[0.9948953,0.0023706788,0.001608612,0.00029008626,0.00031329188,0.0005220609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013656488,0.00019312296,0.0016836332,0.000018734732,0.000057756457,0.000014211071,0.00036208399,0.00039780885,0.00085129077],"category_scores_gemma":[0.0009028452,0.00011320248,0.00067087123,0.00014183475,0.00026684438,0.00013424108,0.00009751347,0.0010200959,0.00001116246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016898869,0.0090274615,0.44521412,0.00012856082,0.018153517,0.00084872526,0.023740228,0.0010824607,0.01802613,0.00023860476,0.06020733,0.406434],"study_design_scores_gemma":[0.015705142,0.048909985,0.7364766,0.0001525585,0.0053127524,0.00003319962,0.01093006,0.0006295197,0.0015157947,0.003457519,0.17661297,0.00026391225],"about_ca_topic_score_codex":0.0021653841,"about_ca_topic_score_gemma":0.0005983964,"teacher_disagreement_score":0.40617007,"about_ca_system_score_codex":0.0001816846,"about_ca_system_score_gemma":0.0040143467,"threshold_uncertainty_score":0.9321037},"labels":[],"label_agreement":null},{"id":"W3000713577","doi":"10.1200/jco.2012.30.15_suppl.5107","title":"Cervical cancer treatment for operable lesions in a low-resource contemporary setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Cervical cancer; Hysterectomy; Surgery; Radical Hysterectomy; Stage (stratigraphy); Cancer; Gynecology; Internal medicine","score_opus":0.31657214073162276,"score_gpt":0.557779729369374,"score_spread":0.24120758863775127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000713577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86927325,0.011538711,0.00016620301,0.06962317,0.0014640907,0.001158932,0.000030370064,0.000015932012,0.04672935],"genre_scores_gemma":[0.98918647,0.00073001627,0.000891334,0.004630367,0.003296005,0.000050255116,0.0000046877362,0.000019294834,0.0011915897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709404,0.00034514497,0.0016763777,0.00015187582,0.00030129458,0.00043127232],"domain_scores_gemma":[0.9951689,0.0031389364,0.00042835053,0.00015106169,0.0003197205,0.0007929905],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033408545,0.00012258746,0.0012986813,0.00012851706,0.00004515731,0.0000072010807,0.00013257655,0.0003413059,0.0013741077],"category_scores_gemma":[0.0019823723,0.00007747633,0.0005088687,0.00014332136,0.00012430886,0.00010632082,0.00004838057,0.0007733398,0.000014701697],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013086018,0.005782995,0.32962206,0.0001197575,0.00027267938,0.00015689517,0.00033176283,0.000024287228,0.000056172186,0.000122244,0.023967784,0.62645733],"study_design_scores_gemma":[0.015554312,0.008432137,0.41073722,0.00008607707,0.00011359768,0.00006598446,0.00022766757,0.00022505704,0.00011842103,0.00007082609,0.56428903,0.00007964279],"about_ca_topic_score_codex":0.00018744552,"about_ca_topic_score_gemma":0.00019871492,"teacher_disagreement_score":0.6263777,"about_ca_system_score_codex":0.00050385785,"about_ca_system_score_gemma":0.0030585106,"threshold_uncertainty_score":0.9995388},"labels":[],"label_agreement":null},{"id":"W3000715936","doi":"10.1200/jco.19.02757","title":"Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Guideline; Systematic review; Medical physics; Randomized controlled trial; Modalities; Evidence-based medicine; Disease; Prostate; Cancer; Radiology; MEDLINE; Internal medicine; Alternative medicine; Pathology","score_opus":0.19539394248530728,"score_gpt":0.5694346840342207,"score_spread":0.3740407415489134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000715936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013858765,0.9790876,0.0002538957,0.015318635,0.0027147166,0.0017710818,0.00017640798,0.000019909647,0.0006438994],"genre_scores_gemma":[0.000017695245,0.97863376,0.014756683,0.0022155684,0.0037923756,0.00028346275,0.00006816452,0.000082595325,0.0001497218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923356,0.00027423113,0.0061984477,0.00045396812,0.00033790304,0.00039981052],"domain_scores_gemma":[0.9897741,0.0022257264,0.0061187395,0.00025771363,0.000991484,0.0006322158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019184445,0.00046333167,0.007935531,0.00014546745,0.00005624892,0.000033343775,0.00027094086,0.0004315891,0.00007609973],"category_scores_gemma":[0.0015804304,0.00029013725,0.0025813002,0.00018076463,0.00018060661,0.000178733,0.00007885413,0.0013471005,0.000011262179],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011171156,0.00060307735,0.000090602094,0.004026913,0.001489859,0.0010670492,0.000024013632,0.000015289845,2.473041e-7,0.00007095793,0.031885248,0.9596096],"study_design_scores_gemma":[0.00695198,0.009463798,0.00002261741,0.010465919,0.006648752,0.00036660343,0.00008972966,0.000033896784,9.022032e-7,0.00026896247,0.9654662,0.00022063465],"about_ca_topic_score_codex":0.000011890177,"about_ca_topic_score_gemma":0.00000817105,"teacher_disagreement_score":0.959389,"about_ca_system_score_codex":0.0007596601,"about_ca_system_score_gemma":0.017944207,"threshold_uncertainty_score":0.99995506},"labels":[],"label_agreement":null},{"id":"W3001160691","doi":"10.1200/jco.2018.36.15_suppl.5511","title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Ovarian cancer; Interim; Internal medicine; Clinical endpoint; Interim analysis; Oncology; Cancer; Progression-free survival; Topotecan; Chemotherapy; Surgery; Clinical trial; Immunotherapy","score_opus":0.08465868098622457,"score_gpt":0.4704217842886687,"score_spread":0.3857631033024441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001160691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921615,0.00018763535,0.00001751533,0.0058370912,0.00089171523,0.00056401035,0.000092909715,0.0000027490937,0.00024488362],"genre_scores_gemma":[0.99779594,0.00077177066,0.0005146633,0.00036457865,0.00052331,0.000008151686,0.0000040984787,0.000010472384,0.0000070187334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972817,0.00043620553,0.0015611146,0.00025635053,0.0003031809,0.00016146078],"domain_scores_gemma":[0.99593645,0.0015283718,0.0017007927,0.00026324225,0.00039620002,0.00017496073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012466637,0.00014078402,0.0012211003,0.000060560964,0.000039588627,0.0000063242214,0.00012271457,0.00010958866,0.00007542157],"category_scores_gemma":[0.0010381652,0.00007392848,0.00012083932,0.00013975055,0.0002840863,0.000100600024,0.00006231023,0.0005353609,0.0000011365559],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15450248,0.011659334,0.39985833,0.0000060086636,0.0004181894,0.000088751054,0.00042915868,0.0000019319723,0.0000102740705,0.0000045599254,0.0002766206,0.43274438],"study_design_scores_gemma":[0.10477282,0.07038839,0.8191268,0.00035115413,0.000356643,0.000005936726,0.00010313469,0.000015715757,0.00006986406,0.000017344184,0.004734704,0.000057513702],"about_ca_topic_score_codex":0.00041386147,"about_ca_topic_score_gemma":0.0012736195,"teacher_disagreement_score":0.43268687,"about_ca_system_score_codex":0.00022654337,"about_ca_system_score_gemma":0.00088991405,"threshold_uncertainty_score":0.3014716},"labels":[],"label_agreement":null},{"id":"W3001713806","doi":"10.1200/jco.19.02931","title":"Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Gemcitabine; Veliparib; Internal medicine; PARP inhibitor; Pancreatic cancer; Clinical endpoint; Population; Oncology; PALB2; Surgery; Randomized controlled trial; Gastroenterology; Cancer; Germline mutation; Mutation","score_opus":0.10606480296064705,"score_gpt":0.4575294089187974,"score_spread":0.3514646059581503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001713806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938505,0.00030818058,0.00035073905,0.0036652994,0.000087634486,0.001553416,0.000007151137,0.0000048672246,0.00017218724],"genre_scores_gemma":[0.98905605,0.00040343497,0.009238716,0.00086152705,0.00033934994,0.000020006035,0.000008643446,0.000018517701,0.0000537283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99567467,0.0008851802,0.0024431413,0.00026345954,0.0004926454,0.00024087598],"domain_scores_gemma":[0.99315083,0.0038805618,0.0017608757,0.00012570438,0.0005554584,0.0005265888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032283387,0.0001877956,0.0036151998,0.00014877583,0.000041174044,0.000006707439,0.000088222114,0.00027361233,0.000063680156],"category_scores_gemma":[0.0072442447,0.00009951303,0.00012660114,0.00019472554,0.0007655461,0.00012833254,0.00006563514,0.00081294676,8.5247086e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61743695,0.003105147,0.367241,0.000073107214,0.00039919725,0.00027595618,0.0003923167,0.0000011491151,0.0000096790045,0.0000074555605,0.000050279537,0.011007748],"study_design_scores_gemma":[0.6992275,0.14185324,0.15503635,0.00018922663,0.0011663284,0.000109832654,0.00013107002,0.0020280094,0.000007064205,0.000014017982,0.00016082106,0.00007651788],"about_ca_topic_score_codex":0.000048737562,"about_ca_topic_score_gemma":0.0000638831,"teacher_disagreement_score":0.21220466,"about_ca_system_score_codex":0.000044710006,"about_ca_system_score_gemma":0.0011876666,"threshold_uncertainty_score":0.86725605},"labels":[],"label_agreement":null},{"id":"W3003338568","doi":"10.1200/jco.2009.27.15_suppl.9612","title":"Relationships among health-related quality of life indicators in cancer patients: A pooled study of baseline EORTC QLQ-C30 data from 6,739 patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Internal medicine; Cronbach's alpha; Nausea; Cluster (spacecraft); Physical therapy; Oncology; Clinical psychology; Psychometrics","score_opus":0.2988692105775341,"score_gpt":0.5048877271811303,"score_spread":0.2060185166035962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003338568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950758,0.00066604663,0.000015740057,0.0022439642,0.0011183501,0.00055653945,0.00016867157,0.0000065822283,0.00014827486],"genre_scores_gemma":[0.9979531,0.00027529997,0.000106602805,0.0012513804,0.00023952629,0.0000034784468,0.00014062885,0.000013741495,0.000016243604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877544,0.0034062078,0.0074604223,0.0003308127,0.00082100043,0.00022718032],"domain_scores_gemma":[0.98767567,0.00330355,0.007183138,0.0005819328,0.0007396993,0.00051599456],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009221199,0.00016682305,0.0025370268,0.00043972896,0.0000357389,0.0000032155929,0.00040694815,0.000442055,0.00018680496],"category_scores_gemma":[0.017082954,0.00013188453,0.00024022661,0.0007453104,0.00015037393,0.00019476048,0.00010417868,0.0016658783,0.0000018101555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005031825,0.014558006,0.94522154,0.00003084798,0.00033104664,0.0000117264435,0.0016437771,0.000023476978,0.0000013886807,0.000006794244,0.0012942632,0.031845335],"study_design_scores_gemma":[0.019431688,0.012952681,0.96495086,0.00025838384,0.00028959833,3.50041e-7,0.0013969833,0.00006249795,0.0000016050158,0.00010132263,0.00045945402,0.00009459301],"about_ca_topic_score_codex":0.008821768,"about_ca_topic_score_gemma":0.026868148,"teacher_disagreement_score":0.03175074,"about_ca_system_score_codex":0.00026311845,"about_ca_system_score_gemma":0.0022199268,"threshold_uncertainty_score":0.9977786},"labels":[],"label_agreement":null},{"id":"W3003499321","doi":"10.1200/jco.19.03022","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":455,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Carboplatin; Medicine; Atezolizumab; Pembrolizumab; Pemetrexed; Bevacizumab; Oncology; Lung cancer; Internal medicine; Guideline; Crizotinib; Cancer; Chemotherapy; Cisplatin; Immunotherapy; Pathology","score_opus":0.130242166794466,"score_gpt":0.46557585869527746,"score_spread":0.3353336919008114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003499321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8944899,0.0075859786,0.00910368,0.08642975,0.0011355048,0.0008788746,0.000030087755,0.000013285444,0.0003329765],"genre_scores_gemma":[0.7424599,0.055260897,0.04953105,0.1445991,0.0065544504,0.000057649744,0.0000211005,0.00007478531,0.0014411025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690217,0.00015896092,0.0023042944,0.00022845341,0.00019997229,0.00020614405],"domain_scores_gemma":[0.99724406,0.00041439044,0.0013766303,0.0001354668,0.0004988919,0.00033056314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019432907,0.00016125504,0.0011485316,0.000050721123,0.00006230574,0.000020488134,0.00011869868,0.00024998284,0.0004756173],"category_scores_gemma":[0.00044210974,0.00010885416,0.00044110883,0.0000941457,0.00014394181,0.00010562862,0.0000315606,0.0005376455,0.0000026055436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08604185,0.002003193,0.09597692,0.00032665234,0.0032794985,0.00029589148,0.0013455567,0.00013001583,0.07441249,0.000056439247,0.20251305,0.53361845],"study_design_scores_gemma":[0.04482719,0.01441536,0.03238003,0.00014083028,0.00051789527,0.000063894586,0.00018558835,0.0055501126,0.0032783337,0.000044520177,0.89838344,0.0002128181],"about_ca_topic_score_codex":0.000035065324,"about_ca_topic_score_gemma":0.000055024906,"teacher_disagreement_score":0.69587034,"about_ca_system_score_codex":0.00009274861,"about_ca_system_score_gemma":0.0014657396,"threshold_uncertainty_score":0.52076757},"labels":[],"label_agreement":null},{"id":"W3003573098","doi":"10.1200/jco.19.03148","title":"Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Prostate cancer; Cancer; Health care; Management of prostate cancer; Family medicine; Oncology; Gynecology; Internal medicine; Pathology","score_opus":0.1338773678251177,"score_gpt":0.5057329835688538,"score_spread":0.37185561574373605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003573098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78870755,0.06283779,0.000031009247,0.14667298,0.00064583344,0.00095154124,0.00007590547,0.0000072843336,0.00007009389],"genre_scores_gemma":[0.9301168,0.024102261,0.011616792,0.033083897,0.00070353184,0.0000627138,0.000023082146,0.000025625504,0.00026532396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625957,0.00014085922,0.002875296,0.00019368621,0.00025199115,0.0002785805],"domain_scores_gemma":[0.9957907,0.00035168236,0.0022409814,0.00009370562,0.00066082075,0.00086209725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090832636,0.00014118703,0.0017937777,0.000056014516,0.000056423552,0.0000031753,0.000051077634,0.00016069411,0.0000862129],"category_scores_gemma":[0.0005252296,0.000095254996,0.00027223994,0.000071549664,0.000105010884,0.000044259807,0.000026011494,0.00047655095,5.943311e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019072104,0.00082352414,0.47266328,0.0005646619,0.00089814304,0.00013334156,0.006856074,0.000011745931,0.000084319756,0.000017691833,0.01648679,0.48238832],"study_design_scores_gemma":[0.031100443,0.04809389,0.13257127,0.0003257708,0.0005405478,0.000054428976,0.0012230477,0.000056141977,0.000114747905,0.00007583728,0.78573716,0.0001067456],"about_ca_topic_score_codex":0.019836465,"about_ca_topic_score_gemma":0.047311842,"teacher_disagreement_score":0.76925033,"about_ca_system_score_codex":0.00043480055,"about_ca_system_score_gemma":0.009863407,"threshold_uncertainty_score":0.9957498},"labels":[],"label_agreement":null},{"id":"W3004077651","doi":"10.1200/jco.2006.24.18_suppl.7117","title":"Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized national cancer institute of Canada Clinical Trials Group (NCIC CTG) trials","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Performance status; Lung cancer; Cancer; Randomized controlled trial; Chemotherapy; Proportional hazards model; Clinical trial; Surgery; Confidence interval","score_opus":0.4992730892395016,"score_gpt":0.6213426952230742,"score_spread":0.12206960598357258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004077651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049991324,0.9845887,0.00001993541,0.00080139545,0.0015344479,0.007282254,0.0005497761,0.0000018267347,0.000222529],"genre_scores_gemma":[0.005212396,0.99315023,0.00036232834,0.00025908084,0.00054185576,0.00032390715,0.00007633174,0.000018789979,0.000055057906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9657149,0.014769026,0.017813928,0.00033715676,0.0011503974,0.0002146168],"domain_scores_gemma":[0.9116919,0.054822292,0.031977568,0.00023516601,0.0010153098,0.00025776925],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04232055,0.00039631285,0.02436603,0.00023685813,0.000032117667,0.000005861332,0.00021370569,0.00038404367,0.000056274275],"category_scores_gemma":[0.09866479,0.00017528901,0.0035153064,0.0003275494,0.0005516524,0.00006450201,0.00002330006,0.000752214,1.4376309e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031896073,0.019663863,0.012294922,0.056066472,0.030753102,0.0015144607,0.0002631199,0.000008575106,3.0613927e-7,0.00037832934,0.006440533,0.84072024],"study_design_scores_gemma":[0.20288421,0.008244891,0.0354688,0.073924534,0.07870396,0.0001676277,0.00008071931,0.000002642253,6.8357906e-7,0.0003384753,0.5999475,0.00023594181],"about_ca_topic_score_codex":0.019206226,"about_ca_topic_score_gemma":0.05668503,"teacher_disagreement_score":0.8404843,"about_ca_system_score_codex":0.0010632436,"about_ca_system_score_gemma":0.026068715,"threshold_uncertainty_score":0.99011827},"labels":[],"label_agreement":null},{"id":"W3004418180","doi":"10.1200/jco.2020.38.4_suppl.641","title":"Determining when endoscopic ultrasound (EUS) changes management for patients with pancreatic cystic neoplasms.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Endoscopic ultrasound; Radiology; Cyst; Medical diagnosis; Magnetic resonance imaging; Pancreas; Internal medicine","score_opus":0.11851926976667072,"score_gpt":0.43776034819588694,"score_spread":0.31924107842921623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004418180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842863,0.00013941796,0.0031667068,0.007998321,0.00037511514,0.00092359056,0.0000077661325,0.000015018401,0.0030877674],"genre_scores_gemma":[0.92265284,0.00044315678,0.07009709,0.005278383,0.0010338202,0.00004231546,0.000010054279,0.000029473975,0.00041285195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713045,0.00030727047,0.0014456261,0.00025635023,0.00047619158,0.0003841286],"domain_scores_gemma":[0.9909178,0.0067079654,0.0010789462,0.0001737002,0.00046873893,0.0006528263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015233316,0.00017588126,0.0019238051,0.00011214729,0.00006898848,0.000012727502,0.00021863371,0.0002575561,0.00019334779],"category_scores_gemma":[0.0060362937,0.00011386527,0.00022413098,0.0001158613,0.00023389146,0.000072863244,0.000056089288,0.0006177356,0.000023896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080766445,0.0010942481,0.928368,0.00034734624,0.0013364577,0.00054468523,0.00038276892,0.0000029340333,0.000026096048,0.00008284351,0.0039015957,0.055836383],"study_design_scores_gemma":[0.033264685,0.08436194,0.82254785,0.00039636297,0.0033434904,0.00014502737,0.0003981059,0.00033792225,0.0000187162,0.00037521237,0.054645322,0.00016538538],"about_ca_topic_score_codex":0.0000033051376,"about_ca_topic_score_gemma":0.000014452249,"teacher_disagreement_score":0.10582017,"about_ca_system_score_codex":0.00012007792,"about_ca_system_score_gemma":0.0008808744,"threshold_uncertainty_score":0.7226443},"labels":[],"label_agreement":null},{"id":"W3004419783","doi":"10.1200/jco.2020.38.4_suppl.571","title":"Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Hazard ratio; Biomarker; Oncology; Gastroenterology; Confidence interval","score_opus":0.14331801661025953,"score_gpt":0.4676500815740795,"score_spread":0.32433206496381994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004419783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320865,0.0010471427,0.0021954847,0.001921082,0.000428154,0.0004825467,0.00006501422,0.0000022540748,0.00064967375],"genre_scores_gemma":[0.99797374,0.00030643636,0.000761955,0.00031291586,0.00047878362,0.000029914423,0.000019557183,0.0000128824495,0.00010382572],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772924,0.00046439364,0.0010703478,0.00027963927,0.00024380081,0.00021258318],"domain_scores_gemma":[0.99780667,0.0003975789,0.0008321094,0.00012494945,0.00053688977,0.00030182645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010300023,0.00013221809,0.0006694498,0.00004316667,0.000054792807,0.000008872186,0.00018887037,0.00026538508,0.000021406458],"category_scores_gemma":[0.0039794417,0.00010315658,0.00054284936,0.00011791486,0.00015127753,0.000019932131,0.00008272097,0.00030350068,0.0000032451521],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12488522,0.002922084,0.6109939,0.00019025692,0.005962396,0.0006745041,0.0017970933,0.00008681774,0.15317851,0.000115535695,0.030180907,0.06901273],"study_design_scores_gemma":[0.029897159,0.33897042,0.105875835,0.0002801765,0.0007791877,0.0001841151,0.0018561534,0.004653015,0.4193957,0.0012057514,0.09634166,0.00056084624],"about_ca_topic_score_codex":0.000023166953,"about_ca_topic_score_gemma":0.000053264903,"teacher_disagreement_score":0.50511813,"about_ca_system_score_codex":0.000056655204,"about_ca_system_score_gemma":0.0014267943,"threshold_uncertainty_score":0.4764051},"labels":[],"label_agreement":null},{"id":"W3004427575","doi":"10.1200/jco.2020.38.4_suppl.324","title":"Blood-based-inflammation-markers, body mass index, and survival of nonmetastatic esophageal cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Body mass index; Hazard ratio; Overweight; Gastroenterology; Underweight; Confidence interval; Univariate analysis; Proportional hazards model; Cancer; Esophageal cancer; Neutrophil to lymphocyte ratio; Systemic inflammation; Multivariate analysis; Inflammation; Oncology; Lymphocyte","score_opus":0.06378382645803936,"score_gpt":0.4088163956060988,"score_spread":0.3450325691480594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004427575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331755,0.0008089844,0.0006067067,0.013419528,0.00077098457,0.00029449246,0.000019917072,0.00001481571,0.00074700045],"genre_scores_gemma":[0.9902599,0.00035500355,0.006720246,0.0015205593,0.0010910177,0.000006519374,0.0000033350782,0.000022869866,0.000020563639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956387,0.0006189198,0.002715729,0.0002204279,0.00058207125,0.0002241191],"domain_scores_gemma":[0.99363476,0.002640487,0.002306872,0.00016028601,0.00053278654,0.00072479906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027227658,0.00017583945,0.001544884,0.0001256066,0.00003556964,0.000009167655,0.00018946751,0.00030695033,0.00034351286],"category_scores_gemma":[0.00543544,0.00014104579,0.00045314425,0.00019736454,0.00042460774,0.00011814157,0.000054907105,0.0007083609,0.0000049496402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01159866,0.00051799096,0.9511038,0.00051878515,0.0015198657,0.0015329435,0.000055533663,0.00007220683,0.0013221137,0.000081593964,0.001274281,0.030402211],"study_design_scores_gemma":[0.020696996,0.010611713,0.94927186,0.0003355542,0.0033713789,0.00008289965,0.00019842082,0.006819224,0.0017972746,0.00022864991,0.006362932,0.00022312664],"about_ca_topic_score_codex":0.0000075851963,"about_ca_topic_score_gemma":0.000005848418,"teacher_disagreement_score":0.030179085,"about_ca_system_score_codex":0.000058208137,"about_ca_system_score_gemma":0.0023315896,"threshold_uncertainty_score":0.6507122},"labels":[],"label_agreement":null},{"id":"W3004429164","doi":"10.1200/jco.2020.38.4_suppl.524","title":"Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Liver function; Hepatocellular carcinoma; Post-hoc analysis; Lenvatinib; Gastroenterology; Adverse effect; Oncology","score_opus":0.19237255479126553,"score_gpt":0.40133500490849194,"score_spread":0.20896245011722642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004429164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942184,0.00037108472,0.000047461148,0.0041391477,0.00011996616,0.0009427747,0.0000020586763,0.000004903108,0.00015419071],"genre_scores_gemma":[0.99706507,0.00005265979,0.00019626025,0.0024099073,0.00022200037,0.000013244439,0.000007425624,0.000013988891,0.000019428755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964966,0.0011356294,0.0014821677,0.0002336741,0.00044301152,0.00020888147],"domain_scores_gemma":[0.99755746,0.0012942237,0.00056583696,0.00015354485,0.00018874444,0.00024018789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033007103,0.0001650183,0.001252628,0.00014032179,0.0000349945,0.0000132231535,0.00012374733,0.00016959087,0.00007407246],"category_scores_gemma":[0.0010595255,0.000086816726,0.00016544995,0.00031281766,0.00007417881,0.00012417011,0.00003984899,0.0008542092,0.0000049541823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01882379,0.0087879235,0.95556104,0.000018539487,0.00018682289,0.0025134985,0.0006807822,8.063243e-7,0.000007930478,0.000003898165,0.00019138427,0.01322356],"study_design_scores_gemma":[0.060574137,0.065415874,0.8705026,0.000023491437,0.0005051712,0.000017576553,0.000422193,0.0012482883,0.000008129012,0.000011770827,0.0011946394,0.000076120334],"about_ca_topic_score_codex":0.0001093808,"about_ca_topic_score_gemma":0.00014689256,"teacher_disagreement_score":0.08505845,"about_ca_system_score_codex":0.00007357203,"about_ca_system_score_gemma":0.00038194246,"threshold_uncertainty_score":0.37111613},"labels":[],"label_agreement":null},{"id":"W3004451357","doi":"10.1200/jco.2020.38.4_suppl.675","title":"Clinicopathological features of pancreatic cancer-related diabetes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Pancreatic cancer; Cancer; Stage (stratigraphy); Cohort; Comorbidity; Retrospective cohort study; Epidemiology; Gastroenterology; Endocrinology","score_opus":0.1996939165587236,"score_gpt":0.5155177851223914,"score_spread":0.31582386856366784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004451357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551079,0.0027445,0.000031312997,0.031791218,0.00057314796,0.00026368783,0.000005496527,0.00001982956,0.009462857],"genre_scores_gemma":[0.9829014,0.0042590834,0.0056994497,0.0057417443,0.0010894873,0.000006306417,0.0000020466118,0.000016711614,0.0002837825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994297,0.0010092846,0.0035991322,0.00023727973,0.0005192167,0.00033802987],"domain_scores_gemma":[0.99073917,0.005273671,0.0022702499,0.00019282235,0.00069659937,0.00082747766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0044181575,0.00016037158,0.0035956725,0.0000970477,0.000032780583,0.000003869089,0.00029175464,0.000792592,0.00079102325],"category_scores_gemma":[0.017507503,0.00010147026,0.0007697124,0.0002887401,0.0006053475,0.00006272123,0.00009603715,0.0020038465,0.0000333054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034754612,0.0017662118,0.92576385,0.00014060683,0.0008624195,0.0009175654,0.00025180657,0.0000044159005,0.0007982619,0.00018123962,0.010792815,0.055045363],"study_design_scores_gemma":[0.00930561,0.032017216,0.94083095,0.00017340218,0.0018409872,0.00019050861,0.000118471944,0.00033029975,0.00016519729,0.0004448897,0.014484124,0.00009833347],"about_ca_topic_score_codex":0.000009654033,"about_ca_topic_score_gemma":0.000003123975,"teacher_disagreement_score":0.054947026,"about_ca_system_score_codex":0.000089053356,"about_ca_system_score_gemma":0.0030974303,"threshold_uncertainty_score":0.99076843},"labels":[],"label_agreement":null},{"id":"W3004513031","doi":"10.1200/jco.2020.38.4_suppl.653","title":"Real-world eligibility of advanced pancreatic (APC) patients for maintenance olaparib.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Olaparib; Hazard ratio; Internal medicine; Interquartile range; Gastroenterology; Confidence interval; Progression-free survival; Clinical endpoint; Surgery; Oncology; Chemotherapy; Clinical trial","score_opus":0.17146633805696232,"score_gpt":0.5271476617648508,"score_spread":0.3556813237078885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004513031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975768,0.00011707901,0.00067266915,0.00920495,0.0004552943,0.0007549316,0.000018390587,0.000010085449,0.012998572],"genre_scores_gemma":[0.9725777,0.0010657158,0.022466445,0.002603162,0.00068812456,0.000015747575,0.000006960491,0.000019166706,0.00055696385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950447,0.0004531733,0.0034186656,0.0002682802,0.00045718875,0.000358],"domain_scores_gemma":[0.9887466,0.0063354224,0.002296184,0.00025798316,0.0016495964,0.000714238],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003651135,0.0001529666,0.0030724597,0.00009827508,0.000038546532,0.0000031356592,0.00025601647,0.00031278958,0.00012214911],"category_scores_gemma":[0.027556572,0.00010545687,0.00066191604,0.00024965926,0.00044011025,0.00009301825,0.00007110413,0.0008484738,0.000013130691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024754139,0.0021633515,0.9056239,0.0002977439,0.0005331791,0.000056228277,0.00015809973,0.000006901077,0.0003618351,0.0004812396,0.017588787,0.0479746],"study_design_scores_gemma":[0.024219414,0.037348557,0.88462746,0.00020589234,0.00089053425,0.000017260343,0.00014289153,0.00061168254,0.00019566815,0.0013227089,0.050305855,0.0001120494],"about_ca_topic_score_codex":0.000030174657,"about_ca_topic_score_gemma":0.0000386168,"teacher_disagreement_score":0.04786255,"about_ca_system_score_codex":0.00018711558,"about_ca_system_score_gemma":0.0024970153,"threshold_uncertainty_score":0.98063475},"labels":[],"label_agreement":null},{"id":"W3004517814","doi":"10.1200/jco.2020.38.4_suppl.512","title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Nivolumab; Sorafenib; Oncology; Hepatocellular carcinoma; Clinical trial; Adverse effect; Cancer; Immunotherapy","score_opus":0.1262848890606197,"score_gpt":0.41459406289929873,"score_spread":0.28830917383867904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004517814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268466,0.0012471501,0.000117952375,0.004692697,0.00052798813,0.0004001929,0.000007972329,0.000015074682,0.00030633176],"genre_scores_gemma":[0.99283284,0.0014419637,0.0010313484,0.0042113303,0.00038408223,0.0000056279473,0.000027852435,0.000030114665,0.000034851222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618006,0.0004600679,0.0022436462,0.00031242069,0.0005414905,0.00026232703],"domain_scores_gemma":[0.9966799,0.0005995684,0.0017358279,0.00021844429,0.00046050068,0.0003057761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009944194,0.00022111968,0.001593639,0.00014089998,0.000040739655,0.000014363091,0.00023116198,0.00033101172,0.00024451196],"category_scores_gemma":[0.00048393733,0.00015321729,0.00046186746,0.0003931846,0.00019537866,0.00021442078,0.00003086393,0.0008442654,0.000009720328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093592234,0.0024771409,0.75170946,0.000019424358,0.0005413648,0.00031571568,0.0003741418,0.000012006945,0.0034653929,0.000005154074,0.0004556601,0.14703228],"study_design_scores_gemma":[0.07998718,0.04418354,0.86452657,0.0001122596,0.00018380808,0.000014188062,0.00018769216,0.0007095802,0.0017175766,0.00006213837,0.008146151,0.00016929928],"about_ca_topic_score_codex":0.00020367016,"about_ca_topic_score_gemma":0.000061375176,"teacher_disagreement_score":0.14686298,"about_ca_system_score_codex":0.0002896689,"about_ca_system_score_gemma":0.0008265551,"threshold_uncertainty_score":0.62480193},"labels":[],"label_agreement":null},{"id":"W3004551912","doi":"10.1200/jco.2020.38.4_suppl.tps268","title":"AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; FOLFOX; Oxaliplatin; Bevacizumab; Internal medicine; Tolerability; Clinical endpoint; Colorectal cancer; Oncology; Irinotecan; Phases of clinical research; Cetuximab; Thymidylate synthase; Progression-free survival; Fluorouracil; Clinical trial; Cancer; Chemotherapy; Adverse effect","score_opus":0.5170207306562354,"score_gpt":0.5729376464985312,"score_spread":0.055916915842295745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004551912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357045,0.0009305821,0.00004306472,0.0023430295,0.00079808134,0.0019199576,0.00007118705,0.000004699546,0.00031895586],"genre_scores_gemma":[0.99675345,0.0015702171,0.00087765674,0.00015266959,0.00040147538,0.00017688767,0.000007642368,0.0000194364,0.000040563533],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996098,0.00027413148,0.0027834252,0.00029908543,0.00029620016,0.00024919864],"domain_scores_gemma":[0.9954099,0.0019204023,0.0017572171,0.00014813757,0.00041514938,0.00034917207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008348044,0.00022044692,0.0031347955,0.000105894986,0.00004616108,0.0000061041574,0.00022789376,0.000114793635,0.000049332157],"category_scores_gemma":[0.0009913475,0.0001515205,0.00026131622,0.00023625835,0.00013089785,0.00011514408,0.000083525396,0.0002267636,4.6553623e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5305307,0.1466764,0.020299694,0.00016199601,0.0069101006,0.0010490696,0.007121553,0.0005181717,0.00042821045,0.00014136013,0.0002668483,0.28589588],"study_design_scores_gemma":[0.35605016,0.61526257,0.018883523,0.000066815766,0.00254889,0.000012453935,0.0024814378,0.0014672991,0.00052035745,0.00007867048,0.0025055981,0.00012223322],"about_ca_topic_score_codex":0.0009020036,"about_ca_topic_score_gemma":0.005715098,"teacher_disagreement_score":0.46858615,"about_ca_system_score_codex":0.00044521719,"about_ca_system_score_gemma":0.0012362465,"threshold_uncertainty_score":0.6178826},"labels":[],"label_agreement":null},{"id":"W3004554229","doi":"10.1200/jco.19.00058","title":"Psychological Interventions for Patients With Advanced Disease: Implications for Oncology and Palliative Care","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Psychological intervention; Medicine; Psychosocial; Palliative care; Distress; Quality of life (healthcare); Anxiety; Disease; Nursing; Psycho-oncology; Family medicine; Psychiatry; Clinical psychology; Internal medicine","score_opus":0.6550465588640451,"score_gpt":0.6942637731406692,"score_spread":0.03921721427662417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004554229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034942516,0.9903081,0.0030251017,0.0026985982,0.0005660088,0.002186523,0.00065128057,0.000008633163,0.00020633642],"genre_scores_gemma":[0.00041054573,0.95907867,0.03886088,0.00042063216,0.0006535446,0.0002620829,0.000251373,0.000032478725,0.000029777599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597555,0.0003381871,0.0029735107,0.00036179155,0.00014444014,0.00020653073],"domain_scores_gemma":[0.9852213,0.008278212,0.0041203275,0.00019489117,0.0016377674,0.0005474572],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0005432701,0.00026735108,0.0050310707,0.00013046822,0.00004965281,0.000004833343,0.00021077087,0.0005718937,0.0000138310925],"category_scores_gemma":[0.009865187,0.00016098453,0.002072569,0.00014822243,0.0003150209,0.00005182593,0.00005492366,0.0007382426,0.0000014294989],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032799286,0.001560905,0.0072394214,0.00823877,0.0009849024,0.000017460125,0.00009065954,2.8025192e-7,3.485546e-8,0.00026330652,0.0016262197,0.9766981],"study_design_scores_gemma":[0.007183187,0.04164392,0.018243179,0.014414472,0.005781525,0.000008112745,0.000106099506,6.96924e-7,3.755278e-8,0.0002728705,0.9122123,0.00013361205],"about_ca_topic_score_codex":3.795365e-7,"about_ca_topic_score_gemma":0.00000613873,"teacher_disagreement_score":0.9765645,"about_ca_system_score_codex":0.00024067439,"about_ca_system_score_gemma":0.0016063477,"threshold_uncertainty_score":0.99847513},"labels":[],"label_agreement":null},{"id":"W3004590183","doi":"10.1200/jco.2020.38.4_suppl.639","title":"A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Neutropenia; Gastroenterology; Clinical endpoint; Hazard ratio; PARP inhibitor; Surgery; Oncology; Randomized controlled trial; Cancer; Toxicity; Confidence interval; Poly ADP ribose polymerase; Biology","score_opus":0.040358469309595114,"score_gpt":0.37151229068042085,"score_spread":0.3311538213708257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004590183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959574,0.0010701914,0.0005237446,0.0014005093,0.0003601843,0.0005640407,0.00003813581,0.0000015209732,0.00008428286],"genre_scores_gemma":[0.9943175,0.0008923444,0.002953064,0.0009621891,0.000800896,0.0000106660455,0.000036144444,0.000016940601,0.0000102702015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968335,0.0003841125,0.0021507211,0.00025296572,0.00019937646,0.00017929326],"domain_scores_gemma":[0.9965791,0.0009379167,0.0016866899,0.00014246146,0.00038380368,0.00027003844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014256547,0.00016075962,0.0013754128,0.00006134391,0.00002799997,0.000008527033,0.00016200646,0.00026205924,0.00002269206],"category_scores_gemma":[0.00680464,0.00011936571,0.0002605981,0.000092837596,0.0002473851,0.000009538205,0.00012866025,0.00033280943,7.429249e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9514098,0.0033328636,0.016583784,0.000025513584,0.00029836557,0.000051502466,0.0001331136,0.0000805211,0.00034950685,0.000025972826,0.00052491814,0.027184092],"study_design_scores_gemma":[0.91664165,0.058998637,0.017842798,0.00003752193,0.00029721155,0.000010026383,0.000038434995,0.0005264231,0.00023739508,0.00004681216,0.005181145,0.00014194695],"about_ca_topic_score_codex":0.00002632477,"about_ca_topic_score_gemma":0.000051102015,"teacher_disagreement_score":0.055665776,"about_ca_system_score_codex":0.000021142656,"about_ca_system_score_gemma":0.0005755692,"threshold_uncertainty_score":0.81462806},"labels":[],"label_agreement":null},{"id":"W3004640604","doi":"10.1200/jco.2020.38.4_suppl.376","title":"Economic evaluation of trifluridine/tipiracil (TT) versus nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastro-esophageal junction cancer (GEJC) in Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pharmacy; Context (archaeology); Population; Cancer; Nivolumab; Regimen; Adverse effect; Health care; Indirect costs; Internal medicine; Oncology; Family medicine; Immunotherapy; Environmental health","score_opus":0.146510627396775,"score_gpt":0.38135869039590553,"score_spread":0.23484806299913052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004640604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993138,0.0015767724,0.00009217433,0.0014240295,0.0024827912,0.00037725442,0.0001505092,0.0000027059416,0.000755736],"genre_scores_gemma":[0.9971043,0.0012639902,0.0004790366,0.00060365244,0.00045395055,0.000029639164,0.0000053283225,0.000025832975,0.000034306126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952115,0.00016133323,0.0036996203,0.000373516,0.00016890051,0.0003851568],"domain_scores_gemma":[0.994483,0.00051030697,0.0042817127,0.00015704519,0.0002894116,0.00027850582],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002300172,0.0002172396,0.001874321,0.0002718874,0.000025486997,0.000012274638,0.00028588163,0.00015478875,0.001057538],"category_scores_gemma":[0.0015636713,0.00019912214,0.00017134061,0.00032504692,0.00008944221,0.0005878883,0.000037044792,0.00065255055,0.000017243989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014640568,0.000303194,0.8002173,0.00002707043,0.00016725215,0.00001848465,0.000093759016,0.05447344,5.1932125e-7,0.00010231798,0.0011520458,0.12880409],"study_design_scores_gemma":[0.033837657,0.0056910133,0.947417,0.00007433721,0.00010585946,0.0000019518375,0.00011236098,0.0061771544,0.000005757086,0.00021926206,0.0061406004,0.0002170478],"about_ca_topic_score_codex":0.11483296,"about_ca_topic_score_gemma":0.5952222,"teacher_disagreement_score":0.4803892,"about_ca_system_score_codex":0.004308275,"about_ca_system_score_gemma":0.011231857,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W3004648541","doi":"10.1200/jco.2020.38.15_suppl.e16795","title":"Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Asymptomatic; Chemotherapy; Pancreatic cancer; Cancer; Logistic regression; Lymph node; Surgery; Retrospective cohort study; Internal medicine","score_opus":0.09957829003136719,"score_gpt":0.48634144860634887,"score_spread":0.38676315857498167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004648541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532866,0.00045464473,0.00010981644,0.0024581065,0.0001753481,0.0003504544,0.000009058673,0.000008638516,0.0011052857],"genre_scores_gemma":[0.99686533,0.0006140733,0.0012987817,0.0006940189,0.00041387705,0.000005199062,0.000004222129,0.000023334293,0.00008114088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640584,0.00053220405,0.0019284647,0.0002005643,0.00061791006,0.0003150231],"domain_scores_gemma":[0.9941675,0.002327511,0.001767276,0.0001837341,0.00090409355,0.00064989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017961033,0.0001634822,0.0028746664,0.000091465976,0.000031605025,0.0000044131693,0.00019688667,0.00031482623,0.00048770703],"category_scores_gemma":[0.005647573,0.000092259004,0.0006827107,0.0003286857,0.00032744,0.00009454438,0.00003769861,0.0009462725,0.000003999082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014241074,0.0010449257,0.95980465,0.00004301566,0.0022955046,0.00024580274,0.00019019964,0.000017187145,0.00012844676,0.000001148362,0.002015212,0.019972835],"study_design_scores_gemma":[0.018043078,0.033028316,0.947244,0.00018651452,0.00046588358,0.000013112436,0.0000362468,0.00042516197,0.0000145716385,0.000012827053,0.00044465694,0.00008562387],"about_ca_topic_score_codex":0.00017947916,"about_ca_topic_score_gemma":0.000057547644,"teacher_disagreement_score":0.03198339,"about_ca_system_score_codex":0.00019860106,"about_ca_system_score_gemma":0.0034162425,"threshold_uncertainty_score":0.67610806},"labels":[],"label_agreement":null},{"id":"W3004681951","doi":"10.1200/jco.2020.38.4_suppl.313","title":"Retrospective comparison of neoadjuvant chemoradiation (nCRT) +/- surgery using the CROSS trial regimen and definitive chemoradiation (dCRT) with carboplatin (C) and paclitaxel (P) in esophageal (EC), and gastroesophageal junction cancer (GEJC) in Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Regimen; Esophageal cancer; Population; Breast-conserving surgery; Carboplatin; Cancer; Adenocarcinoma; Internal medicine; Breast cancer; Radiation therapy; Surgery; Oncology; Chemotherapy; Mastectomy","score_opus":0.14605174969256887,"score_gpt":0.4486906258127292,"score_spread":0.3026388761201604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004681951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201554,0.0044521643,0.000017162354,0.0028174485,0.00016397936,0.00047461982,0.000017157754,0.0000021254075,0.000039774746],"genre_scores_gemma":[0.9981325,0.0007512104,0.00030387114,0.00035043719,0.0004295231,0.000011675543,0.0000050615936,0.00001254118,0.000003159419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972265,0.00042290028,0.0014296768,0.00025325452,0.00042819197,0.00023947434],"domain_scores_gemma":[0.99671894,0.0013938968,0.0012830916,0.00007758621,0.00021210368,0.00031439436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015614373,0.00015272353,0.0014087994,0.00013252157,0.00004768563,0.000014580163,0.000043492128,0.00014190316,0.000009769794],"category_scores_gemma":[0.0014608683,0.00010136944,0.00006927612,0.00030665981,0.0002687188,0.0001405667,0.000032578762,0.00081260945,6.639721e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053074483,0.00021002692,0.9251343,0.00004894012,0.00013296408,0.0004439981,0.0005899969,0.00018082399,0.000024215658,0.000012924184,0.000051746192,0.020095581],"study_design_scores_gemma":[0.040024817,0.006370134,0.94857657,0.000105324,0.00015018672,0.00006859714,0.00054295396,0.0038445308,0.00019467533,0.000044225224,0.000014669433,0.000063314954],"about_ca_topic_score_codex":0.08617617,"about_ca_topic_score_gemma":0.15233679,"teacher_disagreement_score":0.06616062,"about_ca_system_score_codex":0.0009813871,"about_ca_system_score_gemma":0.0048920955,"threshold_uncertainty_score":0.91990906},"labels":[],"label_agreement":null},{"id":"W3004691185","doi":"10.1200/jco.2020.38.4_suppl.34","title":"Outcomes of elderly patients with resectable liver metastases from colorectal cancer (CRLM): Single center experience.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; Single Center; Internal medicine; Chemotherapy; Overall survival; Cancer; Surgery; Gastroenterology","score_opus":0.13731152393570564,"score_gpt":0.4206249374435166,"score_spread":0.2833134135078109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004691185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949632,0.0004543834,0.000045178356,0.0025930826,0.0006575034,0.00019003688,0.00010072613,0.0000064085493,0.000989426],"genre_scores_gemma":[0.9911686,0.0002583842,0.0027356404,0.005316048,0.00044001816,0.0000043585273,0.000015268264,0.00001599096,0.000045681707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732405,0.00023104773,0.0015786776,0.00021053273,0.00045059217,0.00020510364],"domain_scores_gemma":[0.9964927,0.0011457385,0.0013411212,0.00011627453,0.00048717187,0.00041699648],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031954612,0.0001443716,0.0016094039,0.00005439337,0.000026980431,0.0000065548247,0.00017738839,0.00017259382,0.0021153989],"category_scores_gemma":[0.0012418596,0.00008899599,0.000344351,0.00011565579,0.0002545859,0.00021259423,0.000053331547,0.0005663856,0.0000053637323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0148903355,0.0015674083,0.93272454,0.000023777753,0.00077761285,0.00019819876,0.00078676903,0.000011543466,0.0006312675,0.0000022548465,0.004556867,0.043829408],"study_design_scores_gemma":[0.018888328,0.030494021,0.8869169,0.000079602,0.00041951062,0.000012096882,0.0003709035,0.00004493131,0.0016729475,0.000006861024,0.060972404,0.00012149042],"about_ca_topic_score_codex":0.00022226498,"about_ca_topic_score_gemma":0.00018426812,"teacher_disagreement_score":0.056415536,"about_ca_system_score_codex":0.00012475358,"about_ca_system_score_gemma":0.0010885851,"threshold_uncertainty_score":0.9987968},"labels":[],"label_agreement":null},{"id":"W3004728915","doi":"10.1200/jco.2020.38.4_suppl.21","title":"Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatchewan Cancer Agency; Saskatchewan Health; University of Saskatchewan","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Irinotecan; Colorectal cancer; Population; Surgery; Oxaliplatin; Regimen; Oncology; Cancer; Chemotherapy","score_opus":0.0807081213350428,"score_gpt":0.4251813644204341,"score_spread":0.3444732430853913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004728915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952079,0.00010084715,0.000007854815,0.0020104698,0.00025102886,0.0014935229,0.00007788633,0.000011769035,0.00083871384],"genre_scores_gemma":[0.99834627,0.000107880565,0.00048413905,0.000711108,0.00015608844,0.00006356068,0.000028074473,0.000025487365,0.0000773889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961598,0.0006526911,0.0019260708,0.0004110192,0.00056794385,0.00028247046],"domain_scores_gemma":[0.99532664,0.0016974703,0.0014163672,0.00014716045,0.0010194086,0.0003929409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010707133,0.00023612998,0.0026227592,0.00024511453,0.000060617047,0.000009034362,0.00013555792,0.00010949118,0.00033613076],"category_scores_gemma":[0.0021097735,0.00015711141,0.0002365853,0.0009048979,0.00009042081,0.00011200002,0.00006390253,0.0005566678,0.0000038492035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062996194,0.0029074387,0.92962956,0.000028798537,0.0014296579,0.00035724015,0.000408436,0.00029920015,0.0000666297,0.0000023677947,0.00065990863,0.0012145373],"study_design_scores_gemma":[0.024580488,0.05136614,0.9215179,0.0001652623,0.001088058,0.0000011734428,0.00029177096,0.00028197473,0.0003040217,0.00001971471,0.00025725635,0.00012625831],"about_ca_topic_score_codex":0.024500249,"about_ca_topic_score_gemma":0.031909876,"teacher_disagreement_score":0.0484587,"about_ca_system_score_codex":0.0012486888,"about_ca_system_score_gemma":0.0012285955,"threshold_uncertainty_score":0.98575526},"labels":[],"label_agreement":null},{"id":"W3004762359","doi":"10.1200/jco.2020.38.4_suppl.343","title":"Variation in treatment patterns and outcomes for resected esophageal cancer at designated thoracic surgery centers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; University of Manitoba; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Perioperative; Esophagectomy; Neoadjuvant therapy; Cardiothoracic surgery; Surgery; Retrospective cohort study; Esophageal cancer; Lymph node; Cancer; Lung cancer; Population; Internal medicine","score_opus":0.24950416134662526,"score_gpt":0.5197727242358638,"score_spread":0.2702685628892386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004762359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97599745,0.0016445853,0.00017464023,0.021360874,0.00026607988,0.0004952227,0.00003189333,0.0000078339735,0.000021423708],"genre_scores_gemma":[0.99445766,0.0026334291,0.00052997115,0.0017853989,0.00043049612,0.000039657087,0.0000111004465,0.000014538256,0.00009777637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976482,0.0004011124,0.0012592403,0.00020279796,0.00024301828,0.0002456416],"domain_scores_gemma":[0.99530774,0.0032975026,0.0006108435,0.00007686488,0.0002081711,0.0004988941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011175795,0.00012735635,0.001250201,0.00011752228,0.00003264459,0.000007714533,0.000051032785,0.00018123034,0.0001283932],"category_scores_gemma":[0.0018738451,0.000081173996,0.00031731973,0.00011402525,0.00005094989,0.00007366177,0.000027969649,0.0002899171,0.0000027201772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014268488,0.00080533634,0.89655656,0.00006637153,0.0004900811,0.0014619048,0.00017871773,0.000008678551,0.0000635798,0.000003498828,0.00044155758,0.085655235],"study_design_scores_gemma":[0.008447134,0.011946549,0.9776718,0.00006529773,0.00023118265,0.000037519196,0.000020425186,0.00026826595,0.00032352805,0.00003642405,0.00089999137,0.00005189223],"about_ca_topic_score_codex":0.00027616907,"about_ca_topic_score_gemma":0.0005786981,"teacher_disagreement_score":0.08560334,"about_ca_system_score_codex":0.0006705609,"about_ca_system_score_gemma":0.001103877,"threshold_uncertainty_score":0.33101794},"labels":[],"label_agreement":null},{"id":"W3004769662","doi":"10.1200/jco.2020.38.4_suppl.79","title":"Nonoperative management (NOM) in rectal cancer: Physician perspectives on offering NOM as standard of care.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Snowball sampling; Colorectal cancer; Rectum; Population; General surgery; Anal cancer; Family medicine; Cancer; Surgery; Internal medicine; Pathology","score_opus":0.10301105714046971,"score_gpt":0.484157658969846,"score_spread":0.3811466018293763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004769662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95089257,0.0010411382,0.00001454404,0.0076052584,0.00045621867,0.00034748093,0.000010801236,0.0000070993156,0.03962492],"genre_scores_gemma":[0.99501115,0.00162744,0.0009200099,0.0017062863,0.0006478442,0.000011477719,9.606216e-7,0.000016227707,0.000058581052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975303,0.0002701803,0.0013335174,0.0002677298,0.00040700435,0.00019130929],"domain_scores_gemma":[0.99784005,0.00066396856,0.0007622335,0.00011077922,0.00033637366,0.0002866049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047786316,0.00015725529,0.0017497924,0.00010272728,0.000021061122,0.0000050514413,0.00013099103,0.00014826919,0.00016583155],"category_scores_gemma":[0.00060249236,0.000116256975,0.000421588,0.00024334186,0.0001546924,0.00007169072,0.000071357535,0.0007595824,0.000010853977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16092256,0.0037168139,0.10634631,0.0002809312,0.0025717292,0.0058788396,0.015498469,0.00066174404,0.00037976252,0.001129973,0.0006633775,0.7019495],"study_design_scores_gemma":[0.050164707,0.26319897,0.58577716,0.001601542,0.00109009,0.0000777666,0.036093164,0.0001720506,0.0039307494,0.00026046677,0.057197407,0.00043591968],"about_ca_topic_score_codex":0.00004341882,"about_ca_topic_score_gemma":0.00008160872,"teacher_disagreement_score":0.7015136,"about_ca_system_score_codex":0.0009173126,"about_ca_system_score_gemma":0.0008807326,"threshold_uncertainty_score":0.47408217},"labels":[],"label_agreement":null},{"id":"W3004770038","doi":"10.1200/jco.2020.38.4_suppl.50","title":"Eligibility of real-world patients with stage II/III colorectal cancer (CRC) in adjuvant chemotherapy (AC) trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Odds ratio; Colorectal cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy)","score_opus":0.1546030391570677,"score_gpt":0.5004942456292514,"score_spread":0.3458912064721837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004770038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734885,0.0005221098,0.0000048821644,0.007689407,0.00046675914,0.00058609893,0.000031813845,0.000007205825,0.0033428774],"genre_scores_gemma":[0.9939772,0.0032408957,0.0004396152,0.0016884492,0.00049577234,0.000014445122,0.0000032348642,0.000015549693,0.00012486095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956184,0.0004118231,0.0030587811,0.00025734934,0.00043183583,0.00022183552],"domain_scores_gemma":[0.9950274,0.0015637815,0.0024337461,0.0001147447,0.00054729107,0.00031298565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002259164,0.00018572957,0.0034844317,0.00009789326,0.000034538538,0.000003162998,0.00012030869,0.00017825366,0.0003867498],"category_scores_gemma":[0.0020916092,0.000106374544,0.0004673876,0.00031949536,0.00025593047,0.00008315161,0.000059875812,0.0006635286,0.0000010016573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07295969,0.0027830433,0.85330546,0.000039018087,0.0007966288,0.00010642028,0.00070961716,0.000013920933,0.00005773322,0.0000126490195,0.0013197097,0.067896135],"study_design_scores_gemma":[0.03562453,0.036720082,0.912862,0.00011737613,0.00035019414,0.000002028879,0.00013754804,0.000022322378,0.00029258739,0.00002523862,0.013756162,0.00008993708],"about_ca_topic_score_codex":0.00057281874,"about_ca_topic_score_gemma":0.0036642866,"teacher_disagreement_score":0.0678062,"about_ca_system_score_codex":0.0003725822,"about_ca_system_score_gemma":0.0016768352,"threshold_uncertainty_score":0.43378282},"labels":[],"label_agreement":null},{"id":"W3004787369","doi":"10.1200/jco.2020.38.4_suppl.491","title":"Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Cabozantinib; Hepatocellular carcinoma; Internal medicine; Regimen; Regorafenib; Ramucirumab; Population; Oncology; Cancer; Surgery; Colorectal cancer","score_opus":0.1042699116533265,"score_gpt":0.45515339199039073,"score_spread":0.35088348033706424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004787369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920684,0.00042663154,0.0006563986,0.004902806,0.00035292417,0.0015464778,0.000020585001,0.000013210323,0.0000125554325],"genre_scores_gemma":[0.9899786,0.0000181766,0.0040567345,0.0052381363,0.00058998057,0.000059845326,0.0000116548645,0.000035528006,0.0000113224505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668574,0.00027547855,0.0020477741,0.00034210106,0.00039022535,0.00025869824],"domain_scores_gemma":[0.99611366,0.0010382448,0.0014974698,0.00021787015,0.00078703446,0.0003457113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010146238,0.000204624,0.0016762894,0.000088158085,0.000033899916,0.000005052646,0.00016215922,0.00018364174,0.00018740968],"category_scores_gemma":[0.0009773955,0.00013891878,0.00028798956,0.00023240315,0.00007435956,0.00014028863,0.000017462426,0.0006751587,0.0000012383472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060591456,0.0026333977,0.8403245,0.000040569415,0.00016952497,0.000050418355,0.00016512477,0.00049390143,0.00004393527,0.0000020420953,0.000018951452,0.09546617],"study_design_scores_gemma":[0.056417063,0.046282064,0.8922672,0.000056002344,0.00010077306,0.0000018611562,0.00009938511,0.0005942777,0.00010467125,0.00008125103,0.003868498,0.00012693902],"about_ca_topic_score_codex":0.000059019592,"about_ca_topic_score_gemma":0.00020944263,"teacher_disagreement_score":0.09533923,"about_ca_system_score_codex":0.000326976,"about_ca_system_score_gemma":0.0014764506,"threshold_uncertainty_score":0.56649435},"labels":[],"label_agreement":null},{"id":"W3004814819","doi":"10.1200/jco.2020.38.4_suppl.719","title":"A study of preoperative FOLFIRINOX in potentially curable pancreatic cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; FOLFIRINOX; Surgery; Radiation therapy; Adenocarcinoma; Adverse effect; Stage (stratigraphy); Pancreatic cancer; Prospective cohort study; Progressive disease; Chemotherapy; Cancer; Internal medicine; Oxaliplatin","score_opus":0.25323601426554787,"score_gpt":0.5363348346587173,"score_spread":0.28309882039316947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004814819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98415,0.00058790395,0.00008763285,0.010100782,0.0002292672,0.00061228016,0.000001943205,0.000004347366,0.0042258683],"genre_scores_gemma":[0.99491584,0.0011467533,0.0018295852,0.0012864184,0.0005226615,0.000015980706,4.941414e-7,0.000011697966,0.00027056318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951994,0.0010229012,0.0028462375,0.00020078382,0.00048274934,0.00024792107],"domain_scores_gemma":[0.995404,0.0021500944,0.0012431715,0.00014773675,0.00060973124,0.000445234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027705112,0.00012125555,0.0027459983,0.00012304964,0.00002483244,0.0000040360655,0.00021557642,0.0002597507,0.00042070608],"category_scores_gemma":[0.006773744,0.00008276019,0.00024667918,0.00031287418,0.00020101064,0.00009235324,0.00007894391,0.0011828961,0.000011690348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008113436,0.005319053,0.9671128,0.000067469264,0.0008091213,0.0017877315,0.0023622704,0.00006238163,0.00022685766,0.000029468903,0.0014850947,0.012624318],"study_design_scores_gemma":[0.020495938,0.0677343,0.9050815,0.00015966117,0.0009371406,0.0001066773,0.0030524104,0.0005609615,0.000047722246,0.000084269726,0.0016649727,0.00007442138],"about_ca_topic_score_codex":0.00025468165,"about_ca_topic_score_gemma":0.00033694855,"teacher_disagreement_score":0.06241525,"about_ca_system_score_codex":0.0001255814,"about_ca_system_score_gemma":0.0040232027,"threshold_uncertainty_score":0.81092936},"labels":[],"label_agreement":null},{"id":"W3004816554","doi":"10.1200/jco.2020.38.4_suppl.162","title":"A single-arm, phase II study of intrahepatic chemotherapy in patients with unresectable colorectal liver metastases.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Government of Ontario","keywords":"Medicine; Floxuridine; Chemotherapy; FOLFOX; FOLFIRI; Colorectal cancer; Internal medicine; Chemotherapy regimen; Fluorouracil; Surgery; Gastroenterology; Oncology; Cancer; Oxaliplatin","score_opus":0.18331101990442938,"score_gpt":0.39280229784517723,"score_spread":0.20949127794074784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004816554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974171,0.0001755442,0.000017785975,0.0012970545,0.00011182757,0.00077011145,0.0000049952555,0.000005940061,0.0001996577],"genre_scores_gemma":[0.9977676,0.000051312774,0.0011806602,0.00077818433,0.00018102513,0.00000690695,0.000006123731,0.00001920868,0.000008964581],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99685645,0.00051394873,0.0017806125,0.00019366038,0.00045723538,0.00019811025],"domain_scores_gemma":[0.9972751,0.0007495331,0.0011448825,0.00011239413,0.00036780772,0.00035025968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011168927,0.00015740596,0.0016879642,0.00012820231,0.000025122685,0.0000051066163,0.00013241601,0.00016012801,0.00030601176],"category_scores_gemma":[0.0009972951,0.00010115087,0.00024413405,0.00033769017,0.000108978435,0.00010236814,0.0000435323,0.00056480267,0.000003383259],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036276586,0.075534806,0.81390935,0.00003124888,0.0007746372,0.0010878023,0.0012067462,0.0000017617543,0.000097853816,0.0000016649194,0.0002507413,0.07082681],"study_design_scores_gemma":[0.10264098,0.58952004,0.30315655,0.000069097994,0.000970357,0.000020004614,0.0002908674,0.00047243963,0.0006870976,0.000006797679,0.0020603142,0.00010544624],"about_ca_topic_score_codex":0.000042277967,"about_ca_topic_score_gemma":0.000054644184,"teacher_disagreement_score":0.5139852,"about_ca_system_score_codex":0.00009703252,"about_ca_system_score_gemma":0.0005664337,"threshold_uncertainty_score":0.4124813},"labels":[],"label_agreement":null},{"id":"W3004842895","doi":"10.1200/jco.19.03012","title":"Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Lymphovascular invasion; Radical Hysterectomy; Adenosquamous carcinoma; Hazard ratio; Retrospective cohort study; Surgery; Cervical cancer; Radical surgery; Adenocarcinoma; Internal medicine; Cancer; Confidence interval; Metastasis","score_opus":0.14323578953180105,"score_gpt":0.4486631839076241,"score_spread":0.30542739437582306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004842895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909299,0.0019818412,0.000015072384,0.005226044,0.00032908417,0.0012022619,0.000021645497,0.0000094822335,0.00028463895],"genre_scores_gemma":[0.99325114,0.0016234037,0.0016853411,0.0028631582,0.0004883669,0.00004844621,0.000010818602,0.0000176869,0.000011629926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959485,0.000631742,0.0018895639,0.00043751523,0.00080322823,0.00028945264],"domain_scores_gemma":[0.99543566,0.0015583133,0.0012504634,0.00014145138,0.00092318363,0.00069093774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008320125,0.00028511678,0.002538537,0.00011301481,0.000045827295,0.000009638331,0.00020572072,0.00019662475,0.0003145551],"category_scores_gemma":[0.0048877588,0.00014968165,0.0002697059,0.00082586275,0.0003436601,0.0001585603,0.000054064716,0.0012117041,0.000013934933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1254996,0.007008459,0.8456342,0.00015877758,0.0009496923,0.0014428324,0.00009368604,0.0000039563683,0.00000223506,0.0000033739163,0.00016175563,0.019041408],"study_design_scores_gemma":[0.10059765,0.09473864,0.8012465,0.0014748346,0.0011243453,0.000022948398,0.00007034937,0.000011875915,0.000013073882,0.0000020571022,0.0005634932,0.00013420556],"about_ca_topic_score_codex":0.00010947231,"about_ca_topic_score_gemma":0.00065110344,"teacher_disagreement_score":0.08773018,"about_ca_system_score_codex":0.00068819226,"about_ca_system_score_gemma":0.0031407527,"threshold_uncertainty_score":0.61038405},"labels":[],"label_agreement":null},{"id":"W3004870356","doi":"10.1200/jco.2020.38.5_suppl.60","title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Ipilimumab; Internal medicine; Rash; Adverse effect; Adjuvant; Melanoma; Cancer; Gastroenterology; Oncology; Immunotherapy","score_opus":0.06398664518698148,"score_gpt":0.36053636204142514,"score_spread":0.29654971685444365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004870356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984293,0.0006516134,0.0001470842,0.0004222507,0.0000657602,0.00023966737,0.000010305378,0.0000021468095,0.00003189569],"genre_scores_gemma":[0.99796504,0.0006000708,0.0010822464,0.00021258957,0.0000751247,0.0000039100914,0.00000877833,0.000012025912,0.00004020338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722147,0.000498285,0.0015930779,0.0002593314,0.00026904422,0.00015880124],"domain_scores_gemma":[0.99738115,0.00025671595,0.0018249049,0.00018134333,0.00020018421,0.00015572998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017595722,0.00014288192,0.0011681955,0.00008197317,0.000024367278,0.000005106434,0.0001165524,0.00021634657,0.0000037854618],"category_scores_gemma":[0.00086834613,0.00009569848,0.00013730064,0.00015759285,0.00006615689,0.000018634348,0.000115043535,0.0003315413,3.8818558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009867485,0.0008957979,0.98167664,0.0000092836035,0.0017104645,0.00008552758,0.00018028372,0.00010683446,0.0044773156,0.0000025130057,0.00011194558,0.00087591104],"study_design_scores_gemma":[0.011884448,0.034322903,0.9504189,0.000011050912,0.0009266659,0.000017851798,0.00048398884,0.00006303255,0.00050466176,0.0000029553594,0.0012521481,0.00011139777],"about_ca_topic_score_codex":0.00006709688,"about_ca_topic_score_gemma":0.00026366158,"teacher_disagreement_score":0.033427108,"about_ca_system_score_codex":0.0000314289,"about_ca_system_score_gemma":0.00020351246,"threshold_uncertainty_score":0.39024708},"labels":[],"label_agreement":null},{"id":"W3004873611","doi":"10.1200/jco.18.02440","title":"Standards, Guidelines, and Quality Measures for Successful Specialty Palliative Care Integration Into Oncology: Current Approaches and Future Directions","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer","funders":"Agency for Healthcare Research and Quality; National Institute for Health and Care Research","keywords":"Specialty; Medicine; Palliative care; Quality (philosophy); Fidelity; Radiation oncology; Health care; Oncology; Nursing; Family medicine; Internal medicine; Radiation therapy","score_opus":0.7348888183303948,"score_gpt":0.6603369881885748,"score_spread":0.07455183014181999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004873611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000120803335,0.99074644,0.0014555146,0.0035595368,0.0024997345,0.00086387276,0.00026930534,0.000011123964,0.00047367273],"genre_scores_gemma":[0.000052067502,0.9740511,0.015639158,0.00019637845,0.009894202,0.00003524704,0.00008919197,0.000028314464,0.000014345057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926899,0.0014455479,0.004710793,0.00042047922,0.00054287363,0.00019042556],"domain_scores_gemma":[0.98605126,0.0049521714,0.0049173865,0.0001718139,0.0034585926,0.00044876596],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047949688,0.0003854396,0.0067459107,0.00019148452,0.000084959625,0.000017077151,0.00017026575,0.0010315186,0.000012486466],"category_scores_gemma":[0.021573242,0.00024147601,0.0011239919,0.00021926517,0.00041599481,0.000099027944,0.0000851944,0.0017763373,5.3677803e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010888034,0.00026040224,0.0008837659,0.007686541,0.0008523512,0.000019993886,0.001706894,8.758044e-8,1.7913548e-7,0.00027120404,0.0041212416,0.9831085],"study_design_scores_gemma":[0.0025244819,0.0051143686,0.00064945954,0.008144748,0.0042791795,0.000024984192,0.0032408785,0.0000039476645,0.0000014711854,0.00024231049,0.9755832,0.00019095563],"about_ca_topic_score_codex":0.000038459773,"about_ca_topic_score_gemma":0.0007569882,"teacher_disagreement_score":0.9829176,"about_ca_system_score_codex":0.00075841194,"about_ca_system_score_gemma":0.0068406244,"threshold_uncertainty_score":0.99878967},"labels":[],"label_agreement":null},{"id":"W3004883366","doi":"10.1200/jco.2020.38.4_suppl.235","title":"BRCA mutations in metastatic colorectal cancer (mCRC) and response to chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Colorectal cancer; KRAS; Oncology; Internal medicine; Olaparib; Oxaliplatin; Chemotherapy; PARP inhibitor; Cancer; Cancer research; Genetics; Biology","score_opus":0.08031489081257383,"score_gpt":0.45588980222775793,"score_spread":0.3755749114151841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004883366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611472,0.00067291,0.0006031876,0.036938675,0.00033651353,0.00013887224,0.000011627757,0.0000021707137,0.00014886756],"genre_scores_gemma":[0.9811281,0.0004684715,0.008080184,0.009760045,0.0004773492,0.000015192673,0.0000019900622,0.000014878435,0.00005381798],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808145,0.00047789613,0.0009779069,0.00019886516,0.00012376263,0.00014010437],"domain_scores_gemma":[0.998559,0.0004925843,0.00043266374,0.00007570338,0.00018752826,0.0002525425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014840158,0.00009185719,0.0004599011,0.000063853535,0.000023333854,0.0000093783865,0.00015564429,0.00015429911,0.00006513085],"category_scores_gemma":[0.0035670747,0.00008061772,0.00011812992,0.0001753732,0.00012446282,0.000006327026,0.000056524597,0.0002856935,0.000004865048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04255765,0.0009514674,0.05797692,0.000036075413,0.0008736326,0.00029674973,0.0034124963,0.005634137,0.4808584,0.000048634978,0.026808873,0.38054496],"study_design_scores_gemma":[0.011796903,0.019633243,0.38134506,0.000041074352,0.0001788321,0.00017637742,0.0010114796,0.00048694867,0.028351866,0.00033730708,0.5562739,0.00036699403],"about_ca_topic_score_codex":0.000012037081,"about_ca_topic_score_gemma":0.00019125981,"teacher_disagreement_score":0.529465,"about_ca_system_score_codex":0.00008298354,"about_ca_system_score_gemma":0.0019379228,"threshold_uncertainty_score":0.42703792},"labels":[],"label_agreement":null},{"id":"W3004888955","doi":"10.1200/jco.2020.38.4_suppl.1","title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Clinical endpoint; Internal medicine; Phases of clinical research; Surgery; Cancer; Oncology; Gastroenterology; Clinical trial; Immunotherapy","score_opus":0.1401134497973141,"score_gpt":0.4451741765726717,"score_spread":0.3050607267753576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004888955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96896404,0.00055417686,0.00010842545,0.027187258,0.0009898301,0.0008493492,0.00009675939,0.000017065837,0.0012330926],"genre_scores_gemma":[0.9879886,0.000032142947,0.0011025385,0.0060673757,0.0044608233,0.000009264668,0.00002049454,0.00002859689,0.00029019054],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9951938,0.000468173,0.0030506607,0.0004262867,0.0005036393,0.00035747615],"domain_scores_gemma":[0.9900648,0.006520063,0.0017771709,0.0002952874,0.0005907194,0.0007519736],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018292323,0.00024702615,0.0017974093,0.00005584333,0.00016113778,0.000014496542,0.00040202343,0.00028827565,0.0000974229],"category_scores_gemma":[0.010107821,0.00014681567,0.0010235532,0.00020136988,0.00018901048,0.00010112919,0.00016614751,0.001370783,0.000015381229],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54914266,0.028711388,0.115655385,0.00008672542,0.00074155646,0.005814935,0.0065668845,0.00015894957,0.0062200427,0.000025571462,0.04825274,0.23862313],"study_design_scores_gemma":[0.20839664,0.29979864,0.37872392,0.00003539567,0.0021641308,0.0001534817,0.0029025383,0.003835123,0.0007245106,0.00013552424,0.10282186,0.00030825322],"about_ca_topic_score_codex":0.00008035689,"about_ca_topic_score_gemma":0.00012948044,"teacher_disagreement_score":0.34074605,"about_ca_system_score_codex":0.0001058051,"about_ca_system_score_gemma":0.0012185975,"threshold_uncertainty_score":0.99823046},"labels":[],"label_agreement":null},{"id":"W3004908119","doi":"10.1200/jco.2020.38.4_suppl.340","title":"An economic evaluation of palliation of dysphagia in esophageal cancer: Analysis of the TROG 03.01/NCIC ES.2 phase III study in advanced esophageal cancer in patients treated with radiotherapy versus chemoradiotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Dysphagia; Esophageal cancer; Cost–utility analysis; Radiation therapy; Economic evaluation; Cost-effectiveness analysis; Quality of life (healthcare); Minimisation (clinical trials); Quality-adjusted life year; Randomized controlled trial; Cost effectiveness; Surgery; Cancer; Internal medicine","score_opus":0.10278603496573188,"score_gpt":0.5062528580741362,"score_spread":0.4034668231084043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004908119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467087,0.003253973,0.0000058146975,0.0005347848,0.00015133247,0.0013193361,0.000042733394,0.0000025437998,0.000018611612],"genre_scores_gemma":[0.9983398,0.0012022884,0.00014035085,0.000110156456,0.00011218015,0.00006072341,0.000011926562,0.000018397843,0.0000042053875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994878,0.0011962535,0.0025791063,0.0003130437,0.00079505803,0.00023855169],"domain_scores_gemma":[0.9962093,0.00053817086,0.0023237024,0.0002596993,0.00045117945,0.00021791829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025099122,0.00019272054,0.0023532803,0.0004559139,0.000014837327,0.000003670084,0.0002455113,0.0001706658,0.00031750838],"category_scores_gemma":[0.00031390827,0.00012803689,0.00030210114,0.0011193412,0.00015955904,0.00016945992,0.000015696454,0.00053701916,1.6004059e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07940169,0.006466718,0.80662376,0.000026603815,0.0021785444,0.000054700664,0.0010438466,0.034907263,0.00013355716,0.0000020221623,0.00000463617,0.06915665],"study_design_scores_gemma":[0.14439188,0.036634,0.7976788,0.00006355252,0.0014146504,4.5063055e-7,0.00017012144,0.018861514,0.00071842136,0.0000033285075,0.0000024441372,0.00006082588],"about_ca_topic_score_codex":0.0014903022,"about_ca_topic_score_gemma":0.010884535,"teacher_disagreement_score":0.06909582,"about_ca_system_score_codex":0.0017923594,"about_ca_system_score_gemma":0.002926654,"threshold_uncertainty_score":0.6073826},"labels":[],"label_agreement":null},{"id":"W3004915050","doi":"10.1200/jco.2020.38.4_suppl.489","title":"Impact of population center (PC) size on access to care in advanced hepatocellular carcinoma (HCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Population; Gastroenterology; Hepatitis B","score_opus":0.1432439840675946,"score_gpt":0.4894312652430605,"score_spread":0.34618728117546593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004915050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218684,0.00019525981,0.0000142291365,0.005404037,0.00047753804,0.00031087076,0.000012793153,0.0000039862384,0.0013944135],"genre_scores_gemma":[0.9908401,0.00011020708,0.00062501023,0.0078136595,0.0005737498,0.0000019730824,0.000010027831,0.000014096832,0.000011175067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973491,0.00022749827,0.0017935298,0.00018577526,0.0002655243,0.00017856406],"domain_scores_gemma":[0.99745566,0.0008000188,0.00087933143,0.00014591074,0.00025498343,0.000464108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004885969,0.000120954435,0.0013588263,0.00010579098,0.000012604149,0.000004872053,0.00018661912,0.00020907081,0.00031304758],"category_scores_gemma":[0.0026805247,0.00008805073,0.00052262604,0.00018129226,0.000033581073,0.00014894517,0.00005183404,0.000684785,0.0000061460646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017056758,0.00034637554,0.88273275,0.0000566675,0.00007275858,0.0003560559,0.00034692878,0.00045438128,0.0004914202,0.0000025072766,0.0010795675,0.09700386],"study_design_scores_gemma":[0.010325791,0.024034197,0.9574527,0.00009198973,0.000055057488,0.000021493639,0.00009541237,0.00028022024,0.00016031617,0.000014872685,0.007394838,0.00007311653],"about_ca_topic_score_codex":0.00009575038,"about_ca_topic_score_gemma":0.000056417317,"teacher_disagreement_score":0.09693074,"about_ca_system_score_codex":0.0003985371,"about_ca_system_score_gemma":0.0009994062,"threshold_uncertainty_score":0.35906044},"labels":[],"label_agreement":null},{"id":"W3004932776","doi":"10.1200/jco.2020.38.4_suppl.74","title":"Gray areas and evidence gaps in the management of rectal cancer as revealed by the comparison of recommendations from national and international clinical guidelines.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Family medicine; Gray (unit); Cancer; Radiology; Internal medicine","score_opus":0.6811002490470996,"score_gpt":0.6815654961092691,"score_spread":0.00046524706216943823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004932776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5994169,0.002139654,0.0003137991,0.39669508,0.0006455684,0.00029903607,0.000029842578,0.0000022461054,0.00045784717],"genre_scores_gemma":[0.9618094,0.011178697,0.0088955555,0.017213669,0.0008365971,0.000007788616,0.00001752504,0.000007227949,0.000033571352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916973,0.0011507189,0.00619939,0.00021840376,0.0006369303,0.00009724064],"domain_scores_gemma":[0.97330594,0.021304494,0.003945184,0.00013303857,0.0011601249,0.00015123643],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011660074,0.00010182282,0.0008887924,0.000048410504,0.000030228563,0.000010949901,0.00028600538,0.0001576444,0.0002579585],"category_scores_gemma":[0.038035404,0.0000598285,0.00019431715,0.00017421058,0.0003031332,0.00017968443,0.00013227525,0.0009030237,0.0000023979867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044530295,0.0010444894,0.5542304,0.000050507017,0.00067271374,0.000021849703,0.00040148094,0.00002194037,0.00008783057,0.0003362331,0.16672082,0.2719587],"study_design_scores_gemma":[0.011156298,0.0050677694,0.8249747,0.0008020974,0.0011784505,0.00008116543,0.0050184894,0.0029990599,0.000025588854,0.0025345865,0.14604266,0.000119122524],"about_ca_topic_score_codex":0.00024961145,"about_ca_topic_score_gemma":0.00018963692,"teacher_disagreement_score":0.3794814,"about_ca_system_score_codex":0.000054864642,"about_ca_system_score_gemma":0.00062618,"threshold_uncertainty_score":0.9700676},"labels":[],"label_agreement":null},{"id":"W3004936186","doi":"10.1200/jco.2020.38.4_suppl.683","title":"Goals of care designations in advanced pancreatic cancer patients undergoing palliative chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; BC Cancer Agency; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Palliative care; Pancreatic cancer; Medical record; Cohort; Cancer; Retrospective cohort study; Family medicine; Population; Emergency medicine; Internal medicine; Nursing","score_opus":0.3114925732933651,"score_gpt":0.559915520746769,"score_spread":0.24842294745340388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004936186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902209,0.0037669677,0.00030725758,0.0038204265,0.00022901161,0.00020174256,0.000010212494,0.0000034505742,0.001440037],"genre_scores_gemma":[0.9803672,0.010075922,0.0074123796,0.0018860622,0.00022177445,0.0000039989404,0.0000033121291,0.000011359332,0.000017980974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745864,0.00024594617,0.0017845245,0.00012000336,0.00026556195,0.00012534516],"domain_scores_gemma":[0.9940494,0.0031447276,0.0016871924,0.000069835114,0.0008756912,0.00017318169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039271804,0.0000978552,0.001385489,0.000081910366,0.000011037779,0.0000012645089,0.00010624175,0.00017254165,0.00009327197],"category_scores_gemma":[0.0068155658,0.000074178664,0.00026975299,0.00022134585,0.00010560166,0.0000737756,0.000019148903,0.00039466005,0.0000015302477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027962155,0.00053288316,0.95385754,0.00021070862,0.00028405775,0.000028556811,0.0039153253,0.00015751384,0.00039729165,0.000042678526,0.0002977308,0.037479497],"study_design_scores_gemma":[0.019730473,0.018629692,0.9414395,0.002534571,0.00035636095,0.0000010163958,0.0046107606,0.00011628371,0.0032916109,0.00022499949,0.008944668,0.0001200345],"about_ca_topic_score_codex":0.000025416904,"about_ca_topic_score_gemma":0.000112815025,"teacher_disagreement_score":0.037359465,"about_ca_system_score_codex":0.00021653058,"about_ca_system_score_gemma":0.0012754713,"threshold_uncertainty_score":0.81593615},"labels":[],"label_agreement":null},{"id":"W3004949061","doi":"10.1200/jco.2020.38.4_suppl.387","title":"Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Chemotherapy; Cancer; Cisplatin; Internal medicine; Oncology; Surgery","score_opus":0.09834084910250807,"score_gpt":0.4278288746392006,"score_spread":0.32948802553669254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004949061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947135,0.0004233493,0.000069668735,0.003983429,0.00017433081,0.00049671886,0.00003471047,0.0000061675787,0.00009816273],"genre_scores_gemma":[0.99629945,0.0004976728,0.0015152394,0.0013894631,0.00025399527,0.000015018537,0.000007245094,0.000017129656,0.000004794287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968857,0.0004361199,0.0017085326,0.00026429308,0.00044174257,0.0002636192],"domain_scores_gemma":[0.9968505,0.0007940398,0.0012472555,0.00011159343,0.000593267,0.0004033527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011277148,0.00019591524,0.002822177,0.00022770108,0.000031010382,0.000009588053,0.00013019866,0.00023668504,0.00014736803],"category_scores_gemma":[0.00060030696,0.00012829977,0.00038613004,0.00080875953,0.00037456708,0.00013666574,0.000038937138,0.0006962492,4.835016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040334783,0.0020496654,0.87323576,0.00015161785,0.004164905,0.00016878547,0.00039640852,0.00016518327,0.0011304636,0.0000314269,0.000058540172,0.07811246],"study_design_scores_gemma":[0.01745172,0.014233756,0.9612898,0.00010596302,0.0029340107,0.000013467927,0.00012921207,0.00027198947,0.00087301794,0.0000033629133,0.0025705365,0.00012314414],"about_ca_topic_score_codex":0.00011215159,"about_ca_topic_score_gemma":0.0000516073,"teacher_disagreement_score":0.08805406,"about_ca_system_score_codex":0.000067590205,"about_ca_system_score_gemma":0.0005166365,"threshold_uncertainty_score":0.5231913},"labels":[],"label_agreement":null},{"id":"W3004966554","doi":"10.1200/jco.2020.38.5_suppl.tps65","title":"SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Internal medicine; Mucosal melanoma; Adjuvant therapy; Clinical endpoint; Oncology; Clinical trial; Adjuvant; Phases of clinical research; Surgery; Gastroenterology; Cancer; Immunotherapy; Cancer research","score_opus":0.19823788034640213,"score_gpt":0.4882958499286043,"score_spread":0.2900579695822022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004966554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984426,0.0023029065,0.000053296906,0.011466585,0.0006592729,0.0007363194,0.000009077109,0.000011826481,0.0003347167],"genre_scores_gemma":[0.99375176,0.0011237662,0.00072396355,0.0033121647,0.0009827621,0.000006958451,0.0000030178767,0.000023652989,0.000071971226],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99647003,0.00035992655,0.0023729375,0.00023795436,0.00033743828,0.00022173503],"domain_scores_gemma":[0.99582267,0.0015804322,0.0015948893,0.00016612021,0.00047978395,0.0003560942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020191865,0.00015729842,0.0016521825,0.00009516944,0.000067289926,0.000007409467,0.00016838362,0.00027321884,0.0001889771],"category_scores_gemma":[0.0023200794,0.00010896549,0.00043478198,0.00018025015,0.00023030101,0.00007757842,0.00004920502,0.0005543343,0.0000011106359],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31676298,0.02723922,0.004034492,0.000045119978,0.0016259307,0.00024827142,0.0017217202,7.9196496e-7,0.029201185,0.0000092529035,0.0049557844,0.61415523],"study_design_scores_gemma":[0.17820555,0.7145983,0.02223638,0.000071353235,0.00045577265,0.00021674819,0.0016005945,0.00011651146,0.0017353538,0.00009698722,0.080536254,0.00013018548],"about_ca_topic_score_codex":0.00003900524,"about_ca_topic_score_gemma":0.00004793774,"teacher_disagreement_score":0.6873591,"about_ca_system_score_codex":0.00007898594,"about_ca_system_score_gemma":0.0011127477,"threshold_uncertainty_score":0.4443484},"labels":[],"label_agreement":null},{"id":"W3004969922","doi":"10.1200/jco.2020.38.4_suppl.284","title":"Access to care and outcomes for noncurative esophagogastric cancer: A population-based geographic study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; University of Manitoba; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Poisson regression; Cancer registry; Population; Residence; Cancer; Socioeconomic status; Internal medicine; Demography; Family medicine; Environmental health","score_opus":0.181791988006145,"score_gpt":0.5220059450616065,"score_spread":0.3402139570554615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004969922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975093,0.0005595991,0.0003275697,0.022375217,0.0006152297,0.0009000523,0.00002729175,0.000008105395,0.00009392669],"genre_scores_gemma":[0.9713142,0.000098437624,0.002340495,0.0254717,0.00071786443,0.000030201603,0.0000056104227,0.000012265136,0.000009227334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798876,0.00012697767,0.0013036566,0.00020783626,0.00022177119,0.00015102737],"domain_scores_gemma":[0.99641293,0.0017708488,0.00075934164,0.00008748684,0.0004330511,0.00053636485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005274286,0.000121293386,0.0012949699,0.00013827684,0.000055824385,0.000014964946,0.0001483584,0.00013230085,0.00010504012],"category_scores_gemma":[0.0022318983,0.00008535266,0.0003360558,0.0001938504,0.00004248796,0.00012215765,0.00004149034,0.00041540133,8.5650845e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038644029,0.00023535447,0.8636811,0.000055114488,0.0002531892,0.000069879134,0.0005272488,0.00016986537,0.0000040683917,0.000003669429,0.00076782785,0.1303683],"study_design_scores_gemma":[0.012694551,0.021865115,0.95531285,0.000026844158,0.00041589508,0.000005099281,0.0007267003,0.0002541824,0.0000060583,0.000014340857,0.008603836,0.000074550146],"about_ca_topic_score_codex":0.00012131645,"about_ca_topic_score_gemma":0.00031779526,"teacher_disagreement_score":0.13029377,"about_ca_system_score_codex":0.00011667266,"about_ca_system_score_gemma":0.0014975828,"threshold_uncertainty_score":0.34805804},"labels":[],"label_agreement":null},{"id":"W3004978920","doi":"10.1200/jco.2020.38.4_suppl.743","title":"Whole genome and transcriptome analysis and the link between insulin receptor aberration and diabetes in PDAC.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Insulin receptor; Transcriptome; Insulin; Cancer; Type 2 diabetes; Diabetes mellitus; Internal medicine; Alternative splicing; Cancer research; Oncology; Endocrinology; Bioinformatics; Insulin resistance; Gene; Exon; Biology; Gene expression; Genetics","score_opus":0.11987660039110254,"score_gpt":0.44222151197629905,"score_spread":0.3223449115851965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004978920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8614149,0.0020823986,0.00012650313,0.1358655,0.00004321266,0.0001865178,0.000005285328,0.0000027904148,0.00027291046],"genre_scores_gemma":[0.9903959,0.0043089334,0.0017122506,0.0023962045,0.0011099322,0.000004040434,0.0000056171966,0.000006313365,0.000060788778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722683,0.0008096001,0.0014200902,0.000173299,0.00019972803,0.00017042381],"domain_scores_gemma":[0.99510205,0.0038212086,0.0004707277,0.000080600315,0.00013820516,0.0003872232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047094547,0.000093321614,0.0018721733,0.0001564284,0.000044341527,0.000013702694,0.00007819045,0.00030761855,0.00005775166],"category_scores_gemma":[0.0036535347,0.000054460335,0.00015458302,0.00031905784,0.00068358943,0.00008016774,0.000042580592,0.0009651457,0.0000034161558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017696955,0.00006184216,0.93514335,0.00003501161,0.0010074832,0.000028816177,0.0008165962,0.0000010220641,0.0007950542,0.00003078202,0.0000897795,0.060220536],"study_design_scores_gemma":[0.011291484,0.004290589,0.96510345,0.00002085234,0.0018939637,0.000009738065,0.00020414055,0.0013716167,0.0000064303927,0.00035218222,0.015403956,0.000051570063],"about_ca_topic_score_codex":0.000018777315,"about_ca_topic_score_gemma":0.00003868504,"teacher_disagreement_score":0.1334693,"about_ca_system_score_codex":0.000029900411,"about_ca_system_score_gemma":0.00033622625,"threshold_uncertainty_score":0.4373886},"labels":[],"label_agreement":null},{"id":"W3004987220","doi":"10.1200/jco.2020.38.4_suppl.478","title":"Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Tolerability; Ipilimumab; Hepatocellular carcinoma; Sorafenib; Mallinckrodt; Bristol-Myers; Oncology; Gastroenterology; Adverse effect; Cancer; Immunotherapy; Family medicine","score_opus":0.14093982273088967,"score_gpt":0.3533036802127839,"score_spread":0.21236385748189424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004987220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942053,0.00059878384,0.000036415313,0.0073598325,0.000538904,0.0008984749,0.000038130565,0.000029886229,0.001079027],"genre_scores_gemma":[0.99444795,0.00080431433,0.0019922515,0.0019287026,0.0005441436,0.000013468334,0.00014667935,0.000054061282,0.00006841203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944077,0.0007283693,0.0031646178,0.00053571915,0.0007396616,0.00042390122],"domain_scores_gemma":[0.9949597,0.0011041628,0.0021932484,0.00034013414,0.0007652108,0.0006375545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014489979,0.00035246066,0.0021288486,0.000177167,0.000062495455,0.00002205637,0.0002801399,0.0005341663,0.00012514464],"category_scores_gemma":[0.0015011133,0.00025443433,0.00050852215,0.00042974917,0.00017798884,0.00027680796,0.00006058913,0.0012199017,0.000044802717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04627007,0.0034298908,0.84738445,0.000021033697,0.00030049312,0.001539296,0.00065395195,0.0000044364674,0.0002104391,0.000014545253,0.00040799176,0.09976341],"study_design_scores_gemma":[0.1264179,0.050490387,0.80540633,0.00016328473,0.0003063737,0.000022898505,0.00014727222,0.0028393948,0.001660265,0.00006765362,0.012214899,0.0002633266],"about_ca_topic_score_codex":0.00016915576,"about_ca_topic_score_gemma":0.00003843055,"teacher_disagreement_score":0.09950008,"about_ca_system_score_codex":0.00021668022,"about_ca_system_score_gemma":0.0010915492,"threshold_uncertainty_score":0.99999076},"labels":[],"label_agreement":null},{"id":"W3005023047","doi":"10.1200/jco.2020.38.4_suppl.38","title":"Chemotherapy-induced neutropenia with FOLFOX in the adjuvant treatment of colorectal cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Neutropenia; Colorectal cancer; Chemotherapy; Stage (stratigraphy); Retrospective cohort study; Cancer; Gastroenterology; Surgery; Oxaliplatin","score_opus":0.1809831291335125,"score_gpt":0.4763536191225536,"score_spread":0.2953704899890411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005023047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9457112,0.0003388321,0.000010160855,0.05122563,0.00029110914,0.0003119855,0.0000022802797,0.0000038639732,0.0021049508],"genre_scores_gemma":[0.99254316,0.0013117312,0.0002652396,0.005042636,0.0007819101,0.000016933873,5.0730114e-7,0.000011928839,0.000025958332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980828,0.00025739084,0.0011619555,0.00012936756,0.00022398497,0.00014446254],"domain_scores_gemma":[0.9980771,0.00059358956,0.0008677674,0.000101580525,0.00017877354,0.00018119141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048804385,0.00010999823,0.0012050028,0.000043220516,0.000022560778,0.0000043441805,0.00013234177,0.00013203222,0.00015386006],"category_scores_gemma":[0.00013923991,0.000052693693,0.0002966365,0.00023382124,0.00011564377,0.00004959084,0.00000913593,0.00045458067,0.000003926248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047441956,0.0067391167,0.5442423,0.000046734043,0.0011682136,0.0018613322,0.0030897646,0.00011688873,0.0198961,0.00016184861,0.0031124428,0.3721233],"study_design_scores_gemma":[0.024850886,0.1253086,0.77423245,0.00007562239,0.0005802907,0.000533458,0.0005184302,0.000040854775,0.0046140514,0.000023400538,0.06913224,0.00008973066],"about_ca_topic_score_codex":0.0001371057,"about_ca_topic_score_gemma":0.00042752098,"teacher_disagreement_score":0.37203357,"about_ca_system_score_codex":0.00014241996,"about_ca_system_score_gemma":0.0016676623,"threshold_uncertainty_score":0.29583612},"labels":[],"label_agreement":null},{"id":"W3005036535","doi":"10.1200/jco.2020.38.4_suppl.341","title":"Synchronous pulmonary and esophageal cancers: Is combined esophagectomy and anatomic lung resection appropriate?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Esophagectomy; Esophagus; Neoadjuvant therapy; Pneumonectomy; Exact test; Esophageal cancer; Surgery; Stage (stratigraphy); Lung cancer; Cancer; Radiology; Internal medicine","score_opus":0.07041934772610842,"score_gpt":0.4342574619796923,"score_spread":0.36383811425358387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005036535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94583225,0.030352313,0.000067385256,0.022139728,0.000328708,0.00042096563,0.000007721886,0.000017241577,0.0008336725],"genre_scores_gemma":[0.9898856,0.004596325,0.00086301175,0.0034068862,0.0011297275,0.00000779744,0.00000286641,0.000019820487,0.00008795867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759233,0.00026581762,0.001171824,0.0003070395,0.00038442438,0.00027853652],"domain_scores_gemma":[0.9973154,0.0006779222,0.0006222494,0.00012375637,0.00023764688,0.0010230142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011351957,0.00016292692,0.0011748335,0.00010730146,0.000076391516,0.000020626281,0.00009701244,0.00027338133,0.00016560512],"category_scores_gemma":[0.0009200466,0.000119088974,0.00024828166,0.00017290951,0.0002849423,0.00015928228,0.00009234803,0.0010832511,0.000008043889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044419467,0.0014669456,0.5518983,0.00064132665,0.0023068644,0.020365661,0.000722696,0.0000100265,0.00023024625,0.00017221566,0.0074965614,0.37026966],"study_design_scores_gemma":[0.043658663,0.09602874,0.8369472,0.0002418695,0.0014954873,0.0036155207,0.000416102,0.010136498,0.000977001,0.0013879077,0.0047750683,0.00031995165],"about_ca_topic_score_codex":0.000094549556,"about_ca_topic_score_gemma":0.000016217055,"teacher_disagreement_score":0.36994973,"about_ca_system_score_codex":0.00034938386,"about_ca_system_score_gemma":0.0014737076,"threshold_uncertainty_score":0.48563075},"labels":[],"label_agreement":null},{"id":"W3005116118","doi":"10.1200/jco.2020.38.15_suppl.e16656","title":"Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Western University; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Neoadjuvant therapy; Meta-analysis; Immunotherapy; Internal medicine; Oncology; Renal cell carcinoma; Randomized controlled trial; Adverse effect; Hepatocellular carcinoma; Cancer; Surgery; Breast cancer","score_opus":0.10044782707395385,"score_gpt":0.47906806090004056,"score_spread":0.3786202338260867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005116118","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009948163,0.99611527,0.0000015543403,0.0004196575,0.00005925852,0.0023405645,0.000019582594,0.0000034063644,0.000045889916],"genre_scores_gemma":[0.003581677,0.99572015,0.000055744058,0.00042637953,0.000076878285,0.00007088341,0.000010235963,0.000028778928,0.000029303132],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99087596,0.0040838844,0.004140191,0.00029997574,0.0004478405,0.00015214935],"domain_scores_gemma":[0.9913758,0.003653196,0.004306027,0.00025015874,0.0002144758,0.00020033619],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004032175,0.00038463253,0.024680763,0.00030257626,0.000018215476,0.000007839937,0.00011409245,0.0003489911,0.00007135587],"category_scores_gemma":[0.0009565577,0.00016268334,0.0024012055,0.0004489401,0.00014053294,0.000047037032,0.000024309036,0.0010079244,0.0000015548649],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010403256,0.001464195,0.0017184025,0.48696852,0.3866016,0.0007310411,0.00006793729,3.346674e-7,3.66383e-8,0.00000491287,0.000058156907,0.1119816],"study_design_scores_gemma":[0.008906308,0.08372608,0.0010507016,0.049797826,0.8407962,0.00021943408,0.000004149288,9.680547e-7,4.1072306e-7,0.000005222398,0.01533983,0.00015290867],"about_ca_topic_score_codex":0.0000120606655,"about_ca_topic_score_gemma":0.0000058028995,"teacher_disagreement_score":0.45419458,"about_ca_system_score_codex":0.00010557343,"about_ca_system_score_gemma":0.00052121683,"threshold_uncertainty_score":0.98979884},"labels":[],"label_agreement":null},{"id":"W3005126119","doi":"10.1200/jco.2020.38.4_suppl.506","title":"Determination of quality of care for patients with hepatocellular carcinoma in Nova Scotia.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University; Université Laval","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Referral; Malignancy; Cancer; Internal medicine; Sorafenib; Liver cancer; Retrospective cohort study; Family medicine","score_opus":0.15456249670780797,"score_gpt":0.4494805019600084,"score_spread":0.2949180052522004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005126119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974387,0.00015565283,0.00042431368,0.0010931009,0.00022372449,0.0003166059,0.000016744756,0.0000011310135,0.00033002434],"genre_scores_gemma":[0.992753,0.000017521066,0.0060103545,0.0010337589,0.00016247264,8.312135e-7,0.000011246566,0.0000074061136,0.0000033775632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973596,0.0001803774,0.0020187094,0.00010908018,0.0002388103,0.00009344124],"domain_scores_gemma":[0.9962823,0.0009688505,0.0017261736,0.000088659865,0.0007903561,0.00014367969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085798395,0.00006963423,0.0012658427,0.00006556842,0.0000057151187,8.3438863e-7,0.000088422465,0.00016321764,0.000054899454],"category_scores_gemma":[0.0020101508,0.00005017483,0.00024995417,0.00009184228,0.00010743788,0.0000674809,0.000017027223,0.00029939285,4.4945585e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0133518055,0.00048525207,0.93868154,0.00047735425,0.000043406344,0.000024348865,0.00052434707,0.0000070507162,0.00019855038,0.000011930221,0.00007109832,0.04612329],"study_design_scores_gemma":[0.018549584,0.026532004,0.9516774,0.00008445827,0.000118191,0.0000028692232,0.0002816841,0.00044332625,0.0006632061,0.000015604644,0.0015803163,0.000051390172],"about_ca_topic_score_codex":0.00006453414,"about_ca_topic_score_gemma":0.00016384311,"teacher_disagreement_score":0.0460719,"about_ca_system_score_codex":0.00009389455,"about_ca_system_score_gemma":0.0012464662,"threshold_uncertainty_score":0.24064836},"labels":[],"label_agreement":null},{"id":"W3005126836","doi":"10.1200/jco.2020.38.4_suppl.775","title":"Does aberrant hepatic arterial anatomy impact the complication rate or survival following resection of pancreatic adenocarcinoma?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Pancreaticoduodenectomy; Gastroduodenal artery; Surgery; Perioperative; Pancreatic fistula; Pancreatectomy; Pancreatic cancer; Chyle; Univariate analysis; Survival rate; Pancreas; Gastroenterology; Complication; Artery; Internal medicine; Cancer; Multivariate analysis","score_opus":0.19725969206300184,"score_gpt":0.5103352375232965,"score_spread":0.3130755454602946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005126836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738734,0.00021334381,0.0006889186,0.022762561,0.0012392531,0.00047760733,0.0000047652,0.000009482072,0.0007306699],"genre_scores_gemma":[0.99565625,0.0004754362,0.0009194967,0.0009543502,0.0018548704,0.000009207335,0.0000044041126,0.000017039609,0.00010895407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944669,0.0019402447,0.0025745777,0.00021113607,0.00052014145,0.00028700812],"domain_scores_gemma":[0.9898862,0.007178877,0.0017261625,0.00027184704,0.00048435284,0.00045255283],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061523044,0.0001582793,0.002268142,0.00009356538,0.00008869,0.000012095461,0.00027617035,0.00031406104,0.0003484903],"category_scores_gemma":[0.01116033,0.00006361301,0.0007450536,0.00031934044,0.000348065,0.00011150067,0.000063329106,0.0009941491,0.00001808249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038078807,0.0009203555,0.9433208,0.00014504085,0.0022336051,0.0005551636,0.00064645935,0.000011286018,0.0045610815,0.00007077789,0.0021106417,0.007345951],"study_design_scores_gemma":[0.010233073,0.025626715,0.9560275,0.00014196603,0.0017387212,0.00013915937,0.000551935,0.002819367,0.00014661989,0.00038968865,0.002096628,0.000088635985],"about_ca_topic_score_codex":0.000118747674,"about_ca_topic_score_gemma":0.00007259198,"teacher_disagreement_score":0.027845733,"about_ca_system_score_codex":0.00016038974,"about_ca_system_score_gemma":0.0026513662,"threshold_uncertainty_score":0.9971691},"labels":[],"label_agreement":null},{"id":"W3005146430","doi":"10.1200/jco.2020.38.4_suppl.673","title":"First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Gemcitabine; Medicine; Pancreatic cancer; FOLFIRINOX; Internal medicine; Neutropenia; Retrospective cohort study; Log-rank test; Gastroenterology; Toxicity; Chemotherapy; Surgery; Survival analysis; Oncology; Irinotecan; Cancer","score_opus":0.1563189900637684,"score_gpt":0.49416435516315976,"score_spread":0.33784536509939134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005146430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8676685,0.00041535552,0.000261889,0.12644386,0.0010296055,0.0005104127,0.0000214915,0.000010516882,0.0036383527],"genre_scores_gemma":[0.9857891,0.0037137908,0.005041321,0.0031283475,0.0016071077,0.000035771023,0.000007308733,0.000017284194,0.0006599325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996898,0.00043153303,0.0016071557,0.00031265663,0.00033351165,0.0004171478],"domain_scores_gemma":[0.9963003,0.0013800625,0.0006183347,0.000107111424,0.0005729694,0.0010212329],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001070952,0.00020068849,0.0017121775,0.00022525033,0.00011696781,0.000009813076,0.00015055526,0.00032688037,0.0011685414],"category_scores_gemma":[0.0029032591,0.00012714339,0.0003424199,0.00027064257,0.00028085685,0.000129649,0.000026634358,0.0009340525,0.000066958884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02696396,0.002006829,0.9474632,0.00006739132,0.0014008489,0.0026658764,0.0017950407,0.0011351936,0.0001676394,0.00031402562,0.0024253186,0.013594646],"study_design_scores_gemma":[0.06771622,0.026018536,0.8177965,0.00031839582,0.0016431228,0.00036609525,0.0022561206,0.011307038,0.00008871142,0.00022976597,0.07195347,0.0003060195],"about_ca_topic_score_codex":0.068635836,"about_ca_topic_score_gemma":0.5235129,"teacher_disagreement_score":0.45487705,"about_ca_system_score_codex":0.0038386802,"about_ca_system_score_gemma":0.014295632,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W3005156010","doi":"10.1200/jco.2020.38.4_suppl.tps261","title":"NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Oncology; Internal medicine; FOLFOX; Colorectal cancer; Clinical endpoint; Chemotherapy; Adjuvant; Oxaliplatin; Stage (stratigraphy); Biomarker; Prospective cohort study; Cancer; Clinical trial","score_opus":0.04848393316326147,"score_gpt":0.4062087298726107,"score_spread":0.3577247967093492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005156010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804527,0.00028518512,0.000048397873,0.000701723,0.00024393883,0.00050235225,0.00004295975,0.0000017632873,0.00012840815],"genre_scores_gemma":[0.9977924,0.00022650363,0.00015284012,0.0015424164,0.000231561,0.000013464988,0.000009297574,0.000020940432,0.000010557874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973524,0.00021706034,0.0016811544,0.00029944125,0.00023229381,0.0002176423],"domain_scores_gemma":[0.99760836,0.00022916308,0.0015508801,0.00014415884,0.000266772,0.00020065178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008053821,0.00016231182,0.00094000914,0.00007234239,0.000038654052,0.000005495484,0.00022356055,0.00019720204,0.00004073655],"category_scores_gemma":[0.0010551506,0.00013265277,0.00013508911,0.00018307606,0.0001190911,0.000009600358,0.00015177911,0.00038644767,2.839389e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07294438,0.021723777,0.8357915,0.000031030922,0.00073926774,0.000318982,0.0022880768,0.0020301745,0.015564569,0.0000084839485,0.00083852233,0.047721237],"study_design_scores_gemma":[0.10550361,0.22798921,0.6527563,0.000113661,0.0001693365,0.000007903192,0.0013133216,0.0008867297,0.0024977,0.00002432176,0.008432368,0.0003055688],"about_ca_topic_score_codex":0.00018789308,"about_ca_topic_score_gemma":0.0008757209,"teacher_disagreement_score":0.20626543,"about_ca_system_score_codex":0.000091556896,"about_ca_system_score_gemma":0.0012749361,"threshold_uncertainty_score":0.5409423},"labels":[],"label_agreement":null},{"id":"W3005170355","doi":"10.1200/jco.2020.38.4_suppl.339","title":"Economic impacts of care by high-volume providers for noncurative esophagogastric cancer: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Health care; Population; Confidence interval; Emergency medicine; Cancer; Activity-based costing; Cohort; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.07475899169474028,"score_gpt":0.4817596174407549,"score_spread":0.40700062574601464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005170355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96684235,0.006815232,0.0006107933,0.024429925,0.00024812427,0.0007003759,0.0002962035,0.000007570818,0.00004940262],"genre_scores_gemma":[0.9955992,0.00025398002,0.0020589803,0.0013991622,0.00056176266,0.000022212975,0.00006785011,0.000013137626,0.000023694483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753445,0.00016263222,0.0016217434,0.00020156142,0.00025866544,0.00022095571],"domain_scores_gemma":[0.99583805,0.0012293144,0.00171882,0.00011004571,0.00044210444,0.0006616738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005330925,0.00012637803,0.0017526514,0.00015877697,0.000031257397,0.0000067893925,0.0001231617,0.00017046169,0.000269144],"category_scores_gemma":[0.0014686652,0.000091237634,0.0008421878,0.00024666672,0.00008727955,0.00009494646,0.000016433603,0.00037087075,0.00000379832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011742558,0.00046209394,0.95185816,0.00016978648,0.0031369897,0.00011383254,0.00018474598,0.0022300223,0.000018736873,0.00002791552,0.006450944,0.023604216],"study_design_scores_gemma":[0.028827874,0.077401884,0.87963426,0.00007684249,0.005504411,0.000007813695,0.00036327573,0.004391125,0.00081355666,0.00010108481,0.0027355966,0.00014228758],"about_ca_topic_score_codex":0.000947764,"about_ca_topic_score_gemma":0.0006665359,"teacher_disagreement_score":0.07693979,"about_ca_system_score_codex":0.00069409993,"about_ca_system_score_gemma":0.0044548223,"threshold_uncertainty_score":0.79026634},"labels":[],"label_agreement":null},{"id":"W3005182246","doi":"10.1200/jco.2020.38.4_suppl.802","title":"Declining use of red blood cell transfusions for gastrointestinal cancer surgery: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Blood transfusion and management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Sunnybrook Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Centre hospitalier universitaire de Québec; University of Manitoba; Sunnybrook Health Science Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Perioperative; Colorectal cancer; Cancer; Population; Retrospective cohort study; Blood transfusion; Cohort; Internal medicine; Surgery; Environmental health","score_opus":0.26545238065042415,"score_gpt":0.4536763376617031,"score_spread":0.18822395701127898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005182246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9326381,0.00008389096,0.02786488,0.038619984,0.00030757097,0.00035665132,0.000022088809,0.000013721778,0.00009310596],"genre_scores_gemma":[0.9498645,0.00023763672,0.04299767,0.0064425776,0.00038295882,0.0000074770746,0.000012863569,0.0000149399075,0.00003936494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962721,0.0003088556,0.002730974,0.00019958914,0.00030550067,0.00018299841],"domain_scores_gemma":[0.9911903,0.0062105,0.001485393,0.00013068887,0.00052403007,0.00045909823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021143523,0.00012011926,0.001898918,0.00024443158,0.000036335714,0.0000058701407,0.00009295248,0.00013683877,0.00029984416],"category_scores_gemma":[0.004580769,0.00009267353,0.0015949935,0.00047374697,0.000058037276,0.000059630864,0.000011810242,0.00046196193,6.3232204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008616018,0.002503589,0.9683711,0.00017502064,0.0013856527,0.00017762619,0.000051917057,0.002534002,0.0010286593,0.000023479093,0.0034235776,0.01170938],"study_design_scores_gemma":[0.011897251,0.007388449,0.9392796,0.00022026608,0.016199851,0.000026169602,0.00006914663,0.0068809534,0.00023362806,0.0000192349,0.01766789,0.00011756793],"about_ca_topic_score_codex":0.00013177306,"about_ca_topic_score_gemma":0.00021344765,"teacher_disagreement_score":0.032177404,"about_ca_system_score_codex":0.00002332626,"about_ca_system_score_gemma":0.0011150988,"threshold_uncertainty_score":0.54839396},"labels":[],"label_agreement":null},{"id":"W3005185861","doi":"10.1200/jco.2020.38.4_suppl.94","title":"Evaluation of adjuvant chemotherapy-associated steatosis in colorectal cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Steatosis; Internal medicine; Colorectal cancer; Chemotherapy; Cancer; Incidence (geometry); Gastroenterology; Surgery; Oncology","score_opus":0.10127892676408955,"score_gpt":0.4437902897086378,"score_spread":0.34251136294454826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005185861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98918414,0.0032862332,0.00002888425,0.0025898416,0.0042114216,0.00014437232,0.000012311754,0.0000016617005,0.0005411197],"genre_scores_gemma":[0.9872157,0.003986934,0.00015251328,0.0014016673,0.0072053922,0.0000066605753,0.0000048802876,0.00001157568,0.000014661642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971536,0.0007438072,0.0013935025,0.00016518962,0.0003977982,0.00014614577],"domain_scores_gemma":[0.9975543,0.00014058081,0.001323041,0.00007087443,0.0007575295,0.0001536722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044200514,0.00009480823,0.0008182915,0.0000382143,0.000011968027,0.0000029675193,0.00018052028,0.0003582234,0.00008912314],"category_scores_gemma":[0.003819043,0.000079805286,0.0003056348,0.00012643532,0.00009928502,0.0000057380375,0.00003682867,0.00030533073,0.000001087133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00537329,0.001495508,0.09505403,0.000023048276,0.00092805194,0.0000015264446,0.0005261059,0.0011089211,0.2841857,0.000017723116,0.0404319,0.5708542],"study_design_scores_gemma":[0.028038478,0.012451861,0.62698203,0.00007732761,0.00082560256,0.000014028451,0.00039862,0.0016623919,0.036223494,0.0001885691,0.29284987,0.00028771977],"about_ca_topic_score_codex":0.000051516534,"about_ca_topic_score_gemma":0.00055538747,"teacher_disagreement_score":0.5705665,"about_ca_system_score_codex":0.000076128614,"about_ca_system_score_gemma":0.002351116,"threshold_uncertainty_score":0.4572027},"labels":[],"label_agreement":null},{"id":"W3005265102","doi":"10.1200/jco.2020.38.4_suppl.518","title":"Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Pembrolizumab; Phases of clinical research; Adverse effect; Gastroenterology; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.10429450616913653,"score_gpt":0.3754582938832818,"score_spread":0.27116378771414523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005265102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701065,0.00036653134,0.00002137643,0.001139585,0.00010512704,0.0011946164,0.000011626832,0.000007190082,0.00014328523],"genre_scores_gemma":[0.99864894,0.00009088297,0.0008288407,0.0002664892,0.00010400436,0.0000054038283,0.000018135306,0.000026392849,0.000010920071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953332,0.0005841984,0.0030176998,0.0003125703,0.00050737127,0.0002449624],"domain_scores_gemma":[0.996048,0.00070508826,0.001968254,0.00023338367,0.00056264893,0.0004826311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009814927,0.00023759497,0.0025785728,0.00018474464,0.00003723272,0.0000031194968,0.00016397149,0.00026398042,0.000079903184],"category_scores_gemma":[0.0009967936,0.00016438923,0.00025059396,0.00038370982,0.00019067343,0.00011628642,0.00010463452,0.0007095646,0.0000014077317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10432616,0.019953864,0.8388646,0.00007166264,0.00047533915,0.000785532,0.0009882696,0.000007108205,0.00019355226,0.000004343284,0.00006524268,0.034264307],"study_design_scores_gemma":[0.16700546,0.20169671,0.62819046,0.00009894412,0.00080430997,0.000019250763,0.00023375638,0.0006230875,0.00029086234,0.000004467528,0.0009248423,0.00010787188],"about_ca_topic_score_codex":0.000025101934,"about_ca_topic_score_gemma":0.000010926837,"teacher_disagreement_score":0.2106742,"about_ca_system_score_codex":0.00007205844,"about_ca_system_score_gemma":0.00069423165,"threshold_uncertainty_score":0.67035985},"labels":[],"label_agreement":null},{"id":"W3005276288","doi":"10.1200/jco.2020.38.4_suppl.810","title":"The cost of chemotherapy administration: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; Ontario Institute for Cancer Research; University of Toronto; Health Sciences Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Interquartile range; Checklist; Indirect costs; Health care; MEDLINE; Systematic review; Emergency medicine; Intensive care medicine; Internal medicine","score_opus":0.39042669006314795,"score_gpt":0.493838065131639,"score_spread":0.10341137506849107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005276288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.3484138e-7,0.98999697,0.00020857985,0.0062643294,0.0002839681,0.00090396416,0.00010868804,0.000002127554,0.0022311397],"genre_scores_gemma":[0.000049203638,0.9962315,0.00021135935,0.0027335251,0.00025763662,0.000043681088,0.0000026264706,0.000020563612,0.00044992685],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.98845476,0.0003728222,0.010669633,0.00027024088,0.00006178283,0.00017076799],"domain_scores_gemma":[0.9737759,0.0032620744,0.022158228,0.0003947549,0.00017961155,0.00022942961],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008922074,0.0002755953,0.024673937,0.0001370845,0.00004677825,0.000038694758,0.00060554,0.00045630953,0.00024773335],"category_scores_gemma":[0.0053054243,0.00015995314,0.0064479224,0.0003446477,0.00023414304,0.0001227053,0.000049778533,0.00080196606,0.00004154738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092723196,0.0003191356,0.0000207113,0.35694605,0.45954338,0.000049591494,0.00003606408,8.20095e-7,6.79931e-10,0.031287707,0.0071283337,0.14457548],"study_design_scores_gemma":[0.00018821763,0.00063156785,0.000009526926,0.0015938159,0.27076176,0.000038020717,0.0000030001286,0.000002078704,5.693762e-9,0.0006690548,0.7259993,0.00010367679],"about_ca_topic_score_codex":0.0000051499514,"about_ca_topic_score_gemma":0.000018944878,"teacher_disagreement_score":0.71887094,"about_ca_system_score_codex":0.0001006492,"about_ca_system_score_gemma":0.0010274675,"threshold_uncertainty_score":0.9898058},"labels":[],"label_agreement":null},{"id":"W3005279051","doi":"10.1200/jco.2020.38.4_suppl.72","title":"Clinical and pathologic characteristics of early-onset colorectal cancer (EoCRC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Lymphovascular invasion; Perineural invasion; Gastroenterology; Incidence (geometry); Colorectal cancer; Stage (stratigraphy); Cancer; Perforation; Lymph node; Metastasis","score_opus":0.16481222814199348,"score_gpt":0.4855676385267734,"score_spread":0.32075541038477995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005279051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590523,0.0013556211,0.0000125122915,0.01077507,0.0009724954,0.00017073314,0.00003410897,0.000007709088,0.0007665142],"genre_scores_gemma":[0.9865883,0.008162099,0.00091211713,0.002995649,0.0012839289,0.0000047248145,0.0000015407463,0.0000110898145,0.000040547548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996509,0.00033683036,0.0025328984,0.00020915896,0.00023689897,0.00017517443],"domain_scores_gemma":[0.9957045,0.0016658166,0.0016841867,0.00007773516,0.00043167832,0.000436101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001369276,0.00014163504,0.0022734154,0.000040347742,0.000034032855,0.0000048982274,0.0000973786,0.0003172207,0.000119373886],"category_scores_gemma":[0.0040606526,0.00009115339,0.00045325264,0.000106561965,0.0006337591,0.000046856647,0.000103782855,0.00081086287,0.000004745485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009324256,0.00066877773,0.8067643,0.000032709268,0.00048375022,0.00089661137,0.00020804479,1.399883e-7,0.000050433777,0.000010979639,0.0015361594,0.1800238],"study_design_scores_gemma":[0.0054710614,0.038778704,0.94146264,0.00005879072,0.00064083777,0.00019437514,0.000088531626,0.000021533517,0.000029657744,0.00006397029,0.0131165255,0.00007336808],"about_ca_topic_score_codex":0.000018892355,"about_ca_topic_score_gemma":0.000018438353,"teacher_disagreement_score":0.17995045,"about_ca_system_score_codex":0.000041020616,"about_ca_system_score_gemma":0.00089828647,"threshold_uncertainty_score":0.48612738},"labels":[],"label_agreement":null},{"id":"W3005303261","doi":"10.1200/jco.2020.38.15_suppl.e16577","title":"Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"University Health Network","keywords":"Medicine; Internal medicine; Regimen; Gastroenterology; Esophageal cancer; Cancer; Chemotherapy; Stage (stratigraphy); Charlson comorbidity index; Population; Adenocarcinoma; Oncology; Surgery; Retrospective cohort study","score_opus":0.07999913732996283,"score_gpt":0.40706842872832594,"score_spread":0.3270692913983631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005303261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916655,0.0004860695,0.00003331811,0.0068715825,0.00024062353,0.00021064555,0.0000049833684,0.0000058795003,0.00048142616],"genre_scores_gemma":[0.9926248,0.0011645812,0.0034275474,0.0023504358,0.0003093123,0.0000017243494,0.00000177417,0.000008073529,0.000111704685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981399,0.00012592139,0.0011532964,0.00017921886,0.0002543522,0.00014730128],"domain_scores_gemma":[0.99767804,0.00072485657,0.0010197284,0.000080679936,0.00015879414,0.00033787277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047585298,0.00013724722,0.0015112985,0.000070024835,0.000021850454,0.00000636453,0.000064947795,0.00014645497,0.00003372444],"category_scores_gemma":[0.0009477553,0.00007280028,0.00019203016,0.00010776374,0.000231432,0.00006140514,0.000052702293,0.00035129048,6.7870747e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030678324,0.00039259804,0.89983034,0.00002026476,0.00024714597,0.0002848868,0.00010620464,0.0000021390572,0.0000016556347,0.000022372642,0.00067225244,0.095352285],"study_design_scores_gemma":[0.014234103,0.038310017,0.94466555,0.000017754483,0.000679608,0.000079254205,0.00009878128,0.000008942687,0.0000025776887,0.000015426638,0.0018400557,0.000047952923],"about_ca_topic_score_codex":0.000020519925,"about_ca_topic_score_gemma":0.000024281304,"teacher_disagreement_score":0.09530433,"about_ca_system_score_codex":0.000074577554,"about_ca_system_score_gemma":0.00028535753,"threshold_uncertainty_score":0.29687092},"labels":[],"label_agreement":null},{"id":"W3005316833","doi":"10.1200/jco.2020.38.15_suppl.e19301","title":"Real-world treatment attrition rates in advanced esophagogastric cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cancer; Proportional hazards model; Attrition; Adenocarcinoma; Survival analysis; Oncology; Gastroenterology; Surgery","score_opus":0.2571043513110795,"score_gpt":0.5570533939767022,"score_spread":0.29994904266562267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005316833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9448527,0.0070694503,0.000012321128,0.045292776,0.0003696193,0.0004172802,0.000009865076,0.0000122986185,0.0019636848],"genre_scores_gemma":[0.9790052,0.016084334,0.0016723587,0.0016611126,0.001217831,0.000025815028,0.0000050452227,0.000013664323,0.00031459852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973941,0.00030870846,0.0015088815,0.00020477948,0.00031490388,0.0002686454],"domain_scores_gemma":[0.99733204,0.0009732174,0.0006819245,0.00010087,0.00020347598,0.0007084562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065382343,0.0001346336,0.0012997099,0.00016452267,0.000023442222,0.0000060022944,0.00009234933,0.00012895123,0.00032705095],"category_scores_gemma":[0.0009071251,0.00009030856,0.0003606635,0.0004156871,0.00008734281,0.00010358489,0.000022927105,0.00058197894,0.000027367807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0133482935,0.0020768128,0.64193416,0.00003846822,0.00028795202,0.0056668487,0.00009658605,0.00009295996,0.00009854225,0.000050227995,0.0012620355,0.3350471],"study_design_scores_gemma":[0.03102069,0.05951917,0.8926279,0.00013108634,0.0002415376,0.00006559411,0.00009462249,0.00014967687,0.0010763675,0.00016827154,0.014825328,0.0000797558],"about_ca_topic_score_codex":0.00033024384,"about_ca_topic_score_gemma":0.00085838593,"teacher_disagreement_score":0.33496734,"about_ca_system_score_codex":0.00091541663,"about_ca_system_score_gemma":0.0023973095,"threshold_uncertainty_score":0.4252724},"labels":[],"label_agreement":null},{"id":"W3005328484","doi":"10.1200/jco.2020.38.4_suppl.452","title":"Relationship between PET response and pathologic response in distal esophageal/gastroesophageal junction (DE/GEJ) cancers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Esophageal cancer; Neoadjuvant therapy; Perioperative; Internal medicine; Complete response; Adenocarcinoma; Cancer; Chemotherapy; Gastroenterology; Oncology; Surgery; Breast cancer","score_opus":0.18423303917116324,"score_gpt":0.4834497906582558,"score_spread":0.29921675148709254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005328484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96242803,0.0014437092,0.0001551248,0.035398964,0.00017041602,0.00026594364,0.000016652117,0.000015455662,0.00010567336],"genre_scores_gemma":[0.99446946,0.00015952674,0.0023900906,0.0019233173,0.0008761023,0.000009788452,0.0000055602686,0.000018385066,0.00014775338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940294,0.0032211328,0.001650313,0.00029221593,0.00043047508,0.0003764901],"domain_scores_gemma":[0.98956317,0.008363744,0.0007411665,0.00015135725,0.00017651667,0.001004062],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008736295,0.00016701156,0.0011462026,0.0002032556,0.00006685089,0.00001609875,0.00012621714,0.00025908035,0.00007539085],"category_scores_gemma":[0.023034634,0.0001264425,0.00026654606,0.00029983374,0.00030818162,0.00015386778,0.00006975896,0.0017697038,0.000017692784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13890013,0.00025847723,0.8286206,0.0000319914,0.0000691187,0.026155429,0.00028103753,0.000019960742,0.00005748586,0.000024966559,0.00081106287,0.00476971],"study_design_scores_gemma":[0.011114225,0.04067404,0.94555914,0.00004397383,0.00015490172,0.0009504264,0.00015134894,0.000054750195,0.000033552376,0.0003221261,0.000876904,0.00006460613],"about_ca_topic_score_codex":0.000032688804,"about_ca_topic_score_gemma":0.000021990843,"teacher_disagreement_score":0.1277859,"about_ca_system_score_codex":0.00084512355,"about_ca_system_score_gemma":0.0035917824,"threshold_uncertainty_score":0.98519474},"labels":[],"label_agreement":null},{"id":"W3005336040","doi":"10.1200/jco.19.02044","title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":327,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Jounce Therapeutics; AstraZeneca; Bristol-Myers Squibb; Mirati Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Astellas Pharma; Genentech; INOVIO Pharmaceuticals","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Rash; Nausea; Oncology; Regimen; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Gastroenterology","score_opus":0.10935009307479054,"score_gpt":0.4089754387298743,"score_spread":0.29962534565508375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005336040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854285,0.00009613892,0.00029027686,0.00024718768,0.0003064029,0.00034578904,0.000008062729,0.0000024468586,0.00016082775],"genre_scores_gemma":[0.99812806,0.000013495833,0.00085096067,0.00058394397,0.0003694145,0.000007174522,0.000011446021,0.000021779031,0.000013705199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672174,0.00046404797,0.0019587297,0.00027438847,0.0003501228,0.00023096842],"domain_scores_gemma":[0.99737734,0.00022237531,0.0016695857,0.000118975426,0.0004049466,0.00020679845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011103553,0.00018130927,0.0009962734,0.00007765389,0.000037464604,0.000009347382,0.0002708215,0.00013136525,0.000034112716],"category_scores_gemma":[0.001052309,0.00013748425,0.00017603875,0.00016303203,0.00010760951,0.00001247329,0.000111413094,0.0004026854,0.0000016420257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039275046,0.016942069,0.8749006,0.00006258363,0.0013582348,0.00052875717,0.003784819,0.0009732123,0.03784454,0.000005744954,0.0009957701,0.023328628],"study_design_scores_gemma":[0.10809767,0.29888842,0.5096524,0.00025205716,0.00081781176,0.000054969518,0.0042337463,0.00019887509,0.0740802,0.000048925976,0.0029079344,0.00076700817],"about_ca_topic_score_codex":0.000019323503,"about_ca_topic_score_gemma":0.000026773147,"teacher_disagreement_score":0.3652482,"about_ca_system_score_codex":0.000069576054,"about_ca_system_score_gemma":0.0010598954,"threshold_uncertainty_score":0.56064457},"labels":[],"label_agreement":null},{"id":"W3005364819","doi":"10.1200/jco.2020.38.4_suppl.741","title":"Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame; Toronto General Hospital; University Health Network; McGill University; Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Pancreatic ductal adenocarcinoma; Internal medicine; FOLFIRINOX; Chemotherapy; Cisplatin; Oncology; Cohort; Gastroenterology; Pancreatic cancer; Cancer; Oxaliplatin","score_opus":0.05592982729093397,"score_gpt":0.3787030781441937,"score_spread":0.3227732508532597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005364819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698914,0.00163646,0.0004088211,0.010267168,0.000376759,0.00011515985,0.000002680088,0.0000018831003,0.0002019572],"genre_scores_gemma":[0.9914205,0.0015149887,0.002502155,0.0040239003,0.0004971052,0.000002835359,0.0000014380738,0.0000122391,0.000024821025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834335,0.00025635824,0.0009229637,0.00021834111,0.00009640939,0.00016259708],"domain_scores_gemma":[0.99862427,0.00049691164,0.00040959098,0.000104775514,0.000118946635,0.00024552227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015657792,0.000094515184,0.00045853548,0.0000634149,0.00002376796,0.000012228247,0.00015951703,0.0002139282,0.000011338155],"category_scores_gemma":[0.0056608557,0.00008674466,0.00010889728,0.00010865987,0.00007192819,0.000005337218,0.00008999168,0.00026363408,0.0000037203201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032676604,0.0011922779,0.6658248,0.000049361148,0.00016416736,0.00083709956,0.0012334692,0.0006276575,0.16463517,0.00019123909,0.0047519,0.12781626],"study_design_scores_gemma":[0.0058980123,0.024609877,0.9452082,0.00003259741,0.000058667723,0.00029634213,0.00026775795,0.00014097276,0.0036215533,0.00043529048,0.01921395,0.00021679827],"about_ca_topic_score_codex":0.000013125357,"about_ca_topic_score_gemma":0.000031228537,"teacher_disagreement_score":0.2793834,"about_ca_system_score_codex":0.000049300164,"about_ca_system_score_gemma":0.0005961561,"threshold_uncertainty_score":0.6776982},"labels":[],"label_agreement":null},{"id":"W3005364954","doi":"10.1200/jco.2020.38.4_suppl.528","title":"RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nuclear medicine; Discontinuation; Internal medicine; Cancer","score_opus":0.10055749853471928,"score_gpt":0.444024621006399,"score_spread":0.3434671224716797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005364954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97051686,0.0009488068,0.000033637032,0.025005408,0.00026682107,0.00018927138,0.0000031370594,0.000010096898,0.003025937],"genre_scores_gemma":[0.98809296,0.0015061641,0.0022528567,0.007428639,0.00030385194,0.000002920539,0.0000017188769,0.00001741226,0.00039350547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739194,0.00021950301,0.0017565584,0.00020203306,0.0002419397,0.00018800341],"domain_scores_gemma":[0.99730027,0.0011486612,0.0009295659,0.00012148178,0.00016503336,0.0003349669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096847565,0.00014677709,0.0016381027,0.00008889394,0.000023631454,0.0000089474825,0.00010867231,0.00023766537,0.000113928014],"category_scores_gemma":[0.0013995264,0.00008848355,0.00025274837,0.00021187954,0.00024794124,0.00009745163,0.000024076899,0.00074838725,0.0000049871937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13079706,0.00079011556,0.5130747,0.000035603007,0.00044282046,0.0013277882,0.00018320954,0.0000045551947,0.0008007348,0.000012698675,0.0013801554,0.35115054],"study_design_scores_gemma":[0.049041014,0.027393114,0.80994385,0.00014118556,0.00018396051,0.0004861279,0.00018195079,0.000046728892,0.00010481173,0.000027255552,0.11232736,0.00012264772],"about_ca_topic_score_codex":0.00004041956,"about_ca_topic_score_gemma":0.00012431892,"teacher_disagreement_score":0.3510279,"about_ca_system_score_codex":0.00011649673,"about_ca_system_score_gemma":0.0006949241,"threshold_uncertainty_score":0.36082548},"labels":[],"label_agreement":null},{"id":"W3005400447","doi":"10.1200/jco.2020.38.4_suppl.tps602","title":"NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"NuCana","keywords":"Tolerability; Medicine; Cisplatin; Gemcitabine; Internal medicine; Adverse effect; Oncology; Cancer; Combination therapy; Gastroenterology; Chemotherapy","score_opus":0.10767614315687102,"score_gpt":0.4268045667374297,"score_spread":0.3191284235805587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005400447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98213094,0.0008358288,0.00016198757,0.015866794,0.00020639434,0.00061473774,0.000023657078,0.00000462453,0.00015503536],"genre_scores_gemma":[0.99563533,0.0009418868,0.002145484,0.00089366233,0.00030174633,0.00003141212,0.000010733705,0.000016175478,0.000023590766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981086,0.00006540178,0.00126034,0.00017763971,0.00023257811,0.0001553856],"domain_scores_gemma":[0.99707216,0.0010364885,0.0011331916,0.00008917417,0.0004952043,0.00017376238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027246465,0.00013944224,0.0013304389,0.00007232829,0.000023996145,0.00000230124,0.000062356536,0.00011947682,0.00002989232],"category_scores_gemma":[0.0004270967,0.00007996455,0.00020027396,0.00015729554,0.00010844024,0.0000906141,0.00001102084,0.00023267805,5.3510365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025399577,0.003993897,0.84658736,0.00008451735,0.0003501697,0.00007973686,0.00064381125,0.00013505587,0.000011205473,0.000007658353,0.0003914984,0.12231551],"study_design_scores_gemma":[0.04593236,0.092232235,0.85179883,0.00015318173,0.00044300174,0.00000753739,0.00011676159,0.00013555896,0.00006919123,0.000030046747,0.009006193,0.0000750773],"about_ca_topic_score_codex":0.000033890185,"about_ca_topic_score_gemma":0.0005147812,"teacher_disagreement_score":0.12224043,"about_ca_system_score_codex":0.00021091376,"about_ca_system_score_gemma":0.00066120864,"threshold_uncertainty_score":0.32608598},"labels":[],"label_agreement":null},{"id":"W3005419411","doi":"10.1200/jco.2020.38.4_suppl.tps777","title":"The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Medicine; Quality of life (healthcare); Palliative care; Pancreatic cancer; Cancer; Anxiety; Internal medicine; Lung cancer; Depression (economics); Confounding; Nursing","score_opus":0.3686937877477233,"score_gpt":0.5944814169326842,"score_spread":0.22578762918496087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005419411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938629,0.001602731,0.0000134759775,0.003404336,0.00012465847,0.0006059867,0.00006285633,0.0000017403352,0.00032130847],"genre_scores_gemma":[0.9975298,0.0016718183,0.00011432812,0.00047270692,0.00018425295,0.000008829469,0.0000013519027,0.000010350283,0.0000065682343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952362,0.0015503269,0.00229736,0.00013245623,0.0006337058,0.00014993586],"domain_scores_gemma":[0.9797231,0.013258302,0.004354071,0.00025580195,0.0022427288,0.00016602602],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016357286,0.00015509865,0.001838946,0.000027024656,0.000052108386,0.0000027485394,0.00031068135,0.000108006585,0.000034556608],"category_scores_gemma":[0.0132840965,0.000053936947,0.000521523,0.00022882028,0.0006127644,0.00004790914,0.00005018487,0.00070108875,5.586123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021694247,0.000908171,0.9459117,0.00004963036,0.0019854782,0.0000043531036,0.021158976,0.00016082311,0.00007116453,0.000060127935,0.00023317925,0.007762141],"study_design_scores_gemma":[0.006210479,0.05692042,0.9168114,0.0003427609,0.00036953128,1.1861646e-7,0.018739818,0.000010681363,0.0002777011,0.00003659255,0.00023129291,0.000049221486],"about_ca_topic_score_codex":0.0004141575,"about_ca_topic_score_gemma":0.00016889819,"teacher_disagreement_score":0.05601225,"about_ca_system_score_codex":0.00010178703,"about_ca_system_score_gemma":0.0016770067,"threshold_uncertainty_score":0.9950274},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W3005445298","doi":"10.1200/jco.2020.38.4_suppl.608","title":"A real-world observational study of somatostatin analogue use and costs in Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pituitary Gland Disorders and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Ipsen","keywords":"Lanreotide; Octreotide; Medicine; Somatostatin; Internal medicine; Acromegaly; Medical prescription; Gastroenterology; Surgery; Growth hormone; Hormone; Pharmacology","score_opus":0.30806296843249137,"score_gpt":0.464432689079286,"score_spread":0.1563697206467946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005445298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932693,0.00006984154,0.000002650731,0.0060913716,0.00010066372,0.00015991248,0.000009783149,0.0000011684339,0.00029531008],"genre_scores_gemma":[0.9969143,0.00019709782,0.000595996,0.0021926046,0.000075819255,0.0000011994247,0.0000053987615,0.000004403444,0.0000131660745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980194,0.00019867932,0.0013656757,0.000098885655,0.00022444958,0.00009289565],"domain_scores_gemma":[0.9973894,0.0014958952,0.0006426314,0.000056278426,0.00015727016,0.0002585559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004024126,0.00006712058,0.0008720167,0.00005723705,0.000010855984,0.0000022569518,0.000046442023,0.00004883256,0.000023466677],"category_scores_gemma":[0.0015960871,0.00004696264,0.000057612673,0.00015083136,0.00003281969,0.00007523633,0.000023532564,0.0002772831,3.951631e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019728078,0.0016160025,0.98645675,0.000009660906,0.0001886207,0.0013395903,0.00017076563,0.00001648095,0.000005296906,0.000040537598,0.0017110391,0.0064724428],"study_design_scores_gemma":[0.012776975,0.0066336836,0.9786905,0.000031654883,0.00012662742,0.000023004686,0.0007054049,0.00019843571,0.0000014246494,0.000047686062,0.0007309373,0.00003367952],"about_ca_topic_score_codex":0.3667295,"about_ca_topic_score_gemma":0.8959122,"teacher_disagreement_score":0.5291827,"about_ca_system_score_codex":0.00013397535,"about_ca_system_score_gemma":0.0033722615,"threshold_uncertainty_score":0.63748753},"labels":[],"label_agreement":null},{"id":"W3005453403","doi":"10.1200/jco.2020.38.5_suppl.54","title":"Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University Health Network; Windsor Regional Hospital; Juravinski Cancer Centre; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Oncology; Immunotherapy; Clinical endpoint; Cancer; Clinical trial","score_opus":0.06196130539225674,"score_gpt":0.3975799223295604,"score_spread":0.33561861693730366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005453403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870119,0.00036875036,0.00004841868,0.010888368,0.0005610877,0.0007155637,0.000025310748,0.0000048064753,0.00037580807],"genre_scores_gemma":[0.9868192,0.0011215576,0.0020992162,0.009291298,0.000335111,0.000033332726,0.0000071066074,0.000035535628,0.00025765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675316,0.00015971379,0.0023168002,0.00020275111,0.00028882961,0.0002787781],"domain_scores_gemma":[0.99665356,0.0010098917,0.001584527,0.000117401425,0.00034603378,0.00028859932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082661136,0.00019270551,0.0016747952,0.00010286656,0.000026237172,0.000006910379,0.00014680155,0.00010151314,0.000121996934],"category_scores_gemma":[0.00023774325,0.00011905832,0.00037459546,0.0002698944,0.00006760351,0.00005972846,0.000014449308,0.00053756277,5.5048235e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035936967,0.0008467917,0.9380506,0.00011853932,0.0008612235,0.00016181017,0.00019500712,0.000021536764,0.0006802252,7.6375255e-7,0.004481487,0.018645022],"study_design_scores_gemma":[0.047799088,0.010049554,0.9234179,0.00019625685,0.0004027516,0.00000580967,0.00013933357,0.000286824,0.0011818289,0.000002858593,0.016359478,0.00015827332],"about_ca_topic_score_codex":0.20313327,"about_ca_topic_score_gemma":0.5841738,"teacher_disagreement_score":0.38104054,"about_ca_system_score_codex":0.0010426712,"about_ca_system_score_gemma":0.008654753,"threshold_uncertainty_score":0.9969652},"labels":[],"label_agreement":null},{"id":"W3005456087","doi":"10.1200/jco.2020.38.4_suppl.620","title":"The benefits of upfront primary tumor resection for metastatic small bowel neuroendocrine tumors: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; University of Manitoba; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Proportional hazards model; Propensity score matching; Hazard ratio; Neuroendocrine tumors; Internal medicine; Univariate analysis; Primary tumor; Cumulative incidence; Cohort; Population; Confounding; Incidence (geometry); Oncology; Surgery; Multivariate analysis; Cancer; Confidence interval; Metastasis","score_opus":0.1472917108569956,"score_gpt":0.45397889967933813,"score_spread":0.3066871888223425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005456087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534953,0.0007001127,0.00093881023,0.043568783,0.0003771484,0.00074279524,0.000021031028,0.000015611859,0.00014036628],"genre_scores_gemma":[0.9858382,0.0001783886,0.008561955,0.004513621,0.0007588534,0.000022456821,0.000015514623,0.00002780088,0.00008326317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99483865,0.0007557249,0.003118343,0.00027526965,0.0006447979,0.0003672084],"domain_scores_gemma":[0.9872798,0.008426378,0.0025912418,0.00026572042,0.00091011985,0.0005267517],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001759795,0.00016593769,0.001876971,0.00024586436,0.00008648423,0.000015109234,0.00032442843,0.000013851444,0.000030349644],"category_scores_gemma":[0.025509318,0.000102716906,0.0010895398,0.00059838145,0.00017478211,0.00010497038,0.00006573781,0.0008760277,0.0000023838106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19803146,0.0070863,0.61190075,0.0018519216,0.0077161794,0.013186053,0.00008437959,0.043556433,0.002128191,0.00094340224,0.012935795,0.10057916],"study_design_scores_gemma":[0.017642029,0.0744919,0.8564552,0.00013034545,0.0040239,0.0011368331,0.00012814278,0.013285642,0.0015464915,0.000611727,0.030350182,0.00019757949],"about_ca_topic_score_codex":0.00003708026,"about_ca_topic_score_gemma":0.0002673266,"teacher_disagreement_score":0.2445545,"about_ca_system_score_codex":0.00010529846,"about_ca_system_score_gemma":0.001241057,"threshold_uncertainty_score":0.9826992},"labels":[],"label_agreement":null},{"id":"W3005460027","doi":"10.1200/jco.19.00018","title":"Palliative Care for Family Caregivers","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Psychological intervention; Palliative care; Caregiver burden; Family caregivers; Dyad; Distress; Randomized controlled trial; Quality of life (healthcare); Family medicine; Nursing; Clinical psychology; Disease; Psychology; Dementia; Internal medicine","score_opus":0.6441068464656459,"score_gpt":0.6453249080484779,"score_spread":0.0012180615828319974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005460027","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003101961,0.9921779,0.00023825774,0.0007160736,0.0021385672,0.000669236,0.00010648463,0.000007914316,0.0039145295],"genre_scores_gemma":[0.000027771885,0.9870595,0.00868578,0.00067622634,0.0033086778,0.000013647402,0.000042129832,0.000043049135,0.0001432336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99460775,0.0005087378,0.0039716796,0.0002868088,0.00038848107,0.00023657273],"domain_scores_gemma":[0.9833895,0.008854969,0.005531713,0.00020221187,0.0015343381,0.00048724597],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010096161,0.00032866892,0.009712848,0.00017166165,0.00002701615,0.000004432937,0.0003389099,0.0011169626,0.00003143456],"category_scores_gemma":[0.011125574,0.00021543434,0.004004363,0.0002055869,0.0002438996,0.000044507433,0.00006731473,0.0015891246,0.000018989289],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007393767,0.00016622442,0.00025962977,0.010713135,0.0019108751,0.00054755254,0.00076488376,2.7467453e-7,1.5622413e-7,0.000056909583,0.013357157,0.9714838],"study_design_scores_gemma":[0.0034094958,0.011545702,0.00008403616,0.02203808,0.0067230617,0.00002724698,0.0019495127,0.0000011003963,8.0525814e-7,0.000035008885,0.9540288,0.00015717],"about_ca_topic_score_codex":0.000009245171,"about_ca_topic_score_gemma":0.000008142063,"teacher_disagreement_score":0.97132665,"about_ca_system_score_codex":0.00041769704,"about_ca_system_score_gemma":0.0073206485,"threshold_uncertainty_score":0.99830693},"labels":[],"label_agreement":null},{"id":"W3005468001","doi":"10.1200/jco.2020.38.4_suppl.694","title":"Effects of early discontinuation of adjuvant chemotherapy (EDAC) and the timing of treatment on outcomes in patients with early-stage pancreatic cancer (ESPC): Result from a population-based retrospective cohort study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Discontinuation; Surgery; Hazard ratio; Retrospective cohort study; Chemotherapy; Cohort; Proportional hazards model; Multivariate analysis; Stage (stratigraphy); Cancer; Internal medicine; Population; Radiation therapy; Confidence interval","score_opus":0.058561408061570897,"score_gpt":0.42825816815999573,"score_spread":0.36969676009842484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005468001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941949,0.000060289574,0.00002459322,0.004080871,0.000048201768,0.0015234551,0.000015884672,0.0000019722304,0.000049808375],"genre_scores_gemma":[0.9987559,0.00009579531,0.00039783368,0.0006074466,0.0000762114,0.000028449902,0.000003696025,0.0000112565385,0.00002345937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678546,0.00081709283,0.0016031935,0.00017957369,0.00048703892,0.00012764594],"domain_scores_gemma":[0.99140537,0.0060691177,0.0019145872,0.0001484238,0.00035857456,0.00010394782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012642309,0.00012982656,0.0025665413,0.0000923236,0.000019472895,0.0000027257042,0.00008713932,0.00015060746,0.000024107396],"category_scores_gemma":[0.0029642489,0.00006466875,0.00016758441,0.00014337334,0.00026471238,0.00004495782,0.000014872852,0.0003895015,2.39828e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03678747,0.0025787537,0.9546614,0.00003257027,0.0011714884,0.000027750104,0.0016125998,0.000018822479,0.000023295483,0.000008030896,0.00000879428,0.003069004],"study_design_scores_gemma":[0.04916406,0.053787258,0.8953483,0.00020669091,0.0009057363,1.8274825e-7,0.000105337014,0.00033421686,0.00007341415,0.000027332222,0.0000037336913,0.000043729273],"about_ca_topic_score_codex":0.0038850915,"about_ca_topic_score_gemma":0.00026400643,"teacher_disagreement_score":0.05931311,"about_ca_system_score_codex":0.00023124296,"about_ca_system_score_gemma":0.0006184017,"threshold_uncertainty_score":0.5873122},"labels":[],"label_agreement":null},{"id":"W3005480494","doi":"10.1200/jco.2020.38.4_suppl.248","title":"The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Alberta Health Services; Cancer Care Ontario; University of Manitoba; Western University","funders":"","keywords":"Oxaliplatin; Medicine; FOLFOX; Capecitabine; Colorectal cancer; Internal medicine; Fluorouracil; Chemotherapy; Oncology; Stage (stratigraphy); Gastroenterology; Cancer; Surgery","score_opus":0.08885598014739642,"score_gpt":0.4579053635237552,"score_spread":0.3690493833763588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005480494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724777,0.00041082426,0.0000020560167,0.026217444,0.0002969371,0.0002174448,0.0000068434515,0.000003860699,0.0003669378],"genre_scores_gemma":[0.991864,0.0039847135,0.00006823777,0.003776167,0.00026268666,0.0000052250166,6.231006e-7,0.0000066256443,0.00003169851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975632,0.00029326027,0.0014368291,0.00018532175,0.0003491406,0.00017223967],"domain_scores_gemma":[0.99624825,0.0014805237,0.0011920269,0.00012697473,0.0007868959,0.00016531274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011656382,0.000118457014,0.0018369346,0.00007760144,0.000039419785,0.0000045780266,0.00013066888,0.00013966452,0.00003095479],"category_scores_gemma":[0.003753256,0.00006422605,0.00046337207,0.00040003075,0.00024356505,0.000039299957,0.00004984497,0.00078574196,0.0000011858111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058623858,0.00097331085,0.92499757,0.000010066999,0.0027481343,0.00023756361,0.0008347253,0.00030040357,0.0003459502,0.000020753949,0.00054762664,0.01036005],"study_design_scores_gemma":[0.010184414,0.015653428,0.97034717,0.000059715596,0.00058863487,0.0000031634743,0.00017322933,0.00032943083,0.000100636506,0.00004133922,0.0024693084,0.000049548013],"about_ca_topic_score_codex":0.00035252873,"about_ca_topic_score_gemma":0.0021409027,"teacher_disagreement_score":0.048439447,"about_ca_system_score_codex":0.00038224662,"about_ca_system_score_gemma":0.0005241408,"threshold_uncertainty_score":0.44932693},"labels":[],"label_agreement":null},{"id":"W3005488680","doi":"10.1200/jco.2020.38.4_suppl.328","title":"Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Cancer; Esophageal cancer; Internal medicine; Stage (stratigraphy); Head and neck cancer; Palliative care; Surgery; Chemotherapy; Gastroenterology","score_opus":0.1331361255282465,"score_gpt":0.4982730451372478,"score_spread":0.3651369196090013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005488680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97797066,0.009522746,0.00007921836,0.011790437,0.00017904006,0.0003491293,0.000037730373,0.000004267544,0.00006674262],"genre_scores_gemma":[0.9891013,0.0092434455,0.00039832032,0.00078294246,0.00036016916,0.000011025317,0.0000039918937,0.000010009795,0.000088813926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786025,0.00022130564,0.0013790177,0.00015806152,0.0002391121,0.000142241],"domain_scores_gemma":[0.9968265,0.0011193462,0.0011931359,0.000115721705,0.00015413779,0.0005911012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003265856,0.00013354314,0.0013810223,0.00006568682,0.00001947826,0.0000040828595,0.000057701527,0.00011433669,0.00009705668],"category_scores_gemma":[0.00087023905,0.000078805184,0.00038507325,0.0000669154,0.00006419146,0.000063799314,0.000020671147,0.00019346982,8.9818053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005063027,0.0012093202,0.7503145,0.00007444666,0.0009999009,0.0003810221,0.00036037204,0.000018379578,0.000018841809,0.00002052027,0.000060255275,0.24147943],"study_design_scores_gemma":[0.0141731305,0.052907478,0.9287297,0.000095660165,0.0011870879,0.000018225364,0.00006643119,0.00008256316,0.0019976909,0.0000642546,0.00062779716,0.00004996091],"about_ca_topic_score_codex":0.00034249568,"about_ca_topic_score_gemma":0.000090874055,"teacher_disagreement_score":0.24142946,"about_ca_system_score_codex":0.00022032471,"about_ca_system_score_gemma":0.0014222751,"threshold_uncertainty_score":0.3213582},"labels":[],"label_agreement":null},{"id":"W3005492312","doi":"10.1200/jco.2020.38.4_suppl.747","title":"Clinical and molecular profiling of locally advanced compared with metastatic pancreatic adenocarcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University Health Network; Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Government of Ontario","keywords":"Medicine; KRAS; Internal medicine; Pancreatic cancer; Oncology; Adenocarcinoma; FOLFIRINOX; Clinical trial; CDKN2A; Cancer; Colorectal cancer; Oxaliplatin","score_opus":0.17672250178082305,"score_gpt":0.4928377332498502,"score_spread":0.31611523146902715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005492312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819051,0.0021090899,0.0061717667,0.0077097886,0.00011729991,0.0005006713,0.0000031086543,0.000009245885,0.0014739301],"genre_scores_gemma":[0.87864244,0.0008278291,0.11753749,0.00269758,0.00024062034,0.0000051169873,0.0000022054971,0.000019625932,0.00002708073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99424845,0.0010976953,0.003526916,0.0002916702,0.0005460866,0.00028916978],"domain_scores_gemma":[0.99182135,0.004379311,0.0018380865,0.000212454,0.0008058972,0.00094288145],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039674635,0.00017681078,0.0037545576,0.000092121685,0.000029819805,0.0000052859796,0.00019708171,0.0002599483,0.000070581686],"category_scores_gemma":[0.008733294,0.00011295776,0.00035995926,0.00022336926,0.0011219705,0.000082969804,0.00008348397,0.0013542735,0.000007705346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020195171,0.0011329975,0.952321,0.0002943331,0.0016813485,0.002596479,0.00013799737,0.000026873093,0.0008138292,0.00027391396,0.00023335408,0.020292705],"study_design_scores_gemma":[0.04573634,0.095219314,0.84155345,0.00056989084,0.0050965426,0.0014065513,0.0011402463,0.006015349,0.0004917276,0.00055652164,0.0019792323,0.00023486628],"about_ca_topic_score_codex":0.0000062344952,"about_ca_topic_score_gemma":0.0000037552418,"teacher_disagreement_score":0.11136572,"about_ca_system_score_codex":0.00003565529,"about_ca_system_score_gemma":0.003195068,"threshold_uncertainty_score":0.99961656},"labels":[],"label_agreement":null},{"id":"W3005704292","doi":"10.1200/jco.19.02767","title":"Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":830,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Hôtel-Dieu de Montréal","funders":"Takeda Oncology; Astellas Pharma; National Cancer Institute; Novocure; NRG Oncology; Regeneron Pharmaceuticals; Celgene; Pfizer","keywords":"Medicine; Memantine; Oncology; Whole brain radiotherapy; Internal medicine; Radiation therapy; Glioblastoma; Radiation oncology; Hippocampal formation; Brain metastasis; Cancer; Dementia; Metastasis; Disease","score_opus":0.10104598824878566,"score_gpt":0.4584996548227837,"score_spread":0.357453666573998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005704292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86638147,0.00060997094,0.0056456868,0.12394081,0.0011683058,0.002022974,0.00011020212,0.000026748667,0.000093863106],"genre_scores_gemma":[0.9187645,0.00020940817,0.044377435,0.029530574,0.0064744093,0.00008686695,0.000114928465,0.000100919875,0.00034100335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935505,0.0012982102,0.0034552698,0.00052086735,0.00061246566,0.0005627089],"domain_scores_gemma":[0.98819643,0.006635158,0.0032057315,0.00030902174,0.0005785396,0.0010751188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004373404,0.00038697338,0.0037241627,0.00015242373,0.00012851757,0.000021548702,0.00028357617,0.0004211579,0.00028559435],"category_scores_gemma":[0.0066400813,0.00025072892,0.0010710151,0.00026531474,0.00032910935,0.00018894389,0.000056618654,0.0011304341,0.000010799552],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8074043,0.014835066,0.0017131082,0.00013581284,0.003584004,0.0019333145,0.00047163104,0.000085537715,0.00034363355,0.0001014522,0.036916893,0.13247524],"study_design_scores_gemma":[0.5137206,0.16034986,0.0015845922,0.000072601135,0.0010118758,0.00016241783,0.00013855548,0.00020574006,0.000069426314,0.000043720618,0.32246637,0.00017425601],"about_ca_topic_score_codex":0.000008427345,"about_ca_topic_score_gemma":0.00001796464,"teacher_disagreement_score":0.29368374,"about_ca_system_score_codex":0.00041384524,"about_ca_system_score_gemma":0.0025822278,"threshold_uncertainty_score":0.9999945},"labels":[],"label_agreement":null},{"id":"W3006536995","doi":"10.1200/jco.2013.31.15_suppl.1002","title":"The effect of surgery type on survival and recurrence in very young women with breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; University of Toronto; University Health Network; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; Foothills Medical Centre","funders":"","keywords":"Medicine; Mastectomy; Breast cancer; Proportional hazards model; Radiation therapy; Cancer registry; Population; Breast-conserving surgery; Surgery; Cohort; Cancer; Retrospective cohort study; Oncology; Internal medicine","score_opus":0.03742716940639402,"score_gpt":0.3821375655522352,"score_spread":0.3447103961458412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006536995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965656,0.0009395831,0.0000011247017,0.0014767599,0.00070955977,0.00007641695,0.000004053831,7.500224e-7,0.00022614792],"genre_scores_gemma":[0.9957199,0.0038515755,0.000017236976,0.00007499027,0.00029596806,0.0000139474,6.096726e-7,0.000006419511,0.00001937003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859947,0.00040557957,0.0005896047,0.00012245629,0.00011934127,0.00016352939],"domain_scores_gemma":[0.9973058,0.001767087,0.0005658723,0.00010869582,0.00017412304,0.00007840028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015118603,0.00009516673,0.00058081734,0.000026454116,0.000029709086,0.000005698587,0.00009668629,0.00011934538,0.000009308658],"category_scores_gemma":[0.0007223187,0.000048045495,0.0000666964,0.000070921116,0.00025755147,0.000005773043,0.00004431092,0.00021080652,0.0000011810636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009473516,0.000106070576,0.85393566,0.00001096195,0.00022880158,0.000011881724,0.000021060123,0.000008685348,0.00018962227,0.0000033712777,0.00078639516,0.13522394],"study_design_scores_gemma":[0.0015931567,0.0068594175,0.9898728,0.00005844162,0.000028912506,0.000061718834,0.00006816116,0.0000016671788,0.00023184264,0.000018330802,0.0011522601,0.000053305113],"about_ca_topic_score_codex":0.00012217504,"about_ca_topic_score_gemma":0.00024316472,"teacher_disagreement_score":0.1359371,"about_ca_system_score_codex":0.000047958172,"about_ca_system_score_gemma":0.0003468765,"threshold_uncertainty_score":0.19592384},"labels":[],"label_agreement":null},{"id":"W3006685470","doi":"10.1200/jco.2020.38.6_suppl.396","title":"WATChmAN: A randomized trial of virtual surveillance versus standard in-person care for clinical stage I testicular cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Incidence (geometry); Stage (stratigraphy); Patient satisfaction; Internal medicine; Surgery","score_opus":0.6663572902429717,"score_gpt":0.6766849732796522,"score_spread":0.010327683036680413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006685470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93079734,0.0020332392,0.0011265606,0.055144336,0.0064087976,0.0028166254,0.00010920228,0.000016597449,0.0015473296],"genre_scores_gemma":[0.9743876,0.01176183,0.0063505424,0.0023371181,0.004914525,0.000047197344,0.0000072478165,0.000042163334,0.00015179066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9855632,0.0036264658,0.008126825,0.00053098035,0.0016819183,0.00047056627],"domain_scores_gemma":[0.682031,0.3073371,0.0046042614,0.00046867772,0.0043087043,0.0012502839],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.051633805,0.0002316391,0.006748322,0.00011719242,0.00004188594,0.000012294044,0.00053320825,0.0014860758,0.00017315031],"category_scores_gemma":[0.5312027,0.0001634428,0.0023872603,0.00030361844,0.0014876438,0.00007874525,0.00013023692,0.0055723335,0.0000049020286],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9477393,0.0010478466,0.011382163,0.0003172758,0.00074223883,0.00037693031,0.00038156798,0.00006656643,0.000014992587,0.0007003378,0.0011474453,0.036083333],"study_design_scores_gemma":[0.85047704,0.12326453,0.0019487415,0.0002761491,0.00041073933,0.00000428515,0.0010663497,0.00044078132,0.000032662876,0.00028856331,0.021657242,0.0001328923],"about_ca_topic_score_codex":0.000056061253,"about_ca_topic_score_gemma":0.0004975503,"teacher_disagreement_score":0.47956887,"about_ca_system_score_codex":0.00029984216,"about_ca_system_score_gemma":0.011213885,"threshold_uncertainty_score":0.9998102},"labels":[],"label_agreement":null},{"id":"W3006735780","doi":"10.1200/jco.2020.38.6_suppl.131","title":"Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Mount Sinai Hospital; University of Calgary; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Meta-analysis; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Placebo; Randomized controlled trial; Adverse effect; Androgen receptor; Cancer","score_opus":0.3348648572000627,"score_gpt":0.5011682202617322,"score_spread":0.16630336306166954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006735780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81381977,0.025344377,0.00029315136,0.15725827,0.00088471745,0.0013759197,0.00011599186,0.000019983134,0.0008878044],"genre_scores_gemma":[0.98195684,0.0029338556,0.009117271,0.00409188,0.0013735788,0.000043671957,0.000020868205,0.000024294583,0.00043774932],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99570215,0.00045182573,0.002671958,0.00027796254,0.00054669636,0.00034943662],"domain_scores_gemma":[0.99640965,0.0010577213,0.0013660686,0.00013795144,0.0003989632,0.00062961975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029617108,0.00017387824,0.0031981368,0.00016888001,0.00003967648,0.000017402159,0.00013954156,0.00019206821,0.00062814576],"category_scores_gemma":[0.0010690306,0.00010583849,0.0015822358,0.0010247462,0.00016502521,0.00012163336,0.000044940916,0.000954099,0.0000138571695],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06315911,0.006824734,0.31084728,0.0003500221,0.49170113,0.0055929683,0.0025881648,0.015286802,0.006760476,0.00016708537,0.04458469,0.05213753],"study_design_scores_gemma":[0.060141385,0.051363785,0.14238891,0.00016146577,0.4696378,0.00018539143,0.0012090199,0.0032260395,0.0014594976,0.00044099867,0.2689812,0.00080452184],"about_ca_topic_score_codex":0.00010930526,"about_ca_topic_score_gemma":0.00044743516,"teacher_disagreement_score":0.22439648,"about_ca_system_score_codex":0.0002041806,"about_ca_system_score_gemma":0.0026464493,"threshold_uncertainty_score":0.68777555},"labels":[],"label_agreement":null},{"id":"W3006740553","doi":"10.1200/jco.2020.38.6_suppl.148","title":"Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Hôtel-Dieu de Québec; Université Laval","funders":"","keywords":"Castration; Testosterone (patch); Prostate cancer; Androstenedione; Dihydrotestosterone; Androgen receptor; Internal medicine; Medicine; Endocrinology; Androgen; Androstenediol; Dehydroepiandrosterone; Androsterone; Steroid; Cancer; Hormone","score_opus":0.10143218653899995,"score_gpt":0.43400993380110564,"score_spread":0.3325777472621057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006740553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.909668,0.0027088763,0.00007000958,0.086501524,0.00023389982,0.0007536412,0.000012388927,0.0000016233412,0.000050003942],"genre_scores_gemma":[0.9944673,0.0017682563,0.0005423115,0.0027979813,0.00027021416,0.000049094328,0.000002551402,0.0000057099824,0.000096538235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982494,0.00032349126,0.0007996317,0.00014312113,0.00031568133,0.00016866204],"domain_scores_gemma":[0.99857914,0.00045992516,0.00033526676,0.00008284377,0.00029409784,0.00024872998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017285241,0.00008593911,0.00051368255,0.000036858386,0.00003865317,0.000008764134,0.000097938966,0.00007776151,0.000024171231],"category_scores_gemma":[0.000528785,0.00004134969,0.000075138625,0.00016960647,0.00008375317,0.000055824952,0.000042278985,0.00043550832,0.000002444408],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10425115,0.00067342597,0.07638752,0.000063763204,0.0003555472,0.00014901029,0.004624017,0.000032884527,0.0040298267,0.000009929198,0.006813409,0.8026095],"study_design_scores_gemma":[0.005770936,0.00676458,0.65760976,0.00012833554,0.000032753745,0.0000108149425,0.00012405125,0.0000106829975,0.0030443452,0.000009928987,0.3264333,0.000060519716],"about_ca_topic_score_codex":0.000016844802,"about_ca_topic_score_gemma":0.0008832684,"teacher_disagreement_score":0.802549,"about_ca_system_score_codex":0.00036464745,"about_ca_system_score_gemma":0.0023632138,"threshold_uncertainty_score":0.419224},"labels":[],"label_agreement":null},{"id":"W3006752870","doi":"10.1200/jco.2020.38.6_suppl.tps385","title":"DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Prostate cancer; Placebo; Androgen deprivation therapy; Internal medicine; Hazard ratio; Oncology; Docetaxel; Hormonal therapy; Antiandrogen; Randomized controlled trial; Urology; Cancer; Adverse effect; Confidence interval; Pathology","score_opus":0.10058820587345277,"score_gpt":0.4669067357666523,"score_spread":0.3663185298931996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006752870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746821,0.0021715856,0.0003908982,0.0060040676,0.0005700929,0.015590117,0.0005605085,0.000010617043,0.00001999599],"genre_scores_gemma":[0.9365541,0.060810566,0.00045189826,0.0006387928,0.0004882184,0.0009534705,0.00002835408,0.000051359242,0.00002326546],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888693,0.0038282485,0.0053853346,0.0004919251,0.0009500897,0.00047510825],"domain_scores_gemma":[0.97374326,0.017564457,0.0068120398,0.0003692411,0.0011306842,0.00038029757],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01302076,0.00041837402,0.005244651,0.00027488024,0.00014290816,0.000026653424,0.00038110605,0.00046449347,0.00007405411],"category_scores_gemma":[0.010446804,0.000189777,0.0013891741,0.0006398146,0.00090305076,0.00017837597,0.00008156276,0.0013220093,3.721186e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83740616,0.0019114874,0.016143832,0.000055851364,0.0040095877,0.000022449585,0.0014925497,0.0019376762,0.0006332644,0.00002901687,0.00020860837,0.13614954],"study_design_scores_gemma":[0.9152487,0.07158313,0.0054842415,0.00038556007,0.0010980654,0.0000035966254,0.0001806076,0.0017138926,0.0034504852,0.00038932828,0.00029431022,0.00016810994],"about_ca_topic_score_codex":0.0016016498,"about_ca_topic_score_gemma":0.00021803923,"teacher_disagreement_score":0.13598143,"about_ca_system_score_codex":0.00047442762,"about_ca_system_score_gemma":0.0067300396,"threshold_uncertainty_score":0.9989009},"labels":[],"label_agreement":null},{"id":"W3006769654","doi":"10.1200/jco.2020.38.6_suppl.88","title":"Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Enzalutamide; Prednisone; Prostate cancer; Docetaxel; Univariate analysis; Internal medicine; Abiraterone acetate; Logistic regression; Dexamethasone; Oncology; Cancer; Performance status; Multivariate analysis; Androgen deprivation therapy","score_opus":0.19842376105489842,"score_gpt":0.4787457829162528,"score_spread":0.28032202186135435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006769654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252176,0.0002358974,0.00029964725,0.005626531,0.000093145485,0.001075424,0.000112319096,0.0000050458607,0.000030209938],"genre_scores_gemma":[0.9383853,0.000068161055,0.06075243,0.0006172747,0.000059769118,0.0000607729,0.0000068729014,0.000022007804,0.000027376542],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954845,0.00043576423,0.0026929441,0.00033179723,0.0007343372,0.0003206956],"domain_scores_gemma":[0.9962651,0.0009330411,0.0011363325,0.00014134485,0.00081455306,0.00070961274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018888318,0.00019039074,0.0015694315,0.00022625709,0.000021974462,0.000007176011,0.00018574606,0.00015565209,0.000018872113],"category_scores_gemma":[0.0029482457,0.00013030967,0.00016122528,0.00040359396,0.0001341081,0.00006785943,0.00010431682,0.00056744,0.0000030455851],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51271766,0.0059524197,0.050081022,0.00022599593,0.00096546207,0.00030944336,0.012348309,0.001794902,0.35295346,0.0000014875112,0.000268513,0.062381335],"study_design_scores_gemma":[0.05599521,0.1173949,0.48357162,0.00467296,0.00074951554,0.000006019136,0.0015823619,0.004559028,0.33003244,0.00012305503,0.00089308445,0.00041979927],"about_ca_topic_score_codex":0.000041683415,"about_ca_topic_score_gemma":0.000060746308,"teacher_disagreement_score":0.45672244,"about_ca_system_score_codex":0.000501161,"about_ca_system_score_gemma":0.00547838,"threshold_uncertainty_score":0.97184104},"labels":[],"label_agreement":null},{"id":"W3006784906","doi":"10.1200/jco.2020.38.6_suppl.134","title":"PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Taxane; Medicine; Enzalutamide; Hazard ratio; Oncology; Internal medicine; Cohort; Prostate cancer; Population; Olaparib; Cancer; Confidence interval; Breast cancer; Gene; Androgen receptor; Genetics; Biology","score_opus":0.10803314538210798,"score_gpt":0.425071431637462,"score_spread":0.317038286255354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006784906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154043,0.0003746807,0.00012907624,0.0067558065,0.00026975325,0.0008351089,0.00004637457,0.0000129614855,0.00003579287],"genre_scores_gemma":[0.98812646,0.00063052314,0.009097455,0.0018390272,0.00015108605,0.000033092838,0.000029401313,0.000021541438,0.0000714431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961838,0.00055517274,0.0023821085,0.0002737393,0.00041591082,0.00018924706],"domain_scores_gemma":[0.9953553,0.0011419628,0.0022849634,0.0001415136,0.0007977452,0.00027848972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012649555,0.00015895844,0.0011255231,0.00012416116,0.000046927173,0.0000164362,0.00007576833,0.0001516793,0.00006189239],"category_scores_gemma":[0.002155742,0.000119031116,0.000141223,0.00026109396,0.00023543822,0.00029933386,0.000019379255,0.00063987833,0.0000014434028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0812556,0.011000472,0.78335077,0.0004394148,0.0016231196,0.0006821241,0.0026452441,0.0006091672,0.01391297,0.00013653561,0.011187438,0.09315713],"study_design_scores_gemma":[0.07568185,0.05094979,0.8603689,0.00047708803,0.0007076623,0.00013311904,0.0001792931,0.0005063517,0.0032391169,0.00012212023,0.007363328,0.0002713449],"about_ca_topic_score_codex":0.00008095853,"about_ca_topic_score_gemma":0.00016815524,"teacher_disagreement_score":0.09288578,"about_ca_system_score_codex":0.0002660907,"about_ca_system_score_gemma":0.0014346201,"threshold_uncertainty_score":0.4853948},"labels":[],"label_agreement":null},{"id":"W3006786257","doi":"10.1200/jco.2020.38.6_suppl.540","title":"Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Internal medicine; Oncology; Chemotherapy; Histology; Proportional hazards model; Stage (stratigraphy); Demographics; Cisplatin; Neoadjuvant therapy; Carcinoma; Urology; Cancer; Gastroenterology","score_opus":0.0835691232584176,"score_gpt":0.42929613441903136,"score_spread":0.3457270111606138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006786257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939038,0.00035939162,0.000013395449,0.004751657,0.00021420025,0.00018310867,0.000025854428,0.0000033114236,0.00054528104],"genre_scores_gemma":[0.9952593,0.00082419656,0.00044671146,0.003232327,0.00017947555,0.000002355848,0.0000013675335,0.000016543718,0.000037720463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816513,0.0001386333,0.0011643138,0.0001442787,0.00024564416,0.00014200476],"domain_scores_gemma":[0.99687827,0.0010066293,0.0014004754,0.00010139197,0.00037329254,0.00023996009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024257341,0.00013969507,0.0016155015,0.000068000496,0.000015224154,0.0000016978992,0.00008046626,0.00017541612,0.00029079427],"category_scores_gemma":[0.00087314454,0.00007828023,0.00030183184,0.00007608337,0.00026570886,0.000056849727,0.00002097335,0.00035633723,8.043031e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008509881,0.0011328176,0.9268531,0.000037150363,0.0014442151,0.000040348277,0.00075715897,0.0000149135885,0.0001435677,0.00000632486,0.00081397645,0.060246512],"study_design_scores_gemma":[0.013498597,0.046524346,0.9384671,0.00008810609,0.0004146114,0.000008161448,0.00009444801,0.000003933216,0.0002257778,0.000041106003,0.000572866,0.00006096898],"about_ca_topic_score_codex":0.00013084277,"about_ca_topic_score_gemma":0.000055446602,"teacher_disagreement_score":0.06018554,"about_ca_system_score_codex":0.00011064246,"about_ca_system_score_gemma":0.0012562457,"threshold_uncertainty_score":0.31921753},"labels":[],"label_agreement":null},{"id":"W3006826879","doi":"10.1200/jco.2020.38.6_suppl.117","title":"Analysis of prevalence and prognostic implications of early versus delayed PSA declines during radium-223 (Ra223) treatment among men with metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network; Regional Municipality of Durham; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Prostate-specific antigen; Urology; Internal medicine; Cancer; Log-rank test; Overall survival; Oncology","score_opus":0.14763067976685162,"score_gpt":0.4712615864519624,"score_spread":0.3236309066851108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006826879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200696,0.0019917174,0.000029994875,0.0050897747,0.000040822008,0.0006472406,0.00008683122,0.000005487122,0.00010116203],"genre_scores_gemma":[0.9927162,0.0059416364,0.0009959349,0.00003543986,0.00009275085,0.000046592824,0.000010256339,0.0000125572205,0.00014866689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997375,0.00023213905,0.0016141152,0.00023584784,0.00034038493,0.0002025061],"domain_scores_gemma":[0.9955849,0.0016348021,0.0015295515,0.00015387034,0.0007015794,0.00039527632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052617275,0.00015146217,0.0013662771,0.00018517717,0.000048484064,0.00000905777,0.000100233716,0.00008519615,0.00005065296],"category_scores_gemma":[0.0006806607,0.000090156725,0.00028198995,0.0005745974,0.00039872067,0.00012139412,0.000026578782,0.00024368208,4.1544195e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0469803,0.0011721491,0.92847854,0.00023480212,0.011993584,0.00020273037,0.00083581905,0.00038017682,0.0017649101,0.000013320901,0.000026707352,0.007916954],"study_design_scores_gemma":[0.016414292,0.03323609,0.93583685,0.00011160262,0.012783999,0.0000115489665,0.00020044786,0.00051751384,0.00072929874,0.000011099765,0.000072308554,0.000074919335],"about_ca_topic_score_codex":0.00029942105,"about_ca_topic_score_gemma":0.00061635167,"teacher_disagreement_score":0.03206394,"about_ca_system_score_codex":0.0001593498,"about_ca_system_score_gemma":0.0015388244,"threshold_uncertainty_score":0.36764845},"labels":[],"label_agreement":null},{"id":"W3006846003","doi":"10.1200/jco.2020.38.6_suppl.639","title":"Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Hospital; Princess Margaret Cancer Centre; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Cabozantinib; Renal cell carcinoma; Internal medicine; Urology; Surgery","score_opus":0.20021283912474325,"score_gpt":0.4400189675659714,"score_spread":0.23980612844122817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006846003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8834663,0.0009519009,0.00046167834,0.1112262,0.00085081893,0.0015289983,0.00042736813,0.0000062565923,0.0010804634],"genre_scores_gemma":[0.9881223,0.0012569238,0.0034313207,0.005192361,0.0017357303,0.00006359385,0.000106411746,0.00002647576,0.00006491995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99445933,0.0011656936,0.003013463,0.0003990921,0.00066697464,0.00029546538],"domain_scores_gemma":[0.95016366,0.046188682,0.002519152,0.000524915,0.00044006004,0.00016354748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004612686,0.00028706648,0.0015752935,0.00006305613,0.00010686087,0.00002287982,0.00064152485,0.00012760914,0.000049317172],"category_scores_gemma":[0.0038725636,0.00012134385,0.0008568379,0.00026918948,0.00037803434,0.00010709961,0.00008586472,0.00071586354,0.0000069393154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3431828,0.02971469,0.41899127,0.0006492833,0.009809197,0.013276266,0.026309714,0.003007962,0.004839217,0.0011228479,0.082746536,0.06635024],"study_design_scores_gemma":[0.06964199,0.038522303,0.56556,0.00032147003,0.0046477006,0.00024883798,0.0023188998,0.002763446,0.010344137,0.0003109025,0.30507666,0.00024365804],"about_ca_topic_score_codex":0.0012176605,"about_ca_topic_score_gemma":0.0013000162,"teacher_disagreement_score":0.2735408,"about_ca_system_score_codex":0.00024904276,"about_ca_system_score_gemma":0.0010324792,"threshold_uncertainty_score":0.49482587},"labels":[],"label_agreement":null},{"id":"W3006849529","doi":"10.1200/jco.2020.38.6_suppl.402","title":"Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Number needed to harm; Number needed to treat; Chemotherapy; Internal medicine; Surgery; Incidence (geometry); Hazard ratio; Coagulopathy; Complication; Confidence interval; Relative risk","score_opus":0.05024324878098614,"score_gpt":0.3631637280205464,"score_spread":0.3129204792395603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006849529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922705,0.000047303325,0.000049986025,0.0069039073,0.00009959848,0.0003652956,0.0000018330717,0.000004754272,0.00025677326],"genre_scores_gemma":[0.99609745,0.0001887139,0.001508431,0.0019193614,0.00024548132,0.0000020052835,0.0000020574864,0.000017267306,0.000019245877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980603,0.000061929364,0.0012749942,0.00014951354,0.00032554936,0.0001277168],"domain_scores_gemma":[0.9975438,0.00029510827,0.0015908728,0.0000995771,0.00024801155,0.00022262431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046989296,0.000114678085,0.0013064046,0.00007108143,0.00002944643,0.0000053705194,0.00006396847,0.00007229277,0.00005270514],"category_scores_gemma":[0.00043990443,0.000071537,0.00014196403,0.000097757016,0.00008189261,0.00007127164,0.00002569314,0.0002786887,0.0000021330995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011658264,0.011775366,0.8823335,0.001399829,0.00081260724,0.00031500802,0.0010042988,0.00070440874,0.0001664732,0.00017196151,0.00024187184,0.08941637],"study_design_scores_gemma":[0.011677172,0.03969586,0.9465848,0.00014786486,0.00047186197,0.000009532589,0.000037778544,0.00017482451,0.0003685903,0.00010284241,0.00066809094,0.000060758124],"about_ca_topic_score_codex":0.0000057210896,"about_ca_topic_score_gemma":0.000011195224,"teacher_disagreement_score":0.08935561,"about_ca_system_score_codex":0.00003906051,"about_ca_system_score_gemma":0.00013511711,"threshold_uncertainty_score":0.2917194},"labels":[],"label_agreement":null},{"id":"W3006851401","doi":"10.1200/jco.2020.38.6_suppl.343","title":"Predicting biochemical recurrence after prostatectomy: Can machine learning beat CAPRA score? Results of a multicentric retrospective analysis on 4,700 patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Logistic regression; Random forest; Artificial intelligence; Medicine; Receiver operating characteristic; Capra; Classifier (UML); Population; Pairwise comparison; Machine learning; Regression; Artificial neural network; Statistics; Internal medicine; Computer science; Mathematics; Biology","score_opus":0.05525800218745763,"score_gpt":0.3856537087608953,"score_spread":0.33039570657343764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006851401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216884,0.00061689643,0.00001773426,0.0061706663,0.00028217782,0.0003950859,0.00014072243,0.000012253125,0.00019560782],"genre_scores_gemma":[0.99670255,0.0011572483,0.00065356086,0.0010092935,0.00038685912,0.000013595534,0.000045316803,0.000016480848,0.000015096531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959566,0.00037570868,0.002449511,0.00039773967,0.00054813904,0.00027228895],"domain_scores_gemma":[0.9945184,0.0013737291,0.0025256558,0.00016715194,0.0008549423,0.0005601455],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011164634,0.00019847871,0.0018139338,0.00021001301,0.000036655496,0.000008446982,0.000121506666,0.00023322793,0.0000469513],"category_scores_gemma":[0.012664592,0.0001366061,0.0006662945,0.0007585009,0.00017217887,0.00006080781,0.00007174795,0.0013573406,0.000003573476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017687898,0.0021759653,0.9643995,0.000052773714,0.0015750527,0.0003456295,0.0006697779,0.00011909601,0.00003595059,0.00000191213,0.00032979166,0.012606609],"study_design_scores_gemma":[0.01671978,0.03610602,0.93928516,0.00031183392,0.0028384714,0.000008721658,0.00006542056,0.0014922896,0.0015698383,0.000010284054,0.0014736768,0.00011847962],"about_ca_topic_score_codex":0.00008641541,"about_ca_topic_score_gemma":0.00003511386,"teacher_disagreement_score":0.033930056,"about_ca_system_score_codex":0.00045777214,"about_ca_system_score_gemma":0.000617738,"threshold_uncertainty_score":0.99565214},"labels":[],"label_agreement":null},{"id":"W3006870363","doi":"10.1200/jco.2020.38.6_suppl.73","title":"The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; McMaster University; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Montreal Cognitive Assessment; Abiraterone; Cognition; Prostate cancer; Cohort; Oncology; Docetaxel; Abiraterone acetate; Cognitive decline; Internal medicine; Cancer; Androgen deprivation therapy; Cognitive impairment; Disease; Psychiatry; Androgen receptor; Dementia","score_opus":0.053574925818033865,"score_gpt":0.4108163113732621,"score_spread":0.3572413855552282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006870363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986141,0.0024438524,0.000030882828,0.009154086,0.00025796395,0.0009580209,0.000017479451,0.0000067104384,0.0009899641],"genre_scores_gemma":[0.9957826,0.002432478,0.000039454175,0.0013205721,0.00025060767,0.00004234437,0.000001503996,0.00002071072,0.000109724264],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966957,0.00084627396,0.0015628077,0.00023845858,0.00039829322,0.00025849388],"domain_scores_gemma":[0.9930124,0.0048076855,0.0014582678,0.000070904905,0.00040867456,0.00024203063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021372724,0.00020911162,0.0015238174,0.0000884502,0.0000658702,0.000011656718,0.00006353358,0.00011547551,0.00003644498],"category_scores_gemma":[0.002164925,0.000106233114,0.00015663025,0.0002494083,0.00053042604,0.00009789899,0.000033901724,0.0009921066,0.0000037064801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49333325,0.0016435977,0.26447034,0.00077365676,0.006846126,0.0018908463,0.0017166776,0.0001970383,0.0016652112,0.00003221667,0.0041389912,0.22329205],"study_design_scores_gemma":[0.06054054,0.15970382,0.76932216,0.0014691894,0.0034481743,0.0001203893,0.0014930376,0.00016799972,0.0016178476,0.000048237624,0.0019011094,0.00016749615],"about_ca_topic_score_codex":0.0000683896,"about_ca_topic_score_gemma":0.0002355123,"teacher_disagreement_score":0.5048518,"about_ca_system_score_codex":0.00013254829,"about_ca_system_score_gemma":0.00064607157,"threshold_uncertainty_score":0.43320608},"labels":[],"label_agreement":null},{"id":"W3006882092","doi":"10.1200/jco.2020.38.6_suppl.692","title":"A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Renal cell carcinoma; Discontinuation; Internal medicine; Adverse effect; Oncology; Clinical trial","score_opus":0.09318190898553695,"score_gpt":0.3794151476500321,"score_spread":0.2862332386644951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006882092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088985,0.0032914828,0.000009390156,0.0028265798,0.0012593834,0.0009469646,0.000029728533,0.000010646378,0.00073595205],"genre_scores_gemma":[0.9960632,0.0010718448,0.0016353016,0.00015495573,0.00096087134,0.000015704865,0.00002011067,0.00004860863,0.000029405966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99180037,0.0011328259,0.0052702064,0.0004226998,0.00094473624,0.00042913586],"domain_scores_gemma":[0.9919415,0.0027530522,0.0038147266,0.00044403793,0.0005306325,0.0005160444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001281443,0.0004410938,0.0034670176,0.00022621333,0.000046925285,0.00000917535,0.00037135067,0.00046601205,0.00012942018],"category_scores_gemma":[0.0013528554,0.00027693296,0.0018314294,0.00044863144,0.00039299254,0.00010901112,0.00007574534,0.0010383816,0.00001701162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15013205,0.04475233,0.1727562,0.0006522136,0.0010424801,0.0014779331,0.010552445,0.00030028,0.5973911,0.00003743814,0.0011983671,0.019707121],"study_design_scores_gemma":[0.06673408,0.18771322,0.09163335,0.00013638366,0.0009863133,0.000017097169,0.002033139,0.00008910525,0.6432959,0.000012688892,0.0071213897,0.00022736397],"about_ca_topic_score_codex":0.00013301056,"about_ca_topic_score_gemma":0.000019834988,"teacher_disagreement_score":0.14296089,"about_ca_system_score_codex":0.00057215965,"about_ca_system_score_gemma":0.0010870903,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W3006953361","doi":"10.1200/jco.2020.38.6_suppl.294","title":"Deep learning-based approach for automated assessment of PTEN status.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"PTEN; Prostate cancer; Medicine; Artificial intelligence; Biomarker; Machine learning; Cancer; Computer science; Internal medicine; Biology","score_opus":0.09316328120341431,"score_gpt":0.4797399913955277,"score_spread":0.38657671019211337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006953361","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032866996,0.0005201966,0.9628106,0.0016819593,0.00031367826,0.0003943219,0.0000107447095,0.000017832608,0.0013837072],"genre_scores_gemma":[0.9276536,0.000263984,0.0702845,0.0011490776,0.0005162162,0.0000125483575,0.000052994477,0.000029813878,0.000037235422],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9971354,0.0005767755,0.0014119347,0.00025761858,0.00032883167,0.00028942784],"domain_scores_gemma":[0.9971818,0.00031114527,0.0012652559,0.0001556137,0.0007037401,0.00038247928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019883758,0.00012564941,0.0007673865,0.000060682763,0.00003474605,0.00000867049,0.00030575317,0.0005084529,0.00003443498],"category_scores_gemma":[0.003928925,0.000106545274,0.00053201435,0.00012805933,0.00013657271,0.0000040835184,0.00009420285,0.00055470207,0.0000010394953],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010251807,0.0027140982,0.003026683,0.00032251736,0.0018003316,0.00008155971,0.00007975103,0.42815995,0.44448492,0.00021377984,0.011702743,0.097161844],"study_design_scores_gemma":[0.01107882,0.035725154,0.002824673,0.000019663352,0.00021466207,0.000021814267,0.0001380495,0.754192,0.02879863,0.000032791828,0.16673028,0.00022348516],"about_ca_topic_score_codex":0.0000039592805,"about_ca_topic_score_gemma":0.0000034403429,"teacher_disagreement_score":0.89478666,"about_ca_system_score_codex":0.000052490264,"about_ca_system_score_gemma":0.0022526446,"threshold_uncertainty_score":0.47035742},"labels":[],"label_agreement":null},{"id":"W3006963499","doi":"10.1200/jco.2020.38.6_suppl.277","title":"Analysis of small non-coding RNAs in urinary exosomes to classify prostate cancer into low-grade (GG1) and higher-grade (GG2-5).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Internal medicine; Biopsy; Urinary system; Prospective cohort study","score_opus":0.08559994488038075,"score_gpt":0.4374503455875046,"score_spread":0.35185040070712387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006963499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98154074,0.001967759,0.0028422398,0.012811855,0.00037916045,0.00026964082,0.000013309623,0.000003435342,0.0001718555],"genre_scores_gemma":[0.9907134,0.0044166828,0.002134168,0.002101422,0.00048178915,0.000015230258,0.000008117167,0.000026008076,0.000103143815],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968125,0.00042205592,0.0016852618,0.00042572143,0.0003143357,0.00034008225],"domain_scores_gemma":[0.9978757,0.0002497896,0.0008451474,0.00021860369,0.00027306622,0.0005376964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001330632,0.0001875124,0.0012372172,0.000320697,0.000032047563,0.000015507387,0.00037601113,0.0005168062,0.00004367439],"category_scores_gemma":[0.00097433565,0.00016477462,0.00044895426,0.0007128191,0.00016994089,0.00000974835,0.00032484697,0.00081053015,0.000001756561],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061989073,0.0012626455,0.028900899,0.00018808855,0.003329761,0.0007861256,0.0006774017,0.0046678856,0.8768519,0.000072072115,0.0015957374,0.07546856],"study_design_scores_gemma":[0.019774837,0.048276555,0.44618642,0.00047878016,0.0028051306,0.00010852271,0.00078245025,0.0067022284,0.31452146,0.00043566013,0.15869248,0.0012354697],"about_ca_topic_score_codex":0.00012035596,"about_ca_topic_score_gemma":0.00045424962,"teacher_disagreement_score":0.5623304,"about_ca_system_score_codex":0.00009673758,"about_ca_system_score_gemma":0.00094111956,"threshold_uncertainty_score":0.6719314},"labels":[],"label_agreement":null},{"id":"W3007014868","doi":"10.1200/jco.2020.38.6_suppl.414","title":"Expression of circulating miR375 and miR371 to differentiate teratoma and viable germ cell tumor in patients with post-chemotherapy residual disease.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Seminoma; Medicine; Chemotherapy; Teratoma; Germ cell tumors; Germ cell; Pathology; Minimal residual disease; Stage (stratigraphy); Oncology; Internal medicine; Gastroenterology; Biology","score_opus":0.03383408746438837,"score_gpt":0.3595232536693951,"score_spread":0.3256891662050067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007014868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973199,0.00041173183,0.00001619162,0.0019183169,0.000045138935,0.0002561286,0.0000110297005,0.0000035661667,0.000018025457],"genre_scores_gemma":[0.996373,0.000029915034,0.0017996412,0.0016850071,0.000087291584,0.0000019205897,0.000004178432,0.000013649565,0.0000053791746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984708,0.00013247709,0.00086169445,0.00017668921,0.00022928367,0.00012908745],"domain_scores_gemma":[0.99795765,0.00043890844,0.0007089497,0.000084600564,0.00016580627,0.0006440973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017964318,0.000110859495,0.0007442704,0.00005719202,0.000019051196,0.0000075324574,0.000043957174,0.00006436396,0.000022687942],"category_scores_gemma":[0.0009119312,0.00006938805,0.000085711916,0.00006852029,0.000057947665,0.00005919649,0.000041285475,0.00020107816,6.821351e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009651153,0.0016935209,0.9813255,0.00011198904,0.000063113825,0.00041566542,0.00012693094,0.000004266491,0.0007286337,0.0000013390413,0.00005176136,0.0058260914],"study_design_scores_gemma":[0.014761155,0.010197593,0.974023,0.00031058837,0.000218672,0.000010359903,0.000038989197,0.000044108107,0.00021923405,0.000023668821,0.00008914231,0.000063517946],"about_ca_topic_score_codex":0.000007195114,"about_ca_topic_score_gemma":0.0000024512906,"teacher_disagreement_score":0.008504072,"about_ca_system_score_codex":0.000021884478,"about_ca_system_score_gemma":0.00027629372,"threshold_uncertainty_score":0.28295627},"labels":[],"label_agreement":null},{"id":"W3007024026","doi":"10.1200/jco.2020.38.15_suppl.e19390","title":"Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Internal medicine; Bladder cancer; Chemotherapy; Cisplatin; Gemcitabine; Vinblastine; Urology; Oncology; Cancer","score_opus":0.20807854021477282,"score_gpt":0.48082730939563917,"score_spread":0.2727487691808663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007024026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855896,0.0016227978,0.0006833867,0.010074067,0.00033169522,0.00082219037,0.0000733214,0.000015893977,0.00078701193],"genre_scores_gemma":[0.9867214,0.0041151787,0.003781746,0.0043912837,0.0007205304,0.000021550577,0.0000274646,0.00004863826,0.00017221131],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965183,0.00034809325,0.0020193432,0.00043236834,0.00039629324,0.0002856106],"domain_scores_gemma":[0.99131733,0.005518064,0.0017829573,0.00019765299,0.0005986378,0.00058537547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011116443,0.00027959218,0.0022332103,0.00024584564,0.00007272135,0.000017231088,0.00013237091,0.00038233053,0.00036905057],"category_scores_gemma":[0.0045142393,0.0002088014,0.00050762296,0.0005858903,0.000271485,0.00011235039,0.000058378646,0.0005071433,0.0000020605955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.120724715,0.0024666965,0.048509493,0.00027362467,0.016865758,0.00032537535,0.0032744317,0.00082019303,0.01163416,0.000112002745,0.009281975,0.7857116],"study_design_scores_gemma":[0.13602595,0.051127493,0.6799734,0.0003705666,0.02469022,0.00009113477,0.0012391951,0.00838068,0.005768701,0.00012938945,0.09164063,0.00056261284],"about_ca_topic_score_codex":0.0001282503,"about_ca_topic_score_gemma":0.00022155534,"teacher_disagreement_score":0.785149,"about_ca_system_score_codex":0.000104116516,"about_ca_system_score_gemma":0.0009992394,"threshold_uncertainty_score":0.85146743},"labels":[],"label_agreement":null},{"id":"W3007049520","doi":"10.1200/jco.2020.38.6_suppl.315","title":"Quality of life outcomes from a phase III trial exploring optimal sequencing of androgen deprivation therapy with external beam radiotherapy in localized prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Radiation therapy; Wilcoxon signed-rank test; Statistical significance; Clinical endpoint; Randomized controlled trial; Urology; Internal medicine; Prostate; Cancer; Oncology; Mann–Whitney U test","score_opus":0.23446667190027629,"score_gpt":0.48525204558099666,"score_spread":0.2507853736807204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007049520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8401611,0.00054860715,0.15821674,0.00048344937,0.00014908063,0.0003972691,0.000023800794,0.000008681578,0.00001126802],"genre_scores_gemma":[0.93030185,0.0012363307,0.06727384,0.00038115482,0.0007453362,0.000033538483,0.0000026652517,0.00002345341,0.0000018609035],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99573797,0.0004916693,0.0030638597,0.0002116905,0.00031802166,0.00017678803],"domain_scores_gemma":[0.9944421,0.0011970877,0.003822578,0.00014949637,0.00020598985,0.00018276913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014838551,0.00017670564,0.0020218543,0.000073780306,0.000020204247,0.000007450204,0.0002615045,0.00010969068,0.00014093128],"category_scores_gemma":[0.0001858326,0.00012553476,0.00036110228,0.00016701981,0.00016685524,0.00031562932,0.000020317495,0.00054206455,5.503381e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23970138,0.0015277147,0.50090474,0.000011462977,0.0009173029,0.00001467493,0.0019212312,0.00420825,0.022621604,0.00008653407,0.00001574141,0.2280694],"study_design_scores_gemma":[0.8296969,0.045946617,0.03531948,0.0003515806,0.00014740654,0.0000030237131,0.0013084498,0.0039616455,0.07724033,0.0013705163,0.0039745267,0.00067950063],"about_ca_topic_score_codex":0.00055345596,"about_ca_topic_score_gemma":0.000008238435,"teacher_disagreement_score":0.58999556,"about_ca_system_score_codex":0.00011064935,"about_ca_system_score_gemma":0.0013377904,"threshold_uncertainty_score":0.5119159},"labels":[],"label_agreement":null},{"id":"W3007072416","doi":"10.1200/jco.2020.38.6_suppl.364","title":"The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Grand River Hospital; Princess Margaret Cancer Centre; Université de Montréal; Université Laval; Hôtel-Dieu de Québec; McGill University; Sunnybrook Health Science Centre; Jewish General Hospital; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Western University; University of Toronto; Niagara Health System; London Health Sciences Centre; Queen's University; McMaster University","funders":"Prostate Cancer Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Framingham Risk Score; Cohort; Risk factor; Internal medicine; Framingham Heart Study; Disease; Diabetes mellitus; Cohort study; Population; Logistic regression; Cancer; Prospective cohort study; Oncology; Endocrinology","score_opus":0.07506837579378435,"score_gpt":0.3998572973100811,"score_spread":0.32478892151629674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007072416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859947,0.012508179,0.000002891308,0.00094007474,0.000040516607,0.00045728585,0.000032948054,0.0000034257948,0.000019978279],"genre_scores_gemma":[0.9510103,0.04873157,0.000027131986,0.00004831582,0.00008689821,0.000008119287,0.0000018152966,0.000009146223,0.00007672472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844813,0.00026987048,0.00063395634,0.00015870464,0.00035667504,0.00013268818],"domain_scores_gemma":[0.9979514,0.00040941147,0.0006049491,0.000092719885,0.00047447465,0.00046702736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006351062,0.00009433297,0.00062037405,0.000026876956,0.00006863645,0.000008018398,0.00006504003,0.00007174068,0.0000072947564],"category_scores_gemma":[0.0013216027,0.00004267789,0.00014573555,0.0000971053,0.000321509,0.00009474035,0.000040200386,0.00033509525,2.1314398e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006668367,0.00017299152,0.97621816,0.00014493034,0.0018362927,0.000037529,0.00019578649,0.000029314011,0.00000593699,9.678771e-7,0.000035495555,0.014654227],"study_design_scores_gemma":[0.007551286,0.005529407,0.98298705,0.00010700897,0.0019724518,0.0000032742773,0.00004276023,0.0002483256,0.00016538647,0.000009782117,0.0013370293,0.00004626196],"about_ca_topic_score_codex":0.000038401133,"about_ca_topic_score_gemma":0.00000533784,"teacher_disagreement_score":0.03622339,"about_ca_system_score_codex":0.000037519712,"about_ca_system_score_gemma":0.0005119672,"threshold_uncertainty_score":0.17403539},"labels":[],"label_agreement":null},{"id":"W3007130315","doi":"10.1200/jco.2020.38.6_suppl.615","title":"Genetic risk assessment for hereditary RCC: Report from the consensus panel meeting.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Genetic testing; Genetic counseling; Family medicine; Delphi method; Hereditary Cancer; Cancer; Internal medicine; Genetics","score_opus":0.1329547352364224,"score_gpt":0.4509819833224658,"score_spread":0.31802724808604343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007130315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9400711,0.0024810832,0.011990742,0.040960103,0.0030548514,0.00029912946,0.00010049536,0.000005844282,0.0010366751],"genre_scores_gemma":[0.8980643,0.0006682129,0.08469823,0.007641664,0.008812936,0.000014503523,0.00002360023,0.000023782244,0.00005272998],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969128,0.00055909,0.0018631731,0.0002864939,0.00020844468,0.000170034],"domain_scores_gemma":[0.99497575,0.0019069182,0.0021265275,0.0002813312,0.000513363,0.00019611997],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022336023,0.00012135566,0.0005313759,0.000011064149,0.00008104907,0.000013517158,0.0003569034,0.0003378615,0.000037639984],"category_scores_gemma":[0.009181982,0.00008280375,0.00044500656,0.000052679858,0.00021806716,0.000002311681,0.00010824277,0.00051397516,0.0000038223266],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027650765,0.0004892795,0.14859597,0.000016033999,0.001929506,0.00086055725,0.00016674222,0.004096681,0.008982781,0.00001331341,0.6830375,0.14904653],"study_design_scores_gemma":[0.0036804818,0.0050699105,0.16713065,0.0000144207315,0.00049335265,0.00043554613,0.00035362676,0.0009291748,0.0011322884,0.0009794128,0.81961226,0.00016888566],"about_ca_topic_score_codex":0.00003279656,"about_ca_topic_score_gemma":0.000061207014,"teacher_disagreement_score":0.14887765,"about_ca_system_score_codex":0.00005288092,"about_ca_system_score_gemma":0.0024788924,"threshold_uncertainty_score":0.9991641},"labels":[],"label_agreement":null},{"id":"W3007133139","doi":"10.1200/jco.2020.38.6_suppl.58","title":"Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Checklist; Randomized controlled trial; Clinical endpoint; Quality of life (healthcare); Clinical trial; Physical therapy; Internal medicine; Nursing","score_opus":0.7981834155887401,"score_gpt":0.6463273473903383,"score_spread":0.1518560681984018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007133139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9276389,0.011661567,0.002679175,0.05337258,0.0012657287,0.0029485582,0.00018338232,0.000008330198,0.00024181325],"genre_scores_gemma":[0.98901093,0.0014647353,0.0040704478,0.005009792,0.00030267544,0.00007309836,0.000007235554,0.000025094421,0.000035966925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.65847206,0.053327188,0.28615862,0.00077448244,0.00060267706,0.0006649753],"domain_scores_gemma":[0.4398254,0.11362616,0.44432357,0.00047397643,0.0010956448,0.00065526593],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.66254777,0.00027673197,0.043741856,0.0004673894,0.00005134846,0.000013031471,0.0003882674,0.00038138125,0.000367836],"category_scores_gemma":[0.7541392,0.00023659611,0.0030591895,0.0003940455,0.00042085824,0.00034865152,0.000076714576,0.00092794775,0.000006637805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7722648,0.006839061,0.13486053,0.0086555695,0.01023355,0.000022446524,0.014820509,0.0044672913,0.00040667833,0.023199884,0.0022291313,0.022000577],"study_design_scores_gemma":[0.9509196,0.0034610322,0.019670775,0.0005322344,0.0003548137,0.0000047795397,0.0031490831,0.010893214,0.000033960896,0.01017745,0.00044016013,0.0003628402],"about_ca_topic_score_codex":0.009290068,"about_ca_topic_score_gemma":0.0004556061,"teacher_disagreement_score":0.21864668,"about_ca_system_score_codex":0.0003984566,"about_ca_system_score_gemma":0.006548165,"threshold_uncertainty_score":0.99908376},"labels":[],"label_agreement":null},{"id":"W3007178895","doi":"10.1200/jco.2020.38.6_suppl.337","title":"Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Genome British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Prostate cancer; Hazard ratio; Cohort; Disease; Proportional hazards model; Cancer; Confidence interval","score_opus":0.4935468665260189,"score_gpt":0.5608985430108356,"score_spread":0.06735167648481671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007178895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531985,0.0024736112,0.0018394185,0.039375786,0.0011001892,0.001910707,0.000048659676,0.000012523568,0.000040597977],"genre_scores_gemma":[0.8759012,0.11157577,0.008363314,0.0008213004,0.0031728353,0.000078375044,0.000009873899,0.000028002396,0.000049277354],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932415,0.0011013733,0.004785416,0.00038177782,0.0002243724,0.0002655545],"domain_scores_gemma":[0.9850665,0.009510241,0.0036671641,0.000236637,0.0008590318,0.0006604574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008465824,0.00015847146,0.0019170471,0.00008348871,0.00008326775,0.000013325951,0.00021098653,0.00044006036,0.000024177942],"category_scores_gemma":[0.008040077,0.00010644139,0.00072307605,0.00017454181,0.00053900434,0.00010267805,0.000052767416,0.001068724,0.0000035141818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18402185,0.0012461562,0.2564313,0.000029146493,0.00078461366,0.000007899769,0.00005406477,0.0000061857363,0.00057086255,0.000079189944,0.0017438392,0.55502486],"study_design_scores_gemma":[0.14153829,0.06775405,0.7676868,0.00005329409,0.00072315906,0.000009835613,0.00005383065,0.00030594572,0.00022865515,0.001098667,0.020445192,0.000102309845],"about_ca_topic_score_codex":0.000027086293,"about_ca_topic_score_gemma":0.000011260134,"teacher_disagreement_score":0.5549226,"about_ca_system_score_codex":0.000109696965,"about_ca_system_score_gemma":0.003339262,"threshold_uncertainty_score":0.96253043},"labels":[],"label_agreement":null},{"id":"W3007231702","doi":"10.1200/jco.2020.38.6_suppl.539","title":"Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Decipher Biosciences (Canada)","funders":"","keywords":"Medicine; Bladder cancer; Logistic regression; Oncology; Internal medicine; Cystectomy; Biomarker; Pembrolizumab; Stage (stratigraphy); Calculator; Cancer; Immunotherapy","score_opus":0.18666821107000617,"score_gpt":0.4288550273042523,"score_spread":0.24218681623424612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007231702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840162,0.0004103651,0.00021567255,0.014013603,0.0002759199,0.0009000577,0.00007365492,0.0000073812903,0.00008714112],"genre_scores_gemma":[0.98515123,0.000043376305,0.008798635,0.005771613,0.00014134996,0.000064278494,0.0000028448135,0.00001843094,0.000008229159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946062,0.0012610395,0.0030159694,0.00031354546,0.0005201964,0.00028304922],"domain_scores_gemma":[0.99537295,0.002089189,0.0013171205,0.00027884508,0.00050665106,0.00043524837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002690892,0.00021751125,0.0017255188,0.00012605944,0.000033738077,0.000004584924,0.00027582742,0.00026193392,0.00019083047],"category_scores_gemma":[0.0023887837,0.00012878371,0.0004414943,0.0003238925,0.00035817386,0.000049212453,0.00011891866,0.0005806772,0.0000058288633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33906293,0.006345473,0.49530917,0.00047341545,0.001339438,0.0019370398,0.0056558372,0.0005113572,0.07034704,0.000007258336,0.00105061,0.07796044],"study_design_scores_gemma":[0.015594091,0.010072596,0.96426934,0.00032506013,0.00034087952,0.000043063654,0.00014244809,0.00017215231,0.002109198,0.000035361947,0.006781601,0.000114197144],"about_ca_topic_score_codex":0.000072145485,"about_ca_topic_score_gemma":0.000296502,"teacher_disagreement_score":0.46896017,"about_ca_system_score_codex":0.000308795,"about_ca_system_score_gemma":0.0055606845,"threshold_uncertainty_score":0.98644155},"labels":[],"label_agreement":null},{"id":"W3007232749","doi":"10.1200/jco.2020.38.6_suppl.450","title":"Survival outcomes associated with different palliative systemic therapies (PSTs) in patients with metastatic bladder cancer (mBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of the Fraser Valley; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Regimen; Bladder cancer; Chemotherapy; Carboplatin; Cancer; Gastroenterology; Log-rank test; Surgery; Cisplatin; Survival analysis","score_opus":0.13027051627619174,"score_gpt":0.4303632811520404,"score_spread":0.3000927648758487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007232749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919122,0.0003549281,0.00007502558,0.0065549486,0.00038463093,0.000455643,0.000027984408,0.000011107766,0.00022352305],"genre_scores_gemma":[0.99619937,0.00028489716,0.00017263133,0.00303392,0.00018198288,0.00001851006,0.000006732984,0.00003000678,0.00007197588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968456,0.0006016333,0.0014532816,0.00022448016,0.000619275,0.00025573265],"domain_scores_gemma":[0.9962789,0.0013757182,0.0014224723,0.000109314205,0.00047267668,0.00034095487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051544845,0.00023708669,0.0022800833,0.00007052248,0.000026596457,0.000009356021,0.00012627247,0.00014906061,0.0001791141],"category_scores_gemma":[0.00078473636,0.000114193776,0.00023506666,0.00018401323,0.0001365938,0.00010354615,0.00002261287,0.00074104645,0.0000041190697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008813323,0.0023460882,0.9788666,0.000031822736,0.0043758294,0.00023999797,0.0008758308,0.00002791566,0.0000036213937,0.000010536464,0.00013030304,0.0042781387],"study_design_scores_gemma":[0.03420829,0.021225465,0.9422681,0.0002990372,0.0012043875,0.000004184514,0.00042249702,0.000016020811,0.0000073870438,0.000021016975,0.00020462353,0.000118990705],"about_ca_topic_score_codex":0.00006508891,"about_ca_topic_score_gemma":0.00048738084,"teacher_disagreement_score":0.036598492,"about_ca_system_score_codex":0.00033660216,"about_ca_system_score_gemma":0.0010813919,"threshold_uncertainty_score":0.4656687},"labels":[],"label_agreement":null},{"id":"W3007266269","doi":"10.1200/jco.2020.38.6_suppl.642","title":"Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Hospital; University of Calgary; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Oncology; Metastasis; Proportional hazards model; Internal medicine; Thyroid; Pancreas; Cancer; Confidence interval","score_opus":0.22530503151327455,"score_gpt":0.4213904511404731,"score_spread":0.19608541962719853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007266269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96670264,0.001218465,0.000060287577,0.029260924,0.0004491947,0.00021025057,0.00027171447,0.0000037129712,0.0018228084],"genre_scores_gemma":[0.98946124,0.00047715023,0.0070089456,0.002309643,0.00061619945,0.0000022770207,0.000066859575,0.000013167357,0.00004452063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948274,0.0009233045,0.0030715838,0.0003106636,0.0006742718,0.0001928144],"domain_scores_gemma":[0.9882543,0.008716671,0.0019809972,0.00026277968,0.00038638804,0.00039887137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036763556,0.00018150457,0.0015410053,0.00009716967,0.00002249238,0.0000124467215,0.00030990166,0.00013312083,0.00017014267],"category_scores_gemma":[0.007536216,0.00010825722,0.0003731518,0.0001673631,0.00031122135,0.00011823877,0.00018381822,0.0009594738,0.000009460936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05258281,0.0037742625,0.8617379,0.00011548675,0.002178084,0.009614517,0.0017368952,0.00009631463,0.025006492,0.00016247266,0.020271871,0.022722885],"study_design_scores_gemma":[0.039763834,0.013102892,0.9026698,0.0001272138,0.0024380665,0.00029516392,0.0016524337,0.0011254272,0.0135031,0.00020281503,0.024912106,0.00020716868],"about_ca_topic_score_codex":0.00030818203,"about_ca_topic_score_gemma":0.000196297,"teacher_disagreement_score":0.040931877,"about_ca_system_score_codex":0.00009015337,"about_ca_system_score_gemma":0.0010330817,"threshold_uncertainty_score":0.9022099},"labels":[],"label_agreement":null},{"id":"W3007273306","doi":"10.1200/jco.2020.38.6_suppl.728","title":"Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"","keywords":"Renal cell carcinoma; Cell-free fetal DNA; Differentially methylated regions; Urine; Medicine; Cancer; Bladder cancer; Plasma cell; Oncology; DNA methylation; Internal medicine; Biology; Gene; Gene expression; Genetics; Fetus; Multiple myeloma","score_opus":0.053670252018305234,"score_gpt":0.3498623064588789,"score_spread":0.29619205444057367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007273306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955059,0.0006478766,0.0022843038,0.000603995,0.00038780025,0.00006221999,0.000017843468,0.0000010325176,0.0004890221],"genre_scores_gemma":[0.99378234,0.00071309216,0.0036348314,0.0006936138,0.0011459241,3.4453063e-7,0.000002122759,0.000012375392,0.00001537891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984564,0.00017121209,0.0009619171,0.00017456217,0.00010935861,0.00012653791],"domain_scores_gemma":[0.9979949,0.00037516252,0.0010187717,0.00012622731,0.0002550562,0.00022986735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000634087,0.000101024045,0.00054445164,0.000035025896,0.00002559211,0.0000056012914,0.00012787824,0.00027733666,0.000004409986],"category_scores_gemma":[0.0013557611,0.000089867295,0.00021283448,0.000055626675,0.00013300334,0.0000040728582,0.00017046306,0.00028958285,6.468133e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016942013,0.0001744281,0.0019233531,0.000027620896,0.000067958325,0.00007955782,0.00005984849,0.0003435435,0.986308,0.00000510417,0.00054923404,0.008767188],"study_design_scores_gemma":[0.004488681,0.009990772,0.007662447,0.000007186266,0.00019655399,0.00010057959,0.000114888215,0.00084481656,0.9589745,0.00005633695,0.017445173,0.00011807613],"about_ca_topic_score_codex":0.00002057857,"about_ca_topic_score_gemma":0.000031287807,"teacher_disagreement_score":0.027333474,"about_ca_system_score_codex":0.000023082901,"about_ca_system_score_gemma":0.0005016831,"threshold_uncertainty_score":0.3664682},"labels":[],"label_agreement":null},{"id":"W3007275864","doi":"10.1200/jco.2020.38.6_suppl.276","title":"Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences; Genome British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Prostate cancer; Prostatectomy; Internal medicine; Oncology; Randomized controlled trial; Cumulative incidence; Context (archaeology); Cohort; Radiation therapy; Cancer","score_opus":0.11965373547652233,"score_gpt":0.4640600398661545,"score_spread":0.34440630438963216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007275864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869405,0.0021972372,0.00009522431,0.0052281423,0.0007027701,0.0045289528,0.000052798434,0.000007757125,0.00024663983],"genre_scores_gemma":[0.99202675,0.0039680162,0.002687964,0.00044446604,0.0006054937,0.00017033791,0.000023416498,0.000029395029,0.000044172615],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935523,0.0015570523,0.0037691635,0.00031485985,0.0005241118,0.00028245832],"domain_scores_gemma":[0.99287957,0.0030913297,0.0027935593,0.00012587679,0.0008100621,0.0002995822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003324778,0.0001984994,0.003531989,0.00021278727,0.000021200198,0.0000063191665,0.00017795802,0.00040303572,0.00012644526],"category_scores_gemma":[0.003913856,0.00012935474,0.0006885481,0.00033381835,0.00048766084,0.00013453278,0.000027716962,0.001029797,0.0000017320455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7315576,0.0035443765,0.23807816,0.00010325409,0.0011396062,0.000094421215,0.0025488427,0.000026056572,0.011702753,0.000013248823,0.00009349418,0.011098192],"study_design_scores_gemma":[0.883076,0.030556515,0.07660806,0.00029355506,0.0007624007,0.0000033301956,0.00021416569,0.00029708704,0.007182318,0.0003287309,0.000568083,0.0001097332],"about_ca_topic_score_codex":0.000082998165,"about_ca_topic_score_gemma":0.00001631569,"teacher_disagreement_score":0.1614701,"about_ca_system_score_codex":0.0005959976,"about_ca_system_score_gemma":0.0040844143,"threshold_uncertainty_score":0.7245575},"labels":[],"label_agreement":null},{"id":"W3007285443","doi":"10.1200/jco.2020.38.6_suppl.209","title":"Does screening for frailty with the vulnerable elders survey (VES-13) identify older adults with GU malignancy who benefit most from a consultation in a geriatric oncology clinic?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Geriatric oncology; Internal medicine; Comorbidity; Univariate analysis; Malignancy; Odds ratio; Cancer; Polypharmacy; Geriatrics; Multivariate analysis; Psychiatry","score_opus":0.10888433976611814,"score_gpt":0.42641104836967136,"score_spread":0.31752670860355325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007285443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93319625,0.00042841048,0.0060454872,0.057437524,0.0008012389,0.0015529534,0.000111739515,0.000025625706,0.00040080168],"genre_scores_gemma":[0.9710982,0.0005348066,0.014760659,0.011283326,0.0015598757,0.00006914196,0.000080914644,0.00006888635,0.00054421806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99301416,0.0018203162,0.0033565292,0.0006297709,0.0006361123,0.00054309453],"domain_scores_gemma":[0.96192515,0.032198787,0.0033666545,0.00036314747,0.0015680123,0.00057827804],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0066116564,0.0003535274,0.002537197,0.00016847656,0.00015864523,0.000042465534,0.00046405554,0.00074151566,0.00029620438],"category_scores_gemma":[0.020891847,0.00017329956,0.00033582366,0.00071281235,0.00043171874,0.00029796068,0.00008425488,0.002770306,0.00001781318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12833333,0.0024128417,0.5874619,0.00023434321,0.0018689071,0.0015451902,0.0076727076,0.00082276453,0.000079863436,0.000018084143,0.03582083,0.23372923],"study_design_scores_gemma":[0.06543411,0.028648559,0.8800424,0.0010811355,0.00083222584,0.00013858282,0.004804491,0.0012566479,0.000059470927,0.00012200595,0.017255824,0.00032455192],"about_ca_topic_score_codex":0.0011072898,"about_ca_topic_score_gemma":0.01474791,"teacher_disagreement_score":0.2925805,"about_ca_system_score_codex":0.0001700854,"about_ca_system_score_gemma":0.0022476094,"threshold_uncertainty_score":0.9995303},"labels":[],"label_agreement":null},{"id":"W3007309272","doi":"10.1200/jco.2020.38.6_suppl.322","title":"Validation of biochemical definition of cure after low-dose rate prostate brachytherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Urology; Cohort; External beam radiotherapy; Prospective cohort study; Androgen deprivation therapy; Prostate; Radiation therapy; Clinical trial; Clinical endpoint; Internal medicine; Cancer; Surgery; Nuclear medicine","score_opus":0.15663346601302502,"score_gpt":0.4747091916999229,"score_spread":0.3180757256868979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007309272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824257,0.0009577057,0.0000537239,0.015741808,0.00019731809,0.00022158238,0.000013734355,0.000003970668,0.0003844719],"genre_scores_gemma":[0.9939856,0.0026406257,0.0017510183,0.0010989731,0.00045497497,0.000004818282,0.000014144171,0.00001147619,0.000038351453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975054,0.00030838352,0.0016253601,0.00012703762,0.00029514445,0.0001386647],"domain_scores_gemma":[0.99719465,0.00065971847,0.0011639877,0.000095186995,0.0006251806,0.00026129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012905326,0.00008896505,0.00091548194,0.00007061449,0.0000099208655,0.0000029477176,0.00007724593,0.00022804459,0.00018531403],"category_scores_gemma":[0.0012814031,0.000058302085,0.000343161,0.00017077214,0.00023984486,0.00008685206,0.000029108065,0.00054404244,0.000008837448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23554224,0.008921495,0.30744863,0.0015728477,0.0021172648,0.0018534852,0.0025437293,0.00002148597,0.3270191,0.0002413871,0.012600283,0.100118056],"study_design_scores_gemma":[0.06963931,0.08930188,0.35406736,0.0012188337,0.0013316057,0.0002446142,0.00039648486,0.00024116307,0.46210408,0.0066598896,0.014461103,0.00033367495],"about_ca_topic_score_codex":0.0000023436232,"about_ca_topic_score_gemma":3.5672122e-7,"teacher_disagreement_score":0.16590293,"about_ca_system_score_codex":0.00004750797,"about_ca_system_score_gemma":0.0010099374,"threshold_uncertainty_score":0.237749},"labels":[],"label_agreement":null},{"id":"W3007390686","doi":"10.1200/jco.2020.38.6_suppl.657","title":"Cost analysis of post-nephrectomy follow-up schedules from three North American clinical practice guidelines for localized renal cell carcinoma (RCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University; Dalhousie University","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Schedule; Internal medicine; Kidney; Management","score_opus":0.29886250569133854,"score_gpt":0.5021983807769741,"score_spread":0.20333587508563555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007390686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503705,0.0012168597,0.009882372,0.03638131,0.00088525185,0.00077557657,0.00015029447,0.000019374655,0.000318445],"genre_scores_gemma":[0.7683138,0.00053021254,0.21064338,0.017817494,0.0024961026,0.000016206972,0.00010557525,0.000046189303,0.000031024032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881784,0.0011702128,0.008515051,0.00067477894,0.0010012449,0.00046034245],"domain_scores_gemma":[0.96491295,0.017110372,0.008441733,0.00058752025,0.0075390907,0.0014083579],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043962086,0.0004114319,0.005885616,0.0003278293,0.00006160321,0.0000190861,0.0005126257,0.00044954085,0.00015223592],"category_scores_gemma":[0.05888132,0.00029129366,0.003956036,0.0011112726,0.00063423754,0.00018635241,0.0001571169,0.0013840188,0.000022084083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059750084,0.002629903,0.78312755,0.000049750153,0.00958707,0.0011049269,0.00012310292,0.00021692792,0.0002812975,0.000012589728,0.008587041,0.13452975],"study_design_scores_gemma":[0.027040817,0.04689991,0.772924,0.000041488838,0.03458537,0.000057510595,0.0006475697,0.0048565827,0.0004902737,0.000033281776,0.11214334,0.0002798236],"about_ca_topic_score_codex":0.0006098763,"about_ca_topic_score_gemma":0.0017644627,"teacher_disagreement_score":0.20076102,"about_ca_system_score_codex":0.00020211627,"about_ca_system_score_gemma":0.003372804,"threshold_uncertainty_score":0.9999539},"labels":[],"label_agreement":null},{"id":"W3007447088","doi":"10.1200/jco.2020.38.6_suppl.608","title":"Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Calgary; Ottawa Hospital; Dalhousie University; University of Ottawa","funders":"","keywords":"Medicine; Propensity score matching; Renal cell carcinoma; Hazard ratio; Confounding; Internal medicine; Proportional hazards model; Urology; Nephrectomy; Oncology; Gastroenterology; Confidence interval; Kidney","score_opus":0.19717752873204802,"score_gpt":0.38647551463242374,"score_spread":0.18929798590037572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007447088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914534,0.0007982208,0.001262661,0.006424396,0.00019697429,0.0018680271,0.000022374144,0.000031133484,0.00025089085],"genre_scores_gemma":[0.98064303,0.00006669754,0.016481781,0.0016464934,0.0008348196,0.00005876184,0.000056050016,0.00006426331,0.00014809509],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9935233,0.0010018975,0.0036251529,0.00061715697,0.00071548077,0.00051700464],"domain_scores_gemma":[0.991799,0.0017599866,0.0035777502,0.0003943804,0.0014608919,0.0010080175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022213475,0.0004986161,0.004377922,0.00038207596,0.00010865781,0.00002753564,0.00027067872,0.0003195812,0.00021310455],"category_scores_gemma":[0.0013971615,0.0002672232,0.0020697573,0.0011992701,0.00041158855,0.00015654789,0.000045242065,0.0011139427,0.000009718208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4434209,0.0123556135,0.4353776,0.00032199957,0.018055275,0.011207432,0.00086652796,0.001397428,0.05729568,0.000008915265,0.0018710475,0.017821593],"study_design_scores_gemma":[0.06171579,0.15280068,0.54865044,0.00010157863,0.013762049,0.00033119606,0.00032388236,0.0016876231,0.21629436,0.00002086302,0.003879637,0.00043191283],"about_ca_topic_score_codex":0.00014916563,"about_ca_topic_score_gemma":0.00006900605,"teacher_disagreement_score":0.3817051,"about_ca_system_score_codex":0.0004919289,"about_ca_system_score_gemma":0.0044763465,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W3007448899","doi":"10.1200/jco.2020.38.6_suppl.317","title":"Risk of secondary sarcoma after abdominopelvic cancer treatment: Results from a contemporary cohort.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sarcoma; Hazard ratio; Cohort; Internal medicine; Cancer; Population; Perioperative; Retrospective cohort study; Radical surgery; Surgery; Oncology; Pathology; Confidence interval","score_opus":0.13325043050915222,"score_gpt":0.42336786243798596,"score_spread":0.29011743192883377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007448899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692374,0.0063849483,0.000023026412,0.011744606,0.0009872201,0.00032391722,0.00069950055,0.000009878338,0.010589486],"genre_scores_gemma":[0.9799599,0.005785607,0.0014499997,0.010390107,0.0021329639,0.000008716281,0.000029041474,0.000022980857,0.00022069666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949704,0.00060569454,0.0035848357,0.00031917795,0.000321596,0.00019830762],"domain_scores_gemma":[0.9926296,0.0030159547,0.0030943698,0.00026624688,0.0003203172,0.0006735074],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012241103,0.00020483046,0.0025110191,0.000076808974,0.000024974865,0.000005697178,0.000174891,0.00039098435,0.0015953472],"category_scores_gemma":[0.0021101504,0.00013978695,0.0008840332,0.00011459296,0.00027711998,0.00016156666,0.000049382325,0.001084413,0.000022627273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10297663,0.0009564089,0.57807994,0.000039446855,0.0030901986,0.0019739782,0.00094366947,0.000012016513,0.00042261113,0.0000019282456,0.022778882,0.2887243],"study_design_scores_gemma":[0.036849525,0.014595358,0.6769392,0.000090728216,0.0009965905,0.00003467386,0.00014039295,0.00016872727,0.00043332172,0.000046785506,0.2695891,0.00011561762],"about_ca_topic_score_codex":0.0009033083,"about_ca_topic_score_gemma":0.00017746285,"teacher_disagreement_score":0.2886087,"about_ca_system_score_codex":0.00022737037,"about_ca_system_score_gemma":0.0058187214,"threshold_uncertainty_score":0.9998174},"labels":[],"label_agreement":null},{"id":"W3007455364","doi":"10.1200/jco.2020.38.6_suppl.620","title":"Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; McMaster University; McGill University; University of Ottawa; Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; Juravinski Cancer Centre; University of Manitoba; Health Sciences Centre; University Health Network; Ottawa Hospital; University of Alberta; Dalhousie University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Asymptomatic; Interquartile range; Renal cell carcinoma; Hazard ratio; Internal medicine; Cohort; Proportional hazards model; Pathological; Disease; Surgery; Confidence interval","score_opus":0.1657742209134433,"score_gpt":0.48281669037506947,"score_spread":0.3170424694616262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007455364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402535,0.0006996696,0.00051186583,0.004178793,0.00013778146,0.00023331486,0.000053600343,0.0000024623878,0.00015717147],"genre_scores_gemma":[0.9944163,0.00008294731,0.0048432057,0.0004345643,0.000168256,0.0000020915472,0.000009168521,0.000013596998,0.000029878998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994509,0.0010013513,0.003737405,0.00017979252,0.00039325285,0.0001792422],"domain_scores_gemma":[0.9933684,0.0024700356,0.003229741,0.0001940431,0.00037824505,0.00035957745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037628775,0.00014290129,0.0019375695,0.00018848345,0.000010452611,0.000004204461,0.00015271654,0.0001200466,0.00019562838],"category_scores_gemma":[0.0038582848,0.000094685005,0.0010124048,0.00031621015,0.00017159207,0.000106515035,0.000037119265,0.0005114256,0.000007496772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019983271,0.012790947,0.8242161,0.00043139828,0.0027172028,0.0030031533,0.0011837167,0.0005994514,0.038757086,0.00024073952,0.0068245805,0.08925235],"study_design_scores_gemma":[0.012258979,0.04332755,0.93697774,0.000051101055,0.0012267465,0.000115299525,0.00015652638,0.00017899502,0.0047561205,0.00019671349,0.0006777094,0.000076524855],"about_ca_topic_score_codex":0.00015354247,"about_ca_topic_score_gemma":0.000014829379,"teacher_disagreement_score":0.11276163,"about_ca_system_score_codex":0.00009084249,"about_ca_system_score_gemma":0.0014865799,"threshold_uncertainty_score":0.4619006},"labels":[],"label_agreement":null},{"id":"W3007531526","doi":"10.1200/jco.2020.38.6_suppl.473","title":"Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Proportional hazards model; Internal medicine; Oncology; Population; Demographics; Progressive disease; Disease; Demography","score_opus":0.2078916644777719,"score_gpt":0.4648295088600726,"score_spread":0.2569378443823007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007531526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858753,0.00011289992,0.00028166958,0.010321622,0.0020862245,0.0009000611,0.000062516425,0.000009146307,0.00035054976],"genre_scores_gemma":[0.99602544,0.000041782936,0.0017580864,0.0010816213,0.0008966607,0.000049103168,0.0000038088772,0.00003935628,0.0001041208],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9939322,0.001708856,0.0032092961,0.00031389738,0.0005607187,0.0002750186],"domain_scores_gemma":[0.9900885,0.0051092645,0.0032694498,0.0003709906,0.00055615476,0.0006056414],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006390733,0.00025878666,0.0020912585,0.00013851133,0.000057603484,0.000009883406,0.00035149485,0.00019311014,0.00010798648],"category_scores_gemma":[0.0152311595,0.00014764638,0.00089599885,0.00018245875,0.00037239274,0.00015575606,0.000121816,0.0009014981,0.000008162379],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85575235,0.0037574242,0.0043767933,0.00026420673,0.0012833707,0.00079799164,0.0030141675,0.000038986607,0.08334533,0.000057570465,0.0022525073,0.045059305],"study_design_scores_gemma":[0.059524383,0.2332974,0.27961552,0.00056547637,0.0035317985,0.00036723763,0.0029790981,0.00040805712,0.40508392,0.00047837198,0.013739456,0.00040931464],"about_ca_topic_score_codex":0.00012739499,"about_ca_topic_score_gemma":0.00007633059,"teacher_disagreement_score":0.796228,"about_ca_system_score_codex":0.0002086364,"about_ca_system_score_gemma":0.003354307,"threshold_uncertainty_score":0.993064},"labels":[],"label_agreement":null},{"id":"W3007533337","doi":"10.1200/jco.2020.38.6_suppl.533","title":"Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of British Columbia; Decipher Biosciences (Canada)","funders":"","keywords":"Medicine; Oncology; Internal medicine; Bladder cancer; Cohort; Gene signature; Pembrolizumab; Immune system; Chemotherapy; Cancer; Immunology; Immunotherapy; Gene; Biology; Gene expression","score_opus":0.06356085146431742,"score_gpt":0.4128073460469631,"score_spread":0.3492464945826457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007533337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670132,0.0013109449,0.00004273956,0.030697808,0.00030351352,0.0005117115,0.00004396116,0.000011399656,0.00006471186],"genre_scores_gemma":[0.98211634,0.0006706146,0.0029274474,0.013619534,0.0004920116,0.000025195455,0.000004421511,0.000033726512,0.00011073573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597925,0.0008362058,0.0020438118,0.00035024685,0.00047490562,0.0003155858],"domain_scores_gemma":[0.9962129,0.0010796319,0.001500164,0.00020482516,0.00047819363,0.0005242715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016898885,0.0002538715,0.0021095204,0.00014833825,0.00002675325,0.00001103614,0.000163415,0.00048440957,0.00018700861],"category_scores_gemma":[0.0014095794,0.00016814261,0.0002608463,0.00025595853,0.000109553905,0.00013085776,0.000047855825,0.0009788293,0.000003840471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26408008,0.0026139733,0.6519737,0.00008919971,0.0010241248,0.0046881265,0.0037489664,0.0002785661,0.027018635,0.0000019000054,0.0005985089,0.04388422],"study_design_scores_gemma":[0.033072464,0.026401745,0.93539566,0.00013428596,0.00049008086,0.00014622192,0.0002932182,0.00006365036,0.0016139501,0.000028091832,0.0021928025,0.00016780365],"about_ca_topic_score_codex":0.00008998662,"about_ca_topic_score_gemma":0.00036049084,"teacher_disagreement_score":0.28342196,"about_ca_system_score_codex":0.00037982894,"about_ca_system_score_gemma":0.0014608215,"threshold_uncertainty_score":0.68566567},"labels":[],"label_agreement":null},{"id":"W3007537439","doi":"10.1200/jco.2020.38.6_suppl.667","title":"Hospital-level quality indicators for kidney cancer surgery: A Veteran’s Affairs national health system validation of concept.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Veterans Affairs; Nephrectomy; Kidney cancer; Comorbidity; Cancer; Healthcare system; Health care; Emergency medicine; Surgery; Internal medicine; Kidney","score_opus":0.3190371397608172,"score_gpt":0.44968186564032375,"score_spread":0.13064472587950654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007537439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72269005,0.0065519377,0.046114303,0.18768601,0.016134847,0.0014198316,0.006368111,0.000046959725,0.012987961],"genre_scores_gemma":[0.991818,0.000482857,0.0014436444,0.0045516915,0.0016256198,0.000015299041,0.000015155176,0.000018681667,0.000029030238],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99424297,0.00014234788,0.0050097923,0.00025888544,0.00009999061,0.00024603817],"domain_scores_gemma":[0.9877949,0.0016108059,0.009605349,0.000102963066,0.00036396045,0.0005220173],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006349262,0.0001346578,0.0022360613,0.00018807639,0.000052443163,0.000016608717,0.0002577437,0.00029084788,0.00011539698],"category_scores_gemma":[0.009193646,0.00013637457,0.000702683,0.0001791282,0.00015256857,0.00031666036,0.000030884912,0.0003376955,0.000012232717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025977108,0.0012144392,0.4854856,0.0008568924,0.0012223374,0.000008166196,0.002967941,0.00061824045,0.0000041243475,0.1747705,0.22330675,0.10694729],"study_design_scores_gemma":[0.010117714,0.007035079,0.29873386,0.00029392057,0.00006407018,0.0000086513555,0.0009372237,0.00078706385,0.00014151754,0.008212753,0.67304724,0.0006208808],"about_ca_topic_score_codex":0.00017472162,"about_ca_topic_score_gemma":0.000011365271,"teacher_disagreement_score":0.44974053,"about_ca_system_score_codex":0.00052737957,"about_ca_system_score_gemma":0.0035518655,"threshold_uncertainty_score":0.99915236},"labels":[],"label_agreement":null},{"id":"W3007577807","doi":"10.1200/jco.2020.38.6_suppl.198","title":"Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Androgen receptor; Internal medicine; CHEK2; ERCC1; Cancer; Cancer research; Bioinformatics; DNA repair; Gene; Biology; Genetics","score_opus":0.17458778918440596,"score_gpt":0.47428313674197203,"score_spread":0.2996953475575661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007577807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97680444,0.004686922,0.00009181831,0.017200235,0.00036228038,0.0006916306,0.00004210897,0.000005656814,0.00011488878],"genre_scores_gemma":[0.98981917,0.001972249,0.0050777528,0.0026506132,0.0003693428,0.000007797316,0.0000055680707,0.000020903926,0.00007661807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973264,0.000414681,0.0014169024,0.00024037855,0.00031843796,0.00028321045],"domain_scores_gemma":[0.9971471,0.0005856153,0.0008341176,0.0000864893,0.0007437254,0.0006029972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081589323,0.00015670915,0.0013905134,0.000109310626,0.000040692175,0.000008740413,0.00008802558,0.00012057162,0.00004450654],"category_scores_gemma":[0.00034919317,0.00010512664,0.00025289468,0.00018654196,0.00032731425,0.00005340299,0.00007018208,0.00059016264,0.0000059099543],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15137914,0.0017633456,0.07049491,0.00112503,0.011653377,0.00881926,0.0048996047,0.00056247634,0.3664243,0.00005549521,0.0028834217,0.37993965],"study_design_scores_gemma":[0.069842435,0.13483125,0.6927645,0.00088175153,0.0063614477,0.0017664394,0.010363783,0.003757151,0.052593764,0.00073339423,0.025272027,0.0008320393],"about_ca_topic_score_codex":0.000042793195,"about_ca_topic_score_gemma":0.0000071965233,"teacher_disagreement_score":0.62226963,"about_ca_system_score_codex":0.00012239968,"about_ca_system_score_gemma":0.0018149146,"threshold_uncertainty_score":0.42869398},"labels":[],"label_agreement":null},{"id":"W3007610463","doi":"10.1200/jco.2020.38.6_suppl.418","title":"Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled <i>post hoc</i> analysis of trials from the Children’s Oncology Group.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Stollery Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Germ cell tumors; Post-hoc analysis; Lymphovascular invasion; Stage (stratigraphy); Oncology; Prospective cohort study; Choriocarcinoma; Chemotherapy; Cancer; Metastasis","score_opus":0.08393889895254894,"score_gpt":0.4228512391675766,"score_spread":0.3389123402150277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007610463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930597,0.0017208698,0.0000483355,0.0037429312,0.00017401214,0.0007377267,0.00043743878,0.000010701361,0.00006830031],"genre_scores_gemma":[0.9940142,0.0005916824,0.0015016084,0.0033526842,0.00041362725,0.000008550535,0.000087359505,0.000021268224,0.000009012683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906981,0.0026207378,0.005492987,0.0003711792,0.000553091,0.00026389424],"domain_scores_gemma":[0.98068315,0.009906222,0.008221732,0.0003864232,0.00033605858,0.0004664263],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004406274,0.0002745186,0.0060408693,0.00021649171,0.000026210022,0.0000066808843,0.000396498,0.00041103386,0.00016162211],"category_scores_gemma":[0.0128812175,0.0001348591,0.0020024779,0.0005977311,0.00043343008,0.000072747054,0.000110875924,0.00092041306,0.0000043307136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0119072925,0.006593698,0.96330845,0.0000133765725,0.010255303,0.00047745198,0.00021139541,0.0001317772,0.000080021644,0.0000069762004,0.000092182265,0.0069220643],"study_design_scores_gemma":[0.02313456,0.041190192,0.9129147,0.0000607422,0.022185072,0.00003548152,0.0001795606,0.0000457236,0.000030518433,0.000020521302,0.00010441366,0.00009852883],"about_ca_topic_score_codex":0.00031404707,"about_ca_topic_score_gemma":0.0002105062,"teacher_disagreement_score":0.050393775,"about_ca_system_score_codex":0.00010006846,"about_ca_system_score_gemma":0.0016831871,"threshold_uncertainty_score":0.9954337},"labels":[],"label_agreement":null},{"id":"W3007643597","doi":"10.1200/jco.2020.38.6_suppl.20","title":"Multiparametric magnetic resonance imaging of multifocal prostate cancer to reveal intra-prostatic genomic heterogeneity and novel radio-genomic correlates: Results of the Smarter Prostate Interventions and Therapeutics (SPIRIT) study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Ontario Institute for Cancer Research; London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Prostate; Histopathology; Magnetic resonance imaging; Cancer; Gold standard (test); Pathology; Nuclear medicine; Radiology; Internal medicine","score_opus":0.07987718340682844,"score_gpt":0.4291617750754897,"score_spread":0.34928459166866127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007643597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97616947,0.005766223,0.0005613088,0.015998594,0.00044621615,0.0010021381,0.00003953641,0.0000058501932,0.000010676723],"genre_scores_gemma":[0.9898438,0.0009631911,0.006498743,0.0024477236,0.00017405703,0.000010016624,9.891744e-7,0.00002679162,0.000034722827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575603,0.0004787879,0.002883429,0.00032860113,0.00030209048,0.00025103692],"domain_scores_gemma":[0.99607867,0.001357103,0.0016726742,0.00019042501,0.0003220915,0.00037906147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028512834,0.00018597613,0.0012699338,0.00014057544,0.0000611663,0.000017344451,0.00022354198,0.00010760528,0.0000045340325],"category_scores_gemma":[0.004192784,0.00012245742,0.00029035722,0.00030148824,0.0005817987,0.00006306831,0.00019971657,0.0012019469,7.1128204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004202219,0.000950729,0.7122265,0.00019704056,0.00019514652,0.00005430851,0.0027531192,0.00032818023,0.00869861,0.0000028490438,0.0001622732,0.270229],"study_design_scores_gemma":[0.014289349,0.0077014407,0.9550702,0.0005066802,0.00064166676,0.00018933807,0.00043787525,0.018411143,0.00008659434,0.00002467817,0.0025263533,0.00011467125],"about_ca_topic_score_codex":0.00009368693,"about_ca_topic_score_gemma":0.000032860844,"teacher_disagreement_score":0.27011433,"about_ca_system_score_codex":0.0000830191,"about_ca_system_score_gemma":0.00045700575,"threshold_uncertainty_score":0.5221928},"labels":[],"label_agreement":null},{"id":"W3007645860","doi":"10.1200/jco.2020.38.6_suppl.349","title":"Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Radioresistance; Radiosensitivity; Cancer research; Molecular biology; Biology; DU145; Clonogenic assay; Prostate cancer; Cell culture; Internal medicine; LNCaP; Cancer; Medicine; Genetics; Radiation therapy","score_opus":0.07472776025244818,"score_gpt":0.40959738141998703,"score_spread":0.3348696211675388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007645860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693485,0.0022378464,0.000014076824,0.026969938,0.000406603,0.0006880156,0.00005974903,0.00001529774,0.00026001068],"genre_scores_gemma":[0.9884621,0.0030258785,0.0006094958,0.006964742,0.00063242565,0.000016642665,0.000004558866,0.00003893915,0.00024521828],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99607974,0.0006043569,0.0018667427,0.00042060405,0.0004912916,0.00053728133],"domain_scores_gemma":[0.9966026,0.00082215277,0.0007420086,0.0002005985,0.00028575433,0.0013468958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017906857,0.00024776248,0.0017804117,0.00018893785,0.000044491095,0.000018259532,0.00020181388,0.0002106825,0.000119022974],"category_scores_gemma":[0.0007754913,0.00017725551,0.0003986975,0.0004556063,0.00018076201,0.00013483071,0.000120046556,0.0011118825,0.00006538717],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05639899,0.0072361687,0.17208058,0.00052459346,0.001240562,0.033635654,0.0019483782,0.00058488065,0.31767115,0.0000033774088,0.04632983,0.36234584],"study_design_scores_gemma":[0.037571076,0.029083839,0.030118365,0.0004385246,0.00071822084,0.00040648112,0.00032359033,0.0019760795,0.7692835,0.00007749342,0.12938611,0.0006167322],"about_ca_topic_score_codex":0.00010551453,"about_ca_topic_score_gemma":0.000063080864,"teacher_disagreement_score":0.45161235,"about_ca_system_score_codex":0.00042625683,"about_ca_system_score_gemma":0.001753833,"threshold_uncertainty_score":0.722827},"labels":[],"label_agreement":null},{"id":"W3007666443","doi":"10.1200/jco.2020.38.6_suppl.291","title":"GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Standardized uptake value; GLUT1; Positron emission tomography; Biochemical recurrence; Metastasis; Cancer; Biopsy; Stage (stratigraphy); Oncology; Nuclear medicine; Internal medicine; Urology; Glucose transporter","score_opus":0.06061232942779081,"score_gpt":0.4620119878217214,"score_spread":0.4013996583939306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007666443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95463437,0.00043437182,0.0009991438,0.042499676,0.0009723944,0.00021044692,0.0000022330164,0.000013451086,0.00023393407],"genre_scores_gemma":[0.9745977,0.0044599907,0.013426698,0.006252877,0.0011534333,0.000002701146,0.0000026816392,0.00002297499,0.00008097674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531966,0.00075410894,0.003049419,0.00028294095,0.0003702645,0.0002235839],"domain_scores_gemma":[0.9937346,0.0030330566,0.0022367856,0.00012012111,0.00017322734,0.0007022326],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0046906695,0.000147586,0.0015788906,0.00008374956,0.00004466188,0.00001380066,0.0001223018,0.000065367196,0.000062699764],"category_scores_gemma":[0.014318515,0.00009131572,0.00020702837,0.00015790036,0.0003176984,0.00012715562,0.000065962995,0.0033809657,0.0000062403456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034701051,0.0003422956,0.8352251,0.00003092566,0.000091245696,0.0039038993,0.000060671704,0.00036097234,0.000016801783,0.000014409027,0.0014416205,0.15504195],"study_design_scores_gemma":[0.018891837,0.010006828,0.9138933,0.00034833723,0.0004195669,0.0012535725,0.000116069416,0.018273773,0.0000075713824,0.00013115654,0.0365289,0.00012908461],"about_ca_topic_score_codex":0.00009932431,"about_ca_topic_score_gemma":0.00003640461,"teacher_disagreement_score":0.15491287,"about_ca_system_score_codex":0.00007291123,"about_ca_system_score_gemma":0.0007741016,"threshold_uncertainty_score":0.9989183},"labels":[],"label_agreement":null},{"id":"W3007692078","doi":"10.1200/jco.2020.38.6_suppl.113","title":"Systemic therapy for nonmetastatic castrate-resistant prostate cancer (M0 CRPC): A systematic review and network meta-analysis (NMA).","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Enzalutamide; Randomized controlled trial; Meta-analysis; Oncology; Internal medicine; Prostate cancer; Hazard ratio; Adverse effect; Placebo; Confidence interval; Cancer; Alternative medicine; Pathology","score_opus":0.4606557545345176,"score_gpt":0.5830787549479421,"score_spread":0.12242300041342452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007692078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005468441,0.9865951,0.00004950365,0.0035829295,0.00033211164,0.009145365,0.00023713555,0.000010967303,0.000041396594],"genre_scores_gemma":[0.000034657303,0.993927,0.00093672995,0.0016449662,0.00067856786,0.0015582715,0.000047612397,0.00007771067,0.0010944654],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.986264,0.0033552188,0.008511537,0.0006096948,0.00070173916,0.00055780733],"domain_scores_gemma":[0.9819192,0.006655242,0.009115877,0.00049230654,0.0009919624,0.0008254024],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.00994296,0.0006738769,0.03822728,0.00029211206,0.00009036506,0.00004840402,0.00037893472,0.0005509036,0.0001853115],"category_scores_gemma":[0.0021663273,0.00031819695,0.010335054,0.0010277043,0.00023152461,0.00008462507,0.00007230617,0.0015628042,0.000011565015],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009439121,0.00024917236,0.000007230603,0.5788712,0.36898127,0.00080608216,0.000025971167,0.0000025344352,8.627927e-8,0.000009497297,0.0021556385,0.04794739],"study_design_scores_gemma":[0.0021026214,0.005399476,0.0000031406485,0.080368936,0.65331054,0.0005067151,0.00001921257,0.000008551061,4.914598e-8,0.00002415964,0.25807542,0.00018119942],"about_ca_topic_score_codex":0.000016723256,"about_ca_topic_score_gemma":0.000025076244,"teacher_disagreement_score":0.49850228,"about_ca_system_score_codex":0.00045327062,"about_ca_system_score_gemma":0.0068514203,"threshold_uncertainty_score":0.999927},"labels":[],"label_agreement":null},{"id":"W3007700981","doi":"10.1200/jco.2020.38.6_suppl.701","title":"Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Pfizer","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Systemic therapy; Clinical endpoint; Progression-free survival; Surgery; Oncology; Adjuvant therapy; Adjuvant; Retrospective cohort study; Overall survival; Gastroenterology; Cancer; Clinical trial","score_opus":0.13011546843746613,"score_gpt":0.39773260319672904,"score_spread":0.2676171347592629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007700981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949325,0.0013390903,0.000008744918,0.0046072444,0.00016060505,0.00047007366,0.000004582847,0.0000109720295,0.003905422],"genre_scores_gemma":[0.9963634,0.0005100701,0.0007411786,0.0018107514,0.0002952514,0.000006513826,0.000004695461,0.000034818582,0.00023334197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994902,0.0007698153,0.0032161504,0.00027474528,0.00054967974,0.00028759762],"domain_scores_gemma":[0.99442166,0.0018531084,0.0023651766,0.0002645831,0.0005158762,0.0005796006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013496105,0.00025973748,0.0030094394,0.0001949853,0.000018020797,0.0000044589847,0.0002194314,0.00037876258,0.00015451686],"category_scores_gemma":[0.000891696,0.00014842942,0.0005892274,0.0002996016,0.00020132853,0.000056716173,0.000034356224,0.0010616515,0.000022345323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026311869,0.0020611263,0.9407156,0.00009191263,0.0004054124,0.008801028,0.00055329496,0.0000457055,0.008151755,0.000016268756,0.00038721197,0.012458825],"study_design_scores_gemma":[0.040031895,0.089974895,0.85640395,0.00021327146,0.0004649931,0.0011277697,0.00061642623,0.000041588413,0.010200957,0.000015935693,0.0007690447,0.00013929784],"about_ca_topic_score_codex":0.00012576036,"about_ca_topic_score_gemma":0.000020764424,"teacher_disagreement_score":0.08791377,"about_ca_system_score_codex":0.00020474567,"about_ca_system_score_gemma":0.0018590069,"threshold_uncertainty_score":0.60527766},"labels":[],"label_agreement":null},{"id":"W3007782584","doi":"10.1200/jco.2020.38.6_suppl.tps260","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Nuclear medicine; Cancer; Androgen receptor","score_opus":0.08489063859828656,"score_gpt":0.4675145738132983,"score_spread":0.38262393521501176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007782584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97675127,0.0076656262,0.000010167033,0.0067707216,0.000484682,0.008187864,0.000078574034,0.000014689318,0.00003641761],"genre_scores_gemma":[0.9903456,0.0074747535,0.00061560475,0.00090499065,0.0002722829,0.00022583664,0.000039452676,0.000043829008,0.000077678116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902475,0.002696636,0.0050594714,0.00050575775,0.0009594986,0.0005311626],"domain_scores_gemma":[0.99119735,0.0031818755,0.0032005012,0.00022393005,0.0014197481,0.0007765869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005188732,0.0004228901,0.0055327713,0.00029118915,0.0001434757,0.00003265348,0.00022125065,0.00019619988,0.000110764755],"category_scores_gemma":[0.0053477017,0.00024413712,0.00061052426,0.00035046664,0.0006419176,0.00024390443,0.00009687191,0.0010821053,0.0000017203251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8804176,0.013781619,0.036328528,0.00013493186,0.00275502,0.0008255802,0.0042566513,0.00007528574,0.005680191,0.0000021420713,0.00013630568,0.055606138],"study_design_scores_gemma":[0.8818556,0.07121508,0.04133703,0.0005185717,0.0012450872,0.000021334312,0.0007318127,0.0010876507,0.001360258,0.000014756329,0.00041554007,0.00019728119],"about_ca_topic_score_codex":0.0001967149,"about_ca_topic_score_gemma":0.00019039473,"teacher_disagreement_score":0.05743346,"about_ca_system_score_codex":0.0003954813,"about_ca_system_score_gemma":0.0028774103,"threshold_uncertainty_score":0.99556226},"labels":[],"label_agreement":null},{"id":"W3007782755","doi":"10.1200/jco.2020.38.6_suppl.92","title":"Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Abiraterone acetate; Regimen; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.30618120581759056,"score_gpt":0.5441349739554482,"score_spread":0.23795376813785762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007782755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994118,0.00019700047,0.00000854132,0.004633162,0.0000643459,0.00077320414,0.00018425765,0.0000016742094,0.000019866266],"genre_scores_gemma":[0.99684954,0.001624695,0.00076988875,0.00061642885,0.000064084554,0.000014186024,0.000037498623,0.000012057387,0.000011610035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967738,0.00042118636,0.0018134728,0.00013864232,0.00065762963,0.00019531064],"domain_scores_gemma":[0.995555,0.0016660887,0.0014936167,0.00013256147,0.00092109997,0.00023162458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011300556,0.0001352271,0.0010086916,0.00020740452,0.000017382557,0.000005977996,0.000155291,0.00008985277,0.00005009307],"category_scores_gemma":[0.0012301368,0.000062950625,0.00030742286,0.0005101668,0.00020327201,0.00008297265,0.000025282772,0.0004731659,5.143009e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114260994,0.013338933,0.786697,0.00012777047,0.0011124144,0.0001349617,0.0037592868,0.00261711,0.0059570167,0.000017000064,0.0014464812,0.07053104],"study_design_scores_gemma":[0.015996415,0.086109884,0.894047,0.00029805434,0.00013527907,0.0000038023636,0.00020979298,0.00034580048,0.0014708425,0.000023702181,0.0013026772,0.000056732555],"about_ca_topic_score_codex":0.00046666845,"about_ca_topic_score_gemma":0.00006083963,"teacher_disagreement_score":0.10735003,"about_ca_system_score_codex":0.00013484292,"about_ca_system_score_gemma":0.0016423649,"threshold_uncertainty_score":0.2913485},"labels":[],"label_agreement":null},{"id":"W3007807247","doi":"10.1200/jco.2020.38.6_suppl.tps761","title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; Ontario Clinical Oncology Group; Health Sciences Centre; McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Kidney cancer; Renal cell carcinoma; Nivolumab; Contraindication; Internal medicine; Surgery; Sunitinib; Cancer; Oncology; Urology; Immunotherapy; Pathology","score_opus":0.18326508611878303,"score_gpt":0.48248983561421943,"score_spread":0.2992247494954364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007807247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968408,0.0004450426,0.0013133233,0.027201965,0.0010422422,0.0013376212,0.000027204194,0.000010572449,0.0002140137],"genre_scores_gemma":[0.9888082,0.00045198225,0.0071394164,0.0022061276,0.0011588741,0.000046682082,0.000014868546,0.000033150718,0.00014070097],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99657434,0.0004194668,0.0020890739,0.00024263815,0.0004825772,0.00019188822],"domain_scores_gemma":[0.9935027,0.001667572,0.0030019537,0.00014858603,0.001095545,0.0005836869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010912215,0.00018816651,0.001899346,0.00012956504,0.000060439426,0.0000063301836,0.0001195422,0.00016981357,0.00021329893],"category_scores_gemma":[0.0023799532,0.00012553144,0.00053641055,0.000185461,0.00020351916,0.00023458539,0.00001667504,0.00057926896,0.0000017532517],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8653017,0.024816388,0.0006079901,0.00017928898,0.005006455,0.0003484311,0.00050474925,0.000061827166,0.005646134,0.00012673574,0.004463899,0.092936374],"study_design_scores_gemma":[0.55992377,0.40705594,0.0020258122,0.00011381073,0.002674205,0.0002531977,0.00022701197,0.00093776203,0.0034889956,0.00014098412,0.023031393,0.00012712719],"about_ca_topic_score_codex":0.000028957382,"about_ca_topic_score_gemma":0.000004505436,"teacher_disagreement_score":0.38223955,"about_ca_system_score_codex":0.00047321757,"about_ca_system_score_gemma":0.0038018194,"threshold_uncertainty_score":0.67442644},"labels":[],"label_agreement":null},{"id":"W3007839305","doi":"10.1200/jco.2020.38.6_suppl.439","title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Cystectomy; Nivolumab; Bladder cancer; Gemcitabine; Oncology; Internal medicine; Cisplatin; Population; Clinical endpoint; Urology; Chemotherapy; Cancer; Immunotherapy; Clinical trial","score_opus":0.1345553341513558,"score_gpt":0.4258172032994331,"score_spread":0.29126186914807733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007839305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98097944,0.0022256991,0.00009624365,0.013247928,0.0010236787,0.00059194636,0.000117915006,0.000012771318,0.00170438],"genre_scores_gemma":[0.98820996,0.0043109055,0.0011087433,0.0037515846,0.0024220883,0.00002143213,0.000007028176,0.000039686023,0.00012854136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948035,0.0005286764,0.0033125954,0.00046000083,0.00054683187,0.00034838973],"domain_scores_gemma":[0.99180573,0.0047534076,0.0023289751,0.00019578921,0.00040231625,0.0005137974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011953325,0.000272641,0.002179295,0.0001567116,0.00004582456,0.000015537356,0.0001902789,0.0004882414,0.00046431765],"category_scores_gemma":[0.0035212857,0.00021278678,0.0004003951,0.00031954932,0.00023620979,0.00019536314,0.00010235271,0.0011467232,0.000005146878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45334092,0.0044600107,0.18708995,0.00037612693,0.0063689207,0.0030640722,0.0068876487,0.0009832203,0.012744903,0.00003692832,0.011764814,0.3128825],"study_design_scores_gemma":[0.5792053,0.039410494,0.3563605,0.0018320879,0.003014193,0.000073159295,0.0017203215,0.0015261521,0.0019276545,0.0005731174,0.013783561,0.00057349005],"about_ca_topic_score_codex":0.002915338,"about_ca_topic_score_gemma":0.0071768356,"teacher_disagreement_score":0.312309,"about_ca_system_score_codex":0.00025711497,"about_ca_system_score_gemma":0.0045663374,"threshold_uncertainty_score":0.8677193},"labels":[],"label_agreement":null},{"id":"W3007846303","doi":"10.1200/jco.2020.38.6_suppl.348","title":"Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Cohort; Internal medicine; Oncology; Biochemical recurrence; Cancer; Pathology; Prostate cancer","score_opus":0.2682881504647991,"score_gpt":0.5312368767897085,"score_spread":0.26294872632490945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007846303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93268216,0.0017618334,0.000061002993,0.06263648,0.00026519882,0.00070104207,0.00002325453,0.000022273745,0.0018467841],"genre_scores_gemma":[0.97827613,0.000397848,0.008774097,0.010213913,0.001814663,0.000009852341,0.0000148749405,0.000040562798,0.00045807855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608946,0.00043585934,0.002188698,0.00035590623,0.00046095223,0.0004691065],"domain_scores_gemma":[0.9946013,0.002156479,0.0008308822,0.00020371469,0.000751752,0.0014558851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021203621,0.00022408363,0.0020800766,0.00013583402,0.000099571065,0.000037686783,0.00025042554,0.0003142898,0.0003037938],"category_scores_gemma":[0.0030906596,0.0001545765,0.00027904322,0.00028344843,0.00028238265,0.00013278295,0.00019389293,0.001734813,0.00025832164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008058509,0.00076145376,0.8604843,0.00006628353,0.00038724559,0.0007035909,0.00031393996,0.0000056747285,0.0017598688,0.0000040101954,0.009226269,0.11822887],"study_design_scores_gemma":[0.01713305,0.032905895,0.7963264,0.0001017225,0.00044505842,0.00009595591,0.00012277979,0.000110047775,0.0002101226,0.00007550342,0.15231928,0.00015421104],"about_ca_topic_score_codex":0.00013197846,"about_ca_topic_score_gemma":0.0001803255,"teacher_disagreement_score":0.143093,"about_ca_system_score_codex":0.0002528483,"about_ca_system_score_gemma":0.0026136292,"threshold_uncertainty_score":0.75369954},"labels":[],"label_agreement":null},{"id":"W3007846944","doi":"10.1200/jco.2020.38.6_suppl.729","title":"Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cohort; Oncology; Angiogenesis; Stromal cell; Proportional hazards model; RNA-Seq; Internal medicine; Renal cell carcinoma; Cancer research; Gene expression; Transcriptome; Gene; Biology; Genetics","score_opus":0.11423735359886043,"score_gpt":0.3762629841007573,"score_spread":0.26202563050189687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007846944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921269,0.0007741007,0.000104349194,0.0013091376,0.00025969747,0.00085943425,0.000012635814,0.000010031646,0.004543731],"genre_scores_gemma":[0.9942449,0.00006401126,0.003866595,0.0010955893,0.00061304256,0.000013287102,0.000028650918,0.00004769091,0.00002624815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924043,0.0014010747,0.0029069025,0.00050476706,0.0024098605,0.000373112],"domain_scores_gemma":[0.99234635,0.0013742781,0.0030684355,0.00035276893,0.0022096755,0.000648514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034705196,0.00034894093,0.0023150886,0.00021918463,0.000036763435,0.000011719528,0.00028225407,0.00051013223,0.00022838183],"category_scores_gemma":[0.0020697808,0.00022065724,0.0003870565,0.00035776198,0.00025982302,0.00018756288,0.00006796051,0.0016363161,0.000010589813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051986936,0.0024644495,0.9093375,0.00009052814,0.00089261745,0.0016075806,0.00076665066,0.003604765,0.0040745703,0.0000062971944,0.0007751699,0.024392884],"study_design_scores_gemma":[0.05375641,0.05159306,0.8807867,0.0002760238,0.00320245,0.0000570708,0.00026403536,0.0016157381,0.00799281,0.000076548364,0.00016362088,0.00021552856],"about_ca_topic_score_codex":0.00049518823,"about_ca_topic_score_gemma":0.00019744282,"teacher_disagreement_score":0.049128614,"about_ca_system_score_codex":0.0012318107,"about_ca_system_score_gemma":0.005634105,"threshold_uncertainty_score":0.999466},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W3007860954","doi":"10.1200/jco.2020.38.6_suppl.484","title":"An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Urology; Discontinuation; Chemotherapy; Internal medicine; Interim analysis; Clinical endpoint; Adverse effect; Oncology; Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Pembrolizumab","score_opus":0.20180322045614688,"score_gpt":0.4996626713896408,"score_spread":0.297859450933494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007860954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944587,0.00009855132,0.00029936706,0.0019107376,0.0005424013,0.0022226563,0.00021209956,0.000010559441,0.00024497785],"genre_scores_gemma":[0.99464846,0.000065169676,0.0029678014,0.0015301746,0.0006358521,0.000026887794,0.000040641087,0.000044894354,0.000040129235],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9955455,0.00054226123,0.0028097678,0.00041725294,0.0004107829,0.0002744278],"domain_scores_gemma":[0.99553156,0.0007325672,0.0021002041,0.00035668627,0.0006605446,0.0006184381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011105133,0.00025470916,0.0019313489,0.00007749413,0.00006883527,0.000016541719,0.00046887068,0.0002045036,0.00006399906],"category_scores_gemma":[0.00066493265,0.00017040232,0.00019380002,0.00012354244,0.00012695634,0.0003165935,0.000076518685,0.00059403677,0.0000025717545],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56569445,0.169123,0.16018686,0.000044189477,0.0010138329,0.00042708006,0.0014083715,0.000012251602,0.00011922296,0.000001801632,0.0008558523,0.101113126],"study_design_scores_gemma":[0.25493985,0.4128189,0.32734615,0.000048291764,0.00055166736,0.000020660435,0.00040329524,0.00022524588,0.000059046903,0.000004420348,0.0034891025,0.00009336078],"about_ca_topic_score_codex":0.000070675014,"about_ca_topic_score_gemma":0.000030126945,"teacher_disagreement_score":0.31075457,"about_ca_system_score_codex":0.0001540012,"about_ca_system_score_gemma":0.0009854804,"threshold_uncertainty_score":0.6948805},"labels":[],"label_agreement":null},{"id":"W3007869911","doi":"10.1200/jco.2020.38.6_suppl.328","title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Prostate; Urology; Radiation therapy; Cyberknife; Pelvis; Surgery; Cancer; Internal medicine; Radiosurgery","score_opus":0.07591716985570245,"score_gpt":0.42346239813263176,"score_spread":0.3475452282769293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007869911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711926,0.0015004254,0.00008407134,0.026051417,0.00036805676,0.00075108936,0.00002979883,0.0000073012584,0.000015226893],"genre_scores_gemma":[0.9758066,0.020281853,0.0009985097,0.0025067502,0.00032501222,0.0000312944,0.000004132959,0.00002235466,0.000023487451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997858,0.0002281282,0.0012703709,0.00025896795,0.00017801343,0.00020653624],"domain_scores_gemma":[0.9958426,0.002348927,0.0011727456,0.000090218855,0.00015079606,0.00039471523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010244341,0.00017017854,0.0013848589,0.00006640925,0.000032296517,0.000019118568,0.00005242754,0.00015110896,0.000021980457],"category_scores_gemma":[0.000915094,0.00010393379,0.000121827274,0.00009036987,0.00015885473,0.00012763878,0.000026385042,0.0005039511,5.760345e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01274009,0.0006770627,0.83768934,0.0000698851,0.00053094723,0.00018127788,0.00053947384,0.000064687265,0.000030981366,0.0000070989454,0.00012792263,0.1473412],"study_design_scores_gemma":[0.037056003,0.019654052,0.9385863,0.0001628705,0.0004317057,0.000020118407,0.000059700757,0.0006047597,0.000047338435,0.000057314264,0.0032187316,0.00010110874],"about_ca_topic_score_codex":0.00010042593,"about_ca_topic_score_gemma":0.00042065908,"teacher_disagreement_score":0.1472401,"about_ca_system_score_codex":0.00018555301,"about_ca_system_score_gemma":0.000494644,"threshold_uncertainty_score":0.42382967},"labels":[],"label_agreement":null},{"id":"W3007870553","doi":"10.1200/jco.2020.38.6_suppl.120","title":"Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Taxane; Cabazitaxel; Prostate cancer; Docetaxel; Internal medicine; Oncology; Urology; Androgen deprivation therapy; Cancer; Breast cancer","score_opus":0.1391361220339376,"score_gpt":0.4996903683861957,"score_spread":0.3605542463522581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007870553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242085,0.00042696644,0.000058562116,0.0054371664,0.000040190374,0.0014979108,0.000015839807,0.000002622917,0.00009987682],"genre_scores_gemma":[0.99745136,0.0010772552,0.0011156334,0.000059931575,0.0002540434,0.0000052013743,0.000016046517,0.000009350271,0.000011167925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99689263,0.000434468,0.002008134,0.00019404855,0.0003623742,0.00010835404],"domain_scores_gemma":[0.9953154,0.0017669434,0.0020369366,0.00005643163,0.00068131665,0.0001430037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037049565,0.00010787688,0.0011825679,0.0001404555,0.00003304933,0.0000047240533,0.000032310618,0.0001555964,0.0000062153385],"category_scores_gemma":[0.0028159001,0.00007192057,0.00008424831,0.0002099692,0.00028173518,0.00011690219,0.000029833978,0.00035360394,3.8177518e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8844394,0.0032210608,0.0054206485,0.000100543424,0.00024739015,0.000025394196,0.0017954517,0.000021326647,0.017907687,0.000017475864,0.000009557247,0.086794056],"study_design_scores_gemma":[0.7630654,0.19630902,0.02828661,0.0003876804,0.00025680565,0.000020910624,0.00030787452,0.002559381,0.008589663,0.00013702355,0.00002230451,0.000057336485],"about_ca_topic_score_codex":0.00003451048,"about_ca_topic_score_gemma":0.000018558669,"teacher_disagreement_score":0.19308795,"about_ca_system_score_codex":0.000061903025,"about_ca_system_score_gemma":0.00063607295,"threshold_uncertainty_score":0.3371099},"labels":[],"label_agreement":null},{"id":"W3007915670","doi":"10.1200/jco.2020.38.6_suppl.386","title":"Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Internal medicine; Clinical endpoint; Oncology; Medicine; Clinical trial","score_opus":0.11390222209097899,"score_gpt":0.45601007051067366,"score_spread":0.34210784841969466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007915670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98916084,0.0011842287,0.000102413884,0.0091130985,0.00018354734,0.00016706855,0.00001938406,0.000008600203,0.000060813523],"genre_scores_gemma":[0.99431807,0.0001646168,0.0012363008,0.0039042456,0.00033009445,0.000002195741,0.000029851408,0.000009025691,0.0000056015383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765754,0.00037384997,0.0013848133,0.00019456806,0.00023611882,0.00015308759],"domain_scores_gemma":[0.99564314,0.002471689,0.0010092701,0.00017558111,0.00014578583,0.0005545054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044747765,0.00011512175,0.0011632026,0.000052083513,0.000023771296,0.000008913218,0.00015340262,0.00014800784,0.00020414375],"category_scores_gemma":[0.006580332,0.00006158191,0.0005603023,0.0002998693,0.000108953725,0.00008527992,0.00003399098,0.0005196652,0.000014183397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012722516,0.0012902953,0.97662145,0.0000038440166,0.0012641535,0.0013057378,0.00011834922,0.00012266872,0.00002022427,0.000011780582,0.00012222734,0.017847039],"study_design_scores_gemma":[0.0048504528,0.004102416,0.9827122,0.000023712966,0.0047960724,0.000012975916,0.00032305732,0.0007211915,0.000012209343,0.000096929616,0.0022924363,0.000056363257],"about_ca_topic_score_codex":0.00006170812,"about_ca_topic_score_gemma":0.00011789363,"teacher_disagreement_score":0.017790675,"about_ca_system_score_codex":0.000055565422,"about_ca_system_score_gemma":0.00065806444,"threshold_uncertainty_score":0.7877747},"labels":[],"label_agreement":null},{"id":"W3007937037","doi":"10.1200/jco.2020.38.6_suppl.327","title":"Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Radiation therapy; Randomized controlled trial; Oncology; Clinical endpoint; Cancer; Gynecology","score_opus":0.19592806146311179,"score_gpt":0.48174656092871304,"score_spread":0.28581849946560123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007937037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636022,0.004795225,0.0041022333,0.024869958,0.00009392522,0.002389844,0.00012122251,0.000005736734,0.000019647123],"genre_scores_gemma":[0.97207963,0.014315925,0.012192169,0.00091337477,0.00014727154,0.00013386246,0.000028894812,0.000026049964,0.00016282947],"study_design_codex":"meta_analysis","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936839,0.0021511228,0.0031586275,0.00022909313,0.000579679,0.00019758966],"domain_scores_gemma":[0.97134703,0.019020282,0.00800821,0.00013120509,0.0013068669,0.00018638569],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012812131,0.00018941448,0.009098431,0.00021258682,0.000035531433,0.000009411865,0.00010859728,0.00022570988,0.00007459774],"category_scores_gemma":[0.0093996385,0.00008445809,0.003523636,0.0005349758,0.00017393443,0.00011333163,0.000009955851,0.00040066682,1.402661e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38314524,0.00052002043,0.19825436,0.000028483437,0.4094009,0.00001494459,0.0007437503,0.00017246068,0.00029033286,0.000012180224,0.000085612875,0.0073317005],"study_design_scores_gemma":[0.55677164,0.024995975,0.032423023,0.000026019721,0.3797106,0.000001241395,0.0001823684,0.0010210238,0.0039049282,0.0001604145,0.0006749359,0.00012779601],"about_ca_topic_score_codex":0.00011888888,"about_ca_topic_score_gemma":0.00007679826,"teacher_disagreement_score":0.17362641,"about_ca_system_score_codex":0.00019338269,"about_ca_system_score_gemma":0.0016016965,"threshold_uncertainty_score":0.9989446},"labels":[],"label_agreement":null},{"id":"W3007944925","doi":"10.1200/jco.2020.38.6_suppl.690","title":"Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Progression-free survival; Interim analysis; Multivariate analysis; Sunitinib; Proportional hazards model; Urology; Nuclear medicine; Oncology; Clinical trial; Overall survival","score_opus":0.1807682743590052,"score_gpt":0.4563232635441556,"score_spread":0.2755549891851504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007944925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98455906,0.0003164652,0.003181646,0.011110253,0.00021142937,0.00016506301,0.000007865476,0.000007812812,0.00044039296],"genre_scores_gemma":[0.9777624,0.00027166036,0.019368913,0.0020263733,0.00047143703,0.0000011996441,0.00000946494,0.000015330175,0.000073227675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936982,0.0014475114,0.0038549397,0.0003041203,0.0005364987,0.00015876199],"domain_scores_gemma":[0.984936,0.010478028,0.0031515767,0.0002388387,0.00048497735,0.00071055477],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040359944,0.00017582533,0.00289103,0.00017329493,0.000023389208,0.0000067587944,0.000117571304,0.00042036988,0.00015481461],"category_scores_gemma":[0.00950267,0.00010447191,0.0009818889,0.0003544439,0.00033006267,0.000079281126,0.000055606535,0.0009766856,0.000010718436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056817617,0.00078996865,0.90755063,0.000008071289,0.004485058,0.0016072668,0.00012240138,0.000085270534,0.00015145236,0.000004433879,0.0003216908,0.028056147],"study_design_scores_gemma":[0.011013447,0.025513988,0.95276886,0.00004103601,0.007682772,0.000116505056,0.0001044531,0.0007613304,0.00012417532,0.000038616352,0.0017492189,0.00008560467],"about_ca_topic_score_codex":0.000049252118,"about_ca_topic_score_gemma":0.000101089245,"teacher_disagreement_score":0.04580417,"about_ca_system_score_codex":0.00007245523,"about_ca_system_score_gemma":0.0012133499,"threshold_uncertainty_score":0.9988407},"labels":[],"label_agreement":null},{"id":"W3007977248","doi":"10.1200/jco.2020.38.6_suppl.23","title":"FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Ontario Clinical Oncology Group; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Positron emission tomography; Nuclear medicine; Cohort; Standardized uptake value; Prospective cohort study; Cancer; Stage (stratigraphy); PET-CT; Oncology; Internal medicine; Radiology; Androgen receptor","score_opus":0.24960314223376734,"score_gpt":0.5359446657929826,"score_spread":0.28634152355921527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007977248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9309975,0.0026931816,0.00000638812,0.06507714,0.0002149574,0.00027084796,0.000010319104,0.000004160704,0.00072549254],"genre_scores_gemma":[0.9901618,0.005126354,0.0016045276,0.0023397831,0.00040092887,0.000009760968,0.0000026906405,0.000010855724,0.0003433418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777704,0.00026117635,0.001317935,0.00016031221,0.00028195517,0.00020156051],"domain_scores_gemma":[0.9980225,0.0006975066,0.00052686624,0.000065153676,0.00023081533,0.0004571722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281403,0.00009613028,0.00092267955,0.000078256344,0.000023992787,0.000011555579,0.00006604785,0.00006835576,0.00016503558],"category_scores_gemma":[0.0012749417,0.00006078795,0.00013515072,0.0001654624,0.000176128,0.000099926634,0.00003060768,0.0007177171,0.000006822714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060108077,0.002762569,0.53547055,0.0006054995,0.0014981685,0.032240435,0.0026766623,0.00008983988,0.006611084,0.0002866771,0.013012964,0.34463745],"study_design_scores_gemma":[0.04686669,0.03620876,0.81495166,0.0003873053,0.000756252,0.0007634134,0.0013889528,0.0009308532,0.0006043225,0.0008997997,0.09601318,0.00022882379],"about_ca_topic_score_codex":0.00006046815,"about_ca_topic_score_gemma":0.00019079841,"teacher_disagreement_score":0.34440863,"about_ca_system_score_codex":0.00011697991,"about_ca_system_score_gemma":0.002315134,"threshold_uncertainty_score":0.41069484},"labels":[],"label_agreement":null},{"id":"W3007977432","doi":"10.1200/jco.2020.38.6_suppl.296","title":"Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicenter prospective analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ultrasound; Biopsy; Radiology; Magnetic resonance imaging; Prostate cancer; Multiparametric MRI; Prospective cohort study; Prostate; Nuclear medicine; Cancer; Pathology; Internal medicine","score_opus":0.06834707980865913,"score_gpt":0.49947789382797514,"score_spread":0.431130814019316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007977432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967955,0.0024793458,0.010023049,0.018607719,0.0003635158,0.0004596305,0.00000951442,0.000007955556,0.000094284485],"genre_scores_gemma":[0.95535016,0.00074778975,0.040713526,0.0026377845,0.00050428335,0.000006031158,0.000002974925,0.000014357447,0.000023077057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971431,0.00018172458,0.0020072786,0.00023089696,0.00023754436,0.00019946357],"domain_scores_gemma":[0.99358,0.0034155047,0.0019468409,0.000086812826,0.00053991383,0.00043095974],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018295278,0.00012130676,0.002030469,0.00021173862,0.000037084526,0.000012900787,0.000112764705,0.0001115327,0.000023091141],"category_scores_gemma":[0.0119962245,0.00008690875,0.00051092426,0.00042039866,0.00029986777,0.00006906899,0.000039281793,0.000964092,6.017843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002910537,0.0006189957,0.9281254,0.000103195256,0.0013731915,0.000036018802,0.0010318618,0.00041888186,0.001874083,0.00000821982,0.0014461023,0.06205352],"study_design_scores_gemma":[0.014557081,0.0043691783,0.8208048,0.000100015925,0.004113856,0.000050164825,0.00064631354,0.13864806,0.0004893087,0.000052425967,0.016051086,0.00011770967],"about_ca_topic_score_codex":0.000039460647,"about_ca_topic_score_gemma":0.0000070921215,"teacher_disagreement_score":0.13822918,"about_ca_system_score_codex":0.000066349094,"about_ca_system_score_gemma":0.00039479978,"threshold_uncertainty_score":0.99632615},"labels":[],"label_agreement":null},{"id":"W3007977552","doi":"10.1200/jco.2020.38.6_suppl.142","title":"IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; Cancer research; Androgen; Cancer; Potency; Prostate; Cell growth; Small molecule; Medicine; Biology; Pharmacology; In vitro; Internal medicine; Genetics; Hormone","score_opus":0.14780036888435702,"score_gpt":0.49613506772353744,"score_spread":0.34833469883918045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007977552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716881,0.002171642,0.000011691566,0.024629563,0.0004214904,0.0009665053,0.000026167672,0.0000036115034,0.00008121955],"genre_scores_gemma":[0.98556054,0.008704314,0.0029184332,0.0010056737,0.0013420457,0.0001249235,0.000018045695,0.000022590033,0.000303445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730605,0.00023900601,0.0016548545,0.00020583521,0.00031021016,0.0002840448],"domain_scores_gemma":[0.99742645,0.0008966852,0.0008232783,0.000116024545,0.00029073653,0.00044682107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013071786,0.0001468968,0.00109564,0.00006132205,0.000055612534,0.000008400066,0.00014254505,0.0001820523,0.00011534174],"category_scores_gemma":[0.00036386334,0.000076267206,0.00024339223,0.000156762,0.00020836835,0.00007889434,0.000025846432,0.00036036858,0.00000532139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060473237,0.0037994285,0.18871659,0.00011350488,0.00095377036,0.0009261759,0.0076500988,0.000014490608,0.00074960693,0.00002201918,0.0015908434,0.73499024],"study_design_scores_gemma":[0.053391565,0.116874926,0.06148184,0.00028132967,0.00042936395,0.00013638227,0.0017821541,0.00008489639,0.01919946,0.0002448335,0.7458962,0.00019703462],"about_ca_topic_score_codex":0.00009344698,"about_ca_topic_score_gemma":0.00028152805,"teacher_disagreement_score":0.7443054,"about_ca_system_score_codex":0.0004723732,"about_ca_system_score_gemma":0.005168136,"threshold_uncertainty_score":0.91680515},"labels":[],"label_agreement":null},{"id":"W3007983591","doi":"10.1200/jco.2020.38.6_suppl.633","title":"Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Ottawa; Sunnybrook Hospital; University Health Network; Ottawa Hospital; University of Calgary; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Manitoba; BC Cancer Agency; Hôtel-Dieu de Québec; Université Laval; Centre Hospitalier de l’Université de Montréal; University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Discontinuation; Ipilimumab; Tolerability; Nivolumab; Internal medicine; Renal cell carcinoma; Cohort; Hazard ratio; Adverse effect; Cancer; Surgery; Oncology; Immunotherapy; Confidence interval","score_opus":0.11803645853380589,"score_gpt":0.37106025176896706,"score_spread":0.25302379323516117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007983591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98433256,0.00026525033,0.000027896045,0.008839899,0.00047269982,0.00058491767,0.00026155027,0.000005560974,0.005209635],"genre_scores_gemma":[0.9964433,0.00036367268,0.00069439376,0.0020624707,0.0002794459,0.000005881434,0.00010765268,0.000012464304,0.000030729585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503547,0.00065110595,0.0034232712,0.00018462962,0.00047965616,0.0002258576],"domain_scores_gemma":[0.9947178,0.0012925317,0.0023663759,0.00020522108,0.00062203384,0.0007960596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015536976,0.00016677953,0.0012218809,0.00018597335,0.00006328885,0.000014651649,0.00016274567,0.00018415287,0.000039286937],"category_scores_gemma":[0.0025115262,0.00010798516,0.00020174882,0.00033166242,0.00013801854,0.00023036123,0.000046466914,0.0006494222,0.0000062256067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05526923,0.00061072473,0.8555647,0.00053930894,0.000597411,0.00061467336,0.007375294,0.0008268706,0.00005343412,0.00015003447,0.016168755,0.062229533],"study_design_scores_gemma":[0.029305533,0.004797834,0.9451652,0.0003147032,0.0006380008,0.000015073462,0.00073688914,0.0030186097,0.00019150117,0.0000128640395,0.015704103,0.00009966829],"about_ca_topic_score_codex":0.10723529,"about_ca_topic_score_gemma":0.120644696,"teacher_disagreement_score":0.08960049,"about_ca_system_score_codex":0.0015906689,"about_ca_system_score_gemma":0.0062728147,"threshold_uncertainty_score":0.9993607},"labels":[],"label_agreement":null},{"id":"W3008004923","doi":"10.1200/jco.2020.38.6_suppl.406","title":"High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) for relapsed metastatic germ cell tumors (mGCTs): The Alberta experience from 2001 to 2018.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta; Alberta Health Services; London Health Sciences Centre; Western University; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Oncology; Autologous stem-cell transplantation; Surgery","score_opus":0.0759100823230164,"score_gpt":0.3909600793929341,"score_spread":0.3150499970699177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008004923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790098,0.0004241935,0.0037301409,0.01557366,0.00032991898,0.0007436291,0.00002925371,0.000012066701,0.0001473273],"genre_scores_gemma":[0.9727275,0.00024350846,0.016989345,0.009344299,0.00035434405,0.000032775686,0.0000150023225,0.000029810808,0.00026343483],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976205,0.00025768598,0.0012809273,0.00027582305,0.00030666805,0.00025838273],"domain_scores_gemma":[0.99461496,0.0032051485,0.0011652922,0.00019990478,0.0001603212,0.00065435393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041490453,0.00019166445,0.0010893097,0.00003537605,0.00006006169,0.000014525043,0.000203387,0.000118860175,0.00014048985],"category_scores_gemma":[0.00034660794,0.000103059996,0.00035848035,0.00013033423,0.00010974727,0.00007740685,0.000012320538,0.0003434299,0.000028986393],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27883345,0.026206534,0.19253592,0.0010388814,0.0058688694,0.016164182,0.030300645,0.0029257403,0.008006733,0.00018739363,0.043546014,0.39438564],"study_design_scores_gemma":[0.105737105,0.106184274,0.7233951,0.00040162253,0.00829358,0.00073272135,0.0029922288,0.0017766787,0.006005454,0.0003474279,0.04349489,0.0006389358],"about_ca_topic_score_codex":0.0002503286,"about_ca_topic_score_gemma":0.00008956827,"teacher_disagreement_score":0.5308592,"about_ca_system_score_codex":0.00007226388,"about_ca_system_score_gemma":0.0009055382,"threshold_uncertainty_score":0.42026645},"labels":[],"label_agreement":null},{"id":"W3008015121","doi":"10.1200/jco.19.02381","title":"Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Diarrhea; Internal medicine; McNemar's test; Fecal incontinence; Surgery","score_opus":0.1212198213355496,"score_gpt":0.445788081036933,"score_spread":0.3245682597013834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008015121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570683,0.00022449791,0.00017992409,0.04024642,0.0006877347,0.0012730807,0.000009830949,0.000021374872,0.00028878788],"genre_scores_gemma":[0.9840578,0.00010876667,0.0020206703,0.013175376,0.0005431756,0.000018315142,0.000012657965,0.000030255227,0.000032971668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942862,0.0006253726,0.0033861664,0.00045953394,0.0009140189,0.00032873463],"domain_scores_gemma":[0.99251175,0.0023950634,0.003273209,0.00039025702,0.0008694945,0.0005602115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001940385,0.00029632507,0.003455076,0.00010432981,0.000056207482,0.00001629604,0.00022732068,0.0002584352,0.00018854997],"category_scores_gemma":[0.0024919617,0.00013479585,0.0003468209,0.0005465584,0.00024426077,0.0000827893,0.000074760086,0.001397295,0.0000030534452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11204043,0.0049365694,0.7932074,0.000007090018,0.0041762874,0.028935691,0.0015018749,0.00004910279,0.000113491726,7.6237677e-7,0.0008836655,0.05414761],"study_design_scores_gemma":[0.07744594,0.14794256,0.74760807,0.00007787879,0.0011855656,0.0007121429,0.002352069,0.00004798412,0.00007590704,0.000033948552,0.022365462,0.00015248716],"about_ca_topic_score_codex":0.0006466802,"about_ca_topic_score_gemma":0.001072875,"teacher_disagreement_score":0.14300598,"about_ca_system_score_codex":0.0008437296,"about_ca_system_score_gemma":0.002299677,"threshold_uncertainty_score":0.60706294},"labels":[],"label_agreement":null},{"id":"W3008055052","doi":"10.1200/jco.2020.38.6_suppl.715","title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CDKN2A; Cancer research; Immune checkpoint; Medicine; BAP1; Immune system; Transcriptome; Tumor microenvironment; CD8; Downregulation and upregulation; Cancer; Immunotherapy; Oncology; Internal medicine; Biology; Melanoma; Gene expression; Gene; Immunology","score_opus":0.04529062756487279,"score_gpt":0.3560150539376791,"score_spread":0.31072442637280634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008055052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054796,0.0002573687,0.0001966958,0.008104067,0.00017813744,0.0006525336,0.000015891957,0.0000043336104,0.000043028296],"genre_scores_gemma":[0.9940554,0.000074334406,0.0048502586,0.0007478823,0.00020121182,0.00000808328,0.0000034056518,0.000023643413,0.00003577741],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954428,0.0007443456,0.0029127053,0.0002953941,0.00039526244,0.00020951079],"domain_scores_gemma":[0.9962373,0.0004845816,0.001838413,0.00014206902,0.0005951207,0.00070254446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001817635,0.000218142,0.0018210345,0.00022773346,0.00002557619,0.000007772068,0.00012492413,0.0002533204,0.000013793392],"category_scores_gemma":[0.0022903236,0.0001571565,0.0003576297,0.00023641653,0.00018905006,0.00008234971,0.00017063649,0.00044793013,0.000002375683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032165486,0.0006504392,0.06893553,0.00012256367,0.0001008877,0.0010668271,0.0010330079,0.0000018131748,0.8812807,0.0000012000177,0.000045146124,0.014596406],"study_design_scores_gemma":[0.0033380124,0.032048743,0.45788142,0.00018460772,0.00025741634,0.0002726906,0.0001891371,0.00004577872,0.5055474,0.000005373603,0.00015213546,0.00007726972],"about_ca_topic_score_codex":0.000025482363,"about_ca_topic_score_gemma":0.0000032941841,"teacher_disagreement_score":0.38894588,"about_ca_system_score_codex":0.000101192425,"about_ca_system_score_gemma":0.00069584016,"threshold_uncertainty_score":0.64086556},"labels":[],"label_agreement":null},{"id":"W3008128954","doi":"10.1200/jco.2020.38.6_suppl.221","title":"Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia; Health Sciences Centre; University of Toronto; Queen's University; London Health Sciences Centre; Okanagan University College; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Salvage therapy; Prostate cancer; Propensity score matching; Androgen deprivation therapy; Cryotherapy; Internal medicine; Oncology; Prostatectomy; Radiation therapy; Clinical endpoint; Surgery; Proportional hazards model; Cohort; Cancer; Urology; Randomized controlled trial; Chemotherapy","score_opus":0.21207700826277734,"score_gpt":0.5214015873049678,"score_spread":0.30932457904219046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008128954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.911867,0.06963088,0.0006621222,0.015144839,0.001344335,0.001079069,0.00003990503,0.000009535386,0.00022229411],"genre_scores_gemma":[0.9859989,0.010163695,0.0013448709,0.0011169848,0.0011987464,0.000049174243,0.0000063839984,0.000017856462,0.00010338645],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99743205,0.00031739983,0.0015116907,0.00018403887,0.00033066777,0.00022415302],"domain_scores_gemma":[0.995791,0.0022488213,0.0010010104,0.00010414666,0.0005269325,0.00032809106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094943604,0.00014113837,0.0017219118,0.00006253155,0.000023706254,0.00000560475,0.00012848832,0.00017876552,0.00009288582],"category_scores_gemma":[0.000259439,0.00008509406,0.00050756696,0.0001242491,0.00038590524,0.000067481065,0.000026898379,0.00057710276,0.00000296691],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51364696,0.0020211784,0.014953101,0.00068544276,0.0037418744,0.00028013342,0.0046538915,0.00006913432,0.0016685822,0.000025013096,0.008757087,0.44949758],"study_design_scores_gemma":[0.22561224,0.23780456,0.28960392,0.0018175415,0.002156291,0.00013039506,0.0029267082,0.000893926,0.003028735,0.00007796435,0.23550436,0.0004433608],"about_ca_topic_score_codex":0.0000048286047,"about_ca_topic_score_gemma":0.000006283307,"teacher_disagreement_score":0.4490542,"about_ca_system_score_codex":0.00032799065,"about_ca_system_score_gemma":0.002172252,"threshold_uncertainty_score":0.38534817},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W3008151045","doi":"10.1200/jco.2020.38.6_suppl.568","title":"Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Windsor Regional Hospital; University of Windsor","funders":"Windsor Cancer Centre Foundation","keywords":"HRAS; Bladder cancer; Medicine; CDKN2A; Cancer research; PDGFRA; Cancer; Oncology; Neuroblastoma RAS viral oncogene homolog; Cystectomy; KRAS; Internal medicine; Colorectal cancer","score_opus":0.116224501610971,"score_gpt":0.4256094270890541,"score_spread":0.30938492547808305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008151045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9303068,0.0019299043,0.00016866504,0.06369559,0.0014293484,0.0022266016,0.00014741815,0.000020401929,0.0000752716],"genre_scores_gemma":[0.9347865,0.0010200217,0.011388853,0.049444597,0.0030359735,0.00017200311,0.000010530024,0.00007034757,0.00007120511],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99545115,0.00046470185,0.0022262265,0.0006017778,0.00070933206,0.0005468282],"domain_scores_gemma":[0.99375415,0.0016021312,0.0014502666,0.0003614773,0.0014488015,0.0013831592],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004930488,0.00040421454,0.0021259428,0.00017615387,0.00011784648,0.000019508336,0.00054450496,0.0004657772,0.00035933268],"category_scores_gemma":[0.0018489069,0.00025584866,0.00052719994,0.00061368314,0.00018909019,0.00011196136,0.00031845146,0.0012221244,0.00004039723],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017646858,0.002118641,0.026760327,0.0002591541,0.0038949524,0.0014587124,0.008152946,0.0052208635,0.72382075,0.000014443331,0.032788035,0.17786431],"study_design_scores_gemma":[0.019952368,0.062774114,0.5585254,0.0011186652,0.0029057253,0.00013619958,0.0018516255,0.00012935018,0.306021,0.0001275354,0.04569031,0.0007677457],"about_ca_topic_score_codex":0.00039724,"about_ca_topic_score_gemma":0.00065723475,"teacher_disagreement_score":0.53176504,"about_ca_system_score_codex":0.00039977476,"about_ca_system_score_gemma":0.0043283636,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W3008153451","doi":"10.1200/jco.2020.38.6_suppl.145","title":"ADRB2 expression in progressive metastatic castration-resistant prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Hazard ratio; Cancer; Internal medicine; Proportional hazards model; Laser capture microdissection; Oncology; Biopsy; Prostatectomy; Perineural invasion; Prostate biopsy; Gene expression; Pathology; Biology; Gene","score_opus":0.24292302609369104,"score_gpt":0.5439417604283263,"score_spread":0.3010187343346353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008153451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94927514,0.005833428,0.0000233968,0.043088302,0.00037546043,0.0006142248,0.000011862478,0.0000087679155,0.00076940097],"genre_scores_gemma":[0.9918316,0.0017541082,0.0038613589,0.0016361336,0.00064098346,0.00003083523,0.000005153695,0.000014775949,0.00022503937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99708194,0.00038096373,0.0016746137,0.00018728735,0.00042903886,0.00024617204],"domain_scores_gemma":[0.997453,0.00055578013,0.00099979,0.00008834885,0.00039141098,0.0005117017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011676326,0.00011533238,0.0010487401,0.00008796061,0.000029786619,0.000011439085,0.00011198598,0.00012754039,0.0002610756],"category_scores_gemma":[0.0017582336,0.00006939663,0.00022513293,0.00023072172,0.00016612427,0.00013767419,0.00003926184,0.00089684734,0.000010886257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1424973,0.007008103,0.29902455,0.000849189,0.0014059601,0.04596166,0.004755009,0.00023042642,0.041625008,0.00013493322,0.026734155,0.4297737],"study_design_scores_gemma":[0.113636605,0.11439365,0.6177959,0.0028953785,0.0013503713,0.0006431861,0.0039150184,0.0014234968,0.023387687,0.0012181939,0.11874712,0.0005934361],"about_ca_topic_score_codex":0.000015508427,"about_ca_topic_score_gemma":0.000029910721,"teacher_disagreement_score":0.42918026,"about_ca_system_score_codex":0.0001783717,"about_ca_system_score_gemma":0.003397786,"threshold_uncertainty_score":0.6027527},"labels":[],"label_agreement":null},{"id":"W3008168710","doi":"10.1200/jco.2020.38.6_suppl.30","title":"Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Zoledronic acid; Internal medicine; Hazard ratio; Prostate cancer; Denosumab; Concomitant; Proportional hazards model; Cohort; Prednisone; Docetaxel; Gastroenterology; Urology; Surgery; Cancer; Androgen deprivation therapy; Osteoporosis; Confidence interval","score_opus":0.23986552041939718,"score_gpt":0.5165605500960492,"score_spread":0.276695029676652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008168710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712687,0.0010067262,0.00010886412,0.025004633,0.0010030445,0.0012405955,0.00032050448,0.000013266465,0.000033650198],"genre_scores_gemma":[0.981696,0.010110508,0.005665957,0.0009917454,0.0010457514,0.00007570771,0.00021431939,0.000042036565,0.00015797695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460375,0.0004959971,0.003339112,0.0004616956,0.0007351943,0.00036422256],"domain_scores_gemma":[0.994367,0.0018245319,0.0019957635,0.00025290053,0.0010176542,0.00054213713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026564181,0.00026884093,0.0019091049,0.0002068093,0.00005210565,0.00002627233,0.00021368856,0.00024046445,0.00014949543],"category_scores_gemma":[0.0015748764,0.00017049603,0.00041425097,0.00022750099,0.00042609626,0.00050681195,0.00007021806,0.00083043403,0.0000046441887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44557294,0.0068035885,0.48427314,0.00014864902,0.0021481763,0.0010368277,0.0005063086,0.00016976037,0.0062797237,0.000018955183,0.00095590146,0.05208603],"study_design_scores_gemma":[0.22792651,0.10976205,0.628503,0.0006144313,0.0010570353,0.000055988497,0.0006103077,0.0013104314,0.007472146,0.00005895924,0.022252202,0.00037694178],"about_ca_topic_score_codex":0.00019403851,"about_ca_topic_score_gemma":0.0016278153,"teacher_disagreement_score":0.21764645,"about_ca_system_score_codex":0.00022138975,"about_ca_system_score_gemma":0.001586036,"threshold_uncertainty_score":0.6952626},"labels":[],"label_agreement":null},{"id":"W3008176347","doi":"10.1200/jco.2020.38.6_suppl.319","title":"Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: A toxicity and quality-of-life comparison of two prospective trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; SABR volatility model; Tolerability; Toxicity; Prostate; Urology; Clinical trial; Cohort; Internal medicine; Oncology; Surgery; Adverse effect; Cancer","score_opus":0.4902043680764249,"score_gpt":0.6104771879201041,"score_spread":0.12027281984367916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008176347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733732,0.0010127905,0.000071313494,0.023745429,0.00018725706,0.0015096081,0.000036948422,0.0000024830936,0.000060974467],"genre_scores_gemma":[0.99617934,0.00012447138,0.001295791,0.00210078,0.0002611462,0.000027247115,7.561544e-7,0.000008045274,0.0000024421809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99121416,0.0026806132,0.0051777125,0.00023222629,0.0005175472,0.00017773178],"domain_scores_gemma":[0.97017425,0.023364414,0.0051866793,0.00022033312,0.0007543607,0.00029993246],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015353303,0.00013633852,0.0031498543,0.000035928944,0.000035423287,0.0000058443165,0.00016174998,0.00008368013,0.000020167046],"category_scores_gemma":[0.069055125,0.00006592907,0.0003934,0.00022910135,0.0004289073,0.000039255043,0.00010782084,0.00071086054,5.856722e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038130324,0.0042148554,0.8846269,0.00020956107,0.00043088102,0.000040288232,0.005916119,0.0017571058,0.001205827,0.00014343607,0.000116694915,0.063208],"study_design_scores_gemma":[0.033813685,0.09299806,0.85552955,0.0004408527,0.0007099801,0.000029063433,0.0027709354,0.006900966,0.0054511656,0.0007924766,0.00043535666,0.000127929],"about_ca_topic_score_codex":0.00021078027,"about_ca_topic_score_gemma":0.0004429362,"teacher_disagreement_score":0.088783205,"about_ca_system_score_codex":0.00014908327,"about_ca_system_score_gemma":0.001405913,"threshold_uncertainty_score":0.9387866},"labels":[],"label_agreement":null},{"id":"W3008187114","doi":"10.1200/jco.2020.38.6_suppl.tps586","title":"INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Atezolizumab; Gemcitabine; Clinical endpoint; Urology; Oncology; Radiation therapy; Chemoradiotherapy; Internal medicine; Surgery; Cancer; Randomized controlled trial; Immunotherapy; Pembrolizumab","score_opus":0.1448530786885959,"score_gpt":0.4884129881730352,"score_spread":0.34355990948443926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008187114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844101,0.0013304525,0.0006275542,0.009420285,0.001156857,0.0021966374,0.00001909332,0.000013204805,0.0008257903],"genre_scores_gemma":[0.9851748,0.007149054,0.00091928383,0.004861124,0.0016912039,0.00007287092,0.0000048932393,0.00003769667,0.00008909143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99453354,0.00080872525,0.0035203344,0.00030890846,0.0005387335,0.000289745],"domain_scores_gemma":[0.9938902,0.0021926155,0.0027090958,0.00018182836,0.00044739596,0.0005788103],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016703134,0.0002801911,0.005781233,0.00012481287,0.000023184708,0.000008453324,0.00020653955,0.00033918556,0.001144224],"category_scores_gemma":[0.002200655,0.00015489798,0.0006798873,0.0003021377,0.0005378962,0.00011294335,0.00003034441,0.0009172978,0.0000041596345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91000307,0.004194538,0.0014322298,0.000060891467,0.0016948265,0.0006529944,0.0014584005,0.000014124408,0.00019079496,0.000013654351,0.0010686568,0.07921584],"study_design_scores_gemma":[0.9284101,0.057919323,0.00028428953,0.00028877702,0.0011761758,0.00008818666,0.00037487084,0.00031212933,0.0009265507,0.000033855522,0.010035852,0.00014988336],"about_ca_topic_score_codex":0.00028170628,"about_ca_topic_score_gemma":0.0003138692,"teacher_disagreement_score":0.079065956,"about_ca_system_score_codex":0.00023983885,"about_ca_system_score_gemma":0.006780996,"threshold_uncertainty_score":0.99976885},"labels":[],"label_agreement":null},{"id":"W3008234090","doi":"10.1200/jco.2020.38.6_suppl.610","title":"A novel clinical decision aid to support personalized treatment selection for patients with CT1 renal cortical masses: Results from a multi-institutional competing risks analysis including performance status and comorbidity.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Logistic regression; Nephrectomy; Comorbidity; Performance status; Internal medicine; Charlson comorbidity index; Surgery; Cancer; Kidney","score_opus":0.31356580220146196,"score_gpt":0.4835719479463956,"score_spread":0.1700061457449336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008234090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658512,0.000040884057,0.031694658,0.0012265366,0.00026129186,0.00070760306,0.00014777028,0.00001568599,0.000054370492],"genre_scores_gemma":[0.7956091,0.00021442519,0.20256853,0.00080951455,0.00062417606,0.000013351647,0.000131565,0.00001685294,0.000012465824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946034,0.00037574928,0.0033706916,0.0005945718,0.00068295957,0.00037265196],"domain_scores_gemma":[0.9887514,0.0072226943,0.0016960377,0.00015828435,0.0008793546,0.0012922046],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021952179,0.00029489913,0.002325385,0.00020279622,0.00019779042,0.000028152872,0.000110048,0.00032023902,0.00004416078],"category_scores_gemma":[0.008514396,0.0001827318,0.00073412195,0.00039736106,0.00026492795,0.00014558196,0.00008656002,0.00074628764,0.0000067215433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08981927,0.0037448693,0.8604917,0.000013833787,0.002541289,0.000102619495,0.00030298586,0.0007115218,0.00009899486,0.0000048906372,0.000104785584,0.04206326],"study_design_scores_gemma":[0.06697776,0.06919518,0.82883483,0.00010344038,0.0044896626,0.000050454575,0.00010355315,0.021619298,0.000041288837,0.0000026163839,0.008426424,0.00015549094],"about_ca_topic_score_codex":0.00014470806,"about_ca_topic_score_gemma":0.00023284917,"teacher_disagreement_score":0.17087387,"about_ca_system_score_codex":0.0006821454,"about_ca_system_score_gemma":0.0018821281,"threshold_uncertainty_score":0.9998373},"labels":[],"label_agreement":null},{"id":"W3008249356","doi":"10.1200/jco.2020.38.6_suppl.309","title":"The deleterious association between proton pump inhibitors and prostate cancer specific death.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Proportional hazards model; Pantoprazole; Oncology; Cancer; Comorbidity; Population; Prostate biopsy","score_opus":0.059700943006919305,"score_gpt":0.3893040543724121,"score_spread":0.3296031113654928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008249356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750255,0.00465792,0.000054169326,0.01381169,0.0059341956,0.00028669808,0.000012259551,0.0000033176893,0.00021426217],"genre_scores_gemma":[0.8709866,0.05137004,0.00025602418,0.0024545947,0.07455049,0.00002593794,0.000005229792,0.000021987964,0.00032914567],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980886,0.00030688383,0.0010485839,0.00017527863,0.0001851982,0.0001954556],"domain_scores_gemma":[0.997922,0.00032563217,0.0011939221,0.000088235174,0.00024250853,0.00022772065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015958664,0.00010015128,0.00048733014,0.00001418689,0.00007903931,0.000027829185,0.00014970102,0.00029538336,0.000006378092],"category_scores_gemma":[0.001512666,0.00006582051,0.0001985135,0.000048958074,0.000088318506,0.000007439345,0.00007521145,0.00041165177,0.0000024509945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002087371,0.000113114016,0.4691698,0.000033023367,0.0005622972,0.0000027708052,0.00026057567,0.000013855153,0.01826549,0.000026775366,0.09523167,0.41423327],"study_design_scores_gemma":[0.0015990018,0.0019509686,0.06756227,0.000010423052,0.00007641368,0.000006772918,0.000040232153,0.0000031278516,0.0022112138,0.000062312836,0.926402,0.00007527397],"about_ca_topic_score_codex":0.000013457382,"about_ca_topic_score_gemma":0.000046785273,"teacher_disagreement_score":0.8311703,"about_ca_system_score_codex":0.00004808803,"about_ca_system_score_gemma":0.00065422367,"threshold_uncertainty_score":0.26840827},"labels":[],"label_agreement":null},{"id":"W3008273616","doi":"10.1200/jco.2020.38.6_suppl.673","title":"Efficacy of immune checkpoint inhibitors (ICI) treatment in special populations of metastatic renal cell carcinoma (mRCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Creatinine; Renal cell carcinoma; Renal function; Internal medicine; Urology; Oncology; Gastroenterology","score_opus":0.2037736878302232,"score_gpt":0.42828534458615936,"score_spread":0.22451165675593615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008273616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915041,0.00083790516,0.000031444015,0.0037854323,0.0005890427,0.0004894589,0.0000086641785,0.000003852017,0.0027501204],"genre_scores_gemma":[0.9925605,0.00012689015,0.0054005827,0.00013965163,0.0016522389,0.000004122374,0.000009895447,0.000022059361,0.00008402643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99291766,0.0005576973,0.005562178,0.00023500396,0.000486284,0.0002411906],"domain_scores_gemma":[0.99438316,0.0012953326,0.003325652,0.00024105699,0.0003147677,0.00044000542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012943024,0.00022491145,0.0026785422,0.00024415928,0.000018194123,0.0000030079636,0.0001524213,0.00021221547,0.00024926095],"category_scores_gemma":[0.0017275686,0.00015629409,0.0013365004,0.00033587846,0.00021979213,0.000067774585,0.0000571254,0.0005903425,0.0000124459675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0513687,0.0364591,0.7119582,0.0005531272,0.00175329,0.008640529,0.0050259484,0.0016184151,0.07835172,0.00029119707,0.0018162514,0.10216351],"study_design_scores_gemma":[0.029458752,0.049180076,0.85643715,0.000118639386,0.0014561263,0.00015655706,0.0003388546,0.0001323105,0.060468525,0.00011486946,0.0020139485,0.00012421425],"about_ca_topic_score_codex":0.0001883226,"about_ca_topic_score_gemma":0.000060684244,"teacher_disagreement_score":0.14447892,"about_ca_system_score_codex":0.00039995855,"about_ca_system_score_gemma":0.0016883663,"threshold_uncertainty_score":0.63734883},"labels":[],"label_agreement":null},{"id":"W3008280888","doi":"10.1200/jco.2020.38.6_suppl.481","title":"Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Renal cell carcinoma; Internal medicine; Incidence (geometry); Cohort; Pneumonitis; Cumulative incidence; Oncology; Gastroenterology; Lung","score_opus":0.03908389342846681,"score_gpt":0.3479053474469485,"score_spread":0.3088214540184817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008280888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931115,0.00049368263,0.000018808722,0.0054410556,0.00025924057,0.00027061944,0.00001254731,0.0000052058913,0.0003873384],"genre_scores_gemma":[0.9970972,0.00026271818,0.00020432666,0.001814612,0.0005075392,0.000004044236,0.00001781133,0.000016210099,0.00007553169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662995,0.00033680862,0.002391031,0.00018992576,0.00026335975,0.00018894474],"domain_scores_gemma":[0.99763113,0.0003712955,0.001385229,0.000091691385,0.00024065343,0.0002799754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001360559,0.00015522244,0.001040885,0.000094036106,0.000030610336,0.00000510872,0.00008403527,0.0002258126,0.00020393402],"category_scores_gemma":[0.00039766525,0.000104058636,0.00035676235,0.00016271997,0.0002615185,0.0000961671,0.000034756515,0.0007375891,0.0000064649034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17521963,0.0039659967,0.7341563,0.00010491545,0.00053798256,0.0018438052,0.00057151035,0.000031174324,0.061974443,0.00000816671,0.0012070804,0.020379024],"study_design_scores_gemma":[0.046851326,0.026182376,0.90948814,0.00010779003,0.00016341687,0.00007764757,0.00010434489,0.000053482454,0.00817887,0.000013379751,0.0086661745,0.00011304299],"about_ca_topic_score_codex":0.00006573345,"about_ca_topic_score_gemma":0.000014733621,"teacher_disagreement_score":0.17533188,"about_ca_system_score_codex":0.00014914069,"about_ca_system_score_gemma":0.0009566779,"threshold_uncertainty_score":0.42433882},"labels":[],"label_agreement":null},{"id":"W3008324302","doi":"10.1200/jco.2020.38.6_suppl.753","title":"Impact of metastasectomy on progression free and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Metastasectomy; Renal cell carcinoma; Internal medicine; Cohort; Metastasis; Oncology; Urology; Surgery; Gastroenterology; Cancer","score_opus":0.13093625353236332,"score_gpt":0.4454070677849111,"score_spread":0.3144708142525478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008324302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521893,0.00058919255,0.000017892928,0.0028202198,0.00010577659,0.0002638533,0.000037624537,0.0000018946093,0.0009446157],"genre_scores_gemma":[0.99772906,0.00008473792,0.001814725,0.00020513216,0.00011847043,0.0000017759372,0.000006432401,0.000012418071,0.000027220167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952676,0.0011291062,0.0024584522,0.0002361125,0.00071588863,0.00019280124],"domain_scores_gemma":[0.99381155,0.0020427636,0.003062604,0.00041450048,0.00030813203,0.00036047216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024236594,0.00018294727,0.0025695716,0.00025097834,0.000016131504,0.000004176051,0.00026224979,0.00015585632,0.00008697522],"category_scores_gemma":[0.0034813187,0.00009254877,0.0014233008,0.00061889546,0.00025140634,0.000050543753,0.00012432637,0.0008027534,5.4828257e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012443638,0.0024635321,0.97166276,0.00012376292,0.0028555258,0.0010252647,0.00022195696,0.00044806694,0.0032041774,0.00002825585,0.000904517,0.0046185264],"study_design_scores_gemma":[0.010238642,0.02384099,0.95805514,0.000083381216,0.005245631,0.00005209871,0.000055846107,0.00044382192,0.0016786854,0.00007025178,0.00017018916,0.0000653084],"about_ca_topic_score_codex":0.00016256837,"about_ca_topic_score_gemma":0.00007328573,"teacher_disagreement_score":0.021377457,"about_ca_system_score_codex":0.00017136567,"about_ca_system_score_gemma":0.0012290514,"threshold_uncertainty_score":0.4167715},"labels":[],"label_agreement":null},{"id":"W3008352064","doi":"10.1200/jco.2020.38.6_suppl.508","title":"Perioperative chemotherapy for upper tract urothelial carcinoma: A microsimulation Markov model.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Perioperative; Chemotherapy; Bladder cancer; Adverse effect; Gemcitabine; Surgery; Oncology; Internal medicine; Cancer; Urology","score_opus":0.12890917517578315,"score_gpt":0.45625398058955896,"score_spread":0.3273448054137758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008352064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391284,0.00039289054,0.0099007,0.04652328,0.00062674657,0.0008058721,0.00003689475,0.000013929892,0.0025712573],"genre_scores_gemma":[0.96043175,0.00016311923,0.016929109,0.019751098,0.0023547371,0.000011280843,0.0000057038233,0.000029086961,0.0003241134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798524,0.00012307739,0.0013098106,0.00019741821,0.00020391957,0.00018050443],"domain_scores_gemma":[0.9980063,0.0005254107,0.0006037575,0.000092822054,0.00040530215,0.0003664112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060160854,0.00014621892,0.0011114891,0.00004217805,0.000047000758,0.000010751672,0.00009712764,0.0002814491,0.0002074854],"category_scores_gemma":[0.0007443451,0.000101086385,0.0006776687,0.0000649116,0.00009107398,0.00010673893,0.000011929561,0.00046369046,0.000006191904],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15534279,0.009341117,0.2334025,0.00023662516,0.0021053848,0.0005567523,0.0073760278,0.0012932773,0.02812759,0.00026930115,0.02850378,0.5334448],"study_design_scores_gemma":[0.19107729,0.1272055,0.2751569,0.00014550511,0.0026476078,0.0006055811,0.0006900015,0.10162656,0.008465851,0.0006820364,0.2910518,0.00064537703],"about_ca_topic_score_codex":0.0000054278275,"about_ca_topic_score_gemma":0.0000015168754,"teacher_disagreement_score":0.5327995,"about_ca_system_score_codex":0.00011573619,"about_ca_system_score_gemma":0.0019229909,"threshold_uncertainty_score":0.41221833},"labels":[],"label_agreement":null},{"id":"W3008352324","doi":"10.1200/jco.2020.38.6_suppl.78","title":"Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Enzalutamide; Cabazitaxel; Prostate cancer; Abiraterone; Oncology; Internal medicine; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.20814875585988316,"score_gpt":0.5075707712043398,"score_spread":0.29942201534445667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008352324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95547795,0.0016362811,0.0002971157,0.03862436,0.0007574793,0.002592849,0.0005128422,0.000014346852,0.00008679492],"genre_scores_gemma":[0.99131083,0.0013037139,0.0037515936,0.0019520683,0.00058640266,0.00021685127,0.00006723112,0.000041285446,0.0007700333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968561,0.00020524049,0.0017383219,0.00032497026,0.0004231082,0.0004522648],"domain_scores_gemma":[0.99480546,0.0022446155,0.001012915,0.00012691895,0.00078136456,0.0010287062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007429868,0.00025362615,0.0019283231,0.000082001876,0.00010349192,0.000020364696,0.00009884145,0.00011677408,0.000014561113],"category_scores_gemma":[0.0024289258,0.00014766149,0.001398452,0.00012088159,0.00012396435,0.00013505269,0.000029256986,0.00029559704,0.0000045534616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30936524,0.013514519,0.35523123,0.00072851486,0.019088829,0.005223122,0.0022147247,0.00013719397,0.0014788723,0.00013799052,0.013872254,0.27900752],"study_design_scores_gemma":[0.18932784,0.15352952,0.55535203,0.0002611671,0.0105902925,0.000019958516,0.0011047004,0.0014346162,0.0006934646,0.00067660684,0.08651896,0.00049085927],"about_ca_topic_score_codex":0.000029238967,"about_ca_topic_score_gemma":0.000024379839,"teacher_disagreement_score":0.27851665,"about_ca_system_score_codex":0.0005235533,"about_ca_system_score_gemma":0.0029789326,"threshold_uncertainty_score":0.6021461},"labels":[],"label_agreement":null},{"id":"W3008352325","doi":"10.1200/jco.2020.38.6_suppl.36","title":"Edmonton Prostate Interdisciplinary Cancer Clinic (EPICC): Real-world efficacy outcomes of a multidisciplinary clinic for metastatic castration-resistant prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Janssen Biotech","keywords":"Medicine; Enzalutamide; Prostate cancer; Cancer; Internal medicine; Oncology; Chemotherapy; Abiraterone acetate; Docetaxel; Pharmacy; Radiation therapy; Androgen deprivation therapy; Androgen receptor; Family medicine","score_opus":0.23205137625897612,"score_gpt":0.561041721982338,"score_spread":0.32899034572336194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008352325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9270348,0.0026620112,0.000033786535,0.06499972,0.0014756781,0.002652676,0.00029186855,0.000030411102,0.00081902766],"genre_scores_gemma":[0.9765199,0.0101594,0.004866849,0.0009827486,0.001187247,0.0002647158,0.00004980211,0.000084242645,0.0058851074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918409,0.0005353661,0.0056718127,0.00058750587,0.00073409366,0.000630319],"domain_scores_gemma":[0.98853135,0.0047971373,0.004092839,0.00033977654,0.0012877019,0.0009511688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034718956,0.00040393422,0.0036032777,0.00027248915,0.00015071838,0.000021718144,0.00037784432,0.00026497646,0.00046341558],"category_scores_gemma":[0.0019875704,0.00026251384,0.0014835568,0.0005029592,0.00061829394,0.00026077105,0.00029232752,0.0013403256,0.00001963215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19778737,0.008722479,0.6175331,0.0020130214,0.007146056,0.0017803749,0.0053800754,0.00019027462,0.0031953633,0.00003964598,0.02204569,0.13416652],"study_design_scores_gemma":[0.051709786,0.053728297,0.87700504,0.0010418252,0.0031714707,0.000030982927,0.0016643549,0.0006865753,0.00090793165,0.000624731,0.00902851,0.00040050075],"about_ca_topic_score_codex":0.00017200538,"about_ca_topic_score_gemma":0.0010313343,"teacher_disagreement_score":0.25947192,"about_ca_system_score_codex":0.000446252,"about_ca_system_score_gemma":0.006456487,"threshold_uncertainty_score":0.9999827},"labels":[],"label_agreement":null},{"id":"W3008366344","doi":"10.1200/jco.19.01776","title":"Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Cohort; Radiation therapy; Oncology; Atypical teratoid rhabdoid tumor; Internal medicine; Chemotherapy; Hazard ratio; Surgical oncology; Surgery; Confidence interval","score_opus":0.04812531713970524,"score_gpt":0.3846029662468026,"score_spread":0.3364776491070974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008366344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919624,0.0008232395,0.0020305598,0.006596096,0.00084617856,0.00044413062,0.00003146987,0.0000042994197,0.0000277666],"genre_scores_gemma":[0.9851722,0.00025431454,0.0045537744,0.0052069104,0.0047045136,0.000009849659,0.00007473108,0.000017404007,0.0000063147327],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971348,0.00025413148,0.0019459521,0.00027733625,0.00021186806,0.00017590074],"domain_scores_gemma":[0.9963545,0.0011658232,0.0018696713,0.0001873059,0.00022070087,0.0002019689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016409113,0.00015185546,0.0008898143,0.000017802135,0.00006142658,0.000010909948,0.00023502215,0.00042267688,0.000030068764],"category_scores_gemma":[0.0026388534,0.00010042069,0.00042985126,0.000044560606,0.00025267448,0.0000096597005,0.000077902456,0.00042916194,9.389201e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44830403,0.0019567825,0.012749872,0.000020328596,0.0014929993,0.000078282545,0.00018595596,0.00046505377,0.023608163,0.000119421566,0.02396753,0.48705158],"study_design_scores_gemma":[0.3414229,0.07231667,0.35527515,0.00007571382,0.0007246682,0.0010145636,0.00007083765,0.0040230807,0.0076899696,0.0010681517,0.21576722,0.00055108167],"about_ca_topic_score_codex":0.00003716277,"about_ca_topic_score_gemma":0.00004120035,"teacher_disagreement_score":0.48650047,"about_ca_system_score_codex":0.00003030603,"about_ca_system_score_gemma":0.0010560132,"threshold_uncertainty_score":0.4095037},"labels":[],"label_agreement":null},{"id":"W3008368793","doi":"10.1200/jco.2020.38.6_suppl.32","title":"Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Cabazitaxel; Prostate cancer; Docetaxel; Internal medicine; Interim analysis; Radium-223; Clinical endpoint; Oncology; Cancer; Taxane; Clinical trial; Surgery; Androgen deprivation therapy; Breast cancer; Bone metastasis; Androgen receptor","score_opus":0.47194359211004633,"score_gpt":0.5657119235940941,"score_spread":0.09376833148404773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008368793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98317295,0.0008621828,0.0000015981308,0.014509656,0.00027269413,0.0010951512,0.000025894615,0.0000044751173,0.000055387103],"genre_scores_gemma":[0.99626195,0.001058718,0.0013373686,0.0010393657,0.00018871675,0.000043605956,0.000009891842,0.000015566557,0.00004480067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936736,0.0012550813,0.003867451,0.00031779046,0.00063213834,0.00025389742],"domain_scores_gemma":[0.995459,0.0020595337,0.0014073922,0.00014208081,0.00047004732,0.00046195346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003082995,0.00016932562,0.0018381674,0.00014989884,0.000028330283,0.0000114810755,0.00012929307,0.00016645034,0.000057143694],"category_scores_gemma":[0.003152422,0.00010835624,0.00019320982,0.00031498141,0.00023555299,0.00020196915,0.000057602505,0.0009986203,0.0000011765147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013157124,0.009377177,0.9290757,0.00007633207,0.00041345053,0.001089521,0.001558023,0.000055981604,0.00009664418,0.000024024992,0.00030057982,0.0447754],"study_design_scores_gemma":[0.027889976,0.031561557,0.936723,0.00010475133,0.00021365209,0.0000147241835,0.0019961663,0.0002467967,0.000023515877,0.00012781248,0.0010107473,0.00008730909],"about_ca_topic_score_codex":0.00047957752,"about_ca_topic_score_gemma":0.0020644206,"teacher_disagreement_score":0.044688094,"about_ca_system_score_codex":0.00016526107,"about_ca_system_score_gemma":0.0028484473,"threshold_uncertainty_score":0.5053023},"labels":[],"label_agreement":null},{"id":"W3008375373","doi":"10.1200/jco.2020.38.6_suppl.162","title":"Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Decipher Biosciences; National Institutes of Health","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Androgen deprivation therapy; Clinical endpoint; Taxane; Cancer; Breast cancer; Clinical trial","score_opus":0.16326690855705658,"score_gpt":0.48476976302028324,"score_spread":0.3215028544632267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008375373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889569,0.0019933926,0.00016877246,0.005784795,0.00040644512,0.0022667795,0.00018746802,0.0000075860567,0.00022780384],"genre_scores_gemma":[0.99598557,0.0019830812,0.0007492597,0.0005029696,0.0003969732,0.00007935311,0.000014534118,0.000029567022,0.00025867933],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958779,0.00047142926,0.002344092,0.00032272268,0.0006506995,0.00033316456],"domain_scores_gemma":[0.9905633,0.0038328469,0.0026727053,0.00014964551,0.0022472702,0.0005342711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016633577,0.00022874238,0.002397259,0.00018345712,0.0000417433,0.00000535442,0.0001473127,0.00019342176,0.000049831422],"category_scores_gemma":[0.004083068,0.00015233463,0.00051578926,0.00042966235,0.00046913375,0.00014080513,0.00007635804,0.0007552074,0.0000037886232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6211371,0.024081143,0.14771223,0.0005914071,0.022196235,0.005299755,0.0441078,0.00035296983,0.0060503646,0.00007003275,0.008794187,0.1196068],"study_design_scores_gemma":[0.09547513,0.2986034,0.5760855,0.00041283137,0.005408845,0.00013363965,0.017112393,0.0025279126,0.0016262137,0.00038445691,0.0020008744,0.00022883156],"about_ca_topic_score_codex":0.0001976695,"about_ca_topic_score_gemma":0.00008141152,"teacher_disagreement_score":0.52566195,"about_ca_system_score_codex":0.00017861737,"about_ca_system_score_gemma":0.0026572437,"threshold_uncertainty_score":0.6212026},"labels":[],"label_agreement":null},{"id":"W3008394635","doi":"10.1200/jco.2020.38.6_suppl.333","title":"Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Montreal General Hospital; Cancer Care Ontario","funders":"National Institutes of Health","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Radiation therapy; Androgen deprivation therapy; Urology; Gynecology; Cancer","score_opus":0.14307360938030939,"score_gpt":0.5012946278380473,"score_spread":0.35822101845773796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008394635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.880832,0.0068820324,0.000557112,0.10782831,0.0016836416,0.0012902304,0.00020085435,0.000022964612,0.0007028133],"genre_scores_gemma":[0.951603,0.03291622,0.007436797,0.0053433534,0.0020814997,0.000052627565,0.00002467263,0.000042318083,0.0004995366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951195,0.0005670098,0.0030220968,0.000327798,0.0005059579,0.00045760444],"domain_scores_gemma":[0.99272513,0.002099588,0.0028984535,0.00020334973,0.0012182405,0.0008552158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003107549,0.00021688327,0.002845204,0.0001228255,0.00006815648,0.000007824476,0.00028742198,0.00048578746,0.00030272416],"category_scores_gemma":[0.0036692198,0.00013685756,0.0007446978,0.00025880712,0.00053160224,0.000116664756,0.000102397324,0.001333067,0.000022461389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1272389,0.003272721,0.09149726,0.00046798182,0.002979073,0.0012537135,0.0007310565,0.00010333947,0.0014774727,0.0002927596,0.054965004,0.7157207],"study_design_scores_gemma":[0.102647275,0.0984887,0.040394645,0.00032018576,0.002812016,0.00012632181,0.00048679436,0.00085800816,0.0043362505,0.0024490496,0.7468032,0.00027752473],"about_ca_topic_score_codex":0.00009606699,"about_ca_topic_score_gemma":0.000053544463,"teacher_disagreement_score":0.7154432,"about_ca_system_score_codex":0.00033239994,"about_ca_system_score_gemma":0.0059839683,"threshold_uncertainty_score":0.9996512},"labels":[],"label_agreement":null},{"id":"W3008469678","doi":"10.1200/jco.2020.38.6_suppl.195","title":"Next-generation sequencing (NGS) of tumor tissue from &gt;4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Enzalutamide; Prostate cancer; Prostatectomy; Internal medicine; Cancer; Oncology; Biopsy; Prostate; Biomarker; Primary tumor; Pathology; Metastasis; Androgen receptor; Gene","score_opus":0.3364849534888414,"score_gpt":0.5173594748671928,"score_spread":0.18087452137835142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008469678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874676,0.0011263107,0.000084558895,0.009455493,0.00020279287,0.001385795,0.000023648436,0.000006977511,0.0002468094],"genre_scores_gemma":[0.99668336,0.00035555888,0.0010525002,0.00069599476,0.0008588183,0.000087101245,0.000011220281,0.00001833697,0.00023713386],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99636936,0.00055819494,0.0018630854,0.00026429104,0.0007107949,0.00023429094],"domain_scores_gemma":[0.9966771,0.0006815111,0.0014658474,0.000178122,0.00065759063,0.00033984077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014084644,0.00016718982,0.0011515837,0.000056122717,0.0001084667,0.00003441073,0.00018014372,0.000063026324,0.00030116565],"category_scores_gemma":[0.0006039808,0.0000830307,0.00012995684,0.0002586291,0.0003191759,0.00025171763,0.000037312027,0.00060196297,0.0000032800287],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13614585,0.01070772,0.045735538,0.00022980766,0.0060909213,0.011097137,0.08013443,0.0007290685,0.57020414,0.00006927059,0.005788945,0.13306716],"study_design_scores_gemma":[0.2694159,0.35223448,0.05666176,0.0009351129,0.008442962,0.0005082597,0.13836184,0.014106451,0.12938096,0.0003160485,0.028695548,0.0009406825],"about_ca_topic_score_codex":0.00055008614,"about_ca_topic_score_gemma":0.0005161552,"teacher_disagreement_score":0.4408232,"about_ca_system_score_codex":0.000275351,"about_ca_system_score_gemma":0.0044026924,"threshold_uncertainty_score":0.78101873},"labels":[],"label_agreement":null},{"id":"W3008508918","doi":"10.1200/jco.2020.38.6_suppl.371","title":"Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Urology; External beam radiotherapy; Androgen deprivation therapy; Cumulative incidence; Prostate; Internal medicine; Nuclear medicine; Cancer; Cohort","score_opus":0.05056801024914782,"score_gpt":0.4128375472894749,"score_spread":0.3622695370403271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008508918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954038,0.001991203,0.00001157175,0.002006167,0.00011740131,0.0003483794,0.00010751025,0.0000040707805,0.000009899372],"genre_scores_gemma":[0.99260515,0.0054765805,0.0014343583,0.00019341189,0.00023142133,0.0000080135615,0.0000064257415,0.000019813546,0.000024809351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722564,0.00031796467,0.0015199153,0.00023539527,0.00045008134,0.00025101635],"domain_scores_gemma":[0.99722254,0.00070573937,0.0011610946,0.00013370578,0.000326361,0.00045052817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090326247,0.00016319171,0.0015013649,0.00008990898,0.000020871064,0.000007366205,0.00015090713,0.000175145,0.000049603444],"category_scores_gemma":[0.0010682307,0.000091179994,0.00015773019,0.00020383135,0.00036120438,0.00008643543,0.000056895882,0.0007000273,4.1115882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030562444,0.001218471,0.9389391,0.000077972974,0.0003448617,0.0008439113,0.00015344599,0.0000049325763,0.0011804787,0.0000014994523,0.0003695024,0.026303396],"study_design_scores_gemma":[0.04928687,0.032510653,0.9093935,0.0003205415,0.00046128282,0.000043668177,0.000081629725,0.00010862759,0.0064377175,0.00004145944,0.0011930229,0.00012103746],"about_ca_topic_score_codex":0.00024219698,"about_ca_topic_score_gemma":0.00015083844,"teacher_disagreement_score":0.031292185,"about_ca_system_score_codex":0.0001329109,"about_ca_system_score_gemma":0.0008113962,"threshold_uncertainty_score":0.37182122},"labels":[],"label_agreement":null},{"id":"W3008509746","doi":"10.1200/jco.2020.38.6_suppl.118","title":"Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Population; Circulating tumor cell; Oncology; Olaparib; Progression-free survival; Progressive disease; Cancer; Disease; Chemotherapy; Gene; Metastasis; Biology","score_opus":0.1685168687193393,"score_gpt":0.465545764366912,"score_spread":0.2970288956475727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008509746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953337,0.0009240626,0.000004271471,0.0022976329,0.0001104748,0.0012600417,0.000025144285,0.0000059561335,0.000038714847],"genre_scores_gemma":[0.99864244,0.0003520618,0.00047463927,0.00035603295,0.00006993753,0.000036208345,0.00000409019,0.000017658174,0.000046900157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550253,0.0013659049,0.0019667032,0.00028236315,0.00061281124,0.00026967438],"domain_scores_gemma":[0.99643135,0.0013524235,0.0011294064,0.000117371215,0.00058900117,0.00038043648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029953695,0.00018233198,0.0015101574,0.00025619753,0.000044323773,0.000006900172,0.00009049727,0.00009008688,0.00002914154],"category_scores_gemma":[0.0030559893,0.00011457221,0.00015191051,0.00043532604,0.00028863654,0.00013595558,0.000054189164,0.0007630081,9.4789124e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29866034,0.00951343,0.67546546,0.000075763826,0.00062918244,0.0026388797,0.003896381,0.00011653659,0.001579242,0.0000024093424,0.00015768349,0.007264664],"study_design_scores_gemma":[0.07766936,0.15945221,0.7601026,0.00023249148,0.0003835612,0.000019113575,0.001075816,0.00013973402,0.00045390544,0.000018822699,0.00035266666,0.00009968039],"about_ca_topic_score_codex":0.00015823604,"about_ca_topic_score_gemma":0.0009947394,"teacher_disagreement_score":0.22099099,"about_ca_system_score_codex":0.00028133043,"about_ca_system_score_gemma":0.0032681613,"threshold_uncertainty_score":0.5797578},"labels":[],"label_agreement":null},{"id":"W3008524481","doi":"10.1200/jco.2020.38.6_suppl.158","title":"Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Biopsy; Prostate; Pathology; Adenocarcinoma; Metastasis; Internal medicine; Oncology","score_opus":0.14008582028087863,"score_gpt":0.4086209625494445,"score_spread":0.2685351422685659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008524481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94411945,0.011599797,0.000007089753,0.032631073,0.001407487,0.0026843953,0.0073620006,0.000057604128,0.0001310751],"genre_scores_gemma":[0.97645426,0.01788683,0.0004628955,0.0012195552,0.0017037787,0.00034294382,0.0006417221,0.00015929295,0.0011287418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895127,0.0017483443,0.0046780673,0.0012682463,0.0013929601,0.001399727],"domain_scores_gemma":[0.9854533,0.0058884276,0.00514737,0.00065196346,0.00140974,0.00144917],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013441042,0.0009540081,0.0037496975,0.0001947125,0.00030723968,0.00012556216,0.0007683883,0.0003367272,0.00037576564],"category_scores_gemma":[0.0029619709,0.00058043463,0.0010502714,0.000716391,0.0010797288,0.0003782164,0.00033866777,0.002407561,0.000022366876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07731406,0.0018325156,0.877179,0.00019241248,0.0032961091,0.005447157,0.007441076,0.00038014058,0.00394481,0.0000035241321,0.004346833,0.018622339],"study_design_scores_gemma":[0.0491549,0.018389711,0.9094768,0.0012769923,0.0045770407,0.000074702075,0.0035888231,0.0012494915,0.006920666,0.00009029738,0.0045872615,0.000613286],"about_ca_topic_score_codex":0.02336411,"about_ca_topic_score_gemma":0.020279858,"teacher_disagreement_score":0.032334764,"about_ca_system_score_codex":0.0015411422,"about_ca_system_score_gemma":0.008628222,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W3008557183","doi":"10.1200/jco.2020.38.6_suppl.725","title":"The impact of surgical resection on circulating tumor-reactive cytotoxic T cells for patients with renal tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cytotoxic T cell; Peripheral blood mononuclear cell; Renal cell carcinoma; Nephrectomy; CD8; Immune system; Granzyme B; Pathology; Internal medicine; Kidney; Immunology","score_opus":0.0802812113267133,"score_gpt":0.43666816177765955,"score_spread":0.35638695045094626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008557183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963125,0.000045876684,0.00004005527,0.0023614643,0.00024776495,0.00034606335,0.000007782161,0.0000036454296,0.00063486176],"genre_scores_gemma":[0.9985124,0.000053243206,0.00020458948,0.00038792897,0.0008078574,0.0000034077882,0.0000019883184,0.00001301623,0.000015555459],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976414,0.0002617002,0.00147885,0.00013125617,0.0003187073,0.00016809952],"domain_scores_gemma":[0.99376166,0.0034757738,0.00199153,0.00010036593,0.0004704869,0.00020016659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017038727,0.00010464371,0.00083165604,0.00004266796,0.00006128184,0.0000066096295,0.00009960711,0.000121068086,0.000030107565],"category_scores_gemma":[0.0013142026,0.000049656293,0.00069072726,0.00014231414,0.00019150155,0.000053265096,0.000012829815,0.00059415615,0.0000011205474],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77126545,0.003292263,0.114650324,0.000053172796,0.0023406977,0.00039022553,0.0003302351,0.00029372892,0.014956797,0.00003550955,0.005501118,0.08689046],"study_design_scores_gemma":[0.043115675,0.25383887,0.68640697,0.00036773414,0.0002656946,0.00020596883,0.00015324364,0.00041489195,0.0039139325,0.00007560362,0.011100748,0.00014063764],"about_ca_topic_score_codex":0.000019102083,"about_ca_topic_score_gemma":0.000004970522,"teacher_disagreement_score":0.7281498,"about_ca_system_score_codex":0.00019325726,"about_ca_system_score_gemma":0.0009945665,"threshold_uncertainty_score":0.25813457},"labels":[],"label_agreement":null},{"id":"W3008612357","doi":"10.1200/jco.2020.38.6_suppl.684","title":"Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Nivolumab; Renal cell carcinoma; Internal medicine; Proportional hazards model; Gastroenterology; Ipilimumab; Vascular endothelial growth factor; Urology; Oncology; Surgery; Confidence interval; Cancer; VEGF receptors; Immunotherapy","score_opus":0.17863678335251573,"score_gpt":0.4062466362906625,"score_spread":0.22760985293814676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008612357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9197282,0.0010655178,0.00010407558,0.074399784,0.001258477,0.0003310316,0.00021008254,0.000010751567,0.002892041],"genre_scores_gemma":[0.9697773,0.000387766,0.002679718,0.024557836,0.002051714,0.000009601613,0.00016554378,0.000025501437,0.00034506232],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9950479,0.00076320436,0.002865671,0.00036114483,0.00073519757,0.0002268371],"domain_scores_gemma":[0.9919008,0.004577591,0.0020518887,0.0003584073,0.00061286887,0.0004984603],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024090772,0.00022706442,0.0011521451,0.00007292749,0.00004444505,0.00002888341,0.00040416568,0.00018079378,0.0014255204],"category_scores_gemma":[0.00280762,0.00013244578,0.0005698149,0.00013341945,0.00022332747,0.00016817945,0.00012732967,0.0012451907,0.0000948428],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29549447,0.017443663,0.1929199,0.00013538367,0.00622109,0.033337846,0.005021005,0.00010419674,0.029613266,0.0003294475,0.2970625,0.12231724],"study_design_scores_gemma":[0.070193104,0.02879831,0.5541196,0.00011064675,0.0014772228,0.00046238353,0.0004418196,0.0014842207,0.014497576,0.00047565947,0.32763433,0.00030515745],"about_ca_topic_score_codex":0.000048996302,"about_ca_topic_score_gemma":0.000044328783,"teacher_disagreement_score":0.36119968,"about_ca_system_score_codex":0.00018161607,"about_ca_system_score_gemma":0.0013271485,"threshold_uncertainty_score":0.99948734},"labels":[],"label_agreement":null},{"id":"W3008651000","doi":"10.1200/jco.2020.38.6_suppl.532","title":"Comprehensive immune profiling of patients (pts) with metastatic urothelial cancer (mUC) or renal cell cancer (mRCC) receiving immune checkpoint inhibitors (CPIs).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Medicine; Immune system; Immune checkpoint; Granzyme B; CD8; Flow cytometry; Mass cytometry; Peripheral blood mononuclear cell; Immunology; T cell; Cancer; Cancer research; Chemokine; Oncology; Internal medicine; Immunotherapy; Biology; In vitro","score_opus":0.11514704566042708,"score_gpt":0.41860541265549617,"score_spread":0.3034583669950691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008651000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897622,0.0024512557,0.00013714888,0.00465758,0.0014199417,0.00078455656,0.00008612434,0.00001526741,0.00068593124],"genre_scores_gemma":[0.98843694,0.0022353067,0.005837224,0.0017336657,0.001433125,0.0000526345,0.000008114426,0.000062207124,0.00020081383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943586,0.0004735707,0.0036900495,0.00035794437,0.00072931795,0.00039049788],"domain_scores_gemma":[0.99344546,0.0010201402,0.0035699874,0.00021665277,0.0012193901,0.0005284018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076293544,0.00033447176,0.0026974403,0.000117085685,0.00006760364,0.000011031613,0.00024304829,0.0002503372,0.0009115686],"category_scores_gemma":[0.0010499371,0.00020209064,0.0006554061,0.00034610654,0.00031741842,0.000167898,0.00009569081,0.0012527166,0.000011203771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21225272,0.0128109865,0.4266485,0.002454424,0.009996143,0.0022080215,0.004157906,0.0014888543,0.08431797,0.000013643072,0.0031257079,0.24052511],"study_design_scores_gemma":[0.1168734,0.111263245,0.43974075,0.003200808,0.00874626,0.0001967734,0.0017222881,0.00045612338,0.27396703,0.000059541642,0.04281025,0.000963517],"about_ca_topic_score_codex":0.00048795683,"about_ca_topic_score_gemma":0.00007409496,"teacher_disagreement_score":0.23956159,"about_ca_system_score_codex":0.00031381784,"about_ca_system_score_gemma":0.0047672885,"threshold_uncertainty_score":0.9981037},"labels":[],"label_agreement":null},{"id":"W3008659841","doi":"10.1200/jco.2020.38.6_suppl.361","title":"The relationship between socioeconomic status and treatment for prostate cancer in a universal healthcare system: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph's Hospital; Seven Oaks General Hospital; University of Manitoba","funders":"","keywords":"Medicine; Socioeconomic status; Prostate cancer; Prostatectomy; Population; Demography; Logistic regression; Health care; Cancer; Cancer registry; Family medicine; Internal medicine; Environmental health","score_opus":0.3313862527471616,"score_gpt":0.5218675948721847,"score_spread":0.1904813421250231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008659841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94251907,0.0008873332,0.000103206345,0.05605418,0.00009568853,0.0002910904,0.000026477224,0.000004111994,0.000018858369],"genre_scores_gemma":[0.99799895,0.00019419288,0.00043077196,0.00095498684,0.0003852308,0.000009362169,0.000008399176,0.0000049116106,0.000013196438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820584,0.00025246292,0.0011584884,0.00012173118,0.00010244568,0.00015900943],"domain_scores_gemma":[0.99465954,0.003978662,0.0008788007,0.000058837897,0.00014040535,0.00028374296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011026346,0.00006775483,0.0008285519,0.00006899318,0.00007587028,0.0000091969805,0.00004529436,0.0001280746,0.0000037847597],"category_scores_gemma":[0.00096324726,0.000042776148,0.00025526248,0.00013660002,0.00004991665,0.000052761057,0.00000742643,0.0002728683,6.300303e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027176447,0.000021302198,0.9743574,0.000027767983,0.00030269547,0.000018609499,0.00019435592,0.0007396592,1.7042719e-7,0.00022222858,0.000050869734,0.021347279],"study_design_scores_gemma":[0.00567364,0.004363527,0.98331714,0.000053002917,0.0008911194,0.0000018543193,0.00082096306,0.0024307682,3.1382103e-7,0.00008607638,0.002325741,0.00003583762],"about_ca_topic_score_codex":0.001478124,"about_ca_topic_score_gemma":0.004489055,"teacher_disagreement_score":0.05547989,"about_ca_system_score_codex":0.0008899366,"about_ca_system_score_gemma":0.0019364452,"threshold_uncertainty_score":0.3435171},"labels":[],"label_agreement":null},{"id":"W3008661915","doi":"10.1200/jco.2020.38.6_suppl.9","title":"A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Prostate cancer; Occult; Nuclear medicine; Prostatectomy; Radiology; Pelvis; Cancer; Pathology; Internal medicine","score_opus":0.059601925304202226,"score_gpt":0.45438124618992043,"score_spread":0.3947793208857182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008661915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645793,0.0008361746,0.000017658427,0.0010861232,0.00013074311,0.0012868006,0.0001621009,0.000008462895,0.000014022421],"genre_scores_gemma":[0.99891126,0.0005264756,0.00012649801,0.00019906266,0.0000796602,0.00004967881,0.000053442724,0.000026792057,0.00002714425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552894,0.00061917905,0.0022223156,0.0004723966,0.0007915886,0.00036559082],"domain_scores_gemma":[0.99558413,0.0008025594,0.0020739872,0.00016314573,0.0009824187,0.0003937575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012391922,0.00027305726,0.0021215545,0.00039629155,0.000108864064,0.000015193272,0.00012615311,0.000011550105,0.00007938689],"category_scores_gemma":[0.0006594177,0.00017882137,0.00032393637,0.00075924024,0.00044669933,0.00026327238,0.00013332267,0.00072389795,3.1576283e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09185722,0.010211674,0.8815595,0.00008167881,0.0047536823,0.004193975,0.0012083673,0.00007156018,0.001094352,5.0383755e-7,0.0001425818,0.004824897],"study_design_scores_gemma":[0.15815593,0.061744887,0.7519165,0.00033541577,0.009583856,0.00016690152,0.005028987,0.0043334044,0.0080236,0.000016660684,0.00034568034,0.00034813586],"about_ca_topic_score_codex":0.00045594346,"about_ca_topic_score_gemma":0.0008406245,"teacher_disagreement_score":0.12964296,"about_ca_system_score_codex":0.00046796465,"about_ca_system_score_gemma":0.00073331926,"threshold_uncertainty_score":0.72921234},"labels":[],"label_agreement":null},{"id":"W3008697319","doi":"10.1200/jco.2020.38.6_suppl.225","title":"Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Proportional hazards model; Internal medicine; Bone metastasis; Overall survival; Cancer; Survival analysis; Urology; Oncology","score_opus":0.21445699783522373,"score_gpt":0.4776605600352074,"score_spread":0.26320356219998364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008697319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360395,0.00046420537,0.000016414258,0.014062681,0.0001061052,0.0010173067,0.000024032564,0.00001591423,0.00068941154],"genre_scores_gemma":[0.9979192,0.0005413925,0.0005215865,0.0003343812,0.00013040923,0.000037502246,0.000015025535,0.000032490796,0.00046803345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683356,0.00058054767,0.0012002308,0.00029175618,0.00069394213,0.0003999448],"domain_scores_gemma":[0.99585444,0.0021531363,0.000918149,0.00012703355,0.0003292622,0.00061800797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010616966,0.00025833052,0.0019552892,0.0001381904,0.000046451078,0.00002471101,0.00013527687,0.00013117601,0.000107252614],"category_scores_gemma":[0.00087532663,0.00012161734,0.00021390778,0.00036713821,0.00028351948,0.00017889288,0.000024329287,0.0009096159,0.0000040758046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027225278,0.0012915415,0.9610478,0.00010458197,0.0013948081,0.0043281815,0.00055901404,0.000055264074,0.00019567419,0.000007622863,0.00022156196,0.0035686272],"study_design_scores_gemma":[0.028373474,0.031973064,0.9358809,0.00021777645,0.00089307403,0.000060656308,0.0010209096,0.00010076097,0.00047084322,0.000011928536,0.00085072906,0.00014587499],"about_ca_topic_score_codex":0.0003272764,"about_ca_topic_score_gemma":0.001081319,"teacher_disagreement_score":0.030681523,"about_ca_system_score_codex":0.0003092754,"about_ca_system_score_gemma":0.0030944718,"threshold_uncertainty_score":0.548946},"labels":[],"label_agreement":null},{"id":"W3008705236","doi":"10.1200/jco.19.01836","title":"Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Blood transfusion and management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital; London Health Sciences Centre; University of Saskatchewan; University of Ottawa; University of Calgary; Alberta Cancer Foundation; Baker Hughes (Canada); Foothills Medical Centre; Ottawa Hospital","funders":"Canadian Blood Services; London Health Sciences Centre; Canadian Institutes of Health Research; Hamilton Health Sciences","keywords":"Medicine; Hematopoietic cell; Open label; Hematopoietic stem cell transplantation; Transplantation; Red blood cell; Blood transfusion; Randomized controlled trial; Oncology; Haematopoiesis; Internal medicine; Surgery; Immunology; Stem cell","score_opus":0.16602732470582474,"score_gpt":0.460340397095794,"score_spread":0.2943130723899693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008705236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9432556,0.00024710983,0.0006530716,0.024364742,0.0017217335,0.0029917967,0.000006464407,0.000019082401,0.026740424],"genre_scores_gemma":[0.98372775,0.008204286,0.003354067,0.003539172,0.0009110554,0.000042034786,0.000009974031,0.000025250574,0.00018640682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99383414,0.0014132425,0.003557649,0.0003764688,0.0005272675,0.00029124712],"domain_scores_gemma":[0.9950705,0.0027965028,0.0011036838,0.00019221638,0.00021139384,0.00062570156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050959606,0.00024027875,0.003129493,0.00015302321,0.000059778413,0.00003139091,0.00039481965,0.00047538534,0.0004534938],"category_scores_gemma":[0.0007375606,0.00018131803,0.0006306285,0.00038254663,0.00017707996,0.00022486725,0.000061348605,0.0015721698,0.000010460247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9759175,0.014067128,0.00027513976,0.00012950882,0.00032744804,0.0029262549,0.0012959898,0.000010027355,0.00054504786,0.000115256255,0.0012898353,0.0031008718],"study_design_scores_gemma":[0.9477845,0.043453008,0.0004286514,0.00010515362,0.0029167978,0.00007329857,0.00028304732,0.00010510277,0.0006623595,0.00012495613,0.003901213,0.0001619366],"about_ca_topic_score_codex":0.000050532144,"about_ca_topic_score_gemma":0.00008629554,"teacher_disagreement_score":0.040472176,"about_ca_system_score_codex":0.00005340837,"about_ca_system_score_gemma":0.0012701924,"threshold_uncertainty_score":0.7393934},"labels":[],"label_agreement":null},{"id":"W3008719120","doi":"10.1200/jco.2020.38.6_suppl.649","title":"Fear of cancer recurrence among patients and survivors diagnosed with localized renal cell carcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Cancer; Stage (stratigraphy); Disease; Gastroenterology","score_opus":0.06330010600339515,"score_gpt":0.3879197792685291,"score_spread":0.32461967326513397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008719120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995308,0.0010668788,0.0000846212,0.001903041,0.0006535015,0.00016538934,0.000012783735,0.000004374799,0.00080143486],"genre_scores_gemma":[0.99657184,0.00087709766,0.00038209252,0.0016641456,0.00044653678,0.0000034844406,0.0000024780857,0.000014228912,0.000038071834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760187,0.00030936796,0.0013273805,0.00019486857,0.0003958074,0.00017070278],"domain_scores_gemma":[0.9964359,0.0009576465,0.0013731844,0.00010480941,0.00058478815,0.000543719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074751326,0.00012721593,0.0012465562,0.00005151551,0.000020322095,0.000004677725,0.000120429184,0.00021857735,0.00012056134],"category_scores_gemma":[0.0009187403,0.00008473378,0.00020725655,0.00018967356,0.00033962133,0.00007455597,0.000045679157,0.0007242831,0.0000012935947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060927095,0.00041120645,0.9624871,0.00011018769,0.00008733035,0.00020548493,0.0007297625,0.000010595266,0.000025893776,0.000003180064,0.0016095184,0.028227037],"study_design_scores_gemma":[0.011553039,0.01668858,0.9516449,0.00015992518,0.00040480244,0.000010135675,0.00037853248,0.000085274005,0.00032697513,0.000009133768,0.018632235,0.00010648167],"about_ca_topic_score_codex":0.0015736539,"about_ca_topic_score_gemma":0.0038916226,"teacher_disagreement_score":0.028120555,"about_ca_system_score_codex":0.00005265499,"about_ca_system_score_gemma":0.0009672101,"threshold_uncertainty_score":0.34553432},"labels":[],"label_agreement":null},{"id":"W3008727692","doi":"10.1200/jco.2020.38.6_suppl.tps768","title":"UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Immune checkpoint; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunotherapy; Cancer","score_opus":0.09471171853521936,"score_gpt":0.38629953340175954,"score_spread":0.2915878148665402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008727692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96095175,0.0019714164,0.00009284507,0.009511219,0.000822816,0.0005198339,0.0000063016455,0.000027005139,0.026096812],"genre_scores_gemma":[0.98634297,0.00053758675,0.006408593,0.003901461,0.001669484,0.000007702973,0.0000072731227,0.00007281511,0.0010521174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931319,0.0009278515,0.0038380106,0.00061340886,0.0008345486,0.0006543323],"domain_scores_gemma":[0.9939246,0.0015448814,0.0022725319,0.00049983826,0.00049863796,0.001259506],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019218998,0.00041681854,0.0028539118,0.00022913335,0.00006932502,0.0000202574,0.00052481913,0.00069789856,0.0005449231],"category_scores_gemma":[0.000967627,0.0003246344,0.0010855711,0.00042717342,0.00028031433,0.00022789348,0.0002005133,0.0024695934,0.00023489744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13253981,0.019196302,0.43188944,0.0010294205,0.0010718371,0.069525614,0.005668078,0.0015413461,0.05360408,0.00012155397,0.042077273,0.24173523],"study_design_scores_gemma":[0.12466499,0.15368026,0.5329198,0.00030673784,0.0018063304,0.0014608885,0.0025418396,0.0020955552,0.01708339,0.00032856668,0.16218513,0.0009264818],"about_ca_topic_score_codex":0.00007011955,"about_ca_topic_score_gemma":0.000038543847,"teacher_disagreement_score":0.24080876,"about_ca_system_score_codex":0.00095452124,"about_ca_system_score_gemma":0.003499828,"threshold_uncertainty_score":0.99992055},"labels":[],"label_agreement":null},{"id":"W3008777590","doi":"10.1200/jco.2020.38.6_suppl.tps384","title":"INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Androgen deprivation therapy; Brachytherapy; Internal medicine; Randomized controlled trial; Urology; Oncology; Radiation therapy; Cancer","score_opus":0.17134188640697212,"score_gpt":0.49562923973114204,"score_spread":0.3242873533241699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008777590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756641,0.0021754059,0.0002969658,0.016533256,0.0013441137,0.0038889374,0.000018657443,0.0000075991984,0.000070966336],"genre_scores_gemma":[0.92168385,0.07358484,0.00051268854,0.00058888237,0.0032533808,0.00019672142,0.0000130116205,0.000015472027,0.00015114505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962339,0.0010390457,0.002140516,0.00016753295,0.00027412298,0.00014490342],"domain_scores_gemma":[0.992199,0.0043566795,0.002672713,0.00007797276,0.000462717,0.00023089885],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005593469,0.00010345225,0.0017371083,0.00008943839,0.000036887603,0.000009374907,0.00006668567,0.00020754371,0.000032816173],"category_scores_gemma":[0.0135178985,0.00006263124,0.00049327186,0.00011847562,0.00021788783,0.00015976085,0.000018413675,0.00045409438,5.3879296e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6568718,0.0004291215,0.0028131702,0.00003601004,0.00053583964,0.000005438069,0.00034002258,0.000008140483,0.00008767512,0.0000062879876,0.00085250236,0.338014],"study_design_scores_gemma":[0.9244633,0.05784267,0.0048107263,0.000045608722,0.0005042088,0.000003541167,0.00004202898,0.0016594068,0.0005859164,0.00068557804,0.009309164,0.000047871414],"about_ca_topic_score_codex":0.00006606494,"about_ca_topic_score_gemma":0.000014419952,"teacher_disagreement_score":0.33796614,"about_ca_system_score_codex":0.00009347778,"about_ca_system_score_gemma":0.0013626226,"threshold_uncertainty_score":0.9947917},"labels":[],"label_agreement":null},{"id":"W3008812155","doi":"10.1200/jco.2020.38.6_suppl.29","title":"Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; University of Ottawa; McGill University; University of Alberta; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital; Jewish General Hospital; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"Janssen Canada","keywords":"Medicine; Prostate cancer; Docetaxel; Cancer; Oncology; Internal medicine; Prostate; Family medicine","score_opus":0.19338242966842042,"score_gpt":0.5300743591986097,"score_spread":0.3366919295301892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008812155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586291,0.0027215655,0.0000023681912,0.03549543,0.00035418017,0.0007407163,0.00011320853,0.0000067934075,0.0019366894],"genre_scores_gemma":[0.9747466,0.02177495,0.0008899311,0.0018046023,0.00034523112,0.000026837895,0.000017083932,0.000023082877,0.0003716691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964576,0.0005832514,0.0019977908,0.0001791508,0.00043405994,0.0003481411],"domain_scores_gemma":[0.99621683,0.0006258045,0.0017957378,0.00017456751,0.00052773365,0.0006593359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014063503,0.00017008698,0.0017464885,0.00019158893,0.00008681919,0.000005029505,0.00023352391,0.00017138815,0.00005666864],"category_scores_gemma":[0.0001726589,0.00012956752,0.00022293584,0.00042818143,0.0005284614,0.000091231326,0.00007012547,0.0019873034,0.0000011971314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017270241,0.0010406266,0.61531824,0.0015184605,0.0010227865,0.0003012316,0.002944161,0.0004105445,0.0010220646,0.000091201044,0.0054833773,0.35357705],"study_design_scores_gemma":[0.030909756,0.01798695,0.774669,0.0030291253,0.001326655,0.000006304618,0.003183323,0.0005387622,0.00563318,0.00024786612,0.16218518,0.00028392265],"about_ca_topic_score_codex":0.015860649,"about_ca_topic_score_gemma":0.031928938,"teacher_disagreement_score":0.35329312,"about_ca_system_score_codex":0.0004422449,"about_ca_system_score_gemma":0.0033282342,"threshold_uncertainty_score":0.9906928},"labels":[],"label_agreement":null},{"id":"W3008830271","doi":"10.1200/jco.2020.38.6_suppl.55","title":"A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital","funders":"","keywords":"Ordinary least squares; Statistics; Medicine; Sample size determination; Cross-validation; Mean squared error; Predictive modelling; Mathematics","score_opus":0.9642214670620962,"score_gpt":0.7064295196250586,"score_spread":0.2577919474370376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008830271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8676867,0.0024115168,0.112300314,0.016129002,0.00066109915,0.00022600451,0.00045899831,0.0000061407964,0.00012024177],"genre_scores_gemma":[0.8478797,0.0001882492,0.14457479,0.0066715246,0.0006407201,0.000002166516,0.000022983615,0.000011417632,0.000008426389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9802908,0.0025379583,0.016103357,0.000555016,0.00020353995,0.0003093529],"domain_scores_gemma":[0.9707647,0.013289024,0.014655757,0.00034620013,0.0003612908,0.0005830214],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06974353,0.00016630643,0.005541057,0.00056238146,0.00011185199,0.000031297524,0.00050874345,0.00033887924,0.00036054457],"category_scores_gemma":[0.036099315,0.00017447464,0.00048203647,0.0005269952,0.000360269,0.00039110263,0.0002782407,0.00071605656,0.000008552014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038927302,0.0003070694,0.9878662,0.00025871405,0.0014831012,0.0000036550098,0.0013886323,0.0029438853,0.00001070137,0.0013120306,0.0011996465,0.0028370721],"study_design_scores_gemma":[0.0014602764,0.0019504793,0.92060584,0.000037287926,0.00010567783,0.000016431726,0.001687764,0.06713354,0.0000030765304,0.0010023371,0.005861485,0.00013582395],"about_ca_topic_score_codex":0.00048441187,"about_ca_topic_score_gemma":0.0001282959,"teacher_disagreement_score":0.0672604,"about_ca_system_score_codex":0.000282963,"about_ca_system_score_gemma":0.0014490159,"threshold_uncertainty_score":0.97202003},"labels":[],"label_agreement":null},{"id":"W3008832291","doi":"10.1200/jco.2020.38.6_suppl.tps7","title":"A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; London Health Sciences Centre; Juravinski Cancer Centre; Western University; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Avelumab; Oncology; Chemotherapy; Internal medicine; Response Evaluation Criteria in Solid Tumors; Penile cancer; Malignancy; Stage (stratigraphy); Phases of clinical research; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.11733153239947139,"score_gpt":0.49245408787046796,"score_spread":0.3751225554709966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008832291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346083,0.000069618254,0.00007924255,0.0030898545,0.00015182211,0.0030247155,0.00009901873,0.000007324934,0.000017559558],"genre_scores_gemma":[0.9844631,0.0000070023825,0.0029906153,0.012016823,0.00017024536,0.00018030006,0.000007051716,0.000037225775,0.00012763779],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99626327,0.00027089383,0.0022906833,0.00030731037,0.0005246291,0.00034323122],"domain_scores_gemma":[0.99504805,0.0013302659,0.0019036349,0.00017677546,0.00071961834,0.00082167756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005542718,0.00023499872,0.0018803764,0.000119040895,0.00003650253,0.000005593309,0.00013961543,0.00014219526,0.0006354006],"category_scores_gemma":[0.002835105,0.00012062671,0.00020391609,0.00020554969,0.00010597529,0.000093386596,0.000024645999,0.00057132536,0.0000017720039],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7356478,0.036433388,0.15397604,0.0005642893,0.00016631852,0.00089689967,0.0005814018,0.00010118133,0.0000031285251,1.9220663e-7,0.0003541059,0.07127527],"study_design_scores_gemma":[0.31511316,0.45213917,0.22749898,0.0005972528,0.000617689,0.000004045212,0.0010420654,0.0014862206,0.000041752977,0.000004091845,0.0012992944,0.00015628636],"about_ca_topic_score_codex":0.000014690124,"about_ca_topic_score_gemma":0.00076323096,"teacher_disagreement_score":0.42053464,"about_ca_system_score_codex":0.00014675247,"about_ca_system_score_gemma":0.003318135,"threshold_uncertainty_score":0.6957191},"labels":[],"label_agreement":null},{"id":"W3008839696","doi":"10.1200/jco.2020.38.6_suppl.682","title":"Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Manitoba; Juravinski Cancer Centre; University of Ottawa; Sunnybrook Hospital; London Health Sciences Centre; Western University; Princess Margaret Cancer Centre; University of Calgary; Hôtel-Dieu de Québec; Dalhousie University; University Health Network; Université Laval; University of Alberta","funders":"","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Kidney cancer; Tyrosine-kinase inhibitor; Cancer; Population; Clinical trial","score_opus":0.19980846179959852,"score_gpt":0.42616919855497715,"score_spread":0.22636073675537863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008839696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453324,0.0007365053,0.000011586972,0.045434754,0.00069099,0.00051265967,0.00011834432,0.000006651945,0.00715611],"genre_scores_gemma":[0.9927373,0.00044410952,0.001354493,0.0047263415,0.0006195855,0.000009034297,0.000017604008,0.000013647102,0.000077882214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935728,0.00090764504,0.0043797544,0.0002076864,0.0006272401,0.00030488116],"domain_scores_gemma":[0.9907142,0.003896929,0.0032700205,0.00033566268,0.000655897,0.0011272954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035459204,0.00019015813,0.0016242176,0.00021932842,0.000050121533,0.000017566732,0.00033470613,0.00020043619,0.000070725655],"category_scores_gemma":[0.0070718667,0.000115716924,0.00040384973,0.00049298815,0.00016172692,0.0002752235,0.000053741365,0.0010729032,0.000030016308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037281968,0.0006401361,0.8502687,0.00091497425,0.000926577,0.0058159553,0.0069813933,0.0008789297,0.0010896798,0.0002095168,0.069430515,0.025561664],"study_design_scores_gemma":[0.015431949,0.0069485023,0.93400526,0.0015706056,0.0012459729,0.00009050911,0.00093077315,0.0013473361,0.0020286415,0.000016083835,0.03622042,0.00016394409],"about_ca_topic_score_codex":0.27817473,"about_ca_topic_score_gemma":0.19921628,"teacher_disagreement_score":0.08373657,"about_ca_system_score_codex":0.00096630014,"about_ca_system_score_gemma":0.012167609,"threshold_uncertainty_score":0.99343246},"labels":[],"label_agreement":null},{"id":"W3008866163","doi":"10.1200/jco.2020.38.6_suppl.122","title":"Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Internal medicine; Cohort; Enzalutamide; Discontinuation; Abiraterone acetate; Neutropenia; Gastroenterology; Cancer; Androgen deprivation therapy; Urology; Oncology; Androgen receptor; Chemotherapy","score_opus":0.17718702913344445,"score_gpt":0.49150643266501404,"score_spread":0.3143194035315696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008866163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994061,0.0009666968,0.000004222913,0.0033319164,0.00018404143,0.0012920382,0.000034400397,0.0000056158565,0.00012009191],"genre_scores_gemma":[0.9974047,0.0012938386,0.00041752955,0.00053292484,0.00016001124,0.000034729717,0.000021144928,0.000020914758,0.000114205635],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99628186,0.00057274394,0.001995478,0.00024070451,0.0006476196,0.00026159725],"domain_scores_gemma":[0.9969847,0.00045645895,0.0012929101,0.00013605111,0.0007233979,0.00040647783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011285854,0.00016990388,0.001497871,0.00013283057,0.000033626926,0.000009262366,0.00013516072,0.000103933526,0.00024705412],"category_scores_gemma":[0.0004686847,0.000098853176,0.00016118328,0.00038980538,0.00016383566,0.00013409457,0.000024838251,0.00069032056,0.000005520876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2628539,0.03660387,0.580116,0.00011977476,0.002803993,0.0014714926,0.0062575154,0.00018239323,0.0014640201,0.0000041953836,0.0034673417,0.10465555],"study_design_scores_gemma":[0.35899436,0.39273304,0.229643,0.00022606317,0.00064331427,0.000016483353,0.0028014854,0.00019373647,0.0015876504,0.000023683036,0.012915069,0.00022211319],"about_ca_topic_score_codex":0.00008784159,"about_ca_topic_score_gemma":0.00023834646,"teacher_disagreement_score":0.35612917,"about_ca_system_score_codex":0.00025528704,"about_ca_system_score_gemma":0.0029256972,"threshold_uncertainty_score":0.51900613},"labels":[],"label_agreement":null},{"id":"W3008873783","doi":"10.1200/jco.2020.38.6_suppl.119","title":"TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Docetaxel; Oncology; Taxane; Phases of clinical research; Interim analysis; Febrile neutropenia; Urology; Cancer; Chemotherapy; Neutropenia; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.15250295692949076,"score_gpt":0.5082804380046673,"score_spread":0.3557774810751765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008873783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909367,0.00022313933,0.00018056897,0.0072306506,0.00008662828,0.00092054287,0.000044541644,0.000012921963,0.0003643251],"genre_scores_gemma":[0.9968467,0.0001588513,0.002059565,0.00058549026,0.00015282027,0.00008519204,0.000010253553,0.000019972891,0.00008116865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955264,0.00054654095,0.0029270642,0.00032720182,0.00047249874,0.00020033063],"domain_scores_gemma":[0.9958913,0.0008289739,0.0021587277,0.00020349784,0.0005333274,0.00038421393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018009644,0.0001908119,0.0019230642,0.0003296194,0.000073539675,0.000012380673,0.00011398517,0.00010096001,0.00019304403],"category_scores_gemma":[0.0008767313,0.00013940057,0.00029520754,0.0009352063,0.000343566,0.00021119353,0.00004994894,0.00067357096,8.125788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15676092,0.064072706,0.5959372,0.00088030606,0.033140384,0.011813786,0.06558753,0.009429417,0.038227737,0.00010651861,0.0035550422,0.020488454],"study_design_scores_gemma":[0.15400991,0.2900496,0.49662554,0.0006626729,0.014837684,0.00031779002,0.02682865,0.009967391,0.0016834264,0.00018864832,0.004284409,0.00054426456],"about_ca_topic_score_codex":0.0002136994,"about_ca_topic_score_gemma":0.0026414506,"teacher_disagreement_score":0.2259769,"about_ca_system_score_codex":0.00018508216,"about_ca_system_score_gemma":0.0012683214,"threshold_uncertainty_score":0.568459},"labels":[],"label_agreement":null},{"id":"W3008910065","doi":"10.1200/jco.2020.38.15_suppl.tps5095","title":"PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible <i>FGFR3</i> alterations.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Cisplatin; Placebo; Internal medicine; Oncology; Adjuvant therapy; Chemotherapy; Urology; Gastroenterology; Clinical trial; Adverse effect; Pathology","score_opus":0.0946758322408685,"score_gpt":0.4131305022468749,"score_spread":0.3184546700060064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008910065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869666,0.00033965628,0.00010684229,0.0034604971,0.00072285614,0.006678033,0.000015481819,0.000009146796,0.0017008563],"genre_scores_gemma":[0.99466467,0.00036142315,0.0005326117,0.002566164,0.0015261432,0.00023492666,0.000013489993,0.00003531886,0.00006528284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99371123,0.0009143549,0.004030144,0.00032850594,0.00071180187,0.00030394635],"domain_scores_gemma":[0.9934306,0.002249958,0.0028269258,0.00021894685,0.0007914299,0.0004821165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021974037,0.00030954403,0.004449777,0.0002111215,0.00004818242,0.000020166914,0.00020712482,0.0003092438,0.00024219087],"category_scores_gemma":[0.0022287157,0.00018497702,0.0008392592,0.00027895486,0.00026913916,0.00022714336,0.000034323453,0.00093360373,0.0000070603587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96345246,0.0075234375,0.014934134,0.000031642805,0.0012329362,0.00021845977,0.000899459,0.000042342428,0.00015988133,0.000038379,0.00023375361,0.0112331305],"study_design_scores_gemma":[0.8744915,0.12133954,0.0006259851,0.0001263217,0.0008436148,0.000017166345,0.000089184665,0.00005550363,0.0014992275,0.000045283865,0.0007286485,0.00013800744],"about_ca_topic_score_codex":0.00013027985,"about_ca_topic_score_gemma":0.00010052054,"teacher_disagreement_score":0.113816105,"about_ca_system_score_codex":0.00011695125,"about_ca_system_score_gemma":0.0049506314,"threshold_uncertainty_score":0.87822074},"labels":[],"label_agreement":null},{"id":"W3008976335","doi":"10.1200/jco.2020.38.6_suppl.372","title":"Stereotactic radiotherapy +/- HDR boost for unfavorable-risk prostate cancer: Comparison of efficacy, survival, and late toxicity outcomes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Prostate; Pelvis; Radiation therapy; Cyberknife; Urology; Oncology; Cancer; Internal medicine; Surgery; Radiosurgery","score_opus":0.16717037305384957,"score_gpt":0.4901180694608156,"score_spread":0.322947696406966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008976335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95853436,0.0055447263,0.0001583145,0.03407685,0.0007662253,0.0007495525,0.00007278684,0.000009436398,0.00008772964],"genre_scores_gemma":[0.9722439,0.022211824,0.0023234843,0.0026735722,0.00044668763,0.000017670678,0.0000038105543,0.000025750931,0.000053296375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965142,0.0003040747,0.0024293505,0.00024482165,0.00026802486,0.00023952717],"domain_scores_gemma":[0.99199903,0.00417061,0.002809987,0.00014557404,0.00035963306,0.00051518244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015278289,0.0001859515,0.002639547,0.000052873198,0.000048160917,0.000011555082,0.00010961515,0.0002034408,0.000051792624],"category_scores_gemma":[0.0020809933,0.00012306668,0.00046317736,0.00010800666,0.00019258267,0.0000846416,0.000033163426,0.0005960783,0.0000011411273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009404376,0.0020585428,0.84348816,0.00013518687,0.0016098601,0.000055044908,0.00052454264,0.00010558921,0.00017324217,0.00001848411,0.0022014526,0.14022551],"study_design_scores_gemma":[0.03814256,0.04215879,0.8284169,0.00018797917,0.0014782153,0.000016047576,0.00016638756,0.00096455653,0.0010525715,0.00008179049,0.08717509,0.00015912912],"about_ca_topic_score_codex":0.00007184177,"about_ca_topic_score_gemma":0.000061246734,"teacher_disagreement_score":0.14006639,"about_ca_system_score_codex":0.00016808095,"about_ca_system_score_gemma":0.0009822524,"threshold_uncertainty_score":0.5018514},"labels":[],"label_agreement":null},{"id":"W3009099064","doi":"10.1200/jco.19.03136","title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Internal medicine; Hazard ratio; Placebo; Oncology; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Chemotherapy; Confidence interval; Pathology; Immunotherapy; Cisplatin","score_opus":0.10207678282217356,"score_gpt":0.43287407696580105,"score_spread":0.33079729414362746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009099064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164636,0.0033192993,0.004234041,0.00881709,0.00047073155,0.0011374989,0.00012932219,0.000023737739,0.00022190466],"genre_scores_gemma":[0.98039365,0.0023540473,0.008489456,0.007211031,0.00079653895,0.000038859704,0.00007362713,0.000044453554,0.00059834967],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956742,0.00041789643,0.002791268,0.0004176742,0.00032528807,0.00037368966],"domain_scores_gemma":[0.99307877,0.0033714164,0.002235746,0.000216568,0.00046794134,0.0006295579],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014861389,0.00029275595,0.0028943024,0.0002370935,0.00007703072,0.000030093734,0.00022414366,0.0003624385,0.001233588],"category_scores_gemma":[0.001549557,0.00019329318,0.00097598566,0.0007523168,0.00017744029,0.00009568721,0.000055255183,0.00072622194,0.0000035606645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7553523,0.0017394259,0.053486,0.0004940199,0.035242718,0.0016240121,0.00251663,0.000986931,0.0042379107,0.0000024682702,0.03290837,0.1114092],"study_design_scores_gemma":[0.43068293,0.067333,0.1165393,0.0005425394,0.11056574,0.00035804746,0.002472692,0.18966231,0.0025677218,0.000053256557,0.077967025,0.0012554617],"about_ca_topic_score_codex":0.00075949694,"about_ca_topic_score_gemma":0.0011467347,"teacher_disagreement_score":0.3246694,"about_ca_system_score_codex":0.00029864936,"about_ca_system_score_gemma":0.002985124,"threshold_uncertainty_score":0.99967945},"labels":[],"label_agreement":null},{"id":"W3009161381","doi":"10.1200/jco.2007.25.18_suppl.7680","title":"Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Interim analysis; Internal medicine; Toxicity; Adverse effect; Bortezomib; Oncology; Phases of clinical research; Surgery; Cancer; Clinical trial; Multiple myeloma; Epidermal growth factor receptor","score_opus":0.039429499872711354,"score_gpt":0.47383255368477173,"score_spread":0.43440305381206035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009161381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952501,0.001051103,0.00013019175,0.0005693971,0.00017403469,0.0020161225,0.0000017544554,0.000003733695,0.00080358575],"genre_scores_gemma":[0.9976506,0.0008269053,0.0010628483,0.00017202825,0.000070200374,0.000039701034,0.0000035342944,0.000013520968,0.00016064597],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99692565,0.00029901296,0.0022188353,0.00017346433,0.00019686559,0.00018615041],"domain_scores_gemma":[0.99644834,0.0014222917,0.0015307441,0.00010333624,0.00032251378,0.00017278589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030806668,0.00013074139,0.0019234394,0.0002655787,0.000024421617,0.0000028688,0.000056420857,0.00014613614,0.000018368539],"category_scores_gemma":[0.0004685091,0.00008309854,0.00011785594,0.0002524776,0.00010437292,0.000088621855,0.000017718758,0.0004306069,1.419233e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42817947,0.032222595,0.46485195,0.00007324495,0.0006449846,0.0008396881,0.0039984053,0.0001384032,0.00023000811,0.000004679867,0.000040559564,0.06877603],"study_design_scores_gemma":[0.73336077,0.033558186,0.2300253,0.00030928708,0.0012990354,0.000028539613,0.00083814986,0.00026302855,0.00014488162,0.000012247279,0.00009346513,0.0000671138],"about_ca_topic_score_codex":0.0004303766,"about_ca_topic_score_gemma":0.0032363208,"teacher_disagreement_score":0.3051813,"about_ca_system_score_codex":0.00022065725,"about_ca_system_score_gemma":0.0009436784,"threshold_uncertainty_score":0.33886603},"labels":[],"label_agreement":null},{"id":"W3009200944","doi":"10.1200/jco.19.02267","title":"17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Myriad Genetics; Genomic Health; Canary Foundation","keywords":"Medicine; Prostatectomy; Prostate cancer; Prostate-specific antigen; Cohort; Proportional hazards model; Confidence interval; Hazard ratio; Prostate; Biopsy; Internal medicine; Prostate biopsy; Oncology; Urology; Gynecology; Cancer","score_opus":0.12850223301088218,"score_gpt":0.4313337316948993,"score_spread":0.30283149868401715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009200944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.930956,0.0004886941,0.000001170908,0.06521142,0.00037570612,0.0018135008,0.0001520003,0.000009006007,0.0009925169],"genre_scores_gemma":[0.989582,0.0020780216,0.00018120058,0.007146856,0.0008232086,0.00006589961,0.000024712079,0.000022043367,0.00007604841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546844,0.00077222206,0.0025656736,0.00038885963,0.0004659172,0.00033890535],"domain_scores_gemma":[0.99376404,0.0034850829,0.0016783894,0.00027628202,0.00038970192,0.00040653057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004053656,0.00021221665,0.0015486258,0.000071093724,0.000056154473,0.00001790036,0.00026340358,0.00015119181,0.000020087446],"category_scores_gemma":[0.0043233642,0.00012205611,0.00026425862,0.00030950794,0.00017017279,0.00009537755,0.00007871576,0.0011909875,0.000014812968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012580973,0.004575141,0.9385635,0.000017624334,0.00046365618,0.006340793,0.0022523727,0.000060555903,0.00008739228,0.0000014712632,0.009795528,0.025260936],"study_design_scores_gemma":[0.01610996,0.04186548,0.9227054,0.000058080503,0.00024297096,0.00016782647,0.0009667824,0.00003360964,0.00005898915,0.000028088876,0.017657382,0.000105405976],"about_ca_topic_score_codex":0.00019429109,"about_ca_topic_score_gemma":0.00095007796,"teacher_disagreement_score":0.058626026,"about_ca_system_score_codex":0.00041757952,"about_ca_system_score_gemma":0.0024101865,"threshold_uncertainty_score":0.5175783},"labels":[],"label_agreement":null},{"id":"W3009266170","doi":"10.1200/jco.2007.25.18_suppl.1024","title":"Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Progesterone receptor; Breast cancer; Estrogen receptor; Internal medicine; Metastasis; Axilla; Adjuvant therapy; Oncology; Primary tumor; Metastatic breast cancer; Adjuvant; Hormone receptor; Biopsy; HER2/neu; Stage (stratigraphy); Cancer; Gynecology","score_opus":0.04502013857726858,"score_gpt":0.37743468028053756,"score_spread":0.332414541703269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009266170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928123,0.003251153,0.00014912058,0.0032736014,0.00014163512,0.00022105275,0.00009965588,0.0000044514277,0.00004705517],"genre_scores_gemma":[0.9723288,0.0049413946,0.021201633,0.00060263294,0.00074089604,0.000017023987,0.00007351749,0.00003423598,0.000059865844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768215,0.00039368725,0.0009988077,0.00036513145,0.00015407374,0.00040616747],"domain_scores_gemma":[0.9977449,0.00077534385,0.0009125637,0.00015040374,0.0001568204,0.00025993472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016790396,0.00023202373,0.0010961636,0.000082798884,0.000049618055,0.000013015513,0.00011973177,0.0002144707,0.000013320141],"category_scores_gemma":[0.0003480994,0.00016191653,0.00007382623,0.000096157026,0.0005819789,0.000017271077,0.0001390836,0.0003400178,0.0000023787516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036781146,0.00045363535,0.8315338,0.000038945473,0.0004739715,0.00010785064,0.00011620869,8.1589207e-7,0.009547684,0.000009086704,0.00028702876,0.15375288],"study_design_scores_gemma":[0.0051242337,0.007866564,0.97132146,0.000080487815,0.00020770528,0.00063528,0.00025272323,4.1132606e-7,0.0025784834,0.00004878652,0.011685341,0.00019852842],"about_ca_topic_score_codex":0.00003436411,"about_ca_topic_score_gemma":0.0005524072,"teacher_disagreement_score":0.15355435,"about_ca_system_score_codex":0.00006923975,"about_ca_system_score_gemma":0.00035993976,"threshold_uncertainty_score":0.6602765},"labels":[],"label_agreement":null},{"id":"W3009513461","doi":"10.1200/jco.2007.25.18_suppl.5519","title":"CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Sorafenib; Clinical endpoint; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Surrogate endpoint; Phases of clinical research; Ovarian cancer; Chemotherapy; Progression-free survival; Clinical trial; Cancer; Gastroenterology; Surgery; Hepatocellular carcinoma","score_opus":0.07201841788440105,"score_gpt":0.46034708735349583,"score_spread":0.3883286694690948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009513461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215126,0.00029799962,0.0000052771024,0.0055270656,0.00073711394,0.0009246291,0.00003724364,0.0000027824813,0.00031664156],"genre_scores_gemma":[0.9976878,0.0005181987,0.0007207638,0.0005445067,0.00035424804,0.000013561278,0.0000033237227,0.000019515248,0.00013808854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421996,0.0007457394,0.003908918,0.00029588837,0.0005585796,0.00027092185],"domain_scores_gemma":[0.99132794,0.0037473228,0.003455178,0.00032371248,0.00076813623,0.00037771947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063263085,0.00020903893,0.0022292777,0.00016551488,0.00003951118,0.000004017237,0.00013451398,0.00035528318,0.00018972752],"category_scores_gemma":[0.00281212,0.000104493454,0.00034993445,0.0003400131,0.0005552714,0.00006735137,0.000060258757,0.00080887694,6.458475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45109487,0.012130012,0.4585902,0.000013274365,0.0005657249,0.00015541619,0.000054147706,0.0000028074608,0.0000042088395,0.00001962062,0.00019433259,0.07717541],"study_design_scores_gemma":[0.2647023,0.103339665,0.62596136,0.00038962232,0.000831249,0.000027514765,0.00003090598,0.000006627627,0.000041341755,0.000018862589,0.004583591,0.00006694485],"about_ca_topic_score_codex":0.00023785798,"about_ca_topic_score_gemma":0.00083652366,"teacher_disagreement_score":0.18639258,"about_ca_system_score_codex":0.00019224668,"about_ca_system_score_gemma":0.0025312041,"threshold_uncertainty_score":0.44902474},"labels":[],"label_agreement":null},{"id":"W3009722442","doi":"10.1200/jco.2007.25.18_suppl.4028","title":"Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Oxaliplatin; Medicine; FOLFOX; Capecitabine; Bevacizumab; Internal medicine; Oncology; Regimen; Colorectal cancer; Chemotherapy; Fluorouracil; Chemotherapy regimen; Cancer","score_opus":0.1315895413467038,"score_gpt":0.5133118688873759,"score_spread":0.3817223275406721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009722442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98485464,0.00037711542,0.00023172605,0.009589776,0.0020698286,0.0023577225,0.000043863736,0.000016196878,0.00045910515],"genre_scores_gemma":[0.9944268,0.0012087994,0.0016494306,0.00109466,0.0011341564,0.00006326462,0.00013042058,0.000028991331,0.00026351336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920676,0.0012338646,0.0053555113,0.00039774273,0.00049051363,0.0004548038],"domain_scores_gemma":[0.9789698,0.017126353,0.002945512,0.00015144098,0.0004113199,0.00039555453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008811241,0.0003020407,0.004124316,0.00053114473,0.000045141187,0.000011534886,0.0001885874,0.00042691876,0.00068699254],"category_scores_gemma":[0.005447248,0.00018560828,0.00048571755,0.00064869673,0.00035383014,0.00016039977,0.000039583054,0.0014234366,0.000007946927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92018664,0.020900015,0.00097409973,0.000011887203,0.0013212721,0.0036388894,0.0006806276,0.000098565615,0.00013143873,0.000013581267,0.0012759606,0.05076703],"study_design_scores_gemma":[0.93112665,0.049860463,0.00880911,0.0002001078,0.0020260531,0.000095438154,0.00009422768,0.000867558,0.00036974315,0.00015249221,0.0062215826,0.00017658257],"about_ca_topic_score_codex":0.0013643485,"about_ca_topic_score_gemma":0.02189419,"teacher_disagreement_score":0.050590448,"about_ca_system_score_codex":0.0008060448,"about_ca_system_score_gemma":0.0029048882,"threshold_uncertainty_score":0.9959537},"labels":[],"label_agreement":null},{"id":"W3009755741","doi":"10.1200/jco.2007.25.18_suppl.5018","title":"Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); London Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Hazard ratio; Urology; Prostate cancer; Internal medicine; Population; Randomized controlled trial; Surgery; Gastroenterology; Oncology; Cancer; Confidence interval; Pathology","score_opus":0.05724346998701832,"score_gpt":0.47168772083188726,"score_spread":0.4144442508448689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009755741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077374,0.0022509627,0.000025428837,0.0019937705,0.0001836807,0.0034529916,0.000022560624,0.0000013429805,0.0012955212],"genre_scores_gemma":[0.99014145,0.009031078,0.00025496286,0.00006110112,0.00016355328,0.000015633546,0.0000023145976,0.000010081246,0.00031980735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99310744,0.0011237732,0.0048221643,0.00014763525,0.0005793831,0.00021962881],"domain_scores_gemma":[0.9834915,0.011311235,0.004376415,0.00017324921,0.00045070628,0.00019689694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01442396,0.00013709301,0.0043614474,0.00018493258,0.000019590778,0.0000019026611,0.00011625974,0.00015711381,0.000017712808],"category_scores_gemma":[0.0050974903,0.000059090722,0.0005756983,0.00022177257,0.0010071963,0.000054670283,0.00003385677,0.0006369433,9.879868e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9593597,0.005552021,0.001368361,0.00004865724,0.0016873564,0.00016086052,0.0006298198,0.00001372637,0.001360582,0.000010503156,0.000112155045,0.029696258],"study_design_scores_gemma":[0.95529777,0.026851103,0.014795951,0.00029065215,0.0013417877,0.000021755217,0.00026727107,0.000080360755,0.0005675214,0.000036139583,0.0004005231,0.000049151273],"about_ca_topic_score_codex":0.00015467718,"about_ca_topic_score_gemma":0.00011270683,"teacher_disagreement_score":0.029647106,"about_ca_system_score_codex":0.00012740502,"about_ca_system_score_gemma":0.0022008985,"threshold_uncertainty_score":0.610254},"labels":[],"label_agreement":null},{"id":"W3009778269","doi":"10.1200/jco.2007.25.18_suppl.16540","title":"Predictors of toxicity to concurrent chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Head and neck cancer; Toxicity; Internal medicine; Context (archaeology); Cancer; Radiation therapy; Oncology; Surgery","score_opus":0.04742409246323063,"score_gpt":0.4224163027613116,"score_spread":0.37499221029808094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009778269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601144,0.0006649159,0.000099837365,0.0012584996,0.00079268095,0.00031072283,0.0000051820707,0.0000039008137,0.0008528524],"genre_scores_gemma":[0.99704796,0.0004938937,0.00074258755,0.0013225152,0.0003446089,0.0000036819765,9.946787e-7,0.000010070578,0.0000336678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975586,0.000080539845,0.0016358782,0.00016639555,0.0003308053,0.00022778656],"domain_scores_gemma":[0.9974881,0.00068530353,0.0009022266,0.00008530114,0.00047159888,0.00036750286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012125628,0.00011869931,0.0012669398,0.00011977579,0.000018548168,0.0000018468778,0.00006557281,0.00017266248,0.000017220076],"category_scores_gemma":[0.0010531691,0.00008137221,0.00009452043,0.0001813872,0.00012977187,0.00006794517,0.000032292326,0.00048163324,9.828564e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009183253,0.0016903493,0.83367306,0.00006975961,0.000047162735,0.000040753945,0.00032952896,0.00006427365,0.00014754782,0.0000030332512,0.0006539968,0.1540973],"study_design_scores_gemma":[0.023433812,0.038136635,0.9298131,0.00025424192,0.00009586248,0.0000062087374,0.00008771608,0.000021310816,0.00084340473,0.000004212559,0.0072281645,0.00007533651],"about_ca_topic_score_codex":0.000055454268,"about_ca_topic_score_gemma":0.001130404,"teacher_disagreement_score":0.15402196,"about_ca_system_score_codex":0.00027713328,"about_ca_system_score_gemma":0.00080344634,"threshold_uncertainty_score":0.33182624},"labels":[],"label_agreement":null},{"id":"W3009982165","doi":"10.1200/jco.2007.25.18_suppl.2554","title":"Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Capecitabine; Oxaliplatin; Irinotecan; Bevacizumab; Internal medicine; Colorectal cancer; Regimen; FOLFOX; Gastroenterology; Pharmacokinetics; Oncology; Cancer; Chemotherapy","score_opus":0.21257378462741217,"score_gpt":0.5383188680677896,"score_spread":0.32574508344037745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009982165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98895943,0.0008457855,0.0004926094,0.0077086715,0.0009799832,0.00077283726,0.000043236556,0.000005585129,0.00019186184],"genre_scores_gemma":[0.99506944,0.0012703914,0.0024040684,0.00019189669,0.00076771335,0.00004080379,0.000025022664,0.000016900962,0.00021373485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971148,0.00017140359,0.0021289417,0.00017613651,0.00017954202,0.00022922149],"domain_scores_gemma":[0.9922738,0.005774126,0.001329849,0.00006572333,0.0003217239,0.00023476925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013123143,0.00016327309,0.0015370783,0.00030761168,0.000034397184,0.0000036150009,0.00006113642,0.00013991537,0.00028821838],"category_scores_gemma":[0.0003999408,0.00012304261,0.00029418655,0.00015033055,0.00014986533,0.00009404916,0.000016066257,0.00030339637,0.0000011044851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02084366,0.009980496,0.5119502,0.00012744735,0.0020128677,0.00023073837,0.0012253138,0.000059893347,0.0043533663,0.00004638619,0.0009148457,0.4482548],"study_design_scores_gemma":[0.118701495,0.073897935,0.73596954,0.00016117557,0.0046638967,0.00020372598,0.0002103422,0.00093223277,0.00850107,0.0008948296,0.055674072,0.00018969715],"about_ca_topic_score_codex":0.00019468249,"about_ca_topic_score_gemma":0.0029080003,"teacher_disagreement_score":0.44806507,"about_ca_system_score_codex":0.0005527343,"about_ca_system_score_gemma":0.0005406002,"threshold_uncertainty_score":0.5017532},"labels":[],"label_agreement":null},{"id":"W3010040987","doi":"10.1200/jco.2007.25.18_suppl.5002","title":"Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Urology; Prostatectomy; Internal medicine; Goserelin; Clinical endpoint; Cancer; Gynecology; Surgery; Clinical trial","score_opus":0.089814145008371,"score_gpt":0.49152939935460704,"score_spread":0.40171525434623606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010040987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951529,0.0003527498,0.000133084,0.0008643876,0.00026360786,0.003150646,0.00006137245,0.000009538238,0.000011706797],"genre_scores_gemma":[0.99516314,0.0007163384,0.0035648863,0.00023433722,0.00009253318,0.000059764057,0.000014767386,0.000023090808,0.00013114566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966201,0.00031749214,0.0018444064,0.00034670933,0.0005056721,0.0003656015],"domain_scores_gemma":[0.9957855,0.0012376333,0.001361202,0.00016214649,0.00092508964,0.0005284724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024476035,0.00022546187,0.0017269793,0.00025329916,0.00013601253,0.0000143155985,0.000092308364,0.0001941077,0.000018784684],"category_scores_gemma":[0.0015261443,0.00012210311,0.00017581544,0.00020697803,0.00029578418,0.00012332156,0.00008727638,0.00046564193,4.9148764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16531292,0.0094448365,0.7203932,0.00006896811,0.0010562873,0.00023673466,0.0009861932,0.0000074836666,0.00015717043,0.0000026898163,0.00008720599,0.102246344],"study_design_scores_gemma":[0.24444993,0.18256184,0.5692516,0.00012199971,0.0014123536,0.000015316604,0.0007393385,0.000075807,0.00046373362,0.000053920976,0.00072884356,0.00012530135],"about_ca_topic_score_codex":0.00012298323,"about_ca_topic_score_gemma":0.00019167586,"teacher_disagreement_score":0.173117,"about_ca_system_score_codex":0.00014021459,"about_ca_system_score_gemma":0.0004508414,"threshold_uncertainty_score":0.497922},"labels":[],"label_agreement":null},{"id":"W3010060692","doi":"10.1200/jco.2007.25.18_suppl.5543","title":"A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tirapazamine; Medicine; Regimen; Radiation therapy; Cervical cancer; Neutropenia; Urology; Phases of clinical research; Cancer; Nuclear medicine; Internal medicine; Chemotherapy","score_opus":0.04851446259004097,"score_gpt":0.44644198395906926,"score_spread":0.3979275213690283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010060692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982848,0.0001579928,0.000089502784,0.00059668935,0.00012771864,0.00057315856,0.00000181955,0.0000021425517,0.00016613124],"genre_scores_gemma":[0.9989482,0.00008624008,0.00060621195,0.00024611477,0.000080887025,0.0000066482817,0.0000034723164,0.000009098805,0.000013086114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975354,0.00016936824,0.0015782439,0.00015324976,0.0004119693,0.00015177418],"domain_scores_gemma":[0.99737877,0.0010144206,0.0010231674,0.00007711834,0.0003283557,0.0001781571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013760906,0.00010479742,0.0010239115,0.0002988438,0.000010408391,0.0000022554182,0.000051059284,0.00013715358,0.000027456694],"category_scores_gemma":[0.0005602454,0.00006321139,0.000044547734,0.00050515984,0.000077197554,0.00010840582,0.000014355557,0.0004389672,2.7504348e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05578653,0.018486852,0.59966934,0.000016086733,0.000087667,0.00011787665,0.00014591111,0.000024277706,0.000007680519,0.000004871332,0.0000027356366,0.32565016],"study_design_scores_gemma":[0.17650205,0.12535639,0.6975149,0.000119349716,0.00012441305,0.0000051995885,0.00019476503,0.00003418384,0.000019112982,0.000019147605,0.00006711985,0.0000433855],"about_ca_topic_score_codex":0.00013944699,"about_ca_topic_score_gemma":0.0016676027,"teacher_disagreement_score":0.3256068,"about_ca_system_score_codex":0.000208291,"about_ca_system_score_gemma":0.00034302555,"threshold_uncertainty_score":0.25776854},"labels":[],"label_agreement":null},{"id":"W3010105342","doi":"10.1200/jco.19.01265","title":"Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Irinotecan; Wilms' tumor; Vincristine; Oncology; Stage (stratigraphy); Internal medicine; Pediatric oncology; Disease; Anaplasia; Chemotherapy; Cancer; Pathology; Colorectal cancer; Cyclophosphamide","score_opus":0.04122866217729047,"score_gpt":0.3770713239223553,"score_spread":0.33584266174506483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010105342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959768,0.000509442,0.000013486604,0.0029548062,0.00017992489,0.00027830814,0.00005246027,0.0000010058812,0.000033766282],"genre_scores_gemma":[0.9981851,0.0011289566,0.00007611651,0.0004714166,0.000107861735,0.000002582798,0.0000014154298,0.000008378591,0.000018152814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761176,0.0005180457,0.0013338937,0.00022833362,0.00017595048,0.00013199923],"domain_scores_gemma":[0.99732894,0.00043905535,0.0017115559,0.00017032593,0.00011331247,0.00023683022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083867187,0.00013072406,0.0009873423,0.00004983316,0.000026259233,0.000002069731,0.00022837376,0.00017503674,0.0000036165138],"category_scores_gemma":[0.002440521,0.000075839176,0.00018228214,0.00011735601,0.00033301333,0.0000057987636,0.00022936928,0.00040227376,5.4720477e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03436634,0.005716578,0.8775237,0.00004139482,0.00065040815,0.000058494414,0.00039211416,0.00026593747,0.039951272,0.0000082903825,0.0002164207,0.04080902],"study_design_scores_gemma":[0.011274489,0.03545376,0.9491738,0.000028882841,0.00009225461,0.00000948229,0.00010906636,0.000035186382,0.0024309305,0.000012505841,0.0013018807,0.000077727724],"about_ca_topic_score_codex":0.000085134714,"about_ca_topic_score_gemma":0.00024262356,"teacher_disagreement_score":0.0716501,"about_ca_system_score_codex":0.000019732937,"about_ca_system_score_gemma":0.0004039937,"threshold_uncertainty_score":0.3092632},"labels":[],"label_agreement":null},{"id":"W3010131774","doi":"10.1200/jco.2007.25.18_suppl.540","title":"Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Breast cancer; Letrozole; Internal medicine; Tamoxifen; Oncology; Clinical endpoint; Placebo; Cancer; Gynecology; Randomized controlled trial; Pathology","score_opus":0.07493129269012377,"score_gpt":0.47237840394125247,"score_spread":0.3974471112511287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010131774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416894,0.0010103752,0.00033119234,0.0012149987,0.0012605633,0.0016053629,0.000028324337,0.0000062247577,0.0003740511],"genre_scores_gemma":[0.9945441,0.00054948137,0.0026709794,0.00092496263,0.0011671593,0.00003854572,0.0000020169725,0.000029863666,0.000072912],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944825,0.0003413902,0.0040964563,0.00020915852,0.0005034962,0.00036697864],"domain_scores_gemma":[0.9893103,0.0049698898,0.004256479,0.00017646365,0.0010590764,0.00022776896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004694337,0.00020210832,0.003102062,0.00027416064,0.000025570484,0.0000025320871,0.00019426788,0.00031096637,0.00014729559],"category_scores_gemma":[0.002412818,0.00013948925,0.00072435144,0.00016643612,0.00022338316,0.00010345889,0.00002924174,0.00062917685,7.172468e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74978924,0.0041737426,0.0624535,0.000036459653,0.0005426273,0.000046303503,0.0002110344,0.00005059779,0.0008646652,0.000036456935,0.000028190327,0.18176717],"study_design_scores_gemma":[0.6307483,0.02359963,0.34140506,0.00032871272,0.00023269198,0.00007541415,0.00025658976,0.000035208872,0.0006091306,0.00032476187,0.002279659,0.00010486478],"about_ca_topic_score_codex":0.00008697501,"about_ca_topic_score_gemma":0.00018386784,"teacher_disagreement_score":0.27895156,"about_ca_system_score_codex":0.00030022115,"about_ca_system_score_gemma":0.0017711733,"threshold_uncertainty_score":0.56882066},"labels":[],"label_agreement":null},{"id":"W3010161595","doi":"10.1200/jco.2007.25.18_suppl.1003","title":"A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Taxane; Adverse effect; Gastroenterology; Placebo; Nausea; Neutropenia; Febrile neutropenia; Stomatitis; Metastatic breast cancer; Anthracycline; Chemotherapy; Breast cancer; Pharmacology; Oncology; Cancer; Pathology","score_opus":0.17119473350791267,"score_gpt":0.5148333912451809,"score_spread":0.3436386577372682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010161595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98586977,0.00026658576,0.000042827993,0.008674954,0.0012529433,0.0035119688,0.000016297041,0.0000068571576,0.0003577776],"genre_scores_gemma":[0.9975012,0.00008998977,0.0003949611,0.0012289982,0.00046436072,0.00011674983,0.0000048345596,0.000023479495,0.00017542731],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99400175,0.0011834366,0.0035315822,0.00029963502,0.0005889401,0.00039464023],"domain_scores_gemma":[0.99402213,0.0027295481,0.0020989238,0.00021510845,0.00057145883,0.0003628127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071929824,0.00027420343,0.003303928,0.0005134026,0.00006068752,0.000009981035,0.00023658553,0.00018512143,0.00024434997],"category_scores_gemma":[0.00048532902,0.00015913075,0.00034232793,0.00081273826,0.00034116878,0.00014157822,0.00009841632,0.0011234803,0.0000025453903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9181847,0.039464183,0.030759322,0.00004165727,0.00077984494,0.0009220884,0.0018704811,0.0005196083,0.00027108303,0.000048621034,0.00069713726,0.006441273],"study_design_scores_gemma":[0.906879,0.038753476,0.04955614,0.00028304238,0.001634811,0.00025137587,0.000987112,0.00021992363,0.00023976121,0.000053677213,0.0009964887,0.00014516256],"about_ca_topic_score_codex":0.001510682,"about_ca_topic_score_gemma":0.012595554,"teacher_disagreement_score":0.018796818,"about_ca_system_score_codex":0.000759741,"about_ca_system_score_gemma":0.0018521955,"threshold_uncertainty_score":0.7028614},"labels":[],"label_agreement":null},{"id":"W3010193189","doi":"10.1200/jco.2012.30.15_suppl.e21083","title":"Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Calgary","funders":"","keywords":"Immunohistochemistry; Medicine; Oncology; Internal medicine; Estrogen receptor; Breast cancer; Tissue microarray; Cancer; Pathology","score_opus":0.06581803215473112,"score_gpt":0.46434505826316436,"score_spread":0.39852702610843327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010193189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476504,0.002350025,0.0000961866,0.0011781323,0.00082619133,0.00016546331,0.000103985454,0.0000034606605,0.0005114853],"genre_scores_gemma":[0.9909797,0.00099801,0.0071508368,0.00017158102,0.0005972981,0.000025002924,0.000019584946,0.000022614744,0.000035415193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697316,0.0005390667,0.0016417254,0.0002317296,0.0002549851,0.0003593104],"domain_scores_gemma":[0.9968606,0.00059407705,0.0016689944,0.00018976525,0.0004799623,0.00020658299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011818454,0.0002153116,0.0010878771,0.00008228815,0.00003385116,0.000004666363,0.00025372332,0.00038321497,0.000106037674],"category_scores_gemma":[0.00068662676,0.00016950791,0.00038967375,0.0001634452,0.00040417968,0.000024732493,0.00013326362,0.0005259101,0.000005917385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059136814,0.0025333713,0.9246319,0.000022071246,0.0017557377,0.000027849357,0.00044979036,0.00003556491,0.05090539,0.0001975649,0.0026408916,0.010886204],"study_design_scores_gemma":[0.0051498297,0.0033360391,0.979034,0.00008502308,0.00021339534,0.000091492424,0.00041700952,0.000010104234,0.0090342285,0.000058555546,0.0023805054,0.00018978537],"about_ca_topic_score_codex":0.0005610454,"about_ca_topic_score_gemma":0.000083341074,"teacher_disagreement_score":0.05440215,"about_ca_system_score_codex":0.00027947134,"about_ca_system_score_gemma":0.0010314188,"threshold_uncertainty_score":0.6912332},"labels":[],"label_agreement":null},{"id":"W3010324288","doi":"10.1200/jco.2007.25.18_suppl.2019","title":"Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oligodendroglioma; Pathological; Retrospective cohort study; Glioma; Complication; Surgery; Internal medicine; Astrocytoma","score_opus":0.08211298544622352,"score_gpt":0.4832475815914791,"score_spread":0.4011345961452556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010324288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897591,0.0025101807,0.0006695768,0.00558133,0.0006705509,0.00011410214,0.000007764316,0.000009739429,0.0006776392],"genre_scores_gemma":[0.9909777,0.00061469956,0.00492493,0.002357559,0.0010830837,0.0000015351914,0.0000082062315,0.000013983662,0.00001829537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99557745,0.0003529301,0.0030671523,0.00029921727,0.00043766975,0.00026558645],"domain_scores_gemma":[0.99303377,0.0035632225,0.0013093216,0.00026590002,0.00031140848,0.0015163776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004456503,0.00015978978,0.0020724258,0.0003490641,0.00003464833,0.000013344315,0.0001156963,0.00035410924,0.00015228652],"category_scores_gemma":[0.002847184,0.00011112235,0.0013700742,0.00037695302,0.0003265615,0.000066951325,0.00007012035,0.0006870587,0.000014662906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029237303,0.0032350828,0.903368,0.0000047445274,0.004460565,0.015108449,0.000021604374,0.000006442256,0.00009207159,0.0001306091,0.0007309575,0.06991774],"study_design_scores_gemma":[0.009901037,0.003866726,0.96684486,0.000031178002,0.010093821,0.00007609953,0.00004494035,0.00011523956,0.00019379257,0.000478101,0.008260071,0.000094123796],"about_ca_topic_score_codex":0.000024011759,"about_ca_topic_score_gemma":0.000038232458,"teacher_disagreement_score":0.069823615,"about_ca_system_score_codex":0.00006322349,"about_ca_system_score_gemma":0.00049457623,"threshold_uncertainty_score":0.45314378},"labels":[],"label_agreement":null},{"id":"W3010327104","doi":"10.1200/jco.2007.25.18_suppl.4033","title":"Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Clinical endpoint; Irinotecan; Gastroenterology; Placebo; Bevacizumab; Adverse effect; Interim analysis; Phases of clinical research; Cancer; Oncology; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.17972293266487527,"score_gpt":0.5009832734707488,"score_spread":0.3212603408058735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010327104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941017,0.0005920026,0.0000530398,0.0012790642,0.00059729425,0.002472908,0.00003291212,0.000007110487,0.000863975],"genre_scores_gemma":[0.9969943,0.00077375653,0.0012472281,0.00023655916,0.00034869276,0.00008584889,0.000009852024,0.000021488895,0.00028227217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99399376,0.0005642538,0.0040233214,0.00037062482,0.00069832004,0.00034971946],"domain_scores_gemma":[0.98592633,0.009541302,0.002939393,0.0001277088,0.0011600781,0.00030521292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007890206,0.00029259783,0.0033685744,0.00035650798,0.00008461118,0.000012309613,0.00012331728,0.00018139268,0.00009676998],"category_scores_gemma":[0.005072551,0.0001673632,0.00028645722,0.00036743487,0.000504503,0.00014102229,0.000081493854,0.0007886282,7.9138556e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.847251,0.013777354,0.0771781,0.00004277928,0.0019803643,0.0008325232,0.0017694677,0.00003511702,0.000013554358,0.000006452342,0.00018864796,0.056924663],"study_design_scores_gemma":[0.8099039,0.053968724,0.13154943,0.00030050307,0.0015774175,0.00009944694,0.0012360088,0.00015854968,0.00007010595,0.000016405096,0.0009747767,0.00014470713],"about_ca_topic_score_codex":0.00075717375,"about_ca_topic_score_gemma":0.01735056,"teacher_disagreement_score":0.05677996,"about_ca_system_score_codex":0.0003533344,"about_ca_system_score_gemma":0.0014050804,"threshold_uncertainty_score":0.968202},"labels":[],"label_agreement":null},{"id":"W3010524227","doi":"10.1200/jco.2007.25.18_suppl.4051","title":"Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Credit Valley Hospital; University of Toronto","funders":"","keywords":"Medicine; Stage (stratigraphy); Colorectal cancer; Cancer; Internal medicine; General surgery; Gynecology","score_opus":0.22646907430993055,"score_gpt":0.5450717316867966,"score_spread":0.318602657376866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010524227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98065984,0.00065083266,0.01063763,0.003794117,0.0031055128,0.00036656964,0.0000048304114,0.000015775167,0.0007649013],"genre_scores_gemma":[0.9886297,0.00025167945,0.007429319,0.0011609173,0.0018880897,0.000015180898,8.8764574e-7,0.000012044453,0.0006121651],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975347,0.00011107773,0.001651483,0.00021224587,0.00026497425,0.00022552605],"domain_scores_gemma":[0.99577415,0.0018846288,0.0008837241,0.00007173628,0.0010496184,0.00033613166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059976955,0.00011194681,0.0009095868,0.00013385055,0.00012263378,0.000008567173,0.000066183056,0.0002530296,0.000023321287],"category_scores_gemma":[0.008320021,0.00008514538,0.00030895765,0.00022394124,0.000065683154,0.00012331671,0.000045683155,0.00048104982,7.528086e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21505283,0.00037152352,0.10757188,0.000046285666,0.0005043814,0.0001810009,0.0006392917,0.00011047413,0.0068674795,0.00005967958,0.008532605,0.66006255],"study_design_scores_gemma":[0.016353507,0.28966287,0.5255044,0.00036490138,0.0002425157,0.00028851037,0.00094053993,0.00096049975,0.006040732,0.00015879542,0.1592072,0.00027551537],"about_ca_topic_score_codex":0.0002212224,"about_ca_topic_score_gemma":0.0050055087,"teacher_disagreement_score":0.65978706,"about_ca_system_score_codex":0.00020793315,"about_ca_system_score_gemma":0.0007429456,"threshold_uncertainty_score":0.99604446},"labels":[],"label_agreement":null},{"id":"W3010571361","doi":"10.1200/jco.2007.25.18_suppl.5058","title":"A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nomogram; Prostate cancer; Internal medicine; Proportional hazards model; Urology; Docetaxel; Progression-free survival; Oncology; Gastroenterology; Cancer; Chemotherapy","score_opus":0.1563649281206174,"score_gpt":0.5123378466243577,"score_spread":0.35597291850374024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010571361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889138,0.0042669857,0.00030406006,0.0037656447,0.0007718058,0.0007968294,0.00000741148,0.000014403506,0.0011590567],"genre_scores_gemma":[0.98729837,0.0019213186,0.00904963,0.000582819,0.00064001704,0.000021888725,0.0000066694715,0.000030434121,0.0004488273],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953226,0.00040542264,0.002934261,0.0002497894,0.000560349,0.000527575],"domain_scores_gemma":[0.9938525,0.0029216856,0.0018139407,0.0001677363,0.0006749949,0.0005691408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059910263,0.00020096156,0.0014210508,0.00036325716,0.000038993854,0.00001585513,0.00016180448,0.0002662077,0.000046337253],"category_scores_gemma":[0.004356955,0.00013195894,0.00030974735,0.00045239352,0.00032315648,0.00015559708,0.00007087774,0.0016785414,0.000011483749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016200602,0.0071510244,0.4470234,0.00013295597,0.00071020133,0.009338136,0.00064832746,0.00007422056,0.0039293687,0.000043379096,0.0007670252,0.51398134],"study_design_scores_gemma":[0.026163243,0.026823962,0.92819625,0.00041377495,0.00053845765,0.0002719807,0.00043141816,0.00052089634,0.00029756752,0.0006582285,0.0154836085,0.00020063107],"about_ca_topic_score_codex":0.00016042784,"about_ca_topic_score_gemma":0.00048425526,"teacher_disagreement_score":0.5137807,"about_ca_system_score_codex":0.00050694286,"about_ca_system_score_gemma":0.0024257747,"threshold_uncertainty_score":0.72925204},"labels":[],"label_agreement":null},{"id":"W3010594462","doi":"10.1200/jco.19.01825","title":"Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Survivorship curve; Cancer; Internal medicine; Cog; Colorectal cancer; Cancer survivor; Pediatrics","score_opus":0.11064464638705379,"score_gpt":0.44315888142466997,"score_spread":0.3325142350376162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010594462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96384245,0.0029417532,0.00014060331,0.026500348,0.003986508,0.002241977,0.00017999236,0.000032390635,0.00013394994],"genre_scores_gemma":[0.9838061,0.0011888656,0.0007394481,0.0098778745,0.0040101907,0.00018056687,0.000006425109,0.00006844832,0.00012213436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99242467,0.0013776658,0.0039740643,0.00083640526,0.0007737885,0.00061342464],"domain_scores_gemma":[0.99205893,0.003681192,0.0019627684,0.00035195806,0.0007169486,0.0012281864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072522666,0.00042649437,0.0037413265,0.000217858,0.00008815032,0.000038897982,0.00034897384,0.00045090457,0.0002485856],"category_scores_gemma":[0.0061481744,0.00035471498,0.0006058465,0.0006191548,0.00014079835,0.00022846038,0.00016657599,0.0013964509,0.0000107578135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005923853,0.0029122524,0.91058266,0.00020232481,0.0009699841,0.000100283876,0.007815359,0.00009621626,0.00012657857,0.0000136951485,0.003959257,0.0672975],"study_design_scores_gemma":[0.014556257,0.028170533,0.92881733,0.00033492275,0.0003200383,0.000031191157,0.0027401226,0.000046085148,0.00006367459,0.000051753614,0.024504231,0.00036388592],"about_ca_topic_score_codex":0.0040556355,"about_ca_topic_score_gemma":0.060828257,"teacher_disagreement_score":0.06693362,"about_ca_system_score_codex":0.00026994647,"about_ca_system_score_gemma":0.0031365387,"threshold_uncertainty_score":0.9998905},"labels":[],"label_agreement":null},{"id":"W3010644992","doi":"10.1200/jco.2013.31.15_suppl.4504","title":"Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sunitinib; Hazard ratio; Everolimus; Progression-free survival; Internal medicine; Surgery; Renal cell carcinoma; Confidence interval; Overall survival","score_opus":0.11612168074028142,"score_gpt":0.38564449081191227,"score_spread":0.2695228100716308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010644992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921651,0.0007688933,0.00009699374,0.0019059408,0.0013474333,0.002894264,0.00004148341,0.00002207621,0.00075779716],"genre_scores_gemma":[0.9943101,0.0004087738,0.0022818218,0.0007330277,0.0014575297,0.000084917345,0.0001339782,0.0000835841,0.00050626404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99020225,0.0016077972,0.005797974,0.0007669739,0.0008237516,0.00080123456],"domain_scores_gemma":[0.9856653,0.007875098,0.0037285315,0.00049048883,0.0010254151,0.0012151464],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045604073,0.00072951004,0.0059171356,0.0005609837,0.00019854485,0.000057390036,0.00028189822,0.00052853185,0.0017698541],"category_scores_gemma":[0.0026116285,0.00050359074,0.0007322469,0.00031667668,0.00069942675,0.00045310913,0.0002677556,0.00202356,0.000015646221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9536473,0.008802168,0.024739085,0.0002355162,0.0012404418,0.0012848638,0.00030541178,0.000111434674,0.000065367545,0.000006890199,0.0006582452,0.00890324],"study_design_scores_gemma":[0.86269516,0.09457213,0.034551695,0.00021313653,0.002513055,0.00023781466,0.000071228045,0.0024254597,0.00029762895,0.0001396146,0.0018668002,0.0004162523],"about_ca_topic_score_codex":0.00033190113,"about_ca_topic_score_gemma":0.002017915,"teacher_disagreement_score":0.09095215,"about_ca_system_score_codex":0.0004344804,"about_ca_system_score_gemma":0.0010840412,"threshold_uncertainty_score":0.99974155},"labels":[],"label_agreement":null},{"id":"W3010708720","doi":"10.1200/jco.2013.31.15_suppl.e16011","title":"The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Orchiectomy; Endocrinology; Medicine; Internal medicine; Oil Red O; Castration; Lipogenesis; Testosterone (patch); Androgen deprivation therapy; Hormone; Adipose tissue; Adipogenesis; Prostate; Cancer","score_opus":0.044958188050790035,"score_gpt":0.36572414091984995,"score_spread":0.3207659528690599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010708720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919088,0.0040114946,0.000014331279,0.0012596141,0.0021570143,0.0001181925,0.000003939183,0.0000015202481,0.000525121],"genre_scores_gemma":[0.98804575,0.0037886824,0.00037080614,0.000119903736,0.0076026046,0.0000064267238,0.00000278659,0.000008752495,0.000054272405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976474,0.00037293686,0.0014457721,0.00017106347,0.00015923748,0.00020359417],"domain_scores_gemma":[0.9978656,0.0005552933,0.0010573181,0.00015423959,0.0002167284,0.0001507815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014578698,0.00011530423,0.00066538225,0.000044624016,0.00010096268,0.000022294036,0.00026093834,0.00029767628,0.000008409277],"category_scores_gemma":[0.0007945112,0.000073714735,0.0001756724,0.00006416482,0.0002258276,0.000011100352,0.00012807992,0.00030747763,0.0000012726848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037190964,0.00021334074,0.43654895,0.000014464844,0.00024798984,9.763672e-7,0.00016248057,0.0000024440496,0.1803727,0.00028751683,0.0011348434,0.38064238],"study_design_scores_gemma":[0.0019454617,0.0022717547,0.76004535,0.000027285578,0.00009307896,0.000045181252,0.00040169217,0.00001364887,0.00954215,0.0010172854,0.22446886,0.00012826468],"about_ca_topic_score_codex":0.00021730197,"about_ca_topic_score_gemma":0.00054555776,"teacher_disagreement_score":0.38051412,"about_ca_system_score_codex":0.000013781746,"about_ca_system_score_gemma":0.0006332414,"threshold_uncertainty_score":0.30059996},"labels":[],"label_agreement":null},{"id":"W3010726128","doi":"10.1200/jco.2012.30.15_suppl.10583","title":"Antagonistic activity of acolbifene, fulvestrant, tamoxifen, and raloxifene on cancer-associated genes in the mouse mammary gland.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada); Université Laval","funders":"","keywords":"Fulvestrant; Tamoxifen; Raloxifene; Antiestrogen; Selective estrogen receptor modulator; Mammary gland; Medicine; Estrogen; Estrogen receptor; Breast cancer; Endocrinology; Internal medicine; Carcinogenesis; Cancer; Ovariectomized rat; Cancer research","score_opus":0.05131011515343877,"score_gpt":0.4039483934072633,"score_spread":0.35263827825382454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010726128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941088,0.0039420333,0.000028494353,0.0009985123,0.00042940804,0.00012529943,0.000009132738,0.0000019207478,0.00035640574],"genre_scores_gemma":[0.98965025,0.009092322,0.0001535112,0.00050770084,0.0005235161,0.0000042004804,0.0000048123466,0.000010275387,0.00005339082],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99777174,0.0008805584,0.00079404947,0.00013334287,0.00017167273,0.00024864875],"domain_scores_gemma":[0.99811465,0.0005828417,0.00089688145,0.000159779,0.00008919827,0.00015664632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026024806,0.00013179974,0.0006081764,0.000050569084,0.00003735209,0.0000069553116,0.00022968647,0.000536929,0.0000036614983],"category_scores_gemma":[0.0008120732,0.0000811751,0.00020834716,0.00009052033,0.00017163361,0.000012497881,0.000052537976,0.0005813594,7.734432e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005949564,0.005261177,0.2229949,0.000054472344,0.000823401,0.00015711739,0.00019155603,0.00012026297,0.647592,0.00013651828,0.0029251599,0.11379386],"study_design_scores_gemma":[0.010880349,0.020529967,0.71261996,0.0000926544,0.00042020352,0.0003496247,0.000067771485,0.000112428985,0.23986033,0.00016109845,0.014523992,0.00038165384],"about_ca_topic_score_codex":0.000030067036,"about_ca_topic_score_gemma":0.00002922231,"teacher_disagreement_score":0.48962504,"about_ca_system_score_codex":0.000025365347,"about_ca_system_score_gemma":0.0003541052,"threshold_uncertainty_score":0.4141288},"labels":[],"label_agreement":null},{"id":"W3010758688","doi":"10.1200/jco.2013.31.15_suppl.6597","title":"Has the “ASCO top 5” changed radiologic staging practices among physicians who treat breast cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Perioperative; Stage (stratigraphy); Breast cancer; Cancer; Demographics; Retrospective cohort study; Metastatic breast cancer; Radiology; Internal medicine","score_opus":0.20264723721528227,"score_gpt":0.48686085850636734,"score_spread":0.2842136212910851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010758688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8048572,0.0018888576,0.000010116499,0.19037457,0.0008616404,0.00034041647,0.000006333659,0.000009776352,0.0016510754],"genre_scores_gemma":[0.9799453,0.00836037,0.00021299205,0.007020834,0.0038980905,0.00006441858,0.0000014190283,0.000015911302,0.00048066746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754167,0.00045694393,0.0012206904,0.0002065866,0.0002872775,0.00028682555],"domain_scores_gemma":[0.99306214,0.0027670865,0.0033080182,0.0002393556,0.000383973,0.00023943132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013372053,0.00016114936,0.001302426,0.00006266226,0.00011690995,0.00004439212,0.00018563958,0.00020691773,0.0006670271],"category_scores_gemma":[0.00092182483,0.00008118959,0.0005025845,0.0001359458,0.00038515037,0.00024670875,0.000044760673,0.0008319335,0.000026887981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005645127,0.0011887714,0.5575601,0.000015891237,0.00060464436,0.0002165983,0.0003041022,0.000015219662,0.000039553724,0.000016662718,0.034053955,0.40542],"study_design_scores_gemma":[0.004164476,0.0042638155,0.9439881,0.00023231591,0.0008872351,0.00028360725,0.00057893567,0.00014426945,0.000058215523,0.000084886815,0.045231726,0.000082409504],"about_ca_topic_score_codex":0.001820138,"about_ca_topic_score_gemma":0.0005149066,"teacher_disagreement_score":0.4053376,"about_ca_system_score_codex":0.00031302957,"about_ca_system_score_gemma":0.0007891349,"threshold_uncertainty_score":0.7303479},"labels":[],"label_agreement":null},{"id":"W3010760372","doi":"10.1200/jco.2006.24.18_suppl.15523","title":"A phase I/II trial of weekly docetaxel and cisplatin for locoregionally recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Neutropenia; Tolerability; Cisplatin; Internal medicine; Febrile neutropenia; Oncology; Chemotherapy; Phases of clinical research; Adverse effect","score_opus":0.13351680615793263,"score_gpt":0.4633993990421669,"score_spread":0.32988259288423427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010760372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925334,0.0021816627,0.00005851057,0.0064918213,0.00066067127,0.0005640031,0.000021206073,0.0000016873084,0.00076709886],"genre_scores_gemma":[0.9962326,0.0002292236,0.0022529638,0.0003705264,0.0006639782,0.000007530176,0.0000012370475,0.000009718496,0.0002321853],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997077,0.00019787742,0.0021486727,0.00014701905,0.00026257572,0.00016687774],"domain_scores_gemma":[0.9949471,0.0025918998,0.0018243087,0.00012460546,0.0003758491,0.00013624178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015945039,0.00012295213,0.0016380543,0.00007313816,0.00006388371,0.0000025568693,0.0000908384,0.00013578878,0.00001007942],"category_scores_gemma":[0.0017026633,0.000071442584,0.00037748995,0.0000958518,0.00045024685,0.000041027077,0.000060081387,0.00038187086,1.5982363e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5152406,0.044938445,0.06199128,0.0015099962,0.00050748145,0.00021027419,0.0011056882,0.000008679828,0.0030523897,0.0008511718,0.05144458,0.3191394],"study_design_scores_gemma":[0.52067214,0.30388033,0.135992,0.00031333178,0.0013775346,0.00026847204,0.00020137915,0.00023710215,0.0006360605,0.0016875054,0.034591265,0.00014284508],"about_ca_topic_score_codex":0.0000370423,"about_ca_topic_score_gemma":0.00010915232,"teacher_disagreement_score":0.31899655,"about_ca_system_score_codex":0.000030263951,"about_ca_system_score_gemma":0.00088609033,"threshold_uncertainty_score":0.2913344},"labels":[],"label_agreement":null},{"id":"W3010801521","doi":"10.1200/jco.2019.37.15_suppl.11040","title":"Immune signature and molecular profiling of radiation-induced sarcoma (RIS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Sarcoma; CD8; Medicine; Immune system; Exome sequencing; Exome; CD3; Immunotherapy; Pathology; Cancer research; Molecular biology; Biology; Immunology; Gene; Genetics; Mutation","score_opus":0.03887486533423142,"score_gpt":0.39404602381116727,"score_spread":0.35517115847693587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010801521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990672,0.0040940964,0.000086427695,0.0033120613,0.0005459846,0.00019100643,7.7577886e-7,0.00000400691,0.0010936352],"genre_scores_gemma":[0.9949507,0.0003177302,0.0034854803,0.0008233032,0.00034183092,5.8994976e-7,0.0000019646588,0.000013096376,0.00006527437],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99770415,0.00022927868,0.0015249572,0.00012590189,0.00027556892,0.00014014922],"domain_scores_gemma":[0.9976214,0.0005811366,0.0011813899,0.00017115618,0.00025899953,0.00018589149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002015949,0.00009454099,0.0012099951,0.00010225299,0.000013895753,0.0000037368286,0.00009920755,0.0003199855,0.00006429122],"category_scores_gemma":[0.001389139,0.00006636319,0.00052920956,0.00010281895,0.000062656305,0.00006282643,0.000039147657,0.0008075316,0.0000066553407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022559,0.0016706398,0.33281854,0.00021522555,0.0010640112,0.00124188,0.00015240695,0.00001926584,0.4354713,0.0015726768,0.00043059335,0.22308756],"study_design_scores_gemma":[0.025755832,0.025173292,0.83087766,0.00046210887,0.0009206386,0.0016510113,0.00035682062,0.0005783355,0.09537103,0.0012192235,0.017367862,0.0002661726],"about_ca_topic_score_codex":0.0000049763003,"about_ca_topic_score_gemma":4.616892e-7,"teacher_disagreement_score":0.49805912,"about_ca_system_score_codex":0.000027223032,"about_ca_system_score_gemma":0.0005716086,"threshold_uncertainty_score":0.35083678},"labels":[],"label_agreement":null},{"id":"W3010824160","doi":"10.1200/jco.2006.24.18_suppl.1023","title":"Patterns of diagnosis for colorectal cancer (CRC): Screening detected versus symptomatic presentation","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Cohort; Cancer; Stage (stratigraphy); Family history; Internal medicine; Retrospective cohort study; Adenocarcinoma; Cancer registry","score_opus":0.12495666250053501,"score_gpt":0.47904030634447603,"score_spread":0.35408364384394103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010824160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499476,0.0008187483,0.00049426587,0.0017589486,0.0011542579,0.00040584078,0.000025845786,0.000008002519,0.0003393057],"genre_scores_gemma":[0.99580616,0.00064390525,0.0023307092,0.000088465735,0.000956345,0.000088295215,0.0000055433197,0.000012371256,0.00006821273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978566,0.00011479388,0.001498179,0.0001224131,0.00024420972,0.00016377415],"domain_scores_gemma":[0.994295,0.0036387986,0.0013658768,0.0000621829,0.0005404753,0.000097690994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005283233,0.000106751504,0.0010418878,0.00008759333,0.000042820906,0.000004354658,0.00006787052,0.00015772259,0.000084099214],"category_scores_gemma":[0.0013752198,0.000074997195,0.0004372604,0.00009254425,0.000060211136,0.00006258382,0.000025326553,0.00020335833,5.7784507e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01558777,0.0010549446,0.8391096,0.0000861925,0.0010349952,0.000048167247,0.00008936037,0.00005398925,0.00020485275,0.000026191658,0.0016360561,0.14106789],"study_design_scores_gemma":[0.017155161,0.020151729,0.9563564,0.00017877102,0.001158743,0.000018333252,0.00016543167,0.00025005615,0.0017387108,0.00007219786,0.002687859,0.00006662993],"about_ca_topic_score_codex":0.00038481745,"about_ca_topic_score_gemma":0.0013896741,"teacher_disagreement_score":0.14100125,"about_ca_system_score_codex":0.00015771536,"about_ca_system_score_gemma":0.00039656094,"threshold_uncertainty_score":0.30582967},"labels":[],"label_agreement":null},{"id":"W3010833822","doi":"10.1200/jco.2013.31.15_suppl.e15541","title":"A population-based analysis of overall survival associated with sunitinib given as intermittent, continuous, or nonconventional individualized dosing regimens for metastatic renal cell carcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Dosing; Renal cell carcinoma; Discontinuation; Internal medicine; Hazard ratio; Regimen; Population; Adverse effect; Surgery; Urology; Oncology; Confidence interval","score_opus":0.12829375564595036,"score_gpt":0.42057264633582025,"score_spread":0.2922788906898699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010833822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957572,0.00007689937,0.0007417612,0.0015336613,0.0002587413,0.000786372,0.00007136874,0.000009790447,0.0007641895],"genre_scores_gemma":[0.9873127,0.000008648609,0.010535049,0.000638967,0.00017095616,0.000030877985,0.00034022046,0.000032492877,0.0009301054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943501,0.0010774813,0.0031895125,0.00029485393,0.0007546967,0.0003333532],"domain_scores_gemma":[0.98466355,0.007979777,0.004998433,0.00024929614,0.0016973002,0.00041163876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029726005,0.00026170094,0.003187364,0.00059768895,0.00005829648,0.000022980737,0.00018607413,0.00025738412,0.0008230006],"category_scores_gemma":[0.003384562,0.00016538208,0.0014371078,0.00046607386,0.0001761536,0.00013954258,0.00003384646,0.0005179441,0.000004682447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023299038,0.0063011143,0.9474918,0.00012913093,0.0140221175,0.00077902415,0.00019961133,0.00041212386,0.00079521356,0.000085953434,0.0015212086,0.004963623],"study_design_scores_gemma":[0.032210253,0.027040692,0.92174417,0.00019282676,0.015892755,0.000068111476,0.00019396837,0.0014620016,0.00038550765,0.00016492777,0.0004774835,0.00016729487],"about_ca_topic_score_codex":0.00048428605,"about_ca_topic_score_gemma":0.00034603587,"teacher_disagreement_score":0.025747664,"about_ca_system_score_codex":0.00037245787,"about_ca_system_score_gemma":0.001988799,"threshold_uncertainty_score":0.90112793},"labels":[],"label_agreement":null},{"id":"W3010849044","doi":"10.1200/jco.2013.31.15_suppl.9593","title":"Utility of standardized letters in assisting primary care providers (PCPs) with the care of cancer survivors (CS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Family medicine; Logistic regression; Survivorship curve; Graduation (instrument); Primary care; Cancer; Internal medicine","score_opus":0.06666981473719337,"score_gpt":0.41312553797226714,"score_spread":0.3464557232350738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010849044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868319,0.0023011493,0.000060131148,0.0059661935,0.00042899675,0.0005033206,0.000021325382,0.0000039506513,0.0038830054],"genre_scores_gemma":[0.9953067,0.00031594696,0.0015692305,0.0025281585,0.00022510077,0.000010176506,0.0000049571554,0.000015163156,0.00002461149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964356,0.00057164184,0.0020685236,0.00018775884,0.0005069757,0.00022953512],"domain_scores_gemma":[0.99462324,0.0018733668,0.0020754985,0.0002543473,0.0010050315,0.00016852382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016228362,0.00014619798,0.0017112292,0.00010502154,0.000032018732,0.0000055046244,0.00021760513,0.00020346725,0.0002789719],"category_scores_gemma":[0.0007984094,0.000081203456,0.00037138554,0.00017352223,0.00057003536,0.00015149647,0.00004828772,0.0009762372,5.4495104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005969202,0.000174433,0.75264215,0.0005673721,0.00032703677,0.000067620764,0.0020597214,0.000094843264,0.0012305871,0.0000021145947,0.0014317934,0.23543312],"study_design_scores_gemma":[0.009528135,0.0029507065,0.96765286,0.0003573827,0.00029454456,0.000018010322,0.0064120153,0.00004004508,0.0004180864,0.000004110689,0.012233224,0.00009088633],"about_ca_topic_score_codex":0.0027149788,"about_ca_topic_score_gemma":0.0056797583,"teacher_disagreement_score":0.23534222,"about_ca_system_score_codex":0.0003359453,"about_ca_system_score_gemma":0.0047334936,"threshold_uncertainty_score":0.8397015},"labels":[],"label_agreement":null},{"id":"W3010851249","doi":"10.1200/jco.2012.30.15_suppl.e18061","title":"Utility of nonsurgical diagnostic specimens in cellular differentiation and molecular profiling (EGFR mutation and EML4-ALK detection) of NSCLC.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Surgical pathology; Pathology; Fine-needle aspiration; Immunohistochemistry; Cytology; Biopsy","score_opus":0.05134337012688837,"score_gpt":0.43488942561501526,"score_spread":0.38354605548812687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010851249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952159,0.001494052,0.0020563882,0.00038686275,0.00027840395,0.00020660671,0.0000029004402,0.0000018690243,0.00035701905],"genre_scores_gemma":[0.99796873,0.00029555944,0.001544258,0.00004665297,0.00012628993,0.00000273447,0.0000034867583,0.000005372179,0.0000069038915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982883,0.0002177256,0.0011422522,0.00008789276,0.00016013456,0.000103743536],"domain_scores_gemma":[0.99733144,0.0015049865,0.0007654994,0.000067136505,0.00018582575,0.0001450868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009162419,0.00006825835,0.00060907006,0.0001016623,0.000014759856,0.0000020359903,0.000021428883,0.00015053758,0.000022479295],"category_scores_gemma":[0.0020000297,0.00005056181,0.00010207618,0.00008492899,0.00012355206,0.00009176981,0.00001660084,0.00023878804,4.334544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010572928,0.002279085,0.89070857,0.00012376504,0.0002965019,0.00016081223,0.00040150736,0.000008381,0.016338121,0.00023500666,0.000005850586,0.0883851],"study_design_scores_gemma":[0.005210462,0.002031541,0.97728515,0.000092822636,0.0006096132,0.00012886542,0.00016504311,0.0003467351,0.013637772,0.00027066603,0.00018043786,0.000040885294],"about_ca_topic_score_codex":0.000019004225,"about_ca_topic_score_gemma":0.000014185553,"teacher_disagreement_score":0.08834422,"about_ca_system_score_codex":0.000041945023,"about_ca_system_score_gemma":0.00019525635,"threshold_uncertainty_score":0.23943669},"labels":[],"label_agreement":null},{"id":"W3010907432","doi":"10.1200/jco.2013.31.15_suppl.518","title":"A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; McGill University; Royal Victoria Hospital; Queen's University; Cancer Care Ontario; Interior Health; BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Internal medicine; Metastatic breast cancer; Tyrosine-kinase inhibitor; Oncology; Pharmacokinetics; Phases of clinical research; Regimen; Breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Pharmacology; Gastroenterology; Toxicity; Trastuzumab","score_opus":0.10205888868964136,"score_gpt":0.4980479330769425,"score_spread":0.39598904438730115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010907432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940856,0.00018743615,0.000009452377,0.00346638,0.00036269292,0.0015819487,0.000121949175,0.000007762606,0.00017679622],"genre_scores_gemma":[0.99708897,0.00022352657,0.0016205239,0.00043794245,0.00046837513,0.00007770178,0.00002099011,0.00004079276,0.000021157519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99210995,0.0022075868,0.003725071,0.0005046369,0.0010158648,0.00043686843],"domain_scores_gemma":[0.9929798,0.0030059647,0.0020569456,0.00032739888,0.0010927897,0.0005370576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005235115,0.00027261509,0.002304665,0.00056444167,0.000037348527,0.000030251664,0.00024075933,0.000345943,0.00013468755],"category_scores_gemma":[0.0025708426,0.00019866017,0.00012695069,0.0006797326,0.00046260693,0.00043816652,0.000108353066,0.0019977305,0.0000047098433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04321798,0.07078044,0.6013108,0.00014951236,0.00068430055,0.0025067946,0.009542464,0.00005889409,0.0020588213,0.000014590878,0.0008279284,0.2688475],"study_design_scores_gemma":[0.10815804,0.09759741,0.7859658,0.0012756424,0.00025713682,0.00018123085,0.004784813,0.0006595572,0.00047934236,0.0002607138,0.00018737839,0.00019290668],"about_ca_topic_score_codex":0.00911182,"about_ca_topic_score_gemma":0.009576298,"teacher_disagreement_score":0.26865458,"about_ca_system_score_codex":0.00046226426,"about_ca_system_score_gemma":0.0019953593,"threshold_uncertainty_score":0.9974866},"labels":[],"label_agreement":null},{"id":"W3010952792","doi":"10.1200/jco.2012.30.15_suppl.e16505","title":"Global survey on barriers to clinical cancer research.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Family medicine; Clinical Oncology; Cancer; Internal medicine; Oncology","score_opus":0.9002043163190332,"score_gpt":0.7984957030081596,"score_spread":0.10170861331087355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010952792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91557974,0.0005009772,0.00006974742,0.058363225,0.009648753,0.00042937323,0.000038850045,0.000015260508,0.015354076],"genre_scores_gemma":[0.9565388,0.0034294354,0.00247195,0.024542978,0.0111942645,0.0000096654685,0.000002210935,0.000034805886,0.001775879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.977149,0.010655725,0.00657143,0.0005276865,0.0037595916,0.001336571],"domain_scores_gemma":[0.7072359,0.2679215,0.0020661831,0.0012411564,0.00856063,0.012974649],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.25373432,0.00020847232,0.002538358,0.00025816157,0.0001492909,0.000024546713,0.0008986501,0.002261647,0.0014343498],"category_scores_gemma":[0.70983785,0.00014453073,0.0010037065,0.0009497636,0.0015416454,0.00014324662,0.0004680743,0.012545961,0.00061759475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014221152,0.0022107242,0.792052,0.000020830892,0.00034641926,0.00021889835,0.000048262344,0.0000074209142,0.0000042409715,0.0018759347,0.13104495,0.05794922],"study_design_scores_gemma":[0.003925998,0.02135986,0.79656464,0.00023013506,0.00008366282,0.000043533662,0.000100116165,0.000004867059,0.000009867318,0.0026449768,0.17492443,0.00010791149],"about_ca_topic_score_codex":0.00044541023,"about_ca_topic_score_gemma":0.0020967887,"teacher_disagreement_score":0.45610356,"about_ca_system_score_codex":0.0008806077,"about_ca_system_score_gemma":0.01785137,"threshold_uncertainty_score":0.99947846},"labels":[],"label_agreement":null},{"id":"W3010959823","doi":"10.1200/jco.2012.30.15_suppl.9078","title":"Effect of aprepitant on adherence to high-dose cisplatin-based chemotherapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aprepitant; Medicine; Nausea; Vomiting; Cisplatin; Chemotherapy-induced nausea and vomiting; Oncology; Chemotherapy; Internal medicine; Antiemetic","score_opus":0.09986393440077473,"score_gpt":0.4832723019448377,"score_spread":0.383408367544063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010959823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99169147,0.00017664535,0.00013710487,0.0025893496,0.0017310283,0.0002838521,0.0000038027774,0.000006218821,0.0033805477],"genre_scores_gemma":[0.98591506,0.00006808298,0.002855139,0.009813553,0.0011657515,0.0000040932464,0.0000015183359,0.00001554919,0.0001612465],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970573,0.00050526665,0.0017053438,0.00013249338,0.00035106103,0.000248515],"domain_scores_gemma":[0.9927192,0.005126551,0.0011771927,0.00023876544,0.00017967886,0.00055866654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004696511,0.00013804347,0.0015522239,0.00011870944,0.000017810431,0.000002261448,0.00015117765,0.0002637242,0.0008814096],"category_scores_gemma":[0.003227276,0.00008824543,0.00046063756,0.0001142682,0.00010658518,0.00006623072,0.000018208255,0.0006907789,0.000044473407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049701568,0.00157445,0.08729838,0.00012454385,0.00027779792,0.000107771484,0.00013849465,0.000077453005,0.00560657,0.000048954935,0.0071302312,0.8479138],"study_design_scores_gemma":[0.042771325,0.27159423,0.5588315,0.00042848632,0.00053681503,0.0001170627,0.000031429634,0.00019139849,0.032892767,0.00003459587,0.09234219,0.00022817939],"about_ca_topic_score_codex":0.000017288081,"about_ca_topic_score_gemma":0.0000035161004,"teacher_disagreement_score":0.8476856,"about_ca_system_score_codex":0.00015552132,"about_ca_system_score_gemma":0.00093656126,"threshold_uncertainty_score":0.96508175},"labels":[],"label_agreement":null},{"id":"W3011007230","doi":"10.1200/jco.2013.31.15_suppl.e16062","title":"Chemotherapy in hormone-refractory prostate cancer: Docetaxel with and without VT122.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Urology; Clinical endpoint; Internal medicine; Chemotherapy; Cancer; Surgery; Oncology; Gastroenterology; Randomized controlled trial","score_opus":0.08148570485158463,"score_gpt":0.47339873640916286,"score_spread":0.39191303155757823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011007230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96939886,0.006592095,0.000004174385,0.02194499,0.00014114915,0.0004296044,0.0000014034773,0.00000560184,0.0014821247],"genre_scores_gemma":[0.95937926,0.035854623,0.0010544057,0.0015427313,0.0003964107,0.000027140573,9.636098e-7,0.000017959856,0.0017265264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981676,0.00014726321,0.000976869,0.00016426171,0.00028398714,0.0002600244],"domain_scores_gemma":[0.99823666,0.0003324984,0.0006024417,0.00011199432,0.0003494639,0.0003669442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010349387,0.000121582365,0.0010035505,0.00012884567,0.000023232584,0.000013906228,0.00007885775,0.0001956616,0.00014602354],"category_scores_gemma":[0.0002062524,0.00006470802,0.000097548844,0.00012675974,0.00032256846,0.0001898768,0.000021704234,0.0008962781,0.000008995083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010046553,0.00096498017,0.68337506,0.000027776463,0.00026670765,0.00022103463,0.00025609235,0.0000016283942,0.0006135847,0.0000064677947,0.0031585507,0.30106154],"study_design_scores_gemma":[0.029377334,0.016765393,0.904111,0.00014783083,0.00008615408,0.00019244644,0.00015992504,0.000054825457,0.000093288734,0.00023333792,0.048692435,0.00008602127],"about_ca_topic_score_codex":0.00019372895,"about_ca_topic_score_gemma":0.00007435417,"teacher_disagreement_score":0.30097553,"about_ca_system_score_codex":0.0001668486,"about_ca_system_score_gemma":0.0015500362,"threshold_uncertainty_score":0.38939324},"labels":[],"label_agreement":null},{"id":"W3011011573","doi":"10.1200/jco.2013.31.15_suppl.e19032","title":"Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Histology; Lung cancer; Population; Pathology; Cytology; Epidermal growth factor receptor; Internal medicine; Oncology; Cancer","score_opus":0.06873290670080613,"score_gpt":0.46435098595053964,"score_spread":0.3956180792497335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011011573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065465,0.0003289219,0.0007372132,0.0032050945,0.0009339356,0.00046701284,0.0000019042831,0.000008242392,0.0036630344],"genre_scores_gemma":[0.9741189,0.000034087236,0.023392092,0.0014751294,0.00080220605,0.00003363406,0.000010244198,0.000014937327,0.000118808304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997662,0.00014103325,0.0016477222,0.00015332885,0.00019659926,0.00019931045],"domain_scores_gemma":[0.99595785,0.0019800232,0.0012676326,0.000100914214,0.00047874852,0.00021481821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008293932,0.0001099302,0.00070321304,0.00017564387,0.00004915329,0.000013792155,0.000073029536,0.00020686768,0.00020775976],"category_scores_gemma":[0.001097928,0.00008329576,0.00018205454,0.00022820351,0.00003185705,0.0001238669,0.000012170451,0.00051547075,0.000008773886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012936123,0.0006825622,0.86377335,0.000054452143,0.00006459211,0.00020449475,0.00012020463,0.0038607123,0.0000971342,0.000004034307,0.0004945464,0.13051453],"study_design_scores_gemma":[0.0070960363,0.0024780673,0.96217096,0.00026533948,0.00040930024,0.000040097097,0.00009177508,0.02686586,0.000032791682,0.000085732994,0.0003841622,0.000079879035],"about_ca_topic_score_codex":0.0026316668,"about_ca_topic_score_gemma":0.0004820153,"teacher_disagreement_score":0.13043466,"about_ca_system_score_codex":0.0005851999,"about_ca_system_score_gemma":0.0023760125,"threshold_uncertainty_score":0.42149442},"labels":[],"label_agreement":null},{"id":"W3011037833","doi":"10.1200/jco.2006.24.18_suppl.3623","title":"Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Depression (economics); Anxiety; Cognition; Cytokine; Stage (stratigraphy); Colorectal cancer; Neuropsychology; Disease; Gastroenterology; Oncology; Cancer; Psychiatry","score_opus":0.09546781768400052,"score_gpt":0.4002838683081698,"score_spread":0.3048160506241693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011037833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950501,0.000544863,0.0005165916,0.0027245416,0.00038241112,0.000439111,0.000026557676,0.0000067976202,0.0003090288],"genre_scores_gemma":[0.9977553,0.00012342408,0.00012813519,0.0014955539,0.00038054818,0.00003750369,0.000004953159,0.000015553996,0.000059057165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978451,0.0003038391,0.0012375362,0.00020854986,0.0002063247,0.00019864486],"domain_scores_gemma":[0.99437475,0.0041186926,0.0006596753,0.000041217325,0.000621746,0.00018389203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011056587,0.00015665423,0.0010562188,0.00023840278,0.00004381867,0.000007851778,0.000020374213,0.00021897856,0.000052308496],"category_scores_gemma":[0.0022434175,0.00010218883,0.00010158235,0.00024170987,0.00027027135,0.00012335028,0.00003507183,0.00060588017,0.0000019534652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028649993,0.0006477629,0.924734,0.000019650615,0.00026687302,0.000064541666,0.00013351942,0.000009391839,0.000008318951,0.0000037469747,0.0006605127,0.0448017],"study_design_scores_gemma":[0.013099457,0.008911892,0.97511643,0.0005750212,0.00043792557,0.000042209373,0.00017237228,0.00001635494,0.00003186119,0.00013715515,0.0013492291,0.00011006707],"about_ca_topic_score_codex":0.00009530852,"about_ca_topic_score_gemma":0.0010770615,"teacher_disagreement_score":0.050382465,"about_ca_system_score_codex":0.000167293,"about_ca_system_score_gemma":0.0004672473,"threshold_uncertainty_score":0.41671395},"labels":[],"label_agreement":null},{"id":"W3011089553","doi":"10.1200/jco.2013.31.15_suppl.8593","title":"Early versus late treatment for smoldering (asymptomatic) multiple myeloma: A systematic review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Multiple myeloma; Thalidomide; Randomized controlled trial; Internal medicine; Jadad scale; Lenalidomide; Population; MEDLINE; Oncology; Cochrane Library; Surgery","score_opus":0.19860095513282414,"score_gpt":0.48802110782073405,"score_spread":0.2894201526879099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011089553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833638,0.005523608,0.00023531762,0.0045063733,0.00091787043,0.004473829,0.000007299192,0.0000252436,0.0009466731],"genre_scores_gemma":[0.9822271,0.004407209,0.010559564,0.00075303763,0.0005573705,0.00039223765,0.00000749379,0.00003535707,0.0010606718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99569845,0.00042486287,0.0028593247,0.00020180424,0.0004171935,0.00039837154],"domain_scores_gemma":[0.9897292,0.0069264793,0.001609903,0.0003330469,0.00068802264,0.00071334245],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017696626,0.00021050559,0.0028029731,0.00011968315,0.0000603756,0.000020638363,0.00016869453,0.00022701,0.0001344178],"category_scores_gemma":[0.012400995,0.00012143287,0.0010070346,0.000106905034,0.000089922214,0.0001608857,0.00003648009,0.00032733777,0.00020688192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05423316,0.026552372,0.16202518,0.2723966,0.03767372,0.005516478,0.0010042257,0.0000249509,0.0012460763,0.00019395998,0.018554641,0.42057863],"study_design_scores_gemma":[0.2356831,0.23380399,0.40852186,0.09118234,0.013500249,0.0011532636,0.0003155389,0.006612074,0.00039068845,0.00044490115,0.007667675,0.00072432094],"about_ca_topic_score_codex":0.00006374834,"about_ca_topic_score_gemma":0.000018610046,"teacher_disagreement_score":0.4198543,"about_ca_system_score_codex":0.00038604744,"about_ca_system_score_gemma":0.0007187889,"threshold_uncertainty_score":0.995918},"labels":[],"label_agreement":null},{"id":"W3011120444","doi":"10.1200/jco.2013.31.15_suppl.9542","title":"Comparison of toxicity experienced by elderly (E) and younger (Y) patients in breast cancer (BC) clinical trials.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Clinical trial; Toxicity; Adverse effect; Breast cancer; Internal medicine; Clinical endpoint; Cancer","score_opus":0.7055962288774954,"score_gpt":0.6414707169138253,"score_spread":0.06412551196367011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011120444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658435,0.001087515,0.0001728944,0.029664667,0.0022760564,0.0004515124,0.00008503733,0.0000037115974,0.00041508992],"genre_scores_gemma":[0.9911019,0.0012123047,0.001051451,0.005876604,0.00064986735,0.0000264127,0.0000030719866,0.000013736052,0.00006464559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96929735,0.0035373208,0.026368907,0.00035233345,0.00015213812,0.00029197248],"domain_scores_gemma":[0.9647543,0.013731261,0.020453524,0.00023266026,0.000369163,0.0004591055],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07688402,0.00015485616,0.0052762646,0.00020846505,0.00004179706,0.00002663247,0.00030837746,0.0006055192,0.00094577763],"category_scores_gemma":[0.034939405,0.00014474662,0.00041388848,0.0001279825,0.00030935032,0.0006395548,0.00006020281,0.0008000984,0.000083651874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025123797,0.0015020039,0.92534655,0.000035247904,0.000093230716,5.879922e-7,0.0005111812,0.000010132522,0.0000025539784,0.00037910225,0.051185735,0.020682447],"study_design_scores_gemma":[0.005457753,0.0021772955,0.971629,0.00007242399,0.000018557654,0.0000028292511,0.0006721321,0.0009755677,0.0000031799982,0.0014356382,0.01740671,0.0001488676],"about_ca_topic_score_codex":0.0024923668,"about_ca_topic_score_gemma":0.0003109084,"teacher_disagreement_score":0.046282504,"about_ca_system_score_codex":0.00027238618,"about_ca_system_score_gemma":0.00058349053,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W3011122216","doi":"10.1200/jco.2012.30.15_suppl.e19541","title":"Review of practice patterns of primary granulocyte-colony stimulating factor prophylaxis and impact on febrile neutropenia rate and chemotherapy delivery in patients with early breast cancer treated with modern adjuvant chemotherapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Febrile neutropenia; Pegfilgrastim; Internal medicine; Taxane; Regimen; Filgrastim; Granulocyte colony-stimulating factor; Neutropenia; Breast cancer; Chemotherapy; Anthracycline; Chemotherapy regimen; Surgery; Oncology; Cancer","score_opus":0.03558572853380326,"score_gpt":0.3878065697783872,"score_spread":0.3522208412445839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011122216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959218,0.0024829227,0.000012434845,0.0007379442,0.000061485836,0.0006720048,0.000039802944,0.000003686907,0.00006792207],"genre_scores_gemma":[0.98359686,0.0137931835,0.00023941054,0.0021910619,0.00013037745,0.000008842815,0.0000026276869,0.000027434062,0.00001017874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978229,0.00036646886,0.0011627103,0.00017324887,0.00026391234,0.00021080677],"domain_scores_gemma":[0.9963973,0.0007367299,0.0018515049,0.00014906646,0.0006267078,0.00023866641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084366684,0.00019190575,0.001608037,0.00010339473,0.000023396895,0.0000055005385,0.00005996007,0.0001391571,0.00006951241],"category_scores_gemma":[0.00012156842,0.000104991566,0.00012549869,0.00015774988,0.0001297877,0.00031623867,0.000017272547,0.0005685639,2.7531112e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027053343,0.0016328781,0.85879004,0.00049992127,0.0003670333,0.000013662126,0.00015263885,0.000015196789,0.00030092467,4.1191012e-7,0.000029131033,0.111144826],"study_design_scores_gemma":[0.015600439,0.026130538,0.95405406,0.0033617527,0.00034517862,0.0001037623,0.000010837463,0.000009484887,0.0000970896,9.87897e-7,0.00018433774,0.000101510625],"about_ca_topic_score_codex":0.0005333525,"about_ca_topic_score_gemma":0.000038205537,"teacher_disagreement_score":0.11104331,"about_ca_system_score_codex":0.00018841373,"about_ca_system_score_gemma":0.00057335035,"threshold_uncertainty_score":0.42814317},"labels":[],"label_agreement":null},{"id":"W3011197425","doi":"10.1200/jco.2013.31.15_suppl.7517","title":"Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Gene; Gene expression profiling; Microarray; Vinorelbine; Lung cancer; Oncology; Gene signature; Microarray analysis techniques; Cisplatin; Cancer research; ERCC1; Biology; Medicine; Gene expression; Internal medicine; Genetics; Chemotherapy","score_opus":0.024706717994601172,"score_gpt":0.3968956272237569,"score_spread":0.3721889092291557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011197425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484146,0.0009150928,0.0016862403,0.0007752028,0.0003249761,0.0011691109,0.00000507822,0.0000028532452,0.00028001427],"genre_scores_gemma":[0.99538636,0.000035950197,0.0038738407,0.00024049709,0.0002817485,0.00006810083,0.000008952476,0.000010550206,0.00009400614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986166,0.0001440057,0.0008470634,0.00012878381,0.00014298227,0.0001205596],"domain_scores_gemma":[0.9953742,0.0032110896,0.0008292079,0.00007434314,0.00036247118,0.00014870822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037788687,0.00008708408,0.00062628125,0.000098381344,0.000021173237,0.000003880613,0.00003961781,0.00026720227,0.000014645154],"category_scores_gemma":[0.0021053217,0.000056324512,0.00013034613,0.00006619478,0.00006013632,0.0001243234,0.0000142624995,0.00033595887,4.801579e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007038527,0.0073559494,0.69713205,0.0014872747,0.000291365,0.00020435124,0.002381103,0.00012494803,0.19983476,0.000026635857,0.0050951685,0.07902784],"study_design_scores_gemma":[0.018932339,0.021103732,0.90484154,0.00030221647,0.00055803097,0.000027359949,0.00021265213,0.0005399866,0.05267908,0.00032140472,0.00041114408,0.000070542694],"about_ca_topic_score_codex":0.000019183186,"about_ca_topic_score_gemma":0.0000034800503,"teacher_disagreement_score":0.20770943,"about_ca_system_score_codex":0.00012224991,"about_ca_system_score_gemma":0.00070576626,"threshold_uncertainty_score":0.25204188},"labels":[],"label_agreement":null},{"id":"W3011210265","doi":"10.1200/jco.2006.24.18_suppl.3508","title":"Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Clinical endpoint; Irinotecan; Placebo; Bevacizumab; Interim analysis; Adverse effect; Progression-free survival; Oncology; Gastroenterology; Cancer; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.1123602644794425,"score_gpt":0.47535781849672576,"score_spread":0.3629975540172833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011210265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677795,0.00027654733,0.000014379614,0.00026958899,0.00016895324,0.0020298876,0.00005855986,0.0000060758916,0.00039805408],"genre_scores_gemma":[0.9987087,0.00024414275,0.00061508827,0.000048463797,0.00010780947,0.00010901667,0.000034768393,0.00001685862,0.0001151134],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938591,0.0009542591,0.0040286244,0.00036263675,0.0005501091,0.0002452345],"domain_scores_gemma":[0.99138683,0.0036711984,0.0035465185,0.00015139951,0.0010582309,0.00018582094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037770916,0.00026628104,0.004412715,0.00064193935,0.000048248337,0.000010748516,0.0001225927,0.00014329597,0.000078505895],"category_scores_gemma":[0.0016081351,0.00015198946,0.00043793122,0.000749818,0.00041391287,0.00015677579,0.000057979763,0.0004108123,1.7344722e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72681785,0.017153893,0.2259832,0.000030113473,0.007528601,0.00018161607,0.0012255805,0.00018539715,0.000018333236,0.0000025134202,0.000033387638,0.020839525],"study_design_scores_gemma":[0.60982037,0.044813506,0.3350146,0.00014816837,0.008642426,0.000014998479,0.0005540746,0.000783469,0.000057635636,0.000006099426,0.00004579313,0.000098846496],"about_ca_topic_score_codex":0.0037948955,"about_ca_topic_score_gemma":0.040946335,"teacher_disagreement_score":0.11699746,"about_ca_system_score_codex":0.0003028491,"about_ca_system_score_gemma":0.0008150691,"threshold_uncertainty_score":0.9765539},"labels":[],"label_agreement":null},{"id":"W3011225902","doi":"10.1200/jco.2012.30.15_suppl.8060","title":"Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Stage (stratigraphy); Lymphoma; T-cell lymphoma; Chemotherapy; Peripheral T-cell lymphoma; B symptoms; Surgery; T cell; Immunology; Immune system","score_opus":0.09030509670787502,"score_gpt":0.42646321354691463,"score_spread":0.3361581168390396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011225902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722993,0.00046717696,0.000115603776,0.00086272566,0.0008882822,0.0001301647,0.000015554155,0.0000054529696,0.00028508488],"genre_scores_gemma":[0.98969245,0.0013226694,0.0073181638,0.0010830511,0.00049880263,0.0000068954982,0.0000047932663,0.000009724989,0.00006344083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974459,0.00014516686,0.0016894224,0.00013745313,0.0003268098,0.0002552947],"domain_scores_gemma":[0.99634975,0.0011223244,0.0015764243,0.00014604795,0.00023811983,0.00056732364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006740142,0.00016629939,0.0016242051,0.00009000394,0.0000462944,0.0000053382696,0.0000945016,0.00013162299,0.00004110499],"category_scores_gemma":[0.0010776364,0.00010120803,0.0003948237,0.00009933847,0.00068064046,0.00013091243,0.000047253612,0.00017918284,0.000009257637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000586808,0.008923435,0.8598941,0.000020504873,0.00023144625,0.00022580563,0.00029842928,3.3699376e-7,0.000051988267,0.0000678618,0.000096043135,0.12960322],"study_design_scores_gemma":[0.01154804,0.003596104,0.97287273,0.000027472273,0.00038263327,0.00043970146,0.00014005866,0.000028565948,0.0001893919,0.0000021084197,0.010686644,0.00008651872],"about_ca_topic_score_codex":0.000046607438,"about_ca_topic_score_gemma":0.000019815405,"teacher_disagreement_score":0.1295167,"about_ca_system_score_codex":0.00015048073,"about_ca_system_score_gemma":0.0008304403,"threshold_uncertainty_score":0.41271436},"labels":[],"label_agreement":null},{"id":"W3011242490","doi":"10.1200/jco.2013.31.15_suppl.1050","title":"Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Eribulin; Capecitabine; Internal medicine; Metastatic breast cancer; Clinical endpoint; Taxane; Quality of life (healthcare); Anthracycline; Breast cancer; Adverse effect; Oncology; Phases of clinical research; Progression-free survival; Cancer; Clinical trial; Chemotherapy","score_opus":0.12441381449430199,"score_gpt":0.5084301453302427,"score_spread":0.38401633083594067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011242490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062693,0.0006332807,0.00002999665,0.0030029844,0.00020185641,0.0053747213,0.000037068792,0.0000102195245,0.00008296736],"genre_scores_gemma":[0.99171257,0.003472458,0.002558253,0.001076224,0.00016375529,0.000370168,0.000011792469,0.00003747575,0.00059727416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922095,0.002189962,0.0043275305,0.00043789702,0.00045065847,0.00038445124],"domain_scores_gemma":[0.9883766,0.0048563145,0.004464059,0.00024231662,0.0014710267,0.0005896497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003244658,0.00039283212,0.0063252645,0.00019299691,0.00005372888,0.000023795703,0.00025654203,0.00018573111,0.0011397649],"category_scores_gemma":[0.0023253455,0.00018305868,0.00015146754,0.00043359288,0.00066621485,0.00041209444,0.00008495871,0.0006513869,0.0000019411225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71627307,0.029341241,0.177145,0.00010717739,0.0028054505,0.0003384434,0.00040263176,0.00002789615,0.000084638355,9.86572e-7,0.00040052016,0.07307292],"study_design_scores_gemma":[0.7289683,0.08458894,0.18275984,0.0004373584,0.002081183,0.00009960169,0.00039262683,0.00017380039,0.000021099833,0.00001019031,0.00027202925,0.00019504027],"about_ca_topic_score_codex":0.002850792,"about_ca_topic_score_gemma":0.0073828613,"teacher_disagreement_score":0.072877884,"about_ca_system_score_codex":0.00019024352,"about_ca_system_score_gemma":0.0028308933,"threshold_uncertainty_score":0.9997733},"labels":[],"label_agreement":null},{"id":"W3011316687","doi":"10.1200/jco.2013.31.15_suppl.9573","title":"Spiritual/religious struggle in hematopoietic cell transplant survivors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Coping (psychology); Demography; Logistic regression; Gerontology; Feeling; Internal medicine; Clinical psychology; Psychology","score_opus":0.2017714053092085,"score_gpt":0.49421538373079305,"score_spread":0.29244397842158454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011316687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847351,0.0033430224,0.0001440386,0.0039642155,0.0007339541,0.00015464945,0.000002680595,0.0000059437225,0.006916422],"genre_scores_gemma":[0.98875827,0.0065709283,0.0028547677,0.0011959664,0.0004392463,0.0000026545565,0.0000018405922,0.000012776196,0.00016358159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966165,0.00028347038,0.0024393809,0.00013643502,0.0002964285,0.00022782068],"domain_scores_gemma":[0.9958134,0.0024015529,0.000986201,0.00015311327,0.0003434041,0.00030227358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014746622,0.00012378924,0.0016562188,0.000146038,0.000009650703,0.0000040335817,0.00016108777,0.00035216325,0.0002912621],"category_scores_gemma":[0.0010762558,0.00008666991,0.00041357966,0.00013737375,0.0001686139,0.00008101664,0.000019670484,0.00080769206,0.00007432839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013178209,0.0029309248,0.9474959,0.0002555204,0.00018348018,0.0014312833,0.0027877165,0.000016840262,0.0013934703,0.00007655141,0.017382525,0.02472798],"study_design_scores_gemma":[0.037511174,0.035391707,0.6294564,0.0035300716,0.0008917368,0.0010125287,0.0051976885,0.00021322514,0.01010312,0.0061970903,0.26988727,0.00060801016],"about_ca_topic_score_codex":0.0003296669,"about_ca_topic_score_gemma":0.0001687379,"teacher_disagreement_score":0.3180395,"about_ca_system_score_codex":0.000059348426,"about_ca_system_score_gemma":0.00062208594,"threshold_uncertainty_score":0.35342965},"labels":[],"label_agreement":null},{"id":"W3011362962","doi":"10.1200/jco.2012.30.15_suppl.6064","title":"Impact of county-level surgical specialist density on breast (BrCa) and lung cancer (LuCa) mortality.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Demography; Incidence (geometry); Cancer; Breast cancer; Socioeconomic status; Mortality rate; Lung cancer; Surgery; Gynecology; Internal medicine; Population; Environmental health","score_opus":0.14353034823427896,"score_gpt":0.5769233946554873,"score_spread":0.4333930464212083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011362962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896228,0.0023512102,0.0001289804,0.002105217,0.002779645,0.0001342035,0.000043399363,0.000005184465,0.0028293761],"genre_scores_gemma":[0.98487,0.0046892343,0.0010691304,0.0010297956,0.008097465,0.0000014425195,0.0000020874127,0.00001523738,0.00022560956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719095,0.00042510562,0.0015815601,0.00015147391,0.00034513543,0.0003057641],"domain_scores_gemma":[0.9947486,0.0026569276,0.0015062807,0.0001809797,0.00036111873,0.00054609514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030413547,0.00016269527,0.0017702202,0.000088500004,0.00005172053,0.0000029948778,0.000113027156,0.00054918526,0.00050778163],"category_scores_gemma":[0.0008999471,0.00010157058,0.000536785,0.00010190381,0.00075585756,0.00014799432,0.000030754996,0.0010891453,0.0000022172292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007816214,0.002263762,0.93537575,0.000026372807,0.0010485934,0.00038662044,0.000072091025,0.00001443873,0.00007152501,0.00048536411,0.0055633364,0.046875913],"study_design_scores_gemma":[0.006722238,0.0052079097,0.9609067,0.00008861221,0.00047466072,0.003311041,0.000019737941,0.000036686262,0.000019463832,0.00010987058,0.023008944,0.00009414386],"about_ca_topic_score_codex":0.00006882126,"about_ca_topic_score_gemma":0.000048860533,"teacher_disagreement_score":0.046781767,"about_ca_system_score_codex":0.00040799903,"about_ca_system_score_gemma":0.0013893284,"threshold_uncertainty_score":0.5559853},"labels":[],"label_agreement":null},{"id":"W3011396395","doi":"10.1200/jco.2013.31.15_suppl.e20695","title":"Quality of life and symptom burden in Chinese cancer patients: Results of a multicenter research project.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Palliative care; Mainland China; Family medicine; Physical therapy; China; Internal medicine; Nursing","score_opus":0.21524153288954045,"score_gpt":0.5647164941453894,"score_spread":0.3494749612558489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011396395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928239,0.00063092215,0.0000012861689,0.0042950073,0.00054673804,0.0003802885,0.000016164671,0.0000016008421,0.0013041034],"genre_scores_gemma":[0.99786896,0.0009577661,0.00014802303,0.0003555028,0.0005044994,0.000011255709,0.0000017755971,0.000007952595,0.00014429464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949551,0.001151094,0.0029884449,0.00015654997,0.0005600128,0.00018876897],"domain_scores_gemma":[0.99236435,0.0038251195,0.0014571954,0.0001729986,0.0019529042,0.00022742477],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0060267,0.00008345095,0.001310227,0.00021931698,0.000011361201,0.0000037625714,0.00013087466,0.00026132682,0.00007325907],"category_scores_gemma":[0.016685918,0.00005290745,0.00019170444,0.00026405408,0.00031680096,0.000099201694,0.0000883096,0.00088943425,0.0000016689814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011379017,0.0013103859,0.9539207,0.00019305173,0.00011365043,0.000008641481,0.0021027396,0.000001479147,0.00019012619,0.0000064444166,0.0025264728,0.028247295],"study_design_scores_gemma":[0.015778443,0.0051471237,0.9735308,0.00024083868,0.000024460802,0.000001923555,0.00093825284,0.000045985907,0.000014943877,0.00007645623,0.004155157,0.000045595705],"about_ca_topic_score_codex":0.01648881,"about_ca_topic_score_gemma":0.006229794,"teacher_disagreement_score":0.0282017,"about_ca_system_score_codex":0.0001038806,"about_ca_system_score_gemma":0.0016040041,"threshold_uncertainty_score":0.99159694},"labels":[],"label_agreement":null},{"id":"W3011437021","doi":"10.1200/jco.2012.30.15_suppl.6134","title":"Relationship of MRI tests and referral of malignant adnexal masses to gynecologic oncologists for surgery.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Adnexal Diseases; Referral; Radiology; Laparotomy; Adnexal mass; Magnetic resonance imaging; Gynecologic oncology; Logistic regression; Work-up; Obstetrics and gynaecology; Ultrasound; Surgery; Laparoscopy; Pregnancy; Internal medicine","score_opus":0.39359341274623705,"score_gpt":0.5255234633948713,"score_spread":0.13193005064863428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011437021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907533,0.0011307938,0.00018269091,0.005031579,0.0012842764,0.00035404714,0.000014062981,0.0000047642793,0.0012444915],"genre_scores_gemma":[0.9850594,0.0003789904,0.012819387,0.0008085143,0.00074123876,0.0000118987455,0.0000032512312,0.000009716159,0.00016761551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966929,0.00032896493,0.002332325,0.00013009962,0.00025559927,0.0002601274],"domain_scores_gemma":[0.9748516,0.022265313,0.001766812,0.00013163406,0.0004964657,0.00048818561],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045886096,0.00011560063,0.0017823974,0.0002121762,0.000025379992,0.0000021137043,0.00008806683,0.0003672478,0.00011870368],"category_scores_gemma":[0.029750645,0.000072452305,0.00044852358,0.00025033235,0.00017781371,0.00009357621,0.000049048638,0.00031490478,0.0000034850766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006390387,0.0021693814,0.9390454,0.00011347096,0.00020605935,0.000028897606,0.000047525773,0.0000032485214,0.00016441716,0.0004112826,0.0033175112,0.048102375],"study_design_scores_gemma":[0.005067452,0.018719163,0.95650315,0.00009043224,0.0004912403,0.00009914713,0.00006399259,0.0000017147057,0.00038397932,0.00082539767,0.01769053,0.00006382446],"about_ca_topic_score_codex":0.000018195999,"about_ca_topic_score_gemma":0.000029317667,"teacher_disagreement_score":0.048038553,"about_ca_system_score_codex":0.00013216736,"about_ca_system_score_gemma":0.00079872727,"threshold_uncertainty_score":0.97842216},"labels":[],"label_agreement":null},{"id":"W3011454180","doi":"10.1200/jco.2012.30.15_suppl.e17507","title":"Impact of asbestos exposure on survival and treatment of patients with malignant mesothelioma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Asbestos; Mesothelioma; Survival analysis; Asbestosis; Overall survival; Extrapleural Pneumonectomy; Survival rate; Internal medicine; Proportional hazards model; Lung cancer; Surgery; Pneumonectomy; Oncology; Pathology; Lung","score_opus":0.07777439444485608,"score_gpt":0.4284738636738414,"score_spread":0.3506994692289853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011454180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99883944,0.00028480214,0.0000022310655,0.00011345488,0.00014217032,0.000107585205,0.00002928167,0.000001036642,0.00047998133],"genre_scores_gemma":[0.99918497,0.00022557136,0.000308584,0.000045918634,0.0001809199,9.1909214e-7,0.0000060747584,0.0000068773456,0.000040172796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986624,0.000112097856,0.00079234946,0.00006261486,0.00026738588,0.00010314532],"domain_scores_gemma":[0.9982274,0.0005377791,0.0008003276,0.000081739905,0.00007938429,0.00027334804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003079547,0.000085496205,0.000743357,0.000055456887,0.000009328797,6.674121e-7,0.0000281872,0.000089183086,0.00011967913],"category_scores_gemma":[0.00016113838,0.000041583917,0.00024683337,0.000035959794,0.00014393912,0.0000521028,0.000008975568,0.00007785907,0.0000023850653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0129143465,0.010417469,0.9486791,0.000011253765,0.00045434057,0.000016656564,0.0000407661,0.0000079344545,0.000067090434,0.000026770065,0.000055935252,0.027308356],"study_design_scores_gemma":[0.006767269,0.08068005,0.9115173,0.000045383495,0.00035364,0.000014987455,0.000024437797,0.0000012416668,0.00006434291,0.000012175678,0.0004848334,0.000034297504],"about_ca_topic_score_codex":0.000013378973,"about_ca_topic_score_gemma":0.0000020196662,"teacher_disagreement_score":0.07026258,"about_ca_system_score_codex":0.00008413108,"about_ca_system_score_gemma":0.00019634786,"threshold_uncertainty_score":0.16957429},"labels":[],"label_agreement":null},{"id":"W3011510625","doi":"10.1200/jco.2013.31.15_suppl.5543","title":"Ovarian cancer distribution of histology, stage, and screening performance.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ovarian cancer; Serous fluid; Cancer; Clear cell; Oncology; Internal medicine; Stage (stratigraphy); Histology; Carcinosarcoma; Clear cell carcinoma; Gynecology; Pathology; Carcinoma","score_opus":0.12283551436261393,"score_gpt":0.4526101980851283,"score_spread":0.3297746837225144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011510625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814368,0.001315564,0.00029321,0.015305374,0.0006083387,0.00015712707,0.000009259668,0.0000033946123,0.00087095244],"genre_scores_gemma":[0.99221796,0.0036832124,0.0027246256,0.0006741642,0.00044517883,0.000009441026,0.0000041113167,0.0000064130227,0.0002348742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982137,0.000109824185,0.0012708514,0.00011231255,0.00015517701,0.00013809756],"domain_scores_gemma":[0.9976209,0.00053367886,0.0011451052,0.00010203235,0.0003728741,0.00022540022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089348224,0.00008199753,0.00092697534,0.00004807782,0.000028048331,0.000003949052,0.000053591986,0.00020690187,0.000522501],"category_scores_gemma":[0.00045410742,0.0000549904,0.0001696151,0.00006617008,0.00020558866,0.00010748872,0.00002832288,0.00038355534,0.000004357174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054680335,0.000509701,0.5822557,0.000035952267,0.0002867339,0.00004073872,0.000024966199,0.000010018763,0.000026502354,0.00016153548,0.004589161,0.41151217],"study_design_scores_gemma":[0.005483728,0.0057290155,0.9156822,0.00012315427,0.00032454092,0.000100590245,0.000041365784,0.0001942293,0.00008889815,0.00004788982,0.072141394,0.00004299771],"about_ca_topic_score_codex":0.00026026767,"about_ca_topic_score_gemma":0.000023977018,"teacher_disagreement_score":0.4114692,"about_ca_system_score_codex":0.00012743882,"about_ca_system_score_gemma":0.00060840714,"threshold_uncertainty_score":0.572102},"labels":[],"label_agreement":null},{"id":"W3011522756","doi":"10.1200/jco.2012.30.15_suppl.6085","title":"Physical activity (PA) and physical function (PF) in adult cancer survivors (CS).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; National Health and Nutrition Examination Survey; Cohort; Gerontology; Cancer; Confounding; Internal medicine; Proportional hazards model; Longevity; Demography; Multivariate analysis; Population; Environmental health","score_opus":0.2035270438592022,"score_gpt":0.5447227768770231,"score_spread":0.3411957330178209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011522756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822501,0.00017921296,0.00006717691,0.014644377,0.001563813,0.000117030846,0.0000015064448,0.000007894805,0.001168899],"genre_scores_gemma":[0.99030083,0.00064906536,0.0002317037,0.0030320336,0.005707559,0.0000050305352,4.6966787e-7,0.000010406049,0.0000628923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982596,0.00038676325,0.000705548,0.000121838835,0.00025365246,0.00027261616],"domain_scores_gemma":[0.99724174,0.0013489116,0.0006195218,0.00008253851,0.000214388,0.00049291394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016103457,0.00009775126,0.0010382296,0.0000974202,0.000033059903,0.000003911623,0.00004298867,0.00020301637,0.000041095485],"category_scores_gemma":[0.00096614595,0.00007151766,0.00019975395,0.00012627922,0.0001417006,0.0001995582,0.000026434045,0.0013111009,0.000011288774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004386433,0.006130919,0.6911636,0.00011071482,0.00007162475,0.000040994306,0.0003501971,0.0000020002453,0.0005738116,0.0006902702,0.0014327813,0.29504666],"study_design_scores_gemma":[0.0056432267,0.003309676,0.9722793,0.00013517214,0.00014911943,0.000097847995,0.000122944,0.000625106,0.00012437731,0.00048513775,0.01695296,0.00007510138],"about_ca_topic_score_codex":0.00017048222,"about_ca_topic_score_gemma":0.0002663463,"teacher_disagreement_score":0.29497156,"about_ca_system_score_codex":0.00014383072,"about_ca_system_score_gemma":0.00039701475,"threshold_uncertainty_score":0.56961536},"labels":[],"label_agreement":null},{"id":"W3011568159","doi":"10.1200/jco.2013.31.15_suppl.e19039","title":"Benefits of a centralized cancer control program on outcomes: Evaluation of wait times for diagnosis and management of advanced non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Referral; Lung cancer; Cancer registry; Cancer; Population; Internal medicine; Family medicine; Radiation therapy; Oncology; Environmental health","score_opus":0.19029472885616625,"score_gpt":0.5166107487950519,"score_spread":0.3263160199388856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011568159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989534,0.0044635315,0.00006313332,0.002576086,0.00041331415,0.0024168072,0.000025398911,0.0000032740368,0.0005044345],"genre_scores_gemma":[0.98618376,0.007202656,0.0053102733,0.0006585989,0.00013517989,0.00044380498,0.0000016450816,0.000011792853,0.000052305797],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968941,0.00016092278,0.001985091,0.0001730239,0.0005667393,0.00022010408],"domain_scores_gemma":[0.9944679,0.0011368673,0.00245075,0.00014167617,0.0016222439,0.00018054104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021691264,0.00013675052,0.0015346459,0.00008627317,0.000017572089,0.0000036155232,0.00013104192,0.00018207937,0.00019696768],"category_scores_gemma":[0.0005893255,0.00009449423,0.00038175413,0.00009925537,0.00010572698,0.00009095567,0.000026002639,0.00021333765,4.077638e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003396133,0.001308673,0.48416042,0.00056246365,0.0008702829,0.0000034422853,0.000102771606,0.0021741143,0.000109832596,0.000065501576,0.0013965933,0.5058498],"study_design_scores_gemma":[0.031176232,0.010725568,0.94684756,0.0020090526,0.0033211187,0.0000026518753,0.00026464133,0.0034510319,0.0010098112,0.00009647323,0.000998857,0.00009697499],"about_ca_topic_score_codex":0.0002571163,"about_ca_topic_score_gemma":0.0001124365,"teacher_disagreement_score":0.5057528,"about_ca_system_score_codex":0.00015676043,"about_ca_system_score_gemma":0.00064646325,"threshold_uncertainty_score":0.38533628},"labels":[],"label_agreement":null},{"id":"W3011598245","doi":"10.1200/jco.2012.30.15_suppl.e15537","title":"Correlation between marital status and adequate pap test screening among Canadian women: An analysis of sociodemographic factors from the Canadian community health survey, 2007–2008.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Marital status; Demography; Pap test; Confounding; Cervical cancer; Population; Cross-sectional study; Gerontology; Cancer; Cervical cancer screening; Environmental health; Internal medicine","score_opus":0.24396626928717674,"score_gpt":0.4822396283747078,"score_spread":0.23827335908753106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011598245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965288,0.0006891447,0.000029577755,0.0014446337,0.00024718695,0.00015493193,0.0005790799,0.0000028592985,0.000323808],"genre_scores_gemma":[0.9977073,0.00026375207,0.0000872969,0.0011289233,0.00046812216,0.0000013247084,0.00031383208,0.00001275958,0.000016708529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945068,0.0026814726,0.0015273693,0.00012196962,0.00044032175,0.0007220739],"domain_scores_gemma":[0.98413056,0.010290426,0.0009130981,0.00027057395,0.0005089748,0.003886349],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013754842,0.00012977765,0.001413895,0.00049275975,0.00038529318,0.000022630928,0.00018930362,0.00039680232,0.0010071952],"category_scores_gemma":[0.0045446525,0.00008850578,0.00026545278,0.0006568485,0.00055465644,0.00019272193,0.000043987522,0.002509899,0.000001159963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019100436,0.0001857203,0.96609706,0.0000054014504,0.0010163639,0.0000068843724,0.0015561641,0.000010472354,7.889846e-8,0.0000055563737,0.0003152172,0.030610066],"study_design_scores_gemma":[0.0012424467,0.0028626528,0.99153805,0.000010989135,0.0005542886,0.0000019784518,0.0021489428,0.0002900438,1.00789386e-7,0.000039177794,0.0012375534,0.000073751035],"about_ca_topic_score_codex":0.9882966,"about_ca_topic_score_gemma":0.9985407,"teacher_disagreement_score":0.030536316,"about_ca_system_score_codex":0.00086700724,"about_ca_system_score_gemma":0.004923153,"threshold_uncertainty_score":0.999906},"labels":[],"label_agreement":null},{"id":"W3011607805","doi":"10.1200/jco.19.02035","title":"Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Intensive care medicine; Internal medicine; Oncology","score_opus":0.6895133046324171,"score_gpt":0.5813931409468046,"score_spread":0.1081201636856125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011607805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9121325,0.00046538305,0.001463434,0.07915055,0.0028250362,0.00051958434,0.000025152409,0.000017811395,0.0034005202],"genre_scores_gemma":[0.94986737,0.000116828734,0.0010340761,0.047565095,0.0013472851,0.000013035166,0.0000036381357,0.00002056662,0.000032126656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9859062,0.0016664078,0.011682074,0.0002705091,0.00017016944,0.00030465343],"domain_scores_gemma":[0.9632892,0.02370343,0.0119619435,0.00029093958,0.00030884705,0.0004456538],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.036744855,0.00016679021,0.0026887208,0.000120936114,0.00013456639,0.000039002458,0.0005974851,0.00033159365,0.00027578397],"category_scores_gemma":[0.110126965,0.00012854133,0.0006062533,0.00019197901,0.0001511584,0.0004183526,0.00009923659,0.0008756263,0.00076528837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042508185,0.00063064083,0.9631178,0.000097175856,0.00037520428,0.000008705338,0.0017600496,0.00019999551,3.571984e-7,0.00849712,0.014830986,0.010056887],"study_design_scores_gemma":[0.004719656,0.001677046,0.84238887,0.000042920037,0.000022603022,0.0000039787665,0.00038010883,0.00047334086,6.965133e-7,0.0017393847,0.14841342,0.00013796322],"about_ca_topic_score_codex":0.000047904996,"about_ca_topic_score_gemma":0.00001502179,"teacher_disagreement_score":0.13358243,"about_ca_system_score_codex":0.00033323446,"about_ca_system_score_gemma":0.0006568903,"threshold_uncertainty_score":0.99187386},"labels":[],"label_agreement":null},{"id":"W3011608018","doi":"10.1200/jco.2012.30.15_suppl.5571","title":"Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Chemoradiotherapy; Radiation therapy; Internal medicine; Performance status; Cisplatin; Stage (stratigraphy); Head and neck cancer; Karnofsky Performance Status; Cancer; Urology; Chemotherapy; Surgery","score_opus":0.10001710855148996,"score_gpt":0.5146762148792009,"score_spread":0.41465910632771097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011608018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178195,0.002947077,0.00006432082,0.0028834736,0.001066715,0.00047975706,0.00004312657,0.0000028236368,0.00073075405],"genre_scores_gemma":[0.9935648,0.0043160357,0.000671748,0.0004634322,0.0009023028,0.0000130625995,0.000001917475,0.000013263249,0.000053468455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968981,0.0002610396,0.0021261012,0.000107214975,0.0003175456,0.0002899896],"domain_scores_gemma":[0.9880234,0.007999199,0.0028380866,0.00018310118,0.0007122892,0.00024394842],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022893015,0.00012767718,0.0018911553,0.000079049125,0.000023998495,9.2385517e-7,0.00011169383,0.00019689159,0.000023234188],"category_scores_gemma":[0.010768337,0.00006759877,0.0006379014,0.0001368852,0.00021346829,0.00007945927,0.000023269959,0.00041536556,9.2576596e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11496699,0.0055670976,0.11558928,0.0007727437,0.0023054497,0.00002262709,0.0014269646,0.00022848652,0.020222735,0.00019113712,0.017678525,0.721028],"study_design_scores_gemma":[0.03456252,0.089148976,0.84315354,0.0008701371,0.00069571147,0.000013375192,0.00011076677,0.000090301146,0.020940164,0.00011728905,0.010199887,0.00009731634],"about_ca_topic_score_codex":0.00007479349,"about_ca_topic_score_gemma":0.00002521224,"teacher_disagreement_score":0.7275643,"about_ca_system_score_codex":0.00023357604,"about_ca_system_score_gemma":0.0016935682,"threshold_uncertainty_score":0.9975644},"labels":[],"label_agreement":null},{"id":"W3011642026","doi":"10.1200/jco.2006.24.18_suppl.5512","title":"A concerted cell and serum proteomic approach for the identification of oral squamous cell carcinoma biomarkers","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cancer; Pathology; Western blot; Immunohistochemistry; Medicine; Cell; Head and neck squamous-cell carcinoma; Immunofluorescence; Cell culture; Cancer research; Carcinoma; Head and neck cancer; Biology; Antibody; Immunology; Internal medicine; Gene; Biochemistry","score_opus":0.05959457880851371,"score_gpt":0.3999430554462045,"score_spread":0.3403484766376908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011642026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512255,0.0014666787,0.0020181986,0.00040604174,0.00013324448,0.0004352035,0.000029285791,9.432697e-7,0.00038787443],"genre_scores_gemma":[0.9977373,0.00013112894,0.0015531284,0.000058005575,0.00021881709,0.000022247732,0.000016152586,0.000008623354,0.0002545979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850106,0.00017489893,0.0009137129,0.00014880313,0.0001156471,0.00014586262],"domain_scores_gemma":[0.9984669,0.0002085205,0.0008930851,0.00013923421,0.00021651323,0.000075752876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012498164,0.00007656145,0.0003114332,0.000030695348,0.000044322587,0.000009691546,0.00015797686,0.00017643241,0.0000038208605],"category_scores_gemma":[0.00023622821,0.000048641174,0.00020261158,0.00004621837,0.00021988463,0.0000045763745,0.000041478117,0.00013110244,3.8068538e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014227346,0.0042377627,0.22474225,0.00024291938,0.0004950953,0.00003789922,0.000057257395,0.00027864208,0.6826097,0.000038943825,0.021442136,0.051590078],"study_design_scores_gemma":[0.02811336,0.019988429,0.3817245,0.000006791336,0.00052034634,0.00012475508,0.0002451938,0.0025478909,0.541794,0.00036267517,0.024333037,0.00023899092],"about_ca_topic_score_codex":0.00016248556,"about_ca_topic_score_gemma":0.00005648178,"teacher_disagreement_score":0.15698227,"about_ca_system_score_codex":0.000023657081,"about_ca_system_score_gemma":0.0004690314,"threshold_uncertainty_score":0.19835295},"labels":[],"label_agreement":null},{"id":"W3011665030","doi":"10.1200/jco.2012.30.15_suppl.e17521","title":"The utility of DR-70, a novel blood biomarker, in the early detection of lung cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EcoMetrix","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Adenocarcinoma; Cancer; Biomarker; Oncology; Lung; Gastroenterology; Pathology","score_opus":0.12354865599208495,"score_gpt":0.5256315099176719,"score_spread":0.40208285392558696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011665030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035966,0.0029004705,0.00012895165,0.004081207,0.0009181825,0.00020433914,0.0000058058195,0.0000014335556,0.0013999535],"genre_scores_gemma":[0.99853504,0.00073943735,0.00015767422,0.0002158206,0.00028950072,0.000007903226,3.2752732e-7,0.000004455796,0.0000498388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800205,0.00026376816,0.0013102281,0.000059029928,0.00022467024,0.00014023004],"domain_scores_gemma":[0.9962714,0.002058438,0.0011846024,0.0001454875,0.00025421655,0.00008587234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032373557,0.00005823317,0.00050559564,0.00004830897,0.00003733125,0.0000024808708,0.00011161293,0.0001364204,0.000025519825],"category_scores_gemma":[0.0011263863,0.00002771438,0.00024721803,0.00016428398,0.00019419192,0.00007112711,0.000016226944,0.00036296103,3.87553e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027361163,0.004653445,0.76841545,0.000046988007,0.00117913,0.000015943684,0.0011616916,0.0000013484805,0.002950069,0.000115261246,0.00057090307,0.21815364],"study_design_scores_gemma":[0.0048164134,0.0022237916,0.9841406,0.00005846092,0.0010686268,0.00007131261,0.00023187159,0.00008780595,0.000360892,0.00006382734,0.006852966,0.000023482644],"about_ca_topic_score_codex":0.00036287066,"about_ca_topic_score_gemma":0.0003228289,"teacher_disagreement_score":0.21813016,"about_ca_system_score_codex":0.00005914311,"about_ca_system_score_gemma":0.0007228013,"threshold_uncertainty_score":0.15769053},"labels":[],"label_agreement":null},{"id":"W3011685940","doi":"10.1200/jco.2012.30.15_suppl.tps6634","title":"Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Design of CA180-363, a phase II, open-label randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Dasatinib; Medicine; Smoothened; Internal medicine; Tolerability; Imatinib; Clinical endpoint; Imatinib mesylate; Oncology; Phases of clinical research; Nilotinib; Myeloid leukemia; Pharmacology; Clinical trial; Hedgehog signaling pathway; Adverse effect; Signal transduction; Biology","score_opus":0.13809043613215347,"score_gpt":0.45719034527125646,"score_spread":0.319099909139103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011685940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979924,0.0022815296,0.0019704944,0.0010202602,0.0021375874,0.011825821,0.00019113428,0.00003414331,0.0006150321],"genre_scores_gemma":[0.9784247,0.0018008508,0.014581443,0.00042285418,0.003360688,0.00077653717,0.00032780893,0.0001623186,0.00014276875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9863399,0.002563981,0.0076750102,0.0008700939,0.0011180084,0.0014329957],"domain_scores_gemma":[0.9670663,0.021445386,0.0084948,0.0007879562,0.0010467452,0.0011588127],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009629631,0.00092154846,0.008394119,0.0005158562,0.0002975097,0.000051680803,0.00084711134,0.0010131792,0.00033526114],"category_scores_gemma":[0.012803319,0.0006730417,0.0009225454,0.00069065025,0.0011360357,0.00088394905,0.0003147093,0.0018988516,0.000012647553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8998641,0.026097674,0.00028960823,0.00018693233,0.0033435328,0.00049628783,0.00097607344,0.00041758327,0.0015030893,0.00004553807,0.0013463408,0.06543328],"study_design_scores_gemma":[0.78418314,0.2021071,0.00026155467,0.001046821,0.0032623238,0.00012428325,0.00015653654,0.005224956,0.0015920313,0.0000284973,0.001544458,0.00046826506],"about_ca_topic_score_codex":0.00046943207,"about_ca_topic_score_gemma":0.0002624302,"teacher_disagreement_score":0.17600943,"about_ca_system_score_codex":0.01992083,"about_ca_system_score_gemma":0.03280935,"threshold_uncertainty_score":0.9995721},"labels":[],"label_agreement":null},{"id":"W3011711731","doi":"10.1200/jco.2012.30.15_suppl.10622","title":"Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Biomarker; Microarray; Transcriptome; Biomarker discovery; Leukemia; Gene expression; Oncology; Fold change; Internal medicine; Proteomics; Bioinformatics; Gene; Biology; Genetics","score_opus":0.13035543959525103,"score_gpt":0.46624465049795755,"score_spread":0.3358892109027065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011711731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929445,0.0028919554,0.000054830893,0.00037798274,0.0021714137,0.00047366522,0.000003353921,0.0000065046324,0.0010757868],"genre_scores_gemma":[0.9943345,0.0025813247,0.00080971525,0.00036427754,0.001719884,0.000011608189,0.0000042115503,0.000030344554,0.00014413561],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953204,0.00054624514,0.0024666155,0.00024481947,0.0007255967,0.0006963649],"domain_scores_gemma":[0.99369293,0.0028508194,0.0020693766,0.0002652464,0.00032283962,0.0007987899],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037802367,0.00022113233,0.0014555273,0.00030204028,0.00004362556,0.000024198383,0.00022313421,0.0005655566,0.000055146716],"category_scores_gemma":[0.008934087,0.000155755,0.00034937932,0.00024766292,0.0005370149,0.000534588,0.00024531127,0.0013104065,0.000025296775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11039889,0.004016678,0.43304226,0.000622902,0.0018892175,0.0043375106,0.0010130764,0.00020871575,0.0007791068,0.00028721863,0.0067720995,0.43663234],"study_design_scores_gemma":[0.30314714,0.023575053,0.6513158,0.0010163127,0.0004990214,0.002011058,0.00020386909,0.0045949155,0.00047613753,0.00011809571,0.0126842875,0.00035830235],"about_ca_topic_score_codex":0.0001431185,"about_ca_topic_score_gemma":0.00004733717,"teacher_disagreement_score":0.43627405,"about_ca_system_score_codex":0.07964016,"about_ca_system_score_gemma":0.07779411,"threshold_uncertainty_score":0.9994141},"labels":[],"label_agreement":null},{"id":"W3011743004","doi":"10.1200/jco.2012.30.15_suppl.e17518","title":"Prognostic factors and trends in outcome for small cell lung cancer over 20 years.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Proportional hazards model; Cancer registry; Internal medicine; Lung cancer; Incidence (geometry); Hazard ratio; Population; Cancer; Radiation therapy; Clinical trial; Oncology; Relative survival; Confidence interval","score_opus":0.25374892070157656,"score_gpt":0.5750290758065449,"score_spread":0.3212801551049684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011743004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070805,0.004152981,0.000017234503,0.0031709261,0.0009961274,0.00023060462,0.0000081903145,0.0000039077904,0.00071197463],"genre_scores_gemma":[0.99570686,0.0007395265,0.0007239106,0.00060383725,0.0012589145,0.000016202344,0.0000012489307,0.000014387014,0.00093508925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980415,0.0001369857,0.0011475405,0.00011400723,0.00021146472,0.0003484892],"domain_scores_gemma":[0.9962898,0.0026217713,0.0005086627,0.00008035778,0.00013678626,0.00036263897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002097097,0.00010049573,0.0010377773,0.00018688303,0.000018005425,0.0000048392885,0.00008030065,0.00019685391,0.000119740405],"category_scores_gemma":[0.0027697627,0.00006403796,0.00023796875,0.00011614469,0.00012434571,0.000087106906,0.00006189234,0.00068947574,9.76984e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008197912,0.00052945426,0.9658768,0.00008105211,0.00017683224,0.000043031654,0.0002786836,0.0000010198119,0.000030510915,0.000009055975,0.007043646,0.025110086],"study_design_scores_gemma":[0.0059192525,0.0024615054,0.94790584,0.0000519192,0.0003089104,0.0000125462775,0.00007000707,0.000033468576,0.00001548142,0.000014719849,0.04314661,0.00005971863],"about_ca_topic_score_codex":0.00006301718,"about_ca_topic_score_gemma":0.00027894267,"teacher_disagreement_score":0.036102965,"about_ca_system_score_codex":0.00024879945,"about_ca_system_score_gemma":0.0003885513,"threshold_uncertainty_score":0.33158648},"labels":[],"label_agreement":null},{"id":"W3011777578","doi":"10.1200/jco.2012.30.15_suppl.500","title":"Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Queen's University","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Hazard ratio; Anastrozole; Oncology; Internal medicine; Radiation therapy; Adjuvant; Stage (stratigraphy); Aromatase inhibitor; Aromatase; Cancer; Confidence interval","score_opus":0.04458021061345215,"score_gpt":0.4355081585547641,"score_spread":0.39092794794131197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011777578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185663,0.0060828654,0.000048967213,0.0008338223,0.0008271864,0.00015298901,0.0001647882,0.000002466923,0.000030308107],"genre_scores_gemma":[0.994484,0.00371141,0.00022585705,0.00025110703,0.0012633202,0.000005704141,0.000010867715,0.000022325086,0.000025415457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977374,0.00032095358,0.0011765083,0.00022075725,0.00019479236,0.00034960115],"domain_scores_gemma":[0.99803174,0.00015689102,0.0011515382,0.00016943063,0.00019041679,0.0003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008391922,0.00022807202,0.0010307826,0.00008095378,0.000027248456,0.000007871409,0.00013748181,0.00028140325,0.000057007783],"category_scores_gemma":[0.000096672586,0.00014862148,0.0003043009,0.00008899062,0.00041973213,0.000027960448,0.000073559786,0.0003868213,0.0000010654479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051452224,0.0011129418,0.96484333,0.000021206166,0.0010166456,0.000054970547,0.00015675108,0.000059732996,0.0046427967,0.000008992145,0.001262247,0.021675186],"study_design_scores_gemma":[0.008346613,0.0049669542,0.9807943,0.00008540738,0.00017097399,0.00027708337,0.0000460523,0.0000093906,0.0011118662,0.0000061060987,0.004019131,0.00016612379],"about_ca_topic_score_codex":0.00062701345,"about_ca_topic_score_gemma":0.00035344166,"teacher_disagreement_score":0.021509062,"about_ca_system_score_codex":0.00018528056,"about_ca_system_score_gemma":0.00088923617,"threshold_uncertainty_score":0.60606074},"labels":[],"label_agreement":null},{"id":"W3011815213","doi":"10.1200/jco.2006.24.18_suppl.6019","title":"Measuring chemotherapy safety in a community oncology practice: Results of a three-year prospective study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Cancer; Prospective cohort study; Lung cancer; Breast cancer; Neutropenia; Intensive care medicine; Oncology","score_opus":0.20793970800131584,"score_gpt":0.5302978625886811,"score_spread":0.3223581545873652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011815213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551937,0.00026741155,0.000021269083,0.009562315,0.000653786,0.0008172909,0.0000057832563,0.000008881666,0.03346957],"genre_scores_gemma":[0.9956905,0.00033945046,0.002113496,0.0008000217,0.00087602565,0.0000110929905,0.0000024733085,0.000016705622,0.0001502107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349755,0.002397699,0.0033229606,0.00018165426,0.00035697763,0.00024316825],"domain_scores_gemma":[0.9887224,0.0072203465,0.0028767558,0.00025293362,0.0007734878,0.0001541178],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011239758,0.00015981315,0.0020462293,0.0002115249,0.00005522139,0.0000034619698,0.00019977088,0.00037675578,0.00007535774],"category_scores_gemma":[0.0038481671,0.000120175224,0.0003376041,0.0003021949,0.00027408832,0.00012652026,0.000064591695,0.0023153455,0.0000056962917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18616503,0.07683333,0.6826635,0.00003120742,0.0012160854,0.0012383454,0.002102323,0.000054558226,0.0004456261,0.000093230134,0.0025793337,0.046577413],"study_design_scores_gemma":[0.078801595,0.07805769,0.80674094,0.00006199858,0.0005923806,0.0002775436,0.0015893695,0.000014455541,0.00014840356,0.00061118335,0.03302258,0.00008184215],"about_ca_topic_score_codex":0.0017655343,"about_ca_topic_score_gemma":0.006887764,"teacher_disagreement_score":0.12407744,"about_ca_system_score_codex":0.0008575364,"about_ca_system_score_gemma":0.00229994,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W3011863200","doi":"10.1200/jco.2006.24.18_suppl.6129","title":"Drug interactions in ambulatory cancer patients receiving cancer-directed therapy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Internal medicine; Ambulatory; Drug; Chemotherapy; Logistic regression; Breast cancer; Epidemiology; Pharmacology","score_opus":0.12448327550527227,"score_gpt":0.5302975286402103,"score_spread":0.405814253134938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011863200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98278505,0.0024584353,0.0000015652203,0.0068314164,0.004517014,0.00019510536,0.000005076087,0.000015738267,0.0031906206],"genre_scores_gemma":[0.9875199,0.005583739,0.0002867789,0.0024618183,0.002414262,0.000024258557,0.000004499576,0.000016189118,0.001688521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757797,0.00028824134,0.0015866549,0.00015576676,0.00018504173,0.0002063424],"domain_scores_gemma":[0.9972271,0.0010871227,0.0010946855,0.00007975288,0.00035993874,0.00015142502],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000687637,0.0001214679,0.0009514149,0.00015565894,0.000031616673,0.000004514994,0.00008523493,0.00011135928,0.0009337504],"category_scores_gemma":[0.00017372872,0.000089790105,0.0003492924,0.00019967198,0.00007816218,0.00011058181,0.000017784203,0.00086679775,0.0000060631105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028935885,0.0042012073,0.80115354,0.000007730213,0.00025428887,0.00008071804,0.00011619009,0.0000582257,0.0003790779,0.0000033511285,0.056516163,0.13433595],"study_design_scores_gemma":[0.011683399,0.0014049223,0.7771459,0.00009520916,0.00014424782,0.000014045147,0.000016042542,0.00007218899,0.00020531427,0.00005613851,0.20909902,0.00006354598],"about_ca_topic_score_codex":0.0025057164,"about_ca_topic_score_gemma":0.010578551,"teacher_disagreement_score":0.15258285,"about_ca_system_score_codex":0.0006418416,"about_ca_system_score_gemma":0.0013399479,"threshold_uncertainty_score":0.99997956},"labels":[],"label_agreement":null},{"id":"W3011913566","doi":"10.1200/jco.2013.31.15_suppl.9598","title":"Young adult cancer survivors' (CS) follow-up care expectations of their primary care providers (PCPs) and oncologists.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Survivorship curve; Family medicine; Cancer; Primary care; Cancer survivorship; Demographics; Breast cancer; Young adult; CLARITY; Gerontology; Gynecology; Internal medicine; Demography","score_opus":0.0737038050670624,"score_gpt":0.42231052199853686,"score_spread":0.3486067169314745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011913566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600605,0.0028925377,0.000021906093,0.004067165,0.0051902714,0.00048091073,0.000024241659,0.000018501007,0.027243989],"genre_scores_gemma":[0.9947151,0.0021587103,0.0011433988,0.0008108429,0.0008187203,0.000043610617,0.0000051474867,0.000018073482,0.00028638053],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99566925,0.0011971764,0.001961325,0.0002588312,0.00054708496,0.00036636324],"domain_scores_gemma":[0.9911918,0.0035418293,0.0020677838,0.0001906368,0.0026366105,0.0003713406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014983966,0.00016788028,0.0011894557,0.00012034705,0.00024586412,0.000039719944,0.0004963084,0.00059347233,0.00018807633],"category_scores_gemma":[0.003890972,0.00012650555,0.00039677726,0.00023724385,0.001221286,0.0005091288,0.00009995127,0.00071051944,0.000008316299],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031279426,0.0002779089,0.67391175,0.00012435936,0.0002000436,0.000039681716,0.09367506,0.000015193464,0.000055155262,0.0005808541,0.0063453713,0.22446181],"study_design_scores_gemma":[0.0033967593,0.0023929442,0.39067197,0.00015115218,0.00020309763,0.000016944914,0.57153183,0.000009500628,0.00004537734,0.00093116454,0.030364888,0.0002843558],"about_ca_topic_score_codex":0.02494318,"about_ca_topic_score_gemma":0.12861387,"teacher_disagreement_score":0.47785679,"about_ca_system_score_codex":0.0005630368,"about_ca_system_score_gemma":0.0049842224,"threshold_uncertainty_score":0.9815498},"labels":[],"label_agreement":null},{"id":"W3011921832","doi":"10.1200/jco.2012.30.15_suppl.tps4135","title":"A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Gemcitabine; Internal medicine; Gastroenterology; Progression-free survival; Pancreatic cancer; Phases of clinical research; Randomized controlled trial; Urology; Oncology; Cancer; Surgery; Clinical trial; Chemotherapy; Pathology","score_opus":0.18482800677765726,"score_gpt":0.49131948764467853,"score_spread":0.30649148086702127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011921832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96902186,0.0010874834,0.0007124156,0.007339283,0.0010123203,0.020382324,0.000005617727,0.0000045911115,0.0004340992],"genre_scores_gemma":[0.9940835,0.001462944,0.0013071945,0.00044834358,0.00095408043,0.0010642876,0.000004757437,0.000028101962,0.00064673746],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9896707,0.0036584402,0.005165693,0.00020791522,0.00083965017,0.00045761972],"domain_scores_gemma":[0.9473441,0.04564017,0.0052469955,0.00042916715,0.0010472275,0.0002923225],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029107178,0.00026917472,0.0058854218,0.00025989342,0.000090430825,0.000008925999,0.00042836007,0.00034904716,0.00022909677],"category_scores_gemma":[0.022282394,0.00010599965,0.0011634273,0.0003280755,0.0009539606,0.00015025957,0.00005632057,0.0010444445,0.000002225754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95948213,0.029306738,0.0028912732,0.000076973294,0.0030702744,0.000035938734,0.000706716,0.000007453891,0.00002807476,0.0002586941,0.00021456722,0.003921169],"study_design_scores_gemma":[0.9032898,0.08897112,0.0007396291,0.00019081037,0.0037993602,0.00013649922,0.00046239514,0.0013765851,0.00009251299,0.0002256928,0.0006227208,0.000092887596],"about_ca_topic_score_codex":0.000105238316,"about_ca_topic_score_gemma":0.00014905538,"teacher_disagreement_score":0.059664384,"about_ca_system_score_codex":0.00015283083,"about_ca_system_score_gemma":0.0033473056,"threshold_uncertainty_score":0.99973845},"labels":[],"label_agreement":null},{"id":"W3011925872","doi":"10.1200/jco.2006.24.18_suppl.4516","title":"Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Internal medicine; Quality of life (healthcare); Oncology; Cancer; Chemotherapy","score_opus":0.10289521198122166,"score_gpt":0.45506812270593255,"score_spread":0.3521729107247109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011925872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957591,0.00083349965,0.000006914049,0.0022972082,0.00002290792,0.0009965304,0.0000665295,0.0000023528855,0.000014951546],"genre_scores_gemma":[0.99841875,0.00071522215,0.0003233335,0.000077418714,0.00003988379,0.000024411704,0.000005069382,0.00001535045,0.00038057804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98863506,0.008045816,0.0019518317,0.0002072311,0.0009277469,0.00023230178],"domain_scores_gemma":[0.9839568,0.011631657,0.0030880435,0.00018302958,0.0009954531,0.00014503076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02019312,0.00016932395,0.0017266963,0.00020008461,0.000034342465,0.000006843083,0.00009301092,0.00012154423,0.000009151402],"category_scores_gemma":[0.005138477,0.00007288492,0.000069495036,0.0003930674,0.00044920648,0.00011248676,0.000024219355,0.0005367179,6.16124e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42643398,0.004539734,0.5650252,0.000064865584,0.00069928926,0.000110715584,0.0006785077,0.0000082472725,0.00039284842,7.040164e-7,0.00009853431,0.0019473701],"study_design_scores_gemma":[0.049431484,0.10540723,0.8419392,0.00015376511,0.00059994985,0.0000066926236,0.0020802016,0.000009280726,0.000052694377,0.0000062133054,0.00024345543,0.00006979528],"about_ca_topic_score_codex":0.00095890806,"about_ca_topic_score_gemma":0.0037944608,"teacher_disagreement_score":0.3770025,"about_ca_system_score_codex":0.00023275969,"about_ca_system_score_gemma":0.0022414627,"threshold_uncertainty_score":0.6998573},"labels":[],"label_agreement":null},{"id":"W3011965506","doi":"10.1200/jco.2012.30.15_suppl.e16567","title":"Patient and caregiver satisfaction with ambulatory oncology care: Agreement and predictors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ambulatory; Patient satisfaction; Quality of life (healthcare); Cohen's kappa; Family medicine; Ambulatory care; Health care; Cancer; Concordance; Physical therapy; Internal medicine; Nursing","score_opus":0.04899587699118005,"score_gpt":0.39175192323923846,"score_spread":0.34275604624805844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011965506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890286,0.005046375,0.000053812742,0.0013811137,0.0020111175,0.0001576852,0.0000027927404,0.000005705089,0.0023128085],"genre_scores_gemma":[0.9958332,0.0011532563,0.0004314069,0.0014357717,0.0010939271,0.000003793739,0.0000013012833,0.000010121272,0.000037224596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982855,0.0002581293,0.0008492966,0.00012961206,0.00028199196,0.0001955108],"domain_scores_gemma":[0.99782026,0.0004980295,0.0007415505,0.00010613175,0.000301228,0.0005328273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008189429,0.000109984394,0.00080183684,0.00007340961,0.00003817891,0.000004642968,0.00002675881,0.00029383044,0.000067329725],"category_scores_gemma":[0.00020285476,0.00007208103,0.00010366917,0.00005057726,0.0002403565,0.00012422977,0.00004069769,0.00059172703,0.0000022583765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001785552,0.00018198174,0.6890547,0.000037459056,0.00017517654,0.00009336089,0.003801438,9.0705385e-7,0.000019494139,0.000033610766,0.0011080513,0.30370823],"study_design_scores_gemma":[0.003482592,0.017258134,0.7667408,0.000055647823,0.0004191394,0.000656996,0.0039874623,0.0000018684199,0.000021137857,0.0000088466795,0.20730089,0.00006647701],"about_ca_topic_score_codex":0.00022753168,"about_ca_topic_score_gemma":0.0013831529,"teacher_disagreement_score":0.30364174,"about_ca_system_score_codex":0.00029516988,"about_ca_system_score_gemma":0.0006933194,"threshold_uncertainty_score":0.2939379},"labels":[],"label_agreement":null},{"id":"W3011966668","doi":"10.1200/jco.2006.24.18_suppl.4056","title":"Phase II trial of preoperative (POP) irinotecan (I) + cisplatin (C) and radiotherapy for esophageal cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Irinotecan; Surgery; Esophageal cancer; Gastroenterology; Neutropenia; Internal medicine; Esophagitis; Radiation therapy; Esophagectomy; Nausea; Perioperative; Mucositis; Chemoradiotherapy; External beam radiotherapy; Chemotherapy; Cancer; Brachytherapy; Colorectal cancer","score_opus":0.12635949720628864,"score_gpt":0.5338665772900809,"score_spread":0.4075070800837923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011966668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837796,0.008482571,0.00040784595,0.005412172,0.00051064504,0.0009529253,0.00003657487,0.000004310951,0.0004133736],"genre_scores_gemma":[0.9890589,0.0014757504,0.005505052,0.00042420422,0.002697906,0.000042804662,0.0000042008874,0.000015199439,0.00077595125],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743515,0.0002270702,0.0016389046,0.00016898006,0.00031052166,0.00021934463],"domain_scores_gemma":[0.99679404,0.0014049738,0.0009900174,0.00011153009,0.00041367704,0.00028573396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016052484,0.00012456195,0.0013466164,0.000101391655,0.00006047174,0.0000057751113,0.00008204708,0.00020918326,0.00015148507],"category_scores_gemma":[0.0007040258,0.00008123887,0.00037059144,0.00008201147,0.00025962267,0.00007486254,0.000021568892,0.00043511754,3.697455e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48519516,0.01999331,0.013374286,0.00008739972,0.0010916726,0.0004941986,0.00017573305,0.000027354137,0.0005045633,0.00049035467,0.006134285,0.4724317],"study_design_scores_gemma":[0.5377511,0.42045403,0.025481416,0.000080913254,0.00045450317,0.000104359635,0.00002621139,0.00030109784,0.0020743432,0.00059590663,0.012590052,0.00008606282],"about_ca_topic_score_codex":0.00015001954,"about_ca_topic_score_gemma":0.00012868541,"teacher_disagreement_score":0.47234562,"about_ca_system_score_codex":0.00018527427,"about_ca_system_score_gemma":0.0018224828,"threshold_uncertainty_score":0.3312825},"labels":[],"label_agreement":null},{"id":"W3011997600","doi":"10.1200/jco.2013.31.15_suppl.9577","title":"Correlations of patient-reported measures (PRM) for health, quality of life (QOL), functional status, and social supports with survival in early-stage colon cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Quality of life (healthcare); Stage (stratigraphy); Internal medicine; Cancer; Cohort; Oncology; Gerontology","score_opus":0.1780386873874411,"score_gpt":0.4674948832114418,"score_spread":0.2894561958240007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011997600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251753,0.00036473776,0.00024504893,0.0051373653,0.0010662694,0.00043892663,0.00005366865,0.0000034544612,0.00017299571],"genre_scores_gemma":[0.9983284,0.00024383106,0.00023542784,0.00074057834,0.00030697367,0.000021271358,0.000012738582,0.000011132765,0.000099640514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958528,0.00047948596,0.0028275584,0.00014968573,0.00048012676,0.00021030346],"domain_scores_gemma":[0.993335,0.0016771466,0.0034368823,0.000091581045,0.0011782412,0.00028111663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025950249,0.00010130499,0.0014658618,0.00009399893,0.00004606393,0.0000042469583,0.000038472106,0.00023821382,0.00015208281],"category_scores_gemma":[0.0014966838,0.00007606343,0.00021970143,0.00013164413,0.00026197563,0.00009520785,0.000018249573,0.000479582,2.0453875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00978358,0.00072401145,0.9713154,0.00018748903,0.00027994913,0.0000067835254,0.0011598751,0.00003297117,0.000027196746,0.0001325546,0.0019008056,0.014449399],"study_design_scores_gemma":[0.0071637193,0.007989603,0.9775455,0.0000779538,0.00010121007,0.0000070326837,0.0014187415,0.000014911996,0.000009043679,0.00013790214,0.0054694093,0.00006498608],"about_ca_topic_score_codex":0.010863684,"about_ca_topic_score_gemma":0.026685024,"teacher_disagreement_score":0.01582134,"about_ca_system_score_codex":0.0001455144,"about_ca_system_score_gemma":0.0049433154,"threshold_uncertainty_score":0.99572307},"labels":[],"label_agreement":null},{"id":"W3012012183","doi":"10.1200/jco.2013.31.15_suppl.e11580","title":"The impact of estrogen receptor (ER), progesterone receptor (PR), and HER-2 receptor status on treatment of patients with advanced breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Breast cancer; Oncology; Progesterone receptor; Cancer; Metastatic breast cancer; Internal medicine; Biopsy; Estrogen receptor; Metastasis; Gynecology; Retrospective cohort study","score_opus":0.038131964573218484,"score_gpt":0.4167874640582783,"score_spread":0.37865549948505983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012012183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333644,0.0017671859,0.000010656385,0.0031644008,0.00056373107,0.0009277471,0.0001645223,0.000008652976,0.000056642228],"genre_scores_gemma":[0.9860175,0.0059727025,0.007078824,0.0001355729,0.0005202368,0.00006719995,0.000013401585,0.000051025847,0.00014349622],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996638,0.00031991297,0.0019163487,0.00025684954,0.0004557102,0.00041317058],"domain_scores_gemma":[0.99353045,0.0013572728,0.0030831483,0.00032005974,0.0011931175,0.00051594543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004632874,0.00029706868,0.0017809954,0.00008464137,0.00005700006,0.000008726158,0.00015015679,0.00022288808,0.0004174029],"category_scores_gemma":[0.00037352755,0.00013941465,0.0003770795,0.00016353236,0.0006241503,0.00020907851,0.000028970682,0.0004161484,0.000009338641],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031931717,0.0025325064,0.36232433,0.000022123455,0.0010826662,0.0000025989339,0.00018780722,0.000043657576,0.00109035,0.000006207715,0.0004203548,0.6003557],"study_design_scores_gemma":[0.022515282,0.10137631,0.8504299,0.00036292788,0.00023455592,0.000036575537,0.00028554408,0.000007911536,0.0008612295,0.00004588065,0.023690173,0.00015370679],"about_ca_topic_score_codex":0.00020044926,"about_ca_topic_score_gemma":0.00002464448,"teacher_disagreement_score":0.60020196,"about_ca_system_score_codex":0.0008214314,"about_ca_system_score_gemma":0.0015174614,"threshold_uncertainty_score":0.56851643},"labels":[],"label_agreement":null},{"id":"W3012059619","doi":"10.1200/jco.2006.24.18_suppl.1575","title":"An analysis of adjuvant temozolomide plus radiotherapy vs radiotherapy alone in a single academic institution","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Temozolomide; Radiation therapy; Glioblastoma; Internal medicine; Surgery; Oncology","score_opus":0.07736179521541876,"score_gpt":0.45211006076768157,"score_spread":0.3747482655522628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012059619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951703,0.0047945734,0.000781974,0.0041569117,0.0003641306,0.00020812172,0.000004995049,0.00000788528,0.00016436227],"genre_scores_gemma":[0.9906419,0.0029886127,0.0044889995,0.0011576938,0.00067895657,0.0000048327192,0.000010915615,0.000013899169,0.000014204551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958224,0.0004538197,0.0029313315,0.00021816282,0.00034980604,0.00022445693],"domain_scores_gemma":[0.9965054,0.000978414,0.0018519773,0.00023155163,0.0002083168,0.00022435954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022656887,0.00015642578,0.0026669835,0.000780224,0.000021773032,0.000005251135,0.00015431632,0.000508554,0.00009780092],"category_scores_gemma":[0.00040190414,0.00011023781,0.00072028534,0.0006840219,0.00022859048,0.00014185198,0.00000880351,0.0006521841,0.0000011903339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007011398,0.008138194,0.89174783,0.000012940365,0.0020965287,0.00085945445,0.00013992768,0.008563068,0.018498175,0.00021874029,0.00054825074,0.062165517],"study_design_scores_gemma":[0.022436693,0.013661824,0.9471859,0.00008755331,0.0018304503,0.0001360018,0.000044427736,0.0051422254,0.0012632953,0.00009964455,0.008012043,0.00009998656],"about_ca_topic_score_codex":0.0003265216,"about_ca_topic_score_gemma":0.0005018188,"teacher_disagreement_score":0.06206553,"about_ca_system_score_codex":0.0007570472,"about_ca_system_score_gemma":0.00080162054,"threshold_uncertainty_score":0.44953674},"labels":[],"label_agreement":null},{"id":"W3012177874","doi":"10.1200/jco.2013.31.15_suppl.e19542","title":"Identification of ephrinB2 positive vessels in non-Hodgkin lymphoma subtypes.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Angiogenesis; CD34; Lymphoma; Cancer research; Receptor tyrosine kinase; Immunohistochemistry; Pathology; Follicular lymphoma; Medicine; CD163; Tumor microenvironment; Biology; Receptor; Macrophage; Internal medicine; Stem cell; Cell biology; Tumor cells","score_opus":0.04249303608039576,"score_gpt":0.4169508932672588,"score_spread":0.3744578571868631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012177874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055797,0.00035966004,0.00020998839,0.003975984,0.0012408936,0.0002299373,0.0000016717239,0.0000030223487,0.0034208947],"genre_scores_gemma":[0.9965473,0.0005876571,0.00083531236,0.0011977226,0.00057460996,0.0000040499262,0.0000019133001,0.000009973464,0.00024145444],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99658805,0.00026291836,0.0025943622,0.0001316743,0.00026101907,0.00016200147],"domain_scores_gemma":[0.99621564,0.0010588666,0.0017396103,0.0001764484,0.00060075737,0.00020865822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024206708,0.00008913594,0.0011264753,0.00019740454,0.0000119338965,0.0000058344863,0.00014343383,0.0002912144,0.00017196883],"category_scores_gemma":[0.0031729585,0.00006566491,0.00028312305,0.00019781735,0.00017893473,0.00020672967,0.0000307624,0.00031792262,0.00006972287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034922024,0.0060292063,0.2983216,0.000096025,0.00034190324,0.00016878768,0.0007748345,0.000023663524,0.02098163,0.0008004766,0.010649265,0.65832037],"study_design_scores_gemma":[0.007569844,0.0019178933,0.98241514,0.00006266822,0.00014207182,0.00006751808,0.00028087888,0.0000941356,0.0017968039,0.0011569745,0.0044373563,0.000058709473],"about_ca_topic_score_codex":0.00009998981,"about_ca_topic_score_gemma":0.000015495309,"teacher_disagreement_score":0.68409353,"about_ca_system_score_codex":0.000052845706,"about_ca_system_score_gemma":0.0008454082,"threshold_uncertainty_score":0.37985566},"labels":[],"label_agreement":null},{"id":"W3012183740","doi":"10.1200/jco.2013.31.15_suppl.8545","title":"Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Phases of clinical research; Surgery; AL amyloidosis; Gastroenterology; Multiple myeloma; Toxicity; Immunoglobulin light chain","score_opus":0.03643590247432078,"score_gpt":0.3702259658615275,"score_spread":0.33379006338720674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012183740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311787,0.00057900103,0.00001663572,0.0037450553,0.0010572247,0.0013255838,0.00006876705,0.0000070716997,0.00008280061],"genre_scores_gemma":[0.9961796,0.00047269865,0.00022681257,0.0020377142,0.0004405008,0.00013935375,0.00003850789,0.000052364965,0.00041245174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932198,0.0013024688,0.0038117073,0.00062034343,0.0005694127,0.00047626495],"domain_scores_gemma":[0.99338144,0.0013597219,0.003427783,0.0008228851,0.00066074246,0.00034741996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018535377,0.00042305,0.0017665293,0.00013588033,0.000086210406,0.00002788643,0.00073254993,0.0006136054,0.000076079756],"category_scores_gemma":[0.0023157976,0.00023379961,0.00045668235,0.0002342025,0.00020933479,0.00003732791,0.00027036777,0.00074952014,0.00001660203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036849014,0.015335973,0.9209807,0.000014753001,0.0014767111,0.0002353806,0.000664989,0.000013070068,0.0012866207,7.2045907e-7,0.011032098,0.012109983],"study_design_scores_gemma":[0.071867146,0.09299668,0.83009344,0.00023339032,0.00060435606,0.00002782426,0.0009603737,0.0000042307743,0.00056467595,0.000006096002,0.0023539194,0.00028787207],"about_ca_topic_score_codex":0.0007128623,"about_ca_topic_score_gemma":0.0047099525,"teacher_disagreement_score":0.090887256,"about_ca_system_score_codex":0.0001850248,"about_ca_system_score_gemma":0.00081392226,"threshold_uncertainty_score":0.95340717},"labels":[],"label_agreement":null},{"id":"W3012233653","doi":"10.1200/jco.2012.30.15_suppl.634","title":"Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Centre hospitalier universitaire de Québec","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Metastatic breast cancer; Population; Internal medicine; Oncology; Toxicity; Genotyping; Genotype; Cancer; Gastroenterology; Biology; Genetics","score_opus":0.18276055988397144,"score_gpt":0.5201602895009736,"score_spread":0.33739972961700215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012233653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938302,0.0005040312,0.000015575024,0.0039432626,0.00043649002,0.0004113216,0.000015492695,0.0000027901092,0.00084082625],"genre_scores_gemma":[0.99895954,0.00011113762,0.00012908278,0.00018052915,0.0005504743,0.000027774637,0.0000014216508,0.000015920054,0.000024106845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941299,0.0019434283,0.0016108524,0.00012313855,0.0018534604,0.0003392173],"domain_scores_gemma":[0.9950123,0.0017195651,0.0016471598,0.00018025933,0.0011800601,0.00026066718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024742626,0.000114286995,0.0012558283,0.000110925066,0.000028520546,0.0000041348308,0.00015230927,0.00025056873,0.00015719206],"category_scores_gemma":[0.003097875,0.00006345381,0.00019988946,0.00037013312,0.00027048137,0.00015933844,0.000021956826,0.0008829816,6.69574e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022274042,0.0035555225,0.79230654,0.000045225803,0.0019236155,0.000063731444,0.0017681275,0.00014829448,0.0015611382,0.000014483779,0.00034175583,0.17599753],"study_design_scores_gemma":[0.0071050003,0.012970622,0.976688,0.00042846912,0.0007782034,0.00008990827,0.0009271065,0.000120183,0.00061405543,0.000030993673,0.00018221149,0.000065201624],"about_ca_topic_score_codex":0.00017998593,"about_ca_topic_score_gemma":0.00043918553,"teacher_disagreement_score":0.1843815,"about_ca_system_score_codex":0.0014548835,"about_ca_system_score_gemma":0.009502772,"threshold_uncertainty_score":0.9961124},"labels":[],"label_agreement":null},{"id":"W3012258768","doi":"10.1200/jco.2012.30.15_suppl.8053","title":"LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Lenalidomide; Internal medicine; Gastroenterology; Neutropenia; Dexamethasone; Febrile neutropenia; Cyclophosphamide; Toxicity; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Surgery; Chemotherapy","score_opus":0.14689824316387082,"score_gpt":0.4756972759796616,"score_spread":0.3287990328157908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012258768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98313993,0.0018072352,0.00008170848,0.0106451465,0.0016119886,0.00044466724,0.0000042653546,0.00001118478,0.002253902],"genre_scores_gemma":[0.9900217,0.0022482872,0.0019693244,0.0035934302,0.0015992903,0.000019518202,0.000011533356,0.000018597953,0.0005182884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974816,0.00027199797,0.0015828004,0.00012366707,0.00025097938,0.0002889508],"domain_scores_gemma":[0.9947199,0.003057209,0.0012694729,0.00014768585,0.00037396073,0.00043173137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022359442,0.00014219004,0.0011454604,0.00009581738,0.000045996338,0.000008559668,0.00009172508,0.00033957046,0.00012143952],"category_scores_gemma":[0.0009747176,0.000087992514,0.00065581617,0.00008602716,0.000087690045,0.0001298817,0.00001504863,0.00027273534,0.000037946516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115714045,0.0489886,0.64069307,0.000054749642,0.0012220435,0.00021532911,0.00022628166,0.0000051337906,0.0010057994,0.0014213388,0.042491525,0.25210473],"study_design_scores_gemma":[0.08291358,0.02255091,0.62315655,0.00008231252,0.0006698203,0.00025004405,0.000069818525,0.000047657162,0.00668014,0.0005525542,0.26289916,0.00012745893],"about_ca_topic_score_codex":0.0000146225175,"about_ca_topic_score_gemma":0.0000037481846,"teacher_disagreement_score":0.25197726,"about_ca_system_score_codex":0.0002487503,"about_ca_system_score_gemma":0.00061114365,"threshold_uncertainty_score":0.35882306},"labels":[],"label_agreement":null},{"id":"W3012266322","doi":"10.1200/jco.2006.24.18_suppl.681","title":"Bone and cardiac status in 10-year survivors of breast cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Osteoporosis; Bone mineral; Internal medicine; Body mass index; Cancer; Surgery","score_opus":0.061103362110788303,"score_gpt":0.4594009649969029,"score_spread":0.3982976028861146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012266322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990737,0.0022856493,0.0000010660771,0.0040981,0.0005246715,0.00010398032,0.000022709377,0.0000020309906,0.002224765],"genre_scores_gemma":[0.99578464,0.002538134,0.00054843293,0.0002627215,0.00033062918,0.0000018000841,0.0000018876137,0.0000076906035,0.00052408065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773055,0.00021710704,0.001572135,0.00009525134,0.00018106325,0.00020391245],"domain_scores_gemma":[0.9979197,0.00068967295,0.0008264357,0.00007715812,0.00020216628,0.00028487164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013443388,0.00007080284,0.0012307776,0.00010007061,0.000010537648,0.0000013920298,0.000022977087,0.00021118812,0.00012772936],"category_scores_gemma":[0.0003280124,0.00004933286,0.00016565996,0.000098783836,0.00012279944,0.00004055445,0.000015286269,0.00037637283,0.0000040102873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031522166,0.0009162246,0.94150436,0.00003591273,0.00007869995,0.00021045879,0.00001789892,0.000002429156,0.000021817814,0.000048413232,0.0019418509,0.0520697],"study_design_scores_gemma":[0.0072301873,0.0025565107,0.9679171,0.00007226537,0.00013670219,0.00007600397,0.000033043096,0.0000048729867,0.0000074165055,0.00013079453,0.021802297,0.000032834836],"about_ca_topic_score_codex":0.0048896037,"about_ca_topic_score_gemma":0.0017658294,"teacher_disagreement_score":0.052036867,"about_ca_system_score_codex":0.00010532277,"about_ca_system_score_gemma":0.0012466758,"threshold_uncertainty_score":0.73916507},"labels":[],"label_agreement":null},{"id":"W3012324339","doi":"10.1200/jco.2012.30.15_suppl.604","title":"Lapatinib in HER2+ early breast cancer: Quality of life analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Lapatinib; Medicine; Placebo; Quality of life (healthcare); Population; Clinical endpoint; Internal medicine; Breast cancer; Randomized controlled trial; Adverse effect; Oncology; Cancer; Alternative medicine; Trastuzumab","score_opus":0.25999208827237974,"score_gpt":0.5899869266895392,"score_spread":0.3299948384171595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012324339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815846,0.0014027279,0.000012242904,0.007214623,0.0011035608,0.00010496399,0.000017816981,0.0000035211997,0.0019820598],"genre_scores_gemma":[0.99467057,0.0010361696,0.00037764243,0.0020370213,0.0016799741,0.0000045059455,0.0000022084032,0.000007611829,0.000184319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957849,0.0007672109,0.0028229842,0.00010935955,0.00026694697,0.00024860096],"domain_scores_gemma":[0.9953157,0.0015685419,0.0021790143,0.0001318769,0.00030995463,0.00049494376],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004271168,0.000104616585,0.0023349598,0.00023896428,0.000011756415,0.0000016987251,0.0001083172,0.0002926101,0.0012977556],"category_scores_gemma":[0.00083971885,0.00007425558,0.00073384936,0.0004402649,0.00016092959,0.000109504595,0.000029317607,0.0006763997,0.000008189281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069765425,0.0045374273,0.9569815,0.000025827801,0.0021829025,0.000030033072,0.00022125835,0.00001758383,0.00014602208,0.000058882404,0.0016011603,0.027220886],"study_design_scores_gemma":[0.0091430135,0.0028940851,0.97877586,0.00002155661,0.0018303372,0.00002700932,0.00005595755,0.000012216078,0.00002629917,0.000032807708,0.007122343,0.000058513808],"about_ca_topic_score_codex":0.0013678542,"about_ca_topic_score_gemma":0.0009865757,"teacher_disagreement_score":0.027162371,"about_ca_system_score_codex":0.00017349755,"about_ca_system_score_gemma":0.0013388542,"threshold_uncertainty_score":0.9996152},"labels":[],"label_agreement":null},{"id":"W3012425929","doi":"10.1200/jco.2006.24.18_suppl.7163","title":"Previously documented mutations in the epidermal growth factor receptor (EGFR) gene in a non-small cell lung cancer (NSCLC) population treated with gefitinib are not associated with response","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Microdissection; Cancer research; Exon; Population; Adenocarcinoma; Laser capture microdissection; EGFR inhibitors; Oncology; Cancer; Internal medicine; Gene; Biology; Genetics; Gene expression","score_opus":0.04277994712074242,"score_gpt":0.41590917339034617,"score_spread":0.37312922626960376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012425929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905684,0.00020734982,0.00006547544,0.007784156,0.00011813828,0.00091075886,0.000045082437,0.000011481504,0.0002891868],"genre_scores_gemma":[0.99696714,0.000107044274,0.0010100694,0.0011329972,0.00023233455,0.00008845223,0.00008506356,0.000026454505,0.00035046454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963976,0.0010454744,0.001660724,0.0002353579,0.00035252256,0.00030832316],"domain_scores_gemma":[0.99501365,0.0024163902,0.0018187722,0.00014279663,0.00046998516,0.00013842748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015568851,0.00019769787,0.0009792331,0.00024546505,0.00006846646,0.000020402984,0.00011616198,0.00025037935,0.000062088315],"category_scores_gemma":[0.00089732656,0.000108822256,0.00016339737,0.00050407497,0.00008753565,0.00015886933,0.000010716425,0.0006888744,0.0000019684114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011564653,0.0024879992,0.9818886,0.0000228018,0.00028571527,0.0007085815,0.000703841,0.00057377736,0.00023043863,0.000005844968,0.0004359175,0.0010918516],"study_design_scores_gemma":[0.02011524,0.0045852647,0.97297597,0.0004944135,0.0007880812,0.00006742224,0.00029718192,0.00017849845,0.00013651157,0.000012914212,0.0002284566,0.00012005574],"about_ca_topic_score_codex":0.0021458715,"about_ca_topic_score_gemma":0.006673837,"teacher_disagreement_score":0.008912618,"about_ca_system_score_codex":0.0009825233,"about_ca_system_score_gemma":0.001500933,"threshold_uncertainty_score":0.4437643},"labels":[],"label_agreement":null},{"id":"W3012427039","doi":"10.1200/jco.2012.30.15_suppl.3077","title":"Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biopsy; Proteasome inhibitor; Prostate cancer; Cancer; Immunohistochemistry; Cohort; Urology; Internal medicine; Pathology","score_opus":0.03508742714628252,"score_gpt":0.3536339560736916,"score_spread":0.3185465289274091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012427039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989104,0.00019584052,0.00010314012,0.00018316235,0.00021180994,0.00027766038,0.00003204116,0.0000018040022,0.000084085856],"genre_scores_gemma":[0.9940404,0.000028817069,0.0051020593,0.00025613038,0.00046030866,0.0000116633555,0.000081073886,0.000009975461,0.000009514043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977438,0.0005420639,0.0011397216,0.00014836383,0.00022093498,0.00020510073],"domain_scores_gemma":[0.99809945,0.00010247847,0.0011367082,0.000114482675,0.000278163,0.00026871602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025771635,0.000114201066,0.0005022975,0.000040512088,0.000031753832,0.0000047134045,0.00011436221,0.00012967049,0.000013438756],"category_scores_gemma":[0.0012885632,0.00008587102,0.000074388125,0.00006237995,0.00020588408,0.000034349006,0.00007088763,0.00037172483,8.016266e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027019887,0.0023222128,0.97335047,0.00004267647,0.00006736754,0.0000069928356,0.00015799266,0.000058024867,0.009181796,0.00019893567,0.0003791456,0.011532421],"study_design_scores_gemma":[0.005470774,0.009781559,0.9235759,0.000080037156,0.00002707041,0.000015540863,0.0000970853,0.000013104777,0.049615044,0.0003322164,0.010838278,0.00015339299],"about_ca_topic_score_codex":0.00000315586,"about_ca_topic_score_gemma":0.000006549214,"teacher_disagreement_score":0.04977455,"about_ca_system_score_codex":0.000031401596,"about_ca_system_score_gemma":0.000497766,"threshold_uncertainty_score":0.35017186},"labels":[],"label_agreement":null},{"id":"W3012443404","doi":"10.1200/jco.2012.30.15_suppl.7020","title":"Favorable outcomes with chemoradiation and surgery for locally advanced non-small cell lung cancer: The BC Cancer Agency Vancouver experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Retrospective cohort study; Pneumonectomy; Cancer; Surgery; Etoposide; Vinorelbine; Oncology; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.06043489374791306,"score_gpt":0.42563587702538674,"score_spread":0.3652009832774737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012443404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98291016,0.006186593,0.00042240007,0.0070055616,0.0025217028,0.000579853,0.0000051458583,0.000005834239,0.00036278123],"genre_scores_gemma":[0.9839211,0.008984106,0.001827552,0.0033665,0.0010983332,0.00024216964,0.0000012197422,0.00002101347,0.0005379675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981544,0.00008041773,0.0010510746,0.00016826417,0.00022556966,0.0003202737],"domain_scores_gemma":[0.9956268,0.0023754693,0.0011970382,0.00015538283,0.00032126135,0.00032404042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011651346,0.00015872938,0.0011233926,0.00004804988,0.00008171478,0.00000945464,0.00008288367,0.00015949816,0.00009429945],"category_scores_gemma":[0.00029947673,0.00007925044,0.00028524006,0.0000932158,0.00011409045,0.00019013711,0.000019577774,0.000300463,8.916512e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012614357,0.00079150306,0.912531,0.00009640276,0.00032681055,0.000019302879,0.000619002,0.000075279946,0.000014390615,0.0000053925783,0.014985632,0.069273815],"study_design_scores_gemma":[0.009109859,0.002332275,0.9251615,0.0002747666,0.0011273843,0.00001893307,0.0004206,0.00019809902,0.00054228725,0.000018894983,0.060648844,0.00014659106],"about_ca_topic_score_codex":0.00023848414,"about_ca_topic_score_gemma":0.0008662624,"teacher_disagreement_score":0.069127224,"about_ca_system_score_codex":0.00041805496,"about_ca_system_score_gemma":0.0019483746,"threshold_uncertainty_score":0.34563327},"labels":[],"label_agreement":null},{"id":"W3012448436","doi":"10.1200/jco.2006.24.18_suppl.16513","title":"Inhibition of DNA repair in chronic lymphocytic leukemia: Therapeutic implications","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Chlorambucil; Fludarabine; Chronic lymphocytic leukemia; Cancer research; Nitrogen mustard; DNA repair; Cytotoxicity; Leukemia; Medicine; DNA; Biology; Immunology; Chemotherapy; In vitro; Genetics; Internal medicine; Cyclophosphamide","score_opus":0.09953962008648945,"score_gpt":0.45577829265360537,"score_spread":0.35623867256711594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012448436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99023396,0.0016564865,0.00019373054,0.0017783142,0.00028344168,0.00031843415,0.0000040278996,0.000021249018,0.005510383],"genre_scores_gemma":[0.9961758,0.0007279533,0.0009055076,0.0006648642,0.0011380423,0.000009775313,0.000005341685,0.000022344571,0.00035034283],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99503726,0.000419994,0.0034703035,0.00023114913,0.00048575609,0.00035553146],"domain_scores_gemma":[0.9948903,0.0024931629,0.0014795925,0.0003861476,0.000541102,0.00020969931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037130471,0.00014023564,0.0013790093,0.00033215742,0.000027233853,0.0000037242016,0.00017050994,0.0005360782,0.000116796626],"category_scores_gemma":[0.0016004841,0.00010799563,0.00064009556,0.00046340527,0.00044107722,0.00011852623,0.00006530868,0.0008699745,0.000027853956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034281086,0.011790539,0.12923823,0.0030214868,0.0033555687,0.011446695,0.00082639966,0.020822855,0.1941753,0.027861267,0.101676635,0.46150392],"study_design_scores_gemma":[0.19555597,0.034437966,0.6406954,0.0012770654,0.0010926229,0.0064688255,0.00021422432,0.03059791,0.009439366,0.018988486,0.060741786,0.0004903727],"about_ca_topic_score_codex":0.000712507,"about_ca_topic_score_gemma":0.0003988062,"teacher_disagreement_score":0.51145715,"about_ca_system_score_codex":0.08479803,"about_ca_system_score_gemma":0.12873906,"threshold_uncertainty_score":0.91871524},"labels":[],"label_agreement":null},{"id":"W3012526746","doi":"10.1200/jco.2013.31.15_suppl.3633","title":"A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Irinotecan; FOLFIRI; Neutropenia; Internal medicine; Gastroenterology; Sorafenib; Mucositis; Colorectal cancer; Adverse effect; Nausea; Febrile neutropenia; Anemia; Surgery; Toxicity; Cancer","score_opus":0.13369848313710672,"score_gpt":0.4993151273842381,"score_spread":0.36561664424713136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012526746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878205,0.0017030473,0.00005164221,0.0077910046,0.00030384303,0.0018967954,0.000027221713,0.000006537566,0.00039940898],"genre_scores_gemma":[0.993787,0.0041246302,0.0009906043,0.00048874517,0.0003234297,0.0000935687,0.0000029819553,0.000018621113,0.00017042573],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9969997,0.00018831022,0.0020558303,0.00024147615,0.0003006986,0.00021402852],"domain_scores_gemma":[0.9933103,0.0038562291,0.0016187202,0.00012731702,0.0008325806,0.00025486454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012390905,0.00019172794,0.0020255726,0.00008972509,0.00008721782,0.000008458464,0.00009065521,0.00010438303,0.00008871012],"category_scores_gemma":[0.0015787237,0.000102654456,0.00025449804,0.00014182343,0.00025137592,0.00008552688,0.000033908254,0.0003360691,0.0000014317247],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33606645,0.038687855,0.019770743,0.000051471776,0.0061079846,0.00024900676,0.0024201518,0.00004257016,0.00009909067,0.000015561121,0.0018415054,0.5946476],"study_design_scores_gemma":[0.2498319,0.49031526,0.23240359,0.00011988818,0.0016932169,0.00014781348,0.0013595709,0.00014011357,0.00012892936,0.00014209628,0.023576958,0.00014066917],"about_ca_topic_score_codex":0.00034030742,"about_ca_topic_score_gemma":0.0009398357,"teacher_disagreement_score":0.5945069,"about_ca_system_score_codex":0.00010860094,"about_ca_system_score_gemma":0.0008156913,"threshold_uncertainty_score":0.41861272},"labels":[],"label_agreement":null},{"id":"W3012536761","doi":"10.1200/jco.2013.31.15_suppl.11057","title":"Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Proportional hazards model; Hazard ratio; Cancer research; Epigenetics; Gene; Biology; Genetics; Confidence interval","score_opus":0.027867679423001276,"score_gpt":0.39029128653258105,"score_spread":0.36242360710957977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012536761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995785,0.00023385833,0.00023903293,0.00018056839,0.0013159802,0.0002883242,0.000017117554,0.0000018191288,0.0019383229],"genre_scores_gemma":[0.99799794,0.00031917912,0.00039114952,0.00029390235,0.00035679367,0.000008426846,0.0000053977637,0.000017892487,0.000609327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971956,0.000439761,0.001670855,0.00021020435,0.00027437697,0.00020922694],"domain_scores_gemma":[0.9967139,0.0005067871,0.0018059955,0.0002556421,0.0005663299,0.00015136386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016934494,0.0001727213,0.0011492163,0.000047812304,0.000021225364,0.0000053175154,0.00028819605,0.00044098662,0.00012808466],"category_scores_gemma":[0.00068423076,0.00011450391,0.00049439055,0.000047415517,0.000108739274,0.0000069779653,0.00008730461,0.00038572328,0.0000032063676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004339775,0.0030744905,0.7822635,0.00048005796,0.0010867441,0.000015698683,0.00014205593,0.0009038763,0.06982275,0.000009444053,0.0053750533,0.13248654],"study_design_scores_gemma":[0.033588238,0.060758196,0.74580157,0.00039984658,0.0007131178,0.0000061118967,0.00006187205,0.0018692933,0.15009692,0.000039502487,0.006112432,0.000552929],"about_ca_topic_score_codex":0.00016675904,"about_ca_topic_score_gemma":0.00003560133,"teacher_disagreement_score":0.13193361,"about_ca_system_score_codex":0.000034366712,"about_ca_system_score_gemma":0.0006499661,"threshold_uncertainty_score":0.46693343},"labels":[],"label_agreement":null},{"id":"W3012557015","doi":"10.1200/jco.2012.30.15_suppl.501","title":"Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Exemestane; Anastrozole; Osteoporosis; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Aromatase inhibitor; Proportional hazards model; Cancer; Aromatase; Randomized controlled trial","score_opus":0.04281630861576504,"score_gpt":0.4655207316235977,"score_spread":0.4227044230078327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012557015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927178,0.0005851303,0.0000047492254,0.0032038249,0.0021082482,0.0010731483,0.000030811978,0.0000050397707,0.00027123728],"genre_scores_gemma":[0.9960463,0.0005442492,0.0008449887,0.0019268803,0.00039389596,0.000031871823,0.000006679806,0.000021750302,0.00018338798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942616,0.0014526373,0.0031691748,0.00016529835,0.0004516891,0.00049954985],"domain_scores_gemma":[0.9927026,0.0039002246,0.0017832159,0.00016671729,0.0003742082,0.0010730267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005718837,0.00020846108,0.0035682605,0.00022410689,0.000021044101,0.0000025551003,0.00010815641,0.0003217499,0.0003444877],"category_scores_gemma":[0.0035714526,0.00011357229,0.00037121077,0.00024258318,0.00013620338,0.0001239544,0.00004810016,0.00064156303,0.000025798243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37845862,0.0026466085,0.5105987,0.00007699406,0.00021536919,0.0001215401,0.0000929945,0.0000016461597,0.00002614358,0.00000193908,0.00065547647,0.107103944],"study_design_scores_gemma":[0.28118357,0.035123855,0.6808209,0.00028757405,0.0008214738,0.00017635051,0.000016645825,0.000007254617,0.000092284485,0.000003795263,0.0013935117,0.000072816474],"about_ca_topic_score_codex":0.0004410116,"about_ca_topic_score_gemma":0.00015876585,"teacher_disagreement_score":0.17022216,"about_ca_system_score_codex":0.00034175898,"about_ca_system_score_gemma":0.0011862352,"threshold_uncertainty_score":0.46313438},"labels":[],"label_agreement":null},{"id":"W3013286379","doi":"10.1200/jco.20.00280","title":"Reply to P. Ghadjar et al","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine","score_opus":0.3265010091462349,"score_gpt":0.4607899814637804,"score_spread":0.1342889723175455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013286379","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067343595,0.0005808503,0.00006466015,0.9835678,0.0024734088,0.00039015478,0.000011843322,0.000021656433,0.00615528],"genre_scores_gemma":[0.005168319,0.0006680884,0.0067362087,0.97332585,0.012235005,0.000008416212,0.000046716592,0.000062075866,0.0017493268],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437183,0.0009983246,0.0031773073,0.0003945624,0.00071389973,0.00034407573],"domain_scores_gemma":[0.993674,0.00280329,0.0019650124,0.00034360602,0.00048681616,0.000727324],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023975242,0.0003030315,0.0032110454,0.00020508828,0.000028329243,0.000017711413,0.0002903406,0.0011035565,0.0005106],"category_scores_gemma":[0.005252096,0.00021219882,0.0017122,0.00018022036,0.00010845935,0.000058440233,0.00010407885,0.0065929308,0.0004869937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013395303,0.000323507,0.033463124,0.00004146648,0.0007957117,0.06210546,0.000048659836,8.0281794e-8,0.0000090657095,0.0000027187498,0.8792728,0.022597883],"study_design_scores_gemma":[0.0033854656,0.02349358,0.0030856882,0.00017732717,0.0011832265,0.0010882322,0.000008309882,0.000010102387,0.000024036483,0.00008367955,0.9672921,0.00016825601],"about_ca_topic_score_codex":0.00002188089,"about_ca_topic_score_gemma":0.0000020492332,"teacher_disagreement_score":0.088019304,"about_ca_system_score_codex":0.00017689624,"about_ca_system_score_gemma":0.0030073023,"threshold_uncertainty_score":0.9956989},"labels":[],"label_agreement":null},{"id":"W3014191597","doi":"10.1200/jco.2009.27.15_suppl.e17551","title":"A review of physician preparedness in response to a systemic crisis: The case of Eastern Regional Health Authority, Newfoundland, Canada, estrogen receptor (ER) breast cancer (BC) errors","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Preparedness; Health care; Public health; Family medicine; Nursing; Political science; Law","score_opus":0.12859896540351815,"score_gpt":0.544579567980784,"score_spread":0.4159806025772659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014191597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016040017,0.9636724,0.000021681237,0.031072777,0.001962853,0.001477431,0.00014936634,0.000003945497,0.00003556272],"genre_scores_gemma":[0.0003329648,0.98154277,0.00069613516,0.01546561,0.001765271,0.000049491988,0.0000075478224,0.00003710476,0.00010312599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857824,0.0060060937,0.006916122,0.00040304294,0.00048094554,0.00041142726],"domain_scores_gemma":[0.9840041,0.0046375142,0.009514847,0.00058173115,0.00072988274,0.00053193513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010355343,0.00040923385,0.009247109,0.00024864473,0.000059569487,0.000002730311,0.00060849154,0.0006793013,0.00005088818],"category_scores_gemma":[0.0018092646,0.00023755683,0.0012604394,0.0006441851,0.00030880436,0.00006322222,0.00006564773,0.0020423029,0.000002064917],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00753885,0.00089003023,0.0003991468,0.028554246,0.00085717614,0.0017157205,0.00024874494,0.000009434998,2.0466823e-7,0.000024134019,0.04696328,0.91279906],"study_design_scores_gemma":[0.0018569437,0.005003491,0.00026348088,0.15813968,0.0011244451,0.019336773,0.0003251074,0.0000026079738,1.523129e-8,0.000015111815,0.81378025,0.00015208991],"about_ca_topic_score_codex":0.05447857,"about_ca_topic_score_gemma":0.15731937,"teacher_disagreement_score":0.91264695,"about_ca_system_score_codex":0.0031642474,"about_ca_system_score_gemma":0.05078325,"threshold_uncertainty_score":0.96872866},"labels":[],"label_agreement":null},{"id":"W3015308927","doi":"10.1200/jco.19.01866","title":"Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University; Ontario Clinical Oncology Group","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; National Institutes of Health; ECOG-ACRIN Cancer Research Group; Genomic Health; American College of Radiology Imaging Network; Breast Cancer Research Foundation; Susan G. Komen for the Cure","keywords":"Medicine; Conventional PCI; Breast cancer; Internal medicine; Clinical endpoint; Cancer; Randomized controlled trial; Oncology; Myocardial infarction","score_opus":0.08399332970179517,"score_gpt":0.40093475787609567,"score_spread":0.3169414281743005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015308927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9398537,0.00046835837,0.000057822108,0.0559549,0.0011650752,0.0016304847,0.00020180875,0.0000540392,0.0006138058],"genre_scores_gemma":[0.98185337,0.002960502,0.00025561918,0.012324258,0.002250958,0.00016209792,0.0000188751,0.00006592956,0.00010841803],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9937904,0.0005433481,0.0032948242,0.0006479848,0.0010223703,0.00070108764],"domain_scores_gemma":[0.990051,0.003356632,0.0030526936,0.00024152097,0.0019504093,0.0013477966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000986052,0.00047052378,0.0028340332,0.00016547512,0.0001038127,0.00002708182,0.00018599049,0.0001987888,0.00066918944],"category_scores_gemma":[0.0028545007,0.00030769367,0.00044445117,0.00053685915,0.000427168,0.00022571259,0.0001160377,0.0013711819,0.000025817757],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7299293,0.002569747,0.07216466,0.000008140397,0.008821877,0.0031813923,0.0032619806,0.000019150457,0.0005887397,2.3636944e-7,0.0066928733,0.17276186],"study_design_scores_gemma":[0.24436645,0.09738186,0.6452224,0.0003106226,0.00066374516,0.00016350299,0.0015947423,0.000013355006,0.0010725589,0.000008415523,0.008912269,0.00029003274],"about_ca_topic_score_codex":0.00054610794,"about_ca_topic_score_gemma":0.00008402053,"teacher_disagreement_score":0.5730578,"about_ca_system_score_codex":0.0005897728,"about_ca_system_score_gemma":0.0016332761,"threshold_uncertainty_score":0.99993753},"labels":[],"label_agreement":null},{"id":"W3015698333","doi":"10.1200/jco.19.03024","title":"Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Discontinuation; Asparaginase; Internal medicine; Hazard ratio; Acute lymphocytic leukemia; Lymphoblastic Leukemia; Chemotherapy; Leukemia; Surgery; Pediatrics; Oncology; Confidence interval","score_opus":0.08360919335721549,"score_gpt":0.4559111065686997,"score_spread":0.3723019132114842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015698333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778377,0.00012770407,0.0006391623,0.01938331,0.00053511665,0.00056678645,0.000034955716,0.000013046718,0.00086225703],"genre_scores_gemma":[0.99235356,0.00022232671,0.0011571277,0.0041359956,0.0020152424,0.000009959409,0.000037638674,0.000037207687,0.000030945346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921239,0.001145413,0.0048822816,0.00044850752,0.0009379163,0.00046200817],"domain_scores_gemma":[0.9847177,0.009988556,0.0036896681,0.00049799395,0.00040063533,0.00070543034],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039100135,0.0002947643,0.0028030057,0.00018643789,0.000042037296,0.000014210597,0.0005821779,0.00071688514,0.00018317423],"category_scores_gemma":[0.02650578,0.00016452615,0.0011153072,0.00044943352,0.00045986212,0.0001596604,0.00019577677,0.002459797,0.000046341098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01744814,0.0040197293,0.90363884,0.000010203681,0.002168897,0.011208271,0.00068735244,0.0003717032,0.00039830766,0.000056782035,0.009832243,0.050159514],"study_design_scores_gemma":[0.02383403,0.035351865,0.93530405,0.00011106621,0.00074454944,0.0024205754,0.000089115834,0.00096733076,0.0000336993,0.00016495989,0.00085176865,0.00012701919],"about_ca_topic_score_codex":0.00053317886,"about_ca_topic_score_gemma":0.00008553405,"teacher_disagreement_score":0.050032496,"about_ca_system_score_codex":0.0032702265,"about_ca_system_score_gemma":0.011445585,"threshold_uncertainty_score":0.9998416},"labels":[],"label_agreement":null},{"id":"W3016358793","doi":"10.1200/jco.19.03285","title":"Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; William Guy Forbeck Research Foundation; Bear Necessities Pediatric Cancer Foundation; Super Jake Foundation; Children’s Oncology Group; American Society of Clinical Oncology; St. Baldrick's Foundation; Rally Foundation; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Medicine; Karyorrhexis; Neuroblastoma; Mitotic index; Oncology; Pathology; Internal medicine; Mitosis","score_opus":0.1623469264939458,"score_gpt":0.4551598175571616,"score_spread":0.29281289106321584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016358793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057424,0.00029805093,0.000014224625,0.007752734,0.0003156856,0.0007844146,0.000006743633,0.000022868062,0.00023104544],"genre_scores_gemma":[0.9945727,0.00050597044,0.0003400098,0.0037998268,0.00068245345,0.000024874811,0.0000040249524,0.00003960089,0.00003056325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546236,0.0010377723,0.001931858,0.00045359577,0.0006429922,0.0004714362],"domain_scores_gemma":[0.99302024,0.0042261253,0.0011199964,0.00019407159,0.00024587233,0.0011936702],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010313527,0.0002579006,0.0016052488,0.00033597584,0.000047537174,0.000034376386,0.00025540497,0.00027449732,0.000028204708],"category_scores_gemma":[0.018492036,0.00019026628,0.00025520293,0.00044228,0.00029910414,0.00025898774,0.00015849067,0.0021803195,0.000021277918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054716645,0.004675172,0.9022095,0.00013417075,0.0001961365,0.06881835,0.00018921886,0.000010351897,0.00019238956,0.000010630526,0.0016310188,0.016461348],"study_design_scores_gemma":[0.013846494,0.039163318,0.9412662,0.00016424994,0.00021118109,0.0020130773,0.00018722194,0.00026554608,0.00009004304,0.00016185982,0.0024919203,0.00013888728],"about_ca_topic_score_codex":0.00006833731,"about_ca_topic_score_gemma":0.00035158827,"teacher_disagreement_score":0.06680527,"about_ca_system_score_codex":0.000091830436,"about_ca_system_score_gemma":0.0015825634,"threshold_uncertainty_score":0.9897756},"labels":[],"label_agreement":null},{"id":"W3016712946","doi":"10.1200/jco.20.00204","title":"Zero, Some Chemotherapy Game in Early-Stage Germ Cell Tumors","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Chemotherapy; Germ cell tumors; Oncology; Zero (linguistics); Germ cell; Cancer research; Internal medicine; Genetics; Biology","score_opus":0.08904854548773826,"score_gpt":0.42815575927434707,"score_spread":0.3391072137866088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016712946","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28525382,0.0022618952,0.000020164884,0.7095503,0.0014056187,0.000422978,0.000025459558,0.000020635285,0.0010391257],"genre_scores_gemma":[0.20329301,0.0013114767,0.0008449367,0.78339267,0.008892641,0.0000060168054,0.000029279165,0.000082600454,0.002147401],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951232,0.0004709121,0.0030184533,0.0003684469,0.0006171184,0.00040184762],"domain_scores_gemma":[0.99397486,0.0016244889,0.003379487,0.00030677032,0.00017751163,0.0005368997],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00067486,0.00034282837,0.0031931992,0.00020197986,0.000015690479,0.000016115811,0.00027938548,0.0012823757,0.0003010537],"category_scores_gemma":[0.0015056018,0.00024442098,0.0014144689,0.00013530195,0.00018608553,0.00008307798,0.000054817556,0.005186644,0.00013983046],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028258224,0.0032009445,0.13807537,0.00036918474,0.00091134553,0.19811979,0.00009060494,0.00000467138,0.000013489454,0.000007636862,0.63684624,0.019534932],"study_design_scores_gemma":[0.014359712,0.011005108,0.20886183,0.00030050636,0.00073048205,0.0002834892,0.000007914042,0.00001704728,0.000011785801,0.0005944272,0.7636318,0.00019589924],"about_ca_topic_score_codex":0.000040887116,"about_ca_topic_score_gemma":0.0000023495265,"teacher_disagreement_score":0.1978363,"about_ca_system_score_codex":0.0002734419,"about_ca_system_score_gemma":0.0027799727,"threshold_uncertainty_score":0.99710846},"labels":[],"label_agreement":null},{"id":"W3017757900","doi":"10.1200/jco.19.02555","title":"Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hamilton Health Sciences; Centre hospitalier universitaire de Québec; Université de Montréal; McMaster Children's Hospital","funders":"","keywords":"Mucositis; Medicine; Internal medicine; Toxicity; Prospective cohort study; Cancer; Disease","score_opus":0.05624380288534401,"score_gpt":0.3942593296960496,"score_spread":0.33801552681070557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017757900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929981,0.00044583698,0.00007895998,0.0050488287,0.00018526483,0.00091211137,0.0000075109742,0.0000051191137,0.0003182597],"genre_scores_gemma":[0.99778605,0.00068228843,0.0006146483,0.00056885683,0.00030897578,0.000008446075,0.0000035299886,0.000014615781,0.000012608911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569815,0.00077014946,0.0026071707,0.0002608364,0.00046773942,0.0001959744],"domain_scores_gemma":[0.9901725,0.0070295963,0.0019824158,0.00022389696,0.00029469555,0.00029691035],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019349313,0.00015375747,0.0019776423,0.00007317285,0.000020726298,0.0000028422326,0.00017577299,0.00045114316,0.000024476172],"category_scores_gemma":[0.018357694,0.0000863131,0.0003210227,0.0002869237,0.0004939174,0.00007251628,0.00011625956,0.0011659409,0.0000019570084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010561357,0.0029975704,0.88656616,0.0001075028,0.0031185295,0.010075625,0.0017518596,0.000022109003,0.012592085,0.000010851755,0.0005817805,0.07161459],"study_design_scores_gemma":[0.017872663,0.018918917,0.95782995,0.000274549,0.0005738463,0.00067656476,0.0001426656,0.00035438768,0.0028744743,0.000285327,0.00013677056,0.000059884194],"about_ca_topic_score_codex":0.00049774,"about_ca_topic_score_gemma":0.00009172953,"teacher_disagreement_score":0.071554706,"about_ca_system_score_codex":0.00055799645,"about_ca_system_score_gemma":0.0044539785,"threshold_uncertainty_score":0.9899111},"labels":[],"label_agreement":null},{"id":"W3020066230","doi":"10.1200/jco.19.02677","title":"Consistent Physical Activity and Future Neurocognitive Problems in Adult Survivors of Childhood Cancers: A Report From the Childhood Cancer Survivor Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University of Alberta; York University","funders":"American Lebanese Syrian Associated Charities; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Ontario Ministry of Health and Long-Term Care; Princess Margaret Cancer Foundation","keywords":"Neurocognitive; Medicine; Childhood cancer; Cancer; Pediatrics; Internal medicine; Cognition; Psychiatry","score_opus":0.09776574721945264,"score_gpt":0.43100669296004523,"score_spread":0.3332409457405926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020066230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291765,0.0007065004,0.000012294388,0.06727361,0.0011780075,0.0013149547,0.00007515219,0.000015638932,0.00024731862],"genre_scores_gemma":[0.9856602,0.0012635156,0.00010540067,0.0072477963,0.0056409403,0.000032684995,0.000004403481,0.000038727154,0.000006315786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928675,0.0022185,0.0029440892,0.00062510074,0.0009994988,0.00034525464],"domain_scores_gemma":[0.98934376,0.005068241,0.0037699959,0.00037988997,0.00084764085,0.0005904411],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031368057,0.0003461736,0.0031721788,0.00007691785,0.00006307079,0.000017270613,0.00032669475,0.0003099741,0.00004326694],"category_scores_gemma":[0.0066209123,0.00022728264,0.0006147886,0.0004514554,0.00045135853,0.00018249846,0.00019282558,0.0025438182,0.0000019139559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003915969,0.011566039,0.8779025,0.0000927451,0.0018597398,0.00090082677,0.029475644,0.0000357706,0.00007385676,0.000009834431,0.000686195,0.07348089],"study_design_scores_gemma":[0.01235655,0.009890234,0.9649446,0.00031239612,0.0008768046,0.00016878237,0.009069001,0.00005984164,0.000051234285,0.000076421435,0.0019958357,0.00019827657],"about_ca_topic_score_codex":0.011781534,"about_ca_topic_score_gemma":0.026078114,"teacher_disagreement_score":0.08704213,"about_ca_system_score_codex":0.00015622878,"about_ca_system_score_gemma":0.0037657872,"threshold_uncertainty_score":0.99975735},"labels":[],"label_agreement":null},{"id":"W3020479598","doi":"10.1200/jco.19.02856","title":"Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children’s Oncology Group","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Takeda Pharmaceuticals International; Bayer HealthCare","keywords":"Dexrazoxane; Medicine; Anthracycline; Hazard ratio; Internal medicine; Ejection fraction; Myeloid leukemia; Daunorubicin; Chemotherapy; Oncology; Cancer; Heart failure; Breast cancer; Confidence interval","score_opus":0.02539017283621529,"score_gpt":0.3503668711135531,"score_spread":0.32497669827733777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020479598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949274,0.000100378515,0.00006499235,0.0039413855,0.00027898722,0.00060153985,0.000005967737,0.000006180579,0.000073135634],"genre_scores_gemma":[0.9972111,0.00020865694,0.00011699309,0.0019783527,0.00043527427,0.0000057462007,0.000024706454,0.0000124397375,0.000006750255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745303,0.0006245705,0.0012749011,0.00020918284,0.0003066548,0.00013164603],"domain_scores_gemma":[0.99607724,0.0021643068,0.0013191536,0.0001574087,0.00010146337,0.00018040983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001149581,0.00015593032,0.0016193029,0.000059110207,0.00002729528,0.0000040097334,0.0000674705,0.00034817363,0.000012578868],"category_scores_gemma":[0.0009951089,0.00007775834,0.0003248745,0.000093499,0.00011566407,0.000053456602,0.000018589277,0.0006291908,0.0000017668943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01737459,0.00088884786,0.8992128,0.000010695772,0.0016289986,0.0008994903,0.00013278847,0.000019280844,0.00048783387,0.0000052484647,0.00009884259,0.079240605],"study_design_scores_gemma":[0.02399742,0.08704174,0.8848748,0.00006689213,0.0012463413,0.00040428547,0.000020828771,0.000009949853,0.0012498632,0.00001656701,0.0010137457,0.00005757251],"about_ca_topic_score_codex":0.00007421436,"about_ca_topic_score_gemma":0.000041105905,"teacher_disagreement_score":0.0861529,"about_ca_system_score_codex":0.00051156245,"about_ca_system_score_gemma":0.0004908976,"threshold_uncertainty_score":0.31708932},"labels":[],"label_agreement":null},{"id":"W3020580393","doi":"10.1200/jco.20.00275","title":"Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Guideline; Observational study; MEDLINE; Evidence-based medicine; Systematic review; Head and neck squamous-cell carcinoma; Head and neck cancer; Randomized controlled trial; Head and neck; Radiation therapy; Intensive care medicine; General surgery; Medical physics; Surgery; Internal medicine; Alternative medicine; Pathology","score_opus":0.14282563864026895,"score_gpt":0.4494900670558754,"score_spread":0.3066644284156065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020580393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475298,0.0075950637,0.0000110373885,0.040602468,0.00011790161,0.00017225488,0.0000027143942,0.0000011541227,0.0039675925],"genre_scores_gemma":[0.9816828,0.010329674,0.0018021874,0.0059144953,0.0002414172,0.0000028457287,5.847662e-7,0.0000052295663,0.00002079752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764097,0.00015935925,0.0017711142,0.00011244609,0.00020887762,0.00010722069],"domain_scores_gemma":[0.9977019,0.001268858,0.00067290507,0.00008821763,0.0001374547,0.00013068649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013939633,0.00007878216,0.00116992,0.00004263519,0.0000134383945,0.000002020962,0.00009045078,0.00010025481,0.000015623644],"category_scores_gemma":[0.0005631526,0.000046198693,0.00012751781,0.00011007872,0.00017859247,0.000033854325,0.000090084184,0.00035595536,4.375382e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026035004,0.0015105073,0.7319483,0.0008214671,0.0001185864,0.00068728224,0.0009063055,0.0000038624707,0.00006064904,0.000069570946,0.020589707,0.24068026],"study_design_scores_gemma":[0.008626939,0.015092101,0.8880224,0.00014469067,0.00025525512,0.000034685097,0.00049269537,0.00002729344,0.00005856886,0.000045164026,0.08715815,0.000042009986],"about_ca_topic_score_codex":0.000019378822,"about_ca_topic_score_gemma":0.00002235893,"teacher_disagreement_score":0.24063826,"about_ca_system_score_codex":0.000022778746,"about_ca_system_score_gemma":0.00020382077,"threshold_uncertainty_score":0.1883928},"labels":[],"label_agreement":null},{"id":"W3021552082","doi":"10.1200/jco.2017.35.4_suppl.690","title":"Does the addition of biologic agents to chemotherapy in patients with unresectable colorectal cancer metastases result in a higher proportion of patients undergoing resection? A systematic review and meta-analysis.","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Meta-analysis; Oncology; Confidence interval; Relative risk; Randomized controlled trial; Chemotherapy; Subgroup analysis; Cancer; Surgery","score_opus":0.29346933950495463,"score_gpt":0.5110131846635466,"score_spread":0.217543845158592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021552082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023212008,0.9710776,6.6221804e-7,0.0007950019,0.00019897307,0.0044330033,0.0002160091,0.0000020171983,0.00006469499],"genre_scores_gemma":[0.05073021,0.9483876,0.00007179099,0.00024101956,0.000040728108,0.00037059866,0.000036367448,0.000014704668,0.000106985026],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9934773,0.0014462546,0.0040867203,0.0002990355,0.000514785,0.00017594847],"domain_scores_gemma":[0.9891657,0.0016455331,0.008001349,0.00027459222,0.0008216658,0.00009113546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032360048,0.00028653978,0.011714434,0.00039352797,0.000044654727,0.000008291747,0.0001960455,0.00023259077,0.0001478788],"category_scores_gemma":[0.0030659717,0.00009808201,0.0012832494,0.00059612415,0.000180879,0.00008179817,0.00007081469,0.00047425542,3.4129226e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012771491,0.0078052282,0.16176794,0.41157186,0.35671166,0.00007578495,0.00018792223,0.000011644332,7.260422e-8,0.000010821513,0.000697271,0.04838831],"study_design_scores_gemma":[0.006276841,0.0218443,0.3003129,0.04884368,0.60980016,0.0000043380005,0.00002651361,5.4974e-7,6.096626e-7,0.000017463872,0.012680229,0.00019240697],"about_ca_topic_score_codex":0.00016634053,"about_ca_topic_score_gemma":0.0036929483,"teacher_disagreement_score":0.36272818,"about_ca_system_score_codex":0.00036441928,"about_ca_system_score_gemma":0.0007641721,"threshold_uncertainty_score":0.8007753},"labels":[],"label_agreement":null},{"id":"W3021558362","doi":"10.1200/jco.2007.25.18_suppl.10577","title":"Chromosomal alterations in oligodendroglial tumors over multiple surgeries: Is progression associated with change in 1p/19q status?","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Loss of heterozygosity; Medicine; Pathology; Oligodendroglial Tumor; Tumor progression; Oligodendroglioma; Internal medicine; Oncology; Cancer research; Biology; Gene; Cancer; Glioblastoma; Allele; Genetics","score_opus":0.11442116398850753,"score_gpt":0.4675434633871835,"score_spread":0.35312229939867595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021558362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960601,0.0002640978,0.000005139092,0.0025595762,0.00042185767,0.00038892738,0.000010634717,0.0000075573744,0.0002821437],"genre_scores_gemma":[0.99750024,0.0001846455,0.0005077849,0.0012019002,0.00053747563,0.000021046653,0.000013464129,0.000017229388,0.00001618641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677545,0.00024524482,0.0019506586,0.00019579247,0.00041043106,0.0004224443],"domain_scores_gemma":[0.9957725,0.0023737228,0.0011483073,0.0001202582,0.00022648026,0.00035875026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023700262,0.00015212542,0.0011938785,0.0003100147,0.000032040924,0.0000105411955,0.0000643656,0.00032037887,0.0001613063],"category_scores_gemma":[0.0024793623,0.000099759636,0.00021459891,0.0003475698,0.00012515965,0.00017777769,0.00002884203,0.00070288306,0.0000047621597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029593366,0.0063928515,0.9623328,0.0000075610333,0.00013155116,0.006466209,0.0006546562,0.000005427579,0.000092555194,0.000015425858,0.00032579413,0.020615853],"study_design_scores_gemma":[0.01723118,0.008013978,0.9703338,0.00060279417,0.00009056429,0.000108745284,0.00013410041,0.00019455835,0.00054467405,0.000017548491,0.002635918,0.00009210633],"about_ca_topic_score_codex":0.00018781827,"about_ca_topic_score_gemma":0.0056065703,"teacher_disagreement_score":0.020523747,"about_ca_system_score_codex":0.0004634768,"about_ca_system_score_gemma":0.0007645339,"threshold_uncertainty_score":0.406808},"labels":[],"label_agreement":null},{"id":"W3021719484","doi":"10.1200/jco.19.02727","title":"PD-1 Blockade in Anaplastic Thyroid Carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Thyroid carcinoma; Response Evaluation Criteria in Solid Tumors; Malignancy; Thyroid; Population; Cohort; Carcinoma; Gastroenterology; Phases of clinical research; Clinical trial","score_opus":0.14928382160538042,"score_gpt":0.4498904031782846,"score_spread":0.3006065815729042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021719484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93708503,0.0020511507,0.000025309457,0.05759778,0.0005879689,0.00012319059,0.0000021487347,0.0000061121705,0.0025213156],"genre_scores_gemma":[0.9886434,0.0008969975,0.0009237662,0.0077957413,0.0016781009,0.0000036186557,9.4853044e-7,0.000011896155,0.00004551255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997482,0.00018543343,0.0017236952,0.00016870584,0.00024683162,0.00019330888],"domain_scores_gemma":[0.99711335,0.0013543287,0.0007396074,0.00010553995,0.0001312899,0.0005558653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069957937,0.00010988786,0.0012764453,0.000075041426,0.000013420821,0.0000046026003,0.000112511545,0.00021471918,0.00017810307],"category_scores_gemma":[0.0022977428,0.0000757161,0.00037807817,0.00016626755,0.000082979815,0.000049776554,0.000035992103,0.00079806335,0.000047140256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077762203,0.0027291407,0.901164,0.000037451617,0.00030404696,0.0074390937,0.00026972193,0.00007303051,0.00028560564,0.00011630401,0.02167351,0.05813186],"study_design_scores_gemma":[0.015865594,0.037447076,0.867719,0.000060467934,0.00031456683,0.0002521283,0.000113079754,0.00015488683,0.00021798494,0.00009566468,0.07768398,0.00007559551],"about_ca_topic_score_codex":0.000018040218,"about_ca_topic_score_gemma":0.000052309915,"teacher_disagreement_score":0.058056265,"about_ca_system_score_codex":0.00016876128,"about_ca_system_score_gemma":0.0012046142,"threshold_uncertainty_score":0.34672323},"labels":[],"label_agreement":null},{"id":"W3022839611","doi":"10.1200/jco.2014.32.3_suppl.315","title":"Patterns of care and treatment outcomes in older patients with biliary tract cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biliary tract cancer; Internal medicine; Chemotherapy; Retrospective cohort study; Cancer; Stage (stratigraphy); Population; Surgery; Gemcitabine","score_opus":0.056629770823999025,"score_gpt":0.41765439847065516,"score_spread":0.36102462764665616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022839611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964626,0.0008520658,0.0000047503736,0.0018897791,0.00028725437,0.00014864583,0.000008575027,0.0000017548382,0.00034461488],"genre_scores_gemma":[0.9981242,0.00093930884,0.00019836762,0.0004957053,0.00019312027,0.0000044641156,0.000001520377,0.00000747528,0.00003584159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986101,0.00011108093,0.000891132,0.00011261382,0.0001649001,0.00011019452],"domain_scores_gemma":[0.9982548,0.000739221,0.0005847581,0.00009313345,0.00020855872,0.00011958053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027316902,0.000097259,0.0012354412,0.000073851654,0.000011584543,0.0000017142265,0.00004079874,0.00010620227,0.000021007296],"category_scores_gemma":[0.00024346948,0.00005153917,0.00016855854,0.000037985774,0.00006440647,0.00003918267,0.00001642492,0.00022143668,2.936783e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010082137,0.0011149808,0.8301681,0.000039451472,0.0001904406,0.000041071235,0.0006229968,0.0000013242843,0.0000010832175,0.000001959193,0.000058638532,0.16675168],"study_design_scores_gemma":[0.014898435,0.02359164,0.95802414,0.0001492917,0.0002978418,0.000010587742,0.0003260801,0.0000020276136,0.0000116179535,0.0000046321547,0.0026363982,0.00004733134],"about_ca_topic_score_codex":0.0001786797,"about_ca_topic_score_gemma":0.0011355652,"teacher_disagreement_score":0.16670436,"about_ca_system_score_codex":0.00011770318,"about_ca_system_score_gemma":0.00029096875,"threshold_uncertainty_score":0.21017063},"labels":[],"label_agreement":null},{"id":"W3022930418","doi":"10.1200/jco.19.00396","title":"Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Children's Hospital; University of British Columbia","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; CRFS; Hazard ratio; Internal medicine; Gastroenterology; Hematopoietic stem cell transplantation; Graft-versus-host disease; Oncology; Transplantation; Immunology; Confidence interval; Conditional random field","score_opus":0.10141071206880234,"score_gpt":0.4459516127237355,"score_spread":0.34454090065493315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022930418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95401746,0.00015112772,0.0011608353,0.041849475,0.00059062074,0.00015142394,0.0000053029853,0.00000894244,0.002064829],"genre_scores_gemma":[0.9723981,0.00048312626,0.0074093016,0.018881641,0.00073299545,0.0000023514729,0.0000014768543,0.000012721202,0.00007827266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975152,0.000255069,0.0016532465,0.00015736128,0.00028002492,0.00013907558],"domain_scores_gemma":[0.99641687,0.0019256228,0.0007571181,0.0000791474,0.0003213141,0.00049990683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007423556,0.000115579525,0.0012090428,0.00005136485,0.0000168727,0.000008087762,0.00008374356,0.00020424587,0.00014039513],"category_scores_gemma":[0.0012375794,0.00007722573,0.00028047714,0.00006048877,0.00014165556,0.00008531805,0.000024353014,0.0006469634,0.000041285595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006934828,0.0004795075,0.9669655,0.00015104194,0.00053747714,0.0027660925,0.0012836383,0.000004380503,0.00041662197,0.00014335812,0.00084949925,0.019468045],"study_design_scores_gemma":[0.011892609,0.0062600086,0.9702397,0.00017482595,0.0006241419,0.0007652031,0.00016610567,0.00027155402,0.00042075146,0.00022370122,0.008852973,0.00010842927],"about_ca_topic_score_codex":0.000008659963,"about_ca_topic_score_gemma":0.0000075257253,"teacher_disagreement_score":0.022967832,"about_ca_system_score_codex":0.000033081593,"about_ca_system_score_gemma":0.00025733822,"threshold_uncertainty_score":0.3149174},"labels":[],"label_agreement":null},{"id":"W3023069627","doi":"10.1200/jco.2015.33.3_suppl.646","title":"Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of <i>KRAS</i> wild-type (wt) metastatic colorectal cancer (mCRC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"KRAS; Panitumumab; Colorectal cancer; Medicine; Cancer research; Cancer; Mutation; Point mutation; Primary tumor; Oncology; Internal medicine; Gene; Biology; Genetics; Metastasis","score_opus":0.20350739047964492,"score_gpt":0.500983627970606,"score_spread":0.2974762374909611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023069627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915161,0.0038739431,0.000004065196,0.0010138884,0.0010082361,0.0005574171,0.000012777919,0.0000050237722,0.0020085122],"genre_scores_gemma":[0.9973672,0.001145296,0.0008015396,0.00022034632,0.00023071286,0.000018978508,0.0000013247854,0.000019909337,0.00019468735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99522,0.0006918575,0.003051679,0.00024525597,0.00052363175,0.00026758327],"domain_scores_gemma":[0.99491376,0.0012999986,0.0024940048,0.0001687413,0.00084506575,0.00027840427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036791447,0.00020565928,0.002721391,0.00021638435,0.000050669685,0.0000034975142,0.00019004488,0.00013863757,0.00006399807],"category_scores_gemma":[0.0026750066,0.00014686816,0.00029514564,0.00042067136,0.0002680621,0.00009561339,0.00016126923,0.00061241514,0.0000011366972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21537861,0.046558425,0.59976435,0.00024051034,0.006787233,0.0024683124,0.010508603,0.00019064298,0.0031166666,0.000024843786,0.0088743055,0.1060875],"study_design_scores_gemma":[0.120267704,0.3080038,0.5324918,0.00064255606,0.0036689206,0.00013330902,0.013308442,0.00010727611,0.00043723584,0.00035634125,0.020258952,0.00032363547],"about_ca_topic_score_codex":0.00053131254,"about_ca_topic_score_gemma":0.007894334,"teacher_disagreement_score":0.2614454,"about_ca_system_score_codex":0.0007147238,"about_ca_system_score_gemma":0.0026288799,"threshold_uncertainty_score":0.598911},"labels":[],"label_agreement":null},{"id":"W3023374112","doi":"10.1200/jco.20.00344","title":"Reply to S.A. Milgrom et al","year":2020,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine","score_opus":0.20203117134007278,"score_gpt":0.5146998016959903,"score_spread":0.3126686303559175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023374112","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007864484,0.0039125686,0.00081953703,0.93468374,0.044962768,0.00064917165,0.00008054911,0.000036474557,0.006990718],"genre_scores_gemma":[0.0018536602,0.003388465,0.0129646845,0.90005976,0.0787035,0.000007798945,0.000034600973,0.0001532339,0.0028342765],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9739617,0.0077089597,0.013539225,0.0011218842,0.0025078114,0.0011604268],"domain_scores_gemma":[0.9584861,0.026650842,0.00930131,0.0010272189,0.0013833835,0.0031511656],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.019116078,0.00081001647,0.009104079,0.00038228303,0.000092839415,0.00005606613,0.0014115038,0.0023529076,0.002282513],"category_scores_gemma":[0.066160865,0.0007017761,0.0034328995,0.00051879545,0.0007721607,0.00022658175,0.00054089254,0.019165257,0.002443935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053097815,0.0014483226,0.0039080568,0.00035595175,0.0024075415,0.022781193,0.0012281529,0.00001641778,0.000025074965,0.000116147065,0.921565,0.04083838],"study_design_scores_gemma":[0.008338092,0.039598927,0.019489324,0.0026254386,0.0017345477,0.0019424795,0.00031234312,0.000018530844,0.000011130358,0.0005099948,0.9248619,0.0005573072],"about_ca_topic_score_codex":0.00045207245,"about_ca_topic_score_gemma":0.00016021874,"teacher_disagreement_score":0.047044788,"about_ca_system_score_codex":0.0009469979,"about_ca_system_score_gemma":0.0139778415,"threshold_uncertainty_score":0.9995433},"labels":[],"label_agreement":null},{"id":"W3027141275","doi":"10.1200/jco.20.00134","title":"Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Aprepitant; Vomiting; Ondansetron; Chemotherapy; Antiemetic; Internal medicine; Chemotherapy-induced nausea and vomiting; Nausea; Chemotherapy regimen; Regimen; Acute leukemia; Anesthesia; Gastroenterology; Leukemia","score_opus":0.16214673103115088,"score_gpt":0.40856034708644595,"score_spread":0.24641361605529508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027141275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946244,0.000039450995,0.00058046536,0.008983028,0.0001799514,0.00041157124,0.0000029882435,0.000028745622,0.00031136093],"genre_scores_gemma":[0.98903555,0.00009374914,0.0003595309,0.009742516,0.0006669774,0.000003780091,0.0000069048333,0.000040780506,0.00005019789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951934,0.00068873726,0.0027690597,0.0003530368,0.000592844,0.0004028924],"domain_scores_gemma":[0.993072,0.002752815,0.0029811796,0.00016111406,0.00055916485,0.00047376275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027625638,0.00026796266,0.0027337924,0.0004352181,0.00005137237,0.000027139844,0.00022150521,0.00038374917,0.000120165016],"category_scores_gemma":[0.007495266,0.00016624409,0.00069796,0.0014306753,0.000042763328,0.00013446751,0.000030342862,0.0011163082,0.0000028766885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00928105,0.0016681964,0.969131,0.000027318654,0.0051587634,0.00017274408,0.00034069555,0.0001497499,0.00008613435,0.0000019613806,0.00027627082,0.013706117],"study_design_scores_gemma":[0.036576655,0.010433693,0.9443116,0.000054423614,0.004877936,0.0000013697716,0.00011668869,0.0031829274,0.000077233395,0.000010342797,0.00017828077,0.00017883947],"about_ca_topic_score_codex":0.000009996511,"about_ca_topic_score_gemma":0.00011315591,"teacher_disagreement_score":0.027295606,"about_ca_system_score_codex":0.00028005874,"about_ca_system_score_gemma":0.0008417116,"threshold_uncertainty_score":0.89730746},"labels":[],"label_agreement":null},{"id":"W3028453792","doi":"10.1200/jco.20.00611","title":"Management of Cancer Cachexia: ASCO Guideline","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"Marie Curie","keywords":"Medicine; Guideline; Cachexia; Cancer cachexia; Cancer; Oncology; Internal medicine; Intensive care medicine; Pathology","score_opus":0.5349752945125523,"score_gpt":0.6818295106471173,"score_spread":0.14685421613456495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028453792","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000047265917,0.97543734,0.00009005485,0.016600573,0.0024483332,0.00043220934,0.000012178638,0.0000072469425,0.0049673226],"genre_scores_gemma":[0.0000059097647,0.97509754,0.016504548,0.0041914126,0.0036584723,0.00001001678,0.000008717797,0.000029851035,0.0004935272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904672,0.000473674,0.008213772,0.00020696023,0.00043178757,0.00020660825],"domain_scores_gemma":[0.9913825,0.0008926015,0.006434932,0.00020130406,0.000523815,0.0005648801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003744762,0.00020908595,0.007124581,0.00017939904,0.000019402749,0.0000028054772,0.00024662167,0.00067140296,0.0006310528],"category_scores_gemma":[0.00070606294,0.0001389397,0.0016668788,0.00024575865,0.000118152006,0.000026473303,0.00009235125,0.002129608,0.00003371901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027597696,0.0005166287,0.00008419622,0.020877782,0.0012106291,0.0017968756,0.0000055359365,2.218132e-7,2.9870552e-8,0.00016369842,0.046928745,0.9281397],"study_design_scores_gemma":[0.0030654815,0.0025195435,0.00013921212,0.02608733,0.0052313097,0.00032545105,0.000020357827,0.000004105336,1.2387942e-7,0.00007635519,0.96244335,0.00008735583],"about_ca_topic_score_codex":0.000010779172,"about_ca_topic_score_gemma":0.0000050184326,"teacher_disagreement_score":0.9280523,"about_ca_system_score_codex":0.00030983315,"about_ca_system_score_gemma":0.0039078956,"threshold_uncertainty_score":0.92522055},"labels":[],"label_agreement":null},{"id":"W3028610963","doi":"10.1200/jco.2020.38.15_suppl.e13108","title":"A retrospective single-center study investigating the clinical significance of grade in triple-negative breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Breast cancer; Triple-negative breast cancer; Internal medicine; Oncology; Statistical significance; Cancer; Chemotherapy; Biomarker; Proportional hazards model","score_opus":0.16192996611470992,"score_gpt":0.4490460501326307,"score_spread":0.28711608401792077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028610963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814056,0.00027981852,0.00003331554,0.016858568,0.000704805,0.00045030206,0.000048862395,0.0000031324566,0.00021557407],"genre_scores_gemma":[0.9951129,0.0003357514,0.0005320829,0.0023345884,0.001631835,0.000024145587,0.0000014246378,0.000016839505,0.000010457532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99506456,0.001509758,0.002549592,0.00036417003,0.0002879616,0.00022396447],"domain_scores_gemma":[0.9957688,0.00093180407,0.0024593866,0.00019285268,0.00044466712,0.00020249785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239498,0.00018540931,0.0012787827,0.000032030955,0.000049195794,0.0000075515813,0.00038895026,0.00023884214,0.000015496567],"category_scores_gemma":[0.005436826,0.00011969336,0.00041947074,0.00024882104,0.000697821,0.000011283413,0.00018748343,0.00082249474,0.0000012983186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026934927,0.003098295,0.97833616,0.000008973495,0.00075391715,0.00004420226,0.00083482865,0.000036923524,0.00090764737,0.000011123761,0.0015538695,0.011720575],"study_design_scores_gemma":[0.010364758,0.010066753,0.97606236,0.00005015106,0.0001702795,0.00003592173,0.0017215334,0.000020068417,0.00038723595,0.00013754609,0.0008671029,0.00011627918],"about_ca_topic_score_codex":0.00013243801,"about_ca_topic_score_gemma":0.00078860903,"teacher_disagreement_score":0.014523979,"about_ca_system_score_codex":0.00010951176,"about_ca_system_score_gemma":0.00093603873,"threshold_uncertainty_score":0.65087813},"labels":[],"label_agreement":null},{"id":"W3028614809","doi":"10.1200/jco.2020.38.15_suppl.9502","title":"CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Humber River Regional Hospital; University of Saskatchewan; University of Alberta; Centre Hospitalier de l’Université de Montréal; Windsor Regional Hospital; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute","keywords":"Pemetrexed; Medicine; Durvalumab; Internal medicine; Gemcitabine; Lung cancer; Oncology; Chemotherapy; Tremelimumab; Clinical endpoint; Cancer; Randomized controlled trial; Pembrolizumab; Cisplatin; Immunotherapy; Ipilimumab","score_opus":0.04899802443508074,"score_gpt":0.4194738323229189,"score_spread":0.3704758078878382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028614809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174863,0.00038654899,0.00075540494,0.0037761398,0.0003316276,0.0024886962,0.00003288587,0.00000785731,0.00047222053],"genre_scores_gemma":[0.990921,0.00024338778,0.0058440096,0.0024649769,0.0002672651,0.00006133581,0.000009533962,0.00003666535,0.00015182445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958972,0.0005605059,0.002599552,0.00027210516,0.00042576835,0.00024491525],"domain_scores_gemma":[0.9933722,0.003350265,0.0023503432,0.00015478417,0.00039789054,0.00037448845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013841406,0.00023887734,0.0029877375,0.00015266301,0.000033147062,0.000009976072,0.00011593142,0.00018818471,0.00023854345],"category_scores_gemma":[0.0015263604,0.0001368983,0.00041193477,0.00024144999,0.00022456392,0.000080366284,0.00001849196,0.0005646468,0.0000011136829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94483083,0.0048154634,0.034694426,0.00022732155,0.0008273321,0.00023705307,0.0009368381,0.00025048965,0.00002487694,0.000003578062,0.0002430967,0.012908677],"study_design_scores_gemma":[0.94081986,0.03202183,0.020675968,0.00018284525,0.002490963,0.0000062153267,0.00015869767,0.0028853456,0.00007069782,0.00000696137,0.0005459107,0.00013472863],"about_ca_topic_score_codex":0.00017843586,"about_ca_topic_score_gemma":0.00016634609,"teacher_disagreement_score":0.027206367,"about_ca_system_score_codex":0.00022613471,"about_ca_system_score_gemma":0.0041403794,"threshold_uncertainty_score":0.73448557},"labels":[],"label_agreement":null},{"id":"W3028627144","doi":"10.1200/jco.2020.38.15_suppl.e19512","title":"The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Oncology; Hazard ratio; Confidence interval","score_opus":0.04387402461863748,"score_gpt":0.3834264577794724,"score_spread":0.3395524331608349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028627144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936133,0.00012267259,0.0004169483,0.0041161897,0.00022192272,0.0012288919,0.000029326176,0.000007892946,0.00024284452],"genre_scores_gemma":[0.9976148,0.0004554118,0.00049259886,0.0011029928,0.00016787824,0.000035122477,0.00003762651,0.000033312655,0.00006025238],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972225,0.00048801117,0.0011995999,0.0002540805,0.00054336106,0.00029244905],"domain_scores_gemma":[0.98794144,0.0075353426,0.001536445,0.00016601842,0.0025367576,0.00028400726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015275816,0.00021212808,0.0017450837,0.00011144429,0.000049439765,0.00001256045,0.00022031998,0.0002517536,0.000016558235],"category_scores_gemma":[0.0030572405,0.00012298256,0.00016911424,0.00040769827,0.00058564986,0.00015300213,0.000046956684,0.0010226766,0.000004816994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6078534,0.0025211805,0.30075693,0.000440701,0.0030406683,0.00062943675,0.000817085,0.00041195878,0.0015001833,0.00007536553,0.06634767,0.01560537],"study_design_scores_gemma":[0.21328184,0.065534525,0.70406294,0.0012110574,0.00045600752,0.000025347315,0.00068262697,0.0031344942,0.0029915671,0.000059975315,0.008293853,0.00026577277],"about_ca_topic_score_codex":0.000025770296,"about_ca_topic_score_gemma":0.00006389149,"teacher_disagreement_score":0.40330598,"about_ca_system_score_codex":0.0006948493,"about_ca_system_score_gemma":0.0016447303,"threshold_uncertainty_score":0.5015083},"labels":[],"label_agreement":null},{"id":"W3028640094","doi":"10.1200/jco.2020.38.15_suppl.4587","title":"Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; HBsAg; Hepatocellular carcinoma; Hepatitis B virus; Internal medicine; Hepatitis B; Pembrolizumab; Gastroenterology; Virology; Cancer; Virus; Immunotherapy","score_opus":0.04782083512821685,"score_gpt":0.36671289335822027,"score_spread":0.31889205823000344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028640094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613357,0.000623704,0.00004100427,0.0018544069,0.00022256255,0.00078531215,0.000026295163,0.000009163218,0.00030395846],"genre_scores_gemma":[0.99633944,0.0012023008,0.00058657624,0.0016228748,0.00018399213,0.00001321913,0.000003374699,0.00003797235,0.000010229809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99481785,0.0010583034,0.0025852094,0.00045699094,0.00066880515,0.00041286013],"domain_scores_gemma":[0.99523026,0.0028389462,0.0008835262,0.00019634084,0.00034612458,0.0005048242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018183959,0.00035669428,0.0029586682,0.00021730972,0.000040060888,0.000008259682,0.00014660633,0.00039771225,0.00002700462],"category_scores_gemma":[0.0047262018,0.00025905683,0.00021742687,0.0002644718,0.0004494254,0.00019182856,0.00008945042,0.0014125517,0.000004619199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034844235,0.00086353347,0.8933662,0.00034688276,0.00011867942,0.0016100176,0.00066254917,0.000019334002,0.0003236236,0.000014156427,0.000062983134,0.0677678],"study_design_scores_gemma":[0.050274055,0.09864119,0.8478156,0.0004914294,0.00021318268,0.00005167094,0.000020260233,0.0005619084,0.0011762115,0.000024783965,0.00054011046,0.00018963714],"about_ca_topic_score_codex":0.00061761204,"about_ca_topic_score_gemma":0.00092050334,"teacher_disagreement_score":0.09777766,"about_ca_system_score_codex":0.00031045213,"about_ca_system_score_gemma":0.00072055997,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W3028660368","doi":"10.1200/jco.2020.38.15_suppl.12058","title":"The impact of tobacco retail density on overall survival (OS) in lung cancer survivors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Toronto General Hospital; University of Toronto; University Health Network; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research; McMaster University; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Proportional hazards model; Hazard ratio; Christian ministry; Lung cancer screening; Cancer; Internal medicine; Demography; Surgery; Confidence interval","score_opus":0.2857817595716184,"score_gpt":0.5279642733441069,"score_spread":0.2421825137724885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028660368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789554,0.0008944965,0.000023810748,0.016534943,0.00073579105,0.00012270846,0.0000035049907,0.0000039676393,0.0027254052],"genre_scores_gemma":[0.99439096,0.0016513879,0.00009984379,0.0026870696,0.0011094694,0.000001023393,5.079544e-7,0.000008875233,0.000050861792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667156,0.00054139557,0.0018736873,0.00015802828,0.00049861835,0.0002566901],"domain_scores_gemma":[0.9951059,0.0025647448,0.0013411257,0.00016384498,0.0004544595,0.00036988527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038957724,0.00012316677,0.0013769612,0.00004286857,0.00003454188,0.000008113207,0.00024717572,0.0002520425,0.00016698016],"category_scores_gemma":[0.006590279,0.00006846479,0.00065658876,0.00019294699,0.00015102739,0.000090978734,0.000060492766,0.0012815795,0.0000044927096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012574104,0.00020085467,0.94906926,0.000012006947,0.00024709446,0.0003774228,0.000106050094,0.00052200555,0.000105938416,0.000098636185,0.006100285,0.030586317],"study_design_scores_gemma":[0.003760932,0.008205353,0.9820634,0.00014998701,0.000116121366,0.000034073848,0.00009905591,0.00064794754,0.000045963516,0.0000960733,0.0047128233,0.0000682777],"about_ca_topic_score_codex":0.0026229303,"about_ca_topic_score_gemma":0.0030414818,"teacher_disagreement_score":0.032994106,"about_ca_system_score_codex":0.00032832983,"about_ca_system_score_gemma":0.0021400582,"threshold_uncertainty_score":0.7889656},"labels":[],"label_agreement":null},{"id":"W3028700216","doi":"10.1200/jco.2020.38.15_suppl.6580","title":"Upfront DPYD genotyping and toxicity associated with fluoropyrimidine-based concurrent chemoradiotherapy for oropharyngeal carcinomas.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"DPYD; Medicine; Genotyping; Oncology; Internal medicine; Pharmacogenetics; Genotype; Genetics; Biology","score_opus":0.2009376125747487,"score_gpt":0.4472239188581994,"score_spread":0.2462863062834507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028700216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95497125,0.003292239,0.0018023582,0.038741842,0.0004941678,0.0003550441,0.000011642561,0.000016881411,0.00031457364],"genre_scores_gemma":[0.9819272,0.0004726653,0.0031809025,0.013105087,0.0012627366,0.0000067408664,0.0000034356647,0.000020543406,0.000020658326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979693,0.00016175584,0.0011995505,0.00020647509,0.00022810558,0.0002347937],"domain_scores_gemma":[0.9966404,0.0014552656,0.000887167,0.00007003168,0.00045738506,0.0004897923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011435418,0.00015160431,0.00213064,0.000036746373,0.00006362414,0.000007178739,0.00008081738,0.00020399921,0.00003977184],"category_scores_gemma":[0.0023484924,0.0000985724,0.00026319936,0.000087866305,0.00020804047,0.00004925843,0.000018743993,0.0005403271,7.624369e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054315805,0.0039527137,0.3232979,0.0006410065,0.0036263182,0.0012545662,0.0017978891,0.000066297725,0.014699217,0.00011278063,0.048994407,0.5472411],"study_design_scores_gemma":[0.108466715,0.19448294,0.5306935,0.0006789739,0.002118501,0.00017632169,0.00029094005,0.010547412,0.007103629,0.00005139592,0.14482208,0.00056762545],"about_ca_topic_score_codex":0.000006136152,"about_ca_topic_score_gemma":0.000023890852,"teacher_disagreement_score":0.5466735,"about_ca_system_score_codex":0.00017761599,"about_ca_system_score_gemma":0.0015234605,"threshold_uncertainty_score":0.40196657},"labels":[],"label_agreement":null},{"id":"W3028721226","doi":"10.1200/jco.2020.38.15_suppl.e22015","title":"Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nanoplatforms for cancer theranostics","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"","keywords":"Medicine; Trametinib; Dabrafenib; Immune checkpoint; Cancer research; Melanoma; MEK inhibitor; Nivolumab; Neuroblastoma RAS viral oncogene homolog; Ipilimumab; Tumor microenvironment; Targeted therapy; Vemurafenib; Oncology; KRAS; Immunotherapy; Immune system; Immunology; Cancer; Internal medicine; Signal transduction; Metastatic melanoma; MAPK/ERK pathway; Biology; Colorectal cancer","score_opus":0.06447277460282737,"score_gpt":0.36194546889529855,"score_spread":0.2974726942924712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028721226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.817221,0.002819473,0.17763783,0.0009124827,0.0010372051,0.00021526968,0.00004979884,0.000014813665,0.000092154936],"genre_scores_gemma":[0.9489106,0.00074998883,0.049826276,0.00024632257,0.00022053832,0.0000024817314,0.0000010025692,0.00003302844,0.000009741065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975194,0.00006121312,0.001839945,0.00013664694,0.00025357792,0.00018923351],"domain_scores_gemma":[0.99816376,0.00040987707,0.0008151561,0.00011978722,0.00028759855,0.00020384982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006728562,0.00014786614,0.0010669548,0.00008276078,0.00001467638,0.000005719723,0.00022163666,0.0002246778,0.000049574854],"category_scores_gemma":[0.00048065573,0.00013166637,0.0002174031,0.00018084496,0.000075895696,0.00008825785,0.00004493819,0.00042603354,0.0000011290698],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019287261,0.000101258585,0.0009689882,0.00015449646,0.00085239083,0.00010240023,0.00038689154,0.015222277,0.9732483,0.0006356511,0.00008543386,0.0063131866],"study_design_scores_gemma":[0.004822985,0.0031359002,0.0027669035,0.00017489017,0.0002652623,0.000014180477,0.000121477366,0.003736926,0.979693,0.0021269894,0.0028950688,0.00024639492],"about_ca_topic_score_codex":0.000011243889,"about_ca_topic_score_gemma":0.000029164074,"teacher_disagreement_score":0.13168964,"about_ca_system_score_codex":0.00016489277,"about_ca_system_score_gemma":0.00030890465,"threshold_uncertainty_score":0.5369199},"labels":[],"label_agreement":null},{"id":"W3028752192","doi":"10.1200/jco.2020.38.15_suppl.12109","title":"The Quebec Cannabis Registry: a pharmacovigilance and effectiveness study on the use of medical cannabis in cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Brief Pain Inventory; Nausea; Adverse effect; Internal medicine; Lung cancer; Anxiety; Cancer pain; Depression (economics); Cancer; Physical therapy; Psychiatry; Chronic pain","score_opus":0.18124823449646385,"score_gpt":0.5058509826996752,"score_spread":0.32460274820321133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028752192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71623874,0.00031083077,0.0000028419383,0.28252918,0.0003349256,0.0005339089,0.00000707465,0.0000023771029,0.000040134626],"genre_scores_gemma":[0.99166846,0.0009690241,0.000004602495,0.0063860575,0.00052737724,0.000053307434,5.2315335e-7,0.000015733005,0.00037490382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946969,0.0018986147,0.0016308995,0.00023701879,0.0012557254,0.000280804],"domain_scores_gemma":[0.9960091,0.0016337802,0.0009439497,0.00021472167,0.00064365624,0.0005548074],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0059165414,0.00014561613,0.0011168483,0.00006092156,0.0000752399,0.000024668387,0.00038808945,0.00022624256,0.0000670414],"category_scores_gemma":[0.018576065,0.000068912,0.00023159148,0.00032800046,0.0006515533,0.00006958974,0.00015129536,0.0019211926,0.0000011092202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012362671,0.002704735,0.67971104,0.000087463326,0.00033173006,0.0004772641,0.0007022074,0.000024671044,0.000049653027,0.000095627714,0.2191643,0.084288634],"study_design_scores_gemma":[0.0060841856,0.009027191,0.6746021,0.00012220554,0.0000833917,0.000013035388,0.0003414477,0.00016378792,0.000049688784,0.000008199204,0.3094521,0.000052696094],"about_ca_topic_score_codex":0.0066821156,"about_ca_topic_score_gemma":0.008353838,"teacher_disagreement_score":0.2761431,"about_ca_system_score_codex":0.00022171716,"about_ca_system_score_gemma":0.0040711095,"threshold_uncertainty_score":0.99993247},"labels":[],"label_agreement":null},{"id":"W3028754062","doi":"10.1200/jco.2020.38.15_suppl.9582","title":"Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Pemetrexed; Lung cancer; Placebo; Internal medicine; Clinical endpoint; Oncology; Carboplatin; Cisplatin; Randomization; Progression-free survival; Chemotherapy; Clinical trial","score_opus":0.05799861924725461,"score_gpt":0.4282136198917117,"score_spread":0.3702150006444571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028754062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948741,0.00033987407,0.0010212365,0.0016348659,0.000096716256,0.0009906823,0.000036263544,0.000012332394,0.0009938895],"genre_scores_gemma":[0.98729295,0.00035276855,0.009864335,0.0018233744,0.00014247888,0.00003370098,0.00003256139,0.000049119662,0.00040869406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606377,0.00027177314,0.0023003004,0.00040859476,0.0005756468,0.0003798959],"domain_scores_gemma":[0.9949539,0.00077806634,0.0026246724,0.0002618498,0.0008800245,0.0005014987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005623461,0.0003382543,0.0030832896,0.00040613642,0.000042283737,0.000013535564,0.0002090176,0.0002039556,0.00045650735],"category_scores_gemma":[0.0003447726,0.00019012872,0.0004455823,0.0014614392,0.00017600023,0.0001297251,0.000028090715,0.0007169088,0.0000027177612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055065054,0.0039580013,0.90699476,0.00023179929,0.0075632078,0.00040133184,0.0018583984,0.0016643999,0.00005282844,0.0000013635554,0.00034713733,0.021861706],"study_design_scores_gemma":[0.11762588,0.047332242,0.7947602,0.0005207431,0.029799454,0.000047399037,0.00041613367,0.008065905,0.0003043997,0.0000027774888,0.0008052744,0.00031958186],"about_ca_topic_score_codex":0.00050156185,"about_ca_topic_score_gemma":0.0014251195,"teacher_disagreement_score":0.11223456,"about_ca_system_score_codex":0.0004452568,"about_ca_system_score_gemma":0.004271509,"threshold_uncertainty_score":0.7753224},"labels":[],"label_agreement":null},{"id":"W3028754320","doi":"10.1200/jco.2020.38.15_suppl.e13080","title":"Macrocytosis as a predictor of response to capecitabine in solid cancers: A meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; McMaster University; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Capecitabine; Medicine; Macrocytosis; Internal medicine; Mean corpuscular volume; Oncology; Gastroenterology; Hazard ratio; Cancer; Colorectal cancer; Confidence interval; Anemia; Hematocrit","score_opus":0.12770829001360326,"score_gpt":0.44910781181066284,"score_spread":0.32139952179705955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028754320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98314863,0.001705635,0.0006609177,0.013817765,0.00020596122,0.00012795514,0.00006622271,0.0000012311076,0.00026568695],"genre_scores_gemma":[0.98739016,0.0006974832,0.0024191462,0.008861155,0.0005487617,0.000007725404,0.0000039785373,0.000011556656,0.000060009606],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969938,0.00043371695,0.0019497967,0.00024374395,0.00019941683,0.00017951813],"domain_scores_gemma":[0.99719703,0.00079879374,0.00105358,0.00020503155,0.00034154067,0.00040400852],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021137462,0.00012345187,0.0018493372,0.0001252934,0.000011349302,0.000006547469,0.00031404517,0.0002585884,0.00016235115],"category_scores_gemma":[0.008828713,0.00009853762,0.0013334258,0.0003407014,0.000082840495,0.0000036721028,0.00013800924,0.00027686817,0.000005536157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18549499,0.003310223,0.04687979,0.00009230439,0.22609226,0.0011658231,0.002104168,0.06267001,0.3960844,0.0001613958,0.061486296,0.014458363],"study_design_scores_gemma":[0.015297357,0.08123604,0.06931321,0.000020052956,0.09386997,0.000075472715,0.0006803968,0.00069629657,0.047279704,0.0003130421,0.6905274,0.0006910712],"about_ca_topic_score_codex":0.00009474998,"about_ca_topic_score_gemma":0.00065332337,"teacher_disagreement_score":0.6290411,"about_ca_system_score_codex":0.00006497911,"about_ca_system_score_gemma":0.0019585188,"threshold_uncertainty_score":0.99952036},"labels":[],"label_agreement":null},{"id":"W3028754518","doi":"10.1200/jco.2020.38.15_suppl.10505","title":"Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Ceritinib; Tolerability; Internal medicine; Anaplastic large-cell lymphoma; ALK inhibitor; Pharmacokinetics; Lymphoma; Gastroenterology; Oncology; Adverse effect; Lung cancer","score_opus":0.12246669808035617,"score_gpt":0.44534442259846907,"score_spread":0.3228777245181129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028754518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992764,0.000035344754,0.000011426181,0.00024797564,0.00006809029,0.00027508935,0.000014750066,0.0000036836145,0.00006721872],"genre_scores_gemma":[0.999483,0.000064486536,0.00022456274,0.000093784234,0.000110346446,0.0000034502914,0.0000042926913,0.000011406356,0.000004697224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996611,0.00039737113,0.0019473459,0.00020224131,0.0006241088,0.0002179346],"domain_scores_gemma":[0.9958927,0.001435331,0.0015671521,0.00013486412,0.00055729167,0.00041266886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005439256,0.00013240927,0.001796172,0.0005734635,0.000016500177,0.0000034923778,0.00013687079,0.000101798825,0.000052898075],"category_scores_gemma":[0.0031457746,0.000089523564,0.00027334018,0.0014215535,0.00009563979,0.00010163026,0.000053126678,0.00036406747,0.0000013412676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041852783,0.030323902,0.9095901,0.00006580432,0.001823558,0.0024838361,0.00019350956,0.00010952213,0.00042348358,0.0000011881796,0.00003020404,0.013102097],"study_design_scores_gemma":[0.0524338,0.11615839,0.82800764,0.000041602787,0.0025670568,0.0000051623465,0.00018088985,0.00016079057,0.0003578884,0.0000013004238,0.00003499038,0.00005049861],"about_ca_topic_score_codex":0.000023549324,"about_ca_topic_score_gemma":0.0000535435,"teacher_disagreement_score":0.08583448,"about_ca_system_score_codex":0.00007472994,"about_ca_system_score_gemma":0.0008908757,"threshold_uncertainty_score":0.37660134},"labels":[],"label_agreement":null},{"id":"W3028755962","doi":"10.1200/jco.2020.38.15_suppl.570","title":"Psychosocial outcomes following surgery in women with unilateral, nonhereditary breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Mount Sinai Hospital; University of Toronto; Women's College Hospital","funders":"","keywords":"Lumpectomy; Medicine; Mastectomy; Psychosocial; Breast cancer; Prospective cohort study; Surgery; Cancer; Gynecology; Internal medicine; Psychiatry","score_opus":0.09677901833153778,"score_gpt":0.42557351863391385,"score_spread":0.32879450030237606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028755962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9377639,0.0000645953,0.000008731309,0.059001368,0.0028377487,0.000072955336,0.000005244774,0.000008937837,0.00023651308],"genre_scores_gemma":[0.99318594,0.00011445933,0.00036157985,0.003844377,0.0024488713,0.0000025696913,0.0000010263328,0.000012798736,0.000028375423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774104,0.00018817966,0.001471362,0.00013252547,0.00023599467,0.00023092255],"domain_scores_gemma":[0.99782705,0.0008269333,0.0007773784,0.000054419168,0.00010325606,0.00041096783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001137322,0.00011059382,0.0015257542,0.000093596485,0.000023183511,0.0000056931076,0.00007315889,0.00027415637,0.00015570107],"category_scores_gemma":[0.0001722734,0.00006808459,0.0003243293,0.00017905838,0.00009460805,0.00014360086,0.000014657567,0.0008711939,0.00000564832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060282275,0.00022276992,0.7052654,0.000016639055,0.0003383167,0.0011879498,0.00015692457,0.0000033105184,0.000011307398,0.0000014753929,0.0023691952,0.2843985],"study_design_scores_gemma":[0.0056427764,0.0015835955,0.9818935,0.00016462708,0.00013049587,0.007553856,0.00028162557,0.000010333886,0.0000016346311,0.000038256952,0.0026176358,0.00008170509],"about_ca_topic_score_codex":0.00003602165,"about_ca_topic_score_gemma":0.000050510007,"teacher_disagreement_score":0.2843168,"about_ca_system_score_codex":0.00014133065,"about_ca_system_score_gemma":0.0015726042,"threshold_uncertainty_score":0.37849522},"labels":[],"label_agreement":null},{"id":"W3028780244","doi":"10.1200/jco.2020.38.15_suppl.e21714","title":"Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Hazard ratio; Internal medicine; Proportional hazards model; Oncology; Lung cancer; Cohort; Confidence interval; Cancer; Immunotherapy","score_opus":0.021947352179108648,"score_gpt":0.350484239687062,"score_spread":0.32853688750795335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028780244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612665,0.00089829887,0.000013644304,0.0012872876,0.00023971335,0.0002852498,0.000047145488,0.0000034745187,0.0010985257],"genre_scores_gemma":[0.9945807,0.0029948812,0.0006644115,0.0014189021,0.00019659402,0.000005127583,0.00001122984,0.000016481947,0.00011168512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997108,0.00023628424,0.0018537965,0.00024855704,0.0003358696,0.00021751672],"domain_scores_gemma":[0.9968782,0.00070322555,0.0016550153,0.00014871791,0.0003059056,0.0003089127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547814,0.00016025106,0.0020338476,0.00017785776,0.000019319352,0.000004551881,0.00013734937,0.00013231367,0.00011998248],"category_scores_gemma":[0.00011204309,0.00011576166,0.0002698151,0.0006611631,0.00010656561,0.000058132973,0.000027332248,0.00052292284,2.0868276e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02386548,0.0004359211,0.96048456,0.000049972536,0.0030790926,0.00018041834,0.00022708863,0.0001338472,0.00030922878,5.9109476e-7,0.0003587695,0.0108750025],"study_design_scores_gemma":[0.029748693,0.004019516,0.95918906,0.0001838109,0.003941697,0.0000012474148,0.0001535326,0.0005604772,0.00010706324,9.394914e-7,0.0019785552,0.00011542607],"about_ca_topic_score_codex":0.32405207,"about_ca_topic_score_gemma":0.7915125,"teacher_disagreement_score":0.46746042,"about_ca_system_score_codex":0.00027304087,"about_ca_system_score_gemma":0.00266998,"threshold_uncertainty_score":0.6804491},"labels":[],"label_agreement":null},{"id":"W3028807982","doi":"10.1200/jco.2020.38.15_suppl.10500","title":"Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Vincristine; Irinotecan; Clinical endpoint; Refractory (planetary science); Internal medicine; Neuroblastoma; Vorinostat; Regimen; Phases of clinical research; Oncology; Randomized controlled trial; Clinical trial; Surgery; Urology; Chemotherapy; Cyclophosphamide; Cancer","score_opus":0.4324664555464727,"score_gpt":0.48268158462309885,"score_spread":0.050215129076626175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028807982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9318477,0.00036367984,0.0004872889,0.058620922,0.004528863,0.0035069098,0.000064541404,0.000041611034,0.00053851673],"genre_scores_gemma":[0.9859879,0.0006582089,0.004435676,0.003109885,0.0052160225,0.00009533845,0.000031508793,0.00010334341,0.00036213567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903819,0.0020684802,0.0049686134,0.0007893277,0.0011292628,0.0006624391],"domain_scores_gemma":[0.95733035,0.035110418,0.0041887187,0.00079469965,0.00056911935,0.0020067194],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033807198,0.0005037168,0.004055956,0.00018592087,0.00016752789,0.000032092074,0.0006779142,0.00044426305,0.00019877477],"category_scores_gemma":[0.047155377,0.00031536064,0.0022298929,0.00040182765,0.0006973522,0.00016784032,0.0002517337,0.0018449399,0.000031154956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90920675,0.007948705,0.000089653724,0.00002347384,0.0022684147,0.0028211947,0.00023367202,0.000021447324,0.0007916573,0.000038011505,0.032538116,0.044018883],"study_design_scores_gemma":[0.6918517,0.21006373,0.00057677954,0.000048340782,0.001046195,0.000119280965,0.00006746877,0.0001480761,0.0010174396,0.00006799191,0.09483033,0.00016271176],"about_ca_topic_score_codex":0.00009699412,"about_ca_topic_score_gemma":0.000061144965,"teacher_disagreement_score":0.2173551,"about_ca_system_score_codex":0.00011971893,"about_ca_system_score_gemma":0.00427508,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W3028809236","doi":"10.1200/jco.2020.38.15_suppl.5602","title":"HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Castration; Urology; Testosterone (patch); Leuprorelin; Clinical endpoint; Internal medicine; Prostate; Hormone antagonist; Randomized controlled trial; Endocrinology; Antagonist; Cancer; Gynecology; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","score_opus":0.3834256382585731,"score_gpt":0.576770821601796,"score_spread":0.19334518334322293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028809236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94541323,0.0011117852,0.000117752104,0.04709886,0.0035026213,0.0019055338,0.00008907815,0.000042255873,0.00071887346],"genre_scores_gemma":[0.9796398,0.005840799,0.007119239,0.0019417662,0.004251252,0.00010337217,0.000106400315,0.000062444924,0.00093491597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99500406,0.00047135493,0.0030213755,0.0004556196,0.00048732737,0.0005602885],"domain_scores_gemma":[0.99433416,0.0015083397,0.0019752593,0.00024340513,0.00073876185,0.0012000434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003036175,0.0002500397,0.0023269178,0.00009198422,0.00013269667,0.000031736567,0.00028909298,0.00030225082,0.000057628684],"category_scores_gemma":[0.0036624481,0.000173967,0.0005708669,0.00022301072,0.0003086331,0.0003173133,0.00007291183,0.0012130627,0.000011293464],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81261426,0.0018466247,0.000516795,0.00006804887,0.0006119103,0.0003298225,0.00044703996,0.00007744506,0.0012156991,0.000013982894,0.012282702,0.16997565],"study_design_scores_gemma":[0.63664687,0.10032439,0.00022936417,0.000111686946,0.00045321407,0.000019290019,0.00037344478,0.00079266494,0.0016777399,0.000052237916,0.25916415,0.00015493005],"about_ca_topic_score_codex":0.00004180404,"about_ca_topic_score_gemma":0.00007691599,"teacher_disagreement_score":0.24688146,"about_ca_system_score_codex":0.00039512667,"about_ca_system_score_gemma":0.0033291532,"threshold_uncertainty_score":0.7094168},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3028814014","doi":"10.1200/jco.2020.38.15_suppl.e12527","title":"Is the toxicity of breast radiotherapy higher in patients with collagen vascular disease? A systematic review of the literature.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Contraindication; Breast cancer; Toxicity; Radiation therapy; Mastectomy; Disease; Cancer; Internal medicine; Surgery; Oncology; Pathology","score_opus":0.03643619565619861,"score_gpt":0.391789032423174,"score_spread":0.3553528367669754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028814014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003193115,0.99634904,0.0000030427384,0.0015771454,0.00030294017,0.0012638845,0.0001582247,7.761097e-7,0.000025631569],"genre_scores_gemma":[0.0010595185,0.9967863,0.00006836343,0.0016827431,0.0002997792,0.000039839462,0.000013704158,0.000025504762,0.0000242224],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9943062,0.0020465027,0.0028407925,0.0002465399,0.00041712594,0.0001428116],"domain_scores_gemma":[0.993328,0.0005031028,0.0049990853,0.00058145786,0.00047858933,0.00010980331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013304596,0.00029794264,0.0045796935,0.000035942205,0.000025194557,0.0000055448404,0.0006812335,0.00032149375,0.000017916893],"category_scores_gemma":[0.00080906216,0.00011742115,0.0018556503,0.00033658982,0.00025734163,0.0000043775535,0.00013690742,0.0003736897,5.962038e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014731475,0.0022919222,0.010074967,0.91280097,0.012937639,0.000044216336,0.00009849356,0.0000012601847,8.688279e-7,0.000019271925,0.004921379,0.055335887],"study_design_scores_gemma":[0.0028500673,0.0019133175,0.029528545,0.55387634,0.008209484,0.0000447289,0.0000060428138,1.4913017e-7,0.0000012341449,0.0000087551025,0.40336335,0.00019796942],"about_ca_topic_score_codex":0.0000019099189,"about_ca_topic_score_gemma":0.000004206668,"teacher_disagreement_score":0.39844197,"about_ca_system_score_codex":0.00009641991,"about_ca_system_score_gemma":0.0013678783,"threshold_uncertainty_score":0.47882956},"labels":[],"label_agreement":null},{"id":"W3028814746","doi":"10.1200/jco.2020.38.15_suppl.5551","title":"Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Kingston Health Sciences Centre; University of Ottawa; Ottawa Hospital; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Jewish General Hospital; Queen's University; McMaster University; London Health Sciences Centre; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Western University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; PTEN; Biomarker; Palbociclib; Enzalutamide; PARP inhibitor; Cancer research; Breast cancer; Androgen receptor; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Biology","score_opus":0.37479070474399473,"score_gpt":0.5657168146001935,"score_spread":0.1909261098561988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028814746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94406426,0.0074731116,0.000019671568,0.03849755,0.0015168125,0.007801056,0.0005538164,0.000016686514,0.00005703413],"genre_scores_gemma":[0.9755183,0.016974224,0.0005217638,0.0014131577,0.0022646282,0.00209262,0.00004255336,0.00005536115,0.0011173853],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99360776,0.0011742328,0.0033204337,0.0005925283,0.00058712024,0.00071790884],"domain_scores_gemma":[0.9938878,0.0015564112,0.0020499963,0.00014669771,0.00081488723,0.001544249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047795703,0.000392754,0.0028317976,0.000282752,0.00034953677,0.00006278351,0.00012451464,0.00022744063,0.00034656044],"category_scores_gemma":[0.0015168792,0.00024734606,0.000584041,0.00041750522,0.00019162735,0.00017985338,0.00003895863,0.0005323635,0.000001967009],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4365651,0.0072707282,0.010831506,0.00015437519,0.0062894314,0.0006176417,0.0025505098,0.000050043313,0.0028768685,0.000010673621,0.007224855,0.5255583],"study_design_scores_gemma":[0.56114763,0.2457425,0.008910917,0.00023829116,0.0069226674,0.00004440939,0.001465753,0.0010725952,0.0006916012,0.0000697544,0.173309,0.00038487554],"about_ca_topic_score_codex":0.035179697,"about_ca_topic_score_gemma":0.1464067,"teacher_disagreement_score":0.52517337,"about_ca_system_score_codex":0.002050837,"about_ca_system_score_gemma":0.014245087,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W3028820398","doi":"10.1200/jco.2020.38.15_suppl.e19115","title":"Feasibility of randomized controlled trials (RCTs) for drugs approved by the United States Food and Drug Administration (FDA) based on single arm studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Interim analysis; Food and drug administration; Randomized controlled trial; Sample size determination; Interim; Randomization; Clinical trial; Internal medicine; Pharmacology; Statistics","score_opus":0.7167046406051628,"score_gpt":0.5762597893058978,"score_spread":0.14044485129926498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028820398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5857909,0.00321157,0.006360606,0.39888746,0.0010370424,0.004127322,0.00024127077,0.000009692319,0.0003341738],"genre_scores_gemma":[0.9626211,0.0006300338,0.0019926962,0.03390617,0.0006525366,0.000112674854,0.000022693945,0.000016316535,0.000045783283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.96680456,0.00955782,0.022867886,0.0003633899,0.0001829359,0.0002234312],"domain_scores_gemma":[0.67378575,0.28567645,0.038992528,0.00032279722,0.00083787536,0.00038460866],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24898998,0.00019034732,0.011098254,0.00015944906,0.00009801418,0.00003486879,0.00024151205,0.00023604756,0.000042090713],"category_scores_gemma":[0.41399696,0.00012829114,0.0013403094,0.00013416368,0.00040014568,0.00012571223,0.00002482029,0.0004039651,0.000005137232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7629484,0.0073838634,0.0037753715,0.0011313148,0.007281956,0.0000023782402,0.007716655,0.0021526641,0.000014226572,0.021497397,0.18313971,0.0029560884],"study_design_scores_gemma":[0.7998974,0.023860024,0.00033668926,0.00015431123,0.0007891228,0.0000026722648,0.007257346,0.083661415,0.00005336806,0.038074102,0.045576252,0.0003372949],"about_ca_topic_score_codex":0.000024045205,"about_ca_topic_score_gemma":0.00002445407,"teacher_disagreement_score":0.37683025,"about_ca_system_score_codex":0.00020977196,"about_ca_system_score_gemma":0.00075521524,"threshold_uncertainty_score":0.7733229},"labels":[],"label_agreement":null},{"id":"W3028821717","doi":"10.1200/jco.2020.38.15_suppl.e19410","title":"Impact of value frameworks on the magnitude of clinical benefit: Evaluating a decade of randomized trials for systemic therapy in solid malignancies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Baker Hughes (Canada); Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Progression-free survival; Exact test; Randomized controlled trial; Quality of life (healthcare); Clinical trial; Cancer; Oncology; Statistical significance; Surrogate endpoint; Overall survival","score_opus":0.45126646382479907,"score_gpt":0.5333081009055094,"score_spread":0.08204163708071033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028821717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865852,0.0039079865,0.0023560056,0.004296036,0.0009340143,0.0011295457,0.000092707334,0.0000025843967,0.00069589436],"genre_scores_gemma":[0.98761094,0.0069391746,0.0025558833,0.0017825656,0.001048626,0.000024977322,0.0000010978173,0.000025123345,0.00001158857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9806559,0.0012703236,0.017348059,0.000298213,0.00012701796,0.0003004931],"domain_scores_gemma":[0.924675,0.047836185,0.02603833,0.00032570996,0.00089182006,0.000232976],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06628477,0.00021495638,0.009781413,0.00019751664,0.000025122972,0.000012272056,0.00061342976,0.0009739035,0.00017213015],"category_scores_gemma":[0.18002099,0.00014020078,0.004120949,0.00020403326,0.00040978557,0.00014351984,0.000047534264,0.0012324243,0.000005297869],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4807445,0.0032980733,0.189268,0.00026959772,0.0052778237,0.000016474125,0.0018216836,0.020468904,0.00028518148,0.09459858,0.002467408,0.20148377],"study_design_scores_gemma":[0.39609292,0.06234195,0.37672535,0.0013198123,0.0005694517,0.00002556548,0.0003076522,0.022873366,0.00038854044,0.13742079,0.0013661262,0.0005684599],"about_ca_topic_score_codex":0.00010370291,"about_ca_topic_score_gemma":0.000006496596,"teacher_disagreement_score":0.2009153,"about_ca_system_score_codex":0.00011366593,"about_ca_system_score_gemma":0.0012041229,"threshold_uncertainty_score":0.9614563},"labels":[],"label_agreement":null},{"id":"W3028840094","doi":"10.1200/jco.2020.38.15_suppl.5539","title":"Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; Prostate cancer; Cohort; Internal medicine; Oncology; Population; Quality of life (healthcare); Randomized controlled trial; Cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.36714487974955307,"score_gpt":0.5279855929166039,"score_spread":0.1608407131670508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028840094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465277,0.0012800542,0.0007981244,0.048802834,0.0008867439,0.0015489298,0.00007306784,0.000028080787,0.000054458957],"genre_scores_gemma":[0.9710159,0.0009706031,0.023331355,0.0039868653,0.00035554706,0.00016773591,0.0000372468,0.00003245208,0.000102331265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99215215,0.0013106123,0.0054658917,0.00032972643,0.00044993867,0.0002916632],"domain_scores_gemma":[0.99063474,0.0028870646,0.0047744997,0.00019109261,0.0010942871,0.0004182871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005074088,0.0001953776,0.0021381876,0.00015474812,0.0000690524,0.000011810314,0.00011775243,0.00021007769,0.00012298301],"category_scores_gemma":[0.0055640517,0.00013923498,0.00029360317,0.0004156486,0.00024582024,0.00023148637,0.00001611521,0.00072709046,0.0000023599207],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.848769,0.008588866,0.044618424,0.002429042,0.0047704377,0.0007054939,0.006156839,0.0059152623,0.01663957,0.001556879,0.00886769,0.050982468],"study_design_scores_gemma":[0.3447808,0.30311176,0.31940246,0.0019326315,0.001587357,0.0004527146,0.0028525044,0.0053507583,0.0051073073,0.00272117,0.011716062,0.0009844908],"about_ca_topic_score_codex":0.0003264391,"about_ca_topic_score_gemma":0.002193478,"teacher_disagreement_score":0.5039882,"about_ca_system_score_codex":0.0006405681,"about_ca_system_score_gemma":0.008734177,"threshold_uncertainty_score":0.99688536},"labels":[],"label_agreement":null},{"id":"W3028860151","doi":"10.1200/jco.2020.38.15_suppl.3063","title":"Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Response Evaluation Criteria in Solid Tumors; Internal medicine; Monoclonal antibody; Oncology; Immune system; Progressive disease; Antibody; Gastroenterology; Phases of clinical research; Clinical trial; Immunology; Chemotherapy","score_opus":0.047004141341556095,"score_gpt":0.41775422748165525,"score_spread":0.37075008614009913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028860151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951658,0.00013390587,0.00009891261,0.0036071914,0.00029728486,0.00047103365,0.000015079177,0.0000109895,0.00019978543],"genre_scores_gemma":[0.99481505,0.00045460058,0.0025760774,0.0018680783,0.00019755465,0.000002470618,0.000048569847,0.00003180395,0.0000058137093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537253,0.00053717336,0.0028408195,0.0003455983,0.0005825777,0.00032127905],"domain_scores_gemma":[0.9963589,0.00040274826,0.0021642775,0.00022991996,0.0004924803,0.00035170186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018625398,0.00023431341,0.0020202254,0.00028478695,0.00003398424,0.000009860604,0.00025324957,0.0003030848,0.00012024775],"category_scores_gemma":[0.0004392693,0.00016049494,0.00019065606,0.0006065601,0.00036822917,0.0004562353,0.000035572208,0.0009437485,0.0000015820464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09915411,0.00626145,0.83469456,0.00006314899,0.00020848126,0.0003950234,0.00035647527,0.00022590924,0.0028822355,0.000027436978,0.0000491774,0.055681966],"study_design_scores_gemma":[0.05176545,0.06359151,0.88179845,0.00040885512,0.00009462852,0.000054650176,0.00026962388,0.0005229708,0.00041502382,0.00003397115,0.00087150204,0.00017339834],"about_ca_topic_score_codex":0.00006040089,"about_ca_topic_score_gemma":0.00017080877,"teacher_disagreement_score":0.057330057,"about_ca_system_score_codex":0.00018362651,"about_ca_system_score_gemma":0.0013463392,"threshold_uncertainty_score":0.6544794},"labels":[],"label_agreement":null},{"id":"W3028866718","doi":"10.1200/jco.2020.38.29_suppl.159","title":"Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Activities of daily living; Depression (economics); Perioperative; Comorbidity; Geriatric oncology; Cancer; Physical therapy; Geriatric Depression Scale; Internal medicine; Surgery; Anxiety; Depressive symptoms; Psychiatry","score_opus":0.09772491008913638,"score_gpt":0.41734124276765056,"score_spread":0.3196163326785142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028866718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9425259,0.00016825942,0.00022021984,0.05566709,0.0006136885,0.0003103688,0.0000024280153,0.000021787286,0.00047023004],"genre_scores_gemma":[0.9839467,0.00017777891,0.0057649706,0.009381699,0.00060638087,0.000008400019,0.0000027370809,0.000031793137,0.00007954234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949604,0.0002926992,0.0034605055,0.000311656,0.00059264246,0.00038207573],"domain_scores_gemma":[0.9896733,0.0061472706,0.0026706397,0.0001864385,0.00061733334,0.0007049973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011490706,0.00021617727,0.00204412,0.00014525342,0.000024002826,0.000009880089,0.00012437213,0.00019694233,0.00030113183],"category_scores_gemma":[0.019410605,0.00014259756,0.00042748376,0.0003044283,0.0001798703,0.00015744264,0.000054472344,0.001454649,0.0000129596465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007526939,0.0010934859,0.9321721,0.0001244566,0.00020387046,0.007213803,0.00039989423,0.00006166304,0.000019481216,0.0000031435109,0.005648454,0.04553268],"study_design_scores_gemma":[0.015123449,0.010282224,0.9667996,0.0024089108,0.00021826931,0.0024698942,0.0005688663,0.00018463115,0.000029312929,0.000015305006,0.0017529731,0.00014651868],"about_ca_topic_score_codex":0.00009778119,"about_ca_topic_score_gemma":0.0008038318,"teacher_disagreement_score":0.04628539,"about_ca_system_score_codex":0.00019914418,"about_ca_system_score_gemma":0.00434633,"threshold_uncertainty_score":0.98884934},"labels":[],"label_agreement":null},{"id":"W3028871862","doi":"10.1200/jco.2020.38.15_suppl.6046","title":"Long-term survival outcomes of intravenous versus intraperitoneal chemotherapy in the treatment of advanced ovarian cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ovarian cancer; Chemotherapy; Internal medicine; Serous fluid; Proportional hazards model; Oncology; Surgery; Stage (stratigraphy); Survival analysis; Cancer; Cohort","score_opus":0.14716336983891576,"score_gpt":0.47697489983103486,"score_spread":0.3298115299921191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028871862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453387,0.0012390831,0.000013544905,0.051423613,0.0012029536,0.0003300519,0.00001119668,0.0000029068567,0.00043794228],"genre_scores_gemma":[0.98413247,0.013062585,0.00065227906,0.001354263,0.00076080085,0.000013836799,0.0000022391034,0.000013227099,0.000008276011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720037,0.00027549695,0.0018604399,0.00016618651,0.00032034572,0.00017715443],"domain_scores_gemma":[0.9962297,0.0019626564,0.0012683659,0.00018570747,0.00016460543,0.00018897247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060593593,0.00015568969,0.0019946916,0.000053936852,0.000014525396,0.0000033835154,0.0001719188,0.00018503018,0.00017877635],"category_scores_gemma":[0.00030710647,0.000086023065,0.00052926305,0.00016789442,0.00017740135,0.00004128905,0.000008486731,0.00030239995,0.0000013343431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015863586,0.007022064,0.50033844,0.000033526747,0.0012926543,0.0004913142,0.0015694544,0.000030309335,0.000098496974,0.00009609955,0.00004727585,0.47311682],"study_design_scores_gemma":[0.03960419,0.05479785,0.89957356,0.00005656423,0.00052887545,0.00001935361,0.00028262872,0.0000066366156,0.0005237375,0.00001768371,0.0045299064,0.00005903703],"about_ca_topic_score_codex":0.00011250384,"about_ca_topic_score_gemma":0.00027450212,"teacher_disagreement_score":0.47305778,"about_ca_system_score_codex":0.0002254054,"about_ca_system_score_gemma":0.001052717,"threshold_uncertainty_score":0.35079187},"labels":[],"label_agreement":null},{"id":"W3028878399","doi":"10.1200/jco.2020.38.15_suppl.12106","title":"Safety and effectiveness of medical cannabis as a complementary option for supportive cancer care: Results from the Cannabis Pilot Project.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Nausea; Adverse effect; Referral; Cancer; Cannabis; Internal medicine; Depression (economics); Medical cannabis; Colorectal cancer; Breast cancer; Physical therapy; Emergency medicine; Family medicine; Psychiatry","score_opus":0.14204093517284863,"score_gpt":0.509264451496784,"score_spread":0.36722351632393535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028878399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61601937,0.0011797913,0.00022817584,0.37988132,0.0005792295,0.0012951989,0.0005922247,0.000006196906,0.0002184923],"genre_scores_gemma":[0.9879571,0.002109837,0.0003109384,0.007073712,0.0022120073,0.00007142363,0.00008697817,0.000027518452,0.0001504736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948668,0.0011354379,0.0023398872,0.00033125104,0.0010294359,0.00029720092],"domain_scores_gemma":[0.9950275,0.0015759846,0.0012775062,0.00018007413,0.0013094567,0.00062946766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0064866785,0.0001651555,0.0015031886,0.00006134316,0.000086113076,0.000011358041,0.00030734634,0.00028430458,0.00016172526],"category_scores_gemma":[0.012008183,0.00009862086,0.00038316104,0.00020587313,0.0005695009,0.000070829636,0.00016642181,0.0010887629,0.0000010315106],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3057086,0.0015188374,0.033125866,0.00082976086,0.0019198832,0.00054139766,0.004840483,0.000028524124,0.0010014067,0.0005195729,0.44316176,0.20680392],"study_design_scores_gemma":[0.03146547,0.042952362,0.34752122,0.00039708,0.0006168785,0.00009750258,0.0029444995,0.00030907764,0.00056221976,0.00015470217,0.572846,0.00013302962],"about_ca_topic_score_codex":0.010649975,"about_ca_topic_score_gemma":0.002195178,"teacher_disagreement_score":0.37280762,"about_ca_system_score_codex":0.00027366274,"about_ca_system_score_gemma":0.008922791,"threshold_uncertainty_score":0.9966957},"labels":[],"label_agreement":null},{"id":"W3028882299","doi":"10.1200/jco.2020.38.15_suppl.8031","title":"Outcome of elderly patients with classical Hodgkin lymphoma (HL) in British Columbia.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; ABVD; Stage (stratigraphy); Internal medicine; Radiation therapy; Classical Hodgkin lymphoma; Cancer; Gastroenterology; Chemotherapy; Lymphoma; Hodgkin lymphoma; Oncology; Surgery; Pediatrics; Cyclophosphamide; Vincristine","score_opus":0.08608074583885651,"score_gpt":0.39859358734111694,"score_spread":0.31251284150226044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028882299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921875,0.00012588972,0.000009805016,0.0063782553,0.0002905133,0.00022813563,0.000009443922,0.000005621462,0.0007648376],"genre_scores_gemma":[0.9942475,0.00011665019,0.0017779515,0.0034550957,0.0003158109,0.000004325371,0.0000037011582,0.000014618129,0.000064375876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638224,0.00024509156,0.0025208679,0.00019803866,0.00045145236,0.00020229963],"domain_scores_gemma":[0.99660754,0.0011712603,0.0012560408,0.00011955032,0.00036192758,0.00048368727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000667989,0.00009640623,0.0018202806,0.00003993192,0.000016984684,0.000017312288,0.00012975284,0.00029327237,0.00015937755],"category_scores_gemma":[0.0022431891,0.000089557456,0.00037685168,0.00017744502,0.00019076365,0.00008038723,0.00004254886,0.00033036526,0.000010377593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013784117,0.0058313143,0.75511444,0.00002416532,0.00019564187,0.001649123,0.000030298248,0.0000015445283,0.0000011726678,0.00000549751,0.0037472718,0.23202112],"study_design_scores_gemma":[0.036251213,0.037226535,0.909396,0.00014557898,0.00026398047,0.00012227522,0.00004794597,0.000016381218,0.0000048428506,0.000030942207,0.016421108,0.000073227166],"about_ca_topic_score_codex":0.0007182777,"about_ca_topic_score_gemma":0.0056784083,"teacher_disagreement_score":0.23194788,"about_ca_system_score_codex":0.00019560991,"about_ca_system_score_gemma":0.0009689255,"threshold_uncertainty_score":0.3652047},"labels":[],"label_agreement":null},{"id":"W3028893532","doi":"10.1200/jco.2020.38.15_suppl.10543","title":"Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Progressive disease; Bone marrow; Surgery; Gastroenterology; Chemotherapy","score_opus":0.17974337981411284,"score_gpt":0.47391773556725125,"score_spread":0.29417435575313844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028893532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863674,0.0003581182,0.00085624104,0.010753995,0.0008661333,0.0006102137,0.00004117141,0.000017128494,0.00012960672],"genre_scores_gemma":[0.9845775,0.0025506837,0.008256024,0.0010338405,0.0032840024,0.0000074843238,0.000028713062,0.00004111152,0.00022064336],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99593854,0.00051019655,0.0022932044,0.00036510066,0.0005314596,0.0003614738],"domain_scores_gemma":[0.99417984,0.0020041594,0.0019678029,0.00023605721,0.0005017343,0.0011104224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006301516,0.0002503992,0.0019358465,0.00016366571,0.00006927327,0.000013059848,0.00016852251,0.00033429786,0.00015475393],"category_scores_gemma":[0.0032250194,0.00017435226,0.00091526663,0.00018651264,0.00017136824,0.00016462358,0.000041765503,0.0005067035,0.000034990575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06650243,0.023204975,0.12097128,0.00018565069,0.004771921,0.0061716656,0.00046225052,0.00042535967,0.12600152,0.000302714,0.042436104,0.60856414],"study_design_scores_gemma":[0.08349198,0.4305704,0.3628885,0.00009813421,0.002005751,0.00064149854,0.000058535385,0.0031203625,0.017122917,0.00035755674,0.0993656,0.00027877997],"about_ca_topic_score_codex":0.000057487552,"about_ca_topic_score_gemma":0.000021757134,"teacher_disagreement_score":0.60828537,"about_ca_system_score_codex":0.00016819761,"about_ca_system_score_gemma":0.0026803128,"threshold_uncertainty_score":0.71098787},"labels":[],"label_agreement":null},{"id":"W3028905201","doi":"10.1200/jco.2020.38.15_suppl.8015","title":"Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Medicine; Lenalidomide; Bendamustine; Internal medicine; Chronic lymphocytic leukemia; Hazard ratio; Progression-free survival; Gastroenterology; Rituximab; Oncology; Leukemia; Multiple myeloma; Overall survival; Confidence interval; Lymphoma","score_opus":0.27551387914436715,"score_gpt":0.48009032939852325,"score_spread":0.2045764502541561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028905201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95404404,0.0049558887,0.00030660068,0.020189682,0.0054254658,0.0015667343,0.000112100926,0.00016808865,0.013231369],"genre_scores_gemma":[0.97936887,0.0038086034,0.0028601498,0.004361996,0.0077725225,0.000026440146,0.000053674376,0.00015804594,0.0015896913],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98423696,0.0014121274,0.0088167135,0.0013131805,0.0024509302,0.0017700834],"domain_scores_gemma":[0.9779923,0.013581104,0.0037296175,0.0010358606,0.0011075846,0.0025535522],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007824249,0.00079571485,0.005623849,0.00058520865,0.00016188847,0.000065637985,0.0014206691,0.002151517,0.0012047909],"category_scores_gemma":[0.05309672,0.00061083265,0.0013606737,0.0013982719,0.0013248132,0.00044924713,0.0007183953,0.0068529607,0.0006985156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6664007,0.00388743,0.00026184812,0.0012419767,0.0019101133,0.06312366,0.0012527201,0.007606831,0.00053414464,0.00031736397,0.14926651,0.10419674],"study_design_scores_gemma":[0.6372179,0.051143706,0.0018870115,0.0008954628,0.0009104201,0.0032550264,0.00046332742,0.09245481,0.00018353501,0.00008706217,0.21086143,0.000640335],"about_ca_topic_score_codex":0.0008658443,"about_ca_topic_score_gemma":0.0006628822,"teacher_disagreement_score":0.1397502,"about_ca_system_score_codex":0.1620735,"about_ca_system_score_gemma":0.30182368,"threshold_uncertainty_score":0.99970824},"labels":[],"label_agreement":null},{"id":"W3028917365","doi":"10.1200/jco.2020.38.15_suppl.12068","title":"Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Queen's University","funders":"","keywords":"Medicine; Cohort; Life expectancy; Internal medicine; Population; Microsimulation; Cohort study; Pediatrics; Oncology; Environmental health","score_opus":0.12919196518976547,"score_gpt":0.4714911534300442,"score_spread":0.3422991882402787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028917365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856827,0.0006201604,0.00005307339,0.011631864,0.00037361565,0.0014996028,0.00010752953,0.0000057022694,0.000025737301],"genre_scores_gemma":[0.995133,0.0001358565,0.00039003562,0.0024064716,0.0018419578,0.0000387917,0.0000317194,0.000017169428,0.00000501171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968291,0.0004269344,0.0017855674,0.00027244253,0.0005494552,0.00013649189],"domain_scores_gemma":[0.9930978,0.0049705547,0.0010454864,0.0001637153,0.00038929103,0.00033319992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013318395,0.00015866855,0.0011293527,0.00006877711,0.000038530205,0.000021874843,0.00022279355,0.00012729998,0.000048542173],"category_scores_gemma":[0.004062113,0.00009996123,0.00024730637,0.000100355195,0.0000984401,0.00007472175,0.00008579859,0.00019906294,0.000001452778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009401998,0.0073904116,0.9152268,0.000011487511,0.00152723,0.00037057372,0.005298017,0.00055270345,0.0000013984292,0.0000045566676,0.00050180027,0.05971301],"study_design_scores_gemma":[0.040622342,0.013311543,0.9352012,0.00006118821,0.001281305,0.0000051568754,0.0048470357,0.0019515204,0.0000029418243,0.00004857857,0.0025907576,0.00007638508],"about_ca_topic_score_codex":0.00024200273,"about_ca_topic_score_gemma":0.000106800486,"teacher_disagreement_score":0.059636623,"about_ca_system_score_codex":0.00017209158,"about_ca_system_score_gemma":0.00084070594,"threshold_uncertainty_score":0.48630223},"labels":[],"label_agreement":null},{"id":"W3028923172","doi":"10.1200/jco.2020.38.15_suppl.e14024","title":"Clinical trials navigator: Patient-centered access to clinical trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Windsor Regional Hospital","funders":"","keywords":"Medicine; Clinical trial; Referral; Population; Patient recruitment; Family medicine; Internal medicine","score_opus":0.9503050203019292,"score_gpt":0.7966922987611793,"score_spread":0.1536127215407499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028923172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60740525,0.00080294587,0.002046287,0.36170733,0.0202767,0.0026924578,0.00006263464,0.00008143256,0.0049249884],"genre_scores_gemma":[0.7693078,0.009777177,0.014979922,0.17139745,0.034068074,0.000026491845,0.000012920568,0.000121448604,0.00030872077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7905257,0.10610721,0.09300336,0.00246057,0.0061249803,0.0017781913],"domain_scores_gemma":[0.06005746,0.88315356,0.030552033,0.0021060484,0.008232151,0.015898772],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.47553405,0.0005243257,0.016748857,0.00027718872,0.000121234756,0.00015220477,0.0023241346,0.004948038,0.0017386165],"category_scores_gemma":[0.94623864,0.00034904096,0.009247749,0.0008042608,0.0014317582,0.00038408916,0.0014925065,0.022236517,0.00076721056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055537775,0.0059132604,0.21717376,0.00012804638,0.0020129129,0.0019017902,0.00012336345,0.0000060477287,0.00004874829,0.00036103834,0.158996,0.55779725],"study_design_scores_gemma":[0.045093216,0.1089503,0.11093077,0.0010020077,0.00222166,0.00017954723,0.00030936158,0.00023775951,0.00009878051,0.0052515483,0.72524035,0.0004846995],"about_ca_topic_score_codex":0.000014269546,"about_ca_topic_score_gemma":0.000038346316,"teacher_disagreement_score":0.7770463,"about_ca_system_score_codex":0.00023063182,"about_ca_system_score_gemma":0.014014586,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null},{"id":"W3028940670","doi":"10.1200/jco.2020.38.15_suppl.6530","title":"Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Population; Proportional hazards model; Head and neck cancer; Progression-free survival; Chemotherapy; Radiation therapy; Gastroenterology; Nuclear medicine; Confidence interval","score_opus":0.21737407627464134,"score_gpt":0.4607708518681814,"score_spread":0.24339677559354006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028940670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638878,0.010508973,0.0003571279,0.023937847,0.0005164717,0.0005169525,0.00011610818,0.000011017219,0.00014771253],"genre_scores_gemma":[0.9805601,0.013545133,0.0011078325,0.0040397677,0.00047206893,0.000014894597,0.00001661658,0.00003412122,0.00020943124],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99623144,0.000254956,0.0023613223,0.00037515574,0.00043140238,0.00034573567],"domain_scores_gemma":[0.9928852,0.003914828,0.0015343344,0.00021646515,0.00051053264,0.00093865703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009015159,0.00027455878,0.003011046,0.00017278113,0.0000727716,0.000010239933,0.00018087993,0.00015411824,0.00027187692],"category_scores_gemma":[0.0027786745,0.00018266532,0.00091134454,0.0004708393,0.0002483005,0.000082827835,0.00004049054,0.00052854815,0.0000028006714],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6893335,0.0065125586,0.06371742,0.0006014438,0.0043200697,0.00053800095,0.0016352519,0.00008784506,0.0003680146,0.000010556943,0.026078751,0.20679657],"study_design_scores_gemma":[0.21783473,0.30251837,0.19065434,0.00014285101,0.009046951,0.000030306079,0.00041150305,0.006604438,0.0004057226,0.00016046032,0.27167156,0.0005187831],"about_ca_topic_score_codex":0.00004741278,"about_ca_topic_score_gemma":0.00016566887,"teacher_disagreement_score":0.4714988,"about_ca_system_score_codex":0.00011058234,"about_ca_system_score_gemma":0.0013964325,"threshold_uncertainty_score":0.74488753},"labels":[],"label_agreement":null},{"id":"W3028941164","doi":"10.1200/jco.2020.38.15_suppl.5530","title":"Clinical analysis of the extracellular vesicle-fingerprint score blood test to refine the prediction of clinically significant prostate cancer and avoid prostate biopsy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary; University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Medicine; Prostate cancer; Prostate; Rectal examination; Prostate biopsy; Biopsy; Urology; Prostatectomy; Prostate-specific antigen; PCA3; Cohort; Logistic regression; Internal medicine; Oncology; Cancer; Radiology","score_opus":0.14463887982751197,"score_gpt":0.449583885061469,"score_spread":0.30494500523395707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028941164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359067,0.0012051167,0.000051574727,0.061324384,0.00042378786,0.0008535993,0.00011982258,0.000008410453,0.00010660607],"genre_scores_gemma":[0.99003863,0.0067611304,0.0008716465,0.0013473933,0.00065295165,0.000020423586,0.000005207504,0.000021829592,0.0002807814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924409,0.0007953398,0.0053099096,0.00041159443,0.00073120464,0.0003110891],"domain_scores_gemma":[0.98999935,0.004552922,0.0032957594,0.000433202,0.0010810266,0.00063776004],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071346364,0.000200028,0.002121686,0.00014884523,0.00008080109,0.000013375093,0.0003845782,0.00031528148,0.00005986901],"category_scores_gemma":[0.01119058,0.00009531259,0.0009882745,0.0010886586,0.0010625399,0.000065735025,0.00024075866,0.0015533566,0.0000021714225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009276122,0.0021002323,0.93010396,0.00011704234,0.0032917054,0.00015683376,0.00055770716,0.00013225757,0.0108504575,0.000021612024,0.0006351269,0.04275696],"study_design_scores_gemma":[0.0079251025,0.023094418,0.9527167,0.00031505548,0.0070878854,0.000034900975,0.00027561217,0.0010845616,0.0016608879,0.00006396808,0.0056424607,0.000098412514],"about_ca_topic_score_codex":0.000054425545,"about_ca_topic_score_gemma":0.000021573376,"teacher_disagreement_score":0.05997699,"about_ca_system_score_codex":0.000069955335,"about_ca_system_score_gemma":0.0021412354,"threshold_uncertainty_score":0.99713856},"labels":[],"label_agreement":null},{"id":"W3028944537","doi":"10.1200/jco.2020.38.15_suppl.e18010","title":"Effect of the oral CXCR4 inhibitor X4-136 on tumor control and side effects in cervical cancer treated with radiotherapy and concurrent chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute","keywords":"Medicine; Cervical cancer; Toxicity; Cisplatin; Chemotherapy; CXCR4; Radiation therapy; Cancer; Internal medicine; Oncology; Receptor; Chemokine","score_opus":0.018174601825117813,"score_gpt":0.35786573876858707,"score_spread":0.33969113694346925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028944537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465734,0.0017931474,0.000059355345,0.0029475011,0.00016586922,0.00031779,0.000009768817,0.0000014502274,0.00004780184],"genre_scores_gemma":[0.99531734,0.0006440061,0.00009960585,0.0033748723,0.0005345438,0.000008194556,0.0000010798578,0.000014856855,0.000005487458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814814,0.0006734624,0.000683406,0.0002259697,0.00011616411,0.00015283703],"domain_scores_gemma":[0.9982872,0.0007186697,0.00063792267,0.00009861922,0.00008060214,0.0001769725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006031128,0.00016372013,0.0009170823,0.000020809894,0.000018601408,0.0000067474057,0.00014029419,0.00019557787,0.0000038747326],"category_scores_gemma":[0.00057207997,0.00009015155,0.00015106809,0.000055658227,0.00035668354,0.0000043209743,0.00003320226,0.0004236127,1.5740416e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028546212,0.0005349822,0.39632544,0.00018689639,0.0006085391,0.000053825654,0.00013377941,0.0000797259,0.44971234,0.000015473333,0.0005727498,0.12323005],"study_design_scores_gemma":[0.051829442,0.061311845,0.42999837,0.00024420308,0.00024135306,0.00005720189,0.000028581984,0.00035729381,0.4461873,0.000028290806,0.009429897,0.0002862327],"about_ca_topic_score_codex":0.000016331267,"about_ca_topic_score_gemma":0.000039957344,"teacher_disagreement_score":0.12294382,"about_ca_system_score_codex":0.000026203219,"about_ca_system_score_gemma":0.00019796475,"threshold_uncertainty_score":0.36762738},"labels":[],"label_agreement":null},{"id":"W3028956426","doi":"10.1200/jco.2020.38.15_suppl.5063","title":"Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Sunnybrook Hospital; Foothills Medical Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Dalhousie University; University Health Network; Queen's University; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Axitinib; Ipilimumab; Renal cell carcinoma; Pazopanib; Sunitinib; Internal medicine; Everolimus; Oncology; Pembrolizumab; Clinical endpoint; Discontinuation; Cancer; Immunotherapy; Clinical trial","score_opus":0.14365032802286906,"score_gpt":0.4643076875995076,"score_spread":0.32065735957663855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028956426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98413956,0.0021695876,0.00036853744,0.012365246,0.00022543728,0.00047964786,0.000030653006,0.0000049417204,0.00021636485],"genre_scores_gemma":[0.9894409,0.001084561,0.007211288,0.0017554356,0.00035877514,0.0000048139377,0.000030217687,0.000024104205,0.00008987608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928831,0.0005940237,0.005498974,0.00039550802,0.00035988988,0.00026849937],"domain_scores_gemma":[0.9920702,0.0033390967,0.003191374,0.0002990902,0.0004324587,0.0006677536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034967645,0.00026572167,0.00339719,0.000117624,0.000025862571,0.000009555771,0.00018933126,0.00038929866,0.00025623493],"category_scores_gemma":[0.0021092824,0.00018342267,0.0005047966,0.00024503138,0.00045835413,0.00012767164,0.00014055856,0.00095700775,0.00000226638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010926026,0.0023573758,0.9172587,0.0003603076,0.0006788218,0.0004866802,0.0010087256,0.000022254175,0.0024144966,0.000024672017,0.001669211,0.062792726],"study_design_scores_gemma":[0.023681186,0.019651817,0.9452549,0.00006559103,0.00068296393,0.00015177834,0.00027953685,0.0009154054,0.001322031,0.00031194955,0.007543109,0.0001397199],"about_ca_topic_score_codex":0.0001605638,"about_ca_topic_score_gemma":0.0002908426,"teacher_disagreement_score":0.062653005,"about_ca_system_score_codex":0.00005490697,"about_ca_system_score_gemma":0.00073024747,"threshold_uncertainty_score":0.74797595},"labels":[],"label_agreement":null},{"id":"W3028959889","doi":"10.1200/jco.2020.38.15_suppl.e19050","title":"A qualitative study of barriers and facilitators to enrollment of adolescents and young adults onto cancer clinical trials at NCI community oncology research program (NCORP) sites.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Thematic analysis; Family medicine; Stakeholder; Clinical trial; Qualitative research; Prioritization; Young adult; Nursing; Gerontology; Internal medicine; Public relations","score_opus":0.6007170558496081,"score_gpt":0.6761741497957036,"score_spread":0.07545709394609545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028959889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97946566,0.0008947006,0.000010673094,0.016072186,0.0007122264,0.0026402962,0.00007007535,0.000012731468,0.00012142965],"genre_scores_gemma":[0.9941024,0.0009678981,0.0013240385,0.0028306295,0.00066488655,0.000053657877,0.0000030780177,0.000025260399,0.000028110175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.93791986,0.04937999,0.010101117,0.0005400843,0.0015659867,0.00049296353],"domain_scores_gemma":[0.9612025,0.028912496,0.0047723283,0.0004527821,0.002154301,0.0025055788],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09489986,0.00028016203,0.0059681297,0.00024341223,0.00014804055,0.000010362254,0.00042682895,0.00063345797,0.00008253534],"category_scores_gemma":[0.11810486,0.00021548956,0.00060117635,0.0004443118,0.0014228312,0.000107138636,0.0006738425,0.0034520333,0.0000030048595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076885186,0.009227933,0.62192243,0.000578465,0.0015224238,0.00008750985,0.19001682,0.0000027053704,0.0001313459,0.000007111485,0.0048329877,0.0947851],"study_design_scores_gemma":[0.039705116,0.2129651,0.4807477,0.00081501406,0.0006982747,0.000030279816,0.25609842,0.000028298355,0.000049153157,0.000078717596,0.008596819,0.00018709975],"about_ca_topic_score_codex":0.0027639037,"about_ca_topic_score_gemma":0.013165556,"teacher_disagreement_score":0.20373717,"about_ca_system_score_codex":0.0004860771,"about_ca_system_score_gemma":0.0032185595,"threshold_uncertainty_score":0.99884707},"labels":[],"label_agreement":null},{"id":"W3028971888","doi":"10.1200/jco.2020.38.15_suppl.10023","title":"Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Vemurafenib; Internal medicine; Gastroenterology; Magnetic resonance imaging; Placebo; Nuclear medicine; Pathology; Metastatic melanoma; Cancer; Radiology","score_opus":0.06613375915990369,"score_gpt":0.37508031753054516,"score_spread":0.30894655837064144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028971888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945909,0.00009291088,0.0002960927,0.0026897723,0.00019900389,0.0009468795,0.000025986536,0.000010480651,0.001147983],"genre_scores_gemma":[0.99553907,0.000019322111,0.00093413785,0.0025249736,0.00075276376,0.000026689813,0.000017107102,0.000029280814,0.00015667816],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9957251,0.0014181547,0.0016404723,0.0003934984,0.00040678086,0.00041602438],"domain_scores_gemma":[0.9972919,0.0005967243,0.001046261,0.00033500165,0.0002262995,0.0005038169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021983187,0.00027283328,0.0013323177,0.00006428405,0.00007013124,0.00003043246,0.00064540136,0.00022189657,0.0000865854],"category_scores_gemma":[0.0008133791,0.00013571278,0.00021503819,0.0002807195,0.00015829652,0.000010317542,0.00011535339,0.0005528104,0.000034314253],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80411345,0.015780346,0.008900712,0.00019428252,0.003742231,0.020221652,0.0031248236,0.0019085709,0.01842019,0.00016010205,0.04571931,0.077714354],"study_design_scores_gemma":[0.14747831,0.5704144,0.013238982,0.00021109593,0.0015186492,0.0025394687,0.008180088,0.00054812373,0.004050496,0.0000050481904,0.25093666,0.00087865285],"about_ca_topic_score_codex":0.000016782691,"about_ca_topic_score_gemma":0.00013676888,"teacher_disagreement_score":0.6566351,"about_ca_system_score_codex":0.00004288518,"about_ca_system_score_gemma":0.0011439666,"threshold_uncertainty_score":0.55342066},"labels":[],"label_agreement":null},{"id":"W3028973751","doi":"10.1200/jco.2020.38.15_suppl.10512","title":"Temsirolimus combined with etoposide and cyclophosphamide for relapsed/refractory acute lymphoblastic leukemia: Therapeutic advances in Childhood Leukemia Consortium (TACL 2014-001) trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; BC Children's Hospital; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Temsirolimus; Etoposide; Gastroenterology; Mucositis; Febrile neutropenia; Leukopenia; Neutropenia; Toxicity; Chemotherapy; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.040686386837969254,"score_gpt":0.3813894030200393,"score_spread":0.34070301618207005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028973751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979617,0.0052046515,0.001088942,0.009784109,0.0011168424,0.002035387,0.000021808624,0.000044982437,0.0010862965],"genre_scores_gemma":[0.9750607,0.011166622,0.002994779,0.008920974,0.0014875031,0.00006539477,0.000013648315,0.00009128251,0.00019908571],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936877,0.00060020783,0.0035493535,0.00062502513,0.00080297,0.0007347312],"domain_scores_gemma":[0.9849609,0.010793897,0.0022039667,0.00033753138,0.00056780595,0.0011358805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026278943,0.00043441405,0.0031441057,0.00024637222,0.00009535558,0.000031590545,0.00041545558,0.000849437,0.00007239717],"category_scores_gemma":[0.0059458064,0.0002938113,0.0004282936,0.0003504579,0.00079091464,0.00040516965,0.00012924818,0.0021103432,0.000026772766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8537733,0.0035093296,0.017882733,0.00038595576,0.0023115904,0.004756823,0.0004964463,0.00043624197,0.0006884173,0.00038419652,0.009815965,0.105559014],"study_design_scores_gemma":[0.64329493,0.17463219,0.05784598,0.0004708646,0.0021460168,0.0018379589,0.00036399727,0.0035319247,0.00026192973,0.0009989499,0.114052646,0.0005626139],"about_ca_topic_score_codex":0.000023894141,"about_ca_topic_score_gemma":0.000046688325,"teacher_disagreement_score":0.21047835,"about_ca_system_score_codex":0.002088913,"about_ca_system_score_gemma":0.015574262,"threshold_uncertainty_score":0.9999514},"labels":[],"label_agreement":null},{"id":"W3028983586","doi":"10.1200/jco.2021.39.3_suppl.tps148","title":"Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Oncology; Internal medicine; FOLFOX; Colorectal cancer; Clinical endpoint; Chemotherapy; Adjuvant; Oxaliplatin; Stage (stratigraphy); Prospective cohort study; Biomarker; Cancer; Clinical trial","score_opus":0.03798842570987553,"score_gpt":0.4069943381514742,"score_spread":0.36900591244159864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028983586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982186,0.00046573777,0.000033469358,0.00029613014,0.0003895799,0.000357906,0.000041462587,0.0000013115194,0.00019577834],"genre_scores_gemma":[0.99839246,0.00040939587,0.00019305904,0.0007280196,0.00018120631,0.0000140897155,0.000014366508,0.000020138537,0.000047263067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724996,0.00027870358,0.0016932253,0.0003100821,0.00023695508,0.00023106502],"domain_scores_gemma":[0.9974727,0.0002876435,0.001444924,0.00020245301,0.00044763234,0.00014466695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000999484,0.00015823229,0.00094156154,0.000091000846,0.00004300697,0.0000065388335,0.00017861284,0.00021579176,0.000053314354],"category_scores_gemma":[0.001076349,0.00013224776,0.00014657591,0.00019590853,0.00010926343,0.000009378469,0.00016343435,0.000369567,2.1989274e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038888857,0.046087872,0.8311314,0.00002853653,0.0007727037,0.000710248,0.0012205903,0.0012348644,0.022593694,0.000012759622,0.0005578632,0.056760598],"study_design_scores_gemma":[0.11040333,0.13050675,0.7427291,0.00017209188,0.00014921649,0.000023107337,0.0013795001,0.00030035427,0.0056191776,0.0000489523,0.008378772,0.00028963442],"about_ca_topic_score_codex":0.00019674675,"about_ca_topic_score_gemma":0.0024076495,"teacher_disagreement_score":0.08840231,"about_ca_system_score_codex":0.00013331785,"about_ca_system_score_gemma":0.0021509884,"threshold_uncertainty_score":0.5392907},"labels":[],"label_agreement":null},{"id":"W3029005700","doi":"10.1200/jco.2020.38.15_suppl.5035","title":"Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Atezolizumab; Clinical endpoint; Adverse effect; Internal medicine; Performance status; Post-hoc analysis; Population; Clinical trial; Oncology; Cancer; Surgery; Immunotherapy","score_opus":0.06485087495779752,"score_gpt":0.41273114503154756,"score_spread":0.34788027007375005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029005700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963373,0.0003136368,0.00006489588,0.0011287743,0.00021111089,0.0015983949,0.00006044016,0.0000049510195,0.00028051037],"genre_scores_gemma":[0.9975778,0.00019689856,0.00079506973,0.0012410803,0.00011526579,0.00003376932,0.000004636381,0.000017476756,0.000018040075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967868,0.0003255434,0.0017648154,0.00029009883,0.000532996,0.00029975947],"domain_scores_gemma":[0.9970321,0.00044446407,0.0014422853,0.00020024025,0.00060733483,0.00027359044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060131826,0.00021045073,0.0018538237,0.00009804429,0.000044665663,0.0000058298715,0.00021526837,0.000109426954,0.00003775089],"category_scores_gemma":[0.00043683816,0.000112211106,0.0005437336,0.00080345897,0.0001642018,0.00013886034,0.00003704358,0.0004938259,0.0000012197339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059981655,0.011542939,0.8607129,0.000033879776,0.0025402561,0.00013279487,0.00062653836,0.00038719943,0.0000024120038,0.0000024562992,0.000040566294,0.06399641],"study_design_scores_gemma":[0.0436091,0.14973806,0.80318105,0.000044776807,0.002211782,0.000020636713,0.00045979256,0.0003392282,0.000025322854,0.000024145853,0.00026316018,0.00008291792],"about_ca_topic_score_codex":0.000055920893,"about_ca_topic_score_gemma":0.00007407103,"teacher_disagreement_score":0.13819513,"about_ca_system_score_codex":0.0004051842,"about_ca_system_score_gemma":0.0019872237,"threshold_uncertainty_score":0.4575836},"labels":[],"label_agreement":null},{"id":"W3029006566","doi":"10.1200/jco.2020.38.15_suppl.7525","title":"Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Internal medicine; Complete blood count; Gastroenterology","score_opus":0.05853508805701754,"score_gpt":0.43895443334776163,"score_spread":0.38041934529074406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029006566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98738295,0.00020425692,0.00002828384,0.0076168007,0.00067055476,0.00027174855,0.000007784901,0.000010850955,0.00380678],"genre_scores_gemma":[0.99507856,0.0003688789,0.000351048,0.0028896327,0.0010375968,0.0000028584002,0.000007812659,0.00002933889,0.00023429269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944405,0.0017515661,0.0021998056,0.00030994494,0.00091783,0.00038033054],"domain_scores_gemma":[0.98880863,0.008972018,0.0010487906,0.00026560106,0.0003050688,0.00059988414],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0059802704,0.00020490604,0.0027993422,0.00036792227,0.000024742676,0.000013593138,0.00036297415,0.00050418114,0.00036222144],"category_scores_gemma":[0.012101343,0.00014497619,0.0013337944,0.0006929037,0.00015073172,0.00010724549,0.000091264665,0.0020332036,0.00010387998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04697113,0.0024669648,0.8524117,0.00016575145,0.0077277916,0.018813772,0.0003229916,0.00014933983,0.0018652887,0.00014451267,0.0133997975,0.055560943],"study_design_scores_gemma":[0.04838279,0.087638564,0.83519715,0.00019157991,0.004052178,0.00005989989,0.000032930668,0.0005429983,0.00049057725,0.00003443198,0.02315479,0.00022212412],"about_ca_topic_score_codex":0.0001261939,"about_ca_topic_score_gemma":0.00008439195,"teacher_disagreement_score":0.0851716,"about_ca_system_score_codex":0.00024796659,"about_ca_system_score_gemma":0.0016699719,"threshold_uncertainty_score":0.9962202},"labels":[],"label_agreement":null},{"id":"W3029012201","doi":"10.1200/jco.2020.38.15_suppl.10064","title":"Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Lymph node; Pathological; Ipilimumab; Neoadjuvant therapy; Quality of life (healthcare); Internal medicine; Dissection (medical); Population; Nivolumab; Surgery; Melanoma; Oncology; Cancer; Breast cancer; Immunotherapy","score_opus":0.08097641144874315,"score_gpt":0.3835864344973724,"score_spread":0.3026100230486293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029012201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976502,0.00016264756,0.00013033125,0.02107264,0.0005281397,0.0012071928,0.000027561688,0.000013610761,0.00035590003],"genre_scores_gemma":[0.9969765,0.0001398505,0.000103120816,0.002406531,0.000101688565,0.0000068100744,0.000008785392,0.000019995212,0.00023671752],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927078,0.0011915865,0.0048723123,0.00033846026,0.000644264,0.00024561372],"domain_scores_gemma":[0.9934531,0.0013456346,0.004042444,0.0003217326,0.00033527586,0.00050181814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026753473,0.00020585928,0.002322893,0.00014555681,0.00007289787,0.000008737003,0.00019859552,0.0002712519,0.000033405347],"category_scores_gemma":[0.0028056542,0.00012784978,0.00029140906,0.0004966136,0.00016767265,0.00005899958,0.000100056226,0.00047828324,0.0000014346666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51028216,0.0039145797,0.46445858,0.00014192246,0.0005398359,0.00007034031,0.0008134224,0.00027110835,0.00010747586,0.0000081256085,0.00183304,0.017559381],"study_design_scores_gemma":[0.21850406,0.017088244,0.75873274,0.00030264782,0.00015554119,0.000055040455,0.00052909995,0.00079703506,0.000024058772,0.0000059629606,0.0036813281,0.00012422245],"about_ca_topic_score_codex":0.0011579241,"about_ca_topic_score_gemma":0.0008496109,"teacher_disagreement_score":0.29427418,"about_ca_system_score_codex":0.00032946057,"about_ca_system_score_gemma":0.0010368492,"threshold_uncertainty_score":0.5213563},"labels":[],"label_agreement":null},{"id":"W3029017534","doi":"10.1200/jco.2020.38.15_suppl.10513","title":"Dexrazoxane and heart function among long-term childhood cancer survivors: A Children’s Oncology Group study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health","keywords":"Medicine; Dexrazoxane; Internal medicine; Cancer; Ejection fraction; Randomized controlled trial; Cardiotoxicity; Chemotherapy; Surgery; Heart failure; Anthracycline; Breast cancer","score_opus":0.07712296715451639,"score_gpt":0.42046970875244233,"score_spread":0.34334674159792594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029017534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846538,0.00064438046,0.00022991306,0.01261367,0.0009642478,0.0006147309,0.0000029988405,0.00002501949,0.00025129525],"genre_scores_gemma":[0.9847115,0.0011439621,0.00023760578,0.009790552,0.004051857,0.000011497055,0.0000056369504,0.00002596238,0.000021376216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672496,0.0006525007,0.0016973042,0.00032389746,0.00036247043,0.00023886182],"domain_scores_gemma":[0.9971389,0.00074978685,0.0010848711,0.00014747273,0.00024707714,0.0006318523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020700656,0.00018751787,0.0016981978,0.00009734884,0.00006928949,0.000015356893,0.00010727637,0.0005395908,0.00015880661],"category_scores_gemma":[0.0010492405,0.00014824356,0.00043484446,0.00018657025,0.00021835128,0.00018284131,0.000055558117,0.0014121744,0.00000737559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002559749,0.0023297106,0.8484308,0.000021694015,0.0009168163,0.00018308735,0.00066658657,0.000005479483,0.0027503,0.0000068762806,0.0005516911,0.14157721],"study_design_scores_gemma":[0.011552562,0.03212122,0.9514605,0.00006964746,0.00078991835,0.0005038991,0.00025308417,0.000011997225,0.00034621023,0.000025243093,0.0027425056,0.00012325466],"about_ca_topic_score_codex":0.0001395597,"about_ca_topic_score_gemma":0.0008825425,"teacher_disagreement_score":0.14145395,"about_ca_system_score_codex":0.0001736243,"about_ca_system_score_gemma":0.00077402464,"threshold_uncertainty_score":0.61352736},"labels":[],"label_agreement":null},{"id":"W3029031938","doi":"10.1200/jco.2020.38.15_suppl.10554","title":"<i>HAGHL</i> genetic variants increase first fracture risk (FFR) in female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort Study (SJLIFE).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Genome-wide association study; Single-nucleotide polymorphism; SNP; Proportional hazards model; Minor allele frequency; Cohort; Genetic association; Internal medicine; Oncology; Cancer; Genetics; Genotype; Biology; Gene","score_opus":0.024855361400556573,"score_gpt":0.34467001459183,"score_spread":0.31981465319127345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029031938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98705727,0.0055039907,0.00007018243,0.0049868533,0.00083276373,0.0012351624,0.0002715299,0.000007716699,0.00003453932],"genre_scores_gemma":[0.9846898,0.0069592395,0.00016485184,0.005078584,0.00293671,0.00007114486,0.000025554858,0.00005243828,0.000021718224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99373776,0.0019028493,0.0026329358,0.000804966,0.00051098276,0.00041048316],"domain_scores_gemma":[0.996058,0.0010300131,0.0015639506,0.0005282562,0.00024159283,0.00057820603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031787143,0.00040068605,0.0015530589,0.00004777404,0.00017722601,0.00004812427,0.00059725076,0.00049280986,0.0001947579],"category_scores_gemma":[0.0022326752,0.00027346628,0.00036221812,0.00022050962,0.00016824104,0.000019621184,0.00022394431,0.001448253,0.000004628505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001482414,0.0048205736,0.98418486,0.000005951159,0.0014438629,0.0010944993,0.0017248499,0.000687951,0.00014071351,1.3946831e-7,0.0019680702,0.0024461271],"study_design_scores_gemma":[0.0076034404,0.006672935,0.9722815,0.0000384207,0.00096027635,0.00012031836,0.00088561093,0.000042412034,0.000038935632,0.000014346319,0.01103996,0.0003018434],"about_ca_topic_score_codex":0.026305143,"about_ca_topic_score_gemma":0.0737037,"teacher_disagreement_score":0.04739856,"about_ca_system_score_codex":0.00003905375,"about_ca_system_score_gemma":0.0013324361,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W3029044426","doi":"10.1200/jco.2020.38.15_suppl.5041","title":"Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Discontinuation; Bladder cancer; Cystectomy; Pembrolizumab; Cohort; Internal medicine; Clinical endpoint; Surgery; Cancer; Urology; Clinical trial; Immunotherapy","score_opus":0.06598830685295298,"score_gpt":0.40478647719333694,"score_spread":0.33879817034038395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029044426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924733,0.00083004707,0.00038132988,0.0032044915,0.0012736573,0.0012390782,0.0004369067,0.000008156455,0.0001530078],"genre_scores_gemma":[0.9927674,0.0026091717,0.0012953404,0.0018864154,0.0010791224,0.00005869902,0.000014093209,0.00005628378,0.00023348106],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961078,0.00038766876,0.002096874,0.00036795274,0.00066933536,0.0003703734],"domain_scores_gemma":[0.99140066,0.004237062,0.0025258153,0.0003614814,0.0010137644,0.00046119973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050514605,0.00032951904,0.00224762,0.000113443915,0.000065384425,0.000007527448,0.00026531937,0.00030087357,0.00035418733],"category_scores_gemma":[0.0012987823,0.00018382576,0.0009788495,0.00026007355,0.00038155925,0.00009718894,0.000045721077,0.0004870183,0.0000063411567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17200439,0.0063016573,0.3879206,0.00012361853,0.009972875,0.00031071884,0.0021809,0.0005448474,0.00028092595,0.0000380809,0.00659043,0.41373098],"study_design_scores_gemma":[0.11089004,0.105120115,0.74909174,0.00012277455,0.005074513,0.0000109116045,0.00018166886,0.00007675049,0.00084096123,0.00007033427,0.028340137,0.00018004503],"about_ca_topic_score_codex":0.0009224051,"about_ca_topic_score_gemma":0.00057870185,"teacher_disagreement_score":0.41355094,"about_ca_system_score_codex":0.00032982332,"about_ca_system_score_gemma":0.0030279972,"threshold_uncertainty_score":0.74961966},"labels":[],"label_agreement":null},{"id":"W3029047215","doi":"10.1200/jco.2020.38.15_suppl.2518","title":"Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Western University; Cancer Care Ontario","funders":"National Institutes of Health","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Hazard ratio; Glioma; Chemoradiotherapy; Adjuvant; Proportional hazards model; Radiation therapy; Cancer research; Confidence interval","score_opus":0.04789616551493877,"score_gpt":0.37438235578611945,"score_spread":0.3264861902711807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029047215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98328525,0.00053989136,0.00004410807,0.01554257,0.00011566518,0.0003144621,0.00002040821,0.0000068202917,0.00013081086],"genre_scores_gemma":[0.99736625,0.00080425804,0.00042940702,0.001213357,0.00014455366,0.000005883475,0.00001140025,0.00001716277,0.000007717933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635607,0.0007428846,0.0020024402,0.00027044554,0.00044013956,0.0001880194],"domain_scores_gemma":[0.9937704,0.0019838098,0.003292346,0.00027988513,0.00033040083,0.00034314915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010185024,0.00020088136,0.002470893,0.00030141804,0.000056033496,0.0000049221676,0.00016449226,0.0003683648,0.00004247565],"category_scores_gemma":[0.001733508,0.00010833153,0.00073041674,0.00091182865,0.00033319066,0.000050104307,0.00006421103,0.0005705262,0.0000011143488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062146625,0.0035486403,0.9511438,0.00002756471,0.0076595554,0.0008787706,0.00017679104,0.00040894822,0.002036636,0.00021246653,0.00028004337,0.027412105],"study_design_scores_gemma":[0.015125193,0.037166167,0.92541957,0.00008669477,0.013687388,0.000068864305,0.000037199883,0.00024529293,0.0077226507,0.000050405015,0.00030757944,0.00008302515],"about_ca_topic_score_codex":0.000105858766,"about_ca_topic_score_gemma":0.00014080011,"teacher_disagreement_score":0.033617526,"about_ca_system_score_codex":0.00014106913,"about_ca_system_score_gemma":0.0004494845,"threshold_uncertainty_score":0.44176313},"labels":[],"label_agreement":null},{"id":"W3029082024","doi":"10.1200/jco.2020.38.15_suppl.tps3160","title":"A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Nap; Medicine; Immunotherapy; Antigen; Cancer research; Immune system; Immune checkpoint; Oncology; Immunology; Nivolumab; Biology","score_opus":0.1893348622942087,"score_gpt":0.5145610612842015,"score_spread":0.32522619898999283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029082024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982805,0.000060400936,0.00023956488,0.0069533745,0.00016467298,0.002236377,0.000003598073,0.000010843273,0.0005031246],"genre_scores_gemma":[0.9935327,0.00016735033,0.005210674,0.0006685255,0.00020322873,0.00004019411,0.000014849388,0.00004255354,0.000119928445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932985,0.0016066012,0.003344827,0.00035915303,0.0010045258,0.00038639418],"domain_scores_gemma":[0.99260515,0.0033208816,0.0023331156,0.00021598623,0.0010601493,0.00046473937],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004826554,0.00022786295,0.0027923512,0.00042011766,0.00002772642,0.000020851057,0.0003572533,0.00021997964,0.00030347446],"category_scores_gemma":[0.009433542,0.00014571637,0.00010264098,0.0017376282,0.00028655078,0.0003773423,0.00007573746,0.0017219994,0.0000034525938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85961825,0.024309333,0.0032033292,0.0001295099,0.00034700864,0.0035796387,0.00064329564,0.0001153243,0.009007793,0.000035807218,0.00011312937,0.09889761],"study_design_scores_gemma":[0.6677011,0.31093934,0.013050223,0.00046517866,0.00022139982,0.00040836827,0.00036643067,0.0041934033,0.001745012,0.00009784615,0.00065490714,0.00015676953],"about_ca_topic_score_codex":0.000055503162,"about_ca_topic_score_gemma":0.0007007968,"teacher_disagreement_score":0.28663,"about_ca_system_score_codex":0.00036046383,"about_ca_system_score_gemma":0.006954522,"threshold_uncertainty_score":0.9989104},"labels":[],"label_agreement":null},{"id":"W3029103020","doi":"10.1200/jco.2020.38.15_suppl.6577","title":"Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Mucositis; Internal medicine; Ipilimumab; Oncology; Radiation therapy; Odynophagia; Chemotherapy; Gastroenterology; Cancer; Immunotherapy; Esophagus","score_opus":0.0202377699414593,"score_gpt":0.32398098900909666,"score_spread":0.30374321906763735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029103020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945675,0.0011334193,0.000060475148,0.0035765418,0.00012160815,0.00040258217,0.0000028222512,0.0000027964995,0.00013221495],"genre_scores_gemma":[0.99639577,0.00095993164,0.0012139765,0.0013341578,0.000060492577,0.0000030339538,9.105147e-7,0.000016444079,0.000015272119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775696,0.00045019062,0.0011749971,0.0001896486,0.00027891406,0.00014926978],"domain_scores_gemma":[0.9976764,0.000751693,0.001141889,0.00012184808,0.0001769104,0.00013129345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000875465,0.00013354098,0.0009086561,0.00008610891,0.00002502328,0.000006162864,0.00010758102,0.00019999062,0.000010333109],"category_scores_gemma":[0.00026670654,0.000076432734,0.000086490974,0.00025388284,0.000375013,0.00009634308,0.000023530845,0.0007079266,1.2253093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069810025,0.0013606907,0.81261575,0.000057080208,0.000049812254,0.00006917546,0.0005470875,0.0000443387,0.0001853342,0.0000070620217,0.00006264262,0.115190975],"study_design_scores_gemma":[0.11100111,0.048130125,0.83890337,0.00016828354,0.000069113354,0.0000486562,0.0001627098,0.0002565659,0.00013838305,0.000026492058,0.00101838,0.00007682296],"about_ca_topic_score_codex":0.0001995625,"about_ca_topic_score_gemma":0.0006613524,"teacher_disagreement_score":0.11511415,"about_ca_system_score_codex":0.0001435665,"about_ca_system_score_gemma":0.00071132655,"threshold_uncertainty_score":0.31168365},"labels":[],"label_agreement":null},{"id":"W3029117137","doi":"10.1200/jco.2020.38.15_suppl.6004","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Université de Montréal; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Bevacizumab; Neutropenia; Internal medicine; Adverse effect; Gastroenterology; Ovarian cancer; Nausea; Cancer; Oncology; Surgery; Pharmacology; Chemotherapy","score_opus":0.045248737338270374,"score_gpt":0.3865243554198406,"score_spread":0.3412756180815702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029117137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650293,0.00043365912,0.000084697574,0.03288365,0.00048810273,0.000701974,0.00002027115,0.000013544482,0.00034477326],"genre_scores_gemma":[0.99160206,0.0007804609,0.004370299,0.0027457974,0.000377739,0.000020340101,0.000041685227,0.00004183672,0.000019805067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958568,0.0004582489,0.0023465033,0.0004145048,0.000539207,0.00038469437],"domain_scores_gemma":[0.9956978,0.0012911145,0.0018684895,0.0001525347,0.00054148585,0.00044855478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001285814,0.0002787059,0.0018790897,0.00018230104,0.00004436077,0.000021817721,0.00015191815,0.0002572786,0.00016846841],"category_scores_gemma":[0.0014773699,0.00018867542,0.00017194616,0.00050763245,0.0001344402,0.0002455505,0.000039503524,0.0011756861,0.000013667745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021144312,0.0052403687,0.9250747,0.00008642772,0.00044638128,0.001304005,0.0006963521,0.00025750996,0.000038056995,0.00007195434,0.0014045497,0.04423538],"study_design_scores_gemma":[0.098123915,0.038731758,0.85524476,0.0012452159,0.00044863432,0.00003490555,0.00014524107,0.0006925117,0.00009309555,0.00006833253,0.0049340515,0.0002376135],"about_ca_topic_score_codex":0.0003603386,"about_ca_topic_score_gemma":0.00071435416,"teacher_disagreement_score":0.0769796,"about_ca_system_score_codex":0.0005743287,"about_ca_system_score_gemma":0.0018062876,"threshold_uncertainty_score":0.76939607},"labels":[],"label_agreement":null},{"id":"W3029119723","doi":"10.1200/jco.2020.38.15_suppl.e13526","title":"An analysis of growth in the genetic counseling profession 2009 to 2019.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences North; University Health Network","funders":"","keywords":"Genetic counseling; Accreditation; Medicine; Workforce; Family medicine; Certification; Specialty; Genetic testing; Nursing; Gerontology; Medical education; Internal medicine; Genetics; Political science","score_opus":0.06164890979971008,"score_gpt":0.4574698214270651,"score_spread":0.395820911627355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029119723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871736,0.000526833,0.003504699,0.008310698,0.00027011934,0.000098287834,0.000007631152,9.443957e-7,0.000107151194],"genre_scores_gemma":[0.98638994,0.00046461736,0.005323601,0.00716981,0.00062799104,0.0000028891977,0.000006276272,0.0000066921752,0.000008183537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975806,0.0006514809,0.001285328,0.00016601398,0.00020225282,0.00011433489],"domain_scores_gemma":[0.99837756,0.00024953805,0.00072863593,0.00017070393,0.0003432316,0.00013033955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021130624,0.00007124191,0.0005125007,0.00009585898,0.00001923445,0.0000054400352,0.00042315756,0.00022082406,0.000023229662],"category_scores_gemma":[0.0014513663,0.00004754502,0.00024056234,0.00043477214,0.0000659412,0.000004433585,0.000035956193,0.00029032672,0.0000024645994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070722084,0.0031635554,0.4838598,0.000055996003,0.0030541813,0.00018761474,0.006627114,0.10367037,0.18162575,0.000133518,0.06674453,0.14380535],"study_design_scores_gemma":[0.0034309763,0.020676153,0.8979875,0.000035282028,0.0016339814,0.000033796547,0.0026533266,0.005342058,0.007798457,0.00024116102,0.0598806,0.0002867208],"about_ca_topic_score_codex":0.000014129563,"about_ca_topic_score_gemma":0.00008804626,"teacher_disagreement_score":0.41412768,"about_ca_system_score_codex":0.000025429761,"about_ca_system_score_gemma":0.00075526076,"threshold_uncertainty_score":0.19388297},"labels":[],"label_agreement":null},{"id":"W3029121927","doi":"10.1200/jco.2020.38.15_suppl.e24184","title":"Quality assessment of online hepatocellular carcinoma patient education materials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Readability; Medicine; Grading (engineering); Hepatocellular carcinoma; Online search; Accountability; Quality (philosophy); Internal medicine; World Wide Web","score_opus":0.363279194208377,"score_gpt":0.6331169512850903,"score_spread":0.26983775707671326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029121927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97890615,0.000064631844,0.00080256857,0.01327263,0.003461284,0.00042209149,0.00005282792,0.000008289788,0.0030095046],"genre_scores_gemma":[0.9609761,0.00008584367,0.011325937,0.026258186,0.001283764,0.000007885692,0.000029751604,0.0000069886996,0.000025490735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98361075,0.0044519035,0.011193164,0.00013587577,0.00039172327,0.00021661058],"domain_scores_gemma":[0.9849864,0.0023777266,0.010325946,0.00020902438,0.0015927673,0.0005081001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009847471,0.00010230224,0.0013055963,0.0000623959,0.00010777932,0.0000041783383,0.00024748628,0.00040097832,0.0012660926],"category_scores_gemma":[0.007976466,0.00007230027,0.00021463829,0.00014552494,0.0000819659,0.0004272243,0.00010516236,0.0012900918,0.000025168614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008972649,0.001607238,0.8774782,0.00069648336,0.00003113428,0.000003779099,0.0017543708,0.0000032805399,0.00028571158,0.0010262536,0.006742863,0.10947342],"study_design_scores_gemma":[0.0013986706,0.0024563575,0.8170215,0.00009879714,0.00002575968,0.0000019831618,0.001855238,0.0005900795,0.000090391804,0.0002945393,0.17609653,0.00007016262],"about_ca_topic_score_codex":0.00010756648,"about_ca_topic_score_gemma":0.000008316625,"teacher_disagreement_score":0.16935368,"about_ca_system_score_codex":0.00020288123,"about_ca_system_score_gemma":0.011721124,"threshold_uncertainty_score":0.9996469},"labels":[],"label_agreement":null},{"id":"W3029122368","doi":"10.1200/jco.2020.38.15_suppl.e19321","title":"MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Everolimus; Oncology; Renal cell carcinoma; Papillary renal cell carcinomas","score_opus":0.20701632385355448,"score_gpt":0.4314200899178646,"score_spread":0.22440376606431015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029122368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887137,0.003305546,0.000031357147,0.0069437777,0.00021469679,0.00020646042,0.000029796656,0.000004904908,0.0005498011],"genre_scores_gemma":[0.99303705,0.0014446817,0.0041951328,0.00087376626,0.00026304592,0.000002283799,0.000033755463,0.000015639023,0.00013465603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952122,0.00061695074,0.0030368853,0.00038650748,0.00046525744,0.00028217846],"domain_scores_gemma":[0.99458724,0.0023043351,0.0016614274,0.00043001815,0.00019829955,0.00081865746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00125367,0.00022491952,0.003749929,0.00038914557,0.00001741034,0.0000051082748,0.00020362777,0.00028966521,0.00010480022],"category_scores_gemma":[0.0015151235,0.00014285768,0.0007332696,0.00050026417,0.000115498005,0.000093978066,0.00014329382,0.00053983263,0.0000033906704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003853957,0.002597188,0.95803404,0.000030372385,0.003397473,0.002896725,0.0002875915,0.000040368715,0.000612664,0.000008180499,0.0007111968,0.027530229],"study_design_scores_gemma":[0.010540339,0.033143226,0.9300703,0.000011983636,0.013068924,0.000040814793,0.00013795978,0.0004664913,0.00028223603,0.000014174426,0.012118659,0.000104922095],"about_ca_topic_score_codex":0.00031981422,"about_ca_topic_score_gemma":0.00017370822,"teacher_disagreement_score":0.030546037,"about_ca_system_score_codex":0.0009110193,"about_ca_system_score_gemma":0.0012647107,"threshold_uncertainty_score":0.58255666},"labels":[],"label_agreement":null},{"id":"W3029167618","doi":"10.1200/jco.2020.38.15_suppl.e21567","title":"Can polymetastatic disease be arrested using SABR? A dosimetric analysis to inform development of a phase I trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; Cancer Care Ontario","funders":"","keywords":"SABR volatility model; Medicine; Radiation therapy; Nuclear medicine; Clinical trial; Radiosurgery; Medical physics; Ablative case; Radiology; Internal medicine; Mathematics","score_opus":0.2959812198106923,"score_gpt":0.5241001277576268,"score_spread":0.2281189079469345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029167618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812419,0.00038047266,0.0003743975,0.01726686,0.00023608666,0.00041482894,0.00001639533,0.000005084679,0.000063984226],"genre_scores_gemma":[0.9847659,0.000035189354,0.010537548,0.004381206,0.0002456161,0.0000072693606,0.0000089931655,0.000010309508,0.000008004935],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99565494,0.00020000852,0.0032202068,0.00017466409,0.00054597325,0.00020423533],"domain_scores_gemma":[0.9947756,0.0013112072,0.0018506757,0.00015949084,0.0003607141,0.0015423193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012924703,0.00014881448,0.0020607414,0.00070090505,0.000041347255,0.000009088304,0.00012831426,0.00010332907,0.00020895661],"category_scores_gemma":[0.006730495,0.00010167927,0.0008306309,0.0021679248,0.000058408754,0.000051194947,0.000056240573,0.00027641858,0.000004906598],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23953645,0.032967158,0.17128804,0.00015809797,0.031160502,0.004216967,0.0020967685,0.00045305566,0.00084149215,0.00004320308,0.0020157935,0.5152225],"study_design_scores_gemma":[0.512385,0.06750921,0.30419886,0.00025202683,0.06047726,0.000042939835,0.0004916733,0.003970516,0.0026132832,0.0000338044,0.04754446,0.0004809396],"about_ca_topic_score_codex":0.000016961487,"about_ca_topic_score_gemma":0.000029676708,"teacher_disagreement_score":0.51474154,"about_ca_system_score_codex":0.00019553839,"about_ca_system_score_gemma":0.0031634967,"threshold_uncertainty_score":0.80575174},"labels":[],"label_agreement":null},{"id":"W3029173559","doi":"10.1200/jco.2020.38.15_suppl.e15099","title":"Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pneumonitis; Meta-analysis; Confidence interval; Radiation therapy; Internal medicine; Odds ratio; Randomized controlled trial; Oncology; Lung","score_opus":0.049699469839364414,"score_gpt":0.3990097488245701,"score_spread":0.34931027898520567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029173559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9445368,0.0069779893,0.00001850492,0.04760081,0.0002594036,0.0005339613,0.00002566622,0.0000057194275,0.000041117484],"genre_scores_gemma":[0.9834374,0.014162194,0.00039054174,0.0017337286,0.00018774338,0.000037854756,0.000009406246,0.000020335952,0.000020800759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950058,0.0011853839,0.0029779202,0.00021599104,0.00045212312,0.00016278826],"domain_scores_gemma":[0.9935857,0.001665793,0.0039071236,0.00024261509,0.00040625996,0.00019248709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023238643,0.00018878476,0.0030831639,0.00014496724,0.00003569136,0.000009198642,0.00015720453,0.00021050328,0.0003870526],"category_scores_gemma":[0.00068332866,0.000072629,0.001819783,0.0006260069,0.00017582985,0.000097385106,0.000018648763,0.00077813555,9.876665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009267333,0.003188828,0.8430254,0.0000169372,0.1278169,0.00006841038,0.00068403356,0.0004275213,0.00006436675,0.000010175117,0.0001517127,0.015278392],"study_design_scores_gemma":[0.020764718,0.014233316,0.8912303,0.000037529986,0.07055988,0.0000032716048,0.0000620312,0.00019582504,0.00036842786,0.000054490196,0.0023989305,0.00009130569],"about_ca_topic_score_codex":0.00095520244,"about_ca_topic_score_gemma":0.00026902545,"teacher_disagreement_score":0.05725701,"about_ca_system_score_codex":0.00033921015,"about_ca_system_score_gemma":0.0007325196,"threshold_uncertainty_score":0.42379543},"labels":[],"label_agreement":null},{"id":"W3029194496","doi":"10.1200/jco.2020.38.15_suppl.4003","title":"Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Institutes of Health","keywords":"Medicine; Celecoxib; FOLFOX; Internal medicine; Hazard ratio; Colorectal cancer; Oxaliplatin; Clinical endpoint; Irinotecan; Fluorouracil; Oncology; Aspirin; Randomized controlled trial; Cancer; Surgery; Confidence interval","score_opus":0.12029834851332297,"score_gpt":0.4351693026124021,"score_spread":0.31487095409907917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029194496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982903,0.00043664518,0.00012412858,0.014400913,0.00082283566,0.00067069934,0.0001643921,0.000015847283,0.00046152476],"genre_scores_gemma":[0.9885276,0.0013349175,0.0015649858,0.006399828,0.002011331,0.000027677923,0.000028381824,0.000032028125,0.000073258314],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99499166,0.00072601734,0.00287912,0.00038109522,0.00062674924,0.00039538223],"domain_scores_gemma":[0.99474394,0.0024973762,0.0014742546,0.00019906352,0.00035381722,0.0007315396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032605682,0.0002411297,0.0021439006,0.00018158871,0.000032734675,0.000012695287,0.0001886906,0.00046398223,0.00036354363],"category_scores_gemma":[0.0032490946,0.00016914278,0.00020568978,0.00039300421,0.00009997861,0.0001586862,0.000042142008,0.0017073785,0.000019823676],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39018995,0.0018297782,0.18230985,0.00009065722,0.0004078988,0.01382262,0.005202541,0.0015507052,0.004976456,0.00005012765,0.02688247,0.37268695],"study_design_scores_gemma":[0.11394895,0.076356225,0.4678397,0.0010989809,0.0001689398,0.000054188906,0.00075921277,0.00072774035,0.004822146,0.000091355905,0.3336617,0.0004708637],"about_ca_topic_score_codex":0.0006387312,"about_ca_topic_score_gemma":0.0039041718,"teacher_disagreement_score":0.3722161,"about_ca_system_score_codex":0.00052263687,"about_ca_system_score_gemma":0.0027565986,"threshold_uncertainty_score":0.7417805},"labels":[],"label_agreement":null},{"id":"W3029196550","doi":"10.1200/jco.2020.38.15_suppl.12086","title":"Frequency and prediction of non-medical opioid use behaviors (NMOU) among advanced cancer patients referred to a supportive care center (SCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Logistic regression; Multivariate analysis; Descriptive statistics; Retrospective cohort study; Cancer; Internal medicine; Emergency medicine; Family medicine; Psychiatry","score_opus":0.06772125011415202,"score_gpt":0.43278208854935024,"score_spread":0.3650608384351982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029196550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383706,0.00019200018,0.000066088876,0.0028981734,0.0023540694,0.00032466947,0.00014210772,0.000008560935,0.00017729474],"genre_scores_gemma":[0.9954433,0.00057133293,0.00035318485,0.0028044335,0.00074076705,0.000013643732,0.000024548974,0.000019243456,0.000029567233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678594,0.00017785975,0.0019399478,0.00025456958,0.00063147553,0.0002102179],"domain_scores_gemma":[0.9964013,0.00041843395,0.0010395047,0.0001243998,0.00092972716,0.0010866385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044195075,0.00014528695,0.0011589355,0.000086777305,0.000024355777,0.00000590209,0.00013018934,0.00040793812,0.00022370827],"category_scores_gemma":[0.0031622113,0.0001113979,0.00029243392,0.00016428955,0.0001876716,0.00018717055,0.00008032879,0.000871584,0.000002049503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027557528,0.00052119547,0.93036395,0.00008979139,0.00010937963,0.00016706756,0.0030654052,0.0000019535066,0.0001691124,9.511059e-7,0.0019341394,0.060821272],"study_design_scores_gemma":[0.0072688195,0.015405219,0.96742547,0.00038678476,0.00030932066,0.000013084384,0.0011251557,0.00001563026,0.0001416633,0.0000036088659,0.007822264,0.00008295486],"about_ca_topic_score_codex":0.00039606256,"about_ca_topic_score_gemma":0.0013270845,"teacher_disagreement_score":0.060738318,"about_ca_system_score_codex":0.00018095705,"about_ca_system_score_gemma":0.0011180425,"threshold_uncertainty_score":0.45426747},"labels":[],"label_agreement":null},{"id":"W3029199196","doi":"10.1200/jco.2020.38.15_suppl.e15017","title":"Quantification of immune cell-mediated destruction of tumor cells <i>in vitro</i> using the RNA disruption assay.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"K562 cells; Immune system; Cancer research; Medicine; RNA; Cell; Peripheral blood mononuclear cell; Cytotoxic T cell; Population; Leukemia; Cancer cell; Cancer; Immunology; Biology; In vitro; Internal medicine; Gene","score_opus":0.07885706524616938,"score_gpt":0.38195507037569876,"score_spread":0.3030980051295294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029199196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952622,0.0003701677,0.003139519,0.0005450298,0.00051214796,0.00007679456,0.000009688646,8.6492565e-7,0.000083611216],"genre_scores_gemma":[0.9976542,0.00052252284,0.0012090956,0.000276929,0.00031284947,6.6872946e-7,0.000010295475,0.0000068001373,0.000006649571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752176,0.00043584764,0.0016889089,0.0001234779,0.00013359095,0.00009642305],"domain_scores_gemma":[0.9972623,0.00022579017,0.002034868,0.00013100807,0.00028482958,0.00006118238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015127423,0.00007554618,0.00046168576,0.00003637572,0.000015675603,0.0000034915035,0.00021102162,0.00019205602,0.00000858141],"category_scores_gemma":[0.000777123,0.000053619777,0.0002675697,0.00010824776,0.0001398764,0.00000902396,0.00004297928,0.00027936356,0.0000018715349],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016306067,0.00021240959,0.0013575623,0.000017667104,0.000039333863,0.0000057545844,0.000042883876,0.0006645507,0.9911736,0.0000029649677,0.00013361743,0.0047190106],"study_design_scores_gemma":[0.0010818002,0.0022852717,0.006188703,0.000018824638,0.00006227564,0.000016059006,0.00025526856,0.0016718379,0.9871543,0.000023857718,0.0011852633,0.00005655304],"about_ca_topic_score_codex":0.000023394234,"about_ca_topic_score_gemma":0.0000053019003,"teacher_disagreement_score":0.004831141,"about_ca_system_score_codex":0.0000143953575,"about_ca_system_score_gemma":0.00032714702,"threshold_uncertainty_score":0.21865511},"labels":[],"label_agreement":null},{"id":"W3029199437","doi":"10.1200/jco.2020.38.15_suppl.7021","title":"Global perspectives on clinical cancer research: A comparison of randomized controlled trial (RCT) design and outcomes across high income and low-middle income countries.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Clinical trial; Exact test; Sample size determination; Randomization; Research design; Cohort; Low and middle income countries; Internal medicine; Family medicine; Developing country","score_opus":0.706492310545549,"score_gpt":0.6384725861897967,"score_spread":0.06801972435575221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029199437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91600424,0.0055159186,0.0009993617,0.072566494,0.0019621428,0.0026475477,0.00010515661,0.000010640538,0.00018847093],"genre_scores_gemma":[0.98603714,0.004355513,0.0025900055,0.005175544,0.0016861658,0.00009395114,8.784401e-7,0.000020473657,0.00004034284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9623744,0.012163112,0.023881014,0.0006426916,0.00043309052,0.00050569174],"domain_scores_gemma":[0.8694061,0.109709516,0.018816536,0.00032323235,0.0008693272,0.0008752974],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18958281,0.00026167004,0.013803454,0.00020196143,0.00017958035,0.000079182144,0.0004331211,0.0006845216,0.00014358241],"category_scores_gemma":[0.18494856,0.00021494564,0.0009761403,0.00022387384,0.0016602653,0.0002951239,0.00017533512,0.0012634601,0.000042554653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.685717,0.00091063057,0.28700078,0.00014484859,0.0014372313,0.000009598899,0.0024987247,0.00019599125,7.1376064e-8,0.020437675,0.001313879,0.0003335816],"study_design_scores_gemma":[0.85986835,0.009964296,0.114042275,0.00019399759,0.00012521415,0.0000043651116,0.0024015761,0.003333579,3.01037e-7,0.008243575,0.0016044244,0.00021806205],"about_ca_topic_score_codex":0.00033115895,"about_ca_topic_score_gemma":0.000109336055,"teacher_disagreement_score":0.17415136,"about_ca_system_score_codex":0.00050494296,"about_ca_system_score_gemma":0.0017133411,"threshold_uncertainty_score":0.9435766},"labels":[],"label_agreement":null},{"id":"W3029230186","doi":"10.1200/jco.2020.38.15_suppl.8501","title":"Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Clinical endpoint; Surrogate endpoint; Randomization; Oncology; Phases of clinical research; Gastroenterology; Surgery; Randomized controlled trial; Clinical trial","score_opus":0.1266587915961721,"score_gpt":0.4381648612830087,"score_spread":0.3115060696868366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029230186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663145,0.0004386584,0.00009232621,0.010134716,0.00029247295,0.0021803838,0.000089986686,0.00001210757,0.00012790441],"genre_scores_gemma":[0.9913871,0.00017106367,0.006636965,0.001238167,0.00045078478,0.000036569825,0.000009407839,0.00004515483,0.00002477589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99393666,0.0010089088,0.0028242453,0.000608034,0.0010949614,0.00052717485],"domain_scores_gemma":[0.99097043,0.0051909797,0.0015153654,0.00045984908,0.00078298367,0.0010804152],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028136028,0.000374577,0.002267363,0.00022928014,0.00008628155,0.000027466245,0.00031294767,0.00035499161,0.00004530559],"category_scores_gemma":[0.011174348,0.00022789408,0.00024417968,0.00052909675,0.0004971307,0.0002181941,0.00029680764,0.0014238929,0.0000044721974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34838587,0.007955791,0.49212813,0.000040843574,0.0011474469,0.00048741282,0.0015588241,0.0000029178864,0.00019578685,0.0000011061642,0.00017195259,0.14792392],"study_design_scores_gemma":[0.20663227,0.0854845,0.7048336,0.0001769586,0.0005070988,0.00001941134,0.00072436495,0.00015445787,0.0001077521,0.000009282678,0.001194118,0.00015614979],"about_ca_topic_score_codex":0.00033002146,"about_ca_topic_score_gemma":0.0021384733,"teacher_disagreement_score":0.21270551,"about_ca_system_score_codex":0.00015258827,"about_ca_system_score_gemma":0.001029209,"threshold_uncertainty_score":0.99715495},"labels":[],"label_agreement":null},{"id":"W3029230438","doi":"10.1200/jco.2020.38.15_suppl.e21037","title":"Analysis of exhaled breath of lung cancer patients using infrared spectroscopy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Chemical Sensor Technologies","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; University of New Brunswick; Horizon Health Network; Dalhousie University; Saint John Regional Hospital","funders":"","keywords":"Medicine; Lung cancer; Cohort; Receiver operating characteristic; Internal medicine; Nuclear medicine","score_opus":0.06605075994799753,"score_gpt":0.4228840706874037,"score_spread":0.35683331073940616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029230438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659896,0.00039338195,0.0021788492,0.00012535285,0.00017397333,0.000054561257,0.000017460958,0.000028453025,0.00042900268],"genre_scores_gemma":[0.9899511,0.00053308514,0.0092868,0.00008918381,0.00012107466,5.702393e-7,0.000001155634,0.000013839389,0.0000031894638],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974411,0.00005140528,0.0020177034,0.00010768228,0.00022142404,0.00016065576],"domain_scores_gemma":[0.997531,0.0006724356,0.0012743603,0.00012240213,0.000270787,0.00012901808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016459699,0.000111640264,0.0015680688,0.00015019333,0.000007999799,0.0000018970404,0.0002694915,0.00028971263,0.000088760324],"category_scores_gemma":[0.0019085356,0.00009241268,0.00046198178,0.00062033423,0.00014163942,0.00008954419,0.00005503382,0.0005464641,3.1382152e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007670491,0.00052512105,0.6554943,0.0001605866,0.005285316,0.000049008213,0.00014854343,0.17196447,0.15164255,0.000027310367,0.00089599227,0.013039774],"study_design_scores_gemma":[0.009212413,0.0053889793,0.30992338,0.00025075942,0.009382488,0.000007999731,0.00023475886,0.29531872,0.36516607,0.0007195617,0.0037623327,0.0006325452],"about_ca_topic_score_codex":0.0000057550787,"about_ca_topic_score_gemma":0.0000027668548,"teacher_disagreement_score":0.3455709,"about_ca_system_score_codex":0.0001370281,"about_ca_system_score_gemma":0.000060711605,"threshold_uncertainty_score":0.37684795},"labels":[],"label_agreement":null},{"id":"W3029233318","doi":"10.1200/jco.2020.38.15_suppl.e14012","title":"Systematic analysis of chemotherapy agents for home-based administration.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Continuous infusion; Emergency medicine; Intensive care medicine; Internal medicine","score_opus":0.23374951722622045,"score_gpt":0.5476316261068798,"score_spread":0.3138821088806593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029233318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952787,0.0005345008,0.0035119958,0.041189566,0.0007763748,0.0007150049,0.00002125275,0.000008131175,0.00045618354],"genre_scores_gemma":[0.9864454,0.00014037912,0.0025403516,0.010191662,0.00053816766,0.000010692265,0.000009988315,0.000008168073,0.0001151346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725646,0.00020561658,0.0021447479,0.000107343876,0.00018762746,0.00009818135],"domain_scores_gemma":[0.9946446,0.002616668,0.0020263114,0.00008693156,0.0003620922,0.00026344083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011386476,0.00008325136,0.0021715695,0.0001333931,0.000013385945,0.0000026822963,0.00009517888,0.0001713774,0.00046882208],"category_scores_gemma":[0.0012610063,0.00005708967,0.0011173598,0.00030600297,0.00007146013,0.000026399124,0.0000053225344,0.00019149986,0.0000026664197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18591423,0.03527765,0.44212714,0.024621962,0.14292741,0.0013427207,0.0018045226,0.0013964638,0.004690457,0.00063162076,0.12534805,0.033917777],"study_design_scores_gemma":[0.12653305,0.2658562,0.36830863,0.0014331116,0.12838642,0.00010140855,0.0004211783,0.032392368,0.004026576,0.0002261427,0.07188554,0.00042936509],"about_ca_topic_score_codex":0.0000019421514,"about_ca_topic_score_gemma":0.0000067183264,"teacher_disagreement_score":0.23057856,"about_ca_system_score_codex":0.000063390245,"about_ca_system_score_gemma":0.0012435907,"threshold_uncertainty_score":0.5133273},"labels":[],"label_agreement":null},{"id":"W3029255798","doi":"10.1200/jco.2020.38.15_suppl.3054","title":"An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cancer; Cohort; Gastroenterology; Oncology; Phases of clinical research; Surgery; Chemotherapy; Clinical trial","score_opus":0.09753620960378719,"score_gpt":0.4727210745813385,"score_spread":0.3751848649775513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029255798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259794,0.00009210477,0.000035673813,0.0061030155,0.00020465885,0.000702837,0.0000041018625,0.0000030924864,0.0002565694],"genre_scores_gemma":[0.99611396,0.00026483435,0.0017532505,0.0016930365,0.0001386592,0.000006911661,0.0000073749356,0.000014309151,0.0000076887045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711275,0.00036202956,0.0018902342,0.00019402381,0.00028770752,0.00015326969],"domain_scores_gemma":[0.9975702,0.00031874163,0.0015381759,0.00011411601,0.00022904806,0.00022967237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015925982,0.00011954809,0.0014094035,0.00014665957,0.000016047085,0.000009661343,0.00016748156,0.00017533988,0.000027493492],"category_scores_gemma":[0.0006133589,0.00007762435,0.00004437114,0.00033229854,0.00022659216,0.00027217882,0.000028930022,0.00058226247,4.1213642e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7045511,0.0142297475,0.036193434,0.000027897828,0.00011267563,0.00025651176,0.00030767533,0.0000045861593,0.0013822356,0.0000055043147,0.00008904362,0.24283959],"study_design_scores_gemma":[0.58395976,0.292116,0.12127094,0.00027819944,0.000078070414,0.000034731995,0.00021871991,0.0001296612,0.000260854,0.00002716939,0.0015390927,0.00008680911],"about_ca_topic_score_codex":0.000043963097,"about_ca_topic_score_gemma":0.00032365875,"teacher_disagreement_score":0.27788624,"about_ca_system_score_codex":0.00009509247,"about_ca_system_score_gemma":0.00090243487,"threshold_uncertainty_score":0.3165429},"labels":[],"label_agreement":null},{"id":"W3029259560","doi":"10.1200/jco.2020.38.15_suppl.10553","title":"Treatment intensity and risk of chronic health conditions and late mortality among long-term survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Cumulative incidence; Internal medicine; Incidence (geometry); Confidence interval; Pediatrics; Relative risk; Cancer; Cohort","score_opus":0.04991245391789957,"score_gpt":0.40497992228312835,"score_spread":0.3550674683652288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029259560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940677,0.003898072,0.000020432359,0.001330732,0.00033127717,0.00023480903,0.00009126245,0.0000015955148,0.00002406382],"genre_scores_gemma":[0.9798016,0.019546013,0.000016977105,0.00024304887,0.0003587734,0.0000035432881,0.000012924122,0.000007200033,0.000009928616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976547,0.00051936274,0.0013584596,0.00021796972,0.00013107374,0.00011845282],"domain_scores_gemma":[0.9969097,0.0002368526,0.0023092248,0.00016379732,0.00017449111,0.0002059779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009409214,0.00011646695,0.0008817252,0.0000135152395,0.00005318838,0.000004144417,0.000106259526,0.00014747496,0.000009530644],"category_scores_gemma":[0.00039554198,0.000066403314,0.0002165085,0.000055414584,0.00044375626,0.0000058456544,0.00007523223,0.00033585838,1.1469123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044276033,0.0005731002,0.989753,0.0000134482125,0.0018931315,0.00010505992,0.0002865351,0.00008825772,0.00041646019,5.36476e-7,0.00009759517,0.006330129],"study_design_scores_gemma":[0.0023776423,0.009556032,0.98656046,0.000039500297,0.00047422363,0.000056223245,0.00016519234,0.000029255527,0.00043450182,0.000021113807,0.00022531944,0.00006056072],"about_ca_topic_score_codex":0.0058764042,"about_ca_topic_score_gemma":0.012810013,"teacher_disagreement_score":0.015647942,"about_ca_system_score_codex":0.000036881873,"about_ca_system_score_gemma":0.00094930065,"threshold_uncertainty_score":0.8883404},"labels":[],"label_agreement":null},{"id":"W3029263776","doi":"10.1200/jco.2020.38.15_suppl.e21680","title":"Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Pemetrexed; Carboplatin; Medicine; Lung cancer; Internal medicine; Gemcitabine; Oncology; Cancer; Pharmacology; Chemotherapy; Cisplatin","score_opus":0.03141047358839901,"score_gpt":0.371250536843823,"score_spread":0.339840063255424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029263776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970654,0.0006380547,0.00021322636,0.0002469519,0.0009777675,0.00061354815,0.0000076675005,0.0000017286981,0.00023561326],"genre_scores_gemma":[0.9980045,0.000614095,0.00031179385,0.00034489168,0.0006497532,0.000019010859,0.0000151762115,0.000020167947,0.000020604164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970829,0.00035286532,0.0018508588,0.00027589835,0.00023324032,0.00020423072],"domain_scores_gemma":[0.99753183,0.00017471425,0.0015951799,0.00015462926,0.00038939665,0.00015423559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001057943,0.00016724222,0.0009234615,0.00012159059,0.000020118208,0.0000077269615,0.00021834846,0.00028398773,0.000013229386],"category_scores_gemma":[0.0004769952,0.00013847434,0.00015370318,0.0002643438,0.00006619014,0.000017458604,0.00007254925,0.000532143,6.4205204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022227947,0.030877208,0.70475596,0.00013924566,0.00028920048,0.00005927951,0.0031458358,0.0032769688,0.073547676,0.000003637858,0.0009757403,0.1607013],"study_design_scores_gemma":[0.12868695,0.053174425,0.8035903,0.00009162273,0.00029300046,0.0000035391292,0.00078944536,0.0024923051,0.006510107,0.000009700052,0.0040378785,0.0003207251],"about_ca_topic_score_codex":0.00024132227,"about_ca_topic_score_gemma":0.0010351297,"teacher_disagreement_score":0.16038057,"about_ca_system_score_codex":0.000057244128,"about_ca_system_score_gemma":0.0006849027,"threshold_uncertainty_score":0.56468195},"labels":[],"label_agreement":null},{"id":"W3029271584","doi":"10.1200/jco.2020.38.15_suppl.12020","title":"Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS) of patients with metastatic cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Prostate cancer; Cancer; Breast cancer; Colorectal cancer; Psychosocial; Lung cancer; Oncology","score_opus":0.09891887331689363,"score_gpt":0.4000155132463193,"score_spread":0.30109663992942565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029271584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993671,0.00036728135,0.00034074878,0.0021240015,0.00074670167,0.00024185628,0.00054135895,0.0000053582685,0.0019616915],"genre_scores_gemma":[0.9976067,0.00044440202,0.0004273412,0.0011978165,0.00021829832,0.000004003513,0.000014809208,0.000030996725,0.000055618166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99445677,0.00013571167,0.00465087,0.00030870148,0.00015983215,0.00028812198],"domain_scores_gemma":[0.9882218,0.001350462,0.009306052,0.0002337843,0.0004927174,0.00039518464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015726745,0.00024374733,0.0029884889,0.00014016949,0.00002568983,0.000014378623,0.00031929903,0.0002161572,0.0007476278],"category_scores_gemma":[0.004979883,0.00018527152,0.0007298839,0.00016732229,0.00016374707,0.00032344216,0.00004889447,0.0005298199,0.000018937706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004484229,0.0014908197,0.97498184,0.000032331758,0.0015784205,0.000020058094,0.000166948,0.0012651243,0.000011095469,0.0008073269,0.0036380424,0.011523772],"study_design_scores_gemma":[0.011459676,0.022779448,0.9529314,0.000049889302,0.00016435828,0.0000018423679,0.000035279918,0.00032373765,0.000032835615,0.0010353611,0.010933264,0.00025292306],"about_ca_topic_score_codex":0.0009219671,"about_ca_topic_score_gemma":0.00002901055,"teacher_disagreement_score":0.022050448,"about_ca_system_score_codex":0.00022776403,"about_ca_system_score_gemma":0.000989242,"threshold_uncertainty_score":0.81860006},"labels":[],"label_agreement":null},{"id":"W3029297598","doi":"10.1200/jco.2020.38.15_suppl.tps6591","title":"INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Clinical endpoint; Population; Antibody; Phases of clinical research; Oncology; Immunotherapy; Immunology; Clinical trial; Adverse effect; Cancer","score_opus":0.2139246181306748,"score_gpt":0.4678649286594228,"score_spread":0.253940310528748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029297598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856205,0.0037741591,0.00014085667,0.0011507906,0.0011466875,0.004637178,0.00009044185,0.000013758844,0.00048410357],"genre_scores_gemma":[0.9968214,0.0012167478,0.0007104834,0.00029474907,0.0007068076,0.000068536814,0.00005949847,0.000060155475,0.000061638624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99278855,0.0010732161,0.0044152336,0.0006234772,0.00063564675,0.00046389876],"domain_scores_gemma":[0.98830336,0.0058505945,0.004008634,0.00041306304,0.0007114913,0.0007128783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026802875,0.0005087209,0.004930325,0.00030947267,0.00013895263,0.00002515714,0.00029599096,0.00046776375,0.000078907025],"category_scores_gemma":[0.0007581343,0.0003780711,0.0011354461,0.00031937088,0.000635543,0.0001803289,0.000067766436,0.00077861216,0.0000025764487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96489096,0.014782943,0.0034078925,0.00042567306,0.0014840788,0.00036381203,0.004930904,0.00030164747,0.001206568,0.0000066965035,0.00022757259,0.007971248],"study_design_scores_gemma":[0.7674271,0.21718936,0.0041742907,0.00010985813,0.0034024573,0.000093059716,0.0020726856,0.0022068585,0.002116161,0.000009807423,0.00094403385,0.00025434472],"about_ca_topic_score_codex":0.0004756967,"about_ca_topic_score_gemma":0.0003059842,"teacher_disagreement_score":0.2024064,"about_ca_system_score_codex":0.000608807,"about_ca_system_score_gemma":0.0036527351,"threshold_uncertainty_score":0.99986714},"labels":[],"label_agreement":null},{"id":"W3029319309","doi":"10.1200/jco.2020.38.15_suppl.tps9076","title":"Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Stage (stratigraphy); Adjuvant; Randomized controlled trial; Population; Chemotherapy; Cancer; Immunotherapy","score_opus":0.10470251818585603,"score_gpt":0.4519634046092852,"score_spread":0.34726088642342917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029319309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785131,0.0019658452,0.00020055975,0.015173078,0.0012751862,0.0008721529,0.000026895308,0.000020115107,0.0019530616],"genre_scores_gemma":[0.9875681,0.0033061577,0.0008336376,0.0056651477,0.0012699019,0.0000114787,0.000008994333,0.000053451236,0.0012831542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931449,0.00051899144,0.004731238,0.00039855082,0.0007065435,0.0004997183],"domain_scores_gemma":[0.9947801,0.00094607315,0.0030791764,0.0003425655,0.00031486925,0.0005371958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041414783,0.00030382548,0.003408588,0.00018444179,0.000042571817,0.000016031654,0.00042338367,0.0006847796,0.00084614876],"category_scores_gemma":[0.0016556903,0.00023534545,0.0011965352,0.0005161342,0.00035971802,0.00019171632,0.00006649744,0.0014667279,0.000009412193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8267404,0.0040660235,0.0013625731,0.00007767372,0.00074455346,0.0007189199,0.0008744829,0.0000051778447,0.049705576,0.0000072297944,0.023990406,0.09170701],"study_design_scores_gemma":[0.74797314,0.06502085,0.0026758807,0.00030027502,0.00027391466,0.000082330866,0.00039688725,0.0005422016,0.008319706,0.000027836093,0.17411967,0.00026734394],"about_ca_topic_score_codex":0.00046304846,"about_ca_topic_score_gemma":0.000088666086,"teacher_disagreement_score":0.15012926,"about_ca_system_score_codex":0.00039386554,"about_ca_system_score_gemma":0.0028839686,"threshold_uncertainty_score":0.9597109},"labels":[],"label_agreement":null},{"id":"W3029320628","doi":"10.1200/jco.2020.38.15_suppl.6563","title":"18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Clinical endpoint; Internal medicine; Head and neck cancer; Nuclear medicine; Randomized controlled trial; Cancer; Oncology","score_opus":0.10717178070208373,"score_gpt":0.40736173623175825,"score_spread":0.30018995552967453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029320628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896756,0.00029671306,0.000018514771,0.007916755,0.00061912596,0.00038415915,0.00015732135,0.000010678704,0.0009211343],"genre_scores_gemma":[0.9935415,0.00301307,0.0005365227,0.0024456636,0.00034168886,0.0000124449325,0.000028081635,0.00002532518,0.000055708922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963887,0.00039466514,0.002190917,0.0003179256,0.00045621415,0.00025159764],"domain_scores_gemma":[0.9939676,0.0028612188,0.00199257,0.00012731113,0.0007871081,0.00026421642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007840678,0.00022767099,0.002386178,0.000091231756,0.000045911944,0.000005524624,0.00011103057,0.00009425685,0.000036102694],"category_scores_gemma":[0.0024576609,0.00014215127,0.00033313077,0.00018858923,0.00016140209,0.0001321022,0.00003636658,0.0007156413,0.0000010533331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033347677,0.001912106,0.902027,0.000010213225,0.0016340468,0.00073067436,0.0006960392,0.00008960469,0.00011340179,9.2113135e-7,0.00082345516,0.058614846],"study_design_scores_gemma":[0.049726978,0.031600375,0.91542685,0.0006545475,0.00032542768,0.000014000554,0.00020908022,0.00010404309,0.00009342103,0.0000095604355,0.0017363132,0.0000994143],"about_ca_topic_score_codex":0.00035622716,"about_ca_topic_score_gemma":0.00037167207,"teacher_disagreement_score":0.058515433,"about_ca_system_score_codex":0.0006810574,"about_ca_system_score_gemma":0.0013826315,"threshold_uncertainty_score":0.5796761},"labels":[],"label_agreement":null},{"id":"W3029321131","doi":"10.1200/jco.2020.38.15_suppl.6070","title":"Patterns of progression and subsequent management of patients with <i>BRCA1/2</i> mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Clinical endpoint; Ovarian cancer; Progression-free survival; Oncology; Progressive disease; Gastroenterology; Surgery; Cancer; Urology; Chemotherapy; Clinical trial; Pathology","score_opus":0.12830437491644747,"score_gpt":0.4527451347805888,"score_spread":0.32444075986414134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029321131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890083,0.00017446258,0.00015156875,0.006959748,0.0017286368,0.0015596657,0.00007456344,0.000011292234,0.0003317279],"genre_scores_gemma":[0.9963038,0.0004944159,0.001310924,0.00086330547,0.00093576557,0.000040988976,0.000015109532,0.000027871893,0.000007805088],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99553126,0.000768344,0.0022563892,0.0003167325,0.0008594237,0.00026787104],"domain_scores_gemma":[0.9938911,0.0013498425,0.0036096263,0.00019921213,0.000652493,0.00029771408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016178888,0.00023859182,0.0013705501,0.0000787084,0.000069035676,0.00001168126,0.00016010246,0.0002479723,0.00006573831],"category_scores_gemma":[0.00042958252,0.0001358969,0.0002627922,0.00018784871,0.00038762504,0.00008517007,0.00007610246,0.0009863933,0.0000013324175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75188076,0.0024318066,0.019508088,0.00018983912,0.001500379,0.00024413766,0.00092225167,0.00005843756,0.00018427818,0.000082857674,0.00040224614,0.22259489],"study_design_scores_gemma":[0.6459227,0.15199886,0.17651977,0.004700556,0.0020461685,0.00003914017,0.00085573434,0.00036594836,0.00795084,0.00006001162,0.009159144,0.00038112103],"about_ca_topic_score_codex":0.000012030873,"about_ca_topic_score_gemma":0.0000143300185,"teacher_disagreement_score":0.22221376,"about_ca_system_score_codex":0.0002022075,"about_ca_system_score_gemma":0.00070540915,"threshold_uncertainty_score":0.5541715},"labels":[],"label_agreement":null},{"id":"W3029325922","doi":"10.1200/jco.2020.38.15_suppl.e19249","title":"Assessing overall patient satisfaction among cancer patients: A radiotherapy survey.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Family medicine; Respondent; Feeling; Patient satisfaction; Radiation therapy; Cancer; Health care; Lung cancer; Honesty; Kindness; Nursing; Surgery; Internal medicine","score_opus":0.548705906981759,"score_gpt":0.6004722306306026,"score_spread":0.05176632364884359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029325922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977809,0.001285803,0.00022032774,0.014250267,0.0051609143,0.00062360923,0.000023953504,0.000030583873,0.0005955166],"genre_scores_gemma":[0.9753629,0.0013911888,0.0025742007,0.019421497,0.001151041,0.000037255704,0.000009585617,0.000035608977,0.000016746226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9839752,0.009829913,0.004970502,0.0002605533,0.0005609286,0.0004029135],"domain_scores_gemma":[0.9804491,0.00937681,0.0071785273,0.00031295285,0.001984198,0.000698414],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023037242,0.00018214565,0.0013068762,0.000094351686,0.0003631846,0.000017470256,0.00034813993,0.00065382104,0.00057418365],"category_scores_gemma":[0.01256683,0.00014594503,0.00029292156,0.00024176715,0.00015495914,0.0007108253,0.00014480382,0.0030895625,0.00002786239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088854623,0.00027075477,0.8721472,0.000055292094,0.00010616942,0.000005969438,0.0030397032,0.00006402453,0.000009431698,0.000024027302,0.013113941,0.110274926],"study_design_scores_gemma":[0.004250575,0.0033576628,0.95281535,0.00019270094,0.00003773582,7.453163e-7,0.0011514992,0.00045232105,0.0000017693145,0.00010525027,0.037504885,0.00012949128],"about_ca_topic_score_codex":0.0020273174,"about_ca_topic_score_gemma":0.0012963222,"teacher_disagreement_score":0.110145435,"about_ca_system_score_codex":0.0008377028,"about_ca_system_score_gemma":0.0035345315,"threshold_uncertainty_score":0.99921036},"labels":[],"label_agreement":null},{"id":"W3029336272","doi":"10.1200/jco.2020.38.15_suppl.e24088","title":"Determining the unmet survivorship needs in patients with head and neck cancer: A prospective, longitudinal study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Survivorship curve; Head and neck cancer; Cancer; Quality of life (healthcare); Prospective cohort study; Clinical endpoint; Head and neck; Internal medicine; Radiation therapy; Physical therapy; Surgery; Clinical trial","score_opus":0.1732586652832086,"score_gpt":0.4625172944265859,"score_spread":0.2892586291433773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029336272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884416,0.0002865226,0.0000041032595,0.009897278,0.00028525677,0.00039596914,0.000001665626,0.000004879289,0.0006827631],"genre_scores_gemma":[0.9968604,0.00015000507,0.000201,0.002209587,0.00053568155,0.00000945364,2.209472e-7,0.000011638733,0.000022001519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979112,0.00029762049,0.0011046901,0.00016672123,0.0003217224,0.00019805282],"domain_scores_gemma":[0.997691,0.0010447196,0.0006020489,0.0000863638,0.00032694987,0.0002489566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001216055,0.00012536236,0.001332696,0.00006520324,0.000056567,0.000008962855,0.00010191445,0.00009902274,0.000024807348],"category_scores_gemma":[0.0016824503,0.00006443409,0.000094692194,0.00029666594,0.00018238688,0.0000798132,0.00006819827,0.0009120436,0.0000015332699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007062094,0.0012650229,0.9581953,0.000019680925,0.00023251111,0.000112804846,0.0017138658,0.0000023205096,2.6758744e-7,0.000005685555,0.00028226656,0.03110816],"study_design_scores_gemma":[0.018275928,0.049761627,0.92888916,0.00012128007,0.00020602402,0.000008205037,0.00063590566,0.000012125436,8.444988e-7,0.000010709078,0.0020106,0.000067580266],"about_ca_topic_score_codex":0.00009676594,"about_ca_topic_score_gemma":0.00175104,"teacher_disagreement_score":0.048496604,"about_ca_system_score_codex":0.00009577461,"about_ca_system_score_gemma":0.00058961695,"threshold_uncertainty_score":0.39624265},"labels":[],"label_agreement":null},{"id":"W3029352275","doi":"10.1200/jco.2020.38.15_suppl.7004","title":"Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Institutes of Health","keywords":"Medicine; Discontinuation; Breast cancer; Internal medicine; Proportional hazards model; Cancer; Oncology; Hazard ratio; Gynecology; Confidence interval","score_opus":0.22812867516868282,"score_gpt":0.4892987882958757,"score_spread":0.26117011312719285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029352275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86490476,0.0002952383,0.00010567166,0.1311042,0.0013754688,0.00042036,0.0000017951284,0.0000050345243,0.0017874895],"genre_scores_gemma":[0.9673118,0.00051451084,0.00017719883,0.028474178,0.0034017828,0.000013061859,0.0000013004237,0.000010212655,0.000095965006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970165,0.0006509026,0.0016494811,0.00014832855,0.00036084588,0.0001739313],"domain_scores_gemma":[0.9974997,0.001277508,0.00061046245,0.00014686458,0.00018979496,0.00027566665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00258632,0.00009773753,0.0009811639,0.00006376697,0.000017442539,0.000014142044,0.00022191911,0.00011684946,0.00018452219],"category_scores_gemma":[0.0029935718,0.000054347558,0.00037294847,0.0002350719,0.00005151474,0.00007936028,0.000028560846,0.00085298915,0.00003022338],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17358643,0.0016643781,0.038019106,0.0000112137695,0.00014514466,0.0009826242,0.0048505864,0.00000926659,0.00027150198,0.00017011605,0.0112634245,0.7690262],"study_design_scores_gemma":[0.0808056,0.07562494,0.36149347,0.000053146243,0.000104482686,0.00007170731,0.001374994,0.000019507432,0.00008092733,0.00017791918,0.48008993,0.00010339033],"about_ca_topic_score_codex":0.0001225196,"about_ca_topic_score_gemma":0.00049194094,"teacher_disagreement_score":0.7689228,"about_ca_system_score_codex":0.000053714135,"about_ca_system_score_gemma":0.00055264094,"threshold_uncertainty_score":0.3705861},"labels":[],"label_agreement":null},{"id":"W3029353272","doi":"10.1200/jco.2020.38.15_suppl.9623","title":"SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; Amgen","keywords":"Medicine; Tremelimumab; Durvalumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Interim analysis; Progressive disease; Combination therapy; Cancer; Surgery; Immunotherapy; Gastroenterology; Chemotherapy; Clinical trial; Nivolumab; Ipilimumab","score_opus":0.07130632551805678,"score_gpt":0.4141382348314257,"score_spread":0.34283190931336893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029353272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879753,0.0033188474,0.000052711428,0.0029228074,0.00045970114,0.005145524,0.000059044123,0.000020415644,0.000045634744],"genre_scores_gemma":[0.9963926,0.0005285965,0.00033533288,0.0016570432,0.0005762131,0.00013484883,0.0000067380374,0.000059433696,0.00030920512],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947553,0.00052597426,0.0031251542,0.0005300424,0.0006633872,0.00040013765],"domain_scores_gemma":[0.99483997,0.000816664,0.0025282963,0.00032237175,0.0009270288,0.0005656503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017619003,0.00036406767,0.0024088246,0.00015007253,0.00013297106,0.000018091598,0.00024876182,0.00025241554,0.00009323435],"category_scores_gemma":[0.0005852103,0.00024265773,0.00040388055,0.00036334177,0.00016905846,0.00013657229,0.00007232743,0.0004254166,5.087557e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7233912,0.034748588,0.1850331,0.00044300122,0.002129937,0.00025774466,0.011535569,0.000030503146,0.004334186,6.4772445e-7,0.0068836026,0.031211948],"study_design_scores_gemma":[0.39614594,0.41820014,0.16441959,0.00034316274,0.0017187946,0.0000061659207,0.0025067744,0.00025331785,0.0019358469,0.0000019301265,0.014069956,0.00039837413],"about_ca_topic_score_codex":0.00012755163,"about_ca_topic_score_gemma":0.00079589325,"teacher_disagreement_score":0.38345155,"about_ca_system_score_codex":0.00044788205,"about_ca_system_score_gemma":0.001648512,"threshold_uncertainty_score":0.9895295},"labels":[],"label_agreement":null},{"id":"W3029357793","doi":"10.1200/jco.2020.38.15_suppl.12012","title":"Randomized trial of a perioperative geriatric intervention for older adults with cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Perioperative; Randomized controlled trial; Geriatric Depression Scale; Intervention (counseling); Depression (economics); Geriatrics; Clinical endpoint; Geriatric oncology; Cancer; Physical therapy; Internal medicine; Surgery; Anxiety; Depressive symptoms; Nursing; Psychiatry","score_opus":0.09075227229198334,"score_gpt":0.4704802751965041,"score_spread":0.37972800290452075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029357793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528839,0.00068450155,0.0043679876,0.03708448,0.0016408719,0.0026649062,0.000012129023,0.000008946914,0.00065225107],"genre_scores_gemma":[0.987577,0.0005463429,0.006958152,0.0017139007,0.0027815027,0.00008084429,0.0000040853843,0.000018892799,0.00031927877],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99577177,0.0006302609,0.0029796853,0.00017621649,0.00029788862,0.00014417716],"domain_scores_gemma":[0.9922987,0.0034529513,0.0027897407,0.00009650182,0.0010733884,0.0002887058],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027209802,0.0001261132,0.0027924557,0.000071683135,0.00001823815,0.000005155407,0.00012414568,0.0002456119,0.00025614342],"category_scores_gemma":[0.013502228,0.00007420055,0.0010898837,0.00014356391,0.00024316077,0.00009161905,0.000024147881,0.0005554751,0.0000021561157],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90585333,0.0012719353,0.000256831,0.00018350301,0.0007494467,0.00004870964,0.001196377,0.000013763674,0.000020163212,0.00003404297,0.0016798963,0.088692024],"study_design_scores_gemma":[0.9360028,0.054064836,0.0012551445,0.00050163467,0.0011290213,0.000051143285,0.00040842418,0.0006864242,0.00012259513,0.00001699408,0.0056913598,0.00006961218],"about_ca_topic_score_codex":0.000032257918,"about_ca_topic_score_gemma":0.000034152403,"teacher_disagreement_score":0.08862241,"about_ca_system_score_codex":0.00006796231,"about_ca_system_score_gemma":0.0012297697,"threshold_uncertainty_score":0.9948075},"labels":[],"label_agreement":null},{"id":"W3029365355","doi":"10.1200/jco.2020.38.15_suppl.e24018","title":"Sarcopenia and clinical evaluation in predicting treatment tolerability and outcomes in aggressive non-Hodgkin B cell lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Sarcopenia; Interquartile range; Internal medicine; Diffuse large B-cell lymphoma; Proportional hazards model; Clinical endpoint; Chemotherapy; Retrospective cohort study; Population; Cohort; Lymphoma; Tolerability; Hazard ratio; Oncology; Clinical trial; Adverse effect; Confidence interval","score_opus":0.2499355642872632,"score_gpt":0.554106671130012,"score_spread":0.3041711068427488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029365355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96588427,0.0007346428,0.000011931154,0.031885855,0.0003981708,0.0004915766,0.0000018490294,0.000004209368,0.0005875164],"genre_scores_gemma":[0.9895033,0.0023442819,0.0027519718,0.0048921993,0.00048163818,0.0000065344134,0.0000013747597,0.00000778117,0.000010895861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995056,0.0010788095,0.0031746863,0.00025286278,0.00025982142,0.00017783206],"domain_scores_gemma":[0.99391377,0.003757224,0.0015438135,0.00009077569,0.00019390149,0.00050052063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007034057,0.000111843714,0.0016447351,0.000098104836,0.000026657865,0.0000073835695,0.000051812392,0.00030292338,0.000041352287],"category_scores_gemma":[0.007634959,0.000080025355,0.00015533157,0.000105342195,0.00014856538,0.00008672236,0.000042733052,0.00060485996,0.0000027363894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020332162,0.0017067553,0.7474474,0.000049955826,0.000027240283,0.00024704597,0.00031264618,0.0000024330507,0.000009231193,0.0000018079452,0.000073962845,0.24808834],"study_design_scores_gemma":[0.039640952,0.011035029,0.9410749,0.00020156991,0.00014152285,0.000068455185,0.00028003537,0.0056765163,0.000012451323,0.00017831124,0.0016341698,0.00005605609],"about_ca_topic_score_codex":0.00004492348,"about_ca_topic_score_gemma":0.00016106956,"teacher_disagreement_score":0.24803229,"about_ca_system_score_codex":0.00027043695,"about_ca_system_score_gemma":0.0012965971,"threshold_uncertainty_score":0.9140311},"labels":[],"label_agreement":null},{"id":"W3029365679","doi":"10.1200/jco.2020.38.15_suppl.7518","title":"Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anemia; Randomization; Placebo; Surgery; Refractory (planetary science); Internal medicine; Myelodysplastic syndromes; Randomized controlled trial; Gastroenterology; Bone marrow","score_opus":0.048443307988469166,"score_gpt":0.385864352356041,"score_spread":0.3374210443675718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029365679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559397,0.00005548789,0.000069966256,0.0030092269,0.00028597418,0.000682422,0.0000012992152,0.0000054120756,0.00029627627],"genre_scores_gemma":[0.9988559,0.00041453895,0.00012548722,0.0003939584,0.00017911638,0.0000044444623,0.0000021349383,0.000017057186,0.000007382554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964085,0.0007236931,0.0019173038,0.00022669804,0.00051687344,0.00020688844],"domain_scores_gemma":[0.9978773,0.00032341742,0.0012232884,0.00016029074,0.00021545065,0.00020026207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016877071,0.00016091317,0.0011786217,0.00013891462,0.000039868835,0.000006690861,0.00015927631,0.00026772646,0.00004872079],"category_scores_gemma":[0.00043657306,0.00008197095,0.00014229109,0.0003842075,0.00018336736,0.00011709348,0.000022864724,0.0015855754,0.0000015735718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08702523,0.031712323,0.7175282,0.00008585,0.0003848353,0.0017377164,0.02850859,0.0012449863,0.00018739694,0.0000022508646,0.00022312875,0.13135947],"study_design_scores_gemma":[0.16445701,0.2332476,0.5747527,0.00066449476,0.0008264863,0.00023455262,0.024747208,0.00045974363,0.000048515783,0.000011310475,0.0003591045,0.00019126867],"about_ca_topic_score_codex":0.0001387868,"about_ca_topic_score_gemma":0.0005991272,"teacher_disagreement_score":0.20153527,"about_ca_system_score_codex":0.00007828167,"about_ca_system_score_gemma":0.00034587935,"threshold_uncertainty_score":0.6888624},"labels":[],"label_agreement":null},{"id":"W3029368205","doi":"10.1200/jco.2020.38.15_suppl.8525","title":"KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Population; Cohort; Multiple myeloma; Regimen; Refractory (planetary science); Oncology","score_opus":0.14089333641949836,"score_gpt":0.4538049989044175,"score_spread":0.31291166248491914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029368205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974164,0.00017510954,0.00001596017,0.0016078386,0.0002001593,0.00046761497,0.000029490424,0.0000049317996,0.00008249055],"genre_scores_gemma":[0.99832606,0.00013528463,0.0010376143,0.00040709547,0.00002547826,0.000004028831,0.0000031898476,0.00001153339,0.00004970616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958459,0.0012410446,0.0023189234,0.00028786255,0.000096358985,0.00020988352],"domain_scores_gemma":[0.99496716,0.0030778584,0.0014130737,0.00015781977,0.00021948476,0.00016459126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086872984,0.0002032217,0.0023012524,0.00016940729,0.00002895562,0.0000038185976,0.00014675099,0.00033634453,0.000037967187],"category_scores_gemma":[0.0012112024,0.0001204223,0.00013843687,0.00020109817,0.00023829244,0.000053052256,0.000095779964,0.00057868916,9.953279e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010531825,0.0067370553,0.9401542,0.000022487438,0.00069096993,0.000029112867,0.0012726686,0.000004562692,0.0004824735,0.00000396412,0.00012721775,0.039943494],"study_design_scores_gemma":[0.018239332,0.066926636,0.91151875,0.00006509216,0.00033359168,0.0000029369908,0.00078277825,0.000012090418,0.0005606471,0.0000061723645,0.0014458295,0.000106151594],"about_ca_topic_score_codex":0.00037324065,"about_ca_topic_score_gemma":0.002592441,"teacher_disagreement_score":0.060189582,"about_ca_system_score_codex":0.000060168353,"about_ca_system_score_gemma":0.00014762604,"threshold_uncertainty_score":0.4910679},"labels":[],"label_agreement":null},{"id":"W3029372856","doi":"10.1200/jco.2020.38.15_suppl.e22102","title":"Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis","keywords":"Medicine; Dabrafenib; Trametinib; Adverse effect; Internal medicine; Melanoma; Metastatic melanoma; Vemurafenib; Oncology; Cancer","score_opus":0.20203369067340887,"score_gpt":0.4764066622415882,"score_spread":0.2743729715681793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029372856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996659,0.00009347566,0.00014618743,0.00022289879,0.0007580584,0.0002917486,0.000010687645,0.0000023180835,0.0018156589],"genre_scores_gemma":[0.99657893,0.0005597964,0.0018724323,0.0005870038,0.00028650244,0.000007107465,0.000012160769,0.000014270288,0.00008181324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936985,0.0018551255,0.0035906096,0.0003385316,0.0003013328,0.00021591916],"domain_scores_gemma":[0.99674076,0.0005860843,0.0017977466,0.00026278975,0.0003031143,0.00030951892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045996583,0.00015335818,0.0012270854,0.0000667965,0.000017355795,0.0000058604173,0.0004695067,0.00017046185,0.00004316486],"category_scores_gemma":[0.0021628249,0.00012067737,0.00034422264,0.00022249605,0.0001707268,0.000009452559,0.00024189941,0.00042119974,0.0000071583686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003121176,0.0033868859,0.9672778,0.000024602949,0.00034190208,0.00031436636,0.00018569054,0.000010576442,0.00012094785,0.00004555283,0.001260547,0.023909952],"study_design_scores_gemma":[0.00629395,0.020313004,0.96224695,0.000022901446,0.00009139289,0.0000033131594,0.0005064481,0.000018177114,0.0001629093,0.000029062867,0.010194192,0.00011768889],"about_ca_topic_score_codex":0.00007212721,"about_ca_topic_score_gemma":0.0005761447,"teacher_disagreement_score":0.023792263,"about_ca_system_score_codex":0.00001980569,"about_ca_system_score_gemma":0.00034868845,"threshold_uncertainty_score":0.49210802},"labels":[],"label_agreement":null},{"id":"W3029377369","doi":"10.1200/jco.2020.38.15_suppl.2503","title":"The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Cog; Internal medicine; Germ cell tumors; Clinical trial; Population; Oncology; Chemotherapy; Pathology","score_opus":0.07396452243703353,"score_gpt":0.41580437181020385,"score_spread":0.34183984937317036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029377369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957271,0.0006368363,0.00020168048,0.0014736813,0.0007066277,0.0010431499,0.000031563304,0.000006730946,0.00017262524],"genre_scores_gemma":[0.9982993,0.00026831718,0.00046439242,0.0003468239,0.0005510743,0.000038508875,0.0000056936087,0.000020569265,0.0000053044528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98831457,0.0027030732,0.007948715,0.00031036936,0.00039431488,0.00032893827],"domain_scores_gemma":[0.9744416,0.01760993,0.0065905834,0.000240194,0.0005798694,0.0005378381],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012383459,0.00021450677,0.004637912,0.00025323068,0.000056623812,0.000011617766,0.000221097,0.00035681756,0.000016908647],"category_scores_gemma":[0.014264414,0.00012549851,0.0026286175,0.0006647632,0.00024899555,0.00006625076,0.000050413404,0.0007613451,0.0000019609981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083794005,0.011420797,0.64251,0.00038177433,0.012968445,0.0022191333,0.00073200447,0.0012931562,0.005325644,0.00024663788,0.0010801897,0.2380282],"study_design_scores_gemma":[0.03211739,0.043399677,0.8553097,0.000279311,0.013834137,0.0001425167,0.0035267386,0.042443775,0.0059613357,0.000038560578,0.0027495958,0.00019725968],"about_ca_topic_score_codex":0.00007954213,"about_ca_topic_score_gemma":0.00019698967,"teacher_disagreement_score":0.23783095,"about_ca_system_score_codex":0.00022550295,"about_ca_system_score_gemma":0.0010152563,"threshold_uncertainty_score":0.9940389},"labels":[],"label_agreement":null},{"id":"W3029388691","doi":"10.1200/jco.2020.38.15_suppl.1009","title":"Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis","keywords":"Medicine; CDKN2A; Internal medicine; Oncology; Hazard ratio; Biomarker; Proportional hazards model; Breast cancer; Progression-free survival; Cancer; Cancer research; Genetics; Overall survival; Confidence interval; Biology","score_opus":0.17953858133133552,"score_gpt":0.5292489329331808,"score_spread":0.34971035160184527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029388691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90497404,0.0027555036,0.0014664335,0.088334754,0.0015112378,0.00040579433,0.0001235509,0.000016565096,0.0004121303],"genre_scores_gemma":[0.98478675,0.0010078921,0.0016304615,0.010427755,0.0019665766,0.000009180231,0.0000031648774,0.000024948504,0.0001432802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932967,0.0009886227,0.0045061014,0.00028003758,0.0006585292,0.0002700151],"domain_scores_gemma":[0.9896104,0.0028453795,0.0057434086,0.00033793537,0.0009085131,0.0005543634],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034263919,0.00021592817,0.004583086,0.00017768946,0.00005085235,0.0000055188734,0.0004183886,0.00030565646,0.001345437],"category_scores_gemma":[0.005324191,0.00012252762,0.002407877,0.0011169558,0.0004341407,0.00015826577,0.000089003915,0.0011935806,0.0000039889715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07235031,0.0021609778,0.025650917,0.000048052785,0.016661238,0.00017287352,0.00048695688,0.002515065,0.01162719,0.00009707668,0.001059207,0.86717016],"study_design_scores_gemma":[0.1543045,0.013800586,0.5757003,0.00045302857,0.05038011,0.0004466321,0.0010530555,0.0034288927,0.0027423974,0.0006090085,0.19660082,0.00048068017],"about_ca_topic_score_codex":0.000031271655,"about_ca_topic_score_gemma":0.000051278832,"teacher_disagreement_score":0.86668944,"about_ca_system_score_codex":0.00019851624,"about_ca_system_score_gemma":0.0020823854,"threshold_uncertainty_score":0.99956745},"labels":[],"label_agreement":null},{"id":"W3029400833","doi":"10.1200/jco.2020.38.15_suppl.e14044","title":"Utilization of online crowdfunding for alternative cancer treatments at home and abroad.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Cancer; Colorectal cancer; Radiation therapy; Lung cancer; Internal medicine; Family medicine; Surgery","score_opus":0.6368555001257248,"score_gpt":0.6626320944973884,"score_spread":0.025776594371663575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029400833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96278185,0.0006276383,0.0001531999,0.03105272,0.0047991103,0.0003921974,0.00001631591,0.0000038333233,0.00017310998],"genre_scores_gemma":[0.9850062,0.006119489,0.0029331506,0.0011465099,0.0047105355,0.000026693386,0.0000026924793,0.000007672851,0.000047027326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99806654,0.0004242857,0.001052241,0.00010281693,0.00021915014,0.00013493569],"domain_scores_gemma":[0.9900338,0.007524553,0.0016968315,0.000029967585,0.0004217521,0.00029306122],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014776742,0.00005173734,0.00052816956,0.0000399282,0.00010717743,0.000004710722,0.00011100473,0.00018430446,0.00008198215],"category_scores_gemma":[0.017046202,0.00004393309,0.000109415814,0.00013242917,0.000248418,0.000115946415,0.000020532045,0.00016090139,7.9762754e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011275163,0.00055941823,0.41273084,0.000051191088,0.00016805646,0.0000040935056,0.025734793,0.000023387218,0.000055913406,0.0011116898,0.001517116,0.556916],"study_design_scores_gemma":[0.0061286315,0.007229674,0.6503819,0.000111931215,0.00034725774,0.0000020651746,0.005365043,0.0005066671,0.0001672738,0.0032406198,0.32637477,0.00014412237],"about_ca_topic_score_codex":0.0005737709,"about_ca_topic_score_gemma":0.0011303866,"teacher_disagreement_score":0.5567719,"about_ca_system_score_codex":0.00032807374,"about_ca_system_score_gemma":0.0015714349,"threshold_uncertainty_score":0.99123365},"labels":[],"label_agreement":null},{"id":"W3029414691","doi":"10.1200/jco.2020.38.15_suppl.tps3167","title":"Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; Medicine; Isocitrate dehydrogenase; IDH1; Cancer; Cancer research; PARP inhibitor; Internal medicine; Oncology; Poly ADP ribose polymerase; Mutation; Biology; Genetics; Polymerase; Enzyme","score_opus":0.12185797537720819,"score_gpt":0.47379261583734217,"score_spread":0.351934640460134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029414691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931138,0.00010145561,0.00005307063,0.0053948686,0.00035098975,0.00045023215,0.000018572435,0.0000082481365,0.0005087531],"genre_scores_gemma":[0.99403065,0.00021494205,0.0007847835,0.0042700223,0.0006438905,0.0000060479,0.000007535715,0.000021057524,0.00002105593],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99557424,0.00054617616,0.0030005323,0.00022245359,0.00043609878,0.00022048436],"domain_scores_gemma":[0.9958983,0.0007001599,0.002320799,0.00012731261,0.0004422461,0.00051116844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018940432,0.00015912425,0.0019397944,0.00011291689,0.00003294171,0.0000048073025,0.000114572125,0.0002648812,0.00015589356],"category_scores_gemma":[0.0019049243,0.00011515857,0.00024389906,0.00025143515,0.00032015718,0.00012245358,0.000037170656,0.00095446256,0.0000035950347],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88632035,0.021251608,0.029460862,0.00009306807,0.0006975136,0.001140625,0.001187676,0.00006273447,0.0018306279,0.00002587512,0.0027262534,0.055202782],"study_design_scores_gemma":[0.73158735,0.24885364,0.011425198,0.0002476981,0.00029913575,0.00010324896,0.00013429413,0.0005053077,0.002593452,0.00016187748,0.003938765,0.00015001252],"about_ca_topic_score_codex":0.000011251903,"about_ca_topic_score_gemma":0.000012846836,"teacher_disagreement_score":0.22760202,"about_ca_system_score_codex":0.000117579766,"about_ca_system_score_gemma":0.0015604356,"threshold_uncertainty_score":0.46960303},"labels":[],"label_agreement":null},{"id":"W3029418450","doi":"10.1200/jco.2020.38.15_suppl.11564","title":"Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Adverse effect; Sarcoma; Gastroenterology; Oncology; Surgery; Pathology","score_opus":0.01989059988843201,"score_gpt":0.34744818981416203,"score_spread":0.32755758992573003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029418450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975971,0.0007444162,0.0002524336,0.000920627,0.00016494341,0.00018416108,0.0000032083478,0.0000013870133,0.00013170631],"genre_scores_gemma":[0.9985869,0.00035187998,0.0006542665,0.00015032795,0.00022698972,6.350751e-7,0.000009364534,0.000012669533,0.000006972258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978995,0.00040991337,0.0012490294,0.00016015125,0.00015892435,0.00012250846],"domain_scores_gemma":[0.99815214,0.00039839707,0.0010763948,0.000106261214,0.0001407155,0.00012611643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001176422,0.00010352058,0.00071987446,0.00004802362,0.00001447561,0.0000030177623,0.00011747449,0.00025402702,0.0000076127803],"category_scores_gemma":[0.0013783468,0.00007387334,0.0001384155,0.00010166255,0.00013358891,0.0000062065637,0.000078930825,0.00030862648,7.602955e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057304118,0.0005275589,0.42702538,0.0000687435,0.00039478435,0.000017963252,0.00010558622,0.0014998269,0.023619885,0.000008359137,0.00017321466,0.4892546],"study_design_scores_gemma":[0.019453403,0.039052438,0.91817576,0.00006845418,0.0001236645,0.000010713092,0.00001034599,0.00008145949,0.013634153,0.000008075081,0.009271072,0.000110479516],"about_ca_topic_score_codex":0.000005153959,"about_ca_topic_score_gemma":0.000010680961,"teacher_disagreement_score":0.49115038,"about_ca_system_score_codex":0.00002496152,"about_ca_system_score_gemma":0.00023816433,"threshold_uncertainty_score":0.30124673},"labels":[],"label_agreement":null},{"id":"W3029433758","doi":"10.1200/jco.2020.38.15_suppl.e20019","title":"The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Queen's University","funders":"","keywords":"Medicine; Hodgkin lymphoma; Cohort; Survivorship curve; Quality of life (healthcare); Nodular sclerosis; Clinical trial; Lymphoma; Internal medicine; Family medicine; Pediatrics; Cancer","score_opus":0.11986751887498075,"score_gpt":0.47336136035529575,"score_spread":0.353493841480315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029433758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066454,0.0015077619,0.00028470522,0.0052940026,0.0013561549,0.00060671475,0.00001413993,0.000008860336,0.0002631428],"genre_scores_gemma":[0.98945224,0.0013602943,0.004204638,0.0024747353,0.00244197,0.000034091103,0.000004913618,0.000020799529,0.0000062918007],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961261,0.00031380795,0.0023605747,0.0003249322,0.00059697777,0.00027758387],"domain_scores_gemma":[0.98917395,0.008498081,0.0012642546,0.00014807588,0.0006060606,0.0003095859],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002098142,0.00019453192,0.0010696789,0.00015457885,0.00011675903,0.000060870556,0.000297419,0.00025097688,0.000013826158],"category_scores_gemma":[0.011936361,0.00012087996,0.00033037085,0.00018771105,0.000085042666,0.00010817641,0.0001801467,0.00023594158,0.000005778992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041078343,0.0015110009,0.48494297,0.000019512083,0.00021827879,0.000616684,0.0011692378,0.000007084489,0.0000014190251,0.00007132003,0.00090039766,0.50643426],"study_design_scores_gemma":[0.032589406,0.0132011,0.9413855,0.00010131427,0.0006978172,0.0001938875,0.0034853262,0.00020070489,0.000015366955,0.00021802605,0.007799955,0.000111581445],"about_ca_topic_score_codex":0.000019589854,"about_ca_topic_score_gemma":0.00033672943,"teacher_disagreement_score":0.5063227,"about_ca_system_score_codex":0.00040056638,"about_ca_system_score_gemma":0.0011895811,"threshold_uncertainty_score":0.9963865},"labels":[],"label_agreement":null},{"id":"W3029441570","doi":"10.1200/jco.2020.38.15_suppl.1005","title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Seattle Genetics","keywords":"Medicine; Capecitabine; Internal medicine; Metastatic breast cancer; Oncology; Trastuzumab; Progression-free survival; Placebo; Breast cancer; Brain metastasis; Cancer; Surgery; Gastroenterology; Chemotherapy; Metastasis; Pathology; Colorectal cancer","score_opus":0.09446764775303201,"score_gpt":0.42725816797543953,"score_spread":0.3327905202224075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029441570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95381916,0.00038369506,0.0005051288,0.04272139,0.00021367906,0.0018762222,0.00036491858,0.000017473953,0.000098314944],"genre_scores_gemma":[0.9560144,0.00014413077,0.036215108,0.006783402,0.0005111928,0.00012358035,0.000059160746,0.000062047024,0.00008699914],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9968054,0.0004667061,0.0015056187,0.0004009982,0.0004371984,0.00038404364],"domain_scores_gemma":[0.9929233,0.0038864517,0.0011607086,0.00017860119,0.0006962013,0.0011546974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011188133,0.0003199696,0.0020948877,0.00009605597,0.00006482527,0.000020676502,0.0001226994,0.00011129655,0.00025793794],"category_scores_gemma":[0.0018781512,0.00017774598,0.00028281065,0.00027398713,0.00017339403,0.00012245441,0.000032957265,0.00042940897,0.000004934342],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48277727,0.010911418,0.110385485,0.0003587348,0.011520585,0.0009985979,0.00096768345,0.00016067168,0.000027109552,0.00006587564,0.024937924,0.35688865],"study_design_scores_gemma":[0.25613612,0.35046658,0.3066921,0.0005069045,0.0125849955,0.0005512616,0.0010636988,0.00015221034,0.00006239222,0.000019599715,0.07124132,0.00052284217],"about_ca_topic_score_codex":0.00006362983,"about_ca_topic_score_gemma":0.00030024286,"teacher_disagreement_score":0.3563658,"about_ca_system_score_codex":0.00017330634,"about_ca_system_score_gemma":0.0012908357,"threshold_uncertainty_score":0.7248271},"labels":[],"label_agreement":null},{"id":"W3029442987","doi":"10.1200/jco.2020.38.15_suppl.5507","title":"The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"DNA methylation; Epigenomics; Prostate cancer; Methylation; Epigenetics; Transcriptome; Biology; Cancer; Medicine; Epigenome; Oncology; Genetics; Gene; Gene expression","score_opus":0.15295780297870798,"score_gpt":0.4542921394863105,"score_spread":0.3013343365076025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029442987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86976016,0.018789742,0.000021309703,0.10856398,0.0010705377,0.0010558484,0.00038930768,0.000014029819,0.00033509207],"genre_scores_gemma":[0.9751228,0.01982424,0.00039915173,0.0014592541,0.0015058945,0.00003240289,0.00006144399,0.000029452509,0.0015653645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99527824,0.00077773153,0.0025493698,0.00030668962,0.0007520197,0.00033594138],"domain_scores_gemma":[0.99005044,0.005561477,0.0024358334,0.00026847475,0.0012769763,0.0004067797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016502634,0.00022021022,0.0012033422,0.000054951644,0.00019738279,0.000053167983,0.00030703205,0.00014405597,0.00012948528],"category_scores_gemma":[0.0022169775,0.00010569861,0.0003512205,0.00035148472,0.0004800681,0.00017999046,0.00008361741,0.0009973512,0.000012519785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22648239,0.0018447855,0.116082095,0.00043679602,0.009716304,0.0007241703,0.031745218,0.0023959186,0.02666719,0.00016044902,0.1772419,0.40650278],"study_design_scores_gemma":[0.05295495,0.015729582,0.69248146,0.0009924265,0.003999126,0.000046348014,0.015494559,0.0013918304,0.0065691825,0.0021464138,0.20776053,0.00043362065],"about_ca_topic_score_codex":0.0037386157,"about_ca_topic_score_gemma":0.0065639094,"teacher_disagreement_score":0.5763993,"about_ca_system_score_codex":0.00015160092,"about_ca_system_score_gemma":0.005141001,"threshold_uncertainty_score":0.91199154},"labels":[],"label_agreement":null},{"id":"W3029446739","doi":"10.1200/jco.2020.38.15_suppl.6569","title":"SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Cancer; Internal medicine; Biomarker; Oncology; Gastroenterology; Surgery; Immunotherapy","score_opus":0.21989280138548062,"score_gpt":0.4577056458342933,"score_spread":0.23781284444881268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029446739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937304,0.0012554679,0.00002126159,0.0034292547,0.0011293165,0.00016573019,0.000008271732,0.000004205097,0.00025607768],"genre_scores_gemma":[0.99856097,0.0005178508,0.000091196656,0.00064190617,0.0001231482,0.0000021850647,0.0000029871521,0.000007244208,0.00005252924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962271,0.0012433536,0.0020980677,0.00016785965,0.00006428699,0.00019935705],"domain_scores_gemma":[0.99660873,0.0012943238,0.0016531307,0.0001088152,0.0002238352,0.00011117331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027621635,0.00011645149,0.001371491,0.00007208407,0.000036924368,0.0000036974327,0.00019630398,0.0003812248,0.00028571952],"category_scores_gemma":[0.0037008368,0.00009108244,0.00017727302,0.00013486754,0.00028744634,0.00014101336,0.00009808341,0.00091809465,0.000004874061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041748304,0.0027161539,0.69816715,0.000022702166,0.0005107668,0.000064292246,0.0011130054,0.000026821768,0.03540791,0.000055303823,0.0024838878,0.25525716],"study_design_scores_gemma":[0.009197253,0.008680451,0.9655883,0.00003655777,0.0001390773,0.00002842612,0.0005533615,0.000020796277,0.001993339,0.00007023516,0.013598073,0.000094181574],"about_ca_topic_score_codex":0.00030758022,"about_ca_topic_score_gemma":0.00040950603,"teacher_disagreement_score":0.2674211,"about_ca_system_score_codex":0.000049839942,"about_ca_system_score_gemma":0.0010443085,"threshold_uncertainty_score":0.44305146},"labels":[],"label_agreement":null},{"id":"W3029453604","doi":"10.1200/jco.2020.38.15_suppl.7510","title":"Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Cytarabine; Internal medicine; Daunorubicin; Randomization; Surgery; Gastroenterology; Phases of clinical research; Regimen; Randomized controlled trial; Leukemia; Clinical trial","score_opus":0.09289132584472974,"score_gpt":0.44653000318822916,"score_spread":0.3536386773434994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029453604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925049,0.00012574575,0.00003053098,0.0053454945,0.00035849406,0.00084959937,0.00004272124,0.000007900127,0.00073461956],"genre_scores_gemma":[0.9957439,0.00045789752,0.002362179,0.00052590936,0.0007926888,0.000008581336,0.000009098633,0.000028624634,0.00007113434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99313664,0.0011061201,0.0040907743,0.0003949075,0.00090359926,0.00036794183],"domain_scores_gemma":[0.98772854,0.0071235956,0.0032043892,0.00036636996,0.0009231466,0.0006539367],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035531071,0.00021816124,0.0026546794,0.0002851761,0.000027853024,0.0000050190724,0.0004314913,0.00040673505,0.0002366558],"category_scores_gemma":[0.014540951,0.0001523026,0.00031906876,0.000570053,0.0003873376,0.0001432568,0.00015673795,0.0030303267,0.000011392115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78611004,0.021022072,0.044632662,0.0001550809,0.0012851343,0.008878134,0.0066514197,0.00015861765,0.0001289642,0.000011399837,0.016692096,0.11427435],"study_design_scores_gemma":[0.5147561,0.19606307,0.27905473,0.0002996436,0.0005094654,0.000051182833,0.0070056412,0.0003497161,0.00013277378,0.000007969729,0.0016478185,0.000121880636],"about_ca_topic_score_codex":0.00087931915,"about_ca_topic_score_gemma":0.00073094945,"teacher_disagreement_score":0.27135396,"about_ca_system_score_codex":0.00022200306,"about_ca_system_score_gemma":0.0043103625,"threshold_uncertainty_score":0.9992697},"labels":[],"label_agreement":null},{"id":"W3029465352","doi":"10.1200/jco.2020.38.15_suppl.3036","title":"In vitro and in vivo characterization of MDNA11: A long-acting “beta-only” IL-2 superkine in syngeneic mice tumor models and nonhuman primates.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"In vivo; IL-2 receptor; Medicine; In vitro; CD8; Cancer research; Immune system; Pharmacology; Immunotherapy; Interleukin 2; Immunology; T cell; Chemistry; Biology; Biochemistry","score_opus":0.10027242502314637,"score_gpt":0.4046008536617972,"score_spread":0.30432842863865084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029465352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909913,0.000571917,0.00004625621,0.007962884,0.00014423684,0.00018853084,0.0000058486917,0.0000023424955,0.000086717904],"genre_scores_gemma":[0.9946858,0.0017122804,0.0004292457,0.002943185,0.00020483982,0.0000020073019,0.0000021067988,0.000011376629,0.000009156531],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99741995,0.0002116017,0.0019128523,0.00016526895,0.00013921157,0.0001511232],"domain_scores_gemma":[0.9984631,0.0004663642,0.0008149115,0.000060156162,0.00007257471,0.0001228954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015955725,0.00010374104,0.0011218715,0.0001746386,0.000009379419,0.000006009618,0.00006697246,0.00016590666,0.00003525184],"category_scores_gemma":[0.00040236683,0.00008417336,0.00009690095,0.00019924442,0.00012361853,0.00020766818,0.000036719874,0.0005130259,2.1632695e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030792374,0.0007080476,0.15035936,0.00023045554,0.00009359238,0.00063183194,0.0009657779,0.000008405654,0.7798578,0.000004768622,0.00002052611,0.03632706],"study_design_scores_gemma":[0.024310518,0.0058178017,0.9382053,0.0004956409,0.00012749825,0.00051909086,0.00023437188,0.004983802,0.023078918,0.000051439765,0.0019974422,0.00017817975],"about_ca_topic_score_codex":0.00006624205,"about_ca_topic_score_gemma":0.00018072301,"teacher_disagreement_score":0.7878459,"about_ca_system_score_codex":0.00009163651,"about_ca_system_score_gemma":0.00042776455,"threshold_uncertainty_score":0.34324902},"labels":[],"label_agreement":null},{"id":"W3029475900","doi":"10.1200/jco.2020.38.15_suppl.10502","title":"Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥18 months with unfavorable histology and without MYCN amplification: A Children’s Oncology Group (COG) report.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Histology; Cohort; Internal medicine; Stage (stratigraphy); Population; Cog; Neuroblastoma; Gastroenterology; Loss of heterozygosity; Oncology; Allele; Biology; Genetics","score_opus":0.1366729869128355,"score_gpt":0.4900026057362968,"score_spread":0.35332961882346126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029475900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99168336,0.00018275947,0.00013905257,0.006626732,0.00023362301,0.00080785423,0.00004717441,0.000015141528,0.0002642972],"genre_scores_gemma":[0.9951588,0.00032142526,0.0029507163,0.0010944471,0.000262816,0.0000127190815,0.000032018757,0.000029758996,0.00013728115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934977,0.0015050649,0.0036484564,0.000498083,0.0004943144,0.0003563331],"domain_scores_gemma":[0.99204123,0.002722061,0.0031287724,0.00031673844,0.0005267249,0.0012644806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002783749,0.0002561597,0.0023548477,0.0001827678,0.000097500684,0.000013600461,0.00016163418,0.00045058975,0.00013682985],"category_scores_gemma":[0.0061651785,0.00017106665,0.00034508223,0.00021183991,0.0010399565,0.00021618427,0.00014097491,0.001329949,0.000005613799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059189714,0.0044181948,0.925589,0.000028367936,0.0011511422,0.0019628042,0.00014469969,0.0000030121237,0.00041927834,0.00001446276,0.0008010115,0.006278302],"study_design_scores_gemma":[0.027093347,0.09268418,0.8746345,0.000041315463,0.00059260946,0.0022258193,0.000089367204,0.000063937616,0.000029500125,0.000017779837,0.0024123925,0.00011525867],"about_ca_topic_score_codex":0.00008963246,"about_ca_topic_score_gemma":0.00012521718,"teacher_disagreement_score":0.088265985,"about_ca_system_score_codex":0.00027031614,"about_ca_system_score_gemma":0.0018810374,"threshold_uncertainty_score":0.738074},"labels":[],"label_agreement":null},{"id":"W3029487762","doi":"10.1200/jco.2020.38.15_suppl.9600","title":"Physiologic colonic uptake of <sup>18</sup>F-FDG on PET/CT predicts immunotherapy response and gut microbiome diversity in patients with advanced non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Lung cancer; Gastroenterology; Oncology; Microbiome; Immune system; Cancer; Dysbiosis; Immunology; Bioinformatics; Disease","score_opus":0.03424917432139452,"score_gpt":0.36954572707612704,"score_spread":0.3352965527547325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029487762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938764,0.00042928767,0.00004208985,0.0049189925,0.00021078231,0.00038570474,0.000010278662,0.0000075974363,0.000118879616],"genre_scores_gemma":[0.99170846,0.0010109072,0.0022498327,0.0047977674,0.00016841223,0.0000027876076,0.000003446253,0.000019704672,0.00003868229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973648,0.00050428725,0.0013009233,0.0002792397,0.00028538215,0.00026534544],"domain_scores_gemma":[0.99663925,0.0014049745,0.0012434325,0.00014952905,0.00022798868,0.00033480625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001750394,0.00018214661,0.001374651,0.00013031413,0.000059523627,0.0000054059856,0.00023312106,0.00008299159,0.00007571749],"category_scores_gemma":[0.0016037829,0.000124285,0.00020276199,0.0001900116,0.0002939326,0.00006894453,0.0001323003,0.0014377317,0.0000015980892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09517804,0.0021819388,0.85764086,0.00017180879,0.00036503933,0.0012661282,0.0008072049,0.0025021548,0.0055881804,0.0000018782015,0.0015625634,0.032734197],"study_design_scores_gemma":[0.029110659,0.02508551,0.9376596,0.00040967073,0.00017216528,0.000045769728,0.00009798993,0.003696423,0.00006422646,0.000007666851,0.0035314052,0.00011888998],"about_ca_topic_score_codex":0.000027252927,"about_ca_topic_score_gemma":0.0000029292796,"teacher_disagreement_score":0.08001876,"about_ca_system_score_codex":0.00014658115,"about_ca_system_score_gemma":0.00083825254,"threshold_uncertainty_score":0.62463087},"labels":[],"label_agreement":null},{"id":"W3029489750","doi":"10.1200/jco.2020.38.15_suppl.514","title":"Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Estrogen receptor; Anthracycline; Chemotherapy; Taxane; Progesterone receptor; Cancer; Prospective cohort study; Neoadjuvant therapy; Gynecology; Gastroenterology","score_opus":0.02654559309067932,"score_gpt":0.35177627300950526,"score_spread":0.3252306799188259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029489750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.926051,0.00069463067,0.000048112368,0.07266614,0.00018280717,0.00022025859,0.00008710163,0.0000028547709,0.00004704604],"genre_scores_gemma":[0.9926847,0.001504268,0.0006709632,0.004373311,0.0006894818,0.000037472833,0.0000021532721,0.00001921859,0.0000183852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775773,0.00064487976,0.0007975332,0.000323268,0.00019399395,0.0002825818],"domain_scores_gemma":[0.9982676,0.00037135652,0.0006079006,0.00015086801,0.00027774493,0.00032455026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014519125,0.00019040576,0.00079889566,0.000033962275,0.000057406978,0.000017027387,0.00025320268,0.00017460754,0.00001864979],"category_scores_gemma":[0.0003793936,0.000113400405,0.00011071521,0.00017428354,0.00042769522,0.000011310379,0.00011753367,0.00037709172,0.0000027507251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39128673,0.00042738035,0.4536586,0.000008847055,0.0009694139,0.00009971335,0.0032842353,0.00005489529,0.012441668,0.000015570915,0.001046315,0.1367066],"study_design_scores_gemma":[0.0137535855,0.006935149,0.9745727,0.00008203136,0.00006187654,0.00063030317,0.0004412995,0.0000043649525,0.0010446991,0.000020165098,0.0022928165,0.0001609963],"about_ca_topic_score_codex":0.00014086755,"about_ca_topic_score_gemma":0.00012791465,"teacher_disagreement_score":0.5209141,"about_ca_system_score_codex":0.00012679434,"about_ca_system_score_gemma":0.0007851084,"threshold_uncertainty_score":0.46243346},"labels":[],"label_agreement":null},{"id":"W3029508605","doi":"10.1200/jco.2020.38.15_suppl.5024","title":"Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Gene signature; Oncology; Clear cell renal cell carcinoma; Cancer research; Proportional hazards model; Internal medicine; Population; Stromal cell; Gene expression; Gene; Biology; Genetics","score_opus":0.0662741098817285,"score_gpt":0.36992972036046345,"score_spread":0.30365561047873496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029508605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662566,0.0000543824,0.000041805528,0.00198582,0.000086042484,0.00050931453,0.000006492074,0.0000071026834,0.0006833815],"genre_scores_gemma":[0.9939492,0.000035643036,0.0050412863,0.0006086335,0.00019803809,0.000006278183,0.000013865528,0.000033877008,0.00011322694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942053,0.00094271573,0.0032443935,0.00037267964,0.00090862275,0.00032628502],"domain_scores_gemma":[0.99318326,0.0019472594,0.0034892275,0.00023678399,0.0006516698,0.0004918004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015412726,0.000269036,0.0027138437,0.0001977325,0.000017755377,0.0000061921783,0.00016949174,0.0004948276,0.000044428347],"category_scores_gemma":[0.0011893754,0.00014303911,0.00031838444,0.00034116613,0.00014348637,0.00013425921,0.0000390139,0.0013403911,0.0000047431113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0713876,0.004920377,0.9198414,0.00003871963,0.00026050516,0.0013800674,0.0001412403,0.00011731182,0.00014926384,5.192564e-7,0.00020188505,0.0015611354],"study_design_scores_gemma":[0.06625726,0.07380691,0.85727704,0.00015827743,0.0005093086,0.000024395793,0.000068973626,0.00003314519,0.0016154293,0.000002439632,0.00012129969,0.00012552024],"about_ca_topic_score_codex":0.000075478776,"about_ca_topic_score_gemma":0.00014187014,"teacher_disagreement_score":0.06888653,"about_ca_system_score_codex":0.0005055668,"about_ca_system_score_gemma":0.0013297895,"threshold_uncertainty_score":0.58329654},"labels":[],"label_agreement":null},{"id":"W3029511382","doi":"10.1200/jco.2020.38.15_suppl.3581","title":"A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; McGill University Health Centre; Jewish General Hospital; McGill University; Princess Margaret Cancer Centre; Ottawa Hospital; Ozmosis Research (Canada); Université de Montréal; University of Alberta","funders":"","keywords":"Medicine; Gemcitabine; Nausea; Adverse effect; Vomiting; Pharmacokinetics; Dosing; Cancer; Pharmacology; Internal medicine; Oncology; Gastroenterology","score_opus":0.13967479455653486,"score_gpt":0.5086751694984455,"score_spread":0.3690003749419106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029511382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966963,0.000026349628,0.000011619815,0.002186829,0.00008082561,0.00095328334,0.0000054709776,0.0000033465226,0.000035960722],"genre_scores_gemma":[0.998457,0.0000391417,0.0010189549,0.00039063353,0.00004092765,0.000020608415,0.0000032745315,0.00001492893,0.000014501839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715686,0.00042971267,0.0014570052,0.00018566605,0.0005678717,0.00020290079],"domain_scores_gemma":[0.9975829,0.0006119532,0.00095480087,0.00009505305,0.0004272784,0.00032802942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060624717,0.0001258883,0.0013281117,0.00018975046,0.000011715418,0.0000034747768,0.00009225357,0.000055520988,0.000050796363],"category_scores_gemma":[0.0014329456,0.000067980814,0.00006303555,0.00051044737,0.00009725063,0.0001584845,0.000030813902,0.00064011494,0.0000016112351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18519802,0.064419575,0.6715032,0.000060726852,0.0003819942,0.0031378863,0.00035703063,0.00007390739,0.00005619257,0.0000021772605,0.00007223703,0.074737065],"study_design_scores_gemma":[0.19208542,0.3182765,0.4887587,0.00013376684,0.00015359097,0.000011454096,0.00024561153,0.00008719576,0.00006771159,0.0000049147307,0.00013131545,0.000043820066],"about_ca_topic_score_codex":0.000057659352,"about_ca_topic_score_gemma":0.0010444269,"teacher_disagreement_score":0.2538569,"about_ca_system_score_codex":0.00014684185,"about_ca_system_score_gemma":0.00136341,"threshold_uncertainty_score":0.27810165},"labels":[],"label_agreement":null},{"id":"W3029536828","doi":"10.1200/jco.2020.38.15_suppl.tps8553","title":"Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Carfilzomib; Adverse effect; Internal medicine; Dexamethasone; Multiple myeloma; Population; Randomization; Oncology; Clinical trial; Lenalidomide","score_opus":0.05597045505588093,"score_gpt":0.40172916654421975,"score_spread":0.3457587114883388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029536828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928678,0.00023591453,0.00008177241,0.001304297,0.000111372734,0.0047705024,0.000027002327,0.000028195658,0.0005731391],"genre_scores_gemma":[0.9971726,0.00015506275,0.0015130168,0.0005125559,0.0003318504,0.00006689905,0.000043520413,0.000068138484,0.00013633903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99198365,0.0021543105,0.003320674,0.0006231488,0.0011706492,0.00074756495],"domain_scores_gemma":[0.9921896,0.002955652,0.0019888089,0.00039812594,0.0010165104,0.0014512871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022584002,0.00048982585,0.004597129,0.00028469265,0.00018544373,0.000035981608,0.00035364865,0.00033719445,0.000101627666],"category_scores_gemma":[0.0065914225,0.00027915952,0.00047708122,0.00037656902,0.0005123546,0.00022230527,0.0001378065,0.0021526744,0.000018680646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.503927,0.02656343,0.40320364,0.000034245495,0.0017996813,0.014044329,0.0012175653,0.000017287943,0.0000047879403,6.889742e-7,0.00011178351,0.04907556],"study_design_scores_gemma":[0.5803848,0.21704657,0.19834562,0.00020926989,0.0009714507,0.00023761259,0.00043547503,0.0015765581,0.000020362373,0.0000017953666,0.0005848246,0.00018567566],"about_ca_topic_score_codex":0.000208744,"about_ca_topic_score_gemma":0.000739209,"teacher_disagreement_score":0.20485802,"about_ca_system_score_codex":0.00034955828,"about_ca_system_score_gemma":0.001189943,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W3029541940","doi":"10.1200/jco.2020.38.15_suppl.e12556","title":"The association between breast density and HER2-positive breast cancer: A population-based case-control study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Nova Scotia Cancer Centre; Dalhousie University","funders":"Dalhousie University","keywords":"Medicine; Breast cancer; Odds ratio; Gynecology; Confidence interval; Breast biopsy; Obstetrics; Family history; Population; Oncology; Logistic regression; Internal medicine; Cancer; Mammography","score_opus":0.03227930130328613,"score_gpt":0.3798544644318723,"score_spread":0.34757516312858616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029541940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96692365,0.000323122,0.00010503932,0.031980436,0.00025925093,0.00019670952,0.00017369674,0.0000038174326,0.0000343031],"genre_scores_gemma":[0.9962615,0.00012757046,0.00006569772,0.0015569406,0.001953563,0.0000072765597,0.0000048465345,0.000010817454,0.000011799842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793476,0.0006232096,0.0008670438,0.00020765339,0.00019533961,0.00017196691],"domain_scores_gemma":[0.9966157,0.00141858,0.0012215954,0.00009533869,0.00045743477,0.00019135255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013027102,0.00013000307,0.0006279247,0.000014687411,0.00019306918,0.000020370695,0.00010820598,0.00021464797,0.0000055917053],"category_scores_gemma":[0.00079138356,0.00008602056,0.00020126275,0.00006399281,0.000074590236,0.000007136363,0.00005507514,0.0003154901,0.0000011826845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017970472,0.00022074989,0.9539695,0.000002802783,0.0013681621,0.00014224408,0.000053450436,0.000035994206,0.00002788706,0.000003512032,0.00029861505,0.042080052],"study_design_scores_gemma":[0.0048194667,0.001929324,0.9912753,0.000008301559,0.00070560013,0.00033819771,0.0001885965,0.00003323231,0.000019925434,0.000019893077,0.0005794693,0.00008268384],"about_ca_topic_score_codex":0.0003659685,"about_ca_topic_score_gemma":0.0011904963,"teacher_disagreement_score":0.04199737,"about_ca_system_score_codex":0.00013852074,"about_ca_system_score_gemma":0.00035796984,"threshold_uncertainty_score":0.35078168},"labels":[],"label_agreement":null},{"id":"W3029542913","doi":"10.1200/jco.2020.38.15_suppl.10510","title":"Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Anthracycline; Internal medicine; Vincristine; Cog; Minimal residual disease; Lymphoblastic Leukemia; Methotrexate; Clinical trial; Oncology; Leukemia; Chemotherapy; Cancer; Breast cancer; Cyclophosphamide","score_opus":0.0575858487763128,"score_gpt":0.4022068479750589,"score_spread":0.3446209991987461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029542913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783588,0.00032366157,0.0004096772,0.019031601,0.00029097646,0.0007881338,0.000009584213,0.000033768636,0.0007537921],"genre_scores_gemma":[0.9843808,0.00048291555,0.005389945,0.008732193,0.0007993803,0.000017782048,0.000016603895,0.00006220466,0.00011817478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928094,0.00075033004,0.0040290817,0.000691483,0.0009890257,0.00073066924],"domain_scores_gemma":[0.9912201,0.0041097743,0.0023411098,0.00039214277,0.0003526875,0.0015841491],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033449803,0.00040334833,0.0037237448,0.00035223668,0.00005556191,0.000026285243,0.00044926538,0.00095672405,0.000164803],"category_scores_gemma":[0.011104171,0.00026328414,0.00043632128,0.000437409,0.00082530454,0.00023517659,0.00031425545,0.0026701596,0.000046327586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007013564,0.0013210585,0.93699235,0.00003772317,0.0020735043,0.030103805,0.00016466704,0.000047871137,0.00007146645,0.000056750636,0.0020628292,0.020054441],"study_design_scores_gemma":[0.03094122,0.035048842,0.83300805,0.00012060008,0.0008149899,0.09635566,0.0000660007,0.00037011353,0.000006843683,0.0000849449,0.002958773,0.00022395003],"about_ca_topic_score_codex":0.00022924629,"about_ca_topic_score_gemma":0.000120251214,"teacher_disagreement_score":0.10398426,"about_ca_system_score_codex":0.0019123426,"about_ca_system_score_gemma":0.008930047,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W3029545901","doi":"10.1200/jco.2020.38.15_suppl.7502","title":"Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Ponatinib; Interim analysis; Population; Cohort; Gastroenterology; Randomized controlled trial; Dasatinib; Imatinib","score_opus":0.23149264534880898,"score_gpt":0.4974280322814075,"score_spread":0.2659353869325985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029545901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497986,0.00024224739,0.0005923235,0.002595629,0.00028132094,0.00039905874,0.0000036173085,0.000008473615,0.0008974641],"genre_scores_gemma":[0.99186957,0.000043245404,0.007062138,0.00051011646,0.0004669502,0.000004041143,0.0000022465679,0.000019580832,0.000022110265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387115,0.0004762836,0.004475725,0.0002611027,0.0006680961,0.000247653],"domain_scores_gemma":[0.9918553,0.0026891215,0.004164015,0.0002924822,0.0005952638,0.0004037982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003048858,0.00018089531,0.00321661,0.00030117054,0.00002539084,0.0000047946596,0.00028612465,0.00022985076,0.0003823602],"category_scores_gemma":[0.00684565,0.00013284001,0.0010255262,0.0007479845,0.00016158009,0.00009789306,0.00015736956,0.00090726145,0.000006464924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014743906,0.011210151,0.84845144,0.00022208,0.020075187,0.0025443342,0.004140597,0.0013969429,0.0033523412,0.00003347132,0.00030672317,0.093522854],"study_design_scores_gemma":[0.050966706,0.08582002,0.8318751,0.0002965364,0.016619468,0.00014518091,0.0050205393,0.0074823885,0.00069197564,0.000097245145,0.0007657069,0.00021917607],"about_ca_topic_score_codex":0.000098449724,"about_ca_topic_score_gemma":0.00012966634,"teacher_disagreement_score":0.09330368,"about_ca_system_score_codex":0.0003119987,"about_ca_system_score_gemma":0.0015721457,"threshold_uncertainty_score":0.81953764},"labels":[],"label_agreement":null},{"id":"W3029553330","doi":"10.1200/jco.2020.38.15_suppl.e13052","title":"Comparison of treatment-related adverse events (TRAE) of different CDK4/6 inhibitors (CDK4/6i) in metastatic breast cancer (MBC): A network meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Internal medicine; Discontinuation; Hazard ratio; Oncology; Tolerability; Adverse effect; Randomized controlled trial; Metastatic breast cancer; Breast cancer; Cancer; Confidence interval; Estrogen receptor","score_opus":0.2817822888061318,"score_gpt":0.518897369908049,"score_spread":0.2371150811019172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029553330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806552,0.0070532225,0.00051242963,0.010506973,0.00058012526,0.0005141824,0.00006390657,0.000011621985,0.00010236596],"genre_scores_gemma":[0.9960393,0.0004976094,0.0022816765,0.00069821405,0.00037353463,0.000015808895,0.0000080947575,0.000028775345,0.000057027115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99190867,0.0010439408,0.005811443,0.00032520946,0.0005604759,0.000350242],"domain_scores_gemma":[0.99143237,0.001718993,0.005650922,0.00026499623,0.0004393145,0.0004934151],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012248409,0.0003303375,0.008333863,0.00026366,0.000022065022,0.000001528164,0.00022926276,0.0002665165,0.0009775865],"category_scores_gemma":[0.0004517203,0.0002071102,0.003402217,0.00094772386,0.00028765982,0.00012484058,0.00005752327,0.0008692937,0.0000038371313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01504373,0.0064930436,0.6823711,0.00012023732,0.21948591,0.00021246074,0.0010801039,0.040963557,0.0004992471,0.00006522775,0.00018027326,0.0334851],"study_design_scores_gemma":[0.027476678,0.020225206,0.6453499,0.00017056253,0.298536,0.00010804747,0.0007968013,0.0034136116,0.0005584551,0.00052043283,0.002531723,0.00031255893],"about_ca_topic_score_codex":0.00015932666,"about_ca_topic_score_gemma":0.00043972628,"teacher_disagreement_score":0.079050094,"about_ca_system_score_codex":0.00044613506,"about_ca_system_score_gemma":0.0010729948,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W3029554970","doi":"10.1200/jco.2020.38.15_suppl.6057","title":"Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Clinical endpoint; Interim analysis; Progression-free survival; Oncology; Ovarian cancer; BRCA mutation; Tolerability; Phases of clinical research; Adverse effect; Chemotherapy; Surgery; Cancer; Clinical trial","score_opus":0.1323261844005708,"score_gpt":0.4935033366550821,"score_spread":0.3611771522545113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029554970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8822407,0.0002307221,0.071371324,0.039002758,0.0044544428,0.0015698061,0.00033647538,0.000051877894,0.00074186135],"genre_scores_gemma":[0.9575495,0.0013585974,0.0085878465,0.028384645,0.0036520278,0.00006359213,0.00015658846,0.00007739015,0.00016978507],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99320966,0.00049548066,0.004537828,0.00063051254,0.0005790626,0.00054744625],"domain_scores_gemma":[0.9902953,0.001934353,0.0044521494,0.00034486983,0.0020839162,0.00088943803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022388557,0.00041160366,0.0034188735,0.00033228646,0.000108062006,0.000026135443,0.00032335188,0.00067310093,0.00044522065],"category_scores_gemma":[0.002311448,0.00032774577,0.0015593116,0.0008506547,0.00033762155,0.00025148247,0.000055177683,0.0015450077,0.000020715286],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34369868,0.016029023,0.047330253,0.0003100066,0.024874052,0.0009169142,0.0054515274,0.0020636013,0.02208324,0.00014054675,0.1825487,0.35455346],"study_design_scores_gemma":[0.4085389,0.10948082,0.11188426,0.0013396777,0.0050555435,0.0001416252,0.00062434404,0.06149987,0.008854204,0.00053466705,0.29083574,0.0012103326],"about_ca_topic_score_codex":0.00006012631,"about_ca_topic_score_gemma":0.00003344593,"teacher_disagreement_score":0.35334313,"about_ca_system_score_codex":0.0006661578,"about_ca_system_score_gemma":0.0019637605,"threshold_uncertainty_score":0.99991745},"labels":[],"label_agreement":null},{"id":"W3029558061","doi":"10.1200/jco.2020.38.15_suppl.10518","title":"Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Refractory (planetary science); Internal medicine; Blinatumomab; Gastroenterology; Surgery; Lymphoblastic Leukemia; Leukemia","score_opus":0.15579777345609733,"score_gpt":0.46880294045502197,"score_spread":0.31300516699892467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029558061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783966,0.00033804434,0.0003978439,0.017372381,0.0011009413,0.0015701276,0.000011029138,0.000027786502,0.0007852502],"genre_scores_gemma":[0.9841716,0.0004887554,0.0031722726,0.008081801,0.0029047793,0.000026888718,0.0000028278223,0.000083510175,0.0010675625],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9945806,0.0006896993,0.0025545727,0.00061039464,0.00096430385,0.00060037675],"domain_scores_gemma":[0.99075735,0.0054556006,0.0011483969,0.00039020833,0.0007419924,0.001506437],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039019035,0.00032911386,0.0022412564,0.00033545445,0.00012058791,0.000049018872,0.0003987695,0.0005889217,0.00035051754],"category_scores_gemma":[0.009441805,0.0002594747,0.00055394875,0.0003633506,0.00019695667,0.00016713238,0.00021318099,0.0019817797,0.00006322905],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11625657,0.0056313397,0.013346832,0.00016107768,0.0025175544,0.006096353,0.0022873853,0.00009601681,0.041833412,0.00003872011,0.01760921,0.7941255],"study_design_scores_gemma":[0.09369003,0.47975874,0.17828462,0.00033948672,0.0022825275,0.0014397735,0.0013169762,0.00069087883,0.001982982,0.00022603721,0.23940133,0.0005866345],"about_ca_topic_score_codex":0.000008322726,"about_ca_topic_score_gemma":0.00002182142,"teacher_disagreement_score":0.79353887,"about_ca_system_score_codex":0.001015665,"about_ca_system_score_gemma":0.0035383604,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W3029590709","doi":"10.1200/jco.2020.38.15_suppl.5550","title":"Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Abiraterone acetate; Internal medicine; Prednisone; Cohort; Oncology; Biomarker; Cancer; Urology; Androgen receptor; Androgen deprivation therapy","score_opus":0.11320174205275545,"score_gpt":0.4281859025036265,"score_spread":0.314984160450871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029590709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634696,0.00161236,0.000024267916,0.009710722,0.00017008408,0.0016109473,0.00019074437,0.000020149186,0.0003137656],"genre_scores_gemma":[0.98965436,0.00749714,0.0012763042,0.0007551835,0.00013585955,0.00003410169,0.00006027135,0.000046753186,0.0005400505],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943501,0.0007717676,0.002943456,0.0006080755,0.0007349903,0.00059165596],"domain_scores_gemma":[0.99534833,0.001365105,0.0015006072,0.00022977965,0.0006599426,0.0008962365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002068475,0.000377951,0.0022297762,0.0001802332,0.0001093538,0.00004855951,0.0001569455,0.00026057198,0.00006663794],"category_scores_gemma":[0.0020227204,0.00021711885,0.0001576776,0.00049567176,0.0006170619,0.0002837037,0.00011610585,0.0010240298,0.000005117284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6949121,0.0018873666,0.22413762,0.00034373847,0.002096068,0.002900038,0.0012402328,0.00020227354,0.0006239771,0.000007488011,0.00060170004,0.071047455],"study_design_scores_gemma":[0.15708993,0.02845639,0.808353,0.00043979872,0.0009937088,0.00014187623,0.00019338509,0.0009950205,0.00020166689,0.000013562551,0.002884114,0.00023752032],"about_ca_topic_score_codex":0.0002698033,"about_ca_topic_score_gemma":0.0006276727,"teacher_disagreement_score":0.5842154,"about_ca_system_score_codex":0.0005248526,"about_ca_system_score_gemma":0.0029777817,"threshold_uncertainty_score":0.885385},"labels":[],"label_agreement":null},{"id":"W3029595740","doi":"10.1200/jco.2020.38.15_suppl.12063","title":"Impact of preexisting cardiovascular disease (CVD) on treatments and outcomes of patients with breast or lung cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Lung cancer; Internal medicine; Cancer; Cancer registry; Proportional hazards model; Logistic regression; Population; Radiation therapy; Oncology; Disease; Surgery","score_opus":0.09049461674506885,"score_gpt":0.44860574017812926,"score_spread":0.3581111234330604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029595740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841994,0.0002394597,0.00004166097,0.0008141843,0.000079168,0.00025369972,0.0000497095,0.0000030769525,0.00009911584],"genre_scores_gemma":[0.9989087,0.00026574786,0.0002571002,0.00031343478,0.00022623944,0.0000019983438,0.0000037927255,0.000011613431,0.000011390866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983479,0.0001560504,0.00089630636,0.0001311175,0.00036768173,0.00010097165],"domain_scores_gemma":[0.99780434,0.0004838662,0.00090129685,0.00012354758,0.00031337922,0.0003735861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040208336,0.00011022567,0.0014047105,0.00004110149,0.000015601045,0.0000021351927,0.00005119153,0.00011250103,0.00002901277],"category_scores_gemma":[0.0009725327,0.00005883903,0.0007176831,0.000087193606,0.000105963074,0.00006142051,0.000014659167,0.00025487132,1.7361315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015597651,0.0008648296,0.902302,0.00008601635,0.00578593,0.0000732837,0.00011019094,0.00018683652,0.00012620889,0.0000015505341,0.00005330744,0.074812174],"study_design_scores_gemma":[0.013624391,0.012302113,0.9714584,0.0001910045,0.002000639,0.000017356455,0.000019682871,0.00008255118,0.00018665346,0.0000045956263,0.00006161981,0.000051025458],"about_ca_topic_score_codex":0.000045748257,"about_ca_topic_score_gemma":0.0000029211299,"teacher_disagreement_score":0.07476115,"about_ca_system_score_codex":0.00011395506,"about_ca_system_score_gemma":0.0008497172,"threshold_uncertainty_score":0.2399386},"labels":[],"label_agreement":null},{"id":"W3029622210","doi":"10.1200/jco.2020.38.15_suppl.tps5091","title":"A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Bladder cancer; Cystectomy; Cisplatin; Internal medicine; Oncology; Chemotherapy; Nivolumab; Carboplatin; Cancer; Urology; Immunotherapy","score_opus":0.07030212255951653,"score_gpt":0.43265832980849134,"score_spread":0.3623562072489748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029622210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98337823,0.0013233757,0.00017184035,0.011570011,0.0004081347,0.0027897416,0.00003219734,0.000017969705,0.0003085086],"genre_scores_gemma":[0.99065423,0.0040548397,0.0006027138,0.0040155975,0.00028833628,0.00008703845,0.000020117248,0.00006533189,0.00021181339],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919638,0.0013775832,0.0047335215,0.0005693144,0.00087919575,0.00047658902],"domain_scores_gemma":[0.99227536,0.0034864678,0.0027381275,0.0002740998,0.00065004005,0.0005759058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027517783,0.00043305996,0.0055222223,0.0003115549,0.000045162487,0.000016601061,0.00027538257,0.00044921337,0.0005068543],"category_scores_gemma":[0.001994747,0.00027406667,0.0005165144,0.0007498815,0.00036405431,0.00023655788,0.00006555013,0.0013678381,0.0000049335767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86951077,0.03736599,0.026356027,0.00008227545,0.0020254003,0.0037061283,0.006686719,0.00011849961,0.0015902541,0.000008693716,0.0036731923,0.048876043],"study_design_scores_gemma":[0.88662386,0.093807265,0.011835161,0.0004312839,0.0010983099,0.00009771906,0.0019971274,0.0008913865,0.0010016358,0.00005063942,0.0018783245,0.00028728205],"about_ca_topic_score_codex":0.0016001727,"about_ca_topic_score_gemma":0.002259963,"teacher_disagreement_score":0.05644127,"about_ca_system_score_codex":0.00035943347,"about_ca_system_score_gemma":0.0034757736,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W3029637120","doi":"10.1200/jco.19.03355","title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Idelalisib; Medicine; Rituximab; Chronic lymphocytic leukemia; Refractory (planetary science); Internal medicine; Oncology; Leukemia; Lymphoma; Ibrutinib","score_opus":0.20716221785901862,"score_gpt":0.5057558719860992,"score_spread":0.29859365412708055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029637120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823403,0.0021258502,0.00035309378,0.004787802,0.004361278,0.00328856,0.000028401666,0.00006474442,0.002649967],"genre_scores_gemma":[0.98460144,0.00417642,0.0022279834,0.0017643131,0.0061239447,0.00006143848,0.000027447013,0.00010812337,0.0009089108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9821843,0.0026703896,0.011051755,0.00084651704,0.0021144105,0.0011326628],"domain_scores_gemma":[0.96049565,0.030420212,0.0056058723,0.00079825387,0.001028312,0.001651676],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.013952238,0.00061666075,0.010772885,0.0005521682,0.000081132464,0.00002834777,0.0010057942,0.0016473397,0.0023676127],"category_scores_gemma":[0.09644115,0.00039920598,0.0019454845,0.0011102173,0.0015462115,0.00028352594,0.0004001073,0.0040311823,0.00011011053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9460105,0.003717092,0.0000018477683,0.00041215995,0.0013402357,0.010913195,0.00048636264,0.00063049264,0.00018378094,0.000055709457,0.008368178,0.027880482],"study_design_scores_gemma":[0.81852615,0.07638508,0.000006056435,0.0005387063,0.0015338763,0.0007524462,0.0002826987,0.080244265,0.00019025632,0.00003618706,0.021197991,0.00030631092],"about_ca_topic_score_codex":0.00086356443,"about_ca_topic_score_gemma":0.00029411938,"teacher_disagreement_score":0.25970903,"about_ca_system_score_codex":0.09414819,"about_ca_system_score_gemma":0.35385722,"threshold_uncertainty_score":0.999846},"labels":[],"label_agreement":null},{"id":"W3029640994","doi":"10.1200/jco.2020.38.15_suppl.3030","title":"Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Medicine; Lymphoma; Immune system; Refractory (planetary science); Antibody; Cancer; Immune checkpoint; Internal medicine; Cancer research; Oncology; Pharmacology; Immunology; Immunotherapy; Biology","score_opus":0.07030861627519307,"score_gpt":0.38405563916095237,"score_spread":0.3137470228857593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029640994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742246,0.00013831825,0.000008471482,0.0011409568,0.0008017689,0.00041480505,0.000003807569,0.000004859162,0.00006456765],"genre_scores_gemma":[0.9993277,0.00002315721,0.00011651665,0.00038462333,0.00007209003,0.000006747206,0.0000127452895,0.0000124628305,0.000043958327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960269,0.0010482627,0.0023796018,0.00021314695,0.00014849719,0.00018362637],"domain_scores_gemma":[0.99586684,0.0011973953,0.0024238634,0.00018420612,0.00027131574,0.000056385226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011707682,0.00014658972,0.00091569073,0.00011240856,0.000075850636,0.00000434555,0.00028380498,0.00033899082,0.00011824998],"category_scores_gemma":[0.0025123272,0.00008613384,0.00014478365,0.00030813602,0.00024496383,0.00024096339,0.0000786618,0.0006509094,0.000005951161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020488635,0.017446661,0.908738,0.000018994977,0.00028273952,0.000019024857,0.0018826055,0.00071741565,0.0041559325,0.000039680086,0.0008138456,0.045396436],"study_design_scores_gemma":[0.05767741,0.022161478,0.9130584,0.00009411074,0.0000751244,0.0000044627495,0.0002508034,0.000048409736,0.00037299265,0.000040200855,0.006122574,0.00009404491],"about_ca_topic_score_codex":0.000022613349,"about_ca_topic_score_gemma":0.00025088058,"teacher_disagreement_score":0.04530239,"about_ca_system_score_codex":0.00015314741,"about_ca_system_score_gemma":0.0006218312,"threshold_uncertainty_score":0.35124362},"labels":[],"label_agreement":null},{"id":"W3029657105","doi":"10.1200/jco.2020.38.15_suppl.8531","title":"Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cereblon; Bone marrow; Flow cytometry; Pharmacology; Internal medicine; Immunology; Ubiquitin ligase","score_opus":0.20102354672216266,"score_gpt":0.509867596448804,"score_spread":0.3088440497266413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029657105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611753,0.0001219795,0.00018321461,0.0019468743,0.0003067897,0.0011243701,0.000017738093,0.000015449592,0.00016603165],"genre_scores_gemma":[0.99663174,0.000190488,0.002262244,0.00037661,0.0004057465,0.000027292,0.000010729762,0.000031435167,0.000063690735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938652,0.0015005489,0.0031535195,0.0003929557,0.0006936251,0.00039414916],"domain_scores_gemma":[0.9937019,0.003445487,0.001639697,0.0001717513,0.0004377401,0.0006034222],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031081033,0.00023314604,0.0016829991,0.000548698,0.00004042573,0.000008905835,0.00020025254,0.00035328922,0.000097218],"category_scores_gemma":[0.0103782695,0.00018835772,0.00038022682,0.00068923517,0.00014776073,0.00020729756,0.00008197864,0.0017869921,0.0000190901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10633036,0.09549888,0.68217015,0.00006814417,0.00060388417,0.0023011921,0.0011387836,0.000094226525,0.037740596,0.0000036134363,0.00013345011,0.07391672],"study_design_scores_gemma":[0.20298177,0.03859775,0.7308723,0.00010720072,0.00020583381,0.00008668768,0.0005225774,0.02505854,0.0005809969,0.00001019229,0.00086399924,0.00011216976],"about_ca_topic_score_codex":0.00012878823,"about_ca_topic_score_gemma":0.0006522021,"teacher_disagreement_score":0.09665142,"about_ca_system_score_codex":0.0005420847,"about_ca_system_score_gemma":0.0019573711,"threshold_uncertainty_score":0.9979577},"labels":[],"label_agreement":null},{"id":"W3029661519","doi":"10.1200/jco.2020.38.15_suppl.7006","title":"Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcopenia; Cancer; Internal medicine; Lung cancer; Population; Physical therapy","score_opus":0.14793885372919444,"score_gpt":0.4596616396273944,"score_spread":0.3117227858982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029661519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96595407,0.00089434726,0.00004388499,0.032118056,0.00047394098,0.0003538062,0.000008094472,0.000010947463,0.00014282865],"genre_scores_gemma":[0.9893695,0.0015579411,0.0037154185,0.004803867,0.000513835,0.000005212449,0.000008898396,0.00001600182,0.000009301904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702656,0.0005669638,0.0016994762,0.00018691333,0.00030139257,0.0002186935],"domain_scores_gemma":[0.9965203,0.0010145162,0.001200919,0.00007905218,0.000467596,0.00071760785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010259239,0.00010789888,0.0011367218,0.000090831425,0.00006723224,0.000009119266,0.000060177776,0.00019762485,0.000027411177],"category_scores_gemma":[0.002297559,0.000080968864,0.00010217803,0.0001946517,0.00014298325,0.00019966484,0.00002485713,0.0013668395,0.0000012838028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013936791,0.00021574594,0.968794,0.00014294457,0.00003587291,0.00006526999,0.0007049058,0.000021011238,7.145351e-7,0.000038099348,0.0004038518,0.028183931],"study_design_scores_gemma":[0.017034471,0.008028188,0.9562929,0.00039840062,0.000046904992,0.000005204498,0.00059967424,0.000049278202,2.5279806e-7,0.000019043493,0.017453372,0.000072276],"about_ca_topic_score_codex":0.000101488,"about_ca_topic_score_gemma":0.0004769316,"teacher_disagreement_score":0.028111655,"about_ca_system_score_codex":0.0002089966,"about_ca_system_score_gemma":0.00121119,"threshold_uncertainty_score":0.59383136},"labels":[],"label_agreement":null},{"id":"W3029673764","doi":"10.1200/jco.2020.38.15_suppl.e24083","title":"Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; NOSM University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Denosumab; Prostate cancer; Osteonecrosis of the jaw; Internal medicine; Breast cancer; Oncology; Zoledronic acid; Hazard ratio; Bisphosphonate; Bone metastasis; Surgery; Cancer; Osteoporosis; Confidence interval","score_opus":0.1587147414461495,"score_gpt":0.49467693043542915,"score_spread":0.33596218898927965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029673764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983626,0.0103749875,0.000013926629,0.0038383189,0.00017324461,0.0018439856,0.00010946587,0.0000041060966,0.00001593177],"genre_scores_gemma":[0.98864365,0.006586228,0.0014900253,0.0031162635,0.00007866376,0.00004277407,0.0000070134856,0.000016699905,0.000018675524],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9955408,0.00045161272,0.0032720126,0.00019714561,0.00028992945,0.0002484895],"domain_scores_gemma":[0.9953413,0.0013813492,0.0023999214,0.00010045274,0.0002833884,0.00049360376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002270081,0.00014320498,0.0026650683,0.00008959083,0.000026335765,0.000005286519,0.000059571197,0.00010037343,0.000022947317],"category_scores_gemma":[0.0042688474,0.0000913596,0.00022322917,0.00018149265,0.00007931194,0.00009231204,0.00003330346,0.00035131743,0.0000011508329],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17978437,0.023041163,0.21718407,0.4506566,0.0044047907,0.008952051,0.0019577276,0.000066396795,0.0016598674,0.000083003215,0.0047720303,0.10743795],"study_design_scores_gemma":[0.17579958,0.06369021,0.58330894,0.15986782,0.012625139,0.0013960556,0.0004493316,0.0009141105,0.00020767775,0.00014941092,0.0010361153,0.0005556237],"about_ca_topic_score_codex":0.00006758833,"about_ca_topic_score_gemma":0.00007492631,"teacher_disagreement_score":0.36612487,"about_ca_system_score_codex":0.00013453412,"about_ca_system_score_gemma":0.0008081096,"threshold_uncertainty_score":0.5110517},"labels":[],"label_agreement":null},{"id":"W3029686450","doi":"10.1200/jco.2020.38.15_suppl.5566","title":"TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Prostate cancer; Docetaxel; Clinical endpoint; Taxane; Enzalutamide; Phases of clinical research; Urology; Cancer; Surgery; Chemotherapy; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.13251995318821508,"score_gpt":0.494144011813852,"score_spread":0.3616240586256369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029686450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956688,0.00008992304,0.0001182119,0.0028475868,0.00014989292,0.0009392616,0.00007207103,0.000011597952,0.00010261301],"genre_scores_gemma":[0.99730164,0.00006892082,0.0014600732,0.0008961979,0.00012163062,0.00004906643,0.000038464488,0.000018493243,0.000045502824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953629,0.0006536317,0.0029854798,0.00032289606,0.000482745,0.00019234647],"domain_scores_gemma":[0.9961706,0.0003506571,0.0021464266,0.00020835076,0.0007666952,0.00035727155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013024788,0.00018980417,0.0017544245,0.0003029775,0.00006293094,0.000014022678,0.000105573214,0.00009921,0.00023589973],"category_scores_gemma":[0.000589389,0.00013829388,0.0002451278,0.0008436293,0.00022751621,0.00024449953,0.000050187035,0.00063644885,8.632587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08197122,0.04879446,0.8122274,0.0002149969,0.012236073,0.0016104871,0.011571927,0.0024357983,0.012473646,0.00003241517,0.0022426392,0.014188933],"study_design_scores_gemma":[0.11683125,0.2342643,0.63107866,0.00028569068,0.006566052,0.000038684993,0.0032337466,0.0033749812,0.0010817158,0.000037823153,0.0028809893,0.0003261188],"about_ca_topic_score_codex":0.00011701164,"about_ca_topic_score_gemma":0.0011364482,"teacher_disagreement_score":0.18546984,"about_ca_system_score_codex":0.00016163244,"about_ca_system_score_gemma":0.0009640615,"threshold_uncertainty_score":0.56394607},"labels":[],"label_agreement":null},{"id":"W3029699663","doi":"10.1200/jco.2020.38.15_suppl.5515","title":"Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Hazard ratio; Prostate cancer; Internal medicine; Placebo; Discontinuation; Urology; Oncology; Gynecology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","score_opus":0.18356915723541115,"score_gpt":0.4844959808260795,"score_spread":0.30092682359066836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029699663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852928,0.0010719948,0.000049367914,0.0065134033,0.00023196395,0.006049134,0.00004030432,0.0000093158405,0.0007417225],"genre_scores_gemma":[0.9965587,0.0009823133,0.0007111767,0.00038341523,0.0005621729,0.00034195773,0.000017444741,0.000032084714,0.00041069678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923109,0.0014470611,0.004267997,0.00043560853,0.001114111,0.00042436976],"domain_scores_gemma":[0.9919787,0.0038407247,0.0026850346,0.00021913,0.0006940811,0.0005822992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049896436,0.00032202626,0.00527895,0.00020672427,0.000053523192,0.000029040408,0.00023309798,0.00020746917,0.00035687163],"category_scores_gemma":[0.0013268907,0.00018323853,0.0005213576,0.00031627723,0.00036078045,0.00020924922,0.000060079983,0.0013088693,0.000004211122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9495468,0.008961974,0.027069608,0.00007234594,0.003839173,0.0027823113,0.0030360927,0.00046167543,0.0008831197,0.000017562515,0.00028775964,0.0030415787],"study_design_scores_gemma":[0.9513817,0.035976816,0.0063325926,0.00022261812,0.0021939077,0.000021969692,0.00157651,0.0016171607,0.00020822596,0.00007436283,0.00023090276,0.00016327035],"about_ca_topic_score_codex":0.0012113691,"about_ca_topic_score_gemma":0.001838863,"teacher_disagreement_score":0.027014842,"about_ca_system_score_codex":0.00029202484,"about_ca_system_score_gemma":0.004626501,"threshold_uncertainty_score":0.8207214},"labels":[],"label_agreement":null},{"id":"W3029703039","doi":"10.1200/jco.2020.38.15_suppl.e12619","title":"Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy for breast cancer: Results from a prospective institutional database.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Chemotherapy; Oncology; Prospective cohort study; Stage (stratigraphy); Cancer; Neoadjuvant therapy; Gastroenterology; Surgery","score_opus":0.09394041852871565,"score_gpt":0.46541195548165726,"score_spread":0.3714715369529416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029703039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906725,0.0011972984,0.00028140997,0.005144231,0.00013808563,0.00016078551,0.0023775755,0.0000010840259,0.000027005748],"genre_scores_gemma":[0.99172837,0.00355573,0.0037735165,0.00028873084,0.0006049444,0.0000069272355,0.00003263302,0.00000702287,0.000002144995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836034,0.00008113157,0.0011318178,0.00021501063,0.00010335088,0.000108347434],"domain_scores_gemma":[0.9977405,0.0003830378,0.0012225158,0.00009257976,0.00047052413,0.0000908318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038147744,0.00011272675,0.0007549854,0.000027615586,0.000018072074,0.0000020560196,0.00011736681,0.00014406667,0.000008793563],"category_scores_gemma":[0.001455888,0.00007837415,0.00018232693,0.00008674147,0.00037318392,0.000012506451,0.000054543594,0.00014287139,8.801565e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047368605,0.0011958402,0.8203934,0.000039216167,0.0012343724,0.000028643444,0.00032414324,0.00045865992,0.04565613,0.00004253371,0.00069394364,0.08256451],"study_design_scores_gemma":[0.014670117,0.0039601536,0.9762171,0.00009502696,0.00008723203,0.000041732994,0.00007266747,0.00012249796,0.0037116047,0.00014245271,0.0007913407,0.000088060944],"about_ca_topic_score_codex":0.00075369206,"about_ca_topic_score_gemma":0.00039485685,"teacher_disagreement_score":0.15582371,"about_ca_system_score_codex":0.000042771575,"about_ca_system_score_gemma":0.0012227539,"threshold_uncertainty_score":0.31960052},"labels":[],"label_agreement":null},{"id":"W3029703953","doi":"10.1200/jco.2020.38.15_suppl.tps11569","title":"SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Fludarabine; Context (archaeology); Internal medicine; Synovial sarcoma; Myxoid liposarcoma; Phases of clinical research; Sarcoma; Oncology; Clinical trial; Liposarcoma; Surgery; Cyclophosphamide; Chemotherapy; Pathology; Adverse effect","score_opus":0.12720236253995762,"score_gpt":0.47421580929525387,"score_spread":0.3470134467552962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029703953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218637,0.0001116735,0.000047923197,0.0033030766,0.00089962856,0.0012064194,0.000017014221,0.000010441427,0.0022174777],"genre_scores_gemma":[0.9915895,0.00032223391,0.0038161671,0.0015173256,0.0019288078,0.0000049120663,0.000006628811,0.000053998727,0.00076042174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934144,0.0008982844,0.0035972106,0.0003864199,0.0011978903,0.0005058048],"domain_scores_gemma":[0.9936919,0.0023740658,0.0020145644,0.00035025607,0.0006720387,0.00089716713],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027378418,0.00026726953,0.0027157748,0.00025905817,0.0000417801,0.0000114669965,0.00042103944,0.0004316322,0.0020392684],"category_scores_gemma":[0.0022379453,0.00017640303,0.0005625216,0.0005537236,0.00041506966,0.00017521842,0.00016303897,0.0021432247,0.000028907094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8042608,0.034616243,0.007399278,0.00010528402,0.0002848734,0.0014545892,0.00049136387,0.00002058243,0.009376648,0.0000047760636,0.0013835214,0.14060202],"study_design_scores_gemma":[0.46892688,0.45647657,0.006137608,0.00013161269,0.00022156796,0.0000337887,0.00018536784,0.000100033976,0.0020825646,0.000020327116,0.06550667,0.00017701065],"about_ca_topic_score_codex":0.000018470788,"about_ca_topic_score_gemma":0.000035641046,"teacher_disagreement_score":0.42186034,"about_ca_system_score_codex":0.00023410787,"about_ca_system_score_gemma":0.003155931,"threshold_uncertainty_score":0.998873},"labels":[],"label_agreement":null},{"id":"W3029721605","doi":"10.1200/jco.2020.38.15_suppl.12050","title":"External validation of two predictive scores of chemotherapy toxicities among older patients with solid cancer, from ELCAPA prospective cohort.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CNIB","keywords":"Medicine; Internal medicine; Prospective cohort study; Cohort; Cancer; Chemotherapy; Quality of life (healthcare); Cohort study; Oncology; Surgery","score_opus":0.04148314865587492,"score_gpt":0.40168425164794463,"score_spread":0.3602011029920697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029721605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958136,0.00014130378,0.0012826234,0.0013449735,0.0004741356,0.0005807894,0.00006193815,0.00000890553,0.0002917021],"genre_scores_gemma":[0.9949836,0.00025967727,0.0028113676,0.0008268914,0.0010376207,0.0000100095995,0.000007962238,0.00002439461,0.00003846484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966231,0.00022741251,0.0020597205,0.00022854397,0.00069431367,0.00016689383],"domain_scores_gemma":[0.9940739,0.0009660239,0.0031227414,0.00014867357,0.001416348,0.00027226814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005235507,0.00016402263,0.0016315511,0.000073824944,0.000018433291,0.000004901061,0.00018043537,0.000212911,0.0003266166],"category_scores_gemma":[0.0014206852,0.00011260605,0.00026018044,0.00013459439,0.00056583877,0.00020147502,0.000036624995,0.000664924,0.0000015324707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009302276,0.0012681633,0.977819,0.000048111782,0.0011092809,0.00002862509,0.0015921467,0.00020905575,0.00072816573,0.000007207084,0.000514819,0.007373125],"study_design_scores_gemma":[0.019196289,0.017408486,0.93850654,0.0007014233,0.0005464347,0.0000053290846,0.00017788586,0.00021849043,0.022834282,0.00027357574,0.000043391075,0.00008787905],"about_ca_topic_score_codex":0.00018932743,"about_ca_topic_score_gemma":0.000052680713,"teacher_disagreement_score":0.039312493,"about_ca_system_score_codex":0.00014079199,"about_ca_system_score_gemma":0.0008667124,"threshold_uncertainty_score":0.45919415},"labels":[],"label_agreement":null},{"id":"W3029728451","doi":"10.1200/jco.2020.38.15_suppl.10013","title":"Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Family medicine","score_opus":0.08588612701183446,"score_gpt":0.40634895926037484,"score_spread":0.3204628322485404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029728451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422115,0.0013217799,0.0011466944,0.0012397505,0.0007896193,0.00018211917,0.000037599788,0.000006373024,0.0010548849],"genre_scores_gemma":[0.995317,0.0011394897,0.0011104121,0.0008750368,0.0013540016,0.00000409216,0.00012290917,0.000021348927,0.00005573613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969439,0.0005380133,0.0016385963,0.00040185582,0.00021358901,0.00026405696],"domain_scores_gemma":[0.9978729,0.00033250471,0.0010246238,0.0002049239,0.00014766346,0.00041740978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074467895,0.00021510092,0.0011429277,0.00005210412,0.00004368248,0.000015638612,0.00024762747,0.0004782446,0.000093263996],"category_scores_gemma":[0.0008081959,0.00018010903,0.0002800521,0.00008066245,0.00014957857,0.000016086975,0.00013821133,0.0005082031,0.000008148986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06873065,0.0040046,0.4229689,0.00006963026,0.0008954906,0.002363911,0.00040143493,0.00006897827,0.29885057,0.00022593055,0.0021213465,0.19929858],"study_design_scores_gemma":[0.1241998,0.04687355,0.7668882,0.00009399882,0.00038611118,0.00026471712,0.00018714066,0.00031144507,0.014196423,0.00035176138,0.04560596,0.00064088125],"about_ca_topic_score_codex":0.000030568783,"about_ca_topic_score_gemma":0.00018047504,"teacher_disagreement_score":0.3439193,"about_ca_system_score_codex":0.00004141597,"about_ca_system_score_gemma":0.0004124318,"threshold_uncertainty_score":0.7344633},"labels":[],"label_agreement":null},{"id":"W3029749826","doi":"10.1200/jco.2020.38.15_suppl.4032","title":"Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Merck","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Colorectal cancer; Irinotecan; Oxaliplatin; Clinical endpoint; Cancer; Oncology; Microsatellite instability; Surgery; Clinical trial; Immunotherapy","score_opus":0.08085753602692707,"score_gpt":0.4450383076983003,"score_spread":0.3641807716713732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029749826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161845,0.00029423332,0.00012018238,0.0033130078,0.0026505454,0.0018181995,0.00003885076,0.0000106534635,0.00013584387],"genre_scores_gemma":[0.99529445,0.00019067632,0.0015878173,0.0019535702,0.0007903232,0.00006142566,0.0000021362464,0.000044958273,0.000074654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629354,0.00029131034,0.00211052,0.00032429164,0.00067244796,0.0003078882],"domain_scores_gemma":[0.99455833,0.0012748564,0.0024507304,0.00024279622,0.0010786715,0.00039460766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007016154,0.00024645455,0.0018582753,0.00006074221,0.000088937755,0.000006125488,0.00042258462,0.0002803679,0.00020942562],"category_scores_gemma":[0.002226977,0.00014066903,0.00064909185,0.00025548323,0.00030385843,0.00007863417,0.00009945053,0.00081718544,9.589028e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24623232,0.009725216,0.49762225,0.00007714212,0.001402521,0.00004372017,0.0027221476,0.000105896266,0.0019345862,0.00000471343,0.002409182,0.2377203],"study_design_scores_gemma":[0.16752538,0.36832643,0.4511576,0.00014853742,0.0010611307,0.000020506119,0.00035488882,0.00013606019,0.0023721966,0.000054249034,0.0086260615,0.00021695356],"about_ca_topic_score_codex":0.000007635018,"about_ca_topic_score_gemma":0.00007959908,"teacher_disagreement_score":0.3586012,"about_ca_system_score_codex":0.00024590798,"about_ca_system_score_gemma":0.0023246554,"threshold_uncertainty_score":0.57363164},"labels":[],"label_agreement":null},{"id":"W3029769454","doi":"10.1200/jco.2020.38.15_suppl.e15594","title":"CSNK2 in cancer: Pathophysiology and translational applications.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Cancer; PTEN; Protein kinase B; Cancer research; Kinase; Metastasis; Clinical significance; Translational research; Oncology; PI3K/AKT/mTOR pathway; Bioinformatics; Phosphorylation; Internal medicine; Biology; Pathology; Signal transduction; Genetics","score_opus":0.12747150430121712,"score_gpt":0.46871990142756975,"score_spread":0.34124839712635263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029769454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85844433,0.007853526,0.003972215,0.12683196,0.00055565685,0.00048716844,0.000012482897,0.000013951028,0.0018286938],"genre_scores_gemma":[0.9790459,0.004021611,0.0038931712,0.011753982,0.0012427571,0.000014383366,0.0000030218582,0.000011933258,0.000013230956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981607,0.00016714096,0.0012618635,0.000153441,0.00014318312,0.00011364663],"domain_scores_gemma":[0.9984398,0.0005234191,0.0005415614,0.000066665,0.00014739802,0.00028113942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006053645,0.00007259994,0.00078995334,0.00006237282,0.000013309002,0.0000019974423,0.00006828396,0.0002834914,0.000100414756],"category_scores_gemma":[0.0005744177,0.00005934176,0.00017068183,0.00015624613,0.00013838088,0.000037730035,0.000017832179,0.00085149944,0.0000073927604],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048144385,0.000865674,0.05331079,0.00007953803,0.00022651741,0.00051237975,0.00030985315,0.0003334493,0.012130899,0.00074368523,0.003060303,0.9236125],"study_design_scores_gemma":[0.019476822,0.010281088,0.44300005,0.00011170632,0.00037836755,0.0003342172,0.00008902855,0.001764096,0.00028855738,0.0033749929,0.5207208,0.00018029024],"about_ca_topic_score_codex":0.000009550734,"about_ca_topic_score_gemma":0.000022922595,"teacher_disagreement_score":0.9234322,"about_ca_system_score_codex":0.0000392212,"about_ca_system_score_gemma":0.0012915427,"threshold_uncertainty_score":0.36993885},"labels":[],"label_agreement":null},{"id":"W3029786930","doi":"10.1200/jco.2020.38.15_suppl.tps8551","title":"GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Multiple myeloma; Medicine; Antibody; Bone marrow; Plasma cell; CD3; Cancer research; CD8; Immunology; Internal medicine; Immune system; Oncology","score_opus":0.20289295847108563,"score_gpt":0.5178645756702588,"score_spread":0.31497161719917316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029786930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925819,0.00024743826,0.00006982572,0.0053566378,0.00044760358,0.0009907689,0.000029470706,0.000004557136,0.00027177786],"genre_scores_gemma":[0.99580586,0.0010555445,0.0012923611,0.00086953444,0.0007866084,0.000004722176,0.000007744245,0.000021981085,0.00015565469],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994943,0.0012686645,0.0021706324,0.00030643053,0.0009854576,0.00032576898],"domain_scores_gemma":[0.9917518,0.005350749,0.0016858011,0.0001774504,0.00056284486,0.00047135033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003372009,0.00020650173,0.0014418175,0.000117821095,0.000065972075,0.000011723301,0.00024861193,0.0002252936,0.00022952259],"category_scores_gemma":[0.0047255843,0.0001051989,0.000270597,0.00021242574,0.00040891764,0.0001221196,0.00017160554,0.0017751362,0.0000060496645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.726524,0.006990018,0.13453554,0.00012536212,0.00025040298,0.00029681943,0.00033371215,0.000013814246,0.0059383786,0.0000010483476,0.0002681546,0.12472277],"study_design_scores_gemma":[0.45196694,0.18444286,0.34504646,0.0002471607,0.00044417655,0.000034082546,0.00017170337,0.005425585,0.00096961466,0.0000068331033,0.011060346,0.0001842205],"about_ca_topic_score_codex":0.000044213637,"about_ca_topic_score_gemma":0.00004560344,"teacher_disagreement_score":0.27455705,"about_ca_system_score_codex":0.000086482694,"about_ca_system_score_gemma":0.0010517943,"threshold_uncertainty_score":0.77121824},"labels":[],"label_agreement":null},{"id":"W3029791793","doi":"10.1200/jco.2020.38.15_suppl.8530","title":"Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Carfilzomib; Pomalidomide; Refractory (planetary science); Lenalidomide; Regimen; Internal medicine; Dexamethasone; Daratumumab; Bortezomib; Multiple myeloma; Gastroenterology; Oncology","score_opus":0.08850480127217517,"score_gpt":0.4084695183400413,"score_spread":0.3199647170678661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029791793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803537,0.0003772866,0.00015996922,0.017793007,0.00025856463,0.00036265902,0.000007349313,0.000013936951,0.0006735311],"genre_scores_gemma":[0.9782022,0.00047041656,0.014266931,0.0059566377,0.00093031855,0.0000035696155,0.000006108497,0.00003822301,0.00012555426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956441,0.00072249596,0.0021900216,0.00036006692,0.00068446057,0.00039885598],"domain_scores_gemma":[0.99230355,0.004525914,0.0012510038,0.00022004462,0.0007054204,0.0009940516],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026751335,0.00020708522,0.0017867035,0.00017118917,0.000038419195,0.000011994966,0.00024456403,0.00052313134,0.000092931536],"category_scores_gemma":[0.016843714,0.00014124502,0.00019547918,0.00035641066,0.00037647772,0.00022031725,0.00014756009,0.0030970483,0.00002736917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023396054,0.0012130904,0.8544306,0.00005363394,0.00022083221,0.0011656961,0.00028443226,0.00001934141,0.00020722068,0.0000071768764,0.0052773426,0.113724574],"study_design_scores_gemma":[0.04206613,0.029428229,0.8789388,0.00014005085,0.0001522182,0.000091794696,0.00023880156,0.00077608065,0.000046583726,0.000018504828,0.047954734,0.00014808521],"about_ca_topic_score_codex":0.00004223313,"about_ca_topic_score_gemma":0.000070208625,"teacher_disagreement_score":0.11357649,"about_ca_system_score_codex":0.00037552725,"about_ca_system_score_gemma":0.0024821856,"threshold_uncertainty_score":0.99920285},"labels":[],"label_agreement":null},{"id":"W3029795115","doi":"10.1200/jco.2020.38.15_suppl.11028","title":"Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States: A mixed-method study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Family medicine; Feeling; Internal medicine; Oncology; Health care; Cancer; Psychology","score_opus":0.2674962295928081,"score_gpt":0.5374059690861474,"score_spread":0.26990973949333924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029795115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9099155,0.0056500845,0.0000040391114,0.08323443,0.0002594732,0.0006520245,0.0000033291515,0.0000017835027,0.00027935288],"genre_scores_gemma":[0.91451037,0.07669558,0.0013439977,0.007128201,0.00026520382,0.00003881554,0.0000047161902,0.0000085819875,0.000004519665],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99408704,0.0033939753,0.0018306548,0.00018779375,0.00032478108,0.00017576088],"domain_scores_gemma":[0.98518324,0.012792097,0.0014995938,0.00014912184,0.00023105234,0.00014491848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030310934,0.00015354196,0.0011930224,0.00010778838,0.000032621614,0.000011015353,0.00017351023,0.00016817197,0.00001732664],"category_scores_gemma":[0.0037067614,0.00006801974,0.00017242682,0.00026736376,0.000093067334,0.00006925361,0.000031494958,0.0004097536,0.0000011808302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003964714,0.02677949,0.41159344,0.000022171764,0.00063901336,0.0010435759,0.05154513,0.000029839117,0.000001595763,0.00003392523,0.0007071523,0.50363994],"study_design_scores_gemma":[0.0238451,0.07428002,0.6976816,0.00008702976,0.00068927085,0.000059158214,0.042982288,0.00010069651,0.0000062798554,0.00004187497,0.16017844,0.000048241902],"about_ca_topic_score_codex":0.0028040633,"about_ca_topic_score_gemma":0.0030458174,"teacher_disagreement_score":0.5035917,"about_ca_system_score_codex":0.00033991135,"about_ca_system_score_gemma":0.0009765262,"threshold_uncertainty_score":0.44376075},"labels":[],"label_agreement":null},{"id":"W3029806582","doi":"10.1200/jco.2020.38.15_suppl.8005","title":"KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Pembrolizumab; Oncology; Refractory (planetary science); Lymphoma; Hodgkin lymphoma; Cancer; Immunotherapy","score_opus":0.2539880172298434,"score_gpt":0.5011283891179645,"score_spread":0.24714037188812116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029806582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852559,0.00095554354,0.000015508702,0.0073848236,0.0018735275,0.0020317824,0.000009827429,0.000018119845,0.00245499],"genre_scores_gemma":[0.9941282,0.001364507,0.0009933726,0.0023899896,0.0008444624,0.00007267782,0.000008334521,0.000048256778,0.0001501446],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98918676,0.002545011,0.0063612186,0.000585593,0.00085009297,0.000471347],"domain_scores_gemma":[0.98270893,0.01098197,0.0044692443,0.00048277035,0.00049766584,0.00085944287],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004642294,0.00042086781,0.0065436875,0.00026872288,0.00006639293,0.000030740353,0.0006742197,0.00058977836,0.00042011734],"category_scores_gemma":[0.011952449,0.00026968267,0.0006708778,0.00050941063,0.00037739394,0.00021879534,0.0003268942,0.0009118933,0.000039965802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7483604,0.0867192,0.0034178332,0.000045068016,0.0018460937,0.0054490967,0.00075473415,0.0000096164185,0.00007883051,0.00004658016,0.0044845906,0.14878799],"study_design_scores_gemma":[0.83571184,0.13599992,0.012383142,0.00020863645,0.0020330672,0.00017444916,0.0008883234,0.0004550892,0.0000877027,0.00003232109,0.011824202,0.0002013231],"about_ca_topic_score_codex":0.00022850724,"about_ca_topic_score_gemma":0.00023356274,"teacher_disagreement_score":0.14858666,"about_ca_system_score_codex":0.0007266119,"about_ca_system_score_gemma":0.0044316957,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W3029811940","doi":"10.1200/jco.2020.38.15_suppl.11033","title":"Use of oncology electronic learning resources to learn about geriatric oncology.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Medical Council of Canada; University of Ottawa","funders":"","keywords":"Geriatrics; Medicine; Geriatric oncology; Oncology; Internal medicine; Descriptive statistics; Demographics; Reading (process); Medical education; Family medicine; Cancer; Statistics","score_opus":0.11669816333818604,"score_gpt":0.511167542105834,"score_spread":0.394469378767648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029811940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.902047,0.003293831,0.004352075,0.072812445,0.002479123,0.0005289616,0.0000032946944,0.000056245342,0.0144270575],"genre_scores_gemma":[0.89798844,0.011573694,0.040799547,0.0393294,0.008559837,0.000008223908,0.0000038311437,0.00007666297,0.0016603377],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99218935,0.002669683,0.0037117456,0.0004030366,0.00041642212,0.00060978305],"domain_scores_gemma":[0.98557377,0.009064676,0.003562831,0.00023378548,0.00062903255,0.00093589944],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005409131,0.00025912403,0.0032788634,0.00028106052,0.00010250169,0.0000075547237,0.00042564786,0.001142928,0.0004981841],"category_scores_gemma":[0.016875764,0.00019684492,0.00080707594,0.0005420408,0.00062540895,0.00018745751,0.00013001115,0.0041874982,0.00008611057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027815014,0.0023267185,0.046605874,0.000061231614,0.0010882275,0.0017388,0.0019635789,0.0021427348,0.0030618964,0.00031613035,0.019365443,0.89351434],"study_design_scores_gemma":[0.0065104724,0.10611514,0.033544138,0.0000493982,0.0004083249,0.00079194625,0.00032854005,0.00015378799,0.00006800159,0.00013512262,0.8517481,0.00014704603],"about_ca_topic_score_codex":0.000010223464,"about_ca_topic_score_gemma":0.000024841358,"teacher_disagreement_score":0.8933673,"about_ca_system_score_codex":0.0007238934,"about_ca_system_score_gemma":0.004488036,"threshold_uncertainty_score":0.9981099},"labels":[],"label_agreement":null},{"id":"W3029817749","doi":"10.1200/jco.2020.38.15_suppl.10019","title":"CheckMate 067: Long-term outcomes in patients with mucosal melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Placebo; Melanoma; Population; Adverse effect; Gastroenterology; Malignancy; Oncology; Cancer; Immunotherapy; Pathology","score_opus":0.10396400415171521,"score_gpt":0.4380216071559047,"score_spread":0.3340576030041895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029817749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98292285,0.00015281918,0.00002636202,0.015554119,0.00054686546,0.00017554133,0.0000024421183,0.0000068866348,0.00061211997],"genre_scores_gemma":[0.9897365,0.00014736089,0.00057862856,0.009072885,0.00037213328,0.0000012890441,0.0000029414803,0.000013701174,0.00007455691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975452,0.00016130376,0.0016764087,0.00013772736,0.0003031862,0.00017616541],"domain_scores_gemma":[0.99803126,0.00043605635,0.0009880491,0.00010490358,0.00016682914,0.00027291337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089703966,0.00011485637,0.0012149122,0.000067077875,0.000013695255,0.0000060089756,0.00013409909,0.0002149251,0.00023690493],"category_scores_gemma":[0.0007029774,0.00006713075,0.00031290873,0.00013018571,0.0001327215,0.000085799176,0.000027282726,0.0006616412,0.000014658391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032382976,0.0011373289,0.90687555,0.000023295428,0.00037887774,0.00041315274,0.000078152436,7.992799e-7,0.000027378726,0.000002843592,0.00058201386,0.058097646],"study_design_scores_gemma":[0.029066045,0.019842641,0.9461695,0.000065417444,0.00013075442,0.00002798236,0.000017805909,0.000004668131,0.000025398042,0.0000057266775,0.0045705386,0.000073511765],"about_ca_topic_score_codex":0.000007479037,"about_ca_topic_score_gemma":0.000032138778,"teacher_disagreement_score":0.058024134,"about_ca_system_score_codex":0.00009622026,"about_ca_system_score_gemma":0.00066817703,"threshold_uncertainty_score":0.28745386},"labels":[],"label_agreement":null},{"id":"W3029829417","doi":"10.1200/jco.2020.38.15_suppl.e15151","title":"Comparative efficacy, safety, and tolerability of immune checkpoint inhibitors (ICIs) in cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Centre Hospitalier Universitaire de Sherbrooke; University of Toronto; McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Nivolumab; Tolerability; Internal medicine; Avelumab; Oncology; Adverse effect; Lung cancer; Hazard ratio; Head and neck squamous-cell carcinoma; Odds ratio; Cancer; Head and neck cancer; Immunotherapy; Confidence interval","score_opus":0.1782500773696352,"score_gpt":0.4831628988173155,"score_spread":0.3049128214476803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029829417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660503,0.003576217,0.000020108944,0.028831873,0.00047420707,0.00024211021,0.000004272396,0.0000033613271,0.0007974969],"genre_scores_gemma":[0.9946754,0.0030882794,0.00034250403,0.0014485,0.00042119168,0.000001793798,7.727804e-7,0.0000059368604,0.000015608195],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99528366,0.00033687998,0.0038899991,0.00015165526,0.00020794432,0.00012983977],"domain_scores_gemma":[0.99642825,0.0012468458,0.0018112573,0.000097171316,0.00020790298,0.00020859834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028929831,0.00010486489,0.0019989545,0.00005744214,0.000015117,0.0000026802163,0.000098233446,0.00021619633,0.00015509239],"category_scores_gemma":[0.0012330082,0.000074348,0.0004531759,0.00020334216,0.00042988162,0.00005768192,0.0000485838,0.000757664,0.0000010134921],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2236229,0.0041561574,0.24023819,0.00024778658,0.00113046,0.00023051957,0.0037614822,0.00010716684,0.02217175,0.000032683838,0.0015367888,0.5027641],"study_design_scores_gemma":[0.01832167,0.012287238,0.9384334,0.0002038515,0.00012487086,0.00004808365,0.0004037686,0.000121760524,0.0035919864,0.000034327608,0.026349835,0.000079214326],"about_ca_topic_score_codex":0.00016767961,"about_ca_topic_score_gemma":0.00010884273,"teacher_disagreement_score":0.6981952,"about_ca_system_score_codex":0.0001372251,"about_ca_system_score_gemma":0.000915574,"threshold_uncertainty_score":0.3291715},"labels":[],"label_agreement":null},{"id":"W3029839941","doi":"10.1200/jco.2020.38.15_suppl.3095","title":"Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Immune system; Immunotherapy; Cancer; Microbiome; Biomarker; Immunology; Antibody; Gastroenterology; Biology; Bioinformatics","score_opus":0.013864040569183486,"score_gpt":0.3432810408377376,"score_spread":0.3294170002685541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029839941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963602,0.0011773885,0.00019513111,0.0014213752,0.00015838355,0.0005590725,0.000037386882,0.0000066384323,0.00008444089],"genre_scores_gemma":[0.9948996,0.0007059877,0.0015878611,0.0025433619,0.00012077394,0.0000055969053,0.000052661388,0.000039791932,0.000044380016],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974954,0.00023691363,0.0014175274,0.00036903628,0.0001203343,0.00036078648],"domain_scores_gemma":[0.99811727,0.00012808021,0.0009798642,0.00018650154,0.0002872193,0.0003010864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046473628,0.00025581592,0.001035187,0.00010572878,0.000055434393,0.000016168571,0.0002421133,0.00039878133,0.000023848082],"category_scores_gemma":[0.00009264538,0.0001794949,0.00013722648,0.00022503249,0.00017037608,0.000011708719,0.000056954555,0.0005265624,0.000001647947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013970376,0.0009371722,0.42239198,0.00007675105,0.00023915137,0.00003832666,0.00017496746,0.00076911465,0.5574855,4.5765188e-7,0.00023833755,0.0036778483],"study_design_scores_gemma":[0.028243773,0.026091058,0.9281888,0.00024525987,0.00010886615,0.000010476663,0.000046921785,0.000045846595,0.013487352,5.6608576e-7,0.0032630262,0.00026804864],"about_ca_topic_score_codex":0.00003736211,"about_ca_topic_score_gemma":0.00004373413,"teacher_disagreement_score":0.5439982,"about_ca_system_score_codex":0.000056318062,"about_ca_system_score_gemma":0.0010950007,"threshold_uncertainty_score":0.731959},"labels":[],"label_agreement":null},{"id":"W3029846805","doi":"10.1200/jco.2020.38.15_suppl.e16708","title":"Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN): Awareness of specialized techniques and latest interventions.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chromogranin A; Neuroendocrine tumors; Psychological intervention; Internal medicine; Psychiatry; Immunohistochemistry","score_opus":0.43068056172883207,"score_gpt":0.5556978253713385,"score_spread":0.12501726364250643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029846805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864424,0.0013813432,0.000009300734,0.011162114,0.0001286474,0.00076926243,0.00004547577,0.0000045283564,0.00005693166],"genre_scores_gemma":[0.9842384,0.0142712835,0.0010537471,0.00024942044,0.00014063803,0.00002153907,0.00000403912,0.000014881741,0.000006064247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715054,0.00044688385,0.0018313648,0.00019891167,0.000199975,0.0001723484],"domain_scores_gemma":[0.99301165,0.005003897,0.00096752495,0.00010188469,0.0005783814,0.00033665475],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006270295,0.000118360156,0.0014700957,0.00018027866,0.000010489987,0.000005997257,0.00014859537,0.000014206092,0.0000095951245],"category_scores_gemma":[0.01921146,0.00008686324,0.00016081866,0.00015090528,0.00016301547,0.00009921535,0.00015562665,0.00023298441,1.5695474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008612643,0.0023190642,0.83713824,0.00040520434,0.000083767336,0.0017599401,0.00003077307,0.000002648048,0.00006803737,0.000019906534,0.00041826259,0.14914155],"study_design_scores_gemma":[0.009749793,0.058799017,0.9194151,0.00032503286,0.00009389281,0.00016126076,0.000030765772,0.000014680822,0.002916923,0.00007782391,0.008355829,0.000059848215],"about_ca_topic_score_codex":0.00011134158,"about_ca_topic_score_gemma":0.00089945795,"teacher_disagreement_score":0.14908169,"about_ca_system_score_codex":0.00004299308,"about_ca_system_score_gemma":0.00033280693,"threshold_uncertainty_score":0.98905015},"labels":[],"label_agreement":null},{"id":"W3029853203","doi":"10.1200/jco.2020.38.15_suppl.7503","title":"Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Transplantation; Internal medicine; Cohort; Proportional hazards model; Disease; Hematopoietic stem cell transplantation; Leukemia; Oncology; Myeloid leukemia; Hematopoietic cell; Haematopoiesis; Stem cell","score_opus":0.11348362665975205,"score_gpt":0.42955726609701705,"score_spread":0.316073639437265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029853203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98592347,0.00045005768,0.008773217,0.0043553836,0.00010533587,0.00030209066,0.000009875905,0.000004069965,0.000076472264],"genre_scores_gemma":[0.9745231,0.0024506624,0.02159415,0.0007349305,0.00064502173,0.000006573097,0.000007183418,0.000011861458,0.000026487274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763364,0.00020322255,0.0015849385,0.0001430539,0.00029970537,0.00013544068],"domain_scores_gemma":[0.99620557,0.0017238791,0.0010781972,0.00006842365,0.0003457391,0.0005782054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018280232,0.00008181576,0.0006993487,0.000097908254,0.000029181969,0.0000037960506,0.00009555872,0.00016368747,0.000029824432],"category_scores_gemma":[0.0025453058,0.00006104664,0.00019175041,0.00012545595,0.000071484064,0.000054278993,0.000022687218,0.00045415128,0.0000038647213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020098003,0.0011878706,0.9277818,0.0015596374,0.00034154725,0.00049751194,0.0015261658,0.00014891509,0.00063104805,0.000041796662,0.0028424612,0.043343235],"study_design_scores_gemma":[0.027393412,0.008498208,0.9376845,0.000057922203,0.0022929593,0.00012007037,0.00030978528,0.0008163229,0.003904971,0.0003588039,0.018383345,0.00017974256],"about_ca_topic_score_codex":0.0000014117633,"about_ca_topic_score_gemma":9.914327e-7,"teacher_disagreement_score":0.043163493,"about_ca_system_score_codex":0.00006466344,"about_ca_system_score_gemma":0.0030956152,"threshold_uncertainty_score":0.54914886},"labels":[],"label_agreement":null},{"id":"W3029860013","doi":"10.1200/jco.2020.38.15_suppl.6545","title":"Radiomic response evaluation of recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC) patients receiving pembrolizumab on KEYNOTE-012 study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Concordance; Response Evaluation Criteria in Solid Tumors; Cancer; Target lesion; Nuclear medicine; Head and neck cancer; Radiology; Head and neck squamous-cell carcinoma; Feature (linguistics); Oncology; Internal medicine; Clinical trial; Immunotherapy; Phases of clinical research","score_opus":0.174651997589594,"score_gpt":0.5075316327907415,"score_spread":0.33287963520114755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029860013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688096,0.0006522574,0.00006893517,0.01053708,0.0010616458,0.00058253505,0.0000033907902,0.00000766514,0.00020555043],"genre_scores_gemma":[0.9952507,0.00039478508,0.0014109303,0.0023554822,0.00051477243,0.000007809648,0.0000019007308,0.00002587155,0.000037757003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931844,0.0029275753,0.0023581788,0.0002819056,0.0010241601,0.00022377835],"domain_scores_gemma":[0.99198085,0.0045974855,0.0020254904,0.00016201784,0.00067609194,0.0005580464],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009281175,0.00017408303,0.0015222882,0.0001622759,0.00004847796,0.000010309268,0.0001579766,0.00013534902,0.0001705273],"category_scores_gemma":[0.038628507,0.00011555907,0.00024293733,0.00020248382,0.00014520025,0.000081197286,0.000057871806,0.0014128343,0.000004279649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13107064,0.006232047,0.23017591,0.00017971409,0.0003738541,0.000279137,0.0021815274,0.00094813836,0.0004087407,0.000002425185,0.003585148,0.62456274],"study_design_scores_gemma":[0.062222797,0.07496081,0.8339535,0.00029857783,0.0019038484,0.0000631968,0.000321681,0.020739272,0.00004809795,0.00003107634,0.0053165033,0.0001406373],"about_ca_topic_score_codex":0.000030016387,"about_ca_topic_score_gemma":0.000016582275,"teacher_disagreement_score":0.6244221,"about_ca_system_score_codex":0.00025745694,"about_ca_system_score_gemma":0.002034491,"threshold_uncertainty_score":0.96946955},"labels":[],"label_agreement":null},{"id":"W3029871260","doi":"10.1200/jco.2020.38.15_suppl.1091","title":"Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with g<i>BRCA</i>-associated advanced breast cancer: Exploratory results from BROCADE3.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Internal medicine; Veliparib; Breast cancer; Oncology; Carboplatin; Cancer; Discontinuation; PARP inhibitor; Progression-free survival; Urology; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.07922342325583095,"score_gpt":0.392223272220946,"score_spread":0.312999848965115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029871260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980148,0.0005919025,0.00014659119,0.01740288,0.00068304397,0.00061499956,0.00012500142,0.000039590854,0.00024799825],"genre_scores_gemma":[0.9861375,0.0011683255,0.0013531395,0.010596763,0.00056884595,0.000033349057,0.000057741036,0.000067880406,0.000016471875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99489605,0.00069845095,0.002679956,0.00047815175,0.0008798895,0.00036750693],"domain_scores_gemma":[0.9939504,0.0014923994,0.0030260298,0.00025646444,0.00078610715,0.0004885925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013329304,0.00032284128,0.0019504306,0.00014514898,0.00006456022,0.000018956016,0.00023951524,0.00045812983,0.000053881806],"category_scores_gemma":[0.00069905777,0.00022927098,0.00031130126,0.0005458531,0.0001707021,0.00044740934,0.000021304104,0.001495634,0.000004696861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1930981,0.004249371,0.69707614,0.00001153081,0.0016393524,0.000288424,0.0023961493,0.00085533754,0.000993026,0.0000120776,0.001347444,0.09803308],"study_design_scores_gemma":[0.17324962,0.021167122,0.79919666,0.0005925041,0.00016043556,0.0000064151113,0.00030535532,0.00014467147,0.0003917627,0.000109298,0.004393607,0.00028253917],"about_ca_topic_score_codex":0.00013330439,"about_ca_topic_score_gemma":0.00018121411,"teacher_disagreement_score":0.102120556,"about_ca_system_score_codex":0.00067760074,"about_ca_system_score_gemma":0.0019596356,"threshold_uncertainty_score":0.9349399},"labels":[],"label_agreement":null},{"id":"W3029877691","doi":"10.1200/jco.2020.38.15_suppl.e24020","title":"Predictive role of Vulnerable Elders Survey-13 screen tool for elder cancer patients in final oncology treatment plan.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Geriatric oncology; Cancer; Internal medicine; Cancer treatment; Oncology","score_opus":0.1866473015094935,"score_gpt":0.46283845106110144,"score_spread":0.27619114955160795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029877691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020386,0.00035537564,0.00026155522,0.006031637,0.00075681164,0.00084652746,0.00020113082,0.000007960018,0.0013351535],"genre_scores_gemma":[0.9935469,0.0008270961,0.0022765994,0.0022764008,0.00077873067,0.000039709597,0.000038537608,0.000024384673,0.00019161197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955804,0.0008654979,0.0026351218,0.00027749996,0.00030976578,0.00033173675],"domain_scores_gemma":[0.9919027,0.0051392824,0.0016920601,0.0001394097,0.00075009203,0.0003764345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020015182,0.00019168267,0.0020250545,0.00011809493,0.000028921982,0.0000030734204,0.0001971516,0.0005435316,0.00023319744],"category_scores_gemma":[0.0075871376,0.00014227146,0.0004120426,0.00017189373,0.00019193318,0.00011217621,0.000046832214,0.000879381,0.000005640897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030530794,0.0043142075,0.79018277,0.000039210114,0.00065957225,0.000094074225,0.00096322934,0.00028351208,0.00006067542,0.000008217686,0.010155512,0.16270824],"study_design_scores_gemma":[0.03312632,0.10458605,0.8195478,0.00012792532,0.0004041262,0.000020339252,0.0002697609,0.00072503043,0.00038344914,0.00012052447,0.040567618,0.0001211092],"about_ca_topic_score_codex":0.0011099154,"about_ca_topic_score_gemma":0.0026113167,"teacher_disagreement_score":0.16258714,"about_ca_system_score_codex":0.0004806722,"about_ca_system_score_gemma":0.0028149995,"threshold_uncertainty_score":0.90830606},"labels":[],"label_agreement":null},{"id":"W3029883096","doi":"10.1200/jco.2020.38.15_suppl.tps6104","title":"DUETTE: A randomized phase II study to assess a second maintenance treatment with olaparib (ola) or ola+ceralasertib (cer), in patients (pts) with platinum-sensitive relapsed (PSR) epithelial ovarian cancer who have previously received PARP inhibitor maintenance treatment (NCT04239014).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Oncology; BRCA mutation; Population; Internal medicine; Cancer; Clinical trial; Maintenance therapy; Chemotherapy; Biology","score_opus":0.09539568677493485,"score_gpt":0.4226898474471354,"score_spread":0.3272941606722005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029883096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713377,0.00009897177,0.00088771235,0.019245252,0.0006672466,0.0070528043,0.00019094668,0.00004183608,0.0004775401],"genre_scores_gemma":[0.9835245,0.00072878296,0.0030271886,0.009016238,0.0014416965,0.0007255756,0.00002385313,0.00012020794,0.0013919272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99005646,0.0025439349,0.004473569,0.001079991,0.00093796256,0.00090811565],"domain_scores_gemma":[0.9900223,0.002978155,0.0037490593,0.00051384245,0.0013907872,0.0013458742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025212748,0.0008323239,0.006225911,0.00028146012,0.0001774215,0.000046852685,0.00026800713,0.00041349302,0.000517074],"category_scores_gemma":[0.0020019682,0.00045389181,0.0006782276,0.0005637443,0.0004969078,0.00031964298,0.000074979056,0.0013496316,0.000016506643],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8939086,0.022778278,0.03468816,0.00004393673,0.0036214378,0.004317211,0.009612056,0.0002816311,0.00026774115,0.000008211843,0.0031650804,0.02730761],"study_design_scores_gemma":[0.6772853,0.28935483,0.013853129,0.001252844,0.0014011862,0.00017081387,0.0012257159,0.00052488217,0.00097345887,0.000014530567,0.013489145,0.0004541387],"about_ca_topic_score_codex":0.00027409365,"about_ca_topic_score_gemma":0.00435694,"teacher_disagreement_score":0.26657653,"about_ca_system_score_codex":0.0033258877,"about_ca_system_score_gemma":0.0046421895,"threshold_uncertainty_score":0.99979126},"labels":[],"label_agreement":null},{"id":"W3029908290","doi":"10.1200/jco.2020.38.15_suppl.e19306","title":"Predictors of and longitudinal assessment of health utility scores in patients with small cell lung cancer using real-world data.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Disease; Cohort; Internal medicine; Clinical trial; Medical record; Cancer; Performance status; Surgery","score_opus":0.3681568588088141,"score_gpt":0.5781826114878956,"score_spread":0.21002575267908152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029908290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493724,0.0008016729,0.00014304537,0.0033966303,0.00015804182,0.000363459,0.00004261948,0.000002180431,0.00015510361],"genre_scores_gemma":[0.99253136,0.0017787275,0.005197553,0.00026269833,0.00021074626,0.0000013910325,0.0000039385022,0.00000903795,0.0000045403326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964881,0.0005040648,0.0020409017,0.0002303966,0.0005254449,0.00021111088],"domain_scores_gemma":[0.9958445,0.00095822534,0.0022232984,0.00019891019,0.00047574763,0.00029932972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032159528,0.00010215589,0.0017299925,0.00011415147,0.000021985983,0.0000026066273,0.00017832694,0.000061106504,0.000017865968],"category_scores_gemma":[0.0010381262,0.00006646976,0.000074240794,0.00025743272,0.0004425251,0.00009172174,0.00024439135,0.0007224027,3.0451254e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034716206,0.0009351971,0.9859802,0.0006413982,0.00035858556,0.00002912308,0.00015149389,0.00004695596,0.0000054723846,0.000003289444,0.0006521883,0.0077244677],"study_design_scores_gemma":[0.0071659135,0.010382552,0.9798041,0.00047336172,0.00024027286,0.000001361905,0.00006658127,0.0015271724,0.0000078030225,0.0000034246611,0.0002852288,0.000042233893],"about_ca_topic_score_codex":0.0016111966,"about_ca_topic_score_gemma":0.0026779226,"teacher_disagreement_score":0.009447354,"about_ca_system_score_codex":0.00028078476,"about_ca_system_score_gemma":0.0047693825,"threshold_uncertainty_score":0.846068},"labels":[],"label_agreement":null},{"id":"W3029920290","doi":"10.1200/jco.2020.38.15_suppl.e19078","title":"Forecasting global essential childhood cancer drug need and cost: An innovative model-based approach.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Regimen; Disease; Cancer; Health care; Pace; Internal medicine; Economic growth","score_opus":0.17970521816116902,"score_gpt":0.389223053937427,"score_spread":0.209517835776258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029920290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9333733,0.0013420515,0.03943723,0.009866532,0.0009865398,0.00024017015,0.00016941683,0.000013570865,0.014571247],"genre_scores_gemma":[0.98060733,0.00025198693,0.008726569,0.00865999,0.0017020194,0.0000066073485,0.000004386706,0.000019127161,0.000021953892],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9967308,0.000064052394,0.002520828,0.0003385259,0.00005190226,0.0002938589],"domain_scores_gemma":[0.9959368,0.00021459807,0.0030194644,0.000117088566,0.00023688465,0.00047514474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017884717,0.00017534592,0.00146918,0.0000764958,0.000071680864,0.000048315713,0.0002959126,0.0002851979,0.00006703867],"category_scores_gemma":[0.0017390437,0.0001724828,0.00022347103,0.00025570064,0.000219884,0.000534331,0.00006763123,0.00067241385,0.000007654806],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038453762,0.0024650034,0.5042546,0.00009446755,0.0007791216,0.00008307653,0.0030605465,0.06793805,0.000007091997,0.06146778,0.010207232,0.3457977],"study_design_scores_gemma":[0.015178886,0.004138631,0.13750122,0.00005170385,0.00010674567,0.00004107408,0.0003762607,0.76406026,0.000021282847,0.024346508,0.053469397,0.0007080382],"about_ca_topic_score_codex":0.00010318899,"about_ca_topic_score_gemma":0.00004709689,"teacher_disagreement_score":0.69612217,"about_ca_system_score_codex":0.00017969732,"about_ca_system_score_gemma":0.0010521691,"threshold_uncertainty_score":0.70336443},"labels":[],"label_agreement":null},{"id":"W3029931241","doi":"10.1200/jco.2020.38.15_suppl.e17546","title":"Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: Racial considerations for 250 consecutive cases.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Interquartile range; Prostatectomy; Prostate cancer; Surgery; Urology; Stage (stratigraphy); Laparoscopic radical prostatectomy; Prospective cohort study; Cohort; Cancer; Internal medicine","score_opus":0.2570281462761396,"score_gpt":0.47715251360293387,"score_spread":0.22012436732679425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029931241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8860003,0.001968058,0.0010421762,0.107108615,0.0018072807,0.0011980566,0.000042301886,0.000029814986,0.0008034188],"genre_scores_gemma":[0.96942633,0.0005865629,0.014681377,0.013712602,0.0014725615,0.0000418569,0.000013076277,0.000020452148,0.000045180383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685425,0.00030218935,0.0020532105,0.00027574846,0.00024417744,0.0002704491],"domain_scores_gemma":[0.9913135,0.005908638,0.0011693286,0.00012781902,0.00076100917,0.00071968563],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.000845304,0.0001632554,0.0018115958,0.000051045074,0.00010036347,0.00002545396,0.0000630508,0.0002966483,0.00016923601],"category_scores_gemma":[0.016101733,0.00012309152,0.00053221977,0.00011403208,0.0003168156,0.00008965093,0.000039760263,0.00070946885,0.00000829392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06281092,0.021395955,0.40671617,0.0011166391,0.011579009,0.07864094,0.004773767,0.000635377,0.0037262978,0.010598515,0.2618932,0.13611318],"study_design_scores_gemma":[0.16972154,0.14867596,0.33327347,0.0013998646,0.007963222,0.009008674,0.0015164086,0.0018558811,0.013214956,0.0040529445,0.30840966,0.0009074338],"about_ca_topic_score_codex":0.000007085353,"about_ca_topic_score_gemma":0.00003123486,"teacher_disagreement_score":0.13520576,"about_ca_system_score_codex":0.0002363187,"about_ca_system_score_gemma":0.004445298,"threshold_uncertainty_score":0.99218607},"labels":[],"label_agreement":null},{"id":"W3029941476","doi":"10.1200/jco.2020.38.15_suppl.10506","title":"Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Trametinib; Dabrafenib; Tolerability; Oncology; Adverse effect; Internal medicine; Combination therapy; Glioma; Pediatric cancer; Neurocognitive; Cohort; Discontinuation; Clinical trial; Cancer; MAPK/ERK pathway; Cancer research; Vemurafenib","score_opus":0.062153982735338176,"score_gpt":0.3858303784684231,"score_spread":0.32367639573308493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029941476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97183645,0.00032607527,0.000010888851,0.026863964,0.00024459104,0.0004623842,0.000009377699,0.00000944153,0.0002368407],"genre_scores_gemma":[0.99577916,0.0016624868,0.00047442567,0.0016436778,0.00040380447,0.0000030672834,0.0000131954885,0.000017676633,0.000002482862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655527,0.00038870552,0.0021570036,0.00026934803,0.00042163106,0.00020802437],"domain_scores_gemma":[0.9951057,0.0026641649,0.0013625809,0.00012752345,0.00028103613,0.0004589881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001249306,0.0001695527,0.0012539501,0.0001739445,0.000033849137,0.000012469207,0.00010271944,0.0002617906,0.000019707551],"category_scores_gemma":[0.0028254408,0.000103343446,0.00020321054,0.00041045278,0.0001092242,0.00009925677,0.000027871945,0.0006760954,0.0000052019586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03483495,0.021950994,0.8295629,0.00003097834,0.00027033093,0.0014767009,0.00040207556,0.000029646382,0.000057099365,0.00007827638,0.0005906594,0.11071536],"study_design_scores_gemma":[0.11709457,0.031497933,0.8474366,0.000049206203,0.0002142023,0.00003813744,0.000028301445,0.000048063244,0.00010239252,0.00003697923,0.0033659376,0.000087693414],"about_ca_topic_score_codex":0.000005596715,"about_ca_topic_score_gemma":0.000009643015,"teacher_disagreement_score":0.110627666,"about_ca_system_score_codex":0.00008696894,"about_ca_system_score_gemma":0.00042143383,"threshold_uncertainty_score":0.42142233},"labels":[],"label_agreement":null},{"id":"W3029948034","doi":"10.1200/jco.2020.38.15_suppl.3050","title":"TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke; McGill University Health Centre; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Ontario Institute for Cancer Research","keywords":"Durvalumab; Medicine; T-cell receptor; Oncology; Immune system; Immunology; Stage (stratigraphy); Internal medicine; Immunotherapy; Peripheral blood mononuclear cell; T cell; Biology; Nivolumab","score_opus":0.06568743880089119,"score_gpt":0.39861333643065083,"score_spread":0.33292589762975966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029948034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962698,0.0005920795,0.00010603964,0.001590539,0.00016101041,0.00010337469,0.00003103225,0.000001682431,0.0011444376],"genre_scores_gemma":[0.99639434,0.0011214102,0.00062903535,0.0013482324,0.00044526253,0.0000016052883,0.0000073209335,0.000011226545,0.000041550786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978402,0.00019196633,0.0014854326,0.00019766756,0.00014227662,0.00014245254],"domain_scores_gemma":[0.9980939,0.0003342252,0.0010062228,0.00013266383,0.00017723143,0.00025577916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008763819,0.000114599876,0.00077668915,0.000034294382,0.000014263908,0.0000057701877,0.00016410365,0.00028775737,0.000029163395],"category_scores_gemma":[0.0017775074,0.000085818174,0.0001601837,0.000083110914,0.00021804693,0.0000052190776,0.00005528354,0.00032214643,8.3852154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00311712,0.00035956345,0.98571676,0.000020988755,0.00016718352,0.0001394926,0.000061016653,0.00007958115,0.0058946037,0.00013339054,0.0003834847,0.003926821],"study_design_scores_gemma":[0.012389015,0.027011076,0.93221897,0.00003725801,0.00018481203,0.000057560992,0.0001764584,0.00004976218,0.0035358919,0.0001577673,0.02397479,0.00020664287],"about_ca_topic_score_codex":0.00015099408,"about_ca_topic_score_gemma":0.0002677937,"teacher_disagreement_score":0.053497788,"about_ca_system_score_codex":0.000027114118,"about_ca_system_score_gemma":0.00069985987,"threshold_uncertainty_score":0.34995636},"labels":[],"label_agreement":null},{"id":"W3029949142","doi":"10.1200/jco.2020.38.15_suppl.3562","title":"Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Exome sequencing; Medicine; Exome; Genetics; DNA sequencing; Cancer; Transcriptome; Computational biology; Bioinformatics; Mutation; Gene; Biology; Internal medicine; Gene expression","score_opus":0.0681799276964836,"score_gpt":0.3524233963220037,"score_spread":0.2842434686255201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029949142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548316,0.00015068137,0.00013710978,0.0037313872,0.0002048807,0.00011239154,0.000012533996,0.0000013640486,0.00016647432],"genre_scores_gemma":[0.9915047,0.00024634716,0.00303615,0.0048371744,0.000323084,0.0000020721527,0.000004892438,0.000010095107,0.000035473175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988217,0.000080546604,0.0006698943,0.00017488089,0.000112027315,0.00014095406],"domain_scores_gemma":[0.99902904,0.00020661754,0.00027002077,0.00006230904,0.00017331203,0.00025870732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004033503,0.00008892693,0.0004336698,0.000040380874,0.00002123181,0.00000972433,0.00010496548,0.00016401886,0.000012541772],"category_scores_gemma":[0.0016078757,0.00006948494,0.00007608386,0.00008843338,0.0000659228,0.000007667665,0.000037700003,0.00024837567,0.0000015560919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010450297,0.00049694104,0.92744166,0.00003436358,0.00025074906,0.000072197254,0.0006459588,0.00058175507,0.020510023,0.000040132723,0.011913037,0.0275629],"study_design_scores_gemma":[0.0067114946,0.016828228,0.9141423,0.000026164409,0.000050629857,0.000010183767,0.00020024237,0.000017711838,0.0031751585,0.000087636545,0.058588587,0.00016167785],"about_ca_topic_score_codex":0.000015487441,"about_ca_topic_score_gemma":0.0000465707,"teacher_disagreement_score":0.046675548,"about_ca_system_score_codex":0.00004377759,"about_ca_system_score_gemma":0.0005414269,"threshold_uncertainty_score":0.28335133},"labels":[],"label_agreement":null},{"id":"W3029974150","doi":"10.1200/jco.2020.38.15_suppl.4105","title":"Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Assistance Publique - Hôpitaux de Paris","keywords":"Medicine; Internal medicine; Colorectal cancer; Oncology; Stage (stratigraphy); Population; Cancer; Adjuvant; Gastroenterology","score_opus":0.09073854372816458,"score_gpt":0.4280500618833683,"score_spread":0.3373115181552037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029974150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652245,0.0008396317,0.000006505624,0.032501593,0.00070187595,0.0003177714,0.00003518076,0.000007345353,0.00036561792],"genre_scores_gemma":[0.9842612,0.00084136263,0.0004493963,0.013496859,0.0005817279,0.000010576461,0.000003857321,0.000016750906,0.00033828276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973974,0.00029123324,0.0015484513,0.00022046179,0.0003304459,0.00021198965],"domain_scores_gemma":[0.99700767,0.0012094555,0.00078513304,0.00014350499,0.00020299712,0.0006512693],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014038936,0.00012601247,0.00092685444,0.00007071607,0.000040679854,0.000009895433,0.00019024653,0.00017257215,0.0004959411],"category_scores_gemma":[0.011218486,0.00009508293,0.00021135234,0.00020120708,0.00014348078,0.00009665994,0.00014813723,0.0006953456,0.000010322735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08003995,0.0011908832,0.7445682,0.00007157104,0.00031284374,0.0003457575,0.0007057726,0.000009537658,0.0005772598,0.0000064076808,0.010461159,0.1617106],"study_design_scores_gemma":[0.01568846,0.027922276,0.82583,0.00040162762,0.00017313169,0.000010814492,0.00007398847,0.00022694754,0.000032791366,0.00006043784,0.12944375,0.00013578054],"about_ca_topic_score_codex":0.0001065481,"about_ca_topic_score_gemma":0.000053657364,"teacher_disagreement_score":0.16157483,"about_ca_system_score_codex":0.00014932235,"about_ca_system_score_gemma":0.0013566604,"threshold_uncertainty_score":0.9971104},"labels":[],"label_agreement":null},{"id":"W3029992769","doi":"10.1200/jco.2020.38.15_suppl.12097","title":"Development and validation of a risk prediction model for poor performance status and severe symptoms among cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Wilfrid Laurier University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; Ontario Institute for Cancer Research; Cancer Care Ontario; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Logistic regression; Performance status; Population; Cohort; Breast cancer; Cancer; Retrospective cohort study; Quality of life (healthcare); Lung cancer; Prostate cancer; Stepwise regression; Internal medicine","score_opus":0.07060166475428811,"score_gpt":0.3824207540961316,"score_spread":0.31181908934184344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029992769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99797285,0.00022124537,0.0007413987,0.0004570539,0.00034180027,0.0001765585,0.00003420761,0.0000037565173,0.000051149935],"genre_scores_gemma":[0.9962417,0.0014339578,0.0015839732,0.00045548004,0.0002462498,0.000007695203,0.0000074580794,0.0000074321224,0.000016073627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985576,0.00005262328,0.0010018778,0.000110164,0.00017651138,0.00010119762],"domain_scores_gemma":[0.99814755,0.00029096712,0.00091189437,0.000033592656,0.0003778526,0.00023816753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059423305,0.000067086316,0.0005156488,0.00003580642,0.000029188572,0.0000034298039,0.000028351229,0.00014318195,0.000008079152],"category_scores_gemma":[0.00063759787,0.000050579034,0.00007429457,0.00004874488,0.00007087605,0.00010736494,0.000022710294,0.00026090236,1.2168367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025801049,0.000120378325,0.80540997,0.00011645465,0.000112087786,7.427472e-7,0.0021036859,0.0002420698,0.000010750288,0.0000036213708,0.00018910352,0.18911102],"study_design_scores_gemma":[0.0068750894,0.004757155,0.95325017,0.00011984282,0.0003696927,0.0000037695495,0.00024631651,0.028516727,0.00024404046,0.000023694687,0.0055318875,0.00006159429],"about_ca_topic_score_codex":0.00002444031,"about_ca_topic_score_gemma":0.00009914274,"teacher_disagreement_score":0.18904942,"about_ca_system_score_codex":0.00007008546,"about_ca_system_score_gemma":0.0006698499,"threshold_uncertainty_score":0.2062553},"labels":[],"label_agreement":null},{"id":"W3030001291","doi":"10.1200/jco.2020.38.15_suppl.5516","title":"Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Abiraterone acetate; Urology; Androgen deprivation therapy; Doubling time; Tolerability; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Adverse effect; Confidence interval","score_opus":0.25385446503007764,"score_gpt":0.49593352557567943,"score_spread":0.2420790605456018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030001291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417335,0.00016040895,0.0000072440916,0.003544635,0.0005117663,0.0011556782,0.00017437022,0.0000057324337,0.00026680625],"genre_scores_gemma":[0.99856377,0.00024778154,0.0004921685,0.00016592041,0.0003502137,0.000023619135,0.000040161663,0.00002076375,0.000095585245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949059,0.00067037705,0.0028040651,0.00035619875,0.00093790446,0.00032558452],"domain_scores_gemma":[0.9945953,0.0022580032,0.0018214068,0.00019358596,0.0006374445,0.0004942435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015906795,0.00020851448,0.0017283895,0.00013066169,0.000041367424,0.000012215623,0.00017359578,0.00014244799,0.00009820738],"category_scores_gemma":[0.002015451,0.00013433857,0.00016685709,0.00034670823,0.00021799926,0.00014150061,0.00005138482,0.00095853687,0.000005041886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7819016,0.012764948,0.17648542,0.000048672,0.0013256482,0.0021269438,0.003376748,0.0003261349,0.00020893465,0.0000026063155,0.0006120775,0.020820284],"study_design_scores_gemma":[0.48241067,0.15591286,0.35592288,0.00023925994,0.0008762528,0.0000038437847,0.0027210584,0.00034308643,0.00014627655,0.00001341992,0.0012593997,0.00015101414],"about_ca_topic_score_codex":0.0009203523,"about_ca_topic_score_gemma":0.0040528397,"teacher_disagreement_score":0.29949093,"about_ca_system_score_codex":0.00029284385,"about_ca_system_score_gemma":0.0028332176,"threshold_uncertainty_score":0.5478168},"labels":[],"label_agreement":null},{"id":"W3030012453","doi":"10.1200/jco.2020.38.15_suppl.6049","title":"Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Lapatinib; Oncology; Trabectedin; Pharmacology; Cancer; Pathology; Breast cancer; Sarcoma; Soft tissue sarcoma","score_opus":0.04685632051877533,"score_gpt":0.4100023312855443,"score_spread":0.363146010766769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030012453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98966503,0.0014890719,0.00023435685,0.0038453776,0.0041486756,0.0002315475,0.000025781637,0.0000046328532,0.000355546],"genre_scores_gemma":[0.97158724,0.0018646681,0.0015311122,0.0029772993,0.021932192,0.000020783991,0.0000049922073,0.000025506179,0.00005619329],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972447,0.00028954717,0.0015492337,0.00034817218,0.00022479995,0.00034356018],"domain_scores_gemma":[0.9979049,0.00019766676,0.0011649408,0.00014241556,0.00013842148,0.00045163825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014032844,0.00019813582,0.0011173218,0.00005530022,0.00006802536,0.000023340617,0.00019855968,0.00035046475,0.00006472106],"category_scores_gemma":[0.00094294414,0.00015128698,0.00013679444,0.00011935322,0.00020317326,0.0000311728,0.00009445917,0.00061851845,7.487e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3216779,0.0021043723,0.00035695473,0.000030313166,0.0003146414,0.000031440315,0.00050597865,0.00026555217,0.34077248,0.000025088366,0.0024058246,0.33150947],"study_design_scores_gemma":[0.21196789,0.05547526,0.004260467,0.00006473951,0.00013014252,0.000040228344,0.00033882257,0.00011348208,0.0026807252,0.000078517434,0.72456014,0.0002895936],"about_ca_topic_score_codex":0.000030259529,"about_ca_topic_score_gemma":0.00018996427,"teacher_disagreement_score":0.7221543,"about_ca_system_score_codex":0.00005826284,"about_ca_system_score_gemma":0.0016135275,"threshold_uncertainty_score":0.61693037},"labels":[],"label_agreement":null},{"id":"W3030026467","doi":"10.1200/jco.2020.38.15_suppl.e24154","title":"Treatment in patients with cat receiving LMWH: Learnings from predicare, a non-interventional prospective cohort study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prospective cohort study; Internal medicine; Lung cancer; Clinical endpoint; Cancer; Cohort; Pulmonary embolism; Breast cancer; Stage (stratigraphy); Surgery; Clinical trial","score_opus":0.04953096485645615,"score_gpt":0.39543575288261495,"score_spread":0.3459047880261588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030026467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925313,0.000035481688,0.00007030929,0.0046614255,0.0003622737,0.001257321,0.000004437832,0.000009151355,0.0010683031],"genre_scores_gemma":[0.99732125,0.00006189441,0.0009684431,0.00089036947,0.00060383306,0.000038539507,0.000010218972,0.00001826383,0.00008721232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707866,0.00028092,0.0016308816,0.0003057104,0.00051862537,0.00018518702],"domain_scores_gemma":[0.99750596,0.0005295736,0.0011842962,0.00012867214,0.00031933593,0.00033213888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087953097,0.00015384614,0.0017387118,0.00008438246,0.000031647796,0.000011425874,0.000121741505,0.00013521618,0.0002822805],"category_scores_gemma":[0.0012794903,0.00009922418,0.00030217782,0.00014173443,0.00007708643,0.00009769152,0.00006985065,0.0004990307,0.000018555453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036929287,0.017868815,0.9579382,0.000012255416,0.0015760212,0.00043514706,0.0012103681,0.000032942447,0.0000011875297,0.000004347155,0.0015037507,0.015724054],"study_design_scores_gemma":[0.019124947,0.08561134,0.8911357,0.00013808132,0.0008145452,0.0000034863522,0.0006036303,0.00006904495,0.0000021568628,0.000020785825,0.002399921,0.000076357974],"about_ca_topic_score_codex":0.0003023898,"about_ca_topic_score_gemma":0.00028333277,"teacher_disagreement_score":0.06774253,"about_ca_system_score_codex":0.00041524856,"about_ca_system_score_gemma":0.0005587149,"threshold_uncertainty_score":0.40462446},"labels":[],"label_agreement":null},{"id":"W3030038734","doi":"10.1200/jco.2020.38.15_suppl.e12594","title":"Breast cancer in women aged 80 years and older: Clinical characteristics and treatment patterns according to biologic subtype.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Stage (stratigraphy); Oncology; Epidemiology; Logistic regression; Cancer; Disease","score_opus":0.07637785255630963,"score_gpt":0.41714640098132294,"score_spread":0.3407685484250133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030038734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990955,0.00047114602,0.00002607712,0.00792742,0.00040032106,0.00012592979,0.00007766728,0.00000318761,0.000013242912],"genre_scores_gemma":[0.9842909,0.010650527,0.0002138755,0.0035128598,0.0012903695,0.000014472223,0.0000034810548,0.000012697377,0.000010802341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979705,0.0003091758,0.0011035627,0.00031089887,0.00007553418,0.00023029002],"domain_scores_gemma":[0.9985917,0.000317656,0.00055485906,0.00009590376,0.00007215687,0.00036769832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007276663,0.00015310837,0.000939692,0.000036604197,0.000026318781,0.000011534122,0.000108145185,0.00026676324,0.000019520381],"category_scores_gemma":[0.00045773218,0.000113481634,0.00012552623,0.000059427217,0.00012570371,0.0000063534694,0.00015651334,0.0002541258,0.0000021247984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019621532,0.00022968334,0.6792871,0.0000053314066,0.00020317559,0.00008896378,0.00017522294,0.0000012932227,0.00026754406,8.8240165e-7,0.00011509975,0.3176636],"study_design_scores_gemma":[0.0040226304,0.0047442014,0.9856114,0.00003221562,0.00006768688,0.00007563761,0.0003589744,0.000004233883,0.000025837831,0.0000070454444,0.0049394537,0.00011068287],"about_ca_topic_score_codex":0.000048923135,"about_ca_topic_score_gemma":0.00014465835,"teacher_disagreement_score":0.31755292,"about_ca_system_score_codex":0.000084079074,"about_ca_system_score_gemma":0.00027647254,"threshold_uncertainty_score":0.46276468},"labels":[],"label_agreement":null},{"id":"W3030040681","doi":"10.1200/jco.2020.38.15_suppl.e14125","title":"FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Pembrolizumab; Clinical trial; Family medicine; Lenvatinib; Oncology; Center of excellence; Excellence; Internal medicine; Cancer; Political science","score_opus":0.3436398380477416,"score_gpt":0.4953918172448305,"score_spread":0.15175197919708888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030040681","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17306104,0.12885514,0.07583938,0.5399645,0.037911505,0.008729454,0.0015266169,0.00007692018,0.034035455],"genre_scores_gemma":[0.78083944,0.15494299,0.035927586,0.021685444,0.0061066477,0.00015028902,0.00003259373,0.00006154008,0.00025345664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951929,0.000118907315,0.0038882326,0.0004285712,0.000062932,0.00030847607],"domain_scores_gemma":[0.991025,0.0020660805,0.0058903787,0.00015033828,0.0005697308,0.0002985088],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004114628,0.00018604848,0.0023490663,0.000119643155,0.000045800192,0.0000143961315,0.000416581,0.00049472856,0.00010453669],"category_scores_gemma":[0.019743562,0.00016693425,0.00046116408,0.000107455875,0.00032712604,0.0002889237,0.00010879407,0.0006228953,0.00000781719],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062978454,0.0028322123,0.06246951,0.0037860207,0.00084921526,0.000039300216,0.0010989128,0.0000122555375,0.000017635464,0.0733733,0.24844104,0.60078275],"study_design_scores_gemma":[0.0044040983,0.012730702,0.006630579,0.0007796047,0.00007338341,0.000022079632,0.000059237012,0.00032820788,0.000019834875,0.009185694,0.9655922,0.0001743764],"about_ca_topic_score_codex":0.000016114014,"about_ca_topic_score_gemma":0.000012504984,"teacher_disagreement_score":0.71715117,"about_ca_system_score_codex":0.0002794379,"about_ca_system_score_gemma":0.0014901175,"threshold_uncertainty_score":0.9885135},"labels":[],"label_agreement":null},{"id":"W3030043759","doi":"10.1200/jco.2020.38.15_suppl.4515","title":"Phase III APACT trial of adjuvant <i>nab-</i>paclitaxel plus gemcitabine (<i>nab</i>-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Gemcitabine; Hazard ratio; Nab-paclitaxel; Clinical endpoint; Internal medicine; Population; Lymph node; Pancreatic cancer; Oncology; Chemotherapy; Gastroenterology; Surgery; Cancer; Clinical trial; Confidence interval","score_opus":0.1517275925956607,"score_gpt":0.475264856913448,"score_spread":0.3235372643177873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030043759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715895,0.00142003,0.0010908302,0.020901697,0.0012718261,0.0029429784,0.00017120062,0.00003495505,0.0005770023],"genre_scores_gemma":[0.989312,0.0027518095,0.0028543451,0.002914511,0.0013531514,0.00016952556,0.000100415484,0.000083880026,0.0004603594],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99127066,0.0009066524,0.004888707,0.0006414192,0.0013924398,0.00090011745],"domain_scores_gemma":[0.98196584,0.009525534,0.004088589,0.00056024786,0.0023964439,0.0014633449],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031335526,0.000520508,0.0067067095,0.00034849296,0.00014386169,0.000017315977,0.000551087,0.00081389205,0.00026555854],"category_scores_gemma":[0.01517542,0.0003357346,0.0011979126,0.0006838138,0.0010775942,0.00024942914,0.00013474959,0.0017546396,0.0000066551956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7168379,0.010496686,0.21993203,0.00023737834,0.0043710284,0.00031375003,0.00021689464,0.00000830263,0.00017810478,0.000032869633,0.0351169,0.012258202],"study_design_scores_gemma":[0.70846534,0.20727521,0.056029808,0.00028350647,0.0049333014,0.00003327289,0.00020872378,0.000631651,0.000039163973,0.00010130364,0.021661349,0.00033733915],"about_ca_topic_score_codex":0.00022918149,"about_ca_topic_score_gemma":0.000088682784,"teacher_disagreement_score":0.19677854,"about_ca_system_score_codex":0.00037385488,"about_ca_system_score_gemma":0.0040341653,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W3030062209","doi":"10.1200/jco.2020.38.15_suppl.tps11571","title":"Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02<sup>+</sup> previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; Synovial sarcoma; Soft tissue sarcoma; Internal medicine; Oncology; Progressive disease; Chemotherapy; Sarcoma; Immunology; Cancer research; Pathology","score_opus":0.08339887970369389,"score_gpt":0.39242614807332304,"score_spread":0.3090272683696291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030062209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95975643,0.00008483075,0.0008717848,0.0004497153,0.00004580243,0.038470324,0.000013212334,0.000021346923,0.00028652308],"genre_scores_gemma":[0.9906381,0.00019504552,0.0070662824,0.00016489779,0.00012096343,0.0014130421,0.0000043801456,0.00007602917,0.00032126738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99234205,0.0028729434,0.0025182024,0.0007151258,0.0009193915,0.00063227897],"domain_scores_gemma":[0.99234545,0.0037883967,0.0018668589,0.0003714006,0.00087260175,0.0007553153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027219055,0.00045964474,0.003214125,0.00027758186,0.00007235141,0.00002948308,0.00025846958,0.0003214022,0.00050078734],"category_scores_gemma":[0.0009899494,0.0002941654,0.00016438137,0.0006737859,0.0005603577,0.00028521343,0.00014391742,0.0016733935,0.000005284221],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60398674,0.024954967,0.175756,0.000664409,0.0015705595,0.0015670701,0.0031453294,0.0010246239,0.06148893,8.7384564e-7,0.00043304448,0.12540746],"study_design_scores_gemma":[0.27501658,0.52199084,0.13164486,0.00083781057,0.0011994999,0.00014638485,0.0014690615,0.0019836214,0.060287874,0.000016032516,0.004616956,0.0007904535],"about_ca_topic_score_codex":0.000038359227,"about_ca_topic_score_gemma":0.00004221103,"teacher_disagreement_score":0.4970359,"about_ca_system_score_codex":0.0002820245,"about_ca_system_score_gemma":0.0012708062,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W3030076241","doi":"10.1200/jco.2020.38.15_suppl.e20011","title":"Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"AbbVie","keywords":"Neutropenia; Medicine; Internal medicine; Febrile neutropenia; Venetoclax; Absolute neutrophil count; Chronic lymphocytic leukemia; Gastroenterology; Leukemia; Chemotherapy","score_opus":0.25492279895530584,"score_gpt":0.5023426091357484,"score_spread":0.2474198101804425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030076241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964289,0.0016563706,0.00008322983,0.0009017157,0.0002067179,0.0005659088,0.0000864121,0.000008979588,0.000061736326],"genre_scores_gemma":[0.994249,0.0023886934,0.0011402591,0.0012558242,0.00075814116,0.0000047912163,0.000116676514,0.000038064616,0.00004858374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923229,0.0014487305,0.0044368613,0.0005673918,0.00086153415,0.00036254182],"domain_scores_gemma":[0.98783714,0.0068741506,0.0033603648,0.000807499,0.00042579763,0.00069506565],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050477143,0.00025335295,0.0047057234,0.00040006262,0.000040241903,0.000014015062,0.00067887397,0.0005553106,0.0004959114],"category_scores_gemma":[0.010968154,0.00015600852,0.0004094569,0.0010665543,0.00036734168,0.00026420556,0.00032028623,0.001256029,0.0000061894693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.72695136,0.004108296,0.043449614,0.00026097827,0.026993493,0.0040684226,0.0011907045,0.0036355825,0.0015278753,0.0000110262135,0.0064821546,0.18132047],"study_design_scores_gemma":[0.59958893,0.102927625,0.10353546,0.00036535942,0.011880316,0.00003803566,0.000112427995,0.16419682,0.000115130904,0.000023131008,0.016923008,0.0002937712],"about_ca_topic_score_codex":0.00082016416,"about_ca_topic_score_gemma":0.0004928896,"teacher_disagreement_score":0.18102671,"about_ca_system_score_codex":0.026613126,"about_ca_system_score_gemma":0.10399363,"threshold_uncertainty_score":0.99736285},"labels":[],"label_agreement":null},{"id":"W3030083314","doi":"10.1200/jco.2020.38.15_suppl.102","title":"Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Neutropenia; Leukopenia; Cyclophosphamide; Internal medicine; Febrile neutropenia; Regimen; Gastroenterology; Chemotherapy; Oncology; Surgery","score_opus":0.20372602864825018,"score_gpt":0.5361714243604768,"score_spread":0.33244539571222664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030083314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98566437,0.00014251222,0.00018656386,0.012621177,0.0003085747,0.00068626105,0.0000025172856,0.0000033101182,0.00038472013],"genre_scores_gemma":[0.99563974,0.0009943388,0.001009994,0.0013233664,0.0009469901,0.0000018346295,0.0000010863442,0.0000129233385,0.00006972722],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964732,0.00074911217,0.002025925,0.00018888235,0.0003880369,0.0001748545],"domain_scores_gemma":[0.99399686,0.0044653597,0.000752274,0.00014028187,0.0002067867,0.00043842103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042590825,0.00010074209,0.0012673907,0.00009396355,0.000025655114,0.0000081572225,0.0001174427,0.00018112533,0.0001962891],"category_scores_gemma":[0.0057002106,0.0000630215,0.00016902237,0.00021105666,0.00018375517,0.00007630578,0.00008667918,0.0009380001,0.0000031071177],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40672505,0.0018558393,0.0013170891,0.000029955443,0.000064766646,0.00019839968,0.0005970068,0.000088384084,0.1031509,0.000011648291,0.00021237442,0.4857486],"study_design_scores_gemma":[0.61413634,0.15417492,0.15807092,0.00034196314,0.00025904505,0.00016028229,0.0007653257,0.0026229534,0.0114066405,0.00011970389,0.057739865,0.0002020134],"about_ca_topic_score_codex":0.000005905329,"about_ca_topic_score_gemma":0.000009490154,"teacher_disagreement_score":0.4855466,"about_ca_system_score_codex":0.00005873518,"about_ca_system_score_gemma":0.0006161389,"threshold_uncertainty_score":0.68240964},"labels":[],"label_agreement":null},{"id":"W3030145599","doi":"10.1200/jco.2020.38.15_suppl.e15062","title":"Assessing long-term survival improvement of immune-checkpoint inhibitors (ICI) anticancer agents approved by the Food and Drug Administration: A meta-analysis of randomized controlled trials (RCTs).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Randomized controlled trial; Meta-analysis; Survival rate; Drug; Progression-free survival; Hematology; Overall survival; Pharmacology","score_opus":0.2595562271285577,"score_gpt":0.48441830194270097,"score_spread":0.22486207481414328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030145599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95280886,0.011841582,0.000777472,0.032204907,0.00061423425,0.0015361009,0.000021372853,0.0000040908794,0.00019140728],"genre_scores_gemma":[0.9958568,0.001778541,0.00028513477,0.0016274537,0.00034624088,0.000028892444,0.0000067550595,0.0000122039455,0.000057984867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98364305,0.003853926,0.011364793,0.0002374445,0.00073061336,0.00017014865],"domain_scores_gemma":[0.9694388,0.015979841,0.013528415,0.0002317246,0.0006171944,0.00020405646],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.044193953,0.0002269468,0.015952429,0.00013731097,0.0000424677,0.000033467604,0.00018854642,0.00021882892,0.00036628387],"category_scores_gemma":[0.015550384,0.000105066094,0.010225389,0.0003411371,0.00060604844,0.00011166288,0.000049458336,0.0005022717,1.6920353e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53970957,0.0011298279,0.0015563434,0.00009106935,0.41990638,0.000020799223,0.00031449515,0.0000050527033,0.02525488,0.000013415807,0.0002868556,0.011711341],"study_design_scores_gemma":[0.5025857,0.0093864715,0.008815511,0.000053642278,0.4628985,0.000013661257,0.0006378447,0.000292668,0.014793965,0.000029724639,0.00035225716,0.000140058],"about_ca_topic_score_codex":0.00003883056,"about_ca_topic_score_gemma":0.00003582273,"teacher_disagreement_score":0.04304796,"about_ca_system_score_codex":0.00005274093,"about_ca_system_score_gemma":0.0011940332,"threshold_uncertainty_score":0.99968696},"labels":[],"label_agreement":null},{"id":"W3030160694","doi":"10.1200/jco.2020.38.15_suppl.11529","title":"Maximum tumor dimension and tumor volume as prognostic factors in patients with newly diagnosed localized Ewing sarcoma (ES)- a report from the Children’s Oncology Group (COG).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; BC Children's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Hazard ratio; Confidence interval; Context (archaeology); Internal medicine; Sarcoma; Chemotherapy; Primary tumor; Proportional hazards model; Oncology; Cancer; Nuclear medicine; Pathology; Metastasis","score_opus":0.04858930573279407,"score_gpt":0.3509053479047755,"score_spread":0.30231604217198144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030160694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847265,0.0007705479,0.000027872866,0.012868381,0.00041622753,0.001104183,0.0000124371245,0.000018234014,0.000055609307],"genre_scores_gemma":[0.988151,0.00010637333,0.0020933186,0.009042102,0.0004941096,0.000028132625,0.00004458504,0.00003753811,0.0000028386332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952191,0.0007939484,0.002563939,0.00048522456,0.0005633934,0.00037440754],"domain_scores_gemma":[0.99061036,0.0060729226,0.0021177705,0.00026663372,0.00025444455,0.0006778645],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011418405,0.00030774655,0.0021362957,0.00008582057,0.00007942561,0.000023069908,0.00019088964,0.0002485074,0.00011865118],"category_scores_gemma":[0.00871673,0.00016457913,0.0003375891,0.00021299357,0.00030775723,0.00012779862,0.00014350406,0.0011990948,0.00001584118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066568707,0.0049411957,0.94271255,0.000008515638,0.0005477216,0.015287477,0.0002827596,0.0000055582204,0.000007583183,0.000006790038,0.0012649297,0.028278055],"study_design_scores_gemma":[0.031344615,0.027177302,0.9316273,0.00022148964,0.0010238918,0.0006982584,0.00021706863,0.000059407244,0.000013117377,0.0001017392,0.007361103,0.00015473951],"about_ca_topic_score_codex":0.00047109422,"about_ca_topic_score_gemma":0.00019224692,"teacher_disagreement_score":0.028123315,"about_ca_system_score_codex":0.00023106193,"about_ca_system_score_gemma":0.00092208706,"threshold_uncertainty_score":0.99963325},"labels":[],"label_agreement":null},{"id":"W3030168996","doi":"10.1200/jco.2020.38.15_suppl.7052","title":"Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Surrogate endpoint; Logistic regression; Internal medicine; Food and drug administration; Cancer drugs; Quality of life (healthcare); Cancer; Family medicine; Oncology; Pharmacology","score_opus":0.2905068324019257,"score_gpt":0.4223120120468682,"score_spread":0.13180517964494248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030168996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979887,0.0010878401,0.0000036030422,0.0160013,0.00044168043,0.00021323159,0.00007323795,0.000001784049,0.0022903006],"genre_scores_gemma":[0.99256605,0.0013071772,0.00006106969,0.005451966,0.0005817466,0.0000057952852,0.0000020563114,0.000013763728,0.000010396599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943697,0.00044080868,0.0045985626,0.0002219566,0.00010551367,0.00026345192],"domain_scores_gemma":[0.98913074,0.0045697303,0.0058112005,0.00017355684,0.00020845886,0.00010633244],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013609543,0.00015091524,0.002158743,0.0001244237,0.000028282611,0.000016076096,0.000696179,0.0003622311,0.00016190951],"category_scores_gemma":[0.011351775,0.000091111884,0.000489037,0.00030774472,0.00029156965,0.00021045818,0.000055043347,0.0011614958,0.0000034560799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073081185,0.0006150398,0.98093736,0.00001872548,0.000117250565,0.000011631811,0.0033947264,0.000049487808,0.0000015291381,0.001012819,0.00015480547,0.012955824],"study_design_scores_gemma":[0.002904704,0.002536109,0.988618,0.000072933646,0.00003277673,0.0000013435438,0.0011575406,0.00016023952,0.0000028080806,0.00030607558,0.004102335,0.00010510069],"about_ca_topic_score_codex":0.00032507128,"about_ca_topic_score_gemma":0.0007542636,"teacher_disagreement_score":0.012850723,"about_ca_system_score_codex":0.00007153091,"about_ca_system_score_gemma":0.00035419906,"threshold_uncertainty_score":0.996976},"labels":[],"label_agreement":null},{"id":"W3030178583","doi":"10.1200/jco.20.00793","title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":759,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Clinical endpoint; Etoposide; Population; Gastroenterology; Progression-free survival; Oncology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Chemotherapy; Immunotherapy; Pathology","score_opus":0.24579924696283775,"score_gpt":0.5415262119285564,"score_spread":0.2957269649657187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030178583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93631536,0.007962205,0.0011867029,0.044551212,0.000930682,0.008206927,0.000026719827,0.000033002336,0.000787209],"genre_scores_gemma":[0.9619196,0.023626411,0.0009992059,0.0073733577,0.0035605747,0.00048133748,0.000005579063,0.000069885726,0.001964027],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939471,0.0007725986,0.003413784,0.0005643825,0.00072662067,0.0005755172],"domain_scores_gemma":[0.9821501,0.012960614,0.00224054,0.0002803896,0.0013622643,0.0010061256],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005244841,0.00039810172,0.004814168,0.00016882403,0.00021227001,0.000041575022,0.00033860226,0.00037675578,0.00033577436],"category_scores_gemma":[0.008400469,0.0002399045,0.00079381256,0.0002404395,0.0005051063,0.00014434774,0.0002151027,0.0017043373,0.0000048758284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9657739,0.0029187873,0.0020638783,0.00030123728,0.0032083467,0.0017953165,0.002831375,0.00023818301,0.00009315171,0.000016076481,0.0061242976,0.014635446],"study_design_scores_gemma":[0.91138786,0.05873763,0.0002772695,0.00015107777,0.0017269112,0.00012953833,0.0012054541,0.0040579103,0.00023985434,0.000038178892,0.021820042,0.00022826766],"about_ca_topic_score_codex":0.00024064841,"about_ca_topic_score_gemma":0.00040383128,"teacher_disagreement_score":0.05581884,"about_ca_system_score_codex":0.0003914437,"about_ca_system_score_gemma":0.004925498,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W3030218591","doi":"10.1200/jco.2020.38.15_suppl.5071","title":"Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Sunnybrook Hospital; University Health Network; Queen's University; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Chromophobe cell; Papillary renal cell carcinomas; Clear cell renal cell carcinoma; Lymph node; Internal medicine; Cabozantinib; Oncology; Renal cell carcinoma; Clear cell; Metastasectomy; Pathology; Metastasis; Cancer","score_opus":0.1670620845367558,"score_gpt":0.39438467903818003,"score_spread":0.22732259450142422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030218591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985434,0.0035092903,0.000026559077,0.005036592,0.00016227794,0.00035301605,0.0000063992707,0.000004925917,0.0010465932],"genre_scores_gemma":[0.98780096,0.0014852071,0.0077183866,0.0026505059,0.00026624353,0.0000043746477,0.0000080539385,0.000023590757,0.00004270502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950442,0.00069102296,0.003148397,0.00029470903,0.0005315494,0.0002901313],"domain_scores_gemma":[0.9953422,0.0014751178,0.0021121355,0.00018449484,0.00026486296,0.00062117813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022948254,0.00023201911,0.0022967304,0.0001811075,0.000023345588,0.000009732311,0.00015129203,0.00014682247,0.00014853556],"category_scores_gemma":[0.00085504114,0.00016800122,0.0004344746,0.00023003238,0.00020255637,0.00014428467,0.000113596936,0.00091785117,0.000012731785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016729383,0.008977517,0.46510047,0.0026718494,0.001165097,0.02052067,0.00446616,0.000055247223,0.4540164,0.00006143867,0.002039432,0.024196351],"study_design_scores_gemma":[0.035931353,0.10145968,0.7440253,0.0003293777,0.0032598188,0.0007697859,0.0022052699,0.00082009454,0.09920793,0.0001661357,0.01141503,0.00041021602],"about_ca_topic_score_codex":0.00004223155,"about_ca_topic_score_gemma":0.000016017757,"teacher_disagreement_score":0.35480845,"about_ca_system_score_codex":0.00014767835,"about_ca_system_score_gemma":0.0010158228,"threshold_uncertainty_score":0.6850891},"labels":[],"label_agreement":null},{"id":"W3030219555","doi":"10.1200/jco.2020.38.15_suppl.510","title":"Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; U.S. Department of Defense","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Oncology; Cohort; Tumor-infiltrating lymphocytes; Internal medicine; Proportional hazards model; Stromal cell; Gene signature; Adjuvant; Immune system; Pathology; Cancer; Immunology; Immunotherapy; Gene expression; Gene","score_opus":0.07646240536740681,"score_gpt":0.4361222999563779,"score_spread":0.3596598945889711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030219555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97488886,0.0010750314,0.0000017294315,0.022129769,0.00071020896,0.0004946661,0.000020120182,0.0000018020601,0.00067781575],"genre_scores_gemma":[0.9893778,0.004202356,0.00014249816,0.0051394827,0.0010842764,0.000007825327,6.030834e-7,0.000007837861,0.00003731677],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961229,0.00079532486,0.0025040582,0.00015667819,0.0002567522,0.00016429901],"domain_scores_gemma":[0.9959956,0.002287736,0.0013603447,0.00009804738,0.000121085985,0.00013721465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004157176,0.00010804218,0.0013161245,0.00007993446,0.000012814034,0.000005900146,0.00016851035,0.00026393935,0.00038820956],"category_scores_gemma":[0.001116247,0.00006427935,0.00030636886,0.00028329244,0.00032841408,0.000067697794,0.00002633428,0.0011313561,0.0000020429104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63816625,0.0016853659,0.1932541,0.00005131485,0.00035559176,0.00030455625,0.0014910765,0.000005327943,0.0021936574,0.00001350856,0.004378746,0.1581005],"study_design_scores_gemma":[0.13412113,0.01606248,0.8415709,0.0001372596,0.00020242893,0.00011411763,0.001245434,0.0001083468,0.00020692608,0.00017642698,0.005970522,0.00008397828],"about_ca_topic_score_codex":0.00026269507,"about_ca_topic_score_gemma":0.00043461687,"teacher_disagreement_score":0.64831686,"about_ca_system_score_codex":0.00008002094,"about_ca_system_score_gemma":0.0013773862,"threshold_uncertainty_score":0.49152422},"labels":[],"label_agreement":null},{"id":"W3030227576","doi":"10.1200/jco.2020.38.15_suppl.3073","title":"A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Olaparib; Medicine; Cohort; Durvalumab; Internal medicine; Oncology; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy; Nivolumab; Genetics; Biology","score_opus":0.16799720416196628,"score_gpt":0.4745135682877819,"score_spread":0.3065163641258156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030227576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915409,0.0021802122,0.00015048383,0.004825941,0.00019449668,0.0010194503,0.0000029246125,0.00000912724,0.00007646791],"genre_scores_gemma":[0.99606836,0.0005336457,0.0012760137,0.0018234454,0.00025585204,0.00002410153,1.9703837e-7,0.00001574471,0.00000264949],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99589187,0.000917368,0.0023407617,0.00022817327,0.0004463024,0.00017553844],"domain_scores_gemma":[0.9964061,0.0009895624,0.0019742453,0.00017056047,0.000306666,0.00015290896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027804158,0.00013067124,0.001374406,0.00008796311,0.000030883577,0.000005875341,0.00014224729,0.00019718827,0.000010992111],"category_scores_gemma":[0.0009969126,0.00008634155,0.00026612854,0.00034194067,0.00039144032,0.000040847346,0.000092199356,0.0008822634,7.785398e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18491712,0.012640388,0.39758235,0.00025122834,0.0017231997,0.0010428862,0.006050485,0.0005132301,0.02276201,0.00007334354,0.00018903597,0.37225473],"study_design_scores_gemma":[0.44602168,0.21124528,0.3146952,0.0016006357,0.0021395953,0.00054448936,0.0044177966,0.006111438,0.006225216,0.00035772333,0.0062799584,0.0003609638],"about_ca_topic_score_codex":0.00009732756,"about_ca_topic_score_gemma":0.00006792795,"teacher_disagreement_score":0.37189376,"about_ca_system_score_codex":0.00006940242,"about_ca_system_score_gemma":0.0009032486,"threshold_uncertainty_score":0.38330445},"labels":[],"label_agreement":null},{"id":"W3030237145","doi":"10.1200/jco.2020.38.15_suppl.1523","title":"Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lynch syndrome; Medicine; Endometrial cancer; Serous fluid; Epigenetics; Oncology; Ovarian cancer; Germline mutation; Cancer; DNA mismatch repair; Germline; Internal medicine; Cancer research; Mutation; Genetics; Biology; Gene","score_opus":0.4431684828375862,"score_gpt":0.4829195144493834,"score_spread":0.039751031611797216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030237145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372846,0.0004682578,0.0015388959,0.002381804,0.0010084145,0.0002749808,0.0000030419417,0.000011646592,0.0005845024],"genre_scores_gemma":[0.96787065,0.00014200616,0.028450688,0.0031609542,0.00034789025,0.0000024305443,0.0000029909252,0.000018456403,0.0000039341585],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9955584,0.00072201964,0.0026429908,0.0002610963,0.0005608144,0.00025470808],"domain_scores_gemma":[0.9960369,0.0007382299,0.0019874845,0.0001465363,0.0007942342,0.00029663494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016802374,0.00015556626,0.0014898876,0.0001162698,0.000029056535,0.000007147017,0.00015300357,0.00039585755,0.0000875728],"category_scores_gemma":[0.0029793351,0.00013498038,0.0004154938,0.0004039414,0.00015690677,0.00008211789,0.00005842115,0.0009771391,8.7603246e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015633322,0.00091049453,0.19667985,0.00028634915,0.0006283785,0.0024070614,0.0014948425,0.0552159,0.7288258,0.00007728764,0.00085923413,0.011051475],"study_design_scores_gemma":[0.019477867,0.03589645,0.45809722,0.0008243747,0.0013801525,0.00058367214,0.0024647403,0.46539202,0.0129093975,0.00033169557,0.0020740775,0.0005683144],"about_ca_topic_score_codex":0.00028902988,"about_ca_topic_score_gemma":0.000113937465,"teacher_disagreement_score":0.7159164,"about_ca_system_score_codex":0.0018353653,"about_ca_system_score_gemma":0.0075473036,"threshold_uncertainty_score":0.998079},"labels":[],"label_agreement":null},{"id":"W3030299239","doi":"10.1200/jco.2020.38.15_suppl.2019","title":"Methodology, results, and publication of oncology clinical trials: Insights from all the world’s randomized controlled trials (RCTs) 2014-2017.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Randomized controlled trial; Clinical endpoint; Cohort; Sample size determination; Oncology; Cancer","score_opus":0.452667694077942,"score_gpt":0.5585094382439051,"score_spread":0.10584174416596309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030299239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51707256,0.064775296,0.032713823,0.34524396,0.017423855,0.006849798,0.00044108,0.000024204157,0.015455391],"genre_scores_gemma":[0.81279534,0.08381552,0.038182434,0.044914033,0.019706843,0.000071261464,0.00016447311,0.000052997464,0.0002970739],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.90904677,0.06619392,0.023278547,0.0007113283,0.00041717113,0.0003522622],"domain_scores_gemma":[0.59490764,0.37323883,0.028608944,0.0006520316,0.0017656324,0.0008269167],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18746732,0.00025652963,0.011156457,0.00012573447,0.000050137573,0.00003190056,0.00058731023,0.0011536869,0.00006144917],"category_scores_gemma":[0.6200186,0.0001350175,0.0030366539,0.00011629855,0.0010424958,0.000011694221,0.00025465112,0.0010704907,0.0000069469324],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73171586,0.0006816772,0.00026347587,0.000008182447,0.0052040135,0.000027589025,0.000164336,0.000029364566,0.0056569427,0.0015166576,0.16855168,0.08618023],"study_design_scores_gemma":[0.35806623,0.006225277,0.0008578047,0.000014843626,0.0026303704,0.000015377453,0.00012513326,0.00022367251,0.000920242,0.0024413995,0.6283409,0.0001387729],"about_ca_topic_score_codex":0.000056823254,"about_ca_topic_score_gemma":0.0003108928,"teacher_disagreement_score":0.4597892,"about_ca_system_score_codex":0.000032659937,"about_ca_system_score_gemma":0.0021813621,"threshold_uncertainty_score":0.889829},"labels":[],"label_agreement":null},{"id":"W3030329573","doi":"10.1200/jco.2020.38.15_suppl.6001","title":"A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Interim analysis; Surgery; Ovarian cancer; Chemotherapy; Randomization; Randomized controlled trial; Cancer; Phases of clinical research; Internal medicine","score_opus":0.17649892271946693,"score_gpt":0.4878551666987912,"score_spread":0.31135624397932427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030329573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92712104,0.0021589382,0.000037939084,0.06441731,0.004044873,0.0010108168,0.000029237572,0.0000066654866,0.0011731833],"genre_scores_gemma":[0.9871798,0.0057436037,0.0005229649,0.0025854476,0.0038506018,0.00005753908,0.000007245334,0.00001863103,0.000034123277],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936172,0.001199202,0.004314467,0.00027065258,0.00035897986,0.0002395082],"domain_scores_gemma":[0.99076545,0.0054808008,0.0028050903,0.00014718476,0.00033525898,0.00046624063],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004779301,0.0001878171,0.0048035975,0.00016514582,0.000018603323,0.000006592708,0.00011015682,0.00033245253,0.0009346959],"category_scores_gemma":[0.0039467826,0.0001250415,0.0014284004,0.00021019956,0.00028068226,0.00010616017,0.000040177758,0.0010335466,0.000005336317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7804384,0.005371688,0.0022602382,0.000046589128,0.0014190371,0.0007582053,0.0005144517,0.0000043746713,0.000020816013,0.00004880115,0.007775553,0.20134184],"study_design_scores_gemma":[0.9541546,0.013639979,0.0047197784,0.00027902893,0.0012525467,0.000047997568,0.00010188278,0.000054964014,0.0002459353,0.00026308987,0.025134778,0.00010541387],"about_ca_topic_score_codex":0.000088604196,"about_ca_topic_score_gemma":0.000041634972,"teacher_disagreement_score":0.20123643,"about_ca_system_score_codex":0.00027643816,"about_ca_system_score_gemma":0.0050961464,"threshold_uncertainty_score":0.9999786},"labels":[],"label_agreement":null},{"id":"W3030332895","doi":"10.1200/jco.2020.38.15_suppl.4090","title":"Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Oncology; Hazard ratio; Internal medicine; Cetuximab; Colorectal cancer; Biomarker; Panitumumab; Confidence interval; Randomized controlled trial; Cancer","score_opus":0.33927359684083513,"score_gpt":0.4885736924796781,"score_spread":0.14930009563884294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030332895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777776,0.015063399,0.00006948686,0.002636454,0.00017295117,0.0015275526,0.0027165134,0.000003696265,0.00003237192],"genre_scores_gemma":[0.9894567,0.006384231,0.0028723986,0.0006003703,0.00010596848,0.000080298596,0.00048247434,0.000014771371,0.0000027985516],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909164,0.003538221,0.0040856963,0.00042323128,0.0008003043,0.00023615864],"domain_scores_gemma":[0.96455634,0.029595407,0.0048618936,0.00027591747,0.0004733471,0.00023710103],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003857834,0.00031366255,0.009666344,0.0002018602,0.000048971535,0.000013986287,0.0002104354,0.00010835989,0.00013105829],"category_scores_gemma":[0.012448864,0.00014035915,0.0012932193,0.0004553052,0.0005300993,0.0001796833,0.0001857718,0.0003576825,3.9607457e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23198916,0.0037472164,0.26721066,0.00008002764,0.41882607,0.0002516429,0.004364127,0.00022859698,0.00006382615,0.000014324078,0.0003534292,0.07287092],"study_design_scores_gemma":[0.17688638,0.021789957,0.33788186,0.00006926767,0.46037567,0.0000065944473,0.0009146875,0.0011417257,0.00029145693,0.00004402535,0.0004552809,0.00014308059],"about_ca_topic_score_codex":0.0022345558,"about_ca_topic_score_gemma":0.0035025815,"teacher_disagreement_score":0.07272784,"about_ca_system_score_codex":0.00015862462,"about_ca_system_score_gemma":0.0010131465,"threshold_uncertainty_score":0.9958697},"labels":[],"label_agreement":null},{"id":"W3030357868","doi":"10.1200/jco.2020.38.15_suppl.4630","title":"Outcomes and Immunogenicity of pancreatic cancer stratified by the HRDetect score.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Queen's University; McGill University; Centre Hospitalier de l’Université de Montréal; Toronto General Hospital; University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunogenicity; Internal medicine; PALB2; Oncology; Pancreatic cancer; Cancer; Antibody; Gene; Immunology; Germline mutation; Mutation; Genetics","score_opus":0.07716482019828338,"score_gpt":0.4059221294186349,"score_spread":0.3287573092203515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030357868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866477,0.006417919,0.00017107709,0.0061725993,0.00028981201,0.000080801175,0.000028863002,8.4365274e-7,0.00019034502],"genre_scores_gemma":[0.98989,0.006761657,0.00024960717,0.0026629998,0.00039359237,0.0000022120503,0.0000020634193,0.000007564083,0.000030315472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852735,0.00014399784,0.001004973,0.0001189121,0.00010226048,0.000102530495],"domain_scores_gemma":[0.9981465,0.0005808593,0.00088112196,0.000120573895,0.00014295687,0.00012803689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005746409,0.000084505584,0.00055335456,0.000008633192,0.000026848877,0.0000076097203,0.00020208127,0.00017132229,0.000022052012],"category_scores_gemma":[0.0020343917,0.000052014166,0.00022271425,0.00003691391,0.00020345084,0.0000024678181,0.00008309305,0.0002455891,5.400587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047379225,0.0004856623,0.47514105,0.000059195263,0.0017880127,0.00003035882,0.00018364564,0.00015769259,0.33816424,0.0001364069,0.021838449,0.15727738],"study_design_scores_gemma":[0.011844932,0.020154944,0.6234924,0.000051039056,0.0010663905,0.00007918069,0.0003564543,0.0002132709,0.12670726,0.0005706391,0.21505451,0.0004089673],"about_ca_topic_score_codex":0.00008259531,"about_ca_topic_score_gemma":0.00012096058,"teacher_disagreement_score":0.21145698,"about_ca_system_score_codex":0.000009894661,"about_ca_system_score_gemma":0.000535445,"threshold_uncertainty_score":0.24355038},"labels":[],"label_agreement":null},{"id":"W3030378344","doi":"10.1200/jco.2020.38.15_suppl.e15227","title":"Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Infliximab; Adverse effect; Internal medicine; Gastroenterology; Tumor necrosis factor alpha","score_opus":0.08463694468628592,"score_gpt":0.43057567189522455,"score_spread":0.34593872720893865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030378344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923181,0.0009273718,0.0000031836075,0.0054119625,0.0003042019,0.00027766047,0.0000021122164,0.0000063909715,0.00074902177],"genre_scores_gemma":[0.9956118,0.001894428,0.0004609245,0.0018396891,0.00013132115,0.0000016264876,0.000001337927,0.0000145690765,0.00004431082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948528,0.0006333213,0.0038402108,0.000194429,0.0002682765,0.00021098857],"domain_scores_gemma":[0.9957507,0.001711503,0.0020749175,0.00014004852,0.000112149486,0.00021065035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038216142,0.00013690136,0.0014643958,0.0002569449,0.000015542248,0.000001824588,0.00014392607,0.00032116077,0.00008117406],"category_scores_gemma":[0.0028541167,0.000110002606,0.0003242605,0.0004030274,0.00019028182,0.000122052734,0.00007529117,0.0012903613,0.0000020489101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057509914,0.0018186478,0.85531586,0.00010226396,0.00032982792,0.00067631586,0.0013102401,0.00002696769,0.012495924,0.000006955767,0.00022996191,0.07017713],"study_design_scores_gemma":[0.035148922,0.0066200043,0.9518782,0.0006171965,0.000079096586,0.00004693545,0.00018702114,0.00032612885,0.00023623327,0.00002824192,0.004740547,0.00009147055],"about_ca_topic_score_codex":0.00025951752,"about_ca_topic_score_gemma":0.00035378017,"teacher_disagreement_score":0.096562356,"about_ca_system_score_codex":0.0002110485,"about_ca_system_score_gemma":0.0008294773,"threshold_uncertainty_score":0.56060493},"labels":[],"label_agreement":null},{"id":"W3030388014","doi":"10.1200/jco.2020.38.15_suppl.e19360","title":"Examining the relationship between the clinical benefit of oncology drug indications and the time from pan-Canadian Oncology Drug Review (pCODR) recommendation to public reimbursement.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Reimbursement; Clinical Oncology; Internal medicine; Oncology; Cancer; Family medicine","score_opus":0.34360186854908414,"score_gpt":0.42719875122360096,"score_spread":0.08359688267451681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030388014","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22922426,0.0069297305,0.0003871204,0.7397025,0.0011660752,0.00073374755,0.00016549951,0.000007032975,0.021683995],"genre_scores_gemma":[0.9297975,0.012436561,0.000898119,0.0546197,0.0019660129,0.000027540118,0.00002427391,0.000021534668,0.00020876786],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.992003,0.0012703515,0.005918684,0.00038007664,0.000081488215,0.000346395],"domain_scores_gemma":[0.9641158,0.027639039,0.006929379,0.00043379728,0.00026161244,0.00062039297],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022897473,0.00018161525,0.002157569,0.00014776409,0.00028893806,0.00004702443,0.0009652095,0.00040183976,0.0006304319],"category_scores_gemma":[0.030486733,0.00011494931,0.00042595415,0.00036083936,0.0007546068,0.00030553254,0.0001974572,0.001725121,0.00027271276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027487395,0.00014723119,0.5067894,0.000017273327,0.00039789066,0.0000035534536,0.00106719,0.000006160698,1.5734832e-7,0.030579865,0.095405295,0.36531115],"study_design_scores_gemma":[0.0016556979,0.0008742588,0.43306956,0.00004755754,0.00013778784,0.000003849866,0.00015437756,0.00004377512,1.9564689e-7,0.0155449975,0.5483817,0.00008625307],"about_ca_topic_score_codex":0.0020648134,"about_ca_topic_score_gemma":0.004386565,"teacher_disagreement_score":0.7005732,"about_ca_system_score_codex":0.00036458104,"about_ca_system_score_gemma":0.0018087302,"threshold_uncertainty_score":0.9776799},"labels":[],"label_agreement":null},{"id":"W3030398200","doi":"10.1200/jco.2020.38.15_suppl.e19295","title":"Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Lung cancer; Veterans Affairs; Propensity score matching; Stage (stratigraphy); Internal medicine; Proportional hazards model; Cancer; Adverse effect; Medical record; Chemotherapy","score_opus":0.12411274086212391,"score_gpt":0.4799209048690263,"score_spread":0.35580816400690235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030398200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827073,0.0011819816,0.00080373534,0.013600585,0.0010901758,0.00047912335,0.000031174444,0.000006355477,0.00009954523],"genre_scores_gemma":[0.9847664,0.009689011,0.002844845,0.0018408885,0.00074371306,0.000019218813,0.0000045757847,0.000028508848,0.000062787716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749225,0.000076599594,0.001876473,0.00019082552,0.00017633468,0.00018754299],"domain_scores_gemma":[0.99473256,0.002697187,0.0019095477,0.00013132009,0.00026355588,0.00026585808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006474416,0.0001706303,0.002038906,0.00004307603,0.000041875675,0.000009741959,0.00011798667,0.00022485797,0.00008843611],"category_scores_gemma":[0.0004121681,0.000121335754,0.00043774184,0.000063053645,0.0001096198,0.000052878375,0.00002058499,0.00041886177,4.4247022e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011352772,0.0012859643,0.92408425,0.00032869258,0.0010211631,0.000029973957,0.0011037074,0.00002885742,0.00015493031,0.0000027441697,0.00087498064,0.05973197],"study_design_scores_gemma":[0.037814908,0.020300096,0.92281413,0.0002385305,0.00068311096,0.0000020391192,0.00014448968,0.0022397034,0.0006279221,0.0000025756478,0.015023104,0.000109415836],"about_ca_topic_score_codex":0.00007095631,"about_ca_topic_score_gemma":0.000120657394,"teacher_disagreement_score":0.059622556,"about_ca_system_score_codex":0.00018142573,"about_ca_system_score_gemma":0.00046293827,"threshold_uncertainty_score":0.49479285},"labels":[],"label_agreement":null},{"id":"W3030423882","doi":"10.1200/jco.2020.38.15_suppl.tps2579","title":"GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Glioblastoma; Drug development; Investigational Drugs; Phases of clinical research; Agile software development; Oncology; Drug; Internal medicine; Pharmacology; Cancer research; Computer science","score_opus":0.45839795428061403,"score_gpt":0.5956186525679424,"score_spread":0.1372206982873284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030423882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8518612,0.00036677602,0.00014526477,0.1450255,0.0008901161,0.0011661759,0.000013149055,0.000010292697,0.0005215117],"genre_scores_gemma":[0.9564557,0.0013813805,0.0017894949,0.037814334,0.0024803004,0.000019630917,0.0000021339067,0.000013235431,0.000043795437],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99439305,0.0006097104,0.002797971,0.0003214999,0.0010509073,0.00082687254],"domain_scores_gemma":[0.97647864,0.0067579546,0.0011069953,0.00019633597,0.0006040979,0.014855986],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008979945,0.00018625875,0.0019039207,0.00014146267,0.000057862384,0.000010205125,0.0001832657,0.00043258065,0.00015899663],"category_scores_gemma":[0.2964737,0.00011779344,0.00026924306,0.00046590553,0.00021687099,0.00013776317,0.0001574802,0.0019301613,0.000024748031],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44282785,0.0030433624,0.00056395144,0.000028496874,0.000086637556,0.0023066842,0.00043294174,0.0000038908192,0.00003432625,0.00001503896,0.063966155,0.48669067],"study_design_scores_gemma":[0.37575933,0.36018494,0.0037490875,0.00033350015,0.00012578107,0.00012895254,0.00031054454,0.0015874631,0.000020168556,0.00009125807,0.2576024,0.00010655908],"about_ca_topic_score_codex":0.00005868328,"about_ca_topic_score_gemma":0.0002807509,"teacher_disagreement_score":0.4865841,"about_ca_system_score_codex":0.00051990175,"about_ca_system_score_gemma":0.014823054,"threshold_uncertainty_score":0.990762},"labels":[],"label_agreement":null},{"id":"W3030431591","doi":"10.1200/jco.2020.38.15_suppl.1512","title":"Smoking cessation (SC) and lung cancer (LC) outcomes: A survival benefit for recent-quitters? A pooled analysis of 34,649 International Lung Cancer Consortium (ILCCO) patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Lung cancer; Proportional hazards model; Internal medicine; Oncology; Survival analysis; Smoking cessation; Lung; Pooled analysis; Pathology; Confidence interval","score_opus":0.09175959229041371,"score_gpt":0.5037262991453846,"score_spread":0.4119667068549709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030431591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605271,0.0011361022,0.0010290287,0.03413354,0.0020465788,0.00043912354,0.00022344939,0.0000083757795,0.0004566934],"genre_scores_gemma":[0.9917948,0.0021053231,0.0006993616,0.004643565,0.0005375226,0.000039551618,0.00006726916,0.000016716704,0.00009588602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971607,0.00010195554,0.0018957858,0.0002450002,0.00041653338,0.00018008132],"domain_scores_gemma":[0.9951951,0.0010688036,0.0021017836,0.00009661697,0.001256569,0.0002811587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064888987,0.00014898561,0.0014410677,0.00022766583,0.000049072212,0.00001553505,0.00012367275,0.00019055851,0.0004049992],"category_scores_gemma":[0.0014780676,0.0001089607,0.0005088561,0.00032392822,0.00009164324,0.00016310594,0.000044763157,0.00030312082,1.689758e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018122153,0.0005206281,0.93240434,0.000065168526,0.018114734,0.000012766127,0.0006510166,0.00040708997,0.0000323511,0.00009654807,0.0009720696,0.044911075],"study_design_scores_gemma":[0.013870406,0.0013728628,0.94417965,0.00011010593,0.025267469,0.0000018567423,0.00023625049,0.0067266114,0.0000222335,0.000028129838,0.008079206,0.000105242405],"about_ca_topic_score_codex":0.000242513,"about_ca_topic_score_gemma":0.00040643493,"teacher_disagreement_score":0.044805832,"about_ca_system_score_codex":0.0004771578,"about_ca_system_score_gemma":0.0009428684,"threshold_uncertainty_score":0.44432887},"labels":[],"label_agreement":null},{"id":"W3030461309","doi":"10.1200/jco.20.00775","title":"Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":549,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Capecitabine; Hazard ratio; Internal medicine; Breast cancer; Gastroenterology; Trastuzumab; Oncology; Cancer; Confidence interval; Colorectal cancer","score_opus":0.09059561389391593,"score_gpt":0.42854029408853156,"score_spread":0.33794468019461565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030461309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9253925,0.00065311586,0.00020578946,0.07187303,0.000116560645,0.001579996,0.000108744694,0.000005834245,0.000064427215],"genre_scores_gemma":[0.99190515,0.00041148366,0.0029239063,0.0033975565,0.0012500208,0.000054948352,0.000015863705,0.0000251516,0.000015932475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969372,0.00097474206,0.0012166626,0.00029903138,0.00030560614,0.00026676722],"domain_scores_gemma":[0.9921571,0.0063124844,0.0008090783,0.00011007189,0.00023318686,0.0003780555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024113618,0.00023117808,0.001723883,0.00005411434,0.000059401293,0.00002557591,0.000085990265,0.00014636038,0.000042723244],"category_scores_gemma":[0.0010406363,0.00010826217,0.0001656509,0.00018793048,0.00033384314,0.00008366035,0.000020050811,0.00062177214,3.874423e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7694903,0.005330247,0.020407816,0.00010594271,0.002345299,0.0024151092,0.0019346419,0.00003966564,0.00002292203,0.00010204952,0.0009982759,0.19680773],"study_design_scores_gemma":[0.42391855,0.17582555,0.38605773,0.00026837378,0.0034375207,0.0036134445,0.0015492981,0.00017251282,0.000011058794,0.000022471124,0.004920967,0.00020252005],"about_ca_topic_score_codex":0.00016283663,"about_ca_topic_score_gemma":0.00094071415,"teacher_disagreement_score":0.3656499,"about_ca_system_score_codex":0.00009521285,"about_ca_system_score_gemma":0.0011852673,"threshold_uncertainty_score":0.4414803},"labels":[],"label_agreement":null},{"id":"W3030479973","doi":"10.1200/jco.2020.38.15_suppl.3501","title":"Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Diffuse large B-cell lymphoma; Tolerability; CHOP; Pegfilgrastim; Phases of clinical research; Oncology; Gastroenterology; International Prognostic Index; Lymphoma; Surgery; Neutropenia; Clinical trial; Febrile neutropenia; Adverse effect; Chemotherapy","score_opus":0.08757691204413236,"score_gpt":0.43603479329476175,"score_spread":0.3484578812506294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030479973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942113,0.000090051246,0.0016489109,0.0031595358,0.0002658589,0.00044936288,0.0000039688866,0.000002086492,0.0001689107],"genre_scores_gemma":[0.99658245,0.000081056394,0.0015994655,0.0012165998,0.00044741377,0.000013607735,0.000007890924,0.000010872065,0.00004065629],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99787754,0.00028773386,0.0013892044,0.00016961938,0.00016101456,0.00011488761],"domain_scores_gemma":[0.9979304,0.00029695878,0.0011954213,0.000108414526,0.0003190181,0.00014979739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012148338,0.0000934804,0.0005936261,0.000051942832,0.000026970049,0.000004627088,0.0001822304,0.00020863538,0.0000056214044],"category_scores_gemma":[0.0034678036,0.00007055718,0.00015531635,0.00010123697,0.00007479029,0.000010411656,0.00005040291,0.00026409165,7.5507137e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062376335,0.4885381,0.026079373,0.00009354679,0.0008702681,0.00023837131,0.001340933,0.00014097992,0.045924813,0.00025788796,0.034211595,0.33992782],"study_design_scores_gemma":[0.5428956,0.34882542,0.004838565,0.000040770272,0.0001345711,0.00001585466,0.0010262685,0.00035594899,0.01599242,0.00014210124,0.08553131,0.00020115767],"about_ca_topic_score_codex":0.000008741224,"about_ca_topic_score_gemma":0.0000851568,"teacher_disagreement_score":0.48051926,"about_ca_system_score_codex":0.000016425805,"about_ca_system_score_gemma":0.0004153214,"threshold_uncertainty_score":0.41515353},"labels":[],"label_agreement":null},{"id":"W3030494473","doi":"10.1200/jco.20.00158","title":"Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Pediatric Oncology Group; SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"Medical Research Council; University of Exeter; Astellas Pharma; Wellcome Trust; National Institute for Health and Care Research; Gilead Sciences; Pediatric Oncology Group of Ontario; Pfizer","keywords":"Medicine; Posaconazole; Echinocandin; Voriconazole; Guideline; Intensive care medicine; Transplantation; Hematopoietic stem cell transplantation; Itraconazole; Immunosuppression; Cancer; Internal medicine; Antifungal; Fluconazole; Dermatology","score_opus":0.07317244729589775,"score_gpt":0.43790391005571855,"score_spread":0.3647314627598208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030494473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902615,0.0010806655,0.0018178829,0.0054197796,0.0005006027,0.0007588175,0.000014244015,0.0000068061804,0.00013973101],"genre_scores_gemma":[0.9829339,0.0035531,0.009016693,0.003519962,0.0009036311,0.000008854467,0.0000072213934,0.00001903402,0.000037600425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99453545,0.0005036295,0.00393542,0.00034676347,0.0004610777,0.00021765412],"domain_scores_gemma":[0.9928747,0.003130949,0.0021922388,0.00012665466,0.0012512741,0.0004241858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004329976,0.00015232505,0.0014366312,0.00007382373,0.000033071738,0.000009471651,0.00011047726,0.0003792354,0.000015635478],"category_scores_gemma":[0.003074086,0.00010101666,0.00024452133,0.00021185086,0.00011713232,0.00021165865,0.00001606646,0.0009179487,0.00000332833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028685318,0.0017302735,0.93938607,0.0007140419,0.00007537342,0.00026606547,0.0002382901,0.0000108435415,0.0000156661,0.0000061718038,0.002038483,0.026833424],"study_design_scores_gemma":[0.023843799,0.029545583,0.9381174,0.00028728327,0.0011180122,0.000091161106,0.0003372418,0.00012511184,0.0000118010685,0.000014592262,0.0063546086,0.00015344663],"about_ca_topic_score_codex":0.0000070378696,"about_ca_topic_score_gemma":0.000021704209,"teacher_disagreement_score":0.02781531,"about_ca_system_score_codex":0.000085236185,"about_ca_system_score_gemma":0.0013866278,"threshold_uncertainty_score":0.411934},"labels":[],"label_agreement":null},{"id":"W3030496501","doi":"10.1200/jco.2020.38.15_suppl.e24194","title":"Depression in cancer: An evaluation of patient education resources.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of British Columbia","funders":"","keywords":"Readability; Medicine; Online search; Quality (philosophy); Interactivity; Accountability; Depression (economics); Descriptive statistics; Inclusion (mineral); Cancer; The Internet; Family medicine; World Wide Web; Internal medicine; Psychology; Statistics; Computer science; Social psychology","score_opus":0.4108380187155057,"score_gpt":0.6716541976940736,"score_spread":0.26081617897856796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030496501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98760617,0.00039837084,0.00006785977,0.0053175236,0.0016699268,0.0004502016,0.0000037520215,0.000004598212,0.004481587],"genre_scores_gemma":[0.98407745,0.00017819217,0.0013018363,0.013605468,0.000796247,0.000024777471,0.0000040319196,0.000004723299,0.0000072593766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9876908,0.005100417,0.0063934787,0.00011996173,0.00053488277,0.0001604344],"domain_scores_gemma":[0.9902157,0.001389217,0.005973662,0.00014011204,0.0019173095,0.00036401063],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015887216,0.000064564905,0.00064635073,0.00009940059,0.0000729595,0.0000024467006,0.00018209449,0.00034934678,0.0007907599],"category_scores_gemma":[0.012006564,0.00004583861,0.00009421369,0.00021129216,0.000045202243,0.0007063823,0.000046760193,0.0012107954,0.0000123978825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072352967,0.0004572302,0.4476428,0.00008210232,0.0000049799078,3.1467806e-7,0.005990576,0.00018171896,0.000008572476,0.000018077868,0.0017467923,0.5431433],"study_design_scores_gemma":[0.0025732503,0.0019797136,0.8186964,0.00032892742,0.000042765623,7.739401e-7,0.0039613214,0.010283308,0.000022675495,0.00050140906,0.16155209,0.00005739822],"about_ca_topic_score_codex":0.00018429571,"about_ca_topic_score_gemma":0.00012968549,"teacher_disagreement_score":0.5430859,"about_ca_system_score_codex":0.00028783228,"about_ca_system_score_gemma":0.008681572,"threshold_uncertainty_score":0.9969383},"labels":[],"label_agreement":null},{"id":"W3030511752","doi":"10.1200/jco.2020.38.15_suppl.107","title":"Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Refractory (planetary science); Response Evaluation Criteria in Solid Tumors; Internal medicine; Trk receptor; Oncology; Progressive disease; Disease; Cancer; Adenocarcinoma; Receptor","score_opus":0.16081338095773037,"score_gpt":0.46698485287786207,"score_spread":0.3061714719201317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030511752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942118,0.0002453918,0.000008561778,0.004798059,0.00012913358,0.00036531963,0.000022118784,0.000012619412,0.00020701134],"genre_scores_gemma":[0.99543184,0.00072019827,0.0008129962,0.0023468994,0.00059481617,0.0000015157236,0.000045760808,0.000022998125,0.000022997763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966276,0.000514858,0.001644121,0.00038717827,0.00049266516,0.00033352454],"domain_scores_gemma":[0.99722886,0.00046043695,0.0010145903,0.00027091164,0.00015064055,0.00087458943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012544908,0.00017505772,0.0014205636,0.00013952813,0.00003949427,0.000014404894,0.00031076823,0.00014274707,0.000059970414],"category_scores_gemma":[0.003223163,0.00010518539,0.000085845975,0.00024452058,0.00018027888,0.00023034873,0.00040972646,0.001708705,0.000013387513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04484554,0.00409483,0.83157057,0.000083064246,0.0004001511,0.008503167,0.00009800258,0.0000011186092,0.00022143991,0.0000010032343,0.0046384297,0.10554268],"study_design_scores_gemma":[0.018728212,0.028190542,0.947605,0.0007200122,0.00017238862,0.0018674526,0.000049317943,0.000073744486,0.000052923668,0.0000052351506,0.0024344746,0.000100710866],"about_ca_topic_score_codex":0.00001316869,"about_ca_topic_score_gemma":0.00004011903,"teacher_disagreement_score":0.11603442,"about_ca_system_score_codex":0.0001424987,"about_ca_system_score_gemma":0.0020819376,"threshold_uncertainty_score":0.7423568},"labels":[],"label_agreement":null},{"id":"W3030525376","doi":"10.1200/jco.2020.38.15_suppl.7509","title":"Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McMaster University","funders":"Pfizer","keywords":"Medicine; Cytarabine; Internal medicine; Surgery; Chemotherapy","score_opus":0.20678952505096104,"score_gpt":0.4542725518709324,"score_spread":0.24748302681997136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030525376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9407449,0.00023962418,0.00022671882,0.05329114,0.0016761611,0.00052279135,0.000008484494,0.000028302751,0.003261917],"genre_scores_gemma":[0.97175825,0.0024542478,0.0054894025,0.009240007,0.00521722,0.0000109558305,0.000016555317,0.00008960228,0.005723748],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9917772,0.0011529834,0.0044124406,0.0006714678,0.0012093871,0.0007765628],"domain_scores_gemma":[0.9908825,0.0046073785,0.0019279845,0.00045476036,0.0007416783,0.0013856816],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0075150314,0.0003689644,0.0032423944,0.0002800546,0.00007046258,0.000038495946,0.00047910633,0.0008750524,0.000983001],"category_scores_gemma":[0.027015263,0.00025740513,0.0006540757,0.0004914781,0.000520654,0.00029923147,0.00036049463,0.0039519714,0.00011177796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17606048,0.0024901424,0.3058154,0.00053348474,0.001563145,0.30835932,0.00072606467,0.000087743094,0.0014881163,0.00045367735,0.15017304,0.05224937],"study_design_scores_gemma":[0.11099141,0.026624708,0.5146291,0.00045305688,0.0005843227,0.015929613,0.00033673496,0.0029144282,0.0001324929,0.0005880616,0.32626802,0.0005480391],"about_ca_topic_score_codex":0.00013310855,"about_ca_topic_score_gemma":0.00039241527,"teacher_disagreement_score":0.29242972,"about_ca_system_score_codex":0.0008600718,"about_ca_system_score_gemma":0.009430074,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W3030535284","doi":"10.1200/jco.2020.38.29_suppl.283","title":"An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Queen's University; Ontario Institute for Cancer Research; Institute for Clinical Evaluative Sciences; Canadian Agency for Drugs and Technologies in Health; Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Confidence interval; Cancer; Clinical trial; Family medicine","score_opus":0.576607370751638,"score_gpt":0.5787913728956122,"score_spread":0.002184002143974184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030535284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860759,0.00038588775,0.010010666,0.0012220427,0.00066576304,0.00071618945,0.00072990125,0.0000016048207,0.00019207805],"genre_scores_gemma":[0.98085165,0.00059144263,0.01708041,0.00057294505,0.00076519547,0.000010477011,0.00010666864,0.000015966232,0.000005257716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99513006,0.00043000796,0.0035774612,0.00030261223,0.00039040012,0.00016947508],"domain_scores_gemma":[0.991522,0.001456183,0.00399479,0.00040475943,0.002414622,0.0002076069],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011971936,0.00012532272,0.0013834919,0.00003708544,0.000022124961,0.0000034520876,0.00048950856,0.0002477641,0.000007860606],"category_scores_gemma":[0.02238902,0.00010518976,0.00045894505,0.00005791583,0.00014865871,0.0000130531735,0.00011626665,0.0002037598,1.2043847e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035377525,0.008915515,0.19073829,0.00084918545,0.0045859306,0.000019681978,0.0005860373,0.0048306533,0.43781808,0.0013635199,0.007511778,0.30740383],"study_design_scores_gemma":[0.07618611,0.19863117,0.30499443,0.00046235163,0.005725041,0.000016875692,0.0024765455,0.033376224,0.31290072,0.003335439,0.06092139,0.0009736823],"about_ca_topic_score_codex":0.0000073461506,"about_ca_topic_score_gemma":0.00038623507,"teacher_disagreement_score":0.30643013,"about_ca_system_score_codex":0.00005399847,"about_ca_system_score_gemma":0.0045691356,"threshold_uncertainty_score":0.9858458},"labels":[],"label_agreement":null},{"id":"W3030545184","doi":"10.1200/jco.2020.38.15_suppl.3605","title":"Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i>-fusion positive (<i>NTRK</i>-fp) solid tumors: An updated integrated analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; Trk receptor; Population; Clinical endpoint; Phases of clinical research; Progression-free survival; Overall survival; Receptor; Neurotrophin","score_opus":0.03283258638986669,"score_gpt":0.4283467893388865,"score_spread":0.3955142029490198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030545184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463713,0.00008244946,0.00021830357,0.0037231492,0.00012186619,0.00039147152,0.000033431472,0.000009188887,0.0007830181],"genre_scores_gemma":[0.995759,0.00013080834,0.0016676207,0.0021107784,0.00015473127,0.0000018249383,0.00013933668,0.00001468613,0.000021231666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671865,0.00044818266,0.002060539,0.00026851473,0.00031099346,0.00019314467],"domain_scores_gemma":[0.9965253,0.0005780072,0.0015602566,0.00013380223,0.0007117486,0.0004909244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006800695,0.00017143298,0.0018447144,0.00021916644,0.00003689387,0.000008743928,0.00010021494,0.0001979581,0.00014049585],"category_scores_gemma":[0.00078019104,0.00010707296,0.00021652078,0.00074827054,0.000178218,0.00015910773,0.00003658642,0.00064913626,0.0000023248338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046251524,0.0075698905,0.8537114,0.00002134085,0.0041732015,0.00050204,0.0021163416,0.00039365262,0.0001852972,0.000031413307,0.00065634813,0.084387526],"study_design_scores_gemma":[0.034538712,0.03601202,0.9212783,0.00015053527,0.0038841378,0.000029322362,0.00047883394,0.00049522106,0.00016513595,0.000014518048,0.0028424582,0.000110824076],"about_ca_topic_score_codex":0.000108549895,"about_ca_topic_score_gemma":0.00014699067,"teacher_disagreement_score":0.0842767,"about_ca_system_score_codex":0.00015336766,"about_ca_system_score_gemma":0.0010344521,"threshold_uncertainty_score":0.43663087},"labels":[],"label_agreement":null},{"id":"W3030546134","doi":"10.1200/jco.2020.38.15_suppl.3098","title":"First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Internal medicine; Randomized controlled trial; Cancer; Oncology; Clinical trial","score_opus":0.1452259374099921,"score_gpt":0.4684478757853695,"score_spread":0.3232219383753774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030546134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98495144,0.0007417321,0.00006442997,0.012676693,0.00026812401,0.0006067509,0.000014133867,0.0000083103105,0.00066839484],"genre_scores_gemma":[0.9907095,0.0024940418,0.0018395731,0.004425656,0.00036993006,0.000021583197,0.000004297979,0.000034390076,0.00010105659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994958,0.0010577486,0.0027989806,0.00027794743,0.0004516118,0.0004557223],"domain_scores_gemma":[0.99516386,0.00244794,0.0013334049,0.00017332415,0.0004926486,0.00038881224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023381754,0.00022553904,0.0029946635,0.0002381663,0.00003794226,0.00001074,0.00026539832,0.00035595955,0.00030615914],"category_scores_gemma":[0.00081271626,0.0001435063,0.00030625303,0.00046084702,0.00020310906,0.000102299346,0.000041454627,0.0014301317,0.00002476796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016885994,0.0032872907,0.9652121,0.00010142872,0.00174491,0.0011399417,0.0006313978,0.00007244043,0.00024600676,0.000011345546,0.00046624136,0.010200901],"study_design_scores_gemma":[0.0557738,0.03962912,0.8661493,0.0005329989,0.0012369062,0.00015366089,0.00034593762,0.0033820437,0.00016781979,0.000058266665,0.03232616,0.00024397303],"about_ca_topic_score_codex":0.00012022376,"about_ca_topic_score_gemma":0.001465177,"teacher_disagreement_score":0.099062786,"about_ca_system_score_codex":0.0005144032,"about_ca_system_score_gemma":0.0026582028,"threshold_uncertainty_score":0.621329},"labels":[],"label_agreement":null},{"id":"W3030546310","doi":"10.1200/jco.2020.38.15_suppl.6068","title":"Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Tolerability; Hazard ratio; Internal medicine; Oncology; BRCA mutation; Placebo; Ovarian cancer; Confidence interval; Gynecology; Cancer; Adverse effect; Pathology","score_opus":0.10362392140859569,"score_gpt":0.46857242414566164,"score_spread":0.3649485027370659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030546310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386877,0.000063093146,0.00022481853,0.004366856,0.00036434628,0.00088223803,0.00006912269,0.0000055431574,0.0001552414],"genre_scores_gemma":[0.99709266,0.00015109601,0.0005536015,0.001945511,0.00021922316,0.0000080464715,0.000008510926,0.00001618543,0.00000514419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505574,0.0008485476,0.0030241986,0.00030292413,0.0005512399,0.00021734484],"domain_scores_gemma":[0.9940842,0.001957845,0.002694188,0.00022458668,0.00069109944,0.00034813074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018941008,0.00018770467,0.0024923782,0.000294481,0.00004384654,0.000005489393,0.00018482564,0.00018222346,0.000061595965],"category_scores_gemma":[0.0019929372,0.00011926772,0.00031211317,0.0014026999,0.00024931316,0.0000757401,0.000094126466,0.00095548324,6.2159694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14042296,0.0071967845,0.74893135,0.000040934992,0.006202368,0.00031581993,0.0068785944,0.0021332807,0.0016282315,0.000018642406,0.00039150237,0.08583953],"study_design_scores_gemma":[0.095472924,0.02255606,0.8755605,0.00038089912,0.0027874864,0.000009358056,0.0012493388,0.0007695327,0.00033561364,0.0000075116864,0.0007405953,0.00013013693],"about_ca_topic_score_codex":0.00009232372,"about_ca_topic_score_gemma":0.00041483098,"teacher_disagreement_score":0.12662919,"about_ca_system_score_codex":0.00023146585,"about_ca_system_score_gemma":0.0009838638,"threshold_uncertainty_score":0.48635966},"labels":[],"label_agreement":null},{"id":"W3030566019","doi":"10.1200/jco.2020.38.15_suppl.6002","title":"Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Hazard ratio; Oncology; Placebo; Ovarian cancer; Clinical endpoint; PARP inhibitor; Progression-free survival; BRCA mutation; Chemotherapy; Cancer; Confidence interval; Randomized controlled trial; Pathology","score_opus":0.15828171610380812,"score_gpt":0.45732561498715135,"score_spread":0.29904389888334326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030566019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97830075,0.000067316374,0.0012662451,0.017506665,0.00128582,0.000547661,0.000115250856,0.000016026104,0.0008942799],"genre_scores_gemma":[0.9851008,0.00019036843,0.0055251177,0.0068548108,0.0021954672,0.000012240761,0.000040909807,0.00002945293,0.000050839513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946778,0.00079671445,0.0031199486,0.00046490994,0.00060944294,0.00033118608],"domain_scores_gemma":[0.99232,0.0034485175,0.0029042617,0.00016903372,0.000656592,0.0005016119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021743986,0.00024012069,0.0018565798,0.00011765337,0.00006949923,0.000035264402,0.00012059609,0.00041699258,0.00010308252],"category_scores_gemma":[0.0048135878,0.00018195013,0.00021326655,0.00023739245,0.00029517515,0.0003384654,0.00004071842,0.0016904105,0.000003885231],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.914829,0.0027623181,0.017779198,0.000020219191,0.0005463613,0.002026281,0.0018851889,0.00018036936,0.0003096104,0.000058380883,0.004639241,0.054963794],"study_design_scores_gemma":[0.79555553,0.02487744,0.16992252,0.0006186906,0.00028530325,0.00006459017,0.00029652618,0.0016726044,0.00009463966,0.00021490984,0.006168873,0.00022837135],"about_ca_topic_score_codex":0.00027507657,"about_ca_topic_score_gemma":0.00020562416,"teacher_disagreement_score":0.15214331,"about_ca_system_score_codex":0.00037551904,"about_ca_system_score_gemma":0.0024291074,"threshold_uncertainty_score":0.74197114},"labels":[],"label_agreement":null},{"id":"W3030570387","doi":"10.1200/jco.2020.38.15_suppl.e24101","title":"Diabetes mellitus in childhood and young adult cancer survivors: A meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Meta-analysis; Odds ratio; Hazard ratio; Confidence interval; Internal medicine; Relative risk; Cancer; Sequela; Publication bias; Cohort study; Pediatrics; Surgery","score_opus":0.1731784645762879,"score_gpt":0.4583589115425113,"score_spread":0.28518044696622336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030570387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8463681,0.016640002,0.00006163001,0.13560496,0.0005326198,0.00022747737,0.000017757848,0.000014905514,0.0005325721],"genre_scores_gemma":[0.9549234,0.003891283,0.0015932119,0.038030192,0.001483778,0.000010374953,0.0000031881575,0.000023797431,0.000040764444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931601,0.0013269254,0.0040430035,0.0004238974,0.0006865841,0.00035946778],"domain_scores_gemma":[0.9933519,0.0027902045,0.002195431,0.00025498602,0.00050964876,0.0008978437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053003775,0.00025263045,0.0059279487,0.0002520726,0.000031196658,0.000019520916,0.00024685074,0.00040313162,0.00047465583],"category_scores_gemma":[0.008093095,0.00017975685,0.0022904596,0.0007644736,0.00023050189,0.00016956663,0.00009852024,0.0015756936,0.000008987854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011210198,0.0015812785,0.8714206,0.00011565344,0.109748945,0.00031299333,0.0031521523,0.000079738595,0.000020063993,0.00010877696,0.0021613967,0.010177344],"study_design_scores_gemma":[0.0064622266,0.004851268,0.85404474,0.000040269828,0.12589625,0.00004501906,0.00060590624,0.0002990468,0.00004316982,0.00029627173,0.007175237,0.0002406232],"about_ca_topic_score_codex":0.0016702181,"about_ca_topic_score_gemma":0.013540252,"teacher_disagreement_score":0.10855534,"about_ca_system_score_codex":0.00008268054,"about_ca_system_score_gemma":0.0010921397,"threshold_uncertainty_score":0.9688776},"labels":[],"label_agreement":null},{"id":"W3030571229","doi":"10.1200/jco.2020.38.15_suppl.11022","title":"Introduction of a patient communication course to postgraduate oncology training in Russia.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Active listening; Interquartile range; Cohort; Medical education; Empathy; Communication skills; Family medicine; Internal medicine; Oncology; Psychology","score_opus":0.1294976714698742,"score_gpt":0.5329847495082584,"score_spread":0.40348707803838413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030571229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6909182,0.00080565555,0.00088038674,0.30406675,0.0012746359,0.00027348852,0.0000017239912,0.000008027765,0.0017710966],"genre_scores_gemma":[0.9394876,0.0015910631,0.041026175,0.015634783,0.002209764,0.000004726685,0.000003474707,0.000013537766,0.000028891676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603856,0.00087376486,0.002531994,0.00017081424,0.00020540801,0.0001794493],"domain_scores_gemma":[0.99553823,0.0017455736,0.0018632805,0.0001945351,0.0003232217,0.00033516999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025017674,0.00010582145,0.001566142,0.000119478784,0.00002672028,0.0000015543877,0.0001923008,0.00039164297,0.00012789873],"category_scores_gemma":[0.004946202,0.00008066155,0.0002357724,0.00028120884,0.00032532838,0.00009663276,0.000044360382,0.0012690151,0.000010164698],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017080026,0.002405843,0.014884717,0.000027484948,0.00028862036,0.00037019484,0.008181028,0.000731145,0.001252217,0.0009709927,0.0126627255,0.941145],"study_design_scores_gemma":[0.009925719,0.070236675,0.04629036,0.00010197493,0.0002301397,0.0007272496,0.003283035,0.00031417125,0.0002522715,0.0010309468,0.86748195,0.00012553386],"about_ca_topic_score_codex":0.000005136754,"about_ca_topic_score_gemma":0.000030737076,"teacher_disagreement_score":0.9410195,"about_ca_system_score_codex":0.00023756795,"about_ca_system_score_gemma":0.0020161644,"threshold_uncertainty_score":0.59214234},"labels":[],"label_agreement":null},{"id":"W3030582648","doi":"10.1200/jco.2020.38.15_suppl.e19206","title":"Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Discontinuation; Adverse effect; Quality of life (healthcare); Clinical trial; Randomized controlled trial; Breast cancer; Oncology; Cancer","score_opus":0.8178381080444754,"score_gpt":0.6405963177570368,"score_spread":0.17724179028743858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030582648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9130295,0.0019354634,0.000603967,0.08310431,0.0002210293,0.00077787077,0.00014066113,0.0000033942526,0.00018377695],"genre_scores_gemma":[0.9950092,0.0006048453,0.0012278426,0.0029479072,0.00018384129,0.000004703229,0.000010140916,0.0000083228715,0.0000032001476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.7580551,0.029931717,0.21095484,0.0004918374,0.00021003932,0.00035646342],"domain_scores_gemma":[0.5103522,0.15392411,0.3342941,0.0003467966,0.00038025164,0.0007025624],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.584612,0.00012652444,0.025176097,0.0002464297,0.000044210818,0.000008935583,0.00014178165,0.00036588963,0.00004550499],"category_scores_gemma":[0.6059029,0.00012709605,0.000548277,0.0002226908,0.00026885743,0.0002172347,0.00006132239,0.00075359805,0.000001597921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012375536,0.0006042729,0.9764614,0.00025898096,0.00026161197,0.0000022314384,0.0026171238,0.00012876527,0.0000012955844,0.0027952613,0.00018670179,0.004306784],"study_design_scores_gemma":[0.13519034,0.0010224578,0.84667397,0.00012972932,0.000028617747,0.000001804282,0.0004809134,0.0014662439,9.0991557e-7,0.014739507,0.0001639132,0.00010161413],"about_ca_topic_score_codex":0.0030391144,"about_ca_topic_score_gemma":0.0005420978,"teacher_disagreement_score":0.24770293,"about_ca_system_score_codex":0.00030452642,"about_ca_system_score_gemma":0.0014771858,"threshold_uncertainty_score":0.9892962},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"reporting","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["metaresearch","metaepi_broad"],"domain":"reporting","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W3030586169","doi":"10.1200/jco.2020.38.15_suppl.e16504","title":"Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Referral; Cancer; Logistic regression; Internal medicine; Population; Cohort; Cancer registry; Retrospective cohort study; Family medicine","score_opus":0.1101326874718852,"score_gpt":0.4572217740248688,"score_spread":0.3470890865529836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030586169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887331,0.00009358145,0.000021228554,0.010325216,0.00022308453,0.00032570792,0.00001367252,0.0000052905807,0.00025911207],"genre_scores_gemma":[0.99454486,0.0002201835,0.0013055617,0.0036037948,0.00024144207,0.0000028100512,0.0000043431633,0.000010449957,0.000066542976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833906,0.00007953217,0.0009726436,0.00015025145,0.00029993962,0.00015859025],"domain_scores_gemma":[0.9980592,0.00037788192,0.0008201384,0.00008227466,0.00023400142,0.0004265142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025856346,0.00013633272,0.0012699633,0.00009166647,0.000015866995,0.0000033452,0.00006318937,0.0000786284,0.00007653633],"category_scores_gemma":[0.00055103016,0.00007393248,0.0002446639,0.00012250849,0.00003876848,0.000073625735,0.000024403585,0.00024046979,0.000004275414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0169662,0.00061033986,0.917599,0.00002764863,0.00051427126,0.0001054761,0.00008212258,0.00014831331,0.0000120697,0.000011049591,0.00094308343,0.062980376],"study_design_scores_gemma":[0.015284929,0.086052105,0.8954198,0.00004583715,0.0003209008,0.000004043867,0.000037130576,0.000016941129,0.000028940583,0.00000477641,0.0027408872,0.000043754124],"about_ca_topic_score_codex":0.000010130657,"about_ca_topic_score_gemma":0.000010319364,"teacher_disagreement_score":0.08544177,"about_ca_system_score_codex":0.00026921998,"about_ca_system_score_gemma":0.00035727784,"threshold_uncertainty_score":0.3014879},"labels":[],"label_agreement":null},{"id":"W3030598679","doi":"10.1200/jco.2020.38.15_suppl.e14132","title":"Using multiple perspectives analysis to propose state cancer control policy in Abia State, Nigeria.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Abia; Medicine; Descriptive statistics; Thematic analysis; Cancer; Family medicine; Public health; Qualitative research; Nursing; Public administration; Political science; Local government; Internal medicine","score_opus":0.18252926087061389,"score_gpt":0.5045674611381665,"score_spread":0.32203820026755264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030598679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7732429,0.000163255,0.002545086,0.22272003,0.00047560196,0.00024536802,0.000012271376,0.0000137399775,0.0005817781],"genre_scores_gemma":[0.88141704,0.0001871587,0.0006487199,0.114099786,0.003609572,0.000004599455,9.042918e-7,0.000013773151,0.000018422745],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957886,0.00037294638,0.002728935,0.00028748115,0.00022893492,0.0005931505],"domain_scores_gemma":[0.995743,0.0010894301,0.0021529023,0.00012592884,0.00064862065,0.0002401624],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004081513,0.0001732415,0.001910782,0.000586196,0.00006914489,0.000052264233,0.00034516022,0.00018380917,0.0001240015],"category_scores_gemma":[0.018016744,0.0001328732,0.00043645978,0.0016978087,0.00012865681,0.00046883282,0.00013985662,0.00066945044,0.000031265557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002031027,0.00045913644,0.81631196,0.00005461892,0.00082612154,0.00011971809,0.000707547,0.13741793,0.000056584846,0.00038013302,0.027406443,0.014228794],"study_design_scores_gemma":[0.004730336,0.00066889176,0.42995426,0.000024168485,0.00024220943,0.0000036075685,0.0012754635,0.06762644,4.5516748e-7,0.00088757573,0.4943595,0.00022707277],"about_ca_topic_score_codex":0.021506147,"about_ca_topic_score_gemma":0.0060651447,"teacher_disagreement_score":0.46695307,"about_ca_system_score_codex":0.00034751935,"about_ca_system_score_gemma":0.0012915663,"threshold_uncertainty_score":0.99025494},"labels":[],"label_agreement":null},{"id":"W3030599412","doi":"10.1200/jco.2020.38.15_suppl.e19109","title":"Impact of oligometastatic disease on survival in ER positive breast cancer: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Metastasis; Population; Cancer; Disease","score_opus":0.09207549153834477,"score_gpt":0.5002953619202082,"score_spread":0.4082198703818634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030599412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98236245,0.00020814168,0.00061744626,0.016288614,0.0001750242,0.00014961256,0.00014004436,0.0000051436987,0.000053521122],"genre_scores_gemma":[0.99605364,0.000054316355,0.0008017603,0.002606423,0.00044661993,0.000003089234,0.000012864508,0.00001530702,0.0000059872423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685985,0.00049574027,0.0018518562,0.000190289,0.00041350775,0.00018878565],"domain_scores_gemma":[0.995292,0.0018753618,0.0016580021,0.00014237675,0.00041090036,0.00062135473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085198303,0.00014730416,0.0020243537,0.00030887805,0.000012849246,0.0000031830484,0.000116878036,0.00009226449,0.00036113054],"category_scores_gemma":[0.0015583915,0.00010121848,0.0010583389,0.0007849545,0.00011018764,0.00008376485,0.000015092874,0.00060430175,0.0000027522474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03309071,0.001240812,0.8972577,0.000027081363,0.0019732858,0.0003699676,0.00006660893,0.030739846,0.00004605916,0.00002334506,0.000021148038,0.035143454],"study_design_scores_gemma":[0.007773588,0.0050873244,0.982537,0.000117654505,0.0015693984,0.000013071547,0.00003192025,0.0026252195,0.0000051158895,0.00011141824,0.00004917494,0.00007914632],"about_ca_topic_score_codex":0.0003548565,"about_ca_topic_score_gemma":0.00011724979,"teacher_disagreement_score":0.085279286,"about_ca_system_score_codex":0.00041375295,"about_ca_system_score_gemma":0.0022400026,"threshold_uncertainty_score":0.41275698},"labels":[],"label_agreement":null},{"id":"W3030606285","doi":"10.1200/jco.2020.38.15_suppl.tps8067","title":"An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Sunnybrook Health Science Centre; SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Brentuximab vedotin; Dacarbazine; Oncology; Internal medicine; Cancer; Stage (stratigraphy); Young adult; Nivolumab; Hodgkin lymphoma; Vinblastine; Lymphoma; Chemotherapy","score_opus":0.059519700755086766,"score_gpt":0.4348099893307484,"score_spread":0.3752902885756616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030606285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678416,0.00037353425,0.00021936616,0.011239438,0.0007361912,0.000515979,0.000015004874,0.000010919065,0.00010542833],"genre_scores_gemma":[0.9915398,0.00057694427,0.0033209738,0.0037022568,0.0007874372,0.00002098719,0.000009713019,0.000018470304,0.000023417715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721235,0.0002734223,0.0017574943,0.00029236573,0.00024451598,0.000219833],"domain_scores_gemma":[0.9975152,0.00050111004,0.00092856766,0.00012486218,0.00033520235,0.0005950441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007947745,0.0001596349,0.0012008939,0.000082104154,0.000031255044,0.000019968324,0.00010736913,0.00032099412,0.0000141951805],"category_scores_gemma":[0.002183931,0.00011801923,0.00021255987,0.0001559855,0.00010884482,0.00023195468,0.000035646823,0.00024952253,0.000004453563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030932099,0.005692016,0.5980707,0.000116850126,0.00014153836,0.0007737717,0.0006258005,0.000011924109,0.00040441338,0.00014252198,0.001100072,0.36198834],"study_design_scores_gemma":[0.06484803,0.044073638,0.8679506,0.00046655315,0.00021585324,0.000096268406,0.0011585605,0.0020797874,0.00030355118,0.000056523313,0.018612733,0.00013789731],"about_ca_topic_score_codex":0.000014106931,"about_ca_topic_score_gemma":0.00036731045,"teacher_disagreement_score":0.36185044,"about_ca_system_score_codex":0.00030530305,"about_ca_system_score_gemma":0.0008703516,"threshold_uncertainty_score":0.48126844},"labels":[],"label_agreement":null},{"id":"W3030620127","doi":"10.1200/jco.2020.38.15_suppl.e14099","title":"The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Intervention (counseling); Clinical trial; Clinical endpoint; Quality of life (healthcare); Physical therapy; Alternative medicine; Surgery; Internal medicine; Nursing","score_opus":0.34016546224816785,"score_gpt":0.5506548193616266,"score_spread":0.21048935711345879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030620127","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4057089,0.0049820235,0.052079186,0.5114687,0.0094872685,0.008090693,0.000009839655,0.000024822248,0.00814858],"genre_scores_gemma":[0.98991585,0.0007604453,0.006183234,0.0019302467,0.0011419558,0.000020706077,0.0000024147382,0.000012336362,0.00003278806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98461187,0.0092274025,0.005358536,0.00018461327,0.0004203559,0.00019724281],"domain_scores_gemma":[0.94545835,0.04774057,0.005453273,0.00018688563,0.0005874404,0.0005734693],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06524549,0.00011735293,0.003696985,0.0000866136,0.000043235126,0.00001559882,0.00038879475,0.0008205026,0.000081683254],"category_scores_gemma":[0.049321074,0.00006114338,0.0005533911,0.00017270907,0.0009102505,0.00010787239,0.000075851276,0.0015029873,0.0000048419165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60747194,0.0024373059,0.000022229582,0.000011335136,0.00045692216,0.00006912513,0.00019290998,0.000029695228,0.000664488,0.0006731056,0.0002519079,0.38771906],"study_design_scores_gemma":[0.86399114,0.061416157,0.0005338413,0.00012029988,0.00093012495,0.00003783016,0.00041132755,0.042349186,0.00015725715,0.0071103233,0.022873985,0.00006853921],"about_ca_topic_score_codex":0.00004750588,"about_ca_topic_score_gemma":0.000070919494,"teacher_disagreement_score":0.58420694,"about_ca_system_score_codex":0.00012282575,"about_ca_system_score_gemma":0.002342194,"threshold_uncertainty_score":0.9625265},"labels":[],"label_agreement":null},{"id":"W3030656570","doi":"10.1200/jco.2020.38.15_suppl.e12625","title":"Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Breast cancer; Breast-conserving surgery; Radiation therapy; Chemotherapy; Internal medicine; Retrospective cohort study; Stage (stratigraphy); Oncology; Neoadjuvant therapy; Complete response; Cancer; Surgery; Mastectomy","score_opus":0.0478831947817463,"score_gpt":0.3466333199059837,"score_spread":0.2987501251242374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030656570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897186,0.00047631288,0.000068102265,0.0090701915,0.00013777132,0.0002819811,0.00023813597,0.0000030660017,0.000005832162],"genre_scores_gemma":[0.99830705,0.00048600213,0.00022574725,0.0006942813,0.00022592017,0.000009831038,0.000032172997,0.000016803562,0.000002192353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972898,0.0006324895,0.0012846931,0.00031882952,0.00028641525,0.00018776901],"domain_scores_gemma":[0.99686944,0.0006443737,0.0018291166,0.0001400838,0.000355711,0.00016129902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009760398,0.00020498042,0.0011563532,0.000090307556,0.000042409025,0.0000063201887,0.00012412095,0.00022107572,0.000014881306],"category_scores_gemma":[0.00030868573,0.00013847565,0.00022245747,0.00022395096,0.00025884467,0.000024191304,0.000046626632,0.00022961367,2.2647845e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2895468,0.00062314916,0.63928264,0.000020736772,0.00031708454,0.00003694608,0.00015358256,0.000029445791,0.0007919632,3.0454714e-7,0.00023189737,0.06896546],"study_design_scores_gemma":[0.05802936,0.0065582376,0.9339701,0.00025851344,0.00015211134,0.00019005103,0.00008192264,0.00005146755,0.00026624618,0.0000036247598,0.00029838306,0.00014000264],"about_ca_topic_score_codex":0.00008350101,"about_ca_topic_score_gemma":0.000022584123,"teacher_disagreement_score":0.29468742,"about_ca_system_score_codex":0.00006649993,"about_ca_system_score_gemma":0.00083527644,"threshold_uncertainty_score":0.5646873},"labels":[],"label_agreement":null},{"id":"W3030666284","doi":"10.1200/jco.19.03158","title":"Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Carboplatin; Lung cancer; Internal medicine; Adverse effect; Oncology; Paclitaxel; Chemotherapy; Population; Clinical endpoint; Cancer; Surgery; Clinical trial; Nivolumab; Cisplatin; Immunotherapy","score_opus":0.06888573817441451,"score_gpt":0.4097461346332562,"score_spread":0.3408603964588417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030666284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97956663,0.0018013318,0.00018336329,0.016189788,0.00069383933,0.0008852474,0.0000107604865,0.000017174865,0.0006518884],"genre_scores_gemma":[0.981686,0.008407788,0.0022923665,0.0070235594,0.0003198951,0.0000140252,0.0000033321448,0.00006350648,0.00018955425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483484,0.00022956466,0.0035403904,0.0004274524,0.0005633811,0.0004043536],"domain_scores_gemma":[0.994675,0.0009851546,0.0031684865,0.00030265204,0.0004198594,0.00044884023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795664,0.00037679332,0.003217876,0.00016900172,0.000048426435,0.000013447232,0.00024497363,0.00051084853,0.0003777537],"category_scores_gemma":[0.00042816185,0.00023477395,0.00047531334,0.00042417547,0.00038702128,0.00013492236,0.0000508763,0.001012277,0.0000010593702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.644846,0.0009405105,0.1630821,0.00020514056,0.0026568437,0.00064663996,0.0031495746,0.00007187459,0.00079468207,0.000002355358,0.00058383815,0.18302043],"study_design_scores_gemma":[0.45334685,0.06318582,0.44170582,0.0006655134,0.0013972132,0.0004977534,0.0020254203,0.0028474978,0.0018872862,0.0000072949756,0.031811986,0.00062152755],"about_ca_topic_score_codex":0.00036312314,"about_ca_topic_score_gemma":0.0005393766,"teacher_disagreement_score":0.27862376,"about_ca_system_score_codex":0.00070533424,"about_ca_system_score_gemma":0.004559584,"threshold_uncertainty_score":0.95738035},"labels":[],"label_agreement":null},{"id":"W3030671769","doi":"10.1200/jco.2020.38.15_suppl.e16789","title":"Pembrolizumab in combination with the oncolytic virus pelareorep in patients progressing on systemic chemotherapy for advanced pancreatic adenocarcinoma: A phase II study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Oncolytic virus; Response Evaluation Criteria in Solid Tumors; Internal medicine; Progressive disease; Chemotherapy; Oncology; Gastroenterology; Adverse effect; Immunotherapy; Cancer","score_opus":0.061122906112675554,"score_gpt":0.43507942470381433,"score_spread":0.37395651859113876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030671769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950957,0.0004466187,0.00008407798,0.002661784,0.000099178615,0.0015720421,0.0000039299885,0.0000032408102,0.00003345823],"genre_scores_gemma":[0.9981336,0.000090633155,0.00016009517,0.0012414472,0.00023854124,0.00008222793,0.000007818686,0.00003041934,0.000015222585],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9969637,0.0008637424,0.0012357117,0.0003113337,0.00035088306,0.0002746218],"domain_scores_gemma":[0.99795735,0.00041724925,0.0009560845,0.00021791358,0.0003066722,0.00014473734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021203933,0.00017011346,0.00077516044,0.00009074185,0.00007020615,0.00001547911,0.00036250651,0.00020114887,0.00000564049],"category_scores_gemma":[0.0009819071,0.0001085965,0.00016148789,0.00021216545,0.00012193327,0.000012449797,0.000052740845,0.0005634908,0.0000011948425],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5130294,0.023849046,0.15966333,0.0000930114,0.00047421525,0.0001558523,0.0018084173,0.0009454118,0.014674633,0.0000098538285,0.0003985023,0.28489834],"study_design_scores_gemma":[0.14923654,0.77456033,0.069165476,0.00015735766,0.00009143959,0.000021746386,0.0008171065,0.00084500876,0.0038225965,0.000034566892,0.0010129239,0.00023487753],"about_ca_topic_score_codex":0.0000037804411,"about_ca_topic_score_gemma":0.00013218698,"teacher_disagreement_score":0.7507113,"about_ca_system_score_codex":0.0001456494,"about_ca_system_score_gemma":0.0008497835,"threshold_uncertainty_score":0.44284368},"labels":[],"label_agreement":null},{"id":"W3030684391","doi":"10.1200/jco.2020.38.15_suppl.10524","title":"The first report of pediatric patients with solid tumors treated with venetoclax.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"AbbVie","keywords":"Medicine; Venetoclax; Ven; Neutropenia; Febrile neutropenia; Internal medicine; Gastroenterology; Adverse effect; Cyclophosphamide; Absolute neutrophil count; Chemotherapy; Surgery; Oncology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.07918744409552012,"score_gpt":0.4275538104708577,"score_spread":0.3483663663753376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030684391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372685,0.000056340104,0.000008660387,0.0050396086,0.000074373354,0.00025990707,0.000002418886,0.000005763502,0.00082605815],"genre_scores_gemma":[0.9984815,0.00012696137,0.000307566,0.0005121139,0.00046803345,0.000003233463,0.0000025392508,0.000015924183,0.000082145416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974921,0.0001439716,0.0014295273,0.00014958497,0.00057271146,0.00021215116],"domain_scores_gemma":[0.9957558,0.001154539,0.0017471779,0.00016823554,0.0006778425,0.00049638696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058126415,0.00010874288,0.0009034447,0.0000511788,0.000055176355,0.0000056276685,0.00013535586,0.000090830734,0.000022254231],"category_scores_gemma":[0.0021790809,0.00004703231,0.00018158472,0.00024323381,0.00021158556,0.000052436764,0.00003460215,0.0005935758,0.00000841106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020433433,0.0010462279,0.96148163,0.00002614961,0.0004759388,0.009657698,0.000024355291,0.000019272278,0.0000038502562,0.000002708148,0.0026240174,0.004204716],"study_design_scores_gemma":[0.012178925,0.08099397,0.89613235,0.000039944225,0.0004332734,0.0004882978,0.000017124374,0.000021479123,0.0000940336,0.0000074357554,0.009545692,0.00004750017],"about_ca_topic_score_codex":0.000006784566,"about_ca_topic_score_gemma":0.000018489704,"teacher_disagreement_score":0.07994775,"about_ca_system_score_codex":0.00007585492,"about_ca_system_score_gemma":0.0019304387,"threshold_uncertainty_score":0.34245154},"labels":[],"label_agreement":null},{"id":"W3030729340","doi":"10.1200/jco.2020.38.15_suppl.6010","title":"A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Institutes of Health; Conquer Cancer Foundation","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Oncology; Cabozantinib; Progression-free survival; Endometrial cancer; Urology; Cancer; Surgery; Gastroenterology; Immunotherapy; Randomized controlled trial; Chemotherapy","score_opus":0.16613957985584007,"score_gpt":0.4908497602442609,"score_spread":0.3247101803884208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030729340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907607,0.0059912982,0.00006676296,0.0010640864,0.0015527207,0.00036444073,0.000011215199,0.000001608533,0.00018717092],"genre_scores_gemma":[0.99165905,0.006193344,0.000236199,0.00028389524,0.0015777465,0.0000138177975,0.0000023978416,0.000012450997,0.000021112934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99630207,0.0008478071,0.0021756475,0.00026382046,0.00022049532,0.00019017988],"domain_scores_gemma":[0.9970164,0.00076620386,0.0016229004,0.00012380011,0.00024416673,0.00022655496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002735337,0.00014031987,0.0017019163,0.00008195215,0.000033848093,0.0000054506518,0.00021371894,0.00026852792,0.000052472504],"category_scores_gemma":[0.0053643854,0.00010865341,0.00044545555,0.00018066664,0.0002085912,0.0000068659583,0.00015797648,0.00032922134,4.603118e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8209942,0.004579257,0.004817476,0.000020699246,0.00091159093,0.00006403013,0.00041190578,0.00004326862,0.003325805,0.000014973951,0.0024701299,0.16234668],"study_design_scores_gemma":[0.86447924,0.09235495,0.0011101649,0.000030174693,0.0003988606,0.000009725909,0.00050917343,0.00015204214,0.0009618781,0.000010607628,0.039829858,0.000153302],"about_ca_topic_score_codex":0.00010904653,"about_ca_topic_score_gemma":0.00025801765,"teacher_disagreement_score":0.16219337,"about_ca_system_score_codex":0.000025707506,"about_ca_system_score_gemma":0.0008162346,"threshold_uncertainty_score":0.6422058},"labels":[],"label_agreement":null},{"id":"W3030734898","doi":"10.1200/jco.2020.38.15_suppl.3035","title":"Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"CD19; CD22; Medicine; Flow cytometry; T cell; CD8; Immunology; Internal medicine; Molecular biology; Antigen; Biology; Immune system","score_opus":0.3304972255175948,"score_gpt":0.501662195559655,"score_spread":0.17116497004206016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030734898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812784,0.00074630446,0.000008275132,0.015172552,0.0001888192,0.00026294225,0.0000017056202,0.0000027613214,0.002338219],"genre_scores_gemma":[0.99631166,0.0016449698,0.0007110716,0.00067435787,0.00045764048,4.6831795e-7,3.7528235e-7,0.000013197565,0.00018627741],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99695885,0.00055090454,0.001600427,0.0002222302,0.00046067205,0.00020690891],"domain_scores_gemma":[0.9957022,0.0022714878,0.001115739,0.00018964255,0.00036601268,0.00035491947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030812374,0.00010512632,0.0016707708,0.00014360689,0.00000964826,0.000003135408,0.00019944542,0.00019745207,0.00029113347],"category_scores_gemma":[0.005305931,0.00008004633,0.00036118977,0.0002677697,0.00042765986,0.00007681251,0.000099684796,0.001222838,0.0000030869933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023280444,0.0052604303,0.17826526,0.00054228253,0.00037976244,0.0006273374,0.0012634804,0.00004475888,0.53884023,0.00001336546,0.0012278861,0.25025478],"study_design_scores_gemma":[0.032564897,0.04387926,0.7898581,0.0003195035,0.00047559495,0.00032778992,0.0005842566,0.0005136559,0.060266707,0.000043533568,0.070974045,0.00019267412],"about_ca_topic_score_codex":0.000020859701,"about_ca_topic_score_gemma":0.00000701891,"teacher_disagreement_score":0.6115928,"about_ca_system_score_codex":0.000056978548,"about_ca_system_score_gemma":0.0011464428,"threshold_uncertainty_score":0.6352078},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W3030769538","doi":"10.1200/jco.2020.38.15_suppl.4557","title":"Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Sarcopenia; Internal medicine; Gastroenterology; Weight loss; Cancer; Body mass index; Malnutrition; Esophageal cancer; Chemotherapy; Surgery; Obesity","score_opus":0.20599786789500418,"score_gpt":0.47133277117503497,"score_spread":0.2653349032800308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030769538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548247,0.0032553559,0.00044252162,0.04046852,0.00021916504,0.00036192356,0.0000070997075,0.000005074513,0.0004156496],"genre_scores_gemma":[0.96921515,0.000733768,0.024518784,0.0050917007,0.0004161203,0.000003940544,0.0000017369202,0.0000071545446,0.000011657175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704134,0.00038541685,0.0020273132,0.00013158518,0.0002590001,0.00015531063],"domain_scores_gemma":[0.99588275,0.002471138,0.000928846,0.000048888578,0.00022073608,0.00044762887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018628859,0.00007598971,0.0010595095,0.0001436719,0.000014395417,0.000002793389,0.000067964786,0.00010411157,0.000120743054],"category_scores_gemma":[0.003894548,0.00006222832,0.00014936195,0.00023271238,0.00018664484,0.000058683196,0.000020303409,0.0007684233,0.000003376095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005494812,0.001249172,0.9727899,0.0006733272,0.00009440637,0.001467515,0.00009623199,0.0000053242193,0.00021487728,0.00023365032,0.0023145906,0.0153662],"study_design_scores_gemma":[0.010534206,0.009319337,0.9756253,0.00024075071,0.0001713374,0.00050223485,0.00016782193,0.0003521792,0.000026624693,0.0006664585,0.002348025,0.0000457384],"about_ca_topic_score_codex":0.0000038805038,"about_ca_topic_score_gemma":0.0000022573536,"teacher_disagreement_score":0.03537682,"about_ca_system_score_codex":0.000048565737,"about_ca_system_score_gemma":0.0010503475,"threshold_uncertainty_score":0.4662419},"labels":[],"label_agreement":null},{"id":"W3030778984","doi":"10.1200/jco.2020.38.15_suppl.3102","title":"An increase in serum choline levels to predict progression-free survival (PFS) in patients (pts) with advanced cancers receiving pembrolizumab.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Internal medicine; Phosphocholine; Choline; Oncology; Cancer; Gastroenterology; Immunotherapy; Biology","score_opus":0.06200524483020781,"score_gpt":0.42270467627552694,"score_spread":0.36069943144531913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030778984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894281,0.00024887113,0.00002406306,0.008839411,0.0005671567,0.0005552205,0.000017139966,0.00001649177,0.00030352315],"genre_scores_gemma":[0.9929522,0.00035750444,0.0018238615,0.0035032579,0.0012699334,0.000016059397,0.0000052274268,0.00003806989,0.000033885837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952433,0.00094915717,0.002304807,0.0003768023,0.0006877952,0.000438148],"domain_scores_gemma":[0.9960482,0.0011146659,0.0011168779,0.0003611277,0.00040685045,0.000952284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024405564,0.00023614209,0.0018209278,0.00024896688,0.000034937377,0.000010590086,0.00041853276,0.00030724844,0.00009529603],"category_scores_gemma":[0.008734797,0.00017110769,0.0001931233,0.00050802465,0.00015807903,0.00029795698,0.000087388864,0.0013375,0.0000045975385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09535671,0.0013797127,0.672201,0.000051351377,0.000060119233,0.0006558483,0.00048652836,0.0005995797,0.00006308936,0.000001459127,0.00042297723,0.22872168],"study_design_scores_gemma":[0.034844924,0.038687296,0.9129197,0.0008161039,0.000078586294,0.000069016154,0.00029202615,0.0003174135,0.000039096172,0.000008250177,0.011759505,0.00016810962],"about_ca_topic_score_codex":0.0001787587,"about_ca_topic_score_gemma":0.001164943,"teacher_disagreement_score":0.24071872,"about_ca_system_score_codex":0.00059336756,"about_ca_system_score_gemma":0.0036216492,"threshold_uncertainty_score":0.9996151},"labels":[],"label_agreement":null},{"id":"W3030792017","doi":"10.1200/jco.2020.38.15_suppl.9065","title":"Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Adverse effect; Phases of clinical research; Chemotherapy; Gastroenterology; Clinical trial; Poly ADP ribose polymerase","score_opus":0.16719664029712927,"score_gpt":0.5222723428559617,"score_spread":0.3550757025588324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030792017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952224,0.00069932395,0.000018663108,0.0009863736,0.00013603813,0.0026609919,0.000034068464,0.000006641197,0.0002355155],"genre_scores_gemma":[0.99886066,0.00041444748,0.00041916023,0.00010233702,0.00011532606,0.000031933174,0.0000113904025,0.000025772802,0.000018968885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934601,0.00088845217,0.0040362165,0.00042895335,0.0008900718,0.0002961834],"domain_scores_gemma":[0.99288255,0.002360071,0.0031093468,0.00047382535,0.0009248321,0.00024936753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035748165,0.00021762119,0.0032880716,0.00030155276,0.000028278635,0.0000025822378,0.0005612142,0.00015797137,0.000035581583],"category_scores_gemma":[0.005585971,0.0001571736,0.000121103185,0.0007530461,0.00026283585,0.00016879867,0.0004948626,0.0012919537,2.4599706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07046048,0.054299593,0.8534852,0.00045033803,0.001008587,0.00093391904,0.007449586,0.00082586677,0.0011955304,9.612979e-7,0.0003116164,0.009578321],"study_design_scores_gemma":[0.10289354,0.20832528,0.68019366,0.00067736895,0.0008237516,0.000009933495,0.0041793934,0.0022597404,0.00049966434,0.0000028670772,0.00003633717,0.000098453995],"about_ca_topic_score_codex":0.0005448892,"about_ca_topic_score_gemma":0.0013846459,"teacher_disagreement_score":0.17329153,"about_ca_system_score_codex":0.00026367872,"about_ca_system_score_gemma":0.0022599665,"threshold_uncertainty_score":0.66873324},"labels":[],"label_agreement":null},{"id":"W3030794786","doi":"10.1200/jco.2020.38.15_suppl.7081","title":"Health plan expenditures young adults with newly-diagnosed Hodgkin lymphoma (HL) by care at NCI-designated comprehensive cancer centers (CCC) vs. other treatment sites (non-CCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Stand Up To Cancer","keywords":"Medicine; Internal medicine; Cancer; Health care; Adverse effect; Health plan; Demography","score_opus":0.09570162716375813,"score_gpt":0.35774241890601155,"score_spread":0.2620407917422534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030794786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962596,0.016022108,0.00030693153,0.016411588,0.0014262131,0.0005305613,0.00076778413,0.000024180368,0.001914609],"genre_scores_gemma":[0.972355,0.009881031,0.00067205325,0.015538873,0.0012494491,0.000024694313,0.00004183813,0.00006226855,0.00017480893],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99619067,0.00013171462,0.0024841803,0.00054232375,0.00009308494,0.0005580163],"domain_scores_gemma":[0.9941387,0.00059624907,0.004097207,0.00022323246,0.00016176954,0.0007828283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034604906,0.00037208918,0.0026239022,0.00012808436,0.00014121544,0.000045616613,0.00037976474,0.00039645837,0.0004509894],"category_scores_gemma":[0.00019559337,0.00031105243,0.00046991857,0.00010766581,0.00021137291,0.00028262008,0.000061095554,0.0003694798,0.00010099643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017786065,0.001159228,0.6838934,0.00011865418,0.0013600684,0.00036223402,0.0077499645,0.0010524044,0.000033031876,0.00026906218,0.21526651,0.07094937],"study_design_scores_gemma":[0.03159615,0.023220018,0.21216154,0.00017666038,0.00008459599,0.00004782665,0.0014677831,0.0004137903,0.00015567696,0.000092299626,0.7299922,0.00059147715],"about_ca_topic_score_codex":0.0042737294,"about_ca_topic_score_gemma":0.004147195,"teacher_disagreement_score":0.5147257,"about_ca_system_score_codex":0.0016829016,"about_ca_system_score_gemma":0.0010221192,"threshold_uncertainty_score":0.99993414},"labels":[],"label_agreement":null},{"id":"W3030811423","doi":"10.1200/jco.2020.38.15_suppl.8536","title":"Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Neutropenia; Refractory (planetary science); Internal medicine; Gastroenterology; Febrile neutropenia; Multiple myeloma; Surgery; Toxicity","score_opus":0.09030549551261925,"score_gpt":0.384794551510006,"score_spread":0.2944890559973868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030811423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311215,0.00043850098,0.000018780864,0.0029748613,0.0005059173,0.0027888054,0.000051027626,0.000034470428,0.000075507334],"genre_scores_gemma":[0.99435604,0.00027191715,0.0027395415,0.0017631267,0.00063454546,0.000046591995,0.000021654594,0.00008746381,0.00007911432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99274665,0.0010642626,0.003128388,0.0009226027,0.001331581,0.00080652797],"domain_scores_gemma":[0.99387205,0.0015387709,0.0013657688,0.00043639285,0.0006211901,0.0021658482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020081704,0.0005906749,0.0026957777,0.00059955247,0.00016237595,0.00005789227,0.00032269885,0.00046803098,0.00007979075],"category_scores_gemma":[0.005432011,0.0004004103,0.00027794216,0.0004428858,0.00033601464,0.00044272322,0.0004632331,0.0020459366,0.00003414942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05352909,0.012791718,0.8268607,0.0001135574,0.0008716452,0.0034687067,0.001647068,0.000015144562,0.0011505488,7.84666e-7,0.0007802023,0.0987708],"study_design_scores_gemma":[0.035520773,0.088287376,0.8632829,0.0004523797,0.00022815526,0.00009802594,0.0008071794,0.00007126283,0.00012536753,0.000002897835,0.010766549,0.00035709102],"about_ca_topic_score_codex":0.00016647723,"about_ca_topic_score_gemma":0.000240972,"teacher_disagreement_score":0.098413706,"about_ca_system_score_codex":0.0006364467,"about_ca_system_score_gemma":0.0012671176,"threshold_uncertainty_score":0.9998448},"labels":[],"label_agreement":null},{"id":"W3030820321","doi":"10.1200/jco.2020.38.15_suppl.e16571","title":"TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with anti-angiogenic or standard chemotherapy regimens.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Oxaliplatin; Capecitabine; Internal medicine; Oncology; Chemotherapy; Cancer; Ramucirumab; Cisplatin; PTEN; KRAS; Cancer research; Gastroenterology; Colorectal cancer; Apoptosis; PI3K/AKT/mTOR pathway; Biology","score_opus":0.03981938968361203,"score_gpt":0.3958872358211173,"score_spread":0.35606784613750525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030820321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973989,0.00038874746,0.00056857395,0.0013176796,0.00005210594,0.00016887717,0.00009492293,0.0000013192789,0.000008889614],"genre_scores_gemma":[0.99367046,0.0026355565,0.0022847333,0.0012536737,0.00009979099,0.000003170013,0.000027636625,0.000014364427,0.000010601352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791825,0.00019455464,0.0013192989,0.00023846996,0.00019279227,0.00013664547],"domain_scores_gemma":[0.9974476,0.0005018571,0.0013115469,0.00012977194,0.00031118162,0.00029804822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055974605,0.00013293607,0.0011286803,0.000091481816,0.0000144957085,0.000007815502,0.00010861992,0.0000959331,0.000023863226],"category_scores_gemma":[0.0010685989,0.00007937881,0.00028892403,0.0003240278,0.00017795716,0.0000067643505,0.000029302575,0.00017374055,1.8520191e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017331716,0.00053742167,0.9682408,0.000011901365,0.0026053558,0.000097776916,0.000018632038,0.0008232794,0.000018538469,0.0000021693052,0.00016597997,0.010146408],"study_design_scores_gemma":[0.011426819,0.012401814,0.9722586,0.000013625572,0.0021921718,0.0000029885014,0.000031905747,0.00014813687,0.00006171897,0.0000074047966,0.0013512479,0.00010352495],"about_ca_topic_score_codex":0.00003144425,"about_ca_topic_score_gemma":0.00036001034,"teacher_disagreement_score":0.011864391,"about_ca_system_score_codex":0.00003035518,"about_ca_system_score_gemma":0.0009908503,"threshold_uncertainty_score":0.3236974},"labels":[],"label_agreement":null},{"id":"W3030820428","doi":"10.1200/jco.2020.38.15_suppl.8511","title":"Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"AbbVie","keywords":"Daratumumab; Medicine; Venetoclax; Dexamethasone; Lenalidomide; Internal medicine; Bortezomib; Ven; Multiple myeloma; Refractory (planetary science); Adverse effect; Gastroenterology; Oncology; Pharmacology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.07932042657040811,"score_gpt":0.43214285257206797,"score_spread":0.35282242600165986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030820428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988792,0.000065194894,0.000023242646,0.00026819395,0.000028121107,0.0006655756,0.000012566044,0.000002764853,0.00005512166],"genre_scores_gemma":[0.9987721,0.00004157026,0.0010274805,0.00008349389,0.000018957579,0.000006309048,0.000032612646,0.000012132381,0.000005354837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996505,0.00062453956,0.0018744257,0.00023604692,0.00057612767,0.00018384149],"domain_scores_gemma":[0.9962921,0.0011098202,0.0015540415,0.00016887396,0.00055186637,0.0003232672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011458846,0.00013950549,0.0019360177,0.0005765269,0.00002121339,0.0000031472732,0.00010595824,0.0001668689,0.000027953787],"category_scores_gemma":[0.0020874697,0.000089740555,0.000116541494,0.0010845448,0.00017076606,0.00013144399,0.000052370073,0.0007048274,3.1819621e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074126646,0.025392974,0.8676503,0.000023675537,0.002354686,0.00046192907,0.00079572696,0.00016377553,0.000058227673,0.000001628284,0.000019370773,0.028951103],"study_design_scores_gemma":[0.12755708,0.14672157,0.72131574,0.000055970704,0.0009534344,0.000002817741,0.00038549624,0.0028723702,0.000024408942,0.000002087783,0.000057601283,0.000051421117],"about_ca_topic_score_codex":0.00020709941,"about_ca_topic_score_gemma":0.0012513846,"teacher_disagreement_score":0.14633451,"about_ca_system_score_codex":0.00016898004,"about_ca_system_score_gemma":0.00078020466,"threshold_uncertainty_score":0.36595136},"labels":[],"label_agreement":null},{"id":"W3030821017","doi":"10.1200/jco.2020.38.15_suppl.e12532","title":"Usage and factors associated with adjuvant bisphosphonate therapy among postmenopausal women diagnosed with early-stage breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Bisphosphonate; Adjuvant therapy; Odds ratio; Cancer; Stage (stratigraphy); Guideline; Retrospective cohort study; Gynecology; Osteoporosis; Pathology","score_opus":0.09593810887029584,"score_gpt":0.40632740491587294,"score_spread":0.3103892960455771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030821017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347377,0.00042576753,0.00000418592,0.0053656953,0.0001757359,0.00036142094,0.000052890406,0.000019338355,0.000121193465],"genre_scores_gemma":[0.9928284,0.0017538759,0.00009211146,0.0050193486,0.000112119546,0.000012838684,0.0000052878718,0.00003271386,0.00014325096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758625,0.0002629345,0.0011035317,0.0002466873,0.00039334464,0.00040723913],"domain_scores_gemma":[0.9956265,0.0011508465,0.0014518888,0.000102510516,0.00028837862,0.0013798607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007264378,0.00021943511,0.001581358,0.000052007934,0.00006721882,0.000013414831,0.0000872606,0.0002788415,0.00019431586],"category_scores_gemma":[0.0004172755,0.00011555537,0.000093846094,0.00020018646,0.00028889164,0.00014522516,0.000022745602,0.0009317936,0.0000022797344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016264841,0.0011708256,0.95351547,0.00001579579,0.0010820341,0.0023946138,0.0010832935,0.0000035937846,0.000019809671,0.0000020819175,0.00013191455,0.024315711],"study_design_scores_gemma":[0.02404646,0.05167812,0.9215644,0.0001238432,0.00021365822,0.000059728238,0.00024253434,0.00002363531,0.000022684486,0.000006228658,0.0019078343,0.00011085624],"about_ca_topic_score_codex":0.00073803804,"about_ca_topic_score_gemma":0.0005992186,"teacher_disagreement_score":0.050507296,"about_ca_system_score_codex":0.00023644643,"about_ca_system_score_gemma":0.0016693076,"threshold_uncertainty_score":0.47122112},"labels":[],"label_agreement":null},{"id":"W3030823329","doi":"10.1200/jco.2020.38.15_suppl.e14037","title":"Early nutrition intervention in cancer patients: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Malnutrition; Relative risk; Cochrane Library; Cancer; Weight change; Cohort study; MEDLINE; Confidence interval; Psychological intervention; Quality of life (healthcare); CINAHL; Internal medicine; Weight loss; Obesity","score_opus":0.5102526788612985,"score_gpt":0.6254953348174578,"score_spread":0.11524265595615923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030823329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005498292,0.99135464,0.000014991266,0.0061767558,0.00022196617,0.0021485647,0.00001972635,0.0000044729286,0.000053373224],"genre_scores_gemma":[0.000038567858,0.99379647,0.00037157084,0.0052489177,0.00023914027,0.00020634852,0.000016815793,0.000016104446,0.00006609133],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98821944,0.0025945199,0.008483068,0.00023626088,0.0003198296,0.00014690541],"domain_scores_gemma":[0.9901629,0.0014154239,0.0074318335,0.00015069294,0.000481707,0.0003574338],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0052440134,0.00022126475,0.022771822,0.00047109218,0.000016087539,0.000010075068,0.00012646461,0.00045662333,0.0002799771],"category_scores_gemma":[0.003487252,0.00013161676,0.0055129435,0.0006323526,0.000052764266,0.000080149715,0.000038145205,0.0016686962,0.000012097878],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055156914,0.0013841061,0.000057019184,0.90317446,0.054209974,0.00011953947,0.000010357815,8.580481e-9,6.4077194e-10,0.000012633635,0.0007820706,0.04019469],"study_design_scores_gemma":[0.0013958691,0.0017873883,0.000118715274,0.14667538,0.60044944,0.000049677416,0.000004171855,8.0437354e-7,1.651074e-9,0.000021031476,0.24943537,0.000062157604],"about_ca_topic_score_codex":0.00001661497,"about_ca_topic_score_gemma":0.000027919254,"teacher_disagreement_score":0.75649905,"about_ca_system_score_codex":0.0002936013,"about_ca_system_score_gemma":0.00059218775,"threshold_uncertainty_score":0.9917362},"labels":[],"label_agreement":null},{"id":"W3030829389","doi":"10.1200/jco.2020.38.15_suppl.e21558","title":"Does CNS metastases reduce systemic therapy lines for NSCLC patients with EGFR mutation?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Brain metastasis; Clinical endpoint; Epidermal growth factor receptor; Lung cancer; Metastasis; Cancer; Erlotinib; Gefitinib; Clinical trial","score_opus":0.09906560483173175,"score_gpt":0.49189326110002424,"score_spread":0.39282765626829247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030829389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96476924,0.0006145817,0.0011935972,0.031242417,0.00094145763,0.0007784986,0.000051675102,0.000014979846,0.0003935459],"genre_scores_gemma":[0.98642486,0.00027547445,0.007479062,0.004431751,0.001186787,0.000022713126,0.00002664936,0.000017801549,0.00013490366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981955,0.00013288262,0.0011819347,0.00014758394,0.00021835655,0.00012371222],"domain_scores_gemma":[0.99656564,0.001115463,0.0010995562,0.000087108165,0.00085685967,0.00027536086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041785132,0.00010620263,0.000859584,0.000044921617,0.000045560482,0.0000092201135,0.000076370416,0.00010747818,0.00004769284],"category_scores_gemma":[0.0012798798,0.00004552564,0.00027114828,0.00009634233,0.00007478875,0.00010405938,0.000007995929,0.00021689797,0.000004665569],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043671776,0.0075054877,0.3237961,0.0002849859,0.00779865,0.0005133567,0.0018750571,0.00023255571,0.0002933734,0.0003506811,0.018402137,0.5952758],"study_design_scores_gemma":[0.12299671,0.12974396,0.33637437,0.0006263272,0.0061175176,0.00027823015,0.0019851713,0.00015767345,0.0007019699,0.00048468285,0.4001649,0.00036847926],"about_ca_topic_score_codex":0.0000061382466,"about_ca_topic_score_gemma":0.0000049268815,"teacher_disagreement_score":0.59490734,"about_ca_system_score_codex":0.00007964471,"about_ca_system_score_gemma":0.0012715948,"threshold_uncertainty_score":0.22557545},"labels":[],"label_agreement":null},{"id":"W3030843870","doi":"10.1200/jco.2020.38.15_suppl.7554","title":"Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anemia; Population; Internal medicine; Randomization; Placebo; Clinical trial; Myelodysplastic syndromes; Refractory (planetary science); Phases of clinical research; International Prognostic Scoring System; Surgery; Bone marrow","score_opus":0.046706897738745375,"score_gpt":0.40221408753057225,"score_spread":0.3555071897918269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030843870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98533475,0.00017601161,0.000031464326,0.013054169,0.00043352775,0.0006513945,0.0000060977295,0.0000044064122,0.00030817362],"genre_scores_gemma":[0.9947612,0.002850878,0.00018360179,0.001808091,0.00035843565,0.0000030901845,0.0000035669386,0.000016346552,0.0000147435185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946241,0.0010144892,0.0033106357,0.00028791762,0.0005282071,0.0002346651],"domain_scores_gemma":[0.9964707,0.00141753,0.0013256788,0.00019331541,0.00024830925,0.00034447867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004421854,0.00017980418,0.0018730636,0.000113076116,0.00003727256,0.000007232334,0.00023704501,0.0005120913,0.00009676108],"category_scores_gemma":[0.0017601355,0.00009509755,0.0002699281,0.00031883182,0.00035563062,0.00008163513,0.000053932356,0.0021749604,0.000002590753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029658606,0.0102036735,0.74299055,0.000029951296,0.00020572086,0.00071578735,0.0030592065,0.00007444876,0.0000066669127,0.0000086206355,0.00033014425,0.21271661],"study_design_scores_gemma":[0.10857062,0.11239955,0.77009124,0.00019357016,0.00061234954,0.000034248078,0.0036715413,0.00037542195,0.0000018872586,0.00005509314,0.0038769243,0.000117531206],"about_ca_topic_score_codex":0.00043935815,"about_ca_topic_score_gemma":0.0005435824,"teacher_disagreement_score":0.21259908,"about_ca_system_score_codex":0.00004307516,"about_ca_system_score_gemma":0.0003868087,"threshold_uncertainty_score":0.94492424},"labels":[],"label_agreement":null},{"id":"W3030899765","doi":"10.1200/jco.2020.38.15_suppl.e21080","title":"Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Internal medicine; Adenocarcinoma; Oncology; Concomitant; Lung cancer; Proportional hazards model; Stage (stratigraphy); Clinical endpoint; Survival analysis; Cancer; Colorectal cancer; Clinical trial; Biology","score_opus":0.02409773401546675,"score_gpt":0.41632360671051555,"score_spread":0.3922258726950488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030899765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707437,0.000665132,0.00016322495,0.0005794382,0.0002329142,0.00065145374,0.000053435466,0.0000031171303,0.00057693577],"genre_scores_gemma":[0.99744403,0.0010104611,0.0008030302,0.0005046329,0.00016590321,0.000018101964,0.000010418614,0.000012434588,0.00003099175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983502,0.00020768962,0.0009634873,0.00015914507,0.00017086175,0.00014862814],"domain_scores_gemma":[0.9974277,0.0011652613,0.00080330396,0.0000483346,0.00024728553,0.00030810825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004071521,0.0001075142,0.0007944253,0.000044592187,0.000018422488,0.0000057115067,0.000032732652,0.00014728175,0.00002419503],"category_scores_gemma":[0.0007164221,0.00007456734,0.0000875985,0.00010271694,0.000101362835,0.00009136533,0.00002524039,0.00036239804,8.8438094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003563944,0.0004780863,0.9810295,0.00020354126,0.00025700525,0.00015013822,0.0015669288,0.000047104528,0.00009308098,0.000001417008,0.00019863495,0.012410609],"study_design_scores_gemma":[0.01955059,0.019803796,0.95770556,0.00014999192,0.0010310924,0.000009097335,0.00008334613,0.00043279523,0.00053997384,0.0000063014686,0.0006302093,0.000057228997],"about_ca_topic_score_codex":0.00014243586,"about_ca_topic_score_gemma":0.000028979974,"teacher_disagreement_score":0.023323935,"about_ca_system_score_codex":0.00011089192,"about_ca_system_score_gemma":0.0007566815,"threshold_uncertainty_score":0.3040768},"labels":[],"label_agreement":null},{"id":"W3030905798","doi":"10.1200/jco.2020.38.15_suppl.e19240","title":"Number of sentinel lymph nodes (SLN) removed in breast cancer (BC) patients undergoing sentinel lymph node biopsy (SLNB) in the province of Saskatchewan, Canada: Real-world experience.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Sentinel lymph node; Breast cancer; Axillary Lymph Node Dissection; Population; Biopsy; Axillary lymph nodes; Lymph; Cancer; Lymph node; Surgery; Mastectomy; Clinical trial; Radiology; Internal medicine; Pathology","score_opus":0.03384434823883681,"score_gpt":0.3605325480449317,"score_spread":0.32668819980609487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030905798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207157,0.00013180444,0.000011356874,0.006597183,0.0003048668,0.00010416638,0.000042692292,0.0000019038855,0.00073442794],"genre_scores_gemma":[0.9965782,0.0005053667,0.00036377815,0.0020872604,0.000369374,0.000010894738,0.0000093064455,0.000018659077,0.000057172783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964959,0.00042371443,0.002061015,0.00032318023,0.0003856494,0.00031056048],"domain_scores_gemma":[0.99697727,0.0004837577,0.0018192691,0.00022791103,0.0003602761,0.00013148751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062004087,0.00021883589,0.0010147752,0.000050430237,0.00003094295,0.0000057840684,0.00041183023,0.00020070326,0.000027213679],"category_scores_gemma":[0.0005037893,0.00015637405,0.0002394975,0.00029487873,0.0002819296,0.000015630527,0.00017582337,0.00025187642,6.0939533e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016582279,0.0007648726,0.99328613,0.00006417593,0.00018452197,0.00009499501,0.0003738249,0.00010649548,0.0007685004,0.000007203202,0.0003998,0.0022912384],"study_design_scores_gemma":[0.0058464296,0.000055721852,0.99092627,0.00013527839,0.000074353986,0.000036909347,0.0019712616,0.000039785093,0.000527426,0.000015148872,0.00023355831,0.00013788725],"about_ca_topic_score_codex":0.11427194,"about_ca_topic_score_gemma":0.14979602,"teacher_disagreement_score":0.035524085,"about_ca_system_score_codex":0.00024304516,"about_ca_system_score_gemma":0.004789192,"threshold_uncertainty_score":0.8916262},"labels":[],"label_agreement":null},{"id":"W3030929389","doi":"10.1200/jco.2020.38.15_suppl.1006","title":"Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fulvestrant; Internal medicine; Metastatic breast cancer; Clinical endpoint; Cohort; Breast cancer; Letrozole; Oncology; Cancer; Clinical trial; Estrogen receptor; Tamoxifen","score_opus":0.03321510135610873,"score_gpt":0.362653915720541,"score_spread":0.3294388143644323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030929389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842789,0.00031368376,0.00007433689,0.00938916,0.0005155355,0.0036378454,0.0015463384,0.000110888606,0.00013331218],"genre_scores_gemma":[0.9913601,0.00034129107,0.0027399303,0.0032429388,0.0016543202,0.00015797863,0.00023477888,0.00020767805,0.000060956605],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98782206,0.0019647002,0.0058027734,0.0015086016,0.0017328779,0.0011689875],"domain_scores_gemma":[0.9880124,0.0016651712,0.005297332,0.0005808758,0.0026030804,0.0018411686],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001518398,0.0011360635,0.004510754,0.00038896492,0.00021601158,0.000059332924,0.0005694659,0.00068718824,0.00019873753],"category_scores_gemma":[0.0018182918,0.0007830786,0.00051200436,0.0011275227,0.000920072,0.0012046183,0.00017708202,0.003626495,0.000029757228],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5402417,0.027088718,0.30202806,0.00018214593,0.0039657583,0.0048229913,0.0070875385,0.0004801276,0.007692686,0.00000677857,0.0024069094,0.1039966],"study_design_scores_gemma":[0.1659155,0.12879474,0.6912756,0.0013036043,0.0011372202,0.00029959762,0.0029229743,0.000024246296,0.00624718,0.00001844218,0.0009947314,0.0010661813],"about_ca_topic_score_codex":0.0006431667,"about_ca_topic_score_gemma":0.0009155005,"teacher_disagreement_score":0.3892475,"about_ca_system_score_codex":0.0017358252,"about_ca_system_score_gemma":0.0023299314,"threshold_uncertainty_score":0.999462},"labels":[],"label_agreement":null},{"id":"W3030945835","doi":"10.1200/jco.2020.38.15_suppl.tps6589","title":"Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Placebo; Clinical trial; Cancer; Head and neck cancer; Immunotherapy; Pathology; Thyroid cancer","score_opus":0.1601881154732406,"score_gpt":0.4592504337238478,"score_spread":0.29906231825060714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030945835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763996,0.0013359721,0.00007149515,0.009349943,0.00040624785,0.00078994647,0.000006562643,0.000011896036,0.00038796582],"genre_scores_gemma":[0.9936762,0.0005456716,0.0012221582,0.0037104543,0.00064121914,0.0000109970215,0.0000033666577,0.00003267747,0.00015728282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99569046,0.00045070454,0.002761862,0.00035348293,0.00042336257,0.00032010322],"domain_scores_gemma":[0.9961573,0.0013525473,0.0015502302,0.00020186296,0.00023054972,0.0005074924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017424463,0.00026040702,0.002188782,0.0001503457,0.00005664563,0.00001688577,0.00018161343,0.00019090845,0.00024156547],"category_scores_gemma":[0.0010499685,0.00015939598,0.00024493647,0.000369182,0.00026696434,0.00012719141,0.00005223372,0.0013109307,0.000004983084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53151155,0.017034777,0.30710593,0.00024542908,0.00031498843,0.004275679,0.0023231492,0.000011407564,0.00019926803,0.0000015509038,0.0020358032,0.13494045],"study_design_scores_gemma":[0.42148173,0.3888385,0.15072818,0.00021174304,0.0008297718,0.001036272,0.0018352207,0.0009095736,0.00009625755,0.000011797082,0.03373885,0.0002820869],"about_ca_topic_score_codex":0.00013804951,"about_ca_topic_score_gemma":0.001464499,"teacher_disagreement_score":0.37180373,"about_ca_system_score_codex":0.00012729134,"about_ca_system_score_gemma":0.0017396647,"threshold_uncertainty_score":0.64999795},"labels":[],"label_agreement":null},{"id":"W3030953706","doi":"10.1200/jco.2020.38.15_suppl.e17044","title":"Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Oncology; Pembrolizumab; Urology; Cancer; Immunotherapy","score_opus":0.0559710535210633,"score_gpt":0.39404906054533767,"score_spread":0.3380780070242744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030953706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937454,0.00020807974,0.000325773,0.0010816674,0.004083968,0.00038128032,0.000097386794,0.0000032226926,0.00007326062],"genre_scores_gemma":[0.9899459,0.00009335146,0.0011853293,0.00091735454,0.0077714375,0.000009542429,0.000017018163,0.000032967884,0.000027102902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742484,0.00024948988,0.0014464172,0.0002890865,0.00032003142,0.0002701093],"domain_scores_gemma":[0.9966476,0.00042227568,0.0016882012,0.00016938709,0.00067503675,0.00039749133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059203384,0.00024471708,0.0013274989,0.000066549015,0.000033621043,0.000009126403,0.00019135726,0.00021344789,0.000013478441],"category_scores_gemma":[0.0017299423,0.00014219675,0.0007700739,0.00009897611,0.000251288,0.000011145972,0.000045032113,0.00034560918,0.0000015682256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03508184,0.0038127182,0.765982,0.000086475025,0.0025218597,0.000010716205,0.0002989484,0.00054203335,0.006267934,0.000051250918,0.10146341,0.08388087],"study_design_scores_gemma":[0.037428044,0.16981442,0.48365423,0.00010410408,0.0011424967,0.00004476064,0.00013190605,0.000050392686,0.005745235,0.000021517368,0.30135468,0.0005082097],"about_ca_topic_score_codex":0.000027738819,"about_ca_topic_score_gemma":0.000033571472,"teacher_disagreement_score":0.2823277,"about_ca_system_score_codex":0.000047665715,"about_ca_system_score_gemma":0.0016257667,"threshold_uncertainty_score":0.5798615},"labels":[],"label_agreement":null},{"id":"W3030956571","doi":"10.1200/jco.2020.38.15_suppl.12014","title":"Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer (NCT03396510).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Psychological intervention; Randomized controlled trial; Cancer; Clinical endpoint; Genitourinary system; Intervention (counseling); Lung cancer; Internal medicine; Physical therapy","score_opus":0.0820974647898902,"score_gpt":0.465301219944153,"score_spread":0.3832037551542628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030956571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047524,0.00045769894,0.0012122313,0.0029916177,0.0035300849,0.001150283,0.000009329412,0.000007548856,0.00016594118],"genre_scores_gemma":[0.99590564,0.00042224987,0.0012746641,0.0004184212,0.0018561567,0.000064458785,0.0000037372988,0.000017745786,0.000036948466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967731,0.00034093522,0.002250313,0.00014973298,0.00034763702,0.00013824475],"domain_scores_gemma":[0.99451816,0.0016523118,0.0025081728,0.00009385905,0.0009724741,0.000255033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017016073,0.00011547767,0.0023276652,0.000053425483,0.00001615015,0.0000044200447,0.000107265936,0.00018652964,0.000052713327],"category_scores_gemma":[0.0044495566,0.000072864226,0.0010993284,0.00010850252,0.00012382219,0.00009522518,0.000022962837,0.00037433003,5.4451885e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8766864,0.00085513806,0.030141676,0.00011093566,0.00063732016,0.000008048163,0.00026751458,0.000010382777,0.000014006078,0.000012372762,0.00014669384,0.0911095],"study_design_scores_gemma":[0.94136536,0.038373496,0.0135951815,0.00039258922,0.0010477346,0.0000015098019,0.00013504305,0.000038714854,0.00013320567,0.000059511465,0.004784619,0.00007303987],"about_ca_topic_score_codex":0.00003533376,"about_ca_topic_score_gemma":0.00001938869,"teacher_disagreement_score":0.09103646,"about_ca_system_score_codex":0.00008495694,"about_ca_system_score_gemma":0.0005779685,"threshold_uncertainty_score":0.53268564},"labels":[],"label_agreement":null},{"id":"W3030967068","doi":"10.1200/jco.2020.38.15_suppl.tps3656","title":"An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Spinal Cord Injury BC","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; In vivo; Lymphoma; Cancer; Internal medicine; Oncology; Pharmacology; Cancer research; Adverse effect","score_opus":0.18668089231023494,"score_gpt":0.5238295491597984,"score_spread":0.33714865684956347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030967068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909987,0.00036209665,0.00010054211,0.018825099,0.0005257128,0.0005303639,0.000011163477,0.0000034827196,0.00054168806],"genre_scores_gemma":[0.9947635,0.0003066024,0.0016703126,0.0022365192,0.0009677971,0.000001851816,0.0000016418129,0.000015483112,0.000036302674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962306,0.00047775244,0.0026751633,0.00017828064,0.00028837626,0.00014984592],"domain_scores_gemma":[0.994958,0.0019517486,0.0022915956,0.0002550055,0.00025411267,0.0002895803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021657352,0.00011554863,0.0017454291,0.00004766219,0.000035146113,0.000004616389,0.0004589164,0.00020763963,0.00013590658],"category_scores_gemma":[0.0032990966,0.000070941125,0.0001370304,0.00017184546,0.00046296685,0.0001558533,0.00014008,0.00079347374,8.3991387e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66370803,0.015884962,0.0049993508,0.000079212004,0.0003704158,0.00014345489,0.0006464708,0.00006218008,0.0057952967,0.00033694413,0.00043506853,0.3075386],"study_design_scores_gemma":[0.7376835,0.10243385,0.054253925,0.00022874573,0.00035815287,0.00010163957,0.0001797092,0.0001343567,0.0003925374,0.0004218193,0.10370823,0.00010358727],"about_ca_topic_score_codex":0.000020116342,"about_ca_topic_score_gemma":0.000039021477,"teacher_disagreement_score":0.307435,"about_ca_system_score_codex":0.00005963399,"about_ca_system_score_gemma":0.0007413335,"threshold_uncertainty_score":0.3949565},"labels":[],"label_agreement":null},{"id":"W3030975652","doi":"10.1200/jco.2020.38.15_suppl.e21092","title":"Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Lung cancer; Oncology; Internal medicine; Tumor-infiltrating lymphocytes; Stage (stratigraphy); non-small cell lung cancer (NSCLC); Proportional hazards model; Cancer; Confidence interval; Immunotherapy","score_opus":0.057446507698336244,"score_gpt":0.36440029034867566,"score_spread":0.3069537826503394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030975652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936819,0.0013495822,0.000031368443,0.001961373,0.00033183664,0.0003306957,0.00002195597,0.0000019650533,0.0022892966],"genre_scores_gemma":[0.9960102,0.0001728228,0.0011848096,0.0020811893,0.00046936815,0.000014392006,0.0000016488356,0.000012439166,0.00005313614],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99725205,0.00025355394,0.0018760838,0.00015725284,0.00032039292,0.00014065558],"domain_scores_gemma":[0.99608546,0.0012753862,0.00205021,0.00012202548,0.0003412687,0.00012562545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010778676,0.00012440272,0.00088999677,0.000050608876,0.000046797766,0.0000042152956,0.0001410289,0.00012818447,0.00040084895],"category_scores_gemma":[0.00036970302,0.000072198985,0.00023169052,0.000117641124,0.00019706681,0.00006807077,0.000069965114,0.0005373027,4.211808e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029025957,0.0006394101,0.21455911,0.0022395423,0.001476004,0.00005936521,0.018664587,0.002148866,0.5553478,0.000016602116,0.0015973862,0.17422539],"study_design_scores_gemma":[0.007312553,0.004052978,0.9234913,0.0007050344,0.00036006822,0.000045556986,0.0015986577,0.0039602844,0.05546598,0.000016296883,0.0028687457,0.0001225675],"about_ca_topic_score_codex":0.000094829215,"about_ca_topic_score_gemma":0.00022923957,"teacher_disagreement_score":0.70893216,"about_ca_system_score_codex":0.0002493875,"about_ca_system_score_gemma":0.0037956873,"threshold_uncertainty_score":0.67333865},"labels":[],"label_agreement":null},{"id":"W3031004830","doi":"10.1200/jco.2020.38.15_suppl.10022","title":"A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology; Logistic regression","score_opus":0.03068166014931388,"score_gpt":0.37951458013537354,"score_spread":0.34883291998605964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031004830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981852,0.00010650102,0.00016445322,0.00042199864,0.0003164397,0.0006816935,0.000019173423,0.0000037469417,0.000100753845],"genre_scores_gemma":[0.9980772,0.000018126606,0.0011580515,0.00047752447,0.00012830459,0.00002756148,0.00007501093,0.000015265608,0.000022946488],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99685025,0.0005880314,0.0017391797,0.00029759514,0.0003438421,0.00018108229],"domain_scores_gemma":[0.9974885,0.00015731112,0.001572568,0.00013305162,0.00044537225,0.00020319723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008077152,0.00016757373,0.00075399695,0.00006549756,0.000031733987,0.000006370857,0.00019797306,0.00026997243,0.00004412087],"category_scores_gemma":[0.001349654,0.00011775477,0.00016426356,0.00014158746,0.00007632352,0.000021906228,0.000093124705,0.00033936114,0.0000014713545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11178699,0.061653953,0.72948,0.000029024282,0.00037929806,0.00014969095,0.00078528264,0.000033423603,0.042469967,0.0000041457106,0.0018096556,0.051418517],"study_design_scores_gemma":[0.1999237,0.44302237,0.33498114,0.000081078564,0.00019962757,0.000007076543,0.00036247043,0.00017394233,0.012360811,0.00002042443,0.008538069,0.0003292986],"about_ca_topic_score_codex":0.000002001017,"about_ca_topic_score_gemma":0.000017144299,"teacher_disagreement_score":0.3944989,"about_ca_system_score_codex":0.000023449831,"about_ca_system_score_gemma":0.0003233916,"threshold_uncertainty_score":0.48019},"labels":[],"label_agreement":null},{"id":"W3031007885","doi":"10.1200/jco.2020.38.15_suppl.5065","title":"A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Ozmosis Research (Canada); McMaster University; Juravinski Cancer Centre; Baker Hughes (Canada); Princess Margaret Cancer Centre; University of Calgary; McGill University Health Centre; McGill University; Sunnybrook Health Science Centre; Jewish General Hospital; Foothills Medical Centre; University of Alberta; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre; Cancer Care Ontario","funders":"Pfizer Canada","keywords":"Medicine; Sunitinib; Pazopanib; Internal medicine; Renal cell carcinoma; Oncology; Cancer; Cumulative incidence; Surgery; Cohort","score_opus":0.15425976726002352,"score_gpt":0.4720667528457671,"score_spread":0.3178069855857436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031007885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930855,0.0020511108,0.000042533688,0.0024072947,0.00061264716,0.001747454,0.000010188618,0.000005888393,0.0000373974],"genre_scores_gemma":[0.9934546,0.00092130736,0.0035815951,0.0012594624,0.00064526516,0.00005209961,0.000004885066,0.000038887232,0.000041900228],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9950786,0.00073972647,0.0030514796,0.00032758721,0.0005119272,0.00029066278],"domain_scores_gemma":[0.994881,0.0013539554,0.0025825205,0.0001985131,0.00054078613,0.0004432598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013880411,0.00024976072,0.0019921218,0.00017955655,0.00004445391,0.0000086280525,0.00016746568,0.00016252616,0.00010926716],"category_scores_gemma":[0.0010357033,0.0001623042,0.00046730705,0.00022835188,0.00007499286,0.00014085237,0.000051480845,0.0006677688,0.0000012238373],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11342315,0.12585203,0.32881275,0.00025721037,0.0013241641,0.0010196242,0.0055142585,0.00006590337,0.023290105,5.6984834e-7,0.0014128888,0.39902735],"study_design_scores_gemma":[0.3329821,0.4797274,0.15764853,0.0006368654,0.0012066839,0.000018195797,0.0007598684,0.001141924,0.01785261,0.000012044872,0.007749659,0.0002641261],"about_ca_topic_score_codex":0.000038015318,"about_ca_topic_score_gemma":0.000041137362,"teacher_disagreement_score":0.39876324,"about_ca_system_score_codex":0.0003176097,"about_ca_system_score_gemma":0.0006692546,"threshold_uncertainty_score":0.66185737},"labels":[],"label_agreement":null},{"id":"W3031022693","doi":"10.1200/jco.2020.38.15_suppl.1097","title":"Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative g<i>BRCA</i>-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Internal medicine; Hazard ratio; Veliparib; PARP inhibitor; Breast cancer; Progression-free survival; Oncology; Carboplatin; Biomarker; Cancer; Gastroenterology; Confidence interval; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.11059681942288144,"score_gpt":0.48148630515514185,"score_spread":0.37088948573226044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031022693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889796,0.0005501684,0.00001124609,0.009379527,0.00026711542,0.0005839718,0.000056484783,0.000014969995,0.00015690931],"genre_scores_gemma":[0.98937106,0.00055932486,0.00057281146,0.009202762,0.00015946134,0.000072195726,0.0000049876917,0.00004068042,0.0000167018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590963,0.0007228874,0.0020262438,0.00040198115,0.0006064047,0.0003328475],"domain_scores_gemma":[0.9957867,0.0014768727,0.0017587764,0.0001544817,0.00042346562,0.00039969655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008703723,0.0002952408,0.0018180299,0.00021672244,0.000038262217,0.00001629985,0.00011917812,0.0004157186,0.00013191605],"category_scores_gemma":[0.0010218628,0.00019633348,0.00020761808,0.00045994294,0.00034911954,0.0002927618,0.00003549123,0.0011850963,0.0000029265093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1139149,0.001745,0.841914,0.000022954231,0.0004082976,0.00017867849,0.0008134816,0.00010540237,0.00013142679,0.0000014357707,0.00034439383,0.040420003],"study_design_scores_gemma":[0.068097234,0.007890081,0.9220573,0.00064202276,0.00009379946,0.0000059694303,0.00023253032,0.00009650009,0.00015217268,0.00004782495,0.00049403275,0.000190553],"about_ca_topic_score_codex":0.000057112367,"about_ca_topic_score_gemma":0.00030380322,"teacher_disagreement_score":0.08014326,"about_ca_system_score_codex":0.00055821193,"about_ca_system_score_gemma":0.00083798816,"threshold_uncertainty_score":0.80062467},"labels":[],"label_agreement":null},{"id":"W3031038545","doi":"10.1200/jco.2020.38.15_suppl.e20004","title":"Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"National Institutes of Health","keywords":"Medicine; Bendamustine; Interquartile range; Internal medicine; Discontinuation; Adverse effect; Gastroenterology; Rituximab; Tolerability; Chronic lymphocytic leukemia; IGHV@; Toxicity; Leukemia; Lymphoma","score_opus":0.08658744931163549,"score_gpt":0.4047673319118335,"score_spread":0.318179882600198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031038545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050826,0.0006014043,0.0002025237,0.006017624,0.00034910606,0.0009268705,0.000007516828,0.000042028623,0.0013446788],"genre_scores_gemma":[0.9870484,0.0008439663,0.005344885,0.0037837184,0.0022239117,0.000018057179,0.000011113606,0.00008837915,0.00063756376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929636,0.0006175444,0.0032493263,0.00072643027,0.0015049119,0.0009382048],"domain_scores_gemma":[0.9918922,0.0032790932,0.0021276695,0.0005276401,0.0010068411,0.0011665672],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025213175,0.00043402184,0.002896326,0.00017547829,0.00007903139,0.000035454872,0.0006145565,0.0006446021,0.0006637902],"category_scores_gemma":[0.00818927,0.0002638909,0.00028714977,0.0010129919,0.0006427964,0.00034113417,0.00023305947,0.0023612692,0.00007511529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.37539908,0.008507741,0.21354672,0.004141651,0.0048068105,0.055650357,0.004025082,0.018521886,0.00071994774,0.00012330661,0.05664495,0.25791246],"study_design_scores_gemma":[0.5951402,0.116208404,0.1748026,0.0052345255,0.0011182217,0.0029055304,0.00049085123,0.042974986,0.00041270268,0.0000455355,0.059668574,0.0009978733],"about_ca_topic_score_codex":0.00033613003,"about_ca_topic_score_gemma":0.00063105556,"teacher_disagreement_score":0.2569146,"about_ca_system_score_codex":0.051697563,"about_ca_system_score_gemma":0.12989834,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W3031086551","doi":"10.1200/jco.2020.38.15_suppl.6014","title":"Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Concordance; Internal medicine; Surrogate endpoint; Olaparib; Progressive disease; Oncology; Chemotherapy","score_opus":0.04868816954206076,"score_gpt":0.404535055806061,"score_spread":0.3558468862640002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031086551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647968,0.00020516582,0.00014012899,0.033214286,0.00016456403,0.001242474,0.000064814085,0.000027419283,0.00014438828],"genre_scores_gemma":[0.97881913,0.00042273643,0.0038230722,0.015880777,0.0007542415,0.000075195465,0.0000144547375,0.000071671835,0.00013872412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99518937,0.0009634699,0.0022029153,0.00056482153,0.0006452818,0.00043416585],"domain_scores_gemma":[0.9947271,0.0014652228,0.0017388605,0.0002492351,0.0010084179,0.00081116706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600786,0.00037173217,0.0020098076,0.00018690711,0.00005433885,0.000021210823,0.00013956003,0.00041383517,0.00016605573],"category_scores_gemma":[0.0010511035,0.00023350479,0.00015037127,0.00071085,0.00045003145,0.00018197909,0.00003301487,0.0012718533,0.000009243151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4211328,0.0006761007,0.48879302,0.000018455028,0.0003352523,0.0010827142,0.00072421756,0.000015241247,0.00087452884,8.863959e-7,0.0010147488,0.085332036],"study_design_scores_gemma":[0.081615955,0.04921241,0.8420549,0.0015099549,0.000106312094,0.000092329974,0.000077756915,0.000031854877,0.0023603018,0.00001405623,0.022644328,0.0002798476],"about_ca_topic_score_codex":0.0000837066,"about_ca_topic_score_gemma":0.00007904867,"teacher_disagreement_score":0.35326186,"about_ca_system_score_codex":0.00042465766,"about_ca_system_score_gemma":0.0017164765,"threshold_uncertainty_score":0.9522049},"labels":[],"label_agreement":null},{"id":"W3031097250","doi":"10.1200/jco.2020.38.15_suppl.1054","title":"Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Gastroenterology; Cancer; Surgery; Estrogen receptor","score_opus":0.1833542722929642,"score_gpt":0.45652984645030714,"score_spread":0.27317557415734295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031097250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853052,0.0022193925,0.00021015943,0.010816858,0.00007680632,0.0011403821,0.00007318443,0.000021104981,0.0001369149],"genre_scores_gemma":[0.9858561,0.0033436774,0.004868193,0.00536064,0.00038524976,0.00006944588,0.000017051643,0.00007564067,0.000023981689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99381405,0.002124183,0.0020096123,0.0005586872,0.00096085254,0.00053259],"domain_scores_gemma":[0.9932329,0.003259623,0.0022382091,0.0002733292,0.0005663354,0.00042960324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028248364,0.0005151044,0.0033566998,0.00021102063,0.00007645656,0.000034525783,0.00029671603,0.00016124085,0.000103956765],"category_scores_gemma":[0.0005520821,0.00023043744,0.00019726365,0.0006220609,0.000540327,0.00057490944,0.00006597088,0.0016582946,8.011084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29495794,0.0018768135,0.5652824,0.000051868214,0.0015086337,0.0019918636,0.0013188263,0.0017888526,0.00007341994,0.000067315814,0.00003840645,0.13104366],"study_design_scores_gemma":[0.12723036,0.037874777,0.82496727,0.0007071427,0.00070772227,0.0008674316,0.0008564089,0.00014636465,0.00008613689,0.000037608803,0.006154813,0.0003639714],"about_ca_topic_score_codex":0.0005364379,"about_ca_topic_score_gemma":0.0022833173,"teacher_disagreement_score":0.25968483,"about_ca_system_score_codex":0.00041305198,"about_ca_system_score_gemma":0.001746013,"threshold_uncertainty_score":0.9396966},"labels":[],"label_agreement":null},{"id":"W3031108451","doi":"10.1200/jco.2020.38.15_suppl.tps5090","title":"A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Bladder cancer; Internal medicine; Oncology; Tolerability; Mesylate; Immunotherapy; Cancer; Urology; Adverse effect","score_opus":0.11478549514335204,"score_gpt":0.44579637863702554,"score_spread":0.33101088349367347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031108451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847512,0.00102839,0.00018459867,0.008802994,0.0017719031,0.0028483574,0.00014056863,0.000037483056,0.00043447834],"genre_scores_gemma":[0.9877292,0.004076266,0.0012833673,0.0041727154,0.0017430548,0.00012768377,0.000012441524,0.00010088276,0.0007543751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98771805,0.0032892372,0.006162874,0.00086080114,0.0011539058,0.00081513275],"domain_scores_gemma":[0.9864319,0.0068711494,0.003867692,0.00053729356,0.0010073629,0.0012846113],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040496644,0.00069070485,0.007583558,0.00043724527,0.00014802898,0.000026538944,0.0005849179,0.00082824496,0.0015452793],"category_scores_gemma":[0.013198031,0.00046910273,0.0011659958,0.0008369961,0.00075840746,0.00029872553,0.00034071328,0.0028690319,0.000032541087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88663524,0.01949721,0.0034744926,0.00016181706,0.0053590667,0.008377428,0.008211304,0.00053991674,0.0008811262,0.000015444033,0.0050845025,0.06176247],"study_design_scores_gemma":[0.8501204,0.12345165,0.011264106,0.00035049964,0.0042806542,0.00027389597,0.0025681064,0.0012194517,0.0011739589,0.000114790586,0.004674838,0.0005076291],"about_ca_topic_score_codex":0.0037047758,"about_ca_topic_score_gemma":0.0043481337,"teacher_disagreement_score":0.10395444,"about_ca_system_score_codex":0.00092239166,"about_ca_system_score_gemma":0.009400509,"threshold_uncertainty_score":0.99977607},"labels":[],"label_agreement":null},{"id":"W3031116227","doi":"10.1200/jco.2020.38.15_suppl.2055","title":"Fragility index of trials supporting approval of anti-cancer drugs in common solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Internal medicine; Clinical trial; Informed consent; Surgery; Alternative medicine; Pathology","score_opus":0.7327817692465037,"score_gpt":0.6263243023534926,"score_spread":0.10645746689301117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031116227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95588255,0.00069538906,0.00063701253,0.040533856,0.0008935502,0.00035943062,0.00009268129,0.000004461828,0.0009010805],"genre_scores_gemma":[0.9908684,0.00032974037,0.0014121818,0.006343989,0.001003806,0.000006801653,0.0000025742074,0.000015577954,0.000016961028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95725757,0.0029561843,0.038951263,0.00033182028,0.00018797058,0.0003151961],"domain_scores_gemma":[0.93916774,0.012478548,0.047482964,0.0002555155,0.0002712518,0.00034395425],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14481439,0.00014603659,0.008238612,0.00025672707,0.000026631405,0.000008771905,0.00044850056,0.00042172972,0.00047892335],"category_scores_gemma":[0.07342779,0.00014988915,0.00073086005,0.00023578161,0.00022466446,0.00028684712,0.00008914099,0.0008859102,0.000029722265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066871697,0.00076768297,0.9837273,0.00043973105,0.0002138944,0.000006091487,0.0016858621,0.00080088107,0.000028176017,0.0026003527,0.0032908046,0.0057705524],"study_design_scores_gemma":[0.01040886,0.0031871167,0.9436185,0.0002670909,0.000058909558,0.000008280389,0.0021489032,0.010281918,0.00017965228,0.015908187,0.013620293,0.00031231827],"about_ca_topic_score_codex":0.0005523845,"about_ca_topic_score_gemma":0.00010531589,"teacher_disagreement_score":0.0713866,"about_ca_system_score_codex":0.00023640059,"about_ca_system_score_gemma":0.0015862434,"threshold_uncertainty_score":0.93437713},"labels":[],"label_agreement":null},{"id":"W3031124151","doi":"10.1200/jco.2020.38.15_suppl.3016","title":"Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nausea; Pembrolizumab; Toxicity; Dosing; Internal medicine; Cancer; Urology; Gastroenterology; Nuclear medicine; Immunotherapy","score_opus":0.07339698169917563,"score_gpt":0.4612205001343791,"score_spread":0.38782351843520346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031124151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903774,0.00002624726,0.00012478269,0.008231664,0.000067596,0.00072379416,0.00002519109,0.000004759767,0.00041852615],"genre_scores_gemma":[0.9976402,0.00015669326,0.0014899865,0.0004783103,0.00017698528,0.000006729083,0.000021922835,0.0000140550155,0.000015118753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99587137,0.00023130637,0.0030906664,0.00024634352,0.00036483802,0.00019545597],"domain_scores_gemma":[0.9959466,0.0012669084,0.0019777215,0.00013041805,0.00031295005,0.00036540363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010957225,0.00016379365,0.0017034812,0.00010106516,0.0000229817,0.000003008495,0.00014800947,0.00015619429,0.00003834947],"category_scores_gemma":[0.0021481689,0.00010856915,0.00010437434,0.00042466124,0.0003682237,0.00012340421,0.000048479465,0.0010525398,3.3749853e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9242161,0.016746813,0.0034583916,0.000109670545,0.0001338624,0.00018120692,0.00026108362,0.00018722563,0.0021201447,0.000024368428,0.00007818538,0.052482966],"study_design_scores_gemma":[0.8412326,0.108771026,0.04228037,0.00041110598,0.0003279987,0.000052137915,0.00008667254,0.0026241944,0.0032047017,0.000044983062,0.0008197806,0.00014440695],"about_ca_topic_score_codex":0.000006097069,"about_ca_topic_score_gemma":0.000008965828,"teacher_disagreement_score":0.092024215,"about_ca_system_score_codex":0.000080817976,"about_ca_system_score_gemma":0.0008433471,"threshold_uncertainty_score":0.45728204},"labels":[],"label_agreement":null},{"id":"W3031129979","doi":"10.1200/jco.2020.38.15_suppl.1581","title":"Using sequential next-generation sequencing assays to identify germline cancer predisposition variants.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Germline; Germline mutation; Genetics; DNA sequencing; Cancer; Allele; Somatic cell; Medicine; Biology; Computational biology; Mutation; Gene","score_opus":0.33079671923169857,"score_gpt":0.4857790654233472,"score_spread":0.15498234619164863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031129979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95140797,0.0005072043,0.04159143,0.0039208103,0.0022692755,0.0001255212,0.00003221312,0.0000030915771,0.00014247841],"genre_scores_gemma":[0.9713244,0.00076648855,0.009256466,0.0076897023,0.0109070875,0.0000029700593,0.000019345263,0.000018387544,0.000015149364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794525,0.00021328378,0.0012523538,0.0002382302,0.00017600505,0.00017489665],"domain_scores_gemma":[0.9982216,0.00009823444,0.00082298904,0.00011531692,0.00038945628,0.00035244826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010363539,0.0001130997,0.000459307,0.000037933787,0.00005438334,0.00003940457,0.0001820885,0.00030912526,0.000056392546],"category_scores_gemma":[0.0018000541,0.000106023166,0.00024508423,0.000091104856,0.00004446548,0.000015896996,0.00010763559,0.00029013137,0.0000053033623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006157573,0.00009009355,0.0016834467,0.000009442061,0.00014641193,0.000064033986,0.000060896324,0.016880525,0.96050435,0.00003685515,0.0062788404,0.013629343],"study_design_scores_gemma":[0.017943002,0.03612562,0.039218623,0.0002843737,0.0023312448,0.000744434,0.00045504814,0.10705325,0.45314097,0.0006006155,0.34033263,0.0017701826],"about_ca_topic_score_codex":0.00006448547,"about_ca_topic_score_gemma":0.00011355011,"teacher_disagreement_score":0.5073634,"about_ca_system_score_codex":0.00013738581,"about_ca_system_score_gemma":0.0017197453,"threshold_uncertainty_score":0.43234992},"labels":[],"label_agreement":null},{"id":"W3031149933","doi":"10.1200/jco.2020.38.15_suppl.e14025","title":"First validation of the supportive care score (SCC) scale: Alert scale for referral of solid cancer patients to supportive oncology team.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Referral; Cancer; Anxiety; Ambulatory; Internal medicine; Physical therapy; Emergency medicine; Family medicine; Psychiatry; Nursing","score_opus":0.12954832381902817,"score_gpt":0.4652575828470783,"score_spread":0.33570925902805016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031149933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97668856,0.00011962353,0.00014944843,0.018145813,0.0027091391,0.0008541062,0.00029665034,0.000005857178,0.0010307909],"genre_scores_gemma":[0.9934893,0.00013361138,0.00042810448,0.004632295,0.0011030083,0.00003281474,0.000021220798,0.000025016023,0.00013458985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958194,0.00033309168,0.0027662308,0.0002767593,0.00052225025,0.0002822615],"domain_scores_gemma":[0.99270815,0.0009874157,0.0029683888,0.00021316887,0.0026427954,0.00048006422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009711417,0.00017612656,0.0018478839,0.0000853423,0.00005285925,0.000002947145,0.00032044246,0.00045159354,0.00020997727],"category_scores_gemma":[0.0027461182,0.0001164135,0.00081734895,0.00028529856,0.00030633787,0.000090938694,0.00013160318,0.0006705877,0.0000029921216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016716737,0.0014070288,0.89422506,0.000484174,0.00039675957,0.000016652491,0.013669091,0.00013112904,0.0005488577,0.00000865479,0.033179134,0.039216734],"study_design_scores_gemma":[0.011996556,0.054807104,0.77125967,0.0006014564,0.0013810222,0.000018980172,0.007309279,0.000044922428,0.019554928,0.00007877122,0.13272555,0.0002217738],"about_ca_topic_score_codex":0.00017908752,"about_ca_topic_score_gemma":0.0030307686,"teacher_disagreement_score":0.122965395,"about_ca_system_score_codex":0.0004020538,"about_ca_system_score_gemma":0.0031959105,"threshold_uncertainty_score":0.5669408},"labels":[],"label_agreement":null},{"id":"W3031150485","doi":"10.1200/jco.2020.38.15_suppl.e18033","title":"Recurrent vulvar squamous cell carcinoma: An analysis of clinical outcomes by treatment modality including surgery, chemotherapy, and radiation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Surgery; Stage (stratigraphy)","score_opus":0.3038783822287922,"score_gpt":0.5372430724392079,"score_spread":0.23336469021041567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031150485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97590286,0.0014307405,0.0001225366,0.021425925,0.0003182669,0.00018211406,0.000029026254,0.000006732361,0.0005817846],"genre_scores_gemma":[0.9931064,0.002686983,0.0003253912,0.0030968287,0.0007140589,0.0000027193757,0.000018867982,0.000014151142,0.00003459619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940706,0.0010439275,0.0037661467,0.00033347428,0.0005431683,0.00024269188],"domain_scores_gemma":[0.9891152,0.0073891897,0.0016860284,0.00022643525,0.00046610762,0.0011170559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047498364,0.00016812416,0.0035855523,0.00017859602,0.000043095573,0.000010618005,0.00014744443,0.0003627071,0.0007089982],"category_scores_gemma":[0.0042435415,0.000112392154,0.0013759702,0.00040143848,0.00024194366,0.00008810353,0.000060079674,0.00075899035,0.0000021581202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00451195,0.0025555564,0.7224086,0.000036441892,0.0007263625,0.000055663077,0.0001656797,0.000009359392,0.000014346095,0.0000057100387,0.001499843,0.2680105],"study_design_scores_gemma":[0.008949562,0.01634945,0.95758456,0.0000028063846,0.0020348064,0.0000061498927,0.00011977167,0.0023345181,0.00008500072,0.000031347878,0.012410534,0.000091486225],"about_ca_topic_score_codex":0.00024821458,"about_ca_topic_score_gemma":0.000089521614,"teacher_disagreement_score":0.267919,"about_ca_system_score_codex":0.00018534971,"about_ca_system_score_gemma":0.0013841094,"threshold_uncertainty_score":0.7763033},"labels":[],"label_agreement":null},{"id":"W3031163605","doi":"10.1200/jco.2020.38.15_suppl.e21040","title":"Liquid chromatography coupled to multiple reaction monitoring (LC-MRM) for quantification of PD-L1 and PD1-signaling proteins in non-small cell lung carcinoma (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Genome Canada","keywords":"Immunohistochemistry; Selected reaction monitoring; PD-L1; Medicine; Cancer research; Fixation (population genetics); Immunotherapy; Molecular biology; Pathology; Chemistry; Mass spectrometry; Tandem mass spectrometry; Immune system; Biology; Immunology; Chromatography; Population","score_opus":0.09661896366092472,"score_gpt":0.43607204090373164,"score_spread":0.33945307724280693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031163605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895663,0.00039896558,0.0057325023,0.0027647791,0.0004165133,0.0010147963,0.000005439986,0.000006600852,0.00009409323],"genre_scores_gemma":[0.98440427,0.00012322857,0.014551696,0.00022082779,0.00061732874,0.000047342033,0.0000050555896,0.000016316968,0.000013939848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979971,0.00008044231,0.0014321326,0.00019110793,0.00015214158,0.00014705575],"domain_scores_gemma":[0.99752986,0.0007595178,0.00096931297,0.00009644276,0.0003704331,0.0002744422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008260607,0.00010439169,0.00076824235,0.00015611417,0.00003752897,0.0000065768522,0.000066718465,0.00017904729,0.000003738296],"category_scores_gemma":[0.0009079955,0.00008509906,0.00021802865,0.00020088622,0.00003969747,0.00008274116,0.000017964876,0.0002951785,0.0000011912683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012963554,0.0016232152,0.54086775,0.00052347285,0.0003279266,0.000075781674,0.0021572497,0.00026140068,0.42973384,0.00001545164,0.0001964037,0.011253941],"study_design_scores_gemma":[0.022273285,0.022648057,0.89534837,0.0005928106,0.0011667985,0.000032734697,0.0012989463,0.0055195736,0.04771578,0.000021142805,0.0031965268,0.00018596787],"about_ca_topic_score_codex":0.000108855485,"about_ca_topic_score_gemma":0.000025783223,"teacher_disagreement_score":0.38201806,"about_ca_system_score_codex":0.000105715066,"about_ca_system_score_gemma":0.0005965475,"threshold_uncertainty_score":0.3470239},"labels":[],"label_agreement":null},{"id":"W3031183771","doi":"10.1200/jco.2020.38.15_suppl.6062","title":"Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intestinal and Peritoneal Adhesions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Ambulatory; Prospective cohort study; Guideline; Palliative care; Colorectal cancer; Multidisciplinary approach; Cancer; General surgery; Surgery; Internal medicine; Nursing","score_opus":0.11651450689706506,"score_gpt":0.4144329528369105,"score_spread":0.29791844593984546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031183771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436784,0.000043201107,0.000100683406,0.0019108782,0.00045350677,0.002332815,0.00009725834,0.00002651119,0.00066732283],"genre_scores_gemma":[0.9674442,0.0000559546,0.03129244,0.00018752858,0.0007380512,0.00015709108,0.00001035476,0.000018795541,0.00009562011],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99625725,0.00032937297,0.002317048,0.00041364238,0.00039038746,0.0002922775],"domain_scores_gemma":[0.9950152,0.001573723,0.0021899869,0.0001752387,0.000614507,0.00043133277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001204198,0.00020512208,0.0013003075,0.00005233164,0.00008808233,0.000009197944,0.00016707086,0.00023603396,0.000044170032],"category_scores_gemma":[0.0012733642,0.00012528236,0.0002718447,0.00015165504,0.00027794973,0.00009292055,0.000103616556,0.00080069975,0.0000026367481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46819335,0.02796001,0.34151286,0.00028222174,0.0029939723,0.0030784656,0.0058230967,0.0002653796,0.0004936191,0.000028475553,0.0008573537,0.14851119],"study_design_scores_gemma":[0.017561609,0.26772764,0.704477,0.00022650778,0.0006074617,0.00008277243,0.0076847123,0.00048001375,0.000072617666,0.00021962999,0.0007490884,0.000110934234],"about_ca_topic_score_codex":0.000033019678,"about_ca_topic_score_gemma":0.000044430846,"teacher_disagreement_score":0.45063174,"about_ca_system_score_codex":0.00037662152,"about_ca_system_score_gemma":0.00058807293,"threshold_uncertainty_score":0.5108866},"labels":[],"label_agreement":null},{"id":"W3031186117","doi":"10.1200/jco.2020.38.15_suppl.12071","title":"Effects of GC4419 (avasopasem manganese) on chronic kidney disease in head and neck cancer patients treated with radiation and cisplatin.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; Health Sciences North","funders":"","keywords":"Medicine; Kidney disease; Renal function; Mucositis; Internal medicine; Head and neck cancer; Placebo; Cancer; Population; Nephrotoxicity; Creatinine; Adverse effect; Acute kidney injury; Urology; Radiation therapy; Surgery; Kidney; Pathology","score_opus":0.04153603501043827,"score_gpt":0.4061209020341034,"score_spread":0.3645848670236651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031186117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989761,0.0023917744,0.0000011785867,0.007355274,0.00012724617,0.0002465104,0.000006648593,0.0000031738,0.00010719607],"genre_scores_gemma":[0.9924459,0.004423026,0.000047989408,0.0026983714,0.00035533137,0.0000056951344,0.0000024335943,0.000008940177,0.000012348901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986471,0.00015421804,0.0007529745,0.00014450932,0.00018026361,0.000120913435],"domain_scores_gemma":[0.99795157,0.0008367046,0.0005177693,0.000045296234,0.000110507855,0.00053815416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023500025,0.00009987926,0.0009819686,0.0000594465,0.000017972821,0.0000023549567,0.000029969005,0.00009886564,0.000012686572],"category_scores_gemma":[0.0017390504,0.000063240215,0.0000651866,0.00010978357,0.00011002139,0.00005064856,0.00001824579,0.0003482777,6.6886463e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01081318,0.00062299037,0.90624917,0.00039410123,0.00013378783,0.0002569655,0.00018874487,0.0000069477464,0.00007143461,0.0000037198233,0.00090212916,0.08035686],"study_design_scores_gemma":[0.021486355,0.03880367,0.9353077,0.0008640973,0.00026796112,0.000003898906,0.0000078324665,0.0001951781,0.0001317115,0.000004805059,0.0028721262,0.00005466699],"about_ca_topic_score_codex":0.000037543825,"about_ca_topic_score_gemma":0.000051347786,"teacher_disagreement_score":0.080302194,"about_ca_system_score_codex":0.000103962026,"about_ca_system_score_gemma":0.000741382,"threshold_uncertainty_score":0.2578861},"labels":[],"label_agreement":null},{"id":"W3031210843","doi":"10.1200/jco.2020.38.15_suppl.2513","title":"MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Cancer Prevention and Research Institute of Texas","keywords":"Medicine; Pseudomonas exotoxin; Clinical endpoint; Internal medicine; Population; Oncology; Surgery; Gastroenterology; Clinical trial; Recombinant DNA","score_opus":0.07652944038184845,"score_gpt":0.4307242144887502,"score_spread":0.35419477410690176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031210843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896679,0.00022059485,0.00013244389,0.008537601,0.0007046054,0.0003044492,0.0000158574,0.0000031225227,0.00041340588],"genre_scores_gemma":[0.996896,0.00015517615,0.00021132853,0.0019939502,0.0006728701,0.000016109749,0.0000059675363,0.00001631105,0.0000322513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969521,0.00087246555,0.0012725666,0.00027245475,0.00032887913,0.00030149418],"domain_scores_gemma":[0.9979979,0.00046118206,0.0006190475,0.00018819491,0.00027040302,0.0004633048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011158991,0.00015095211,0.0007453255,0.00004948724,0.00005930899,0.000022683409,0.00043413087,0.00018499902,0.00007098417],"category_scores_gemma":[0.0037724043,0.00009062685,0.0003101778,0.0001223854,0.00012946506,0.000008100235,0.00022936458,0.00051685254,0.000043166794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22216947,0.009085191,0.2244697,0.000086962005,0.002145476,0.0006117657,0.002429732,0.00051810296,0.0415132,0.000041065265,0.059919674,0.43700963],"study_design_scores_gemma":[0.050569642,0.114673324,0.12015707,0.00039549236,0.00023643185,0.000084046886,0.0009906625,0.0002892528,0.015333429,0.00023223297,0.69639146,0.00064695446],"about_ca_topic_score_codex":0.000042559517,"about_ca_topic_score_gemma":0.00046773782,"teacher_disagreement_score":0.6364718,"about_ca_system_score_codex":0.00009521198,"about_ca_system_score_gemma":0.0005570862,"threshold_uncertainty_score":0.45161927},"labels":[],"label_agreement":null},{"id":"W3031211198","doi":"10.1200/jco.2020.38.15_suppl.7520","title":"A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Myeloid leukemia; Family medicine; Internal medicine","score_opus":0.6410594235326907,"score_gpt":0.5639875825057539,"score_spread":0.07707184102693687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031211198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354032,0.000738801,0.00303678,0.058323525,0.0011626688,0.0010890851,0.000016453794,0.000014439154,0.00021504443],"genre_scores_gemma":[0.9694068,0.0008935477,0.007869364,0.020186512,0.001347934,0.0002326108,0.0000026073035,0.00003736623,0.000023303124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9848841,0.004300622,0.009753771,0.00049258256,0.00017765019,0.0003912772],"domain_scores_gemma":[0.98436755,0.007823642,0.0068875905,0.00039624187,0.00010886114,0.00041611167],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033359863,0.00026185127,0.0032497435,0.00019565511,0.0000935268,0.00004918557,0.0005266783,0.00022748287,0.00007714097],"category_scores_gemma":[0.0073172473,0.00017483468,0.0004432036,0.00023927314,0.00007760613,0.00037494462,0.00006762778,0.00082496356,0.00008010837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063202716,0.009698601,0.53651625,0.00021138706,0.0036438117,0.0006680955,0.10695459,0.0005974393,0.0000016166525,0.0020967848,0.014001759,0.31928942],"study_design_scores_gemma":[0.018224863,0.019064263,0.8937219,0.00013391343,0.00019186769,0.00006083716,0.02706648,0.0021950582,0.00000327419,0.0009872727,0.03803524,0.00031502882],"about_ca_topic_score_codex":0.00032855172,"about_ca_topic_score_gemma":0.0006096486,"teacher_disagreement_score":0.35720566,"about_ca_system_score_codex":0.0010978949,"about_ca_system_score_gemma":0.00078772096,"threshold_uncertainty_score":0.9953594},"labels":[],"label_agreement":null},{"id":"W3031215633","doi":"10.1200/jco.2020.38.15_suppl.11505","title":"Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Progressive disease; Clinical endpoint; Oncology; Sarcoma; Neoadjuvant therapy; Cohort; Pathology; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy; Breast cancer","score_opus":0.1772293650814535,"score_gpt":0.44438812813890505,"score_spread":0.26715876305745156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031215633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895232,0.0014585834,0.000054797427,0.007246168,0.00029064025,0.0012646402,0.000075658514,0.000015251459,0.000071089664],"genre_scores_gemma":[0.997496,0.0005701035,0.0012040649,0.0002481882,0.0003599089,0.000023723647,0.00003276682,0.00003292394,0.000032305314],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99303544,0.00068173173,0.004919607,0.0004260046,0.0005839588,0.00035326104],"domain_scores_gemma":[0.9903152,0.0042205187,0.0035317568,0.00031854335,0.00092001737,0.0006939896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020184726,0.00029464278,0.0032445472,0.00021130902,0.00007999913,0.000008851398,0.0002475158,0.00039345762,0.00007429741],"category_scores_gemma":[0.005004955,0.00020214391,0.0006731447,0.00029465195,0.0002456151,0.00007590398,0.00022729504,0.0007280642,0.0000011338648],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4376007,0.21370243,0.21780887,0.0005767222,0.007752501,0.0039333785,0.0034718744,0.000027583565,0.013417774,0.000055524324,0.00348661,0.09816604],"study_design_scores_gemma":[0.17578624,0.4520607,0.3591805,0.00037255613,0.0033437226,0.0003393884,0.00068553176,0.0016884196,0.00449612,0.0001436604,0.0017169466,0.000186197],"about_ca_topic_score_codex":0.00008229866,"about_ca_topic_score_gemma":0.00005423927,"teacher_disagreement_score":0.26181448,"about_ca_system_score_codex":0.00006133513,"about_ca_system_score_gemma":0.00069384085,"threshold_uncertainty_score":0.82431895},"labels":[],"label_agreement":null},{"id":"W3031216611","doi":"10.1200/jco.2020.38.15_suppl.10559","title":"Prevalence and predictors of high-intensity end-of-life care among adolescents and young adults with cancer in Ontario: a population-based study using the IMPACT cohort.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Ottawa; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; End-of-life care; Population; Retrospective cohort study; Emergency department; Intensive care unit; Mechanical ventilation; Cohort; Cause of death; Emergency medicine; Cancer; Young adult; Advance care planning; Cohort study; Pediatrics; Palliative care; Internal medicine; Disease; Nursing","score_opus":0.06988675279267693,"score_gpt":0.41452793812719557,"score_spread":0.34464118533451865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031216611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978642,0.00040002438,0.000016108901,0.000693054,0.00032749586,0.0006745251,0.000016672859,0.00000350522,0.0000044130124],"genre_scores_gemma":[0.99906254,0.000060431936,0.00015746304,0.00046907572,0.00023412971,0.0000022032843,0.0000013415025,0.000011653242,0.0000011380602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679977,0.0005104714,0.0018120796,0.00022268816,0.00050977565,0.0001452179],"domain_scores_gemma":[0.9964253,0.0006091589,0.0019674571,0.00015280659,0.00050220115,0.00034308128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013997537,0.00014499466,0.0015310668,0.000066550616,0.000029333201,0.0000051618,0.00011177101,0.00014675167,0.000026670776],"category_scores_gemma":[0.0017680544,0.00008725568,0.00013512334,0.00013051632,0.0002527771,0.0000900688,0.000052366846,0.00084557536,3.1399583e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01206257,0.0005708821,0.97878826,0.00028599365,0.00033095098,0.00004535652,0.006949799,0.0004398189,0.0000039379875,2.0168576e-7,0.000012045302,0.00051018613],"study_design_scores_gemma":[0.009612248,0.008944768,0.9766931,0.0014748633,0.00058839377,0.000015410906,0.0022319176,0.0003582173,0.0000044785024,0.000001992218,0.0000019440051,0.00007268358],"about_ca_topic_score_codex":0.23504241,"about_ca_topic_score_gemma":0.3391677,"teacher_disagreement_score":0.10412531,"about_ca_system_score_codex":0.0002587614,"about_ca_system_score_gemma":0.002610968,"threshold_uncertainty_score":0.7700515},"labels":[],"label_agreement":null},{"id":"W3031218912","doi":"10.1200/jco.2020.38.15_suppl.e13632","title":"Reproductive risk factor patterns in the Caribbean affecting breast cancer age of onset.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Menarche; Demography; Family history; Cancer; Gynecology; Logistic regression; Pregnancy; Obstetrics; Internal medicine","score_opus":0.15733526688501587,"score_gpt":0.47861316038366375,"score_spread":0.3212778934986479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031218912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733922,0.0002186749,0.00007229793,0.025123283,0.0007241795,0.00018332625,0.00009709677,0.00000363317,0.0001853128],"genre_scores_gemma":[0.9945174,0.0008708589,0.00008544924,0.0022129659,0.0022913434,0.000001743473,0.0000010707696,0.00001077735,0.000008428432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972633,0.00061646197,0.0014807412,0.00019179874,0.0002891186,0.00015856775],"domain_scores_gemma":[0.9960576,0.0017296983,0.0016628605,0.00017450545,0.00019231699,0.00018298424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00206234,0.000101397534,0.0011231669,0.000054180993,0.000022474904,0.000004764141,0.00016791098,0.00017626933,0.00018920917],"category_scores_gemma":[0.003469966,0.000057115747,0.00040605164,0.00017099892,0.00012946923,0.000056967478,0.00003781624,0.0015735554,0.0000017269437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022020156,0.00036927246,0.8918982,0.00003064489,0.00018104896,0.0004086217,0.0031406812,0.000023196466,0.00012082175,0.000002525099,0.00077769236,0.10084529],"study_design_scores_gemma":[0.002759575,0.0036284868,0.98623,0.00008921373,0.00023064158,0.00017261367,0.0015861369,0.000020074143,0.000060343325,0.000027014976,0.005142156,0.000053717184],"about_ca_topic_score_codex":0.0015515925,"about_ca_topic_score_gemma":0.0010094423,"teacher_disagreement_score":0.10079157,"about_ca_system_score_codex":0.000109052824,"about_ca_system_score_gemma":0.0006940496,"threshold_uncertainty_score":0.6836403},"labels":[],"label_agreement":null},{"id":"W3031233120","doi":"10.1200/jco.2020.38.15_suppl.4618","title":"Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Concordance; Hazard ratio; Internal medicine; Randomization; Adjuvant therapy; Gemcitabine; Oncology; Distributed File System; Clinical trial; Cancer; Clinical endpoint; Surgery; Confidence interval","score_opus":0.33894063844081623,"score_gpt":0.5483053384502897,"score_spread":0.2093647000094735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031233120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92646104,0.00027394202,0.00012114599,0.06995358,0.00030358156,0.00047789147,0.000009491754,0.0000027907006,0.002396504],"genre_scores_gemma":[0.99202085,0.0006183774,0.0015179524,0.0041305497,0.0016677476,0.000007117175,0.0000017861595,0.000008604366,0.000027012387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945738,0.0019366929,0.002335965,0.00018062875,0.0007611799,0.00021174799],"domain_scores_gemma":[0.9865997,0.010490123,0.0013717368,0.0002683752,0.00025225707,0.0010178144],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00944614,0.000114708804,0.0020590061,0.000076433804,0.000026942143,0.000007011143,0.00038515765,0.00024747034,0.000057259684],"category_scores_gemma":[0.027820587,0.00006640154,0.00025435298,0.00018263973,0.0006193367,0.000067852925,0.00012453452,0.0014968745,0.0000021682015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01966773,0.00073830644,0.97145534,0.000069430054,0.00026400178,0.0004387927,0.00019650835,0.000001049083,0.000026833442,0.00039924617,0.002596756,0.004145981],"study_design_scores_gemma":[0.060617298,0.019340541,0.9115855,0.00007383568,0.0004930002,0.00002128039,0.00039059122,0.00014214785,0.0000028960856,0.0012358286,0.006043371,0.000053699332],"about_ca_topic_score_codex":0.000025306636,"about_ca_topic_score_gemma":0.000020277494,"teacher_disagreement_score":0.06582303,"about_ca_system_score_codex":0.00008007208,"about_ca_system_score_gemma":0.005127515,"threshold_uncertainty_score":0.9803685},"labels":[],"label_agreement":null},{"id":"W3031239197","doi":"10.1200/jco.2020.38.15_suppl.e14505","title":"CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cumulative incidence; Cohort; Radiation therapy; Chemotherapy; Incidence (geometry); Lung cancer","score_opus":0.07697062753607034,"score_gpt":0.3951752315358707,"score_spread":0.31820460399980033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031239197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637177,0.00028672174,0.00004800369,0.034757618,0.00024076866,0.00049342465,0.000016115777,0.000017518085,0.00042215455],"genre_scores_gemma":[0.9883117,0.00008399001,0.005320722,0.005815472,0.0002905315,0.0000055633955,0.000032990738,0.00003990522,0.000099133555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953347,0.00067650026,0.002719196,0.00032659114,0.00058825786,0.0003547647],"domain_scores_gemma":[0.9950895,0.0017711854,0.0017889832,0.0002462364,0.0004712305,0.00063290854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017332671,0.00031451375,0.00266022,0.00016742271,0.00003950187,0.00001373171,0.00015552453,0.00023287043,0.000183831],"category_scores_gemma":[0.0032094992,0.00016383702,0.0004972438,0.0004647254,0.00024531776,0.00015201805,0.000057036897,0.0010243218,0.000021910715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020094818,0.0060023554,0.93877864,0.00003416684,0.0019606594,0.0028547633,0.00015863293,0.000054439373,0.000062884676,0.000026065036,0.0013869153,0.028585667],"study_design_scores_gemma":[0.045652453,0.080346055,0.8516177,0.0002256645,0.001330817,0.0001272134,0.000262134,0.000023686196,0.0002955205,0.000019358113,0.019895166,0.00020421072],"about_ca_topic_score_codex":0.00010694728,"about_ca_topic_score_gemma":0.000099410885,"teacher_disagreement_score":0.087160915,"about_ca_system_score_codex":0.0001823008,"about_ca_system_score_gemma":0.0010037731,"threshold_uncertainty_score":0.668108},"labels":[],"label_agreement":null},{"id":"W3031257206","doi":"10.1200/jco.2020.38.15_suppl.e20001","title":"Clonal lineage analysis of CLL research samples by IGH chain sequencing to reveal novel CLL subgroups defined by ongoing class-switch recombination and somatic hypermutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"Thermo Fisher Scientific","keywords":"Somatic hypermutation; Immunoglobulin class switching; Biology; Genetics; Chronic lymphocytic leukemia; breakpoint cluster region; Molecular biology; Gene; B cell; Antibody; Leukemia","score_opus":0.29517940042495433,"score_gpt":0.49828547135339674,"score_spread":0.2031060709284424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031257206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710132,0.00037757357,0.0050025918,0.02258191,0.00015769374,0.00040331765,0.000044561264,0.000012599563,0.00040659073],"genre_scores_gemma":[0.98422027,0.0003952593,0.012312795,0.0023091075,0.00048595338,0.000009121734,0.000060397626,0.00003166895,0.0001754409],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929456,0.0010811156,0.0034912173,0.00046083124,0.0015111136,0.0005100934],"domain_scores_gemma":[0.9820194,0.013844159,0.0013611534,0.0002627834,0.0015477119,0.00096475217],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012252095,0.00019384288,0.0021445404,0.0006477761,0.000099226316,0.00003294489,0.00033322253,0.0004969252,0.00008869963],"category_scores_gemma":[0.03398191,0.00015902736,0.00044457105,0.0017336918,0.00033959295,0.00017532468,0.00019770594,0.0016176888,0.00001112839],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02343307,0.007955325,0.08343484,0.0021080943,0.011062747,0.0014059695,0.0077476026,0.0021584383,0.6249102,0.002265655,0.12596773,0.10755037],"study_design_scores_gemma":[0.16193923,0.08955515,0.11964647,0.0016155171,0.009128878,0.0015256177,0.006856751,0.54639417,0.02128453,0.0017386678,0.038941707,0.0013733442],"about_ca_topic_score_codex":0.00040296328,"about_ca_topic_score_gemma":0.000116604104,"teacher_disagreement_score":0.60362566,"about_ca_system_score_codex":0.004767921,"about_ca_system_score_gemma":0.010093187,"threshold_uncertainty_score":0.9990526},"labels":[],"label_agreement":null},{"id":"W3031273809","doi":"10.1200/jco.2020.38.15_suppl.8519","title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Renal function; Internal medicine; Gastroenterology; Tolerability; Neutropenia; Anemia; Creatinine; Population; Urology; Surgery; Adverse effect; Toxicity","score_opus":0.09016006363210953,"score_gpt":0.3858816295409379,"score_spread":0.29572156590882837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031273809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935963,0.00023136768,0.000041016458,0.004748968,0.00020540137,0.00051814056,0.000017248603,0.000013555059,0.0006279702],"genre_scores_gemma":[0.99395937,0.00020688272,0.0036791228,0.001560188,0.00045993982,0.0000058685196,0.000019571129,0.000031038875,0.00007802255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960336,0.0005313595,0.0019061451,0.00035095646,0.000726762,0.00045119133],"domain_scores_gemma":[0.9955993,0.0016037113,0.0010608459,0.00018576243,0.00033547555,0.0012148503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001177513,0.00023494156,0.0014392185,0.00017471833,0.000050384795,0.000016466396,0.00015794122,0.0003263179,0.00015109958],"category_scores_gemma":[0.0034732,0.0001513391,0.0002447218,0.00020418418,0.0002419587,0.000175504,0.00011442334,0.0013285406,0.000027562435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03447106,0.005485079,0.845224,0.000042134536,0.0004215459,0.002438722,0.00014963212,0.0000050129393,0.00019786769,0.0000027911742,0.0012535516,0.110308595],"study_design_scores_gemma":[0.05576918,0.056865573,0.8741105,0.00016398185,0.0001680807,0.00010310574,0.00007841337,0.00014651676,0.00010399536,0.000012279599,0.012355078,0.00012328061],"about_ca_topic_score_codex":0.00003065373,"about_ca_topic_score_gemma":0.00007236687,"teacher_disagreement_score":0.11018531,"about_ca_system_score_codex":0.0002843616,"about_ca_system_score_gemma":0.0008588657,"threshold_uncertainty_score":0.617143},"labels":[],"label_agreement":null},{"id":"W3031285742","doi":"10.1200/jco.2020.38.15_suppl.11513","title":"Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional TARPSWG study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Sarcoma; Systemic therapy; Neoadjuvant therapy; Internal medicine; Radiation therapy; Surgery; Oncology; Cancer; Radiology; Breast cancer; Pathology","score_opus":0.08580589145852363,"score_gpt":0.4097744949523239,"score_spread":0.32396860349380024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031285742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98192126,0.011987086,0.000026090822,0.005052677,0.00043061917,0.00043659654,0.000007677174,0.0000064633678,0.0001315128],"genre_scores_gemma":[0.9942119,0.0021885342,0.0019399773,0.0011045601,0.0005234756,0.000014500566,0.0000017247776,0.000012666992,0.0000026705216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959073,0.00090133847,0.0023901074,0.00019632453,0.00042029988,0.00018460953],"domain_scores_gemma":[0.9957309,0.002111582,0.0014936822,0.00017833592,0.00025727705,0.00022823828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023009651,0.00015384052,0.0016149334,0.00007667377,0.000056028835,0.000006589782,0.0002131045,0.00018873677,0.000040949824],"category_scores_gemma":[0.0025068668,0.00007637026,0.0004392283,0.00019231826,0.00019082523,0.000056847824,0.000060582002,0.0010103171,0.000014997373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031112712,0.006099752,0.8334743,0.0000074122568,0.00048529817,0.0011386124,0.0006361443,0.00012791478,0.00009054901,0.00029974838,0.000089190755,0.15443982],"study_design_scores_gemma":[0.023822412,0.022182165,0.94714594,0.00013035342,0.00030553175,0.00039802646,0.0018606306,0.0005819169,0.000113764014,0.000056213714,0.0033337108,0.00006936597],"about_ca_topic_score_codex":0.00035599814,"about_ca_topic_score_gemma":0.000103043,"teacher_disagreement_score":0.15437046,"about_ca_system_score_codex":0.00014255145,"about_ca_system_score_gemma":0.001058756,"threshold_uncertainty_score":0.43893814},"labels":[],"label_agreement":null},{"id":"W3031285794","doi":"10.1200/jco.2020.38.15_suppl.11020","title":"Exploring glocalization in the construction and implementation of global curricula.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Snowball sampling; Curriculum; Context (archaeology); Medicine; Medical education; Engineering ethics; Sociology; Pedagogy; Engineering","score_opus":0.2308863016799335,"score_gpt":0.5674420779701448,"score_spread":0.3365557762902113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031285794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972256,0.00048405214,0.008362443,0.017931443,0.000599988,0.000112814814,0.0000010564223,0.0000020996783,0.00025008735],"genre_scores_gemma":[0.9839138,0.0033092084,0.0087897265,0.003270744,0.00071186246,0.0000016096586,7.2391003e-7,0.0000020395942,3.317527e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985267,0.00025935954,0.0009725423,0.00006289877,0.00011991454,0.00005859965],"domain_scores_gemma":[0.9985804,0.0005252357,0.00070312124,0.000035426943,0.00009456793,0.00006122897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009998746,0.000040803094,0.00042564567,0.000017052376,0.000014615923,0.0000013293883,0.000047751728,0.00008754131,0.00002300475],"category_scores_gemma":[0.0006707559,0.000024399485,0.00007255941,0.00014819209,0.00019456416,0.00011947265,0.000008330323,0.00024982417,3.6866703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007649098,0.000121431665,0.5844088,0.000015418847,0.00003982752,0.000055320546,0.00031938753,0.000033051347,0.000048803613,0.0019449319,0.00018687433,0.4120612],"study_design_scores_gemma":[0.007756659,0.009851113,0.9400924,0.000042965694,0.00014027393,0.0007402227,0.0036416915,0.00018576087,0.00006809595,0.0012269854,0.036210712,0.000043127944],"about_ca_topic_score_codex":0.000004636961,"about_ca_topic_score_gemma":0.000013573046,"teacher_disagreement_score":0.4120181,"about_ca_system_score_codex":0.000054207296,"about_ca_system_score_gemma":0.0002670609,"threshold_uncertainty_score":0.10853756},"labels":[],"label_agreement":null},{"id":"W3031292296","doi":"10.1200/jco.2020.38.15_suppl.3064","title":"Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dosing; Neutropenia; Pharmacodynamics; Pharmacokinetics; Adverse effect; Internal medicine; Cmax; Antibody; Anemia; Oncology; Leukopenia; Pharmacology; Gastroenterology; Toxicity; Immunology","score_opus":0.13734463295780808,"score_gpt":0.46658433866071186,"score_spread":0.3292397057029038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031292296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622893,0.0004177994,0.000025904523,0.0014963059,0.0011494991,0.0002829256,0.000024159252,0.0000085515285,0.00036590712],"genre_scores_gemma":[0.9993557,0.00014072079,0.000073385396,0.00013452201,0.00021688179,0.0000018210986,0.000025583979,0.00001350936,0.000037876],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99265677,0.0014733891,0.005186286,0.0002839092,0.00012651412,0.0002731257],"domain_scores_gemma":[0.9926953,0.0017513324,0.0047080247,0.00029152798,0.00046906708,0.00008477739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034654243,0.00019224538,0.0024354719,0.00020220863,0.00008633321,0.000004665165,0.000496097,0.00056581304,0.00015181975],"category_scores_gemma":[0.0033526267,0.00015291461,0.00043498658,0.00028175328,0.00036417623,0.00015957798,0.00015745907,0.0010637009,0.000010789583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021546626,0.051103324,0.119381055,0.000120437435,0.0017966175,0.00027200498,0.003523009,0.0002600101,0.780608,0.00040214724,0.0067487066,0.014238097],"study_design_scores_gemma":[0.09748911,0.10139204,0.75679725,0.00016649818,0.00047256437,0.000049874805,0.0011101783,0.000027092976,0.023955934,0.00019913563,0.018079303,0.0002610387],"about_ca_topic_score_codex":0.00022350253,"about_ca_topic_score_gemma":0.00018330138,"teacher_disagreement_score":0.75665206,"about_ca_system_score_codex":0.00004507384,"about_ca_system_score_gemma":0.0003112603,"threshold_uncertainty_score":0.6235677},"labels":[],"label_agreement":null},{"id":"W3031294038","doi":"10.1200/jco.2020.38.15_suppl.2520","title":"The imaging substudy of the randomized ARTE trial: MRI and 18FET PET associations with overall survival benefit from bevacizumab in elderly patients with newly diagnosed IDH wildtype glioblastoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Roche","keywords":"Medicine; Bevacizumab; Hazard ratio; Imaging biomarker; Internal medicine; Temozolomide; Progression-free survival; Oncology; Nuclear medicine; Glioblastoma; Magnetic resonance imaging; Radiology; Radiation therapy; Overall survival; Chemotherapy; Confidence interval","score_opus":0.03232240713995644,"score_gpt":0.3460986467569197,"score_spread":0.31377623961696327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031294038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734644,0.00030983443,0.000013201103,0.02465448,0.00038639523,0.0010569636,0.000022698983,0.0000048403203,0.00008717763],"genre_scores_gemma":[0.99808985,0.00036015932,0.0003305357,0.0009461999,0.00022491722,0.000020874948,0.000005351827,0.000017022126,0.0000051013744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637586,0.00088887376,0.0017772821,0.00020162397,0.00055732665,0.00019905872],"domain_scores_gemma":[0.9853744,0.011570747,0.002223934,0.00019186153,0.0004236175,0.00021547318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015911703,0.00016945037,0.0018636341,0.000050445637,0.00008693979,0.000025370682,0.00016480395,0.00008856949,0.000015806878],"category_scores_gemma":[0.0039984244,0.000072868395,0.00033055505,0.00019149044,0.0002521411,0.00009343705,0.000051503903,0.0005855584,0.0000011604491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36592618,0.0019593365,0.62561107,0.0000031483653,0.00089648966,0.00018337878,0.00032375404,0.000056231456,0.000003289739,0.000048839916,0.00027691154,0.0047113635],"study_design_scores_gemma":[0.47051248,0.007721829,0.5200983,0.00007071374,0.00075401005,0.0000049849664,0.000120864956,0.0001058014,0.0000062495355,0.00016665606,0.00038855107,0.000049567443],"about_ca_topic_score_codex":0.0001921728,"about_ca_topic_score_gemma":0.0018857147,"teacher_disagreement_score":0.10551277,"about_ca_system_score_codex":0.000094407085,"about_ca_system_score_gemma":0.0005279687,"threshold_uncertainty_score":0.47867766},"labels":[],"label_agreement":null},{"id":"W3031295683","doi":"10.1200/jco.2020.38.15_suppl.1518","title":"Expanding the diagnostic yield of germline genetic testing in cancer patients using deep learning.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Conquer Cancer Foundation","keywords":"Germline; Medicine; Prostate cancer; Cancer; Genetic testing; Germline mutation; Exome sequencing; Oncology; Deep sequencing; Cancer screening; Internal medicine; Mutation; Genetics; Biology; Genome; Gene","score_opus":0.1289311827715004,"score_gpt":0.44797591163195827,"score_spread":0.31904472886045787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031295683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920741,0.001054947,0.005590288,0.0009438216,0.00010672778,0.00012460932,0.0000020454343,0.0000022876707,0.00010121894],"genre_scores_gemma":[0.99179864,0.0007662272,0.0058663064,0.0011210069,0.0004238825,0.0000071397462,0.0000024017518,0.000010387627,0.00000398764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822646,0.00025489362,0.0011409023,0.00015124952,0.00009117743,0.00013532588],"domain_scores_gemma":[0.9976223,0.0008742439,0.0010911692,0.00009764201,0.00022411281,0.000090494505],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006539709,0.00008397631,0.00038987622,0.000025882786,0.000036217407,0.0000033805843,0.00023981546,0.0002429107,0.0000131198385],"category_scores_gemma":[0.010155584,0.000058357826,0.00015315252,0.00013171085,0.00013309001,0.0000024789717,0.0001117015,0.00044153896,4.7609512e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019391005,0.0003741608,0.81177294,0.000014934472,0.000075452976,0.000017817194,0.000055050827,0.002423921,0.095782645,0.000008802813,0.00021581206,0.08906456],"study_design_scores_gemma":[0.003774068,0.016542496,0.9110991,0.00019520629,0.00029895097,0.000062034866,0.00015739267,0.0047229016,0.038010333,0.0002416998,0.024513347,0.00038246933],"about_ca_topic_score_codex":0.00003129377,"about_ca_topic_score_gemma":0.000026593309,"teacher_disagreement_score":0.09932617,"about_ca_system_score_codex":0.000015182572,"about_ca_system_score_gemma":0.00022613433,"threshold_uncertainty_score":0.9981823},"labels":[],"label_agreement":null},{"id":"W3031296897","doi":"10.1200/jco.2020.38.15_suppl.e12608","title":"Predictors of post-mastectomy radiation (PMRT) in node-negative breast cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Internal medicine; Cancer; Oncology; Univariate analysis; Sentinel lymph node; Sentinel node; Lymphovascular invasion; Lymph node; Multivariate analysis; Metastasis","score_opus":0.05755735300654186,"score_gpt":0.419390536980284,"score_spread":0.36183318397374215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031296897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683834,0.00025607235,0.0000049505425,0.029923752,0.0006963317,0.00023109099,0.00005379503,0.0000034758616,0.00044714301],"genre_scores_gemma":[0.99422073,0.0011483316,0.00018893619,0.0035730249,0.00083786476,0.000008334579,0.000004299248,0.000010061475,0.000008436136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975558,0.00018265666,0.0017102826,0.00013714578,0.0002874543,0.00012668349],"domain_scores_gemma":[0.9966218,0.0009947506,0.0014362741,0.00006835006,0.00058930326,0.00028955605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045608194,0.00009668859,0.0010847665,0.00008433642,0.000009952228,0.0000023260168,0.00007271943,0.00017709334,0.00028660204],"category_scores_gemma":[0.0017019211,0.00006614812,0.0003034501,0.00017882179,0.0000916185,0.00009514471,0.000026052081,0.00045237993,0.000004929316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041870223,0.0021447802,0.89869124,0.000030126348,0.0003439931,0.000067822635,0.0004108897,0.000056906447,0.000021878124,0.00000697662,0.0019541425,0.09208421],"study_design_scores_gemma":[0.015536207,0.011020673,0.9680944,0.00013516161,0.00031080015,0.000013367897,0.00008615111,0.00006284354,0.00017224239,0.000012026641,0.004508394,0.00004769403],"about_ca_topic_score_codex":0.00023469214,"about_ca_topic_score_gemma":0.00017696337,"teacher_disagreement_score":0.092036515,"about_ca_system_score_codex":0.00029960458,"about_ca_system_score_gemma":0.0012499962,"threshold_uncertainty_score":0.31380913},"labels":[],"label_agreement":null},{"id":"W3031345523","doi":"10.1200/jco.2020.38.15_suppl.e15537","title":"The systemic inflammation response index (SIRI) predicts oncological outcome and correlates with tumor burden in metastatic pancreatic cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Hazard ratio; Chemotherapy; Pancreatic cancer; Confidence interval; Gastroenterology; Oncology; Cancer","score_opus":0.09781789178369836,"score_gpt":0.42192208751983457,"score_spread":0.3241041957361362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031345523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694773,0.0014581243,0.00006154294,0.027876062,0.00033133038,0.0006576457,0.0000033676326,0.000018221948,0.00011641251],"genre_scores_gemma":[0.99668646,0.0005267276,0.0006757346,0.0014712884,0.000546227,0.000044895056,8.0776215e-7,0.000018065182,0.000029779916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941282,0.001949067,0.0029320666,0.00022596761,0.0004937593,0.00027092593],"domain_scores_gemma":[0.98802453,0.008888602,0.0020579575,0.00015597683,0.00035502433,0.00051789876],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006546602,0.00018483929,0.001481991,0.0001026224,0.00007434046,0.00002518505,0.00020923959,0.00021991515,0.000032227552],"category_scores_gemma":[0.018628452,0.00009742132,0.00019150924,0.0002522237,0.00050403393,0.00012880763,0.00008132808,0.0011004931,0.00000690877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0721404,0.00012896849,0.9073116,0.00017627163,0.0004718872,0.0031321493,0.00030207125,0.00014361125,0.00018238254,0.000023253066,0.0003189004,0.015668487],"study_design_scores_gemma":[0.011731595,0.010807231,0.96541804,0.00060712005,0.0010213421,0.0011344997,0.0010975257,0.004512323,0.000019941252,0.00008364622,0.003440023,0.0001267084],"about_ca_topic_score_codex":0.0000070645087,"about_ca_topic_score_gemma":0.00002797349,"teacher_disagreement_score":0.060408805,"about_ca_system_score_codex":0.00028059157,"about_ca_system_score_gemma":0.0020929442,"threshold_uncertainty_score":0.98963803},"labels":[],"label_agreement":null},{"id":"W3031352686","doi":"10.1200/jco.2020.38.15_suppl.10529","title":"Obstetrical and perinatal complications in survivors of childhood, adolescent, and young adult cancer: A population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; St. Michael's Hospital; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Pregnancy; Hazard ratio; Cancer; Cancer registry; Obstetrics; Gestation; Population; Confidence interval; Pediatrics; Internal medicine","score_opus":0.09959334801497009,"score_gpt":0.44757443791623236,"score_spread":0.34798108990126225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031352686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912576,0.0008677918,0.000024777579,0.0073268674,0.00023028393,0.00022861864,0.000011646224,0.0000034264908,0.000048991173],"genre_scores_gemma":[0.99790215,0.00044460376,0.0002483837,0.001190373,0.0002000751,0.000002813643,0.0000015406697,0.000007364867,0.0000026611356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998159,0.00014584468,0.0012680127,0.00014528797,0.00018735022,0.000094509924],"domain_scores_gemma":[0.9981241,0.00067227404,0.00065891957,0.00007184017,0.00019547995,0.00027737432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003075311,0.00007880038,0.00086145604,0.000091655274,0.000020245021,0.0000042540146,0.000059549566,0.00011721918,0.00001834504],"category_scores_gemma":[0.0019888293,0.000060420203,0.00010913303,0.00018912065,0.000080167185,0.00004108374,0.000029033645,0.00054682646,2.7900245e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007560006,0.00092768995,0.9705858,0.000038582282,0.000051794512,0.00004007444,0.00038162008,0.000018222598,0.000008991129,0.00001739499,0.000060717135,0.02711312],"study_design_scores_gemma":[0.006838039,0.0041236244,0.9873482,0.00007966496,0.00011148301,0.000026868023,0.00045210193,0.00050470815,0.0000020877221,0.000009322277,0.0004534125,0.000050505154],"about_ca_topic_score_codex":0.0017992617,"about_ca_topic_score_gemma":0.002257281,"teacher_disagreement_score":0.027062614,"about_ca_system_score_codex":0.00006651421,"about_ca_system_score_gemma":0.00042391135,"threshold_uncertainty_score":0.27199575},"labels":[],"label_agreement":null},{"id":"W3031402932","doi":"10.1200/jco.2020.38.15_suppl.5525","title":"<i>HSD3B1</i> (1245A&gt;C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Kelowna General Hospital; BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Genotype; Oncology; Abiraterone acetate; Cohort; Hazard ratio; Prospective cohort study; Proportional hazards model; Androgen receptor; Cancer; Androgen deprivation therapy; Genetics; Biology; Confidence interval","score_opus":0.15767112275387948,"score_gpt":0.47544971927027724,"score_spread":0.3177785965163977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031402932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794176,0.0033637814,0.000002242921,0.015630517,0.00024421295,0.0010446847,0.00018444743,0.000014173235,0.000098292185],"genre_scores_gemma":[0.98692554,0.009488069,0.0013016126,0.001624141,0.00030823666,0.00002892069,0.000024798526,0.00003332774,0.00026536896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99459505,0.0007371704,0.003103538,0.0005957108,0.00056402996,0.00040448172],"domain_scores_gemma":[0.9939795,0.0027803823,0.0016214293,0.00017527238,0.00072841154,0.00071500713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017899398,0.00032352752,0.0025684896,0.00012623504,0.00007659199,0.000031178348,0.000113519876,0.00017690324,0.000016271695],"category_scores_gemma":[0.0028201153,0.00018602678,0.00019255721,0.00026897734,0.0008130554,0.00024140095,0.0001005355,0.0011364584,0.0000036607034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06371767,0.0011527253,0.90934396,0.00004491123,0.0025803172,0.0018228978,0.0013777522,0.000009855452,0.00015590226,0.000004907158,0.00036054786,0.019428587],"study_design_scores_gemma":[0.080598116,0.021957275,0.8943447,0.00026353623,0.0010554482,0.000025967553,0.00052142225,0.00007285955,0.00016349537,0.00013140914,0.00068948243,0.00017628273],"about_ca_topic_score_codex":0.0005012436,"about_ca_topic_score_gemma":0.0014667037,"teacher_disagreement_score":0.020804549,"about_ca_system_score_codex":0.00030154982,"about_ca_system_score_gemma":0.0013960678,"threshold_uncertainty_score":0.75859517},"labels":[],"label_agreement":null},{"id":"W3031403900","doi":"10.1200/jco.2020.38.15_suppl.e19369","title":"A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Quality-adjusted life year; Cost effectiveness; Oncology; Adverse effect; Clinical trial; Internal medicine; Cancer; Androgen receptor","score_opus":0.2546280226356184,"score_gpt":0.5177659532317747,"score_spread":0.26313793059615626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031403900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99081016,0.0006451226,0.00047202417,0.006347152,0.000102075384,0.0012840431,0.0002950918,0.0000019182496,0.000042437772],"genre_scores_gemma":[0.9967641,0.0015952856,0.0011005251,0.00030079333,0.00010459225,0.000040273004,0.000027933627,0.000007885429,0.000058603055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776775,0.00023505963,0.0013375041,0.0001464731,0.00035824106,0.00015495766],"domain_scores_gemma":[0.99409384,0.0027692935,0.0014149175,0.00012245741,0.0013878873,0.00021159479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070937985,0.00010805669,0.0015168114,0.000090247115,0.00003274311,0.0000033300903,0.00006657618,0.000064170905,0.00005927162],"category_scores_gemma":[0.00068715686,0.000048739552,0.00054616836,0.0003924847,0.00032884485,0.000048061884,0.000009562697,0.00017801448,3.8396743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06471446,0.0041598375,0.7069065,0.000094933945,0.021057198,0.00008018688,0.002409394,0.00066998956,0.000052772346,0.000011520424,0.0002214436,0.19962178],"study_design_scores_gemma":[0.019281665,0.04280018,0.9143274,0.000037339392,0.014486567,0.0000023188957,0.00057523,0.0031313933,0.0007679566,0.000019132953,0.004519155,0.00005169115],"about_ca_topic_score_codex":0.00009654993,"about_ca_topic_score_gemma":0.00028942298,"teacher_disagreement_score":0.20742089,"about_ca_system_score_codex":0.00014582937,"about_ca_system_score_gemma":0.0015859241,"threshold_uncertainty_score":0.2813361},"labels":[],"label_agreement":null},{"id":"W3031418164","doi":"10.1200/jco.2020.38.15_suppl.8510","title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Vancouver General Hospital; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Tolerability; Medicine; Daratumumab; Internal medicine; Dexamethasone; Refractory (planetary science); Phases of clinical research; Oncology; Gastroenterology; Adverse effect; Pharmacology; Lenalidomide; Clinical trial","score_opus":0.06782082982133822,"score_gpt":0.3764753852132049,"score_spread":0.3086545553918667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031418164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98448855,0.00029604018,0.000060480812,0.013846996,0.00023431763,0.0002379006,0.0000023049643,0.000009431006,0.0008239951],"genre_scores_gemma":[0.982396,0.00024494206,0.0145089375,0.0021763719,0.00033117947,0.0000026002947,0.0000074300706,0.000018536393,0.00031397157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997397,0.00025827723,0.0015744086,0.00022135573,0.00034619594,0.00020274479],"domain_scores_gemma":[0.99677163,0.0014814149,0.0008482138,0.000104376435,0.00026657566,0.00052777457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009919688,0.00015738524,0.0012559308,0.000103799066,0.000029704705,0.0000065984873,0.000083213636,0.00026293838,0.00007223588],"category_scores_gemma":[0.0031837828,0.00009905764,0.00013023985,0.00017868706,0.000137432,0.00012451268,0.000047126003,0.00094427215,0.000023268514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009372086,0.0019047273,0.90397793,0.000020185455,0.00026267656,0.00071824726,0.00036329444,0.000002686672,0.000010814449,0.0000062577315,0.0029506302,0.08041046],"study_design_scores_gemma":[0.036340527,0.011893774,0.872935,0.00010372781,0.00019982178,0.00003568817,0.00010388262,0.00009456977,0.00002089234,0.000015078874,0.07815348,0.000103585415],"about_ca_topic_score_codex":0.0000029915846,"about_ca_topic_score_gemma":0.000032834505,"teacher_disagreement_score":0.08030687,"about_ca_system_score_codex":0.000105500316,"about_ca_system_score_gemma":0.0007316628,"threshold_uncertainty_score":0.41024452},"labels":[],"label_agreement":null},{"id":"W3031419286","doi":"10.1200/jco.2020.38.15_suppl.e20532","title":"The impact of first-line therapy with novel agents in multiple myeloma patients age 80 and above: A systematic review.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Anemia; Adverse effect; Population; Retrospective cohort study; Randomized controlled trial; Surgery; Pediatrics","score_opus":0.21368511920464062,"score_gpt":0.49357388088968407,"score_spread":0.27988876168504345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031419286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945177,0.0053366283,0.000027177535,0.003617066,0.00005668082,0.0013941836,0.0000153833,0.0000030663034,0.00009805121],"genre_scores_gemma":[0.97862566,0.019993346,0.00035251994,0.0008718846,0.00010142726,0.000015383666,0.0000043498158,0.00001447348,0.000020986525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655247,0.00041704366,0.0021633322,0.0001536353,0.00047914404,0.00023438547],"domain_scores_gemma":[0.994044,0.0032628397,0.0015996359,0.0001965073,0.00041518718,0.00048183592],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017945353,0.00015484699,0.001966144,0.00005900287,0.000040916144,0.000008344447,0.0001759681,0.00012557775,0.000020793184],"category_scores_gemma":[0.011513533,0.00006523476,0.00035906507,0.00020446679,0.00018778781,0.00006827667,0.00004742667,0.00056002237,0.0000030026883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013359415,0.0032790995,0.96260667,0.006605557,0.0012895772,0.0006602098,0.00016169777,0.000007771874,0.00002738955,0.00000188375,0.0005950737,0.01140566],"study_design_scores_gemma":[0.029013328,0.030442374,0.9305596,0.008473286,0.00020803131,0.000072964314,0.000030850897,0.0008097707,0.000010017999,0.000008743764,0.00031065225,0.000060399198],"about_ca_topic_score_codex":0.000050039594,"about_ca_topic_score_gemma":0.00007142508,"teacher_disagreement_score":0.032047085,"about_ca_system_score_codex":0.00010459276,"about_ca_system_score_gemma":0.0004517385,"threshold_uncertainty_score":0.9968129},"labels":[],"label_agreement":null},{"id":"W3031438637","doi":"10.1200/jco.2020.38.15_suppl.e15253","title":"Technical validation of PD-L1 SP142 assay for TNBC in a large academic center: Unexpected challenges.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Staining; Cutoff; Medical physics; Pathology; Nuclear medicine","score_opus":0.12173184570092865,"score_gpt":0.43989142286942146,"score_spread":0.3181595771684928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031438637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696826,0.0035970893,0.0072981683,0.017221631,0.0008636429,0.0003515922,0.00008120039,0.000004831697,0.0008992764],"genre_scores_gemma":[0.98617905,0.008460005,0.002450467,0.0015216301,0.0013323518,0.000007011739,0.00002575815,0.000015514655,0.000008189847],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997526,0.0002200051,0.001715676,0.00021127645,0.00013156186,0.000195513],"domain_scores_gemma":[0.99759626,0.0006978543,0.0011353389,0.00012742507,0.00025693892,0.00018616514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020387177,0.00010339015,0.00069381465,0.000049912906,0.000013195098,0.0000031349402,0.00027199058,0.00063746556,0.00001226293],"category_scores_gemma":[0.0077639488,0.000092316084,0.0003372486,0.0000754203,0.00007448143,0.000005241111,0.00011413795,0.0005265493,0.0000016174243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028632004,0.0070880326,0.099931605,0.0003826942,0.0007608863,0.00022380821,0.00064141967,0.000841737,0.61139,0.0047271936,0.054681387,0.19069923],"study_design_scores_gemma":[0.021910958,0.023616118,0.05729669,0.0001160823,0.00020262244,0.00008244169,0.00030107744,0.00047871727,0.04203676,0.0013328514,0.8522377,0.00038797784],"about_ca_topic_score_codex":0.0000019034733,"about_ca_topic_score_gemma":0.000039107716,"teacher_disagreement_score":0.79755634,"about_ca_system_score_codex":0.000039170263,"about_ca_system_score_gemma":0.00061692804,"threshold_uncertainty_score":0.9294733},"labels":[],"label_agreement":null},{"id":"W3031446019","doi":"10.1200/jco.2020.38.15_suppl.3511","title":"CodeBreak 100: Phase I study of AMG 510, a novel KRAS<sup>G12C</sup> inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Amgen","keywords":"KRAS; Medicine; Colorectal cancer; Cancer; Tolerability; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Lung cancer; Oncology; Phases of clinical research; Gastroenterology; Clinical trial; Adverse effect","score_opus":0.04131832107028971,"score_gpt":0.4393586368519075,"score_spread":0.3980403157816178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031446019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594724,0.00062677823,0.00004519498,0.0013260219,0.0003043407,0.001270184,0.00006957308,0.000008543597,0.00040210236],"genre_scores_gemma":[0.99689037,0.00033789955,0.0006100147,0.0015110445,0.00046547857,0.00007607957,0.000004998552,0.000044198907,0.000059948485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968601,0.00016222516,0.0019054401,0.0003651526,0.00039857265,0.00030850703],"domain_scores_gemma":[0.9968978,0.00037064287,0.0015901662,0.00013278215,0.0005141679,0.0004944249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041109565,0.00026770486,0.0017943176,0.00013571628,0.000047396188,0.000008933329,0.00013879176,0.00019610429,0.00008426948],"category_scores_gemma":[0.0002420985,0.00017883194,0.00017804548,0.00028472382,0.00015979694,0.00014579101,0.00005926369,0.0007114841,0.0000012984947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021069389,0.02035051,0.9189163,0.00015602881,0.0011026994,0.0002544056,0.00826841,0.0013890286,0.0007848548,0.0000017330273,0.00058153196,0.027125113],"study_design_scores_gemma":[0.18046986,0.10598107,0.7008085,0.00093030295,0.0024350763,0.000029201303,0.0035273258,0.0025465176,0.0007050465,0.0000035330156,0.0022379677,0.00032560766],"about_ca_topic_score_codex":0.0009235454,"about_ca_topic_score_gemma":0.0016297522,"teacher_disagreement_score":0.2181078,"about_ca_system_score_codex":0.00035030275,"about_ca_system_score_gemma":0.0025957564,"threshold_uncertainty_score":0.72925544},"labels":[],"label_agreement":null},{"id":"W3031455888","doi":"10.1200/jco.2020.38.15_suppl.6517","title":"Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Refractory (planetary science); Population; Gastroenterology; Cancer; Head and neck cancer; Combination therapy; Oncology; Immunotherapy","score_opus":0.052614902764829545,"score_gpt":0.3573437048378566,"score_spread":0.30472880207302705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031455888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959921,0.0003471735,0.0000080305335,0.002112813,0.0001747778,0.00049240305,0.000027584903,0.0000072613043,0.0008378472],"genre_scores_gemma":[0.9980263,0.000181733,0.00022181758,0.0013296887,0.00009107749,0.000003989826,0.00003943759,0.00002491965,0.00008099728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966836,0.00050030363,0.0017738492,0.00032908132,0.00046468692,0.00024847148],"domain_scores_gemma":[0.99646556,0.0005217881,0.002068884,0.000277923,0.00039108016,0.00027476542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069639354,0.00024247274,0.0017373093,0.00026193896,0.00006485516,0.000013801951,0.00018220102,0.00032579547,0.00012806208],"category_scores_gemma":[0.00015368692,0.00013696725,0.00040182396,0.0008909175,0.00035286127,0.000115663446,0.00003090677,0.0006174425,0.0000023389678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05361314,0.004902,0.93250895,0.000048848276,0.00086385326,0.00006736977,0.00051889097,0.00016826553,0.0009850689,0.0000023646762,0.0007989723,0.0055222497],"study_design_scores_gemma":[0.07276722,0.049774773,0.86930656,0.00004948725,0.0020424887,0.000013679464,0.00020188004,0.0005066849,0.001780515,0.0000020416876,0.0034145364,0.00014012637],"about_ca_topic_score_codex":0.00021001213,"about_ca_topic_score_gemma":0.0001843547,"teacher_disagreement_score":0.0632024,"about_ca_system_score_codex":0.0003650797,"about_ca_system_score_gemma":0.0014022563,"threshold_uncertainty_score":0.55853623},"labels":[],"label_agreement":null},{"id":"W3031458532","doi":"10.1200/jco.2020.38.15_suppl.5501","title":"Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Clinical endpoint; Nuclear medicine; Prostate cancer; Occult; Bone scintigraphy; Clinical trial; Radiology; Cancer; Internal medicine; Pathology","score_opus":0.09672968866034382,"score_gpt":0.49941317306536337,"score_spread":0.40268348440501955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031458532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944733,0.00034655005,0.000009762911,0.0017163128,0.00031444873,0.002489177,0.0003375238,0.00001393846,0.00029898947],"genre_scores_gemma":[0.9967223,0.0011343395,0.0013552369,0.00027519302,0.00030750735,0.0000403114,0.0000663201,0.00004123392,0.00005759326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934828,0.00055272516,0.0038514482,0.00065403903,0.0010232917,0.00043566062],"domain_scores_gemma":[0.99293154,0.0010733841,0.003450638,0.00037091813,0.0014601754,0.000713342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015869762,0.00035389795,0.002371829,0.0001441682,0.000042461215,0.000013201083,0.0002991356,0.000049936658,0.000106344676],"category_scores_gemma":[0.0008335621,0.00018958148,0.00055618474,0.00037168793,0.000534198,0.00013578575,0.00013312616,0.0013527565,0.0000038129704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31058386,0.025598362,0.6181983,0.00006664047,0.0042544627,0.0032024637,0.0003788307,0.000016299917,0.00007130302,5.443293e-7,0.001072961,0.036556024],"study_design_scores_gemma":[0.21296231,0.14314121,0.6398896,0.000826702,0.0013981374,0.000015491067,0.0005404706,0.00018985625,0.0004817363,0.000008003352,0.00037243802,0.00017404843],"about_ca_topic_score_codex":0.00018528546,"about_ca_topic_score_gemma":0.000040506613,"teacher_disagreement_score":0.11754284,"about_ca_system_score_codex":0.00043310775,"about_ca_system_score_gemma":0.0015802556,"threshold_uncertainty_score":0.77309084},"labels":[],"label_agreement":null},{"id":"W3031465744","doi":"10.1200/jco.2020.38.15_suppl.5545","title":"Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Cohort; Internal medicine; Abiraterone acetate; Biomarker; Oncology; Cancer; Urology; Androgen receptor; Androgen deprivation therapy","score_opus":0.10664875430892808,"score_gpt":0.42883531223814014,"score_spread":0.3221865579292121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031465744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335785,0.0011204653,0.000024974359,0.012864036,0.00024732173,0.0014240532,0.00014257204,0.000021460068,0.00079730013],"genre_scores_gemma":[0.9938355,0.0036055571,0.0008750762,0.00095993734,0.00016916629,0.000027802358,0.00007642491,0.000049883485,0.00040063253],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939495,0.00083558937,0.0031539528,0.0005762147,0.0008609232,0.0006238335],"domain_scores_gemma":[0.99519086,0.0012444634,0.0016203129,0.00025014675,0.00080237637,0.0008918362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022418785,0.00036710507,0.0022115598,0.00023674787,0.00009824923,0.000042204152,0.00019467802,0.0002623859,0.000072453586],"category_scores_gemma":[0.0018270329,0.00022917883,0.00022383903,0.0005486225,0.00054111745,0.00025862586,0.00010775485,0.0011706704,0.000011517198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.584489,0.002400741,0.3204602,0.00028640055,0.0025452166,0.0039261403,0.0012449018,0.0005063747,0.0010044024,0.000012959379,0.0012586096,0.08186508],"study_design_scores_gemma":[0.13024788,0.024250701,0.8388086,0.00039016316,0.00087745866,0.0000815387,0.0001434807,0.0007618557,0.00027893326,0.000020736441,0.003903548,0.00023508978],"about_ca_topic_score_codex":0.00030513998,"about_ca_topic_score_gemma":0.00045393294,"teacher_disagreement_score":0.5183484,"about_ca_system_score_codex":0.00072205934,"about_ca_system_score_gemma":0.0032605773,"threshold_uncertainty_score":0.9345641},"labels":[],"label_agreement":null},{"id":"W3031475478","doi":"10.1200/jco.2020.38.15_suppl.6505","title":"KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Population; Proportional hazards model; Progression-free survival; Chemotherapy; Cancer; Immunotherapy","score_opus":0.19787854319714904,"score_gpt":0.44318689677225587,"score_spread":0.24530835357510683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031475478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93454486,0.026451424,0.0003499679,0.035934668,0.0009959197,0.0016069404,0.000012156334,0.000017541199,0.00008653945],"genre_scores_gemma":[0.9655942,0.016083082,0.0026506402,0.013949065,0.0014366262,0.000059427228,0.0000070070532,0.00007058328,0.00014937959],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9951138,0.0004647196,0.0029633688,0.0004256709,0.0005953143,0.00043711285],"domain_scores_gemma":[0.99373,0.0029665672,0.0021378302,0.00034688655,0.00040362764,0.0004150598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022833175,0.00039673285,0.0021756734,0.00011706335,0.00012406966,0.00003540137,0.0003600048,0.00038627294,0.00034890138],"category_scores_gemma":[0.000966728,0.00020847532,0.0013047594,0.00032004758,0.00035172093,0.00017460847,0.00004955043,0.00091126503,0.0000030544034],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55501026,0.0020693983,0.008030216,0.00019582025,0.00051023206,0.00027056382,0.0014454186,0.0000066724924,0.0021248497,0.0000023741384,0.0015312557,0.42880297],"study_design_scores_gemma":[0.27204943,0.32711726,0.06993236,0.00066804595,0.00077039294,0.0006152575,0.0005771176,0.0023545108,0.004733358,0.00025302352,0.32034525,0.00058401225],"about_ca_topic_score_codex":0.000036497517,"about_ca_topic_score_gemma":0.000051997074,"teacher_disagreement_score":0.42821896,"about_ca_system_score_codex":0.00013272186,"about_ca_system_score_gemma":0.0017334406,"threshold_uncertainty_score":0.85013765},"labels":[],"label_agreement":null},{"id":"W3031480296","doi":"10.1200/jco.2020.38.15_suppl.tps6108","title":"DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Carboplatin; PARP inhibitor; Cancer; Ovarian cancer; Bevacizumab; Hazard ratio; Atezolizumab; Nivolumab; Chemotherapy; Immunotherapy; Cisplatin; Confidence interval; Poly ADP ribose polymerase","score_opus":0.06261902169067038,"score_gpt":0.4049392146227062,"score_spread":0.34232019293203586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031480296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843171,0.0006880837,0.00034830417,0.008482643,0.00071502244,0.0052452907,0.00008937326,0.00001556893,0.00009857034],"genre_scores_gemma":[0.9904876,0.00499456,0.0028986745,0.0007018198,0.00043012146,0.0003230236,0.000038383874,0.0000632778,0.00006255678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922135,0.001303215,0.0042229895,0.00070716656,0.0010189763,0.00053417776],"domain_scores_gemma":[0.986479,0.007327891,0.004450523,0.00030510596,0.000770479,0.0006670355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003228339,0.0005401348,0.0059947195,0.00035231776,0.000060190207,0.000025843568,0.00020825602,0.0004709984,0.00010928613],"category_scores_gemma":[0.008067063,0.00028405117,0.00035094356,0.0010203057,0.00048804402,0.0003115465,0.000048655213,0.0014383531,7.689971e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169047,0.013645922,0.1207487,0.000119536446,0.0011047875,0.000745217,0.0007646606,0.00009774519,0.000010721018,0.000012057553,0.0005025923,0.045343325],"study_design_scores_gemma":[0.8175413,0.16055258,0.01594879,0.0014541934,0.0013831056,0.000030377065,0.00021935656,0.00074829865,0.000047489266,0.000013965026,0.0017724013,0.00028812373],"about_ca_topic_score_codex":0.0007327507,"about_ca_topic_score_gemma":0.008710954,"teacher_disagreement_score":0.14690666,"about_ca_system_score_codex":0.000627544,"about_ca_system_score_gemma":0.0028649808,"threshold_uncertainty_score":0.99996114},"labels":[],"label_agreement":null},{"id":"W3031496221","doi":"10.1200/jco.2020.38.15_suppl.e19094","title":"Application of neo-bioscore to a real-world cohort: Potential implications for patient selection, for escalation, and de-escalation of therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Cohort; Neoadjuvant therapy; Oncology; Adjuvant therapy; Breast cancer; Internal medicine; Disease; De-escalation; Surgery; Cancer","score_opus":0.051243485558482335,"score_gpt":0.4187517025738084,"score_spread":0.36750821701532604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031496221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8158236,0.00015007511,0.16949613,0.013604537,0.00009539751,0.0007262857,0.000053521457,0.0000028615439,0.000047561778],"genre_scores_gemma":[0.9838164,0.0003449195,0.014670695,0.0006195965,0.0004231304,0.00008187694,0.000027206315,0.000009775149,0.000006415187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866515,0.00006775966,0.0009530359,0.0001616449,0.000062862826,0.00008951565],"domain_scores_gemma":[0.99780333,0.00022838125,0.0010217676,0.00007841101,0.0007645835,0.00010351341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039934405,0.000074327574,0.0003955694,0.000038372087,0.000040554838,0.0000025197148,0.000069084956,0.00012727083,0.0000014749592],"category_scores_gemma":[0.00051686144,0.00006301226,0.00016716178,0.000100641955,0.000057313657,0.0000054153347,0.000024996742,0.000057411668,9.565228e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050846497,0.0005481273,0.725528,0.000034799148,0.00050752267,8.528255e-8,0.00015551453,0.00072421826,0.06818436,0.0005155619,0.0034400083,0.19527717],"study_design_scores_gemma":[0.0024757502,0.006649111,0.96534884,0.000008044643,0.00017676919,0.0000060916127,0.000033265584,0.0004925409,0.0087115895,0.0009532882,0.015077723,0.000067007495],"about_ca_topic_score_codex":0.000026750264,"about_ca_topic_score_gemma":0.00008252027,"teacher_disagreement_score":0.23982084,"about_ca_system_score_codex":0.000028777917,"about_ca_system_score_gemma":0.00026934582,"threshold_uncertainty_score":0.25695655},"labels":[],"label_agreement":null},{"id":"W3031509379","doi":"10.1200/jco.2020.38.15_suppl.521","title":"Dementia risk among post-menopausal women treated with endocrine therapy for early-stage breast cancer in Ontario, Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Toronto; University of Manitoba; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Tamoxifen; Aromatase inhibitor; Breast cancer; Hazard ratio; Dementia; Anastrozole; Internal medicine; Population; Exemestane; Oncology; Proportional hazards model; Gynecology; Cumulative incidence; Cancer; Confidence interval; Disease; Cohort","score_opus":0.046669113610868874,"score_gpt":0.3727590457903208,"score_spread":0.3260899321794519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031509379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984445,0.00025707422,0.000022093198,0.013750057,0.00033469373,0.00068769313,0.00012730945,0.000009665968,0.00036642674],"genre_scores_gemma":[0.9929648,0.00081106724,0.00016415179,0.0049522584,0.0005713181,0.00006383378,0.000004805533,0.000028952076,0.00043882657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997163,0.00021136427,0.001554691,0.00026067081,0.0003603521,0.00044990066],"domain_scores_gemma":[0.99641293,0.0008509379,0.0013810106,0.00009351833,0.00073233264,0.00052928366],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007416116,0.00021369482,0.0014679005,0.00008524575,0.000056972705,0.000008105488,0.00012107658,0.00013692208,0.0010840984],"category_scores_gemma":[0.00053178455,0.00014377151,0.000113974085,0.00018211675,0.0001754935,0.000109517794,0.00003630842,0.0012288948,0.0000012271166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040408485,0.00060842995,0.9339372,0.000015949974,0.002758691,0.0008468779,0.0005339168,0.0000614154,0.0000840738,0.000001107564,0.0022720715,0.01847179],"study_design_scores_gemma":[0.02654774,0.035951972,0.9123257,0.00009250718,0.0005501226,0.000060378683,0.00041809326,0.00002605803,0.000042773656,0.000005200043,0.023845652,0.00013385035],"about_ca_topic_score_codex":0.7357792,"about_ca_topic_score_gemma":0.9654128,"teacher_disagreement_score":0.22963357,"about_ca_system_score_codex":0.0015060116,"about_ca_system_score_gemma":0.007364228,"threshold_uncertainty_score":0.99982905},"labels":[],"label_agreement":null},{"id":"W3031537076","doi":"10.1200/jco.2020.38.15_suppl.4605","title":"Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; University of Manitoba; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer; Interquartile range; Hazard ratio; Internal medicine; Population; Oncology; Colorectal cancer; Cohort; Cause of death; Lung cancer; Proportional hazards model; Retrospective cohort study; Disease; Confidence interval","score_opus":0.09925222438367114,"score_gpt":0.463092101600706,"score_spread":0.36383987721703487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031537076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194866,0.00021904067,0.0005294704,0.0064405827,0.0001700752,0.0005747742,0.000058884878,0.000011575558,0.000046908695],"genre_scores_gemma":[0.99120235,0.0005679115,0.0059955106,0.0015458986,0.0006040178,0.000022475213,0.00001877953,0.00002679424,0.000016254362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597055,0.0004569843,0.0023074106,0.0002928338,0.0006604438,0.00031180173],"domain_scores_gemma":[0.990234,0.0049733575,0.0028508625,0.00020938649,0.0010931203,0.00063922757],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00046963547,0.00016776785,0.002103964,0.00025769253,0.00003890566,0.0000072298776,0.00022771212,0.000019655072,0.00010144945],"category_scores_gemma":[0.010586481,0.000110416404,0.00075918186,0.00063435134,0.00012169235,0.00010238488,0.000033874127,0.00076921814,0.0000016494082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015308927,0.0015652592,0.96658784,0.00007278868,0.0008130869,0.0018820019,0.000010409976,0.002131188,0.000018938523,0.000015447647,0.0008378079,0.01075628],"study_design_scores_gemma":[0.016165778,0.037777428,0.9296142,0.000056385812,0.0016461356,0.000029446868,0.000020974421,0.0012532469,0.00017193053,0.000044195585,0.013133478,0.00008682651],"about_ca_topic_score_codex":0.00013226963,"about_ca_topic_score_gemma":0.00018546173,"teacher_disagreement_score":0.03697369,"about_ca_system_score_codex":0.000085231375,"about_ca_system_score_gemma":0.0008715171,"threshold_uncertainty_score":0.9977478},"labels":[],"label_agreement":null},{"id":"W3031541689","doi":"10.1200/jco.19.02959","title":"Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University","funders":"","keywords":"Medicine; Bladder cancer; Chemotherapy; Cancer; Oncology; Urothelial cancer; Internal medicine","score_opus":0.26619828502869874,"score_gpt":0.5065429100194535,"score_spread":0.24034462499075476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031541689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66998047,0.003816652,0.001245294,0.31869835,0.0032205652,0.0014337058,0.00015478334,0.000031588013,0.0014185825],"genre_scores_gemma":[0.8661502,0.01289263,0.0008752901,0.11512892,0.004727836,0.000033523243,0.0000039134584,0.00003293383,0.00015474929],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970024,0.00020851815,0.0018363326,0.0003038964,0.00036695861,0.0002818748],"domain_scores_gemma":[0.99580455,0.0014724373,0.0013353821,0.00016196037,0.0006223209,0.00060334406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087110855,0.00021210594,0.0017625426,0.00003778141,0.000050888866,0.000010435028,0.00019706583,0.00035682064,0.00092543394],"category_scores_gemma":[0.00092748075,0.00014307759,0.0010194822,0.00011506144,0.00017081588,0.00008481054,0.000019761785,0.00064942724,0.000013658479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020026065,0.0025935397,0.012650284,0.000062087325,0.002441684,0.0001141739,0.0014382233,0.0000029236526,0.0015074197,0.00011265806,0.060464025,0.8985869],"study_design_scores_gemma":[0.057646316,0.040078904,0.07478327,0.00007284223,0.00067277707,0.00003809993,0.00015865269,0.000059805785,0.009876113,0.00028457804,0.8161367,0.00019192723],"about_ca_topic_score_codex":0.000043404103,"about_ca_topic_score_gemma":0.000011129287,"teacher_disagreement_score":0.898395,"about_ca_system_score_codex":0.00015768058,"about_ca_system_score_gemma":0.0042621233,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W3031543727","doi":"10.1200/jco.2020.38.15_suppl.7011","title":"Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Clinical Oncology; Clinical trial; Internal medicine; Oncology; Drug approval; Family medicine; Cancer; Drug; Pharmacology","score_opus":0.8144880414825163,"score_gpt":0.6431365135436177,"score_spread":0.17135152793889863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031543727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69135416,0.0051023425,0.029102981,0.27260378,0.0011130372,0.0005250433,0.00005334148,0.0000063291345,0.00013901031],"genre_scores_gemma":[0.9075649,0.0046810717,0.05134177,0.03433949,0.002020143,0.000009935334,0.0000010387707,0.000028365937,0.0000133266885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.975654,0.0039886613,0.01908273,0.00048356713,0.00036349404,0.00042753553],"domain_scores_gemma":[0.90809673,0.035047803,0.05515948,0.0005659045,0.00072051125,0.00040957148],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.080502845,0.00021286723,0.005271555,0.00009417569,0.00016715411,0.00001628487,0.0008313172,0.00045495425,0.000056921683],"category_scores_gemma":[0.025781123,0.00013968747,0.0009522107,0.0005583232,0.0015907693,0.0003435681,0.00014547912,0.00176866,0.000004528541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004167595,0.0018120346,0.84308434,0.0011153785,0.002158917,0.000003433106,0.009752287,0.023519805,0.00002420154,0.026265798,0.019483656,0.068612576],"study_design_scores_gemma":[0.0061645024,0.0223112,0.7658005,0.0025964903,0.0004669522,0.000043570002,0.020460756,0.10518429,0.000012041078,0.017230688,0.059193555,0.00053547084],"about_ca_topic_score_codex":0.005296208,"about_ca_topic_score_gemma":0.0003356761,"teacher_disagreement_score":0.23826429,"about_ca_system_score_codex":0.00096107495,"about_ca_system_score_gemma":0.0092503,"threshold_uncertainty_score":0.9963663},"labels":[],"label_agreement":null},{"id":"W3031543858","doi":"10.1200/jco.2020.38.15_suppl.6579","title":"Risk of chronic opioid use after radiation for head and neck cancer: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Meta-analysis; Head and neck cancer; Cochrane Library; Chemoradiotherapy; Radiation therapy; Internal medicine; MEDLINE; Larynx; Cancer; Hazard ratio; Opioid; Incidence (geometry); Confidence interval; Surgery; Oncology","score_opus":0.29852215519232306,"score_gpt":0.5468370935578298,"score_spread":0.24831493836550678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031543858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033508204,0.99499446,0.000037085894,0.0024800852,0.00018618922,0.002102654,0.00015250141,0.000002957615,0.000010579066],"genre_scores_gemma":[0.00006104669,0.99671817,0.00062548986,0.0017044032,0.0004780108,0.00028676915,0.000005254382,0.000021946717,0.000098900135],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9924668,0.0012152616,0.0056036464,0.00029445262,0.0002508539,0.00016899494],"domain_scores_gemma":[0.9861225,0.0055624903,0.0073417816,0.000236212,0.00041842234,0.00031860647],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0037172926,0.00030278636,0.031497646,0.0001699524,0.000028091239,0.000008736206,0.000102916085,0.0004008491,0.000058532707],"category_scores_gemma":[0.007543204,0.00015936779,0.0048907464,0.000304802,0.00013672566,0.000073270574,0.00005681105,0.0008172435,0.0000012140296],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015726696,0.00012859063,0.00013877526,0.6456783,0.21693215,0.00004005639,0.000024981518,1.4461062e-7,5.928719e-9,0.0000036542242,0.0011322298,0.13576385],"study_design_scores_gemma":[0.0007882272,0.0034600622,0.00019313693,0.027555589,0.5607031,0.000054280754,0.0000016932235,0.0000056737217,1.19606876e-8,0.0000043115656,0.40716586,0.00006809364],"about_ca_topic_score_codex":0.0000285988,"about_ca_topic_score_gemma":0.00014294148,"teacher_disagreement_score":0.6181227,"about_ca_system_score_codex":0.00020648928,"about_ca_system_score_gemma":0.0022300119,"threshold_uncertainty_score":0.9828808},"labels":[],"label_agreement":null},{"id":"W3031549216","doi":"10.1200/jco.2020.38.15_suppl.7001","title":"A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Public Health; Baker Hughes (Canada); Juravinski Cancer Centre; McGill University Health Centre; NOSM University; University of Alberta; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Febrile neutropenia; Cyclophosphamide; Internal medicine; Neutropenia; Breast cancer; Antibiotic prophylaxis; Chemotherapy; Docetaxel; Randomized controlled trial; Gastroenterology; Surgery; Granulocyte colony-stimulating factor; Antibiotics; Cancer","score_opus":0.10606235621412048,"score_gpt":0.41455397752018386,"score_spread":0.3084916213060634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031549216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633354,0.000010411466,0.000084157466,0.00081743527,0.0005719523,0.002074624,0.000033441014,0.000009939088,0.00006451721],"genre_scores_gemma":[0.9977992,0.0000074142745,0.0011046801,0.00073073036,0.00030024015,0.000007202422,0.0000030053013,0.000033605425,0.000013925612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967022,0.00021746995,0.0020991066,0.00030213015,0.0003887347,0.00029038923],"domain_scores_gemma":[0.9966568,0.0006093961,0.0014328153,0.00016845224,0.000693252,0.0004393358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060413737,0.00020424214,0.0019049728,0.00012822836,0.00005480882,0.000014313165,0.00018853172,0.00015995759,0.000032712],"category_scores_gemma":[0.00052071735,0.0001433464,0.00025349186,0.00033951603,0.000068862035,0.00014729507,0.00009555121,0.00082427857,0.000001719467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023029352,0.0033221168,0.9663821,0.0001290922,0.00028436218,0.000058236987,0.0006546848,0.0009149737,0.00059287064,0.0000012243065,0.00004400177,0.004586986],"study_design_scores_gemma":[0.022229472,0.04594374,0.9304603,0.00020034064,0.00027952102,0.0000029253583,0.00020534509,0.00009184831,0.00023259984,5.374853e-7,0.00022461043,0.00012878666],"about_ca_topic_score_codex":0.00048795412,"about_ca_topic_score_gemma":0.000449481,"teacher_disagreement_score":0.042621624,"about_ca_system_score_codex":0.0002744554,"about_ca_system_score_gemma":0.000757078,"threshold_uncertainty_score":0.5845497},"labels":[],"label_agreement":null},{"id":"W3031553269","doi":"10.1200/jco.2020.38.15_suppl.e22076","title":"Cost-effectiveness of nodal observation versus completion lymphadenectomy in patients with melanoma and sentinel lymph node metastases.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Lymphadenectomy; Quality-adjusted life year; Cost effectiveness; Surgery; Lymph node; Internal medicine","score_opus":0.6403976922795797,"score_gpt":0.5235383858158342,"score_spread":0.11685930646374543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031553269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880573,0.00022370004,0.0017435437,0.008798151,0.00052735157,0.0003700663,0.00005676941,0.000004342147,0.0002187378],"genre_scores_gemma":[0.9932384,0.00005760086,0.0031540114,0.0032734983,0.00022950786,0.000009487674,0.00002184898,0.000013799282,0.000001885483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99204284,0.0014055866,0.0059763147,0.00026263398,0.00013537364,0.00017725061],"domain_scores_gemma":[0.98621076,0.0066305986,0.00654696,0.00012613522,0.00026417212,0.00022138454],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0190144,0.00012259082,0.0021067294,0.0001661505,0.000031833337,0.000013062581,0.00015549107,0.00019160625,0.000047537065],"category_scores_gemma":[0.011355802,0.000121757,0.00014099995,0.0001843535,0.000114102586,0.00036849745,0.00004133552,0.0002238231,0.000024779587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034106548,0.00043704305,0.9922503,0.00017982665,0.00015494939,0.00000401244,0.0001330387,0.00040947302,0.0000013669517,0.0019891798,0.00017689935,0.0008532303],"study_design_scores_gemma":[0.0206867,0.0013211538,0.97252643,0.000076287426,0.00003313243,0.000002271816,0.00009530038,0.0019364096,0.0000022928893,0.0003281875,0.002882885,0.000108945555],"about_ca_topic_score_codex":0.00012997432,"about_ca_topic_score_gemma":0.00001742415,"teacher_disagreement_score":0.019723892,"about_ca_system_score_codex":0.00034503714,"about_ca_system_score_gemma":0.00044689354,"threshold_uncertainty_score":0.99697196},"labels":[],"label_agreement":null},{"id":"W3031565651","doi":"10.1200/jco.2020.38.15_suppl.e24042","title":"Enhancing safety of exercise for individuals with bone metastases: Screening recommendations developed through Delphi consensus process.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Victoria; University of British Columbia","funders":"","keywords":"Medicine; Delphi method; Referral; Physical therapy; MEDLINE; Exercise prescription; Family medicine","score_opus":0.2203007026920489,"score_gpt":0.48045753495572663,"score_spread":0.2601568322636777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031565651","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3339368,0.0014207702,0.4527268,0.2053545,0.00062145607,0.0034060876,0.00026397125,0.000054875538,0.0022147223],"genre_scores_gemma":[0.37093675,0.00030930768,0.6226815,0.005717568,0.00021413443,0.000019499204,0.000036502937,0.00002925224,0.000055454213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99490225,0.0003468064,0.0037279283,0.00025009882,0.00052299775,0.00024991328],"domain_scores_gemma":[0.99114096,0.0034748244,0.0036526588,0.00016733461,0.0011020318,0.00046216397],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047726217,0.00018148114,0.002093352,0.00011277023,0.00006406191,0.000009082831,0.00017491014,0.00013605686,0.0002389276],"category_scores_gemma":[0.011347765,0.00013065753,0.0003754892,0.0003284154,0.00019977715,0.00014730183,0.00006328647,0.00051862217,0.0000035256296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1553308,0.010460357,0.049524482,0.006160417,0.01338198,0.0021057136,0.008677658,0.0007278751,0.00043087514,0.001618705,0.09662514,0.654956],"study_design_scores_gemma":[0.15520751,0.05938748,0.0282697,0.0065229908,0.029510794,0.00062500336,0.033746082,0.001987783,0.0034564922,0.003138221,0.6769974,0.0011505359],"about_ca_topic_score_codex":0.000003826579,"about_ca_topic_score_gemma":0.0000074401623,"teacher_disagreement_score":0.65380543,"about_ca_system_score_codex":0.000034642126,"about_ca_system_score_gemma":0.0021351497,"threshold_uncertainty_score":0.9969801},"labels":[],"label_agreement":null},{"id":"W3031574240","doi":"10.1200/jco.2020.38.15_suppl.1568","title":"A comparison of patients' and physicians' expectations regarding precision oncology tests.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Concordance; Medicine; Biomarker; Genetic testing; Cancer; Test (biology); Internal medicine; Oncology; Family medicine; Medical physics","score_opus":0.19625554917073215,"score_gpt":0.4436952558724567,"score_spread":0.24743970670172452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031574240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710911,0.0020112894,0.0020222648,0.006333791,0.0011167064,0.00012438263,0.00003164804,0.0000053231215,0.017263507],"genre_scores_gemma":[0.9937703,0.00047122265,0.0036349883,0.0014805701,0.00059937534,0.0000017531063,0.0000017008954,0.000011725101,0.000028366301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629396,0.00007600173,0.0032298118,0.0001969276,0.000044267144,0.000159024],"domain_scores_gemma":[0.99354196,0.0013023486,0.0046486715,0.00009357625,0.00020937723,0.00020409103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010269624,0.00010014442,0.0018255052,0.000102018304,0.000039956758,0.00001159171,0.00019933758,0.00026723638,0.000071684706],"category_scores_gemma":[0.005631854,0.000098786215,0.00028353432,0.000116785166,0.00017729642,0.00029914864,0.00006471305,0.00048388456,0.000032105072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009775432,0.0010945532,0.7031376,0.00002289,0.00016034533,0.000006507745,0.0026926855,0.00009680744,0.000016624435,0.010353551,0.011987293,0.26945364],"study_design_scores_gemma":[0.005746454,0.013290452,0.594588,0.000036538127,0.000060148002,0.000003182736,0.00093683886,0.0011555736,0.00005958688,0.009576243,0.37434605,0.00020097622],"about_ca_topic_score_codex":0.000010782018,"about_ca_topic_score_gemma":0.000013174009,"teacher_disagreement_score":0.36235875,"about_ca_system_score_codex":0.00010117211,"about_ca_system_score_gemma":0.00021901718,"threshold_uncertainty_score":0.6742262},"labels":[],"label_agreement":null},{"id":"W3031577106","doi":"10.1200/jco.2020.38.15_suppl.e17097","title":"Understanding the treatment effect modification of mono- or combination PD-1/PD-L1 inhibitor therapies on survival outcomes in patients with metastatic renal cell carcinoma: What does the literature say?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Meta-analysis; Renal cell carcinoma; Oncology; Subgroup analysis; Clinical trial; Confidence interval","score_opus":0.16007684425755733,"score_gpt":0.38822200967647424,"score_spread":0.2281451654189169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031577106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98369163,0.0005023584,0.00007999938,0.0141868275,0.00044579446,0.0009813898,0.0000067043816,0.0000049697114,0.00010032985],"genre_scores_gemma":[0.99851286,0.00039037695,0.00016716037,0.00064688403,0.00017346282,0.000019158811,0.000013267955,0.00002013804,0.000056698973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960181,0.0015400201,0.0014204251,0.0002257235,0.0006123509,0.00018335515],"domain_scores_gemma":[0.99198425,0.0059122476,0.0014528333,0.00025029187,0.00024783134,0.00015253216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014719308,0.0002525858,0.0013826968,0.00011506537,0.00006781356,0.000041810865,0.00016404706,0.00014901815,0.000015773468],"category_scores_gemma":[0.000543141,0.00007917042,0.00038582046,0.0002611548,0.00018869323,0.0001878131,0.000020442785,0.00061236235,0.0000021119852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0631937,0.008312395,0.9004401,0.00016393822,0.0012812243,0.000367482,0.009056582,0.00024620828,0.00022474273,0.00026473313,0.00011993506,0.016328968],"study_design_scores_gemma":[0.026683385,0.09865117,0.8689067,0.00022537181,0.000936859,0.000010579601,0.0023039277,0.00014084585,0.0016178068,0.00026868287,0.00015069082,0.000104025465],"about_ca_topic_score_codex":0.00001035582,"about_ca_topic_score_gemma":0.000033129883,"teacher_disagreement_score":0.090338774,"about_ca_system_score_codex":0.00057918817,"about_ca_system_score_gemma":0.0003559636,"threshold_uncertainty_score":0.3228476},"labels":[],"label_agreement":null},{"id":"W3031611603","doi":"10.1200/jco.2020.38.15_suppl.10515","title":"Underdiagnosis and undertreament of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Dyslipidemia; Diabetes mellitus; Odds ratio; Cancer; Population; Internal medicine; Blood pressure; Anthropometry; Physical therapy; Disease; Pediatrics; Environmental health; Endocrinology","score_opus":0.1663950986718015,"score_gpt":0.4357949337521754,"score_spread":0.2693998350803739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031611603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336886,0.001528593,0.00048308045,0.0034225676,0.0003810022,0.00046633463,0.000008359892,0.0000097403845,0.00033146166],"genre_scores_gemma":[0.9940619,0.0041005393,0.00033787012,0.0006563114,0.000801733,0.000006624485,0.0000018913607,0.000018123212,0.000015045186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663764,0.0005672296,0.0018511227,0.000261497,0.0005282028,0.00015433112],"domain_scores_gemma":[0.99635583,0.0011493244,0.0015357927,0.00023282309,0.00032535614,0.00040088184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002607177,0.00014754382,0.0020678837,0.00006470705,0.000040893337,0.000007927656,0.00008649248,0.00027403896,0.00004502073],"category_scores_gemma":[0.0027982139,0.00010786535,0.0009568361,0.00016467067,0.00011415098,0.000085544314,0.00004459013,0.00074362033,8.1928385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014151,0.0053187385,0.89142174,0.00010089388,0.0140959965,0.0010035854,0.003027933,0.001417993,0.0010440779,0.000011316091,0.0009306393,0.08021199],"study_design_scores_gemma":[0.018128464,0.019363465,0.9341737,0.0001621795,0.005320258,0.0003388359,0.0042687343,0.00014754548,0.0072339955,0.000239337,0.0104112895,0.0002121761],"about_ca_topic_score_codex":0.0009293859,"about_ca_topic_score_gemma":0.000065871325,"teacher_disagreement_score":0.07999981,"about_ca_system_score_codex":0.00011882134,"about_ca_system_score_gemma":0.0009052768,"threshold_uncertainty_score":0.43986216},"labels":[],"label_agreement":null},{"id":"W3031646075","doi":"10.1200/jco.2020.38.15_suppl.502","title":"Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Roche","keywords":"Medicine; Breast cancer; Oncology; Trastuzumab; Internal medicine; Neoadjuvant therapy; Adjuvant; Population; Biomarker; Cancer; Biology","score_opus":0.09424698101711733,"score_gpt":0.4212322075352192,"score_spread":0.3269852265181019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031646075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911666,0.0013784576,0.00007004957,0.002575531,0.00036164484,0.0008873431,0.0035479083,0.0000035533612,0.000008944494],"genre_scores_gemma":[0.99720156,0.0007358932,0.0003015682,0.0006186727,0.00066774164,0.00006689533,0.00036586606,0.000038967337,0.0000028625368],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968386,0.0003973688,0.0015433462,0.00060234434,0.00034136933,0.00027693657],"domain_scores_gemma":[0.9968423,0.0006693063,0.0012585608,0.00040355365,0.0005102137,0.00031605078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038276525,0.00030920716,0.0013254692,0.00005195655,0.000041642536,0.000009752584,0.00045817398,0.00017392411,0.000047265803],"category_scores_gemma":[0.0005065135,0.00021507127,0.00018537142,0.0001344063,0.00023773627,0.00003045375,0.00021000294,0.00026171992,6.4669035e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6112182,0.01875207,0.29183686,0.000020347663,0.0039256993,0.00031206934,0.0009093405,0.000041566782,0.00036418566,3.9177e-7,0.0016309003,0.07098834],"study_design_scores_gemma":[0.12625249,0.041681174,0.82951576,0.00008923535,0.0006333423,0.0000032573878,0.00082981656,0.000020102429,0.000115543546,0.000005073694,0.0006522266,0.00020199908],"about_ca_topic_score_codex":0.0002746809,"about_ca_topic_score_gemma":0.002177402,"teacher_disagreement_score":0.5376789,"about_ca_system_score_codex":0.00010913534,"about_ca_system_score_gemma":0.0015754489,"threshold_uncertainty_score":0.87703514},"labels":[],"label_agreement":null},{"id":"W3031660308","doi":"10.1200/jco.2020.38.15_suppl.5043","title":"Dissecting outcomes of patients (pts) with &lt;ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Internal medicine; Regimen; Cisplatin; Gemcitabine; Oncology; Urology; Chemotherapy; Gastroenterology; Cancer","score_opus":0.06037504938319243,"score_gpt":0.4225081107538845,"score_spread":0.36213306137069207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031660308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692886,0.00023773083,0.00023768295,0.026932959,0.0012494723,0.0006703205,0.0012043886,0.0000070247534,0.00017184782],"genre_scores_gemma":[0.9872712,0.00038599412,0.002374436,0.008488001,0.0011927997,0.000043135125,0.00007156747,0.000031048017,0.00014184506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727666,0.000101369165,0.0017141957,0.00028598146,0.00043016564,0.0001915997],"domain_scores_gemma":[0.9948949,0.0012707746,0.0016110727,0.00015346645,0.0016254558,0.00044429093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032672696,0.00018205422,0.0010447676,0.000057419744,0.000034156565,0.000014329172,0.00015064266,0.00014795952,0.0003731256],"category_scores_gemma":[0.0037000217,0.00011631897,0.00034651623,0.0001122194,0.00008529131,0.00018076046,0.000036822476,0.00028861978,0.0000041850953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0892683,0.0036966433,0.88543826,0.000034493238,0.002272475,0.00012828481,0.001888853,0.00003771738,0.00006818192,0.0000036795798,0.003780744,0.013382372],"study_design_scores_gemma":[0.05811441,0.006199383,0.89798653,0.00017367076,0.0008131196,6.5583197e-7,0.00046408141,0.00019683322,0.00018638714,0.000043057316,0.035703164,0.00011872006],"about_ca_topic_score_codex":0.00004257237,"about_ca_topic_score_gemma":0.00033168428,"teacher_disagreement_score":0.03192242,"about_ca_system_score_codex":0.0001584253,"about_ca_system_score_gemma":0.0012653535,"threshold_uncertainty_score":0.474335},"labels":[],"label_agreement":null},{"id":"W3031669561","doi":"10.1200/jco.2020.38.15_suppl.5553","title":"Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (<sup>18</sup>F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Probe Development and Commercialization; University Health Network; McMaster University; University of Toronto","funders":"Terry Fox Research Institute; University of Toronto","keywords":"Medicine; Prostate cancer; Prostatectomy; Nuclear medicine; Clinical endpoint; SABR volatility model; Ablative case; Radiation therapy; Salvage therapy; Lymph node; Biochemical recurrence; Androgen deprivation therapy; Metastasis; Stage (stratigraphy); Phases of clinical research; Radiology; Cancer; Surgery; Clinical trial; Internal medicine; Chemotherapy","score_opus":0.22933058198063608,"score_gpt":0.5298790695593609,"score_spread":0.3005484875787249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031669561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874157,0.002496125,0.00002284364,0.007976746,0.00018636633,0.0013810714,0.000118589385,0.000017659628,0.00038490628],"genre_scores_gemma":[0.9928253,0.0045961086,0.0010213115,0.000992266,0.00030257163,0.00005392785,0.000031158568,0.000026817932,0.0001504878],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99384534,0.0010901124,0.0033044566,0.000416813,0.0009546261,0.00038863916],"domain_scores_gemma":[0.9935509,0.0016101389,0.002226673,0.0002876184,0.0015167574,0.00080790534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022503473,0.00028271702,0.003933175,0.000583197,0.00005965775,0.000007656162,0.00031015195,0.00009469976,0.00044530953],"category_scores_gemma":[0.0016865548,0.00017910067,0.0009964071,0.0020623428,0.00024586284,0.00010803091,0.00015109325,0.00090274244,0.0000027790556],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16704333,0.05462851,0.22914483,0.00022343699,0.05976732,0.0026103323,0.013678303,0.0024312802,0.0030459662,0.000009987482,0.009020115,0.4583966],"study_design_scores_gemma":[0.16430952,0.5098044,0.2605153,0.0003725286,0.023995226,0.000083291285,0.005128332,0.0070035383,0.0035291486,0.00006898928,0.02463757,0.0005521149],"about_ca_topic_score_codex":0.0001831947,"about_ca_topic_score_gemma":0.000089396766,"teacher_disagreement_score":0.4578445,"about_ca_system_score_codex":0.0002942315,"about_ca_system_score_gemma":0.0026850943,"threshold_uncertainty_score":0.73035127},"labels":[],"label_agreement":null},{"id":"W3031687780","doi":"10.1200/jco.2020.38.15_suppl.5584","title":"Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Adjuvant; Oncology; Internal medicine; Neoadjuvant therapy; Androgen deprivation therapy; Randomized controlled trial; Radiation therapy; Cumulative incidence; Cancer; Cohort; Breast cancer","score_opus":0.27743583142348527,"score_gpt":0.5433279895238516,"score_spread":0.26589215810036637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031687780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795753,0.010908394,0.000037763984,0.007875331,0.0005187289,0.000872753,0.00009870925,0.000008692869,0.000104347346],"genre_scores_gemma":[0.97193915,0.026268631,0.0003142316,0.0008923837,0.00046555843,0.000033720877,0.000050811348,0.000019439685,0.000016062342],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923357,0.0013358905,0.00474809,0.0003234265,0.0008669954,0.00038990966],"domain_scores_gemma":[0.99401975,0.0022823245,0.0022178658,0.00020073292,0.00055942824,0.0007199141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004684048,0.0002319093,0.0048215585,0.0004971643,0.00003050906,0.000012696461,0.00023666579,0.0002746195,0.00024251644],"category_scores_gemma":[0.002040982,0.00014103446,0.0012791898,0.0010775079,0.00029299062,0.00010537314,0.00008450726,0.0011098031,0.00000201668],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2697092,0.0040251184,0.04503667,0.000017568642,0.011605141,0.0016456965,0.0016923436,0.00019269163,0.0019887863,0.0000055137434,0.0007128029,0.66336846],"study_design_scores_gemma":[0.59191597,0.18808818,0.18339151,0.00023109386,0.017317558,0.000026916825,0.0011072094,0.0034378676,0.0030302992,0.000060971743,0.011018962,0.0003734744],"about_ca_topic_score_codex":0.00012001315,"about_ca_topic_score_gemma":0.000100354075,"teacher_disagreement_score":0.662995,"about_ca_system_score_codex":0.00026613876,"about_ca_system_score_gemma":0.0025750957,"threshold_uncertainty_score":0.5751218},"labels":[],"label_agreement":null},{"id":"W3031689252","doi":"10.1200/jco.2020.38.15_suppl.tps6107","title":"ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline","keywords":"Carboplatin; Medicine; Paclitaxel; Clinical endpoint; Internal medicine; Placebo; Radiation therapy; Oncology; Endometrial cancer; Surgery; Chemotherapy; Clinical trial; Cancer; Cisplatin; Pathology","score_opus":0.23713950963434113,"score_gpt":0.5052744386797309,"score_spread":0.2681349290453897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031689252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980441,0.0036972158,0.0000382765,0.003002926,0.0056869006,0.0052241585,0.00005802257,0.000027289865,0.0018242359],"genre_scores_gemma":[0.99132997,0.0028199367,0.0014984744,0.0011084825,0.0027929253,0.00027751047,0.00002240366,0.00006199584,0.00008830221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9872348,0.0019966185,0.007803844,0.000769399,0.0014977092,0.00069767167],"domain_scores_gemma":[0.97394377,0.018685425,0.004889809,0.0004303085,0.000866008,0.001184658],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005343656,0.0005992117,0.0077071064,0.0006824745,0.000066306544,0.000023028924,0.00046835805,0.0005936239,0.0007398682],"category_scores_gemma":[0.019028395,0.00039148715,0.0014466554,0.0015211311,0.0003497272,0.00029609117,0.0002338995,0.0024199209,0.000010881563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87441313,0.016516201,0.0041839043,0.00016102268,0.002946718,0.001144801,0.001885694,0.000101906866,0.00023909957,0.000009811819,0.0001940858,0.09820363],"study_design_scores_gemma":[0.91449517,0.075265326,0.0016216977,0.00029905085,0.0030747163,0.000021847709,0.0018147198,0.00025325152,0.00020337789,0.000016160644,0.0026249834,0.00030971787],"about_ca_topic_score_codex":0.0007147653,"about_ca_topic_score_gemma":0.0009091983,"teacher_disagreement_score":0.09789391,"about_ca_system_score_codex":0.0009123803,"about_ca_system_score_gemma":0.0029283843,"threshold_uncertainty_score":0.99988157},"labels":[],"label_agreement":null},{"id":"W3031699081","doi":"10.1200/jco.2020.38.15_suppl.5542","title":"Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Taxane; Cabazitaxel; Enzalutamide; Internal medicine; Prostate cancer; Docetaxel; Oncology; Neutropenia; Interim analysis; Regimen; Clinical trial; Chemotherapy; Cancer; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.12707540710585571,"score_gpt":0.4252723192815633,"score_spread":0.29819691217570754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031699081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560005,0.0014112775,0.000015488144,0.011512711,0.00012025018,0.0009259565,0.00004323946,0.00000975144,0.00036128543],"genre_scores_gemma":[0.99139696,0.006445015,0.00054427685,0.0009928585,0.00021176615,0.000021169613,0.000030760206,0.000031746993,0.00032541485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965804,0.0005427621,0.0015054777,0.00032790238,0.00065994106,0.00038350472],"domain_scores_gemma":[0.9971087,0.0006213396,0.000997602,0.00013133392,0.00051797077,0.0006230611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011012511,0.00024550184,0.0015528679,0.00010557248,0.000058688584,0.000023850778,0.000108903994,0.00013882243,0.00013027118],"category_scores_gemma":[0.0002775657,0.00013060131,0.00012832823,0.0002805165,0.00028034626,0.00017465132,0.000027089396,0.0008471683,0.0000027607744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2789094,0.0029817342,0.65861404,0.00011782239,0.0016149463,0.0034375356,0.00085886696,0.00024586337,0.00025823023,0.00003065146,0.00038003948,0.05255089],"study_design_scores_gemma":[0.13662982,0.056728724,0.7956087,0.00025811957,0.00041976964,0.0000660298,0.00026171733,0.00019774199,0.00018620469,0.0000215704,0.009413839,0.00020777957],"about_ca_topic_score_codex":0.00047996198,"about_ca_topic_score_gemma":0.0009264701,"teacher_disagreement_score":0.14227958,"about_ca_system_score_codex":0.0005539215,"about_ca_system_score_gemma":0.002861304,"threshold_uncertainty_score":0.5325767},"labels":[],"label_agreement":null},{"id":"W3031702393","doi":"10.1200/jco.2020.38.15_suppl.e19268","title":"Clinical outcomes of pancreas cancer patients with peritoneal spread: Results from the chord consortium.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; University of Calgary; CancerCare Manitoba; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Proportional hazards model; Pancreatic cancer; Chemotherapy; Lung cancer; Oncology; FOLFIRINOX; Gastroenterology; Univariate analysis; Retrospective cohort study; Cohort; Adenocarcinoma; Cancer; Surgery; Oxaliplatin; Multivariate analysis","score_opus":0.19314147705073587,"score_gpt":0.5092081906408686,"score_spread":0.3160667135901328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031702393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500813,0.00027881132,0.000039135062,0.046182007,0.0006728352,0.0003893483,0.000109306195,0.000008267311,0.002238985],"genre_scores_gemma":[0.9836917,0.0013496359,0.0033484574,0.009424995,0.001971505,0.0000061471455,0.00001360351,0.000019918274,0.00017404568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928241,0.0013007021,0.0044576665,0.00031345952,0.0007960763,0.00030802193],"domain_scores_gemma":[0.9753741,0.019215267,0.0030888042,0.00034494454,0.0011751591,0.000801728],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040559457,0.0001853742,0.0033321274,0.000039099596,0.000055659093,0.0000069551606,0.00040274858,0.0005155592,0.00036444634],"category_scores_gemma":[0.026094839,0.00008915911,0.0006327044,0.00016623647,0.0012034299,0.0000771819,0.00011629624,0.001927598,0.000022833055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032470383,0.0018253758,0.92596173,0.000012764765,0.0018682592,0.00017706772,0.00025760182,0.0000020225677,0.0000058915825,0.000021385471,0.01274171,0.024655834],"study_design_scores_gemma":[0.024326907,0.017930117,0.9203943,0.00010134484,0.0013922037,0.000011897477,0.0001828459,0.00006494865,0.000005936669,0.000044880577,0.035461523,0.000083117855],"about_ca_topic_score_codex":0.00048421137,"about_ca_topic_score_gemma":0.00017172,"teacher_disagreement_score":0.036757015,"about_ca_system_score_codex":0.00007127452,"about_ca_system_score_gemma":0.0037853306,"threshold_uncertainty_score":0.9821088},"labels":[],"label_agreement":null},{"id":"W3031713048","doi":"10.1200/jco.2020.38.15_suppl.e24033","title":"Preoperative frailty assessment with Robinson Frailty Score (RFS) and Edmonton Frail Scale (EFS) in older surgical patients with cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Polypharmacy; Geriatric oncology; Activities of daily living; Mood; Cohort; Adverse effect; Comorbidity; Sarcopenia; Geriatrics; Internal medicine; Quality of life (healthcare); Cancer; Physical therapy; Gerontology","score_opus":0.08519593389334616,"score_gpt":0.43156125114402777,"score_spread":0.3463653172506816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031713048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710985,0.0003742567,0.00016456026,0.025375368,0.00031248268,0.0007507661,0.000020378364,0.000018046605,0.0018856402],"genre_scores_gemma":[0.98889357,0.0004925494,0.0057221297,0.003788962,0.00082875637,0.000023438119,0.000012887872,0.00004219625,0.00019549008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955832,0.00053845317,0.0020665866,0.000521649,0.00087049,0.0004196604],"domain_scores_gemma":[0.99553704,0.0011961875,0.0012859211,0.0002262367,0.0008030545,0.0009515593],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010357845,0.00033255448,0.0021695262,0.00010816099,0.00006110011,0.000026615986,0.00021818069,0.00050431944,0.00039952487],"category_scores_gemma":[0.0007186877,0.00020131917,0.00018625367,0.00033462374,0.00048073183,0.0003319254,0.000104959414,0.0023557905,0.000005480432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009019907,0.0022978815,0.9451719,0.00008167031,0.00030503896,0.0009848868,0.00086868496,0.00015462164,0.000018944853,0.000015381896,0.0031136482,0.037967443],"study_design_scores_gemma":[0.036044046,0.0289686,0.9163505,0.0006987998,0.00029233375,0.00012261308,0.00024979864,0.00035823765,0.000052704694,0.000013468337,0.01661974,0.00022917044],"about_ca_topic_score_codex":0.00014621827,"about_ca_topic_score_gemma":0.0014184961,"teacher_disagreement_score":0.03773827,"about_ca_system_score_codex":0.00033499958,"about_ca_system_score_gemma":0.0024187341,"threshold_uncertainty_score":0.9999458},"labels":[],"label_agreement":null},{"id":"W3031718783","doi":"10.1200/jco.2020.38.15_suppl.e22504","title":"Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Internal medicine; Lymphoma; Refractory (planetary science); Cytokine release syndrome; Gastroenterology; Surgery; Oncology; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.08639205978262311,"score_gpt":0.4210383654333999,"score_spread":0.3346463056507768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031718783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290967,0.00018568475,0.0001017166,0.0025034077,0.0007840768,0.0011334773,0.000022761942,0.000010857948,0.0023483746],"genre_scores_gemma":[0.9928822,0.0008064975,0.0023092146,0.0018164415,0.0019834922,0.0000070686065,0.000006599027,0.000041106454,0.00014736906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99402994,0.0006359745,0.0034032408,0.00047223608,0.00096924166,0.00048936426],"domain_scores_gemma":[0.99373394,0.0021835028,0.001763411,0.0002908093,0.0008268673,0.0012014955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002056707,0.00029391676,0.0022221492,0.0002214523,0.0000542341,0.0000137858815,0.00032789534,0.0005261393,0.00027834493],"category_scores_gemma":[0.006015982,0.00022477319,0.00036365833,0.000680062,0.00024124225,0.00014812271,0.00020306121,0.000996351,0.000012386857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5277516,0.02936918,0.061385464,0.00009452214,0.00016070728,0.0010757361,0.00041130942,0.000009546706,0.002415176,0.0000014552506,0.001959107,0.37536615],"study_design_scores_gemma":[0.5231495,0.36049554,0.10511056,0.00013659774,0.00039962959,0.00011307995,0.00007451819,0.00015608013,0.00036535627,0.000007668807,0.009764104,0.00022739176],"about_ca_topic_score_codex":0.00003871928,"about_ca_topic_score_gemma":0.00010540504,"teacher_disagreement_score":0.37513876,"about_ca_system_score_codex":0.0004751563,"about_ca_system_score_gemma":0.0019139309,"threshold_uncertainty_score":0.91659844},"labels":[],"label_agreement":null},{"id":"W3031739372","doi":"10.1200/jco.2020.38.15_suppl.e14049","title":"Multistate Markov modelling of long-term outcomes in immunotherapy for metastatic renal cell carcinoma (mRCC) using machine-learned dynamic Bayesian networks.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Renal cell carcinoma; Medicine; Multivariate statistics; Bayesian probability; Bayesian network; Multivariate analysis; Machine learning; Computer science; Statistic; Artificial intelligence; Clinical trial; Nomogram; Immunotherapy; Oncology; Statistics; Internal medicine; Cancer; Mathematics","score_opus":0.6619624007968893,"score_gpt":0.6021213185195662,"score_spread":0.0598410822773231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031739372","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30325943,0.00024197451,0.6941115,0.0010393529,0.00074311637,0.00052041165,0.000041625586,0.000008985228,0.000033588414],"genre_scores_gemma":[0.44889498,0.00019428231,0.55018574,0.00044300145,0.00020872378,0.000004901179,0.0000011775303,0.000049114136,0.000018094786],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98641515,0.003727799,0.008452573,0.00042420658,0.00047554297,0.00050472806],"domain_scores_gemma":[0.88400775,0.109506674,0.0053970353,0.00031342372,0.00037797578,0.00039714636],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013811081,0.00034679208,0.004517574,0.00016280949,0.000049731734,0.000021740118,0.00064307556,0.00046759038,0.00011881297],"category_scores_gemma":[0.04676788,0.00026729912,0.0012622066,0.00025902956,0.00031309598,0.00012366562,0.00011340388,0.0015408754,0.0000012401513],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07192699,0.013914446,0.21954887,0.0027972048,0.0039998214,0.0033187151,0.0014261933,0.13546023,0.0024181094,0.0031321796,0.0003454564,0.5417118],"study_design_scores_gemma":[0.019758714,0.0063939043,0.008791023,0.00016976951,0.0007601045,0.000033623677,0.000056603712,0.87493837,0.00014412426,0.0885697,0.000037733,0.000346307],"about_ca_topic_score_codex":0.000024560619,"about_ca_topic_score_gemma":0.0000375463,"teacher_disagreement_score":0.7394782,"about_ca_system_score_codex":0.00015262149,"about_ca_system_score_gemma":0.0006127536,"threshold_uncertainty_score":0.99997795},"labels":[],"label_agreement":null},{"id":"W3031754935","doi":"10.1200/jco.2020.38.15_suppl.1077","title":"Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Olaparib; PARP inhibitor; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple-negative breast cancer; Response Evaluation Criteria in Solid Tumors; Tolerability; Clinical endpoint; Phases of clinical research; Cancer; Gastroenterology; Adverse effect; Clinical trial; Poly ADP ribose polymerase","score_opus":0.1740430128635073,"score_gpt":0.5207388288404442,"score_spread":0.3466958159769369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031754935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947067,0.00014287725,0.000053880784,0.0026570286,0.00027369236,0.0019621206,0.000087467444,0.000005144446,0.00011112738],"genre_scores_gemma":[0.998691,0.00019746282,0.0004735677,0.00037851965,0.00018965326,0.000030395036,0.000009573106,0.000021651344,0.0000081584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327004,0.00096280937,0.0044687656,0.0003629283,0.0007421084,0.00019333817],"domain_scores_gemma":[0.99238,0.0017486392,0.004393516,0.00040035453,0.0008642342,0.00021324544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033324505,0.0001864064,0.0029809505,0.00026544658,0.000020106234,0.0000017660387,0.00041505057,0.00016150122,0.000089669775],"category_scores_gemma":[0.0025308174,0.00014323184,0.0001262814,0.00070313347,0.0002934681,0.0002467583,0.00015056103,0.0010429936,3.5776694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21059707,0.107332826,0.6295634,0.00014357163,0.0009958987,0.00057876314,0.008901054,0.00077398337,0.0016358561,0.0000073691895,0.00042496345,0.03904526],"study_design_scores_gemma":[0.15569344,0.17826866,0.6596296,0.00056677056,0.00039960706,0.000048854585,0.004172522,0.0005841299,0.00047133147,0.000022894974,0.00005296724,0.00008921284],"about_ca_topic_score_codex":0.00024010848,"about_ca_topic_score_gemma":0.00044970412,"teacher_disagreement_score":0.07093584,"about_ca_system_score_codex":0.0002106463,"about_ca_system_score_gemma":0.0020875202,"threshold_uncertainty_score":0.5840825},"labels":[],"label_agreement":null},{"id":"W3031773775","doi":"10.1200/jco.2020.38.15_suppl.8541","title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Cytogenetics; Adverse effect; Nausea; Gastroenterology; Refractory (planetary science); Oncology; Lenalidomide; Surgery; Multiple myeloma","score_opus":0.08724952197433244,"score_gpt":0.3742772388134105,"score_spread":0.2870277168390781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031773775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995544,0.0003572191,0.00008097281,0.002895785,0.00028216187,0.00051394926,0.00004542039,0.000013128541,0.00026736013],"genre_scores_gemma":[0.99155915,0.0007464762,0.005949418,0.0011103599,0.0005140441,0.000005660145,0.000026621583,0.000040211657,0.000048062047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571335,0.000706343,0.0019920156,0.00039484166,0.00073304283,0.00046041387],"domain_scores_gemma":[0.9946337,0.002163973,0.0013520423,0.00023126366,0.0004035257,0.0012155484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001127877,0.00025982436,0.0015774849,0.00017744303,0.000060466133,0.000017384706,0.00018328604,0.000395752,0.00013027647],"category_scores_gemma":[0.005531071,0.00017225646,0.00023123661,0.0002112362,0.00028001485,0.00012225189,0.00013007244,0.0015163218,0.000034793888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021138659,0.0036106326,0.78755015,0.000034262237,0.00044106867,0.0014826041,0.00011269073,0.000012497821,0.00009961139,0.0000030658357,0.00049650244,0.18501823],"study_design_scores_gemma":[0.051916286,0.047890216,0.89139056,0.00011595119,0.00028774206,0.000060713526,0.00006785794,0.00015633854,0.00017132005,0.000023003706,0.0077781193,0.00014190069],"about_ca_topic_score_codex":0.000111340414,"about_ca_topic_score_gemma":0.00021823417,"teacher_disagreement_score":0.18487632,"about_ca_system_score_codex":0.00023869012,"about_ca_system_score_gemma":0.0007653797,"threshold_uncertainty_score":0.70244145},"labels":[],"label_agreement":null},{"id":"W3031783140","doi":"10.1200/jco.2020.38.15_suppl.10077","title":"Incidence and trends of skin cancer in the United States, 1999-2016.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Incidence (geometry); National Health and Nutrition Examination Survey; Demography; Epidemiology; Population; Skin cancer; Surveillance, Epidemiology, and End Results; Cancer; Cancer registry; Gerontology; Internal medicine; Environmental health","score_opus":0.13300689959777903,"score_gpt":0.48309801100334504,"score_spread":0.35009111140556604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031783140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91756994,0.003356172,0.000023792483,0.07776961,0.00027267414,0.00006414275,0.000006346501,0.0000018190254,0.0009355203],"genre_scores_gemma":[0.97885585,0.009868865,0.0005138318,0.010051124,0.00065786863,0.0000027740875,9.944175e-7,0.000006480094,0.000042241012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771833,0.00036099707,0.0014190634,0.000111029345,0.0002613134,0.00012928453],"domain_scores_gemma":[0.99621445,0.002399702,0.00097382476,0.000092684844,0.00017405377,0.00014525792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017642102,0.00008222941,0.0009800965,0.00011954636,0.000015796128,0.0000027570807,0.00015529378,0.00012688455,0.00009318834],"category_scores_gemma":[0.0017654983,0.00004612408,0.00013104008,0.00040906112,0.00030897357,0.00004442567,0.00006170641,0.0007367593,0.0000012692427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033746553,0.00040152462,0.7147313,0.00005991056,0.00027465104,0.0006822533,0.0034684974,0.00006351173,0.000032963188,0.00006001466,0.027702445,0.24914831],"study_design_scores_gemma":[0.003782771,0.005683384,0.85703564,0.00011119101,0.00015590698,0.0001022909,0.00074992597,0.00015671847,0.000021259955,0.000105839914,0.13205144,0.000043610646],"about_ca_topic_score_codex":0.0004388541,"about_ca_topic_score_gemma":0.00040701663,"teacher_disagreement_score":0.2491047,"about_ca_system_score_codex":0.00005857536,"about_ca_system_score_gemma":0.0005029004,"threshold_uncertainty_score":0.32008934},"labels":[],"label_agreement":null},{"id":"W3031787110","doi":"10.1200/jco.2020.38.15_suppl.2014","title":"Mapping PRO-CTCAE responses to clinician-graded adverse events, dose reductions, interruptions, and discontinuations in phase I cancer trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Clinical trial; Internal medicine","score_opus":0.875711508504094,"score_gpt":0.7220151033976008,"score_spread":0.15369640510649318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031787110","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85647976,0.0002864052,0.042111963,0.09489709,0.004382803,0.0015075781,0.00012464641,0.000037315986,0.00017242758],"genre_scores_gemma":[0.37247118,0.0013346304,0.6172883,0.004478973,0.004069745,0.00009444701,0.0000012403137,0.00004338738,0.00021809424],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97582793,0.012000463,0.01089406,0.0004766175,0.00045630184,0.00034465038],"domain_scores_gemma":[0.8058292,0.1864555,0.0057964073,0.00034482955,0.0005351011,0.0010389498],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.042116567,0.00024322695,0.0037105416,0.0003152833,0.0000779257,0.000017039547,0.0004014304,0.00051076413,0.00032987632],"category_scores_gemma":[0.72240084,0.00018674908,0.000692808,0.0005873347,0.00028943637,0.00020662967,0.00019241049,0.0017424,0.000017897046],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03948005,0.008272638,0.020717481,0.00020814287,0.001312288,0.00041706505,0.0035882953,0.000038144557,0.0011620037,0.014446139,0.026087472,0.8842703],"study_design_scores_gemma":[0.060159657,0.020619877,0.10499041,0.0018176452,0.0017398838,0.00010563139,0.005643002,0.00067859254,0.0001526825,0.7245816,0.07861512,0.00089589815],"about_ca_topic_score_codex":0.000013660803,"about_ca_topic_score_gemma":0.000062237836,"teacher_disagreement_score":0.8833744,"about_ca_system_score_codex":0.00016172708,"about_ca_system_score_gemma":0.0013110097,"threshold_uncertainty_score":0.98634255},"labels":[],"label_agreement":null},{"id":"W3031793799","doi":"10.1200/jco.2020.38.15_suppl.522","title":"HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Tamoxifen; Oncology; Breast cancer; Internal medicine; Proportional hazards model; Hazard ratio; Confidence interval; Cancer","score_opus":0.04448079074561311,"score_gpt":0.38279053604600793,"score_spread":0.3383097453003948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031793799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093956,0.00039401033,0.000017392944,0.007979825,0.00021306904,0.00031325157,0.00008725086,0.0000012669918,0.0000543814],"genre_scores_gemma":[0.9961204,0.0012521531,0.00012455686,0.0020462929,0.00040635985,0.00002700395,0.0000072749026,0.000010088459,0.000005876269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812335,0.00020240806,0.0010325675,0.0002186219,0.0002264344,0.00019660492],"domain_scores_gemma":[0.99875736,0.00016931209,0.000595671,0.0001152699,0.00021577923,0.00014658287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041668944,0.00013075823,0.0006705448,0.00005145744,0.000016636475,0.0000043606633,0.0001370214,0.0001269502,0.000012055574],"category_scores_gemma":[0.00035224436,0.000077667915,0.00009122865,0.00014332175,0.00012713902,0.000009966057,0.000086364074,0.0002848936,2.9378896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07018537,0.0011682336,0.88832605,0.000013534285,0.00018851944,0.000033078122,0.0003366368,0.00016275792,0.00011824654,0.0000046084333,0.0004841767,0.038978804],"study_design_scores_gemma":[0.040641807,0.008807256,0.9473691,0.000041102583,0.000071975075,0.000021400534,0.00022155039,0.000014310783,0.00010491459,0.000021488702,0.0026209955,0.000064076456],"about_ca_topic_score_codex":0.00032496575,"about_ca_topic_score_gemma":0.0013431802,"teacher_disagreement_score":0.059043083,"about_ca_system_score_codex":0.00005812802,"about_ca_system_score_gemma":0.0003252519,"threshold_uncertainty_score":0.31672058},"labels":[],"label_agreement":null},{"id":"W3031795832","doi":"10.1200/jco.2020.38.15_suppl.3068","title":"Circulating tumor DNA dynamics as prognostic and predictive biomarkers of response to pembrolizumab in patients with virally-related tumors (VRT) treated within the INSPIRE study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University of Alberta; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Nasopharyngeal carcinoma; Head and neck cancer; Progression-free survival; Confidence interval; Pathology; Cancer; Overall survival; Immunotherapy; Progressive disease; Radiation therapy; Chemotherapy","score_opus":0.017904381131290174,"score_gpt":0.32235387402083904,"score_spread":0.30444949288954887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031795832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980089,0.000066899884,0.000028105962,0.0010664139,0.00010981293,0.0006152321,0.000027041326,0.0000023629223,0.00007523163],"genre_scores_gemma":[0.99899805,0.000012874077,0.00018142974,0.0006982992,0.00006882083,0.000007668031,0.000009282622,0.000019777948,0.000003823869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973032,0.00060862995,0.0014672444,0.00025705242,0.00020543291,0.00015846454],"domain_scores_gemma":[0.99729407,0.000773158,0.0012263518,0.00015459275,0.0003209421,0.00023088952],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0013833025,0.00015085739,0.00062298344,0.00006923266,0.00003783414,0.00001155093,0.00021180243,0.0001540915,0.0000024880292],"category_scores_gemma":[0.008620413,0.00010058217,0.00010129688,0.00023192835,0.00019671742,0.000007459419,0.00013913032,0.0003501503,6.294475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054794814,0.0010212902,0.937037,0.000012039788,0.0004184689,0.0002468862,0.0006985054,0.0019331109,0.0011647975,0.000011257073,0.000044806504,0.0026170083],"study_design_scores_gemma":[0.0096808495,0.055998977,0.93172073,0.00006461598,0.00016821394,0.00003658519,0.00087105384,0.0010764359,0.00016627659,0.000031348944,0.0000628259,0.000122059646],"about_ca_topic_score_codex":0.00003528357,"about_ca_topic_score_gemma":0.00016487385,"teacher_disagreement_score":0.05497769,"about_ca_system_score_codex":0.00007255619,"about_ca_system_score_gemma":0.0009844824,"threshold_uncertainty_score":0.9997304},"labels":[],"label_agreement":null},{"id":"W3031796418","doi":"10.1200/jco.2020.38.15_suppl.6548","title":"Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Peripheral blood mononuclear cell; Durvalumab; Germline; Gastroenterology; Oncology; Cancer; Immunotherapy; Head and neck cancer; Nivolumab; In vitro; Biology","score_opus":0.10542487010938492,"score_gpt":0.4275511045825271,"score_spread":0.32212623447314215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031796418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723192,0.014796076,0.00002018425,0.010785446,0.0012312339,0.0006268858,0.00010959404,0.00001176222,0.000099624674],"genre_scores_gemma":[0.9875252,0.0029187256,0.0013709834,0.0077873864,0.00030446355,0.0000068662202,0.000028205122,0.00004356787,0.000014560839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468374,0.00059715705,0.003094977,0.000642408,0.00056001154,0.00042171913],"domain_scores_gemma":[0.9954107,0.0017979909,0.0014193003,0.00027229774,0.0003759798,0.000723726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012611266,0.00037275863,0.0026625362,0.00023826634,0.000066588174,0.000040871164,0.00024379505,0.00032550143,0.000104064566],"category_scores_gemma":[0.0019670848,0.00030355944,0.00043129537,0.00036989813,0.0003441715,0.00016564252,0.00018193178,0.00081869465,0.000010556673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04182181,0.002561528,0.80330795,0.00021582226,0.0015900212,0.0023074541,0.002125746,0.000011263327,0.010765927,0.000002913219,0.006758788,0.12853076],"study_design_scores_gemma":[0.056640733,0.015453886,0.91778636,0.00034260636,0.0007861075,0.00003294726,0.0008902258,0.00015821117,0.0011581357,0.00010878382,0.0063379356,0.0003040982],"about_ca_topic_score_codex":0.0007250186,"about_ca_topic_score_gemma":0.00030256712,"teacher_disagreement_score":0.12822665,"about_ca_system_score_codex":0.0002321515,"about_ca_system_score_gemma":0.0005178831,"threshold_uncertainty_score":0.99994165},"labels":[],"label_agreement":null},{"id":"W3031806342","doi":"10.1200/jco.2020.38.15_suppl.2032","title":"Impact of an immuno-oncology (IO) education/monitoring program on patient’s self-efficacy and adverse event reporting from immune checkpoint inhibitors (ICIs).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Adverse effect; Cancer; Internal medicine; Renal cell carcinoma; Prospective cohort study; Patient education; Oncology; Family medicine; Immunotherapy","score_opus":0.12076754883808541,"score_gpt":0.43105014824038934,"score_spread":0.31028259940230396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031806342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084306,0.0017936325,0.00002170916,0.0014450758,0.0027870033,0.00036604068,0.000021884098,0.000018763738,0.0027028255],"genre_scores_gemma":[0.99245155,0.0010353344,0.0040941373,0.0003215046,0.0020393876,0.000014057434,0.000005195364,0.000028413131,0.000010399663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.990126,0.00013227413,0.008995908,0.00037650645,0.000072990944,0.00029630002],"domain_scores_gemma":[0.9803049,0.00064913696,0.018051298,0.00025955957,0.00024157758,0.0004935577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002931812,0.00021614948,0.0020717222,0.00016398908,0.00006298163,0.000023501867,0.00026982784,0.00044357256,0.00010409746],"category_scores_gemma":[0.007305452,0.00020085005,0.0008215019,0.00014816676,0.00014404007,0.00045213988,0.00009947269,0.00082528865,0.000019190598],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020154568,0.007328462,0.1901511,0.000022601555,0.0006137786,0.00005631855,0.0017223328,0.0003254003,0.00011953594,0.0002908707,0.00038934508,0.7969648],"study_design_scores_gemma":[0.00374765,0.027126538,0.92570347,0.00007916867,0.00007217668,0.00003064392,0.00039476546,0.0002062336,0.00022422646,0.0013170134,0.040854238,0.0002438685],"about_ca_topic_score_codex":0.00043929956,"about_ca_topic_score_gemma":0.000009383502,"teacher_disagreement_score":0.7967209,"about_ca_system_score_codex":0.0005477988,"about_ca_system_score_gemma":0.0015346142,"threshold_uncertainty_score":0.8745836},"labels":[],"label_agreement":null},{"id":"W3031809543","doi":"10.1200/jco.2020.38.15_suppl.1088","title":"Clinical predictors of long-term response to capecitabine in metastatic breast cancer (MBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Alberta; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Metastatic breast cancer; Breast cancer; Cohort; Oncology; Cancer; Docetaxel; Proportional hazards model; Stage (stratigraphy); Hormonal therapy; Surgery","score_opus":0.18164664771792685,"score_gpt":0.5443573413343225,"score_spread":0.36271069361639563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031809543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92800534,0.00058300735,0.000046152516,0.06881849,0.0019529621,0.00034951782,0.00003839778,0.0000074680243,0.00019865796],"genre_scores_gemma":[0.9849989,0.001286051,0.0009834174,0.010157548,0.0023504223,0.000010657982,0.000002582977,0.000021328675,0.0001890955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937296,0.0013941035,0.003974744,0.00027042098,0.00035444906,0.00027670639],"domain_scores_gemma":[0.9925116,0.004445471,0.0015112214,0.00015345571,0.0003994024,0.000978902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041334783,0.00017309115,0.0024905228,0.00018960312,0.000013714315,0.0000031804357,0.00021815834,0.00026985677,0.0013206329],"category_scores_gemma":[0.003389867,0.00012503502,0.00063367654,0.00037325246,0.00025389288,0.00007957871,0.00008020021,0.0011022667,0.000023769328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097981766,0.003946379,0.82107395,0.000059027952,0.00087062415,0.0024364265,0.00026817343,0.000035716937,0.001080419,0.0000027994784,0.008733907,0.06351083],"study_design_scores_gemma":[0.020368157,0.030405901,0.9340759,0.00013670283,0.001036477,0.00030577704,0.00004636906,0.000032244137,0.00009542639,0.000008559284,0.013399895,0.00008860762],"about_ca_topic_score_codex":0.000039730345,"about_ca_topic_score_gemma":0.00017614137,"teacher_disagreement_score":0.11300195,"about_ca_system_score_codex":0.00022684333,"about_ca_system_score_gemma":0.0031289926,"threshold_uncertainty_score":0.9995923},"labels":[],"label_agreement":null},{"id":"W3031823031","doi":"10.1200/jco.2020.38.15_suppl.e19267","title":"The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; CancerCare Manitoba; Juravinski Cancer Centre; University of Calgary; University of Ottawa","funders":"","keywords":"Medicine; Pancreatic cancer; Adenocarcinoma; Internal medicine; Oncology; Cancer; Primary tumor; Proportional hazards model; Lung cancer; Metastasis","score_opus":0.19707854251733142,"score_gpt":0.5315291757659468,"score_spread":0.3344506332486154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031823031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94780904,0.000708559,0.00003532221,0.04885377,0.00034091517,0.00052746315,0.000029976074,0.000006114573,0.0016888212],"genre_scores_gemma":[0.9908891,0.0024184226,0.00059116265,0.005096059,0.0008467889,0.00000930242,0.00000989822,0.0000140775155,0.00012522709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919855,0.0022358282,0.004645427,0.00026433283,0.00057422684,0.0002947089],"domain_scores_gemma":[0.93241286,0.06225703,0.0035537127,0.000496365,0.0005772028,0.00070282805],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007921122,0.00016566276,0.0024649415,0.000047573747,0.000065461616,0.000008686567,0.0004239205,0.00023557663,0.00005287852],"category_scores_gemma":[0.11789957,0.00007171904,0.00080454024,0.00024237485,0.0008516628,0.00006622971,0.00008456642,0.0018278289,0.000028242574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05684516,0.0014729322,0.9049569,0.000013218419,0.00067167555,0.00030922255,0.00010095208,0.000065361346,0.000017101407,0.00004299323,0.0048503014,0.030654179],"study_design_scores_gemma":[0.01483257,0.016964598,0.9633683,0.00016264632,0.0004380581,0.000012972696,0.00015226523,0.00062482775,0.0000018882669,0.0003822855,0.0029975807,0.000062033156],"about_ca_topic_score_codex":0.00012345337,"about_ca_topic_score_gemma":0.000047521844,"teacher_disagreement_score":0.109978445,"about_ca_system_score_codex":0.00022414097,"about_ca_system_score_gemma":0.0060838107,"threshold_uncertainty_score":0.99955076},"labels":[],"label_agreement":null},{"id":"W3031823049","doi":"10.1200/jco.2020.38.15_suppl.7019","title":"Predictive survival ability of patient-reported in comparison to physician-reported performance status in solid malignancies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Sunnybrook Health Science Centre; Cancer Care Ontario; Health Sciences Centre; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Performance status; Internal medicine; Cancer; Hazard ratio; Proportional hazards model; Oncology; Confidence interval","score_opus":0.0888066843451651,"score_gpt":0.4491425284582962,"score_spread":0.36033584411313113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031823049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907336,0.00009802516,0.0004953779,0.006485471,0.00073414424,0.00028914105,0.0000020330517,0.000008267243,0.0011539012],"genre_scores_gemma":[0.99450403,0.00011671389,0.0019321886,0.003085019,0.00033720487,0.0000031996385,0.0000032505739,0.000013847681,0.000004511452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99393576,0.00045776437,0.004471713,0.00025686898,0.00055029534,0.00032760715],"domain_scores_gemma":[0.9952066,0.0011411186,0.002452918,0.00017577065,0.00045684463,0.00056674884],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033845631,0.0001389832,0.0021274977,0.00014941901,0.000014825853,0.000003952938,0.00013934581,0.00020409096,0.000027402266],"category_scores_gemma":[0.017504182,0.0001096923,0.00024641235,0.000449595,0.0002185115,0.00009565221,0.000078076504,0.0017622496,0.0000026852724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004619906,0.0016505772,0.888864,0.000070968286,0.00014899943,0.00051781983,0.0012355057,0.004147529,0.0016420181,0.000005403033,0.00044831444,0.09664899],"study_design_scores_gemma":[0.005841911,0.011025959,0.9478483,0.00026155362,0.000119346856,0.000033882363,0.0005402472,0.0292732,0.0002755713,0.000038639973,0.0046528173,0.00008857751],"about_ca_topic_score_codex":0.00009123968,"about_ca_topic_score_gemma":0.000022948823,"teacher_disagreement_score":0.09656041,"about_ca_system_score_codex":0.00019006037,"about_ca_system_score_gemma":0.0014703812,"threshold_uncertainty_score":0.9907718},"labels":[],"label_agreement":null},{"id":"W3031830911","doi":"10.1200/jco.2020.38.29_suppl.281","title":"Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Proportional hazards model; Chemotherapy; Epidermal growth factor receptor; Cancer","score_opus":0.03915315525862403,"score_gpt":0.395961877732396,"score_spread":0.356808722473772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031830911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98457295,0.00013817028,0.00004111082,0.013270632,0.00054139755,0.0009757788,0.00005504541,0.000031843687,0.00037305406],"genre_scores_gemma":[0.99231493,0.0012024622,0.0025174387,0.002826572,0.0005554735,0.000042801734,0.000050599374,0.000086028274,0.00040368282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965834,0.00020505922,0.0020022143,0.00039169905,0.00040370863,0.0004139258],"domain_scores_gemma":[0.9955313,0.0012217168,0.0018839703,0.0001862728,0.0006451163,0.00053162745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033249106,0.00038849958,0.0018310852,0.00020976306,0.00007876621,0.000020361302,0.00016628826,0.000271976,0.000438272],"category_scores_gemma":[0.0003241952,0.00021348534,0.00028475613,0.0006087031,0.0001919008,0.00020531366,0.000023201392,0.0008611662,0.000004129874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05283383,0.0025326596,0.9303497,0.000080980746,0.0013484143,0.0004581294,0.00086713827,0.000135558,0.00006489715,7.505033e-7,0.0013268463,0.010001101],"study_design_scores_gemma":[0.094036855,0.020715067,0.8807225,0.00035469854,0.0006594433,0.0000037601044,0.000112907685,0.0001765513,0.0006282323,8.0376833e-7,0.0023502442,0.00023889059],"about_ca_topic_score_codex":0.0015525785,"about_ca_topic_score_gemma":0.002645698,"teacher_disagreement_score":0.049627148,"about_ca_system_score_codex":0.0008234399,"about_ca_system_score_gemma":0.0018106899,"threshold_uncertainty_score":0.870568},"labels":[],"label_agreement":null},{"id":"W3031847233","doi":"10.1200/jco.2020.38.15_suppl.tps6595","title":"Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Lymph node; Internal medicine; Primary tumor; Oncology; Nasal cavity; Stage (stratigraphy); Melanoma; Cancer; Gastroenterology; Surgery; Immunotherapy; Metastasis; Cancer research","score_opus":0.091868815051498,"score_gpt":0.3802406123352916,"score_spread":0.2883717972837936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031847233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949367,0.00019815125,0.0000039573374,0.003363578,0.00030237355,0.0007239989,0.000008471601,0.0000018019192,0.0004609731],"genre_scores_gemma":[0.9983471,0.000060611506,0.00025152802,0.0009431362,0.00030300478,0.0000028881716,7.976165e-7,0.000015075247,0.00007588318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966332,0.00055823603,0.001968117,0.00015250777,0.0005176587,0.00017033539],"domain_scores_gemma":[0.995589,0.001083983,0.002489793,0.0002501087,0.00040287283,0.00018420609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001762836,0.00013591678,0.0013741849,0.000060241513,0.00003331585,0.0000036485965,0.0002215731,0.00021080922,0.00006083983],"category_scores_gemma":[0.0012122933,0.000055974426,0.00021736085,0.00031876686,0.0006721244,0.00007019586,0.00006164635,0.00078223966,1.5499901e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47129497,0.0015145751,0.5215296,0.00008256176,0.0000929885,0.000022343744,0.00037906397,0.0000030948713,0.00027739565,0.0000011919466,0.0004550925,0.0043470934],"study_design_scores_gemma":[0.2080268,0.11723015,0.6703697,0.000209542,0.0002744004,0.000028948709,0.00041781602,0.000020314033,0.0012398867,0.0000066035223,0.0021045553,0.00007130002],"about_ca_topic_score_codex":0.0002590576,"about_ca_topic_score_gemma":0.00052044075,"teacher_disagreement_score":0.2632682,"about_ca_system_score_codex":0.00006122631,"about_ca_system_score_gemma":0.002786029,"threshold_uncertainty_score":0.49422958},"labels":[],"label_agreement":null},{"id":"W3031848108","doi":"10.1200/jco.2020.38.15_suppl.10501","title":"Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Research UK","keywords":"Medicine; Bevacizumab; Internal medicine; Irinotecan; Hazard ratio; Refractory (planetary science); Progression-free survival; Oncology; Chemotherapy; Randomized controlled trial; Topotecan; Surgery; Gastroenterology; Confidence interval; Cancer; Colorectal cancer","score_opus":0.09320385933477743,"score_gpt":0.4166054603129126,"score_spread":0.3234016009781352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031848108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98265123,0.00004987042,0.00002636181,0.013781833,0.00035487147,0.002831691,0.000118619355,0.000014098268,0.00017139428],"genre_scores_gemma":[0.9972986,0.00038560046,0.0010295176,0.0007811817,0.00032516778,0.000024816534,0.000006035105,0.00004725414,0.00010182402],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9901127,0.003318715,0.004594943,0.0005553606,0.00095832086,0.0004599538],"domain_scores_gemma":[0.9845889,0.009272565,0.0041212332,0.00054336706,0.0004821971,0.0009917346],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038096877,0.00036996938,0.0044619855,0.00030228894,0.000119982455,0.0000129895125,0.00055548846,0.00032065244,0.000044298013],"category_scores_gemma":[0.027096618,0.00019858642,0.00064070406,0.0006641956,0.0008390189,0.00013794664,0.00041872138,0.00204513,0.000004711761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9744886,0.008908926,0.0041093,0.000041261777,0.0010857881,0.0005302447,0.00025037423,0.00011259276,0.00074398046,0.000006865902,0.002525965,0.007196057],"study_design_scores_gemma":[0.7279875,0.17689493,0.090589866,0.00023304927,0.0007644528,0.00021466202,0.00005444009,0.00013424546,0.0013886169,0.000010161475,0.0015964377,0.00013160775],"about_ca_topic_score_codex":0.0002775697,"about_ca_topic_score_gemma":0.00085240306,"teacher_disagreement_score":0.24650112,"about_ca_system_score_codex":0.00009721808,"about_ca_system_score_gemma":0.0019412538,"threshold_uncertainty_score":0.98109853},"labels":[],"label_agreement":null},{"id":"W3031849367","doi":"10.1200/jco.2020.38.15_suppl.5535","title":"Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Prostate cancer; Medicine; Population; Androgen deprivation therapy; Internal medicine; Oncology; Placebo; Androgen receptor; Proportional hazards model; Cancer; Pathology","score_opus":0.23171827487795327,"score_gpt":0.5132525809369715,"score_spread":0.2815343060590182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031849367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940284,0.00015068043,0.0005258924,0.0039632064,0.00007468898,0.0011503105,0.00007343887,0.0000024880674,0.00003093419],"genre_scores_gemma":[0.9921909,0.00043691514,0.0063513606,0.0008204162,0.00009080138,0.000050007424,0.000010697649,0.000015206091,0.000033688993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976951,0.0002078268,0.001467015,0.00015548104,0.00031006453,0.00016449895],"domain_scores_gemma":[0.9970694,0.0009528902,0.0010277893,0.00008004315,0.0006731469,0.00019669492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009683844,0.00010694559,0.001088599,0.00012313506,0.000014749192,0.0000034584987,0.000067369416,0.000092523886,0.000035313726],"category_scores_gemma":[0.0013516687,0.00006361985,0.00014900773,0.00023650186,0.00010917113,0.00009120644,0.000013998757,0.00023870658,9.152784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26793084,0.0016787414,0.44291493,0.0004669107,0.0011955734,0.0018160667,0.0021664314,0.00096606027,0.012543787,0.00003435942,0.00033443156,0.26795188],"study_design_scores_gemma":[0.10221983,0.13381325,0.54994124,0.001235265,0.0011085006,0.00023836702,0.0016423075,0.004175791,0.20203096,0.00026949658,0.0029695875,0.0003554171],"about_ca_topic_score_codex":0.000041200692,"about_ca_topic_score_gemma":0.00033463797,"teacher_disagreement_score":0.26759648,"about_ca_system_score_codex":0.00012370627,"about_ca_system_score_gemma":0.0014486426,"threshold_uncertainty_score":0.25943422},"labels":[],"label_agreement":null},{"id":"W3031851949","doi":"10.1200/jco.2020.38.15_suppl.3579","title":"A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; McGill University Health Centre; Ozmosis Research (Canada); University of Alberta; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Adverse effect; Cancer; Pharmacology; Internal medicine; Dosing; Gastroenterology; Oncology","score_opus":0.18998515577389555,"score_gpt":0.5541876983150399,"score_spread":0.36420254254114437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031851949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632466,0.000066358276,0.000008085997,0.0025500925,0.00015126052,0.00083094003,0.0000069475827,0.000004526688,0.000057103287],"genre_scores_gemma":[0.99714094,0.00015990183,0.0010936632,0.0014139399,0.000115135386,0.000016605456,0.0000012898735,0.00001978795,0.000038710674],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99695045,0.00045423166,0.0016084107,0.00019790148,0.00056837243,0.00022063457],"domain_scores_gemma":[0.9972066,0.0007230901,0.0010558037,0.000120991885,0.00037487407,0.0005186021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005188563,0.0001385154,0.0015172538,0.00012187142,0.000016170397,0.000004017389,0.0001232665,0.00006786351,0.00018970938],"category_scores_gemma":[0.0015892184,0.0000761196,0.00014242111,0.00032174843,0.000101345555,0.00012099629,0.000030525684,0.000640525,0.0000066170396],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34640768,0.070059046,0.31101894,0.000050691822,0.0013415873,0.0043646465,0.0006775229,0.000042839365,0.00028293757,0.0000015954511,0.00041238134,0.26534012],"study_design_scores_gemma":[0.2431275,0.54000205,0.21384548,0.00010913526,0.00030344975,0.000023034174,0.00036148337,0.000048465827,0.0003212193,0.000012183085,0.0017721583,0.00007386361],"about_ca_topic_score_codex":0.00005000662,"about_ca_topic_score_gemma":0.00019447775,"teacher_disagreement_score":0.469943,"about_ca_system_score_codex":0.00010097346,"about_ca_system_score_gemma":0.001581977,"threshold_uncertainty_score":0.3104067},"labels":[],"label_agreement":null},{"id":"W3031858365","doi":"10.1200/jco.2020.38.15_suppl.6531","title":"Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Cancer Care Ontario; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Adverse effect; Durvalumab; Internal medicine; Head and neck cancer; Head and neck squamous-cell carcinoma; Phases of clinical research; Nuclear medicine; Clinical trial; Radiation therapy; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.28005804536798734,"score_gpt":0.5396743364935574,"score_spread":0.2596162911255701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031858365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902018,0.0037626831,0.0003442697,0.0045685004,0.0004348916,0.000590258,0.000023938042,0.0000037780487,0.00006992387],"genre_scores_gemma":[0.992793,0.0021222048,0.0027593602,0.0014312512,0.0008500601,0.0000053058434,0.000003000077,0.000018077428,0.00001770689],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996145,0.00036496826,0.0028297454,0.00019732921,0.00028718179,0.00017576265],"domain_scores_gemma":[0.99485815,0.002156372,0.0022582943,0.0001330214,0.00029941255,0.0002947818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001668441,0.00016121258,0.0023671726,0.00016800285,0.00003840341,0.000006769377,0.000103631704,0.00020291144,0.00007773842],"category_scores_gemma":[0.0018758983,0.0001151842,0.0005932498,0.00019595114,0.0003828599,0.00010152697,0.000027433465,0.00034668655,1.2245151e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8261946,0.0030569467,0.0016448667,0.00030775726,0.00243008,0.00011602503,0.00075334194,0.0000018766888,0.018290166,0.000011304152,0.00057547,0.14661755],"study_design_scores_gemma":[0.647443,0.32088482,0.017303046,0.0001416344,0.0020884387,0.00029227455,0.0003169032,0.0013208236,0.0015804471,0.00006430217,0.00842647,0.00013784754],"about_ca_topic_score_codex":0.00004421227,"about_ca_topic_score_gemma":0.000010816434,"teacher_disagreement_score":0.31782788,"about_ca_system_score_codex":0.00008048714,"about_ca_system_score_gemma":0.0014787293,"threshold_uncertainty_score":0.46970755},"labels":[],"label_agreement":null},{"id":"W3031862419","doi":"10.1200/jco.2020.38.15_suppl.e14101","title":"Use of Twitter among cancer clinicians and researchers and the associations with scientific impact of its users and followers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Social media; Directory; Medicine; Citation; Altmetrics; Internet privacy; World Wide Web; Computer science","score_opus":0.6652436969074669,"score_gpt":0.6280295989480383,"score_spread":0.03721409795942854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031862419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95127183,0.00049487717,0.0000033616004,0.046909917,0.0008435569,0.00038197546,0.0000070742703,0.000001942621,0.00008546122],"genre_scores_gemma":[0.99581575,0.0029013115,0.00027315092,0.0004920741,0.00048027068,0.000008498871,2.4698727e-7,0.000005419077,0.000023259583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656403,0.0016595457,0.0010302166,0.00012759356,0.0004359188,0.00018267833],"domain_scores_gemma":[0.97388613,0.023074366,0.0018351807,0.00006233542,0.00074796,0.00039405338],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.008858547,0.000057073514,0.000631564,0.00006314156,0.00019928168,0.000040240015,0.00012865018,0.00020626943,0.000022168426],"category_scores_gemma":[0.052509826,0.000034621964,0.000118709104,0.00034957123,0.0031609684,0.0002695029,0.000034412446,0.00053689134,2.1176743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062104384,0.00007334527,0.9543012,0.000013367208,0.0001391284,0.0000019309896,0.030724281,0.0000075315575,0.000008494007,0.0001227467,0.0012902083,0.012696724],"study_design_scores_gemma":[0.0017615709,0.0013334394,0.98614866,0.000045499313,0.00012505508,4.857687e-7,0.00554806,0.000059830727,0.000002799152,0.00014837626,0.0047875475,0.00003867851],"about_ca_topic_score_codex":0.0036929734,"about_ca_topic_score_gemma":0.004539234,"teacher_disagreement_score":0.046417844,"about_ca_system_score_codex":0.0001158038,"about_ca_system_score_gemma":0.0035893822,"threshold_uncertainty_score":0.99955183},"labels":[],"label_agreement":null},{"id":"W3031874598","doi":"10.1200/jco.2020.38.15_suppl.10551","title":"Lung cancer as a subsequent neoplasm: A report from the Childhood Cancer Survivor Study (CCSS).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Cumulative incidence; Cancer; Proportional hazards model; Internal medicine; Hazard ratio; Incidence (geometry); Univariate analysis; Epidemiology; Radiation therapy; Confidence interval; Multivariate analysis; Cohort","score_opus":0.14471593337249153,"score_gpt":0.4897102574731136,"score_spread":0.34499432410062203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031874598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87686557,0.008027239,0.000023049122,0.10952811,0.0029998308,0.0006253097,0.000027622269,0.000016257029,0.0018870356],"genre_scores_gemma":[0.9098663,0.004652029,0.00019100044,0.07845955,0.006400328,0.000034902147,0.0000066080397,0.000031457326,0.00035782598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950937,0.00066355366,0.0029110692,0.0003821977,0.0006532877,0.0002962176],"domain_scores_gemma":[0.9940771,0.0022514942,0.0022023586,0.00033746634,0.00043195442,0.0006996428],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022082627,0.0002139948,0.0018444597,0.00003791815,0.000083510386,0.000019167259,0.00036239973,0.00027479813,0.0033608575],"category_scores_gemma":[0.0035671587,0.00012519993,0.0006364615,0.00020371922,0.00015789997,0.0001518864,0.00010785004,0.0018988957,0.000019196563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053031566,0.0016627802,0.8040518,0.00002002772,0.00278108,0.0078058355,0.0028426552,0.00009511767,0.000108542896,0.0000037871987,0.105351776,0.06997343],"study_design_scores_gemma":[0.009910149,0.00458041,0.63248783,0.00007069384,0.0012352933,0.00034835376,0.000767835,0.0001856432,0.000027420043,0.000014344334,0.35024896,0.00012302524],"about_ca_topic_score_codex":0.0036295338,"about_ca_topic_score_gemma":0.0027794,"teacher_disagreement_score":0.2448972,"about_ca_system_score_codex":0.0003478629,"about_ca_system_score_gemma":0.009017632,"threshold_uncertainty_score":0.9975502},"labels":[],"label_agreement":null},{"id":"W3031882118","doi":"10.1200/jco.2020.38.15_suppl.3546","title":"Demonstrating the value of liquid biopsy for lung cancer in a public health care system.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Niagara Health System; University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; Baker Hughes (Canada); University of Calgary; University of Ottawa; Jewish General Hospital; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; KRAS; ROS1; Lung cancer; Internal medicine; Cohort; Oncology; Liquid biopsy; Adenocarcinoma; Prospective cohort study; Clinical endpoint; Clinical trial; Cancer","score_opus":0.08628722851747576,"score_gpt":0.44523973116539717,"score_spread":0.3589525026479214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031882118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9478092,0.010439842,0.0036190453,0.036465477,0.00093543716,0.00032566715,0.00007219133,0.0000018857245,0.00033121175],"genre_scores_gemma":[0.9909819,0.0011282596,0.0025775617,0.0039154915,0.0013693299,0.000010870331,0.000004192246,0.000010392879,0.0000020192829],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788535,0.00024334964,0.0014559057,0.00013911733,0.00009552123,0.00018076634],"domain_scores_gemma":[0.9975418,0.0005308937,0.0013437512,0.000105666,0.00029506377,0.00018281885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015759235,0.000077660465,0.00056687766,0.00002385055,0.000035555488,0.000007650708,0.00024006126,0.00019143852,0.000002832116],"category_scores_gemma":[0.002390927,0.000054430267,0.0002626676,0.00007823014,0.000089323585,0.0000030072204,0.000064350665,0.00024532742,1.0949801e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027910626,0.0027357521,0.28200272,0.0048030806,0.003743976,0.00024085701,0.010271385,0.025501173,0.09842018,0.027613541,0.061303347,0.45545337],"study_design_scores_gemma":[0.03183127,0.10688319,0.05236568,0.0009589772,0.00069550483,0.00037990286,0.02223608,0.01946797,0.0115778055,0.000086573404,0.75245816,0.0010588797],"about_ca_topic_score_codex":0.00005439375,"about_ca_topic_score_gemma":0.00019049403,"teacher_disagreement_score":0.69115484,"about_ca_system_score_codex":0.00008468057,"about_ca_system_score_gemma":0.003945741,"threshold_uncertainty_score":0.69995743},"labels":[],"label_agreement":null},{"id":"W3031893936","doi":"10.1200/jco.2020.38.15_suppl.9576","title":"Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Biomarker; Nivolumab; Oncology; Lung cancer; Ipilimumab; Internal medicine; Durvalumab; Clinical trial; Cancer; Immunotherapy","score_opus":0.31570217002083223,"score_gpt":0.5403117599691646,"score_spread":0.22460958994833236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031893936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44508618,0.004827917,0.03192402,0.38886377,0.0020410542,0.12643015,0.00034027634,0.00013352513,0.0003531299],"genre_scores_gemma":[0.9008217,0.0022780441,0.030880462,0.032849103,0.0055138646,0.02663919,0.00009285444,0.00021134151,0.0007134257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99587405,0.0005919532,0.0024803628,0.00039111474,0.0003017966,0.00036070705],"domain_scores_gemma":[0.99505866,0.0019163566,0.001894827,0.00017399756,0.00046295504,0.00049322844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016658565,0.00024800785,0.0014039238,0.00009343821,0.00009132709,0.00003486217,0.00019182381,0.00038529647,0.00093496154],"category_scores_gemma":[0.0006344886,0.00017970604,0.00051600544,0.00017293783,0.00020245455,0.00015180466,0.000058488215,0.0005203352,0.0000032119776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13692772,0.0010175611,0.17226636,0.00054507406,0.0035711143,0.0002718987,0.0010869645,0.000018128441,0.01525233,0.000013236359,0.14049637,0.5285332],"study_design_scores_gemma":[0.11670745,0.028779587,0.16106695,0.00058582297,0.0031431871,0.00010709442,0.0008075282,0.0051472406,0.0028110582,0.00021269557,0.6800864,0.00054500863],"about_ca_topic_score_codex":0.00017313189,"about_ca_topic_score_gemma":0.00015754854,"teacher_disagreement_score":0.53959,"about_ca_system_score_codex":0.0002452844,"about_ca_system_score_gemma":0.0018228749,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W3031910208","doi":"10.1200/jco.2020.38.15_suppl.tps6592","title":"CCTG HN.10: A phase II single-arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma (NCT03822897).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer; University Health Network; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Oncology; Radiation therapy; Internal medicine; Clinical endpoint; Chemoradiotherapy; Stage (stratigraphy); Head and neck cancer; Head and neck squamous-cell carcinoma; Quality of life (healthcare); Clinical trial","score_opus":0.05362477730388759,"score_gpt":0.37546150511150733,"score_spread":0.32183672780761974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031910208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945511,0.0006470615,0.00012748184,0.0026596114,0.0005262767,0.00074288587,0.000012507714,0.000013995404,0.0007190587],"genre_scores_gemma":[0.9972831,0.0001782753,0.0007278255,0.0008378709,0.0008251814,0.000006989932,0.0000080004575,0.000034981655,0.00009776037],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9951738,0.0008594001,0.0028023673,0.00030631185,0.0004976447,0.00036043802],"domain_scores_gemma":[0.9950998,0.001192784,0.0024064814,0.00014635023,0.0006945582,0.00046002975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013181588,0.00023643045,0.002469926,0.00017770368,0.00006543908,0.000004750455,0.000145529,0.00047969373,0.00034692517],"category_scores_gemma":[0.0026262156,0.00017177897,0.00039836107,0.00045977705,0.00023265033,0.00012545196,0.000037262023,0.0013756927,0.000004806543],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5869867,0.032372512,0.26978844,0.0000974137,0.0004276905,0.00035719963,0.0030872673,0.00010932987,0.00056230463,0.0000015656109,0.003104462,0.103105076],"study_design_scores_gemma":[0.340725,0.34514147,0.30986512,0.0000608923,0.0005017767,0.000013840025,0.000111607005,0.001372624,0.0002432409,0.000010032046,0.0018183852,0.00013600466],"about_ca_topic_score_codex":0.000058492245,"about_ca_topic_score_gemma":0.000035991045,"teacher_disagreement_score":0.31276897,"about_ca_system_score_codex":0.00048380802,"about_ca_system_score_gemma":0.0019124079,"threshold_uncertainty_score":0.7004943},"labels":[],"label_agreement":null},{"id":"W3031916639","doi":"10.1200/jco.2020.38.15_suppl.7501","title":"Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant<i>-IDH2</i> (<i>mIDH2</i>) newly diagnosed acute myeloid leukemia (ND-AML).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Clinical endpoint; Gastroenterology; Azacitidine; Myeloid leukemia; Surrogate endpoint; Phases of clinical research; Surgery; Oncology; Chemotherapy; Randomized controlled trial","score_opus":0.09172971033791527,"score_gpt":0.43506980538103923,"score_spread":0.34334009504312396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031916639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706608,0.00062972185,0.00008835833,0.026436403,0.0007236889,0.00087614614,0.00003161505,0.000030513816,0.00052273186],"genre_scores_gemma":[0.98390305,0.005663395,0.0017796275,0.0070255585,0.0013882356,0.0000153943,0.000011720817,0.000090348665,0.00012266173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9897843,0.0040866844,0.0035591975,0.0006671151,0.0011981644,0.000704546],"domain_scores_gemma":[0.96476597,0.030890355,0.0020429988,0.0005038019,0.00042162256,0.0013752774],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00932563,0.00049435516,0.0038582813,0.0004434218,0.00007652677,0.000024967714,0.0005533109,0.0009537653,0.00014544741],"category_scores_gemma":[0.021163804,0.00036184717,0.00073871465,0.000541563,0.00060173514,0.00022917948,0.00022282971,0.003667427,0.000030319105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73278016,0.0005067146,0.0067646895,0.00019258968,0.0008981888,0.013068889,0.00060522207,0.00023536877,0.16677548,0.000033160864,0.012508169,0.065631375],"study_design_scores_gemma":[0.3865669,0.35096782,0.09867344,0.0016019135,0.0013219619,0.0015571429,0.00027159843,0.008169671,0.057181317,0.00016580199,0.09262993,0.000892489],"about_ca_topic_score_codex":0.000083540595,"about_ca_topic_score_gemma":0.000024715046,"teacher_disagreement_score":0.35046113,"about_ca_system_score_codex":0.0017043104,"about_ca_system_score_gemma":0.004932673,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W3031927075","doi":"10.1200/jco.2020.38.15_suppl.e20523","title":"Error propagation in simulated treatment comparisons for multiple myeloma: Results from a simulation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Waterloo; McMaster University","funders":"","keywords":"Covariate; Bootstrapping (finance); Statistics; Medicine; Bayesian probability; Parametric statistics; Multiple myeloma; Accelerated failure time model; Survival analysis; Econometrics; Mathematics; Internal medicine","score_opus":0.8640452475509691,"score_gpt":0.6774853501021025,"score_spread":0.18655989744886659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031927075","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4743769,0.00005807553,0.49775082,0.02234439,0.002291309,0.0021594898,0.00057441386,0.000060721282,0.0003838889],"genre_scores_gemma":[0.5606444,0.000012529381,0.4376589,0.00057939335,0.0010619336,0.000006111038,0.0000064604583,0.00001748996,0.00001277523],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9892685,0.0025986715,0.007182269,0.00036398746,0.00033179423,0.00025476838],"domain_scores_gemma":[0.5768291,0.4180616,0.0039772834,0.00022423442,0.0004958385,0.00041193725],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007280251,0.00019888485,0.0025689392,0.00006955355,0.000041949592,0.000016125732,0.00026248305,0.0006272343,0.00006272749],"category_scores_gemma":[0.5843877,0.0001424554,0.000525082,0.00020102123,0.00014775812,0.00009431619,0.000047384874,0.0007266778,0.000015752334],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20074937,0.02170156,0.028938131,0.0001868969,0.002528137,0.0007230035,0.003979917,0.18894693,0.0005053691,0.0052123913,0.024860388,0.5216679],"study_design_scores_gemma":[0.059166692,0.018016689,0.0152423605,0.000111567875,0.00060448336,0.0000023321575,0.00018342467,0.7114657,0.0001577422,0.15372428,0.04105598,0.0002687131],"about_ca_topic_score_codex":0.000023689076,"about_ca_topic_score_gemma":0.00005838587,"teacher_disagreement_score":0.5771075,"about_ca_system_score_codex":0.00019271942,"about_ca_system_score_gemma":0.00064299826,"threshold_uncertainty_score":0.5809163},"labels":[],"label_agreement":null},{"id":"W3031930276","doi":"10.1200/jco.2020.38.15_suppl.5002","title":"SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Sunitinib; Medicine; Tolerability; Internal medicine; Oncology; Renal cell carcinoma; Adverse effect; Papillary renal cell carcinomas; Expanded access; Tyrosine-kinase inhibitor; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Urology; Clinical trial; Cancer","score_opus":0.23402722043556454,"score_gpt":0.4389662506684173,"score_spread":0.2049390302328528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031930276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908853,0.00043798942,0.000014564241,0.0019931204,0.00040237323,0.0007890619,0.000008392443,0.0000114495515,0.0054577114],"genre_scores_gemma":[0.99625856,0.000108435335,0.0018271281,0.00077805645,0.00091654935,0.00001047904,0.000007919424,0.00003933945,0.00005350711],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99358577,0.0011257246,0.0036600512,0.0004022642,0.0008188937,0.00040727208],"domain_scores_gemma":[0.9919657,0.0036526008,0.0025160073,0.00034784788,0.00060204684,0.00091576425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016785504,0.00031171876,0.0029635592,0.00024820308,0.000036479214,0.000007669811,0.00030249255,0.00033280588,0.00020816489],"category_scores_gemma":[0.0016872641,0.00021305187,0.00051585294,0.00041431357,0.00025280254,0.00011676872,0.00011704262,0.0015459884,0.000012890651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3614571,0.05037604,0.46390465,0.00030410342,0.0022589976,0.062082175,0.0073196082,0.00026365207,0.005452175,0.00005154711,0.0030298813,0.04350005],"study_design_scores_gemma":[0.27676755,0.49207392,0.21180214,0.00016559742,0.0023743184,0.0004750668,0.007793589,0.00015386238,0.0026639553,0.000016220813,0.0054286527,0.00028510927],"about_ca_topic_score_codex":0.00010315113,"about_ca_topic_score_gemma":0.00016377949,"teacher_disagreement_score":0.4416979,"about_ca_system_score_codex":0.00030751224,"about_ca_system_score_gemma":0.0024538503,"threshold_uncertainty_score":0.8688003},"labels":[],"label_agreement":null},{"id":"W3031933721","doi":"10.1200/jco.2020.38.15_suppl.5007","title":"FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McMaster University; Juravinski Cancer Centre; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Discontinuation; Refractory (planetary science); Oncology; Renal cell carcinoma; Cancer; Immunotherapy","score_opus":0.13842810872226372,"score_gpt":0.4579737183330004,"score_spread":0.31954560961073664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031933721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567134,0.0005564553,0.0029110233,0.005395317,0.00088293257,0.00085615716,0.00004184154,0.000017870527,0.0036670617],"genre_scores_gemma":[0.9503072,0.00035333564,0.04603361,0.0013197281,0.0015741757,0.000031973148,0.000042675838,0.000050037277,0.00028728522],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99433076,0.0004457627,0.0037425642,0.00047005233,0.0006210095,0.000389819],"domain_scores_gemma":[0.990058,0.0031365105,0.004165977,0.000360834,0.0016699448,0.0006087409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00107172,0.0003581686,0.0030335244,0.00018735306,0.00007157771,0.000009050572,0.00022501228,0.00047032686,0.000251085],"category_scores_gemma":[0.0013265013,0.00025852167,0.0009584203,0.00037869808,0.00025841678,0.00024670758,0.00006396309,0.00078371685,0.000012447893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07338187,0.027699511,0.2574175,0.00076990825,0.004015252,0.0029832604,0.00069804327,0.0005032838,0.0984531,0.0006132522,0.016078245,0.5173868],"study_design_scores_gemma":[0.07283718,0.2234682,0.55828863,0.0001073973,0.0017299465,0.00017740819,0.00049794087,0.00046150252,0.02690594,0.00023763134,0.1149565,0.00033170683],"about_ca_topic_score_codex":0.000047389723,"about_ca_topic_score_gemma":0.000009685134,"teacher_disagreement_score":0.5170551,"about_ca_system_score_codex":0.0011406314,"about_ca_system_score_gemma":0.0047702887,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W3031935808","doi":"10.1200/jco.2020.38.15_suppl.e21101","title":"Extensive small cell lung cancer (SCLC) chemotherapy: A population kinetics assessment.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Etoposide; Population; Oncology; Nuclear medicine; Urology","score_opus":0.16877054844918138,"score_gpt":0.5475295781569021,"score_spread":0.3787590297077207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031935808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8427701,0.002887992,0.0012825178,0.14651397,0.0011423252,0.00048081865,0.000005556646,0.000019831663,0.004896894],"genre_scores_gemma":[0.96199584,0.0051362845,0.00864228,0.02025005,0.0036210783,0.0000075490534,0.0000024092321,0.000026937905,0.00031759572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972609,0.00028987625,0.0015280526,0.00019813802,0.0004732988,0.00024970103],"domain_scores_gemma":[0.9962243,0.0010414188,0.0012253675,0.00012600845,0.00089228014,0.00049061904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010623477,0.00013078627,0.0012854344,0.000063225125,0.000034249246,0.000010050262,0.00015217837,0.00022506148,0.00027554994],"category_scores_gemma":[0.0022959264,0.00009215147,0.00036772672,0.00017091523,0.0001157931,0.00006202486,0.00007456759,0.0011878045,0.0000051825305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005784069,0.0015800319,0.7734298,0.00041355065,0.0013328117,0.0010192492,0.0006693359,0.00019122966,0.0046046614,0.00004751302,0.08301922,0.12790854],"study_design_scores_gemma":[0.011531054,0.012992541,0.87144226,0.00014924539,0.00063757424,0.000046486497,0.00019178582,0.0016198828,0.0002577807,0.000088733155,0.10091578,0.00012685331],"about_ca_topic_score_codex":0.00005318325,"about_ca_topic_score_gemma":0.000035078334,"teacher_disagreement_score":0.12778169,"about_ca_system_score_codex":0.0003822434,"about_ca_system_score_gemma":0.0014848191,"threshold_uncertainty_score":0.51604855},"labels":[],"label_agreement":null},{"id":"W3031942086","doi":"10.1200/jco.2020.38.15_suppl.5001","title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Interim analysis; Renal cell carcinoma; Axitinib; Clinical endpoint; Internal medicine; Discontinuation; Temsirolimus; Pazopanib; Oncology; Clinical trial","score_opus":0.1829514474236072,"score_gpt":0.44503408824110696,"score_spread":0.26208264081749977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031942086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268306,0.0011636451,0.0004502267,0.010762118,0.0006910931,0.00070049556,0.00006588286,0.000021177048,0.0034623279],"genre_scores_gemma":[0.99141,0.00089937,0.004000463,0.0020947135,0.0011414142,0.000017426084,0.00015717742,0.000051665585,0.00022774322],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9940246,0.00046052714,0.0038912152,0.00047163214,0.0006912975,0.00046077312],"domain_scores_gemma":[0.98918605,0.0046389434,0.0034369568,0.00042091156,0.0013694161,0.0009477454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014372501,0.00036477562,0.0037877255,0.00039321955,0.000072666604,0.000010911613,0.0003857062,0.0005395995,0.0007248172],"category_scores_gemma":[0.002794364,0.00027005983,0.0023992585,0.00084025494,0.00026937656,0.00011509285,0.00007698771,0.0009694931,0.00001969],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8286354,0.0073097986,0.023925202,0.0002805863,0.01573602,0.0042010183,0.001250341,0.0052641556,0.008219082,0.00019851455,0.008643513,0.09633638],"study_design_scores_gemma":[0.28727302,0.33037817,0.18419178,0.00010256551,0.021573236,0.00023754917,0.0007338319,0.0057450645,0.033038516,0.00016138722,0.13589086,0.00067404145],"about_ca_topic_score_codex":0.000040469225,"about_ca_topic_score_gemma":0.000037634712,"teacher_disagreement_score":0.54136235,"about_ca_system_score_codex":0.00032645368,"about_ca_system_score_gemma":0.0024789316,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W3031944432","doi":"10.1200/jco.2020.38.15_suppl.e19213","title":"Choosing Wisely Africa: 10 low-value or harmful practices that should be avoided in cancer care.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Best practice; Palliative care; Family medicine; Medical education; Public relations; Nursing; Management; Political science","score_opus":0.9057067707014974,"score_gpt":0.6450021784064092,"score_spread":0.26070459229508824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031944432","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45738393,0.0066417446,0.0003051251,0.52543914,0.0029522167,0.00048589238,0.000077755954,0.000020309444,0.006693851],"genre_scores_gemma":[0.90338063,0.0025763244,0.004879546,0.08572586,0.0029194918,0.00002884527,0.0000039191696,0.00004547014,0.00043992218],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857619,0.0017476603,0.011291156,0.0005142911,0.00022268534,0.0004623015],"domain_scores_gemma":[0.96517223,0.011747148,0.021857332,0.00026796255,0.00030994948,0.0006453501],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032155152,0.00022036197,0.0031881765,0.00026938968,0.00009680806,0.00007117795,0.00056878803,0.0005826333,0.0018218171],"category_scores_gemma":[0.09542478,0.0002109448,0.00041920814,0.00030398043,0.00014695503,0.00095420476,0.00010034333,0.0014544436,0.00037729696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067358348,0.0023419585,0.51895446,0.0015017061,0.001077249,0.00043315013,0.025716888,0.0041564372,0.000017525857,0.008683029,0.41180202,0.018579746],"study_design_scores_gemma":[0.0060013095,0.0027703778,0.073973484,0.00022165406,0.0000719945,0.000026694326,0.006067745,0.0033505468,0.00001007628,0.0017706591,0.90535504,0.00038039457],"about_ca_topic_score_codex":0.0006022757,"about_ca_topic_score_gemma":0.00090128393,"teacher_disagreement_score":0.49355304,"about_ca_system_score_codex":0.0009784995,"about_ca_system_score_gemma":0.002951859,"threshold_uncertainty_score":0.9990907},"labels":[],"label_agreement":null},{"id":"W3031951218","doi":"10.1200/jco.2020.38.15_suppl.e23000","title":"HemeOncoPoeisis: A fellow’s perspective on training.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Workload; Medical education; Quarter (Canadian coin); Family medicine; Academic year; Psychology; Management","score_opus":0.2276232019111383,"score_gpt":0.5766887857442903,"score_spread":0.349065583833152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031951218","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20981352,0.003066199,0.0042103445,0.64509803,0.0067910315,0.00039609533,0.000004586749,0.000056024786,0.1305642],"genre_scores_gemma":[0.7864628,0.0018048969,0.019741202,0.17867936,0.012764539,0.000002564123,6.365914e-7,0.000027218295,0.0005167875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734324,0.0003613059,0.0015612311,0.00022374198,0.00029700797,0.00021346753],"domain_scores_gemma":[0.994724,0.002943582,0.0012025025,0.00013014386,0.00040463018,0.00059517985],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015913983,0.0001385758,0.0016613943,0.000076419434,0.00003932326,0.0000032897642,0.00018936777,0.00047917166,0.00044822856],"category_scores_gemma":[0.008845964,0.0000927156,0.00063547335,0.00017201032,0.0004078973,0.00008025366,0.000019183517,0.0018272506,0.00006825477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052808125,0.0047161244,0.010788528,0.000036904414,0.0022516467,0.007550028,0.008077642,0.00015816011,0.00042779595,0.009629709,0.20019606,0.7033593],"study_design_scores_gemma":[0.013256018,0.071238674,0.010317346,0.00006989186,0.00027235597,0.00070758053,0.0038719259,0.00014998522,0.000055084733,0.002110914,0.89782786,0.00012236249],"about_ca_topic_score_codex":0.0000014320254,"about_ca_topic_score_gemma":0.0000024212084,"teacher_disagreement_score":0.70323694,"about_ca_system_score_codex":0.0002977882,"about_ca_system_score_gemma":0.0021095637,"threshold_uncertainty_score":0.99950296},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3031962090","doi":"10.1200/jco.2020.38.15_suppl.12110","title":"Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CNIB","keywords":"Medicine; Palliative care; Referral; Quality of life (healthcare); Anxiety; Coping (psychology); Family medicine; Cancer; End-of-life care; Life expectancy; Clinical endpoint; Nursing; Randomized controlled trial; Internal medicine; Population; Psychiatry","score_opus":0.21206160751727984,"score_gpt":0.5303634976124684,"score_spread":0.3183018900951885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031962090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668341,0.0061298376,0.00004477354,0.025769608,0.00025416445,0.00047847562,0.00010524581,0.000012002451,0.00037176663],"genre_scores_gemma":[0.98852265,0.006546749,0.0030530384,0.0013238925,0.0003958556,0.000026321124,0.000020105526,0.000022152446,0.0000892452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971898,0.0003123069,0.0015836123,0.00025091664,0.00047046904,0.0001928684],"domain_scores_gemma":[0.99526685,0.0014288304,0.0016919369,0.00011107811,0.00094638794,0.0005549101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000309501,0.00019444706,0.0016732098,0.00007366673,0.000043421383,0.0000049676637,0.00012285713,0.000237191,0.00007673415],"category_scores_gemma":[0.0048689176,0.00010931251,0.00024357013,0.00020742316,0.00038456297,0.00010846292,0.000040300354,0.0006778399,0.0000019250608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055815405,0.0017150118,0.9029881,0.00021236714,0.00052560476,0.000033384647,0.0062234583,0.000019965086,0.00019376504,0.000043785276,0.005064788,0.077398255],"study_design_scores_gemma":[0.022258531,0.07451215,0.61029685,0.004636031,0.0011663084,0.0000026400357,0.007810577,0.000046374804,0.0035134838,0.000046473247,0.27537504,0.0003355788],"about_ca_topic_score_codex":0.00007740615,"about_ca_topic_score_gemma":0.000082551225,"teacher_disagreement_score":0.29269126,"about_ca_system_score_codex":0.00010370469,"about_ca_system_score_gemma":0.0010892815,"threshold_uncertainty_score":0.5828901},"labels":[],"label_agreement":null},{"id":"W3032001277","doi":"10.1200/jco.2020.38.15_suppl.5578","title":"Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Kelowna General Hospital; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Prednisone; Sequence (biology); Abiraterone; Urology; Gastroenterology; Surgery; Oncology; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.5228100287158628,"score_gpt":0.5821295097350553,"score_spread":0.05931948101919249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032001277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9280985,0.005332279,0.0011011305,0.052156944,0.0012277581,0.007672236,0.0043750275,0.000010886675,0.00002526382],"genre_scores_gemma":[0.97806144,0.013723938,0.004846493,0.0011535916,0.0008792679,0.0007313116,0.00019053959,0.000036043857,0.00037739865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.988249,0.0030558717,0.007086619,0.0004826064,0.00071381003,0.00041210474],"domain_scores_gemma":[0.94203675,0.049939156,0.005897275,0.00043079394,0.0011528793,0.00054315943],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014245117,0.00031748178,0.004208661,0.000048487684,0.00018553935,0.00002406632,0.00041997156,0.00024311528,0.00003335606],"category_scores_gemma":[0.025633741,0.00014764853,0.001774879,0.00020841781,0.0012985525,0.00013956515,0.000060805767,0.00058832514,9.0245305e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94718593,0.0033360594,0.000056097157,0.00010605737,0.0060583157,0.000041675237,0.0016202478,0.00016643996,0.011327546,0.000029963325,0.0026775894,0.02739408],"study_design_scores_gemma":[0.88944316,0.08884668,0.00012044588,0.00012380921,0.00402216,0.0000025455583,0.0005126408,0.003653729,0.0027873265,0.00017621361,0.010180038,0.00013124797],"about_ca_topic_score_codex":0.0006401273,"about_ca_topic_score_gemma":0.00033316336,"teacher_disagreement_score":0.08551063,"about_ca_system_score_codex":0.00037121953,"about_ca_system_score_gemma":0.0070823203,"threshold_uncertainty_score":0.9985466},"labels":[],"label_agreement":null},{"id":"W3032002642","doi":"10.1200/jco.2020.38.15_suppl.e19248","title":"Impact of a multidisciplinary tumor board in the treatment of genitourinary tumors: Real-world data from a referral center in Mexico.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Genitourinary system; Referral; Cancer; Medical diagnosis; Disease; Family medicine; General surgery; Internal medicine; Radiology","score_opus":0.3323337824359782,"score_gpt":0.46276263845131166,"score_spread":0.13042885601533344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032002642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990208,0.00077861577,0.000021178286,0.0033044184,0.0003264566,0.00019433635,0.00048306325,0.0000020677471,0.0046818117],"genre_scores_gemma":[0.99546236,0.002525965,0.0008625728,0.0003547952,0.00074345863,0.0000036291603,0.00001569377,0.00001550912,0.00001604283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950691,0.00019380465,0.0041046273,0.00031304575,0.000059704053,0.0002597208],"domain_scores_gemma":[0.99434835,0.001134975,0.0038383785,0.00045188935,0.00005270357,0.00017372385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017955612,0.00017137862,0.002243299,0.00023346231,0.000014911906,0.000009795337,0.0008019862,0.00012826972,0.0001379996],"category_scores_gemma":[0.00083217083,0.00012357885,0.0005348351,0.00025779038,0.00021069954,0.0003358002,0.00013132875,0.0004731143,0.000020401123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038060674,0.0029963637,0.98375297,0.000009428964,0.00014492284,0.0002526577,0.0011523851,0.0001579646,0.000005176082,0.00026237933,0.001361507,0.006098164],"study_design_scores_gemma":[0.0055950675,0.011373586,0.9724176,0.00004528109,0.0000222198,0.000008229537,0.00019909268,0.0012543069,0.000004589469,0.0025006146,0.006468482,0.00011095381],"about_ca_topic_score_codex":0.0042441017,"about_ca_topic_score_gemma":0.003493225,"teacher_disagreement_score":0.011335406,"about_ca_system_score_codex":0.0003265351,"about_ca_system_score_gemma":0.00054184155,"threshold_uncertainty_score":0.64158404},"labels":[],"label_agreement":null},{"id":"W3032004581","doi":"10.1200/jco.2020.38.15_suppl.12087","title":"Feasibility of olanzapine at reduced dose in highly emetogenic chemotherapy: A randomised controlled trial against aprepitant in triple therapy (FORESIGHT).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne","funders":"","keywords":"Aprepitant; Medicine; Olanzapine; Nausea; Tolerability; Chemotherapy-induced nausea and vomiting; Ondansetron; Antiemetic; Internal medicine; Adverse effect; Anesthesia; Vomiting; Chemotherapy; Psychiatry","score_opus":0.1956888943895678,"score_gpt":0.4568244673290757,"score_spread":0.26113557293950795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032004581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97632766,0.00065950037,0.00002281708,0.01732998,0.00069925253,0.0038924303,0.0000016981081,0.000010519812,0.0010561688],"genre_scores_gemma":[0.9915834,0.001917562,0.0005666858,0.0048003956,0.00094987964,0.000036473222,0.0000027675849,0.000021542124,0.00012128469],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917779,0.0016208917,0.005515702,0.00032404606,0.0004676277,0.00029382476],"domain_scores_gemma":[0.9928664,0.0033525026,0.0028964968,0.00027865623,0.0002500129,0.0003559144],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009942865,0.00020932688,0.0041569453,0.000235388,0.000019251662,0.0000057376633,0.00025397725,0.00036100327,0.00018368057],"category_scores_gemma":[0.011318046,0.0001368214,0.0011733889,0.00036505132,0.0001480658,0.00006526278,0.000055007516,0.00085249834,0.000004579074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9508415,0.0042106076,0.015381294,0.00004151765,0.0005460824,0.0003720148,0.0003178534,0.000019287474,0.010496312,0.000015483649,0.0011425377,0.016615544],"study_design_scores_gemma":[0.9289493,0.018379714,0.04802614,0.00007698453,0.00016465393,0.000008788432,0.000057354777,0.00040899953,0.0008553223,0.0001361632,0.0028281445,0.00010844671],"about_ca_topic_score_codex":0.000013791803,"about_ca_topic_score_gemma":0.000035908186,"teacher_disagreement_score":0.032644846,"about_ca_system_score_codex":0.00029603264,"about_ca_system_score_gemma":0.0011076797,"threshold_uncertainty_score":0.99701005},"labels":[],"label_agreement":null},{"id":"W3032017578","doi":"10.1200/jco.2020.38.15_suppl.6087","title":"Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) versus PAC alone in patients (pts) with advanced, recurrent, or persistent endometrial cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Hazard ratio; Endometrial cancer; Internal medicine; Taxane; Randomization; Urology; Randomized controlled trial; Paclitaxel; Progression-free survival; Chemotherapy; Cancer; Gastroenterology; Phases of clinical research; Surgery; Confidence interval; Breast cancer","score_opus":0.20814091963827205,"score_gpt":0.486112074713504,"score_spread":0.27797115507523196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032017578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914633,0.0012345596,0.000011224907,0.0028856474,0.0020779602,0.0018965678,0.000033023065,0.000010257885,0.00038747495],"genre_scores_gemma":[0.9961698,0.0015806742,0.00056559464,0.0005623418,0.0009882852,0.000051868214,0.000008831135,0.000027376513,0.000045223253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930454,0.0012091008,0.0039505935,0.00040914986,0.0010133014,0.0003724752],"domain_scores_gemma":[0.9894326,0.0057304995,0.0030726944,0.00022543618,0.0007270381,0.00081177347],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021984365,0.00030716814,0.004967404,0.00031095144,0.000054845877,0.000007057733,0.00025070662,0.00025299983,0.00038394448],"category_scores_gemma":[0.017996568,0.00017092432,0.00096960313,0.0011100556,0.00024535274,0.00015421626,0.00010856062,0.0010097756,0.0000042799343],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78095406,0.028688485,0.015507037,0.000052172785,0.0024047517,0.00034478906,0.00066361926,0.00003328928,0.000015233494,0.0000034839456,0.00013796438,0.1711951],"study_design_scores_gemma":[0.65305215,0.33757055,0.004643898,0.00013796479,0.0021470215,0.0000066236094,0.0009730862,0.000026510379,0.000022534416,0.0000064706446,0.0013001283,0.00011309277],"about_ca_topic_score_codex":0.00014920777,"about_ca_topic_score_gemma":0.00020415727,"teacher_disagreement_score":0.30888206,"about_ca_system_score_codex":0.00042893257,"about_ca_system_score_gemma":0.0012525128,"threshold_uncertainty_score":0.99027526},"labels":[],"label_agreement":null},{"id":"W3032033385","doi":"10.1200/jco.2020.38.15_suppl.6586","title":"Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"CDKN2A; Medicine; Salivary gland cancer; Salivary gland; STK11; Fluorescence in situ hybridization; Cancer research; Cancer; Acinic cell carcinoma; Internal medicine; Salivary duct carcinoma; Immunohistochemistry; Pathology; Oncology; KRAS; Biology; Gene; Genetics; Colorectal cancer","score_opus":0.12168032174826218,"score_gpt":0.41651397416167807,"score_spread":0.29483365241341586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032033385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98841774,0.00039414634,0.000009508939,0.009966195,0.00026615013,0.0005654549,0.0000127016965,0.00001378355,0.0003543056],"genre_scores_gemma":[0.99270487,0.00035709253,0.0022608726,0.0040241685,0.0005581598,0.0000292797,0.000015173911,0.000028438715,0.000021924658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574494,0.00045702537,0.002713869,0.00032050765,0.00046423275,0.00029939372],"domain_scores_gemma":[0.9944288,0.0024260276,0.0018887385,0.00013260801,0.00050061,0.0006232212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008905257,0.00024402473,0.0019910482,0.00013521682,0.000035541983,0.000010610563,0.000111136746,0.00014722458,0.00012975666],"category_scores_gemma":[0.0039678724,0.00013238545,0.00032310915,0.0004278398,0.00010908092,0.00010309251,0.000042355496,0.0008928532,0.000021305448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026119135,0.010068563,0.92251843,0.000051853214,0.000669248,0.0077099977,0.00029648427,0.000012101983,0.0000036099182,0.0000036785154,0.008361756,0.02418517],"study_design_scores_gemma":[0.042132735,0.07711327,0.8476174,0.00043346966,0.0010909932,0.0004346105,0.00020027718,0.00022603846,0.000137692,0.000019547731,0.030419463,0.00017453238],"about_ca_topic_score_codex":0.000034983837,"about_ca_topic_score_gemma":0.00031751135,"teacher_disagreement_score":0.07490104,"about_ca_system_score_codex":0.00030706983,"about_ca_system_score_gemma":0.0013378863,"threshold_uncertainty_score":0.5398522},"labels":[],"label_agreement":null},{"id":"W3032035362","doi":"10.1200/jco.2020.38.15_suppl.e20058","title":"Presenting international prognostic scoring system affects time to treatment: A retrospective single center review.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor","funders":"","keywords":"Medicine; Retrospective cohort study; Internal medicine; Single Center; Chemotherapy; Stage (stratigraphy); International Prognostic Index; Proportional hazards model; Cancer; Lymphoma; Diffuse large B-cell lymphoma; Oncology; Surgery","score_opus":0.11855910705570989,"score_gpt":0.4364936455012911,"score_spread":0.3179345384455812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032035362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8932137,0.0020448149,0.00004598972,0.07118764,0.0015019535,0.0012890893,0.000013164899,0.000047957317,0.030655712],"genre_scores_gemma":[0.9916209,0.0006331823,0.0013867093,0.0039032851,0.0021827766,0.000019649931,0.0000051978363,0.000016614484,0.00023170578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977271,0.00022645353,0.0012650547,0.0002375133,0.00035400395,0.00018986191],"domain_scores_gemma":[0.9971919,0.0008481364,0.000978981,0.00011506082,0.0003287165,0.0005372284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006692521,0.00014420493,0.0013377949,0.00006123777,0.000028760907,0.000015790489,0.00011999655,0.00011144046,0.00017136909],"category_scores_gemma":[0.004529816,0.00009397925,0.0005184915,0.00013030531,0.00003254653,0.00008641526,0.00006797446,0.000207868,0.0003085445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020423017,0.0054759444,0.88016605,0.00036263771,0.0018908047,0.0049104644,0.00019620475,0.0000067081896,0.00028728947,0.00006474217,0.017380219,0.08721661],"study_design_scores_gemma":[0.025994273,0.0626868,0.6145532,0.008527252,0.0025101255,0.0025215112,0.000089851506,0.0004604969,0.00055604894,0.000012496845,0.28183147,0.00025645818],"about_ca_topic_score_codex":0.000003057125,"about_ca_topic_score_gemma":0.0000013159608,"teacher_disagreement_score":0.26561284,"about_ca_system_score_codex":0.00090477424,"about_ca_system_score_gemma":0.00037468306,"threshold_uncertainty_score":0.542294},"labels":[],"label_agreement":null},{"id":"W3032053629","doi":"10.1200/jco.2020.38.15_suppl.8545","title":"Sporadic late-onset nemaline myopathy with monoclonal paraprotein as a malignancy rather than disimmunity and treatment with chemotherapy-based approach.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Barrie Urology Group","funders":"","keywords":"Medicine; Nemaline myopathy; Plasmapheresis; Rituximab; Monoclonal gammopathy of undetermined significance; Internal medicine; Chemotherapy; Gastroenterology; Malignancy; Autologous stem-cell transplantation; Immunosuppression; Monoclonal; Lymphoma; Oncology; Immunology; Myopathy; Antibody; Monoclonal antibody","score_opus":0.10818178105452365,"score_gpt":0.4064592163675243,"score_spread":0.29827743531300066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032053629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609987,0.00045173123,0.0011311074,0.035967283,0.000031795615,0.000697481,0.000009825924,0.00002024867,0.0006918244],"genre_scores_gemma":[0.96897805,0.00063051865,0.022819927,0.0065128296,0.0005697882,0.00002414827,0.000016263859,0.000054256103,0.00039419893],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99689245,0.00063077913,0.0012682712,0.00034044855,0.0005121848,0.0003558447],"domain_scores_gemma":[0.9966814,0.000797031,0.0010228347,0.0002906063,0.00028980122,0.000918363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015459388,0.0002939754,0.0017883127,0.00010552546,0.000068183996,0.00001941073,0.00020183926,0.00032779766,0.00013637047],"category_scores_gemma":[0.00040534837,0.00014285489,0.00026560944,0.00028699875,0.00057863316,0.00009269523,0.00003503051,0.0012798305,0.000011709481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19064099,0.007009328,0.6728712,0.0001542845,0.0022238395,0.009069745,0.0010901416,0.00017332168,0.000565113,0.000046563833,0.0011042973,0.11505118],"study_design_scores_gemma":[0.14073469,0.40034992,0.3655046,0.00054324075,0.0016158188,0.0041336003,0.0013803031,0.008334315,0.0012017204,0.00017536055,0.075310595,0.0007158463],"about_ca_topic_score_codex":0.0001289287,"about_ca_topic_score_gemma":0.000021918204,"teacher_disagreement_score":0.3933406,"about_ca_system_score_codex":0.00023977258,"about_ca_system_score_gemma":0.0045155883,"threshold_uncertainty_score":0.801046},"labels":[],"label_agreement":null},{"id":"W3032053855","doi":"10.1200/jco.2020.38.15_suppl.2547","title":"Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Queen's University; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Temozolomide; Internal medicine; Proportional hazards model; Radiation therapy; Oncology; Glioblastoma; Randomized controlled trial; Survival analysis; Chemotherapy; Clinical trial; Logistic regression; Gastroenterology","score_opus":0.08457982440486765,"score_gpt":0.4503361373210625,"score_spread":0.3657563129161948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032053855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934307,0.00010517883,0.0000967022,0.0034285688,0.0008277308,0.0017112669,0.000092882954,0.0000058251285,0.00030114947],"genre_scores_gemma":[0.9979256,0.00011976337,0.0005010162,0.0007910472,0.0005805162,0.000027638587,0.000013503525,0.000027398552,0.000013546943],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905411,0.002320148,0.0057873894,0.00035275344,0.00071483804,0.0002837844],"domain_scores_gemma":[0.97168726,0.019762503,0.006514334,0.00041593055,0.0010429013,0.00057706755],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066297986,0.00028597526,0.0070468527,0.0002513495,0.000045066354,0.000009865343,0.0003317234,0.0004401729,0.0002706848],"category_scores_gemma":[0.016295189,0.00013195472,0.006820912,0.0006852054,0.00050117896,0.000074994474,0.00006486899,0.0006959026,0.0000025597578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6980964,0.0123847285,0.24052703,0.000022384971,0.01800024,0.000047413916,0.00006915923,0.00008466671,0.0000074022782,0.000025800267,0.001311175,0.029423572],"study_design_scores_gemma":[0.5489953,0.099856555,0.33719972,0.0000635576,0.012861735,0.00000393314,0.000025064439,0.00022231747,0.000034054134,0.000029911555,0.00063128164,0.00007656019],"about_ca_topic_score_codex":0.000033199245,"about_ca_topic_score_gemma":0.00006693276,"teacher_disagreement_score":0.14910111,"about_ca_system_score_codex":0.0001445423,"about_ca_system_score_gemma":0.0027156686,"threshold_uncertainty_score":0.991991},"labels":[],"label_agreement":null},{"id":"W3032057138","doi":"10.1200/jco.2020.38.15_suppl.e19066","title":"Access to new therapies: FDA accelerated approvals and the corresponding Canadian regulatory and funding decisions.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Health Canada","funders":"","keywords":"Medicine; Formulary; Drug approval; Notice; Rulemaking; Food and drug administration; Family medicine; Pharmacology; Drug","score_opus":0.8179383796198489,"score_gpt":0.5889342435503934,"score_spread":0.22900413606945558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032057138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6289142,0.0024558452,0.0019762411,0.3639835,0.0010519373,0.00039411793,0.000012984364,0.0000063924,0.0012047506],"genre_scores_gemma":[0.859205,0.0009217638,0.003715486,0.1344997,0.0014669973,0.0000059953218,8.7639205e-7,0.000019262296,0.00016488899],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918523,0.0009955831,0.006436262,0.00031850004,0.00009740612,0.00029997437],"domain_scores_gemma":[0.97793883,0.015546298,0.004595716,0.00020381008,0.00013570338,0.0015796261],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.042233963,0.0001320532,0.0019168688,0.00029497079,0.00019150313,0.00018500452,0.00047605016,0.00023809246,0.00019749346],"category_scores_gemma":[0.058464088,0.00010847629,0.00015427895,0.000271892,0.00016923252,0.00048819257,0.00011381481,0.0005567838,0.000086136046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029386692,0.000117523494,0.42139786,0.000086169865,0.0007718273,0.00004547841,0.013506147,0.00041534143,0.0000046558725,0.064707585,0.3786302,0.11737854],"study_design_scores_gemma":[0.006387557,0.0009834778,0.38662028,0.00008437663,0.000035176654,0.000049957627,0.0015749051,0.0022310852,0.0000011560404,0.014494165,0.5872941,0.00024379819],"about_ca_topic_score_codex":0.0047905017,"about_ca_topic_score_gemma":0.0063308617,"teacher_disagreement_score":0.23029082,"about_ca_system_score_codex":0.00027461644,"about_ca_system_score_gemma":0.0018395191,"threshold_uncertainty_score":0.9862217},"labels":[],"label_agreement":null},{"id":"W3032077319","doi":"10.1200/jco.2020.38.15_suppl.5046","title":"Detection of urothelial carcinoma using plasma cell-free methylated DNA.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"Dana-Farber Cancer Institute","keywords":"Differentially methylated regions; Bladder cancer; DNA methylation; Cell-free fetal DNA; Bisulfite sequencing; Medicine; Methylated DNA immunoprecipitation; Epigenetics; Molecular biology; Cancer research; Oncology; Cancer; Internal medicine; Biology; Gene; Gene expression; Genetics; Fetus; Prenatal diagnosis","score_opus":0.16159154446492577,"score_gpt":0.4295596021902208,"score_spread":0.2679680577252951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032077319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992697,0.0002770463,0.0007496589,0.0026970645,0.001067297,0.0001786416,0.00000916167,0.000009179863,0.0023149643],"genre_scores_gemma":[0.9938966,0.000095843,0.00304847,0.0013216985,0.0015689649,9.242066e-7,6.270182e-7,0.000020779014,0.000046113226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972432,0.00031219207,0.0017955209,0.00015800325,0.0003265618,0.0001644841],"domain_scores_gemma":[0.9971766,0.00056729064,0.001345323,0.00016165683,0.0003500325,0.000399108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007547103,0.00012627884,0.0012507738,0.00008084967,0.000027743044,0.000003504918,0.0001617493,0.00033771235,0.00013818548],"category_scores_gemma":[0.0016086746,0.00009281448,0.0005100816,0.00017592974,0.00012047427,0.00007207324,0.000051095143,0.00065964175,0.000009723179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053642165,0.0040937546,0.08559131,0.00030375575,0.0018265673,0.0021916127,0.0011271276,0.00018409171,0.6486019,0.000025196132,0.0020451434,0.2003674],"study_design_scores_gemma":[0.08918588,0.107096165,0.123719804,0.00015369967,0.0049022133,0.001123289,0.00052702776,0.0039572846,0.621581,0.00053739926,0.046846572,0.00036964976],"about_ca_topic_score_codex":0.00006467076,"about_ca_topic_score_gemma":0.000011072562,"teacher_disagreement_score":0.19999775,"about_ca_system_score_codex":0.00012284,"about_ca_system_score_gemma":0.0016634098,"threshold_uncertainty_score":0.37848648},"labels":[],"label_agreement":null},{"id":"W3032079924","doi":"10.1200/jco.2020.38.15_suppl.5070","title":"Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Foothills Medical Centre; Dalhousie University; Queen's University; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Clinical trial; Internal medicine; Gastroenterology; Oncology; Urology; Surgery","score_opus":0.3327149293955883,"score_gpt":0.5213296342139913,"score_spread":0.18861470481840298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032079924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792434,0.00035121408,0.00049625954,0.0077645564,0.0006139647,0.00216799,0.00018025533,0.000017800863,0.00048364385],"genre_scores_gemma":[0.9819571,0.00033145858,0.013876207,0.0028647543,0.00069307355,0.00004455451,0.000065945664,0.00007218714,0.00009474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9840172,0.003975829,0.009725223,0.0007637654,0.00095551077,0.00056246895],"domain_scores_gemma":[0.966742,0.02068479,0.008469657,0.00065011415,0.0021917028,0.001261748],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011858269,0.00057314994,0.008985617,0.00019859264,0.00008146624,0.000019689498,0.00045031845,0.0006551827,0.0002871482],"category_scores_gemma":[0.01750415,0.0003133892,0.0020138852,0.00031109716,0.000682405,0.00017201442,0.00013023084,0.001054402,0.000008079789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15856728,0.009666602,0.8085906,0.00031981905,0.0029748497,0.0009280919,0.0002397016,0.00003080897,0.00009746334,0.000008172763,0.0065787346,0.011997906],"study_design_scores_gemma":[0.08057256,0.16533478,0.7363443,0.000115083254,0.0062602893,0.00006164727,0.00009336309,0.00014590839,0.00096472737,0.000042742984,0.009824433,0.00024015861],"about_ca_topic_score_codex":0.0000436492,"about_ca_topic_score_gemma":0.00007590925,"teacher_disagreement_score":0.15566818,"about_ca_system_score_codex":0.00039981733,"about_ca_system_score_gemma":0.0029552698,"threshold_uncertainty_score":0.9999318},"labels":[],"label_agreement":null},{"id":"W3032096744","doi":"10.1200/jco.2020.38.15_suppl.9001","title":"KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Placebo; Carboplatin; Internal medicine; Population; Etoposide; Interim analysis; Pembrolizumab; Clinical endpoint; Oncology; Clinical trial; Cisplatin; Chemotherapy; Cancer; Pathology; Immunotherapy","score_opus":0.2029837320610601,"score_gpt":0.5117943962480638,"score_spread":0.30881066418700365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032096744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87866193,0.011837988,0.0009703418,0.103458084,0.0011422524,0.002116637,0.000054579446,0.00004087274,0.0017172914],"genre_scores_gemma":[0.8927283,0.05645387,0.0062584076,0.03236153,0.0065886034,0.00016510344,0.000007761635,0.00012169783,0.005314699],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955638,0.00037106374,0.0023238927,0.0005090287,0.0006125796,0.0006196362],"domain_scores_gemma":[0.98795897,0.008020091,0.0015699108,0.0002555331,0.001180105,0.001015414],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020133047,0.00034957004,0.0025344475,0.00012738636,0.0001760433,0.000031573683,0.000322066,0.00047989638,0.0005191393],"category_scores_gemma":[0.010123159,0.00022373373,0.00056699925,0.00021073481,0.00040797278,0.00013707663,0.00021132053,0.0016840218,0.00001058231],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6868974,0.002295306,0.0444676,0.0026397903,0.005063762,0.0060244515,0.0049735145,0.0010725857,0.0030611341,0.00018194705,0.1304716,0.112850904],"study_design_scores_gemma":[0.20680428,0.090516604,0.033596482,0.0007501755,0.0015803359,0.00058740604,0.0011066033,0.011930772,0.0021097565,0.00023018854,0.65010875,0.00067864935],"about_ca_topic_score_codex":0.00012186006,"about_ca_topic_score_gemma":0.00033949668,"teacher_disagreement_score":0.51963717,"about_ca_system_score_codex":0.0004490904,"about_ca_system_score_gemma":0.005405172,"threshold_uncertainty_score":0.998215},"labels":[],"label_agreement":null},{"id":"W3032154372","doi":"10.1200/jco.2020.38.15_suppl.6015","title":"Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Internal medicine; BRCA mutation; Oncology; PARP inhibitor; Ovarian cancer; Loss of heterozygosity; Cancer; Poly ADP ribose polymerase; Allele; Polymerase; Genetics; Gene","score_opus":0.16166968674323198,"score_gpt":0.48598209628339095,"score_spread":0.32431240954015894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032154372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97422594,0.00006237665,0.00047590418,0.02402468,0.00075556606,0.0003049998,0.000024605813,0.000005102516,0.00012083414],"genre_scores_gemma":[0.98979306,0.00054628367,0.0007790809,0.007999076,0.0008087155,0.000011759321,0.000009594689,0.000015598223,0.000036844234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970331,0.00039605313,0.0018976819,0.00016866287,0.0003544455,0.00015001233],"domain_scores_gemma":[0.9970003,0.00046240247,0.0015199586,0.00011341326,0.00054057874,0.00036334357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009360645,0.00010506399,0.0010193896,0.00013942827,0.000012439534,0.0000041312114,0.00011694336,0.00017945557,0.00033083287],"category_scores_gemma":[0.0013036896,0.00007645222,0.00013397573,0.00028128785,0.00009173554,0.00009774689,0.000025301168,0.00055778807,0.0000073129772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05153063,0.0013216097,0.8571147,0.00005185762,0.00012137296,0.0001181885,0.00051221176,0.0000069491257,0.00465311,0.000014778252,0.0004671557,0.08408744],"study_design_scores_gemma":[0.012205491,0.018032258,0.9561124,0.00041534024,0.000086171356,0.000014247157,0.000014140927,0.000010847358,0.0013351829,0.000008869857,0.011692519,0.000072565876],"about_ca_topic_score_codex":0.00000894914,"about_ca_topic_score_gemma":0.000049801874,"teacher_disagreement_score":0.09899767,"about_ca_system_score_codex":0.00021412405,"about_ca_system_score_gemma":0.0014010263,"threshold_uncertainty_score":0.3622388},"labels":[],"label_agreement":null},{"id":"W3032163036","doi":"10.1200/jco.2020.38.15_suppl.tps5601","title":"RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Enzalutamide; Biochemical recurrence; Androgen deprivation therapy; Radiation therapy; Lymph node; Oncology; Nocturia; Urology; Internal medicine; Cancer; Surgery; Androgen receptor","score_opus":0.22287370133834156,"score_gpt":0.5239089853556419,"score_spread":0.30103528401730034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032163036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866749,0.0031460552,0.000012899493,0.008610644,0.0004911374,0.00091503054,0.0000035862288,0.000008432516,0.00013731947],"genre_scores_gemma":[0.9932927,0.004227759,0.0005976122,0.001037854,0.00053718395,0.00003124988,0.0000013406341,0.000030143687,0.00024415372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959344,0.0006644203,0.0021854434,0.00026322834,0.0006325481,0.0003199517],"domain_scores_gemma":[0.9961696,0.001753303,0.0012253848,0.00015079205,0.00026753446,0.00043334105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002554119,0.0001771491,0.002424775,0.00018387218,0.000026510648,0.000008487252,0.00014461763,0.00015799262,0.000106284184],"category_scores_gemma":[0.0010963003,0.000093855284,0.0003509004,0.0004698499,0.00013600932,0.000115162584,0.00003523229,0.0010122545,0.0000014161843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07098251,0.0036751323,0.8326018,0.00009684563,0.0010879604,0.003706499,0.003086614,0.000028192251,0.00031857612,7.881314e-7,0.0010248718,0.083390236],"study_design_scores_gemma":[0.0942348,0.15649135,0.71369195,0.0015514026,0.000996924,0.00016794757,0.004410144,0.00038245934,0.00047513278,0.00001688464,0.027269611,0.00031136116],"about_ca_topic_score_codex":0.00014495372,"about_ca_topic_score_gemma":0.0006413249,"teacher_disagreement_score":0.15281624,"about_ca_system_score_codex":0.00028662678,"about_ca_system_score_gemma":0.0039708624,"threshold_uncertainty_score":0.70441395},"labels":[],"label_agreement":null},{"id":"W3032169917","doi":"10.1200/jco.2020.38.15_suppl.5022","title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Atezolizumab; Concomitant; Bladder cancer; Clinical endpoint; Cystectomy; Urology; Cystoscopy; Internal medicine; Oncology; Surgery; Cancer; Clinical trial; Immunotherapy; Urinary system; Pembrolizumab","score_opus":0.16231594956720488,"score_gpt":0.4948129775006119,"score_spread":0.33249702793340696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032169917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729054,0.0007184803,0.000037214748,0.020988429,0.0016943046,0.00072502694,0.000039362618,0.000008549565,0.0028832334],"genre_scores_gemma":[0.9872896,0.0023410337,0.0005080433,0.0067126406,0.0028985906,0.000022336173,0.0000043701475,0.000031270567,0.00019213452],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995125,0.00055314484,0.00315034,0.00031792987,0.00051433913,0.00033923893],"domain_scores_gemma":[0.9945497,0.0020104835,0.002004298,0.00022199939,0.00055652903,0.000657016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012725497,0.0002394413,0.0025347376,0.00017639658,0.000044503104,0.0000057646334,0.00025915142,0.00047172586,0.0007857903],"category_scores_gemma":[0.0050447625,0.00017697817,0.00076332106,0.00034515737,0.0002621424,0.00014302359,0.000106343294,0.0011678732,0.000024010398],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6423087,0.019553192,0.0059659216,0.00010357869,0.0017808732,0.00361929,0.0027608515,0.00004745954,0.003838389,0.000027351382,0.018554915,0.30143946],"study_design_scores_gemma":[0.6204429,0.2937184,0.02451529,0.00032215603,0.001431242,0.000121052406,0.00062756287,0.00009288843,0.00308752,0.00026435696,0.055133056,0.00024353349],"about_ca_topic_score_codex":0.00020415844,"about_ca_topic_score_gemma":0.00019152483,"teacher_disagreement_score":0.30119592,"about_ca_system_score_codex":0.00025529103,"about_ca_system_score_gemma":0.0073071374,"threshold_uncertainty_score":0.9983205},"labels":[],"label_agreement":null},{"id":"W3032176512","doi":"10.1200/jco.2020.38.15_suppl.1055","title":"Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Population; Adverse effect; Phases of clinical research; Nausea; Febrile neutropenia; Gastroenterology; Surgery; Clinical trial; Chemotherapy","score_opus":0.1977987316976941,"score_gpt":0.5158389428914423,"score_spread":0.31804021119374815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032176512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488155,0.0010713321,0.00006512568,0.048293687,0.00040273613,0.000852163,0.0003617176,0.000007947672,0.00012979034],"genre_scores_gemma":[0.99363995,0.0009103818,0.0006407808,0.0036822187,0.0010335146,0.00002331629,0.00002453164,0.000022961345,0.00002234853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941666,0.0010629299,0.003559469,0.0003021831,0.00062640005,0.00028239438],"domain_scores_gemma":[0.9926359,0.003165904,0.0031014401,0.00043140913,0.00045320878,0.00021214118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014367463,0.00023830167,0.0020821022,0.000059283768,0.000053666754,0.0000057142956,0.00047286492,0.00014524689,0.00026075315],"category_scores_gemma":[0.0005676479,0.00012132096,0.0003936889,0.0003707895,0.0003711835,0.000104773855,0.00005473066,0.00070784835,0.0000030997876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22136688,0.032813553,0.06855508,0.000029344672,0.0031209907,0.0008337593,0.026449706,0.0024840664,0.0026150735,0.000036690224,0.0026757484,0.63901913],"study_design_scores_gemma":[0.27293903,0.087311015,0.44265822,0.00023238672,0.0014380643,0.00011762325,0.025272632,0.0004901163,0.00053140573,0.00016163582,0.16862017,0.00022771605],"about_ca_topic_score_codex":0.00086737116,"about_ca_topic_score_gemma":0.0011767414,"teacher_disagreement_score":0.6387914,"about_ca_system_score_codex":0.00035188664,"about_ca_system_score_gemma":0.0009924287,"threshold_uncertainty_score":0.4947325},"labels":[],"label_agreement":null},{"id":"W3032203419","doi":"10.1200/jco.2020.38.15_suppl.e21737","title":"Activin as a biomarker for platinum resistance in non-small cell lung cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Biomarker; Immunohistochemistry; Cancer; Proportional hazards model; Chemotherapy; Cohort; Pathology","score_opus":0.07129174731401532,"score_gpt":0.4318166434436265,"score_spread":0.3605248961296112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032203419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905164,0.0025825491,0.0016691214,0.0030297402,0.00049413176,0.000229673,0.00001687744,0.0000033696463,0.0014581274],"genre_scores_gemma":[0.9900666,0.00024268097,0.0056354576,0.0025483225,0.0011678911,0.000020052179,0.0000058262976,0.000022751114,0.0002904591],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789643,0.00021320736,0.0012760415,0.00026307727,0.000124319,0.00022691354],"domain_scores_gemma":[0.9977175,0.0006367435,0.001055637,0.0001341699,0.00017639266,0.00027953653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095750956,0.00012984913,0.0006075831,0.00003628465,0.000028576516,0.000009791851,0.00032238348,0.00037432255,0.00004521726],"category_scores_gemma":[0.00294449,0.000113679285,0.00033882936,0.000083818646,0.00008256791,0.0000058457085,0.000076162476,0.00032107127,0.0000029629762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044995062,0.0030564696,0.23462802,0.0006480655,0.0009357771,0.0005087261,0.0006305945,0.0006882004,0.5007118,0.00003625543,0.16067594,0.05248506],"study_design_scores_gemma":[0.022209747,0.010806874,0.16776642,0.00031865307,0.00041929606,0.000020921818,0.0002788961,0.001444357,0.097169705,0.00032379784,0.69852877,0.00071253616],"about_ca_topic_score_codex":0.000007707943,"about_ca_topic_score_gemma":0.00020313414,"teacher_disagreement_score":0.5378528,"about_ca_system_score_codex":0.00004205415,"about_ca_system_score_gemma":0.0015171522,"threshold_uncertainty_score":0.46357065},"labels":[],"label_agreement":null},{"id":"W3032210158","doi":"10.1200/jco.2020.38.15_suppl.e24085","title":"Incidence of breast pain in breast cancer patients in a multi-ethnic cohort.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Incidence (geometry); Ethnic group; Breast pain; Cohort; Physical therapy; Cancer; Internal medicine","score_opus":0.11172953548533182,"score_gpt":0.4594603136765283,"score_spread":0.34773077819119647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032210158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859406,0.00044670113,0.000058461475,0.012599646,0.0006174131,0.00018637883,0.00002358637,0.0000034911557,0.00012374877],"genre_scores_gemma":[0.9929082,0.0010114003,0.00019464942,0.00546727,0.00038475022,0.0000059753265,0.0000018482381,0.000011923112,0.000013989006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961815,0.0007240999,0.0023363032,0.00018542554,0.0003696614,0.00020299513],"domain_scores_gemma":[0.9968019,0.001084011,0.0011939006,0.000106920896,0.0004656455,0.00034759595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003503251,0.000111339876,0.0013937328,0.0001201306,0.0000063971256,0.0000020481668,0.00017800299,0.0002986273,0.00021376232],"category_scores_gemma":[0.0024509875,0.00008681378,0.00027797863,0.00041527476,0.00013504252,0.000089129804,0.000059377515,0.0010980155,0.000003754366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003607267,0.0011652794,0.8561543,0.000063327934,0.00005455062,0.00022994052,0.00051517965,0.000024014897,0.0000510815,0.0000025207282,0.00047254047,0.13765995],"study_design_scores_gemma":[0.007625696,0.0030868864,0.98703927,0.0003916296,0.000074334275,0.00006123309,0.00026457018,0.00041218242,0.000007494191,0.000013431482,0.0009501431,0.000073133946],"about_ca_topic_score_codex":0.0021169125,"about_ca_topic_score_gemma":0.012978937,"teacher_disagreement_score":0.13758683,"about_ca_system_score_codex":0.0002422981,"about_ca_system_score_gemma":0.0014783618,"threshold_uncertainty_score":0.72425514},"labels":[],"label_agreement":null},{"id":"W3032218776","doi":"10.1200/jco.2020.38.15_suppl.5048","title":"Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Taxane; Carboplatin; Oncology; Bladder cancer; Cancer; Chemotherapy; Breast cancer; Cisplatin","score_opus":0.12284921663075102,"score_gpt":0.4289152680741216,"score_spread":0.3060660514433706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032218776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952939,0.00015183674,0.00078997464,0.002368316,0.0005061907,0.0003511774,0.000030733205,0.0000036613812,0.0005042004],"genre_scores_gemma":[0.99365884,0.000057448746,0.005444081,0.00052321766,0.0001949318,0.0000033097074,0.000005039457,0.000019428602,0.00009372542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959707,0.00023387762,0.0028235198,0.00016689337,0.0006330748,0.00017190659],"domain_scores_gemma":[0.99546224,0.0007783342,0.0028556022,0.000160889,0.00040436062,0.00033859911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074044114,0.00016867583,0.0021696428,0.00010352896,0.000015079343,0.0000021260962,0.00017632864,0.00011616347,0.00022065766],"category_scores_gemma":[0.0026234922,0.0001064849,0.0006895367,0.00022774328,0.0001304322,0.0001339949,0.00003308782,0.0003297747,0.000002096351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006808784,0.0016916135,0.95940727,0.000082382074,0.0014025888,0.00006764907,0.00093857246,0.000026842676,0.00032709315,0.000037261718,0.000819485,0.028390434],"study_design_scores_gemma":[0.025656058,0.032195117,0.93414795,0.00016246397,0.002924628,0.0000106662455,0.00062515005,0.00006407208,0.003099667,0.00010299572,0.0008979324,0.00011328144],"about_ca_topic_score_codex":0.00024260682,"about_ca_topic_score_gemma":0.000056883222,"teacher_disagreement_score":0.030503506,"about_ca_system_score_codex":0.00003700858,"about_ca_system_score_gemma":0.0022379635,"threshold_uncertainty_score":0.4342328},"labels":[],"label_agreement":null},{"id":"W3032221313","doi":"10.1200/jco.2020.38.15_suppl.2018","title":"Post-hoc power of clinical trials supporting anticancer drug approval by FDA.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sample size determination; Clinical endpoint; Post-hoc analysis; Statistical significance; Clinical trial; Oncology; Post hoc; Logistic regression; Statistical power; Internal medicine; Cancer; Statistics","score_opus":0.33078100817881045,"score_gpt":0.60078077008646,"score_spread":0.26999976190764957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032221313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6739839,0.0008679085,0.0008916238,0.3192634,0.00307619,0.0003131022,0.000019656682,0.000013205283,0.0015710271],"genre_scores_gemma":[0.9716321,0.0009787235,0.004024942,0.019369507,0.0037402655,9.4582805e-7,0.000009422602,0.000021044698,0.00022305423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9851109,0.0023945188,0.01101317,0.00029016435,0.0009147656,0.00027653124],"domain_scores_gemma":[0.974956,0.012723311,0.009468339,0.00021468868,0.0013248151,0.0013128737],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.045330785,0.00015438967,0.004000208,0.0000696231,0.000031821546,0.0000076013403,0.00023116107,0.001104159,0.0007833479],"category_scores_gemma":[0.06797656,0.00009442591,0.001579685,0.00020071611,0.0012991765,0.000086775566,0.00008815084,0.002598102,0.000016103992],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029217444,0.0039697243,0.026329452,0.00023808637,0.0015113453,0.0004844815,0.00087618583,0.0000039399283,0.0046595866,0.0008716496,0.116525605,0.8153125],"study_design_scores_gemma":[0.045140203,0.06867724,0.104296565,0.00047336367,0.0022409784,0.00028577764,0.0015118042,0.0022763666,0.00075996487,0.0021235105,0.77181727,0.00039695064],"about_ca_topic_score_codex":0.000008375244,"about_ca_topic_score_gemma":0.0000028430497,"teacher_disagreement_score":0.81491554,"about_ca_system_score_codex":0.000033365275,"about_ca_system_score_gemma":0.0034681326,"threshold_uncertainty_score":0.99970293},"labels":[],"label_agreement":null},{"id":"W3032236989","doi":"10.1200/jco.2020.38.15_suppl.tps9079","title":"A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health","keywords":"Medicine; Clinical endpoint; Pemetrexed; Extrapleural Pneumonectomy; Decortication; Neoadjuvant therapy; Lung cancer; Oncology; Randomized controlled trial; Radiation therapy; Internal medicine; Surgery; Chemotherapy; Cancer; Pneumonectomy; Breast cancer; Cisplatin","score_opus":0.10567793385147223,"score_gpt":0.44829701521195786,"score_spread":0.34261908136048563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032236989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883573,0.0002945128,0.00234259,0.0060656094,0.00046804134,0.0023880762,0.000025041232,0.000023469049,0.000035371177],"genre_scores_gemma":[0.99136937,0.000873049,0.0028498324,0.0035725997,0.0010936434,0.00006111437,0.000060788156,0.00004081517,0.000078815785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954134,0.0005211715,0.00296438,0.00031802082,0.0005386921,0.00024428492],"domain_scores_gemma":[0.994135,0.0018985956,0.0028923003,0.00019065273,0.00041585873,0.0004675797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019722804,0.00026624525,0.003186314,0.00012265492,0.00005751764,0.000011734685,0.00017255885,0.00026186215,0.00017686613],"category_scores_gemma":[0.0023923614,0.00014991265,0.00084544125,0.00020090461,0.00038607293,0.00015665451,0.000024132896,0.00045104194,0.0000044525254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92547864,0.003390635,0.004614383,0.000053301217,0.0010365046,0.0000652762,0.000331563,0.00005111581,0.0043913606,0.000011109233,0.000326502,0.060249593],"study_design_scores_gemma":[0.91208225,0.052005157,0.015560921,0.00010055043,0.0010086319,0.00016467625,0.00019405689,0.013319816,0.00407847,0.000101296464,0.0012037253,0.00018042908],"about_ca_topic_score_codex":0.000019556583,"about_ca_topic_score_gemma":0.0000056767467,"teacher_disagreement_score":0.060069162,"about_ca_system_score_codex":0.00015878984,"about_ca_system_score_gemma":0.00106301,"threshold_uncertainty_score":0.61132604},"labels":[],"label_agreement":null},{"id":"W3032239860","doi":"10.1200/jco.2020.38.15_suppl.e19538","title":"A population-based study of chronic neutrophilic leukemia in the United States: 2004 to 2015.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Interquartile range; Hazard ratio; Internal medicine; Confidence interval; Incidence (geometry); Proportional hazards model; Population; Epidemiology; Survival analysis; Univariate analysis; Surveillance, Epidemiology, and End Results; Surgery; Cancer registry; Multivariate analysis","score_opus":0.14441882143898901,"score_gpt":0.4873208696631166,"score_spread":0.3429020482241276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032239860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401912,0.0001057598,0.00011050565,0.058672354,0.00015296183,0.00067972863,0.0000029343826,0.0000058578803,0.000078699515],"genre_scores_gemma":[0.9836326,0.000061813145,0.00034275366,0.015030244,0.0008766896,0.000008262613,0.000010019791,0.000017339793,0.000020246796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99483,0.0014465757,0.0025494995,0.00019814669,0.0006988745,0.0002768835],"domain_scores_gemma":[0.99407345,0.003746829,0.0009540144,0.00028503942,0.0004991831,0.00044149766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040970966,0.0001296842,0.0013201815,0.00034202886,0.000027882646,0.000007311899,0.00046324756,0.00022271399,0.00011511627],"category_scores_gemma":[0.0063463068,0.0000783246,0.00023083568,0.0010715288,0.00007678848,0.000051740626,0.00006634201,0.001840468,0.000024736126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027249565,0.008130443,0.73867697,0.00021007507,0.0006901869,0.004533348,0.0050202846,0.13446711,0.00042074098,0.000053067666,0.057810917,0.022737276],"study_design_scores_gemma":[0.025466071,0.09031647,0.8349549,0.00010505233,0.00025887735,0.00005660066,0.0024234182,0.0179929,0.000014057684,0.000057182264,0.028243816,0.00011066345],"about_ca_topic_score_codex":0.0008548016,"about_ca_topic_score_gemma":0.00041486372,"teacher_disagreement_score":0.11647422,"about_ca_system_score_codex":0.0015159643,"about_ca_system_score_gemma":0.0065605068,"threshold_uncertainty_score":0.99907136},"labels":[],"label_agreement":null},{"id":"W3032246744","doi":"10.1200/jco.2020.38.15_suppl.10076","title":"Effect of automated TIL quantification in early-stage melanoma on accuracy of standard T staging using AJCC guidelines.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Institutes of Health; Melanoma Research Alliance","keywords":"Medicine; Melanoma; Tumor-infiltrating lymphocytes; Stage (stratigraphy); Cancer staging; Cutoff; Adjuvant therapy; H&E stain; Internal medicine; Cancer; Cohort; Oncology; Nuclear medicine; Surgery; Artificial intelligence; Immunotherapy; Immunohistochemistry; Cancer research","score_opus":0.24113845237824974,"score_gpt":0.5412683804119947,"score_spread":0.30012992803374494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032246744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943012,0.00036168957,0.0002961525,0.004153591,0.000450121,0.00023714965,0.000011054726,0.000013093527,0.00017595985],"genre_scores_gemma":[0.9968044,0.0003942606,0.0016781302,0.0008445985,0.00025058232,7.5283924e-7,0.0000021126707,0.000013999839,0.000011153757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99536026,0.00063647184,0.0033338957,0.00014657514,0.00038459912,0.00013818635],"domain_scores_gemma":[0.99368167,0.002666357,0.0029027862,0.00015452779,0.0004632236,0.00013143981],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056673964,0.00011612891,0.0014568615,0.00015463599,0.000013953855,0.000004398223,0.00014076778,0.0002346052,0.000055635715],"category_scores_gemma":[0.008657964,0.000081175196,0.00038680434,0.00029003495,0.0001424418,0.00008510885,0.00002289708,0.00048966566,0.0000015632329],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19662003,0.00076642947,0.2812141,0.00052511937,0.00066433905,0.00038303208,0.00058394787,0.0008175752,0.12835711,0.000027858356,0.0019741107,0.38806635],"study_design_scores_gemma":[0.07042696,0.15129371,0.5263706,0.0027973275,0.00088735943,0.00010484806,0.00037728902,0.03791538,0.16675502,0.00002355314,0.042686325,0.00036161285],"about_ca_topic_score_codex":0.00008764057,"about_ca_topic_score_gemma":0.000007774164,"teacher_disagreement_score":0.38770473,"about_ca_system_score_codex":0.00014421082,"about_ca_system_score_gemma":0.0010668148,"threshold_uncertainty_score":0.99969256},"labels":[],"label_agreement":null},{"id":"W3032247240","doi":"10.1200/jco.2020.38.15_suppl.e21683","title":"Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Ipilimumab; Taxane; Oncology; Interim analysis; Lung cancer; Progressive disease; Phases of clinical research; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Cancer; Immunotherapy; Breast cancer","score_opus":0.11981197337168767,"score_gpt":0.4534532654417884,"score_spread":0.33364129207010074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032247240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974997,0.0003751485,0.000086804626,0.007056521,0.0011439315,0.0014289147,0.000053398486,0.000005206491,0.00010009626],"genre_scores_gemma":[0.9956838,0.00089626975,0.00090052874,0.0017879546,0.000643337,0.000011315438,0.000025829202,0.000018899733,0.000032085976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99377626,0.0010588376,0.004314523,0.00029593363,0.00036508538,0.00018933201],"domain_scores_gemma":[0.99173087,0.0037821059,0.003649807,0.00019872293,0.00039467734,0.00024384685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037796628,0.00018246437,0.0018418233,0.00007446038,0.000041133153,0.000011508332,0.00020545351,0.00026069584,0.00007545929],"category_scores_gemma":[0.0030136986,0.000104847655,0.00039210627,0.00024319069,0.00036700306,0.000094782044,0.00006841979,0.0009711215,6.047091e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8818654,0.009311935,0.0132033,0.0000218809,0.00079121796,0.000065278015,0.0006619386,0.00000764097,0.000069383066,5.5423993e-7,0.0015224132,0.09247905],"study_design_scores_gemma":[0.76542634,0.17412232,0.056129523,0.0002467438,0.0009283314,0.0000028173652,0.00018454558,0.0008563218,0.000056013898,0.0000037873306,0.0019526891,0.00009059608],"about_ca_topic_score_codex":0.00036408886,"about_ca_topic_score_gemma":0.00016231368,"teacher_disagreement_score":0.16481037,"about_ca_system_score_codex":0.000109124725,"about_ca_system_score_gemma":0.0015312644,"threshold_uncertainty_score":0.42755634},"labels":[],"label_agreement":null},{"id":"W3032248100","doi":"10.1200/jco.2020.38.15_suppl.tps2580","title":"Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Novocure","keywords":"Temozolomide; Medicine; Concomitant; Clinical endpoint; Oncology; Internal medicine; Radiation therapy; Phases of clinical research; Progression-free survival; Clinical trial; Surgery; Chemotherapy","score_opus":0.0924280266626136,"score_gpt":0.45271531495605744,"score_spread":0.3602872882934438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032248100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709296,0.00081711664,0.00003871914,0.02702154,0.00047549108,0.00045756294,0.0000017867649,0.000009171432,0.0002490037],"genre_scores_gemma":[0.99228644,0.0007848114,0.0004875149,0.005083372,0.0013205433,0.00001502921,0.0000017164822,0.000011723925,0.000008847303],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99672824,0.000337203,0.002327656,0.00019821216,0.00022956402,0.00017911545],"domain_scores_gemma":[0.9944358,0.0035387191,0.0013375791,0.00009336828,0.00010293429,0.00049164146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014092275,0.00013240105,0.001482433,0.00013586167,0.000027451108,0.000013954717,0.00007098814,0.00021532344,0.000071949755],"category_scores_gemma":[0.0074924747,0.00009443063,0.00031979027,0.00018211076,0.00006172124,0.00010244198,0.000029544124,0.0005704502,0.000005974979],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19521216,0.012111033,0.07788406,0.00003724503,0.00045228467,0.010804007,0.00072702515,0.000056907014,0.0003550914,0.000052115625,0.008449893,0.6938582],"study_design_scores_gemma":[0.79997665,0.113093466,0.06803401,0.00014440334,0.0006686403,0.00024580484,0.00036836765,0.0013805397,0.0008925137,0.00010298787,0.014955697,0.00013692786],"about_ca_topic_score_codex":0.000039991424,"about_ca_topic_score_gemma":0.000081395774,"teacher_disagreement_score":0.69372123,"about_ca_system_score_codex":0.00011126982,"about_ca_system_score_gemma":0.0005265485,"threshold_uncertainty_score":0.8969734},"labels":[],"label_agreement":null},{"id":"W3032259164","doi":"10.1200/jco.2020.38.15_suppl.5521","title":"Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Internal medicine; Basal (medicine); Population; Oncology; Androgen deprivation therapy; Urology; Cancer","score_opus":0.11356616701887173,"score_gpt":0.4601772755687373,"score_spread":0.34661110854986554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032259164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914404,0.0005062507,0.000010083454,0.0066634337,0.00016980249,0.0011317782,0.000039520564,0.0000035638325,0.000035124496],"genre_scores_gemma":[0.9947371,0.0019172304,0.0024735061,0.00068993913,0.00010037128,0.000016129306,0.000004259535,0.000028888735,0.00003257728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99449694,0.000963031,0.003132988,0.0003837765,0.00062218565,0.0004010757],"domain_scores_gemma":[0.9962545,0.0012142063,0.0011734958,0.00018620504,0.0004994212,0.0006721687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028293852,0.00021148489,0.0017211973,0.00025013584,0.000020410213,0.000014943859,0.00015021453,0.00019670655,0.000022734235],"category_scores_gemma":[0.0022498702,0.0001448678,0.00015956824,0.00047522952,0.000379385,0.00010761456,0.000075724834,0.00081692194,0.0000037245943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13621654,0.0018273724,0.8220363,0.0000996928,0.000141974,0.0031055633,0.0006415378,0.00012419466,0.0028376915,0.0000015906786,0.0001038532,0.032863684],"study_design_scores_gemma":[0.02353735,0.054962642,0.91730285,0.00050251366,0.00012208588,0.000019298099,0.00021137047,0.00015862414,0.0012404919,0.000021403257,0.0017886374,0.00013275947],"about_ca_topic_score_codex":0.00004739924,"about_ca_topic_score_gemma":0.00044054585,"teacher_disagreement_score":0.11267918,"about_ca_system_score_codex":0.00021166833,"about_ca_system_score_gemma":0.0017791975,"threshold_uncertainty_score":0.5907537},"labels":[],"label_agreement":null},{"id":"W3032274390","doi":"10.1200/jco.2020.38.15_suppl.e13079","title":"A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Infectious Diseases Centre","funders":"","keywords":"Medicine; Eribulin; Cyclophosphamide; Internal medicine; Docetaxel; Breast cancer; Toxicity; Metastatic breast cancer; Cancer; Gastroenterology; Oncology; Surgery; Chemotherapy","score_opus":0.11389035408599417,"score_gpt":0.517889981634441,"score_spread":0.4039996275484468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032274390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899889,0.00015539334,0.000022198536,0.008306071,0.00025506155,0.00082936336,0.000024362187,0.000008789097,0.00040983272],"genre_scores_gemma":[0.99631375,0.0002570788,0.0009305868,0.0019175082,0.00047001892,0.000027475035,0.0000020860418,0.000038868115,0.00004260515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995057,0.0006647087,0.0025190865,0.0003161407,0.0010610005,0.0003820704],"domain_scores_gemma":[0.9953471,0.0008814865,0.0016703416,0.00025882912,0.001101999,0.0007402883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001987647,0.00020629942,0.0020942965,0.00013640184,0.00004747527,0.000005243821,0.0003108189,0.000213635,0.00029993913],"category_scores_gemma":[0.0016852067,0.00012857375,0.00015045282,0.00060490373,0.00029994655,0.00013821226,0.00011098134,0.002297613,0.0000054100915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10446409,0.026388139,0.67635614,0.00009894875,0.00042056473,0.0010994674,0.0014312812,0.00026791063,0.0000764968,0.000001905443,0.00088871893,0.18850634],"study_design_scores_gemma":[0.10477135,0.29062638,0.59619194,0.0004264707,0.00023131118,0.00006856672,0.0010960747,0.00005528825,0.00006813688,0.0000064139736,0.0063326233,0.00012547689],"about_ca_topic_score_codex":0.00023631287,"about_ca_topic_score_gemma":0.00066587643,"teacher_disagreement_score":0.26423824,"about_ca_system_score_codex":0.00034297918,"about_ca_system_score_gemma":0.0035798233,"threshold_uncertainty_score":0.9982113},"labels":[],"label_agreement":null},{"id":"W3032296787","doi":"10.1200/jco.2020.38.15_suppl.e21107","title":"Is there a role for hypofractionated thoracic radiotherapy in limited-stage small cell lung cancer? a propensity score matched analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; University of Toronto; London Health Sciences Centre","funders":"","keywords":"Medicine; Propensity score matching; Chemoradiotherapy; Radiation therapy; Internal medicine; Lung cancer; Proportional hazards model; Performance status; Retrospective cohort study; Gemcitabine; Regimen; Stage (stratigraphy); Surgery; Oncology; Cancer","score_opus":0.26795590326361335,"score_gpt":0.5248756010756432,"score_spread":0.2569196978120299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032296787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.922062,0.00765041,0.0008075964,0.06787385,0.00020495962,0.0008746386,0.000022458247,0.000015788368,0.00048832776],"genre_scores_gemma":[0.97528404,0.0073748957,0.003474342,0.011909765,0.0011262029,0.000049209273,0.00000429352,0.000031289273,0.0007459554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967257,0.00047619327,0.0017283773,0.00032475847,0.00040434682,0.00034066488],"domain_scores_gemma":[0.99554425,0.0016923124,0.0013524265,0.0001835038,0.00079146744,0.00043605306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024644078,0.00017546192,0.0023193348,0.0002308603,0.00005222819,0.000015939913,0.00023657433,0.00030997253,0.00028974513],"category_scores_gemma":[0.0020601344,0.000120379926,0.00080617366,0.00079597376,0.0001355647,0.00012881347,0.000063983636,0.0013563914,0.0000029808314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020550456,0.0011592637,0.9379677,0.0003768973,0.0045259274,0.00050078036,0.0010235797,0.00047843234,0.0017065196,0.000006336222,0.0066662314,0.025037851],"study_design_scores_gemma":[0.014327423,0.009412397,0.8593696,0.00018299984,0.0027047205,0.00002166114,0.00056093873,0.022461297,0.0008222313,0.00005448091,0.08986831,0.00021395997],"about_ca_topic_score_codex":0.00021662665,"about_ca_topic_score_gemma":0.0004546736,"teacher_disagreement_score":0.08320208,"about_ca_system_score_codex":0.0005418097,"about_ca_system_score_gemma":0.0025171717,"threshold_uncertainty_score":0.5892921},"labels":[],"label_agreement":null},{"id":"W3032303480","doi":"10.1200/jco.2020.38.15_suppl.e24112","title":"Real-world implementation of serious illness care program (SICP) in cancer care.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Conversation; Medicine; Advance care planning; Palliative care; Family medicine; Nursing; Psychology","score_opus":0.35776175772347835,"score_gpt":0.6402334154220972,"score_spread":0.28247165769861887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032303480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894408,0.0025461721,0.000010620362,0.005069559,0.0005761131,0.0003102237,0.000015081165,0.0000071382437,0.0020243013],"genre_scores_gemma":[0.9903811,0.0048717097,0.0030034818,0.0009027636,0.00079312315,0.000010853718,0.000009607821,0.000011522557,0.000015787966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972653,0.000223204,0.0019570468,0.00012875487,0.00027325438,0.00015244383],"domain_scores_gemma":[0.9969296,0.00056913745,0.001423957,0.000085443506,0.0007860673,0.00020578183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045979078,0.000096044845,0.0012878458,0.00010157526,0.000011296139,0.000002097402,0.00011285436,0.00015346547,0.000120917706],"category_scores_gemma":[0.0007151501,0.00007309753,0.00028317128,0.00027148952,0.00011717225,0.0000606193,0.000034568362,0.00047417058,0.0000014229125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010905971,0.00018874061,0.5539071,0.00022252659,0.000118581214,0.0001405321,0.006742987,0.000016121712,0.00014488141,0.000023147739,0.000712618,0.43669218],"study_design_scores_gemma":[0.010147587,0.016293425,0.68694776,0.00060992513,0.00042272705,0.0000070772953,0.033827845,0.000018813711,0.0034180987,0.00002937235,0.24815999,0.00011735562],"about_ca_topic_score_codex":0.001138321,"about_ca_topic_score_gemma":0.0055243964,"teacher_disagreement_score":0.43657485,"about_ca_system_score_codex":0.00019934271,"about_ca_system_score_gemma":0.0015957812,"threshold_uncertainty_score":0.3082743},"labels":[],"label_agreement":null},{"id":"W3032325473","doi":"10.1200/jco.2020.38.15_suppl.3571","title":"Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Exome sequencing; Oncology; ROS1; Cohort; Adenocarcinoma; Internal medicine; Cancer; Bioinformatics; Genetics; Mutation; Gene; Biology","score_opus":0.07473910902682052,"score_gpt":0.47507493574155163,"score_spread":0.4003358267147311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032325473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801193,0.0006398037,0.00017477338,0.015410757,0.00018095788,0.00014213753,0.000009135776,0.000003622809,0.0033195058],"genre_scores_gemma":[0.99353254,0.00027167506,0.0024532045,0.0033391747,0.00029256404,0.0000018107861,0.000004017383,0.000008713257,0.00009627222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975813,0.0002977452,0.0016384001,0.00015062139,0.00020747005,0.00012447871],"domain_scores_gemma":[0.9966757,0.0015338109,0.0011619625,0.00010169248,0.00023361164,0.0002932137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007057549,0.000091715825,0.001485697,0.00023815404,0.000013432662,0.0000032576563,0.00010621631,0.00020310719,0.00030386698],"category_scores_gemma":[0.0014660811,0.00006703761,0.00061410974,0.0005169734,0.00014671471,0.00009254571,0.0000346669,0.0005181707,0.000006528188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017436012,0.0007185218,0.9794028,0.000018346538,0.0061223824,0.00067876285,0.0013217375,0.00044409206,0.0001341884,0.00009409508,0.001588931,0.007732589],"study_design_scores_gemma":[0.0067303334,0.003462842,0.97516996,0.0000302409,0.007698201,0.000020370218,0.0003058398,0.0015859334,0.000027699032,0.00005417141,0.0048625525,0.000051873616],"about_ca_topic_score_codex":0.000059089518,"about_ca_topic_score_gemma":0.000027639402,"teacher_disagreement_score":0.013413262,"about_ca_system_score_codex":0.00021355893,"about_ca_system_score_gemma":0.0014760082,"threshold_uncertainty_score":0.33271304},"labels":[],"label_agreement":null},{"id":"W3032335069","doi":"10.1200/jco.2020.38.15_suppl.7513","title":"Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Dosing; Internal medicine; Maintenance therapy; Neutropenia; Minimal residual disease; Febrile neutropenia; Surgery; Oncology; Chemotherapy; Bone marrow; Gastroenterology","score_opus":0.11128410234474692,"score_gpt":0.43992396344434664,"score_spread":0.32863986109959975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032335069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601105,0.00023216657,0.0012377081,0.03494032,0.0016958242,0.0013076692,0.00015012863,0.000024950734,0.00030077368],"genre_scores_gemma":[0.97937393,0.0012490693,0.011342875,0.004526293,0.003148394,0.000027209848,0.00009877271,0.00005976384,0.0001737198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99153686,0.00074798195,0.0056424905,0.0005392902,0.00092429185,0.00060906267],"domain_scores_gemma":[0.9786419,0.013808047,0.004503595,0.0005451775,0.0016770846,0.00082414696],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004508211,0.0003123546,0.0025412145,0.00011582576,0.00019982748,0.00002897738,0.0007898979,0.0007526527,0.000059208254],"category_scores_gemma":[0.048239596,0.00019380452,0.0008837704,0.00044499268,0.00063050305,0.0002695406,0.00024763276,0.0023610399,0.000017642884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8145219,0.008960428,0.0012492363,0.00007066427,0.0019196008,0.00068627123,0.0034539504,0.000036954385,0.0020665987,0.00011377919,0.07702336,0.08989727],"study_design_scores_gemma":[0.8227042,0.041247733,0.0024054328,0.0005247831,0.0009906301,0.00005521054,0.0014126798,0.005434223,0.0014304926,0.00017133601,0.12336219,0.00026110696],"about_ca_topic_score_codex":0.0001491329,"about_ca_topic_score_gemma":0.000034621975,"teacher_disagreement_score":0.08963616,"about_ca_system_score_codex":0.0009408631,"about_ca_system_score_gemma":0.004056866,"threshold_uncertainty_score":0.9999406},"labels":[],"label_agreement":null},{"id":"W3032353482","doi":"10.1200/jco.2020.38.15_suppl.9517","title":"Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; Medicine; Internal medicine; Lung cancer; ALK inhibitor; Fusion gene; ROS1; Anaplastic lymphoma kinase; Population; Oncology; Cancer; Cancer research; Adenocarcinoma; Gene; Biology; Genetics","score_opus":0.06326360016946156,"score_gpt":0.4715406169423998,"score_spread":0.40827701677293826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032353482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746041,0.00053425645,0.0050022565,0.017836036,0.0004088729,0.00025890826,0.000004194478,0.0000053240888,0.0013460129],"genre_scores_gemma":[0.98288476,0.00035032147,0.013375073,0.0027429531,0.00060133205,0.0000013343224,0.000005471053,0.000010730534,0.000028022609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971969,0.00033746925,0.0020028395,0.00015449995,0.00020572572,0.00010252887],"domain_scores_gemma":[0.99610615,0.002145214,0.0010716537,0.00008414042,0.00028169653,0.0003111512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016537353,0.0000869801,0.0010336606,0.00006156498,0.00001231787,0.0000032485827,0.0000488008,0.00022058334,0.000045803252],"category_scores_gemma":[0.0043078642,0.000055896286,0.00016571041,0.0001551773,0.00015575968,0.000066657645,0.000022188384,0.00057015865,0.000002459347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015457457,0.0073968847,0.72364086,0.00010304062,0.0015082716,0.0018806343,0.00046068875,0.0011847349,0.0003794396,0.0005538217,0.0031470794,0.24428712],"study_design_scores_gemma":[0.07108703,0.06332155,0.8064809,0.0005947616,0.0034407147,0.00033198067,0.00033286368,0.0061268215,0.00019578406,0.00022315865,0.047669146,0.00019532381],"about_ca_topic_score_codex":0.000016098244,"about_ca_topic_score_gemma":0.000014107722,"teacher_disagreement_score":0.2440918,"about_ca_system_score_codex":0.00004416137,"about_ca_system_score_gemma":0.0011215087,"threshold_uncertainty_score":0.51572275},"labels":[],"label_agreement":null},{"id":"W3032359244","doi":"10.1200/jco.2020.38.15_suppl.3530","title":"Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; London Health Sciences Centre; Sunnybrook Health Science Centre; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Chemotherapy; Oncology; Prospective cohort study; Cohort; Cancer; Gastroenterology","score_opus":0.10694864228399238,"score_gpt":0.44213925809975907,"score_spread":0.3351906158157667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032359244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976881,0.00007929523,0.0009933289,0.00086561474,0.00012270486,0.00017662396,0.00001048423,8.795061e-7,0.0000629687],"genre_scores_gemma":[0.9983231,0.00012785994,0.00076366065,0.00046898774,0.00029341277,0.000005704969,0.0000036757474,0.0000075226194,0.0000060915204],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99761087,0.00036489643,0.0015709045,0.00021161893,0.0001286604,0.000113049384],"domain_scores_gemma":[0.9974942,0.0005580975,0.0012457733,0.00017213429,0.0003535753,0.00017617655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012586326,0.00010380134,0.0010515614,0.000107731685,0.000015823642,0.0000034800953,0.00011463884,0.00007915683,0.000010736313],"category_scores_gemma":[0.002690538,0.000089068104,0.00029448653,0.00032301617,0.000042897347,0.0000039319,0.0000650856,0.00012631441,9.806969e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00852565,0.01007386,0.2759502,0.000046844754,0.0039348155,0.00023052511,0.0015122481,0.018433625,0.6562392,0.000027412283,0.00043775188,0.024587858],"study_design_scores_gemma":[0.006368911,0.270595,0.5983695,0.000041110805,0.0021822297,0.000008259304,0.0013489093,0.00049161376,0.11794513,0.000064062115,0.00230667,0.00027861528],"about_ca_topic_score_codex":0.00028264022,"about_ca_topic_score_gemma":0.0045573437,"teacher_disagreement_score":0.5382941,"about_ca_system_score_codex":0.00006690539,"about_ca_system_score_gemma":0.00049737265,"threshold_uncertainty_score":0.3632092},"labels":[],"label_agreement":null},{"id":"W3032362629","doi":"10.1200/jco.2020.38.15_suppl.e20516","title":"First-line CyborD treatment for graft ineligible multiple myeloma patients: Real-life efficacy and tolerability.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Regimen; Tolerability; Neutropenia; Internal medicine; Multiple myeloma; Surgery; Population; Anemia; Adverse effect; Chemotherapy","score_opus":0.2225687004561233,"score_gpt":0.48105982702739764,"score_spread":0.2584911265712744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032362629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971772,0.0002992566,0.00034322185,0.02579537,0.00029885137,0.0011245884,0.000039568007,0.00002015391,0.00030699428],"genre_scores_gemma":[0.9886026,0.002434593,0.0056379666,0.0019411885,0.0012052638,0.000032644573,0.000031449443,0.000026876574,0.00008744958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644214,0.00024559107,0.0022219683,0.00034959696,0.00036759913,0.00037310296],"domain_scores_gemma":[0.99124986,0.005311513,0.0009063115,0.00021102212,0.0006846164,0.0016366552],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0008661395,0.0002269247,0.0018589421,0.00009290549,0.00009129281,0.000015632191,0.00012790096,0.00029687776,0.00006701147],"category_scores_gemma":[0.01887701,0.0001450563,0.0004982753,0.00014272981,0.00019153471,0.00010723209,0.000068526315,0.0004164612,0.000017730867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03685606,0.007229383,0.7356587,0.000114911265,0.00094416615,0.0002549472,0.00021037055,0.00003546499,0.00004074443,0.00002809828,0.002305648,0.21632153],"study_design_scores_gemma":[0.077382,0.07770662,0.75320166,0.00006153921,0.0004136974,0.00002731901,0.000043093907,0.0021265375,0.00008276626,0.000075869364,0.088759944,0.00011896501],"about_ca_topic_score_codex":0.00007373958,"about_ca_topic_score_gemma":0.00010671168,"teacher_disagreement_score":0.21620256,"about_ca_system_score_codex":0.00021307812,"about_ca_system_score_gemma":0.0010406112,"threshold_uncertainty_score":0.9893874},"labels":[],"label_agreement":null},{"id":"W3032366211","doi":"10.1200/jco.2020.38.15_suppl.5538","title":"Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Brief Pain Inventory; Internal medicine; Enzalutamide; Oncology; Population; Cohort; Prostate cancer; Clinical endpoint; Cancer; Randomized controlled trial; Physical therapy; Chronic pain","score_opus":0.21953474328731185,"score_gpt":0.5179045079760652,"score_spread":0.2983697646887534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032366211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862358,0.00062940654,0.00011017669,0.011930553,0.00024820265,0.0004918981,0.0000571864,0.000003900314,0.0002928693],"genre_scores_gemma":[0.9954354,0.0005604577,0.0013980798,0.0016190095,0.0008865387,0.000010140027,0.000005124067,0.00002066562,0.00006453817],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947884,0.00069438247,0.003428872,0.00020419463,0.0006559168,0.00022825296],"domain_scores_gemma":[0.99299854,0.0019763561,0.0039136275,0.0001706689,0.0005788249,0.0003619659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023514698,0.0001819972,0.002041195,0.00014828025,0.000012861564,0.0000037873613,0.0001747455,0.00015559293,0.00021610456],"category_scores_gemma":[0.002421264,0.00013289112,0.00063666713,0.00035241354,0.0002267609,0.00010944539,0.00002168565,0.00078117795,0.0000024829042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16556188,0.010021088,0.128342,0.001382679,0.0057797357,0.00078047375,0.008244208,0.018999934,0.26384625,0.00032452872,0.04208921,0.35462803],"study_design_scores_gemma":[0.043228276,0.1469839,0.7794897,0.0019715256,0.00092740625,0.000032864777,0.0005559959,0.0015770277,0.009307119,0.0008791956,0.014736798,0.00031018959],"about_ca_topic_score_codex":0.0008579634,"about_ca_topic_score_gemma":0.00016475614,"teacher_disagreement_score":0.65114766,"about_ca_system_score_codex":0.00038736948,"about_ca_system_score_gemma":0.005757421,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W3032371821","doi":"10.1200/jco.2020.38.15_suppl.tps1111","title":"CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Taxane; Internal medicine; Tolerability; Oncology; Cohort; Chemotherapy; Nivolumab; Metastatic breast cancer; Breast cancer; Cancer; Immunotherapy; Adverse effect","score_opus":0.09154226995387651,"score_gpt":0.4490843375037694,"score_spread":0.35754206754989293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032371821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881716,0.0006396732,0.000048050224,0.0073136236,0.00029180353,0.0025458012,0.0003207415,0.000008573288,0.000014596698],"genre_scores_gemma":[0.99723417,0.00052192155,0.00051147724,0.0012119003,0.0002128622,0.00022149784,0.000011959064,0.000045356173,0.00002883696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99488133,0.00080106483,0.0026977055,0.00051195524,0.000693719,0.00041420932],"domain_scores_gemma":[0.99395204,0.002017786,0.0025517468,0.00015220305,0.00080626627,0.0005199737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000789059,0.000449492,0.0029295792,0.00036107685,0.00006308686,0.000014023731,0.00019332107,0.00014237435,0.00026054718],"category_scores_gemma":[0.00035994942,0.0002761598,0.00020260458,0.0005354704,0.0003774179,0.0002595581,0.00006612483,0.0011083751,7.6403046e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.146509,0.048146952,0.67200035,0.00012863596,0.0022304882,0.0005260922,0.0034725142,0.0001943472,0.000119157514,0.0000015586751,0.00017751635,0.12649335],"study_design_scores_gemma":[0.27496445,0.10596346,0.6138553,0.00039457713,0.001238751,0.000060132832,0.0012898108,0.0019049601,0.00003974318,0.0000124979615,0.00007941328,0.00019691381],"about_ca_topic_score_codex":0.00278444,"about_ca_topic_score_gemma":0.020813068,"teacher_disagreement_score":0.12845543,"about_ca_system_score_codex":0.00069033774,"about_ca_system_score_gemma":0.0013233094,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W3032384758","doi":"10.1200/jco.2020.38.15_suppl.12084","title":"Symptom burden as a predictor of emergency room use and unplanned hospitalization in patients with head and neck cancer: A population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Confidence interval; Odds ratio; Emergency department; Logistic regression; Population; Head and neck cancer; Cancer; Emergency medicine; Internal medicine; Physical therapy; Pediatrics; Psychiatry","score_opus":0.07383447775409613,"score_gpt":0.4216285449839173,"score_spread":0.34779406722982115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032384758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946451,0.00034878403,0.000009332215,0.0043785004,0.00022340823,0.00036250192,0.000008379637,0.0000040845043,0.00001987364],"genre_scores_gemma":[0.9987333,0.00032166525,0.0001957051,0.0005034311,0.00022157653,0.0000047803564,0.0000036698598,0.000008954041,0.000006956362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981414,0.00014935216,0.0012116097,0.00014570402,0.00025085686,0.00010106757],"domain_scores_gemma":[0.99835736,0.00032486915,0.00072645285,0.000058470294,0.00032181668,0.00021105919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031904588,0.00009163166,0.0009903165,0.00006434256,0.000021094533,0.000003313828,0.00003683913,0.00010234679,0.000025909752],"category_scores_gemma":[0.0016531983,0.000062063904,0.00005301226,0.00015094984,0.000026630587,0.00009899439,0.00002211296,0.00022835664,2.0216896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064504864,0.0008249238,0.98742825,0.000057931367,0.00017128699,0.000030486472,0.0007713394,0.000060996026,0.0000021056246,0.0000036489362,0.0001756528,0.0040228856],"study_design_scores_gemma":[0.015888637,0.040483736,0.9423741,0.00021451795,0.00020702968,0.0000010272873,0.00014412918,0.00027279402,9.103379e-7,0.00001331828,0.00034642752,0.000053361935],"about_ca_topic_score_codex":0.00037681643,"about_ca_topic_score_gemma":0.0005162537,"teacher_disagreement_score":0.045054145,"about_ca_system_score_codex":0.000048952614,"about_ca_system_score_gemma":0.00040935684,"threshold_uncertainty_score":0.25308925},"labels":[],"label_agreement":null},{"id":"W3032399294","doi":"10.1200/jco.2020.38.15_suppl.10009","title":"Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Ipilimumab; Nivolumab; Immune checkpoint; Transcriptome; Medicine; Immune system; Immunotherapy; Melanoma; Proportional hazards model; Oncology; Blockade; Cancer research; Immunology; Internal medicine; Biology; Gene; Gene expression; Receptor; Genetics","score_opus":0.07680348163036638,"score_gpt":0.42447522961412304,"score_spread":0.34767174798375666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032399294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811432,0.0019384568,0.0023893993,0.013576176,0.00049802597,0.00021647598,0.00003671487,0.0000035789499,0.00019797149],"genre_scores_gemma":[0.983544,0.0006002193,0.0098679755,0.0049300813,0.00088189344,0.0000067127185,0.00000502911,0.000021993192,0.00014207906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716055,0.00041435834,0.0017428462,0.00031902164,0.00013585949,0.0002273357],"domain_scores_gemma":[0.99723804,0.0007440919,0.0008215047,0.00021334067,0.0003215976,0.0006614302],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016846842,0.00018943843,0.00095824356,0.00007937143,0.00004293542,0.000022238864,0.0003294775,0.00023185987,0.00002819333],"category_scores_gemma":[0.00976266,0.00014712308,0.0003891903,0.00012812244,0.00011435841,0.0000049982737,0.00032682368,0.00045088844,0.000018615212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016303109,0.0003926521,0.0020760894,0.000009872437,0.00022555866,0.00015358586,0.00033877336,0.00035181924,0.97211987,0.0000026696814,0.0026977705,0.005328204],"study_design_scores_gemma":[0.009502228,0.055109177,0.1479619,0.00006867971,0.00035332984,0.00015783748,0.0010557539,0.0004225785,0.51418346,0.000038453043,0.2706834,0.0004632097],"about_ca_topic_score_codex":0.000031082942,"about_ca_topic_score_gemma":0.000044457593,"teacher_disagreement_score":0.45793644,"about_ca_system_score_codex":0.00005266417,"about_ca_system_score_gemma":0.00095731014,"threshold_uncertainty_score":0.99857855},"labels":[],"label_agreement":null},{"id":"W3032403368","doi":"10.1200/jco.2020.38.15_suppl.tps1597","title":"ECOG-ACRIN tomosynthesis mammographic imaging screening trial (EA1151).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Mammography; Population; Oncology; Internal medicine; Randomized controlled trial; Breast cancer screening; Clinical endpoint; Randomization; Biopsy; Cancer; Atypia; Gynecology; Pathology","score_opus":0.12401787704730786,"score_gpt":0.4636063458305183,"score_spread":0.3395884687832104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032403368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78891987,0.0008387999,0.02191075,0.17944254,0.0025774804,0.0003082774,0.0000016174223,0.000055850687,0.0059448145],"genre_scores_gemma":[0.94161016,0.000487906,0.031173592,0.020835705,0.005792459,0.0000021749754,0.0000016801125,0.000037107086,0.00005924068],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955255,0.00063543126,0.002689282,0.00027162043,0.0005386347,0.00033956132],"domain_scores_gemma":[0.99418217,0.002677944,0.0016222054,0.00017363379,0.00025983813,0.0010841799],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005400339,0.00017523655,0.0017696988,0.00016413917,0.00006910349,0.000027181448,0.00029520635,0.00022645123,0.0003782649],"category_scores_gemma":[0.021669395,0.00013003468,0.0009886296,0.0002602024,0.00028839582,0.00013926109,0.000090575144,0.0024643417,0.000024219145],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038170602,0.0005682568,0.08683164,0.000039424845,0.0003928761,0.0024144857,0.00011729066,0.000034013843,0.0003144276,0.00008419757,0.008719172,0.8623136],"study_design_scores_gemma":[0.15861893,0.017532088,0.07042734,0.00038020866,0.0015492559,0.0017435469,0.0003961856,0.025241997,0.00009106609,0.00042371443,0.7232,0.00039566247],"about_ca_topic_score_codex":0.000013478554,"about_ca_topic_score_gemma":0.0000014419741,"teacher_disagreement_score":0.861918,"about_ca_system_score_codex":0.00003941027,"about_ca_system_score_gemma":0.0007452677,"threshold_uncertainty_score":0.99983704},"labels":[],"label_agreement":null},{"id":"W3032414505","doi":"10.1200/jco.2020.38.15_suppl.e13682","title":"Characteristics of probands with mutations predisposing to gynecologic cancers enrolled in a facilitated cascade testing protocol.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Endometrial cancer; Family history; Ovarian cancer; Cancer; Lynch syndrome; Proband; Genetic testing; Internal medicine; Oncology; Breast cancer; Germline mutation; CHEK2; Genetic counseling; MSH6; Gynecology; MLH1; Mutation; Genetics; Colorectal cancer","score_opus":0.10647809649454955,"score_gpt":0.4288277836318992,"score_spread":0.3223496871373497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032414505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907594,0.000020210246,0.0014200035,0.0022599197,0.00019565008,0.004780537,0.000025548912,0.0000043041337,0.00053443323],"genre_scores_gemma":[0.97214377,0.000008604194,0.024913866,0.0011290952,0.00038851672,0.001364776,0.0000068308505,0.000014101026,0.00003044998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749553,0.00029712557,0.0016438793,0.00022451041,0.00016351562,0.00017542108],"domain_scores_gemma":[0.9972441,0.00050382037,0.0011928277,0.00011508647,0.00075160107,0.00019255275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00090170174,0.000114248476,0.000648788,0.000060027203,0.000027221133,0.0000070056294,0.0001855074,0.00024091665,0.000017614448],"category_scores_gemma":[0.010195659,0.000089907175,0.00010663379,0.00035204503,0.00013721276,0.000007636936,0.000063727006,0.00036943602,0.0000016661533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02257635,0.0017506847,0.5617383,0.00040325016,0.0008690498,0.0006496248,0.0023682336,0.050340414,0.18405259,0.000021407133,0.00399343,0.17123666],"study_design_scores_gemma":[0.024653131,0.07197781,0.7640642,0.00032896982,0.0003270033,0.00030669768,0.0009969436,0.0026765408,0.040203124,0.00020950088,0.09360634,0.000649718],"about_ca_topic_score_codex":0.0000100320185,"about_ca_topic_score_gemma":0.00012912831,"teacher_disagreement_score":0.20232591,"about_ca_system_score_codex":0.00016015941,"about_ca_system_score_gemma":0.00479658,"threshold_uncertainty_score":0.9981419},"labels":[],"label_agreement":null},{"id":"W3032485582","doi":"10.1200/jco.2020.38.15_suppl.e19121","title":"Prognostic value of programmed death-ligand 1 in solid tumors: A meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier Universitaire de Sherbrooke; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Subgroup analysis; Oncology; Internal medicine; Meta-analysis; Confidence interval; Stage (stratigraphy); Cancer; Disease","score_opus":0.3049344548205364,"score_gpt":0.5032714261614165,"score_spread":0.19833697134088013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032485582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657537,0.0033953944,0.00025760927,0.029497357,0.00017133034,0.00040391117,0.0000038773333,0.0000074512923,0.0005094095],"genre_scores_gemma":[0.9909704,0.0002673417,0.0032602402,0.0051067723,0.00033558265,0.00000813063,0.0000020156028,0.000010853283,0.00003868477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950133,0.0005073592,0.0036885925,0.00018979085,0.00039179038,0.000209143],"domain_scores_gemma":[0.9953787,0.0016074595,0.002224843,0.00015104101,0.00032263313,0.00031537417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039177733,0.00013499486,0.0040524267,0.00019357985,0.000011561276,0.000006159586,0.00018224519,0.00024697869,0.00019830227],"category_scores_gemma":[0.0043916167,0.00008365746,0.0029430715,0.0006920859,0.0001878609,0.000059136113,0.000032220894,0.00070850307,0.0000033822778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05191592,0.006900742,0.5540971,0.0002480735,0.3222491,0.0030576186,0.0011119421,0.00022790158,0.003052156,0.00016934965,0.0017673349,0.055202737],"study_design_scores_gemma":[0.018664619,0.041286472,0.67490906,0.00007331152,0.23934652,0.0002827407,0.00030404187,0.0009376803,0.0013368509,0.00031073627,0.022330517,0.0002174654],"about_ca_topic_score_codex":0.000044909968,"about_ca_topic_score_gemma":0.000048527632,"teacher_disagreement_score":0.12081195,"about_ca_system_score_codex":0.00005683628,"about_ca_system_score_gemma":0.0013696379,"threshold_uncertainty_score":0.52574927},"labels":[],"label_agreement":null},{"id":"W3032504166","doi":"10.1200/jco.2020.38.15_suppl.5034","title":"First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Université Laval","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Internal medicine; Renal cell carcinoma; Urology; Oncology; Surgery; Gastroenterology; Cancer; Immunotherapy","score_opus":0.07859138688941952,"score_gpt":0.38474361828413406,"score_spread":0.30615223139471454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032504166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98212945,0.0008731466,0.0015575626,0.00970025,0.001133561,0.0014717465,0.000019431262,0.000026342568,0.0030885262],"genre_scores_gemma":[0.98151946,0.0008343374,0.010113505,0.0047049425,0.0014660145,0.000041580362,0.000038613,0.000104546234,0.0011770065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935292,0.00040079548,0.0040944032,0.00067433005,0.00062997534,0.0006712715],"domain_scores_gemma":[0.9936271,0.0018804678,0.0022920442,0.00044505368,0.00065507763,0.0011003116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017649612,0.0004710156,0.0032069902,0.00024430224,0.000078041354,0.000018095749,0.0004384326,0.0007478741,0.00031148433],"category_scores_gemma":[0.0010073531,0.00036698297,0.0013757136,0.00037744016,0.00016775126,0.00017640869,0.0000930918,0.0016094787,0.00006657095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3875469,0.009310754,0.48960122,0.00066494767,0.0011152363,0.008304117,0.001231571,0.0030111365,0.028300514,0.000023499977,0.032831613,0.03805848],"study_design_scores_gemma":[0.21766533,0.13909625,0.49423507,0.00018446369,0.0016345246,0.0003239019,0.0002394577,0.009024141,0.024180328,0.0001989935,0.112501346,0.00071619306],"about_ca_topic_score_codex":0.00005291122,"about_ca_topic_score_gemma":0.00007195682,"teacher_disagreement_score":0.16988157,"about_ca_system_score_codex":0.0005524228,"about_ca_system_score_gemma":0.0019418452,"threshold_uncertainty_score":0.9998782},"labels":[],"label_agreement":null},{"id":"W3032523202","doi":"10.1200/jco.2020.38.15_suppl.7511","title":"A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"AbbVie","keywords":"Medicine; Cytarabine; Internal medicine; Clinical endpoint; Ven; Hazard ratio; Venetoclax; Gastroenterology; Myeloid leukemia; Febrile neutropenia; Neutropenia; Leukemia; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Chronic lymphocytic leukemia","score_opus":0.05466129522622532,"score_gpt":0.41438983872249535,"score_spread":0.35972854349627004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032523202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945315,0.00014288405,0.00005685017,0.0024503567,0.00022702229,0.0022910296,0.000016573338,0.000020770707,0.00026301038],"genre_scores_gemma":[0.99579453,0.00038857723,0.0008704594,0.0021141665,0.0005949676,0.000028233584,0.000033351276,0.00006305353,0.0001126396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922616,0.0010686025,0.004339069,0.0005370978,0.001164033,0.0006295965],"domain_scores_gemma":[0.9934173,0.0012783692,0.0025825473,0.00045963158,0.0011625382,0.0010995865],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002372322,0.0003761394,0.0036599059,0.00028820723,0.00004462455,0.000013867577,0.00056066446,0.00052282424,0.00023670286],"category_scores_gemma":[0.0026990273,0.00025344995,0.000375204,0.0009079607,0.00035211,0.00023540569,0.00023492245,0.002675087,0.000029060031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53790456,0.03334156,0.28455523,0.0003368169,0.005869471,0.026929244,0.006612387,0.0015443214,0.0008658335,0.000011055336,0.012587764,0.08944178],"study_design_scores_gemma":[0.50085616,0.24087992,0.24680518,0.00048085913,0.0018612343,0.00023417523,0.00088179106,0.0039482145,0.00017814628,0.000012155506,0.0035093667,0.0003528156],"about_ca_topic_score_codex":0.00028625,"about_ca_topic_score_gemma":0.00030288717,"teacher_disagreement_score":0.20753837,"about_ca_system_score_codex":0.0030038033,"about_ca_system_score_gemma":0.014665632,"threshold_uncertainty_score":0.9999918},"labels":[],"label_agreement":null},{"id":"W3032561883","doi":"10.1200/jco.2020.38.15_suppl.tps8074","title":"A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; CD20; Lymphoma; Adverse effect; Ofatumumab; Oncology; Internal medicine; Pharmacodynamics; Rituximab; Pharmacology; Cancer research; Pharmacokinetics","score_opus":0.10107067104318164,"score_gpt":0.4645030107838141,"score_spread":0.3634323397406325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032561883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383503,0.00024983974,0.00032875055,0.0037582298,0.00026367736,0.0012698291,0.000015180093,0.0000169098,0.0002625784],"genre_scores_gemma":[0.99504447,0.0005579889,0.0018298662,0.0016013806,0.0005656579,0.00000992431,0.0000048571396,0.00006155174,0.00032432776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99394166,0.0011654021,0.0030154225,0.0004482708,0.00091342995,0.000515799],"domain_scores_gemma":[0.99258924,0.004346902,0.0012169569,0.00026577557,0.0005484545,0.0010326973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008467413,0.00028400906,0.0023021966,0.00034800897,0.00005971148,0.000011230825,0.000314239,0.0003125316,0.000304233],"category_scores_gemma":[0.008390957,0.00019615529,0.0002371174,0.00063626224,0.00012258139,0.00011585045,0.00025055945,0.0015618135,0.00000440034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3230998,0.2802429,0.005187941,0.00021071512,0.0010749517,0.0041569113,0.006723295,0.00015753224,0.29971588,0.0000046003656,0.0007720419,0.07865344],"study_design_scores_gemma":[0.62554646,0.32296568,0.0123664355,0.00025658173,0.0007015555,0.0002164142,0.0019387692,0.014251723,0.0014331208,0.0000030881133,0.020007508,0.00031269452],"about_ca_topic_score_codex":0.000032585056,"about_ca_topic_score_gemma":0.00011293941,"teacher_disagreement_score":0.30244663,"about_ca_system_score_codex":0.00033414207,"about_ca_system_score_gemma":0.0020992823,"threshold_uncertainty_score":0.9999618},"labels":[],"label_agreement":null},{"id":"W3032571742","doi":"10.1200/jco.2020.38.15_suppl.12013","title":"Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Palliative care; Clinical endpoint; Head and neck cancer; Randomization; Randomized controlled trial; Physical therapy; Cancer; Internal medicine","score_opus":0.23720613223846115,"score_gpt":0.5656287885498491,"score_spread":0.32842265631138795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032571742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936454,0.0013640748,0.00021267579,0.00091613503,0.00021851879,0.003288913,0.00005233659,0.0000023978635,0.00029952062],"genre_scores_gemma":[0.9961895,0.0022484167,0.0011239768,0.00019388027,0.00017930909,0.000045115237,0.000007446742,0.000008276472,0.00000411167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913785,0.0036409486,0.0041469145,0.0001634959,0.000562325,0.00010784714],"domain_scores_gemma":[0.96795887,0.022161718,0.0079062125,0.00014195108,0.0016540338,0.00017724215],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036261878,0.00019944782,0.008034238,0.00008040083,0.000017720296,0.0000017621655,0.000102974314,0.00019899293,0.00003898527],"category_scores_gemma":[0.03253684,0.00008695663,0.0009133929,0.00015459074,0.00061726396,0.00004932383,0.000019104036,0.00031106922,1.0131909e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9447037,0.0014565595,0.01926421,0.00016692269,0.0020717047,0.000005991756,0.006214206,0.000023806495,0.0003801341,0.00006416929,0.000026531921,0.02562209],"study_design_scores_gemma":[0.7360613,0.25300238,0.003773949,0.0007030087,0.0012399672,6.858449e-8,0.0011116726,0.000021079733,0.0038177054,0.00003706311,0.00018386162,0.00004797581],"about_ca_topic_score_codex":0.00024292072,"about_ca_topic_score_gemma":0.00016967973,"teacher_disagreement_score":0.25154582,"about_ca_system_score_codex":0.00024336053,"about_ca_system_score_gemma":0.0015620058,"threshold_uncertainty_score":0.9756125},"labels":[],"label_agreement":null},{"id":"W3032613529","doi":"10.1200/jco.2020.38.15_suppl.e14133","title":"Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Canadian Agency for Drugs and Technologies in Health; University of Toronto","funders":"","keywords":"Reimbursement; Medicine; Logistic regression; Family medicine; Test (biology); Internal medicine; Health care","score_opus":0.7807678611486495,"score_gpt":0.6254082072699962,"score_spread":0.15535965387865325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032613529","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24791521,0.0024037494,0.0016795832,0.74484986,0.0020314825,0.0004595964,0.00037758265,0.0000042273878,0.00027871845],"genre_scores_gemma":[0.8026289,0.00286755,0.0051636836,0.18745005,0.0014807994,0.00008632457,0.000024587789,0.000024590494,0.00027355494],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868818,0.00057366834,0.011818703,0.00031045295,0.000110881614,0.00030449603],"domain_scores_gemma":[0.98320353,0.007160029,0.008839653,0.00015928851,0.00020857809,0.00042891648],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025768226,0.00011964166,0.0019550005,0.00010445404,0.0000861498,0.000012905462,0.00034142015,0.00016648493,0.0010633026],"category_scores_gemma":[0.026018709,0.00013452892,0.00021006852,0.0001580249,0.000044744087,0.00035828317,0.00004588067,0.0004989833,0.000029096653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034861497,0.0004693029,0.02261651,0.00007010533,0.00012465344,0.0000046184796,0.0008202462,0.0001098374,0.0000041687736,0.0009493027,0.9567634,0.01771928],"study_design_scores_gemma":[0.0053463764,0.0026060974,0.0037163543,0.000104507846,0.000024043891,0.0000021668761,0.0009929177,0.004052138,0.0000072897087,0.0010810144,0.98191327,0.00015383681],"about_ca_topic_score_codex":0.15734643,"about_ca_topic_score_gemma":0.25951815,"teacher_disagreement_score":0.5573998,"about_ca_system_score_codex":0.0019591926,"about_ca_system_score_gemma":0.008097134,"threshold_uncertainty_score":0.99984986},"labels":[],"label_agreement":null},{"id":"W3032615215","doi":"10.1200/jco.2020.38.15_suppl.e14122","title":"The use of patient health information outside the circle of care: Consent preferences of patients from a large academic cancer centre.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Informed consent; Family medicine; Ethnic group; Health care; Alternative medicine","score_opus":0.6663703332667378,"score_gpt":0.6303254432748137,"score_spread":0.03604488999192412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032615215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9306989,0.0009810309,0.000043850563,0.06697295,0.00064427993,0.00041726715,0.00014573193,0.0000022275933,0.00009378944],"genre_scores_gemma":[0.9793173,0.0134321,0.0003903511,0.006648415,0.00018931624,0.000002646182,0.000007463225,0.000005772565,0.000006606515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992094,0.0012706419,0.0049830535,0.00011373547,0.0013103174,0.0002282564],"domain_scores_gemma":[0.9376429,0.053235747,0.005916945,0.00024835326,0.0026111782,0.00034489785],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004691207,0.00008471573,0.0011216605,0.00003916526,0.000051247556,0.0000050194394,0.0003740028,0.0004380018,0.000055569406],"category_scores_gemma":[0.09489844,0.00004432645,0.00034186602,0.00015342515,0.0006424997,0.00012189492,0.00020271417,0.0030400057,0.000003056088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008834133,0.0008297069,0.7456507,0.00043874394,0.0004754777,0.0000034823306,0.009869622,0.00008897312,0.000020238942,0.00046037824,0.008324509,0.22500403],"study_design_scores_gemma":[0.007908949,0.020160599,0.8619053,0.0010490848,0.00024682176,0.0000011976576,0.005655538,0.00022335822,0.0004171296,0.0019470507,0.10040624,0.00007874898],"about_ca_topic_score_codex":0.00043372868,"about_ca_topic_score_gemma":0.00089065544,"teacher_disagreement_score":0.22492528,"about_ca_system_score_codex":0.00011184807,"about_ca_system_score_gemma":0.0061295033,"threshold_uncertainty_score":0.9995048},"labels":[],"label_agreement":null},{"id":"W3032628507","doi":"10.1200/jco.2020.38.15_suppl.12021","title":"Integrating PROs with prognostic value into oncologic care: High ESAS global distress score associated with lower overall survival in advanced cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Palliative care; Psychosocial; Performance status; Distress; Cancer; Internal medicine; Anxiety; Depression (economics); Hospital Anxiety and Depression Scale; Physical therapy; Psychiatry; Nursing","score_opus":0.04836268966291685,"score_gpt":0.3941209251259601,"score_spread":0.34575823546304324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032628507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917393,0.0003957894,0.000086634376,0.0047019264,0.0015033787,0.0006465037,0.000035708224,0.000025628533,0.0008651473],"genre_scores_gemma":[0.9958503,0.00009041616,0.00069730653,0.002617377,0.0006236963,0.000036449546,0.00003651262,0.000028232314,0.000019679257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621874,0.0005627348,0.0016996213,0.00039904227,0.0007334393,0.0003864003],"domain_scores_gemma":[0.9953252,0.0010388971,0.0017450004,0.00014307811,0.0012330068,0.0005148369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007113722,0.00028549912,0.0018591849,0.000046324465,0.000048724498,0.00002001442,0.00023729529,0.00040454243,0.000055909666],"category_scores_gemma":[0.0049071796,0.00017237391,0.00024443847,0.00047967373,0.00025978766,0.00016762892,0.000076258395,0.0014961702,0.000001889448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016412724,0.0014506727,0.9418507,0.000102480655,0.00028514466,0.0010224027,0.00094605127,0.00036299508,0.000006861581,0.00008941993,0.0001467016,0.037323836],"study_design_scores_gemma":[0.019894466,0.056088377,0.91883,0.0012457236,0.00049882085,0.000017242399,0.0011888496,0.000101652564,0.000010907724,0.000089060064,0.0017839957,0.00025091],"about_ca_topic_score_codex":0.00092959206,"about_ca_topic_score_gemma":0.026033254,"teacher_disagreement_score":0.054637704,"about_ca_system_score_codex":0.0013931325,"about_ca_system_score_gemma":0.0031726256,"threshold_uncertainty_score":0.9917391},"labels":[],"label_agreement":null},{"id":"W3032643077","doi":"10.1200/jco.2020.38.15_suppl.2013","title":"Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Patient satisfaction; Cancer; Depression (economics); Comorbidity; Marital status; Health care; Family medicine; Internal medicine; Population; Nursing","score_opus":0.043568700642791704,"score_gpt":0.3919022279780861,"score_spread":0.3483335273352944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032643077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280685,0.00071428117,0.000008601009,0.0049505546,0.000799907,0.00021063424,0.0000051335664,0.0000070472543,0.00049700664],"genre_scores_gemma":[0.9970428,0.00036100467,0.00015426925,0.0019541534,0.00046053418,0.0000047568697,0.0000040784876,0.000012065205,0.0000063556713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980579,0.00014327897,0.001202341,0.00016226227,0.00030750345,0.00012672266],"domain_scores_gemma":[0.99789304,0.00022665707,0.0009891615,0.00007668494,0.00048764696,0.000326797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002206064,0.00009819415,0.00087297533,0.00005363847,0.000016637836,0.0000060254174,0.000033062708,0.00019398645,0.00007847454],"category_scores_gemma":[0.00068106555,0.00006750884,0.00011864194,0.00014152855,0.00007775357,0.000086694374,0.000019074594,0.0005566557,0.0000010138156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004091381,0.00007818174,0.80418587,0.00003673712,0.00011582304,0.00018954182,0.0021609305,0.000009037748,0.0000066532934,0.0000017107299,0.00024307409,0.18888105],"study_design_scores_gemma":[0.010388606,0.012489091,0.96351063,0.00013912388,0.00022621949,0.000018937972,0.0014491791,0.000012869232,0.000007000983,0.000006945465,0.01167741,0.00007397892],"about_ca_topic_score_codex":0.0008109167,"about_ca_topic_score_gemma":0.0013240232,"teacher_disagreement_score":0.18880707,"about_ca_system_score_codex":0.00014957217,"about_ca_system_score_gemma":0.00076127844,"threshold_uncertainty_score":0.27529305},"labels":[],"label_agreement":null},{"id":"W3032651552","doi":"10.1200/jco.20.00818","title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1242,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Place Centre; Nova Scotia Cancer Centre; Health Sciences Centre; McGill University Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Positive Living North; London Health Sciences Centre","funders":"","keywords":"Medicine; SABR volatility model; Randomized controlled trial; Clinical endpoint; Radiation therapy; Radiosurgery; Prostate cancer; Internal medicine; Ablative case; Oncology; Quality of life (healthcare); Surgery; Cancer","score_opus":0.35479052065845407,"score_gpt":0.4845785244643184,"score_spread":0.12978800380586436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032651552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97376055,0.0038128523,0.00042610517,0.017400512,0.00088611484,0.0035622625,0.000063695836,0.0000035580824,0.000084377876],"genre_scores_gemma":[0.9933854,0.0032949534,0.001298754,0.0009944745,0.00084133336,0.00006036021,0.0000068298355,0.000017025146,0.00010092071],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99473965,0.0014772124,0.0030876156,0.00017865194,0.0003383915,0.00017847515],"domain_scores_gemma":[0.97556585,0.01965893,0.0038081666,0.00024846222,0.00050968496,0.00020890258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018050949,0.00019658344,0.0033163177,0.00007015007,0.00006929724,0.0000054065604,0.0001942263,0.0001611185,0.0000740027],"category_scores_gemma":[0.0032929934,0.000083693994,0.0020764216,0.00021060654,0.00052619353,0.000052439802,0.000024252564,0.0002842062,6.0273624e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92377025,0.003580077,0.0057101496,0.000050446837,0.00844685,0.00008634174,0.0021930574,0.000009949778,0.00022394999,0.000013325222,0.00037973525,0.05553589],"study_design_scores_gemma":[0.8721866,0.111239016,0.0026549567,0.0000772653,0.005387204,0.000035022436,0.00013729806,0.0013031553,0.0011184269,0.000034679244,0.005762626,0.00006373445],"about_ca_topic_score_codex":0.000045497243,"about_ca_topic_score_gemma":0.0000130409435,"teacher_disagreement_score":0.107658945,"about_ca_system_score_codex":0.00020401542,"about_ca_system_score_gemma":0.0014078065,"threshold_uncertainty_score":0.39422584},"labels":[],"label_agreement":null},{"id":"W3032683499","doi":"10.1200/jco.2020.38.15_suppl.e17503","title":"Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Conquer Cancer Foundation","keywords":"Medicine; Prostate cancer; Nivolumab; Androgen deprivation therapy; Immunotherapy; Castration; Immune system; Antigen; Oncology; Cancer; Immunology; Antibody; Internal medicine; Cancer research; Hormone","score_opus":0.08106360437378021,"score_gpt":0.4440707087000578,"score_spread":0.3630071043262776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032683499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769891,0.00066073716,0.0000059210356,0.021265505,0.00010928713,0.0008830807,0.0000049783625,0.0000038468525,0.00007754285],"genre_scores_gemma":[0.99770147,0.0015741163,0.00003151054,0.00049175776,0.00012946546,0.000017942904,0.0000025192169,0.0000107531605,0.00004045717],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967237,0.001668863,0.0010343194,0.00012607181,0.0003093508,0.00013771147],"domain_scores_gemma":[0.9948341,0.0037218374,0.00088462024,0.00010893718,0.00033514923,0.00011530631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003780664,0.00010190867,0.0009506117,0.00007321991,0.00003122128,0.000005638983,0.00008474608,0.00010431618,0.000014966952],"category_scores_gemma":[0.0015459623,0.0000469112,0.00014369174,0.00024142074,0.00018627253,0.00005368716,0.000013804192,0.00059031247,0.000002633581],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7936522,0.0006029857,0.1469152,0.00009992992,0.00055575586,0.0014519537,0.00096958084,0.00013261946,0.020928204,0.000025009154,0.00017771457,0.03448887],"study_design_scores_gemma":[0.06265995,0.3466575,0.4907313,0.0011201667,0.00020627712,0.00032004633,0.0005146927,0.00041791005,0.09686739,0.00001749845,0.00037756137,0.000109691144],"about_ca_topic_score_codex":0.00003376297,"about_ca_topic_score_gemma":0.000009479347,"teacher_disagreement_score":0.7309922,"about_ca_system_score_codex":0.00015852354,"about_ca_system_score_gemma":0.001846619,"threshold_uncertainty_score":0.32758227},"labels":[],"label_agreement":null},{"id":"W3032708276","doi":"10.1200/jco.2020.38.15_suppl.e17608","title":"Is prostate brachytherapy a dying art? Evidence of increasing utilization in Ontario, Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Health Sciences Centre; Western University; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Prostatectomy; Brachytherapy; Prostate cancer; Urology; Logistic regression; Prostate; Gynecology; Internal medicine; Cancer; Radiation therapy","score_opus":0.2734200844066182,"score_gpt":0.4698676477899788,"score_spread":0.1964475633833606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032708276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639227,0.0016896264,0.00004814287,0.033550642,0.00025565675,0.00021444655,0.0000016709328,0.0000021168999,0.0003150035],"genre_scores_gemma":[0.98573035,0.0024771108,0.0012449039,0.010352225,0.00014336211,0.0000032875976,0.0000015590346,0.000008085272,0.0000391316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748933,0.00023304237,0.0017155916,0.00013933325,0.00028431026,0.0001384082],"domain_scores_gemma":[0.9968407,0.0013002009,0.0012324591,0.00008358512,0.00028661554,0.0002564165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00127759,0.0000867527,0.0009640312,0.000045304372,0.000013676568,0.0000041413923,0.0000672404,0.00010339144,0.00019483047],"category_scores_gemma":[0.0019049397,0.000064678425,0.00013477453,0.00014300791,0.000052827887,0.000117177144,0.000020464173,0.0005063161,0.0000014281501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00655463,0.00046517001,0.9309527,0.000060217488,0.00014561914,0.00066172803,0.00095404225,0.000042473144,0.00020783606,0.000007453283,0.003094299,0.056853835],"study_design_scores_gemma":[0.005903737,0.00995311,0.9481123,0.0009600743,0.00014929342,0.00008818632,0.000110242436,0.00021458368,0.00076178124,0.000063269814,0.033620022,0.00006338645],"about_ca_topic_score_codex":0.23847276,"about_ca_topic_score_gemma":0.6778568,"teacher_disagreement_score":0.439384,"about_ca_system_score_codex":0.0006668354,"about_ca_system_score_gemma":0.009643673,"threshold_uncertainty_score":0.9959707},"labels":[],"label_agreement":null},{"id":"W3032719171","doi":"10.1200/jco.2020.38.15_suppl.e20003","title":"Retrospective cohort study of real-world treatment patterns and overall survival in patients with chronic lymphocytic leukemia (CLL) diagnosed between 2010 to 2017 in Ontario, Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca Canada","keywords":"Ibrutinib; Medicine; Rituximab; Fludarabine; Discontinuation; Chronic lymphocytic leukemia; Chlorambucil; Alemtuzumab; Internal medicine; Cohort; Population; Cancer registry; Bendamustine; Cyclophosphamide; Retrospective cohort study; Oncology; Chemoimmunotherapy; Obinutuzumab; Cancer; Chemotherapy; Leukemia; Lymphoma; Transplantation","score_opus":0.07610665831292557,"score_gpt":0.3883402262317307,"score_spread":0.31223356791880513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032719171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973266,0.00001814782,0.0000020671607,0.0005460424,0.00028160113,0.0014299996,0.000015467294,0.000003711907,0.00037633447],"genre_scores_gemma":[0.99902976,0.0001234871,0.000056595174,0.00026525423,0.0003143327,0.000018406665,0.000009305318,0.000025000754,0.00015784302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531806,0.00048406058,0.0022936708,0.00044659895,0.0010214244,0.00043619424],"domain_scores_gemma":[0.99593157,0.0016885927,0.00096110825,0.00030743895,0.0003517127,0.000759591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014264772,0.00024386545,0.0027354932,0.00022586482,0.000023391185,0.000008273797,0.00022342212,0.00020222076,0.00009609166],"category_scores_gemma":[0.0011878599,0.00017360755,0.00010897557,0.000283114,0.000107069354,0.00008507808,0.00013093239,0.000969121,0.0000018769563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007345092,0.000903807,0.98557705,0.00003096094,0.0005280758,0.002445613,0.0007383601,0.00031224464,0.0000010140577,0.0000017895842,0.00054625125,0.0015697541],"study_design_scores_gemma":[0.10334443,0.046720624,0.8488445,0.00015488792,0.00024300635,0.000008664091,0.00010356449,0.0001558437,0.0000048663787,0.0000040823197,0.00029382878,0.000121678866],"about_ca_topic_score_codex":0.9829692,"about_ca_topic_score_gemma":0.9984702,"teacher_disagreement_score":0.13673252,"about_ca_system_score_codex":0.22809504,"about_ca_system_score_gemma":0.14084698,"threshold_uncertainty_score":0.8640236},"labels":[],"label_agreement":null},{"id":"W3032719268","doi":"10.1200/jco.2020.38.15_suppl.7040","title":"Morbidity, mortality and healthcare use among siblings of children with cancer: A population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Interquartile range; Population; Confidence interval; Emergency department; Pediatrics; Cancer; Health care; Cohort; Demography; Internal medicine; Environmental health; Psychiatry","score_opus":0.27416923920598985,"score_gpt":0.5127901622898574,"score_spread":0.23862092308386756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032719268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96815974,0.00026328486,0.00005851682,0.030706096,0.00024399345,0.0005174421,0.000023932918,0.000014398979,0.000012586],"genre_scores_gemma":[0.9896067,0.00014390657,0.0010541634,0.008106691,0.0010538978,0.0000038092198,0.0000059928816,0.000020664165,0.0000042094316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954729,0.00074538717,0.0026038566,0.0002780329,0.00071943266,0.00018040498],"domain_scores_gemma":[0.9942042,0.0015306678,0.002769145,0.00021833838,0.00057256984,0.0007050656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025438166,0.00016041262,0.0019689396,0.00009691086,0.000040593666,0.000011806879,0.0001448515,0.0002229793,0.000041754553],"category_scores_gemma":[0.0037093863,0.00011753696,0.00025273554,0.00027123495,0.00018843476,0.00016624265,0.000053325835,0.0009904625,4.833619e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002542192,0.00117711,0.9919905,0.00011130772,0.00063913787,0.00007364226,0.0005292704,0.00009498139,0.0000029443527,0.0000078147195,0.00031358667,0.002517519],"study_design_scores_gemma":[0.008492749,0.016108533,0.97389984,0.00019979049,0.0006631728,0.000020201642,0.00024942908,0.00011760359,0.000011722752,0.000020723714,0.00011442299,0.00010183008],"about_ca_topic_score_codex":0.022423267,"about_ca_topic_score_gemma":0.017087687,"teacher_disagreement_score":0.022599405,"about_ca_system_score_codex":0.000089818575,"about_ca_system_score_gemma":0.001941392,"threshold_uncertainty_score":0.9840865},"labels":[],"label_agreement":null},{"id":"W3032723625","doi":"10.1200/jco.2020.38.15_suppl.tps596","title":"KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Chemotherapy; Internal medicine; Carboplatin; Pembrolizumab; Olaparib; Induction chemotherapy; Immunotherapy; Cancer; Cisplatin","score_opus":0.11161118700935518,"score_gpt":0.44691181015717585,"score_spread":0.33530062314782066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032723625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754114,0.00046851032,0.0012654525,0.0141648445,0.0008685165,0.007512219,0.0000947006,0.00003482212,0.00017953823],"genre_scores_gemma":[0.9825232,0.0024716964,0.0034026708,0.009481585,0.00084884744,0.00074405555,0.000025524332,0.00014492986,0.0003574702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98897934,0.001940999,0.0057849614,0.0010041494,0.0015519031,0.000738647],"domain_scores_gemma":[0.98856246,0.002337175,0.005425943,0.00057789765,0.00219482,0.0009017194],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035203563,0.00084444234,0.007566139,0.00045969375,0.0001710043,0.00006491752,0.0007215413,0.0004716495,0.0020303049],"category_scores_gemma":[0.0012031274,0.0005185518,0.00041664863,0.0013394232,0.000811444,0.00077396457,0.0001559373,0.002441577,0.000005290711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9283372,0.02780454,0.002544963,0.00020148016,0.0036386691,0.00042591398,0.0076520136,0.0012486113,0.00004544774,0.0000044144017,0.0019723196,0.026124435],"study_design_scores_gemma":[0.84303784,0.13927929,0.008666274,0.001294277,0.0012994587,0.00019597025,0.0010447585,0.0026197254,0.00013502411,0.00003582254,0.0018672415,0.0005243008],"about_ca_topic_score_codex":0.0006315143,"about_ca_topic_score_gemma":0.0016236961,"teacher_disagreement_score":0.11147475,"about_ca_system_score_codex":0.0019469763,"about_ca_system_score_gemma":0.009431979,"threshold_uncertainty_score":0.9998598},"labels":[],"label_agreement":null},{"id":"W3032725515","doi":"10.1200/jco.2020.38.15_suppl.e22013","title":"Adjuvant systemic therapies for melanoma in Alberta: An early descriptive analysis of population characteristics and treatment outcomes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary; BC Cancer Agency","funders":"Alberta Health Services","keywords":"Medicine; Adjuvant; Pembrolizumab; Dabrafenib; Adjuvant therapy; Melanoma; Surgery; Internal medicine; Nivolumab; Lymph node; Population; Trametinib; Systemic therapy; Cancer; Metastatic melanoma; Vemurafenib; Immunotherapy; Breast cancer","score_opus":0.12489749196694427,"score_gpt":0.41376437563500135,"score_spread":0.2888668836680571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032725515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623346,0.00007121143,0.0002702745,0.0028120098,0.00025305006,0.00030085613,0.000007079473,0.000003369975,0.000048661146],"genre_scores_gemma":[0.9983427,0.0002657356,0.00067115854,0.00045090078,0.0001527631,0.000005179497,0.000008563945,0.0000073851556,0.00009560983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799675,0.00017604842,0.0014951417,0.00012908329,0.00011537759,0.000087586355],"domain_scores_gemma":[0.99781156,0.00073466334,0.0010680457,0.00008131117,0.00013670874,0.00016770848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005322517,0.00008968651,0.0015849408,0.00019666375,0.000013371426,0.000005356999,0.000041423176,0.00012870914,0.000016576616],"category_scores_gemma":[0.000775022,0.00005952816,0.0003243776,0.00014385635,0.000035281602,0.00005896074,0.000011086185,0.00013109647,5.890758e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003973545,0.0006107999,0.90628594,0.000029385132,0.002462412,0.00009076527,0.0017949837,0.000022774353,0.00018684105,0.00012494689,0.000010197951,0.08440738],"study_design_scores_gemma":[0.0039141295,0.01920303,0.9705986,0.000024318173,0.0025799249,0.000040391264,0.00070171244,0.0016342965,0.00000598837,0.000016543385,0.0012325181,0.000048581445],"about_ca_topic_score_codex":0.00037547163,"about_ca_topic_score_gemma":0.0008032633,"teacher_disagreement_score":0.0843588,"about_ca_system_score_codex":0.00012586088,"about_ca_system_score_gemma":0.000085812884,"threshold_uncertainty_score":0.24274878},"labels":[],"label_agreement":null},{"id":"W3032726707","doi":"10.1200/jco.2020.38.15_suppl.e12544","title":"Real-world data on adjuvant bisphosphonate use in a breast cancer center in Mexico.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Cancer; Internal medicine; Guideline; Population; Oncology; Gynecology","score_opus":0.3060094542503715,"score_gpt":0.5288679555621366,"score_spread":0.2228585013117651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032726707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.873752,0.000104887324,0.0000014419409,0.124385625,0.00069132436,0.00020307468,0.000082263265,0.0000059188505,0.0007734467],"genre_scores_gemma":[0.9631519,0.0037573522,0.0006346899,0.032030705,0.00025663045,0.0000036031283,0.000014401916,0.00001704807,0.00013371758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966577,0.00032591526,0.0021589336,0.00028020312,0.00027652824,0.00030069824],"domain_scores_gemma":[0.9969392,0.0010543908,0.0009492621,0.0002671311,0.00010487088,0.0006851391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013014356,0.00012879769,0.0014750367,0.00015081608,0.000012061124,0.0000054417046,0.00020171574,0.000167024,0.00014158964],"category_scores_gemma":[0.001097786,0.00008727068,0.00013618023,0.00032192896,0.000086704385,0.00015695093,0.00009731542,0.0013132497,0.00003656098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016654314,0.0022995067,0.8855221,0.000020279009,0.00008601166,0.0035169825,0.000048183607,0.000009254786,0.0000028408747,0.00001815356,0.00978357,0.08203876],"study_design_scores_gemma":[0.015913976,0.0032556986,0.92354965,0.0002681678,0.000070815986,0.00009650996,0.00001626524,0.00036759107,0.000004456153,0.000021988897,0.05637632,0.0000585725],"about_ca_topic_score_codex":0.003922321,"about_ca_topic_score_gemma":0.025140235,"teacher_disagreement_score":0.092354916,"about_ca_system_score_codex":0.00029395346,"about_ca_system_score_gemma":0.0017290792,"threshold_uncertainty_score":0.9926484},"labels":[],"label_agreement":null},{"id":"W3032740647","doi":"10.1200/jco.2020.38.15_suppl.8500","title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Tolerability; Neutropenia; Adverse effect; Internal medicine; Dexamethasone; Multiple myeloma; Bortezomib; Febrile neutropenia; Gastroenterology; Pharmacology; Oncology; Toxicity","score_opus":0.05902830631515678,"score_gpt":0.363408366161987,"score_spread":0.30438005984683025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032740647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980499,0.00003762614,0.00012885265,0.0009009939,0.00021831387,0.0005448815,0.0000054805073,0.0000023980647,0.00011153844],"genre_scores_gemma":[0.99844545,0.000019944062,0.000595074,0.0007006366,0.00017016058,0.000009835943,0.0000064222245,0.000019041108,0.000033416884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720836,0.0004404497,0.0015484847,0.0002738559,0.0003418538,0.00018698996],"domain_scores_gemma":[0.9975371,0.00022734012,0.001534087,0.00026399278,0.00025687861,0.00018059867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090725726,0.00016657815,0.0007336828,0.0000606632,0.00004426875,0.000006722679,0.0003679671,0.00024994803,0.000011596424],"category_scores_gemma":[0.001425611,0.00010021218,0.00014658525,0.00020285624,0.00017142235,0.0000146647435,0.00012094745,0.0006642791,8.9632425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028362261,0.079658866,0.86957407,0.000037801296,0.0003716255,0.0000881666,0.0008110602,0.0004287617,0.011140115,0.00001402926,0.0007543509,0.00875892],"study_design_scores_gemma":[0.20824288,0.17440039,0.5947683,0.00011978453,0.00011870186,0.0000101187425,0.0006871894,0.000251688,0.007282862,0.000009344005,0.013829432,0.00027930434],"about_ca_topic_score_codex":0.000031495623,"about_ca_topic_score_gemma":0.00085314724,"teacher_disagreement_score":0.27480575,"about_ca_system_score_codex":0.00006591747,"about_ca_system_score_gemma":0.00050384033,"threshold_uncertainty_score":0.4086534},"labels":[],"label_agreement":null},{"id":"W3032744764","doi":"10.1200/jco.2020.38.15_suppl.4544","title":"Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcopenia; Internal medicine; Hazard ratio; Quality of life (healthcare); Cancer; Underweight; Esophageal cancer; Overweight; Proportional hazards model; Body mass index; Sarcopenic obesity; Oncology; Confidence interval","score_opus":0.3698820977893117,"score_gpt":0.5505533510807885,"score_spread":0.18067125329147682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032744764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966027,0.0006269936,0.000006070661,0.0014746167,0.00011510187,0.00037472777,0.000040668405,0.0000028645184,0.00075624767],"genre_scores_gemma":[0.9982174,0.0007343571,0.00031808173,0.00050060765,0.00017801153,0.0000054150128,0.000004890276,0.000015135009,0.00002612078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951068,0.0010336814,0.0023253844,0.00022387576,0.0010452388,0.00026502548],"domain_scores_gemma":[0.9949902,0.0015447295,0.0018912152,0.00015282033,0.0006006957,0.0008203058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026220602,0.00017301831,0.002214541,0.00014820024,0.000016140133,0.000004264255,0.00012789281,0.00009335435,0.00015772389],"category_scores_gemma":[0.0031773585,0.000104513034,0.00033890194,0.00023488636,0.00020115625,0.00009164747,0.00004421467,0.00070256996,0.0000016714745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047960907,0.0036790182,0.9390214,0.0001771162,0.0013786859,0.00019811875,0.00010748319,0.00008397892,0.000043880846,0.000038132333,0.00025654002,0.0070547196],"study_design_scores_gemma":[0.031023202,0.055120822,0.91320866,0.00014955788,0.0002266011,0.000001986158,0.000018655259,0.000027148255,0.000096511154,0.000041280604,0.000026144382,0.000059433307],"about_ca_topic_score_codex":0.002837401,"about_ca_topic_score_gemma":0.0016678239,"teacher_disagreement_score":0.051441804,"about_ca_system_score_codex":0.000419936,"about_ca_system_score_gemma":0.0029183794,"threshold_uncertainty_score":0.517708},"labels":[],"label_agreement":null},{"id":"W3032794423","doi":"10.1200/jco.2020.38.15_suppl.10509","title":"Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Minimal residual disease; Regimen; Gastroenterology; Vincristine; Leukemia; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.07197307475791795,"score_gpt":0.41124957678521573,"score_spread":0.33927650202729775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032794423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899696,0.00033642436,0.0012151308,0.0064173355,0.0005419407,0.0010084534,0.00028567808,0.000031296087,0.0001941544],"genre_scores_gemma":[0.98475695,0.002493102,0.007003956,0.004093279,0.0014358887,0.00003336908,0.00009167705,0.00007036465,0.00002144259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99137837,0.00095261395,0.004199459,0.0008066662,0.0020276236,0.000635268],"domain_scores_gemma":[0.987657,0.0033372093,0.005392603,0.00044534815,0.0021902954,0.0009775145],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039320267,0.00049645384,0.004028644,0.00036086526,0.00008057744,0.000020318368,0.0005987689,0.0008530192,0.00016845964],"category_scores_gemma":[0.012157248,0.0003082383,0.0005421933,0.0006459191,0.0012889771,0.00031602287,0.00015994404,0.003234159,0.000008921844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07537589,0.0014642833,0.8918327,0.000021194994,0.0050744913,0.003371691,0.0005520352,0.0010681606,0.00021409949,0.000012356842,0.0026950156,0.018318074],"study_design_scores_gemma":[0.054869596,0.029780628,0.9088509,0.00031622234,0.0010091729,0.0023690683,0.00009292657,0.00062329904,0.00023928267,0.000122027915,0.0014312859,0.00029556852],"about_ca_topic_score_codex":0.0036560134,"about_ca_topic_score_gemma":0.003360573,"teacher_disagreement_score":0.028987406,"about_ca_system_score_codex":0.00431249,"about_ca_system_score_gemma":0.033299897,"threshold_uncertainty_score":0.999937},"labels":[],"label_agreement":null},{"id":"W3032799488","doi":"10.1200/jco.2020.38.15_suppl.e16539","title":"Outcomes relative to paclitaxel dose-intensity when administered with ramucirumab in gastric and gastroesophageal junction (GEJ) adenocarcinoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ramucirumab; Docetaxel; Neutropenia; Internal medicine; Paclitaxel; Taxane; Oxaliplatin; Cancer; Gastroenterology; Cisplatin; Chemotherapy; Breast cancer; Oncology; Surgery; Colorectal cancer","score_opus":0.14635471000253267,"score_gpt":0.41425662499691007,"score_spread":0.26790191499437743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032799488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91207516,0.00017919058,0.0018706635,0.08383477,0.0005094812,0.0004190252,0.0000019853464,0.000015356967,0.0010943412],"genre_scores_gemma":[0.9731728,0.000058476293,0.01210845,0.01366641,0.00052837847,0.0000035979583,0.00000177008,0.000016241467,0.0004438785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715155,0.00022506007,0.0016498464,0.00030052834,0.00038662856,0.0002863631],"domain_scores_gemma":[0.99728054,0.0007437785,0.0009163189,0.00014713823,0.00023333401,0.0006789101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010978545,0.00019006997,0.0017293397,0.00028708283,0.000030531748,0.000015418214,0.00012281074,0.0001760941,0.000080318794],"category_scores_gemma":[0.0026269276,0.00012687288,0.00025087368,0.00034934597,0.00012771203,0.00018329274,0.00010932876,0.0009916913,0.000013745637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014722603,0.00029670127,0.9448376,0.000032699376,0.0002903562,0.0016599402,0.00045106807,0.000007506792,0.000005843791,0.000045703968,0.0039898218,0.03366014],"study_design_scores_gemma":[0.014025828,0.026464624,0.95064867,0.00006159737,0.0004247078,0.00027962454,0.0005307501,0.000041233823,0.0000025011043,0.000095688316,0.007340597,0.00008419588],"about_ca_topic_score_codex":0.000025616519,"about_ca_topic_score_gemma":0.000066060726,"teacher_disagreement_score":0.07016836,"about_ca_system_score_codex":0.00017530656,"about_ca_system_score_gemma":0.00047463874,"threshold_uncertainty_score":0.5173726},"labels":[],"label_agreement":null},{"id":"W3032800512","doi":"10.1200/jco.2020.38.15_suppl.1000","title":"KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Gemcitabine; Carboplatin; Internal medicine; Taxane; Pembrolizumab; Oncology; Chemotherapy; Breast cancer; Cancer; Cisplatin; Immunotherapy","score_opus":0.17572670217811448,"score_gpt":0.48563345592442453,"score_spread":0.30990675374631005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032800512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675404,0.0015282696,0.0010708797,0.01955591,0.0017216983,0.008295908,0.00005806982,0.00002989944,0.00019896566],"genre_scores_gemma":[0.9828848,0.00888327,0.0015038161,0.0047479547,0.0012496705,0.00030544333,0.000012674822,0.00008007232,0.0003322719],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99232435,0.0010653858,0.0050077415,0.00048524243,0.0006537389,0.00046355446],"domain_scores_gemma":[0.98841685,0.0052174795,0.004230204,0.000299235,0.0012657276,0.0005705287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046258955,0.00044804896,0.005302915,0.0001897234,0.00009052134,0.000024840445,0.00040166295,0.00033973722,0.001113326],"category_scores_gemma":[0.001634668,0.00027650147,0.0013767759,0.0005868929,0.00048762577,0.0001823588,0.000034256638,0.00094079203,0.0000027072533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8035804,0.0093653165,0.00011205998,0.00014284924,0.008958656,0.00010602628,0.002649546,0.000044299733,0.00022904531,0.0000054523384,0.00305346,0.17175287],"study_design_scores_gemma":[0.88439745,0.1028555,0.00019851803,0.0002532456,0.0028152857,0.00013592832,0.0015361349,0.0011402313,0.0007152423,0.000016280504,0.005692683,0.00024350337],"about_ca_topic_score_codex":0.00031917353,"about_ca_topic_score_gemma":0.00029469124,"teacher_disagreement_score":0.17150936,"about_ca_system_score_codex":0.00041667043,"about_ca_system_score_gemma":0.0044367155,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W3032812050","doi":"10.1200/jco.2020.38.15_suppl.9574","title":"Nazartinib (EGF816) in patients with treatment-naïve <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): Updated phase II results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Internal medicine; Clinical endpoint; Phases of clinical research; non-small cell lung cancer (NSCLC); Gastroenterology; Lung cancer; Progression-free survival; Progressive disease; Brain metastasis; Adverse effect; Surgery; Oncology; Cancer; Metastasis; Toxicity; Overall survival; Clinical trial; Disease","score_opus":0.05481077897376951,"score_gpt":0.45096508008845376,"score_spread":0.39615430111468425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032812050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789743,0.00032805046,0.0000621666,0.0155599965,0.0004804541,0.00075825356,0.00011826273,0.000015160629,0.003703368],"genre_scores_gemma":[0.99174297,0.0004005912,0.0018911876,0.0048268265,0.00067391107,0.000022846516,0.00007462213,0.000032035896,0.00033499053],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965322,0.00017802273,0.0022880288,0.00034243887,0.00031856276,0.0003407623],"domain_scores_gemma":[0.9966363,0.00037858705,0.0016432034,0.00018560898,0.00048920914,0.0006671313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004507661,0.00024361376,0.0014525127,0.00010738585,0.00007168134,0.0000108693275,0.00013415508,0.0002536581,0.0001582114],"category_scores_gemma":[0.00029167134,0.00014774842,0.0003016398,0.0003194643,0.00010144967,0.00013193063,0.000039290375,0.0006187281,0.000011259407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09779196,0.03769835,0.6535768,0.000087301145,0.0028862692,0.003078038,0.0047818385,0.0004018314,0.00047940016,0.0000123429345,0.01932296,0.1798829],"study_design_scores_gemma":[0.37331212,0.19176638,0.2501447,0.0004406284,0.0046819677,0.000036261696,0.0004270256,0.0009610071,0.0010014704,0.00001236155,0.17681955,0.00039652112],"about_ca_topic_score_codex":0.00012667257,"about_ca_topic_score_gemma":0.00014034484,"teacher_disagreement_score":0.4034321,"about_ca_system_score_codex":0.00059577246,"about_ca_system_score_gemma":0.0034996397,"threshold_uncertainty_score":0.62082106},"labels":[],"label_agreement":null},{"id":"W3032839191","doi":"10.1200/jco.2020.38.15_suppl.10546","title":"Neuromuscular dysfunction and associated health/socioeconomic outcomes: A report from the Childhood Cancer Survivor Study (CCSS).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"","keywords":"Medicine; Cumulative incidence; Incidence (geometry); Internal medicine; Cancer; Cumulative dose; Cohort; Pediatrics","score_opus":0.15684115146891286,"score_gpt":0.47432139853177535,"score_spread":0.3174802470628625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032839191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7157954,0.0020120107,0.000030562835,0.279545,0.0020116502,0.0005059791,0.000018293367,0.000023862976,0.000057252535],"genre_scores_gemma":[0.8713366,0.0012664547,0.00010962354,0.124588065,0.0025977488,0.000009388681,0.000009167452,0.000033337437,0.00004961944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921234,0.002300334,0.004252333,0.00044787934,0.00059039565,0.00028563995],"domain_scores_gemma":[0.9891918,0.00483243,0.0045928583,0.00035302577,0.00030119004,0.0007287084],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008204348,0.00023292877,0.002727795,0.000044189932,0.00012999648,0.000025719628,0.00024212536,0.00029351487,0.00026978296],"category_scores_gemma":[0.012893124,0.00015186546,0.00063789444,0.00012820642,0.00015829287,0.00015021104,0.000120149125,0.0018509972,0.000017523713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091036,0.0021992142,0.949568,0.000015681879,0.0021270711,0.00045057994,0.004049533,0.000011493924,0.000003762764,0.000001635586,0.027484084,0.013178597],"study_design_scores_gemma":[0.010478693,0.008995352,0.93908584,0.00005796431,0.00066467037,0.000100295816,0.002202627,0.00003214584,7.293519e-7,0.000050758994,0.038212426,0.00011847277],"about_ca_topic_score_codex":0.003078349,"about_ca_topic_score_gemma":0.004336864,"teacher_disagreement_score":0.15554121,"about_ca_system_score_codex":0.00026093394,"about_ca_system_score_gemma":0.0028740328,"threshold_uncertainty_score":0.9954217},"labels":[],"label_agreement":null},{"id":"W3032848507","doi":"10.1200/jco.2020.38.15_suppl.3587","title":"AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Immunohistochemistry; Phases of clinical research; Oncology; Gastroenterology; Clinical trial","score_opus":0.03327003852538488,"score_gpt":0.3791147057798268,"score_spread":0.3458446672544419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032848507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985129,0.00043061902,0.000051673487,0.00056502846,0.000051060844,0.00034306553,0.000016853992,0.0000017109928,0.000027073162],"genre_scores_gemma":[0.99902225,0.00024849363,0.00042008387,0.00020235025,0.00008252354,0.000002921322,0.000007467061,0.0000118375665,0.0000021059677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977334,0.00032362845,0.0013781277,0.00028417964,0.00014855331,0.0001320998],"domain_scores_gemma":[0.9983416,0.00029391784,0.0009194492,0.00008749104,0.000180915,0.00017659614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076007657,0.00012915175,0.0006657508,0.0000639598,0.000024280524,0.0000066811945,0.00007121021,0.00016083171,0.0000012436253],"category_scores_gemma":[0.0008264706,0.0000991106,0.00004996208,0.00009840715,0.00015321946,0.0000153754,0.00005875641,0.00022539055,8.5983594e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104487665,0.004455833,0.81419635,0.000027576321,0.00022609577,0.000049107162,0.00059840275,0.0002788945,0.0048973043,9.2693404e-7,0.000072308925,0.07070954],"study_design_scores_gemma":[0.044693664,0.029385509,0.9234129,0.00006048975,0.000049484966,0.000004756479,0.00014447261,0.0002321318,0.0011370949,0.000009950203,0.00075932185,0.00011018807],"about_ca_topic_score_codex":0.0000071028076,"about_ca_topic_score_gemma":0.000109746536,"teacher_disagreement_score":0.10921659,"about_ca_system_score_codex":0.00002553019,"about_ca_system_score_gemma":0.00022587513,"threshold_uncertainty_score":0.40416127},"labels":[],"label_agreement":null},{"id":"W3032852436","doi":"10.1200/jco.2020.38.15_suppl.tps6101","title":"ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Carboplatin; Internal medicine; Bevacizumab; Oncology; Performance status; Urology; Maintenance therapy; Surgery; Chemotherapy; Gastroenterology","score_opus":0.19125014731522183,"score_gpt":0.4841571363752475,"score_spread":0.29290698906002566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032852436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801565,0.0035820818,0.0009879962,0.0065340633,0.0007690283,0.006987312,0.0006499473,0.000028335222,0.00030473742],"genre_scores_gemma":[0.9908354,0.005864096,0.0011459688,0.0010261107,0.00057340506,0.0003428838,0.000027432861,0.00008662087,0.00009805197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9884604,0.0014871499,0.0072735706,0.0006953834,0.0015579509,0.00052549585],"domain_scores_gemma":[0.9831674,0.005289421,0.007929851,0.00065162557,0.0022891115,0.00067258155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032237933,0.0006419868,0.008344642,0.00031804873,0.00012148243,0.000014098039,0.0004808275,0.0004935655,0.0011507082],"category_scores_gemma":[0.001195832,0.00041551667,0.0014939684,0.00071858533,0.0007183704,0.00016960008,0.00006360781,0.0009706168,0.0000020293173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91472274,0.03524105,0.010458858,0.00015716882,0.0061605736,0.0006995538,0.0126913395,0.0007499338,0.0005173556,0.00002245805,0.0010432734,0.017535673],"study_design_scores_gemma":[0.7020187,0.26837555,0.00027100794,0.00032341917,0.001645721,0.0000140437505,0.008470041,0.00020136719,0.003967606,0.000012374825,0.014460294,0.00023988228],"about_ca_topic_score_codex":0.0014343883,"about_ca_topic_score_gemma":0.0025089732,"teacher_disagreement_score":0.2331345,"about_ca_system_score_codex":0.0009188233,"about_ca_system_score_gemma":0.005300913,"threshold_uncertainty_score":0.99982965},"labels":[],"label_agreement":null},{"id":"W3032859441","doi":"10.1200/jco.2020.38.15_suppl.4061","title":"Consensus molecular subtypes in colorectal cancer differ by geographic region.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Medicine; Population; Internal medicine; Cohort; Oncology; Cancer; Environmental health","score_opus":0.08755574764602513,"score_gpt":0.4280378023588747,"score_spread":0.34048205471284954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032859441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9290406,0.0067342576,0.000009833322,0.062219474,0.00045637225,0.0001649857,0.000005690994,0.0000078743315,0.0013608827],"genre_scores_gemma":[0.9893045,0.0034417852,0.00016130753,0.0066475687,0.00037361606,0.000009180856,0.0000012757662,0.000012386171,0.000048375503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790275,0.00021530948,0.001260394,0.00018848004,0.00023073536,0.00020232577],"domain_scores_gemma":[0.9980169,0.0007430917,0.00062741735,0.00005704119,0.00022737983,0.0003281999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040102078,0.00013233392,0.0013364141,0.00006730662,0.000024660954,0.0000044552917,0.00008519978,0.00022296523,0.00007689116],"category_scores_gemma":[0.0013492538,0.00008909788,0.0003889025,0.00020029349,0.00025062246,0.000022213633,0.000041340583,0.00068353204,0.000004069063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0124605065,0.0010653677,0.91320455,0.00002628388,0.0008085051,0.004697959,0.00020147895,0.000007856266,0.0014257447,0.0000363219,0.024006825,0.042058602],"study_design_scores_gemma":[0.012178416,0.01906284,0.8963121,0.00008025371,0.00048702996,0.0002367026,0.00017370752,0.00006850418,0.0005701144,0.00014116455,0.07055593,0.00013321468],"about_ca_topic_score_codex":0.00008568939,"about_ca_topic_score_gemma":0.00013965662,"teacher_disagreement_score":0.060263876,"about_ca_system_score_codex":0.000116780524,"about_ca_system_score_gemma":0.0006505593,"threshold_uncertainty_score":0.3633306},"labels":[],"label_agreement":null},{"id":"W3032863401","doi":"10.1200/jco.2020.38.15_suppl.e22072","title":"Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CDKN2A; Malignant peripheral nerve sheath tumor; Melanoma; Exome sequencing; Medicine; Cancer research; CDKN2B; Comparative genomic hybridization; Nerve sheath neoplasm; Exome; Pathology; Mutation; Biology; Cancer; Neurofibromatosis; Internal medicine; Gene; Genetics; Genome","score_opus":0.07270049739820927,"score_gpt":0.37394262626665886,"score_spread":0.3012421288684496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032863401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97510993,0.00042852786,0.00032455704,0.012892002,0.001660909,0.00020863677,0.0000035721453,0.000017479302,0.009354369],"genre_scores_gemma":[0.9876327,0.00022902862,0.0023842175,0.007401731,0.0016784688,0.0000016869569,0.0000017238207,0.000019573912,0.0006508903],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687797,0.00023609193,0.0021729833,0.00019486729,0.00031270596,0.00020540596],"domain_scores_gemma":[0.9973808,0.00036497982,0.0013437839,0.00016256796,0.00023024736,0.0005176197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011803048,0.00013764799,0.0014434283,0.00009164028,0.00002648751,0.0000075602056,0.00017737783,0.0001739243,0.0010899878],"category_scores_gemma":[0.00078128936,0.000098016564,0.00061781576,0.0001296101,0.000108901615,0.00004487479,0.00008364054,0.00064217014,0.000039545273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05628699,0.0066245617,0.3662812,0.00074881996,0.004446675,0.04244046,0.0020181492,0.00056446804,0.03375024,0.0011364947,0.17415272,0.31154922],"study_design_scores_gemma":[0.013339164,0.04563043,0.16357642,0.00010611321,0.0009723122,0.005701206,0.00096595276,0.001840917,0.00043397915,0.000090179026,0.7671122,0.00023115559],"about_ca_topic_score_codex":0.0000114069535,"about_ca_topic_score_gemma":0.000011613153,"teacher_disagreement_score":0.59295946,"about_ca_system_score_codex":0.00008100686,"about_ca_system_score_gemma":0.00068303896,"threshold_uncertainty_score":0.99982315},"labels":[],"label_agreement":null},{"id":"W3032874360","doi":"10.1200/jco.2020.38.15_suppl.3084","title":"Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Thymic stromal lymphopoietin; Peripheral blood mononuclear cell; Myeloid; Myeloid-derived Suppressor Cell; Oncology; Immune system; Immunology; Internal medicine; Immunotherapy; Cancer research; Cancer; Suppressor; Biology","score_opus":0.06187199663641098,"score_gpt":0.34923468477830333,"score_spread":0.28736268814189236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032874360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105823,0.0032537489,0.0000587684,0.004532826,0.0006249394,0.00016044213,0.000015025481,0.0000028633726,0.00029313366],"genre_scores_gemma":[0.99428004,0.00085517927,0.0037067814,0.0009429007,0.00006136432,0.0000020174944,0.000001753505,0.00001037159,0.00013957615],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99688596,0.0008003016,0.0018628841,0.00017761893,0.000102658734,0.00017056959],"domain_scores_gemma":[0.99431103,0.0031776165,0.002104629,0.000092484355,0.00025737306,0.00005687804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002455966,0.0001150137,0.0013072214,0.00010633048,0.000021786249,0.0000026327064,0.00013045207,0.00033897327,0.00005705003],"category_scores_gemma":[0.0024533249,0.000087216315,0.00008422427,0.00016788206,0.0002472609,0.00010091505,0.00008375314,0.0006848746,0.0000028482707],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044704616,0.001321942,0.13918123,0.0006004851,0.001865123,0.00017605704,0.0049405,0.00011485509,0.5536809,0.00035231508,0.016129151,0.23693281],"study_design_scores_gemma":[0.026608985,0.021852002,0.7194931,0.0007423807,0.0005336591,0.00008664742,0.000854689,0.000005221529,0.17076042,0.00034656923,0.0583816,0.0003347148],"about_ca_topic_score_codex":0.000013057324,"about_ca_topic_score_gemma":0.000044677985,"teacher_disagreement_score":0.5803119,"about_ca_system_score_codex":0.00010657419,"about_ca_system_score_gemma":0.00060614134,"threshold_uncertainty_score":0.35565782},"labels":[],"label_agreement":null},{"id":"W3032882035","doi":"10.1200/jco.2020.38.15_suppl.2044","title":"Improved prognostication for lung cancer patients from computed tomography imaging using deep learning.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Concordance; Lung cancer; Stage (stratigraphy); Rank correlation; Cancer staging; TNM staging system; Radiology; Cancer; Computed tomography; Correlation; Survival analysis; Internal medicine; Oncology; Neoplasm staging; Machine learning","score_opus":0.04989980656603694,"score_gpt":0.44028108604561444,"score_spread":0.3903812794795775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032882035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82131004,0.0011623864,0.15844688,0.01703684,0.0014944834,0.00043776527,0.0000045064544,0.00002821159,0.0000788667],"genre_scores_gemma":[0.92314696,0.000117818585,0.06688103,0.007138249,0.0026565061,0.0000051566158,0.000020802278,0.00002830792,0.0000051882885],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997481,0.00023999118,0.0015825082,0.00022699025,0.00024709527,0.00022243649],"domain_scores_gemma":[0.9952348,0.001850848,0.0016357638,0.00007191045,0.00070202316,0.00050466036],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010817244,0.00012591065,0.0009595273,0.00008569599,0.00007369052,0.000019475197,0.00014871516,0.00015598824,0.00004156129],"category_scores_gemma":[0.010028348,0.00009834479,0.00042082838,0.00016373479,0.00012878081,0.00010153675,0.000047021407,0.0012495462,5.5836097e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012161057,0.00040913845,0.6961747,0.000051938798,0.00030592628,0.000026970058,0.0001727833,0.0004396374,0.00096983986,0.0000066935368,0.00081431674,0.29941198],"study_design_scores_gemma":[0.007647896,0.0020898606,0.17504513,0.00013476651,0.00071701704,0.000010101941,0.000037244245,0.80124366,0.000038039547,0.000034082397,0.012909417,0.00009280361],"about_ca_topic_score_codex":0.00004104878,"about_ca_topic_score_gemma":0.0000016385263,"teacher_disagreement_score":0.800804,"about_ca_system_score_codex":0.00007619508,"about_ca_system_score_gemma":0.0005061198,"threshold_uncertainty_score":0.9983106},"labels":[],"label_agreement":null},{"id":"W3032886415","doi":"10.1200/jco.2020.38.15_suppl.5541","title":"Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Hazard ratio; Urology; Confidence interval; Titan (rocket family); Internal medicine; Post-hoc analysis; Oncology; Cancer","score_opus":0.15271574737130175,"score_gpt":0.4460716657522297,"score_spread":0.2933559183809279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032886415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677726,0.00429122,0.0000014821878,0.02662319,0.00013180633,0.00088702503,0.000072871786,0.000009369259,0.00021040923],"genre_scores_gemma":[0.9758647,0.021629289,0.0007226087,0.0012374248,0.0003291881,0.000018172961,0.000026346688,0.000027259428,0.00014502284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720746,0.00023740904,0.001390239,0.00034697252,0.00049422134,0.00032368425],"domain_scores_gemma":[0.9966517,0.0011447035,0.00094544195,0.00017840075,0.00070477516,0.00037496444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066228077,0.00020541553,0.0011927778,0.00005505425,0.00005521109,0.000017325037,0.00013026207,0.00013461265,0.0000145297],"category_scores_gemma":[0.000735339,0.00009259361,0.00007586952,0.0003420309,0.0005409687,0.000110312125,0.000057924386,0.00083795097,0.0000030635567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11553391,0.0009021704,0.8104253,0.000027525024,0.0007001486,0.00089348364,0.0022734925,0.00007297553,0.00014086762,0.0000027656708,0.002182693,0.06684469],"study_design_scores_gemma":[0.051487315,0.047022637,0.8707301,0.00046102106,0.00021026214,0.000009932483,0.0012050894,0.000036369813,0.00021571532,0.00003361161,0.028459197,0.00012872113],"about_ca_topic_score_codex":0.00005986552,"about_ca_topic_score_gemma":0.00031094826,"teacher_disagreement_score":0.06671596,"about_ca_system_score_codex":0.00024025819,"about_ca_system_score_gemma":0.0006204778,"threshold_uncertainty_score":0.37758577},"labels":[],"label_agreement":null},{"id":"W3033340144","doi":"10.1200/jco.2020.38.18_suppl.lba1","title":"Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Interim analysis; Clinical endpoint; Chemotherapy; Hazard ratio; Carboplatin; Regimen; Progression-free survival; Randomization; Chemotherapy regimen; Oncology; Progressive disease; Gastroenterology; Bladder cancer; Randomized controlled trial; Cisplatin; Cancer; Urothelial carcinoma; Nivolumab; Immunotherapy; Confidence interval","score_opus":0.09353558699766583,"score_gpt":0.4407492632393891,"score_spread":0.3472136762417233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033340144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98079187,0.0008403589,0.0017901073,0.013511398,0.001132982,0.0007451163,0.0001389045,0.000022826072,0.0010264687],"genre_scores_gemma":[0.9861536,0.00039408277,0.0026712746,0.0089359395,0.0015212772,0.00004636304,0.000052195846,0.00006286223,0.00016238658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99449074,0.00033169717,0.0033466157,0.0006288351,0.0005884625,0.0006136325],"domain_scores_gemma":[0.99545693,0.0009537965,0.0016882843,0.0003744615,0.00071969535,0.00080680626],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007592545,0.00045204212,0.0031990416,0.0003190667,0.000057257075,0.000016727969,0.00031316586,0.00052278914,0.0017535194],"category_scores_gemma":[0.0012023558,0.00035058678,0.0012806006,0.00068434194,0.00031053158,0.0001658576,0.00007011043,0.0014044606,0.00005100394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6387374,0.011706474,0.1155323,0.00019343353,0.006751261,0.011932488,0.0054318714,0.0009454704,0.00072229054,0.000008080095,0.0018058207,0.2062331],"study_design_scores_gemma":[0.6076801,0.17062984,0.14730307,0.0004956505,0.008798133,0.00014198301,0.0031252226,0.0042615277,0.0041158856,0.000054017157,0.052384384,0.0010101789],"about_ca_topic_score_codex":0.00017564709,"about_ca_topic_score_gemma":0.0010350306,"teacher_disagreement_score":0.20522292,"about_ca_system_score_codex":0.00059359294,"about_ca_system_score_gemma":0.0025226218,"threshold_uncertainty_score":0.9998946},"labels":[],"label_agreement":null},{"id":"W3033719574","doi":"10.1200/jco.2020.38.18_suppl.lba2","title":"A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Systemic therapy; Clinical endpoint; Hazard ratio; Breast cancer; Cumulative incidence; Internal medicine; Proportional hazards model; Log-rank test; Cancer; Surgery; Oncology; Confidence interval; Cohort","score_opus":0.13043095729392054,"score_gpt":0.4569970571346781,"score_spread":0.3265660998407576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033719574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903106,0.0041812574,0.0001284216,0.0021246276,0.0009075604,0.00224102,0.000054639804,0.000004712719,0.00004712922],"genre_scores_gemma":[0.96837056,0.029412312,0.00004578423,0.00030110002,0.0014972265,0.00031698073,0.0000023951322,0.000037115682,0.00001651179],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913021,0.0044240127,0.0026966766,0.00040327053,0.0006722889,0.00050170184],"domain_scores_gemma":[0.99459314,0.0018473418,0.002330472,0.00038469833,0.00060297456,0.00024139378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007061326,0.00029969297,0.0029247187,0.00010482366,0.000069154,0.000013224135,0.0006589532,0.00046145628,0.00003002338],"category_scores_gemma":[0.0005899563,0.00016754447,0.00060894806,0.0003545963,0.0010481459,0.000015998301,0.00011328577,0.00081638485,5.948087e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93461907,0.0024642602,0.0008255365,0.00003912924,0.0025873017,0.000053725398,0.0014979673,0.00014410085,0.0084790075,0.000008303209,0.000058588346,0.049223024],"study_design_scores_gemma":[0.94248074,0.05291258,0.0012994179,0.00019655611,0.00008553876,0.000093187846,0.0009741356,0.00003765875,0.001307087,0.00000956017,0.00045687097,0.00014667929],"about_ca_topic_score_codex":0.000587825,"about_ca_topic_score_gemma":0.00014688322,"teacher_disagreement_score":0.05044832,"about_ca_system_score_codex":0.0004348304,"about_ca_system_score_gemma":0.0035650067,"threshold_uncertainty_score":0.6832265},"labels":[],"label_agreement":null},{"id":"W3033769547","doi":"10.1200/jco.20.00056","title":"De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Tata Memorial Centre; European Organisation for Research and Treatment of Cancer; Fudan University; National Cancer Institute; Cancer Research UK; National Cancer Centre of Singapore; National Institute for Health and Care Research; National Cancer Research Institute; Cancer Research Institute","keywords":"De-escalation; Medicine; Head and neck cancer; Context (archaeology); Oncology; Radiation therapy; Head and neck; Clinical trial; Population; Randomized controlled trial; Cancer; Internal medicine; Gynecology; Surgery; Environmental health","score_opus":0.19958164867796332,"score_gpt":0.557645895538048,"score_spread":0.35806424686008465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033769547","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068129976,0.9715625,0.0017518708,0.017717166,0.0013440532,0.00067883375,0.000020034815,0.000016568729,0.00009595509],"genre_scores_gemma":[0.0018685024,0.97108096,0.015391474,0.002982515,0.008364435,0.00013938916,0.0000037512777,0.000055720167,0.00011327764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99558294,0.00060533604,0.002735929,0.00040687597,0.00023757115,0.00043136737],"domain_scores_gemma":[0.9924717,0.004402904,0.0019649675,0.00014951776,0.00041933742,0.00059156015],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002443214,0.00041318368,0.0057527474,0.00015245339,0.00009377624,0.000027243073,0.000114921786,0.0013983946,0.000040577735],"category_scores_gemma":[0.004724563,0.00027861117,0.00089188776,0.00018721084,0.0002813951,0.00010826701,0.0001294928,0.0021989094,0.0000032077792],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021221405,0.0001926435,0.0063350205,0.0064891283,0.00183057,0.00018881854,0.0010313082,3.6560868e-7,3.4383376e-7,0.000076464356,0.0034744055,0.9782588],"study_design_scores_gemma":[0.0026089032,0.0072083347,0.030417228,0.019497935,0.0045514144,0.0005000242,0.00019763147,0.00006051066,2.4871306e-7,0.0017947669,0.9329318,0.00023123914],"about_ca_topic_score_codex":0.000008557587,"about_ca_topic_score_gemma":0.000077621364,"teacher_disagreement_score":0.9780275,"about_ca_system_score_codex":0.0007146838,"about_ca_system_score_gemma":0.0022537885,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W3033780291","doi":"10.1200/jco.19.02760","title":"Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; MUTYH; DNA repair; Cancer; Internal medicine; Oncology; Breast cancer; Relative risk; Germline mutation; Gene; Mutation; Genetics; Biology","score_opus":0.05923782374277466,"score_gpt":0.38866627321057395,"score_spread":0.3294284494677993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033780291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476916,0.003242279,0.000018880475,0.0011533431,0.00031578707,0.00044518764,0.000029126768,0.0000052621226,0.000020962565],"genre_scores_gemma":[0.986352,0.01256095,0.0007684244,0.0001051671,0.00015151572,0.0000318113,0.0000043731484,0.00001657052,0.00000914676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969073,0.0004518144,0.00196796,0.00021735377,0.00029536692,0.00016018384],"domain_scores_gemma":[0.9966197,0.0009796222,0.0017653276,0.00011699183,0.00031521224,0.00020312896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085047545,0.00015120507,0.0013014858,0.0001593782,0.000013985038,0.0000023058826,0.00007898849,0.00022252774,0.00007419206],"category_scores_gemma":[0.00077003334,0.000104793755,0.00021735055,0.0002747771,0.00028729383,0.00005773708,0.000026583737,0.0004091697,1.6321299e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002606738,0.0014218173,0.9488635,0.00007349262,0.00043437455,0.00015756558,0.0012418835,0.0014908755,0.000845198,0.0000022016134,0.000008764137,0.042853598],"study_design_scores_gemma":[0.010317163,0.018152386,0.9674784,0.00023995631,0.00051023805,0.000030124374,0.00015882989,0.00027905722,0.00269714,0.000022511535,0.000031788768,0.00008238816],"about_ca_topic_score_codex":0.0017606529,"about_ca_topic_score_gemma":0.04675867,"teacher_disagreement_score":0.044998016,"about_ca_system_score_codex":0.0002893068,"about_ca_system_score_gemma":0.0016338554,"threshold_uncertainty_score":0.9706355},"labels":[],"label_agreement":null},{"id":"W3036153593","doi":"10.1200/jco.19.03114","title":"Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Medical Research Council","keywords":"Medicine; Prostate cancer; Surrogate endpoint; Proportional hazards model; Oncology; Hazard ratio; Clinical endpoint; Internal medicine; Prostate-specific antigen; Clinical trial; Radiation therapy; Survival analysis; Cancer; Urology; Confidence interval","score_opus":0.1259666433807745,"score_gpt":0.44436487174168127,"score_spread":0.31839822836090675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036153593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007493619,0.9700621,0.00013562998,0.012512024,0.00071288546,0.007527451,0.0012671308,0.000038833427,0.0002503492],"genre_scores_gemma":[0.001979726,0.9932348,0.0017275988,0.0010957331,0.0006983677,0.0006574879,0.00031233643,0.00016315703,0.00013076133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916988,0.0012637406,0.0045610094,0.00088710117,0.00090739015,0.00068193447],"domain_scores_gemma":[0.98878735,0.0034805255,0.005577662,0.0005489589,0.00085280504,0.0007527246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027551542,0.00084186305,0.008964169,0.00036680952,0.000074879186,0.000058224934,0.0003787649,0.0006603731,0.00012221662],"category_scores_gemma":[0.00041790993,0.00049738155,0.0012902358,0.0006045902,0.00029365227,0.0001881486,0.0000692265,0.0014826236,0.000007280425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071729556,0.003714212,0.03277709,0.004900799,0.0045226594,0.0037192798,0.00022129406,0.00008737712,0.000004133977,0.000021314181,0.0049976,0.87330467],"study_design_scores_gemma":[0.061921615,0.03309162,0.005767416,0.0143418815,0.003835296,0.00010592428,0.00003693305,0.00016158291,0.000037084323,0.000021947742,0.8801819,0.0004968101],"about_ca_topic_score_codex":0.00027309603,"about_ca_topic_score_gemma":0.00044474532,"teacher_disagreement_score":0.8751843,"about_ca_system_score_codex":0.0016413197,"about_ca_system_score_gemma":0.008623722,"threshold_uncertainty_score":0.99974775},"labels":[],"label_agreement":null},{"id":"W3041685519","doi":"10.1200/jco.20.01296","title":"Antiemetics: ASCO Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":457,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Ottawa Hospital; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Medicine; Aprepitant; Antiemetic; Palonosetron; Guideline; Olanzapine; Dexamethasone; Intensive care medicine; Clinical trial; Regimen; Randomized controlled trial; Internal medicine; Oncology; Chemotherapy","score_opus":0.2375116014783388,"score_gpt":0.5256872531517247,"score_spread":0.2881756516733859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041685519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48390093,0.0006513074,0.0090374015,0.47896096,0.0023930054,0.00023932621,0.0000023093794,0.00003584713,0.024778936],"genre_scores_gemma":[0.8529762,0.0008464258,0.043172818,0.09714528,0.005538045,4.7307935e-7,0.0000027759475,0.00001772928,0.0003002396],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964773,0.0002037142,0.0027069678,0.00013444482,0.00031465272,0.00016292869],"domain_scores_gemma":[0.9971312,0.0005244329,0.0012905241,0.00012908893,0.00042883187,0.000495893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031980337,0.00008768423,0.0011116568,0.000045728284,0.000019099487,0.000007111877,0.00016254933,0.00017362705,0.00048184345],"category_scores_gemma":[0.007120008,0.000060849987,0.00041731296,0.00012591125,0.00008720639,0.00005462907,0.000081721475,0.00074261636,0.00014760868],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003214318,0.00095197157,0.029048081,0.000054929744,0.00062798493,0.0023036238,0.00005516484,0.000020745174,0.00028539324,0.00069814443,0.62001294,0.3427267],"study_design_scores_gemma":[0.0062218662,0.008954292,0.016430235,0.00003402635,0.0004416707,0.000099786106,0.000068115376,0.00040008605,0.00012674034,0.0002940519,0.9668681,0.00006105632],"about_ca_topic_score_codex":0.0000016715437,"about_ca_topic_score_gemma":8.400939e-7,"teacher_disagreement_score":0.38181567,"about_ca_system_score_codex":0.000032085925,"about_ca_system_score_gemma":0.00054998935,"threshold_uncertainty_score":0.8523829},"labels":[],"label_agreement":null},{"id":"W3043096450","doi":"10.1200/jco.20.00147","title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Puma Biotechnology; American Society of Clinical Oncology","keywords":"Capecitabine; Medicine; Lapatinib; Internal medicine; Neratinib; Hazard ratio; Metastatic breast cancer; Clinical endpoint; Gastroenterology; Oncology; Cancer; Breast cancer; Trastuzumab; Randomized controlled trial; Confidence interval; Colorectal cancer","score_opus":0.12862131070580513,"score_gpt":0.467998518340425,"score_spread":0.33937720763461987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043096450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96566427,0.0013839003,0.000031709074,0.027544105,0.0015934705,0.0019352052,0.00011098297,0.00005839851,0.001677982],"genre_scores_gemma":[0.9867949,0.0016937648,0.0016498856,0.004570308,0.0042464742,0.00016021643,0.000094152456,0.000076888784,0.0007134414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934542,0.0013560749,0.003388042,0.00057958387,0.00060182705,0.00062025565],"domain_scores_gemma":[0.9928884,0.0025917196,0.0024440365,0.0002260292,0.0008374167,0.0010123801],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013587964,0.0004933127,0.0039609494,0.00021871108,0.00007673886,0.00002204002,0.00023975405,0.00038534333,0.002069716],"category_scores_gemma":[0.001023859,0.00034077934,0.00056760473,0.00075318065,0.00038153213,0.00021097355,0.000058058344,0.0017186694,0.00001907635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93102497,0.009077248,0.0020058022,0.00007192568,0.0036658705,0.007380187,0.0014160341,0.00030746893,0.0004522916,0.0000147712,0.013286006,0.03129744],"study_design_scores_gemma":[0.8342323,0.13420704,0.00591717,0.00033485788,0.0049196645,0.000802552,0.00045593776,0.0024863116,0.00019673115,0.0000068668874,0.016057637,0.00038296316],"about_ca_topic_score_codex":0.0009939742,"about_ca_topic_score_gemma":0.002074658,"teacher_disagreement_score":0.12512979,"about_ca_system_score_codex":0.0012118343,"about_ca_system_score_gemma":0.005768008,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W3043951483","doi":"10.1200/jco.19.02427","title":"Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Internal medicine; Clinical trial; Cancer; Surgery; Confidence interval","score_opus":0.07562327189543909,"score_gpt":0.4009059600004262,"score_spread":0.3252826881049871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043951483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963733,0.0004975231,0.000018093415,0.002479385,0.00012495519,0.00021441333,0.0002764591,3.9212202e-7,0.000015466485],"genre_scores_gemma":[0.99575734,0.0038089019,0.00014671005,0.0001515486,0.00012295604,0.0000046819414,0.0000041359226,0.000003443836,2.893638e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997234,0.0013530027,0.0010305078,0.00014082801,0.00015718366,0.00008451309],"domain_scores_gemma":[0.9957233,0.0015760332,0.0024098768,0.00008126813,0.00016432583,0.000045160406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017670338,0.000092395174,0.0006815179,0.000017936803,0.00003220276,0.000004749381,0.00012344957,0.00010950613,0.0000018197065],"category_scores_gemma":[0.0035204343,0.000043112508,0.00008628238,0.00009011179,0.0003019643,0.00001112678,0.00007525374,0.0002817897,3.187523e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004607763,0.00027884636,0.96030384,0.000014384558,0.00013622771,0.0000020110185,0.00035619343,0.00007554264,0.00004356119,0.000008658165,0.00009935235,0.034073602],"study_design_scores_gemma":[0.0051740548,0.0026080413,0.99114335,0.00010355694,0.00021943466,0.00000467096,0.0001302962,0.000020848034,0.000196839,0.00027909115,0.00007526815,0.000044566303],"about_ca_topic_score_codex":0.0006665884,"about_ca_topic_score_gemma":0.0011333169,"teacher_disagreement_score":0.034029037,"about_ca_system_score_codex":0.000021188842,"about_ca_system_score_gemma":0.00028126352,"threshold_uncertainty_score":0.4214543},"labels":[],"label_agreement":null},{"id":"W3044418753","doi":"10.1200/jco.20.01757","title":"Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; HBsAg; Hepatitis B virus; Hepatitis B; Immunology; Internal medicine; Cancer; Antibody; Virus","score_opus":0.1552008710272226,"score_gpt":0.4818714192590749,"score_spread":0.32667054823185226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044418753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95098674,0.0006101137,0.0033182432,0.04242688,0.0010783324,0.001370445,0.000044523345,0.000014854962,0.00014984224],"genre_scores_gemma":[0.7383605,0.059468836,0.13495521,0.063103564,0.003857713,0.0000989459,0.000015282598,0.00006559503,0.00007433953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966365,0.00024615237,0.0020828473,0.0003254406,0.00045839415,0.0002506841],"domain_scores_gemma":[0.99634165,0.0012325544,0.0010445642,0.00011645532,0.0006297671,0.0006349899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016254282,0.00016803098,0.0013986019,0.000057761757,0.00008313248,0.000013628333,0.0001353537,0.00018711879,0.00006749472],"category_scores_gemma":[0.002055521,0.000109086985,0.00026745538,0.000119571836,0.00015773113,0.00011060726,0.00013588493,0.00052431435,0.000008655689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009713914,0.000548901,0.56762177,0.00004126359,0.0005763014,0.00004136145,0.00006211397,0.0000036322483,0.000001666326,0.00002916061,0.011901721,0.40945822],"study_design_scores_gemma":[0.010590374,0.022685792,0.6412349,0.00017856312,0.00014509911,0.000004233321,0.000008553575,0.00007745823,0.0000038076269,0.000019530264,0.32496786,0.00008387929],"about_ca_topic_score_codex":0.00010678977,"about_ca_topic_score_gemma":0.0003786988,"teacher_disagreement_score":0.40937436,"about_ca_system_score_codex":0.00005948187,"about_ca_system_score_gemma":0.00043861414,"threshold_uncertainty_score":0.44484383},"labels":[],"label_agreement":null},{"id":"W3044938198","doi":"10.1200/jco.19.02983","title":"Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Lomustine; Medicine; Procarbazine; Oncology; Internal medicine; Hazard ratio; Proportional hazards model; Progression-free survival; Glioma; Chemoradiotherapy; Radiation therapy; Vincristine; Chemotherapy; Cancer research; Confidence interval","score_opus":0.08840937308299648,"score_gpt":0.43500520832321393,"score_spread":0.3465958352402174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044938198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899072,0.0013730832,0.00007629202,0.0070323534,0.0006596205,0.0008616817,0.00002765376,0.000008221338,0.000053900556],"genre_scores_gemma":[0.9952364,0.0023550743,0.00085775787,0.00046247302,0.0009963794,0.000020297788,0.00005288777,0.000017220606,0.0000014946178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99441147,0.0009168683,0.0036769721,0.00036752192,0.000361573,0.00026559195],"domain_scores_gemma":[0.99177,0.004021314,0.00331877,0.00017424148,0.00027886586,0.00043675178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016351348,0.00023333449,0.0031351184,0.0007637354,0.000029844594,0.000008683358,0.00012804217,0.0004757417,0.00004632222],"category_scores_gemma":[0.0044612866,0.0001884921,0.0005036843,0.0011200175,0.00018215516,0.00010571015,0.00005912829,0.00085430575,0.0000038575345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58097446,0.014419907,0.13917017,0.00010198495,0.004077865,0.0036137914,0.00095456245,0.0037027511,0.0026002284,0.00005035229,0.0007177819,0.24961612],"study_design_scores_gemma":[0.55452764,0.043779317,0.38530815,0.00004803069,0.0041283253,0.0000388125,0.0001906486,0.009661756,0.00037108889,0.00003452791,0.0017783489,0.00013337721],"about_ca_topic_score_codex":0.0004503349,"about_ca_topic_score_gemma":0.0003978599,"teacher_disagreement_score":0.24948274,"about_ca_system_score_codex":0.0006679762,"about_ca_system_score_gemma":0.0013019564,"threshold_uncertainty_score":0.76864845},"labels":[],"label_agreement":null},{"id":"W3045271368","doi":"10.1200/jco.20.00315","title":"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Prostatectomy; Prostate cancer; Oncology; Cancer; Internal medicine; Prostate; Urology","score_opus":0.06954885573671507,"score_gpt":0.4080124734975627,"score_spread":0.33846361776084766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045271368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96127504,0.010772642,0.000050172574,0.026315302,0.00034401895,0.0011193353,0.00004368536,0.000018823384,0.000060957507],"genre_scores_gemma":[0.8293835,0.15859038,0.00326213,0.007513774,0.00094770157,0.00018945277,0.000005652112,0.000044992546,0.00006241544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961216,0.00027442115,0.0021177784,0.0004997353,0.0005258323,0.00046063875],"domain_scores_gemma":[0.9962155,0.0007679359,0.0016725755,0.00015647757,0.00029635,0.00089112116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011245691,0.00033574735,0.0023464453,0.000065342734,0.0000548032,0.000024442657,0.0001506608,0.00032349804,0.0002187304],"category_scores_gemma":[0.00048068503,0.00018039608,0.00020691677,0.0003069372,0.0005457685,0.00018465964,0.00005306517,0.0015068636,0.0000037413565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058676273,0.00075380894,0.5853236,0.0000704764,0.0006164387,0.0017789303,0.000368085,0.00009236852,0.00007252671,0.00001617177,0.0012918287,0.3509395],"study_design_scores_gemma":[0.107963055,0.07072035,0.65709823,0.0010615917,0.0007371019,0.0003497025,0.00021700145,0.0010703631,0.0007986262,0.0001716651,0.15940882,0.00040349938],"about_ca_topic_score_codex":0.0009590005,"about_ca_topic_score_gemma":0.00081260706,"teacher_disagreement_score":0.35053602,"about_ca_system_score_codex":0.000730767,"about_ca_system_score_gemma":0.004670551,"threshold_uncertainty_score":0.8285357},"labels":[],"label_agreement":null},{"id":"W3045454960","doi":"10.1200/jco.20.00493","title":"Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; University of Alberta","funders":"Baxalta; National Cancer Institute; Boston Scientific Corporation; Adaptive Biotechnologies; American Lebanese Syrian Associated Charities; Servier; Amgen","keywords":"Medicine; Childhood cancer; Lymphoblastic Leukemia; Pediatrics; Cancer; Childhood leukemia; Cancer survivor; Pediatric cancer; Survivorship curve; Acute lymphocytic leukemia; Leukemia; Internal medicine","score_opus":0.09914925984512434,"score_gpt":0.43954355501414233,"score_spread":0.340394295169018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045454960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893701,0.0004201984,0.00006345231,0.008205414,0.00083503156,0.0007858381,0.000043627366,0.000012436971,0.00026390614],"genre_scores_gemma":[0.9954182,0.0009389106,0.0002839882,0.0016746735,0.0016073181,0.000015385342,0.000006198722,0.00003358354,0.000021732743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921926,0.0014977755,0.0042309137,0.0005327781,0.0011419546,0.00040396184],"domain_scores_gemma":[0.98888725,0.0067101093,0.0025955762,0.00051445555,0.0005767431,0.00071588904],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005868904,0.000272913,0.0027267446,0.000100701975,0.000055476776,0.0000150264505,0.00049693143,0.00046493276,0.00011604267],"category_scores_gemma":[0.0173331,0.00016762105,0.00042095763,0.00053109997,0.0005176073,0.00013531464,0.0003456164,0.0019402965,0.000004806759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031759087,0.0031624448,0.9734739,0.000026513504,0.0022920805,0.00621755,0.002275631,0.00005830704,0.00033292745,0.0000045496936,0.0014760642,0.007504128],"study_design_scores_gemma":[0.016522037,0.006467744,0.97281796,0.00011291862,0.0012964541,0.000619368,0.0009938402,0.00044330952,0.00010817595,0.000119739336,0.0003651521,0.00013328789],"about_ca_topic_score_codex":0.008266947,"about_ca_topic_score_gemma":0.0038479252,"teacher_disagreement_score":0.013346127,"about_ca_system_score_codex":0.0007315075,"about_ca_system_score_gemma":0.012597142,"threshold_uncertainty_score":0.9983371},"labels":[],"label_agreement":null},{"id":"W3046741455","doi":"10.1200/jco.2020.38.15_suppl.e21684","title":"Efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with different metastatic sites: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; Meta-analysis; Subgroup analysis; Confidence interval","score_opus":0.12092407219383365,"score_gpt":0.48668873935238266,"score_spread":0.365764667158549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046741455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008587277,0.9943581,0.000022321025,0.00056620216,0.000099902456,0.0039750733,0.000053829594,0.0000028489324,0.00006294808],"genre_scores_gemma":[0.0025405374,0.99611664,0.0004979013,0.0003864374,0.000061242186,0.00022435315,0.00004292613,0.000036734356,0.0000932559],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98954856,0.0011279316,0.008336718,0.0003463965,0.00043849807,0.00020190865],"domain_scores_gemma":[0.9857752,0.0024911596,0.010600336,0.0003221061,0.0004632239,0.0003480067],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016966703,0.000463034,0.026841711,0.00037067788,0.000018612227,0.000008931661,0.00019016425,0.0002338971,0.00011170747],"category_scores_gemma":[0.0013074784,0.00020989576,0.0050378703,0.0006883014,0.000096479605,0.000049275695,0.00006898128,0.0010028634,0.0000016889194],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014917683,0.0029192488,0.0009604172,0.6773513,0.31188715,0.00019208377,0.00013406274,0.000003019883,5.289956e-8,0.0000012830334,0.000059691178,0.006342522],"study_design_scores_gemma":[0.004441971,0.003089121,0.001395652,0.061159577,0.9257948,0.000020994523,0.000016518416,0.000005343604,2.3114623e-7,0.0000010167553,0.0039247633,0.00015005875],"about_ca_topic_score_codex":0.000039291626,"about_ca_topic_score_gemma":0.000057989855,"teacher_disagreement_score":0.61619174,"about_ca_system_score_codex":0.00039150834,"about_ca_system_score_gemma":0.0019054142,"threshold_uncertainty_score":0.98760587},"labels":[],"label_agreement":null},{"id":"W3046898665","doi":"10.1200/jco.20.01573","title":"Reply to S.A. Upadhyaya","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; General surgery","score_opus":0.10015690817374431,"score_gpt":0.443568413137424,"score_spread":0.34341150496367967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046898665","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071818624,0.000803758,0.0010813413,0.98351336,0.00383692,0.00012420055,0.000017705346,0.0000071785576,0.0034336515],"genre_scores_gemma":[0.0028672356,0.00067198125,0.005080858,0.9470216,0.042166993,0.0000034534355,0.000036731875,0.000048504004,0.002102643],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961323,0.00044810132,0.0023863844,0.00039830126,0.00036134286,0.00027352705],"domain_scores_gemma":[0.9966481,0.00030747123,0.0018973289,0.00038621502,0.00045285275,0.00030803093],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012435687,0.00022952727,0.0013649216,0.000060506874,0.000031005806,0.000016536267,0.0006106063,0.0014355566,0.000076772325],"category_scores_gemma":[0.0041711642,0.00018379065,0.0009286949,0.00007895423,0.000099671466,0.0000022710713,0.00018025878,0.0026345823,0.000077883364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000439741,0.000061835985,0.000069273054,0.000029144432,0.00026476162,0.000708289,0.000012354472,0.000038230388,0.00075663143,7.5192554e-7,0.9697446,0.027874341],"study_design_scores_gemma":[0.0009787016,0.006951554,0.00007864313,0.00005771348,0.00013979668,0.00020595099,0.000008854677,0.000015328565,0.00032152768,0.0001275765,0.9909122,0.00020214012],"about_ca_topic_score_codex":0.000010202228,"about_ca_topic_score_gemma":0.0000037273096,"teacher_disagreement_score":0.038330074,"about_ca_system_score_codex":0.00005341355,"about_ca_system_score_gemma":0.0021525356,"threshold_uncertainty_score":0.99986076},"labels":[],"label_agreement":null},{"id":"W3047016852","doi":"10.1200/jco.20.00799","title":"Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Olaparib; Ovarian cancer; Oncology; Placebo; Confidence interval; Surgery; Gastroenterology; Cancer; Pathology","score_opus":0.07789584514667676,"score_gpt":0.42765471376798503,"score_spread":0.3497588686213083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047016852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660933,0.00013616227,0.013680474,0.018417189,0.0005054933,0.0010214812,0.00008137021,0.00000930794,0.000055239943],"genre_scores_gemma":[0.9799657,0.00015006174,0.011340772,0.0072942795,0.0011132925,0.00006253619,0.000030595933,0.000023531762,0.000019250148],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966951,0.00029262257,0.001977411,0.00028951542,0.0005166535,0.00022871849],"domain_scores_gemma":[0.98778695,0.007964162,0.0026957963,0.00021812826,0.0010375206,0.00029746667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009663393,0.000174581,0.0017786736,0.0000740217,0.0000615252,0.00001100611,0.00023713379,0.0002077535,0.00023855428],"category_scores_gemma":[0.0040093404,0.00009263876,0.0005765159,0.0005819806,0.00031135374,0.00013185573,0.000018989293,0.0006284933,0.0000014861618],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82140905,0.0022434744,0.13214557,0.000024723427,0.0057197916,0.000121812875,0.0010570961,0.0018544688,0.00008009278,0.00011315664,0.004335615,0.030895183],"study_design_scores_gemma":[0.45023373,0.040159985,0.49667796,0.00020930378,0.0037241753,0.000005768235,0.0001605286,0.00035436839,0.00007203346,0.00018049355,0.008085141,0.00013651846],"about_ca_topic_score_codex":0.00007052836,"about_ca_topic_score_gemma":0.00020852349,"teacher_disagreement_score":0.3711753,"about_ca_system_score_codex":0.00015473638,"about_ca_system_score_gemma":0.00149801,"threshold_uncertainty_score":0.47998446},"labels":[],"label_agreement":null},{"id":"W3047152751","doi":"10.1200/jco.20.00549","title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":837,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Sherbrooke; Sunnybrook Health Science Centre","funders":"Manchester Biomedical Research Centre; Cancer Research UK; Institut Gustave-Roussy; KWF Kankerbestrijding; National Institute for Health and Care Research; National Cancer Research Institute; Cancer Research Institute","keywords":"Medicine; Endometrial cancer; Internal medicine; Oncology; Radiation therapy; Adjuvant therapy; Chemotherapy; Cancer","score_opus":0.174394381990507,"score_gpt":0.46864838175384405,"score_spread":0.29425399976333705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047152751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815223,0.0017620946,0.000058992082,0.014063882,0.0013207817,0.0010708956,0.00013875925,0.00000492481,0.000057337515],"genre_scores_gemma":[0.9912667,0.0038421783,0.00041516157,0.0016372128,0.002773122,0.000036992133,0.00000658574,0.000015607064,0.0000064008987],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972107,0.0002495463,0.0017530398,0.00021762948,0.00042003114,0.00014906796],"domain_scores_gemma":[0.9928228,0.003941891,0.0024502287,0.00014615126,0.0003179388,0.00032096237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010196158,0.00014757174,0.0015565408,0.00008040502,0.000035617355,0.0000071838726,0.00016238584,0.00027821373,0.00010340228],"category_scores_gemma":[0.004997817,0.00007121753,0.00086506194,0.00031447405,0.000100506426,0.00004033748,0.000026433529,0.0005110919,8.187078e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40272662,0.0015875194,0.08085897,0.000010574197,0.0015014493,0.000016284017,0.00004956249,0.000019840933,0.001134157,0.00010050556,0.00027717484,0.5117174],"study_design_scores_gemma":[0.28197828,0.084894046,0.62335604,0.000058763442,0.0012937469,0.0000036347708,0.00002584751,0.00006665564,0.00385448,0.0015389381,0.0028548292,0.000074747244],"about_ca_topic_score_codex":0.00026120187,"about_ca_topic_score_gemma":0.000013634018,"teacher_disagreement_score":0.54249704,"about_ca_system_score_codex":0.000115767376,"about_ca_system_score_gemma":0.0006629771,"threshold_uncertainty_score":0.59832144},"labels":[],"label_agreement":null},{"id":"W3047866783","doi":"10.1200/jco.20.01584","title":"ASCO Voices 2020","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Family medicine","score_opus":0.33923635244928674,"score_gpt":0.591611317636924,"score_spread":0.25237496518763725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047866783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7436511,0.0010525034,0.00023134518,0.22819732,0.0015732123,0.00012979485,8.0363884e-7,0.000011921787,0.025152033],"genre_scores_gemma":[0.9481551,0.0017387633,0.0023177594,0.039454196,0.0076492517,7.2914435e-7,6.282057e-7,0.000008347335,0.0006751961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971064,0.00023862175,0.0015545301,0.00016230613,0.0007016387,0.00023654338],"domain_scores_gemma":[0.99557346,0.0017035492,0.00074826815,0.000117744225,0.00047465696,0.0013823133],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004168092,0.000078947276,0.0011224144,0.00006227021,0.000029235409,0.0000061365217,0.00025160852,0.00021078625,0.00069884775],"category_scores_gemma":[0.019299906,0.00004688676,0.0003424448,0.00028074597,0.00038186257,0.000098041965,0.00005756031,0.0012476641,0.00013945879],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065708268,0.0012687928,0.18110646,0.00009115885,0.0003252658,0.006143836,0.0007460809,0.0000053784834,0.002524541,0.00017519073,0.27242693,0.52861553],"study_design_scores_gemma":[0.0072423285,0.025907306,0.22184555,0.00006963309,0.00017992409,0.0005556999,0.00054071046,0.00025019865,0.00016945091,0.00013524137,0.74304557,0.000058377125],"about_ca_topic_score_codex":0.0000075618996,"about_ca_topic_score_gemma":0.000006073615,"teacher_disagreement_score":0.5285572,"about_ca_system_score_codex":0.00003890324,"about_ca_system_score_gemma":0.0022723638,"threshold_uncertainty_score":0.9889609},"labels":[],"label_agreement":null},{"id":"W3048886922","doi":"10.1200/jco.2009.27.15_suppl.e20576","title":"Health-related quality of life indicators and overall quality of life: Results from a cluster analysis on baseline EORTC QLQ-C30 data from 6,739 cancer patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Breast cancer; Physical therapy; Oncology; Internal medicine","score_opus":0.2025922459814889,"score_gpt":0.50664131821099,"score_spread":0.3040490722295011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048886922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728361,0.0017260509,0.000081648635,0.021288011,0.0008630792,0.00021013204,0.0027987042,0.000007731534,0.0001885483],"genre_scores_gemma":[0.98234206,0.0016944703,0.00037479866,0.014275202,0.00065230805,0.0000010145341,0.00061582826,0.000012264897,0.00003206949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9866672,0.003165713,0.008418686,0.00053276605,0.0009615373,0.00025409737],"domain_scores_gemma":[0.9799636,0.008054776,0.009539585,0.0009017824,0.00061028963,0.00092998333],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011080658,0.00022034903,0.0042397915,0.00031719144,0.000036216683,0.0000068580844,0.0003994195,0.00059019245,0.000273811],"category_scores_gemma":[0.020527933,0.00016456703,0.0006129256,0.0005182075,0.0002339426,0.00013256706,0.0001374729,0.0011910932,0.0000020443651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050845947,0.0034666653,0.87479883,0.000052927888,0.0031131767,0.000010319596,0.00081503816,0.00005750073,0.000016129572,0.000014827069,0.009584826,0.05722379],"study_design_scores_gemma":[0.018721296,0.004911416,0.9714803,0.00018077999,0.00111767,3.53986e-7,0.00014518392,0.00024789054,0.000007243893,0.0001795455,0.0028772969,0.00013101667],"about_ca_topic_score_codex":0.032165717,"about_ca_topic_score_gemma":0.019948479,"teacher_disagreement_score":0.09668145,"about_ca_system_score_codex":0.00017756292,"about_ca_system_score_gemma":0.0024466007,"threshold_uncertainty_score":0.9979349},"labels":[],"label_agreement":null},{"id":"W3048967410","doi":"10.1200/jco.20.01924","title":"PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; Oncology; Internal medicine; BRCA mutation; Ovarian cancer; Bevacizumab; Guideline; PARP inhibitor; Cancer; Chemotherapy; Pathology; Poly ADP ribose polymerase; Polymerase; Biology; Genetics; Gene","score_opus":0.25277200376666575,"score_gpt":0.5568653200599185,"score_spread":0.30409331629325276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048967410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018432058,0.96751297,0.000011670658,0.025777537,0.0017993473,0.0008371335,0.000020596754,0.0000032152182,0.00401911],"genre_scores_gemma":[0.00016311389,0.99210274,0.0028247403,0.0018555077,0.0028965722,0.00005749221,0.00001017468,0.000028450422,0.00006119369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914028,0.00079923135,0.0067456975,0.00028459114,0.0005492215,0.00021843812],"domain_scores_gemma":[0.9927269,0.0015542532,0.0049132193,0.00034962856,0.00021118569,0.00024479293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004389175,0.0002912022,0.0058440766,0.00016131086,0.000019383777,0.0000074952723,0.00040848795,0.00054293143,0.000180231],"category_scores_gemma":[0.00037739973,0.00014833425,0.0018347042,0.00041767836,0.00013050206,0.000033711556,0.00009421943,0.001501716,0.000014426897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025483867,0.001604311,0.00044447873,0.0031313396,0.00268306,0.003838339,0.00003124482,0.0000018420128,6.1165e-9,0.00031555307,0.026752237,0.96094275],"study_design_scores_gemma":[0.0043337904,0.004237875,0.0014694855,0.014803102,0.008457959,0.00023777688,0.000059896895,0.0000017036672,1.3311552e-7,0.00006632933,0.9662323,0.000099641606],"about_ca_topic_score_codex":0.000075971155,"about_ca_topic_score_gemma":0.000035155983,"teacher_disagreement_score":0.9608431,"about_ca_system_score_codex":0.00045076074,"about_ca_system_score_gemma":0.003254066,"threshold_uncertainty_score":0.6524292},"labels":[],"label_agreement":null},{"id":"W3049075803","doi":"10.1200/jco.2009.27.15_suppl.e20646","title":"A systematic review of the impact of comorbidity on chemotherapy utilization and outcomes in solid tumors","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Comorbidity; Medicine; Internal medicine; Checklist; MEDLINE; Retrospective cohort study; Tolerability; Cancer; Oncology; Adverse effect","score_opus":0.25744584290701306,"score_gpt":0.5728542867962853,"score_spread":0.3154084438892722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049075803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002161172,0.99541366,0.0000018245079,0.00045512748,0.00022211314,0.001288659,0.000011319404,0.0000014027834,0.00044473162],"genre_scores_gemma":[0.001033689,0.9970429,0.000049955783,0.0017099589,0.000101669015,0.0000043100044,0.0000034157015,0.000013712618,0.00004042004],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9917686,0.00143399,0.0062195696,0.00013644231,0.00032011443,0.000121305646],"domain_scores_gemma":[0.9877348,0.002855011,0.008718691,0.0003368734,0.00022953271,0.00012507419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047005285,0.00022376736,0.01176405,0.00015681428,0.000009728121,0.0000019103202,0.0002347922,0.00037448524,0.000075905744],"category_scores_gemma":[0.0065321946,0.00009850223,0.002270769,0.00020498184,0.0001494744,0.000036569287,0.000024217868,0.001029032,7.601614e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023857057,0.0007683297,0.0011890021,0.5484458,0.0007897839,0.00003727367,0.000023182389,7.01549e-7,1.8136222e-7,0.0000063777597,0.00062332203,0.44787744],"study_design_scores_gemma":[0.0031383045,0.00806311,0.025685824,0.93732643,0.0028777174,0.00036943526,0.000008177621,0.000011275044,6.292227e-7,0.00002724652,0.022383634,0.000108200125],"about_ca_topic_score_codex":0.000014037269,"about_ca_topic_score_gemma":0.000006136294,"teacher_disagreement_score":0.44776925,"about_ca_system_score_codex":0.00032242658,"about_ca_system_score_gemma":0.0036565496,"threshold_uncertainty_score":0.804167},"labels":[],"label_agreement":null},{"id":"W3049349368","doi":"10.1200/jco.20.00418","title":"Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Cohort; Quality-adjusted life year; Anthracycline; Cost effectiveness; Cancer; Cohort study; Confidence interval; Pediatrics; Internal medicine; Breast cancer; Pathology","score_opus":0.09935556073375235,"score_gpt":0.4477352982066428,"score_spread":0.34837973747289047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049349368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645557,0.0004416775,0.0030971915,0.030135138,0.0008342514,0.0008904526,0.000018407369,0.000004315873,0.000022909238],"genre_scores_gemma":[0.99046105,0.00053290685,0.0040865196,0.0040508406,0.00081864616,0.000019246589,0.000006546633,0.000018224584,0.000006014482],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961549,0.0005981998,0.0024287887,0.00018483416,0.00050394743,0.00012931626],"domain_scores_gemma":[0.99590707,0.001022375,0.0016530574,0.00013368196,0.0011297453,0.00015409192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027898604,0.00013298845,0.0012663788,0.000111527734,0.000016389762,0.0000030312688,0.00023055027,0.00024136978,0.000037373273],"category_scores_gemma":[0.005406167,0.00009391337,0.00046113104,0.0003806448,0.000079303696,0.000089725996,0.000080189544,0.00052349694,2.7271292e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042288024,0.002989766,0.32844517,0.0005592996,0.0016889346,0.000019093413,0.0014964857,0.027335426,0.46289408,0.00004888441,0.0029755223,0.16731852],"study_design_scores_gemma":[0.007835347,0.0024975345,0.6983577,0.0023147298,0.00026906855,0.000017231765,0.00009380281,0.00057051337,0.28300577,0.00006618579,0.0048782225,0.00009391153],"about_ca_topic_score_codex":0.00033885962,"about_ca_topic_score_gemma":0.00044050012,"teacher_disagreement_score":0.3699125,"about_ca_system_score_codex":0.0001278668,"about_ca_system_score_gemma":0.00085023546,"threshold_uncertainty_score":0.64720774},"labels":[],"label_agreement":null},{"id":"W3049465296","doi":"10.1200/jco.20.00522","title":"Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Genentech; U.S. Food and Drug Administration; Plexxikon; Sirtex Medical; Toray Industries; Springworks Therapeutics; Syndax Pharmaceuticals; BeiGene; Arog Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Five Prime Therapeutics; Astex Pharmaceuticals; MacroGenics; Celldex Therapeutics; GlaxoSmithKline; IFM Therapeutics; American Society of Clinical Oncology; Valeant Pharmaceuticals International; Eli Lilly and Company; National Comprehensive Cancer Network; Iterion Therapeutics; Halozyme; Revolution Medicines; Karyopharm Therapeutics; Exelixis; Endocyte; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Astellas Pharma; Eisai; FibroGen; Celgene; Bristol-Myers Squibb; Deciphera Pharmaceuticals; Amgen; Symphogen; Pfizer; PharmaMar; U.S. Department of Veterans Affairs","keywords":"Medicine; GiST; Internal medicine; Adverse effect; Nausea; Gastroenterology; Constipation; PDGFRA; Imatinib mesylate; Rash; Phases of clinical research; Oncology; Imatinib; Clinical trial; Stromal cell","score_opus":0.06473184962436974,"score_gpt":0.4269756399044538,"score_spread":0.3622437902800841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049465296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979898,0.000027528366,0.00016761363,0.0010360079,0.000023408795,0.0006587585,0.000012367929,0.000003371627,0.00008116454],"genre_scores_gemma":[0.99515045,0.000004218228,0.0045756674,0.0001705379,0.00007920687,0.000004967737,0.0000026152604,0.000010777512,0.0000015642399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968094,0.00035689343,0.0019143217,0.00018850996,0.00051356864,0.00021727421],"domain_scores_gemma":[0.9962184,0.00093979266,0.0015767643,0.00009964276,0.00067452533,0.0004908688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009178155,0.00013568196,0.0014375581,0.000116492905,0.000012871533,0.000002967464,0.00006875324,0.000034113942,0.00003444977],"category_scores_gemma":[0.0042632245,0.00008956927,0.00012684976,0.00015550102,0.00019960791,0.00008356328,0.00003680978,0.0007100176,9.172614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07963025,0.017662663,0.8913789,0.00006027203,0.000117495736,0.002045691,0.00011084354,0.000023517434,0.00075097836,0.0000042635634,0.000022672699,0.0081924535],"study_design_scores_gemma":[0.08892118,0.31502932,0.5946473,0.0003104496,0.00015240043,0.0002811432,0.00041920118,0.00012252829,0.00006169221,0.0000111916515,0.000010018441,0.00003355863],"about_ca_topic_score_codex":0.000020187825,"about_ca_topic_score_gemma":0.000019522173,"teacher_disagreement_score":0.29736665,"about_ca_system_score_codex":0.000054734723,"about_ca_system_score_gemma":0.000568637,"threshold_uncertainty_score":0.5103786},"labels":[],"label_agreement":null},{"id":"W3063038225","doi":"10.1200/jco.20.00256","title":"Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Randomization; Regimen; Refractory (planetary science); Lymphoblastic Leukemia; Methotrexate; Acute lymphocytic leukemia; Gastroenterology; Clinical trial; Surgery; Leukemia; Oncology","score_opus":0.11865863205610801,"score_gpt":0.45946638576928317,"score_spread":0.3408077537131752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3063038225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746886,0.000394444,0.0037232044,0.0122937355,0.003046599,0.0030476663,0.000013740339,0.00006933964,0.0027226778],"genre_scores_gemma":[0.95383346,0.0015428868,0.01698752,0.014063778,0.013230905,0.00008812224,0.00003069969,0.00009908469,0.00012356463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9736801,0.007999683,0.014567691,0.0010642494,0.0014584535,0.0012298466],"domain_scores_gemma":[0.89483416,0.09331388,0.0071551073,0.0005954647,0.0010798308,0.0030215655],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.027483212,0.0006371228,0.010584767,0.0004937711,0.00010342214,0.000044183238,0.0010309548,0.0021340922,0.00029701865],"category_scores_gemma":[0.16142216,0.00046454222,0.0025323036,0.0010610716,0.00159434,0.0003017611,0.00048485302,0.0056859646,0.00015283344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8497209,0.009459338,0.0054010986,0.000046737892,0.0015353546,0.016303541,0.00023513283,0.00009379895,0.0004659149,0.000035632784,0.010542753,0.10615981],"study_design_scores_gemma":[0.8734226,0.09133192,0.0034040883,0.00018874252,0.0025143242,0.0015484289,0.000085057116,0.020765219,0.000031203603,0.00011996061,0.0062430296,0.00034542556],"about_ca_topic_score_codex":0.00018460634,"about_ca_topic_score_gemma":0.000033585846,"teacher_disagreement_score":0.13393895,"about_ca_system_score_codex":0.0030388362,"about_ca_system_score_gemma":0.028219765,"threshold_uncertainty_score":0.99978065},"labels":[],"label_agreement":null},{"id":"W3080135677","doi":"10.1200/jco.2009.27.15_suppl.3510","title":"A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Tolerability; Neutropenia; Carboplatin; Internal medicine; Pharmacodynamics; Pharmacology; Oncology; Cancer; Pharmacokinetics; Cisplatin; Chemotherapy; Adverse effect","score_opus":0.03808350545614243,"score_gpt":0.4159918490186893,"score_spread":0.3779083435625469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080135677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791825,0.000223003,0.000032069212,0.00059396663,0.00007999054,0.0011006134,0.0000028527895,0.000004942396,0.000044334352],"genre_scores_gemma":[0.9979414,0.00016736882,0.0013453349,0.00046549656,0.0000456378,0.000011604619,0.0000028261782,0.000015641148,0.000004689951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967995,0.0003827646,0.0019699263,0.00027245775,0.00035418526,0.00022113707],"domain_scores_gemma":[0.9978269,0.0005008709,0.0011592428,0.000102993974,0.00021487953,0.00019515307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012025065,0.0001894732,0.0015346543,0.00038762068,0.000014855894,0.0000054036427,0.000065183,0.00020989747,0.000011970273],"category_scores_gemma":[0.00063712866,0.00012129447,0.000044440872,0.00045569465,0.00014719168,0.00013330723,0.000020791962,0.0009814511,9.7693544e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21404664,0.054351687,0.53879124,0.000035812325,0.00013719859,0.003265078,0.0011886548,0.00046794006,0.0058403946,0.000005988712,0.000026202493,0.18184315],"study_design_scores_gemma":[0.18404755,0.15714604,0.6572677,0.00033111058,0.00009364899,0.00005646713,0.0002171047,0.0004383911,0.0002499385,0.000027111779,0.000025880772,0.00009908395],"about_ca_topic_score_codex":0.000033594784,"about_ca_topic_score_gemma":0.00060187705,"teacher_disagreement_score":0.18174407,"about_ca_system_score_codex":0.00018919098,"about_ca_system_score_gemma":0.00057654845,"threshold_uncertainty_score":0.4946245},"labels":[],"label_agreement":null},{"id":"W3080206596","doi":"10.1200/jco.2009.27.15_suppl.1534","title":"Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Breast cancer; Mammography; Magnetic resonance imaging; Population; Breast MRI; Mastectomy; Guideline; Hormonal therapy; Cohort; Cancer; Gynecology; Radiology; Surgery; Internal medicine; Pathology","score_opus":0.03248917357598317,"score_gpt":0.40824536351528,"score_spread":0.3757561899392968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080206596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133384,0.0026232323,0.00004473259,0.0030753908,0.0005201496,0.0021525966,0.00013309154,0.0000052344094,0.000111702815],"genre_scores_gemma":[0.9973271,0.0014463834,0.00014465321,0.0002819238,0.0004872674,0.00024129087,0.0000023953944,0.000023810877,0.00004517235],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939398,0.001348966,0.0032925927,0.00047187821,0.0005194525,0.00042727502],"domain_scores_gemma":[0.99477804,0.0010893076,0.0025028342,0.00032099034,0.001056577,0.0002522781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003942572,0.00035792994,0.00482431,0.00019396086,0.000041216368,0.0000204187,0.0003386775,0.00018602765,0.000044259377],"category_scores_gemma":[0.0011250927,0.00021307134,0.00073911954,0.00051956397,0.0005263647,0.000027603011,0.00008280023,0.00032699414,4.3814714e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52051777,0.002372442,0.45965874,0.000009451556,0.00041562447,0.000042175085,0.0001301551,0.000092427086,0.000037789945,0.0000014984402,0.000025187685,0.016696723],"study_design_scores_gemma":[0.47964036,0.0060355407,0.5132791,0.00012014329,0.0003475509,0.00006381246,0.00021159816,0.000022393895,0.00002023956,0.000027351589,0.00008077142,0.00015116573],"about_ca_topic_score_codex":0.0022402902,"about_ca_topic_score_gemma":0.010713177,"teacher_disagreement_score":0.053620305,"about_ca_system_score_codex":0.00008112782,"about_ca_system_score_gemma":0.0015685431,"threshold_uncertainty_score":0.86887974},"labels":[],"label_agreement":null},{"id":"W3080216678","doi":"10.1200/jco.2009.27.15_suppl.5559","title":"A phase II trial of voreloxin in women with platinum-resistant ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Neutropenia; Internal medicine; Nausea; Febrile neutropenia; Ovarian cancer; Regimen; Dosing; Cancer; Gastroenterology; Surgery; Chemotherapy","score_opus":0.062282198757724644,"score_gpt":0.44043237218573456,"score_spread":0.37815017342800994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080216678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965292,0.0003450949,0.00033612215,0.0016034894,0.00047813953,0.00015062845,0.000008394915,0.0000011602569,0.0005477195],"genre_scores_gemma":[0.9956057,0.0007516043,0.0012511524,0.0014704422,0.0007960115,0.0000068233317,0.0000013727349,0.0000088286915,0.00010805731],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99799603,0.00016173265,0.0013114542,0.00015486832,0.00017226305,0.00020367249],"domain_scores_gemma":[0.9983262,0.000074259486,0.0011340607,0.00015348493,0.0001623269,0.00014966755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016464705,0.00010478793,0.0007175367,0.000061444065,0.00002104408,0.000003848613,0.00018283201,0.0002791086,0.000042466352],"category_scores_gemma":[0.00020403329,0.00007492197,0.00012614172,0.00009132766,0.000075284246,0.0000042290435,0.00002843963,0.00030029623,2.2109103e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39003196,0.004952573,0.000039065217,0.0000051432366,0.0002102999,0.000063488005,0.00015674818,0.00004980371,0.23436795,0.00024139583,0.00028166518,0.3695999],"study_design_scores_gemma":[0.32086155,0.47237337,0.0023707652,0.00008819324,0.00011887248,0.000036650345,0.00016701574,0.000031506057,0.023794195,0.002086305,0.17783847,0.0002331065],"about_ca_topic_score_codex":0.000018627085,"about_ca_topic_score_gemma":0.00013627562,"teacher_disagreement_score":0.4674208,"about_ca_system_score_codex":0.00006023158,"about_ca_system_score_gemma":0.0013291584,"threshold_uncertainty_score":0.30552292},"labels":[],"label_agreement":null},{"id":"W3080408553","doi":"10.1200/jco.2009.27.15_suppl.9631","title":"Bone health practices in men on androgen deprivation therapy (ADT): A population-based analysis of 25,802 patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Osteoporosis; Prostate cancer; Bone mineral; Population; Diagnosis code; Pediatrics; Internal medicine; Physical therapy; Surgery; Cancer","score_opus":0.16743344979296132,"score_gpt":0.5351681237235163,"score_spread":0.367734673930555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080408553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811244,0.00025819906,0.000017931668,0.017788975,0.00011734096,0.00029757185,0.0000035416629,0.0000036908564,0.00038837444],"genre_scores_gemma":[0.9894623,0.00056333496,0.0014853384,0.008360253,0.000070326,0.000001963565,0.000038461545,0.0000053072645,0.000012674346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962358,0.00056686,0.0024937124,0.00014719309,0.0003871307,0.00016933997],"domain_scores_gemma":[0.99238217,0.0014123208,0.005505744,0.00015654386,0.00027043198,0.00027276337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002461801,0.00009331661,0.0014427681,0.0005018111,0.000027487666,0.0000028051875,0.0000556542,0.00020150274,0.00003605419],"category_scores_gemma":[0.0027277374,0.00006484598,0.0003058012,0.0005235994,0.0000212873,0.00008526649,0.0000037299449,0.0004007305,0.0000020145571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055027553,0.005659247,0.7937475,0.000007824333,0.00033350888,0.000028511178,0.00004549314,0.000090939044,0.0000022567642,0.00001941509,0.00016039387,0.19440217],"study_design_scores_gemma":[0.013617867,0.02298355,0.9610699,0.00005469414,0.00033592724,0.0000033378274,0.000012274546,0.0005286545,0.0000091010725,0.00013641884,0.0012108659,0.000037457503],"about_ca_topic_score_codex":0.00046864792,"about_ca_topic_score_gemma":0.00029811013,"teacher_disagreement_score":0.19436471,"about_ca_system_score_codex":0.00025527694,"about_ca_system_score_gemma":0.001107046,"threshold_uncertainty_score":0.32655534},"labels":[],"label_agreement":null},{"id":"W3080493019","doi":"10.1200/jco.2009.27.15_suppl.4092","title":"Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Irinotecan; Nausea; Surgery; Internal medicine; Colorectal cancer; Cancer","score_opus":0.1280866564755752,"score_gpt":0.38436623138501497,"score_spread":0.25627957490943976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080493019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789995,0.00013891826,0.00005524277,0.00042933645,0.00026159076,0.0008790179,0.00006774624,0.000011707212,0.00025649735],"genre_scores_gemma":[0.99719274,0.00002405213,0.0020862776,0.00013628263,0.0004592758,0.000004448259,0.000062624065,0.000021245922,0.000013024906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994992,0.00076574925,0.0030125675,0.0003219152,0.00064523635,0.00026249027],"domain_scores_gemma":[0.9946726,0.0012962922,0.002844165,0.00022065661,0.00068596203,0.00028030755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017052349,0.0002597165,0.0020033112,0.00020434265,0.00007327175,0.0000073082283,0.00016361375,0.00024838702,0.000031537562],"category_scores_gemma":[0.0013594325,0.00018096984,0.0004528562,0.00024770587,0.00014172749,0.00012800036,0.000027878821,0.0005436991,0.0000012091879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10373717,0.046004042,0.678537,0.00003521687,0.0010571332,0.00075372594,0.0044099716,0.00001013419,0.0030565595,0.0000043236028,0.00018958794,0.16220514],"study_design_scores_gemma":[0.07982072,0.24950485,0.64479053,0.00028289467,0.002464989,0.000023668343,0.00051621406,0.00047143118,0.021754304,0.0000072312655,0.00020049389,0.00016269044],"about_ca_topic_score_codex":0.00017334806,"about_ca_topic_score_gemma":0.000047517322,"teacher_disagreement_score":0.2035008,"about_ca_system_score_codex":0.00013738756,"about_ca_system_score_gemma":0.0006219191,"threshold_uncertainty_score":0.73797363},"labels":[],"label_agreement":null},{"id":"W3080528524","doi":"10.1200/jco.2009.27.15_suppl.e20569","title":"Use of the Prostate Cancer–specific Quality of Life Instrument (PROSQOLI) in clinical practice","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Constipation; Quality of life (healthcare); Mood; Prostate cancer; Cancer; Clinical Practice; Outpatient clinic; Physical therapy; Internal medicine; Family medicine; Psychiatry","score_opus":0.3426317769428979,"score_gpt":0.5497276641024599,"score_spread":0.20709588715956195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080528524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579843,0.001222366,0.000011626843,0.036588237,0.0027554932,0.00030960402,0.000010495694,0.000003208978,0.0011146105],"genre_scores_gemma":[0.98379636,0.0065439073,0.0009846755,0.0077266484,0.0008290685,0.000002598117,6.2994945e-7,0.000008634503,0.000107456304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905928,0.0019975922,0.0063179247,0.00020207479,0.00068090524,0.00020872917],"domain_scores_gemma":[0.98735875,0.005384093,0.0055488143,0.00039129486,0.0010127727,0.00030428517],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010494005,0.00012551718,0.0019880165,0.000082681385,0.000018323657,0.000006142012,0.00024208504,0.00038970818,0.00006273735],"category_scores_gemma":[0.019826045,0.000076733464,0.00077314157,0.00031521398,0.0003706515,0.00018892626,0.000062721534,0.0016205576,0.0000014700464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020694215,0.0037277471,0.64033526,0.000061686085,0.00019478174,0.000057037632,0.00053330406,0.00003141006,0.00014024792,0.0005667928,0.003128615,0.33052891],"study_design_scores_gemma":[0.0054486482,0.006265464,0.83796424,0.00022476607,0.00014044886,0.000029511,0.00049169053,0.000008473148,0.00007877534,0.0002207579,0.14906323,0.000063979096],"about_ca_topic_score_codex":0.00059415353,"about_ca_topic_score_gemma":0.0011523801,"teacher_disagreement_score":0.33046493,"about_ca_system_score_codex":0.0001719281,"about_ca_system_score_gemma":0.003577263,"threshold_uncertainty_score":0.9884304},"labels":[],"label_agreement":null},{"id":"W3080596891","doi":"10.1200/jco.2009.27.15_suppl.1041","title":"Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Chemotherapy; Internal medicine; Oncology; Tamoxifen; Percentile; Breast cancer; Cancer; Surgery","score_opus":0.14181232783530565,"score_gpt":0.47138593484849833,"score_spread":0.3295736070131927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080596891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622804,0.00044924932,0.027121011,0.008887459,0.0005601488,0.00045164232,0.00020080798,0.000014886649,0.00003439509],"genre_scores_gemma":[0.9459931,0.00034927143,0.0502464,0.002830545,0.00048622786,0.000018028059,0.000021738402,0.00001865514,0.000035984176],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99698126,0.00009278107,0.0021404366,0.00022505638,0.00029053816,0.00026993267],"domain_scores_gemma":[0.9972381,0.00061247696,0.001173004,0.0001234561,0.00062524417,0.00022773299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007317484,0.00016412055,0.0012790083,0.00014401277,0.000029725232,0.0000060296943,0.000114884395,0.00020943559,0.00002415308],"category_scores_gemma":[0.00045658648,0.00012325152,0.0002688209,0.00015627853,0.00006845236,0.00022692756,0.0000114640525,0.0005407732,0.0000010265561],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022812702,0.0022894547,0.13936695,0.000035438996,0.0004936137,0.00006827121,0.0003900869,0.006708931,0.0003828643,0.000117873344,0.0000933041,0.8272405],"study_design_scores_gemma":[0.021397168,0.005401993,0.943196,0.00048910826,0.00040988522,0.000082440085,0.000056199267,0.017937474,0.00007856972,0.010092213,0.0007355926,0.00012335552],"about_ca_topic_score_codex":0.00005595122,"about_ca_topic_score_gemma":0.00012263874,"teacher_disagreement_score":0.82711715,"about_ca_system_score_codex":0.0006755176,"about_ca_system_score_gemma":0.0015567391,"threshold_uncertainty_score":0.50260514},"labels":[],"label_agreement":null},{"id":"W3080783669","doi":"10.1200/jco.2009.27.15_suppl.9526","title":"Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Grip strength; Prospective cohort study; Cohort; Analysis of variance; Internal medicine; Repeated measures design; Physical therapy; Cancer","score_opus":0.09426715439337446,"score_gpt":0.47526946658727026,"score_spread":0.3810023121938958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080783669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363554,0.0005446115,0.000019705387,0.0044131936,0.000103507555,0.0011095055,0.0000026417401,0.000006240761,0.00016505302],"genre_scores_gemma":[0.9964129,0.0022398953,0.00033855464,0.000486729,0.0003866419,0.000043312757,0.00000866923,0.0000112458365,0.000072074945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749327,0.00042536022,0.001208535,0.00022746739,0.00043206158,0.00021330424],"domain_scores_gemma":[0.99822545,0.000645031,0.0006136594,0.00013492526,0.0002246619,0.00015625027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017267825,0.00013329106,0.0012342146,0.00017636879,0.00001975129,0.000010031328,0.0000837143,0.00011002386,0.000033208325],"category_scores_gemma":[0.00023477468,0.00007638512,0.00011281175,0.00032308104,0.000073627,0.00014599349,0.000012533716,0.00066479034,0.000003382565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028878063,0.005771792,0.8033626,0.000004099268,0.00033619298,0.00072267617,0.000642907,0.000058557085,0.00023215491,0.0000015390054,0.00008452765,0.15990485],"study_design_scores_gemma":[0.031178044,0.02590735,0.9404215,0.00008543049,0.0001878157,0.000013575416,0.0004778654,0.0004494709,0.00011097434,0.0007973186,0.00030033605,0.00007030555],"about_ca_topic_score_codex":0.0003563576,"about_ca_topic_score_gemma":0.00065757765,"teacher_disagreement_score":0.15983455,"about_ca_system_score_codex":0.00027995693,"about_ca_system_score_gemma":0.0010575232,"threshold_uncertainty_score":0.31148946},"labels":[],"label_agreement":null},{"id":"W3080835754","doi":"10.1200/jco.2009.27.15_suppl.5064","title":"Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Panobinostat; Docetaxel; Prostate cancer; Internal medicine; Neutropenia; Cohort; Febrile neutropenia; Clinical endpoint; Adverse effect; Oncology; Cancer; Chemotherapy; Clinical trial","score_opus":0.052424964516917465,"score_gpt":0.44028511698111555,"score_spread":0.3878601524641981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080835754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983598,0.00013245361,0.000030762774,0.0005306891,0.00022340618,0.00047149896,0.000026437312,0.0000016465178,0.00022330294],"genre_scores_gemma":[0.9984295,0.00018844056,0.00073420134,0.0001390225,0.000383945,0.0000073790525,0.000017828354,0.000014363795,0.000085315616],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970509,0.00036508695,0.0016062901,0.0002407307,0.00044186975,0.0002951302],"domain_scores_gemma":[0.99748486,0.00016721258,0.0013696498,0.00019188048,0.00057997956,0.00020641541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013002905,0.000153298,0.0007720329,0.0001279204,0.000037448484,0.000011335859,0.00019288086,0.00026039055,0.000016673373],"category_scores_gemma":[0.0007030587,0.00010355472,0.0001369422,0.00017309736,0.00023020194,0.000016459566,0.000023969242,0.0005551782,9.516558e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7584111,0.017411519,0.011820815,0.000037325135,0.0003307011,0.0004802322,0.00037566328,0.00040126278,0.054974064,0.000017053875,0.0012023292,0.1545379],"study_design_scores_gemma":[0.4717691,0.38910413,0.09336048,0.00027729123,0.00017104986,0.00005939796,0.00016491323,0.000021699781,0.033359844,0.00004262669,0.011258222,0.00041127205],"about_ca_topic_score_codex":0.000048263737,"about_ca_topic_score_gemma":0.00045584977,"teacher_disagreement_score":0.3716926,"about_ca_system_score_codex":0.00011047311,"about_ca_system_score_gemma":0.0023613682,"threshold_uncertainty_score":0.4222839},"labels":[],"label_agreement":null},{"id":"W3080944707","doi":"10.1200/jco.2009.27.15_suppl.5056","title":"Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Denosumab; Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Osteoporosis; Bone mineral; Surgery; Internal medicine; Incidence (geometry); Urology; Randomized controlled trial; Cancer","score_opus":0.1391858494390476,"score_gpt":0.5426261746982857,"score_spread":0.40344032525923806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080944707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878857,0.0015360462,0.00046639913,0.008688942,0.00023801374,0.0010323158,0.00000426457,0.0000030465994,0.00014525217],"genre_scores_gemma":[0.9893608,0.0026073211,0.0063137184,0.0013164701,0.0002451133,0.00003356903,0.000006121873,0.00000770214,0.000109163986],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980229,0.00011376566,0.0014871026,0.00010354848,0.00012404476,0.000148601],"domain_scores_gemma":[0.99723446,0.0009057568,0.0013795622,0.000069747206,0.0002948914,0.00011554909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015633197,0.00007085753,0.00075609965,0.000088461326,0.00002284347,0.0000022257616,0.000045289133,0.00021450638,0.000014164339],"category_scores_gemma":[0.0011960719,0.000048442213,0.00022603937,0.00006478676,0.00002317844,0.0000764773,0.0000034267546,0.00021026109,2.4000843e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015953738,0.0014224054,0.17988151,0.00003790418,0.0001321141,0.000008196776,0.00012711549,0.000016559863,0.00025544214,0.00002541189,0.0009061882,0.8012334],"study_design_scores_gemma":[0.0269027,0.023319567,0.9288833,0.00019775776,0.0001380409,0.000021230404,0.000027476814,0.00012090765,0.0014714513,0.0067863856,0.01208591,0.000045231263],"about_ca_topic_score_codex":0.000033388278,"about_ca_topic_score_gemma":0.00013504126,"teacher_disagreement_score":0.8011882,"about_ca_system_score_codex":0.00012967129,"about_ca_system_score_gemma":0.0009063819,"threshold_uncertainty_score":0.19754161},"labels":[],"label_agreement":null},{"id":"W3080988574","doi":"10.1200/jco.20.01164","title":"MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Cycle for Survival; Ovarian Cancer Research Fund Alliance; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Pfizer; Ovarian Cancer Research Fund","keywords":"Medicine; Hazard ratio; Chemotherapy; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; KRAS; Serous fluid; Chemotherapy regimen; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Confidence interval","score_opus":0.18735918239603108,"score_gpt":0.4321359889363601,"score_spread":0.24477680654032904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080988574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9098423,0.0017293687,0.0000016314099,0.08438636,0.0023077864,0.0005623753,0.000014547448,0.000008964027,0.0011466272],"genre_scores_gemma":[0.97712904,0.0045208605,0.000881414,0.014920363,0.002346603,0.000018535302,0.000003845775,0.00003852411,0.00014078326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960539,0.00050940446,0.0022024363,0.0003602712,0.00054570864,0.0003282793],"domain_scores_gemma":[0.9953664,0.0022261892,0.0014244411,0.00033087633,0.00023305861,0.00041903518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008180338,0.0002611388,0.001972653,0.000081528706,0.000043886284,0.000009649157,0.00036308717,0.0003079555,0.00018051676],"category_scores_gemma":[0.0012559528,0.00014074604,0.0010780517,0.00040371792,0.00024525874,0.00007573921,0.00009510497,0.0011144899,0.0000072301605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15220708,0.025963163,0.37741956,0.00081053,0.00469137,0.0019297939,0.0034220426,0.00009508113,0.00084057485,0.000072688104,0.033865113,0.398683],"study_design_scores_gemma":[0.04167304,0.044783384,0.7243214,0.00051002385,0.00089582126,0.00009956567,0.00051024917,0.000114872084,0.00045794068,0.00000658654,0.18643728,0.00018979376],"about_ca_topic_score_codex":0.0000828408,"about_ca_topic_score_gemma":0.00019426268,"teacher_disagreement_score":0.39849323,"about_ca_system_score_codex":0.00050003646,"about_ca_system_score_gemma":0.0028351864,"threshold_uncertainty_score":0.5739457},"labels":[],"label_agreement":null},{"id":"W3081040439","doi":"10.1200/jco.2009.27.15_suppl.4530","title":"Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Single-nucleotide polymorphism; Internal medicine; Irinotecan; Esophageal cancer; Adenocarcinoma; Nuclear medicine; Cancer; Colorectal cancer; Genotype","score_opus":0.03095420599544157,"score_gpt":0.3104222838268247,"score_spread":0.2794680778313831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081040439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966615,0.00009841424,0.00027349143,0.0014288765,0.00028980902,0.00065926096,0.00016494052,0.000009184991,0.0004145602],"genre_scores_gemma":[0.9934986,0.000035214263,0.0016626485,0.0038872587,0.0005692093,0.000018281395,0.0002775546,0.000027913871,0.000023294358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958343,0.0009233139,0.0020713173,0.00054374116,0.00031224662,0.00031508476],"domain_scores_gemma":[0.99619263,0.0014776085,0.0014046292,0.00036744995,0.00036260812,0.00019509447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013171778,0.00030413756,0.0009380362,0.000127827,0.0000681777,0.000028084307,0.0002593961,0.0005104806,0.000010492163],"category_scores_gemma":[0.0016711943,0.0001987411,0.00019368602,0.00023165437,0.00019011741,0.000025676447,0.000031949894,0.0007324667,0.0000032136734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044097755,0.004247529,0.9277879,0.0000028215368,0.00010006625,0.0002351939,0.00021721513,0.011664555,0.0004765826,0.0000059545105,0.00046185104,0.010702558],"study_design_scores_gemma":[0.030580716,0.09463636,0.86444217,0.00009933525,0.00011659434,0.000006869471,0.00009425654,0.008107414,0.001012998,0.000012455908,0.0006853803,0.00020547168],"about_ca_topic_score_codex":0.00019209197,"about_ca_topic_score_gemma":0.0023711903,"teacher_disagreement_score":0.09038883,"about_ca_system_score_codex":0.00041494434,"about_ca_system_score_gemma":0.0011843363,"threshold_uncertainty_score":0.8104427},"labels":[],"label_agreement":null},{"id":"W3081040693","doi":"10.1200/jco.2009.27.15_suppl.8102","title":"Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; KRAS; Internal medicine; Oncology; Lung cancer; T790M; Adenocarcinoma; Population; Cancer; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.04097041188195424,"score_gpt":0.4639908822884745,"score_spread":0.4230204704065203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081040693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281263,0.00009097544,0.0009624155,0.001679401,0.0012405125,0.0030154595,0.000055479966,0.0000068707823,0.00013626799],"genre_scores_gemma":[0.9929832,0.00046597823,0.004821623,0.0010576774,0.00040747796,0.00006794211,0.00009150675,0.000026709122,0.00007785309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925676,0.00031334563,0.005993579,0.00037655,0.0004013492,0.00034756257],"domain_scores_gemma":[0.99218905,0.002774674,0.0032849668,0.00019775846,0.0012617783,0.00029178703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019242215,0.00023882405,0.0022641711,0.0002610294,0.000044907018,0.000007935098,0.00016452186,0.0004364989,0.000015797923],"category_scores_gemma":[0.00390897,0.00016707004,0.0005338785,0.00043730627,0.0001132889,0.00028877886,0.000014914063,0.00085187005,3.518075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2728707,0.042477638,0.60766965,0.00005102022,0.00022819467,0.000035101642,0.00030643705,0.00025774172,0.0000056106037,0.0000021103176,0.00017813327,0.07591766],"study_design_scores_gemma":[0.3578277,0.14819467,0.49221316,0.00028339753,0.0006409159,7.174687e-7,0.000025887117,0.00019308434,0.000013362915,0.000029376508,0.00048466105,0.00009307251],"about_ca_topic_score_codex":0.000036965965,"about_ca_topic_score_gemma":0.0004778662,"teacher_disagreement_score":0.115456484,"about_ca_system_score_codex":0.0003277688,"about_ca_system_score_gemma":0.0028347524,"threshold_uncertainty_score":0.6812919},"labels":[],"label_agreement":null},{"id":"W3081126751","doi":"10.1200/jco.2009.27.15_suppl.3526","title":"Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Sorafenib; Toxicity; Cyclophosphamide; Pharmacology; Internal medicine; Urology; Oncology; Chemotherapy; Hepatocellular carcinoma","score_opus":0.06726536667610367,"score_gpt":0.47146421395119115,"score_spread":0.4041988472750875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081126751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403113,0.00015123945,0.00005570976,0.0040031658,0.00029975362,0.001058076,0.0000047854205,0.000011172343,0.00038495593],"genre_scores_gemma":[0.9933873,0.00076242426,0.005221341,0.00036878246,0.000167326,0.000011641635,0.0000115290595,0.000018285735,0.00005141053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935895,0.0008180737,0.0042764274,0.00033856765,0.00054524676,0.0004321761],"domain_scores_gemma":[0.99464715,0.0015442282,0.0028489863,0.00023121058,0.00044267598,0.00028576443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018266279,0.00023747388,0.002196388,0.000655898,0.000022283853,0.000004722986,0.00032115396,0.000048440175,0.000053905216],"category_scores_gemma":[0.004910959,0.00017672556,0.00030804635,0.0005704027,0.0003305978,0.00033267343,0.00006132293,0.0013130846,0.0000015296481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72901344,0.05053348,0.011039752,0.00010325997,0.00016267212,0.012785357,0.00004824778,0.007727864,0.071059994,0.00035396407,0.0001772868,0.11699466],"study_design_scores_gemma":[0.5770485,0.3413583,0.059855606,0.0002312385,0.00016119778,0.0012638493,0.00008068065,0.0029986335,0.015248513,0.0005865965,0.00095856574,0.0002083184],"about_ca_topic_score_codex":0.000023963956,"about_ca_topic_score_gemma":0.00006164668,"teacher_disagreement_score":0.29082483,"about_ca_system_score_codex":0.00023849544,"about_ca_system_score_gemma":0.0014205326,"threshold_uncertainty_score":0.72066593},"labels":[],"label_agreement":null},{"id":"W3081165226","doi":"10.1200/jco.2009.27.15_suppl.5121","title":"Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prostatectomy; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Urology; Regimen; Cancer; Febrile neutropenia; Prostate; Chemotherapy; Neutropenia; Clinical trial","score_opus":0.049772438768947075,"score_gpt":0.42451753496175637,"score_spread":0.37474509619280927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081165226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841208,0.005835712,0.000054833752,0.0077451896,0.0011302559,0.0007643401,0.00006717257,0.00000828234,0.00027341073],"genre_scores_gemma":[0.97738016,0.016317789,0.0039019901,0.0002061823,0.0008685867,0.000016494843,0.000006284753,0.000018730234,0.0012837651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971398,0.00039801773,0.0015114147,0.00025881728,0.000394123,0.0002977934],"domain_scores_gemma":[0.99587643,0.0019330137,0.0009894525,0.00018118767,0.0006199921,0.0003999245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026574957,0.00017058439,0.0016026332,0.00011822172,0.000084870066,0.000012022476,0.00011965061,0.0003044931,0.000018050307],"category_scores_gemma":[0.005744884,0.00010732456,0.0002919548,0.00012160108,0.0003423067,0.00016313042,0.000059173177,0.000744729,4.5900217e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06787652,0.0020518673,0.8454488,0.00019563231,0.0031847488,0.00039510147,0.0017145864,0.00002874397,0.0006933211,0.00046026762,0.009481095,0.06846934],"study_design_scores_gemma":[0.108488336,0.066901065,0.8063954,0.000586993,0.002478185,0.000046153044,0.0009092263,0.00014877324,0.0009056825,0.0037652124,0.009154414,0.00022057001],"about_ca_topic_score_codex":0.00009026088,"about_ca_topic_score_gemma":0.00006200049,"teacher_disagreement_score":0.06824876,"about_ca_system_score_codex":0.00011883804,"about_ca_system_score_gemma":0.0011966324,"threshold_uncertainty_score":0.68775773},"labels":[],"label_agreement":null},{"id":"W3081248513","doi":"10.1200/jco.2009.27.15_suppl.3591","title":"Functional imaging of neoadjuvant chemotherapy response in women with locally advanced breast cancer using diffuse optical spectroscopy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Optical Imaging and Spectroscopy Techniques","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Chemotherapy; Chemoradiotherapy; Nuclear medicine; Breast-conserving surgery; Mastectomy; Cancer; Diffuse optical imaging; Radiology; Internal medicine; Urology; Oncology; Tomography","score_opus":0.03513549779335395,"score_gpt":0.4394787267757074,"score_spread":0.4043432289823534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081248513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629387,0.00019346122,0.008409136,0.027763616,0.00017933156,0.00015922448,0.0000024418941,0.00002069637,0.00033335126],"genre_scores_gemma":[0.9214692,0.0003305077,0.07331232,0.004468562,0.00036767084,0.0000027265673,2.7532369e-7,0.000019554074,0.000029172084],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969479,0.00023966037,0.001749503,0.00023250064,0.0004322169,0.00039823228],"domain_scores_gemma":[0.99736065,0.0007970635,0.0008407331,0.00019073501,0.00043885823,0.0003719534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025053436,0.00018129118,0.0014890621,0.00023041402,0.000024308889,0.000010191463,0.00012827637,0.00017534099,0.00012464744],"category_scores_gemma":[0.00070198067,0.00012309423,0.000186387,0.00025168672,0.00039157254,0.00016550424,0.000017842458,0.0011391292,9.4568327e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4217507,0.0071856435,0.09737788,0.000029363908,0.00020712947,0.0014640308,0.00018618791,0.00028743842,0.2900404,0.00016632011,0.00042605583,0.18087886],"study_design_scores_gemma":[0.018263737,0.021041341,0.94746554,0.0006832765,0.00011437673,0.0015951794,0.00014648904,0.0017277487,0.007622459,0.00072556396,0.00044484786,0.00016944917],"about_ca_topic_score_codex":0.000012050612,"about_ca_topic_score_gemma":0.0000029484288,"teacher_disagreement_score":0.85008764,"about_ca_system_score_codex":0.00061390805,"about_ca_system_score_gemma":0.0020069166,"threshold_uncertainty_score":0.5019637},"labels":[],"label_agreement":null},{"id":"W3081302025","doi":"10.1200/jco.2009.27.15_suppl.4082","title":"Phase I study of the IXO regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), as first-line therapy for metastatic colorectal cancer: Final survival results","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Irinotecan; Capecitabine; Neutropenia; Oxaliplatin; Internal medicine; Regimen; Gastroenterology; Adverse effect; Toxicity; Phases of clinical research; Colorectal cancer; Febrile neutropenia; Vomiting; Nausea; Mucositis; Rash; Cancer; Surgery","score_opus":0.20771728861559652,"score_gpt":0.5094003698731585,"score_spread":0.301683081257562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081302025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97139394,0.0012049093,0.000020782549,0.023558363,0.001411542,0.00137301,0.00005815095,0.000008772454,0.0009705276],"genre_scores_gemma":[0.9955777,0.0016621612,0.0004224826,0.00086272846,0.0009623689,0.00004024707,0.0000038613707,0.000016220145,0.0004522133],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99559766,0.00041451413,0.00283159,0.00028819224,0.00056943553,0.00029859703],"domain_scores_gemma":[0.9933102,0.002877076,0.0025247273,0.00025079484,0.00082371593,0.00021348875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024652549,0.00024667234,0.002160238,0.00009754932,0.00015254124,0.000008095273,0.00025333953,0.00014746268,0.000059307513],"category_scores_gemma":[0.0031115955,0.00013302997,0.0006710468,0.0002771789,0.00020981966,0.00006341509,0.000045471123,0.0006067152,0.000001047126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27194768,0.07241332,0.019101186,0.000040483592,0.004046373,0.00043340144,0.0024635063,0.00016223868,0.00046276272,0.00008936924,0.008515412,0.62032425],"study_design_scores_gemma":[0.16983138,0.47275862,0.31525066,0.00013569772,0.0016376692,0.0001422148,0.0011278458,0.00015024572,0.00065500406,0.0006541251,0.037469883,0.0001866515],"about_ca_topic_score_codex":0.00021777026,"about_ca_topic_score_gemma":0.0016320914,"teacher_disagreement_score":0.62013763,"about_ca_system_score_codex":0.00023687202,"about_ca_system_score_gemma":0.0013989398,"threshold_uncertainty_score":0.54248047},"labels":[],"label_agreement":null},{"id":"W3081331636","doi":"10.1200/jco.2009.27.15_suppl.4130","title":"A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Irinotecan; Clinical endpoint; Internal medicine; Panitumumab; Colorectal cancer; Pharmacokinetics; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Adverse effect; Oncology; Nausea; Cancer; Gastroenterology; Clinical trial; Cetuximab","score_opus":0.17687572878812993,"score_gpt":0.5258757551113273,"score_spread":0.3490000263231974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081331636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182386,0.0035799774,0.000043606284,0.0115563655,0.0008719018,0.0011892165,0.00015102717,0.000003954875,0.00078010355],"genre_scores_gemma":[0.98736364,0.01046929,0.0009080562,0.0003278697,0.0006666281,0.000034755678,0.000003930443,0.000008619323,0.00021724206],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99661523,0.00021264539,0.0025147477,0.00018239062,0.0002760395,0.00019892842],"domain_scores_gemma":[0.992648,0.004517033,0.0020658018,0.00013755319,0.00047116305,0.00016046564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016794802,0.00017561269,0.002054685,0.00007386073,0.000103002785,0.0000034835775,0.00009223596,0.00012764012,0.00002877757],"category_scores_gemma":[0.0019738239,0.00008700439,0.0006505536,0.000113101254,0.000324281,0.00004541337,0.000023306919,0.00023862765,2.2192965e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4995258,0.011135572,0.0002279709,0.000019222281,0.0018432542,0.000055210672,0.000724862,0.0000073835954,0.00020739419,0.00006412472,0.0007988122,0.4853904],"study_design_scores_gemma":[0.43615,0.4746909,0.02596362,0.000091806236,0.0043931124,0.00007433348,0.0004228306,0.00014257793,0.0006260363,0.00038112493,0.056974743,0.00008891041],"about_ca_topic_score_codex":0.00010436683,"about_ca_topic_score_gemma":0.00038989144,"teacher_disagreement_score":0.4853015,"about_ca_system_score_codex":0.00024090493,"about_ca_system_score_gemma":0.001193092,"threshold_uncertainty_score":0.35479358},"labels":[],"label_agreement":null},{"id":"W3081339262","doi":"10.1200/jco.2009.27.15_suppl.519","title":"Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Epirubicin; Anthracycline; Breast cancer; Internal medicine; Cyclophosphamide; Oncology; Hazard ratio; Population; Cancer; Chemotherapy; Basal (medicine); Confidence interval","score_opus":0.09731894785661191,"score_gpt":0.479279693781526,"score_spread":0.38196074592491414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081339262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534309,0.0011789968,0.000058056325,0.04238647,0.0019221138,0.0002237818,0.000013670484,0.0000036894824,0.00078232016],"genre_scores_gemma":[0.9888286,0.0014659902,0.00048231022,0.004819723,0.0043263007,0.000011473014,0.000002767634,0.0000111930285,0.000051623785],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99728155,0.0003606591,0.0015799268,0.0002587318,0.0002163206,0.0003028367],"domain_scores_gemma":[0.9982057,0.00035485724,0.00080261927,0.00023119732,0.00022156684,0.00018405079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014869627,0.00017816611,0.0010093536,0.000060366732,0.00006784992,0.0000132028035,0.00037440174,0.00024419435,0.000023779005],"category_scores_gemma":[0.0007521213,0.00010917794,0.0003461071,0.00012622986,0.00014649707,0.000008612418,0.000111395595,0.00045237222,0.000005519025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19490145,0.0047532585,0.24928416,0.000009984814,0.0007263,0.0002658169,0.00024073156,0.00092163734,0.0027450442,0.00010388042,0.03174119,0.51430655],"study_design_scores_gemma":[0.039245486,0.0067539844,0.90940475,0.000059805807,0.00014037603,0.000146553,0.00014598564,0.000027230448,0.00043250658,0.00020147942,0.043269843,0.00017201478],"about_ca_topic_score_codex":0.0001095562,"about_ca_topic_score_gemma":0.0010595084,"teacher_disagreement_score":0.66012055,"about_ca_system_score_codex":0.00009161301,"about_ca_system_score_gemma":0.0006285302,"threshold_uncertainty_score":0.44521475},"labels":[],"label_agreement":null},{"id":"W3081446560","doi":"10.1200/jco.2009.27.15_suppl.9591","title":"Evaluation of the Edmonton Symptoms Assesment Scale (ESAS) symptoms improvement (SI) assessment as a prognostic factor for survival in advanced cancer patients (pts) undergoing palliative care (PC): An observational prospective study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; McNemar's test; Observational study; Internal medicine; Cancer; Proportional hazards model; Lung cancer; Prospective cohort study; Performance status; Palliative care","score_opus":0.15188344493183975,"score_gpt":0.5150371920618424,"score_spread":0.36315374713000265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081446560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922043,0.00019522726,0.00009886789,0.0008511609,0.002044529,0.0042115767,0.00004484387,0.0000069069565,0.00034256463],"genre_scores_gemma":[0.9984953,0.000047696838,0.00024929497,0.00046635265,0.0004078452,0.0002771209,0.00001555552,0.000018344666,0.000022534367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942452,0.00097322394,0.002160576,0.0003880392,0.001951295,0.00028167907],"domain_scores_gemma":[0.9914723,0.0014015546,0.002208082,0.00024534194,0.0044773426,0.00019537895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036602959,0.00022689615,0.0011599417,0.000106572974,0.000078931254,0.000015824337,0.00023409129,0.0002156284,0.000047282796],"category_scores_gemma":[0.002354513,0.00015281749,0.00037457643,0.00026215945,0.000072669674,0.0002289912,0.0000512614,0.0006290602,2.8147875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0018793216,0.005837166,0.8354686,0.000041004405,0.00034682598,0.000002776628,0.002237805,0.00035663968,0.000111210415,0.00006259461,0.0000049427285,0.15365112],"study_design_scores_gemma":[0.019852502,0.056907024,0.91424096,0.00034992897,0.00096091424,6.20041e-7,0.0062806234,0.00059120887,0.000101940444,0.0005133802,0.00006605436,0.00013484158],"about_ca_topic_score_codex":0.00026272272,"about_ca_topic_score_gemma":0.021783732,"teacher_disagreement_score":0.15351628,"about_ca_system_score_codex":0.0039481716,"about_ca_system_score_gemma":0.0066914815,"threshold_uncertainty_score":0.9998755},"labels":[],"label_agreement":null},{"id":"W3081488978","doi":"10.1200/jco.2009.27.15_suppl.2073","title":"A comprehensive view of the structure and expression of the ependymoma genome at presentation and relapse","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Biology; Gene; Ependymoma; microRNA; Comparative genomic hybridization; Gene expression; Gene expression profiling; DNA microarray; Fluorescence in situ hybridization; Genetics; Cancer research; Microarray; Genome; Pathology; Medicine; Chromosome","score_opus":0.043902365048298676,"score_gpt":0.40998399534914426,"score_spread":0.36608163030084556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081488978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480075,0.003301056,0.00017844036,0.0012417088,0.0002098104,0.00017985418,0.000008470399,4.586825e-7,0.00007947133],"genre_scores_gemma":[0.9975341,0.0014218773,0.00042983165,0.00042464316,0.000110808796,4.3604044e-7,0.0000014449283,0.0000055273244,0.000071355775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831086,0.00052854174,0.00071413943,0.00013019114,0.00021996575,0.0000963165],"domain_scores_gemma":[0.9984191,0.00014590731,0.00088523875,0.00021474047,0.00026072504,0.00007428073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042448254,0.000074816715,0.00035961586,0.000022356087,0.00004522707,0.0000033852182,0.00021145088,0.00028915826,0.000014270041],"category_scores_gemma":[0.00056562107,0.000040367308,0.00016653446,0.000064458516,0.00023962145,0.000004375193,0.00023962969,0.00035084892,9.3610126e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007214597,0.000066923516,0.00045889028,0.000020453464,0.000048681777,0.000006580403,0.000045956316,0.00007506256,0.98357505,0.000030279136,0.00024011516,0.01471053],"study_design_scores_gemma":[0.0032343462,0.0043182448,0.18654591,0.00009487403,0.00010054762,0.00048438786,0.00006833475,0.000040401846,0.7837638,0.0010702044,0.02019524,0.00008367909],"about_ca_topic_score_codex":0.0000032781033,"about_ca_topic_score_gemma":0.000010645725,"teacher_disagreement_score":0.19981125,"about_ca_system_score_codex":0.000017062343,"about_ca_system_score_gemma":0.00023106822,"threshold_uncertainty_score":0.22302532},"labels":[],"label_agreement":null},{"id":"W3083966623","doi":"10.1200/jco.19.03205","title":"Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Agence Nationale de la Recherche","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Colorectal cancer; Stage (stratigraphy); Cohort; Chemotherapy; Proportional hazards model; Cancer; Immunotherapy; Confidence interval","score_opus":0.13079305623513682,"score_gpt":0.4778639689212401,"score_spread":0.3470709126861033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083966623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657359,0.0010695752,0.0001032099,0.030219566,0.0012443956,0.0014726077,0.0001450261,0.0000016049149,0.000008121566],"genre_scores_gemma":[0.9947076,0.0023357538,0.00035352138,0.002169535,0.00025833328,0.000053394368,6.846534e-7,0.000012952583,0.00010826979],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99758667,0.0002122291,0.0017187805,0.00012686518,0.00024958738,0.00010584436],"domain_scores_gemma":[0.9944772,0.0032391204,0.0015688253,0.00012913067,0.0005380259,0.0000476578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027372073,0.00009498674,0.0008296809,0.00003823731,0.000030496327,0.0000029451317,0.0002074693,0.00013683841,0.00004364508],"category_scores_gemma":[0.00074556743,0.000053019652,0.00048624675,0.0001344041,0.00025610407,0.000023740802,0.00003118018,0.0002653595,1.7123114e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58107346,0.0018561155,0.21357504,0.00008268934,0.003155708,0.0000015844925,0.008318295,0.0001462341,0.15435955,0.000004569992,0.0022333043,0.03519344],"study_design_scores_gemma":[0.07249534,0.020174827,0.8595287,0.00019557605,0.00027396216,0.000002754545,0.0067969626,0.0012741805,0.0044234293,0.0000056717863,0.034770433,0.00005815525],"about_ca_topic_score_codex":0.0004375615,"about_ca_topic_score_gemma":0.00048689707,"teacher_disagreement_score":0.64595366,"about_ca_system_score_codex":0.0001433748,"about_ca_system_score_gemma":0.00097034004,"threshold_uncertainty_score":0.21620786},"labels":[],"label_agreement":null},{"id":"W3085379405","doi":"10.1200/jco.20.00131","title":"Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"","keywords":"Medicine; Nivolumab; Population; Internal medicine; Progression-free survival; Lung cancer; Hazard ratio; Surgery; Continuous variable; Cancer; Oncology; Chemotherapy; Immunotherapy; Confidence interval","score_opus":0.06764736034788141,"score_gpt":0.41848049003450555,"score_spread":0.35083312968662417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085379405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836813,0.0023851178,0.000059389367,0.009519853,0.0013004153,0.0005035969,0.0000044862236,0.000017565519,0.0025282726],"genre_scores_gemma":[0.9876652,0.006654013,0.0011747192,0.0031593775,0.0009728355,0.000013645021,0.000005774303,0.000026047153,0.0003284171],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996617,0.00026037722,0.0023684471,0.00023516752,0.00023749241,0.00028151672],"domain_scores_gemma":[0.9970262,0.0006047553,0.0016418212,0.00014128078,0.00027689795,0.0003090584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012576607,0.0001677685,0.001385542,0.00008506509,0.00002971603,0.000011581527,0.00016963894,0.00036890118,0.00028131434],"category_scores_gemma":[0.0009771626,0.00013249529,0.00044599746,0.0002756169,0.000100554746,0.00011775097,0.000029518054,0.00084217486,0.0000115299845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29983154,0.0020312485,0.26079008,0.0003330475,0.0011824896,0.0014660883,0.0014072186,0.00013107409,0.024701586,0.000006491439,0.014112803,0.39400634],"study_design_scores_gemma":[0.29760227,0.084923565,0.38212267,0.0011401104,0.0019839073,0.00017120426,0.001576017,0.0035298178,0.008711043,0.0000139038275,0.21754012,0.0006853952],"about_ca_topic_score_codex":0.00014595022,"about_ca_topic_score_gemma":0.0003142115,"teacher_disagreement_score":0.39332095,"about_ca_system_score_codex":0.0003717291,"about_ca_system_score_gemma":0.0016082836,"threshold_uncertainty_score":0.54030013},"labels":[],"label_agreement":null},{"id":"W3086164260","doi":"10.1200/jco.20.01255","title":"Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":467,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Internal medicine; Oncology; Brain metastasis; Lung cancer; Clinical trial; Overall survival; Cancer; Metastasis","score_opus":0.15151153055419755,"score_gpt":0.4268679492283408,"score_spread":0.2753564186741433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086164260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584365,0.000108593435,0.000026865084,0.040116664,0.0002862952,0.0007718389,0.000026672415,0.000003544078,0.00022303549],"genre_scores_gemma":[0.9954051,0.00014197761,0.0012199754,0.0030751424,0.00009940589,0.000016017902,0.00002926087,0.000010713519,0.000002401447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99532366,0.0017384088,0.0019319308,0.0002476797,0.00060183107,0.00015648607],"domain_scores_gemma":[0.99226403,0.005248941,0.0016998858,0.00028077472,0.00030129918,0.00020506649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004360056,0.0001469622,0.0010419178,0.000044778997,0.000042522854,0.000008403308,0.00011955676,0.00010772651,0.000049357837],"category_scores_gemma":[0.0039091343,0.000063132,0.00026127623,0.00023770942,0.00028087804,0.00004838202,0.00006624946,0.0007569205,9.0989346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030292969,0.0046563214,0.9826955,0.000022384653,0.00034180548,0.00041229086,0.000050022783,0.000009356773,0.000002686592,0.00083001057,0.0028115057,0.0051388075],"study_design_scores_gemma":[0.007981393,0.016950812,0.96996796,0.00013864404,0.00037632696,0.000039941595,0.00012881139,0.000008080519,0.00002206155,0.00044195162,0.0038872906,0.000056753877],"about_ca_topic_score_codex":0.000014520665,"about_ca_topic_score_gemma":0.000029393623,"teacher_disagreement_score":0.03704152,"about_ca_system_score_codex":0.00011630165,"about_ca_system_score_gemma":0.0006531686,"threshold_uncertainty_score":0.46798813},"labels":[],"label_agreement":null},{"id":"W3087401339","doi":"10.1200/jco.20.02110","title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Population; Oncology; Melanoma; Lymph node; Cancer; Stage (stratigraphy); Surgery; Gastroenterology; Pathology; Immunotherapy; Confidence interval; Cancer research","score_opus":0.11065833192108306,"score_gpt":0.39444315962501014,"score_spread":0.2837848277039271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087401339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673995,0.001144064,0.00005589148,0.023743564,0.005606128,0.0006179881,0.00049915095,0.000014510778,0.0009192232],"genre_scores_gemma":[0.9908791,0.0031027119,0.0003770405,0.0023273705,0.0029519538,0.0000049532064,0.00007326034,0.000028761411,0.00025485674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99145526,0.0012526681,0.0056196824,0.00044248076,0.00083306286,0.00039685823],"domain_scores_gemma":[0.98767143,0.0062605324,0.004553722,0.00064994796,0.00047721688,0.00038713947],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065674894,0.00029015983,0.0029957076,0.00010583875,0.00005982171,0.000018138093,0.00081857195,0.00069040037,0.000685111],"category_scores_gemma":[0.009787506,0.00017636394,0.000993767,0.0004166983,0.00048115652,0.000127498,0.00016746907,0.002102517,0.000010754443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88802373,0.001109184,0.016001882,0.000013805645,0.0012414395,0.0004920474,0.00090393424,0.000021044909,0.00029942492,0.00007820051,0.0156096835,0.07620562],"study_design_scores_gemma":[0.60666174,0.031021638,0.2884036,0.00021237269,0.00084822596,0.000027686485,0.00066341506,0.00020258494,0.0002354801,0.00043310394,0.07104573,0.00024443222],"about_ca_topic_score_codex":0.0026322622,"about_ca_topic_score_gemma":0.002712057,"teacher_disagreement_score":0.281362,"about_ca_system_score_codex":0.00017515098,"about_ca_system_score_gemma":0.002066949,"threshold_uncertainty_score":0.99855345},"labels":[],"label_agreement":null},{"id":"W3088078660","doi":"10.1200/jco.20.00948","title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"National Cancer Institute; University of California, San Diego; University of Texas MD Anderson Cancer Center; National Institutes of Health; Apellis Pharmaceuticals; BeiGene; National Comprehensive Cancer Network; University of Nebraska Medical Center; Universiteit van Amsterdam; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine; AstraZeneca; Loxo Oncology; TG Therapeutics; Amgen; Breast Cancer Research Foundation","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Rituximab; Chronic lymphocytic leukemia; Regimen; Hazard ratio; Oncology; Progression-free survival; Gastroenterology; Alemtuzumab; Minimal residual disease; Leukemia; Chemotherapy; Lymphoma; Confidence interval; Transplantation","score_opus":0.27852723156453724,"score_gpt":0.5228803570445849,"score_spread":0.24435312548004767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088078660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964168,0.0016411791,0.000022724682,0.00064593315,0.00010950901,0.0010048255,0.00005182113,0.0000037784894,0.00010341522],"genre_scores_gemma":[0.99859136,0.00044784884,0.0003806354,0.000115512215,0.00042440748,0.000006615598,0.0000145204485,0.000015223579,0.0000038523876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99431777,0.0015022448,0.0028879684,0.00028432373,0.00078428455,0.00022341024],"domain_scores_gemma":[0.9925478,0.004629144,0.0016316331,0.000286228,0.0005931233,0.0003120403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070667746,0.00014888587,0.0016463307,0.00010853458,0.00004245369,0.000008198866,0.00021196608,0.00024665604,0.00007447821],"category_scores_gemma":[0.0068065724,0.00009791143,0.0002426684,0.0002396445,0.0006946064,0.0000682865,0.00013689263,0.0007586842,0.0000034682357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5136901,0.010144687,0.046756145,0.00063625554,0.010780449,0.00308753,0.040894475,0.15491591,0.046118036,0.000110255416,0.0036753106,0.16919082],"study_design_scores_gemma":[0.44077137,0.023990497,0.19142298,0.00009390489,0.00092382147,0.00014204366,0.00083003973,0.34134543,0.000109345216,0.0002651792,0.000032876247,0.00007251453],"about_ca_topic_score_codex":0.0040621264,"about_ca_topic_score_gemma":0.0006035519,"teacher_disagreement_score":0.1864295,"about_ca_system_score_codex":0.045978792,"about_ca_system_score_gemma":0.12630308,"threshold_uncertainty_score":0.9576835},"labels":[],"label_agreement":null},{"id":"W3090469545","doi":"10.1200/jco.20.00995","title":"Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University; University of British Columbia; BC Cancer Agency","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Melanoma; Oncology; Internal medicine; Metastatic melanoma; Ipilimumab; Cancer research; Cancer; Immunotherapy","score_opus":0.029349432258848444,"score_gpt":0.3323646425640745,"score_spread":0.30301521030522605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090469545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661756,0.000082151884,0.00010552452,0.0013785813,0.0003158374,0.0001427555,0.000005271531,0.0000039673405,0.0013483325],"genre_scores_gemma":[0.9930516,0.00006376246,0.0034514286,0.0029507817,0.00032575193,0.0000017560031,0.000013589097,0.000020585909,0.000120783196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813807,0.00020730791,0.00095839816,0.0002508349,0.0002290319,0.00021635697],"domain_scores_gemma":[0.99831975,0.00013662773,0.0008011399,0.0001742759,0.00029298244,0.0002752184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004175025,0.00015583073,0.00080108683,0.0000354453,0.000022845135,0.00000690355,0.00025657794,0.00027046434,0.000026441174],"category_scores_gemma":[0.0008369702,0.00009853877,0.000142632,0.00011500934,0.00011083969,0.000012616293,0.00007018324,0.00043098885,0.000011422409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010034859,0.00059888675,0.97602886,0.000010272061,0.00017681491,0.0001294032,0.000045646782,0.00009188448,0.0005786257,0.00002378343,0.0018709421,0.010410012],"study_design_scores_gemma":[0.018591339,0.060705174,0.85153806,0.000028559753,0.00007131189,0.00001609894,0.00009100756,0.0000067718647,0.0006033509,0.000020643134,0.06812043,0.0002072691],"about_ca_topic_score_codex":0.0000047600897,"about_ca_topic_score_gemma":0.000060939135,"teacher_disagreement_score":0.12449082,"about_ca_system_score_codex":0.000019200119,"about_ca_system_score_gemma":0.0006083183,"threshold_uncertainty_score":0.40182942},"labels":[],"label_agreement":null},{"id":"W3090930865","doi":"10.1200/jco.20.01566","title":"Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Okanagan University College; University of British Columbia; Western University","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Oncology; Prostate; Androgen; Cancer; Internal medicine; Gynecology; Urology; Radiation therapy; Hormone","score_opus":0.0768048921112965,"score_gpt":0.4319979745032296,"score_spread":0.3551930823919331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090930865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8229798,0.0015358679,0.000010916261,0.17425212,0.00042470213,0.0007327018,0.000048937447,0.000007692037,0.0000072409034],"genre_scores_gemma":[0.5005648,0.15915622,0.0016464248,0.3341501,0.004013153,0.00004823175,0.00013937583,0.00011528303,0.00016639511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962016,0.00061804656,0.0017566794,0.00045859822,0.0006461186,0.0003189707],"domain_scores_gemma":[0.99524105,0.0018669094,0.0018864506,0.00019854151,0.0004672832,0.00033978673],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011190567,0.0003053446,0.0018661945,0.00025941434,0.000056793782,0.00004158656,0.00016302246,0.00079738075,0.00006289554],"category_scores_gemma":[0.0006524234,0.00015978428,0.000118460805,0.00019238645,0.00037074886,0.00024507858,0.000054942637,0.003329259,0.0000014276025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05871002,0.00040726984,0.46956924,0.000040179842,0.00034269714,0.00111987,0.0002078836,8.787218e-7,0.0000026710654,2.389644e-7,0.010579645,0.4590194],"study_design_scores_gemma":[0.045651294,0.06740443,0.75769943,0.0004178521,0.00020204003,0.00004098138,0.000028886132,0.000034049972,0.00002103425,0.00022757311,0.1280887,0.00018376076],"about_ca_topic_score_codex":0.00013135347,"about_ca_topic_score_gemma":0.00015564742,"teacher_disagreement_score":0.45883563,"about_ca_system_score_codex":0.00019168285,"about_ca_system_score_gemma":0.001571316,"threshold_uncertainty_score":0.9989701},"labels":[],"label_agreement":null},{"id":"W3091774332","doi":"10.1200/jco.2020.38.29_suppl.93","title":"Eligibility of real-world patients with metastatic lung cancer for clinical trial participation: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Internal medicine; Odds ratio; Population; Confidence interval; Clinical trial; Immunosuppression; Anemia; Cancer; Renal function; Surgery","score_opus":0.744805996341694,"score_gpt":0.73683195274419,"score_spread":0.007974043597503977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091774332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734078,0.00007183218,0.0031522033,0.021221403,0.0006448222,0.0012498619,0.000039891394,0.000009541721,0.00020266215],"genre_scores_gemma":[0.97869784,0.00025098046,0.015476651,0.0041638273,0.0012664638,0.000039707367,0.000030843843,0.00002097725,0.00005273393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9879276,0.001758828,0.008075058,0.00045161144,0.001482381,0.00030448],"domain_scores_gemma":[0.88654596,0.10127078,0.005785615,0.0004813147,0.004814797,0.0011015633],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.023370458,0.0001661858,0.0036313622,0.00020984511,0.000048421276,0.000010457015,0.0003034064,0.00047353646,0.00030704617],"category_scores_gemma":[0.16433282,0.000108431515,0.0016910197,0.000956275,0.00044838147,0.000092208815,0.00005551489,0.0024013293,0.0000016853428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18152288,0.0036314933,0.8042923,0.00020340296,0.0026427372,0.00001555712,0.000027140592,0.00054414116,4.4212538e-7,0.00022845574,0.0006674208,0.0062240316],"study_design_scores_gemma":[0.09310793,0.030409591,0.8609046,0.00010330397,0.007063756,1.6399852e-7,0.000010580637,0.006738778,0.0000050872327,0.00070928293,0.00085617945,0.00009074591],"about_ca_topic_score_codex":0.00016207661,"about_ca_topic_score_gemma":0.0019327312,"teacher_disagreement_score":0.14096236,"about_ca_system_score_codex":0.00018496705,"about_ca_system_score_gemma":0.006414293,"threshold_uncertainty_score":0.99990016},"labels":[],"label_agreement":null},{"id":"W3091846264","doi":"10.1200/jco.2020.38.29_suppl.41","title":"Assessing burnout among oncologists in Ontario, Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Western University; St. Michael's Hospital; University of Toronto; Queen's University; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Burnout; Emotional exhaustion; Medicine; Depersonalization; Family medicine; Feeling; Logistic regression; Nursing; Clinical psychology; Psychology","score_opus":0.1498036770650328,"score_gpt":0.5199886008350653,"score_spread":0.3701849237700324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091846264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517665,0.00041658137,0.00065485714,0.028248703,0.002677379,0.00014100436,4.8306595e-7,0.000007669078,0.016086819],"genre_scores_gemma":[0.95963603,0.00023296886,0.011488362,0.026459053,0.0018478194,0.0000015812294,0.0000012122636,0.000013068991,0.00031987458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964616,0.0004341588,0.0023286515,0.00020024384,0.00030757883,0.00026779718],"domain_scores_gemma":[0.99472076,0.0028079764,0.0016009915,0.000117126736,0.00021161702,0.0005415409],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002016383,0.00013475501,0.0017578107,0.000061886945,0.00003730468,0.000007317833,0.0002080711,0.00052245235,0.0005496907],"category_scores_gemma":[0.0050656428,0.0000967467,0.000247084,0.0001528497,0.000352478,0.00022289847,0.00003550818,0.0027136467,0.0000033536526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002049389,0.0005505936,0.9065538,0.000012193472,0.00014545221,0.007686716,0.00022121084,0.00017305139,0.000047521473,0.000036532554,0.0083965985,0.07412694],"study_design_scores_gemma":[0.0049784593,0.0048730806,0.70403594,0.000055871933,0.00007104541,0.00029400396,0.0002036296,0.000083728424,0.000009761476,0.000107158434,0.28521457,0.00007272411],"about_ca_topic_score_codex":0.17536664,"about_ca_topic_score_gemma":0.9291976,"teacher_disagreement_score":0.75383097,"about_ca_system_score_codex":0.0015780402,"about_ca_system_score_gemma":0.021809796,"threshold_uncertainty_score":0.9995871},"labels":[],"label_agreement":null},{"id":"W3091848917","doi":"10.1200/jco.2020.38.29_suppl.184","title":"Improving the quality of oral cancer drug delivery across a health system.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Documentation; Coaching; Quality management; Baseline (sea); Quality (philosophy); Health care; Cancer; Family medicine; Management system; Operations management; Internal medicine","score_opus":0.27198299979127166,"score_gpt":0.47111583637004356,"score_spread":0.1991328365787719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091848917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95018107,0.008303038,0.0013146978,0.035576273,0.002426147,0.00016370455,0.00016198203,0.000008587218,0.0018644764],"genre_scores_gemma":[0.9877684,0.0016792521,0.0006510641,0.008686829,0.0011370158,0.0000033596264,4.90426e-7,0.0000144352725,0.000059152193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99408245,0.00020988392,0.005086573,0.00021829309,0.000064545704,0.00033822475],"domain_scores_gemma":[0.98948437,0.0008447333,0.008943441,0.00018635586,0.00020217152,0.00033891964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010443438,0.00012185246,0.0021282125,0.000036406487,0.000087691726,0.000022838605,0.00048177384,0.00018729597,0.00007917348],"category_scores_gemma":[0.002439752,0.000093197435,0.0005839631,0.00012723355,0.00023119102,0.0002659068,0.00010581869,0.000706877,0.000034358527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029589096,0.00056995155,0.46258488,0.00054388907,0.0007346012,0.000026723521,0.004461446,0.0005016065,0.00002997732,0.046375036,0.02793341,0.45327955],"study_design_scores_gemma":[0.0077700606,0.004047009,0.59213287,0.00012100304,0.000048641145,0.000018217203,0.0025980417,0.0022435917,0.000039086943,0.0026356096,0.38795897,0.00038689314],"about_ca_topic_score_codex":0.0046388614,"about_ca_topic_score_gemma":0.0008002096,"teacher_disagreement_score":0.45289266,"about_ca_system_score_codex":0.00032670845,"about_ca_system_score_gemma":0.0012709744,"threshold_uncertainty_score":0.70126015},"labels":[],"label_agreement":null},{"id":"W3091878497","doi":"10.1200/jco.2020.38.29_suppl.54","title":"Process of the integration of patient advisors in oncology: Patient advisors' views.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"General partnership; Medicine; Health care; Qualitative research; Schedule; Presentation (obstetrics); Medical education; Health professionals; Facilitator; Nursing; Family medicine; Psychology","score_opus":0.40883452586702074,"score_gpt":0.5876585085033473,"score_spread":0.1788239826363266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091878497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521843,0.00016034213,0.00021773424,0.045032546,0.0009770901,0.0006119114,0.0000058813307,0.0000043280593,0.0008058749],"genre_scores_gemma":[0.98581415,0.00032517078,0.0030601404,0.010426004,0.00034302357,0.0000071897944,0.000004149471,0.000014977041,0.000005202004],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9887934,0.001432544,0.0087138675,0.00021356343,0.00066669704,0.00017995783],"domain_scores_gemma":[0.98319227,0.0060351207,0.008910495,0.00022773852,0.0013604889,0.00027389763],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042652404,0.00014735694,0.0017356444,0.000112112466,0.00001933723,0.0000024113306,0.00025050182,0.000374319,0.0001659557],"category_scores_gemma":[0.068119496,0.00008913477,0.00056354783,0.00047017675,0.0002682983,0.00018601413,0.00010991936,0.0015015479,0.0000060696934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009888227,0.005037307,0.10890288,0.00015437842,0.00020545853,0.00008289705,0.004898398,0.0004236588,0.0015644387,0.00007847457,0.0049142777,0.8638496],"study_design_scores_gemma":[0.034325108,0.17034501,0.5099064,0.0013529416,0.0018753457,0.00028732547,0.029844407,0.003413306,0.008991742,0.0020222007,0.23723005,0.00040613706],"about_ca_topic_score_codex":0.000049750855,"about_ca_topic_score_gemma":0.00018755624,"teacher_disagreement_score":0.8634435,"about_ca_system_score_codex":0.00017942244,"about_ca_system_score_gemma":0.002905022,"threshold_uncertainty_score":0.9397301},"labels":[],"label_agreement":null},{"id":"W3091975324","doi":"10.1200/jco.20.01980","title":"Valete et Plaudite","year":2020,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Renaissance Literature and Culture","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine","score_opus":0.2556130187689464,"score_gpt":0.45728729863381773,"score_spread":0.20167427986487135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091975324","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023461951,0.06310291,0.0000820358,0.5939396,0.02011693,0.00012414147,0.000054061897,0.00001570173,0.2991027],"genre_scores_gemma":[0.40336388,0.026667137,0.0031417862,0.29822043,0.16312923,0.0000030463857,0.000014277064,0.00007902126,0.10538118],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957436,0.0009199915,0.0025438352,0.00019084687,0.0003298752,0.00027189247],"domain_scores_gemma":[0.9951408,0.0012944203,0.0023357768,0.000112870315,0.00055449497,0.0005616451],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020151706,0.00019666953,0.0014905038,0.000032705477,0.000114885646,0.0001424194,0.0003381886,0.00060684176,0.0032252537],"category_scores_gemma":[0.0018285486,0.00013589983,0.0009376037,0.000056675348,0.00061139336,0.0004995844,0.00005781421,0.0026469545,0.00034540144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009034793,0.0006843074,0.0003953153,0.00009232974,0.00051051937,0.0010459652,0.009990193,0.00001247478,0.000018149745,0.11358156,0.824818,0.047947697],"study_design_scores_gemma":[0.0019613514,0.009291961,0.0009834766,0.00023481475,0.00035479924,0.000094779956,0.0007576074,0.00002578311,0.000007895329,0.0024198948,0.9837158,0.00015186888],"about_ca_topic_score_codex":0.00000961759,"about_ca_topic_score_gemma":0.00003740044,"teacher_disagreement_score":0.37990195,"about_ca_system_score_codex":0.000032740983,"about_ca_system_score_gemma":0.0007317017,"threshold_uncertainty_score":0.999654},"labels":[],"label_agreement":null},{"id":"W3092021101","doi":"10.1200/jco.2020.38.29_suppl.99","title":"Access to palliative care services for limited English proficient patients with advanced NSCLC.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Health Services Authority","funders":"","keywords":"Medicine; Limited English proficiency; Referral; Palliative care; Family medicine; Advance care planning; Health literacy; Health care; Nursing","score_opus":0.27214429918728683,"score_gpt":0.5976112244398761,"score_spread":0.3254669252525893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092021101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963087,0.00016699538,0.0006750895,0.028868105,0.0022938736,0.0017109634,0.0000514349,0.000036837395,0.0031096593],"genre_scores_gemma":[0.9570638,0.000052839736,0.0065926625,0.035097606,0.0009985483,0.00013014291,0.000019437492,0.000022686763,0.000022278104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954572,0.001347956,0.0023488284,0.00022029885,0.00029975176,0.00032598205],"domain_scores_gemma":[0.98413557,0.0059112515,0.002682445,0.00024925836,0.0064985957,0.0005228544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012443387,0.00013134532,0.00086701673,0.00006367614,0.00031365387,0.000011338062,0.00079398917,0.00034045673,0.000047589674],"category_scores_gemma":[0.007289534,0.00008926368,0.00017042535,0.00022272462,0.000047653524,0.00015716304,0.00023764595,0.0014426337,0.000016463282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016721124,0.0004669681,0.8329086,0.00079137116,0.00012452471,0.0000039726,0.074220635,0.00022860031,0.000001954969,0.0001848318,0.0045338445,0.069813624],"study_design_scores_gemma":[0.010238325,0.026423272,0.53856915,0.0015818028,0.00011468041,1.5233812e-7,0.05116737,0.00025731747,0.0000109394805,0.00007578077,0.37134036,0.00022084599],"about_ca_topic_score_codex":0.000015797961,"about_ca_topic_score_gemma":0.000107137086,"teacher_disagreement_score":0.36680654,"about_ca_system_score_codex":0.00020448402,"about_ca_system_score_gemma":0.0014861628,"threshold_uncertainty_score":0.872678},"labels":[],"label_agreement":null},{"id":"W3092023809","doi":"10.1200/jco.2020.38.29_suppl.21","title":"Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Trillium Health Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Lung cancer; Comorbidity; Internal medicine; Medical diagnosis; Pharmacy; COPD; Disease; Emergency medicine; Palliative care; Intensive care medicine; Family medicine","score_opus":0.1782562831017295,"score_gpt":0.5098065614300716,"score_spread":0.33155027832834216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092023809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564619,0.00011630241,0.00019786153,0.040239103,0.0013054301,0.00025564796,0.0000104167775,0.0000059109498,0.0014074094],"genre_scores_gemma":[0.9784582,0.00034471718,0.000643474,0.01872212,0.0016274903,0.000006049813,0.000002742114,0.00001422015,0.00018093511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997195,0.00007987778,0.001964611,0.00018695825,0.0003879924,0.00018555552],"domain_scores_gemma":[0.9972592,0.00036567898,0.0010601388,0.00010298899,0.00040864715,0.0008033559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051902677,0.00014190353,0.0017487549,0.00011059978,0.000015955336,0.0000067346123,0.00018156921,0.000094415984,0.00040953662],"category_scores_gemma":[0.0021573363,0.000098642864,0.00015859609,0.00013790154,0.00012456486,0.000060555267,0.00018346481,0.0003985604,0.0000066475604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029221196,0.00040905157,0.9403051,0.000114978,0.00058916555,0.00007958539,0.00030875628,0.00003069302,0.0001421397,0.000030142275,0.0160972,0.03897106],"study_design_scores_gemma":[0.0070601683,0.0069598095,0.9595731,0.00032166508,0.0005687491,0.0000023169475,0.000089878195,0.00042697604,0.000018930054,0.000012790596,0.024885243,0.00008037808],"about_ca_topic_score_codex":0.00016328339,"about_ca_topic_score_gemma":0.000067320296,"teacher_disagreement_score":0.03889068,"about_ca_system_score_codex":0.00012199086,"about_ca_system_score_gemma":0.00048807,"threshold_uncertainty_score":0.44841388},"labels":[],"label_agreement":null},{"id":"W3092071269","doi":"10.1200/jco.2020.38.29_suppl.224","title":"Improving medication reconciliation in ambulatory cancer care.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; PDCA; Pharmacy; Ambulatory; Adverse effect; Documentation; Ambulatory care; Medical record; Family medicine; Emergency medicine; Quality management; Health care; Internal medicine","score_opus":0.475014555081775,"score_gpt":0.5929106917150136,"score_spread":0.11789613663323867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092071269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374134,0.0017738923,0.0002601771,0.057232432,0.0014791267,0.00015765698,0.0000011192357,0.000006936021,0.0016752777],"genre_scores_gemma":[0.9745208,0.0011102193,0.0013809614,0.021638911,0.0013221579,0.0000019541098,0.0000013820288,0.00000622112,0.00001739291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781644,0.00022303854,0.0014913338,0.00010802577,0.00025501178,0.00010611952],"domain_scores_gemma":[0.9968468,0.0012545711,0.0012795079,0.000056363042,0.00021959652,0.0003431391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014824958,0.000058767353,0.0006122419,0.000039257535,0.000012626547,0.0000031492136,0.000071853116,0.00019534279,0.00019938113],"category_scores_gemma":[0.0059811464,0.000042925516,0.00020420502,0.00009858858,0.000049594208,0.00016380816,0.000021372522,0.00094560505,0.000011824174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019580438,0.00020081937,0.52806,0.00009098247,0.000073084804,0.00007592629,0.000576504,0.0000295202,0.00040440637,0.00001624477,0.0011857975,0.46732867],"study_design_scores_gemma":[0.012197116,0.006190102,0.60363734,0.00011173677,0.00045603456,0.000030910393,0.0006985724,0.011918296,0.00022944988,0.00004174694,0.36438456,0.00010413489],"about_ca_topic_score_codex":0.000035596375,"about_ca_topic_score_gemma":0.00002779741,"teacher_disagreement_score":0.4672245,"about_ca_system_score_codex":0.00016745705,"about_ca_system_score_gemma":0.0012784085,"threshold_uncertainty_score":0.7160423},"labels":[],"label_agreement":null},{"id":"W3092071285","doi":"10.1200/jco.2020.38.29_suppl.207","title":"Comparing cancer survivors' perceptions on lifestyle behaviors between adolescent-young adult (AYA) and middle-aged patients (pts).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Wellbeing Research","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Logistic regression; Survivorship curve; Young adult; Alcohol consumption; Cancer; Demography; Cancer survivorship; Quality of life (healthcare); Gerontology; Physical activity; Univariate analysis; Internal medicine; Alcohol; Multivariate analysis; Physical therapy","score_opus":0.3396067898766038,"score_gpt":0.569611104131684,"score_spread":0.23000431425508022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092071285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807143,0.000059433165,0.000046264617,0.01602691,0.0016937711,0.00047740937,0.000027112621,0.000021144997,0.0009336433],"genre_scores_gemma":[0.9866735,0.0008157932,0.00020554851,0.008926847,0.0031824007,0.000016526506,0.000008704974,0.000028816346,0.00014191092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99217767,0.003230341,0.0030262824,0.0002970834,0.0005976024,0.0006710258],"domain_scores_gemma":[0.990814,0.0049467958,0.0014981182,0.0001609855,0.00081420527,0.0017658984],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003947147,0.00017363904,0.0013391091,0.00012105063,0.0005455659,0.000011027393,0.0003124777,0.0006358406,0.00030544368],"category_scores_gemma":[0.007166018,0.00013595416,0.00022057662,0.0001908149,0.00018907155,0.0001279917,0.00016917818,0.004797293,0.00016910948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080572924,0.00052203395,0.97670424,0.0002091604,0.00004240584,0.000024962297,0.0016081532,0.000004778983,0.000008121417,0.000014151171,0.0067109573,0.013345333],"study_design_scores_gemma":[0.004985472,0.0034693358,0.982183,0.0005353827,0.000089337955,0.0000011005035,0.0008045984,0.00007303155,0.000001294482,0.000016616117,0.0077240556,0.0001167844],"about_ca_topic_score_codex":0.0011283158,"about_ca_topic_score_gemma":0.0028270776,"teacher_disagreement_score":0.013228549,"about_ca_system_score_codex":0.00027564086,"about_ca_system_score_gemma":0.0018995435,"threshold_uncertainty_score":0.9974987},"labels":[],"label_agreement":null},{"id":"W3092074431","doi":"10.1200/jco.2020.38.29_suppl.160","title":"Demographic, socioeconomic, and clinical factors associated with oncology patient experience in the Ontario cancer system.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Socioeconomic status; Cancer; Health care; Logistic regression; Family medicine; Patient experience; Disease; Internal medicine; Immigration; Demography; Gerontology; Population; Environmental health","score_opus":0.43566337694789453,"score_gpt":0.5747479909744866,"score_spread":0.13908461402659206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092074431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773872,0.00016544596,0.000018312792,0.017534647,0.003344842,0.0006897458,0.000013826506,0.000016907032,0.00082906254],"genre_scores_gemma":[0.9856637,0.0003451935,0.00016557734,0.013181371,0.00055650907,0.000055875178,0.0000026237753,0.000016739375,0.000012418119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98583645,0.0077242204,0.0052945204,0.00033908215,0.00035161315,0.00045411626],"domain_scores_gemma":[0.973152,0.020011013,0.005656024,0.00017115471,0.00044372777,0.0005661126],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005412259,0.00019229195,0.0018083191,0.00009339063,0.0003108189,0.000006361979,0.00033470863,0.0010373674,0.0002670109],"category_scores_gemma":[0.004112657,0.00011252609,0.00026628823,0.00016628142,0.00045222594,0.00018083044,0.000097364085,0.0048490777,0.000012588311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094188686,0.00019708878,0.96504545,0.00003198617,0.00015162952,0.00007492963,0.024330193,0.000012706842,4.497292e-7,0.000079984995,0.0015640515,0.0075696544],"study_design_scores_gemma":[0.003804261,0.00839288,0.9292341,0.0001838074,0.00009545025,0.000007044434,0.026724394,0.000060250808,2.395991e-7,0.000030200867,0.031358078,0.000109297886],"about_ca_topic_score_codex":0.0064136544,"about_ca_topic_score_gemma":0.15099482,"teacher_disagreement_score":0.14458117,"about_ca_system_score_codex":0.0015488338,"about_ca_system_score_gemma":0.0061219777,"threshold_uncertainty_score":0.9995124},"labels":[],"label_agreement":null},{"id":"W3092119605","doi":"10.1200/jco.20.01336","title":"Prospective Cohort Study of Pre- and Postdiagnosis Physical Activity and Endometrial Cancer Survival","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Endometrial cancer; Prospective cohort study; Cohort; Oncology; Cancer; Internal medicine","score_opus":0.1363042937347639,"score_gpt":0.48963040922037043,"score_spread":0.35332611548560655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092119605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450046,0.00028556993,0.000008250869,0.0033453426,0.0009098855,0.0005489274,0.000009534559,0.00000516073,0.0003868724],"genre_scores_gemma":[0.9967589,0.0007313482,0.0000252964,0.00032215455,0.002122804,0.000013112398,2.1878898e-7,0.000010497905,0.000015678499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980424,0.00043982945,0.0007654118,0.00022855266,0.00040312923,0.00012069184],"domain_scores_gemma":[0.9953641,0.0029536874,0.0008617324,0.00008823566,0.0003575175,0.0003747062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012175186,0.00011327631,0.0017909191,0.000060589427,0.00002351718,0.0000062760173,0.000068886024,0.0001509619,0.000028655993],"category_scores_gemma":[0.0034439317,0.000081235165,0.00020141716,0.0002050882,0.00019154942,0.000083084626,0.00008245898,0.0007534422,3.7343193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016348794,0.002879199,0.9250475,0.000038964616,0.0007224286,0.00008628748,0.0017170554,0.0000015240236,0.000305779,0.000013298298,0.0001320958,0.05270708],"study_design_scores_gemma":[0.011578932,0.03378565,0.9519051,0.000026993119,0.00088971265,0.000020002111,0.0007298272,0.000028354529,0.00025011197,0.000022656199,0.00069739483,0.00006530419],"about_ca_topic_score_codex":0.0007374334,"about_ca_topic_score_gemma":0.00072891935,"teacher_disagreement_score":0.052641775,"about_ca_system_score_codex":0.00006456721,"about_ca_system_score_gemma":0.0005505394,"threshold_uncertainty_score":0.41229567},"labels":[],"label_agreement":null},{"id":"W3092138439","doi":"10.1200/jco.2020.38.29_suppl.268","title":"Readiness of health care systems to generate RWE: Frequency of radiographic imaging of metastatic disease during first-line systemic therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Metastatic breast cancer; Systemic therapy; Cohort; Breast cancer; Clinical trial; Internal medicine; Population; Cancer; Lung cancer; Oncology; Radiology","score_opus":0.08282330971798137,"score_gpt":0.43865604401145425,"score_spread":0.3558327342934729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092138439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94847304,0.028272588,0.0034936303,0.018369403,0.0008848991,0.00044048313,0.000018103285,0.0000102160775,0.000037635462],"genre_scores_gemma":[0.9912831,0.0035775925,0.0031231625,0.0013233895,0.0006434928,0.0000047397643,0.000005559919,0.000031663476,0.000007280265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99353963,0.00089080975,0.0045245555,0.00023880598,0.00054683624,0.0002593865],"domain_scores_gemma":[0.99308777,0.00092236826,0.004022069,0.00025906652,0.000842074,0.0008666784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033279995,0.00018154627,0.0028600313,0.00031164987,0.00004210197,0.0000056978834,0.00028696549,0.0000716986,0.000016552955],"category_scores_gemma":[0.0045517245,0.00013052158,0.00060496,0.00047552743,0.00020187312,0.00007164644,0.000048494265,0.0007669507,7.9289134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005772865,0.0015135753,0.8917128,0.013464155,0.0018381474,0.0015809508,0.002883383,0.011734879,0.010692552,0.0002875134,0.0009042807,0.057614937],"study_design_scores_gemma":[0.07532879,0.04403456,0.7841142,0.026167605,0.004667136,0.0035316176,0.0067333253,0.045443293,0.0014636344,0.00032752246,0.006981076,0.0012072729],"about_ca_topic_score_codex":0.00014219045,"about_ca_topic_score_gemma":0.0000029855967,"teacher_disagreement_score":0.107598595,"about_ca_system_score_codex":0.00009164479,"about_ca_system_score_gemma":0.0014777782,"threshold_uncertainty_score":0.5449168},"labels":[],"label_agreement":null},{"id":"W3092187314","doi":"10.1200/jco.2020.38.29_suppl.59","title":"Fostering interspeciality learning in cancer survivorship care: Learning suite results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; McGill University","funders":"","keywords":"Survivorship curve; Medicine; General partnership; Family medicine; Radiation oncologist; Psychological intervention; Cancer; Radiation oncology; Oncology; Nursing; Radiation therapy; Internal medicine","score_opus":0.27330824891054456,"score_gpt":0.5684231340440897,"score_spread":0.29511488513354517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092187314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91666704,0.0043783537,0.0015461273,0.05559791,0.0043815724,0.00023271062,0.0000023318628,0.00004138581,0.017152568],"genre_scores_gemma":[0.9814642,0.0040651993,0.0026620433,0.0060342094,0.005431647,0.000002572112,0.0000022842423,0.000021120382,0.00031672133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956609,0.0012623036,0.002312626,0.00025477094,0.00023862522,0.0002707691],"domain_scores_gemma":[0.99396,0.0037097898,0.00161078,0.00009104606,0.00028495933,0.00034343055],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0036553359,0.00013866616,0.0014971478,0.00009345189,0.00005574174,0.000006769751,0.0001900545,0.00047774546,0.00012979448],"category_scores_gemma":[0.0148001285,0.00010785084,0.0003396843,0.000221377,0.00025846512,0.00013110401,0.00012556226,0.003729775,0.000008751032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018583179,0.00028802973,0.40835652,0.000065063556,0.00017926625,0.001249365,0.004953371,0.0021557163,0.00026889986,0.000043782027,0.0006237669,0.563233],"study_design_scores_gemma":[0.020272281,0.026626065,0.22597998,0.00034264775,0.00017337374,0.00021550065,0.004153242,0.00049801136,0.00010009724,0.00020945512,0.72119606,0.00023329443],"about_ca_topic_score_codex":0.00006243098,"about_ca_topic_score_gemma":0.0003467724,"teacher_disagreement_score":0.7205723,"about_ca_system_score_codex":0.00040232018,"about_ca_system_score_gemma":0.0011408555,"threshold_uncertainty_score":0.99856865},"labels":[],"label_agreement":null},{"id":"W3092213113","doi":"10.1200/jco.20.01933","title":"Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"National Cancer Institute; Medical Research Council; Vascular Society; Association of Upper Gastrointestinal Surgery of Great Britain and Ireland; Urology Foundation; Bowel Disease Research Foundation; British Gynaecological Cancer Society; Academy of Medical Sciences; Cancer Research UK; Sarcoma UK; Department of Health and Social Care; Government of the United Kingdom; European Society of Coloproctology; National Institute for Health and Care Research","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Cohort study; Cohort; Elective surgery; Cancer; Virology; Surgery; Internal medicine; Outbreak; Disease; Infectious disease (medical specialty)","score_opus":0.5744273529482795,"score_gpt":0.6120001683662466,"score_spread":0.03757281541796709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092213113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540237,0.00028921897,0.000023420784,0.043690562,0.0010311842,0.00074638135,0.000013838726,0.000021025371,0.00016067814],"genre_scores_gemma":[0.97150946,0.0019064171,0.000044556065,0.02451275,0.0019786807,0.000021929263,0.0000029339715,0.000015212313,0.00000808447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994203,0.0018060489,0.0026575562,0.00035082674,0.000643264,0.00033930354],"domain_scores_gemma":[0.9875731,0.00923873,0.0015475136,0.00026056753,0.0005670872,0.00081304146],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005674399,0.00019038295,0.0019457575,0.00017209664,0.00008657984,0.000022972177,0.00041033584,0.0002690784,0.00009798022],"category_scores_gemma":[0.016081708,0.00012048067,0.00038523244,0.00029187283,0.00020696042,0.0002677503,0.00013525556,0.0020139073,0.0000065985555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016896462,0.0025910144,0.9673922,0.000040710038,0.00045502433,0.0034314715,0.0035676463,0.000051794173,0.0001925932,0.000007671701,0.0016045333,0.003768847],"study_design_scores_gemma":[0.013247873,0.0040639765,0.9569628,0.00008588079,0.00015596222,0.00027405497,0.0015798064,0.000421462,0.00005065637,0.000038973827,0.023006877,0.000111641166],"about_ca_topic_score_codex":0.0013125341,"about_ca_topic_score_gemma":0.0057310127,"teacher_disagreement_score":0.021402342,"about_ca_system_score_codex":0.0011564669,"about_ca_system_score_gemma":0.0062104105,"threshold_uncertainty_score":0.99942344},"labels":[],"label_agreement":null},{"id":"W3092264537","doi":"10.1200/jco.2020.38.29_suppl.90","title":"Associations of rural residence and low socioeconomic status on the risk of new onset cardiovascular disease (CVD) in cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Health and Risk Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Residence; Socioeconomic status; Cancer registry; Cancer; Demography; Prostate cancer; Logistic regression; Population; Disease; Rural area; Educational attainment; Confounding; Internal medicine; Gerontology; Environmental health; Pathology","score_opus":0.08754886421411805,"score_gpt":0.41580914580355244,"score_spread":0.3282602815894344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092264537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876278,0.004153319,0.000008252266,0.0075161806,0.00033276228,0.0002356135,0.00009386292,0.0000017454813,0.000030452431],"genre_scores_gemma":[0.9794513,0.018815082,0.000054249493,0.0013143941,0.00034562813,0.0000016342005,0.0000035557432,0.000007911894,0.000006275501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970465,0.0007594872,0.0015712456,0.00010606424,0.0003464384,0.00017031321],"domain_scores_gemma":[0.995649,0.0020864904,0.0013027178,0.00017283093,0.00021345833,0.00057552016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022861348,0.00008576353,0.0013678205,0.000056432837,0.000027808976,0.0000023306172,0.00008561186,0.00016017686,0.000040930827],"category_scores_gemma":[0.008422627,0.00005272659,0.0010594956,0.00008566638,0.00015800516,0.000045479843,0.00003119953,0.00077764335,0.000002632973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016390384,0.0002508333,0.9647019,0.000039191847,0.0010716929,0.000015951768,0.00040759583,0.00055283046,0.0000014730333,0.0000103574575,0.0022830758,0.029026045],"study_design_scores_gemma":[0.0048397114,0.0019170584,0.9895467,0.00010197993,0.0009450525,0.0000016885602,0.00020877444,0.00007299208,0.000009701305,0.00012443027,0.00218801,0.000043876833],"about_ca_topic_score_codex":0.0014437268,"about_ca_topic_score_gemma":0.00015188972,"teacher_disagreement_score":0.028982168,"about_ca_system_score_codex":0.00016480644,"about_ca_system_score_gemma":0.0030594955,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W3092276302","doi":"10.1200/jco.2020.38.29_suppl.60","title":"Better treatment at what cost? A study of myeloma spending.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Multiple myeloma; Cancer drugs; Lenalidomide; Cancer; Pharmacy; Bortezomib; Government (linguistics); Family medicine; Internal medicine","score_opus":0.43226107861873403,"score_gpt":0.4829282545247874,"score_spread":0.05066717590605335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092276302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96938217,0.00089473656,0.000027490107,0.021053819,0.0012544658,0.00022652485,0.000020642365,0.0000035905152,0.007136551],"genre_scores_gemma":[0.9873249,0.002534185,0.00023544222,0.008682243,0.0011134074,0.0000039136803,9.3923813e-7,0.00001522941,0.000089722154],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996001,0.000109997614,0.0033931134,0.00023582173,0.000042126478,0.00021792411],"domain_scores_gemma":[0.99563366,0.0009193252,0.0027901297,0.00015893644,0.000045472276,0.00045247813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014220458,0.00013384319,0.0017484531,0.00010530338,0.00003259942,0.000027637874,0.00029318038,0.00018313024,0.001033459],"category_scores_gemma":[0.0006585592,0.0001168982,0.0004818651,0.00009974476,0.00009115511,0.00026826584,0.000110850866,0.0003561889,0.0003635708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002986818,0.0068536173,0.6100637,0.00002559092,0.0017039587,0.00031882292,0.0032351778,0.00015233988,0.000033960663,0.0074103917,0.005867923,0.36134776],"study_design_scores_gemma":[0.011665231,0.02077284,0.11488063,0.000011787651,0.000102045466,0.000027705406,0.000414783,0.001000534,0.0000616651,0.002805881,0.84806186,0.00019505474],"about_ca_topic_score_codex":0.000018254965,"about_ca_topic_score_gemma":0.000029656574,"teacher_disagreement_score":0.8421939,"about_ca_system_score_codex":0.00024103258,"about_ca_system_score_gemma":0.000110028326,"threshold_uncertainty_score":0.9998797},"labels":[],"label_agreement":null},{"id":"W3092305301","doi":"10.1200/jco.2020.38.29_suppl.186","title":"Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Internal medicine; Performance status; Disease; Physical therapy","score_opus":0.1408492913414822,"score_gpt":0.38250178265213614,"score_spread":0.24165249131065394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092305301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246,0.0001637592,0.0000904908,0.005421741,0.0008814346,0.00039051927,0.0001291229,0.0000059290383,0.0004569626],"genre_scores_gemma":[0.9941483,0.00032812802,0.0020236452,0.0032846283,0.00010455377,0.000014120208,0.0000022105107,0.000021508695,0.00007286821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953895,0.00004470735,0.003932948,0.00028870397,0.00007865965,0.0002654346],"domain_scores_gemma":[0.9945478,0.00053603953,0.004134634,0.00019773976,0.0001984587,0.00038533765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044776592,0.00019355041,0.0024862627,0.00016784052,0.000019414829,0.000013686389,0.00019264211,0.00019939712,0.00010436042],"category_scores_gemma":[0.0029489354,0.00014524387,0.0003561418,0.00017551356,0.00008240323,0.00043359902,0.000047163037,0.00029024083,0.000015636204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022878076,0.0010579169,0.9406338,0.0000068759646,0.00033972782,0.0000201726,0.00027410194,0.0012382466,5.5678845e-7,0.00029525516,0.00028840033,0.053557195],"study_design_scores_gemma":[0.0069790687,0.015811458,0.93444145,0.00002501579,0.00003722845,5.973165e-7,0.00002614282,0.0000366826,0.000009526365,0.00020510354,0.04228107,0.00014665254],"about_ca_topic_score_codex":0.0002854646,"about_ca_topic_score_gemma":0.00021349007,"teacher_disagreement_score":0.05341054,"about_ca_system_score_codex":0.00033357626,"about_ca_system_score_gemma":0.00042768373,"threshold_uncertainty_score":0.5922873},"labels":[],"label_agreement":null},{"id":"W3092348034","doi":"10.1200/jco.2020.38.29_suppl.20","title":"Current state assessment of the organization and delivery of systemic treatment in Ontario.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Healthcare delivery; Quality management; Drug delivery; Family medicine; Medical physics; Health care; Operations management","score_opus":0.42501086368849317,"score_gpt":0.5786081912572215,"score_spread":0.15359732756872835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092348034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916793,0.00019041602,0.0003475426,0.006922812,0.000513681,0.00029858667,0.0000030788158,0.0000015343513,0.000043062966],"genre_scores_gemma":[0.99637336,0.001426061,0.0013998953,0.00063811045,0.00014358104,8.9839114e-7,0.0000025198888,0.0000065937793,0.000008995724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99522156,0.000519724,0.0038038422,0.000106856685,0.00027254445,0.00007548552],"domain_scores_gemma":[0.99307156,0.0028551912,0.0032239994,0.00010299481,0.0006127565,0.00013352426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020654993,0.0000732521,0.0009309614,0.00004575921,0.000010020633,0.000002292606,0.00007668959,0.000078591285,0.00005692607],"category_scores_gemma":[0.006370735,0.0000435968,0.0001493904,0.00015953774,0.00008264307,0.00008122671,0.00005618063,0.00049954694,6.768817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007114506,0.0009148604,0.9013784,0.000056357265,0.0001222687,0.00002249534,0.00044717218,0.00011104631,0.0008002214,0.000018845272,0.00016576826,0.09525112],"study_design_scores_gemma":[0.0073350915,0.007498383,0.9808652,0.00017547887,0.00041935136,0.00007911474,0.00025651915,0.00035808576,0.0001345121,0.00005334942,0.002791082,0.000033823246],"about_ca_topic_score_codex":0.0012442977,"about_ca_topic_score_gemma":0.005021035,"teacher_disagreement_score":0.095217295,"about_ca_system_score_codex":0.00033947648,"about_ca_system_score_gemma":0.005706548,"threshold_uncertainty_score":0.9999302},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3092419908","doi":"10.1200/jco.2020.38.29_suppl.201","title":"Characteristics and outcomes of patients (pts) who developed immune-related adverse events (irAEs) with an initial presentation in the emergency department (ED).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Interquartile range; Emergency department; Population; Adverse effect; Internal medicine; Pneumonitis; Pediatrics; Surgery","score_opus":0.07883268291152917,"score_gpt":0.4337724043749996,"score_spread":0.3549397214634704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092419908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960574,0.00008332524,0.000022236227,0.003012234,0.0003920374,0.00030737123,0.000008916252,0.000002303544,0.00011415653],"genre_scores_gemma":[0.99733675,0.0009691454,0.00031948395,0.0012309742,0.00010050215,0.000003447997,0.0000186748,0.000008118446,0.000012918604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969086,0.0004247606,0.0021532495,0.00010761008,0.00029698823,0.000108788925],"domain_scores_gemma":[0.9977682,0.00029853344,0.0015145191,0.00008849456,0.00021874777,0.00011145385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011671514,0.000097609045,0.00074703,0.00004928466,0.000022915965,0.000001633136,0.00011312755,0.00014019966,0.00009614021],"category_scores_gemma":[0.00073255866,0.000054309556,0.00014969405,0.0001268201,0.000094490504,0.00011648365,0.000022258779,0.00036053619,0.0000013090661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019778922,0.0011340084,0.93956274,0.000024387136,0.00035644555,0.00006765444,0.0009723953,0.0000012287923,0.00003644689,0.0000057923658,0.00012883727,0.03793112],"study_design_scores_gemma":[0.013039401,0.012546316,0.9719175,0.000041987227,0.00019848504,0.000016867414,0.00026765186,0.00003923599,0.000018560897,0.000019656782,0.0018375433,0.0000567958],"about_ca_topic_score_codex":0.00001873237,"about_ca_topic_score_gemma":0.00002972394,"teacher_disagreement_score":0.037874322,"about_ca_system_score_codex":0.000039713108,"about_ca_system_score_gemma":0.0003824799,"threshold_uncertainty_score":0.22146793},"labels":[],"label_agreement":null},{"id":"W3092427939","doi":"10.1200/jco.2020.38.29_suppl.171","title":"Machine learning to classify clinically meaningful patient groups by ESAS symptom clusters in oropharyngeal cancer patients undergoing initial treatment.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Anxiety; Internal medicine; Population; Radiation therapy; Psychiatry","score_opus":0.1007627107677236,"score_gpt":0.44407263160099986,"score_spread":0.34330992083327627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092427939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96870804,0.0007520734,0.000053857028,0.026131507,0.0014703653,0.00036151652,0.00001632633,0.000018211815,0.0024881333],"genre_scores_gemma":[0.9747766,0.0032230858,0.00070016755,0.019984491,0.0011929094,0.00001492173,0.000010695786,0.000036611393,0.00006049268],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9944176,0.0007119996,0.0035101748,0.00039168552,0.0005020314,0.0004665049],"domain_scores_gemma":[0.99428767,0.0028182957,0.0014429555,0.00010664815,0.00032487078,0.001019561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010293686,0.00026781694,0.0025087323,0.000118704025,0.00007904819,0.000012565065,0.00015911757,0.00035512671,0.00012955698],"category_scores_gemma":[0.0059197946,0.00019370412,0.00047051616,0.0002656789,0.0001224822,0.00012183709,0.00013854793,0.00144649,0.000022425902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014775336,0.0025094752,0.7262793,0.0000475932,0.00053517404,0.0005688126,0.0031705862,0.00014951563,0.0000775562,0.0000051375455,0.0068019954,0.2450795],"study_design_scores_gemma":[0.07686279,0.41399947,0.277355,0.0010316884,0.0010457899,0.000057570658,0.0022989933,0.0020268308,0.00010406793,0.000035614787,0.22453642,0.00064579054],"about_ca_topic_score_codex":0.000099310695,"about_ca_topic_score_gemma":0.00045120544,"teacher_disagreement_score":0.44892433,"about_ca_system_score_codex":0.00074222777,"about_ca_system_score_gemma":0.0016751401,"threshold_uncertainty_score":0.78990245},"labels":[],"label_agreement":null},{"id":"W3092481325","doi":"10.1200/jco.2020.38.29_suppl.241","title":"Investigating factors associated with postmastectomy emergency department visits: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Mastectomy; Emergency department; Perioperative; Univariate analysis; Population; Nausea; Multivariate analysis; Emergency medicine; Breast cancer; Surgery; Internal medicine; Cancer","score_opus":0.13691880135099846,"score_gpt":0.41740557355113533,"score_spread":0.28048677220013685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092481325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438614,0.000041110055,0.00035276034,0.0045320895,0.00041549673,0.00011339913,0.000007959715,0.000017740667,0.00013329819],"genre_scores_gemma":[0.99726737,0.000004740262,0.0014350569,0.0007435239,0.000473032,7.9506884e-7,0.00005445274,0.000009668402,0.000011380148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727315,0.00032313465,0.0017772642,0.00014617709,0.00032824592,0.00015203038],"domain_scores_gemma":[0.9962482,0.0007006722,0.0021265072,0.00006827092,0.0003463853,0.0005099563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082563865,0.0001179165,0.0012442013,0.00014437392,0.000047089507,0.000005289418,0.00006771636,0.0002474228,0.00021359045],"category_scores_gemma":[0.0019489136,0.00007228095,0.00048160332,0.0005771893,0.00004482338,0.00007584548,0.0000108566655,0.0006192161,0.0000026269981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044349112,0.00024759967,0.9829664,0.000009951577,0.0019180805,0.000050974402,0.000052648422,0.0003041527,0.000032348704,0.0000060226525,0.00015902218,0.0138093],"study_design_scores_gemma":[0.0034637426,0.0042733382,0.9870075,0.000045849094,0.002797868,0.00021154864,0.000086887674,0.0018132721,0.00003339992,0.000024339077,0.00016308343,0.00007914785],"about_ca_topic_score_codex":0.000016775079,"about_ca_topic_score_gemma":0.00012497097,"teacher_disagreement_score":0.013730152,"about_ca_system_score_codex":0.000092531256,"about_ca_system_score_gemma":0.00073042174,"threshold_uncertainty_score":0.29475316},"labels":[],"label_agreement":null},{"id":"W3092568945","doi":"10.1200/jco.2020.38.29_suppl.239","title":"Using the Risk Assessment Index to predict mortality and quality of life in breast and gynecologic cancer patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Gynecologic cancer; Quality of life (healthcare); Gynecologic oncology; Cancer; Depression (economics); Internal medicine; Anxiety; Gynecology; Ovarian cancer","score_opus":0.28440776309939425,"score_gpt":0.5300624891048104,"score_spread":0.2456547260054161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092568945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892917,0.0002942926,0.00013729533,0.009411771,0.00045949884,0.00019720104,0.000033343356,0.0000021598923,0.0001726908],"genre_scores_gemma":[0.9929912,0.00066590187,0.00016882064,0.0057892557,0.00037478926,0.000002807276,5.157649e-7,0.0000049239516,0.00000180261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969873,0.0008241785,0.0016319664,0.00014716711,0.0002914734,0.0001179519],"domain_scores_gemma":[0.9964815,0.001522823,0.0012275535,0.00009047379,0.0003001353,0.0003775199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032421607,0.000081547856,0.001043782,0.00003547409,0.00002353315,0.0000053325607,0.000080415164,0.00017377264,0.000051389547],"category_scores_gemma":[0.0034261984,0.00004836433,0.00012749869,0.00013801348,0.00017248989,0.000051677176,0.000094160685,0.000734881,1.0703886e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015546868,0.00033900488,0.9803494,0.000053030777,0.0001388836,0.000009083354,0.00034829957,0.000056470137,0.000016217728,0.000012783497,0.00013674669,0.016985372],"study_design_scores_gemma":[0.003640291,0.0027485772,0.9916475,0.00004320663,0.00017676924,0.0000045977313,0.00050448143,0.00038196435,0.0000016052427,0.000051238974,0.0007543182,0.00004547429],"about_ca_topic_score_codex":0.0025734366,"about_ca_topic_score_gemma":0.00450061,"teacher_disagreement_score":0.016939899,"about_ca_system_score_codex":0.00010571768,"about_ca_system_score_gemma":0.0011059701,"threshold_uncertainty_score":0.41017267},"labels":[],"label_agreement":null},{"id":"W3092585107","doi":"10.1200/jco.20.02374","title":"Cardiac Screening for Childhood Cancer Survivors Can Be Improved With Existing Technology","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Pediatric Oncology Group","funders":"","keywords":"Medicine; Childhood cancer; Cancer; Internal medicine; Oncology; Intensive care medicine","score_opus":0.167547175515747,"score_gpt":0.4582898794575488,"score_spread":0.2907427039418018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092585107","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0077721234,0.0017571865,0.0010855438,0.98226887,0.004694758,0.0013678604,0.0003005991,0.000107300104,0.00064575375],"genre_scores_gemma":[0.0048046103,0.0009417212,0.03684764,0.90461737,0.051563483,0.00011501053,0.00012905654,0.0002840931,0.0006970138],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99074155,0.000908272,0.0053542564,0.0009290884,0.0010986014,0.0009682462],"domain_scores_gemma":[0.98238933,0.0067406264,0.00787488,0.00066399464,0.0016468199,0.0006843707],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004160389,0.00072790124,0.0072337585,0.00052808115,0.00016833348,0.000034544028,0.00079026935,0.0032727215,0.00006702813],"category_scores_gemma":[0.011472904,0.00056025846,0.0019375067,0.0005690812,0.0007396946,0.00012805662,0.00020512362,0.011622111,0.0000027086844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004467129,0.0005937654,0.017754313,0.0010176677,0.007615092,0.0026200502,0.0007673301,0.000012468285,0.000058188663,0.000025540634,0.85866064,0.1064078],"study_design_scores_gemma":[0.008955497,0.017691227,0.0031449595,0.0013031687,0.003256307,0.00039673375,0.0005829269,0.000029211722,0.00005545693,0.00027157538,0.96372724,0.0005856759],"about_ca_topic_score_codex":0.001190029,"about_ca_topic_score_gemma":0.0019626122,"teacher_disagreement_score":0.10582212,"about_ca_system_score_codex":0.000428675,"about_ca_system_score_gemma":0.008910518,"threshold_uncertainty_score":0.9996849},"labels":[],"label_agreement":null},{"id":"W3092588340","doi":"10.1200/jco.2020.38.29_suppl.57","title":"Support by peers in the clinical team in oncology: Perception of the contribution of patient advisors to improve the patient experience.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Logbook; Anxiety; Family medicine; Breast cancer; Descriptive statistics; Test (biology); Health care; Cancer; Internal medicine; Psychiatry","score_opus":0.22061894454097844,"score_gpt":0.5619364774404672,"score_spread":0.34131753289948874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092588340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8662785,0.00002808611,0.00010118494,0.13102728,0.0012023874,0.0011093593,0.000011512715,0.0000026098699,0.00023901774],"genre_scores_gemma":[0.9655439,0.00021064123,0.00050523755,0.03328263,0.00041094536,0.00002399097,0.0000073111923,0.000010414836,0.0000049271907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9856089,0.0036629757,0.009270921,0.0002875233,0.0008936205,0.0002760997],"domain_scores_gemma":[0.97852355,0.014343557,0.0055889823,0.00037814106,0.0008891367,0.0002766265],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011730371,0.00015257373,0.0014142424,0.000069724665,0.00003905851,0.0000058384894,0.0004678876,0.00041373307,0.00014737215],"category_scores_gemma":[0.08294591,0.00007406099,0.00062415254,0.0004508731,0.0005144352,0.00014367817,0.00017768567,0.0019778807,0.000008057451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01279328,0.005582403,0.50230724,0.000019264106,0.00012899301,0.000055596243,0.0123217665,0.0001343151,0.002437376,0.000054741642,0.04386068,0.42030436],"study_design_scores_gemma":[0.013555381,0.07884596,0.59172547,0.000102325575,0.00041170887,0.00008283328,0.06421942,0.00050490245,0.00031664473,0.00015644863,0.24993585,0.00014302715],"about_ca_topic_score_codex":0.00013714566,"about_ca_topic_score_gemma":0.00022233125,"teacher_disagreement_score":0.42016134,"about_ca_system_score_codex":0.0002721625,"about_ca_system_score_gemma":0.001714523,"threshold_uncertainty_score":0.9247788},"labels":[],"label_agreement":null},{"id":"W3092643411","doi":"10.1200/jco.2020.38.29_suppl.223","title":"Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Context (archaeology); Test (biology); Cancer; Hearing loss; Audiology; Internal medicine","score_opus":0.09329862026677935,"score_gpt":0.47714153841168755,"score_spread":0.38384291814490823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092643411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973188,0.00013917458,0.000078690886,0.0016637525,0.00019147644,0.00046344538,0.00011838962,0.000003296102,0.000022976701],"genre_scores_gemma":[0.99609315,0.00002247567,0.003067356,0.00060209294,0.00018667818,0.000003918729,0.0000061095257,0.00001662792,0.0000015827861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729043,0.00019592007,0.0016505622,0.00021455543,0.00042360747,0.00022494826],"domain_scores_gemma":[0.99733704,0.00059926993,0.00080802606,0.000089790294,0.00057866215,0.00058719364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069006317,0.00012377379,0.0010255834,0.00028186225,0.000021188443,0.000003997397,0.000094848154,0.0001616339,0.00028862737],"category_scores_gemma":[0.0023050609,0.000107303094,0.00018276904,0.0004907972,0.00015655535,0.00009906563,0.000059489368,0.00040912116,4.429388e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072202943,0.00025669675,0.9350596,0.00030612157,0.00014735931,0.000027029288,0.00072771276,0.00028297256,0.013303833,0.0000013665472,0.000033731114,0.042633295],"study_design_scores_gemma":[0.018837778,0.005892029,0.9701058,0.00021152108,0.00010699062,0.0000040379696,0.001803924,0.0006842783,0.0020971496,0.000006178921,0.0001704549,0.00007984844],"about_ca_topic_score_codex":0.00039135735,"about_ca_topic_score_gemma":0.00012625028,"teacher_disagreement_score":0.042553447,"about_ca_system_score_codex":0.00056565984,"about_ca_system_score_gemma":0.0025313639,"threshold_uncertainty_score":0.44905308},"labels":[],"label_agreement":null},{"id":"W3094290388","doi":"10.1200/jco.20.02510","title":"Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre; Amgen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Trastuzumab emtansine; Internal medicine; Guideline; Hazard ratio; Targeted therapy; Adjuvant therapy; Cancer; Chemotherapy; Pathology; Confidence interval","score_opus":0.044419927553881,"score_gpt":0.40857449637091475,"score_spread":0.36415456881703373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094290388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96825665,0.0029640559,0.0016104234,0.026608447,0.00027894502,0.00017204734,0.00008204287,0.000003822485,0.000023579307],"genre_scores_gemma":[0.97323376,0.012180484,0.008698599,0.004095703,0.001741748,0.000009785407,0.0000099677545,0.000019179735,0.000010748639],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983292,0.00010291713,0.0011193943,0.00019743628,0.00010657651,0.00014445455],"domain_scores_gemma":[0.99812984,0.000100737576,0.0010269373,0.00006755092,0.0005337998,0.00014112584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053738034,0.0001280476,0.00071468373,0.000018676272,0.000036486348,0.0000044375884,0.00011650564,0.00021259983,0.00003320908],"category_scores_gemma":[0.00019011825,0.000094473646,0.00025129554,0.00006003692,0.0001400528,0.0000074540953,0.000032639153,0.00015737115,3.652553e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04476908,0.0011307045,0.22086178,0.00003432051,0.0030835273,0.00001013959,0.00022310183,0.00021495826,0.061013404,0.000024375724,0.03637546,0.63225913],"study_design_scores_gemma":[0.023659745,0.020119265,0.7053187,0.00002813568,0.00026620377,0.00012549236,0.000092165385,0.00033792172,0.031037008,0.00007151692,0.21869144,0.0002524277],"about_ca_topic_score_codex":0.00003407581,"about_ca_topic_score_gemma":0.000016406377,"teacher_disagreement_score":0.6320067,"about_ca_system_score_codex":0.000020706235,"about_ca_system_score_gemma":0.00043947244,"threshold_uncertainty_score":0.38525236},"labels":[],"label_agreement":null},{"id":"W3095552675","doi":"10.1200/jco.20.01632","title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Agence Nationale de la Recherche; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; Neutropenia; Myeloid leukemia; Adverse effect; Gastroenterology; Azacitidine; Isocitrate dehydrogenase; Oncology; Surgery; Chemotherapy","score_opus":0.08517720452467968,"score_gpt":0.4167741424278661,"score_spread":0.3315969379031864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095552675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9468987,0.0001559954,0.0016787404,0.049643673,0.000316317,0.000917574,0.000017597418,0.000022026554,0.0003493694],"genre_scores_gemma":[0.9772133,0.0007748895,0.010587299,0.009416717,0.001783696,0.000037804082,0.000020094943,0.000054734217,0.00011145923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99531406,0.00046205302,0.0027263395,0.00036615337,0.0006332959,0.0004980936],"domain_scores_gemma":[0.99281794,0.0037451878,0.0014684097,0.00019276496,0.00083216856,0.0009435169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030795299,0.00024336309,0.001960782,0.00022328399,0.000055864333,0.000022275579,0.0002959056,0.000560256,0.00007545526],"category_scores_gemma":[0.0064931624,0.0001730169,0.00048418035,0.00046927523,0.0003016933,0.00026538753,0.0000755862,0.0020279035,0.00002591382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2788719,0.009967294,0.11915019,0.0009635256,0.0062577613,0.079555765,0.0034730383,0.0015184877,0.14935884,0.0015444412,0.10220724,0.24713154],"study_design_scores_gemma":[0.39803165,0.26236615,0.098432735,0.0011384828,0.0031656108,0.00446978,0.0020351412,0.040213455,0.054657802,0.0021674496,0.13206376,0.0012580117],"about_ca_topic_score_codex":0.000030706,"about_ca_topic_score_gemma":0.00008442987,"teacher_disagreement_score":0.25239885,"about_ca_system_score_codex":0.0011705871,"about_ca_system_score_gemma":0.007469028,"threshold_uncertainty_score":0.9981577},"labels":[],"label_agreement":null},{"id":"W3096418954","doi":"10.1200/jco.20.02253","title":"In Response to “Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations”","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Germline; BRCA mutation; Breast cancer; Oncology; Cancer; Gynecology; Germline mutation; Pregnancy; Internal medicine; Mutation; Obstetrics; Genetics; Gene; Biology","score_opus":0.0455631681745216,"score_gpt":0.42366577982959064,"score_spread":0.37810261165506903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096418954","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35268763,0.00024033092,0.0000067187248,0.64525014,0.0012785302,0.00037281396,0.000109828,0.000003724592,0.000050269533],"genre_scores_gemma":[0.26143157,0.00026264793,0.00039107646,0.7329716,0.004375575,0.00004135374,0.000015975744,0.000056808803,0.00045336862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534386,0.00061715284,0.0027518643,0.00035202384,0.00058989663,0.00034522096],"domain_scores_gemma":[0.9961573,0.0014064793,0.0014028559,0.00022225411,0.0004619337,0.00034917088],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00078796747,0.00026795067,0.0022760334,0.00045561846,0.000011772608,0.000009792483,0.0001894031,0.0008836869,0.0006052291],"category_scores_gemma":[0.0009952176,0.00018321874,0.00034950481,0.00042234166,0.00013336926,0.00011505751,0.000056304336,0.0048314827,0.000024840288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07089944,0.0008125404,0.5542134,0.00007957473,0.00017037436,0.015985375,0.00021286224,0.000020740124,0.0000018427476,1.3182513e-7,0.33333567,0.024268033],"study_design_scores_gemma":[0.0090273665,0.005601295,0.62285036,0.0012409211,0.00016304146,0.000061627004,0.0000075473654,0.000001934673,3.3183e-7,0.0000119146425,0.36090395,0.00012971165],"about_ca_topic_score_codex":0.00016323676,"about_ca_topic_score_gemma":0.00052437163,"teacher_disagreement_score":0.09125604,"about_ca_system_score_codex":0.00067616085,"about_ca_system_score_gemma":0.0032873244,"threshold_uncertainty_score":0.9974644},"labels":[],"label_agreement":null},{"id":"W3100629716","doi":"10.1200/jco.20.02672","title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":614,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenvatinib; Sorafenib; Atezolizumab; Nivolumab; Regorafenib; Ramucirumab; Oncology; Bevacizumab; Internal medicine; Pembrolizumab; Hepatocellular carcinoma; Population; Cabozantinib; Cancer; Colorectal cancer; Chemotherapy; Immunotherapy","score_opus":0.24899582746258023,"score_gpt":0.5172099093082254,"score_spread":0.2682140818456452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100629716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455568,0.0038154353,0.0077105765,0.039774347,0.0006660873,0.00082301017,0.000005509954,0.00001501384,0.001633209],"genre_scores_gemma":[0.95954096,0.0019462091,0.023881556,0.011327096,0.0029522395,0.000019447982,0.000006476295,0.000025735168,0.00030029425],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952445,0.00043942104,0.0033636375,0.00023719342,0.00039447934,0.00032078123],"domain_scores_gemma":[0.99338806,0.0029021597,0.0014794174,0.00019912039,0.0012584099,0.00077285006],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045862435,0.00015256317,0.0025627362,0.00007789723,0.000049610688,0.000005396513,0.0002521092,0.00046152915,0.00020193594],"category_scores_gemma":[0.009251284,0.000101622056,0.0007174849,0.00014356697,0.0001945496,0.00007093855,0.000042973086,0.0009018632,0.00003349611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030215418,0.0014034417,0.7814413,0.00017415018,0.00088341115,0.0013753515,0.00025135907,0.000013710264,0.005370928,0.00022161889,0.05263094,0.12601838],"study_design_scores_gemma":[0.081787206,0.116281345,0.08163072,0.0002094873,0.001189323,0.0019200678,0.0007544899,0.016427798,0.000754461,0.00069098145,0.698051,0.00030312463],"about_ca_topic_score_codex":0.0000060623006,"about_ca_topic_score_gemma":0.0000010438087,"teacher_disagreement_score":0.69981056,"about_ca_system_score_codex":0.00012425179,"about_ca_system_score_gemma":0.0036564348,"threshold_uncertainty_score":0.9990942},"labels":[],"label_agreement":null},{"id":"W3107516644","doi":"10.1200/jco.20.02905","title":"Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma?","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lymphoma; Hodgkin lymphoma; Oncology; Internal medicine","score_opus":0.16888680036052317,"score_gpt":0.4373481157804325,"score_spread":0.2684613154199093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107516644","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066770025,0.0011966082,7.8036874e-7,0.92752117,0.0011559656,0.0008009729,0.000016057673,0.0000071064733,0.0025313026],"genre_scores_gemma":[0.024083354,0.005311079,0.00059477246,0.9518373,0.01693212,0.000121288336,0.000045217403,0.000043726726,0.0010311425],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99562246,0.0009277349,0.0024126174,0.0002679818,0.00052577397,0.00024345484],"domain_scores_gemma":[0.99378437,0.003696918,0.0018449035,0.0002957623,0.00018739342,0.00019063865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009669312,0.000262079,0.0027142577,0.00022938178,0.000021669175,0.00000706573,0.00020078121,0.0009249769,0.00022066761],"category_scores_gemma":[0.00089975883,0.0001374813,0.0010691604,0.00024780704,0.00011450894,0.00003920055,0.000022209138,0.00062301755,0.00021348956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016856894,0.0049533113,0.0036015783,0.000030885065,0.00061202294,0.011128149,0.00051529787,4.863471e-7,0.0000038622234,0.0000011169933,0.6658235,0.31164408],"study_design_scores_gemma":[0.010310091,0.050592277,0.09822713,0.00019451849,0.0010324414,0.00039899565,0.000025741714,0.000006903036,0.00001689272,0.000023907694,0.8390855,0.00008559266],"about_ca_topic_score_codex":0.000087204025,"about_ca_topic_score_gemma":0.000022315626,"teacher_disagreement_score":0.31155849,"about_ca_system_score_codex":0.00087267614,"about_ca_system_score_gemma":0.0009523998,"threshold_uncertainty_score":0.7134269},"labels":[],"label_agreement":null},{"id":"W3108655367","doi":"10.1200/jco.20.01762","title":"Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer drugs; Drug; Adjuvant; Cancer; Drug trial; Oncology; Clinical trial; Internal medicine; Family medicine; Pharmacology","score_opus":0.42379225680721055,"score_gpt":0.5354944543091659,"score_spread":0.11170219750195531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108655367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8913066,0.010727145,0.00018087198,0.09563107,0.0017166233,0.00010257474,0.00010061904,0.0000021716103,0.00023234353],"genre_scores_gemma":[0.8556393,0.11498817,0.001077935,0.022997092,0.0052304007,0.0000034328848,0.00000660689,0.000016477503,0.000040578383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692583,0.00079697254,0.0017282497,0.00029053283,0.00010731938,0.00015108244],"domain_scores_gemma":[0.99113333,0.0065610246,0.0015623013,0.00015513257,0.0002079675,0.00038021416],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043561957,0.00013494333,0.0011119676,0.000024341034,0.000051921943,0.000024635374,0.00024772395,0.00045717103,0.00005287203],"category_scores_gemma":[0.026880743,0.00010711571,0.00034914384,0.000031086824,0.0001618149,0.0000069168514,0.00013137999,0.0010049572,0.000005695303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01803653,0.00075646455,0.028677618,0.00005163315,0.0016605005,0.00016754186,0.00094325235,0.0024175558,0.012271745,0.0012320267,0.1535214,0.7802637],"study_design_scores_gemma":[0.004934822,0.0070115332,0.01837106,0.00013456751,0.00040212282,0.000013255255,0.00028969618,0.00026695678,0.0042410605,0.0013062705,0.96275455,0.0002741118],"about_ca_topic_score_codex":0.000116598625,"about_ca_topic_score_gemma":0.0005043408,"teacher_disagreement_score":0.8092331,"about_ca_system_score_codex":0.00003810134,"about_ca_system_score_gemma":0.0020295237,"threshold_uncertainty_score":0.98131627},"labels":[],"label_agreement":null},{"id":"W3110475042","doi":"10.1200/jco.20.02438","title":"Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Oncology; Internal medicine; Neoadjuvant therapy; Meta-analysis; Adjuvant; Metastasis; Adjuvant therapy; Chemotherapy; Cancer; Breast cancer","score_opus":0.341041792039653,"score_gpt":0.4930464918284645,"score_spread":0.15200469978881148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110475042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044390536,0.98684496,0.0002377255,0.0041551627,0.0005507958,0.0031014222,0.0006013498,0.000029423456,0.00004013281],"genre_scores_gemma":[0.0010466401,0.98131055,0.013054739,0.0030362569,0.00075250096,0.00032182437,0.00033996932,0.00011654756,0.000020972237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98902524,0.0019886438,0.0060447403,0.00096649287,0.0014280409,0.0005468395],"domain_scores_gemma":[0.98749787,0.002067126,0.0069821477,0.0010545226,0.0009240073,0.0014743309],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0035315577,0.00091649534,0.01998395,0.0006411672,0.00008989531,0.00008497829,0.0007499327,0.000566474,0.00022731305],"category_scores_gemma":[0.0006211273,0.00047633803,0.0063621835,0.0011856391,0.00019377137,0.00022624702,0.00015124705,0.0014668651,0.0000092035025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026229082,0.0024648681,0.00070831587,0.0003044944,0.28450334,0.0010149057,0.000291941,0.000036358255,7.5719237e-7,0.000011283688,0.0006077901,0.70743304],"study_design_scores_gemma":[0.0067047956,0.035694525,0.0014085682,0.00029338722,0.3047295,0.0001854626,0.00006669517,0.000011012438,0.000008830997,0.000025872294,0.6505337,0.0003376683],"about_ca_topic_score_codex":0.000047049318,"about_ca_topic_score_gemma":0.00013405803,"teacher_disagreement_score":0.7070954,"about_ca_system_score_codex":0.0005711594,"about_ca_system_score_gemma":0.0038589297,"threshold_uncertainty_score":0.99976885},"labels":[],"label_agreement":null},{"id":"W3112002107","doi":"10.1200/jco.20.01370","title":"Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Biotech; Juno Therapeutics; Pharmacyclics; Kite Pharma; Servier; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Array BioPharma; Legend Biotech; Celgene; Takeda Pharmaceuticals North America; Exelixis; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Medicine; Multiple myeloma; Quality of life (healthcare); Internal medicine; Oncology; Nursing","score_opus":0.1781192389579719,"score_gpt":0.46776651708590544,"score_spread":0.28964727812793356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112002107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97769225,0.00029988334,0.000078194,0.020411734,0.00030136324,0.0010382725,0.00010752688,0.000008219702,0.00006257465],"genre_scores_gemma":[0.9958708,0.00033229977,0.00088947854,0.0024301475,0.00036948992,0.000009892024,0.00007102715,0.000017036296,0.000009815785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930809,0.0013518,0.004231865,0.00025431227,0.00072926795,0.00035185507],"domain_scores_gemma":[0.9874537,0.009049529,0.0020513635,0.00019976884,0.00029260223,0.00095305406],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027686427,0.00017751606,0.0024993464,0.00008254095,0.000051392068,0.000007579994,0.00024958942,0.00028256146,0.00015508296],"category_scores_gemma":[0.010781993,0.00009604891,0.00040434158,0.00029147835,0.00021508375,0.000100701174,0.000034965506,0.0012226257,0.000011212714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39504772,0.0052822703,0.58122766,0.000025225325,0.00048813078,0.00028087033,0.0005630466,0.000008931457,0.000019866111,0.0000044237017,0.0010406091,0.016011247],"study_design_scores_gemma":[0.41825312,0.020502998,0.5602042,0.000101899546,0.00008857637,0.0000029981754,0.00008736006,0.00013760704,0.000015498877,0.000017915974,0.0005348409,0.000052970812],"about_ca_topic_score_codex":0.001872112,"about_ca_topic_score_gemma":0.00095103844,"teacher_disagreement_score":0.023205373,"about_ca_system_score_codex":0.00011677904,"about_ca_system_score_gemma":0.0023565853,"threshold_uncertainty_score":0.9975506},"labels":[],"label_agreement":null},{"id":"W3112175219","doi":"10.1200/jco.20.02529","title":"Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Alberta Children's Hospital","funders":"","keywords":"Medicine; Total body irradiation; Cumulative incidence; Busulfan; ThioTEPA; Internal medicine; Surgery; Hematopoietic stem cell transplantation; Population; Treosulfan; Transplantation; Chemotherapy; Cyclophosphamide","score_opus":0.09409068729701432,"score_gpt":0.4730154490263991,"score_spread":0.3789247617293848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112175219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848175,0.000048757658,0.0019558023,0.011076269,0.00041281708,0.0011842902,0.000004308059,0.000015657646,0.000484596],"genre_scores_gemma":[0.9914016,0.00018290401,0.0034983985,0.0040134545,0.0008247158,0.000018891922,0.000014227513,0.000016911134,0.000028860451],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951144,0.0008871467,0.0031528524,0.0002103571,0.00046701747,0.00016825621],"domain_scores_gemma":[0.9936627,0.0040928246,0.0015354941,0.00008960001,0.0002915285,0.00032783547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004514709,0.00014430405,0.002064824,0.0001328067,0.000032256,0.000013044869,0.0000934177,0.0002393824,0.0005201869],"category_scores_gemma":[0.005093789,0.000103629965,0.000362702,0.00019594446,0.0001024368,0.00016450879,0.000011576893,0.00082192454,0.00001574999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80778927,0.034822397,0.0922417,0.00015105985,0.002348739,0.0039561945,0.020205002,0.00023209945,0.0014018886,0.0002515284,0.0008730455,0.03572708],"study_design_scores_gemma":[0.7001473,0.011878538,0.28191718,0.0000907658,0.00050222524,0.00045709923,0.0008428884,0.003388204,0.000069775175,0.000052432944,0.0005474255,0.00010618081],"about_ca_topic_score_codex":0.000017092805,"about_ca_topic_score_gemma":0.000013910317,"teacher_disagreement_score":0.18967548,"about_ca_system_score_codex":0.000109864144,"about_ca_system_score_gemma":0.0012567668,"threshold_uncertainty_score":0.6098109},"labels":[],"label_agreement":null},{"id":"W3118711697","doi":"10.1200/jco.20.01055","title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":824,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Lung cancer; Hazard ratio; Placebo; Carboplatin; Oncology; Etoposide; Interim analysis; Gastroenterology; Surgery; Clinical trial; Cancer; Chemotherapy; Pembrolizumab; Immunotherapy; Confidence interval; Pathology; Cisplatin","score_opus":0.05157558275665592,"score_gpt":0.4224178008924977,"score_spread":0.3708422181358418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118711697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947345,0.0026860002,0.000032264383,0.0012924712,0.00011983904,0.00027594226,0.00005363185,0.000007258554,0.0007980717],"genre_scores_gemma":[0.99422807,0.003843591,0.000767523,0.00043021224,0.000113837435,0.000005144765,0.000029768127,0.00002479482,0.0005570564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967782,0.00047852704,0.0014453728,0.00036367626,0.0006044324,0.00032980164],"domain_scores_gemma":[0.9942303,0.0013200599,0.0013816742,0.0002422147,0.0023884145,0.000437363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091323495,0.00022600683,0.002457977,0.00026061898,0.000058191323,0.000016024187,0.00009039621,0.00021906571,0.00013821684],"category_scores_gemma":[0.0008104297,0.00013839596,0.0002205681,0.00060275564,0.0004495656,0.000087174165,0.0001239003,0.00075767195,2.0153969e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014489717,0.0007126959,0.9722599,0.00014318892,0.008307744,0.0012469045,0.0001962541,0.00013842604,0.00025289628,0.000013406912,0.00039075024,0.0018481635],"study_design_scores_gemma":[0.018020738,0.0068854876,0.9658987,0.00017750674,0.006972529,0.000026797086,0.00024432133,0.00057345995,0.0002598549,0.000004509907,0.0007911802,0.00014491766],"about_ca_topic_score_codex":0.00056883733,"about_ca_topic_score_gemma":0.002309302,"teacher_disagreement_score":0.0063611553,"about_ca_system_score_codex":0.00021558336,"about_ca_system_score_gemma":0.0014361901,"threshold_uncertainty_score":0.56436235},"labels":[],"label_agreement":null},{"id":"W3118854714","doi":"10.1200/jco.20.01372","title":"Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Genentech; Cancer Research UK; Brain Tumour Charity; AstraZeneca","keywords":"Medicine; Medulloblastoma; Oncology; Clinical trial; Pediatrics; Internal medicine; Pathology","score_opus":0.04546255588695881,"score_gpt":0.44352544750182044,"score_spread":0.39806289161486164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118854714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358857,0.00043154502,0.0000081686685,0.0051339744,0.00019368145,0.00039076342,0.00005374934,0.000006413061,0.00019310832],"genre_scores_gemma":[0.995803,0.0013419421,0.0015924645,0.0009545515,0.00020502668,0.000007261462,0.000051877953,0.000018057835,0.00002584855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587506,0.00084318075,0.002325172,0.000326134,0.00046152572,0.0001689093],"domain_scores_gemma":[0.9956289,0.0013731046,0.0019342889,0.00024081442,0.00046709942,0.00035579834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018333258,0.0001922954,0.0018265608,0.00013995821,0.00002137635,0.000012717109,0.00012954237,0.0003298416,0.000031832824],"category_scores_gemma":[0.0019879683,0.00010533627,0.00028897557,0.00017504695,0.0002975186,0.000099517616,0.000029053259,0.00076276273,3.8404795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26149273,0.015780592,0.65015566,0.0000012241411,0.0028179213,0.0016692954,0.000035665103,0.0000083044715,0.00011925754,0.000013041207,0.000536702,0.06736962],"study_design_scores_gemma":[0.37727723,0.044376142,0.5750924,0.000053014814,0.00044059442,0.0004011056,0.000044785844,0.00002072946,0.001038813,0.000014192024,0.0011713684,0.00006964266],"about_ca_topic_score_codex":0.00012812395,"about_ca_topic_score_gemma":0.00024019665,"teacher_disagreement_score":0.11578449,"about_ca_system_score_codex":0.000045987974,"about_ca_system_score_gemma":0.00078379654,"threshold_uncertainty_score":0.42954886},"labels":[],"label_agreement":null},{"id":"W3118937854","doi":"10.1200/jco.20.03237","title":"Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":391,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Guideline; Nasopharyngeal carcinoma; Radiation therapy; Oncology; Stage (stratigraphy); Evidence-based medicine; Randomized controlled trial; Systematic review; Internal medicine; Chemoradiotherapy; Evidence-based practice; Family medicine; MEDLINE; Head and neck cancer; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.23568033157597473,"score_gpt":0.5220879905845084,"score_spread":0.28640765900853365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118937854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008714387,0.98639756,0.00012751183,0.0029596458,0.00046749023,0.001058672,0.000032004635,0.000003391585,0.00023932566],"genre_scores_gemma":[0.0007769264,0.9908246,0.0066734273,0.00063800556,0.0006689463,0.000047261274,0.000029841529,0.000041372743,0.000299665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951354,0.00039958005,0.003681666,0.0002989984,0.00025810942,0.0002262267],"domain_scores_gemma":[0.99387115,0.0024241428,0.00263115,0.00017441322,0.0007027409,0.00019637933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001708571,0.00032423605,0.008221746,0.0002242414,0.000036278077,0.000004472222,0.00008718324,0.00046204522,0.000045347442],"category_scores_gemma":[0.00059539435,0.00019005647,0.0009308933,0.00016752326,0.00021314221,0.000042039806,0.000021949618,0.00047896412,1.9026649e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030840063,0.0036708545,0.0017158142,0.0017191704,0.0016311588,0.0004005226,0.00021405763,3.0421216e-7,0.0000012050136,0.00009454204,0.00096143497,0.98650694],"study_design_scores_gemma":[0.029048216,0.086496204,0.0018653701,0.0048142765,0.0013470983,0.00032500998,0.00010297377,0.000012673321,0.000005412817,0.000012492679,0.87583566,0.00013460469],"about_ca_topic_score_codex":0.00003474638,"about_ca_topic_score_gemma":0.00007313849,"teacher_disagreement_score":0.98637235,"about_ca_system_score_codex":0.000613807,"about_ca_system_score_gemma":0.0037072182,"threshold_uncertainty_score":0.7750278},"labels":[],"label_agreement":null},{"id":"W3119228723","doi":"10.1200/jco.20.00494","title":"Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Vincristine; Dexamethasone; Lymphoblastic Leukemia; Randomized controlled trial; Methotrexate; Confidence interval; Group B; Maintenance therapy; Leukemia; Gastroenterology; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.04999027893045217,"score_gpt":0.39592770641100344,"score_spread":0.3459374274805513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119228723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909985,0.0012835622,0.00078409666,0.0048755594,0.0005451219,0.00034506584,0.00016903007,0.000013543562,0.0009855423],"genre_scores_gemma":[0.9575829,0.0038915237,0.03709752,0.00060478004,0.0006257361,0.0000066759103,0.000034790293,0.000045810964,0.00011027292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99108535,0.0018284918,0.0047781407,0.0006575811,0.0010830072,0.0005674487],"domain_scores_gemma":[0.97277683,0.021417838,0.0032822564,0.0005524313,0.001214908,0.0007557465],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0051137055,0.00035463244,0.003919876,0.00034514393,0.00005760344,0.000015567532,0.00032619387,0.0009120109,0.0001628225],"category_scores_gemma":[0.03944593,0.00024040803,0.00039119617,0.00048402406,0.000959312,0.0001463538,0.00025894647,0.0023485522,0.000006200339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04869396,0.0037140117,0.82322186,0.00008851064,0.0022900982,0.012392404,0.00051256653,0.00011466098,0.0033554744,0.00010958352,0.0019663686,0.1035405],"study_design_scores_gemma":[0.07225221,0.026114559,0.8946264,0.00050989044,0.001059867,0.0014981197,0.00047859052,0.00023201897,0.00081531587,0.0007363472,0.0014410352,0.00023564379],"about_ca_topic_score_codex":0.0020489744,"about_ca_topic_score_gemma":0.0017645028,"teacher_disagreement_score":0.103304856,"about_ca_system_score_codex":0.0027067869,"about_ca_system_score_gemma":0.016269013,"threshold_uncertainty_score":0.9999531},"labels":[],"label_agreement":null},{"id":"W3120023782","doi":"10.1200/jco.20.01845","title":"Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Manitoba; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Dalhousie University; Institute for Clinical Evaluative Sciences; Public Health Ontario","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Emergency department; Odds ratio; Population; Logistic regression; Confidence interval; Generalized estimating equation; Outpatient clinic; Emergency medicine; Pediatrics; Physical therapy; Internal medicine; Psychiatry","score_opus":0.08312162718921741,"score_gpt":0.43443081056637173,"score_spread":0.35130918337715433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120023782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621636,0.0011593373,0.000018136507,0.0011926547,0.0010566842,0.00031757838,0.000010853209,0.0000042520946,0.00002411792],"genre_scores_gemma":[0.99886394,0.000590239,0.00010310736,0.00016619345,0.00021477201,0.000010973126,0.000016641869,0.000009350376,0.000024809506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720544,0.00029472745,0.0018578006,0.00019852843,0.00032397654,0.00011950391],"domain_scores_gemma":[0.9975967,0.00039849753,0.0011082758,0.00012558082,0.0005674944,0.00020347515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057054224,0.00010197598,0.0008655712,0.00010072444,0.000020931573,0.0000069432735,0.000029859697,0.00015080045,0.00008908752],"category_scores_gemma":[0.0017307502,0.00008350102,0.00011951281,0.0001992623,0.000028855007,0.000094666546,0.000029958846,0.0002445441,1.5149021e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024080472,0.0013821997,0.9875659,0.000049850623,0.0002617363,0.00066110573,0.0005991851,0.00008499177,0.000014744323,0.000006997322,0.00008408557,0.006881211],"study_design_scores_gemma":[0.0070173102,0.010455705,0.98043317,0.00020885415,0.00041632168,0.000053021722,0.00051073456,0.00016938637,0.000012430005,0.000050726576,0.00060573226,0.00006662129],"about_ca_topic_score_codex":0.0021919787,"about_ca_topic_score_gemma":0.0118540265,"teacher_disagreement_score":0.009662048,"about_ca_system_score_codex":0.00011518428,"about_ca_system_score_gemma":0.00095677975,"threshold_uncertainty_score":0.6614825},"labels":[],"label_agreement":null},{"id":"W3120895755","doi":"10.1200/jco.20.01086","title":"Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Food and Drug Administration","keywords":"Abatacept; Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Calcineurin; Methotrexate; Transplantation; Gastroenterology; Immunology; Clinical trial; Confidence interval; Rituximab","score_opus":0.1483854092688785,"score_gpt":0.5169486579838362,"score_spread":0.36856324871495766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120895755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720711,0.000057440553,0.024368765,0.0015572152,0.00068230886,0.0005279177,0.000017302244,0.0000031631266,0.00071476895],"genre_scores_gemma":[0.97247946,0.00016730296,0.026468474,0.00008961157,0.00045774656,0.00000502011,0.000031923108,0.000010747921,0.00028968792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686486,0.00023499188,0.0023661836,0.00011468118,0.00031975913,0.00009954859],"domain_scores_gemma":[0.9947429,0.0019123439,0.0021817472,0.00012857177,0.00090972614,0.00012471894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016883438,0.00007759727,0.001174885,0.00007764604,0.000019279887,0.0000015832512,0.00005551655,0.00024964512,0.00015489552],"category_scores_gemma":[0.0011853412,0.000056481796,0.00040773232,0.00011900963,0.00009051602,0.000068321555,0.000009276258,0.00025438244,6.9694926e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6430504,0.034061514,0.0031018653,0.0006840235,0.0032323,0.00048411972,0.0006845756,0.00015313787,0.038237117,0.0003430698,0.0009275201,0.2750404],"study_design_scores_gemma":[0.65745664,0.25714946,0.008667197,0.0005414536,0.006157397,0.00073186273,0.000178553,0.00062017696,0.06260901,0.0005875103,0.0051898975,0.00011086882],"about_ca_topic_score_codex":0.0000010229967,"about_ca_topic_score_gemma":0.0000040786076,"teacher_disagreement_score":0.27492952,"about_ca_system_score_codex":0.000036286645,"about_ca_system_score_gemma":0.0013493074,"threshold_uncertainty_score":0.23936133},"labels":[],"label_agreement":null},{"id":"W3121188369","doi":"10.1200/jco.2021.39.3_suppl.269","title":"Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Hepatocellular carcinoma; Gastroenterology; Cohort; Nivolumab; Sorafenib; Surgery; Adverse effect; Cancer; Immunotherapy","score_opus":0.11717102684756653,"score_gpt":0.36306532777690764,"score_spread":0.24589430092934111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121188369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424803,0.0013820308,0.0000436259,0.0019458411,0.0008461846,0.00063961913,0.000024447081,0.000019595302,0.0008506201],"genre_scores_gemma":[0.9954291,0.0013977359,0.0014611792,0.0006605749,0.00039385876,0.000014727117,0.00026719665,0.00004754768,0.00032808614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994612,0.0008441166,0.002889356,0.0005184535,0.0007206601,0.00041545508],"domain_scores_gemma":[0.99496484,0.001185685,0.0018376196,0.00047004054,0.0011025697,0.00043924467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001490476,0.0003237063,0.002014775,0.00020049517,0.00006530644,0.000026356516,0.00021572398,0.00055996684,0.00016510277],"category_scores_gemma":[0.0010583824,0.00024059923,0.0005350249,0.0003709181,0.00016451291,0.00025711418,0.000067879926,0.001083394,0.000029241688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027473468,0.004810009,0.8526533,0.00002366811,0.0003739324,0.0059869806,0.00029534174,0.0000037990483,0.00014978518,0.000010687763,0.00011089791,0.108108126],"study_design_scores_gemma":[0.1117418,0.021570405,0.8615971,0.000262516,0.00031200232,0.00008466273,0.00006508328,0.00070739427,0.002011072,0.00007689401,0.0013606828,0.0002103676],"about_ca_topic_score_codex":0.00009543375,"about_ca_topic_score_gemma":0.00013062077,"teacher_disagreement_score":0.10789776,"about_ca_system_score_codex":0.0006010908,"about_ca_system_score_gemma":0.0021206294,"threshold_uncertainty_score":0.9811352},"labels":[],"label_agreement":null},{"id":"W3121205494","doi":"10.1200/jco.2021.39.3_suppl.290","title":"Low energy amplitude modulated radiofrequency electromagnetic fields in combination with standard treatment or as monotherapy to show improvement in quality of life in patients with advanced hepatocellular carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electromagnetic Fields and Biological Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Quality of life (healthcare); Internal medicine; Cancer; Prospective cohort study; Transcatheter arterial chemoembolization; Surgery","score_opus":0.02243192153042627,"score_gpt":0.3358600636058511,"score_spread":0.3134281420754248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121205494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823046,0.00038822976,0.0003727306,0.00059352216,0.00005647045,0.00029766146,0.000002978961,0.0000013850762,0.000056546836],"genre_scores_gemma":[0.9970451,0.00058824464,0.0015646237,0.0006790004,0.00003397348,0.00002145415,0.000017492228,0.000009596837,0.000040533465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973986,0.00052975904,0.0013187547,0.0002975835,0.00020190018,0.00025338406],"domain_scores_gemma":[0.9986197,0.00024025537,0.000543094,0.00018414846,0.00027354207,0.00013931192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006704612,0.00016358198,0.000924609,0.000080631326,0.0000103172615,0.0000057314637,0.00012819644,0.00035092238,0.000023834005],"category_scores_gemma":[0.00058142544,0.00010031068,0.00010207393,0.0002331128,0.000055027875,0.000007113552,0.000024308829,0.00024170893,1.1385919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042588126,0.005442316,0.628177,0.000029929624,0.00012399902,0.00021104564,0.00006629774,0.00040223214,0.19377868,0.00008117899,0.00001188049,0.12908731],"study_design_scores_gemma":[0.025677944,0.3673767,0.5551134,0.0000665774,0.000018750705,0.000006230191,0.000031785894,0.000075850956,0.05097831,0.00023810934,0.00022658276,0.00018979667],"about_ca_topic_score_codex":0.00028342,"about_ca_topic_score_gemma":0.002541857,"teacher_disagreement_score":0.36193436,"about_ca_system_score_codex":0.0001615563,"about_ca_system_score_gemma":0.0010763361,"threshold_uncertainty_score":0.40905508},"labels":[],"label_agreement":null},{"id":"W3121240759","doi":"10.1200/jco.2021.39.3_suppl.10","title":"Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Institutes of Health","keywords":"Medicine; Perineural invasion; Lymphovascular invasion; Internal medicine; Stage (stratigraphy); Hazard ratio; Colorectal cancer; Oncology; Lymph node; Cancer; Population; Gastroenterology; Primary tumor; Post-hoc analysis; Proportional hazards model; Metastasis; Confidence interval","score_opus":0.07512560153324191,"score_gpt":0.47951879485831095,"score_spread":0.40439319332506907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121240759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638313,0.0011373586,0.000011513128,0.0006491941,0.000642961,0.00074406376,0.000057229565,0.0000054909515,0.00036903718],"genre_scores_gemma":[0.9983201,0.00035647707,0.0003777765,0.00060478307,0.00013434143,0.000031267693,0.00001744516,0.000018950877,0.00013885717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931998,0.0010197852,0.0042924415,0.00035979695,0.00081409357,0.00031408644],"domain_scores_gemma":[0.9907182,0.0032076836,0.0030639274,0.00027551345,0.0023174356,0.00041728254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017028238,0.00022073057,0.003911747,0.000461486,0.0000260698,0.0000053929225,0.00019308584,0.00025327475,0.00046850162],"category_scores_gemma":[0.0051009953,0.00016621024,0.0009556046,0.001547831,0.00019379954,0.00009046667,0.0001356536,0.00078458234,0.0000014806366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04165064,0.038730413,0.88378805,0.00007192742,0.0056579565,0.004632555,0.0005464011,0.00021236169,0.00032729752,0.000011105651,0.00006812032,0.024303172],"study_design_scores_gemma":[0.055881858,0.066711456,0.8675612,0.00020346872,0.0076776044,0.00003057733,0.0004989114,0.0003391947,0.00047910897,0.000007958882,0.0004924363,0.00011620152],"about_ca_topic_score_codex":0.0006000023,"about_ca_topic_score_gemma":0.004710177,"teacher_disagreement_score":0.02798104,"about_ca_system_score_codex":0.0005461627,"about_ca_system_score_gemma":0.0030949968,"threshold_uncertainty_score":0.6777857},"labels":[],"label_agreement":null},{"id":"W3121448666","doi":"10.1200/jco.2021.39.3_suppl.tps152","title":"Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Antibody; Chemotherapy; Bevacizumab; Internal medicine; Oncology; Progressive disease; Cancer; Cancer research; Immunology","score_opus":0.04148958753402491,"score_gpt":0.4308969426276206,"score_spread":0.3894073550935957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121448666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988233,0.00020161628,0.00004348905,0.00014173576,0.00016819192,0.00041210675,0.000011842115,0.0000034419286,0.00019430695],"genre_scores_gemma":[0.99836594,0.00046778223,0.00067736115,0.00009232233,0.00017893763,0.0000096650265,0.00014672954,0.000023212184,0.000038028727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973402,0.0003187551,0.00130834,0.00030997422,0.00040325386,0.00031950165],"domain_scores_gemma":[0.99735737,0.00013986652,0.0012664605,0.0002496085,0.00075738295,0.00022931823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079211866,0.0001776045,0.0009958441,0.00012635761,0.00004040849,0.000015936535,0.00019336143,0.00025390525,0.000013334971],"category_scores_gemma":[0.0006194587,0.00012224546,0.00018498383,0.0002548187,0.00017020151,0.00003850702,0.000068178575,0.0003521414,9.1105187e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24920267,0.015807051,0.66172856,0.00006478759,0.0009861414,0.0008099366,0.00009715929,0.00019243703,0.014839573,0.000019926385,0.00009207588,0.05615966],"study_design_scores_gemma":[0.31877422,0.20460793,0.43376064,0.00050541264,0.00024026509,0.000118406875,0.00016044154,0.0000600033,0.039219633,0.0000922471,0.0021046805,0.00035611467],"about_ca_topic_score_codex":0.00006020688,"about_ca_topic_score_gemma":0.0006697247,"teacher_disagreement_score":0.22796793,"about_ca_system_score_codex":0.00008721901,"about_ca_system_score_gemma":0.0016453783,"threshold_uncertainty_score":0.49850252},"labels":[],"label_agreement":null},{"id":"W3121502959","doi":"10.1200/jco.2021.39.3_suppl.332","title":"Low energy amplitude modulated radiofrequency electromagnetic fields to show antitumor effect in combination with standard treatment or as monotherapy in patients with advanced hepatocellular carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Internal medicine; Radiofrequency ablation; Oncology; Surgery; Radiology; Ablation","score_opus":0.03909282751237067,"score_gpt":0.3355003623729274,"score_spread":0.2964075348605567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121502959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967942,0.0005723725,0.00025059498,0.0013437733,0.00013494439,0.00072909344,0.0000029667585,0.000009641949,0.00016239399],"genre_scores_gemma":[0.99599403,0.00043306427,0.002722453,0.0005177639,0.00006984235,0.00004955849,0.000028247056,0.000032481294,0.00015256692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969555,0.00063795544,0.0012787398,0.0003546393,0.00042454273,0.00034861584],"domain_scores_gemma":[0.99787396,0.00065171224,0.00048624293,0.00024859197,0.00040984483,0.0003296664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006128127,0.00027097648,0.0016886279,0.0002694772,0.000028197795,0.00001619381,0.000094331364,0.00027378683,0.00010893076],"category_scores_gemma":[0.00033105127,0.00016158326,0.00020286812,0.0005326846,0.000056777622,0.00010887274,0.000013142313,0.00039100792,0.0000024991195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041929934,0.0037908358,0.8471429,0.000026458962,0.00024124219,0.009067312,0.00014249545,0.000033754317,0.0005111554,0.00001888759,0.000013769185,0.09708128],"study_design_scores_gemma":[0.06286627,0.26919895,0.6542752,0.00027371428,0.00027543167,0.00013663885,0.000021265181,0.00042775704,0.011261601,0.00007631473,0.0009894633,0.00019739638],"about_ca_topic_score_codex":0.00014352707,"about_ca_topic_score_gemma":0.00039913802,"teacher_disagreement_score":0.26540813,"about_ca_system_score_codex":0.0008383111,"about_ca_system_score_gemma":0.0018334867,"threshold_uncertainty_score":0.6589174},"labels":[],"label_agreement":null},{"id":"W3121515605","doi":"10.1200/jco.2021.39.3_suppl.184","title":"A multicountry chart review of treatment patterns and outcomes for patients with resected esophageal or gastroesophageal junction cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Esophageal cancer; Stage (stratigraphy); Internal medicine; Pathological; Cancer; Neoadjuvant therapy; Adjuvant therapy; Adenocarcinoma; Surgery; Gastroenterology","score_opus":0.09950610405251034,"score_gpt":0.4856461712492881,"score_spread":0.38614006719677774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121515605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774565,0.016369464,0.00009424157,0.004448045,0.00046885855,0.0009967323,0.00011937368,0.000006719993,0.000040034563],"genre_scores_gemma":[0.94862723,0.04533554,0.003091991,0.001783093,0.00046887458,0.00008117127,0.000046653287,0.000022992921,0.00054247316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974142,0.00026272782,0.0014334498,0.00022752404,0.00040809732,0.00025400557],"domain_scores_gemma":[0.9957841,0.0012916704,0.0010187118,0.00017950153,0.0013158496,0.00041017713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069287827,0.00016889395,0.0017380068,0.00007056129,0.000040321844,0.000006009908,0.00005844424,0.00013168521,0.00028110994],"category_scores_gemma":[0.0016489106,0.00008697874,0.00033622092,0.000114812596,0.00011118106,0.00008328073,0.000027389246,0.00029947402,0.000001043284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01216231,0.0030725286,0.8798253,0.0012905692,0.0011991769,0.0009338776,0.0000306076,9.832595e-7,0.0000031439488,0.0000049192613,0.0006156361,0.10086097],"study_design_scores_gemma":[0.028634764,0.06650162,0.8994029,0.0019787194,0.00107263,0.00012602285,0.000029993967,0.000015817184,0.0001108434,0.0000075370554,0.0020634108,0.00005574542],"about_ca_topic_score_codex":0.000095041214,"about_ca_topic_score_gemma":0.00032901767,"teacher_disagreement_score":0.100805216,"about_ca_system_score_codex":0.00046344212,"about_ca_system_score_gemma":0.0032470059,"threshold_uncertainty_score":0.5760049},"labels":[],"label_agreement":null},{"id":"W3121707006","doi":"10.1200/jco.2021.39.3_suppl.472","title":"Beyond <i>BRCA</i>? clinical utility of homologous recombination deficiency in gastrointestinal cancers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia; Pancreas Centre (Canada); Genome British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Loss of heterozygosity; Oncology; Proportional hazards model; Cancer; Allele; Gastroenterology; Gene; Genetics","score_opus":0.12318244080525653,"score_gpt":0.4720998223900755,"score_spread":0.34891738158481894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121707006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96988046,0.0015657071,0.000059657996,0.0045373854,0.0012464123,0.0001278051,0.00000495134,0.0000046130585,0.022573033],"genre_scores_gemma":[0.9921083,0.0011822553,0.0054234145,0.0007453458,0.00032558735,0.000003055908,0.000002517556,0.000007264815,0.00020226334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953564,0.00061608636,0.0032477814,0.00024371082,0.00031372014,0.00022231291],"domain_scores_gemma":[0.9944715,0.00259709,0.0015666215,0.00017229683,0.000991063,0.00020146224],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038493348,0.00012101199,0.0017634312,0.000091476366,0.000029406072,0.0000033698238,0.000105279876,0.00020411603,0.00023963864],"category_scores_gemma":[0.008915472,0.000089930756,0.00055987923,0.0002667546,0.00039122519,0.000063425934,0.000075382544,0.0009780113,0.000003251104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034706837,0.0040841317,0.80828804,0.000036581077,0.00011881356,0.0019781333,0.00007129706,0.0000034527166,0.00003744136,0.00010185139,0.002379464,0.17943013],"study_design_scores_gemma":[0.00819625,0.019668201,0.965947,0.00018469637,0.00021790693,0.0013808776,0.0002806049,0.00006826026,0.00007672677,0.0015559623,0.002360978,0.00006258239],"about_ca_topic_score_codex":0.00007820466,"about_ca_topic_score_gemma":0.00090421387,"teacher_disagreement_score":0.17936754,"about_ca_system_score_codex":0.0002732584,"about_ca_system_score_gemma":0.0042383657,"threshold_uncertainty_score":0.99943286},"labels":[],"label_agreement":null},{"id":"W3121895660","doi":"10.1200/jco.2021.39.3_suppl.tps145","title":"BOLD-100-001 (TRIO039): A phase Ib dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University; McMaster University; Alberta Health Services","funders":"","keywords":"FOLFOX; Medicine; Tolerability; Oncology; Internal medicine; Chemotherapy; Colorectal cancer; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Combination therapy; Cancer; Oxaliplatin; Gastroenterology; Adverse effect","score_opus":0.03731174198347995,"score_gpt":0.4351419497730816,"score_spread":0.39783020778960165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121895660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989947,0.00008103799,0.00010605243,0.00020957508,0.00006665466,0.00040811935,0.000006759036,0.0000017380045,0.00012536456],"genre_scores_gemma":[0.99874014,0.00008186363,0.0008843453,0.000092884555,0.00008020741,0.0000145102695,0.000046376543,0.000017150353,0.000042514028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742097,0.00037759033,0.0013114404,0.00027293764,0.00036779657,0.00024927806],"domain_scores_gemma":[0.997853,0.00015284805,0.0010460746,0.00018712216,0.0006063699,0.0001545937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007337952,0.00014825686,0.0007523946,0.00012648667,0.000022334283,0.000008387505,0.0001379513,0.000107832035,0.000029232897],"category_scores_gemma":[0.00047726103,0.00011011266,0.000094939955,0.00025226243,0.00009556642,0.000021788263,0.000044172604,0.00038722355,7.0926427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033894528,0.065307766,0.84335387,0.000016747868,0.00018780965,0.0003773256,0.00007426622,0.00023080606,0.0025265894,0.0000031777188,0.00008573296,0.05394135],"study_design_scores_gemma":[0.09618851,0.15861595,0.7420712,0.00012519705,0.000036132267,0.00005543766,0.00016734927,0.00004541366,0.0022675612,0.00003215575,0.00029026825,0.000104839004],"about_ca_topic_score_codex":0.000109149165,"about_ca_topic_score_gemma":0.0021628183,"teacher_disagreement_score":0.10128271,"about_ca_system_score_codex":0.00011841265,"about_ca_system_score_gemma":0.0010263611,"threshold_uncertainty_score":0.4490264},"labels":[],"label_agreement":null},{"id":"W3122345229","doi":"10.1200/jco.20.03128","title":"Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":374,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Baker Hughes (Canada); University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Internal medicine; Quality of life (healthcare); Oncology; Adverse effect; Nuclear medicine","score_opus":0.18295623760765342,"score_gpt":0.502584635409797,"score_spread":0.3196283978021436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122345229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94514555,0.0072784643,0.000034817625,0.036245182,0.0042876746,0.00031459084,0.000011347658,0.000016012465,0.0066663767],"genre_scores_gemma":[0.97264975,0.010536496,0.0017321504,0.010461832,0.003711371,0.000018691313,0.000015609086,0.000028324295,0.0008457441],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996031,0.0007072214,0.0023283982,0.0002675769,0.00030505093,0.00036074745],"domain_scores_gemma":[0.9925878,0.0038741042,0.0016092057,0.00018156733,0.0013418307,0.00040551674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031687883,0.00016881023,0.0024861314,0.00009936555,0.000099547135,0.000007981076,0.0001271451,0.00062283035,0.00023337931],"category_scores_gemma":[0.008239364,0.00012673606,0.00077863527,0.00020996864,0.00016250245,0.00009173325,0.00004092313,0.0009151814,0.0000122342835],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010894251,0.0039023801,0.040959977,0.0000322772,0.0010136007,0.0013910965,0.00044656676,0.0000027641233,0.0022932396,0.00008947371,0.0685908,0.87038356],"study_design_scores_gemma":[0.026243174,0.032527238,0.50354207,0.00003964239,0.00033651988,0.00024728826,0.00017958837,0.00006164331,0.00083637406,0.00023471288,0.43564254,0.00010920284],"about_ca_topic_score_codex":0.000015300526,"about_ca_topic_score_gemma":0.00006573474,"teacher_disagreement_score":0.87027436,"about_ca_system_score_codex":0.0005836488,"about_ca_system_score_gemma":0.007329724,"threshold_uncertainty_score":0.9982978},"labels":[],"label_agreement":null},{"id":"W3122388634","doi":"10.1200/jco.2021.39.3_suppl.193","title":"Impact of age on outcomes and symptoms in patients with advanced gastroesophageal cancer (GEC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Confidence interval; Proportional hazards model; Cohort; Internal medicine; Cancer; Multivariate analysis; Hazard ratio; Young adult","score_opus":0.05440839687204197,"score_gpt":0.4913069580602958,"score_spread":0.4368985611882538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122388634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975548,0.0010768404,0.000002238833,0.0007499083,0.00013351174,0.00015834806,0.0000124616445,0.0000018782873,0.00031005577],"genre_scores_gemma":[0.99855554,0.00036286985,0.0005204969,0.00036128098,0.00009663319,0.000004401229,0.0000035886349,0.0000103366865,0.00008484919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806213,0.00020079728,0.00097110396,0.00015097689,0.000396401,0.00021860619],"domain_scores_gemma":[0.997826,0.00074386544,0.00058409653,0.00013053231,0.0003541144,0.0003614166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004700248,0.00011382943,0.001233724,0.0001020484,0.000012220113,0.000003780457,0.000055859426,0.00010779042,0.00013286721],"category_scores_gemma":[0.0006743226,0.0000621063,0.00025126408,0.00012061771,0.00013547158,0.0000656593,0.000029346806,0.0005833637,0.0000012572086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010588274,0.0025746631,0.8805729,0.000019004137,0.0005199356,0.002742479,0.000027789945,0.000042190462,0.0000048595116,0.000010210644,0.00005892786,0.10283877],"study_design_scores_gemma":[0.025931468,0.059239097,0.9144001,0.00014389229,0.00010280095,0.000024559902,0.000010191875,0.0000022438348,0.00004062975,0.00002673612,0.000044664393,0.000033620414],"about_ca_topic_score_codex":0.00004246154,"about_ca_topic_score_gemma":0.000111277695,"teacher_disagreement_score":0.10280515,"about_ca_system_score_codex":0.00030033075,"about_ca_system_score_gemma":0.0016929448,"threshold_uncertainty_score":0.30032113},"labels":[],"label_agreement":null},{"id":"W3122395164","doi":"10.1200/jco.2021.39.3_suppl.164","title":"Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Capecitabine; Medicine; Tolerability; Trastuzumab; Immunohistochemistry; Internal medicine; Paclitaxel; Chemotherapy; Oncology; Cancer; Breast cancer; Adverse effect","score_opus":0.14674479215752895,"score_gpt":0.48070532223831064,"score_spread":0.3339605300807817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122395164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98785174,0.00081319583,0.00014841388,0.0076580923,0.0015525685,0.0002230684,0.000020898531,0.000010874292,0.0017211427],"genre_scores_gemma":[0.9904183,0.00018810746,0.0046763206,0.0019536873,0.0021426093,0.0000024859214,0.000026220428,0.000017500619,0.00057475205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99481136,0.0006730554,0.0032985813,0.00036465604,0.0005318195,0.00032054787],"domain_scores_gemma":[0.9958968,0.0015998603,0.001481878,0.00038356273,0.00028408706,0.00035382487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002916179,0.00017212016,0.0017569215,0.00018799472,0.00003541234,0.000029796642,0.00023255331,0.00021129285,0.0003711064],"category_scores_gemma":[0.005119621,0.0001370518,0.00042361591,0.0003082186,0.00009604871,0.00017134112,0.00017996415,0.0012537435,0.000018665856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015959596,0.009671707,0.77014494,0.000016950566,0.000501626,0.041855834,0.00053993106,0.000015541333,0.00011711769,0.000007811592,0.011975798,0.14919317],"study_design_scores_gemma":[0.072424814,0.010816715,0.8965531,0.00013090928,0.000544673,0.00018479195,0.0017277155,0.00008773358,0.00005000242,0.00007812286,0.017314963,0.00008646506],"about_ca_topic_score_codex":0.000121752564,"about_ca_topic_score_gemma":0.00023485158,"teacher_disagreement_score":0.14910671,"about_ca_system_score_codex":0.00019197984,"about_ca_system_score_gemma":0.0013069869,"threshold_uncertainty_score":0.6129034},"labels":[],"label_agreement":null},{"id":"W3122478037","doi":"10.1200/jco.2021.39.3_suppl.430","title":"Familial pancreatic cancer (FPC) status as a clinical biomarker in patients receiving platinum-based systemic therapy: A case-control analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; Mount Sinai Hospital; Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Internal medicine; Cohort; Population; Oncology; Chemotherapy; Cancer; Retrospective cohort study; Proportional hazards model; Surgery","score_opus":0.13827604457724438,"score_gpt":0.5028331864428486,"score_spread":0.3645571418656042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122478037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923108,0.002116766,0.0003193926,0.0019951912,0.0010946684,0.0005986921,0.000026198226,0.000012971451,0.0015252728],"genre_scores_gemma":[0.9904417,0.0031523604,0.0017791928,0.0036639012,0.0006245025,0.00003404623,0.000012788029,0.000030447003,0.0002610789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.986829,0.005260557,0.0058719995,0.0005160267,0.0008148172,0.0007076377],"domain_scores_gemma":[0.97805977,0.016433556,0.0024896793,0.0004679202,0.0016321901,0.0009169073],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010951798,0.0002820031,0.005318457,0.0005462706,0.00007718439,0.000020562746,0.00020045268,0.0010070247,0.0009322263],"category_scores_gemma":[0.02382869,0.0002024177,0.0014505854,0.0010637493,0.00039853362,0.00010651012,0.000057508176,0.0020898532,0.000028458788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015333286,0.0036238201,0.8645155,0.000052258434,0.005538155,0.015079789,0.00010894636,0.00006222507,0.00004502129,0.000005390552,0.0005669178,0.09506872],"study_design_scores_gemma":[0.048729483,0.008724445,0.9295813,0.00032058492,0.004475531,0.0008389374,0.0002516056,0.0054107364,0.0000035678186,0.00004569915,0.0014541051,0.00016401452],"about_ca_topic_score_codex":0.000588852,"about_ca_topic_score_gemma":0.0011862809,"teacher_disagreement_score":0.094904706,"about_ca_system_score_codex":0.0006654479,"about_ca_system_score_gemma":0.012496781,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W3122478524","doi":"10.1200/jco.2021.39.3_suppl.8","title":"NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health","keywords":"Medicine; Pembrolizumab; Capecitabine; Colorectal cancer; Total mesorectal excision; Population; Internal medicine; FOLFOX; Clinical endpoint; Neoadjuvant therapy; Randomized controlled trial; Phases of clinical research; Surgery; Oncology; Cancer; Clinical trial; Oxaliplatin; Breast cancer","score_opus":0.2935761635148743,"score_gpt":0.5580124301005489,"score_spread":0.2644362665856746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122478524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98035604,0.0063706934,0.000027310432,0.0022879802,0.005964618,0.0010972932,0.000037609007,0.00003052222,0.0038279293],"genre_scores_gemma":[0.98419726,0.0045493334,0.00404378,0.002750269,0.0039616134,0.00005296689,0.000037535152,0.000069349684,0.0003379011],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98885036,0.001109935,0.007321789,0.00085541455,0.0011016611,0.0007608592],"domain_scores_gemma":[0.9912501,0.0036428669,0.0029277345,0.0004919355,0.00066890754,0.001018437],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004314768,0.00048815936,0.0041832323,0.00023063087,0.0001278398,0.000027803564,0.00030628903,0.0010270656,0.00059724814],"category_scores_gemma":[0.004457146,0.0003742669,0.0018228709,0.0005454875,0.000501797,0.0003821713,0.00030007702,0.0027639163,0.000008316402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5751195,0.028523143,0.001757265,0.000014154224,0.0006972024,0.009588849,0.00019678031,0.000080911675,0.0022614808,0.0000104861065,0.00037921732,0.38137102],"study_design_scores_gemma":[0.7665537,0.1744506,0.015770936,0.00061595347,0.00038544717,0.002558081,0.00027142002,0.00078908587,0.003355507,0.00011057093,0.034687363,0.00045135198],"about_ca_topic_score_codex":0.000102803184,"about_ca_topic_score_gemma":0.00017045694,"teacher_disagreement_score":0.38091967,"about_ca_system_score_codex":0.002065445,"about_ca_system_score_gemma":0.010400408,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W3122499681","doi":"10.1200/jco.2021.39.3_suppl.9","title":"Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Oncology; Cohort; Population; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research","score_opus":0.058116479416154644,"score_gpt":0.42887647007267116,"score_spread":0.3707599906565165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122499681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588853,0.0005994865,0.000014705317,0.0010622386,0.0011356288,0.0004551942,0.000054336586,0.000008927216,0.00078094867],"genre_scores_gemma":[0.99584454,0.0008686443,0.0024366293,0.00047558348,0.00027349658,0.0000016272147,0.000025877802,0.000023245906,0.00005036043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941994,0.00071073585,0.003559312,0.00047717805,0.0007456879,0.0003076802],"domain_scores_gemma":[0.99337566,0.002919641,0.0019988804,0.00042086092,0.0009646941,0.00032025838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024389105,0.00021398027,0.0021973588,0.00013494404,0.000033844517,0.000008469224,0.00015871863,0.00033041264,0.00009068683],"category_scores_gemma":[0.005784778,0.00015317525,0.0002579351,0.0003321086,0.0002856242,0.000062282226,0.00014198881,0.0010304347,0.000002433315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059090924,0.007914383,0.91510636,0.00003984277,0.0006069176,0.0010291492,0.0012491328,0.00044581847,0.00043340374,0.0000015867001,0.0007519848,0.013330526],"study_design_scores_gemma":[0.049237568,0.03576958,0.9083582,0.0003747919,0.00042075646,0.000051242114,0.00090230576,0.00009786588,0.00025138105,0.000012361517,0.0043896763,0.00013425268],"about_ca_topic_score_codex":0.00043430657,"about_ca_topic_score_gemma":0.0009746752,"teacher_disagreement_score":0.027855199,"about_ca_system_score_codex":0.00041823837,"about_ca_system_score_gemma":0.0029421058,"threshold_uncertainty_score":0.69253373},"labels":[],"label_agreement":null},{"id":"W3122551414","doi":"10.1200/jco.2021.39.3_suppl.192","title":"Lymph node mapping in gastric cancer: A pilot study in Western patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lymphadenectomy; Lymph node; Indocyanine green; Gastrectomy; Lymph; Lymphatic system; Adenocarcinoma; Cancer; Surgery; Stomach; Dissection (medical); Radiology; Internal medicine; Pathology","score_opus":0.17118739952647544,"score_gpt":0.4581420166387653,"score_spread":0.28695461711228987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122551414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914808,0.0003263144,0.00003202352,0.005572737,0.0012928277,0.00021416381,7.664444e-7,0.0000041218987,0.0010762379],"genre_scores_gemma":[0.9946279,0.0007080602,0.00048325415,0.0032027196,0.00049930677,0.000007487885,0.0000011923562,0.000010366998,0.0004597455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662447,0.00036306295,0.0022331004,0.00019099301,0.00034460143,0.00024380014],"domain_scores_gemma":[0.9979294,0.0006867046,0.0008497333,0.00014482527,0.0002303402,0.00015902641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018000454,0.00010852393,0.0013043791,0.00034028568,0.000012134058,0.000008658195,0.00012949917,0.00008118758,0.00012763095],"category_scores_gemma":[0.0015456681,0.00008693024,0.00015821464,0.0005574376,0.00003659844,0.000085399806,0.000106726766,0.0006481873,0.0000076029764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001029856,0.006286686,0.90584207,0.000025562716,0.00011515055,0.0021411013,0.00013894387,0.00003804959,0.000004455744,0.0000019932181,0.00046474917,0.083911404],"study_design_scores_gemma":[0.024911836,0.0066582877,0.9599724,0.00014915186,0.00012374295,0.000033098568,0.0005168201,0.000022120445,7.6480376e-7,0.00002022621,0.0075300788,0.00006147436],"about_ca_topic_score_codex":0.0002259395,"about_ca_topic_score_gemma":0.0014788663,"teacher_disagreement_score":0.08384993,"about_ca_system_score_codex":0.00045771291,"about_ca_system_score_gemma":0.0012189344,"threshold_uncertainty_score":0.35449123},"labels":[],"label_agreement":null},{"id":"W3122558395","doi":"10.1200/jco.2021.39.3_suppl.61","title":"Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University Health Network; Queen's University; Genome British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Microsatellite instability; Population; Oncology; Pembrolizumab; Durvalumab; Gastroenterology; Oxaliplatin; Immunotherapy; Hazard ratio; Cancer; Confidence interval","score_opus":0.09661752577408858,"score_gpt":0.478105301557651,"score_spread":0.3814877757835624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122558395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018896,0.0023085554,0.0000015363177,0.0028568646,0.0010107066,0.0007336489,0.000039623363,0.0000034044697,0.0028566895],"genre_scores_gemma":[0.9977965,0.0014359306,0.00018308814,0.0001267388,0.00034156683,0.000063136016,0.000009300201,0.000013694819,0.00003006808],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964851,0.00085265964,0.0017539182,0.0002421769,0.00045256971,0.00021355717],"domain_scores_gemma":[0.99439436,0.0037647008,0.0011125406,0.00009404205,0.0005114295,0.00012292711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013133929,0.00016755283,0.0014788896,0.00015333963,0.000042221967,0.000008922467,0.00009125912,0.00014048234,0.00010402923],"category_scores_gemma":[0.003941846,0.000108790904,0.00022422074,0.00029168883,0.00034757782,0.00008876345,0.000041065374,0.0005321519,0.0000022939696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7119199,0.0033593553,0.025591342,0.00013315551,0.003235727,0.011403281,0.014657223,0.0000759801,0.00024597236,0.00002485981,0.00045081537,0.22890237],"study_design_scores_gemma":[0.41641417,0.19657251,0.28260782,0.00045382485,0.0032611361,0.00093430665,0.092500836,0.00020197229,0.001852414,0.0001941249,0.0047683967,0.00023849719],"about_ca_topic_score_codex":0.0007899153,"about_ca_topic_score_gemma":0.0066389674,"teacher_disagreement_score":0.29550576,"about_ca_system_score_codex":0.0005474981,"about_ca_system_score_gemma":0.0031686777,"threshold_uncertainty_score":0.5621098},"labels":[],"label_agreement":null},{"id":"W3122630168","doi":"10.1200/jco.20.03288","title":"Burkitt Lymphoma International Prognostic Index","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"International Prognostic Index; Lymphoma; Risk stratification; Overall survival; Survival analysis; Stage (stratigraphy); Index (typography)","score_opus":0.1068606257422721,"score_gpt":0.46839124888687095,"score_spread":0.36153062314459883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122630168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94858754,0.00081764173,0.00008372995,0.026421348,0.003311233,0.00008306263,0.0000022541788,0.0000082786355,0.02068489],"genre_scores_gemma":[0.9893668,0.0009599279,0.002469902,0.004514945,0.0018817259,0.0000039905453,0.0000056441568,0.000009247584,0.00078780594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975872,0.000177094,0.0015487692,0.00015127973,0.0003889398,0.00014670611],"domain_scores_gemma":[0.9962541,0.0016587089,0.00083714124,0.0001407314,0.0007838537,0.00032549552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091447996,0.00009404767,0.00087728596,0.00007193695,0.000021603753,0.000013292566,0.00010844921,0.0002472788,0.00055113446],"category_scores_gemma":[0.005546883,0.000064392625,0.00051535864,0.000099502984,0.00008810993,0.00007209902,0.000062024075,0.00022863716,0.00006575637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073136727,0.0049673887,0.62421227,0.000006825529,0.0006882343,0.008885067,0.000022178496,0.0000027868643,0.000023047898,0.00033732803,0.0072848885,0.35283864],"study_design_scores_gemma":[0.010609025,0.00268319,0.721203,0.00007578758,0.00027567786,0.0029711018,0.000052758223,0.00005267864,0.0001685096,0.00033780924,0.26152626,0.000044168322],"about_ca_topic_score_codex":0.0000065668346,"about_ca_topic_score_gemma":0.000010396407,"teacher_disagreement_score":0.35279447,"about_ca_system_score_codex":0.00025659276,"about_ca_system_score_gemma":0.0029995015,"threshold_uncertainty_score":0.6640538},"labels":[],"label_agreement":null},{"id":"W3122808051","doi":"10.1200/jco.2021.39.3_suppl.477","title":"Effect of food on exposure to napabucasin: Data from two phase I studies.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacology","score_opus":0.6275197424482802,"score_gpt":0.6712003606688983,"score_spread":0.043680618220618084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122808051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262143,0.003493529,0.0000612624,0.003910557,0.008189238,0.00016882394,0.00022175998,0.000007940089,0.0013254775],"genre_scores_gemma":[0.9898292,0.001398503,0.0006487349,0.0055730417,0.002370526,0.0000023463924,0.000024116578,0.00001682271,0.0001367368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99319136,0.0038236044,0.0020292166,0.00038239025,0.00028991397,0.00028352524],"domain_scores_gemma":[0.9840068,0.013093831,0.0014210374,0.00046448628,0.00055312406,0.00046071768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060471594,0.00021446864,0.0018129469,0.00008997652,0.00008378907,0.000008707091,0.0007321423,0.0004159155,0.0007606592],"category_scores_gemma":[0.007180624,0.00015588218,0.0004043858,0.0002071957,0.0002899954,0.000115044124,0.000425885,0.0016362651,0.00006422631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037030857,0.011269086,0.038830973,0.00011696017,0.008496553,0.0043665464,0.00047745235,0.00017953893,0.02561277,0.0002746106,0.13301027,0.7403344],"study_design_scores_gemma":[0.05070926,0.11758284,0.0077733127,0.00020911002,0.002104684,0.00020453465,0.0003704118,0.00020411998,0.07877243,0.00062330323,0.74108374,0.00036222854],"about_ca_topic_score_codex":0.0000032586217,"about_ca_topic_score_gemma":0.00003508177,"teacher_disagreement_score":0.7399722,"about_ca_system_score_codex":0.0000763437,"about_ca_system_score_gemma":0.0006373121,"threshold_uncertainty_score":0.85963964},"labels":[],"label_agreement":null},{"id":"W3122964662","doi":"10.1200/jco.2021.39.3_suppl.336","title":"Role of ctDNA to predict risk of recurrence following potentially curative resection of biliary tract and pancreatic malignancies.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Intrahepatic Cholangiocarcinoma; Gallbladder cancer; Ampulla of Vater; Pancreatic cancer; Gallbladder; Biliary tract cancer; Gemcitabine; Oncology; Cancer; Carcinoma","score_opus":0.05893257849553382,"score_gpt":0.40256960759060956,"score_spread":0.34363702909507576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122964662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901286,0.006889382,0.00017005787,0.0010899317,0.0005461222,0.0001398991,0.00001377093,0.0000021096312,0.0010201398],"genre_scores_gemma":[0.9937737,0.0031340392,0.0026951116,0.000109355344,0.00023149149,0.00000204115,0.000001089138,0.000006711859,0.00004644138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971375,0.0004089268,0.0018363055,0.00015859032,0.000335407,0.00012328637],"domain_scores_gemma":[0.9956871,0.0016816802,0.0015633486,0.00014848732,0.0007659963,0.00015333321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018689688,0.0000942678,0.00146076,0.00010806928,0.000024388255,0.0000021193123,0.00007415697,0.00015706322,0.000020023197],"category_scores_gemma":[0.00737304,0.000069783404,0.00048096996,0.00022326935,0.00016316333,0.00008525399,0.00006441712,0.00043423296,3.4293882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033717926,0.0010117019,0.89854574,0.00014664081,0.0011960826,0.00020292545,0.0013006886,0.0000142824165,0.021432033,0.000019640898,0.00067023636,0.07208823],"study_design_scores_gemma":[0.0032219377,0.013437324,0.97103953,0.00066971185,0.0012692531,0.00015814127,0.001591173,0.00002702323,0.0071751876,0.0003368852,0.0010190015,0.000054822834],"about_ca_topic_score_codex":0.00007392738,"about_ca_topic_score_gemma":0.00009296943,"teacher_disagreement_score":0.072493784,"about_ca_system_score_codex":0.00004299801,"about_ca_system_score_gemma":0.0010605613,"threshold_uncertainty_score":0.88267505},"labels":[],"label_agreement":null},{"id":"W3123001931","doi":"10.1200/jco.2021.39.3_suppl.224","title":"Gastric and gastroesophageal adenocarcinoma survival outcomes relative to completion of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A single-center retrospective analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Perioperative; Docetaxel; Oxaliplatin; Internal medicine; Neoadjuvant therapy; Cancer; Oncology; Adenocarcinoma; Surgery; Retrospective cohort study; Chemotherapy; Gastroenterology; Colorectal cancer","score_opus":0.10930711783676073,"score_gpt":0.4131982975255693,"score_spread":0.3038911796888086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123001931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880414,0.00048651747,0.003109566,0.0056498465,0.00048209226,0.0002571766,0.000019011606,0.0000074178006,0.0019469663],"genre_scores_gemma":[0.9853647,0.00018387688,0.012308313,0.0009232344,0.0003178235,0.0000031165507,0.0000086012205,0.000013196366,0.0008771387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963944,0.00052285596,0.0019442565,0.00035369632,0.0005268943,0.00025787836],"domain_scores_gemma":[0.9960782,0.0011479646,0.0012579146,0.00018865103,0.0009409004,0.0003863721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014483174,0.00021377965,0.0027562003,0.00047442515,0.000062328254,0.000026015909,0.00009049487,0.00016980473,0.0001455758],"category_scores_gemma":[0.003111957,0.00016165695,0.00053361437,0.00080347137,0.00023163944,0.00019748119,0.00017387074,0.000666921,0.0000020591365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012987833,0.0006699672,0.98636234,0.000029343455,0.0024799746,0.00049226865,0.00043435014,0.000015342855,0.00016546437,0.00046889027,0.00021458245,0.007368672],"study_design_scores_gemma":[0.008079939,0.008066726,0.9788609,0.000045789722,0.0023666406,0.00024583138,0.00072009175,0.00006660967,0.000028090883,0.000052490694,0.0013715148,0.0000953796],"about_ca_topic_score_codex":0.000024960102,"about_ca_topic_score_gemma":0.0001547008,"teacher_disagreement_score":0.009198747,"about_ca_system_score_codex":0.00022969881,"about_ca_system_score_gemma":0.00034043894,"threshold_uncertainty_score":0.6592179},"labels":[],"label_agreement":null},{"id":"W3123016286","doi":"10.1200/jco.2021.39.3_suppl.348","title":"Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Biliary tract cancer; Gallbladder cancer; Systemic therapy; Clinical endpoint; Oncology; Cancer; Clinical Oncology; Family medicine; Surgery; Gemcitabine; Breast cancer","score_opus":0.5885940818088715,"score_gpt":0.5731801830088509,"score_spread":0.015413898800020642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123016286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98021185,0.006702653,0.00020893083,0.0039495234,0.004809903,0.0002532436,0.000043273016,0.0000043114,0.0038163015],"genre_scores_gemma":[0.98553044,0.011004557,0.00047746356,0.0013601416,0.0013856529,0.000016638025,0.0000043366167,0.000021715166,0.00019906908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98227704,0.0023600336,0.014366568,0.0005101613,0.00007225611,0.00041396992],"domain_scores_gemma":[0.98590255,0.0072447406,0.0061516888,0.00028153547,0.00013535489,0.00028412245],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.053200785,0.00017795558,0.0042942706,0.0005562739,0.000017284303,0.000037212434,0.0002905274,0.0009824291,0.00053081615],"category_scores_gemma":[0.039737858,0.00017644973,0.0008178453,0.00043490002,0.0001152818,0.00053420244,0.0000565472,0.0018294659,0.00005907848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001323532,0.001975258,0.92625713,0.000031734642,0.00007660783,0.00081363344,0.00033640262,0.0004964102,0.00001119479,0.0020829472,0.00097345974,0.065621704],"study_design_scores_gemma":[0.015217165,0.0008481824,0.9409123,0.00016113532,0.000027819027,0.00007286865,0.00019969293,0.000917873,0.000017391869,0.027751552,0.01366022,0.00021376742],"about_ca_topic_score_codex":0.00037897078,"about_ca_topic_score_gemma":0.0018258437,"teacher_disagreement_score":0.06540793,"about_ca_system_score_codex":0.0006199408,"about_ca_system_score_gemma":0.0018057782,"threshold_uncertainty_score":0.97492903},"labels":[],"label_agreement":null},{"id":"W3123141270","doi":"10.1200/jco.2021.39.3_suppl.275","title":"Efficacy and safety of lenvatinib in the real-world treatment of hepatocellular carcinoma: Results from a Canadian multicenter database (HCC CHORD).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Ottawa Regional Cancer Foundation; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Nova Scotia Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Dalhousie University; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Lenvatinib; Hepatocellular carcinoma; Sorafenib; Internal medicine; Hepatitis C; Liver cancer; Oncology; Surgery; Gastroenterology","score_opus":0.19581243525026476,"score_gpt":0.40012071697481816,"score_spread":0.2043082817245534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123141270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894592,0.0015923053,0.000004595936,0.0059507582,0.00023857223,0.00045768303,0.00018909038,0.0000019720892,0.002105812],"genre_scores_gemma":[0.9940076,0.0031079056,0.0019052712,0.000373339,0.00034083502,0.000005233316,0.00014473568,0.000013584471,0.00010149664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954857,0.00095977593,0.0027424786,0.0002663305,0.00029916575,0.00024650586],"domain_scores_gemma":[0.9932064,0.0045107724,0.0011473179,0.00043030878,0.00030702137,0.00039820967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019497204,0.0001777378,0.0016184405,0.00020348067,0.000034661898,0.000005979662,0.00013367175,0.0002232681,0.00009640183],"category_scores_gemma":[0.0017388316,0.00011024394,0.0003781398,0.00026800466,0.00019446129,0.000061002997,0.000033249846,0.0004121558,0.000002873524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007703495,0.0029016542,0.959331,0.000026618643,0.00037880597,0.0059936517,0.0010058766,8.983166e-7,0.0003031359,0.000040624873,0.00026333405,0.022050912],"study_design_scores_gemma":[0.035506308,0.00562235,0.9266822,0.0002049892,0.000933814,0.00005677569,0.00032639975,0.0005676346,0.0017053306,0.000023309665,0.028282413,0.000088499095],"about_ca_topic_score_codex":0.06254523,"about_ca_topic_score_gemma":0.09017669,"teacher_disagreement_score":0.032648817,"about_ca_system_score_codex":0.00021897444,"about_ca_system_score_gemma":0.0023926494,"threshold_uncertainty_score":0.94369733},"labels":[],"label_agreement":null},{"id":"W3123172421","doi":"10.1200/jco.2021.39.3_suppl.457","title":"Gastrointestinal cancer mortality rate global trends over the last century.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mortality rate; Cancer; Obesity; Demography; Colorectal cancer; Gastrointestinal cancer; Environmental health; Red meat; Incidence (geometry); Consumption (sociology); Disease; Internal medicine; Pathology","score_opus":0.12286266120952274,"score_gpt":0.48655225536641694,"score_spread":0.36368959415689417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123172421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979773,0.00095455744,0.0002756485,0.009693165,0.002427506,0.00003636178,0.000006098391,0.00001209579,0.006821562],"genre_scores_gemma":[0.9928998,0.00036928037,0.00059716136,0.0031338532,0.002686569,0.0000023645557,0.0000013815924,0.0000066374314,0.00030297696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765414,0.00049489265,0.0011768095,0.00016434502,0.00031072416,0.00019910093],"domain_scores_gemma":[0.9974366,0.0007020791,0.0008926201,0.00016964164,0.0005290996,0.0002699763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019548896,0.000102075915,0.0007298577,0.0000302193,0.000054685563,0.000014377305,0.00009929138,0.00011109526,0.00058283797],"category_scores_gemma":[0.0024558357,0.00006104494,0.0005270733,0.00032860064,0.00015968368,0.00005899246,0.000054579166,0.00090809073,0.0000056673834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074657802,0.00061661087,0.6867087,0.000015969956,0.00032864843,0.0018006929,0.000022014492,0.00006939184,0.000141135,0.00008346676,0.010488719,0.2922589],"study_design_scores_gemma":[0.002947761,0.0070824586,0.91691417,0.000099212186,0.00034374333,0.0026988129,0.000069032,0.00016315139,0.000040458355,0.00010653176,0.069484346,0.00005033095],"about_ca_topic_score_codex":0.000115358096,"about_ca_topic_score_gemma":0.0015149177,"teacher_disagreement_score":0.29220855,"about_ca_system_score_codex":0.0002650862,"about_ca_system_score_gemma":0.001989041,"threshold_uncertainty_score":0.6381667},"labels":[],"label_agreement":null},{"id":"W3123216051","doi":"10.1200/jco.2021.39.3_suppl.361","title":"Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health","keywords":"Medicine; Concordance; Clinical endpoint; Clinical trial; Internal medicine; Progressive disease; Pazopanib; Randomized controlled trial; Oncology; Nuclear medicine; Disease; Cancer","score_opus":0.11320243322595831,"score_gpt":0.5099707410543219,"score_spread":0.39676830782836364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123216051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019045,0.00016900842,0.00003881537,0.007017263,0.0016609228,0.0003471887,0.000009054818,0.000008880641,0.0005584272],"genre_scores_gemma":[0.996615,0.00027180987,0.0011992983,0.00097645354,0.00057365437,0.0000096106405,0.000008499139,0.00003353941,0.00031212295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911623,0.0031220568,0.003409977,0.0004618071,0.00097385375,0.0008699835],"domain_scores_gemma":[0.9890697,0.008246605,0.0011239005,0.00034599894,0.0004389611,0.0007748314],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017589901,0.0002421556,0.0021371585,0.00036967846,0.000028958937,0.000018131665,0.00034692697,0.000031726944,0.00016430377],"category_scores_gemma":[0.02448818,0.00019956766,0.00041038575,0.00066616706,0.00029940324,0.0003687278,0.0002653213,0.0027341493,0.000020301812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08162517,0.0035763206,0.7323994,0.0000372625,0.00009306047,0.15170445,0.000011540631,0.0001006747,0.00013468896,0.000012380436,0.00064032106,0.029664738],"study_design_scores_gemma":[0.052908015,0.020328961,0.9036444,0.00017106997,0.000072134266,0.0009638548,0.00013992615,0.00010814949,0.00034925507,0.00012352079,0.021059256,0.00013145519],"about_ca_topic_score_codex":0.00003354344,"about_ca_topic_score_gemma":0.00033495697,"teacher_disagreement_score":0.171245,"about_ca_system_score_codex":0.0006559878,"about_ca_system_score_gemma":0.0037202374,"threshold_uncertainty_score":0.99956656},"labels":[],"label_agreement":null},{"id":"W3123221708","doi":"10.1200/jco.2021.39.3_suppl.190","title":"Is shift-work associated with increased risk of esophageal cancer for males? A meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sleep and Work-Related Fatigue","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Esophageal cancer; Meta-analysis; Odds ratio; Confidence interval; Cochrane Library; Subgroup analysis; Publication bias; Shift work; Cancer; Internal medicine; Oncology; Demography","score_opus":0.23641942759232928,"score_gpt":0.49562846010334866,"score_spread":0.25920903251101934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123221708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980459,0.008050056,0.0018126647,0.005368092,0.00130113,0.0002468708,0.00021393882,0.000013620923,0.0025346535],"genre_scores_gemma":[0.9930611,0.00021739824,0.0026306377,0.0032380589,0.00041436614,0.000028762524,0.000014070612,0.00002794699,0.00036764942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99316037,0.0025663427,0.0031457718,0.00036691976,0.0003964102,0.00036418092],"domain_scores_gemma":[0.9812116,0.011564402,0.0054455767,0.00039118467,0.0010678094,0.000319446],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0058219414,0.0002234094,0.004040356,0.0002088709,0.0000644772,0.000011860015,0.00033671508,0.0009228068,0.006264584],"category_scores_gemma":[0.0038376632,0.00014791264,0.0038807385,0.001124693,0.00023977456,0.00006817699,0.00004059071,0.0013390188,0.000014568475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003149437,0.0022110273,0.54322296,0.0000028034085,0.43540755,0.00047808993,0.00036106654,0.00027221674,0.0000010099587,0.00033282227,0.008061907,0.0064991405],"study_design_scores_gemma":[0.0072900867,0.0023466137,0.648298,0.00002595262,0.33905894,0.000008470947,0.00010791555,0.000014942594,0.000031468397,0.0003437908,0.002310491,0.00016330807],"about_ca_topic_score_codex":0.0002155375,"about_ca_topic_score_gemma":0.0009120663,"teacher_disagreement_score":0.10507508,"about_ca_system_score_codex":0.00008326747,"about_ca_system_score_gemma":0.0010213349,"threshold_uncertainty_score":0.9946438},"labels":[],"label_agreement":null},{"id":"W3123427197","doi":"10.1200/jco.2021.39.3_suppl.385","title":"Treatment patterns and survival outcomes of older patients with advanced pancreatic cancer (APC): A Canadian real-world evidence study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; Juravinski Cancer Centre; Nova Scotia Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; FOLFIRINOX; Chemotherapy; Proportional hazards model; Cohort; Retrospective cohort study; Pancreatic cancer; Geriatric oncology; Cancer; Performance status; Oncology; Irinotecan; Colorectal cancer","score_opus":0.15231461339135394,"score_gpt":0.5152287870047169,"score_spread":0.3629141736133629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123427197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340725,0.00038711636,0.000010865225,0.004194426,0.00034848586,0.0005329302,0.000016993496,0.00000343922,0.0010984855],"genre_scores_gemma":[0.993159,0.004208244,0.0009222054,0.00040360674,0.00015967572,0.000024515297,0.0000030957078,0.000016447224,0.0011032259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964745,0.0007551893,0.0016687297,0.00026071,0.00050731906,0.00033353944],"domain_scores_gemma":[0.9927159,0.004209484,0.000940949,0.00027612012,0.0010921649,0.0007653848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012629142,0.00017874208,0.0027190798,0.00018997738,0.000054060023,0.0000069105645,0.00010814925,0.00016736082,0.00036541774],"category_scores_gemma":[0.00235037,0.00010535334,0.00019663587,0.00020673934,0.0002136627,0.00010018806,0.00004162785,0.0004711712,0.0000022438094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022370582,0.0027761706,0.95273685,0.000048832586,0.001520753,0.0012504138,0.00035406917,0.0000020997998,0.0000039121246,0.000012612327,0.000060903687,0.038996324],"study_design_scores_gemma":[0.014861296,0.02137067,0.9604,0.00035096955,0.001646367,0.000035307054,0.0005995757,0.000014090532,0.000007994612,0.000012086377,0.0006144579,0.00008718879],"about_ca_topic_score_codex":0.047074117,"about_ca_topic_score_gemma":0.40654513,"teacher_disagreement_score":0.35947102,"about_ca_system_score_codex":0.0005692788,"about_ca_system_score_gemma":0.007884226,"threshold_uncertainty_score":0.99774015},"labels":[],"label_agreement":null},{"id":"W3123434280","doi":"10.1200/jco.2021.39.3_suppl.318","title":"Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Landmark; Clinical trial; Internal medicine; Placebo; Post hoc; Oncology; Cartography; Pathology; Alternative medicine","score_opus":0.06225089998967214,"score_gpt":0.3794926021912214,"score_spread":0.31724170220154924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123434280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966897,0.00088133104,0.000045936915,0.00048316977,0.00016164726,0.001507376,0.000095762014,0.000006199748,0.00012890702],"genre_scores_gemma":[0.99867815,0.00042620412,0.00022882846,0.0001975373,0.00004278216,0.000034845238,0.00011485125,0.000026839605,0.00024999154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9862768,0.0076220953,0.0042880657,0.00049427757,0.00095615955,0.00036259202],"domain_scores_gemma":[0.9848553,0.008487737,0.0037269122,0.00063630065,0.0019603781,0.0003333855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070669674,0.0003629037,0.007129527,0.00093766395,0.000054924716,0.000010947581,0.00028659726,0.00036806805,0.00028781706],"category_scores_gemma":[0.005792781,0.00019654572,0.00283592,0.003421439,0.00033670673,0.00012508393,0.000101171565,0.00073334976,8.2916785e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4255517,0.009384623,0.54097813,0.00001496423,0.019430954,0.0010163669,0.0007646438,0.00004323897,0.00020049214,0.0000011017705,0.000018973593,0.0025947967],"study_design_scores_gemma":[0.33246493,0.027910009,0.57632416,0.00007458514,0.059064806,0.000012007742,0.0005928462,0.0027391985,0.0005429977,0.000003367952,0.000120684446,0.00015043614],"about_ca_topic_score_codex":0.0005484801,"about_ca_topic_score_gemma":0.001621483,"teacher_disagreement_score":0.0930868,"about_ca_system_score_codex":0.00032846595,"about_ca_system_score_gemma":0.0018604142,"threshold_uncertainty_score":0.8014902},"labels":[],"label_agreement":null},{"id":"W3123439150","doi":"10.1200/jco.2021.39.3_suppl.292","title":"Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Gastroenterology; Cohort; Response Evaluation Criteria in Solid Tumors; Toxicity; Cancer; Refractory (planetary science); Adverse effect; Progressive disease; Oncology; Intrahepatic Cholangiocarcinoma; Phases of clinical research; Surgery; Clinical trial; Chemotherapy","score_opus":0.13513911484461974,"score_gpt":0.4849624684913671,"score_spread":0.3498233536467473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123439150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940028,0.0023564685,0.000006155341,0.001225689,0.0009193291,0.000779289,0.000018254123,0.0000065854806,0.00068539707],"genre_scores_gemma":[0.99394524,0.002322018,0.0020506082,0.0010381765,0.0004873449,0.000020046942,0.00001639347,0.000028430906,0.00009174536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958348,0.0005449688,0.0024485432,0.00041056174,0.00049232575,0.00026880082],"domain_scores_gemma":[0.9954239,0.0011874923,0.0019094485,0.0003049868,0.00080218964,0.00037197166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019455438,0.00021603423,0.0023311381,0.00013269144,0.00005264491,0.0000145192225,0.00018805698,0.00030513483,0.000095201714],"category_scores_gemma":[0.0019171628,0.0001487985,0.00012834721,0.00026156788,0.00025548783,0.0003904402,0.00013551004,0.0010263368,6.4700885e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14375325,0.014928319,0.64179635,0.000061457664,0.00037231098,0.00050164893,0.00033056666,0.000008103031,0.00045875902,0.0000032561609,0.00058548455,0.19720046],"study_design_scores_gemma":[0.25082663,0.04984475,0.6951289,0.00032010087,0.00040830128,0.00003403546,0.00021019515,0.000029849876,0.000058948743,0.000013810578,0.0030054296,0.000119014694],"about_ca_topic_score_codex":0.00011421363,"about_ca_topic_score_gemma":0.00043414693,"teacher_disagreement_score":0.19708145,"about_ca_system_score_codex":0.00023149715,"about_ca_system_score_gemma":0.0028870497,"threshold_uncertainty_score":0.6067827},"labels":[],"label_agreement":null},{"id":"W3123446117","doi":"10.1200/jco.2021.39.3_suppl.425","title":"Molecular profiling of advanced pancreatic ductal adenocarcinoma (PDAC): Role of ctDNA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Internal medicine; Pancreatic cancer; Oncology; Chemotherapy; Pancreatic ductal adenocarcinoma; Population; Pathology; Cancer; Colorectal cancer","score_opus":0.02711881269169134,"score_gpt":0.37210799920329746,"score_spread":0.3449891865116061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123446117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98479515,0.012668679,0.00041237357,0.00028605637,0.0005401312,0.00007927308,0.000017486405,0.00000106767,0.0011997895],"genre_scores_gemma":[0.9826072,0.0025608095,0.014021108,0.00028592863,0.00046192927,0.0000020677467,0.000013520852,0.000016582948,0.00003084012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975236,0.0002061748,0.0017192798,0.00019735213,0.00018317139,0.00017043542],"domain_scores_gemma":[0.99696946,0.0003665946,0.0015110469,0.00027340837,0.000724872,0.00015461851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000779395,0.000114626026,0.0008755606,0.00004230632,0.000015039711,0.0000037587422,0.00021650821,0.000300941,0.00002355652],"category_scores_gemma":[0.003627097,0.00010467964,0.00048014984,0.00009284962,0.00016319966,0.0000046667797,0.00013684791,0.0002680626,0.0000011034067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010639139,0.0006461005,0.060534462,0.00004431066,0.00037473417,0.00020030497,0.000029979808,0.0007576793,0.9206258,0.00059094833,0.00017949149,0.014952265],"study_design_scores_gemma":[0.0035928607,0.0069318716,0.04396392,0.00006467461,0.00032464217,0.0002897911,0.00044013825,0.00007143835,0.9306582,0.0013353978,0.012159559,0.00016748751],"about_ca_topic_score_codex":0.0000065448066,"about_ca_topic_score_gemma":0.000013297466,"teacher_disagreement_score":0.01657054,"about_ca_system_score_codex":0.000022631832,"about_ca_system_score_gemma":0.0017461187,"threshold_uncertainty_score":0.4342236},"labels":[],"label_agreement":null},{"id":"W3123515346","doi":"10.1200/jco.2021.39.3_suppl.82","title":"Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Regorafenib; Atezolizumab; Oncology; Internal medicine; Colorectal cancer; Irinotecan; Oxaliplatin; Clinical endpoint; Phases of clinical research; Cancer; Clinical trial; Pembrolizumab; Immunotherapy","score_opus":0.2516595996139932,"score_gpt":0.548639827681197,"score_spread":0.2969802280672038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123515346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98041934,0.010075849,0.000007907064,0.00372129,0.0012205453,0.0009248888,0.000019351744,0.0000027786648,0.0036080508],"genre_scores_gemma":[0.98896337,0.0096230125,0.0009514795,0.000120339675,0.0002211906,0.000034204375,0.000006485118,0.000012265451,0.00006764584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99476486,0.0012512354,0.0029491517,0.00025386643,0.00058553944,0.00019536831],"domain_scores_gemma":[0.9916957,0.004325158,0.0021616316,0.00015281304,0.001495705,0.00016898387],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061389836,0.00017054859,0.0037005667,0.00011669832,0.00005357673,0.0000061069823,0.00014018243,0.00024811472,0.00024087816],"category_scores_gemma":[0.011531798,0.00011978084,0.00027749848,0.00028080537,0.00046729992,0.00011533394,0.00021860322,0.0004960526,5.016563e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72981894,0.008288502,0.0008145925,0.000041918887,0.0016661776,0.00022619742,0.0005247715,0.000056725672,0.000621512,0.00009286247,0.00032410026,0.2575237],"study_design_scores_gemma":[0.9440226,0.031522375,0.016731706,0.0003325077,0.0029892635,0.00009782153,0.00031221934,0.0014146834,0.0008865559,0.00019474955,0.0013943451,0.000101157595],"about_ca_topic_score_codex":0.00021830293,"about_ca_topic_score_gemma":0.0006983837,"teacher_disagreement_score":0.25742254,"about_ca_system_score_codex":0.00060742564,"about_ca_system_score_gemma":0.0053970553,"threshold_uncertainty_score":0.99679446},"labels":[],"label_agreement":null},{"id":"W3123581284","doi":"10.1200/jco.20.02019","title":"Incidence and Predictors of Mental Health Outcomes Among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study Using the IMPACT Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; SickKids Foundation; University of Toronto; Pediatric Oncology Group; Centre for Addiction and Mental Health; Public Health Ontario; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Incidence (geometry); Population; Cohort; Cumulative incidence; Mental health; Rate ratio; Cohort study; Psychiatry; Confidence interval; Pediatrics; Internal medicine","score_opus":0.08430229534926975,"score_gpt":0.49170652692768957,"score_spread":0.4074042315784198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123581284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300927,0.000980265,0.00003482246,0.0045868917,0.00086108834,0.00049156003,0.0000253485,0.0000037930781,0.0000069543275],"genre_scores_gemma":[0.9978281,0.0005745152,0.00032173155,0.0010168353,0.00023600191,0.0000018325286,0.000002849373,0.000012788417,0.0000053490826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947733,0.0013285707,0.0028501835,0.0002019333,0.00066856405,0.00017743447],"domain_scores_gemma":[0.9942578,0.0015241434,0.0030959125,0.00021734096,0.00058080343,0.00032397817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049075554,0.00014810768,0.0019263066,0.00008955248,0.00006670605,0.0000072848197,0.00010533125,0.00013230406,0.000019588091],"category_scores_gemma":[0.0030337274,0.00009278172,0.00029758803,0.00017468397,0.00025987177,0.000088976725,0.00007404467,0.00057786354,3.501511e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008886457,0.0014541317,0.9936372,0.000112911905,0.0006528563,0.000025165707,0.0015639864,0.0000860328,0.000013644147,0.0000020585244,0.00009913664,0.0014642462],"study_design_scores_gemma":[0.0047283634,0.003990176,0.98703474,0.0005623607,0.00034583933,0.00006909262,0.0027880406,0.00038346474,0.000015832837,0.0000101142305,0.0000061978017,0.00006575827],"about_ca_topic_score_codex":0.036459725,"about_ca_topic_score_gemma":0.034977254,"teacher_disagreement_score":0.0066024247,"about_ca_system_score_codex":0.00027267545,"about_ca_system_score_gemma":0.0028121828,"threshold_uncertainty_score":0.9826319},"labels":[],"label_agreement":null},{"id":"W3123764157","doi":"10.1200/jco.2021.39.3_suppl.268","title":"Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Interim analysis; Internal medicine; Placebo; Clinical trial; Hepatocellular carcinoma; Alternative medicine","score_opus":0.12097494491905073,"score_gpt":0.3799611787441557,"score_spread":0.258986233825105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123764157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234325,0.0012799983,0.0001325498,0.0019399098,0.00029381557,0.0035196778,0.0000695298,0.000031060874,0.00039020667],"genre_scores_gemma":[0.99563646,0.0004415144,0.0014708064,0.00085748103,0.00040804074,0.00008148108,0.0008148231,0.00008066005,0.00020871867],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98971057,0.0039984067,0.0037688424,0.0008910117,0.0010172798,0.00061390444],"domain_scores_gemma":[0.98985845,0.004492099,0.002508228,0.0014327959,0.0011012341,0.0006072078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043654544,0.0005652911,0.0047180047,0.00017428899,0.00013412035,0.000052808427,0.00072053744,0.00045293928,0.000443571],"category_scores_gemma":[0.0023704786,0.00029620057,0.00054164854,0.0006534695,0.00044441049,0.00038103483,0.00026247444,0.0016782483,0.000027023609],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4225206,0.00927766,0.54827744,0.000013075741,0.001455635,0.007872907,0.00030546615,0.0000044483727,0.000013162214,0.000001972844,0.00048763998,0.009769999],"study_design_scores_gemma":[0.7958716,0.037378144,0.15320483,0.0002776442,0.0056322883,0.0002536474,0.00052311586,0.003191836,0.00019734209,0.00001718982,0.0031231379,0.00032918173],"about_ca_topic_score_codex":0.0005026547,"about_ca_topic_score_gemma":0.0007540256,"teacher_disagreement_score":0.39507258,"about_ca_system_score_codex":0.00028977927,"about_ca_system_score_gemma":0.003018327,"threshold_uncertainty_score":0.99994904},"labels":[],"label_agreement":null},{"id":"W3123822883","doi":"10.1200/jco.2021.39.3_suppl.175","title":"Using breath analysis as a screening tool to detect gastric cancer: A systematic review.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Chemical Sensor Technologies","field":"Engineering","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Internal medicine; Breath gas analysis; Meta-analysis; Oncology; Gastroenterology","score_opus":0.10835774756399118,"score_gpt":0.44946232320831164,"score_spread":0.34110457564432045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123822883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80262864,0.04580451,0.14852685,0.0014641508,0.0005919636,0.00040377557,0.000008363223,0.00018609657,0.00038563702],"genre_scores_gemma":[0.76085085,0.021964364,0.21442278,0.002208151,0.00041268658,0.000020446978,0.000001073498,0.000048598078,0.0000710366],"study_design_codex":"simulation_or_modeling","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963991,0.00019507504,0.0026247995,0.00018450312,0.00030797083,0.00028853893],"domain_scores_gemma":[0.99682724,0.0014225396,0.00085277815,0.0003163874,0.00037525504,0.00020579215],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00086982694,0.00016932606,0.0027033158,0.00021175074,0.000027599759,0.000013230519,0.00031847475,0.0002747243,0.00007315738],"category_scores_gemma":[0.012687019,0.0001343287,0.0007818171,0.001468553,0.000042219406,0.00009948347,0.0000879049,0.0008139105,0.000009743383],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047298308,0.0004693231,0.009486494,0.065816656,0.021465186,0.007663585,0.00009593346,0.57653046,0.077225246,0.00007448576,0.002959305,0.23774032],"study_design_scores_gemma":[0.019097995,0.013470346,0.0210383,0.35626736,0.1819853,0.021280333,0.0020215935,0.17582884,0.16367666,0.006237843,0.031948403,0.0071470034],"about_ca_topic_score_codex":0.0000067005026,"about_ca_topic_score_gemma":0.000014883467,"teacher_disagreement_score":0.4007016,"about_ca_system_score_codex":0.00030552005,"about_ca_system_score_gemma":0.0001207525,"threshold_uncertainty_score":0.99562955},"labels":[],"label_agreement":null},{"id":"W3123856695","doi":"10.1200/jco.2021.39.3_suppl.230","title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Phases of clinical research; Adverse effect; Gastroenterology; Surgery; Clinical trial; Immunotherapy","score_opus":0.06305905101085445,"score_gpt":0.4187735071312949,"score_spread":0.35571445612044045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123856695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965685,0.00019565884,0.00001330694,0.0014933174,0.000360158,0.0011192425,0.000029699488,0.000010565261,0.00020955206],"genre_scores_gemma":[0.998053,0.00027524677,0.00025878922,0.0006220435,0.00040824598,0.00002180073,0.000041629406,0.000022737395,0.00029650945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946011,0.00063037284,0.0033507925,0.00035257463,0.0007232173,0.00034197865],"domain_scores_gemma":[0.9938923,0.0018283007,0.002620719,0.00035879354,0.0010793372,0.0002205519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013378052,0.00022765216,0.0022547462,0.00015918247,0.00006045873,0.000010841946,0.00024462084,0.00016261039,0.00015702461],"category_scores_gemma":[0.0039785104,0.00013221941,0.00023039884,0.00088425865,0.00012409431,0.0000950237,0.00012205047,0.0009855627,0.0000014663639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036280107,0.012836486,0.9172413,0.00001466484,0.0014373374,0.00062184705,0.0007924765,0.00020537508,0.000011497663,5.441314e-7,0.0020348243,0.028523581],"study_design_scores_gemma":[0.1337051,0.033073153,0.8298945,0.00019075604,0.0015602466,0.000018116976,0.00045239928,0.00022687197,0.000016673594,0.0000022925924,0.00076683855,0.000093048264],"about_ca_topic_score_codex":0.00116984,"about_ca_topic_score_gemma":0.002942947,"teacher_disagreement_score":0.097424984,"about_ca_system_score_codex":0.00036148477,"about_ca_system_score_gemma":0.0023947586,"threshold_uncertainty_score":0.5391751},"labels":[],"label_agreement":null},{"id":"W3123908305","doi":"10.1200/jco.2021.39.3_suppl.321","title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Adverse effect; Clinical endpoint; Phases of clinical research; Cohort; Gastroenterology; Surgery; Toxicity; Cancer; Sorafenib; Clinical trial; Immunotherapy; Hepatocellular carcinoma","score_opus":0.1123646056471813,"score_gpt":0.45857021251970864,"score_spread":0.3462056068725273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123908305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925572,0.001128238,0.000011560652,0.003931339,0.00046969915,0.0011747705,0.000010601677,0.0000067210826,0.0007098257],"genre_scores_gemma":[0.99646354,0.0002806076,0.0003874623,0.0019858172,0.0006479955,0.00006174223,0.000011854228,0.000020223642,0.00014076344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967676,0.00043983283,0.0017790489,0.0002779254,0.00043436818,0.0003012355],"domain_scores_gemma":[0.9958922,0.0021509884,0.0009060069,0.00026094873,0.0006162059,0.00017362699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016894663,0.00018875606,0.0015746537,0.00009014918,0.00010268223,0.000010743245,0.00017248593,0.00016683193,0.00003899859],"category_scores_gemma":[0.0023063025,0.00010199809,0.00039484273,0.00024168096,0.00015015586,0.000099244055,0.00004394625,0.00080149266,0.0000010168897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020183977,0.016281927,0.8792486,0.000042221513,0.0008306919,0.0012288204,0.003075056,0.000020412097,0.000008526562,0.0000032725666,0.0033581392,0.07571833],"study_design_scores_gemma":[0.08449443,0.068605304,0.8307397,0.000102988175,0.0010920321,0.00014159422,0.0019930725,0.000049714432,0.000011728107,0.000010469742,0.0126544405,0.00010452521],"about_ca_topic_score_codex":0.00010659665,"about_ca_topic_score_gemma":0.001094816,"teacher_disagreement_score":0.075613804,"about_ca_system_score_codex":0.00040914715,"about_ca_system_score_gemma":0.0028775944,"threshold_uncertainty_score":0.5104729},"labels":[],"label_agreement":null},{"id":"W3124012519","doi":"10.1200/jco.2021.39.3_suppl.114","title":"Multifocal extramural venous invasion detected with an elastin stain as a predictor of cancer-specific outcomes in stage I-III resected colorectal cancer (CRC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; Brampton Civic Hospital; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Nomogram; Stage (stratigraphy); Proportional hazards model; Hazard ratio; Stain; Colorectal cancer; Pathology; Log-rank test; T-stage; Cancer; Oncology; Radiology; Internal medicine; Staining; Confidence interval","score_opus":0.11285626525298634,"score_gpt":0.4585439096404497,"score_spread":0.34568764438746336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124012519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956016,0.0013783583,0.000023417693,0.0010497575,0.0009869477,0.00057310483,0.00006123819,0.000026197367,0.00029941244],"genre_scores_gemma":[0.9959019,0.001290357,0.001720971,0.00022278065,0.0004462591,0.00005766041,0.000013187281,0.000044286724,0.00030260588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421275,0.0010702128,0.0028307913,0.0004905118,0.0008943112,0.00050140184],"domain_scores_gemma":[0.9932343,0.0027611994,0.0017557372,0.00027962128,0.0012720114,0.0006971479],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012413223,0.00031107265,0.0027441955,0.00025451402,0.000048968595,0.000014113157,0.00023162422,0.0005690952,0.0011028474],"category_scores_gemma":[0.0026233774,0.00021187829,0.0004213748,0.00069288147,0.00041288973,0.00018339058,0.00010334388,0.0015985419,0.000003454358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079818115,0.007876808,0.8364414,0.000067693996,0.00085347844,0.009873253,0.0004727775,0.00020353985,0.007769355,0.0000142574545,0.000056021447,0.05655333],"study_design_scores_gemma":[0.030940345,0.04706254,0.91175425,0.0004372161,0.00031315393,0.00030992075,0.0004663128,0.00031569955,0.0061713774,0.00003702898,0.0020051515,0.00018702811],"about_ca_topic_score_codex":0.0014308473,"about_ca_topic_score_gemma":0.02420501,"teacher_disagreement_score":0.07531285,"about_ca_system_score_codex":0.0011741321,"about_ca_system_score_gemma":0.0066876896,"threshold_uncertainty_score":0.9998103},"labels":[],"label_agreement":null},{"id":"W3124129499","doi":"10.1200/jco.2021.39.3_suppl.tps352","title":"A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Response Evaluation Criteria in Solid Tumors; Gallbladder cancer; Internal medicine; Oncology; Clinical endpoint; Trastuzumab; Discontinuation; Immunohistochemistry; Gallbladder; Phases of clinical research; Regimen; Cancer; Chemotherapy; Clinical trial; Breast cancer","score_opus":0.2870316309922513,"score_gpt":0.5130706577274244,"score_spread":0.22603902673517312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124129499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924024,0.0023759992,0.000042147833,0.0030751212,0.0005249795,0.00080893136,0.00001069808,0.000006917648,0.0007528587],"genre_scores_gemma":[0.9911408,0.0015802586,0.0045049735,0.0022933881,0.0002430271,0.000029319446,0.0000042002725,0.000033772223,0.00017026314],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99560463,0.0006734757,0.0025384105,0.0003968774,0.0004657686,0.00032082302],"domain_scores_gemma":[0.99461776,0.002327854,0.0017025498,0.000395099,0.00067384343,0.00028288618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001863748,0.0002420253,0.0028367257,0.00017446051,0.00004377176,0.000019678779,0.00031264496,0.00013805328,0.00016562839],"category_scores_gemma":[0.0018060141,0.0001535225,0.00016963124,0.0005900976,0.00017924042,0.00024791597,0.0001056519,0.00091369747,0.0000016228239],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20180006,0.24884827,0.0785199,0.00022171234,0.00406588,0.027212374,0.005326085,0.000061001963,0.0044233627,0.000018324214,0.0021264132,0.4273766],"study_design_scores_gemma":[0.35485485,0.44506565,0.16564831,0.00070044823,0.0015963924,0.0014203469,0.0152984215,0.00005420591,0.0015949061,0.000107307154,0.013285854,0.00037330756],"about_ca_topic_score_codex":0.00027889034,"about_ca_topic_score_gemma":0.0057633733,"teacher_disagreement_score":0.4270033,"about_ca_system_score_codex":0.00027617416,"about_ca_system_score_gemma":0.0044912584,"threshold_uncertainty_score":0.7967299},"labels":[],"label_agreement":null},{"id":"W3124229040","doi":"10.1200/jco.2021.39.3_suppl.299","title":"Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Cohort; Adverse effect; Immunohistochemistry; Trastuzumab; Oncology; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Gallbladder; Chemotherapy; Surgery; Phases of clinical research; Cancer; Breast cancer","score_opus":0.13742726358658322,"score_gpt":0.4865471462798224,"score_spread":0.3491198826932391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124229040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786243,0.0025489742,0.000013027845,0.012310396,0.001706026,0.00025303586,0.00010621758,0.00000813487,0.004429877],"genre_scores_gemma":[0.9930331,0.00122625,0.0006798544,0.0029137419,0.0018784908,0.0000056730614,0.000028837358,0.000017395556,0.00021666811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953742,0.0007318328,0.002783705,0.00039899754,0.00043355755,0.00027771306],"domain_scores_gemma":[0.9946634,0.0030020373,0.0011486103,0.00032578336,0.0005207117,0.0003394396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002247714,0.0001832432,0.0019354371,0.00012625603,0.00004166073,0.000013312103,0.00016461448,0.00026906646,0.00015480105],"category_scores_gemma":[0.005212203,0.00014000807,0.00047708114,0.000283114,0.00013507677,0.00013857911,0.00010036043,0.0014662236,0.000013476667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040256184,0.024562804,0.6510293,0.000021089374,0.0020434144,0.05934494,0.0048414045,0.000018194654,0.00038594526,0.0000094439065,0.020675458,0.19681183],"study_design_scores_gemma":[0.053989764,0.017142072,0.90167314,0.00019536195,0.0006662002,0.00032005776,0.0043261647,0.000028333492,0.00015241247,0.000085445754,0.02128961,0.00013146596],"about_ca_topic_score_codex":0.001210003,"about_ca_topic_score_gemma":0.0025497673,"teacher_disagreement_score":0.25064382,"about_ca_system_score_codex":0.0005031656,"about_ca_system_score_gemma":0.003943784,"threshold_uncertainty_score":0.6996104},"labels":[],"label_agreement":null},{"id":"W3124250901","doi":"10.1200/jco.2021.39.3_suppl.289","title":"Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Gastroenterology; Cohort; Proportional hazards model; Fatty liver; Liver disease; Incidence (geometry); Oncology; Disease","score_opus":0.23849266734135485,"score_gpt":0.4779935213378557,"score_spread":0.23950085399650087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124250901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969095,0.00007261684,0.000007962436,0.0007391065,0.00046487348,0.00054549536,0.000009612701,0.000009654804,0.0012412067],"genre_scores_gemma":[0.99819386,0.00015807683,0.0006904387,0.00026519675,0.00043093122,0.000010178691,0.000027414033,0.00003000583,0.00019389627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936456,0.0014584884,0.0035555093,0.00039993142,0.0006775165,0.00026295998],"domain_scores_gemma":[0.9945573,0.0019617425,0.0016093437,0.000435688,0.0009275965,0.0005083136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039828504,0.00025717224,0.002862513,0.0002755181,0.000023229337,0.000012865304,0.00023147963,0.00043139365,0.0003342972],"category_scores_gemma":[0.0022299225,0.00015621001,0.0012111142,0.0002781812,0.0001823761,0.00015589796,0.000051708674,0.0011200306,0.000011685204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090904245,0.024706956,0.93681157,0.0000072416615,0.0028000548,0.017597452,0.00008125668,0.0000054264747,0.00003374561,0.000011638741,0.000075257274,0.008778994],"study_design_scores_gemma":[0.018307958,0.07525117,0.90420777,0.000057732443,0.0008685438,0.0003043169,0.00012299401,0.00040711174,0.00010183582,0.0000149109055,0.0002351152,0.000120574565],"about_ca_topic_score_codex":0.00024057458,"about_ca_topic_score_gemma":0.00014374075,"teacher_disagreement_score":0.050544214,"about_ca_system_score_codex":0.00027630987,"about_ca_system_score_gemma":0.0023730185,"threshold_uncertainty_score":0.6370059},"labels":[],"label_agreement":null},{"id":"W3124546863","doi":"10.1200/jco.20.03256","title":"Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Abiraterone acetate; Guideline; Oncology; Androgen deprivation therapy; Internal medicine; Cancer; Clinical trial; Radiation therapy; Management of prostate cancer; Gynecology; Pathology","score_opus":0.22149227194068663,"score_gpt":0.5749504827356309,"score_spread":0.3534582107949442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124546863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337688,0.017968165,0.0003598131,0.035828847,0.003833531,0.000959563,0.00014794133,0.00001790452,0.007115449],"genre_scores_gemma":[0.6092141,0.26061934,0.11349803,0.003807245,0.002154921,0.00007599257,0.00012449166,0.000088766144,0.01041708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953665,0.00037684973,0.0031051,0.00025001608,0.0005664481,0.00033504283],"domain_scores_gemma":[0.9958344,0.00048172535,0.0016627169,0.00023258377,0.0014003977,0.00038815496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022514905,0.00016784544,0.0015330539,0.00009419899,0.000039966606,0.000009471869,0.00016045531,0.000119853474,0.000788992],"category_scores_gemma":[0.0005902217,0.00010383978,0.00042713276,0.00033853782,0.00024976808,0.00013659886,0.00011173794,0.0007436312,0.000014795438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03377062,0.0028464631,0.0034645777,0.00046504298,0.0025307527,0.017624237,0.00007077794,0.00006317481,0.00023299266,0.00015143135,0.009943947,0.928836],"study_design_scores_gemma":[0.071163505,0.035060138,0.022656724,0.0022195207,0.0036032419,0.0016523565,0.0014294946,0.00025124324,0.0063504823,0.0014096263,0.8538631,0.00034055975],"about_ca_topic_score_codex":0.000010106207,"about_ca_topic_score_gemma":0.000043466775,"teacher_disagreement_score":0.9284954,"about_ca_system_score_codex":0.00018442242,"about_ca_system_score_gemma":0.004080524,"threshold_uncertainty_score":0.8638909},"labels":[],"label_agreement":null},{"id":"W3124587416","doi":"10.1200/jco.20.03579","title":"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Internal medicine; Placebo; Lung cancer; Hazard ratio; Population; Oncology; Adverse effect; Cancer; Surgery; Immunotherapy; Confidence interval; Pathology","score_opus":0.15214844631860835,"score_gpt":0.48328001778486057,"score_spread":0.3311315714662522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124587416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819226,0.0029016733,0.0042964946,0.0027795085,0.0017840151,0.005840981,0.000015420914,0.00001839543,0.00044090682],"genre_scores_gemma":[0.9867811,0.0014282205,0.0041373153,0.0020857658,0.0014705398,0.0005364182,0.000019423436,0.00007018265,0.003471003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99326617,0.0007897009,0.0042763064,0.0004989075,0.0006899432,0.000478979],"domain_scores_gemma":[0.9909409,0.0030586908,0.0037935255,0.00037126805,0.0013942958,0.00044129306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006839171,0.000373422,0.004099119,0.00021588276,0.00013994944,0.00004510379,0.00023750169,0.00024747464,0.00077646127],"category_scores_gemma":[0.0011216006,0.0002140886,0.0011287192,0.0003634198,0.0003629474,0.00017921535,0.000054952074,0.0010840216,0.0000028676843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96211195,0.009080695,0.0010780864,0.00035302056,0.0046310634,0.0028660323,0.0006052472,0.000107887914,0.00047724595,0.000004636318,0.0013915651,0.017292565],"study_design_scores_gemma":[0.94591606,0.033387527,0.00074319215,0.000468176,0.00810885,0.0014551391,0.0015834813,0.0013843486,0.0008365635,0.000015719543,0.005832949,0.00026801182],"about_ca_topic_score_codex":0.00015110547,"about_ca_topic_score_gemma":0.0010052067,"teacher_disagreement_score":0.024306834,"about_ca_system_score_codex":0.0006003005,"about_ca_system_score_gemma":0.01445833,"threshold_uncertainty_score":0.9911288},"labels":[],"label_agreement":null},{"id":"W3124598730","doi":"10.1200/jco.2021.39.3_suppl.117","title":"ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Queen's University; Princess Margaret Cancer Centre; Genome British Columbia","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; PTEN; Cancer research; Oncology; Exome sequencing; Internal medicine; Cancer; Mutation; PI3K/AKT/mTOR pathway; Gene; Biology; Genetics; Signal transduction","score_opus":0.06512520792348801,"score_gpt":0.42750489627135846,"score_spread":0.36237968834787043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124598730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903653,0.0009512759,0.0019419516,0.004690953,0.0013694295,0.00023247306,0.00004992587,0.0000016792179,0.00039697252],"genre_scores_gemma":[0.9891628,0.0003527208,0.0056963745,0.004195017,0.00048130847,0.000023311233,0.000021702004,0.000017684148,0.00004908283],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974545,0.00039912513,0.0013532437,0.00026406872,0.0002884061,0.0002406027],"domain_scores_gemma":[0.9972898,0.00165414,0.0005786736,0.00015120824,0.0002191575,0.00010707191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026749196,0.00014010575,0.0007328164,0.00008844561,0.00004190491,0.00002836091,0.0002592372,0.00019778461,0.000032924047],"category_scores_gemma":[0.0040868944,0.0001076082,0.0003535394,0.00022227304,0.00005754179,0.000008235489,0.000052655836,0.00036451506,0.0000026492505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13513725,0.017253328,0.22316217,0.0002021209,0.002439262,0.009268528,0.0013030223,0.069987506,0.47483775,0.004266967,0.04841343,0.01372865],"study_design_scores_gemma":[0.19172071,0.0136747295,0.5748011,0.0004052448,0.0006302152,0.00017396612,0.0019068139,0.0006041988,0.047258824,0.0033759999,0.16440721,0.0010410217],"about_ca_topic_score_codex":0.00003665358,"about_ca_topic_score_gemma":0.006166299,"teacher_disagreement_score":0.42757893,"about_ca_system_score_codex":0.000081594306,"about_ca_system_score_gemma":0.002935029,"threshold_uncertainty_score":0.5206616},"labels":[],"label_agreement":null},{"id":"W3124600345","doi":"10.1200/jco.2021.39.3_suppl.167","title":"Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Quality of life (healthcare); Adjuvant; Placebo; Esophageal cancer; Randomized controlled trial; Oncology; Cancer; Nursing; Pathology; Immunotherapy","score_opus":0.19971153984124687,"score_gpt":0.518683180574019,"score_spread":0.31897164073277207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124600345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991111,0.0034089535,0.0000072686094,0.0009167586,0.0007293823,0.0035912879,0.000027171898,0.000010773977,0.0001973998],"genre_scores_gemma":[0.9974348,0.0014118577,0.00024220243,0.000114382136,0.00020512746,0.00020708884,0.000044039898,0.000036754445,0.00030375534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98604774,0.0043122447,0.0070887026,0.0005669702,0.0013524328,0.00063188147],"domain_scores_gemma":[0.98913026,0.0035349906,0.004723063,0.00044157106,0.0013074788,0.00086260895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006570707,0.0003935925,0.0063560037,0.0005595004,0.000060292496,0.000011163665,0.00019586187,0.0003815089,0.0005667794],"category_scores_gemma":[0.0034563043,0.00024718462,0.0005894001,0.000943838,0.00037027008,0.0001850464,0.000086045,0.0013193773,0.000004617553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8000277,0.044090826,0.12680967,0.00012449377,0.0026667528,0.0033139768,0.0013901661,0.00023996455,0.000007121577,0.000009951818,0.000057826786,0.021261519],"study_design_scores_gemma":[0.73207843,0.1326914,0.13292645,0.0002826048,0.00057623023,0.00003624349,0.001060247,0.000093758616,0.00013010566,0.0000124341095,0.000012986469,0.00009912369],"about_ca_topic_score_codex":0.012785141,"about_ca_topic_score_gemma":0.027340485,"teacher_disagreement_score":0.088600576,"about_ca_system_score_codex":0.0021765076,"about_ca_system_score_gemma":0.014453878,"threshold_uncertainty_score":0.99999803},"labels":[],"label_agreement":null},{"id":"W3124605455","doi":"10.1200/jco.20.02298","title":"Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Statistics Canada; Institute for Clinical Evaluative Sciences; Kingston Health Sciences Centre; Hospital for Sick Children; Cancer Care Ontario; Queen's University; SickKids Foundation; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Mental health; Testicular cancer; Cancer registry; Population; Cohort; Mental health service; Confidence interval; Cancer; Demography; Psychiatry; Internal medicine; Environmental health","score_opus":0.1159836285205769,"score_gpt":0.49358586489066647,"score_spread":0.37760223637008955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124605455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945404,0.0016143502,0.00010367427,0.0025403185,0.00063087227,0.0005169207,0.000015802461,0.000008315548,0.000029328803],"genre_scores_gemma":[0.99773794,0.00025193478,0.00054171635,0.0011573279,0.00018050254,0.000007120069,0.00008089401,0.000014762187,0.000027814553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968238,0.0005617092,0.0018021349,0.00019068636,0.00047195324,0.00014971013],"domain_scores_gemma":[0.9961249,0.00059560564,0.0018940989,0.00019877337,0.0007998455,0.00038673263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001049995,0.00011701443,0.0011988254,0.000071354014,0.000047606456,0.000005888742,0.00006956273,0.000121152574,0.00020537991],"category_scores_gemma":[0.0014619945,0.000089778325,0.00029786996,0.00026459107,0.000043943342,0.00005760107,0.000027045457,0.0002446952,0.0000022749841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005490305,0.008144416,0.97493273,0.0001108594,0.00070702226,0.00062282954,0.00004514207,0.00014443815,0.000004908855,0.000002900311,0.000060822244,0.0146748815],"study_design_scores_gemma":[0.0074823448,0.0046204734,0.9857394,0.0002935284,0.0010323856,0.00005754573,0.00007160077,0.0005711419,0.000010913227,0.000007903385,0.000054060813,0.000058718557],"about_ca_topic_score_codex":0.0016030247,"about_ca_topic_score_gemma":0.0039612157,"teacher_disagreement_score":0.0146161625,"about_ca_system_score_codex":0.0002548943,"about_ca_system_score_gemma":0.0030975048,"threshold_uncertainty_score":0.5494841},"labels":[],"label_agreement":null},{"id":"W3124675115","doi":"10.1200/jco.2021.39.3_suppl.396","title":"Genomic characterization of <i>ATM</i> alterations in advanced pancreatic ductal adenocarcinoma (PDAC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; McGill University; Princess Margaret Cancer Centre; Mount Sinai Hospital; Nova Scotia Cancer Centre; Ontario Institute for Cancer Research; Toronto General Hospital; Dalhousie University; University of Toronto; University Health Network","funders":"","keywords":"PALB2; Medicine; Genome instability; Loss of heterozygosity; Germline; MUTYH; Homologous recombination; DNA repair; Gene; Cancer research; Genetics; Germline mutation; Biology; Mutation; Allele; DNA damage; DNA","score_opus":0.03449373534263918,"score_gpt":0.3664201265853688,"score_spread":0.33192639124272966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124675115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597335,0.0012859829,0.0006898763,0.0007435465,0.00082564086,0.00007327803,0.000024320389,8.5170177e-7,0.0003831503],"genre_scores_gemma":[0.9919443,0.003799345,0.0025562446,0.00077365094,0.0007447803,0.0000030507547,0.000061662504,0.000011799786,0.00010514044],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99798197,0.00019090604,0.001442438,0.0001636898,0.00009127521,0.00012972133],"domain_scores_gemma":[0.9982521,0.0002258404,0.0009213099,0.00017720548,0.00032183426,0.00010173863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058091135,0.00008574179,0.0005570984,0.000046603425,0.00001773145,0.0000071579793,0.00012723205,0.00021149055,0.00003245301],"category_scores_gemma":[0.0014159482,0.00008245602,0.00020960612,0.00008726296,0.00007140132,0.00000752073,0.00007150926,0.00021208846,0.0000024105068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071076606,0.000542866,0.15753236,0.000014535211,0.000095946685,0.00012992235,0.000047606565,0.0002107579,0.83196837,0.00014463664,0.00019109524,0.008411167],"study_design_scores_gemma":[0.0039073834,0.0034164174,0.91591424,0.00004248286,0.00010991259,0.00023986305,0.000083136976,0.000085680585,0.049675617,0.00023527947,0.02614414,0.0001458687],"about_ca_topic_score_codex":0.0000059871745,"about_ca_topic_score_gemma":0.00010014282,"teacher_disagreement_score":0.7822927,"about_ca_system_score_codex":0.0000393749,"about_ca_system_score_gemma":0.0013692433,"threshold_uncertainty_score":0.3362459},"labels":[],"label_agreement":null},{"id":"W3124907493","doi":"10.1200/jco.20.01359","title":"Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre; Dalhousie University; University of Toronto; BC Children's Hospital; SickKids Foundation; Hospital for Sick Children","funders":"National Institute of Environmental Health Sciences; Canadian Institutes of Health Research; Genentech; Eli Lilly and Company","keywords":"Medulloblastoma; Medicine; Oncology; Internal medicine; Sonic hedgehog; Radiation therapy; Cohort; Vismodegib; Pathology; Gene; Genetics; Biology","score_opus":0.06197669489408308,"score_gpt":0.44256872999066127,"score_spread":0.3805920350965782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124907493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98528826,0.00092070835,0.000051675077,0.012280967,0.00082388177,0.00011384743,0.0000033845013,0.0000047406315,0.00051254465],"genre_scores_gemma":[0.9889243,0.0005553506,0.007449204,0.0029300915,0.00011441601,0.000001992264,0.0000038697176,0.000010868226,0.0000098649925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582535,0.00061717327,0.0029180117,0.00017695795,0.00032737068,0.00013516488],"domain_scores_gemma":[0.9942053,0.0029748662,0.0016463608,0.00018990885,0.0006225225,0.00036105854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011912066,0.000114305236,0.0018829845,0.00007278995,0.000019269119,0.0000049365494,0.000055969416,0.00034479416,0.00007989356],"category_scores_gemma":[0.0030685612,0.00007810341,0.0007668023,0.000099281366,0.00020505555,0.00004680547,0.00006036384,0.00050683395,0.000005495738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015449004,0.007848851,0.8567115,0.000028932873,0.0013993358,0.0049440553,0.00006533518,0.0000055929236,0.003216996,0.0002953061,0.0012113302,0.12272784],"study_design_scores_gemma":[0.016515039,0.013924268,0.95709527,0.00017099374,0.0010429883,0.0006995515,0.00016049617,0.000024973886,0.0049511865,0.0004508565,0.004887344,0.00007702343],"about_ca_topic_score_codex":0.0000037971563,"about_ca_topic_score_gemma":0.00000568266,"teacher_disagreement_score":0.12265082,"about_ca_system_score_codex":0.00004234048,"about_ca_system_score_gemma":0.00059932255,"threshold_uncertainty_score":0.3673576},"labels":[],"label_agreement":null},{"id":"W3125095552","doi":"10.1200/jco.2021.39.3_suppl.383","title":"Adjuvant therapy in patients with resected pancreatic adenocarcinoma: Analysis of treatment allocation patterns in a Canadian provincial institution.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Regimen; Internal medicine; Pancreatic cancer; Capecitabine; Stage (stratigraphy); Oncology; Lymphovascular invasion; Surgery; Oxaliplatin; Cancer; Metastasis","score_opus":0.09057299451951543,"score_gpt":0.43431213703848076,"score_spread":0.3437391425189653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125095552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973454,0.00030073355,0.00003191694,0.0011632701,0.00009016674,0.00039064535,0.000014864471,0.0000017330497,0.00066128577],"genre_scores_gemma":[0.9982642,0.0007270473,0.0005280435,0.0002673826,0.000086701664,0.000014668748,0.000043576063,0.000007196669,0.00006118787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662614,0.000721371,0.0018207908,0.00019898733,0.0003317339,0.00030098998],"domain_scores_gemma":[0.9969747,0.0008844947,0.00070318126,0.00021208209,0.0008385937,0.0003869676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015738395,0.00011849988,0.0020803367,0.0008775572,0.000023454157,0.000003960049,0.000094190065,0.00029852445,0.00017907663],"category_scores_gemma":[0.0021310095,0.0000767562,0.00023186291,0.0009751212,0.00015527231,0.00007067753,0.000014362643,0.00047918715,0.0000014863035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005058306,0.0030711081,0.97379106,0.000014573,0.0015653939,0.0011209429,0.00031495045,0.000074105905,0.000012811387,0.00003490086,0.000016443433,0.014925397],"study_design_scores_gemma":[0.017102726,0.019646723,0.9606861,0.00010878643,0.0012147127,0.000023272825,0.00014583337,0.00070496043,0.000014758202,0.000014372493,0.00027765764,0.00006012802],"about_ca_topic_score_codex":0.091573395,"about_ca_topic_score_gemma":0.6606321,"teacher_disagreement_score":0.56905866,"about_ca_system_score_codex":0.0016298136,"about_ca_system_score_gemma":0.018791579,"threshold_uncertainty_score":0.986771},"labels":[],"label_agreement":null},{"id":"W3125253513","doi":"10.1200/jco.2021.39.3_suppl.tps147","title":"Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metastasectomy; Internal medicine; Bevacizumab; Colorectal cancer; Oncology; Irinotecan; Regimen; Oxaliplatin; Cetuximab; Surgery; Cancer; Chemotherapy","score_opus":0.0968890785395865,"score_gpt":0.40987955055097386,"score_spread":0.31299047201138736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125253513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924339,0.002073236,0.00000900934,0.0024870615,0.0005901377,0.0011858385,0.00009670652,0.000013048363,0.0011110809],"genre_scores_gemma":[0.9924867,0.0035122447,0.0010024031,0.0012812937,0.00038143396,0.000057370362,0.00004494837,0.000033085245,0.0012004857],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957859,0.0010261477,0.0014831139,0.0004686269,0.0007963622,0.0004398799],"domain_scores_gemma":[0.99313414,0.003944183,0.0011027252,0.0002634164,0.0011586652,0.00039685477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011443098,0.00031623023,0.0022445647,0.00022493488,0.00016105549,0.0000301836,0.0001962467,0.00014666446,0.0008444718],"category_scores_gemma":[0.0010920184,0.00016265264,0.0003161179,0.00075579574,0.00026879786,0.0002544709,0.0001542793,0.000797619,0.000016197535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5760279,0.004222084,0.38618007,0.000061359904,0.0035028374,0.005754186,0.00055660855,0.00013335703,0.000050224804,0.00002319993,0.007861283,0.015626881],"study_design_scores_gemma":[0.23169594,0.07022254,0.65767306,0.00064052845,0.004160294,0.00008496902,0.0010918827,0.00016695067,0.0014539297,0.000023900167,0.032459173,0.00032684839],"about_ca_topic_score_codex":0.010266093,"about_ca_topic_score_gemma":0.039142124,"teacher_disagreement_score":0.34433195,"about_ca_system_score_codex":0.0012320742,"about_ca_system_score_gemma":0.0040889564,"threshold_uncertainty_score":0.99632466},"labels":[],"label_agreement":null},{"id":"W3125260594","doi":"10.1200/jco.20.01814","title":"Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Daratumumab; Medicine; Oncology; Minimal residual disease; Multiple myeloma; Refractory (planetary science); Internal medicine; Negativity effect; Lenalidomide; Bone marrow","score_opus":0.13877459397116443,"score_gpt":0.4711845921469824,"score_spread":0.33240999817581796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125260594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689776,0.0006520543,0.000016142336,0.0019363079,0.000054076183,0.00028005283,0.000019409981,0.000001951794,0.00014221849],"genre_scores_gemma":[0.9979156,0.00022493045,0.0016111959,0.000041166313,0.000056018307,0.0000054436578,0.000017525843,0.000008170684,0.00011990508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956367,0.0016751753,0.0013800545,0.00022164374,0.00092017715,0.0001662525],"domain_scores_gemma":[0.9930081,0.0032501642,0.0012440586,0.00019431135,0.0019420449,0.00036134443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050231367,0.00011065176,0.001289009,0.0004516549,0.00003045866,0.000004894283,0.000047495203,0.00016826103,0.000053861233],"category_scores_gemma":[0.024058683,0.00007375343,0.00016124517,0.0005512577,0.00030097135,0.0001128235,0.000045904155,0.00040680097,1.7922794e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03993668,0.0045857695,0.89653206,0.0000917535,0.0025124783,0.0017943559,0.00030741643,0.00004413444,0.0008201652,0.00003294025,0.000063267355,0.053278957],"study_design_scores_gemma":[0.031880833,0.009530177,0.9467479,0.00011429909,0.00418534,0.00004851562,0.00062594685,0.0064490507,0.00024469278,0.000062656676,0.000054891563,0.00005569425],"about_ca_topic_score_codex":0.00007445036,"about_ca_topic_score_gemma":0.0015100981,"teacher_disagreement_score":0.053223263,"about_ca_system_score_codex":0.00024936083,"about_ca_system_score_gemma":0.003911435,"threshold_uncertainty_score":0.9841621},"labels":[],"label_agreement":null},{"id":"W3125547578","doi":"10.1200/jco.2021.39.3_suppl.tps445","title":"Systemic therapy with a loco-regional treatment in patients with locally advanced pancreatic cancer: The SMART study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Cancer Agency","keywords":"Medicine; Irreversible electroporation; Pancreatic cancer; Cancer; Oncology; Chemotherapy; Internal medicine; Surgery","score_opus":0.06411792994582981,"score_gpt":0.43136455072976376,"score_spread":0.36724662078393394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125547578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971046,0.00071584736,0.000518915,0.00092823565,0.00019339887,0.00045838792,0.0000026199762,0.0000016183538,0.000076366465],"genre_scores_gemma":[0.995017,0.0009823429,0.0024825577,0.0010498465,0.00024165427,0.000036690653,0.000006120292,0.000016454838,0.00016736351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725306,0.0012222619,0.0009425038,0.0002270803,0.00019661826,0.00015845547],"domain_scores_gemma":[0.9977949,0.00034060035,0.0009244214,0.00024323523,0.00060828886,0.000088514134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010124935,0.00014491577,0.00067332387,0.000031868603,0.00003861956,0.000009833157,0.00016385656,0.0001520493,0.00002478852],"category_scores_gemma":[0.00028594528,0.0000715848,0.00012389255,0.00013994086,0.00011998583,0.00000738365,0.000026724136,0.00026903642,8.872119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015835203,0.0043458166,0.86995804,0.000007363988,0.0008311019,0.00010122656,0.00015533106,0.00074021285,0.0077629727,0.000007327679,0.0002350566,0.10002033],"study_design_scores_gemma":[0.03170272,0.05233466,0.8715672,0.00014841213,0.00016612635,0.00014331739,0.00075922254,0.000007959325,0.003611006,0.000017325256,0.039334796,0.00020724155],"about_ca_topic_score_codex":0.000048114434,"about_ca_topic_score_gemma":0.0007774177,"teacher_disagreement_score":0.09981309,"about_ca_system_score_codex":0.00013091974,"about_ca_system_score_gemma":0.0021119288,"threshold_uncertainty_score":0.37464708},"labels":[],"label_agreement":null},{"id":"W3125577801","doi":"10.1200/jco.2021.39.3_suppl.464","title":"Association of perioperative red blood cell transfusions with all-cause and cancer-specific death in patients undergoing surgery for gastrointestinal cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Centre hospitalier universitaire de Québec; University of Manitoba; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Perioperative; Gastrointestinal cancer; Cancer; Interquartile range; Colorectal cancer; Blood transfusion; Population; Surgery; Proportional hazards model; Anemia; Retrospective cohort study; Internal medicine; Confidence interval","score_opus":0.07445381230343684,"score_gpt":0.41177198646306873,"score_spread":0.3373181741596319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125577801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851019,0.00050856156,0.00085470686,0.012920324,0.00029329033,0.00013587183,0.0000061431965,0.0000024804967,0.00017675865],"genre_scores_gemma":[0.97659826,0.0079080565,0.014306949,0.00064482284,0.00033309247,0.000005092473,0.0000050745925,0.000015636737,0.00018301595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795854,0.00027826696,0.0011904341,0.00015431327,0.00023968621,0.00017878768],"domain_scores_gemma":[0.9933126,0.004826776,0.0010018655,0.00005957868,0.0006116752,0.00018752206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015765156,0.000088910296,0.000940366,0.00007912871,0.000033650107,0.000007509997,0.00004001291,0.00010363362,0.000043320884],"category_scores_gemma":[0.004621153,0.00006546705,0.00015742527,0.00010308787,0.00006377555,0.000056425983,0.000012917935,0.0007095009,6.985407e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016711019,0.00093418726,0.9804474,0.00008036945,0.00028917505,0.00018645303,0.00015684095,0.00012768648,0.00065503124,0.000014135787,0.0005387282,0.014898864],"study_design_scores_gemma":[0.018316543,0.0058569973,0.96780217,0.0011742176,0.00087659206,0.0001484394,0.00020255946,0.00069511775,0.00020038427,0.000026565658,0.0046094945,0.000090918795],"about_ca_topic_score_codex":0.000045551435,"about_ca_topic_score_gemma":0.00040751018,"teacher_disagreement_score":0.01664544,"about_ca_system_score_codex":0.00017273241,"about_ca_system_score_gemma":0.002401741,"threshold_uncertainty_score":0.55322856},"labels":[],"label_agreement":null},{"id":"W3126003668","doi":"10.1200/jco.2021.39.3_suppl.tps351","title":"Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"NuCana","keywords":"Gemcitabine; Cisplatin; Medicine; Tolerability; Internal medicine; Oncology; Gallbladder cancer; Chemotherapy; Cancer; Biliary tract cancer; Phases of clinical research; Biliary tract; Gastroenterology; Adverse effect","score_opus":0.10507343026136758,"score_gpt":0.46243938858106615,"score_spread":0.3573659583196986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126003668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936903,0.0021344766,0.000093316856,0.0020759942,0.0007249378,0.0010152577,0.00010113707,0.0000059680137,0.00015860691],"genre_scores_gemma":[0.9957104,0.0013921103,0.0017736622,0.00026964277,0.00058157207,0.000055724147,0.0000234215,0.000028932878,0.00016457922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958341,0.00016896294,0.0029592232,0.00032233258,0.0004490883,0.00026629676],"domain_scores_gemma":[0.9930415,0.002288663,0.0025296966,0.00030488375,0.0015890166,0.00024620935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006279857,0.00025505,0.0028960528,0.00012965125,0.00005986601,0.0000035978744,0.00011337542,0.00018518892,0.00014964241],"category_scores_gemma":[0.0009290625,0.00016257715,0.00055589696,0.00024420375,0.00015992188,0.000104468396,0.000041173767,0.00032522253,5.539363e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06037904,0.065248504,0.692853,0.00016436036,0.0024023217,0.00037160428,0.0016094978,0.000118739845,0.00017919861,0.0000045512993,0.0008639806,0.17580523],"study_design_scores_gemma":[0.16240811,0.17206262,0.6563354,0.00020632369,0.0022218127,0.000028446208,0.0007505446,0.000055625867,0.0004667972,0.000023662802,0.005311187,0.00012945457],"about_ca_topic_score_codex":0.00007163007,"about_ca_topic_score_gemma":0.0010347193,"teacher_disagreement_score":0.17567576,"about_ca_system_score_codex":0.0002334818,"about_ca_system_score_gemma":0.0012246403,"threshold_uncertainty_score":0.6629704},"labels":[],"label_agreement":null},{"id":"W3126014926","doi":"10.1200/jco.2021.39.3_suppl.340","title":"Whole-genome sequencing of cholangiocarcinoma to reveal distinct profiles of patients with underlying cirrhosis or inflammatory disorders.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Malignancy; Gastroenterology; Exome sequencing; MLH1; Inflammatory bowel disease; Cirrhosis; Cancer; Colorectal cancer; Disease; Mutation; Genetics; Gene; DNA mismatch repair; Biology","score_opus":0.11567807180876355,"score_gpt":0.3982925960360022,"score_spread":0.28261452422723865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126014926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950231,0.00073280523,0.00013498745,0.0024962774,0.00035171368,0.00027265513,0.000029262503,0.000006343602,0.0009529],"genre_scores_gemma":[0.9959519,0.000087708024,0.0029230854,0.00052968017,0.00030210527,0.0000061040546,0.000011844931,0.000023606,0.00016395665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661475,0.00024494174,0.002151151,0.00023872203,0.0005026589,0.00024775448],"domain_scores_gemma":[0.99569565,0.0010171153,0.0016166063,0.00026629423,0.0011148883,0.00028945235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010191911,0.00017491585,0.0017043308,0.00015842053,0.000045799687,0.000005793499,0.00016220982,0.0001862841,0.00006240785],"category_scores_gemma":[0.0024235868,0.000113804,0.00041313298,0.00032052977,0.00021833439,0.00010508822,0.00012325514,0.00052938785,0.0000027981557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042164694,0.0006718573,0.9736601,0.00028561847,0.00069273374,0.00026875976,0.0007027362,0.000010795126,0.0013517273,0.000015755282,0.0004567325,0.01766669],"study_design_scores_gemma":[0.005529202,0.008389459,0.9793129,0.00036987854,0.00051142223,0.00005538643,0.0008802492,0.0000030113522,0.00018177429,0.000041576128,0.0046064556,0.00011870223],"about_ca_topic_score_codex":0.000023557606,"about_ca_topic_score_gemma":0.00022120701,"teacher_disagreement_score":0.017547987,"about_ca_system_score_codex":0.00020444301,"about_ca_system_score_gemma":0.002305399,"threshold_uncertainty_score":0.46407926},"labels":[],"label_agreement":null},{"id":"W3126084116","doi":"10.1200/jco.2021.39.3_suppl.411","title":"Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Genome British Columbia; Sunnybrook Health Science Centre; Cancer Care Ontario; Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; BC Cancer Agency; Hôpital Notre-Dame; Centre hospitalier universitaire de Québec; Vancouver General Hospital; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Ottawa Hospital; McGill University; Moncton Hospital","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Clinical endpoint; Microsatellite instability; Gastroenterology; Oncology; Urology; Randomized controlled trial; Cancer; Allele; Gene","score_opus":0.10604216909671703,"score_gpt":0.44378324718740436,"score_spread":0.3377410780906873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126084116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773371,0.005488589,0.000056745816,0.01460397,0.00034044293,0.0014258191,0.000015972371,0.000008132821,0.00072322745],"genre_scores_gemma":[0.98691404,0.009129537,0.0020529123,0.00085225323,0.0007263795,0.00007215849,0.000014928555,0.00003463363,0.00020316987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99086696,0.0033339786,0.0038541534,0.0005045785,0.000917505,0.0005227964],"domain_scores_gemma":[0.98267937,0.014106458,0.0017421362,0.0003894711,0.0007006786,0.00038186612],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009537204,0.0003369929,0.0034263548,0.00043112747,0.000095546675,0.000027869779,0.0002793572,0.00041875604,0.00016868909],"category_scores_gemma":[0.019360436,0.00022182321,0.0003639086,0.000566985,0.0008770962,0.0002193714,0.00012198661,0.0017421491,0.0000063389407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23279622,0.00834491,0.70132375,0.0005441799,0.0024881125,0.019701311,0.0083466945,0.00010984765,0.0003595657,0.0006312719,0.0006083126,0.024745839],"study_design_scores_gemma":[0.14110582,0.054964032,0.7838835,0.0004002229,0.0011829883,0.0050847363,0.004582234,0.004691572,0.000047266436,0.003133723,0.00074601424,0.0001778785],"about_ca_topic_score_codex":0.0003798732,"about_ca_topic_score_gemma":0.00034451156,"teacher_disagreement_score":0.09169041,"about_ca_system_score_codex":0.00027924226,"about_ca_system_score_gemma":0.0034525339,"threshold_uncertainty_score":0.9888999},"labels":[],"label_agreement":null},{"id":"W3126738486","doi":"10.1200/jco.20.02365","title":"Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Université Laval","funders":"National Cancer Institute","keywords":"Medicine; Pembrolizumab; Chromophobe cell; Internal medicine; Renal cell carcinoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Clinical endpoint; Histology; Phases of clinical research; Cohort; Clear cell; Surgery; Oncology; Urology; Cancer; Chemotherapy; Immunotherapy; Clinical trial","score_opus":0.11567608040251645,"score_gpt":0.4254655043625331,"score_spread":0.30978942396001663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126738486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414474,0.00074386236,0.000014630026,0.0008879753,0.0003628782,0.0013095023,0.0000055634323,0.000005779938,0.0025250886],"genre_scores_gemma":[0.99524915,0.00050592417,0.0024600367,0.0009520998,0.00022374136,0.000017729837,0.000011503982,0.00006325218,0.0005165641],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99449456,0.00068241556,0.0031452652,0.0005157971,0.0007678701,0.0003941172],"domain_scores_gemma":[0.99430716,0.0009352475,0.002564497,0.0005843351,0.0011426241,0.00046613853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011141768,0.00035345182,0.0026143591,0.00022367042,0.00007833646,0.00001836951,0.00045008265,0.0003150333,0.0003015879],"category_scores_gemma":[0.00030457863,0.00024141696,0.00026091456,0.00041156015,0.00013949457,0.00021221706,0.00018843493,0.0010552873,0.000007903601],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22682932,0.41646066,0.23239376,0.000058844053,0.0005273953,0.005639953,0.0012825269,0.00018184457,0.006265782,0.0000017449577,0.00035163615,0.11000652],"study_design_scores_gemma":[0.27392477,0.53669924,0.17617054,0.00009313236,0.00025830866,0.000059754562,0.00033292215,0.000038440856,0.010007698,0.00001859634,0.002232503,0.00016411075],"about_ca_topic_score_codex":0.000067420435,"about_ca_topic_score_gemma":0.00010148541,"teacher_disagreement_score":0.12023854,"about_ca_system_score_codex":0.0003759168,"about_ca_system_score_gemma":0.001927923,"threshold_uncertainty_score":0.9844698},"labels":[],"label_agreement":null},{"id":"W3126915654","doi":"10.1200/jco.20.03420","title":"Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Cancer Research UK; Bowel Cancer UK","keywords":"Medicine; Cancer; Oncology; Internal medicine","score_opus":0.06905533953624172,"score_gpt":0.49741782359836517,"score_spread":0.42836248406212346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126915654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94099015,0.034491085,0.00012320436,0.0089373635,0.0108486125,0.00013262656,0.00004457111,0.000003714208,0.004428696],"genre_scores_gemma":[0.72031265,0.24341619,0.0037920105,0.011812409,0.018986287,0.000035181736,0.00004320191,0.00005169814,0.0015503803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99582016,0.0004152441,0.0026909483,0.00047503263,0.0002961306,0.00030246392],"domain_scores_gemma":[0.9952749,0.00072550843,0.002236469,0.00041377047,0.0009588793,0.00039046528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023822293,0.00018747155,0.0010721305,0.00003790139,0.00005765583,0.000023747309,0.00029970089,0.0005881901,0.00016581647],"category_scores_gemma":[0.005110904,0.00015326381,0.00073484384,0.000109945984,0.00032253936,0.000009240929,0.00016468973,0.0007717334,0.000008248493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001450958,0.0012682532,0.22081488,0.000017784825,0.0005125803,0.0023798773,0.000008699785,0.00049926224,0.0008545336,0.00006118704,0.03980551,0.73232645],"study_design_scores_gemma":[0.0025781514,0.003522208,0.045398496,0.000093688745,0.00014341473,0.00016274062,0.000035762925,0.000017885064,0.0027174193,0.00012247912,0.9450128,0.00019495112],"about_ca_topic_score_codex":0.000013079065,"about_ca_topic_score_gemma":0.00044453904,"teacher_disagreement_score":0.9052073,"about_ca_system_score_codex":0.00007759175,"about_ca_system_score_gemma":0.005150912,"threshold_uncertainty_score":0.91374964},"labels":[],"label_agreement":null},{"id":"W3127156566","doi":"10.1200/jco.20.01802","title":"CanDirect: Effectiveness of a Telephone-Supported Depression Self-Care Intervention for Cancer Survivors","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; St Mary's Hospital Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Depression (economics); Quality of life (healthcare); Anxiety; Mental health; Population; Randomized controlled trial; Telephone interview; Physical therapy; Psychiatry; Internal medicine","score_opus":0.061490303496826715,"score_gpt":0.46741850206569324,"score_spread":0.4059281985688665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127156566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883992,0.005069911,0.0010671464,0.0003683303,0.0041482504,0.00028175837,0.000024680725,0.00001194439,0.0006287615],"genre_scores_gemma":[0.9974312,0.0009116884,0.0006139442,0.00022117194,0.0006741642,0.00002547878,0.000017912766,0.000019269519,0.00008513539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692,0.0008235595,0.0015975315,0.00020095719,0.00028516783,0.00017278787],"domain_scores_gemma":[0.99381626,0.0025217112,0.0013074541,0.00016845892,0.0019640245,0.0002220886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027038562,0.000117209696,0.0014855093,0.00009307477,0.000028339247,0.0000047054114,0.00009695933,0.000363403,0.00017052119],"category_scores_gemma":[0.0020411569,0.00008944439,0.00097393116,0.0001996985,0.00006361139,0.00006678105,0.00004354637,0.00046953588,9.2978604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014862997,0.0019063787,0.6466502,0.0020584387,0.0010790018,0.0003591366,0.00083508156,0.000019161791,0.003986996,0.000021050973,0.00059861457,0.32762298],"study_design_scores_gemma":[0.018509582,0.008729049,0.84655577,0.002205919,0.0016920461,0.00025725577,0.0019792002,0.00006565285,0.041444324,0.00014910409,0.07823749,0.00017461735],"about_ca_topic_score_codex":0.0007847625,"about_ca_topic_score_gemma":0.0090989955,"teacher_disagreement_score":0.32744834,"about_ca_system_score_codex":0.00024256945,"about_ca_system_score_gemma":0.002195844,"threshold_uncertainty_score":0.5077453},"labels":[],"label_agreement":null},{"id":"W3128028170","doi":"10.1200/jco.20.01375","title":"Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Cancer Institute","keywords":"Medicine; Diffuse large B-cell lymphoma; Vincristine; Internal medicine; International Prognostic Index; Rituximab; Lenalidomide; Clinical endpoint; CHOP; Prednisone; Gastroenterology; Cyclophosphamide; Performance status; Phases of clinical research; Oncology; Lymphoma; Surgery; Randomized controlled trial; Chemotherapy; Multiple myeloma","score_opus":0.05037879450228988,"score_gpt":0.4354927524106929,"score_spread":0.385113957908403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128028170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323714,0.00048880524,0.000028069428,0.0037824733,0.00096042413,0.0010852651,0.000027084758,0.000007147459,0.00038362027],"genre_scores_gemma":[0.99470365,0.00074720994,0.0013092366,0.0026492137,0.00026018382,0.00012522444,0.0000103708735,0.000022518392,0.00017240789],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924109,0.0016459901,0.004785893,0.00036388985,0.00042092762,0.00037241998],"domain_scores_gemma":[0.98852795,0.008623004,0.0017368367,0.0003256206,0.0003607095,0.0004258935],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004449298,0.00027184107,0.0048167743,0.00041127583,0.00003020545,0.000013677092,0.00017838858,0.0002870051,0.00020714449],"category_scores_gemma":[0.013375373,0.00018438773,0.0011103452,0.000321188,0.00009655219,0.00014849938,0.00018334495,0.0003903086,0.000010161018],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17854086,0.41337278,0.28891534,0.00004425819,0.0010629337,0.014279269,0.0015733283,0.0000048565666,0.00075407216,0.000029564224,0.0010044888,0.10041824],"study_design_scores_gemma":[0.6781491,0.018715534,0.29919133,0.0002458448,0.0005538234,0.00010165033,0.0009407047,0.00004597145,0.0005146836,0.000087806955,0.0013397716,0.0001137797],"about_ca_topic_score_codex":0.00026077963,"about_ca_topic_score_gemma":0.002126712,"teacher_disagreement_score":0.49960825,"about_ca_system_score_codex":0.00050009013,"about_ca_system_score_gemma":0.0012668517,"threshold_uncertainty_score":0.9949354},"labels":[],"label_agreement":null},{"id":"W3129039703","doi":"10.1200/jco.2015.33.7_suppl.248","title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Orchiectomy; Radiation therapy; Internal medicine; Gynecology; Urology; Oncology; Cancer","score_opus":0.3006676408482751,"score_gpt":0.5581479475104603,"score_spread":0.2574803066621852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129039703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900005,0.0014376667,0.00015599832,0.0065539763,0.0009101036,0.0005355885,0.00006347049,0.000002050981,0.00034067902],"genre_scores_gemma":[0.98808557,0.0094190035,0.001223034,0.00057583116,0.00028736403,0.000027101485,0.00003011927,0.000011453352,0.00034053143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977907,0.00023285054,0.0013613517,0.00011008211,0.00035548775,0.00014954424],"domain_scores_gemma":[0.99568367,0.0015316212,0.0009131721,0.000080500904,0.0015827193,0.00020832321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056753336,0.00007512306,0.00076677586,0.0001579455,0.000010899669,0.0000057227107,0.00011926783,0.00010766244,0.00006404699],"category_scores_gemma":[0.0030988166,0.0000483243,0.00012681235,0.00014709204,0.00013798398,0.000102909806,0.000021219857,0.00027890812,0.000002137712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02812519,0.00090961455,0.8727941,0.00003002235,0.00041980256,0.00007816616,0.00030463398,0.000056026463,0.00006598247,0.000010510664,0.0053746495,0.091831304],"study_design_scores_gemma":[0.045969654,0.010150707,0.86431944,0.00011685073,0.00007239165,0.000038127753,0.00012351641,0.0006543281,0.0006262388,0.00052880263,0.07732923,0.00007069163],"about_ca_topic_score_codex":0.00033429064,"about_ca_topic_score_gemma":0.00026159597,"teacher_disagreement_score":0.09176061,"about_ca_system_score_codex":0.00030656808,"about_ca_system_score_gemma":0.0052652275,"threshold_uncertainty_score":0.9340288},"labels":[],"label_agreement":null},{"id":"W3132205831","doi":"10.1200/jco.20.01366","title":"ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Chugai Pharmaceutical; MorphoSys; Kite Pharma; Incyte; Eisai; Karyopharm Therapeutics; Genentech; Celgene; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Medicine; CHOP; Lenalidomide; Internal medicine; International Prognostic Index; Placebo; Diffuse large B-cell lymphoma; Vincristine; Gastroenterology; Neutropenia; Clinical endpoint; Rituximab; Surgery; Lymphoma; Oncology; Cyclophosphamide; Chemotherapy; Pathology; Clinical trial; Multiple myeloma","score_opus":0.09420162739570512,"score_gpt":0.4095635778351286,"score_spread":0.3153619504394235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132205831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956602,0.0007547352,0.000010955797,0.00044710198,0.0010374401,0.0010815302,0.000012734301,0.000012614311,0.0009826729],"genre_scores_gemma":[0.9976996,0.0007438389,0.00048744978,0.0004641742,0.0002593318,0.000024189947,0.000023226945,0.00003888729,0.000259289],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99418545,0.0008991788,0.0032111933,0.0004549873,0.0007533084,0.00049587776],"domain_scores_gemma":[0.99240625,0.0031510862,0.0022575597,0.00047296844,0.001141762,0.0005704044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014733463,0.00034422043,0.002997529,0.0002318197,0.000059799582,0.000017117647,0.0002082681,0.00040400316,0.00015770439],"category_scores_gemma":[0.0023746477,0.00022924076,0.00041816264,0.0005155094,0.00013002813,0.00014356276,0.00012801775,0.0005045303,0.00001613676],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30426306,0.27603126,0.3813756,0.00008082706,0.0022876672,0.013696119,0.0015037312,0.0002667637,0.000016050246,0.000012888179,0.0015268971,0.018939134],"study_design_scores_gemma":[0.7236745,0.06862385,0.20097785,0.00028553177,0.0019480538,0.0001134215,0.001143689,0.00021038153,0.00009316567,0.00000473212,0.0027455618,0.00017930828],"about_ca_topic_score_codex":0.00018403718,"about_ca_topic_score_gemma":0.0010343138,"teacher_disagreement_score":0.4194114,"about_ca_system_score_codex":0.0012531205,"about_ca_system_score_gemma":0.0045106113,"threshold_uncertainty_score":0.93481666},"labels":[],"label_agreement":null},{"id":"W3132415718","doi":"10.1200/jco.20.01186","title":"Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Hodgkin lymphoma; Childhood cancer; Lymphoma; Oncology; Cancer; Pediatric cancer; Cancer therapy; Pediatrics; Internal medicine","score_opus":0.11489340953421741,"score_gpt":0.48009353934775706,"score_spread":0.36520012981353966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132415718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343836,0.0036661902,0.000019767776,0.00081999646,0.0010584099,0.0007022394,0.00023417339,0.000005136794,0.000055720873],"genre_scores_gemma":[0.9777468,0.019742202,0.0002762216,0.00020803834,0.0019438433,0.00002863982,0.00001490655,0.000023710429,0.000015655698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99501973,0.0011351875,0.0027934744,0.00030051943,0.00053717213,0.00021391772],"domain_scores_gemma":[0.9810667,0.011696506,0.00554328,0.00052750594,0.00093484577,0.00023113184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031155893,0.00021401289,0.0022338096,0.00008445244,0.000057448335,0.000007920949,0.00019113164,0.00026913226,0.00017862822],"category_scores_gemma":[0.0069683157,0.00010847545,0.0015886481,0.00023239784,0.00009014251,0.000043106476,0.00004796649,0.00037022866,0.0000018282051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058148447,0.027279824,0.8006082,0.0000059462354,0.004466367,0.0015033303,0.00032458975,0.000025389772,0.000007259816,0.0000010129929,0.0010207843,0.15894243],"study_design_scores_gemma":[0.033175144,0.026791021,0.93572557,0.00006477669,0.0034340157,0.00018708223,0.00012489944,0.000008725729,0.0001749726,0.00007332342,0.0001573,0.000083159706],"about_ca_topic_score_codex":0.0031342926,"about_ca_topic_score_gemma":0.001267844,"teacher_disagreement_score":0.15885927,"about_ca_system_score_codex":0.00026500417,"about_ca_system_score_gemma":0.0044149165,"threshold_uncertainty_score":0.8342228},"labels":[],"label_agreement":null},{"id":"W3133576337","doi":"10.1200/jco.2021.39.6_suppl.12","title":"CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Internal medicine; Nivolumab; Oncology; Abiraterone acetate; Chemotherapy; Cancer; Prednisone; Androgen deprivation therapy; Immunotherapy; Androgen receptor","score_opus":0.17478267805292091,"score_gpt":0.5093775652134046,"score_spread":0.3345948871604837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133576337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97847015,0.007215573,0.0003294153,0.012689785,0.0002821746,0.0006052291,0.00008923694,0.000005656757,0.00031276626],"genre_scores_gemma":[0.9792714,0.011379581,0.00687744,0.00046756028,0.00033324797,0.000024558705,0.00002996393,0.000016845423,0.0015994168],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99665356,0.0002678463,0.002130788,0.00026044823,0.00039826904,0.00028911044],"domain_scores_gemma":[0.99532896,0.0015401213,0.0014305726,0.00018448706,0.0011910736,0.00032477753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020928395,0.00016042197,0.0019774823,0.00017049817,0.00006808365,0.000016558572,0.00009731686,0.00015178228,0.00019506193],"category_scores_gemma":[0.0011410604,0.000109693676,0.00060913083,0.00042521147,0.0002902226,0.000089140914,0.000031898,0.00047347517,9.409834e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28813463,0.0117258085,0.050307017,0.0018502556,0.04679149,0.0034842838,0.0025851757,0.001236093,0.01530205,0.00055082515,0.0040334268,0.5739989],"study_design_scores_gemma":[0.21263936,0.046709895,0.64365804,0.00088754494,0.022587962,0.0005833315,0.0018403961,0.0036614318,0.01201713,0.0014307707,0.053477254,0.0005068762],"about_ca_topic_score_codex":0.000048235914,"about_ca_topic_score_gemma":0.00020244003,"teacher_disagreement_score":0.593351,"about_ca_system_score_codex":0.00024820617,"about_ca_system_score_gemma":0.005087714,"threshold_uncertainty_score":0.90253866},"labels":[],"label_agreement":null},{"id":"W3133638241","doi":"10.1200/jco.2021.39.6_suppl.133","title":"Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Abiraterone; Cohort; Internal medicine; Log-rank test; Exact test; Oncology; Androgen deprivation therapy; Retrospective cohort study; Docetaxel; Cancer; Survival analysis; Androgen receptor","score_opus":0.36925050314898716,"score_gpt":0.5771850649322998,"score_spread":0.20793456178331265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133638241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500884,0.005380321,0.00006519393,0.00753274,0.0009298888,0.00052733015,0.00007484272,0.0000043888913,0.00047648727],"genre_scores_gemma":[0.97792846,0.015995696,0.004598533,0.00012186839,0.00038115887,0.000028415128,0.000024437326,0.000020793364,0.0009006559],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996125,0.00029331984,0.0026884114,0.00018828885,0.00045405948,0.000250944],"domain_scores_gemma":[0.9928423,0.0030799557,0.0020093948,0.00019522983,0.0016429672,0.00023012597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016717279,0.00014344411,0.0018739419,0.00013820849,0.000043721895,0.000006616889,0.00011416522,0.00012332936,0.0002019976],"category_scores_gemma":[0.0010285778,0.0000954002,0.00046086268,0.00026307066,0.00028019823,0.000079431746,0.000026943688,0.0004385634,0.0000011222672],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35459414,0.015321885,0.15917246,0.0013436624,0.008482062,0.0010913118,0.0018345431,0.0009355104,0.07249648,0.00067795016,0.0072263987,0.3768236],"study_design_scores_gemma":[0.1910289,0.13058387,0.317636,0.0013916594,0.0028027417,0.00006382251,0.0018369793,0.0013523268,0.25579527,0.0016671472,0.095412605,0.0004286677],"about_ca_topic_score_codex":0.00014966339,"about_ca_topic_score_gemma":0.0019925272,"teacher_disagreement_score":0.37639493,"about_ca_system_score_codex":0.00021594654,"about_ca_system_score_gemma":0.0040353774,"threshold_uncertainty_score":0.71585864},"labels":[],"label_agreement":null},{"id":"W3133664994","doi":"10.1200/jco.2021.39.6_suppl.453","title":"Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cancer; Clinical endpoint; Proportional hazards model; Clinical trial","score_opus":0.039129252296962284,"score_gpt":0.40273625088766446,"score_spread":0.36360699859070217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133664994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392545,0.00021060956,0.00021560989,0.000988169,0.0042921137,0.00021682963,0.00009276354,0.0000014666111,0.000056981877],"genre_scores_gemma":[0.98743606,0.000061070285,0.0042632944,0.0007492365,0.0072416174,0.000007115046,0.0000108161985,0.000024770234,0.00020599405],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975541,0.000546496,0.0011910447,0.00024008185,0.00023159046,0.00023663431],"domain_scores_gemma":[0.99682766,0.0007690593,0.000866429,0.00024548,0.0009839742,0.00030740895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013891096,0.00015457127,0.00090651977,0.00008887856,0.000029283492,0.0000072318026,0.00014780519,0.00021681329,0.000021431477],"category_scores_gemma":[0.006130051,0.000106984,0.0006948352,0.000113438764,0.00010534226,0.0000051714533,0.00005092729,0.0002322539,0.0000018481435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29656065,0.007447118,0.15411022,0.00004864082,0.0024284364,0.000036959693,0.0002659701,0.0009897146,0.27709386,0.000030395857,0.17220339,0.08878464],"study_design_scores_gemma":[0.012341415,0.049456824,0.51819235,0.000046101457,0.00035800855,0.00005753688,0.000042013224,0.0000059075423,0.017022444,0.000031801068,0.402249,0.0001965983],"about_ca_topic_score_codex":0.000014974038,"about_ca_topic_score_gemma":0.0000347258,"teacher_disagreement_score":0.36408213,"about_ca_system_score_codex":0.000051830582,"about_ca_system_score_gemma":0.0028547829,"threshold_uncertainty_score":0.7338686},"labels":[],"label_agreement":null},{"id":"W3133767883","doi":"10.1200/jco.2021.39.6_suppl.tps180","title":"UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Cabazitaxel; Androgen deprivation therapy; Oncology; Cancer; Internal medicine; Prostate; Nuclear medicine; Urology","score_opus":0.2086462485145681,"score_gpt":0.5499936979897206,"score_spread":0.34134744947515255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133767883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759134,0.016716782,0.000016847065,0.0044998275,0.001073573,0.0012629788,0.000024746329,0.0000062815143,0.00048557695],"genre_scores_gemma":[0.98165697,0.015911171,0.00089415984,0.00019128292,0.00037066193,0.00007003657,0.000009259303,0.000023565293,0.0008728724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99346614,0.0017826665,0.0032768718,0.00036681013,0.0006932985,0.0004142141],"domain_scores_gemma":[0.99386925,0.0027983573,0.0017105109,0.00024613598,0.00091954326,0.00045622516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005538153,0.0002445482,0.0037906773,0.00027603924,0.000071447634,0.000017707547,0.00014727926,0.00020224763,0.00018003002],"category_scores_gemma":[0.0041830665,0.00015886225,0.00053126295,0.00037265843,0.0005354785,0.00019105972,0.00017575336,0.0011843984,0.0000022461302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8736087,0.024195904,0.008045124,0.00014115346,0.0053032376,0.008845764,0.0031126805,0.00003685421,0.001396745,0.000038509683,0.0012542617,0.07402108],"study_design_scores_gemma":[0.9302632,0.051514287,0.008313255,0.00017150077,0.0030431943,0.00021871713,0.0026484176,0.00029817878,0.0004689561,0.00028708807,0.0026127226,0.00016044384],"about_ca_topic_score_codex":0.00029070853,"about_ca_topic_score_gemma":0.00056920183,"teacher_disagreement_score":0.07386064,"about_ca_system_score_codex":0.0002642918,"about_ca_system_score_gemma":0.004165306,"threshold_uncertainty_score":0.73890746},"labels":[],"label_agreement":null},{"id":"W3133812191","doi":"10.1200/jco.2021.39.6_suppl.432","title":"Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Gemcitabine; Urology; Oncology; Cystectomy; Cancer; Gastroenterology","score_opus":0.1304839120686588,"score_gpt":0.47286151696030826,"score_spread":0.3423776048916495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133812191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508334,0.0007045567,0.0001065177,0.012755151,0.00065059273,0.0003865407,0.000084605934,0.00000832243,0.00022035911],"genre_scores_gemma":[0.9885314,0.0009795547,0.0038145713,0.005287908,0.001111078,0.0000120014265,0.000006429405,0.000037583042,0.00021948476],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970477,0.00051981624,0.001499894,0.00029084997,0.00034797072,0.00029376612],"domain_scores_gemma":[0.9936689,0.0031177702,0.0014184099,0.000278103,0.0011871413,0.00032965394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013543761,0.00022346697,0.0018088447,0.00012084063,0.00004158425,0.000006718998,0.0001028583,0.00034457102,0.0002698276],"category_scores_gemma":[0.0019644126,0.00012945515,0.0010401558,0.0001853762,0.00025064673,0.000054898894,0.000020821033,0.00055780064,0.000003702114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41095603,0.010799304,0.16282922,0.00008786996,0.0068008355,0.009893874,0.0010103126,0.00035124415,0.047929496,0.000028034437,0.030816695,0.3184971],"study_design_scores_gemma":[0.030022293,0.0981989,0.8518991,0.00038781215,0.0007996703,0.00078491936,0.00014420498,0.000017695489,0.0043436238,0.00015509326,0.013090921,0.00015580682],"about_ca_topic_score_codex":0.000049588867,"about_ca_topic_score_gemma":0.00007684016,"teacher_disagreement_score":0.68906987,"about_ca_system_score_codex":0.00033387137,"about_ca_system_score_gemma":0.0061756237,"threshold_uncertainty_score":0.99945843},"labels":[],"label_agreement":null},{"id":"W3133826468","doi":"10.1200/jco.2021.39.6_suppl.441","title":"Identification of characteristics associated with long-term survival in patients with metastatic urothelial carcinoma (mUC) who received durvalumab (D) with or without tremelimumab (T) in clinical studies.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Univariate analysis; Logistic regression; Post-hoc analysis; Oncology; Tremelimumab; Cabozantinib; Proportional hazards model; Multivariate analysis; Cancer; Immunotherapy; Ipilimumab; Nivolumab","score_opus":0.14393099389388747,"score_gpt":0.45100364951715444,"score_spread":0.30707265562326697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133826468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997898,0.00014574568,0.00005801286,0.00053718424,0.00058037887,0.00064066023,0.000036080335,0.000007081499,0.000096890784],"genre_scores_gemma":[0.9981736,0.0004778977,0.00047226323,0.0002939748,0.00022710951,0.000021662863,0.000027937522,0.000047955094,0.00025759742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99216646,0.0017621388,0.00443001,0.0004358716,0.00086268666,0.0003428177],"domain_scores_gemma":[0.9909302,0.0025998657,0.0037546738,0.00035038288,0.002088435,0.00027644163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034858382,0.0002973469,0.0036850236,0.00020676832,0.000034320146,0.000013836577,0.00017339842,0.00027505035,0.00006413146],"category_scores_gemma":[0.006120504,0.0001703667,0.00023565194,0.00053527503,0.00047103045,0.00016502212,0.00004418789,0.0010734058,0.000002617405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059344277,0.007867813,0.9157584,0.00009369058,0.0019717054,0.0020187532,0.00035509485,0.0000060611496,0.0000117188065,0.0000021078902,0.000021547052,0.012548846],"study_design_scores_gemma":[0.06439225,0.028325403,0.9038291,0.0009676885,0.0017989199,0.00008176393,0.00030588105,0.00002978985,0.0000697268,0.000009306173,0.000022569151,0.00016762498],"about_ca_topic_score_codex":0.000032177468,"about_ca_topic_score_gemma":0.002210532,"teacher_disagreement_score":0.02045759,"about_ca_system_score_codex":0.0004561815,"about_ca_system_score_gemma":0.0051945415,"threshold_uncertainty_score":0.92148936},"labels":[],"label_agreement":null},{"id":"W3133841503","doi":"10.1200/jco.2021.39.6_suppl.76","title":"Impact of treatment and frailty on elder-relevant physical function outcomes in older adults with metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Enzalutamide; Grip strength; Geriatric oncology; Logistic regression; Activities of daily living; Cohort; Prospective cohort study; Performance status; Gerontology; Physical therapy; Cancer; Internal medicine","score_opus":0.08304001130764442,"score_gpt":0.4623121076593699,"score_spread":0.3792720963517255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133841503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962182,0.0002663988,0.000020026266,0.0026575825,0.00024358837,0.00036659374,0.000025683874,0.000004605743,0.00019731205],"genre_scores_gemma":[0.9978675,0.00046319532,0.0009116974,0.00025175564,0.00015589877,0.000015579595,0.0000059442173,0.000017150482,0.0003112728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974627,0.00031275649,0.0014851306,0.00024403652,0.00028293527,0.0002124235],"domain_scores_gemma":[0.99649286,0.0015136956,0.00106851,0.00018308949,0.00048299946,0.00025886807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044940194,0.00020015443,0.0016357356,0.00011364684,0.000019263141,0.000006658297,0.000045032055,0.00012331273,0.00011400438],"category_scores_gemma":[0.00094244874,0.00010995167,0.00036195197,0.00016085483,0.00015905492,0.00010305378,0.000014810015,0.00051225483,0.0000023001455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044434436,0.015590126,0.6795816,0.00017223707,0.002888865,0.0021299256,0.0027650106,0.00044585878,0.0016172095,0.000054643057,0.00035912046,0.24996097],"study_design_scores_gemma":[0.02282425,0.059474703,0.91501737,0.00054201426,0.00069692085,0.0001822109,0.0003912139,0.00014388638,0.00030819533,0.00010718221,0.00021827212,0.000093760114],"about_ca_topic_score_codex":0.0004223411,"about_ca_topic_score_gemma":0.0020184861,"teacher_disagreement_score":0.24986722,"about_ca_system_score_codex":0.00039745576,"about_ca_system_score_gemma":0.0026464197,"threshold_uncertainty_score":0.46946347},"labels":[],"label_agreement":null},{"id":"W3133853946","doi":"10.1200/jco.2021.39.6_suppl.438","title":"Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Avelumab; Carboplatin; Internal medicine; Metastatic Urothelial Carcinoma; Regimen; Gemcitabine; Oncology; Chemotherapy regimen; Urothelial carcinoma; Cisplatin; Bladder cancer; Urology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.07232360652710555,"score_gpt":0.41668956359386167,"score_spread":0.3443659570667561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133853946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98311585,0.0010409754,0.0052720434,0.007859239,0.0010657003,0.00070162985,0.00021680506,0.000011310992,0.00071645714],"genre_scores_gemma":[0.98937476,0.0010667722,0.0068131527,0.0014641299,0.00082960905,0.00002729336,0.00009000028,0.000040072544,0.00029419386],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961329,0.00023881294,0.0023549488,0.00044815117,0.00046661546,0.00035855],"domain_scores_gemma":[0.99422365,0.0019488886,0.0017555059,0.00032845314,0.0014034292,0.00034008324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084003253,0.0002867344,0.0021784422,0.00022852037,0.00009255488,0.000012831742,0.00013067517,0.00040499406,0.00028156367],"category_scores_gemma":[0.0018481541,0.00022320036,0.000928313,0.00035145198,0.00024758014,0.00010375015,0.000031990367,0.00049728487,0.0000038104056],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40151292,0.012216263,0.18079005,0.0008957845,0.015211186,0.0030189443,0.003525415,0.0043602823,0.0041698753,0.00017353619,0.0020535882,0.37207216],"study_design_scores_gemma":[0.30018586,0.11673369,0.50347126,0.00067836355,0.018505264,0.00023560449,0.0040359586,0.010870388,0.026519129,0.00034618576,0.01754348,0.000874825],"about_ca_topic_score_codex":0.00010147027,"about_ca_topic_score_gemma":0.0010831997,"teacher_disagreement_score":0.37119734,"about_ca_system_score_codex":0.00039788565,"about_ca_system_score_gemma":0.0024137397,"threshold_uncertainty_score":0.9101846},"labels":[],"label_agreement":null},{"id":"W3133924450","doi":"10.1200/jco.2021.39.6_suppl.338","title":"Plasma exosome microRNAs in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab: Potential biomarkers of response to therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; microRNA; Ipilimumab; Biomarker; Renal cell carcinoma; Nivolumab; Exosome; TaqMan; Oncology; Internal medicine; Microvesicles; Real-time polymerase chain reaction; Downregulation and upregulation; Cancer; Immunotherapy; Gene","score_opus":0.014032968639324484,"score_gpt":0.30642976351273704,"score_spread":0.2923967948734126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133924450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862015,0.00070542865,0.00006580989,0.00025338383,0.00009479513,0.00016931674,0.000017254757,0.0000015941007,0.00007227161],"genre_scores_gemma":[0.9946663,0.000118486576,0.004818054,0.00019294371,0.00007207529,0.0000026339892,0.000014072798,0.00002308193,0.00009237969],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975518,0.0007121757,0.0010099075,0.0003035331,0.00021187177,0.00021073976],"domain_scores_gemma":[0.99807036,0.00020127077,0.00075370475,0.00025612963,0.00044715955,0.00027139974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007921476,0.00015718148,0.00059657585,0.00009513505,0.00002354208,0.0000076161937,0.00017296753,0.0002494008,0.000014510089],"category_scores_gemma":[0.00045991488,0.00011645308,0.00013852204,0.00015620972,0.00019403719,0.000010636032,0.00008015736,0.00024615982,7.4653417e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18188056,0.001989492,0.29059446,0.000013613939,0.00019490272,0.0006829489,0.000036089186,0.00014257597,0.5054515,5.37403e-7,0.00016137284,0.018851962],"study_design_scores_gemma":[0.02941301,0.028850198,0.7645543,0.000045399403,0.00007672811,0.00007521642,0.00009198397,0.000010078885,0.17451157,0.000005925445,0.0021947317,0.00017081793],"about_ca_topic_score_codex":0.0000050257822,"about_ca_topic_score_gemma":0.00003372717,"teacher_disagreement_score":0.47395986,"about_ca_system_score_codex":0.00003659711,"about_ca_system_score_gemma":0.0009486712,"threshold_uncertainty_score":0.47488186},"labels":[],"label_agreement":null},{"id":"W3133927564","doi":"10.1200/jco.2021.39.6_suppl.tps498","title":"TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Irinotecan; Internal medicine; Chemotherapy; Docetaxel; Oncology; Paclitaxel; Phases of clinical research; Cancer; Gastroenterology; Urology; Bladder cancer; Colorectal cancer; Urothelial carcinoma","score_opus":0.16044961041482275,"score_gpt":0.4574683434969437,"score_spread":0.29701873308212096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133927564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925169,0.0034979244,0.00003859683,0.0023225767,0.0006579503,0.00078564533,0.000017261627,0.000006024464,0.0001571333],"genre_scores_gemma":[0.995218,0.0015157341,0.0016562572,0.00078650424,0.00041797306,0.000082267245,0.0000012927954,0.0000294665,0.00029254874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641097,0.0005568222,0.0019671125,0.0003032316,0.00048124624,0.00028061387],"domain_scores_gemma":[0.9973207,0.0007632762,0.0010198185,0.0002182561,0.00041276548,0.0002651702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088393665,0.0002145388,0.0018623612,0.00012542002,0.000032033302,0.000018829833,0.00010307754,0.00018144403,0.0004617773],"category_scores_gemma":[0.0007627146,0.00013351256,0.00023245893,0.00024308669,0.00018894604,0.00013820798,0.000058665504,0.00071030355,0.0000012721027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10359435,0.016596787,0.5101344,0.00019967575,0.0018775342,0.006518857,0.0024615496,0.000047479924,0.0023239597,0.0000054473967,0.00016649751,0.35607344],"study_design_scores_gemma":[0.1341421,0.09113795,0.7484147,0.0008892803,0.0010043617,0.00050276355,0.0035110563,0.00007027814,0.008402699,0.0002459823,0.011383813,0.000294996],"about_ca_topic_score_codex":0.00017828138,"about_ca_topic_score_gemma":0.003026528,"teacher_disagreement_score":0.35577846,"about_ca_system_score_codex":0.00020046873,"about_ca_system_score_gemma":0.004336102,"threshold_uncertainty_score":0.7692058},"labels":[],"label_agreement":null},{"id":"W3133939255","doi":"10.1200/jco.2021.39.6_suppl.435","title":"Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Population; Urothelial cancer; Randomization; Clinical trial; Internal medicine; Cancer","score_opus":0.0722298073030398,"score_gpt":0.44491928812126624,"score_spread":0.37268948081822645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133939255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945746,0.00014543858,0.00017633253,0.003320817,0.0003519171,0.001213391,0.00008174681,0.000008160828,0.00012758812],"genre_scores_gemma":[0.98641473,0.00015985483,0.0050289542,0.0075964257,0.00016907541,0.000056070538,0.000037001173,0.00005432234,0.00048358054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955831,0.0003267686,0.0025897287,0.0004536535,0.0005994633,0.00044726764],"domain_scores_gemma":[0.99481225,0.0021265133,0.0012930926,0.0004017644,0.0010122498,0.0003541519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008155161,0.00033530107,0.0032256742,0.0005725882,0.000032594013,0.000012074666,0.00024306317,0.00038917494,0.0006146926],"category_scores_gemma":[0.001494721,0.00019785475,0.0007745133,0.00087736716,0.000114929666,0.000115757946,0.00003136939,0.00053350674,0.0000029456808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26737237,0.005571278,0.64828646,0.000041622974,0.0014189287,0.0004876217,0.00024258986,0.000095215866,0.00018044851,0.0000017803297,0.000026941128,0.076274745],"study_design_scores_gemma":[0.12686938,0.06122342,0.8088445,0.00013530029,0.0007919123,0.000020163374,0.00007060543,0.000042355954,0.0015034067,0.0000116668925,0.00031287578,0.00017438336],"about_ca_topic_score_codex":0.000098562065,"about_ca_topic_score_gemma":0.0021331767,"teacher_disagreement_score":0.16055806,"about_ca_system_score_codex":0.00040614876,"about_ca_system_score_gemma":0.004863398,"threshold_uncertainty_score":0.86274594},"labels":[],"label_agreement":null},{"id":"W3133979739","doi":"10.1200/jco.2021.39.6_suppl.111","title":"Local prostate radiotherapy in metastatic prostate cancer and symptomatic local events.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Cohort; Proportional hazards model; Cystoscopy; Retrospective cohort study; Internal medicine; Population; Genitourinary system; Oncology; Cancer; Prostate; Urology; Surgery; Urinary system","score_opus":0.06961135948999361,"score_gpt":0.46620716421319147,"score_spread":0.3965958047231979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133979739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563303,0.016220765,0.00043780849,0.02593594,0.00061610696,0.000328567,0.0000067462383,0.0000051462403,0.00011859097],"genre_scores_gemma":[0.9640359,0.02927474,0.0025896488,0.0035481635,0.00020982772,0.000034411663,0.0000026591035,0.000019424742,0.00028518308],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99712884,0.0003342563,0.0017983028,0.0002131226,0.00028806148,0.00023740953],"domain_scores_gemma":[0.99748766,0.0010654615,0.0007419316,0.00013027486,0.00024279598,0.00033187325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013290932,0.0001424545,0.0015117301,0.000093745926,0.000020474183,0.00000832716,0.000050527775,0.00012246368,0.00018659899],"category_scores_gemma":[0.0003690301,0.000097367825,0.00025576225,0.00017704867,0.000214344,0.00008428224,0.000028368358,0.00053840305,0.0000037405262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022325052,0.0028624744,0.31572935,0.00013322952,0.0008526614,0.0041845865,0.00036973634,0.00021085572,0.0000312442,0.000053435902,0.0011537857,0.67218614],"study_design_scores_gemma":[0.041039485,0.013083344,0.88025445,0.0011330909,0.0010257525,0.002132325,0.0006943739,0.0015790383,0.0003738015,0.0010136473,0.057472304,0.0001983901],"about_ca_topic_score_codex":0.000104488725,"about_ca_topic_score_gemma":0.00051980925,"teacher_disagreement_score":0.6719878,"about_ca_system_score_codex":0.00047032634,"about_ca_system_score_gemma":0.0026175184,"threshold_uncertainty_score":0.4643365},"labels":[],"label_agreement":null},{"id":"W3133992222","doi":"10.1200/jco.2021.39.6_suppl.311","title":"Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"University of Texas Southwestern Medical Center","keywords":"SABR volatility model; Medicine; Radiation therapy; Interquartile range; Internal medicine; Radiosurgery; Clinical endpoint; Surgery; Oncology; Randomized controlled trial","score_opus":0.19837727583993428,"score_gpt":0.5219639427385421,"score_spread":0.3235866668986078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133992222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850065,0.001078492,0.00042600077,0.0095232595,0.0023212172,0.00059749343,0.00003288793,0.000003630862,0.0010104793],"genre_scores_gemma":[0.9896666,0.0009792123,0.0055895494,0.0014849027,0.0014440521,0.000023423427,0.000016564298,0.00001717786,0.0007785356],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961715,0.0005031706,0.002614686,0.00017584144,0.00035137098,0.00018348265],"domain_scores_gemma":[0.9920685,0.0035351026,0.0027688672,0.00017994092,0.0009745431,0.00047303666],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002018212,0.00012757946,0.0017818338,0.00012114647,0.00003819743,0.0000046412542,0.00007787533,0.00020203029,0.0002709572],"category_scores_gemma":[0.011346104,0.000091801405,0.0007720324,0.00017420838,0.00010765581,0.00010028648,0.00002889165,0.00042334388,0.0000027903043],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3963087,0.034985125,0.0031979142,0.00031130863,0.0052220933,0.0014839371,0.0008136705,0.00003175523,0.0046370216,0.0002256202,0.012690053,0.5400928],"study_design_scores_gemma":[0.6090771,0.26933765,0.007903149,0.0002531002,0.00479516,0.0003619155,0.0001922989,0.00034428033,0.011773882,0.00078343874,0.095035195,0.00014285013],"about_ca_topic_score_codex":0.0000131092,"about_ca_topic_score_gemma":0.000008726925,"teacher_disagreement_score":0.53994995,"about_ca_system_score_codex":0.00030960783,"about_ca_system_score_gemma":0.0057466663,"threshold_uncertainty_score":0.99988985},"labels":[],"label_agreement":null},{"id":"W3134000103","doi":"10.1200/jco.2021.39.6_suppl.47","title":"Real-world utilization of docetaxel among men with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre; London Health Sciences Centre; Western University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; Jewish General Hospital; BC Cancer Agency; Ottawa Hospital; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Febrile neutropenia; Neutropenia; Cancer; Population; Metastatic breast cancer; Oncology; Chemotherapy; Breast cancer","score_opus":0.15116936125868657,"score_gpt":0.49948466006961684,"score_spread":0.34831529881093026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134000103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953975,0.00012319649,0.000055136363,0.0021557368,0.00008680675,0.00095280225,0.00001591609,0.000006314655,0.0012065895],"genre_scores_gemma":[0.9959097,0.0005984885,0.0015085874,0.00017849363,0.00012515318,0.000037504014,0.000033021173,0.000019693387,0.0015893868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612707,0.0010486164,0.0018037519,0.00023426564,0.00053373893,0.0002525725],"domain_scores_gemma":[0.9957678,0.0016241154,0.0012848013,0.0001606787,0.00092877616,0.00023384645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023380406,0.00014758245,0.0013240037,0.00023386988,0.000045738412,0.000013412604,0.00006983602,0.00009356274,0.00011355],"category_scores_gemma":[0.0009140448,0.00009123698,0.00014191908,0.0006754084,0.00012474156,0.00014131222,0.000020587337,0.00058813056,6.1191247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015283864,0.0038601283,0.96646065,0.00010382526,0.00064756494,0.0050148373,0.0010523526,0.0008268976,0.00025399122,0.000012293215,0.00017670948,0.0063069],"study_design_scores_gemma":[0.026284643,0.006936604,0.9610937,0.00039180802,0.00064721546,0.000057704216,0.0024309852,0.0009181403,0.001069646,0.000032991713,0.000051504172,0.00008504313],"about_ca_topic_score_codex":0.0014570233,"about_ca_topic_score_gemma":0.024364758,"teacher_disagreement_score":0.022907736,"about_ca_system_score_codex":0.0005153404,"about_ca_system_score_gemma":0.0067215534,"threshold_uncertainty_score":0.9989094},"labels":[],"label_agreement":null},{"id":"W3134007156","doi":"10.1200/jco.2021.39.6_suppl.62","title":"Comparative cardiotoxicity of the novel hormonal agents abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; McGill University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Cohort; Incidence (geometry); Population; Cancer; Cardiotoxicity; Clinical trial; Abiraterone acetate; Disease; Androgen deprivation therapy; Chemotherapy; Androgen receptor","score_opus":0.5192197711273235,"score_gpt":0.5764238078082177,"score_spread":0.05720403668089413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134007156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955285,0.0013043991,0.000020139812,0.0022606868,0.00025965972,0.0002842928,0.00011592903,0.0000012401664,0.00022512392],"genre_scores_gemma":[0.99463594,0.0018517654,0.0028906583,0.00021732366,0.0001547403,0.0000035783116,0.000009296217,0.000007486594,0.00022922804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723935,0.0005186382,0.0014417662,0.00019927562,0.00041218236,0.00018875791],"domain_scores_gemma":[0.99737096,0.00078288483,0.0009955254,0.0002277007,0.00046246013,0.00016048066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956393,0.000105904575,0.0012498613,0.00008607461,0.000042848813,0.000010777181,0.00013576122,0.000059110178,0.000023833918],"category_scores_gemma":[0.00047651108,0.00006136503,0.00013220399,0.00031532563,0.00043792013,0.00012819585,0.00014464534,0.0006043808,2.9381337e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016567055,0.0038686004,0.8305616,0.00028855618,0.0031050516,0.0021968258,0.0014137405,0.0009877632,0.12631154,0.00013005633,0.0010264834,0.013542721],"study_design_scores_gemma":[0.008054733,0.0012874221,0.9816103,0.00028226813,0.00048995443,0.000113012386,0.00044073196,0.0012864601,0.005142362,0.00009169541,0.0011374814,0.00006359235],"about_ca_topic_score_codex":0.0007656026,"about_ca_topic_score_gemma":0.006162822,"teacher_disagreement_score":0.15104868,"about_ca_system_score_codex":0.0002692333,"about_ca_system_score_gemma":0.004307485,"threshold_uncertainty_score":0.7641294},"labels":[],"label_agreement":null},{"id":"W3134043050","doi":"10.1200/jco.2021.39.6_suppl.261","title":"Extraperitoneal versus transperitoneal approach for robot-assisted radical prostatectomy: An updated systematic review and meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ureteral procedures and complications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"","keywords":"Medicine; Prostatectomy; Meta-analysis; Systematic review; Randomized controlled trial; Population; MEDLINE; Urology; Internal medicine; Surgery; Prostate cancer; Cancer","score_opus":0.32535705845513396,"score_gpt":0.5020032118868957,"score_spread":0.1766461534317617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134043050","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1168793,0.4893969,0.12851909,0.2416164,0.0017307362,0.016990867,0.0003833257,0.00025796393,0.0042254333],"genre_scores_gemma":[0.8636575,0.0029752536,0.121302925,0.010602877,0.00043587878,0.00022782508,0.00027493268,0.000043096225,0.000479749],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99537843,0.00077637605,0.0029749568,0.00034819846,0.00030295303,0.000219079],"domain_scores_gemma":[0.996254,0.00080942403,0.0011952365,0.0003607805,0.0008444281,0.00053607475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393739,0.0001890754,0.0056930594,0.00009427709,0.00007704451,0.000026093227,0.0001700784,0.0002983309,0.0001832953],"category_scores_gemma":[0.0011436188,0.00011889352,0.0022609474,0.00041372306,0.00018461644,0.00011566495,0.000021495445,0.0006517481,9.95367e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014609513,0.016235387,0.0003901615,0.12204126,0.8333758,0.0009769489,0.00029691958,0.00012081334,0.001809301,0.0024719466,0.0048163333,0.0028556206],"study_design_scores_gemma":[0.006651448,0.0067966995,0.003365425,0.00021552198,0.9778027,0.0015939104,0.0000938685,0.0014163746,0.00003649497,0.000076539276,0.0017652333,0.00018579856],"about_ca_topic_score_codex":0.0000028904585,"about_ca_topic_score_gemma":0.000013234584,"teacher_disagreement_score":0.7467782,"about_ca_system_score_codex":0.000048507005,"about_ca_system_score_gemma":0.00095389,"threshold_uncertainty_score":0.48483372},"labels":[],"label_agreement":null},{"id":"W3134095416","doi":"10.1200/jco.2021.39.6_suppl.tps504","title":"A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Atezolizumab; Gemcitabine; Oncology; Internal medicine; Carboplatin; Chemotherapy; Hazard ratio; Population; Clinical endpoint; Pembrolizumab; Cancer; Cisplatin; Immunotherapy; Ipilimumab; Clinical trial; Confidence interval","score_opus":0.10570315610834291,"score_gpt":0.4850514354823192,"score_spread":0.3793482793739763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134095416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803552,0.010494334,0.0003655749,0.0035542846,0.0009601641,0.0038203462,0.00020620566,0.00001445424,0.00022943864],"genre_scores_gemma":[0.95566994,0.037772804,0.004365488,0.0013996048,0.0003645982,0.00013260111,0.000013107277,0.00008155477,0.00020031804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99252814,0.0011411445,0.004092924,0.00072230195,0.000954278,0.00056119857],"domain_scores_gemma":[0.9928195,0.0022968033,0.002566502,0.00047643099,0.0013502368,0.0004905467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00256557,0.00057279196,0.007036438,0.00016349641,0.00010839332,0.000042757667,0.0004040382,0.00038105075,0.0006144522],"category_scores_gemma":[0.0013647975,0.00041466873,0.00043392525,0.0004916283,0.00066805375,0.00028322815,0.00015543604,0.0007765855,6.610764e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7978611,0.014196859,0.0025446261,0.00030090724,0.0040764306,0.00064516766,0.0034241143,0.00009676198,0.00030746445,0.0000062783197,0.00018697554,0.17635334],"study_design_scores_gemma":[0.9140008,0.072944336,0.00140911,0.0006615792,0.0018592996,0.00012089642,0.0042101336,0.000822412,0.0015296305,0.000089741785,0.0020305854,0.0003214636],"about_ca_topic_score_codex":0.0012986636,"about_ca_topic_score_gemma":0.011645791,"teacher_disagreement_score":0.17603187,"about_ca_system_score_codex":0.0010956097,"about_ca_system_score_gemma":0.0064175273,"threshold_uncertainty_score":0.99983054},"labels":[],"label_agreement":null},{"id":"W3134108600","doi":"10.1200/jco.2021.39.6_suppl.63","title":"The potential role of frailty in modifying quality-of-life related outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel, abiraterone, enzalutamine, and radium 223.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Docetaxel; Mood; Enzalutamide; Cohort; Internal medicine; Physical therapy; Oncology; Cancer; Psychiatry","score_opus":0.1044263283584014,"score_gpt":0.4489344362996103,"score_spread":0.3445081079412089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134108600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052644,0.002257993,0.000012074671,0.006083799,0.00065472163,0.00030511693,0.000019909772,0.0000031974791,0.00013674646],"genre_scores_gemma":[0.99641883,0.0015400575,0.0014986198,0.0002661715,0.00005784997,0.000007669931,0.0000052085084,0.0000165519,0.00018902797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992696,0.0013434567,0.0049311407,0.00022598749,0.00052957196,0.00027386262],"domain_scores_gemma":[0.9923893,0.0037135454,0.0027889032,0.0002119538,0.00069633656,0.00019991273],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039916905,0.00016363374,0.0018029287,0.00015418089,0.000039489896,0.000013306076,0.00014077194,0.00022131602,0.000031778705],"category_scores_gemma":[0.014187529,0.00011008117,0.00022903291,0.00028346188,0.0002770048,0.00017357946,0.0000715522,0.0010052961,7.018035e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038540706,0.0020793309,0.9385058,0.00020505815,0.00050742243,0.00021786828,0.001196234,0.0005920682,0.0053209877,0.0000689943,0.00007800815,0.04737415],"study_design_scores_gemma":[0.01722163,0.0016832473,0.9775504,0.00037781263,0.00016752772,0.000025683872,0.0010761246,0.0005188854,0.00031057757,0.00064606284,0.0003272662,0.00009480787],"about_ca_topic_score_codex":0.0005550879,"about_ca_topic_score_gemma":0.0038792556,"teacher_disagreement_score":0.047279343,"about_ca_system_score_codex":0.00016386074,"about_ca_system_score_gemma":0.0019673128,"threshold_uncertainty_score":0.99411637},"labels":[],"label_agreement":null},{"id":"W3134153606","doi":"10.1200/jco.2021.39.6_suppl.101","title":"Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Bicalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen deprivation therapy; Androgen receptor; Clinical endpoint; Antiandrogen; Prostate-specific antigen; Clinical trial; Cancer; Pathology","score_opus":0.42566985796274126,"score_gpt":0.5246021642651568,"score_spread":0.09893230630241556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134153606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96022373,0.030099135,0.00024824782,0.0076162578,0.0004936294,0.0009700286,0.00010982041,0.0000063089583,0.00023286167],"genre_scores_gemma":[0.9868553,0.006168731,0.0056880913,0.0001995796,0.0004207942,0.00007031532,0.000026937096,0.000025877998,0.00054436096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99448156,0.00084230874,0.0032266986,0.00037237204,0.0006428681,0.00043418378],"domain_scores_gemma":[0.9848892,0.010760445,0.0024387778,0.00041566364,0.0011491429,0.00034676102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027949195,0.00027936127,0.004619013,0.0001903559,0.00011610948,0.000021509637,0.0001710791,0.00019787336,0.0001267274],"category_scores_gemma":[0.0018285967,0.00015104112,0.0023530237,0.0007263998,0.00064533117,0.000092572736,0.00006615339,0.00033951638,8.553398e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13456503,0.009221573,0.15668371,0.00065659906,0.6013165,0.0011511451,0.0018143458,0.026274463,0.0041116355,0.0008297439,0.0012864098,0.06208881],"study_design_scores_gemma":[0.06288967,0.03606919,0.36081207,0.00013345142,0.51746917,0.000108561115,0.0010733305,0.0034283698,0.003745815,0.0010050283,0.012907846,0.00035748607],"about_ca_topic_score_codex":0.00016714259,"about_ca_topic_score_gemma":0.0009554837,"teacher_disagreement_score":0.20412837,"about_ca_system_score_codex":0.00026255363,"about_ca_system_score_gemma":0.002691045,"threshold_uncertainty_score":0.6159278},"labels":[],"label_agreement":null},{"id":"W3134158292","doi":"10.1200/jco.2021.39.6_suppl.249","title":"Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada); Genome British Columbia; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Subtyping; Medicine; Oncology; Prostate cancer; Cohort; Internal medicine; Radiogenomics; Cancer; Pathology; Radiomics","score_opus":0.15193007226466507,"score_gpt":0.4764153505461325,"score_spread":0.32448527828146745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134158292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916747,0.0018390552,0.00017996103,0.005566781,0.00018287566,0.0004258151,0.0000153545,0.0000022181162,0.00011323323],"genre_scores_gemma":[0.99027646,0.0036876171,0.0054560397,0.00024328938,0.00018831206,0.000026480368,0.000025604639,0.0000114974555,0.00008467485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979291,0.0003893825,0.0011800416,0.00018198762,0.00017283569,0.00014667571],"domain_scores_gemma":[0.99781513,0.00035742237,0.0009028219,0.00011828855,0.0005907747,0.00021555374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001967354,0.00007605574,0.0006415772,0.00009947566,0.000026627918,0.000009504445,0.000049643284,0.00019561865,0.000020279045],"category_scores_gemma":[0.0008336798,0.00005828634,0.000112684436,0.00013109941,0.0001740085,0.00009926676,0.00001649095,0.0004185304,3.251316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002658522,0.00025475337,0.8321145,0.000076636454,0.00022221169,0.00013054536,0.00028922764,0.00002126854,0.09787038,0.00008419134,0.00008256793,0.066195175],"study_design_scores_gemma":[0.0069508427,0.003588015,0.96222967,0.000112240574,0.00028499297,0.000037158254,0.00026340882,0.0005644445,0.023087913,0.0022228672,0.00059927336,0.000059182395],"about_ca_topic_score_codex":0.000036175483,"about_ca_topic_score_gemma":0.00024510783,"teacher_disagreement_score":0.13011514,"about_ca_system_score_codex":0.00017535694,"about_ca_system_score_gemma":0.002860924,"threshold_uncertainty_score":0.5075156},"labels":[],"label_agreement":null},{"id":"W3134178812","doi":"10.1200/jco.2021.39.6_suppl.270","title":"Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Sunitinib; Cabozantinib; Internal medicine; Crizotinib; Renal cell carcinoma; Oncology; Pazopanib; Progression-free survival; Urology; Surgery; Chemotherapy; Lung cancer","score_opus":0.2216947371488914,"score_gpt":0.4630707397537619,"score_spread":0.2413760026048705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134178812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756728,0.002238476,0.0000144111955,0.009780387,0.00251877,0.0014738262,0.00011516249,0.000018485103,0.008167676],"genre_scores_gemma":[0.99047565,0.00086998823,0.0031022984,0.0018449775,0.0020540345,0.000036886846,0.00010628549,0.000059823058,0.0014500484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98154825,0.00810264,0.0077442997,0.0007278112,0.0011805852,0.00069644157],"domain_scores_gemma":[0.93904907,0.054034203,0.0039543062,0.0009754789,0.0011957763,0.0007911527],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01311347,0.0005191373,0.005368309,0.00022914578,0.00017748412,0.000042804353,0.0004995418,0.0004080692,0.00088946323],"category_scores_gemma":[0.03617648,0.0002854519,0.0016193816,0.00059941877,0.00055352855,0.00016367476,0.000310772,0.0024934406,0.000041206884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87982446,0.022760814,0.0041238316,0.00003515869,0.0018686868,0.06201598,0.0025540418,0.000019347019,0.0004504385,0.000031468328,0.00644435,0.01987144],"study_design_scores_gemma":[0.8724425,0.059035517,0.035848454,0.00020274696,0.004945144,0.0008274608,0.005516389,0.00010640824,0.0016846338,0.00018918885,0.018891938,0.00030965233],"about_ca_topic_score_codex":0.0005293956,"about_ca_topic_score_gemma":0.0008471002,"teacher_disagreement_score":0.06118852,"about_ca_system_score_codex":0.0002869216,"about_ca_system_score_gemma":0.006651421,"threshold_uncertainty_score":0.99995977},"labels":[],"label_agreement":null},{"id":"W3134182875","doi":"10.1200/jco.2021.39.6_suppl.57","title":"Sequence decision making for cabazitaxel (Cbz) versus abiraterone (Abt) or enzalutamide (Enz) post-docetaxel (Dtx) in a publicly funded health care system.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Cabazitaxel; Enzalutamide; Medicine; Docetaxel; Prostate cancer; Internal medicine; Abiraterone acetate; Oncology; Chemotherapy; Cancer; Androgen receptor; Androgen deprivation therapy","score_opus":0.3593705298942796,"score_gpt":0.5842240712661738,"score_spread":0.22485354137189423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134182875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664524,0.0098502645,0.000620228,0.017973261,0.003259429,0.00097292406,0.00007721977,0.000025267946,0.0007689579],"genre_scores_gemma":[0.97642565,0.0017272835,0.018206276,0.0021898444,0.0009849643,0.000033224675,0.000030977204,0.000036717465,0.0003650778],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948161,0.00067292294,0.002802426,0.00042698404,0.00064237294,0.00063918694],"domain_scores_gemma":[0.99072045,0.005127514,0.0013411999,0.0003295689,0.0019122353,0.0005690338],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037596857,0.0002147071,0.0019531047,0.00024806638,0.0001129594,0.000045929675,0.0002501301,0.00042467847,0.00008835769],"category_scores_gemma":[0.008576314,0.00014077203,0.0004930429,0.00042006062,0.00015965928,0.00023001939,0.00011873102,0.0011038525,0.0000138992955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22032608,0.0028799283,0.043554217,0.00190829,0.0011329676,0.016940005,0.0015442063,0.000062832376,0.0006324461,0.00067487336,0.006815286,0.7035289],"study_design_scores_gemma":[0.3276598,0.22654368,0.21038868,0.012687349,0.0014523395,0.008871904,0.048296418,0.0014792843,0.0011689736,0.0009000368,0.15934646,0.0012050903],"about_ca_topic_score_codex":0.00014952586,"about_ca_topic_score_gemma":0.0038765613,"teacher_disagreement_score":0.7023238,"about_ca_system_score_codex":0.0025535554,"about_ca_system_score_gemma":0.012046555,"threshold_uncertainty_score":0.9997749},"labels":[],"label_agreement":null},{"id":"W3134199561","doi":"10.1200/jco.2021.39.6_suppl.149","title":"Prognostic association between common laboratory tests and overall survival in men with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre; Western University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; Jewish General Hospital; BC Cancer Agency; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Proportional hazards model; Prostate-specific antigen; Cohort; Population; Cancer; Relative survival; Cancer registry","score_opus":0.08136567479624043,"score_gpt":0.45968797456301114,"score_spread":0.3783222997667707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134199561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241483,0.00027002714,0.0000072963453,0.0064911293,0.00008902706,0.00055801164,0.00003498903,0.0000055043965,0.0001291758],"genre_scores_gemma":[0.9984512,0.00018594539,0.0006308787,0.00032624218,0.00021474432,0.000020584208,0.000029100634,0.000013363768,0.00012795017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969168,0.0011669825,0.0010475251,0.00017924585,0.00046355516,0.00022594095],"domain_scores_gemma":[0.9939741,0.003996298,0.00084418117,0.00008219872,0.0008814473,0.0002217999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028449127,0.00011384576,0.0010394639,0.00009666468,0.000043844382,0.000022090966,0.00003636233,0.00011524416,0.000011220226],"category_scores_gemma":[0.0020205772,0.00007991106,0.00006688529,0.00026170313,0.00004519513,0.00011128602,0.000017117867,0.00067793665,7.347093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024452633,0.0014422478,0.98821014,0.000045330456,0.0006127044,0.0026042482,0.0003305639,0.00010283219,0.00007156905,0.0000047046865,0.000057411253,0.0040729977],"study_design_scores_gemma":[0.015788352,0.006506701,0.97594804,0.00016690817,0.00065847515,0.000024969639,0.00045822226,0.000116260766,0.00008395843,0.00005845462,0.00011685743,0.00007277622],"about_ca_topic_score_codex":0.00028751144,"about_ca_topic_score_gemma":0.0033855936,"teacher_disagreement_score":0.013343089,"about_ca_system_score_codex":0.0007563351,"about_ca_system_score_gemma":0.0049237595,"threshold_uncertainty_score":0.87345374},"labels":[],"label_agreement":null},{"id":"W3134226198","doi":"10.1200/jco.2021.39.6_suppl.415","title":"The prognostic impact of bone metastasis in urothelial carcinoma treated with first-line platinum-based chemotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Chemotherapy; Proportional hazards model; Univariate analysis; Bone metastasis; Progression-free survival; Cancer; Progressive disease; Nomogram; Metastasis; Multivariate analysis; Bladder cancer; Urothelial carcinoma","score_opus":0.08253672856301551,"score_gpt":0.4298449654276273,"score_spread":0.34730823686461176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134226198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924371,0.0011364749,0.00007940926,0.005229052,0.00014460387,0.00031390297,0.00001969441,0.0000051465518,0.0006345624],"genre_scores_gemma":[0.9971955,0.00048516216,0.0012703498,0.0005411593,0.00033850214,0.000009622948,0.000005136081,0.00002509585,0.0001294814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970243,0.00038457644,0.0018122963,0.00017703847,0.0003521991,0.00024956453],"domain_scores_gemma":[0.99464077,0.0031830394,0.0011516426,0.00024182466,0.00055265246,0.00023005849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001210855,0.00017710325,0.0015271825,0.0000966991,0.000040903433,0.000008434721,0.000099804165,0.00019728958,0.00021239709],"category_scores_gemma":[0.0019321091,0.00008673923,0.0006350707,0.00032653715,0.00022450452,0.000045477864,0.0000152801,0.0005594575,0.000002745052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023327418,0.003308856,0.91298825,0.00003805015,0.0010774746,0.0022235895,0.00007354831,0.0001776449,0.00026810763,0.0000059049535,0.00037613916,0.056135017],"study_design_scores_gemma":[0.034765948,0.034694273,0.92432934,0.0001959587,0.00081950915,0.000556912,0.00004898177,0.00018373203,0.0020198366,0.00006587656,0.0022314042,0.00008825161],"about_ca_topic_score_codex":0.00019132973,"about_ca_topic_score_gemma":0.000654724,"teacher_disagreement_score":0.056046765,"about_ca_system_score_codex":0.00020331003,"about_ca_system_score_gemma":0.0054954537,"threshold_uncertainty_score":0.9748699},"labels":[],"label_agreement":null},{"id":"W3134307717","doi":"10.1200/jco.2021.39.6_suppl.448","title":"Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine","score_opus":0.11866519032482792,"score_gpt":0.4613152924776658,"score_spread":0.34265010215283787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134307717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98499924,0.005127626,0.00026061875,0.005795475,0.0015783673,0.00095873745,0.000086496424,0.000018307952,0.0011751585],"genre_scores_gemma":[0.97469896,0.016123535,0.0022315646,0.004487525,0.0010363318,0.00007040868,0.000065902925,0.00008738661,0.0011983962],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940734,0.0005083116,0.0033221252,0.00064578536,0.0007920469,0.00065836194],"domain_scores_gemma":[0.9932398,0.00255645,0.0020057978,0.0006108819,0.0010810881,0.0005059472],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016889949,0.0004755581,0.0042066663,0.00040149066,0.00006954665,0.00001982522,0.00039870772,0.00074107165,0.001319655],"category_scores_gemma":[0.0013030705,0.0003408998,0.0019331453,0.0010194156,0.00029327322,0.0001655704,0.00004648972,0.00091452105,0.0000066500934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58692247,0.009689595,0.037212946,0.00009003491,0.012372936,0.0008798199,0.0009156522,0.00017000617,0.024733685,0.000038415288,0.0030014701,0.32397297],"study_design_scores_gemma":[0.5488403,0.08841889,0.1622723,0.000182692,0.004314141,0.00038459257,0.0008554014,0.00072783337,0.092676625,0.0002981456,0.10021389,0.000815175],"about_ca_topic_score_codex":0.0002533346,"about_ca_topic_score_gemma":0.00030937543,"teacher_disagreement_score":0.3231578,"about_ca_system_score_codex":0.0008090486,"about_ca_system_score_gemma":0.006747637,"threshold_uncertainty_score":0.9999043},"labels":[],"label_agreement":null},{"id":"W3134327766","doi":"10.1200/jco.2021.39.6_suppl.94","title":"Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Placebo; Hazard ratio; Prostate cancer; Urology; Post-hoc analysis; Internal medicine; Proportional hazards model; Prostate-specific antigen; Oncology; Gynecology; Cancer; Confidence interval","score_opus":0.11753508138163961,"score_gpt":0.44699884395670697,"score_spread":0.3294637625750674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134327766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891259,0.003062506,0.000035414832,0.005004495,0.00015448089,0.0017848558,0.0002734758,0.000005837489,0.0005530265],"genre_scores_gemma":[0.9894122,0.008053892,0.0016143878,0.00015633786,0.00022336809,0.00006769126,0.000082510865,0.00004084612,0.00034876872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934686,0.0013786355,0.002880207,0.00044385553,0.001347681,0.0004810234],"domain_scores_gemma":[0.993933,0.0020749196,0.0020306122,0.00045295208,0.0011779218,0.00033056168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004887649,0.00033795636,0.002532946,0.00018259142,0.00007150536,0.000036344885,0.00028010723,0.00019625183,0.000100129044],"category_scores_gemma":[0.0006862369,0.00017319106,0.00025990233,0.00056477526,0.0007554739,0.00022551185,0.000083981104,0.00088146166,5.3059836e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7878945,0.011898565,0.15551773,0.00028366037,0.0029329015,0.0035516147,0.0014192505,0.00007352167,0.014777657,0.00011133342,0.0014872819,0.020051999],"study_design_scores_gemma":[0.71608883,0.08587018,0.17009777,0.0006901098,0.0020763704,0.00036829634,0.003074347,0.00012833999,0.014061037,0.00025149097,0.006873202,0.00042004616],"about_ca_topic_score_codex":0.00052785437,"about_ca_topic_score_gemma":0.0030257963,"teacher_disagreement_score":0.073971614,"about_ca_system_score_codex":0.00018113866,"about_ca_system_score_gemma":0.003826692,"threshold_uncertainty_score":0.70625263},"labels":[],"label_agreement":null},{"id":"W3134337523","doi":"10.1200/jco.2021.39.6_suppl.40","title":"Time trends of drug specific adverse events among patients on androgen receptor antagonists: Implications for remote monitoring.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"University Health Network","keywords":"Enzalutamide; Medicine; Prostate cancer; Adverse effect; Abiraterone; Incidence (geometry); Internal medicine; Oncology; Pharmacology; Androgen receptor; Cancer","score_opus":0.11291019692692938,"score_gpt":0.4734092523733782,"score_spread":0.36049905544644884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134337523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913453,0.0003329751,0.000013131929,0.0055414946,0.0010306718,0.00020031765,0.00006356758,0.000005192537,0.0014673655],"genre_scores_gemma":[0.98070115,0.0032700642,0.0055505764,0.00016885634,0.0016025176,0.000007655665,0.00010063694,0.000029851346,0.0085686995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978031,0.00019164706,0.0013440904,0.00018715093,0.0002738175,0.0002002229],"domain_scores_gemma":[0.9966562,0.0009652112,0.00092853,0.00021988689,0.0009331313,0.00029706868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092017447,0.0001019215,0.0008361287,0.00013467173,0.000052648138,0.0000022820327,0.00011917649,0.00017880023,0.00016947972],"category_scores_gemma":[0.00084204914,0.00007287583,0.00050222786,0.00020288372,0.00015647244,0.000064743166,0.000036412344,0.0003954712,0.00001667663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007988849,0.0039584218,0.6494627,0.00004096572,0.0006218556,0.000067112895,0.00011304565,0.000005031267,0.0009076429,0.000016935333,0.025397118,0.3114203],"study_design_scores_gemma":[0.01482366,0.0075840172,0.86835426,0.00021284835,0.00020970138,0.000017759143,0.00008120052,0.000011659891,0.004030812,0.00018891034,0.1044068,0.00007837317],"about_ca_topic_score_codex":0.0000032075948,"about_ca_topic_score_gemma":0.0000018157716,"teacher_disagreement_score":0.31134194,"about_ca_system_score_codex":0.0002600745,"about_ca_system_score_gemma":0.000774109,"threshold_uncertainty_score":0.297179},"labels":[],"label_agreement":null},{"id":"W3134411589","doi":"10.1200/jco.2021.39.6_suppl.126","title":"Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"","keywords":"Olaparib; Medicine; Oncology; Enzalutamide; CHEK2; Prostate cancer; Clinical endpoint; PALB2; Internal medicine; PARP inhibitor; Population; Cancer research; Cancer; Clinical trial; Gene; Genetics; Mutation; Poly ADP ribose polymerase; Biology; Germline mutation; Androgen receptor","score_opus":0.11753096355619325,"score_gpt":0.46210208616355647,"score_spread":0.3445711226073632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134411589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954341,0.0012210157,0.0001729858,0.0022585853,0.00040687984,0.000273335,0.00009048881,0.000004430228,0.0001381583],"genre_scores_gemma":[0.9931442,0.0011759674,0.003830796,0.0014440955,0.00015768872,0.000034162134,0.000050583636,0.000020663207,0.00014182518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521744,0.0006889066,0.002930386,0.0002668629,0.000661816,0.00023456164],"domain_scores_gemma":[0.9945288,0.0007008162,0.0024813216,0.00024806525,0.0017734066,0.000267601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018495483,0.00016246176,0.0019503928,0.00030947296,0.000028133269,0.000009655544,0.000105879495,0.00015678152,0.00030715548],"category_scores_gemma":[0.00070727675,0.00011928145,0.00037587606,0.001017414,0.00021751816,0.00017369131,0.000021423557,0.0006145385,0.0000023265657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025292976,0.008981821,0.89659375,0.00014532967,0.010481876,0.00134302,0.001133737,0.0018843153,0.025943201,0.000041437223,0.0032620332,0.024896514],"study_design_scores_gemma":[0.04911347,0.018153643,0.88479203,0.0004300906,0.007341492,0.000064338536,0.00074932544,0.00020209202,0.02622553,0.00018564485,0.012405361,0.00033697134],"about_ca_topic_score_codex":0.00005168938,"about_ca_topic_score_gemma":0.00091748725,"teacher_disagreement_score":0.024559543,"about_ca_system_score_codex":0.00045826746,"about_ca_system_score_gemma":0.004409492,"threshold_uncertainty_score":0.78222495},"labels":[],"label_agreement":null},{"id":"W3134437253","doi":"10.1200/jco.2021.39.6_suppl.51","title":"Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Princess Margaret Cancer Centre; University of Saskatchewan; University of Calgary","funders":"","keywords":"Medicine; Proportional hazards model; Enzalutamide; Prostate cancer; Hazard ratio; Cohort; Oncology; Internal medicine; Retrospective cohort study; Abiraterone acetate; Androgen deprivation therapy; Survival analysis; Urology; Cancer; Androgen receptor; Confidence interval","score_opus":0.10002027299648605,"score_gpt":0.46719824009257044,"score_spread":0.3671779670960844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134437253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948249,0.00037570577,0.000011305016,0.0028047184,0.00037149148,0.0005608768,0.00023727679,0.000008426668,0.00080531044],"genre_scores_gemma":[0.9912769,0.0039063906,0.0021865908,0.00023704699,0.00025075796,0.000032899625,0.0000778846,0.000029021012,0.0020025007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933278,0.0007539793,0.0041758777,0.00048048559,0.00086993945,0.00039195028],"domain_scores_gemma":[0.9931632,0.0019322135,0.0023965756,0.00033056177,0.0016971801,0.0004802685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003948389,0.0002567009,0.0039108563,0.00062483735,0.000046768295,0.000016718865,0.00013448526,0.00029251387,0.0003448444],"category_scores_gemma":[0.0019778488,0.00015751125,0.000955724,0.00196805,0.00050003955,0.00014663534,0.00005208653,0.0011746754,0.000002606938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01163845,0.0042106253,0.96407264,0.000040891297,0.011248522,0.0019192104,0.00015571223,0.00007814333,0.0011976189,0.000034300894,0.00023136628,0.005172517],"study_design_scores_gemma":[0.014607859,0.007828983,0.9700893,0.00021533239,0.0042059277,0.000027055732,0.0002841585,0.00008690269,0.0014224558,0.000022883236,0.0010634242,0.00014571131],"about_ca_topic_score_codex":0.0009960684,"about_ca_topic_score_gemma":0.012588386,"teacher_disagreement_score":0.011592318,"about_ca_system_score_codex":0.0008401688,"about_ca_system_score_gemma":0.0058350344,"threshold_uncertainty_score":0.999801},"labels":[],"label_agreement":null},{"id":"W3134452282","doi":"10.1200/jco.2021.39.6_suppl.450","title":"1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Gemcitabine; Cisplatin; Internal medicine; Oncology; Randomization; Urothelial carcinoma; Chemotherapy; Clinical trial; Cancer; Bladder cancer","score_opus":0.09046999123262707,"score_gpt":0.43794919409116073,"score_spread":0.3474792028585337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134452282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302834,0.00041571195,0.00011783176,0.0018671582,0.0014175579,0.00056144845,0.000028208045,0.000007376278,0.0025563892],"genre_scores_gemma":[0.99033046,0.00020353873,0.0072106556,0.0011369968,0.00083974964,0.00002006822,0.000015225462,0.000046168625,0.00019712505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967395,0.00020405481,0.0019305031,0.00031360233,0.0004475221,0.00036480592],"domain_scores_gemma":[0.9953139,0.0019669277,0.0012863565,0.0002797679,0.00086547295,0.00028756258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060134014,0.00023125591,0.0017914325,0.00012507374,0.00003299953,0.000006515881,0.00015943593,0.00036962616,0.00015475952],"category_scores_gemma":[0.0018612993,0.00016848244,0.00050025695,0.00022711494,0.00015205568,0.00011519248,0.000033146098,0.0006344239,0.0000032229016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1655303,0.005557474,0.603913,0.00012672144,0.00082004163,0.00029070987,0.00023727409,0.00003113116,0.0006820653,0.00004474483,0.0006068859,0.22215965],"study_design_scores_gemma":[0.19403511,0.031494927,0.7552489,0.00016155023,0.0004553816,0.000037772897,0.000080805665,0.00004007952,0.0031785124,0.00011256034,0.014990374,0.00016403393],"about_ca_topic_score_codex":0.000045001452,"about_ca_topic_score_gemma":0.00015992463,"teacher_disagreement_score":0.22199562,"about_ca_system_score_codex":0.00029086668,"about_ca_system_score_gemma":0.0031243688,"threshold_uncertainty_score":0.6870514},"labels":[],"label_agreement":null},{"id":"W3134531349","doi":"10.1200/jco.2021.39.6_suppl.50","title":"Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Western University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; BC Cancer Agency; University Health Network; Ottawa Hospital; Jewish General Hospital","funders":"Janssen Biotech","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Abiraterone acetate; Docetaxel; Internal medicine; Enzalutamide; Population; Oncology; Cancer; Prednisone; Systemic therapy; Gynecology; Androgen receptor; Breast cancer","score_opus":0.0956582054972567,"score_gpt":0.4575031590966921,"score_spread":0.36184495359943536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134531349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926968,0.0011945908,0.00001925345,0.0049500912,0.00008497955,0.0010308513,0.00000473609,0.000003571525,0.000015076403],"genre_scores_gemma":[0.99831134,0.00064431614,0.0005840105,0.00029526302,0.00006777733,0.000055411536,0.000007087099,0.000011827486,0.000022977843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965309,0.0014422548,0.0013232061,0.00019825797,0.00028253812,0.00022284049],"domain_scores_gemma":[0.99839586,0.0005456954,0.0006045056,0.000087816516,0.00022850739,0.00013762344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029830234,0.00009918798,0.0009707316,0.00032930807,0.000020016409,0.000015891885,0.000031917225,0.00008868942,0.0000036043657],"category_scores_gemma":[0.00021909547,0.00006930935,0.000058378064,0.00044781124,0.00002667485,0.000079127334,0.000008666464,0.0004909256,2.4491575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004436181,0.0023556794,0.97127914,0.00010688899,0.00017036147,0.0074210856,0.0028756498,0.0004925987,0.00019216759,0.0000059666154,0.0000039808115,0.010660315],"study_design_scores_gemma":[0.02642865,0.0069215847,0.96087766,0.00078012154,0.000050787563,0.00021930654,0.0042633326,0.0003612322,0.000011902909,0.000022178045,0.000007537543,0.00005568979],"about_ca_topic_score_codex":0.0031678497,"about_ca_topic_score_gemma":0.017895786,"teacher_disagreement_score":0.021992467,"about_ca_system_score_codex":0.0008144484,"about_ca_system_score_gemma":0.0033473696,"threshold_uncertainty_score":0.9986269},"labels":[],"label_agreement":null},{"id":"W3134553248","doi":"10.1200/jco.2021.39.6_suppl.136","title":"Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Bayer (Canada); McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cohort; Docetaxel; Androgen deprivation therapy; Radium-223; Oncology; Cancer; Bone metastasis","score_opus":0.23699086339588288,"score_gpt":0.5181500086195547,"score_spread":0.28115914522367186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134553248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096537,0.0008780637,0.00000311337,0.006337466,0.0008304815,0.00057373155,0.000043620006,0.000004187423,0.00036397926],"genre_scores_gemma":[0.9917573,0.0054989103,0.0014663766,0.00037345203,0.00021120628,0.00003071246,0.000019708112,0.000018655981,0.0006237184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948917,0.001232531,0.0025395867,0.00027635854,0.00071127585,0.00034852512],"domain_scores_gemma":[0.9925426,0.004688969,0.0014107852,0.0002763499,0.00081118505,0.00027009757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002723706,0.00019951221,0.0016674623,0.00010644927,0.000057777674,0.000020557376,0.00016941676,0.00016871485,0.00010855849],"category_scores_gemma":[0.0015234674,0.00009557576,0.00048316014,0.00033301723,0.00038076268,0.00014401152,0.000026366939,0.00081101316,0.0000045256606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024820432,0.006442846,0.8965474,0.000035778336,0.001686544,0.0020034588,0.0007665692,0.000029007537,0.000027003765,0.000018110703,0.00014187614,0.067480974],"study_design_scores_gemma":[0.046401363,0.030256826,0.9173961,0.00015578605,0.00083172694,0.000014509382,0.00035703156,0.000014680754,0.000052397074,0.0000783133,0.004351644,0.00008956745],"about_ca_topic_score_codex":0.00030924965,"about_ca_topic_score_gemma":0.0016753526,"teacher_disagreement_score":0.06739141,"about_ca_system_score_codex":0.00047412462,"about_ca_system_score_gemma":0.004293822,"threshold_uncertainty_score":0.76170564},"labels":[],"label_agreement":null},{"id":"W3134581025","doi":"10.1200/jco.2021.39.6_suppl.241","title":"Early surrogate measures for ablative therapies for intermediate-risk prostate cancer patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cumulative incidence; Androgen deprivation therapy; Population; Urology; Brachytherapy; Radiation therapy; Prostate; Biochemical recurrence; Internal medicine; Cancer; Incidence (geometry); Cohort; Oncology; Nuclear medicine; Surgery; Prostatectomy","score_opus":0.13940411079361129,"score_gpt":0.49675106391983487,"score_spread":0.35734695312622355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134581025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640794,0.0041835248,0.00019224524,0.006285302,0.001746268,0.00082969305,0.0001444438,0.0000074540794,0.0002031547],"genre_scores_gemma":[0.9820434,0.0115244035,0.0022453102,0.0007482495,0.0012348439,0.00012720928,0.000024871457,0.000029411214,0.0020223293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974277,0.00031484177,0.0014338555,0.00020361603,0.00031113843,0.00030882485],"domain_scores_gemma":[0.9918198,0.0036529407,0.0012060498,0.00010962861,0.0029346633,0.00027690607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002216898,0.00013090829,0.001086801,0.00007891192,0.00007690204,0.00001664779,0.00009945253,0.0002177663,0.000057983234],"category_scores_gemma":[0.0062542334,0.00008013673,0.0006149171,0.00010127424,0.00022592129,0.000114109724,0.000032574546,0.0005438069,0.0000028492432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02577333,0.0017550832,0.5055249,0.000084902436,0.002178126,0.00009126849,0.0013696103,0.000004640713,0.00014347878,0.0000389914,0.006554177,0.45648152],"study_design_scores_gemma":[0.044172533,0.03709761,0.6753426,0.00023019027,0.0008958845,0.000011785977,0.00048769233,0.00005002497,0.0021011152,0.0030096532,0.23645449,0.00014640683],"about_ca_topic_score_codex":0.000020810638,"about_ca_topic_score_gemma":0.00009020087,"teacher_disagreement_score":0.4563351,"about_ca_system_score_codex":0.00019612427,"about_ca_system_score_gemma":0.0028100985,"threshold_uncertainty_score":0.7487353},"labels":[],"label_agreement":null},{"id":"W3134598999","doi":"10.1200/jco.2021.39.6_suppl.tps506","title":"SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Pembrolizumab; Cystectomy; Tolerability; Bladder cancer; Irinotecan; Oncology; Internal medicine; Cisplatin; Durvalumab; Clinical trial; Chemotherapy; Urology; Cancer; Surgery; Adverse effect; Immunotherapy; Colorectal cancer","score_opus":0.1177163740229022,"score_gpt":0.46546898106996776,"score_spread":0.34775260704706557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134598999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929872,0.0003050708,0.00009201493,0.00286409,0.00064969255,0.0026158872,0.0003428863,0.000015719374,0.00012739706],"genre_scores_gemma":[0.99281734,0.00026402913,0.0025697972,0.002949547,0.00068200566,0.00013963967,0.00006823967,0.00009639176,0.00041301674],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946329,0.0007558501,0.0025919212,0.00070885936,0.0008048633,0.0005056273],"domain_scores_gemma":[0.9932044,0.001202097,0.0023231066,0.0005389825,0.001917491,0.00081389456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011599826,0.00045545396,0.003123935,0.00016918598,0.00021212744,0.00004466401,0.00041268388,0.0004954281,0.0004470304],"category_scores_gemma":[0.001190662,0.00029409165,0.00023809806,0.00036592656,0.00040844348,0.0002889306,0.00014080564,0.00088818173,6.105932e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40534216,0.093740046,0.052371137,0.00046190896,0.00805114,0.003464847,0.0069707767,0.00010687117,0.00087165646,0.000025745838,0.003124483,0.42546922],"study_design_scores_gemma":[0.46822065,0.4469006,0.06505532,0.0006976756,0.003817284,0.00023735085,0.0009345209,0.00030570425,0.0007873494,0.000062557236,0.012567755,0.00041325376],"about_ca_topic_score_codex":0.0010371534,"about_ca_topic_score_gemma":0.009715917,"teacher_disagreement_score":0.42505598,"about_ca_system_score_codex":0.0006763938,"about_ca_system_score_gemma":0.012677714,"threshold_uncertainty_score":0.9999511},"labels":[],"label_agreement":null},{"id":"W3134647918","doi":"10.1200/jco.2021.39.6_suppl.429","title":"An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Durvalumab; Clinical endpoint; Discontinuation; Internal medicine; Adverse effect; Urology; Cisplatin; Tolerability; Response Evaluation Criteria in Solid Tumors; Oncology; Chemotherapy; Phases of clinical research; Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Pembrolizumab","score_opus":0.19688640836431157,"score_gpt":0.5069534400515107,"score_spread":0.31006703168719907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134647918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971448,0.00023265839,0.00054967107,0.00041047213,0.00039120734,0.001075695,0.00008884532,0.0000055003197,0.00010112305],"genre_scores_gemma":[0.9942854,0.00006954783,0.004497253,0.0005348293,0.00036434055,0.00002507192,0.00005182016,0.000032360833,0.00013938197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961322,0.00061563,0.002114077,0.00039468164,0.00047073694,0.00027270147],"domain_scores_gemma":[0.9956033,0.00070355687,0.0016818307,0.00045586043,0.0011370619,0.0004183618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010367458,0.00022609328,0.0022364578,0.00018022867,0.00007678277,0.00002102123,0.00032650647,0.0001970196,0.00024295026],"category_scores_gemma":[0.00033651723,0.00015659338,0.00035417685,0.00032551686,0.00010212515,0.00026533141,0.000053526284,0.0004664117,0.0000013308885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08615019,0.2049444,0.6540355,0.000021346032,0.004066055,0.000773592,0.00030439234,0.000035736903,0.000055365374,0.0000017395071,0.00012561328,0.049486063],"study_design_scores_gemma":[0.16340433,0.23749453,0.59334207,0.000023171557,0.0042099007,0.000035608766,0.00033350312,0.0002633326,0.0000704443,0.000009234935,0.00072317565,0.00009072513],"about_ca_topic_score_codex":0.000088954424,"about_ca_topic_score_gemma":0.00012672528,"teacher_disagreement_score":0.07725414,"about_ca_system_score_codex":0.00015481244,"about_ca_system_score_gemma":0.001588207,"threshold_uncertainty_score":0.63856924},"labels":[],"label_agreement":null},{"id":"W3134670647","doi":"10.1200/jco.2021.39.6_suppl.166","title":"Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Oncology; Concordance; Cancer; Internal medicine; Cancer research","score_opus":0.18360204486629517,"score_gpt":0.5024349575496707,"score_spread":0.31883291268337555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134670647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986976,0.0027105198,0.0001521851,0.007454558,0.0008098284,0.0004107343,0.000016376498,0.000003858741,0.0014658866],"genre_scores_gemma":[0.9674469,0.0032332484,0.025300676,0.002501028,0.00071467867,0.000009248606,0.000006734763,0.000018101608,0.000769373],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99658144,0.0003303007,0.0019507009,0.00024102273,0.0006318868,0.0002646776],"domain_scores_gemma":[0.9937189,0.0018338247,0.0011695594,0.00027490046,0.0024609515,0.00054181676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023918042,0.000117807416,0.001568385,0.00018450564,0.00003369101,0.0000056732842,0.00022090368,0.00018895547,0.00010292229],"category_scores_gemma":[0.0038735324,0.000086914115,0.00016145744,0.00031251632,0.00047097268,0.00007911568,0.00016883637,0.00060545886,0.0000024615306],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032453635,0.0012502577,0.09798953,0.00082113646,0.00029268613,0.00091758027,0.0013418321,0.000069026406,0.8137779,0.00004590213,0.0022844698,0.07796427],"study_design_scores_gemma":[0.014284261,0.011349119,0.8047892,0.0005211157,0.0004989582,0.000474671,0.0031117748,0.000083766805,0.14748298,0.00032648907,0.016936013,0.0001416576],"about_ca_topic_score_codex":0.000075503674,"about_ca_topic_score_gemma":0.00006703709,"teacher_disagreement_score":0.7067997,"about_ca_system_score_codex":0.00014540143,"about_ca_system_score_gemma":0.005525667,"threshold_uncertainty_score":0.9802297},"labels":[],"label_agreement":null},{"id":"W3134704630","doi":"10.1200/jco.2021.39.6_suppl.117","title":"UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Ottawa; London Health Sciences Centre; Western University; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; University of Toronto","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Metastasis; Internal medicine; Cancer; Urology","score_opus":0.19613867306482594,"score_gpt":0.5038224550843591,"score_spread":0.30768378201953317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134704630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95727414,0.018782768,0.000035329806,0.021376444,0.0008396564,0.0006415557,0.000037170652,0.0000056923254,0.0010072547],"genre_scores_gemma":[0.9858446,0.010377152,0.0017379941,0.000634124,0.0007239634,0.00003784181,0.0000108269915,0.000020848442,0.00061261386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733233,0.00046202465,0.0013245547,0.0001890505,0.0004116613,0.00028038956],"domain_scores_gemma":[0.99553436,0.0022513808,0.0008589212,0.00016187446,0.0009826407,0.00021084743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026941786,0.00013836447,0.0013167508,0.000059961887,0.00006891029,0.0000096539625,0.0001147519,0.00015611168,0.000044927478],"category_scores_gemma":[0.00095264177,0.00007483919,0.0007940642,0.00014489307,0.00021308199,0.00008106949,0.00003137483,0.00067022315,0.0000013540105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03682955,0.004781041,0.025817214,0.00014260222,0.009833996,0.0030427657,0.0022815592,0.000029114144,0.03651809,0.0002604713,0.0030037605,0.8774598],"study_design_scores_gemma":[0.1299507,0.07728173,0.14717734,0.0013273823,0.0050582993,0.0016373703,0.020709299,0.0014009296,0.20866157,0.013998906,0.39213547,0.00066098943],"about_ca_topic_score_codex":0.000030379919,"about_ca_topic_score_gemma":0.00006538496,"teacher_disagreement_score":0.87679887,"about_ca_system_score_codex":0.0001560624,"about_ca_system_score_gemma":0.0046248236,"threshold_uncertainty_score":0.8204239},"labels":[],"label_agreement":null},{"id":"W3134708025","doi":"10.1200/jco.2021.39.6_suppl.422","title":"Bladder cancer research funding in Canada and the United States: A comparison between stakeholder priorities and resource allocation from 2017 to 2019.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Baker Hughes (Canada); University of Calgary; University of Alberta","funders":"","keywords":"Stakeholder; Bladder cancer; Agency (philosophy); Funding Agency; Medicine; Grant funding; Business; Cancer; Public relations; Political science; Public administration; Sociology; Internal medicine","score_opus":0.3931288184999084,"score_gpt":0.5199015900021072,"score_spread":0.12677277150219884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134708025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95702916,0.0033920056,0.00001944195,0.038877536,0.00021570115,0.00019694267,0.00003125986,0.0000015885262,0.00023636216],"genre_scores_gemma":[0.99270004,0.003005333,0.00023050181,0.0031097047,0.0005907816,0.000007301235,0.000014515465,0.000009984207,0.00033186446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971738,0.0009692835,0.0010422498,0.00017246486,0.0004099093,0.00023231759],"domain_scores_gemma":[0.9937144,0.0051151896,0.00031008877,0.00013675973,0.00041223798,0.00031132824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025671776,0.00008644764,0.00086586276,0.00011118207,0.00007055761,0.00002279831,0.00008480398,0.00011784736,0.000052726635],"category_scores_gemma":[0.0013874137,0.00005495911,0.000043846787,0.00022307347,0.00020364765,0.000046038804,0.00007411474,0.00090655993,8.453507e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030523113,0.00014794039,0.91953176,0.00001897778,0.00052103197,0.00028151475,0.0021801544,0.00008347928,0.000025911553,0.000026362244,0.030411487,0.043719083],"study_design_scores_gemma":[0.009660412,0.0009893324,0.88101274,0.00019940047,0.00023231347,0.000022969352,0.0048624347,0.00009260427,0.00005295728,0.0002756401,0.10253893,0.00006026547],"about_ca_topic_score_codex":0.7465228,"about_ca_topic_score_gemma":0.80080134,"teacher_disagreement_score":0.07212744,"about_ca_system_score_codex":0.00048606133,"about_ca_system_score_gemma":0.0057985545,"threshold_uncertainty_score":0.99983764},"labels":[],"label_agreement":null},{"id":"W3134766511","doi":"10.1200/jco.2021.39.6_suppl.tps501","title":"A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cisplatin; Internal medicine; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Bladder cancer; Urothelial carcinoma","score_opus":0.23587582299242751,"score_gpt":0.5225873593168417,"score_spread":0.28671153632441426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134766511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758155,0.0060219984,0.00064465025,0.0020050504,0.0013485786,0.0018266763,0.00013395264,0.000007418019,0.00043009702],"genre_scores_gemma":[0.9893308,0.0058093006,0.00258343,0.00038280044,0.00064548576,0.00012694714,0.0000041716094,0.00003457351,0.0010824599],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961386,0.00041506364,0.002460228,0.00026461328,0.00043846824,0.0002830405],"domain_scores_gemma":[0.9926706,0.0039847977,0.0016862082,0.00034380812,0.0010622066,0.00025237157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079210196,0.00022569021,0.002232708,0.00008804828,0.000057114492,0.0000074482655,0.00016904829,0.00014037825,0.0004957969],"category_scores_gemma":[0.0014302308,0.00011415103,0.00066775293,0.00027879444,0.00020226528,0.00007473589,0.000023490291,0.00025958338,0.0000013675635],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09780615,0.1707683,0.005906942,0.00014243677,0.007503483,0.001182695,0.0012464132,0.00029521395,0.0027018907,0.000013682012,0.00052752125,0.71190524],"study_design_scores_gemma":[0.20221981,0.7087326,0.003335406,0.0003028123,0.010025137,0.0003400937,0.002764709,0.0002847474,0.021219783,0.0001518561,0.05045665,0.00016637518],"about_ca_topic_score_codex":0.00022139771,"about_ca_topic_score_gemma":0.0011659192,"teacher_disagreement_score":0.7117389,"about_ca_system_score_codex":0.0002803634,"about_ca_system_score_gemma":0.0043566516,"threshold_uncertainty_score":0.7728513},"labels":[],"label_agreement":null},{"id":"W3134768182","doi":"10.1200/jco.2021.39.6_suppl.6","title":"177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Hazard ratio; Internal medicine; Adverse effect; Progression-free survival; Oncology; Urology; Confidence interval; Randomized controlled trial; Cancer; Overall survival; Androgen deprivation therapy","score_opus":0.19541153809071804,"score_gpt":0.513257776138573,"score_spread":0.317846238047855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134768182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97163504,0.007842597,0.000004202202,0.01743359,0.0016504487,0.00092088344,0.00007687565,0.000024207791,0.000412127],"genre_scores_gemma":[0.99242544,0.0022240598,0.0040485896,0.00039409657,0.00028936024,0.00011216711,0.000052467385,0.000050025974,0.0004037719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99272054,0.0010267105,0.0037683712,0.0006164682,0.0011867967,0.00068113615],"domain_scores_gemma":[0.9934204,0.0017281172,0.0023510621,0.00045945324,0.0014316686,0.00060929713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032485037,0.00037459665,0.0020573866,0.00030290082,0.00015647756,0.00009983946,0.0001877686,0.00032633787,0.000117197094],"category_scores_gemma":[0.005120313,0.0002466198,0.0003624362,0.00062027806,0.00047095207,0.00040288232,0.00024544806,0.001397077,0.0000029662103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1288361,0.0046367864,0.5493989,0.00025435165,0.0031558697,0.034805074,0.002429808,0.000033396078,0.0019132098,0.000023520583,0.0013159394,0.27319705],"study_design_scores_gemma":[0.10974488,0.013944477,0.852351,0.0016410911,0.0013476722,0.00052389153,0.0024213453,0.00021666648,0.00181557,0.0004102668,0.015058834,0.0005242995],"about_ca_topic_score_codex":0.000111547,"about_ca_topic_score_gemma":0.0013380637,"teacher_disagreement_score":0.3029521,"about_ca_system_score_codex":0.00050476595,"about_ca_system_score_gemma":0.0049208757,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W3134785045","doi":"10.1200/jco.2021.39.6_suppl.148","title":"5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"National Institutes of Health; Svenska Läkaresällskapet; Prostate Cancer Foundation","keywords":"Epigenetics; DNA methylation; 5-Hydroxymethylcytosine; Gene; Liquid biopsy; Bisulfite sequencing; Biomarker; Medicine; Biology; Gene expression; Cancer; Cancer research; Genetics","score_opus":0.19257127429109278,"score_gpt":0.5391417807923622,"score_spread":0.3465705065012694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134785045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94474757,0.004303303,0.000020952162,0.03526342,0.0008990183,0.000113604234,0.0000019524925,0.0000058219343,0.014644352],"genre_scores_gemma":[0.98735565,0.0042323256,0.0019011216,0.0023799052,0.0005828636,0.0000038238154,0.0000058491046,0.00001610745,0.0035223702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969092,0.0005202561,0.0017200575,0.00019246133,0.00037686407,0.00028117752],"domain_scores_gemma":[0.99694264,0.0013875645,0.00053563813,0.00018663683,0.0005298656,0.00041762818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029057022,0.00010852193,0.0011952386,0.00020779658,0.000022041406,0.0000078567655,0.00010815274,0.00037055725,0.00084017974],"category_scores_gemma":[0.004723563,0.00007149649,0.00042590543,0.00042699283,0.00020432487,0.000081885235,0.00007532587,0.0009830527,0.00007873652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08759309,0.017108327,0.21578763,0.00019348823,0.0024224625,0.16426857,0.0004274617,0.000007531918,0.06459974,0.0005171647,0.020720454,0.42635408],"study_design_scores_gemma":[0.046105262,0.035976972,0.49547234,0.0005481723,0.00046053794,0.009596069,0.00042900816,0.000094598734,0.011055679,0.0013737134,0.39865205,0.00023561741],"about_ca_topic_score_codex":0.000023729515,"about_ca_topic_score_gemma":0.000023451998,"teacher_disagreement_score":0.42611846,"about_ca_system_score_codex":0.00022359133,"about_ca_system_score_gemma":0.0045653554,"threshold_uncertainty_score":0.9199379},"labels":[],"label_agreement":null},{"id":"W3134793717","doi":"10.1200/jco.2021.39.6_suppl.69","title":"Comparative analysis of sarcopenia induced by long-term abiraterone (A) versus enzalutamide (E) therapy in men with metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcopenia; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Skeletal muscle; Osteoporosis; Internal medicine; Urology; Prostate; Cancer; Oncology; Androgen receptor","score_opus":0.21269588064578887,"score_gpt":0.521420595218706,"score_spread":0.3087247145729171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134793717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499893,0.0017134057,0.000008686844,0.0023379915,0.00015964304,0.00033274156,0.000029408897,0.000002674308,0.00041650533],"genre_scores_gemma":[0.99691796,0.0014625156,0.00090096705,0.00046132455,0.000037586753,0.000017085467,0.000030392546,0.000009570892,0.0001625819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963691,0.0006767406,0.0021182997,0.00021631601,0.00038332518,0.00023618154],"domain_scores_gemma":[0.9960018,0.001166693,0.0017302906,0.00016907124,0.0006168115,0.00031533453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010364283,0.00015676559,0.0023330688,0.00019633528,0.00002842994,0.000008359142,0.00007414364,0.00013052374,0.0002039973],"category_scores_gemma":[0.00020942296,0.00010072043,0.0002335327,0.00064453954,0.00012754125,0.00010893472,0.000014130836,0.00054636836,0.0000022592276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12168186,0.007953514,0.77114195,0.000090119625,0.020019146,0.0036972866,0.0016288538,0.0001735338,0.016200483,0.000017144568,0.0004135947,0.056982517],"study_design_scores_gemma":[0.035001136,0.017763974,0.9404679,0.000116575415,0.00284425,0.000029796216,0.00028550788,0.00007617736,0.0030905423,0.000008518177,0.00022935838,0.00008629216],"about_ca_topic_score_codex":0.0005390854,"about_ca_topic_score_gemma":0.009517811,"teacher_disagreement_score":0.16932592,"about_ca_system_score_codex":0.0002600151,"about_ca_system_score_gemma":0.0036632996,"threshold_uncertainty_score":0.64985365},"labels":[],"label_agreement":null},{"id":"W3134803739","doi":"10.1200/jco.2021.39.6_suppl.327","title":"Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Sunitinib; Renal cell carcinoma; Internal medicine; Clinical endpoint; Population; Oncology; Surgery; Clinical trial; Cancer; Immunotherapy","score_opus":0.10072991463613369,"score_gpt":0.46138044553359125,"score_spread":0.3606505308974576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134803739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958769,0.00021430923,0.000014105775,0.0023039952,0.00024301949,0.00095750316,0.00001711734,0.0000016417206,0.0003713953],"genre_scores_gemma":[0.997455,0.00015528116,0.00032470003,0.0018106794,0.00014026726,0.000033218792,0.000011699461,0.000011473319,0.00005768447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663544,0.00078883115,0.0018464522,0.00017589361,0.00034306577,0.00021029798],"domain_scores_gemma":[0.99486065,0.0034443857,0.0011105052,0.00026625054,0.0002521023,0.00006612533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001845595,0.0001418304,0.0012662931,0.000095091615,0.000031077427,0.000007282109,0.0002134283,0.00009900792,0.000037112284],"category_scores_gemma":[0.0004378347,0.000068922964,0.00040312085,0.0002333708,0.00015530428,0.000043543565,0.000017814536,0.00042348308,4.3214396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13107054,0.03433164,0.61296624,0.000024770767,0.00047010023,0.0010700603,0.004735815,0.000028967055,0.00019768965,0.00001353131,0.00046844702,0.21462223],"study_design_scores_gemma":[0.16941895,0.08061647,0.7377317,0.00005042004,0.00024308843,0.00005663533,0.0027530794,0.000027127428,0.00005847768,0.00002442536,0.008956767,0.00006286385],"about_ca_topic_score_codex":0.00019045401,"about_ca_topic_score_gemma":0.0012194884,"teacher_disagreement_score":0.21455936,"about_ca_system_score_codex":0.00019441059,"about_ca_system_score_gemma":0.0010701347,"threshold_uncertainty_score":0.2810597},"labels":[],"label_agreement":null},{"id":"W3134804872","doi":"10.1200/jco.2021.39.6_suppl.444","title":"Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Bladder cancer; Cohort; Proportional hazards model; Cystectomy; Hazard ratio; Oncology; Retrospective cohort study; Gastroenterology; Progression-free survival; Urology; Logistic regression; Overall survival; Cancer; Confidence interval","score_opus":0.08179383011864462,"score_gpt":0.41513063319375476,"score_spread":0.33333680307511016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134804872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738179,0.0015623451,0.00016838536,0.022814656,0.001000511,0.00040614232,0.000022525324,0.000010737121,0.00019681011],"genre_scores_gemma":[0.98991853,0.001338692,0.0037957663,0.0019290025,0.0021482185,0.000019488021,0.000011492311,0.000033195567,0.0008056417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968106,0.00031827096,0.0019334317,0.00024239956,0.0004149064,0.00028040342],"domain_scores_gemma":[0.99272734,0.0047435137,0.0014605103,0.00015714132,0.00058485754,0.00032661523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021698726,0.00018319243,0.0020816855,0.00007828352,0.000067873625,0.000014367661,0.000065760956,0.00038939776,0.00007366997],"category_scores_gemma":[0.003182063,0.00011635162,0.0006607089,0.00010087401,0.00014806789,0.00010848446,0.000025271323,0.00059365993,0.0000027383915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007464318,0.0009060986,0.84196776,0.000032742875,0.0013997996,0.00023757634,0.00009484554,4.065951e-7,0.0008813571,0.0000067127985,0.00066313887,0.14634524],"study_design_scores_gemma":[0.02830332,0.008936236,0.915237,0.000093113864,0.0007895536,0.00013887516,0.00008490249,0.0000028570253,0.0053721247,0.00014031063,0.040780738,0.00012097357],"about_ca_topic_score_codex":0.000016326574,"about_ca_topic_score_gemma":0.000016953782,"teacher_disagreement_score":0.14622426,"about_ca_system_score_codex":0.0002686324,"about_ca_system_score_gemma":0.0030078623,"threshold_uncertainty_score":0.53358185},"labels":[],"label_agreement":null},{"id":"W3134832274","doi":"10.1200/jco.2021.39.15_suppl.5023","title":"PSMA-targeted imaging with <sup>18</sup>F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Nuclear medicine; Confidence interval; Histopathology; Prostate cancer; Population; Clinical endpoint; Radiation therapy; Radiology; Cancer; Clinical trial; Pathology; Internal medicine","score_opus":0.031066895960023825,"score_gpt":0.421542854466676,"score_spread":0.3904759585066522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134832274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550843,0.0020774014,0.00019495808,0.00069776387,0.00016388085,0.0009443891,0.00033304395,0.0000052215587,0.0000748853],"genre_scores_gemma":[0.99761343,0.0017460106,0.00022486974,0.00012663317,0.000068726964,0.00002652568,0.00011488309,0.000026261981,0.000052640855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950944,0.0011921264,0.0022517934,0.00042835844,0.0007161556,0.0003171634],"domain_scores_gemma":[0.9939909,0.0011534726,0.0017871577,0.00019083059,0.0025608952,0.00031675602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020146493,0.00024373374,0.002046138,0.0002515259,0.0000440193,0.000012411687,0.00011217511,0.00005895747,0.00007351675],"category_scores_gemma":[0.0018943732,0.00016479846,0.00021728383,0.00063869887,0.00046000927,0.00016830038,0.00007443076,0.0007504319,2.5458974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097618505,0.010602329,0.8542582,0.00011600985,0.0022697193,0.0015324374,0.0011125405,0.00036747998,0.00054525747,0.0000016481947,0.0005955533,0.030980352],"study_design_scores_gemma":[0.30931777,0.2192596,0.3847904,0.0035539358,0.008048312,0.00038654954,0.009042778,0.02080863,0.043376923,0.00019234668,0.00050739455,0.000715366],"about_ca_topic_score_codex":0.00014653768,"about_ca_topic_score_gemma":0.00007123672,"teacher_disagreement_score":0.4694678,"about_ca_system_score_codex":0.00052829605,"about_ca_system_score_gemma":0.0027814538,"threshold_uncertainty_score":0.67202866},"labels":[],"label_agreement":null},{"id":"W3134838209","doi":"10.1200/jco.2021.39.6_suppl.379","title":"Longer follow-up data of circulating miR371a-3p expression across the spectrum of germ cell tumors (GCT).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Seminoma; Stage (stratigraphy); Internal medicine; Oncology; Germ cell tumors; Malignancy; Chemotherapy; Orchiectomy; Testicular Germ Cell Tumor; Gastroenterology","score_opus":0.19068912186958978,"score_gpt":0.49851252549118824,"score_spread":0.30782340362159843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134838209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382305,0.0027999224,0.00012944016,0.0017063536,0.00081393536,0.00012430584,0.00003489256,0.0000039120046,0.0005641602],"genre_scores_gemma":[0.9964265,0.0002236945,0.0023094392,0.00033980326,0.0004832037,8.67024e-7,0.000017739572,0.000015845522,0.00018289742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657524,0.0004050883,0.0021149556,0.00022495085,0.00046108718,0.00021866958],"domain_scores_gemma":[0.9935273,0.0023487608,0.0028086992,0.00070186396,0.00035485293,0.0002585151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001747853,0.00012406852,0.0012284153,0.000029745264,0.000047558773,0.0000069760827,0.0003145157,0.00018615245,0.00019407913],"category_scores_gemma":[0.0059850677,0.00007103063,0.0005770408,0.00013956452,0.00020576738,0.000087676766,0.00029721213,0.00051820395,0.000005461869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025824574,0.0064911875,0.92158484,0.00028581588,0.0009216953,0.006104189,0.00043162587,0.00003870223,0.009311622,0.000042486572,0.0021944365,0.050010916],"study_design_scores_gemma":[0.012389498,0.0032568292,0.97076607,0.0005949607,0.0012933074,0.0007953139,0.0008386403,0.00021847794,0.006359224,0.00043845383,0.0029480308,0.000101213824],"about_ca_topic_score_codex":0.000022442999,"about_ca_topic_score_gemma":0.000023071507,"teacher_disagreement_score":0.049909703,"about_ca_system_score_codex":0.0000438514,"about_ca_system_score_gemma":0.0015408136,"threshold_uncertainty_score":0.7165118},"labels":[],"label_agreement":null},{"id":"W3134850825","doi":"10.1200/jco.2021.39.6_suppl.451","title":"Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cystectomy; Cohort; Bladder cancer; Pembrolizumab; Internal medicine; Carcinoma in situ; Interim analysis; Cancer; Surgery; Urology; Clinical trial; Immunotherapy","score_opus":0.05192132035304191,"score_gpt":0.3963315178186893,"score_spread":0.3444101974656474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134850825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079454,0.00095307763,0.00063274667,0.0035341966,0.0019527102,0.0015102609,0.00039995674,0.0000056765502,0.00021685634],"genre_scores_gemma":[0.9906384,0.0035623938,0.0025788043,0.0013509234,0.0007898755,0.00013591378,0.00002065216,0.000048431208,0.0008746284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591106,0.00042952632,0.0021786268,0.0004039475,0.00069305097,0.00038376646],"domain_scores_gemma":[0.98912936,0.0051145502,0.0020507718,0.00051050686,0.0027439601,0.00045087398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070028636,0.00032366926,0.002452512,0.00013517255,0.000088097695,0.000007649763,0.00021135506,0.00033121792,0.00030781707],"category_scores_gemma":[0.0021309815,0.0001767447,0.00093571923,0.00030056402,0.00027668526,0.00007230836,0.000048340567,0.0003908003,0.000005152037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1074011,0.010457589,0.46067077,0.00010399958,0.013658854,0.0005283525,0.0013115713,0.0002966151,0.00030661302,0.000031671785,0.0044039967,0.40082887],"study_design_scores_gemma":[0.055251665,0.09128252,0.8261632,0.00016688876,0.0059776288,0.00003255116,0.00030695702,0.000012132716,0.0034793336,0.00008745531,0.017080905,0.00015882452],"about_ca_topic_score_codex":0.0005956113,"about_ca_topic_score_gemma":0.0012372793,"teacher_disagreement_score":0.40067005,"about_ca_system_score_codex":0.0005054253,"about_ca_system_score_gemma":0.005428968,"threshold_uncertainty_score":0.9630756},"labels":[],"label_agreement":null},{"id":"W3134870122","doi":"10.1200/jco.2021.39.6_suppl.375","title":"SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Retroperitoneal lymph node dissection; Seminoma; Surgery; Radiation therapy; Testicular cancer; Etoposide; Chemotherapy; Stage (stratigraphy); Lymph node; Germ cell tumors; Lymphadenectomy; Internal medicine","score_opus":0.35990938239095427,"score_gpt":0.5549502563573714,"score_spread":0.19504087396641712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134870122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947348,0.0013436144,0.00012989496,0.0007857501,0.0021199987,0.0006827486,0.00003345233,0.0000051561706,0.00016456],"genre_scores_gemma":[0.9914688,0.00043096006,0.0070357285,0.00016816407,0.00074234937,0.000012495554,0.00001422943,0.000013047781,0.00011423118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99150145,0.0011643799,0.006287515,0.00028401738,0.00055303256,0.0002096185],"domain_scores_gemma":[0.9872334,0.0074523534,0.0036873478,0.00027362895,0.00093246694,0.00042080777],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005530723,0.00016793105,0.0032109194,0.00019066926,0.000030120878,0.000004434028,0.000105211235,0.00030087386,0.00007128833],"category_scores_gemma":[0.047439408,0.00011569733,0.001756865,0.00032240362,0.00043136004,0.00010383383,0.000068217865,0.0007377367,0.0000034579305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64210385,0.093864135,0.2026961,0.000081106,0.001589551,0.0073309205,0.000054449567,0.00000968732,0.00006478065,0.00009894197,0.0002591409,0.051847316],"study_design_scores_gemma":[0.62139297,0.0407472,0.3346092,0.00025116396,0.0014803571,0.00023888252,0.000039052848,0.000086425134,0.00008644163,0.00019235889,0.000801549,0.00007439816],"about_ca_topic_score_codex":0.00003761942,"about_ca_topic_score_gemma":0.000031296237,"teacher_disagreement_score":0.13191311,"about_ca_system_score_codex":0.00011560097,"about_ca_system_score_gemma":0.008172822,"threshold_uncertainty_score":0.99744993},"labels":[],"label_agreement":null},{"id":"W3134908202","doi":"10.1200/jco.2021.39.6_suppl.269","title":"Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Everolimus; Renal cell carcinoma; Clinical endpoint; Sunitinib; Progression-free survival; Oncology; Clinical trial; Urology; Confidence interval; Overall survival","score_opus":0.1826300684046734,"score_gpt":0.46084979122176783,"score_spread":0.2782197228170944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134908202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289274,0.00038544546,0.00006723276,0.0009182525,0.0012488754,0.0029859573,0.000053451062,0.000017823164,0.0014302478],"genre_scores_gemma":[0.9925031,0.0007533692,0.0035659168,0.00036796287,0.0012669995,0.00014849067,0.000070661255,0.00009781118,0.0012256764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99289,0.00086606777,0.004045801,0.0006554433,0.0009582218,0.0005844752],"domain_scores_gemma":[0.9873643,0.0058086044,0.0035285975,0.0006774132,0.0018942873,0.00072679616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011578028,0.0005572555,0.0036910353,0.0002453561,0.00012294251,0.000017428452,0.00027404408,0.00044998678,0.00040575117],"category_scores_gemma":[0.0021546239,0.00035226674,0.0011806048,0.000337086,0.00022333555,0.00017627227,0.00006768458,0.0006796954,0.000012056541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83798623,0.06938973,0.0026853695,0.00008397218,0.0016001938,0.0029928426,0.00063813955,0.00012971257,0.00015682902,0.000007745488,0.0002628484,0.08406638],"study_design_scores_gemma":[0.52321774,0.45561087,0.004690559,0.00007666476,0.0016751115,0.00014087334,0.00043507142,0.0000729482,0.0020301098,0.000014159367,0.011852992,0.00018287513],"about_ca_topic_score_codex":0.00008372741,"about_ca_topic_score_gemma":0.0003158581,"teacher_disagreement_score":0.38622114,"about_ca_system_score_codex":0.0011451286,"about_ca_system_score_gemma":0.0065186108,"threshold_uncertainty_score":0.99989295},"labels":[],"label_agreement":null},{"id":"W3134910506","doi":"10.1200/jco.2021.39.6_suppl.239","title":"Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Placebo; Incidence (geometry); Internal medicine; Rash","score_opus":0.18057939522637942,"score_gpt":0.5243375010670506,"score_spread":0.3437581058406711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134910506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784377,0.0029939343,0.00022923834,0.015083207,0.0012574579,0.0013212471,0.00022304154,0.000003310675,0.0004508336],"genre_scores_gemma":[0.9909489,0.003849401,0.0024101664,0.00088532263,0.00073764054,0.000086057924,0.00006398545,0.00001797451,0.0010005467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952106,0.00078732765,0.0028948719,0.0002447361,0.0005564825,0.00030600783],"domain_scores_gemma":[0.9923565,0.004998602,0.0014423826,0.0002612186,0.000731006,0.00021029804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041052885,0.00015232668,0.0016340027,0.00010136408,0.000060429255,0.00001523828,0.00018437069,0.00019526975,0.00023749589],"category_scores_gemma":[0.003467995,0.00008743559,0.0006021708,0.0002650081,0.00023882781,0.00010269923,0.000030413263,0.00072183,0.0000016476599],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7733226,0.007919832,0.0024152196,0.00012299462,0.0014804032,0.002394638,0.0016102477,0.000038049475,0.007766156,0.00012567543,0.0036017955,0.1992024],"study_design_scores_gemma":[0.8585524,0.038773865,0.041303813,0.00052380457,0.0020843442,0.00010304706,0.0031711005,0.00039020923,0.0036775873,0.0036896039,0.047528114,0.00020209036],"about_ca_topic_score_codex":0.00018484997,"about_ca_topic_score_gemma":0.0010238604,"teacher_disagreement_score":0.19900031,"about_ca_system_score_codex":0.00024728297,"about_ca_system_score_gemma":0.0063977847,"threshold_uncertainty_score":0.99923503},"labels":[],"label_agreement":null},{"id":"W3134943972","doi":"10.1200/jco.2021.39.6_suppl.114","title":"A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Adverse effect; Urology; Hydroxychloroquine; Cancer; Oncology; Gastroenterology","score_opus":0.0846700058237099,"score_gpt":0.4817066438143889,"score_spread":0.397036637990679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134943972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179894,0.00091385026,0.000009103056,0.0059974706,0.00017169633,0.00036897536,0.000021435844,0.0000041988337,0.0007143441],"genre_scores_gemma":[0.9971417,0.0013447467,0.0007180285,0.00031941978,0.0002636474,0.000013457942,0.000006866417,0.000015127908,0.00017696709],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583775,0.000363392,0.0029591199,0.00024944777,0.00042419028,0.00016611246],"domain_scores_gemma":[0.9958912,0.0008848337,0.0021174026,0.00020871358,0.00068646134,0.00021135384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002327209,0.00013162517,0.0014167042,0.00015505668,0.00002072534,0.000002845337,0.000077020806,0.00023120786,0.000060858885],"category_scores_gemma":[0.0010821825,0.00009579639,0.0001269964,0.00033275687,0.00027332894,0.000107462176,0.000045927205,0.00075429457,3.695017e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3344023,0.0977073,0.23685928,0.00034492736,0.0019157421,0.0032328584,0.008964064,0.00039095888,0.18520702,0.0000711154,0.006727129,0.12417731],"study_design_scores_gemma":[0.45096982,0.20872319,0.24390532,0.0016320179,0.0011085279,0.0007835602,0.0034265073,0.0008386957,0.081336886,0.00051171996,0.006427269,0.0003364933],"about_ca_topic_score_codex":0.00006356104,"about_ca_topic_score_gemma":0.00016005083,"teacher_disagreement_score":0.12384082,"about_ca_system_score_codex":0.00013395135,"about_ca_system_score_gemma":0.0013789763,"threshold_uncertainty_score":0.39064637},"labels":[],"label_agreement":null},{"id":"W3135044645","doi":"10.1200/jco.2021.39.6_suppl.291","title":"Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Low molecular weight heparin; Cabozantinib; Renal cell carcinoma; Hemostasis; Internal medicine; Rivaroxaban; Cancer; Clinical endpoint; Concomitant; Fondaparinux; Apixaban; Thrombosis; Anticoagulant; Surgery; Clinical trial; Warfarin; Venous thromboembolism","score_opus":0.11574646549341908,"score_gpt":0.4399190406476532,"score_spread":0.32417257515423414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135044645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914772,0.00056753174,0.0000730376,0.0020929037,0.00044874422,0.00040257035,0.0000018772647,0.0000035169041,0.0049326424],"genre_scores_gemma":[0.99706393,0.0005287703,0.0015854844,0.00057728024,0.00012072427,0.000008836568,0.000009039011,0.000017778068,0.0000881582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949274,0.0014301386,0.0021393849,0.000258669,0.0009922977,0.00025209566],"domain_scores_gemma":[0.9965572,0.00063538336,0.0012927696,0.00022855781,0.0011279722,0.0001581267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0078987265,0.00015014967,0.0020004937,0.0003003474,0.00001622362,0.0000083166215,0.00012634655,0.00025484184,0.0002060989],"category_scores_gemma":[0.002235744,0.000106293555,0.00020057218,0.00044338172,0.0000871268,0.00010336049,0.00006256118,0.00056628924,0.0000037614204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063999197,0.033831876,0.80783856,0.00036190604,0.00069145067,0.011404903,0.0005903686,0.0014611683,0.0059627695,0.00044448161,0.0026443752,0.12836824],"study_design_scores_gemma":[0.024483763,0.007867923,0.9524692,0.00044095961,0.0010829084,0.00011918187,0.00017356867,0.0024022965,0.00927471,0.00019070023,0.0013694436,0.0001253354],"about_ca_topic_score_codex":0.0001760754,"about_ca_topic_score_gemma":0.001453781,"teacher_disagreement_score":0.14463067,"about_ca_system_score_codex":0.00021220242,"about_ca_system_score_gemma":0.00286864,"threshold_uncertainty_score":0.50888443},"labels":[],"label_agreement":null},{"id":"W3135052528","doi":"10.1200/jco.2021.39.6_suppl.412","title":"Trends over time in survival in patients with urothelial carcinoma in the real-world: A multicenter analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; St. Michael's Hospital; University Health Network; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Multivariate analysis; Metastatic Urothelial Carcinoma; Oncology; Cancer; Urothelial cancer; Chemotherapy; Disease; Urothelial carcinoma","score_opus":0.053593956733377475,"score_gpt":0.42198054696491355,"score_spread":0.3683865902315361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135052528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890425,0.000053284242,0.0000020064685,0.0024001384,0.00023566964,0.00013064746,0.000008732013,0.0000018305196,0.008125178],"genre_scores_gemma":[0.99722505,0.000051866427,0.00018092938,0.0016371611,0.0002868554,0.000005069173,0.000012122064,0.000011802769,0.0005891694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964907,0.0009989811,0.0016071711,0.0002157271,0.00044388845,0.00024353438],"domain_scores_gemma":[0.9979828,0.0009892165,0.00051441684,0.00022005879,0.00016315049,0.0001303525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016372055,0.00013668771,0.0014326184,0.00056924764,0.000011866534,0.000008788223,0.00013506811,0.00016288819,0.00051973003],"category_scores_gemma":[0.0003783081,0.00007693232,0.00035875023,0.001240331,0.00008035673,0.000077762794,0.000029441355,0.0008190345,0.00000738849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007612548,0.004430191,0.9731815,0.000004944866,0.00039138977,0.0018709087,0.00029503225,0.0000361678,0.0000029301216,0.000008482894,0.00019568637,0.011970259],"study_design_scores_gemma":[0.031279515,0.004049909,0.96167845,0.00004497602,0.00067169487,0.0000073946912,0.00005803611,0.00012614956,0.0000038403996,0.000016089276,0.0019961854,0.000067762754],"about_ca_topic_score_codex":0.0006921581,"about_ca_topic_score_gemma":0.016888706,"teacher_disagreement_score":0.023666967,"about_ca_system_score_codex":0.00025790898,"about_ca_system_score_gemma":0.00091903127,"threshold_uncertainty_score":0.9424294},"labels":[],"label_agreement":null},{"id":"W3135075565","doi":"10.1200/jco.2021.39.6_suppl.26","title":"Concordance of <i>BRCA1</i>, <i>BRCA2</i> (BRCA), and <i>ATM</i> mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Concordance; Olaparib; Enzalutamide; Internal medicine; Oncology; Cancer; Prostate cancer; Gene; Genetics; Poly ADP ribose polymerase","score_opus":0.047417192115772465,"score_gpt":0.39012865003113095,"score_spread":0.3427114579153585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135075565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962351,0.0018683377,0.000037147096,0.0010050769,0.00009481977,0.0005474486,0.000029064993,8.928481e-7,0.00018215115],"genre_scores_gemma":[0.9976059,0.0004717498,0.001103021,0.00063342246,0.00009085186,0.000049571307,0.000008822672,0.000014606586,0.00002205637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971108,0.000558607,0.0016207503,0.00029851298,0.00020575103,0.00020557044],"domain_scores_gemma":[0.9976313,0.0008007514,0.0010472847,0.00017695029,0.00025729186,0.00008640628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021258746,0.00014826117,0.00076023693,0.00007071203,0.000037302067,0.00003706825,0.00013907516,0.00006982431,0.000004541999],"category_scores_gemma":[0.0010533233,0.00011220878,0.0000541304,0.00024859537,0.00021508188,0.000020576572,0.00007042391,0.00034040713,1.3134846e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044410327,0.0033648154,0.6982991,0.00026204318,0.0004465894,0.004130723,0.003798196,0.0033564013,0.27104124,0.00023623026,0.00022811723,0.010395473],"study_design_scores_gemma":[0.018165527,0.0059383167,0.94893384,0.0002771835,0.00026261123,0.00042079546,0.011891107,0.0002615295,0.011621539,0.00072322384,0.0011999927,0.00030434196],"about_ca_topic_score_codex":0.0005405673,"about_ca_topic_score_gemma":0.037183423,"teacher_disagreement_score":0.2594197,"about_ca_system_score_codex":0.00005176237,"about_ca_system_score_gemma":0.0015531592,"threshold_uncertainty_score":0.9803855},"labels":[],"label_agreement":null},{"id":"W3135084125","doi":"10.1200/jco.2021.39.6_suppl.93","title":"TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Enzalutamide; Oncology; Clinical endpoint; Taxane; Urology; Cancer; Surgery; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.11234208764431837,"score_gpt":0.48639998507008797,"score_spread":0.3740578974257696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135084125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965096,0.00027457753,0.000019505562,0.0018623312,0.0003432285,0.0006661853,0.000041065145,0.000008023761,0.00027546976],"genre_scores_gemma":[0.99680823,0.00020212417,0.0019608268,0.0005633052,0.00015899634,0.000041090843,0.000014270875,0.000018651532,0.00023250912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958765,0.00060356513,0.0025597448,0.00027331265,0.0004941652,0.0001927448],"domain_scores_gemma":[0.9962371,0.000596261,0.0016245118,0.00023487017,0.0010627738,0.00024450204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014514374,0.00015933925,0.0012817439,0.00015846611,0.00007345623,0.000011893059,0.00006605964,0.00010034756,0.00015567827],"category_scores_gemma":[0.0008459767,0.00011806097,0.00014963592,0.0003242714,0.00021408917,0.00022076684,0.00004084377,0.00061973714,6.928073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044032432,0.09568464,0.7827418,0.00032265176,0.0027351442,0.0047949725,0.0074418085,0.00066515483,0.011710608,0.00015460142,0.0027971012,0.046919085],"study_design_scores_gemma":[0.1429184,0.15120867,0.69225603,0.00066429115,0.00114389,0.00020159346,0.0030692196,0.00033312035,0.0017741428,0.00016996304,0.006002151,0.00025851463],"about_ca_topic_score_codex":0.00006758551,"about_ca_topic_score_gemma":0.0015372398,"teacher_disagreement_score":0.09888597,"about_ca_system_score_codex":0.0001852606,"about_ca_system_score_gemma":0.0022520265,"threshold_uncertainty_score":0.48143867},"labels":[],"label_agreement":null},{"id":"W3135119657","doi":"10.1200/jco.2021.39.6_suppl.439","title":"Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine","score_opus":0.16968554216152343,"score_gpt":0.48443187904374607,"score_spread":0.31474633688222264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135119657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875925,0.0019715067,0.000110752146,0.005064272,0.0026510516,0.0012164408,0.000066176784,0.000020051122,0.0013072558],"genre_scores_gemma":[0.9801326,0.01355123,0.0012623437,0.0019250463,0.0023032746,0.00005714417,0.000029657214,0.00011221014,0.00062648585],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944456,0.00047118065,0.0029774078,0.00060628215,0.0007794028,0.00072010304],"domain_scores_gemma":[0.9925049,0.0035566492,0.0017637898,0.0006078322,0.0010210131,0.0005457929],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016420216,0.00054845156,0.0035190855,0.00024271087,0.000078205296,0.000018092836,0.0003737234,0.0007211741,0.0010992832],"category_scores_gemma":[0.001872018,0.00036188815,0.0018510215,0.00042579806,0.00026128077,0.00014990334,0.000044286844,0.0010931866,0.000012098144],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7581407,0.010492652,0.027571041,0.00008152918,0.0023512212,0.001029355,0.0005482872,0.00030672047,0.0056142383,0.00003956039,0.00076922716,0.19305547],"study_design_scores_gemma":[0.4571058,0.16817303,0.32963306,0.00026034567,0.00033839437,0.00047626614,0.00016972127,0.0001979824,0.025706327,0.00036958596,0.01707872,0.0004907594],"about_ca_topic_score_codex":0.00032476478,"about_ca_topic_score_gemma":0.0003316456,"teacher_disagreement_score":0.30206203,"about_ca_system_score_codex":0.0012458744,"about_ca_system_score_gemma":0.009696111,"threshold_uncertainty_score":0.9998833},"labels":[],"label_agreement":null},{"id":"W3135123677","doi":"10.1200/jco.2021.39.6_suppl.9","title":"Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Placebo; Progression-free survival; Androgen deprivation therapy; Prednisone; Mallinckrodt; Enzalutamide; Randomization; Randomized controlled trial; Gastroenterology; Urology; Oncology; Androgen receptor; Cancer; Chemotherapy; Pathology","score_opus":0.1758181269716558,"score_gpt":0.4757662955401537,"score_spread":0.29994816856849793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135123677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203426,0.0016626565,0.000009588687,0.0018272407,0.0004748498,0.0036711565,0.00014137846,0.000006189888,0.00017270538],"genre_scores_gemma":[0.9962466,0.001750258,0.0009422633,0.00007991696,0.00019406047,0.00019063386,0.0000727791,0.00002826532,0.0004952374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928658,0.0014559131,0.0038424935,0.0005076381,0.0009149819,0.00041320102],"domain_scores_gemma":[0.9908919,0.004376028,0.002731225,0.00028359253,0.0013015011,0.0004158033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039049247,0.00032391617,0.0042314525,0.00024072175,0.000068078814,0.000037520123,0.00014255058,0.00019351531,0.00008013478],"category_scores_gemma":[0.0024734864,0.00019668076,0.00030738223,0.00032626014,0.0004538124,0.00021986698,0.0000795494,0.00096277584,0.0000021201934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96376175,0.010228234,0.0055887746,0.00007559745,0.0045709177,0.0023257374,0.0032491554,0.0003090481,0.0003245935,0.0000026708549,0.00009345179,0.009470067],"study_design_scores_gemma":[0.9419839,0.036024734,0.015324431,0.00036016706,0.0029312307,0.000022518132,0.0019426008,0.0005020121,0.0006237397,0.000036491147,0.000086715234,0.00016149817],"about_ca_topic_score_codex":0.00066868437,"about_ca_topic_score_gemma":0.0026357844,"teacher_disagreement_score":0.025796501,"about_ca_system_score_codex":0.0004621773,"about_ca_system_score_gemma":0.00423279,"threshold_uncertainty_score":0.8020409},"labels":[],"label_agreement":null},{"id":"W3135144655","doi":"10.1200/jco.2021.39.6_suppl.84","title":"PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Internal medicine; Oncology; Post-hoc analysis; Subgroup analysis; Placebo; Adverse effect; Proportional hazards model; Multivariate analysis; Gynecology; Cancer; Androgen receptor; Confidence interval; Alternative medicine","score_opus":0.09074979996232181,"score_gpt":0.42452423312065346,"score_spread":0.33377443315833166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135144655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871034,0.005906417,0.000074919786,0.0061467155,0.00005745652,0.00035780406,0.000009822471,0.0000036469764,0.00033979138],"genre_scores_gemma":[0.9684482,0.029466229,0.0009713064,0.0002772619,0.00010698386,0.000015284912,0.000024670078,0.0000133361655,0.00067671685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759156,0.00045396184,0.0011138477,0.00027313046,0.0003592127,0.00020827523],"domain_scores_gemma":[0.9980052,0.00076010404,0.0005901364,0.00012438942,0.00029173156,0.00022840942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00164566,0.00013622601,0.0011170462,0.00013291147,0.000056940476,0.0000331631,0.000045902427,0.0001373668,0.00003948513],"category_scores_gemma":[0.0002892594,0.00008567129,0.00011571844,0.0003814549,0.00018797563,0.00016964992,0.000028072014,0.0004742729,1.9715264e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035950273,0.00054570666,0.9191216,0.000064058055,0.002169502,0.0041656564,0.0006859036,0.00008161284,0.0015350078,0.000044616525,0.00023363835,0.035402395],"study_design_scores_gemma":[0.021114323,0.005736635,0.96886075,0.0001448886,0.0006642102,0.00016673387,0.00038778476,0.00032952582,0.00029102288,0.00016607034,0.0020220352,0.00011605233],"about_ca_topic_score_codex":0.00015145386,"about_ca_topic_score_gemma":0.0021514972,"teacher_disagreement_score":0.049739085,"about_ca_system_score_codex":0.00027977373,"about_ca_system_score_gemma":0.0013595627,"threshold_uncertainty_score":0.34935737},"labels":[],"label_agreement":null},{"id":"W3135168894","doi":"10.1200/jco.2021.39.6_suppl.tps372","title":"Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Cabozantinib; Lenvatinib; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Targeted therapy; Tyrosine-kinase inhibitor; Systemic therapy; Clear cell renal cell carcinoma; Kidney cancer; Cancer","score_opus":0.1325635417962137,"score_gpt":0.463206243036248,"score_spread":0.3306427012400343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135168894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994066,0.0016982207,0.000018548844,0.00041633873,0.0004216262,0.0032175004,0.000027184693,0.000008369078,0.00012623666],"genre_scores_gemma":[0.9932176,0.0003352489,0.005543493,0.00030768052,0.00032289384,0.00007385264,0.00002312219,0.000054343385,0.00012175644],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99391973,0.00091339275,0.003452203,0.00055124314,0.00073568005,0.0004277399],"domain_scores_gemma":[0.9910074,0.0040934957,0.0026403253,0.000419264,0.001507835,0.00033170547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029581694,0.00037877494,0.0027378814,0.00018488154,0.00006949326,0.000016083373,0.00017169818,0.0002981182,0.00017838106],"category_scores_gemma":[0.0013819349,0.00022750322,0.00035299824,0.00032166715,0.00019890719,0.00016173592,0.00006983978,0.00083067745,7.104942e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50787866,0.029172553,0.25466585,0.00008788645,0.0006847331,0.0015863627,0.0010288463,0.000020076204,0.0012279177,8.218606e-7,0.000032132433,0.20361415],"study_design_scores_gemma":[0.2920789,0.21391861,0.48909673,0.00015499994,0.0003017984,0.000040229446,0.00031501817,0.00004999201,0.0034784987,0.0000021985215,0.00043199793,0.00013101057],"about_ca_topic_score_codex":0.000005840805,"about_ca_topic_score_gemma":0.00006014723,"teacher_disagreement_score":0.2344309,"about_ca_system_score_codex":0.00013725806,"about_ca_system_score_gemma":0.002486207,"threshold_uncertainty_score":0.9277312},"labels":[],"label_agreement":null},{"id":"W3135186447","doi":"10.1200/jco.2021.39.6_suppl.106","title":"Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Concomitant; Docetaxel; Urology; Clinical endpoint; Prostate; Testosterone (patch); Internal medicine; Cancer; Subgroup analysis; Oncology; Enzalutamide; Gynecology; Randomized controlled trial; Androgen receptor; Confidence interval","score_opus":0.09848423727485707,"score_gpt":0.5165458415783135,"score_spread":0.41806160430345646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135186447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98701847,0.007895012,0.0000020478294,0.0035528576,0.0001491149,0.0010950993,0.0001081685,0.0000035737514,0.00017568287],"genre_scores_gemma":[0.9498736,0.049567685,0.00009902913,0.000114635026,0.00014663281,0.00003763485,0.000013417372,0.000019146864,0.00012819165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960131,0.000808018,0.0019864363,0.00032856004,0.000555094,0.0003087878],"domain_scores_gemma":[0.9935192,0.003483158,0.0016966629,0.00032993112,0.00071068783,0.0002603874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018318455,0.00021764067,0.0023276012,0.00015838098,0.000047642454,0.000009421361,0.0001597421,0.0001431006,0.00012489829],"category_scores_gemma":[0.0005308077,0.0001044339,0.00040595434,0.0007154878,0.00040328744,0.000095225194,0.000051323812,0.00087745354,2.5742008e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35326713,0.004649599,0.5226592,0.000012706944,0.007832335,0.00061639736,0.0021046887,0.0007180347,0.0009011358,0.000002017123,0.000106072745,0.10713068],"study_design_scores_gemma":[0.19016264,0.05267238,0.7526615,0.0002484206,0.0014573385,0.000007326914,0.0012670711,0.00011244416,0.0008276744,0.000017045983,0.0004732664,0.000092868126],"about_ca_topic_score_codex":0.002198275,"about_ca_topic_score_gemma":0.0028188825,"teacher_disagreement_score":0.23000231,"about_ca_system_score_codex":0.00046313804,"about_ca_system_score_gemma":0.003769704,"threshold_uncertainty_score":0.66872925},"labels":[],"label_agreement":null},{"id":"W3135248026","doi":"10.1200/jco.2021.39.6_suppl.463","title":"Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Bladder cancer; Medicine; Cancer; Cancer research; FOXA1; Internal medicine; GATA3; Oncology; Biology; Breast cancer; Gene; Transcription factor; Genetics","score_opus":0.09092638528811434,"score_gpt":0.4885105235147176,"score_spread":0.3975841382266032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135248026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479634,0.00081290153,0.0001526321,0.002471495,0.001188857,0.00016670283,0.000027153124,0.0000051534466,0.00037877247],"genre_scores_gemma":[0.9952179,0.00049895735,0.0015063714,0.0020556292,0.0006395278,0.000006053999,0.0000022114975,0.000017322776,0.000056006433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970386,0.0005419117,0.0015506351,0.0002289024,0.00037574937,0.00026417774],"domain_scores_gemma":[0.9972939,0.0009140102,0.0007229553,0.00020028799,0.00052180944,0.00034706667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016789936,0.00014085842,0.0013852699,0.000065560525,0.000023745064,0.0000055101495,0.00008093812,0.00029082282,0.00011103931],"category_scores_gemma":[0.002676426,0.00010524207,0.00041409835,0.00018769837,0.00009880586,0.00006592038,0.0000907425,0.00056376605,0.0000057279844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01219981,0.0032848578,0.71749544,0.000092574424,0.000488399,0.006318176,0.00063241366,0.00030093052,0.15373528,0.0000138510195,0.0004843959,0.10495386],"study_design_scores_gemma":[0.009474674,0.004662179,0.5165558,0.00031435752,0.00020842766,0.0003432919,0.0001636702,0.000024438717,0.46170744,0.00008383923,0.006345155,0.00011675933],"about_ca_topic_score_codex":0.00023463772,"about_ca_topic_score_gemma":0.0011856783,"teacher_disagreement_score":0.30797216,"about_ca_system_score_codex":0.00013864461,"about_ca_system_score_gemma":0.0023651563,"threshold_uncertainty_score":0.4291647},"labels":[],"label_agreement":null},{"id":"W3135266275","doi":"10.1200/jco.2021.39.6_suppl.316","title":"Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Juravinski Cancer Centre; Queen's University; Sunnybrook Hospital; University of Alberta; University of Ottawa; Dalhousie University; Ottawa Hospital; University Health Network; University of Calgary; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Hazard ratio; Clear cell renal cell carcinoma; Renal cell carcinoma; Internal medicine; Oncology; Proportional hazards model; Combination therapy; Targeted therapy; Vascular endothelial growth factor; Cancer; Urology; VEGF receptors; Confidence interval","score_opus":0.04911479647460906,"score_gpt":0.37492427423794855,"score_spread":0.32580947776333946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135266275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896653,0.0025244914,0.000091745096,0.0008392455,0.0011833075,0.00042342275,0.0000038703624,0.0000062503786,0.0052623353],"genre_scores_gemma":[0.9954005,0.0006834049,0.0028814056,0.000104581784,0.0004918514,0.0000091662405,0.000009545198,0.00004384722,0.00037572955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932225,0.0010735042,0.004320977,0.00041095563,0.0005648293,0.0004072815],"domain_scores_gemma":[0.992192,0.003589673,0.0024271803,0.00046400918,0.0008820849,0.00044507012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004319091,0.00030005624,0.0029744755,0.0002574013,0.0000347613,0.000006209236,0.00021188773,0.00054691994,0.00015222459],"category_scores_gemma":[0.0018023008,0.0002322712,0.001257141,0.00041801922,0.00021579982,0.00011348183,0.00016630316,0.0015457663,0.000023104647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037173726,0.015782412,0.48027363,0.0019695833,0.0003657729,0.020393874,0.0003538218,0.0011791736,0.42786503,0.000009234773,0.00021567036,0.014418062],"study_design_scores_gemma":[0.020344418,0.020183269,0.5225447,0.00051942514,0.00031523165,0.00030484193,0.00015953029,0.00009473531,0.43439656,0.00006211466,0.0009432478,0.00013193657],"about_ca_topic_score_codex":0.000095036135,"about_ca_topic_score_gemma":0.00006203158,"teacher_disagreement_score":0.042271048,"about_ca_system_score_codex":0.00055979536,"about_ca_system_score_gemma":0.0020344097,"threshold_uncertainty_score":0.94717443},"labels":[],"label_agreement":null},{"id":"W3135309578","doi":"10.1200/jco.2021.39.6_suppl.209","title":"Multimodal biomarkers overcome sampling bias to predict presence of aggressive localized prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre; University of Toronto; Ontario Institute for Cancer Research; McGill University; Queen's University","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Prostatectomy; Cohort; Biopsy; Prostate; Grading (engineering); Oncology; Biochemical recurrence; Confounding; Internal medicine; Pathology; Cancer","score_opus":0.09853010566795427,"score_gpt":0.4642023355632301,"score_spread":0.3656722298952758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135309578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724465,0.0046125636,0.018087946,0.002279311,0.0017903176,0.0003852528,0.000076570686,0.000005476793,0.0003160836],"genre_scores_gemma":[0.97739583,0.005547929,0.014949464,0.0008844554,0.0007937543,0.000021809125,0.00001836129,0.00003973281,0.0003486584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960534,0.0008049315,0.0018257148,0.00039895062,0.0005376033,0.0003793762],"domain_scores_gemma":[0.99493635,0.00058720954,0.002218393,0.00037258642,0.001412812,0.00047264525],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002229791,0.00017436586,0.0009158493,0.00011632226,0.00004430228,0.000015562015,0.00042204792,0.0005297056,0.00010674685],"category_scores_gemma":[0.016065605,0.00015062526,0.00050927023,0.00030699922,0.00022323639,0.000009612632,0.00037755095,0.00061941263,0.000003921923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01042922,0.0009400433,0.0065305033,0.00009401661,0.0016179804,0.0007932377,0.00013774038,0.007864923,0.8015812,0.00003154877,0.0055874907,0.16439207],"study_design_scores_gemma":[0.01558427,0.01807308,0.016961142,0.0008538989,0.00037120475,0.00061250734,0.000469687,0.0017365218,0.7581317,0.00040059778,0.18623415,0.0005712298],"about_ca_topic_score_codex":0.00007720121,"about_ca_topic_score_gemma":0.00018604448,"teacher_disagreement_score":0.18064666,"about_ca_system_score_codex":0.00009520694,"about_ca_system_score_gemma":0.004264944,"threshold_uncertainty_score":0.9922225},"labels":[],"label_agreement":null},{"id":"W3135310517","doi":"10.1200/jco.2021.39.6_suppl.tps266","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Tolerability; Oncology; Randomized controlled trial; Interim analysis; Urology; Cancer; Adverse effect; Pathology","score_opus":0.11763635021972726,"score_gpt":0.4702516051159598,"score_spread":0.3526152548962326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135310517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130924,0.0038300883,0.00095412123,0.004192741,0.00089787773,0.008561352,0.00017357986,0.000007382041,0.00007364751],"genre_scores_gemma":[0.95075065,0.04511882,0.0017727229,0.0008326925,0.0005475832,0.0006746997,0.000032958254,0.000035768877,0.00023411338],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936209,0.0017265478,0.003232516,0.00033576484,0.0007505769,0.0003337204],"domain_scores_gemma":[0.986185,0.008453257,0.0033414694,0.00027736518,0.0014549004,0.0002879708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00763009,0.0002519674,0.0036617846,0.00020772494,0.00013841415,0.000024282457,0.00018849439,0.0003181412,0.00013257159],"category_scores_gemma":[0.0047455695,0.00013045875,0.0008749743,0.00035254873,0.00042353466,0.00014831367,0.00006239065,0.0005931683,3.6836119e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8591486,0.0017688526,0.0018878579,0.000033332006,0.0041608703,0.000045123306,0.00047841817,0.00006670219,0.0010843703,0.000073147836,0.00027724577,0.13097546],"study_design_scores_gemma":[0.9610691,0.019448265,0.000652501,0.00020897068,0.0011748986,0.000016054208,0.00013779779,0.000209872,0.0128432335,0.0006034916,0.0035164373,0.000119348806],"about_ca_topic_score_codex":0.000083322106,"about_ca_topic_score_gemma":0.00005546656,"teacher_disagreement_score":0.13085611,"about_ca_system_score_codex":0.0002760524,"about_ca_system_score_gemma":0.005487106,"threshold_uncertainty_score":0.973389},"labels":[],"label_agreement":null},{"id":"W3135314217","doi":"10.1200/jco.2021.39.15_suppl.e17003","title":"A prospective phase 2/3 study of PSMA-targeted <sup>18</sup>F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Bone scintigraphy; Nuclear medicine; Prostate cancer; Stage (stratigraphy); Radiology; Positron emission tomography; Cancer; Internal medicine","score_opus":0.09436800555742343,"score_gpt":0.4742779297651016,"score_spread":0.37990992420767816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135314217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608314,0.00074558414,0.0000056480644,0.0014573724,0.00008614402,0.0013137431,0.00026231082,0.000004923698,0.00004114109],"genre_scores_gemma":[0.9985092,0.00072181935,0.00022773191,0.00015455311,0.000060137914,0.00012940867,0.00006859716,0.000022237027,0.0001062631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952565,0.00095933623,0.0018227258,0.00049861876,0.0010744889,0.00038834492],"domain_scores_gemma":[0.9948551,0.0011732129,0.0016785673,0.00027340354,0.00163728,0.00038241324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017096204,0.00025965594,0.002234661,0.00080309156,0.00003897253,0.000012586975,0.00015782335,0.000030203768,0.0002891602],"category_scores_gemma":[0.0013953282,0.00015160684,0.00026668338,0.0017068516,0.00036162304,0.00017194082,0.00007095958,0.0008130904,6.1834953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117977016,0.029413158,0.82791597,0.00014008197,0.0038241644,0.0077904826,0.0006550074,0.0007394399,0.000016208973,0.0000039551937,0.000081544764,0.011442961],"study_design_scores_gemma":[0.07655315,0.041961275,0.8721298,0.0010754109,0.0041001327,0.000028992625,0.0022156255,0.0011750509,0.00044337072,0.000026951731,0.00011552891,0.00017474192],"about_ca_topic_score_codex":0.00021049762,"about_ca_topic_score_gemma":0.00257656,"teacher_disagreement_score":0.044213794,"about_ca_system_score_codex":0.0005475875,"about_ca_system_score_gemma":0.004165108,"threshold_uncertainty_score":0.7388723},"labels":[],"label_agreement":null},{"id":"W3135328828","doi":"10.1200/jco.2021.39.6_suppl.13","title":"PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"PTEN; Medicine; Prostate cancer; Immunohistochemistry; Internal medicine; Cancer; Population; Oncology; Abiraterone acetate; Pathology; PI3K/AKT/mTOR pathway; Androgen deprivation therapy; Apoptosis; Biology","score_opus":0.200979632659316,"score_gpt":0.5116480651843357,"score_spread":0.3106684325250197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135328828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865393,0.0035695655,0.00006780381,0.008071179,0.00078043406,0.0005731331,0.00030065913,0.000003735684,0.00009416599],"genre_scores_gemma":[0.9951863,0.0029292067,0.00068307726,0.00032932925,0.00040723613,0.000032906522,0.00016521677,0.000014007772,0.00025271985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942254,0.0012899303,0.0032303836,0.00028744814,0.00065284676,0.00031400385],"domain_scores_gemma":[0.9947806,0.002114112,0.0017810989,0.0003225064,0.00070575665,0.0002959466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003430832,0.00017341902,0.0020749187,0.00021409932,0.00006081373,0.000022690509,0.00019049969,0.00016963317,0.000536689],"category_scores_gemma":[0.0014533661,0.00009809752,0.00075225567,0.00092741026,0.0003537581,0.00012337443,0.00005909991,0.0006897896,0.0000029265696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79486316,0.009759252,0.020605808,0.00008683015,0.019411579,0.009387434,0.0011664972,0.00034933395,0.022750527,0.00002514104,0.001849275,0.11974517],"study_design_scores_gemma":[0.8378677,0.034145866,0.08275879,0.00044101794,0.013436092,0.00006108262,0.002998725,0.0013815158,0.018309802,0.00048330915,0.0078096306,0.00030647326],"about_ca_topic_score_codex":0.0016457834,"about_ca_topic_score_gemma":0.0044899886,"teacher_disagreement_score":0.1194387,"about_ca_system_score_codex":0.00032600772,"about_ca_system_score_gemma":0.0073709036,"threshold_uncertainty_score":0.9982564},"labels":[],"label_agreement":null},{"id":"W3135425547","doi":"10.1200/jco.2021.39.6_suppl.325","title":"UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Discontinuation; Oncology; Chromophobe cell; Adverse effect; Cancer; Clear cell; Immunotherapy","score_opus":0.06523054393215995,"score_gpt":0.3812463822326602,"score_spread":0.3160158383005003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135425547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970939,0.004430044,0.00010630038,0.0028678253,0.0019065384,0.0006004647,0.0000112041025,0.000029021749,0.019109637],"genre_scores_gemma":[0.978788,0.0023614787,0.006782371,0.0017401846,0.0015470036,0.000021135455,0.000022349635,0.00012684528,0.008610587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909457,0.0013855852,0.0047351373,0.0009072304,0.0010552891,0.00097105466],"domain_scores_gemma":[0.99237865,0.0018664267,0.0027351798,0.0010527814,0.00097064313,0.0009963382],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026989977,0.00059846375,0.0035716682,0.000376686,0.00012722735,0.000043717817,0.00055076415,0.001027845,0.0012452964],"category_scores_gemma":[0.00068856776,0.00050394086,0.0015249577,0.0005470105,0.00034870906,0.00032251762,0.00020350757,0.0026755428,0.00023833619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097127676,0.036398917,0.39064917,0.000832849,0.0018570665,0.08115211,0.0037982604,0.0014000651,0.067344226,0.00007200787,0.039288502,0.28007916],"study_design_scores_gemma":[0.1517418,0.08820469,0.5261391,0.0007597599,0.0019947677,0.0027989433,0.0034491394,0.0015268028,0.047073208,0.0005718057,0.17441034,0.0013296404],"about_ca_topic_score_codex":0.00021068199,"about_ca_topic_score_gemma":0.0002802806,"teacher_disagreement_score":0.2787495,"about_ca_system_score_codex":0.0017495668,"about_ca_system_score_gemma":0.006653997,"threshold_uncertainty_score":0.9997412},"labels":[],"label_agreement":null},{"id":"W3135441040","doi":"10.1200/jco.2021.39.6_suppl.tps190","title":"A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Oncology; Internal medicine; Cancer; Enzalutamide; Nivolumab; Immunotherapy; Androgen receptor","score_opus":0.19548848981625613,"score_gpt":0.4756110529767282,"score_spread":0.280122563160472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135441040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279547,0.001935704,0.000021293978,0.00066137937,0.00056629267,0.0029895862,0.000053432905,0.000004322915,0.0009725265],"genre_scores_gemma":[0.99526715,0.0010486083,0.002757334,0.00029954372,0.000117418946,0.00011472522,0.000021960046,0.000035470628,0.0003377983],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931585,0.0010987886,0.0042231414,0.00041788555,0.00074627943,0.00035541528],"domain_scores_gemma":[0.9916227,0.002683791,0.0034312534,0.0003620453,0.0015243135,0.00037590432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032475747,0.00032634137,0.004423536,0.00018127126,0.000049279344,0.000034586927,0.00025057996,0.00016757943,0.0002963349],"category_scores_gemma":[0.0011098891,0.00020300661,0.00030962395,0.00033519883,0.00021497114,0.00025979365,0.00009140671,0.00083091116,0.0000024009123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9078396,0.057979677,0.0055392846,0.000035210836,0.0039798236,0.003817286,0.001297714,0.000029684814,0.0022770956,0.000025210978,0.00022150623,0.016957887],"study_design_scores_gemma":[0.8397111,0.109738775,0.04614086,0.00013109439,0.0013407958,0.00008371604,0.0009728385,0.00007216239,0.0007916496,0.000010631565,0.00084536604,0.00016095134],"about_ca_topic_score_codex":0.0006893925,"about_ca_topic_score_gemma":0.0031576108,"teacher_disagreement_score":0.06812847,"about_ca_system_score_codex":0.0004957822,"about_ca_system_score_gemma":0.0064485664,"threshold_uncertainty_score":0.99918395},"labels":[],"label_agreement":null},{"id":"W3135473217","doi":"10.1200/jco.2021.39.6_suppl.27","title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in <i>BRCA1</i>, <i>BRCA2</i> or <i>ATM</i>: Results from the PROfound study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; Oncology; Internal medicine; BRCA mutation; Cohort; Cancer; Proportional hazards model; Progression-free survival; Prostate cancer; Cancer research; Gene; Chemotherapy; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics","score_opus":0.1359905281967922,"score_gpt":0.44993887441197955,"score_spread":0.31394834621518736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135473217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038285,0.0003208509,0.000015562502,0.0068622036,0.0007667022,0.0013556862,0.00009576999,0.000013717765,0.00018664898],"genre_scores_gemma":[0.993951,0.00008777407,0.0017755519,0.003446016,0.0005243422,0.000080787606,0.00003368383,0.00004302744,0.0000577845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925865,0.0015967842,0.004155836,0.00047654813,0.0007992476,0.00038507997],"domain_scores_gemma":[0.99041694,0.005666894,0.0023866727,0.00041038598,0.0008820998,0.000236985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033343409,0.00025836285,0.0015160403,0.000120197554,0.00013405972,0.00006297053,0.00019221054,0.00008184705,0.000090261405],"category_scores_gemma":[0.004594014,0.00015522003,0.0001985712,0.0007179429,0.00018422381,0.00028804413,0.000048989597,0.0014835568,0.0000043501836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060004495,0.016369892,0.8781088,0.00006789567,0.0013659546,0.01036313,0.009998291,0.004531593,0.0017502332,0.000028613294,0.0011792352,0.016231868],"study_design_scores_gemma":[0.08033637,0.0062324004,0.90598625,0.0010584706,0.00045407075,0.00013301922,0.002271777,0.00014275087,0.00029344083,0.00007489826,0.0027982541,0.0002182784],"about_ca_topic_score_codex":0.00071916525,"about_ca_topic_score_gemma":0.01385489,"teacher_disagreement_score":0.02787747,"about_ca_system_score_codex":0.00061925914,"about_ca_system_score_gemma":0.005886683,"threshold_uncertainty_score":0.999749},"labels":[],"label_agreement":null},{"id":"W3135535477","doi":"10.1200/jco.2021.39.6_suppl.10","title":"KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Abiraterone; Cohort; Prednisone; Cabazitaxel; Internal medicine; Oncology; Cancer; Adverse effect; Androgen deprivation therapy; Androgen receptor","score_opus":0.13968818408775974,"score_gpt":0.45052115223611805,"score_spread":0.3108329681483583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135535477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949723,0.0012666056,0.000015478025,0.0009232179,0.0002346711,0.00065065734,0.0017874155,0.000006873296,0.00014279495],"genre_scores_gemma":[0.99043995,0.0017675782,0.0044650272,0.0002680833,0.00022752718,0.0000472782,0.00095865916,0.000036488793,0.0017893983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959729,0.00051822595,0.0019016296,0.00047013414,0.0007802233,0.00035690315],"domain_scores_gemma":[0.99622506,0.00085956143,0.0009878894,0.00041771648,0.0009863354,0.0005234333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010187504,0.0002351981,0.0015336216,0.00015162288,0.000040698877,0.000028732386,0.00018905634,0.00019528878,0.0018870013],"category_scores_gemma":[0.001229714,0.00014530007,0.0001157251,0.00032836635,0.00032616095,0.0004578962,0.00011816381,0.0006594871,0.0000035967912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28542796,0.0045612287,0.6689049,0.0003621316,0.0026035002,0.004666352,0.0005902539,0.00007188966,0.00044007754,0.0000139436925,0.005027486,0.027330285],"study_design_scores_gemma":[0.06961071,0.012135739,0.91304576,0.0006200171,0.0008239399,0.00014177657,0.00020485402,0.00017610338,0.00022895956,0.00008485558,0.0027593507,0.00016793543],"about_ca_topic_score_codex":0.0002688881,"about_ca_topic_score_gemma":0.003466753,"teacher_disagreement_score":0.24414088,"about_ca_system_score_codex":0.00035561764,"about_ca_system_score_gemma":0.0092241885,"threshold_uncertainty_score":0.9990254},"labels":[],"label_agreement":null},{"id":"W3135598234","doi":"10.1200/jco.2021.39.6_suppl.60","title":"Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital","funders":"National Institutes of Health","keywords":"Medicine; Baseline (sea); Clinical trial; Quality of life (healthcare); Prostate cancer; Oncology; Algorithm; Internal medicine; Cancer; Computer science","score_opus":0.6212673079366525,"score_gpt":0.574440450973169,"score_spread":0.04682685696348354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135598234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94322836,0.0037480693,0.016108857,0.022336472,0.0028616877,0.0002929895,0.0004922015,0.000010053703,0.010921322],"genre_scores_gemma":[0.9723936,0.0008658191,0.022113858,0.0034748318,0.00097430154,0.000009185259,0.000022432041,0.00001900398,0.00012697066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97563213,0.0024702467,0.020786451,0.0005331215,0.00023053445,0.0003475091],"domain_scores_gemma":[0.9589955,0.015675671,0.023114895,0.0005708045,0.0012540829,0.00038903768],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0687024,0.00019527711,0.006593996,0.00080088107,0.00006891568,0.000012172084,0.00046013208,0.0007190022,0.0016647172],"category_scores_gemma":[0.039031584,0.00021459234,0.0016051448,0.0008697297,0.0005026427,0.00039933738,0.00014779993,0.0010817021,0.000050241473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005996319,0.0031815516,0.95142674,0.0004017783,0.009206203,0.00008165769,0.0019283076,0.001608751,0.000026477825,0.0057553747,0.008240401,0.017543143],"study_design_scores_gemma":[0.0031194089,0.0025822928,0.9353797,0.000081274826,0.00059210113,0.00004053376,0.00211301,0.00532114,0.000018018194,0.008121025,0.04244707,0.00018446977],"about_ca_topic_score_codex":0.00020856822,"about_ca_topic_score_gemma":0.00027926717,"teacher_disagreement_score":0.03420667,"about_ca_system_score_codex":0.00089700223,"about_ca_system_score_gemma":0.0044533405,"threshold_uncertainty_score":0.9992479},"labels":[],"label_agreement":null},{"id":"W3135651958","doi":"10.1200/jco.2021.39.6_suppl.48","title":"Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Cohort; Prostate cancer; Internal medicine; Incidence (geometry); Abiraterone acetate; Cancer; Surgery; Gastroenterology; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.3834570783091499,"score_gpt":0.5611084279878157,"score_spread":0.1776513496786658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135651958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825777,0.002822976,0.000014754514,0.0058463668,0.0010957898,0.0016479092,0.0001463148,0.000011339763,0.00015678917],"genre_scores_gemma":[0.97372067,0.020642534,0.0022575208,0.000228193,0.0006558732,0.00012750154,0.000030388603,0.000044695626,0.0022926321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921867,0.0009502814,0.004714659,0.0005056779,0.0011507722,0.00049189525],"domain_scores_gemma":[0.9916394,0.003088662,0.0028756207,0.00044797448,0.0014211034,0.00052723446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025436764,0.0003870209,0.0035912427,0.00025029993,0.00008039287,0.000024821975,0.00021335647,0.00025399373,0.00056574686],"category_scores_gemma":[0.0006889474,0.00021035863,0.0011259501,0.0004622577,0.00058617035,0.00016340837,0.00007224454,0.00069697265,0.0000028004301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09292175,0.061342545,0.7651578,0.00014475205,0.0067827404,0.0056630694,0.0008816663,0.000026297364,0.0005415112,0.000009183484,0.000269981,0.06625866],"study_design_scores_gemma":[0.089487575,0.06898683,0.83107674,0.00023406166,0.0018672426,0.000110990906,0.00071529014,0.00005223017,0.0018086777,0.00004219744,0.005431788,0.00018637383],"about_ca_topic_score_codex":0.0006503088,"about_ca_topic_score_gemma":0.008043877,"teacher_disagreement_score":0.066072285,"about_ca_system_score_codex":0.00044830993,"about_ca_system_score_gemma":0.0070020054,"threshold_uncertainty_score":0.99862736},"labels":[],"label_agreement":null},{"id":"W3135745963","doi":"10.1200/jco.2021.39.6_suppl.339","title":"The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Sunnybrook Hospital; University Health Network; Dalhousie University; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; Queen's University; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Internal medicine; Systemic therapy; Oncology; Proportional hazards model; Targeted therapy; Performance status; Surgery; Database; Confidence interval; Cancer","score_opus":0.2169414105789285,"score_gpt":0.43149203378909984,"score_spread":0.21455062321017135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135745963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95977116,0.0098013375,0.0010965619,0.021481864,0.0038828983,0.0003749877,0.0005473478,0.000011994031,0.0030318787],"genre_scores_gemma":[0.9716385,0.0043396214,0.01640271,0.0042013796,0.0017993222,0.000010364643,0.0005447643,0.000039603416,0.0010237299],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921078,0.0025900744,0.00319712,0.00054310693,0.0011498677,0.00041200194],"domain_scores_gemma":[0.9717074,0.022570852,0.002854789,0.0016452267,0.0007387191,0.0004830245],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008408845,0.0002866795,0.0014992686,0.00006745354,0.00023574193,0.0000982729,0.0013554989,0.00013260845,0.0007052923],"category_scores_gemma":[0.011751903,0.00014502986,0.0006475271,0.0002136661,0.00049950037,0.00032066507,0.0007714559,0.001981921,0.00012941338],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019834066,0.012098035,0.28496158,0.00011583618,0.013370701,0.05109219,0.00047209527,0.00015557605,0.006978236,0.0005685891,0.5100834,0.10026969],"study_design_scores_gemma":[0.024175372,0.0068100416,0.30716974,0.00017222141,0.01136045,0.0031306427,0.0024254427,0.0031128193,0.0032336614,0.0018653518,0.6361809,0.00036339174],"about_ca_topic_score_codex":0.00046941344,"about_ca_topic_score_gemma":0.00078507094,"teacher_disagreement_score":0.12609746,"about_ca_system_score_codex":0.00026489756,"about_ca_system_score_gemma":0.0036515351,"threshold_uncertainty_score":0.99657255},"labels":[],"label_agreement":null},{"id":"W3135809705","doi":"10.1200/jco.2021.39.6_suppl.42","title":"Symptom burden, functional status, and clinical outcomes of hospitalized patients with advanced genitourinary cancers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Conquer Cancer Foundation","keywords":"Medicine; Cancer; Prostate cancer; Internal medicine; Genitourinary system; Bladder cancer; Kidney cancer; Univariate analysis; Performance status; Oncology; Multivariate analysis","score_opus":0.05310652804474687,"score_gpt":0.41406597832809355,"score_spread":0.3609594502833467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135809705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939597,0.0008255587,0.000037302612,0.002012246,0.0018594835,0.00016704101,0.00001951171,0.0000060824163,0.0011130383],"genre_scores_gemma":[0.986159,0.0035523607,0.006514307,0.0026363966,0.0007406471,0.0000016563681,0.000023584444,0.000020041101,0.00035195056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960886,0.00034232312,0.0025780967,0.0002653616,0.00048489784,0.00024067593],"domain_scores_gemma":[0.99423087,0.002145484,0.0017482075,0.00021552618,0.0011460066,0.00051391224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009869523,0.00016071965,0.0019798062,0.00007935892,0.00003612867,0.0000053155145,0.00007509628,0.0002986958,0.00051618216],"category_scores_gemma":[0.0023727145,0.00010835026,0.00050125725,0.0001139389,0.00039233192,0.00016724781,0.000069884685,0.0008840322,0.0000023191374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009870335,0.0009317141,0.9004766,0.000037279147,0.0012370236,0.00029155932,0.000040499835,0.000026431684,0.000016517353,0.00001374161,0.0009868415,0.08607149],"study_design_scores_gemma":[0.02830175,0.014582743,0.92063576,0.0000728858,0.0005443879,0.000057597103,0.00012873,0.000017321297,0.000008736766,0.000036269696,0.035509385,0.00010444014],"about_ca_topic_score_codex":0.000028437862,"about_ca_topic_score_gemma":0.00003313447,"teacher_disagreement_score":0.08596705,"about_ca_system_score_codex":0.00020837481,"about_ca_system_score_gemma":0.0054287133,"threshold_uncertainty_score":0.96303046},"labels":[],"label_agreement":null},{"id":"W3135839740","doi":"10.1200/jco.2021.39.6_suppl.314","title":"Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lenvatinib; Everolimus; Renal cell carcinoma; Clinical endpoint; Internal medicine; Quality of life (healthcare); Oncology; Kidney cancer; Clinical trial; Phases of clinical research; Cancer","score_opus":0.337874391333938,"score_gpt":0.5052543612984711,"score_spread":0.16737996996453314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135839740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934023,0.0016872815,0.00008758906,0.0021491793,0.00040996523,0.002085518,0.00010409947,0.000004432442,0.000069618014],"genre_scores_gemma":[0.99039173,0.0002023788,0.008949155,0.00009534552,0.00009526701,0.000048061826,0.00010952351,0.000032113603,0.000076423516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894777,0.0015664437,0.0076236315,0.00037215234,0.0006369532,0.00032314044],"domain_scores_gemma":[0.9831566,0.00688827,0.0085810935,0.00038930879,0.0006468972,0.00033780446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002085458,0.00033060557,0.0063515087,0.0002538104,0.000055164764,0.000005383147,0.00017776137,0.00026749272,0.00004172783],"category_scores_gemma":[0.00208204,0.00021736792,0.0009027803,0.0002647592,0.00014647057,0.00011458373,0.00007151498,0.00023817885,2.042419e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4376134,0.17673112,0.28517163,0.0003160115,0.0045931437,0.0003051525,0.002617607,0.000045694,0.0343715,0.000060202707,0.000018088667,0.058156453],"study_design_scores_gemma":[0.5431491,0.25077012,0.16038713,0.00034023577,0.0014997124,0.000005805371,0.00037351175,0.00011079371,0.043024708,0.00020625223,0.000020962543,0.000111644105],"about_ca_topic_score_codex":0.0017446915,"about_ca_topic_score_gemma":0.0007451174,"teacher_disagreement_score":0.12478451,"about_ca_system_score_codex":0.00077173114,"about_ca_system_score_gemma":0.0040859194,"threshold_uncertainty_score":0.88640064},"labels":[],"label_agreement":null},{"id":"W3135882965","doi":"10.1200/jco.2021.39.6_suppl.15","title":"Prospective randomized trial of gene expression classifier utility following radical prostatectomy (G-MINOR).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Prostatectomy; Randomization; Randomized controlled trial; Prostate cancer; Clinical endpoint; Internal medicine; Clinical trial; Prospective cohort study; Surgery; Cancer","score_opus":0.14080071263276195,"score_gpt":0.49748572608388647,"score_spread":0.3566850134511245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135882965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98462254,0.001832005,0.00041187368,0.0030623875,0.0020735145,0.0013029324,0.000004623188,0.000009537226,0.0066805654],"genre_scores_gemma":[0.98918533,0.0009297526,0.0072631245,0.00020788272,0.0011559174,0.00003414993,0.000007473858,0.000016611915,0.0011997437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937884,0.0018323518,0.0029895506,0.00028945066,0.00080667844,0.00029356667],"domain_scores_gemma":[0.9928199,0.0041642804,0.0014351669,0.0002596754,0.00087882305,0.0004421331],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0074907104,0.00015776294,0.00321871,0.00011064971,0.00005191343,0.000009804478,0.00012863702,0.00045979102,0.00029260013],"category_scores_gemma":[0.013628378,0.00009211019,0.0017646082,0.00021854942,0.00059832924,0.000112990056,0.00007508096,0.0012295918,0.000004961463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9524328,0.0041456395,0.015134999,0.000051182386,0.001110864,0.0023824405,0.00014251367,4.781153e-7,0.004771074,0.000044707376,0.00083966646,0.018943628],"study_design_scores_gemma":[0.9385546,0.008221342,0.010312763,0.00020532285,0.00073383976,0.00015347327,0.0001316661,0.000038741146,0.035819497,0.0013318696,0.0044157347,0.00008117183],"about_ca_topic_score_codex":0.000004800351,"about_ca_topic_score_gemma":0.0000019722004,"teacher_disagreement_score":0.031048425,"about_ca_system_score_codex":0.00018746142,"about_ca_system_score_gemma":0.005310743,"threshold_uncertainty_score":0.9946802},"labels":[],"label_agreement":null},{"id":"W3136415921","doi":"10.1200/jco.20.03292","title":"Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Genentech; Ipsen; PharmaMar; Astellas Pharma; Eisai; Astex Pharmaceuticals; Sveučilište u Zagrebu; Karyopharm Therapeutics; MacroGenics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Movember Foundation; Sanofi; GlaxoSmithKline; Pfizer","keywords":"Medicine; Internal medicine; Etoposide; Germ cell tumors; Oncology; Seminoma; Chemotherapy","score_opus":0.17431203716021162,"score_gpt":0.4614101840789835,"score_spread":0.2870981469187719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136415921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96642566,0.006294925,0.000047796297,0.026054043,0.0005923758,0.00013463493,0.000028289565,0.00000430049,0.00041800665],"genre_scores_gemma":[0.99186945,0.00093356223,0.0051417635,0.0014998029,0.00044090737,0.0000011907133,0.00001724995,0.000008712066,0.000087353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974997,0.0004240158,0.0015179539,0.0001845468,0.00022408048,0.00014972618],"domain_scores_gemma":[0.9910442,0.007339444,0.0008237812,0.00019188177,0.00017165081,0.00042900853],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011690933,0.000098346165,0.00087870844,0.000028623985,0.000021441749,0.000012653449,0.00007387662,0.000104234336,0.00006437125],"category_scores_gemma":[0.019395808,0.000055529843,0.0002119663,0.000115692535,0.00014604178,0.000045458808,0.000055877903,0.00046662978,0.0000126789755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035877172,0.0023711377,0.8538502,0.0000122075135,0.0009393368,0.013163819,0.00010717039,0.000004018586,0.000023362043,0.00030238004,0.004424426,0.12121426],"study_design_scores_gemma":[0.015095064,0.0014878382,0.9648081,0.00011082208,0.0012965488,0.00037670374,0.0002459032,0.000036673453,0.000025957937,0.0013327717,0.015130772,0.000052820254],"about_ca_topic_score_codex":0.000114114504,"about_ca_topic_score_gemma":0.00018399069,"teacher_disagreement_score":0.12116144,"about_ca_system_score_codex":0.000037886595,"about_ca_system_score_gemma":0.0026671563,"threshold_uncertainty_score":0.98886424},"labels":[],"label_agreement":null},{"id":"W3137447968","doi":"10.1200/jco.20.03175","title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Gastroenterology; Refractory (planetary science); Follicular lymphoma; Lymphoma; Rituximab; Adverse effect; CD20; Alemtuzumab; Oncology; T cell; Immunology; Immune system; Transplantation","score_opus":0.26594447380813624,"score_gpt":0.5123547411190288,"score_spread":0.24641026731089255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137447968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98090696,0.0019094034,0.0001347108,0.0062603615,0.0026310147,0.0005699631,0.000011344359,0.000023838022,0.007552407],"genre_scores_gemma":[0.97916365,0.005144499,0.005942306,0.0011055714,0.0030752723,0.000010009691,0.000024132994,0.00007525072,0.005459333],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99032706,0.0023782093,0.004807657,0.000600286,0.001121412,0.00076539395],"domain_scores_gemma":[0.9844342,0.01085221,0.0023040853,0.00053968444,0.0009294188,0.0009403929],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012967927,0.0003229704,0.002680075,0.0005304338,0.00017846431,0.00004956509,0.00042109736,0.0007482478,0.0030995267],"category_scores_gemma":[0.01589971,0.00023855723,0.00089482265,0.00095274515,0.00030414425,0.00017027688,0.00021616698,0.003278981,0.00003957582],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15898047,0.032038487,0.0017145505,0.00016274025,0.00022849784,0.010803118,0.00036493794,0.000013631509,0.74148434,0.000007578538,0.004853024,0.049348626],"study_design_scores_gemma":[0.51290476,0.024366738,0.0017364459,0.00068242336,0.00029105323,0.0012110994,0.0022442804,0.00066772493,0.013005949,0.000051604442,0.44248554,0.00035236633],"about_ca_topic_score_codex":0.00004031485,"about_ca_topic_score_gemma":0.000022757056,"teacher_disagreement_score":0.7284784,"about_ca_system_score_codex":0.0007590653,"about_ca_system_score_gemma":0.009032334,"threshold_uncertainty_score":0.9990205},"labels":[],"label_agreement":null},{"id":"W3138143474","doi":"10.1200/jco.20.03681","title":"Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pediatric oncology; Oncology; Internal medicine; Cancer","score_opus":0.16179332461210907,"score_gpt":0.4934108235959522,"score_spread":0.3316174989838431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138143474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9078237,0.001538976,0.00007054778,0.057872612,0.0064650807,0.00014030724,0.0000032963248,0.000018337385,0.026067134],"genre_scores_gemma":[0.9676886,0.0036822949,0.008275907,0.011689697,0.008255554,0.0000024000071,0.000006012288,0.00003604996,0.00036344715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99096143,0.0026170635,0.0046669,0.00038821378,0.0009295626,0.00043680795],"domain_scores_gemma":[0.98650557,0.008933547,0.0025854895,0.00038710097,0.00095620356,0.00063208764],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016563393,0.00020382994,0.002878833,0.00028198308,0.000049216796,0.000018072293,0.00033727314,0.00096527603,0.00043298388],"category_scores_gemma":[0.020057833,0.00017737724,0.0007410772,0.0006306038,0.00020968194,0.00019585766,0.00018503079,0.0034203865,0.000046301757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002954458,0.003513754,0.9455521,0.00015171104,0.00027279358,0.007687722,0.0014683304,0.000017267605,0.00003581886,0.0008338196,0.0076522827,0.029859956],"study_design_scores_gemma":[0.0162767,0.006976739,0.89015037,0.00016490716,0.00053079316,0.0009387504,0.0009250753,0.000017011796,0.000063156236,0.0061217956,0.077608846,0.00022588695],"about_ca_topic_score_codex":0.00007731439,"about_ca_topic_score_gemma":0.0017704979,"teacher_disagreement_score":0.06995656,"about_ca_system_score_codex":0.00045942105,"about_ca_system_score_gemma":0.009942165,"threshold_uncertainty_score":0.9988788},"labels":[],"label_agreement":null},{"id":"W3139163066","doi":"10.1200/jco.20.02619","title":"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Placebo; Internal medicine; Adverse effect; Myelodysplastic syndromes; Anemia; Gastroenterology; Clinical endpoint; International Prognostic Scoring System; Azacitidine; Interim analysis; Randomized controlled trial; Surgery; Bone marrow","score_opus":0.05024886019407585,"score_gpt":0.4222112638362222,"score_spread":0.37196240364214633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139163066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191326,0.00017488106,0.00036745647,0.0022773833,0.0015288467,0.0022041593,0.000009568271,0.000007807979,0.00151664],"genre_scores_gemma":[0.99506074,0.0005836928,0.0023923963,0.00040394993,0.00075843005,0.00004207153,0.000011279435,0.000033377266,0.0007140363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989515,0.003422619,0.005111741,0.0003399089,0.0011354594,0.00047525368],"domain_scores_gemma":[0.9755242,0.018111108,0.0038028234,0.00036249516,0.0016108103,0.0005885954],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011912035,0.0002738978,0.0074216817,0.00041961652,0.000038391936,0.000012903216,0.00026401455,0.0005747553,0.00037135434],"category_scores_gemma":[0.04692469,0.00016683798,0.0012428114,0.000427647,0.000664759,0.00015795228,0.00010334719,0.0024475262,0.000014491293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93736297,0.036487132,0.0047661816,0.000036194513,0.0019054557,0.0031832003,0.000055920646,0.000021101336,0.000009566622,0.00003055385,0.0012156228,0.014926079],"study_design_scores_gemma":[0.93946576,0.05433955,0.0019509592,0.00023338977,0.0016590221,0.0002079513,0.000066651235,0.0007383491,0.000025751064,0.00011665364,0.0010589481,0.00013699316],"about_ca_topic_score_codex":0.00002415295,"about_ca_topic_score_gemma":0.000040587125,"teacher_disagreement_score":0.03501266,"about_ca_system_score_codex":0.00038338764,"about_ca_system_score_gemma":0.0065930644,"threshold_uncertainty_score":0.99985385},"labels":[],"label_agreement":null},{"id":"W3142784366","doi":"10.1200/jco.20.02871","title":"Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Adrenocortical carcinoma; Retroperitoneal lymph node dissection; Pediatric oncology; Chemotherapy; Dissection (medical); Lymph node; Lymph; Carcinoma; Oncology; Surgery; General surgery; Internal medicine; Cancer; Pathology","score_opus":0.06180415610358443,"score_gpt":0.40020560040619346,"score_spread":0.33840144430260904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142784366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868259,0.000283597,0.00007486195,0.00833127,0.00029262766,0.0036590619,0.0000037857205,0.000008377496,0.00052051485],"genre_scores_gemma":[0.9942529,0.00027044318,0.0011005035,0.0008178588,0.0027783962,0.00059014244,0.000005224445,0.000024254863,0.00016027683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965546,0.0006248045,0.0019521149,0.0002639579,0.00033650786,0.0002679808],"domain_scores_gemma":[0.9954075,0.0021577885,0.0013836196,0.0002449916,0.00043553492,0.0003705489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009564208,0.00020082523,0.0017424832,0.000098549965,0.000076026125,0.000008733573,0.000094276525,0.00032049423,0.00015376185],"category_scores_gemma":[0.00070049416,0.00009880894,0.00045122203,0.00030138408,0.0004475936,0.000059435642,0.000031264444,0.00049177237,0.000002829705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012472031,0.004540221,0.92445546,0.00004362172,0.00045326274,0.008019067,0.00013135564,0.0000031141055,0.00002359537,0.00007287389,0.000619958,0.049165424],"study_design_scores_gemma":[0.010964231,0.01845125,0.9176956,0.00002986063,0.0006186332,0.044781312,0.00010080305,0.000023399632,0.00015861225,0.00005012348,0.0070278756,0.00009831158],"about_ca_topic_score_codex":0.00004007108,"about_ca_topic_score_gemma":0.000022811248,"teacher_disagreement_score":0.049067114,"about_ca_system_score_codex":0.00017734693,"about_ca_system_score_gemma":0.0031061966,"threshold_uncertainty_score":0.551026},"labels":[],"label_agreement":null},{"id":"W3148345241","doi":"10.1200/jco.20.03639","title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Oncology; Internal medicine; Lapatinib; Taxane; Breast cancer; Letrozole; Estrogen receptor; Hormone receptor; Aromatase inhibitor; Gynecology; Tamoxifen; Cancer; Trastuzumab; Metastatic breast cancer","score_opus":0.08584686499972378,"score_gpt":0.4566029099254679,"score_spread":0.37075604492574415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148345241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484771,0.0011307308,0.00029233444,0.047230765,0.0018223731,0.00065865467,0.00015989676,0.000009022399,0.00021911337],"genre_scores_gemma":[0.97644764,0.0033048005,0.0071878945,0.0050673992,0.0072172717,0.00005826026,0.0000049534247,0.000041606672,0.0006701474],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962011,0.0010111831,0.0017768502,0.0003225135,0.0003736487,0.0003147351],"domain_scores_gemma":[0.98284024,0.012742495,0.002197641,0.00021225508,0.0016581522,0.0003492074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00223858,0.00020389582,0.001622408,0.00005865182,0.00015448769,0.000024411003,0.00017060582,0.00034899043,0.00017529611],"category_scores_gemma":[0.0067536877,0.00012932913,0.00042499896,0.00016098519,0.000638083,0.00015892205,0.00009182459,0.0012378985,0.0000040385285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39613768,0.0012943911,0.03206012,0.00005085299,0.0029967765,0.00086382066,0.0019028095,0.000031434603,0.00029291608,0.0004960574,0.002871875,0.5610013],"study_design_scores_gemma":[0.17343986,0.019896468,0.77394915,0.00034006746,0.0015393525,0.0014328624,0.0013840641,0.00000641762,0.0013537881,0.010544686,0.015900506,0.00021280255],"about_ca_topic_score_codex":0.00038771302,"about_ca_topic_score_gemma":0.0011352276,"teacher_disagreement_score":0.741889,"about_ca_system_score_codex":0.00023075142,"about_ca_system_score_gemma":0.004112468,"threshold_uncertainty_score":0.8085283},"labels":[],"label_agreement":null},{"id":"W3148747298","doi":"10.1200/jco.2014.60.3555","title":"Reply to B. O'Sullivan et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Cancer Institute","keywords":"Medicine; Humanities; Philosophy","score_opus":0.15961020442785756,"score_gpt":0.5566031253860996,"score_spread":0.396992920958242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148747298","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033604202,0.00320082,0.00031409174,0.91951734,0.028012563,0.00046621962,0.000057679634,0.000011165359,0.045059696],"genre_scores_gemma":[0.0016770097,0.0019871881,0.0102245305,0.93518126,0.024657628,0.000011636715,0.00004828593,0.000068218935,0.026144223],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99147356,0.0014769087,0.0049826354,0.0004636331,0.0009886348,0.0006146133],"domain_scores_gemma":[0.9875321,0.0047457544,0.0037465328,0.000516899,0.0019006273,0.0015581236],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0073749027,0.0003952832,0.0035301633,0.0002880914,0.000055739893,0.000028491826,0.00041564967,0.001270801,0.0011882057],"category_scores_gemma":[0.011598353,0.00028035804,0.0012017956,0.00022544406,0.00030079632,0.00015441459,0.00012780479,0.0053123008,0.001118933],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015336087,0.0014901069,0.0035735387,0.000042639276,0.0022018084,0.009945843,0.00039586873,0.000043367898,0.000004526185,0.0001219629,0.85386026,0.12678647],"study_design_scores_gemma":[0.009201094,0.033466563,0.009639907,0.0007678203,0.0033577573,0.0015917663,0.0001521484,0.000009396717,0.0000021822093,0.00035469877,0.94123137,0.00022527973],"about_ca_topic_score_codex":0.00020401651,"about_ca_topic_score_gemma":0.000049635728,"teacher_disagreement_score":0.1265612,"about_ca_system_score_codex":0.0015902945,"about_ca_system_score_gemma":0.01698643,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W3150204614","doi":"10.1200/jco.20.03296","title":"Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Movember Foundation","keywords":"Germ cell tumors; Etoposide; Medicine; Oncology; Internal medicine; Chemotherapy; Progression-free survival; Cisplatin; Clinical trial","score_opus":0.06655173729970275,"score_gpt":0.4109720866439836,"score_spread":0.34442034934428084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150204614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986721,0.0013927916,0.000023776105,0.009737145,0.00025145258,0.00020264738,0.00005961592,0.000009453889,0.0016021135],"genre_scores_gemma":[0.9929497,0.00024113074,0.004116407,0.0022287478,0.00020714929,0.000004495118,0.00002183676,0.000017347187,0.00021317208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625057,0.00064120855,0.0022494802,0.00024021034,0.0003828494,0.0002356524],"domain_scores_gemma":[0.98936415,0.0077237515,0.0019788488,0.00031710428,0.0002737414,0.00034242182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014676175,0.00016040444,0.0013809268,0.000045670626,0.000042764634,0.000016751566,0.00013701974,0.00010894074,0.00006584428],"category_scores_gemma":[0.007624214,0.00008108932,0.0003586924,0.00013760144,0.00015659546,0.00006694824,0.0000617308,0.00069295126,0.000018386145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033881909,0.002665148,0.96396685,0.000013959005,0.0008033507,0.022169134,0.00013331075,0.00004125513,0.000021031365,0.000009750015,0.0011017281,0.005686311],"study_design_scores_gemma":[0.022285176,0.0024950725,0.96967304,0.00020812047,0.0016542837,0.00080155936,0.00075104646,0.00024337668,0.00011038766,0.00015495779,0.0015393487,0.00008364312],"about_ca_topic_score_codex":0.0001582412,"about_ca_topic_score_gemma":0.00017300643,"teacher_disagreement_score":0.021367576,"about_ca_system_score_codex":0.00009342861,"about_ca_system_score_gemma":0.0025445875,"threshold_uncertainty_score":0.9127447},"labels":[],"label_agreement":null},{"id":"W3154805493","doi":"10.1200/jco.21.00174","title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Chemotherapy; Lung cancer; Hazard ratio; Oncology; Clinical endpoint; Cancer; Surgery; Randomized controlled trial; Immunotherapy; Confidence interval","score_opus":0.08258638092140791,"score_gpt":0.4375760962292222,"score_spread":0.3549897153078143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154805493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856274,0.0013241404,0.0010451286,0.009631712,0.0010202894,0.00068177504,0.000010871007,0.000011161419,0.00064748735],"genre_scores_gemma":[0.9612191,0.0020132214,0.025478972,0.007031133,0.0010670109,0.00007821779,0.000013834134,0.00007940272,0.003019142],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974313,0.00014168578,0.0014675072,0.00026946992,0.00039388478,0.00029617886],"domain_scores_gemma":[0.99613076,0.0008953079,0.0016961752,0.00022368984,0.0008205129,0.00023353825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011545545,0.0002110467,0.001496945,0.000086232896,0.000060093298,0.000017984821,0.00012944223,0.0001491685,0.00035458844],"category_scores_gemma":[0.00031251728,0.00012134755,0.0005190231,0.00018291944,0.00020094296,0.000099304445,0.000015457093,0.00056624203,0.0000018502562],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61257714,0.004374218,0.29761884,0.0007353609,0.007841227,0.0020581097,0.00047552848,0.000087594584,0.0021662703,0.000031747506,0.0078185145,0.06421545],"study_design_scores_gemma":[0.27890897,0.06574297,0.5732024,0.00090541865,0.0048455657,0.0010456642,0.0014347654,0.00035287003,0.0039879954,0.000042827243,0.069036335,0.00049426674],"about_ca_topic_score_codex":0.000050492625,"about_ca_topic_score_gemma":0.00035294134,"teacher_disagreement_score":0.3336682,"about_ca_system_score_codex":0.00028464026,"about_ca_system_score_gemma":0.0055023986,"threshold_uncertainty_score":0.9761019},"labels":[],"label_agreement":null},{"id":"W3154927734","doi":"10.1200/jco.20.02338","title":"Cognitive Risk in Survivors of Pediatric Brain Tumors","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Citation; Family medicine; Gerontology; Pediatrics; Library science","score_opus":0.23556768344702367,"score_gpt":0.5465503668680151,"score_spread":0.3109826834209914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154927734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010279165,0.9839502,0.000032806554,0.0012541959,0.002567698,0.0006098861,0.000076192686,0.000008272503,0.0012216057],"genre_scores_gemma":[0.0007111212,0.9918457,0.0006290235,0.0011307067,0.0054137995,0.000008514802,0.00002814013,0.00007055094,0.00016241729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97703356,0.008366226,0.0126582645,0.00050896744,0.0010113165,0.0004216668],"domain_scores_gemma":[0.9338375,0.046824098,0.01716103,0.00043015528,0.0010787972,0.00066842424],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.022888811,0.0004757319,0.01610901,0.0008257307,0.000024675728,0.000008195575,0.00043886865,0.0015969179,0.0002911042],"category_scores_gemma":[0.08558606,0.00036477591,0.0039808624,0.0011087719,0.00034033126,0.00008964629,0.00018978243,0.0057796063,0.000029360948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005865444,0.0028507046,0.023688748,0.008326318,0.0014105715,0.0023164682,0.00025457348,6.882781e-7,1.22900765e-8,0.000025400674,0.0043976847,0.9561423],"study_design_scores_gemma":[0.0077589927,0.009050702,0.022814134,0.029580072,0.009340964,0.0010250936,0.000515489,0.0000011222105,2.4204286e-7,0.0001060809,0.91940355,0.00040357048],"about_ca_topic_score_codex":0.00034042553,"about_ca_topic_score_gemma":0.0008364528,"teacher_disagreement_score":0.9557387,"about_ca_system_score_codex":0.00030934438,"about_ca_system_score_gemma":0.017194854,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W3155146570","doi":"10.1200/jco.20.02516","title":"Cognitive Impairment and Family Functioning of Survivors of Pediatric Cancer: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Psychosocial; Medicine; Neurocognitive; Pediatric cancer; Citation; Gerontology; Population; Family medicine; Cognition; Cancer; Psychiatry; Internal medicine; Library science","score_opus":0.21519146626120977,"score_gpt":0.5229400670084856,"score_spread":0.30774860074727584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155146570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010665483,0.9945985,0.00003507018,0.0004893362,0.0018311316,0.001734105,0.00005265041,0.000005800517,0.00018685884],"genre_scores_gemma":[0.00017615574,0.9965987,0.00027340624,0.0012061477,0.0015697802,0.000046640438,0.00001240574,0.000042940967,0.00007383204],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9815169,0.0044054873,0.012488757,0.0003664074,0.00097250345,0.00024992265],"domain_scores_gemma":[0.96327424,0.014287517,0.019833578,0.0003556081,0.0018071318,0.0004418965],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.014988579,0.00040258467,0.021189524,0.00032752217,0.000027837756,0.0000058753335,0.00023318302,0.00071041397,0.000095277326],"category_scores_gemma":[0.018437365,0.00027584733,0.002901898,0.0006241693,0.00024071141,0.00006908269,0.00014468112,0.0017255073,0.0000034214227],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016439156,0.00090773456,0.0008921961,0.88645595,0.0034519986,0.0001433169,0.000097886325,1.2549103e-7,2.7545266e-8,0.000008567351,0.0012369211,0.10664087],"study_design_scores_gemma":[0.0025071187,0.00650695,0.0009970996,0.8819096,0.06473721,0.00065309956,0.00036070278,5.8827567e-7,1.1472998e-7,0.000006719034,0.042109147,0.0002116339],"about_ca_topic_score_codex":0.00016864919,"about_ca_topic_score_gemma":0.00007351782,"teacher_disagreement_score":0.106429234,"about_ca_system_score_codex":0.00023092322,"about_ca_system_score_gemma":0.009759219,"threshold_uncertainty_score":0.99996936},"labels":[],"label_agreement":null},{"id":"W3155409941","doi":"10.1200/jco.20.02471","title":"Systematic Review of Educational Supports of Pediatric Cancer Survivors: Current Approaches and Future Directions","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Health and Medical Research Council; American Lebanese Syrian Associated Charities; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Atlanta; Citation; Psychosocial; Memphis; Family medicine; Cancer; Library science; Gerontology; Internal medicine; Psychiatry; Pathology; Metropolitan area","score_opus":0.24085260548397133,"score_gpt":0.5335546631357387,"score_spread":0.2927020576517674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155409941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005656208,0.98772514,0.000004069502,0.0055322275,0.0052615893,0.0011204506,0.000070803566,0.000003353259,0.00022579003],"genre_scores_gemma":[0.0000060548427,0.98948777,0.0004635693,0.0003150064,0.009487819,0.00006555506,0.00004418955,0.00003506021,0.0000949586],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9849289,0.003177385,0.010501473,0.00035077022,0.00084051536,0.0002009719],"domain_scores_gemma":[0.97380805,0.00875754,0.015379902,0.00046936574,0.0011573196,0.0004278523],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009189637,0.0003583446,0.014090491,0.00032347706,0.000028572846,0.0000056102876,0.00026920097,0.0006170687,0.00039885868],"category_scores_gemma":[0.011252542,0.000241268,0.0026311052,0.0006186905,0.00020373869,0.000073476076,0.00009986286,0.0017107091,0.0000023193365],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020200496,0.001348802,0.0006550886,0.78401273,0.0013925621,0.0000107008245,0.00007912036,2.9494869e-8,2.216063e-9,0.00008609863,0.003963726,0.2084309],"study_design_scores_gemma":[0.00041652404,0.0006005814,0.00043913335,0.44721037,0.019371781,0.00045239332,0.00006688739,1.7303678e-7,2.2220814e-8,0.000016334967,0.53130114,0.00012465335],"about_ca_topic_score_codex":0.00005705104,"about_ca_topic_score_gemma":0.000111350375,"teacher_disagreement_score":0.52733743,"about_ca_system_score_codex":0.00020299866,"about_ca_system_score_gemma":0.015369741,"threshold_uncertainty_score":0.9970761},"labels":[],"label_agreement":null},{"id":"W3157018884","doi":"10.1200/jco.20.02534","title":"Aging in Adult Survivors of Childhood Cancer: Implications for Future Care","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Memphis; Medicine; Neurocognitive; Gerontology; Citation; Childhood cancer; Cancer; Pediatrics; Psychiatry; Cognition; Library science; Internal medicine","score_opus":0.13761193793166143,"score_gpt":0.5442986360906509,"score_spread":0.40668669815898945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157018884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006146649,0.9885221,0.000022937782,0.0063139317,0.0028403979,0.0010897223,0.00017403712,0.000005791369,0.00041642133],"genre_scores_gemma":[0.00046250006,0.99365014,0.0006371966,0.00062721246,0.0043472685,0.00012664501,0.000046825397,0.000043085933,0.00005912828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942589,0.00049817015,0.004435185,0.00030669643,0.00022377635,0.0002772618],"domain_scores_gemma":[0.9887955,0.0037845515,0.004610241,0.0002344501,0.0023676879,0.0002075559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012832476,0.00028635576,0.00689576,0.00032253296,0.000041838717,0.000004088698,0.00021191943,0.0008690944,0.000041030133],"category_scores_gemma":[0.004427164,0.00020826943,0.0022442094,0.00046952342,0.0001545308,0.000044844746,0.000086039305,0.0019273354,0.0000012570471],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012319742,0.0007081636,0.005605163,0.005269961,0.001635658,0.000040942705,0.0002319608,0.0000012614087,6.228211e-8,0.000069106696,0.0017556571,0.9845589],"study_design_scores_gemma":[0.00419095,0.0028676952,0.025616601,0.026227178,0.00566292,0.00021176515,0.00089757505,2.6007737e-7,3.322034e-7,0.000026411499,0.93414265,0.00015568454],"about_ca_topic_score_codex":0.00005303629,"about_ca_topic_score_gemma":0.00094664784,"teacher_disagreement_score":0.9844032,"about_ca_system_score_codex":0.0006725272,"about_ca_system_score_gemma":0.008253541,"threshold_uncertainty_score":0.99736875},"labels":[],"label_agreement":null},{"id":"W3157336873","doi":"10.1200/jco.21.00449","title":"Management of Salivary Gland Malignancy: ASCO Guideline","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Guideline; Malignancy; Evidence-based medicine; MEDLINE; Observational study; Systematic review; Radiation therapy; Medical physics; Intensive care medicine; Oncology; Internal medicine; Alternative medicine; Pathology","score_opus":0.12293266281217707,"score_gpt":0.4802856230953731,"score_spread":0.357352960283196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157336873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508694,0.0051259305,0.00017716251,0.014579224,0.001554242,0.0001482455,0.0000074808177,0.0000075969256,0.02753075],"genre_scores_gemma":[0.9641053,0.0063128183,0.025692295,0.0023311828,0.0007860696,0.0000027544147,0.000013644729,0.0000139548,0.0007419722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962321,0.00023728459,0.0028346016,0.00016837605,0.00036202063,0.00016563362],"domain_scores_gemma":[0.99689394,0.00075696065,0.0012650947,0.00025138358,0.00056282635,0.0002697939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017346691,0.000118105454,0.0014200128,0.000067503875,0.000018024477,0.0000039705055,0.00009783984,0.00017574124,0.00067592086],"category_scores_gemma":[0.00046858922,0.00007796504,0.00059951126,0.00014464636,0.00007796285,0.000044658253,0.000072603594,0.00031834395,0.000019705501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027951517,0.009641789,0.762393,0.00017115456,0.0031175273,0.04760908,0.000041320545,0.00001590125,0.0000346365,0.0024176678,0.039102953,0.13265982],"study_design_scores_gemma":[0.015112626,0.009076815,0.82936835,0.0005827581,0.0016106804,0.0021333261,0.00014816993,0.000017792387,0.0007606594,0.0013058077,0.13978745,0.00009557047],"about_ca_topic_score_codex":0.000009205096,"about_ca_topic_score_gemma":0.0000057304214,"teacher_disagreement_score":0.13256426,"about_ca_system_score_codex":0.0000598589,"about_ca_system_score_gemma":0.00071780785,"threshold_uncertainty_score":0.74008596},"labels":[],"label_agreement":null},{"id":"W3157439907","doi":"10.1200/jco.21.00456","title":"Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer","year":2021,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Emergency department; Head and neck cancer; Head and neck; Cancer; Emergency medicine; Intensive care medicine; Physical therapy; Surgery; Internal medicine; Psychiatry","score_opus":0.23712257879947518,"score_gpt":0.5114668637658931,"score_spread":0.27434428496641794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157439907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92124236,0.008488139,0.000025912477,0.068341106,0.0014679453,0.00025309183,0.00003721141,0.000004214715,0.00014004805],"genre_scores_gemma":[0.71764845,0.20542262,0.0050379564,0.06157542,0.0088127395,0.000054904747,0.00038479883,0.00010404434,0.0009590673],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959421,0.00041669692,0.0028618465,0.00023513233,0.00037298718,0.00017121554],"domain_scores_gemma":[0.9947279,0.0011709621,0.0028560895,0.00015415324,0.00093357597,0.00015733333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000576848,0.00017558248,0.0017976249,0.00020374464,0.00001707367,0.0000057078396,0.000057973608,0.0007924923,0.00006531162],"category_scores_gemma":[0.006939698,0.00013836121,0.00024355882,0.00015427063,0.000118092634,0.000110961366,0.00005389455,0.0010363664,2.4183737e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072523294,0.00027107666,0.9007554,0.00027554657,0.0009401478,0.0020294292,0.0006185044,0.000015412665,0.00003071494,0.0000072211847,0.0906315,0.003699834],"study_design_scores_gemma":[0.0058764606,0.008753461,0.4247263,0.0068243784,0.0014858138,0.00018408067,0.00020883688,0.00005554604,0.000042147618,0.0001606818,0.5515067,0.0001755883],"about_ca_topic_score_codex":0.0004228355,"about_ca_topic_score_gemma":0.0001812356,"teacher_disagreement_score":0.47602907,"about_ca_system_score_codex":0.0001403493,"about_ca_system_score_gemma":0.0010762761,"threshold_uncertainty_score":0.8307968},"labels":[],"label_agreement":null},{"id":"W3157950444","doi":"10.1200/jco.20.02822","title":"Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Pertuzumab; Metastatic breast cancer; Internal medicine; Clinical endpoint; Oncology; Brain metastasis; Adverse effect; Breast cancer; Cancer; Phases of clinical research; Radiation therapy; Chemotherapy; Surgery; Metastasis; Clinical trial","score_opus":0.04527426126557866,"score_gpt":0.43415220770450125,"score_spread":0.3888779464389226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157950444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934214,0.0016406223,0.000052036685,0.003575908,0.0001211016,0.0007300098,0.00043346433,0.0000039642014,0.000021489332],"genre_scores_gemma":[0.994584,0.00019435523,0.004005498,0.0009702541,0.00007687882,0.000027209735,0.00009249346,0.000020210407,0.000029102273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99472487,0.0016355087,0.0023057915,0.00039496785,0.0006664931,0.0002723814],"domain_scores_gemma":[0.99405074,0.0022863883,0.0020378619,0.00025176647,0.0009984458,0.00037476717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001942755,0.0002616995,0.0036548725,0.00042298666,0.000058636273,0.000012066127,0.000099294135,0.000103781706,0.00022744123],"category_scores_gemma":[0.0008031246,0.00016242488,0.00048712527,0.0009023221,0.00028874556,0.00014722014,0.000098353376,0.00057576847,3.3837208e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050582606,0.11980024,0.42938408,0.00012099938,0.045657776,0.012463017,0.0015682698,0.00032295764,0.000019357049,0.000028427217,0.0002177079,0.33983457],"study_design_scores_gemma":[0.07797869,0.08276517,0.8146833,0.00017404898,0.022457149,0.00025603644,0.0013046595,0.00011440394,0.000015811476,0.000014774014,0.00011258393,0.00012336689],"about_ca_topic_score_codex":0.00022061737,"about_ca_topic_score_gemma":0.0003996451,"teacher_disagreement_score":0.38529924,"about_ca_system_score_codex":0.00045701046,"about_ca_system_score_gemma":0.0029235089,"threshold_uncertainty_score":0.66234946},"labels":[],"label_agreement":null},{"id":"W3158449383","doi":"10.1200/jco.20.02636","title":"Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Children's Hospital of Eastern Ontario; University of Ottawa; McGill University Health Centre; London Health Sciences Centre; SickKids Foundation; University of Toronto; Izaak Walton Killam Health Centre; Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; International Development Research Centre; Stand Up To Cancer; Azrieli Foundation; Israel Science Foundation; American Association for Cancer Research","keywords":"Medicine; Internal medicine; Cohort; Cancer; Surgery; Gastroenterology; Oncology","score_opus":0.11431359714104065,"score_gpt":0.4368328932942725,"score_spread":0.3225192961532318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158449383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768556,0.0012413207,0.0045291795,0.006882645,0.0029011255,0.0002339815,0.00002208317,0.00002073948,0.0073133493],"genre_scores_gemma":[0.93429875,0.00032409522,0.062576085,0.0014826406,0.00093190605,0.000006479269,0.000007491969,0.000013996051,0.00035856428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996946,0.00022659237,0.0017239038,0.00026801685,0.0005562424,0.00027929657],"domain_scores_gemma":[0.98991597,0.007082232,0.0010785214,0.00020108501,0.0014236512,0.0002985272],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033877885,0.00014037982,0.0012510689,0.00006618687,0.00007202665,0.000011052382,0.0001293277,0.00032277885,0.00020701555],"category_scores_gemma":[0.009154272,0.00010108734,0.0004919716,0.00019791223,0.00057122484,0.00005549313,0.000050641942,0.0005973017,0.000005586256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025608973,0.0010242705,0.977718,0.0001092426,0.00051921327,0.00046340976,0.000049394715,0.0003563983,0.00018358197,0.004843252,0.004148568,0.008023792],"study_design_scores_gemma":[0.017093513,0.018730761,0.7792019,0.0002804723,0.0004433618,0.0032861943,0.00036801636,0.00009382191,0.0004928254,0.0030210607,0.1767216,0.00026641705],"about_ca_topic_score_codex":0.0000027250207,"about_ca_topic_score_gemma":0.00018142941,"teacher_disagreement_score":0.19851603,"about_ca_system_score_codex":0.00021020492,"about_ca_system_score_gemma":0.009294543,"threshold_uncertainty_score":0.99919206},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W3159434627","doi":"10.1200/jco.2000.18.13.2640","title":"A Revisitation of “Doc, How Much Time Do I Have?”","year":2000,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Citation; Medicine; Library science; Clinical Oncology; Bioethics; Oncology; Cancer; Family medicine; Internal medicine; Political science; Law","score_opus":0.3764673986195616,"score_gpt":0.5725125485377611,"score_spread":0.19604514991819955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159434627","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059274584,0.008615484,0.00006687664,0.9096912,0.0014491675,0.00029863778,0.000034970755,0.000009451955,0.020559622],"genre_scores_gemma":[0.021841336,0.05089471,0.024906492,0.82020676,0.05380627,0.000007762947,0.0001760958,0.00015031273,0.028010262],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948595,0.0008219027,0.0031592683,0.00022367678,0.0006976884,0.00023796632],"domain_scores_gemma":[0.9875789,0.005897721,0.00486007,0.00029639868,0.0011922024,0.00017469413],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002353068,0.00023032766,0.0037383738,0.0002965817,0.000014295175,0.0000067020596,0.0002672919,0.0018550211,0.0009634097],"category_scores_gemma":[0.007178612,0.00016488504,0.001257237,0.00012487758,0.00032076787,0.00008752151,0.000032198503,0.0032764638,0.00005627085],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012548816,0.00030441635,0.0040745214,0.0003094189,0.0007518688,0.0017198647,0.00019422024,7.6029204e-7,0.00006675611,0.000005678891,0.92730635,0.06401124],"study_design_scores_gemma":[0.0034404234,0.008390057,0.0029859687,0.0025319036,0.0011306325,0.00015594419,0.00007488089,0.00000973988,0.0000724755,0.0004390131,0.98064554,0.00012342301],"about_ca_topic_score_codex":0.000008026658,"about_ca_topic_score_gemma":0.0000012328915,"teacher_disagreement_score":0.08948445,"about_ca_system_score_codex":0.00012424545,"about_ca_system_score_gemma":0.0014007317,"threshold_uncertainty_score":0.9999499},"labels":[],"label_agreement":null},{"id":"W3159441190","doi":"10.1200/jco.21.00688","title":"Reply to K. Yokoyama et al","year":2021,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine","score_opus":0.1359303231355118,"score_gpt":0.5515343569202396,"score_spread":0.41560403378472777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159441190","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004843087,0.005798531,0.00042702287,0.93028843,0.030058151,0.00035563094,0.00004728179,0.000008611893,0.028173251],"genre_scores_gemma":[0.0014263839,0.0041491794,0.011184423,0.9298277,0.02301197,0.000013312279,0.00006505489,0.00006285209,0.030259134],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914085,0.0016648864,0.005010987,0.0005194003,0.0008005936,0.00059559854],"domain_scores_gemma":[0.98721975,0.0063967723,0.003326665,0.00052224385,0.0015012941,0.0010332527],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004433203,0.00037892524,0.0036415276,0.00023901917,0.00007032601,0.000039850816,0.00033813578,0.0012844735,0.0029442552],"category_scores_gemma":[0.009858678,0.00028189286,0.0016898433,0.0002762019,0.0002431216,0.00013408106,0.00014329565,0.0056498703,0.0005395288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008203026,0.0016590833,0.004719858,0.000065361,0.0030443922,0.026288863,0.00028739744,0.00003220462,0.000013783674,0.00014116209,0.83237374,0.13055389],"study_design_scores_gemma":[0.0075149494,0.018338086,0.022693412,0.0012803075,0.0037125943,0.002393843,0.00018333638,0.000007386642,0.000008042118,0.00014490788,0.9435049,0.00021821694],"about_ca_topic_score_codex":0.00014375857,"about_ca_topic_score_gemma":0.000052698826,"teacher_disagreement_score":0.13033566,"about_ca_system_score_codex":0.001151695,"about_ca_system_score_gemma":0.015094851,"threshold_uncertainty_score":0.99996334},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3159700540","doi":"10.1200/jco.21.00411","title":"Reply to S. Sundar et al and S. Höcht et al","year":2021,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Humanities; Philosophy","score_opus":0.20017974508941583,"score_gpt":0.5752673338191591,"score_spread":0.37508758872974324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159700540","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011824199,0.019265646,0.00012336747,0.94689804,0.013860502,0.0004894637,0.000058537244,0.000011573545,0.007468669],"genre_scores_gemma":[0.0012366321,0.05133439,0.0050677834,0.9239214,0.01148944,0.00001566976,0.000019659825,0.00008136108,0.006833672],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98601973,0.0048598764,0.005196624,0.0008893035,0.0019071639,0.0011272862],"domain_scores_gemma":[0.97276604,0.020284751,0.0027400127,0.000641332,0.002063928,0.0015039442],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020703858,0.00054307637,0.0054622926,0.00036872257,0.00012252932,0.00008395765,0.0005539551,0.0011659074,0.0012061005],"category_scores_gemma":[0.05326574,0.00041200488,0.00120878,0.00033458072,0.0013854816,0.00021217196,0.0010019211,0.014546966,0.00015909983],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031185898,0.0007654294,0.016072923,0.00020799483,0.0028049666,0.031028429,0.00037331347,0.0000053343097,0.000050041475,0.00011069721,0.8932667,0.05219559],"study_design_scores_gemma":[0.007574719,0.021366043,0.04912501,0.0018512432,0.00081379904,0.0028328642,0.00020440052,0.000009700101,0.000009591037,0.0001420268,0.9157606,0.00031004284],"about_ca_topic_score_codex":0.00025765144,"about_ca_topic_score_gemma":0.00027913752,"teacher_disagreement_score":0.05188555,"about_ca_system_score_codex":0.0010705207,"about_ca_system_score_gemma":0.013879729,"threshold_uncertainty_score":0.99983317},"labels":[],"label_agreement":null},{"id":"W3162334759","doi":"10.1200/jco.20.03613","title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Breast cancer; Clinical endpoint; Cancer; Clinical trial; Oncology; Surrogate endpoint; Internal medicine; Adjuvant therapy; Surgery","score_opus":0.2333773198881165,"score_gpt":0.5225413800965529,"score_spread":0.28916406020843644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162334759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96587604,0.0037346957,0.00072873506,0.021803627,0.005603756,0.00045721678,0.0011275095,0.000009200459,0.0006591971],"genre_scores_gemma":[0.9782816,0.011529848,0.004760908,0.0023741093,0.00271179,0.000032769003,0.0001830751,0.000034228833,0.00009165574],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9925619,0.0026317888,0.0037811985,0.0004325147,0.00026239562,0.00033023345],"domain_scores_gemma":[0.9923134,0.0041337702,0.0020011307,0.0002748311,0.0010010955,0.00027577768],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008827832,0.00021604646,0.0022156953,0.00007666437,0.00008260208,0.000015701748,0.00021729911,0.0006238433,0.00028383808],"category_scores_gemma":[0.0118375765,0.00016755205,0.0012449322,0.00015225989,0.00026230616,0.000013093004,0.00015710443,0.0005646255,0.000007903409],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08036845,0.010818735,0.20427427,0.0000581386,0.0057968665,0.0007108834,0.000119015574,0.00017975955,0.003452598,0.00026220348,0.1052306,0.5887285],"study_design_scores_gemma":[0.08068209,0.005312872,0.56161904,0.00022314404,0.0014635853,0.00040057808,0.0004338447,0.000026170273,0.0019522089,0.00066181255,0.3468325,0.0003921739],"about_ca_topic_score_codex":0.00002265577,"about_ca_topic_score_gemma":0.00046456754,"teacher_disagreement_score":0.5883363,"about_ca_system_score_codex":0.00015857258,"about_ca_system_score_gemma":0.0029091956,"threshold_uncertainty_score":0.9964861},"labels":[],"label_agreement":null},{"id":"W3164713850","doi":"10.1200/jco.2018.36.15_suppl.e13590","title":"Cancer incidence and mortality in Greenland 1983-2014, including comparison with the other Nordic countries.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Incidence (geometry); Cancer registry; Breast cancer; Danish; Demography; Mortality rate; Prostate cancer; Gynecology; Internal medicine","score_opus":0.08381483960304688,"score_gpt":0.45904578346790004,"score_spread":0.3752309438648532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164713850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385583,0.0029587175,0.00031624484,0.0021464105,0.0002943363,0.00008580959,0.000007968977,0.0000012880247,0.00033338295],"genre_scores_gemma":[0.9937644,0.0017693778,0.00025031168,0.002522465,0.0016402502,0.0000038023852,0.0000012717177,0.000008256149,0.000039870407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985285,0.00027981497,0.0007130895,0.00016700204,0.00016093251,0.00015070463],"domain_scores_gemma":[0.99860466,0.00018629542,0.00062243984,0.00015404352,0.0002909195,0.00014163133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016204895,0.0000922825,0.0004109917,0.000029230787,0.00006568491,0.000013252666,0.00017145195,0.00018340847,0.000034017015],"category_scores_gemma":[0.00031033944,0.000056240573,0.00007117295,0.000049254293,0.00066121307,0.0000068734826,0.00007363816,0.0002311856,0.0000019583902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013597504,0.00018187422,0.9891276,0.000009333823,0.000081627484,0.000014162234,0.00007617097,0.000018643017,0.0007050707,0.000015767322,0.005300998,0.0031090023],"study_design_scores_gemma":[0.0029331213,0.0031142782,0.8521361,0.00003975531,0.00009849317,0.000029667002,0.00012789939,0.000059036545,0.00085852714,0.00020304121,0.14029634,0.00010374762],"about_ca_topic_score_codex":0.00021941953,"about_ca_topic_score_gemma":0.007157222,"teacher_disagreement_score":0.1369915,"about_ca_system_score_codex":0.000022160717,"about_ca_system_score_gemma":0.0005992248,"threshold_uncertainty_score":0.39938977},"labels":[],"label_agreement":null},{"id":"W3165887919","doi":"10.1200/jco.2021.39.15_suppl.10530","title":"Cancer surveillance in adults with germline <i>TP53</i> pathogenic variants: A single-center observational study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Malignancy; Breast cancer; Internal medicine; Cancer screening; Family history; Oncology","score_opus":0.15505388579826915,"score_gpt":0.4300421242638823,"score_spread":0.27498823846561316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165887919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644364,0.0014199776,0.00023185503,0.009290309,0.0014176092,0.00036444928,0.000023824878,0.000010172572,0.0007981524],"genre_scores_gemma":[0.99071544,0.0007253987,0.0026910433,0.0045731408,0.0010644292,0.000017323222,0.000015279145,0.00003272364,0.0001651926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99558836,0.0007180763,0.0024520725,0.00035169246,0.00059338566,0.0002964066],"domain_scores_gemma":[0.99588776,0.0008890127,0.0013668406,0.0002851717,0.0012730041,0.0002982293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002157044,0.00017934045,0.0014837808,0.00011258752,0.000025544296,0.000010233937,0.00014472757,0.0003225909,0.00028011712],"category_scores_gemma":[0.0023916275,0.00013535273,0.00031644528,0.00049813505,0.00012772693,0.000101875725,0.00006646649,0.0013038641,0.000007441645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01449483,0.013931735,0.9099329,0.000056371868,0.0007213457,0.01594908,0.00026929897,0.0002513754,0.0027521958,0.000025143456,0.0017000076,0.039915692],"study_design_scores_gemma":[0.039143704,0.012598488,0.9225909,0.000681422,0.00020965816,0.002105575,0.00019524503,0.00015962876,0.00006283215,0.000034751443,0.022047943,0.00016986599],"about_ca_topic_score_codex":0.000040035666,"about_ca_topic_score_gemma":0.0033247345,"teacher_disagreement_score":0.039745826,"about_ca_system_score_codex":0.00042104325,"about_ca_system_score_gemma":0.005031583,"threshold_uncertainty_score":0.8925812},"labels":[],"label_agreement":null},{"id":"W3165908483","doi":"10.1200/jco.2021.39.15_suppl.e18513","title":"Impact of universal health care on trends of incidence and mortality of cancers with screening recommendations in North America. A GLOBOCAN 2020 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Demography; Incidence (geometry); Population; Mortality rate; Breast cancer; Cancer; Environmental health; Internal medicine","score_opus":0.19088789901363523,"score_gpt":0.5432226082098326,"score_spread":0.35233470919619736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165908483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973348,0.00042746382,0.00009203195,0.0015804211,0.0000728739,0.0000930882,0.00003275015,0.0000014875742,0.00036511576],"genre_scores_gemma":[0.99618536,0.00057248893,0.00282067,0.000330916,0.0000717131,6.985996e-7,0.00000679638,0.000005151568,0.0000062237364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713475,0.00048674401,0.0016784586,0.00016651544,0.00037903257,0.00015449234],"domain_scores_gemma":[0.9960949,0.0005982787,0.0022545147,0.00016644239,0.00064616615,0.00023970524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010642549,0.00009975303,0.0014727389,0.00013968536,0.000020402063,0.0000018851346,0.00010256677,0.00007629468,0.000059705755],"category_scores_gemma":[0.00081040896,0.000073354495,0.00020851425,0.00067264494,0.00022541621,0.00009497726,0.000044834876,0.0005291084,6.638342e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033910961,0.00045907733,0.8717391,0.000026528254,0.00031816715,0.00027328846,0.0015940391,0.0012423124,0.000007986509,0.0000032091687,0.00023066626,0.120714515],"study_design_scores_gemma":[0.0042461203,0.03731718,0.9465962,0.00036148174,0.0001753068,0.00005873765,0.010979448,0.000051742878,0.0000073942497,0.0000021439773,0.00015645559,0.00004777764],"about_ca_topic_score_codex":0.008766621,"about_ca_topic_score_gemma":0.03435331,"teacher_disagreement_score":0.120666735,"about_ca_system_score_codex":0.00045606008,"about_ca_system_score_gemma":0.005399569,"threshold_uncertainty_score":0.9978341},"labels":[],"label_agreement":null},{"id":"W3165926603","doi":"10.1200/jco.2021.39.15_suppl.e16131","title":"PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Hepatocellular carcinoma; Nivolumab; Ipilimumab; Internal medicine; Gastroenterology; Adverse effect; Hazard ratio; Cirrhosis; Oncology; Liver cancer; Surgery; Cancer; Immunotherapy; Confidence interval","score_opus":0.25718428397964765,"score_gpt":0.45110398212902464,"score_spread":0.19391969814937698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165926603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347556,0.0022397405,0.00044826855,0.0018064794,0.00064186455,0.001239416,0.000007183344,0.000007993115,0.00013348515],"genre_scores_gemma":[0.99459845,0.00031087457,0.0036121882,0.00029130487,0.00075916876,0.000026565986,0.0000066724506,0.000026386642,0.00036837786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962755,0.0005717948,0.0021477682,0.00034010757,0.0003853002,0.00027952867],"domain_scores_gemma":[0.9957015,0.0013332381,0.0010101512,0.0002929015,0.001112747,0.00054944976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025657734,0.00018261904,0.0017966657,0.00018653707,0.000074917334,0.000012206057,0.00010302991,0.0003180333,0.00008850401],"category_scores_gemma":[0.0025874912,0.00014330652,0.0004928475,0.00022439969,0.00008483009,0.00009196698,0.00008785502,0.0004910514,0.000005367311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020884348,0.013695354,0.781555,0.000124827,0.000730005,0.0035055662,0.0010586152,8.996148e-7,0.0031233525,0.000013619253,0.0009592096,0.17434919],"study_design_scores_gemma":[0.13509022,0.3884258,0.39098552,0.00031880784,0.005116971,0.0016417311,0.0024126708,0.004422855,0.02557962,0.00013916263,0.045468017,0.00039863217],"about_ca_topic_score_codex":0.000052599957,"about_ca_topic_score_gemma":0.00010659857,"teacher_disagreement_score":0.39056948,"about_ca_system_score_codex":0.00015216097,"about_ca_system_score_gemma":0.0014400177,"threshold_uncertainty_score":0.58438706},"labels":[],"label_agreement":null},{"id":"W3165955961","doi":"10.1200/jco.2021.39.15_suppl.6014","title":"TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novartis","keywords":"Medicine; Clinical endpoint; Interim analysis; Internal medicine; Randomized controlled trial; Hazard ratio; Radiation therapy; Stage (stratigraphy); Progression-free survival; Oncology; Surgery; Confidence interval; Chemotherapy","score_opus":0.14555708591810446,"score_gpt":0.5294386839519649,"score_spread":0.38388159803386046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165955961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881315,0.00031549492,0.005381503,0.002083851,0.0012379789,0.0022363546,0.000044902834,0.000007552355,0.00056081614],"genre_scores_gemma":[0.9924595,0.00038203588,0.0044886805,0.00048609107,0.00089906575,0.00010583859,0.00014481068,0.000022736773,0.0010112501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99621904,0.00042423868,0.0025760792,0.00025826378,0.0003258179,0.0001965711],"domain_scores_gemma":[0.9933715,0.002600515,0.0026805548,0.00015348112,0.0009122884,0.0002816483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017455771,0.00019018361,0.0026064762,0.00011518905,0.00010742624,0.000022035745,0.00006348288,0.00024107138,0.00027599637],"category_scores_gemma":[0.002722904,0.00011573655,0.00037807733,0.00018056012,0.0001975951,0.0001836934,0.000024469882,0.00037047043,9.627113e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8551906,0.0032298113,0.0018378479,0.000087342516,0.0012543272,0.00012126685,0.00090100913,0.000026771231,0.00015906485,0.00007915613,0.000571177,0.13654163],"study_design_scores_gemma":[0.91771394,0.058716618,0.0023274415,0.00015518938,0.0029107688,0.00011173029,0.00029703698,0.0058053154,0.0003259395,0.00003412339,0.011486673,0.00011525349],"about_ca_topic_score_codex":0.00006624378,"about_ca_topic_score_gemma":0.00020266823,"teacher_disagreement_score":0.13642639,"about_ca_system_score_codex":0.00022511338,"about_ca_system_score_gemma":0.0057643163,"threshold_uncertainty_score":0.9998721},"labels":[],"label_agreement":null},{"id":"W3165960112","doi":"10.1200/jco.2021.39.15_suppl.e18616","title":"Optimism bias in the design of phase III randomized control trials (RCTs) evaluating PD-1/PD-L1 targeting monoclonal antibodies (mAbs).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Hazard ratio; Internal medicine; Monoclonal antibody; Confidence interval; Oncology; Clinical endpoint; Clinical trial; non-small cell lung cancer (NSCLC); Lung cancer; Antibody; Immunology","score_opus":0.8947952863249296,"score_gpt":0.7201853843460729,"score_spread":0.17460990197885662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165960112","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20118551,0.0016513834,0.7802129,0.008453226,0.0045690374,0.0026381577,0.000051019248,0.000021538175,0.001217263],"genre_scores_gemma":[0.18635088,0.0010436984,0.8089414,0.0015074103,0.0020368635,0.00003835366,0.0000012213768,0.0000339186,0.000046235615],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.80198115,0.16410074,0.030572386,0.0006292675,0.0019680501,0.0007483982],"domain_scores_gemma":[0.09068836,0.88982445,0.016762685,0.00051039946,0.0019096711,0.00030445025],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.43835115,0.00037317458,0.012532473,0.00018644331,0.00010308782,0.000052199368,0.0008128593,0.0008275659,0.0007647198],"category_scores_gemma":[0.9448312,0.00021181398,0.0026116907,0.00037981084,0.0009390558,0.00013890321,0.00014072278,0.0023293027,0.0000067430487],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73132294,0.01403453,0.0004848598,0.00031293873,0.005399372,0.0023360366,0.0014750478,0.0034816882,0.003727288,0.03450192,0.010564981,0.19235836],"study_design_scores_gemma":[0.477835,0.0040606,0.00011212971,0.00033735746,0.00248752,0.00010051114,0.0005179367,0.016317733,0.0005220104,0.4971989,0.0002974597,0.00021283347],"about_ca_topic_score_codex":0.0000078266485,"about_ca_topic_score_gemma":0.0000024602507,"teacher_disagreement_score":0.7257237,"about_ca_system_score_codex":0.00009342053,"about_ca_system_score_gemma":0.0025881813,"threshold_uncertainty_score":0.99997234},"labels":[],"label_agreement":null},{"id":"W3165986417","doi":"10.1200/jco.2021.39.15_suppl.567","title":"Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Lymphoma; Radiation therapy; Internal medicine; Population; Malignancy; Epidemiology; Cancer; Cohort; Chemotherapy; Hodgkin lymphoma; Gynecology","score_opus":0.07719767955081487,"score_gpt":0.4173071556359994,"score_spread":0.34010947608518455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165986417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417037,0.0013277947,0.000051885017,0.0031470729,0.00039563046,0.00049800164,0.000218259,0.000007911045,0.00018307948],"genre_scores_gemma":[0.9900665,0.0018337861,0.004839942,0.0023482218,0.0005140706,0.000019671936,0.00031629324,0.000018201448,0.000043302174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996223,0.0005840726,0.0024247512,0.00030574173,0.000272939,0.00018954309],"domain_scores_gemma":[0.9897753,0.0069945743,0.0022956799,0.00022975076,0.00053004746,0.0001746279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019482172,0.00015870138,0.001675187,0.00014272236,0.00003098567,0.0000074297436,0.00010826713,0.0004017932,0.000074215364],"category_scores_gemma":[0.0035244029,0.00010861389,0.00039635279,0.00022132954,0.00012270991,0.000087547975,0.000009132824,0.00035938708,4.414728e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045219425,0.0009105465,0.69617957,0.000016864282,0.00021244232,0.00050785724,0.000072672556,0.00035305944,0.00018128319,0.0000031354716,0.0003664595,0.25597665],"study_design_scores_gemma":[0.061102152,0.0067536687,0.9287842,0.0001680857,0.0002188682,0.0000869338,0.00009403918,0.00027291488,0.00038742856,0.00003300084,0.0019980897,0.00010065029],"about_ca_topic_score_codex":0.0010320095,"about_ca_topic_score_gemma":0.0018962923,"teacher_disagreement_score":0.255876,"about_ca_system_score_codex":0.0005004772,"about_ca_system_score_gemma":0.0057611912,"threshold_uncertainty_score":0.99987525},"labels":[],"label_agreement":null},{"id":"W3166028383","doi":"10.1200/jco.2021.39.15_suppl.tps10609","title":"Engaging the radiology community in the National Clinical Trials Network: The ECOG-ACRIN TMIST experience.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Mammography; Clinical trial; Breast cancer; Population; Tomosynthesis; Breast imaging; Breast cancer screening; Medical physics; Randomized controlled trial; Family medicine; Cancer; Surgery; Internal medicine","score_opus":0.7963101545154544,"score_gpt":0.6615069437329162,"score_spread":0.1348032107825382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166028383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87727827,0.0019199969,0.00020715786,0.10769297,0.0027415624,0.00024427148,0.0000019259523,0.000005278302,0.009908555],"genre_scores_gemma":[0.9291026,0.0013284078,0.00069542427,0.062425293,0.006364676,0.000011555818,0.0000021982073,0.0000067124997,0.00006310607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9587879,0.03496322,0.0049980627,0.00017876792,0.00070396176,0.00036807964],"domain_scores_gemma":[0.8957241,0.09994493,0.002728596,0.0004904582,0.00090106216,0.00021086121],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14394227,0.00013298084,0.0016878172,0.00003197041,0.00039774185,0.00003544652,0.000834023,0.0003611528,0.00022812662],"category_scores_gemma":[0.112136275,0.00005573081,0.0009059313,0.0003319085,0.0007551901,0.0000971898,0.00017294908,0.005714111,0.000009633237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073792287,0.002153609,0.5197838,0.000017848331,0.0008891958,0.0019230263,0.005931145,0.0012248044,0.00007158926,0.004850739,0.2173717,0.23840334],"study_design_scores_gemma":[0.005106233,0.002636326,0.59707826,0.00010996591,0.00024968426,0.0036740773,0.014053333,0.00041326837,0.000007684913,0.004384939,0.37219667,0.000089537265],"about_ca_topic_score_codex":0.00007308997,"about_ca_topic_score_gemma":0.00046762812,"teacher_disagreement_score":0.2383138,"about_ca_system_score_codex":0.00013326047,"about_ca_system_score_gemma":0.002755166,"threshold_uncertainty_score":0.99657977},"labels":[],"label_agreement":null},{"id":"W3166078442","doi":"10.1200/jco.2021.39.15_suppl.e21127","title":"Impact of <i>KRAS</i> mutational variant on response to immunotherapy in metastatic NSCLC.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"KRAS; Medicine; Mutation; Internal medicine; Oncology; Cancer; Cancer research; Colorectal cancer; Genetics; Biology; Gene","score_opus":0.09607797808659894,"score_gpt":0.5561180739738766,"score_spread":0.4600400958872776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166078442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98619956,0.00030379408,0.0003719553,0.01082689,0.00041121454,0.00015128058,0.000017051752,0.0000021250034,0.0017161218],"genre_scores_gemma":[0.9884507,0.00012588469,0.008042006,0.0028824226,0.00015086126,0.000004542458,0.000004721795,0.000010570629,0.00032828847],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973596,0.0006119853,0.001518156,0.00011681785,0.00026700847,0.00012646326],"domain_scores_gemma":[0.9952746,0.003259427,0.000657342,0.00013851537,0.00047378443,0.00019631654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019695526,0.00008531698,0.0009060889,0.00017238507,0.000014336425,0.0000042308625,0.000060860184,0.00008921064,0.00037160265],"category_scores_gemma":[0.0036007059,0.000055691246,0.0004452866,0.00025336302,0.00004823211,0.00004918474,0.000011040255,0.00033443482,0.000012689385],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25923797,0.03572533,0.1287983,0.000059062553,0.009934398,0.032985512,0.0037035167,0.0058458527,0.026048318,0.0014487131,0.011797707,0.4844153],"study_design_scores_gemma":[0.016632836,0.02644106,0.94466555,0.00015485904,0.00030172343,0.000886333,0.00014556684,0.000026607564,0.00020720171,0.000528912,0.009950594,0.0000587557],"about_ca_topic_score_codex":0.000035211877,"about_ca_topic_score_gemma":0.000020603793,"teacher_disagreement_score":0.81586725,"about_ca_system_score_codex":0.00034818015,"about_ca_system_score_gemma":0.0065311943,"threshold_uncertainty_score":0.99910086},"labels":[],"label_agreement":null},{"id":"W3166145929","doi":"10.1200/jco.2021.39.15_suppl.e16526","title":"Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Logistic regression; Cohort; Oncology; Population; Proportional hazards model; Retrospective cohort study","score_opus":0.04954485064468183,"score_gpt":0.3603492603798838,"score_spread":0.31080440973520196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166145929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947458,0.0005627724,0.000032933225,0.0010168027,0.000290022,0.00034901692,0.000020992285,0.000010668777,0.0029710305],"genre_scores_gemma":[0.99577147,0.00014608155,0.0020018893,0.0004892471,0.00017944053,0.00001328732,0.000017552009,0.00003748287,0.0013435632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969895,0.00026626108,0.0017125069,0.0002614471,0.0005351452,0.00023516615],"domain_scores_gemma":[0.995918,0.0006235475,0.0020955675,0.00021638464,0.00087940576,0.0002671177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058901455,0.00023064432,0.001908219,0.000117013915,0.000052280884,0.0000068056725,0.0000780591,0.00022823528,0.00007339849],"category_scores_gemma":[0.0005423688,0.00013336407,0.00025612183,0.00017307799,0.00030251523,0.00013589243,0.00003304166,0.0006214875,7.334812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070215636,0.0022804828,0.9640904,0.000029945832,0.0014072248,0.0010364042,0.00029956145,0.000011315767,0.0000945073,0.0000069531857,0.00014271977,0.023578925],"study_design_scores_gemma":[0.035228,0.021602433,0.9341921,0.00014002707,0.001455443,0.00015763845,0.00019778662,0.0000031041905,0.0010306385,0.0000097508955,0.0058452,0.0001378577],"about_ca_topic_score_codex":0.0001061504,"about_ca_topic_score_gemma":0.00018839994,"teacher_disagreement_score":0.029898275,"about_ca_system_score_codex":0.0005631445,"about_ca_system_score_gemma":0.0019330306,"threshold_uncertainty_score":0.5438429},"labels":[],"label_agreement":null},{"id":"W3166150115","doi":"10.1200/jco.2021.39.15_suppl.8038","title":"Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Dalhousie University; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba","funders":"Karyopharm Therapeutics","keywords":"Carfilzomib; Medicine; Regimen; Dexamethasone; Bortezomib; Pharmacology; Internal medicine; Refractory (planetary science); Oncology; Multiple myeloma; Cancer research; Biology","score_opus":0.13274553903255915,"score_gpt":0.4615143807599671,"score_spread":0.32876884172740795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166150115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916672,0.0019363791,0.00005495115,0.003657397,0.0007769444,0.00029871287,0.000024478,0.00001055997,0.0015733913],"genre_scores_gemma":[0.9811821,0.0020858794,0.013891842,0.0014314062,0.0007278405,0.000008797193,0.000028507015,0.000031449294,0.00061216776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99479896,0.0010889348,0.0024985136,0.00041852563,0.00067839824,0.00051669584],"domain_scores_gemma":[0.9908957,0.0055993637,0.0010751126,0.0003202211,0.0011509694,0.00095867406],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025963392,0.00024530813,0.001964506,0.00023378713,0.000058576756,0.000020066946,0.00016468341,0.000527501,0.00020967999],"category_scores_gemma":[0.021931818,0.00018518677,0.00041551184,0.00031218532,0.00027245493,0.00020545613,0.00016869589,0.0017252348,0.000032242013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043353327,0.0032692992,0.7413558,0.000048456684,0.0003457621,0.0046277875,0.000119639575,0.000007996944,0.0005763941,0.000007743778,0.0012442764,0.24406154],"study_design_scores_gemma":[0.03492581,0.00616327,0.9218796,0.00017268845,0.0001770206,0.00036955712,0.00026759438,0.00041739523,0.00046853343,0.0000593714,0.03494815,0.00015102369],"about_ca_topic_score_codex":0.00015368099,"about_ca_topic_score_gemma":0.0006963051,"teacher_disagreement_score":0.24391052,"about_ca_system_score_codex":0.000363271,"about_ca_system_score_gemma":0.0025642135,"threshold_uncertainty_score":0.98630685},"labels":[],"label_agreement":null},{"id":"W3166171733","doi":"10.1200/jco.2021.39.15_suppl.tps5612","title":"ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; KRAS; Serous fluid; Internal medicine; Clear cell carcinoma; Oncology; Neuroblastoma RAS viral oncogene homolog; Carcinoma; Cancer","score_opus":0.20018233589876983,"score_gpt":0.5105117308033281,"score_spread":0.3103293949045583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166171733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348223,0.0026114548,0.000077739736,0.0020426754,0.0009174405,0.0006002959,0.00001364433,0.0000015112737,0.0002529807],"genre_scores_gemma":[0.99530107,0.0020690013,0.001101748,0.0004883176,0.00041816337,0.000013650016,0.0000111316685,0.000015882953,0.0005810449],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99732697,0.0005588993,0.0014527353,0.00030000648,0.00015531521,0.00020605567],"domain_scores_gemma":[0.9974713,0.00060789153,0.0010616839,0.00023575505,0.00042836455,0.00019502494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009964434,0.00017447575,0.0008212768,0.000025533796,0.00010571644,0.00003845002,0.00026368097,0.00022234379,0.000026330912],"category_scores_gemma":[0.0009239723,0.000092550166,0.00028230785,0.000070908936,0.00015817434,0.000013017995,0.00020278897,0.0002610589,5.055137e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09741086,0.07012112,0.0045422926,0.000094392984,0.004776457,0.0008133462,0.0008247407,0.00016011008,0.059689168,0.000008806399,0.0013613072,0.7601974],"study_design_scores_gemma":[0.17284341,0.46832433,0.008862022,0.0002891649,0.002332492,0.0009378846,0.004332416,0.0005286929,0.018193673,0.000021258613,0.32292208,0.0004125678],"about_ca_topic_score_codex":0.00002341184,"about_ca_topic_score_gemma":0.00010159917,"teacher_disagreement_score":0.7597848,"about_ca_system_score_codex":0.00009740568,"about_ca_system_score_gemma":0.0011869464,"threshold_uncertainty_score":0.37740862},"labels":[],"label_agreement":null},{"id":"W3166204225","doi":"10.1200/jco.21.00972","title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Ixazomib; Lenalidomide; Medicine; Placebo; Hazard ratio; Internal medicine; Multiple myeloma; Population; Surgery; Gastroenterology; Oncology; Confidence interval; Pathology; Carfilzomib","score_opus":0.14823605115153535,"score_gpt":0.462971200887676,"score_spread":0.3147351497361407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166204225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981609,0.00014001221,0.000044573284,0.00072620634,0.00033564423,0.00041767018,0.000035074496,0.0000020256448,0.00013788861],"genre_scores_gemma":[0.99688953,0.00029689152,0.0022188344,0.00015681345,0.00019068124,0.0000042010543,0.000018194734,0.000013004103,0.00021182871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944776,0.0014339517,0.0027367272,0.00024817677,0.0008426626,0.00026083997],"domain_scores_gemma":[0.98967916,0.006441834,0.0022414003,0.00035370202,0.0009557259,0.00032815433],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00292947,0.00016728512,0.0025329334,0.00030788605,0.000032546875,0.0000064656333,0.00016427267,0.00028528518,0.00020216979],"category_scores_gemma":[0.014915794,0.00008698896,0.0006206932,0.0006436207,0.00032769403,0.0001147451,0.000104184925,0.00085856445,4.6945115e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44135475,0.009230348,0.5186693,0.000025568965,0.0029222053,0.00047425507,0.00006246507,0.000027118658,0.00018183097,0.0000054003567,0.00006720159,0.02697953],"study_design_scores_gemma":[0.36201298,0.018283915,0.61704856,0.00009320774,0.0014918505,0.000013878384,0.000057180514,0.0003131523,0.00020917463,0.000008931021,0.00041360105,0.000053572316],"about_ca_topic_score_codex":0.00012811767,"about_ca_topic_score_gemma":0.00090786093,"teacher_disagreement_score":0.09837925,"about_ca_system_score_codex":0.00012582324,"about_ca_system_score_gemma":0.0021612337,"threshold_uncertainty_score":0.993382},"labels":[],"label_agreement":null},{"id":"W3166226934","doi":"10.1200/jco.2021.39.15_suppl.9552","title":"Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Canada Health Infoway; Western University; Cancer Care Ontario; Queen's University","funders":"","keywords":"Medicine; Melanoma; Oncology; Internal medicine; Ipilimumab; Confounding; Proportional hazards model; Cancer; Overall survival; Targeted therapy; Prospective cohort study; Survival analysis; Immunotherapy; Cancer research","score_opus":0.05012170822073858,"score_gpt":0.4084136466025933,"score_spread":0.35829193838185475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166226934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977951,0.000613809,0.0004546711,0.000086801425,0.0006575497,0.00015615429,0.00004925723,0.0000012745654,0.00018536247],"genre_scores_gemma":[0.99626946,0.0017387331,0.0012104447,0.00030025328,0.00040088088,0.0000030494105,0.000035565638,0.000018626946,0.000022988686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834573,0.00016408516,0.001009062,0.00017813378,0.00013947969,0.00016350439],"domain_scores_gemma":[0.9968419,0.0007205136,0.0011772554,0.00018112788,0.00094992353,0.00012925261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005839412,0.00011921796,0.0006924857,0.00003032264,0.000021530854,0.0000068473564,0.00013196786,0.0002223226,0.00001076605],"category_scores_gemma":[0.0014816034,0.00008228511,0.00041582235,0.000047274174,0.000046976693,0.0000046223336,0.000028695811,0.00017869269,5.210962e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05229773,0.0054574935,0.539862,0.00008399284,0.0034586117,0.00018395454,0.00014296352,0.017757546,0.25447977,0.0001847648,0.0026806558,0.123410515],"study_design_scores_gemma":[0.0642256,0.22423084,0.6508502,0.00037305214,0.0003020552,0.00020156741,0.00017652645,0.000111956,0.043099023,0.00045588764,0.015343584,0.00062975375],"about_ca_topic_score_codex":0.000009711309,"about_ca_topic_score_gemma":0.000022316963,"teacher_disagreement_score":0.21877335,"about_ca_system_score_codex":0.000106429965,"about_ca_system_score_gemma":0.0023639395,"threshold_uncertainty_score":0.4193527},"labels":[],"label_agreement":null},{"id":"W3166268850","doi":"10.1200/jco.2021.39.15_suppl.e16561","title":"Real-world treatment patterns and overall survival in previously treated advanced renal cell carcinoma patients receiving nivolumab in the UK.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Nivolumab; Medicine; Pazopanib; Axitinib; Sunitinib; Renal cell carcinoma; Cabozantinib; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Surgery; Cancer; Immunotherapy","score_opus":0.0763595982025691,"score_gpt":0.3890791354664847,"score_spread":0.3127195372639156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166268850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917338,0.00042825763,0.0000020496427,0.0013634254,0.0003662149,0.00047650625,0.0000056654703,0.0000045046186,0.0056196083],"genre_scores_gemma":[0.9958374,0.0022292193,0.00053467054,0.00039456438,0.00027789935,0.000016059246,0.000025166308,0.000022553419,0.0006625038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949776,0.0015237093,0.0023120418,0.00036763787,0.00043188335,0.00038713843],"domain_scores_gemma":[0.9956602,0.0024224196,0.0010353837,0.00033075464,0.00026884893,0.00028238774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016285636,0.00025552075,0.0016781882,0.0002076077,0.00003471988,0.000017358505,0.00013631773,0.00023119053,0.0000728528],"category_scores_gemma":[0.0006512775,0.00015692659,0.00037776495,0.00025796425,0.000077890625,0.00009148029,0.000058533966,0.00077041605,0.0000035355201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028531458,0.0035354896,0.94062203,0.000032640728,0.00008000848,0.0062423623,0.0005096433,0.000017337952,0.000103873586,0.0000055496766,0.00011158194,0.045886345],"study_design_scores_gemma":[0.026324008,0.016379539,0.9546782,0.00018065299,0.00028293766,0.00016716975,0.00021970016,0.000022933453,0.00046652232,0.000041496998,0.0011191978,0.00011769078],"about_ca_topic_score_codex":0.0013450625,"about_ca_topic_score_gemma":0.015078062,"teacher_disagreement_score":0.045768656,"about_ca_system_score_codex":0.0010160794,"about_ca_system_score_gemma":0.0010168178,"threshold_uncertainty_score":0.84139127},"labels":[],"label_agreement":null},{"id":"W3166274652","doi":"10.1200/jco.2021.39.15_suppl.5002","title":"Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Denosumab; Population; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Incidence (geometry); FRAX; Asymptomatic; Surgery; Cancer; Osteoporosis; Androgen receptor; Bone mineral","score_opus":0.13460935779372213,"score_gpt":0.4848886222871188,"score_spread":0.3502792644933967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166274652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900312,0.0006475953,0.0003747467,0.007093891,0.0004187326,0.00079698465,0.00001275626,0.000015673464,0.0006084384],"genre_scores_gemma":[0.99452865,0.00047780445,0.0017709993,0.0021605836,0.000577356,0.000021468313,0.00028015545,0.000029984998,0.00015296877],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99139374,0.004290729,0.0025458767,0.0004338804,0.00081145077,0.00052433665],"domain_scores_gemma":[0.99224293,0.0044073253,0.0018744313,0.00040069292,0.00059844577,0.00047617205],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012628425,0.00026413813,0.0021064884,0.00025407903,0.00023004352,0.00006267196,0.0002753064,0.00043000665,0.00031293143],"category_scores_gemma":[0.005597774,0.00014975618,0.00046048508,0.0011462332,0.00022035491,0.00023664995,0.00006942679,0.0030242638,0.000004291239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8601562,0.008105811,0.04732068,0.000049595652,0.0076311817,0.016836002,0.0015284424,0.0006845872,0.0019660986,0.000013702716,0.0030511967,0.05265655],"study_design_scores_gemma":[0.7512624,0.043706164,0.14084274,0.00039935307,0.00776664,0.0006341913,0.0059079737,0.0031322716,0.0021790394,0.00016391737,0.043462947,0.0005423229],"about_ca_topic_score_codex":0.00015199641,"about_ca_topic_score_gemma":0.0005330325,"teacher_disagreement_score":0.108893715,"about_ca_system_score_codex":0.00038287003,"about_ca_system_score_gemma":0.0028858841,"threshold_uncertainty_score":0.9992758},"labels":[],"label_agreement":null},{"id":"W3166306390","doi":"10.1200/jco.2021.39.15_suppl.4570","title":"Plasma exosome microRNA-155 expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: A potential biomarker of response to systemic therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Biomarker; Nivolumab; Exosome; Ipilimumab; microRNA; Oncology; Renal cell carcinoma; Axitinib; Internal medicine; Progressive disease; Immune checkpoint; Immune system; Cancer; Microvesicles; Immunotherapy; Cancer research; Immunology; Disease; Sunitinib","score_opus":0.02269505269315119,"score_gpt":0.31616795472180625,"score_spread":0.29347290202865506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166306390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777776,0.001303741,0.00022777621,0.00018132146,0.00016833468,0.00028886553,0.000020303485,0.0000023701373,0.000029553052],"genre_scores_gemma":[0.9952677,0.00006697657,0.0042976625,0.000091240116,0.000110619636,0.0000081168055,0.000024019051,0.00003401569,0.00009966873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995337,0.0016442367,0.0020624432,0.00034891217,0.0003461004,0.00026132446],"domain_scores_gemma":[0.99684507,0.0002465823,0.0015808487,0.00039130097,0.0006550556,0.0002811228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017792545,0.00021788954,0.00090914895,0.0001465462,0.000026787837,0.0000114261275,0.00026115205,0.00027022354,0.00002407593],"category_scores_gemma":[0.00071833417,0.00014719274,0.00031537662,0.0002235627,0.00014442916,0.000013938478,0.00012347732,0.00033997622,0.0000024337703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080461904,0.0024184561,0.07336563,0.000034499386,0.00016307819,0.00089223636,0.00005175479,0.0001490797,0.8404956,1.4092059e-7,0.00011106734,0.0018565553],"study_design_scores_gemma":[0.018056817,0.013142751,0.28702688,0.00023584504,0.00011086469,0.00018522926,0.00013293831,0.000011460556,0.68041503,0.0000030539165,0.0005068923,0.00017222916],"about_ca_topic_score_codex":0.0000066006137,"about_ca_topic_score_gemma":0.000009457545,"teacher_disagreement_score":0.21366124,"about_ca_system_score_codex":0.00006705157,"about_ca_system_score_gemma":0.0012646425,"threshold_uncertainty_score":0.60023457},"labels":[],"label_agreement":null},{"id":"W3166316371","doi":"10.1200/jco.2021.39.15_suppl.e18805","title":"Propping up the parents: An environmental scan of childcare programs available to cancer patients in North America.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Foundation","keywords":"Medicine; Childhood cancer; Family medicine; Cancer; Phone; Pediatric oncology; Internal medicine","score_opus":0.10752777976543454,"score_gpt":0.4332535473153206,"score_spread":0.3257257675498861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166316371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993896,0.00015398036,0.0000035674818,0.0022750932,0.0018356724,0.0002720915,0.000013231583,0.0000036067931,0.001546741],"genre_scores_gemma":[0.996855,0.000729709,0.0003546294,0.0014325123,0.00036178844,0.000014988351,0.00000823183,0.000009550706,0.00023359014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634445,0.0010462083,0.0015014552,0.00019963748,0.00060319324,0.000305078],"domain_scores_gemma":[0.99774,0.00041898756,0.0011648536,0.00016874791,0.00022163388,0.00028582956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017398932,0.00009238051,0.00064717117,0.00005009029,0.00011982168,0.00001938474,0.00047348617,0.0001530015,0.0003908028],"category_scores_gemma":[0.0016618824,0.00006470492,0.00017505258,0.00038779582,0.00049198203,0.00021738585,0.00011508396,0.0005199699,0.000017550168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105146864,0.0011789652,0.74005365,0.0000032154724,0.00003231369,0.000023035958,0.0041469825,0.00003922937,0.000004106923,0.0000063893876,0.0005377556,0.25386918],"study_design_scores_gemma":[0.00093723595,0.0015376651,0.7972654,0.000045552413,0.000033135686,0.0000015038565,0.012939423,0.0000075189805,0.000010207108,0.000027541484,0.18710816,0.00008665556],"about_ca_topic_score_codex":0.0023773643,"about_ca_topic_score_gemma":0.030247826,"teacher_disagreement_score":0.25378254,"about_ca_system_score_codex":0.0003377118,"about_ca_system_score_gemma":0.0018788107,"threshold_uncertainty_score":0.9874476},"labels":[],"label_agreement":null},{"id":"W3166337570","doi":"10.1200/jco.2021.39.15_suppl.4090","title":"Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Adverse effect; Dosing; Internal medicine; Discontinuation; FGF19; Gastroenterology; Nausea; Oncology; Tolerability; Toxicity; Liver function; Fibroblast growth factor","score_opus":0.1431479451627062,"score_gpt":0.4652234205137144,"score_spread":0.3220754753510082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166337570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978909,0.0006620807,0.00007527905,0.0003505481,0.00046068366,0.00026708932,0.0000069786643,0.0000021928754,0.0002842343],"genre_scores_gemma":[0.9982527,0.00017342651,0.0005820565,0.00018077383,0.0005451236,0.0000068650725,0.000010160994,0.000026919646,0.00022200483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947878,0.0014438621,0.002594347,0.00036176087,0.0004550679,0.00035716878],"domain_scores_gemma":[0.99690837,0.0006361626,0.0010456429,0.0004557328,0.00064705434,0.00030706736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026722916,0.00018564925,0.0012788876,0.00017011238,0.000027868798,0.000012782372,0.00046935945,0.00045645362,0.00014504403],"category_scores_gemma":[0.0048755943,0.00014416392,0.0003807626,0.000318171,0.00017411307,0.0000130256385,0.00027886027,0.0008554856,0.0000074171685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006618939,0.015654944,0.849244,0.000072226496,0.0003485964,0.0043283263,0.0002808139,0.000018155239,0.10827723,0.000010398658,0.0012521949,0.013894203],"study_design_scores_gemma":[0.057661217,0.14634307,0.67902774,0.00013023379,0.00026395667,0.0008794333,0.0024946204,0.0006692199,0.0963711,0.00012318487,0.015551235,0.00048501388],"about_ca_topic_score_codex":0.00006145093,"about_ca_topic_score_gemma":0.0002818229,"teacher_disagreement_score":0.17021626,"about_ca_system_score_codex":0.00006523299,"about_ca_system_score_gemma":0.0023123422,"threshold_uncertainty_score":0.5878834},"labels":[],"label_agreement":null},{"id":"W3166340336","doi":"10.1200/jco.2021.39.15_suppl.6593","title":"Efficacy and cost-effectiveness of breast cancer (BC) screening in female survivors of childhood Hodgkin lymphoma (HL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; American Cancer Society","keywords":"Medicine; Breast cancer; Cohort; Digital mammography; Population; Mammography; Quality of life (healthcare); Pediatrics; Gynecology; Internal medicine; Oncology; Cancer","score_opus":0.05960417250782561,"score_gpt":0.4184234990604868,"score_spread":0.3588193265526612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166340336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959251,0.0028138245,0.00010547218,0.00046488692,0.00031945095,0.00013043788,0.000038487502,0.0000011665104,0.00020115232],"genre_scores_gemma":[0.99630165,0.0025827584,0.00072501204,0.000100132485,0.000253366,0.000008026706,0.00000639696,0.000012832409,0.000009836607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975788,0.0007610587,0.0011137035,0.00022685593,0.00015029575,0.00016930283],"domain_scores_gemma":[0.9973838,0.001015024,0.0009405523,0.00015279409,0.00040568088,0.000102188635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014449216,0.00013324269,0.0010511182,0.000058014346,0.000021592821,0.0000030760605,0.00012463743,0.00025949776,0.000016949061],"category_scores_gemma":[0.0008793833,0.00010998793,0.00021953293,0.00013794558,0.00025919598,0.000007265298,0.00014801708,0.00016881876,2.3985527e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041367807,0.0018418219,0.80872476,0.000056231343,0.00071758137,0.0000646137,0.00007441985,0.0001709636,0.0041400096,0.000018288214,0.000036062116,0.18001848],"study_design_scores_gemma":[0.0108640315,0.0012216838,0.97638357,0.00023409247,0.00013404433,0.0001949933,0.0001433799,0.000003765385,0.009833254,0.000026434273,0.000871424,0.00008933015],"about_ca_topic_score_codex":0.00048832176,"about_ca_topic_score_gemma":0.001105546,"teacher_disagreement_score":0.17992915,"about_ca_system_score_codex":0.000035595418,"about_ca_system_score_gemma":0.00083639147,"threshold_uncertainty_score":0.44851777},"labels":[],"label_agreement":null},{"id":"W3166379207","doi":"10.1200/jco.2021.39.15_suppl.1060","title":"Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) from BYLieve.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Oncology; Palbociclib; Proportional hazards model; Gastroenterology; Cancer; Breast cancer; Metastatic breast cancer; Estrogen receptor; Aromatase","score_opus":0.03335397663975626,"score_gpt":0.39071425035157153,"score_spread":0.3573602737118153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166379207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492675,0.00078598596,0.00007662345,0.0016388333,0.0006655499,0.00081099686,0.0009735459,0.000017131862,0.00010456242],"genre_scores_gemma":[0.9931012,0.0019549187,0.0032861892,0.00058686273,0.00077338034,0.000027411113,0.00014140528,0.000086354565,0.00004227599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99279284,0.0008952053,0.004097967,0.0006444684,0.0010643122,0.000505187],"domain_scores_gemma":[0.9881216,0.0020593703,0.0056103407,0.00039754756,0.0033266863,0.00048443547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007999029,0.00053990405,0.0030511706,0.00028930666,0.000077419754,0.0000136783465,0.0002756452,0.0005694204,0.0007254286],"category_scores_gemma":[0.0011253555,0.00038495768,0.000702941,0.00055487663,0.00048547162,0.00060155656,0.000074851225,0.0015771204,0.0000053250287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15747455,0.01305585,0.3923499,0.000045848235,0.0026675642,0.0002449813,0.001933744,0.00077422743,0.10976064,0.000021729898,0.00017030547,0.32150066],"study_design_scores_gemma":[0.049401946,0.029874904,0.8750042,0.0008783426,0.00018404884,0.00003614863,0.00027602882,0.000014239306,0.04373559,0.00017032133,0.00010215899,0.00032212396],"about_ca_topic_score_codex":0.0010148663,"about_ca_topic_score_gemma":0.0005253778,"teacher_disagreement_score":0.48265424,"about_ca_system_score_codex":0.0014187807,"about_ca_system_score_gemma":0.0020672285,"threshold_uncertainty_score":0.9998602},"labels":[],"label_agreement":null},{"id":"W3166385880","doi":"10.1200/jco.2021.39.15_suppl.9531","title":"Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Chills; Cytokine release syndrome; Gastroenterology; Internal medicine; Dosing; Cytokine; Adverse effect; Immunotherapy; Cancer","score_opus":0.042929026118249475,"score_gpt":0.36940185894261707,"score_spread":0.32647283282436756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166385880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997952,0.00012931167,0.000042695887,0.00082080235,0.00021964627,0.00053298794,0.000014644478,0.00000832501,0.00027961237],"genre_scores_gemma":[0.99682677,0.00024730805,0.0021308246,0.0002716646,0.00006209094,0.0000152164985,0.0001328586,0.000029507677,0.0002837667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638003,0.0007052868,0.0019435049,0.0002940793,0.0003934028,0.0002836742],"domain_scores_gemma":[0.99678373,0.00056102086,0.0016951734,0.00025049888,0.0003969175,0.00031265922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006623007,0.00024484697,0.0023371696,0.00019586293,0.000032593183,0.0000060339353,0.00007998929,0.00024894028,0.000100612764],"category_scores_gemma":[0.00040884985,0.00014737737,0.00038497042,0.0003487032,0.0001212298,0.00017359768,0.000024042422,0.00040551517,0.000008529971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010351056,0.012976226,0.923693,0.00004529468,0.002828011,0.022715788,0.00012420585,0.000007955325,0.0004005062,0.0000080642785,0.0000059720896,0.026843945],"study_design_scores_gemma":[0.05279748,0.10109938,0.838081,0.00044714546,0.0034213336,0.0015285168,0.00006833416,0.000022113483,0.0009062226,0.000016222733,0.00148523,0.00012704918],"about_ca_topic_score_codex":0.000039451566,"about_ca_topic_score_gemma":0.00021330788,"teacher_disagreement_score":0.08812315,"about_ca_system_score_codex":0.00046688272,"about_ca_system_score_gemma":0.0017584212,"threshold_uncertainty_score":0.6009875},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W3166408331","doi":"10.1200/jco.2021.39.15_suppl.5016","title":"Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ear and Head Tumors","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Logistic regression; Concordance; Tinnitus; Multinomial logistic regression; Hearing loss; Audiogram; Audiology; Internal medicine","score_opus":0.1819849873186283,"score_gpt":0.5152062759703074,"score_spread":0.3332212886516791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166408331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830875,0.00030539892,0.00023398716,0.007830862,0.0025278258,0.00010644929,0.0000014544596,0.000012892595,0.0058936765],"genre_scores_gemma":[0.98518485,0.00007769322,0.0072285268,0.0066439235,0.00050559104,0.000002813855,0.0000032981495,0.000023066024,0.00033022068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963082,0.00026530618,0.00237695,0.00021229919,0.00058127695,0.0002559443],"domain_scores_gemma":[0.9945735,0.002663364,0.0013879878,0.0002650923,0.00069384853,0.0004162263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016287823,0.00014626396,0.0015205081,0.0002859574,0.000033436267,0.000013216105,0.000083748746,0.00031506145,0.00083990814],"category_scores_gemma":[0.0051041064,0.00010720603,0.00074425887,0.00051440735,0.000106771506,0.00007323572,0.000038424503,0.0010519635,0.0000266956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006711737,0.0018480445,0.9091277,0.000029798546,0.0006763868,0.008820381,0.000030008277,0.000010088234,0.000066223416,0.00001011099,0.0011092415,0.0715603],"study_design_scores_gemma":[0.019852027,0.008139362,0.9473726,0.00007928088,0.00034639184,0.00034609318,0.00006312126,0.000068604604,0.00025418706,0.00004519678,0.023331717,0.00010142345],"about_ca_topic_score_codex":0.000007636412,"about_ca_topic_score_gemma":0.0000116320625,"teacher_disagreement_score":0.071458876,"about_ca_system_score_codex":0.0001974175,"about_ca_system_score_gemma":0.0034010937,"threshold_uncertainty_score":0.91964054},"labels":[],"label_agreement":null},{"id":"W3166432245","doi":"10.1200/jco.2021.39.15_suppl.4553","title":"Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Internal medicine; Sunitinib; Nivolumab; Cabozantinib; Renal cell carcinoma; Post-hoc analysis; Clinical trial; Progression-free survival; Gastroenterology; Surgery; Oncology; Cancer; Overall survival; Immunotherapy","score_opus":0.15932828886876876,"score_gpt":0.4703809437933762,"score_spread":0.31105265492460743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166432245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98047304,0.0009858371,0.00022281594,0.013840678,0.0024575929,0.0010602148,0.00024845698,0.000010002471,0.00070135866],"genre_scores_gemma":[0.9920683,0.00042016528,0.0019802982,0.0027340548,0.0012129412,0.00006555474,0.00033647812,0.000045396693,0.0011368081],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99352276,0.0012598049,0.0036621285,0.00040585885,0.00064269017,0.0005067712],"domain_scores_gemma":[0.9870692,0.008735374,0.0021423912,0.0005425998,0.0008299738,0.00068045716],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004392965,0.00033216228,0.002412569,0.00013124943,0.00008353269,0.00002848153,0.00031472687,0.00031620055,0.00020019383],"category_scores_gemma":[0.010908379,0.00021269906,0.001138242,0.00022601851,0.00019738644,0.00012240792,0.00007068688,0.0011207279,0.0000137614925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84789896,0.02056826,0.019710977,0.0002665619,0.0005180792,0.017169498,0.00029584015,0.000012847209,0.0016645914,0.00006965104,0.024460897,0.06736385],"study_design_scores_gemma":[0.68922156,0.038036287,0.06644194,0.00012150784,0.0021563645,0.00020782668,0.0006041255,0.00036251073,0.0016419416,0.000054349093,0.20082425,0.00032735715],"about_ca_topic_score_codex":0.000013596533,"about_ca_topic_score_gemma":0.00002477205,"teacher_disagreement_score":0.17636335,"about_ca_system_score_codex":0.00031135973,"about_ca_system_score_gemma":0.004052055,"threshold_uncertainty_score":0.9974232},"labels":[],"label_agreement":null},{"id":"W3166447977","doi":"10.1200/jco.2021.39.15_suppl.2002","title":"Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Trk receptor; Medicine; Internal medicine; Neuroblastoma; Oncology; Fusion gene; Tropomyosin receptor kinase B; Tropomyosin receptor kinase A; Cancer; Cancer research; Neurotrophin; Receptor; Neurotrophic factors; Gene; Cell culture","score_opus":0.02027564014817056,"score_gpt":0.3446496620390374,"score_spread":0.32437402189086684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166447977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798065,0.00028048264,0.0000054027178,0.00075401197,0.00020620569,0.00037676352,0.000019566265,0.00000449629,0.00037240295],"genre_scores_gemma":[0.997353,0.00082860305,0.0013051335,0.00019519968,0.00024824138,0.0000025488953,0.000011161164,0.00001456585,0.000041543874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698186,0.0007015836,0.0014101396,0.00023328445,0.00040067566,0.00027246532],"domain_scores_gemma":[0.996116,0.0017742233,0.00084129506,0.00011429657,0.0006319857,0.00052222906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055909774,0.00013739012,0.0012245771,0.0001451556,0.00003620571,0.0000069647376,0.000054689554,0.00015895357,0.000021527434],"category_scores_gemma":[0.0018761382,0.00009067619,0.00011721584,0.00023401981,0.00014929772,0.00008082249,0.0000768343,0.00070266053,0.0000017178868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038248163,0.0050228103,0.87923354,0.00024666765,0.00020010535,0.0042458517,0.00011021894,0.000002310408,0.0001806286,0.000020480084,0.00015110457,0.072338104],"study_design_scores_gemma":[0.0325725,0.01892839,0.9470026,0.00043182258,0.0002187844,0.00035077985,0.00010265799,0.0000073503807,0.00020229573,0.0000030507595,0.00011481925,0.00006497414],"about_ca_topic_score_codex":0.000022565453,"about_ca_topic_score_gemma":0.00003172815,"teacher_disagreement_score":0.07227313,"about_ca_system_score_codex":0.00018521427,"about_ca_system_score_gemma":0.0012440091,"threshold_uncertainty_score":0.36976677},"labels":[],"label_agreement":null},{"id":"W3166449210","doi":"10.1200/jco.2021.39.15_suppl.e23539","title":"Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Amputation; Medicine; Quality of life (healthcare); Sarcoma; Survivorship curve; Soft tissue sarcoma; Surgery; Cancer; Physical therapy; Soft tissue; Internal medicine; Nursing","score_opus":0.1525011054402118,"score_gpt":0.47971590560962996,"score_spread":0.3272148001694182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166449210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96097463,0.0031053221,0.0012221613,0.033051625,0.000642617,0.000896496,0.000019100755,0.00001494018,0.000073078954],"genre_scores_gemma":[0.9886525,0.0009387537,0.003344066,0.0065640314,0.00027478565,0.000034919594,0.000018821916,0.000024039657,0.00014804915],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932215,0.001078967,0.0045205075,0.00035777283,0.0004937177,0.00032753445],"domain_scores_gemma":[0.9905755,0.0041803075,0.0026166402,0.00036129035,0.001696061,0.00057022274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037363223,0.00021173303,0.0021812976,0.00012260281,0.00011590661,0.00001662644,0.00014094633,0.0003542331,0.00023416728],"category_scores_gemma":[0.0047676098,0.00012516415,0.0007779424,0.0004399399,0.00013479903,0.00009563454,0.000068096306,0.000713624,0.00000679034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2264273,0.017183794,0.3696606,0.0003002176,0.001324894,0.0007030765,0.0010868338,0.0005486337,0.0004499858,0.00007803349,0.006212318,0.37602434],"study_design_scores_gemma":[0.016385779,0.024813661,0.9538087,0.00034570656,0.00028866442,0.00020003135,0.00059261714,0.0007011596,0.00012699874,0.00035694422,0.0022601841,0.00011954709],"about_ca_topic_score_codex":0.00009550112,"about_ca_topic_score_gemma":0.001263628,"teacher_disagreement_score":0.5841481,"about_ca_system_score_codex":0.00027578842,"about_ca_system_score_gemma":0.0034750118,"threshold_uncertainty_score":0.61645216},"labels":[],"label_agreement":null},{"id":"W3166456623","doi":"10.1200/jco.2021.39.15_suppl.6571","title":"Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Breast cancer; Quality of life (healthcare); Clinical Oncology; Internal medicine; Cancer; Cancer drugs; Oncology","score_opus":0.5720931720890339,"score_gpt":0.5828935797739606,"score_spread":0.010800407684926738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166456623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690688,0.0029761244,0.000061108796,0.024104077,0.0020561768,0.00015222389,0.0003846401,0.0000024950787,0.0011943536],"genre_scores_gemma":[0.98588586,0.004979071,0.0012240285,0.006517849,0.0012276096,0.0000034952693,0.0000028523452,0.000017747298,0.00014146387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97686267,0.0022307131,0.020089788,0.00032780584,0.00025179054,0.00023723053],"domain_scores_gemma":[0.95952284,0.018078009,0.020893643,0.00044717334,0.00073729845,0.0003210329],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06938872,0.000141015,0.0043456033,0.00012317165,0.0000358283,0.000012431811,0.00038662087,0.0004549752,0.0008096773],"category_scores_gemma":[0.02868147,0.00012703202,0.00074612466,0.00015108222,0.0005042025,0.00021377875,0.00016154083,0.0007164067,0.000017177392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005638627,0.0009760939,0.9639919,0.00027755194,0.0005686606,0.0000028453476,0.00039764435,0.00008994072,0.0000044728595,0.022325238,0.0058929436,0.004908863],"study_design_scores_gemma":[0.003997232,0.00052019407,0.9709316,0.00009241925,0.000043810538,0.00000747748,0.0004744407,0.00013278908,0.0000015699405,0.0050334837,0.018656852,0.000108159205],"about_ca_topic_score_codex":0.0011333673,"about_ca_topic_score_gemma":0.0011063801,"teacher_disagreement_score":0.04070725,"about_ca_system_score_codex":0.00010928343,"about_ca_system_score_gemma":0.0021797852,"threshold_uncertainty_score":0.97950035},"labels":[],"label_agreement":null},{"id":"W3166474048","doi":"10.1200/jco.2021.39.15_suppl.2015","title":"Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Bevacizumab; Nivolumab; Internal medicine; Oncology; Progression-free survival; Overall survival; Gastroenterology; Surgery; Chemotherapy; Immunotherapy; Cancer","score_opus":0.11832731631170054,"score_gpt":0.49497315283957277,"score_spread":0.3766458365278722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166474048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991735,0.0012720147,0.000015937982,0.0040296996,0.0014355355,0.001017233,0.000010951905,0.000008672958,0.00047498726],"genre_scores_gemma":[0.9972171,0.0009994396,0.0008100035,0.00029080067,0.00045244492,0.000036990365,0.0000029541677,0.000027552705,0.00016272043],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916856,0.0021733884,0.0047226446,0.0003544318,0.000748724,0.00031515464],"domain_scores_gemma":[0.991031,0.004584085,0.0025473475,0.00039395335,0.0010159203,0.00042770072],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004791239,0.00025130366,0.0049331645,0.0003150941,0.000035672074,0.000012869473,0.00017277592,0.00033941437,0.00079814944],"category_scores_gemma":[0.00967741,0.00014207202,0.0009367811,0.0004526921,0.00021308554,0.00008895631,0.00009458918,0.00092352997,0.0000088636025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7794118,0.042753443,0.0021804662,0.00004085226,0.001737775,0.013881727,0.0008520109,0.000022986624,0.0002061942,0.00002168917,0.0016882621,0.15720281],"study_design_scores_gemma":[0.8838419,0.098789185,0.0057216347,0.00040567014,0.0018044575,0.000640709,0.0017055192,0.00012262602,0.0013461884,0.00011937121,0.0053646658,0.00013811905],"about_ca_topic_score_codex":0.00003548389,"about_ca_topic_score_gemma":0.0008160016,"teacher_disagreement_score":0.15706469,"about_ca_system_score_codex":0.000518453,"about_ca_system_score_gemma":0.003903714,"threshold_uncertainty_score":0.9986645},"labels":[],"label_agreement":null},{"id":"W3166483804","doi":"10.1200/jco.2021.39.15_suppl.lba3","title":"Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cervical cancer; Carboplatin; Clinical endpoint; Oncology; Radiation therapy; Internal medicine; Chemoradiotherapy; Randomized controlled trial; Cancer; Chemotherapy; Gynecology; Cisplatin","score_opus":0.0977657035544692,"score_gpt":0.4811256810939971,"score_spread":0.3833599775395279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166483804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9211532,0.0041924734,0.0019660539,0.06077108,0.0055271164,0.004812481,0.000035916644,0.0000339489,0.0015077438],"genre_scores_gemma":[0.9566092,0.004682204,0.006264451,0.023308074,0.006754029,0.00070917135,0.00014692805,0.00007326327,0.0014526694],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938272,0.00078328466,0.0036110957,0.0005052032,0.0008011451,0.00047201785],"domain_scores_gemma":[0.98969793,0.006333825,0.0020307645,0.00037875972,0.0008266257,0.00073211256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033208854,0.00038662512,0.0047913827,0.00014067584,0.00015625868,0.00003963648,0.0002413405,0.00043796835,0.00047560237],"category_scores_gemma":[0.005171026,0.00022938645,0.0024665017,0.0005046455,0.00014353341,0.00016481074,0.000044995006,0.00053850847,0.000021796794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66587394,0.0045199916,0.00019036914,0.000028021352,0.0020297968,0.00017342178,0.0002311734,0.000118850985,0.00058203423,0.000020895923,0.0012754147,0.3249561],"study_design_scores_gemma":[0.91824436,0.01738768,0.0016461833,0.00013464082,0.0027175825,0.000059128633,0.00012901599,0.00046271106,0.0024221768,0.0003672184,0.056212336,0.00021693563],"about_ca_topic_score_codex":0.00014086894,"about_ca_topic_score_gemma":0.000104535466,"teacher_disagreement_score":0.32473913,"about_ca_system_score_codex":0.0014127161,"about_ca_system_score_gemma":0.004394229,"threshold_uncertainty_score":0.93541086},"labels":[],"label_agreement":null},{"id":"W3166495841","doi":"10.1200/jco.2021.39.15_suppl.e24009","title":"Palliative care as a predictor of healthcare resource use at end-of-life in adult Albertan lung cancer decedents between 2008-2015: A secondary data analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palliative care; End-of-life care; Psychological intervention; Odds ratio; Lung cancer; Logistic regression; Health care; Confounding; Cancer; Emergency medicine; Intensive care unit; Internal medicine; Nursing","score_opus":0.3461979247843146,"score_gpt":0.5795745001692227,"score_spread":0.23337657538490814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166495841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689576,0.022911279,0.000038047852,0.006187202,0.0003508396,0.00021929415,0.0008849641,0.0000039398683,0.00044685105],"genre_scores_gemma":[0.9842869,0.009920299,0.0028011124,0.0017102847,0.0006576639,0.000004706559,0.00036415542,0.000024644076,0.00023021454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99286187,0.0012257374,0.0043427604,0.0004403128,0.00080056087,0.0003287788],"domain_scores_gemma":[0.9853479,0.007122665,0.0038816063,0.00069151475,0.00232586,0.0006303986],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015344649,0.00022483367,0.0038405352,0.00035613627,0.000029194867,0.0000047531785,0.00047736193,0.00056876935,0.00042359906],"category_scores_gemma":[0.01906989,0.00018183822,0.0006914924,0.00079092704,0.00032095806,0.00018001147,0.00036039352,0.0011589152,0.00000176397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029979579,0.0004443191,0.9761682,0.00047852765,0.004172668,0.00036313158,0.0032279007,0.000045984463,0.000034719193,0.000014833228,0.00553815,0.0065135825],"study_design_scores_gemma":[0.008576219,0.0025106126,0.9297208,0.0022011655,0.0033971218,0.000009516065,0.0032103762,0.00015158996,0.00033402682,0.000018869505,0.049726065,0.00014361557],"about_ca_topic_score_codex":0.004274385,"about_ca_topic_score_gemma":0.03325168,"teacher_disagreement_score":0.046447407,"about_ca_system_score_codex":0.00046713414,"about_ca_system_score_gemma":0.006682756,"threshold_uncertainty_score":0.99894845},"labels":[],"label_agreement":null},{"id":"W3166496575","doi":"10.1200/jco.2021.39.15_suppl.3015","title":"A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AbbVie","keywords":"Medicine; Nausea; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Taxane; Vomiting; Diarrhea; Tolerability; Chills; Surgery; Cancer; Breast cancer","score_opus":0.13510556123169,"score_gpt":0.5069815495929816,"score_spread":0.37187598836129154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166496575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927024,0.00040526217,0.000004900831,0.0054881102,0.00012723822,0.0006825959,0.0000011644969,0.000003820497,0.0005844783],"genre_scores_gemma":[0.9973604,0.0016317675,0.00034014674,0.00037684685,0.00014934457,0.000018990624,0.0000025062657,0.000021934584,0.00009806296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99466085,0.0012905392,0.0029071728,0.00029587332,0.0006077686,0.00023778567],"domain_scores_gemma":[0.995521,0.0022318335,0.0013331828,0.0002571992,0.00048242885,0.00017436822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058138724,0.00013769744,0.0014227614,0.00045460957,0.000023646013,0.000010446244,0.00013091009,0.00031473732,0.0000630771],"category_scores_gemma":[0.0026192728,0.00010522089,0.00009147764,0.0005236893,0.0001763641,0.00011689538,0.000034929548,0.001645715,0.0000013968549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061262883,0.027678713,0.805192,0.00007845926,0.0001809261,0.0059314673,0.0046599316,0.00055662537,0.0014438313,0.000044533426,0.00019809556,0.092772566],"study_design_scores_gemma":[0.07939788,0.06380761,0.85217375,0.0005267963,0.000018795416,0.00014291337,0.0016611067,0.00040670935,0.00018242683,0.0003564218,0.0012397883,0.00008578143],"about_ca_topic_score_codex":0.00043965367,"about_ca_topic_score_gemma":0.0059209885,"teacher_disagreement_score":0.09268679,"about_ca_system_score_codex":0.00046682724,"about_ca_system_score_gemma":0.0018876238,"threshold_uncertainty_score":0.71499044},"labels":[],"label_agreement":null},{"id":"W3166543567","doi":"10.1200/jco.2021.39.15_suppl.7017","title":"A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Hematopoietic stem cell transplantation; Internal medicine; Salvage therapy; Hepatic veno-occlusive disease; Busulfan; Adverse effect; Transplantation; Surgery; Oncology; Chemotherapy","score_opus":0.06862428910625668,"score_gpt":0.37675921794490985,"score_spread":0.3081349288386532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166543567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569356,0.00005453313,0.00050557585,0.0013762348,0.00022451545,0.0014642028,0.00005089472,0.000011520456,0.0006189626],"genre_scores_gemma":[0.9953712,0.00010177279,0.0024236136,0.0009244198,0.00016162716,0.000046888017,0.000032415654,0.000052634266,0.00088538555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99276286,0.0007213563,0.0038414935,0.0006011817,0.0014994106,0.00057368504],"domain_scores_gemma":[0.99235344,0.003113173,0.0018317697,0.0004975578,0.0014745718,0.00072948734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014024031,0.00040092014,0.0027117655,0.00032048553,0.00005031317,0.000017547747,0.00038786957,0.00046299057,0.00006134766],"category_scores_gemma":[0.0005137794,0.0002779116,0.00038196074,0.00068126275,0.0001784238,0.00012633452,0.00008174473,0.0008239627,0.0000178162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14247064,0.06876208,0.7478777,0.0009321199,0.0021350612,0.01070379,0.007034421,0.004904627,0.0013743169,0.000030436406,0.0017897112,0.011985069],"study_design_scores_gemma":[0.2679013,0.20476231,0.50363934,0.0017006707,0.0033432944,0.0007719241,0.0030062934,0.003050251,0.0086688055,0.000028077386,0.0025319294,0.0005957905],"about_ca_topic_score_codex":0.00010890085,"about_ca_topic_score_gemma":0.00030802953,"teacher_disagreement_score":0.24423835,"about_ca_system_score_codex":0.0057894136,"about_ca_system_score_gemma":0.022266537,"threshold_uncertainty_score":0.9999673},"labels":[],"label_agreement":null},{"id":"W3166578944","doi":"10.1200/jco.2021.39.15_suppl.9506","title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Placebo; Oncology; Immunotherapy; Cancer; Pathology","score_opus":0.05612230571088557,"score_gpt":0.43305479178709033,"score_spread":0.3769324860762048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166578944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905738,0.00029095952,0.00001170164,0.0052442113,0.0008788786,0.000106888394,0.0000021649003,0.0000047627923,0.0028866169],"genre_scores_gemma":[0.9922613,0.0006231242,0.0028423204,0.0034792395,0.0001844127,0.0000018806393,0.000003114369,0.000013768153,0.00059086684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975966,0.0002045625,0.00158307,0.00014374545,0.0002921686,0.0001798293],"domain_scores_gemma":[0.99789226,0.0005487846,0.00087692344,0.00016311483,0.00036092347,0.0001580143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011472384,0.000103503975,0.0011721436,0.000078905265,0.000015608732,0.000005398013,0.0000903277,0.00020799792,0.00025104042],"category_scores_gemma":[0.0011047451,0.00006412593,0.00031328626,0.00016594454,0.00010667578,0.000085539374,0.00002542824,0.0005807907,0.000011092343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018019145,0.0019530278,0.848212,0.000015124154,0.00035887212,0.00059320615,0.000050041413,0.000002962822,0.00014711909,0.000013776789,0.0005394078,0.13009533],"study_design_scores_gemma":[0.033196658,0.011706448,0.9082076,0.00011517417,0.00009404073,0.000066176,0.00012306539,0.0000023224995,0.00021819002,0.00003682356,0.046161573,0.00007194],"about_ca_topic_score_codex":0.000007264855,"about_ca_topic_score_gemma":0.00007675297,"teacher_disagreement_score":0.13002339,"about_ca_system_score_codex":0.0001571743,"about_ca_system_score_gemma":0.0012052371,"threshold_uncertainty_score":0.27487165},"labels":[],"label_agreement":null},{"id":"W3166598389","doi":"10.1200/jco.2021.39.15_suppl.11573","title":"VAC temporization pending final margins after suprafascial myxofibrosarcoma excision to reduce the rate of local recurrence.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Surgery; Stage (stratigraphy); Myxofibrosarcoma; Exact test; Soft tissue; Cancer; Wide local excision; Internal medicine","score_opus":0.15785035055083527,"score_gpt":0.4711267788358079,"score_spread":0.3132764282849726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166598389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97021264,0.00095259905,0.0013971465,0.024750061,0.0017934712,0.00019205925,0.0000058077912,0.0000035679614,0.0006926754],"genre_scores_gemma":[0.9935336,0.0006716106,0.0027512943,0.0016996245,0.0012011176,0.000009145012,0.0000055899595,0.0000119705455,0.000116057825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966217,0.000716135,0.001890228,0.0002090072,0.00036247604,0.00020039856],"domain_scores_gemma":[0.9952579,0.0026888368,0.00091760483,0.00023653249,0.00061948824,0.0002796278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025885487,0.00012727488,0.0010014487,0.000102148275,0.000050874358,0.000012474152,0.00013839467,0.00021524089,0.00042521892],"category_scores_gemma":[0.0028601342,0.00007578785,0.00047253573,0.00029546418,0.00014668657,0.00008609062,0.000099702855,0.0005243372,0.000025564297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011305046,0.004990932,0.33568475,0.00004634966,0.00039206483,0.0039003212,0.00032576977,0.00004761566,0.0012071747,0.0005229811,0.01277111,0.6288059],"study_design_scores_gemma":[0.0044892076,0.0058892807,0.9287336,0.00031803513,0.00033803406,0.0006065796,0.00032667659,0.000048760525,0.0032074798,0.00037063967,0.055593867,0.00007785338],"about_ca_topic_score_codex":0.000011201268,"about_ca_topic_score_gemma":0.000039196173,"teacher_disagreement_score":0.62872803,"about_ca_system_score_codex":0.00014164757,"about_ca_system_score_gemma":0.0015098677,"threshold_uncertainty_score":0.4655849},"labels":[],"label_agreement":null},{"id":"W3166629602","doi":"10.1200/jco.2021.39.15_suppl.e15539","title":"Detailed incidence and mortality trends of early-onset colorectal cancer in Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Incidence (geometry); Cancer registry; Rectum; Demography; Cancer; Logistic regression; Odds ratio; Confidence interval; Mortality rate; Internal medicine","score_opus":0.0825468852844596,"score_gpt":0.44096523905642215,"score_spread":0.3584183537719626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166629602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996228,0.0009663346,0.000013036482,0.0013357697,0.00078523724,0.000036524158,0.000008162665,0.0000022675288,0.00062466494],"genre_scores_gemma":[0.9985817,0.0005057857,0.0002774859,0.00033478744,0.00022862728,0.0000026044297,6.1063525e-7,0.0000052722685,0.00006314037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771816,0.00030292454,0.0014017416,0.00014204645,0.0002967527,0.00013836757],"domain_scores_gemma":[0.99753374,0.00095407176,0.0008265562,0.000084306674,0.00038038444,0.00022096375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012753797,0.00007670546,0.0010317714,0.0000909476,0.000014906369,0.0000029286898,0.00005545908,0.00016448672,0.00015695713],"category_scores_gemma":[0.0019873793,0.000062190724,0.00014175309,0.00031435626,0.00010624185,0.00005589629,0.000040293777,0.0006637744,1.9717658e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005776176,0.00012673036,0.8973035,0.000016166721,0.000107280335,0.000719834,0.000052727886,0.000020176907,0.00024110674,0.0000019888869,0.00018043222,0.095453866],"study_design_scores_gemma":[0.002836202,0.0053730025,0.98906094,0.00009905227,0.00015322676,0.00043639514,0.00010029889,0.00021285404,0.0012241924,0.000051118,0.00039984862,0.00005288155],"about_ca_topic_score_codex":0.25671476,"about_ca_topic_score_gemma":0.96161544,"teacher_disagreement_score":0.7049007,"about_ca_system_score_codex":0.0004137752,"about_ca_system_score_gemma":0.01064327,"threshold_uncertainty_score":0.9949655},"labels":[],"label_agreement":null},{"id":"W3166631750","doi":"10.1200/jco.2021.39.15_suppl.4554","title":"Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; London Health Sciences Centre; Western University; Dalhousie University; St. Joseph’s Healthcare Hamilton; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Ipilimumab; Internal medicine; Nephrectomy; Gastroenterology; Clear cell renal cell carcinoma; Oncology; Urology; Surgery; Cancer; Kidney; Immunotherapy","score_opus":0.15046309236316988,"score_gpt":0.4077470997826623,"score_spread":0.2572840074194924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166631750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721625,0.0041394527,0.0000304072,0.022063864,0.0006694022,0.00026880158,0.00013955205,0.0000038607373,0.0005221715],"genre_scores_gemma":[0.989228,0.005300166,0.003275115,0.0015523748,0.00033230483,0.0000050691992,0.000066525776,0.000018934827,0.00022148235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509794,0.00068996847,0.002996279,0.00038702454,0.0005804043,0.0002484048],"domain_scores_gemma":[0.9892925,0.007740238,0.0017046788,0.00042293262,0.0005299876,0.00030965277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028704738,0.00023058338,0.0016411801,0.00012477628,0.000042430034,0.00001916899,0.00022966632,0.00017583088,0.00014200539],"category_scores_gemma":[0.0034556277,0.00013820255,0.00033272835,0.00013369687,0.00039603558,0.00011995335,0.00017636924,0.0008486666,0.000002698586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017627137,0.003432003,0.9457024,0.00004195294,0.001026507,0.0064002546,0.0006779984,0.000026624708,0.0028747634,0.000040477138,0.0018064565,0.020343477],"study_design_scores_gemma":[0.043917544,0.0058681215,0.936428,0.00012469235,0.000531007,0.00060103455,0.00057604356,0.00031153715,0.0048003616,0.0002816841,0.006432739,0.00012723208],"about_ca_topic_score_codex":0.0005260584,"about_ca_topic_score_gemma":0.0012538038,"teacher_disagreement_score":0.026290407,"about_ca_system_score_codex":0.00019495482,"about_ca_system_score_gemma":0.0012676517,"threshold_uncertainty_score":0.5635736},"labels":[],"label_agreement":null},{"id":"W3166632772","doi":"10.1200/jco.2021.39.15_suppl.1048","title":"Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Population; Cohort; Pertuzumab; Internal medicine; Cancer registry; Breast cancer; Propensity score matching; Trastuzumab; Cancer; Oncology; Demography; Environmental health; Confidence interval","score_opus":0.31204948936514104,"score_gpt":0.5283286827249328,"score_spread":0.2162791933597918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166632772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792532,0.0003538558,0.00009452144,0.014452096,0.000555355,0.004154059,0.00079266215,0.000005026464,0.00033922738],"genre_scores_gemma":[0.99601865,0.00020272117,0.00080136716,0.0017412128,0.00017510401,0.00085761637,0.000040571034,0.000040592855,0.00012214901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9884009,0.0031533074,0.0068896823,0.00067061145,0.0004157835,0.00046973204],"domain_scores_gemma":[0.9793586,0.011168775,0.0071331747,0.0004273509,0.0015836899,0.0003283941],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.034805875,0.00028467996,0.003291184,0.00059813,0.00016621605,0.00005745049,0.00036194533,0.00016978904,0.00015384387],"category_scores_gemma":[0.006631767,0.00023789164,0.0001895287,0.0013950221,0.00017909326,0.0004966972,0.000024048237,0.00068327156,0.000002963756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023122279,0.0015109751,0.9832817,0.00020105038,0.00041954266,0.000008619194,0.0007348776,0.009381812,4.360836e-7,0.000898435,0.00077600783,0.00047432928],"study_design_scores_gemma":[0.010084312,0.002094575,0.9820712,0.0007219192,0.00016823025,0.0000026863922,0.0008100286,0.0029830574,0.0000049092164,0.0004715821,0.00033485485,0.00025260117],"about_ca_topic_score_codex":0.632362,"about_ca_topic_score_gemma":0.94052875,"teacher_disagreement_score":0.30816674,"about_ca_system_score_codex":0.024545575,"about_ca_system_score_gemma":0.0154843265,"threshold_uncertainty_score":0.99387044},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3166697471","doi":"10.1200/jco.2021.39.15_suppl.tps6090","title":"The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Placebo; Internal medicine; Paclitaxel; Head and neck squamous-cell carcinoma; Hazard ratio; Chemotherapy; Oncology; Tolerability; Surgery; Head and neck cancer; Cancer; Adverse effect; Confidence interval; Pathology","score_opus":0.06951416991493115,"score_gpt":0.4445522497361714,"score_spread":0.37503807982124027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166697471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961208,0.00038453695,0.000013879746,0.0021634428,0.0002025237,0.00088393915,0.000008172377,0.0000019159081,0.00022075036],"genre_scores_gemma":[0.998312,0.000044476426,0.0012476358,0.00024051212,0.000028760329,0.00002240896,0.000008062431,0.000011655208,0.00008451735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971843,0.0005208349,0.0015320356,0.0001966332,0.00038400636,0.00018220782],"domain_scores_gemma":[0.9965487,0.001641814,0.00079415255,0.00018408583,0.00062745274,0.00020380806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000878084,0.0001301792,0.0010755892,0.00012888203,0.000042666168,0.000011853144,0.000076368095,0.000058966434,0.000010947487],"category_scores_gemma":[0.0007765884,0.000065068234,0.00006136644,0.00036340687,0.000087577486,0.000080209014,0.000032163192,0.0004055755,7.132406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016377512,0.017379072,0.95179695,0.00004707138,0.00016771973,0.00047996998,0.0020697217,0.00007536358,0.0000023127495,0.000014206892,0.0001656928,0.011424385],"study_design_scores_gemma":[0.062571235,0.060035925,0.8716798,0.00012820851,0.00046586408,0.000023427883,0.004469326,0.000035489848,0.0000058946057,0.000035938545,0.00048518073,0.00006372699],"about_ca_topic_score_codex":0.00026359898,"about_ca_topic_score_gemma":0.0076483856,"teacher_disagreement_score":0.080117196,"about_ca_system_score_codex":0.00020793833,"about_ca_system_score_gemma":0.0012031303,"threshold_uncertainty_score":0.42679787},"labels":[],"label_agreement":null},{"id":"W3166702288","doi":"10.1200/jco.2021.39.15_suppl.7031","title":"Predictors of clinical trial enrollment and impact on outcome in children and adolescents with acute lymphoblastic leukemia: A population based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; McMaster Children's Hospital; London Health Sciences Centre; Children's Hospital of Eastern Ontario; Canadian Agency for Drugs and Technologies in Health; Kingston General Hospital","funders":"","keywords":"Medicine; Clinical trial; Hazard ratio; Confidence interval; Odds ratio; Pediatrics; Disease; Population; Proportional hazards model; Logistic regression; Internal medicine","score_opus":0.08730455530277233,"score_gpt":0.4791751569255119,"score_spread":0.39187060162273957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166702288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971039,0.00008883004,0.000026182368,0.0012632271,0.00078631233,0.00069655286,0.0000110925275,0.0000060351276,0.000017839673],"genre_scores_gemma":[0.9971207,0.000101910555,0.00037982166,0.0013523086,0.001008979,0.0000030725657,0.000006293085,0.000018862516,0.000008080336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921598,0.0017413276,0.00480527,0.00035517273,0.00072805927,0.0002103952],"domain_scores_gemma":[0.9940354,0.002464886,0.0025244418,0.000255561,0.00022781423,0.0004918975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067011914,0.0002077755,0.0028490198,0.00018063506,0.000023838027,0.000010435941,0.00009939386,0.00038602971,0.000017420301],"category_scores_gemma":[0.005946778,0.00013520251,0.00040332062,0.00018131424,0.00013615182,0.00008158059,0.00006375211,0.0010998981,6.709699e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13806376,0.0052808058,0.85065174,0.000031136096,0.00078516215,0.00031257776,0.00008887353,0.000060831222,0.0000015721074,0.0000012974133,0.00004565246,0.004676576],"study_design_scores_gemma":[0.17276558,0.052791942,0.7728263,0.0003944162,0.0008127465,0.00015421212,0.00007800149,0.000069044676,0.0000022748238,0.000011784851,0.000010381877,0.000083297324],"about_ca_topic_score_codex":0.00018787477,"about_ca_topic_score_gemma":0.00026198704,"teacher_disagreement_score":0.07782545,"about_ca_system_score_codex":0.0003121257,"about_ca_system_score_gemma":0.003149793,"threshold_uncertainty_score":0.71192783},"labels":[],"label_agreement":null},{"id":"W3166705212","doi":"10.1200/jco.2021.39.15_suppl.e16263","title":"Prevalence of germline mutations in pancreatic carcinoma patients (PCP) unselected for family history (FH).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; PALB2; Cohort; CDKN2A; Germline mutation; Oncology; Germline; CHEK2; MSH6; Internal medicine; Cancer; Genetics; Mutation; Gene; Colorectal cancer; Biology","score_opus":0.15225953823350602,"score_gpt":0.4657380422268423,"score_spread":0.31347850399333627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166705212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933024,0.0023578322,0.0003809276,0.0010916186,0.00055564306,0.0003909685,0.000013674043,0.000004152071,0.0019027526],"genre_scores_gemma":[0.9853358,0.0009044142,0.010888785,0.00080103124,0.00030065802,0.000019503383,0.000017592663,0.000014986125,0.0017171872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955943,0.0007242538,0.0028205148,0.0002041517,0.00038208725,0.00027465503],"domain_scores_gemma":[0.9896037,0.006338723,0.0013648039,0.00021103247,0.002202603,0.0002791661],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002548827,0.000115755385,0.0018188037,0.00021510455,0.000022401826,0.0000015787572,0.00014865908,0.00037415486,0.00024653485],"category_scores_gemma":[0.017546065,0.00009324213,0.00037620778,0.00021090773,0.00033556673,0.00006969352,0.000035729045,0.00073149597,0.0000053092067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002968044,0.0035379434,0.97857183,0.0003890034,0.00022952829,0.00032610373,0.00022085903,0.000004160932,0.000867308,0.00009269567,0.003625118,0.009167398],"study_design_scores_gemma":[0.013166233,0.010446072,0.9666246,0.00019080797,0.00067317503,0.00008607582,0.000114665156,0.0004988586,0.000062742416,0.0003393411,0.007727195,0.000070191905],"about_ca_topic_score_codex":0.000030578667,"about_ca_topic_score_gemma":0.000032526303,"teacher_disagreement_score":0.014997238,"about_ca_system_score_codex":0.00052911846,"about_ca_system_score_gemma":0.008341819,"threshold_uncertainty_score":0.99727994},"labels":[],"label_agreement":null},{"id":"W3166711975","doi":"10.1200/jco.2021.39.15_suppl.2612","title":"First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Antigen; Internal medicine; Prostate-specific antigen; Immunotherapy; Regimen; Oncology; Immunology; Cancer","score_opus":0.05778106570875469,"score_gpt":0.4243905280793919,"score_spread":0.36660946237063724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166711975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97102004,0.02562232,0.000012888292,0.0021934458,0.00061528734,0.00047376563,0.000016885391,0.0000070431383,0.000038306527],"genre_scores_gemma":[0.9955424,0.0032823728,0.00030646526,0.00037841176,0.000044183653,0.000037285958,0.000010563553,0.000027220247,0.0003710779],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9929241,0.0024552292,0.0037512095,0.00036074655,0.00012169777,0.000387],"domain_scores_gemma":[0.9941975,0.0030349195,0.0019771236,0.0003536905,0.00038151295,0.000055237448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003344102,0.0002728375,0.0019578345,0.00034639356,0.00009524881,0.000015626425,0.00029567274,0.00041600346,0.00043250286],"category_scores_gemma":[0.0012687184,0.000220128,0.0002897149,0.00038676834,0.00027339533,0.00016115516,0.00005953257,0.0012686221,0.000003790102],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087192856,0.028510734,0.032504976,0.00011535445,0.0020109457,0.0015759632,0.0035551991,0.00018957263,0.81273997,0.000083962,0.0011861145,0.030334348],"study_design_scores_gemma":[0.3362315,0.082362436,0.34476516,0.0012818824,0.0008560282,0.0008255952,0.008928952,0.000080717626,0.16589363,0.00072989,0.056993175,0.0010510386],"about_ca_topic_score_codex":0.0004376052,"about_ca_topic_score_gemma":0.0011771373,"teacher_disagreement_score":0.64684635,"about_ca_system_score_codex":0.0001526575,"about_ca_system_score_gemma":0.0016859965,"threshold_uncertainty_score":0.8976559},"labels":[],"label_agreement":null},{"id":"W3166741510","doi":"10.1200/jco.2021.39.15_suppl.tps9587","title":"CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Immunotherapy; Melanoma; Oncology; Biomarker; Clinical endpoint; Liquid biopsy; Targeted therapy; Phases of clinical research; Clinical trial; Internal medicine; Cancer research; Cancer; Immunology; Biology","score_opus":0.0664869218459965,"score_gpt":0.3820331397867959,"score_spread":0.3155462179407994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166741510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748474,0.0014315712,0.00003799498,0.0003331126,0.00017575423,0.00048647527,0.000016143887,0.0000010289233,0.000033189957],"genre_scores_gemma":[0.9972988,0.00068416767,0.001482803,0.00031055894,0.00018401718,0.00000976022,0.000013122051,0.000014843586,0.000001932479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974875,0.00034829153,0.0015501978,0.00026056718,0.00014884345,0.00020459577],"domain_scores_gemma":[0.99773455,0.000696221,0.00094274763,0.0002363987,0.00027231046,0.00011780084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010197638,0.00014462428,0.000811663,0.00005638862,0.000039352017,0.0000096637295,0.00017591215,0.00016776792,0.0000099701565],"category_scores_gemma":[0.0017393616,0.00009770732,0.00016436403,0.00013986822,0.000089958994,0.000007178713,0.00010133723,0.00021793476,1.01282254e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10537417,0.0037259469,0.47134525,0.000006044139,0.00027594445,0.00013637493,0.000288221,0.0002723676,0.102770336,0.0000044627295,0.000012266389,0.31578863],"study_design_scores_gemma":[0.17970616,0.07626313,0.7192286,0.00009257213,0.00006193341,0.0000678447,0.00026439628,0.00018420018,0.019250346,0.0003707921,0.0042029405,0.00030707364],"about_ca_topic_score_codex":0.00003068906,"about_ca_topic_score_gemma":0.00017361916,"teacher_disagreement_score":0.31548154,"about_ca_system_score_codex":0.00005328297,"about_ca_system_score_gemma":0.0007035308,"threshold_uncertainty_score":0.3984389},"labels":[],"label_agreement":null},{"id":"W3166746419","doi":"10.1200/jco.2021.39.15_suppl.e15038","title":"Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Jewish General Hospital","funders":"Pfizer; Conquer Cancer Foundation","keywords":"Medicine; Internal medicine; Melanoma; Oncology; Adverse effect; Cancer research","score_opus":0.14984054108063805,"score_gpt":0.49207966214937027,"score_spread":0.3422391210687322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166746419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961956,0.0008924186,0.000016281327,0.0016365175,0.0001849465,0.0008286365,0.000080641024,0.0000032979344,0.00016164886],"genre_scores_gemma":[0.9963148,0.0010480423,0.002244126,0.000115968825,0.00012828413,0.00003943286,0.000013609591,0.000012855018,0.00008282997],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9970158,0.00025823456,0.00212891,0.00020864734,0.0002492244,0.00013919077],"domain_scores_gemma":[0.99258614,0.0038061421,0.002114363,0.00021849948,0.0010509501,0.00022391611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007478941,0.00015528702,0.0016937483,0.00008778071,0.000091950766,0.0000024543187,0.000076052806,0.00009636565,0.0000085515485],"category_scores_gemma":[0.0020855719,0.0000835869,0.00022580636,0.0002050091,0.00045073967,0.00007003483,0.00003515356,0.00016832685,7.306965e-8],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3388086,0.1462398,0.071408816,0.000209604,0.009691004,0.0012538573,0.028509008,0.0005538482,0.003053809,0.000025017307,0.00062902825,0.3996176],"study_design_scores_gemma":[0.08654181,0.7139584,0.17800103,0.00018759469,0.0029171647,0.00014236833,0.011752953,0.0002110502,0.0046956236,0.00006656667,0.0014437777,0.00008169757],"about_ca_topic_score_codex":0.00005481782,"about_ca_topic_score_gemma":0.0002256095,"teacher_disagreement_score":0.56771857,"about_ca_system_score_codex":0.00006526425,"about_ca_system_score_gemma":0.0018031569,"threshold_uncertainty_score":0.3408575},"labels":[],"label_agreement":null},{"id":"W3166774130","doi":"10.1200/jco.2021.39.15_suppl.9519","title":"Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Dexamethasone; Internal medicine; Toxicity; Metastatic melanoma; Melanoma; Clinical trial; Gastroenterology; Surgery; Cancer","score_opus":0.08438844637087858,"score_gpt":0.4242624189216966,"score_spread":0.33987397255081797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166774130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98665845,0.00079263165,0.0015493745,0.009819449,0.00049018016,0.0003865469,0.000039824452,0.000006544091,0.00025701371],"genre_scores_gemma":[0.96623033,0.00031372524,0.029882053,0.0027166568,0.0005434803,0.000014952657,0.00003216494,0.000026057782,0.00024055224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99722075,0.000391306,0.0014864455,0.00026822742,0.0003495286,0.00028372713],"domain_scores_gemma":[0.9954825,0.0020352586,0.00088299316,0.0001867835,0.00061322795,0.0007992579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013810745,0.00018111097,0.0014117219,0.00007245602,0.00006712272,0.000019926227,0.00007632299,0.000121033816,0.00013127095],"category_scores_gemma":[0.0022674769,0.00011465309,0.00035642693,0.000096020776,0.00021380903,0.000088694476,0.00004331136,0.00048131446,0.00000502697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03144166,0.016563497,0.14931577,0.00028155363,0.0037416462,0.011281053,0.00036668335,0.000017964305,0.0000244348,0.0008324291,0.007096802,0.7790365],"study_design_scores_gemma":[0.10766617,0.14124145,0.5826799,0.00047172874,0.009791449,0.0028296213,0.00080444966,0.0005167478,0.000119086464,0.002668115,0.1507591,0.0004521492],"about_ca_topic_score_codex":0.000004881176,"about_ca_topic_score_gemma":0.0000352428,"teacher_disagreement_score":0.77858436,"about_ca_system_score_codex":0.00012653886,"about_ca_system_score_gemma":0.0019818444,"threshold_uncertainty_score":0.46754172},"labels":[],"label_agreement":null},{"id":"W3166786170","doi":"10.1200/jco.2021.39.15_suppl.e14550","title":"Side effects of extended interval dosing of checkpoint inhibitors among patients during COVID-19 pandemic at the Moncton and the Miramichi hospitals.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Moncton Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Cancer; Dosing; Durvalumab; Population; Lung cancer; Nivolumab; Internal medicine; Adverse effect; Pandemic; Emergency medicine; Coronavirus disease 2019 (COVID-19); Disease; Immunotherapy","score_opus":0.0744582731295056,"score_gpt":0.46081390793252686,"score_spread":0.38635563480302126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166786170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844342,0.0017612968,0.000025512072,0.012246957,0.0010241697,0.00039770632,0.0000025115453,0.0000059000045,0.00010178605],"genre_scores_gemma":[0.99419403,0.0015552564,0.000102081154,0.0036790534,0.00039541334,0.0000027358954,0.0000014979059,0.00001517308,0.000054785818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952057,0.0012149217,0.0026851536,0.00019523012,0.00045066842,0.00024834217],"domain_scores_gemma":[0.9849581,0.011039729,0.0027626562,0.00027668182,0.00048129642,0.00048155274],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004110035,0.00015329517,0.001580262,0.00008847681,0.0000996726,0.000007647543,0.00014380287,0.00031565168,0.00001780569],"category_scores_gemma":[0.038137555,0.000078816214,0.0006072488,0.00015983584,0.0009111426,0.000080960446,0.0002433687,0.0010612033,8.061561e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00774484,0.0007308532,0.95532554,0.0009678876,0.00036510968,0.00030704789,0.002037166,0.000013382095,0.0025749234,0.000019822,0.00016710877,0.029746324],"study_design_scores_gemma":[0.020035157,0.004289384,0.9692638,0.0006362242,0.00043421664,0.00022476062,0.00034192196,0.000036601847,0.0036689339,0.00036366883,0.00063619565,0.00006916035],"about_ca_topic_score_codex":0.00030865616,"about_ca_topic_score_gemma":0.00054690085,"teacher_disagreement_score":0.03402752,"about_ca_system_score_codex":0.0004286101,"about_ca_system_score_gemma":0.0018212347,"threshold_uncertainty_score":0.9699646},"labels":[],"label_agreement":null},{"id":"W3166806880","doi":"10.1200/jco.2021.39.15_suppl.7006","title":"Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) m<i>IDH1</i> acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Gastroenterology; Myeloid leukemia; Refractory (planetary science); Interim analysis; Clinical endpoint; Surrogate endpoint; Cytarabine; Clinical trial; Surgery; Adverse effect","score_opus":0.10968179849111843,"score_gpt":0.4842132280598578,"score_spread":0.37453142956873936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166806880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521804,0.00011529546,0.00005445164,0.0017825749,0.00077614,0.00076251605,0.000526337,0.000011879546,0.00075276196],"genre_scores_gemma":[0.9950476,0.0006824106,0.0020477248,0.001022467,0.0006134211,0.000009495479,0.00036718108,0.000048438847,0.00016121838],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9816817,0.0060886545,0.009365139,0.000771527,0.0015613941,0.00053156127],"domain_scores_gemma":[0.9526821,0.037322532,0.006484962,0.0011117543,0.0014413651,0.000957293],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01332669,0.00040535087,0.006963435,0.00095615676,0.000048194106,0.000012681595,0.00064696564,0.0011218328,0.00020354342],"category_scores_gemma":[0.04571485,0.00026763976,0.0019497995,0.0015468254,0.0007077423,0.00015920826,0.00028565445,0.0043235077,0.000013138408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8713604,0.011330494,0.051929433,0.000050525785,0.010040406,0.0032604078,0.00017112074,0.00009947227,0.0019980543,0.000004177764,0.006069176,0.04368629],"study_design_scores_gemma":[0.52471256,0.26098433,0.19367844,0.0010295203,0.0089389365,0.00003971125,0.00009052093,0.0006489143,0.001445686,0.000023122007,0.008157765,0.0002504837],"about_ca_topic_score_codex":0.00013355563,"about_ca_topic_score_gemma":0.00014479093,"teacher_disagreement_score":0.3466479,"about_ca_system_score_codex":0.0010375683,"about_ca_system_score_gemma":0.006893709,"threshold_uncertainty_score":0.9999776},"labels":[],"label_agreement":null},{"id":"W3166810068","doi":"10.1200/jco.2021.39.15_suppl.tps2661","title":"Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; T-cell receptor; T cell; CD8; Tolerability; Response Evaluation Criteria in Solid Tumors; Synovial sarcoma; Immunology; Cancer; Cancer research; Progressive disease; Sarcoma; Immune system; Pathology; Chemotherapy; Adverse effect","score_opus":0.2679764927034616,"score_gpt":0.49486231230405103,"score_spread":0.22688581960058946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166810068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863551,0.00016917856,0.00012075141,0.0022619218,0.00034242182,0.010324537,0.00001231602,0.0000025882734,0.00041116265],"genre_scores_gemma":[0.9734116,0.0031173108,0.0137989335,0.002595508,0.0019802218,0.0025506823,0.000013491274,0.000083364306,0.0024488636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963804,0.0006483978,0.0019581527,0.00032467933,0.00040804746,0.0002803405],"domain_scores_gemma":[0.9963245,0.0013761466,0.0008367428,0.00020109002,0.0009119236,0.00034963022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019937023,0.00018266414,0.0014220863,0.00016968706,0.00004623587,0.00002782395,0.000100608544,0.00024457573,0.0007709032],"category_scores_gemma":[0.00043311002,0.00012021259,0.00011344285,0.0002563525,0.00013665491,0.0001278851,0.0001264969,0.0008229192,0.0000010897561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11782938,0.011092719,0.37615684,0.0005093768,0.0005777585,0.0011929417,0.0011033257,0.000026439673,0.11114067,0.0000038690264,0.0053013437,0.37506533],"study_design_scores_gemma":[0.2419994,0.08545054,0.47187018,0.0012220582,0.00055277435,0.00019886733,0.0010826862,0.0011745208,0.031060662,0.000019894203,0.16477829,0.0005901263],"about_ca_topic_score_codex":0.000019683708,"about_ca_topic_score_gemma":0.0005734726,"teacher_disagreement_score":0.3744752,"about_ca_system_score_codex":0.00023499818,"about_ca_system_score_gemma":0.0013229895,"threshold_uncertainty_score":0.844085},"labels":[],"label_agreement":null},{"id":"W3166835056","doi":"10.1200/jco.2021.39.15_suppl.6517","title":"Should we routinely screen for frailty prior to gynecologic oncology surgery? Frailty as a potential predictor of adverse postoperative outcomes in elderly patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Gynecologic oncology; Adverse effect; Internal medicine; Logistic regression; Comorbidity; Cohort; Surgery; Complication","score_opus":0.14765784004888424,"score_gpt":0.4505681329532515,"score_spread":0.3029102929043672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166835056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9487788,0.00018602966,0.00028102516,0.04558624,0.0016296686,0.00088131696,0.00004969232,0.000014253685,0.0025929783],"genre_scores_gemma":[0.98025954,0.00031818447,0.0055128154,0.011598678,0.0005271526,0.000029251045,0.000028702385,0.00003395907,0.0016916991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992416,0.0013806022,0.0045087654,0.00045241803,0.00070993847,0.000532275],"domain_scores_gemma":[0.9743831,0.020963117,0.0018271051,0.00032812826,0.0017376556,0.00076088327],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004410229,0.000319955,0.0057893284,0.00033138535,0.000058290043,0.000007521383,0.00024402104,0.0010817804,0.0005067862],"category_scores_gemma":[0.041299105,0.00022263174,0.0028423748,0.00034548066,0.00025214878,0.00014935475,0.00013051786,0.0011473984,0.000022771614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0145571735,0.005945773,0.8593429,0.000056025132,0.0009563952,0.00337551,0.00035420753,0.00007183977,0.00013293805,0.00041038266,0.003022207,0.11177469],"study_design_scores_gemma":[0.013774645,0.02131551,0.78355455,0.00009794253,0.0005430868,0.00023279057,0.0004709947,0.00002154669,0.000112559814,0.00015643834,0.17953305,0.00018685107],"about_ca_topic_score_codex":0.000055161323,"about_ca_topic_score_gemma":0.00021097003,"teacher_disagreement_score":0.17651086,"about_ca_system_score_codex":0.00035754414,"about_ca_system_score_gemma":0.0049235043,"threshold_uncertainty_score":0.96677643},"labels":[],"label_agreement":null},{"id":"W3166882697","doi":"10.1200/jco.2021.39.15_suppl.12018","title":"Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Acupuncture; Brief Pain Inventory; Randomized controlled trial; Breast cancer; Physical therapy; Internal medicine; WOMAC; Osteoarthritis; Cancer; Chronic pain","score_opus":0.07492004897205339,"score_gpt":0.4576652551877509,"score_spread":0.3827452062156975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166882697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768775,0.0011840467,0.000012176335,0.015788633,0.0027452426,0.0028652959,0.00040114607,0.0000072781822,0.00011869969],"genre_scores_gemma":[0.99458957,0.0012751822,0.00044468656,0.0012887231,0.0015587952,0.00012687243,0.00005546445,0.000023498164,0.00063720386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935634,0.0010130387,0.004494485,0.0003565084,0.0003018437,0.00027068346],"domain_scores_gemma":[0.988679,0.0077863135,0.0023803168,0.00019581971,0.0005276138,0.0004309693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038187825,0.00027108128,0.005467976,0.00022758877,0.000026139624,0.000012524736,0.00009564773,0.0006033347,0.00025667428],"category_scores_gemma":[0.005394436,0.00015069573,0.0011687762,0.00020690775,0.00020285357,0.000082278624,0.00005938444,0.0007879838,0.0000018038638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9657867,0.0033260426,0.007332117,0.000034261106,0.0023875171,0.0011495424,0.0004845678,0.000019089772,0.0010605137,0.000009207915,0.0016532749,0.01675716],"study_design_scores_gemma":[0.9242464,0.010280153,0.061102428,0.00029492815,0.0025298686,0.000104622464,0.000035192177,0.000085016385,0.00035327376,0.0001364662,0.0007140549,0.00011765281],"about_ca_topic_score_codex":0.00025242817,"about_ca_topic_score_gemma":0.00063042814,"teacher_disagreement_score":0.05377031,"about_ca_system_score_codex":0.00020085352,"about_ca_system_score_gemma":0.0021442324,"threshold_uncertainty_score":0.64580333},"labels":[],"label_agreement":null},{"id":"W3166905971","doi":"10.1200/jco.2021.39.15_suppl.e15581","title":"A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Grand River Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Health Sciences Centre; University Health Network; Ottawa Hospital; Windsor Regional Hospital; Princess Margaret Cancer Centre; University of Calgary; Queen's University; Sunnybrook Health Science Centre; Canadian Agency for Drugs and Technologies in Health; University of Toronto; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Tremelimumab; Durvalumab; Medicine; Adverse effect; Oncology; Colorectal cancer; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Cost effectiveness; Cancer; Immunotherapy; Nivolumab; Nursing","score_opus":0.4701810542366179,"score_gpt":0.528333415253758,"score_spread":0.05815236101714011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166905971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908585,0.00096829,0.000050551564,0.006092375,0.0005840389,0.0008808759,0.0005196778,0.0000029790947,0.000042730353],"genre_scores_gemma":[0.9977266,0.00046679276,0.0007374692,0.00080537284,0.0001394052,0.00006416686,0.000028217428,0.000016215205,0.000015725858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98532665,0.0037263515,0.009988807,0.00045505128,0.00020297797,0.00030018322],"domain_scores_gemma":[0.98113525,0.008050384,0.009660284,0.00018508626,0.0005188678,0.0004501436],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03709947,0.00018866657,0.0048818593,0.0008190562,0.00007933097,0.00003409016,0.00014835206,0.00021758558,0.0003642795],"category_scores_gemma":[0.018837161,0.00018042195,0.00023597958,0.0005696858,0.00016347396,0.00032195944,0.00003789295,0.00048582407,0.0000027630488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002128949,0.0011636049,0.98144853,0.00007582626,0.002856729,0.000039426053,0.0016413761,0.0006648744,0.0000010148455,0.00020229914,0.0001867678,0.00959063],"study_design_scores_gemma":[0.01577162,0.0034229842,0.9718688,0.00006298297,0.0008680601,0.0000032352302,0.0017718306,0.005060109,9.774735e-7,0.0004062687,0.00060248224,0.0001606262],"about_ca_topic_score_codex":0.110652804,"about_ca_topic_score_gemma":0.6255885,"teacher_disagreement_score":0.5149357,"about_ca_system_score_codex":0.0010498723,"about_ca_system_score_gemma":0.002899141,"threshold_uncertainty_score":0.9915087},"labels":[],"label_agreement":null},{"id":"W3166907380","doi":"10.1200/jco.2021.39.15_suppl.e20545","title":"Neoadjuvant prehabilitation therapy for locally advanced non-small-cell lung cancer: Optimizing outcomes throughout the trajectory of care.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Prehabilitation; Medicine; Neoadjuvant therapy; Lung cancer; Surgery; Cancer; Physical therapy; Internal medicine","score_opus":0.07939965269770198,"score_gpt":0.48665998483581013,"score_spread":0.40726033213810814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166907380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94824976,0.03001513,0.0020546494,0.01554311,0.0022485664,0.0007116639,0.00001157177,0.000007359257,0.0011581825],"genre_scores_gemma":[0.9477337,0.017889813,0.029615348,0.003754453,0.0007373429,0.000058586756,0.0000024789204,0.000025643818,0.00018263956],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971519,0.0002689532,0.0019064705,0.0001937505,0.0002581611,0.00022075037],"domain_scores_gemma":[0.9919198,0.005177673,0.0011997422,0.00020780737,0.0013680392,0.00012694484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014417007,0.00014533188,0.0018321262,0.00004209539,0.00007378458,0.000004661192,0.00014506331,0.00020700862,0.000028533843],"category_scores_gemma":[0.0017105006,0.00008256491,0.00081919605,0.00010998643,0.00018106829,0.000068034766,0.000033601835,0.0005433522,3.7103962e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010891927,0.0022828935,0.23308282,0.0008382421,0.0016010914,0.00010002948,0.010713053,0.0021547035,0.0058573354,0.00004890732,0.0034702313,0.7289588],"study_design_scores_gemma":[0.065043814,0.057139996,0.7606561,0.0014798216,0.001778768,0.000066523375,0.019527271,0.0010925791,0.012235945,0.00017683487,0.08041174,0.0003906021],"about_ca_topic_score_codex":0.000022629276,"about_ca_topic_score_gemma":0.00016988626,"teacher_disagreement_score":0.7285682,"about_ca_system_score_codex":0.00018034884,"about_ca_system_score_gemma":0.0037635642,"threshold_uncertainty_score":0.6676401},"labels":[],"label_agreement":null},{"id":"W3166910956","doi":"10.1200/jco.2021.39.15_suppl.4540","title":"Impact of recurrence on health-related quality of life in patients at high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Quality of life (healthcare); Proportional hazards model; Internal medicine; Placebo; Surgery; Post-hoc analysis; Oncology; Urology; Pathology","score_opus":0.16943839481837106,"score_gpt":0.47023146081041095,"score_spread":0.3007930659920399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166910956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912018,0.0008604969,0.00000981084,0.0023201958,0.0017906529,0.00089742686,0.0028850534,0.0000028960453,0.000031649048],"genre_scores_gemma":[0.99682504,0.0018981154,0.00025657448,0.00043863925,0.00044360143,0.000018788283,0.00008917551,0.000018314277,0.000011776605],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9885987,0.0031068295,0.006974464,0.0003699592,0.0006365064,0.0003135147],"domain_scores_gemma":[0.9683675,0.022330776,0.0074754083,0.00046951693,0.00094050216,0.000416301],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061816755,0.00023474792,0.0033756755,0.000118411124,0.000037079102,0.000003345658,0.00020253212,0.00041583387,0.00013127927],"category_scores_gemma":[0.04661556,0.00014122238,0.0014232667,0.00028239185,0.00039045422,0.000068723115,0.00006327729,0.00086103025,0.0000022388897],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4905851,0.009550087,0.4484825,0.00008359565,0.000714423,0.00005347482,0.00047317182,0.000008603827,0.000039668612,0.000003491885,0.00217047,0.047835406],"study_design_scores_gemma":[0.16716902,0.032471962,0.7985556,0.00059780886,0.00030850963,0.0000036496197,0.000034737455,0.000008872533,0.00034658134,0.00022456267,0.00019303038,0.000085634856],"about_ca_topic_score_codex":0.0029324542,"about_ca_topic_score_gemma":0.00047825882,"teacher_disagreement_score":0.3500731,"about_ca_system_score_codex":0.00037420267,"about_ca_system_score_gemma":0.0077820136,"threshold_uncertainty_score":0.99784297},"labels":[],"label_agreement":null},{"id":"W3166951434","doi":"10.1200/jco.2021.39.15_suppl.e20562","title":"Real-world prognostic model for malignant pleural mesothelioma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Mesothelioma; Internal medicine; Univariate analysis; Oncology; Population; Pemetrexed; Surgery; Multivariate analysis; Pathology; Chemotherapy","score_opus":0.17311202071058004,"score_gpt":0.4822907033157326,"score_spread":0.3091786826051526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166951434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808214,0.0003845483,0.0010917261,0.011196674,0.0008303792,0.00021923825,0.000032633052,0.000009841107,0.005413562],"genre_scores_gemma":[0.9760662,0.00041030906,0.014971031,0.002595618,0.00084202446,0.000007921965,0.000018532788,0.000015121418,0.00507324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980488,0.00012707539,0.0012631414,0.00013904205,0.00026554067,0.00015643882],"domain_scores_gemma":[0.997165,0.0016190755,0.0005737752,0.00010623212,0.00020898753,0.0003269182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008422005,0.000086025546,0.0007413079,0.000056362755,0.000036555837,0.000004939102,0.000068431575,0.00011619237,0.00016832082],"category_scores_gemma":[0.0022636056,0.00005913897,0.0005177135,0.000075735166,0.00010705132,0.000059625025,0.000034101784,0.0002818492,0.000016433863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010786432,0.006503022,0.9113804,0.00016183584,0.0007498106,0.0017822694,0.000057364028,0.0012030766,0.0018561007,0.0043569086,0.021103945,0.04005881],"study_design_scores_gemma":[0.0066613513,0.004413808,0.94467664,0.00013072512,0.0009575102,0.00025848227,0.000062974614,0.014324452,0.0002098782,0.006613165,0.02158028,0.00011073369],"about_ca_topic_score_codex":0.000002882211,"about_ca_topic_score_gemma":0.00002678969,"teacher_disagreement_score":0.039948076,"about_ca_system_score_codex":0.000092542796,"about_ca_system_score_gemma":0.0012537246,"threshold_uncertainty_score":0.2709911},"labels":[],"label_agreement":null},{"id":"W3166956800","doi":"10.1200/jco.2021.39.15_suppl.e17056","title":"Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with metastatic prostate cancer: A real-world, population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Interquartile range; Cancer; Internal medicine; Cancer registry; Population; Proportional hazards model; Oncology; Radiation therapy; Comorbidity; Disease","score_opus":0.13442533197162196,"score_gpt":0.476342423185486,"score_spread":0.34191709121386404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166956800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779755,0.0002911361,0.00001105547,0.0008998605,0.00010204496,0.0007482093,0.00010667386,0.0000039281185,0.000039532464],"genre_scores_gemma":[0.998829,0.00028719328,0.0005080016,0.0000427599,0.000052234154,0.00003703512,0.000059328173,0.00001639,0.00016802529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970913,0.00068702357,0.0011610365,0.00021886018,0.00064909866,0.00019265883],"domain_scores_gemma":[0.9969247,0.0011467739,0.00080888596,0.0001943165,0.00065880973,0.00026651283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010237518,0.00014231198,0.0016471036,0.00014841516,0.00004317875,0.000009926464,0.000043115117,0.000040773408,0.000015744263],"category_scores_gemma":[0.00060023885,0.000078644814,0.00024700098,0.00024147383,0.000056074878,0.000071423856,0.000019852465,0.00025602346,1.4413294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00628815,0.0058957846,0.96886957,0.000060788105,0.0038482342,0.0007970095,0.00020848424,0.0007948339,1.9360307e-7,0.0000029357707,0.0000016945181,0.013232338],"study_design_scores_gemma":[0.03222561,0.009443635,0.9555465,0.00018259496,0.0022556442,0.0000012403804,0.00016777914,0.00005411721,0.000003695971,0.0000114944805,0.000036016885,0.00007166813],"about_ca_topic_score_codex":0.003211636,"about_ca_topic_score_gemma":0.010332527,"teacher_disagreement_score":0.025937459,"about_ca_system_score_codex":0.000530794,"about_ca_system_score_gemma":0.0024691785,"threshold_uncertainty_score":0.5765792},"labels":[],"label_agreement":null},{"id":"W3166977957","doi":"10.1200/jco.2021.39.15_suppl.10043","title":"Predicting decreased health-related quality of life (HRQL) in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta; University of Calgary","funders":"National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Logistic regression; Quality of life (healthcare); Demography; Confidence interval; Gerontology; Educational attainment; Childhood cancer; Cancer; Internal medicine","score_opus":0.12450245074063802,"score_gpt":0.4746957799865248,"score_spread":0.35019332924588675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166977957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9367289,0.01402032,0.000018724784,0.044480767,0.003172864,0.0010881807,0.00019128324,0.000027566588,0.0002714134],"genre_scores_gemma":[0.9843721,0.0047543375,0.0004743515,0.0084648905,0.001753934,0.000034143064,0.000032757278,0.00006529499,0.000048212445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97097427,0.008980206,0.016537217,0.0008128015,0.002053785,0.0006417012],"domain_scores_gemma":[0.9635978,0.015192069,0.016438706,0.0012117131,0.0025294002,0.0010303282],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024795363,0.00045008986,0.006614661,0.00021249932,0.00011331717,0.000014761068,0.0006644128,0.0006720726,0.0005919652],"category_scores_gemma":[0.060875442,0.00033400283,0.0013254655,0.0011210045,0.0004590924,0.00020755838,0.00026165997,0.0030510018,0.0000021474677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034430567,0.014654734,0.9563539,0.00016241027,0.0029805393,0.00046403872,0.009166341,0.00011329324,0.000039213122,0.000016081149,0.0015942943,0.011012075],"study_design_scores_gemma":[0.021126628,0.004187426,0.96167904,0.0014897214,0.0006584392,0.00015816555,0.009379541,0.00004382986,0.000080272555,0.00014708955,0.00080320076,0.00024665214],"about_ca_topic_score_codex":0.21114624,"about_ca_topic_score_gemma":0.30281872,"teacher_disagreement_score":0.091672465,"about_ca_system_score_codex":0.0004473925,"about_ca_system_score_gemma":0.023898462,"threshold_uncertainty_score":0.9999112},"labels":[],"label_agreement":null},{"id":"W3166983543","doi":"10.1200/jco.2021.39.15_suppl.4066","title":"Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Internal medicine; Cancer; Interim analysis; Quality of life (healthcare); Interim; Randomized controlled trial; Gastroenterology; Nivolumab; Oncology; Immunotherapy","score_opus":0.118919829687064,"score_gpt":0.44009199661064907,"score_spread":0.3211721669235851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166983543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890541,0.0025773356,0.00010616221,0.004900952,0.0026774267,0.00045485274,0.000078506164,0.000013908067,0.00013677328],"genre_scores_gemma":[0.9928725,0.0028483083,0.002330979,0.0010351652,0.00048864086,0.00001267062,0.00004383042,0.00003556337,0.0003323748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99202526,0.000740767,0.0055164783,0.0004667941,0.0008034394,0.00044728193],"domain_scores_gemma":[0.990937,0.0011539153,0.006225779,0.00037525553,0.00087678764,0.00043124805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019124277,0.0003005233,0.0034193704,0.00028824297,0.000036772664,0.000008256391,0.00025938326,0.00032263473,0.0003917542],"category_scores_gemma":[0.0019202961,0.00022310491,0.00045533184,0.0007901365,0.0002400493,0.00019922575,0.00009814112,0.001074385,0.000001958275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.248697,0.001897752,0.5844314,0.0001917959,0.0011320984,0.0002181878,0.00045377747,0.00052617677,0.000041727595,0.0000051235356,0.0016213534,0.16078359],"study_design_scores_gemma":[0.121877015,0.020011283,0.8560976,0.0004416667,0.00028970634,0.000009223154,0.00039240211,0.00012983102,0.0000917388,0.000010601875,0.0005321545,0.00011682161],"about_ca_topic_score_codex":0.0046866722,"about_ca_topic_score_gemma":0.005219495,"teacher_disagreement_score":0.27166614,"about_ca_system_score_codex":0.00124863,"about_ca_system_score_gemma":0.0055345926,"threshold_uncertainty_score":0.98181295},"labels":[],"label_agreement":null},{"id":"W3166998794","doi":"10.1200/jco.2021.39.15_suppl.6055","title":"Survival outcomes in primary head and neck adult sarcoma: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Sarcoma; Meta-analysis; Chondrosarcoma; Soft tissue sarcoma; Cochrane Library; MEDLINE; Head and neck; Systematic review; Rhabdomyosarcoma; Surgery; Internal medicine; Pathology","score_opus":0.32955253048554095,"score_gpt":0.538300608002466,"score_spread":0.2087480775169251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166998794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012638622,0.9923224,0.0000014859125,0.0057079736,0.00016885686,0.0014226824,0.00001827305,0.000003957333,0.00022800952],"genre_scores_gemma":[0.000045304387,0.9932467,0.0011330813,0.005137083,0.00009538554,0.00011299574,0.000019128753,0.000027664215,0.0001826729],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9871213,0.003607175,0.008081831,0.00044642205,0.0004944058,0.0002488941],"domain_scores_gemma":[0.9796373,0.013871457,0.0051168418,0.00049930025,0.00042706754,0.00044799276],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.006039344,0.0004887258,0.053056672,0.00038627998,0.000022968708,0.000020538824,0.00017248778,0.0006256256,0.000107794076],"category_scores_gemma":[0.009199604,0.00024154698,0.007934139,0.0005021545,0.0001252752,0.00005982127,0.00014310304,0.0013144461,0.000006717622],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031834836,0.0032533633,0.010750815,0.58245265,0.36054856,0.0047155283,0.000008895878,3.244678e-8,9.971828e-10,0.00006407479,0.00039519896,0.037779067],"study_design_scores_gemma":[0.0021031564,0.001347811,0.009005484,0.05724949,0.88146776,0.0013925292,0.000008785032,2.1505271e-7,2.2149496e-9,0.000010078743,0.047258057,0.00015665154],"about_ca_topic_score_codex":0.000021746799,"about_ca_topic_score_gemma":0.00016438794,"teacher_disagreement_score":0.52520317,"about_ca_system_score_codex":0.00022653036,"about_ca_system_score_gemma":0.0016583445,"threshold_uncertainty_score":0.99914634},"labels":[],"label_agreement":null},{"id":"W3167009795","doi":"10.1200/jco.2021.39.15_suppl.e18551","title":"Racial, ethnic, and socioeconomic disparities in diagnosis, treatment, and survival of patients with breast cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Brampton Civic Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Socioeconomic status; Cancer; Odds ratio; Proportional hazards model; Mastectomy; Internal medicine; Cancer registry; Gynecology; Population; Confidence interval; Environmental health","score_opus":0.1714050253180164,"score_gpt":0.48426790524861135,"score_spread":0.3128628799305949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167009795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910693,0.0036265843,0.0000024382507,0.0048313974,0.00022957395,0.00006724071,0.000024980813,0.0000011923688,0.00014726445],"genre_scores_gemma":[0.9826286,0.01625518,0.00021844836,0.0006411043,0.00022146669,0.000003878639,0.0000020307334,0.00000523734,0.000024096908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985999,0.00016709912,0.00088438997,0.00012035442,0.00010657562,0.00012168447],"domain_scores_gemma":[0.9979969,0.00094032276,0.0006058593,0.00006140207,0.00023725846,0.00015823827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058347196,0.00007925895,0.0010092481,0.00003842461,0.00001675753,0.000004760943,0.000033204953,0.00014428222,0.00008009879],"category_scores_gemma":[0.00031589624,0.000053690186,0.00008938804,0.00004521873,0.0002291242,0.000106762585,0.000026896189,0.00026588,3.2622097e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002223414,0.00044179877,0.89716655,0.000019830595,0.00013970945,0.000100992715,0.00009687457,0.000003823382,0.0000030475178,0.000030033349,0.00013100903,0.0996429],"study_design_scores_gemma":[0.007940373,0.004863166,0.9851141,0.00014791233,0.0001960295,0.00006368657,0.00024136982,0.0000052408805,0.0000145624535,0.00007703672,0.0012885181,0.00004799735],"about_ca_topic_score_codex":0.00037009458,"about_ca_topic_score_gemma":0.004151314,"teacher_disagreement_score":0.099594906,"about_ca_system_score_codex":0.00013063592,"about_ca_system_score_gemma":0.0009834912,"threshold_uncertainty_score":0.23165305},"labels":[],"label_agreement":null},{"id":"W3167046238","doi":"10.1200/jco.2021.39.15_suppl.6074","title":"Efficacy of selpercatinib after prior systemic therapy in patients with <i>RET</i> mutant medullary thyroid cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eli Lilly and Company","keywords":"Medicine; Medullary thyroid cancer; Cabozantinib; Vandetanib; Internal medicine; Oncology; Thyroid cancer; Cancer; Context (archaeology); Tyrosine kinase","score_opus":0.036999834271307944,"score_gpt":0.4385540106506166,"score_spread":0.4015541763793087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167046238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287,0.0034382772,0.000009216862,0.0022971076,0.00057005254,0.00033555066,0.000012979963,0.000003691374,0.00046316953],"genre_scores_gemma":[0.9948224,0.0022810285,0.0009667803,0.0015294258,0.00027840456,0.000016328115,0.0000060690945,0.000016592936,0.00008301135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974649,0.00025721744,0.001621599,0.00016385267,0.0003345028,0.00015791372],"domain_scores_gemma":[0.9971261,0.00072906946,0.0010324633,0.00018219526,0.00074928475,0.00018090542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056278484,0.00011580145,0.0011436961,0.00007281874,0.000016234582,0.000003925704,0.00007694891,0.0001788067,0.00014111945],"category_scores_gemma":[0.0004803533,0.00006828802,0.00022527485,0.0001977443,0.00009850643,0.000067303685,0.000018507853,0.00043966755,0.00000247167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012248818,0.0044784816,0.8818846,0.000055168373,0.0008028161,0.00065284973,0.00059086835,0.000033806435,0.00022037442,0.000007553046,0.00020658279,0.09881809],"study_design_scores_gemma":[0.034974825,0.011250059,0.94846314,0.0006270728,0.0004605341,0.00013354504,0.00015939523,0.000005580508,0.00025244855,0.000011441601,0.003591752,0.000070230155],"about_ca_topic_score_codex":0.000027584309,"about_ca_topic_score_gemma":0.000059196926,"teacher_disagreement_score":0.098747864,"about_ca_system_score_codex":0.00023583444,"about_ca_system_score_gemma":0.0038678395,"threshold_uncertainty_score":0.6861381},"labels":[],"label_agreement":null},{"id":"W3167056942","doi":"10.1200/jco.2021.39.15_suppl.e23508","title":"Overall survival after perioperative chemotherapy in the management of pulmonary metastasis in osteosarcoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; Ottawa Hospital","funders":"","keywords":"Metastasectomy; Medicine; Osteosarcoma; Perioperative; Chemotherapy; Cochrane Library; Cohort; Internal medicine; Metastasis; Surgery; Oncology; Meta-analysis; Cancer; Pathology","score_opus":0.10680799679086721,"score_gpt":0.4504698477497219,"score_spread":0.34366185095885465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167056942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971896,0.0034052553,0.0000055866117,0.019835982,0.0002565857,0.00019745424,0.0000026136227,0.0000010927179,0.00439946],"genre_scores_gemma":[0.9894648,0.0045937453,0.002521015,0.0031777376,0.0001432922,0.00001882844,0.0000020096318,0.000008591762,0.00006995127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969936,0.000782846,0.0015805741,0.00015317947,0.00033233524,0.00015747143],"domain_scores_gemma":[0.9979302,0.0011943262,0.0004441142,0.00019694278,0.0001556716,0.00007869594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023383205,0.000109926856,0.0011297539,0.00008442203,0.000009761492,0.0000059560543,0.00011629313,0.00012566334,0.0003318044],"category_scores_gemma":[0.00015779126,0.000062669606,0.0004099336,0.00019241379,0.0000893152,0.00005509319,0.000042797154,0.00047642537,0.000004138885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003873085,0.011447127,0.7582825,0.00004787355,0.000824246,0.030440416,0.00053111603,0.000007859218,0.000038179143,0.0004932082,0.00010283217,0.19391157],"study_design_scores_gemma":[0.008731165,0.001702843,0.9731214,0.00016960064,0.0002512415,0.00035881207,0.0015276307,0.000014489876,0.0001180989,0.00018741263,0.013766698,0.00005060816],"about_ca_topic_score_codex":0.000019059236,"about_ca_topic_score_gemma":0.00008597251,"teacher_disagreement_score":0.21483892,"about_ca_system_score_codex":0.00010765012,"about_ca_system_score_gemma":0.00032829205,"threshold_uncertainty_score":0.36330253},"labels":[],"label_agreement":null},{"id":"W3167076087","doi":"10.1200/jco.2021.39.15_suppl.1061","title":"Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Taxane; Capecitabine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Breast cancer; Phases of clinical research; Cancer; Oncology; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.09543072615978272,"score_gpt":0.4480371251360116,"score_spread":0.3526063989762289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167076087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526423,0.00053550786,0.000005772586,0.0019620813,0.00022685941,0.0012901543,0.0006492377,0.000006538174,0.000059628925],"genre_scores_gemma":[0.99636143,0.0006025708,0.0021372908,0.00032515975,0.00019297093,0.0000643115,0.00012760618,0.000030470135,0.00015816878],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943443,0.0009772928,0.003324919,0.00042111002,0.00063970994,0.00029268744],"domain_scores_gemma":[0.99073356,0.0026280296,0.0038742332,0.00026737704,0.002157604,0.00033916766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010521071,0.0002858169,0.002701074,0.00022040564,0.000026985303,0.0000058712835,0.00016007153,0.00016786395,0.00030032135],"category_scores_gemma":[0.00149394,0.00018381426,0.00023030804,0.00047196704,0.00024994236,0.00013575183,0.000049985916,0.0006896633,0.0000017556497],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5780258,0.151164,0.191504,0.0000903681,0.0055013704,0.0018500346,0.0025921108,0.00014667404,0.007895494,8.4123064e-7,0.0010642617,0.060165007],"study_design_scores_gemma":[0.38213924,0.097882666,0.51361585,0.0005102498,0.0027749457,0.00007995862,0.0011734997,0.00027494482,0.0009828092,0.0000012730114,0.00040907727,0.00015546856],"about_ca_topic_score_codex":0.0026430213,"about_ca_topic_score_gemma":0.003081654,"teacher_disagreement_score":0.32211185,"about_ca_system_score_codex":0.00053136586,"about_ca_system_score_gemma":0.0023428595,"threshold_uncertainty_score":0.7495728},"labels":[],"label_agreement":null},{"id":"W3167082767","doi":"10.1200/jco.2021.39.15_suppl.3591","title":"Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health","keywords":"Medicine; Adiponectin; Internal medicine; Oncology; Colorectal cancer; KRAS; Vitamin D and neurology; Body mass index; Cancer; Gastroenterology; Insulin resistance; Obesity","score_opus":0.022941224135577597,"score_gpt":0.3441339748518466,"score_spread":0.321192750716269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167082767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996415,0.0006827701,0.000025172141,0.0002858761,0.0021988077,0.00009611062,0.000020346288,0.0000014006811,0.0002744864],"genre_scores_gemma":[0.9943176,0.001504674,0.000987027,0.0003559475,0.0024123834,0.0000054874904,0.0000099144845,0.000014456018,0.0003924984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804115,0.00032802272,0.000991413,0.00020123848,0.00024838347,0.00018975993],"domain_scores_gemma":[0.9971301,0.0003709402,0.0016564087,0.000104067265,0.0006239561,0.00011453098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001171901,0.00011592591,0.00078659196,0.000030569445,0.000026791982,0.000009346772,0.00008689824,0.00022141363,0.000020934178],"category_scores_gemma":[0.0012099558,0.00008760518,0.000087296656,0.00010710142,0.00009148077,0.0000135901155,0.000041235286,0.0002874239,2.2440457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058712037,0.00048228982,0.977748,0.000029522762,0.00033957668,0.0000052160026,0.00008065273,0.00034064328,0.00545691,0.000011771127,0.0010818073,0.0085524535],"study_design_scores_gemma":[0.02055805,0.005465672,0.8368246,0.000112655136,0.00017069088,0.000014867519,0.0002589789,0.000034545024,0.0060408167,0.0000071452914,0.13034043,0.00017154562],"about_ca_topic_score_codex":0.00010105589,"about_ca_topic_score_gemma":0.004186834,"teacher_disagreement_score":0.14092334,"about_ca_system_score_codex":0.00010110512,"about_ca_system_score_gemma":0.0019317488,"threshold_uncertainty_score":0.35724354},"labels":[],"label_agreement":null},{"id":"W3167094271","doi":"10.1200/jco.2021.39.15_suppl.3559","title":"Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Regorafenib; TIGIT; Colorectal cancer; Oncology; Clinical endpoint; Bevacizumab; Internal medicine; Immune checkpoint; Cancer research; Cancer; Clinical trial; Immunotherapy; Nivolumab; Chemotherapy","score_opus":0.18330794189422442,"score_gpt":0.5130975292467511,"score_spread":0.3297895873525267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167094271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691339,0.020286942,0.000085385785,0.0055821217,0.002033174,0.0016994188,0.0000528965,0.000011890445,0.0011142499],"genre_scores_gemma":[0.9784832,0.013508645,0.005115125,0.0015463511,0.00042251055,0.0001005239,0.0000541968,0.00005786766,0.000711599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9870793,0.0040445486,0.0065296446,0.0005650803,0.0012009686,0.00058043684],"domain_scores_gemma":[0.98824674,0.0035869547,0.004667187,0.00046575975,0.0026425964,0.00039077015],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.022237824,0.0003996798,0.005230676,0.00034172848,0.00011013163,0.000046930916,0.0005492095,0.0005631651,0.0025129984],"category_scores_gemma":[0.0076635107,0.00030537395,0.0009341763,0.0008012995,0.0006942253,0.0004303687,0.00025322643,0.001275193,0.00001129556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6315868,0.012381565,0.0005819912,0.000118651384,0.0028984314,0.00062810536,0.0005546043,0.00006343538,0.11301452,0.00004667695,0.0019756753,0.23614955],"study_design_scores_gemma":[0.89482176,0.017513525,0.0016427165,0.000666925,0.003985633,0.0008030334,0.00039881712,0.0032310784,0.058225695,0.0007209884,0.017622495,0.00036730492],"about_ca_topic_score_codex":0.00080987107,"about_ca_topic_score_gemma":0.00064038346,"teacher_disagreement_score":0.263235,"about_ca_system_score_codex":0.001230854,"about_ca_system_score_gemma":0.014089893,"threshold_uncertainty_score":0.99993986},"labels":[],"label_agreement":null},{"id":"W3167096582","doi":"10.1200/jco.2021.39.15_suppl.10028","title":"Efficacy of clinical breast examination in chest-irradiated female survivors of childhood Hodgkin lymphoma (HL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; American Cancer Society","keywords":"Medicine; Breast cancer; Cohort; Population; Radiation therapy; Incidence (geometry); Pediatrics; Cancer; Internal medicine","score_opus":0.060200895519690184,"score_gpt":0.4137417909702146,"score_spread":0.35354089545052436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167096582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962769,0.0010965059,0.00003869587,0.00077515835,0.0008512761,0.00010138099,0.00002588438,0.0000024789342,0.0008317231],"genre_scores_gemma":[0.99596804,0.0017589413,0.0012688031,0.00019994288,0.00071400317,0.0000028990214,0.000028202156,0.000018048464,0.000041125248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99440295,0.0013937614,0.0034018748,0.00031929178,0.0002636153,0.00021849213],"domain_scores_gemma":[0.9948699,0.0014939416,0.002507272,0.00029614844,0.0006721648,0.00016057602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035673417,0.00017224676,0.0015749639,0.00009170255,0.000021189258,0.0000036413442,0.00024766437,0.00058273075,0.0000382092],"category_scores_gemma":[0.005294958,0.00014597965,0.0006195265,0.00024049754,0.00034905862,0.000010063264,0.00014675269,0.00030577544,0.0000026737644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020966092,0.0075123315,0.64166087,0.000026812899,0.0007387416,0.00011951867,0.00013108367,0.000051638213,0.0010783456,0.000027904678,0.00018817474,0.34636796],"study_design_scores_gemma":[0.012662836,0.0026941733,0.9789459,0.000075018186,0.00016539558,0.00020612478,0.00020029437,0.000008202405,0.002582889,0.000036443696,0.0023091366,0.000113566435],"about_ca_topic_score_codex":0.000083104846,"about_ca_topic_score_gemma":0.0005282764,"teacher_disagreement_score":0.34625438,"about_ca_system_score_codex":0.000049712995,"about_ca_system_score_gemma":0.0017116936,"threshold_uncertainty_score":0.6338942},"labels":[],"label_agreement":null},{"id":"W3167099310","doi":"10.1200/jco.2021.39.15_suppl.tps5087","title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup>Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Prostate cancer; Oncology; Hormonal therapy; Radionuclide therapy; Internal medicine; Androgen deprivation therapy; Cabazitaxel; Abiraterone acetate; Chemotherapy; Clinical trial; Cancer; Androgen receptor","score_opus":0.41269038254573515,"score_gpt":0.5696239092667471,"score_spread":0.15693352672101196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167099310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805463,0.01407815,0.000007850695,0.0029385278,0.00051104143,0.0014743442,0.00011154018,0.000016214422,0.00031602813],"genre_scores_gemma":[0.9788241,0.010429899,0.0039088577,0.0005166367,0.0015149504,0.00019770514,0.000023045213,0.00007007915,0.0045147617],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9926335,0.0018136372,0.00316093,0.0006411614,0.0009964048,0.0007543417],"domain_scores_gemma":[0.9945154,0.0015833562,0.0014259662,0.00044184655,0.0012695858,0.0007638155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027286925,0.00051234337,0.0026768402,0.00023324424,0.00017716085,0.000066570225,0.00014744596,0.00024075349,0.0015057295],"category_scores_gemma":[0.00045145967,0.00030367772,0.00091878616,0.0003893084,0.00026307857,0.00020592098,0.00006662141,0.00079575327,0.000018978302],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11470712,0.040869996,0.14787486,0.00013027148,0.018126687,0.07234017,0.0069253445,0.0024776007,0.007762697,0.000006054659,0.00042721632,0.58835196],"study_design_scores_gemma":[0.2130234,0.48470813,0.22889037,0.00085113756,0.0104392255,0.0041150884,0.014506958,0.00711261,0.008522282,0.00046541088,0.026297906,0.0010674712],"about_ca_topic_score_codex":0.00021140346,"about_ca_topic_score_gemma":0.00070218503,"teacher_disagreement_score":0.5872845,"about_ca_system_score_codex":0.002312071,"about_ca_system_score_gemma":0.010878177,"threshold_uncertainty_score":0.9999415},"labels":[],"label_agreement":null},{"id":"W3167111856","doi":"10.1200/jco.2020.39.28_suppl.154","title":"Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Conquer Cancer Foundation","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cancer; Oncology; Progressive disease; Disease; Gastrointestinal cancer; Colorectal cancer","score_opus":0.06667505428971564,"score_gpt":0.40258730955506233,"score_spread":0.3359122552653467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167111856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873164,0.00010839953,0.000010573579,0.011779326,0.00028294607,0.00042744222,0.0000074249633,0.0000044177395,0.00006304941],"genre_scores_gemma":[0.9951128,0.00015168918,0.0031434554,0.0013254895,0.00005758373,0.000019600737,0.0000027001738,0.000013190498,0.00017351139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737144,0.00047672915,0.0013028198,0.00025337454,0.00034247807,0.0002531562],"domain_scores_gemma":[0.99705386,0.001552508,0.0007359288,0.0001273753,0.00021603525,0.00031426759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014997378,0.0001676285,0.0013477633,0.0002640765,0.00001766685,0.000012119997,0.00004542429,0.000041241794,0.000051783933],"category_scores_gemma":[0.0030631092,0.00010830205,0.00008731788,0.00025330595,0.00009012594,0.00006454812,0.00006501402,0.000299855,4.1660041e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030280387,0.0010183272,0.91996384,0.00002829315,0.00022953429,0.004401223,0.00011474294,0.000011119102,0.000008983986,0.000001474502,0.000120109755,0.04382196],"study_design_scores_gemma":[0.022164345,0.02730492,0.9477482,0.00024905588,0.00033010618,0.00022850923,0.00049123017,0.00002010556,0.0000048385173,0.000007528118,0.0013730321,0.00007815617],"about_ca_topic_score_codex":0.00013132406,"about_ca_topic_score_gemma":0.00305189,"teacher_disagreement_score":0.043743804,"about_ca_system_score_codex":0.0003062521,"about_ca_system_score_gemma":0.000816465,"threshold_uncertainty_score":0.4416429},"labels":[],"label_agreement":null},{"id":"W3167115701","doi":"10.1200/jco.2021.39.15_suppl.10027","title":"Low-dose radiation to cardiac substructures and late-onset cardiac disease: A report from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Cumulative dose; Coronary artery disease; Cardiology; Internal medicine; Cumulative incidence; Radiation therapy; Heart failure; Cohort","score_opus":0.04641555106680829,"score_gpt":0.4222322378134983,"score_spread":0.37581668674669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167115701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97402656,0.008299178,0.000012303467,0.014261768,0.002720852,0.00051859464,0.00006942478,0.000009874974,0.00008141631],"genre_scores_gemma":[0.98802096,0.003730776,0.00011938272,0.0044500344,0.0034555697,0.000015593097,0.000029636243,0.000019717396,0.0001583222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672806,0.00097170525,0.0013560418,0.0002991536,0.0004690359,0.00017597816],"domain_scores_gemma":[0.9961815,0.0017743927,0.00077017385,0.00035618973,0.00042417776,0.00049359555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023309432,0.00015034559,0.0012920381,0.000044729444,0.000082725666,0.000027621061,0.00009315644,0.00022623157,0.00007879614],"category_scores_gemma":[0.0039689555,0.000100577534,0.00055303675,0.00020198585,0.00008419114,0.000093597555,0.00005108876,0.00073946576,0.0000028379436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016959903,0.00087589445,0.8512715,0.000012337744,0.0019352093,0.0013988261,0.0012888561,0.00004403009,0.0026551695,0.0000028784589,0.008168522,0.13065076],"study_design_scores_gemma":[0.0030642876,0.0007986639,0.95727944,0.00006815776,0.0010178542,0.00008284197,0.0004765542,0.0000037335205,0.0017097666,0.00010988445,0.035289213,0.00009962723],"about_ca_topic_score_codex":0.00019005984,"about_ca_topic_score_gemma":0.00018195708,"teacher_disagreement_score":0.13055113,"about_ca_system_score_codex":0.00013171988,"about_ca_system_score_gemma":0.0020748165,"threshold_uncertainty_score":0.47514972},"labels":[],"label_agreement":null},{"id":"W3167119435","doi":"10.1200/jco.2021.39.15_suppl.e16169","title":"Computational extraction and analysis of de-identified medical records to characterize hyperammonemia in patients with fibrolamellar carcinoma (FLC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Hyperammonemia; Medicine; Internal medicine; Context (archaeology); Everolimus; Incidence (geometry); Oncology; Cancer; Gastroenterology","score_opus":0.03433985110914035,"score_gpt":0.4078413049839669,"score_spread":0.3735014538748266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167119435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900007,0.00006369179,0.0029847862,0.006493986,0.00027710394,0.000060848983,0.0000025219624,0.0000023314528,0.000114015085],"genre_scores_gemma":[0.9819347,0.000083392704,0.01588665,0.0018502728,0.00018033528,7.544391e-7,0.00002375355,0.000008090936,0.000032032793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732053,0.00037135478,0.0014694374,0.00016295892,0.0005367219,0.00013901868],"domain_scores_gemma":[0.9967156,0.0015727328,0.0007151076,0.00009215639,0.0004642048,0.0004401793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026685533,0.00007839458,0.0011351157,0.00028487493,0.000018103048,0.000008457162,0.00006999719,0.00021521159,0.00017619049],"category_scores_gemma":[0.006592498,0.00005901824,0.00017734052,0.0004087306,0.00010771409,0.00005999218,0.000035853882,0.00091087044,8.4125423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016669596,0.00069316546,0.90761936,0.000022317348,0.00045717988,0.0005262238,0.00009085368,0.00035005712,0.00010489239,0.000011229335,0.00014256283,0.088315226],"study_design_scores_gemma":[0.004907298,0.0017094003,0.97962683,0.000104667575,0.0007015397,0.00014599517,0.000034723264,0.011152412,0.000015610613,0.000034805103,0.0015149235,0.000051790365],"about_ca_topic_score_codex":0.000040274812,"about_ca_topic_score_gemma":0.000032667118,"teacher_disagreement_score":0.08826343,"about_ca_system_score_codex":0.00008675475,"about_ca_system_score_gemma":0.0012253035,"threshold_uncertainty_score":0.78923124},"labels":[],"label_agreement":null},{"id":"W3167163899","doi":"10.1200/jco.2021.39.15_suppl.2570","title":"Mega- and meta-analyses of fecal metagenomic studies in predicting response to immune checkpoint inhibitors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Metagenomics; Meta-analysis; Microbiome; Bacteroides thetaiotaomicron; Bacteroides; Medicine; Biology; Immune system; Computational biology; Microbiology; Immunology; Internal medicine; Bioinformatics; Genetics; Bacteria; Gene","score_opus":0.35430971938043715,"score_gpt":0.554297626154189,"score_spread":0.19998790677375183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167163899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97718334,0.018106917,0.000039434035,0.004157582,0.00036607828,0.0000797142,0.0000063096822,0.0000010120791,0.0000596208],"genre_scores_gemma":[0.9921764,0.00205819,0.0046062693,0.00067762716,0.00027113318,0.0000022823162,0.0000016451346,0.0000096486865,0.00019678606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99541193,0.0014208045,0.0026395556,0.0002282847,0.00011875313,0.0001806983],"domain_scores_gemma":[0.99720955,0.0008412768,0.0011707735,0.00018540488,0.0004324362,0.00016056742],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007566518,0.00012414705,0.0017456944,0.00010314978,0.000028532584,0.000005382294,0.00012403999,0.00026062268,0.000024898578],"category_scores_gemma":[0.009474392,0.000088287976,0.00060794124,0.00012338626,0.0001702727,0.000005587252,0.0002292432,0.00037923316,8.8739006e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002720557,0.00032208118,0.0033888796,0.000035568457,0.003279832,0.00013216343,0.00017868594,0.000056408557,0.98838323,0.0000041083817,0.00037607027,0.0011223833],"study_design_scores_gemma":[0.0065756054,0.014334449,0.22703741,0.00007014836,0.0071970457,0.00069900695,0.002249886,0.000011093506,0.69504184,0.00016561548,0.04630972,0.00030815075],"about_ca_topic_score_codex":0.000019199657,"about_ca_topic_score_gemma":0.00012057519,"teacher_disagreement_score":0.2933414,"about_ca_system_score_codex":0.00004035253,"about_ca_system_score_gemma":0.0010197045,"threshold_uncertainty_score":0.99886924},"labels":[],"label_agreement":null},{"id":"W3167185898","doi":"10.1200/jco.2021.39.15_suppl.e18044","title":"Association of tumor volume and outcomes in T3 larynx cancer with organ preservation approach.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Calgary; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Toronto","funders":"","keywords":"Medicine; Larynx; Laryngectomy; Radiation therapy; Cancer; Glottis; Proportional hazards model; Retrospective cohort study; Cohort; Clinical endpoint; Primary tumor; Oncology; Surgery; Internal medicine; Clinical trial; Metastasis","score_opus":0.10041671915602585,"score_gpt":0.4516976489824816,"score_spread":0.35128092982645576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167185898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97155005,0.0008319944,0.00003075077,0.025796399,0.000226222,0.00007558593,0.000002458273,0.0000021742471,0.0014843752],"genre_scores_gemma":[0.9917833,0.0013595765,0.0030904175,0.0017351425,0.0002836345,0.000004018697,0.0000011931677,0.000007159737,0.0017355207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983483,0.0002006491,0.0010139113,0.000095851196,0.00023733742,0.00010397387],"domain_scores_gemma":[0.9976648,0.000730599,0.0009445022,0.00006231585,0.0005138744,0.000083887164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014877133,0.000058312486,0.0011577713,0.000047161466,0.000013564099,0.0000026391363,0.000034011722,0.00012222207,0.000043502296],"category_scores_gemma":[0.003481165,0.000037672693,0.00008190903,0.00013282889,0.000051088635,0.000090787595,0.00002687515,0.0004112102,4.305113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006633102,0.0006549252,0.9887465,0.000064058426,0.0002917275,0.00009557081,0.00020467199,0.000008439352,0.000093443385,0.000017674467,0.0020661,0.0070935683],"study_design_scores_gemma":[0.0055866716,0.0025278027,0.97282755,0.000100880265,0.00019201999,0.000035978115,0.00021772111,0.00009266886,0.00007090897,0.00004072269,0.01827081,0.000036276277],"about_ca_topic_score_codex":0.0000661528,"about_ca_topic_score_gemma":0.00063737284,"teacher_disagreement_score":0.024061257,"about_ca_system_score_codex":0.00014749652,"about_ca_system_score_gemma":0.0011846854,"threshold_uncertainty_score":0.4167531},"labels":[],"label_agreement":null},{"id":"W3167215844","doi":"10.1200/jco.2021.39.15_suppl.12101","title":"The effectiveness of a provincial symptom assessment program in reaching adolescents and young adults with cancer: A population-based cohort study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Hospital for Sick Children","funders":"Terry Fox Research Institute","keywords":"Medicine; Cancer; Logistic regression; Population; Young adult; Cohort; Family medicine; Gerontology; Demography; Internal medicine; Environmental health","score_opus":0.02747475694233396,"score_gpt":0.43712720194224763,"score_spread":0.40965244499991366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167215844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974831,0.00026976396,0.000037706068,0.0003471247,0.00070729665,0.0009702157,0.0000021434103,0.0000046365003,0.00017801982],"genre_scores_gemma":[0.99926054,0.00011014362,0.00023615515,0.000084501306,0.00022501516,0.00006527786,0.0000027669334,0.000009840709,0.0000057382845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662566,0.0015600579,0.0010807872,0.00017471844,0.0004215644,0.00013720173],"domain_scores_gemma":[0.9969017,0.0015396678,0.0007929303,0.0001347303,0.00051000516,0.00012097863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048334296,0.000093303046,0.0009270711,0.000051194973,0.00004212855,0.000011778126,0.000068728405,0.00012068637,0.0000029879125],"category_scores_gemma":[0.0010306137,0.000054579818,0.00012521597,0.00016833033,0.000077323915,0.000043118955,0.000028469412,0.00069621374,4.311639e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0111357905,0.0022560284,0.8661761,0.00018766185,0.00016674011,0.00026179312,0.00014087533,0.00001906033,0.000007840856,0.000009955795,0.000002518219,0.11963559],"study_design_scores_gemma":[0.010194597,0.009021528,0.97795063,0.0015300952,0.000296688,0.000040918087,0.00057952513,0.00018314824,0.000008517751,0.000014301813,0.00012637724,0.000053679643],"about_ca_topic_score_codex":0.00332127,"about_ca_topic_score_gemma":0.05482191,"teacher_disagreement_score":0.119581915,"about_ca_system_score_codex":0.00032165996,"about_ca_system_score_gemma":0.0027998756,"threshold_uncertainty_score":0.9624251},"labels":[],"label_agreement":null},{"id":"W3167298412","doi":"10.1200/jco.2021.39.15_suppl.10033","title":"Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Leukemia; Childhood leukemia; Cancer research; Apoptosis; Oncology; Immunology; Internal medicine; Biology; Lymphoblastic Leukemia","score_opus":0.1278196523602415,"score_gpt":0.4724181942432934,"score_spread":0.3445985418830519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167298412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796297,0.0012385523,0.000023196375,0.011240141,0.0016541574,0.00030362216,0.0000038738385,0.00000517287,0.0059015704],"genre_scores_gemma":[0.99194676,0.0013770796,0.0015895682,0.0030018897,0.0017273384,0.0000030116773,0.0000030754761,0.00002085796,0.00033041643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9922129,0.002541754,0.0031112507,0.0002778625,0.0016103208,0.00024593296],"domain_scores_gemma":[0.98492557,0.009577375,0.0021023417,0.0004579001,0.0025094226,0.00042738102],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013578801,0.00013976553,0.0013325482,0.00008765388,0.000051576968,0.000009217368,0.00022841287,0.0007359178,0.00014248653],"category_scores_gemma":[0.095439166,0.00008391486,0.0005524876,0.00024796132,0.00056654203,0.000114243965,0.0002433406,0.0020838054,0.0000107699525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068123043,0.006505273,0.086081855,0.0001644367,0.001728005,0.0009433526,0.0007052855,0.00017710094,0.007249729,0.00015114233,0.049135853,0.8403457],"study_design_scores_gemma":[0.043740757,0.007941667,0.89530414,0.00069313205,0.00153334,0.0013430051,0.000334872,0.0028700833,0.00213687,0.00083732797,0.04311598,0.00014883299],"about_ca_topic_score_codex":0.0000045795996,"about_ca_topic_score_gemma":0.000015345116,"teacher_disagreement_score":0.84019685,"about_ca_system_score_codex":0.0010396075,"about_ca_system_score_gemma":0.029892504,"threshold_uncertainty_score":0.9756071},"labels":[],"label_agreement":null},{"id":"W3167303800","doi":"10.1200/jco.2021.39.15_suppl.10020","title":"Low-dose metronomic topotecan and pazopanib in children with recurrent or refractory solid tumors: A C17 Canadian phase I trial (TOPAZ).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Children's Hospital; University of Calgary; Children's Hospital of Eastern Ontario; London Health Sciences Centre; Centre Hospitalier Universitaire Sainte-Justine; C17 Council; University of Toronto; BC Children's Hospital; SickKids Foundation; Hospital for Sick Children","funders":"Novartis","keywords":"Medicine; Pazopanib; Neutropenia; Internal medicine; Rhabdomyosarcoma; Topotecan; Adverse effect; Pharmacokinetics; Cmax; Febrile neutropenia; Gastroenterology; Oncology; Sarcoma; Surgery; Toxicity; Chemotherapy; Cancer; Sunitinib; Pathology","score_opus":0.10057012017225421,"score_gpt":0.4840360349547482,"score_spread":0.383465914782494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167303800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957328,0.00022504767,0.0000027326707,0.0028990342,0.00032495856,0.00041282887,0.00001332644,0.0000039289293,0.00038536562],"genre_scores_gemma":[0.9971371,0.00057978666,0.00054423924,0.0007114751,0.00082090654,0.00000819905,0.000008205,0.000018533163,0.00017152431],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99703586,0.0005805566,0.0014261168,0.0002740212,0.00028083276,0.0004026],"domain_scores_gemma":[0.9969139,0.0007907948,0.0005986586,0.00019732524,0.00020271273,0.0012966007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013306534,0.00015284192,0.0013134114,0.00029331128,0.000041993397,0.000018883615,0.000108567,0.00018019161,0.00022129061],"category_scores_gemma":[0.0030937085,0.00009844173,0.00018259978,0.00019081827,0.0001711419,0.00010736714,0.00004205982,0.0012506982,0.000010218688],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36191472,0.014790831,0.05935489,0.00003191367,0.0011878632,0.035700515,0.00010250822,0.0000028970487,0.0003106816,0.000016310993,0.0014216689,0.5251652],"study_design_scores_gemma":[0.39809832,0.16027671,0.42619255,0.00034696248,0.0003997291,0.0055959933,0.00015853884,0.00004626646,0.0004305115,0.00006079248,0.00819907,0.00019457928],"about_ca_topic_score_codex":0.00109669,"about_ca_topic_score_gemma":0.038589343,"teacher_disagreement_score":0.5249706,"about_ca_system_score_codex":0.00048693753,"about_ca_system_score_gemma":0.011813749,"threshold_uncertainty_score":0.99378836},"labels":[],"label_agreement":null},{"id":"W3167315086","doi":"10.1200/jco.2021.39.15_suppl.e19540","title":"First-line treatment with Bendamustine plus Rituximab for patients with indolent non-Hodgkin’s lymphoma or Mantle cell lymphoma: Real-world experience.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Western University; Barrie Urology Group","funders":"","keywords":"Medicine; Bendamustine; Rituximab; Mantle cell lymphoma; Follicular lymphoma; Lymphoplasmacytic Lymphoma; Internal medicine; Lymphoma; Marginal zone B-cell lymphoma; Gastroenterology; B symptoms; Malignancy; Surgery; Oncology; Waldenstrom macroglobulinemia; B cell; Immunology; Marginal zone; Antibody","score_opus":0.0777758476360086,"score_gpt":0.4087968008083785,"score_spread":0.3310209531723699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167315086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279803,0.0003030109,0.0001774504,0.0027081026,0.0008088995,0.0009219675,0.000048470214,0.000018459865,0.0022155826],"genre_scores_gemma":[0.9781809,0.0021504988,0.015162945,0.0011597687,0.00091685785,0.00017496121,0.000060772472,0.000057566598,0.00213574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959667,0.00014554408,0.002197021,0.00053964683,0.0006261481,0.0005249628],"domain_scores_gemma":[0.9938067,0.0021392535,0.0017673139,0.00045256526,0.001122424,0.00071173545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004497062,0.00042740162,0.0025754066,0.00016728269,0.0001470759,0.000029067218,0.0001673372,0.00028898258,0.0002206225],"category_scores_gemma":[0.00032047034,0.0002203118,0.0005583152,0.00031848153,0.00022156865,0.00014138142,0.000067786816,0.0001432584,0.000018524555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080063485,0.11027028,0.49622476,0.00018275793,0.0019325607,0.010672271,0.00086536905,0.00008036305,0.0000063394446,0.000047846268,0.0026856612,0.2969683],"study_design_scores_gemma":[0.2525539,0.10864842,0.5074769,0.00044320954,0.0018052863,0.00053657923,0.00034633212,0.00016700731,0.0009367895,0.000015298108,0.12678368,0.00028657482],"about_ca_topic_score_codex":0.00019734903,"about_ca_topic_score_gemma":0.0019072671,"teacher_disagreement_score":0.29668173,"about_ca_system_score_codex":0.0018701436,"about_ca_system_score_gemma":0.0055677323,"threshold_uncertainty_score":0.9876918},"labels":[],"label_agreement":null},{"id":"W3167330796","doi":"10.1200/jco.2021.39.15_suppl.e16083","title":"Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and curative esophagectomy: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Neoadjuvant therapy; Esophageal cancer; Esophagectomy; Adjuvant therapy; Meta-analysis; Internal medicine; Radiation therapy; Subgroup analysis; Oncology; Chemoradiotherapy; Surgery; Grading (engineering); Cancer; Breast cancer","score_opus":0.21730899064774092,"score_gpt":0.5294928982143985,"score_spread":0.3121839075666576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167330796","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067403424,0.995585,7.409191e-7,0.0005512302,0.000073428964,0.0029908079,0.0000977847,0.000002844878,0.000024121133],"genre_scores_gemma":[0.005737199,0.9919828,0.00017069912,0.0013118605,0.00009648623,0.0005387545,0.000020114463,0.000037095873,0.000104967185],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9889371,0.00371913,0.0057653915,0.0005098279,0.00073227275,0.00033630812],"domain_scores_gemma":[0.990467,0.0027988367,0.0049144346,0.00041629322,0.00088541687,0.00051801105],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003794912,0.000542045,0.028035726,0.00048226002,0.000023969213,0.00001723314,0.00021255437,0.00049612654,0.00052542187],"category_scores_gemma":[0.0011265695,0.000268347,0.0043876,0.00072118104,0.000251345,0.00011452071,0.000099338315,0.0014622414,0.000002134294],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010264355,0.0036674622,0.0044311467,0.20845073,0.36824802,0.0026830228,0.00020849273,3.1281604e-7,3.8221376e-8,0.000014779974,0.00011153012,0.41115806],"study_design_scores_gemma":[0.008141966,0.016920954,0.010973814,0.054022342,0.89386535,0.00019150745,0.00003568517,0.000002998466,0.0000014476236,0.00006343531,0.015453962,0.00032656253],"about_ca_topic_score_codex":0.00006611913,"about_ca_topic_score_gemma":0.000089738314,"teacher_disagreement_score":0.5256173,"about_ca_system_score_codex":0.0002647583,"about_ca_system_score_gemma":0.0027128034,"threshold_uncertainty_score":0.9999769},"labels":[],"label_agreement":null},{"id":"W3167348704","doi":"10.1200/jco.2021.39.15_suppl.8548","title":"NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Carboplatin; Chemoradiotherapy; Radiation therapy; Oncology; Internal medicine; Lung cancer; Nuclear medicine; Clinical trial; Chemotherapy; Cisplatin","score_opus":0.13194428327960817,"score_gpt":0.5175746026962688,"score_spread":0.3856303194166606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167348704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94381565,0.00052937254,0.030831125,0.02037274,0.0023985647,0.0011649242,0.000108434986,0.000018039138,0.00076112803],"genre_scores_gemma":[0.942949,0.00054792763,0.05219444,0.0016108502,0.001963548,0.00002978984,0.00004878751,0.000047671994,0.0006080003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947511,0.0005659957,0.003116267,0.00046560753,0.0007010007,0.0004000082],"domain_scores_gemma":[0.99009115,0.005881163,0.0020227823,0.00031143453,0.0008350438,0.00085844117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040583243,0.00031021461,0.0031328222,0.00019900932,0.000106827356,0.00003022558,0.00017256963,0.00026996713,0.0001591424],"category_scores_gemma":[0.0073547685,0.0002354899,0.0008143223,0.00022275643,0.00037358477,0.00009109098,0.00004322446,0.00091736886,0.0000021072553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79080635,0.0054403525,0.0007618938,0.000059057733,0.001186409,0.0007504618,0.0006386589,0.0005223149,0.0010962351,0.00010804206,0.00400702,0.1946232],"study_design_scores_gemma":[0.7654048,0.08274998,0.0010047888,0.00025665373,0.0009846996,0.00010087865,0.00058650156,0.019031117,0.0012791503,0.00004888107,0.12832719,0.00022531654],"about_ca_topic_score_codex":0.000051414067,"about_ca_topic_score_gemma":0.000039784598,"teacher_disagreement_score":0.19439788,"about_ca_system_score_codex":0.00047880734,"about_ca_system_score_gemma":0.003771428,"threshold_uncertainty_score":0.96029997},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3167362023","doi":"10.1200/jco.2021.39.15_suppl.10031","title":"Forecasting asparaginase quantity required to treat pediatric ALL in LMICs using ACCESS FORxECAST.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Pediatric cancer; Blood cancer; Regimen; Asparaginase; Pediatric oncology; Incidence (geometry); Pediatrics; Intensive care medicine; Lymphoblastic Leukemia; Cancer; Internal medicine; Leukemia","score_opus":0.521018095501978,"score_gpt":0.572379110597152,"score_spread":0.05136101509517399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167362023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886644,0.00033367242,0.0024550497,0.006184708,0.0009231592,0.00021763408,0.0000035725384,0.000007947717,0.0012098685],"genre_scores_gemma":[0.9717739,0.000537118,0.021871466,0.003137164,0.002473177,0.000002683862,0.0000028010847,0.000032796263,0.00016887789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99496967,0.0006425744,0.0028238292,0.00034193211,0.00066243805,0.0005595787],"domain_scores_gemma":[0.99203163,0.0046700556,0.0011232515,0.00030563583,0.001021655,0.0008477611],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0044942484,0.00017825543,0.0016705549,0.0004249701,0.000042436466,0.000038749444,0.00034944326,0.0004810051,0.000108684006],"category_scores_gemma":[0.027305914,0.0001437867,0.00040140128,0.00084576,0.00010030908,0.00032300607,0.00036973107,0.0012996661,0.000017685694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010807514,0.0041395463,0.81345004,0.00040297827,0.0002594134,0.07132437,0.0003509369,0.0022172343,0.0014554209,0.00008411911,0.0097377105,0.08577069],"study_design_scores_gemma":[0.123094715,0.042472243,0.59861636,0.0016613979,0.0044950764,0.043768745,0.0012090872,0.14266707,0.003265628,0.0024875582,0.03479241,0.0014697419],"about_ca_topic_score_codex":0.00011596602,"about_ca_topic_score_gemma":0.00022944498,"teacher_disagreement_score":0.21483374,"about_ca_system_score_codex":0.0015092638,"about_ca_system_score_gemma":0.010637787,"threshold_uncertainty_score":0.994971},"labels":[],"label_agreement":null},{"id":"W3167387657","doi":"10.1200/jco.2021.39.15_suppl.11522","title":"A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Urology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Immunohistochemistry; Oncology; Gastroenterology; Randomized controlled trial; Progressive disease; Chemotherapy; Confidence interval","score_opus":0.13899322669740014,"score_gpt":0.4789900451769662,"score_spread":0.3399968184795661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167387657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196297,0.00032615874,0.00007270301,0.0036568192,0.000889157,0.0013398881,0.0000080343025,0.000004626729,0.0017396585],"genre_scores_gemma":[0.9907949,0.0006976593,0.005250483,0.0020926986,0.00043933038,0.000024661973,0.000010578608,0.00002809159,0.00066161447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937716,0.00130596,0.0037549068,0.00027439036,0.00062147656,0.00027165897],"domain_scores_gemma":[0.99286157,0.0027541008,0.0029331155,0.00030596825,0.000892829,0.00025242518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006195168,0.00020765649,0.0039244406,0.00016469836,0.000047298803,0.00001701411,0.00029821126,0.0003315806,0.0005291115],"category_scores_gemma":[0.003728282,0.0001087409,0.00035451064,0.00046556132,0.00052430533,0.00019230461,0.00009523556,0.00084694166,0.0000014963194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8539688,0.0401809,0.0019397398,0.00003317645,0.001404136,0.0010711601,0.00014422084,7.990282e-7,0.00020101448,0.000016224905,0.0009877695,0.10005204],"study_design_scores_gemma":[0.7897825,0.19478038,0.0020289957,0.00042587967,0.0006504748,0.00025166053,0.00008799189,0.000022569644,0.00018948487,0.000032117,0.011633435,0.000114483635],"about_ca_topic_score_codex":0.00007490554,"about_ca_topic_score_gemma":0.000356968,"teacher_disagreement_score":0.15459947,"about_ca_system_score_codex":0.00017063656,"about_ca_system_score_gemma":0.005861959,"threshold_uncertainty_score":0.99977386},"labels":[],"label_agreement":null},{"id":"W3167422454","doi":"10.1200/jco.2021.39.15_suppl.tps2681","title":"Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Immunotherapy; Melanoma; Response Evaluation Criteria in Solid Tumors; Ipilimumab; Oncology; Internal medicine; Cabozantinib; Clinical trial; Cancer research; Phases of clinical research; Cancer","score_opus":0.09879509858647831,"score_gpt":0.4692649152665609,"score_spread":0.3704698166800826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167422454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905338,0.005181124,0.00015106767,0.0030852214,0.00020746514,0.00080727827,0.000020380687,0.0000020367002,0.000011614326],"genre_scores_gemma":[0.9909952,0.006215054,0.0020806515,0.00050583907,0.00015545922,0.0000137402585,0.0000019153306,0.000013543795,0.000018591532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969555,0.0005536759,0.0019669,0.00015761085,0.00021208583,0.00015419417],"domain_scores_gemma":[0.99077076,0.006852106,0.0017994996,0.00022878168,0.00026557513,0.00008326078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022673951,0.00013645375,0.0015567755,0.00006169911,0.000057285448,0.000006473196,0.00009996596,0.00006950941,0.000019949379],"category_scores_gemma":[0.0011315079,0.000060752955,0.00028956047,0.00020638971,0.0003921868,0.00006622277,0.0000125445495,0.00023790526,4.278143e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07356052,0.02539595,0.49425483,0.00010461985,0.005462096,0.0004290329,0.0031672122,0.0001397315,0.04226251,0.000010499291,0.00007298253,0.35514],"study_design_scores_gemma":[0.15200052,0.13058862,0.6845638,0.0003334281,0.0013691193,0.00048788884,0.006600583,0.0007537862,0.011926552,0.000020568343,0.0112279765,0.00012715797],"about_ca_topic_score_codex":0.000050547107,"about_ca_topic_score_gemma":0.00016812919,"teacher_disagreement_score":0.35501286,"about_ca_system_score_codex":0.000099138946,"about_ca_system_score_gemma":0.0010155931,"threshold_uncertainty_score":0.24774335},"labels":[],"label_agreement":null},{"id":"W3167468110","doi":"10.1200/jco.2021.39.15_suppl.e18791","title":"Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Trastuzumab; Stage (stratigraphy); Neoadjuvant therapy; Cancer; Multivariate analysis; Hormonal therapy","score_opus":0.07554557994226987,"score_gpt":0.46417011618723103,"score_spread":0.3886245362449612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167468110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863665,0.0010007855,0.00012016918,0.009332764,0.0011692841,0.00018859064,0.0005241463,0.0000034527818,0.0012943055],"genre_scores_gemma":[0.98872566,0.004901512,0.0025446233,0.0006256737,0.0010096002,0.00002591479,0.000025522435,0.00002338114,0.0021181053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978011,0.00022612518,0.0013294702,0.0002597787,0.00015225755,0.00023123788],"domain_scores_gemma":[0.9969472,0.00062029477,0.0012991106,0.0002182498,0.0007525909,0.00016253666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044360344,0.00018747571,0.0012737014,0.000044901935,0.000048742873,0.0000059592526,0.00013981784,0.0002146172,0.00004857102],"category_scores_gemma":[0.0003038022,0.00013176692,0.00079407403,0.00008033102,0.00017554143,0.000006764728,0.000078278565,0.0001400766,0.0000013461636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054357713,0.002966615,0.8668497,0.000022857812,0.0048005665,0.00020943773,0.0001336153,0.00006536297,0.0038586627,0.00027298077,0.0020850808,0.11329931],"study_design_scores_gemma":[0.007095873,0.0051735747,0.9478471,0.000041218773,0.00049744104,0.00006783379,0.0001363715,0.0000032416817,0.011455472,0.000080563594,0.027472625,0.00012864872],"about_ca_topic_score_codex":0.0006357389,"about_ca_topic_score_gemma":0.0027839474,"teacher_disagreement_score":0.11317066,"about_ca_system_score_codex":0.00016769336,"about_ca_system_score_gemma":0.0014749883,"threshold_uncertainty_score":0.5373299},"labels":[],"label_agreement":null},{"id":"W3167481271","doi":"10.1200/jco.2021.39.15_suppl.e19537","title":"Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Neutropenia; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Oncology; Toxicity","score_opus":0.04626106429265371,"score_gpt":0.4152705730423476,"score_spread":0.3690095087496939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167481271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695647,0.00041711357,0.000040439325,0.00041119175,0.00027746736,0.0005667679,0.00003711435,0.0000054125753,0.0012880339],"genre_scores_gemma":[0.99759156,0.0007298065,0.00018854164,0.00039229615,0.000100711106,0.0000027739225,0.000027400098,0.000035946825,0.00093096605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99228907,0.0018982979,0.0038599453,0.000415156,0.0011257664,0.00041175776],"domain_scores_gemma":[0.99242073,0.0024895233,0.0028752158,0.00072566274,0.001114473,0.00037439147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033774092,0.0002516124,0.0030385118,0.0004257621,0.00005661354,0.000009656336,0.0003619343,0.0003998045,0.0007449521],"category_scores_gemma":[0.002450545,0.00015966636,0.0007535116,0.001496139,0.00040554046,0.00011871236,0.00023988339,0.0011694562,0.0000023720274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11346769,0.26078573,0.5494288,0.0000763956,0.005709156,0.001510209,0.0014629823,0.00004097966,0.0024362407,0.000012465897,0.00045062014,0.06461869],"study_design_scores_gemma":[0.32351696,0.017968927,0.6483046,0.000075492506,0.0027843316,0.000049767354,0.0004895469,0.00026469026,0.00043234433,0.0000054455695,0.0059956834,0.00011224765],"about_ca_topic_score_codex":0.00008713536,"about_ca_topic_score_gemma":0.00048193816,"teacher_disagreement_score":0.24281679,"about_ca_system_score_codex":0.00040727973,"about_ca_system_score_gemma":0.002862236,"threshold_uncertainty_score":0.8156703},"labels":[],"label_agreement":null},{"id":"W3167482687","doi":"10.1200/jco.2021.39.15_suppl.12092","title":"Province-wide analysis of patient reported outcomes for stage IV non-small cell lung cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; University of Manitoba; Centre for Addiction and Mental Health; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Comorbidity; Lung cancer; Stage (stratigraphy); Depression (economics); Nausea; Anxiety; Cancer; Poisson regression; Internal medicine; Polypharmacy; Physical therapy; Population; Psychiatry","score_opus":0.07701379704352407,"score_gpt":0.4885437870052284,"score_spread":0.4115299899617043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167482687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989672,0.0007077289,0.0012820777,0.0050223605,0.00089090667,0.00037758524,0.000043157466,0.000004327784,0.0019998297],"genre_scores_gemma":[0.9831938,0.0005213107,0.009806312,0.00210704,0.00018824064,0.00002471626,0.000025324724,0.000014772314,0.004118451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967816,0.000108819986,0.0025193093,0.00018776188,0.00023852181,0.00016400186],"domain_scores_gemma":[0.99374634,0.0017868647,0.002893425,0.00022577344,0.0011180188,0.0002296056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072140025,0.000107763044,0.0017410949,0.0001566767,0.00003214746,0.000005072434,0.000067928195,0.00017713553,0.0001685563],"category_scores_gemma":[0.0020000595,0.000072142044,0.0010842681,0.00028278417,0.000056773693,0.000046210087,0.000028427492,0.00027172043,3.9096028e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080581725,0.0022199075,0.96489745,0.000112933434,0.010294305,0.0007571099,0.00024889526,0.00057327654,0.000117949916,0.000019599396,0.0021812315,0.017771514],"study_design_scores_gemma":[0.010032608,0.005125892,0.9056527,0.000088832385,0.029129276,0.000018570476,0.0005023511,0.0008826612,0.00080196786,0.000027122569,0.047640894,0.00009709826],"about_ca_topic_score_codex":0.00011289499,"about_ca_topic_score_gemma":0.0005418143,"teacher_disagreement_score":0.059244733,"about_ca_system_score_codex":0.00027706788,"about_ca_system_score_gemma":0.006112561,"threshold_uncertainty_score":0.99952185},"labels":[],"label_agreement":null},{"id":"W3167491954","doi":"10.1200/jco.2021.39.15_suppl.3126","title":"The value of defining molecular resistance in patients with progressive <i>EGFR</i> and <i>ALK</i>-driven lung cancer in a public system.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Osimertinib; T790M; Lung cancer; Internal medicine; Oncology; KRAS; Clinical trial; Cancer; Erlotinib; Epidermal growth factor receptor; Gefitinib","score_opus":0.022069826684956714,"score_gpt":0.42201902908191746,"score_spread":0.39994920239696075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167491954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814199,0.010606648,0.000022219381,0.0054006265,0.00022125321,0.00024344507,0.000008620093,0.0000021066458,0.0020751401],"genre_scores_gemma":[0.996852,0.00044332148,0.0022136595,0.00039032337,0.000041554154,0.000013899022,0.0000024535407,0.000009034753,0.000033764954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980611,0.00030981505,0.0010929746,0.00013074407,0.00025151065,0.00015382684],"domain_scores_gemma":[0.99760956,0.00070424884,0.0009250998,0.00011476963,0.00053215143,0.0001141993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006631232,0.00007595106,0.00067314855,0.000060105627,0.000030418343,0.000009907221,0.00006401726,0.000104295694,0.000004681216],"category_scores_gemma":[0.0007517822,0.00004325009,0.00008010506,0.00018691728,0.00013274541,0.000070525886,0.000028753933,0.00036873395,1.6425197e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012715334,0.0006419353,0.9872712,0.00010445917,0.00035850785,0.0008231809,0.00024594346,0.000051555144,0.000009980156,0.0017632334,0.00011428863,0.007344197],"study_design_scores_gemma":[0.014585226,0.0017801246,0.97719353,0.0015675928,0.0004117054,0.00004953092,0.00045993784,0.00009379514,0.00002173021,0.00006983407,0.003706935,0.000060037542],"about_ca_topic_score_codex":0.000020211486,"about_ca_topic_score_gemma":0.00055457396,"teacher_disagreement_score":0.015432049,"about_ca_system_score_codex":0.00027897305,"about_ca_system_score_gemma":0.0025194834,"threshold_uncertainty_score":0.44694555},"labels":[],"label_agreement":null},{"id":"W3167503877","doi":"10.1200/jco.2021.39.15_suppl.2027","title":"Real-world outcomes of breast cancer patients with brain metastases treated with radiotherapy in Ontario: A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Ottawa; University of Toronto","funders":"","keywords":"Medicine; Cumulative incidence; Radiation therapy; Population; Breast cancer; Clinical endpoint; Internal medicine; Incidence (geometry); Retrospective cohort study; Metastatic breast cancer; Oncology; Proportional hazards model; Cancer; Cohort; Clinical trial","score_opus":0.06208446927075798,"score_gpt":0.4310374588121331,"score_spread":0.3689529895413751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167503877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947128,0.00006305101,0.000017561906,0.0045644827,0.00011253385,0.00040950996,0.00003959447,0.0000044572353,0.000075988086],"genre_scores_gemma":[0.9929781,0.000020543264,0.0053749057,0.0012315621,0.000057111458,0.000011808257,0.000032689404,0.000020937765,0.00027236386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966675,0.00073417294,0.0017233538,0.00022115505,0.00047010824,0.00018371141],"domain_scores_gemma":[0.99578893,0.0017975733,0.0014160771,0.0002182928,0.0005653133,0.00021383842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010944399,0.00018603473,0.0020947221,0.00020677129,0.000022220189,0.000006248727,0.00006982586,0.00008820824,0.000610329],"category_scores_gemma":[0.00024333876,0.000099416815,0.00027119054,0.00034155548,0.000067777655,0.00006956562,0.0000106077905,0.00045726536,3.6837483e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011490634,0.015422477,0.95902824,0.000013428499,0.0022256311,0.001303461,0.00007454842,0.0002836116,0.000003132432,0.000010956465,0.000107877226,0.010035989],"study_design_scores_gemma":[0.04049625,0.016965777,0.94062436,0.00014925834,0.0010191654,0.000033845045,0.00008036445,0.000010719195,0.0000089741825,0.0000060552647,0.00051724893,0.00008800802],"about_ca_topic_score_codex":0.05811465,"about_ca_topic_score_gemma":0.541863,"teacher_disagreement_score":0.48374835,"about_ca_system_score_codex":0.0005727713,"about_ca_system_score_gemma":0.0030503545,"threshold_uncertainty_score":0.9481574},"labels":[],"label_agreement":null},{"id":"W3167506953","doi":"10.1200/jco.2021.39.15_suppl.6011","title":"Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Carboplatin; Clinical endpoint; Internal medicine; Oncology; Nivolumab; Head and neck cancer; Response Evaluation Criteria in Solid Tumors; Cetuximab; Radiation therapy; Cancer; Surgery; Clinical trial; Progressive disease; Chemotherapy; Cisplatin; Immunotherapy","score_opus":0.11907083903988791,"score_gpt":0.46383454051710116,"score_spread":0.34476370147721325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167506953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681957,0.011244095,0.00012630045,0.018206384,0.0012641249,0.00057440874,0.00010047799,0.000014717691,0.00027384172],"genre_scores_gemma":[0.97415227,0.01762492,0.002375381,0.0033676503,0.0010650238,0.000060082042,0.000010259821,0.0000367193,0.0013077116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99543065,0.0014907599,0.0019713067,0.00033402385,0.0003514159,0.00042186253],"domain_scores_gemma":[0.9894055,0.007184157,0.0016890048,0.00014274035,0.0010786626,0.00049993244],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049021156,0.0002299374,0.0025749572,0.00008122931,0.00022159168,0.000010924422,0.00011073802,0.000596981,0.00014744271],"category_scores_gemma":[0.0100491885,0.00017511219,0.0006665849,0.00020833733,0.00030922252,0.000082788676,0.00006504093,0.001066544,9.894188e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6831174,0.0042707548,0.018248776,0.000017555103,0.003062729,0.0006951337,0.0006517294,0.000010861219,0.0025088096,0.000018155793,0.1292264,0.15817171],"study_design_scores_gemma":[0.4156068,0.1603246,0.31033656,0.0002732818,0.0014284889,0.00026032169,0.0006870546,0.0011673239,0.00072414486,0.00035471606,0.108450696,0.00038600244],"about_ca_topic_score_codex":0.0001287813,"about_ca_topic_score_gemma":0.00019034864,"teacher_disagreement_score":0.2920878,"about_ca_system_score_codex":0.00047351798,"about_ca_system_score_gemma":0.005610426,"threshold_uncertainty_score":0.9982896},"labels":[],"label_agreement":null},{"id":"W3167507808","doi":"10.1200/jco.2021.39.15_suppl.9546","title":"KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Discontinuation; Quality of life (healthcare); Cohort; Interim; Interim analysis; Pembrolizumab; Population; Clinical endpoint; Cancer; Clinical trial; Internal medicine; Gerontology; Oncology","score_opus":0.12768831402553285,"score_gpt":0.4580371891146894,"score_spread":0.33034887508915656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167507808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334395,0.0010687138,0.00014762973,0.0026800528,0.00040739123,0.00092712435,0.000017611927,0.000013690561,0.0013938269],"genre_scores_gemma":[0.99135035,0.0006318037,0.0050359056,0.0011883167,0.00013077336,0.000013333975,0.000016763173,0.00007024504,0.0015625026],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9870793,0.0042608627,0.005848747,0.00055365474,0.0015592865,0.00069813686],"domain_scores_gemma":[0.9830357,0.009161285,0.0040689874,0.000596441,0.0019894382,0.0011481912],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004827642,0.00037113085,0.004183963,0.00031560854,0.00005486601,0.000015157672,0.00034257572,0.0004055651,0.0015548855],"category_scores_gemma":[0.008989393,0.0002174154,0.00044366546,0.0008759152,0.000526505,0.00012575954,0.000112656504,0.0027174274,0.000010273794],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6098757,0.01808645,0.13624163,0.0011760411,0.000599265,0.010808135,0.00073773635,0.0004613995,0.00039002163,0.00002137811,0.00055280695,0.22104947],"study_design_scores_gemma":[0.23846425,0.3145222,0.42772675,0.001034902,0.00063027046,0.0045239963,0.0015219958,0.000481761,0.0005719725,0.00008908595,0.009823082,0.0006097383],"about_ca_topic_score_codex":0.00020451905,"about_ca_topic_score_gemma":0.0020385887,"teacher_disagreement_score":0.3714114,"about_ca_system_score_codex":0.00077305443,"about_ca_system_score_gemma":0.020216106,"threshold_uncertainty_score":0.99958336},"labels":[],"label_agreement":null},{"id":"W3167509426","doi":"10.1200/jco.2021.39.15_suppl.4502","title":"Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Everolimus; Internal medicine; Nursing","score_opus":0.20489345872894418,"score_gpt":0.465467439747845,"score_spread":0.26057398101890084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167509426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288386,0.000939104,0.00018864735,0.0028535838,0.001069142,0.0011923348,0.00020761513,0.000010941546,0.00065479055],"genre_scores_gemma":[0.99317557,0.000367696,0.0043878537,0.0008490705,0.00064930064,0.000026753349,0.00028370463,0.00005300515,0.0002070516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98737764,0.002954961,0.007372707,0.00055259955,0.0012057732,0.0005363406],"domain_scores_gemma":[0.96838355,0.018963715,0.008834435,0.00079067744,0.002259345,0.00076828396],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037412252,0.00040276637,0.0052843112,0.0002612398,0.00012391647,0.0000119231145,0.0004054206,0.0005147683,0.00041912677],"category_scores_gemma":[0.00965495,0.00023885485,0.0019296933,0.00088035275,0.00042860178,0.00014696407,0.000109917935,0.0011796198,0.000004825253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9417692,0.010402656,0.014809391,0.00015509849,0.005022474,0.0003050505,0.00060719065,0.0002652488,0.00015986411,0.00003813347,0.0008194611,0.025646243],"study_design_scores_gemma":[0.69100434,0.16786897,0.12868042,0.00015116626,0.0062233023,0.000031360207,0.00092756056,0.00025288112,0.0007084556,0.000050050858,0.0038515334,0.00024992359],"about_ca_topic_score_codex":0.00051136204,"about_ca_topic_score_gemma":0.0006697772,"teacher_disagreement_score":0.25076482,"about_ca_system_score_codex":0.0005419521,"about_ca_system_score_gemma":0.009527881,"threshold_uncertainty_score":0.99868715},"labels":[],"label_agreement":null},{"id":"W3167584894","doi":"10.1200/jco.2021.39.15_suppl.5574","title":"Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Cancer Care Ontario; McMaster University; University of Toronto; Royal Victoria Hospital; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; PTEN; Olaparib; Clinical endpoint; Oncology; Internal medicine; Endometrial cancer; Biomarker; Cohort; Serous fluid; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; PI3K/AKT/mTOR pathway; Biology","score_opus":0.2521662109518682,"score_gpt":0.5363523493509751,"score_spread":0.2841861383991069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167584894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98358876,0.0012031836,0.000081669845,0.009270091,0.0039509437,0.00049878703,0.000007207098,0.0000075613893,0.0013917888],"genre_scores_gemma":[0.9879718,0.0009757188,0.0064034504,0.0009787827,0.003489805,0.000017997823,0.000008976367,0.000024453326,0.00012905433],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950426,0.0007515432,0.0029041492,0.0003697176,0.0005784071,0.0003535828],"domain_scores_gemma":[0.9939686,0.0029428336,0.0018070431,0.00028065572,0.00053276593,0.00046808398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030094828,0.00022074125,0.002811896,0.0002815448,0.00006934726,0.00003715898,0.00012230968,0.0003469932,0.0004575256],"category_scores_gemma":[0.004837072,0.00013009734,0.000524321,0.00057036936,0.00015444515,0.00019109737,0.000071251,0.0012364052,0.0000052011205],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38392758,0.052942406,0.15911095,0.000043021762,0.000902686,0.017081594,0.00018466928,0.00000585771,0.00006851301,0.000049465874,0.0017514735,0.3839318],"study_design_scores_gemma":[0.7050112,0.18181226,0.052002706,0.00044905054,0.0014099668,0.0012368144,0.000280535,0.00006115078,0.0003695042,0.000038797338,0.057156786,0.00017126874],"about_ca_topic_score_codex":0.000033399276,"about_ca_topic_score_gemma":0.00020954364,"teacher_disagreement_score":0.3837605,"about_ca_system_score_codex":0.0004765684,"about_ca_system_score_gemma":0.009115296,"threshold_uncertainty_score":0.9965021},"labels":[],"label_agreement":null},{"id":"W3167602226","doi":"10.1200/jco.2021.39.15_suppl.2032","title":"Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Feature selection; Receiver operating characteristic; Cohort; Cancer; Lung cancer; Logistic regression; Artificial intelligence","score_opus":0.0776540938749829,"score_gpt":0.5077409547707102,"score_spread":0.43008686089572734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167602226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205625,0.0038857954,0.00019680215,0.0019721556,0.0006975487,0.00030567264,0.000051618874,0.0000043289247,0.00082981173],"genre_scores_gemma":[0.9870753,0.0038262412,0.0064306958,0.0014733153,0.00079330197,0.000011321666,0.000023603117,0.000017900651,0.00034828013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953963,0.00085186533,0.002974816,0.00032222987,0.00023087267,0.00022388235],"domain_scores_gemma":[0.99561507,0.0018549506,0.0014877623,0.0002436927,0.00044212717,0.00035638033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029614922,0.00015390886,0.002150312,0.0002917807,0.000027581045,0.000009714741,0.000116903735,0.00030400345,0.00012245051],"category_scores_gemma":[0.0011866613,0.00011102718,0.0006947025,0.0004633573,0.00022212627,0.00010118614,0.000060793795,0.0006798634,7.893888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010346163,0.0029313765,0.9688871,0.00007390771,0.0042704893,0.0007967136,0.0004033452,0.00014652083,0.0003127663,0.000010435652,0.001657342,0.019475376],"study_design_scores_gemma":[0.011984897,0.004867434,0.9625081,0.00009418084,0.011094315,0.0000715527,0.00044504812,0.0006366206,0.00011905186,0.000026568143,0.008050089,0.00010214515],"about_ca_topic_score_codex":0.0003084331,"about_ca_topic_score_gemma":0.0017623659,"teacher_disagreement_score":0.01937323,"about_ca_system_score_codex":0.00015548195,"about_ca_system_score_gemma":0.005961362,"threshold_uncertainty_score":0.9996739},"labels":[],"label_agreement":null},{"id":"W3167608264","doi":"10.1200/jco.2021.39.15_suppl.8011","title":"Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Carfilzomib; Minimal residual disease; Lenalidomide; Dexamethasone; Oncology; Internal medicine; Multiple myeloma; Autologous stem-cell transplantation; Interim analysis; Clinical endpoint; Phases of clinical research; Chemotherapy; Clinical trial; Bone marrow","score_opus":0.2087677462614769,"score_gpt":0.5099627723187464,"score_spread":0.30119502605726955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167608264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471503,0.0012019896,0.0008001952,0.0016437834,0.00035953353,0.00083713565,0.0003051087,0.000006139051,0.00013107705],"genre_scores_gemma":[0.9813506,0.00084342225,0.016652502,0.00022342023,0.00063772214,0.000040141473,0.000072041425,0.00002703658,0.0001530935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99360317,0.0011934697,0.0036368738,0.0004402748,0.0007112582,0.00041497042],"domain_scores_gemma":[0.9782372,0.016065378,0.0025136876,0.00039066348,0.0016909211,0.001102156],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030453622,0.00026323347,0.003729413,0.0005555825,0.00005435766,0.000013655264,0.00020025858,0.00034425803,0.00017374686],"category_scores_gemma":[0.040665735,0.00019834176,0.0016320249,0.0005767398,0.00058339763,0.00014115259,0.0001485272,0.0006028387,0.0000013196125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7772789,0.013217377,0.04713023,0.00013489297,0.012959293,0.0032847456,0.00021319145,0.000025985966,0.0023793506,0.000046976787,0.0007134347,0.14261565],"study_design_scores_gemma":[0.575037,0.076985694,0.32130787,0.00025995547,0.0139548145,0.00008618522,0.0007520597,0.0045920955,0.0039793113,0.00016173709,0.0026572733,0.00022598155],"about_ca_topic_score_codex":0.000108367036,"about_ca_topic_score_gemma":0.0003607871,"teacher_disagreement_score":0.27417764,"about_ca_system_score_codex":0.00017112953,"about_ca_system_score_gemma":0.0038391212,"threshold_uncertainty_score":0.96741515},"labels":[],"label_agreement":null},{"id":"W3167654629","doi":"10.1200/jco.2021.39.15_suppl.2640","title":"Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of Ottawa; University of Calgary; University of Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Diabetic ketoacidosis; Gastroenterology; Adverse effect; Insulin; Ketoacidosis; Cancer; Cohort; Regimen; Endocrinology; Type 1 diabetes","score_opus":0.07205876432353381,"score_gpt":0.40113513153111413,"score_spread":0.3290763672075803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167654629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731913,0.008882047,0.000002558673,0.011710716,0.0021866313,0.00022387301,0.000012642425,0.000004732868,0.003785478],"genre_scores_gemma":[0.98737186,0.009362939,0.0005710465,0.0013543788,0.0011809581,0.00001028398,0.000008509634,0.000020035184,0.00012000233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540883,0.00029369033,0.0032700445,0.00024243837,0.00044780012,0.00033718752],"domain_scores_gemma":[0.99529254,0.0011669345,0.0016149649,0.00032158854,0.00085162296,0.0007523356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002449864,0.00017018776,0.0021178368,0.00015792318,0.00004000242,0.000010460424,0.00012488403,0.00041698167,0.000517938],"category_scores_gemma":[0.0024685347,0.00012802689,0.00092129543,0.00017414252,0.00012540977,0.00006466473,0.000058666163,0.0008342769,0.000027011494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008281197,0.0043540015,0.6725489,0.000077129014,0.0025091209,0.0029689635,0.00011208689,0.000004225093,0.005358076,0.00012716706,0.001212867,0.30989933],"study_design_scores_gemma":[0.008802827,0.00785678,0.91459125,0.00030408922,0.0009889614,0.00019249854,0.0001225412,0.0000079319125,0.0380097,0.0002006701,0.02880553,0.000117210155],"about_ca_topic_score_codex":0.0036273368,"about_ca_topic_score_gemma":0.012585263,"teacher_disagreement_score":0.30978212,"about_ca_system_score_codex":0.00063359865,"about_ca_system_score_gemma":0.006401155,"threshold_uncertainty_score":0.99923164},"labels":[],"label_agreement":null},{"id":"W3167655766","doi":"10.1200/jco.2021.39.15_suppl.tps5607","title":"Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"Mersana Therapeutics","keywords":"Medicine; Ovarian cancer; Oncology; Internal medicine; Cohort; Bevacizumab; Cancer; Olaparib; Fallopian tube cancer; Chemotherapy","score_opus":0.08863282984229492,"score_gpt":0.4842604555080846,"score_spread":0.3956276256657897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167655766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9292513,0.0028239216,0.0004001476,0.058368713,0.004772783,0.001535027,0.00020039413,0.000059464448,0.0025882246],"genre_scores_gemma":[0.9663207,0.0023424767,0.018109415,0.007671632,0.0034982294,0.00018883111,0.00006350296,0.000086737266,0.0017184851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935489,0.00071087666,0.003561905,0.0007062621,0.0007958931,0.00067610573],"domain_scores_gemma":[0.99053574,0.003951038,0.0019327673,0.00050955644,0.0019234989,0.0011474158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046103788,0.00039744147,0.0031553998,0.00018931346,0.00014716315,0.000048843758,0.00024575743,0.00043690062,0.0008506844],"category_scores_gemma":[0.005826826,0.00030625655,0.0010377595,0.00044228864,0.00016290181,0.00012735724,0.00011543884,0.00095724966,0.000043124695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05150066,0.01589871,0.40174666,0.0005018211,0.01686456,0.012839538,0.0010963922,0.0003517968,0.010835461,0.0018003946,0.1537634,0.3328006],"study_design_scores_gemma":[0.039091207,0.0152706755,0.74933386,0.000978412,0.0042440016,0.0006355584,0.00023286219,0.0007350831,0.0015482361,0.00045230545,0.1870443,0.00043352766],"about_ca_topic_score_codex":0.00025512534,"about_ca_topic_score_gemma":0.00092614815,"teacher_disagreement_score":0.34758717,"about_ca_system_score_codex":0.00071687694,"about_ca_system_score_gemma":0.006271608,"threshold_uncertainty_score":0.99993896},"labels":[],"label_agreement":null},{"id":"W3167698157","doi":"10.1200/jco.2021.39.15_suppl.tps10056","title":"FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MAPK/ERK pathway; Cancer; MEK inhibitor; Glioma; Oncology; Internal medicine; Kinase; Adverse effect; Cancer research; Biology; Genetics","score_opus":0.039711479461763115,"score_gpt":0.3844723848679845,"score_spread":0.3447609054062214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167698157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981991,0.00023682257,0.000010349687,0.00022120283,0.00092108326,0.00019127503,0.000007635343,0.0000011896896,0.00021130756],"genre_scores_gemma":[0.9986315,0.000081180784,0.00016529423,0.00021571688,0.0008407686,0.0000039482247,0.0000053988624,0.0000118630915,0.000044364842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718714,0.0006669996,0.0014621716,0.00021839587,0.00028791864,0.00017738355],"domain_scores_gemma":[0.997763,0.00023492376,0.0012111992,0.0002993874,0.00036984583,0.00012169433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009457762,0.00012191626,0.00063589535,0.000057377605,0.000028903409,0.000005765168,0.0002724246,0.00026936075,0.0000130709395],"category_scores_gemma":[0.0014791212,0.00007278496,0.00022293846,0.00023678657,0.00007641191,0.0000064073215,0.00015608108,0.0004247736,0.0000013767992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003199104,0.024536537,0.9490259,0.000032604483,0.00018648469,0.00053399376,0.00017857118,0.000021455997,0.011367837,0.0000061941273,0.0015798513,0.009331452],"study_design_scores_gemma":[0.03054237,0.035240274,0.9191407,0.0000330634,0.00021851284,0.00006249538,0.00028461745,0.0000059611593,0.008951676,0.000035445104,0.0053282063,0.00015670709],"about_ca_topic_score_codex":0.000006600965,"about_ca_topic_score_gemma":0.00016688906,"teacher_disagreement_score":0.029885244,"about_ca_system_score_codex":0.000019754247,"about_ca_system_score_gemma":0.0010238938,"threshold_uncertainty_score":0.29680845},"labels":[],"label_agreement":null},{"id":"W3167722320","doi":"10.1200/jco.2021.39.15_suppl.7021","title":"Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Interim analysis; Oncology; Transplantation; Chemotherapy regimen; Myeloid leukemia; Comorbidity; Chemotherapy; Clinical trial","score_opus":0.031118780944988284,"score_gpt":0.42508589455219487,"score_spread":0.3939671136072066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167722320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953021,0.00044869818,0.0002772507,0.0012557531,0.0005046906,0.00049124815,0.000007767024,0.000006136593,0.0017063875],"genre_scores_gemma":[0.9816876,0.0024231137,0.014560633,0.0003071995,0.0007416836,0.0000074279333,0.000006425373,0.000035540237,0.00023038234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944409,0.0015193671,0.0023424807,0.00035689012,0.0009853325,0.00035503795],"domain_scores_gemma":[0.99016076,0.0061629037,0.0018665543,0.00035800718,0.0010137102,0.00043804146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004122079,0.00023198932,0.0024906385,0.00021604866,0.000032447777,0.0000087612025,0.00020215896,0.00046443657,0.00010467495],"category_scores_gemma":[0.0025162231,0.00014795987,0.00040613077,0.00029630534,0.00030865532,0.00007746178,0.00014806623,0.0017484084,0.0000031055838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10828801,0.0033648096,0.5154371,0.0024042474,0.0053410493,0.018832423,0.00028808299,0.0002996678,0.036454737,0.00021456115,0.0020425005,0.30703276],"study_design_scores_gemma":[0.05058781,0.08722372,0.83301604,0.0009101665,0.0017419177,0.0024793907,0.0001223976,0.0008818669,0.021994477,0.000037927774,0.00079443195,0.0002098426],"about_ca_topic_score_codex":0.000022206506,"about_ca_topic_score_gemma":0.000009933939,"teacher_disagreement_score":0.3175789,"about_ca_system_score_codex":0.00051991607,"about_ca_system_score_gemma":0.0074295267,"threshold_uncertainty_score":0.99819744},"labels":[],"label_agreement":null},{"id":"W3167762794","doi":"10.1200/jco.2021.39.15_suppl.12006","title":"Does early palliative care reduce end-of-life hospital costs? A propensity-score matched, population-based, cohort study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Toronto; Dalhousie University; University of British Columbia; Wilfrid Laurier University; Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University","funders":"Canadian Centre for Applied Research in Cancer Control","keywords":"Medicine; Propensity score matching; Palliative care; Retrospective cohort study; Cohort; Cancer; Population; End-of-life care; Cohort study; Emergency medicine; Health care; Family medicine; Nursing; Internal medicine","score_opus":0.2533970075311658,"score_gpt":0.5082037632659006,"score_spread":0.25480675573473477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167762794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922454,0.0012957295,0.000071884526,0.0031249833,0.001775846,0.0006245914,0.000024942456,0.000010769223,0.00082587026],"genre_scores_gemma":[0.9936427,0.0004815964,0.004072141,0.0006407591,0.00094929273,0.00000997393,0.00002664207,0.000025506659,0.00015141355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948041,0.0007921637,0.0030100269,0.00033728592,0.0008077387,0.0002487107],"domain_scores_gemma":[0.99028,0.0028672994,0.0028026418,0.000352351,0.0032760054,0.0004217587],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016281974,0.0002236536,0.0027914532,0.00013030437,0.00004608526,0.000010918691,0.00021378502,0.00037928004,0.00018484452],"category_scores_gemma":[0.012395864,0.00013588602,0.0006812652,0.00029241364,0.000252454,0.000120884586,0.000086152555,0.0009806287,0.000007842864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022709854,0.0025230728,0.98172516,0.00013051015,0.0009648821,0.0010588143,0.0017612849,0.000017765678,0.000070366215,0.000032273747,0.00041090098,0.009033975],"study_design_scores_gemma":[0.0066966256,0.010923631,0.970868,0.0008814817,0.00081707083,0.000009858768,0.0054898974,0.000008346141,0.0008405525,0.000060116374,0.003253256,0.00015116886],"about_ca_topic_score_codex":0.00041896175,"about_ca_topic_score_gemma":0.00039087344,"teacher_disagreement_score":0.010857172,"about_ca_system_score_codex":0.00031275663,"about_ca_system_score_gemma":0.0037502083,"threshold_uncertainty_score":0.99592316},"labels":[],"label_agreement":null},{"id":"W3167778461","doi":"10.1200/jco.2021.39.15_suppl.3003","title":"Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Lung cancer; Internal medicine; Pancreas; Oncology; Phases of clinical research; Clinical trial","score_opus":0.06311970170415009,"score_gpt":0.49937346485275863,"score_spread":0.43625376314860853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167778461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888607,0.0044943583,0.000019746796,0.0038148323,0.00032126237,0.00012558293,0.0000072150947,0.0000027482358,0.0023535304],"genre_scores_gemma":[0.9903023,0.0055624554,0.00263279,0.0010024654,0.00024441502,0.0000035945045,8.79591e-7,0.000011169272,0.00023988406],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983141,0.000110928115,0.0011842632,0.00013718478,0.00012996423,0.00012355225],"domain_scores_gemma":[0.9980924,0.0008182507,0.0006147907,0.000092909395,0.00019256829,0.00018908473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005530227,0.000079487356,0.000939806,0.00006604925,0.000025643436,0.0000033335925,0.00003300352,0.00011628179,0.0001109613],"category_scores_gemma":[0.0011006384,0.00005682193,0.00009441432,0.000105435574,0.00011442516,0.000055582826,0.000036727946,0.00033802286,5.649985e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006549186,0.0015544238,0.406411,0.00008894588,0.0006682566,0.0009938189,0.00071482034,0.00011212119,0.0020333205,0.000393421,0.00020004755,0.58028066],"study_design_scores_gemma":[0.021764612,0.0025673178,0.9281981,0.00063197897,0.0005010825,0.0003059557,0.00032914634,0.000042194428,0.00034179667,0.00016706265,0.045081727,0.00006903899],"about_ca_topic_score_codex":0.00008192895,"about_ca_topic_score_gemma":0.00014861743,"teacher_disagreement_score":0.5802116,"about_ca_system_score_codex":0.00012453896,"about_ca_system_score_gemma":0.0015202909,"threshold_uncertainty_score":0.26969308},"labels":[],"label_agreement":null},{"id":"W3167778695","doi":"10.1200/jco.2021.39.15_suppl.e20575","title":"Real-world treatment patterns, clinical outcomes, and health care resource utilization in extensive-stage small cell lung cancer in Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary","funders":"","keywords":"Medicine; Etoposide; Radiation therapy; Carboplatin; Medical record; Population; Chemotherapy; Internal medicine; Stage (stratigraphy); Retrospective cohort study; Cohort; Lung cancer; Disease; Oncology; Cisplatin","score_opus":0.2390552102471624,"score_gpt":0.5576946155708685,"score_spread":0.31863940532370616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167778695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95121825,0.010490718,0.0000075639646,0.036126427,0.0006952107,0.00042469543,0.000035904905,0.000004030265,0.0009972254],"genre_scores_gemma":[0.92675674,0.06411613,0.00041010242,0.006952615,0.00049588905,0.000015386895,0.000012269613,0.000022829608,0.0012180626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947329,0.0011864728,0.0029273676,0.0003487818,0.00039779374,0.0004066876],"domain_scores_gemma":[0.99526143,0.002457777,0.0010718491,0.0002284497,0.0004657588,0.00051475374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002329095,0.0001710762,0.0021769372,0.00016780104,0.00003786825,0.000007423835,0.00009607574,0.0001617628,0.00007056493],"category_scores_gemma":[0.001574685,0.00012413281,0.00020881146,0.00024818908,0.000089500274,0.00003939876,0.000107439184,0.0010847775,3.7014306e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00081056677,0.0005062582,0.9093581,0.00019603904,0.00016429734,0.0034883493,0.0003888356,0.000049549013,8.6926093e-7,0.000005785485,0.0031636623,0.08186773],"study_design_scores_gemma":[0.010694591,0.0022028978,0.939048,0.00036325894,0.000101731726,0.000018611181,0.0020265325,0.00011234773,0.0000096426265,0.0000026546284,0.04533568,0.00008403476],"about_ca_topic_score_codex":0.6250309,"about_ca_topic_score_gemma":0.9939252,"teacher_disagreement_score":0.36889437,"about_ca_system_score_codex":0.005636226,"about_ca_system_score_gemma":0.03090895,"threshold_uncertainty_score":0.998181},"labels":[],"label_agreement":null},{"id":"W3167778991","doi":"10.1200/jco.2021.39.15_suppl.e24129","title":"Adaptive and maladaptive coping strategies among patients with advanced cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Coping (psychology); Denial; Anxiety; Clinical psychology; Multivariate analysis; Univariate analysis; Disengagement theory; Social support; Psychiatry; Internal medicine; Gerontology; Psychology","score_opus":0.06926077268379084,"score_gpt":0.4238803575331861,"score_spread":0.35461958484939526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167778991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915837,0.0018272043,0.00029903042,0.0015745487,0.0009301192,0.000105453524,0.000006102517,0.0000055502032,0.0036682757],"genre_scores_gemma":[0.9959133,0.0012766854,0.0012409501,0.00101418,0.00040764434,0.000004019615,0.0000017118426,0.000011721172,0.00012973313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983931,0.00019159704,0.00082179724,0.00016717208,0.00027062546,0.00015566424],"domain_scores_gemma":[0.9970647,0.00069188257,0.0008126904,0.000093009025,0.0010805195,0.00025719992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041597377,0.00010531451,0.00092965673,0.000040093913,0.000033436994,0.000011836986,0.00004947271,0.00017283793,0.00009991747],"category_scores_gemma":[0.00038763607,0.00007209412,0.00013983824,0.000117412485,0.00023891605,0.00020416298,0.000035025743,0.00065898884,7.851144e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008167644,0.0005530585,0.7418277,0.000046719688,0.0005528174,0.00084122084,0.0006102816,0.00007214657,0.000016994309,0.00030856917,0.00046092557,0.2465419],"study_design_scores_gemma":[0.0074201715,0.010721437,0.9665831,0.00036939725,0.0002437815,0.00005415971,0.003828308,0.00001813299,0.0000444296,0.00014965657,0.010473237,0.00009423224],"about_ca_topic_score_codex":0.000079206075,"about_ca_topic_score_gemma":0.0022224074,"teacher_disagreement_score":0.24644767,"about_ca_system_score_codex":0.00010864677,"about_ca_system_score_gemma":0.0023277476,"threshold_uncertainty_score":0.41293243},"labels":[],"label_agreement":null},{"id":"W3167779332","doi":"10.1200/jco.2021.39.15_suppl.5042","title":"Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Enzalutamide; Medicine; Pembrolizumab; Abiraterone; Prostate cancer; Cohort; Internal medicine; Oncology; Clinical endpoint; Docetaxel; Cancer; Clinical trial; Immunotherapy; Androgen receptor","score_opus":0.17601262121427924,"score_gpt":0.48352181287242263,"score_spread":0.3075091916581434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167779332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047875,0.002906225,0.000030704075,0.0021524564,0.00041461145,0.0008737193,0.003056773,0.0000039550755,0.00008281998],"genre_scores_gemma":[0.9955469,0.0007904437,0.0020911582,0.00027982172,0.00025929196,0.00008857305,0.00014348961,0.000023115845,0.00077720574],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99557036,0.000689404,0.0023507453,0.0003124406,0.0008096224,0.00026745422],"domain_scores_gemma":[0.9936363,0.0027055189,0.0016490896,0.00028530514,0.0014362563,0.00028751415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013054913,0.00019101953,0.0017852858,0.00012765148,0.00007461461,0.000016828782,0.0001458356,0.00015621475,0.001511169],"category_scores_gemma":[0.0023215672,0.000117739386,0.00055501366,0.00028923346,0.0004376486,0.000106845146,0.0000918045,0.0004998262,0.0000010205962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.515832,0.018117571,0.266507,0.0012948024,0.035809807,0.004861411,0.0041568563,0.00045247126,0.10166781,0.00028813354,0.024500612,0.026511565],"study_design_scores_gemma":[0.052943718,0.012019586,0.911163,0.000699057,0.0053725154,0.00006738616,0.0021692172,0.00013328917,0.0074101756,0.0016194991,0.0061891642,0.00021342399],"about_ca_topic_score_codex":0.0003609459,"about_ca_topic_score_gemma":0.0024493358,"teacher_disagreement_score":0.644656,"about_ca_system_score_codex":0.0002918665,"about_ca_system_score_gemma":0.006513799,"threshold_uncertainty_score":0.99940157},"labels":[],"label_agreement":null},{"id":"W3167799926","doi":"10.1200/jco.2021.39.15_suppl.e23546","title":"Preoperative stereotactic ablative body radiotherapy with postoperative conventional irradiation of soft tissue sarcomas: Protocol overview with a preliminary safety report.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiation therapy; Soft tissue; Surgery; Soft tissue sarcoma; Complication; Sarcoma; Radiology","score_opus":0.08091829143469897,"score_gpt":0.4597960720510191,"score_spread":0.3788777806163201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167799926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85364765,0.006694605,0.004820518,0.058415662,0.0007303538,0.068176255,0.000068083355,0.000041192972,0.007405695],"genre_scores_gemma":[0.9648824,0.0005229546,0.02677143,0.0026354557,0.00048063998,0.0038159061,0.000044756845,0.000051587842,0.0007949169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956972,0.000956947,0.0022795438,0.00031324322,0.0005684256,0.00018464425],"domain_scores_gemma":[0.9925965,0.002249368,0.0027889602,0.00026095568,0.0018533516,0.00025083052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012664291,0.00022298595,0.0017432956,0.000089171706,0.00006248932,0.000013328793,0.000079951955,0.00021061861,0.0007375277],"category_scores_gemma":[0.0009829776,0.0001292385,0.00028695547,0.00022253119,0.00026709255,0.0002454534,0.000026180032,0.00058070023,0.0000031601564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08112328,0.026512511,0.75265217,0.00032475812,0.0099651925,0.040382046,0.0016994291,0.00022594017,0.0005345974,0.0012215943,0.0015220742,0.08383641],"study_design_scores_gemma":[0.024238724,0.07362865,0.8446538,0.0008692612,0.00085016433,0.013394819,0.00032546537,0.00011747305,0.0009961267,0.00006130129,0.04071563,0.00014858846],"about_ca_topic_score_codex":0.000014596104,"about_ca_topic_score_gemma":0.000034369536,"teacher_disagreement_score":0.11123472,"about_ca_system_score_codex":0.000314673,"about_ca_system_score_gemma":0.004373756,"threshold_uncertainty_score":0.8075411},"labels":[],"label_agreement":null},{"id":"W3167858868","doi":"10.1200/jco.2021.39.15_suppl.4515","title":"Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Clinical endpoint; Renal cell carcinoma; Tolerability; Clinical trial; Brain metastasis; Oncology; Adverse effect; Surgery; Cancer; Immunotherapy; Metastasis","score_opus":0.05059253940692358,"score_gpt":0.3618151297599955,"score_spread":0.3112225903530719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167858868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898431,0.0008287188,0.000017580314,0.0077976077,0.00021441243,0.0006729131,0.000058320446,0.000005499628,0.00056185806],"genre_scores_gemma":[0.9941806,0.00021466568,0.0038604666,0.0012460889,0.00018623218,0.0000045746497,0.000047838792,0.000025204647,0.00023428714],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954665,0.0010587353,0.0022363197,0.0004299314,0.0005259855,0.00028256117],"domain_scores_gemma":[0.9894308,0.007891745,0.0015448828,0.00039169446,0.00037106694,0.0003698299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020489662,0.00026220112,0.0020429455,0.000074397285,0.00006538319,0.00002171199,0.00012345324,0.00020315759,0.000021247699],"category_scores_gemma":[0.0029856244,0.0001278901,0.00020395781,0.00017986521,0.00029930976,0.00012033035,0.00009879895,0.0009192088,0.0000018852319],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.652082,0.002999572,0.3052832,0.000023180519,0.0006199371,0.0029491696,0.000499031,0.000064007094,0.000035518224,0.000007645287,0.0004113641,0.035025347],"study_design_scores_gemma":[0.33389258,0.024459912,0.6379709,0.00009756666,0.00056821643,0.00007583016,0.00021257096,0.000012678243,0.00011235453,0.000012141102,0.002490189,0.00009503427],"about_ca_topic_score_codex":0.00009171922,"about_ca_topic_score_gemma":0.0003507133,"teacher_disagreement_score":0.33268774,"about_ca_system_score_codex":0.00024191552,"about_ca_system_score_gemma":0.0015632511,"threshold_uncertainty_score":0.5215207},"labels":[],"label_agreement":null},{"id":"W3167872510","doi":"10.1200/jco.2021.39.15_suppl.12118","title":"Neuropsychiatric disorders in hospitalized patients undergoing chimeric antigen receptor T-cell therapy for aggressive lymphomas and acute lymphoblastic leukemia: A national study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Cart; Internal medicine; Depression (economics); Delirium; Anxiety; Odds ratio; Lymphoma; Oncology; Psychiatry","score_opus":0.03194019469593549,"score_gpt":0.39077844786975363,"score_spread":0.3588382531738181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167872510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269146,0.0011217329,0.00006463323,0.0025736203,0.0018205408,0.00082659227,0.000010925895,0.000008056184,0.00088243966],"genre_scores_gemma":[0.9788589,0.018207112,0.0009138038,0.0014089785,0.00043661147,0.0000300996,0.000008055218,0.000028213186,0.00010825033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695456,0.00042266466,0.001621544,0.00031632071,0.00043031984,0.00025458416],"domain_scores_gemma":[0.9939136,0.0030804586,0.001855801,0.000085241496,0.0008870743,0.0001778202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083570887,0.00019159519,0.0011646091,0.0002271684,0.00008432,0.0000124146045,0.0000864646,0.0001936492,0.000042396256],"category_scores_gemma":[0.005089662,0.00013903373,0.00031957848,0.00039548334,0.00014683162,0.000106317304,0.00006720055,0.0004098563,0.0000031605846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008546401,0.006450615,0.92348427,0.000029203578,0.0011007141,0.00012103233,0.00027581674,0.000017554756,0.000033244934,0.000005033613,0.0017233556,0.05821276],"study_design_scores_gemma":[0.074608564,0.028813936,0.8922529,0.000106002466,0.00034978456,0.000058041423,0.0004127865,0.000075818185,0.00001011743,0.00029499808,0.002880577,0.00013643129],"about_ca_topic_score_codex":0.00000700634,"about_ca_topic_score_gemma":0.000047269365,"teacher_disagreement_score":0.06606217,"about_ca_system_score_codex":0.0005142634,"about_ca_system_score_gemma":0.0039901007,"threshold_uncertainty_score":0.70782673},"labels":[],"label_agreement":null},{"id":"W3167878998","doi":"10.1200/jco.2021.39.15_suppl.9561","title":"Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Meta-analysis; Population; Oncology; Clinical trial; Randomized controlled trial; Systematic review; Systemic therapy; MEDLINE; Immunotherapy; Cancer","score_opus":0.11176986199588293,"score_gpt":0.42660527052806263,"score_spread":0.31483540853217973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167878998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7033139,0.2810073,0.00003304646,0.013440122,0.000060593327,0.0019469195,0.000086546715,0.000011687884,0.00009990375],"genre_scores_gemma":[0.9481349,0.040605564,0.0038056937,0.0061719813,0.000055646255,0.00012944745,0.00008682027,0.00003765348,0.0009722723],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.992814,0.0031287044,0.0028716656,0.0004003468,0.00053550117,0.00024977452],"domain_scores_gemma":[0.99317086,0.0030036326,0.002250568,0.00048406908,0.0007344762,0.00035638415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024104994,0.0004011788,0.009723277,0.00027100064,0.000034037224,0.000031853873,0.000091088004,0.00018734211,0.00011730958],"category_scores_gemma":[0.0009978038,0.00015847577,0.0017665285,0.00078704336,0.00009340939,0.00011146014,0.000021743092,0.0004076019,0.0000028237296],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040993625,0.010886016,0.39856088,0.009390566,0.55476063,0.018326744,0.00019598113,0.000019773846,0.0000021079945,0.000053937183,0.0002655483,0.003438452],"study_design_scores_gemma":[0.0365211,0.05831004,0.110992886,0.006648963,0.78110814,0.0045826356,0.00018621524,0.0000121731455,0.000017613875,0.000011201938,0.0013239699,0.00028504393],"about_ca_topic_score_codex":0.000022712831,"about_ca_topic_score_gemma":0.00014093262,"teacher_disagreement_score":0.287568,"about_ca_system_score_codex":0.00020608246,"about_ca_system_score_gemma":0.0006170171,"threshold_uncertainty_score":0.6646638},"labels":[],"label_agreement":null},{"id":"W3167895093","doi":"10.1200/jco.2021.39.15_suppl.536","title":"Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Tolerability; Neratinib; Diarrhea; Internal medicine; Adverse effect; Loperamide; Cohort; Regimen; Metastatic breast cancer; Breast cancer; Gastroenterology; Oncology; Cancer; Trastuzumab","score_opus":0.08832419187128898,"score_gpt":0.46732509355213603,"score_spread":0.37900090168084705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167895093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778445,0.000054505836,0.001289906,0.008424228,0.0014102345,0.0007674628,0.000037457303,0.0000053097824,0.00022644854],"genre_scores_gemma":[0.9816115,0.0001319031,0.01676921,0.0005966311,0.0006932531,0.000030304278,0.000018434766,0.000015391137,0.00013341031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960701,0.00033024914,0.0027724982,0.00024491065,0.0003208459,0.00026139212],"domain_scores_gemma":[0.99376154,0.00288024,0.0019950627,0.00017253155,0.0010156966,0.00017493677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036681972,0.00013114653,0.0015418542,0.00010559344,0.000047850175,0.00001227235,0.000093146744,0.00021375895,0.00006356164],"category_scores_gemma":[0.003067831,0.00010936055,0.00050812913,0.0002018002,0.000083126084,0.00015137249,0.000044988992,0.0004682314,1.4914289e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016445242,0.0011158623,0.93928295,0.00023060718,0.00022068473,0.000014013224,0.00009591077,0.00020724682,0.0000859193,0.00006969083,0.00054889556,0.056483686],"study_design_scores_gemma":[0.021511093,0.0032340707,0.971715,0.0002720777,0.00026620404,0.000004694906,0.00009961561,0.0017084397,0.00006219884,0.00008744244,0.00095789856,0.00008128736],"about_ca_topic_score_codex":0.00005794931,"about_ca_topic_score_gemma":0.00021935065,"teacher_disagreement_score":0.0564024,"about_ca_system_score_codex":0.0003273161,"about_ca_system_score_gemma":0.001422964,"threshold_uncertainty_score":0.4459594},"labels":[],"label_agreement":null},{"id":"W3167903547","doi":"10.1200/jco.2021.39.15_suppl.e17046","title":"Evaluating the prevalence and nature of sleep disturbances in prostate cancer patients receiving androgen deprivation therapy using a combination of actigraphy and sleep questionnaires.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Actigraphy; Medicine; Pittsburgh Sleep Quality Index; Epworth Sleepiness Scale; Prostate cancer; Androgen deprivation therapy; Physical therapy; Sleep diary; Sleep (system call); Sleep onset; Sleep deprivation; Internal medicine; Insomnia; Cancer; Sleep quality; Polysomnography; Circadian rhythm; Psychiatry","score_opus":0.08501849638750722,"score_gpt":0.4659514608576291,"score_spread":0.3809329644701219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167903547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794274,0.018589262,0.000011978966,0.0012552508,0.0005087236,0.00018144601,0.000003259722,0.0000012740105,0.000021429298],"genre_scores_gemma":[0.99147266,0.007923835,0.00028224415,0.00022664727,0.00008068596,0.0000037864081,0.0000011909748,0.000004970605,0.0000039829283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980839,0.00050086924,0.0009344107,0.00012219741,0.00028564225,0.00007301765],"domain_scores_gemma":[0.99689156,0.0009705866,0.0012352545,0.000077890756,0.00077732466,0.00004741436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019532193,0.00006598294,0.0004798256,0.00006703541,0.000028975766,0.0000055978157,0.000048439073,0.000144911,0.0000058838755],"category_scores_gemma":[0.0023335044,0.0000433177,0.00008271588,0.00021974144,0.00014708337,0.00011982274,0.000025800979,0.0004678315,8.512795e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010605342,0.00025385202,0.7841437,0.00013594895,0.000080349324,0.0000042639026,0.00087397936,0.000022736713,0.0005652543,0.00001767091,0.0000034584418,0.21283828],"study_design_scores_gemma":[0.0035051184,0.0022287434,0.99100083,0.0006289892,0.00014398128,0.000017477112,0.00016620193,0.0008358057,0.000907636,0.00045579096,0.00007009813,0.000039336508],"about_ca_topic_score_codex":0.00010026349,"about_ca_topic_score_gemma":0.0005276491,"teacher_disagreement_score":0.21279894,"about_ca_system_score_codex":0.000051582996,"about_ca_system_score_gemma":0.000367694,"threshold_uncertainty_score":0.2793591},"labels":[],"label_agreement":null},{"id":"W3167948962","doi":"10.1200/jco.2021.39.15_suppl.10024","title":"Inflammatory myofibroblastic tumor: A multi-institutional study from the pediatric surgical oncology research collaborative.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Children's Hospital of Western Ontario; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Cohort; Malignancy; Interquartile range; Anaplastic lymphoma kinase; Internal medicine; Oncology; Surgery; Radiology; Pleural effusion","score_opus":0.18329047796742767,"score_gpt":0.5087383028339852,"score_spread":0.32544782486655754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167948962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475856,0.0034561977,0.000023836941,0.0053484268,0.0021373117,0.00048974523,0.000023531828,0.000020632791,0.003741732],"genre_scores_gemma":[0.9900484,0.0013820463,0.0008793254,0.000992903,0.006328546,0.00001797296,0.000010304684,0.000023902468,0.00031658655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892163,0.005480943,0.0032856062,0.0003941489,0.001171086,0.00045188883],"domain_scores_gemma":[0.9765582,0.01739273,0.0013417441,0.00040201494,0.003530754,0.0007745364],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008000217,0.00022789455,0.0017370528,0.00019638566,0.0003246513,0.000034773795,0.00038006925,0.0005186744,0.0007606127],"category_scores_gemma":[0.016296864,0.00013237764,0.0005797259,0.00077547936,0.0008623971,0.0001915487,0.00024983106,0.0033334482,0.00020148791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010684917,0.017118393,0.8421115,0.00004621915,0.0013481545,0.08847803,0.00085292594,0.00015807462,0.00017857239,0.0008704459,0.024588745,0.013563971],"study_design_scores_gemma":[0.019523844,0.010820353,0.5771057,0.00010172106,0.0009100595,0.0015686881,0.003348947,0.000116008545,0.000028116787,0.00021392276,0.38610917,0.00015349439],"about_ca_topic_score_codex":0.000014873733,"about_ca_topic_score_gemma":0.00009202437,"teacher_disagreement_score":0.3615204,"about_ca_system_score_codex":0.00042966526,"about_ca_system_score_gemma":0.026750132,"threshold_uncertainty_score":0.9989659},"labels":[],"label_agreement":null},{"id":"W3167966244","doi":"10.1200/jco.2021.39.15_suppl.e16521","title":"Bladder cancer in young adults: Disease and treatment characteristics of patients treated at tertiary cancer center.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Gemcitabine; Cancer; Population; Internal medicine; Chemotherapy; Oncology; Urology","score_opus":0.04657035451728113,"score_gpt":0.40792344655921176,"score_spread":0.3613530920419306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167966244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439186,0.0020866934,7.977882e-7,0.001766014,0.0009611734,0.0002266355,0.00032772755,0.0000033740776,0.0002357273],"genre_scores_gemma":[0.97928166,0.018778954,0.000054123157,0.00079561106,0.00051349064,0.00002136289,0.000032223306,0.000017642038,0.0005049228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765056,0.00020265438,0.0015114257,0.00021524522,0.00022531161,0.0001947826],"domain_scores_gemma":[0.99797434,0.00023684163,0.000832788,0.00013389067,0.00041221958,0.00040993438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015853232,0.00016212926,0.001170904,0.00007169927,0.000022024831,0.000003816918,0.000049365186,0.00016762599,0.00054027117],"category_scores_gemma":[0.00023149303,0.00011021079,0.0002606982,0.00009387623,0.00011644582,0.00006413307,0.000043251548,0.00022375348,0.0000018271043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009761843,0.004233256,0.8772418,0.00004734138,0.0007163786,0.0007348253,0.00015728736,8.0565735e-7,0.000054306092,6.770289e-7,0.00032711442,0.106724344],"study_design_scores_gemma":[0.02154417,0.0034659558,0.96948665,0.00036383947,0.0010025596,0.000026766713,0.00002674426,0.00002386806,0.00025652556,0.000005402408,0.0037179568,0.000079556725],"about_ca_topic_score_codex":0.00039751307,"about_ca_topic_score_gemma":0.0014903161,"teacher_disagreement_score":0.10664479,"about_ca_system_score_codex":0.0004979112,"about_ca_system_score_gemma":0.001327626,"threshold_uncertainty_score":0.59155905},"labels":[],"label_agreement":null},{"id":"W3168021460","doi":"10.1200/jco.2021.39.15_suppl.e19565","title":"Clinical utility of interim CT scans in patients receiving bendamustine and rituximab for first line treatment of follicular lymphoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Bendamustine; Chemoimmunotherapy; Follicular lymphoma; Internal medicine; Interim analysis; Interim; Progressive disease; Clinical trial; Surgery; Lymphoma; Radiology; Chemotherapy","score_opus":0.14042864320139395,"score_gpt":0.4673864648399128,"score_spread":0.32695782163851883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168021460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951867,0.00136721,0.000051174215,0.0020730163,0.0006930002,0.00035314242,0.000039335264,0.0000027241504,0.00023368567],"genre_scores_gemma":[0.9909688,0.004389451,0.0040675444,0.00022305113,0.00027683467,0.000010367214,0.000018556824,0.00001267068,0.000032711767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950151,0.00035609317,0.003915264,0.0002781592,0.00023750524,0.00019791443],"domain_scores_gemma":[0.99269587,0.00424119,0.0018145601,0.00024742683,0.0007227124,0.00027824016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018213228,0.00016752657,0.002705155,0.00009630474,0.000022969569,0.0000037761763,0.000075209144,0.00023407368,0.00005107072],"category_scores_gemma":[0.005468362,0.00011552851,0.000776974,0.00014054908,0.00022546378,0.00005464729,0.00005823091,0.00013613806,7.3052166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033974054,0.033479158,0.60079104,0.00007262424,0.00046286502,0.00024784182,0.000045249006,0.0000014038187,0.0000031318116,0.000010479812,0.00018156628,0.36130723],"study_design_scores_gemma":[0.08417028,0.03242811,0.8690684,0.00038744422,0.0007733135,0.00009027605,0.000057329456,0.00019131828,0.00041274153,0.00009162743,0.012262023,0.00006714125],"about_ca_topic_score_codex":0.000059038004,"about_ca_topic_score_gemma":0.00036226877,"teacher_disagreement_score":0.3612401,"about_ca_system_score_codex":0.00021747871,"about_ca_system_score_gemma":0.0012566494,"threshold_uncertainty_score":0.6546535},"labels":[],"label_agreement":null},{"id":"W3168041049","doi":"10.1200/jco.2021.39.15_suppl.8033","title":"Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Ophthalmology; Common Terminology Criteria for Adverse Events; Visual acuity; Adverse effect; Internal medicine","score_opus":0.1078112055969082,"score_gpt":0.4274042842452491,"score_spread":0.3195930786483409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168041049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979922,0.00020148327,0.000054421555,0.00061753055,0.0003722944,0.00049570395,0.0000225534,0.000018764102,0.00022504675],"genre_scores_gemma":[0.9955232,0.00014492533,0.003131628,0.0002047418,0.0003984409,0.00000905959,0.00011082233,0.00004385901,0.00043329506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943036,0.0014654541,0.0023462342,0.00048663456,0.00084312214,0.00055497524],"domain_scores_gemma":[0.9848486,0.011983999,0.001140056,0.00028901288,0.0009174589,0.0008208257],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024862865,0.0002921837,0.0018117436,0.00032927314,0.00014367363,0.00003229078,0.00016067772,0.0007070774,0.00014422389],"category_scores_gemma":[0.030055191,0.0001994952,0.00022001025,0.0005969752,0.00026824558,0.00028243935,0.0001455178,0.0023782789,0.000024078325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01441171,0.0030490602,0.90869856,0.000054426273,0.00048208062,0.003154547,0.0001208293,0.0000021951728,0.000028931947,0.0000035187634,0.00018017217,0.069813944],"study_design_scores_gemma":[0.042698544,0.018575525,0.9361685,0.0004750052,0.00044339974,0.0002616157,0.00012612794,0.00009536437,0.00007470608,0.000023361063,0.00087441487,0.0001834193],"about_ca_topic_score_codex":0.000060673676,"about_ca_topic_score_gemma":0.00041019788,"teacher_disagreement_score":0.069630526,"about_ca_system_score_codex":0.0004856483,"about_ca_system_score_gemma":0.0025410154,"threshold_uncertainty_score":0.9999233},"labels":[],"label_agreement":null},{"id":"W3168051285","doi":"10.1200/jco.2021.39.15_suppl.6081","title":"Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; HRAS; Clinical endpoint; Oncology; Immunohistochemistry; Cancer; Clinical trial; Gastroenterology; Colorectal cancer; KRAS","score_opus":0.12379570284832303,"score_gpt":0.45734289222824165,"score_spread":0.3335471893799186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168051285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945271,0.0028391776,0.0000039024044,0.0012510114,0.000647795,0.00032151566,0.000019340114,0.000008010559,0.00038212148],"genre_scores_gemma":[0.99477226,0.0018760216,0.0010524304,0.0019850726,0.00016391907,0.000010416763,0.00007396473,0.000023255621,0.00004268681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960448,0.0007891804,0.0021620386,0.00032438725,0.00036711828,0.00031248978],"domain_scores_gemma":[0.997003,0.001004805,0.00108903,0.0001596185,0.00028256842,0.0004609723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010769992,0.0002116445,0.0014981132,0.00016201058,0.00003532957,0.000008356667,0.00008837612,0.0001516708,0.0001150163],"category_scores_gemma":[0.0020225148,0.00015018742,0.00032004103,0.00021634973,0.000090484944,0.000090981026,0.000104838065,0.0008693458,0.000011530032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026215536,0.0034625526,0.97617394,0.000049510567,0.00047078804,0.0114131,0.00004109375,0.0000075148155,0.00011543244,0.000019744957,0.0005972067,0.0050275894],"study_design_scores_gemma":[0.03107459,0.0060474994,0.95730376,0.00036244333,0.0007766684,0.00074253563,0.00004117428,0.00017149851,0.0016211196,0.0001579479,0.0015700994,0.00013065395],"about_ca_topic_score_codex":0.000021113385,"about_ca_topic_score_gemma":0.00002847408,"teacher_disagreement_score":0.028453035,"about_ca_system_score_codex":0.0002829813,"about_ca_system_score_gemma":0.00046423526,"threshold_uncertainty_score":0.61244655},"labels":[],"label_agreement":null},{"id":"W3168075620","doi":"10.1200/jco.2021.39.15_suppl.3016","title":"A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Tolerability; Pharmacokinetics; Nausea; Pharmacodynamics; Dosing; Internal medicine; Gastroenterology; Pharmacology; Toxicity; Adverse effect","score_opus":0.03434385017398364,"score_gpt":0.41152732962645333,"score_spread":0.37718347945246966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168075620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983459,0.00016422741,0.00004992473,0.00037544305,0.0005962567,0.0001888036,0.0000118199805,7.4024285e-7,0.00026688603],"genre_scores_gemma":[0.9986136,0.0002519162,0.00035599314,0.0004468667,0.00027872936,0.0000034611337,0.00000888478,0.000011499416,0.00002905054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977958,0.00028350047,0.0013946409,0.00018859917,0.00019491748,0.00014253723],"domain_scores_gemma":[0.997684,0.00022170488,0.0012783172,0.00025083797,0.0004703971,0.00009475462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006739204,0.00010152122,0.0005985487,0.000032730015,0.000033891087,0.000008398868,0.00019481374,0.00015537025,0.0000096205595],"category_scores_gemma":[0.0015459936,0.000067748115,0.00016351906,0.00013673956,0.0001066366,0.000005779445,0.00011773947,0.00031160068,6.1142384e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011642912,0.038872868,0.7786989,0.000026038311,0.00037773553,0.0001958899,0.00029941465,0.0023191823,0.018056637,0.00003766973,0.0010832895,0.14838944],"study_design_scores_gemma":[0.0510965,0.06746077,0.8543172,0.00008215747,0.00017280581,0.000040321145,0.0006740836,0.0000752415,0.0107127875,0.000110978726,0.015057402,0.00019979452],"about_ca_topic_score_codex":0.000013208007,"about_ca_topic_score_gemma":0.00055762264,"teacher_disagreement_score":0.14818965,"about_ca_system_score_codex":0.00004621742,"about_ca_system_score_gemma":0.001118462,"threshold_uncertainty_score":0.2762688},"labels":[],"label_agreement":null},{"id":"W3168083756","doi":"10.1200/jco.2021.39.15_suppl.4560","title":"Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Internal medicine; Sunitinib; Pembrolizumab; Renal cell carcinoma; Oncology; Urology; Surgery; Cancer; Immunotherapy","score_opus":0.06677471698010366,"score_gpt":0.384418699788275,"score_spread":0.3176439828081713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168083756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763215,0.00036136858,0.0000046162772,0.0007093945,0.0000548872,0.0011218789,0.000014208357,0.0000018866889,0.0000995846],"genre_scores_gemma":[0.99893636,0.000121996476,0.0006793602,0.00013439539,0.000039766823,0.00002191687,0.000010932995,0.000018314411,0.00003693743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421394,0.0025662992,0.002184279,0.00032329475,0.0004597054,0.00025249188],"domain_scores_gemma":[0.9900276,0.0071011065,0.0016334122,0.000386068,0.0007051315,0.00014669138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023751364,0.00022360233,0.0019910866,0.00034363556,0.000040542513,0.0000072892435,0.0001582929,0.00017627556,0.000010249058],"category_scores_gemma":[0.0021608998,0.00011315139,0.00035326273,0.0010488189,0.00023539105,0.00006006158,0.000056870624,0.00048970064,1.2003333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10266111,0.011126375,0.86684656,0.000035911566,0.0008653173,0.00031727005,0.0023892662,0.00011417645,0.0004509265,0.0000034107902,0.00000804106,0.015181642],"study_design_scores_gemma":[0.06058386,0.07974078,0.8533681,0.000060972805,0.0029264374,0.000057978228,0.0018961484,0.00008313265,0.0011052686,0.0000053977783,0.00009340981,0.00007853772],"about_ca_topic_score_codex":0.00008709637,"about_ca_topic_score_gemma":0.0017198098,"teacher_disagreement_score":0.0686144,"about_ca_system_score_codex":0.00023307765,"about_ca_system_score_gemma":0.0012352805,"threshold_uncertainty_score":0.46141797},"labels":[],"label_agreement":null},{"id":"W3168085238","doi":"10.1200/jco.2021.39.15_suppl.e18621","title":"Health-related quality of life in the treatment and survivorship phases of breast cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Medicine; Survivorship curve; Breast cancer; Quality of life (healthcare); Cancer; Cancer survivorship; Gerontology; Family medicine; Demography; Oncology; Internal medicine; Nursing","score_opus":0.29198196866330306,"score_gpt":0.5311552330096143,"score_spread":0.23917326434631125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168085238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95581317,0.0072258688,0.0000031884506,0.035839237,0.00036225416,0.00010434782,0.00003077535,0.0000010974894,0.00062006793],"genre_scores_gemma":[0.9842171,0.012057865,0.00015151431,0.0033108944,0.00019319773,0.0000015920382,0.0000032835042,0.0000041427893,0.000060400027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533033,0.0013931282,0.002866628,0.00010622354,0.00018433202,0.000119352946],"domain_scores_gemma":[0.99367064,0.0038872235,0.0018735488,0.00013938673,0.00024396292,0.00018525546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039285594,0.000075386895,0.0017642211,0.000050986142,0.000014968807,0.0000016527696,0.000069943344,0.00014877532,0.00027700874],"category_scores_gemma":[0.0013726905,0.000043466087,0.00027043113,0.00013659336,0.00020519097,0.000039783623,0.000011661483,0.00039061648,2.1920408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070890086,0.0032700219,0.77037317,0.00014098441,0.00045286864,0.00012471665,0.0010105368,0.000015031248,0.00023924983,0.00009374812,0.0007297665,0.21646091],"study_design_scores_gemma":[0.011934417,0.006487424,0.9757454,0.00010994193,0.00010041297,0.0001975377,0.00070424407,0.000015203436,0.00005174243,0.0000864537,0.004531197,0.0000360545],"about_ca_topic_score_codex":0.0031751152,"about_ca_topic_score_gemma":0.005315525,"teacher_disagreement_score":0.21642487,"about_ca_system_score_codex":0.0001407877,"about_ca_system_score_gemma":0.004997063,"threshold_uncertainty_score":0.8864575},"labels":[],"label_agreement":null},{"id":"W3168125055","doi":"10.1200/jco.2021.39.15_suppl.4556","title":"Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Roche","keywords":"Medicine; Bevacizumab; Atezolizumab; Internal medicine; Renal cell carcinoma; Oncology; Phases of clinical research; Urology; Gastroenterology; Cancer; Surgery; Chemotherapy; Immunotherapy; Nivolumab","score_opus":0.06200820168896527,"score_gpt":0.4398082610935457,"score_spread":0.37780005940458045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168125055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969398,0.00015126415,0.00041764052,0.0012619969,0.000044572822,0.0008936766,0.000007838746,0.0000030826113,0.0002801462],"genre_scores_gemma":[0.9982855,0.00009327823,0.0010805703,0.0004029244,0.000029444296,0.000012558386,0.000008290531,0.000016838008,0.00007065079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99441487,0.0023927516,0.0019658303,0.0002794686,0.00071615755,0.00023090935],"domain_scores_gemma":[0.99523497,0.0020720756,0.0013142896,0.0001788299,0.0009395981,0.00026023854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003974501,0.00019228194,0.0024336085,0.00039406103,0.000028421078,0.000009572473,0.00008819923,0.0000770237,0.00013400617],"category_scores_gemma":[0.0010848955,0.00012488247,0.00019562393,0.00062554085,0.00016357856,0.000104435334,0.00005277759,0.0007083187,0.0000010969213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79898465,0.03666376,0.09011955,0.00010700495,0.0007349148,0.001102581,0.000731672,0.0012645673,0.0015919384,0.000007819423,0.00002061506,0.06867093],"study_design_scores_gemma":[0.7766644,0.033403832,0.18291642,0.00032443146,0.0014372661,0.00003741205,0.00038830467,0.0020797153,0.002472398,0.00009089203,0.000047224057,0.00013770902],"about_ca_topic_score_codex":0.00002752069,"about_ca_topic_score_gemma":0.00018666028,"teacher_disagreement_score":0.09279688,"about_ca_system_score_codex":0.00018328585,"about_ca_system_score_gemma":0.0010565986,"threshold_uncertainty_score":0.50925595},"labels":[],"label_agreement":null},{"id":"W3168166940","doi":"10.1200/jco.2021.39.15_suppl.524","title":"The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Trastuzumab; Breast cancer; Stage (stratigraphy); Oncology; Receiver operating characteristic; Confidence interval; Cancer; Adjuvant therapy","score_opus":0.07048322028907646,"score_gpt":0.4645412224529246,"score_spread":0.3940580021638482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168166940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098796,0.00039465484,0.000006374325,0.0059057865,0.0005723953,0.00038462828,0.000029063378,0.000004097961,0.0017150204],"genre_scores_gemma":[0.9957261,0.0022353951,0.0002825012,0.00052740943,0.0005346591,0.000019757188,0.000002537645,0.000024192237,0.00064741017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583995,0.0007127137,0.0018826616,0.00022294758,0.0009460354,0.00039568997],"domain_scores_gemma":[0.993848,0.0025639043,0.0011218467,0.00026668012,0.001866858,0.00033268795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029144476,0.00014078579,0.0010671354,0.00008740226,0.000055779663,0.000013286442,0.0002618195,0.00026411473,0.00023715045],"category_scores_gemma":[0.0023000105,0.00008050102,0.00019569996,0.00038373165,0.00054752687,0.000120283126,0.00010258757,0.001758951,0.000008687992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007963082,0.0017882338,0.9063845,0.00009220156,0.0002552337,0.0004575547,0.00016473523,0.000045825578,0.000017041368,0.000011771099,0.00069273025,0.082127064],"study_design_scores_gemma":[0.0073214523,0.018367302,0.9647605,0.0009221064,0.00013158249,0.00013901418,0.0001371706,0.0001530004,0.00015102694,0.000009116291,0.007833129,0.00007464021],"about_ca_topic_score_codex":0.00017337292,"about_ca_topic_score_gemma":0.00052411924,"teacher_disagreement_score":0.082052425,"about_ca_system_score_codex":0.0003923432,"about_ca_system_score_gemma":0.005652931,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W3168187683","doi":"10.1200/jco.2021.39.15_suppl.12086","title":"Radiofrequency ablation for palliative treatment of osseous metastases results in rapid, significant, and durable improvements in pain relief and quality of life: Results from the OPuS One trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Analgesic; Surgery; Brief Pain Inventory; Radiofrequency ablation; Visual analogue scale; Adverse effect; Percutaneous; Palliative care; Bone pain; Anesthesia; Ablation; Chronic pain; Physical therapy; Internal medicine","score_opus":0.2750179938864449,"score_gpt":0.46692942002992077,"score_spread":0.1919114261434759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168187683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98091453,0.0035691324,0.00017953833,0.013283658,0.00022574715,0.0012719687,0.0004243022,0.0000020091195,0.000129088],"genre_scores_gemma":[0.97804177,0.011498275,0.0095110005,0.0005869376,0.00015488066,0.000024281773,0.00008403952,0.000009961144,0.000088858615],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99123067,0.0031154687,0.004838747,0.0002941131,0.0003569827,0.00016403446],"domain_scores_gemma":[0.9714407,0.023932915,0.003754046,0.00029511616,0.0003848607,0.00019238245],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016081251,0.00013527957,0.0018659343,0.00010543167,0.000020116868,0.0000073796436,0.00007882447,0.00013427941,0.000015622938],"category_scores_gemma":[0.060299084,0.000089675304,0.00022954626,0.00017590058,0.00018656504,0.00007755327,0.000027748663,0.00021729525,1.3124031e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57444984,0.016411413,0.039525516,0.00029233142,0.0020196533,0.000226127,0.0013863648,0.000037934176,0.00290935,0.00027218304,0.0011416255,0.36132768],"study_design_scores_gemma":[0.4210667,0.036421884,0.5293743,0.00041120432,0.0012835735,0.0000011908855,0.002565003,0.00042018204,0.00082570047,0.0028568346,0.004629876,0.00014353034],"about_ca_topic_score_codex":0.00079690374,"about_ca_topic_score_gemma":0.0002220685,"teacher_disagreement_score":0.4898488,"about_ca_system_score_codex":0.00010684874,"about_ca_system_score_gemma":0.0009859296,"threshold_uncertainty_score":0.9476164},"labels":[],"label_agreement":null},{"id":"W3168206392","doi":"10.1200/jco.2021.39.15_suppl.e14544","title":"Pre-clinical evaluation of PV-10 for <i><i>in vitro</i></i> anti-tumor activity in refractory and high-risk adult solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Melanoma; Cancer research; Refractory (planetary science); In vitro; Cancer; Cytotoxic T cell; Metastasis; Oncology; Internal medicine; Pathology; Biology","score_opus":0.10936692441501217,"score_gpt":0.5161462309395831,"score_spread":0.40677930652457095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168206392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473965,0.00083012827,0.000060044873,0.0029730357,0.0005771044,0.0005880704,0.000027633074,0.000004111816,0.00020019186],"genre_scores_gemma":[0.9928882,0.004331764,0.001502504,0.0005950305,0.00056261424,0.000022489086,0.000004341521,0.00001841348,0.0000746382],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99236155,0.00290432,0.0033184423,0.00034507422,0.00074214616,0.00032846408],"domain_scores_gemma":[0.9844708,0.0106020635,0.00242734,0.00026846142,0.0019581877,0.00027314303],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021735206,0.00015904711,0.0027035635,0.00019323031,0.000030062936,0.000005904916,0.00014256794,0.00033919254,0.00006345721],"category_scores_gemma":[0.0553307,0.00012414818,0.0004264007,0.00022498501,0.00042450815,0.00014500812,0.000107485255,0.0017099386,0.0000014473408],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06941046,0.014321648,0.20617394,0.0003219464,0.0011566065,0.0010138525,0.00033171376,0.00007362758,0.12503806,0.000018833853,0.0018383974,0.5803009],"study_design_scores_gemma":[0.030528769,0.011781741,0.941034,0.0002877187,0.00040867954,0.000106843145,0.00014999877,0.0038794565,0.009486798,0.0009450729,0.0012752314,0.0001156435],"about_ca_topic_score_codex":0.00008109509,"about_ca_topic_score_gemma":0.00047393737,"teacher_disagreement_score":0.7348601,"about_ca_system_score_codex":0.00025562683,"about_ca_system_score_gemma":0.003871323,"threshold_uncertainty_score":0.95262665},"labels":[],"label_agreement":null},{"id":"W3168214302","doi":"10.1200/jco.2021.39.15_suppl.tps12136","title":"Technology-enhanced palliative care for patients with cancer on phase 1 clinical trials.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Cancer Society","keywords":"Medicine; Palliative care; Psychosocial; Nausea; Quality of life (healthcare); Clinical trial; Distress; Cancer; TEC; Physical therapy; Anxiety; Randomized controlled trial; Depression (economics); Internal medicine; Nursing; Psychiatry","score_opus":0.2463950899857636,"score_gpt":0.5925228355910674,"score_spread":0.34612774560530385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168214302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695554,0.0021424056,0.0013861767,0.019019244,0.0046319203,0.0013563012,0.000097215154,0.00003009329,0.0017812446],"genre_scores_gemma":[0.9846503,0.0039594043,0.0035471749,0.0048355293,0.002549978,0.00010061086,0.000023031504,0.000036281515,0.00029768742],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9939107,0.0009208039,0.003999952,0.0003990384,0.00044592435,0.00032363724],"domain_scores_gemma":[0.98003596,0.010501028,0.0037552055,0.0002185985,0.0051441737,0.00034503127],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035104016,0.00022958833,0.0035522345,0.00017414056,0.00009593744,0.0000073076944,0.0001274601,0.00071850413,0.00020812915],"category_scores_gemma":[0.053110138,0.00014482187,0.0009779063,0.00033312725,0.0004643995,0.000064047184,0.000057019493,0.0017585142,0.000010017265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056114566,0.008293348,0.13528621,0.00006758884,0.0032752196,0.00021612438,0.00019634406,0.0000089799905,0.000028613016,0.00003750745,0.006678227,0.78979725],"study_design_scores_gemma":[0.24002402,0.2201326,0.3242754,0.0017938804,0.0057375664,0.000020133888,0.0027715645,0.000034231376,0.0013109285,0.00054581766,0.20296498,0.00038886894],"about_ca_topic_score_codex":0.0000018647847,"about_ca_topic_score_gemma":0.00007026537,"teacher_disagreement_score":0.7894084,"about_ca_system_score_codex":0.0004102671,"about_ca_system_score_gemma":0.0032596579,"threshold_uncertainty_score":0.95486593},"labels":[],"label_agreement":null},{"id":"W3168252000","doi":"10.1200/jco.2021.39.15_suppl.e12590","title":"H&amp;E-like histology of unstained fresh and formalin fixed breast tissue with Photo Acoustic Remote Sensing (PARS) microscopy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Pathology; H&E stain; Histology; Medicine; Staining; Microscopy; Frozen section procedure; Breast cancer; Cancer","score_opus":0.033724642090723206,"score_gpt":0.39916302025355965,"score_spread":0.3654383781628364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168252000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8379169,0.001016215,0.15777583,0.0024756056,0.00021472135,0.00014337621,0.00002520338,0.00000623746,0.0004258833],"genre_scores_gemma":[0.8513265,0.0010353554,0.145169,0.0018316067,0.0002455743,9.079281e-7,0.000045749137,0.000021385318,0.00032391603],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978724,0.00033808002,0.001185351,0.00028098814,0.00010265316,0.0002205234],"domain_scores_gemma":[0.9976186,0.00018973873,0.0011048347,0.0003251965,0.0005884859,0.00017309976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008890358,0.00015166757,0.00077151024,0.00004994498,0.000053204196,0.000006301106,0.00016202372,0.00056829856,0.000027641121],"category_scores_gemma":[0.0004600528,0.00012062414,0.00016470958,0.000098367454,0.00045171997,0.000004511998,0.00013259683,0.00038463535,0.0000011749167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009736886,0.00021314844,0.0010732377,0.000029625282,0.00021471696,0.00016507815,0.000017969767,0.000017294578,0.9554129,0.000059633105,0.004240277,0.037582394],"study_design_scores_gemma":[0.005278892,0.0086455345,0.0055939234,0.00012454085,0.0005234071,0.011431636,0.00015243304,0.0001732218,0.33749866,0.0008034017,0.6293315,0.00044282744],"about_ca_topic_score_codex":0.000031001804,"about_ca_topic_score_gemma":0.00041664034,"teacher_disagreement_score":0.62509125,"about_ca_system_score_codex":0.000021950178,"about_ca_system_score_gemma":0.0007877076,"threshold_uncertainty_score":0.491891},"labels":[],"label_agreement":null},{"id":"W3168280453","doi":"10.1200/jco.2021.39.15_suppl.4579","title":"Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; Kidney Foundation of Canada","funders":"","keywords":"Medicine; Psychosocial; Family medicine; Quality of life (healthcare); Cancer; Renal cell carcinoma; Kidney cancer; Nursing; Pathology; Internal medicine; Psychiatry","score_opus":0.08695324726702812,"score_gpt":0.3398234670527546,"score_spread":0.2528702197857265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168280453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098445,0.009885385,0.00011403544,0.0010960618,0.0014653712,0.00012416005,0.0019420012,0.0000020455202,0.0043865177],"genre_scores_gemma":[0.98796016,0.010158506,0.00078832754,0.00068305427,0.00033282142,0.0000040262416,0.00002622927,0.000008823014,0.000038076294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946631,0.00019371358,0.0044972436,0.0003427384,0.0001005397,0.00020265633],"domain_scores_gemma":[0.99038714,0.002419042,0.006329401,0.0003645079,0.00033009856,0.00016981755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015818515,0.00014416009,0.0013828634,0.00003362488,0.000041965388,0.00002319402,0.00028251676,0.00024517195,0.0002011436],"category_scores_gemma":[0.0034124255,0.00012223487,0.00026537152,0.00015149236,0.00032103472,0.00018999074,0.00019188726,0.00030115643,0.0000074311683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016482668,0.00040577544,0.9632257,0.000009172869,0.00038287375,0.00015820374,0.0013674469,0.000105562074,0.0000037897823,0.0005240868,0.0115561625,0.020612955],"study_design_scores_gemma":[0.0032326218,0.001118264,0.88796455,0.00005295551,0.00006396866,0.0000057421676,0.0006103221,0.000050933886,0.00017166867,0.0033286386,0.10327254,0.00012781899],"about_ca_topic_score_codex":0.0060052886,"about_ca_topic_score_gemma":0.0007742964,"teacher_disagreement_score":0.09171639,"about_ca_system_score_codex":0.00011993336,"about_ca_system_score_gemma":0.00036238504,"threshold_uncertainty_score":0.907824},"labels":[],"label_agreement":null},{"id":"W3168293474","doi":"10.1200/jco.2021.39.15_suppl.tps599","title":"Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Institute of Health Economics; University of Alberta","funders":"National Institute for Health and Care Research","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Internal medicine; Chemotherapy; Randomized controlled trial; Randomization; Anthracycline; Population; Cancer; Menopause; Gynecology","score_opus":0.06543597956316917,"score_gpt":0.43736191586316114,"score_spread":0.371925936299992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168293474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973768,0.0006245498,0.00066033646,0.00034327022,0.00034299787,0.0003650516,0.0002728103,0.0000029665625,0.000011213664],"genre_scores_gemma":[0.94521296,0.001433852,0.05261442,0.0000752436,0.00046150965,0.000040572206,0.000119814045,0.000017328452,0.000024295272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965837,0.00083354744,0.0018135208,0.00034806016,0.00024271081,0.00017847694],"domain_scores_gemma":[0.99636376,0.0007253506,0.001913722,0.00020119028,0.0006776207,0.00011834824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005719523,0.00023316575,0.002086804,0.00016650857,0.000030752406,0.000009402378,0.00012729195,0.00022544111,0.000061311104],"category_scores_gemma":[0.00049397215,0.00016461576,0.0010981834,0.00020198032,0.00016627212,0.000023431232,0.00003413706,0.00010028757,1.4632539e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63408226,0.014279535,0.29343644,0.0000047428457,0.007623155,0.00011168563,0.0004442897,0.003460361,0.04088229,0.000001080094,0.000003681781,0.0056704646],"study_design_scores_gemma":[0.5854933,0.0049332464,0.37274417,0.00004383455,0.001852869,0.000062544816,0.00008787245,0.0033576547,0.031246489,0.0000039829297,0.00002706271,0.00014694482],"about_ca_topic_score_codex":0.0009970375,"about_ca_topic_score_gemma":0.00028121448,"teacher_disagreement_score":0.07930773,"about_ca_system_score_codex":0.00033333545,"about_ca_system_score_gemma":0.0007994175,"threshold_uncertainty_score":0.6712836},"labels":[],"label_agreement":null},{"id":"W3168316637","doi":"10.1200/jco.2021.39.15_suppl.2023","title":"A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; McGill University; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Radiosurgery; Clinical endpoint; Brain metastasis; Lung cancer; Internal medicine; Oncology; Neurocognitive; Radiation therapy; Cancer; Clinical trial; Immunotherapy; Metastasis","score_opus":0.1204013645088234,"score_gpt":0.45732431924254013,"score_spread":0.33692295473371675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168316637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071854,0.0007592476,0.000110674,0.0071422467,0.00046715589,0.00070339383,0.000047018006,0.000003093928,0.0000486233],"genre_scores_gemma":[0.9921672,0.00013326643,0.0062532425,0.0009860584,0.00026036674,0.000018135925,0.000037559654,0.000019309138,0.00012491061],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99638784,0.0007891934,0.0020936704,0.00023329633,0.0002702444,0.00022572927],"domain_scores_gemma":[0.9894197,0.008260614,0.0015099006,0.00018679413,0.00034009153,0.00028291217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022208528,0.0001759917,0.0023535464,0.00015961865,0.00004326901,0.000007849601,0.000042816402,0.00015122909,0.000056247914],"category_scores_gemma":[0.0041186614,0.000112261456,0.00048483777,0.00015107576,0.00014404708,0.00009321996,0.000024734367,0.00018204602,3.108958e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36628735,0.085898586,0.05154663,0.000070116526,0.0029043404,0.0017430561,0.0002723727,0.0000038108742,0.000032170756,0.00011970792,0.0018590458,0.48926282],"study_design_scores_gemma":[0.619632,0.33087432,0.029210297,0.00017256151,0.0013449813,0.00020140568,0.00016061941,0.000029709072,0.00009009902,0.00010922485,0.01807719,0.00009756451],"about_ca_topic_score_codex":0.000014592413,"about_ca_topic_score_gemma":0.00004011769,"teacher_disagreement_score":0.48916525,"about_ca_system_score_codex":0.0001539855,"about_ca_system_score_gemma":0.001483665,"threshold_uncertainty_score":0.49307197},"labels":[],"label_agreement":null},{"id":"W3168328251","doi":"10.1200/jco.2021.39.15_suppl.e21575","title":"BRAF testing timelines and impact on the starting of systemic treatment.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Vemurafenib; Melanoma; Stage (stratigraphy); Internal medicine; Oncology; Turnaround time; Cancer; Timeline; Retrospective cohort study; Disease; Log-rank test; Metastatic melanoma; Survival analysis; Cancer research","score_opus":0.15285928230950835,"score_gpt":0.4414122225085154,"score_spread":0.28855294019900707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168328251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670935,0.0011891827,0.000045184668,0.00054429955,0.00025724497,0.000046426983,0.0000053886174,0.0000011862229,0.0012017669],"genre_scores_gemma":[0.9975825,0.00039378405,0.00076275435,0.00033773493,0.00078095536,8.5793215e-7,0.0000020589046,0.000006694612,0.0001326907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983829,0.00038243283,0.0009277107,0.000112630645,0.000085252905,0.00010906088],"domain_scores_gemma":[0.9972526,0.0013181437,0.000907493,0.00014283582,0.00028768895,0.00009128455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012703829,0.000083867526,0.00047718463,0.000017746614,0.000031399224,0.000006145684,0.00008277465,0.00016348691,0.000016622951],"category_scores_gemma":[0.0046556895,0.00004317066,0.00022111493,0.00004747457,0.00007299157,0.0000024192445,0.000042616728,0.00015153058,0.0000016629986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010074466,0.00071390433,0.10934329,0.000030900184,0.00057109055,0.0002760003,0.000118524185,0.00016334422,0.7427471,0.00013184136,0.0022894086,0.14260714],"study_design_scores_gemma":[0.019162772,0.17045243,0.2360462,0.0011057726,0.0011912473,0.0074212668,0.0034376464,0.001323361,0.5153191,0.0019435501,0.041774835,0.0008217927],"about_ca_topic_score_codex":0.000007547066,"about_ca_topic_score_gemma":0.000008018233,"teacher_disagreement_score":0.22742796,"about_ca_system_score_codex":0.000015041251,"about_ca_system_score_gemma":0.0007724406,"threshold_uncertainty_score":0.5573631},"labels":[],"label_agreement":null},{"id":"W3168343092","doi":"10.1200/jco.2021.39.15_suppl.e18583","title":"Patient-reported outcomes predicting non-fatal self-injury after a cancer diagnosis: A population-based case-control study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Toronto; University Health Network; Sunnybrook Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; University of Manitoba; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Conditional logistic regression; Cancer; Logistic regression; Distress; Population; Internal medicine; Pediatrics; Case-control study; Clinical psychology; Environmental health","score_opus":0.04487236537602575,"score_gpt":0.42937418443824843,"score_spread":0.3845018190622227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168343092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99094003,0.0006457332,0.000045985456,0.0035206198,0.004227238,0.0004314064,0.000058846555,0.000026912636,0.00010324774],"genre_scores_gemma":[0.99208343,0.000060833056,0.00031274685,0.005869122,0.0013307278,0.00026341362,0.0000035592782,0.000028417799,0.000047750877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951935,0.0006539207,0.0029855575,0.00030711936,0.0005810445,0.0002789034],"domain_scores_gemma":[0.9936598,0.0027233055,0.001854437,0.00030736686,0.0010145016,0.0004405724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017516869,0.00019944714,0.001733566,0.00012591295,0.00006446123,0.00001978767,0.00007522078,0.0003324931,0.0007425024],"category_scores_gemma":[0.0037611222,0.00014800212,0.00080259744,0.00023240453,0.000039669707,0.000115660034,0.000041475756,0.0010106509,0.0000034350755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030375156,0.0029235464,0.9029878,0.000037438964,0.0013514729,0.039387457,0.00059930433,0.000027108226,0.0000023001467,2.975288e-7,0.00040221712,0.04924355],"study_design_scores_gemma":[0.010001385,0.0064392793,0.97513956,0.00017026541,0.002068626,0.0012884747,0.0012636472,0.0002495832,0.000020757856,0.000007387445,0.003212376,0.00013863503],"about_ca_topic_score_codex":0.0010741462,"about_ca_topic_score_gemma":0.0075967214,"teacher_disagreement_score":0.072151795,"about_ca_system_score_codex":0.0003243849,"about_ca_system_score_gemma":0.0028514778,"threshold_uncertainty_score":0.81298804},"labels":[],"label_agreement":null},{"id":"W3168345821","doi":"10.1200/jco.2021.39.15_suppl.7014","title":"Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Internal medicine; Proportional hazards model; Multivariate analysis; Myeloid leukemia; Neutropenia; Induction chemotherapy; Univariate analysis; Chemotherapy; Gastroenterology; Oncology","score_opus":0.11093611767303269,"score_gpt":0.44106333653889807,"score_spread":0.3301272188658654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168345821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932782,0.00018189922,0.00025926213,0.004490678,0.0005342404,0.0010748738,0.00013005322,0.000005974992,0.000044798544],"genre_scores_gemma":[0.9900229,0.0008946889,0.007502375,0.00088304013,0.00041538005,0.000017093547,0.000083471234,0.00004806269,0.00013298067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99419874,0.0011554834,0.0029647222,0.00042323914,0.0008584611,0.000399353],"domain_scores_gemma":[0.98335594,0.010577192,0.002317136,0.0005191934,0.0028640856,0.00036648402],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028404656,0.00030307792,0.0027320911,0.00019306573,0.00004093525,0.0000149377975,0.0003672638,0.0005787909,0.00012048896],"category_scores_gemma":[0.024508148,0.00016749001,0.0005003426,0.00033903203,0.0005124064,0.00018979605,0.00021157647,0.0014368038,8.3771226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47683915,0.0031670851,0.49032182,0.00008432754,0.0029276423,0.0005814945,0.0007433635,0.000014556603,0.0060286955,0.000015929714,0.0030755443,0.01620039],"study_design_scores_gemma":[0.22912404,0.021399342,0.7422966,0.0004574945,0.0011822215,0.000029984398,0.0005004429,0.0003046519,0.002206901,0.00042005721,0.0018949666,0.0001833414],"about_ca_topic_score_codex":0.0005438964,"about_ca_topic_score_gemma":0.0003247884,"teacher_disagreement_score":0.25197473,"about_ca_system_score_codex":0.00043736858,"about_ca_system_score_gemma":0.0033952533,"threshold_uncertainty_score":0.98370886},"labels":[],"label_agreement":null},{"id":"W3168388716","doi":"10.1200/jco.2021.39.15_suppl.11023","title":"Faculty development: What do we know about barriers, enablers, and satisfaction levels among African oncology faculty?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Oncology; Curriculum; Faculty development; Medicine; Medical education; Internal medicine; Thematic analysis; Interim; Descriptive statistics; Psychology; Professional development; Qualitative research; Pedagogy; Political science","score_opus":0.10109483370222992,"score_gpt":0.4854677371085485,"score_spread":0.3843729034063186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168388716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87446463,0.06291003,0.002919144,0.04581912,0.009320244,0.00049236964,0.00002693711,0.00005125333,0.003996273],"genre_scores_gemma":[0.66093373,0.22663556,0.09643247,0.008182844,0.0040876335,0.000020674408,0.000032269487,0.0000697848,0.0036050247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99529135,0.0008569769,0.002557994,0.0004348203,0.0004064,0.00045242716],"domain_scores_gemma":[0.9935304,0.002545899,0.0020460975,0.00022062211,0.00075873616,0.0008982726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028968316,0.0002771792,0.0022084173,0.00016359819,0.0002258213,0.00003647673,0.00016519353,0.0012087453,0.000892758],"category_scores_gemma":[0.004008135,0.00020643337,0.00036721217,0.00026029898,0.0009480392,0.0006505672,0.00009302397,0.001968732,0.00001709161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016723374,0.00041485883,0.08549623,0.000038116727,0.00081916334,0.0019725333,0.0014088049,0.000017816425,0.00017564713,0.00013153338,0.0046461034,0.9032068],"study_design_scores_gemma":[0.006259624,0.0033839787,0.2863904,0.000318784,0.00021903579,0.001895174,0.0034957433,0.00001463817,0.00019246076,0.00045792674,0.69721365,0.00015857942],"about_ca_topic_score_codex":0.0000070708893,"about_ca_topic_score_gemma":0.00018823273,"teacher_disagreement_score":0.9030483,"about_ca_system_score_codex":0.00074390654,"about_ca_system_score_gemma":0.0063148215,"threshold_uncertainty_score":0.9993185},"labels":[],"label_agreement":null},{"id":"W3168388852","doi":"10.1200/jco.2021.39.15_suppl.5080","title":"A phase II randomized controlled trial of exercise on biochemical progression in men with prostate cancer on active surveillance.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cardiorespiratory fitness; Prostate cancer; High-intensity interval training; Interval training; Internal medicine; Randomized controlled trial; Aerobic exercise; Oncology; Confidence interval; Physical therapy; Cancer","score_opus":0.05441700543241077,"score_gpt":0.5210251765491142,"score_spread":0.4666081711167034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168388852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821118,0.00072246953,0.0000021257422,0.009556648,0.00092690054,0.00368463,0.000008589822,0.0000040131945,0.0029828],"genre_scores_gemma":[0.9915307,0.006104706,0.00025873858,0.0010671851,0.0006616336,0.00019529094,0.000007043345,0.000013341988,0.00016134717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943396,0.0015538586,0.0030595697,0.0002183542,0.00055061147,0.0002779992],"domain_scores_gemma":[0.99191195,0.0045669945,0.002361086,0.00014614733,0.00048300833,0.0005308319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069866036,0.00015090061,0.0055332338,0.00013467281,0.000029380117,0.0000021756882,0.000051546565,0.00029695104,0.00005816986],"category_scores_gemma":[0.0050278055,0.00008047584,0.00072075985,0.00017976585,0.0001953433,0.00003026773,0.000023255334,0.0010315297,0.000001131967],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8775805,0.0153567465,0.00041810615,0.00009990386,0.00018149719,0.00045507198,0.00018326858,0.0000033205783,0.00018802904,0.000006508071,0.0006285967,0.10489841],"study_design_scores_gemma":[0.9193468,0.07571491,0.0008840323,0.0013534236,0.00025854557,0.000048657537,0.00013218811,0.00006282313,0.0012603082,0.000028040007,0.00084719417,0.00006304852],"about_ca_topic_score_codex":0.000024517341,"about_ca_topic_score_gemma":0.000021629676,"teacher_disagreement_score":0.10483536,"about_ca_system_score_codex":0.00030126923,"about_ca_system_score_gemma":0.005911507,"threshold_uncertainty_score":0.99972403},"labels":[],"label_agreement":null},{"id":"W3168407158","doi":"10.1200/jco.2021.39.15_suppl.8006","title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Neutropenia; Internal medicine; Multiple myeloma; Gastroenterology; Anemia; Toxicity; Chimeric antigen receptor; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.06914840343259031,"score_gpt":0.42732675216882743,"score_spread":0.3581783487362371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168407158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595976,0.0005506964,0.000063415915,0.0013363296,0.0004335226,0.00049484253,0.000010064867,0.0000070243595,0.0011443195],"genre_scores_gemma":[0.9921785,0.003297985,0.0030276948,0.00029479977,0.00034665715,0.0000017309221,0.00003644734,0.000034192148,0.00078198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952179,0.000872274,0.002521382,0.00033208658,0.0007424827,0.00031382623],"domain_scores_gemma":[0.99283415,0.003978402,0.0014340864,0.00036414192,0.0010502365,0.00033899496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025020423,0.00018606948,0.0016547474,0.00028391686,0.000044445227,0.00001411496,0.0001657843,0.0004751503,0.00089051516],"category_scores_gemma":[0.0040487666,0.00012432084,0.00022535388,0.00046721596,0.00031517533,0.00017536523,0.00008640144,0.0015061096,0.000008018424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19196032,0.008018151,0.60857147,0.00014777009,0.00038347606,0.0017822467,0.0003223863,0.00001379111,0.02283327,0.000009073268,0.00076076214,0.16519727],"study_design_scores_gemma":[0.05807777,0.01620515,0.88843024,0.0003134708,0.000102511985,0.00012838154,0.00018164929,0.00007814161,0.001418151,0.000011332436,0.034931645,0.00012155338],"about_ca_topic_score_codex":0.00001931834,"about_ca_topic_score_gemma":0.00013772267,"teacher_disagreement_score":0.27985877,"about_ca_system_score_codex":0.00019881416,"about_ca_system_score_gemma":0.0020541963,"threshold_uncertainty_score":0.9750517},"labels":[],"label_agreement":null},{"id":"W3168412060","doi":"10.1200/jco.2021.39.15_suppl.11504","title":"SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Tolerability; Internal medicine; Sarcoma; Progressive disease; Phases of clinical research; Leukapheresis; Surgery; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Oncology; Gastroenterology; Clinical trial; Pathology; Adverse effect; Stem cell; CD34","score_opus":0.10599834406556526,"score_gpt":0.48494079997412204,"score_spread":0.3789424559085568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168412060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251366,0.00033393883,0.000062424915,0.0013036398,0.0012156208,0.0007827143,0.000016464248,0.000009206924,0.003762339],"genre_scores_gemma":[0.98947173,0.0005464066,0.0056405184,0.000640048,0.0011845548,0.000009407634,0.000018050836,0.00005457798,0.00243473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929148,0.0010368148,0.0037967765,0.0003972157,0.0012875348,0.00056687556],"domain_scores_gemma":[0.9925403,0.0030614063,0.0019756295,0.00049780036,0.0012882944,0.0006365989],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003131225,0.00027156415,0.0027317991,0.00035469842,0.00003908236,0.000017164934,0.00032901915,0.00050829054,0.0020168666],"category_scores_gemma":[0.0028778187,0.00018337919,0.0006438753,0.00064593274,0.00039369566,0.00020992696,0.00011344022,0.001927728,0.000016505988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61791015,0.03680768,0.01983756,0.00009462387,0.00039080973,0.003066973,0.00016272119,0.000011173859,0.0062748706,0.000009360879,0.00046708575,0.314967],"study_design_scores_gemma":[0.614065,0.27536997,0.06258947,0.00028254863,0.00035441644,0.00024133008,0.00031116666,0.00008295749,0.0029347448,0.00006959605,0.04345336,0.00024544165],"about_ca_topic_score_codex":0.000027196125,"about_ca_topic_score_gemma":0.00019605039,"teacher_disagreement_score":0.31472158,"about_ca_system_score_codex":0.00038842647,"about_ca_system_score_gemma":0.0073380694,"threshold_uncertainty_score":0.9988954},"labels":[],"label_agreement":null},{"id":"W3168426595","doi":"10.1200/jco.2021.39.15_suppl.6567","title":"Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Hazard ratio; Sunitinib; Internal medicine; Renal cell carcinoma; Cabozantinib; Oncology; Proportional hazards model; Adverse effect; Gastroenterology; Surgery; Confidence interval","score_opus":0.18635390962431345,"score_gpt":0.4391770804113108,"score_spread":0.25282317078699734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168426595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992158,0.002653874,0.0001504835,0.00040139022,0.00054836855,0.0002769327,0.0017780752,0.0000053446615,0.00202753],"genre_scores_gemma":[0.9941996,0.0014152562,0.0033883564,0.00012917057,0.00015027473,0.000006896601,0.00015013553,0.000031084473,0.0005292797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99202263,0.0004347352,0.0063879127,0.0005605662,0.00016567735,0.00042845687],"domain_scores_gemma":[0.9874606,0.0019882494,0.008692983,0.00084530486,0.0006132628,0.00039961044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003020768,0.00030216927,0.004472548,0.00065525103,0.00003875559,0.00001660879,0.00062430586,0.00030232896,0.00064650795],"category_scores_gemma":[0.004011006,0.00026613227,0.00087468297,0.0008428601,0.0004148527,0.000528513,0.00022378837,0.00045199858,0.000013162237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15503147,0.013375676,0.68107,0.0007784459,0.0057518296,0.00076968066,0.0013039644,0.0036233794,0.0007927846,0.0025779693,0.00042455608,0.1345002],"study_design_scores_gemma":[0.045643594,0.023060251,0.91282773,0.0002689148,0.0020698998,0.000014649552,0.0005363974,0.00654458,0.00070707046,0.0005689867,0.0071683275,0.0005895746],"about_ca_topic_score_codex":0.00037155056,"about_ca_topic_score_gemma":0.0012293616,"teacher_disagreement_score":0.23175772,"about_ca_system_score_codex":0.00036392524,"about_ca_system_score_gemma":0.0028386351,"threshold_uncertainty_score":0.9999791},"labels":[],"label_agreement":null},{"id":"W3168437780","doi":"10.1200/jco.2021.39.15_suppl.11566","title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Clinical endpoint; Quality assurance; Protocol (science); Clinical trial; Randomized controlled trial; Surgery; Internal medicine","score_opus":0.3897984177472391,"score_gpt":0.5976754563498785,"score_spread":0.2078770386026394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168437780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755181,0.001615964,0.000008363239,0.015451752,0.00018750044,0.0068743112,0.00007061323,0.0000018394068,0.00027157832],"genre_scores_gemma":[0.9948255,0.0013597062,0.0019326168,0.00053828687,0.0006957172,0.0006250015,0.0000049121095,0.000009044199,0.000009209364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938249,0.0024044034,0.0029918822,0.0002083514,0.0003936255,0.00017680877],"domain_scores_gemma":[0.9786041,0.019196818,0.0012634653,0.00041364157,0.00037092977,0.0001510895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031349154,0.00015130219,0.0018101129,0.00003189845,0.000031955344,0.000012273514,0.00015423652,0.00021270137,0.000071991286],"category_scores_gemma":[0.00487005,0.000063954416,0.0007228547,0.00013989917,0.00046092964,0.000047199403,0.000016669299,0.00041357405,5.563598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20056827,0.041190628,0.58730125,0.000039812,0.0013492182,0.0011683073,0.0012551917,0.0000062472755,0.00048802575,0.00024944707,0.0010033122,0.16538028],"study_design_scores_gemma":[0.11683346,0.04063481,0.8347786,0.00017143213,0.00021522674,0.00010702949,0.00033677788,0.000025840303,0.00024830716,0.00022905304,0.0063698324,0.00004959448],"about_ca_topic_score_codex":0.0006397783,"about_ca_topic_score_gemma":0.00022275328,"teacher_disagreement_score":0.24747738,"about_ca_system_score_codex":0.0002188124,"about_ca_system_score_gemma":0.0011994668,"threshold_uncertainty_score":0.5830257},"labels":[],"label_agreement":null},{"id":"W3168439929","doi":"10.1200/jco.2021.39.15_suppl.4011","title":"hENT1 gene expression as a predictor of response to gemcitabine and nab-paclitaxel in advanced pancreatic cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Toronto General Hospital; Dalhousie University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Oncology; Internal medicine; Pancreatic cancer; Regimen; Chemotherapy; Cancer; Irinotecan","score_opus":0.10347659647722598,"score_gpt":0.5148480682784685,"score_spread":0.41137147180124256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168439929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818615,0.0032992538,0.00010465103,0.013299952,0.00035196744,0.00031574964,0.000009633742,0.0000044779217,0.0007528429],"genre_scores_gemma":[0.9727128,0.004592794,0.019372176,0.0014395912,0.00035862467,0.000023541455,0.0000017634339,0.000015893456,0.001482788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952907,0.0013585538,0.0023110877,0.00026044616,0.00047308407,0.00030610643],"domain_scores_gemma":[0.9916609,0.0058684396,0.000831457,0.00025897493,0.00073225785,0.00064799923],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004920449,0.00013445843,0.0022389668,0.00022855913,0.000028116447,0.000004075738,0.00012930697,0.00036841552,0.0003489295],"category_scores_gemma":[0.028298015,0.00009852091,0.0002074421,0.0003019921,0.00024414874,0.00008160436,0.00013591515,0.0008017907,0.0000070428673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06561741,0.0017845435,0.78969073,0.00012323866,0.00027232547,0.0027399773,0.00052781356,0.00001484402,0.11551062,0.000027411217,0.0011361648,0.022554904],"study_design_scores_gemma":[0.017418314,0.019144244,0.9471257,0.00088364014,0.00032613703,0.0006604227,0.00055626075,0.00007990336,0.004700087,0.000428031,0.008584409,0.00009285077],"about_ca_topic_score_codex":0.00004649515,"about_ca_topic_score_gemma":0.000064847416,"teacher_disagreement_score":0.15743496,"about_ca_system_score_codex":0.00022351636,"about_ca_system_score_gemma":0.004888695,"threshold_uncertainty_score":0.97988707},"labels":[],"label_agreement":null},{"id":"W3168443498","doi":"10.1200/jco.2021.39.15_suppl.4042","title":"Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Immune checkpoint; Medicine; Nivolumab; Cancer research; Neoadjuvant therapy; Cancer; Immunotherapy; Esophageal cancer; Immune system; Bladder cancer; Oncology; Internal medicine; Immunology; Breast cancer","score_opus":0.08984423630729234,"score_gpt":0.4839543154257004,"score_spread":0.39411007911840806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168443498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9381685,0.04044039,0.000008096666,0.020142939,0.00059744326,0.0002511564,0.00001467622,0.000004946065,0.0003718458],"genre_scores_gemma":[0.99112475,0.003733203,0.0029767726,0.00090862776,0.00043471594,0.000015111329,0.0000027692197,0.000017208064,0.0007868182],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951004,0.0011874449,0.0026175084,0.00025846425,0.00045562212,0.00038055508],"domain_scores_gemma":[0.99586105,0.0017728568,0.0009897209,0.00032830116,0.0005701004,0.00047797637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050219567,0.0001642943,0.0019190995,0.00023694779,0.00002815636,0.00000709878,0.00022178928,0.00031092425,0.000334831],"category_scores_gemma":[0.006415156,0.00011665371,0.00064634345,0.0003524024,0.00017569872,0.00004888428,0.00015309447,0.001275485,0.000015787795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17844968,0.007902038,0.15309183,0.00015155262,0.0011887853,0.13491122,0.00090685365,0.00026655092,0.19215868,0.000057024612,0.0009179864,0.3299978],"study_design_scores_gemma":[0.012674196,0.019210162,0.9203523,0.00024028856,0.00015109518,0.0017612082,0.0001937856,0.0000043774244,0.042802583,0.00017994094,0.0023498544,0.00008020057],"about_ca_topic_score_codex":0.0001777288,"about_ca_topic_score_gemma":0.00018703485,"teacher_disagreement_score":0.7672605,"about_ca_system_score_codex":0.00061763276,"about_ca_system_score_gemma":0.005601399,"threshold_uncertainty_score":0.99366415},"labels":[],"label_agreement":null},{"id":"W3168444608","doi":"10.1200/jco.2021.39.15_suppl.4520","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Carboplatin; Gemcitabine; Internal medicine; Oncology; Bladder cancer; Clinical endpoint; Cystectomy; Chemotherapy; Cisplatin; Clinical trial; Pembrolizumab; Cancer; Urothelial carcinoma; Immunotherapy","score_opus":0.13188379846529086,"score_gpt":0.45187604112465235,"score_spread":0.3199922426593615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168444608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980093,0.0025631774,0.0017828741,0.011902245,0.0023666427,0.0007139437,0.00022887265,0.0000072344383,0.00034203377],"genre_scores_gemma":[0.9814482,0.004176446,0.006095339,0.004163484,0.0034856345,0.000024848901,0.00003496023,0.000035576224,0.0005355103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99318033,0.00074188,0.0048009125,0.00049787684,0.00041133614,0.00036766237],"domain_scores_gemma":[0.9858137,0.009709803,0.0025365597,0.0005244028,0.0009991443,0.00041641598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040042656,0.00025794795,0.0036464238,0.00012006626,0.00009743456,0.000015420066,0.00027947567,0.0005349426,0.0003998018],"category_scores_gemma":[0.00811276,0.00015917962,0.002064295,0.00035636636,0.00050741737,0.00008137615,0.00011501213,0.0009198939,0.0000057541265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32767206,0.006619,0.36629808,0.00005963295,0.020046173,0.0008020858,0.00045818268,0.00014000223,0.00043110902,0.0002117628,0.0050107418,0.27225116],"study_design_scores_gemma":[0.21207856,0.02052122,0.6911002,0.00009516007,0.015821135,0.00009091821,0.00030120552,0.00094644405,0.00020811366,0.0010429118,0.057585936,0.00020824469],"about_ca_topic_score_codex":0.00015867708,"about_ca_topic_score_gemma":0.0008998209,"teacher_disagreement_score":0.32480207,"about_ca_system_score_codex":0.00009928443,"about_ca_system_score_gemma":0.0029171158,"threshold_uncertainty_score":0.9712318},"labels":[],"label_agreement":null},{"id":"W3168464126","doi":"10.1200/jco.2021.39.15_suppl.5038","title":"Complementary detection of genomic alterations in metastatic castration-resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Medicine; Germline; Oncology; Cancer research; Gene; Fusion gene; DNA sequencing; Internal medicine; Cancer; Computational biology; Biology; Genetics; Androgen receptor","score_opus":0.26212701438473324,"score_gpt":0.5410428733183825,"score_spread":0.2789158589336493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168464126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994093,0.0029973602,0.000062043255,0.0021792024,0.00021755256,0.00023403321,0.0001237195,0.0000017259777,0.00009134246],"genre_scores_gemma":[0.99231696,0.002783591,0.0045018406,0.00014225088,0.00013269197,0.000009611968,0.000030160267,0.000008523341,0.00007439426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99725074,0.00036100036,0.0018498881,0.00015496506,0.00024062989,0.00014278892],"domain_scores_gemma":[0.99750876,0.00084230315,0.0010267156,0.00010515681,0.00040679253,0.000110295296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006795882,0.00009573507,0.001028346,0.00010464241,0.000031116364,0.0000072140338,0.00005122303,0.00005698934,0.00023758019],"category_scores_gemma":[0.000317731,0.000069434245,0.0001301,0.00016421205,0.00018462563,0.00011935238,0.000034230936,0.00031641647,9.987647e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007993553,0.0013834748,0.033152644,0.00019095515,0.0014198987,0.0011369862,0.001002421,0.00023950859,0.92632216,0.000025205003,0.00011615301,0.027017063],"study_design_scores_gemma":[0.017564999,0.007189929,0.47762287,0.00033960698,0.0012708502,0.00014579484,0.0018481169,0.0006423494,0.4899177,0.0009951126,0.0023521716,0.0001105161],"about_ca_topic_score_codex":0.0015403484,"about_ca_topic_score_gemma":0.0049510724,"teacher_disagreement_score":0.44447023,"about_ca_system_score_codex":0.00016005068,"about_ca_system_score_gemma":0.0016804562,"threshold_uncertainty_score":0.29810572},"labels":[],"label_agreement":null},{"id":"W3168490437","doi":"10.1200/jco.2021.39.15_suppl.tps5610","title":"SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Karyopharm Therapeutics","keywords":"Medicine; Internal medicine; Endometrial cancer; Taxane; Oncology; Placebo; Chemotherapy; Radiation therapy; Phases of clinical research; Refractory (planetary science); Gastroenterology; Surgery; Cancer; Breast cancer; Pathology","score_opus":0.06155120322114999,"score_gpt":0.44916052571359727,"score_spread":0.3876093224924473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168490437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546904,0.0033483757,0.001243201,0.001840447,0.037593868,0.0009915573,0.000056851437,0.0000045996803,0.00023071509],"genre_scores_gemma":[0.96004635,0.015380334,0.0039716284,0.00101875,0.018940892,0.00019802213,0.000041519732,0.000038414506,0.0003641004],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99451697,0.0014193174,0.0030228666,0.00036667867,0.00036282005,0.00031135557],"domain_scores_gemma":[0.9934704,0.0028935664,0.002382095,0.0002706911,0.00078125665,0.00020204879],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004465745,0.00022967812,0.0022234807,0.0001633043,0.000024001698,0.000011360055,0.00023816219,0.00046660306,0.00019347687],"category_scores_gemma":[0.018059224,0.00017188326,0.000927549,0.00031201573,0.0002570265,0.00001620825,0.000048309554,0.00056378805,0.0000010596628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8477957,0.0027282615,0.0000449286,0.000023011862,0.00027759362,0.00001170107,0.00004650901,0.00011911846,0.006779468,0.000020806057,0.0023406858,0.13981222],"study_design_scores_gemma":[0.76069874,0.010753239,0.00009962291,0.0000800356,0.00017018434,0.0000106830075,0.000057107893,0.00020122233,0.005260839,0.00003827411,0.22248033,0.00014973765],"about_ca_topic_score_codex":0.000019516357,"about_ca_topic_score_gemma":0.00038636872,"teacher_disagreement_score":0.22013964,"about_ca_system_score_codex":0.00011506598,"about_ca_system_score_gemma":0.0038120893,"threshold_uncertainty_score":0.9902121},"labels":[],"label_agreement":null},{"id":"W3168499052","doi":"10.1200/jco.2021.39.15_suppl.11022","title":"The clinician educator career in oncology.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Medical education; Family medicine; Oncology; Internal medicine","score_opus":0.15420463643018323,"score_gpt":0.5894574233845854,"score_spread":0.43525278695440217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168499052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7015696,0.018662153,0.00025032499,0.20262454,0.02710228,0.00029272234,0.0000023522834,0.0000144590185,0.04948153],"genre_scores_gemma":[0.7957006,0.05633958,0.035129197,0.0827493,0.020820588,0.000018247552,0.0000045782267,0.00006287368,0.009175019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949,0.0013036658,0.0029900689,0.00021024619,0.00026541247,0.0003306381],"domain_scores_gemma":[0.9826116,0.014476135,0.0016049478,0.00032414548,0.0006315968,0.00035159572],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0070337523,0.00012832251,0.0016350832,0.00008165827,0.000094713476,0.0000065780164,0.00027109386,0.0008118657,0.00024290824],"category_scores_gemma":[0.013963666,0.00007456535,0.0005724001,0.00025122258,0.00071095856,0.00008224506,0.000054909797,0.0025425858,0.000031852283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039609238,0.0027758274,0.1832297,0.000009407211,0.0003592414,0.0052771815,0.0002197683,0.000011334453,0.00007525232,0.00089553435,0.02969915,0.7734867],"study_design_scores_gemma":[0.0063141445,0.007133448,0.1375752,0.000049620932,0.00011913532,0.0020197802,0.0009271096,0.000014229893,0.000037025613,0.0017944007,0.8439481,0.00006776068],"about_ca_topic_score_codex":0.0000041733338,"about_ca_topic_score_gemma":0.00037506263,"teacher_disagreement_score":0.814249,"about_ca_system_score_codex":0.0004832054,"about_ca_system_score_gemma":0.012036364,"threshold_uncertainty_score":0.9997586},"labels":[],"label_agreement":null},{"id":"W3168516575","doi":"10.1200/jco.2021.39.15_suppl.3604","title":"Impact of radiotherapy for local control in T3 N0 rectal cancer managed with total mesorectal excision: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Total mesorectal excision; Meta-analysis; Colorectal cancer; Randomized controlled trial; Relative risk; Population; Radiation therapy; Cohort study; Internal medicine; Surgery; Cancer; Oncology; Confidence interval; Environmental health","score_opus":0.24437191315119133,"score_gpt":0.5686373063951621,"score_spread":0.32426539324397075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168516575","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021327213,0.994199,0.0005478497,0.0005171517,0.00015031394,0.0041959826,0.00011149384,0.000004884657,0.000060059352],"genre_scores_gemma":[0.0021527589,0.9955172,0.0008770994,0.00048534875,0.00019512478,0.0005223872,0.000015336673,0.000054027016,0.00018070974],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9883281,0.003137746,0.006998437,0.0005479889,0.0006332098,0.00035453963],"domain_scores_gemma":[0.9811889,0.010195954,0.0069543384,0.00044166684,0.00073202903,0.00048713945],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0058789053,0.0006154488,0.044599835,0.00048049516,0.000022138196,0.000013003355,0.00023201444,0.00071511714,0.00060102483],"category_scores_gemma":[0.0024912322,0.00028973757,0.013614325,0.0010862608,0.00027495297,0.0000817144,0.00004405343,0.00129094,7.465734e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003810909,0.0014253944,0.00025607488,0.25318718,0.6416121,0.0017928327,0.000020286612,0.000029489407,4.4635197e-8,0.0000056769777,0.00023846183,0.09762152],"study_design_scores_gemma":[0.008065722,0.017910674,0.0005130466,0.048026726,0.9137426,0.0023115003,0.00000977321,0.00006156912,2.9502644e-8,0.0000042708048,0.009110497,0.00024360625],"about_ca_topic_score_codex":0.00007372239,"about_ca_topic_score_gemma":0.00013487514,"teacher_disagreement_score":0.27213046,"about_ca_system_score_codex":0.00108907,"about_ca_system_score_gemma":0.004052476,"threshold_uncertainty_score":0.9999555},"labels":[],"label_agreement":null},{"id":"W3168540735","doi":"10.1200/jco.2021.39.15_suppl.9502","title":"Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Oncology; Regimen; Response Evaluation Criteria in Solid Tumors; Progressive disease; Stage (stratigraphy); Melanoma; Surgery; Gastroenterology; Chemotherapy; Cancer; Immunotherapy; Cancer research","score_opus":0.06720521001582311,"score_gpt":0.4402667250112583,"score_spread":0.37306151499543516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168540735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933524,0.0024025207,0.0005477229,0.003841173,0.0012144586,0.0005720624,0.000023848423,0.000017678629,0.0020453054],"genre_scores_gemma":[0.9745252,0.0064294874,0.012916801,0.002561498,0.0009241602,0.00000866319,0.000035868055,0.00006557195,0.0025327487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945871,0.00055174105,0.0032355154,0.0005307931,0.0006045885,0.00049022824],"domain_scores_gemma":[0.99248177,0.0028283694,0.0023681477,0.0004210131,0.0013749903,0.00052568794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004078418,0.0002887918,0.0026382394,0.00013104407,0.00013679688,0.00003308526,0.0001900464,0.0006317503,0.0001885918],"category_scores_gemma":[0.0017330539,0.00017921865,0.0005797235,0.00027896286,0.00063420506,0.00023189637,0.00008343929,0.0013996544,0.0000036806236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14959447,0.0064159506,0.6988151,0.00013662195,0.0025565806,0.0026020943,0.00014050896,0.000005534274,0.00058789854,0.000085428255,0.0068824403,0.13217734],"study_design_scores_gemma":[0.10780467,0.09232767,0.5792056,0.0006885059,0.0010553702,0.0011122791,0.00044670218,0.00012221174,0.0001619549,0.000041246236,0.21673413,0.00029970356],"about_ca_topic_score_codex":0.00004565503,"about_ca_topic_score_gemma":0.0001940941,"teacher_disagreement_score":0.20985168,"about_ca_system_score_codex":0.00016453442,"about_ca_system_score_gemma":0.0034273162,"threshold_uncertainty_score":0.73083246},"labels":[],"label_agreement":null},{"id":"W3168544199","doi":"10.1200/jco.2021.39.15_suppl.e21029","title":"Molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes: Multi-institution study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Trametinib; Vemurafenib; Dabrafenib; Oncology; Internal medicine; Lung cancer; KRAS; V600E; Cancer; Population; Adenocarcinoma; MEK inhibitor; Cancer research; Mutation; Kinase; Colorectal cancer; MAPK/ERK pathway; Metastatic melanoma","score_opus":0.0757969087840747,"score_gpt":0.48943926647804803,"score_spread":0.41364235769397334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168544199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460566,0.0013328983,0.0010865417,0.0015831791,0.0008065528,0.00028176224,0.000009335924,0.0000039299775,0.00029013012],"genre_scores_gemma":[0.9959507,0.00072149426,0.0017439482,0.0012281819,0.000117552816,0.000006741159,0.0000038648486,0.000010778487,0.0002167582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981536,0.00014951886,0.0012795312,0.00013817695,0.00016365868,0.00011549176],"domain_scores_gemma":[0.99783397,0.00035443297,0.00093633303,0.00012406976,0.0005838357,0.00016734321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048732,0.00010360431,0.001002378,0.00005958922,0.000029810239,0.0000060046623,0.0000507245,0.00014834083,0.00003749791],"category_scores_gemma":[0.00037508283,0.000070778595,0.00020694599,0.000098129894,0.00008640457,0.00003359344,0.00002663574,0.00034880845,0.0000010499704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041621496,0.0051467046,0.9406373,0.00008972369,0.0015893705,0.0018047973,0.00066091056,0.000034755027,0.002019926,0.000015342699,0.000028754743,0.047556195],"study_design_scores_gemma":[0.014027448,0.0031592024,0.9771573,0.00009571616,0.0029548772,0.0000902017,0.0004476618,0.00040036227,0.0006393889,0.000009631031,0.0009526575,0.000065581095],"about_ca_topic_score_codex":0.000052575928,"about_ca_topic_score_gemma":0.000053656997,"teacher_disagreement_score":0.047490615,"about_ca_system_score_codex":0.00011855039,"about_ca_system_score_gemma":0.0021894928,"threshold_uncertainty_score":0.3884066},"labels":[],"label_agreement":null},{"id":"W3168558887","doi":"10.1200/jco.2020.39.28_suppl.86","title":"Financial toxicity, symptom burden, illness perceptions, and communication confidence in cancer clinical trial participants.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Marital status; Confidence interval; Clinical trial; Adverse effect; Cancer; Internal medicine; Population; Environmental health","score_opus":0.27305430890683235,"score_gpt":0.47996332636134903,"score_spread":0.20690901745451667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168558887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97683394,0.007147577,0.0003855225,0.009255028,0.003341243,0.0001731356,0.0000310735,0.0000057901575,0.0028266679],"genre_scores_gemma":[0.95922506,0.03527979,0.0008034182,0.0025015047,0.0018600706,0.000015746475,0.0000024121578,0.000014712314,0.00029727235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934287,0.00042777843,0.0053651053,0.00035780246,0.00006672937,0.00035387257],"domain_scores_gemma":[0.9941541,0.001930125,0.0030272752,0.0003388751,0.0002713965,0.00027821536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0084655695,0.0001545565,0.0020092658,0.00013836168,0.000090059904,0.000054380158,0.00036715288,0.0006295116,0.00061116525],"category_scores_gemma":[0.012691644,0.00016131246,0.00040100762,0.00017684135,0.00044877996,0.00046303464,0.0001630262,0.0011771601,0.00005257667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012103346,0.0023655784,0.64786893,0.000036215202,0.000221469,0.00016262064,0.0011009485,0.00017985344,0.000011094307,0.10831484,0.0072242464,0.22041082],"study_design_scores_gemma":[0.037797287,0.0024351547,0.7530115,0.00012684865,0.000060359576,0.000036317277,0.00034202283,0.0004079912,0.000009088989,0.053727437,0.15171564,0.00033035057],"about_ca_topic_score_codex":0.00035816443,"about_ca_topic_score_gemma":0.0015557646,"teacher_disagreement_score":0.22008048,"about_ca_system_score_codex":0.00021555417,"about_ca_system_score_gemma":0.001603765,"threshold_uncertainty_score":0.9956249},"labels":[],"label_agreement":null},{"id":"W3168583568","doi":"10.1200/jco.2021.39.15_suppl.e18039","title":"Survival outcomes in primary angiosarcoma of the head and neck: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Meta-analysis; Radiation therapy; Systematic review; MEDLINE; Cochrane Library; Surgery; Chemoradiotherapy; Angiosarcoma; Internal medicine","score_opus":0.279921598983607,"score_gpt":0.5101907742514514,"score_spread":0.2302691752678444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168583568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022081519,0.99499255,0.0000035599396,0.0034450623,0.00015368877,0.0010148403,0.000011722497,0.0000018403177,0.00015592261],"genre_scores_gemma":[0.00012820157,0.99689925,0.00045172143,0.0020448389,0.00007563003,0.00001612167,0.000005044385,0.000020966807,0.0003582363],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.988,0.0041662413,0.006829618,0.00028814166,0.0005233863,0.00019264806],"domain_scores_gemma":[0.9890819,0.004225457,0.005580523,0.0005901973,0.00028836666,0.00023355467],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.009363807,0.00034023175,0.038714267,0.00025914653,0.000021349952,0.000009659586,0.0002894334,0.00044349258,0.000052576313],"category_scores_gemma":[0.006022905,0.00014506617,0.012692577,0.00066198385,0.00020263619,0.00004392439,0.00022783871,0.0013063097,9.154948e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019567637,0.0010227488,0.005184617,0.7123847,0.26766852,0.0008977499,0.00001579263,1.01044975e-7,3.088416e-8,0.00009099883,0.00020172687,0.012513439],"study_design_scores_gemma":[0.0010246943,0.00067039666,0.008027706,0.05563945,0.88611513,0.0012714829,0.000010703454,4.665162e-7,1.1566835e-8,0.000013326723,0.047107965,0.00011867637],"about_ca_topic_score_codex":0.000011898927,"about_ca_topic_score_gemma":0.000046775473,"teacher_disagreement_score":0.65674525,"about_ca_system_score_codex":0.0000708137,"about_ca_system_score_gemma":0.0014944222,"threshold_uncertainty_score":0.99719507},"labels":[],"label_agreement":null},{"id":"W3168593142","doi":"10.1200/jco.2021.39.15_suppl.12002","title":"Feasibility of a virtual hybrid resistance and balance training program for older patients with cancer and its preliminary effects on lower body strength and balance.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Stroke Rehabilitation and Recovery","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; University of Saskatchewan; University of Alberta; University of Regina","funders":"","keywords":"Medicine; Physical therapy; Population; Cancer; Balance (ability); Strength training; Internal medicine","score_opus":0.04288734671792831,"score_gpt":0.41571288966331305,"score_spread":0.3728255429453847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168593142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952931,0.0018870741,0.000022335033,0.0015473794,0.00048860855,0.00063126616,0.000023330897,0.000004861829,0.000102081605],"genre_scores_gemma":[0.99551576,0.0007072841,0.002884937,0.00046926033,0.0002298955,0.000021122789,0.0000033548044,0.000010621212,0.0001577831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837744,0.00019185795,0.00082081236,0.00024756775,0.00021159448,0.00015072031],"domain_scores_gemma":[0.99391806,0.0046174875,0.00065380527,0.000094009214,0.0004965413,0.00022010466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007642562,0.000114081704,0.0009735451,0.000044618348,0.00003108096,0.0000063638026,0.000032157688,0.00013575048,0.000009794035],"category_scores_gemma":[0.003994334,0.000075236065,0.00011826899,0.0000595438,0.00018942567,0.000074757874,0.000020633544,0.00035109176,7.7510364e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021526875,0.0025568358,0.7234711,0.000645769,0.00024926933,0.000090798545,0.00020564065,0.0000017892079,0.00009526839,0.000040980696,0.0006968718,0.25041878],"study_design_scores_gemma":[0.016747516,0.033360247,0.945875,0.0010015215,0.00020368633,0.000037729216,0.00011008966,0.00013113549,0.00014315617,0.000045787427,0.0022699935,0.00007412083],"about_ca_topic_score_codex":5.94193e-7,"about_ca_topic_score_gemma":0.000006971391,"teacher_disagreement_score":0.25034466,"about_ca_system_score_codex":0.000046610312,"about_ca_system_score_gemma":0.0005721259,"threshold_uncertainty_score":0.47818792},"labels":[],"label_agreement":null},{"id":"W3168598724","doi":"10.1200/jco.2021.39.15_suppl.4135","title":"Predictive value of germline <i>ATM</i> mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Genome British Columbia; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Cancer Care Ontario; Centre hospitalier universitaire de Québec; BC Cancer Agency; Vancouver General Hospital; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Moncton Hospital","funders":"","keywords":"Medicine; Internal medicine; Germline; Gemcitabine; Clinical endpoint; Oncology; Surrogate endpoint; Gastroenterology; Urology; Randomized controlled trial; Cancer; Gene; Genetics; Biology","score_opus":0.1648503272818469,"score_gpt":0.47713324895637704,"score_spread":0.31228292167453015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168598724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97378755,0.010435577,0.00008265572,0.012836263,0.00051163905,0.0012846142,0.000027108295,0.000008311571,0.0010262872],"genre_scores_gemma":[0.9814815,0.014307956,0.002318797,0.000980583,0.00061705464,0.00007184457,0.000020805546,0.000033651708,0.00016779518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912322,0.0030673165,0.0038307148,0.000488284,0.00085100124,0.0005304672],"domain_scores_gemma":[0.9773868,0.019438129,0.0015549227,0.0004500327,0.0007584623,0.00041167298],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0085376855,0.00033295644,0.0032720577,0.00038931603,0.000106652464,0.000023112838,0.0002771744,0.0004631227,0.00017946617],"category_scores_gemma":[0.01944599,0.00022097434,0.00041684354,0.00067349226,0.0010425413,0.00020727524,0.00012564543,0.00176026,0.000005678013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2689617,0.013836251,0.6747261,0.000381843,0.0034555849,0.011236187,0.005323857,0.0000903874,0.0003406333,0.0012210392,0.0007741598,0.019652247],"study_design_scores_gemma":[0.19890407,0.051867515,0.73657376,0.0002491485,0.0016161869,0.0016392842,0.003417967,0.0015583131,0.000026805486,0.0029806714,0.0009935863,0.00017267003],"about_ca_topic_score_codex":0.00022774872,"about_ca_topic_score_gemma":0.0004972462,"teacher_disagreement_score":0.070057616,"about_ca_system_score_codex":0.0002447848,"about_ca_system_score_gemma":0.0035243724,"threshold_uncertainty_score":0.98881364},"labels":[],"label_agreement":null},{"id":"W3168603500","doi":"10.1200/jco.2021.39.15_suppl.7000","title":"OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ponatinib; Clinical endpoint; Internal medicine; Regimen; Adverse effect; Gastroenterology; Dasatinib; Randomized controlled trial; Myeloid leukemia; Imatinib","score_opus":0.11285544431389544,"score_gpt":0.46048573744329807,"score_spread":0.34763029312940263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168603500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958384,0.0005762774,0.00041879312,0.0007241628,0.00030551723,0.00022242207,0.000003374629,0.0000057617985,0.001905264],"genre_scores_gemma":[0.9721675,0.00025583038,0.026835937,0.0003037245,0.00025325554,0.000002607796,0.000010397413,0.000013808623,0.00015693682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940759,0.00079518446,0.0040916232,0.00021763178,0.0006431017,0.00017656614],"domain_scores_gemma":[0.99117297,0.0029959495,0.004025102,0.00032697624,0.0012722417,0.00020674939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002854856,0.00013535944,0.0025181933,0.00029139413,0.000023687104,0.000004164086,0.00013677534,0.0002340572,0.0003970717],"category_scores_gemma":[0.00661989,0.00010257721,0.00068536,0.00075043534,0.00011153343,0.0000955777,0.00008886929,0.0005626397,0.0000020300886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009844232,0.039554436,0.79901564,0.00031076433,0.02369278,0.0043564388,0.0018730912,0.05503899,0.0018686133,0.00004686214,0.00044043866,0.06395773],"study_design_scores_gemma":[0.054190166,0.038425982,0.8727036,0.00030913405,0.020526228,0.0003353422,0.0039979955,0.008107849,0.0006573084,0.00007656085,0.00048872037,0.00018109364],"about_ca_topic_score_codex":0.000034190612,"about_ca_topic_score_gemma":0.000054717493,"teacher_disagreement_score":0.07368799,"about_ca_system_score_codex":0.00042527966,"about_ca_system_score_gemma":0.004374439,"threshold_uncertainty_score":0.7925105},"labels":[],"label_agreement":null},{"id":"W3168647721","doi":"10.1200/jco.2021.39.15_suppl.9504","title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Tolerability; Adjuvant; Phases of clinical research; Lenvatinib; Clinical trial; Adverse effect; Melanoma; Immunotherapy; Cancer; Cancer research","score_opus":0.06523484828108818,"score_gpt":0.43359733112642074,"score_spread":0.3683624828453326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168647721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944761,0.00045272737,0.000038155733,0.0029706855,0.00079591444,0.0006228737,0.000022619226,0.000010258434,0.0006106929],"genre_scores_gemma":[0.99248,0.0006662437,0.0040423977,0.0018664562,0.00033276906,0.000015075182,0.000033847533,0.00003124921,0.00053196255],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966115,0.00025909673,0.0021103441,0.0002994317,0.00044468264,0.00027499255],"domain_scores_gemma":[0.9947914,0.0019985412,0.0018695063,0.00019939212,0.0008940179,0.0002471489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011693164,0.0002087719,0.0015805931,0.00012654575,0.000060146827,0.000011078859,0.00011534909,0.0004062434,0.00021799089],"category_scores_gemma":[0.0023356874,0.00012450614,0.00032185783,0.00020741028,0.00032795483,0.0001214959,0.00004156551,0.0005775226,0.0000016137835],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63067496,0.0041599227,0.037828915,0.0002840783,0.0010032458,0.00038060584,0.00030803794,0.0000036981116,0.004416312,0.00004368755,0.007178074,0.31371847],"study_design_scores_gemma":[0.23323295,0.2084197,0.29798296,0.0024557495,0.00076084066,0.000675613,0.00045223653,0.00009395185,0.014157947,0.000063766805,0.2413436,0.00036068447],"about_ca_topic_score_codex":0.0000048231163,"about_ca_topic_score_gemma":0.000039643077,"teacher_disagreement_score":0.39744198,"about_ca_system_score_codex":0.00018848751,"about_ca_system_score_gemma":0.0024383597,"threshold_uncertainty_score":0.50772136},"labels":[],"label_agreement":null},{"id":"W3168673883","doi":"10.1200/jco.2021.39.15_suppl.e20020","title":"Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of British Columbia; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Karyopharm Therapeutics","keywords":"Daratumumab; Medicine; Pomalidomide; Carfilzomib; Lenalidomide; Bortezomib; Refractory (planetary science); Internal medicine; Regimen; Multiple myeloma; Population; Dexamethasone; Oncology; Gastroenterology; Pharmacology; Biology","score_opus":0.07674062404312741,"score_gpt":0.41199405177640797,"score_spread":0.33525342773328054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168673883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962288,0.00038950887,0.000043966815,0.0019878228,0.00013496805,0.0005052838,0.000013867129,0.00001684227,0.0006789367],"genre_scores_gemma":[0.9874304,0.00039541794,0.010892461,0.0005445713,0.0002891819,0.000009532572,0.000059298935,0.000037741716,0.0003413735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568874,0.00064673915,0.0019407066,0.00040123853,0.00075062725,0.0005719716],"domain_scores_gemma":[0.99422324,0.0020501183,0.0011983631,0.0003143041,0.0015563702,0.0006575984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013245636,0.0002792548,0.0020525858,0.00023114737,0.0000728591,0.000022977856,0.0001492769,0.00030676523,0.00011267306],"category_scores_gemma":[0.0035049596,0.00016551602,0.0002826245,0.0003491144,0.00027593007,0.00019430477,0.000072762734,0.0011124666,0.00001804235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02510832,0.004563085,0.93338054,0.000044112734,0.001100503,0.010276398,0.00010125675,0.000032423177,0.00008141634,0.000007477849,0.00033867973,0.024965798],"study_design_scores_gemma":[0.05464182,0.02382001,0.9169223,0.0005145796,0.00031394506,0.0005435205,0.00018289959,0.00020813377,0.00030010892,0.00000944588,0.0023868906,0.00015636104],"about_ca_topic_score_codex":0.00006550204,"about_ca_topic_score_gemma":0.0003584121,"teacher_disagreement_score":0.0295335,"about_ca_system_score_codex":0.0002641353,"about_ca_system_score_gemma":0.0024860674,"threshold_uncertainty_score":0.6749547},"labels":[],"label_agreement":null},{"id":"W3168714410","doi":"10.1200/jco.2021.39.15_suppl.tps5601","title":"A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Letrozole; Carboplatin; Internal medicine; Oncology; Aromatase inhibitor; Clinical endpoint; Serous fluid; Serous carcinoma; Taxane; Surgery; Randomized controlled trial; Chemotherapy; Breast cancer; Aromatase; Cancer; Cisplatin; Ovarian cancer","score_opus":0.06425841964498205,"score_gpt":0.4032444483881785,"score_spread":0.3389860287431965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168714410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930043,0.0013085209,0.0000119651595,0.0032799907,0.0010134979,0.0010182182,0.000031297495,0.0000027518486,0.00032945076],"genre_scores_gemma":[0.99629056,0.0014283581,0.0009990849,0.0007751966,0.00032568717,0.000027357448,0.0000057544257,0.000021372063,0.0001266116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995635,0.0008619484,0.002504964,0.00025874318,0.0004975482,0.00024181402],"domain_scores_gemma":[0.9939373,0.0028703169,0.00224754,0.0003278325,0.00042441208,0.00019258956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017752134,0.00020544256,0.002925424,0.00009738908,0.00004015094,0.0000061772726,0.00013010134,0.00019781095,0.00007885089],"category_scores_gemma":[0.0012625057,0.00010760691,0.000521271,0.00023874316,0.000450274,0.00008439891,0.000074459436,0.00062643696,1.7783235e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9111439,0.013296206,0.05912801,0.000066246845,0.00095729117,0.00050200586,0.00031587228,0.00001738639,0.000074746305,0.000034999623,0.00021328316,0.014250068],"study_design_scores_gemma":[0.8651763,0.036213256,0.09596578,0.00029375535,0.00060699356,0.000031711174,0.00015623565,0.000043229884,0.00035284692,0.000019868181,0.0010494341,0.00009059772],"about_ca_topic_score_codex":0.00014619298,"about_ca_topic_score_gemma":0.00016036812,"teacher_disagreement_score":0.045967594,"about_ca_system_score_codex":0.00024738323,"about_ca_system_score_gemma":0.0023744707,"threshold_uncertainty_score":0.43880823},"labels":[],"label_agreement":null},{"id":"W3168762354","doi":"10.1200/jco.2021.39.15_suppl.11531","title":"Comparison of treatment effect and long-term outcomes for pediatric and adult Ewing sarcoma patients in British Columbia, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; BC Children's Hospital","funders":"","keywords":"Medicine; Sarcoma; Cohort; Ewing's sarcoma; Regimen; Internal medicine; Chemotherapy; Pediatric cancer; Overall survival; Cancer; Pediatrics; Pathology","score_opus":0.06825205247459631,"score_gpt":0.43326001670738007,"score_spread":0.36500796423278375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168762354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611527,0.0024909857,0.000001598572,0.00068852864,0.00033835173,0.00032478076,0.00001707746,0.00000135509,0.000022053653],"genre_scores_gemma":[0.99730825,0.0017239844,0.00044335146,0.00032924197,0.00013490644,0.000011762852,0.000010116531,0.000008831001,0.000029535104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978762,0.000205948,0.0014365185,0.00015937079,0.00016676311,0.00015514289],"domain_scores_gemma":[0.99458194,0.004130691,0.0007024318,0.0000793031,0.00029135277,0.00021426297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040113655,0.00008793661,0.0017380131,0.000038572136,0.00002868187,0.000015050327,0.000032741107,0.00014046601,0.000012930935],"category_scores_gemma":[0.0020545102,0.00008270405,0.00019840235,0.00006491005,0.00004622732,0.000032498036,0.000027327558,0.00017295677,9.543129e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020803187,0.0027933633,0.7931045,0.00007647584,0.00021150928,0.0006178612,0.000024447292,2.635886e-7,7.9884046e-7,5.4397384e-7,0.00042737843,0.20253481],"study_design_scores_gemma":[0.022094289,0.013190978,0.96337825,0.00009895266,0.0007344162,0.0001222563,0.000046482466,0.000010911871,0.000019115798,0.000008544656,0.00023950543,0.000056300363],"about_ca_topic_score_codex":0.061983503,"about_ca_topic_score_gemma":0.8492091,"teacher_disagreement_score":0.78722554,"about_ca_system_score_codex":0.0002754462,"about_ca_system_score_gemma":0.001157217,"threshold_uncertainty_score":0.9442628},"labels":[],"label_agreement":null},{"id":"W3168788346","doi":"10.1200/jco.2021.39.15_suppl.10047","title":"Development and validation of a prediction model for kidney failure in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cohort; Kidney transplantation; Kidney disease; Cancer; Kidney cancer; Dialysis; Proportional hazards model; Concordance; Internal medicine; Transplantation; Oncology","score_opus":0.0960716860114755,"score_gpt":0.438679783435627,"score_spread":0.34260809742415155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168788346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822107,0.0019500143,0.0008708943,0.0124916,0.0012150764,0.0010372321,0.00018754335,0.000009419267,0.000027534346],"genre_scores_gemma":[0.99194026,0.0015475765,0.0036875794,0.0016399899,0.0009525242,0.00007283927,0.00006861166,0.000034656154,0.00005597192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99250454,0.00081027724,0.005131253,0.0004589828,0.0008291109,0.00026583334],"domain_scores_gemma":[0.9919208,0.002224903,0.003995288,0.0004193794,0.0010927236,0.00034689467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006595868,0.00024425643,0.002216317,0.00013875606,0.000063588275,0.0000121032535,0.00023264806,0.0003740418,0.00006872668],"category_scores_gemma":[0.006121327,0.00018048742,0.00039049904,0.0003152059,0.0001628133,0.00018742839,0.00012614044,0.0008486593,2.4865628e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015244719,0.006041302,0.9604924,0.00015923705,0.0015242724,0.000117051226,0.011587743,0.00031781028,0.00013645159,0.000005755909,0.0013261118,0.016767396],"study_design_scores_gemma":[0.012412258,0.0017624527,0.9791622,0.0009872126,0.0008697369,0.00012478263,0.0017280817,0.00028193335,0.0009216858,0.00009188591,0.0015100234,0.00014770274],"about_ca_topic_score_codex":0.0017362667,"about_ca_topic_score_gemma":0.03754359,"teacher_disagreement_score":0.035807323,"about_ca_system_score_codex":0.00022508543,"about_ca_system_score_gemma":0.009801055,"threshold_uncertainty_score":0.9958125},"labels":[],"label_agreement":null},{"id":"W3168836567","doi":"10.1200/jco.2021.39.15_suppl.7519","title":"Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dosing; Refractory (planetary science); Internal medicine; Cytokine release syndrome; Gastroenterology; Rituximab; Neutropenia; Lymphoma; Surgery; Chemotherapy; Cancer; Immunotherapy","score_opus":0.15882958560774624,"score_gpt":0.4813478106215453,"score_spread":0.32251822501379906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168836567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925511,0.0005506239,0.000035414632,0.004133848,0.0014229161,0.0005771122,0.000050341907,0.000017155697,0.00066149735],"genre_scores_gemma":[0.9940196,0.0008319324,0.0018168606,0.0015795348,0.00044864893,0.000004793106,0.000239376,0.000069558206,0.0009896471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98774475,0.005270019,0.004511002,0.00071957515,0.0010325257,0.0007221325],"domain_scores_gemma":[0.98457235,0.010893138,0.0015683859,0.0012309629,0.0010853822,0.00064978725],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011799244,0.00033115046,0.0026062988,0.0006568359,0.000062493804,0.000045062796,0.0007734988,0.0008240389,0.0011440347],"category_scores_gemma":[0.019803915,0.00027900675,0.00037937026,0.0011890327,0.00036989833,0.0003629922,0.00053416996,0.0023111708,0.00006792506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17325576,0.012332214,0.41637635,0.00005694306,0.0004949633,0.009743982,0.0003387296,0.00001509489,0.0181539,0.0000041891144,0.008017745,0.36121014],"study_design_scores_gemma":[0.073036656,0.011250604,0.8167631,0.0005477823,0.00013444795,0.0003173946,0.00021616161,0.0012764464,0.00043869024,0.000021601472,0.09577714,0.00021998338],"about_ca_topic_score_codex":0.00017243187,"about_ca_topic_score_gemma":0.00042568834,"teacher_disagreement_score":0.40038675,"about_ca_system_score_codex":0.0012317463,"about_ca_system_score_gemma":0.005951606,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W3168841030","doi":"10.1200/jco.2021.39.15_suppl.e19568","title":"Association of PET/CT response assessment prior to CAR T-cell infusion with outcomes after CAR T-cell therapy in aggressive B-cell lymphomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Gastroenterology; CAR T-cell therapy; Nuclear medicine; Surgery; Immunotherapy; Cancer","score_opus":0.05233808995743192,"score_gpt":0.45334641170646206,"score_spread":0.4010083217490301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168841030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608714,0.0006176955,0.00001791152,0.009328197,0.00057779555,0.0005557534,0.000008350229,0.0000068981276,0.0028002749],"genre_scores_gemma":[0.978908,0.0022462874,0.0037366392,0.0026004342,0.00033127947,0.000021817788,0.0000032856622,0.000044850603,0.012107422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924818,0.002879874,0.002501029,0.0003639434,0.0013233471,0.00044995284],"domain_scores_gemma":[0.98779,0.007077835,0.0026841222,0.00043802965,0.0015194754,0.0004905602],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008313269,0.00024841525,0.0020993005,0.00037743023,0.000035275527,0.000019597164,0.00024691958,0.00019111727,0.0010964752],"category_scores_gemma":[0.0032832576,0.00017243774,0.0006087376,0.00047624685,0.000104947314,0.000101911115,0.00012678985,0.0013859072,0.000017714334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056863762,0.007015934,0.7877309,0.000075133205,0.00036310597,0.021487933,0.0005223255,0.000054754546,0.10264386,0.0000012440697,0.0014422415,0.021798808],"study_design_scores_gemma":[0.046236716,0.025833497,0.84853035,0.00028426456,0.0002442541,0.0006054004,0.00077263115,0.000036792633,0.027066465,0.000027379194,0.05012655,0.00023569628],"about_ca_topic_score_codex":0.00004916132,"about_ca_topic_score_gemma":0.00018011905,"teacher_disagreement_score":0.0755774,"about_ca_system_score_codex":0.00143993,"about_ca_system_score_gemma":0.0072376453,"threshold_uncertainty_score":0.99981666},"labels":[],"label_agreement":null},{"id":"W3168870529","doi":"10.1200/jco.2021.39.15_suppl.e21513","title":"Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Metastasis; Gastroenterology; Internal medicine; Liver function; Melanoma; Oncology; Cancer research; Cancer","score_opus":0.06740674829782799,"score_gpt":0.40003390837726627,"score_spread":0.33262716007943827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168870529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708015,0.0003118565,0.0000756518,0.0005803533,0.0010637068,0.00033472807,0.0000057199045,0.000007821843,0.0005400403],"genre_scores_gemma":[0.9974323,0.00035844857,0.0009877007,0.0006281138,0.00019086419,0.000006449612,0.00009773764,0.000019203573,0.00027916933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99586236,0.00093997683,0.0023689156,0.00024091602,0.00034734735,0.00024045439],"domain_scores_gemma":[0.9964287,0.0009445808,0.0017146121,0.00018325339,0.0005036037,0.0002252448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014333532,0.00017124617,0.0016870907,0.00020180199,0.00003140017,0.000005669737,0.00008214387,0.00037419976,0.00022661625],"category_scores_gemma":[0.002413375,0.000132318,0.00057791406,0.00030810863,0.00008201544,0.00021675305,0.000043556378,0.0005785317,0.000028139872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031923724,0.007425848,0.9011209,0.000052888277,0.001119995,0.0031074025,0.000121630444,0.0000025036168,0.0028081853,0.000019894487,0.000058762766,0.08096962],"study_design_scores_gemma":[0.017962448,0.017473597,0.95825976,0.00022084544,0.0016278833,0.00017531657,0.0000403834,0.000042023905,0.00079660077,0.000092043556,0.0032201698,0.0000889128],"about_ca_topic_score_codex":0.000026440539,"about_ca_topic_score_gemma":0.00016589291,"teacher_disagreement_score":0.0808807,"about_ca_system_score_codex":0.0002593014,"about_ca_system_score_gemma":0.0010719644,"threshold_uncertainty_score":0.5395772},"labels":[],"label_agreement":null},{"id":"W3168899802","doi":"10.1200/jco.2021.39.15_suppl.tps7568","title":"A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Incyte","keywords":"Medicine; Lenalidomide; Rituximab; Follicular lymphoma; Internal medicine; Phases of clinical research; Lymphoma; CD20; Oncology; Clinical trial; Gastroenterology; Multiple myeloma","score_opus":0.06115347712354767,"score_gpt":0.4049968544559293,"score_spread":0.34384337733238163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168899802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247694,0.0024035755,0.000029937231,0.0028925657,0.00045288316,0.0015842452,0.000025156332,0.000008748728,0.00012592286],"genre_scores_gemma":[0.99628425,0.0013033061,0.0012947068,0.00073158176,0.00023381486,0.000039289636,0.000009275208,0.000039987306,0.00006380166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99383456,0.0014793266,0.0026653104,0.0006311173,0.00092696806,0.00046271502],"domain_scores_gemma":[0.99030334,0.006637826,0.0012087589,0.00046910948,0.00070514064,0.0006758063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035871523,0.00043851635,0.0031002893,0.00023685505,0.00014823461,0.00004433832,0.00018608422,0.00029255147,0.000048351194],"category_scores_gemma":[0.003764972,0.00024875527,0.0002549256,0.0003625169,0.00044612616,0.00019851036,0.0002679736,0.00040099755,0.000005379606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.634282,0.08954216,0.09571536,0.00009130856,0.0026393405,0.0067709694,0.0013825289,0.000022149576,0.000022134895,0.000037528745,0.00030266034,0.16919185],"study_design_scores_gemma":[0.5323523,0.04508533,0.41655093,0.00032545207,0.0018326241,0.00051743764,0.0009284816,0.00007604217,0.0000510836,0.000009779636,0.0021011538,0.00016935058],"about_ca_topic_score_codex":0.0001636823,"about_ca_topic_score_gemma":0.00044157694,"teacher_disagreement_score":0.32083556,"about_ca_system_score_codex":0.0009307283,"about_ca_system_score_gemma":0.0033538695,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W3168906818","doi":"10.1200/jco.2021.39.15_suppl.e24108","title":"Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"V Foundation for Cancer Research","keywords":"Medicine; Breast cancer; Internal medicine; Malignancy; Cancer; Population; Oncology; Surgery","score_opus":0.13045949852623762,"score_gpt":0.4894860790317181,"score_spread":0.3590265805054805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168906818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412585,0.00028677788,0.00017435134,0.014016975,0.0006977681,0.00014559033,0.000022665095,0.0000033530062,0.0005266811],"genre_scores_gemma":[0.98506606,0.00022171541,0.012341312,0.0008953642,0.0012332306,0.0000071510685,0.0000020948764,0.000019229434,0.00021382504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633497,0.00039210072,0.0023879984,0.00018219982,0.00040729783,0.0002954478],"domain_scores_gemma":[0.99219257,0.004375013,0.0012431002,0.00014955636,0.0017764057,0.00026334234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003937567,0.00010472254,0.0015727695,0.00017274833,0.00002272003,0.000005416745,0.00017011561,0.00038143276,0.00019918589],"category_scores_gemma":[0.008001089,0.0000814182,0.00043180346,0.0003206289,0.0002094509,0.00008413423,0.00010698804,0.0010587237,0.0000021302951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068704574,0.0017634743,0.74610376,0.0003338271,0.00038278825,0.0042663016,0.000083222236,0.00006281748,0.012824695,0.00006158106,0.0023785802,0.2248685],"study_design_scores_gemma":[0.011088161,0.0028401446,0.975381,0.0003802274,0.0002286477,0.0035014055,0.00020454216,0.0012943646,0.0013830643,0.0004971094,0.0031060842,0.00009522362],"about_ca_topic_score_codex":0.00024207028,"about_ca_topic_score_gemma":0.00029051164,"teacher_disagreement_score":0.22927728,"about_ca_system_score_codex":0.0002922506,"about_ca_system_score_gemma":0.007182613,"threshold_uncertainty_score":0.99844575},"labels":[],"label_agreement":null},{"id":"W3168933935","doi":"10.1200/jco.2021.39.15_suppl.e22525","title":"Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Mount Sinai Hospital; Health Sciences Centre; Ovarian Cancer Canada; Sunnybrook Health Science Centre; Sinai Health System; Princess Margaret Cancer Centre; Toronto Metropolitan University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Family history; Lynch syndrome; Ovarian cancer; Gynecology; Internal medicine; Referral; Population; Cohort; Serous fluid; Oncology; Cancer; Endometrial cancer; Prospective cohort study; Family medicine; Colorectal cancer; DNA mismatch repair","score_opus":0.0627927829543057,"score_gpt":0.3709041533057003,"score_spread":0.30811137035139463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168933935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941968,0.00044150214,0.00033917703,0.0026169734,0.0015597824,0.00031890633,0.00001118726,0.0000053497984,0.0005103276],"genre_scores_gemma":[0.98220164,0.00048510422,0.012295402,0.004274278,0.00044973692,0.00003378149,0.0000025321356,0.000024299161,0.00023323913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970983,0.00018190159,0.0018431005,0.00022774782,0.00035410863,0.00029482465],"domain_scores_gemma":[0.99646884,0.0009120306,0.0010751192,0.00022353228,0.0009258675,0.00039458342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017216235,0.00014294255,0.0015291638,0.00014430823,0.000017118942,0.0000033026854,0.00016529401,0.00029757677,0.00011345033],"category_scores_gemma":[0.0034641935,0.00011632628,0.00014472674,0.0002002894,0.0001788567,0.00006565891,0.000043659875,0.0006128414,0.0000023305984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038902834,0.0018202597,0.55369306,0.0004956792,0.00057129294,0.003017922,0.001333289,0.00031364878,0.002272832,0.000045750356,0.00841213,0.3891213],"study_design_scores_gemma":[0.007704238,0.025164288,0.9171006,0.00065082224,0.0001162297,0.0003787869,0.00011663869,0.000098776094,0.000066611065,0.000016831715,0.048474137,0.00011201884],"about_ca_topic_score_codex":0.00010499258,"about_ca_topic_score_gemma":0.00023802239,"teacher_disagreement_score":0.3890093,"about_ca_system_score_codex":0.0022912954,"about_ca_system_score_gemma":0.009301972,"threshold_uncertainty_score":0.99631435},"labels":[],"label_agreement":null},{"id":"W3168937052","doi":"10.1200/jco.2021.39.15_suppl.e16060","title":"Predictors of survival after metastasectomy of oligometastatic recurrence following gastroesophageal cancer treatment.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Metastasectomy; Proportional hazards model; Internal medicine; Surgery; Lymph node; Cancer; Retrospective cohort study; Oncology; Metastasis","score_opus":0.10488642596179064,"score_gpt":0.4534370141124685,"score_spread":0.34855058815067785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168937052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916251,0.0029763575,0.00021667137,0.0011367582,0.0030889595,0.0001419366,0.000029555853,0.0000041078147,0.00078059797],"genre_scores_gemma":[0.99289936,0.0016453303,0.004033633,0.00024114437,0.00057067693,0.000006935735,0.0000048364927,0.000012890796,0.0005852161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634814,0.00039739587,0.002349986,0.00017943712,0.00049858075,0.00022646187],"domain_scores_gemma":[0.99618363,0.0013064416,0.0016541376,0.00020565398,0.00040893696,0.00024122334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001535804,0.00015198812,0.0022176513,0.0001745951,0.000012971001,0.000004119458,0.00011714337,0.00010992521,0.00054736616],"category_scores_gemma":[0.0014591665,0.00010601144,0.0011485156,0.00033612884,0.00013735105,0.00009878576,0.00005533004,0.0003301823,0.0000017805176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022936512,0.0013090156,0.9382361,0.00012098103,0.0031854538,0.0018464337,0.00012877726,0.00002310096,0.00010578183,0.000021709091,0.00058456714,0.05214441],"study_design_scores_gemma":[0.015845256,0.009657011,0.95309246,0.00025090185,0.004757115,0.00007413986,0.00028040522,0.00001717045,0.00085224316,0.000055427474,0.015036433,0.00008145923],"about_ca_topic_score_codex":0.000047614794,"about_ca_topic_score_gemma":0.00010518717,"teacher_disagreement_score":0.05206295,"about_ca_system_score_codex":0.00014604082,"about_ca_system_score_gemma":0.0017655785,"threshold_uncertainty_score":0.59932756},"labels":[],"label_agreement":null},{"id":"W3168959694","doi":"10.1200/jco.2021.39.15_suppl.6561","title":"Concomitant infections in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institutes of Health","keywords":"Medicine; Coinfection; Interquartile range; Cancer; Concomitant; Internal medicine; Coronavirus disease 2019 (COVID-19); Immunology; Infectious disease (medical specialty); Disease; Virus","score_opus":0.20937620857142314,"score_gpt":0.561569376922252,"score_spread":0.3521931683508288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168959694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91525304,0.0018395656,0.000083013496,0.08155493,0.0006103838,0.0005116501,0.000027450285,0.0000101568285,0.000109809764],"genre_scores_gemma":[0.93047124,0.003946362,0.00011850205,0.06495146,0.00037221055,0.000020318821,0.0000021080125,0.000015002696,0.000102772945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663943,0.0006584932,0.0017314485,0.00031406185,0.00035565544,0.00030091152],"domain_scores_gemma":[0.99118173,0.0048186057,0.0010435989,0.0001744612,0.0006157214,0.00216589],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021778846,0.00016844775,0.0015243507,0.00020262724,0.000111581234,0.000017366456,0.000060513143,0.0002965506,0.0003112231],"category_scores_gemma":[0.019549053,0.000118662196,0.000105128085,0.00030415913,0.00036039457,0.00011122175,0.00007434272,0.0011358522,9.4963207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047970377,0.0024949424,0.96949023,0.00020114859,0.00029515495,0.0013483552,0.00086508,0.000052360276,0.0000045967,0.00002871844,0.0025596316,0.017862767],"study_design_scores_gemma":[0.030252226,0.012061554,0.8449681,0.00011689678,0.00037668963,0.00023341953,0.0006636945,0.000021371674,0.0000014661684,0.000089572466,0.111105286,0.00010975658],"about_ca_topic_score_codex":0.0041513112,"about_ca_topic_score_gemma":0.034846704,"teacher_disagreement_score":0.12452214,"about_ca_system_score_codex":0.0010792378,"about_ca_system_score_gemma":0.02943522,"threshold_uncertainty_score":0.9887097},"labels":[],"label_agreement":null},{"id":"W3168980224","doi":"10.1200/jco.2021.39.15_suppl.4142","title":"Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University Health Centre; Ontario Institute for Cancer Research; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Toronto General Hospital; Dalhousie University; University Health Network","funders":"","keywords":"KRAS; Medicine; Gemcitabine; Internal medicine; Hazard ratio; Overall survival; Pancreatic cancer; Oncology; Cancer; Cohort; CDKN2A; STK11; Proportional hazards model; Cancer research; Colorectal cancer; Confidence interval","score_opus":0.1185812994060208,"score_gpt":0.5432070720378153,"score_spread":0.42462577263179446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168980224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995404,0.00015257,0.000018892273,0.0015278246,0.0002129243,0.00018573157,0.00001964306,0.0000021715928,0.0024762147],"genre_scores_gemma":[0.996306,0.00033881515,0.0022591606,0.00056503655,0.00015832444,0.0000058918995,0.000009483339,0.000012013128,0.00034528028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966077,0.00051971053,0.0018046134,0.0001567411,0.0006193911,0.0002918431],"domain_scores_gemma":[0.9929076,0.004346938,0.0010875311,0.0001631886,0.0011397229,0.00035506164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012703208,0.00012407947,0.0021400072,0.00018244189,0.000018252593,0.000003146162,0.00008356054,0.00024919698,0.0009786504],"category_scores_gemma":[0.0060962625,0.000070500006,0.00036232243,0.00021979003,0.00023484392,0.00006371534,0.00002702863,0.0008454755,0.000009019909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009797183,0.0052370564,0.9693909,0.00002649313,0.0012082325,0.00060302747,0.00009244607,0.000073788295,0.000010605395,0.000044538818,0.00047042777,0.013045287],"study_design_scores_gemma":[0.019318422,0.024952676,0.9545311,0.00017551881,0.0003811621,0.00003576854,0.000056425986,0.00004582698,0.000008324534,0.00015289406,0.00028256656,0.000059354858],"about_ca_topic_score_codex":0.00016098784,"about_ca_topic_score_gemma":0.00014659889,"teacher_disagreement_score":0.019715618,"about_ca_system_score_codex":0.00045508635,"about_ca_system_score_gemma":0.009121246,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W3169007939","doi":"10.1200/jco.2021.39.15_suppl.2575","title":"CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Immunogenicity; Internal medicine; Cancer; Oncology; Immunotherapy; Antibody; Immunology","score_opus":0.21387878469376403,"score_gpt":0.5434117586399005,"score_spread":0.3295329739461365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169007939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943677,0.0024440305,0.00032018046,0.0012973695,0.0006200397,0.00012313414,0.00000952682,0.0000046023074,0.00081341877],"genre_scores_gemma":[0.9932517,0.0013412866,0.0044096904,0.00039447937,0.00031586405,0.0000010414697,0.0000072848807,0.000011617048,0.00026704857],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961126,0.00027066164,0.0030059456,0.00013424968,0.00033092377,0.00014565165],"domain_scores_gemma":[0.9948406,0.0012155279,0.002719916,0.00021199184,0.0008708639,0.00014106573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015294738,0.00010727052,0.0014753477,0.00013228062,0.000020272,0.0000028778368,0.00010567847,0.00025690824,0.00035709538],"category_scores_gemma":[0.0020235938,0.000079982,0.00084478944,0.00023407825,0.00017977403,0.00008496499,0.00003201131,0.00038093157,0.000001860486],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16386566,0.009634165,0.008880612,0.00034262752,0.00242883,0.0040173205,0.00032726603,0.00007288352,0.37886477,0.000032324417,0.0018141943,0.42971933],"study_design_scores_gemma":[0.13768677,0.19952722,0.28563398,0.0016582436,0.0053888126,0.016381111,0.0013583993,0.0054238564,0.3056292,0.0005301694,0.0403069,0.0004753407],"about_ca_topic_score_codex":0.000042610216,"about_ca_topic_score_gemma":0.000021812859,"teacher_disagreement_score":0.429244,"about_ca_system_score_codex":0.00009185699,"about_ca_system_score_gemma":0.0017169826,"threshold_uncertainty_score":0.39099443},"labels":[],"label_agreement":null},{"id":"W3169033212","doi":"10.1200/jco.2021.39.15_suppl.7016","title":"A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Myeloid leukemia; Internal medicine; Chemotherapy; Family medicine; Intensive care medicine","score_opus":0.0943905675052841,"score_gpt":0.500058440569318,"score_spread":0.40566787306403396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169033212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566054,0.0007393593,0.000069025686,0.00097096525,0.0012349137,0.000623078,0.0000012616356,0.0000058931546,0.00069496455],"genre_scores_gemma":[0.9870909,0.0011227845,0.010461326,0.00056514854,0.00060512853,0.00007132311,0.000001031586,0.000020996617,0.00006137439],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995786,0.0018030237,0.0015629199,0.0002823221,0.000320512,0.00024521328],"domain_scores_gemma":[0.9815707,0.016811928,0.00090126996,0.00025862106,0.00028122606,0.00017621525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019065673,0.00021199095,0.0018227821,0.00015635572,0.00004549334,0.000006402939,0.00013714448,0.00016093139,0.000068597095],"category_scores_gemma":[0.0013408826,0.00010692524,0.0004197846,0.00026575875,0.0000898746,0.00007124848,0.000057844023,0.0007392502,0.000003673194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030819647,0.00668883,0.04269395,0.000016035272,0.0019428054,0.0062999045,0.003986134,0.00008968059,0.001626672,0.0000060837624,0.00005565065,0.9057746],"study_design_scores_gemma":[0.03572052,0.063250996,0.88586974,0.00078725896,0.0022678773,0.0005672558,0.004955193,0.00009614379,0.0040610023,0.00015453906,0.0021655746,0.000103914215],"about_ca_topic_score_codex":0.00005321199,"about_ca_topic_score_gemma":0.0005832696,"teacher_disagreement_score":0.9056707,"about_ca_system_score_codex":0.00077632064,"about_ca_system_score_gemma":0.0019369504,"threshold_uncertainty_score":0.43602848},"labels":[],"label_agreement":null},{"id":"W3169033905","doi":"10.1200/jco.2013.31.4_suppl.314","title":"A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Axitinib; Medicine; Sorafenib; Pazopanib; Internal medicine; Clinical endpoint; Temsirolimus; Hepatocellular carcinoma; Oncology; Progressive disease; Gastroenterology; Interim analysis; Sunitinib; Surgery; Clinical trial; Renal cell carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.17128108671582384,"score_gpt":0.4200956653860514,"score_spread":0.24881457867022758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169033905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915079,0.0028443704,0.00002348864,0.0023308978,0.0011576482,0.0015147252,0.000004707394,0.0000112117505,0.0006050803],"genre_scores_gemma":[0.9950269,0.0005660884,0.0025930097,0.00057182094,0.00087490963,0.00004065949,0.00001138469,0.000035345336,0.00027986933],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944366,0.00061561645,0.003813389,0.00029433193,0.0004434797,0.00039656428],"domain_scores_gemma":[0.99571097,0.0012684903,0.001886295,0.00032124328,0.00037583083,0.00043714803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029386708,0.0002594009,0.0027110195,0.00032984826,0.000051050625,0.00000863754,0.00022543207,0.000520977,0.0009224215],"category_scores_gemma":[0.001272563,0.00018852492,0.0019140742,0.00031845906,0.00013081855,0.00022123188,0.000058423593,0.00078262127,0.00002206634],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0743969,0.01855138,0.54430723,0.00004323522,0.0008715803,0.0027159909,0.0003167778,5.165294e-7,0.01335203,0.000012754626,0.00042885178,0.34500274],"study_design_scores_gemma":[0.6505088,0.25149152,0.064072534,0.00022303061,0.0007413847,0.00022833335,0.00018363787,0.0011037714,0.012592606,0.0002714557,0.01828178,0.00030113477],"about_ca_topic_score_codex":0.000042632306,"about_ca_topic_score_gemma":0.000017209759,"teacher_disagreement_score":0.5761119,"about_ca_system_score_codex":0.00010616398,"about_ca_system_score_gemma":0.0014133838,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W3169039496","doi":"10.1200/jco.2021.39.15_suppl.e15091","title":"Antitumor effects of local anesthetic agents in vitro and in vivo.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Programmed cell death; Pharmacology; Cancer research; Apoptosis; Biology","score_opus":0.05399309749384339,"score_gpt":0.4239048518997509,"score_spread":0.3699117544059075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169039496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930344,0.0040451623,0.000024341494,0.002052123,0.0004887942,0.000102847145,4.837987e-7,0.0000017528872,0.00025004792],"genre_scores_gemma":[0.99484485,0.0034526498,0.00033852606,0.0009304676,0.0002628332,0.0000015204067,4.4366604e-7,0.000009410612,0.00015926771],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973014,0.00062536466,0.0015539234,0.00013843666,0.00020484027,0.00017601522],"domain_scores_gemma":[0.9967702,0.0021909892,0.0006032326,0.00013439577,0.00014180112,0.0001593623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014739758,0.000094120136,0.0014444301,0.0001700563,0.00000869262,0.0000033338151,0.00007290567,0.00023014875,0.00004437387],"category_scores_gemma":[0.002333424,0.00007463632,0.00022347149,0.00018401496,0.00027918373,0.00005262724,0.00003174472,0.00060422474,0.000002032207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060107924,0.008438789,0.38234338,0.0009823107,0.0002458084,0.0674255,0.0005077735,0.000048345217,0.03667858,0.000030149462,0.0018393276,0.44135213],"study_design_scores_gemma":[0.015789652,0.0052990173,0.922365,0.0007295014,0.00014503724,0.0047653737,0.00024589646,0.00013791036,0.023572233,0.00006404275,0.02679623,0.0000901085],"about_ca_topic_score_codex":0.000037099984,"about_ca_topic_score_gemma":0.000057623005,"teacher_disagreement_score":0.5400216,"about_ca_system_score_codex":0.00008762378,"about_ca_system_score_gemma":0.0013031779,"threshold_uncertainty_score":0.3043581},"labels":[],"label_agreement":null},{"id":"W3169052906","doi":"10.1200/jco.2021.39.15_suppl.10030","title":"Resolving driver events in MLL-r negative high-risk infant ALL.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; London Health Sciences Centre","funders":"","keywords":"Fusion gene; Medicine; Gene duplication; Gene expression profiling; Leukemia; Oncology; Gene; Transcriptome; Gene expression; Internal medicine; Bioinformatics; Genetics; Biology","score_opus":0.0832777811511743,"score_gpt":0.46244365409022997,"score_spread":0.3791658729390557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169052906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846055,0.00022630635,0.00029812226,0.011515758,0.001122747,0.00015428313,0.000003509454,0.0000065585896,0.0020672218],"genre_scores_gemma":[0.980685,0.0018496166,0.012065043,0.003300135,0.0012794975,0.0000031301722,0.0000028511236,0.000022261587,0.00079248473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945237,0.0014613118,0.002584332,0.0002692626,0.0007586359,0.0004027483],"domain_scores_gemma":[0.9877398,0.009108059,0.0014064854,0.00027980347,0.0009163908,0.00054946134],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0047894493,0.00014251794,0.0015798676,0.0002080827,0.000032315573,0.0000061346436,0.00022993202,0.00052442885,0.000447305],"category_scores_gemma":[0.041768037,0.00010427997,0.00040267783,0.00034489395,0.0002097449,0.00014706695,0.00022741861,0.0024575256,0.00007492405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009690957,0.0035603666,0.82464254,0.000057745758,0.0014454812,0.037734002,0.0007613665,0.00015119674,0.0008462502,0.00026019666,0.025744572,0.09510533],"study_design_scores_gemma":[0.024732167,0.0057689673,0.92899835,0.00028431593,0.0002995309,0.0011264394,0.0002719078,0.000750466,0.00035462534,0.0020895947,0.03520794,0.00011571195],"about_ca_topic_score_codex":0.00025584263,"about_ca_topic_score_gemma":0.00034145647,"teacher_disagreement_score":0.1043558,"about_ca_system_score_codex":0.00106786,"about_ca_system_score_gemma":0.007904208,"threshold_uncertainty_score":0.99984384},"labels":[],"label_agreement":null},{"id":"W3169070561","doi":"10.1200/jco.2021.39.15_suppl.11016","title":"Prevalence and risk factors of burnout among female oncology professionals from the Middle East and North Africa (MENA).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare professionals’ stress and burnout","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Burnout; Marital status; Family medicine; Workforce; Cohort; Demography; Internal medicine; Population; Environmental health; Clinical psychology","score_opus":0.33906249295778473,"score_gpt":0.5078246199815335,"score_spread":0.16876212702374876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169070561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766601,0.011640482,0.000024977238,0.007379965,0.002655247,0.00045701294,0.00018569244,0.000009502615,0.0009870344],"genre_scores_gemma":[0.9794394,0.016028473,0.0012173452,0.0011836682,0.0012557858,0.000020962807,0.0000082401075,0.000022239818,0.0008239263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9857501,0.00872527,0.004017257,0.00040363747,0.0005636104,0.0005401403],"domain_scores_gemma":[0.9628322,0.029593281,0.005333066,0.00035140474,0.001229579,0.0006604819],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0063843946,0.00024217613,0.0018826423,0.00006268858,0.00066191494,0.000008121934,0.0003804696,0.0010165768,0.0006006003],"category_scores_gemma":[0.012681624,0.00013294318,0.00028519734,0.00019854386,0.00068184227,0.00019570853,0.0005593876,0.003854816,0.000009335462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005492809,0.0007763388,0.9513135,0.00023503168,0.00023337227,0.00009838056,0.0122974,0.0000017621522,0.00001357654,0.00007429779,0.0018801669,0.03252692],"study_design_scores_gemma":[0.0024067506,0.0018792535,0.94732785,0.0021654216,0.00026342686,0.000011779026,0.023184355,0.000036820635,0.000006597949,0.00072875543,0.021857893,0.00013111396],"about_ca_topic_score_codex":0.00046585765,"about_ca_topic_score_gemma":0.0019237122,"teacher_disagreement_score":0.032395806,"about_ca_system_score_codex":0.00011667848,"about_ca_system_score_gemma":0.0054566837,"threshold_uncertainty_score":0.9984433},"labels":[],"label_agreement":null},{"id":"W3169076687","doi":"10.1200/jco.2021.39.15_suppl.e12569","title":"Trastuzumab-dkst versus trastuzumab: Real-world pCR rates in patients with HER2+ breast cancer treated with neoadjuvant chemotherapy plus trastuzumab from Alberta, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Baker Hughes (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Biosimilar; Oncology; Breast cancer; Internal medicine; Anthracycline; Chemotherapy; Metastatic breast cancer; Cancer","score_opus":0.04144275719447472,"score_gpt":0.3705143256458127,"score_spread":0.329071568451338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169076687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772943,0.00063577003,0.000038363,0.007899324,0.0016510047,0.0002718288,0.00023656728,0.000012059119,0.0015256392],"genre_scores_gemma":[0.9942314,0.0007334666,0.0011001981,0.0021391998,0.00032650793,0.000010710234,0.00006990953,0.00005323371,0.0013353523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946053,0.0013939262,0.0023772845,0.00064920436,0.00025291205,0.00072139705],"domain_scores_gemma":[0.99310595,0.0040548923,0.001495109,0.0003610272,0.0007099762,0.00027304364],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089151185,0.00046671482,0.0026776064,0.00014871256,0.0001098772,0.000025077097,0.0003714507,0.0007390871,0.0021550336],"category_scores_gemma":[0.00036241184,0.00029933828,0.0003169177,0.0005919474,0.0005672059,0.00014985356,0.000053096108,0.0018235483,0.000007298027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08930301,0.004914744,0.6920773,0.00002316562,0.0048880405,0.0011295459,0.00024230317,0.00009961277,0.00037548185,0.000042243137,0.008997,0.19790758],"study_design_scores_gemma":[0.04074538,0.007063153,0.92446864,0.00020898494,0.00061704323,0.000088752364,0.00028451305,0.000018341054,0.0011820423,0.000024799721,0.024886454,0.00041187924],"about_ca_topic_score_codex":0.2709047,"about_ca_topic_score_gemma":0.8890763,"teacher_disagreement_score":0.61817163,"about_ca_system_score_codex":0.001286336,"about_ca_system_score_gemma":0.007896309,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3169092451","doi":"10.1200/jco.2021.39.15_suppl.4565","title":"Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Refractory (planetary science); Internal medicine; Oncology; Immunotherapy; Urology; Cancer","score_opus":0.03373645546351024,"score_gpt":0.32763049100636693,"score_spread":0.2938940355428567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169092451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800155,0.0032419658,0.00018652859,0.0017085987,0.0014240238,0.0016800568,0.000071649476,0.00004075502,0.011630882],"genre_scores_gemma":[0.98360634,0.0007521182,0.008677851,0.0008262718,0.0010401933,0.00007681448,0.00008720405,0.00026702273,0.0046661673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9836622,0.0025100664,0.0076720007,0.0019916536,0.0022257739,0.0019382949],"domain_scores_gemma":[0.98662394,0.002732147,0.004645473,0.0021603925,0.0020108086,0.0018272466],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.003948934,0.001281561,0.0066122697,0.0012737974,0.00020676237,0.0000660987,0.0012009003,0.0015747513,0.00082171545],"category_scores_gemma":[0.0010495823,0.0011087655,0.0015375804,0.0019657689,0.00055189856,0.0006292088,0.0006152378,0.004439579,0.00011832933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16690226,0.048870962,0.5579293,0.0023247767,0.0010434467,0.09145465,0.008899562,0.004323822,0.07135265,0.000028621087,0.015495158,0.031374816],"study_design_scores_gemma":[0.12253447,0.091603555,0.71264297,0.0014061816,0.0018942627,0.0026505885,0.005299132,0.0008270659,0.044865154,0.00009646557,0.014549112,0.0016310578],"about_ca_topic_score_codex":0.0016929181,"about_ca_topic_score_gemma":0.004901554,"teacher_disagreement_score":0.15471369,"about_ca_system_score_codex":0.0034976103,"about_ca_system_score_gemma":0.01226577,"threshold_uncertainty_score":0.9999936},"labels":[],"label_agreement":null},{"id":"W3169097194","doi":"10.1200/jco.2021.39.15_suppl.7040","title":"Health-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Quality of life (healthcare); Observational study; Cohort; International Prognostic Scoring System; Disease; Pediatrics; Surgery; Bone marrow","score_opus":0.12903294958259393,"score_gpt":0.45768460865129085,"score_spread":0.3286516590686969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169097194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958306,0.000675492,0.000020008554,0.039732423,0.00029729246,0.00037253168,0.00001552598,0.0000048636957,0.00057585427],"genre_scores_gemma":[0.99520075,0.00049365225,0.0004986594,0.0034413661,0.00016353383,0.0000066568114,0.000023568713,0.000020139609,0.00015166358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98954666,0.0038695766,0.0047721914,0.00031426025,0.0010566129,0.00044072457],"domain_scores_gemma":[0.98455787,0.010047865,0.003138248,0.0005531678,0.0008937489,0.0008091008],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009886767,0.00018331154,0.0025362538,0.00023294298,0.00003763643,0.000009997538,0.0003864944,0.00033345108,0.00014510978],"category_scores_gemma":[0.047171965,0.000109619694,0.00033362798,0.0007625894,0.0004801953,0.0001087201,0.00010369794,0.0025356752,0.000012113965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021431116,0.0049070874,0.95295954,0.00031114774,0.0003013732,0.0033681311,0.00034795023,0.000100602185,0.000008738328,0.00027284678,0.0030262093,0.012965265],"study_design_scores_gemma":[0.024112387,0.0082869455,0.96375334,0.000484482,0.00008869447,0.0002097742,0.0005444911,0.000097999306,0.0000026217374,0.00023593564,0.0020819178,0.00010142404],"about_ca_topic_score_codex":0.00027435098,"about_ca_topic_score_gemma":0.0005437581,"teacher_disagreement_score":0.037285198,"about_ca_system_score_codex":0.000617966,"about_ca_system_score_gemma":0.015356685,"threshold_uncertainty_score":0.9997655},"labels":[],"label_agreement":null},{"id":"W3169114157","doi":"10.1200/jco.2021.39.15_suppl.10048","title":"Health-related unemployment trends among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Behavioral Risk Factor Surveillance System; Medicine; Unemployment; Demography; Confidence interval; Socioeconomic status; Population; Gerontology; Health equity; Public health; Environmental health; Internal medicine","score_opus":0.1065318027309665,"score_gpt":0.4880422973787179,"score_spread":0.3815104946477514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169114157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934761,0.012035727,0.0000022213185,0.04987813,0.0021801267,0.00038514,0.000044192177,0.000012589218,0.0007009028],"genre_scores_gemma":[0.9864157,0.00835375,0.00008119876,0.0018986174,0.0012921836,0.000020377343,0.000021928434,0.000038261176,0.0018779777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990716,0.002066222,0.005098626,0.0004462807,0.0011915278,0.00048135137],"domain_scores_gemma":[0.9915631,0.0027210594,0.0034369587,0.00063540123,0.0010381107,0.00060539786],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006945947,0.0002421085,0.0028328565,0.00016964485,0.00011700149,0.000016042615,0.00037803646,0.0004009142,0.0015621086],"category_scores_gemma":[0.0030692953,0.0001447894,0.00082491233,0.00082596234,0.00031322555,0.00011371821,0.00019164635,0.0022785752,0.000005931891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007593015,0.009526981,0.816737,0.000014226239,0.0030777862,0.0031054742,0.0014248554,0.00003940676,0.000027387916,0.000002571696,0.011749393,0.15353565],"study_design_scores_gemma":[0.008906397,0.008385551,0.95662564,0.00027381687,0.000639177,0.0003986677,0.0011097494,0.00002606742,0.000066427405,0.000028552364,0.023420796,0.00011916874],"about_ca_topic_score_codex":0.027457064,"about_ca_topic_score_gemma":0.0500061,"teacher_disagreement_score":0.15341648,"about_ca_system_score_codex":0.00030466937,"about_ca_system_score_gemma":0.00793866,"threshold_uncertainty_score":0.9993506},"labels":[],"label_agreement":null},{"id":"W3169138340","doi":"10.1200/jco.2021.39.15_suppl.2653","title":"Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pharmacodynamics; Clinical trial; Biomarker; Internal medicine; Oncology; Phases of clinical research; Pharmacokinetics","score_opus":0.23179269958224755,"score_gpt":0.6457526772047778,"score_spread":0.41395997762253023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169138340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97851413,0.0021935701,0.00083277834,0.011131561,0.004126937,0.00022523975,0.0000074679174,0.000009498355,0.0029588363],"genre_scores_gemma":[0.9815403,0.0066348417,0.007603164,0.002120602,0.0019542153,0.0000025168501,0.0000133808635,0.000031701053,0.00009923703],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98072237,0.0078065856,0.010233791,0.0003421494,0.0004760697,0.00041904568],"domain_scores_gemma":[0.9697004,0.02204707,0.0061451383,0.00035903105,0.0008187041,0.0009296883],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05243638,0.00022398528,0.005430336,0.00036158127,0.000028534823,0.000009602259,0.00030992535,0.0008147598,0.00094574393],"category_scores_gemma":[0.10180269,0.00015420697,0.0029752506,0.0004529413,0.0006759351,0.000114542745,0.00011493212,0.003604377,0.0000102197655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014717959,0.010223302,0.1675907,0.000041470557,0.0030066506,0.0061838212,0.000079367426,0.00006223383,0.009331107,0.000026966101,0.0081310235,0.7806054],"study_design_scores_gemma":[0.20389059,0.06598301,0.5445098,0.00073102704,0.0034598305,0.0069003506,0.000402872,0.030170826,0.00025528815,0.00081774476,0.14244026,0.0004383385],"about_ca_topic_score_codex":0.00006209481,"about_ca_topic_score_gemma":0.000014537907,"teacher_disagreement_score":0.78016704,"about_ca_system_score_codex":0.00042164724,"about_ca_system_score_gemma":0.009775217,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W3169161004","doi":"10.1200/jco.2021.39.15_suppl.586","title":"Impact of different sequencing strategies of talazoparib and carboplatin combination upon efficacy and toxicity in BRCA-wild type and BRCA-mutant triple-negative breast cancer models.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Pfizer Canada","keywords":"Carboplatin; Medicine; PARP inhibitor; Olaparib; BRCA mutation; Concomitant; Cancer; Combination therapy; Population; Internal medicine; Ovarian cancer; Oncology; Breast cancer; Triple-negative breast cancer; Veliparib; Pharmacology; Cancer research; Chemotherapy; Biology; Poly ADP ribose polymerase; Cisplatin","score_opus":0.1231611615651621,"score_gpt":0.4682478282487527,"score_spread":0.3450866666835906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169161004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969474,0.001105,0.00006987067,0.0012288678,0.00020038986,0.00017062445,0.000026600155,0.000002667915,0.00024854814],"genre_scores_gemma":[0.99552524,0.0040064277,0.00025041177,0.00009176055,0.00010616574,0.0000018195493,0.000002063497,0.00000927045,0.000006850081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763685,0.00038857124,0.0014424942,0.00017077864,0.00022601834,0.00013526878],"domain_scores_gemma":[0.9964455,0.0014413358,0.0012085796,0.000090052185,0.0006449532,0.00016959163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009108433,0.00012941603,0.0012745117,0.00012039563,0.000019117197,0.00000890712,0.000039132472,0.00022372541,0.000043077518],"category_scores_gemma":[0.0007292599,0.00009437681,0.00010354307,0.0001890916,0.0002572428,0.00016990262,0.00003589933,0.00054829987,4.2002235e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027625829,0.00443751,0.5825407,0.0004780351,0.0016650301,0.00047112015,0.0043004397,0.0029472697,0.29187727,0.0021475232,0.00013074989,0.08137851],"study_design_scores_gemma":[0.019320259,0.0063966447,0.957924,0.00061639625,0.00017498662,0.0005096677,0.00056097336,0.0041338108,0.006014475,0.004256446,0.000003620067,0.000088697154],"about_ca_topic_score_codex":0.00031490528,"about_ca_topic_score_gemma":0.00038228638,"teacher_disagreement_score":0.37538332,"about_ca_system_score_codex":0.00032509217,"about_ca_system_score_gemma":0.0021198974,"threshold_uncertainty_score":0.38485745},"labels":[],"label_agreement":null},{"id":"W3169177304","doi":"10.1200/jco.2021.39.15_suppl.7046","title":"Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Anemia; Randomized controlled trial; Clinical trial; Gastroenterology; Phases of clinical research; Oncology; Bone marrow","score_opus":0.04754202071381504,"score_gpt":0.38199009167777626,"score_spread":0.33444807096396123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169177304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935792,0.00007519711,0.00006923432,0.0041836253,0.0005683751,0.00019663518,0.000005074264,0.0000031892198,0.0013194613],"genre_scores_gemma":[0.9948204,0.0014233983,0.0029515834,0.00040329868,0.00018270302,0.0000051428387,0.000006376633,0.000011990343,0.00019510258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996482,0.00059932563,0.0019247758,0.00020092462,0.0006036958,0.00018925898],"domain_scores_gemma":[0.9939915,0.002701286,0.0017077101,0.00011816537,0.0013039977,0.00017736113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023301695,0.00012476913,0.0013998586,0.000097268334,0.000022772187,0.000006845742,0.0000655566,0.00037319813,0.00012512985],"category_scores_gemma":[0.00438711,0.000085376814,0.00026349426,0.0001953037,0.000038918406,0.00012426234,0.000025679761,0.0007273763,0.0000021221463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002972168,0.0039182054,0.9568414,0.00003375115,0.00035221595,0.00015340932,0.000186887,0.000015362135,0.0007944517,0.000023098986,0.00012805889,0.034580957],"study_design_scores_gemma":[0.0168553,0.011098638,0.96749073,0.00030098882,0.00025077714,0.000023029927,0.00008012302,0.000045256344,0.002888513,0.000056169174,0.0008389442,0.00007150379],"about_ca_topic_score_codex":0.000057010824,"about_ca_topic_score_gemma":0.0010541667,"teacher_disagreement_score":0.034509454,"about_ca_system_score_codex":0.0003584155,"about_ca_system_score_gemma":0.0014544401,"threshold_uncertainty_score":0.5252097},"labels":[],"label_agreement":null},{"id":"W3169203421","doi":"10.1200/jco.2021.39.15_suppl.tps4164","title":"Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gemcitabine; Medicine; Tolerability; Cisplatin; Regimen; Internal medicine; Oncology; Cancer; Phases of clinical research; Population; Chemotherapy; Gastroenterology; Pharmacology; Adverse effect","score_opus":0.1383867645147306,"score_gpt":0.4770054619385265,"score_spread":0.3386186974237959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169203421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939251,0.002164023,0.00006234715,0.0014660127,0.0011642171,0.0009121852,0.0000940428,0.0000056852746,0.00020641573],"genre_scores_gemma":[0.9962017,0.001301074,0.001560613,0.00013679147,0.0005878631,0.000049261806,0.000023522744,0.000026775626,0.00011238314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961857,0.00015265319,0.0026605974,0.00030771745,0.00043745185,0.0002558893],"domain_scores_gemma":[0.99276155,0.0029108715,0.0023187469,0.00029219387,0.0014824342,0.00023420544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005451309,0.00024348396,0.0025937855,0.00011990171,0.00005764897,0.0000033407537,0.00010798318,0.00017724706,0.00013679547],"category_scores_gemma":[0.0010591095,0.00015778275,0.00053007796,0.00023584213,0.00015490028,0.0000997464,0.000039361672,0.00030728962,5.432056e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14291164,0.07198054,0.5314624,0.00016038724,0.0036504893,0.0004292399,0.0017880825,0.00015893967,0.00017732126,0.000006054016,0.0008256905,0.24644922],"study_design_scores_gemma":[0.25407287,0.20713922,0.52949274,0.0001628198,0.002631709,0.000016205555,0.0010195546,0.000050678744,0.00040541327,0.000014246776,0.0048654075,0.00012913211],"about_ca_topic_score_codex":0.000068312824,"about_ca_topic_score_gemma":0.0012138594,"teacher_disagreement_score":0.24632008,"about_ca_system_score_codex":0.0002603148,"about_ca_system_score_gemma":0.0012160745,"threshold_uncertainty_score":0.6434194},"labels":[],"label_agreement":null},{"id":"W3169211964","doi":"10.1200/jco.2021.39.15_suppl.e12561","title":"Can high Ki67 predict distant recurrence in early-stage breast cancer with low Oncotype Dx score?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Internal medicine; Retrospective cohort study; Distant metastasis; Oncology; Gynecology; Cancer; Metastasis","score_opus":0.036165820200059366,"score_gpt":0.3794604837748852,"score_spread":0.34329466357482585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169211964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99017864,0.0011059181,0.000060045542,0.006963585,0.0011276108,0.00008900004,0.00014066407,0.0000034683494,0.00033105793],"genre_scores_gemma":[0.9939286,0.0034416793,0.00061621406,0.0007500216,0.0010132049,0.0000129270475,0.000016810833,0.000019560686,0.00020094372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768627,0.0003223602,0.0010842327,0.00035315246,0.0002535512,0.00030040997],"domain_scores_gemma":[0.99794996,0.00021278205,0.00085375184,0.0002594069,0.0005023805,0.00022173063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060928223,0.00018891311,0.00084092276,0.00004316932,0.000042235908,0.000012832763,0.00021759169,0.00028338926,0.000070099835],"category_scores_gemma":[0.00041707177,0.00013427493,0.0001901205,0.00017512188,0.0002844526,0.000009787275,0.0001246199,0.00052914815,0.0000023821271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004532756,0.0012423032,0.9606053,0.000029831614,0.0005688971,0.001214418,0.000099118915,0.00015602993,0.000748543,0.00006924172,0.0013793058,0.029354233],"study_design_scores_gemma":[0.005025235,0.0026107149,0.9798065,0.00021330753,0.00012871511,0.00029014182,0.000107921274,0.000004784023,0.0012687619,0.00008604199,0.010288027,0.00016989345],"about_ca_topic_score_codex":0.00053892273,"about_ca_topic_score_gemma":0.009215517,"teacher_disagreement_score":0.02918434,"about_ca_system_score_codex":0.000168129,"about_ca_system_score_gemma":0.0027910122,"threshold_uncertainty_score":0.5475573},"labels":[],"label_agreement":null},{"id":"W3169214555","doi":"10.1200/jco.2021.39.15_suppl.10535","title":"Pan-cancer evaluation of homologous repair deficiency somatic mutations and response to first-line anti-neoplastic therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PALB2; CHEK2; FANCA; Oncology; BAP1; Cancer; ERCC1; Synthetic lethality; Internal medicine; Cancer research; Mutation; Germline mutation; DNA repair; Gene; Genetics; Biology; Nucleotide excision repair","score_opus":0.09461476001155193,"score_gpt":0.4499433690321441,"score_spread":0.35532860902059216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169214555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896828,0.0065477695,0.00071308255,0.0020904576,0.0007075495,0.00013474724,0.000018591378,0.0000019873094,0.00010299943],"genre_scores_gemma":[0.99004674,0.0063491603,0.0025389143,0.00067695056,0.0003275462,0.000009478953,0.000004974409,0.000009775249,0.000036481328],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978017,0.00053637376,0.0011284692,0.00018735844,0.000219576,0.00012649842],"domain_scores_gemma":[0.9964866,0.001549212,0.0006975269,0.0001851637,0.0009540676,0.00012741107],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003228024,0.000087985965,0.0004743425,0.00005904248,0.000044310484,0.0000075615685,0.00009887065,0.00020090085,0.00005108353],"category_scores_gemma":[0.012741298,0.000074723364,0.00020236234,0.0001039729,0.00010020272,0.000004227927,0.00006983265,0.00015020977,0.00000202233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011984802,0.005215171,0.12048215,0.00011570419,0.0011027235,0.0003029901,0.00088479824,0.039935067,0.290234,0.00015359244,0.0065078624,0.5230811],"study_design_scores_gemma":[0.011809177,0.022613129,0.8921644,0.00013206754,0.0008556852,0.0005066396,0.00040150923,0.0020759036,0.030370366,0.0019239367,0.036792755,0.00035445177],"about_ca_topic_score_codex":0.000010824793,"about_ca_topic_score_gemma":0.00018506889,"teacher_disagreement_score":0.77168226,"about_ca_system_score_codex":0.0000450296,"about_ca_system_score_gemma":0.002703909,"threshold_uncertainty_score":0.9955748},"labels":[],"label_agreement":null},{"id":"W3169225089","doi":"10.1200/jco.2021.39.15_suppl.10044","title":"Late morbidity and mortality among survivors of neuroblastoma treated with contemporary therapy: A report from the Childhood Cancer Survivor Study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Hazard ratio; Cumulative incidence; Confidence interval; Standardized mortality ratio; Proportional hazards model; Incidence (geometry); Internal medicine; Neuroblastoma; Mortality rate; Risk of mortality; Radiation therapy; Pediatrics; Surgery; Demography; Cohort","score_opus":0.15449552971719277,"score_gpt":0.4529038262629614,"score_spread":0.2984082965457686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169225089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639726,0.00065379235,0.000002681586,0.0017600383,0.00025546196,0.00047618928,0.000028411518,0.000009340238,0.00041681805],"genre_scores_gemma":[0.9981055,0.0009730591,0.00004692592,0.0004009843,0.0002846523,0.000009817731,0.000006175688,0.000021634112,0.00015120249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955992,0.0015928812,0.0016912388,0.0003180947,0.0005988113,0.00019976968],"domain_scores_gemma":[0.9943284,0.0025857803,0.0016141568,0.0004086459,0.0006895766,0.0003734531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019329252,0.00017895903,0.0015042692,0.000048062982,0.000056361194,0.000013720651,0.00013287351,0.00014507918,0.00007715312],"category_scores_gemma":[0.0014938376,0.00009063448,0.00027298124,0.00023555568,0.00042627024,0.00010911482,0.000081219914,0.00087836175,9.047127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045185047,0.005494186,0.9566814,0.0000072062644,0.0025145188,0.024748087,0.00015229234,0.000003566854,0.00022333337,4.586597e-7,0.0002837554,0.0053727357],"study_design_scores_gemma":[0.011611843,0.012744819,0.9732626,0.00008317343,0.00036695655,0.00048692187,0.00018120332,0.000011792225,0.0006841632,0.000027111188,0.00047229594,0.00006708365],"about_ca_topic_score_codex":0.006943555,"about_ca_topic_score_gemma":0.01063357,"teacher_disagreement_score":0.024261165,"about_ca_system_score_codex":0.000034348734,"about_ca_system_score_gemma":0.0022832567,"threshold_uncertainty_score":0.9996693},"labels":[],"label_agreement":null},{"id":"W3169263352","doi":"10.1200/jco.2021.39.15_suppl.e15589","title":"Rationale for the utilization of biological targeted agents (bTAs) in the treatment of metastatic colorectal cancer (mCRC), single tertiary cancer center experience.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Cetuximab; Panitumumab; Internal medicine; Bevacizumab; Chemotherapy; Oncology; Cancer","score_opus":0.354941269453887,"score_gpt":0.5149097789229988,"score_spread":0.15996850946911184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169263352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850886,0.00798127,0.000059639297,0.0053879675,0.0007446409,0.0005516453,0.000056232668,0.0000014692185,0.00012852911],"genre_scores_gemma":[0.9872071,0.011118022,0.00036499754,0.00080413773,0.0002411038,0.00018041451,0.000012291882,0.0000053252247,0.00006656879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997967,0.00030912986,0.0012371683,0.00013303576,0.00021866456,0.00013497498],"domain_scores_gemma":[0.9963115,0.002320514,0.00079208874,0.00008756196,0.00043984214,0.000048485224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048851676,0.00010470187,0.0008403475,0.000039323728,0.00004640022,0.000003629819,0.00008930318,0.000084228224,0.00026154114],"category_scores_gemma":[0.0007237906,0.00004537531,0.00037249172,0.00016020007,0.00023757933,0.00003820796,0.000017782348,0.000111753514,2.114011e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009674825,0.015344868,0.73599106,0.00005156744,0.0021942016,0.00017276556,0.0074924426,0.00014050002,0.003424019,0.00006787068,0.0019502005,0.22349569],"study_design_scores_gemma":[0.009641014,0.014353654,0.9171167,0.00007946817,0.00062275055,0.000047957263,0.0031086064,0.0002788248,0.006237097,0.000091149814,0.048361138,0.000061658975],"about_ca_topic_score_codex":0.00009022664,"about_ca_topic_score_gemma":0.0010307481,"teacher_disagreement_score":0.22343403,"about_ca_system_score_codex":0.00019384672,"about_ca_system_score_gemma":0.0007059511,"threshold_uncertainty_score":0.2863692},"labels":[],"label_agreement":null},{"id":"W3169299949","doi":"10.1200/jco.2021.39.15_suppl.8034","title":"Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"Sanofi","keywords":"Medicine; Carfilzomib; Regimen; Refractory (planetary science); Lenalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Gastroenterology; Urology; Oncology; Surgery; Randomized controlled trial","score_opus":0.08195935304219472,"score_gpt":0.4289977155027925,"score_spread":0.34703836246059777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169299949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782705,0.0008610723,0.0000561019,0.000661559,0.00010602031,0.00038729075,0.00002104994,0.000004156865,0.00007567647],"genre_scores_gemma":[0.9835597,0.0011279564,0.014903929,0.00017513715,0.00010735731,0.000008080119,0.00001979903,0.000017202654,0.00008083986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680626,0.00052217644,0.0016242468,0.00033993216,0.00036029922,0.00034707194],"domain_scores_gemma":[0.9940254,0.003286851,0.0010484619,0.00024587405,0.0006730689,0.0007203348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010088361,0.00019518804,0.002278244,0.00043538184,0.00003754763,0.000012653415,0.00006363237,0.00023525501,0.000025638536],"category_scores_gemma":[0.006712435,0.00012427804,0.00024642452,0.00053348165,0.00016132128,0.00012196068,0.00008560377,0.00045103754,0.0000012132675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018256107,0.0024709578,0.84659874,0.000037184138,0.0019713917,0.0006101493,0.0002851686,0.000024699862,0.00021826525,0.0000016869758,0.00001486892,0.12951078],"study_design_scores_gemma":[0.050657813,0.023409834,0.9226357,0.00012124293,0.0011138447,0.00003282473,0.0005185232,0.0002596274,0.00018629998,0.000006274644,0.0009648065,0.00009322536],"about_ca_topic_score_codex":0.00028275247,"about_ca_topic_score_gemma":0.0014803862,"teacher_disagreement_score":0.12941755,"about_ca_system_score_codex":0.00051854824,"about_ca_system_score_gemma":0.0016061997,"threshold_uncertainty_score":0.80358964},"labels":[],"label_agreement":null},{"id":"W3169315270","doi":"10.1200/jco.2021.39.15_suppl.4003","title":"Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Adjuvant; Adverse effect; Oncology; Discontinuation; Cancer; Immunotherapy","score_opus":0.17700549080337008,"score_gpt":0.5273111111710322,"score_spread":0.35030562036766216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169315270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96545523,0.029120678,0.00015321742,0.0033752767,0.0011857663,0.00041174813,0.000025261977,0.000025533256,0.00024731204],"genre_scores_gemma":[0.9807828,0.011259096,0.004288757,0.0010875607,0.0016857438,0.000021449665,0.000033559674,0.000047779093,0.00079322857],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99415547,0.001019666,0.002746974,0.0006006931,0.00084082154,0.0006363901],"domain_scores_gemma":[0.9950564,0.0021315354,0.0010930826,0.00036914082,0.0004708855,0.0008789872],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019390347,0.00034708713,0.0030207937,0.00028139245,0.00011187519,0.00004346303,0.00019275333,0.00045956008,0.0012894963],"category_scores_gemma":[0.0023696746,0.00023940197,0.0006746519,0.0005874158,0.0002154968,0.0002528079,0.00010000928,0.00162384,0.0000079961255],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09907064,0.0054331687,0.33582038,0.000097689604,0.004141602,0.07928516,0.00065013143,0.0002087725,0.0059702257,0.000010033185,0.0016730836,0.46763912],"study_design_scores_gemma":[0.08032567,0.014859029,0.89457643,0.0005798194,0.0009337515,0.00073603174,0.00027389088,0.0005747545,0.0053776614,0.0001300941,0.0014162428,0.00021659669],"about_ca_topic_score_codex":0.00092539215,"about_ca_topic_score_gemma":0.0020035894,"teacher_disagreement_score":0.5587561,"about_ca_system_score_codex":0.0009966888,"about_ca_system_score_gemma":0.004895215,"threshold_uncertainty_score":0.9996235},"labels":[],"label_agreement":null},{"id":"W3169327621","doi":"10.1200/jco.2021.39.15_suppl.7019","title":"Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; Medicine; Myeloid leukemia; Bone marrow; Chemotherapy; Cancer research; Oncology; Internal medicine; Survival analysis","score_opus":0.05231776550546937,"score_gpt":0.4423689324410603,"score_spread":0.39005116693559094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169327621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96102047,0.0013184146,0.0018973678,0.03335942,0.0007826916,0.0010440861,0.000065893284,0.00001630288,0.00049533177],"genre_scores_gemma":[0.96770084,0.0030721093,0.016955057,0.008834217,0.0016637363,0.000056076642,0.000022392313,0.00007987254,0.0016157083],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99413323,0.0014331716,0.0026873318,0.0004830632,0.0006501203,0.00061309506],"domain_scores_gemma":[0.9867673,0.009440205,0.0012969591,0.00036316246,0.001543714,0.0005886703],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007679247,0.0002765511,0.0023341472,0.0003220431,0.000065349406,0.00002051864,0.00034799566,0.0010690712,0.00019966716],"category_scores_gemma":[0.011361666,0.0002148442,0.00086614955,0.000451715,0.0004004415,0.00016820522,0.00010366627,0.0032172713,0.000013975665],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73870933,0.0028795046,0.0041863094,0.00008689838,0.003360196,0.025620755,0.0014397185,0.0003024276,0.15238634,0.00012656508,0.012733129,0.05816882],"study_design_scores_gemma":[0.16061868,0.10027228,0.42788306,0.0011052,0.001551299,0.0072886813,0.0019000614,0.006656932,0.2222705,0.0029221717,0.06677536,0.00075575005],"about_ca_topic_score_codex":0.000020961916,"about_ca_topic_score_gemma":0.000028259223,"teacher_disagreement_score":0.57809067,"about_ca_system_score_codex":0.0023399214,"about_ca_system_score_gemma":0.016788596,"threshold_uncertainty_score":0.9990823},"labels":[],"label_agreement":null},{"id":"W3169329629","doi":"10.1200/jco.2021.39.15_suppl.e17052","title":"Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation oncologist; Logistic regression; Population; Odds ratio; Cancer registry; Internal medicine; Cancer; Gynecology; Radiation therapy; Environmental health","score_opus":0.4361590091225278,"score_gpt":0.5421362238029388,"score_spread":0.10597721468041099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169329629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.859788,0.00018261684,0.00016340689,0.13747895,0.00092828146,0.00027974503,0.0000096944505,0.0000040245,0.0011653046],"genre_scores_gemma":[0.96250147,0.00075197435,0.008080535,0.027267585,0.00031008018,0.00001088296,0.000028721937,0.000010746311,0.0010380312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526507,0.00048627972,0.003549817,0.00017759153,0.00033372914,0.00018749737],"domain_scores_gemma":[0.98835576,0.008650773,0.001338738,0.0001232069,0.0010702602,0.00046128043],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003475312,0.00009935918,0.00095845124,0.00010421011,0.00004256584,0.000016599517,0.00005914364,0.00017652448,0.00028934225],"category_scores_gemma":[0.041158948,0.000086230306,0.00009486724,0.00013122914,0.00011936699,0.00017949138,0.000056515422,0.0009498695,0.0000019356758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003090975,0.0011348623,0.53744286,0.00003791574,0.00019648064,0.0038183287,0.00038564496,0.00005809083,0.00007378313,0.00052468805,0.038995326,0.41424108],"study_design_scores_gemma":[0.0059869713,0.0017184811,0.67820567,0.000047692545,0.00015261114,0.0003699501,0.0010834535,0.00003476095,0.000018544975,0.000156482,0.312161,0.00006437894],"about_ca_topic_score_codex":0.56668735,"about_ca_topic_score_gemma":0.98693806,"teacher_disagreement_score":0.4202507,"about_ca_system_score_codex":0.0010563018,"about_ca_system_score_gemma":0.03985453,"threshold_uncertainty_score":0.96691775},"labels":[],"label_agreement":null},{"id":"W3169355614","doi":"10.1200/jco.2021.39.15_suppl.4557","title":"Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Pancreas; Internal medicine; Oncology; Systemic therapy; Nephrectomy; Cancer; Gastroenterology; Urology; Kidney","score_opus":0.10001248264545146,"score_gpt":0.3989554250508949,"score_spread":0.2989429424054434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169355614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909706,0.0007573244,0.0000086035725,0.0063341227,0.00014603527,0.00029322077,0.0000130895405,0.0000026060948,0.0014743631],"genre_scores_gemma":[0.9935197,0.00006717716,0.0028692419,0.00274941,0.00019241066,0.000008761541,0.000004159777,0.00001634683,0.0005727784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976071,0.00050034036,0.0011495006,0.00021392984,0.00032154724,0.0002075426],"domain_scores_gemma":[0.9970462,0.0015504907,0.00053440325,0.0002447959,0.00026648928,0.0003576397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066340686,0.00017006253,0.0013008126,0.00008844294,0.000028560324,0.000010910511,0.00007304467,0.00011394662,0.000095575575],"category_scores_gemma":[0.0006391943,0.00007517411,0.00026114317,0.00013715937,0.0000869581,0.000039856914,0.000045303448,0.00031631457,0.000012234465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025839352,0.0032037557,0.9744587,0.0000083236555,0.0002750779,0.0023010897,0.00015400775,0.0000106177595,0.000057589245,0.000010109321,0.0003923943,0.016544398],"study_design_scores_gemma":[0.01299854,0.022484278,0.9299228,0.000023697921,0.00065589754,0.00026404634,0.0001236319,0.0000036507693,0.0006942278,0.000013846828,0.032745074,0.000070269656],"about_ca_topic_score_codex":0.00009416916,"about_ca_topic_score_gemma":0.00045322938,"teacher_disagreement_score":0.044535864,"about_ca_system_score_codex":0.00023465097,"about_ca_system_score_gemma":0.00083506113,"threshold_uncertainty_score":0.30655113},"labels":[],"label_agreement":null},{"id":"W3169357178","doi":"10.1200/jco.2021.39.15_suppl.4098","title":"The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Medicine; Sorafenib; Oncology; Atezolizumab; Bevacizumab; Internal medicine; Hepatocellular carcinoma; Clinical endpoint; Clinical trial; Cancer; Nivolumab; Chemotherapy; Immunotherapy","score_opus":0.09492213808112498,"score_gpt":0.33451042320627483,"score_spread":0.23958828512514985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169357178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995018,0.0016110637,0.000027443235,0.00039920502,0.00094366417,0.00020243558,0.000034517947,7.585283e-7,0.0017629082],"genre_scores_gemma":[0.99896926,0.0006993565,0.00009910053,0.00009806829,0.000073524054,0.0000061675455,0.0000023818109,0.00001310711,0.000039039976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712414,0.00021233498,0.002089602,0.00021547715,0.00007104743,0.00028738953],"domain_scores_gemma":[0.9946167,0.0032355175,0.0016278283,0.0001829682,0.00020480274,0.00013222182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002676516,0.00012315204,0.0013374281,0.0000965748,0.000040690215,0.000017465925,0.000221209,0.00016621567,0.000044063127],"category_scores_gemma":[0.0030524677,0.00009113856,0.00008896603,0.00022314866,0.00014075698,0.00019543205,0.00006937477,0.0005166584,0.0000020046027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013137146,0.0002379365,0.972301,0.00003089139,0.000072768446,0.0001345202,0.000037772897,0.00011671903,5.8059265e-7,0.002012033,0.000079625395,0.011839023],"study_design_scores_gemma":[0.01863648,0.0022398648,0.9677124,0.000062398976,0.000012017508,0.0000067124424,0.00009366684,0.0002140688,0.00003730432,0.0009212145,0.009949269,0.00011459339],"about_ca_topic_score_codex":0.08532652,"about_ca_topic_score_gemma":0.5250434,"teacher_disagreement_score":0.4397169,"about_ca_system_score_codex":0.00088701467,"about_ca_system_score_gemma":0.0045916173,"threshold_uncertainty_score":0.9207644},"labels":[],"label_agreement":null},{"id":"W3169372071","doi":"10.1200/jco.2021.39.15_suppl.502","title":"Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Letrozole; Proportional hazards model; Log-rank test; Confidence interval; Cancer; Gynecology; Randomized controlled trial; Tamoxifen","score_opus":0.1189310745460365,"score_gpt":0.42697324543150733,"score_spread":0.3080421708854708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169372071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883777,0.0021410608,0.0004066933,0.006368001,0.001548273,0.0003959514,0.00018682002,0.0000015735216,0.000573962],"genre_scores_gemma":[0.99499255,0.0019026966,0.0012235147,0.0007979371,0.0009845203,0.000029770184,0.000022080121,0.000010085877,0.000036846017],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99638176,0.0011179388,0.0018269649,0.00025157357,0.00024527241,0.00017648033],"domain_scores_gemma":[0.9956604,0.0016446903,0.0016868055,0.00042296873,0.0005309979,0.000054102034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032890732,0.00014052687,0.000933491,0.00002752433,0.00004889969,0.0000041094713,0.0003969083,0.00043441172,0.00003858083],"category_scores_gemma":[0.0021326337,0.0000791861,0.0007247662,0.00011087048,0.00031100324,0.000006062056,0.00012730966,0.0003722433,4.0328797e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19339113,0.017854199,0.23788795,0.000044217653,0.0035927086,0.00006006947,0.00065834535,0.00012824216,0.0996473,0.00038116425,0.0077961814,0.4385585],"study_design_scores_gemma":[0.04387417,0.006283075,0.841501,0.000028367393,0.0002370827,0.00002994496,0.0003515903,0.00001806441,0.058401905,0.0019586007,0.047242045,0.00007416454],"about_ca_topic_score_codex":0.000049363065,"about_ca_topic_score_gemma":0.00046052798,"teacher_disagreement_score":0.603613,"about_ca_system_score_codex":0.00005515014,"about_ca_system_score_gemma":0.0011886468,"threshold_uncertainty_score":0.3350581},"labels":[],"label_agreement":null},{"id":"W3169399702","doi":"10.1200/jco.2021.39.15_suppl.6036","title":"Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Amgen","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncolytic virus; Oncology; Refractory (planetary science); Cancer; Surgery; Immunotherapy","score_opus":0.11108374656335238,"score_gpt":0.4540985133859306,"score_spread":0.34301476682257825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169399702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442095,0.003741607,0.00028583518,0.00024298197,0.00021618613,0.0009699568,0.00009018507,6.316645e-7,0.000031654254],"genre_scores_gemma":[0.9985694,0.0008465339,0.00031430426,0.000058825222,0.00006639746,0.00003219601,0.000018349883,0.0000151438335,0.000078824996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945757,0.0021427744,0.0024525905,0.00025583705,0.0003811235,0.00019199566],"domain_scores_gemma":[0.99333984,0.002374924,0.002670227,0.00046904292,0.0010486756,0.000097315606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026735405,0.00017945142,0.0018626319,0.00013814021,0.00004906377,0.0000059829163,0.0003302583,0.00015077741,0.00002955422],"category_scores_gemma":[0.0012563891,0.00010333199,0.0011741451,0.00028657066,0.00042095542,0.0000069657876,0.00010829041,0.00020081065,1.0591324e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79422647,0.055799697,0.022775214,0.00023774621,0.009245016,0.000036386602,0.0017692144,0.0018666134,0.07284585,0.000011618318,0.000116707786,0.041069485],"study_design_scores_gemma":[0.6785212,0.1412961,0.014371407,0.000039700983,0.008327784,0.00001909487,0.0015079842,0.008114883,0.14722365,0.00003579782,0.0003898626,0.00015248155],"about_ca_topic_score_codex":0.00007758855,"about_ca_topic_score_gemma":0.0009570011,"teacher_disagreement_score":0.11570522,"about_ca_system_score_codex":0.000053002288,"about_ca_system_score_gemma":0.00089432526,"threshold_uncertainty_score":0.42137563},"labels":[],"label_agreement":null},{"id":"W3169437264","doi":"10.1200/jco.2021.39.15_suppl.1001","title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Fulvestrant; Internal medicine; Breast cancer; Placebo; Oncology; Cancer; Nuclear medicine; Surgery; Confidence interval; Estrogen receptor; Pathology","score_opus":0.052988043005200325,"score_gpt":0.41162090071855323,"score_spread":0.3586328577133529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169437264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742354,0.0004345973,0.00010808136,0.008824598,0.0009879627,0.0007275337,0.0010298707,0.000025166577,0.0004386778],"genre_scores_gemma":[0.9933224,0.00066178467,0.0023576412,0.0015943925,0.0014457126,0.000019303541,0.00025401384,0.00007002164,0.00027473117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99340266,0.00094629056,0.0034512659,0.0005744287,0.00112218,0.0005031691],"domain_scores_gemma":[0.9897849,0.0026986676,0.004036696,0.00060305226,0.0023560915,0.0005205969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013067559,0.0004348794,0.0027578138,0.00008102599,0.00009727649,0.000017338358,0.00035813675,0.0003911288,0.0004184484],"category_scores_gemma":[0.00077003014,0.00023655387,0.00038465072,0.0004078696,0.0007029335,0.00031249286,0.00006944861,0.0014387885,0.0000038305093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8564014,0.008872553,0.018820211,0.0000140935235,0.0028447153,0.0011868684,0.00025004783,0.00032757872,0.001628015,0.000026247973,0.00038587814,0.10924241],"study_design_scores_gemma":[0.669721,0.052027438,0.2562574,0.00055891386,0.0018032257,0.0004673628,0.00037186185,0.000045752124,0.0009061275,0.00012006013,0.017391877,0.00032892782],"about_ca_topic_score_codex":0.0004965048,"about_ca_topic_score_gemma":0.00080602034,"teacher_disagreement_score":0.23743722,"about_ca_system_score_codex":0.0003538871,"about_ca_system_score_gemma":0.0037058475,"threshold_uncertainty_score":0.96463865},"labels":[],"label_agreement":null},{"id":"W3169492982","doi":"10.1200/jco.2021.39.15_suppl.5517","title":"Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; BRCA mutation; Hazard ratio; Cisplatin; Chemotherapy; Clinical endpoint; Progression-free survival; Confidence interval; Gastroenterology; Randomized controlled trial; Ovarian cancer; Cancer","score_opus":0.09322569958094554,"score_gpt":0.500486568795579,"score_spread":0.40726086921463345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169492982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376637,0.00043384382,0.0006699131,0.002316033,0.0007831708,0.0015472696,0.00002725518,0.0000046616437,0.0004514701],"genre_scores_gemma":[0.99756014,0.00036784165,0.001127127,0.00049833104,0.00030219698,0.00006379842,0.000023248194,0.00001845973,0.000038828504],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920051,0.0037728215,0.0032179365,0.00029632906,0.00047712645,0.00023067354],"domain_scores_gemma":[0.96647274,0.029593302,0.002765873,0.00041836625,0.0006020982,0.00014761619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0113487765,0.00023255523,0.004890972,0.0003008327,0.00003836983,0.0000063657913,0.00011854271,0.0002910267,0.000112467686],"category_scores_gemma":[0.0051778853,0.0001393056,0.0019207996,0.00077667896,0.00032239975,0.000071693175,0.000015736729,0.0005574169,8.531962e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9036213,0.011709564,0.03618085,0.00003942541,0.010546708,0.0012694934,0.0020247616,0.00050227385,0.0024623354,0.00008447478,0.00008198163,0.031476792],"study_design_scores_gemma":[0.8817035,0.07175176,0.025223665,0.00006249996,0.010067611,0.00014482805,0.0011765972,0.00096238026,0.008055746,0.00013020086,0.000606461,0.00011475782],"about_ca_topic_score_codex":0.00013395475,"about_ca_topic_score_gemma":0.00037010343,"teacher_disagreement_score":0.060042195,"about_ca_system_score_codex":0.00032013826,"about_ca_system_score_gemma":0.0013441674,"threshold_uncertainty_score":0.61987865},"labels":[],"label_agreement":null},{"id":"W3169509716","doi":"10.1200/jco.2021.39.15_suppl.9038","title":"Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Medicine; Discontinuation; Placebo; Lung cancer; Internal medicine; Quality of life (healthcare); Oncology; Pathology; Alternative medicine","score_opus":0.14657495138159443,"score_gpt":0.44327872357133413,"score_spread":0.2967037721897397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169509716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910806,0.0013437695,0.00044800216,0.004307859,0.0011292362,0.0013977092,0.000032762495,0.000015513686,0.0002445479],"genre_scores_gemma":[0.9937128,0.00020880744,0.004156747,0.0014072648,0.00022021044,0.000029053617,0.000057476904,0.000048054208,0.00015960833],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9914831,0.0012127178,0.005425267,0.00043914551,0.0009409845,0.0004987851],"domain_scores_gemma":[0.98884743,0.003151453,0.0058420985,0.00039257458,0.0012789912,0.00048743185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004806674,0.00031449881,0.00339565,0.00023640798,0.00007906947,0.000013804663,0.0002018702,0.00029874386,0.00014424301],"category_scores_gemma":[0.00466633,0.00021067537,0.00059473864,0.0004925913,0.00044942324,0.00019603567,0.000044640918,0.0011267703,0.0000022234174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9119538,0.0034179222,0.059971757,0.0006659009,0.0018660667,0.00018117025,0.00035808384,0.00027364015,0.000060579478,0.000043867614,0.0006336383,0.020573562],"study_design_scores_gemma":[0.2965145,0.05311432,0.6461345,0.00082617113,0.0005195662,0.00012722565,0.00053054205,0.00019904564,0.000052018782,0.000047179194,0.0017032811,0.00023167119],"about_ca_topic_score_codex":0.0003952342,"about_ca_topic_score_gemma":0.0015032872,"teacher_disagreement_score":0.6154393,"about_ca_system_score_codex":0.0011587954,"about_ca_system_score_gemma":0.016562728,"threshold_uncertainty_score":0.9890124},"labels":[],"label_agreement":null},{"id":"W3169516452","doi":"10.1200/jco.2021.39.15_suppl.e18577","title":"Non-fatal self-injury after a diagnosis of cancer: A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary; Princess Margaret Cancer Centre; University of Manitoba; Health Sciences Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Confounding; Incidence (geometry); Cancer; Hazard ratio; Population; Internal medicine; Confidence interval; Environmental health","score_opus":0.053799599638846625,"score_gpt":0.4620057722458632,"score_spread":0.4082061726070166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169516452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268645,0.0010277411,0.000013510214,0.0035536834,0.0022585941,0.00016605998,0.000016949549,0.0000068673553,0.0002701362],"genre_scores_gemma":[0.9953756,0.0003502676,0.00044669028,0.0024263477,0.001261611,0.000032543503,0.0000032774471,0.000014966063,0.000088733716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970564,0.00029975228,0.0018833741,0.0001751105,0.0004305949,0.00015477161],"domain_scores_gemma":[0.9964218,0.0012152862,0.0010680069,0.00022270491,0.0008060019,0.00026618523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012409,0.00011062057,0.0013528971,0.000096475094,0.00001879976,0.000005450567,0.00009860544,0.00023947105,0.0007765425],"category_scores_gemma":[0.0010000524,0.00008546466,0.0006123765,0.00023676555,0.00003973185,0.000054462376,0.00003958782,0.0006084956,0.0000041156986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032871624,0.0034762048,0.9530275,0.00006718557,0.00041934568,0.0009917245,0.00027530824,0.000009395854,0.000014471992,0.0000020814323,0.0007893239,0.03764031],"study_design_scores_gemma":[0.0043651517,0.007593481,0.9701055,0.0001824041,0.0007422731,0.000025372303,0.00040172713,0.000031326563,0.0002895595,0.000021339896,0.016161753,0.00008010033],"about_ca_topic_score_codex":0.00066204934,"about_ca_topic_score_gemma":0.005759713,"teacher_disagreement_score":0.03756021,"about_ca_system_score_codex":0.0001850416,"about_ca_system_score_gemma":0.003011919,"threshold_uncertainty_score":0.8502596},"labels":[],"label_agreement":null},{"id":"W3169520333","doi":"10.1200/jco.2021.39.15_suppl.e24031","title":"Impact of adding plinabulin to pegfilgrastim for the prevention of TAC chemotherapy (Chemo) induced neutropenia (CIN), on patient quality of life (QoL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pegfilgrastim; Medicine; Docetaxel; Neutropenia; Internal medicine; Cyclophosphamide; Breast cancer; Chemotherapy; Cancer; Quality of life (healthcare); Oncology; Filgrastim; Febrile neutropenia; Nursing","score_opus":0.23838285049957028,"score_gpt":0.5513046962059804,"score_spread":0.31292184570641013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169520333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366796,0.00013501888,0.0006675518,0.0040047104,0.0006287463,0.00049109873,0.000018840283,0.0000029459786,0.00038312975],"genre_scores_gemma":[0.99659437,0.00022012039,0.0017296757,0.00086693885,0.00048422534,0.000012374767,0.0000028185818,0.000016344085,0.00007314155],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99608505,0.00041261766,0.0028431655,0.000165137,0.00033223344,0.0001617737],"domain_scores_gemma":[0.99220777,0.0030800914,0.002926757,0.00028453037,0.0012706133,0.00023022939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020659408,0.0001253363,0.001589052,0.00009295671,0.000036210542,0.0000036891606,0.00014443375,0.00022062933,0.00030275004],"category_scores_gemma":[0.004374682,0.000077138895,0.0011928976,0.00025585562,0.000089774934,0.00004832383,0.00004184257,0.0005395482,0.0000017582666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07621259,0.01404446,0.15255484,0.00036241752,0.0038301907,0.000026730118,0.00087414397,0.0013703568,0.23918189,0.0005635055,0.010741956,0.5002369],"study_design_scores_gemma":[0.013157137,0.058239266,0.89516026,0.00033070653,0.0005141846,0.000040926894,0.00030826454,0.00005223792,0.02733413,0.0002179447,0.0045372215,0.00010771512],"about_ca_topic_score_codex":0.00008471248,"about_ca_topic_score_gemma":0.00007161685,"teacher_disagreement_score":0.74260545,"about_ca_system_score_codex":0.00014972668,"about_ca_system_score_gemma":0.0026996054,"threshold_uncertainty_score":0.52372193},"labels":[],"label_agreement":null},{"id":"W3169526934","doi":"10.1200/jco.2021.39.15_suppl.9526","title":"Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Interim analysis; Oncology; Nivolumab; Hazard ratio; Pembrolizumab; Progression-free survival; Combination therapy; Refractory (planetary science); Clinical trial; Cancer; Overall survival; Immunotherapy; Confidence interval","score_opus":0.0808076675845741,"score_gpt":0.4353919557677527,"score_spread":0.3545842881831786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169526934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936788,0.00025079786,0.000028502634,0.0027809672,0.0017528036,0.00085549726,0.00001001747,0.0000032337489,0.00063938356],"genre_scores_gemma":[0.99654704,0.0003468266,0.0020994227,0.00046022993,0.00040100174,0.00002267062,0.000024647426,0.000017646495,0.000080535516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99042886,0.0031446582,0.0054129977,0.00026891558,0.00045014085,0.00029444357],"domain_scores_gemma":[0.99092245,0.005680307,0.0025081406,0.00018076571,0.0004625312,0.00024580493],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007406576,0.0002101682,0.0045818673,0.0002593369,0.00002064954,0.000005100636,0.00010017048,0.00036193678,0.0002908736],"category_scores_gemma":[0.014456175,0.00015275535,0.0010101133,0.00022443823,0.00025974453,0.00009945943,0.00007884339,0.0010648137,0.000005967187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7057883,0.01857863,0.2640839,0.000044307795,0.0007377346,0.0028608893,0.00017636693,0.00001443534,0.000011664704,0.0000091361835,0.000049898936,0.007644717],"study_design_scores_gemma":[0.865046,0.018648231,0.11345712,0.00033326363,0.00076046423,0.000044455453,0.0000658432,0.00016943524,0.00010301447,0.00034277537,0.0009319296,0.00009744666],"about_ca_topic_score_codex":0.00006520264,"about_ca_topic_score_gemma":0.00059744844,"teacher_disagreement_score":0.1592577,"about_ca_system_score_codex":0.0002783306,"about_ca_system_score_gemma":0.0010828396,"threshold_uncertainty_score":0.99384546},"labels":[],"label_agreement":null},{"id":"W3169551188","doi":"10.1200/jco.2021.39.15_suppl.10500","title":"Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health; Breast Cancer Research Foundation","keywords":"CHEK2; PALB2; Medicine; Breast cancer; Mammography; Cancer; Oncology; Magnetic resonance imaging; Internal medicine; Breast cancer screening; Radiology; Germline mutation; Genetics; Biology; Mutation","score_opus":0.12878933245098664,"score_gpt":0.46801659309328425,"score_spread":0.3392272606422976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169551188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8903818,0.0041332957,0.103401095,0.0013144576,0.00040626145,0.00009341768,0.00014852459,0.000001353594,0.00011979474],"genre_scores_gemma":[0.9687915,0.0013930949,0.028774278,0.00039679074,0.0005633386,0.000008979222,0.000018103961,0.000009850569,0.0000440829],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979306,0.00027501787,0.0012671095,0.00024156313,0.00013231074,0.00015341143],"domain_scores_gemma":[0.9973634,0.00025676392,0.0009840397,0.00016454929,0.0010863991,0.00014483811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001298726,0.000105435865,0.00090773037,0.000064871834,0.000046062087,0.000008328866,0.00013237432,0.00027864723,0.000036257512],"category_scores_gemma":[0.00041849323,0.00009203377,0.00049706,0.00020248191,0.00017042698,0.000007877797,0.00007326994,0.00022503198,1.15881896e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011111024,0.0017181006,0.14223525,0.00019132646,0.03730886,0.00014012074,0.0015443906,0.36254838,0.16227977,0.0004074598,0.005337493,0.27517784],"study_design_scores_gemma":[0.044949338,0.013730063,0.38001505,0.00041099818,0.026321117,0.0021228483,0.011824676,0.42727938,0.033112496,0.0028305585,0.05546536,0.001938149],"about_ca_topic_score_codex":0.000019436187,"about_ca_topic_score_gemma":0.00024595446,"teacher_disagreement_score":0.2732397,"about_ca_system_score_codex":0.00003902823,"about_ca_system_score_gemma":0.0018487714,"threshold_uncertainty_score":0.3753028},"labels":[],"label_agreement":null},{"id":"W3169575541","doi":"10.1200/jco.2021.39.15_suppl.6505","title":"Temporal trends in oncology drug revenue among the world’s major pharmaceutical companies: A 2010-2019 cohort study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Manitoba; University of Calgary","funders":"","keywords":"Revenue; Medicine; Cancer drugs; Cohort; Cancer; Family medicine; Internal medicine; Finance; Business","score_opus":0.14427608442977238,"score_gpt":0.44247204461932593,"score_spread":0.2981959601895535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169575541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93730587,0.0026580058,0.000043012682,0.019088896,0.0057211067,0.00024142122,0.00005407593,0.0000068579525,0.034880735],"genre_scores_gemma":[0.9797177,0.00079047366,0.000388934,0.0031833109,0.0016373716,0.000014295689,0.000004720648,0.000026593307,0.014236607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938553,0.00055637985,0.004608474,0.00042494957,0.00009383527,0.0004610772],"domain_scores_gemma":[0.99394214,0.0019262943,0.003243438,0.00038709026,0.0001797106,0.00032130352],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010237851,0.00021261672,0.002560982,0.00039919384,0.00008682117,0.00005040377,0.0005920318,0.000324863,0.001449488],"category_scores_gemma":[0.0019226524,0.00017841243,0.0006055086,0.0005241142,0.00042937795,0.00035148286,0.00017327342,0.0019499272,0.00016507007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048260484,0.0018253376,0.8832931,0.00000449423,0.0002962413,0.00048270985,0.00036603562,0.000056974786,5.832308e-7,0.0023388362,0.085752696,0.025100412],"study_design_scores_gemma":[0.0033640217,0.0007456394,0.60680133,0.000013586916,0.000050457773,0.00003841784,0.00020456631,0.000121615,0.0000017624508,0.0021232816,0.38640854,0.00012677888],"about_ca_topic_score_codex":0.000696546,"about_ca_topic_score_gemma":0.015205644,"teacher_disagreement_score":0.30065584,"about_ca_system_score_codex":0.0005650795,"about_ca_system_score_gemma":0.00088704866,"threshold_uncertainty_score":0.9994633},"labels":[],"label_agreement":null},{"id":"W3169602208","doi":"10.1200/jco.2021.39.15_suppl.e19040","title":"Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Repeated measures design; Population; Clinical endpoint; Internal medicine; Clinical trial; Gee; Generalized estimating equation; Statistics; Mathematics; Bone marrow","score_opus":0.22903750908956824,"score_gpt":0.47981538160230097,"score_spread":0.25077787251273276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169602208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954866,0.0014200741,0.000011053158,0.002131884,0.0002164413,0.00014090493,0.0001052032,0.0000051326588,0.00048267338],"genre_scores_gemma":[0.993727,0.0021859296,0.0029057201,0.00073334645,0.00033254817,0.0000042197576,0.000057037792,0.000014308456,0.000039887604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654037,0.00042637126,0.0021142939,0.00030601796,0.00040918594,0.00020376845],"domain_scores_gemma":[0.993193,0.0039131544,0.0014171946,0.00016178806,0.0008466369,0.000468244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066075893,0.00019737055,0.0020261614,0.00012765237,0.000049476635,0.00001887108,0.0000674677,0.00031782055,0.00022184735],"category_scores_gemma":[0.0027413655,0.00013528409,0.00032221002,0.00016358949,0.0002698838,0.000100824844,0.00010388812,0.00042326015,0.000002954363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012886046,0.002976053,0.9494602,0.000028303013,0.0020071885,0.00035105256,0.00012368803,0.0000013581678,0.00023080742,0.000066074645,0.0005195871,0.0429471],"study_design_scores_gemma":[0.01232827,0.00943509,0.9701323,0.0001750447,0.0020760396,0.00011785296,0.00012453742,0.000014073916,0.0037280247,0.0002449561,0.001525516,0.00009828775],"about_ca_topic_score_codex":0.00007835995,"about_ca_topic_score_gemma":0.000042132375,"teacher_disagreement_score":0.04284881,"about_ca_system_score_codex":0.000049648286,"about_ca_system_score_gemma":0.0005919377,"threshold_uncertainty_score":0.5516725},"labels":[],"label_agreement":null},{"id":"W3169630256","doi":"10.1200/jco.2021.39.15_suppl.e16183","title":"A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Hepatocellular carcinoma; Oncology; Phases of clinical research; Combination therapy; Cancer; Gastroenterology; Clinical trial; Immunotherapy","score_opus":0.10721597398580457,"score_gpt":0.4048920208627741,"score_spread":0.2976760468769695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169630256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99753445,0.00066353625,0.000020897116,0.0006596203,0.00014966859,0.00074999325,0.0000026415878,0.0000039248544,0.00021523878],"genre_scores_gemma":[0.9987134,0.00017962232,0.0007979296,0.00014293354,0.00005868116,0.000023144217,0.0000091066995,0.000020333042,0.000054879507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968383,0.00059474166,0.0016763365,0.00022889591,0.0004651996,0.00019655682],"domain_scores_gemma":[0.9972103,0.00048146403,0.0011867492,0.00019143033,0.0007680784,0.00016194278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009315021,0.00015691713,0.0014903601,0.00014445736,0.00001774464,0.0000047924295,0.000091803675,0.00018876136,0.000118062046],"category_scores_gemma":[0.00033871472,0.00010375262,0.00013900305,0.00048896426,0.000077073724,0.00012764026,0.000023528379,0.0006291114,0.0000011233171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017988082,0.047389273,0.8509827,0.000034467805,0.00031029736,0.0026775422,0.0004577112,0.0000154205,0.000051699037,0.0000044622507,0.000017427468,0.08007089],"study_design_scores_gemma":[0.15552653,0.1075985,0.73427176,0.00031054343,0.00036461907,0.000022006947,0.000775435,0.0003220001,0.0003298211,0.000019107918,0.00036126218,0.000098393015],"about_ca_topic_score_codex":0.00014310425,"about_ca_topic_score_gemma":0.0010916122,"teacher_disagreement_score":0.13753845,"about_ca_system_score_codex":0.0002333028,"about_ca_system_score_gemma":0.0015347087,"threshold_uncertainty_score":0.42309093},"labels":[],"label_agreement":null},{"id":"W3169642351","doi":"10.1200/jco.2021.39.15_suppl.3089","title":"Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre; McGill University Health Centre; McGill University","funders":"Conquer Cancer Foundation","keywords":"Medicine; Internal medicine; Oncology; Cancer; Logistic regression; Odds ratio; Clinical trial","score_opus":0.3203318339859995,"score_gpt":0.6138911154320323,"score_spread":0.2935592814460328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169642351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91623724,0.076879136,0.00019524158,0.0049856724,0.00016982792,0.0013769323,0.000014487611,0.00000381839,0.00013767678],"genre_scores_gemma":[0.9814211,0.010206578,0.0060224105,0.0020755692,0.00006629415,0.00009066309,0.0000071706595,0.000012646848,0.000097537406],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9942117,0.0015992951,0.003380771,0.00024616817,0.00042111354,0.00014099167],"domain_scores_gemma":[0.9912087,0.003714393,0.0034167175,0.0002114526,0.001282749,0.00016600377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044259,0.0001451123,0.005136498,0.00014354404,0.00003565885,0.0000087926155,0.00006919964,0.00015029991,0.00023339588],"category_scores_gemma":[0.0047098864,0.00008207757,0.00094073766,0.0005275235,0.00013677409,0.00013881418,0.000029239021,0.0004622377,0.0000010242384],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001671645,0.012374212,0.47020668,0.05682472,0.43529394,0.00046700996,0.0012844633,0.0005240933,0.000054489967,0.0000215819,0.00014227538,0.021134883],"study_design_scores_gemma":[0.010433777,0.007307634,0.30993766,0.013760006,0.6578331,0.00004514631,0.00020089882,0.0002511803,0.000032235617,0.000049453454,0.00001802114,0.00013085149],"about_ca_topic_score_codex":0.00006486455,"about_ca_topic_score_gemma":0.00053875666,"teacher_disagreement_score":0.22253919,"about_ca_system_score_codex":0.00013090236,"about_ca_system_score_gemma":0.0031298865,"threshold_uncertainty_score":0.5638514},"labels":[],"label_agreement":null},{"id":"W3169652452","doi":"10.1200/jco.2021.39.15_suppl.4552","title":"The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Oncology; Proportional hazards model; Gastroenterology","score_opus":0.06997620596433854,"score_gpt":0.40645599253833703,"score_spread":0.33647978657399846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169652452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645793,0.0011884784,0.0000045743586,0.0011686374,0.00046519528,0.0005094822,0.00001326312,0.0000073829374,0.00018506768],"genre_scores_gemma":[0.99738866,0.0011776491,0.00051921495,0.00044819192,0.000194886,0.0000030211274,0.000012941078,0.000042514934,0.0002129152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926461,0.0014314901,0.0045209965,0.0003353194,0.0006525488,0.00041356817],"domain_scores_gemma":[0.9914808,0.0036272753,0.0033355863,0.0004843688,0.0007916382,0.00028032615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036953466,0.00034843266,0.0027028352,0.00017586973,0.00006841996,0.00001896891,0.000245649,0.00034430952,0.00013459621],"category_scores_gemma":[0.0012711261,0.0001425189,0.0013002785,0.0005374883,0.00057376473,0.000098112796,0.000035273602,0.0013689081,0.0000026402406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15875816,0.007365903,0.8037669,0.000021345952,0.0019977954,0.0007910894,0.00011096794,0.000018479761,0.0009203889,7.6392706e-7,0.00024549014,0.02600273],"study_design_scores_gemma":[0.05502865,0.12816052,0.81194955,0.0002420735,0.00030988143,0.000077434444,0.000228611,0.000009597082,0.0035070933,0.0000050675008,0.0003348456,0.0001466975],"about_ca_topic_score_codex":0.00019185488,"about_ca_topic_score_gemma":0.00015699319,"teacher_disagreement_score":0.12079462,"about_ca_system_score_codex":0.00027672775,"about_ca_system_score_gemma":0.0035312308,"threshold_uncertainty_score":0.62642515},"labels":[],"label_agreement":null},{"id":"W3169669455","doi":"10.1200/jco.2021.39.15_suppl.tps2071","title":"A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Karyopharm Therapeutics","keywords":"Medicine; Temozolomide; Oncology; Internal medicine; Radiation therapy; Phases of clinical research; Clinical trial","score_opus":0.04485776485031373,"score_gpt":0.43070233480645953,"score_spread":0.3858445699561458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169669455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998203,0.00038727507,0.00044494687,0.00023979708,0.00042962475,0.0002553462,0.000013100672,8.5059105e-7,0.000026094045],"genre_scores_gemma":[0.99741185,0.000459521,0.0017580088,0.000109544715,0.00022099985,0.000004884694,0.000008888327,0.0000093173,0.00001701528],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984077,0.00024183416,0.0009962621,0.00013181713,0.00014316762,0.00007917601],"domain_scores_gemma":[0.99770784,0.0002519204,0.00091631414,0.00012078892,0.00095165544,0.00005147966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005746382,0.00007429937,0.0005960597,0.000048970054,0.000012869543,0.0000028075162,0.00008362971,0.00016709807,0.000014475339],"category_scores_gemma":[0.00087948435,0.00004421372,0.00013301607,0.00010275203,0.00004681432,0.000004795266,0.00001926149,0.00016421282,6.0893555e-8],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24872877,0.012944209,0.011689122,0.00007048552,0.00046479862,0.00012390215,0.0011730841,0.00011171679,0.01539085,0.000021723621,0.0013647607,0.70791656],"study_design_scores_gemma":[0.10999288,0.7748522,0.014564726,0.00008062328,0.00015979951,0.000051773415,0.005969834,0.000035613517,0.025712717,0.00007916912,0.06837141,0.00012924048],"about_ca_topic_score_codex":0.0000035638516,"about_ca_topic_score_gemma":0.00068410306,"teacher_disagreement_score":0.761908,"about_ca_system_score_codex":0.000024611456,"about_ca_system_score_gemma":0.00077047426,"threshold_uncertainty_score":0.18029831},"labels":[],"label_agreement":null},{"id":"W3169699131","doi":"10.1200/jco.2021.39.15_suppl.e16538","title":"Assessment of the alignment between research funding allocation and consensus research priority areas in kidney cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Alberta; University of Calgary","funders":"","keywords":"Stakeholder; Prioritization; General partnership; Medicine; Translational research; Cancer; Kidney cancer; Business; Public relations; Finance; Political science; Process management; Internal medicine","score_opus":0.5359676965593122,"score_gpt":0.6544762826725995,"score_spread":0.1185085861132873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169699131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77409965,0.0003924416,0.000026870255,0.22360976,0.00049173256,0.00016614467,0.0000026615994,8.7139654e-7,0.0012098695],"genre_scores_gemma":[0.9960744,0.0016057186,0.0010331342,0.00043609692,0.0006578316,0.000002628302,0.0000017618512,0.000004861395,0.00018355959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993877,0.0029617692,0.0014889312,0.0001574638,0.0012896451,0.000225192],"domain_scores_gemma":[0.9898912,0.0071138013,0.00056098454,0.00018194325,0.001836005,0.00041612354],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033705696,0.000049802074,0.000631774,0.0001495352,0.00007991533,0.000007866519,0.00010850119,0.00045170583,0.00004316299],"category_scores_gemma":[0.012481725,0.00002987285,0.000110026864,0.00048671692,0.0014956844,0.000020826934,0.00016666202,0.0026410432,3.44728e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003120837,0.00089219416,0.87747145,0.00019415919,0.00017901293,0.00013166289,0.00023138983,0.000005607993,0.0047490844,0.0061555468,0.0021301596,0.10754765],"study_design_scores_gemma":[0.002596713,0.0014528753,0.97237253,0.00074087497,0.000053814027,0.00003433113,0.0003829421,0.00023650327,0.0003475909,0.0053760246,0.016378863,0.000026934693],"about_ca_topic_score_codex":0.00016506892,"about_ca_topic_score_gemma":0.00018925582,"teacher_disagreement_score":0.22317366,"about_ca_system_score_codex":0.0004264725,"about_ca_system_score_gemma":0.011108885,"threshold_uncertainty_score":0.9996599},"labels":[],"label_agreement":null},{"id":"W3169728670","doi":"10.1200/jco.2021.39.15_suppl.4518","title":"PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Cisplatin; Cystectomy; Cohort; Bladder cancer; Urology; Internal medicine; Oncology; Neoadjuvant therapy; Clinical endpoint; Nivolumab; Chemotherapy; Gastroenterology; Cancer; Randomized controlled trial; Immunotherapy","score_opus":0.13624497872604938,"score_gpt":0.48572026279155106,"score_spread":0.34947528406550166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169728670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445975,0.00038317675,0.00007520051,0.0014488751,0.0008473135,0.0012139255,0.000049892045,0.000010613991,0.0015112411],"genre_scores_gemma":[0.993947,0.0007333747,0.0028285824,0.0010049301,0.000807663,0.000046665784,0.000012670558,0.000045211378,0.0005738463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947664,0.0006065398,0.0028598027,0.00050209067,0.00084960845,0.00041554144],"domain_scores_gemma":[0.99385685,0.0012573826,0.0022741682,0.00045388928,0.0016648774,0.0004928571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011389952,0.00032314012,0.0027515683,0.00016606355,0.000044876804,0.000013562732,0.00018586018,0.0003944,0.0005831888],"category_scores_gemma":[0.0022826432,0.00018437744,0.00040088495,0.0004757952,0.0003389778,0.00020893542,0.00006253138,0.0010177847,0.000004491301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54055816,0.023560828,0.34982318,0.00013167794,0.0013787211,0.0020799038,0.00046043066,0.00004399797,0.00010326908,0.0000048170396,0.0008124626,0.08104257],"study_design_scores_gemma":[0.6487303,0.14754312,0.19474672,0.0009813138,0.0023246242,0.00029472433,0.00036144804,0.000044649852,0.0009085559,0.00007651544,0.0037227387,0.00026530545],"about_ca_topic_score_codex":0.00033724276,"about_ca_topic_score_gemma":0.005235875,"teacher_disagreement_score":0.15507644,"about_ca_system_score_codex":0.00045374234,"about_ca_system_score_gemma":0.013658491,"threshold_uncertainty_score":0.99193317},"labels":[],"label_agreement":null},{"id":"W3169739440","doi":"10.1200/jco.2021.39.15_suppl.12063","title":"Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Cisplatin; Interquartile range; Renal function; Internal medicine; Oncology; Cumulative dose; Kidney disease; Cohort; Urology; Chemotherapy","score_opus":0.11447322152867585,"score_gpt":0.39557839741050715,"score_spread":0.2811051758818313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169739440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870057,0.00033055403,0.009662951,0.0013765437,0.00042069503,0.00031258812,0.00022922676,0.0000026737496,0.0006590332],"genre_scores_gemma":[0.9923564,0.0003185585,0.0063475836,0.00048325968,0.00027239096,0.0000028925222,0.000015353546,0.0000089280375,0.00019462942],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977542,0.00025283828,0.0015709207,0.00011932165,0.00021681009,0.000085867076],"domain_scores_gemma":[0.99356127,0.0029955634,0.0023449976,0.00012952398,0.0008391729,0.00012945515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016912118,0.00008708904,0.0008779393,0.000070909824,0.000032338405,0.0000023656912,0.000049516137,0.00020240371,0.00024231093],"category_scores_gemma":[0.0043513807,0.000050117073,0.00020626858,0.00013407093,0.00020965285,0.00011939887,0.000020354186,0.00041390472,1.9632292e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066502534,0.0017158082,0.33581066,0.00057948,0.004613933,0.00002977559,0.002026768,0.0012336456,0.07142491,0.00059999136,0.0060162195,0.50944626],"study_design_scores_gemma":[0.014443686,0.020958984,0.93993086,0.0004329949,0.0018353331,0.000114095674,0.00053520524,0.014746689,0.003482935,0.0006921471,0.0027698854,0.0000572026],"about_ca_topic_score_codex":0.000023446177,"about_ca_topic_score_gemma":0.000028741495,"teacher_disagreement_score":0.6041202,"about_ca_system_score_codex":0.000051517716,"about_ca_system_score_gemma":0.002579689,"threshold_uncertainty_score":0.5209323},"labels":[],"label_agreement":null},{"id":"W3169799884","doi":"10.1200/jco.2021.39.15_suppl.12054","title":"High intensity interval training safety and efficacy in patients with advanced NSCLC receiving systemic treatment: Results of a prospective trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Quality of life (healthcare); Physical therapy; Prospective cohort study; Internal medicine","score_opus":0.06521087935418624,"score_gpt":0.39502299456038914,"score_spread":0.3298121152062029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169799884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659145,0.0002649745,0.000026986821,0.000886833,0.0012381839,0.00039605057,0.000010928246,0.000004841937,0.0005797295],"genre_scores_gemma":[0.9985249,0.00036415405,0.00056541275,0.0001561587,0.00030394207,0.0000029127104,0.000005968066,0.000011371143,0.00006515054],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967657,0.00044376688,0.0021596437,0.00023462164,0.00023863444,0.00015768355],"domain_scores_gemma":[0.9954406,0.001898509,0.0015024332,0.00015841411,0.0008263355,0.000173735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016057293,0.00012737991,0.0021176613,0.000091487964,0.00001890597,0.0000044819067,0.000054473974,0.00019756341,0.00000906893],"category_scores_gemma":[0.0050755395,0.00008413798,0.00022700829,0.00019499543,0.00012523831,0.00007921167,0.000034074743,0.00055753085,3.5510678e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5948086,0.0023916964,0.11567135,0.000041373827,0.00040002854,0.00035852598,0.003383789,0.000016005013,0.000024284178,0.000016393054,0.000013789056,0.28287417],"study_design_scores_gemma":[0.2575501,0.046483953,0.69172245,0.0013776724,0.0002740841,0.00014286832,0.001772518,0.000005211454,0.00006284684,0.000019581024,0.0005154936,0.0000732185],"about_ca_topic_score_codex":0.00007912128,"about_ca_topic_score_gemma":0.00081348687,"teacher_disagreement_score":0.5760511,"about_ca_system_score_codex":0.00037812215,"about_ca_system_score_gemma":0.0011591758,"threshold_uncertainty_score":0.60762614},"labels":[],"label_agreement":null},{"id":"W3169805422","doi":"10.1200/jco.2021.39.15_suppl.e21198","title":"Thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université de Montréal","funders":"","keywords":"Medicine; Thrombosis; Internal medicine; Retrospective cohort study; Cumulative incidence; Cohort; Venous thrombosis; Lung cancer; Incidence (geometry); Oncology; Cancer; Univariate analysis; Surgery; Multivariate analysis","score_opus":0.029385519575219326,"score_gpt":0.3763706140697316,"score_spread":0.34698509449451226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169805422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947346,0.0003370156,0.0000438953,0.00090559694,0.0010215648,0.0025117577,0.000004063013,0.0000072947437,0.00043419798],"genre_scores_gemma":[0.997099,0.000998619,0.0008431279,0.00037809828,0.00039251058,0.00009606258,0.000007911013,0.00003384222,0.00015084745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959772,0.0003159277,0.0025239491,0.00037270912,0.00044493383,0.00036523945],"domain_scores_gemma":[0.9960162,0.00057202677,0.0018133284,0.000247819,0.0010922102,0.0002584366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002176985,0.00021478524,0.0025833512,0.00018076165,0.000050494484,0.000007849102,0.00013659683,0.00022362129,0.000074112206],"category_scores_gemma":[0.0011775644,0.0001528668,0.0004442192,0.0003819476,0.00007040485,0.000081169565,0.00008906222,0.0007051008,0.0000030025637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019577097,0.027119163,0.9660325,0.000110622175,0.0012577821,0.00037686466,0.00032177617,0.00007098316,0.000029112072,0.0000025893648,0.0005284542,0.0021924467],"study_design_scores_gemma":[0.03416534,0.019571334,0.942283,0.0003711554,0.0022803226,0.000007479841,0.0005194478,0.0001931381,0.0002495283,0.000008951638,0.00020912646,0.00014118808],"about_ca_topic_score_codex":0.0003398766,"about_ca_topic_score_gemma":0.0005671875,"teacher_disagreement_score":0.032207634,"about_ca_system_score_codex":0.0008907435,"about_ca_system_score_gemma":0.0011749956,"threshold_uncertainty_score":0.62337273},"labels":[],"label_agreement":null},{"id":"W3169813977","doi":"10.1200/jco.2021.39.15_suppl.10035","title":"Discovery and validation of a cross-platform 21-gene prognostic signature in neuroblastoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Univariate; Nomogram; Medicine; Proportional hazards model; Neuroblastoma; Oncology; Internal medicine; Gene signature; Multivariate statistics; Survival analysis; Stage (stratigraphy); Gene; Machine learning; Computer science; Biology; Gene expression; Genetics","score_opus":0.10111006747452032,"score_gpt":0.4758837573232002,"score_spread":0.37477368984867987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169813977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733365,0.0003182927,0.000024159615,0.0014538172,0.000271967,0.00014550044,0.000005127393,0.0000027159772,0.0004447503],"genre_scores_gemma":[0.997978,0.0005038568,0.00074144953,0.00032650857,0.0001941459,0.0000019704453,0.0000048638876,0.000010134494,0.00023907138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977889,0.00021522159,0.0013186786,0.00016442251,0.00033290216,0.00017985846],"domain_scores_gemma":[0.99661136,0.0019653034,0.0006543681,0.00011930308,0.00042719423,0.0002224714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088421884,0.00009125219,0.0008387334,0.00012692984,0.000016495575,0.0000171423,0.00006361077,0.00021409862,0.000027960317],"category_scores_gemma":[0.006884737,0.000064536885,0.0001982604,0.0001998725,0.00018487657,0.00025919898,0.000067116875,0.0008005823,0.0000029278103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010695151,0.006265513,0.8594298,0.00019625988,0.0004207121,0.018349953,0.00008291433,0.00005017852,0.06371511,0.0001044817,0.00035041562,0.04033951],"study_design_scores_gemma":[0.010264649,0.012711452,0.9281938,0.00018087165,0.00013558574,0.0017595382,0.000025591666,0.00003563694,0.04546166,0.0005445566,0.0006320524,0.000054601027],"about_ca_topic_score_codex":0.000003520537,"about_ca_topic_score_gemma":0.000017693208,"teacher_disagreement_score":0.06876401,"about_ca_system_score_codex":0.000050534527,"about_ca_system_score_gemma":0.0013566022,"threshold_uncertainty_score":0.824217},"labels":[],"label_agreement":null},{"id":"W3169843089","doi":"10.1200/jco.2021.39.15_suppl.e24051","title":"Assessment of chemotherapy-induced cognitive impairment: A prospective study of the biochemical and metabolic effects of platinum/taxane-based chemotherapy in gynecologic cancer patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Oxidative stress; Oncology; Montreal Cognitive Assessment; Cancer; Docetaxel; Prospective cohort study; Breast cancer; Cognitive impairment; Disease","score_opus":0.03638826791673704,"score_gpt":0.4274259176513759,"score_spread":0.39103764973463884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169843089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958808,0.00072025263,0.000007915667,0.0009932708,0.00042880795,0.0017764803,0.000011933364,0.0000034862526,0.00017706418],"genre_scores_gemma":[0.99808687,0.0006681239,0.00019343817,0.0008508753,0.00010787721,0.00006151072,0.0000011971681,0.00001857621,0.000011507953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593145,0.00077678595,0.0022323716,0.00028720312,0.00055129145,0.00022088081],"domain_scores_gemma":[0.99103695,0.0041139936,0.0030473464,0.00015602465,0.0015316842,0.00011397284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012448026,0.00021709222,0.0023569237,0.0001525735,0.000029253344,0.0000024823114,0.0001175451,0.00027845034,0.00006450769],"category_scores_gemma":[0.0036769405,0.00013917622,0.00038783735,0.00051855994,0.00040041827,0.000045706885,0.00007325526,0.0008522909,1.1008204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047947764,0.023281412,0.9434401,0.0001931865,0.0020176214,0.000046734345,0.0010034097,0.0000048994466,0.009489916,0.0000056695408,0.00004416885,0.01567813],"study_design_scores_gemma":[0.057523355,0.028255155,0.84783345,0.0006433414,0.0009209673,0.0000082295055,0.0010828483,0.000027458884,0.06355572,0.00004415859,0.000014725987,0.000090573274],"about_ca_topic_score_codex":0.00006069026,"about_ca_topic_score_gemma":0.00009502242,"teacher_disagreement_score":0.0956066,"about_ca_system_score_codex":0.00025041687,"about_ca_system_score_gemma":0.0019465759,"threshold_uncertainty_score":0.56754416},"labels":[],"label_agreement":null},{"id":"W3169892706","doi":"10.1200/jco.2021.39.15_suppl.3508","title":"CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority; CancerCare Manitoba; Juravinski Cancer Centre; Health Sciences North; University of Manitoba; Providence Health Care; Ottawa Hospital; University of Ottawa; Queen's University; St. Paul's Hospital","funders":"","keywords":"Medicine; FOLFOX; Total mesorectal excision; Colorectal cancer; Clinical endpoint; Surgery; Oxaliplatin; Chemotherapy; Adenocarcinoma; Stage (stratigraphy); Oncology; Internal medicine; Cancer; Randomized controlled trial","score_opus":0.21231549132063168,"score_gpt":0.5117352955454573,"score_spread":0.2994198042248256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169892706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97293365,0.0025587524,0.0003834384,0.021603199,0.0012134475,0.0005832398,0.000012325633,0.00000910312,0.000702854],"genre_scores_gemma":[0.9793813,0.0073917992,0.0039554224,0.0059018326,0.0023096155,0.000062572806,0.000020862837,0.000024992187,0.00095160515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99665034,0.0004994271,0.0019303813,0.00028193166,0.0004238871,0.00021405492],"domain_scores_gemma":[0.9929716,0.00451022,0.0013933864,0.00022426262,0.0006308274,0.00026970095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028634095,0.0001549213,0.0017542075,0.00009273058,0.00007561312,0.000023945031,0.00011712572,0.00031049174,0.00020602625],"category_scores_gemma":[0.0023701314,0.00009033713,0.0009686063,0.00040115044,0.00014498037,0.00010576536,0.00004449861,0.0005921461,0.0000018319663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20742854,0.0022880435,0.11021318,0.000038685484,0.0045060716,0.0004977264,0.00023905035,0.000018666458,0.00045542838,0.000037336213,0.0028853428,0.6713919],"study_design_scores_gemma":[0.07560225,0.015249326,0.8192424,0.00006346462,0.0025650884,0.00010248492,0.000066634086,0.00020196706,0.00027485713,0.0004359517,0.08610003,0.00009550604],"about_ca_topic_score_codex":0.00004092113,"about_ca_topic_score_gemma":0.00008590683,"teacher_disagreement_score":0.70902926,"about_ca_system_score_codex":0.00032955583,"about_ca_system_score_gemma":0.0016755958,"threshold_uncertainty_score":0.36838415},"labels":[],"label_agreement":null},{"id":"W3169900915","doi":"10.1200/jco.2021.39.15_suppl.e18762","title":"Retrospective study on the management of patients admitted for febrile neutropenia and considered to be at low risk at the Centre Hospitalier Universitaire de Québec.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Febrile neutropenia; Neutropenia; Retrospective cohort study; Cancer; Internal medicine; Pediatrics; Intensive care medicine; Chemotherapy","score_opus":0.05018960475239871,"score_gpt":0.37904037672590374,"score_spread":0.32885077197350504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169900915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666751,0.000050172155,0.000006294742,0.031097952,0.0003853598,0.000755404,0.000029710802,0.0000029807038,0.0009969949],"genre_scores_gemma":[0.9946873,0.00015914478,0.0000912598,0.00271055,0.00011351883,0.0000070068922,0.00000157341,0.000010234141,0.0022194085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984303,0.000389276,0.00064590096,0.00017185886,0.00021487982,0.00014779561],"domain_scores_gemma":[0.99751353,0.000919422,0.0006570966,0.00021814248,0.0005180263,0.00017379857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000742532,0.000093206334,0.0005750279,0.000028710687,0.00018090189,0.000006308636,0.00009466161,0.00007710703,0.00025955366],"category_scores_gemma":[0.00060879526,0.000051610357,0.00023717615,0.00011826995,0.00013571387,0.00002799405,0.00016733562,0.00032497506,0.0000051560683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047974256,0.001851543,0.9509602,0.000014964533,0.001285233,0.00020237648,0.0009317234,0.00001534231,0.00004781791,0.0001533082,0.03660955,0.00313048],"study_design_scores_gemma":[0.0074216076,0.010683873,0.937557,0.000048294452,0.0010653489,0.000023129234,0.005089999,0.0000029902953,0.00012896958,0.000048216803,0.037880786,0.00004979694],"about_ca_topic_score_codex":0.00009023304,"about_ca_topic_score_gemma":0.0026415745,"teacher_disagreement_score":0.028387403,"about_ca_system_score_codex":0.0005719357,"about_ca_system_score_gemma":0.0004953007,"threshold_uncertainty_score":0.28419307},"labels":[],"label_agreement":null},{"id":"W3169905521","doi":"10.1200/jco.2021.39.15_suppl.11020","title":"Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Family medicine; Internal medicine; Hematology; Transplantation; Hematopoietic stem cell transplantation; Gerontology","score_opus":0.49928800903919496,"score_gpt":0.5416355033229853,"score_spread":0.04234749428379031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169905521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.933363,0.008605684,0.006829373,0.049755067,0.00058231084,0.0003272661,0.00001106637,0.000003716512,0.0005225095],"genre_scores_gemma":[0.9782666,0.0072578173,0.0033070866,0.010919001,0.00014324882,0.0000048964484,0.000007866356,0.0000069225143,0.00008656286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965627,0.00039017363,0.00204924,0.00012552865,0.0004930763,0.00037926895],"domain_scores_gemma":[0.9950415,0.0025665327,0.000735123,0.00006477843,0.0005799203,0.0010121339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0080283005,0.00007879191,0.001085101,0.00012051347,0.000039659986,0.000005111562,0.00006210974,0.00022062816,0.000015785705],"category_scores_gemma":[0.005165847,0.00005739219,0.0001445576,0.00013096177,0.0002115893,0.00008207796,0.000013725251,0.0005202114,6.150048e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01745743,0.014483947,0.43773332,0.054525554,0.0013336949,0.007573853,0.009280718,0.00008652468,0.021259287,0.058474172,0.021685049,0.35610646],"study_design_scores_gemma":[0.083822235,0.035891224,0.46553716,0.0047429637,0.00074773555,0.0068370155,0.005718314,0.00093006575,0.018906804,0.032953355,0.34326497,0.0006481541],"about_ca_topic_score_codex":0.000011003219,"about_ca_topic_score_gemma":0.000026212367,"teacher_disagreement_score":0.35545832,"about_ca_system_score_codex":0.0001575609,"about_ca_system_score_gemma":0.020823328,"threshold_uncertainty_score":0.9847277},"labels":[],"label_agreement":null},{"id":"W3169921727","doi":"10.1200/jco.2021.39.15_suppl.e16200","title":"Treatments and ongoing monitoring for patients with neuroendocrine tumors, monitored by medical oncologists: Scan comparative data between advanced economies (AE) and emerging and developing economies (EDE).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Internal medicine; Family medicine","score_opus":0.15671848732456412,"score_gpt":0.4933759783652361,"score_spread":0.336657491040672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169921727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909173,0.0015355544,0.000046674624,0.00664581,0.00030375185,0.00041423878,0.00005558636,0.000012049756,0.000069038564],"genre_scores_gemma":[0.9749368,0.0053789304,0.018684128,0.00023307315,0.0006071036,0.000015924901,0.000044145876,0.000026829104,0.00007307188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682224,0.00030823122,0.0016110794,0.00053788046,0.00030595934,0.000414638],"domain_scores_gemma":[0.9923507,0.0053695594,0.0010346369,0.00023663547,0.0003483706,0.0006600741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006487633,0.00024660458,0.0018511271,0.00011468655,0.0001546775,0.000047257465,0.00020879442,0.000038450424,0.0000072682683],"category_scores_gemma":[0.00465862,0.00018530154,0.00006604333,0.0000826972,0.0005293602,0.00056047883,0.00043430878,0.00066336564,4.0935168e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019817501,0.00032477968,0.8878192,0.00009189441,0.00045245647,0.0012098856,0.0000450887,0.0000025479408,0.000026614312,0.000010358166,0.00033857036,0.10769689],"study_design_scores_gemma":[0.025869558,0.014523939,0.92735964,0.0005473322,0.00039418964,0.0014291516,0.0010963663,0.00015767639,0.00090278866,0.00016228454,0.027294531,0.00026252263],"about_ca_topic_score_codex":0.00001595041,"about_ca_topic_score_gemma":0.000052514788,"teacher_disagreement_score":0.10743437,"about_ca_system_score_codex":0.00017563313,"about_ca_system_score_gemma":0.0011891602,"threshold_uncertainty_score":0.75563776},"labels":[],"label_agreement":null},{"id":"W3169946715","doi":"10.1200/jco.2021.39.15_suppl.11553","title":"ESMO Magnitude of Clinical Benefit Scale (MCBS): An evaluation of systemic treatment trials for soft tissue sarcomas (STS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Oncology; Overall survival; Randomized controlled trial","score_opus":0.5741635868700541,"score_gpt":0.6283817473008004,"score_spread":0.05421816043074634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169946715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932614,0.0017362303,0.00036225817,0.002221186,0.0007350012,0.0011721401,0.000050067374,0.0000062310646,0.0004555094],"genre_scores_gemma":[0.9727081,0.0007592637,0.024732918,0.00010796309,0.00128937,0.00003572249,0.00003507545,0.000022430739,0.00030916525],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98759973,0.0033572223,0.007302083,0.0003359223,0.0010824673,0.0003225773],"domain_scores_gemma":[0.9769772,0.012127829,0.004616693,0.00043610932,0.0050876774,0.00075444096],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028766358,0.00020122953,0.0043183584,0.0001504771,0.00003582717,0.0000081500775,0.0001730825,0.0003050745,0.00029552035],"category_scores_gemma":[0.038121622,0.00013166938,0.0014489004,0.00014427457,0.00025716398,0.00009101288,0.00004767511,0.00046956286,0.000009224615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018265953,0.017142726,0.22123557,0.00022692507,0.0017143163,0.00077144953,0.00008475965,0.000104975355,0.0040887017,0.00011529629,0.0004109078,0.7358384],"study_design_scores_gemma":[0.102506556,0.2764956,0.579074,0.0015641369,0.0104900515,0.005385285,0.0009048139,0.0013121181,0.014371741,0.0027657012,0.004918282,0.0002116927],"about_ca_topic_score_codex":0.000056040102,"about_ca_topic_score_gemma":0.00015451417,"teacher_disagreement_score":0.7356267,"about_ca_system_score_codex":0.0003246118,"about_ca_system_score_gemma":0.0064606555,"threshold_uncertainty_score":0.9991718},"labels":[],"label_agreement":null},{"id":"W3169955705","doi":"10.1200/jco.2021.39.15_suppl.1051","title":"Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Quality of life (healthcare); Cancer; Physical therapy; Correlation; Placebo; Gerontology; Internal medicine","score_opus":0.15065157392538775,"score_gpt":0.48617013079030325,"score_spread":0.3355185568649155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169955705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989005,0.0021728158,0.00089697423,0.0067898966,0.00026455405,0.0007205371,0.00013025822,0.0000052940686,0.0000146665925],"genre_scores_gemma":[0.9954726,0.0017428492,0.0011985475,0.00005187679,0.0014193028,0.0000228928,0.000012176852,0.000030488984,0.000049257484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960437,0.001297414,0.0016818886,0.00029452238,0.00048522282,0.00019725879],"domain_scores_gemma":[0.9922544,0.0026608794,0.0022428911,0.0002514689,0.0023893854,0.00020097331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030278342,0.00014776684,0.0013584243,0.000056869576,0.00008371376,0.000006398051,0.000087346176,0.00014428927,0.000039588747],"category_scores_gemma":[0.0024393518,0.000092519964,0.00006957847,0.00035756544,0.0008217081,0.00014371038,0.000050574166,0.0003564595,1.11942185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12730537,0.0013480175,0.6580009,0.000082889244,0.0009084893,0.000009228469,0.0011489488,0.00019168241,0.0010522146,0.000040917963,0.00001115636,0.20990023],"study_design_scores_gemma":[0.04584252,0.011465308,0.939661,0.00042634024,0.00031966768,0.000018242723,0.000435725,0.0000037771306,0.0005539743,0.0004912371,0.0007053991,0.000076795266],"about_ca_topic_score_codex":0.0002920289,"about_ca_topic_score_gemma":0.00048790482,"teacher_disagreement_score":0.28166014,"about_ca_system_score_codex":0.0003906738,"about_ca_system_score_gemma":0.0018940669,"threshold_uncertainty_score":0.37728545},"labels":[],"label_agreement":null},{"id":"W3169970067","doi":"10.1200/jco.2021.39.15_suppl.2036","title":"Palliative care service utilization and advance care planning issues for adult glioblastoma patients: A systematic review.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Palliative care; Advance care planning; Cochrane Library; Family medicine; MEDLINE; Systematic review; Documentation; End-of-life care; Quality of life (healthcare); Inclusion (mineral); Gerontology; Internal medicine; Nursing; Meta-analysis","score_opus":0.285379886324309,"score_gpt":0.5819613464859245,"score_spread":0.29658146016161546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169970067","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38288876,0.6084686,0.0009076989,0.004886017,0.0009402243,0.0012442173,0.00005623637,0.000014529629,0.0005937314],"genre_scores_gemma":[0.6799382,0.24627544,0.041044973,0.030664515,0.0015585837,0.00008545563,0.00016290597,0.00007601297,0.00019391492],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969856,0.00036382754,0.0020402926,0.00017915518,0.00029138188,0.00013973817],"domain_scores_gemma":[0.9865119,0.002186431,0.0019805117,0.00015171732,0.009002384,0.00016705814],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00049082946,0.00013648423,0.0020541542,0.000056594505,0.000034779925,0.000005047598,0.000087411594,0.00020006929,0.000009713995],"category_scores_gemma":[0.023935772,0.00009907204,0.00027606369,0.00018383065,0.000054755037,0.00010551014,0.00003810989,0.00029033056,0.0000016865034],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045697223,0.0009830933,0.30683625,0.6313799,0.0014259052,0.00044388842,0.026602147,0.000029380917,0.00004313792,0.0002313095,0.0045283837,0.022926873],"study_design_scores_gemma":[0.020566909,0.027646502,0.040548187,0.730661,0.0063102227,0.00008203325,0.08485462,0.00023928564,0.0014983355,0.00022401253,0.08693349,0.00043542395],"about_ca_topic_score_codex":0.0000037380794,"about_ca_topic_score_gemma":0.00004745606,"teacher_disagreement_score":0.36219314,"about_ca_system_score_codex":0.00010960772,"about_ca_system_score_gemma":0.0005007047,"threshold_uncertainty_score":0.984286},"labels":[],"label_agreement":null},{"id":"W3169994009","doi":"10.1200/jco.2021.39.15_suppl.9574","title":"Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Discontinuation; Internal medicine; Randomization; Quality of life (healthcare); Population; Ipilimumab; Adverse effect; Oncology; Randomized controlled trial; Cancer; Immunotherapy; Nursing","score_opus":0.15403626871309478,"score_gpt":0.4370518829146876,"score_spread":0.2830156142015928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169994009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685323,0.00054694497,0.00003846593,0.0018718836,0.00013574596,0.00026974003,0.00017341664,0.0000032691655,0.000107279506],"genre_scores_gemma":[0.99572176,0.0023035987,0.00117242,0.00016499283,0.000031273976,0.0000015494721,0.00011237199,0.000012578084,0.0004794462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99307096,0.0016209326,0.0042608413,0.00025748846,0.0005917103,0.00019805392],"domain_scores_gemma":[0.98993653,0.0018926319,0.006722788,0.00039213125,0.00089364377,0.00016226762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060600243,0.00014578777,0.0030595497,0.00025244485,0.000028041439,0.0000036937072,0.00012678574,0.00029930883,0.00018889153],"category_scores_gemma":[0.0028568974,0.00008901338,0.0002912065,0.00095384923,0.00016505212,0.000108086584,0.000047675236,0.00035670502,1.926832e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15438768,0.002688278,0.81212896,0.00010977051,0.010309739,0.00005185513,0.00036656935,0.00002032335,0.00012076112,0.0000055227492,0.00015382878,0.019656716],"study_design_scores_gemma":[0.06468013,0.023718257,0.9081321,0.00020312355,0.0017266121,0.0000055801065,0.00044433266,0.00013450216,0.000067997506,0.0000029991058,0.0008083631,0.00007599725],"about_ca_topic_score_codex":0.0020764181,"about_ca_topic_score_gemma":0.020213768,"teacher_disagreement_score":0.09600315,"about_ca_system_score_codex":0.0006028071,"about_ca_system_score_gemma":0.0035139427,"threshold_uncertainty_score":0.99766475},"labels":[],"label_agreement":null},{"id":"W3170014144","doi":"10.1200/jco.2021.39.15_suppl.e18819","title":"Prevalence-adjusted trends in U.S. healthcare spending on colorectal cancer, 1996-2016.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus; Kingston General Hospital; University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Health care; Per capita; Confidence interval; Cancer; Medical prescription; Ambulatory; Demography; Environmental health; Internal medicine; Population; Nursing","score_opus":0.16676553495835067,"score_gpt":0.48388303473999783,"score_spread":0.31711749978164716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170014144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745025,0.0026471685,0.000015634654,0.0155975595,0.0029720769,0.00008634212,0.000006086233,0.00001703788,0.004155587],"genre_scores_gemma":[0.99240005,0.0026848156,0.0006630331,0.0015466141,0.0017812182,0.0000069312423,0.0000027156323,0.000016100448,0.0008985042],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965752,0.00063406304,0.0018092894,0.0002819177,0.0004136504,0.00028592884],"domain_scores_gemma":[0.99698716,0.0011753283,0.0010319252,0.00011917411,0.00030802283,0.00037836464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020840198,0.00013928651,0.0012290884,0.0003313752,0.000042796466,0.000009091428,0.00010288991,0.0004394974,0.0003980476],"category_scores_gemma":[0.002259025,0.00011160239,0.00044882408,0.000577508,0.00008889907,0.00008236351,0.000041830925,0.0016834319,0.000009348559],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020450395,0.000708849,0.35890606,0.00006433527,0.00010181664,0.0015813385,0.00008665911,0.00004728105,0.0002986182,0.000040895375,0.001607875,0.61610585],"study_design_scores_gemma":[0.0059522022,0.029425308,0.9525586,0.0005736774,0.00014461433,0.0008876633,0.00010892765,0.00021522828,0.0008488052,0.000079011785,0.009102415,0.00010358205],"about_ca_topic_score_codex":0.00040121563,"about_ca_topic_score_gemma":0.0021160676,"teacher_disagreement_score":0.61600226,"about_ca_system_score_codex":0.00063943863,"about_ca_system_score_gemma":0.0018022183,"threshold_uncertainty_score":0.73137677},"labels":[],"label_agreement":null},{"id":"W3170024542","doi":"10.1200/jco.2021.39.15_suppl.8503","title":"Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Chemotherapy; Neoadjuvant therapy; Adverse effect; Randomized controlled trial; Surgery; Cancer; Immunotherapy; Breast cancer","score_opus":0.07011551329818771,"score_gpt":0.44438780891467977,"score_spread":0.37427229561649206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170024542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97226727,0.0020715601,0.00003505795,0.020825522,0.0015234082,0.002013813,0.000118822914,0.000016608998,0.0011279238],"genre_scores_gemma":[0.98013866,0.006662161,0.0029491766,0.004618961,0.0025900481,0.00034789284,0.00012893755,0.00009917331,0.0024649724],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957412,0.00028703644,0.0022824318,0.0005594956,0.0005891125,0.00054075103],"domain_scores_gemma":[0.9917996,0.004379286,0.001903043,0.00054642174,0.00086454727,0.0005071065],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010478452,0.00042945126,0.0029687914,0.000053559477,0.00014301676,0.00004930863,0.00024921057,0.00042599434,0.0009607522],"category_scores_gemma":[0.00044367398,0.00021965253,0.001072481,0.00017855446,0.00014410826,0.0001093447,0.00005830775,0.0006114607,0.000011271118],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35998586,0.03446708,0.50109434,0.000080100435,0.005545188,0.0015122127,0.0005513872,0.000024695117,0.00005867642,0.00000935937,0.01801268,0.0786584],"study_design_scores_gemma":[0.73165643,0.05015557,0.08337531,0.00052016275,0.0032111325,0.000059524245,0.00012063742,0.00013865111,0.004520527,0.00004270375,0.12588906,0.00031029523],"about_ca_topic_score_codex":0.0007417779,"about_ca_topic_score_gemma":0.0004538529,"teacher_disagreement_score":0.41771904,"about_ca_system_score_codex":0.0012898307,"about_ca_system_score_gemma":0.004312733,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W3170076218","doi":"10.1200/jco.2021.39.15_suppl.e17542","title":"Stem-like markers in the circulating tumor cells assessment in ovarian cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Russian Foundation for Basic Research","keywords":"Circulating tumor cell; Medicine; CD44; Ovarian cancer; Epithelial cell adhesion molecule; Internal medicine; Oncology; Stem cell; Cancer stem cell; Progression-free survival; Stage (stratigraphy); Cancer; Pathology; Biology; Overall survival; Cell; Metastasis","score_opus":0.14685132375934673,"score_gpt":0.4917609700602732,"score_spread":0.34490964630092646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170076218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643977,0.0012653603,0.000092545684,0.021892235,0.0027463706,0.00020193555,0.0000043180385,0.0000020751218,0.009397411],"genre_scores_gemma":[0.9851201,0.0012497111,0.0034364243,0.009206512,0.0007681952,0.0000071550166,0.000001020122,0.000010811913,0.000200033],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961976,0.0009811049,0.0020469911,0.0001725866,0.00037026068,0.0002314982],"domain_scores_gemma":[0.9965858,0.0019307501,0.00095444993,0.00018443532,0.00018452006,0.00016004177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006416068,0.00009679205,0.0010882525,0.00009066549,0.000020815563,0.000012232494,0.00013750316,0.00013790293,0.00037730986],"category_scores_gemma":[0.00038547302,0.00006275145,0.00034274705,0.00031610785,0.00006797336,0.000054267526,0.00004064952,0.0014557478,0.0000026343628],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022206302,0.0036323713,0.38234317,0.0001806137,0.00043325668,0.027460584,0.0006818858,0.0006152538,0.0061925054,0.00022892447,0.009495874,0.5665149],"study_design_scores_gemma":[0.011790305,0.0023001777,0.8064982,0.00040224227,0.0003344684,0.0009514283,0.0031052323,0.0002380321,0.00026577138,0.0001339098,0.17386049,0.00011971419],"about_ca_topic_score_codex":0.0002451685,"about_ca_topic_score_gemma":0.0012475346,"teacher_disagreement_score":0.5663952,"about_ca_system_score_codex":0.00036865208,"about_ca_system_score_gemma":0.004730209,"threshold_uncertainty_score":0.8391188},"labels":[],"label_agreement":null},{"id":"W3170092667","doi":"10.1200/jco.2021.39.15_suppl.8547","title":"Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Pemetrexed; Stage (stratigraphy); Cohort; Lung cancer; Chemotherapy; Cancer; Oncology; Surgery; Cisplatin; Nivolumab","score_opus":0.05682704528010051,"score_gpt":0.4074493283473341,"score_spread":0.3506222830672336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170092667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929387,0.00015489862,0.00010226748,0.003169177,0.000100853234,0.0003915206,0.000020650246,0.000011087909,0.0031108188],"genre_scores_gemma":[0.99275273,0.0005652966,0.004000423,0.0013650572,0.00012611329,0.000012149855,0.000025955687,0.00003095305,0.0011213192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976727,0.00024202986,0.0010368422,0.00029415885,0.00051279645,0.00024152025],"domain_scores_gemma":[0.99587345,0.0013320092,0.0011522927,0.00019923714,0.0010597052,0.00038329032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061463896,0.00021240064,0.0016724368,0.00007144381,0.000067533285,0.000023177232,0.00005654433,0.00018761333,0.00018059315],"category_scores_gemma":[0.0006026989,0.00009773696,0.00011262369,0.00022153974,0.0001888211,0.00016741725,0.00002262396,0.00049388193,0.0000034778761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040417265,0.0026676378,0.92984885,0.000042570104,0.0015153715,0.0014165934,0.00009184203,0.000014117112,9.673244e-7,0.000029834775,0.0001528508,0.023802072],"study_design_scores_gemma":[0.05702588,0.054965872,0.8801638,0.0003594553,0.0013308622,0.00023446363,0.00019420551,0.000016629505,0.0000679961,0.0000050415597,0.0055073923,0.00012839111],"about_ca_topic_score_codex":0.00008644447,"about_ca_topic_score_gemma":0.0011452683,"teacher_disagreement_score":0.052298237,"about_ca_system_score_codex":0.0004001963,"about_ca_system_score_gemma":0.0026658683,"threshold_uncertainty_score":0.4729136},"labels":[],"label_agreement":null},{"id":"W3170115330","doi":"10.1200/jco.2021.39.15_suppl.6053","title":"Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Clinical endpoint; Adjuvant; Immunotherapy; Head and neck squamous-cell carcinoma; Neoadjuvant therapy; Surgery; Gastroenterology; Head and neck cancer; Cancer; Clinical trial","score_opus":0.05406926666760677,"score_gpt":0.3827591285447156,"score_spread":0.32868986187710886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170115330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867896,0.008736923,9.751709e-7,0.0028487206,0.00034893877,0.00014785757,0.0000039727192,0.0000013165651,0.0011217097],"genre_scores_gemma":[0.99753284,0.0013356963,0.00038193946,0.00047957405,0.00012539125,0.000001313222,5.105276e-7,0.000008769105,0.00013396773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807394,0.0002697362,0.0010584323,0.00018261526,0.0002338778,0.00018143142],"domain_scores_gemma":[0.9979576,0.0007691169,0.00059309683,0.000138602,0.000355465,0.00018613652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007387072,0.00010628923,0.0012412403,0.0000539978,0.000044739947,0.0000052297214,0.000052576903,0.00014682747,0.000012255412],"category_scores_gemma":[0.0011741393,0.000059965747,0.00007858235,0.00013163833,0.00027842037,0.000058102105,0.0001248823,0.0006428754,1.7200477e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003857213,0.00093997904,0.9430754,0.00009397921,0.00003133738,0.00014846546,0.00032964387,4.6872242e-7,0.000034342203,0.000006905333,0.0010599837,0.05042228],"study_design_scores_gemma":[0.022208497,0.018973412,0.9524417,0.0002985834,0.00013153191,0.00012081981,0.0002326539,0.000020429694,0.000087096465,0.000043512817,0.005381281,0.000060506547],"about_ca_topic_score_codex":0.00006707306,"about_ca_topic_score_gemma":0.0007916939,"teacher_disagreement_score":0.050361775,"about_ca_system_score_codex":0.000054239004,"about_ca_system_score_gemma":0.00083247176,"threshold_uncertainty_score":0.27930096},"labels":[],"label_agreement":null},{"id":"W3170117047","doi":"10.1200/jco.2021.39.15_suppl.e13020","title":"First-line treatment with a cyclin-dependent kinase 4/6 inhibitor combined with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: Population-based outcomes for patients treated in Alberta, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Metastatic breast cancer; Aromatase inhibitor; Oncology; Population; Breast cancer; Progression-free survival; Proportional hazards model; Cancer; Hazard ratio; Gastroenterology; Aromatase; Chemotherapy; Confidence interval","score_opus":0.03958041499443192,"score_gpt":0.37131618201223004,"score_spread":0.3317357670177981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170117047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371255,0.00008882043,0.00028921213,0.01104434,0.00040575396,0.0019966313,0.0024428815,0.000015184524,0.0000046279956],"genre_scores_gemma":[0.98482156,0.0000490344,0.011853478,0.0011913106,0.0004751326,0.0003767333,0.0010278634,0.00009127906,0.0001136107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952252,0.00049773045,0.0025841554,0.0005866701,0.00057077,0.00053547864],"domain_scores_gemma":[0.9901471,0.0047523635,0.0023524342,0.00029142402,0.0017695993,0.0006870889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004239327,0.0005266336,0.0027588569,0.00019577473,0.00017036845,0.000021174312,0.00014058416,0.00022529141,0.00009281761],"category_scores_gemma":[0.0010652515,0.00034280776,0.00034973823,0.0002863586,0.00016253171,0.00031951044,0.000020545316,0.00045828192,6.1245976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11803287,0.011742741,0.84139,0.00013771828,0.00198719,0.00034910737,0.00023122679,0.0005090244,0.00019439215,0.000023201412,0.00020809672,0.025194405],"study_design_scores_gemma":[0.11003605,0.07056803,0.81376016,0.00046124728,0.0010250199,0.000068873305,0.00020909586,0.00022373753,0.002332834,0.000094949806,0.0007710747,0.00044889483],"about_ca_topic_score_codex":0.098157056,"about_ca_topic_score_gemma":0.66613585,"teacher_disagreement_score":0.5679788,"about_ca_system_score_codex":0.002674544,"about_ca_system_score_gemma":0.0044309595,"threshold_uncertainty_score":0.99990237},"labels":[],"label_agreement":null},{"id":"W3170130315","doi":"10.1200/jco.2021.39.15_suppl.10009","title":"Oral selpercatinib in pediatric patients (pts) with advanced <i>RET</i>-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Medullary thyroid cancer; Vandetanib; Internal medicine; Cancer; Oncology; Thyroid cancer; Papillary thyroid cancer; Dosing; Phases of clinical research; Chemotherapy; Tyrosine kinase","score_opus":0.09927461659817029,"score_gpt":0.44181607033859704,"score_spread":0.34254145374042677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170130315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856951,0.00079428515,0.000005617733,0.010841105,0.0012636355,0.00077546004,0.00008168489,0.00001223855,0.00053083093],"genre_scores_gemma":[0.9875754,0.0014736064,0.0039023135,0.004533376,0.0022270833,0.000038316528,0.00013782081,0.00003524779,0.00007681476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940246,0.0010631847,0.003513961,0.0004388602,0.0005975598,0.0003618637],"domain_scores_gemma":[0.9871145,0.008999235,0.0023698714,0.00047877742,0.0006102819,0.00042734155],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017572449,0.00026331854,0.0020053124,0.0001107411,0.000062071784,0.0000235718,0.0002498494,0.00030446934,0.00011631931],"category_scores_gemma":[0.0087772375,0.00013398001,0.0004199294,0.00045469124,0.0001336715,0.00020569186,0.00011510206,0.0011389356,0.000014000857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64606863,0.044694964,0.10888981,0.000034271823,0.00048455,0.008537546,0.00047032893,0.000038385097,0.000054145316,0.0000032133853,0.01654906,0.17417508],"study_design_scores_gemma":[0.4483165,0.10160013,0.43655637,0.0003245559,0.0010514319,0.00015194602,0.0002090643,0.000034344182,0.00017057182,0.00005023076,0.011372324,0.00016251819],"about_ca_topic_score_codex":0.000016763903,"about_ca_topic_score_gemma":0.000091978654,"teacher_disagreement_score":0.32766655,"about_ca_system_score_codex":0.00022826865,"about_ca_system_score_gemma":0.003609961,"threshold_uncertainty_score":0.9995723},"labels":[],"label_agreement":null},{"id":"W3170197695","doi":"10.1200/jco.2021.39.15_suppl.6524","title":"Association of electronic-health record (EHR)-derived race with BRCA testing in patients (pts) with breast cancer (BC) with similar genetic ancestry (GA) in a clinicogenomic database (CGDB).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cohort; Demography; Breast cancer; Population; Cancer; Health equity; Race (biology); Oncology; Electronic health record; Family medicine; Internal medicine; Gerontology; Public health; Health care; Environmental health; Pathology","score_opus":0.04995331594883752,"score_gpt":0.3931200680316245,"score_spread":0.343166752082787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170197695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593014,0.00072712806,0.00031516742,0.0024460966,0.00021551842,0.00023453787,0.000050297476,0.0000025961876,0.00007849445],"genre_scores_gemma":[0.97724324,0.0018652991,0.019425677,0.0009889149,0.00034232088,0.000018646877,0.000031098112,0.000035689674,0.00004909636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962122,0.00073853834,0.0018449818,0.0004351548,0.0003380526,0.00043109112],"domain_scores_gemma":[0.9948308,0.0005177037,0.0031881821,0.00029661704,0.0010143034,0.00015238974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018295721,0.00019454974,0.00096540735,0.00009367293,0.000036944406,0.000010590001,0.0002328361,0.0003135468,0.000031964944],"category_scores_gemma":[0.0010249076,0.00015252567,0.000090244714,0.00041872886,0.00013230187,0.0000233194,0.00007157871,0.0008358095,8.903013e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004327646,0.001041123,0.9481667,0.00004236804,0.00028311918,0.00005642705,0.00005013714,0.0044878973,0.0014655872,9.531077e-7,0.00040312103,0.039674867],"study_design_scores_gemma":[0.011726691,0.010357471,0.9724562,0.00032240985,0.00012461493,0.00010048419,0.00015222431,0.00015962285,0.0009529046,0.000018740133,0.0034139208,0.00021469404],"about_ca_topic_score_codex":0.00027316168,"about_ca_topic_score_gemma":0.020154478,"teacher_disagreement_score":0.039460175,"about_ca_system_score_codex":0.00086172076,"about_ca_system_score_gemma":0.012649494,"threshold_uncertainty_score":0.9977251},"labels":[],"label_agreement":null},{"id":"W3170198976","doi":"10.1200/jco.2021.39.15_suppl.3005","title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis","keywords":"Medicine; Tolerability; Pharmacodynamics; Adverse effect; Pharmacokinetics; Internal medicine; Regimen; Oncology; Gastroenterology; Pharmacology","score_opus":0.05399099045793521,"score_gpt":0.4246390614126213,"score_spread":0.3706480709546861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170198976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706906,0.0016280587,0.00004870169,0.00033359835,0.00043801268,0.00022913782,0.000069797374,0.0000024961216,0.00018111918],"genre_scores_gemma":[0.9947042,0.0002686314,0.0039212536,0.0002715344,0.00074453704,0.000007997905,0.000049165516,0.000017857617,0.000014812813],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958072,0.0006318556,0.0026655628,0.0003756588,0.0002907219,0.00022903642],"domain_scores_gemma":[0.99627423,0.00068991526,0.002054373,0.00033793313,0.00047423205,0.00016932849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014580505,0.00016462123,0.001107418,0.000071381335,0.00002494476,0.000008925675,0.00027702143,0.00028924915,0.000014877011],"category_scores_gemma":[0.008044064,0.0001311983,0.00017685538,0.00018058886,0.00013565097,0.000016313546,0.00021882865,0.0005878916,0.0000015897348],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35448205,0.041007385,0.1276294,0.00013989682,0.0019709014,0.019929912,0.0028995732,0.0026392553,0.11087967,0.00010972605,0.0040943543,0.33421788],"study_design_scores_gemma":[0.118442565,0.10777575,0.25832614,0.0013515461,0.00025032222,0.00036335105,0.0036458978,0.000059081467,0.5021689,0.0003691905,0.006636215,0.0006110692],"about_ca_topic_score_codex":0.00009476574,"about_ca_topic_score_gemma":0.0013478152,"teacher_disagreement_score":0.3912892,"about_ca_system_score_codex":0.00003514728,"about_ca_system_score_gemma":0.001704664,"threshold_uncertainty_score":0.96300775},"labels":[],"label_agreement":null},{"id":"W3170320287","doi":"10.1200/jco.2021.39.15_suppl.e18564","title":"Cancer care during COVID-19: Data from 157 patient organizations.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Medicine; Cancer; Pandemic; Health care; Telemedicine; Family medicine; Nursing; Coronavirus disease 2019 (COVID-19); Economic growth; Pathology","score_opus":0.19277825689450642,"score_gpt":0.43052431460584295,"score_spread":0.23774605771133653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170320287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9445897,0.025158284,0.001654333,0.012813883,0.005706866,0.00009319322,0.0012031839,0.00001288364,0.008767673],"genre_scores_gemma":[0.97768587,0.008915021,0.0022388834,0.008577834,0.0021950542,0.0000023827636,0.000065251625,0.000027095786,0.00029263773],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645823,0.00008031442,0.0028035464,0.00038087342,0.00005200656,0.00022500746],"domain_scores_gemma":[0.99520016,0.0006185768,0.0027685636,0.00052202056,0.0003977404,0.00049293967],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008164877,0.0001226496,0.0012081184,0.00009044948,0.00011022529,0.000042678348,0.00052728836,0.00031868555,0.003919479],"category_scores_gemma":[0.012519932,0.00012780668,0.00018560207,0.00020414944,0.00010287652,0.00044824445,0.00028523643,0.00052922487,0.00016993287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004974746,0.0007819651,0.9020594,0.00005485185,0.00068111694,0.0005751442,0.0017597617,0.0012700469,0.000021619488,0.0066935606,0.048146036,0.03745903],"study_design_scores_gemma":[0.0026861401,0.0004167246,0.17965953,0.00002267293,0.000052141102,0.000028403456,0.0005456125,0.00010968266,0.00005350897,0.0058845812,0.8103468,0.00019421412],"about_ca_topic_score_codex":0.00060590566,"about_ca_topic_score_gemma":0.0010214776,"teacher_disagreement_score":0.7622008,"about_ca_system_score_codex":0.0005480545,"about_ca_system_score_gemma":0.0032236571,"threshold_uncertainty_score":0.9969911},"labels":[],"label_agreement":null},{"id":"W3170341220","doi":"10.1200/jco.2021.39.15_suppl.9000","title":"First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Pemetrexed; Internal medicine; Nivolumab; Ipilimumab; Clinical endpoint; Lung cancer; Oncology; Chemotherapy; Cancer; Randomized controlled trial; Cisplatin; Immunotherapy","score_opus":0.030966787785416724,"score_gpt":0.37581410776589413,"score_spread":0.3448473199804774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170341220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085385,0.0028421264,0.00014324917,0.0026479936,0.0019361419,0.000566131,0.00006258453,0.000018738803,0.00092917023],"genre_scores_gemma":[0.9818263,0.008032996,0.0071177385,0.0018138551,0.00087545556,0.000016900114,0.000051749925,0.00008855234,0.00017644365],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99478644,0.00025366084,0.003116811,0.00058085856,0.0006897278,0.0005725014],"domain_scores_gemma":[0.9944597,0.0010341932,0.0027343815,0.0005700098,0.0008373988,0.00036430522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011620256,0.00043540105,0.0028190613,0.00018636849,0.00006441832,0.000018726972,0.00040796597,0.0004769419,0.0007736182],"category_scores_gemma":[0.0003149536,0.00034861758,0.0006812285,0.0004842266,0.00034771377,0.00020578213,0.00011321509,0.0012654867,0.000008242767],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5469348,0.0069457223,0.29632312,0.0003918517,0.0034584505,0.00082046306,0.0011138387,0.0025081546,0.0063308417,0.000008108922,0.0013397457,0.13382494],"study_design_scores_gemma":[0.4518663,0.008846334,0.5124533,0.0016231518,0.0009658107,0.00002879441,0.00051880995,0.0016087171,0.015586385,0.000049720526,0.005854095,0.00059855083],"about_ca_topic_score_codex":0.000782397,"about_ca_topic_score_gemma":0.0026631695,"teacher_disagreement_score":0.21613023,"about_ca_system_score_codex":0.0012199591,"about_ca_system_score_gemma":0.0038148863,"threshold_uncertainty_score":0.9998966},"labels":[],"label_agreement":null},{"id":"W3170350390","doi":"10.1200/jco.2021.39.15_suppl.1580","title":"Patterns of telehealth utilization during the COVID-19 pandemic and preferences for post-pandemic telehealth use: A national survey of oncology clinicians.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Conquer Cancer Foundation","keywords":"Telehealth; Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Telemedicine; Descriptive statistics; Family medicine; Health care; Nursing; Medical emergency; Disease; Internal medicine; Infectious disease (medical specialty)","score_opus":0.46577549674971447,"score_gpt":0.49050714282708496,"score_spread":0.024731646077370495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170350390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039793,0.002231791,0.0022977847,0.0027126244,0.0010343592,0.00024728652,0.0007564457,0.0000043652512,0.00031743065],"genre_scores_gemma":[0.9780618,0.017028717,0.0005540876,0.0038617817,0.00035683496,0.0000067289093,0.0000207212,0.000013729378,0.00009560381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944464,0.00046330135,0.004463582,0.0002842043,0.00008414882,0.0002583795],"domain_scores_gemma":[0.98211205,0.009781143,0.006632806,0.00016362937,0.0010473544,0.00026301984],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011686,0.0001308281,0.0017202524,0.00016989559,0.00008927524,0.000015371279,0.0002625337,0.000477956,0.000097922646],"category_scores_gemma":[0.030482981,0.00010957389,0.00026900784,0.00015200092,0.00023625509,0.00026639525,0.00006836998,0.0005480004,0.0000018067698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011765183,0.00032632097,0.9664955,0.00013451958,0.00013939416,0.0000026671457,0.0002171953,0.000093718285,0.000005622526,0.003127702,0.0003937153,0.027887112],"study_design_scores_gemma":[0.0034403314,0.002657632,0.9384313,0.000026072583,0.000025313013,0.00007407172,0.00013505892,0.000116359595,0.0000048271067,0.0073625124,0.047630228,0.000096278935],"about_ca_topic_score_codex":0.0012503047,"about_ca_topic_score_gemma":0.008711907,"teacher_disagreement_score":0.047236513,"about_ca_system_score_codex":0.00040279503,"about_ca_system_score_gemma":0.0058787847,"threshold_uncertainty_score":0.99975693},"labels":[],"label_agreement":null},{"id":"W3170353804","doi":"10.1200/jco.2021.39.15_suppl.e23004","title":"A scoping review of oncology medical education interventions in low and middle income countries.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia; Alberta Health Services","funders":"","keywords":"Medicine; Psychological intervention; Workforce; Intervention (counseling); Global health; MEDLINE; Family medicine; Population; Oncology; Medical education; Internal medicine; Nursing; Public health; Environmental health; Political science","score_opus":0.21841825626278621,"score_gpt":0.6398247740576878,"score_spread":0.42140651779490157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170353804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030421861,0.98932785,0.00010458773,0.0047391704,0.0038301137,0.00088459614,0.00000396659,0.000003897445,0.0010753962],"genre_scores_gemma":[0.0000032919033,0.98798656,0.004774778,0.0053854366,0.001601226,0.000041091065,0.0000150388,0.000025287021,0.00016726361],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.98805326,0.0025965679,0.008397721,0.0003009229,0.0004233377,0.00022821444],"domain_scores_gemma":[0.9816686,0.009502083,0.007360702,0.000298582,0.0007119851,0.0004580539],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010635741,0.00025833253,0.010247585,0.00037680494,0.000027898124,0.000003168841,0.0003029854,0.0018507824,0.0011243919],"category_scores_gemma":[0.02743965,0.00018041513,0.0016648838,0.00037931936,0.000836279,0.0000945476,0.0001189548,0.00288854,0.0000055559017],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011382099,0.0017529501,0.00028320446,0.2926111,0.00035310353,0.0005523556,0.00001711295,4.958909e-8,3.5252852e-9,0.00015490934,0.00066864735,0.70349276],"study_design_scores_gemma":[0.0013515732,0.0030266384,0.00005324669,0.51795423,0.0009303994,0.0030864289,0.000011422058,6.105493e-7,2.0006707e-8,0.000036794183,0.4734813,0.000067320216],"about_ca_topic_score_codex":0.0000037850166,"about_ca_topic_score_gemma":0.00008053265,"teacher_disagreement_score":0.7034254,"about_ca_system_score_codex":0.0006427981,"about_ca_system_score_gemma":0.051738158,"threshold_uncertainty_score":0.9997887},"labels":[],"label_agreement":null},{"id":"W3170362163","doi":"10.1200/jco.2021.39.15_suppl.e21010","title":"The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"KRAS; STK11; Medicine; Internal medicine; Oncology; Cancer; Overall survival; Mutation; Gene; Colorectal cancer; Biology; Genetics","score_opus":0.02976515583640647,"score_gpt":0.403708412751568,"score_spread":0.3739432569151615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170362163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940805,0.0023877544,0.0000016226134,0.0030424073,0.00007181462,0.0002906681,0.0000043950467,0.0000010689416,0.00011977063],"genre_scores_gemma":[0.9971382,0.0023536347,0.000054584518,0.00037343122,0.000031040847,0.0000038206786,6.6103945e-7,0.0000065097593,0.000038101498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977777,0.0005998945,0.0012237024,0.00008314883,0.0002065732,0.00010898201],"domain_scores_gemma":[0.99410623,0.004010819,0.001211693,0.00017115542,0.0004508099,0.00004928348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016631476,0.000084496896,0.0006222159,0.000035604757,0.000055622502,0.0000079817655,0.00011171504,0.00010344201,0.000011939259],"category_scores_gemma":[0.0019600876,0.000030089057,0.00021578044,0.00024696763,0.0011421591,0.00005076534,0.00002652611,0.00039523735,9.161441e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019519955,0.00058508397,0.93572783,0.000012666907,0.0005574593,0.000016921107,0.00047742476,0.000025905987,0.0006865198,0.00002292355,0.000035958805,0.04233132],"study_design_scores_gemma":[0.01847653,0.0052551953,0.9748794,0.00018359232,0.00019155147,0.00011665312,0.00020365574,0.000019950805,0.000091820926,0.00011288839,0.0004360528,0.000032747146],"about_ca_topic_score_codex":0.00018654302,"about_ca_topic_score_gemma":0.00024633412,"teacher_disagreement_score":0.042298574,"about_ca_system_score_codex":0.000049467188,"about_ca_system_score_gemma":0.0010952807,"threshold_uncertainty_score":0.4208333},"labels":[],"label_agreement":null},{"id":"W3170399786","doi":"10.1200/jco.2021.39.15_suppl.tps7572","title":"ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Population; Diffuse large B-cell lymphoma; CHOP; Gastroenterology; Rituximab; Vincristine; Phases of clinical research; Ibrutinib; Oncology; Cyclophosphamide; Surgery; Lymphoma; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Chemotherapy","score_opus":0.027573694381186314,"score_gpt":0.3926581560045246,"score_spread":0.3650844616233383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170399786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667114,0.00020119392,0.00026612304,0.00035916397,0.00029132076,0.001724638,0.00004416946,0.000010377233,0.00043187643],"genre_scores_gemma":[0.9962956,0.00031563098,0.0021928586,0.00041334773,0.00017702482,0.00004792936,0.000056486268,0.00006567967,0.0004354698],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405533,0.00051779504,0.0030686622,0.0006179981,0.0010527624,0.0006874678],"domain_scores_gemma":[0.99219304,0.002697545,0.0020005787,0.00045060302,0.0020213951,0.0006368094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021190604,0.0003852999,0.0025788345,0.00032295662,0.00008516926,0.0000260201,0.00025750854,0.00048528542,0.000037842052],"category_scores_gemma":[0.0015122959,0.00026735905,0.0002377911,0.0005920924,0.00035673162,0.00020068481,0.00018699636,0.0008467597,0.0000040678174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10143344,0.51144516,0.35504466,0.0007304237,0.0006393187,0.0053430093,0.0011857017,0.00000784595,0.0003911733,0.0000055362766,0.0017914417,0.02198226],"study_design_scores_gemma":[0.76125634,0.094207294,0.13534328,0.00047800242,0.0007027748,0.00048876496,0.0009962438,0.0034176644,0.0007988009,0.000014601108,0.0020597235,0.00023651456],"about_ca_topic_score_codex":0.00017741782,"about_ca_topic_score_gemma":0.00028771488,"teacher_disagreement_score":0.6598229,"about_ca_system_score_codex":0.002368015,"about_ca_system_score_gemma":0.010671245,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W3170449450","doi":"10.1200/jco.2021.39.15_suppl.501","title":"Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Internal medicine; Letrozole; Cancer; Oncology; Proportional hazards model; Clinical endpoint; Aromatase inhibitor; Hazard ratio; Aromatase; Confidence interval; Randomized controlled trial","score_opus":0.026153736246228305,"score_gpt":0.37875543597618405,"score_spread":0.35260169972995575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170449450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829255,0.010707722,0.000022506605,0.004159286,0.0013573214,0.00013957052,0.00057308166,0.000004468801,0.00011058643],"genre_scores_gemma":[0.97089154,0.026064435,0.0002007824,0.0010725596,0.001643877,0.00001229465,0.000047850957,0.000022585502,0.000044103894],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970203,0.0005122957,0.0016007981,0.00037191398,0.00022738388,0.0002673278],"domain_scores_gemma":[0.99760145,0.00029856872,0.0011623304,0.00022604474,0.0004277309,0.000283855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009571697,0.00020744918,0.0010233772,0.00008414362,0.000041980766,0.000011530184,0.00018533219,0.0011522211,0.00011283641],"category_scores_gemma":[0.00015611276,0.00016373259,0.00030702085,0.00015591897,0.000273665,0.000022519807,0.000117032825,0.00094617845,0.0000013910102],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025129389,0.0031896208,0.3010464,0.00003196537,0.0011417603,0.0006022246,0.000104250816,0.00025350798,0.18922918,0.000022659693,0.0056424607,0.4736066],"study_design_scores_gemma":[0.012806618,0.0040087467,0.94670856,0.00020254639,0.00019407278,0.0012476447,0.00012493395,0.00018050006,0.019599587,0.0002942252,0.014429809,0.00020276639],"about_ca_topic_score_codex":0.0002978374,"about_ca_topic_score_gemma":0.00042210275,"teacher_disagreement_score":0.6456621,"about_ca_system_score_codex":0.00011805855,"about_ca_system_score_gemma":0.0019072865,"threshold_uncertainty_score":0.8886984},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W3170450105","doi":"10.1200/jco.2021.39.15_suppl.2565","title":"Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Internal medicine; Oncology; Cohort; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Discontinuation; Cancer; Phases of clinical research; Clinical trial; Immunotherapy; Allele; Microsatellite","score_opus":0.09582486090055382,"score_gpt":0.465837091688276,"score_spread":0.37001223078772216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170450105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99261844,0.002040835,0.00010755366,0.0017857085,0.002444786,0.0004181606,0.000060576407,0.000028631557,0.00049528125],"genre_scores_gemma":[0.99253905,0.00048350485,0.0046354043,0.0015099752,0.00058065786,0.000008514306,0.00006159584,0.000028038781,0.00015324121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915042,0.0017197646,0.004724741,0.00074226275,0.0008266564,0.00048236107],"domain_scores_gemma":[0.99350715,0.0019996818,0.0018349019,0.0008084386,0.0012687921,0.0005810212],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003946688,0.00030913053,0.003382342,0.00037267717,0.000049207338,0.000023824194,0.00031615768,0.00061910466,0.0022731924],"category_scores_gemma":[0.0043731085,0.00025203297,0.0013063011,0.0016421663,0.00029909378,0.0000965211,0.00019149945,0.0018546626,0.000019088451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023535114,0.017186197,0.90986305,0.000035423876,0.004495407,0.005393079,0.0011882776,0.0012239285,0.002471276,0.000005474507,0.0018656404,0.032737147],"study_design_scores_gemma":[0.03503847,0.01542636,0.91606003,0.00010590333,0.004631376,0.00012576202,0.0014334212,0.00091460114,0.0019371113,0.00026855047,0.023761768,0.00029664917],"about_ca_topic_score_codex":0.0015565777,"about_ca_topic_score_gemma":0.007990122,"teacher_disagreement_score":0.0324405,"about_ca_system_score_codex":0.0017996059,"about_ca_system_score_gemma":0.0061758687,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W3170460635","doi":"10.1200/jco.2021.39.15_suppl.12073","title":"Overall and cardiac-specific mortality following serious cardiovascular events in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Proportional hazards model; Cancer; Cohort; Hazard ratio; Stroke (engine); Internal medicine; Cohort study; Confidence interval; Pediatrics","score_opus":0.09090049920843464,"score_gpt":0.434546309106509,"score_spread":0.34364580989807436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170460635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9131511,0.07420854,0.000014337796,0.0052500246,0.0061907307,0.0009384926,0.00007571739,0.000016126507,0.00015496864],"genre_scores_gemma":[0.97523415,0.019893663,0.00020931737,0.0015443239,0.0029502807,0.000038960552,0.000015620719,0.000060767405,0.000052924563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9871003,0.004125191,0.0055407686,0.00084525073,0.0018781081,0.00051035883],"domain_scores_gemma":[0.99141973,0.0033631145,0.0027781746,0.0012572721,0.00067366054,0.00050802727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.014427768,0.00042470352,0.0053167045,0.00012687645,0.000105427076,0.000020430152,0.0004305769,0.0004966942,0.000115032584],"category_scores_gemma":[0.0044321613,0.0003182473,0.0026502155,0.00052966026,0.00020885887,0.0002452425,0.00030780828,0.0020434018,0.0000017549115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005629722,0.004208809,0.9602804,0.00004193225,0.010782505,0.002813853,0.0036175493,0.00012276896,0.000026219146,0.0000042259444,0.0007119326,0.016826823],"study_design_scores_gemma":[0.011238794,0.0013767391,0.9604091,0.000539033,0.0025103055,0.00018834296,0.002347443,0.000003678863,0.000040010007,0.00013575895,0.02093644,0.00027436094],"about_ca_topic_score_codex":0.0363924,"about_ca_topic_score_gemma":0.030178368,"teacher_disagreement_score":0.062083084,"about_ca_system_score_codex":0.00035137052,"about_ca_system_score_gemma":0.004623086,"threshold_uncertainty_score":0.999927},"labels":[],"label_agreement":null},{"id":"W3170480273","doi":"10.1200/jco.2021.39.15_suppl.tps9596","title":"Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Oncology; Internal medicine; Regimen; Immunotherapy; Targeted therapy; Vemurafenib; Cancer research; Metastatic melanoma; Cancer","score_opus":0.046277413154985965,"score_gpt":0.3880112685749552,"score_spread":0.34173385541996926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170480273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846137,0.0003746435,0.00012157919,0.00034479742,0.00019340632,0.00027187527,0.0000070373453,0.0000012566016,0.00022401687],"genre_scores_gemma":[0.99604285,0.00046612116,0.003150568,0.00016006433,0.000099781966,0.0000062845634,0.000011025384,0.000013325786,0.00004999201],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975317,0.00050498353,0.0013424032,0.00026579795,0.00018018384,0.00017491549],"domain_scores_gemma":[0.9982546,0.00025307917,0.00095790747,0.00015455486,0.00023450024,0.00014533204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016278897,0.00014463729,0.00092474703,0.000108663444,0.000022614682,0.0000090212225,0.00009374584,0.00019487664,0.000009627072],"category_scores_gemma":[0.00089334906,0.000101611775,0.00007992419,0.00012104045,0.00022399086,0.000016611795,0.00008041734,0.0003420292,2.6130104e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49490798,0.02626962,0.12247586,0.00021469967,0.00079136377,0.0016648722,0.00064134155,0.000029230481,0.2134286,0.00018927835,0.00012180953,0.13926533],"study_design_scores_gemma":[0.698932,0.20332295,0.044097636,0.00033513186,0.00035202084,0.00091795827,0.00072961126,0.00037912413,0.04702865,0.00017882022,0.0033684555,0.0003576627],"about_ca_topic_score_codex":0.000015762382,"about_ca_topic_score_gemma":0.00053842005,"teacher_disagreement_score":0.20402399,"about_ca_system_score_codex":0.000018862487,"about_ca_system_score_gemma":0.0008657229,"threshold_uncertainty_score":0.4143608},"labels":[],"label_agreement":null},{"id":"W3170494628","doi":"10.1200/jco.2021.39.15_suppl.7018","title":"Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Venetoclax; Azacitidine; Internal medicine; Minimal residual disease; Gastroenterology; Ven; Oncology; Myeloid leukemia; Induction chemotherapy; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.0880853813681059,"score_gpt":0.42639400827745705,"score_spread":0.33830862690935115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170494628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981633,0.0010177682,0.00002445144,0.015941031,0.00012433495,0.00021326674,0.000009803356,0.00001202375,0.0010242999],"genre_scores_gemma":[0.9893788,0.0024609976,0.0031964525,0.001971734,0.0005188219,0.000008310304,0.000008730401,0.00003674175,0.0024193914],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99488395,0.0018721027,0.0017944713,0.0003567235,0.0006560008,0.00043673188],"domain_scores_gemma":[0.99302036,0.0039697583,0.00066723704,0.00034681585,0.00088787253,0.0011079813],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058906875,0.00019563791,0.0015834969,0.000277433,0.000051918647,0.000022329219,0.00016410214,0.00038718397,0.00013280887],"category_scores_gemma":[0.010897517,0.00013592948,0.00021062988,0.00048242122,0.00042341065,0.0001746798,0.00010710723,0.0019505834,0.000015330777],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41133803,0.0009616632,0.37956715,0.000096031355,0.0012468826,0.15694757,0.0001614462,0.00017829094,0.009467665,0.000072969524,0.010202688,0.029759608],"study_design_scores_gemma":[0.02482588,0.014243824,0.9266178,0.0003787759,0.0006545698,0.0046289754,0.00021435216,0.00038026532,0.0013054467,0.00016973856,0.02639851,0.00018189092],"about_ca_topic_score_codex":0.000039876013,"about_ca_topic_score_gemma":0.00006599031,"teacher_disagreement_score":0.5470506,"about_ca_system_score_codex":0.0018236456,"about_ca_system_score_gemma":0.026983539,"threshold_uncertainty_score":0.99743414},"labels":[],"label_agreement":null},{"id":"W3170497674","doi":"10.1200/jco.2021.39.15_suppl.10029","title":"Neurocognitive outcomes in survivors of early adolescent and young adult (eAYA) hematologic cancers from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Neurocognitive; Pediatrics; Odds ratio; Logistic regression; Cancer; Internal medicine; Young adult; Psychiatry; Cognition","score_opus":0.07733504454593909,"score_gpt":0.4320392771232334,"score_spread":0.35470423257729433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170497674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820761,0.0038253265,0.000008101091,0.011036863,0.0020280413,0.0006911002,0.000047066354,0.000007790026,0.0002796148],"genre_scores_gemma":[0.9871878,0.0074023586,0.000052300085,0.004849821,0.00038110634,0.000026040096,0.0000017343966,0.000020700518,0.0000781551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951703,0.0012752523,0.0023772004,0.0003520304,0.0005253162,0.0002998859],"domain_scores_gemma":[0.9920596,0.0045458525,0.0016738977,0.0001927767,0.0013246567,0.00020323803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014618353,0.00023814876,0.002373856,0.00010015607,0.000063056,0.0000102405,0.00015973201,0.00023423025,0.00009669592],"category_scores_gemma":[0.0071942597,0.00014737254,0.00037339903,0.0003187471,0.00040528274,0.00010566806,0.00017027066,0.0014978361,0.0000025251438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023410094,0.0034631125,0.97907394,0.000022215574,0.001481943,0.0008510842,0.00211506,0.000006021538,0.000019703946,0.000004248556,0.00049035426,0.0101313265],"study_design_scores_gemma":[0.013348615,0.0062646708,0.97012746,0.000462639,0.0009919604,0.00009219409,0.008225982,0.000008087971,0.000061824205,0.00005760744,0.00023424506,0.00012471592],"about_ca_topic_score_codex":0.0071215234,"about_ca_topic_score_gemma":0.053563334,"teacher_disagreement_score":0.04644181,"about_ca_system_score_codex":0.00025114193,"about_ca_system_score_gemma":0.0018323184,"threshold_uncertainty_score":0.99949014},"labels":[],"label_agreement":null},{"id":"W3170518524","doi":"10.1200/jco.2021.39.15_suppl.4500","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Interim analysis; Clinical endpoint; Renal cell carcinoma; Discontinuation; Internal medicine; Population; Temsirolimus; Randomization; Oncology; Clinical trial","score_opus":0.13693495747674775,"score_gpt":0.4100780355737302,"score_spread":0.27314307809698246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170518524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719769,0.0036372691,0.00014534134,0.0042224554,0.0035084526,0.0008663725,0.00023465742,0.000026314765,0.015382236],"genre_scores_gemma":[0.98062015,0.0030508977,0.009897376,0.0008380481,0.0022919145,0.000023676346,0.00023871915,0.00010928172,0.0029299192],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913373,0.00088018394,0.0052390513,0.0008192281,0.0009924518,0.00073180516],"domain_scores_gemma":[0.9790179,0.0126701975,0.0043213256,0.00094082096,0.0020929996,0.00095674815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002194509,0.0005545973,0.003617002,0.00022970064,0.00013715202,0.00002329014,0.00049610116,0.0009391106,0.0004454437],"category_scores_gemma":[0.00566754,0.00044085752,0.0022137386,0.00032268028,0.0003355596,0.00017676623,0.00015896329,0.0015606008,0.000043128202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90095055,0.0076807835,0.0018930846,0.00022006189,0.0013334817,0.00746959,0.0010512072,0.0005875072,0.016644739,0.00006130318,0.008190626,0.053917054],"study_design_scores_gemma":[0.5004011,0.16664787,0.042902295,0.00038059606,0.0021978659,0.0004251132,0.001165327,0.00037720436,0.14723161,0.0005229003,0.1371141,0.0006340467],"about_ca_topic_score_codex":0.00022440293,"about_ca_topic_score_gemma":0.0002557334,"teacher_disagreement_score":0.40054947,"about_ca_system_score_codex":0.0005997381,"about_ca_system_score_gemma":0.0054981066,"threshold_uncertainty_score":0.9998043},"labels":[],"label_agreement":null},{"id":"W3170529957","doi":"10.1200/jco.2021.39.15_suppl.e13529","title":"Predicting symptom complexity: Using autoregressive integrated moving average (ARIMA) models to create responsive clinic scheduling.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Autoregressive integrated moving average; Medicine; Bayesian information criterion; Statistics; Mean squared error; Mean absolute percentage error; Autocorrelation; Moving average; Autoregressive model; Bayesian probability; Time series; Mathematics","score_opus":0.4588943520867815,"score_gpt":0.5226227466199679,"score_spread":0.0637283945331864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170529957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723317,0.0008930941,0.015373883,0.0047757626,0.0017571482,0.00022444986,0.000013852337,0.000035503086,0.0045946236],"genre_scores_gemma":[0.8843146,0.00026999236,0.10524274,0.008112372,0.001669422,0.0000024119986,0.000006726078,0.000034279718,0.0003474585],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9934411,0.0011439216,0.0036161894,0.00047390556,0.0007976283,0.0005272523],"domain_scores_gemma":[0.9895659,0.0034719864,0.0024527847,0.00038189068,0.0031578653,0.0009695745],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005283606,0.00027202175,0.0023516447,0.0002475552,0.00016890411,0.000051778552,0.00029648776,0.000600641,0.00033280152],"category_scores_gemma":[0.019763526,0.00021877815,0.000784254,0.00047589975,0.00027832168,0.00045150713,0.0002584833,0.0023111633,0.00002886322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077656336,0.004215495,0.5465016,0.00032334216,0.006076379,0.07674964,0.005906903,0.09430566,0.012921014,0.0025856504,0.0067861103,0.1659719],"study_design_scores_gemma":[0.041296516,0.04465386,0.24402657,0.016099352,0.00535835,0.02129266,0.017813649,0.55692786,0.0034952376,0.013123635,0.034100633,0.001811649],"about_ca_topic_score_codex":0.00017198376,"about_ca_topic_score_gemma":0.00010299317,"teacher_disagreement_score":0.46262223,"about_ca_system_score_codex":0.00068008935,"about_ca_system_score_gemma":0.008117838,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W3170530345","doi":"10.1200/jco.2021.39.15_suppl.e14574","title":"Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus - VG161.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada)","funders":"","keywords":"Oncolytic virus; Medicine; Immune system; Cohort; Tolerability; Adverse effect; Virus; Immunology; Internal medicine; Oncology; Gastroenterology","score_opus":0.24475479337815131,"score_gpt":0.5044252886294944,"score_spread":0.2596704952513431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170530345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976881,0.00021595604,0.00019739593,0.0005441841,0.0005074157,0.00023703455,0.000042845757,0.0000029449227,0.00056411506],"genre_scores_gemma":[0.9956459,0.00010161959,0.002201001,0.00022460213,0.0016461738,0.000004528092,0.00011880745,0.000021579383,0.000035794696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99448943,0.00090154266,0.0037017548,0.00031799698,0.0003575364,0.00023173007],"domain_scores_gemma":[0.99527633,0.0012030584,0.0023702106,0.0003102016,0.00069331663,0.00014689972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044099432,0.00015613029,0.0009810979,0.00011197596,0.00006597621,0.000024641637,0.00030478524,0.00057755376,0.00005630843],"category_scores_gemma":[0.0082701305,0.00014446989,0.00033758229,0.0002640811,0.00016875731,0.000019082592,0.00015671807,0.00082633056,0.0000022460506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16751873,0.0024016981,0.0005516948,0.000008647445,0.00020005436,0.00017998989,0.000099069635,0.0024029303,0.81823605,0.000009319742,0.00008903383,0.008302767],"study_design_scores_gemma":[0.36673445,0.10438205,0.014209503,0.000313185,0.00015688874,0.000069227644,0.0002948661,0.0046507474,0.5063182,0.0005458613,0.0018481562,0.0004768735],"about_ca_topic_score_codex":0.00020806269,"about_ca_topic_score_gemma":0.0043461425,"teacher_disagreement_score":0.31191784,"about_ca_system_score_codex":0.00008810725,"about_ca_system_score_gemma":0.0028948134,"threshold_uncertainty_score":0.99007154},"labels":[],"label_agreement":null},{"id":"W3170554531","doi":"10.1200/jco.2021.39.15_suppl.5541","title":"Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario; Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Tolerability; Placebo; Internal medicine; Gemcitabine; Adverse effect; Nausea; Cancer","score_opus":0.1365709277447514,"score_gpt":0.44964866762829697,"score_spread":0.3130777398835456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170554531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913344,0.00017584107,0.00009424189,0.0029933336,0.0004982073,0.004613259,0.000005646968,0.000009524883,0.00027556796],"genre_scores_gemma":[0.9932686,0.00009741341,0.00572695,0.00016856276,0.00027488964,0.00041540182,0.0000049282767,0.000025586405,0.00001767735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98806334,0.0015505684,0.008847902,0.00042981864,0.00069962174,0.00040876947],"domain_scores_gemma":[0.98354775,0.0041322378,0.010745813,0.00027123574,0.0009926163,0.00031032285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01123173,0.0002917868,0.006442153,0.0002610409,0.000072386814,0.00002078355,0.00009125284,0.00028438884,0.00012136553],"category_scores_gemma":[0.0055705192,0.00016840911,0.00030254104,0.0005037966,0.0001931233,0.00015655004,0.00006079027,0.0009147688,1.550381e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9395955,0.025227746,0.019493846,0.00012723212,0.0019195273,0.002393874,0.0016413694,0.0014955085,0.00019095436,0.00004262757,0.0000072094754,0.007864598],"study_design_scores_gemma":[0.9310228,0.05571575,0.005902105,0.0012975212,0.0012188097,0.00016373492,0.000564656,0.003377534,0.00040369216,0.000047573998,0.00012171235,0.0001641097],"about_ca_topic_score_codex":0.00045309527,"about_ca_topic_score_gemma":0.00250921,"teacher_disagreement_score":0.030488007,"about_ca_system_score_codex":0.0015078128,"about_ca_system_score_gemma":0.010413812,"threshold_uncertainty_score":0.9951962},"labels":[],"label_agreement":null},{"id":"W3170567207","doi":"10.1200/jco.2021.39.15_suppl.6573","title":"A new option in pain prevention with bliss, a therapeutic virtual reality solution in bone marrow biopsy context: Results of a French open-label multicenter randomized phase II/III study (REVEH Trial).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec en Outaouais","funders":"Roche","keywords":"Medicine; Randomized controlled trial; Biopsy; Visual analogue scale; Context (archaeology); Surgery; Radiology","score_opus":0.1985158832071704,"score_gpt":0.4933911113220393,"score_spread":0.2948752281148689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170567207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740237,0.0008515409,0.012983388,0.008639147,0.0003254629,0.002927686,0.0000057112284,0.0000053468425,0.00023800733],"genre_scores_gemma":[0.9946767,0.00050276384,0.0035630926,0.0007771481,0.00013527983,0.000034354034,0.000018722965,0.000010136734,0.00028176693],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98814726,0.005854106,0.005014351,0.00032833318,0.00041163826,0.00024431763],"domain_scores_gemma":[0.9882778,0.008021225,0.0026530751,0.00025329512,0.0005292832,0.00026531128],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021264348,0.00017840893,0.0032862423,0.0001794591,0.000028671959,0.000015645484,0.0001630191,0.00040442223,0.00008507754],"category_scores_gemma":[0.035471648,0.0001152455,0.00027976616,0.00040999346,0.00017973219,0.00016504775,0.0001040216,0.0008467432,0.0000012329108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80275273,0.070078425,0.002032414,0.0000218906,0.00028282695,0.0010217298,0.00052143127,0.0000106215,0.00017021364,0.00013107683,0.0007774723,0.12219917],"study_design_scores_gemma":[0.90983856,0.07852904,0.00606405,0.0005723374,0.0005240333,0.00007497851,0.0010352902,0.0017138538,0.000020733749,0.00107498,0.00044522164,0.00010693049],"about_ca_topic_score_codex":0.0006575797,"about_ca_topic_score_gemma":0.0034167315,"teacher_disagreement_score":0.12209224,"about_ca_system_score_codex":0.000116936666,"about_ca_system_score_gemma":0.002084499,"threshold_uncertainty_score":0.972653},"labels":[],"label_agreement":null},{"id":"W3170576371","doi":"10.1200/jco.2021.39.15_suppl.2648","title":"A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Adverse effect; Limiting; Clinical trial; Risk stratification; Oncology; Mathematics","score_opus":0.18347534907522878,"score_gpt":0.5084742425795569,"score_spread":0.3249988935043281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170576371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9477242,0.0035144654,0.043412253,0.0024086724,0.0016554313,0.00027027767,0.00013957678,0.0000022706922,0.000872815],"genre_scores_gemma":[0.96803033,0.011894118,0.01667372,0.0013429581,0.0016976683,0.000026664837,0.000065327244,0.000018472796,0.00025076693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959169,0.0007429146,0.0027863283,0.00024011945,0.00010701028,0.00020672716],"domain_scores_gemma":[0.9945967,0.0023841392,0.002137151,0.00023084652,0.00050670933,0.00014445254],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0064103347,0.00012279813,0.0011683786,0.00006226888,0.000041949315,0.000018166993,0.00019806657,0.0005886529,0.000024501098],"category_scores_gemma":[0.01881491,0.00010830082,0.00057018147,0.00006617278,0.000119147946,0.0000072433395,0.00006165605,0.00037841752,0.000001240259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017031834,0.0071234307,0.002234215,0.000041964428,0.00081581593,0.00015455713,0.0004165658,0.013540776,0.20186166,0.0022034012,0.030849433,0.72372633],"study_design_scores_gemma":[0.07250365,0.043197285,0.003260016,0.000076505894,0.0010491703,0.00029634914,0.0016014993,0.048138168,0.061171778,0.030131062,0.7378332,0.00074131996],"about_ca_topic_score_codex":0.000011051769,"about_ca_topic_score_gemma":0.0006517406,"teacher_disagreement_score":0.722985,"about_ca_system_score_codex":0.000096237105,"about_ca_system_score_gemma":0.004300159,"threshold_uncertainty_score":0.98945004},"labels":[],"label_agreement":null},{"id":"W3170586961","doi":"10.1200/jco.2021.39.15_suppl.e23515","title":"Epidemiology, clinical features, and histopathology of sarcomas managed in a Haitian cancer clinic.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Sarcoma; Rhabdomyosarcoma; Leiomyosarcoma; Cancer registry; Dermatofibrosarcoma protuberans; Epidemiology; Histopathology; Liposarcoma; Soft tissue sarcoma; Cancer; Retrospective cohort study; Surgery; Internal medicine; Pathology","score_opus":0.2522214741316344,"score_gpt":0.5423130315900391,"score_spread":0.29009155745840465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170586961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9044484,0.04841889,0.000011444923,0.04298477,0.0018158857,0.00018352534,0.000007505923,0.000005680554,0.0021239398],"genre_scores_gemma":[0.9424417,0.034207854,0.010286574,0.01162654,0.0008694887,0.000010951755,0.0000051328075,0.000019373296,0.000532399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99099135,0.0027428765,0.0053659845,0.0003947231,0.00018204542,0.00032300712],"domain_scores_gemma":[0.9819099,0.0143680265,0.0025523389,0.00032124692,0.00039743917,0.00045105],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010299843,0.00017983704,0.0038825003,0.00017440844,0.00002483331,0.0000017944366,0.00014017677,0.00088484434,0.00027476184],"category_scores_gemma":[0.017996894,0.00013019251,0.000844461,0.00017592144,0.00071396533,0.000052031497,0.0001246483,0.0018020207,0.0000073333563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017160304,0.0036692014,0.7856145,0.000037901955,0.00026949478,0.0073696286,0.0000368949,0.0000012552817,0.000010903245,0.00035411195,0.008136304,0.19278379],"study_design_scores_gemma":[0.011496291,0.005137858,0.9266577,0.00022760712,0.00059336104,0.0023793997,0.00011498758,0.000009332418,0.000016545779,0.0013066838,0.051972955,0.00008730693],"about_ca_topic_score_codex":0.000111314825,"about_ca_topic_score_gemma":0.000815517,"teacher_disagreement_score":0.19269648,"about_ca_system_score_codex":0.00014319914,"about_ca_system_score_gemma":0.0016746704,"threshold_uncertainty_score":0.9902749},"labels":[],"label_agreement":null},{"id":"W3170634136","doi":"10.1200/jco.2021.39.15_suppl.10022","title":"Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Neuroblastoma; Refractory (planetary science); Progressive disease; Internal medicine; Bone marrow; Confidence interval; Surgery; Bone pain; Minimal residual disease; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Chemotherapy","score_opus":0.03775779962690827,"score_gpt":0.3884141539435884,"score_spread":0.35065635431668013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170634136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967958,0.00049351825,0.000009735199,0.0017401223,0.00033429783,0.00045413084,0.000081142374,0.000006018703,0.00008526294],"genre_scores_gemma":[0.99821585,0.00039744828,0.0007461543,0.00019752061,0.00021361918,0.0000054187476,0.00006902845,0.00003060804,0.00012436103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99288297,0.0018838084,0.0027395713,0.00037423827,0.001764489,0.00035492828],"domain_scores_gemma":[0.99204654,0.002172797,0.0025454336,0.00040919118,0.002167263,0.0006587694],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021150545,0.00022074756,0.0016484008,0.00028912237,0.000039885686,0.000008592134,0.0001667247,0.00026637904,0.00028727233],"category_scores_gemma":[0.011511893,0.00016028107,0.00038637136,0.0003830897,0.0003626765,0.00017111057,0.00010840562,0.001205792,0.000011403941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10236666,0.031351592,0.81272507,0.00012371986,0.0010370043,0.0044123726,0.000060188635,0.00021181203,0.0041086785,0.00001361302,0.0081206085,0.03546867],"study_design_scores_gemma":[0.05325853,0.029149361,0.9143205,0.00021501705,0.0009847201,0.000068918605,0.000024153505,0.000056684603,0.0012128657,0.00012208887,0.00048340127,0.00010375779],"about_ca_topic_score_codex":0.00003070038,"about_ca_topic_score_gemma":0.000053150376,"teacher_disagreement_score":0.101595424,"about_ca_system_score_codex":0.0001640805,"about_ca_system_score_gemma":0.003053606,"threshold_uncertainty_score":0.99681455},"labels":[],"label_agreement":null},{"id":"W3170677659","doi":"10.1200/jco.2021.39.15_suppl.4144","title":"Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Oncolytic virus; FOXP3; Response Evaluation Criteria in Solid Tumors; Pancreatic cancer; CD8; Progressive disease; Adenocarcinoma; Internal medicine; Gastroenterology; Pathology; Oncology; Cancer research; Immune system; Immunotherapy; Cancer; Immunology; Disease","score_opus":0.03302991991368527,"score_gpt":0.3718352763674642,"score_spread":0.33880535645377896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170677659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975792,0.0007281128,0.000032165615,0.00096781354,0.000049882794,0.0004783524,0.0000047841463,0.0000023749592,0.00015727086],"genre_scores_gemma":[0.9987673,0.00033385193,0.00044569984,0.00024890734,0.00007027423,0.000029438668,0.000023269531,0.000026245098,0.000055024477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698365,0.0012136248,0.0008514605,0.0002837443,0.00036409168,0.00030344425],"domain_scores_gemma":[0.99781024,0.0003958766,0.0007327745,0.00038519036,0.00054721144,0.0001287051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010308331,0.00019600205,0.00078687177,0.00009026002,0.000058586596,0.00001846164,0.0002550202,0.00015986043,0.000018749819],"category_scores_gemma":[0.00035661182,0.00010353712,0.00010694567,0.0002918853,0.00026859864,0.000017694389,0.0000558281,0.0005823668,0.0000018831107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082178496,0.0073769814,0.87037295,0.000022802174,0.00046938675,0.00084670796,0.0002042419,0.00050969387,0.0057003447,0.0000087881135,0.00001777616,0.032291815],"study_design_scores_gemma":[0.0319259,0.17969306,0.77759004,0.00008110066,0.00009887035,0.00014025276,0.00025216583,0.000055161778,0.009422367,0.00002505679,0.00055510574,0.00016090182],"about_ca_topic_score_codex":0.000043338507,"about_ca_topic_score_gemma":0.0033900144,"teacher_disagreement_score":0.17231607,"about_ca_system_score_codex":0.00022599714,"about_ca_system_score_gemma":0.0025556872,"threshold_uncertainty_score":0.45336795},"labels":[],"label_agreement":null},{"id":"W3170722196","doi":"10.1200/jco.2021.39.15_suppl.6515","title":"Health outcomes and resource utilization associated with postsurgical opioid use among cancer patients undergoing curative-intent surgery.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Enhanced Recovery After Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Opioid; Retrospective cohort study; Cohort; Medical prescription; Population; Cohort study; Surgery; Emergency medicine; Internal medicine","score_opus":0.15525339987152156,"score_gpt":0.4433483804730705,"score_spread":0.2880949806015489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170722196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960537,0.00048789382,0.00021752054,0.008468105,0.00093144015,0.0001443901,0.000007685044,0.000013355242,0.00012422296],"genre_scores_gemma":[0.990961,0.00241897,0.0003579095,0.005559578,0.00016158297,0.0000032101366,0.000025632839,0.00002367275,0.0004884301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955929,0.0011876497,0.002200401,0.00025499228,0.00047705095,0.0002869971],"domain_scores_gemma":[0.9827748,0.0130270785,0.002516013,0.000137478,0.0010538964,0.00049074244],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022389393,0.00016382424,0.0019930017,0.0001264032,0.00006799629,0.00002540965,0.000047872258,0.00028180465,0.0000538432],"category_scores_gemma":[0.018355217,0.00010940179,0.00034641626,0.00024375548,0.00018759168,0.00029333992,0.000055845136,0.00081499823,9.46957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013238877,0.0012091167,0.96810573,0.000033080632,0.0004993744,0.00047615464,0.00011772599,0.000015490283,0.0000030184135,0.000006934854,0.0026832272,0.025526261],"study_design_scores_gemma":[0.0037416616,0.0025287466,0.98572546,0.0010536058,0.00014504806,0.00008591348,0.000094655785,0.000053365227,0.00003739404,0.000017290798,0.006412489,0.00010439215],"about_ca_topic_score_codex":0.000036831105,"about_ca_topic_score_gemma":0.00083274354,"teacher_disagreement_score":0.025421869,"about_ca_system_score_codex":0.00037144593,"about_ca_system_score_gemma":0.0032293722,"threshold_uncertainty_score":0.9899136},"labels":[],"label_agreement":null},{"id":"W3170743116","doi":"10.1200/jco.2021.39.15_suppl.5064","title":"PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Western University; University of Toronto; McMaster University","funders":"Cancer Care Ontario","keywords":"Medicine; Prostate cancer; Prostatectomy; Cohort; Glutamate carboxypeptidase II; Stage (stratigraphy); Prospective cohort study; Biochemical recurrence; Single Center; Radiation therapy; Cancer; Radiology; Nuclear medicine; Oncology; Internal medicine","score_opus":0.22626698630054612,"score_gpt":0.539504332170889,"score_spread":0.3132373458703429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170743116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96866006,0.003793961,0.00003511431,0.02238743,0.003352455,0.00036957033,0.0001749949,0.000010787949,0.0012156515],"genre_scores_gemma":[0.97953564,0.006529049,0.0049657,0.0023292967,0.0032917939,0.000048167447,0.00011075989,0.000037134996,0.0031524466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970451,0.0002565037,0.0016535141,0.0002988488,0.00038643915,0.00035956502],"domain_scores_gemma":[0.99600834,0.0015690716,0.0008631262,0.00020793999,0.0009014087,0.00045012918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001134671,0.00015064701,0.0011979253,0.00006971914,0.00006448055,0.000025856581,0.0001445585,0.00008334626,0.0003930684],"category_scores_gemma":[0.0031321521,0.00010593001,0.00060519954,0.00013109666,0.00020050831,0.00010500342,0.0000806145,0.0009225847,0.00000926938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061676353,0.011208669,0.20427859,0.0003111085,0.0026114848,0.037748907,0.00036177426,0.0000053860126,0.003369288,0.00004801332,0.12376948,0.55461097],"study_design_scores_gemma":[0.056882836,0.029896295,0.041594457,0.0014977946,0.0010437948,0.0043713315,0.00050159526,0.0001176641,0.011780559,0.0017798498,0.85023683,0.00029699213],"about_ca_topic_score_codex":0.00003785807,"about_ca_topic_score_gemma":0.000110926885,"teacher_disagreement_score":0.7264674,"about_ca_system_score_codex":0.0004400898,"about_ca_system_score_gemma":0.0041214805,"threshold_uncertainty_score":0.7311329},"labels":[],"label_agreement":null},{"id":"W3170764582","doi":"10.1200/jco.2021.39.15_suppl.tps9138","title":"An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Chemotherapy; Immunotherapy; Immunology; Cancer research; Internal medicine","score_opus":0.15880713877515426,"score_gpt":0.5660918804300211,"score_spread":0.40728474165486683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170764582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964091,0.00013558811,0.000055619217,0.0007087721,0.00054823625,0.0018011603,0.000019053741,0.0000025091242,0.00031995762],"genre_scores_gemma":[0.9953358,0.00073651574,0.002893787,0.0004683925,0.00033573413,0.000013171386,0.000004087921,0.000032605,0.00017988475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923408,0.0034730576,0.002579555,0.00048148062,0.0007728493,0.0003522645],"domain_scores_gemma":[0.9903668,0.005296964,0.0021429143,0.0004628015,0.0013138884,0.00041661228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010163131,0.00020971207,0.0019487765,0.0000871387,0.00007826161,0.00002420476,0.0004141596,0.00026544483,0.00037363192],"category_scores_gemma":[0.0015929625,0.00012891488,0.00015552493,0.00024485152,0.0003253338,0.00025603638,0.0003129316,0.0022351078,0.0000012231275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117592625,0.03664686,0.57281137,0.000028895656,0.00051392365,0.00019887893,0.0004699801,0.00003919926,0.016722078,2.9678762e-7,0.00002232322,0.25495356],"study_design_scores_gemma":[0.114943705,0.10483318,0.77476037,0.00016286662,0.0005531841,0.00000940798,0.0005296314,0.0025462785,0.0011598244,0.000002839993,0.00038297035,0.00011575989],"about_ca_topic_score_codex":0.00012116742,"about_ca_topic_score_gemma":0.00060602586,"teacher_disagreement_score":0.25483778,"about_ca_system_score_codex":0.00025160634,"about_ca_system_score_gemma":0.0033975404,"threshold_uncertainty_score":0.97105557},"labels":[],"label_agreement":null},{"id":"W3170771096","doi":"10.1200/jco.2021.39.15_suppl.e13509","title":"Encouraging teamwork and innovative practices by creating proximity: A qualitative study of continuous improvements in the Quebec Cancer Network.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École Nationale d'Administration Publique","funders":"","keywords":"Teamwork; Promotion (chess); Knowledge management; Public relations; Qualitative research; Multidisciplinary approach; Quality (philosophy); Medicine; Sociology; Computer science; Political science","score_opus":0.3750902649756839,"score_gpt":0.6384438550338575,"score_spread":0.2633535900581736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170771096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97352725,0.0006611382,0.00015076474,0.02402033,0.0004180132,0.0006358439,0.0000038736325,0.0000030520553,0.0005797604],"genre_scores_gemma":[0.989715,0.00036154757,0.0034859611,0.0055215945,0.0007043476,0.000023346704,0.0000043493533,0.000011894886,0.00017199846],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9894165,0.004370888,0.0051603196,0.00024950012,0.0005819154,0.00022092102],"domain_scores_gemma":[0.95088834,0.035289437,0.011414688,0.00018477665,0.002111847,0.00011088888],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022534998,0.00013330164,0.0013653528,0.00006746099,0.000059131555,0.00002412329,0.00013423139,0.00016102583,0.00005285411],"category_scores_gemma":[0.08437003,0.00008641462,0.00010594662,0.00060151576,0.0001620863,0.0004126576,0.000102004546,0.0015229172,5.228823e-7],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006272609,0.011975846,0.5622749,0.00010557616,0.0016905033,0.0008668601,0.082110494,0.00002490148,0.00054551737,0.00013816485,0.01568423,0.31831044],"study_design_scores_gemma":[0.024817206,0.012417084,0.17711088,0.000493327,0.0012622341,0.00015419419,0.76393604,0.00014121582,0.000053919775,0.00089600874,0.018541243,0.0001766553],"about_ca_topic_score_codex":0.004468248,"about_ca_topic_score_gemma":0.02123654,"teacher_disagreement_score":0.6818255,"about_ca_system_score_codex":0.00013382427,"about_ca_system_score_gemma":0.0025266933,"threshold_uncertainty_score":0.99662334},"labels":[],"label_agreement":null},{"id":"W3170771486","doi":"10.1200/jco.2021.39.15_suppl.e20592","title":"Incidence of pneumonitis among limited-stage small cell lung cancer patients exposed to concurrent chemoradiation: A systematic literature review and meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Pneumonitis; Systematic review; Internal medicine; Observational study; Lung cancer; Meta-analysis; Oncology; MEDLINE; Lung","score_opus":0.15368868871070734,"score_gpt":0.4874924618875805,"score_spread":0.33380377317687315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170771486","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38749364,0.5997576,0.00005953241,0.010707299,0.00034130467,0.0013016583,0.000065970635,0.0000055844357,0.00026736292],"genre_scores_gemma":[0.87613875,0.117198855,0.00066959223,0.0047389334,0.00017276035,0.00008836211,0.00000847194,0.000014088369,0.00097017444],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947763,0.0010794941,0.0030142132,0.0002738786,0.00064438645,0.00021173996],"domain_scores_gemma":[0.9914778,0.002132249,0.0025597026,0.00027814915,0.0030935754,0.0004585437],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002869719,0.00017748825,0.0055376976,0.00019336464,0.000033447643,0.000019089453,0.0001679625,0.0001659725,0.00017417404],"category_scores_gemma":[0.009093293,0.00011198975,0.0012619698,0.0008804704,0.00012011625,0.00010830756,0.00015192425,0.0007495926,0.0000012623573],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054817565,0.0029596852,0.52714294,0.25028107,0.20135447,0.002618931,0.0019390569,0.000077041215,0.00021065258,0.00002689394,0.011234931,0.0016061717],"study_design_scores_gemma":[0.005376993,0.005499959,0.2698079,0.014185227,0.7022533,0.000075646276,0.00018295704,0.000170234,0.00045425238,0.0000056986696,0.001714873,0.00027296878],"about_ca_topic_score_codex":0.000012914495,"about_ca_topic_score_gemma":0.00014934855,"teacher_disagreement_score":0.5008988,"about_ca_system_score_codex":0.00022009062,"about_ca_system_score_gemma":0.0010704149,"threshold_uncertainty_score":0.9992535},"labels":[],"label_agreement":null},{"id":"W3170783707","doi":"10.1200/jco.2021.39.15_suppl.8018","title":"Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Vancouver General Hospital; CancerCare Manitoba; University of Calgary; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Pomalidomide; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Dexamethasone; Regimen; Phases of clinical research; Gastroenterology; Bortezomib; Multiple myeloma; Pharmacology; Oncology; Toxicity","score_opus":0.1983294157969046,"score_gpt":0.5080308278211916,"score_spread":0.30970141202428697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170783707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863587,0.0018607122,0.00002502078,0.009617768,0.0006550084,0.00029175586,0.000014229751,0.000012872105,0.0011639151],"genre_scores_gemma":[0.97525764,0.0026096518,0.018296862,0.0018910978,0.00056212937,0.000009096458,0.000028558541,0.000031479893,0.0013135135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99424034,0.0016793465,0.002691731,0.00039576684,0.0005053383,0.00048747985],"domain_scores_gemma":[0.98959047,0.0073453044,0.0011127973,0.00033411043,0.000582267,0.0010350636],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004333866,0.00022905493,0.0020328257,0.00024114201,0.00006862838,0.000015813042,0.0001362459,0.00056475867,0.0006668476],"category_scores_gemma":[0.024689345,0.00017190084,0.0004275104,0.00029198834,0.00020700754,0.00013578495,0.00018938445,0.0016270418,0.000040397466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043351125,0.010223562,0.36777782,0.00005309755,0.0007082611,0.026208222,0.000120810946,0.0000025187232,0.005509203,0.00001139591,0.00526326,0.5407707],"study_design_scores_gemma":[0.20400056,0.02046238,0.63918436,0.00024499124,0.00035846763,0.0033715956,0.00025039917,0.001153582,0.0018706719,0.00023562773,0.12862763,0.00023971025],"about_ca_topic_score_codex":0.000053181713,"about_ca_topic_score_gemma":0.0007175257,"teacher_disagreement_score":0.54053104,"about_ca_system_score_codex":0.0004739951,"about_ca_system_score_gemma":0.0017901206,"threshold_uncertainty_score":0.9835261},"labels":[],"label_agreement":null},{"id":"W3170806165","doi":"10.1200/jco.2021.39.15_suppl.5037","title":"Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Clinical endpoint; Placebo; Prednisone; Progression-free survival; Adverse effect; Population; Randomization; Enzalutamide; Randomized controlled trial; Urology; Gastroenterology; Oncology; Surgery; Cancer; Chemotherapy; Androgen deprivation therapy; Pathology","score_opus":0.24598597854768942,"score_gpt":0.5368218909530965,"score_spread":0.29083591240540707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170806165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897553,0.0034698003,0.000020820187,0.0050605442,0.00052567665,0.0008653898,0.000056808072,0.0000076097267,0.00023805762],"genre_scores_gemma":[0.9917602,0.0028378605,0.0044167424,0.00018732226,0.000172576,0.000117267904,0.000045009816,0.000029994351,0.00043302414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99180317,0.0017431384,0.0043272716,0.00048428355,0.0010464452,0.00059566594],"domain_scores_gemma":[0.99288356,0.0030832882,0.0022002775,0.00026351417,0.00118902,0.00038035927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071098134,0.00028192668,0.0030176383,0.0008039405,0.000051299994,0.000030303849,0.00020617545,0.00021975131,0.0003616476],"category_scores_gemma":[0.0037872645,0.00021122533,0.00063338224,0.0019493694,0.00031856474,0.0002499142,0.0001007478,0.0011637605,0.0000046979058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17967129,0.006723421,0.5814055,0.0006597047,0.015913323,0.0095304195,0.0043857303,0.02270976,0.034852423,0.000050630028,0.00019376093,0.143904],"study_design_scores_gemma":[0.18353383,0.022538623,0.72923243,0.0012013721,0.014087926,0.000111060275,0.0038546345,0.03437146,0.009869712,0.00025621464,0.00044955403,0.0004931992],"about_ca_topic_score_codex":0.0007262847,"about_ca_topic_score_gemma":0.014567787,"teacher_disagreement_score":0.14782688,"about_ca_system_score_codex":0.0012428848,"about_ca_system_score_gemma":0.0071527287,"threshold_uncertainty_score":0.9984758},"labels":[],"label_agreement":null},{"id":"W3170865790","doi":"10.1200/jco.2021.39.15_suppl.10013","title":"Mortality among five-year survivors of childhood cancer: Results over five decades of follow-up in the Childhood Cancer Survivor Study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Cancer; Mortality rate; Confidence interval; Pediatrics; National Death Index; Population; Cause of death; Demography; Standardized mortality ratio; Internal medicine; Hazard ratio; Disease; Environmental health","score_opus":0.10195283158851787,"score_gpt":0.4699536561197976,"score_spread":0.36800082453127975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170865790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852641,0.0021970142,0.000007718992,0.007292469,0.0030481264,0.00086318905,0.00022933401,0.0000123103,0.0010856993],"genre_scores_gemma":[0.9926156,0.003172758,0.00024948403,0.0019874938,0.0016684966,0.000026533136,0.000013097852,0.000046193458,0.0002203473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9852826,0.0043390524,0.007252143,0.00065938395,0.0019147767,0.0005520729],"domain_scores_gemma":[0.9839672,0.0074677872,0.005742768,0.0009820325,0.0014061081,0.00043409533],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015181669,0.0004096461,0.004144237,0.00027254008,0.000076217424,0.000018158627,0.0008222754,0.0006422818,0.00026933337],"category_scores_gemma":[0.011757408,0.00029190135,0.0013360153,0.0010402185,0.0006328774,0.0002452432,0.00024214642,0.002440315,0.0000027251078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036274756,0.01015251,0.95692825,0.00013328636,0.002260108,0.0003821441,0.01718924,0.0001386834,0.000022874008,0.00007945075,0.0024926348,0.006593349],"study_design_scores_gemma":[0.02512208,0.005424865,0.9527237,0.0008045837,0.0011567491,0.000045416633,0.012007961,0.000010731498,0.00022108955,0.00027356338,0.0019663689,0.00024293261],"about_ca_topic_score_codex":0.030877229,"about_ca_topic_score_gemma":0.18625037,"teacher_disagreement_score":0.15537316,"about_ca_system_score_codex":0.00024684076,"about_ca_system_score_gemma":0.0059478837,"threshold_uncertainty_score":0.9999533},"labels":[],"label_agreement":null},{"id":"W3170880688","doi":"10.1200/jco.2021.39.15_suppl.e24068","title":"Opioid screening and urine toxicology results in outpatient oncology palliative medicine.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oxycodone; Opioid; Palliative care; Urinalysis; Urine","score_opus":0.4456882373800889,"score_gpt":0.5824125689106666,"score_spread":0.13672433153057773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170880688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94460225,0.007012854,0.00032544727,0.03388886,0.0014753594,0.0001763622,0.000008506978,0.0000066242415,0.012503715],"genre_scores_gemma":[0.9469716,0.019796705,0.026175238,0.0049781557,0.0016101298,0.000004531949,0.000015280419,0.000018563407,0.00042977527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994327,0.001058159,0.0036882989,0.00029411606,0.0003473083,0.00028512074],"domain_scores_gemma":[0.98623675,0.009869606,0.0022629378,0.00019170223,0.0010364149,0.00040260307],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003970374,0.00017037743,0.00260583,0.00024053508,0.00002424403,0.0000023417601,0.000127912,0.0006286314,0.000116254014],"category_scores_gemma":[0.02734148,0.00012347217,0.00025649724,0.00027982375,0.0005753334,0.000073871015,0.0001273823,0.0013760743,0.0000035417027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0169022,0.0034955526,0.53244925,0.00015765884,0.0008182393,0.00894489,0.006281963,0.00005456448,0.00091745955,0.0005494463,0.009234031,0.42019477],"study_design_scores_gemma":[0.033596657,0.043114897,0.4660033,0.0016508086,0.00038547927,0.0005166135,0.0041620876,0.0001637357,0.0007824837,0.0007672892,0.4487134,0.00014325877],"about_ca_topic_score_codex":0.00005926804,"about_ca_topic_score_gemma":0.00032929736,"teacher_disagreement_score":0.43947935,"about_ca_system_score_codex":0.0002011764,"about_ca_system_score_gemma":0.0016984631,"threshold_uncertainty_score":0.98085165},"labels":[],"label_agreement":null},{"id":"W3170881181","doi":"10.1200/jco.2021.39.15_suppl.9527","title":"Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Rash; Clinical endpoint; Erythema; Interim analysis; Adverse effect; Internal medicine; Randomized controlled trial; Melanoma; Population; Dermatology; Surgery; Gastroenterology; Cancer research","score_opus":0.27629155697554575,"score_gpt":0.50746883025471,"score_spread":0.23117727327916426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170881181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990072,0.0004609548,0.00014777851,0.003828467,0.0029758937,0.0014157376,0.000017457813,0.000007625184,0.0010740989],"genre_scores_gemma":[0.99360204,0.0003084832,0.0041686352,0.0009436681,0.0007569401,0.000054420518,0.00007253793,0.000027636268,0.00006562795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911094,0.002595868,0.005057132,0.00036824483,0.00046005961,0.00040930603],"domain_scores_gemma":[0.9731221,0.023072047,0.0026441938,0.00026690832,0.00036722491,0.00052748335],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008930096,0.0002853219,0.005972941,0.00032243357,0.000042321513,0.000008762001,0.00019735355,0.0004972071,0.00013136194],"category_scores_gemma":[0.030734539,0.00022363255,0.0012044018,0.00024157036,0.0003417188,0.00014737007,0.00006657179,0.0012819446,0.000005279885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93648195,0.016785007,0.034879737,0.00014598953,0.0022652592,0.0028880632,0.0001585982,0.00005380288,0.00064669974,0.00015844806,0.00030785459,0.005228583],"study_design_scores_gemma":[0.9581138,0.017168274,0.017901732,0.00019562832,0.0018622851,0.000088745386,0.00009395213,0.00043693738,0.0010629562,0.0006366352,0.002282181,0.00015689671],"about_ca_topic_score_codex":0.00013569699,"about_ca_topic_score_gemma":0.001645136,"teacher_disagreement_score":0.021804443,"about_ca_system_score_codex":0.00053512247,"about_ca_system_score_gemma":0.0047345213,"threshold_uncertainty_score":0.97743},"labels":[],"label_agreement":null},{"id":"W3170936139","doi":"10.1200/jco.2021.39.15_suppl.1086","title":"The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Confidence interval; Metastatic breast cancer; Internal medicine; Hazard ratio; Breast cancer; Oncology; Meta-analysis; Subgroup analysis; Cancer; Randomized controlled trial; Progression-free survival; Overall survival","score_opus":0.26687377171932375,"score_gpt":0.6124790798086444,"score_spread":0.3456053080893206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170936139","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018677012,0.99011946,0.000055600918,0.008515318,0.00026526683,0.00071283896,0.000042248164,0.0000035292976,0.00009899958],"genre_scores_gemma":[0.000636197,0.99643767,0.0020510643,0.00047436636,0.0002799121,0.000052794403,0.000011611834,0.00002436982,0.000032035718],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9849571,0.007463948,0.0061215307,0.00039022046,0.00075124804,0.00031596664],"domain_scores_gemma":[0.9771555,0.01438306,0.0069644367,0.000581741,0.00046804867,0.00044722322],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.023578439,0.00040768975,0.022062885,0.0002829878,0.0000490622,0.00002185992,0.000546416,0.00039845656,0.00020864942],"category_scores_gemma":[0.013138662,0.00015513776,0.007815196,0.000685448,0.0004531796,0.00003762404,0.0001753966,0.004021909,7.130266e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014566505,0.00096868415,0.0019999244,0.00956026,0.20168471,0.0009497718,0.0000047173216,0.000042870124,7.178049e-8,0.00025066859,0.00093945954,0.78345317],"study_design_scores_gemma":[0.0022062242,0.0037040159,0.0057217963,0.01694108,0.88083637,0.0039523584,0.000023581333,0.00019286653,6.2054326e-9,0.00007853139,0.08613321,0.00020995665],"about_ca_topic_score_codex":0.000047427242,"about_ca_topic_score_gemma":0.0000105759755,"teacher_disagreement_score":0.78324324,"about_ca_system_score_codex":0.00036881477,"about_ca_system_score_gemma":0.0054453476,"threshold_uncertainty_score":0.9982759},"labels":[],"label_agreement":null},{"id":"W3170977860","doi":"10.1200/jco.2021.39.15_suppl.5515","title":"Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Manitoba; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Internal medicine; BRCA mutation; Clinical endpoint; Oncology; Tolerability; Ovarian cancer; Discontinuation; Gastroenterology; Cancer; Clinical trial; Adverse effect","score_opus":0.06458866069387688,"score_gpt":0.4171793893224604,"score_spread":0.35259072862858354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170977860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640287,0.00040564203,0.0000746126,0.010150612,0.0011656131,0.0006731899,0.00020623131,0.000010859715,0.00091034477],"genre_scores_gemma":[0.99639016,0.0010455726,0.00055400224,0.0012928774,0.00033368787,0.000024207333,0.00014579645,0.00002282372,0.0001908479],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948691,0.001586982,0.0022294596,0.00045441347,0.0005602483,0.00029981154],"domain_scores_gemma":[0.9932949,0.0033633828,0.0019658604,0.00025969045,0.00087965495,0.00023652562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018747529,0.00023082268,0.0011647348,0.00009869351,0.00015066807,0.00002447431,0.00008707195,0.00029828827,0.00009301269],"category_scores_gemma":[0.0020089713,0.00014685016,0.00014356768,0.00026201995,0.00016606203,0.00019042459,0.000039144616,0.0008222396,0.0000026518985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1445242,0.066986196,0.37148538,0.000018227815,0.0020703226,0.0034415901,0.022633417,0.0002874973,0.0009924052,0.00012942935,0.00881892,0.3786124],"study_design_scores_gemma":[0.25743082,0.08890727,0.6409263,0.00026407957,0.00061212067,0.000095876065,0.0023369032,0.00019031786,0.00069775706,0.00046094638,0.007837213,0.0002403823],"about_ca_topic_score_codex":0.0008925645,"about_ca_topic_score_gemma":0.0021265063,"teacher_disagreement_score":0.378372,"about_ca_system_score_codex":0.0010856274,"about_ca_system_score_gemma":0.0018527218,"threshold_uncertainty_score":0.59883755},"labels":[],"label_agreement":null},{"id":"W3170999361","doi":"10.1200/jco.2021.39.15_suppl.2623","title":"Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Oncology; Pharmacodynamics; Anemia; Pharmacology; Gastroenterology","score_opus":0.06246022385941271,"score_gpt":0.41585739515185527,"score_spread":0.3533971712924426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170999361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975382,0.0010026139,0.000016496251,0.00038518035,0.00046813142,0.00049684354,0.000046874335,0.0000023514233,0.000043316402],"genre_scores_gemma":[0.99899524,0.00065939,0.00017845235,0.000029082063,0.000029026054,0.0000033020158,0.00008388153,0.000012450456,0.000009184496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948507,0.0012990496,0.003215822,0.00032952655,0.00010067569,0.00020424685],"domain_scores_gemma":[0.9948841,0.0022411323,0.002194086,0.00028675186,0.00035829915,0.000035650763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024035238,0.00015705077,0.0013799968,0.0002845079,0.00002317257,0.0000031672498,0.00022012764,0.00027645816,0.000014131032],"category_scores_gemma":[0.0017419988,0.00012427614,0.000069315334,0.00037049621,0.00022201668,0.00024355447,0.00015455224,0.0005860673,5.499317e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1972681,0.03640517,0.5477804,0.000033664543,0.0005300851,0.00007959063,0.0011783399,0.0006996637,0.026598653,0.0000025810614,0.00026512454,0.18915865],"study_design_scores_gemma":[0.11308352,0.020885626,0.85869735,0.00023456864,0.00008098154,0.000010979801,0.00019556096,0.00036094975,0.005661135,0.000013979135,0.0006739743,0.000101371756],"about_ca_topic_score_codex":0.000035271398,"about_ca_topic_score_gemma":0.0003089759,"teacher_disagreement_score":0.310917,"about_ca_system_score_codex":0.000096640004,"about_ca_system_score_gemma":0.00042782107,"threshold_uncertainty_score":0.50678337},"labels":[],"label_agreement":null},{"id":"W3171039744","doi":"10.1200/jco.2021.39.15_suppl.12095","title":"The PROVIEW+ tool: Developing and validating a tool to predict risk of poor performance status and severe symptoms in cancer patients over time.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Trillium Health Centre; Wilfrid Laurier University; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Performance status; Logistic regression; Palliative care; Lung cancer; Cancer; Population; Depression (economics); Retrospective cohort study; Cohort; Breast cancer; Internal medicine; Physical therapy; Emergency medicine","score_opus":0.1370586675898048,"score_gpt":0.49023163578005446,"score_spread":0.3531729681902497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171039744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964838,0.002132418,0.000013676556,0.0007753577,0.00023926442,0.00016271393,0.00001214008,0.0000016922294,0.00017890777],"genre_scores_gemma":[0.9751825,0.019854289,0.0039080144,0.0007554368,0.00018962883,0.0000047549906,0.0000017578517,0.000008326313,0.00009533763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782073,0.00025441288,0.0013985398,0.000122069774,0.00023547004,0.00016875705],"domain_scores_gemma":[0.9961562,0.0021891017,0.0009528137,0.00007756188,0.00051669317,0.00010759853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014681965,0.0000843221,0.00078162714,0.000047683705,0.000031916807,0.0000061435103,0.00005573717,0.000120529105,0.00001853627],"category_scores_gemma":[0.008062603,0.00005199397,0.00007786779,0.00013366483,0.00009899239,0.000092995964,0.00008575148,0.00038901702,6.0180247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007096598,0.00010984508,0.78667426,0.00008331931,0.00013862988,0.000013297449,0.0003883184,0.000010018713,0.000042759257,0.000006580776,0.00024590184,0.21157743],"study_design_scores_gemma":[0.0039980006,0.0028957531,0.96259165,0.0014081155,0.00014923411,0.000011763427,0.00013343611,0.0002221288,0.0003289707,0.0000330506,0.02816477,0.000063127154],"about_ca_topic_score_codex":0.0000359159,"about_ca_topic_score_gemma":0.00005884894,"teacher_disagreement_score":0.2115143,"about_ca_system_score_codex":0.00009146831,"about_ca_system_score_gemma":0.0011893989,"threshold_uncertainty_score":0.9652272},"labels":[],"label_agreement":null},{"id":"W3171042113","doi":"10.1200/jco.2021.39.15_suppl.tps11582","title":"IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Oncology; Medicine; Internal medicine; Anthracycline; Cancer research; Cancer; Breast cancer","score_opus":0.1751760736806835,"score_gpt":0.4692052168953547,"score_spread":0.2940291432146712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171042113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691463,0.00011265414,0.00011952155,0.002494056,0.00020593592,0.008908172,0.000014167645,0.000006788444,0.0012240653],"genre_scores_gemma":[0.99223036,0.00020276842,0.004157588,0.00073910336,0.00040014306,0.00059298275,0.0000023108585,0.00004910019,0.0016256194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948421,0.00119505,0.0021559147,0.00047126078,0.0008648308,0.00047084977],"domain_scores_gemma":[0.9930915,0.0038952925,0.0011210588,0.00035004306,0.00096543034,0.0005766697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002895059,0.00028813444,0.0023790328,0.0002838113,0.00006552295,0.000030307641,0.00018641501,0.00037836313,0.00040652556],"category_scores_gemma":[0.0017919699,0.00019021686,0.00021543255,0.00043363933,0.00045957827,0.00017940109,0.00034703387,0.0013916255,0.0000031685843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11536046,0.0137212565,0.6311778,0.00057459454,0.00067523815,0.0026434397,0.000489151,0.000009602175,0.023132699,0.000006974801,0.000544481,0.21166433],"study_design_scores_gemma":[0.041698463,0.06106491,0.8533941,0.00039008007,0.00020826414,0.0002923135,0.00027374903,0.00007613975,0.005166346,0.0000291403,0.037157007,0.00024950848],"about_ca_topic_score_codex":0.000038334303,"about_ca_topic_score_gemma":0.00062749564,"teacher_disagreement_score":0.22221631,"about_ca_system_score_codex":0.00027698049,"about_ca_system_score_gemma":0.0021289731,"threshold_uncertainty_score":0.77568185},"labels":[],"label_agreement":null},{"id":"W3171043130","doi":"10.1200/jco.2021.39.15_suppl.12051","title":"Patient experience of early high grade symptomatic adverse events on early phase clinical trials using the PRO-CTCAE.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Clinical trial; Internal medicine","score_opus":0.4021495012938674,"score_gpt":0.5913232899915838,"score_spread":0.1891737886977164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171043130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98183334,0.00016563087,0.0006416971,0.0135214785,0.0033944785,0.00036219636,0.0000044664503,0.0000054666057,0.00007122842],"genre_scores_gemma":[0.9930467,0.0002956967,0.00311698,0.0021779374,0.0012891592,0.0000035306748,0.0000023020675,0.000013995606,0.000053684515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98812586,0.003999183,0.006383919,0.00023812459,0.0010323183,0.00022058118],"domain_scores_gemma":[0.98458135,0.009045803,0.0047861272,0.0003360215,0.00078253186,0.00046815985],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014593283,0.00014682335,0.0021567682,0.00009059791,0.00006834045,0.0000053271615,0.0001794011,0.00076713494,0.00014359869],"category_scores_gemma":[0.020969165,0.000076971955,0.0010785365,0.00026164582,0.0010080062,0.000086290966,0.000077256285,0.0016460476,0.000005873259],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024539169,0.03786027,0.06864766,0.00025417825,0.0027291577,0.002304165,0.0050427425,0.00011229864,0.007358963,0.0035162843,0.0012420189,0.8463931],"study_design_scores_gemma":[0.07233878,0.11702716,0.7662596,0.0032037701,0.0031078008,0.00087397086,0.0020016322,0.0037090883,0.0032736405,0.010956401,0.016804457,0.00044370547],"about_ca_topic_score_codex":0.000023342971,"about_ca_topic_score_gemma":0.00000309774,"teacher_disagreement_score":0.8459494,"about_ca_system_score_codex":0.00008311764,"about_ca_system_score_gemma":0.0022805068,"threshold_uncertainty_score":0.9872776},"labels":[],"label_agreement":null},{"id":"W3171050513","doi":"10.1200/jco.2021.39.15_suppl.9010","title":"Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Concordance; Internal medicine; Oncology; Nivolumab; Lung cancer; Cancer; Immunotherapy","score_opus":0.0729004882346902,"score_gpt":0.4156880520774406,"score_spread":0.3427875638427504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171050513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501944,0.002988982,0.0006467517,0.0006632432,0.00041453828,0.00008447334,0.000006535151,5.7336456e-7,0.00017547341],"genre_scores_gemma":[0.98436457,0.0054974975,0.009333245,0.00037737368,0.00038821928,0.0000012503485,0.0000037870407,0.000009172398,0.000024911336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847347,0.00016517908,0.0010075162,0.00015837357,0.00007493391,0.00012050335],"domain_scores_gemma":[0.9983419,0.00044039259,0.0007973129,0.00012540874,0.00022023081,0.00007471709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012713954,0.000081419326,0.00048040343,0.000026697177,0.000032878135,0.000014842072,0.00009736396,0.00017310349,0.000006627866],"category_scores_gemma":[0.0013843585,0.00006423202,0.00007094405,0.000050365914,0.00022929713,0.0000058212445,0.00013648011,0.00023044217,2.732519e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007045586,0.0001921271,0.058327142,0.000036262754,0.00014430375,0.00008696032,0.000099805875,0.0005057346,0.9083896,0.0002183808,0.00010464588,0.031190459],"study_design_scores_gemma":[0.016663348,0.0066945716,0.3437265,0.00019850138,0.00042425026,0.0016311246,0.0014390007,0.0048545212,0.5364905,0.0021926437,0.08513531,0.0005497494],"about_ca_topic_score_codex":0.000025732117,"about_ca_topic_score_gemma":0.00018676968,"teacher_disagreement_score":0.37189913,"about_ca_system_score_codex":0.000027334569,"about_ca_system_score_gemma":0.00094100524,"threshold_uncertainty_score":0.26193058},"labels":[],"label_agreement":null},{"id":"W3171053777","doi":"10.1200/jco.2021.39.15_suppl.e18768","title":"Your voice matters during COVID-19: Evaluation of digital divides across a tertiary cancer center.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Demography; Socioeconomic status; Logistic regression; Demographics; Family medicine; Coronavirus disease 2019 (COVID-19); Environmental health; Population; Internal medicine","score_opus":0.29868019623186703,"score_gpt":0.6007069243108613,"score_spread":0.3020267280789942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171053777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9155811,0.0005250618,0.00017028862,0.08246989,0.0008910442,0.00018049372,0.000034241766,0.0000066132898,0.00014127008],"genre_scores_gemma":[0.97755975,0.00046794864,0.00048357967,0.019815413,0.0015504005,0.000006876372,0.000019194002,0.000011679285,0.00008514514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960022,0.00038142994,0.0024823537,0.00016140412,0.00073354953,0.00023909028],"domain_scores_gemma":[0.9954904,0.0009980968,0.0018664338,0.00014003376,0.0009840372,0.00052104675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003810215,0.000097334494,0.000831301,0.00007430174,0.000054834072,0.000009624129,0.00008683889,0.00014608851,0.0004943258],"category_scores_gemma":[0.007648238,0.000075322336,0.00026317325,0.00013664192,0.00011568753,0.00022781997,0.000059512044,0.00045225603,0.000005525636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010829782,0.0008055923,0.8193483,0.00019763754,0.00028667922,0.0002372613,0.00065837405,0.000040657906,0.00053968973,0.0000027399817,0.005764728,0.17103538],"study_design_scores_gemma":[0.017366042,0.0015098474,0.9270035,0.0001479269,0.0004995789,0.0007568487,0.0013971874,0.00008988787,0.00045922358,0.000096262345,0.050610173,0.0000635334],"about_ca_topic_score_codex":0.000052234867,"about_ca_topic_score_gemma":0.0001837634,"teacher_disagreement_score":0.17097184,"about_ca_system_score_codex":0.00035765354,"about_ca_system_score_gemma":0.0040702443,"threshold_uncertainty_score":0.9156208},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3171065483","doi":"10.1200/jco.2021.39.15_suppl.e24086","title":"ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of continuous cycles of carboplatin-based chemotherapy with focus on nausea: A MASCC emesis study group, prospective, observational, real-world multi-centric study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Élisabeth Bruyère Hospital","funders":"","keywords":"Nausea; Carboplatin; Medicine; Vomiting; Antiemetic; Regimen; Incidence (geometry); Population; Internal medicine; Chemotherapy; Chemotherapy-induced nausea and vomiting; Anesthesia; Cisplatin","score_opus":0.32561344800434083,"score_gpt":0.503355475869832,"score_spread":0.17774202786549115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171065483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994001,0.00010506852,0.00026836677,0.0024349438,0.00045718727,0.0024819663,0.000029401153,0.000004864732,0.00021720842],"genre_scores_gemma":[0.99779785,0.0000482135,0.0015402206,0.00020482857,0.00022444197,0.0000588732,0.00000564783,0.000021746395,0.00009818964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935428,0.0018965605,0.0025068568,0.00028854574,0.001602413,0.00016285595],"domain_scores_gemma":[0.98301065,0.00849717,0.004093364,0.00039924012,0.0039305375,0.00006902726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012699557,0.0001817346,0.0013582923,0.00018169083,0.00007276972,0.000010110745,0.00034637356,0.00010414906,0.00005885693],"category_scores_gemma":[0.0074839597,0.000099921584,0.00046784067,0.00060423696,0.00016779365,0.000052077616,0.000062886735,0.00037464683,1.5457226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077948333,0.013948831,0.961986,0.000043401582,0.0031639135,0.000012992889,0.0003602436,0.00081083697,0.0002384972,0.00006314904,0.00014838285,0.01142892],"study_design_scores_gemma":[0.030627284,0.008563492,0.95249444,0.00012275774,0.0021838031,0.0000026289977,0.0014577238,0.0032670607,0.0010774152,0.0000715823,0.000050987197,0.00008082767],"about_ca_topic_score_codex":0.0006475577,"about_ca_topic_score_gemma":0.0074051344,"teacher_disagreement_score":0.022832451,"about_ca_system_score_codex":0.00021788788,"about_ca_system_score_gemma":0.0014241608,"threshold_uncertainty_score":0.89595395},"labels":[],"label_agreement":null},{"id":"W3171070684","doi":"10.1200/jco.2021.39.15_suppl.9024","title":"A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Oncology; Cohort; Lung cancer; Cancer; Interim analysis; Stage (stratigraphy); PARP inhibitor; Clinical trial; Genetics; Poly ADP ribose polymerase","score_opus":0.058909348607396515,"score_gpt":0.4388653226790993,"score_spread":0.3799559740717028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171070684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632335,0.0005500034,0.000033211396,0.00077403773,0.00095159025,0.0012289315,0.000034855067,0.0000076647875,0.00009638041],"genre_scores_gemma":[0.9974474,0.00040850596,0.00046907697,0.0009018741,0.00038084935,0.00003651256,0.0000081261705,0.0000392987,0.00030839755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505186,0.0007313166,0.0029842986,0.00040182087,0.00049981236,0.00033087464],"domain_scores_gemma":[0.9951295,0.0009753709,0.0022828223,0.00032109485,0.00091800245,0.00037317508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016753762,0.0002499571,0.0021580774,0.00022668493,0.00006116993,0.0000101319365,0.00017594283,0.00026476185,0.00048345342],"category_scores_gemma":[0.00031673422,0.00017756912,0.0001626799,0.0003435807,0.00016590119,0.00010600479,0.00011562648,0.001190412,0.0000017318406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04178005,0.065152496,0.87972426,0.00013408948,0.0009896812,0.0022143668,0.0025193915,0.00017305334,0.001098934,0.0000012299475,0.0010941997,0.0051182625],"study_design_scores_gemma":[0.21973146,0.13103816,0.6439323,0.00031079576,0.00090379734,0.000031392807,0.0016415374,0.00019148667,0.00075408816,0.0000069271,0.0012533137,0.0002047676],"about_ca_topic_score_codex":0.0002670294,"about_ca_topic_score_gemma":0.0015180416,"teacher_disagreement_score":0.23579197,"about_ca_system_score_codex":0.00047447393,"about_ca_system_score_gemma":0.0033167782,"threshold_uncertainty_score":0.72410583},"labels":[],"label_agreement":null},{"id":"W3171080294","doi":"10.1200/jco.2021.39.15_suppl.3074","title":"First-in-human phase I study of the bifunctional EGFR/TGF<b>β</b> fusion protein BCA101 in patients with EGFR-driven advanced solid cancers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cetuximab; Cancer; Lung cancer; Cancer research; Melanoma; Internal medicine; Oncology; Colorectal cancer","score_opus":0.042004209548837296,"score_gpt":0.44017151081843164,"score_spread":0.3981673012695943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171080294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985669,0.00012800242,0.000009727702,0.00045218237,0.00022393216,0.00044446558,0.000010660316,8.3007285e-7,0.00016329595],"genre_scores_gemma":[0.9993051,0.00008701779,0.00017485562,0.00011440639,0.00016135623,0.000024682764,0.0000111091085,0.000010663904,0.00011076702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777615,0.00040460713,0.0010113905,0.00023586706,0.00036438616,0.00020762085],"domain_scores_gemma":[0.9984437,0.00008730609,0.0007289443,0.00022954818,0.00039150298,0.00011897744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049955613,0.00011189916,0.000527052,0.00006096696,0.000051723036,0.000005579825,0.00020497186,0.00015429406,0.00005020016],"category_scores_gemma":[0.00054427877,0.00007082471,0.00015278267,0.0001804111,0.000113339054,0.0000106264515,0.00013918524,0.00043337865,6.854071e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015692905,0.020760564,0.9310393,0.000027278842,0.00040484106,0.00026479462,0.00012815783,0.0018794584,0.0093681915,0.000007858688,0.0003375116,0.020089151],"study_design_scores_gemma":[0.06554929,0.051926818,0.8680404,0.0001601091,0.00006136897,0.000012099286,0.00029013667,0.00002548251,0.0052444567,0.00006545306,0.008488688,0.00013574336],"about_ca_topic_score_codex":0.00018454168,"about_ca_topic_score_gemma":0.012635537,"teacher_disagreement_score":0.062998936,"about_ca_system_score_codex":0.00020605297,"about_ca_system_score_gemma":0.0014587715,"threshold_uncertainty_score":0.70509267},"labels":[],"label_agreement":null},{"id":"W3171092377","doi":"10.1200/jco.2021.39.15_suppl.tps2679","title":"Immune Resistance Interrogation Study (IRIS): A prospective comprehensive multi-omic analysis in patients with intrinsic and acquired resistance to immunotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; Biopsy; Immune checkpoint; Prospective cohort study; Immune system; Tumor microenvironment; Oncology; Internal medicine; Immunology","score_opus":0.02592243022296907,"score_gpt":0.36588778650153797,"score_spread":0.3399653562785689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171092377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667215,0.0016349141,0.00061715266,0.00050267595,0.00020877102,0.00030016957,0.0000113198475,0.0000014052517,0.000051415143],"genre_scores_gemma":[0.99404645,0.00041694217,0.0046743443,0.00057683716,0.000108645305,0.000009697832,0.000011393595,0.000012839582,0.00014282907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978896,0.00032124115,0.0011793161,0.00031202618,0.00014870721,0.00014913837],"domain_scores_gemma":[0.99774677,0.00026547606,0.000792657,0.0002524714,0.0008370063,0.00010560876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005965963,0.000128684,0.000806292,0.00011880601,0.00003547798,0.000020678954,0.00014064924,0.00014393083,0.000006436738],"category_scores_gemma":[0.0006166497,0.000109052315,0.00015661366,0.0003364955,0.00009340521,0.000008414037,0.00010599897,0.00019684699,7.5665605e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018972546,0.0031313482,0.9642686,0.000010907533,0.0018404429,0.00011427588,0.00068772933,0.00022131641,0.003109052,0.00001677911,0.00024109312,0.0073859],"study_design_scores_gemma":[0.010016852,0.0044510956,0.9790754,0.000030928433,0.00020162325,0.0000019149766,0.0006941148,0.000004505573,0.0004991129,0.000024642251,0.0048772236,0.0001225931],"about_ca_topic_score_codex":0.000016409109,"about_ca_topic_score_gemma":0.0056004794,"teacher_disagreement_score":0.014806785,"about_ca_system_score_codex":0.00013235146,"about_ca_system_score_gemma":0.00058831443,"threshold_uncertainty_score":0.44470242},"labels":[],"label_agreement":null},{"id":"W3171125284","doi":"10.1200/jco.2021.39.15_suppl.e18656","title":"Can online patient reviews be used to assess oncologist competency? RateMD as a cancer care evaluation tool.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Interpersonal communication; Medical education; Descriptive statistics; Health care; Family medicine; Psychology; Social psychology","score_opus":0.8217213815862203,"score_gpt":0.6869679878308012,"score_spread":0.13475339375541917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171125284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78928983,0.019797878,0.000032131644,0.17283423,0.011856075,0.0029671406,0.00015683351,0.000032648062,0.003033218],"genre_scores_gemma":[0.89754075,0.007858732,0.017443478,0.07376282,0.0021260346,0.0006858727,0.00018409347,0.00005384125,0.00034436872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97055113,0.019827798,0.0075210216,0.00044648224,0.0010754433,0.00057810644],"domain_scores_gemma":[0.97325855,0.009558815,0.006530998,0.0010116226,0.00887883,0.0007612014],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0049623726,0.00026978538,0.00234166,0.00016701235,0.0005102562,0.00001473995,0.0007223024,0.0008267001,0.0014095375],"category_scores_gemma":[0.04728612,0.00021449987,0.00050078204,0.0005538405,0.0001457957,0.00017853167,0.00048741436,0.003313895,0.00010049574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016959447,0.002718872,0.27436006,0.0007823097,0.00030298295,0.00023790142,0.025517087,0.00052222406,0.00024928653,0.00092622434,0.07218382,0.6205033],"study_design_scores_gemma":[0.005366574,0.0059622647,0.06529464,0.0014556727,0.00035030796,0.000024951405,0.04906138,0.00017705275,0.000030429817,0.0005182948,0.871467,0.00029145513],"about_ca_topic_score_codex":0.0011726839,"about_ca_topic_score_gemma":0.042019445,"teacher_disagreement_score":0.79928315,"about_ca_system_score_codex":0.0031368618,"about_ca_system_score_gemma":0.040688407,"threshold_uncertainty_score":0.9995033},"labels":[],"label_agreement":null},{"id":"W3171133605","doi":"10.1200/jco.2021.39.15_suppl.9120","title":"Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Medicine; Systemic therapy; Internal medicine; Population; Cohort; Stage (stratigraphy); Proportional hazards model; Lung cancer; Retrospective cohort study; Hazard ratio; Comorbidity; Cancer; Oncology; Breast cancer","score_opus":0.09882337109539505,"score_gpt":0.5213115592388393,"score_spread":0.42248818814344424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171133605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809142,0.0009656067,0.00062008115,0.015334138,0.001067722,0.0002806552,0.000028157874,0.000004197715,0.000785245],"genre_scores_gemma":[0.9841435,0.00030877738,0.008542592,0.0038544873,0.0005269257,0.0000069103717,0.00001406719,0.000015549977,0.0025871694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983038,0.00007963508,0.0011876205,0.00011511583,0.0001756034,0.00013825361],"domain_scores_gemma":[0.99613714,0.0019073726,0.0011648174,0.00013684804,0.00041885837,0.00023498943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046405953,0.00009920864,0.0009960482,0.000068106034,0.000030257766,0.0000054752913,0.00006067359,0.00015946041,0.00019969269],"category_scores_gemma":[0.0008828158,0.000063870015,0.00049363816,0.00007743135,0.000025308442,0.0000386287,0.000007621574,0.00023498484,9.695282e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013766818,0.001270688,0.9717191,0.0001123332,0.00072307984,0.0000749496,0.000223107,0.00035055607,0.00015889415,0.0000594393,0.003092645,0.020838529],"study_design_scores_gemma":[0.015562707,0.005198722,0.9643825,0.00016421611,0.00097142946,0.000004691591,0.00014100914,0.00020010181,0.0006405124,0.000109822686,0.012563392,0.000060843176],"about_ca_topic_score_codex":0.0002919255,"about_ca_topic_score_gemma":0.00032304606,"teacher_disagreement_score":0.020777686,"about_ca_system_score_codex":0.00021219332,"about_ca_system_score_gemma":0.0054761255,"threshold_uncertainty_score":0.97144115},"labels":[],"label_agreement":null},{"id":"W3171149386","doi":"10.1200/jco.2021.39.15_suppl.9572","title":"Propensity weighted indirect treatment comparison of nivolumab (NIVO) versus placebo (PBO) as adjuvant therapy for resected melanoma: A number needed to treat and overall survival analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Internal medicine; Nivolumab; Ipilimumab; Oncology; Overall survival; Adjuvant; Placebo; Clinical trial; Cancer; Immunotherapy; Pathology","score_opus":0.17490114042853275,"score_gpt":0.4660421051953497,"score_spread":0.29114096476681695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171149386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890599,0.00026967743,0.00015917515,0.003969847,0.0008730354,0.00074438733,0.000008973788,0.000015419972,0.0048995838],"genre_scores_gemma":[0.9935358,0.0005615492,0.0021864623,0.0005253366,0.00037211916,0.000014666376,0.0000167411,0.000018528073,0.0027687647],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99665487,0.00064643903,0.0017693869,0.00032229535,0.0003662082,0.00024078596],"domain_scores_gemma":[0.99533767,0.0021687422,0.0010834215,0.00026678806,0.0007368466,0.00040653802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011549309,0.00020259627,0.0028263982,0.00023455879,0.000064865504,0.00001681947,0.000089224945,0.00027905678,0.0003621746],"category_scores_gemma":[0.0013437498,0.00014108788,0.00072571123,0.00040693488,0.00008675577,0.000044158343,0.000056213,0.00032553132,0.0000090294725],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5032666,0.013817763,0.12352263,0.00009996939,0.020248534,0.0028269393,0.0016053512,0.00007758796,0.005235023,0.00018648736,0.012428858,0.31668425],"study_design_scores_gemma":[0.20832023,0.17339954,0.31845206,0.00013133028,0.014411717,0.0011114794,0.0028346083,0.0019236695,0.021545233,0.00017515237,0.25710577,0.00058919395],"about_ca_topic_score_codex":0.00034617065,"about_ca_topic_score_gemma":0.0017426962,"teacher_disagreement_score":0.31609505,"about_ca_system_score_codex":0.0003137596,"about_ca_system_score_gemma":0.0008414775,"threshold_uncertainty_score":0.5753397},"labels":[],"label_agreement":null},{"id":"W3171153388","doi":"10.1200/jco.2021.39.15_suppl.e18578","title":"Prognostic impact of obesity in cancer patients with COVID-19 infection: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Disease and Adiposity","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Publication bias; Odds ratio; Obesity; Funnel plot; Confidence interval; Internal medicine; Population; Cancer; Environmental health","score_opus":0.25762346260820035,"score_gpt":0.555470400763304,"score_spread":0.29784693815510366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171153388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070617016,0.99711734,0.000023320634,0.00018259179,0.00005548561,0.001854797,0.000041204483,0.0000024705516,0.000016634207],"genre_scores_gemma":[0.0012555494,0.99783236,0.00004934552,0.0006589694,0.00007980903,0.000060349765,0.000023564955,0.000013934083,0.000026134514],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99125063,0.003544293,0.0043064575,0.00027604692,0.0004738484,0.00014870364],"domain_scores_gemma":[0.9904063,0.0027083503,0.005282684,0.00037732683,0.0005982452,0.00062710745],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.004704606,0.00028984807,0.029067721,0.00031372317,0.000018077817,0.0000072006533,0.000103237886,0.00041019116,0.0002110655],"category_scores_gemma":[0.008908145,0.00013912313,0.014006962,0.00092326186,0.00011099857,0.000054924483,0.000058668917,0.0010260049,9.3710224e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059325255,0.0014225533,0.05055147,0.5029768,0.4421728,0.00039935307,0.0000043214022,0.000005678022,4.6427664e-10,0.0000011825396,0.000088738096,0.0023178046],"study_design_scores_gemma":[0.0012237027,0.0018893535,0.036596864,0.04448807,0.9089357,0.00028516792,8.219677e-7,4.1235856e-7,1.7846286e-9,0.0000014281324,0.00647413,0.0001043192],"about_ca_topic_score_codex":0.000112196234,"about_ca_topic_score_gemma":0.0000980062,"teacher_disagreement_score":0.46676293,"about_ca_system_score_codex":0.0003207063,"about_ca_system_score_gemma":0.006869114,"threshold_uncertainty_score":0.99944025},"labels":[],"label_agreement":null},{"id":"W3171181967","doi":"10.1200/jco.2021.39.15_suppl.11038","title":"Impact of the COVID-19 pandemic on the wellbeing of international fellows training in hematology/oncology at the Princess Margaret Cancer Centre (PMCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Subspecialty; Medicine; Pandemic; Coping (psychology); Workforce; Family medicine; Gynecologic oncology; Demographics; Scale (ratio); Population; Coronavirus disease 2019 (COVID-19); Gerontology; Internal medicine; Demography; Clinical psychology; Disease; Infectious disease (medical specialty)","score_opus":0.3249334887775289,"score_gpt":0.5763147930533387,"score_spread":0.25138130427580974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171181967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7831817,0.0005739553,0.000016494027,0.2134763,0.0013786044,0.00022963936,0.000013710011,0.0000032133219,0.0011263427],"genre_scores_gemma":[0.97441274,0.0020884024,0.00005648007,0.022626352,0.00054541806,0.000004234119,0.0000020195966,0.000012782584,0.00025159869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946697,0.0018871609,0.0024106523,0.00020849382,0.00049614854,0.00032785413],"domain_scores_gemma":[0.9794365,0.016752241,0.0026728841,0.00033433147,0.0004857648,0.00031826942],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005902993,0.00015424479,0.0014225704,0.00010837892,0.000082536106,0.0000048046354,0.00048618382,0.0004532287,0.00093774893],"category_scores_gemma":[0.022178795,0.00006806199,0.0007366837,0.0002871971,0.00057486567,0.000044704982,0.00020456503,0.0017562021,0.0000024955154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035763825,0.0005665967,0.96467924,0.000068878704,0.00044257296,0.0003558692,0.0028435476,0.0004944327,0.00041251813,0.0005306477,0.0046222922,0.021406997],"study_design_scores_gemma":[0.0064858315,0.002661544,0.8679125,0.00042353553,0.00021229705,0.0014268216,0.0019296841,0.00018640405,0.0001528259,0.00082652684,0.11769631,0.00008574282],"about_ca_topic_score_codex":0.00059637846,"about_ca_topic_score_gemma":0.0106361555,"teacher_disagreement_score":0.19123098,"about_ca_system_score_codex":0.0016888102,"about_ca_system_score_gemma":0.019058986,"threshold_uncertainty_score":0.9999755},"labels":[],"label_agreement":null},{"id":"W3171232767","doi":"10.1200/jco.2021.39.15_suppl.11557","title":"Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Sarcoma; Internal medicine; Combination therapy; Cancer; Dosing; Oncology; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Pharmacology; Immunotherapy; Pathology","score_opus":0.08994067627134944,"score_gpt":0.4523935307635861,"score_spread":0.3624528544922367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171232767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909306,0.00021326945,0.00002221768,0.0060002315,0.00018270775,0.0002898454,0.0000018840822,0.000004352652,0.002354889],"genre_scores_gemma":[0.9935841,0.00048588833,0.0046338993,0.00038860543,0.00013538406,0.00000449677,0.0000052263294,0.000020606829,0.00074182457],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956031,0.00085975643,0.0023576638,0.0002404222,0.00064907066,0.000290002],"domain_scores_gemma":[0.9943604,0.003124504,0.0011309426,0.00025341602,0.0009008561,0.00022988528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003902973,0.00013177522,0.0016235057,0.00032016623,0.000011861325,0.0000076799515,0.00014880931,0.00025671424,0.00014912785],"category_scores_gemma":[0.0047553596,0.00008244227,0.00012366094,0.00083749957,0.00030336634,0.00016007591,0.000045888257,0.0016982673,0.0000023423547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4468972,0.009703353,0.24699646,0.000121923236,0.00030318135,0.022275861,0.00093195855,0.00010218833,0.015602271,0.00010288669,0.0003768798,0.2565858],"study_design_scores_gemma":[0.109006435,0.07509562,0.80557406,0.0007122168,0.00006484353,0.0011324267,0.0005408214,0.00007116805,0.0046543134,0.00020736684,0.0028274064,0.00011330368],"about_ca_topic_score_codex":0.00008602688,"about_ca_topic_score_gemma":0.003383208,"teacher_disagreement_score":0.5585776,"about_ca_system_score_codex":0.0002956679,"about_ca_system_score_gemma":0.00418545,"threshold_uncertainty_score":0.7424809},"labels":[],"label_agreement":null},{"id":"W3171232878","doi":"10.1200/jco.2021.39.15_suppl.e16064","title":"Prevalence-adjusted trends in U.S. healthcare spending on upper gastrointestinal cancers, 1996 to 2016.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus; Kingston General Hospital; University of Calgary","funders":"","keywords":"Medicine; Per capita; Health care; Confidence interval; Cancer; Gastrointestinal cancer; Emergency department; Demography; Emergency medicine; Environmental health; Population; Internal medicine; Colorectal cancer; Economic growth; Nursing","score_opus":0.1882769671180242,"score_gpt":0.5179248891437289,"score_spread":0.3296479220257047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171232878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90847415,0.0045332196,0.000021514317,0.08194053,0.00076871517,0.00021350103,0.000017839964,0.000009933098,0.00402057],"genre_scores_gemma":[0.98718923,0.0010737735,0.0046287454,0.00373138,0.0010847889,0.000007433578,0.0000048798306,0.000015564816,0.0022641807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966983,0.000522455,0.0015084716,0.00028295745,0.00054806523,0.00043975242],"domain_scores_gemma":[0.9970763,0.000961855,0.00048548874,0.00017907127,0.0003153346,0.0009819792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001687815,0.00013924214,0.0010682755,0.00032567044,0.00003224334,0.000009051286,0.00013173696,0.00013515083,0.00094505923],"category_scores_gemma":[0.0025225095,0.00010118923,0.0003515778,0.00038690795,0.000072889976,0.00006344687,0.000057614303,0.0013394179,0.000053367825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058674486,0.0009783759,0.76746386,0.00006556931,0.00007844444,0.014499896,0.00004364003,0.000033137003,0.000030263642,0.00009535988,0.006177142,0.20466685],"study_design_scores_gemma":[0.006494678,0.032236826,0.9538549,0.000996045,0.00007226628,0.0018601293,0.0000863439,0.000020595937,0.00010591876,0.0000771548,0.004129744,0.0000653776],"about_ca_topic_score_codex":0.00041879062,"about_ca_topic_score_gemma":0.0009912046,"teacher_disagreement_score":0.20460148,"about_ca_system_score_codex":0.0013771411,"about_ca_system_score_gemma":0.0035573165,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W3171334864","doi":"10.1200/jco.2021.39.15_suppl.4527","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Avelumab; Chemotherapy; Hazard ratio; Internal medicine; Metastatic Urothelial Carcinoma; Urology; Gastroenterology; Neutropenia; Intention-to-treat analysis; Post-hoc analysis; Surgery; Urothelial carcinoma; Bladder cancer; Oncology; Randomized controlled trial; Pembrolizumab; Immunotherapy; Cancer; Confidence interval","score_opus":0.07614720092709548,"score_gpt":0.40875762380772296,"score_spread":0.3326104228806275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171334864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811572,0.00058129616,0.0044074706,0.0114022745,0.0005971978,0.0010874558,0.00054595893,0.0000036445908,0.00021749476],"genre_scores_gemma":[0.9894556,0.0012372216,0.0069599594,0.001376411,0.0005168782,0.00005389685,0.00005843242,0.000028071914,0.00031352905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947562,0.00045195656,0.0036915937,0.0003505365,0.00043712367,0.0003125854],"domain_scores_gemma":[0.99357784,0.0024420356,0.0023089424,0.00058570155,0.00091065187,0.00017483528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017185562,0.00025261167,0.0027400914,0.00020718903,0.00002835202,0.000006262133,0.00035487316,0.00029144154,0.00030391378],"category_scores_gemma":[0.0026602475,0.00015823761,0.0012956291,0.0005240579,0.00021480217,0.000090976006,0.000044980774,0.00031980473,0.0000011533884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6483689,0.022436982,0.077821106,0.00018929076,0.013251633,0.0004353656,0.004459485,0.0003587543,0.0233388,0.00015452213,0.010554772,0.19863038],"study_design_scores_gemma":[0.5487382,0.1550815,0.18672867,0.0005322315,0.008706754,0.000090046924,0.0027634164,0.0007413079,0.061340794,0.002385351,0.032439973,0.00045180006],"about_ca_topic_score_codex":0.0008021789,"about_ca_topic_score_gemma":0.0032706966,"teacher_disagreement_score":0.19817857,"about_ca_system_score_codex":0.0003411956,"about_ca_system_score_gemma":0.0015733556,"threshold_uncertainty_score":0.6452742},"labels":[],"label_agreement":null},{"id":"W3171364159","doi":"10.1200/jco.2021.39.15_suppl.6073","title":"Selpercatinib efficacy and safety in patients with <i>RET</i>-altered thyroid cancer: A clinical trial update.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eli Lilly and Company","keywords":"Medicine; Medullary thyroid cancer; Vandetanib; Internal medicine; Cabozantinib; Thyroid cancer; Clinical endpoint; Population; Adverse effect; Oncology; Cancer; Clinical trial; Thyroid","score_opus":0.09458236338123119,"score_gpt":0.4656421353871166,"score_spread":0.37105977200588536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171364159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98168856,0.0023104507,0.000007860887,0.013067441,0.0019208606,0.00053020124,0.000015447753,0.000007290862,0.00045186374],"genre_scores_gemma":[0.97805744,0.01324813,0.001918305,0.0046832263,0.0019805536,0.000016846658,0.000014410479,0.000023972156,0.000057097957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99461854,0.0008368944,0.00344755,0.00039197347,0.00041867958,0.00028634426],"domain_scores_gemma":[0.9942133,0.0028700663,0.0015450899,0.00028169295,0.0005367491,0.00055313954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024311845,0.00019750163,0.0022862135,0.00006309345,0.000038662758,0.0000152129405,0.00011466029,0.00037664716,0.00019052648],"category_scores_gemma":[0.0024768696,0.00012693407,0.00036722567,0.00020292091,0.00022915009,0.000101426325,0.00007435574,0.0012060857,0.0000075394073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18417828,0.009589367,0.62805796,0.000015049416,0.0005422877,0.00050472945,0.00005054695,0.000005306509,0.0000020812172,0.000030236037,0.0034151527,0.17360902],"study_design_scores_gemma":[0.27240136,0.02907647,0.65086764,0.0001780555,0.00046577601,0.00004809897,0.000027687538,0.0000037024422,0.000008919392,0.000025664085,0.04680883,0.000087773515],"about_ca_topic_score_codex":0.00002437363,"about_ca_topic_score_gemma":0.00021437662,"teacher_disagreement_score":0.17352124,"about_ca_system_score_codex":0.00023262319,"about_ca_system_score_gemma":0.003156129,"threshold_uncertainty_score":0.5598837},"labels":[],"label_agreement":null},{"id":"W3171382390","doi":"10.1200/jco.2021.39.15_suppl.568","title":"Impact of patient, tumour and treatment factors on psychosocial outcomes in invasive breast cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Mount Sinai Hospital; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Psychosocial; Lumpectomy; Breast cancer; Mastectomy; Quality of life (healthcare); Prospective cohort study; Stage (stratigraphy); Internal medicine; Distress; Anxiety; Cancer; Gynecology; Oncology; Clinical psychology; Nursing; Psychiatry","score_opus":0.1037501946269409,"score_gpt":0.4885980962227237,"score_spread":0.3848479015957828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171382390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937782,0.00029168808,3.7884183e-7,0.0042112786,0.0010734914,0.00008470146,0.000047594247,0.0000017466225,0.0005108726],"genre_scores_gemma":[0.99738485,0.0016916123,0.000020383988,0.0005070214,0.00033137537,0.0000021391563,0.0000020554373,0.000008209404,0.0000523359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981283,0.00025605163,0.0011469658,0.00013046035,0.00020054236,0.0001376761],"domain_scores_gemma":[0.99713427,0.0014062834,0.0008648111,0.000089563524,0.00027129354,0.00023377615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002725235,0.00011570712,0.0013671229,0.00008675823,0.000012617012,0.0000034731104,0.000041337702,0.00019441357,0.00019513679],"category_scores_gemma":[0.0007826179,0.00006922654,0.0005786437,0.000111833986,0.0000830907,0.000039183375,0.000016521137,0.0003748907,7.627553e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027072113,0.0018297943,0.91815734,0.000009729349,0.0004257151,0.00036965567,0.00089574367,0.00000529448,0.0001063739,0.000009202913,0.00025500474,0.07522896],"study_design_scores_gemma":[0.0057992833,0.015259119,0.9769464,0.00012014894,0.00015454089,0.000100463156,0.00078659406,7.885474e-7,0.0001463605,0.000058477304,0.0005745186,0.00005331165],"about_ca_topic_score_codex":0.0013689802,"about_ca_topic_score_gemma":0.008701751,"teacher_disagreement_score":0.07517565,"about_ca_system_score_codex":0.00044850164,"about_ca_system_score_gemma":0.0026826146,"threshold_uncertainty_score":0.48557812},"labels":[],"label_agreement":null},{"id":"W3171392184","doi":"10.1200/jco.2021.39.15_suppl.e21531","title":"Prognostic pathological and clinical factors associated with overall survival in metastatic melanoma undergoing anti PD-1 treatment.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Pembrolizumab; Internal medicine; Oncology; Melanoma; Immunotherapy; Cohort; Proportional hazards model; Gastroenterology; Cancer","score_opus":0.21448340736016416,"score_gpt":0.45974703263170025,"score_spread":0.24526362527153608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171392184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951618,0.00092371996,0.000040483996,0.002559942,0.0006674155,0.0001851457,0.0000059119307,0.0000096076865,0.00044599175],"genre_scores_gemma":[0.9949983,0.0030044313,0.00081371213,0.0008067168,0.00020594615,0.0000017851572,0.000011080828,0.000015952019,0.0001421035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951399,0.0016179566,0.0023909416,0.0002822366,0.0002952203,0.00027373442],"domain_scores_gemma":[0.9862134,0.011867712,0.0012603372,0.00013769227,0.00023989838,0.00028094684],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003347209,0.0001883354,0.0020861528,0.00008829065,0.000036351197,0.000018003628,0.00007289265,0.00036423188,0.00011732731],"category_scores_gemma":[0.009070379,0.00010839121,0.00049431995,0.00019555377,0.00033575433,0.000088674686,0.00003231466,0.00076980126,0.0000013315873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052079824,0.003731733,0.96419126,0.000013074066,0.0014322511,0.0061804717,0.00006935946,0.000002378125,0.00010294208,0.000022949933,0.00006252476,0.018983064],"study_design_scores_gemma":[0.024878414,0.028271027,0.9434304,0.00021866822,0.0007806937,0.00046071457,0.00030558716,0.00003191527,0.000025283523,0.00011623432,0.0013682375,0.000112783404],"about_ca_topic_score_codex":0.000019599629,"about_ca_topic_score_gemma":0.00070696144,"teacher_disagreement_score":0.024539296,"about_ca_system_score_codex":0.00023823848,"about_ca_system_score_gemma":0.002540727,"threshold_uncertainty_score":0.99927664},"labels":[],"label_agreement":null},{"id":"W3171393216","doi":"10.1200/jco.2021.39.15_suppl.6059","title":"Prospective manipulation of the gut microbiome with Microbial Ecosystem Therapeutic 4 (MET4) in locoregionally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation (ROMA2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Guelph; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Interquartile range; Oncology; Gastroenterology","score_opus":0.04276970624319562,"score_gpt":0.34963139502683055,"score_spread":0.30686168878363496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171393216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925426,0.001387255,0.00006849654,0.0028129157,0.0005745201,0.00035848215,0.0000048090114,0.000004831243,0.002246072],"genre_scores_gemma":[0.9969811,0.00017100066,0.0014660759,0.00084217143,0.00035410674,0.000005662311,0.0000041905714,0.000020136358,0.00015557866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725443,0.0005048324,0.0015481474,0.00022531585,0.00027378608,0.0001935129],"domain_scores_gemma":[0.9963306,0.0014115305,0.0014577758,0.00017458959,0.0005340988,0.00009139404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010014392,0.00015111487,0.0013286145,0.00009683082,0.000046984675,0.000006285339,0.00012018191,0.00022882991,0.000017803748],"category_scores_gemma":[0.0003463764,0.00009563115,0.00028561117,0.00030855866,0.00013838572,0.00009928476,0.000053701475,0.00062900106,0.0000017079798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013424104,0.0037236372,0.781144,0.0009322124,0.00036308003,0.001191667,0.0012205921,0.0003811082,0.1736261,0.00017301802,0.00045063836,0.023369804],"study_design_scores_gemma":[0.01708959,0.0055321543,0.9687616,0.0003053333,0.00027461286,0.00078006426,0.00028274363,0.00005186944,0.0053939708,0.000098709694,0.0013224502,0.0001068504],"about_ca_topic_score_codex":0.000010316442,"about_ca_topic_score_gemma":0.0005305642,"teacher_disagreement_score":0.18761761,"about_ca_system_score_codex":0.0005971335,"about_ca_system_score_gemma":0.0038441913,"threshold_uncertainty_score":0.68194306},"labels":[],"label_agreement":null},{"id":"W3171410766","doi":"10.1200/jco.2021.39.15_suppl.e13551","title":"Determining the cancer diagnostic interval using administrative data in a cohort of patients with pancreatic ductal adenocarcinoma (PDAC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Coding and Health Information","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Manitoba; Queen's University; Ottawa Hospital; Alberta Health Services","funders":"","keywords":"Medicine; Cancer registry; Retrospective cohort study; Cancer; Cohort; Stage (stratigraphy); Population; Percentile; Internal medicine; Emergency medicine","score_opus":0.6426268908284004,"score_gpt":0.6269891530061406,"score_spread":0.015637737822259856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171410766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950958,0.00019946971,0.00032408186,0.0023257732,0.0012870607,0.00033549182,0.000035885452,0.0000026292573,0.00039379674],"genre_scores_gemma":[0.994911,0.00028096145,0.002113829,0.0020911957,0.00054509356,0.0000101576115,0.000020890095,0.000008671958,0.000018210974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938008,0.0019035505,0.0034243097,0.00016004918,0.00043171216,0.00027956153],"domain_scores_gemma":[0.97849613,0.016717544,0.003337982,0.0003231604,0.00089077884,0.00023438508],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0057749967,0.00009980193,0.0010030245,0.00006308089,0.0001416461,0.0000043319837,0.00037522317,0.0002672811,0.00024273242],"category_scores_gemma":[0.031748343,0.00005691423,0.00007190098,0.00017825046,0.00019057868,0.00022300801,0.00020810768,0.0017525179,0.000004010001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006298821,0.0003087304,0.9914236,0.00014166144,0.00008615999,0.00006377639,0.0010465364,0.000009829988,4.5182531e-7,0.000022584101,0.00054536917,0.0057213954],"study_design_scores_gemma":[0.0036563843,0.0017777147,0.9898084,0.001041806,0.00020580293,0.000009915333,0.0012138588,0.0009309308,0.0000011261897,0.000042101932,0.0012550445,0.000056920995],"about_ca_topic_score_codex":0.000115203955,"about_ca_topic_score_gemma":0.0008846493,"teacher_disagreement_score":0.025973344,"about_ca_system_score_codex":0.00020689823,"about_ca_system_score_gemma":0.0072934604,"threshold_uncertainty_score":0.9983343},"labels":[],"label_agreement":null},{"id":"W3171411687","doi":"10.1200/jco.2021.39.15_suppl.e16142","title":"Impact of lenvatinib (LEN) dose-intensity and starting dose on survival among patients with advanced hepatocellular carcinoma (HCC): Results from a Canadian multicenter database (HCC CHORD).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Ottawa Regional Cancer Foundation; Dalhousie University; University Health Network; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Nova Scotia Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Lenvatinib; Internal medicine; Adverse effect; Liver cancer; Liver disease; Proportional hazards model; Gastroenterology; Portal vein thrombosis; Milan criteria; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Oncology; Progressive disease; Sorafenib; Cirrhosis; Liver transplantation; Disease; Confidence interval; Transplantation","score_opus":0.11354363906530106,"score_gpt":0.3683170677907923,"score_spread":0.25477342872549125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171411687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971566,0.00023730154,0.000009723284,0.0008480711,0.00046251246,0.0004494039,0.00034904806,0.0000074085974,0.00047989786],"genre_scores_gemma":[0.9965907,0.00012591005,0.002156495,0.00042325462,0.0003181661,0.0000033821732,0.00030221327,0.000033530814,0.0000463606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568975,0.0006150907,0.0022640286,0.00046331965,0.00052238326,0.00044539978],"domain_scores_gemma":[0.9934411,0.0019054067,0.0017322327,0.00045572018,0.001301212,0.0011643094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015675761,0.00030142453,0.0019901202,0.0001793779,0.000079433295,0.000017492897,0.00012756676,0.00032897637,0.00009306668],"category_scores_gemma":[0.00424596,0.00020602782,0.00050231064,0.00019845854,0.00023251648,0.00021910892,0.00007206306,0.0009808519,0.0000057226166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021756066,0.0018442714,0.95652604,0.000026113743,0.000752356,0.004513993,0.00028331624,0.000005143954,0.00024341868,0.000002629711,0.00019878607,0.013847868],"study_design_scores_gemma":[0.031671047,0.012275422,0.95223695,0.00037100684,0.000658168,0.000017013299,0.0001376018,0.0013248275,0.0006352554,0.000011301931,0.00048510885,0.00017627567],"about_ca_topic_score_codex":0.022492865,"about_ca_topic_score_gemma":0.015692057,"teacher_disagreement_score":0.013671593,"about_ca_system_score_codex":0.0003233058,"about_ca_system_score_gemma":0.0024257984,"threshold_uncertainty_score":0.9840164},"labels":[],"label_agreement":null},{"id":"W3171413004","doi":"10.1200/jco.2021.39.15_suppl.7523","title":"Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chlorambucil; Medicine; Hazard ratio; Chronic lymphocytic leukemia; IGHV@; Internal medicine; Oncology; Neutropenia; Progression-free survival; Confidence interval; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.11741288571340827,"score_gpt":0.45220317969151624,"score_spread":0.334790293978108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171413004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969561,0.0002892175,0.000023499764,0.00072004466,0.00051178364,0.0013289669,0.000012708752,0.0000032033424,0.00015446033],"genre_scores_gemma":[0.99805063,0.0002817196,0.0005187102,0.00026819544,0.00035177823,0.000040551728,0.000007752737,0.000026124002,0.00045456248],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953807,0.0005620228,0.0025136769,0.00029193575,0.00088336354,0.00036828028],"domain_scores_gemma":[0.99102247,0.006126952,0.001116686,0.0005120238,0.0009731649,0.00024873333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002786774,0.00017081176,0.0018135177,0.0001832725,0.000030272638,0.0000062806184,0.00034031723,0.0002478517,0.000051386964],"category_scores_gemma":[0.005384056,0.00010218953,0.0003991086,0.0004830061,0.00015838441,0.00005292731,0.000103765946,0.0003937106,0.000004474926],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.18758927,0.029613368,0.27917254,0.0009505561,0.0056539173,0.0061949673,0.02096783,0.007845699,0.00011989244,0.00010073493,0.00798601,0.4538052],"study_design_scores_gemma":[0.48673815,0.27683833,0.19368033,0.00070487754,0.0012278482,0.00031616268,0.0033147093,0.0023992655,0.00032250074,0.00010497846,0.034137312,0.00021552466],"about_ca_topic_score_codex":0.00052709994,"about_ca_topic_score_gemma":0.003401738,"teacher_disagreement_score":0.45358968,"about_ca_system_score_codex":0.026925841,"about_ca_system_score_gemma":0.059456058,"threshold_uncertainty_score":0.9768096},"labels":[],"label_agreement":null},{"id":"W3171415456","doi":"10.1200/jco.2021.39.15_suppl.10565","title":"The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment, and overall survival in colorectal cancer patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Socioeconomic status; Colorectal cancer; Cohort; Cancer registry; Stage (stratigraphy); Oxaliplatin; Receipt; Cancer; Internal medicine; Oncology; Population; Environmental health","score_opus":0.05186494591028377,"score_gpt":0.43354820985728004,"score_spread":0.38168326394699625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171415456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969396,0.0010167861,0.000002616045,0.0005253171,0.0006607554,0.000184901,0.000051305466,0.000002064957,0.0006166382],"genre_scores_gemma":[0.9922318,0.007392986,0.000051125047,0.00004025308,0.00014033527,0.0000061115675,0.000006232234,0.000010178934,0.00012097084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743533,0.00051063026,0.0015809014,0.0001491772,0.00015424163,0.00016972156],"domain_scores_gemma":[0.98987097,0.007546328,0.0018668262,0.00010057131,0.00047476313,0.00014052636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009364607,0.000109182736,0.0009951645,0.000085198175,0.000028794371,0.0000039504657,0.000052464275,0.00012645814,0.00011819172],"category_scores_gemma":[0.0046553975,0.00007012358,0.0003366805,0.00008756575,0.00023805075,0.00006289749,0.00003737312,0.00030285143,5.180441e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021845363,0.00082187675,0.91885686,0.000020918265,0.00032251512,0.000016787637,0.00030684294,0.0002753149,0.00069519336,0.000007647154,0.00045578388,0.056374915],"study_design_scores_gemma":[0.008935109,0.034533255,0.9519923,0.000081447186,0.00013352341,0.000012276879,0.00015327193,0.00017486744,0.0028829314,0.00007685431,0.0009740618,0.000050122057],"about_ca_topic_score_codex":0.0019236883,"about_ca_topic_score_gemma":0.0029335606,"teacher_disagreement_score":0.056324795,"about_ca_system_score_codex":0.0009000563,"about_ca_system_score_gemma":0.0018983352,"threshold_uncertainty_score":0.55732816},"labels":[],"label_agreement":null},{"id":"W3171431515","doi":"10.1200/jco.2021.39.15_suppl.6010","title":"Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Surgery; Head and neck cancer; Swallowing; Randomized controlled trial; Randomization; Cancer; Radiation therapy; Internal medicine","score_opus":0.14670277360566758,"score_gpt":0.5476167240429163,"score_spread":0.4009139504372487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171431515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97890604,0.0038402516,0.000015207236,0.011560967,0.0025016384,0.0025917196,0.00009632555,0.0000051417132,0.0004826871],"genre_scores_gemma":[0.96431285,0.033315405,0.00024838833,0.00020356641,0.0007378577,0.00018973225,0.000010600434,0.000029306046,0.0009522979],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9856681,0.0059196656,0.0060641053,0.00043009364,0.0014583904,0.00045961104],"domain_scores_gemma":[0.9883406,0.00525173,0.0026325819,0.00039488764,0.0031238082,0.00025637491],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017324263,0.00024613502,0.0060330313,0.0002312626,0.00011942092,0.000006967035,0.00027736125,0.0004795447,0.00066953624],"category_scores_gemma":[0.00995553,0.00013630753,0.0011772692,0.001097794,0.0010649335,0.00015854056,0.000103605846,0.0018539152,1.6698347e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92749906,0.009245689,0.00016920172,0.00007626353,0.0010944862,0.0015047818,0.0007248369,0.00003243801,0.02158246,0.000015309046,0.0037665733,0.034288913],"study_design_scores_gemma":[0.8449448,0.11509763,0.000096642114,0.0007100202,0.00025181868,0.00010890468,0.00036354887,0.000043128886,0.015943082,0.00004640715,0.022287754,0.00010626657],"about_ca_topic_score_codex":0.0009792908,"about_ca_topic_score_gemma":0.0044714864,"teacher_disagreement_score":0.10585194,"about_ca_system_score_codex":0.00045692534,"about_ca_system_score_gemma":0.012466173,"threshold_uncertainty_score":0.99838406},"labels":[],"label_agreement":null},{"id":"W3171441932","doi":"10.1200/jco.2021.39.15_suppl.5005","title":"A prospective validation of the genomic classifier to define high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Prospective cohort study; Oncology; Prostate cancer; DECIPHER; Metastasis; Cohort; Classifier (UML); Biopsy; Internal medicine; Cancer; Artificial intelligence; Bioinformatics; Biology; Computer science","score_opus":0.06911415077130584,"score_gpt":0.43875848641769244,"score_spread":0.3696443356463866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171441932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343044,0.00026561235,0.000023179762,0.0047728755,0.00013453157,0.0010146176,0.000056434365,0.000002667819,0.00029963074],"genre_scores_gemma":[0.9973554,0.0009083538,0.0012304623,0.00010252766,0.000099568846,0.000050305094,0.0000023203022,0.000016949465,0.00023408169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962953,0.0010969798,0.0015788327,0.00024258213,0.0005505503,0.00023579532],"domain_scores_gemma":[0.9958635,0.0007892601,0.0018572937,0.00026020425,0.0010202853,0.00020947901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021606816,0.00013457178,0.0015924987,0.00016716425,0.000032778276,0.0000069331563,0.00015885523,0.00007909786,0.000048240647],"category_scores_gemma":[0.001151953,0.00007083037,0.00022053957,0.0009343816,0.00041447426,0.00005481191,0.00009233182,0.00071734947,0.0000011329391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026781831,0.0029034584,0.9359872,0.000027238959,0.0010621154,0.00022624216,0.0020660553,0.00015262405,0.00074899447,0.000011620565,0.00020471118,0.029827928],"study_design_scores_gemma":[0.017749647,0.025361076,0.9485733,0.00013086142,0.00069528533,0.00002328424,0.0023717298,0.000013710855,0.0041094623,0.0001283886,0.00077453227,0.00006872964],"about_ca_topic_score_codex":0.001957049,"about_ca_topic_score_gemma":0.0020764268,"teacher_disagreement_score":0.029759198,"about_ca_system_score_codex":0.00044518462,"about_ca_system_score_gemma":0.0036506124,"threshold_uncertainty_score":0.647603},"labels":[],"label_agreement":null},{"id":"W3171449955","doi":"10.1200/jco.2021.39.15_suppl.2597","title":"Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Fundación BBVA","keywords":"Medicine; Internal medicine; Clinical endpoint; Clinical trial; Adverse effect; Cancer; Oncology; Gastroenterology; Surrogate endpoint; Biomarker","score_opus":0.1917864217343856,"score_gpt":0.5045492575025499,"score_spread":0.31276283576816427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171449955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943265,0.00067278446,0.0000060454668,0.0032777295,0.0005704776,0.00065284816,0.0000031356817,0.0000047879107,0.0004857141],"genre_scores_gemma":[0.99770314,0.0002814055,0.0009916903,0.0005794909,0.00034545295,0.000029328912,0.0000045365996,0.000021035303,0.000043947934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9832203,0.006392485,0.009082015,0.0002746747,0.00074862555,0.0002819192],"domain_scores_gemma":[0.98230773,0.010663173,0.004916596,0.00029629492,0.0016026921,0.00021349931],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029556973,0.00016924825,0.0031941142,0.00019746932,0.000041746665,0.000013035178,0.00021403535,0.00027145565,0.00011849676],"category_scores_gemma":[0.042161096,0.00009965276,0.0008382784,0.0007116016,0.00029698844,0.00009909905,0.00007573668,0.0018820554,0.0000038738754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010504208,0.010452754,0.9038054,0.000023491875,0.00038168958,0.00011768847,0.00031457195,0.00004819218,0.0011402037,0.000102728474,0.00008011987,0.07302896],"study_design_scores_gemma":[0.048653424,0.0330156,0.9127675,0.0006042674,0.00041881637,0.000029916891,0.0005900827,0.00037728497,0.00253782,0.00029812136,0.000603891,0.00010324902],"about_ca_topic_score_codex":0.00009062565,"about_ca_topic_score_gemma":0.00018141612,"teacher_disagreement_score":0.07292571,"about_ca_system_score_codex":0.00020406659,"about_ca_system_score_gemma":0.0038280305,"threshold_uncertainty_score":0.9992753},"labels":[],"label_agreement":null},{"id":"W3171453021","doi":"10.1200/jco.2021.39.15_suppl.e21123","title":"Sequencing of systemic therapies in advanced NSCLC with <i>MET</i> exon 14 skipping mutation: A multicenter experience.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Population; non-small cell lung cancer (NSCLC); Cancer; Adenocarcinoma","score_opus":0.07604376916599374,"score_gpt":0.47834963173901063,"score_spread":0.40230586257301687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171453021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948798,0.0020783227,0.0005398721,0.000852529,0.0004917771,0.00016608855,0.0000012734226,0.0000043843033,0.0009859824],"genre_scores_gemma":[0.98589635,0.00060314377,0.012487726,0.0007356847,0.0001741664,0.000010959806,0.0000019827644,0.000009554227,0.00008044378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787444,0.00020165456,0.0014265841,0.0001372575,0.00023070179,0.0001293584],"domain_scores_gemma":[0.99749106,0.00072197313,0.0010252617,0.00012067426,0.00053298956,0.00010805304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055848056,0.000084014784,0.00085358834,0.0000856404,0.000018575862,0.0000049922655,0.00005529148,0.000111492845,0.000049076654],"category_scores_gemma":[0.00071832753,0.000056294633,0.00016281336,0.00018789907,0.000099472054,0.0001749166,0.000013586654,0.0003072106,0.0000012908982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008900369,0.0032590486,0.54390246,0.00034815085,0.0019019404,0.014504836,0.052410424,0.0016444549,0.024348652,0.00026055978,0.00007406285,0.3484451],"study_design_scores_gemma":[0.10740755,0.030613156,0.6516635,0.011129445,0.0020478298,0.010367386,0.16920348,0.000385004,0.0066647166,0.00024880757,0.009805333,0.00046384125],"about_ca_topic_score_codex":0.000017672523,"about_ca_topic_score_gemma":0.000056529778,"teacher_disagreement_score":0.34798124,"about_ca_system_score_codex":0.00027940696,"about_ca_system_score_gemma":0.002014795,"threshold_uncertainty_score":0.357416},"labels":[],"label_agreement":null},{"id":"W3171490265","doi":"10.1200/jco.2021.39.15_suppl.tps9590","title":"NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Melanoma; Nivolumab; Immunotherapy; Oncology; CD8; Ipilimumab; Internal medicine; Blockade; Cancer; Cancer research; Immunology; Immune system; Receptor","score_opus":0.08066561788258836,"score_gpt":0.45148595488321247,"score_spread":0.3708203370006241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171490265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960302,0.00038721957,0.000030065758,0.0010085156,0.0006878192,0.0006027368,0.000009540485,0.000007247379,0.0012366284],"genre_scores_gemma":[0.9953799,0.00006738977,0.0034379466,0.00053667085,0.0001572486,0.000009309518,0.000014497177,0.00002744235,0.00036954644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99444485,0.0012185215,0.0030292303,0.00034514576,0.0006172536,0.00034498627],"domain_scores_gemma":[0.99495137,0.001396842,0.0021005436,0.0003629036,0.00081134273,0.00037697767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001859115,0.00024360484,0.0028475353,0.00024927297,0.000074213094,0.0000047821586,0.000175574,0.00035753788,0.00031664985],"category_scores_gemma":[0.0019985414,0.0001650384,0.00040242833,0.0003844338,0.000247636,0.00015100258,0.00012278782,0.0012494891,0.000018117826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030692449,0.1007743,0.79247344,0.000042192427,0.0032424007,0.013558552,0.00080025557,0.000030632287,0.000011653579,0.00003160135,0.0003648594,0.057977676],"study_design_scores_gemma":[0.20441622,0.23622395,0.55250335,0.00014964015,0.0025414221,0.00036520427,0.00084692176,0.000049790044,0.000027979257,0.00011988535,0.002623188,0.00013246409],"about_ca_topic_score_codex":0.00004321053,"about_ca_topic_score_gemma":0.00042954372,"teacher_disagreement_score":0.23997009,"about_ca_system_score_codex":0.00036228474,"about_ca_system_score_gemma":0.0031255234,"threshold_uncertainty_score":0.673007},"labels":[],"label_agreement":null},{"id":"W3171495697","doi":"10.1200/jco.2021.39.15_suppl.2592","title":"A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Cancer; Oncology; Tolerability; Phases of clinical research; Gastroenterology; Chemotherapy; Immunotherapy; Adverse effect","score_opus":0.06703042630878267,"score_gpt":0.4407346407945011,"score_spread":0.37370421448571844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171495697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584347,0.00053690746,0.00009879299,0.0025163407,0.00015852992,0.00073113415,0.000002302856,0.0000045038396,0.00010798904],"genre_scores_gemma":[0.9951556,0.00094960205,0.0019058993,0.0018027882,0.00006402317,0.000022376467,0.0000029166993,0.000023788267,0.000073061026],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99604714,0.00072110695,0.0021918651,0.00029312735,0.00047182344,0.00027496525],"domain_scores_gemma":[0.99644816,0.0012581985,0.0011768347,0.00021294282,0.0006780529,0.0002258206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001999058,0.00019869737,0.0018273789,0.00033400787,0.000024563415,0.0000129008,0.0001227307,0.00012311601,0.0000639994],"category_scores_gemma":[0.0014434194,0.00012116475,0.00009020076,0.0007913591,0.00017583983,0.00020642315,0.0000326107,0.00087580696,4.7272334e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7219125,0.039048173,0.042699814,0.00012369038,0.00072267436,0.010320727,0.0028495782,0.00014914744,0.0048240838,0.000009978957,0.00014670486,0.17719294],"study_design_scores_gemma":[0.36294022,0.40478185,0.2155403,0.0014657517,0.00022875024,0.0017714491,0.009914125,0.00017667832,0.0020290373,0.000056596546,0.0008424725,0.000252781],"about_ca_topic_score_codex":0.00024591415,"about_ca_topic_score_gemma":0.010644714,"teacher_disagreement_score":0.36573365,"about_ca_system_score_codex":0.00023496206,"about_ca_system_score_gemma":0.0032938442,"threshold_uncertainty_score":0.59400004},"labels":[],"label_agreement":null},{"id":"W3171509414","doi":"10.1200/jco.2021.39.15_suppl.9501","title":"Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Ipilimumab; Pembrolizumab; Internal medicine; Melanoma; Adjuvant; Randomized controlled trial; Surgery; Lymph node; Oncology; Gastroenterology; Immunotherapy; Cancer","score_opus":0.07201326935886022,"score_gpt":0.40374774333367636,"score_spread":0.33173447397481615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171509414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575585,0.00018638652,0.00014413874,0.0016925787,0.001163924,0.00085548084,0.00001812921,0.0000055163487,0.00017800568],"genre_scores_gemma":[0.9981418,0.00040241942,0.00049760146,0.00049111806,0.00031710922,0.000018275532,0.000024034853,0.000021542279,0.00008608432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905942,0.003976496,0.004006257,0.00037834558,0.0007235918,0.00032112648],"domain_scores_gemma":[0.9902632,0.0064491946,0.0021537938,0.00049072376,0.00044576608,0.00019728279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008608944,0.00026601716,0.0044666394,0.0005933733,0.00003995914,0.000025732368,0.00038484315,0.0003220354,0.00030845831],"category_scores_gemma":[0.005223353,0.00014547269,0.0006787547,0.0010029378,0.0003350863,0.0001257186,0.00014783598,0.0012838473,7.700096e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91760534,0.005115928,0.059957314,0.000020835994,0.00417987,0.00034974795,0.0007984579,0.00006518973,0.00006610864,0.000039027716,0.00020018156,0.011601991],"study_design_scores_gemma":[0.6531644,0.02670172,0.31712133,0.00018890262,0.0019314961,0.000012330468,0.00028503343,0.00021392827,0.00001799755,0.000047019068,0.00020362284,0.000112218324],"about_ca_topic_score_codex":0.0011948367,"about_ca_topic_score_gemma":0.011303499,"teacher_disagreement_score":0.26444092,"about_ca_system_score_codex":0.00027355488,"about_ca_system_score_gemma":0.00085774506,"threshold_uncertainty_score":0.6307618},"labels":[],"label_agreement":null},{"id":"W3171523520","doi":"10.1200/jco.2021.39.15_suppl.e16219","title":"Pancreatic cancer outcomes in Nova Scotia: Searching for small windows of opportunity.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Internal medicine; Charlson comorbidity index; Referral; Pancreatic cancer; Cancer; Stage (stratigraphy); Multivariate analysis; Proportional hazards model; Nova scotia; Chemotherapy; Surgery; Retrospective cohort study","score_opus":0.3138590354827412,"score_gpt":0.4491416868811709,"score_spread":0.1352826513984297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171523520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976919,0.002593486,0.0016054362,0.00647067,0.0023173192,0.00016696683,0.00008735687,0.0000025251925,0.009837227],"genre_scores_gemma":[0.9896913,0.0017800702,0.0050850627,0.0021078493,0.0005644901,0.0000043899254,0.0000021527796,0.000019985186,0.00074468186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561393,0.0000857593,0.003756193,0.00021272896,0.00003949972,0.0002918977],"domain_scores_gemma":[0.99419945,0.0020400838,0.0030665407,0.00018736674,0.00026226725,0.0002443074],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043391143,0.00012243575,0.0022992154,0.00021137366,0.000021032854,0.000015236365,0.0002638728,0.0002945055,0.0004702241],"category_scores_gemma":[0.009298461,0.00011910097,0.0005745507,0.00013188095,0.00012510513,0.0002145894,0.00006198151,0.0005871287,0.000015092013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003939186,0.00066564465,0.9399645,0.00006233745,0.00028547726,0.00006141045,0.00013968983,0.0002684402,0.000014252631,0.014604418,0.00083960424,0.04270031],"study_design_scores_gemma":[0.006542815,0.0017015244,0.9000614,0.00012397794,0.000061286504,0.000022719365,0.0001532287,0.00028032248,0.00008589478,0.03258471,0.058167055,0.00021502175],"about_ca_topic_score_codex":0.00083877257,"about_ca_topic_score_gemma":0.003931305,"teacher_disagreement_score":0.05732745,"about_ca_system_score_codex":0.00020134488,"about_ca_system_score_gemma":0.001842989,"threshold_uncertainty_score":0.9990466},"labels":[],"label_agreement":null},{"id":"W3171525383","doi":"10.1200/jco.2021.39.15_suppl.e19518","title":"Outcomes after initial refusal of curative treatment in patients with Hodgkin’s lymphoma in British Columbia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; ABVD; Cohort; Stage (stratigraphy); Internal medicine; Cancer; Log-rank test; Radiation therapy; B symptoms; Surgery; Statistical significance; Survival analysis; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.05185446579312523,"score_gpt":0.41581073256228457,"score_spread":0.3639562667691593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171525383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973228,0.00021931175,8.029213e-7,0.0011415104,0.00036950453,0.0002514522,0.000021228874,0.000002229386,0.0006711566],"genre_scores_gemma":[0.9974956,0.0002699311,0.0010124289,0.00091008516,0.000106399275,0.00002512981,0.000009749164,0.00001209013,0.00015859188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685043,0.0004115082,0.0019994788,0.00020580558,0.00033125756,0.00020152617],"domain_scores_gemma":[0.99718183,0.0011890589,0.0008550463,0.0001475585,0.0004336513,0.00019284835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045325718,0.00011389361,0.0018156229,0.00007662316,0.0000118670205,0.0000151627,0.000055201413,0.0002415851,0.00023134865],"category_scores_gemma":[0.0008956199,0.00009928175,0.00031564967,0.00016836544,0.00014165803,0.000101476384,0.00003332093,0.00017613289,0.0000036224149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027886052,0.018127516,0.8111665,0.000009238875,0.0003547178,0.009827932,0.00011290233,0.0000011919901,4.4943636e-7,0.0000024214662,0.00015802294,0.15745048],"study_design_scores_gemma":[0.06051434,0.018316664,0.91774696,0.00027305383,0.00022485109,0.00016859522,0.00013437423,0.0000015906237,0.00001640194,0.00004788479,0.0024787576,0.0000765389],"about_ca_topic_score_codex":0.002140914,"about_ca_topic_score_gemma":0.06958701,"teacher_disagreement_score":0.15737393,"about_ca_system_score_codex":0.0007149415,"about_ca_system_score_gemma":0.0024353222,"threshold_uncertainty_score":0.9473906},"labels":[],"label_agreement":null},{"id":"W3171658130","doi":"10.1200/jco.2021.39.15_suppl.e14026","title":"Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; PARP inhibitor; Medicine; Glioma; Isocitrate dehydrogenase; Cancer research; Durvalumab; Cancer; Oncology; Internal medicine; Poly ADP ribose polymerase; Immunotherapy; Biology; Nivolumab; Polymerase","score_opus":0.07358273245928833,"score_gpt":0.4347585393750165,"score_spread":0.3611758069157282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171658130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917699,0.00041871093,0.000048564016,0.006519825,0.0006857107,0.00026491506,0.0000065889494,0.000004430147,0.00028136317],"genre_scores_gemma":[0.9964737,0.00031778403,0.0024060963,0.00057279546,0.0001614572,0.000009347764,0.000028344568,0.000010332901,0.000020115978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827504,0.00016519487,0.0010405981,0.00014792218,0.00024075333,0.00013046924],"domain_scores_gemma":[0.9962845,0.0013349267,0.0008232016,0.00009305575,0.0012263353,0.00023799314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074402615,0.00009127796,0.00082390796,0.00007275646,0.000038335973,0.0000105969375,0.00003452405,0.00016394624,0.00002935653],"category_scores_gemma":[0.002312805,0.000057846788,0.00018116835,0.0001143764,0.00007590648,0.000064597865,0.000021109421,0.00025057668,0.0000021181897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061947913,0.017105201,0.62635064,0.00005974966,0.00092987204,0.0007010741,0.00008011278,0.00000232233,0.0000666377,0.0004981271,0.0041607562,0.3438507],"study_design_scores_gemma":[0.04891872,0.03244052,0.89577186,0.00014553456,0.0007942008,0.0001647753,0.000050898678,0.000076738805,0.0002964017,0.00052115315,0.020748476,0.000070689566],"about_ca_topic_score_codex":0.0000016378987,"about_ca_topic_score_gemma":0.000015244322,"teacher_disagreement_score":0.34378,"about_ca_system_score_codex":0.000093571296,"about_ca_system_score_gemma":0.00059381383,"threshold_uncertainty_score":0.27688107},"labels":[],"label_agreement":null},{"id":"W3171697095","doi":"10.1200/jco.2021.39.15_suppl.5543","title":"The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; BRCA mutation; Disease; Perioperative; Serous fluid; Stage (stratigraphy); Minimal residual disease; Ovarian cancer; Surgery; Cancer","score_opus":0.08983597700166294,"score_gpt":0.427390041657983,"score_spread":0.33755406465632004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171697095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633085,0.0019979253,0.000025430287,0.03270051,0.0014197428,0.00010861137,0.0000030262906,0.000003408643,0.0004328058],"genre_scores_gemma":[0.9936364,0.0035411753,0.00073146285,0.0002310592,0.001705339,0.000003266326,0.000007630866,0.000008695656,0.00013495883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975746,0.0005032191,0.0013351117,0.00016487156,0.00022659104,0.00019560134],"domain_scores_gemma":[0.9960437,0.0027257192,0.00062438723,0.00013134234,0.00020302134,0.00027185143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001527597,0.000088350986,0.0007870979,0.000053429514,0.000058582635,0.000016985983,0.000034380475,0.00026073074,0.000039794366],"category_scores_gemma":[0.00085507234,0.00005477942,0.00016393172,0.00014623669,0.00012654372,0.00006958094,0.000029553657,0.0007040254,0.0000038076414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067136384,0.0005841951,0.86013615,0.0000063783427,0.00017530411,0.001865248,0.00006619706,0.000014451702,0.000003368956,0.0007429376,0.00051545806,0.13521896],"study_design_scores_gemma":[0.00984575,0.002752921,0.91901547,0.00004109333,0.0003083919,0.0007556876,0.00012444198,0.000028057697,0.000026872684,0.00076868274,0.066287905,0.00004470959],"about_ca_topic_score_codex":0.00013694422,"about_ca_topic_score_gemma":0.00016981013,"teacher_disagreement_score":0.13517426,"about_ca_system_score_codex":0.00028921288,"about_ca_system_score_gemma":0.0014056388,"threshold_uncertainty_score":0.3058679},"labels":[],"label_agreement":null},{"id":"W3171740981","doi":"10.1200/jco.2021.39.15_suppl.e24080","title":"A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Diphenhydramine; Cetirizine; Premedication; Placebo; Anesthesia; Adverse effect; Randomized controlled trial; Sedative; Paclitaxel; Context (archaeology); Chemotherapy; Internal medicine","score_opus":0.26571369849716064,"score_gpt":0.5104193089121388,"score_spread":0.24470561041497818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171740981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885959,0.00044290334,0.000014975151,0.0055905697,0.00053069653,0.001067211,8.2472127e-7,0.0000065053573,0.003750403],"genre_scores_gemma":[0.9981874,0.00042791673,0.00018198494,0.00030516807,0.00021108829,0.00003184341,0.000013872157,0.000011078681,0.0006296505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936845,0.0025384033,0.0030494903,0.0001704519,0.00038576854,0.00017142217],"domain_scores_gemma":[0.9917956,0.004813795,0.0025017601,0.000173086,0.0006003973,0.000115390554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007721944,0.00013950503,0.0024079524,0.00016373684,0.000040589148,0.000007167945,0.00011505954,0.00015552854,0.00023039749],"category_scores_gemma":[0.001937067,0.000076749995,0.00035065025,0.00053663517,0.0002186552,0.00008152822,0.000039566745,0.001078811,0.0000028579987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8440217,0.05124388,0.09626301,0.000026968679,0.0028083473,0.0009978568,0.0007986976,0.00009487294,0.000739649,0.000068285924,0.00039593302,0.0025408238],"study_design_scores_gemma":[0.7988165,0.049827658,0.1461828,0.00020136073,0.00270585,0.0003011988,0.0006990971,0.00008889788,0.000075356395,0.00024205445,0.0007908839,0.00006836163],"about_ca_topic_score_codex":0.00017415658,"about_ca_topic_score_gemma":0.0013989706,"teacher_disagreement_score":0.0499198,"about_ca_system_score_codex":0.00015139021,"about_ca_system_score_gemma":0.0011976627,"threshold_uncertainty_score":0.4686957},"labels":[],"label_agreement":null},{"id":"W3171741649","doi":"10.1200/jco.2021.39.15_suppl.e18011","title":"Circulating tumor cells demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Circulating tumor cell; Population; Cancer; Oncology; Liquid biopsy; Biomarker; Internal medicine; Head and neck cancer; Pathology; Environmental health; Metastasis; Biology","score_opus":0.08481939387255207,"score_gpt":0.40655492720009645,"score_spread":0.3217355333275444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171741649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584144,0.0017736484,0.000013953964,0.00069688744,0.00038002935,0.0001475601,0.00000797374,0.0000017774147,0.001136728],"genre_scores_gemma":[0.99563056,0.00012929416,0.0036213,0.00046870898,0.000116256204,0.0000011875051,0.0000038979542,0.000011755983,0.000017031325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660033,0.0006484632,0.0021527437,0.00019998856,0.00019139801,0.00020707367],"domain_scores_gemma":[0.9963517,0.0019569139,0.0011540004,0.00010584044,0.00023852168,0.00019302964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002241017,0.00011454416,0.0012412275,0.00019205379,0.00002092358,0.000006842577,0.0000458494,0.0001932651,0.000052340067],"category_scores_gemma":[0.0012830499,0.000100732075,0.00022764887,0.000271638,0.00009751988,0.00008176549,0.000039873838,0.00077282515,8.4157216e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001514445,0.00091016607,0.9132416,0.00010710328,0.000032809876,0.004865636,0.00022039042,0.00002720603,0.028293326,0.000011764744,0.00003728752,0.050738253],"study_design_scores_gemma":[0.010234028,0.0015047999,0.98057675,0.0002571718,0.00016622305,0.0006817111,0.0005127938,0.0002107196,0.0054841256,0.00005003745,0.00023605445,0.00008555805],"about_ca_topic_score_codex":0.0005154261,"about_ca_topic_score_gemma":0.00092570164,"teacher_disagreement_score":0.067335166,"about_ca_system_score_codex":0.00016137904,"about_ca_system_score_gemma":0.00100078,"threshold_uncertainty_score":0.4107735},"labels":[],"label_agreement":null},{"id":"W3171749475","doi":"10.1200/jco.2021.39.15_suppl.e13618","title":"Virtual health in cancer care: Results from a semi-structured interview-survey of oncology health care providers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Family medicine; Health care; Descriptive statistics; Workflow; Nursing; Oncology","score_opus":0.22870017298630516,"score_gpt":0.5592912901480239,"score_spread":0.33059111716171874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171749475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80317503,0.01733604,0.00020798999,0.1738658,0.0038506887,0.00073395885,0.0005600063,0.000011764974,0.00025872455],"genre_scores_gemma":[0.9492055,0.0067131706,0.0036749127,0.03876902,0.0011312363,0.000007900878,0.0004480817,0.000022514347,0.000027666296],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9877497,0.0040146396,0.0069478173,0.00037951142,0.0004609499,0.00044736892],"domain_scores_gemma":[0.9884977,0.0034653505,0.005553435,0.00029614443,0.0015237648,0.00066365086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061084693,0.00018879729,0.0031996514,0.00021566839,0.000043982236,0.000004407826,0.00017517644,0.0004113897,0.0001535109],"category_scores_gemma":[0.007887058,0.00014904837,0.00027223752,0.00043608737,0.00015777432,0.00008888663,0.000081867714,0.0015989876,0.0000019234253],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058723423,0.00062530447,0.094519325,0.00024396749,0.00019822492,0.00028028854,0.010080034,0.000015191852,0.000023201674,0.000007995459,0.034016527,0.8541176],"study_design_scores_gemma":[0.026451144,0.03463202,0.7616231,0.0005554499,0.000095879004,0.00011779656,0.012745776,0.000015547352,0.00007147759,0.000037058202,0.16356286,0.00009187013],"about_ca_topic_score_codex":0.01831992,"about_ca_topic_score_gemma":0.14153326,"teacher_disagreement_score":0.8540257,"about_ca_system_score_codex":0.0017011226,"about_ca_system_score_gemma":0.0363115,"threshold_uncertainty_score":0.9882172},"labels":[],"label_agreement":null},{"id":"W3171766889","doi":"10.1200/jco.2021.39.15_suppl.4564","title":"Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"SABR volatility model; Medicine; Radiation therapy; Systemic therapy; Internal medicine; Oncology; Cancer; Surgery; Breast cancer","score_opus":0.17402539456067206,"score_gpt":0.5261665231081906,"score_spread":0.3521411285475185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171766889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98339134,0.001667692,0.0001337625,0.010377802,0.0025350444,0.0006535106,0.000028724335,0.000004097886,0.0012079937],"genre_scores_gemma":[0.99130225,0.0010365747,0.0033794018,0.0012206743,0.0023698127,0.000030974923,0.000016181422,0.00001688616,0.000627272],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99649024,0.00042507926,0.0023639202,0.00018708777,0.0003460122,0.00018768391],"domain_scores_gemma":[0.9923947,0.0024931445,0.0032148312,0.00017858457,0.001240791,0.00047798493],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001484842,0.00013053321,0.0016589811,0.00009168181,0.000043782973,0.000004846633,0.00008264873,0.0002883353,0.00019965506],"category_scores_gemma":[0.009022164,0.00009296779,0.00078361563,0.00013879483,0.00013482808,0.00009928721,0.00003496833,0.00046333123,0.0000021018711],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38520613,0.026665902,0.0049919826,0.00014461766,0.0041785426,0.0017581023,0.00063816353,0.000012247671,0.0026858929,0.0001510611,0.011426031,0.5621413],"study_design_scores_gemma":[0.5871262,0.27261388,0.008944952,0.0003100995,0.0036211703,0.0003981036,0.00018262124,0.000198571,0.022174865,0.00052103656,0.10376596,0.00014255187],"about_ca_topic_score_codex":0.000010680969,"about_ca_topic_score_gemma":0.000007639542,"teacher_disagreement_score":0.5619988,"about_ca_system_score_codex":0.00032016827,"about_ca_system_score_gemma":0.0059355064,"threshold_uncertainty_score":0.9996999},"labels":[],"label_agreement":null},{"id":"W3171789324","doi":"10.1200/jco.2021.39.15_suppl.e24011","title":"A 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) in older adults with cancer: Development and construct validation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Geriatric oncology; Gerontology; Construct validity; Mood; Comorbidity; Geriatrics; Activities of daily living; Cognition; Geriatric Depression Scale; Psychometrics; Cancer; Physical therapy; Clinical psychology; Internal medicine; Psychiatry; Depressive symptoms","score_opus":0.07599751939733715,"score_gpt":0.42865939537662023,"score_spread":0.3526618759792831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171789324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875962,0.00035254407,0.0003432241,0.008221582,0.00049585494,0.00040391885,0.000007507724,0.000011230965,0.0025679348],"genre_scores_gemma":[0.97184324,0.00020510842,0.023483638,0.0030490006,0.00038168338,0.000025124875,0.00001742587,0.000024442303,0.00097033445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588597,0.0006456301,0.0021655823,0.00037293788,0.00064409577,0.00028576216],"domain_scores_gemma":[0.9926499,0.0041350364,0.0013784615,0.00022455664,0.0012083993,0.00040361076],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011775319,0.00022615308,0.0015131733,0.00025428153,0.000047159072,0.000020183408,0.00011410201,0.00036900502,0.0018798674],"category_scores_gemma":[0.0018354262,0.00016676201,0.0001522665,0.0003655953,0.00019802312,0.000093535185,0.000058426136,0.0011228287,0.000013077457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0121376235,0.0033899655,0.5204999,0.00028848124,0.0005281206,0.0045213983,0.00041825278,0.00051440456,0.00003889177,0.00001999132,0.006625678,0.45101732],"study_design_scores_gemma":[0.033831645,0.005648011,0.9000337,0.001293537,0.00017674494,0.00057088555,0.00042230604,0.0015134179,0.00018144505,0.000013304074,0.05612577,0.00018922616],"about_ca_topic_score_codex":0.00002764,"about_ca_topic_score_gemma":0.00019835778,"teacher_disagreement_score":0.4508281,"about_ca_system_score_codex":0.000498915,"about_ca_system_score_gemma":0.008642122,"threshold_uncertainty_score":0.99903256},"labels":[],"label_agreement":null},{"id":"W3171802215","doi":"10.1200/jco.2021.39.15_suppl.e21570","title":"Recurrent disease in patients with stage III melanoma in the era of adjuvant immune and targeted therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Niagara Health System; McMaster University","funders":"","keywords":"Medicine; Melanoma; Adjuvant therapy; Surgery; Stage (stratigraphy); Sentinel lymph node; Dissection (medical); Cancer; Adjuvant; Lymph node; Biopsy; Internal medicine; Breast cancer","score_opus":0.03970168503262259,"score_gpt":0.36899382873809117,"score_spread":0.32929214370546855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171802215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937907,0.0015514526,0.000011908456,0.0037391677,0.00035972937,0.00024285882,0.000002608933,0.0000016911494,0.00029992653],"genre_scores_gemma":[0.99734366,0.0013645502,0.00019346745,0.0009166658,0.000077839315,0.000002738125,0.0000036414272,0.000005848898,0.00009161045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978236,0.0004451886,0.0012399247,0.00011387585,0.00026632907,0.00011111322],"domain_scores_gemma":[0.99839544,0.0005020515,0.000654651,0.0001493849,0.00017928136,0.00011918449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012683261,0.00007786947,0.0007097607,0.00007757243,0.0000129448445,0.000004414221,0.00007115771,0.00007417967,0.00010531281],"category_scores_gemma":[0.00063815917,0.000042412234,0.00011733324,0.00015623317,0.000072333234,0.000033851386,0.000032087173,0.0006441584,8.564544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023071207,0.0052203587,0.722246,0.000038158872,0.0001676808,0.0025776897,0.000424142,0.000017762095,0.0000471018,0.000054088538,0.0001953876,0.24594046],"study_design_scores_gemma":[0.014224251,0.008658076,0.9596004,0.00011576802,0.00006474056,0.00003607921,0.0003139657,0.000041950858,0.000019908744,0.00003807978,0.016842812,0.00004399595],"about_ca_topic_score_codex":0.000019545058,"about_ca_topic_score_gemma":0.000109181,"teacher_disagreement_score":0.24589646,"about_ca_system_score_codex":0.00004788374,"about_ca_system_score_gemma":0.00041029908,"threshold_uncertainty_score":0.27985835},"labels":[],"label_agreement":null},{"id":"W3171809046","doi":"10.1200/jco.2021.39.15_suppl.10025","title":"Household material hardship and parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health","keywords":"Medicine; Psychosocial; Distress; Pediatric cancer; Quality of life (healthcare); Clinical trial; Poverty; Pediatrics; Cancer; Internal medicine; Psychiatry; Clinical psychology","score_opus":0.16997147793042652,"score_gpt":0.48137965873869043,"score_spread":0.31140818080826393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171809046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986623,0.0003143863,0.00009915427,0.0040017515,0.008246742,0.0005156946,0.0001272388,0.000013598193,0.00005846445],"genre_scores_gemma":[0.97971296,0.0015188445,0.0027523781,0.0033147002,0.012548932,0.000015855137,0.00002458944,0.000035805366,0.00007593707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920843,0.0012467882,0.005371381,0.0004449605,0.00047078237,0.00038178902],"domain_scores_gemma":[0.9892381,0.0075135906,0.002061238,0.00023541837,0.0003049905,0.0006466759],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062434776,0.0002214261,0.0026241464,0.00012411403,0.00004061378,0.00003610307,0.00019264081,0.0006722569,0.000056838635],"category_scores_gemma":[0.0142625915,0.00017991125,0.0008741377,0.0001424341,0.00023929216,0.00013293012,0.00014805247,0.001011721,0.000004363383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38283536,0.0068352846,0.57610005,0.00030554237,0.00081720954,0.0023499355,0.00024766944,0.000007864188,0.000051836163,0.000040357445,0.008723287,0.021685611],"study_design_scores_gemma":[0.32936907,0.017109679,0.63990813,0.00020506777,0.0016485117,0.0005548365,0.00023710026,0.00013051048,0.00005011392,0.00018378727,0.010376839,0.00022636702],"about_ca_topic_score_codex":0.00002969167,"about_ca_topic_score_gemma":0.00016739451,"teacher_disagreement_score":0.06380807,"about_ca_system_score_codex":0.0003088183,"about_ca_system_score_gemma":0.003357944,"threshold_uncertainty_score":0.99404067},"labels":[],"label_agreement":null},{"id":"W3171896314","doi":"10.1200/jco.2021.39.15_suppl.10052","title":"Integration and feasibility of symptom burden assessment and early palliative care into an adolescent and young adult leukemia clinic.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Neurocognitive; Population; Family medicine; Outpatient clinic; Telehealth; Survivorship curve; Cancer; Health care; Telemedicine; Cognition; Psychiatry; Nursing; Internal medicine","score_opus":0.14184692969171103,"score_gpt":0.5199102241937501,"score_spread":0.37806329450203907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171896314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99145544,0.00198955,0.0002570101,0.0052478216,0.0005134037,0.00024461962,0.0000065049308,0.0000064368705,0.00027924526],"genre_scores_gemma":[0.9858076,0.0029084787,0.009341449,0.0011540684,0.00074076833,0.000001925769,0.0000057107245,0.000012558249,0.000027472286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540806,0.001152367,0.0025093239,0.00035021245,0.00043183807,0.00014820977],"domain_scores_gemma":[0.99474615,0.0014671711,0.001652905,0.00023701046,0.0014168998,0.00047986512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031844068,0.0001596396,0.0015776188,0.00006845141,0.00004921753,0.000021399712,0.000080812024,0.00038699736,0.000022846974],"category_scores_gemma":[0.00394729,0.000126674,0.00019173998,0.000089787056,0.00040571095,0.0001797205,0.000109418725,0.0011300866,3.9899396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014867721,0.00046053762,0.91832405,0.00027586194,0.0001687411,0.00008141534,0.00668703,7.0929013e-7,0.000332581,0.00010166893,0.00012405524,0.0719566],"study_design_scores_gemma":[0.0070040263,0.009585419,0.96956533,0.00069475744,0.0003762404,0.00008528709,0.011552415,0.00007459772,0.000109897395,0.000572794,0.00027438015,0.00010483989],"about_ca_topic_score_codex":0.00048733843,"about_ca_topic_score_gemma":0.0018809685,"teacher_disagreement_score":0.07185175,"about_ca_system_score_codex":0.00038496064,"about_ca_system_score_gemma":0.0026303963,"threshold_uncertainty_score":0.5165616},"labels":[],"label_agreement":null},{"id":"W3171910277","doi":"10.1200/jco.2021.39.15_suppl.tps1101","title":"SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Anastrozole; Oncology; Internal medicine; Breast cancer; Metastatic breast cancer; Cancer; Aromatase inhibitor; Estrogen receptor; Tamoxifen","score_opus":0.08469489683910919,"score_gpt":0.4701901440886904,"score_spread":0.38549524724958123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171910277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822991,0.0017004281,0.0052476227,0.0040234188,0.0012557573,0.003460454,0.0019234655,0.00003175268,0.0000580178],"genre_scores_gemma":[0.9786606,0.00095308997,0.018166333,0.0004834411,0.0007075601,0.00045812535,0.0001611315,0.000108687964,0.00030102386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941615,0.0005014726,0.003256836,0.0007146472,0.0006506214,0.00071494235],"domain_scores_gemma":[0.98501855,0.0058801505,0.0044274083,0.00046616947,0.0033529901,0.0008547122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005605218,0.00057196413,0.0042675333,0.00013670528,0.0001436469,0.0000178814,0.00026371793,0.00034018807,0.00005965226],"category_scores_gemma":[0.0016119491,0.00042048265,0.0010546837,0.00023666587,0.00047059523,0.0003510643,0.000048236998,0.000609352,0.0000012871988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6039305,0.006894081,0.030297799,0.000602596,0.003636068,0.00015946751,0.0012342263,0.0056346385,0.0005524847,0.000028230148,0.00015912452,0.3468708],"study_design_scores_gemma":[0.6832679,0.12141042,0.15637568,0.006972224,0.0069135865,0.00019155414,0.0050156303,0.004244287,0.004764929,0.00013946186,0.0097212605,0.0009830709],"about_ca_topic_score_codex":0.00005599745,"about_ca_topic_score_gemma":0.000495232,"teacher_disagreement_score":0.34588775,"about_ca_system_score_codex":0.0020248315,"about_ca_system_score_gemma":0.0058614514,"threshold_uncertainty_score":0.9998247},"labels":[],"label_agreement":null},{"id":"W3171912160","doi":"10.1200/jco.2021.39.15_suppl.9516","title":"Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Discontinuation; Ipilimumab; Internal medicine; Clinical endpoint; Incidence (geometry); Adverse effect; Safety profile; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Immunotherapy","score_opus":0.10085294632141979,"score_gpt":0.4533463520984132,"score_spread":0.3524934057769934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171912160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346895,0.0028722421,0.0005116828,0.00584876,0.002070425,0.00035506807,0.00004184846,0.0000102296635,0.0048207715],"genre_scores_gemma":[0.973555,0.0016172628,0.022478951,0.00065219303,0.0008545135,0.000004090144,0.000010520848,0.000030648258,0.0007968092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950897,0.00024963287,0.0037211063,0.00026153363,0.00039334426,0.0002846726],"domain_scores_gemma":[0.99251455,0.0022302181,0.0035251507,0.00038366418,0.0011568707,0.00018953333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034518642,0.0001671935,0.0020802107,0.00012354774,0.000041270727,0.0000051765637,0.0001977422,0.00034760093,0.000098559154],"category_scores_gemma":[0.0030771561,0.0001311612,0.0010551341,0.00024131883,0.00034322726,0.000107161686,0.000059802638,0.00056059676,0.0000020682382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59145707,0.0038104465,0.004404247,0.00052187376,0.0031133073,0.0006368513,0.00061888795,0.00013916256,0.10660402,0.00048761783,0.007572278,0.28063422],"study_design_scores_gemma":[0.4976778,0.089520045,0.07243883,0.002740163,0.0025736257,0.0016316312,0.0022031064,0.0007791233,0.09655507,0.0023382055,0.23092115,0.0006212627],"about_ca_topic_score_codex":0.00003906776,"about_ca_topic_score_gemma":0.00021787598,"teacher_disagreement_score":0.28001297,"about_ca_system_score_codex":0.00024796685,"about_ca_system_score_gemma":0.0030014785,"threshold_uncertainty_score":0.53485984},"labels":[],"label_agreement":null},{"id":"W3171916291","doi":"10.1200/jco.2021.39.15_suppl.9023","title":"Clinicogenomic real-world data analysis of patients (pts) with <i>KRAS G12C-</i>mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; KRAS; Lung cancer; Internal medicine; Cohort; Oncology; Cancer; Population; Colorectal cancer","score_opus":0.04369022432411717,"score_gpt":0.3546123260805614,"score_spread":0.31092210175644425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171916291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927943,0.0033348312,0.00025251228,0.00045463577,0.0020557318,0.00030783453,0.00054060406,0.0000012507988,0.00025832423],"genre_scores_gemma":[0.9879861,0.007662848,0.002105895,0.0008825586,0.0010006796,0.000007120361,0.00020398397,0.000025375102,0.00012542335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961397,0.00055164023,0.0022753184,0.0004620043,0.0003383588,0.00023298974],"domain_scores_gemma":[0.9916027,0.0024347769,0.0040299543,0.0010628888,0.0007349519,0.00013470373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020910446,0.00020590948,0.001392711,0.000059116926,0.00006599844,0.000009770529,0.0010550403,0.00022605153,0.000048159465],"category_scores_gemma":[0.0018884143,0.00012464273,0.00074085384,0.00028797396,0.00035344815,0.000010534152,0.00053116184,0.0006388363,2.1949617e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018431367,0.0014639983,0.95480096,0.000019713056,0.0064626494,0.000025089847,0.00007975337,0.0029209156,0.0055251596,0.0000066282337,0.003462729,0.0068010166],"study_design_scores_gemma":[0.03930966,0.003594626,0.8507942,0.00011989747,0.014733935,0.0000035020544,0.000104246945,0.0010949844,0.005793537,0.000008120668,0.084132716,0.00031060484],"about_ca_topic_score_codex":0.00083704654,"about_ca_topic_score_gemma":0.02928541,"teacher_disagreement_score":0.104006805,"about_ca_system_score_codex":0.00012316358,"about_ca_system_score_gemma":0.0032229896,"threshold_uncertainty_score":0.9884276},"labels":[],"label_agreement":null},{"id":"W3171945717","doi":"10.1200/jco.2021.39.15_suppl.5075","title":"Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Urology; Randomization; Randomized controlled trial; Subgroup analysis; Internal medicine; Adverse effect; Clinical endpoint; Prostate; Cancer; Gynecology; Confidence interval","score_opus":0.093369394868022,"score_gpt":0.5226232800088864,"score_spread":0.4292538851408644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171945717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422705,0.0024251319,0.000007694591,0.001887359,0.00009009491,0.0009440034,0.000031963136,0.0000020625348,0.00038465342],"genre_scores_gemma":[0.9911966,0.008278946,0.00021327767,0.000055289544,0.00011515817,0.000019862073,0.000010812241,0.000011204922,0.000098896955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958418,0.0013926674,0.0018783386,0.00022954088,0.0004528518,0.00020479884],"domain_scores_gemma":[0.9891879,0.008531432,0.0013825141,0.0002629434,0.00043285475,0.00020235681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031977294,0.0001494175,0.00290605,0.00015036832,0.000027716964,0.000006220705,0.000116688294,0.00011438873,0.00007875784],"category_scores_gemma":[0.0026802148,0.00006791748,0.0005504964,0.000600447,0.0004179439,0.000059857826,0.000047968704,0.0007194704,2.817786e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7504334,0.0055881087,0.19850029,0.000012734938,0.009443779,0.0014289616,0.0011046827,0.00045893138,0.00020039637,0.000002803211,0.000052344065,0.03277356],"study_design_scores_gemma":[0.5506267,0.031844813,0.41310173,0.00015225938,0.003110692,0.000007368726,0.00078995747,0.000101291116,0.0001289909,0.000024790777,0.00006271085,0.00004871111],"about_ca_topic_score_codex":0.0007451973,"about_ca_topic_score_gemma":0.0011850296,"teacher_disagreement_score":0.21460144,"about_ca_system_score_codex":0.00023728191,"about_ca_system_score_gemma":0.0018761432,"threshold_uncertainty_score":0.33281973},"labels":[],"label_agreement":null},{"id":"W3171947585","doi":"10.1200/jco.2021.39.15_suppl.tps5600","title":"Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Endometrial cancer; Oncology; Internal medicine; Triple-negative breast cancer; Cancer; Serous fluid; Response Evaluation Criteria in Solid Tumors; Ovarian cancer; Breast cancer; Clinical trial; Phases of clinical research; Adverse effect","score_opus":0.14727016886627176,"score_gpt":0.5227100427634691,"score_spread":0.37543987389719735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171947585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995703,0.0014156445,0.000042193766,0.001381034,0.0003150779,0.0011100544,0.0000056173167,8.747955e-7,0.000026540347],"genre_scores_gemma":[0.99459225,0.0028060204,0.0020434507,0.00025842385,0.00025244732,0.000023173287,0.000007911674,0.000012201929,0.000004105253],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667,0.00087806076,0.0017900375,0.00030811795,0.00019069317,0.00016306127],"domain_scores_gemma":[0.99723655,0.0010233454,0.0010915083,0.0001958682,0.00034846124,0.00010425796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035499719,0.00013130349,0.0007977108,0.00004762186,0.00003857663,0.00003157061,0.00019361847,0.00012358505,0.0000040635014],"category_scores_gemma":[0.003591297,0.00009140361,0.000047279707,0.00012901954,0.00020598428,0.000021603464,0.00030914738,0.00036074707,9.5561674e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3634861,0.028910732,0.047601487,0.00005221127,0.00021459532,0.00024344238,0.0010819687,0.002054283,0.03822728,0.000010717697,0.00004999045,0.5180672],"study_design_scores_gemma":[0.70948017,0.1682202,0.10888332,0.00027458215,0.00028530072,0.0000675694,0.0018220888,0.0037136336,0.005900567,0.00016068903,0.0009120411,0.00027983027],"about_ca_topic_score_codex":0.000025430136,"about_ca_topic_score_gemma":0.00073624373,"teacher_disagreement_score":0.51778734,"about_ca_system_score_codex":0.000036452548,"about_ca_system_score_gemma":0.0010461571,"threshold_uncertainty_score":0.42993775},"labels":[],"label_agreement":null},{"id":"W3171965251","doi":"10.1200/jco.2021.39.15_suppl.4539","title":"Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Discontinuation; Internal medicine; Docetaxel; Randomized controlled trial; Performance status; Oncology; Cancer","score_opus":0.08126607043643114,"score_gpt":0.43399669406402647,"score_spread":0.35273062362759533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171965251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968899,0.00058540725,0.0001920554,0.00022792908,0.00061885803,0.0011984067,0.00004039119,0.0000049463806,0.0002421457],"genre_scores_gemma":[0.9970517,0.00035459164,0.0019329773,0.00029698107,0.00022046927,0.000023776593,0.000021782485,0.00002246521,0.00007526986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943153,0.001282588,0.0034610794,0.0002579585,0.0004893335,0.00019373388],"domain_scores_gemma":[0.99191165,0.0041535925,0.0027517916,0.00022255187,0.0006764025,0.00028403927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001821724,0.00020863106,0.003756072,0.000108350025,0.000018910974,0.000005577897,0.00008471903,0.00019139453,0.00031540816],"category_scores_gemma":[0.0058648023,0.00012535554,0.00046760394,0.0001999239,0.00031824512,0.00009895448,0.000018835379,0.00040838655,6.731163e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84954727,0.007054771,0.06818125,0.000053797678,0.00211718,0.00009281646,0.00021077438,0.0000074812424,0.000056929282,0.000005604835,0.00001801449,0.072654106],"study_design_scores_gemma":[0.8391362,0.06892653,0.089632645,0.00017027449,0.0014357166,0.000007184319,0.00009373094,0.000031069623,0.0002737011,0.000037877435,0.00016451273,0.00009058509],"about_ca_topic_score_codex":0.0002983952,"about_ca_topic_score_gemma":0.00021186999,"teacher_disagreement_score":0.07256352,"about_ca_system_score_codex":0.00011273793,"about_ca_system_score_gemma":0.004234257,"threshold_uncertainty_score":0.75113904},"labels":[],"label_agreement":null},{"id":"W3171968864","doi":"10.1200/jco.2021.39.15_suppl.10026","title":"Financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Worry; Cancer; Finance; Demography; Gerontology; Psychiatry; Internal medicine; Anxiety","score_opus":0.09754254427621223,"score_gpt":0.46052617766767256,"score_spread":0.36298363339146034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171968864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9383644,0.007628683,0.000017262604,0.046443168,0.0061005647,0.0007621166,0.00012357978,0.000019515634,0.00054070493],"genre_scores_gemma":[0.97361714,0.0053683445,0.000453639,0.014198959,0.006044245,0.000045971443,0.000017454446,0.00006123574,0.00019300441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9861082,0.0032362824,0.0076502906,0.0007518686,0.0016654753,0.0005878885],"domain_scores_gemma":[0.98393077,0.0069559445,0.005536487,0.0010365552,0.002049935,0.00049032434],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010150799,0.00042449398,0.0042654937,0.00017415319,0.0000986527,0.000024066185,0.00069442915,0.00068151136,0.0007778442],"category_scores_gemma":[0.031897347,0.00030306444,0.0012220482,0.00087509706,0.00037288162,0.00022018848,0.00026898534,0.0031559735,0.000008459256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021928356,0.0127128,0.9345905,0.000048254853,0.001267391,0.003566204,0.0055903443,0.00005814417,0.000028229779,0.000031555606,0.009756526,0.030157207],"study_design_scores_gemma":[0.014715422,0.0036650074,0.9549309,0.00082383695,0.0009187184,0.00041378336,0.002951563,0.000008723178,0.00014253575,0.0002893187,0.020867176,0.00027301905],"about_ca_topic_score_codex":0.03004079,"about_ca_topic_score_gemma":0.21535808,"teacher_disagreement_score":0.1853173,"about_ca_system_score_codex":0.00035587946,"about_ca_system_score_gemma":0.016172372,"threshold_uncertainty_score":0.9999421},"labels":[],"label_agreement":null},{"id":"W3171972617","doi":"10.1200/jco.2021.39.15_suppl.1552","title":"Automated imaging-based stratification of early-stage lung cancer patients prior to receiving surgical resection using deep learning applied to CTs.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Proportional hazards model; Cancer; Hazard ratio; Internal medicine; Radiology; Oncology; Confidence interval","score_opus":0.04646463709203122,"score_gpt":0.4621154341330034,"score_spread":0.4156507970409722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171972617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860218,0.00011452932,0.008262832,0.0036281128,0.0009881664,0.00027073643,0.0000010615967,0.00003665678,0.000676077],"genre_scores_gemma":[0.98010117,0.00003857571,0.018127142,0.0010249441,0.0005709021,0.000005255579,0.0000073592323,0.00002962478,0.000095046846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961674,0.00056860223,0.0021116398,0.0002954064,0.00057560246,0.0002813295],"domain_scores_gemma":[0.99554443,0.0012521925,0.0014203793,0.00016810957,0.0010697925,0.00054509396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032301003,0.00014247348,0.0010662681,0.00024377002,0.00009293181,0.000026238718,0.00013355695,0.00020541059,0.0001741867],"category_scores_gemma":[0.0081327595,0.00012233274,0.00024610618,0.00047322974,0.000084867286,0.00008104029,0.00005910571,0.0013554967,0.000003709333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033553585,0.0010281127,0.7430477,0.00013983564,0.00018251527,0.00033090293,0.00036980963,0.043484442,0.009939239,0.000033067194,0.00036266004,0.19772632],"study_design_scores_gemma":[0.006936194,0.002353497,0.7304524,0.0005903534,0.00032433678,0.000061663006,0.00013627387,0.24938147,0.0012350634,0.000009343974,0.008347572,0.00017182057],"about_ca_topic_score_codex":0.00009072682,"about_ca_topic_score_gemma":0.000033279808,"teacher_disagreement_score":0.20589702,"about_ca_system_score_codex":0.0003326432,"about_ca_system_score_gemma":0.001427662,"threshold_uncertainty_score":0.973626},"labels":[],"label_agreement":null},{"id":"W3171991570","doi":"10.1200/jco.2021.39.15_suppl.e15600","title":"Is shift-work associated with increased risk of rectal cancer? A meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sleep and Work-Related Fatigue","field":"Psychology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Meta-analysis; Odds ratio; Cancer; Confidence interval; Shift work; Subgroup analysis; Cochrane Library; Publication bias; Internal medicine","score_opus":0.23802846435555983,"score_gpt":0.49160658473229785,"score_spread":0.253578120376738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171991570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97946787,0.005660947,0.00029907923,0.0047891256,0.0012404879,0.00010596512,0.00007254679,0.000014125528,0.008349827],"genre_scores_gemma":[0.9953687,0.00036035152,0.0010253236,0.0026132385,0.00033068875,0.000009218761,0.000007998857,0.000023692113,0.0002607756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99113625,0.004368504,0.0032944614,0.0003637219,0.0004955028,0.00034153374],"domain_scores_gemma":[0.98338836,0.009122916,0.005781634,0.0004317375,0.0009258274,0.00034953226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006004245,0.00022259838,0.004210809,0.00023156077,0.000057897883,0.000011401581,0.0003497102,0.00095177785,0.00956655],"category_scores_gemma":[0.0044099283,0.00014592377,0.0034947959,0.0017257348,0.00026949478,0.00007097315,0.00005203089,0.0020095685,0.000029508843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002234189,0.0023058911,0.49451283,0.0000012295114,0.48120606,0.0009168342,0.00053070695,0.00018758643,0.0000019570662,0.00013421585,0.008128271,0.009840215],"study_design_scores_gemma":[0.005094273,0.002454685,0.64776176,0.000032701548,0.3418364,0.000015632495,0.00017425956,0.000007237335,0.000038851747,0.00021237713,0.002189491,0.00018236508],"about_ca_topic_score_codex":0.00055335305,"about_ca_topic_score_gemma":0.0015380329,"teacher_disagreement_score":0.15324889,"about_ca_system_score_codex":0.00009728642,"about_ca_system_score_gemma":0.0011639472,"threshold_uncertainty_score":0.99133885},"labels":[],"label_agreement":null},{"id":"W3171995199","doi":"10.1200/jco.2021.39.15_suppl.2593","title":"Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Fludarabine; Nivolumab; Neutropenia; Internal medicine; Cyclophosphamide; Progressive disease; Chemotherapy; Refractory (planetary science); Oncology; Gastroenterology; Immunotherapy; Cancer; Biology","score_opus":0.09142502707162185,"score_gpt":0.4643852496822118,"score_spread":0.3729602226105899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171995199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741276,0.0029094527,0.0000141396295,0.017627725,0.0008794923,0.00022707728,0.000006790336,0.000008451116,0.0041992576],"genre_scores_gemma":[0.98323256,0.0069997874,0.0015929979,0.00422826,0.0008804022,0.0000032978712,0.000010449903,0.000033120803,0.0030191042],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99542856,0.0009323049,0.0023576047,0.00029170743,0.00057829526,0.000411524],"domain_scores_gemma":[0.9942257,0.00321788,0.0006049159,0.00032003378,0.0011343063,0.0004971717],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004525709,0.00016804322,0.001719988,0.00022024693,0.000037216374,0.000018891114,0.00019479817,0.00053559,0.001980295],"category_scores_gemma":[0.0041830195,0.00013157385,0.00051752804,0.0002472675,0.00030825025,0.00011580942,0.000091243965,0.0022414154,0.000028503888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032915644,0.0050895894,0.092467986,0.00012952668,0.0009900911,0.017767116,0.00064745644,0.0000033501808,0.27747914,0.000088114546,0.0007628935,0.5716591],"study_design_scores_gemma":[0.036026392,0.018447418,0.872706,0.00027229605,0.00029033681,0.0074934987,0.0004814379,0.00006339892,0.0033111016,0.00017338141,0.06055064,0.00018409052],"about_ca_topic_score_codex":0.00012607635,"about_ca_topic_score_gemma":0.00034279458,"teacher_disagreement_score":0.78023803,"about_ca_system_score_codex":0.00024132695,"about_ca_system_score_gemma":0.004712392,"threshold_uncertainty_score":0.998932},"labels":[],"label_agreement":null},{"id":"W3172015782","doi":"10.1200/jco.2021.39.15_suppl.e19039","title":"Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Internal medicine; Phases of clinical research; Gastroenterology; Clinical trial; Surgery; Bone marrow","score_opus":0.09036830015533458,"score_gpt":0.4395758205238465,"score_spread":0.34920752036851194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172015782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436903,0.00034887076,0.00038266383,0.0021238555,0.0014365152,0.0010059279,0.00013370703,0.000008081427,0.00019134529],"genre_scores_gemma":[0.9840977,0.008121959,0.0066045215,0.0005618477,0.000350914,0.000050239087,0.00009068567,0.000034539145,0.00008760266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99390733,0.000647641,0.003811399,0.00046965678,0.0006833433,0.00048064417],"domain_scores_gemma":[0.9883531,0.0077198716,0.0015022487,0.00023990696,0.0016858339,0.0004990479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002717943,0.0003030767,0.002306971,0.00024533254,0.000059588234,0.000011996426,0.00015153758,0.00072414055,0.0004981999],"category_scores_gemma":[0.0070968214,0.00020939093,0.00066361524,0.0003317246,0.00013552372,0.00017294838,0.00004530249,0.0010381881,0.0000030857123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15373601,0.017556699,0.5035872,0.00041190902,0.0009089591,0.0009850705,0.0009813433,0.00007797703,0.008260508,0.000078727455,0.0005279792,0.31288767],"study_design_scores_gemma":[0.17073983,0.08412476,0.65839064,0.0010153081,0.0009699785,0.00019889863,0.0012657227,0.0009426756,0.07239118,0.00014983647,0.009394335,0.0004168045],"about_ca_topic_score_codex":0.00011690133,"about_ca_topic_score_gemma":0.0013451561,"teacher_disagreement_score":0.31247085,"about_ca_system_score_codex":0.0003462859,"about_ca_system_score_gemma":0.0037227238,"threshold_uncertainty_score":0.8538714},"labels":[],"label_agreement":null},{"id":"W3172027519","doi":"10.1200/jco.2021.39.15_suppl.5025","title":"Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Anxiety; Common Terminology Criteria for Adverse Events; Depression (economics); Testicular cancer; Internal medicine; Quality of life (healthcare); Adverse effect; Cancer; Psychiatry","score_opus":0.1767086377752125,"score_gpt":0.48501139322897313,"score_spread":0.3083027554537606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172027519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569935,0.00067901023,0.00016664248,0.0029631108,0.00026645247,0.0001792802,0.000020711406,0.0000026198395,0.000022801722],"genre_scores_gemma":[0.9967827,0.0005311324,0.0011475907,0.0013086421,0.0001282339,0.000017525397,0.000011842312,0.000010318387,0.00006196633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986001,0.00018990025,0.00082903233,0.00012257091,0.00014555086,0.000112840695],"domain_scores_gemma":[0.9943266,0.004238102,0.00074059964,0.00007199997,0.00047493906,0.00014778947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006018715,0.00008509463,0.0008060985,0.00006424221,0.000014165782,0.0000025204477,0.000028150695,0.00022043049,0.00017102397],"category_scores_gemma":[0.0015700988,0.00005271249,0.00014502463,0.00013902118,0.00012554375,0.000043296575,0.0000086662085,0.0002833523,5.055269e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002652554,0.0016543518,0.9838282,0.000024876665,0.00047263637,0.000061054845,0.000100495134,0.000056874975,0.0005284762,9.684642e-7,0.0002704432,0.010349075],"study_design_scores_gemma":[0.012077552,0.0021146254,0.9792668,0.00020226563,0.00082403544,0.000009242166,0.000036556165,0.00041805915,0.0012499775,0.000015915533,0.003735307,0.000049624632],"about_ca_topic_score_codex":0.00007149332,"about_ca_topic_score_gemma":0.0018371565,"teacher_disagreement_score":0.010299451,"about_ca_system_score_codex":0.0000958138,"about_ca_system_score_gemma":0.0014652788,"threshold_uncertainty_score":0.25993416},"labels":[],"label_agreement":null},{"id":"W3172035145","doi":"10.1200/jco.2021.39.15_suppl.e16506","title":"Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Meta-analysis; Cochrane Library; Randomized controlled trial; Subgroup analysis; Confidence interval; Oncology; Study heterogeneity; Inclusion and exclusion criteria; Pathology","score_opus":0.12480162678074795,"score_gpt":0.42039177917739434,"score_spread":0.2955901523966464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172035145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803902,0.0013299924,0.00033193582,0.014398596,0.000955141,0.0005380698,0.00008451884,0.000016322312,0.0019552237],"genre_scores_gemma":[0.98617107,0.00022105193,0.0055743787,0.00593877,0.0011984042,0.000027922188,0.000024372475,0.00004732607,0.00079668494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99407905,0.00030548224,0.0036976007,0.0005340534,0.0009359869,0.000447799],"domain_scores_gemma":[0.9946125,0.00072581694,0.0018416482,0.0005079117,0.0015853277,0.00072680315],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012127053,0.0003776212,0.0046145367,0.0003116921,0.00010321891,0.000023673485,0.00021994788,0.00038639875,0.001453448],"category_scores_gemma":[0.0012822412,0.00024044156,0.0033196271,0.00088110304,0.0001118739,0.0001426073,0.00011846114,0.00089862297,0.0000538463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06169212,0.02475475,0.497088,0.00019879533,0.32193848,0.005108308,0.0023216459,0.0030772514,0.0011949893,0.000069881484,0.005463664,0.077092126],"study_design_scores_gemma":[0.05610101,0.076225996,0.44513464,0.000100936806,0.3189389,0.0003261792,0.00030702696,0.00010284178,0.018950632,0.00029886997,0.08278853,0.0007244366],"about_ca_topic_score_codex":0.00021601755,"about_ca_topic_score_gemma":0.00061688595,"teacher_disagreement_score":0.07732487,"about_ca_system_score_codex":0.0002869795,"about_ca_system_score_gemma":0.0022498711,"threshold_uncertainty_score":0.9994594},"labels":[],"label_agreement":null},{"id":"W3172048335","doi":"10.1200/jco.2021.39.15_suppl.e18600","title":"Clinical outcomes of cancer patients with COVID-19: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Confidence interval; Internal medicine; ARDS; Population; Lung cancer; Cancer; Mortality rate; Lung","score_opus":0.6050536741633162,"score_gpt":0.6815157613296826,"score_spread":0.07646208716636638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172048335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023471905,0.9851767,0.000038010752,0.011986493,0.00033176018,0.0023107599,0.00009453235,0.0000061937576,0.00003206803],"genre_scores_gemma":[0.000058820773,0.9523829,0.00056788337,0.046386223,0.00021068795,0.000057229732,0.000021903792,0.000036721696,0.00027758596],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9765438,0.00591364,0.015704827,0.00052024605,0.0009894241,0.0003280894],"domain_scores_gemma":[0.9408039,0.031826228,0.022176666,0.0008589365,0.002089225,0.0022450825],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.016402654,0.0005320843,0.06499059,0.00045824685,0.000040524556,0.000011385743,0.00035363509,0.0011235778,0.00069555064],"category_scores_gemma":[0.08132762,0.0002425798,0.012931673,0.0008722943,0.00035523836,0.000069432506,0.00013255965,0.0024510475,0.0000045691527],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010698752,0.0011388878,0.019120404,0.62514395,0.33450317,0.00030271025,0.000011713454,2.4496399e-7,1.1643014e-10,0.000012065801,0.001288039,0.01837182],"study_design_scores_gemma":[0.0015280679,0.0033909765,0.004078413,0.035027903,0.66921186,0.000076680124,0.000005375804,1.5572967e-7,6.03776e-10,0.000004019013,0.28654355,0.00013299414],"about_ca_topic_score_codex":0.00013840616,"about_ca_topic_score_gemma":0.0003845613,"teacher_disagreement_score":0.590116,"about_ca_system_score_codex":0.00042464054,"about_ca_system_score_gemma":0.025423598,"threshold_uncertainty_score":0.99985033},"labels":[],"label_agreement":null},{"id":"W3172086766","doi":"10.1200/jco.2021.39.15_suppl.lba4","title":"Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Taxane; Progression-free survival; Urology; Internal medicine; Oncology; Clinical endpoint; Abiraterone acetate; Prostate; Response Evaluation Criteria in Solid Tumors; Confidence interval; Phases of clinical research; Cancer; Nuclear medicine; Randomized controlled trial; Clinical trial; Androgen deprivation therapy; Chemotherapy; Breast cancer","score_opus":0.12652740242309743,"score_gpt":0.5251846662483957,"score_spread":0.3986572638252982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172086766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960607,0.0007007743,0.000004746111,0.0019262682,0.00034388615,0.0006911947,0.000020265297,0.000002758825,0.00024940708],"genre_scores_gemma":[0.9980524,0.0004892135,0.0006441727,0.00018173938,0.00012104608,0.000019134148,0.0000129233385,0.000014561107,0.00046482068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609053,0.00054542883,0.0021706708,0.00022447997,0.000723659,0.00024521968],"domain_scores_gemma":[0.99618506,0.0007326471,0.0012114849,0.00019924121,0.0013911776,0.00028036363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015357905,0.00013754748,0.0014353584,0.00016645412,0.000035731977,0.0000103234015,0.00009853667,0.00009332916,0.0002038494],"category_scores_gemma":[0.00068952516,0.00008107031,0.00015928641,0.00036397864,0.00016643605,0.00013370824,0.00004254923,0.0006811483,0.0000019857416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11267852,0.08825267,0.6865283,0.00015373841,0.0019597176,0.0066932975,0.002110739,0.0001099794,0.0006208799,0.000013125101,0.0011528672,0.09972613],"study_design_scores_gemma":[0.19176911,0.09512278,0.7077525,0.00031904713,0.00070674234,0.000028597051,0.0017183032,0.000031036503,0.00034345116,0.000044846805,0.0020639524,0.00009962903],"about_ca_topic_score_codex":0.000121838566,"about_ca_topic_score_gemma":0.00096667744,"teacher_disagreement_score":0.099626504,"about_ca_system_score_codex":0.00022159552,"about_ca_system_score_gemma":0.004178946,"threshold_uncertainty_score":0.74132705},"labels":[],"label_agreement":null},{"id":"W3172087835","doi":"10.1200/jco.2021.39.15_suppl.4147","title":"Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Immunohistochemistry; Cancer; Internal medicine; Oncology; Biomarker; Phases of clinical research; Colorectal cancer; Cancer research; Clinical trial; Biology","score_opus":0.27128782466024287,"score_gpt":0.5991039623348068,"score_spread":0.3278161376745639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172087835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893868,0.0013043728,0.0007432709,0.003749278,0.0010782382,0.0012465393,0.0003659591,0.0000059733093,0.0021195465],"genre_scores_gemma":[0.9916224,0.0008020793,0.0054535735,0.0005069074,0.00123113,0.000020460317,0.0001954918,0.000017425393,0.00015056597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894334,0.00396342,0.005621373,0.00028267363,0.00046089117,0.00023823508],"domain_scores_gemma":[0.93561745,0.0575609,0.005134417,0.000444561,0.00084022625,0.00040245842],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0130964145,0.00020050329,0.008807442,0.00014808023,0.000019240986,0.00001428037,0.00019225155,0.00015121234,0.0011837515],"category_scores_gemma":[0.13032144,0.00010886507,0.0017290572,0.00012940353,0.00017658364,0.00012203081,0.000052065523,0.0007031121,0.000006236122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9122884,0.008512824,0.05056385,0.000023016733,0.0067943125,0.003339814,0.000098100165,0.0002598961,0.00042004234,0.00006361513,0.0034918487,0.014144247],"study_design_scores_gemma":[0.9329659,0.014409384,0.04271853,0.00094788783,0.005707914,0.00020939698,0.00010856238,0.0017086888,0.000020017125,0.00060735474,0.0005099404,0.000086464635],"about_ca_topic_score_codex":0.00063930434,"about_ca_topic_score_gemma":0.000277955,"teacher_disagreement_score":0.117225036,"about_ca_system_score_codex":0.0004924374,"about_ca_system_score_gemma":0.012877676,"threshold_uncertainty_score":0.9997293},"labels":[],"label_agreement":null},{"id":"W3172139422","doi":"10.1200/jco.2021.39.15_suppl.4002","title":"First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Randomized controlled trial; Ipilimumab; Cancer; Population; Oncology; Adverse effect; FOLFOX; Clinical endpoint; Gastroenterology; Oxaliplatin; Colorectal cancer; Immunotherapy","score_opus":0.12660364820692074,"score_gpt":0.43636560363353427,"score_spread":0.30976195542661356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172139422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704211,0.011347495,0.000636483,0.012239318,0.0044114306,0.00053751626,0.00007366193,0.00003883023,0.00029418143],"genre_scores_gemma":[0.95748043,0.030564327,0.0050233076,0.0020988553,0.003724643,0.000020144515,0.00014428966,0.00006551026,0.0008784847],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99451107,0.0002918878,0.0029447936,0.00088141335,0.00071072,0.00066009886],"domain_scores_gemma":[0.99475515,0.0016091135,0.0018976975,0.0007779949,0.00039870152,0.0005613733],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015663501,0.00044548322,0.0026845383,0.00026483944,0.00011207816,0.000041320847,0.00055083673,0.0004835779,0.001012221],"category_scores_gemma":[0.0015390976,0.00039352576,0.0003664511,0.00068232237,0.00024388204,0.000427457,0.0004135987,0.0016258358,0.000010015449],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07815094,0.0018257474,0.37255886,0.00017968363,0.0016458799,0.0033990857,0.0002833646,0.0010627102,0.00032135184,0.000012220777,0.0066128336,0.53394735],"study_design_scores_gemma":[0.11138378,0.0038957435,0.8645616,0.00031695832,0.001037718,0.00016027085,0.00025244217,0.0027482358,0.00019408387,0.00004264093,0.015153232,0.00025329404],"about_ca_topic_score_codex":0.0008083299,"about_ca_topic_score_gemma":0.0030415852,"teacher_disagreement_score":0.533694,"about_ca_system_score_codex":0.0013390507,"about_ca_system_score_gemma":0.0026178092,"threshold_uncertainty_score":0.999901},"labels":[],"label_agreement":null},{"id":"W3172178421","doi":"10.1200/jco.2021.39.15_suppl.5049","title":"Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation","keywords":"Medicine; Internal medicine; Prostate cancer; Oncology; Proportional hazards model; Univariate analysis; Cancer; Multivariate analysis","score_opus":0.07229293748004152,"score_gpt":0.43917392334359995,"score_spread":0.36688098586355844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172178421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963894,0.00018290107,0.00073836907,0.0009658756,0.001133347,0.0004078638,0.00009545247,0.0000020888572,0.00008474088],"genre_scores_gemma":[0.9909611,0.00030231912,0.0058879065,0.002074994,0.0005975992,0.000037206366,0.000042803702,0.000024420937,0.00007168329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667335,0.00028566553,0.0021904514,0.0003400569,0.0002588005,0.00025166204],"domain_scores_gemma":[0.99637294,0.00097002974,0.0013803554,0.00019372733,0.0008214659,0.00026148898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017331631,0.00015470127,0.0008771517,0.00006164279,0.000046357425,0.00002922026,0.00014518373,0.0001860514,0.000018011935],"category_scores_gemma":[0.005753526,0.00012335504,0.0003123314,0.000101425285,0.00006445408,0.00001471571,0.00006839022,0.00038644974,0.0000015073897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051301974,0.0018261354,0.95401126,0.00003212823,0.00050545397,0.0002074885,0.000042245443,0.0014610891,0.001643855,0.000022177252,0.0014736699,0.03364427],"study_design_scores_gemma":[0.011040612,0.011533983,0.95081884,0.000069726666,0.00024111435,0.000032026197,0.00016422046,0.0000744581,0.00074518955,0.00014416184,0.024934841,0.00020081406],"about_ca_topic_score_codex":0.000049680442,"about_ca_topic_score_gemma":0.0021148536,"teacher_disagreement_score":0.033443455,"about_ca_system_score_codex":0.00012691722,"about_ca_system_score_gemma":0.0026743354,"threshold_uncertainty_score":0.68879235},"labels":[],"label_agreement":null},{"id":"W3172183878","doi":"10.1200/jco.2021.39.15_suppl.tps9129","title":"KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS<sup>G12C</sup> mutation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KRAS; Medicine; Docetaxel; Tolerability; Regimen; Oncology; Lung cancer; Internal medicine; Phases of clinical research; Clinical endpoint; Cancer; Cancer research; Chemotherapy; Pharmacology; Clinical trial; Adverse effect; Colorectal cancer","score_opus":0.04474401398625628,"score_gpt":0.44161075779425446,"score_spread":0.3968667438079982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172183878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416924,0.0008656167,0.00013945607,0.0005215026,0.00028077146,0.0022525787,0.00001754724,0.000009705334,0.0017435574],"genre_scores_gemma":[0.99678195,0.00052497676,0.0015746682,0.0002690234,0.00019674163,0.00013166368,0.000035081714,0.00003807912,0.00044780626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952507,0.0008372846,0.0026407135,0.00037184448,0.0005782739,0.0003211837],"domain_scores_gemma":[0.9936711,0.002013572,0.0022549808,0.00028682523,0.0014052059,0.00036829227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011999436,0.0002957328,0.0029470804,0.00022429423,0.000055305176,0.000015814152,0.0001338009,0.00021692505,0.0001680396],"category_scores_gemma":[0.0008966968,0.0001742586,0.00037560659,0.0004546072,0.00017988088,0.00016007468,0.000032642245,0.00066351047,0.0000019158117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51142496,0.04245688,0.4141764,0.0001713369,0.005724998,0.0030678236,0.004619851,0.0020111797,0.000013884899,0.0000041227413,0.00044237726,0.015886217],"study_design_scores_gemma":[0.86980057,0.0506417,0.065769754,0.00062122976,0.009362046,0.000068201894,0.0024180943,0.0007056305,0.000059047725,0.0000049689575,0.0003678143,0.00018096458],"about_ca_topic_score_codex":0.00048720985,"about_ca_topic_score_gemma":0.0013983264,"teacher_disagreement_score":0.3583756,"about_ca_system_score_codex":0.00048286936,"about_ca_system_score_gemma":0.0046922984,"threshold_uncertainty_score":0.8323936},"labels":[],"label_agreement":null},{"id":"W3172184696","doi":"10.1200/jco.2021.39.15_suppl.5537","title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical trial; Pathology; Genetics; Gene; Poly ADP ribose polymerase; Alternative medicine; Polymerase","score_opus":0.10476870770512772,"score_gpt":0.45278381508441456,"score_spread":0.34801510737928687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172184696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825362,0.00058223796,0.0036853561,0.010255822,0.0022059693,0.00028461815,0.0003712868,0.0000053046992,0.000073187184],"genre_scores_gemma":[0.96924704,0.0058337646,0.017670514,0.0050276993,0.0019319968,0.00002976579,0.000086012646,0.000027561677,0.00014561538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571615,0.00030037193,0.0031023733,0.0003237526,0.00032802342,0.00022930051],"domain_scores_gemma":[0.9936577,0.0022194772,0.0022454574,0.00023099658,0.0012598591,0.00038651028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008607099,0.00018517727,0.00201908,0.000057345584,0.00004041792,0.000009530554,0.00010233426,0.00047300835,0.0003370495],"category_scores_gemma":[0.0017045471,0.0001450999,0.00056884164,0.00007912832,0.00039713635,0.00006738919,0.00003883103,0.0004940182,0.0000020304822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013213284,0.005950852,0.68105984,0.000053200587,0.002267738,0.00035147843,0.00014925878,0.000011807856,0.003735172,0.0018260699,0.0027583411,0.28862295],"study_design_scores_gemma":[0.032257434,0.00809799,0.9199454,0.00030829274,0.00066098425,0.000036409125,0.000030944797,0.0000602987,0.0017822257,0.0047317566,0.031957835,0.00013041147],"about_ca_topic_score_codex":0.000056066387,"about_ca_topic_score_gemma":0.000048170474,"teacher_disagreement_score":0.28849253,"about_ca_system_score_codex":0.00022900656,"about_ca_system_score_gemma":0.0018117514,"threshold_uncertainty_score":0.5917002},"labels":[],"label_agreement":null},{"id":"W3172195548","doi":"10.1200/jco.2021.39.15_suppl.5519","title":"Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; KRAS; Internal medicine; Oncology; Logistic regression; Progression-free survival; Proportional hazards model; Vemurafenib; Cancer; Chemotherapy; Metastatic melanoma","score_opus":0.10353998515697357,"score_gpt":0.4774920960452308,"score_spread":0.3739521108882572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172195548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882307,0.0021390445,0.000021664933,0.006825987,0.0021665818,0.00042251052,0.0000917419,0.0000043583577,0.00009741021],"genre_scores_gemma":[0.99465024,0.003466371,0.000814586,0.00043547264,0.00056782225,0.000012250854,0.000015749234,0.000024402148,0.000013076214],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99535674,0.00072324637,0.0027773597,0.0004208804,0.0004892666,0.00023251477],"domain_scores_gemma":[0.9949996,0.0017570612,0.0022277946,0.0003398394,0.0004484014,0.00022732661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011864526,0.00021063171,0.0019307013,0.00016020084,0.000023753188,0.000010114001,0.00014862386,0.00027156615,0.00007387795],"category_scores_gemma":[0.0011799028,0.00017671564,0.0004121885,0.00035646462,0.00016978093,0.00006916654,0.000057091773,0.00055266375,8.3182977e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115585305,0.099332444,0.083510116,0.00015836212,0.013220326,0.0050589326,0.0027367221,0.00014541528,0.02376584,0.000016956099,0.00229356,0.654176],"study_design_scores_gemma":[0.26239416,0.03274677,0.68302983,0.0007842375,0.0025952193,0.000024130455,0.0015974918,0.00013877371,0.013618339,0.00006590571,0.0027911614,0.00021394998],"about_ca_topic_score_codex":0.0012881408,"about_ca_topic_score_gemma":0.0010017679,"teacher_disagreement_score":0.6539621,"about_ca_system_score_codex":0.0001779406,"about_ca_system_score_gemma":0.0010304108,"threshold_uncertainty_score":0.72062546},"labels":[],"label_agreement":null},{"id":"W3172200015","doi":"10.1200/jco.2021.39.15_suppl.6529","title":"Uptake of immunotherapy in patients with advanced cancer: A population-based study using health administrative data from Ontario, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Cancer; Internal medicine; Hazard ratio; Cohort; Bladder cancer; Population; Ipilimumab; Proportional hazards model; Melanoma; Lung cancer; Retrospective cohort study; Oncology; Cancer registry; Immunotherapy; Confidence interval; Cancer research; Environmental health","score_opus":0.17895957994067835,"score_gpt":0.48796057311026697,"score_spread":0.3090009931695886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172200015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996344,0.0009811799,0.000025662559,0.0015730507,0.00061975897,0.00033441998,0.000100568715,0.0000014421925,0.000019932011],"genre_scores_gemma":[0.99340504,0.000103733895,0.0041841227,0.0021026316,0.0000960739,0.0000018894452,0.00007861948,0.000011973406,0.000015935988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964437,0.00037364656,0.0023573234,0.00022268853,0.00044529897,0.00015735571],"domain_scores_gemma":[0.99626684,0.0005993197,0.0022293788,0.00035940192,0.00041097502,0.00013409989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010551148,0.00011825199,0.0013471865,0.000056719535,0.000030126264,0.00000416835,0.00017287927,0.00009607796,0.00035334847],"category_scores_gemma":[0.00028572703,0.00008645801,0.00009637318,0.00020044892,0.000043646214,0.00008744426,0.00002193206,0.0005026567,5.036404e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033282332,0.0030187827,0.8940255,0.000008614541,0.00059503043,0.00012027324,0.00021343342,0.0000920039,0.000028661638,2.4591597e-7,0.00013603264,0.06847907],"study_design_scores_gemma":[0.029450782,0.010759933,0.9547637,0.0003303998,0.00009755602,0.000003615031,0.00048362056,0.00004832418,0.000014490888,0.0000037256013,0.0039724996,0.00007136239],"about_ca_topic_score_codex":0.82824916,"about_ca_topic_score_gemma":0.99094486,"teacher_disagreement_score":0.1626957,"about_ca_system_score_codex":0.0014427847,"about_ca_system_score_gemma":0.048856303,"threshold_uncertainty_score":0.9565358},"labels":[],"label_agreement":null},{"id":"W3172218079","doi":"10.1200/jco.2021.39.15_suppl.e18514","title":"Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Medicaid; Socioeconomic status; Ethnic group; Internal medicine; Demography; Cancer; Health equity; Retrospective cohort study; Hazard ratio; Gerontology; Proportional hazards model; Health care; Family medicine; Population; Confidence interval; Public health; Environmental health; Nursing","score_opus":0.1067497117266627,"score_gpt":0.40604532253296993,"score_spread":0.29929561080630723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172218079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589753,0.0015890223,0.00007400562,0.0010735635,0.00056814065,0.00038334256,0.000080175065,0.0000053294816,0.0003288938],"genre_scores_gemma":[0.98846394,0.009407066,0.00051067566,0.0011514156,0.00015457618,0.000015074962,0.000008986769,0.000032464057,0.0002558197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951272,0.00032822083,0.0033530788,0.00046611472,0.000050683007,0.00067469926],"domain_scores_gemma":[0.995858,0.00069472665,0.002832279,0.00027561665,0.00007264774,0.00026671658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030993423,0.00024945123,0.0025642314,0.00037972353,0.00007939719,0.000054737844,0.00019237507,0.00020159585,0.000056394325],"category_scores_gemma":[0.0003964874,0.00023796491,0.00023543983,0.00015561172,0.000109931345,0.00047802256,0.000098469456,0.0005061437,0.0000110267065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010008112,0.01659939,0.9658333,0.000019645551,0.00017707626,0.000083560386,0.0008990087,0.000013341026,7.6270493e-7,0.0006526338,0.00006590248,0.014654581],"study_design_scores_gemma":[0.046273686,0.005187075,0.9433259,0.00003744263,0.000037093057,0.000005407189,0.00043866818,0.00018631255,0.0000027225644,0.0013321528,0.002948889,0.00022465138],"about_ca_topic_score_codex":0.0049753683,"about_ca_topic_score_gemma":0.11265749,"teacher_disagreement_score":0.107682124,"about_ca_system_score_codex":0.002851267,"about_ca_system_score_gemma":0.0023072897,"threshold_uncertainty_score":0.9703927},"labels":[],"label_agreement":null},{"id":"W3172243611","doi":"10.1200/jco.20.03698","title":"Impact of Palliative Care Involvement on End-of-Life Care Patterns Among Adolescents and Young Adults With Cancer: A Population-Based Cohort Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; University of Ottawa; Hospital for Sick Children; Ottawa Hospital; Southlake Regional Health Center","funders":"","keywords":"Medicine; Palliative care; End-of-life care; Advance care planning; Retrospective cohort study; Population; Cancer; Young adult; Odds ratio; Cancer registry; Intensive care unit; Cohort study; Cohort; Emergency medicine; Emergency department; Internal medicine; Nursing; Environmental health","score_opus":0.08010902905498349,"score_gpt":0.46254268068230636,"score_spread":0.3824336516273229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172243611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754584,0.00074965495,0.00002179917,0.00033125613,0.00051507016,0.00070706144,0.00008748914,0.0000051640436,0.00003667642],"genre_scores_gemma":[0.9985734,0.00026064238,0.00017088283,0.00052030804,0.00040488032,0.000011458639,0.000032963337,0.000022138529,0.0000033306837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954716,0.0007465241,0.0023657097,0.00030741017,0.0009145768,0.00019420142],"domain_scores_gemma":[0.9940622,0.0007774554,0.0028067876,0.00028517243,0.0016394628,0.000428953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093594246,0.00020497631,0.002037512,0.000119632,0.000035007455,0.000006122469,0.000117020085,0.0001983879,0.000072909344],"category_scores_gemma":[0.0013715685,0.00014523942,0.00041514065,0.00015874172,0.00012758412,0.00005584804,0.0000454713,0.0007049693,2.5614167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007636321,0.0026199624,0.97468364,0.00056024786,0.0011833515,0.0001707902,0.006840646,0.0002143,0.000002421378,7.560942e-7,0.000029371193,0.0060581714],"study_design_scores_gemma":[0.017014105,0.024770856,0.94039667,0.003142174,0.0006866419,0.000002647595,0.013810167,0.00002459375,0.000024133122,0.0000015537521,0.000009993535,0.00011647113],"about_ca_topic_score_codex":0.0116419485,"about_ca_topic_score_gemma":0.046957895,"teacher_disagreement_score":0.035315946,"about_ca_system_score_codex":0.00056691235,"about_ca_system_score_gemma":0.0042477855,"threshold_uncertainty_score":0.9949396},"labels":[],"label_agreement":null},{"id":"W3172262340","doi":"10.1200/jco.2021.39.15_suppl.9019","title":"Intestinal <i>Akkermansia muciniphila</i> predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Internal medicine; Clinical endpoint; Akkermansia muciniphila; Gastroenterology; Biology; Cancer; Medicine; Clinical trial; Immunology","score_opus":0.03420998630677771,"score_gpt":0.40040929604146663,"score_spread":0.36619930973468895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172262340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715513,0.0004135885,0.00003440686,0.0005185143,0.0006948494,0.00039086325,0.000066807326,0.0000050348517,0.0007208157],"genre_scores_gemma":[0.9961942,0.0012852029,0.00086436665,0.00081047096,0.0004754648,0.0000068727504,0.00009165643,0.000028289933,0.00024346828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960852,0.0005818678,0.0021763982,0.0005062661,0.00022230759,0.00042791697],"domain_scores_gemma":[0.9967634,0.000252886,0.0015152814,0.00028827557,0.00087208877,0.0003080442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013117025,0.00025927133,0.0011817317,0.00008634146,0.00008591419,0.000013724124,0.0002610986,0.00035899287,0.000013718162],"category_scores_gemma":[0.0007896456,0.0002003981,0.00021124538,0.00018600267,0.000110333,0.000015896083,0.00017667848,0.0007826555,0.0000013084584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012268572,0.015996493,0.91364163,0.00007382219,0.00025280882,0.00096433185,0.00040675973,0.000202907,0.049452376,7.968195e-7,0.0031644963,0.0035750028],"study_design_scores_gemma":[0.06573089,0.054100577,0.8647544,0.00028192802,0.00023483724,0.00007329024,0.0002732093,0.00008229394,0.0050930176,0.0000023772543,0.009063268,0.00030991583],"about_ca_topic_score_codex":0.00008841265,"about_ca_topic_score_gemma":0.0013088431,"teacher_disagreement_score":0.053462315,"about_ca_system_score_codex":0.00008734557,"about_ca_system_score_gemma":0.0025161584,"threshold_uncertainty_score":0.81719977},"labels":[],"label_agreement":null},{"id":"W3172298753","doi":"10.1200/jco.2021.39.15_suppl.9027","title":"Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Genotyping; Internal medicine; Oncology; Lung cancer; ROS1; Prospective cohort study; Targeted therapy; Biomarker; Adenocarcinoma; Cancer; Genotype","score_opus":0.13839739365952386,"score_gpt":0.46860854919385003,"score_spread":0.3302111555343262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172298753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202347,0.0017622176,0.0012209468,0.0008399989,0.0036120336,0.00026893648,0.000027129307,0.0000035847659,0.00024170215],"genre_scores_gemma":[0.909344,0.0004929863,0.08699981,0.0015880872,0.0014477433,0.0000134794645,0.00003442806,0.00003131136,0.000048123526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963868,0.00032493155,0.0024516778,0.0003875916,0.00013406365,0.0003149056],"domain_scores_gemma":[0.9902594,0.007153169,0.0013023919,0.00026854643,0.0007827935,0.00023366525],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014816504,0.00017822781,0.0011388417,0.00006016991,0.000047297024,0.000016561997,0.00026168313,0.00049783365,0.0000083839295],"category_scores_gemma":[0.016417231,0.00016646147,0.0005006884,0.00009922654,0.00013586831,0.00000631239,0.00013598053,0.00055240205,0.0000027191954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007321729,0.0009827744,0.8481286,0.000060643724,0.00038250728,0.00038196286,0.000013656606,0.00614706,0.018539941,0.0000832546,0.0011575657,0.11680031],"study_design_scores_gemma":[0.049965695,0.019565647,0.7792064,0.00010548354,0.0004446352,0.00009833372,0.0002911334,0.0048024026,0.012715085,0.00022941493,0.13198982,0.00058593083],"about_ca_topic_score_codex":0.000007029667,"about_ca_topic_score_gemma":0.00014922007,"teacher_disagreement_score":0.13083225,"about_ca_system_score_codex":0.000096796655,"about_ca_system_score_gemma":0.0032589918,"threshold_uncertainty_score":0.9918679},"labels":[],"label_agreement":null},{"id":"W3172376856","doi":"10.1200/jco.2021.39.15_suppl.2513","title":"ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Royal Victoria Hospital; McGill University Health Centre; University of Alberta; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chills; Internal medicine; Melanoma; Renal cell carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Tolerability; Gastroenterology; Aldesleukin; Toxicity; Oncology; Phases of clinical research; Surgery; Interleukin 2; Cytokine; Immunotherapy; Cancer; Cancer research","score_opus":0.03361205118455683,"score_gpt":0.3936374816355411,"score_spread":0.36002543045098423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172376856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955938,0.0004963348,0.000053232936,0.0030556894,0.00016973024,0.00017604836,0.0000013976136,0.0000032030073,0.00045057756],"genre_scores_gemma":[0.9955316,0.0011046781,0.0015391957,0.0016388021,0.000082885286,0.0000043396667,0.000004864873,0.000013963997,0.000079655765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781764,0.00023311675,0.001346987,0.00017593816,0.0002549486,0.00017139812],"domain_scores_gemma":[0.9982949,0.00036397233,0.00082839065,0.00012236282,0.000270925,0.00011945914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085733144,0.00011266536,0.00096471887,0.000118892865,0.00001649322,0.000008612559,0.000058788508,0.00016205826,0.00005521957],"category_scores_gemma":[0.00029056869,0.00007557552,0.00008177567,0.0002347655,0.00015668874,0.0001290752,0.000013178368,0.0005772497,7.1789617e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09758047,0.0029313508,0.6376279,0.000026859556,0.00013390495,0.0009969645,0.00013925474,0.000030027039,0.0003775356,0.000012567148,0.00012195823,0.2600212],"study_design_scores_gemma":[0.07644003,0.021165343,0.89717513,0.00035912608,0.000037796286,0.00031139044,0.00012984904,0.000060619517,0.0002876316,0.000083538675,0.003862736,0.00008680085],"about_ca_topic_score_codex":0.000020721573,"about_ca_topic_score_gemma":0.00043798794,"teacher_disagreement_score":0.25993443,"about_ca_system_score_codex":0.00020716157,"about_ca_system_score_gemma":0.0011254695,"threshold_uncertainty_score":0.30818802},"labels":[],"label_agreement":null},{"id":"W3172389519","doi":"10.1200/jco.2021.39.15_suppl.e18713","title":"Head-to-head comparison of first-line FOLFIRINOX versus gemcitabine plus nabpaclitaxel (GN) in advanced pancreatic cancer (APC): A target trial emulation using Canadian real-world data.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; FOLFIRINOX; Pancreatic cancer; Observational study; Hazard ratio; Randomized controlled trial; Gemcitabine; Internal medicine; Oncology; Clinical trial; Cancer; Irinotecan; Confidence interval","score_opus":0.47383884265115966,"score_gpt":0.6103206065594997,"score_spread":0.13648176390834005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172389519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843695,0.00093209796,0.0004598018,0.009920056,0.0019852805,0.0007810559,0.00006272141,0.000006897472,0.0014825821],"genre_scores_gemma":[0.97027487,0.0010221569,0.026209624,0.00054405926,0.0015107531,0.000016384716,0.000062620544,0.00003060739,0.0003289258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99304134,0.0010134752,0.0041733645,0.0004603459,0.0006656303,0.0006458751],"domain_scores_gemma":[0.98933923,0.006053008,0.0017794797,0.00066428515,0.001070281,0.0010937417],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045403615,0.000236347,0.0041514887,0.0006287891,0.00008899828,0.000010550408,0.00037770317,0.00042549288,0.0004036179],"category_scores_gemma":[0.014594455,0.00020234838,0.00030362443,0.0009566204,0.00029401865,0.00018982927,0.00016797075,0.0014185429,0.000009094521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15867066,0.0017921452,0.80970913,0.00011534491,0.0006664029,0.0011596724,0.0002725336,0.0035280348,0.00011375739,0.000058788795,0.0009169841,0.022996522],"study_design_scores_gemma":[0.18897937,0.021814642,0.7004317,0.0008394681,0.0014830464,0.00008773894,0.0005535251,0.061192535,0.00004448227,0.00021763978,0.02408005,0.00027579445],"about_ca_topic_score_codex":0.062498298,"about_ca_topic_score_gemma":0.75704515,"teacher_disagreement_score":0.6945469,"about_ca_system_score_codex":0.001923591,"about_ca_system_score_gemma":0.017081428,"threshold_uncertainty_score":0.99370605},"labels":[],"label_agreement":null},{"id":"W3172395074","doi":"10.1200/jco.2021.39.15_suppl.4046","title":"Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Université de Montréal; McGill University Health Centre","funders":"EMD Serono","keywords":"Medicine; Perioperative; Chemotherapy; Chemotherapy regimen; Docetaxel; Regimen; Lymphadenectomy; Clinical endpoint; Internal medicine; Adenocarcinoma; Surgery; Gastroenterology; Urology; Oncology; Cancer; Clinical trial","score_opus":0.07797025291275897,"score_gpt":0.4527505003876589,"score_spread":0.3747802474748999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172395074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98081136,0.0008364278,0.00024370516,0.012697593,0.0011240571,0.0004145125,0.000006044306,0.000005645325,0.0038606618],"genre_scores_gemma":[0.98801243,0.0008998766,0.006354,0.00175361,0.0010709233,0.0000057518296,0.000007328338,0.000015425687,0.0018806225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954546,0.00037825142,0.003253092,0.00025309323,0.0004127102,0.0002482264],"domain_scores_gemma":[0.99656343,0.00088547124,0.0015808544,0.00023910124,0.0005131768,0.00021798989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022590102,0.00015744272,0.0018793028,0.00016562417,0.00003107579,0.0000055616274,0.00016412244,0.00023314213,0.00020694341],"category_scores_gemma":[0.003222938,0.0001217114,0.0005555891,0.0002809839,0.0001912978,0.00012364352,0.000092808754,0.00088439265,0.0000024531873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7096684,0.014387904,0.0076350374,0.000045511897,0.00035921516,0.0042848727,0.0006515254,0.000053347874,0.00024004563,0.00007583726,0.0022807054,0.2603176],"study_design_scores_gemma":[0.6486788,0.23203664,0.104516394,0.00015384752,0.00027537206,0.00023076509,0.00085331924,0.00015755389,0.00048624072,0.000044160548,0.012476791,0.00009012046],"about_ca_topic_score_codex":0.0000068059917,"about_ca_topic_score_gemma":0.000019551528,"teacher_disagreement_score":0.26022747,"about_ca_system_score_codex":0.00017425069,"about_ca_system_score_gemma":0.0024432628,"threshold_uncertainty_score":0.4963247},"labels":[],"label_agreement":null},{"id":"W3172413452","doi":"10.1200/jco.2021.39.15_suppl.9509","title":"Overall survival benefit from tebentafusp in patients with best response of progressive disease.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Pembrolizumab; Progressive disease; Oncology; Interim analysis; Randomized controlled trial; Disease; Nuclear medicine; Cancer; Immunotherapy","score_opus":0.07157264237981696,"score_gpt":0.4179175306840169,"score_spread":0.3463448883041999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172413452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422103,0.0015606856,0.00002672808,0.002712372,0.0010419334,0.0001314118,0.00008611605,0.0000026765347,0.00021705934],"genre_scores_gemma":[0.99535733,0.00013733614,0.0032288246,0.00074076623,0.00012808215,0.0000023570817,0.000017232664,0.000011468173,0.000376608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954518,0.0020783124,0.0018590679,0.00024097666,0.0001263569,0.00024347613],"domain_scores_gemma":[0.9929487,0.004670577,0.0013979959,0.00023221385,0.0006216046,0.00012888259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021583815,0.00014415344,0.0013521182,0.00008218283,0.000025962476,0.000005925738,0.00024502433,0.0005056378,0.00088654045],"category_scores_gemma":[0.004612009,0.00009317858,0.00032770226,0.0001449567,0.00044074643,0.00007755033,0.00011210812,0.00087716366,0.000010965594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058843154,0.0058128294,0.90355825,0.00000936907,0.00056848745,0.00042951075,0.000031098643,0.0000048401234,0.00087902276,0.00019079757,0.00053541653,0.02913722],"study_design_scores_gemma":[0.010204305,0.006645468,0.96422124,0.00016324315,0.0002675583,0.000008375931,0.00006002118,0.0000016120026,0.0009332856,0.0007323536,0.016649833,0.00011272761],"about_ca_topic_score_codex":0.000016405485,"about_ca_topic_score_gemma":0.000049857284,"teacher_disagreement_score":0.060662966,"about_ca_system_score_codex":0.000058999925,"about_ca_system_score_gemma":0.0009877236,"threshold_uncertainty_score":0.9706996},"labels":[],"label_agreement":null},{"id":"W3172419753","doi":"10.1200/jco.2021.39.15_suppl.e20005","title":"Testing Mayo Clinic’s new 20/20/20 risk stratification model in another cohort of smoldering myeloma patients: A retrospective study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Notre-Dame; Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Multiple myeloma; Hazard ratio; Internal medicine; Retrospective cohort study; Asymptomatic; Cohort; Population; Clinical endpoint; Proportional hazards model; Oncology; Gastroenterology; Confidence interval; Clinical trial","score_opus":0.16988610431133744,"score_gpt":0.46645491912553005,"score_spread":0.2965688148141926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172419753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931635,0.00013481072,0.00042371877,0.0008107875,0.00026646652,0.00064744893,0.000018375262,0.000008888296,0.0045259837],"genre_scores_gemma":[0.9833675,0.00014879911,0.015171693,0.00017930573,0.00033936507,0.000009785433,0.000011798856,0.000026585281,0.00074517966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945479,0.00082973513,0.0031912583,0.00037964204,0.00072906516,0.0003223874],"domain_scores_gemma":[0.9934729,0.0020448647,0.0023201846,0.0003639639,0.0014071749,0.00039096686],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032602488,0.00018257594,0.0016414345,0.00018847894,0.00004685802,0.000013620932,0.00016816249,0.0003089451,0.00017537303],"category_scores_gemma":[0.018408855,0.00014268799,0.00033253172,0.0004035089,0.00012349391,0.00016064936,0.000085379346,0.0012946635,0.000013746291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024250573,0.0069597387,0.91611516,0.000019528208,0.00062064745,0.00055976806,0.00024322065,0.00018513121,0.0003087379,0.000007478656,0.0004607022,0.07209483],"study_design_scores_gemma":[0.017277353,0.011119029,0.96607816,0.00016272851,0.0003325647,0.000035260404,0.0003237061,0.0036276544,0.000102623846,0.0006877215,0.00015628304,0.00009690465],"about_ca_topic_score_codex":0.00015679403,"about_ca_topic_score_gemma":0.00072527333,"teacher_disagreement_score":0.07199792,"about_ca_system_score_codex":0.00038917354,"about_ca_system_score_gemma":0.003192129,"threshold_uncertainty_score":0.9898595},"labels":[],"label_agreement":null},{"id":"W3172478157","doi":"10.1200/jco.2021.39.15_suppl.12004","title":"Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Tinnitus; Cisplatin; Internal medicine; Hearing loss; Peripheral neuropathy; Pharmacogenomics; Ototoxicity; Confounding; Neurotoxicity; Oncology; Auditory neuropathy; Cohort; Gastroenterology; Chemotherapy; Endocrinology; Toxicity; Pharmacology; Diabetes mellitus; Audiology","score_opus":0.22732918067206553,"score_gpt":0.4978560729158356,"score_spread":0.2705268922437701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172478157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148375,0.0010748308,0.000014235386,0.0031657256,0.0017420854,0.00013481874,0.0000056229896,0.0000066062726,0.0023723114],"genre_scores_gemma":[0.99004567,0.0028350833,0.0011415761,0.0039698277,0.0014528501,0.0000018075834,0.0000016936461,0.000020360278,0.00053110486],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972904,0.00047798597,0.0016544143,0.00018709418,0.00018777706,0.00020235685],"domain_scores_gemma":[0.99679595,0.0013787716,0.0010042636,0.00011786192,0.00038416556,0.00031898113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086362957,0.0001358148,0.0012793326,0.00007299683,0.000036449404,0.0000063311304,0.00006902984,0.00019945235,0.0003953238],"category_scores_gemma":[0.0007663816,0.00011389138,0.00034160874,0.00009110794,0.00019373659,0.00006629115,0.00007075902,0.0008735662,0.0000028518668],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013774567,0.004837029,0.23101023,0.00023261581,0.0013749524,0.020888798,0.0007871221,0.000059563623,0.54651755,0.000094110736,0.002169508,0.17825393],"study_design_scores_gemma":[0.07780361,0.060769357,0.53979665,0.00030534124,0.0042989654,0.03095182,0.00080793095,0.0014190284,0.10204974,0.00035490034,0.18086092,0.0005817291],"about_ca_topic_score_codex":0.000010052634,"about_ca_topic_score_gemma":0.00000663179,"teacher_disagreement_score":0.44446784,"about_ca_system_score_codex":0.00007962022,"about_ca_system_score_gemma":0.0014753782,"threshold_uncertainty_score":0.46443555},"labels":[],"label_agreement":null},{"id":"W3172509781","doi":"10.1200/jco.2021.39.15_suppl.6046","title":"Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Nasopharyngeal carcinoma; Internal medicine; Oncology; Population; Stage (stratigraphy); Cancer; Radiation therapy","score_opus":0.12949020051391455,"score_gpt":0.45389557175738415,"score_spread":0.3244053712434696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172509781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837176,0.004741827,0.00038762478,0.008798508,0.0005921463,0.00015479041,0.000007308355,0.000014066987,0.0015861043],"genre_scores_gemma":[0.97973686,0.00083944993,0.0150392875,0.0028994628,0.00079743704,0.000015430542,0.000008646085,0.000028522923,0.0006348801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970922,0.00034563185,0.0016696495,0.00023672795,0.00025217613,0.00040360348],"domain_scores_gemma":[0.9947254,0.0028484957,0.0009206458,0.00017506801,0.0009303116,0.00040009708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022640158,0.0001750928,0.0022096387,0.00008863326,0.0000873035,0.00001218271,0.000105945466,0.00018163011,0.000064061984],"category_scores_gemma":[0.003329791,0.000115138006,0.00038571493,0.00021522236,0.00021493362,0.00009281141,0.000039982773,0.00070031895,0.0000040342356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029586846,0.0027131815,0.8007006,0.00067871757,0.0041955546,0.020379746,0.0018784307,0.00003212443,0.0011347915,0.0011637161,0.011553164,0.12598312],"study_design_scores_gemma":[0.07612116,0.088012494,0.6403145,0.0009039561,0.0075536445,0.016596375,0.0028695827,0.00034735416,0.0033917737,0.0011248881,0.16217244,0.00059182034],"about_ca_topic_score_codex":0.000049012415,"about_ca_topic_score_gemma":0.0006209885,"teacher_disagreement_score":0.16038609,"about_ca_system_score_codex":0.00028008508,"about_ca_system_score_gemma":0.0058620945,"threshold_uncertainty_score":0.99977374},"labels":[],"label_agreement":null},{"id":"W3172523404","doi":"10.1200/jco.2021.39.15_suppl.12011","title":"Comprehensive geriatric assessment and management for Canadian elders with Cancer: The 5C study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Calgary; Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Ottawa Hospital; Royal Columbian Hospital; Jewish General Hospital; Sunnybrook Health Science Centre; Lakeridge Health; McGill University; University of Toronto","funders":"","keywords":"Medicine; Geriatric oncology; Quality of life (healthcare); Cancer; Randomization; Randomized controlled trial; Palliative care; Performance status; Physical therapy; Family medicine; Internal medicine; Nursing","score_opus":0.12690635503302625,"score_gpt":0.49215747599908016,"score_spread":0.36525112096605394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172523404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86279655,0.0013267893,0.00030017245,0.12828839,0.0017160553,0.001259112,0.00000910268,0.00000536509,0.004298498],"genre_scores_gemma":[0.9752858,0.0031272178,0.009477476,0.01001172,0.00085361523,0.000041345906,0.0000024076348,0.000017432289,0.0011829407],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981757,0.0002560817,0.00092650234,0.00016981708,0.00025825494,0.00021363742],"domain_scores_gemma":[0.9966981,0.0015700508,0.0005335869,0.00018119055,0.0006363932,0.00038072193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010045371,0.000100204314,0.00078146777,0.000079527905,0.00008742613,0.000015394004,0.0001073514,0.000104996434,0.00007318515],"category_scores_gemma":[0.0002462232,0.000056827987,0.00013804222,0.00014089119,0.00012230869,0.000038428312,0.000039996732,0.0005205608,0.0000010145285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023683975,0.0020734866,0.38073644,0.00022943532,0.004372648,0.006501929,0.0005733878,0.00015255983,0.0000145708855,0.0002932368,0.077631555,0.52505237],"study_design_scores_gemma":[0.00984362,0.008407885,0.63957024,0.00006571763,0.0009218925,0.00037726565,0.0027469783,0.000052780826,0.0000023304774,0.0000624379,0.3378901,0.000058762456],"about_ca_topic_score_codex":0.0022654696,"about_ca_topic_score_gemma":0.06548473,"teacher_disagreement_score":0.5249936,"about_ca_system_score_codex":0.00028430353,"about_ca_system_score_gemma":0.0034472963,"threshold_uncertainty_score":0.9515677},"labels":[],"label_agreement":null},{"id":"W3172607654","doi":"10.1200/jco.2021.39.15_suppl.9557","title":"Outcomes of non-treatment naive melanoma patients with central nervous system relapse.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Ipilimumab; Melanoma; Acral lentiginous melanoma; Internal medicine; Proportional hazards model; Nivolumab; Oncology; Survival analysis; Log-rank test; Retrospective cohort study; Cancer; Immunotherapy","score_opus":0.05475909038247613,"score_gpt":0.40142435798834003,"score_spread":0.3466652676058639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172607654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468833,0.00033132092,0.000100190846,0.002023944,0.0010925854,0.00023686564,0.000021540453,0.000005436733,0.0014997772],"genre_scores_gemma":[0.9908065,0.00014983614,0.007999469,0.00041576018,0.00026653337,0.0000021609674,0.000014753839,0.000016192556,0.00032879814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969673,0.00036232552,0.0018553735,0.00018161793,0.0003945837,0.00023877998],"domain_scores_gemma":[0.9959204,0.0011369102,0.0016132392,0.00025518204,0.0006735665,0.0004006951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005936005,0.00016749869,0.0020498282,0.00006077948,0.000028746468,0.0000045544284,0.00007339945,0.00020239473,0.00008009179],"category_scores_gemma":[0.0005459479,0.00008829513,0.0006489036,0.00010275971,0.000107769076,0.0000485498,0.000030735384,0.00031231542,0.000009824526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002720875,0.005834351,0.9076898,0.00005235839,0.0028539435,0.004416485,0.00009157412,0.000024851543,0.000005149569,0.0001252351,0.00042918054,0.075756215],"study_design_scores_gemma":[0.02063857,0.03342441,0.93438625,0.00016912073,0.001758032,0.0004397112,0.00031039037,0.0000162883,0.00012262403,0.000011150279,0.008654038,0.000069416594],"about_ca_topic_score_codex":0.000033907058,"about_ca_topic_score_gemma":0.000020794836,"teacher_disagreement_score":0.0756868,"about_ca_system_score_codex":0.00036249892,"about_ca_system_score_gemma":0.0015332157,"threshold_uncertainty_score":0.3600571},"labels":[],"label_agreement":null},{"id":"W3172614201","doi":"10.1200/jco.2021.39.15_suppl.e23002","title":"Challenges in lung cancer multidisciplinary collaboration experienced by specialists in four countries.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Pulmonologists; Lung cancer; Family medicine; Referral; Multidisciplinary approach; KRAS; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.12607868855980775,"score_gpt":0.5599785551932158,"score_spread":0.43389986663340807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172614201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88208205,0.049416475,0.00011960062,0.060318217,0.0043732836,0.00020816975,0.000004698933,0.0000055308747,0.0034719785],"genre_scores_gemma":[0.8032466,0.18537544,0.004674571,0.0031686933,0.0029637562,0.00002338845,0.0000032133062,0.000017820892,0.00052649016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707174,0.0005466899,0.0017199788,0.00022097614,0.00023475941,0.00020582417],"domain_scores_gemma":[0.99666494,0.0018236567,0.0008454604,0.00013222029,0.00038360144,0.00015014385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019349343,0.000108608256,0.0011982657,0.00010435466,0.000029673556,0.000004295062,0.000106473984,0.00051181443,0.00023701612],"category_scores_gemma":[0.0021256802,0.000086186155,0.00012369422,0.00024968077,0.00024945018,0.0001858741,0.000029331408,0.0008479436,0.0000017534186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011518611,0.003654153,0.73905313,0.000115388204,0.00023966713,0.011895442,0.0056342604,0.00026487085,0.0015761529,0.0006495031,0.012189496,0.21320933],"study_design_scores_gemma":[0.020873178,0.004237709,0.58119535,0.0003907468,0.000076328644,0.0006364112,0.003390477,0.0005358455,0.0003135081,0.000524743,0.38763472,0.00019099761],"about_ca_topic_score_codex":0.000007371544,"about_ca_topic_score_gemma":0.0018651527,"teacher_disagreement_score":0.37544522,"about_ca_system_score_codex":0.0006666339,"about_ca_system_score_gemma":0.0034836063,"threshold_uncertainty_score":0.6179768},"labels":[],"label_agreement":null},{"id":"W3172653524","doi":"10.1200/jco.2021.39.15_suppl.5044","title":"CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; PARP inhibitor; Nivolumab; Cohort; Clinical endpoint; Docetaxel; Taxane; Cancer; Clinical trial; Immunotherapy; Poly ADP ribose polymerase; Breast cancer; Androgen receptor","score_opus":0.15264023800292983,"score_gpt":0.502956627245222,"score_spread":0.35031638924229225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172653524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96050483,0.0035193062,0.00206001,0.030738238,0.0015469916,0.0007513831,0.00017868384,0.000025314457,0.0006752255],"genre_scores_gemma":[0.95550966,0.004443545,0.023244236,0.011630377,0.0016552745,0.00014175697,0.00009273834,0.00006573775,0.003216674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99423414,0.00054954377,0.0036481188,0.00044837687,0.00067174673,0.0004480987],"domain_scores_gemma":[0.99213076,0.0015984882,0.0027933044,0.00038441218,0.0026078431,0.00048517413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035161516,0.0002793765,0.0026416737,0.00026972103,0.000114145296,0.000040210223,0.00019320784,0.00020290303,0.0016692209],"category_scores_gemma":[0.0015301168,0.00022631552,0.0014987498,0.00063859747,0.00027400136,0.00019475594,0.000023995874,0.0008799646,0.000012269719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1318,0.016139515,0.275947,0.0010931413,0.08645225,0.011876108,0.0018610165,0.0041753286,0.08736579,0.0020846257,0.07435156,0.30685365],"study_design_scores_gemma":[0.083853155,0.022817114,0.49761963,0.0006320387,0.021517785,0.002536823,0.0012944692,0.002283806,0.013442047,0.003056266,0.35006204,0.00088481087],"about_ca_topic_score_codex":0.00011311442,"about_ca_topic_score_gemma":0.0006890283,"teacher_disagreement_score":0.30596885,"about_ca_system_score_codex":0.000548504,"about_ca_system_score_gemma":0.00745472,"threshold_uncertainty_score":0.9992434},"labels":[],"label_agreement":null},{"id":"W3172690078","doi":"10.1200/jco.2021.39.15_suppl.7011","title":"Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Venetoclax; Hypomethylating agent; Gastroenterology; Decitabine; Ven; Oncology; Lenalidomide; Anagrelide; Chemotherapy; Essential thrombocythemia; Leukemia; Bone marrow; Polycythemia vera; Chronic lymphocytic leukemia; Multiple myeloma","score_opus":0.05267757731609547,"score_gpt":0.38625079278427527,"score_spread":0.3335732154681798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172690078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992812,0.00067352713,0.000111713,0.004489356,0.00054368796,0.00081604556,0.00001583576,0.000030913205,0.000506924],"genre_scores_gemma":[0.9870702,0.007931894,0.0024047366,0.0013931984,0.00022171657,0.000023320257,0.000076900986,0.00007983176,0.00079820293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99384195,0.00091102364,0.0030262147,0.0006071416,0.0009605864,0.0006531064],"domain_scores_gemma":[0.99140716,0.004086104,0.0015199551,0.000331942,0.0019617768,0.0006930385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001953886,0.00045873728,0.0025307105,0.0005854355,0.0001077159,0.000054243566,0.00024076943,0.0007913719,0.00045949678],"category_scores_gemma":[0.0042709652,0.00029942507,0.00022103763,0.0012413458,0.00050537183,0.00032784216,0.000114359624,0.0022294326,0.000025992967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0934504,0.007429698,0.77591944,0.00023542793,0.003025203,0.01284446,0.0011253278,0.00048605856,0.0015115618,0.00035430532,0.0026197538,0.10099835],"study_design_scores_gemma":[0.09727765,0.0332103,0.85343504,0.00082661206,0.00029680674,0.003583598,0.00029881,0.002614827,0.0013996644,0.000291911,0.0063379277,0.0004268352],"about_ca_topic_score_codex":0.00004431678,"about_ca_topic_score_gemma":0.00018619621,"teacher_disagreement_score":0.10057151,"about_ca_system_score_codex":0.0011929859,"about_ca_system_score_gemma":0.008144341,"threshold_uncertainty_score":0.99994576},"labels":[],"label_agreement":null},{"id":"W3172696999","doi":"10.1200/jco.2021.39.15_suppl.e18719","title":"Clinical pathways implementation in a community-based oncology practice: Real-world outcomes in patients with non-small cell lung cancer segmented by disease stage at diagnosis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Oncology; Lung cancer; Cancer; Chemotherapy; Disease; Clinical pathway","score_opus":0.09545766596060024,"score_gpt":0.4393592607243687,"score_spread":0.34390159476376847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172696999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880742,0.0007127405,0.00016948239,0.0055207666,0.0012408,0.00045676634,0.00048750584,0.00000581135,0.003331964],"genre_scores_gemma":[0.983746,0.0035735997,0.0015437214,0.010447454,0.00018723164,0.000077270895,0.00009116207,0.00003821013,0.00029538365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99276704,0.0010319077,0.0052421708,0.0003913274,0.000100093355,0.0004674935],"domain_scores_gemma":[0.9880195,0.005200399,0.0056306347,0.00036516102,0.00031913756,0.0004651676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066153137,0.00024713026,0.0022977279,0.0003035178,0.00009096533,0.00003255515,0.00035375843,0.0003596982,0.0004893618],"category_scores_gemma":[0.0022309585,0.00023725112,0.0003868873,0.0002998286,0.00016592961,0.00047021633,0.00015197907,0.0017251057,0.000018369792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027847292,0.007176066,0.97570425,0.00005482696,0.00015300098,0.00017808785,0.00020105368,0.0002912573,5.9466464e-7,0.00023079009,0.004539684,0.008685671],"study_design_scores_gemma":[0.02014692,0.0028538043,0.88215667,0.000061229024,0.000079103454,4.443152e-7,0.00019489115,0.00013826431,0.000008503786,0.00017863509,0.09394763,0.00023389564],"about_ca_topic_score_codex":0.0022502497,"about_ca_topic_score_gemma":0.022205623,"teacher_disagreement_score":0.09354756,"about_ca_system_score_codex":0.0020033247,"about_ca_system_score_gemma":0.0026656506,"threshold_uncertainty_score":0.9956366},"labels":[],"label_agreement":null},{"id":"W3172699038","doi":"10.1200/jco.2021.39.15_suppl.4549","title":"Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Progression-free survival; Renal cell carcinoma; Proportional hazards model; Interim analysis; Multivariate analysis; Gastroenterology; Urology; Oncology; Surgery; Confidence interval; Clinical trial; Overall survival","score_opus":0.14057200808294745,"score_gpt":0.45513004038616495,"score_spread":0.3145580323032175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172699038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93661237,0.00021176705,0.000019394543,0.061790705,0.00038073809,0.0003879619,0.000002313308,0.0000041186768,0.0005906117],"genre_scores_gemma":[0.99406475,0.00012913569,0.0008645355,0.0031487136,0.0012605791,0.000005780213,0.000003664955,0.000012347198,0.00051048223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99501544,0.0016649215,0.0022168262,0.00023290978,0.00064217637,0.00022774152],"domain_scores_gemma":[0.9908417,0.0071359044,0.0010844343,0.00024017655,0.0004269544,0.00027084776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005346236,0.00015116701,0.0015588085,0.00013211978,0.000048942744,0.000026519832,0.00014431443,0.00026841788,0.00003946542],"category_scores_gemma":[0.007752473,0.000087352084,0.00033167162,0.00024415617,0.00004616714,0.000065240325,0.0000727719,0.0010859373,0.000020852583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075218873,0.0031117888,0.96908695,0.0000060211387,0.00068358524,0.0024533914,0.0005325046,0.000017753206,0.00016582373,0.000013277896,0.0014232588,0.021753464],"study_design_scores_gemma":[0.010764433,0.0127366,0.96891105,0.000033239514,0.000957437,0.00016378715,0.00036147432,0.000005653065,0.00007196772,0.00010108327,0.005822305,0.0000709475],"about_ca_topic_score_codex":0.000022669117,"about_ca_topic_score_gemma":0.00009595466,"teacher_disagreement_score":0.058641993,"about_ca_system_score_codex":0.00033385376,"about_ca_system_score_gemma":0.00086810737,"threshold_uncertainty_score":0.92809945},"labels":[],"label_agreement":null},{"id":"W3172704995","doi":"10.1200/jco.2021.39.15_suppl.e18008","title":"Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Subgroup analysis; Population; Gastroenterology; Immunotherapy; Confidence interval; Cancer","score_opus":0.10989313684410822,"score_gpt":0.4529072815231682,"score_spread":0.34301414467906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172704995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704224,0.00094726816,0.0000076988945,0.0008081571,0.00051833445,0.000105049396,0.000003997759,0.00000478043,0.0005624775],"genre_scores_gemma":[0.9955617,0.0027579067,0.00029257053,0.000188897,0.00044609292,0.0000020612092,0.0000026115079,0.000009099861,0.0007390342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701446,0.00026809156,0.0021191256,0.00016060693,0.00028397265,0.00015376783],"domain_scores_gemma":[0.997137,0.00061973114,0.0014093823,0.00024785413,0.00044230596,0.000143739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010964434,0.00011410719,0.0018632256,0.00025610143,0.000035561065,0.0000052240293,0.000098338445,0.0001690695,0.00043835488],"category_scores_gemma":[0.0005071315,0.00007701241,0.0011477445,0.0006831147,0.00010892817,0.000079249345,0.00002591098,0.00027633933,0.0000020229645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019588202,0.0057560485,0.86974806,0.000033113116,0.013030844,0.00084524835,0.00037140324,0.000016969603,0.0055083814,0.0000015505258,0.00006651967,0.085033655],"study_design_scores_gemma":[0.01572526,0.017765174,0.9528425,0.000047496247,0.0051042554,0.00019484133,0.0005253169,0.000079218094,0.0019540694,0.0000017689857,0.0056953263,0.000064782405],"about_ca_topic_score_codex":0.000054310214,"about_ca_topic_score_gemma":0.00024656492,"teacher_disagreement_score":0.08496887,"about_ca_system_score_codex":0.00022704028,"about_ca_system_score_gemma":0.00106296,"threshold_uncertainty_score":0.47996786},"labels":[],"label_agreement":null},{"id":"W3172717443","doi":"10.1200/jco.2021.39.15_suppl.7037","title":"The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Imatinib; Bosutinib; Myeloid leukemia; Body mass index; Gastroenterology; Imatinib mesylate; Cumulative incidence; Dasatinib; Surgery; Cohort","score_opus":0.02403921838685768,"score_gpt":0.37050232835505315,"score_spread":0.34646310996819546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172717443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969443,0.00047348355,0.000015010167,0.0008135929,0.00038812502,0.00062444597,0.000007849055,0.0000045565503,0.0007286097],"genre_scores_gemma":[0.9976138,0.0012317679,0.00054885,0.00017958577,0.0002586034,0.000007318611,0.0000078383055,0.000026442598,0.00012579678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484843,0.0010631724,0.002859584,0.00027144141,0.0006299793,0.00032738136],"domain_scores_gemma":[0.97927225,0.01731554,0.0023862817,0.00040329248,0.00036115167,0.00026147437],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027770498,0.00023906623,0.0021869915,0.000112803944,0.00004567129,0.0000065741483,0.0001932966,0.00038085366,0.000093084906],"category_scores_gemma":[0.009640202,0.000118925826,0.0002756331,0.00028880642,0.00043475846,0.000067883135,0.000080680955,0.0011831515,0.000003575514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0751636,0.001389093,0.7541687,0.00017655258,0.0007824492,0.00082222384,0.000060483806,0.00020077784,0.0001113244,0.00002089017,0.0003076522,0.16679627],"study_design_scores_gemma":[0.11655149,0.06541593,0.81289977,0.00083294115,0.00038903183,0.00007163987,0.000035046505,0.00012425709,0.0007405714,0.000013260591,0.0028395117,0.00008655083],"about_ca_topic_score_codex":0.000027595199,"about_ca_topic_score_gemma":0.00011380481,"teacher_disagreement_score":0.16670972,"about_ca_system_score_codex":0.0014043342,"about_ca_system_score_gemma":0.0064067673,"threshold_uncertainty_score":0.999226},"labels":[],"label_agreement":null},{"id":"W3172781556","doi":"10.1200/jco.2021.39.15_suppl.6568","title":"Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Confidence interval; Internal medicine; Twist; Adverse effect; Renal cell carcinoma; Oncology; Sunitinib; Surgery; Gastroenterology","score_opus":0.1826640897285275,"score_gpt":0.40764530672311505,"score_spread":0.22498121699458756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172781556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880398,0.004776648,0.00040974538,0.0010741117,0.0014194918,0.00027733642,0.00049688714,0.000004104401,0.0035018756],"genre_scores_gemma":[0.9933345,0.0028816035,0.00092623825,0.0001711882,0.0006507254,0.000012343481,0.000018603914,0.000029724884,0.0019751184],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943656,0.00011729073,0.0048175585,0.00028934024,0.00008830822,0.00032192277],"domain_scores_gemma":[0.98774594,0.0048075896,0.0064233146,0.0004263197,0.00043663773,0.0001601766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001586037,0.00023288872,0.0028750692,0.00016865532,0.00006238056,0.0000114502545,0.0003780602,0.00034956716,0.0005158821],"category_scores_gemma":[0.0016498405,0.00017822058,0.0009923074,0.0001679848,0.00048437002,0.00019898525,0.000061030845,0.00025902074,0.0000068392746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1366782,0.013570532,0.32890236,0.0011487561,0.004437525,0.00018063925,0.0033678152,0.0025833366,0.0006829581,0.018998653,0.0019020992,0.48754713],"study_design_scores_gemma":[0.09154895,0.08610526,0.7324831,0.00025625032,0.0009015138,0.00006584434,0.00084742374,0.00080220675,0.0094921095,0.0029968182,0.073768996,0.0007315272],"about_ca_topic_score_codex":0.000110336114,"about_ca_topic_score_gemma":0.001163006,"teacher_disagreement_score":0.4868156,"about_ca_system_score_codex":0.00028881192,"about_ca_system_score_gemma":0.0010205674,"threshold_uncertainty_score":0.7267625},"labels":[],"label_agreement":null},{"id":"W3172791693","doi":"10.1200/jco.2021.39.15_suppl.9569","title":"Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Clinical endpoint; Oncology; Population; Adjuvant; Clinical trial; Cancer; Immunotherapy","score_opus":0.07024500424129045,"score_gpt":0.4155460451486779,"score_spread":0.34530104090738745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172791693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782497,0.0005401661,0.00004120079,0.00092089106,0.00009772266,0.00014664062,0.000019015812,0.0000037933887,0.00040561453],"genre_scores_gemma":[0.9970607,0.0009342006,0.001068337,0.0006721049,0.00005329667,0.0000029324526,0.000020679456,0.00001477213,0.00017294096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631083,0.00048874354,0.0023424516,0.00022758734,0.0004067857,0.00022358689],"domain_scores_gemma":[0.99684876,0.00088140083,0.0013261609,0.00022572544,0.00056911,0.00014881413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00151226,0.00015941955,0.0023372748,0.0005000395,0.00001662479,0.000006015799,0.000113910566,0.00021980499,0.00056616333],"category_scores_gemma":[0.00047019715,0.00008969589,0.00045875937,0.001743076,0.00022634518,0.00010396687,0.000015781363,0.0005334317,9.4415464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14564706,0.0047371197,0.7861404,0.000046368186,0.005357826,0.002262364,0.00020273452,0.00012392462,0.00024431507,0.0000018921344,0.00008552967,0.055150498],"study_design_scores_gemma":[0.045869198,0.019335693,0.9268193,0.00027802333,0.0034742472,0.00009124221,0.0004041363,0.000110954694,0.0006497403,0.000003236045,0.0028529647,0.00011126991],"about_ca_topic_score_codex":0.00022370096,"about_ca_topic_score_gemma":0.0076358225,"teacher_disagreement_score":0.14067893,"about_ca_system_score_codex":0.00022287027,"about_ca_system_score_gemma":0.0018615994,"threshold_uncertainty_score":0.6199091},"labels":[],"label_agreement":null},{"id":"W3172804543","doi":"10.1200/jco.2021.39.15_suppl.9568","title":"Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Oncology; Internal medicine; Melanoma; Progression-free survival; Prospective cohort study; Chemotherapy; Cancer research","score_opus":0.15827150236902757,"score_gpt":0.48052849117317575,"score_spread":0.3222569888041482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172804543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966218,0.0003424343,0.00008035593,0.0011600486,0.00030132648,0.001265192,0.000012319227,0.0000077381765,0.00020878974],"genre_scores_gemma":[0.99482656,0.00009653527,0.004033506,0.0004871395,0.00027374673,0.00007187593,0.000010841345,0.000023949471,0.00017586276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486876,0.0012418167,0.0025892607,0.00030616124,0.0007615584,0.00023243],"domain_scores_gemma":[0.9949627,0.0023928313,0.0012450244,0.00018393164,0.0009389753,0.00027653406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037815806,0.00016905589,0.0014471055,0.0002570529,0.000031776082,0.0000115790735,0.00008405874,0.00015045768,0.0010713263],"category_scores_gemma":[0.0043515596,0.00011926632,0.00032225213,0.0002416296,0.00022517874,0.00011778937,0.00006203462,0.00095739705,0.000005543689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02478472,0.012302588,0.8472686,0.00008390317,0.00046229924,0.005024918,0.00091705815,0.000033895223,0.09842684,0.000004706844,0.000055239736,0.010635223],"study_design_scores_gemma":[0.04045477,0.019559082,0.8773783,0.0001413809,0.00016206241,0.0004999019,0.0012124407,0.00048759885,0.059559643,0.00016317815,0.0002830788,0.00009854967],"about_ca_topic_score_codex":0.000027834603,"about_ca_topic_score_gemma":0.000053263997,"teacher_disagreement_score":0.038867194,"about_ca_system_score_codex":0.0002614442,"about_ca_system_score_gemma":0.0021057485,"threshold_uncertainty_score":0.9998418},"labels":[],"label_agreement":null},{"id":"W3172838457","doi":"10.1200/jco.2021.39.15_suppl.tps2670","title":"A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Tolerability; Pembrolizumab; Stimulator of interferon genes; Oncology; Agonist; Internal medicine; Immunotherapy; Sting; Immune system; Pharmacology; Cancer; Immunology; Innate immune system; Adverse effect; Receptor","score_opus":0.07458423942254296,"score_gpt":0.41165501651634934,"score_spread":0.3370707770938064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172838457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986883,0.00018784599,0.00018070953,0.00020744021,0.00022294286,0.0004374338,0.0000072649377,0.000004140887,0.00006391644],"genre_scores_gemma":[0.9988875,0.000039876733,0.0008109501,0.00011362941,0.000012240375,0.000010365572,0.000016584878,0.00001566553,0.0000932119],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957844,0.0012620802,0.0023596617,0.00024166508,0.000106338965,0.0002458516],"domain_scores_gemma":[0.99578214,0.0015777636,0.0019382592,0.00014795625,0.0005064546,0.000047456164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001351492,0.00017607772,0.0015415073,0.00025607814,0.000046890727,0.000010856774,0.00013170535,0.00017431626,0.000049720547],"category_scores_gemma":[0.00203417,0.00011792083,0.00006733207,0.00026937466,0.00022495141,0.00018145038,0.00006003559,0.0007647464,0.0000016440675],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53174824,0.1463312,0.09683262,0.00014813337,0.0013565492,0.0015632757,0.006420321,0.00020010941,0.029470643,0.00005527981,0.00003712673,0.18583648],"study_design_scores_gemma":[0.22456041,0.2379243,0.52739024,0.00051657896,0.00025649942,0.00086010626,0.0047772387,0.00010139253,0.0031272268,0.000020640287,0.00025364704,0.00021171775],"about_ca_topic_score_codex":0.000039383987,"about_ca_topic_score_gemma":0.0011621418,"teacher_disagreement_score":0.43055764,"about_ca_system_score_codex":0.00010617002,"about_ca_system_score_gemma":0.0011407775,"threshold_uncertainty_score":0.48086718},"labels":[],"label_agreement":null},{"id":"W3172847254","doi":"10.1200/jco.2021.39.15_suppl.12034","title":"Incidence and risk factors for euthanasia or physician-assisted suicide in oncology patients: A systematic review.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Manitoba; Western University; University of Toronto; London Health Sciences Centre","funders":"","keywords":"Medicine; Incidence (geometry); Odds ratio; MEDLINE; Internal medicine; Family medicine; Emergency medicine","score_opus":0.46695782270563824,"score_gpt":0.5957346758948961,"score_spread":0.1287768531892579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172847254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97688156,0.01972183,0.000175133,0.0016242417,0.000542694,0.00065187615,0.00001691507,0.000004326421,0.0003814154],"genre_scores_gemma":[0.8756571,0.10885189,0.008252654,0.006542745,0.0004354563,0.000029799696,0.000017491631,0.000027583525,0.00018527012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99488646,0.0011674847,0.003283865,0.00019412398,0.0002705392,0.00019753248],"domain_scores_gemma":[0.98051757,0.01449604,0.003392826,0.0001837554,0.0011858074,0.00022398161],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029197356,0.00014758218,0.003597382,0.00010643368,0.00002262332,0.0000035649923,0.0001224066,0.00029825568,0.000021130261],"category_scores_gemma":[0.07474146,0.00009046016,0.0004459775,0.00025225113,0.00014820536,0.000094995754,0.000050390223,0.00060780055,0.000002030551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002852929,0.0028614511,0.92965454,0.0367955,0.0010348804,0.00083358533,0.0008373587,0.0000018115451,0.00006792019,0.00004500564,0.0021761777,0.022838863],"study_design_scores_gemma":[0.019003864,0.031308457,0.74765337,0.1749638,0.006220302,0.00020898822,0.0037166276,0.00008289453,0.0004217679,0.0004063852,0.015718468,0.00029507413],"about_ca_topic_score_codex":0.0000414365,"about_ca_topic_score_gemma":0.00039831825,"teacher_disagreement_score":0.18200114,"about_ca_system_score_codex":0.00021757679,"about_ca_system_score_gemma":0.0015104426,"threshold_uncertainty_score":0.93305236},"labels":[],"label_agreement":null},{"id":"W3172851126","doi":"10.1200/jco.2021.39.15_suppl.543","title":"Survival following locoregional recurrence in breast cancer by clinical subtype.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Kelowna General Hospital","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Cohort; Oncology; Cancer; Mastectomy; Estrogen receptor; Radiation therapy; Triple-negative breast cancer; Stage (stratigraphy); Metastasis","score_opus":0.0930485039421,"score_gpt":0.4679808840977072,"score_spread":0.3749323801556072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172851126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755224,0.005238237,0.000107973035,0.012548105,0.005781356,0.00006139285,0.0000446831,0.0000029838143,0.0006928586],"genre_scores_gemma":[0.9864713,0.00837764,0.0006602519,0.0019630187,0.0023137154,0.0000072882335,0.000020921167,0.00001721454,0.00016867393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963905,0.0008145215,0.0018917987,0.00036351138,0.00026441706,0.00027520928],"domain_scores_gemma":[0.99749833,0.0007631741,0.0009354911,0.00020024898,0.00038370796,0.00021904957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022876363,0.0001629638,0.0010438602,0.000031881733,0.00003830333,0.000009208914,0.00024155932,0.00044905246,0.000067320965],"category_scores_gemma":[0.0015724038,0.00013399689,0.0006751865,0.00014288038,0.00021909356,0.000010344166,0.00015728212,0.00063574396,0.0000067414253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001440262,0.0013544273,0.89008415,0.000005719685,0.00055864744,0.00039530263,0.000013443848,0.000011251732,0.0006094818,0.000021803977,0.02883502,0.076670475],"study_design_scores_gemma":[0.0060546705,0.0008922932,0.8645747,0.000078850375,0.00014150394,0.00018565943,0.00010060832,0.0000058839123,0.00030639794,0.00013591493,0.1273451,0.000178444],"about_ca_topic_score_codex":0.00005324125,"about_ca_topic_score_gemma":0.00051438593,"teacher_disagreement_score":0.09851008,"about_ca_system_score_codex":0.000081771854,"about_ca_system_score_gemma":0.0023218188,"threshold_uncertainty_score":0.5464235},"labels":[],"label_agreement":null},{"id":"W3172867079","doi":"10.1200/jco.2021.39.15_suppl.1004","title":"Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Clinical endpoint; Ven; Fulvestrant; Venetoclax; Oncology; Progression-free survival; Neutropenia; Estrogen receptor; Phases of clinical research; Gastroenterology; Cancer; Breast cancer; Chemotherapy; Randomized controlled trial; Leukemia","score_opus":0.08351404281916895,"score_gpt":0.45458919973083395,"score_spread":0.371075156911665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172867079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889971,0.0028072118,0.00032758247,0.0039674337,0.0018243779,0.001245712,0.0006287035,0.000017692504,0.00018419321],"genre_scores_gemma":[0.9763542,0.0022802462,0.019384513,0.00064377644,0.0008888216,0.00008345478,0.000037565867,0.00006664048,0.000260816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9890728,0.0029750122,0.005952087,0.00068259734,0.00080663513,0.0005108664],"domain_scores_gemma":[0.9774518,0.015551008,0.004218464,0.0005236435,0.0017085187,0.00054655486],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040547703,0.00045440262,0.005434746,0.00021129356,0.00006980739,0.000012547231,0.00035757048,0.00037086513,0.00086696993],"category_scores_gemma":[0.009666689,0.00033135363,0.000769686,0.0005776109,0.000801088,0.0003419219,0.00016108512,0.0019128467,0.0000069044113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8209911,0.012926553,0.00022313859,0.000051111972,0.0042221257,0.0032754098,0.0014196356,0.0016833523,0.0022167005,0.000016698623,0.000111429705,0.15286277],"study_design_scores_gemma":[0.9292941,0.04906695,0.005844117,0.0012119503,0.0022194278,0.0005629414,0.0034885197,0.00021507136,0.0023079119,0.0003197209,0.0051266747,0.0003426163],"about_ca_topic_score_codex":0.0005051652,"about_ca_topic_score_gemma":0.0037272822,"teacher_disagreement_score":0.15252015,"about_ca_system_score_codex":0.0008969576,"about_ca_system_score_gemma":0.008731761,"threshold_uncertainty_score":0.9999139},"labels":[],"label_agreement":null},{"id":"W3172886624","doi":"10.1200/jco.2021.39.15_suppl.10585","title":"Germline testing and somatic tumor testing for <i>BRCA1/2</i> pathogenic variants in ovarian cancer: What is the optimal sequence of testing?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Michael Smith Health Research BC","keywords":"Medicine; Germline; Oncology; Ovarian cancer; Genetic testing; Germline mutation; Cancer; Internal medicine; Genetics; Mutation; Biology","score_opus":0.12354802541700811,"score_gpt":0.42829403364463803,"score_spread":0.3047460082276299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172886624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956776,0.0044949483,0.0010241721,0.003797374,0.00074273197,0.00021844338,0.00003376468,0.0000024446354,0.00011835839],"genre_scores_gemma":[0.82628065,0.00046142278,0.16995183,0.002374868,0.00084868015,0.000024948366,0.000003037075,0.000021719474,0.000032875843],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971263,0.00035086257,0.0018066894,0.0002997848,0.00016488104,0.0002514767],"domain_scores_gemma":[0.99267334,0.0041211015,0.0016984324,0.0002480137,0.001150482,0.000108641485],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029387374,0.00014269131,0.00065133243,0.000043131953,0.00007493557,0.00003236638,0.00027292152,0.00022066382,0.000011280617],"category_scores_gemma":[0.020133657,0.00010989437,0.00015313947,0.0003195626,0.00027959983,0.000023915256,0.00015397297,0.00039579775,3.7474982e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003302658,0.00039093875,0.11087929,0.00012560516,0.00020611614,0.00018395015,0.00017388842,0.0025734212,0.65022796,0.000018840588,0.0003843338,0.23450539],"study_design_scores_gemma":[0.030208556,0.029401287,0.6913986,0.0038934234,0.001882819,0.010730134,0.0033430792,0.05491475,0.1473872,0.009687399,0.015477995,0.0016747274],"about_ca_topic_score_codex":0.000031674906,"about_ca_topic_score_gemma":0.00006577628,"teacher_disagreement_score":0.5805193,"about_ca_system_score_codex":0.0000760106,"about_ca_system_score_gemma":0.0042171488,"threshold_uncertainty_score":0.9881202},"labels":[],"label_agreement":null},{"id":"W3172937358","doi":"10.1200/jco.2021.39.15_suppl.4514","title":"Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Axitinib; Cabozantinib; Internal medicine; Oncology; Renal cell carcinoma; Everolimus; Regimen; Clinical trial; Interim analysis; Neutropenia; Sunitinib; Chemotherapy","score_opus":0.13137860493998124,"score_gpt":0.4213184102139248,"score_spread":0.2899398052739436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172937358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99186146,0.0010628252,0.000008174469,0.003806718,0.0005016053,0.00043533868,0.000011676149,0.0000064417163,0.0023057559],"genre_scores_gemma":[0.9914973,0.0020422358,0.005291701,0.00037755756,0.00023852603,0.000014394088,0.000020663942,0.000026568843,0.00049106934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99441314,0.00089049985,0.003454741,0.00036371342,0.00053818047,0.00033969997],"domain_scores_gemma":[0.9941784,0.0021637196,0.0020512473,0.00030458765,0.00086905237,0.00043296872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017503193,0.00026517146,0.0026192416,0.00020318881,0.00003270515,0.000011852178,0.00011228781,0.0003923662,0.00019181384],"category_scores_gemma":[0.003342362,0.00018003098,0.000566872,0.00020163412,0.00021432276,0.0001005014,0.000078289595,0.0006251244,0.000006225962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032830941,0.00547278,0.86124694,0.000049324033,0.00060016016,0.002031431,0.00037023306,0.000009536701,0.0002650194,0.00001242608,0.0002210488,0.12643799],"study_design_scores_gemma":[0.022426141,0.017972086,0.95050234,0.00034521028,0.00048519621,0.0002005794,0.00019452587,0.000040592935,0.0024948828,0.00008154658,0.0051289177,0.00012800154],"about_ca_topic_score_codex":0.00003606961,"about_ca_topic_score_gemma":0.00019345169,"teacher_disagreement_score":0.12630999,"about_ca_system_score_codex":0.00062517606,"about_ca_system_score_gemma":0.0018300021,"threshold_uncertainty_score":0.73414505},"labels":[],"label_agreement":null},{"id":"W3172939869","doi":"10.1200/jco.2021.39.15_suppl.8563","title":"Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; PARP inhibitor; Cancer research; Internal medicine; Oncology; Poly ADP ribose polymerase; Biology; Gene; Polymerase","score_opus":0.06330536481527846,"score_gpt":0.44215222228506307,"score_spread":0.37884685746978464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172939869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981626,0.0005561996,0.000029830126,0.00044146448,0.00009229988,0.0005265209,0.00001491359,0.000006731714,0.00016938653],"genre_scores_gemma":[0.99771845,0.0006086659,0.0013296644,0.00016823306,0.000034739638,0.000019375626,0.000020216949,0.000014295887,0.000086345106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658406,0.00088719313,0.0014446264,0.0002838703,0.0005648795,0.00023537762],"domain_scores_gemma":[0.9952563,0.0015703326,0.0012911404,0.00017790389,0.0015084286,0.00019587133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016792269,0.0001441361,0.0016979525,0.0004701505,0.000033731103,0.000006428389,0.000056924568,0.00009631999,0.000040585066],"category_scores_gemma":[0.0015782684,0.00009012056,0.00016929428,0.0009366862,0.0001410591,0.000076501754,0.000034702025,0.0005535809,2.46587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010565599,0.0058370885,0.96809787,0.00010448932,0.00589369,0.0012097039,0.00069736486,0.0006083397,0.000028991444,0.0000015990904,0.00006587821,0.0068893647],"study_design_scores_gemma":[0.023881389,0.0342348,0.9336508,0.00012065858,0.006613896,0.00001173083,0.00064362556,0.00053539954,0.0001934313,0.000005690052,0.00002940583,0.000079153346],"about_ca_topic_score_codex":0.00037917728,"about_ca_topic_score_gemma":0.003121303,"teacher_disagreement_score":0.03444707,"about_ca_system_score_codex":0.00051713525,"about_ca_system_score_gemma":0.0014467586,"threshold_uncertainty_score":0.36750096},"labels":[],"label_agreement":null},{"id":"W3172986545","doi":"10.1200/jco.2021.39.15_suppl.10568","title":"Prior tonsillectomy and subsequent risk of breast cancer in females: Systematic review and meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tonsillectomy; Medicine; Meta-analysis; Odds ratio; Publication bias; Breast cancer; Cancer; Risk factor; Internal medicine; Pediatrics; Surgery","score_opus":0.1451825606164366,"score_gpt":0.4715037627538687,"score_spread":0.3263212021374321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172986545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6076802,0.37922534,0.000013534169,0.012150556,0.00010209457,0.0006298704,0.000041432995,0.0000034581533,0.00015351597],"genre_scores_gemma":[0.91771626,0.078023426,0.0016159056,0.0024568683,0.000062160376,0.000032178064,9.958984e-7,0.000010875951,0.0000813456],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99401176,0.0018253877,0.003511446,0.00020465768,0.0003055753,0.00014116954],"domain_scores_gemma":[0.993798,0.0020930062,0.0028185921,0.0002498424,0.00075054436,0.00028997895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062187547,0.00013757557,0.006186447,0.00017965908,0.000019329296,0.0000060583416,0.000084165484,0.00019282967,0.00046450575],"category_scores_gemma":[0.0057399054,0.000084001906,0.0013465588,0.00042745483,0.0002255137,0.00006054343,0.00006537739,0.00046901184,8.8998587e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073283544,0.00091280264,0.7011417,0.07872417,0.21578895,0.0014642811,0.000090928486,0.0000037795385,0.00002693114,0.000026693835,0.00024473638,0.00084215245],"study_design_scores_gemma":[0.0013987833,0.0002809885,0.44750333,0.0019687435,0.5480597,0.0005457659,0.00006881846,0.000020810381,0.000015581369,0.00003077578,0.00004698532,0.000059690647],"about_ca_topic_score_codex":0.000017652876,"about_ca_topic_score_gemma":0.0001531707,"teacher_disagreement_score":0.33227077,"about_ca_system_score_codex":0.00008586052,"about_ca_system_score_gemma":0.0011737064,"threshold_uncertainty_score":0.68716174},"labels":[],"label_agreement":null},{"id":"W3173018072","doi":"10.1200/jco.2021.39.15_suppl.9523","title":"Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in <i>BRAF</i><sup>V600</sup> mutation–positive advanced melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Hazard ratio; Internal medicine; Lactate dehydrogenase; Atezolizumab; Vemurafenib; Oncology; Cancer; Metastatic melanoma; Pembrolizumab; Immunotherapy; Confidence interval; Enzyme; Biology","score_opus":0.021735436523024704,"score_gpt":0.3452379577453137,"score_spread":0.32350252122228895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173018072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625605,0.0010156619,0.00038193143,0.0016989072,0.00017931437,0.0003355738,0.00005409595,0.0000034898549,0.0000749906],"genre_scores_gemma":[0.9952568,0.0005271235,0.00299537,0.00067161245,0.00031054017,0.000026522752,0.00005254728,0.000022342521,0.00013715602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996499,0.0012434202,0.0014096592,0.00041576175,0.00019863498,0.00023350629],"domain_scores_gemma":[0.9954272,0.0029625965,0.00073787075,0.00018045718,0.00035254247,0.00033932173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001272556,0.00023972765,0.00089549477,0.0001355467,0.000049965136,0.000011724199,0.00011752036,0.00024453155,0.000019194333],"category_scores_gemma":[0.0044257883,0.00018886414,0.00018728225,0.00011180674,0.0001283575,0.000015759593,0.00010975851,0.00025212576,0.0000030046904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09503812,0.002783965,0.0018277427,0.00012678368,0.00045531156,0.006549996,0.0013656061,0.0060415976,0.80701876,0.000032549102,0.00038830983,0.07837124],"study_design_scores_gemma":[0.024286412,0.05764819,0.023045205,0.0004756413,0.00019871448,0.0011361255,0.00037907486,0.0007254999,0.87734383,0.00016060246,0.014253506,0.00034722412],"about_ca_topic_score_codex":0.000012714122,"about_ca_topic_score_gemma":0.00007869634,"teacher_disagreement_score":0.078024015,"about_ca_system_score_codex":0.00007527892,"about_ca_system_score_gemma":0.00066329684,"threshold_uncertainty_score":0.7701656},"labels":[],"label_agreement":null},{"id":"W3173023813","doi":"10.1200/jco.2021.39.15_suppl.e21216","title":"Overall survival comparison in patients with and without brain metastases treated with osimertinib for metastatic EGFR mutation positive non-small cell lung cancer (NSCLC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Pediatric Oncology Group; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brain metastasis; Osimertinib; Metastasis; Radiosurgery; Oncology; Internal medicine; Lung cancer; Population; non-small cell lung cancer (NSCLC); Radiation therapy; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.051671690123083786,"score_gpt":0.4544418732681256,"score_spread":0.40277018314504176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173023813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424076,0.0006234939,0.0019247663,0.001896307,0.00015768694,0.00074434665,0.00007090231,0.000004648671,0.00033711144],"genre_scores_gemma":[0.98506635,0.00006265632,0.013365321,0.0010235807,0.00009564495,0.00003643821,0.00009926172,0.000024951374,0.00022578379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978446,0.0003286586,0.0011394098,0.00023964731,0.00024055071,0.00020713508],"domain_scores_gemma":[0.99631023,0.0014529143,0.0010793181,0.000095524505,0.0008392526,0.0002227839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059879187,0.00017204415,0.0013158441,0.00010272857,0.00004614473,0.000016665328,0.00004206725,0.00009284788,0.00002878152],"category_scores_gemma":[0.00034957685,0.0001058924,0.00012822515,0.00015093731,0.00009170398,0.00012835364,0.0000137148345,0.00031865848,4.052266e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011434944,0.0031980304,0.9701275,0.00008701609,0.0017128907,0.00022043302,0.0004940851,0.00032592766,0.000037335576,0.000015824327,0.00035596397,0.011990017],"study_design_scores_gemma":[0.057967443,0.015937032,0.91908795,0.00036836963,0.0043301196,0.00003997528,0.00041340126,0.0007310929,0.00038206574,0.000016830401,0.0005929424,0.00013278084],"about_ca_topic_score_codex":0.00019166585,"about_ca_topic_score_gemma":0.0008589148,"teacher_disagreement_score":0.051039584,"about_ca_system_score_codex":0.00021918255,"about_ca_system_score_gemma":0.0019135618,"threshold_uncertainty_score":0.43181667},"labels":[],"label_agreement":null},{"id":"W3173030298","doi":"10.1200/jco.2021.39.15_suppl.2546","title":"A 4-chemokine signature to predict intermediate immunogenicity in homologous recombination repair deficient tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McGill University Health Centre","funders":"","keywords":"Chemokine; Medicine; Immune checkpoint; Cancer research; Immunology; Immunotherapy; Gene signature; Immune system; Cancer; Biology; Internal medicine; Gene expression; Gene","score_opus":0.053055332531290286,"score_gpt":0.41124278167931455,"score_spread":0.35818744914802425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173030298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572725,0.0017445689,0.00006912756,0.008938078,0.002108125,0.00019828204,0.0000040957,0.000015590238,0.0011948547],"genre_scores_gemma":[0.99058485,0.0008938533,0.0016416137,0.005965453,0.00044852204,0.0000054453726,0.000006791919,0.000012698286,0.00044079326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961594,0.00047309534,0.002566167,0.00023819324,0.00032613814,0.00023704385],"domain_scores_gemma":[0.99713165,0.00087328424,0.0009665005,0.00024007872,0.0005670511,0.00022145173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038876229,0.00012835512,0.0011920991,0.00020123132,0.000024116605,0.0000073608007,0.0001489505,0.0004218244,0.00028044384],"category_scores_gemma":[0.005620515,0.00009930118,0.0007067075,0.00043771297,0.00011537214,0.00006519743,0.0000774564,0.0012131409,0.00001033615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06889544,0.011203452,0.3139142,0.00014866766,0.0013973862,0.01568931,0.0011317651,0.0000734637,0.029630287,0.00006924383,0.026908796,0.53093797],"study_design_scores_gemma":[0.01315967,0.011611096,0.9281237,0.0003844006,0.0001486013,0.0014716953,0.00020748955,0.000082973624,0.0027683198,0.00020367856,0.041726217,0.000112147616],"about_ca_topic_score_codex":0.00002761642,"about_ca_topic_score_gemma":0.00011816934,"teacher_disagreement_score":0.6142095,"about_ca_system_score_codex":0.00047457858,"about_ca_system_score_gemma":0.0017774851,"threshold_uncertainty_score":0.6728687},"labels":[],"label_agreement":null},{"id":"W3173104081","doi":"10.1200/jco.2021.39.15_suppl.e24091","title":"Implementation of virtual mentoring to optimize collection of patient-reported data in the COVID-19 era: A prospective cohort study with adaptive design.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Prospective cohort study; Family medicine; Ambulatory; Cohort study; Physical therapy; Surgery; Internal medicine","score_opus":0.3435884605274133,"score_gpt":0.5696552764718703,"score_spread":0.226066815944457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173104081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831141,0.000044794626,0.0068462566,0.0076039024,0.0002837525,0.0020122258,0.000008401544,0.0000034083357,0.00008315415],"genre_scores_gemma":[0.99173754,0.000070922026,0.005541599,0.002450346,0.00014640357,0.000024960385,0.000005169686,0.000008523892,0.000014520954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503654,0.0014153608,0.0024222746,0.0002545417,0.0006992209,0.00017206301],"domain_scores_gemma":[0.9921433,0.0040048747,0.0021632174,0.00036057454,0.0010217595,0.00030632011],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007932079,0.0001039718,0.0011309698,0.00018448013,0.000044951932,0.0000054444754,0.0001529539,0.0001084874,0.000051155053],"category_scores_gemma":[0.010819521,0.00006564096,0.000087950364,0.0006199278,0.000072001785,0.00012435442,0.00008934754,0.00055550504,2.9876912e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01891465,0.0032436973,0.9592695,0.00002723015,0.00074304023,0.0008392236,0.0073927906,0.00057101273,0.000092116104,0.000020458396,0.0009488507,0.007937404],"study_design_scores_gemma":[0.011575189,0.07457163,0.88691765,0.00006406404,0.0005856812,0.0002771859,0.025086563,0.00007233425,0.00017991678,0.000039018807,0.00057493965,0.000055821358],"about_ca_topic_score_codex":0.0015342361,"about_ca_topic_score_gemma":0.004323298,"teacher_disagreement_score":0.07235187,"about_ca_system_score_codex":0.0006645359,"about_ca_system_score_gemma":0.012724955,"threshold_uncertainty_score":0.99751276},"labels":[],"label_agreement":null},{"id":"W3173110589","doi":"10.1200/jco.2021.39.15_suppl.2509","title":"Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis","keywords":"Medicine; Tolerability; Lung cancer; Internal medicine; Cancer; Monoclonal antibody; Oncology; Pharmacology; Antibody; Adverse effect; Immunology","score_opus":0.04631767264630706,"score_gpt":0.4352997352500569,"score_spread":0.38898206260374985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173110589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965908,0.00019855327,0.000009259042,0.0014829674,0.00077875686,0.0006481032,0.000007509705,0.000005952626,0.00027811603],"genre_scores_gemma":[0.9982653,0.00014907095,0.00037744935,0.00089084794,0.0002143436,0.0000070071897,0.0000074573773,0.00002610044,0.000062383835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99535984,0.0006095405,0.0027036432,0.00029438408,0.0007368011,0.00029578136],"domain_scores_gemma":[0.9957361,0.00054991647,0.0023757266,0.0003816973,0.000760284,0.00019626242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013170339,0.00022698173,0.0020061412,0.0001256512,0.000058682188,0.000010896879,0.00023121168,0.00019679686,0.00011111063],"category_scores_gemma":[0.00059327506,0.00012300233,0.00032648983,0.00053974177,0.00036805173,0.00013609324,0.000074476215,0.0009688218,0.000001298658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16369255,0.05406021,0.747776,0.00005036546,0.0010573524,0.001562128,0.00056864275,0.000061048755,0.00249252,0.000007605979,0.0003858876,0.028285751],"study_design_scores_gemma":[0.16100648,0.1395308,0.69402707,0.0005558727,0.00032214422,0.00024028504,0.00090149004,0.0000325513,0.001616766,0.000015040331,0.0016131711,0.00013833534],"about_ca_topic_score_codex":0.000046301593,"about_ca_topic_score_gemma":0.0004107428,"teacher_disagreement_score":0.08547058,"about_ca_system_score_codex":0.00016720718,"about_ca_system_score_gemma":0.0027734027,"threshold_uncertainty_score":0.50158894},"labels":[],"label_agreement":null},{"id":"W3173121018","doi":"10.1200/jco.2021.39.15_suppl.10011","title":"Pilot study of nivolumab in pediatric patients with hypermutant cancers.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; BC Children's Hospital; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Anaplastic astrocytoma; Cancer; Gastroenterology; Immunotherapy; Astrocytoma; Glioma; Cancer research","score_opus":0.09674376150019964,"score_gpt":0.42357655444252346,"score_spread":0.3268327929423238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173121018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775565,0.00040463026,7.359969e-7,0.00066260365,0.0005024017,0.00020082951,0.0000019723866,0.0000016902426,0.00046950954],"genre_scores_gemma":[0.99878067,0.00030794594,0.0003430716,0.00026387864,0.00027640688,0.0000041897106,0.000001183982,0.000009072754,0.000013580963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750304,0.0002608827,0.0015927072,0.00014245603,0.00036559903,0.00013534093],"domain_scores_gemma":[0.9971176,0.00090962945,0.001050044,0.00014748932,0.0005981841,0.00017706199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063996913,0.00008732573,0.001187368,0.00012544263,0.00001211693,0.0000024492692,0.00006504034,0.00006196305,0.000073207324],"category_scores_gemma":[0.001139457,0.00005438072,0.00011552219,0.00027503466,0.000039395578,0.000041187774,0.00003115287,0.00040869112,0.000002478764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003124903,0.040369295,0.9448715,0.000015623504,0.00024314845,0.0025330673,0.00008809943,0.000025127652,0.000012150112,0.0000037957873,0.00035580993,0.0083575],"study_design_scores_gemma":[0.03462394,0.10466226,0.8594539,0.00004581488,0.000572143,0.000036216683,0.00021478986,0.000003255689,0.000024182864,0.0000116581305,0.00031114332,0.000040689676],"about_ca_topic_score_codex":0.00009696354,"about_ca_topic_score_gemma":0.0014105209,"teacher_disagreement_score":0.085417576,"about_ca_system_score_codex":0.00020983088,"about_ca_system_score_gemma":0.0018682247,"threshold_uncertainty_score":0.33141506},"labels":[],"label_agreement":null},{"id":"W3173121797","doi":"10.1200/jco.2021.39.15_suppl.512","title":"Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Breast cancer; Cohort; Oncology; Breast-conserving surgery; Internal medicine; Proportional hazards model; Radiation therapy; Stage (stratigraphy); Gene signature; Adjuvant; Cancer; Adjuvant therapy; Mastectomy; Gene","score_opus":0.026738581134378003,"score_gpt":0.3647800698453662,"score_spread":0.3380414887109882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173121797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913425,0.0029781873,0.00014425804,0.004870237,0.00033136606,0.00011729646,0.00019059208,0.0000018089901,0.000023794975],"genre_scores_gemma":[0.99272215,0.0043391087,0.0005108641,0.001538715,0.0006273463,0.00002504233,0.000006838339,0.000024274332,0.00020568578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979109,0.00036186882,0.00096895854,0.0003217086,0.00018930055,0.00024726844],"domain_scores_gemma":[0.99771154,0.0004889372,0.00094420323,0.0002081198,0.00046062036,0.00018657975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075163756,0.00018903064,0.0010320105,0.00007143257,0.000037782662,0.000029188177,0.00012678247,0.00025654168,0.00008744105],"category_scores_gemma":[0.00019043413,0.00014030426,0.00020296597,0.00010250531,0.00016765772,0.000031066393,0.00012620442,0.00025607497,9.304041e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01665197,0.00043347228,0.8820249,0.00007431495,0.0020462093,0.00035203496,0.00052998005,0.000110175555,0.07405745,0.0000035712073,0.0007434808,0.022972448],"study_design_scores_gemma":[0.0024330341,0.000987927,0.9862349,0.0001709818,0.00014947217,0.00053615036,0.00026640054,7.287277e-7,0.0073339744,0.00001571648,0.001713562,0.00015715334],"about_ca_topic_score_codex":0.000112232505,"about_ca_topic_score_gemma":0.00044952356,"teacher_disagreement_score":0.10421001,"about_ca_system_score_codex":0.00015017886,"about_ca_system_score_gemma":0.0015573159,"threshold_uncertainty_score":0.57214415},"labels":[],"label_agreement":null},{"id":"W3173494220","doi":"10.1200/jco.21.00169","title":"Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Astellas Pharma; University of Wisconsin Carbone Cancer Center; U.S. Department of Defense","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen receptor; Prospective cohort study; Internal medicine; Oncology; Hazard ratio; Cancer; Prostate biopsy; Prostate; Androgen deprivation therapy; PTEN; Confidence interval; Biology; PI3K/AKT/mTOR pathway","score_opus":0.3465071294292043,"score_gpt":0.5814825905054469,"score_spread":0.23497546107624262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173494220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925053,0.0024674134,0.00013809439,0.0027320716,0.0011430314,0.00071647204,0.000020399339,0.0000053525396,0.00027182433],"genre_scores_gemma":[0.9726804,0.0015810168,0.024814138,0.0002561644,0.00027724926,0.000023560051,0.000006132875,0.000019980547,0.00034137067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99246377,0.00203909,0.0037422406,0.00034254143,0.0010895394,0.00032283674],"domain_scores_gemma":[0.99166805,0.0023998083,0.0024462852,0.00019338695,0.0030119552,0.00028050394],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014866581,0.00016575286,0.0021345192,0.00018273761,0.00004881187,0.0000084952435,0.00012176043,0.00024075754,0.00022279528],"category_scores_gemma":[0.018223811,0.00011280338,0.00062056934,0.00041409812,0.00027757106,0.00017063426,0.00009731187,0.0010307176,0.0000026594964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02726835,0.004052116,0.9377983,0.0001800264,0.001759779,0.0024175658,0.0007612059,0.0003676638,0.004507357,0.0001188311,0.00019739222,0.020571416],"study_design_scores_gemma":[0.05708764,0.007525248,0.91751957,0.0009377436,0.0024165942,0.00010165835,0.0028120207,0.0033808881,0.0043082014,0.0029291806,0.00075042556,0.0002308282],"about_ca_topic_score_codex":0.00010022799,"about_ca_topic_score_gemma":0.0004152186,"teacher_disagreement_score":0.029819293,"about_ca_system_score_codex":0.0005988903,"about_ca_system_score_gemma":0.0086858,"threshold_uncertainty_score":0.99693406},"labels":[],"label_agreement":null},{"id":"W3175822154","doi":"10.1200/jco.2017.35.15_suppl.4559","title":"Applying radiomics to predict pathology of post chemotherapy retroperitoneal nodal masses in germ cell tumors (GCT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiomics; Germ cell tumors; Lymph node; Radiology; Pathological; Retroperitoneal lymph node dissection; Chemotherapy; Internal medicine; Testicular cancer","score_opus":0.08234636476161329,"score_gpt":0.4388052458194278,"score_spread":0.35645888105781454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175822154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98614407,0.00041108404,0.00002073917,0.00989416,0.0008502038,0.00041741654,0.0000078471485,0.000004589098,0.0022498856],"genre_scores_gemma":[0.98782367,0.0010411039,0.00757676,0.0026223855,0.0008420809,0.000020284015,0.000001836538,0.000023087998,0.000048803715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967496,0.0002479311,0.0022220847,0.00022375573,0.0002848818,0.0002717559],"domain_scores_gemma":[0.99558216,0.0012009416,0.0021606192,0.00041359162,0.00029861182,0.00034409002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002274063,0.00015988786,0.0018960097,0.00018210462,0.0000545439,0.000013150087,0.00032445704,0.00035195268,0.00009399851],"category_scores_gemma":[0.0028175635,0.00011301913,0.00045014787,0.00006297351,0.0002459314,0.00008479169,0.00008442835,0.0006838184,0.000010673045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038494917,0.0035954672,0.8563751,0.00003131476,0.000121059726,0.004300584,0.00013008338,0.000008144325,0.002593101,0.000027617165,0.00072729576,0.12824076],"study_design_scores_gemma":[0.01159255,0.01244406,0.95815134,0.00015009445,0.00014201846,0.00076359435,0.0001452534,0.00003332636,0.0020406253,0.000052478743,0.014394686,0.00008998978],"about_ca_topic_score_codex":0.000069383874,"about_ca_topic_score_gemma":0.00004744176,"teacher_disagreement_score":0.12815078,"about_ca_system_score_codex":0.00017889241,"about_ca_system_score_gemma":0.00096155243,"threshold_uncertainty_score":0.46087864},"labels":[],"label_agreement":null},{"id":"W3179702411","doi":"10.1200/jco.21.00703","title":"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Vincristine; Neuroblastoma; Refractory (planetary science); Irinotecan; Clinical endpoint; Internal medicine; Surgery; Vorinostat; Randomized controlled trial; Chemotherapy; Cyclophosphamide; Oncology; Cancer","score_opus":0.11370924759814623,"score_gpt":0.4651826797140354,"score_spread":0.35147343211588916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179702411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945583,0.00022841271,0.000038805025,0.0013661715,0.002309657,0.0012251859,0.00008270711,0.000009644342,0.00018114732],"genre_scores_gemma":[0.99366945,0.00074521784,0.0044333586,0.00015438048,0.00056459423,0.000029155604,0.000047641715,0.000036422596,0.0003197743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994827,0.00092587824,0.002806376,0.00046924414,0.0006243465,0.00034719563],"domain_scores_gemma":[0.97680455,0.01832941,0.0026245401,0.0003365936,0.0011589965,0.0007459332],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001687865,0.00025790956,0.002826951,0.00014655483,0.00009475482,0.000014451549,0.00009997216,0.0002797537,0.00008683263],"category_scores_gemma":[0.035878893,0.00015743893,0.0004536011,0.00013929732,0.0006716448,0.0001224871,0.0001244644,0.00077206333,0.0000013524651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9568937,0.011833662,0.0015746737,0.00005129581,0.0017471634,0.0092455745,0.000038300477,3.1226836e-7,0.0002547806,0.000005443102,0.0013021413,0.017052978],"study_design_scores_gemma":[0.77837104,0.20252061,0.0058369567,0.00011402296,0.0016455615,0.00023621113,0.000039937935,0.000029819208,0.00028784407,0.000021759388,0.010791002,0.000105251595],"about_ca_topic_score_codex":0.00004044925,"about_ca_topic_score_gemma":0.0001090817,"teacher_disagreement_score":0.19068696,"about_ca_system_score_codex":0.00008041315,"about_ca_system_score_gemma":0.0026396406,"threshold_uncertainty_score":0.9722423},"labels":[],"label_agreement":null},{"id":"W3184057816","doi":"10.1200/jco.21.00278","title":"Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":474,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Neuroblastoma; Medicine; Cog; Oncology; Histology; Internal medicine; Stage (stratigraphy); Disease; Pathology; Biology","score_opus":0.12262370967840236,"score_gpt":0.46339577302063695,"score_spread":0.3407720633422346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184057816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770829,0.0005142575,0.00020926636,0.015394736,0.0014994912,0.00037321053,0.000018298964,0.000026915157,0.004880928],"genre_scores_gemma":[0.9918235,0.001424324,0.0021838357,0.0018628471,0.0023828088,0.0000108942495,0.000032567565,0.000027254706,0.00025199575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99260736,0.0031066563,0.002896391,0.00040376993,0.00066651264,0.00031928776],"domain_scores_gemma":[0.9880137,0.00667348,0.0032499593,0.00064114964,0.00083108776,0.0005906643],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036239203,0.00017863429,0.0015408434,0.00007686085,0.00012698256,0.00002404291,0.00026293137,0.00040215987,0.00013410472],"category_scores_gemma":[0.0150077455,0.00010456426,0.0007806037,0.00027917582,0.00027761233,0.00010116235,0.000117718875,0.0020373603,0.000107041844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010436943,0.007115802,0.5792899,0.00004646507,0.0028898267,0.07559879,0.00007916457,0.0000047336434,0.003010642,0.00025871777,0.040715616,0.28055337],"study_design_scores_gemma":[0.008341029,0.009534642,0.893884,0.00014158954,0.00095378014,0.0171172,0.00015795586,0.000073054274,0.00014910907,0.000096177704,0.06947884,0.00007263783],"about_ca_topic_score_codex":0.00006485023,"about_ca_topic_score_gemma":0.000080564685,"teacher_disagreement_score":0.31459406,"about_ca_system_score_codex":0.00033803185,"about_ca_system_score_gemma":0.0031501437,"threshold_uncertainty_score":0.9932893},"labels":[],"label_agreement":null},{"id":"W3184088459","doi":"10.1200/jco.21.01208","title":"Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; University of British Columbia; BC Cancer Agency","funders":"National Institute for Health and Care Research; American Society of Clinical Oncology; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Guideline; Cancer; Salivary gland; Salivary gland cancer; Internal medicine; Oncology; Gynecology; Pathology","score_opus":0.14200916481561912,"score_gpt":0.4699000816716563,"score_spread":0.3278909168560372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184088459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9424693,0.0071328827,0.0008272164,0.04348751,0.0030564154,0.0001440241,0.000018073455,0.000020888601,0.0028437153],"genre_scores_gemma":[0.9501168,0.017492801,0.0031295088,0.023106314,0.0036123516,0.0000107194255,0.00003893192,0.00003749294,0.0024550918],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674946,0.00036201507,0.0020767946,0.0002599125,0.00031978646,0.00023201415],"domain_scores_gemma":[0.99629253,0.0016455579,0.00078749284,0.0001936812,0.0006341832,0.00044654953],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015868151,0.00016974605,0.0012750454,0.000083013816,0.000086890264,0.000018072216,0.00007637065,0.0005223833,0.002087756],"category_scores_gemma":[0.0023646876,0.00010525937,0.00036216134,0.00022098461,0.00013635388,0.00012011205,0.000051129533,0.00094281806,0.000013057928],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021580629,0.0041820155,0.2758085,0.00005364156,0.0015172061,0.0012728347,0.00021746119,0.0000072577704,0.004715063,0.00009361993,0.38784268,0.30270907],"study_design_scores_gemma":[0.018984778,0.008994632,0.15710203,0.00009722486,0.0007336791,0.0015863355,0.00064225163,0.00015517608,0.00009412096,0.0003078759,0.8111162,0.00018565304],"about_ca_topic_score_codex":0.00009487807,"about_ca_topic_score_gemma":0.00013010792,"teacher_disagreement_score":0.42327356,"about_ca_system_score_codex":0.00007790261,"about_ca_system_score_gemma":0.0021528369,"threshold_uncertainty_score":0.9988245},"labels":[],"label_agreement":null},{"id":"W3184914919","doi":"10.1200/jco.21.00934","title":"Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":287,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Western University; Juravinski Cancer Centre; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Guideline; Breast cancer; Axilla; Stage (stratigraphy); Cancer; Cancer registry; Gynecology; Oncology; Family medicine; General surgery; Internal medicine; Pathology","score_opus":0.04774061728456526,"score_gpt":0.4223733268439016,"score_spread":0.37463270955933636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184914919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97296005,0.009375157,0.000008899979,0.015791038,0.000899049,0.00012323263,0.00004264313,9.925167e-7,0.0007989384],"genre_scores_gemma":[0.97682774,0.018005483,0.0016156464,0.0021801766,0.00032990976,0.00001152936,0.0000065946097,0.000012673412,0.001010274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977849,0.00021642003,0.0013720174,0.00023624917,0.0001914938,0.00019889261],"domain_scores_gemma":[0.9981373,0.000050281687,0.0010150844,0.00027441798,0.00041359718,0.00010933536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006040759,0.00013264321,0.00074308645,0.000024599176,0.000045663666,0.000005637662,0.00021774544,0.00016433423,0.00012798498],"category_scores_gemma":[0.00005598372,0.000090752685,0.00021670634,0.00008483574,0.0001449259,0.0000054730167,0.000350215,0.0003608368,2.9442347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007321027,0.0003069613,0.8981832,0.000037414786,0.0005913197,0.00008797523,0.0006538426,0.000113622424,0.00004522794,0.000023089342,0.0016468032,0.0975784],"study_design_scores_gemma":[0.0030506605,0.0005344088,0.8216402,0.00012224431,0.00009371121,0.000053415162,0.00053978,4.7983235e-7,0.0001438519,0.000027526115,0.17372666,0.00006706835],"about_ca_topic_score_codex":0.11192833,"about_ca_topic_score_gemma":0.8695572,"teacher_disagreement_score":0.75762886,"about_ca_system_score_codex":0.00062757684,"about_ca_system_score_gemma":0.004456832,"threshold_uncertainty_score":0.8939854},"labels":[],"label_agreement":null},{"id":"W3188798727","doi":"10.1200/jco.21.00018","title":"Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Children's Hospital of Eastern Ontario; McMaster Children's Hospital; London Health Sciences Centre; Hamilton Health Sciences; Montreal Children's Hospital; University of Toronto; SickKids Foundation; Hospital for Sick Children; Pediatric Oncology Group; McGill University Health Centre; Kingston Health Sciences Centre; Public Health Ontario","funders":"","keywords":"Medicine; Cancer; Oncology; Malignancy; Hazard ratio; Cancer registry; Internal medicine; Genetic predisposition; Confidence interval; Disease","score_opus":0.12420558472700689,"score_gpt":0.4623034389435252,"score_spread":0.33809785421651833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188798727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808434,0.0030533138,0.0016363325,0.011255658,0.0022986315,0.0005687269,0.00012337351,0.000014361515,0.00020616414],"genre_scores_gemma":[0.98761684,0.0015825672,0.0066009066,0.002108666,0.0019370718,0.000038757906,0.000016865035,0.0000324392,0.00006588873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928741,0.00090294174,0.0046776826,0.00041014573,0.0007129565,0.00042216718],"domain_scores_gemma":[0.9915705,0.0036039755,0.0029992831,0.000305403,0.0011835862,0.0003372751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070105647,0.00022078943,0.0023955544,0.00015717119,0.00005352281,0.000011258473,0.00019880128,0.0004868675,0.0002504767],"category_scores_gemma":[0.0070319925,0.00018997407,0.0008547283,0.00035228414,0.00018333283,0.00019265029,0.00009076624,0.001097232,5.7131155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044595003,0.0021739912,0.9215033,0.0003592942,0.0006704971,0.00016932604,0.00096051034,0.0002402131,0.00043819746,0.000045994657,0.00043984622,0.068539314],"study_design_scores_gemma":[0.0105347205,0.002770784,0.9761627,0.0019517775,0.00060882466,0.00014514354,0.0006909984,0.000944208,0.0023908936,0.00019685608,0.0034381964,0.00016489788],"about_ca_topic_score_codex":0.0022644594,"about_ca_topic_score_gemma":0.018720243,"teacher_disagreement_score":0.06837442,"about_ca_system_score_codex":0.00020617536,"about_ca_system_score_gemma":0.0054461625,"threshold_uncertainty_score":0.99918556},"labels":[],"label_agreement":null},{"id":"W3190024175","doi":"10.1200/jco.21.01631","title":"Reasonable Attempt at a Randomized Trial in Relapsed Rhabdomyosarcoma","year":2021,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Randomized controlled trial; Rhabdomyosarcoma; Oncology; Internal medicine; Sarcoma; Pathology","score_opus":0.08271557551981908,"score_gpt":0.4634830703908841,"score_spread":0.38076749487106504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190024175","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10537902,0.011906367,0.0000025613406,0.008547273,0.8684635,0.001543343,0.000020794783,0.000013207289,0.004123943],"genre_scores_gemma":[0.006850722,0.013803106,0.0019528355,0.000962075,0.97171456,0.00014440752,0.00012895944,0.00008762481,0.0043556904],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98500144,0.004209048,0.008055358,0.0005991963,0.0016234446,0.00051153],"domain_scores_gemma":[0.9166007,0.07418523,0.0065686875,0.000620487,0.0013056712,0.00071921636],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01639405,0.000477929,0.011848424,0.00037099488,0.000051781477,0.000024628534,0.00032795663,0.0037716888,0.0008118045],"category_scores_gemma":[0.10175873,0.0003195518,0.00410341,0.0002723629,0.0003757042,0.00005844888,0.00021020525,0.004517626,0.00006739787],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4848616,0.005196529,0.00093375094,0.000041645533,0.0011558699,0.01133002,0.000021640251,7.0573236e-7,7.586337e-7,0.000010393865,0.48959908,0.006847996],"study_design_scores_gemma":[0.50387365,0.0065012057,0.00033854909,0.00058739196,0.0016822519,0.00015974286,0.00001467815,0.0000048375678,0.0000030774263,0.00010881467,0.4866016,0.00012419507],"about_ca_topic_score_codex":0.00011519376,"about_ca_topic_score_gemma":0.00023998918,"teacher_disagreement_score":0.10325109,"about_ca_system_score_codex":0.001465259,"about_ca_system_score_gemma":0.010549177,"threshold_uncertainty_score":0.9999257},"labels":[],"label_agreement":null},{"id":"W3191219220","doi":"10.1200/jco.21.00662","title":"Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":632,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Cedars-Sinai Medical Center","keywords":"Medicine; Rash; Lung cancer; Internal medicine; Population; Adverse effect; Epidermal growth factor receptor; Erlotinib; Oncology; Gastroenterology; Cancer","score_opus":0.10153645254976759,"score_gpt":0.5266134971143889,"score_spread":0.42507704456462125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191219220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757372,0.0006486306,0.000031126132,0.02009044,0.001153671,0.0006341472,0.00005683922,0.000011516686,0.0016363888],"genre_scores_gemma":[0.9924316,0.00037218383,0.00072638266,0.0045656115,0.0015416314,0.000027924312,0.00005241988,0.00002731685,0.00025493867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99649304,0.00055938447,0.0020702954,0.00029624728,0.00035202503,0.00022899867],"domain_scores_gemma":[0.9958752,0.0019827243,0.0012933225,0.0002498797,0.00040892104,0.00018994705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011832524,0.0001740695,0.0009824904,0.00007997068,0.000084778054,0.00003065366,0.00013453675,0.00022768602,0.00013788916],"category_scores_gemma":[0.0010342756,0.00010594197,0.0002358768,0.00027943356,0.0000903725,0.000095612195,0.000034720015,0.0009960374,0.000003962022],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055432174,0.055025037,0.36333737,0.00004865158,0.0033826586,0.0128737185,0.015529876,0.00046175593,0.0028388433,0.0000046130826,0.011547822,0.4795175],"study_design_scores_gemma":[0.24086122,0.024642048,0.70272815,0.001186406,0.0027736106,0.00013953038,0.0054616523,0.0018278458,0.0031085156,0.0000767053,0.016902996,0.00029132987],"about_ca_topic_score_codex":0.00044441468,"about_ca_topic_score_gemma":0.0012161798,"teacher_disagreement_score":0.47922614,"about_ca_system_score_codex":0.0004483917,"about_ca_system_score_gemma":0.003564687,"threshold_uncertainty_score":0.63236016},"labels":[],"label_agreement":null},{"id":"W3192759045","doi":"10.1200/jco.21.00443","title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Venetoclax; Multiple myeloma; Refractory (planetary science); Phases of clinical research; Clinical trial; Salvage therapy; Chemotherapy","score_opus":0.10622742260560453,"score_gpt":0.45977177651391904,"score_spread":0.3535443539083145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192759045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818987,0.00019669732,0.000048462636,0.00016057072,0.00008599974,0.0011774137,0.000011953502,0.000008538277,0.00012049532],"genre_scores_gemma":[0.989296,0.00015598895,0.009924413,0.00013712498,0.000102017315,0.000024127761,0.000010702199,0.000046879926,0.00030271334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957233,0.0008045769,0.0016928099,0.000492239,0.0008830748,0.00040397243],"domain_scores_gemma":[0.99447584,0.001948453,0.0014463677,0.00039187924,0.0010130185,0.0007244303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012755677,0.000313621,0.0025105446,0.00024473158,0.00007358801,0.000020669255,0.00012280307,0.00027625015,0.000048053756],"category_scores_gemma":[0.0028704284,0.00015266147,0.00007211429,0.00039607566,0.0004928951,0.00023221844,0.00008731379,0.0011100838,8.078525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24264602,0.010082498,0.71600497,0.00007090203,0.00094258203,0.0040733204,0.0004988404,0.00000918637,0.00002318649,6.689024e-7,0.00003014729,0.025617678],"study_design_scores_gemma":[0.21731596,0.16506208,0.6142454,0.00039431592,0.00049957825,0.0005189454,0.0011018737,0.00025398625,0.000043090706,0.0000015048257,0.00043389943,0.00012936097],"about_ca_topic_score_codex":0.00016096431,"about_ca_topic_score_gemma":0.008085179,"teacher_disagreement_score":0.15497959,"about_ca_system_score_codex":0.0003511173,"about_ca_system_score_gemma":0.00541614,"threshold_uncertainty_score":0.96079993},"labels":[],"label_agreement":null},{"id":"W3192856091","doi":"10.1200/jco.2009.27.15_suppl.9629","title":"Differential time course of action of 5-HT<sub>3</sub> and NK<sub>1</sub> antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ondansetron; Chemotherapy; Dexamethasone; Antagonist; Randomized controlled trial; Internal medicine; Cyclophosphamide; Gastroenterology; NK1 receptor antagonist; Anesthesia; Vomiting; Receptor","score_opus":0.06496943103202647,"score_gpt":0.38885020861773695,"score_spread":0.3238807775857105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192856091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419427,0.0003030864,0.00039495897,0.004566631,0.00016206306,0.0002713681,0.000004551701,0.000009969507,0.00009312828],"genre_scores_gemma":[0.9952599,0.0027969226,0.0008742669,0.00064248435,0.00037724746,0.0000011642717,0.0000031427078,0.000019266801,0.000025635263],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99750954,0.00024243063,0.0014426034,0.00024957035,0.0003367127,0.00021914559],"domain_scores_gemma":[0.9971441,0.0005922479,0.0015294045,0.00016222121,0.0002819238,0.00029009732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011670399,0.00020174596,0.0015239685,0.00015147393,0.00004842124,0.000016871712,0.000078232115,0.00029508254,0.000014253213],"category_scores_gemma":[0.00019639924,0.00014115019,0.00016490041,0.00008523977,0.00032905536,0.00012958742,0.00003442211,0.00049080444,8.330859e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015171954,0.001979221,0.014105475,0.00015424567,0.0010069895,0.00013843633,0.00026338288,0.0000049422083,0.6601269,0.00006814698,0.0009780973,0.3060022],"study_design_scores_gemma":[0.030993635,0.03274015,0.56011814,0.00038010578,0.0017546238,0.0005530144,0.00012932192,0.0010218893,0.37011316,0.0012464899,0.000679499,0.00026997057],"about_ca_topic_score_codex":0.000004670348,"about_ca_topic_score_gemma":0.000016755379,"teacher_disagreement_score":0.54601264,"about_ca_system_score_codex":0.000041695,"about_ca_system_score_gemma":0.00031131608,"threshold_uncertainty_score":0.57559377},"labels":[],"label_agreement":null},{"id":"W3192951813","doi":"10.1200/jco.2021.39.suppl.e18600","title":"Clinical outcomes of cancer patients with COVID-19: A systematic review and metaanalysis","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; ARDS; Confidence interval; Internal medicine; Population; Cancer; Lung cancer; Mortality rate; Lung","score_opus":0.4245888157481381,"score_gpt":0.6662853190417404,"score_spread":0.24169650329360226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192951813","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009751939,0.9895773,0.000031024334,0.0077690333,0.0005639192,0.0018744164,0.00004510828,0.0000061958144,0.00003547632],"genre_scores_gemma":[0.00006400618,0.97024757,0.00059951347,0.028462296,0.00035875675,0.0000361957,0.000016890694,0.0000403403,0.00017442841],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9794735,0.0047780303,0.014089303,0.00045158181,0.00089263957,0.0003149584],"domain_scores_gemma":[0.94612795,0.029223334,0.019655442,0.0007221684,0.0020197728,0.0022513282],"candidate_categories":["metaresearch","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014147194,0.0004603727,0.03491914,0.00035488204,0.000041494375,0.000010140458,0.00032210673,0.0010665157,0.0002848613],"category_scores_gemma":[0.11575362,0.0002264931,0.0043586004,0.00059417856,0.0003489063,0.00007129326,0.00012751439,0.0023696446,0.0000049633904],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014580553,0.0011868204,0.06296408,0.7433613,0.013170609,0.00034254912,0.000013717671,9.702114e-8,4.2076276e-10,0.000010032198,0.0014483874,0.17735663],"study_design_scores_gemma":[0.0029337823,0.0049973666,0.009451382,0.3333846,0.17085354,0.0001591627,0.000010944431,2.943428e-7,1.5573676e-9,0.000005524728,0.47803974,0.00016365072],"about_ca_topic_score_codex":0.00012953593,"about_ca_topic_score_gemma":0.00024005247,"teacher_disagreement_score":0.47659135,"about_ca_system_score_codex":0.0005501404,"about_ca_system_score_gemma":0.030116776,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W3193941051","doi":"10.1200/jco.21.01083","title":"Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Hôtel-Dieu de Québec; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Surgical excision; Ductal carcinoma; Reduction (mathematics); Surgical resection; Randomized controlled trial; Radiation therapy; Breast cancer; Absolute risk reduction","score_opus":0.10778645265493396,"score_gpt":0.5026501064794995,"score_spread":0.3948636538245655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193941051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880515,0.0040906286,0.0009168421,0.0013076356,0.004491016,0.00074829126,0.000020550331,0.0000052664436,0.00036832268],"genre_scores_gemma":[0.99017996,0.0012406282,0.002995603,0.0001844958,0.004993915,0.00007917496,0.00023049014,0.000025686695,0.000070039816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922867,0.0026399458,0.003822508,0.0005718051,0.00034156055,0.00033750816],"domain_scores_gemma":[0.9900293,0.005739693,0.0032476238,0.00030477624,0.000464314,0.00021434332],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009464421,0.00025492813,0.002593432,0.00008261344,0.000110506095,0.000019717605,0.00019279747,0.00074717443,0.00003471964],"category_scores_gemma":[0.015731158,0.00020368063,0.0017158219,0.000117109375,0.00017180496,0.000021137766,0.00015289239,0.00057766563,0.000001927955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8033031,0.0026965633,0.040686257,0.0000067050987,0.0014977938,0.005599291,0.00012754243,0.000033165205,0.002810084,0.000005696435,0.0003948501,0.14283895],"study_design_scores_gemma":[0.9527855,0.00822582,0.030988777,0.00004813923,0.001423992,0.0007286293,0.00011217721,0.000105200335,0.002093868,0.00032943863,0.0029442676,0.00021417826],"about_ca_topic_score_codex":0.000069242,"about_ca_topic_score_gemma":0.0003623526,"teacher_disagreement_score":0.14948241,"about_ca_system_score_codex":0.00026238748,"about_ca_system_score_gemma":0.0027092295,"threshold_uncertainty_score":0.99255973},"labels":[],"label_agreement":null},{"id":"W3195589874","doi":"10.1200/jco.21.00006","title":"Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université de Montréal; University of Toronto","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Vulvar cancer; Sentinel node; Radiation therapy; Lymphadenectomy; Vulvar neoplasm; Sentinel lymph node; Oncology; Surgery; Cancer; Internal medicine; Vulva; Breast cancer","score_opus":0.13563377523408687,"score_gpt":0.4745811313528252,"score_spread":0.33894735611873833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195589874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98485345,0.0019390791,0.000008207809,0.011367508,0.00083896826,0.00037729947,0.00007282279,0.0000030203369,0.00053963665],"genre_scores_gemma":[0.9913519,0.0018995698,0.0029726557,0.0027370192,0.0007787522,0.000026071184,0.000037042577,0.000017816925,0.00017916542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711627,0.0003600106,0.0016833742,0.00021706022,0.000394008,0.00022930013],"domain_scores_gemma":[0.9944428,0.003329747,0.0012397276,0.0001965234,0.00062798435,0.00016320517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008882474,0.00016601931,0.0014271798,0.00012520887,0.000044425014,0.0000068845693,0.00013325349,0.00016194752,0.00009586593],"category_scores_gemma":[0.0020805958,0.00008354712,0.0004603003,0.00042524084,0.00012107938,0.000056820558,0.000022440878,0.00021424916,9.577491e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.312399,0.027123716,0.49796316,0.00008343634,0.004014362,0.0012671557,0.00071321207,0.00005634029,0.00047784322,0.000062858846,0.0033915986,0.1524473],"study_design_scores_gemma":[0.34550142,0.081242844,0.46003023,0.00021924231,0.0015131038,0.00011687921,0.00023160772,0.000011123808,0.001601478,0.000081750266,0.10929938,0.00015096519],"about_ca_topic_score_codex":0.00025296854,"about_ca_topic_score_gemma":0.00022319992,"teacher_disagreement_score":0.15229633,"about_ca_system_score_codex":0.00038531088,"about_ca_system_score_gemma":0.0018848311,"threshold_uncertainty_score":0.3406953},"labels":[],"label_agreement":null},{"id":"W3198781344","doi":"10.1200/jco.21.00693","title":"Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; Population Health Research Institute; McMaster University; Women's College Hospital; Toronto General Hospital; Hamilton Health Sciences; University of Toronto; University Health Network","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Chronic lymphocytic leukemia; Atrial fibrillation; Population; Myocardial infarction; Cohort; Leukemia","score_opus":0.08873278683277927,"score_gpt":0.42102028761526383,"score_spread":0.3322875007824846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198781344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714494,0.000989696,0.00013827719,0.00014855852,0.0004268559,0.0008071297,0.000005319857,0.00002278187,0.0003164693],"genre_scores_gemma":[0.99768317,0.0003827448,0.00059800426,0.00039308367,0.00062223186,0.000021177006,0.00002186658,0.000048552803,0.00022915902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99097496,0.003098219,0.0031193062,0.0005302256,0.0017100255,0.000567288],"domain_scores_gemma":[0.9874249,0.00840073,0.0015612039,0.00077936804,0.0012997744,0.0005339885],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0115593355,0.0002587706,0.0032097264,0.00029053673,0.00007227365,0.000035831472,0.0002419492,0.0006435972,0.00014559164],"category_scores_gemma":[0.033787258,0.00019003876,0.0010388172,0.00088675926,0.000202496,0.00017814094,0.00009596562,0.0020468032,0.000018616212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027696127,0.0012145,0.9246776,0.000037543356,0.0037692976,0.02057893,0.00004630519,0.04124017,0.0000052480545,0.0000032424693,0.00025367254,0.0054038875],"study_design_scores_gemma":[0.10642878,0.010009747,0.85212207,0.00032203554,0.0020770896,0.000653168,0.00010969421,0.026866192,0.000020856196,0.000019293599,0.0011993784,0.00017170173],"about_ca_topic_score_codex":0.005188863,"about_ca_topic_score_gemma":0.006149153,"teacher_disagreement_score":0.10365916,"about_ca_system_score_codex":0.16140877,"about_ca_system_score_gemma":0.25625047,"threshold_uncertainty_score":0.9743516},"labels":[],"label_agreement":null},{"id":"W3199015518","doi":"10.1200/jco.2020.39.28_suppl.160","title":"Illness perceptions, financial toxicity, symptom burden, and survival in cancer clinical trial (CCT) participants.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Marital status; Clinical trial; Disease; Internal medicine; Population; Environmental health","score_opus":0.2646246850141837,"score_gpt":0.4709603013862452,"score_spread":0.2063356163720615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199015518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97318333,0.0036350626,0.00024249508,0.008124403,0.010125307,0.00016765509,0.00005321832,0.0000069138855,0.004461587],"genre_scores_gemma":[0.97294253,0.016836636,0.0004397708,0.0019680485,0.0072690905,0.000013428876,0.0000022078223,0.000022854892,0.0005054445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923998,0.00038780484,0.0061408374,0.00048009143,0.00008534126,0.00050612673],"domain_scores_gemma":[0.99445456,0.0017351358,0.002842121,0.0002590365,0.00023955348,0.00046961705],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009163951,0.00020173391,0.0027471264,0.00017416822,0.000081366175,0.000056035547,0.0003069745,0.0007929395,0.00089015503],"category_scores_gemma":[0.013002964,0.00020507911,0.00061510626,0.00021243325,0.00037396312,0.00041271746,0.00015672702,0.0012934895,0.00007254027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012138328,0.0016917672,0.72632295,0.000027703843,0.00022600856,0.0003135543,0.00045969675,0.0001261348,0.0000070638516,0.024435882,0.0045306263,0.2297203],"study_design_scores_gemma":[0.041227207,0.002830506,0.70846057,0.00005824995,0.000057782225,0.000026094362,0.00022096248,0.00021210242,0.000005208154,0.015179716,0.23139842,0.00032320872],"about_ca_topic_score_codex":0.00028647747,"about_ca_topic_score_gemma":0.0017676656,"teacher_disagreement_score":0.22939709,"about_ca_system_score_codex":0.00025942168,"about_ca_system_score_gemma":0.0020516466,"threshold_uncertainty_score":0.9953109},"labels":[],"label_agreement":null},{"id":"W3199128283","doi":"10.1200/jco.2020.39.28_suppl.273","title":"Development of patient reported outcomes-based machine learning algorithm for the six-month mortality prediction in patients with advanced cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Machine Learning in Healthcare","field":"Computer Science","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Algorithm; Machine learning; Cohort; Physical therapy; Internal medicine","score_opus":0.08104287175604558,"score_gpt":0.44463526537444564,"score_spread":0.36359239361840007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199128283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8594089,0.00017064177,0.13662623,0.002023342,0.001375547,0.00035059103,0.0000064403534,0.000014397149,0.000023930897],"genre_scores_gemma":[0.7530854,0.000019271083,0.24631137,0.00047151078,0.000055756773,0.000024534549,0.000007992692,0.0000096109825,0.000014612481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953056,0.0006907249,0.0029044806,0.0002754864,0.0006000176,0.00022370028],"domain_scores_gemma":[0.99226034,0.0026083132,0.003573947,0.000303211,0.0011184927,0.00013570284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033862954,0.00013119138,0.00085398403,0.000078355035,0.00014271634,0.0000100642355,0.00035284302,0.00014643818,0.000012397422],"category_scores_gemma":[0.0037172649,0.00007951831,0.00018345525,0.00029300925,0.00005822146,0.00013907443,0.00013278627,0.0009716453,1.9720719e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018108392,0.0004246432,0.56066895,0.000014405396,0.00008674388,0.000023334256,0.00018409305,0.009548065,7.7933515e-7,0.0000087720155,0.0000076065235,0.42885154],"study_design_scores_gemma":[0.004583078,0.003498854,0.87543285,0.00008239308,0.000038183396,0.0000043199157,0.000033051765,0.108135715,0.000031223506,0.00002205879,0.008065173,0.000073077805],"about_ca_topic_score_codex":0.000075666016,"about_ca_topic_score_gemma":0.00061669876,"teacher_disagreement_score":0.42877847,"about_ca_system_score_codex":0.00024248424,"about_ca_system_score_gemma":0.003157311,"threshold_uncertainty_score":0.5600934},"labels":[],"label_agreement":null},{"id":"W3199134341","doi":"10.1200/jco.2020.39.28_suppl.303","title":"Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Pembrolizumab; Internal medicine; Ipilimumab; Cohort; Proportional hazards model; Hazard ratio; Population; Cancer; Nivolumab; Retrospective cohort study; Oncology; Immunotherapy; Confidence interval","score_opus":0.09860802118991938,"score_gpt":0.4615979562461227,"score_spread":0.36298993505620336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199134341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942908,0.0003802187,0.000013448298,0.0032332754,0.001400218,0.0004595611,0.000011246578,0.00000734988,0.00020382598],"genre_scores_gemma":[0.9977082,0.000114505005,0.0006177885,0.00053529005,0.0007740772,0.000002070345,0.000009126816,0.000021427451,0.00021748511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955753,0.00061255344,0.0028869803,0.00023855554,0.0004607177,0.000225875],"domain_scores_gemma":[0.99611443,0.0012743408,0.0014995877,0.00034778987,0.0004731342,0.00029070445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002041198,0.00020420474,0.0019035627,0.00016455707,0.000037904123,0.000009932159,0.00010639021,0.0002591499,0.00035601566],"category_scores_gemma":[0.0015110702,0.0001304416,0.0014926104,0.00023052032,0.00005924891,0.00004527308,0.000024655808,0.000411756,0.0000073644196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06995694,0.01952595,0.8029307,0.00003487881,0.002307497,0.0009576679,0.00029717723,0.00020526738,0.024940152,0.0000036148808,0.00021977803,0.07862036],"study_design_scores_gemma":[0.025906095,0.1103113,0.85966986,0.00022705761,0.00034333926,0.000054564644,0.00017129275,0.00001396572,0.002493473,0.000006422406,0.00070379284,0.00009886071],"about_ca_topic_score_codex":0.0003744012,"about_ca_topic_score_gemma":0.00020086349,"teacher_disagreement_score":0.09078535,"about_ca_system_score_codex":0.0008106908,"about_ca_system_score_gemma":0.0028636388,"threshold_uncertainty_score":0.5319254},"labels":[],"label_agreement":null},{"id":"W3199192590","doi":"10.1200/jco.2020.39.28_suppl.269","title":"Clinical practice patterns for advanced breast cancer patients on CDK4/6 inhibitors receiving palliative radiation therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Concomitant; Palliative care; Cancer; Radiation therapy; Internal medicine; Oncology; Nursing","score_opus":0.09959189659249712,"score_gpt":0.5173216568826743,"score_spread":0.41772976029017717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199192590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95440876,0.0017535476,0.0013068371,0.034074873,0.007361988,0.0006157014,0.00007888662,0.0000216368,0.0003777758],"genre_scores_gemma":[0.94869715,0.012267318,0.012146763,0.019922012,0.0066594426,0.00004465568,0.000021351456,0.00006370694,0.00017761509],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99453175,0.0009217576,0.0032268863,0.00041062507,0.00057457475,0.00033442752],"domain_scores_gemma":[0.98232347,0.009940092,0.0041189957,0.00025444847,0.00295289,0.00041008083],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002867822,0.0002309222,0.0016230687,0.00009260324,0.00007815051,0.000014540266,0.0001502574,0.00045463495,0.00016745851],"category_scores_gemma":[0.013806052,0.0001748124,0.0007731238,0.00019151303,0.00011891672,0.00039975284,0.000039296177,0.0013437025,0.000007376403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017472493,0.0030680555,0.29732442,0.000021784994,0.0005953808,0.00008185568,0.0001416592,0.000051049836,0.00006664252,0.000021504478,0.0007131762,0.680442],"study_design_scores_gemma":[0.024458922,0.011086605,0.7506747,0.00041864882,0.0002594894,0.00008792116,0.0002837003,0.000026083198,0.0002801672,0.00018460669,0.2120819,0.00015724004],"about_ca_topic_score_codex":0.000009356468,"about_ca_topic_score_gemma":0.000024972007,"teacher_disagreement_score":0.68028474,"about_ca_system_score_codex":0.0004938351,"about_ca_system_score_gemma":0.0022572733,"threshold_uncertainty_score":0.99450105},"labels":[],"label_agreement":null},{"id":"W3199345440","doi":"10.1200/jco.2020.39.28_suppl.99","title":"Association between oncology drug review times and public funding recommendations.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Cancer; Clinical Oncology; Family medicine; Drug; Pharmacology","score_opus":0.7393889961557929,"score_gpt":0.6110504355194513,"score_spread":0.12833856063634164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199345440","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043941125,0.03355139,0.0007010531,0.90387815,0.0030190481,0.00024095643,0.000057634825,0.000013586807,0.014597037],"genre_scores_gemma":[0.3024375,0.29698974,0.053210516,0.32317504,0.01216814,0.000054017208,0.00014588682,0.00009815238,0.011721014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9830994,0.003379415,0.012716673,0.00032983418,0.00013335221,0.00034131887],"domain_scores_gemma":[0.95771974,0.023054542,0.01791937,0.0002475516,0.00058362965,0.00047516476],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09944311,0.0001257168,0.0031166691,0.00021002401,0.00013169693,0.000049698014,0.00022368705,0.0004208498,0.0016195523],"category_scores_gemma":[0.106813855,0.00014034071,0.00034807264,0.00022370656,0.0000671479,0.0005953996,0.000095190284,0.00085858785,0.00044250005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001237713,0.00031370975,0.38707584,0.0002926033,0.00056150014,0.000011673534,0.00016394214,0.0000010873573,2.6464343e-7,0.012917295,0.5582755,0.040374167],"study_design_scores_gemma":[0.0013094558,0.00038986423,0.053295054,0.00026153523,0.000087958055,0.0000363277,0.0003364433,0.00004251742,5.502163e-7,0.012169597,0.9319436,0.00012707831],"about_ca_topic_score_codex":0.000039618117,"about_ca_topic_score_gemma":0.0001425629,"teacher_disagreement_score":0.58070314,"about_ca_system_score_codex":0.0014134165,"about_ca_system_score_gemma":0.001983841,"threshold_uncertainty_score":0.9992931},"labels":[],"label_agreement":null},{"id":"W3199405193","doi":"10.1200/jco.2020.39.28_suppl.220","title":"Myocardial injury after gynecologic oncology surgery in septuagenarians and octogenarians: Is there a role for routine postoperative cardiac biomarker monitoring?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Univariate analysis; Biomarker; Troponin; Cohort; Coronary artery disease; Diabetes mellitus; Troponin T; Surgery; Cardiology; Myocardial infarction; Multivariate analysis","score_opus":0.08239612274683984,"score_gpt":0.4235175674850531,"score_spread":0.34112144473821326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199405193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95752627,0.007285564,0.00003424697,0.02812421,0.003404415,0.00043314084,0.000031211177,0.000012229082,0.0031487306],"genre_scores_gemma":[0.9831148,0.0039982535,0.001663426,0.008219445,0.002013953,0.00005412134,0.000007178439,0.000035649868,0.0008932229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99430794,0.001898341,0.0025539326,0.00042735532,0.0003359077,0.00047652767],"domain_scores_gemma":[0.98106414,0.016525278,0.00078387704,0.00025584918,0.0008783777,0.00049248384],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061945026,0.000281514,0.0043992247,0.00021002674,0.00005805252,0.000025374307,0.000099530764,0.0010376815,0.00024042588],"category_scores_gemma":[0.011060549,0.00020265157,0.0023142379,0.0002742637,0.00027966563,0.0001366353,0.00008845217,0.0009299983,0.000010840664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010314754,0.0010735615,0.8700757,0.000035869467,0.0013482294,0.005807473,0.0006130191,0.0000018765737,0.00039337474,0.00006953136,0.0029975167,0.1072691],"study_design_scores_gemma":[0.0033590223,0.0031876133,0.59883446,0.000069937356,0.00055163546,0.0004867332,0.0009656961,0.000010558036,0.00021068504,0.00008758988,0.39207622,0.00015987938],"about_ca_topic_score_codex":0.000024167806,"about_ca_topic_score_gemma":0.00002108136,"teacher_disagreement_score":0.3890787,"about_ca_system_score_codex":0.000288918,"about_ca_system_score_gemma":0.0030050916,"threshold_uncertainty_score":0.9972697},"labels":[],"label_agreement":null},{"id":"W3199508174","doi":"10.1200/jco.2020.39.28_suppl.246","title":"Recovery of a quality improvement project during the COVID pandemic.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Documentation; Workflow; Pandemic; Quality management; Patient safety; Best practice; Coronavirus disease 2019 (COVID-19); Medical emergency; Health care; Medical education; Operations management; Pathology","score_opus":0.24806289386015168,"score_gpt":0.4501666339475136,"score_spread":0.20210374008736193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199508174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747196,0.0024178394,0.0005820801,0.004428207,0.0020895405,0.00011525156,0.000055306722,0.0000041702624,0.015588049],"genre_scores_gemma":[0.9878725,0.0053510834,0.0008041933,0.0036379045,0.0009826608,0.0000041704243,9.850917e-7,0.000012369003,0.0013341344],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952235,0.00014686029,0.0041600084,0.00020206282,0.00005354449,0.0002139858],"domain_scores_gemma":[0.9930338,0.0012676495,0.0050798133,0.00027317004,0.00022496202,0.000120595476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068809316,0.00010143863,0.0014391004,0.0000809635,0.000052123643,0.000018012506,0.00029500612,0.00025644962,0.00028017518],"category_scores_gemma":[0.0074876444,0.000079178695,0.0006364344,0.00012578444,0.00017123342,0.0002153681,0.0000971551,0.0005851367,0.000022354929],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002854561,0.0016586265,0.7813551,0.00018383721,0.0011161143,0.00011373629,0.0005503956,0.00018953923,0.00047823176,0.039684538,0.01026731,0.16154802],"study_design_scores_gemma":[0.004111034,0.0024061522,0.47620577,0.00002601289,0.000036089958,0.00008449661,0.00023955028,0.000018417393,0.00021673022,0.033913437,0.48256257,0.00017972941],"about_ca_topic_score_codex":0.00017627611,"about_ca_topic_score_gemma":0.00016807864,"teacher_disagreement_score":0.47229525,"about_ca_system_score_codex":0.0002548651,"about_ca_system_score_gemma":0.0013565791,"threshold_uncertainty_score":0.8963951},"labels":[],"label_agreement":null},{"id":"W3199544345","doi":"10.1200/jco.2020.39.28_suppl.279","title":"The evolution of the education module for men with metastatic prostate cancer (mPC) in the prostate cancer supportive care (PCSC) program.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Attendance; Internal medicine; Family medicine; Oncology; Cancer; Gynecology","score_opus":0.07036860269764252,"score_gpt":0.40971238006158966,"score_spread":0.33934377736394716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199544345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93440455,0.02509375,0.0001375352,0.030436933,0.0021627482,0.0017489386,0.00023638089,0.000004114861,0.0057750726],"genre_scores_gemma":[0.99282354,0.004056232,0.0006471306,0.00074428483,0.00038902814,0.00037087244,0.0000033156728,0.000016938815,0.0009486319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972614,0.00016879532,0.002000917,0.000211642,0.00007713537,0.00028012018],"domain_scores_gemma":[0.99496955,0.0006804724,0.003389751,0.00024821112,0.000641119,0.000070871276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025632454,0.00012519235,0.0007873792,0.00005727388,0.0001264359,0.000041958232,0.0003662933,0.00010854147,0.00002594155],"category_scores_gemma":[0.001200371,0.0000663694,0.00029207303,0.00025678857,0.00028296397,0.0002410474,0.00003917526,0.00045822532,0.000001885136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022901949,0.0013203666,0.5582282,0.00015916221,0.00051439105,0.000009045666,0.0061012674,0.001525874,0.0000061133646,0.033126794,0.009068553,0.38765],"study_design_scores_gemma":[0.003923533,0.002532425,0.66261697,0.00015198368,0.00015819388,0.000019446106,0.0085551,0.00045935588,0.000062481966,0.029373132,0.29196343,0.0001839625],"about_ca_topic_score_codex":0.0009863507,"about_ca_topic_score_gemma":0.0058260313,"teacher_disagreement_score":0.38746607,"about_ca_system_score_codex":0.0006530447,"about_ca_system_score_gemma":0.0051390636,"threshold_uncertainty_score":0.91164786},"labels":[],"label_agreement":null},{"id":"W3199590448","doi":"10.1200/jco.2020.39.28_suppl.296","title":"Real-world trends in EU4 and the UK in frontline (1L) maintenance (MT) for nonsquamous (NSQ) advanced non-small cell lung cancer (aNSCLC) without actionable mutations after introduction of immune checkpoint inhibitors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pemetrexed; Lung cancer; Medicine; Internal medicine; Oncology; Pembrolizumab; Tumor microenvironment; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.025836235520329928,"score_gpt":0.3920085313243367,"score_spread":0.3661722958040068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199590448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712362,0.0035958136,0.000297177,0.022505527,0.0014626379,0.00039608256,0.000012349029,0.0000034564937,0.0004907225],"genre_scores_gemma":[0.9855301,0.004976702,0.004996859,0.0004806923,0.0011186965,0.00009084865,0.000011237201,0.000019222556,0.002775638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653983,0.00024837593,0.0025830113,0.00023616332,0.00016732489,0.00022528793],"domain_scores_gemma":[0.99707115,0.00080030476,0.0014186208,0.0001890119,0.00043856696,0.0000823447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028438508,0.0001418041,0.0012046928,0.00025664305,0.000033179673,0.0000074294758,0.00007933025,0.0001906738,0.00018327877],"category_scores_gemma":[0.0006256095,0.00009539025,0.00042858714,0.0004376415,0.00029708314,0.000100806654,0.000030188476,0.0006889839,2.665458e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30157873,0.004461191,0.36091205,0.00058938726,0.001059491,0.00033848226,0.0029261904,0.0014118361,0.08248691,0.00008220459,0.006218988,0.23793456],"study_design_scores_gemma":[0.07188872,0.0026273027,0.8896117,0.00055149535,0.00049820467,0.0001325767,0.0009877189,0.0014984446,0.009041206,0.00018914598,0.022783754,0.00018970847],"about_ca_topic_score_codex":0.00081019534,"about_ca_topic_score_gemma":0.012281294,"teacher_disagreement_score":0.5286997,"about_ca_system_score_codex":0.00041559094,"about_ca_system_score_gemma":0.0011369808,"threshold_uncertainty_score":0.685325},"labels":[],"label_agreement":null},{"id":"W3199628774","doi":"10.1200/jco.2020.39.28_suppl.196","title":"Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency (PEI) in patients with advanced pancreatic cancer (aPC): PanDA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Steatorrhea; Prospective cohort study; Pancreatic cancer; Cohort; Exocrine pancreatic insufficiency; Cancer; Gastroenterology; Pancreatitis","score_opus":0.1318798063173366,"score_gpt":0.4867283076980574,"score_spread":0.3548485013807208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199628774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680585,0.001382907,0.0000056060876,0.0004851283,0.00016659447,0.0009392804,0.00001966574,0.0000022778854,0.00019268636],"genre_scores_gemma":[0.9924141,0.0054364796,0.001824513,0.00006732642,0.00008041147,0.00009914567,0.000004997218,0.000011043467,0.00006193798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969389,0.00025802333,0.0018832955,0.00026078516,0.0005022567,0.00015673398],"domain_scores_gemma":[0.9960906,0.0011104963,0.0015183085,0.00018876661,0.00094213506,0.00014967874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043287803,0.00016330746,0.0018101329,0.00010646058,0.000022430568,0.0000036781867,0.00005247972,0.0000819784,0.00009117392],"category_scores_gemma":[0.000348757,0.0001009892,0.00014209023,0.0002798393,0.00012766532,0.00009134377,0.000028942175,0.00019980813,1.5092084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040587713,0.05352224,0.9020345,0.000100896614,0.00086700416,0.00015148295,0.00040509165,0.00010252201,0.000014016066,0.000038075228,0.000010211339,0.03869518],"study_design_scores_gemma":[0.035937976,0.09593522,0.8656791,0.00047141363,0.0012089134,0.00001364884,0.00046412973,0.000023272189,0.000058799982,0.00003066333,0.00010913702,0.00006775167],"about_ca_topic_score_codex":0.00013026003,"about_ca_topic_score_gemma":0.0005929117,"teacher_disagreement_score":0.042412974,"about_ca_system_score_codex":0.0006049753,"about_ca_system_score_gemma":0.0022692895,"threshold_uncertainty_score":0.411822},"labels":[],"label_agreement":null},{"id":"W3199767937","doi":"10.1200/jco.21.02072","title":"Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Medical physics; Nuclear medicine","score_opus":0.10949717507999111,"score_gpt":0.4568581657929333,"score_spread":0.3473609907129422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199767937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89021784,0.0018504604,0.000023091088,0.09089657,0.0023571667,0.00021042237,0.0000060549887,0.00001266939,0.014425753],"genre_scores_gemma":[0.910898,0.0032986137,0.0033022496,0.04429852,0.0048682694,0.000007781307,0.000015984084,0.00005240381,0.0332582],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613345,0.00058272644,0.0022216511,0.00025378878,0.0004994299,0.00030897776],"domain_scores_gemma":[0.994738,0.0021870008,0.0013238264,0.00046186603,0.00084397994,0.00044535223],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019980373,0.00017533245,0.0014374218,0.000049910625,0.00011611035,0.000021497568,0.00021147887,0.00049499306,0.0040922356],"category_scores_gemma":[0.0037019548,0.000100156685,0.0006232306,0.00020869223,0.0003045145,0.000069943824,0.0001472273,0.0011757012,0.00042062718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009398449,0.004174938,0.07482755,0.00006757747,0.002759092,0.02300049,0.0008686448,0.000015558167,0.0032439374,0.00006649605,0.6122132,0.2693641],"study_design_scores_gemma":[0.017917778,0.0054109646,0.1229786,0.000106409236,0.00075186463,0.004339577,0.000144979,0.00008031601,0.0023222035,0.00033230733,0.8455119,0.000103100036],"about_ca_topic_score_codex":0.000032973538,"about_ca_topic_score_gemma":0.0001152707,"teacher_disagreement_score":0.269261,"about_ca_system_score_codex":0.0010768225,"about_ca_system_score_gemma":0.0067755478,"threshold_uncertainty_score":0.9988551},"labels":[],"label_agreement":null},{"id":"W3199828166","doi":"10.1200/jco.2020.39.28_suppl.40","title":"Reporting of tobacco use and impact on outcomes in cancer cooperative group clinical trials: A systematic scoping review.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; Sunnybrook Hospital; Centre for Addiction and Mental Health; McMaster University; Cancer Care Ontario; Health Sciences North; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Cancer; Lung cancer; Internal medicine; Systematic review; Adverse effect; Clinical endpoint; Randomized controlled trial; MEDLINE; Oncology","score_opus":0.8133070687068217,"score_gpt":0.7566167623292728,"score_spread":0.056690306377548905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199828166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774716,0.008549271,0.000067463625,0.0108105065,0.0010977103,0.0014649577,0.0000043169243,0.000009208252,0.00052496366],"genre_scores_gemma":[0.9226472,0.07321819,0.001898917,0.0016047582,0.0004945169,0.000034582157,3.714005e-7,0.000012653063,0.00008881111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9509297,0.02787896,0.019705521,0.0002819207,0.000887206,0.00031668134],"domain_scores_gemma":[0.82240564,0.14660883,0.027754813,0.00038417772,0.0023386949,0.0005078641],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21868241,0.00012815102,0.0060137166,0.00014253819,0.00006752213,0.000049475475,0.0002844219,0.00043283042,0.000115977695],"category_scores_gemma":[0.7307645,0.000078875026,0.00092993095,0.00042776356,0.0004606646,0.00029520123,0.00011393038,0.0013355626,0.0000015763013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005565746,0.0012793108,0.96804947,0.004182858,0.00040703034,0.001092332,0.00039099294,0.00001593651,0.000023593724,0.00053791166,0.0014241083,0.022039862],"study_design_scores_gemma":[0.005848262,0.0093103675,0.5770399,0.40162376,0.0007045726,0.00012792289,0.0033060538,0.00007772341,0.00005189187,0.0010010604,0.0005210269,0.00038747795],"about_ca_topic_score_codex":0.0006218175,"about_ca_topic_score_gemma":0.0038481834,"teacher_disagreement_score":0.5120821,"about_ca_system_score_codex":0.00028110956,"about_ca_system_score_gemma":0.0062520276,"threshold_uncertainty_score":0.9993816},"labels":[],"label_agreement":null},{"id":"W3199856239","doi":"10.1200/jco.2020.39.28_suppl.162","title":"Examining social media peer support and improving psychosocial outcomes for young women with breast cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Ottawa; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; York University; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Psychosocial; Medicine; Breast cancer; Survivorship curve; Social support; Peer support; Feeling; Qualitative research; Snowball sampling; Family medicine; Social media; Coping (psychology); Gerontology; Cancer; Clinical psychology; Psychiatry; Psychology; Psychotherapist; Social psychology","score_opus":0.13485513008810784,"score_gpt":0.4639623475582088,"score_spread":0.32910721747010097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199856239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602001,0.000045135497,0.00009965495,0.028683871,0.0057366383,0.0001366741,0.000049720013,0.00001539824,0.00503285],"genre_scores_gemma":[0.98982364,0.00013382627,0.0020149867,0.002006352,0.0050522,0.000023519962,0.0000022242332,0.000023575001,0.0009196966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964261,0.00055216806,0.0014355576,0.0002636075,0.0007961261,0.00052645674],"domain_scores_gemma":[0.99187565,0.004625503,0.0015578588,0.00008354159,0.001443834,0.00041363377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008202702,0.00014457798,0.0012165173,0.000062912404,0.00041903692,0.00007264826,0.00027124753,0.00047783635,0.00034851133],"category_scores_gemma":[0.0068596443,0.00011267512,0.00018589791,0.0001820927,0.0006902299,0.000345542,0.00006708982,0.00064986653,0.0000017368326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012040976,0.0003639994,0.62660354,0.000022159289,0.00033493643,0.0002576696,0.029800378,7.916912e-7,0.0000271931,0.0010691924,0.010135099,0.33018097],"study_design_scores_gemma":[0.004123885,0.0008757372,0.8664808,0.000018216908,0.00015977306,0.00008993931,0.049010057,0.0000023739658,0.0000022231502,0.00095549336,0.07808444,0.00019701451],"about_ca_topic_score_codex":0.00016551166,"about_ca_topic_score_gemma":0.0051036626,"teacher_disagreement_score":0.32998395,"about_ca_system_score_codex":0.00035919852,"about_ca_system_score_gemma":0.006285252,"threshold_uncertainty_score":0.99934816},"labels":[],"label_agreement":null},{"id":"W3199894516","doi":"10.1200/jco.2020.39.28_suppl.28","title":"Feasibility of a child life specialist program for oncology patients with minor children at home: Demand and implementation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Juravinski Hospital; McMaster University; Hamilton Health Sciences; McMaster Children's Hospital","funders":"","keywords":"Medicine; Referral; Psychological intervention; Pediatrics; Minor (academic); Grandparent; Family medicine; Psychiatry","score_opus":0.08885442368087895,"score_gpt":0.4847866644229417,"score_spread":0.3959322407420628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199894516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935056,0.00017560429,0.00003262543,0.006571876,0.0010085128,0.0009016832,0.00005895838,0.000007275655,0.0018929002],"genre_scores_gemma":[0.99113184,0.0002226792,0.0061677936,0.0013310218,0.0010156288,0.000019333498,0.000026240408,0.0000121475805,0.000073331554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611366,0.00095290196,0.0019198296,0.0002603555,0.00045346687,0.00029980394],"domain_scores_gemma":[0.9936507,0.0024304215,0.002225009,0.00014565558,0.0011302589,0.0004179539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040046033,0.00011715239,0.0011129249,0.00005903997,0.00024343515,0.000020803704,0.00022156895,0.0003298501,0.00027949017],"category_scores_gemma":[0.004329511,0.00009021161,0.00025358633,0.00019028166,0.00091351336,0.00017582263,0.000102809296,0.00032423149,0.000001226924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013567439,0.0020734551,0.90764254,0.00001654047,0.00019246183,0.000014769364,0.000851402,0.0000011498105,8.656628e-7,0.00043532375,0.0052624135,0.08215232],"study_design_scores_gemma":[0.008026173,0.0054812045,0.8935195,0.000016902131,0.00018922637,0.000015426676,0.0010405907,8.2981893e-7,0.00000903476,0.0004527546,0.0911495,0.000098808196],"about_ca_topic_score_codex":0.00014830442,"about_ca_topic_score_gemma":0.008498619,"teacher_disagreement_score":0.08588709,"about_ca_system_score_codex":0.0002761882,"about_ca_system_score_gemma":0.003304044,"threshold_uncertainty_score":0.5861232},"labels":[],"label_agreement":null},{"id":"W3200159260","doi":"10.1200/jco.2020.39.28_suppl.93","title":"Overall survival benefits of advances in NSCLC systemic treatments: Younger versus older adults.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Systemic therapy; Tolerability; Performance status; Comorbidity; Oncology; Log-rank test; Cancer; Survival analysis; Adverse effect","score_opus":0.08946220534220825,"score_gpt":0.44009138552760724,"score_spread":0.350629180185399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200159260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665201,0.019954296,0.000011805699,0.0012144314,0.0038327063,0.0001429157,0.000011341371,0.0000040216873,0.008308406],"genre_scores_gemma":[0.97746474,0.019722762,0.00079860806,0.00091371697,0.0007754164,0.0000031524403,0.000010029291,0.000014450113,0.00029714016],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965371,0.00036581024,0.002327873,0.00020891883,0.00035080366,0.00020948144],"domain_scores_gemma":[0.9958643,0.0019647721,0.0012551714,0.00019776532,0.00049703685,0.00022095743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001105939,0.00013490889,0.0017304252,0.00010432786,0.000013791592,0.0000032718108,0.000114050345,0.00030171726,0.00042997292],"category_scores_gemma":[0.0016376021,0.0001014653,0.00046838616,0.00013514418,0.00009611193,0.00026785483,0.000036110814,0.0006115145,0.0000072041203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051734444,0.0035702304,0.21149056,0.00034875426,0.0010776032,0.0021840418,0.00048730956,0.00022674185,0.0003230221,0.00032026888,0.0008521109,0.7273849],"study_design_scores_gemma":[0.09692819,0.013265629,0.85237235,0.0016313766,0.0006642453,0.0006269998,0.001165173,0.000066103166,0.0002809879,0.0000402089,0.032766096,0.00019263],"about_ca_topic_score_codex":0.000028867078,"about_ca_topic_score_gemma":0.00016848299,"teacher_disagreement_score":0.7271923,"about_ca_system_score_codex":0.0003154386,"about_ca_system_score_gemma":0.0021441537,"threshold_uncertainty_score":0.47079018},"labels":[],"label_agreement":null},{"id":"W3200209659","doi":"10.1200/jco.2020.39.28_suppl.30","title":"Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Juravinski Hospital; McMaster University; Hamilton Health Sciences; McMaster Children's Hospital","funders":"","keywords":"Focus group; Medicine; Thematic analysis; Psychosocial; Coaching; Grief; Formative assessment; Qualitative research; Medical home; Family medicine; Nursing; Medical education; Psychology; Psychiatry; Psychotherapist","score_opus":0.14700570924185738,"score_gpt":0.5313755688698306,"score_spread":0.3843698596279732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200209659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836078,0.00013254501,0.00012497528,0.0078140935,0.0012921472,0.00083538145,0.000111695714,0.00001288711,0.0060684728],"genre_scores_gemma":[0.9872946,0.000090887515,0.0096280165,0.0014909734,0.0011490957,0.000022800585,0.00005505603,0.000016127473,0.00025244136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99125963,0.0038775532,0.0031626308,0.0004062319,0.00085507164,0.0004388729],"domain_scores_gemma":[0.9841898,0.007699785,0.004429143,0.00029926817,0.0027805862,0.0006013968],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009842432,0.00018094355,0.0025895436,0.00017713141,0.00026318306,0.000021802467,0.00049905176,0.00060450897,0.00040680458],"category_scores_gemma":[0.020267807,0.00013698354,0.0011363904,0.00097511435,0.0016721704,0.00020119056,0.00012497467,0.0006317562,0.00000458413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035701725,0.007566442,0.9457725,0.000016938207,0.0022517338,0.000031110554,0.007566955,0.000017484212,5.2050893e-7,0.0010005919,0.0052001146,0.027005397],"study_design_scores_gemma":[0.006333229,0.007038503,0.91319925,0.000020368474,0.0013883745,0.0000047972158,0.004506515,0.0000035976877,0.0000047690705,0.0007134886,0.06661584,0.00017125583],"about_ca_topic_score_codex":0.00029219897,"about_ca_topic_score_gemma":0.012561496,"teacher_disagreement_score":0.061415724,"about_ca_system_score_codex":0.0006090925,"about_ca_system_score_gemma":0.0055339676,"threshold_uncertainty_score":0.9879849},"labels":[],"label_agreement":null},{"id":"W3200217880","doi":"10.1200/jco.2020.39.28_suppl.195","title":"The impact of the COVID-19 pandemic on patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in an Australian outpatient oncology setting.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pandemic; Telehealth; Coronavirus disease 2019 (COVID-19); Quality of life (healthcare); Family medicine; Lung cancer; Telemedicine; Internal medicine; Health care; Nursing; Disease","score_opus":0.43329575519651803,"score_gpt":0.5695387612243837,"score_spread":0.1362430060278657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200217880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716095,0.0004397378,0.000010515379,0.02568583,0.0013772097,0.00069558166,0.000009228882,0.000016158954,0.00015627382],"genre_scores_gemma":[0.9892538,0.00045681495,0.00011908976,0.009865305,0.00022493763,0.00001570978,0.0000029505582,0.00002448617,0.00003686511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98886293,0.0031368935,0.005778163,0.00047016275,0.0011488559,0.0006030139],"domain_scores_gemma":[0.9842933,0.0063899746,0.0056713363,0.0007911892,0.0014498804,0.0014043268],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006450587,0.00031635433,0.0019667447,0.00020019712,0.00021382279,0.000027211574,0.0003196599,0.00074986205,0.000053834156],"category_scores_gemma":[0.0707243,0.00016426478,0.00072458107,0.00043503795,0.000679976,0.00014842195,0.00015140265,0.0022494285,0.000001163815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005571063,0.001876428,0.823316,0.000036233625,0.0002707642,0.0014604775,0.004554562,0.00017970217,0.0007736407,0.00000842096,0.0010570446,0.16089566],"study_design_scores_gemma":[0.0066643567,0.026736796,0.92257786,0.00015574547,0.00022418924,0.0025010826,0.0030271977,0.000044379216,0.00015695686,0.00022781076,0.03751663,0.00016698516],"about_ca_topic_score_codex":0.0011326207,"about_ca_topic_score_gemma":0.0034193236,"teacher_disagreement_score":0.16072868,"about_ca_system_score_codex":0.0016760583,"about_ca_system_score_gemma":0.013585665,"threshold_uncertainty_score":0.99200636},"labels":[],"label_agreement":null},{"id":"W3200258717","doi":"10.1200/jco.2020.39.28_suppl.304","title":"The Association of Antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on early emergency room and hospitalization utilization: A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Internal medicine; Cohort; Population; Cancer; Retrospective cohort study; Pembrolizumab; Medical prescription; Hazard ratio; Emergency medicine; Immunotherapy","score_opus":0.07636916128264709,"score_gpt":0.42637820734376414,"score_spread":0.35000904606111705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200258717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914224,0.00032515018,0.00009492459,0.005963082,0.0015150863,0.00042401958,0.000002752709,0.000006103526,0.0002464773],"genre_scores_gemma":[0.9983422,0.00037626555,0.00014040136,0.00015722697,0.0004980287,0.000005641208,0.0000049169607,0.000011200169,0.00046412484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972321,0.00041980683,0.0017547259,0.00014990543,0.00032847325,0.00011498739],"domain_scores_gemma":[0.9968935,0.00061954017,0.0013690009,0.00016851648,0.00081696647,0.00013247895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001180457,0.00009960603,0.0006740719,0.00007340975,0.00011223355,0.000012595806,0.0000464685,0.00015242392,0.000054161577],"category_scores_gemma":[0.0022757407,0.000064566004,0.0002507807,0.00027518123,0.00001535879,0.000056622106,0.000016876063,0.000211464,0.0000028115583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009883714,0.002736928,0.9721239,0.000013813897,0.00028038307,0.000030725805,0.00024170992,0.000120294295,0.0006906222,0.00007271412,0.00010277619,0.022597747],"study_design_scores_gemma":[0.0046758233,0.024293073,0.9667083,0.00007592059,0.000414084,0.000008883896,0.00027632315,0.000025097159,0.0012812596,0.00004069689,0.0021471484,0.000053418058],"about_ca_topic_score_codex":0.00004378419,"about_ca_topic_score_gemma":0.00029096883,"teacher_disagreement_score":0.022544328,"about_ca_system_score_codex":0.0003511665,"about_ca_system_score_gemma":0.0006994274,"threshold_uncertainty_score":0.27244386},"labels":[],"label_agreement":null},{"id":"W3200270219","doi":"10.1200/jco.2020.39.28_suppl.336","title":"Determining the cancer diagnostic interval using administrative data in a cohort of patients with pancreatic cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Queen's University; Ottawa Hospital; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Cancer registry; Cancer; Retrospective cohort study; Cohort; Pancreatic cancer; Stage (stratigraphy); Population; Percentile; Internal medicine; Emergency medicine","score_opus":0.34323328903335565,"score_gpt":0.5721008937219952,"score_spread":0.2288676046886396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200270219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960635,0.000632385,0.000113773094,0.00199921,0.0003441986,0.0003380647,0.000041037332,0.0000017193219,0.00046615122],"genre_scores_gemma":[0.9939355,0.001527113,0.0034061386,0.000681776,0.00035356043,0.000013611937,0.000012021364,0.000013328156,0.000056938352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961434,0.0008760091,0.001979938,0.00024938674,0.00049474975,0.0002565215],"domain_scores_gemma":[0.98539144,0.011338918,0.001528715,0.00043146338,0.0010907388,0.00021875184],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029555615,0.00012650275,0.0018844659,0.0000751537,0.0000390909,0.0000070759456,0.0003641993,0.00020998504,0.0002686054],"category_scores_gemma":[0.019598745,0.00007013658,0.00012874904,0.0002480494,0.00051714334,0.00011795965,0.00020431087,0.0010019898,0.0000010307289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002311764,0.0014991339,0.97737694,0.000057611844,0.00080571393,0.0005979865,0.00017693656,0.000011623847,0.000011975233,0.000006302298,0.0002340539,0.016909955],"study_design_scores_gemma":[0.0075149764,0.005231538,0.98291993,0.00082142564,0.0015337958,0.000064308595,0.00028924504,0.00082637026,0.000024076659,0.0000263342,0.00068118825,0.00006679679],"about_ca_topic_score_codex":0.00024348334,"about_ca_topic_score_gemma":0.0016610395,"teacher_disagreement_score":0.016843159,"about_ca_system_score_codex":0.00025281913,"about_ca_system_score_gemma":0.009364941,"threshold_uncertainty_score":0.99625105},"labels":[],"label_agreement":null},{"id":"W3200302605","doi":"10.1200/jco.2020.39.28_suppl.10","title":"Using blood wisely in oncology patients: An institutional analysis of the Choosing Wisely Canada restrictive transfusion strategy guidelines.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Blood transfusion; Emergency medicine; Univariate analysis; Internal medicine; Multivariate analysis","score_opus":0.26627504841836036,"score_gpt":0.507220859713824,"score_spread":0.24094581129546366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200302605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934713,0.00021152016,0.00017351803,0.0033635758,0.0012426167,0.00013396403,0.000018449502,0.0000022238696,0.0013828052],"genre_scores_gemma":[0.99601096,0.00046641374,0.0011331633,0.00195496,0.00039727002,0.0000016896817,0.000008124928,0.000007789095,0.000019651321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567044,0.0007778455,0.002685477,0.00021100703,0.0004704541,0.00018475683],"domain_scores_gemma":[0.9952129,0.0006493503,0.0013632146,0.00020034781,0.0023444232,0.00022974682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012390304,0.00011788347,0.0013347423,0.00023203246,0.00008963565,0.000005797128,0.00015158467,0.00027945524,0.00011281343],"category_scores_gemma":[0.002474283,0.00008118833,0.00047798888,0.0013253186,0.00019249824,0.00014802975,0.00003725801,0.00095712603,1.5582405e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015883604,0.0044154385,0.92362493,0.00001717826,0.0018933758,0.0007575793,0.000102485865,0.02409494,0.0020956355,0.00024641995,0.00037627862,0.04078738],"study_design_scores_gemma":[0.0069517014,0.0030590522,0.97528386,0.000107648615,0.0044860127,0.00023816149,0.0002839601,0.0008002214,0.00034973773,0.00009041056,0.008263889,0.00008531669],"about_ca_topic_score_codex":0.04724629,"about_ca_topic_score_gemma":0.445698,"teacher_disagreement_score":0.39845172,"about_ca_system_score_codex":0.0007832016,"about_ca_system_score_gemma":0.027611166,"threshold_uncertainty_score":0.9779014},"labels":[],"label_agreement":null},{"id":"W3200539468","doi":"10.1200/jco.21.01371","title":"Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Drug; Drug administration; Administration (probate law); Pharmacology","score_opus":0.08411590816840064,"score_gpt":0.43765098846508205,"score_spread":0.3535350802966814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200539468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804514,0.00076033775,0.00048503611,0.016157664,0.0004901548,0.00015065429,0.000004154598,0.0000040554096,0.0014965242],"genre_scores_gemma":[0.988592,0.0011738283,0.008280167,0.0012143236,0.00043581842,0.0000017850052,0.000003861384,0.000009739758,0.00028842574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977342,0.00035891743,0.0013984139,0.00013184859,0.00026659752,0.00011004995],"domain_scores_gemma":[0.9964304,0.0016169179,0.001275466,0.00016715196,0.00035798698,0.00015210279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015172949,0.000085995445,0.000725775,0.000043669446,0.000038145743,0.000008964775,0.000063838306,0.00018444064,0.00018782052],"category_scores_gemma":[0.002464168,0.000054092496,0.00022356046,0.000117230484,0.00013363575,0.000082885745,0.000040359988,0.0004507596,0.0000016781582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01447992,0.010849968,0.5290346,0.0006024287,0.0069009117,0.0058302386,0.003749604,0.0023615768,0.0018177278,0.0015770262,0.025701104,0.3970949],"study_design_scores_gemma":[0.10743284,0.06161378,0.6688775,0.0015147905,0.007577559,0.015212919,0.0037016193,0.014617153,0.026755812,0.0018414651,0.09026464,0.00058994826],"about_ca_topic_score_codex":0.000004951934,"about_ca_topic_score_gemma":0.000028385015,"teacher_disagreement_score":0.39650494,"about_ca_system_score_codex":0.00019753003,"about_ca_system_score_gemma":0.0030869877,"threshold_uncertainty_score":0.5476183},"labels":[],"label_agreement":null},{"id":"W3200563737","doi":"10.1200/jco.2020.39.28_suppl.177","title":"Patient-reported outcomes to assess symptoms in patients with metastatic breast cancer: Pilot implementation project.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Distress; Quality of life (healthcare); Breast cancer; Anxiety; Metastatic breast cancer; Patient experience; Physical therapy; Patient Health Questionnaire; Cancer; Internal medicine; Health care; Psychiatry; Nursing; Clinical psychology; Depressive symptoms","score_opus":0.1311115779327206,"score_gpt":0.4968080502384081,"score_spread":0.3656964723056875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200563737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344385,0.00005428531,0.00004676854,0.0044555245,0.0013417413,0.00040857238,0.000036442896,0.00000645989,0.00020638046],"genre_scores_gemma":[0.9947069,0.000055830096,0.0007894935,0.00418869,0.00016331763,0.00002574974,0.000018651164,0.000017640848,0.000033725013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964883,0.00040089444,0.0020689932,0.00021587076,0.0005740375,0.00025193035],"domain_scores_gemma":[0.99658513,0.0005436732,0.0012642518,0.0001715386,0.0011739765,0.0002614462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009580517,0.00013600072,0.0012166767,0.00016984266,0.00002271755,0.0000127436615,0.0000697463,0.000075718526,0.00023733784],"category_scores_gemma":[0.00051640114,0.00009047162,0.00018806237,0.00040437368,0.000039690294,0.00012554324,0.00004726356,0.0004802166,0.0000024334124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004082114,0.0017700313,0.83978814,0.000028116612,0.00043821096,0.00047054555,0.00024201056,0.000008260598,0.00000920527,0.000010437578,0.00048140116,0.15267155],"study_design_scores_gemma":[0.013505253,0.012337579,0.9682231,0.00013252748,0.00046797204,0.00012746056,0.0009880805,0.0000021021378,0.00002866652,0.000010846442,0.004077936,0.000098464676],"about_ca_topic_score_codex":0.00062780513,"about_ca_topic_score_gemma":0.009256647,"teacher_disagreement_score":0.15257308,"about_ca_system_score_codex":0.00034348873,"about_ca_system_score_gemma":0.0032822802,"threshold_uncertainty_score":0.5822624},"labels":[],"label_agreement":null},{"id":"W3200713508","doi":"10.1200/jco.2020.39.28_suppl.90","title":"Fertility preservation in young breast cancer patients: A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"Fondation du cancer des Cèdres","keywords":"Medicine; Fertility preservation; Breast cancer; Mastectomy; Infertility; Logistic regression; Population; Fertility; Gynecology; Cancer; Internal medicine; Obstetrics; Pregnancy","score_opus":0.11562754039453832,"score_gpt":0.4750184994683246,"score_spread":0.35939095907378626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200713508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922677,0.00011415549,0.000024574736,0.006027076,0.0010865481,0.00024107526,0.0000057323887,0.000004419745,0.00022869844],"genre_scores_gemma":[0.998653,0.000012177615,0.00021277246,0.0007100219,0.00032796327,0.0000070108144,0.000010072169,0.000004928341,0.00006205893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649656,0.0010747698,0.0018334131,0.00024418734,0.00022362414,0.00012743977],"domain_scores_gemma":[0.9969003,0.0006751118,0.00079680985,0.0002180197,0.0012868285,0.0001228982],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030538202,0.000080464124,0.0008605422,0.00006076774,0.000026419613,0.0000033041078,0.00007363437,0.00025227206,0.0002295264],"category_scores_gemma":[0.00869529,0.000057668465,0.00019929711,0.00019374532,0.000057153116,0.000136548,0.000028919843,0.0006868557,0.0000021899727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013577546,0.008807438,0.9621893,0.000015223188,0.00009597554,0.000065268556,0.000058173016,0.000022052163,0.000031541033,0.00000221925,0.00006467496,0.015070566],"study_design_scores_gemma":[0.0062861685,0.0025098734,0.9904562,0.000037266742,0.000108557375,0.000009595205,0.00006459408,0.000074728305,0.00001555411,0.00018762241,0.00020432797,0.00004546303],"about_ca_topic_score_codex":0.000300771,"about_ca_topic_score_gemma":0.0016669916,"teacher_disagreement_score":0.028266927,"about_ca_system_score_codex":0.00024953784,"about_ca_system_score_gemma":0.001361769,"threshold_uncertainty_score":0.9996549},"labels":[],"label_agreement":null},{"id":"W3200776324","doi":"10.1200/jco.21.01972","title":"Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Colorectal cancer; Perioperative; Chemotherapy; Adjuvant chemotherapy; Metastasectomy; Metastasis; Cisplatin; Cancer","score_opus":0.2546511992195498,"score_gpt":0.4621196728258507,"score_spread":0.20746847360630088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200776324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96715766,0.015480851,0.000047028767,0.015485788,0.00044100685,0.00046759658,0.000021180556,0.0000043439113,0.0008945654],"genre_scores_gemma":[0.973897,0.016211092,0.0070870346,0.0010404533,0.0009619706,0.000052307514,0.0000082980305,0.000021157863,0.00072070456],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974021,0.0004883221,0.0013821386,0.00023540607,0.00023112209,0.00026094986],"domain_scores_gemma":[0.99628747,0.0020818368,0.00057714706,0.000102240614,0.0006910024,0.00026030827],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019226159,0.00015009417,0.0015124885,0.00012385861,0.00004348809,0.000019241917,0.00008745583,0.00031850295,0.0010595715],"category_scores_gemma":[0.0016634453,0.0001065821,0.0006268529,0.00018314486,0.00012621278,0.000103783765,0.000027922375,0.0005981795,0.000006073195],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028367054,0.003987615,0.7100182,0.000081765524,0.001331282,0.0070647905,0.0011697579,0.0000061968904,0.0032549342,0.0001196566,0.0043062377,0.24029252],"study_design_scores_gemma":[0.1005511,0.041758336,0.13884372,0.000697341,0.0019322445,0.0014246278,0.0023997517,0.00240919,0.07457475,0.00040462686,0.6345865,0.0004177949],"about_ca_topic_score_codex":0.00005488244,"about_ca_topic_score_gemma":0.0005039669,"teacher_disagreement_score":0.63028026,"about_ca_system_score_codex":0.0002285922,"about_ca_system_score_gemma":0.003154133,"threshold_uncertainty_score":0.9998536},"labels":[],"label_agreement":null},{"id":"W3200968113","doi":"10.1200/jco.2020.39.28_suppl.230","title":"Improving management of hypersensitivity reactions: A BC Cancer-Victoria quality improvement initiative.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Health Services Authority; BC Cancer Agency","funders":"","keywords":"Medicine; Psychological intervention; Family medicine; Pharmacy; Cancer; Nursing; PDCA; Audit; Attendance; Quality management; Emergency medicine; Internal medicine","score_opus":0.21788812378767436,"score_gpt":0.5122426947073759,"score_spread":0.2943545709197016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200968113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93606305,0.0002260503,0.0008448915,0.007986256,0.0056692273,0.00030514432,0.00001731284,0.00001956169,0.04886851],"genre_scores_gemma":[0.98873377,0.0015686168,0.0070457407,0.0008768222,0.0011161605,0.000007379671,0.0000032137148,0.000016401807,0.0006319194],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99576724,0.0005300947,0.0027517444,0.00024323726,0.00048522992,0.00022247153],"domain_scores_gemma":[0.9933786,0.0017471411,0.0029778173,0.0003025471,0.0012825286,0.00031138462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034245935,0.00013903041,0.0013774898,0.000111206624,0.000051431478,0.000006228546,0.000080378006,0.00026628995,0.000048290607],"category_scores_gemma":[0.0029088582,0.00011667004,0.00061493716,0.00026682994,0.0001418259,0.00017873212,0.00009924565,0.0010573093,0.000009748611],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007028585,0.0050264825,0.003677915,0.0003600475,0.0020802636,0.0017206705,0.00012163285,0.000017325383,0.03823797,0.0011850599,0.00016643509,0.9467033],"study_design_scores_gemma":[0.020170908,0.0031274508,0.6821064,0.0009915861,0.003100889,0.0007890435,0.008569608,0.00013422887,0.016581628,0.0007047557,0.26338455,0.00033898902],"about_ca_topic_score_codex":0.00026904346,"about_ca_topic_score_gemma":0.00013045092,"teacher_disagreement_score":0.94636434,"about_ca_system_score_codex":0.00059872185,"about_ca_system_score_gemma":0.0025515791,"threshold_uncertainty_score":0.4757666},"labels":[],"label_agreement":null},{"id":"W3201061561","doi":"10.1200/jco.2020.39.28_suppl.320","title":"Technology interventions to support adherence to oral oncolytic agents: A systematic review and meta-analysis.","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Psychological intervention; Observational study; CINAHL; Grading (engineering); MEDLINE; Randomized controlled trial; Cochrane Library; Guideline; Meta-analysis; Family medicine; Medical physics; Nursing; Internal medicine; Pathology","score_opus":0.7092841818890313,"score_gpt":0.650731808521637,"score_spread":0.05855237336739427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201061561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017944889,0.98586375,0.0012881239,0.009480091,0.000304331,0.002566171,0.000016055463,0.00001326334,0.00046643583],"genre_scores_gemma":[0.000011173189,0.9678104,0.00615765,0.015381255,0.00011046971,0.0004703946,0.000014106987,0.00002238448,0.0100221755],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9876704,0.0016292225,0.009318659,0.00052878604,0.0005618441,0.0002910753],"domain_scores_gemma":[0.9888835,0.0016201879,0.006293713,0.00091818155,0.001233576,0.0010508666],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007924759,0.0003858601,0.028923772,0.00087015243,0.00003542579,0.000020560725,0.0006842044,0.0006778672,0.0059789526],"category_scores_gemma":[0.021545742,0.00023182394,0.0079568215,0.0023762602,0.00013561638,0.000059191698,0.0002688001,0.0016019846,0.0010324196],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018037592,0.0009141325,0.000008712771,0.60635173,0.14233841,0.0008337291,0.000010534959,1.5325939e-7,1.6964027e-8,0.00014283917,0.044231147,0.20515054],"study_design_scores_gemma":[0.00021199176,0.0053099017,0.0000032084017,0.075211786,0.50652915,0.00083722174,0.00002168906,1.8481094e-7,1.228991e-8,0.0000146929215,0.4117588,0.00010135569],"about_ca_topic_score_codex":0.0000032529363,"about_ca_topic_score_gemma":0.000021990494,"teacher_disagreement_score":0.53113997,"about_ca_system_score_codex":0.0002052162,"about_ca_system_score_gemma":0.0035698554,"threshold_uncertainty_score":0.99974537},"labels":[],"label_agreement":null},{"id":"W3201164661","doi":"10.1200/jco.2020.39.28_suppl.34","title":"Can high-dose methotrexate be safely administered to outpatients?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Toronto East General Hospital; Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Febrile neutropenia; Mucositis; Ambulatory; Neutropenia; Regimen; Methotrexate; Internal medicine; Cohort; Outpatient clinic; Chemotherapy; Retrospective cohort study; Surgery","score_opus":0.2003902248172111,"score_gpt":0.5095833943449846,"score_spread":0.3091931695277734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201164661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8689214,0.000114829025,0.00051463104,0.12207989,0.0024379801,0.00023083358,0.00001962711,0.000012499417,0.0056682923],"genre_scores_gemma":[0.9245039,0.00019685483,0.0401857,0.027674234,0.0018131312,0.000005353954,0.000010249726,0.000036899462,0.005573644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437416,0.0010774506,0.0028475912,0.00032801542,0.0009141688,0.00045862494],"domain_scores_gemma":[0.9904642,0.00478004,0.00113492,0.00044097335,0.001639454,0.0015404252],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003649673,0.00017823219,0.0019349211,0.0001950931,0.000047078785,0.000018144909,0.00030322187,0.00046312602,0.0007732765],"category_scores_gemma":[0.029089293,0.00013117271,0.00054544955,0.00038255824,0.00018271347,0.00007139643,0.00025986272,0.0013021633,0.000107355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042761896,0.008866556,0.038540173,0.00019139395,0.0030356771,0.061760478,0.0011715505,0.00005550082,0.008225752,0.0010884859,0.18068467,0.65361786],"study_design_scores_gemma":[0.043528363,0.047395624,0.22452655,0.0003292605,0.0010566574,0.0045974366,0.000603147,0.00016290293,0.004396237,0.0009024804,0.67216116,0.00034016158],"about_ca_topic_score_codex":0.000055012693,"about_ca_topic_score_gemma":0.0001226071,"teacher_disagreement_score":0.6532777,"about_ca_system_score_codex":0.0008915012,"about_ca_system_score_gemma":0.012901308,"threshold_uncertainty_score":0.9926946},"labels":[],"label_agreement":null},{"id":"W3201169911","doi":"10.1200/jco.2020.39.28_suppl.21","title":"Implementation and impact of Choosing Wisely recommendations in oncology: A scoping review.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare cost, quality, practices","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Concordance; Psychological intervention; MEDLINE; Family medicine; Scopus; Oncology; Internal medicine; Nursing","score_opus":0.8932412389038807,"score_gpt":0.7968389402786572,"score_spread":0.09640229862522354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201169911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85947675,0.009628565,0.00019200222,0.12627077,0.0016493164,0.0008306059,0.000010543324,0.0000069005264,0.0019345592],"genre_scores_gemma":[0.8043439,0.15230024,0.012297991,0.029885173,0.001040515,0.000033495624,0.00001688549,0.0000257514,0.00005609539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9785909,0.014059589,0.0065788,0.00020005615,0.00023694102,0.0003337306],"domain_scores_gemma":[0.96851754,0.02258482,0.0070649013,0.00018560447,0.0013147377,0.00033238676],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029384619,0.00011052884,0.0017419783,0.0001635371,0.0001407392,0.0000045312586,0.00013144121,0.00041950878,0.0009696431],"category_scores_gemma":[0.026409043,0.00009062785,0.0002544524,0.0003478579,0.000105602485,0.0004354645,0.00013120829,0.0022273401,0.000009309016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048984133,0.0006870626,0.5330606,0.0019125002,0.00014146358,0.0001108686,0.0013961893,0.0000019597417,0.00010846761,0.0001890631,0.008291181,0.45361078],"study_design_scores_gemma":[0.011774127,0.0069731823,0.8895934,0.040561356,0.00033693612,0.00017870658,0.011264545,0.000025753794,0.000023044679,0.0014707232,0.037583288,0.00021489711],"about_ca_topic_score_codex":0.00069313013,"about_ca_topic_score_gemma":0.006987262,"teacher_disagreement_score":0.45339587,"about_ca_system_score_codex":0.00072971435,"about_ca_system_score_gemma":0.019155215,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W3201297985","doi":"10.1200/jco.2020.39.28_suppl.140","title":"Promotion of prostate cancer screening equity: A quality improvement education initiative.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Family medicine; Health equity; Promotion (chess); Prostate cancer screening; Equity (law); Cancer screening; Demographics; Quality management; Prostate cancer; Gerontology; Cancer; Public health; Demography; Prostate-specific antigen; Service (business); Nursing; Internal medicine","score_opus":0.698322802645852,"score_gpt":0.6973056606781258,"score_spread":0.0010171419677261762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201297985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9320127,0.00037316486,0.0024991324,0.061582305,0.0018297932,0.0003825487,0.000012091137,0.0000068791865,0.0013013844],"genre_scores_gemma":[0.9680193,0.0011455945,0.021947192,0.0071948026,0.0014075986,0.00001308763,0.00002383885,0.000013780266,0.00023479178],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99202085,0.0009785892,0.00600838,0.00020552985,0.00061392214,0.00017271265],"domain_scores_gemma":[0.9859892,0.0034513131,0.0063705803,0.00019963816,0.0037246766,0.00026457527],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010881493,0.00010545308,0.0011559676,0.00008769167,0.000031334308,0.000009817741,0.00009199218,0.00021360726,0.0004275113],"category_scores_gemma":[0.04226177,0.00008532969,0.00039018615,0.00023192422,0.00011971199,0.0003012051,0.0001277201,0.00081816874,0.0000035449166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021693846,0.003969254,0.09949593,0.00013711177,0.00035081067,0.00004328269,0.00015423709,0.000010708995,0.0040054666,0.00014577502,0.0021917652,0.88732624],"study_design_scores_gemma":[0.016843414,0.020930067,0.8831875,0.00078144076,0.0015935008,0.00021459219,0.0039020586,0.00019265254,0.009222113,0.0039182813,0.059008494,0.00020590326],"about_ca_topic_score_codex":0.00013312066,"about_ca_topic_score_gemma":0.00015939091,"teacher_disagreement_score":0.88712037,"about_ca_system_score_codex":0.00022636369,"about_ca_system_score_gemma":0.0115476195,"threshold_uncertainty_score":0.994056},"labels":[],"label_agreement":null},{"id":"W3201469468","doi":"10.1200/jco.2020.39.28_suppl.292","title":"Patterns of first-line systemic therapy delivery and adoption of bevacizumab in advanced ovarian cancer in Ontario, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Bevacizumab; Systemic therapy; Internal medicine; Cancer registry; Cohort; Population; Cancer; Oncology; Ovarian cancer; Stage (stratigraphy); Logistic regression; Retrospective cohort study; Chemotherapy; Breast cancer","score_opus":0.06744635450047,"score_gpt":0.3884308034953431,"score_spread":0.3209844489948731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201469468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911945,0.0041235667,0.000012417894,0.0038646988,0.00055590936,0.00015313755,0.0000149751295,6.9721983e-7,0.000080113794],"genre_scores_gemma":[0.9817693,0.01733597,0.00035434024,0.00037876886,0.00010415243,0.0000077091645,0.0000034739908,0.000006978104,0.000039306327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975587,0.00016967776,0.0017966074,0.0001436552,0.00020858557,0.0001227632],"domain_scores_gemma":[0.9976921,0.00072182,0.0010205826,0.0001209023,0.00033040173,0.00011419448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064903736,0.0000912266,0.001240594,0.000083985135,0.000007421238,0.000001504643,0.000049668954,0.00016303026,0.00020161297],"category_scores_gemma":[0.00021715135,0.000069927664,0.00011978591,0.000099829456,0.000027038168,0.000047649883,0.000019938763,0.00041611862,9.165747e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025221226,0.0010835065,0.89035255,0.00009014679,0.00020222605,0.0009252488,0.00016460833,0.00034015803,0.00009074344,0.000017276523,0.000039449973,0.104171984],"study_design_scores_gemma":[0.018378602,0.002904122,0.9742032,0.0013973775,0.00010831193,0.00014862009,0.00020197716,0.00003148422,0.0002487271,0.000026292377,0.002301528,0.000049700833],"about_ca_topic_score_codex":0.5713695,"about_ca_topic_score_gemma":0.98986244,"teacher_disagreement_score":0.4184929,"about_ca_system_score_codex":0.000957581,"about_ca_system_score_gemma":0.0066846246,"threshold_uncertainty_score":0.99894655},"labels":[],"label_agreement":null},{"id":"W3203149991","doi":"10.1200/jco.21.01220","title":"Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Radiation therapy; Adenocarcinoma; Value (mathematics); Neoadjuvant therapy; Pancreatic ductal adenocarcinoma; Chemotherapy","score_opus":0.15862059641064763,"score_gpt":0.4986456958704825,"score_spread":0.3400250994598349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203149991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800633,0.004853164,0.0001204567,0.0066165994,0.00023016483,0.0002470904,0.000001159444,0.0000012348154,0.007866788],"genre_scores_gemma":[0.978475,0.01546595,0.0047158063,0.00089224294,0.00023663527,0.0000050580193,0.0000019265638,0.0000063816306,0.00020101394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582386,0.0011948608,0.0022140397,0.000114505245,0.0004864573,0.0001662577],"domain_scores_gemma":[0.99497473,0.0031159716,0.0011750584,0.00025650373,0.00037541072,0.00010231994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059213545,0.00007944129,0.001502029,0.0001112599,0.000015614267,0.000002172115,0.00019466583,0.00021638807,0.00016222722],"category_scores_gemma":[0.0011447516,0.000045867728,0.00032802467,0.0002717561,0.00022423654,0.000038780436,0.000036032914,0.00059338106,0.0000038719463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027630096,0.0026437899,0.8240197,0.00013500579,0.0009855758,0.0018125962,0.000513312,0.000010703763,0.00023245368,0.0022605439,0.00068771007,0.1639356],"study_design_scores_gemma":[0.009211342,0.009144093,0.97470343,0.00019558198,0.00051500375,0.00033971138,0.0010239868,0.00019277951,0.00018598138,0.0012013686,0.003251848,0.000034895605],"about_ca_topic_score_codex":0.000026026682,"about_ca_topic_score_gemma":0.000006371887,"teacher_disagreement_score":0.16390072,"about_ca_system_score_codex":0.00007320285,"about_ca_system_score_gemma":0.0014226461,"threshold_uncertainty_score":0.25779784},"labels":[],"label_agreement":null},{"id":"W3203864709","doi":"10.1200/jco.21.00838","title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"National Cancer Institute; Pharmacyclics","keywords":"Rituximab; Medicine; Ibrutinib; Internal medicine; Placebo; Waldenstrom macroglobulinemia; Clinical endpoint; Adverse effect; Regimen; Gastroenterology; Surgery; Oncology; Randomized controlled trial; Lymphoma; Chronic lymphocytic leukemia; Leukemia; Pathology","score_opus":0.20186389114135905,"score_gpt":0.5228453159033778,"score_spread":0.32098142476201874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203864709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740515,0.0017539299,0.0045861723,0.013373127,0.0028772606,0.0022384783,0.00007942801,0.000028952125,0.0010111926],"genre_scores_gemma":[0.98538923,0.00064347696,0.006700195,0.002098182,0.003982396,0.000081958264,0.00009869725,0.000049660597,0.0009561819],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9880322,0.0028835873,0.006058122,0.00072761386,0.0014992664,0.00079917646],"domain_scores_gemma":[0.9490152,0.044048686,0.0026451019,0.0009818192,0.0026537937,0.00065541],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015760932,0.00042435073,0.0075029195,0.00029813492,0.00022788858,0.00008649318,0.0007733982,0.00076487573,0.0009937908],"category_scores_gemma":[0.032909267,0.0002631573,0.0029408066,0.0013991869,0.00091713655,0.00014343897,0.00041541338,0.0026829864,0.000055357763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.92197484,0.010043098,0.00021139627,0.000035228288,0.01927054,0.008884718,0.00060017843,0.0003488899,0.000042938627,0.000108149354,0.0086023705,0.02987764],"study_design_scores_gemma":[0.9220491,0.0092744855,0.000264637,0.000073947565,0.016872909,0.00054706977,0.001899667,0.036237687,0.00012120064,0.00016220762,0.01227063,0.00022648033],"about_ca_topic_score_codex":0.00076609105,"about_ca_topic_score_gemma":0.0007620042,"teacher_disagreement_score":0.04519546,"about_ca_system_score_codex":0.006789547,"about_ca_system_score_gemma":0.051985007,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W3203871429","doi":"10.1200/jco.21.00899","title":"Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chemotherapy; Carboplatin; Ototoxicity; Cisplatin; Cochlea; Hearing loss; Radiation therapy","score_opus":0.0948873367607509,"score_gpt":0.43852471223993994,"score_spread":0.34363737547918904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203871429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933151,0.0005052236,0.00011736938,0.0055956873,0.00021456133,0.00014662051,0.0000022815796,0.000003911629,0.00009925891],"genre_scores_gemma":[0.98980737,0.0020232252,0.003066134,0.00465119,0.00038248533,0.0000030841097,2.2838714e-7,0.000014105341,0.000052181735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809325,0.00029018472,0.0010265642,0.0002542623,0.00013558888,0.00020014896],"domain_scores_gemma":[0.9976962,0.0015216818,0.00041668443,0.00009541287,0.00006935793,0.00020067014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001376056,0.000093240444,0.0005694438,0.00007861118,0.000039970033,0.00003410483,0.000074405696,0.00019096631,0.000012038605],"category_scores_gemma":[0.004311405,0.00008386698,0.000076883094,0.00009932991,0.00017945962,0.000101520694,0.000073172596,0.0004782019,0.000001048216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006040043,0.0002396716,0.90865874,0.000015071824,0.000014895977,0.00011097954,0.00023083818,0.000014933849,0.0017351169,0.00006761461,0.00009427249,0.08821384],"study_design_scores_gemma":[0.004474887,0.001435667,0.98289007,0.000041471747,0.000013778658,0.00063697936,0.000017218577,0.00029344324,0.0018891571,0.0007026871,0.007518878,0.000085778425],"about_ca_topic_score_codex":0.000008708,"about_ca_topic_score_gemma":0.000028668444,"teacher_disagreement_score":0.08812806,"about_ca_system_score_codex":0.000038589013,"about_ca_system_score_gemma":0.0004357019,"threshold_uncertainty_score":0.5161466},"labels":[],"label_agreement":null},{"id":"W3204760583","doi":"10.1200/jco.21.00920","title":"Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Prednisone; Vincristine; Rituximab; Cyclophosphamide; Multicenter study; Phases of clinical research","score_opus":0.03384742794814694,"score_gpt":0.35893940788864404,"score_spread":0.3250919799404971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204760583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010485,0.0067201983,0.000011808168,0.002079091,0.00017684653,0.0007939459,0.000011011347,0.000008721994,0.00009352857],"genre_scores_gemma":[0.9857974,0.008644361,0.00323159,0.0017986596,0.00043350368,0.000016841446,0.000014083964,0.000026339754,0.00003723664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702114,0.0003410188,0.0015021438,0.00043119767,0.00039840498,0.0003060669],"domain_scores_gemma":[0.99738353,0.0006672034,0.0009541762,0.00017727178,0.00028959848,0.00052823126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087049237,0.00028923716,0.0018807041,0.000115414965,0.000067224406,0.000024979157,0.00006841967,0.00026995776,0.000015237519],"category_scores_gemma":[0.0003715639,0.00017272757,0.000113520924,0.0001505864,0.00037754423,0.00013018517,0.000101697835,0.0004190808,6.80779e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3339159,0.035971124,0.4780023,0.00006201602,0.00043099848,0.004036331,0.00021834816,9.219404e-7,0.00013430898,0.000002474461,0.0001303367,0.14709495],"study_design_scores_gemma":[0.44087988,0.047518525,0.5077474,0.0004044343,0.0004389931,0.0022859154,0.000057437523,0.0000259042,0.00021217755,0.000004182905,0.00032602123,0.000099119105],"about_ca_topic_score_codex":0.00011314931,"about_ca_topic_score_gemma":0.00011392911,"teacher_disagreement_score":0.14699583,"about_ca_system_score_codex":0.00021394812,"about_ca_system_score_gemma":0.0016230291,"threshold_uncertainty_score":0.70436263},"labels":[],"label_agreement":null},{"id":"W3205415979","doi":"10.1200/jco.21.00358","title":"Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Izaak Walton Killam Health Centre","funders":"National Cancer Institute","keywords":"Chemotherapy; Clinical trial; Phases of clinical research; Overall survival; Confidence interval","score_opus":0.09052216572152885,"score_gpt":0.45213264498310773,"score_spread":0.36161047926157885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205415979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082506,0.00063420384,0.00021775912,0.005026396,0.0014816346,0.0010787304,0.000032709242,0.000008826085,0.00069466187],"genre_scores_gemma":[0.9876954,0.00030799786,0.008953359,0.0013158052,0.0015188288,0.00005656884,0.00006913928,0.000030718264,0.000052184416],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994205,0.0007641229,0.0036434596,0.0003812293,0.0006402677,0.00036595057],"domain_scores_gemma":[0.99126744,0.00422446,0.002860725,0.0004435131,0.0006958028,0.0005080366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018087361,0.0002757645,0.0027176838,0.0001433771,0.00010492051,0.000013256895,0.00015874063,0.00024907856,0.00022584919],"category_scores_gemma":[0.0036010265,0.00015239883,0.0007861455,0.00031229685,0.00019994035,0.00007695422,0.00008039931,0.00050575385,0.0000090320245],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18701579,0.086389825,0.16629848,0.000019389014,0.0036818779,0.025823794,0.00042626561,0.00001265911,0.000024059584,0.000048009366,0.0015628696,0.528697],"study_design_scores_gemma":[0.43193623,0.18450768,0.31703255,0.00018598225,0.0038241958,0.0028913603,0.00025334625,0.000008555219,0.00031614493,0.000045338107,0.0588131,0.00018552794],"about_ca_topic_score_codex":0.00009940327,"about_ca_topic_score_gemma":0.000142365,"teacher_disagreement_score":0.52851146,"about_ca_system_score_codex":0.00060913054,"about_ca_system_score_gemma":0.0024954567,"threshold_uncertainty_score":0.6214644},"labels":[],"label_agreement":null},{"id":"W3207414919","doi":"10.1200/jco.21.02287","title":"Acknowledging Disparities in Hereditary Cancer Testing","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hereditary Cancer; Cancer; Disease; Genetic testing; Genetic counseling; MEDLINE","score_opus":0.133719805647876,"score_gpt":0.4709708367723409,"score_spread":0.3372510311244649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207414919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818032,0.0075906576,0.0002695103,0.0035465327,0.00313416,0.000034222325,0.000004623412,0.000002186096,0.0036149328],"genre_scores_gemma":[0.98326254,0.0012002377,0.010072678,0.0016391914,0.003361732,0.0000056220724,0.000003858672,0.00001336424,0.00044079786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981977,0.00027835916,0.0010862564,0.00016294184,0.00011371548,0.00016107771],"domain_scores_gemma":[0.998215,0.00048096752,0.00050707726,0.00013205783,0.00057286484,0.00009199552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012318469,0.00007579762,0.00041872286,0.000039770843,0.000025943615,0.000008519006,0.00015426033,0.0002587822,0.00007150622],"category_scores_gemma":[0.006098429,0.000068744965,0.000152457,0.00013927119,0.000110507324,0.0000067741084,0.00010202581,0.0004314268,0.0000034117554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000388982,0.0006940961,0.5925419,0.000040256193,0.00028274662,0.00084850175,0.000073379946,0.0026662115,0.019787617,0.0000630868,0.033655707,0.3489575],"study_design_scores_gemma":[0.00507262,0.0023437454,0.58358425,0.00022903652,0.00013083103,0.0007440412,0.00048709908,0.00039391042,0.018053094,0.001564186,0.38706207,0.0003351307],"about_ca_topic_score_codex":0.00002521426,"about_ca_topic_score_gemma":0.0007616306,"teacher_disagreement_score":0.35340637,"about_ca_system_score_codex":0.00010405427,"about_ca_system_score_gemma":0.0037236067,"threshold_uncertainty_score":0.730083},"labels":[],"label_agreement":null},{"id":"W3216620312","doi":"10.1200/jco.21.02112","title":"Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"European Social Fund; National Cancer Institute; NIHR Cambridge Biomedical Research Centre; National Center for Advancing Translational Sciences; Medical Research Council; lékařská fakulta Univerzity Karlovy; Manchester Biomedical Research Centre; National Institutes of Health; Kerry Group Kuok Foundation; Centro de Investigación Biomédica en Red de Cáncer; Deutsche Krebshilfe; Sahlgrenska Universitetssjukhuset; Uppsala Universitet; NRG Oncology; Ministero dell’Istruzione, dell’Università e della Ricerca; Canadian Institutes of Health Research; Cancerfonden; Cancer Australia; National Breast Cancer Foundation; European Commission; Ministerio de Ciencia e Innovación; Korea Health Industry Development Institute; National Institute for Health and Care Research; Wellcome Trust; Cancer Research UK; Royal Marsden NHS Foundation Trust; Fondation ARC pour la Recherche sur le Cancer; General Secretariat for Research and Technology; National Health and Medical Research Council; Institut National Du Cancer; Ministério da Ciência, Tecnologia e Inovação; Hospital de Câncer de Barretos; Fundación Cellex; Associazione Italiana per la Ricerca sul Cancro; Gray Foundation; Univerzita Karlova v Praze; Deutsches Krebsforschungszentrum; Dipartimenti di Eccellenza; Instituto de Salud Carlos III; Ohio State University","keywords":"Cancer; Prostate cancer; Breast cancer; Ovarian cancer; Risk assessment; Prostate; Genetic variants","score_opus":0.08240164660513276,"score_gpt":0.4232068951971806,"score_spread":0.3408052485920478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216620312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911028,0.003454242,0.00025172098,0.0026596554,0.0013661024,0.00012007928,0.00006084069,0.0000044653375,0.0009800928],"genre_scores_gemma":[0.99277705,0.0013167666,0.0010000943,0.0038317177,0.00069365336,0.000027887623,0.000012546677,0.000025083331,0.00031519917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997509,0.00071444735,0.001008698,0.00026428688,0.00028984784,0.00021372856],"domain_scores_gemma":[0.9976793,0.00029172903,0.0013763163,0.0001898752,0.00029161482,0.00017119518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025885531,0.00012589229,0.00054895907,0.000049633843,0.00014404167,0.000010863622,0.0002708785,0.0002240327,0.00015321857],"category_scores_gemma":[0.00081300904,0.00010261052,0.00017490039,0.00015049303,0.00024306381,0.000006853487,0.00020504385,0.00068993703,0.0000010489935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010546328,0.00424234,0.34108466,0.000029176364,0.006348708,0.0009779972,0.00055821554,0.010232404,0.07153613,0.00024271631,0.13273339,0.42146793],"study_design_scores_gemma":[0.012490622,0.019726593,0.34352747,0.00003205189,0.00067203876,0.0008681102,0.00042302837,0.00015570263,0.0014435848,0.0005799494,0.6196246,0.00045624905],"about_ca_topic_score_codex":0.00001827957,"about_ca_topic_score_gemma":0.00013357258,"teacher_disagreement_score":0.4868912,"about_ca_system_score_codex":0.00018047619,"about_ca_system_score_gemma":0.0025776264,"threshold_uncertainty_score":0.45725983},"labels":[],"label_agreement":null},{"id":"W3217126890","doi":"10.1200/jco.21.02229","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; EMD Serono; Genentech; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Amgen; Celldex Therapeutics; Array BioPharma; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Melanoma; Metastatic melanoma; Clinical trial; Immunotherapy","score_opus":0.07445865462662754,"score_gpt":0.41722741619718856,"score_spread":0.342768761570561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217126890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356127,0.00072835723,0.00005375833,0.0025919904,0.001717326,0.0004093765,0.000007883538,0.000018597493,0.000911462],"genre_scores_gemma":[0.9933701,0.00066605175,0.002983546,0.0014751999,0.00032036053,0.000009570471,0.000019325644,0.0000512925,0.0011045564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954136,0.00038841422,0.0024901486,0.000433071,0.0007879325,0.00048683106],"domain_scores_gemma":[0.99497026,0.0016582061,0.0016943399,0.0004778527,0.00082745776,0.00037187114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010556577,0.00032774007,0.0025069078,0.00020276813,0.00006481287,0.000021491815,0.00025852467,0.00043083003,0.0005245098],"category_scores_gemma":[0.0010772252,0.00019354273,0.00046357542,0.0004831111,0.00037869543,0.00027335357,0.00007042516,0.0011874202,0.000012671675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34801444,0.0027425897,0.5247004,0.000044753564,0.0011601452,0.0030793871,0.00009290258,0.000012298404,0.000022610206,0.0000031682875,0.0002534264,0.119873844],"study_design_scores_gemma":[0.20517702,0.05007746,0.73991066,0.00036205928,0.00040498908,0.00031120633,0.0001778579,0.0000072004814,0.00007107936,0.0000042067336,0.0032852492,0.00021103233],"about_ca_topic_score_codex":0.00003377469,"about_ca_topic_score_gemma":0.0023042732,"teacher_disagreement_score":0.21521021,"about_ca_system_score_codex":0.00089621823,"about_ca_system_score_gemma":0.005240915,"threshold_uncertainty_score":0.9297158},"labels":[],"label_agreement":null},{"id":"W33351285","doi":"10.1200/jco.2006.24.18_suppl.6066","title":"Quality indicators for end-of-life breast cancer care: Testing the use of administrative databases","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Cohort; Emergency medicine; Health care; Population; Cancer registry; Cancer; Family medicine; Database; Medical emergency; Internal medicine; Environmental health","score_opus":0.8871532316655606,"score_gpt":0.6391548155119606,"score_spread":0.24799841615359997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W33351285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546394,0.0020600501,0.0030780127,0.034154348,0.0015799911,0.00057081,0.0031237183,0.000006246081,0.0007874416],"genre_scores_gemma":[0.97756135,0.00014799692,0.016572975,0.004187028,0.0014394798,0.000023158324,0.0000136469,0.000015943071,0.00003844132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9844507,0.0011254231,0.013803647,0.00024599474,0.00014033566,0.00023392399],"domain_scores_gemma":[0.9363683,0.0390252,0.023576245,0.0003100463,0.00053576805,0.00018444666],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.030235061,0.00013009823,0.002359731,0.000190087,0.000090534006,0.0000143798325,0.00034209655,0.00020492628,0.00013398433],"category_scores_gemma":[0.05285032,0.000108759814,0.00040924363,0.00020535085,0.0004275064,0.0003474669,0.000049775335,0.0003915539,0.000007657329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004622459,0.00057219324,0.9330739,0.000290535,0.00024172214,0.0000013679836,0.0003848748,0.0004773232,0.000003870466,0.03691325,0.018602962,0.008975747],"study_design_scores_gemma":[0.0021062,0.0008782608,0.84458303,0.00009154583,0.000045150347,0.0000103379725,0.0008789007,0.00025640722,0.000008663182,0.0020277798,0.14898029,0.00013342056],"about_ca_topic_score_codex":0.0034270294,"about_ca_topic_score_gemma":0.0012963737,"teacher_disagreement_score":0.13037734,"about_ca_system_score_codex":0.00026755893,"about_ca_system_score_gemma":0.0035388996,"threshold_uncertainty_score":0.99857706},"labels":[],"label_agreement":null},{"id":"W34287195","doi":"10.1200/jco.2012.30.15_suppl.9519","title":"A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Smoothened; Medicine; Medulloblastoma; Internal medicine; Toxicity; Vismodegib; Oncology; Pharmacokinetics; Hedgehog signaling pathway; Pharmacology; Cancer research; Signal transduction; Chemistry","score_opus":0.07447724908856515,"score_gpt":0.4326452897642589,"score_spread":0.35816804067569374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34287195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982488,0.00046327885,0.000051463976,0.00010178273,0.0005928558,0.00036906745,0.000012687829,0.000003313686,0.00015674255],"genre_scores_gemma":[0.9981399,0.00010406913,0.00046004285,0.00018612765,0.0010082095,0.000014024248,0.0000027662504,0.00002891271,0.000055936227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606735,0.00065004826,0.0023008774,0.00024639576,0.00035635944,0.00037895094],"domain_scores_gemma":[0.9966887,0.00032182233,0.0020790708,0.00024558412,0.00041665952,0.0002481488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023456507,0.0002192556,0.0012483275,0.00015375456,0.000054760054,0.0000046533396,0.00029912384,0.00025890654,0.000025837644],"category_scores_gemma":[0.0019088228,0.00013901501,0.00020378391,0.00021135478,0.00015692758,0.000012854788,0.00017003663,0.00043573463,0.0000025533077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022871723,0.0635189,0.88103443,0.000044506167,0.0005202184,0.00007900847,0.0011167725,0.000036035282,0.001481045,0.0000029967284,0.0011016028,0.028192751],"study_design_scores_gemma":[0.06415553,0.3641722,0.54860973,0.000112602036,0.0005647026,0.000045611978,0.0013134382,0.00001516123,0.00244688,0.000015560261,0.018050076,0.00049851957],"about_ca_topic_score_codex":0.000008846348,"about_ca_topic_score_gemma":0.00024733203,"teacher_disagreement_score":0.33242473,"about_ca_system_score_codex":0.000045115383,"about_ca_system_score_gemma":0.000694988,"threshold_uncertainty_score":0.5668868},"labels":[],"label_agreement":null},{"id":"W38662536","doi":"10.1200/jco.2006.24.18_suppl.8610","title":"Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; University of Waterloo","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Zoledronic acid; Parathyroid hormone; Relative risk; Urology; Placebo; Gastroenterology; Cancer; Confidence interval; Endocrinology; Pathology; Calcium","score_opus":0.04274616033718478,"score_gpt":0.4084792750282681,"score_spread":0.3657331146910833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W38662536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590427,0.000824196,0.000013884072,0.0018946825,0.0001850746,0.0007084528,0.00003190569,0.000007345325,0.00043018564],"genre_scores_gemma":[0.99851733,0.00012412341,0.0003374134,0.00066098373,0.00015729785,0.0000202672,0.00001675741,0.000024144047,0.00014165894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959231,0.0007281146,0.0022040503,0.0002538623,0.00049676554,0.00039411747],"domain_scores_gemma":[0.99616545,0.0012304852,0.0015113093,0.00028066622,0.00017772181,0.0006343908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014647084,0.0002584017,0.001975553,0.00021087874,0.00003216382,0.0000035235637,0.00007532705,0.00025106256,0.00003085622],"category_scores_gemma":[0.0004513134,0.00014200891,0.0004057876,0.00017174365,0.0001317771,0.00006308858,0.000013274612,0.00045967486,0.000020177276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07892023,0.016679345,0.8411146,0.000070340175,0.00017576442,0.0024638376,0.000011576474,0.00016123836,0.000053650394,0.000010178129,0.00038965882,0.059949625],"study_design_scores_gemma":[0.06633275,0.17347407,0.757982,0.00018146205,0.0005386988,0.00002308123,0.0000020534671,0.00013268292,0.00032291297,0.000022260874,0.00090751884,0.000080476246],"about_ca_topic_score_codex":0.000096627846,"about_ca_topic_score_gemma":0.000098387696,"teacher_disagreement_score":0.15679473,"about_ca_system_score_codex":0.00059251854,"about_ca_system_score_gemma":0.0018416941,"threshold_uncertainty_score":0.57909554},"labels":[],"label_agreement":null},{"id":"W4200095907","doi":"10.1200/jco.21.00941","title":"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of Ottawa; Alberta Cancer Foundation; BC Cancer Agency","funders":"National Health and Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma","keywords":"Medicine; Enzalutamide; Quality of life (healthcare); Prostate cancer; Internal medicine; Discontinuation; Randomized controlled trial; Cancer; Oncology; Physical therapy","score_opus":0.20635219679472658,"score_gpt":0.5675658819912144,"score_spread":0.3612136851964878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200095907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954419,0.007128731,0.00006998602,0.035224617,0.0013930543,0.001265061,0.00012370596,0.000008184711,0.0003676208],"genre_scores_gemma":[0.9671723,0.0284964,0.0011522835,0.0017323783,0.00043893975,0.000043946904,0.00013312182,0.00002214206,0.0008084425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98650604,0.0055929148,0.006439609,0.00033742224,0.0007697545,0.00035423864],"domain_scores_gemma":[0.9880628,0.005384602,0.004226775,0.0002320621,0.0014065558,0.00068721315],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016166741,0.00020002144,0.0052348757,0.00023310506,0.00004143418,0.00001568025,0.00017354205,0.00025514018,0.00025664168],"category_scores_gemma":[0.013975627,0.0001366695,0.0007684714,0.0003321748,0.0005133611,0.0002525978,0.00006492323,0.0012465211,0.0000029618102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94364625,0.008879023,0.0015115027,0.000044933287,0.0026666254,0.00078038446,0.0010317187,0.000013242533,0.0011142985,0.00007871783,0.0036139488,0.03661933],"study_design_scores_gemma":[0.9765884,0.014224271,0.0030448178,0.00013897248,0.00038667407,0.00005748349,0.00075152813,0.00030677515,0.00054706633,0.00033221446,0.0035035058,0.00011825092],"about_ca_topic_score_codex":0.0012230446,"about_ca_topic_score_gemma":0.00035616776,"teacher_disagreement_score":0.03650108,"about_ca_system_score_codex":0.00045923077,"about_ca_system_score_gemma":0.009163462,"threshold_uncertainty_score":0.99645364},"labels":[],"label_agreement":null},{"id":"W4200103238","doi":"10.1200/jco.21.01546","title":"Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Venetoclax; Medicine; Azacitidine; Internal medicine; Minimal residual disease; Myeloid leukemia; Oncology; Complete remission; Gastroenterology; Multivariate analysis; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.10115982711630152,"score_gpt":0.4356241830475861,"score_spread":0.3344643559312846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200103238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756107,0.001940533,0.000008857353,0.021592226,0.00009603702,0.00032399586,0.000012857292,0.000008944107,0.00040588205],"genre_scores_gemma":[0.98569334,0.006943158,0.004580177,0.00084104977,0.00046149723,0.000021158008,0.0000068478275,0.000031832293,0.0014209696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603456,0.0013259411,0.0013956552,0.00037508042,0.000478309,0.00039046552],"domain_scores_gemma":[0.9939666,0.0036821393,0.0005462779,0.00023012733,0.00055042456,0.0010244462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035443634,0.00020516792,0.0014862086,0.00022627646,0.000059291793,0.0000275248,0.000095810574,0.00031058738,0.000062569685],"category_scores_gemma":[0.005830083,0.00013566688,0.00015523817,0.00030687428,0.00046871562,0.00017180477,0.000094382754,0.0010604288,0.0000047842627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21727754,0.0013145499,0.58923453,0.00010055808,0.0015640578,0.087852806,0.00036780155,0.000032787262,0.0046653347,0.000054512893,0.00290587,0.09462964],"study_design_scores_gemma":[0.029891478,0.02705143,0.91228104,0.0003440158,0.0009907858,0.005646705,0.0003545431,0.00025417376,0.0015532362,0.0001646824,0.02129029,0.000177628],"about_ca_topic_score_codex":0.000043152133,"about_ca_topic_score_gemma":0.00013355615,"teacher_disagreement_score":0.3230465,"about_ca_system_score_codex":0.0016988391,"about_ca_system_score_gemma":0.018416464,"threshold_uncertainty_score":0.9871482},"labels":[],"label_agreement":null},{"id":"W4200190043","doi":"10.1200/jco.21.02314","title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","year":2021,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":798,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Erasmus Universiteit Rotterdam; American Society of Clinical Oncology","keywords":"Medicine; Radiosurgery; Asymptomatic; Systemic therapy; Guideline; Radiation therapy; Lung cancer; Brain metastasis; Cancer; Oncology; Surgery; Breast cancer; Radiology; Internal medicine; Metastasis; Pathology","score_opus":0.41612498375506346,"score_gpt":0.6143550303667267,"score_spread":0.1982300466116632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200190043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009772388,0.9852818,0.0019195158,0.008176079,0.0023023756,0.001506362,0.0003406549,0.000012305665,0.0004511229],"genre_scores_gemma":[0.0000019913282,0.90425444,0.08654706,0.0021475658,0.0046374486,0.00009059012,0.00053462014,0.00008489178,0.0017013693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98741895,0.0021931862,0.008839978,0.0005632961,0.00048852933,0.0004960579],"domain_scores_gemma":[0.9785884,0.01251098,0.0064049554,0.00064312515,0.000955281,0.0008972354],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007411038,0.00066474255,0.014410805,0.00028953466,0.00006367654,0.000024788065,0.00026653733,0.0009871682,0.00059567305],"category_scores_gemma":[0.009707043,0.0003733514,0.009340615,0.0002477046,0.00016561667,0.00006314007,0.00008278407,0.0010922196,0.00003939036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005417478,0.004152404,0.00000905673,0.0015284781,0.009058266,0.0036908998,0.0000081332455,0.0000013771804,7.451969e-8,0.00018492859,0.08286438,0.89796025],"study_design_scores_gemma":[0.0121750375,0.03886381,0.000005324236,0.0043304022,0.023696823,0.005024088,0.00005026486,0.000005523451,6.418692e-7,0.00004700975,0.9155882,0.00021288612],"about_ca_topic_score_codex":0.00001250472,"about_ca_topic_score_gemma":0.000017654302,"teacher_disagreement_score":0.89774734,"about_ca_system_score_codex":0.00085128023,"about_ca_system_score_gemma":0.012038034,"threshold_uncertainty_score":0.99987185},"labels":[],"label_agreement":null},{"id":"W4200255107","doi":"10.1200/jco.21.00931","title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Cilag; Genentech; MorphoSys; Yuhan; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Karyopharm Therapeutics; MEI Pharma; Sunesis; Juno Therapeutics; Celltrion; Adaptive Biotechnologies; Loxo Oncology; Astex Pharmaceuticals; H. Lundbeck A/S; TG Therapeutics; Pfizer; Incyte; F. Hoffmann-La Roche; University of Pennsylvania; Janssen Biotech; Teva Pharmaceutical Industries; Unum Therapeutics; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Gilead Sciences; GlaxoSmithKline; Amgen; LAM Therapeutics; Alimera Sciences; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Refractory (planetary science); Safety profile; Phases of clinical research; Clinical trial; Cancer; Stage (stratigraphy); Maximum tolerated dose","score_opus":0.19324063152143237,"score_gpt":0.4643134210697562,"score_spread":0.2710727895483238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200255107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947761,0.00023558793,0.000015351934,0.002176553,0.00049297285,0.00043955824,0.000015802889,0.000007983818,0.0018400821],"genre_scores_gemma":[0.99208474,0.00017619981,0.001636939,0.0009960709,0.0003813158,0.000005352885,0.000021675833,0.000024197056,0.0046735164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942738,0.0016155356,0.0024594858,0.00031999685,0.0009707059,0.0003604972],"domain_scores_gemma":[0.99348533,0.0037040014,0.0010979375,0.00027522587,0.0009840176,0.00045348096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002569112,0.00019566077,0.0014832041,0.00021320979,0.00007688715,0.000020618672,0.00017213405,0.00025664375,0.0007482075],"category_scores_gemma":[0.0034563632,0.00011864914,0.0002594109,0.00035125887,0.0001858005,0.0001599901,0.00009503898,0.0011044849,0.000027592274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21032263,0.06287921,0.6524192,0.00006675053,0.00036485645,0.008548298,0.0003266933,0.000021267262,0.0017276366,0.0000060953553,0.002051857,0.06126551],"study_design_scores_gemma":[0.06817798,0.101558425,0.77154714,0.00015294291,0.00019751095,0.00018075036,0.00047851505,0.00012923928,0.00018129873,0.000020932564,0.057230882,0.00014435794],"about_ca_topic_score_codex":0.000038130667,"about_ca_topic_score_gemma":0.00021811483,"teacher_disagreement_score":0.14214465,"about_ca_system_score_codex":0.000406951,"about_ca_system_score_gemma":0.0029456147,"threshold_uncertainty_score":0.8192347},"labels":[],"label_agreement":null},{"id":"W4200317568","doi":"10.1200/jco.21.02036","title":"Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health; Jazz Pharmaceuticals; American Board of Psychiatry and Neurology; Alpha Omega Alpha Honor Medical Society","keywords":"Temozolomide; Bevacizumab; Adjuvant; Vincristine; Chemotherapy; Lomustine; Guideline","score_opus":0.07905023577336648,"score_gpt":0.45116769909193255,"score_spread":0.3721174633185661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200317568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841619,0.0023026688,0.000066428285,0.012444903,0.0006322488,0.00021024024,0.0000054470584,0.000003931839,0.00017220213],"genre_scores_gemma":[0.98546356,0.0029985805,0.0072207297,0.0031407524,0.0011094633,0.000013138212,0.000006798044,0.00001494104,0.000032019532],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971113,0.0001759695,0.0021296344,0.0001894937,0.00019148743,0.00020209771],"domain_scores_gemma":[0.9958688,0.002547447,0.0007153041,0.00013341726,0.00044381258,0.00029123775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012807526,0.00012009097,0.0012617335,0.000097692275,0.00002060261,0.000010351666,0.00006318707,0.00020976365,0.000069122674],"category_scores_gemma":[0.0047810287,0.00008105478,0.00036974892,0.000094119285,0.00008237405,0.0000659468,0.000028876653,0.00037834395,0.0000027511421],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016983455,0.017452525,0.38301912,0.00007109947,0.00079849845,0.008509621,0.00023682426,0.000021785116,0.0008191205,0.00029100088,0.010007008,0.56178993],"study_design_scores_gemma":[0.17262775,0.03719234,0.6522709,0.00070187857,0.00036801366,0.0020342085,0.0007262967,0.0006544564,0.0022535515,0.0009045041,0.13005766,0.00020845709],"about_ca_topic_score_codex":0.000012162691,"about_ca_topic_score_gemma":0.00008782563,"teacher_disagreement_score":0.5615815,"about_ca_system_score_codex":0.000106379564,"about_ca_system_score_gemma":0.001027004,"threshold_uncertainty_score":0.5723683},"labels":[],"label_agreement":null},{"id":"W4205118722","doi":"10.1200/jco.2021.39.15_suppl.3564","title":"LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Irinotecan; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cancer; Oxaliplatin; Phases of clinical research; Clinical trial; Immunotherapy","score_opus":0.06010222905887123,"score_gpt":0.4302120549211831,"score_spread":0.37010982586231184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205118722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996539,0.0005309161,0.0000014278619,0.00083945616,0.0003398099,0.0013045855,0.00009035582,0.000010032076,0.0003444245],"genre_scores_gemma":[0.9986763,0.0004137763,0.000115165574,0.00027612806,0.00031215826,0.000059153845,0.000043046883,0.000023981054,0.00008028366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99492645,0.00073339586,0.0029931443,0.00038847048,0.0006317522,0.00032676532],"domain_scores_gemma":[0.99316674,0.0026877995,0.0021169905,0.00024214601,0.0015733911,0.00021291178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090231607,0.00026071153,0.0026621153,0.00008142997,0.00007467181,0.000010340898,0.000164883,0.00019457754,0.00009920538],"category_scores_gemma":[0.00385059,0.00014094131,0.0002399835,0.000529551,0.00021919711,0.00007596563,0.00008475795,0.00087514275,0.0000013254073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10192976,0.018340267,0.85531896,0.000010008719,0.0028963028,0.0009129276,0.0021967802,0.00006976878,0.000039133745,3.8807212e-7,0.0005252632,0.01776045],"study_design_scores_gemma":[0.12512852,0.05101824,0.8206408,0.00020745017,0.0015150093,0.000028128732,0.0007945938,0.00012747209,0.00013322048,0.0000026239252,0.00029542792,0.00010850409],"about_ca_topic_score_codex":0.0019852372,"about_ca_topic_score_gemma":0.013483826,"teacher_disagreement_score":0.03467815,"about_ca_system_score_codex":0.00055454485,"about_ca_system_score_gemma":0.003320108,"threshold_uncertainty_score":0.7524291},"labels":[],"label_agreement":null},{"id":"W4205194661","doi":"10.1200/jco.21.01918","title":"Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Palbociclib; Discontinuation; Adjuvant; Breast cancer; Cancer; Endocrine system; Adjuvant therapy; Hormone","score_opus":0.0664875891783569,"score_gpt":0.410618722763568,"score_spread":0.3441311335852111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205194661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257416,0.0021683623,0.000050981507,0.011081663,0.00047849282,0.0030320622,0.00055323716,0.000013091622,0.00004797255],"genre_scores_gemma":[0.994612,0.0019803825,0.00096708944,0.0007100919,0.000853266,0.0006542515,0.00002746208,0.000060266284,0.0001351837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936079,0.0021840218,0.0024391022,0.0005190182,0.0007983013,0.00045165612],"domain_scores_gemma":[0.99177516,0.003392061,0.0030780584,0.00028641426,0.0012205752,0.0002477573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013556717,0.00043768645,0.0024634362,0.0002168528,0.00025514053,0.000022289345,0.0002895877,0.00014821746,0.00016842782],"category_scores_gemma":[0.0004014097,0.00025216016,0.00030644637,0.00050764,0.00047004438,0.0002862653,0.00007595088,0.0010063364,6.719639e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12730892,0.015475596,0.45338717,0.000030240417,0.0029937383,0.00032735584,0.033775114,0.000068140675,0.004564296,0.00008756015,0.00037475795,0.3616071],"study_design_scores_gemma":[0.074182056,0.13530122,0.76734626,0.000082270366,0.00037302612,0.00020555382,0.019334247,0.000010013751,0.00044282764,0.000120511504,0.002367406,0.00023461302],"about_ca_topic_score_codex":0.00046920325,"about_ca_topic_score_gemma":0.0011101088,"teacher_disagreement_score":0.3613725,"about_ca_system_score_codex":0.00070613256,"about_ca_system_score_gemma":0.0012622944,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W4205202585","doi":"10.1200/jco.21.02006","title":"Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Randomized controlled trial; Stage (stratigraphy); Breast cancer; Overall survival; Quality of life (healthcare); Clinical endpoint; Metastatic breast cancer; Clinical trial","score_opus":0.07269402368998494,"score_gpt":0.44387070943732376,"score_spread":0.3711766857473388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205202585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863954,0.0022964813,0.0008019698,0.007638692,0.0015991452,0.00087300764,0.00025999476,0.0000025567465,0.00013273653],"genre_scores_gemma":[0.98786336,0.0076543763,0.0004623375,0.0018925054,0.0017581303,0.00019471098,0.000013746469,0.000019907437,0.00014089492],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99301845,0.0027219339,0.003402626,0.00028842562,0.00029269897,0.00027585917],"domain_scores_gemma":[0.9900401,0.0067598983,0.002534035,0.00026329004,0.0002897337,0.000112923124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0161957,0.00016401602,0.001895305,0.000056619312,0.000089525434,0.0000059706085,0.00040084636,0.0002739146,0.000028189197],"category_scores_gemma":[0.002369768,0.000102100166,0.0012100603,0.00010935145,0.0006443555,0.0000062709473,0.00019714909,0.00066959567,3.7570965e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83117485,0.0018092316,0.02018935,0.0000070050355,0.0010892685,0.000026835447,0.00010825632,0.0004049629,0.00014070478,0.000013529212,0.0011638455,0.14387217],"study_design_scores_gemma":[0.78956854,0.01181806,0.16727738,0.000015907433,0.00026905863,0.00007080506,0.000102887054,0.0000988273,0.00006617131,0.00007214038,0.030528408,0.00011180885],"about_ca_topic_score_codex":0.00025953908,"about_ca_topic_score_gemma":0.0002033535,"teacher_disagreement_score":0.14708802,"about_ca_system_score_codex":0.00016435781,"about_ca_system_score_gemma":0.002360177,"threshold_uncertainty_score":0.56131387},"labels":[],"label_agreement":null},{"id":"W4205205028","doi":"10.1200/jco.21.01784","title":"Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Nomogram; Internal medicine; Proportional hazards model; Colorectal cancer; Cancer; Stage (stratigraphy); Oncology; Clinical trial; Surgery","score_opus":0.1139080157467273,"score_gpt":0.45190063321948293,"score_spread":0.3379926174727556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205205028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99129945,0.0013795168,0.00010586511,0.0061894464,0.00044395958,0.00035713968,0.00010441241,0.000004867923,0.00011534985],"genre_scores_gemma":[0.9931717,0.0020960763,0.0017661566,0.0026040652,0.00021294183,0.00007441044,0.0000058302703,0.000009987802,0.000058815524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827063,0.00013771273,0.0008474832,0.00020563247,0.00035632038,0.00018224027],"domain_scores_gemma":[0.99843746,0.0004602202,0.000500661,0.0000638707,0.00026612374,0.00027166944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008224455,0.00010513909,0.00074404204,0.000061409606,0.00010154855,0.000005745804,0.00005645015,0.000083561026,0.00005217823],"category_scores_gemma":[0.00021331735,0.00007737237,0.000055001794,0.00013203832,0.000079421814,0.00008004642,0.00008175287,0.0005897499,2.2292532e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023140378,0.001150074,0.95896006,0.00004162772,0.000087373126,0.00008691081,0.00007952691,0.004210226,0.0000031487562,0.00004335497,0.0019752933,0.010222002],"study_design_scores_gemma":[0.013567715,0.022639846,0.94346964,0.00025165794,0.00012688397,0.000008105252,0.000051246945,0.003152958,0.0000013889271,0.00013608784,0.016513092,0.000081387974],"about_ca_topic_score_codex":0.0002744373,"about_ca_topic_score_gemma":0.0005348279,"teacher_disagreement_score":0.021489773,"about_ca_system_score_codex":0.00027928108,"about_ca_system_score_gemma":0.0005179332,"threshold_uncertainty_score":0.31551537},"labels":[],"label_agreement":null},{"id":"W4205313036","doi":"10.1200/jco.2022.40.4_suppl.469","title":"Prognostic ability of the Gustave Roussy Immune Score for patients with advanced pancreatic adenocarcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Ontario Institute for Cancer Research; Toronto General Hospital; Dalhousie University; University Health Network; University of Toronto; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Hazard ratio; Gastroenterology; Immune system; Oncology; Confidence interval; Immunology","score_opus":0.08896260422423194,"score_gpt":0.43722339105216634,"score_spread":0.3482607868279344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205313036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938515,0.0005479177,0.00013827528,0.0027446281,0.00051523297,0.0015848245,0.00002115164,0.000004869941,0.0005916439],"genre_scores_gemma":[0.9948172,0.000061231236,0.0041684024,0.00042229795,0.00018634822,0.00007913696,0.000006501885,0.000018913634,0.00023998212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955907,0.00091773644,0.0022580675,0.00020790249,0.0007149075,0.00031069128],"domain_scores_gemma":[0.98957074,0.006507975,0.0022134325,0.00040404638,0.0010805819,0.00022322772],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0041307923,0.00013570955,0.0019255426,0.000085821295,0.00015624621,0.0000028487327,0.0003716416,0.00016372823,0.00021729112],"category_scores_gemma":[0.011836619,0.00007336773,0.000516129,0.00024831126,0.00057516375,0.000057843718,0.00018398139,0.0011740279,0.0000013881903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016100643,0.0035550909,0.96671885,0.000120659104,0.0004989115,0.000038311653,0.00014527606,0.000028116307,0.000053202788,0.00008209543,0.0004129275,0.01224593],"study_design_scores_gemma":[0.01424751,0.05007439,0.9306822,0.000097353026,0.0011703881,0.00010615512,0.0003017163,0.00012405808,0.000012108085,0.00053130847,0.0025858488,0.00006696056],"about_ca_topic_score_codex":0.00001408935,"about_ca_topic_score_gemma":0.000007324387,"teacher_disagreement_score":0.0465193,"about_ca_system_score_codex":0.0003112765,"about_ca_system_score_gemma":0.0036989518,"threshold_uncertainty_score":0.9964871},"labels":[],"label_agreement":null},{"id":"W4205314496","doi":"10.1200/jco.2021.39.15_suppl.4030","title":"LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Adverse effect; Phases of clinical research; Gastroenterology; Surgery; Clinical trial; Immunotherapy","score_opus":0.06555682777850554,"score_gpt":0.42408217362888634,"score_spread":0.3585253458503808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205314496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968253,0.0001955284,0.000016333386,0.001262421,0.00035078166,0.0010966811,0.000028831255,0.000009991991,0.00021415218],"genre_scores_gemma":[0.9981444,0.0002847882,0.0002616129,0.00060095615,0.00040309952,0.00002081008,0.000041034767,0.00002231533,0.0002210008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99463683,0.00067152065,0.0033057705,0.0003422224,0.0007127111,0.00033091646],"domain_scores_gemma":[0.9936545,0.0021188043,0.0025856213,0.0003513719,0.001073285,0.00021640808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013281503,0.00021980469,0.0022172676,0.00015463294,0.000040110433,0.0000123558375,0.0002362237,0.00015720527,0.00015087076],"category_scores_gemma":[0.004088468,0.00012710923,0.00022447905,0.00086840603,0.00012068151,0.00009188648,0.00008698128,0.0009621158,0.0000019124957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035307936,0.009663269,0.9247906,0.000015515332,0.0013979129,0.00070844544,0.00059151556,0.0002057924,0.000009801436,4.943306e-7,0.0018028364,0.025505874],"study_design_scores_gemma":[0.13060904,0.020010045,0.84616786,0.00018717693,0.0015524846,0.00001884219,0.00047018734,0.00023253249,0.000016321486,0.000002242172,0.0006425282,0.000090747155],"about_ca_topic_score_codex":0.0012108404,"about_ca_topic_score_gemma":0.0029562535,"teacher_disagreement_score":0.09530111,"about_ca_system_score_codex":0.0003579571,"about_ca_system_score_gemma":0.002379783,"threshold_uncertainty_score":0.5183364},"labels":[],"label_agreement":null},{"id":"W4205354480","doi":"10.1200/jco.21.01249","title":"Spare Parts: Navigating Ovarian Cancer as a Transgender Man","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"LGBTQ Health, Identity, and Policy","field":"Psychology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Ovarian cancer; Transgender; Cancer; Gynecology; Oncology; Internal medicine; Gender studies","score_opus":0.3011002194760258,"score_gpt":0.6018132940836435,"score_spread":0.3007130746076177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205354480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84363455,0.0021217694,0.000068109664,0.075297266,0.014741564,0.00021475837,0.000037214555,0.000023541235,0.06386126],"genre_scores_gemma":[0.96597433,0.0007404657,0.00036723004,0.021865098,0.0056512365,0.000038353337,0.0000035810149,0.000035546967,0.005324156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99398905,0.0022171715,0.0025841424,0.00027001908,0.00045286122,0.0004867685],"domain_scores_gemma":[0.9956262,0.0015023818,0.0019423674,0.00026388356,0.00018091037,0.00048425826],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047330176,0.00015186497,0.0010192943,0.00009657848,0.00031953058,0.000016703758,0.0005151571,0.00032211124,0.015843054],"category_scores_gemma":[0.0006262885,0.00013531587,0.00053518225,0.00022533204,0.00016201255,0.00010447192,0.00008823381,0.00301118,0.00015122496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032709565,0.0033120418,0.31156972,0.00014038233,0.0009819801,0.0028421655,0.0067024496,0.00030815697,0.000011980781,0.009047389,0.23988421,0.42192855],"study_design_scores_gemma":[0.0056495992,0.0058130664,0.20454644,0.000018491513,0.0003306665,0.0010585181,0.0017811288,0.000014327133,7.981863e-7,0.0057878583,0.77480286,0.00019626506],"about_ca_topic_score_codex":0.003716039,"about_ca_topic_score_gemma":0.00077535724,"teacher_disagreement_score":0.5349186,"about_ca_system_score_codex":0.00027509851,"about_ca_system_score_gemma":0.002098236,"threshold_uncertainty_score":0.9992889},"labels":[],"label_agreement":null},{"id":"W4205376135","doi":"10.1200/jco.2022.40.4_suppl.078","title":"Adjuvant oxaliplatin and fall-related injury in patients with colorectal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute of Health Services and Policy Research; Sunnybrook Health Science Centre; Mount Sinai Hospital; University of Toronto","funders":"Physicians' Services Incorporated Foundation","keywords":"Medicine; Oxaliplatin; Colorectal cancer; Cohort; Hazard ratio; Internal medicine; Proportional hazards model; Population; Retrospective cohort study; Adjuvant chemotherapy; Oncology; Cancer; Surgery; Confidence interval","score_opus":0.04708204055723457,"score_gpt":0.44939695461691265,"score_spread":0.40231491405967806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205376135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939209,0.0004204144,4.2850726e-7,0.003452612,0.001064548,0.00025665207,0.000015401729,0.000004912538,0.0008640994],"genre_scores_gemma":[0.99774796,0.00030200253,0.00014326442,0.001400456,0.00018343417,0.000017462424,0.0000067583273,0.0000116910705,0.00018694536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978699,0.00037337787,0.0011840789,0.00014686801,0.00025497298,0.00017080294],"domain_scores_gemma":[0.99818367,0.0005647677,0.0008754974,0.00005171754,0.00012538976,0.00019894131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010022959,0.000099909834,0.0009778494,0.00013339442,0.00004761785,0.0000023496987,0.00007055727,0.00012967944,0.00072924723],"category_scores_gemma":[0.00017421502,0.00006985027,0.0001096755,0.00018007042,0.00013850226,0.000051306422,0.00006937024,0.0010949823,0.0000016059782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024617879,0.002737695,0.9043427,0.0000071952713,0.00031738426,0.00033293894,0.00017587261,0.000032025175,0.000046140754,0.000016016564,0.0026329907,0.064741164],"study_design_scores_gemma":[0.025450472,0.052703574,0.9030818,0.000023244143,0.00031298082,0.00008289072,0.00005776116,0.00004098828,0.000012973078,0.000063435196,0.01810257,0.0000673585],"about_ca_topic_score_codex":0.00010500341,"about_ca_topic_score_gemma":0.00015679053,"teacher_disagreement_score":0.064673804,"about_ca_system_score_codex":0.0003397446,"about_ca_system_score_gemma":0.0011696095,"threshold_uncertainty_score":0.79847455},"labels":[],"label_agreement":null},{"id":"W4205454814","doi":"10.1200/jco.2022.40.4_suppl.tps363","title":"SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Internal medicine; Oncology; Gastroenterology; Adverse effect; Antigen; Phases of clinical research; Chemotherapy; Immunology","score_opus":0.3690196111746434,"score_gpt":0.5659463194330353,"score_spread":0.19692670825839192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205454814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184537,0.00028330443,0.00012229415,0.00072881713,0.0033646633,0.0030823452,0.000008956345,0.000008226012,0.00055604865],"genre_scores_gemma":[0.99084526,0.00043235192,0.0026755044,0.0005542071,0.0012768842,0.000106986954,0.0000032096227,0.000044122287,0.004061456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98990536,0.004008416,0.0039393315,0.00041867307,0.0012762249,0.00045198126],"domain_scores_gemma":[0.9918287,0.0044205994,0.002424365,0.00040388957,0.00048050735,0.00044197965],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014481993,0.00021840961,0.0026210067,0.0005982699,0.00009613678,0.000017450468,0.00070765533,0.00022928398,0.0044698236],"category_scores_gemma":[0.0029748972,0.00016931357,0.00028342975,0.0011345085,0.00016266307,0.00020555411,0.00038188975,0.0026436795,0.000008521578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7594308,0.052857883,0.001265367,0.000020722973,0.0004530646,0.005129875,0.00043095608,0.0009928204,0.0041683805,0.0000028822126,0.0037084385,0.17153879],"study_design_scores_gemma":[0.5900089,0.38814935,0.002051999,0.000030845975,0.00028974225,0.0002549624,0.0017682329,0.0004994645,0.00045840375,0.000034443503,0.016333649,0.00012002105],"about_ca_topic_score_codex":0.00030684788,"about_ca_topic_score_gemma":0.0002571214,"teacher_disagreement_score":0.33529148,"about_ca_system_score_codex":0.0013545908,"about_ca_system_score_gemma":0.00883958,"threshold_uncertainty_score":0.9996573},"labels":[],"label_agreement":null},{"id":"W4205476752","doi":"10.1200/jco.2022.40.4_suppl.tps635","title":"PASS-01: Pancreatic adenocarcinoma signature stratification for treatment–01.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Pancreatic cancer; Internal medicine; Pancreatic ductal adenocarcinoma; Chemotherapy; Paclitaxel; Adenocarcinoma; Cancer","score_opus":0.07209908724501828,"score_gpt":0.40700040969853546,"score_spread":0.33490132245351717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205476752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888352,0.0037540286,0.0015043503,0.0030580424,0.0017121538,0.0003339199,0.00010562241,0.0000031846912,0.0006934685],"genre_scores_gemma":[0.99323565,0.00097299647,0.0022048089,0.0011592387,0.0018762909,0.00004616988,0.000084807696,0.000017681017,0.00040234777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825686,0.00022097393,0.0010232271,0.00020863656,0.00012320199,0.0001670721],"domain_scores_gemma":[0.9978344,0.00066798873,0.0009954558,0.00020914778,0.00014884293,0.00014419245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000986843,0.000111624984,0.0005291317,0.000038628874,0.00010705822,0.00000885598,0.00022015037,0.00022020898,0.00006960175],"category_scores_gemma":[0.0009530086,0.00009400873,0.00041891212,0.00005178561,0.000062621686,0.0000034857405,0.000058041696,0.00020917601,0.0000015225738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027413225,0.009703994,0.1503695,0.00009001313,0.0034317137,0.0003712749,0.00045071632,0.008575397,0.15873607,0.005512947,0.22386901,0.41147617],"study_design_scores_gemma":[0.007702985,0.048641965,0.0552777,0.000006230666,0.00046768328,0.00018087136,0.00035265816,0.00027652856,0.003445413,0.0020534226,0.8813591,0.00023545267],"about_ca_topic_score_codex":0.0000097568145,"about_ca_topic_score_gemma":0.000048015205,"teacher_disagreement_score":0.6574901,"about_ca_system_score_codex":0.00012398562,"about_ca_system_score_gemma":0.0012813848,"threshold_uncertainty_score":0.38335648},"labels":[],"label_agreement":null},{"id":"W4205498652","doi":"10.1200/jco.21.01719","title":"Practical Management of Oligometastatic Non–Small-Cell Lung Cancer","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of British Columbia; Western University","funders":"","keywords":"Medicine; SABR volatility model; Radiosurgery; Lung cancer; Ablative case; Radiation therapy; Oncology; Disease; Randomized controlled trial; Internal medicine; Medical physics; Intensive care medicine","score_opus":0.28687388575559275,"score_gpt":0.5834728715918964,"score_spread":0.2965989858363037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205498652","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011867234,0.98645025,0.000053196996,0.0017331877,0.002616984,0.0010847388,0.000023273707,0.000004635981,0.007915079],"genre_scores_gemma":[0.000060330272,0.98814005,0.009372725,0.00051664317,0.00079425424,0.00017599523,0.000011954209,0.00005038992,0.0008776419],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931332,0.00076414517,0.004819603,0.0003378201,0.0006518205,0.00029344525],"domain_scores_gemma":[0.98785865,0.0046000173,0.006525859,0.00038454353,0.00020540216,0.0004255182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032296279,0.00032905187,0.006851635,0.0002408735,0.000034173983,0.000007007773,0.00026268163,0.00040303275,0.0018554453],"category_scores_gemma":[0.00042224568,0.00020887807,0.0024494058,0.00031192988,0.00011234975,0.000045510136,0.00020327684,0.001870073,0.00001516515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036944041,0.005363874,0.000551187,0.032339588,0.008321591,0.0053254254,0.000020469886,0.0000024976891,1.0898967e-8,0.00008274606,0.022456812,0.92516637],"study_design_scores_gemma":[0.004571511,0.006795054,0.00035439074,0.010772331,0.04542262,0.00049225014,0.00005228743,0.000006384612,3.7214892e-7,0.0000123684185,0.9313812,0.00013917651],"about_ca_topic_score_codex":0.000024281504,"about_ca_topic_score_gemma":0.000008362915,"teacher_disagreement_score":0.9250272,"about_ca_system_score_codex":0.0014320974,"about_ca_system_score_gemma":0.006588025,"threshold_uncertainty_score":0.999057},"labels":[],"label_agreement":null},{"id":"W4205561311","doi":"10.1200/jco.21.02647","title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McMaster University; London Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Adjuvant; Denosumab; Bisphosphonate; Breast cancer; Adjuvant therapy; Guideline; Exemestane; Zoledronic acid","score_opus":0.21506457596248454,"score_gpt":0.5088892296439328,"score_spread":0.2938246536814483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205561311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758181,0.0028159283,0.0000048147017,0.020202642,0.00075567776,0.00019989247,0.00008943194,0.0000046440837,0.00010889192],"genre_scores_gemma":[0.9803829,0.004001503,0.0021704782,0.013090199,0.0001361944,0.000009838996,0.0000050143485,0.000021157659,0.00018272316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961103,0.00033527188,0.0027697568,0.00018214968,0.00034984906,0.000252678],"domain_scores_gemma":[0.9970171,0.00061386824,0.0016734406,0.00014419571,0.00019459377,0.000356792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002164322,0.00012416995,0.0013630623,0.0001380631,0.000055283774,0.0000038361486,0.00008411675,0.00015327612,0.00051162625],"category_scores_gemma":[0.0004834171,0.00009199726,0.00020336169,0.00016670968,0.000119778626,0.000086647946,0.00010635511,0.00082604005,0.0000028666873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069883685,0.001914636,0.82832366,0.000039397597,0.00022818976,0.000978649,0.00007091551,0.00010519281,0.000037708676,0.00003495303,0.007402681,0.15387563],"study_design_scores_gemma":[0.011862298,0.0031071883,0.7166999,0.000113007525,0.00023787392,0.0010772058,0.00007338457,0.00053127337,0.000023386376,0.00012498128,0.26607174,0.0000777511],"about_ca_topic_score_codex":0.0026515264,"about_ca_topic_score_gemma":0.00036761267,"teacher_disagreement_score":0.25866905,"about_ca_system_score_codex":0.00023181208,"about_ca_system_score_gemma":0.001233881,"threshold_uncertainty_score":0.5601949},"labels":[],"label_agreement":null},{"id":"W4205561348","doi":"10.1200/jco.2021.39.15_suppl.6560","title":"Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Conquer Cancer Foundation","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cancer; Oncology; Progressive disease; Gastrointestinal cancer; Disease; Colorectal cancer","score_opus":0.06682619705709317,"score_gpt":0.40487520703102853,"score_spread":0.3380490099739354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205561348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831689,0.00009521285,0.0000108190625,0.015758118,0.00036438418,0.0005250765,0.000011458741,0.0000063836605,0.000059667287],"genre_scores_gemma":[0.9943096,0.00013773913,0.003458611,0.0017147347,0.00004979263,0.000026901915,0.0000033008578,0.000017615646,0.0002816998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680305,0.0005408164,0.0016023756,0.00030924493,0.0004310614,0.0003134594],"domain_scores_gemma":[0.9961809,0.0021428359,0.00089367793,0.00016630678,0.00024769828,0.0003685851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016224526,0.00022378216,0.001890971,0.00033421064,0.0000230061,0.000016304535,0.00006128088,0.00005237517,0.000058182013],"category_scores_gemma":[0.0039986786,0.00014069804,0.00012860182,0.0002733368,0.00010952639,0.00008367938,0.00008563816,0.0003532392,5.9126205e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023924427,0.0013819806,0.93713504,0.00003257097,0.00037293896,0.0042386507,0.00013115702,0.0000115468865,0.000007258082,0.000002027554,0.00010056699,0.032661844],"study_design_scores_gemma":[0.024976254,0.024583837,0.94789094,0.00022146545,0.0004193992,0.0001859933,0.0005596641,0.000016435031,0.000004482782,0.0000092236305,0.0010288432,0.000103435894],"about_ca_topic_score_codex":0.00016574479,"about_ca_topic_score_gemma":0.0036050424,"teacher_disagreement_score":0.032558408,"about_ca_system_score_codex":0.00035457406,"about_ca_system_score_gemma":0.0008450531,"threshold_uncertainty_score":0.57374996},"labels":[],"label_agreement":null},{"id":"W4205565447","doi":"10.1200/jco.2022.40.4_suppl.379","title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":400,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Regimen; Confidence interval; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Randomized controlled trial; Surgery; Toxicity","score_opus":0.10917407562743807,"score_gpt":0.43190488269526556,"score_spread":0.3227308070678275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205565447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941605,0.0013342438,0.000006483774,0.0013751981,0.00047448426,0.0024010828,0.000008212901,0.000003901838,0.00023591601],"genre_scores_gemma":[0.9971689,0.0011189054,0.00020339171,0.0011405685,0.00011776119,0.00006654422,0.00000630522,0.000028848106,0.00014879601],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941031,0.0017138354,0.0029229147,0.00030457182,0.0006961649,0.00025944365],"domain_scores_gemma":[0.9953126,0.0017006038,0.0021060435,0.00028652587,0.0003966029,0.00019763045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067779194,0.00021040201,0.0026106015,0.00024309583,0.00010423036,0.00001693485,0.00037903182,0.00013343668,0.00054630986],"category_scores_gemma":[0.00078801444,0.00013726123,0.00021426502,0.00030876388,0.00027135824,0.00015394363,0.00020377226,0.00088836387,9.63464e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60234565,0.048391573,0.3114041,0.00001742889,0.00074566255,0.0004007767,0.00068225665,0.000008123126,0.00009048205,0.0000016367042,0.00019803034,0.035714265],"study_design_scores_gemma":[0.73649436,0.20326802,0.053927723,0.000059292975,0.0002946373,0.000061896535,0.0007492317,0.000602131,0.00006362613,0.000016535452,0.0043501165,0.00011243659],"about_ca_topic_score_codex":0.000780736,"about_ca_topic_score_gemma":0.00019538257,"teacher_disagreement_score":0.2574764,"about_ca_system_score_codex":0.00025962983,"about_ca_system_score_gemma":0.0009055207,"threshold_uncertainty_score":0.598171},"labels":[],"label_agreement":null},{"id":"W4205576580","doi":"10.1200/jco.2022.40.4_suppl.659","title":"Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta; Université Laval; Princess Margaret Cancer Centre; McMaster University; Alberta Health Services; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cancer; Colorectal cancer; Pancreatic cancer; Adenocarcinoma; Clinical trial; Gastroenterology; Immunotherapy","score_opus":0.46681925037491434,"score_gpt":0.5574949983397592,"score_spread":0.0906757479648449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205576580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93349475,0.0060698283,0.00084619864,0.05389809,0.004163868,0.0012936352,0.00014247093,0.000013400208,0.00007776213],"genre_scores_gemma":[0.9504324,0.015390216,0.008672034,0.018209219,0.0067846985,0.00006693666,0.00009430769,0.0000392656,0.00031092338],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99276626,0.00203847,0.0039165583,0.0004546323,0.0005724274,0.00025165832],"domain_scores_gemma":[0.9586376,0.036653366,0.0032748554,0.00077311584,0.00037347773,0.0002875711],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021809736,0.00016510225,0.001344225,0.00004252604,0.0002056914,0.00003205229,0.0008158779,0.00018764067,0.00048137445],"category_scores_gemma":[0.019125612,0.00010512843,0.0006229174,0.00014370338,0.0006369892,0.00020248216,0.00029739577,0.0017325808,0.0000021554765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49450994,0.0027542028,0.10408618,0.000009587666,0.00065584225,0.00009404414,0.000041919662,0.0000030972915,0.00008508648,0.000026984448,0.07471946,0.32301366],"study_design_scores_gemma":[0.16945226,0.097798124,0.39208898,0.00025367213,0.0006460502,0.0006696453,0.0002996194,0.0015295432,0.0000060738244,0.0007378346,0.33636928,0.00014890761],"about_ca_topic_score_codex":0.00018422028,"about_ca_topic_score_gemma":0.00012309321,"teacher_disagreement_score":0.32505766,"about_ca_system_score_codex":0.00024231894,"about_ca_system_score_gemma":0.0042347843,"threshold_uncertainty_score":0.9891367},"labels":[],"label_agreement":null},{"id":"W4205645249","doi":"10.1200/jco.2022.40.4_suppl.081","title":"Survival outcomes associated with chemotherapy-induced neutropenia in the adjuvant treatment of colorectal cancer with FOLFOX.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Neutropenia; Oxaliplatin; Cohort; Colorectal cancer; Cancer; Proportional hazards model; Surgery; Chemotherapy; Retrospective cohort study; Oncology","score_opus":0.13661883874933028,"score_gpt":0.45916353231756574,"score_spread":0.32254469356823545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205645249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842765,0.00012530516,0.000002765146,0.013066175,0.00055903813,0.00040133783,0.0000097324455,0.0000052691666,0.0015538881],"genre_scores_gemma":[0.99783677,0.0002137583,0.000064973465,0.0014469974,0.00017251326,0.0000690204,0.0000022904048,0.000018326316,0.00017533128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973125,0.0007400372,0.0011248413,0.00014965814,0.00047416205,0.00019880048],"domain_scores_gemma":[0.9967747,0.0014448917,0.0013121589,0.0001430326,0.00021795052,0.00010731478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013866378,0.00014133542,0.0015549136,0.00009412555,0.000075735836,0.0000050307713,0.00016333659,0.00009399534,0.00031524268],"category_scores_gemma":[0.0001461753,0.00006587857,0.00029629678,0.00033490706,0.00012776916,0.00004737216,0.00001923487,0.0006829275,6.79648e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013458361,0.0057816235,0.9586485,0.000004312478,0.0011359801,0.00069666246,0.00060680293,0.00017975712,0.000583231,0.000048273167,0.00027005607,0.018586434],"study_design_scores_gemma":[0.021865906,0.067698136,0.90047216,0.000028262253,0.00052914314,0.0002700695,0.00069196976,0.000010220238,0.00020036635,0.000013518757,0.008146853,0.00007336109],"about_ca_topic_score_codex":0.00038768732,"about_ca_topic_score_gemma":0.0033746941,"teacher_disagreement_score":0.061916515,"about_ca_system_score_codex":0.00054415886,"about_ca_system_score_gemma":0.0022451894,"threshold_uncertainty_score":0.39828694},"labels":[],"label_agreement":null},{"id":"W4205690438","doi":"10.1200/jco.2022.40.4_suppl.tps622","title":"Phase 1b expansion study of CX-5461 in patients with solid tumors and <i>BRCA2 </i>and/or <i>PALB2</i> mutation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; PALB2; Synthetic lethality; DNA repair; PARP inhibitor; Olaparib; Cancer research; Population; Oncology; BRCA mutation; Carcinogenesis; Cancer; Genome instability; Germline mutation; BRCA2 Protein; Prostate cancer; Internal medicine; Mutation; Ovarian cancer; DNA damage; Genetics; Poly ADP ribose polymerase; Biology; Polymerase; Gene; DNA","score_opus":0.0278695928459738,"score_gpt":0.42471991768904405,"score_spread":0.39685032484307026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205690438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990862,0.00027613962,0.00016690342,0.000089397014,0.00018779834,0.00016089485,0.0000044984727,0.0000010687198,0.00002709548],"genre_scores_gemma":[0.99913836,0.000097765325,0.00045485405,0.0001865596,0.00008616695,0.000005491922,0.000004359638,0.000009509423,0.000016950433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984425,0.00019665278,0.0009287862,0.00015348253,0.0001715908,0.00010704204],"domain_scores_gemma":[0.9990717,0.00014184357,0.0004912895,0.000099289195,0.000100540696,0.0000953115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008299415,0.00008388031,0.00046299756,0.000053438325,0.0000338425,0.0000033920355,0.00009198289,0.000070965056,0.000009765144],"category_scores_gemma":[0.00030663415,0.00006168725,0.00004702818,0.000073489966,0.000058617843,0.000004535571,0.00011120117,0.00026886474,7.3917825e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035755582,0.052611474,0.65569973,0.000098181416,0.0006669171,0.00067323266,0.002594032,0.009295564,0.016335405,0.000009974743,0.0015190367,0.22474086],"study_design_scores_gemma":[0.104668684,0.2934769,0.5834582,0.000052146082,0.00022973395,0.00025191027,0.0045136265,0.00041647663,0.0035323831,0.00004617881,0.008990636,0.00036314558],"about_ca_topic_score_codex":0.0000070286,"about_ca_topic_score_gemma":0.00004454849,"teacher_disagreement_score":0.24086542,"about_ca_system_score_codex":0.0000120383165,"about_ca_system_score_gemma":0.00018682503,"threshold_uncertainty_score":0.2515533},"labels":[],"label_agreement":null},{"id":"W4205716885","doi":"10.1200/jco.2022.40.4_suppl.032","title":"Impact of the COVID-19 pandemic on primary care access for patients with gastrointestinal malignancies.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cohort; Pandemic; Retrospective cohort study; Population; Cohort study; Cancer; Emergency department; Malignancy; Emergency medicine; Pediatrics; Family medicine; Coronavirus disease 2019 (COVID-19); Internal medicine; Disease; Infectious disease (medical specialty)","score_opus":0.27766170727419065,"score_gpt":0.5556828565555103,"score_spread":0.27802114928131966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205716885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164116,0.000074670854,0.0001480336,0.006680212,0.0004793937,0.00066377607,0.00009306921,0.000007222283,0.00021248292],"genre_scores_gemma":[0.9794571,0.000025352023,0.00045728422,0.019608019,0.0003695742,0.000011298473,0.000012583191,0.00001708257,0.00004174965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698406,0.0004629719,0.0014783902,0.00016826871,0.00062240305,0.00028390053],"domain_scores_gemma":[0.99138445,0.004673282,0.0023012075,0.000252892,0.0007811532,0.0006070302],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020072393,0.0001334827,0.0010811756,0.00012435103,0.00014177218,0.000005649049,0.00036380382,0.000097464435,0.000116319614],"category_scores_gemma":[0.009219886,0.00006958422,0.0006653379,0.00019798499,0.00018089978,0.00006593311,0.00014502548,0.0011287985,4.886553e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024951858,0.0012915039,0.9544282,0.00022904159,0.000100157245,0.00006723178,0.00015893023,0.00037363783,0.00001644512,0.000010017273,0.005452973,0.0129200015],"study_design_scores_gemma":[0.011942915,0.0812216,0.88973534,0.00013681808,0.00017998266,0.00051610556,0.000093141694,0.0000060566667,0.0000010111617,0.00007520388,0.016034016,0.00005779046],"about_ca_topic_score_codex":0.00012034583,"about_ca_topic_score_gemma":0.00007043926,"teacher_disagreement_score":0.0799301,"about_ca_system_score_codex":0.002239646,"about_ca_system_score_gemma":0.0202968,"threshold_uncertainty_score":0.9991259},"labels":[],"label_agreement":null},{"id":"W4205731320","doi":"10.1200/jco.2022.40.4_suppl.529","title":"Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer: A population-based retrospective cohort study in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Kingston Health Sciences Centre; Public Health Ontario; Sunnybrook Hospital; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Women's College Hospital; Cancer Care Ontario; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Cost effectiveness; Propensity score matching; Cohort; Pancreatic cancer; Retrospective cohort study; Population; Randomized controlled trial; Oncology; Quality-adjusted life year; Internal medicine; Cancer; Irinotecan; Environmental health","score_opus":0.07156346936748291,"score_gpt":0.43730307594042994,"score_spread":0.365739606572947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205731320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508303,0.000049512146,0.000008138282,0.00043143352,0.000636166,0.0029516118,0.000028339704,0.000004484507,0.0008073036],"genre_scores_gemma":[0.9989104,0.00004068971,0.00034736493,0.000098819306,0.00006593638,0.0003470808,0.000035586123,0.000023854083,0.00013025533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937422,0.0017720492,0.0024902474,0.00037531427,0.0012142967,0.00040589337],"domain_scores_gemma":[0.9901182,0.0068300897,0.0016578073,0.0003158665,0.00079540425,0.00028260984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057572946,0.00021631039,0.0032735146,0.00044702747,0.00008220967,0.0000029500036,0.00022740824,0.00013324438,0.0004679417],"category_scores_gemma":[0.0031577381,0.0001705188,0.00015742696,0.00076245697,0.00013371928,0.000081224076,0.00008910602,0.0018556198,3.0475522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.091764905,0.006710795,0.896507,0.000056092267,0.00060581387,0.0005262781,0.00010397708,0.002593132,9.133916e-7,0.0000135219825,0.000052574105,0.0010649591],"study_design_scores_gemma":[0.06470786,0.039668035,0.89410216,0.00021538342,0.00054677203,0.0000039090846,0.00016381293,0.0002511417,0.0000010774518,0.000053951208,0.00015917006,0.00012674459],"about_ca_topic_score_codex":0.9002792,"about_ca_topic_score_gemma":0.9947442,"teacher_disagreement_score":0.09446498,"about_ca_system_score_codex":0.01246971,"about_ca_system_score_gemma":0.0143407015,"threshold_uncertainty_score":0.99132127},"labels":[],"label_agreement":null},{"id":"W4205793481","doi":"10.1200/jco.2022.40.4_suppl.502","title":"Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): The diagnostic process of GEP-NETs in Australia, Canada, China, France, Germany, the United Kingdom, and the United States of America.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Respondent; Neuroendocrine tumors; Internal medicine; Family medicine; Demography; Pediatrics","score_opus":0.1651956918194236,"score_gpt":0.47079240415657314,"score_spread":0.3055967123371496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205793481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97465557,0.0006284819,0.0000012380008,0.023089878,0.00016246007,0.0013100117,0.00014710448,0.0000011686612,0.000004065697],"genre_scores_gemma":[0.9927105,0.0059912875,0.00001859035,0.001107993,0.000029435383,0.00010227967,0.000015554851,0.000014729184,0.000009665776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571,0.001613362,0.0016925915,0.00018495442,0.0005067674,0.0002923296],"domain_scores_gemma":[0.965722,0.031993315,0.0014346538,0.00021284613,0.00048400392,0.00015318168],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0013507676,0.00015399714,0.0011834627,0.00027895495,0.00005156194,0.0000056621047,0.00042416021,0.000008873599,0.000009375395],"category_scores_gemma":[0.01897777,0.00007571711,0.00007522747,0.0007316541,0.00063546083,0.000051128205,0.00021855588,0.0006418799,2.7009161e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0085456325,0.0020728435,0.97329485,0.00017107205,0.00016833762,0.0010047824,0.00047777098,0.0077157337,0.0000030436993,0.000030195723,0.0005172414,0.005998496],"study_design_scores_gemma":[0.011304083,0.012256102,0.9688667,0.00010287776,0.000098971956,0.0001233083,0.00039172755,0.0003545557,0.000057408644,0.0001686183,0.006218909,0.000056746594],"about_ca_topic_score_codex":0.22603191,"about_ca_topic_score_gemma":0.23679334,"teacher_disagreement_score":0.030379951,"about_ca_system_score_codex":0.00010994693,"about_ca_system_score_gemma":0.0009540578,"threshold_uncertainty_score":0.98928577},"labels":[],"label_agreement":null},{"id":"W4205821347","doi":"10.1200/jco.2021.39.15_suppl.e16122","title":"Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Landmark; Post hoc; Placebo; Internal medicine; Clinical trial; Oncology; Cartography; Alternative medicine; Pathology","score_opus":0.06621968003366781,"score_gpt":0.3826547853940737,"score_spread":0.3164351053604059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205821347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684495,0.00086494314,0.000038367732,0.000501515,0.00015422386,0.001360269,0.0001116328,0.000005605725,0.00011848463],"genre_scores_gemma":[0.9987458,0.0004189299,0.00023461648,0.00018316059,0.000041564006,0.000030069663,0.000112765105,0.000025884177,0.00020719154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9865768,0.007717464,0.003964203,0.00047323824,0.00092242204,0.00034586032],"domain_scores_gemma":[0.985111,0.008579282,0.0035042411,0.00061422295,0.0018713771,0.0003198654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067291935,0.0003469534,0.0066633704,0.0009144532,0.000050851173,0.000010927758,0.00027471315,0.00035000936,0.00026276906],"category_scores_gemma":[0.0068360195,0.00018703076,0.002730687,0.003416981,0.0003314407,0.00011910433,0.00009372131,0.0007035742,9.09349e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4029299,0.009820445,0.56382656,0.00001653992,0.01889612,0.0010603105,0.00065182435,0.00004070426,0.00020710712,9.870391e-7,0.0000190299,0.0025304891],"study_design_scores_gemma":[0.26760462,0.026088666,0.6465867,0.000072924246,0.05597034,0.00001165163,0.0004932531,0.0023549043,0.0005483687,0.0000030836836,0.00012440844,0.0001410749],"about_ca_topic_score_codex":0.0004500497,"about_ca_topic_score_gemma":0.0015254418,"teacher_disagreement_score":0.13532528,"about_ca_system_score_codex":0.00031676795,"about_ca_system_score_gemma":0.0017954416,"threshold_uncertainty_score":0.81838477},"labels":[],"label_agreement":null},{"id":"W4205824700","doi":"10.1200/jco.2021.39.15_suppl.2582","title":"Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Cohort; Oncology; Bevacizumab; Internal medicine; Cancer; Chemotherapy; Cancer research","score_opus":0.05288422157225228,"score_gpt":0.4208904504800132,"score_spread":0.3680062289077609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205824700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973265,0.00026862707,0.000039453033,0.00075561996,0.0005282745,0.0006854568,0.000005681669,0.000013886291,0.0003765256],"genre_scores_gemma":[0.997137,0.000672449,0.0012749737,0.00050748495,0.00025989316,0.0000074463023,0.00005326127,0.000035820365,0.000051674324],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954214,0.0003958274,0.002855686,0.00032634544,0.0006457095,0.0003550322],"domain_scores_gemma":[0.99500066,0.0006060189,0.0028664807,0.0002921222,0.001007659,0.00022706446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019642143,0.00024559165,0.0021720827,0.000278662,0.00004966985,0.000016149777,0.00018196506,0.00034898345,0.000055534605],"category_scores_gemma":[0.00078256323,0.00016215158,0.00033524632,0.00059142447,0.0002764607,0.00036830376,0.000035266494,0.0007422483,0.0000011827974],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60464215,0.016036047,0.24845167,0.00012838983,0.0008945454,0.0010903608,0.00042050122,0.000040468407,0.0052192444,0.00001800222,0.0000767813,0.12298181],"study_design_scores_gemma":[0.40226895,0.16412137,0.42488253,0.001818696,0.00048184325,0.0003344921,0.00046531676,0.00013489212,0.0037818095,0.000044481432,0.0014160632,0.00024956046],"about_ca_topic_score_codex":0.000059833066,"about_ca_topic_score_gemma":0.0002619023,"teacher_disagreement_score":0.20237325,"about_ca_system_score_codex":0.0002946346,"about_ca_system_score_gemma":0.002312353,"threshold_uncertainty_score":0.661235},"labels":[],"label_agreement":null},{"id":"W4205909873","doi":"10.1200/jco.2022.40.4_suppl.tps629","title":"PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Pancreatic cancer; Internal medicine; Paclitaxel; Cancer; Chemotherapy; Adenocarcinoma; Mesothelioma; Pathology","score_opus":0.08986867900744284,"score_gpt":0.4414931922473728,"score_spread":0.35162451323993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205909873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940339,0.0025210215,0.0002141763,0.0015673529,0.00019591884,0.0013259535,0.000032088166,0.0000058803594,0.0001037607],"genre_scores_gemma":[0.99455386,0.00022735294,0.00450546,0.00024055284,0.00020013747,0.00016411266,0.0000074467807,0.000022461116,0.0000785963],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9965343,0.00028434242,0.0023066404,0.00027282772,0.00037127399,0.00023064339],"domain_scores_gemma":[0.9940452,0.002922592,0.0021205326,0.00026409447,0.0004025529,0.00024504497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008869573,0.0002158498,0.0023761627,0.00017060534,0.000078411904,0.00000390101,0.000101851205,0.00010376939,0.00010984474],"category_scores_gemma":[0.00081102486,0.00013591092,0.0003585253,0.00013982953,0.00011371498,0.000055520344,0.00004892673,0.0002905198,2.4970686e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060475457,0.094801955,0.5883205,0.00020744852,0.004236354,0.0024435357,0.0024970677,0.0005054853,0.00083481625,0.000052918345,0.00025915593,0.24536532],"study_design_scores_gemma":[0.17027873,0.68814796,0.1257651,0.00016670437,0.004414588,0.0005785395,0.0074561485,0.00073962385,0.0008991716,0.0001144607,0.0012751746,0.00016377107],"about_ca_topic_score_codex":0.00011284422,"about_ca_topic_score_gemma":0.0001580525,"teacher_disagreement_score":0.593346,"about_ca_system_score_codex":0.00016742448,"about_ca_system_score_gemma":0.0006385393,"threshold_uncertainty_score":0.5542286},"labels":[],"label_agreement":null},{"id":"W4205914018","doi":"10.1200/jco.2022.40.4_suppl.482","title":"Perioperative optimization with nutritional supplements in patients undergoing gastrointestinal surgery for cancer: A randomized, placebo controlled feasibility clinical trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Juravinski Cancer Centre; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Perioperative; Randomized controlled trial; Placebo; Surgery; Clinical trial; Complication; Cancer; Internal medicine","score_opus":0.21203191366150864,"score_gpt":0.5111535123903732,"score_spread":0.29912159872886457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205914018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96457136,0.00017205522,0.007687618,0.018652098,0.0020001873,0.006676332,0.000062820676,0.000011679402,0.00016582431],"genre_scores_gemma":[0.95060235,0.0005138324,0.04178132,0.0048342803,0.0012997064,0.00076258683,0.00009277807,0.000024961731,0.00008817544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9893412,0.0039077364,0.005581372,0.00028963975,0.0005792986,0.00030073567],"domain_scores_gemma":[0.9640024,0.030703647,0.003602049,0.00012629492,0.0011799644,0.00038565602],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022791002,0.00015581396,0.0036700345,0.00024948225,0.00017193126,0.000013175174,0.000098469645,0.000111865134,0.00068382215],"category_scores_gemma":[0.02068559,0.00011308028,0.00091890356,0.00017103394,0.00023564202,0.00011010191,0.000041891024,0.0012092199,5.0950916e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6659796,0.005896095,0.32436296,0.000054291642,0.00015124402,0.000045059725,0.000020043724,0.0012676395,1.2389681e-7,0.00004558286,0.0013713375,0.0008059868],"study_design_scores_gemma":[0.9398511,0.027821705,0.023942875,0.0003181577,0.0003074886,0.00009832524,0.00018768983,0.005465857,2.5926565e-7,0.00012155834,0.0017916101,0.00009335542],"about_ca_topic_score_codex":0.000012317158,"about_ca_topic_score_gemma":0.00006678016,"teacher_disagreement_score":0.3004201,"about_ca_system_score_codex":0.00067870214,"about_ca_system_score_gemma":0.0063378345,"threshold_uncertainty_score":0.9992953},"labels":[],"label_agreement":null},{"id":"W4205954025","doi":"10.1200/jco.21.01460","title":"Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Brock University","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Receiver operating characteristic; Lung cancer; Cancer screening; Biomarker; Carcinoembryonic antigen; Oncology; Cancer; Colorectal cancer","score_opus":0.1663937033088291,"score_gpt":0.5327343387159769,"score_spread":0.3663406354071478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205954025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93938476,0.004044598,0.00070992927,0.05004825,0.0036663543,0.0008952692,0.00014942621,0.000015299784,0.0010861079],"genre_scores_gemma":[0.98162496,0.0016281618,0.0075613954,0.0071199834,0.0010290316,0.00033898544,0.000013715793,0.000027255976,0.00065649353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704427,0.0005463388,0.0014881209,0.00021922134,0.0004711659,0.00023088063],"domain_scores_gemma":[0.99424094,0.0031538901,0.0017797074,0.00016337325,0.00036005772,0.00030200556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003443684,0.00013154604,0.0012162135,0.00009831049,0.00014753398,0.000008112422,0.0001314484,0.00013010723,0.0017110266],"category_scores_gemma":[0.0007305665,0.00009170354,0.00095929415,0.00011550449,0.00010049013,0.000037726568,0.000044979868,0.0007021489,9.375884e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073648533,0.007923743,0.85194117,0.00009801092,0.00380093,0.00056619616,0.00006024306,0.00024151767,0.00005439778,0.00018500807,0.061468337,0.06629559],"study_design_scores_gemma":[0.045636777,0.018122908,0.49123466,0.00009091025,0.0065960577,0.00012366417,0.00011179959,0.003143102,0.00003862958,0.00013093872,0.43464485,0.00012571942],"about_ca_topic_score_codex":0.000092570495,"about_ca_topic_score_gemma":0.00003205358,"teacher_disagreement_score":0.37317652,"about_ca_system_score_codex":0.0009953615,"about_ca_system_score_gemma":0.0044969344,"threshold_uncertainty_score":0.99920154},"labels":[],"label_agreement":null},{"id":"W4206001413","doi":"10.1200/jco.2021.39.15_suppl.e16236","title":"Adjuvant therapy in patients with resected pancreatic adenocarcinoma: Analysis of treatment patterns in a Canadian provincial institution.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Regimen; Pancreatic cancer; Stage (stratigraphy); Internal medicine; Capecitabine; Lymphovascular invasion; Oncology; Surgery; Adjuvant therapy; Oxaliplatin; Cancer; Metastasis","score_opus":0.0947636422419413,"score_gpt":0.43864699643299093,"score_spread":0.34388335419104965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206001413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971884,0.00033622127,0.000015358328,0.0009669922,0.00010115321,0.0003751486,0.000022248485,0.0000017607467,0.0009927275],"genre_scores_gemma":[0.9982338,0.0007374161,0.0005055512,0.0003021449,0.00009598484,0.000012432663,0.00002874441,0.000008021536,0.0000758899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963494,0.00076740887,0.0019578277,0.00021297311,0.00035231418,0.0003600949],"domain_scores_gemma":[0.99675757,0.0010786684,0.00070347206,0.00023012226,0.00074973016,0.0004804438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015932339,0.0001321691,0.0025815414,0.0009502976,0.000024325867,0.0000040428304,0.000107724,0.0003246186,0.00026938558],"category_scores_gemma":[0.0022795475,0.00008316019,0.0002957098,0.0010366356,0.00019096583,0.000064053595,0.00001859046,0.0005855968,0.0000016816122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062465514,0.0033964023,0.97298294,0.000014816836,0.0019433923,0.0022503913,0.00029033644,0.000043685868,0.0000072343873,0.000027459522,0.000022085896,0.012774715],"study_design_scores_gemma":[0.0205581,0.02428858,0.95262796,0.00011667975,0.0013393492,0.000028942248,0.00014381041,0.0003903348,0.000010141953,0.000014472946,0.0004160671,0.00006555395],"about_ca_topic_score_codex":0.10940342,"about_ca_topic_score_gemma":0.6980844,"teacher_disagreement_score":0.588681,"about_ca_system_score_codex":0.0015656432,"about_ca_system_score_gemma":0.020725533,"threshold_uncertainty_score":0.984826},"labels":[],"label_agreement":null},{"id":"W4206003793","doi":"10.1200/jco.2022.40.4_suppl.400","title":"Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AstraZeneca (Canada); University of Calgary","funders":"AstraZeneca Canada","keywords":"Medicine; Sorafenib; Systemic therapy; Hepatocellular carcinoma; Internal medicine; Population; Incidence (geometry); Retrospective cohort study; Cohort; Medical record; Cancer","score_opus":0.3035430139531079,"score_gpt":0.47207123105787896,"score_spread":0.16852821710477106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206003793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986537,0.003796152,0.00001662536,0.0070649465,0.0006269153,0.0008163082,0.000021652262,0.000017362827,0.0011030796],"genre_scores_gemma":[0.9926287,0.0033983144,0.00097080634,0.0018936936,0.00035035022,0.000045145884,0.00009323944,0.00003730527,0.000582459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930066,0.0020675566,0.003566486,0.00043949453,0.0005015131,0.0004183635],"domain_scores_gemma":[0.99573094,0.0014482364,0.0016984505,0.00033998647,0.00016343656,0.000618933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004523808,0.00025634246,0.0024328611,0.00037181526,0.00015389924,0.000011542724,0.00015688242,0.00021311986,0.00018720535],"category_scores_gemma":[0.000424708,0.00019634547,0.0006714024,0.00034147906,0.0000998587,0.00008695314,0.00013822885,0.0010802475,0.000003250654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002206452,0.0019185896,0.8522793,0.000048623737,0.00019063725,0.0020403778,0.0003805746,0.000006946401,0.0000015783562,0.000039296257,0.00058353064,0.1403041],"study_design_scores_gemma":[0.0152174095,0.02481404,0.8417575,0.00004886767,0.0002478508,0.0001169248,0.0009463428,0.00045857517,0.000015320078,0.000022518489,0.116229,0.0001256858],"about_ca_topic_score_codex":0.0013775891,"about_ca_topic_score_gemma":0.0015356002,"teacher_disagreement_score":0.14017841,"about_ca_system_score_codex":0.001319633,"about_ca_system_score_gemma":0.0025285303,"threshold_uncertainty_score":0.8006736},"labels":[],"label_agreement":null},{"id":"W4206041598","doi":"10.1200/jco.21.01874","title":"Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Microsatellite instability; Internal medicine; Oncology; Clinical endpoint; Cancer; Population; Colorectal cancer; Clinical trial; Immunotherapy","score_opus":0.07263340930963263,"score_gpt":0.4163725069951964,"score_spread":0.34373909768556377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206041598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919036,0.00072641164,0.0000023821697,0.003263292,0.002497432,0.0010967292,0.00020890681,0.000008045153,0.00029319533],"genre_scores_gemma":[0.9967753,0.00024979218,0.000283223,0.0015587662,0.00096655457,0.00003485721,0.000041360923,0.00002099708,0.00006910721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936126,0.0016014755,0.0030292678,0.00040242233,0.0010352832,0.0003189675],"domain_scores_gemma":[0.9895219,0.0074234894,0.0019793736,0.00039743775,0.00039744633,0.00028033147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003332698,0.00020610973,0.0018316216,0.00020547355,0.00011464976,0.000012336429,0.00038717358,0.00013642758,0.0003819353],"category_scores_gemma":[0.005668002,0.000111772526,0.00034800058,0.0010374557,0.00016188358,0.0001042661,0.00020089712,0.0017458048,0.000004991137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25100204,0.008946575,0.59878385,0.0000031087593,0.0004660472,0.00022689495,0.00031890665,0.00014666839,0.0000060128677,0.0000034752359,0.00009332493,0.14000307],"study_design_scores_gemma":[0.1831684,0.049677413,0.7513714,0.000038459635,0.0003779584,0.000006478881,0.0003744384,0.0000019366983,0.000010526111,0.00012996777,0.014754443,0.00008859858],"about_ca_topic_score_codex":0.0016851169,"about_ca_topic_score_gemma":0.0008668164,"teacher_disagreement_score":0.15258752,"about_ca_system_score_codex":0.0008592383,"about_ca_system_score_gemma":0.00147479,"threshold_uncertainty_score":0.758475},"labels":[],"label_agreement":null},{"id":"W4206121794","doi":"10.1200/jco.2022.40.4_suppl.124","title":"Periop-01: A randomized controlled trial of extended perioperative tinzaparin to improve disease-free survival in patients with resectable colorectal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"North York General Hospital; Humber River Regional Hospital; Essar Steel Algoma (Canada); Group Health Centre; St Joseph's Health Centre; Western University; University of Toronto; University of Ottawa; Kingston Health Sciences Centre; McGill University; Sunnybrook Health Science Centre; Jewish General Hospital; Queen's University; Queensway-Carleton Hospital; London Health Sciences Centre; Montfort Hospital; Health Sciences Centre; Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Perioperative; Hazard ratio; Randomized controlled trial; Colorectal cancer; Interim analysis; Surgery; Low molecular weight heparin; Incidence (geometry); Cancer; Internal medicine; Heparin; Confidence interval","score_opus":0.032335206958391774,"score_gpt":0.38781398032930453,"score_spread":0.35547877337091277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206121794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98433423,0.00017104618,0.000013118837,0.0047789738,0.0023107375,0.0058876327,0.000025345695,0.000005866172,0.0024730298],"genre_scores_gemma":[0.9967333,0.00016752316,0.00037607964,0.0009133024,0.000502272,0.0009471072,0.0000044376725,0.000023976225,0.00033202057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99284166,0.0022958673,0.0032523843,0.0003015376,0.0009840336,0.0003245389],"domain_scores_gemma":[0.99346566,0.0030944846,0.0021617496,0.00026710905,0.0005749812,0.0004359881],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008332884,0.00020233095,0.0063042687,0.00025049117,0.000085590706,0.000011935932,0.00032134654,0.00010393563,0.0007313528],"category_scores_gemma":[0.011205709,0.00012694647,0.00081920595,0.0002599025,0.00022321999,0.00007771248,0.0002917862,0.0008457117,0.0000013266317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9655213,0.0124855405,0.01530476,0.00002796571,0.0013407513,0.00016966223,0.00043307012,0.00034017503,0.00003093334,0.00029812197,0.0009380117,0.0031097324],"study_design_scores_gemma":[0.775839,0.048719622,0.1721903,0.00006003627,0.0009961289,0.0000017847716,0.00031705675,0.00013057081,0.000007146522,0.00005542612,0.0015778015,0.00010514443],"about_ca_topic_score_codex":0.00024986858,"about_ca_topic_score_gemma":0.00043021372,"teacher_disagreement_score":0.18968228,"about_ca_system_score_codex":0.00042798618,"about_ca_system_score_gemma":0.002995863,"threshold_uncertainty_score":0.9971233},"labels":[],"label_agreement":null},{"id":"W4206124890","doi":"10.1200/jco.2021.39.15_suppl.4072","title":"Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Placebo; Interim analysis; Clinical trial; Internal medicine; Hepatocellular carcinoma; Alternative medicine","score_opus":0.16639763902489035,"score_gpt":0.3974421513583694,"score_spread":0.23104451233347906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206124890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302757,0.0013032936,0.00007647961,0.0015388974,0.00045421423,0.0030298843,0.00007001571,0.000028150162,0.00047151573],"genre_scores_gemma":[0.99623233,0.00039299086,0.0014901481,0.000444602,0.00040931685,0.00006779326,0.00076240365,0.00007388196,0.00012653999],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99071956,0.0037239841,0.0031904092,0.0008261475,0.0009692057,0.0005707166],"domain_scores_gemma":[0.98906124,0.0058345157,0.0021657008,0.0013507965,0.0010265495,0.0005611907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036878346,0.00052075245,0.0039504524,0.00015580033,0.00011885966,0.000048329828,0.00066564203,0.00041717527,0.00038208585],"category_scores_gemma":[0.0031830692,0.00027555498,0.0005001157,0.0006165514,0.00041539012,0.0003536615,0.00023612386,0.0015462724,0.00003045133],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4546475,0.008055743,0.51674247,0.000010775507,0.0015741758,0.0070969434,0.0002246488,0.000004391323,0.000009953286,0.0000018224108,0.0003489787,0.011282583],"study_design_scores_gemma":[0.8254363,0.045912217,0.11585571,0.00020547485,0.005896614,0.00013875651,0.0005795984,0.0025624747,0.00016611323,0.000010686447,0.002935045,0.0003010134],"about_ca_topic_score_codex":0.00037948962,"about_ca_topic_score_gemma":0.0007954453,"teacher_disagreement_score":0.40088677,"about_ca_system_score_codex":0.0003122777,"about_ca_system_score_gemma":0.0029344372,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W4206178195","doi":"10.1200/jco.2022.40.4_suppl.475","title":"Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Cirrhosis; Gemcitabine; Oxaliplatin; Chemotherapy; Cancer; Surgery","score_opus":0.04011104319199139,"score_gpt":0.37934579306868565,"score_spread":0.3392347498766943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206178195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966463,0.00029616445,0.0000056855215,0.0019916506,0.00028621292,0.0002251461,0.00000985269,0.0000048717443,0.00053412333],"genre_scores_gemma":[0.99689764,0.00015979444,0.00082757656,0.0019662916,0.000085218264,0.000008333081,0.0000019319157,0.000017374095,0.000035831414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709517,0.00021870853,0.0017411006,0.00016662285,0.0006082897,0.00017011644],"domain_scores_gemma":[0.9955278,0.0013687378,0.002213812,0.00023570754,0.0005229383,0.00013098678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010451003,0.0001385001,0.0016470447,0.00017072342,0.00004727395,0.0000016420117,0.00020027932,0.00008277922,0.000083241874],"category_scores_gemma":[0.0013375873,0.00009300286,0.0003803288,0.00022979698,0.00018082882,0.00007445868,0.00007591805,0.0006801457,7.785871e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006304304,0.0017036751,0.9475211,0.00004640419,0.0006433264,0.000038119615,0.00044953276,0.00028384925,0.00007101878,0.000012888977,0.00027484994,0.04265092],"study_design_scores_gemma":[0.009884867,0.026791262,0.96083754,0.00009030935,0.00027692213,0.000015007484,0.00018235388,0.0000051861157,0.00012504123,0.00003473197,0.0016779697,0.000078825244],"about_ca_topic_score_codex":0.000020112673,"about_ca_topic_score_gemma":0.000008636634,"teacher_disagreement_score":0.042572092,"about_ca_system_score_codex":0.00014355134,"about_ca_system_score_gemma":0.00048909365,"threshold_uncertainty_score":0.37925467},"labels":[],"label_agreement":null},{"id":"W4206327726","doi":"10.1200/jco.2022.40.4_suppl.172","title":"Rapid point of care NGS in colorectal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; William Osler Health System","funders":"","keywords":"Turnaround time; Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Oncology; Point of care; ROS1; Internal medicine; Cancer; Pathology; Adenocarcinoma","score_opus":0.039548435930366284,"score_gpt":0.4023890998237231,"score_spread":0.36284066389335684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206327726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99006975,0.0058794,0.000013922787,0.0011794723,0.0014568146,0.00008457856,0.000044508673,7.097571e-7,0.0012708758],"genre_scores_gemma":[0.99376136,0.0042679487,0.00041526923,0.0009218749,0.00058774423,0.000009522942,0.0000085879155,0.000010037887,0.00001764458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811715,0.00024683788,0.0012120195,0.00013651735,0.00014875182,0.00013870095],"domain_scores_gemma":[0.99831665,0.0003040771,0.0009823042,0.000098553945,0.00020005736,0.00009834261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011723323,0.000073553725,0.0005654493,0.000060081224,0.000028043172,0.000002456357,0.00024586375,0.00014751837,0.00020357288],"category_scores_gemma":[0.00094940665,0.00006861359,0.0002877573,0.0000829788,0.00012616151,0.0000021308538,0.00020695447,0.00041515217,4.9527375e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021347739,0.0032704188,0.25239778,0.000099274745,0.00064567593,0.0005462679,0.0011920658,0.009617264,0.13044588,0.0010882488,0.04431698,0.5350324],"study_design_scores_gemma":[0.010740998,0.05069954,0.12206951,0.000032590946,0.00014098277,0.00018990079,0.002393337,0.00008279521,0.030332524,0.0005347771,0.78248465,0.00029842448],"about_ca_topic_score_codex":0.000068014735,"about_ca_topic_score_gemma":0.0003645042,"teacher_disagreement_score":0.73816764,"about_ca_system_score_codex":0.00011409105,"about_ca_system_score_gemma":0.0017955126,"threshold_uncertainty_score":0.31851622},"labels":[],"label_agreement":null},{"id":"W4206341203","doi":"10.1200/jco.2022.40.4_suppl.tps216","title":"GOBLET: A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech","keywords":"Atezolizumab; Medicine; Blockade; Immune checkpoint; Oncology; Cancer; Pembrolizumab; Colorectal cancer; Internal medicine; Cancer research; Immunotherapy; Melanoma; Receptor","score_opus":0.21386098103290557,"score_gpt":0.48079493828909386,"score_spread":0.2669339572561883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206341203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995889,0.00052398077,0.00012841719,0.0024042362,0.00016670124,0.00082991086,0.000010109809,0.000010762275,0.000036866324],"genre_scores_gemma":[0.996363,0.0011265366,0.0021779384,0.00016025393,0.00003905241,0.000067911555,0.000005639314,0.00001928089,0.000040384606],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973631,0.00052716833,0.0014227189,0.00023009592,0.00027413378,0.00018280184],"domain_scores_gemma":[0.9965264,0.0020385135,0.0010184195,0.00012733221,0.000103081176,0.0001862144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017370947,0.00014624505,0.0008998819,0.00025270897,0.00011262735,0.000009318821,0.0000715487,0.000025833644,0.00006112118],"category_scores_gemma":[0.0007284126,0.000095979376,0.00010030117,0.0003017443,0.00018727864,0.000121373785,0.000041386364,0.00039522757,1.9252936e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2046616,0.011812052,0.13395461,0.000023268058,0.00067233003,0.0018022784,0.0016049335,0.00012691751,0.00031154117,0.000007832872,0.000023285134,0.6449993],"study_design_scores_gemma":[0.17578898,0.24428685,0.5616916,0.00016258647,0.0005257448,0.0035479076,0.008239333,0.00083064055,0.000013674555,0.0000126802615,0.0047762413,0.0001237943],"about_ca_topic_score_codex":0.0002002928,"about_ca_topic_score_gemma":0.00094829773,"teacher_disagreement_score":0.6448755,"about_ca_system_score_codex":0.0008562509,"about_ca_system_score_gemma":0.0013792025,"threshold_uncertainty_score":0.39139253},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4206368364","doi":"10.1200/jco.2022.40.4_suppl.033","title":"COVID-19 impact on diagnosis and staging of colorectal cancer: A single tertiary Canadian oncology center experience.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colonoscopy; Pandemic; Colorectal cancer; General surgery; Grading (engineering); Coronavirus disease 2019 (COVID-19); Pathological staging; Cancer; Surgery; Internal medicine; Disease; Infectious disease (medical specialty)","score_opus":0.2335511522213549,"score_gpt":0.5633832148056191,"score_spread":0.32983206258426423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206368364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89687824,0.00057880493,0.000005510906,0.10043379,0.0012285466,0.0002938777,0.00008466279,0.0000071164473,0.000489451],"genre_scores_gemma":[0.9284526,0.0011006085,0.00014181506,0.06978025,0.00044813717,0.00003081843,0.0000042803317,0.000017091874,0.000024356088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622625,0.00084300665,0.0017979579,0.00024454112,0.00041895415,0.0004693106],"domain_scores_gemma":[0.9906941,0.004692778,0.0013772441,0.0001519184,0.00021793034,0.00286605],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026918328,0.00016489378,0.0014874705,0.00045475233,0.00017282601,0.0000070700485,0.00018457077,0.00026095475,0.0017524994],"category_scores_gemma":[0.0073971385,0.00012458791,0.00037732619,0.00022477159,0.00030479513,0.000081955775,0.00010097815,0.0013284562,0.0000014014909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005905123,0.0017521865,0.8747555,0.00006973697,0.00020441062,0.0020409545,0.0027719042,0.000104985054,0.00019201933,0.000014726386,0.01727122,0.094917245],"study_design_scores_gemma":[0.0066692024,0.044659197,0.5969844,0.00008360881,0.00013848982,0.0008022869,0.0013599993,0.00007678219,0.00008338894,0.00006712584,0.34895945,0.000116072544],"about_ca_topic_score_codex":0.059753146,"about_ca_topic_score_gemma":0.040892474,"teacher_disagreement_score":0.33168823,"about_ca_system_score_codex":0.005481313,"about_ca_system_score_gemma":0.032527275,"threshold_uncertainty_score":0.99916005},"labels":[],"label_agreement":null},{"id":"W4206450867","doi":"10.1200/jco.2021.39.15_suppl.tps2074","title":"GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Randomization; Glioblastoma; Agile software development; Dosing; Oncology; Internal medicine; Medical physics; Computer science; Cancer research","score_opus":0.17363243255270722,"score_gpt":0.49798269044341115,"score_spread":0.32435025789070393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206450867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831588,0.0012343935,0.000023570727,0.012843201,0.0016577478,0.0006647867,0.000019946538,0.0000075840962,0.00038995608],"genre_scores_gemma":[0.9933564,0.0010035627,0.0028055797,0.0018953665,0.0008590604,0.000035782767,0.000004239553,0.000013294833,0.000026698905],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619114,0.00043727344,0.002237734,0.00034435446,0.00046308312,0.00032639474],"domain_scores_gemma":[0.99405617,0.0034159177,0.0009644204,0.000221659,0.0005452674,0.000796577],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022054447,0.00020228402,0.0017650943,0.0001430202,0.000037145328,0.000017626702,0.00009534866,0.00031517714,0.00011020723],"category_scores_gemma":[0.010907232,0.00013424586,0.00042489142,0.0003697476,0.00010042751,0.00010334226,0.00010148593,0.0006134621,0.000021236694],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31799015,0.025889719,0.032050233,0.000019215395,0.0008021742,0.020657483,0.00027281133,0.00004199457,0.00015975653,0.00014507363,0.015172953,0.5867984],"study_design_scores_gemma":[0.6608914,0.16005707,0.110870935,0.00054995844,0.0010060667,0.00094256847,0.0005420113,0.0005502032,0.0004576261,0.0004350667,0.06347054,0.00022656634],"about_ca_topic_score_codex":0.000029382269,"about_ca_topic_score_gemma":0.0010806457,"teacher_disagreement_score":0.5865719,"about_ca_system_score_codex":0.0004599096,"about_ca_system_score_gemma":0.0017921209,"threshold_uncertainty_score":0.9974243},"labels":[],"label_agreement":null},{"id":"W4206475688","doi":"10.1200/jco.21.01961","title":"Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Ottawa; University Health Network; University of Toronto; McGill University; University of British Columbia; Western University","funders":"","keywords":"Transoral robotic surgery; Swallowing; Randomized controlled trial; Radiation therapy; Squamous cell cancer; Quality of life (healthcare); Robotic surgery; Head and neck","score_opus":0.16966850090294666,"score_gpt":0.44852152278654317,"score_spread":0.2788530218835965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206475688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736801,0.0019261184,0.00006643368,0.0054101585,0.016670182,0.0019584596,0.000035803492,0.000004259822,0.00024851068],"genre_scores_gemma":[0.995752,0.00047885728,0.00027115576,0.00036043537,0.0028565172,0.000056592653,0.0000037546617,0.000022401948,0.00019830186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917774,0.00246705,0.004686967,0.00020442109,0.00060354784,0.00026056502],"domain_scores_gemma":[0.9694793,0.025987394,0.0036865682,0.00026745166,0.0003939914,0.00018524943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010772186,0.000170237,0.005448345,0.00012866313,0.00009553433,0.0000028990885,0.00025812618,0.00021286591,0.000088450724],"category_scores_gemma":[0.007576259,0.00010095909,0.0027930313,0.00020856163,0.00045572166,0.0000418565,0.0000432821,0.00080078415,2.1267824e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98191077,0.0039265277,0.000680692,0.00010503805,0.0004464154,0.0000931112,0.00027398916,0.000056779143,0.00012879877,0.0000076011256,0.005751035,0.0066192406],"study_design_scores_gemma":[0.9222976,0.07119002,0.0019842868,0.00002361884,0.0013320603,0.000024378649,0.00006411168,0.000051881118,0.00021113579,0.00001389985,0.0027267085,0.00008029473],"about_ca_topic_score_codex":0.000026308615,"about_ca_topic_score_gemma":0.000023826547,"teacher_disagreement_score":0.0672635,"about_ca_system_score_codex":0.00018994123,"about_ca_system_score_gemma":0.0039249784,"threshold_uncertainty_score":0.90700364},"labels":[],"label_agreement":null},{"id":"W4206488373","doi":"10.1200/jco.2022.40.4_suppl.201","title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Kelowna General Hospital","funders":"","keywords":"Medicine; Irinotecan; Internal medicine; Endometrial cancer; Oncology; Colorectal cancer; Regimen; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Oxaliplatin; Discontinuation; Cohort; Cancer; Progressive disease; Clinical trial; Surgery; Phases of clinical research; Disease","score_opus":0.023791752964228266,"score_gpt":0.3612927453165167,"score_spread":0.3375009923522884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206488373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807423,0.00014662973,0.000027348531,0.00022303784,0.00046619523,0.0008136602,0.00019738296,0.0000057270418,0.000045803776],"genre_scores_gemma":[0.9981976,0.00013154707,0.0013555984,0.00018207819,0.00006585899,0.000020333011,0.000016783742,0.000025342926,0.0000048315283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953178,0.0005733437,0.0023171797,0.0003661392,0.001119359,0.00030617887],"domain_scores_gemma":[0.9935152,0.0015969855,0.003367394,0.0002384357,0.0010503181,0.00023167008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002096197,0.00022806198,0.0028905708,0.00080867537,0.000062818224,0.000004392199,0.00019903878,0.00016101447,0.00021533339],"category_scores_gemma":[0.0008569637,0.00015821702,0.0004735353,0.001572294,0.0003869608,0.000089753295,0.00012722905,0.00089187094,1.3130888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22897856,0.0049794056,0.75553614,0.000042081596,0.0017363073,0.000043633612,0.00035699163,0.0011715621,0.0002445255,9.059684e-7,0.000026610238,0.0068832603],"study_design_scores_gemma":[0.036673676,0.09729362,0.86366343,0.00007389896,0.0012956253,0.0000066326597,0.0001709672,0.00033555686,0.00025781005,0.000002545655,0.00009344313,0.00013276626],"about_ca_topic_score_codex":0.00040392778,"about_ca_topic_score_gemma":0.00079652696,"teacher_disagreement_score":0.19230488,"about_ca_system_score_codex":0.0006529559,"about_ca_system_score_gemma":0.0019782332,"threshold_uncertainty_score":0.64519024},"labels":[],"label_agreement":null},{"id":"W4206516249","doi":"10.1200/jco.2022.40.4_suppl.003","title":"Are two too many when it comes to the treatment of anal canal cancer with concurrent radiation and mitomycin C?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta Hospital; University of Alberta","funders":"","keywords":"Medicine; Anal cancer; Cancer; Surgery; Population; Mitomycin C; Stage (stratigraphy); Radiation therapy; Cancer registry; Proportional hazards model; Internal medicine; Fluorouracil; Gastroenterology","score_opus":0.1337349986935019,"score_gpt":0.4655634177896912,"score_spread":0.3318284190961893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206516249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93748933,0.0019579192,0.000013112909,0.059535105,0.00055973296,0.00018371927,0.000021255244,0.000001709496,0.00023809416],"genre_scores_gemma":[0.99467963,0.0005174304,0.00008451994,0.0034487539,0.000789632,0.000014978455,0.0000019456168,0.0000054816833,0.00045760933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843234,0.00024660944,0.0007897077,0.000112807196,0.00029884724,0.00011968917],"domain_scores_gemma":[0.9979787,0.0006135815,0.0009582795,0.000077349534,0.00015112155,0.00022101047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062934245,0.00008493749,0.00078136317,0.000074424635,0.000064392676,0.000004361191,0.00007609899,0.000037789447,0.0002902857],"category_scores_gemma":[0.00013886958,0.00004388509,0.00018169069,0.000102964266,0.00009365083,0.000025197169,0.000031989213,0.00029909567,7.3889805e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054082796,0.0011260723,0.6888698,0.0000135483215,0.0005051675,0.00038233117,0.00080554775,0.00027640845,0.000038244816,0.000069177426,0.017406017,0.28509945],"study_design_scores_gemma":[0.0055527175,0.025269477,0.6540054,0.000023509854,0.00042887655,0.00023751211,0.0007610393,0.00019083051,0.000026181,0.000023983539,0.31343535,0.00004510629],"about_ca_topic_score_codex":0.0009391027,"about_ca_topic_score_gemma":0.0058180913,"teacher_disagreement_score":0.29602933,"about_ca_system_score_codex":0.0003103898,"about_ca_system_score_gemma":0.0007422713,"threshold_uncertainty_score":0.32466316},"labels":[],"label_agreement":null},{"id":"W4206528461","doi":"10.1200/jco.2022.40.4_suppl.641","title":"Outcomes of patients with small intestine adenocarcinoma (SIA) in a Canadian province: A population-based cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Population; Cohort; Retrospective cohort study; Cancer; Surgery; Chemotherapy; Gastroenterology","score_opus":0.0803753240533508,"score_gpt":0.412358457704483,"score_spread":0.3319831336511322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206528461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686396,0.000023807244,0.0000076263645,0.001896005,0.000092132585,0.00095424755,0.00001329856,0.0000031408088,0.00014575722],"genre_scores_gemma":[0.99713075,7.01804e-7,0.0023879812,0.00032110297,0.000036803245,0.000027539008,0.00001795271,0.000012764179,0.000064398795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969613,0.0004940215,0.0014966733,0.00016866282,0.0005875749,0.0002917495],"domain_scores_gemma":[0.9968616,0.001050593,0.0009173913,0.0001618419,0.00042069584,0.0005878769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023496544,0.000104791536,0.0011199268,0.00032720264,0.000045591056,0.0000042862484,0.00015215794,0.00003781144,0.00016237542],"category_scores_gemma":[0.004346129,0.00007410816,0.00015935698,0.00022723804,0.00006819829,0.000027899589,0.000046038927,0.0008583847,0.0000012155255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037795505,0.007023637,0.9815558,0.000014327106,0.0001776779,0.004297114,0.000019211577,0.000111990106,2.5123688e-7,0.000004607819,0.000045624278,0.002970183],"study_design_scores_gemma":[0.012393984,0.0589491,0.92792994,0.000040461895,0.00016322632,0.00013176243,0.000111381516,0.0000858954,4.0277618e-7,0.000015070677,0.00013131312,0.000047450943],"about_ca_topic_score_codex":0.10550819,"about_ca_topic_score_gemma":0.33117956,"teacher_disagreement_score":0.22567135,"about_ca_system_score_codex":0.0008728025,"about_ca_system_score_gemma":0.0065459083,"threshold_uncertainty_score":0.9990861},"labels":[],"label_agreement":null},{"id":"W4206528874","doi":"10.1200/jco.2022.40.4_suppl.tps638","title":"GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; BC Cancer Agency; Cancer Care Ontario; University Health Network; Ottawa Hospital; Health Sciences Centre; Kingston Health Sciences Centre; University of Ottawa; McGill University Health Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Kingston General Hospital; St Joseph's Health Centre; University of Toronto","funders":"","keywords":"Medicine; FOLFIRINOX; Oncology; Gemcitabine; Internal medicine; Perioperative; Biomarker; Chemotherapy; Induction chemotherapy; Pancreatic cancer; Cancer; Oxaliplatin; Surgery; Colorectal cancer","score_opus":0.10569141977539707,"score_gpt":0.49664092471301163,"score_spread":0.39094950493761454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206528874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823804,0.0003577421,0.000009681994,0.008325376,0.00035389364,0.0015807577,0.000025640204,0.000005103182,0.0011037767],"genre_scores_gemma":[0.99427426,0.00007475848,0.0012796859,0.0020545362,0.00026861503,0.00012685508,0.0000031277393,0.000025617173,0.0018925468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99220216,0.003624278,0.0025874046,0.00033506865,0.00075647165,0.00049460976],"domain_scores_gemma":[0.9940045,0.0032316314,0.00083254505,0.00037993366,0.0005152176,0.0010361975],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0105584785,0.00018343498,0.0023519832,0.00072533684,0.00019694425,0.0000066856583,0.00036720835,0.00021805796,0.002578571],"category_scores_gemma":[0.010173296,0.00014011974,0.00025171938,0.0004706345,0.00020602367,0.00009596224,0.00021262269,0.0016325011,0.000010547263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19102518,0.014909842,0.76334375,0.000023993654,0.00039164012,0.00408323,0.0136859985,0.000020434478,0.0064135594,0.0000055410424,0.003516351,0.0025804976],"study_design_scores_gemma":[0.072617374,0.23698823,0.65715194,0.00016046323,0.00029543875,0.00037981846,0.016055422,0.00042150167,0.00023121799,0.000022700751,0.015543786,0.00013209322],"about_ca_topic_score_codex":0.010251997,"about_ca_topic_score_gemma":0.007853539,"teacher_disagreement_score":0.2220784,"about_ca_system_score_codex":0.0010311421,"about_ca_system_score_gemma":0.011237493,"threshold_uncertainty_score":0.9983332},"labels":[],"label_agreement":null},{"id":"W4206552099","doi":"10.1200/jco.2022.40.4_suppl.025","title":"Colorectal cancer biomarker, AABH (Aspartyl [Asparaginyl] β- hydroxylase), a companion imaging and treatment strategy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colonoscopy; Colorectal cancer; Fecal occult blood; Cancer; Internal medicine; Oncology; Stage (stratigraphy); Biomarker; Blood test; Metastasis; Gastroenterology","score_opus":0.06755837550060996,"score_gpt":0.4094154946986027,"score_spread":0.3418571191979928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206552099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759079,0.017392175,0.00006810986,0.0015115254,0.0041162414,0.00016265549,0.000048396916,0.0000053366402,0.0007876173],"genre_scores_gemma":[0.98585,0.009707036,0.0002662196,0.0008298046,0.0029285175,0.00003185353,0.000021338212,0.000020800962,0.00034445073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975532,0.0005504636,0.0010743577,0.00029914104,0.00021766218,0.00030513926],"domain_scores_gemma":[0.9983287,0.00017425511,0.0009426225,0.00014332676,0.00013070212,0.0002804224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014053098,0.0001794887,0.00077714113,0.00007535105,0.00015634208,0.000018048511,0.00019583166,0.00014118725,0.00015259878],"category_scores_gemma":[0.00015825579,0.00014828387,0.00034083307,0.00009237639,0.00020506482,0.000010137111,0.00017518329,0.0003762399,0.0000012848476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006179766,0.0021255773,0.044437416,0.000013788826,0.0010346594,0.00017878546,0.00015725385,0.0010733276,0.13305199,0.000092644535,0.04616197,0.7654928],"study_design_scores_gemma":[0.006918339,0.006277009,0.05788903,0.000008653661,0.00025809568,0.0007076396,0.00028080202,0.0006860212,0.0023553746,0.00009413392,0.9243069,0.00021800003],"about_ca_topic_score_codex":0.00013218822,"about_ca_topic_score_gemma":0.00021289254,"teacher_disagreement_score":0.8781449,"about_ca_system_score_codex":0.000116467934,"about_ca_system_score_gemma":0.0013230173,"threshold_uncertainty_score":0.60468405},"labels":[],"label_agreement":null},{"id":"W4206576793","doi":"10.1200/jco.2021.39.15_suppl.4080","title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Adverse effect; Phases of clinical research; Cohort; Gastroenterology; Surgery; Cancer; Sorafenib; Toxicity; Clinical trial; Immunotherapy; Hepatocellular carcinoma","score_opus":0.11921027431839577,"score_gpt":0.46679183434862254,"score_spread":0.3475815600302268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206576793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332947,0.0011309189,0.000014742221,0.0032710133,0.0004551152,0.00115515,0.000010062959,0.000006301208,0.00062720384],"genre_scores_gemma":[0.9965157,0.00032686983,0.00039786968,0.001927965,0.0006387351,0.00005935038,0.000011567869,0.000019716972,0.000102207654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968076,0.00047026467,0.0017390789,0.00026768903,0.00042536942,0.00029001004],"domain_scores_gemma":[0.9955639,0.002521919,0.00088185724,0.00025349396,0.00060964044,0.00016914545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016856152,0.00018082929,0.0015368033,0.00008720708,0.000065647626,0.000012555133,0.00016526144,0.00016052285,0.00003674648],"category_scores_gemma":[0.0023657046,0.00009716602,0.0003844722,0.00023511892,0.00014462027,0.0000958941,0.000029891118,0.0007785989,0.0000013498154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017516188,0.010804679,0.9034987,0.000040772717,0.000715805,0.0012881522,0.002036964,0.00001800301,0.000006423199,0.0000022711529,0.0028178,0.061254248],"study_design_scores_gemma":[0.08009761,0.039600775,0.8656606,0.00009702358,0.0010562567,0.00014775654,0.0020558927,0.000049553422,0.000011063073,0.000008263323,0.011116099,0.00009910624],"about_ca_topic_score_codex":0.000106589534,"about_ca_topic_score_gemma":0.0010749275,"teacher_disagreement_score":0.06258142,"about_ca_system_score_codex":0.0004047118,"about_ca_system_score_gemma":0.0028614623,"threshold_uncertainty_score":0.50761116},"labels":[],"label_agreement":null},{"id":"W4206581770","doi":"10.1200/jco.2022.40.4_suppl.357","title":"Survival prediction using radiomic signatures in metastatic gastric and esophageal adenocarcinoma (GEA).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Proportional hazards model; Concordance; Oncology; Retrospective cohort study; Radiology","score_opus":0.08355915223648386,"score_gpt":0.435015212716623,"score_spread":0.35145606048013917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206581770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990455,0.0031038898,0.0013123497,0.0030799527,0.0016513434,0.0001443718,0.00000385595,0.0000078081375,0.00024146141],"genre_scores_gemma":[0.98943526,0.0002571259,0.008163843,0.0012516903,0.0007964224,0.000002150302,0.0000026989517,0.000017837014,0.00007294994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962754,0.0011363261,0.0016876885,0.00019418272,0.00047543313,0.0002309427],"domain_scores_gemma":[0.9968715,0.0016975285,0.00093790033,0.00010249219,0.00008070385,0.00030989046],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00668043,0.0001138458,0.00112599,0.00036625864,0.00008605502,0.000009859106,0.00013166954,0.000105717474,0.00017598685],"category_scores_gemma":[0.0032336835,0.00009250772,0.00022007388,0.00026464753,0.00017065102,0.000084463514,0.00010006534,0.0027007817,5.6320073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027035812,0.0010774431,0.9072959,0.000053359545,0.00032528836,0.00568316,0.00024508234,0.008024598,0.0010946885,0.00014295068,0.001599735,0.071754254],"study_design_scores_gemma":[0.011248683,0.0069419527,0.86489093,0.000049456285,0.0005044707,0.004694235,0.000356338,0.105360344,0.0000045291918,0.0003916894,0.00546461,0.000092760085],"about_ca_topic_score_codex":0.00004222972,"about_ca_topic_score_gemma":0.0000028513477,"teacher_disagreement_score":0.09733574,"about_ca_system_score_codex":0.00024783096,"about_ca_system_score_gemma":0.001009637,"threshold_uncertainty_score":0.99960005},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4206648200","doi":"10.1200/jco.2022.40.4_suppl.587","title":"Integrative analysis of <i>KRAS</i>-wildtype pancreatic ductal adenocarcinoma reveals unique similarities to extrahepatic cholangiocarcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; University of British Columbia; Toronto General Hospital; Ottawa Hospital; University Health Network; Ontario Institute for Cancer Research; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"","keywords":"KRAS; Medicine; Malignancy; Adenocarcinoma; Oncology; Internal medicine; Pancreatic cancer; Cancer research; Colorectal cancer; Cancer","score_opus":0.10500189816582091,"score_gpt":0.43538560235138707,"score_spread":0.3303837041855662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206648200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98384297,0.0053808363,0.00017833902,0.0059864926,0.0008271766,0.00038138998,0.00005673639,0.00001451328,0.003331518],"genre_scores_gemma":[0.991407,0.0004189946,0.0022114157,0.004552744,0.0005253674,0.000032715536,0.000017354498,0.000027212542,0.0008072273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943815,0.0010497225,0.0030779226,0.00035672938,0.00077737565,0.00035677757],"domain_scores_gemma":[0.9939735,0.0024777143,0.0018546092,0.00042046516,0.000821792,0.00045192227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033197533,0.00027091525,0.0036058642,0.00090464053,0.00013570093,0.000010541719,0.00039375588,0.00018947815,0.0005157262],"category_scores_gemma":[0.003054635,0.00020588886,0.0016203596,0.0014869135,0.00027057686,0.00010968706,0.00027625987,0.0013757284,0.0000042529214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034541003,0.0010183743,0.9671459,0.00005878289,0.0077889366,0.0010508166,0.0032654072,0.00011338625,0.00054108055,0.00022538626,0.012839458,0.00249835],"study_design_scores_gemma":[0.0026765554,0.0144976685,0.9617026,0.00007637057,0.009310691,0.00039444707,0.0047102855,0.000092736205,0.000079362966,0.0002488465,0.0060281917,0.0001822755],"about_ca_topic_score_codex":0.00018018817,"about_ca_topic_score_gemma":0.00017225886,"teacher_disagreement_score":0.013479294,"about_ca_system_score_codex":0.00042180743,"about_ca_system_score_gemma":0.0013531205,"threshold_uncertainty_score":0.83959043},"labels":[],"label_agreement":null},{"id":"W4206730501","doi":"10.1200/jco.2022.40.4_suppl.427","title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Interim analysis; Tolerability; Interim; Oncology; Cohort; Population; Progression-free survival; Tumor progression; Clinical trial; Gastroenterology; Progressive disease; Phases of clinical research; Surgery; Adverse effect; Cancer; Disease; Chemotherapy","score_opus":0.1625817100748356,"score_gpt":0.46499766093313655,"score_spread":0.302415950858301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206730501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935652,0.00032395485,0.00003314387,0.0044863406,0.0004922867,0.0008102514,0.00008652295,0.0000065755385,0.00019574566],"genre_scores_gemma":[0.9981554,0.000041660656,0.00054490304,0.00083087775,0.00029081208,0.000039288174,0.000050738796,0.000016197404,0.000030132864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955514,0.0008248182,0.002681459,0.0002512402,0.00051016564,0.00018093623],"domain_scores_gemma":[0.99037343,0.0068967557,0.0018631675,0.00036802044,0.0003724793,0.00012616148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020624136,0.00014504885,0.0011327951,0.00015720446,0.00012538061,0.000010065725,0.00031079128,0.00006687825,0.00013979172],"category_scores_gemma":[0.0056729927,0.000080682104,0.00024451563,0.00043607975,0.00020836564,0.000079350124,0.00013380231,0.0010093994,0.0000026305686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0430649,0.015876064,0.8998423,0.000007873931,0.00075210293,0.00030217346,0.0057207746,0.000038633847,0.000012517631,0.0000059926283,0.0027045072,0.031672135],"study_design_scores_gemma":[0.056696452,0.027823055,0.9063939,0.00006486304,0.00058333843,0.000031882206,0.0049088066,0.00003235658,0.000006650825,0.000030022273,0.0033512437,0.00007741238],"about_ca_topic_score_codex":0.00028457187,"about_ca_topic_score_gemma":0.0005069153,"teacher_disagreement_score":0.03159472,"about_ca_system_score_codex":0.0001398899,"about_ca_system_score_gemma":0.0010006601,"threshold_uncertainty_score":0.6791512},"labels":[],"label_agreement":null},{"id":"W4206789975","doi":"10.1200/jco.2022.40.4_suppl.240","title":"Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Cancer; Randomized controlled trial; FOLFOX; Oncology; Chemotherapy; Gastroesophageal Junction; Gastroenterology; Adenocarcinoma; Oxaliplatin; Immunotherapy; Colorectal cancer","score_opus":0.14218708746149783,"score_gpt":0.46442552840616286,"score_spread":0.322238440944665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206789975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751194,0.008303443,0.0009827327,0.00973142,0.004236942,0.001257337,0.000110729554,0.000056562887,0.00020144065],"genre_scores_gemma":[0.9755421,0.014438016,0.0027752542,0.0016484638,0.003320582,0.00018215744,0.00010894646,0.000080991995,0.0019034492],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99495435,0.00026483677,0.002600503,0.000728064,0.00077181385,0.00068046025],"domain_scores_gemma":[0.9943315,0.0018719962,0.0024947452,0.00040039237,0.000319883,0.0005815225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011130861,0.0005233259,0.0028953461,0.00036188873,0.0003620359,0.00003429569,0.00035706654,0.00028405146,0.0012287818],"category_scores_gemma":[0.0004852285,0.0004345255,0.0010452487,0.0005239847,0.00021782187,0.0002054535,0.00018572426,0.0009123806,0.000004433433],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22554198,0.0028764256,0.09435271,0.000107021835,0.0049338033,0.00089934474,0.0005243043,0.00487307,0.0005822416,0.000023377888,0.004595867,0.66068983],"study_design_scores_gemma":[0.26561293,0.06688382,0.5911337,0.0001304629,0.006143981,0.00028364017,0.0009513189,0.0035359534,0.0009953172,0.00013899828,0.063638575,0.0005512887],"about_ca_topic_score_codex":0.0017096525,"about_ca_topic_score_gemma":0.0008575436,"teacher_disagreement_score":0.66013855,"about_ca_system_score_codex":0.0033000663,"about_ca_system_score_gemma":0.001886662,"threshold_uncertainty_score":0.99981064},"labels":[],"label_agreement":null},{"id":"W4206792321","doi":"10.1200/jco.2022.40.4_suppl.020","title":"Incomplete preoperative staging results in suboptimal treatment in rectal cancer patients: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Colorectal cancer; Stage (stratigraphy); Cancer registry; Population; Cancer; Cancer staging; Surgery; Cohort; Internal medicine","score_opus":0.13704459692707135,"score_gpt":0.4844871866361942,"score_spread":0.3474425897091229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206792321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512076,0.000094439056,0.0000011252798,0.0022711398,0.0007774263,0.0010239898,0.00004376138,0.0000073685496,0.0006599946],"genre_scores_gemma":[0.9985906,0.000026758737,0.0003944775,0.00049803103,0.00018680138,0.00017503023,0.000023600456,0.000016635164,0.000088079294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945784,0.0015674006,0.002714263,0.00032301593,0.00055147725,0.00026540403],"domain_scores_gemma":[0.99609816,0.0021885168,0.0011568592,0.00014611642,0.00020595461,0.00020441292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002078702,0.00017674938,0.0014842252,0.0003400921,0.00006275742,0.0000068439886,0.0001194019,0.00009868538,0.00028501978],"category_scores_gemma":[0.0015301537,0.00013184077,0.00027882215,0.0004869924,0.00003894582,0.00009299723,0.00008036934,0.0008854912,0.0000018070841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033912778,0.015038886,0.9175654,0.000004604771,0.00016758984,0.0014197199,0.00077658705,0.004383782,0.0000019238462,0.0000017419871,0.000039112172,0.026687846],"study_design_scores_gemma":[0.046002295,0.059759155,0.89142764,0.000047104742,0.00011376023,0.000009040785,0.0003915282,0.00080860464,0.0000037115428,0.00001607494,0.0013276659,0.000093418006],"about_ca_topic_score_codex":0.0027129701,"about_ca_topic_score_gemma":0.005408839,"teacher_disagreement_score":0.04472027,"about_ca_system_score_codex":0.0046241228,"about_ca_system_score_gemma":0.0020729199,"threshold_uncertainty_score":0.99919695},"labels":[],"label_agreement":null},{"id":"W4206807902","doi":"10.1200/jco.2022.40.4_suppl.008","title":"Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Bevacizumab; Oncology; Nivolumab; Colorectal cancer; Clinical endpoint; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy","score_opus":0.23524631327943235,"score_gpt":0.501040987722398,"score_spread":0.2657946744429657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206807902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795443,0.0047827857,0.00007112678,0.0060864957,0.0048211603,0.0013190338,0.0022849287,0.000030090365,0.0010600816],"genre_scores_gemma":[0.9891967,0.004553024,0.0030688082,0.0002597944,0.001519461,0.00036454617,0.00018182119,0.000060289804,0.00079552544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930891,0.0005048183,0.0043342994,0.00062767795,0.00085206574,0.0005920458],"domain_scores_gemma":[0.9876296,0.006871028,0.003925271,0.0003826842,0.00072305714,0.0004683478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016844647,0.0004967204,0.003693059,0.00022953255,0.0003646404,0.000015658441,0.00030486696,0.00024135681,0.00070336746],"category_scores_gemma":[0.0025040673,0.00036841768,0.0015062845,0.00035250114,0.00031132283,0.00014319606,0.0001713806,0.00068687403,0.000006840083],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4905436,0.019712025,0.003865706,0.00010073046,0.01095217,0.0015607189,0.002436847,0.00088293967,0.00065065606,0.00008265243,0.0056793164,0.46353263],"study_design_scores_gemma":[0.34093782,0.3207947,0.016026983,0.00016598328,0.008961464,0.00025041384,0.0019157119,0.0022784877,0.0024415697,0.0005808317,0.30509144,0.00055457663],"about_ca_topic_score_codex":0.0014517546,"about_ca_topic_score_gemma":0.003293057,"teacher_disagreement_score":0.46297804,"about_ca_system_score_codex":0.0023719522,"about_ca_system_score_gemma":0.0027138498,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W4206817023","doi":"10.1200/jco.2013.31.18_suppl.lba10504","title":"MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Clinical endpoint; Randomization; Surgery; Chemotherapy; Osteosarcoma; Stage (stratigraphy); Internal medicine; Response Evaluation Criteria in Solid Tumors; Concomitant; Progressive disease; Randomized controlled trial; Oncology; Pathology","score_opus":0.039691872270587375,"score_gpt":0.34050655602900914,"score_spread":0.3008146837584218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206817023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93716645,0.00054162927,0.000013297995,0.059775956,0.000854017,0.0015324204,0.000026052487,0.000008857515,0.00008129554],"genre_scores_gemma":[0.99619395,0.000094041905,0.0021877005,0.0006347286,0.00009039513,0.000061485545,0.000008820287,0.000025477899,0.00070342876],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99363154,0.0026917795,0.0024134344,0.00039195485,0.0004943223,0.00037695616],"domain_scores_gemma":[0.986615,0.010143046,0.0016203619,0.00044525345,0.0008422979,0.00033404527],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035965275,0.00027020407,0.0017678632,0.000233933,0.00008946772,0.000021305363,0.0002824278,0.0003396749,0.00007350762],"category_scores_gemma":[0.008948647,0.00014547394,0.00021695846,0.00028085796,0.0003497771,0.0001659491,0.00016892522,0.0007866427,0.000027804086],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8035231,0.0034610599,0.1826222,0.000032175492,0.00042467538,0.00036443173,0.0007000942,0.00015676024,0.00007149752,0.000023957311,0.0067055905,0.0019144343],"study_design_scores_gemma":[0.16597585,0.046576012,0.77828974,0.00053582544,0.0002443601,0.000041565752,0.00023368443,0.000055106088,0.00019765666,0.00004346269,0.007677632,0.00012913224],"about_ca_topic_score_codex":0.00027621418,"about_ca_topic_score_gemma":0.00062819355,"teacher_disagreement_score":0.63754725,"about_ca_system_score_codex":0.000691925,"about_ca_system_score_gemma":0.00079522433,"threshold_uncertainty_score":0.9993994},"labels":[],"label_agreement":null},{"id":"W4206819073","doi":"10.1200/jco.2021.39.15_suppl.5545","title":"Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Clinical endpoint; Progression-free survival; Ovarian cancer; Oncology; Progressive disease; Phases of clinical research; BRCA mutation; Placebo; Cancer; Chemotherapy; Clinical trial; Pathology","score_opus":0.08132424089107043,"score_gpt":0.47161472250334985,"score_spread":0.3902904816122794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206819073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9334654,0.0006505261,0.038726415,0.01733144,0.006292816,0.0013001453,0.00036673064,0.000041397627,0.0018251217],"genre_scores_gemma":[0.9401475,0.0048108087,0.02193941,0.026741913,0.0044120466,0.00010073008,0.00054844713,0.00011188464,0.0011872533],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927986,0.0006554432,0.004561938,0.0006713767,0.00070836756,0.0006042751],"domain_scores_gemma":[0.98814905,0.002866664,0.0042524925,0.00050559803,0.0035722353,0.0006539388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030983493,0.00040493684,0.0035850736,0.0003958652,0.00014065213,0.000028164943,0.00024624233,0.0007915306,0.00045795421],"category_scores_gemma":[0.0020039368,0.000333784,0.0017042042,0.0009929613,0.0003255291,0.00025786422,0.00005552198,0.0015206254,0.00001325633],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1879217,0.030330908,0.07768453,0.00038240643,0.029846746,0.0025105907,0.00206691,0.0019979517,0.028722802,0.00019380263,0.15167002,0.48667163],"study_design_scores_gemma":[0.35684767,0.034426425,0.3399415,0.001402172,0.0050993785,0.0003711696,0.0003186164,0.010705344,0.010265997,0.0009288564,0.23867594,0.0010169214],"about_ca_topic_score_codex":0.00005117765,"about_ca_topic_score_gemma":0.00006174415,"teacher_disagreement_score":0.4856547,"about_ca_system_score_codex":0.0011336529,"about_ca_system_score_gemma":0.0048315628,"threshold_uncertainty_score":0.9999114},"labels":[],"label_agreement":null},{"id":"W4206922330","doi":"10.1200/jco.2022.40.36_suppl.359881","title":"INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Sunitinib; GiST; Imatinib; Internal medicine; Clinical endpoint; Population; Imatinib mesylate; Interim analysis; Oncology; Randomization; Tyrosine-kinase inhibitor; Gastroenterology; Surgery; Randomized controlled trial; Cancer; Stromal cell","score_opus":0.09788494523111237,"score_gpt":0.46943147212767905,"score_spread":0.3715465268965667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206922330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207246,0.00004258678,0.00004787677,0.0010297972,0.000065182176,0.0063820006,0.000023724415,0.0000072395014,0.00032911322],"genre_scores_gemma":[0.99114805,0.000009122882,0.008394663,0.0001510515,0.00005624102,0.0001700533,0.000013960004,0.000027568653,0.000029306633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99231976,0.003090043,0.0026896005,0.00036952674,0.0010562383,0.00047483871],"domain_scores_gemma":[0.988378,0.007924337,0.001781531,0.00034447317,0.00095315714,0.00061850634],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0088289725,0.00028503238,0.002753238,0.00022047981,0.00014226911,0.000022827602,0.00043758753,0.000021760266,0.00015337655],"category_scores_gemma":[0.009734856,0.00014517996,0.00013162097,0.00046976795,0.0004792605,0.0001135682,0.0003808909,0.0013618182,0.0000014831828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7966692,0.036279473,0.1512644,0.000015135386,0.0005007593,0.002087057,0.00026627645,0.000093368464,0.000011681591,0.0000113505985,0.000042001368,0.012759309],"study_design_scores_gemma":[0.5612568,0.3149568,0.12093885,0.0002753245,0.0006238486,0.0007947733,0.0009308035,0.00010458283,0.0000044256094,0.000005337653,0.000036400583,0.00007202295],"about_ca_topic_score_codex":0.00012312012,"about_ca_topic_score_gemma":0.00010205161,"teacher_disagreement_score":0.27867734,"about_ca_system_score_codex":0.00026831104,"about_ca_system_score_gemma":0.0017125414,"threshold_uncertainty_score":0.99860656},"labels":[],"label_agreement":null},{"id":"W4210620015","doi":"10.1200/jco.21.02377","title":"Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Adverse effect; Chemotherapy; Pharmacogenomics; Clinical trial; Drug; Cancer; Modalities; Cancer treatment","score_opus":0.19273730881806414,"score_gpt":0.4954685399841905,"score_spread":0.3027312311661263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210620015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338275,0.0018296954,0.00000429448,0.0016889278,0.0021106375,0.00085685536,0.0000261148,0.000005412897,0.000095308664],"genre_scores_gemma":[0.9617618,0.03519906,0.00030848966,0.0021432538,0.0003157847,0.000040655108,0.0000038169937,0.000030396326,0.00019678324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98148364,0.008798336,0.008336589,0.0003481553,0.0006735037,0.00035976677],"domain_scores_gemma":[0.98579234,0.007654679,0.00592723,0.0002845462,0.00018623819,0.00015494914],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.033793543,0.00025000438,0.0039820964,0.00051025586,0.000042326705,0.00000240709,0.00042475254,0.000474612,0.0019721484],"category_scores_gemma":[0.0049737003,0.00016715832,0.0010363908,0.00073065504,0.0002009475,0.00012414559,0.00006901456,0.0023553781,8.3051333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12186218,0.0050968346,0.59927064,0.000011333754,0.0005122286,0.00004395328,0.000525229,0.00003693095,0.00008898583,3.2923109e-7,0.00020885553,0.2723425],"study_design_scores_gemma":[0.08947843,0.017589035,0.88692516,0.00022826817,0.00005495784,0.000013625498,0.0005990828,0.000066144225,0.000027204134,0.000096903896,0.004764061,0.00015712251],"about_ca_topic_score_codex":0.000990268,"about_ca_topic_score_gemma":0.0011072964,"teacher_disagreement_score":0.28765452,"about_ca_system_score_codex":0.0006348871,"about_ca_system_score_gemma":0.0026406774,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W4212773488","doi":"10.1200/jco.2022.40.6_suppl.224","title":"Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cabazitaxel; Internal medicine; Prostatectomy; Randomized controlled trial; Abiraterone acetate; Urology; Prostate; Oncology; Neoadjuvant therapy; Prednisone; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.14061371387660235,"score_gpt":0.5090536018849796,"score_spread":0.36843988800837724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212773488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815746,0.0032117446,0.000010296956,0.009996901,0.002923622,0.0019632664,0.00010306975,0.000007811226,0.00020869198],"genre_scores_gemma":[0.9793153,0.013854901,0.0005925018,0.0004820462,0.0011623341,0.00024573688,0.000017717697,0.000029262083,0.004300244],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916983,0.0024313224,0.004334761,0.00028195887,0.00082359964,0.00043005813],"domain_scores_gemma":[0.99164885,0.0040261243,0.0032953767,0.00024010813,0.00040110858,0.00038840174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010843166,0.00020453356,0.0039859437,0.00034104625,0.00012437538,0.0000067551887,0.00026524675,0.00022386563,0.001023743],"category_scores_gemma":[0.004918665,0.000119013006,0.00071481644,0.00037555388,0.0004967458,0.000100272475,0.000215377,0.0019107461,0.0000030768203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8548308,0.008111446,0.00092198723,0.000043509033,0.0008222091,0.002938744,0.00071506476,0.00016503628,0.00016819368,0.000011214171,0.0032963604,0.12797545],"study_design_scores_gemma":[0.861632,0.11517692,0.00049807684,0.00009312939,0.00072573294,0.00013240962,0.00031991123,0.0002862822,0.00019173528,0.00023973819,0.020601446,0.000102635735],"about_ca_topic_score_codex":0.00089184544,"about_ca_topic_score_gemma":0.00026622321,"teacher_disagreement_score":0.12787281,"about_ca_system_score_codex":0.0008341846,"about_ca_system_score_gemma":0.0077749803,"threshold_uncertainty_score":0.99988943},"labels":[],"label_agreement":null},{"id":"W4212779525","doi":"10.1200/jco.2022.40.6_suppl.313","title":"Mixed methods assessment of providers’ needs in the management of advanced renal cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Eisai Incorporated","keywords":"Medicine; Multidisciplinary approach; Renal cell carcinoma; Adverse effect; Family medicine; Health professionals; Internal medicine; Nursing; Health care","score_opus":0.15636773416292116,"score_gpt":0.4439124119965805,"score_spread":0.28754467783365933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212779525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9352386,0.0017097538,0.0035599337,0.0023959302,0.0017784287,0.00026095493,0.000030346284,0.0000015617169,0.0550245],"genre_scores_gemma":[0.9629009,0.0004207248,0.035731304,0.0005847802,0.0001181058,0.000015938493,0.0000012901091,0.000010351009,0.00021660357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99544495,0.00040350496,0.0036969248,0.00015995804,0.000087274835,0.00020737741],"domain_scores_gemma":[0.9938231,0.000935718,0.0048437207,0.0002548729,0.000070235335,0.000072365176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012210196,0.00010466836,0.0013466876,0.00029093385,0.00004089524,0.0000066644657,0.00060539995,0.00010861507,0.00022329715],"category_scores_gemma":[0.00022645343,0.00009002244,0.00043080465,0.00029788987,0.00012547393,0.00016344593,0.00015851425,0.00072095497,0.0000018226256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021706645,0.005410043,0.22358003,0.0003047912,0.00062609266,0.00018932941,0.0026412008,0.013407565,0.00014312999,0.2876039,0.0074057677,0.4565175],"study_design_scores_gemma":[0.005800479,0.006681784,0.73682237,0.000019353285,0.000071812574,0.00001675877,0.0035943203,0.00050993427,0.000081299826,0.021950476,0.22428961,0.00016180315],"about_ca_topic_score_codex":0.00005875009,"about_ca_topic_score_gemma":0.000011224456,"teacher_disagreement_score":0.5132423,"about_ca_system_score_codex":0.00024041678,"about_ca_system_score_gemma":0.00039078348,"threshold_uncertainty_score":0.42318347},"labels":[],"label_agreement":null},{"id":"W4212779820","doi":"10.1200/jco.2022.40.6_suppl.085","title":"Exposure-adjusted safety analyses of the VISION phase 3 trial of <sup>177</sup>Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Incidence (geometry); Adverse effect; Internal medicine; Clinical endpoint; Taxane; Oncology; Confidence interval; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.17771800703188737,"score_gpt":0.5205111701276368,"score_spread":0.3427931630957495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212779820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956939,0.00051487726,0.000004709873,0.0021502227,0.00030011454,0.0010827843,0.00011813764,0.0000022755346,0.00013297143],"genre_scores_gemma":[0.99887055,0.00036119472,0.0003030027,0.000118638956,0.00011175062,0.000029343732,0.000021194666,0.000013863749,0.00017043539],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944325,0.0013286612,0.0027529732,0.00018909862,0.0010681257,0.00022864046],"domain_scores_gemma":[0.9953218,0.0012013215,0.0023906606,0.00024424275,0.0006732335,0.00016872116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028290255,0.0001414747,0.0014569828,0.0002140556,0.0000835087,0.0000049827718,0.0002138075,0.00008160673,0.00022824242],"category_scores_gemma":[0.0010236144,0.00007310116,0.00037239539,0.0005774347,0.00031780993,0.00010150437,0.000086735694,0.0008520308,3.0514568e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79203945,0.014809985,0.121433035,0.00012519248,0.0012771807,0.00026531826,0.00080993574,0.004663127,0.00077164173,0.000011569975,0.0004237614,0.06336982],"study_design_scores_gemma":[0.4870159,0.1391036,0.36739853,0.00028879504,0.0014198591,0.000019577259,0.0013638429,0.00044308577,0.0008690826,0.00007625101,0.0018811519,0.00012033623],"about_ca_topic_score_codex":0.00020239012,"about_ca_topic_score_gemma":0.00014956816,"teacher_disagreement_score":0.30502352,"about_ca_system_score_codex":0.0003728795,"about_ca_system_score_gemma":0.0037720336,"threshold_uncertainty_score":0.66914254},"labels":[],"label_agreement":null},{"id":"W4212780237","doi":"10.1200/jco.2022.40.6_suppl.012","title":"Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Abiraterone acetate; Enzalutamide; Oncology; Progression-free survival; Cancer; Androgen deprivation therapy; Androgen receptor; Randomized controlled trial; Chemotherapy","score_opus":0.08166941178403357,"score_gpt":0.42743641200162674,"score_spread":0.34576700021759316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212780237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355954,0.00050843856,0.000061262384,0.0036595794,0.00015344049,0.0018845665,0.000105420266,0.000017357754,0.00005042055],"genre_scores_gemma":[0.99179184,0.0014571393,0.0056816568,0.000528049,0.000077691606,0.0002485818,0.000039121165,0.000039623475,0.0001362869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955411,0.0007618254,0.0022717547,0.000454565,0.00071367505,0.00025705446],"domain_scores_gemma":[0.9955055,0.0005561537,0.0025796266,0.0002684256,0.00086877844,0.00022149808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024953932,0.00027101778,0.0014018224,0.00028131623,0.00018866907,0.000022704226,0.0001040277,0.00008377186,0.00005894652],"category_scores_gemma":[0.0002452209,0.00017908184,0.00007212204,0.0003863501,0.00039590348,0.0002601509,0.000038951915,0.0007312207,3.4559343e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40788275,0.028646132,0.5135117,0.0001473063,0.0020366206,0.00088135124,0.0052577136,0.0033942896,0.0005081762,0.000010480139,0.00033196618,0.037391488],"study_design_scores_gemma":[0.2617451,0.3602795,0.37263873,0.00031002448,0.00064172025,0.00051369925,0.0007581025,0.0003533793,0.0005284859,0.00008971786,0.0018706485,0.00027088734],"about_ca_topic_score_codex":0.00029957388,"about_ca_topic_score_gemma":0.0030425787,"teacher_disagreement_score":0.33163336,"about_ca_system_score_codex":0.00031672232,"about_ca_system_score_gemma":0.0012714288,"threshold_uncertainty_score":0.73027456},"labels":[],"label_agreement":null},{"id":"W4212782745","doi":"10.1200/jco.2022.40.6_suppl.318","title":"CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Ipsen","keywords":"Medicine; Cabozantinib; Ipilimumab; Nivolumab; Internal medicine; Renal cell carcinoma; Oncology; Hazard ratio; Cohort; Clear cell renal cell carcinoma; Cancer; Immunotherapy; Confidence interval","score_opus":0.05525645971141906,"score_gpt":0.35960726905927937,"score_spread":0.3043508093478603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212782745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822687,0.00067703554,0.000023211047,0.010734656,0.0019877746,0.0010805392,0.00089224445,0.000007408909,0.002328455],"genre_scores_gemma":[0.9952316,0.00006559661,0.001774565,0.0015098952,0.00027623767,0.00004365549,0.0007022925,0.000041448813,0.00035465218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99103326,0.0023892617,0.0042050877,0.0005295101,0.0013846371,0.00045824263],"domain_scores_gemma":[0.98138726,0.011578062,0.004648447,0.00086052384,0.0012277593,0.00029793772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042374902,0.0003563049,0.0017667438,0.00026888418,0.00022561644,0.000017879194,0.001034658,0.00016447977,0.00035349125],"category_scores_gemma":[0.0028271908,0.00020214317,0.0005596388,0.00034047788,0.00062413735,0.00017096383,0.0005125566,0.0022135251,0.000010418614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23157871,0.04914625,0.6447136,0.00007751052,0.0019086449,0.0058142794,0.0067397635,0.0031632388,0.0076197656,0.0002087995,0.026835904,0.022193575],"study_design_scores_gemma":[0.088477954,0.027237933,0.86163896,0.0000507892,0.0011420054,0.00018038032,0.0020376677,0.0001530028,0.0015257077,0.000040503717,0.017319141,0.00019592611],"about_ca_topic_score_codex":0.00095920684,"about_ca_topic_score_gemma":0.00046857947,"teacher_disagreement_score":0.21692543,"about_ca_system_score_codex":0.0008309805,"about_ca_system_score_gemma":0.0043462375,"threshold_uncertainty_score":0.96167886},"labels":[],"label_agreement":null},{"id":"W4212819065","doi":"10.1200/jco.2022.40.6_suppl.252","title":"Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Jewish General Hospital; Ottawa Hospital; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; McMaster University; Juravinski Cancer Centre; University of Manitoba; St. Joseph’s Healthcare Hamilton; University of Toronto; Hôpital Charles-Le Moyne; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Ottawa","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Cohort; Internal medicine; Cabazitaxel; Docetaxel; Cancer; Prednisone; Prospective cohort study; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.17470189149900983,"score_gpt":0.5368501938432154,"score_spread":0.3621483023442056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212819065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715544,0.0003700007,0.0000041171197,0.004172491,0.0007118109,0.0013283709,0.000048085367,0.000005579994,0.00620409],"genre_scores_gemma":[0.9918572,0.001179331,0.0014996143,0.00027720077,0.00017804757,0.00016042708,0.000012356694,0.00001457936,0.004821299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956857,0.0005926911,0.0020073932,0.00020083206,0.0013032131,0.00021015963],"domain_scores_gemma":[0.9969872,0.00062568695,0.001323926,0.00013525638,0.00072654,0.00020138135],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045398637,0.00011337381,0.000966908,0.00023651507,0.00009107382,0.0000070740366,0.00015243345,0.000031188705,0.00091856095],"category_scores_gemma":[0.00017060449,0.0000792165,0.00028108078,0.00031599496,0.00013469864,0.00007441792,0.000116041236,0.0006407685,0.0000034876905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026941799,0.012608912,0.92213315,0.0001996978,0.006271506,0.003912631,0.000516544,0.00047035317,0.00026377328,0.00032970353,0.005670325,0.020681633],"study_design_scores_gemma":[0.018078987,0.011220418,0.95086205,0.00007564043,0.0011221432,0.000034854525,0.0015422378,0.0001499585,0.000046121502,0.00021116433,0.016579868,0.00007655807],"about_ca_topic_score_codex":0.00021700664,"about_ca_topic_score_gemma":0.00028086518,"teacher_disagreement_score":0.028728925,"about_ca_system_score_codex":0.0007650835,"about_ca_system_score_gemma":0.0021880073,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4212821853","doi":"10.1200/jco.2022.40.6_suppl.tps200","title":"A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Docetaxel; Adverse effect; Placebo; Tolerability; Clinical endpoint; Abiraterone acetate; Randomized controlled trial; Cancer; Androgen receptor; Pathology","score_opus":0.1408623413131093,"score_gpt":0.5041841219842379,"score_spread":0.36332178067112864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212821853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890762,0.0023522244,0.000021703632,0.0035317633,0.00042235284,0.0044517955,0.000041191415,0.0000041019016,0.000098685785],"genre_scores_gemma":[0.9948213,0.003675836,0.00019563957,0.00043992235,0.00014084058,0.0006202951,0.00001838715,0.000016723512,0.00007106951],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930187,0.0029743384,0.002814883,0.00023771309,0.0006885155,0.000265869],"domain_scores_gemma":[0.9931052,0.0046641477,0.0014708597,0.00014391793,0.0004227677,0.00019315259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0084167505,0.00015753218,0.0034287078,0.00056572,0.000046703008,0.000005859775,0.00011366887,0.000077958815,0.00013679522],"category_scores_gemma":[0.002882686,0.00010471016,0.0003943994,0.00051574426,0.0001315953,0.0001085353,0.00006157699,0.00086903217,0.000001669947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92835367,0.010343624,0.0039266916,0.000009468294,0.001553805,0.0015449486,0.002566535,0.0008500731,0.0006764053,0.0000049907844,0.0002205578,0.049949255],"study_design_scores_gemma":[0.936552,0.047680635,0.010578069,0.000052482406,0.0004958915,0.00003482297,0.0029077106,0.0006367076,0.00022301983,0.00011355772,0.0006384332,0.00008671128],"about_ca_topic_score_codex":0.00041841556,"about_ca_topic_score_gemma":0.00048645693,"teacher_disagreement_score":0.049862545,"about_ca_system_score_codex":0.0006142949,"about_ca_system_score_gemma":0.0017245504,"threshold_uncertainty_score":0.42699564},"labels":[],"label_agreement":null},{"id":"W4212858891","doi":"10.1200/jco.2022.40.36_suppl.360490","title":"First data for sotorasib in patients with pancreatic cancer with <i>KRAS</i> p.G12C mutation: A phase I/II study evaluating efficacy and safety","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"KRAS; Medicine; Pancreatic cancer; Clinical endpoint; Internal medicine; Oncology; Stage (stratigraphy); Cancer; Phases of clinical research; Pancreas; Clinical trial; Gastroenterology; Colorectal cancer","score_opus":0.2485349792514154,"score_gpt":0.5629428002952457,"score_spread":0.31440782104383025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212858891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934888,0.00026142228,0.00017638813,0.0033332722,0.0001781999,0.0023574173,0.000060079994,0.000005664392,0.00013876722],"genre_scores_gemma":[0.9928157,0.00009630466,0.005816582,0.00066228013,0.00026044482,0.00015596348,0.000041646028,0.000023008643,0.00012812096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590355,0.00085305946,0.0017984669,0.00036564545,0.00077850476,0.00030078748],"domain_scores_gemma":[0.99173415,0.005755091,0.0013005309,0.0003772693,0.0005420152,0.00029095396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00769549,0.00015976193,0.0018131003,0.00014922519,0.0003089805,0.000008833349,0.0002842726,0.000104605184,0.00022181951],"category_scores_gemma":[0.0041489503,0.00010027218,0.000063037296,0.0002734354,0.00022903812,0.00014223022,0.00026228317,0.0009927042,5.767009e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09144039,0.015146351,0.85207367,0.000058485803,0.0008161284,0.00033571248,0.00073329796,0.00014221574,0.0000018838531,0.0000049090813,0.00075670105,0.03849026],"study_design_scores_gemma":[0.12087171,0.22763695,0.6430268,0.00012162567,0.0014132994,0.000093998795,0.0009161106,0.0022593592,1.6878896e-7,0.000017430211,0.0035540326,0.0000884851],"about_ca_topic_score_codex":0.00008992546,"about_ca_topic_score_gemma":0.00043484644,"teacher_disagreement_score":0.21249059,"about_ca_system_score_codex":0.00031435527,"about_ca_system_score_gemma":0.0035305691,"threshold_uncertainty_score":0.6263078},"labels":[],"label_agreement":null},{"id":"W4212861966","doi":"10.1200/jco.2022.40.6_suppl.tps404","title":"Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lenvatinib; Clear cell renal cell carcinoma; Pembrolizumab; Internal medicine; Renal cell carcinoma; Oncology; Phases of clinical research; Clinical trial; Kidney cancer; Tolerability; Adverse effect; Cancer; Immunotherapy","score_opus":0.06351321590298831,"score_gpt":0.38292504736327515,"score_spread":0.31941183146028684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212861966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971297,0.00076019054,0.000025985833,0.0005231516,0.00029663532,0.001030767,0.000018922236,0.0000047647686,0.00020991774],"genre_scores_gemma":[0.9964026,0.00003786331,0.0030476449,0.00020770077,0.00009298975,0.00003379156,0.00003961852,0.000024924115,0.00011283209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670154,0.0005540768,0.0017589816,0.00022410936,0.0005927305,0.0001685434],"domain_scores_gemma":[0.9954368,0.001258501,0.0022151892,0.00016957175,0.00070464,0.0002152851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013247038,0.0001600623,0.0010781495,0.00016309286,0.000116545096,0.0000050350104,0.00012408142,0.00009508365,0.000057668592],"category_scores_gemma":[0.00029100975,0.000115264535,0.00020308323,0.0001446411,0.00016753079,0.00008374643,0.00006977509,0.0005436958,5.284718e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1185681,0.2061917,0.61280084,0.00026098196,0.0010695106,0.00038815133,0.0037762527,0.00040953248,0.01491319,0.00006904632,0.0012465857,0.040306102],"study_design_scores_gemma":[0.13249,0.3384517,0.5231581,0.000017322876,0.0005695059,0.000032163694,0.0012968703,0.00014544169,0.0019935032,0.00015285269,0.00158634,0.00010619179],"about_ca_topic_score_codex":0.000013789249,"about_ca_topic_score_gemma":0.0000037595212,"teacher_disagreement_score":0.13226001,"about_ca_system_score_codex":0.00017005793,"about_ca_system_score_gemma":0.00070278073,"threshold_uncertainty_score":0.47003514},"labels":[],"label_agreement":null},{"id":"W4212864413","doi":"10.1200/jco.2022.40.6_suppl.tps210","title":"PSMAddition: A phase 3 trial to compare treatment with <sup>177</sup>Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Androgen deprivation therapy; Oncology; Internal medicine; Hazard ratio; Urology; Nuclear medicine; Randomized controlled trial; Cancer; Confidence interval","score_opus":0.12006038377425364,"score_gpt":0.47611275525506047,"score_spread":0.3560523714808068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212864413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228185,0.0008411007,0.000013733213,0.0028517025,0.00032671055,0.0023753,0.0010855853,0.000008596794,0.00021542335],"genre_scores_gemma":[0.9973208,0.00052415737,0.001043553,0.00021256853,0.00029919547,0.00022925859,0.00021831856,0.000033442364,0.000118727075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99571204,0.0007265504,0.0016264634,0.00034794395,0.0011606325,0.0004263926],"domain_scores_gemma":[0.9959282,0.0010417867,0.0011882304,0.00022575214,0.0011156839,0.0005003291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008739025,0.0002696354,0.0025222625,0.00028404416,0.00012776547,0.000011368444,0.00013749616,0.00007001959,0.00019429885],"category_scores_gemma":[0.00023663556,0.00016427734,0.00029326338,0.0004574483,0.00030089883,0.00011108024,0.00007673609,0.0008006342,0.0000021887931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9267083,0.005543941,0.008570897,0.00005240503,0.0018786548,0.0023508042,0.0047569205,0.001683074,0.0000050928184,0.000004447415,0.0014606204,0.04698485],"study_design_scores_gemma":[0.55655825,0.41809627,0.007715148,0.0001578851,0.0011254438,0.000033733795,0.008862293,0.00006657198,0.000097115284,0.000008068461,0.0071271164,0.00015211159],"about_ca_topic_score_codex":0.00020179518,"about_ca_topic_score_gemma":0.0005981609,"teacher_disagreement_score":0.41255233,"about_ca_system_score_codex":0.0031812543,"about_ca_system_score_gemma":0.0065933154,"threshold_uncertainty_score":0.9990384},"labels":[],"label_agreement":null},{"id":"W4212868495","doi":"10.1200/jco.2022.40.6_suppl.187","title":"Trends in disease burden from prostate cancer amongst different regions of the world and extensively the European Union 15+ countries, from 1990 to 2019: Estimates from the Global Burden of Disease study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; European union; Prostate cancer; Disease burden; Demography; Incidence (geometry); Burden of disease; Disease; Global health; Cancer; Environmental health; Public health; Population; Pathology; Internal medicine; International trade","score_opus":0.05250379207331117,"score_gpt":0.3974270707622168,"score_spread":0.3449232786889056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212868495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8861732,0.0075602015,0.0000023221162,0.10278129,0.00061340287,0.00060824305,0.0022160616,0.0000039783827,0.000041303447],"genre_scores_gemma":[0.99532306,0.002155633,0.000029184646,0.0016501176,0.0006146926,0.000053575986,0.000047089365,0.000017201579,0.000109459455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562305,0.0018939879,0.001440459,0.00029829005,0.0005486436,0.00019557853],"domain_scores_gemma":[0.9947667,0.0028162778,0.0013434981,0.00047014587,0.00020932629,0.00039402273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011346964,0.00019451596,0.0009838995,0.00005707246,0.00013076475,0.00001693785,0.00040704902,0.000032374417,0.00017748933],"category_scores_gemma":[0.00070918974,0.000088287496,0.0002848852,0.00029151211,0.00037468973,0.000046617228,0.00046450848,0.00054743845,9.3013364e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059305527,0.0015129072,0.94893855,0.0000054415646,0.000624349,0.00034110327,0.0015737369,0.0008401886,0.000008871469,0.000025628253,0.009741954,0.030456726],"study_design_scores_gemma":[0.0060268687,0.002112381,0.96833766,0.00029424342,0.0016158744,0.0000016342069,0.0011620075,0.00010165992,0.00000448155,0.0010187537,0.019243909,0.00008050232],"about_ca_topic_score_codex":0.014780315,"about_ca_topic_score_gemma":0.006338356,"teacher_disagreement_score":0.10914985,"about_ca_system_score_codex":0.00036421663,"about_ca_system_score_gemma":0.00069779105,"threshold_uncertainty_score":0.99178034},"labels":[],"label_agreement":null},{"id":"W4212871063","doi":"10.1200/jco.2022.40.6_suppl.172","title":"Correlation of ABI1 and PTEN expression during prostate tumor progression.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia","funders":"National Institutes of Health","keywords":"PTEN; Cancer research; Protein kinase B; Downregulation and upregulation; Tumor progression; Prostate cancer; PI3K/AKT/mTOR pathway; Cancer; Biology; Medicine; Signal transduction; Internal medicine; Cell biology; Gene","score_opus":0.06565843723274652,"score_gpt":0.45995210069204195,"score_spread":0.39429366345929545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212871063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468815,0.0012847177,0.000008183214,0.0028778743,0.00053916353,0.00020737198,0.000003432852,0.000003553792,0.0003875413],"genre_scores_gemma":[0.9979029,0.00047721463,0.0010193599,0.00022533014,0.00022363977,0.00001715737,0.0000016590208,0.000007198537,0.0001254829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981991,0.00018805622,0.0011415784,0.00010307226,0.00027974273,0.000088455476],"domain_scores_gemma":[0.9977395,0.0005140299,0.0013938629,0.000079745885,0.00012729956,0.00014557337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010199284,0.000058858237,0.0006369927,0.000069206755,0.000058379628,0.000002319457,0.00004038584,0.000050522034,0.00018187569],"category_scores_gemma":[0.0004745858,0.00003871106,0.00015682023,0.00006275619,0.00007227207,0.000049514103,0.00008149585,0.0004267305,7.901004e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075405,0.0029582342,0.8562411,0.00006979565,0.0001428809,0.000839153,0.0002894892,0.0001268588,0.0014999176,0.000025444619,0.0021359848,0.12813064],"study_design_scores_gemma":[0.0104151005,0.013568271,0.9541178,0.00023374999,0.00023474975,0.0007542311,0.00022273543,0.0001400214,0.0010914112,0.00012616812,0.019048244,0.00004753477],"about_ca_topic_score_codex":0.000005112475,"about_ca_topic_score_gemma":0.0000018395393,"teacher_disagreement_score":0.12808311,"about_ca_system_score_codex":0.0001102899,"about_ca_system_score_gemma":0.00041134094,"threshold_uncertainty_score":0.19914111},"labels":[],"label_agreement":null},{"id":"W4212879952","doi":"10.1200/jco.2022.40.6_suppl.053","title":"Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Dalhousie University; University of Toronto; BC Cancer Agency; Ottawa Hospital; University of Calgary; Princess Margaret Cancer Centre; Jewish General Hospital; University of Ottawa; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Population; Cancer; Enzalutamide; Disease; Androgen receptor","score_opus":0.06834058048368173,"score_gpt":0.43431885696779426,"score_spread":0.3659782764841125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212879952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971939,0.0000794397,0.000004362922,0.0007811516,0.00033079914,0.0014373708,0.00015153675,0.0000010812888,0.000020411422],"genre_scores_gemma":[0.9991154,0.0000063535276,0.00031583983,0.00016804032,0.000040291114,0.00012226826,0.00009132728,0.000011949809,0.00012853979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975146,0.00021215655,0.0013379898,0.00014519524,0.0006075932,0.00018243518],"domain_scores_gemma":[0.99746203,0.0006836194,0.0009782172,0.000107451975,0.00062365935,0.00014503468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000697359,0.00009539548,0.0008762643,0.00012391174,0.00006745366,0.0000035188673,0.000090525085,0.0000313243,0.00015012205],"category_scores_gemma":[0.0001801266,0.0000641089,0.00010412414,0.00012155154,0.000017937497,0.00003882309,0.000020405929,0.0005000868,4.099961e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021319553,0.0027765057,0.96861434,0.00009779408,0.00022208267,0.000285154,0.0007088842,0.0013482238,0.0000028856605,8.24089e-7,0.00011572904,0.0045080227],"study_design_scores_gemma":[0.026581915,0.039267123,0.93068844,0.000079412086,0.00023124355,0.0000018454662,0.0020392735,0.00003405429,0.000006430659,0.000005735958,0.0010086374,0.000055897493],"about_ca_topic_score_codex":0.7487063,"about_ca_topic_score_gemma":0.9910735,"teacher_disagreement_score":0.24236716,"about_ca_system_score_codex":0.0021543866,"about_ca_system_score_gemma":0.019343095,"threshold_uncertainty_score":0.9862163},"labels":[],"label_agreement":null},{"id":"W4212884503","doi":"10.1200/jco.2022.40.6_suppl.363","title":"A prospective randomized parallel-controlled pilot trial of stereotactic body radiation therapy versus radiofrequency ablation for the management of small renal masses.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Radiofrequency ablation; Renal cell carcinoma; Chromophobe cell; Randomized controlled trial; Percutaneous; Radiology; Radiosurgery; Surgery; Clinical trial; Prospective cohort study; Ablation; Nuclear medicine; Radiation therapy; Clear cell; Internal medicine","score_opus":0.14709121753467136,"score_gpt":0.42575915079908083,"score_spread":0.2786679332644095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212884503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97656363,0.0034554598,0.0017097789,0.0036515933,0.0027022734,0.009615373,0.000006200258,0.000007019769,0.0022886947],"genre_scores_gemma":[0.99132806,0.0030313216,0.0041193045,0.00011657721,0.0006305502,0.0005496732,0.0000060571415,0.000017582137,0.00020089032],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994156,0.0016329257,0.003280735,0.00018519332,0.0005759458,0.00016917883],"domain_scores_gemma":[0.9827434,0.011527846,0.004969345,0.00024866877,0.00041007236,0.00010067998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009564558,0.00015585155,0.002592674,0.00015016054,0.000075279124,0.0000056953,0.00018862919,0.00009355841,0.00012476483],"category_scores_gemma":[0.0015401221,0.00008768404,0.0013640134,0.00015242396,0.00016369109,0.00005907514,0.00003378127,0.0004812107,5.263858e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95744544,0.003531152,0.00080744695,0.000035651654,0.007751323,0.00008344547,0.0001279059,0.0003221162,0.00012348138,0.00094473583,0.00009335347,0.028733961],"study_design_scores_gemma":[0.8867202,0.09200676,0.013379603,0.000023772862,0.0036445113,0.000039735773,0.00010054554,0.00084446877,0.000076806195,0.0010149389,0.002087472,0.00006123287],"about_ca_topic_score_codex":0.000024523317,"about_ca_topic_score_gemma":0.0000028263444,"teacher_disagreement_score":0.08847561,"about_ca_system_score_codex":0.00044129175,"about_ca_system_score_gemma":0.0008549983,"threshold_uncertainty_score":0.35756513},"labels":[],"label_agreement":null},{"id":"W4212884885","doi":"10.1200/jco.2022.40.6_suppl.411","title":"Accuracy of germ cell tumor histological subtype and stage within the Canadian cancer registry.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Cancer registry; Stage (stratigraphy); Germ cell tumors; Seminoma; Population; Cohort; Cancer; Biopsy; Testicular cancer; Internal medicine; Oncology; Chemotherapy","score_opus":0.11368252527772313,"score_gpt":0.4477183990521462,"score_spread":0.3340358737744231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212884885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98365843,0.005041069,0.0000016160037,0.009309617,0.00057961344,0.00014187123,0.000038326187,0.000002583377,0.0012268622],"genre_scores_gemma":[0.9959996,0.00015589339,0.00038253417,0.0027151806,0.00017055143,0.0000043649306,0.0000028864742,0.000007090707,0.0005619491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982227,0.00031748787,0.0009472127,0.00011367974,0.0002620048,0.00013691136],"domain_scores_gemma":[0.99532795,0.0010994916,0.00281904,0.00016200823,0.0001586772,0.0004328143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011865381,0.00007671634,0.0006324006,0.000045900568,0.00011603896,0.000004674385,0.00013636918,0.000076328404,0.00042741743],"category_scores_gemma":[0.0042999,0.00004295144,0.00020787519,0.00007869008,0.0002365597,0.0000231901,0.000055188924,0.0006998391,0.0000014068518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021317718,0.001346585,0.96546876,0.000046050518,0.0003104477,0.005404697,0.00013468775,0.000080887854,0.00003419005,0.00053357193,0.0052947397,0.019213606],"study_design_scores_gemma":[0.004054022,0.0059416476,0.8577385,0.000020962132,0.00064409507,0.0006992803,0.00026918887,0.000091335154,0.000012900423,0.00023455931,0.1302363,0.000057227786],"about_ca_topic_score_codex":0.024073526,"about_ca_topic_score_gemma":0.026673293,"teacher_disagreement_score":0.12494156,"about_ca_system_score_codex":0.00030345598,"about_ca_system_score_gemma":0.009896279,"threshold_uncertainty_score":0.9957167},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"reporting","study_design":"observational","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"split"},{"id":"W4212895767","doi":"10.1200/jco.2022.40.6_suppl.tps285","title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Urology; Prostatectomy; Clinical endpoint; Perioperative; Lymph node; Internal medicine; Nuclear medicine; Oncology; Cancer; Surgery; Randomized controlled trial","score_opus":0.08082467148519223,"score_gpt":0.45035102151859246,"score_spread":0.36952635003340023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212895767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96813,0.0009652288,0.00034784415,0.0028710442,0.0012119901,0.026295735,0.00007687023,0.00002652142,0.00007477458],"genre_scores_gemma":[0.98555195,0.004263448,0.0027718998,0.0005210289,0.0005603488,0.005815973,0.000062847575,0.000088554,0.0003639553],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98889947,0.0027525732,0.0049651833,0.0006824105,0.0019336725,0.0007666807],"domain_scores_gemma":[0.9891829,0.0044134124,0.0040969076,0.0004239585,0.0011402059,0.00074263685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008876495,0.00048523836,0.005254607,0.00065194076,0.00018819117,0.00002945347,0.00044374372,0.00037246934,0.0003398502],"category_scores_gemma":[0.004604301,0.00027905492,0.0007386179,0.00094833254,0.00062214234,0.00025202078,0.000178004,0.002123568,0.0000044895705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84603554,0.0077396017,0.0027011975,0.00007917811,0.0023240088,0.0006162777,0.00072223507,0.0035228813,0.00004327494,0.000012486383,0.00014932716,0.13605401],"study_design_scores_gemma":[0.8627543,0.12768054,0.00027603735,0.00026486412,0.0008139869,0.000029229415,0.00022733407,0.0009064722,0.00043601534,0.00006298626,0.0062815915,0.0002666441],"about_ca_topic_score_codex":0.00038280414,"about_ca_topic_score_gemma":0.00032954494,"teacher_disagreement_score":0.13578737,"about_ca_system_score_codex":0.0021970682,"about_ca_system_score_gemma":0.012818695,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W4212904242","doi":"10.1200/jco.2022.40.6_suppl.324","title":"Prospective assessment of a smartphone-app based mindfulness program for patients with metastatic renal cell carcinoma (mRCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social and Behavioral Studies","field":"Social Sciences","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Mindfulness; Breast cancer; Quality of life (healthcare); Survivorship curve; mHealth; Physical therapy; Cancer; Coping (psychology); Anxiety; Distress; Meditation; Internal medicine; Psychological intervention; Clinical psychology; Psychiatry; Nursing","score_opus":0.11689216360806086,"score_gpt":0.4891302967066441,"score_spread":0.3722381330985832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212904242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995233,0.00003631852,0.00025123756,0.001124817,0.0008994182,0.0010188172,0.000033779565,0.000008940967,0.0013936894],"genre_scores_gemma":[0.9902849,0.000001604962,0.008885587,0.0001458839,0.00025587948,0.00028158564,0.000003650563,0.0000097353195,0.0001311584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654603,0.0009921382,0.0012108007,0.00017272531,0.00080830196,0.00027000776],"domain_scores_gemma":[0.9949234,0.001840875,0.002069931,0.00007264445,0.00093048345,0.00016266402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00353701,0.00010955892,0.0009518373,0.000068179004,0.00047468115,0.000012609627,0.00027806513,0.00008290523,0.0001520504],"category_scores_gemma":[0.00062958477,0.000077118355,0.0003847334,0.00030386823,0.0004935986,0.00008925994,0.0000700446,0.00048030372,3.7770474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022118702,0.011789596,0.8499841,0.000022894159,0.00014029504,0.000035764624,0.0012292493,0.00002521485,0.0000031733932,0.0003570059,0.0017596579,0.13244118],"study_design_scores_gemma":[0.010449776,0.04396021,0.89832145,0.000012181045,0.0005644326,9.557726e-7,0.0053815497,0.000022755734,0.0000701002,0.0010800008,0.039975766,0.00016080063],"about_ca_topic_score_codex":0.00026133662,"about_ca_topic_score_gemma":0.000521397,"teacher_disagreement_score":0.13228038,"about_ca_system_score_codex":0.00036347203,"about_ca_system_score_gemma":0.0028959678,"threshold_uncertainty_score":0.51373225},"labels":[],"label_agreement":null},{"id":"W4212907592","doi":"10.1200/jco.2022.40.6_suppl.002","title":"Longitudinal trends of \"manels\" and gender representation at the ASCO Genitourinary Cancers Symposium.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Specialty; Moderation; Genitourinary system; Family medicine; Demography; Gynecology; Internal medicine; Psychology","score_opus":0.2649937088856908,"score_gpt":0.5025679590999395,"score_spread":0.23757425021424866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212907592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9327099,0.000637224,0.000010111812,0.019848097,0.002169176,0.000045983103,0.0000048356687,0.0000028334573,0.04457187],"genre_scores_gemma":[0.9942918,0.0011560778,0.00006587575,0.0008802867,0.0008630305,0.0000013393618,0.0000010672437,0.0000025682882,0.002737992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712574,0.0011865465,0.0006619056,0.000104518105,0.0007932385,0.00012806313],"domain_scores_gemma":[0.9972382,0.0015069016,0.0008830338,0.00008626815,0.00015386053,0.0001317144],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0065734703,0.000045402892,0.00036978858,0.000056241228,0.0004026262,0.000007429509,0.00034458988,0.00008172295,0.0011969688],"category_scores_gemma":[0.0005771158,0.000032571734,0.00017640278,0.00019727273,0.0007565683,0.0000909819,0.00023043719,0.00047638806,0.0000012111526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003017425,0.000569881,0.6580864,0.000017796927,0.0005561701,0.00074425485,0.024765901,0.0011852848,0.00010170909,0.0023960592,0.117923394,0.19063571],"study_design_scores_gemma":[0.0028944754,0.0051575336,0.52816623,0.000008913699,0.00048228743,0.00018041048,0.046576176,0.000028409588,0.000011386782,0.0012756669,0.41512153,0.000097003736],"about_ca_topic_score_codex":0.0006175748,"about_ca_topic_score_gemma":0.0005579213,"teacher_disagreement_score":0.29719812,"about_ca_system_score_codex":0.00027854324,"about_ca_system_score_gemma":0.00072905945,"threshold_uncertainty_score":0.99971604},"labels":[],"label_agreement":null},{"id":"W4212908325","doi":"10.1200/jco.2022.40.6_suppl.083","title":"Statin use and survival in men receiving androgen-ablative therapies for advanced prostate cancer: A systematic review and meta-analysis of cohort studies.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Hazard ratio; Internal medicine; Statin; Androgen deprivation therapy; Oncology; Publication bias; Confidence interval; Systematic review; Subgroup analysis; Cohort study; Proportional hazards model; Cancer; MEDLINE","score_opus":0.24962576518342053,"score_gpt":0.5122185332929383,"score_spread":0.2625927681095178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212908325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035491606,0.9962524,0.000011080654,0.00016085294,0.0008041788,0.0021031275,0.0003008393,0.0000012093622,0.000011368614],"genre_scores_gemma":[0.000026649719,0.99793327,0.00053891697,0.00023537483,0.00036992988,0.000594758,0.00003205827,0.000027204245,0.00024185402],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924351,0.0025547533,0.0041689686,0.00041611612,0.00022870004,0.00019634247],"domain_scores_gemma":[0.989552,0.003565352,0.006032223,0.00026960668,0.0004636067,0.000117187614],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008462153,0.00032445276,0.014987246,0.00019901955,0.000041770792,0.000011103019,0.00020224298,0.00025567994,0.000021854124],"category_scores_gemma":[0.0060652997,0.00020452979,0.0020409904,0.00032039924,0.00019739325,0.000015212447,0.00015174314,0.00043008578,3.4605897e-8],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048700592,0.00026282045,0.00037529456,0.26523957,0.66666466,0.0000031192428,0.00034671032,0.000021837823,0.000005246371,0.000022987695,0.0015724455,0.06499834],"study_design_scores_gemma":[0.0007731068,0.00094764866,0.000057188045,0.0029153721,0.49568978,0.000013555726,0.00021824853,0.0000014794822,3.975479e-7,0.0000137164825,0.49921098,0.00015853596],"about_ca_topic_score_codex":0.00003197563,"about_ca_topic_score_gemma":0.00033634945,"teacher_disagreement_score":0.49763852,"about_ca_system_score_codex":0.000074671094,"about_ca_system_score_gemma":0.0009803646,"threshold_uncertainty_score":0.9996363},"labels":[],"label_agreement":null},{"id":"W4212908656","doi":"10.1200/jco.2022.40.6_suppl.454","title":"Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Regimen; Interim analysis; Adjuvant; Oncology; Adjuvant therapy; Cancer; Randomized controlled trial","score_opus":0.07644560047612209,"score_gpt":0.44121323392000267,"score_spread":0.3647676334438806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212908656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937705,0.0012441507,0.00002125019,0.0010403541,0.0014344532,0.0020138253,0.00014317913,0.000008431735,0.00032386064],"genre_scores_gemma":[0.99667305,0.00044855403,0.0005763904,0.0011497174,0.00056492136,0.00042163618,0.000017027663,0.000039169277,0.000109562425],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.995655,0.0009135116,0.0021235782,0.00038443282,0.00056531857,0.00035814074],"domain_scores_gemma":[0.9942468,0.0034878673,0.0015437655,0.000286366,0.00014900826,0.00028619345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012185103,0.0003235996,0.0021753763,0.00019480388,0.000079935395,0.00000626486,0.00020600857,0.00019957586,0.00019936601],"category_scores_gemma":[0.0007337082,0.00020431678,0.00076973304,0.00013525673,0.00013523645,0.000057967172,0.00005622455,0.0005569974,0.0000023075531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10283704,0.018538816,0.15792385,0.00019447907,0.0014421094,0.0007864121,0.0036827414,0.0004251807,0.004232833,0.000018679924,0.00070296775,0.70921487],"study_design_scores_gemma":[0.12152934,0.58280563,0.22222991,0.00028934696,0.00093879824,0.00012310586,0.0009803132,0.00025434344,0.0347761,0.00005083331,0.035705127,0.0003171749],"about_ca_topic_score_codex":0.0005305312,"about_ca_topic_score_gemma":0.00019838118,"teacher_disagreement_score":0.7088977,"about_ca_system_score_codex":0.0010035865,"about_ca_system_score_gemma":0.0020316085,"threshold_uncertainty_score":0.83317965},"labels":[],"label_agreement":null},{"id":"W4212920865","doi":"10.1200/jco.2022.40.6_suppl.361","title":"Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Princess Margaret Cancer Centre; University of Calgary; Université Laval; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; Montreal General Hospital; University of Manitoba; University Health Network; Ottawa Hospital; University of Toronto; Dalhousie University; University of Ottawa; University of Alberta; Queen Elizabeth II Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Renal cell carcinoma; Nephrectomy; Adjuvant therapy; Cohort; Randomized controlled trial; Surgery; Cancer; Kidney","score_opus":0.2181427939916996,"score_gpt":0.4663297890566239,"score_spread":0.2481869950649243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212920865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455774,0.00041336886,0.000012791992,0.0003468776,0.0027324224,0.0015498373,0.000065160835,0.000005831563,0.0003159947],"genre_scores_gemma":[0.9966972,0.0001674547,0.0022118103,0.00022380943,0.00054259953,0.000031720083,0.000056788627,0.000042130265,0.00002650643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.983651,0.005964042,0.008018275,0.00040984486,0.0015695256,0.00038732402],"domain_scores_gemma":[0.9761049,0.013128089,0.009250647,0.00043627276,0.00061305607,0.00046701168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010077451,0.0003120674,0.00549615,0.0003485483,0.000080782615,0.000007504907,0.0003468289,0.00028356147,0.00056438334],"category_scores_gemma":[0.0054705953,0.00019823496,0.0011355389,0.00034625226,0.0002732945,0.000091440554,0.00014574111,0.0022867187,0.000008675493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45902318,0.01830671,0.49363804,0.00001210354,0.0004241638,0.00016836559,0.00015509575,0.00021950732,0.000006890707,0.0000029948187,0.0005982211,0.02744472],"study_design_scores_gemma":[0.3005454,0.22147448,0.47430304,0.000017316761,0.0008784366,0.0000030567883,0.00014094861,0.00004265102,0.00011125421,0.000017921402,0.0023679638,0.00009753428],"about_ca_topic_score_codex":0.00011183015,"about_ca_topic_score_gemma":0.000035438123,"teacher_disagreement_score":0.20316778,"about_ca_system_score_codex":0.00050225254,"about_ca_system_score_gemma":0.0019542102,"threshold_uncertainty_score":0.99347824},"labels":[],"label_agreement":null},{"id":"W4212922210","doi":"10.1200/jco.2022.40.6_suppl.tps587","title":"Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Oncology; Internal medicine; Cohort; Cancer; Durvalumab; Lymph node; Cisplatin; Perioperative; Urology; Chemotherapy; Surgery; Pembrolizumab; Immunotherapy","score_opus":0.2125772542963511,"score_gpt":0.542032694900749,"score_spread":0.3294554406043979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212922210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989147,0.0012466777,0.0000029897515,0.0030320953,0.00176933,0.0027269751,0.000010019224,0.000010278543,0.0013101528],"genre_scores_gemma":[0.9947034,0.00062007114,0.0005077839,0.0019824188,0.0011527052,0.00070171437,0.0000042594247,0.000039573944,0.00028809087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935489,0.0017117276,0.0030113414,0.00042028213,0.0009120862,0.00039560965],"domain_scores_gemma":[0.9966406,0.0011775396,0.0013463866,0.00024489776,0.00035091102,0.00023966917],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005662004,0.00024570807,0.0019240744,0.00032992256,0.000110253524,0.000018602754,0.00026025902,0.00019300543,0.0013972087],"category_scores_gemma":[0.0013043195,0.00019036148,0.000350946,0.00047703067,0.000147003,0.00015429204,0.00010011803,0.001773524,0.0000060348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09442851,0.011506382,0.80519104,0.00001215617,0.000848132,0.0020164945,0.004850422,0.00079531595,0.00008995085,0.000008878506,0.000588031,0.07966471],"study_design_scores_gemma":[0.25320467,0.09439513,0.6404054,0.00009772166,0.0005045323,0.00011034022,0.0058285818,0.0002461986,0.000065356944,0.00010204213,0.004816878,0.00022313422],"about_ca_topic_score_codex":0.0008553047,"about_ca_topic_score_gemma":0.0020847516,"teacher_disagreement_score":0.16478561,"about_ca_system_score_codex":0.0011348759,"about_ca_system_score_gemma":0.008642611,"threshold_uncertainty_score":0.99951565},"labels":[],"label_agreement":null},{"id":"W4212936557","doi":"10.1200/jco.2022.40.6_suppl.521","title":"First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Urothelial carcinoma; Pembrolizumab; Population; Clinical trial; Multivariate analysis; Logistic regression; Univariate analysis; Cisplatin; Proportional hazards model; Exploratory analysis; Cancer; Chemotherapy; Bladder cancer; Immunotherapy","score_opus":0.21384800772911303,"score_gpt":0.5081010446714576,"score_spread":0.2942530369423445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212936557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868402,0.00078714977,0.00006148798,0.009569261,0.0011347283,0.001235807,0.00006779421,0.000012595009,0.00029101595],"genre_scores_gemma":[0.99353296,0.00070524524,0.00051165547,0.0043400335,0.0007183294,0.00006210885,0.000020901043,0.000039554205,0.00006922995],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98835576,0.0050053834,0.0048836353,0.00048080902,0.00078792055,0.0004864685],"domain_scores_gemma":[0.979926,0.016371166,0.0026968692,0.00037460218,0.00019678306,0.0004345937],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0151571715,0.00032334542,0.0034480062,0.0002835602,0.00013846146,0.000021057815,0.00036661947,0.0003772688,0.00018982147],"category_scores_gemma":[0.016044231,0.00019488775,0.0007220377,0.000509451,0.00041022227,0.00012863062,0.000099665245,0.0030783468,0.0000031588584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38120043,0.07386334,0.18597531,0.00004052852,0.0012944086,0.012083099,0.001543235,0.0009354881,0.000049195918,0.000036784222,0.0015361533,0.341442],"study_design_scores_gemma":[0.49522611,0.15549454,0.32704398,0.00015677209,0.0015351039,0.0008110449,0.0005342043,0.00081215554,0.000023164148,0.00031401918,0.017762108,0.00028677873],"about_ca_topic_score_codex":0.0001207609,"about_ca_topic_score_gemma":0.0003436992,"teacher_disagreement_score":0.34115523,"about_ca_system_score_codex":0.00043831213,"about_ca_system_score_gemma":0.0024396414,"threshold_uncertainty_score":0.99922156},"labels":[],"label_agreement":null},{"id":"W4212943765","doi":"10.1200/jco.2022.40.6_suppl.013","title":"Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Androgen deprivation therapy; Internal medicine; Oncology; Placebo; Adverse effect; Cancer; Urology; Randomized controlled trial; Pathology","score_opus":0.1866927260760188,"score_gpt":0.4892049602523721,"score_spread":0.3025122341763533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212943765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864141,0.00076214096,0.000046269633,0.010369049,0.00020183522,0.0020970562,0.000028685008,0.0000026884898,0.00007822057],"genre_scores_gemma":[0.9964736,0.0023816228,0.0003428773,0.00040616916,0.00010967425,0.00020184672,0.000019266367,0.000012952179,0.00005195592],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975976,0.00083637575,0.0007619022,0.00016983584,0.0004360707,0.0001982688],"domain_scores_gemma":[0.99604326,0.0029228572,0.00064301596,0.00008858546,0.00021761477,0.000084632535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040979898,0.00010903405,0.00073218404,0.00015640889,0.00007233522,0.000012409722,0.00006786227,0.000048855272,0.000010241466],"category_scores_gemma":[0.00040450037,0.000056707864,0.00007733656,0.00021900868,0.0001526453,0.000107159874,0.000017639448,0.0006482253,1.190537e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95157367,0.0037295027,0.007817898,0.000014043391,0.00045576325,0.0007797985,0.0012566629,0.00023742963,0.00013516277,0.00011093464,0.00014540175,0.033743754],"study_design_scores_gemma":[0.80918986,0.13324776,0.050167795,0.000039862316,0.00024535356,0.00011631281,0.002257184,0.0009589613,0.00008307453,0.00032276657,0.0032742221,0.000096866475],"about_ca_topic_score_codex":0.00006535578,"about_ca_topic_score_gemma":0.00028773322,"teacher_disagreement_score":0.14238381,"about_ca_system_score_codex":0.00028354937,"about_ca_system_score_gemma":0.0014017638,"threshold_uncertainty_score":0.28162524},"labels":[],"label_agreement":null},{"id":"W4212951999","doi":"10.1200/jco.2022.40.6_suppl.304","title":"Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa; McGill University Health Centre; Université Laval; Centre Hospitalier de l’Université de Montréal; Dalhousie University; Health Sciences Centre; Ottawa Hospital; University Health Network; University of British Columbia; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary; Princess Margaret Cancer Centre; Hôtel-Dieu de Québec; BC Cancer Agency; McMaster University","funders":"","keywords":"Medicine; Pazopanib; Temsirolimus; Sunitinib; Axitinib; Nivolumab; Everolimus; Internal medicine; Pembrolizumab; Discontinuation; Renal cell carcinoma; Oncology; Ipilimumab; Sorafenib; Clinical endpoint; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Immunotherapy; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors","score_opus":0.042089863589646614,"score_gpt":0.36731685818673926,"score_spread":0.32522699459709264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212951999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729496,0.00034152815,0.00002489022,0.00029753466,0.00041709334,0.00062542147,0.0000061850237,0.0000034535499,0.0009889525],"genre_scores_gemma":[0.9985627,0.00011160889,0.0009174962,0.00017546915,0.00011751448,0.000019829884,0.00000886784,0.000028883063,0.00005761809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617696,0.00094114064,0.0017633577,0.00024325788,0.0006344229,0.00024083875],"domain_scores_gemma":[0.99539375,0.0020880215,0.0016051049,0.0002619108,0.00042002063,0.00023116493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025459547,0.00017934576,0.0016848102,0.00021431402,0.000046501358,0.000002155367,0.00019468654,0.00014248375,0.00016490076],"category_scores_gemma":[0.0003004581,0.00011905771,0.00038350228,0.00027072636,0.00013045126,0.00006898044,0.0000861247,0.0010612914,0.00000271645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09212176,0.00746535,0.87901235,0.00009014598,0.00015236909,0.00083296164,0.000091610156,0.00088986976,0.00049696193,0.0000023307296,0.00006819736,0.018776082],"study_design_scores_gemma":[0.04218635,0.15487978,0.7990035,0.00008068718,0.00011680833,0.00004333768,0.000046378405,0.000030264158,0.0022912342,0.000025696247,0.0012122993,0.00008370821],"about_ca_topic_score_codex":0.000028996401,"about_ca_topic_score_gemma":0.000009375714,"teacher_disagreement_score":0.14741443,"about_ca_system_score_codex":0.00045237248,"about_ca_system_score_gemma":0.0008811342,"threshold_uncertainty_score":0.48550326},"labels":[],"label_agreement":null},{"id":"W4212977599","doi":"10.1200/jco.2022.40.6_suppl.011","title":"PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Androgen deprivation therapy; Abiraterone acetate; Oncology; Interim analysis; Progression-free survival; Prednisone; Olaparib; Confidence interval; Docetaxel; Randomized controlled trial; Urology; Androgen receptor; Cancer; Chemotherapy; Pathology; Poly ADP ribose polymerase","score_opus":0.1667641359119953,"score_gpt":0.4970009066430789,"score_spread":0.3302367707310836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212977599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906515,0.0013916007,0.000014075234,0.0042793057,0.0006506784,0.0027883393,0.00010996783,0.00000524932,0.00010928806],"genre_scores_gemma":[0.9938931,0.004094461,0.00070708565,0.00020685197,0.00027973336,0.00028936387,0.0000317955,0.00002667273,0.00047096377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99699396,0.00035002024,0.0015584027,0.00026335928,0.0005597472,0.0002744948],"domain_scores_gemma":[0.99608463,0.0015107411,0.0013835235,0.00013286105,0.0005840678,0.00030415546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020679573,0.000179425,0.0012765717,0.00013016888,0.00016709337,0.0000167947,0.00009499619,0.000089189016,0.00012812349],"category_scores_gemma":[0.00058501743,0.00010719997,0.00015005254,0.00014246174,0.00034667965,0.00012816265,0.000049610568,0.0005653065,3.6783518e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89529365,0.0062513147,0.002856368,0.00011287939,0.00118956,0.00017134349,0.0005075801,0.000036215246,0.00033610757,0.000025652187,0.0005217629,0.092697546],"study_design_scores_gemma":[0.6835711,0.2865301,0.0025154215,0.00007525712,0.00063742604,0.000036423833,0.00032392613,0.00013650695,0.00030017484,0.000092487244,0.025669005,0.0001121694],"about_ca_topic_score_codex":0.0001072449,"about_ca_topic_score_gemma":0.00018425522,"teacher_disagreement_score":0.28027877,"about_ca_system_score_codex":0.0001847706,"about_ca_system_score_gemma":0.0022816877,"threshold_uncertainty_score":0.4371488},"labels":[],"label_agreement":null},{"id":"W4212979192","doi":"10.1200/jco.2022.40.6_suppl.175","title":"Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Alberta; University of Calgary","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; PI3K/AKT/mTOR pathway; Protein kinase B; Cancer; Proportional hazards model; Androgen deprivation therapy; Androgen receptor; Cancer research; Biology; Genetics; Signal transduction","score_opus":0.07549861582318416,"score_gpt":0.47072017186039483,"score_spread":0.39522155603721065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212979192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955793,0.0013339127,6.5431203e-7,0.0017992561,0.00038838276,0.0004584839,0.00014316005,0.0000029776993,0.0002938738],"genre_scores_gemma":[0.9980314,0.0012096916,0.00028379605,0.00014484827,0.00006250893,0.000016114709,0.000007601146,0.000012521373,0.00023153366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993382,0.0013625446,0.0041266745,0.00023755619,0.00067422766,0.00021704531],"domain_scores_gemma":[0.99315363,0.0029133577,0.0030983472,0.00030367565,0.0003209678,0.00021004923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061792443,0.00013671412,0.0022941686,0.00042352197,0.000049329978,0.0000031638538,0.0002291314,0.00013902254,0.00022782157],"category_scores_gemma":[0.0022461633,0.00008127937,0.0010661348,0.00071281404,0.0007171174,0.00006322151,0.00018070142,0.0007697862,2.7004504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010306264,0.0021281512,0.9712741,0.00006889058,0.0073570944,0.00013489167,0.0004962157,0.00024712266,0.0021526744,0.000019067362,0.00012174858,0.005693794],"study_design_scores_gemma":[0.0072983387,0.009166802,0.9763578,0.00005624144,0.0032799835,0.000012454075,0.0014443775,0.0005728678,0.0002935138,0.00011846103,0.0013389672,0.000060197402],"about_ca_topic_score_codex":0.0005937135,"about_ca_topic_score_gemma":0.0007384208,"teacher_disagreement_score":0.0070386515,"about_ca_system_score_codex":0.00020116182,"about_ca_system_score_gemma":0.0033834372,"threshold_uncertainty_score":0.6002072},"labels":[],"label_agreement":null},{"id":"W4212983849","doi":"10.1200/jco.2022.40.6_suppl.306","title":"Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results &gt;2,000 patients in 41 countries, with focus on older patients.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; Kidney Foundation of Canada","funders":"","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Family medicine; Renal cell carcinoma; Cancer; Nursing; Internal medicine; Psychiatry","score_opus":0.04392241437515805,"score_gpt":0.30725319759945036,"score_spread":0.2633307832242923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212983849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876732,0.0006510622,0.000015005517,0.00023505767,0.0006007401,0.00030661677,0.00023254324,0.0000020925484,0.010283649],"genre_scores_gemma":[0.99799067,0.0012643946,0.00024875163,0.0002836233,0.000067848334,0.000024899342,0.0000071748077,0.000015975334,0.000096656746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952736,0.00009787006,0.0039151516,0.0003192781,0.00014865652,0.00024546738],"domain_scores_gemma":[0.99269015,0.00052611355,0.0062146597,0.0002406299,0.00018890506,0.00013955486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013259974,0.00015308821,0.0012693482,0.00032715147,0.000049917475,0.000008717617,0.00024966017,0.00013880082,0.00013120563],"category_scores_gemma":[0.0005591139,0.00014381425,0.00014971958,0.00019409883,0.00021281134,0.00021452627,0.000141999,0.0004354221,0.00000200634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003850876,0.0017177674,0.9737735,0.000027058584,0.000097101234,0.00004779393,0.0014040415,0.00044655256,2.8412092e-7,0.0011299087,0.0015846962,0.015920438],"study_design_scores_gemma":[0.01175342,0.012465237,0.9077389,0.00005907512,0.00003090433,0.0000025804147,0.00029972958,0.000032996966,0.000039521063,0.000815715,0.06659612,0.00016579521],"about_ca_topic_score_codex":0.0005079475,"about_ca_topic_score_gemma":0.00006034939,"teacher_disagreement_score":0.06603458,"about_ca_system_score_codex":0.00023585086,"about_ca_system_score_gemma":0.00015899287,"threshold_uncertainty_score":0.5864575},"labels":[],"label_agreement":null},{"id":"W4212984292","doi":"10.1200/jco.2022.40.6_suppl.528","title":"Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Medicine; Cystectomy; Bladder cancer; Gemcitabine; Oncology; Nivolumab; Internal medicine; Biomarker; Clinical endpoint; Cisplatin; Cancer; Urology; Clinical trial; Chemotherapy; Immunotherapy","score_opus":0.060952022965494866,"score_gpt":0.39643526319870204,"score_spread":0.3354832402332072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212984292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551016,0.0010435139,0.00011290168,0.0011277379,0.0011165793,0.0007033908,0.00016886675,0.000010007097,0.00020684136],"genre_scores_gemma":[0.9962437,0.0012256954,0.0007117741,0.0011033347,0.00042353995,0.000049179216,0.000038365455,0.000043619482,0.00016079747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349535,0.0012861671,0.003415958,0.00059609115,0.00082319946,0.00038323956],"domain_scores_gemma":[0.9922501,0.0037067318,0.002818517,0.00027841312,0.00052062963,0.00042560036],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021844048,0.00032480233,0.002909498,0.0005159186,0.00011978566,0.00001893366,0.00018615933,0.0003720386,0.0012098302],"category_scores_gemma":[0.0008202392,0.00024184152,0.0005854858,0.00092082034,0.00035824344,0.00018115461,0.00019011025,0.0012133555,7.5227337e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093118526,0.0019844044,0.8461787,0.00002520212,0.009278913,0.00020956344,0.00025438474,0.00008734572,0.00006392421,0.0000019684,0.00055564346,0.048241407],"study_design_scores_gemma":[0.18290864,0.014490883,0.79319936,0.00012700712,0.007290167,0.0000098461,0.00033466876,0.0003855838,0.000016324137,0.00005304095,0.0009820567,0.00020243815],"about_ca_topic_score_codex":0.0028501484,"about_ca_topic_score_gemma":0.011342368,"teacher_disagreement_score":0.08979011,"about_ca_system_score_codex":0.0003358214,"about_ca_system_score_gemma":0.0029402075,"threshold_uncertainty_score":0.9997032},"labels":[],"label_agreement":null},{"id":"W4212987985","doi":"10.1200/jco.2022.40.6_suppl.269","title":"Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University Health Centre; Lawson Health Research Institute; Juravinski Cancer Centre; University of Alberta; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Prostatectomy; Prostate; Randomized controlled trial; Cancer; Hormonal therapy","score_opus":0.11494132322920023,"score_gpt":0.47666074038401957,"score_spread":0.36171941715481937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212987985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818455,0.0004497246,0.0000022479271,0.012012518,0.0030330056,0.0020317554,0.000022892369,0.0000022510599,0.0006001011],"genre_scores_gemma":[0.9950515,0.002838484,0.000028383281,0.00067738525,0.0005157913,0.00018225965,0.000002424029,0.000014829235,0.00068892137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99223745,0.003919732,0.0027823173,0.00017479021,0.000638858,0.00024683957],"domain_scores_gemma":[0.9899287,0.0056849113,0.0036891417,0.00032539954,0.00027711727,0.000094707684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012220736,0.00014080464,0.0015877471,0.000118688054,0.0001500152,0.000004871078,0.0004907782,0.00018302504,0.0005160904],"category_scores_gemma":[0.0033885846,0.0000549529,0.00076617365,0.0003462436,0.0009787576,0.00005286013,0.00022686427,0.0019900037,0.0000019652493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9270609,0.0026939504,0.027507296,0.000019857587,0.0005295227,0.000027440294,0.0011419068,0.0003623909,0.0011642511,0.00002685365,0.0010440034,0.038421623],"study_design_scores_gemma":[0.9427719,0.015784793,0.027528455,0.00013579462,0.0006654727,0.00003714454,0.00064176234,0.0011435758,0.0024770617,0.00023052961,0.008508723,0.00007477567],"about_ca_topic_score_codex":0.0000717186,"about_ca_topic_score_gemma":0.00004170131,"teacher_disagreement_score":0.038346846,"about_ca_system_score_codex":0.0006663492,"about_ca_system_score_gemma":0.003736735,"threshold_uncertainty_score":0.8645687},"labels":[],"label_agreement":null},{"id":"W4212989002","doi":"10.1200/jco.2022.40.6_suppl.310","title":"Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; London Health Sciences Centre; Western University; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Medicine; Nivolumab; Axitinib; Internal medicine; Ipilimumab; Renal cell carcinoma; Pembrolizumab; Oncology; Cabozantinib; Response Evaluation Criteria in Solid Tumors; Progressive disease; Expanded access; Pazopanib; Sunitinib; Cancer; Disease; Immunotherapy","score_opus":0.08989455035986191,"score_gpt":0.3886909595547798,"score_spread":0.2987964091949179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212989002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733609,0.0010418512,0.00016950721,0.021153191,0.0018661072,0.00089758384,0.00061389076,0.000009044048,0.0008879413],"genre_scores_gemma":[0.99283946,0.00024399346,0.0042667175,0.0016618123,0.0003292605,0.00006711905,0.00018513198,0.000034233322,0.000372247],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98817104,0.005119302,0.0046041734,0.00049543916,0.0012436047,0.00036644723],"domain_scores_gemma":[0.97159773,0.0229789,0.0037699623,0.0005688806,0.0007615181,0.00032298767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012861754,0.0003100581,0.0019201977,0.00052078266,0.00013092546,0.000014527287,0.0007135449,0.00014309249,0.0003958333],"category_scores_gemma":[0.007319883,0.00021176247,0.0005878041,0.000486306,0.00036975622,0.00015914612,0.00043525812,0.0016549987,0.000010565662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6694174,0.03586446,0.11366957,0.00010614845,0.0046423837,0.014863055,0.020174831,0.0074477824,0.08769567,0.00009787703,0.03417538,0.011845448],"study_design_scores_gemma":[0.092232496,0.10165712,0.69659114,0.00017006334,0.0029137677,0.0008741134,0.008944487,0.000976611,0.01962306,0.0006880746,0.07490587,0.00042319746],"about_ca_topic_score_codex":0.0006196756,"about_ca_topic_score_gemma":0.000437887,"teacher_disagreement_score":0.58292156,"about_ca_system_score_codex":0.0014309154,"about_ca_system_score_gemma":0.003840828,"threshold_uncertainty_score":0.87631124},"labels":[],"label_agreement":null},{"id":"W4212992860","doi":"10.1200/jco.2022.40.6_suppl.163","title":"Immune profiling of advanced prostate cancer harboring homologous recombination deficiency.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Immune system; Prostate; Stromal cell; CD8; Internal medicine; Oncology; Cancer research; Cancer; Pathology; Immunology","score_opus":0.06820284130697328,"score_gpt":0.4411733774309218,"score_spread":0.3729705361239485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212992860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581123,0.0061094216,0.00002873557,0.0039906343,0.0028364589,0.00026605054,0.000005620608,0.000007738503,0.0009440766],"genre_scores_gemma":[0.9938801,0.0026467163,0.0024180943,0.0005014142,0.00016851844,0.000022628075,0.0000022911358,0.000012787938,0.00034747657],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968604,0.0003112621,0.00216912,0.00013722313,0.00034839966,0.00017362526],"domain_scores_gemma":[0.996526,0.000520626,0.0023929325,0.00013183657,0.00034950615,0.00007909903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041179173,0.000084726096,0.00087554095,0.00014193801,0.00007876546,0.000002684172,0.00015511537,0.00009999578,0.00027772682],"category_scores_gemma":[0.00078315195,0.00006725446,0.0003916894,0.00026368193,0.00013941781,0.00008084889,0.00006107436,0.0008105884,6.5051034e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0334088,0.0023509732,0.04778374,0.00010034042,0.00035989558,0.00026789503,0.00044774267,0.0006459697,0.07912534,0.00011824346,0.00034822308,0.83504283],"study_design_scores_gemma":[0.058050293,0.08985065,0.6971292,0.00047046642,0.00088107167,0.0016828859,0.0034573127,0.00048497293,0.040262714,0.001183125,0.10609926,0.00044807245],"about_ca_topic_score_codex":0.00004664931,"about_ca_topic_score_gemma":0.0000063260936,"teacher_disagreement_score":0.8345948,"about_ca_system_score_codex":0.00035543126,"about_ca_system_score_gemma":0.0018467621,"threshold_uncertainty_score":0.35216483},"labels":[],"label_agreement":null},{"id":"W4212999409","doi":"10.1200/jco.2022.40.6_suppl.239","title":"Prostate specific antigen dynamics and prostate cancer risk: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Prostate; Cohort; Internal medicine; Cancer; Retrospective cohort study; Population; Urology; Logistic regression; Gynecology; Oncology","score_opus":0.10090647405238626,"score_gpt":0.4847770033301339,"score_spread":0.3838705292777477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212999409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890318,0.0020814864,0.000010155086,0.006936637,0.0008110447,0.000865996,0.00006404768,0.0000104853,0.00018835394],"genre_scores_gemma":[0.99503607,0.0027216964,0.00047246995,0.00036833002,0.00035908245,0.00004810906,0.000022061626,0.000022281527,0.00094992673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673665,0.00076740433,0.001410251,0.00023985715,0.00058209896,0.0002637702],"domain_scores_gemma":[0.9972168,0.000778973,0.0012176565,0.00016311539,0.00030963926,0.0003137867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003328685,0.00012898009,0.0009500065,0.00018957815,0.00021692144,0.000016311566,0.00011528869,0.000085411666,0.0003088689],"category_scores_gemma":[0.00041385167,0.00008947052,0.00020676991,0.0002501481,0.000106782616,0.0000706475,0.00009677663,0.001296657,0.0000024268222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011368995,0.0020968074,0.86484927,0.000018004383,0.00029257312,0.0008632193,0.00028541643,0.00024608098,0.000012244208,0.00001094016,0.0007893577,0.11916707],"study_design_scores_gemma":[0.0144330105,0.0220562,0.9455309,0.000027538981,0.00020298363,0.000050627026,0.0008392452,0.001267864,0.000005582132,0.0001725078,0.015325011,0.00008851738],"about_ca_topic_score_codex":0.000280913,"about_ca_topic_score_gemma":0.00023870109,"teacher_disagreement_score":0.119078554,"about_ca_system_score_codex":0.00064216927,"about_ca_system_score_gemma":0.0019795252,"threshold_uncertainty_score":0.5633401},"labels":[],"label_agreement":null},{"id":"W4213002141","doi":"10.1200/jco.2022.40.6_suppl.101","title":"Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Concomitant; Adverse effect; Internal medicine; Population; Clinical endpoint; Urology; Cancer; Oncology; Randomized controlled trial","score_opus":0.06994853966378729,"score_gpt":0.47151785376177063,"score_spread":0.40156931409798335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213002141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804164,0.009442997,0.000004099089,0.0013561795,0.00006868452,0.0008845495,0.00007838911,0.000002584161,0.00012085036],"genre_scores_gemma":[0.99090403,0.008783016,0.00007333265,0.00006740142,0.00008700072,0.000031951415,0.0000070246274,0.000013632924,0.000032586544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610555,0.0012981382,0.001481743,0.00022727024,0.00068185193,0.00020544873],"domain_scores_gemma":[0.99567103,0.0025214013,0.0010819988,0.0003292274,0.00024622105,0.00015010567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035640183,0.00014749078,0.002197952,0.00018311734,0.00006401497,0.0000042832385,0.00017851537,0.00006876293,0.00009333585],"category_scores_gemma":[0.00035996654,0.00007107921,0.00069529953,0.0005319332,0.0003053262,0.000053009462,0.00007375338,0.0008680102,1.4624725e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16285102,0.004668146,0.71277183,0.000011303288,0.02190058,0.000609912,0.0024747944,0.004031968,0.00022066146,0.0000021654562,0.00006611589,0.0903915],"study_design_scores_gemma":[0.074736126,0.06391863,0.85458827,0.00006538463,0.0028912106,0.000016094114,0.002496491,0.000113281654,0.00007681437,0.000024396808,0.0010073396,0.00006597884],"about_ca_topic_score_codex":0.0013850363,"about_ca_topic_score_gemma":0.00025324814,"teacher_disagreement_score":0.14181642,"about_ca_system_score_codex":0.00041571405,"about_ca_system_score_gemma":0.0013832332,"threshold_uncertainty_score":0.37711206},"labels":[],"label_agreement":null},{"id":"W4213010155","doi":"10.1200/jco.2022.40.6_suppl.316","title":"Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; BC Cancer Agency; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; McMaster University; Juravinski Cancer Centre; University of Manitoba; University Health Network; University of Alberta","funders":"","keywords":"Medicine; Sunitinib; Cabozantinib; Pazopanib; Hazard ratio; Axitinib; Renal cell carcinoma; Discontinuation; Internal medicine; Toxicity; Tyrosine-kinase inhibitor; Cohort; Cancer; Oncology; Kidney cancer; Urology; Gastroenterology; Confidence interval","score_opus":0.09265056873236414,"score_gpt":0.4041913901613804,"score_spread":0.31154082142901623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213010155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872886,0.00011096842,0.00005208967,0.008467733,0.0015851725,0.0010770584,0.0006591828,0.0000051581715,0.00075405044],"genre_scores_gemma":[0.99715185,0.000033479588,0.0012646675,0.0007517943,0.00051746785,0.00009656559,0.00008790638,0.000014075461,0.00008221363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99275094,0.002597059,0.0035189062,0.00021190364,0.0006351854,0.00028601207],"domain_scores_gemma":[0.98603946,0.008186337,0.004178807,0.00026852006,0.00085604546,0.0004708527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012552167,0.00015694415,0.0014600029,0.00021208214,0.00017626307,0.000013467898,0.00020936017,0.00022037524,0.000033482644],"category_scores_gemma":[0.005995344,0.00009992737,0.00047361554,0.0003442321,0.000115910036,0.0001620073,0.000044548826,0.001231126,0.0000020523855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05308105,0.0019039443,0.9109364,0.00023826401,0.0015383529,0.00040045817,0.001239448,0.003002331,0.00023122595,0.000084112544,0.016751233,0.010593143],"study_design_scores_gemma":[0.026990129,0.011257075,0.9377267,0.00017265246,0.0015032218,0.000105533756,0.0010663441,0.0005197058,0.00052743097,0.000026948428,0.020000197,0.000104095336],"about_ca_topic_score_codex":0.046554502,"about_ca_topic_score_gemma":0.049975,"teacher_disagreement_score":0.02679023,"about_ca_system_score_codex":0.002858744,"about_ca_system_score_gemma":0.011315025,"threshold_uncertainty_score":0.9942899},"labels":[],"label_agreement":null},{"id":"W4213017115","doi":"10.1200/jco.2022.40.6_suppl.001","title":"First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Mitotane; Medicine; Observational study; Adrenocortical carcinoma; Randomization; Adjuvant; Internal medicine; Clinical endpoint; Randomized controlled trial; Stage (stratigraphy); Oncology; Surgery","score_opus":0.0845839881317905,"score_gpt":0.42259097660742845,"score_spread":0.3380069884756379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213017115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827496,0.0002054276,0.000006501393,0.010883049,0.0031829346,0.0017047373,0.000003877976,0.0000061506203,0.0012577411],"genre_scores_gemma":[0.9945072,0.00001910772,0.00005934602,0.0035729993,0.0015006299,0.00007770215,0.0000028123288,0.000015990936,0.00024419863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99173546,0.0032040428,0.003671914,0.00023231925,0.00087125937,0.00028500985],"domain_scores_gemma":[0.98718196,0.01044155,0.001611732,0.00026654187,0.00021364106,0.00028457353],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009068353,0.00016778217,0.0026078261,0.00016887176,0.00013347971,0.000006259842,0.00031445592,0.00013555671,0.0007982624],"category_scores_gemma":[0.01164835,0.000086865424,0.00088491524,0.00027973723,0.00027282367,0.000039258997,0.0001518221,0.0024197316,0.000019433202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9379878,0.012804741,0.028550055,0.000004978365,0.00021191391,0.009744914,0.00041381226,0.00013068326,1.06420565e-7,0.000116355404,0.0027824778,0.007252172],"study_design_scores_gemma":[0.715878,0.05676503,0.219647,0.000021552043,0.0004080216,0.0007772664,0.0005107286,0.00016513452,5.8074534e-7,0.00021993762,0.0055316114,0.000075117205],"about_ca_topic_score_codex":0.000050031384,"about_ca_topic_score_gemma":0.00006337091,"teacher_disagreement_score":0.22210978,"about_ca_system_score_codex":0.00023433409,"about_ca_system_score_gemma":0.0010302721,"threshold_uncertainty_score":0.99988174},"labels":[],"label_agreement":null},{"id":"W4213017791","doi":"10.1200/jco.2022.40.6_suppl.149","title":"A microRNA-based classifier for identification of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Applied Biological Materials (Canada)","funders":"U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; Neuroendocrine differentiation; Chromogranin A; Androgen receptor; Cancer research; LNCaP; Synaptophysin; Medicine; Androgen deprivation therapy; microRNA; Cancer; Immunohistochemistry; Biology; Pathology; Internal medicine; Gene; Genetics","score_opus":0.18065944680797397,"score_gpt":0.5010320664564488,"score_spread":0.32037261964847485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213017791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849772,0.0005596945,0.00021655868,0.0127932215,0.00061797496,0.00072413275,0.00007935504,0.0000029555963,0.000028938814],"genre_scores_gemma":[0.99814457,0.00027069708,0.0005897928,0.00025705856,0.00010490546,0.00013103303,0.00003725668,0.000011819323,0.00045284748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683315,0.00042701833,0.0020602783,0.00014786593,0.0003613746,0.0001702968],"domain_scores_gemma":[0.99675775,0.0009421392,0.001678693,0.00011096252,0.00040406742,0.000106367785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016620561,0.00008045853,0.00072091946,0.00023559366,0.000052022802,0.000006360273,0.00009804559,0.00002855712,0.00009965135],"category_scores_gemma":[0.000821817,0.000060292085,0.00026120522,0.00022218536,0.000088877125,0.00006386179,0.00002285378,0.00044976646,4.358207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14863624,0.016539495,0.32834923,0.0012051312,0.0014358571,0.0017158721,0.0006877818,0.005059398,0.30612317,0.00044618477,0.006467223,0.18333441],"study_design_scores_gemma":[0.049280122,0.028112799,0.8739677,0.00013087002,0.0009242191,0.000117309,0.00062763947,0.008041467,0.018260116,0.0009822109,0.019402232,0.00015331173],"about_ca_topic_score_codex":0.000039318584,"about_ca_topic_score_gemma":0.00010396651,"teacher_disagreement_score":0.5456185,"about_ca_system_score_codex":0.00033035432,"about_ca_system_score_gemma":0.0024462636,"threshold_uncertainty_score":0.43395665},"labels":[],"label_agreement":null},{"id":"W4213022323","doi":"10.1200/jco.2022.40.6_suppl.tps405","title":"TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Phases of clinical research; Randomized controlled trial; Urology; Clinical trial; Cancer; Immunotherapy","score_opus":0.14702469632031276,"score_gpt":0.4409735268817561,"score_spread":0.2939488305614434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213022323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98502636,0.0013085781,0.0001319733,0.0034611905,0.00023640908,0.009676855,0.000010474315,0.000013350326,0.00013483521],"genre_scores_gemma":[0.9909934,0.00010478037,0.0069000246,0.0005560131,0.00024126258,0.0007785915,0.000017192951,0.00009168786,0.0003170773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98831964,0.004031619,0.0052361283,0.00067414757,0.0012203334,0.00051813445],"domain_scores_gemma":[0.99219906,0.0025278784,0.003301332,0.0005382397,0.00089432695,0.0005391394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009664431,0.0005162811,0.007453195,0.0007577405,0.0001280584,0.00006607718,0.0005786792,0.00012145932,0.000094045026],"category_scores_gemma":[0.0007298546,0.00032789633,0.0004499741,0.000763457,0.00018894736,0.000269076,0.00019915737,0.0013569482,0.0000014726402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7742681,0.15118201,0.050245773,0.00004970274,0.0011711575,0.0031607712,0.0049824486,0.00040941543,0.0056101913,0.0000021944616,0.000022535787,0.0088957045],"study_design_scores_gemma":[0.7567201,0.21194951,0.020136094,0.00066293974,0.0006193374,0.00008342625,0.0035230822,0.0016939744,0.0042344015,0.000006979863,0.00009737184,0.00027272987],"about_ca_topic_score_codex":0.0016846869,"about_ca_topic_score_gemma":0.009034368,"teacher_disagreement_score":0.060767498,"about_ca_system_score_codex":0.00073972787,"about_ca_system_score_gemma":0.002320004,"threshold_uncertainty_score":0.9999173},"labels":[],"label_agreement":null},{"id":"W4213025187","doi":"10.1200/jco.2022.40.6_suppl.279","title":"Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Pharmacokinetics; Pharmacodynamics; Cancer; Oncology; Pharmacology; Urology; Gastroenterology; Androgen receptor","score_opus":0.21401462625642037,"score_gpt":0.5365450964972351,"score_spread":0.32253047024081477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213025187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97445303,0.013745303,0.00005616732,0.009281633,0.00067805813,0.0014045252,0.00028081462,0.000004177777,0.00009628095],"genre_scores_gemma":[0.9379048,0.060049728,0.00083196413,0.00011335475,0.00028219182,0.0000704315,0.000009536558,0.000022541128,0.0007154538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995581,0.0009243903,0.002380279,0.00031771217,0.0004759387,0.00032072398],"domain_scores_gemma":[0.98992634,0.0071135256,0.0019727908,0.00025737964,0.00041367835,0.00031628943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042413957,0.0002045625,0.0020504545,0.00013350307,0.00017780835,0.000008923148,0.00014696187,0.00013408634,0.00009620364],"category_scores_gemma":[0.00058458856,0.00011182192,0.00055661454,0.0001922638,0.00096329453,0.0000792233,0.00010931575,0.0006428692,2.9129654e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2680245,0.011171659,0.11817168,0.00043144764,0.0043524047,0.0008403706,0.0010273833,0.000080912236,0.0030674296,0.0001101926,0.00095915946,0.59176284],"study_design_scores_gemma":[0.03904802,0.18129918,0.69457316,0.0001528,0.0028917259,0.00038859266,0.001290003,0.00084005966,0.0006997683,0.00029497794,0.07836161,0.0001600915],"about_ca_topic_score_codex":0.0001689104,"about_ca_topic_score_gemma":0.00008035969,"teacher_disagreement_score":0.59160274,"about_ca_system_score_codex":0.00025299602,"about_ca_system_score_gemma":0.002499045,"threshold_uncertainty_score":0.45599657},"labels":[],"label_agreement":null},{"id":"W4213037612","doi":"10.1200/jco.2022.40.6_suppl.tps7","title":"The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Institutes of Health; Cancer Research UK","keywords":"Medicine; Penile cancer; Lymph node; Chemoradiotherapy; Neoadjuvant therapy; Radiation therapy; Oncology; Dissection (medical); Cancer; Internal medicine; Surgery","score_opus":0.12445212140819147,"score_gpt":0.47888026732252265,"score_spread":0.3544281459143312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213037612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9164769,0.0010116275,0.00002160435,0.07531168,0.005082479,0.0015516155,0.00013303383,0.0000035209075,0.00040753477],"genre_scores_gemma":[0.9886877,0.000049521936,0.00014312881,0.0075763753,0.0027515437,0.00025908917,0.00000953296,0.000016100745,0.0005069889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961339,0.00055522413,0.0019674585,0.00018207583,0.0008902954,0.0002710195],"domain_scores_gemma":[0.9894607,0.0069133984,0.002473536,0.00031033525,0.0005352105,0.00030679422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004071276,0.00013661661,0.0008255087,0.00004980332,0.00055433944,0.000011602869,0.0006133955,0.000086907196,0.0003112714],"category_scores_gemma":[0.004032791,0.000058050195,0.0008514087,0.0001459597,0.0003729733,0.00006211217,0.00012524563,0.0008055761,8.4571576e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95550114,0.002798954,0.0017377089,0.000019728774,0.00015535642,0.000056676156,0.00012410792,0.00018102529,0.000007535155,0.00014895914,0.024125246,0.015143533],"study_design_scores_gemma":[0.6332969,0.022668108,0.0053477795,0.000010397644,0.00075842877,0.00019293178,0.00065390725,0.00030272262,0.000017113744,0.00018657597,0.3364985,0.00006659654],"about_ca_topic_score_codex":0.00010981909,"about_ca_topic_score_gemma":0.00020260377,"teacher_disagreement_score":0.32220423,"about_ca_system_score_codex":0.00030146397,"about_ca_system_score_gemma":0.0076751,"threshold_uncertainty_score":0.99795043},"labels":[],"label_agreement":null},{"id":"W4213038657","doi":"10.1200/jco.2022.40.6_suppl.118","title":"Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Cohort; Internal medicine; Pembrolizumab; Oncology; Urology; Cancer; Surgery; Androgen deprivation therapy","score_opus":0.06470924380485907,"score_gpt":0.412626171794028,"score_spread":0.34791692798916896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213038657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949385,0.0010840375,0.000006392382,0.007234573,0.0003623481,0.0011967202,0.00034601183,0.000009861959,0.00026619693],"genre_scores_gemma":[0.99505144,0.0015907075,0.0013430301,0.0008014115,0.00017574932,0.00009128756,0.00010885781,0.00003776629,0.00079971884],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9953968,0.00072653196,0.00214429,0.00043781867,0.00088261685,0.000411954],"domain_scores_gemma":[0.99645615,0.0009374191,0.001522859,0.00023897031,0.0004640367,0.00038058136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018584918,0.00024308151,0.0015820677,0.0001996522,0.00012595355,0.000025926036,0.00016466886,0.000119716846,0.00020021119],"category_scores_gemma":[0.00040492733,0.00016099005,0.00015052552,0.0002821202,0.00032021123,0.0001861715,0.00009572134,0.0012246534,0.0000024816618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47847572,0.0037510507,0.4609899,0.00007961821,0.0022630799,0.0018802993,0.0026234845,0.0008326194,0.00036232875,0.0000072422476,0.0017697526,0.04696492],"study_design_scores_gemma":[0.12866443,0.022612175,0.8433027,0.00013440692,0.00047987598,0.000041669842,0.00052571134,0.0002634707,0.00012212318,0.00011936874,0.0035656441,0.00016841236],"about_ca_topic_score_codex":0.0010324578,"about_ca_topic_score_gemma":0.0004138196,"teacher_disagreement_score":0.3823128,"about_ca_system_score_codex":0.00094903493,"about_ca_system_score_gemma":0.0031840045,"threshold_uncertainty_score":0.6564984},"labels":[],"label_agreement":null},{"id":"W4213040106","doi":"10.1200/jco.2022.40.6_suppl.493","title":"Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cohort; Bladder cancer; Atezolizumab; Urology; Cystectomy; Internal medicine; Carcinoma in situ; Cancer; Oncology; Surgery; Immunotherapy; Pembrolizumab","score_opus":0.07484964919512821,"score_gpt":0.4236228981067292,"score_spread":0.348773248911601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213040106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938804,0.00015588892,0.000017013823,0.0021730498,0.0010013384,0.0014400522,0.0006833445,0.000022175087,0.00062675064],"genre_scores_gemma":[0.99506986,0.0003136149,0.0010239193,0.0018449845,0.0008037142,0.00015533493,0.000055590324,0.00007656672,0.0006564027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99337244,0.0012245649,0.0028550527,0.0007183921,0.0012821585,0.0005474168],"domain_scores_gemma":[0.99403346,0.0015403023,0.0027204219,0.0005263519,0.00058797887,0.0005914638],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015755779,0.00043337978,0.0026368455,0.00028014247,0.00025833258,0.000017285838,0.0003685492,0.00024616942,0.0013234211],"category_scores_gemma":[0.0009909885,0.00025253656,0.00027273523,0.0005495764,0.0002394929,0.00019685342,0.0002220102,0.0021817966,0.000012051621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26874232,0.027190553,0.6167679,0.000012339862,0.0027926445,0.0040610856,0.0023406153,0.00038469385,0.000008820594,0.0000013480909,0.002664911,0.07503279],"study_design_scores_gemma":[0.26540282,0.27020973,0.450021,0.00016501891,0.0021570916,0.00010677619,0.0019342507,0.000048417653,0.000052354808,0.000030061166,0.009561091,0.00031138846],"about_ca_topic_score_codex":0.0091076,"about_ca_topic_score_gemma":0.01467236,"teacher_disagreement_score":0.24301918,"about_ca_system_score_codex":0.0010162127,"about_ca_system_score_gemma":0.0052112653,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W4213046634","doi":"10.1200/jco.2022.40.6_suppl.tps600","title":"A prospective, single-center, phase II randomized controlled trial to evaluate the safety, feasibility, and preliminary efficacy of exercise during intravesical therapy for nonmuscle invasive bladder cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bladder cancer; Cystoscopy; Randomized controlled trial; Quality of life (healthcare); Adverse effect; Cancer; Internal medicine; Urology; Surgery; Urinary system","score_opus":0.11565192505267594,"score_gpt":0.46069845958973743,"score_spread":0.34504653453706147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213046634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732544,0.0020864569,0.0000451752,0.0079651475,0.0013199657,0.015103473,0.000045917,0.000007471729,0.00017201446],"genre_scores_gemma":[0.99446845,0.0020484198,0.00033206868,0.0008248803,0.00085439376,0.0012806992,0.0000029919713,0.00002640916,0.0001616937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99453795,0.0014488315,0.002871776,0.00031749866,0.00056036905,0.0002635699],"domain_scores_gemma":[0.9896779,0.007789757,0.0014584962,0.0002383096,0.0005314658,0.00030406337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061777714,0.00021800383,0.0039273812,0.00011556301,0.00025618591,0.00000994286,0.00021471047,0.00013590335,0.00027240335],"category_scores_gemma":[0.005657587,0.00011915393,0.0012628881,0.00014467527,0.00035743602,0.00006109295,0.00017897652,0.0006256331,3.88185e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93664527,0.021405982,0.0009931225,0.000030507634,0.0020821926,0.000048959664,0.0010908626,0.000030103078,0.0007024622,0.000014384897,0.00034090702,0.03661524],"study_design_scores_gemma":[0.85856825,0.13128923,0.0064925626,0.00010302707,0.0020768472,0.00009839817,0.0001580414,0.000060952334,0.0003629799,0.00032215833,0.00037758634,0.000089970876],"about_ca_topic_score_codex":0.00002545402,"about_ca_topic_score_gemma":0.000014692562,"teacher_disagreement_score":0.109883256,"about_ca_system_score_codex":0.00034846543,"about_ca_system_score_gemma":0.0021086822,"threshold_uncertainty_score":0.6773069},"labels":[],"label_agreement":null},{"id":"W4213047087","doi":"10.1200/jco.2022.40.6_suppl.412","title":"Stage I testicular cancer: Five-year follow-up rates and reasons for non-adherence.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Cancer; Stage (stratigraphy); Seminoma; Testicular cancer; Milestone; Cohort; Internal medicine; Pediatrics; Gynecology; Surgery; Chemotherapy","score_opus":0.10378133804411988,"score_gpt":0.4738188161937789,"score_spread":0.37003747814965904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213047087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917538,0.0025306782,0.00009653104,0.0037015476,0.001172259,0.00040105893,0.0000876241,0.000008072556,0.00024840908],"genre_scores_gemma":[0.9922304,0.0005801649,0.0037696585,0.0010538001,0.00044624702,0.000054939614,0.000009368872,0.000017232886,0.0018381467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998354,0.00015842369,0.0008712856,0.00017901283,0.0002482956,0.00018896084],"domain_scores_gemma":[0.9966179,0.0017080639,0.000877807,0.00013106078,0.00025934062,0.00040582367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000943377,0.000109521156,0.000879075,0.000045353656,0.00011476982,0.000008562801,0.00009398775,0.00009813696,0.0003812249],"category_scores_gemma":[0.003415381,0.00007959667,0.00040084263,0.00008888382,0.000102574144,0.00004543822,0.000073919226,0.00041696004,0.0000032339192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069269333,0.00239073,0.8941441,0.00008992168,0.001142784,0.0015530001,0.00009002137,0.000053265696,0.00009550467,0.00020515644,0.015382626,0.07792593],"study_design_scores_gemma":[0.03795844,0.038768753,0.80666405,0.00012575404,0.0024975447,0.00037385934,0.00063257327,0.000711766,0.000026119336,0.0007965219,0.11128496,0.00015969005],"about_ca_topic_score_codex":0.000073913616,"about_ca_topic_score_gemma":0.000024480498,"teacher_disagreement_score":0.09590233,"about_ca_system_score_codex":0.00012303209,"about_ca_system_score_gemma":0.0016939356,"threshold_uncertainty_score":0.41741455},"labels":[],"label_agreement":null},{"id":"W4213047154","doi":"10.1200/jco.2022.40.6_suppl.223","title":"An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Saskatchewan; Dalhousie University","funders":"","keywords":"Medicine; Prostate cancer; Biomarker; Oncology; Androgen deprivation therapy; Randomized controlled trial; Radiation therapy; Internal medicine; Cohort; Cancer","score_opus":0.04698736294900667,"score_gpt":0.4218052130759005,"score_spread":0.37481785012689384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213047154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738622,0.00014383161,0.0009926634,0.024260735,0.00026044017,0.00042200292,0.00000708201,0.0000059281324,0.000045153512],"genre_scores_gemma":[0.99361634,0.00016884466,0.0011146386,0.004914273,0.00010644343,0.000036106456,0.000015041243,0.000016831262,0.0000114696595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973083,0.00055429584,0.0013818161,0.0001857315,0.00039199303,0.00017785106],"domain_scores_gemma":[0.9979118,0.0007115536,0.0008643953,0.00016839046,0.00019156096,0.00015230358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038892175,0.00010226448,0.0007255817,0.00023161575,0.00004130916,0.0000108364875,0.00018938023,0.00010018933,0.00006030072],"category_scores_gemma":[0.00135242,0.00006154868,0.0001128792,0.00037493824,0.00017696495,0.00011055597,0.000037044403,0.0009565782,3.477267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010162771,0.0009897875,0.7341302,0.0000092410755,0.00006452513,0.00025911053,0.00038851518,0.018377371,0.0019879518,0.000008303246,0.00012887124,0.23349337],"study_design_scores_gemma":[0.020015165,0.014397333,0.93265444,0.00017443365,0.00007605973,0.00019096605,0.0002984649,0.023182955,0.00047965205,0.0003730874,0.008042236,0.00011519299],"about_ca_topic_score_codex":0.00007371148,"about_ca_topic_score_gemma":0.00004956152,"teacher_disagreement_score":0.23337817,"about_ca_system_score_codex":0.00015268134,"about_ca_system_score_gemma":0.0010995935,"threshold_uncertainty_score":0.41559094},"labels":[],"label_agreement":null},{"id":"W4213063616","doi":"10.1200/jco.2022.40.6_suppl.241","title":"Contemporary outcomes of a systematic prostate cancer active surveillance program: Results from the Niagara Health System, Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Brock University; Niagara Health System; McMaster University","funders":"","keywords":"Medicine; Biopsy; Prostate cancer; Stage (stratigraphy); Prostate; Prostate biopsy; Cancer; Prostate-specific antigen; Radiation therapy; General surgery; Internal medicine","score_opus":0.13128087036636818,"score_gpt":0.4385501513823179,"score_spread":0.30726928101594975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213063616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9203308,0.008316139,0.0000013563438,0.06372134,0.002767606,0.0029821328,0.0011611251,0.000013695244,0.000705814],"genre_scores_gemma":[0.9953277,0.0004697973,0.0001449014,0.0032919282,0.00019007365,0.0003034725,0.00003265266,0.000016042497,0.00022342746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99319327,0.0015964322,0.0039536087,0.00023921933,0.00076874794,0.00024873982],"domain_scores_gemma":[0.9875732,0.005100045,0.0062257852,0.0003495959,0.00045272295,0.00029865216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040825675,0.00017346829,0.002959226,0.000040088114,0.00012157153,0.000007520396,0.0002483332,0.000074884585,0.000035727666],"category_scores_gemma":[0.0012352798,0.000093282804,0.00038192957,0.00014551147,0.000109347464,0.000046428748,0.00009036036,0.00090138864,5.03543e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010991082,0.002328247,0.88975745,0.0015675172,0.0035012178,0.0010262567,0.0023066888,0.000088880995,0.00000107501,0.000018768207,0.07792147,0.010491316],"study_design_scores_gemma":[0.013172922,0.012111856,0.9273464,0.0023350907,0.00033903835,0.00009858779,0.00277758,0.000026069407,0.000008378764,0.000011381701,0.041673265,0.00009943644],"about_ca_topic_score_codex":0.82713085,"about_ca_topic_score_gemma":0.8368941,"teacher_disagreement_score":0.07499691,"about_ca_system_score_codex":0.0038480277,"about_ca_system_score_gemma":0.032862753,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W4213064176","doi":"10.1200/jco.2022.40.6_suppl.082","title":"Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Prospective cohort study; Quality of life (healthcare); Androgen deprivation therapy; Cancer; Cohort; Physical therapy","score_opus":0.20375292736056624,"score_gpt":0.5337860924145994,"score_spread":0.33003316505403313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213064176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804075,0.0017229916,0.000026265418,0.013797287,0.0022145105,0.0016339227,0.000047502064,0.000012125027,0.00013789025],"genre_scores_gemma":[0.99152833,0.0022726753,0.0021084985,0.0006635575,0.0008867885,0.0011532572,0.000018955669,0.000030000228,0.0013379527],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996872,0.0004647775,0.0017719233,0.00030234834,0.00025161635,0.00033732774],"domain_scores_gemma":[0.9965544,0.0017503158,0.0009944486,0.00017172658,0.00020546735,0.0003236839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011684628,0.00020869193,0.0014197427,0.00025801995,0.00010877602,0.000008496255,0.00012057259,0.000090785834,0.0001811458],"category_scores_gemma":[0.00020401826,0.0001550727,0.0004181606,0.00023209177,0.000048122663,0.0000788721,0.000036663227,0.00035744254,0.0000043968244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025132166,0.010825772,0.39365712,0.000043502943,0.0008376821,0.0003524788,0.0038310972,0.0019903819,0.0006908462,0.0000104798355,0.001204549,0.56142396],"study_design_scores_gemma":[0.08075416,0.11333024,0.6873646,0.0002517819,0.0022127598,0.00022558442,0.0015902882,0.0006719221,0.001572468,0.000076061624,0.11167759,0.00027259084],"about_ca_topic_score_codex":0.00044404893,"about_ca_topic_score_gemma":0.00043561214,"teacher_disagreement_score":0.5611513,"about_ca_system_score_codex":0.003312697,"about_ca_system_score_gemma":0.0017299827,"threshold_uncertainty_score":0.86625874},"labels":[],"label_agreement":null},{"id":"W4213066787","doi":"10.1200/jco.2022.40.6_suppl.tps284","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Randomization; Oncology; Randomized controlled trial; Antiandrogen; Tolerability; Urology; Cancer; Adverse effect; Pathology","score_opus":0.1202845928115184,"score_gpt":0.46894021180677387,"score_spread":0.34865561899525543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213066787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97979486,0.0026115058,0.00047600782,0.003944449,0.0009242584,0.011875917,0.0003150521,0.000007904149,0.000050062004],"genre_scores_gemma":[0.9773761,0.018385144,0.0010333224,0.0008480951,0.00040883714,0.0017141777,0.000028541617,0.000036798072,0.00016900558],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932301,0.0022240218,0.0030014664,0.0003108539,0.00090826716,0.0003252981],"domain_scores_gemma":[0.9869857,0.008039513,0.0037103,0.0002507494,0.0007642704,0.00024949003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010414128,0.00023615964,0.0032228157,0.0002866356,0.00023003129,0.000017472425,0.0002504127,0.00019209865,0.00020000344],"category_scores_gemma":[0.0031752104,0.00012486785,0.0008229181,0.0003594214,0.00039112824,0.00012297095,0.00009419996,0.0007293619,2.5652776e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8708524,0.0020333847,0.0022331835,0.000025929578,0.0034927079,0.000026578731,0.0006601898,0.00021186382,0.00052315975,0.000059765433,0.00038300705,0.11949781],"study_design_scores_gemma":[0.9488745,0.039861456,0.0005286126,0.000083900115,0.0009581118,0.000014530236,0.00018163804,0.00034421706,0.0024429876,0.0006045516,0.005992079,0.00011341709],"about_ca_topic_score_codex":0.00011319839,"about_ca_topic_score_gemma":0.000027367221,"teacher_disagreement_score":0.1193844,"about_ca_system_score_codex":0.00041428444,"about_ca_system_score_gemma":0.004302416,"threshold_uncertainty_score":0.7632301},"labels":[],"label_agreement":null},{"id":"W4213072175","doi":"10.1200/jco.2022.40.6_suppl.487","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Randomization; Clinical endpoint; Urology; Randomized controlled trial; Progression-free survival; Oncology; Carboplatin; Gemcitabine; Chemotherapy; Surgery; Bladder cancer; Urothelial carcinoma; Cisplatin; Nivolumab; Immunotherapy; Cancer","score_opus":0.13200194208637328,"score_gpt":0.42959722158729624,"score_spread":0.29759527950092296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213072175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414519,0.0011367048,0.00095258775,0.04025677,0.012006713,0.0022675921,0.0007619316,0.00002591966,0.0011398996],"genre_scores_gemma":[0.9781856,0.00069410045,0.0014949904,0.008362228,0.006434861,0.00017779767,0.00007982918,0.00006545343,0.0045051277],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99395645,0.000676673,0.0035337682,0.000523175,0.0007498309,0.0005600956],"domain_scores_gemma":[0.9893405,0.0066382103,0.0024415688,0.00060395605,0.00056804,0.00040775858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038258093,0.00031614158,0.0019331134,0.00009214859,0.00037127867,0.000020269104,0.0005927302,0.0003094093,0.00069713395],"category_scores_gemma":[0.0063137906,0.00019857715,0.0013663059,0.00020333908,0.000239706,0.00010887555,0.000200023,0.0015136217,0.00002303092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78347784,0.0038984728,0.011391873,0.000021901265,0.0014025129,0.0010629167,0.0006205441,0.000106142106,0.00009711079,0.000047065987,0.041897304,0.15597633],"study_design_scores_gemma":[0.581315,0.066577524,0.089432135,0.00011264727,0.0019270205,0.00034646224,0.00031013635,0.0001448038,0.00015243293,0.0010438483,0.25833666,0.00030130724],"about_ca_topic_score_codex":0.00016976781,"about_ca_topic_score_gemma":0.00040648677,"teacher_disagreement_score":0.21643937,"about_ca_system_score_codex":0.00048589325,"about_ca_system_score_gemma":0.0031389575,"threshold_uncertainty_score":0.80977416},"labels":[],"label_agreement":null},{"id":"W4213073484","doi":"10.1200/jco.2022.40.6_suppl.516","title":"Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Docetaxel; Pembrolizumab; Metastatic Urothelial Carcinoma; Phases of clinical research; Primary tumor; Internal medicine; Oncology; Clinical trial; Urology; Surgery; Chemotherapy; Cancer; Urothelial carcinoma; Metastasis; Bladder cancer; Immunotherapy","score_opus":0.09334664641587365,"score_gpt":0.4576947460580274,"score_spread":0.36434809964215376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213073484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968281,0.00038585835,0.0000882697,0.0005305886,0.0001715568,0.0017262462,0.00008790479,0.0000029649038,0.00017855495],"genre_scores_gemma":[0.9983725,0.0002130201,0.00047620133,0.0007381509,0.00010842678,0.00003409342,0.000017048946,0.000024116183,0.000016461254],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99332535,0.0023334576,0.003138389,0.00028393703,0.00065503235,0.00026383038],"domain_scores_gemma":[0.9921151,0.0047244728,0.0024191139,0.0002483867,0.000285296,0.00020762185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004705564,0.00024673188,0.0026926342,0.00032540594,0.000056324563,0.00000622485,0.00017919831,0.00009702726,0.00011989421],"category_scores_gemma":[0.0032978463,0.00013043133,0.00027895655,0.00041003566,0.0002559482,0.000110459376,0.00005750928,0.0008643803,4.006487e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73625743,0.023779687,0.050189093,0.000116413656,0.00052607065,0.0005183547,0.000816218,0.0004921284,0.0002772314,0.000009515308,0.00007159522,0.18694629],"study_design_scores_gemma":[0.3469357,0.18293107,0.4684477,0.00015104267,0.0006349301,0.00017366308,0.0001879287,0.00014522861,0.00006109089,0.000040782466,0.00019595328,0.00009495713],"about_ca_topic_score_codex":0.00012291511,"about_ca_topic_score_gemma":0.000045385023,"teacher_disagreement_score":0.41825858,"about_ca_system_score_codex":0.00042815015,"about_ca_system_score_gemma":0.003565136,"threshold_uncertainty_score":0.63243985},"labels":[],"label_agreement":null},{"id":"W4213073706","doi":"10.1200/jco.2022.40.6_suppl.437","title":"BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Population; Olaparib; Oncology; PARP inhibitor; Phases of clinical research; Gastroenterology; Chemotherapy; Surgery; Urology; Randomized controlled trial; Poly ADP ribose polymerase","score_opus":0.10989278370184659,"score_gpt":0.43211884893655506,"score_spread":0.3222260652347085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213073706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189585,0.00033017097,0.00018427125,0.00066284527,0.00043924636,0.0062204544,0.00009854795,0.000004854086,0.00016373693],"genre_scores_gemma":[0.99842334,0.00013857847,0.0003177492,0.00015117099,0.00015586868,0.0004789142,0.000026232306,0.000032292453,0.00027587533],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956304,0.0005370895,0.002500856,0.00026819643,0.0007880656,0.00027539764],"domain_scores_gemma":[0.99366826,0.0027539378,0.0024889724,0.00029804633,0.0006506342,0.00014013993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002250953,0.0002448922,0.0024275521,0.00024769953,0.00016606697,0.000006743582,0.00021632019,0.00010579176,0.00013353603],"category_scores_gemma":[0.00033307116,0.000125354,0.0003706919,0.00030704582,0.00019823013,0.00010083392,0.000071566894,0.00040986403,2.6877157e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71406627,0.07278608,0.20075057,0.0000420753,0.0014179376,0.00007998071,0.0016587623,0.0007945747,0.0000064480973,0.00001502908,0.00003616774,0.008346098],"study_design_scores_gemma":[0.7258765,0.23965546,0.029169245,0.000044579672,0.0016952415,0.000014928658,0.0008091889,0.00083148724,0.000079034064,0.000013951766,0.0017280998,0.0000822832],"about_ca_topic_score_codex":0.0013058698,"about_ca_topic_score_gemma":0.0014965917,"teacher_disagreement_score":0.17158133,"about_ca_system_score_codex":0.00036415877,"about_ca_system_score_gemma":0.0011752999,"threshold_uncertainty_score":0.5111788},"labels":[],"label_agreement":null},{"id":"W4213087577","doi":"10.1200/jco.2022.40.6_suppl.277","title":"Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"Medical Research Council","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Randomization; Internal medicine; Proportional hazards model; Radiation therapy; Oncology; Survival analysis; Cancer","score_opus":0.28879920908749546,"score_gpt":0.4965052661920813,"score_spread":0.20770605710458584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213087577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624431,0.02623943,0.0021239533,0.0030902259,0.0005895045,0.0016109375,0.003888917,0.0000050270087,0.000008908128],"genre_scores_gemma":[0.98038554,0.014141715,0.0042298567,0.00049216056,0.0001551946,0.0004303517,0.000099336896,0.000023686453,0.00004217579],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9888319,0.006286902,0.0035601829,0.00034285404,0.00069621,0.00028198896],"domain_scores_gemma":[0.9802376,0.015306108,0.0033347365,0.00016665598,0.0005470482,0.0004078526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021470591,0.00022773058,0.008028391,0.00045880972,0.00009599149,0.000021182586,0.00012979443,0.00016501937,0.0006365756],"category_scores_gemma":[0.0040810043,0.00012681483,0.0023290606,0.00031502405,0.00088438403,0.00011971635,0.00011074651,0.0008168254,8.015631e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54767716,0.0014128636,0.014263766,0.00004133868,0.30628774,0.0001726936,0.0014112596,0.00006332047,0.000012418573,0.00008311871,0.0003489191,0.12822542],"study_design_scores_gemma":[0.3758036,0.036568232,0.030763883,0.000015363878,0.5442531,0.00004158971,0.002308033,0.00062327896,0.000145222,0.0013653887,0.007874111,0.00023820275],"about_ca_topic_score_codex":0.0002532588,"about_ca_topic_score_gemma":0.00033864664,"teacher_disagreement_score":0.23796538,"about_ca_system_score_codex":0.00015812537,"about_ca_system_score_gemma":0.0011471807,"threshold_uncertainty_score":0.7441321},"labels":[],"label_agreement":null},{"id":"W4213095052","doi":"10.1200/jco.2022.40.6_suppl.035","title":"Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Medicine; Standardized uptake value; Prostate cancer; Nuclear medicine; Prostatectomy; Biopsy; Radiology; Cohort; Cancer; Positron emission tomography; Pathology; Internal medicine","score_opus":0.08366524849573825,"score_gpt":0.4622275587104839,"score_spread":0.3785623102147456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213095052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944097,0.0025158986,0.0000032001801,0.0015275775,0.00026091278,0.0005520675,0.0005113685,0.000004940031,0.00021433944],"genre_scores_gemma":[0.9930002,0.0060196877,0.00033175916,0.00025941752,0.000061421764,0.000026436213,0.000089663736,0.000015754185,0.00019567773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954406,0.00088769523,0.0022645406,0.00036451424,0.0007389403,0.0003037227],"domain_scores_gemma":[0.99668443,0.00089448446,0.001364122,0.00018814657,0.0004347778,0.00043405997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039910157,0.0001672969,0.001866549,0.00038469606,0.00008298798,0.000017954622,0.00011486462,0.00004246534,0.0001482012],"category_scores_gemma":[0.0010890499,0.00011946995,0.00024249793,0.0005774274,0.00029371853,0.00016870657,0.00010440817,0.00090039085,1.3700291e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056805406,0.0035938828,0.8811066,0.00006587018,0.0024054,0.0016840163,0.0004743356,0.0002779986,0.00035988356,0.00001511891,0.0024676102,0.050743856],"study_design_scores_gemma":[0.04265883,0.033632405,0.90958065,0.0001319411,0.0023109561,0.00010426305,0.00088549854,0.0011882436,0.00020590296,0.00013879775,0.008999429,0.00016305843],"about_ca_topic_score_codex":0.0004913002,"about_ca_topic_score_gemma":0.00059344753,"teacher_disagreement_score":0.050580796,"about_ca_system_score_codex":0.00038494548,"about_ca_system_score_gemma":0.0016260546,"threshold_uncertainty_score":0.48718432},"labels":[],"label_agreement":null},{"id":"W4213139730","doi":"10.1200/jco.2022.40.6_suppl.505","title":"Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Oncology; Cisplatin; Cohort; Proportional hazards model; Progression-free survival; Cancer; Retrospective cohort study; Carboplatin; Logistic regression; Hazard ratio; Confidence interval","score_opus":0.025143724840372726,"score_gpt":0.35011932856241934,"score_spread":0.3249756037220466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213139730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946024,0.00008915337,0.0000070858514,0.0036942335,0.00030965407,0.00047556835,0.00003527039,0.0000048722604,0.00078176084],"genre_scores_gemma":[0.9963754,0.000019960542,0.0008345859,0.001276521,0.00014591505,0.000017100661,0.000006673805,0.000023569437,0.0013003147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690056,0.00031051598,0.0018063578,0.00019937126,0.000569588,0.00021359192],"domain_scores_gemma":[0.99704677,0.000637451,0.001628279,0.00014354028,0.00033476902,0.00020916256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001447647,0.00015790628,0.0014323212,0.0001856397,0.000041739986,0.0000040982786,0.00009770888,0.00012741426,0.000595367],"category_scores_gemma":[0.0006581974,0.000103134706,0.00018746847,0.00020148832,0.000060900722,0.00008764276,0.00007391155,0.0006721838,0.0000059098134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018595828,0.0021539703,0.9579097,0.000020541702,0.00039898895,0.00010899286,0.00031818709,0.000084806394,0.00022685259,0.0000015089737,0.0004120747,0.019768529],"study_design_scores_gemma":[0.032667384,0.06288477,0.89684135,0.000057125653,0.00031587857,0.000036430298,0.00013931672,0.0000110306955,0.00039189233,0.000021510232,0.006531158,0.00010213887],"about_ca_topic_score_codex":0.00008160166,"about_ca_topic_score_gemma":0.00013920236,"teacher_disagreement_score":0.061068356,"about_ca_system_score_codex":0.00054013985,"about_ca_system_score_gemma":0.000893969,"threshold_uncertainty_score":0.6518851},"labels":[],"label_agreement":null},{"id":"W4213155579","doi":"10.1200/jco.2022.40.6_suppl.540","title":"Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Logistic regression; Oncology; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.045399942099561205,"score_gpt":0.37121616113505207,"score_spread":0.32581621903549085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213155579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960678,0.00018588256,0.000025922978,0.0019685365,0.0005713644,0.0005964962,0.00007717364,0.000007777498,0.0004990458],"genre_scores_gemma":[0.9968868,0.00033372885,0.0015553472,0.0005229043,0.0003980021,0.000017900868,0.000022451464,0.000044837147,0.00021805242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963452,0.00031486183,0.001842733,0.0003356147,0.00084828,0.00031330177],"domain_scores_gemma":[0.9942981,0.0021152983,0.0026131915,0.00026235756,0.00048365394,0.00022740403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008672452,0.00025648504,0.0019266066,0.00016492454,0.00006284087,0.0000051687425,0.00019772102,0.0002568024,0.00042483263],"category_scores_gemma":[0.0009839572,0.00017236799,0.00024234806,0.0003052678,0.00016409432,0.000113529444,0.00007403526,0.00086807087,0.0000010820637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39633045,0.005427668,0.5631383,0.000055833683,0.00092371873,0.000092090806,0.0005284115,0.00013256932,0.00012330341,0.000002098942,0.00031537635,0.032930218],"study_design_scores_gemma":[0.21720515,0.069638506,0.70750964,0.000116782016,0.00070453255,0.000027748083,0.00023712467,0.00006908593,0.0007986529,0.00002140543,0.003521008,0.00015038466],"about_ca_topic_score_codex":0.000361617,"about_ca_topic_score_gemma":0.00043501423,"teacher_disagreement_score":0.17912528,"about_ca_system_score_codex":0.000733755,"about_ca_system_score_gemma":0.0015126168,"threshold_uncertainty_score":0.70289624},"labels":[],"label_agreement":null},{"id":"W4213167571","doi":"10.1200/jco.2022.40.6_suppl.tps190","title":"IRONMAN: The international registry for men with advanced prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Cancer registry; Cohort; Ethnic group; Population; Socioeconomic status; Cancer; Disease; Quality of life (healthcare); Gerontology; Demography; Environmental health; Internal medicine","score_opus":0.12151832978571304,"score_gpt":0.5171844721595642,"score_spread":0.39566614237385117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213167571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7278818,0.0024528631,0.000056513956,0.2555585,0.001701508,0.0009665286,0.000055322093,0.000009519097,0.011317475],"genre_scores_gemma":[0.96603763,0.0034399177,0.0021150527,0.0040060114,0.0016255837,0.00028233448,0.000017231161,0.000024226618,0.022452034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843115,0.00012308075,0.00071173586,0.0001244599,0.00044430594,0.00016529324],"domain_scores_gemma":[0.9977599,0.0008630544,0.00080817076,0.00013289036,0.0003036757,0.00013232784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001840474,0.00006864859,0.00046537037,0.00004291927,0.00011999671,0.000007836519,0.0002618209,0.00004961756,0.00028507423],"category_scores_gemma":[0.0004708584,0.000033637378,0.00019265916,0.000077907636,0.00017391186,0.000054636006,0.00008246495,0.0007492001,0.0000011752842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.124689355,0.002254272,0.121904366,0.000057763576,0.0020363093,0.0011206468,0.0006377233,0.00088615966,0.0004951372,0.00035976895,0.20357582,0.54198265],"study_design_scores_gemma":[0.017505148,0.019210337,0.028008822,0.000035401663,0.00019254643,0.00034721172,0.0010763122,0.000240565,0.00012345563,0.00036653332,0.93283886,0.000054790395],"about_ca_topic_score_codex":0.000011115132,"about_ca_topic_score_gemma":0.000013967319,"teacher_disagreement_score":0.72926307,"about_ca_system_score_codex":0.00037728963,"about_ca_system_score_gemma":0.0023488952,"threshold_uncertainty_score":0.4166839},"labels":[],"label_agreement":null},{"id":"W4213174616","doi":"10.1200/jco.2022.40.6_suppl.tps221","title":"Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Olaparib; PARP inhibitor; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen receptor; Cancer; Poly ADP ribose polymerase; Pathology; Genetics; Biology; Gene","score_opus":0.15707699717238072,"score_gpt":0.4840448733343991,"score_spread":0.3269678761620184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213174616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917149,0.00029987836,0.00009953671,0.0006834383,0.0015970767,0.005282289,0.000121447025,0.000016467193,0.00018495275],"genre_scores_gemma":[0.9974956,0.00014572384,0.000835627,0.0005166722,0.00024723742,0.0005483452,0.000071120594,0.000053340755,0.00008636396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904537,0.002709536,0.00450455,0.0004741064,0.0014179617,0.0004401475],"domain_scores_gemma":[0.9895832,0.003667052,0.0047950502,0.00031296533,0.0012601227,0.0003816207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044171843,0.00036092603,0.0039570946,0.0005193793,0.00012377312,0.000016185062,0.0002185823,0.00016021432,0.0003283927],"category_scores_gemma":[0.0010804555,0.00027627512,0.00045023576,0.0007259299,0.00048741224,0.00023299803,0.00009618821,0.0017993607,0.0000031412474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9547411,0.011342919,0.005114655,0.000038234924,0.0028505488,0.0016503253,0.0043277727,0.015856337,0.00026551867,0.000012629051,0.00017910622,0.0036208362],"study_design_scores_gemma":[0.93657756,0.05131045,0.004936619,0.00012124664,0.0017323988,0.00014795783,0.0030733428,0.00084836484,0.0007063762,0.000028090373,0.000276707,0.00024091521],"about_ca_topic_score_codex":0.00040834327,"about_ca_topic_score_gemma":0.00055452756,"teacher_disagreement_score":0.03996753,"about_ca_system_score_codex":0.0016034083,"about_ca_system_score_gemma":0.0058071217,"threshold_uncertainty_score":0.99996895},"labels":[],"label_agreement":null},{"id":"W4213177806","doi":"10.1200/jco.2022.40.6_suppl.265","title":"Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"","keywords":"Medicine; Prostatectomy; Bicalutamide; Prostate cancer; Urology; Lymph node; Clinical endpoint; Prostate-specific antigen; Oncology; Radiation therapy; Cohort; Biochemical recurrence; Internal medicine; Surgery; Clinical trial; Cancer","score_opus":0.13117631161704618,"score_gpt":0.49090786706743034,"score_spread":0.35973155545038416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213177806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889871,0.00035640397,0.0000014253342,0.007798343,0.0007283392,0.00027747592,0.000036535086,0.0000046931777,0.0018097023],"genre_scores_gemma":[0.9967644,0.0005773686,0.00019139347,0.0019712306,0.00015849266,0.000027999991,0.0000041555677,0.000015847128,0.00028909277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687153,0.00029330765,0.001986454,0.00017999056,0.00042676282,0.00024194067],"domain_scores_gemma":[0.9952784,0.002667141,0.0014491851,0.00020962756,0.00014543449,0.0002501666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017427182,0.00014228684,0.0016648887,0.00019147967,0.000038080754,0.0000026807973,0.0001340544,0.00013132778,0.00086620013],"category_scores_gemma":[0.0016344106,0.000089192035,0.0008071065,0.00016047855,0.000094107425,0.00004353787,0.0001162227,0.0006934222,0.000010438332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008753614,0.0061204867,0.9571889,0.000018431596,0.0005269383,0.0013201688,0.0001219996,0.0003799476,0.00010589766,0.000019790717,0.0034372932,0.022006532],"study_design_scores_gemma":[0.014192233,0.03215938,0.9468793,0.00008588023,0.00016035902,0.00018713658,0.00005718401,0.000020442072,0.00017775413,0.000109579356,0.005900561,0.000070146634],"about_ca_topic_score_codex":0.00012549257,"about_ca_topic_score_gemma":0.00003241544,"teacher_disagreement_score":0.026038894,"about_ca_system_score_codex":0.0015755405,"about_ca_system_score_gemma":0.0016507065,"threshold_uncertainty_score":0.9484284},"labels":[],"label_agreement":null},{"id":"W4213178610","doi":"10.1200/jco.2022.40.6_suppl.467","title":"Use of perioperative treatment (tx) among patients (pts) undergoing radical resection (RR) for muscle-invasive urothelial cancer (MIUC) in France, Germany, Italy, Spain, the United Kingdom, the United States, Canada, China, and Japan.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Perioperative; Internal medicine; Cancer; Cisplatin; Disease; Chemotherapy; Surgery","score_opus":0.08708786525005241,"score_gpt":0.38404967564862247,"score_spread":0.29696181039857006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213178610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996735,0.0001844432,0.000025259347,0.0075866664,0.00088908104,0.0010950604,0.00019425571,0.000004143229,0.000053723983],"genre_scores_gemma":[0.99478364,0.0012246742,0.000069953094,0.0030543613,0.00036316636,0.00013513619,0.000051115545,0.000028136052,0.00028983335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996414,0.0011393228,0.0014184616,0.00024189675,0.0004931304,0.0002932002],"domain_scores_gemma":[0.993888,0.0042501786,0.0010793126,0.00019684626,0.00038882167,0.00019681283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010599649,0.0002093629,0.0008978357,0.00021064392,0.0003110865,0.0000169286,0.00016421768,0.00013769059,0.00010359588],"category_scores_gemma":[0.0012052116,0.00011468662,0.00022998905,0.00042210665,0.00038933533,0.00009741283,0.00007579795,0.0008194694,1.5987182e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015910914,0.0042068255,0.9310762,0.0000959584,0.002723867,0.00031061075,0.0065082344,0.011868407,0.000090330395,0.00020684046,0.0037069719,0.023294797],"study_design_scores_gemma":[0.020387322,0.019280048,0.84466654,0.0001351734,0.00067180797,0.000042085678,0.0013466123,0.0018249542,0.00006194878,0.00004346841,0.11140836,0.00013168051],"about_ca_topic_score_codex":0.35837853,"about_ca_topic_score_gemma":0.36014658,"teacher_disagreement_score":0.10770139,"about_ca_system_score_codex":0.0011703518,"about_ca_system_score_gemma":0.004291471,"threshold_uncertainty_score":0.7612886},"labels":[],"label_agreement":null},{"id":"W4213180043","doi":"10.1200/jco.2022.40.6_suppl.317","title":"First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Calgary; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Nivolumab; Internal medicine; Proportional hazards model; Gastroenterology; Carcinoma; Population; Urology; Oncology; Vascular endothelial growth factor; Clear cell renal cell carcinoma; Cancer; VEGF receptors; Immunotherapy","score_opus":0.13729454401842792,"score_gpt":0.3912992254531915,"score_spread":0.2540046814347636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213180043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973475,0.0033509987,0.0018592482,0.01492473,0.0012589971,0.0017478268,0.0024084332,0.000019806963,0.0009549756],"genre_scores_gemma":[0.96081156,0.00044158558,0.030959146,0.004599762,0.0011741442,0.00020410377,0.0008564606,0.000087372326,0.00086586195],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903723,0.0019704853,0.004519517,0.0008103182,0.0016937569,0.0006336081],"domain_scores_gemma":[0.97593796,0.016934438,0.004558117,0.000993456,0.0009001385,0.0006758645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072990186,0.00056611374,0.002654229,0.0002829648,0.00036660765,0.000055070028,0.0009935126,0.000119618235,0.00091071497],"category_scores_gemma":[0.0022713442,0.00032636456,0.0012122233,0.0003686023,0.00044075496,0.00022749309,0.00029880306,0.001802163,0.000018013949],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5399528,0.04189662,0.09798382,0.00049258507,0.01556924,0.044053815,0.0039215502,0.008525032,0.012729381,0.00029554448,0.2049043,0.029675286],"study_design_scores_gemma":[0.23554315,0.16859902,0.14276133,0.00024593924,0.020773374,0.0053581893,0.0048026335,0.00592398,0.021801244,0.0010960934,0.391811,0.0012840336],"about_ca_topic_score_codex":0.0005370807,"about_ca_topic_score_gemma":0.0002090265,"teacher_disagreement_score":0.30440968,"about_ca_system_score_codex":0.0006331386,"about_ca_system_score_gemma":0.0038974893,"threshold_uncertainty_score":0.9999188},"labels":[],"label_agreement":null},{"id":"W4213184329","doi":"10.1200/jco.2022.40.6_suppl.069","title":"First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Cancer registry; Population; Cohort; Cancer; Internal medicine; Gynecology; Physical therapy; Environmental health","score_opus":0.09518366232032556,"score_gpt":0.45430079222864544,"score_spread":0.3591171299083199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213184329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94788796,0.0010553014,0.000002561973,0.04717736,0.00070683757,0.00032783407,0.000044186123,0.0000045239394,0.002793452],"genre_scores_gemma":[0.9914917,0.0020084463,0.000491004,0.0010839339,0.00021170233,0.0000532201,0.00001979379,0.0000142860235,0.0046259314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725366,0.00017281693,0.001461159,0.00017357069,0.00078135397,0.0001574496],"domain_scores_gemma":[0.99584,0.0010978509,0.0023146162,0.00026532603,0.000333379,0.00014882153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009884799,0.00009861946,0.0007637946,0.00005205383,0.00010453022,0.0000046137857,0.00025419667,0.00006679269,0.0008520154],"category_scores_gemma":[0.0007018413,0.00004872092,0.00023698603,0.00009062912,0.00026680602,0.00005220623,0.00021803511,0.0007294816,0.0000015132463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02901232,0.0012077788,0.9126622,0.000015077755,0.0016819069,0.0016064423,0.0006026805,0.0005656751,0.00017451105,0.000008229108,0.01863721,0.03382597],"study_design_scores_gemma":[0.017422084,0.014329855,0.665977,0.00009957854,0.00040533516,0.0002837713,0.0014453294,0.00010663205,0.0004406775,0.00016224963,0.29923952,0.00008794759],"about_ca_topic_score_codex":0.00012945467,"about_ca_topic_score_gemma":0.00015850787,"teacher_disagreement_score":0.2806023,"about_ca_system_score_codex":0.00065893936,"about_ca_system_score_gemma":0.0014979398,"threshold_uncertainty_score":0.9328971},"labels":[],"label_agreement":null},{"id":"W4213214577","doi":"10.1200/jco.2022.40.6_suppl.332","title":"Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Proportional hazards model; Renal cell carcinoma; Chemotherapy; Survival analysis; Cancer; Meta-analysis; Progression-free survival; Targeted therapy; Confidence interval","score_opus":0.16146357670425726,"score_gpt":0.4184731399109814,"score_spread":0.25700956320672413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213214577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929944,0.0035585752,0.00071303494,0.0020627538,0.00030536423,0.00013710845,0.000030628064,0.000003610031,0.00019448182],"genre_scores_gemma":[0.9961195,0.000086454515,0.0027610497,0.00075157726,0.00006944545,0.000009543363,0.000014787228,0.0000075518906,0.0001800892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652934,0.00070094457,0.0017690563,0.00019501442,0.0006633892,0.00014227616],"domain_scores_gemma":[0.9966164,0.00095021114,0.0018267652,0.00017711996,0.00028257666,0.00014688262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019354995,0.00014788963,0.0023766898,0.00026337834,0.00009207557,0.000013124601,0.00013747164,0.00008049056,0.0004727889],"category_scores_gemma":[0.00024425177,0.000085772874,0.0013334611,0.000458157,0.0002951173,0.000110150795,0.00005632039,0.0005592676,1.9383312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0421815,0.00847286,0.7602829,0.00016077596,0.16496651,0.0022011972,0.0032081197,0.0003981192,0.010758401,0.00045042514,0.00035912785,0.0065600956],"study_design_scores_gemma":[0.012078544,0.014634286,0.8840212,0.000011301376,0.08087059,0.0008654867,0.0006916818,0.00016589943,0.00077488355,0.00008776939,0.005626928,0.00017143278],"about_ca_topic_score_codex":0.000025590898,"about_ca_topic_score_gemma":0.000030875417,"teacher_disagreement_score":0.123738326,"about_ca_system_score_codex":0.000101618134,"about_ca_system_score_gemma":0.0006244128,"threshold_uncertainty_score":0.5176707},"labels":[],"label_agreement":null},{"id":"W4213216277","doi":"10.1200/jco.2022.40.6_suppl.308","title":"Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Juravinski Cancer Centre; McMaster University; London Health Sciences Centre; Western University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"","keywords":"Medicine; Pazopanib; Axitinib; Sunitinib; Nivolumab; Internal medicine; Pembrolizumab; Oncology; Ipilimumab; Renal cell carcinoma; Interquartile range; Cabozantinib; Context (archaeology); Bevacizumab; Everolimus; Clinical endpoint; Vascular endothelial growth factor; Clinical trial; Cancer; Immunotherapy; Chemotherapy; VEGF receptors","score_opus":0.19155119367960255,"score_gpt":0.41269984314129327,"score_spread":0.22114864946169072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213216277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824665,0.0018800551,0.00019899446,0.0127987405,0.00091687735,0.0010524963,0.00001574367,0.000009609845,0.0006609564],"genre_scores_gemma":[0.99542004,0.00010170649,0.0019539895,0.00170789,0.00041111087,0.00012523495,0.00004958692,0.00003268505,0.00019774829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955004,0.0008166489,0.0026779554,0.00025479324,0.00047528176,0.00027495588],"domain_scores_gemma":[0.992988,0.004176521,0.002112467,0.00018307903,0.00030459944,0.00023532652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004393828,0.00019385201,0.0015762354,0.0003034269,0.00010595723,0.000011417646,0.0001878613,0.000118997465,0.000120440985],"category_scores_gemma":[0.0012196016,0.00014868888,0.0005728767,0.0002023602,0.00010500449,0.0001407777,0.00008632794,0.0009772481,0.000003836088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039056584,0.02602721,0.8512433,0.0006599133,0.0010916833,0.010605435,0.002892488,0.0001613168,0.0072498694,0.00042991358,0.004879515,0.055702776],"study_design_scores_gemma":[0.03975932,0.08178059,0.83873457,0.00009764742,0.00067317905,0.0009359895,0.0009642553,0.0008434274,0.001060523,0.0014012153,0.033528227,0.0002210528],"about_ca_topic_score_codex":0.000025620273,"about_ca_topic_score_gemma":0.00001848432,"teacher_disagreement_score":0.05575338,"about_ca_system_score_codex":0.0004668219,"about_ca_system_score_gemma":0.0013821014,"threshold_uncertainty_score":0.60633564},"labels":[],"label_agreement":null},{"id":"W4213222613","doi":"10.1200/jco.2022.40.6_suppl.051","title":"Impact of U.S. Preventative Services Task Force grade D recommendation against prostate-specific antigen screening on prostate cancer mortality.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Demography; Prostate cancer screening; Prostate-specific antigen; Cancer; Incidence (geometry); Gynecology; Internal medicine; Oncology; Gerontology","score_opus":0.14662644354118506,"score_gpt":0.4979762225728437,"score_spread":0.35134977903165865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213222613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269056,0.001055049,0.000018705958,0.0040785824,0.0006928106,0.00079061027,0.00027956275,0.000009239556,0.00038487854],"genre_scores_gemma":[0.9865502,0.010925824,0.00062609697,0.0012269592,0.0003425895,0.000089668,0.00012577421,0.00002729161,0.000085589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962236,0.0006236598,0.002124449,0.0002819994,0.00046602736,0.00028026514],"domain_scores_gemma":[0.995222,0.0007301374,0.0032135602,0.00018271516,0.00037397852,0.00027760703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020401021,0.00019725863,0.0012974618,0.0001658318,0.00011331592,0.000010947401,0.00015102311,0.00010138613,0.00035312359],"category_scores_gemma":[0.00011229895,0.00013988426,0.00064619764,0.0002563851,0.00010725267,0.00017739947,0.000089914276,0.0008180356,0.0000020907414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084674265,0.0036180338,0.73552036,0.000067861976,0.0017450372,0.0002587604,0.0012286311,0.0022530677,0.00068157143,0.000014743879,0.0024247612,0.24371976],"study_design_scores_gemma":[0.010001946,0.040857848,0.92158216,0.0002797685,0.00031058106,0.000035375197,0.00079695083,0.00019867763,0.0006037102,0.0001914701,0.025007196,0.0001343048],"about_ca_topic_score_codex":0.00022251783,"about_ca_topic_score_gemma":0.000046677113,"teacher_disagreement_score":0.24358545,"about_ca_system_score_codex":0.00072766235,"about_ca_system_score_gemma":0.0011894553,"threshold_uncertainty_score":0.5704315},"labels":[],"label_agreement":null},{"id":"W4213223108","doi":"10.1200/jco.2022.40.6_suppl.060","title":"Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; BC Cancer Agency; Kelowna General Hospital; University of British Columbia","funders":"BC Cancer Foundation","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Docetaxel; Oncology; Androgen deprivation therapy; Proportional hazards model; Abiraterone acetate; Progression-free survival; Cancer; Chemotherapy; Androgen receptor","score_opus":0.13477310959720806,"score_gpt":0.4716707362161949,"score_spread":0.3368976266189868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213223108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786216,0.0022862877,0.00011067562,0.010583333,0.0011485488,0.006451038,0.0007414642,0.000025096428,0.00003195615],"genre_scores_gemma":[0.9836919,0.0018684308,0.007740849,0.0006230029,0.00043900713,0.0042197374,0.0003163019,0.00009252825,0.0010082821],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.995161,0.000646426,0.0020898296,0.0005625741,0.00094741426,0.00059276127],"domain_scores_gemma":[0.99455833,0.0018648073,0.0020539958,0.00023630015,0.0008778891,0.0004086599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002104937,0.00042968462,0.0018503929,0.0002668238,0.00049475604,0.000052994958,0.00013270517,0.00011602061,0.00007363489],"category_scores_gemma":[0.0004033821,0.0002523378,0.00077647634,0.0003002443,0.00015990355,0.00026827332,0.00003261287,0.0005151268,0.0000014942528],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18877518,0.010796628,0.11322229,0.0003415661,0.014137538,0.0020658213,0.0055401507,0.0025979641,0.015202653,0.00013959057,0.0020069901,0.6451736],"study_design_scores_gemma":[0.26415175,0.3992081,0.050439503,0.0014375984,0.0073663057,0.00056161516,0.00984921,0.0021064328,0.09830003,0.0010063009,0.16389585,0.0016773044],"about_ca_topic_score_codex":0.00015028128,"about_ca_topic_score_gemma":0.00042187367,"teacher_disagreement_score":0.64349633,"about_ca_system_score_codex":0.001737991,"about_ca_system_score_gemma":0.00629689,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W4213229213","doi":"10.1200/jco.2022.40.6_suppl.104","title":"Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Testosterone (patch); Prostate cancer; Androgen deprivation therapy; Urology; Population; Adverse effect; Androgen; Internal medicine; Gynecology; Cancer; Hormone","score_opus":0.17911277608448398,"score_gpt":0.5206814600689443,"score_spread":0.3415686839844604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213229213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96659386,0.0015652213,0.0000059959593,0.028300257,0.00086951896,0.0017766504,0.00017770602,0.000007299366,0.0007034591],"genre_scores_gemma":[0.9939102,0.0019663135,0.00074203854,0.00079607696,0.00070979475,0.00032931045,0.000033353568,0.000028085497,0.0014848217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965332,0.00065311685,0.0016676966,0.00029791414,0.0005237314,0.00032430593],"domain_scores_gemma":[0.9919751,0.006058287,0.0012078043,0.0002716549,0.00028560677,0.00020153518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003865628,0.00014239858,0.0010505822,0.00008960399,0.00013242583,0.000010991221,0.00024669492,0.000084466046,0.00005817732],"category_scores_gemma":[0.002144316,0.00007666368,0.00018577125,0.00024751306,0.00014541784,0.00011499976,0.00010870173,0.0012491698,0.0000014944499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6662197,0.0053895297,0.028538588,0.000009781178,0.0007855651,0.001257622,0.0012627936,0.00048947777,0.0001187442,0.0000020564923,0.008722731,0.2872034],"study_design_scores_gemma":[0.48131844,0.29650944,0.070619546,0.00016088605,0.0007077591,0.00006730403,0.008111762,0.00020827103,0.00014081286,0.0003082874,0.14166388,0.00018359175],"about_ca_topic_score_codex":0.00030140806,"about_ca_topic_score_gemma":0.0007629068,"teacher_disagreement_score":0.29111993,"about_ca_system_score_codex":0.0007023684,"about_ca_system_score_gemma":0.0029008857,"threshold_uncertainty_score":0.54270905},"labels":[],"label_agreement":null},{"id":"W4213230310","doi":"10.1200/jco.20.02363","title":"Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Open label; Phases of clinical research; First line therapy; Chemotherapy; Immunotherapy; Cancer; Clinical trial","score_opus":0.12702959612721465,"score_gpt":0.42852472236053935,"score_spread":0.3014951262333247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213230310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940129,0.0009870532,0.000010495296,0.0009671714,0.00035655682,0.0012084718,0.0000055065443,0.000006267256,0.0024455986],"genre_scores_gemma":[0.99545157,0.00059018104,0.0022782674,0.00096756284,0.00022475689,0.000015536634,0.000011225398,0.000059413498,0.00040147663],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9944775,0.0007777052,0.003116995,0.00049502525,0.0007564197,0.00037633133],"domain_scores_gemma":[0.9943461,0.0009849598,0.0025328172,0.0005601025,0.0011276451,0.00044838976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011640781,0.00033462033,0.0025124396,0.00021203491,0.00007565332,0.000017533514,0.00042794037,0.0003049503,0.00030705295],"category_scores_gemma":[0.00034277045,0.00022756071,0.0002518201,0.00039247054,0.00014033413,0.00020209272,0.0001792119,0.001031635,0.0000069264306],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25618365,0.43289313,0.16308396,0.000052917232,0.00050250883,0.0052442476,0.001236359,0.00018804867,0.003990695,0.0000030389542,0.0003258,0.13629563],"study_design_scores_gemma":[0.27791098,0.5611708,0.14810021,0.00008458559,0.00025264957,0.00007170391,0.00034892547,0.00002323956,0.008316784,0.000027920645,0.0035340155,0.00015817015],"about_ca_topic_score_codex":0.000058251415,"about_ca_topic_score_gemma":0.00010714867,"teacher_disagreement_score":0.13613746,"about_ca_system_score_codex":0.00037807573,"about_ca_system_score_gemma":0.0018270763,"threshold_uncertainty_score":0.92796564},"labels":[],"label_agreement":null},{"id":"W4213238101","doi":"10.1200/jco.2022.40.6_suppl.346","title":"Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Université Laval; McMaster University; University of Ottawa; Sunnybrook Hospital; BC Cancer Agency; Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; University of Calgary; Juravinski Cancer Centre; University of Manitoba; Dalhousie University; University Health Network; University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Discontinuation; Nivolumab; Renal cell carcinoma; Internal medicine; Ipilimumab; Oncology; Tyrosine-kinase inhibitor; Cabozantinib; Cancer; Immunotherapy","score_opus":0.04212863513743546,"score_gpt":0.3229918578124641,"score_spread":0.2808632226750286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213238101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922152,0.00044655456,0.0000043780465,0.0029801577,0.0015749546,0.0008666735,0.00037784266,0.000006971105,0.0015272709],"genre_scores_gemma":[0.9976784,0.00003884015,0.0002921523,0.0013889364,0.00026929143,0.000044305496,0.00019054048,0.00002458591,0.000072945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99313635,0.0013250527,0.00395541,0.00024970324,0.0009775787,0.0003559149],"domain_scores_gemma":[0.9935991,0.0015362995,0.003122646,0.00038786023,0.00071520446,0.00063884654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027851523,0.00023670362,0.001286962,0.00041525427,0.00014222827,0.000021733698,0.00029542632,0.00020711987,0.00014937608],"category_scores_gemma":[0.0015876268,0.00016893096,0.0004399335,0.00043701805,0.00015285399,0.00025836483,0.000121722114,0.0013276924,0.000016175532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.22058329,0.012582346,0.6417709,0.00082467875,0.00093541184,0.0040502814,0.013974672,0.006271216,0.0004103861,0.00008212883,0.056888875,0.0416258],"study_design_scores_gemma":[0.07926997,0.017812952,0.8805286,0.00027243842,0.00093099533,0.000044342825,0.0015110772,0.0012665249,0.0009673979,0.000017362625,0.017170481,0.0002078307],"about_ca_topic_score_codex":0.066052996,"about_ca_topic_score_gemma":0.017260415,"teacher_disagreement_score":0.23875771,"about_ca_system_score_codex":0.0045770295,"about_ca_system_score_gemma":0.0067133424,"threshold_uncertainty_score":0.9992442},"labels":[],"label_agreement":null},{"id":"W4213241801","doi":"10.1200/jco.2022.40.6_suppl.222","title":"Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Saskatchewan; Horizon Health Network; Saint John Regional Hospital","funders":"","keywords":"Histopathology; Medicine; Prostate cancer; Cancer; Oncology; Biopsy; Clinical trial; Stage (stratigraphy); Prostate; Internal medicine; Radiology; Pathology","score_opus":0.18158956860530254,"score_gpt":0.5355532580715139,"score_spread":0.3539636894662114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213241801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872859,0.00046369876,0.007176895,0.003478498,0.0009329942,0.0005602176,0.0000026003217,0.000010707144,0.000088474546],"genre_scores_gemma":[0.98007846,0.00023051065,0.01793246,0.0013720271,0.0002597483,0.000028257891,0.0000141218125,0.000031178723,0.000053208314],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99001974,0.0037600233,0.0050161043,0.00038194205,0.0004901728,0.00033200975],"domain_scores_gemma":[0.9895848,0.005567732,0.0040335516,0.00011984843,0.00030118236,0.00039289295],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022087118,0.00020363274,0.0028330137,0.00038297227,0.00011209837,0.000013837271,0.00014274754,0.0003008076,0.00008468556],"category_scores_gemma":[0.020183219,0.00014562729,0.00027997236,0.00025690545,0.0005661656,0.000109798464,0.00013695672,0.0031592974,7.452232e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030903434,0.0046364646,0.30369744,0.000046314217,0.00026010623,0.0020156156,0.00091557833,0.002505952,0.00039725652,0.000012911806,0.000034504897,0.65457445],"study_design_scores_gemma":[0.2468372,0.07365245,0.22729425,0.00078341924,0.0017458288,0.004695677,0.0021822606,0.2613487,0.00010113137,0.000104203486,0.18064433,0.0006105379],"about_ca_topic_score_codex":0.000029029066,"about_ca_topic_score_gemma":0.000018200584,"teacher_disagreement_score":0.6539639,"about_ca_system_score_codex":0.0005386005,"about_ca_system_score_gemma":0.0032385476,"threshold_uncertainty_score":0.99914044},"labels":[],"label_agreement":null},{"id":"W4213261511","doi":"10.1200/jco.2010.28.18_suppl.lba5012b","title":"PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Interim analysis; Adverse effect; Internal medicine; Ovarian cancer; Oncology; Discontinuation; Randomized controlled trial; Cancer; Urology; Surgery","score_opus":0.07929973743231516,"score_gpt":0.439236840127927,"score_spread":0.35993710269561185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213261511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878769,0.00037264713,0.000009216218,0.007226417,0.0020944197,0.001286075,0.000004809529,0.0000096479935,0.0011198962],"genre_scores_gemma":[0.997334,0.0005487499,0.0010982985,0.00021923649,0.0006563936,0.00007251457,0.0000072021007,0.000021364047,0.000042227904],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957768,0.0005357077,0.0026713524,0.0003161475,0.00038694777,0.00031307258],"domain_scores_gemma":[0.9938765,0.0036647706,0.001649378,0.0001836139,0.00026346993,0.0003622631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003709364,0.00022929772,0.002931947,0.0003045217,0.00006546147,0.00002386851,0.00012151624,0.00039392686,0.00014047744],"category_scores_gemma":[0.002309065,0.00015521584,0.00021787005,0.00029287176,0.00026867035,0.00014616358,0.000051660903,0.0014583472,0.0000015507325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9332918,0.009845278,0.03949058,0.000026586351,0.00069157605,0.0010649526,0.0005099262,0.000033646367,0.00021102799,0.00038263504,0.00013436754,0.014317656],"study_design_scores_gemma":[0.8640987,0.03959788,0.0930128,0.0003488996,0.000720582,0.000085120824,0.00007451824,0.00073482643,0.00014935099,0.0001446953,0.00089873536,0.00013384319],"about_ca_topic_score_codex":0.0008292645,"about_ca_topic_score_gemma":0.020493394,"teacher_disagreement_score":0.06919301,"about_ca_system_score_codex":0.00027118318,"about_ca_system_score_gemma":0.0017758645,"threshold_uncertainty_score":0.9973801},"labels":[],"label_agreement":null},{"id":"W4213265377","doi":"10.1200/jco.2022.40.6_suppl.238","title":"Successful same-day discharge for robot-assisted radical prostatectomy: A systematic review and meta-analysis.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University","funders":"","keywords":"Medicine; Prostatectomy; Meta-analysis; Systematic review; MEDLINE; Population; Randomized controlled trial; Surgery; Internal medicine; Prostate cancer","score_opus":0.3272279215202967,"score_gpt":0.5301134331962204,"score_spread":0.20288551167592367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213265377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010938905,0.98746645,0.00016549531,0.0066540316,0.0003588289,0.004853462,0.00006265092,0.000017371867,0.00042058958],"genre_scores_gemma":[0.0000066432635,0.98927915,0.0012112232,0.00543973,0.00036458304,0.00064896175,0.00007182988,0.000067373454,0.0029105209],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9793589,0.007920232,0.01070205,0.0006120611,0.00095680676,0.0004499228],"domain_scores_gemma":[0.94657737,0.04238216,0.009084326,0.0006755423,0.0003728283,0.00090776203],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.027079746,0.00066250714,0.06912094,0.000515162,0.00010282437,0.000037505815,0.0004697222,0.0008739886,0.0013555139],"category_scores_gemma":[0.026450623,0.0003307255,0.036336217,0.0009040096,0.00029308783,0.00009193216,0.00013880599,0.002407277,0.000011789608],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020145775,0.0007480762,0.00003389921,0.5989026,0.35775164,0.0010759487,0.000011070653,2.3974732e-7,7.127608e-9,0.00027930207,0.00081163965,0.040184118],"study_design_scores_gemma":[0.00089742104,0.0012773849,0.000039175786,0.0058150217,0.4965769,0.001661571,0.000007946842,0.0000012146169,3.6823948e-9,0.000007420255,0.4935599,0.00015603658],"about_ca_topic_score_codex":0.000004634572,"about_ca_topic_score_gemma":0.0000042913707,"teacher_disagreement_score":0.5930876,"about_ca_system_score_codex":0.0002728473,"about_ca_system_score_gemma":0.002647435,"threshold_uncertainty_score":0.99991447},"labels":[],"label_agreement":null},{"id":"W4213275011","doi":"10.1200/jco.2022.40.6_suppl.433","title":"Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Sinai Health System; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Proportional hazards model; Clinical endpoint; Oncology; Urology; Stage (stratigraphy); Randomized controlled trial; Internal medicine; Surgery; Cancer","score_opus":0.22967271024806532,"score_gpt":0.5197063525925104,"score_spread":0.29003364234444506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213275011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98045605,0.0012444075,0.003195186,0.0113801565,0.0022640426,0.0010329372,0.00014240418,0.000011070716,0.00027373922],"genre_scores_gemma":[0.9858325,0.00022702436,0.008687509,0.0040174844,0.0009561722,0.0001243555,0.00000891469,0.00001747133,0.00012852815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996415,0.00043294657,0.0021531752,0.00022981767,0.0005381525,0.0002308928],"domain_scores_gemma":[0.99601084,0.001691385,0.0012618846,0.0001742113,0.0004702364,0.00039144247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001845262,0.00015686965,0.0018616489,0.00011527326,0.00012352296,0.0000037770028,0.00022409312,0.00018761533,0.0005982365],"category_scores_gemma":[0.0012284531,0.000109894674,0.00076212035,0.0001783788,0.0002165189,0.000048144062,0.000062830375,0.00070747506,0.0000029091836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10171262,0.037422664,0.332769,0.00018937839,0.006211329,0.00049339136,0.002754322,0.0020417098,0.016030565,0.00051493646,0.033093624,0.46676645],"study_design_scores_gemma":[0.09058528,0.06644213,0.5443193,0.000110259454,0.0010610302,0.00022981546,0.0010000321,0.00045308168,0.004036983,0.000334269,0.2911653,0.00026259563],"about_ca_topic_score_codex":0.0001485502,"about_ca_topic_score_gemma":0.00008016873,"teacher_disagreement_score":0.46650386,"about_ca_system_score_codex":0.00043202523,"about_ca_system_score_gemma":0.0061819195,"threshold_uncertainty_score":0.9994521},"labels":[],"label_agreement":null},{"id":"W4213280237","doi":"10.1200/jco.2022.40.6_suppl.512","title":"Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Oncology; Internal medicine; Clinical trial; Cancer; Immunotherapy","score_opus":0.03649077028794652,"score_gpt":0.41552770364427966,"score_spread":0.37903693335633315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213280237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939079,0.0026444974,0.0000029973678,0.0025194322,0.00040499846,0.00034179605,0.000037484093,0.0000016838728,0.00013916602],"genre_scores_gemma":[0.9984563,0.0005419548,0.0003997451,0.00042877556,0.00008700606,0.000008507089,0.0000028787977,0.000010945692,0.00006387265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960869,0.000670097,0.0023789497,0.00017942804,0.00051521196,0.00016944401],"domain_scores_gemma":[0.99579287,0.0011690722,0.002396304,0.00029069622,0.00025637524,0.000094659445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019807967,0.00012727524,0.0016035712,0.00033306403,0.000033719916,0.0000017414648,0.00018919545,0.0001613433,0.00022301901],"category_scores_gemma":[0.0007075711,0.000076130025,0.0009049764,0.0006303266,0.0003834641,0.00004099494,0.00013709615,0.00054534466,1.1787615e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29098347,0.0035546573,0.4993748,0.000070001755,0.0018436312,0.00017158006,0.0008060091,0.0001005954,0.010979933,0.0000088763945,0.000069963,0.19203648],"study_design_scores_gemma":[0.024602614,0.02739371,0.9421854,0.00012389077,0.001541652,0.000070954775,0.00026920118,0.00007014293,0.0013850281,0.000016404025,0.0022786974,0.0000622772],"about_ca_topic_score_codex":0.000075262855,"about_ca_topic_score_gemma":0.00008246221,"teacher_disagreement_score":0.44281062,"about_ca_system_score_codex":0.00021258574,"about_ca_system_score_gemma":0.0009997921,"threshold_uncertainty_score":0.31044924},"labels":[],"label_agreement":null},{"id":"W4213290660","doi":"10.1200/jco.2022.40.6_suppl.086","title":"Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of British Columbia; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Manitoba; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton; Hôpital Charles-Le Moyne; University of Toronto; University of Calgary; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital; University of Ottawa; McGill University; McMaster University; Jewish General Hospital","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Cohort; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.21638830712805274,"score_gpt":0.5691707472062537,"score_spread":0.352782440078201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213290660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797119,0.00050746667,0.0000025642075,0.014597465,0.0005710787,0.0016819938,0.000046513902,0.0000033690787,0.0028776827],"genre_scores_gemma":[0.996089,0.0012246772,0.0002907343,0.000497059,0.00039494302,0.00018324771,0.000009566144,0.000017275017,0.0012935337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99027187,0.0050079986,0.0021111474,0.00026124125,0.0019968888,0.0003508736],"domain_scores_gemma":[0.98341495,0.0119176805,0.0013669103,0.00018100633,0.0029402399,0.00017918626],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019983577,0.00011963538,0.0009088779,0.0004318477,0.00019178037,0.000016395872,0.00020435458,0.00005333129,0.00038821643],"category_scores_gemma":[0.006112733,0.00007633416,0.00019527406,0.0005344573,0.00030168824,0.00021236925,0.00020987276,0.0024222285,0.00000331306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012582829,0.0062809624,0.96492577,0.00003640629,0.001253694,0.0040542227,0.002737541,0.0003048021,0.00010677963,0.000037859572,0.0017103448,0.005968783],"study_design_scores_gemma":[0.00927799,0.01016776,0.96208805,0.00007467448,0.00035484042,0.00022348118,0.0123374285,0.00031270596,0.000056199904,0.00007897646,0.0049628434,0.00006507676],"about_ca_topic_score_codex":0.002059038,"about_ca_topic_score_gemma":0.0019391312,"teacher_disagreement_score":0.016377099,"about_ca_system_score_codex":0.0010822762,"about_ca_system_score_gemma":0.0059791342,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W4213300962","doi":"10.1200/jco.2022.40.6_suppl.460","title":"Impact of COVID-19 on cancer caregivers: Results from the Global Carer Well-being Index.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family caregivers; Gerontology; Cancer; Population; Pandemic; Caregiver burden; Family medicine; Psychiatry; Coronavirus disease 2019 (COVID-19); Disease; Dementia; Environmental health","score_opus":0.21606005538840292,"score_gpt":0.5761264377965025,"score_spread":0.36006638240809963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213300962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8775956,0.0005457413,0.000025302195,0.11630027,0.0019360547,0.00024633436,0.00028157292,0.000009694781,0.003059446],"genre_scores_gemma":[0.9687894,0.0005963734,0.00004743081,0.028568283,0.0018872587,0.0000035065052,0.000010280408,0.000012386799,0.00008506859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951439,0.0012079885,0.0022238577,0.00025189907,0.0008439685,0.0003283743],"domain_scores_gemma":[0.9858677,0.009831309,0.0024498703,0.00040380497,0.0004426872,0.001004634],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040639094,0.00016259917,0.0013612347,0.00009479965,0.00016269073,0.0000075928338,0.00037706434,0.00027893487,0.0010103519],"category_scores_gemma":[0.016466213,0.0000971459,0.0008831653,0.00033186254,0.00021347967,0.000058716792,0.00015906552,0.001867015,0.000006797396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0536586,0.0010750707,0.78241384,0.000036275316,0.000931456,0.0014957088,0.003351498,0.003735953,0.000013307609,0.00012057781,0.11307353,0.040094182],"study_design_scores_gemma":[0.013672278,0.018214306,0.7161383,0.00008458547,0.00031377477,0.00014426096,0.0015547349,0.00006755538,0.0000028660625,0.0008338445,0.24888614,0.00008734983],"about_ca_topic_score_codex":0.028282514,"about_ca_topic_score_gemma":0.002336971,"teacher_disagreement_score":0.13581261,"about_ca_system_score_codex":0.004056103,"about_ca_system_score_gemma":0.02318124,"threshold_uncertainty_score":0.99990284},"labels":[],"label_agreement":null},{"id":"W4213306332","doi":"10.1200/jco.2022.40.6_suppl.073","title":"Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Proportional hazards model; Titan (rocket family); Placebo; Androgen deprivation therapy; Post-hoc analysis; Prostate-specific antigen; Prostate; Cancer; Urology; Pathology","score_opus":0.10570767842556247,"score_gpt":0.438367632866634,"score_spread":0.33265995444107155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213306332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711747,0.0017999306,8.218901e-8,0.009525035,0.00009284562,0.0013837565,0.000022795517,0.000004741628,0.000053354714],"genre_scores_gemma":[0.9930403,0.0061675697,0.000076839824,0.00036368406,0.000045574758,0.00015050647,0.00002088461,0.000017513808,0.000117131836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691534,0.0006168368,0.0011815104,0.00028155508,0.00065570214,0.00034902946],"domain_scores_gemma":[0.9973844,0.000858824,0.0012215456,0.00011952747,0.00029438277,0.00012126523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022970352,0.00017249714,0.0011927928,0.00027433853,0.000077728015,0.000013482503,0.0000778664,0.0000902152,0.000009557961],"category_scores_gemma":[0.0004359002,0.00009035933,0.00004308356,0.00049508235,0.00016765199,0.000120261255,0.000064948654,0.0009278796,1.6753536e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010395015,0.00091837917,0.93760365,0.000029430432,0.0003757254,0.00073376653,0.0028911587,0.000024869727,0.000013236797,0.000001016428,0.00011275787,0.046901017],"study_design_scores_gemma":[0.025424302,0.021897927,0.9462387,0.00016190179,0.0001293976,0.000014810687,0.0033836123,0.000005783295,0.000022226948,0.00003193773,0.002589425,0.00009997135],"about_ca_topic_score_codex":0.00012518714,"about_ca_topic_score_gemma":0.0025407437,"teacher_disagreement_score":0.046801046,"about_ca_system_score_codex":0.0009571274,"about_ca_system_score_gemma":0.00046376706,"threshold_uncertainty_score":0.40312266},"labels":[],"label_agreement":null},{"id":"W4213306983","doi":"10.1200/jco.2022.40.6_suppl.065","title":"Prevalence and natural history of non-metastatic castrate resistant prostate cancer: A population-based analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Interquartile range; Internal medicine; Hazard ratio; Population; Cancer; Urology; Oncology; Gynecology; Confidence interval","score_opus":0.0925722429414721,"score_gpt":0.4692166344822014,"score_spread":0.3766443915407293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213306983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854726,0.011048053,0.000008451854,0.0024609114,0.00058012136,0.00026007104,0.000032700005,0.000003165414,0.00013391917],"genre_scores_gemma":[0.99505126,0.0011766636,0.0009236872,0.00037635668,0.00008749676,0.000018278512,0.000010793166,0.0000085520405,0.00234688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717516,0.00049381354,0.0014623262,0.00017299486,0.00051797694,0.00017772472],"domain_scores_gemma":[0.9968924,0.0009398546,0.0014762925,0.00013639183,0.00034567103,0.00020939365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023941519,0.00009563749,0.0011268611,0.00030803928,0.000046998535,0.0000029849225,0.00010371969,0.00004912938,0.00029881226],"category_scores_gemma":[0.00049426453,0.00006691035,0.00035449123,0.00030399178,0.00019915734,0.000058376452,0.000044470937,0.00075461547,3.328232e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017707983,0.0010760789,0.957702,0.00034698966,0.0018962168,0.0009598435,0.0002945543,0.0008033622,0.0006535546,0.000010162018,0.0014583763,0.017090907],"study_design_scores_gemma":[0.0069558737,0.008868553,0.9739103,0.000069067675,0.0023741003,0.000044043358,0.00010320528,0.0028619084,0.00002523706,0.000052314314,0.0046665715,0.00006883029],"about_ca_topic_score_codex":0.0003149834,"about_ca_topic_score_gemma":0.000112983864,"teacher_disagreement_score":0.017022077,"about_ca_system_score_codex":0.0009903581,"about_ca_system_score_gemma":0.004818194,"threshold_uncertainty_score":0.85472697},"labels":[],"label_agreement":null},{"id":"W4213307792","doi":"10.1200/jco.2022.40.6_suppl.tps582","title":"TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Internal medicine; Cancer; Chemotherapy; Phases of clinical research; Oncology; Gastroenterology; Surgery","score_opus":0.0877426200166195,"score_gpt":0.4071169907731531,"score_spread":0.31937437075653363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213307792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603236,0.0006718019,0.000018393075,0.0008657529,0.00044634927,0.0018070007,0.000043383865,0.000008629723,0.00010631382],"genre_scores_gemma":[0.99756753,0.00022559772,0.00090119534,0.00050848245,0.00019438424,0.0004048419,0.0000023619796,0.000046534253,0.00014906385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568313,0.0009019939,0.0018526084,0.00036262284,0.00086536165,0.00033425834],"domain_scores_gemma":[0.9968038,0.00086270116,0.001515926,0.00023481711,0.0003122132,0.0002705386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011833378,0.0002735477,0.0018112672,0.00020282356,0.00008652563,0.000019686568,0.00017683541,0.00012404687,0.00048125966],"category_scores_gemma":[0.0004131505,0.00016561101,0.00018224503,0.0002911748,0.0002506739,0.00016042792,0.00010926276,0.0010305877,6.3672303e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17020704,0.015373678,0.6375373,0.00007966572,0.0010253052,0.00095925404,0.0018581685,0.0001427832,0.00006948425,0.000001550153,0.00008854303,0.1726572],"study_design_scores_gemma":[0.119274884,0.15816677,0.7130606,0.00026383775,0.00064333726,0.00009318105,0.0016534103,0.000056545356,0.00033128186,0.000037357764,0.0062086107,0.00021016998],"about_ca_topic_score_codex":0.00022238605,"about_ca_topic_score_gemma":0.0012397498,"teacher_disagreement_score":0.17244703,"about_ca_system_score_codex":0.00042620944,"about_ca_system_score_gemma":0.0034283344,"threshold_uncertainty_score":0.67534214},"labels":[],"label_agreement":null},{"id":"W4213308820","doi":"10.1200/jco.2022.40.6_suppl.075","title":"The effects of a preference-based exercise trial on outcomes in men on androgen deprivation therapy (ADT) for prostate cancer compared to an exercise randomized controlled trial of the same interventions.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Cancer Care Ontario; University Health Network; Toronto Metropolitan University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Physical therapy; Psychological intervention; Androgen deprivation therapy; Randomization; Prostate cancer; Clinical trial; Aerobic exercise; Internal medicine; Cancer","score_opus":0.1778331054713292,"score_gpt":0.49773628455946867,"score_spread":0.3199031790881395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213308820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97106445,0.00071239145,0.000009843579,0.0064242845,0.0015091398,0.020220622,0.000017437056,0.0000033751282,0.000038449103],"genre_scores_gemma":[0.9931176,0.0017545951,0.00006808457,0.0002939688,0.00014893479,0.004260979,0.0000055304313,0.0000134670245,0.00033687957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938154,0.002556378,0.0026532994,0.00016886204,0.0006149114,0.00019112413],"domain_scores_gemma":[0.98380274,0.013295953,0.0021652293,0.00025655684,0.0003564038,0.00012311702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008783084,0.00014009094,0.003157731,0.0001952656,0.000100571655,0.000008887918,0.0002922415,0.00010111232,0.000030206273],"category_scores_gemma":[0.00571553,0.000059123267,0.00151054,0.00018811937,0.00018417077,0.000033517194,0.0000431579,0.0005028305,2.1245012e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93926287,0.00690148,0.002020483,0.000058518388,0.0005919903,0.0000067882597,0.00034917746,0.00023678175,0.000083997365,0.000024065857,0.00028651673,0.050177317],"study_design_scores_gemma":[0.9364831,0.05593141,0.004303313,0.0005199854,0.000510972,4.407863e-7,0.000107788655,0.00029824182,0.0010269356,0.00048000136,0.00028772038,0.00005007696],"about_ca_topic_score_codex":0.00005654767,"about_ca_topic_score_gemma":0.00005505127,"teacher_disagreement_score":0.050127238,"about_ca_system_score_codex":0.00024561983,"about_ca_system_score_gemma":0.001626563,"threshold_uncertainty_score":0.6842436},"labels":[],"label_agreement":null},{"id":"W4213309199","doi":"10.1200/jco.2022.40.6_suppl.519","title":"Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Cisplatin; Internal medicine; Exploratory analysis; Oncology; Cancer; Chemotherapy","score_opus":0.05767378072511174,"score_gpt":0.41509262318174606,"score_spread":0.3574188424566343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213309199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776281,0.0018062677,0.000093849994,0.018433437,0.00066478836,0.0006538104,0.0005686622,0.000010244961,0.00014080653],"genre_scores_gemma":[0.9931795,0.00046604848,0.0010082882,0.0030751335,0.00018283472,0.000051542123,0.00005237574,0.000043284497,0.0019409959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945609,0.0008963061,0.0030599262,0.00043419155,0.0006052163,0.0004434471],"domain_scores_gemma":[0.99135095,0.0055914936,0.0018548442,0.00035650746,0.00043627614,0.0004099153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032564518,0.00029997912,0.0032289291,0.0006703148,0.00014670471,0.0000068240606,0.00026708946,0.00028661214,0.0006156313],"category_scores_gemma":[0.0036326498,0.00023389368,0.001114733,0.00056373846,0.0002303314,0.00010002704,0.00021118941,0.0007986558,0.0000019746806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45653135,0.0048501333,0.5049937,0.00006778005,0.004188369,0.00061556825,0.00047693058,0.00041910142,0.0040717474,0.000012681313,0.0020290962,0.02174356],"study_design_scores_gemma":[0.089653656,0.07683849,0.7881667,0.000037727703,0.0067669842,0.00021769902,0.00027867212,0.0006284821,0.0005229582,0.00009021722,0.036544707,0.00025369896],"about_ca_topic_score_codex":0.00018549322,"about_ca_topic_score_gemma":0.00064260967,"teacher_disagreement_score":0.36687768,"about_ca_system_score_codex":0.00065629213,"about_ca_system_score_gemma":0.0012515029,"threshold_uncertainty_score":0.9537907},"labels":[],"label_agreement":null},{"id":"W4213314922","doi":"10.1200/jco.2022.40.6_suppl.345","title":"The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Renal cell carcinoma; Systemic therapy; Thrombus; Nephrectomy; Internal medicine; Cancer; Urology; Oncology; Progression-free survival; Cohort; Surgery; Chemotherapy; Kidney","score_opus":0.04280343870933002,"score_gpt":0.34677186268360116,"score_spread":0.30396842397427115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213314922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950074,0.0029186052,0.0000015724295,0.00037855597,0.00011596248,0.00072206254,0.0000037139462,8.2634364e-7,0.0008513191],"genre_scores_gemma":[0.9990086,0.00026326388,0.0005399096,0.00010375518,0.00003468408,0.000023966979,0.000001394576,0.000010017114,0.000014427516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641126,0.0011876855,0.001540959,0.00014066456,0.0005577911,0.00016166428],"domain_scores_gemma":[0.99674773,0.001275772,0.0015440515,0.00021041941,0.00015767416,0.00006432992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00294588,0.00011570219,0.00094130205,0.00011771848,0.000042702814,0.000003361381,0.00021427688,0.000032386783,0.000013778276],"category_scores_gemma":[0.0000549686,0.000053074593,0.00015384109,0.00023545965,0.00020753428,0.000037610345,0.00006692536,0.0005861918,2.4645374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017799165,0.0040477356,0.94966966,0.000089296926,0.00057100685,0.0007894991,0.0014488546,0.00014258431,0.00021149048,0.0001536997,0.000054939774,0.025022093],"study_design_scores_gemma":[0.01437556,0.026618615,0.94962686,0.00007342134,0.00031531576,0.00019707103,0.007591892,0.000019028395,0.0002954625,0.00025809483,0.0005818332,0.00004684341],"about_ca_topic_score_codex":0.00005907139,"about_ca_topic_score_gemma":0.0000135201335,"teacher_disagreement_score":0.02497525,"about_ca_system_score_codex":0.00020591328,"about_ca_system_score_gemma":0.00040119808,"threshold_uncertainty_score":0.25467443},"labels":[],"label_agreement":null},{"id":"W4213324432","doi":"10.1200/jco.2022.40.6_suppl.154","title":"Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Simvastatin; Medicine; Prostate cancer; Internal medicine; Oncology; Statin; Lipid profile; Sphingomyelin; Androgen deprivation therapy; Endocrinology; Cancer; Cholesterol","score_opus":0.04378713731768275,"score_gpt":0.3811738052585788,"score_spread":0.33738666794089606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213324432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397254,0.0004887176,0.000051125502,0.0008972344,0.004081144,0.00028165386,0.000057005298,0.0000011173094,0.00016944353],"genre_scores_gemma":[0.9958294,0.0003097092,0.0011790713,0.0002822016,0.0019664122,0.00004159357,0.000008516446,0.000013325184,0.00036974202],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974601,0.000635219,0.0012921898,0.00016496427,0.0002919667,0.00015551943],"domain_scores_gemma":[0.9978208,0.00016013526,0.0015807685,0.0001632839,0.00020511895,0.00006989777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016578131,0.00009993966,0.0005309824,0.00006276394,0.000057390553,0.0000051912857,0.00020277684,0.00007040747,0.00008817234],"category_scores_gemma":[0.00044920263,0.00006493515,0.00018428569,0.00017449188,0.00013989126,0.000008566613,0.00007692339,0.00040842683,3.476693e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02858646,0.0024933687,0.075113915,0.00012615323,0.00081574183,0.000011312373,0.0010926652,0.12587641,0.5974911,0.0003245251,0.029710753,0.13835764],"study_design_scores_gemma":[0.017170832,0.010013465,0.4179777,0.00007902682,0.00035762668,0.0001502579,0.0014742475,0.0019486587,0.00814603,0.00038180157,0.5419621,0.00033827967],"about_ca_topic_score_codex":0.00011916515,"about_ca_topic_score_gemma":0.0013193507,"teacher_disagreement_score":0.58934504,"about_ca_system_score_codex":0.00006467922,"about_ca_system_score_gemma":0.0022521736,"threshold_uncertainty_score":0.39952594},"labels":[],"label_agreement":null},{"id":"W4213325738","doi":"10.1200/jco.2022.40.6_suppl.142","title":"Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Enzalutamide; Internal medicine; Androgen receptor; Proportional hazards model; Biomarker; Univariate analysis; Abiraterone; Population; Log-rank test; Cancer; Multivariate analysis; Androgen deprivation therapy; Biology","score_opus":0.1469827745264745,"score_gpt":0.4600745671581061,"score_spread":0.31309179263163156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213325738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992917,0.00043870282,0.000012756595,0.00475432,0.00017599326,0.001551542,0.00011634762,0.000006851479,0.000026467384],"genre_scores_gemma":[0.997497,0.00070535264,0.0008134809,0.00013389652,0.00007725827,0.00014006226,0.000019676627,0.00002132629,0.00059190457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929964,0.0023763075,0.0027068693,0.00040388957,0.0011916192,0.00032493935],"domain_scores_gemma":[0.9894202,0.0066873822,0.002888738,0.0002847241,0.00048182352,0.00023716688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062028114,0.00023077849,0.0024743457,0.000259347,0.00014126116,0.000031819138,0.00021974619,0.000111943256,0.0001825389],"category_scores_gemma":[0.0010745539,0.000110335604,0.00025850878,0.0008396951,0.00031093633,0.00013403405,0.000114505616,0.0011239477,4.2490757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18543261,0.004927647,0.78229046,0.00002071391,0.021908771,0.0012466004,0.0012876575,0.0006762752,0.0000458931,0.0000013035558,0.00012155574,0.002040482],"study_design_scores_gemma":[0.07241511,0.048953373,0.8641083,0.00005050739,0.009839717,0.000026275844,0.004051269,0.00029808006,0.000026549385,0.000016648095,0.00010607222,0.000108097745],"about_ca_topic_score_codex":0.0014020365,"about_ca_topic_score_gemma":0.02061474,"teacher_disagreement_score":0.11301751,"about_ca_system_score_codex":0.00048839155,"about_ca_system_score_gemma":0.00256169,"threshold_uncertainty_score":0.9972565},"labels":[],"label_agreement":null},{"id":"W4213328782","doi":"10.1200/jco.2022.40.6_suppl.tps211","title":"PSMAfore: A phase 3 study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Taxane; Glutamate carboxypeptidase II; Androgen receptor; Internal medicine; Androgen deprivation therapy; Urology; Oncology; Androgen; Cancer research; Cancer; Hormone; Breast cancer","score_opus":0.16307149764116535,"score_gpt":0.47556676565976025,"score_spread":0.3124952680185949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213328782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161434,0.00053968845,0.0000011670302,0.0030966273,0.0001666411,0.0042257123,0.00030652192,0.000008540331,0.00004075838],"genre_scores_gemma":[0.9972145,0.00017722501,0.00056027237,0.00040743419,0.00023702979,0.0011147136,0.00008212278,0.000037702353,0.00016902256],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99529666,0.0009666941,0.0018480575,0.0004385863,0.0009349798,0.0005150143],"domain_scores_gemma":[0.9973065,0.00050283544,0.0009756751,0.00023691372,0.0004253961,0.0005526769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016351112,0.00030104944,0.0017649538,0.00044581178,0.00011400543,0.000021403117,0.00016519107,0.000050103754,0.0002475507],"category_scores_gemma":[0.00017103208,0.00017713635,0.0001512588,0.00076194305,0.00013014517,0.00016945213,0.00007933211,0.0008365943,0.000004113988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10819262,0.03560573,0.75874674,0.000049314353,0.0007418201,0.005551854,0.011487974,0.00041115005,0.000035708534,0.0000019219144,0.00025761413,0.078917556],"study_design_scores_gemma":[0.22042194,0.44838268,0.2959678,0.0004524657,0.0006518042,0.00012388866,0.020483451,0.00028555823,0.00015569125,0.000011744201,0.012668186,0.00039478915],"about_ca_topic_score_codex":0.0014508951,"about_ca_topic_score_gemma":0.009494777,"teacher_disagreement_score":0.46277896,"about_ca_system_score_codex":0.0020414777,"about_ca_system_score_gemma":0.0038906108,"threshold_uncertainty_score":0.72234106},"labels":[],"label_agreement":null},{"id":"W4213331669","doi":"10.1200/jco.2022.40.6_suppl.470","title":"Real-world treatment patterns, survival outcomes, and health care resource utilization among individuals with nonmuscle-invasive bladder cancer in Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Population; Oncology; Disease; Internal medicine; Retrospective cohort study; Cohort; Receipt; Radiation therapy; Cancer registry; Cancer; Environmental health","score_opus":0.1290476684208425,"score_gpt":0.44996257573215875,"score_spread":0.3209149073113162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213331669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854078,0.0009025012,0.0000040914792,0.011519098,0.0005241774,0.00048514866,0.00016178403,0.0000054097277,0.0009899581],"genre_scores_gemma":[0.9935956,0.002206697,0.00011635672,0.0034290436,0.00025318304,0.000044840952,0.000029815401,0.00002605845,0.00029839206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968859,0.0006263498,0.0013850295,0.00025603417,0.0005599432,0.000286749],"domain_scores_gemma":[0.997522,0.0006449319,0.0011597708,0.00016217327,0.00012322032,0.00038788584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008355795,0.00018323437,0.0014581628,0.00016254398,0.000099983015,0.000006633816,0.00009572945,0.000070864335,0.0002663289],"category_scores_gemma":[0.00007703712,0.00012360569,0.0001180032,0.00020186948,0.00006314712,0.00005301144,0.000054849294,0.00056337984,2.1754073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00089976226,0.00045133175,0.9279996,0.000027274891,0.00051126804,0.00058588915,0.0008472908,0.00014105349,2.1562752e-7,0.000005430727,0.0010021736,0.06752872],"study_design_scores_gemma":[0.0123684965,0.008777561,0.95680404,0.000086197484,0.00029462474,0.000042217143,0.0034270524,0.000006526924,0.0000066813577,0.000004994513,0.018085212,0.00009638628],"about_ca_topic_score_codex":0.77191925,"about_ca_topic_score_gemma":0.98660076,"teacher_disagreement_score":0.2146815,"about_ca_system_score_codex":0.004069553,"about_ca_system_score_gemma":0.019288572,"threshold_uncertainty_score":0.99975365},"labels":[],"label_agreement":null},{"id":"W4213332982","doi":"10.1200/jco.2022.40.6_suppl.tps191","title":"PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; PALB2; MSH2; Prostate cancer; MSH6; Genetic testing; PTEN; Oncology; Germline; MLH1; Internal medicine; Cancer; Germline mutation; Genetics; DNA mismatch repair; Mutation; Gene; Colorectal cancer; Biology","score_opus":0.1326945739031199,"score_gpt":0.507687326157604,"score_spread":0.37499275225448414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213332982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847338,0.0022331066,0.000020920215,0.0112656485,0.0003952349,0.0010902574,0.000154098,0.0000047437343,0.00010215194],"genre_scores_gemma":[0.9938202,0.0028732342,0.0010383935,0.000106833904,0.00020421366,0.00025799422,0.000020577236,0.000017188495,0.0016613986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817216,0.00034041426,0.0009490718,0.00018910281,0.00017678089,0.00017243886],"domain_scores_gemma":[0.99602777,0.0023041463,0.0010092399,0.00013188133,0.00030912878,0.00021783258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018332221,0.00011622363,0.0011921903,0.000082351085,0.00009388547,0.000006450819,0.000061531704,0.00009580135,0.000023777662],"category_scores_gemma":[0.001154775,0.00007286661,0.00023189606,0.0000857734,0.00029489465,0.000045149154,0.00005684618,0.00033238306,7.025678e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049463585,0.0034484018,0.69107735,0.00040099537,0.002269595,0.00030669218,0.0004167015,0.000024152858,0.002837365,0.00011207367,0.00048546196,0.24915764],"study_design_scores_gemma":[0.06444539,0.051205706,0.84559983,0.0001123264,0.0012069022,0.00024795256,0.0006635154,0.00030106117,0.00062433386,0.0008811068,0.034575645,0.00013623944],"about_ca_topic_score_codex":0.000111357454,"about_ca_topic_score_gemma":0.000050470328,"teacher_disagreement_score":0.2490214,"about_ca_system_score_codex":0.0002856276,"about_ca_system_score_gemma":0.0021746948,"threshold_uncertainty_score":0.38578153},"labels":[],"label_agreement":null},{"id":"W4213335399","doi":"10.1200/jco.2022.40.6_suppl.485","title":"Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Cystectomy; Gemcitabine; Bladder cancer; Internal medicine; Oncology; Cancer; Urology","score_opus":0.11419018168274969,"score_gpt":0.4498631705032262,"score_spread":0.3356729888204765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213335399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819196,0.0005458059,0.00006807337,0.009451643,0.00084154826,0.0006459564,0.00011441889,0.000012649705,0.00012791647],"genre_scores_gemma":[0.99128956,0.0002637707,0.0013516869,0.0059693605,0.00088204554,0.000037904465,0.0000060265047,0.000047165096,0.00015246564],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9963168,0.00074528676,0.001766294,0.0003193079,0.00048780223,0.00036454623],"domain_scores_gemma":[0.9933014,0.0033580062,0.0022059407,0.00026809733,0.0005603351,0.00030622055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025721441,0.0002499333,0.0017843125,0.00019935601,0.000117863136,0.0000055675146,0.00017688767,0.00020979752,0.0005084839],"category_scores_gemma":[0.001267935,0.0001550512,0.0010472656,0.00021014396,0.00023588198,0.00006148589,0.000049649105,0.0008863553,0.0000022185973],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55954444,0.008527523,0.13599484,0.000072010305,0.0055051195,0.0040909806,0.0022515159,0.0018996538,0.037447292,0.000021264668,0.027785046,0.2168603],"study_design_scores_gemma":[0.044655062,0.22898819,0.694678,0.00024671713,0.0010332187,0.0009908073,0.0005574787,0.0001356995,0.0027784342,0.00014484584,0.025515651,0.0002759003],"about_ca_topic_score_codex":0.000100656216,"about_ca_topic_score_gemma":0.000033580287,"teacher_disagreement_score":0.55868316,"about_ca_system_score_codex":0.00067944394,"about_ca_system_score_gemma":0.004330751,"threshold_uncertainty_score":0.7682566},"labels":[],"label_agreement":null},{"id":"W4213345473","doi":"10.1200/jco.2022.40.6_suppl.105","title":"Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Subgroup analysis; Testosterone (patch); Randomized controlled trial; Internal medicine; Gynecology; Hormone antagonist; Urology; Oncology; Cancer; Hormone; Confidence interval; Endocrine system","score_opus":0.08102293201287776,"score_gpt":0.48518651769014726,"score_spread":0.4041635856772695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213345473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869011,0.0030772614,0.000008382329,0.0077513596,0.00014884994,0.0016968233,0.000032339154,0.0000037813713,0.0003800991],"genre_scores_gemma":[0.99244857,0.006761003,0.0001671367,0.00016493394,0.00015226778,0.00008657109,0.000010715007,0.0000135213395,0.00019525875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99496275,0.0019753925,0.0019532552,0.0002588126,0.0006162549,0.00023355277],"domain_scores_gemma":[0.9904524,0.0074293907,0.0014418216,0.00024215497,0.00023430803,0.00019990755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059053577,0.00014632748,0.0025297191,0.00018872072,0.00008053732,0.0000072005855,0.00019165367,0.000073188305,0.00018424906],"category_scores_gemma":[0.0012092345,0.00007297206,0.0003498866,0.00064772647,0.00054235326,0.00007018676,0.00012382146,0.001110681,4.832359e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8120215,0.0043383497,0.1409004,0.0000092299015,0.006270466,0.0006329564,0.00228274,0.00096897426,0.000024769204,0.000005239453,0.0001942557,0.03235112],"study_design_scores_gemma":[0.81292504,0.033112627,0.14151743,0.000047563637,0.00483674,0.0000111076815,0.0048061237,0.0006635276,0.000017166361,0.000048531147,0.0019353369,0.000078816985],"about_ca_topic_score_codex":0.00074776955,"about_ca_topic_score_gemma":0.0007200351,"teacher_disagreement_score":0.032272305,"about_ca_system_score_codex":0.00030122555,"about_ca_system_score_gemma":0.0013648387,"threshold_uncertainty_score":0.48254183},"labels":[],"label_agreement":null},{"id":"W4213347865","doi":"10.1200/jco.2022.40.6_suppl.tps580","title":"Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible<i> FGFR3 </i>genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Cisplatin; Tolerability; Chemotherapy; Urology; Internal medicine; Oncology; Bladder cancer; Placebo; Cancer; Gastroenterology; Adverse effect; Pathology","score_opus":0.07437173397062297,"score_gpt":0.4142051565024548,"score_spread":0.33983342253183185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213347865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799719,0.0011418639,0.0005100334,0.0017605164,0.0029947695,0.013000371,0.00010179741,0.000021167161,0.0004975658],"genre_scores_gemma":[0.9888307,0.00037129648,0.00214428,0.0025012116,0.002920674,0.0028034265,0.00006622219,0.00007391337,0.00028827766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99289656,0.0014536686,0.0037524172,0.00047431258,0.0009470417,0.00047599504],"domain_scores_gemma":[0.99037087,0.0046551498,0.0030670944,0.00034122032,0.0010537639,0.00051192124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032504562,0.00040991744,0.003851575,0.00032088882,0.00032274355,0.000041947904,0.0002922753,0.00025515238,0.00081144186],"category_scores_gemma":[0.0022803068,0.00026236023,0.0014970151,0.0002494007,0.00023149101,0.00017207125,0.000056299676,0.0010586323,0.0000062787485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95959866,0.010475509,0.0029731137,0.00002338184,0.0021164138,0.00022783155,0.00045890332,0.00014375555,0.00013478019,0.00003200103,0.00070160115,0.023114074],"study_design_scores_gemma":[0.8264627,0.16225375,0.0006217424,0.00004035945,0.001959044,0.0000665489,0.000152325,0.00012272585,0.00023829048,0.00016631423,0.007704078,0.00021211992],"about_ca_topic_score_codex":0.000083700055,"about_ca_topic_score_gemma":0.000068229856,"teacher_disagreement_score":0.15177824,"about_ca_system_score_codex":0.00031288547,"about_ca_system_score_gemma":0.006412044,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W4213356935","doi":"10.1200/jco.2022.40.6_suppl.338","title":"Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Odds ratio; Population; Clinical trial; Confidence interval; Oncology","score_opus":0.0947188487294451,"score_gpt":0.3856240920916396,"score_spread":0.29090524336219453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213356935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933017,0.0004185455,0.000006882713,0.0022703472,0.0005145151,0.0011819166,0.0001423083,0.0000034171308,0.0021603613],"genre_scores_gemma":[0.9985802,0.00008360557,0.00051235844,0.0003555909,0.00031862882,0.000019467352,0.00007845987,0.000027243525,0.00002445447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99328655,0.0023519592,0.0028035266,0.0002933201,0.00096814655,0.00029649274],"domain_scores_gemma":[0.98954123,0.0064514675,0.0029569783,0.0004903905,0.00034125982,0.00021867831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028277305,0.00024093068,0.001736798,0.00013340876,0.0001104567,0.0000066099124,0.00044955272,0.00016489858,0.00025867767],"category_scores_gemma":[0.0014405709,0.00012943926,0.0003787539,0.00031643375,0.0004745861,0.00008708664,0.00015108322,0.0015018967,0.000001336413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9288829,0.007609595,0.021940032,0.000029882094,0.00030253374,0.00046142007,0.00206631,0.000117676114,0.00009961994,0.000038831346,0.0003617583,0.038089424],"study_design_scores_gemma":[0.4396892,0.111494035,0.43892667,0.000050452378,0.0006371791,0.000045738423,0.002564998,0.000025506515,0.00009173695,0.000019887293,0.006360029,0.000094605144],"about_ca_topic_score_codex":0.000091899106,"about_ca_topic_score_gemma":0.000095472875,"teacher_disagreement_score":0.48919374,"about_ca_system_score_codex":0.00025887345,"about_ca_system_score_gemma":0.0015473948,"threshold_uncertainty_score":0.65250766},"labels":[],"label_agreement":null},{"id":"W4213357340","doi":"10.1200/jco.2022.40.6_suppl.167","title":"Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Cancer; Androgen receptor; Internal medicine; Oncology; Hazard ratio; Biopsy; Enzalutamide; Adenocarcinoma; Pathology; Cancer research; Confidence interval","score_opus":0.07253319436913555,"score_gpt":0.4405875813106236,"score_spread":0.36805438694148807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213357340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993371,0.002987273,0.0000073551814,0.0021574418,0.00035139182,0.0008997268,0.000044009565,0.0000047826447,0.0001769988],"genre_scores_gemma":[0.991926,0.0054120957,0.0020220063,0.00025728493,0.00009981597,0.000041403106,0.000025875903,0.000025487672,0.00019003845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950907,0.0011451425,0.0022593522,0.00033219132,0.000871623,0.000300995],"domain_scores_gemma":[0.99678504,0.0006744564,0.0015117838,0.00020029739,0.0005213533,0.00030708953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032456985,0.00017583086,0.0014025375,0.00023333487,0.000076421566,0.000012109414,0.00013855868,0.0001302261,0.00010241842],"category_scores_gemma":[0.0004382998,0.00011090495,0.00020598412,0.00030279296,0.00042584978,0.00013238814,0.00010470359,0.001304502,5.861963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105484255,0.006010225,0.7947761,0.00029561023,0.000517258,0.0027475136,0.00070793706,0.00022023772,0.009051324,0.000027583194,0.0015394564,0.07862251],"study_design_scores_gemma":[0.038322885,0.03702651,0.9117846,0.0004890689,0.00020819288,0.00008704008,0.00062382483,0.000029167462,0.0047064074,0.00013439405,0.0064307917,0.00015713504],"about_ca_topic_score_codex":0.000034244422,"about_ca_topic_score_gemma":0.00005240298,"teacher_disagreement_score":0.11700849,"about_ca_system_score_codex":0.00019991862,"about_ca_system_score_gemma":0.0017931939,"threshold_uncertainty_score":0.56674844},"labels":[],"label_agreement":null},{"id":"W4213359718","doi":"10.1200/jco.2022.40.6_suppl.333","title":"The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Targeted therapy; Internal medicine; Oncology; Cancer; Proportional hazards model; Immunotherapy; Survival analysis; Confidence interval","score_opus":0.04377406322178455,"score_gpt":0.38425183223526216,"score_spread":0.3404777690134776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213359718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963957,0.00084334763,0.00018414957,0.0013419582,0.0009690497,0.00010699582,0.000009334326,7.721708e-7,0.00014867308],"genre_scores_gemma":[0.99861556,0.0005181346,0.00016330961,0.0003684055,0.00011971745,0.00002048992,0.0000022428062,0.00000996763,0.00018214296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773866,0.0006958206,0.0009836802,0.0001306678,0.00030619363,0.00014498389],"domain_scores_gemma":[0.9982505,0.00023923775,0.0011409861,0.0002085087,0.00012290476,0.000037875016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011637812,0.000093197115,0.00042832666,0.000021057032,0.00010404606,0.000006824004,0.00041024009,0.000059652444,0.000047530382],"category_scores_gemma":[0.00011199547,0.000045447377,0.00022956509,0.00007891568,0.00015131195,0.0000045854367,0.00011598167,0.00041185034,8.679433e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002102505,0.0006210157,0.9698055,0.000010073091,0.00018128919,0.000007814038,0.00037169844,0.0020558476,0.011360387,0.000020610116,0.00030399294,0.013159277],"study_design_scores_gemma":[0.0051303287,0.0022444872,0.9696755,0.00001381131,0.00004931654,0.000023040546,0.0007584899,0.00025045508,0.005700497,0.00007180192,0.015977569,0.000104723986],"about_ca_topic_score_codex":0.00008534851,"about_ca_topic_score_gemma":0.00050373084,"teacher_disagreement_score":0.015673576,"about_ca_system_score_codex":0.00006429683,"about_ca_system_score_gemma":0.0006952461,"threshold_uncertainty_score":0.18532903},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4213383767","doi":"10.1200/jco.2022.40.6_suppl.410","title":"CT abdomen only for active surveillance in patients with stage I germ cell tumor (GCT): A multi-institutional study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pelvis; Abdomen; Stage (stratigraphy); Seminoma; Radiology; Population; Surgery; Chemotherapy","score_opus":0.06351616274417257,"score_gpt":0.4268947867737644,"score_spread":0.36337862402959187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213383767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792415,0.00011313934,0.000061186794,0.00027366175,0.00040228872,0.00097189966,0.00012107236,0.000005519683,0.00012710388],"genre_scores_gemma":[0.9974575,0.0000061081123,0.0017248833,0.0004720559,0.00011859282,0.000042438118,0.000020079244,0.000013949076,0.00014437757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769926,0.00036826357,0.0010817995,0.00020764644,0.00044393237,0.0001991047],"domain_scores_gemma":[0.99688005,0.0011690083,0.0012946316,0.00013151136,0.00027557413,0.00024921802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011044481,0.00013034974,0.00095198903,0.00010250198,0.000087041095,0.0000047223834,0.00011230295,0.00003160623,0.000093782626],"category_scores_gemma":[0.001254972,0.00008384504,0.00026055195,0.00012541974,0.00008312486,0.00006432425,0.00006221586,0.00050864957,0.0000032161727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01579882,0.031101583,0.93625677,0.000019811574,0.00034914736,0.0022516772,0.00006158038,0.00020600113,0.0000010348668,0.000008354841,0.00008976045,0.013855444],"study_design_scores_gemma":[0.055116273,0.034450743,0.9041561,0.000015829602,0.00019140607,0.00006070055,0.00029607597,0.00007965851,0.0000011717751,0.000010579003,0.005546869,0.00007462392],"about_ca_topic_score_codex":0.000037521015,"about_ca_topic_score_gemma":0.0001160114,"teacher_disagreement_score":0.039317455,"about_ca_system_score_codex":0.00044820708,"about_ca_system_score_gemma":0.0029931879,"threshold_uncertainty_score":0.5309787},"labels":[],"label_agreement":null},{"id":"W4213390394","doi":"10.1200/jco.2022.40.6_suppl.562","title":"Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Government of Ontario","keywords":"Medicine; Oncology; Amplicon; Internal medicine; Cancer; Disease; Bioinformatics; Gene; Biology; Genetics; Polymerase chain reaction","score_opus":0.04726898439369516,"score_gpt":0.37408223804212215,"score_spread":0.326813253648427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213390394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817675,0.0000338178,0.0004451824,0.00045384504,0.00041009218,0.00038035365,0.00003809361,0.0000022970944,0.000059556765],"genre_scores_gemma":[0.99853665,0.00006620167,0.00073462847,0.00032344286,0.00008196923,0.000022451715,0.000016814627,0.000012762949,0.00020505377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787205,0.00027718072,0.0013248796,0.00013782851,0.00028358313,0.00010445724],"domain_scores_gemma":[0.9980106,0.00027242932,0.0013045666,0.000097605225,0.0002183516,0.000096463584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008523504,0.00007953822,0.0006723557,0.00013579153,0.00003868809,0.0000038299554,0.00006774596,0.000049236034,0.00020726115],"category_scores_gemma":[0.0003597018,0.000055173252,0.000065033026,0.00014701587,0.00006245934,0.00012825929,0.000030708143,0.0003012902,0.0000012213867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0527241,0.0032328076,0.8308374,0.00005133114,0.00027014737,0.00012996701,0.00019187992,0.000090907735,0.0038338783,0.00002274988,0.000026149983,0.10858864],"study_design_scores_gemma":[0.016941544,0.015452588,0.96565104,0.000021962143,0.00026080132,0.00007235157,0.00008234936,0.00008835304,0.00015160607,0.000033188306,0.0011963064,0.000047902537],"about_ca_topic_score_codex":0.00001906954,"about_ca_topic_score_gemma":0.000010894702,"teacher_disagreement_score":0.1348136,"about_ca_system_score_codex":0.00017923837,"about_ca_system_score_gemma":0.0014737743,"threshold_uncertainty_score":0.26144123},"labels":[],"label_agreement":null},{"id":"W4213427186","doi":"10.1200/jco.21.00714","title":"Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Radioactive iodine; Selumetinib; Placebo; Thyroid cancer; Adjuvant; Randomized controlled trial; Oncology; Internal medicine; Cancer; Thyroid; Pathology","score_opus":0.031232796640490525,"score_gpt":0.38376368692971613,"score_spread":0.35253089028922563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213427186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793256,0.001370965,0.00004586678,0.0027727757,0.0026644592,0.0049396968,0.00008703041,0.000015031261,0.00017159259],"genre_scores_gemma":[0.99490684,0.0018640469,0.00036164795,0.00067754934,0.000953227,0.0010278671,0.000036055728,0.000034807923,0.00013794952],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99147934,0.0028988032,0.0038900254,0.00040276788,0.0009161452,0.0004129459],"domain_scores_gemma":[0.98863316,0.005311231,0.004974612,0.00024744353,0.00037879025,0.00045478673],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004577869,0.000335356,0.0066721602,0.00031269595,0.00012347558,0.000013391342,0.0002129663,0.00021269031,0.0010499392],"category_scores_gemma":[0.0017820465,0.00020008723,0.0011114153,0.00028446064,0.00023408812,0.00009599781,0.0000804045,0.0019174506,0.0000024663557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9306269,0.019778835,0.017732132,0.000007258826,0.0043867733,0.00052009616,0.0002175285,0.00054838817,0.0000033968254,0.000013832817,0.0019440355,0.024220776],"study_design_scores_gemma":[0.89115506,0.077379756,0.0250902,0.000071475624,0.0044451635,0.000026832786,0.00013348527,0.00027429938,0.000013460797,0.0000436959,0.0011990581,0.00016750889],"about_ca_topic_score_codex":0.00040855707,"about_ca_topic_score_gemma":0.00017708348,"teacher_disagreement_score":0.05760092,"about_ca_system_score_codex":0.0013352677,"about_ca_system_score_gemma":0.0027857616,"threshold_uncertainty_score":0.9998632},"labels":[],"label_agreement":null},{"id":"W4214490213","doi":"10.1200/jco.21.02592","title":"Risk of COVID-19 Infections and of Severe Complications Among Survivors of Childhood, Adolescent, and Young Adult Cancer: A Population-Based Study in Ontario, Canada","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Pediatric Oncology Group; Hospital for Sick Children; Public Health Ontario; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hazard ratio; Odds ratio; Population; Pediatrics; Intensive care unit; Emergency department; Young adult; Confidence interval; Internal medicine; Environmental health; Psychiatry","score_opus":0.05962043512096464,"score_gpt":0.4092450296851968,"score_spread":0.34962459456423217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214490213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955596,0.00018747813,0.0000266177,0.0029895909,0.00044178718,0.0005693708,0.00014257309,0.0000030185124,0.00008001597],"genre_scores_gemma":[0.99855876,0.000111014015,0.00018104845,0.0010387297,0.000059752954,0.000015577087,0.000009801197,0.000010767326,0.000014565184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950572,0.0012614438,0.002810533,0.00020438171,0.0005308687,0.00013555579],"domain_scores_gemma":[0.9930364,0.002570797,0.0034490745,0.0002268749,0.00038783893,0.00032902628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002861948,0.00012287266,0.0014492089,0.00022861772,0.00009445371,0.0000022084703,0.00013004035,0.00010040206,0.000099337725],"category_scores_gemma":[0.0037717647,0.00011663807,0.00016278248,0.00029580764,0.00016968072,0.000050921826,0.000084144274,0.0010947392,2.2871044e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074010325,0.0037049854,0.9895012,0.00011222026,0.00030774303,0.0000143405105,0.0017892877,0.0025913524,0.000001831354,0.000016759375,0.00042802677,0.0007921499],"study_design_scores_gemma":[0.008318259,0.003808674,0.9839762,0.000118424556,0.000407675,0.00004767233,0.0027558745,0.00008900737,0.000001365476,0.000077306984,0.00031461098,0.0000849598],"about_ca_topic_score_codex":0.9920208,"about_ca_topic_score_gemma":0.9994025,"teacher_disagreement_score":0.009783826,"about_ca_system_score_codex":0.00080226926,"about_ca_system_score_gemma":0.010586095,"threshold_uncertainty_score":0.99502295},"labels":[],"label_agreement":null},{"id":"W4220664559","doi":"10.1200/jco.21.01612","title":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Sorafenib; Chemotherapy; Standard of care; Myeloid leukemia; Myeloid","score_opus":0.03873391942983144,"score_gpt":0.40885538987138687,"score_spread":0.3701214704415554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220664559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9052615,0.00004204006,0.0030243462,0.046677656,0.000279216,0.04428743,0.000075408636,0.000034873396,0.00031748615],"genre_scores_gemma":[0.8964101,0.00029563237,0.039367586,0.019063113,0.0035833225,0.039796796,0.0005748205,0.00024841586,0.00066019024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927241,0.0014842417,0.003116814,0.000649419,0.0014012264,0.00062415807],"domain_scores_gemma":[0.9916459,0.0030146874,0.0035080106,0.00064234296,0.00081773434,0.0003713704],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008373816,0.00037119514,0.0024044593,0.00025435627,0.00029401807,0.000036873033,0.0007443255,0.0005128643,0.00027982498],"category_scores_gemma":[0.0010433996,0.00021630808,0.00041503113,0.0005797258,0.00057871296,0.00022954424,0.00021010835,0.004129044,0.0000034680556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25868934,0.0069488375,0.5197179,0.000036484886,0.0059087477,0.0051057814,0.0012257345,0.00046698024,0.0007075103,0.00046754323,0.062264208,0.13846093],"study_design_scores_gemma":[0.12413931,0.10219697,0.63111496,0.000074479016,0.0007035849,0.008616961,0.00035860285,0.00015544982,0.00024716943,0.0008723579,0.13119541,0.00032474354],"about_ca_topic_score_codex":0.00047894393,"about_ca_topic_score_gemma":0.00059527805,"teacher_disagreement_score":0.1381362,"about_ca_system_score_codex":0.0042492473,"about_ca_system_score_gemma":0.013869433,"threshold_uncertainty_score":0.9995733},"labels":[],"label_agreement":null},{"id":"W4220675084","doi":"10.1200/jco.21.01805","title":"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dosing; Regimen; Melanoma; Metastatic melanoma; Phases of clinical research; Maximum tolerated dose","score_opus":0.08841826685890203,"score_gpt":0.4522091769482753,"score_spread":0.36379091008937325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220675084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873877,0.00017292875,0.000023595765,0.00021767155,0.00019241493,0.000614459,0.000005445263,0.0000015866283,0.000033134875],"genre_scores_gemma":[0.9979302,0.000021725593,0.001921534,0.00008007797,0.00002530516,0.0000023499151,0.0000027703443,0.000009499979,0.0000065368095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633414,0.0011499828,0.0018400749,0.0001900954,0.0003538026,0.00013192285],"domain_scores_gemma":[0.9965654,0.0014098499,0.001581762,0.0001447074,0.00015709428,0.00014116618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002279356,0.000113349255,0.0015595809,0.00018219188,0.00005926159,0.0000019590482,0.00006462776,0.000080300946,0.000033028635],"category_scores_gemma":[0.00053040235,0.00007907128,0.00009172816,0.0001571047,0.00020451749,0.00007642544,0.00013377731,0.0005175084,7.3492906e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037069704,0.03722636,0.84400064,0.00003623341,0.00060408935,0.00037027206,0.00090401655,0.000029676485,0.000047649017,0.0000041739877,0.0000058764485,0.07970129],"study_design_scores_gemma":[0.12392026,0.14415611,0.72872686,0.00007809361,0.001113432,0.00014619777,0.001533105,0.0001590318,0.000013894551,0.000029682087,0.000070720605,0.00005260629],"about_ca_topic_score_codex":0.00007072577,"about_ca_topic_score_gemma":0.00004717738,"teacher_disagreement_score":0.115273796,"about_ca_system_score_codex":0.00014815577,"about_ca_system_score_gemma":0.00053899415,"threshold_uncertainty_score":0.3224433},"labels":[],"label_agreement":null},{"id":"W4220725716","doi":"10.1200/jco.21.02125","title":"Ethical Considerations for Phase I Trials in Oncology","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Clinical trial; Medicine; Informed consent; Engineering ethics; Ethical issues; Alternative medicine; Drug trial; Pathology","score_opus":0.976741155736704,"score_gpt":0.8443057191136619,"score_spread":0.13243543662304202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220725716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015665733,0.9304682,0.00020896897,0.054713514,0.005878523,0.003067297,0.00009487474,0.000013255522,0.0055396724],"genre_scores_gemma":[0.000020037178,0.96742916,0.01634437,0.010087554,0.005051404,0.0002885949,0.00003391724,0.0000767626,0.00066820136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.92354286,0.037804745,0.034814294,0.0009080424,0.0020992926,0.0008307786],"domain_scores_gemma":[0.027341641,0.9541886,0.014749503,0.00073425716,0.0017859386,0.0012000836],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.3504727,0.00041374395,0.02487528,0.00091451034,0.00013035139,0.00002631798,0.0006672037,0.010722332,0.0043927063],"category_scores_gemma":[0.9148008,0.00028285338,0.0075381272,0.00047227368,0.0010540123,0.00005874488,0.00036780693,0.048659693,0.000039494884],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003716811,0.0065447516,0.0000072708117,0.0046688532,0.0012215244,0.0033267317,0.000046667814,9.881243e-7,2.474288e-7,0.011135276,0.024335146,0.9449957],"study_design_scores_gemma":[0.019227399,0.047222275,0.0000040478003,0.003691008,0.0037743687,0.0015272194,0.00006161387,0.000009676506,1.3852386e-7,0.044707328,0.879592,0.00018289978],"about_ca_topic_score_codex":0.000008814243,"about_ca_topic_score_gemma":0.00019703251,"teacher_disagreement_score":0.94481283,"about_ca_system_score_codex":0.0016404344,"about_ca_system_score_gemma":0.094765,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W4220822578","doi":"10.1200/jco.21.02011","title":"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Michigan Comprehensive Cancer Center; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; University of Florida Health; Genentech; National Institutes of Health; University of California, San Francisco; Barbara Ann Karmanos Cancer Institute; University of Arkansas for Medical Sciences; Hamilton Health Sciences; University of South Alabama; Florida Department of Health; Sidney Kimmel Comprehensive Cancer Center; West Virginia University; National Cancer Institute; Cleveland Clinic; NRG Oncology; Incyte; Medical College of Wisconsin; Wayne State University; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Chemotherapy; Paclitaxel; Phases of clinical research; Germline","score_opus":0.23370454872828425,"score_gpt":0.5331871418585143,"score_spread":0.29948259313023007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220822578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96518576,0.00035650542,0.0012557327,0.017949339,0.007302539,0.004798073,0.00008184256,0.00003324878,0.0030369759],"genre_scores_gemma":[0.9767447,0.00052352593,0.007731514,0.010817859,0.0030646063,0.00061285734,0.00002790249,0.000085024025,0.0003919928],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907562,0.0028251512,0.0043188683,0.00053728966,0.0010662988,0.0004961736],"domain_scores_gemma":[0.98603034,0.008047416,0.004480233,0.0003724516,0.0005695615,0.00050000194],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010237859,0.00038655766,0.004850702,0.0003390059,0.00017627685,0.000036551508,0.0004637934,0.0003634637,0.0029423074],"category_scores_gemma":[0.0021813845,0.00026118796,0.000448007,0.0006193488,0.00048742202,0.00020784323,0.00010226589,0.0028962875,0.0000049186096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9322037,0.010311985,0.00026076136,0.000017964116,0.001153552,0.0012734585,0.0007431038,0.00025567634,0.00015680946,0.00008080566,0.0038106297,0.049731538],"study_design_scores_gemma":[0.87390876,0.08529351,0.000082997634,0.00031580045,0.00056634005,0.000256719,0.00041374742,0.0030607479,0.00018616914,0.00008488005,0.035553113,0.00027720936],"about_ca_topic_score_codex":0.00022192634,"about_ca_topic_score_gemma":0.0004956184,"teacher_disagreement_score":0.074981526,"about_ca_system_score_codex":0.001363196,"about_ca_system_score_gemma":0.010040414,"threshold_uncertainty_score":0.999984},"labels":[],"label_agreement":null},{"id":"W4220839064","doi":"10.1200/jco.21.02198","title":"Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Center for Advancing Translational Sciences; Eisai; National Institute for Health and Care Research; Genentech; AstraZeneca; Amgen; Pfizer; Cancer Research UK","keywords":"Pembrolizumab; Subgroup analysis; Head and neck squamous-cell carcinoma; Exploratory analysis; Chemotherapy; Head and neck; Survival analysis; Immunotherapy","score_opus":0.082683424774584,"score_gpt":0.41771685456812785,"score_spread":0.33503342979354384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220839064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880941,0.0021221808,0.00015267874,0.008378468,0.00020886876,0.00085825933,0.000039134266,0.00000848071,0.00013782264],"genre_scores_gemma":[0.9943125,0.0004302318,0.0022554214,0.0025201363,0.00015081267,0.00008635735,0.000028950984,0.000028053555,0.00018752352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665815,0.0004305392,0.0017657815,0.0003379537,0.00041004637,0.0003975171],"domain_scores_gemma":[0.99575794,0.0022824758,0.0011576251,0.00015445075,0.00029722758,0.00035026146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018358848,0.0002244178,0.0027221893,0.00027599986,0.00012736562,0.000012508081,0.00013516932,0.00011696637,0.000046697493],"category_scores_gemma":[0.00055541785,0.00014706547,0.00039583977,0.00062414765,0.0002050833,0.000063381056,0.000057643218,0.00089161546,3.7508784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24262534,0.009773411,0.68342656,0.00021699311,0.0016520694,0.0014537318,0.0014490666,0.00002068777,0.000117986645,0.000022725026,0.0040616975,0.05517971],"study_design_scores_gemma":[0.11704723,0.2790032,0.58972645,0.000093498355,0.003295382,0.00042118927,0.0008867313,0.0007921678,0.00023128737,0.00008214956,0.008141378,0.00027931973],"about_ca_topic_score_codex":0.000110759276,"about_ca_topic_score_gemma":0.00062630896,"teacher_disagreement_score":0.26922977,"about_ca_system_score_codex":0.0003109298,"about_ca_system_score_gemma":0.00122065,"threshold_uncertainty_score":0.5997156},"labels":[],"label_agreement":null},{"id":"W4221033594","doi":"10.1200/jco.21.02669","title":"Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Medicine; Concordance; Common Terminology Criteria for Adverse Events; Adverse effect; Nausea; Anxiety; Anorexia; Pediatrics; Physical therapy; Psychiatry; Internal medicine","score_opus":0.36644212187263436,"score_gpt":0.6009493856902682,"score_spread":0.23450726381763387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221033594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95142955,0.0028017526,0.00031818092,0.04239687,0.0016938377,0.0010852437,0.00016508278,0.000009946972,0.00009952888],"genre_scores_gemma":[0.9875136,0.0026004834,0.0021698782,0.0062798527,0.0012262217,0.000075704054,0.000017778175,0.000026881624,0.00008958796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97575754,0.0038120584,0.019262258,0.00041644377,0.0004595734,0.00029215304],"domain_scores_gemma":[0.951195,0.020784626,0.026705276,0.00037976052,0.0005117531,0.0004235887],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06487101,0.00017429303,0.004467941,0.00014807847,0.000081386774,0.000004285825,0.0002692621,0.0002993201,0.00009649023],"category_scores_gemma":[0.07949577,0.00015193668,0.0012762968,0.00023706663,0.0003466898,0.000095842224,0.00014405324,0.0014193594,5.7975325e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035691953,0.0019933286,0.88943464,0.00012160639,0.0007148064,0.000023973293,0.0004567654,0.00007793888,0.000047542955,0.00010054651,0.026617447,0.07684223],"study_design_scores_gemma":[0.021797437,0.010900623,0.9222081,0.00039932798,0.0010193221,0.00023764651,0.0019440337,0.00014167944,0.0000180311,0.00087554374,0.040277667,0.0001806192],"about_ca_topic_score_codex":0.00031963486,"about_ca_topic_score_gemma":0.00037649658,"teacher_disagreement_score":0.07666162,"about_ca_system_score_codex":0.0002846533,"about_ca_system_score_gemma":0.0036269373,"threshold_uncertainty_score":0.9629121},"labels":[],"label_agreement":null},{"id":"W4221105120","doi":"10.1200/jco.21.02678","title":"Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; Stollery Children's Hospital; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Bortezomib; Internal medicine; Regimen; Lymphoblastic lymphoma; Prednisone; Proteasome inhibitor; Clinical trial; Lymphoma; Oncology; Multiple myeloma; Dexamethasone; Surgery; Gastroenterology; Immunology; T cell","score_opus":0.1056531384057165,"score_gpt":0.4566537923573419,"score_spread":0.3510006539516254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221105120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867221,0.00037281163,0.00026151957,0.002271634,0.0057757925,0.0026232756,0.000033077013,0.000045850215,0.0018939513],"genre_scores_gemma":[0.9787162,0.0009804373,0.0062738443,0.0040709483,0.009382611,0.0001696797,0.00003593227,0.00009410969,0.00027622937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98001564,0.005500831,0.010397485,0.0011059991,0.0017301199,0.0012499413],"domain_scores_gemma":[0.9479973,0.04343484,0.005522521,0.0006690973,0.00055541034,0.0018208743],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.022136403,0.0005675631,0.005623821,0.0008122415,0.0002940725,0.00005008091,0.00095013325,0.0013487854,0.00029213613],"category_scores_gemma":[0.03389511,0.00047463598,0.0012603888,0.0010527639,0.0011197062,0.0002702294,0.0010335593,0.004184312,0.000024581952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.70798224,0.01885342,0.008831285,0.00002110421,0.0008316466,0.016941767,0.00014057751,0.00004191853,0.00014925706,0.000028729113,0.008394975,0.23778309],"study_design_scores_gemma":[0.75215805,0.20029542,0.017979164,0.000069586284,0.0012904741,0.0045090136,0.00023405996,0.0030416874,0.0000072514777,0.0001475225,0.019943656,0.00032411373],"about_ca_topic_score_codex":0.00032425622,"about_ca_topic_score_gemma":0.00007393619,"teacher_disagreement_score":0.23745897,"about_ca_system_score_codex":0.0063066776,"about_ca_system_score_gemma":0.036536418,"threshold_uncertainty_score":0.99994767},"labels":[],"label_agreement":null},{"id":"W4223496858","doi":"10.1200/jco.21.01829","title":"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Placebo; Internal medicine; Clinical endpoint; Adverse effect; Nausea; Randomized controlled trial; Hazard ratio; Crossover study; Gastroenterology; Phases of clinical research; Clinical trial; Surgery; Confidence interval; Pathology","score_opus":0.13921206141576267,"score_gpt":0.4680230417605064,"score_spread":0.32881098034474376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223496858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798305,0.0022917185,0.00007202123,0.010462138,0.0023905982,0.0043694978,0.0000056253525,0.000012575421,0.0005653328],"genre_scores_gemma":[0.9917175,0.00054791605,0.00419341,0.0013630217,0.0006484688,0.0011836273,0.00002074973,0.000024397772,0.00030091542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99099755,0.0027664474,0.004859817,0.00027709757,0.00080608093,0.00029303343],"domain_scores_gemma":[0.9801538,0.015934965,0.002986236,0.00019728941,0.00042103094,0.00030666462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0100432,0.00022290664,0.004543547,0.0004605304,0.000086025175,0.000011875323,0.00020933006,0.00014631958,0.0008343776],"category_scores_gemma":[0.0072714193,0.00014522174,0.001625367,0.00029739234,0.00013498189,0.00009507666,0.0001044755,0.0013376756,0.00001361031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95323014,0.022356097,0.003005186,0.000011442943,0.0018451058,0.0017122574,0.000077688994,0.00033655314,0.0000072000676,0.00019491848,0.0006995194,0.016523888],"study_design_scores_gemma":[0.9786652,0.01072016,0.0017049779,0.000038221333,0.0021083206,0.0004514771,0.00016569319,0.0014349399,0.00000942081,0.0005405325,0.004046921,0.00011418214],"about_ca_topic_score_codex":0.000022945253,"about_ca_topic_score_gemma":0.000042119624,"teacher_disagreement_score":0.02543501,"about_ca_system_score_codex":0.00036728664,"about_ca_system_score_gemma":0.0017418382,"threshold_uncertainty_score":0.91358495},"labels":[],"label_agreement":null},{"id":"W4223973406","doi":"10.1200/jco.22.00449","title":"High-Risk Ewing Sarcoma: It Is Time to Break the Ceiling","year":2022,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Ewing's sarcoma; Sarcoma; Internal medicine; Oncology; Surgery; Pathology","score_opus":0.10173325907439561,"score_gpt":0.4276053569371984,"score_spread":0.3258720978628028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223973406","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030104348,0.0014294866,0.000007933872,0.96229863,0.0028674193,0.00044102597,0.000049566268,0.000014537564,0.0027870473],"genre_scores_gemma":[0.0057200445,0.00097019825,0.0018763669,0.96777576,0.019669525,0.00003066988,0.00002798755,0.00007431722,0.0038551106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931673,0.0014368828,0.003424022,0.00042898295,0.0010535236,0.0004893209],"domain_scores_gemma":[0.98235357,0.01321937,0.0031003333,0.0006248648,0.00035556615,0.0003463204],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047691977,0.0003610029,0.0030974005,0.0002435758,0.00019557662,0.000029992329,0.0005891115,0.0010983475,0.008975071],"category_scores_gemma":[0.0035687492,0.00020707739,0.0018206962,0.00023384648,0.00014820659,0.000051651536,0.0002940546,0.008035219,0.00076172664],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071217923,0.0010140316,0.0043973993,0.000019118432,0.0015804428,0.014336137,0.000106353895,0.000010555783,0.0000013926374,0.0000017864769,0.88960373,0.08821688],"study_design_scores_gemma":[0.004392751,0.010416142,0.011974852,0.00016566615,0.0028414426,0.0020816068,0.000053499225,0.000012092985,0.00000840848,0.00015872945,0.96771896,0.00017587733],"about_ca_topic_score_codex":0.0001028752,"about_ca_topic_score_gemma":0.00000865035,"teacher_disagreement_score":0.088041,"about_ca_system_score_codex":0.0005732702,"about_ca_system_score_gemma":0.0015937043,"threshold_uncertainty_score":0.9942533},"labels":[],"label_agreement":null},{"id":"W4226221611","doi":"10.1200/jco.2022.40.6_suppl.274","title":"Impact of AR-V7 and other androgen receptor splice variant expression on outcomes of post-prostatectomy salvage therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Radiological Society of North America","keywords":"Prostate cancer; Prostatectomy; Medicine; Androgen receptor; Androgen deprivation therapy; Salvage therapy; Biochemical recurrence; Oncology; Radiation therapy; Internal medicine; Cancer; Cancer research; Chemotherapy","score_opus":0.12622327562448948,"score_gpt":0.5020454190808953,"score_spread":0.3758221434564058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226221611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533844,0.0013497418,0.000003640746,0.0020380535,0.00027646025,0.0003186561,0.00006962096,0.000003857288,0.00060154905],"genre_scores_gemma":[0.99691147,0.0014686598,0.00045794144,0.00069993065,0.00014706976,0.0000075807206,0.0000044025487,0.000018973955,0.00028396654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744225,0.0005379454,0.0012346769,0.00015299453,0.00044784482,0.00018427361],"domain_scores_gemma":[0.99666977,0.0014801353,0.0011773754,0.0001817913,0.00026639973,0.00022454945],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020739613,0.00012078151,0.0011960226,0.0001636347,0.000046222314,0.0000025374059,0.000131766,0.0001324951,0.0010253007],"category_scores_gemma":[0.0006196935,0.00006467321,0.00045673255,0.00012410905,0.00015744838,0.000046852405,0.0000846379,0.000689349,0.0000020919613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055490237,0.0051318826,0.8342617,0.000043157917,0.0014704216,0.00038985081,0.0007548411,0.000020076599,0.04104302,0.000022575712,0.0024589503,0.058913287],"study_design_scores_gemma":[0.029247483,0.104156,0.8367812,0.0001132683,0.00016442106,0.00017659142,0.00045473926,0.000017129556,0.00731649,0.00017160793,0.021286331,0.000114704955],"about_ca_topic_score_codex":0.00006460147,"about_ca_topic_score_gemma":0.0000019301106,"teacher_disagreement_score":0.09902412,"about_ca_system_score_codex":0.0001389107,"about_ca_system_score_gemma":0.0010203541,"threshold_uncertainty_score":0.9998879},"labels":[],"label_agreement":null},{"id":"W4226437517","doi":"10.1200/jco.2022.40.6_suppl.tps398","title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Population Health Research Institute; McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; Western University; Ontario Clinical Oncology Group; Health Sciences Centre; Ottawa Hospital; London Health Sciences Centre; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Sunitinib; Kidney cancer; Oncology; Internal medicine; Nephrectomy; Immunotherapy; Urology; Cancer; Kidney","score_opus":0.14227262965147133,"score_gpt":0.47897360899517044,"score_spread":0.33670097934369914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226437517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634166,0.00051939965,0.00042790768,0.008939682,0.0020387024,0.0014394135,0.00004959122,0.000008600334,0.00023505435],"genre_scores_gemma":[0.9932945,0.00027515955,0.004082692,0.0009501654,0.00063849904,0.00016190678,0.000024984829,0.000034008724,0.0005381174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961112,0.0007403001,0.0020492764,0.00023419688,0.00065963535,0.00020538567],"domain_scores_gemma":[0.99331886,0.0019138021,0.0033764732,0.0001973123,0.00085386523,0.00033971257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022016934,0.00017390147,0.0017033713,0.0002475206,0.00015313798,0.0000050739227,0.00014104006,0.000101688034,0.00057385536],"category_scores_gemma":[0.0011805984,0.00012400397,0.00054813747,0.00021131369,0.00018311897,0.00018803753,0.000033307628,0.0007578233,6.5153665e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8457272,0.049153484,0.00061551464,0.000092462964,0.004852296,0.0004132133,0.00037522754,0.00021540324,0.0031062616,0.00018912918,0.004739713,0.09052007],"study_design_scores_gemma":[0.5340148,0.41652036,0.0020765732,0.0000525269,0.0023051808,0.0007492797,0.0004281322,0.0005516372,0.001175391,0.0002892276,0.041714735,0.00012214626],"about_ca_topic_score_codex":0.000057757443,"about_ca_topic_score_gemma":0.0000066398115,"teacher_disagreement_score":0.36736688,"about_ca_system_score_codex":0.0011906163,"about_ca_system_score_gemma":0.0048226435,"threshold_uncertainty_score":0.85551625},"labels":[],"label_agreement":null},{"id":"W4229497923","doi":"10.1200/jco.2004.22.90140.522","title":"An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Lymphovascular invasion; Internal medicine; Stage (stratigraphy); Cancer; Tamoxifen; Population; Gynecology; Proportional hazards model; Oncology; Adjuvant therapy; Cancer registry; Metastasis","score_opus":0.05224858097771272,"score_gpt":0.443099204210998,"score_spread":0.3908506232332853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229497923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920196,0.00021331114,0.0031157637,0.003358656,0.0009809185,0.00017112902,0.00012003595,0.000001796778,0.000018765575],"genre_scores_gemma":[0.99499553,0.00010270403,0.003566908,0.0006061642,0.0006720879,0.000012589323,0.000015856003,0.0000116396695,0.00001652488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982902,0.00013579201,0.0010564763,0.00016712365,0.0002244001,0.00012605207],"domain_scores_gemma":[0.9977062,0.00022869249,0.0013071148,0.00021903591,0.0004477906,0.00009121366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008721506,0.00010331427,0.0004660737,0.000032975047,0.000089995454,0.000004464244,0.00023612031,0.00022352427,0.000023220735],"category_scores_gemma":[0.0005358621,0.00006332471,0.0003509559,0.000058450605,0.00008581945,0.0000091199,0.00005396919,0.00014853996,3.1077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006362165,0.0020852387,0.86359525,0.00001894844,0.0004266558,0.0000049207856,0.000058341564,0.027917698,0.003266771,0.00011072019,0.00038453608,0.09576877],"study_design_scores_gemma":[0.00928004,0.0030409482,0.9734743,0.00006010277,0.0001863404,0.000022826991,0.00004998651,0.00003550646,0.008214151,0.0006899141,0.004851926,0.000093926465],"about_ca_topic_score_codex":0.00017350973,"about_ca_topic_score_gemma":0.000585711,"teacher_disagreement_score":0.1098791,"about_ca_system_score_codex":0.00011392635,"about_ca_system_score_gemma":0.0011410975,"threshold_uncertainty_score":0.2582307},"labels":[],"label_agreement":null},{"id":"W4229798922","doi":"10.1200/jco.2019.37.15_suppl.tps2072","title":"EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"Temozolomide; Medicine; Oncology; Internal medicine; Dacarbazine; Radiation therapy; Population; Phases of clinical research; Clinical trial; Quality of life (healthcare); Chemotherapy; Concomitant; Randomized controlled trial; Surgery","score_opus":0.026558526709444048,"score_gpt":0.36938339883945576,"score_spread":0.3428248721300117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229798922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925979,0.00018366872,0.00028840775,0.0028839472,0.00082902034,0.0030133866,0.0000511479,0.000019219868,0.00013330775],"genre_scores_gemma":[0.9947198,0.00016501202,0.0038592943,0.0008580343,0.00019943551,0.000056311215,0.00005224606,0.00007834585,0.000011546622],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931945,0.00080651604,0.0035554774,0.0005572766,0.0013415179,0.0005447195],"domain_scores_gemma":[0.99067396,0.0040421323,0.0033517184,0.0005534242,0.0009231611,0.00045560705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032331145,0.0004935545,0.003924974,0.00084379496,0.000039412764,0.000024299328,0.00028066797,0.0006009941,0.00025387527],"category_scores_gemma":[0.0009350744,0.00033823008,0.00050635077,0.0007301329,0.00036999487,0.0001938607,0.000019600808,0.0009925532,0.0000040999457],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67396265,0.019754743,0.26723015,0.00004752874,0.00060329406,0.0005420519,0.00009870882,0.00038979336,0.00012558095,0.000016058984,0.00045748832,0.03677198],"study_design_scores_gemma":[0.6667814,0.2622898,0.06485722,0.00047615313,0.00031879876,0.000008679409,0.00007140406,0.00021622896,0.0031402952,0.000027926604,0.0015749399,0.00023712801],"about_ca_topic_score_codex":0.0000942795,"about_ca_topic_score_gemma":0.00038370508,"teacher_disagreement_score":0.24253505,"about_ca_system_score_codex":0.0014491808,"about_ca_system_score_gemma":0.0041106436,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W4229908018","doi":"10.1200/jco.2018.36.6_suppl.685","title":"Oncologic and functional outcomes of radical and partial nephrecotmy in PT3A patholigically upstaged renal cell carcinoma: A multi-instituitional analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Renal cell carcinoma; Nephrectomy; Urology; Clear cell renal cell carcinoma; Internal medicine; Kidney","score_opus":0.14072555501568418,"score_gpt":0.41401696267779275,"score_spread":0.2732914076621086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229908018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502206,0.00046759844,0.0009340794,0.0020797234,0.00035437554,0.00022136554,0.000009995157,0.0000056410977,0.00090514007],"genre_scores_gemma":[0.98543876,0.00015360925,0.012720682,0.0009235225,0.00060525606,0.0000064947594,0.000008383943,0.000010480381,0.00013281273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995553,0.0006630351,0.0026484695,0.0003474948,0.00050589355,0.00028206763],"domain_scores_gemma":[0.995359,0.002161616,0.0013476955,0.00017446786,0.00042718052,0.00053004245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030123026,0.00021813592,0.002303163,0.00043570937,0.00005666101,0.000009641673,0.00009510973,0.00046480502,0.00026538133],"category_scores_gemma":[0.0016242529,0.00014375987,0.00059409474,0.0003088545,0.0011529933,0.00010077912,0.00009508105,0.00084790506,0.0000059471427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057943496,0.0033976848,0.9804823,0.00002701499,0.0006671215,0.0014572447,0.000129297,0.000022230515,0.0012376589,0.00015769181,0.00026004866,0.006367383],"study_design_scores_gemma":[0.016665304,0.01183012,0.9658982,0.000021156924,0.0016868054,0.00046622436,0.000064528394,0.000604015,0.00037758774,0.00015337723,0.002119706,0.00011294198],"about_ca_topic_score_codex":0.00003628413,"about_ca_topic_score_gemma":0.00014788604,"teacher_disagreement_score":0.014584042,"about_ca_system_score_codex":0.00017576355,"about_ca_system_score_gemma":0.0012124884,"threshold_uncertainty_score":0.5862357},"labels":[],"label_agreement":null},{"id":"W4230001518","doi":"10.1200/jco.2018.36.7_suppl.110","title":"Cancer patient attitudes and preferences towards smoking status assessment.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; McMaster University; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Logistic regression; Head and neck cancer; Family medicine; Multivariate analysis; Cancer; Health care; Survivorship curve; Internal medicine","score_opus":0.2118625668063667,"score_gpt":0.5545314227814698,"score_spread":0.3426688559751031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230001518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97469115,0.002388316,0.000029888313,0.005086184,0.0018982552,0.0000807798,0.0000033882575,0.000006091418,0.015815917],"genre_scores_gemma":[0.98447484,0.008644031,0.002722631,0.0025111372,0.0015632248,0.0000038399385,3.0323147e-7,0.0000064486167,0.00007354311],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980655,0.00016377452,0.0011321038,0.00013651962,0.0002911753,0.00021096511],"domain_scores_gemma":[0.99782264,0.00056064944,0.0007274832,0.00007722055,0.0005202111,0.0002918118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001092105,0.000089835536,0.0010341787,0.000055434957,0.00006290086,0.00000866206,0.000055314467,0.0001558628,0.0002915187],"category_scores_gemma":[0.00093951524,0.000054963934,0.00012577065,0.000066292334,0.0003590142,0.00007761733,0.00006766176,0.000531204,0.000001703026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004734381,0.0002735562,0.49757016,0.00002121434,0.00026511773,0.00004201518,0.00022548571,1.4286194e-7,0.00004065901,0.000026738659,0.0034277542,0.49763373],"study_design_scores_gemma":[0.0022782155,0.020084413,0.82553595,0.00019406182,0.00017271454,0.000038776434,0.00018742666,0.000009504612,0.000065605236,0.00013083898,0.1512506,0.000051909294],"about_ca_topic_score_codex":0.0001184897,"about_ca_topic_score_gemma":0.00030696104,"teacher_disagreement_score":0.4975818,"about_ca_system_score_codex":0.00013140668,"about_ca_system_score_gemma":0.0021267475,"threshold_uncertainty_score":0.37727585},"labels":[],"label_agreement":null},{"id":"W4230024050","doi":"10.1200/jco.2004.22.14_suppl.4257","title":"Stimulation of natural killer (NK) cell and macrophage infiltration in pancreatic cancer with virulizin (V), an immunotherapeutic agent","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Infiltration (HVAC); Natural killer cell; Cancer research; Medicine; Cell; Pancreatic cancer; Pathology; Biology; Cytotoxic T cell; In vitro; Cancer; Internal medicine","score_opus":0.04566316185272936,"score_gpt":0.3817187661244594,"score_spread":0.33605560427173004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230024050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923012,0.0035449823,0.00027940652,0.00031630902,0.0031394523,0.00013048353,5.0970357e-7,0.000004867469,0.00028275332],"genre_scores_gemma":[0.99718493,0.0013484019,0.00034170802,0.0004946559,0.000067941364,0.0000031182951,0.000007703304,0.000009488831,0.0005420311],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99794763,0.0004592873,0.0012795937,0.00012685155,0.000052387975,0.000134242],"domain_scores_gemma":[0.9981634,0.00037047346,0.001149454,0.00009861576,0.00019036706,0.000027701506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008210838,0.00010899491,0.00060778466,0.0001402008,0.000037397465,0.000006182248,0.00008163381,0.00029090725,0.00032076158],"category_scores_gemma":[0.00012790751,0.00007679535,0.00009472143,0.00009526086,0.00016644398,0.00026470382,0.000012948722,0.0007050141,0.000012916725],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015509266,0.0023222454,0.045392837,0.000050757128,0.00041041806,0.00003740982,0.0013333184,0.0037385111,0.8730993,0.00014688735,0.00023037118,0.057728622],"study_design_scores_gemma":[0.031709224,0.022508033,0.81785846,0.0003198897,0.0003907408,0.00037665814,0.0010236407,0.00022388532,0.09910144,0.00027584634,0.025898121,0.00031404267],"about_ca_topic_score_codex":0.00023008793,"about_ca_topic_score_gemma":0.00020983901,"teacher_disagreement_score":0.7739979,"about_ca_system_score_codex":0.0001218376,"about_ca_system_score_gemma":0.000356716,"threshold_uncertainty_score":0.35121146},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4230033845","doi":"10.1200/jco.2009.27.15_suppl.e14519","title":"Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Oncolytic virus; Carboplatin; Tolerability; Gastroenterology; Nausea; Clinical endpoint; Chills; Cancer; Oncology; Pharmacology; Chemotherapy; Adverse effect; Clinical trial; Cisplatin","score_opus":0.046825855510149866,"score_gpt":0.4531171503903668,"score_spread":0.406291294880217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230033845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813485,0.00014194909,0.000029563966,0.0005370792,0.000182688,0.00050038006,0.0000052799064,0.0000017616678,0.00046644438],"genre_scores_gemma":[0.99834204,0.00030511603,0.000700122,0.0003951137,0.00018130193,0.000008771533,0.000011771338,0.000015685213,0.000040082738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99671197,0.0005765258,0.0017073216,0.0002615011,0.00044664514,0.0002960445],"domain_scores_gemma":[0.9974828,0.00021720215,0.0014263877,0.00024988767,0.00045604116,0.00016770362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183762,0.00016275902,0.00096731144,0.00020351411,0.000027832886,0.000004870868,0.0002649465,0.000312745,0.000010875191],"category_scores_gemma":[0.000902113,0.00012061281,0.00014659586,0.00029048347,0.00019882887,0.000019705845,0.000032599026,0.0006079482,5.9297514e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.724852,0.012870627,0.0046376656,0.000009066204,0.0001308567,0.000072421964,0.000099669734,0.0015032614,0.01728115,0.000008088363,0.00009887451,0.23843628],"study_design_scores_gemma":[0.3323906,0.6417836,0.012251866,0.00008682749,0.000042934425,0.000007182618,0.000060856444,0.00011192367,0.012169245,0.00009934449,0.00083446514,0.00016112655],"about_ca_topic_score_codex":0.000035085235,"about_ca_topic_score_gemma":0.0014178975,"teacher_disagreement_score":0.628913,"about_ca_system_score_codex":0.0002576406,"about_ca_system_score_gemma":0.0024636018,"threshold_uncertainty_score":0.49184474},"labels":[],"label_agreement":null},{"id":"W4230099636","doi":"10.1200/jco.2019.37.7_suppl.432","title":"First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Durvalumab; Nivolumab; Internal medicine; Cisplatin; Gastroenterology; Urology; Oncology; Surgery; Cancer; Immunotherapy; Chemotherapy","score_opus":0.0845193435001139,"score_gpt":0.4387206548824291,"score_spread":0.3542013113823152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230099636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777428,0.0006623571,0.00042839348,0.0076558627,0.005377238,0.0009929691,0.000031654294,0.00002180496,0.0070869015],"genre_scores_gemma":[0.9833056,0.00035106647,0.0056451233,0.0030607576,0.004372188,0.000022521703,0.000007885145,0.000048292375,0.0031865982],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964063,0.00012126294,0.0023411387,0.0003094441,0.0003993018,0.0004225423],"domain_scores_gemma":[0.9956501,0.0017659058,0.0013423614,0.00028827044,0.00048831844,0.00046501312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013966894,0.00023660278,0.0018097702,0.00014093536,0.00006350473,0.0000104515775,0.0001911744,0.00046048156,0.00045482244],"category_scores_gemma":[0.0014640901,0.0001665406,0.000884011,0.00014330329,0.00010861327,0.00015159557,0.000052715834,0.0007280467,0.000116983654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07526787,0.0055930666,0.61348975,0.00041415734,0.0014482432,0.00069915986,0.00039726758,0.00048192943,0.0023601754,0.00035735915,0.02959525,0.26989576],"study_design_scores_gemma":[0.08626444,0.07280307,0.17217931,0.00033822577,0.0011013275,0.0005694858,0.00015805011,0.00042266757,0.0028110258,0.0018522323,0.66113573,0.00036444722],"about_ca_topic_score_codex":0.000031539734,"about_ca_topic_score_gemma":0.00003835561,"teacher_disagreement_score":0.6315405,"about_ca_system_score_codex":0.00021426486,"about_ca_system_score_gemma":0.0016878074,"threshold_uncertainty_score":0.6791329},"labels":[],"label_agreement":null},{"id":"W4230163924","doi":"10.1200/jco.2004.22.14_suppl.706","title":"Trastuzumab (T) and docetaxel (D) for the treatment of HER2 metastatic breast cancer (MBC): A literature based (LB) and individual patient data (IPD) meta-analysis (MA) of phase II trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Metastatic breast cancer; Oncology; Trastuzumab; Meta-analysis; Breast cancer; Clinical trial; MEDLINE; Cochrane Library; CINAHL; Systematic review; Cancer","score_opus":0.41150323797398336,"score_gpt":0.5572722318948445,"score_spread":0.14576899392086118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230163924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581158,0.024078824,0.00027585283,0.013385493,0.00043279852,0.0012051096,0.0024873638,0.0000029009122,0.000015832156],"genre_scores_gemma":[0.9913009,0.0037066392,0.0034641966,0.0008969053,0.0004296215,0.0000672515,0.00008257901,0.000012557541,0.000039386607],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967717,0.0003809847,0.0020522259,0.00028299194,0.00032801184,0.00018409333],"domain_scores_gemma":[0.9938357,0.0031367894,0.0021201172,0.00031802637,0.00035271712,0.00023665019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015583694,0.00021649135,0.003256429,0.00020347194,0.00006672379,0.000010479887,0.00016916127,0.00016878241,0.00026895225],"category_scores_gemma":[0.00025963737,0.00010646851,0.0012888903,0.00029226491,0.00033485188,0.00010065134,0.000046981993,0.00026998232,8.526083e-8],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25485927,0.063628174,0.0013024547,0.0001389265,0.41486838,0.00025486213,0.002326732,0.00028635628,0.00018877423,0.000044957196,0.0013564407,0.26074466],"study_design_scores_gemma":[0.27333868,0.1566664,0.0042770873,0.000025295016,0.55224633,0.00016040477,0.00016514743,0.0003785396,0.00020643424,0.00011413496,0.01231699,0.000104557905],"about_ca_topic_score_codex":0.00014532222,"about_ca_topic_score_gemma":0.00032527448,"teacher_disagreement_score":0.26064008,"about_ca_system_score_codex":0.0001151769,"about_ca_system_score_gemma":0.0014067305,"threshold_uncertainty_score":0.43416598},"labels":[],"label_agreement":null},{"id":"W4230409425","doi":"10.1200/jco.2019.37.7_suppl.tps499","title":"A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Internal medicine; Gemcitabine; Carboplatin; Chemotherapy; Cetuximab; Response Evaluation Criteria in Solid Tumors; Cisplatin; Immunotherapy; Cancer; Ipilimumab; Phases of clinical research; Nivolumab","score_opus":0.045782223811546334,"score_gpt":0.42176746985698266,"score_spread":0.3759852460454363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230409425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173766,0.0005958096,0.0001379462,0.0010416773,0.00018845561,0.0061636404,0.000049859333,0.000006461697,0.000078485355],"genre_scores_gemma":[0.99518055,0.0021960605,0.0020228317,0.00034075195,0.000031617557,0.00011814622,0.000015829717,0.00005280556,0.00004142432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535704,0.00066386035,0.002263533,0.00048772243,0.0008793937,0.0003484302],"domain_scores_gemma":[0.9955942,0.0009606724,0.0020553975,0.00026349054,0.00094304327,0.00018316688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001741802,0.0003983247,0.0037846642,0.00025118556,0.00004086739,0.000024000467,0.00023177154,0.00020347085,0.0000921547],"category_scores_gemma":[0.00024099242,0.00024889992,0.00008720492,0.0005214945,0.0003562907,0.0003720752,0.000044147866,0.0005180869,2.0827841e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70098275,0.026926234,0.19013368,0.00016711578,0.0010695476,0.000060987342,0.0025204227,0.00010547847,0.000021705724,0.00000485762,0.0000059412837,0.078001305],"study_design_scores_gemma":[0.7553938,0.18039736,0.060340133,0.0008389476,0.00044795984,0.000010015465,0.0016537663,0.00046429003,0.00016431931,0.00003228382,0.00006248278,0.00019465387],"about_ca_topic_score_codex":0.0017076567,"about_ca_topic_score_gemma":0.019709967,"teacher_disagreement_score":0.15347113,"about_ca_system_score_codex":0.000872911,"about_ca_system_score_gemma":0.0016873585,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4230500670","doi":"10.1200/jco.2004.22.90140.8525","title":"Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prednisone; Dexamethasone; Internal medicine; Incidence (geometry); Gastroenterology; Corticosteroid; Endocrinology","score_opus":0.08692777188741585,"score_gpt":0.45612747869914366,"score_spread":0.3691997068117278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230500670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945491,0.00012755855,0.000054759174,0.0004043976,0.00031698696,0.004283408,0.000014145227,0.000011870491,0.00023779273],"genre_scores_gemma":[0.99763274,0.00038868978,0.0011978059,0.00021858611,0.00031259705,0.00017070897,0.0000062697745,0.000046336034,0.000026242125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550617,0.00059939455,0.0022069677,0.00039185208,0.0008497578,0.00044583197],"domain_scores_gemma":[0.9942886,0.0027699233,0.0016363354,0.0003846004,0.00046169362,0.0004588252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021019923,0.00034048356,0.0030013104,0.00039490807,0.00002822124,0.000009594423,0.00031612895,0.00063707115,0.000031142976],"category_scores_gemma":[0.002651877,0.00021119064,0.00024725316,0.00055895076,0.0009437279,0.00019650368,0.00011321654,0.0010998297,0.000004748734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2948563,0.0038108185,0.6054457,0.00041313053,0.008564814,0.0021067816,0.00066480064,0.0020055848,0.009034661,0.00016612299,0.00027839816,0.072652906],"study_design_scores_gemma":[0.17564829,0.10971413,0.70430166,0.0014816602,0.0018692035,0.0006701054,0.000034201585,0.00023340748,0.00545936,0.000045928744,0.00031961154,0.00022246939],"about_ca_topic_score_codex":0.001026096,"about_ca_topic_score_gemma":0.00044948512,"teacher_disagreement_score":0.11920802,"about_ca_system_score_codex":0.00221083,"about_ca_system_score_gemma":0.008477485,"threshold_uncertainty_score":0.9971435},"labels":[],"label_agreement":null},{"id":"W4230501139","doi":"10.1200/jco.2004.22.14_suppl.7018","title":"A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Neutropenia; Febrile neutropenia; Internal medicine; Lung cancer; Regimen; Nausea; Vinorelbine; Surgery; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.05815052593919202,"score_gpt":0.4588959697301544,"score_spread":0.4007454437909624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230501139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334645,0.0010795044,0.00016985288,0.0018215048,0.00047349298,0.0013125096,0.00002075429,0.0000047123767,0.0017712327],"genre_scores_gemma":[0.99603724,0.001005863,0.0017747232,0.00026202743,0.0003703144,0.00003640759,0.0000045066004,0.000016031447,0.00049286307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972136,0.00020277356,0.0019529598,0.00022598935,0.00020854,0.00019612155],"domain_scores_gemma":[0.99684024,0.0011007008,0.0013616821,0.00011911233,0.00033584403,0.00024244706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012106617,0.00015752162,0.0016166356,0.00017866214,0.000045230114,0.0000072728703,0.00007465685,0.0002301119,0.00010129344],"category_scores_gemma":[0.0010626479,0.000107447944,0.00020513611,0.00014757446,0.00020519282,0.00008270228,0.00006309081,0.00062323327,5.100889e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88753074,0.008023661,0.06471552,0.00025714317,0.0011726052,0.0007856088,0.0034993626,0.000108480504,0.0032815584,0.000099672354,0.00050104095,0.030024601],"study_design_scores_gemma":[0.7518973,0.042219553,0.20217645,0.00053334696,0.000964164,0.000055130724,0.00024889444,0.0002884321,0.00038969063,0.0001802914,0.0009357546,0.000110999434],"about_ca_topic_score_codex":0.00044603398,"about_ca_topic_score_gemma":0.0011552607,"teacher_disagreement_score":0.13746093,"about_ca_system_score_codex":0.00035003686,"about_ca_system_score_gemma":0.0016837567,"threshold_uncertainty_score":0.43816},"labels":[],"label_agreement":null},{"id":"W4230554543","doi":"10.1200/jco.2004.22.14_suppl.7022","title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Erlotinib Hydrochloride; Regimen; Chemotherapy; Oncology; Chemotherapy regimen; Pemetrexed; Progression-free survival; Carboplatin; Placebo; Randomized controlled trial; Gastroenterology; Epidermal growth factor receptor; Cancer; Cisplatin; Pathology","score_opus":0.0520902160985434,"score_gpt":0.4512543726723138,"score_spread":0.39916415657377036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230554543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838412,0.00062289083,0.00038221007,0.0030237855,0.002516264,0.009243582,0.00015756475,0.000008217088,0.00020429921],"genre_scores_gemma":[0.98917866,0.0007391328,0.005961256,0.0008584893,0.0023913484,0.00052405015,0.000048729453,0.000057456837,0.000240867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98441225,0.0018985777,0.011313321,0.00050311023,0.0013955138,0.00047724225],"domain_scores_gemma":[0.9779771,0.010378094,0.009172579,0.0003022794,0.0016901628,0.0004797676],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013263103,0.00047327485,0.00976462,0.00037981503,0.000064212196,0.000009384715,0.00033355007,0.00067011465,0.00020640588],"category_scores_gemma":[0.01694616,0.00028304636,0.002164645,0.0005172906,0.00035768843,0.00023383838,0.000043651595,0.0011681177,2.8714894e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94185287,0.009386052,0.0054785777,0.00015338098,0.0059142946,0.00009509577,0.0005438735,0.02916705,0.00001501774,0.000015084484,0.00039538692,0.0069832886],"study_design_scores_gemma":[0.9635171,0.025429364,0.0013542911,0.0012232303,0.0049834717,0.000005418561,0.00014106379,0.0016688167,0.000046356283,0.000046523783,0.001354061,0.00023030085],"about_ca_topic_score_codex":0.0104246745,"about_ca_topic_score_gemma":0.044781245,"teacher_disagreement_score":0.04032827,"about_ca_system_score_codex":0.0011164735,"about_ca_system_score_gemma":0.041444745,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W4230770514","doi":"10.1200/jco.2013.31.31_suppl.138","title":"Patients’ perceptions of early palliative oncology care: A qualitative analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palliative care; Referral; Family medicine; Qualitative research; Oncology; Focus group; Intervention (counseling); Grounded theory; Internal medicine; Nursing","score_opus":0.35479636619545246,"score_gpt":0.6218203949452622,"score_spread":0.26702402874980974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230770514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897374,0.0006629026,0.0006995084,0.002027412,0.0004534823,0.0002505015,0.000022895902,0.0000051372303,0.006140757],"genre_scores_gemma":[0.98208743,0.0011938467,0.015427651,0.00074332854,0.00035031672,0.00000858588,0.000015912903,0.000011565894,0.00016135153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432653,0.0014581996,0.003326204,0.00019375463,0.00047262586,0.00022268484],"domain_scores_gemma":[0.9846487,0.0068608252,0.0036317308,0.00021125676,0.0042847595,0.00036273673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001731805,0.00015968346,0.0029554972,0.00038526527,0.000028391143,0.0000034644033,0.00019683327,0.000474573,0.000666046],"category_scores_gemma":[0.0076568173,0.00011199168,0.0012757239,0.00053107395,0.0006048504,0.00014555207,0.000055409004,0.00082061713,0.00004387534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014187297,0.0022046703,0.9086484,0.00005789991,0.0037934526,0.00003065333,0.045992732,0.000015904332,0.00013028625,0.00018505703,0.0028956821,0.034626536],"study_design_scores_gemma":[0.0056745512,0.027811581,0.91530496,0.00016791101,0.0026803166,0.00000248515,0.033738915,0.000021049504,0.00006443822,0.00045776833,0.013975709,0.000100296136],"about_ca_topic_score_codex":0.0003493261,"about_ca_topic_score_gemma":0.00012048892,"teacher_disagreement_score":0.03452624,"about_ca_system_score_codex":0.00026478324,"about_ca_system_score_gemma":0.0012710994,"threshold_uncertainty_score":0.91664785},"labels":[],"label_agreement":null},{"id":"W4230918009","doi":"10.1200/jco.2004.22.90140.581","title":"Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Gefitinib; Medicine; Breast cancer; Pharmacokinetics; Lung cancer; Adenocarcinoma; Cancer; Internal medicine; Colorectal cancer; Oncology; Urology; Epidermal growth factor receptor","score_opus":0.14831609006630797,"score_gpt":0.48750950387369624,"score_spread":0.33919341380738827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230918009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845714,0.0002686808,0.000001824143,0.009457051,0.00060182717,0.0005515142,0.0001607316,0.00000586946,0.00049536314],"genre_scores_gemma":[0.9973455,0.0005942558,0.00073419866,0.00061601383,0.0006505777,0.000015145489,0.000008545325,0.000015408998,0.00002036426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947932,0.0007607155,0.0031804207,0.0003040799,0.0006735688,0.00028806418],"domain_scores_gemma":[0.9948031,0.002469732,0.0012552612,0.00020956207,0.0006438021,0.0006185621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025856316,0.00014802604,0.0013263623,0.00014593585,0.00003058895,0.0000098715645,0.00019278345,0.00033093742,0.00009086655],"category_scores_gemma":[0.0049506417,0.00011342236,0.0001523055,0.00022755374,0.00069668447,0.00015329002,0.00010449066,0.0015891779,0.0000030956153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03159426,0.008777791,0.94087195,0.00003608258,0.00023206937,0.001080526,0.001348892,0.0001135346,0.00009480638,0.000050118015,0.002187704,0.013612237],"study_design_scores_gemma":[0.039546635,0.023106936,0.9341145,0.00048652652,0.00016099204,0.000096253956,0.00050826767,0.00010140201,0.00006025362,0.00024906074,0.0014794135,0.00008975811],"about_ca_topic_score_codex":0.0008887728,"about_ca_topic_score_gemma":0.00054123445,"teacher_disagreement_score":0.014329145,"about_ca_system_score_codex":0.00036873698,"about_ca_system_score_gemma":0.0051861536,"threshold_uncertainty_score":0.9200014},"labels":[],"label_agreement":null},{"id":"W4230998282","doi":"10.1200/jco.2016.34.15_suppl.e21557","title":"Developing and evaluating new models of care in hematology.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Hematologist; Family medicine; Survivorship curve; Health care; Shared care; Cancer; Internal medicine; Primary care","score_opus":0.31443327419487516,"score_gpt":0.46190529674402603,"score_spread":0.14747202254915087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230998282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96837944,0.009617602,0.008654447,0.005151905,0.0007905528,0.0000740426,0.0000066661573,0.0000021788142,0.0073231882],"genre_scores_gemma":[0.9834184,0.0028121234,0.012964344,0.00046398188,0.0002493394,8.00328e-7,1.12928554e-7,0.000008381175,0.00008253614],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9967692,0.000050529936,0.0028310227,0.00015318103,0.000027179896,0.00016891185],"domain_scores_gemma":[0.99616885,0.00095380563,0.0025391262,0.000097210635,0.00011574158,0.00012526374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026579674,0.0000790246,0.0013352655,0.00016689187,0.000013647295,0.000004777067,0.00015860847,0.00026022136,0.000054020726],"category_scores_gemma":[0.0030897092,0.00006172316,0.00015040618,0.00006360626,0.00011313226,0.00031998026,0.00005201083,0.0002144459,0.000010614991],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055073755,0.00006460603,0.2255036,0.000030078489,0.00006343472,0.000015807494,0.00049512315,0.00007868976,0.0000072224725,0.27176368,0.00040224055,0.5010248],"study_design_scores_gemma":[0.010010857,0.004841504,0.25406358,0.00036755463,0.000023180732,0.00006676432,0.0003364488,0.0004104989,0.00008025924,0.69901794,0.030516425,0.00026497],"about_ca_topic_score_codex":0.00007813213,"about_ca_topic_score_gemma":0.00018851332,"teacher_disagreement_score":0.5007598,"about_ca_system_score_codex":0.00016903368,"about_ca_system_score_gemma":0.0008891704,"threshold_uncertainty_score":0.36988935},"labels":[],"label_agreement":null},{"id":"W4231003556","doi":"10.1200/jco.2005.05.229","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health; BC Cancer Agency","funders":"","keywords":"Medicine","score_opus":0.04247458816059575,"score_gpt":0.4405696937563816,"score_spread":0.39809510559578587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231003556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500204,0.0016550893,0.00004671108,0.0066144243,0.00068118237,0.000042743726,3.0374912e-7,0.0000013577745,0.0059561185],"genre_scores_gemma":[0.98753315,0.0013246465,0.002934701,0.005236253,0.002259904,8.077695e-7,0.0000010002195,0.000008386634,0.0007011454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998321,0.00026349298,0.0010783183,0.000111385525,0.00009081658,0.00013498217],"domain_scores_gemma":[0.9989642,0.00015530163,0.0005455438,0.00011967629,0.00008323434,0.00013206308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020327284,0.000064702304,0.00039008004,0.00004547317,0.000011189406,0.0000029303858,0.00014844135,0.00037389307,0.000030576597],"category_scores_gemma":[0.0013018672,0.000047371614,0.0002388995,0.000052043808,0.000073579366,0.000005347974,0.000040654704,0.0004988673,0.000027900423],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061641284,0.0035690186,0.048137974,0.000013679501,0.0005228084,0.0010095639,0.000097083175,0.00077829097,0.10152976,0.00044719846,0.21170542,0.6260251],"study_design_scores_gemma":[0.0029959092,0.005160849,0.009649323,0.000010865794,0.000025546971,0.00030175364,0.000014752199,0.000037076497,0.009349616,0.00012385003,0.9722549,0.000075577336],"about_ca_topic_score_codex":0.0000025909808,"about_ca_topic_score_gemma":0.000010662738,"teacher_disagreement_score":0.7605495,"about_ca_system_score_codex":0.000020656353,"about_ca_system_score_gemma":0.00040076155,"threshold_uncertainty_score":0.28838056},"labels":[],"label_agreement":null},{"id":"W4231021439","doi":"10.1200/jco.2013.31.6_suppl.146","title":"Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Docetaxel; Oncology; Ketoconazole; Refractory (planetary science); Progression-free survival; Urology; Proportional hazards model; Cancer; Androgen deprivation therapy; Chemotherapy","score_opus":0.18144906861543683,"score_gpt":0.5111045380899563,"score_spread":0.3296554694745194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231021439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361295,0.000505849,0.0000072210614,0.0035098472,0.00048993144,0.0012274178,0.000017976106,0.0000051586853,0.00062362914],"genre_scores_gemma":[0.9968941,0.00037334085,0.001763239,0.0002579818,0.00013084897,0.00008282632,0.0000102578915,0.00002237822,0.0004650199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601865,0.000364332,0.0023480435,0.00023776572,0.0006521419,0.0003790934],"domain_scores_gemma":[0.9958911,0.00082846207,0.0014709133,0.00020155469,0.0011283241,0.0004796623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011485465,0.00019155271,0.0016680666,0.00023879623,0.000034331475,0.00001643208,0.00016128499,0.00014006654,0.00035776652],"category_scores_gemma":[0.00051603024,0.00011657355,0.00016614691,0.00027605786,0.00023788748,0.00025198117,0.00003698292,0.0007916188,0.000032185133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09734785,0.007810124,0.7553464,0.00022251239,0.0012171943,0.00027079522,0.0013685398,0.0003853701,0.0029070007,0.00001500054,0.0039640297,0.12914519],"study_design_scores_gemma":[0.051158458,0.049181636,0.89101094,0.00032451923,0.0003481467,0.000005978929,0.0005790242,0.00009068522,0.0012379304,0.00003623489,0.0058819293,0.00014451642],"about_ca_topic_score_codex":0.00040931648,"about_ca_topic_score_gemma":0.00074991485,"teacher_disagreement_score":0.13566455,"about_ca_system_score_codex":0.00047585997,"about_ca_system_score_gemma":0.0022587462,"threshold_uncertainty_score":0.47537315},"labels":[],"label_agreement":null},{"id":"W4231121000","doi":"10.1200/jco.2019.37.15_suppl.tps4155","title":"Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Oncology; Cancer; Clinical trial","score_opus":0.11552060169493483,"score_gpt":0.4541062629948091,"score_spread":0.3385856612998743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231121000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98578703,0.00089628674,0.000055952296,0.0027132528,0.0011449158,0.008523857,0.0000077371715,0.000008524141,0.00086245936],"genre_scores_gemma":[0.9963174,0.00014245842,0.002059704,0.0007340659,0.0003299691,0.00022850391,0.000015069734,0.00003234765,0.00014046817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99494034,0.0010258132,0.0026286233,0.0003913188,0.00068462774,0.0003292646],"domain_scores_gemma":[0.99282265,0.0036989164,0.0018713119,0.0005033928,0.0008697429,0.00023400015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037503953,0.0002971846,0.002804388,0.00018004174,0.00010325509,0.000037195983,0.00045694798,0.00016256467,0.000077258046],"category_scores_gemma":[0.002167217,0.00014464585,0.00022535182,0.00041684316,0.00028029492,0.00030468765,0.00012873705,0.0011091109,0.00000953813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81162465,0.013212951,0.15373896,0.00001887006,0.0010878462,0.000115491894,0.0011713807,0.00004233587,0.000008159505,0.000007661441,0.00016933317,0.018802391],"study_design_scores_gemma":[0.72152054,0.085085586,0.19035754,0.00014030484,0.00095477403,0.000013215554,0.0010245987,0.00010812617,0.000007354612,0.0000040863456,0.0006511427,0.00013273828],"about_ca_topic_score_codex":0.0000664765,"about_ca_topic_score_gemma":0.0005118045,"teacher_disagreement_score":0.09010407,"about_ca_system_score_codex":0.0002039257,"about_ca_system_score_gemma":0.0014781655,"threshold_uncertainty_score":0.58984864},"labels":[],"label_agreement":null},{"id":"W4231367171","doi":"10.1200/jco.2020.39.28_suppl.180","title":"Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Patient satisfaction; Cancer; Health care; Family medicine; Internal medicine; Nursing","score_opus":0.03389410486856965,"score_gpt":0.39635921622520104,"score_spread":0.3624651113566314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231367171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433076,0.0015464663,0.000005674507,0.0016756527,0.0014695865,0.00013575672,0.000004923514,0.0000047980525,0.00082639145],"genre_scores_gemma":[0.99795145,0.00071649975,0.00022124461,0.00072062964,0.0003296826,0.0000050124254,0.0000072170146,0.000011363829,0.00003688797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797887,0.0001960946,0.0012050614,0.00016778425,0.00031709034,0.00013512328],"domain_scores_gemma":[0.9975301,0.0002965357,0.0008975445,0.00011752438,0.00094529305,0.000212983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029099104,0.000094180876,0.000863002,0.00006804619,0.000019536137,0.0000075173753,0.000024577106,0.00021647236,0.00011893319],"category_scores_gemma":[0.00071984273,0.000067086905,0.00013096079,0.00015509425,0.000074784126,0.000082856626,0.000020804791,0.0005262969,6.7584756e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017772937,0.00014688082,0.7770609,0.000029943074,0.0001366255,0.00054258504,0.0009267226,0.000005667124,0.000009799144,0.0000028484806,0.00014452638,0.21921617],"study_design_scores_gemma":[0.009822927,0.0052137864,0.97117954,0.0002386008,0.0002511378,0.00008470167,0.0017431026,0.0000035913392,0.00002173325,0.000017499437,0.011349509,0.000073861695],"about_ca_topic_score_codex":0.0008811942,"about_ca_topic_score_gemma":0.0051657185,"teacher_disagreement_score":0.21914232,"about_ca_system_score_codex":0.00022177302,"about_ca_system_score_gemma":0.001482433,"threshold_uncertainty_score":0.2882592},"labels":[],"label_agreement":null},{"id":"W4231449485","doi":"10.1200/jco.2019.37.15_suppl.3612","title":"Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Colorectal cancer; Hazard ratio; Hepatectomy; Cohort; Resection; Proportional hazards model; Surgery; Population; Cancer; Internal medicine; Confidence interval","score_opus":0.07944958598568663,"score_gpt":0.4608492941564335,"score_spread":0.38139970817074687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231449485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929396,0.0006308713,0.000045493533,0.0006802678,0.0033711232,0.0018927933,0.000029623248,0.000014500407,0.00039573753],"genre_scores_gemma":[0.99759567,0.00019340261,0.0007644031,0.00027862587,0.0007983999,0.000091207716,0.000011912671,0.000020907439,0.00024548382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734426,0.000328448,0.0014144345,0.00027213088,0.00040813582,0.0002326015],"domain_scores_gemma":[0.99175066,0.0060324823,0.001124741,0.00013768254,0.00075998285,0.00019446465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017902635,0.0001701104,0.0015892129,0.000118852426,0.000092623064,0.000010922266,0.000087914384,0.00019310277,0.00036629618],"category_scores_gemma":[0.0036084135,0.00011758286,0.0005110801,0.00013945677,0.00006319546,0.00007026413,0.00002699188,0.0004577128,0.000009764679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.113119975,0.0032260204,0.8326915,0.000051701572,0.0027620287,0.00037326996,0.00013075086,0.0012614054,0.00002607952,0.0000053112203,0.0005896494,0.045762338],"study_design_scores_gemma":[0.033225775,0.14026849,0.8148394,0.000056032008,0.0023809331,0.000030027284,0.00046144333,0.0021562744,0.00003389303,0.000009792122,0.0064058406,0.00013204549],"about_ca_topic_score_codex":0.00056969706,"about_ca_topic_score_gemma":0.0040101735,"teacher_disagreement_score":0.13704248,"about_ca_system_score_codex":0.0009370651,"about_ca_system_score_gemma":0.0014473252,"threshold_uncertainty_score":0.47948897},"labels":[],"label_agreement":null},{"id":"W4231738730","doi":"10.1200/jco.2007.25.18_suppl.15514","title":"Durable complete responses and near complete responses to sunitinib in metastatic renal cell carcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Bevacizumab; Tyrosine-kinase inhibitor; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Oncology; Urology; Progressive disease; Disease; Chemotherapy","score_opus":0.24304686232044342,"score_gpt":0.4546096296690946,"score_spread":0.21156276734865115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231738730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898625,0.00079883396,0.00014484569,0.006407297,0.0003594631,0.0004419797,0.000019536601,0.000009484392,0.0028323003],"genre_scores_gemma":[0.9714587,0.00010584251,0.024073813,0.0031504384,0.00032766,0.0000040775462,0.0000043312666,0.00003075434,0.0008444289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365056,0.0016021903,0.0032957816,0.00033976138,0.0005588165,0.0005528856],"domain_scores_gemma":[0.9843034,0.012768149,0.001167927,0.00032021262,0.0004571429,0.0009831754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009933696,0.00025859647,0.0020671112,0.00053069595,0.00008626637,0.000025198242,0.00019785216,0.00022228052,0.00014036313],"category_scores_gemma":[0.0054568765,0.00019354631,0.00036610445,0.00035345193,0.00039120406,0.00010198616,0.00010973645,0.0011091504,0.000050459115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17438492,0.003772911,0.6900724,0.00018887088,0.00040407447,0.055615917,0.0011878435,0.000043218526,0.0460884,0.00014615241,0.0048694364,0.02322586],"study_design_scores_gemma":[0.011089903,0.02557075,0.9047748,0.00010733503,0.00034176308,0.0026899823,0.00038605527,0.00004810367,0.0015687123,0.0001284866,0.053133324,0.00016079459],"about_ca_topic_score_codex":0.0001564402,"about_ca_topic_score_gemma":0.0002070188,"teacher_disagreement_score":0.2147024,"about_ca_system_score_codex":0.00031368484,"about_ca_system_score_gemma":0.0016320553,"threshold_uncertainty_score":0.78925896},"labels":[],"label_agreement":null},{"id":"W4231747722","doi":"10.1200/jco.2015.33.3_suppl.139","title":"Comparison of adjuvant chemoradiation to perioperative chemotherapy for the treatment of resected gastric and gastroesophageal junction adenocarincoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Chemotherapy; Cancer; Adenocarcinoma; Gastroesophageal Junction; Perioperative; Surgery; Internal medicine","score_opus":0.20368778632879517,"score_gpt":0.5038486586966492,"score_spread":0.30016087236785405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231747722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795044,0.00092448085,0.0027244806,0.007022066,0.0005983732,0.00057700305,0.0000024020173,0.000003170639,0.00019756127],"genre_scores_gemma":[0.9932896,0.0004371165,0.005119163,0.00027451574,0.0006084313,0.0000091154225,0.0000024780743,0.0000073806827,0.00025218172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982547,0.00010097006,0.0012095207,0.00009952446,0.0002260223,0.00010923193],"domain_scores_gemma":[0.99748594,0.0007804042,0.001006538,0.0001077841,0.00044958416,0.0001697571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009754644,0.00008835022,0.0010806135,0.0001421216,0.000021633286,0.00000430011,0.00006525276,0.00008664973,0.00001790038],"category_scores_gemma":[0.0007385561,0.000049730086,0.000204939,0.00018774661,0.00009236357,0.00004200118,0.000012634689,0.0001297383,4.4891294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015436572,0.0015813751,0.5083286,0.000028372813,0.00053421955,0.000009043161,0.001593495,0.0002073111,0.00026424733,0.000035623594,0.0043104375,0.46767068],"study_design_scores_gemma":[0.019639978,0.075583294,0.87796736,0.000023743814,0.0005918626,0.000026416676,0.0016732337,0.0011055787,0.00075379707,0.000018313473,0.022579655,0.000036765716],"about_ca_topic_score_codex":0.000030823874,"about_ca_topic_score_gemma":0.000032124,"teacher_disagreement_score":0.4676339,"about_ca_system_score_codex":0.00017538948,"about_ca_system_score_gemma":0.00039673268,"threshold_uncertainty_score":0.2027934},"labels":[],"label_agreement":null},{"id":"W4231799243","doi":"10.1200/jco.2004.22.14_suppl.5522","title":"Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Radiation therapy; Randomized controlled trial; Meta-analysis; Randomization; Internal medicine; Oncology; Sample size determination","score_opus":0.24637724918698017,"score_gpt":0.48881789715948903,"score_spread":0.24244064797250886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231799243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87898415,0.10245836,0.0034154968,0.007750538,0.003773465,0.0028076223,0.00028864597,0.000019728579,0.0005019757],"genre_scores_gemma":[0.9393067,0.0231786,0.029385649,0.002532984,0.0053128954,0.00013914723,0.000035330282,0.000038698534,0.00007001178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899939,0.0019203194,0.006819709,0.00040486036,0.00054542325,0.00031579324],"domain_scores_gemma":[0.9205271,0.071074195,0.0058040856,0.00039382867,0.0017399181,0.00046085517],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.023586465,0.00036026482,0.037034027,0.00041050112,0.00006628935,0.00001582346,0.00019693522,0.0003566508,0.00035376952],"category_scores_gemma":[0.057511877,0.00020052452,0.010499382,0.0003152746,0.0005358392,0.0001575173,0.000030435938,0.00060220866,2.3278047e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62658405,0.0011225399,0.0005942043,0.000028375733,0.36664915,0.00007205288,0.0011208726,0.000041453295,0.00034737829,0.000053445874,0.0014760745,0.001910391],"study_design_scores_gemma":[0.6614974,0.007190777,0.001382722,0.000022052205,0.3226774,0.0000043931377,0.000218914,0.00018351723,0.00027214497,0.000054146713,0.0063674166,0.00012908265],"about_ca_topic_score_codex":0.00023544875,"about_ca_topic_score_gemma":0.00016167488,"teacher_disagreement_score":0.07927976,"about_ca_system_score_codex":0.00018738561,"about_ca_system_score_gemma":0.0015168106,"threshold_uncertainty_score":0.9994102},"labels":[],"label_agreement":null},{"id":"W4232050684","doi":"10.1200/jco.2010.34.1537","title":"Reply to J.C. Lindsey et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Medicine","score_opus":0.12528119161184487,"score_gpt":0.4485799330484658,"score_spread":0.3232987414366209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232050684","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57015586,0.022610396,0.0052752034,0.3065773,0.032871652,0.0003584731,0.00009317815,0.0000058339774,0.062052105],"genre_scores_gemma":[0.4509109,0.031971984,0.04335459,0.46328518,0.0059211007,0.000005154639,0.000010026122,0.000062353225,0.0044787414],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961394,0.00052337215,0.0024434815,0.0003333186,0.00019187282,0.00036853887],"domain_scores_gemma":[0.99592716,0.00068728806,0.0015646698,0.00038354628,0.0006563442,0.0007809772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004401422,0.00019658817,0.0009676303,0.000071971306,0.000035304678,0.000017097927,0.00044947668,0.0006160624,0.0003018532],"category_scores_gemma":[0.0075074816,0.00018271063,0.00067601167,0.00009543496,0.000249024,0.000008927821,0.00027056906,0.0008562793,0.000110726665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030003507,0.001814039,0.006788954,0.000011475224,0.00041573154,0.00045515288,0.00021472496,0.000055614437,0.0010843741,0.0013667413,0.77354664,0.2112462],"study_design_scores_gemma":[0.0021424163,0.022908935,0.014638842,0.00005409258,0.00016048214,0.00031573157,0.000073533265,0.000009870386,0.0016232171,0.0007219796,0.95715386,0.0001970495],"about_ca_topic_score_codex":0.00016220902,"about_ca_topic_score_gemma":0.00022282726,"teacher_disagreement_score":0.21104915,"about_ca_system_score_codex":0.000075563716,"about_ca_system_score_gemma":0.0031234745,"threshold_uncertainty_score":0.8987699},"labels":[],"label_agreement":null},{"id":"W4232127070","doi":"10.1200/jco.2020.38.15_suppl.tps5101","title":"PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kidney Foundation of Canada; Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Nivolumab; Perioperative; Internal medicine; Neoadjuvant therapy; Kidney cancer; Oncology; Surgery; Urology; Immunotherapy; Kidney; Cancer; Breast cancer","score_opus":0.1456851587564778,"score_gpt":0.4030842746793476,"score_spread":0.2573991159228698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232127070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440134,0.0001305218,0.00011574137,0.000986695,0.00048807467,0.0022137621,0.0000015426084,0.0000143903235,0.0016479075],"genre_scores_gemma":[0.99576646,0.000029117049,0.0030699903,0.0004960359,0.0004887148,0.000034921184,0.0000144626,0.000034972676,0.00006529481],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938811,0.0013596816,0.0032983476,0.00042512149,0.0006961161,0.00033963085],"domain_scores_gemma":[0.99409807,0.0024975927,0.0019977668,0.00021753939,0.00065708836,0.000531933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020843502,0.0003179608,0.0035558783,0.00015190091,0.000076172015,0.000029310668,0.00018994005,0.00020742875,0.000094736424],"category_scores_gemma":[0.002064581,0.0002121973,0.00045273534,0.0003248455,0.00019684588,0.00026307369,0.00008833618,0.0012456658,0.000014721455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46944952,0.0057817423,0.5198093,0.000028469307,0.00037711335,0.00074697443,0.0014908799,0.00013563545,0.000054104457,0.000004946737,0.00006995033,0.002051356],"study_design_scores_gemma":[0.5498387,0.062309824,0.38502356,0.000059997597,0.00070317707,0.000011164653,0.000682943,0.0008893712,0.000114045,0.0000019245247,0.00023835599,0.00012690728],"about_ca_topic_score_codex":0.00009435661,"about_ca_topic_score_gemma":0.000251782,"teacher_disagreement_score":0.13478576,"about_ca_system_score_codex":0.00058634876,"about_ca_system_score_gemma":0.0018357418,"threshold_uncertainty_score":0.8653155},"labels":[],"label_agreement":null},{"id":"W4232131900","doi":"10.1200/jco.2017.35.15_suppl.e16003","title":"A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Propensity score matching; Radiation therapy; Urology; Cohort; Proportional hazards model; Surgery; Cancer; Internal medicine","score_opus":0.2912530431791022,"score_gpt":0.5083917734414531,"score_spread":0.21713873026235092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232131900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916435,0.0007810199,0.000020828162,0.0043320437,0.0007768227,0.0004719583,0.000012890694,0.000003825356,0.001957116],"genre_scores_gemma":[0.9970157,0.0014345604,0.00052240543,0.0003172824,0.0006299126,0.0000142134495,0.0000023521015,0.00001598641,0.000047598696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953755,0.00064931164,0.0028080859,0.0002784817,0.00060858566,0.00028001048],"domain_scores_gemma":[0.9925598,0.0023245092,0.0038791462,0.0005966798,0.00044617004,0.0001937063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004954684,0.00019568122,0.0026829778,0.00026845466,0.000121073084,0.000013989654,0.0005694768,0.00039618852,0.00019164183],"category_scores_gemma":[0.002226343,0.0001102519,0.0011670287,0.00032948656,0.00060415873,0.00014308587,0.00012970032,0.001157372,0.0000017288482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02924335,0.0025417511,0.896538,0.0000352664,0.006356043,0.00031168977,0.0009441289,0.00006874731,0.00018029942,0.0000075367593,0.00018875,0.06358442],"study_design_scores_gemma":[0.030326152,0.010502259,0.9529526,0.00015963714,0.0045810007,0.000036868412,0.0002768694,0.00039825088,0.0002099365,0.000042194264,0.00042134375,0.000092867835],"about_ca_topic_score_codex":0.0008864479,"about_ca_topic_score_gemma":0.0013800904,"teacher_disagreement_score":0.06349155,"about_ca_system_score_codex":0.00011616388,"about_ca_system_score_gemma":0.0021567703,"threshold_uncertainty_score":0.502827},"labels":[],"label_agreement":null},{"id":"W4232266420","doi":"10.1200/jco.2019.37.15_suppl.4577","title":"First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Dalhousie University; Princess Margaret Cancer Centre; University of Manitoba; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Hazard ratio; Internal medicine; Renal cell carcinoma; Ipilimumab; Proportional hazards model; Oncology; Cohort; Cancer; Urology; Gastroenterology; Confidence interval; Immunotherapy","score_opus":0.11860912169424005,"score_gpt":0.4072306054144365,"score_spread":0.28862148372019647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232266420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94571406,0.001722075,0.00007199548,0.043537382,0.0030222808,0.0006729254,0.000091993046,0.0000112616235,0.0051560225],"genre_scores_gemma":[0.98992276,0.0015244926,0.0030878005,0.003606991,0.00077050494,0.000015521497,0.00019045692,0.000032227825,0.00084923644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99294364,0.00130446,0.0041363263,0.00045656282,0.00079796126,0.00036101666],"domain_scores_gemma":[0.98171407,0.013483745,0.003175137,0.0006618258,0.00069960544,0.00026563986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061748186,0.00029944582,0.0018523952,0.00025053121,0.000059941787,0.000027321224,0.00062161946,0.00035008046,0.000602699],"category_scores_gemma":[0.0038963656,0.00018353945,0.00057877746,0.00022328214,0.00032329326,0.00023936201,0.00020817897,0.0015328212,0.00014667654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.120873965,0.02925737,0.6630632,0.00015843354,0.0044623283,0.013721425,0.004848697,0.0008973715,0.02118231,0.0008250113,0.045812476,0.09489736],"study_design_scores_gemma":[0.0805127,0.025170956,0.7106995,0.0002798505,0.0010791902,0.00073396857,0.0013782462,0.0017335886,0.0026006713,0.001303755,0.17419791,0.00030966278],"about_ca_topic_score_codex":0.0005967948,"about_ca_topic_score_gemma":0.00075499486,"teacher_disagreement_score":0.12838544,"about_ca_system_score_codex":0.00079156907,"about_ca_system_score_gemma":0.001977378,"threshold_uncertainty_score":0.7484522},"labels":[],"label_agreement":null},{"id":"W4232357092","doi":"10.1200/jco.2019.37.15_suppl.e15717","title":"Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Saskatchewan; Nova Scotia Cancer Centre; Moncton Hospital; Dalhousie University; Dr. H. Bliss Murphy Cancer Centre; Health Sciences Centre; CancerCare Manitoba; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Chemotherapy regimen; Gastroenterology; Logistic regression; Oncology; Surgery","score_opus":0.12357370107798958,"score_gpt":0.4624129602761002,"score_spread":0.3388392591981106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232357092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935999,0.00036706027,0.000020610938,0.0034092108,0.0005068016,0.00074319536,0.00004259772,0.0000069847615,0.0013036678],"genre_scores_gemma":[0.99769676,0.0004534746,0.00022004632,0.000952136,0.0002361087,0.000022098298,0.00003309761,0.000021377426,0.00036489865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953103,0.0012383254,0.0019783718,0.00031693926,0.00058319146,0.0005728562],"domain_scores_gemma":[0.98461825,0.012786962,0.00095240166,0.00032790133,0.0005893463,0.00072513206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003087837,0.0002184412,0.0028875405,0.00030984884,0.000059489277,0.000016574577,0.00031634976,0.00047471127,0.0012179042],"category_scores_gemma":[0.0076970006,0.00011722152,0.00045370407,0.0006620161,0.00034469485,0.00010428712,0.000040471958,0.0016417885,0.000016496308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023656061,0.0006941711,0.9877654,0.000009480773,0.0052985363,0.00047456202,0.00031301266,0.00005758876,0.00004649265,0.0000048470615,0.0001027003,0.002867612],"study_design_scores_gemma":[0.0075366613,0.0031944448,0.9814798,0.0002696935,0.005088755,0.000006760126,0.0006317796,0.00082123745,0.000004808604,0.00001334681,0.00082770805,0.00012497955],"about_ca_topic_score_codex":0.02298093,"about_ca_topic_score_gemma":0.4408092,"teacher_disagreement_score":0.41782826,"about_ca_system_score_codex":0.0007957255,"about_ca_system_score_gemma":0.0057218526,"threshold_uncertainty_score":0.99991477},"labels":[],"label_agreement":null},{"id":"W4232377306","doi":"10.1200/jco.19.02007","title":"Camouflage","year":2019,"lang":"de","type":"article","venue":"Journal of Clinical Oncology","topic":"French Urban and Social Studies","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine","score_opus":0.1977216777119754,"score_gpt":0.4784629566119233,"score_spread":0.2807412788999479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232377306","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36139092,0.04701757,0.000026772077,0.021043438,0.08936603,0.00030950244,0.0000061620376,0.000014916242,0.48082468],"genre_scores_gemma":[0.9172741,0.030989563,0.00050817407,0.003667082,0.022452272,8.811578e-7,5.0806165e-7,0.000018305771,0.0250891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99355584,0.001871785,0.0030697854,0.00021763463,0.00081418594,0.0004707825],"domain_scores_gemma":[0.9898012,0.0053513926,0.0034912804,0.00015891275,0.000673838,0.00052334263],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.010405282,0.00017111533,0.0021558502,0.00007782189,0.00020199297,0.000040002902,0.00062190933,0.00094955333,0.0021761474],"category_scores_gemma":[0.0073789437,0.00013404271,0.0011747597,0.00028419035,0.0010136125,0.00021588772,0.00012432435,0.0015962116,0.0023140137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009766888,0.002859245,0.09511733,0.000055553744,0.0022847862,0.00062513875,0.017891627,0.000016220405,0.000014348794,0.056426875,0.55102646,0.27270573],"study_design_scores_gemma":[0.002141246,0.0045594065,0.03045628,0.00005323803,0.0002777848,0.0000025626534,0.0030288901,0.000011283375,0.0000012194345,0.0039312798,0.9553887,0.00014808564],"about_ca_topic_score_codex":0.00053984777,"about_ca_topic_score_gemma":0.0006047231,"teacher_disagreement_score":0.55588317,"about_ca_system_score_codex":0.00045720278,"about_ca_system_score_gemma":0.0032365397,"threshold_uncertainty_score":0.998736},"labels":[],"label_agreement":null},{"id":"W4232398903","doi":"10.1200/jco.2013.31.4_suppl.419","title":"Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; BC Cancer Agency; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Proportional hazards model; Cohort; Univariate analysis; Clinical endpoint; Cancer; Lymphovascular invasion; Primary tumor; Oncology; Multivariate analysis; Surgery; Randomized controlled trial; Metastasis","score_opus":0.053169390733071635,"score_gpt":0.37283235200375325,"score_spread":0.3196629612706816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232398903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934353,0.0010516272,0.0000029832443,0.002382508,0.00056374737,0.0011527911,0.000027005392,0.000015851896,0.0013681736],"genre_scores_gemma":[0.9945203,0.0025988123,0.00021902323,0.0010915246,0.0004265137,0.00020446672,0.0000051291204,0.000043067845,0.00089115225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659806,0.00038847319,0.0015707323,0.00034487355,0.00063934526,0.0004584853],"domain_scores_gemma":[0.9963789,0.000966547,0.0014048045,0.00015414726,0.0008131631,0.00028244613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008379939,0.00023889843,0.001797433,0.000052087493,0.00021727684,0.000114396,0.00018828375,0.000115049,0.0011880886],"category_scores_gemma":[0.0003803541,0.00015589026,0.0002529389,0.0003108283,0.0004035447,0.0002068604,0.00004576899,0.0008703573,0.0000034198922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004635443,0.0017947046,0.8554149,0.000025782241,0.0016082965,0.00040061842,0.00020867896,0.00003545831,0.000008785991,6.08891e-7,0.0031226499,0.13274407],"study_design_scores_gemma":[0.025282856,0.019924488,0.95067203,0.0004425311,0.0007096086,0.00013206406,0.00016915615,0.00009651814,0.000009023341,0.00003541637,0.0023597775,0.00016650115],"about_ca_topic_score_codex":0.09623892,"about_ca_topic_score_gemma":0.3593281,"teacher_disagreement_score":0.26308918,"about_ca_system_score_codex":0.00066609634,"about_ca_system_score_gemma":0.0015467339,"threshold_uncertainty_score":0.999725},"labels":[],"label_agreement":null},{"id":"W4232405844","doi":"10.1200/jco.2002.20.4.1017","title":"Dietary Change After Breast Cancer: Extent, Predictors, and Relation With Psychological Distress","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Psychosocial; Breast cancer; Distress; Disease; Affect (linguistics); Cancer; Internal medicine; Clinical psychology; Psychiatry; Psychology","score_opus":0.26261573843204333,"score_gpt":0.4936758604039551,"score_spread":0.23106012197191178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232405844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716704,0.0029165933,0.000023683055,0.023747567,0.00069693406,0.0001565091,0.000023436385,0.000006753043,0.0007581618],"genre_scores_gemma":[0.98600966,0.008691444,0.00036104867,0.0015767375,0.0031876431,0.00001343935,0.0000024655853,0.0000066621647,0.00015092528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984208,0.00015615889,0.00086864544,0.00016315357,0.00024481764,0.00014645598],"domain_scores_gemma":[0.99846756,0.0004928366,0.0005622201,0.00008707715,0.00015565676,0.00023464368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004194938,0.000111200075,0.0007564828,0.00005301926,0.000037704845,0.0000030657397,0.000055838736,0.000052151616,0.0007494866],"category_scores_gemma":[0.00015342988,0.000059394624,0.00011737733,0.000065568944,0.00033604642,0.000109700595,0.00003127822,0.000563507,0.000002635871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002640921,0.000713244,0.7032142,0.000015435968,0.00022302695,0.0007105809,0.00018648464,1.70882e-7,0.0000045544575,0.0000056826007,0.0010754538,0.2912102],"study_design_scores_gemma":[0.005533927,0.014855878,0.9617836,0.00019759889,0.00038021227,0.0013366865,0.00010457859,0.000055891396,5.7306914e-7,0.000030683408,0.015661461,0.000058931608],"about_ca_topic_score_codex":0.000016019063,"about_ca_topic_score_gemma":0.000041539744,"teacher_disagreement_score":0.2911513,"about_ca_system_score_codex":0.000039897433,"about_ca_system_score_gemma":0.000015727464,"threshold_uncertainty_score":0.82063526},"labels":[],"label_agreement":null},{"id":"W4232434482","doi":"10.1200/jco.2004.22.14_suppl.633","title":"Patterns of trastuzumab (T) use in three Canadian provinces","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; McMaster University; BC Cancer Agency","funders":"","keywords":"Medicine; Vinorelbine; Trastuzumab; Taxane; Breast cancer; Cancer; Family medicine; Metastatic breast cancer; Cancer registry; Internal medicine; Chemotherapy","score_opus":0.18032151794858894,"score_gpt":0.4878412718449584,"score_spread":0.30751975389636943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232434482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798364,0.00019031622,0.000023723016,0.009714117,0.00081609626,0.00017165004,0.000007884277,0.0000021788503,0.0010903664],"genre_scores_gemma":[0.99668604,0.0003087243,0.0006505292,0.0018254992,0.00042898254,0.000002348403,0.000001727871,0.000007598723,0.00008853299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800915,0.000104130355,0.001439355,0.00010236841,0.0001489011,0.00019609678],"domain_scores_gemma":[0.99803185,0.00066377776,0.0006934869,0.00008498836,0.00015656641,0.0003693129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008778287,0.0000825482,0.00096994406,0.00020877164,0.000012135924,0.0000026911528,0.000098029486,0.00023454726,0.00022326197],"category_scores_gemma":[0.0005533998,0.000058945312,0.00024729833,0.000093049784,0.000083893065,0.00009223492,0.000011740091,0.0005660633,0.0000051330726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019346882,0.0020548971,0.94414586,0.000018641764,0.00020794383,0.0019519738,0.00013785483,0.0000476902,0.000089729256,0.00015268741,0.0004355357,0.048822474],"study_design_scores_gemma":[0.013256315,0.015648937,0.9485896,0.00009391644,0.00020860221,0.00025412472,0.00005531944,0.000005178275,0.00013651121,0.00046096652,0.021241039,0.000049457733],"about_ca_topic_score_codex":0.060036324,"about_ca_topic_score_gemma":0.68598163,"teacher_disagreement_score":0.6259453,"about_ca_system_score_codex":0.0006537799,"about_ca_system_score_gemma":0.007029417,"threshold_uncertainty_score":0.9985998},"labels":[],"label_agreement":null},{"id":"W4232493431","doi":"10.1200/jco.2020.38.6_suppl.tps765","title":"PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Nivolumab; Perioperative; Internal medicine; Neoadjuvant therapy; Kidney cancer; Adjuvant; Oncology; Surgery; Urology; Immunotherapy; Kidney; Cancer; Breast cancer","score_opus":0.1456851587564778,"score_gpt":0.4030842746793476,"score_spread":0.2573991159228698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232493431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440134,0.0001305218,0.00011574137,0.000986695,0.00048807467,0.0022137621,0.0000015426084,0.0000143903235,0.0016479075],"genre_scores_gemma":[0.99576646,0.000029117049,0.0030699903,0.0004960359,0.0004887148,0.000034921184,0.0000144626,0.000034972676,0.00006529481],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938811,0.0013596816,0.0032983476,0.00042512149,0.0006961161,0.00033963085],"domain_scores_gemma":[0.99409807,0.0024975927,0.0019977668,0.00021753939,0.00065708836,0.000531933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020843502,0.0003179608,0.0035558783,0.00015190091,0.000076172015,0.000029310668,0.00018994005,0.00020742875,0.000094736424],"category_scores_gemma":[0.002064581,0.0002121973,0.00045273534,0.0003248455,0.00019684588,0.00026307369,0.00008833618,0.0012456658,0.000014721455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46944952,0.0057817423,0.5198093,0.000028469307,0.00037711335,0.00074697443,0.0014908799,0.00013563545,0.000054104457,0.000004946737,0.00006995033,0.002051356],"study_design_scores_gemma":[0.5498387,0.062309824,0.38502356,0.000059997597,0.00070317707,0.000011164653,0.000682943,0.0008893712,0.000114045,0.0000019245247,0.00023835599,0.00012690728],"about_ca_topic_score_codex":0.00009435661,"about_ca_topic_score_gemma":0.000251782,"teacher_disagreement_score":0.13478576,"about_ca_system_score_codex":0.00058634876,"about_ca_system_score_gemma":0.0018357418,"threshold_uncertainty_score":0.8653155},"labels":[],"label_agreement":null},{"id":"W4232508436","doi":"10.1200/jco.2014.32.4_suppl.29","title":"Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Abiraterone acetate; Prostate cancer; Internal medicine; Proportional hazards model; Hazard ratio; Oncology; Cohort; Chemotherapy; Population; Enzalutamide; Cancer; Gastroenterology; Urology; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.15423682002521794,"score_gpt":0.4708057749667629,"score_spread":0.31656895494154497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232508436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991437,0.000092187365,0.0059596114,0.0012919332,0.00009391804,0.0009210102,0.0001522882,0.000007514073,0.00004452875],"genre_scores_gemma":[0.9876858,0.00005987579,0.011398603,0.00022112062,0.00007412912,0.00008196196,0.00016032958,0.000024268582,0.00029388643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677503,0.00020793307,0.0019526106,0.00024543196,0.00053221895,0.00028675955],"domain_scores_gemma":[0.99439913,0.0014934633,0.0019192606,0.00018091478,0.0017090129,0.0002982348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014658027,0.00018347721,0.0018105119,0.0003801804,0.000056341403,0.000012785438,0.00010331173,0.00012565195,0.000030166666],"category_scores_gemma":[0.001180553,0.00010698697,0.00043677413,0.00050695875,0.0001515606,0.00010779062,0.000011793703,0.00028489647,5.671812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03344255,0.005297645,0.872256,0.0002475226,0.0061266934,0.000026939244,0.00015760124,0.06374257,0.00066285505,0.00004379106,0.00008730404,0.01790854],"study_design_scores_gemma":[0.031879906,0.015211627,0.6201279,0.00017038027,0.008962162,0.0000020613593,0.00002714543,0.32318977,0.00015198195,0.000048868773,0.00011620413,0.00011198945],"about_ca_topic_score_codex":0.00016941671,"about_ca_topic_score_gemma":0.00075952325,"teacher_disagreement_score":0.2594472,"about_ca_system_score_codex":0.00023710138,"about_ca_system_score_gemma":0.0017392307,"threshold_uncertainty_score":0.4362802},"labels":[],"label_agreement":null},{"id":"W4232532436","doi":"10.1200/jco.2004.22.14_suppl.6606","title":"RECIST (Response Evaluation Criteria in Solid Tumors) applied to response in lymphoma","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Solid tumor; Lymphoma; Oncology; Internal medicine; Cancer research; Cancer; Medical physics; Chemotherapy; Progressive disease","score_opus":0.12350108275360973,"score_gpt":0.5644260150150573,"score_spread":0.4409249322614476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232532436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748105,0.00010218473,0.0001029309,0.022052754,0.0006031067,0.0004825267,0.0000027370181,0.000004942762,0.001838331],"genre_scores_gemma":[0.9915555,0.00003362766,0.004192064,0.0037471247,0.00029217903,0.000034670305,0.000002422995,0.000013108725,0.00012931772],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9962514,0.00094629364,0.0020424172,0.00018676401,0.0003704001,0.0002026943],"domain_scores_gemma":[0.9967722,0.0018906977,0.0005827458,0.0001685743,0.0003043023,0.00028147173],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011386333,0.000105692205,0.0009342863,0.00041109096,0.000021579935,0.000008251398,0.000096443066,0.00020694887,0.00013674676],"category_scores_gemma":[0.010380013,0.00008198259,0.00014969031,0.00031668617,0.00006304244,0.00007263018,0.000025281397,0.00029169474,0.000050276587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5614309,0.007950568,0.012407437,0.000019374273,0.00023197236,0.004098847,0.0034805536,0.002790783,0.009061804,0.00015578353,0.0015516724,0.39682034],"study_design_scores_gemma":[0.03641744,0.011879881,0.9371287,0.00021941231,0.0001802095,0.0002696153,0.00037339146,0.000053515658,0.00024429618,0.0011238449,0.012026477,0.00008321314],"about_ca_topic_score_codex":0.00004875791,"about_ca_topic_score_gemma":0.0001608542,"teacher_disagreement_score":0.92472124,"about_ca_system_score_codex":0.0018789276,"about_ca_system_score_gemma":0.0069298623,"threshold_uncertainty_score":0.9986999},"labels":[],"label_agreement":null},{"id":"W4232538195","doi":"10.1200/jco.2004.22.14_suppl.6521","title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Follicular lymphoma; Radiation therapy; Internal medicine; Gastroenterology; Incidence (geometry); Surgery; Cumulative incidence; Lymphoma; Cohort","score_opus":0.09243860262198297,"score_gpt":0.42922491079748964,"score_spread":0.3367863081755067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232538195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890438,0.0028262176,0.00003602218,0.007304806,0.00030091556,0.0003288527,9.1782516e-7,0.000006826001,0.00015166463],"genre_scores_gemma":[0.9916319,0.0047928398,0.000994464,0.002231314,0.00024052117,0.000014346543,0.0000037815473,0.000012605603,0.000078224555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979858,0.00012245474,0.0012841241,0.00018544048,0.00023279851,0.00018939632],"domain_scores_gemma":[0.9981772,0.00071478897,0.00064535317,0.00015016405,0.00006048849,0.00025203367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007118253,0.00016234045,0.0012532055,0.00011839346,0.00004770564,0.000010620255,0.000053380358,0.00024450518,0.00002103408],"category_scores_gemma":[0.00022597102,0.00009244961,0.00036092856,0.000096869306,0.000047273257,0.00011081716,0.00001767896,0.00014023135,0.000002293812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021198501,0.0043744263,0.76070195,0.0000060128996,0.000556024,0.004613291,0.00016751893,0.000009664113,0.000027956703,0.000027174752,0.0000097464645,0.2273864],"study_design_scores_gemma":[0.07479484,0.046093486,0.875443,0.00010203848,0.00027927032,0.00016476713,0.000044824697,0.0000045979127,0.0006043441,0.00004829738,0.0023393768,0.00008120259],"about_ca_topic_score_codex":0.00017852792,"about_ca_topic_score_gemma":0.0003472666,"teacher_disagreement_score":0.2273052,"about_ca_system_score_codex":0.00063752214,"about_ca_system_score_gemma":0.00081430277,"threshold_uncertainty_score":0.37699857},"labels":[],"label_agreement":null},{"id":"W4232553190","doi":"10.1200/jco.2004.22.90140.6526","title":"CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; CHOP; Diffuse large B-cell lymphoma; Internal medicine; Oncology; Lymphoma; Stage (stratigraphy); Biology","score_opus":0.053011621939452344,"score_gpt":0.40569978897706094,"score_spread":0.3526881670376086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232553190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933491,0.0019183612,0.0000079386655,0.0035502098,0.00031819945,0.0003692672,0.0000033459135,0.000005826222,0.00047777506],"genre_scores_gemma":[0.9918164,0.0050408253,0.00060894946,0.0022333676,0.00023170956,0.000014316388,0.0000010299213,0.000012937532,0.0000404813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690807,0.00032286078,0.0019369511,0.00017243081,0.00040537486,0.00025431017],"domain_scores_gemma":[0.9953539,0.0024936649,0.001429491,0.00027396705,0.00022683376,0.00022217874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016151316,0.00015844665,0.0011323602,0.00010961145,0.000037601683,0.0000045853812,0.00021508617,0.0002850798,0.00002611621],"category_scores_gemma":[0.0018079606,0.00007920429,0.0004716337,0.00016871252,0.00018111487,0.00012781669,0.0000583242,0.00032897305,0.000014991039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036477274,0.086351134,0.8731461,0.00003458794,0.0001744607,0.0013224476,0.00051408756,0.000105451494,0.00085857906,0.00012219018,0.0003942691,0.03332894],"study_design_scores_gemma":[0.11555936,0.0063386187,0.8629396,0.0003422294,0.00011509977,0.00013717913,0.00015612523,0.0000063422804,0.0014793478,0.000299119,0.012560745,0.000066208166],"about_ca_topic_score_codex":0.00004335996,"about_ca_topic_score_gemma":0.000034133518,"teacher_disagreement_score":0.11191163,"about_ca_system_score_codex":0.0002669558,"about_ca_system_score_gemma":0.0014584194,"threshold_uncertainty_score":0.32298574},"labels":[],"label_agreement":null},{"id":"W4232564297","doi":"10.1200/jco.2004.22.90140.624","title":"Risk of radiation pneumonitis in breast cancer patients treated with adjuvant taxanes and radiation","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Pneumonitis; Paclitaxel; Internal medicine; Cancer; Oncology; Retrospective cohort study; Adjuvant; Concomitant; Chemotherapy; Surgery; Lung","score_opus":0.03415493484110391,"score_gpt":0.41780437077431004,"score_spread":0.3836494359332061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232564297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523294,0.0008737737,0.000003994965,0.003257917,0.0002788068,0.0001863353,0.000028532822,0.0000028546312,0.00013486974],"genre_scores_gemma":[0.9873353,0.011884627,0.0001069124,0.0003197114,0.00031335338,0.000005728511,0.0000075033445,0.000007793403,0.000019025962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844134,0.00019005277,0.00100281,0.000106088686,0.00014826357,0.00011146089],"domain_scores_gemma":[0.9977469,0.0004086467,0.0014459108,0.00004695384,0.00020821978,0.00014336282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045050884,0.00008674656,0.00079832674,0.00013933059,0.000015967038,0.0000020162895,0.000032291704,0.00016345414,0.00005980201],"category_scores_gemma":[0.0001664133,0.000057155725,0.0000925219,0.0001333077,0.00011130858,0.00009143527,0.000007357974,0.00032640382,9.312397e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047318614,0.0015671535,0.7407843,0.000011811695,0.00020532185,0.000083603234,0.000109498724,0.00009442799,0.000071279974,0.000003327534,0.00010558188,0.2522318],"study_design_scores_gemma":[0.029471703,0.01224206,0.95596373,0.000086108834,0.00064171193,0.00012949109,0.00002340558,0.000020943196,0.00026184414,0.000044985405,0.0010660643,0.000047931324],"about_ca_topic_score_codex":0.0007959357,"about_ca_topic_score_gemma":0.00037783317,"teacher_disagreement_score":0.25218388,"about_ca_system_score_codex":0.00025220294,"about_ca_system_score_gemma":0.000680392,"threshold_uncertainty_score":0.23307428},"labels":[],"label_agreement":null},{"id":"W4232692388","doi":"10.1200/jco.2018.36.4_suppl.283","title":"A study of pelareorep in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Chills; Internal medicine; Gastroenterology; Oncolytic virus; Chemotherapy; Pancreatic cancer; Gemcitabine; Oncology; Surgery; Cancer; Immunotherapy","score_opus":0.045399663778894365,"score_gpt":0.3925562066802916,"score_spread":0.34715654290139725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232692388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990025,0.00013112715,0.000010393469,0.00032835267,0.000057108085,0.00040213548,0.000001765325,5.435739e-7,0.00006604136],"genre_scores_gemma":[0.9994795,0.00006469672,0.0002249443,0.00014826491,0.000045914854,0.0000051787883,0.0000013244185,0.000013617909,0.000016587008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735904,0.0009622826,0.001030811,0.00017721993,0.00032477858,0.0001458955],"domain_scores_gemma":[0.9979934,0.00020234183,0.0010190742,0.00024482634,0.0004745921,0.000065776076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019027535,0.00010351869,0.0006244762,0.000105679406,0.000018630639,0.0000033747115,0.0002400825,0.00012181397,0.00001062906],"category_scores_gemma":[0.00040330738,0.00005947964,0.000065626395,0.00019283108,0.0003979431,0.000008134846,0.000055065626,0.0003211515,2.4498144e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060929045,0.004668955,0.9251093,0.000015583782,0.00022421357,0.000014997171,0.00045076327,0.000018387562,0.0012081992,0.0000065246636,0.00004271624,0.0073112887],"study_design_scores_gemma":[0.03317924,0.17402977,0.7890285,0.00004332867,0.00004442002,0.000014628651,0.0004017037,0.000019189358,0.0030432953,0.000065791035,0.000071964416,0.00005816897],"about_ca_topic_score_codex":0.00004434326,"about_ca_topic_score_gemma":0.0016401978,"teacher_disagreement_score":0.16936082,"about_ca_system_score_codex":0.000033022465,"about_ca_system_score_gemma":0.00056696055,"threshold_uncertainty_score":0.24255092},"labels":[],"label_agreement":null},{"id":"W4232775912","doi":"10.1200/jco.2002.20.6.1519","title":"Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre","funders":"","keywords":"Medicine; Fluorouracil; Tolerability; Gastroenterology; Internal medicine; Regimen; Hazard ratio; Mucositis; Colorectal cancer; Clinical endpoint; Phases of clinical research; Surgery; Randomized controlled trial; Confidence interval; Chemotherapy; Cancer; Adverse effect","score_opus":0.16168140471130935,"score_gpt":0.45884860527447285,"score_spread":0.2971672005631635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232775912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911805,0.002395573,0.000018721594,0.0011191113,0.00089513755,0.00335712,0.000030543095,0.000009371931,0.0009939626],"genre_scores_gemma":[0.99279916,0.0052267364,0.0011308168,0.00017431358,0.00016082736,0.00020358321,0.000006935634,0.00003835168,0.00025924682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928453,0.0012200268,0.004065574,0.0004492359,0.0009662628,0.00045361646],"domain_scores_gemma":[0.9897247,0.0043405923,0.0039096116,0.0003097562,0.0013876271,0.00032770028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00324235,0.0004415888,0.0062219687,0.00024426825,0.00009916888,0.000016373964,0.0004207398,0.0002133508,0.0004157346],"category_scores_gemma":[0.002756277,0.00027182783,0.00035307228,0.00048701165,0.0005104529,0.0003114892,0.00017173256,0.0008787303,0.0000034056425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7096422,0.030710323,0.0048160623,0.000031470816,0.0044613006,0.0005371809,0.004523105,0.00031454637,0.000018079378,0.000008824182,0.00018664417,0.24475029],"study_design_scores_gemma":[0.76159203,0.22619751,0.0075178533,0.00017488969,0.0014501899,0.00002896487,0.0013431906,0.00039650314,0.00010620892,0.000026035666,0.0009619245,0.00020471874],"about_ca_topic_score_codex":0.0014291706,"about_ca_topic_score_gemma":0.0035094162,"teacher_disagreement_score":0.24454556,"about_ca_system_score_codex":0.0010222462,"about_ca_system_score_gemma":0.0015670876,"threshold_uncertainty_score":0.9999734},"labels":[],"label_agreement":null},{"id":"W4232838246","doi":"10.1200/jco.2015.33.15_suppl.tps5077","title":"Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Hazard ratio; Docetaxel; Hormone therapy; Adverse effect; Cancer; Androgen receptor; Breast cancer; Confidence interval","score_opus":0.32340789363280126,"score_gpt":0.5553874240841372,"score_spread":0.23197953045133596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232838246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742108,0.0032408554,0.00021564354,0.015427107,0.0014954477,0.0052780206,0.0000342622,0.0000053349895,0.00009255429],"genre_scores_gemma":[0.9821378,0.012900833,0.001159321,0.00075074297,0.0022981174,0.000422909,0.000023556033,0.000028226394,0.00027848137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949731,0.00095022033,0.0030145268,0.00020562919,0.0005572985,0.00029918095],"domain_scores_gemma":[0.99059725,0.0059649134,0.0020764226,0.00022488287,0.000824581,0.0003119255],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011973934,0.00016842886,0.0019177013,0.00019281643,0.00004716668,0.000013228641,0.00021655679,0.000201813,0.000048168375],"category_scores_gemma":[0.009152535,0.00008652613,0.00061500823,0.00027002138,0.00027904942,0.00012836362,0.000029919294,0.00061776297,0.0000014194987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.841588,0.004972188,0.0013551791,0.000032620686,0.0006710665,0.000082208484,0.00044572845,0.00006149245,0.00012094706,0.000011780761,0.001757844,0.14890091],"study_design_scores_gemma":[0.87689644,0.075767964,0.0003339621,0.00008236999,0.0004236056,0.000020881924,0.00013879081,0.0003370887,0.0013821935,0.001056354,0.043487556,0.00007280259],"about_ca_topic_score_codex":0.00007370813,"about_ca_topic_score_gemma":0.00012433212,"teacher_disagreement_score":0.1488281,"about_ca_system_score_codex":0.00026152073,"about_ca_system_score_gemma":0.0047049425,"threshold_uncertainty_score":0.9991938},"labels":[],"label_agreement":null},{"id":"W4232912661","doi":"10.1200/jco.2013.31.4_suppl.545","title":"Risk of arterial (ATE) and venous thromboembolism (VTE) in a population-based cohort of bevacizumab-treated metastatic colorectal cancer (mCRC) patients.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Bevacizumab; Colorectal cancer; Internal medicine; Cohort; Venous thromboembolism; Population; Incidence (geometry); Cancer; Surgery; Oncology; Chemotherapy; Thrombosis","score_opus":0.033500789246145926,"score_gpt":0.3775969711679279,"score_spread":0.344096181921782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232912661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747294,0.00018686571,0.000012374697,0.0005409381,0.00066300615,0.000855677,0.000023649935,0.0000050042263,0.0002395229],"genre_scores_gemma":[0.99775827,0.0008534039,0.00082298106,0.00032750878,0.0001665793,0.000030871957,0.000014931838,0.00001866236,0.000006790957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959109,0.0005087802,0.0027584312,0.00020150508,0.00039206818,0.00022834308],"domain_scores_gemma":[0.99511534,0.0011951104,0.002727905,0.00014986702,0.000597829,0.00021396799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014900273,0.00016764308,0.0028472398,0.00024779578,0.000026697173,0.000006670739,0.00011282981,0.00021120076,0.00035722659],"category_scores_gemma":[0.0015947941,0.00012368022,0.0002941345,0.00018257351,0.00019270918,0.00011021618,0.00004335591,0.00041553055,0.000003558342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012026,0.0065239444,0.96178144,0.00011055518,0.0009351132,0.000033198456,0.00018293544,0.0001451429,0.00021393519,0.0000386838,0.0005502062,0.028282227],"study_design_scores_gemma":[0.010340948,0.008942475,0.97773683,0.00018794763,0.0015089555,0.000006021217,0.000058614372,0.00036201632,0.00018069959,0.0003431254,0.00023776482,0.00009457614],"about_ca_topic_score_codex":0.0058611925,"about_ca_topic_score_gemma":0.0007614517,"teacher_disagreement_score":0.02818765,"about_ca_system_score_codex":0.00015201523,"about_ca_system_score_gemma":0.0005269299,"threshold_uncertainty_score":0.88604087},"labels":[],"label_agreement":null},{"id":"W4232929949","doi":"10.1200/jco.2017.35.6_suppl.133","title":"Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Medicine; Prostatectomy; Hazard ratio; Prostate cancer; Meta-analysis; Confidence interval; Oncology; Disease; Internal medicine; Metastasis; Bioinformatics; Cancer; Biology","score_opus":0.2852279736251007,"score_gpt":0.46173713160756474,"score_spread":0.17650915798246403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232929949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524355,0.00043911225,0.000012514986,0.0031995957,0.00022003945,0.00059636094,0.00017941241,9.0215565e-7,0.000108529064],"genre_scores_gemma":[0.99724954,0.00019117992,0.0020618865,0.00020739884,0.000032980657,0.000021734437,0.0000041800095,0.000010547885,0.00022054632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538016,0.0006557972,0.0026424539,0.00018343073,0.0009097877,0.00022837942],"domain_scores_gemma":[0.99398243,0.0009063455,0.003598242,0.0005998075,0.0006774414,0.00023572959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037016913,0.00014739743,0.0021138273,0.00023448121,0.0001104687,0.000007655645,0.0006631869,0.00009084815,0.00013658011],"category_scores_gemma":[0.0022482472,0.000062725354,0.0011997259,0.00029413158,0.00045275738,0.00008174661,0.00037783483,0.0005721811,0.0000014737207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050148084,0.0013257436,0.9127165,0.00006351044,0.056517337,0.000024190997,0.0010533049,0.00054109923,0.0002840107,0.0000079070605,0.00016922494,0.02228238],"study_design_scores_gemma":[0.003707628,0.002438512,0.94426495,0.00004850744,0.04702375,0.0000021180203,0.00017971448,0.00014899511,0.0015533245,0.000033223147,0.00054530695,0.000053950538],"about_ca_topic_score_codex":0.00010029815,"about_ca_topic_score_gemma":0.00028773316,"teacher_disagreement_score":0.03154849,"about_ca_system_score_codex":0.00017701322,"about_ca_system_score_gemma":0.003301275,"threshold_uncertainty_score":0.585632},"labels":[],"label_agreement":null},{"id":"W4232987374","doi":"10.1200/jco.2013.31.18_suppl.lba4510","title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Goserelin; Hazard ratio; Urology; Randomization; Clinical endpoint; Proportional hazards model; Radiation therapy; Internal medicine; Cancer; Surgery; Confidence interval","score_opus":0.09654002515118829,"score_gpt":0.4726979184230209,"score_spread":0.3761578932718326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232987374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727816,0.0017991879,0.000032017342,0.008372516,0.0004933221,0.0018244642,0.0000024254123,0.0000034853288,0.00019442113],"genre_scores_gemma":[0.9518407,0.046308674,0.00082219025,0.00024512922,0.00043182497,0.000105172134,0.000004609582,0.000008653508,0.00023301953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995767,0.0010175736,0.0026594838,0.00011311242,0.0002945098,0.00014833345],"domain_scores_gemma":[0.9943393,0.0025492967,0.0022474884,0.00010601373,0.0006198347,0.00013806684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005327292,0.00008466813,0.0015953392,0.0001681845,0.000017965669,0.0000066236507,0.00007476556,0.00020688606,0.00019558845],"category_scores_gemma":[0.0042950986,0.00004702208,0.0003237522,0.0001715695,0.00018846556,0.00014463,0.0000145443255,0.00050307147,0.0000055383443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66689736,0.0009833762,0.07490205,0.000012021188,0.00033487173,0.00002827133,0.00016116054,0.000010686,0.00024484977,0.000020705273,0.00048204508,0.25592262],"study_design_scores_gemma":[0.9113613,0.011507853,0.07173991,0.00007710363,0.00013654017,0.000010058809,0.000045319684,0.00017984545,0.0011305242,0.0023650203,0.0014026756,0.000043859567],"about_ca_topic_score_codex":0.0006907461,"about_ca_topic_score_gemma":0.00004796891,"teacher_disagreement_score":0.25587875,"about_ca_system_score_codex":0.00013628785,"about_ca_system_score_gemma":0.0016989468,"threshold_uncertainty_score":0.5141944},"labels":[],"label_agreement":null},{"id":"W4232987386","doi":"10.1200/jco.2004.22.14_suppl.4545","title":"Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Cancer; Genitourinary system; Center (category theory); Retrospective cohort study; Oncology; Carcinoma; Internal medicine; Gynecology; General surgery","score_opus":0.24924841216649174,"score_gpt":0.5285793021020718,"score_spread":0.2793308899355801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232987386","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021559969,0.98538125,0.00000177571,0.008340102,0.001131727,0.0014093956,0.00015192608,0.0000045712222,0.0014232796],"genre_scores_gemma":[0.00048870634,0.9940396,0.00009668668,0.000778904,0.0026913162,0.000093902985,0.00001834115,0.000052641033,0.0017399113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928159,0.0017208754,0.0038693948,0.0004825005,0.00066550024,0.0004458281],"domain_scores_gemma":[0.9903958,0.0031635542,0.0046141692,0.00049805787,0.0008718459,0.00045658447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033669632,0.0004959845,0.0075562177,0.00014783186,0.000090153866,0.000006667348,0.00036499582,0.0005102237,0.00032055314],"category_scores_gemma":[0.0011647742,0.00024045487,0.0024084495,0.00019358334,0.00065084593,0.000040181272,0.0003407698,0.0018236439,0.000008968806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017479573,0.0028843915,0.09916898,0.16272883,0.005822257,0.0027253067,0.00018059216,4.688108e-7,5.920725e-7,0.000020489013,0.027850585,0.69686955],"study_design_scores_gemma":[0.004775036,0.01484529,0.019530362,0.067435175,0.005453264,0.0010898215,0.000025907468,1.4252043e-7,8.131172e-7,0.000011567943,0.8866651,0.00016749317],"about_ca_topic_score_codex":0.00050514215,"about_ca_topic_score_gemma":0.0007098594,"teacher_disagreement_score":0.85881454,"about_ca_system_score_codex":0.004663402,"about_ca_system_score_gemma":0.008809813,"threshold_uncertainty_score":0.99915755},"labels":[],"label_agreement":null},{"id":"W4233043602","doi":"10.1200/jco.2017.35.15_suppl.e16078","title":"Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Renal cell carcinoma; Internal medicine; Toxicity; Dosing; Urology; Oncology; Proportional hazards model; Gastroenterology","score_opus":0.13482162064300587,"score_gpt":0.39222614925670485,"score_spread":0.257404528613699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233043602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917377,0.000055772296,0.000010499621,0.003318341,0.00047893677,0.0011475171,0.0008226143,0.000009875316,0.004982645],"genre_scores_gemma":[0.9954277,0.000046408804,0.0032585817,0.0005926777,0.0003152623,0.000039474304,0.0002059325,0.000035624995,0.00007833218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517876,0.0007256301,0.002247302,0.0002963263,0.0010297261,0.0005222425],"domain_scores_gemma":[0.99118346,0.0019957742,0.0040000575,0.000687201,0.0010385108,0.0010949945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018460376,0.00039115432,0.0017875952,0.00024821234,0.00039946058,0.00015715942,0.00036622753,0.00023650755,0.00006602369],"category_scores_gemma":[0.0011586382,0.00017157698,0.00018119106,0.00017859077,0.00039815556,0.000490081,0.000041981693,0.0008454407,0.0000071176837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37671155,0.0006885816,0.5903329,0.00006644204,0.0014223827,0.0035297468,0.0021686747,0.00008320955,0.0000016907096,0.0000134701495,0.0007078579,0.024273472],"study_design_scores_gemma":[0.16854893,0.07688274,0.73491323,0.000941234,0.0025296495,0.00011695984,0.0013517397,0.00003270366,0.0001914213,0.000002588156,0.014257013,0.0002317903],"about_ca_topic_score_codex":0.09782696,"about_ca_topic_score_gemma":0.3644581,"teacher_disagreement_score":0.26663116,"about_ca_system_score_codex":0.0029866411,"about_ca_system_score_gemma":0.015487612,"threshold_uncertainty_score":0.99009365},"labels":[],"label_agreement":null},{"id":"W4233112648","doi":"10.1200/jco.2005.01.6592","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.11725802081902201,"score_gpt":0.5767194063668202,"score_spread":0.45946138554779814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233112648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79998016,0.00068388577,0.000052523534,0.14573003,0.0010109749,0.000098642,6.105373e-7,0.000003981042,0.05243919],"genre_scores_gemma":[0.96657616,0.00036145054,0.0084639555,0.020422714,0.0018278382,0.0000013588995,4.221837e-7,0.0000050034146,0.0023410725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985707,0.00006941183,0.0011104158,0.00006009842,0.00010784974,0.00008153913],"domain_scores_gemma":[0.9987975,0.0004169573,0.00045639317,0.000074018506,0.00011556139,0.00013958054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095176086,0.000037375863,0.0005072665,0.000067627676,0.000007952449,0.0000016392402,0.000037984315,0.00009395792,0.00027910894],"category_scores_gemma":[0.0010454071,0.000024026682,0.00016601292,0.000063770865,0.0000401435,0.000082223436,0.0000078800595,0.00034504305,0.000040413834],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017566594,0.003731246,0.1564184,0.00000940035,0.00033850793,0.001555155,0.00030693618,0.000048055634,0.000055071807,0.00057225395,0.07451944,0.7606889],"study_design_scores_gemma":[0.0061524366,0.003198375,0.18540074,0.000024943593,0.00014667524,0.00029607132,0.000040614806,0.000023163391,0.000023125807,0.00026856092,0.80440456,0.000020761243],"about_ca_topic_score_codex":0.000011740969,"about_ca_topic_score_gemma":0.000034242596,"teacher_disagreement_score":0.7606681,"about_ca_system_score_codex":0.0001679504,"about_ca_system_score_gemma":0.0010976468,"threshold_uncertainty_score":0.3056047},"labels":[],"label_agreement":null},{"id":"W4233116961","doi":"10.1200/jco.2012.30.5_suppl.387","title":"A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Temsirolimus; Sunitinib; Everolimus; Hazard ratio; Renal cell carcinoma; Internal medicine; Oncology; Targeted therapy; Population; Urology; PI3K/AKT/mTOR pathway; Cancer; Discovery and development of mTOR inhibitors; Confidence interval","score_opus":0.2574749230303926,"score_gpt":0.47014693469336427,"score_spread":0.21267201166297167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233116961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862932,0.012049322,0.000031676038,0.00063248305,0.00033556487,0.0002435791,0.0000050968747,0.0000023397627,0.00040676526],"genre_scores_gemma":[0.99067557,0.0004773334,0.008162735,0.00041844335,0.00021492755,0.0000038896146,0.0000070533456,0.00001365381,0.000026368543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951966,0.0009161874,0.003054758,0.00012187942,0.00047437052,0.00023619876],"domain_scores_gemma":[0.9941571,0.0022405002,0.0027709284,0.00020341137,0.000348869,0.00027919724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033700748,0.00014946802,0.0019497966,0.00024329641,0.000010877714,0.000001552679,0.00013299094,0.00018464598,0.00030105823],"category_scores_gemma":[0.00081994524,0.00009646284,0.0006054798,0.00023718474,0.00012421125,0.00010183243,0.000016448877,0.0004583059,0.000003660423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029376626,0.0035459963,0.9717823,0.00016096528,0.00014284962,0.00020241979,0.00016345215,0.00011443325,0.0076105916,0.000032785698,0.00010789804,0.013198627],"study_design_scores_gemma":[0.008399946,0.013598323,0.9568515,0.00012882985,0.00032703608,0.00007396956,0.000078737285,0.00007555606,0.019832795,0.00013642118,0.00042569364,0.00007122137],"about_ca_topic_score_codex":0.00027622384,"about_ca_topic_score_gemma":0.00003785522,"teacher_disagreement_score":0.014930847,"about_ca_system_score_codex":0.00017651216,"about_ca_system_score_gemma":0.0013694502,"threshold_uncertainty_score":0.39336404},"labels":[],"label_agreement":null},{"id":"W4233221569","doi":"10.1200/jco.2015.33.15_suppl.lba5002","title":"A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Clinical Oncology; Chemotherapy; Internal medicine; Prednisone; Gynecology; Cancer","score_opus":0.08920992381682366,"score_gpt":0.5058327657049976,"score_spread":0.4166228418881739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233221569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710548,0.0027451168,0.00007570154,0.0045967754,0.00022022185,0.02101848,0.00007589716,0.00001134768,0.00020164094],"genre_scores_gemma":[0.9703576,0.012015693,0.0046308334,0.0007226423,0.0007030254,0.008755605,0.00003167586,0.00009755234,0.0026853879],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969944,0.00027860122,0.0014332185,0.00039277272,0.00051669695,0.00038435264],"domain_scores_gemma":[0.99585444,0.0010226187,0.0014175926,0.00019452094,0.0006386836,0.0008721753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020335023,0.00026906905,0.0016758803,0.00011424295,0.000086790475,0.000024930518,0.0001138304,0.00026544536,0.000059646798],"category_scores_gemma":[0.00087853696,0.00015745482,0.00014738431,0.00013265149,0.00069174723,0.00019818089,0.00007337298,0.00057403604,8.1988844e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.700618,0.0044689607,0.040912498,0.00042536305,0.0020365762,0.00049950636,0.0008124583,0.0000045856127,0.0024053429,0.000024830226,0.027544878,0.22024696],"study_design_scores_gemma":[0.6227087,0.16485152,0.0011865462,0.0005582624,0.0012087441,0.00048604544,0.00049162534,0.00029829695,0.013473718,0.00079699495,0.19365528,0.00028428735],"about_ca_topic_score_codex":0.00031006965,"about_ca_topic_score_gemma":0.000054294047,"teacher_disagreement_score":0.21996267,"about_ca_system_score_codex":0.00014826252,"about_ca_system_score_gemma":0.0024224578,"threshold_uncertainty_score":0.6420821},"labels":[],"label_agreement":null},{"id":"W4233437458","doi":"10.1200/jco.2012.30.27_suppl.129","title":"A review of clinical endpoints and use of quality-of-life outcomes in phase III metastatic breast cancer clinical trials.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Clinical endpoint; Clinical trial; Quality of life (healthcare); Metastatic breast cancer; Internal medicine; Breast cancer; Cancer; Disease; Oncology; Intensive care medicine","score_opus":0.8390301528975707,"score_gpt":0.7464270069315143,"score_spread":0.09260314596605634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233437458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008420733,0.9826557,0.000009971289,0.0024200229,0.004118418,0.0018389348,0.00045466717,0.0000042257984,0.00007729871],"genre_scores_gemma":[0.0008172913,0.99232316,0.0013072965,0.0034231788,0.0018847786,0.00004246825,0.000029113571,0.0000482896,0.00012441652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.92783195,0.025274199,0.04529382,0.00050889945,0.0006671037,0.00042405864],"domain_scores_gemma":[0.8647982,0.09156446,0.04105517,0.0005340531,0.00091994734,0.001128187],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.08903336,0.0005815558,0.0465335,0.00044311275,0.000015718715,0.000003921744,0.00038305097,0.0013984046,0.0013841578],"category_scores_gemma":[0.06362593,0.00034438015,0.00787078,0.0004044282,0.0011686863,0.00017474833,0.00018837136,0.0033798951,0.0000053837207],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011945276,0.018010795,0.04343538,0.05134015,0.00867194,0.00012491706,0.000021241614,6.503728e-8,3.5338556e-7,0.000035133067,0.004399339,0.8620154],"study_design_scores_gemma":[0.05246844,0.010722979,0.018618053,0.053706948,0.04252847,0.00028935712,0.0000123004165,0.0000017431264,2.4597549e-7,0.000026596277,0.82137704,0.00024781056],"about_ca_topic_score_codex":0.00021175532,"about_ca_topic_score_gemma":0.0001302062,"teacher_disagreement_score":0.8617676,"about_ca_system_score_codex":0.00016146494,"about_ca_system_score_gemma":0.010948902,"threshold_uncertainty_score":0.9999008},"labels":[],"label_agreement":null},{"id":"W4233443513","doi":"10.1200/jco.2004.22.14_suppl.5105","title":"Metastatic uterine sarcoma: A systematic review of the literature","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Uterine Myomas and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Sarcoma; Uterine sarcoma; Systematic review; Oncology; Internal medicine; Cancer research; Pathology; MEDLINE","score_opus":0.16681373294550028,"score_gpt":0.5339274188256189,"score_spread":0.3671136858801186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233443513","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000103017355,0.9953434,0.0000052528667,0.001392653,0.0011707101,0.001710827,0.000027569171,0.0000039066053,0.00033537683],"genre_scores_gemma":[0.000022842429,0.99591017,0.0016460947,0.0011809476,0.0004048802,0.000027928409,0.000010491075,0.000034146826,0.000762511],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9896813,0.0017016435,0.00769965,0.00019636007,0.0005313072,0.00018973762],"domain_scores_gemma":[0.9863354,0.0018373418,0.010375858,0.00066392816,0.0005349426,0.00025253967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034817867,0.00036457827,0.014423481,0.00013734424,0.000021022526,0.000008344548,0.00046181265,0.00039783138,0.00009065352],"category_scores_gemma":[0.006085835,0.00014412851,0.0048446003,0.00042588965,0.00013667371,0.00005108663,0.00014298676,0.0015735383,0.000019648378],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046699122,0.0010833411,0.000005318636,0.9031695,0.0031368244,0.0018663781,0.000010306415,1.7999804e-8,2.0744125e-8,0.000055169498,0.00044471168,0.09018168],"study_design_scores_gemma":[0.0013233743,0.0025493235,0.000018105802,0.57944685,0.020207461,0.008537148,0.0000013208085,6.850034e-8,4.909831e-8,0.000040035593,0.38781998,0.00005626058],"about_ca_topic_score_codex":0.0000018411332,"about_ca_topic_score_gemma":9.01218e-7,"teacher_disagreement_score":0.38737527,"about_ca_system_score_codex":0.000248281,"about_ca_system_score_gemma":0.0035529437,"threshold_uncertainty_score":0.9859603},"labels":[],"label_agreement":null},{"id":"W4233486866","doi":"10.1200/jco.2014.32.15_suppl.10023","title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Metabolic equivalent; Poisson regression; Cumulative incidence; Coronary artery disease; Physical therapy; Cohort; Population; Physical activity","score_opus":0.04066454707337199,"score_gpt":0.3864510809198766,"score_spread":0.34578653384650465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233486866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845678,0.010019037,0.000071083494,0.0024091697,0.0016523598,0.0010760232,0.00005222238,0.000011522275,0.00014074295],"genre_scores_gemma":[0.98598886,0.011263615,0.00058707985,0.0007295898,0.0013272696,0.000023853298,0.0000057274324,0.00005139815,0.000022609474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98683757,0.0043731146,0.006251395,0.00059751794,0.0015487869,0.00039163203],"domain_scores_gemma":[0.9856043,0.0061733583,0.005700773,0.001154799,0.0009316587,0.00043514828],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.021396678,0.00037162675,0.0049914233,0.00022071844,0.00006649086,0.0000067162387,0.00055407354,0.0005056135,0.000058070847],"category_scores_gemma":[0.016652614,0.00024980344,0.0014815021,0.00044649193,0.00039000495,0.00016030754,0.00023593583,0.0012148384,0.000002537065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021051732,0.0077798073,0.9030548,0.00006282937,0.004273327,0.00017142978,0.0035333154,0.000050909566,0.0000047072376,0.0000047210187,0.0003529597,0.07860602],"study_design_scores_gemma":[0.02537035,0.004583251,0.96041274,0.000987977,0.0037743528,0.00018132717,0.0019689759,0.00002093936,0.000057891775,0.00025115797,0.0021818278,0.00020923596],"about_ca_topic_score_codex":0.044879466,"about_ca_topic_score_gemma":0.025243185,"teacher_disagreement_score":0.07839678,"about_ca_system_score_codex":0.0001272613,"about_ca_system_score_gemma":0.0018005107,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W4233687895","doi":"10.1200/jco.2006.09.4813","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine","score_opus":0.1388950118554293,"score_gpt":0.5277704356645774,"score_spread":0.3888754238091481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233687895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567932,0.0007252295,0.00013291228,0.023754954,0.0020173923,0.00006293524,1.5562901e-7,0.000002803521,0.016510412],"genre_scores_gemma":[0.9636023,0.00067873875,0.002585713,0.030715184,0.0015472414,2.173057e-7,1.534282e-7,0.0000059992144,0.00086442765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751705,0.00009109222,0.0020273756,0.00006893602,0.00016221788,0.00013331028],"domain_scores_gemma":[0.99768764,0.0011695363,0.000783263,0.00009339281,0.00012445675,0.00014169843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008918492,0.00004574017,0.0006399189,0.000117553645,0.0000073332753,0.0000015768279,0.000067244284,0.00018303828,0.00026554012],"category_scores_gemma":[0.001796685,0.000030809166,0.00030925754,0.00013162564,0.000103617785,0.000053668176,0.000009700094,0.00059386186,0.000010278208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05805624,0.0016824505,0.1741443,0.000013934112,0.00022670838,0.0046235826,0.00012536653,5.8361286e-7,0.0023902818,0.00009341916,0.039044224,0.7195989],"study_design_scores_gemma":[0.006836199,0.005324885,0.45140544,0.000033730787,0.000026458021,0.0005586882,0.000056552173,0.0000015556087,0.00021566756,0.00015202964,0.5353645,0.000024278295],"about_ca_topic_score_codex":0.000027130101,"about_ca_topic_score_gemma":0.000065730805,"teacher_disagreement_score":0.71957463,"about_ca_system_score_codex":0.00012216417,"about_ca_system_score_gemma":0.00072563393,"threshold_uncertainty_score":0.3090989},"labels":[],"label_agreement":null},{"id":"W4233800443","doi":"10.1200/jco.2021.39.6_suppl.33","title":"PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Nuclear medicine; Histopathology; Confidence interval; Prostate cancer; Clinical endpoint; Population; PET-CT; Radiation therapy; Radiology; Cancer; Clinical trial; Positron emission tomography; Pathology; Internal medicine","score_opus":0.02631628057664302,"score_gpt":0.41594388490857565,"score_spread":0.3896276043319326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233800443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599516,0.0017798151,0.00024892436,0.0006348741,0.0001668142,0.0008782307,0.00023452657,0.0000044773774,0.00005715833],"genre_scores_gemma":[0.9978194,0.0016232962,0.0002251994,0.0001033837,0.000048922026,0.000023198012,0.00009356176,0.000022935219,0.00004005966],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99589163,0.0008915192,0.0018948795,0.0003841633,0.00065887446,0.0002789152],"domain_scores_gemma":[0.9943648,0.0009169214,0.0018142334,0.00016644238,0.002460364,0.00027726288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016305816,0.00021831303,0.0019086989,0.00022979049,0.000040687773,0.000010821829,0.00009230452,0.000038908653,0.00003781855],"category_scores_gemma":[0.0009546776,0.00013596113,0.00015538865,0.00063169113,0.00047070294,0.00014741535,0.000054850127,0.00063384575,1.294195e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1573218,0.009730098,0.8029262,0.00009125172,0.0023549842,0.0019762474,0.00082576025,0.00011302307,0.0006814537,0.0000017195741,0.00025889926,0.023718605],"study_design_scores_gemma":[0.35561717,0.22957449,0.34489843,0.0030163291,0.0067738355,0.0003925073,0.006244441,0.0045958613,0.04801309,0.00008814137,0.0002629649,0.00052274927],"about_ca_topic_score_codex":0.00017832949,"about_ca_topic_score_gemma":0.00018948394,"teacher_disagreement_score":0.45802772,"about_ca_system_score_codex":0.00045315738,"about_ca_system_score_gemma":0.0028868536,"threshold_uncertainty_score":0.5544334},"labels":[],"label_agreement":null},{"id":"W4233839508","doi":"10.1200/jco.2017.35.15_suppl.10024","title":"The PULSES project: Teaching the vital elements of code status discussions to oncology residents.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Ottawa Hospital; Pediatric Oncology Group; Cancer Care Ontario; McMaster University","funders":"","keywords":"Medicine; Radiation oncology; Randomization; Randomized controlled trial; Medical physics; Internal medicine; Oncology; Medical education; Radiation therapy","score_opus":0.44963145367920315,"score_gpt":0.6446933264741107,"score_spread":0.19506187279490755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233839508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9246572,0.00080146344,0.00012957843,0.0539885,0.0020553845,0.00042100516,0.00002476345,0.0000045994857,0.017917497],"genre_scores_gemma":[0.98939925,0.0031161066,0.0040555126,0.0012386012,0.0010551681,0.000007262114,0.0000016992633,0.000013675086,0.0011127306],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957747,0.0009155766,0.00237597,0.00014605325,0.00047528275,0.00031243023],"domain_scores_gemma":[0.988781,0.0066132816,0.0033652126,0.000485067,0.000501454,0.0002540041],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062216287,0.00012088917,0.0011826863,0.00007741301,0.00034148386,0.000017745122,0.000627783,0.00021516872,0.000026792017],"category_scores_gemma":[0.044322208,0.000050610077,0.0004195569,0.00005177721,0.0006116923,0.00011075307,0.00026519652,0.0011501164,0.0000066490084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005558012,0.001488203,0.55283976,0.000034151424,0.00086712046,0.00023359853,0.0028218266,0.0000047617746,0.0009777772,0.00086612045,0.05075546,0.3835532],"study_design_scores_gemma":[0.0030822086,0.009361566,0.3476965,0.00039026572,0.00031169903,0.000038573857,0.0033775114,0.000010318162,0.00026788472,0.00049002917,0.63491684,0.000056626053],"about_ca_topic_score_codex":0.00025971702,"about_ca_topic_score_gemma":0.00076117367,"teacher_disagreement_score":0.58416134,"about_ca_system_score_codex":0.00014178127,"about_ca_system_score_gemma":0.0017447462,"threshold_uncertainty_score":0.9637279},"labels":[],"label_agreement":null},{"id":"W4233888257","doi":"10.1200/jco.2018.36.15_suppl.e18803","title":"Does the risk of emergency department visits and hospitalizations during systemic therapy for cancer influence patients’ decisions regarding treatment?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Emergency department; Systemic therapy; Multinomial logistic regression; Internal medicine; Cancer; Breast cancer; Emergency medicine","score_opus":0.0645679619291827,"score_gpt":0.45286394221386556,"score_spread":0.3882959802846829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233888257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588,0.00064418145,0.00019131081,0.0009509909,0.001719197,0.0005058785,0.000025550322,0.0000043495647,0.00007851221],"genre_scores_gemma":[0.97171086,0.026990736,0.00025346622,0.00011970346,0.000762465,0.000047452926,8.4840997e-7,0.000009486531,0.00010497153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823475,0.00016740077,0.001213053,0.00012380928,0.00014111015,0.00011985538],"domain_scores_gemma":[0.9965911,0.000906803,0.0012499379,0.00015051145,0.000978837,0.00012283924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054295786,0.000087650486,0.0005762699,0.000057229812,0.00018762464,0.000005485772,0.000077468845,0.00009618033,0.000043821645],"category_scores_gemma":[0.0013397306,0.000036613288,0.0002769666,0.00011261748,0.000105057625,0.00008954976,0.000020298654,0.00014129435,9.1028147e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011862704,0.0005067047,0.9642167,0.0000104443625,0.0005302667,0.0000024618444,0.0002053045,0.000037561666,0.0003408057,0.000039069873,0.00028352058,0.0326409],"study_design_scores_gemma":[0.0059495396,0.010466864,0.9649572,0.0001425601,0.00061179505,0.0000233131,0.00009231247,0.000013720432,0.0006675707,0.00021220144,0.016813226,0.000049734783],"about_ca_topic_score_codex":0.000040688552,"about_ca_topic_score_gemma":0.00021290951,"teacher_disagreement_score":0.032591164,"about_ca_system_score_codex":0.000120199176,"about_ca_system_score_gemma":0.00036520674,"threshold_uncertainty_score":0.16038793},"labels":[],"label_agreement":null},{"id":"W4233923410","doi":"10.1200/jco.2016.34.15_suppl.e18204","title":"Evaluating the utility of the QUAL-EC in the clinical care of patients with advanced cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Distress; Lung cancer; Palliative care; Cancer; Family medicine; Clinical psychology; Internal medicine; Nursing","score_opus":0.2669408118199125,"score_gpt":0.49704903767880787,"score_spread":0.23010822585889534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233923410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880469,0.0014076681,0.0000833218,0.0051192655,0.0014665775,0.00027579168,0.00008032199,0.0000010988937,0.0035190857],"genre_scores_gemma":[0.99748975,0.00091748254,0.00027352333,0.00093781814,0.00032657594,0.0000067794613,2.8677923e-7,0.000009360455,0.00003844936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949205,0.00049220235,0.0040636053,0.00019760641,0.000117100295,0.00020901953],"domain_scores_gemma":[0.9887057,0.004094362,0.006314668,0.0004332631,0.00038585806,0.00006612674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00926891,0.00011336826,0.0012583581,0.000047098187,0.000051856787,0.000006197371,0.0007922856,0.00022165917,0.00014686727],"category_scores_gemma":[0.007742138,0.000046051104,0.00046565625,0.00015404673,0.0006603922,0.00018678911,0.000082690385,0.0006011787,0.0000045100896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010633811,0.00028158008,0.7636578,0.000009395755,0.00005814999,6.0617924e-7,0.00033948466,0.000034329474,6.22336e-7,0.0014616441,0.00032616424,0.23276685],"study_design_scores_gemma":[0.0043267133,0.0036515994,0.9710673,0.00008186258,0.000033067427,8.500595e-7,0.00022781489,0.00004417952,0.000005572027,0.0039123395,0.016580302,0.00006836585],"about_ca_topic_score_codex":0.0001324674,"about_ca_topic_score_gemma":0.00057085085,"teacher_disagreement_score":0.23269849,"about_ca_system_score_codex":0.00010668612,"about_ca_system_score_gemma":0.00085503364,"threshold_uncertainty_score":0.9268622},"labels":[],"label_agreement":null},{"id":"W4233963088","doi":"10.1200/jco.2004.22.90140.9652","title":"Chemopredictive diagnostic project in patients (pts) receiving capecitabine (X) or 5-FU/leucovorin (LV) as first-line chemotherapy for metastatic colorectal cancer (MCRC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Colorectal cancer; Thymidylate synthase; Dihydropyrimidine dehydrogenase; Oncology; Immunohistochemistry; Regimen; Thymidine phosphorylase; Chemotherapy; Fluorouracil; Cancer","score_opus":0.09194507561271979,"score_gpt":0.45739552513309006,"score_spread":0.36545044952037026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233963088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887747,0.0010672936,0.00010313674,0.00638084,0.0013837416,0.0016740765,0.000047094592,0.000015566606,0.0005535346],"genre_scores_gemma":[0.98653555,0.007496778,0.002837606,0.0015718249,0.0010264101,0.00028627683,0.000010655994,0.00004179718,0.00019309483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644995,0.00013943264,0.0021897494,0.00035763337,0.0004314852,0.00043172942],"domain_scores_gemma":[0.9924006,0.0052618226,0.0013026622,0.00013096539,0.00065998884,0.00024398512],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012972526,0.0002949772,0.0021545584,0.00020548828,0.00008940152,0.000011355316,0.00015577505,0.00020752902,0.00014758071],"category_scores_gemma":[0.012082121,0.00018700346,0.0004927731,0.00035883172,0.00020329401,0.00014435081,0.000053407304,0.00067245733,0.0000039414967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11019508,0.018011155,0.47179794,0.00029624908,0.003317287,0.0016216022,0.002291866,0.00042938459,0.000035379027,0.000047623416,0.0027450244,0.38921142],"study_design_scores_gemma":[0.08953633,0.08439802,0.803141,0.0006715767,0.0010076583,0.00015342419,0.00033859708,0.00008727746,0.0003394788,0.00057341787,0.019500189,0.00025305504],"about_ca_topic_score_codex":0.0005678039,"about_ca_topic_score_gemma":0.0049890904,"teacher_disagreement_score":0.38895836,"about_ca_system_score_codex":0.001537625,"about_ca_system_score_gemma":0.0030340678,"threshold_uncertainty_score":0.99623954},"labels":[],"label_agreement":null},{"id":"W4233974029","doi":"10.1200/jco.2017.35.15_suppl.3600","title":"Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Quartile; Cetuximab; Internal medicine; KRAS; Confidence interval; Colorectal cancer; Population; Progression-free survival; Gastroenterology; Pharmacokinetics; Oxaliplatin; Oncology; Urology; Overall survival; Cancer","score_opus":0.10138674971268885,"score_gpt":0.4622945622062024,"score_spread":0.36090781249351356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233974029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076676,0.00071851065,0.0000031193015,0.0034962513,0.0007872576,0.0002174916,0.0000064094106,0.0000033471329,0.004000848],"genre_scores_gemma":[0.9971121,0.001537752,0.0005623702,0.00036001176,0.00027198283,0.0000094942625,5.931193e-7,0.0000126344285,0.00013305461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815905,0.00015539778,0.0009840702,0.00018809795,0.0003002265,0.00021315124],"domain_scores_gemma":[0.9975492,0.00053999503,0.0012423877,0.00013758377,0.00032961936,0.00020121252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009544907,0.00013863617,0.001495375,0.00006274419,0.00011139492,0.000019096731,0.000120976896,0.00010503243,0.000048889717],"category_scores_gemma":[0.0012881497,0.000082557824,0.00014073498,0.00004731983,0.0004058099,0.00014556883,0.00007137882,0.0005318279,0.0000026107994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016144287,0.001327095,0.8131758,0.000020962936,0.0004487388,0.0003555202,0.0001154808,0.0000023406858,0.0000037196596,0.000018018605,0.0002352293,0.16815282],"study_design_scores_gemma":[0.025433157,0.021297641,0.9463665,0.0001328703,0.00034972292,0.000038242415,0.000088127985,0.000022219396,0.00001123258,0.00006304018,0.0061168117,0.00008043982],"about_ca_topic_score_codex":0.00023263144,"about_ca_topic_score_gemma":0.0027849916,"teacher_disagreement_score":0.16807239,"about_ca_system_score_codex":0.00019191211,"about_ca_system_score_gemma":0.0006531392,"threshold_uncertainty_score":0.336661},"labels":[],"label_agreement":null},{"id":"W4234185004","doi":"10.1200/jco.2013.31.18_suppl.cra9003","title":"Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; GNAQ; Selumetinib; Clinical endpoint; Hazard ratio; Internal medicine; Temozolomide; Progression-free survival; Gastroenterology; Randomization; Dacarbazine; Phases of clinical research; Oncology; Randomized controlled trial; Cancer; Chemotherapy; Confidence interval; KRAS","score_opus":0.11766408194807756,"score_gpt":0.4830187535876331,"score_spread":0.3653546716395555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234185004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063253,0.0002488201,0.0000066804096,0.0031994286,0.0020918106,0.00089766906,0.00000440002,0.000013474859,0.0029051944],"genre_scores_gemma":[0.9967421,0.00015058366,0.0015586184,0.0005712395,0.00060640665,0.000022288143,0.0000046814444,0.000027330978,0.0003167128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99357814,0.0012116743,0.0039171576,0.00035443075,0.0004958682,0.00044274094],"domain_scores_gemma":[0.9929118,0.003205183,0.0024388132,0.000388531,0.0005234219,0.00053222285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00330978,0.00027482564,0.0028075017,0.00033270355,0.000077898585,0.0000063482785,0.00030582128,0.00075602095,0.00074510975],"category_scores_gemma":[0.0036582435,0.00019765785,0.00055010535,0.00030419233,0.0003202091,0.00018924366,0.0001468753,0.0014004292,0.00009484011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031646017,0.1161228,0.61526203,0.000040934938,0.0026787363,0.008763924,0.001125134,0.000012915213,0.0006325275,0.00006942903,0.0024564748,0.22118908],"study_design_scores_gemma":[0.20412199,0.37201276,0.40677533,0.00010573624,0.0016793173,0.0005771712,0.002146394,0.00009984397,0.00026840233,0.00023223892,0.011776781,0.00020401727],"about_ca_topic_score_codex":0.00027142494,"about_ca_topic_score_gemma":0.00063159154,"teacher_disagreement_score":0.25588998,"about_ca_system_score_codex":0.00028454055,"about_ca_system_score_gemma":0.0014350236,"threshold_uncertainty_score":0.8158429},"labels":[],"label_agreement":null},{"id":"W4234219959","doi":"10.1200/jco.2003.01.192","title":"Adjuvant Chemotherapy For Women With Young Children: Our Patients as Parents","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Adjuvant; Chemotherapy; Adjuvant chemotherapy; Oncology; Internal medicine; Pediatrics; Cancer; Breast cancer","score_opus":0.06211984529643631,"score_gpt":0.44068216962344947,"score_spread":0.37856232432701314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234219959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97925067,0.000037840247,0.000084480525,0.0018801996,0.0029892626,0.00036508378,0.000005499416,0.000010346906,0.015376646],"genre_scores_gemma":[0.99407613,0.0002031935,0.0014760229,0.0025315583,0.0007944009,0.000015077598,0.0000013699723,0.00002043707,0.00088178104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966159,0.0007027835,0.001414369,0.00019543125,0.00059928105,0.00047226003],"domain_scores_gemma":[0.99626523,0.0008142738,0.0016865708,0.00013826818,0.00062802946,0.0004676075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00556499,0.00013105854,0.0009056383,0.00006665509,0.00018917507,0.000026444664,0.0003854089,0.00034774726,0.00012266461],"category_scores_gemma":[0.0051850495,0.00009310032,0.00021484737,0.0001575137,0.00020978415,0.00022038879,0.000015269025,0.00045132035,0.000019728277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015415712,0.0014524305,0.9270111,0.0000036902536,0.000209002,0.000018734449,0.0021862073,0.0000051942948,0.0000011882369,0.0006981212,0.007119417,0.059753377],"study_design_scores_gemma":[0.011221131,0.0108143855,0.68019617,0.000028857994,0.000057119232,0.000021477439,0.008230338,0.0000011481744,0.000011345478,0.0036684847,0.28553423,0.00021531225],"about_ca_topic_score_codex":0.000076111086,"about_ca_topic_score_gemma":0.000195997,"teacher_disagreement_score":0.27841482,"about_ca_system_score_codex":0.00029758978,"about_ca_system_score_gemma":0.0023783965,"threshold_uncertainty_score":0.6207363},"labels":[],"label_agreement":null},{"id":"W4234221845","doi":"10.1200/jco.2004.22.14_suppl.4063","title":"A phase II study to assess the efficacy of combined preoperative irinotecan (I)/cisplatin (C) chemotherapy and conformal radiotherapy (RT) followed by surgery for potentially resectable esophageal cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Irinotecan; Cisplatin; Chemotherapy; Radiation therapy; Oncology; Esophageal cancer; Cancer; Phases of clinical research; Internal medicine; Surgery; Colorectal cancer","score_opus":0.11921696576726887,"score_gpt":0.5026467028786833,"score_spread":0.3834297371114144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234221845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825413,0.0022103863,0.0009834993,0.011615603,0.00035679602,0.002205354,0.00003554238,0.000007109908,0.000044411252],"genre_scores_gemma":[0.9950749,0.00078382576,0.001609704,0.0016845191,0.00047040326,0.00008083876,0.000005364111,0.000026602265,0.00026384252],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99667937,0.0003884678,0.001781232,0.0002453334,0.00053538685,0.00037023067],"domain_scores_gemma":[0.994488,0.003251725,0.00093261374,0.00021855457,0.00061121606,0.00049787835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037389493,0.00020102359,0.0017155142,0.00012788891,0.00015912078,0.000021656446,0.00019537137,0.00014749887,0.00009670753],"category_scores_gemma":[0.0014167796,0.000117271535,0.00042930184,0.00020442468,0.00022591413,0.000122892,0.000047967664,0.0005712664,4.899897e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.407318,0.106789514,0.124864295,0.00017769556,0.008937761,0.0012188018,0.0060415627,0.0004322164,0.0042522135,0.00016099763,0.018500187,0.32130677],"study_design_scores_gemma":[0.27876338,0.55808073,0.14815374,0.00022793509,0.00080914167,0.00013293883,0.00064651464,0.00014281133,0.00846642,0.000095441064,0.004240408,0.00024054627],"about_ca_topic_score_codex":0.0002558177,"about_ca_topic_score_gemma":0.00017797461,"teacher_disagreement_score":0.4512912,"about_ca_system_score_codex":0.00028869766,"about_ca_system_score_gemma":0.0034039542,"threshold_uncertainty_score":0.60384685},"labels":[],"label_agreement":null},{"id":"W4234246777","doi":"10.1200/jco.2013.31.15_suppl.10015","title":"Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Neuroblastoma; Stage (stratigraphy); Internal medicine; Gastroenterology; Lymph; Disease; Confidence interval; Exact test; Oncology; Pathology","score_opus":0.07172043648359831,"score_gpt":0.41222868884860514,"score_spread":0.3405082523650068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234246777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897499,0.00001391203,0.00031197743,0.0061044213,0.0007721121,0.002330264,0.00061133516,0.000022393817,0.000083698316],"genre_scores_gemma":[0.9937293,0.000022196497,0.0013295941,0.00409776,0.00026640165,0.000105333624,0.0000442635,0.000054237713,0.00035093684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931794,0.0014103262,0.0025974875,0.0006263294,0.0016339226,0.00055257085],"domain_scores_gemma":[0.99165875,0.0042352905,0.0012149247,0.00070840656,0.0005810713,0.0016015575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016813162,0.00036809096,0.001442242,0.00032788835,0.00009330231,0.00009107195,0.000774411,0.000071671326,0.0005592892],"category_scores_gemma":[0.008064627,0.00020419546,0.00030225894,0.00040057153,0.00018530233,0.0003445668,0.00045132704,0.0011106326,0.00019926517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028054923,0.011138843,0.94911814,0.000016450676,0.00076714956,0.003128619,0.00012558828,0.000115500494,0.00008514457,0.000009571962,0.0012362748,0.006203819],"study_design_scores_gemma":[0.024817964,0.025326788,0.945087,0.00012050098,0.0003912947,0.000012597455,0.00023974263,0.0003125119,0.0000072406524,0.000020839698,0.0035093534,0.00015415081],"about_ca_topic_score_codex":0.00055316323,"about_ca_topic_score_gemma":0.00072004914,"teacher_disagreement_score":0.014187946,"about_ca_system_score_codex":0.00026538945,"about_ca_system_score_gemma":0.00071265094,"threshold_uncertainty_score":0.9654694},"labels":[],"label_agreement":null},{"id":"W4234258422","doi":"10.1200/jco.2009.27.15_suppl.571","title":"Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acupuncture; Breast cancer; Randomized controlled trial; Discontinuation; Adverse effect; Joint pain; Placebo; Physical therapy; Internal medicine; Aromatase inhibitor; Brief Pain Inventory; Osteoarthritis; WOMAC; Body mass index; Exemestane; Cancer; Tamoxifen; Chronic pain","score_opus":0.05758300344351331,"score_gpt":0.42965069926841143,"score_spread":0.3720676958248981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234258422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98444796,0.0004822666,0.000032166325,0.009445445,0.0009268575,0.0043083723,0.000043466578,0.000004728973,0.0003087701],"genre_scores_gemma":[0.9959189,0.0014934574,0.00018620324,0.001060343,0.00070694997,0.00026518162,0.000002863543,0.000012739293,0.00035335662],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957164,0.0006011176,0.0028477896,0.00016977855,0.00037833312,0.00028657104],"domain_scores_gemma":[0.99212915,0.003922222,0.00327855,0.00016112614,0.00033453476,0.00017443526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058345105,0.00022696926,0.0042091385,0.00016000328,0.000026424317,0.000004712421,0.0001509166,0.0003012581,0.0001732533],"category_scores_gemma":[0.00040266788,0.00009282207,0.0008261882,0.00018710751,0.00025213367,0.00005735586,0.000023312194,0.00057528995,5.034205e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96471065,0.005457385,0.00075438013,0.000051479798,0.0059607103,0.00017038343,0.0002561544,0.00015509513,0.00006287422,0.000046407324,0.0009822854,0.021392206],"study_design_scores_gemma":[0.9430563,0.02806339,0.02345429,0.00024809095,0.0036827961,0.000030026371,0.00014691366,0.00009226246,0.000054629796,0.00016444454,0.0009295436,0.000077313474],"about_ca_topic_score_codex":0.000054358985,"about_ca_topic_score_gemma":0.00006187747,"teacher_disagreement_score":0.02269991,"about_ca_system_score_codex":0.00035042546,"about_ca_system_score_gemma":0.0008876749,"threshold_uncertainty_score":0.37851742},"labels":[],"label_agreement":null},{"id":"W4234341710","doi":"10.1200/jco.2004.22.14_suppl.3033","title":"A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to <i>clusterin</i>, in patients with prostate cancer prior to radical prostatectomy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Clusterin; Pharmacokinetics; Prostatectomy; Prostate cancer; Pharmacodynamics; Prostate; Urology; Cancer; Pharmacology; Internal medicine; Oncology; Apoptosis","score_opus":0.04688705222068034,"score_gpt":0.4775213126929641,"score_spread":0.43063426047228376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234341710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912971,0.00022318315,0.00012455146,0.0034602045,0.0007058105,0.0040819016,0.00004614022,0.000016676728,0.00004439391],"genre_scores_gemma":[0.99074197,0.00018431585,0.0053536426,0.0033059649,0.0001967131,0.00012533972,0.000002589458,0.000058230056,0.000031245483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944463,0.0007147951,0.0030743754,0.0005657462,0.0006666746,0.0005321192],"domain_scores_gemma":[0.99592316,0.00062151876,0.0013574813,0.000301225,0.0006471687,0.0011494632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022034724,0.00034636087,0.0022916899,0.00049493025,0.00004003726,0.0000117754125,0.00024271668,0.00021115638,0.00007364941],"category_scores_gemma":[0.0013038839,0.00025671354,0.00017286552,0.0006006362,0.0003318314,0.00011989531,0.00026505216,0.0011036595,0.00000590939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29832143,0.053741414,0.38344026,0.00038890677,0.00079223263,0.007631301,0.0053894715,0.0016391417,0.009247668,0.0000017629019,0.00022875512,0.23917769],"study_design_scores_gemma":[0.21460974,0.10581512,0.6742519,0.0006549237,0.00093406875,0.00035514255,0.00031255253,0.00011920918,0.0009803666,0.00002687779,0.0016240425,0.00031603186],"about_ca_topic_score_codex":0.00010674341,"about_ca_topic_score_gemma":0.00012811414,"teacher_disagreement_score":0.2908117,"about_ca_system_score_codex":0.00035388148,"about_ca_system_score_gemma":0.0014201443,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W4234388821","doi":"10.1200/jco.2011.29.4_suppl.481","title":"The relationship between the development of rash and clinical and quality of life outcomes by Kras mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Rash; Medicine; KRAS; Cetuximab; Internal medicine; Colorectal cancer; Quality of life (healthcare); Oncology; Clinical trial; Cancer","score_opus":0.2094409259009805,"score_gpt":0.4772855547581914,"score_spread":0.2678446288572109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234388821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984257,0.0003724007,0.000004878758,0.00054304005,0.000049874354,0.00036652279,0.000013122256,0.0000016285411,0.00022283597],"genre_scores_gemma":[0.9992079,0.00022166783,0.00042131727,0.00008998906,0.000019941917,0.000011671836,0.0000039267848,0.0000065247136,0.000017035352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966262,0.00057220436,0.0022447647,0.00013494153,0.0002736021,0.00014829879],"domain_scores_gemma":[0.9911728,0.006816176,0.0015431348,0.00007269089,0.00027142724,0.00012375572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025388673,0.000112213565,0.0011790057,0.000057368172,0.00005832967,0.0000030819542,0.000056417903,0.00013666281,0.000006188019],"category_scores_gemma":[0.0023725412,0.000047846377,0.000065403256,0.00013530866,0.0006410453,0.00005364694,0.000027693188,0.00043309006,1.05418486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014543995,0.0009510425,0.96413225,0.000015117228,0.00052709685,0.0000041551066,0.0011269808,4.1033329e-7,3.8597096e-7,0.000009100297,0.00003829142,0.018651152],"study_design_scores_gemma":[0.0184558,0.0081323525,0.9723974,0.00007160701,0.00020337502,0.0000010089678,0.0005407031,0.0000013886614,0.000008533872,0.000036280442,0.00009936921,0.000052201387],"about_ca_topic_score_codex":0.00036530182,"about_ca_topic_score_gemma":0.0070732506,"teacher_disagreement_score":0.018598951,"about_ca_system_score_codex":0.000117185904,"about_ca_system_score_gemma":0.0009790522,"threshold_uncertainty_score":0.39470398},"labels":[],"label_agreement":null},{"id":"W4234586490","doi":"10.1200/jco.2004.22.14_suppl.716","title":"Adherence to clinical practice guidelines for adjuvant therapy of breast cance","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Breast cancer; Clinical Practice; Adjuvant; Oncology; Internal medicine; Cancer; Family medicine","score_opus":0.4053728410215956,"score_gpt":0.6160540627697916,"score_spread":0.21068122174819598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234586490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7698463,0.005715111,0.008591626,0.20059007,0.012123697,0.00089488976,0.00004831144,0.000018707236,0.0021712582],"genre_scores_gemma":[0.85647166,0.0062030824,0.072392024,0.057024647,0.0076270327,0.000017182978,0.0000023270313,0.000030437928,0.00023158618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99429315,0.00027512366,0.004508515,0.00023510802,0.00045728142,0.00023080967],"domain_scores_gemma":[0.98582536,0.0039717793,0.0026205557,0.00028103616,0.0067612673,0.0005399844],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077499785,0.0001403553,0.0018296787,0.00007632508,0.00002529653,0.000005632266,0.00026107804,0.0003767728,0.00006781324],"category_scores_gemma":[0.031928632,0.000095980475,0.00084748515,0.00018592976,0.00017665721,0.00012367673,0.000039497805,0.00072049844,0.000009757378],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027903246,0.0021857333,0.014527539,0.000038154576,0.0004138335,0.00018397022,0.00025584595,0.000068217996,0.00017744442,0.0002709389,0.022944175,0.9310309],"study_design_scores_gemma":[0.016916247,0.055567335,0.103835136,0.00041993006,0.00030538175,0.0010764061,0.0008500512,0.000011520911,0.00018285603,0.00074274617,0.81994444,0.00014792912],"about_ca_topic_score_codex":0.0004249031,"about_ca_topic_score_gemma":0.00079895224,"teacher_disagreement_score":0.930883,"about_ca_system_score_codex":0.00012438762,"about_ca_system_score_gemma":0.004934206,"threshold_uncertainty_score":0.97622585},"labels":[],"label_agreement":null},{"id":"W4234681670","doi":"10.1200/jco.2016.34.15_suppl.lba506","title":"Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Cancer Care Ontario; Sunnybrook Health Science Centre; The Quebec Population Health Research Network","funders":"","keywords":"Letrozole; Medicine; Aromatase inhibitor; Tamoxifen; Oncology; Randomized controlled trial; Aromatase; Anastrozole; Internal medicine; Adjuvant; Clinical trial; Breast cancer; Cancer","score_opus":0.03197038114061333,"score_gpt":0.3784559607070892,"score_spread":0.34648557956647585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234681670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979162,0.00029776833,0.00005381971,0.00016712064,0.0003918844,0.000768204,0.00039607903,0.000003213191,0.0000057075163],"genre_scores_gemma":[0.9980181,0.00042090306,0.000951425,0.00014640453,0.0003135445,0.000075808166,0.00002853881,0.000028028551,0.000017237622],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963034,0.00083162123,0.0021077776,0.00024917754,0.00024091713,0.00026711044],"domain_scores_gemma":[0.9958462,0.0012476508,0.0023675878,0.00018760897,0.00016382808,0.00018711104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018753018,0.00016947638,0.0016274694,0.000081453436,0.000014704806,0.000006868251,0.00015449185,0.00037010864,0.000049711143],"category_scores_gemma":[0.00090407406,0.000096876545,0.00024668852,0.00006458959,0.00027725467,0.000021545286,0.000051133393,0.00023449135,3.4847653e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83182025,0.0012668492,0.008331201,0.0000070918422,0.0008250358,0.00013113735,0.00016147598,0.0000042827173,0.119510256,6.0984394e-7,0.00007811447,0.0378637],"study_design_scores_gemma":[0.8658471,0.044984184,0.07024574,0.00019342918,0.00019050462,0.000046862897,0.00012421017,0.000009440684,0.017490076,0.000029028095,0.0006104527,0.00022896368],"about_ca_topic_score_codex":0.00014495154,"about_ca_topic_score_gemma":0.000031448624,"teacher_disagreement_score":0.10202018,"about_ca_system_score_codex":0.000050025923,"about_ca_system_score_gemma":0.00047893266,"threshold_uncertainty_score":0.39505106},"labels":[],"label_agreement":null},{"id":"W4234684676","doi":"10.1200/jco.2019.37.15_suppl.e15579","title":"Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Perioperative; Gastroesophageal Junction; Confidence interval; Surgery; Internal medicine; Cancer; Adenocarcinoma; Hazard ratio; Interquartile range; Gastroenterology","score_opus":0.07005323955273658,"score_gpt":0.44046466582890903,"score_spread":0.37041142627617246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234684676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98512805,0.0005425021,0.0003392148,0.010935007,0.0018055188,0.00038272294,0.0000034755167,0.000006524345,0.0008569845],"genre_scores_gemma":[0.9921042,0.00016787674,0.002401122,0.0023034702,0.00074000505,0.0000072788903,0.0000015714952,0.000010758841,0.002263762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981502,0.00014156433,0.0011419515,0.00016563511,0.00021399366,0.00018659847],"domain_scores_gemma":[0.99706864,0.0015813734,0.00078772823,0.0001224073,0.00026582676,0.00017404648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018247669,0.000106919826,0.001109008,0.00011154872,0.000019808407,0.000009939244,0.000069919086,0.00015106243,0.0001351808],"category_scores_gemma":[0.0012448631,0.000071259834,0.00035128518,0.00007142398,0.0000808534,0.00012043221,0.000041785683,0.000411059,0.000011039293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007862609,0.00014395204,0.9699565,0.000045357847,0.00022349789,0.00009304723,0.000045419063,0.0000015924062,0.000005857563,0.0000585127,0.003754654,0.017808972],"study_design_scores_gemma":[0.008708364,0.012244765,0.9563361,0.000024445402,0.00012925421,0.000087314475,0.00010780498,0.000049105838,0.000004967696,0.00016478829,0.022093834,0.00004928213],"about_ca_topic_score_codex":0.0000047753033,"about_ca_topic_score_gemma":0.00003983432,"teacher_disagreement_score":0.018339181,"about_ca_system_score_codex":0.00007877424,"about_ca_system_score_gemma":0.00024202844,"threshold_uncertainty_score":0.29058915},"labels":[],"label_agreement":null},{"id":"W4234863521","doi":"10.1200/jco.2019.37.7_suppl.tps684","title":"PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Internal medicine; Kidney cancer; Perioperative; Oncology; Urology; Surgery; Cancer; Immunotherapy; Kidney","score_opus":0.08673618800770104,"score_gpt":0.39256042846608613,"score_spread":0.3058242404583851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234863521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923787,0.00014072066,0.00009527064,0.0002328652,0.0008869101,0.0034786905,0.0000014332433,0.000015019236,0.002770379],"genre_scores_gemma":[0.99549484,0.000030125138,0.0035763818,0.00020604274,0.00025946388,0.0000468337,0.000017185323,0.00004265099,0.00032647332],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929635,0.0016875102,0.0036180618,0.00048694055,0.0008188121,0.00042517076],"domain_scores_gemma":[0.992907,0.0032055755,0.0023519504,0.00036683545,0.0007792897,0.0003893564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033490392,0.00037542026,0.004296887,0.00027858053,0.000067999346,0.00003348147,0.00021194931,0.00027661354,0.00019401967],"category_scores_gemma":[0.0011853983,0.00024705153,0.0005469705,0.00033261086,0.00020862743,0.00030432848,0.00009283745,0.0012495226,0.000034016524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45603696,0.0075969957,0.5329262,0.000032930613,0.00042077765,0.00042188662,0.00071189116,0.00015693466,0.000057695433,0.000007567931,0.000031781066,0.0015983847],"study_design_scores_gemma":[0.6071054,0.05673197,0.33286068,0.00012715999,0.000741074,0.000021186568,0.00065585785,0.0010975595,0.00010207964,0.0000043057316,0.00038960917,0.00016317605],"about_ca_topic_score_codex":0.00020310485,"about_ca_topic_score_gemma":0.00044686534,"teacher_disagreement_score":0.20006554,"about_ca_system_score_codex":0.00096487097,"about_ca_system_score_gemma":0.0022273147,"threshold_uncertainty_score":0.99999815},"labels":[],"label_agreement":null},{"id":"W4234885285","doi":"10.1200/jco.2020.38.4_suppl.511","title":"Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Western University; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Neoadjuvant therapy; Meta-analysis; Immunotherapy; Internal medicine; Oncology; Renal cell carcinoma; Randomized controlled trial; Cancer; Surgery; Breast cancer","score_opus":0.10044782707395385,"score_gpt":0.47906806090004056,"score_spread":0.3786202338260867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234885285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009948163,0.99611527,0.0000015543403,0.0004196575,0.00005925852,0.0023405645,0.000019582594,0.0000034063644,0.000045889916],"genre_scores_gemma":[0.003581677,0.99572015,0.000055744058,0.00042637953,0.000076878285,0.00007088341,0.000010235963,0.000028778928,0.000029303132],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99087596,0.0040838844,0.004140191,0.00029997574,0.0004478405,0.00015214935],"domain_scores_gemma":[0.9913758,0.003653196,0.004306027,0.00025015874,0.0002144758,0.00020033619],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004032175,0.00038463253,0.024680763,0.00030257626,0.000018215476,0.000007839937,0.00011409245,0.0003489911,0.00007135587],"category_scores_gemma":[0.0009565577,0.00016268334,0.0024012055,0.0004489401,0.00014053294,0.000047037032,0.000024309036,0.0010079244,0.0000015548649],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010403256,0.001464195,0.0017184025,0.48696852,0.3866016,0.0007310411,0.00006793729,3.346674e-7,3.66383e-8,0.00000491287,0.000058156907,0.1119816],"study_design_scores_gemma":[0.008906308,0.08372608,0.0010507016,0.049797826,0.8407962,0.00021943408,0.000004149288,9.680547e-7,4.1072306e-7,0.000005222398,0.01533983,0.00015290867],"about_ca_topic_score_codex":0.0000120606655,"about_ca_topic_score_gemma":0.0000058028995,"teacher_disagreement_score":0.45419458,"about_ca_system_score_codex":0.00010557343,"about_ca_system_score_gemma":0.00052121683,"threshold_uncertainty_score":0.98979884},"labels":[],"label_agreement":null},{"id":"W4234944024","doi":"10.1200/jco.2019.37.15_suppl.e15073","title":"Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Likert scale; Colorectal cancer; Resection; Internal medicine; Hepatectomy; General surgery; Gastroenterology; Surgery; Cancer","score_opus":0.0697438093664471,"score_gpt":0.43846108735309847,"score_spread":0.3687172779866514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234944024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646413,0.001491783,0.0001518718,0.0003888543,0.00043771073,0.00028392085,0.000037825466,0.0000054791567,0.00073842425],"genre_scores_gemma":[0.9975859,0.00064035284,0.0011565,0.00028727643,0.00015330572,0.00000678568,0.000008288742,0.000011671372,0.00014994964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731135,0.000518949,0.0013692889,0.00020575093,0.00041062845,0.00018402781],"domain_scores_gemma":[0.99237335,0.0045919344,0.0015993817,0.0001422795,0.0011135751,0.00017948747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019505438,0.0001456986,0.0022463314,0.00022979916,0.000030149848,0.000004555159,0.000088274915,0.000176871,0.00048709594],"category_scores_gemma":[0.0015040872,0.00008506033,0.00058493594,0.00055053027,0.00020617717,0.00004959219,0.000024603269,0.00044515706,0.000005746976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06071001,0.002273713,0.8901101,0.00006497192,0.011182669,0.00077139324,0.000101965416,0.006552416,0.0001167043,0.0000035429807,0.0002925832,0.027819932],"study_design_scores_gemma":[0.010521048,0.07931808,0.8963228,0.0000882748,0.0065769134,0.000083446845,0.00011184745,0.0036660214,0.00028170872,0.0000033991982,0.0029206085,0.00010589361],"about_ca_topic_score_codex":0.0011984514,"about_ca_topic_score_gemma":0.010590492,"teacher_disagreement_score":0.07704436,"about_ca_system_score_codex":0.00031393158,"about_ca_system_score_gemma":0.0020534098,"threshold_uncertainty_score":0.59097433},"labels":[],"label_agreement":null},{"id":"W4234988212","doi":"10.1200/jco.2017.35.6_suppl.47","title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Toxicity; Prostate; Acute toxicity; Radiation therapy; Urology; Genitourinary system; Regimen; Surgery; Internal medicine; Cancer","score_opus":0.05082966512565027,"score_gpt":0.4448511044698952,"score_spread":0.3940214393442449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234988212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942237,0.0011485463,0.0000012434662,0.003987152,0.00018162053,0.00033940587,0.000024799769,0.0000044905996,0.000089008514],"genre_scores_gemma":[0.96445733,0.034477387,0.00029505583,0.0001980097,0.00013135355,0.000008055801,0.0000059660274,0.000013400257,0.00041342335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984308,0.00021676815,0.0007330314,0.00019266135,0.0002294789,0.00019728376],"domain_scores_gemma":[0.99776644,0.00040249046,0.0011363333,0.00013457963,0.00027972754,0.0002804194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007656441,0.00012091053,0.0008224515,0.00010249996,0.00012791352,0.000026575279,0.00006908424,0.00020764674,0.0000388215],"category_scores_gemma":[0.0004120496,0.00006610892,0.000060454713,0.000052073334,0.00031733926,0.00027987536,0.00004043958,0.00064911187,5.9205377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019200396,0.00067103136,0.8523006,0.000015259266,0.00048410374,0.00047385282,0.00008657804,0.0000023057955,0.00040458154,8.115637e-7,0.0001755053,0.12618501],"study_design_scores_gemma":[0.033777356,0.010669222,0.9515043,0.00015630144,0.00028148654,0.000062223495,0.000011984437,0.00012797563,0.00083384133,0.00006161319,0.002443323,0.000070379],"about_ca_topic_score_codex":0.00029360777,"about_ca_topic_score_gemma":0.00016031918,"teacher_disagreement_score":0.12611464,"about_ca_system_score_codex":0.00014514798,"about_ca_system_score_gemma":0.00046648877,"threshold_uncertainty_score":0.2820104},"labels":[],"label_agreement":null},{"id":"W4235064994","doi":"10.1200/jco.2019.37.15_suppl.6072","title":"Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—An update and retrospective review of non-study patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Docetaxel; Neck dissection; Surgery; Induction chemotherapy; Regimen; Radiation therapy; Carboplatin; Chemotherapy; Quality of life (healthcare); Stage (stratigraphy); Internal medicine; Cancer; Cisplatin","score_opus":0.0737434428438148,"score_gpt":0.4438629599489248,"score_spread":0.37011951710511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235064994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917648,0.004157066,0.000007890507,0.0011821921,0.00052355614,0.0021783235,0.00001897458,0.000004453328,0.00016277465],"genre_scores_gemma":[0.9847391,0.01335648,0.000270326,0.0013175763,0.0002204401,0.000036570873,0.0000063128214,0.000021302913,0.000031853888],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99712986,0.00032841272,0.001757397,0.00032552687,0.00025963888,0.00019919648],"domain_scores_gemma":[0.99689215,0.00077024143,0.0011880172,0.00015260243,0.0007157746,0.00028121888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015903894,0.00020846329,0.0029223734,0.00009507555,0.00006894388,0.0000032737037,0.000050625003,0.00013699033,0.000041311938],"category_scores_gemma":[0.00055912393,0.00014229532,0.0002815825,0.00010391576,0.00012871747,0.00014308268,0.000020585303,0.00032724097,9.494716e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029709937,0.043099325,0.3815734,0.00053843186,0.00040771093,0.00009799337,0.002066826,2.3768708e-7,0.00011871011,0.0000030742988,0.00026770128,0.54211664],"study_design_scores_gemma":[0.06780978,0.5156779,0.41270173,0.0002904141,0.0007878145,0.000022451062,0.0011274449,0.000005936909,0.00016121627,0.000022242197,0.0012812804,0.000111792964],"about_ca_topic_score_codex":0.000039139955,"about_ca_topic_score_gemma":0.000046262463,"teacher_disagreement_score":0.5420048,"about_ca_system_score_codex":0.00017781874,"about_ca_system_score_gemma":0.0008105802,"threshold_uncertainty_score":0.5802635},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4235183483","doi":"10.1200/jco.2019.37.7_suppl.60","title":"A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; University Health Network; Memorial University of Newfoundland; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Common Terminology Criteria for Adverse Events; Prostatectomy; Toxicity; Genitourinary system; Radiation therapy; Prostate; Surgery; Urology; Cancer; Adverse effect; Internal medicine","score_opus":0.21373529248580928,"score_gpt":0.5616994062389005,"score_spread":0.3479641137530912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235183483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913696,0.0017776106,0.000028086803,0.0034027547,0.00059340976,0.0026821785,0.00001763957,0.000005392023,0.00012330397],"genre_scores_gemma":[0.99368805,0.0035185474,0.0005229198,0.0006522467,0.00027311087,0.00006044724,0.0000021882352,0.000015306545,0.001267168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973724,0.0003534232,0.0015187286,0.00022554595,0.00029540807,0.00023451558],"domain_scores_gemma":[0.9961061,0.0018030747,0.0011005363,0.00015541703,0.00056811667,0.0002667672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020509986,0.00014801175,0.0018798837,0.00011243555,0.00003729739,0.000008328535,0.000121012636,0.00012813049,0.000121299774],"category_scores_gemma":[0.00054437143,0.000082566214,0.00020009295,0.000099000295,0.00020054597,0.000101230245,0.000038977363,0.00051631284,0.000001210253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048166562,0.03324936,0.84027433,0.00010344497,0.0013978563,0.00016416698,0.0007364844,0.000004944299,0.0013663343,0.000006354938,0.00030089568,0.07422927],"study_design_scores_gemma":[0.102942504,0.37586692,0.51955235,0.00006741007,0.0002922215,0.00003397506,0.0002371836,0.000048001184,0.00028388633,0.000027759932,0.00058410503,0.000063648156],"about_ca_topic_score_codex":0.000032859163,"about_ca_topic_score_gemma":0.00011263599,"teacher_disagreement_score":0.34261757,"about_ca_system_score_codex":0.00026028857,"about_ca_system_score_gemma":0.0016060139,"threshold_uncertainty_score":0.33669522},"labels":[],"label_agreement":null},{"id":"W4235223714","doi":"10.1200/jco.2021.39.15_suppl.5504","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Bevacizumab; Ovarian cancer; Internal medicine; Adverse effect; Cancer; Sorafenib; Cohort; Gastroenterology; Oncology; Surgery; Chemotherapy","score_opus":0.04251350568788086,"score_gpt":0.3952454323940415,"score_spread":0.3527319267061606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235223714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872435,0.0007791483,0.00014669674,0.010594561,0.0004784659,0.00040437462,0.000025799445,0.000008894238,0.00031857187],"genre_scores_gemma":[0.9910966,0.0011962424,0.006237398,0.0009919527,0.00022796362,0.000019344765,0.00011957859,0.000031012252,0.00007991333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952275,0.00068082963,0.0025769903,0.00048006757,0.00061908265,0.0004155066],"domain_scores_gemma":[0.9948618,0.0015851617,0.0019834763,0.00024287701,0.0010035308,0.0003231642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018304094,0.00028483284,0.0024456924,0.00043619022,0.000054666863,0.000029981331,0.00013052668,0.00027556982,0.00030279002],"category_scores_gemma":[0.0012918289,0.00019967565,0.00032880766,0.0012434239,0.00013067391,0.00022732743,0.000042143638,0.0011084129,0.0000071051877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010047222,0.008030042,0.94437397,0.0000494759,0.0019576265,0.002682995,0.00027249692,0.00077427103,0.000022591277,0.00007347502,0.000500646,0.0312152],"study_design_scores_gemma":[0.066932894,0.012635397,0.9140017,0.00081576867,0.0021514725,0.000056436456,0.0001149579,0.0006786359,0.000094661424,0.00007994541,0.002229149,0.00020897374],"about_ca_topic_score_codex":0.0005364954,"about_ca_topic_score_gemma":0.0043586837,"teacher_disagreement_score":0.05688567,"about_ca_system_score_codex":0.0007684737,"about_ca_system_score_gemma":0.0028641566,"threshold_uncertainty_score":0.8142536},"labels":[],"label_agreement":null},{"id":"W4235293821","doi":"10.1200/jco.2019.37.15_suppl.10006","title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Asparaginase; Minimal residual disease; Lymphoblastic lymphoma; Surgery; Leukemia; Lymphoblastic Leukemia; Immunology","score_opus":0.03669631804816333,"score_gpt":0.3868964793915374,"score_spread":0.35020016134337406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235293821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605465,0.0003849622,0.00003538623,0.0016476677,0.0003720427,0.0005490339,0.00004274993,0.000007934997,0.00090557244],"genre_scores_gemma":[0.99615365,0.001260206,0.0016245742,0.00037442122,0.0003251456,0.000002850372,0.000007789284,0.00003308597,0.00021825843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993408,0.00062772614,0.0041860943,0.00045919002,0.00081710884,0.0005018323],"domain_scores_gemma":[0.9866781,0.009041435,0.0024528683,0.00044696667,0.000610184,0.00077044993],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035239046,0.00028856006,0.0029558039,0.00047025157,0.00002437436,0.000009290436,0.00030320958,0.00069302233,0.00006549943],"category_scores_gemma":[0.012265514,0.00021438175,0.0002844362,0.00038260565,0.00080065435,0.00017689676,0.00029436205,0.0008099411,0.0000129149275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23941493,0.03835622,0.44337946,0.001849105,0.0045536384,0.017245932,0.003751107,0.0004934022,0.04317809,0.00066934666,0.015375064,0.19173369],"study_design_scores_gemma":[0.18494308,0.027424362,0.7726065,0.00079382665,0.0008346544,0.005354316,0.00021180547,0.0021953427,0.0029863499,0.00016735318,0.002228139,0.00025429486],"about_ca_topic_score_codex":0.00020505386,"about_ca_topic_score_gemma":0.00007526191,"teacher_disagreement_score":0.329227,"about_ca_system_score_codex":0.0007748942,"about_ca_system_score_gemma":0.006523678,"threshold_uncertainty_score":0.99910843},"labels":[],"label_agreement":null},{"id":"W4235546527","doi":"10.1200/jco.2017.77.0446","title":"Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Chimeric antigen receptor; Clinical trial; Immunotherapy; Cancer immunotherapy; Oncology; Clinical Oncology; Internal medicine; Immunology; Family medicine","score_opus":0.24770995579533853,"score_gpt":0.6188850474531973,"score_spread":0.3711750916578588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235546527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92311716,0.0030239623,0.00003887865,0.061113123,0.008383761,0.00060816424,0.000086144064,0.00002342848,0.0036053858],"genre_scores_gemma":[0.74122286,0.11563906,0.011516664,0.055909127,0.07134074,0.000082177154,0.000020490796,0.00014077224,0.0041280906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9837399,0.0036649308,0.009559057,0.0008130932,0.001500226,0.0007227797],"domain_scores_gemma":[0.9615395,0.021800313,0.01164507,0.0010004477,0.0029658626,0.001048806],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.02420774,0.00036097912,0.005309136,0.000091324124,0.00013730327,0.000014533178,0.0009290253,0.0010732288,0.0015161742],"category_scores_gemma":[0.010348538,0.00021003658,0.0028189982,0.0004886036,0.009241926,0.0001733684,0.00029336134,0.0050763004,0.0000367783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016251607,0.0025578814,0.38307253,0.000012333922,0.001346793,0.00048289332,0.00012340097,0.0000035440257,0.00007126235,0.0000049638206,0.0893618,0.506711],"study_design_scores_gemma":[0.006279618,0.029660802,0.39365864,0.00018183635,0.0003809205,0.00009767679,0.00039145752,0.00008430905,0.00006327149,0.00007569395,0.5689986,0.00012722265],"about_ca_topic_score_codex":0.0006003127,"about_ca_topic_score_gemma":0.0012317945,"teacher_disagreement_score":0.50658375,"about_ca_system_score_codex":0.0004562285,"about_ca_system_score_gemma":0.0123642,"threshold_uncertainty_score":0.99939656},"labels":[],"label_agreement":null},{"id":"W4235615815","doi":"10.1200/jco.2017.35.15_suppl.lba10001","title":"Managing cancer and living meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Clinical Oncology; Randomized controlled trial; Clinical trial; Intervention (counseling); Family medicine; Gerontology; Internal medicine; Psychiatry","score_opus":0.07562103310577026,"score_gpt":0.49490435624890006,"score_spread":0.41928332314312977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235615815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884296,0.00087382767,0.00083864114,0.0035106027,0.0032182592,0.0020177274,0.000005452839,0.00000492395,0.000687583],"genre_scores_gemma":[0.9955962,0.0020214587,0.0008451444,0.00034594937,0.0008071782,0.00021453432,7.4522154e-7,0.000013395983,0.00015543449],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996746,0.00042404913,0.002172083,0.00019634665,0.0002910927,0.00017043484],"domain_scores_gemma":[0.9903224,0.0037229375,0.00478631,0.00018318638,0.00080393715,0.00018119228],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048178965,0.00013492767,0.0035409287,0.00007842248,0.00007793702,0.000018033605,0.00015604038,0.00020949493,0.0000622724],"category_scores_gemma":[0.010384613,0.00007597001,0.00096994505,0.00002996662,0.00034788685,0.0001250993,0.000045553712,0.0004210275,1.2333727e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7638334,0.0010581295,0.018287038,0.00006414486,0.000646214,0.000010541796,0.00011102884,0.00000368878,0.000004970508,0.000035094454,0.00007817461,0.2158676],"study_design_scores_gemma":[0.9339465,0.024144882,0.037884615,0.0010847094,0.001468213,0.0000071272325,0.00008894302,0.00015157825,0.0000028860031,0.00029650825,0.0008450624,0.000078997014],"about_ca_topic_score_codex":0.00013114206,"about_ca_topic_score_gemma":0.0006392342,"teacher_disagreement_score":0.2157886,"about_ca_system_score_codex":0.00007430224,"about_ca_system_score_gemma":0.00027276407,"threshold_uncertainty_score":0.9979513},"labels":[],"label_agreement":null},{"id":"W4235681351","doi":"10.1200/jco.2004.22.14_suppl.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Cancer; Epitope; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","score_opus":0.18380388789095847,"score_gpt":0.5762637421299914,"score_spread":0.39245985423903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235681351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393661,0.0016878415,0.00031632674,0.054018542,0.0014406288,0.00038268228,0.000013390329,0.0000146613,0.0027598378],"genre_scores_gemma":[0.9863661,0.0027280967,0.0025635879,0.005414544,0.0027121515,0.000013231006,0.0000023170123,0.000038827162,0.00016113755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948683,0.0007288536,0.0026810865,0.00032396193,0.00080652646,0.00059131376],"domain_scores_gemma":[0.99558836,0.0016953927,0.0011891604,0.00020992177,0.0007324998,0.0005846338],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005358683,0.00021150864,0.0017031835,0.0002552645,0.000053752345,0.000017287382,0.00033028977,0.0004932882,0.0009476503],"category_scores_gemma":[0.0023477008,0.00015439065,0.00049270596,0.00046536932,0.00044196303,0.00016851531,0.00008297834,0.0030321013,0.000043176093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01275529,0.004804071,0.6852301,0.00014841942,0.00087409955,0.0044901855,0.0008684942,0.0008250019,0.0045863865,0.00038788226,0.0029884805,0.28204164],"study_design_scores_gemma":[0.021582188,0.009439007,0.93448555,0.0009440861,0.00022198119,0.0015859054,0.0006428962,0.00016375571,0.0006023139,0.0044919923,0.025569187,0.0002711543],"about_ca_topic_score_codex":0.0011260009,"about_ca_topic_score_gemma":0.0006424463,"teacher_disagreement_score":0.28177047,"about_ca_system_score_codex":0.0014418387,"about_ca_system_score_gemma":0.007918887,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W4235760362","doi":"10.1200/jco.2004.22.90140.611","title":"The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Hazard ratio; Proportional hazards model; Breast cancer; Internal medicine; Stage (stratigraphy); Multivariate analysis; Cancer; Oncology; Confidence interval","score_opus":0.0519062164857443,"score_gpt":0.42219272848660727,"score_spread":0.370286512000863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235760362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868176,0.0006372517,0.00002565534,0.011685091,0.00043280306,0.00018263528,0.000032003376,8.3355127e-7,0.00018614312],"genre_scores_gemma":[0.99731994,0.0015719457,0.00026266064,0.00050996017,0.00025713578,0.000011771684,7.3944193e-7,0.000010537658,0.000055309643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976014,0.00043466123,0.001427817,0.00013455673,0.0002377284,0.00016385347],"domain_scores_gemma":[0.99638593,0.0010685064,0.0017894674,0.00027455576,0.0004337971,0.00004774866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092743407,0.00012582807,0.0006374349,0.000016207601,0.000053948148,0.000003831453,0.00042634775,0.00020691859,0.000020342892],"category_scores_gemma":[0.0019004327,0.000047859234,0.000356335,0.00012921213,0.0006949651,0.000006048249,0.00014473424,0.00030017272,7.368191e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004379169,0.0010021422,0.9736101,0.000030082547,0.00079548213,0.000008804352,0.0002732517,0.000339216,0.008960714,0.00034350957,0.00015620979,0.010101337],"study_design_scores_gemma":[0.003784719,0.0005561622,0.98400897,0.000134222,0.00016852176,0.00007657664,0.00033337137,0.000008431308,0.009248328,0.00069458,0.0009251538,0.00006098914],"about_ca_topic_score_codex":0.0004483767,"about_ca_topic_score_gemma":0.0010055876,"teacher_disagreement_score":0.011175131,"about_ca_system_score_codex":0.00006626695,"about_ca_system_score_gemma":0.0018695153,"threshold_uncertainty_score":0.331644},"labels":[],"label_agreement":null},{"id":"W4235865027","doi":"10.1200/jco.2011.29.15_suppl.cra9006","title":"Barriers in providing breast and colorectal cancer survivorship care: Perceptions of U.S. primary care physicians (PCPs) and medical oncologists (MOs).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Survivorship curve; Primary care; Breast cancer; Colorectal cancer; Family medicine; Cancer survivorship; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.06393365687828821,"score_gpt":0.39753327055803955,"score_spread":0.33359961367975133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235865027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902592,0.0031162351,0.000014155944,0.0016120763,0.0011946051,0.00024337324,0.000032685137,0.000009307023,0.0035183849],"genre_scores_gemma":[0.9953442,0.0026273772,0.00026239612,0.0010518181,0.00065292895,0.0000138838395,0.000004864768,0.000019881323,0.000022633407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968539,0.00058376195,0.0015372549,0.0002698961,0.0004757644,0.0002794398],"domain_scores_gemma":[0.99690944,0.000986696,0.00084067864,0.00012465107,0.0005366903,0.00060187065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017580882,0.0001746368,0.0015851224,0.0001586436,0.000050205577,0.000005705448,0.0001624713,0.00061192847,0.00020217619],"category_scores_gemma":[0.0010780619,0.0001381181,0.00026054683,0.00019474351,0.00076052535,0.00012074243,0.000102749276,0.0011969492,7.0832965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028347825,0.00023084373,0.77189624,0.00028947613,0.00010688319,0.00029964186,0.011175611,6.9699206e-7,0.00013437899,0.000036633995,0.000112986636,0.21288182],"study_design_scores_gemma":[0.004553485,0.00519842,0.9691172,0.00057212205,0.0003110605,0.00047243503,0.01841534,0.000013014584,0.00004994322,0.000052383195,0.0011069933,0.000137563],"about_ca_topic_score_codex":0.004141784,"about_ca_topic_score_gemma":0.052620456,"teacher_disagreement_score":0.21274425,"about_ca_system_score_codex":0.0005799545,"about_ca_system_score_gemma":0.003943762,"threshold_uncertainty_score":0.9646667},"labels":[],"label_agreement":null},{"id":"W4236042667","doi":"10.1200/jco.2012.30.4_suppl.668","title":"Treatment patterns and outcomes of acneiform eruptions from anti-epidermal growth factor receptor (EGFR) therapies for metastatic colorectal cancer (MCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Cetuximab; Panitumumab; Colorectal cancer; Proportional hazards model; Internal medicine; Epidermal growth factor receptor; EGFR inhibitors; Oncology; Dermatology; Cancer","score_opus":0.1551614387503832,"score_gpt":0.47628590432804935,"score_spread":0.32112446557766616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236042667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98799384,0.003397856,0.00007040311,0.0062268004,0.001320159,0.00043522404,0.00045326017,0.000006946355,0.00009550589],"genre_scores_gemma":[0.98813295,0.007933981,0.002660389,0.00039528968,0.00069789327,0.00005872714,0.000010992303,0.000017103624,0.00009265468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782604,0.00014585395,0.0014115084,0.00014815775,0.00019895552,0.00026949833],"domain_scores_gemma":[0.995034,0.0031821283,0.0011159094,0.00008317909,0.00031146023,0.00027334984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004071559,0.000202794,0.0020385897,0.0000823882,0.00006881496,0.000006106027,0.0000637536,0.00014025379,0.00027591834],"category_scores_gemma":[0.00067172287,0.00011230401,0.0005761593,0.00005180957,0.00018362365,0.00015046491,0.000032361582,0.00019746173,0.0000018291917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022025555,0.0021094976,0.89668393,0.000028580334,0.0043558367,0.0000112550715,0.0012475882,3.1837578e-7,0.00032843262,0.000040100775,0.0002421415,0.09274978],"study_design_scores_gemma":[0.009133545,0.012714112,0.9652245,0.00004131878,0.001577341,0.000026052234,0.0006971351,0.0000072968674,0.0007362357,0.00007766708,0.009669842,0.00009495656],"about_ca_topic_score_codex":0.0005513361,"about_ca_topic_score_gemma":0.0005232248,"teacher_disagreement_score":0.092654824,"about_ca_system_score_codex":0.0002623495,"about_ca_system_score_gemma":0.0004030481,"threshold_uncertainty_score":0.45796245},"labels":[],"label_agreement":null},{"id":"W4236074251","doi":"10.1200/jco.2005.23.16_suppl.6006","title":"The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Anxiety; Medicine; Clinical trial; Hospital Anxiety and Depression Scale; Depression (economics); Psychiatry; Clinical psychology; Internal medicine","score_opus":0.34530523547202185,"score_gpt":0.5961133466012616,"score_spread":0.25080811112923973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236074251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397624,0.0040329304,0.00034676812,0.0005554064,0.0007691091,0.00020725183,0.000059021684,4.0693476e-7,0.00005288869],"genre_scores_gemma":[0.9739796,0.022479175,0.0022189566,0.00026587062,0.0010172401,0.0000043429245,0.0000026960238,0.00000745768,0.000024660023],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960276,0.00045120745,0.0031593575,0.00013821948,0.00009694331,0.00012667348],"domain_scores_gemma":[0.9901623,0.0064820917,0.0027192947,0.00011857305,0.0004349,0.00008281075],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011695871,0.00009359049,0.0011650311,0.000042277476,0.000027934644,0.0000040780988,0.00013138368,0.00020419543,0.00000568628],"category_scores_gemma":[0.024842294,0.0000557073,0.0005279824,0.000038047107,0.0006403227,0.0000062470776,0.0000759753,0.0002178853,2.0748725e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031402994,0.0047647697,0.33427006,0.00012318771,0.0033904044,0.000014461874,0.0010098665,0.0018514298,0.036061537,0.00031671827,0.030670522,0.55612403],"study_design_scores_gemma":[0.02688572,0.030928344,0.85423326,0.00022349115,0.0006251284,0.00007059949,0.0032961804,0.0018388921,0.0024369948,0.00073854375,0.078446485,0.00027635638],"about_ca_topic_score_codex":0.000007041325,"about_ca_topic_score_gemma":0.000074277945,"teacher_disagreement_score":0.5558477,"about_ca_system_score_codex":0.000041484054,"about_ca_system_score_gemma":0.00064124784,"threshold_uncertainty_score":0.98337185},"labels":[],"label_agreement":null},{"id":"W4236114868","doi":"10.1200/jco.2004.22.14_suppl.6052","title":"Does supportive-expressive group therapy for metastatic breast cancer patients lower health care services resource utilization","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Mood; Psychosocial; Profile of mood states; Physical therapy; Quality of life (healthcare); Randomized controlled trial; Patient satisfaction; Metastatic breast cancer; Health care; Cancer; Family medicine; Internal medicine; Nursing; Psychiatry","score_opus":0.09892220443071154,"score_gpt":0.5150214318762829,"score_spread":0.4160992274455714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236114868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97246575,0.002280789,0.00011910898,0.021571936,0.0023653926,0.0008844322,0.00016103197,0.000012212025,0.00013935352],"genre_scores_gemma":[0.97938466,0.0034103247,0.0012863656,0.014300874,0.0013701482,0.00004438264,0.000082421415,0.000025611194,0.00009519398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99752116,0.0002575887,0.0015042129,0.00021008367,0.00024865038,0.000258311],"domain_scores_gemma":[0.9962928,0.0005705819,0.0020085422,0.0001019765,0.00069938437,0.00032668858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006316701,0.00015469293,0.0011360937,0.000091300906,0.00007613107,0.0000073170813,0.0001149824,0.00015705638,0.000252798],"category_scores_gemma":[0.000079948266,0.000082188286,0.00039652927,0.000097338234,0.00010583325,0.00012151024,0.000020383422,0.00033655306,0.0000022983118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07520796,0.023813916,0.28164238,0.00063757,0.0028706216,0.00025190203,0.0056622983,0.0001559953,0.00020559704,0.00009010829,0.011748908,0.59771276],"study_design_scores_gemma":[0.07788256,0.06797416,0.5307423,0.000353314,0.0009178246,0.00007163399,0.0013011809,0.0000127968415,0.00028353644,0.00039801243,0.31987578,0.00018693737],"about_ca_topic_score_codex":0.0001252139,"about_ca_topic_score_gemma":0.00032350127,"teacher_disagreement_score":0.5975258,"about_ca_system_score_codex":0.00046572948,"about_ca_system_score_gemma":0.001659471,"threshold_uncertainty_score":0.3351541},"labels":[],"label_agreement":null},{"id":"W4236152380","doi":"10.1200/jco.2019.37.15_suppl.4516","title":"Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton; Ottawa Hospital; CancerCare Manitoba; Dalhousie University; McMaster University; Sunnybrook Health Science Centre; University of Alberta; Université Laval; Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Systemic therapy; Internal medicine; Cancer; Renal cell carcinoma; Metastasectomy; Kidney cancer; Surgery; Metastasis; Breast cancer","score_opus":0.07726084313189555,"score_gpt":0.37699534627771164,"score_spread":0.29973450314581607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236152380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728256,0.00026272226,0.000005184523,0.010654058,0.0015832318,0.00052769436,0.00020794307,0.000005076363,0.013928531],"genre_scores_gemma":[0.995843,0.00007686053,0.0004540236,0.0028624164,0.0005126174,0.000009173526,0.000046307407,0.000012356807,0.00018322373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99549717,0.0008601262,0.002626701,0.0001883977,0.00050068466,0.00032694987],"domain_scores_gemma":[0.99354434,0.002773493,0.0020947391,0.0003442114,0.0005134946,0.00072973355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032808022,0.00017617526,0.0012948936,0.00018550827,0.000049403632,0.000021461352,0.00024368722,0.0002661648,0.00011181223],"category_scores_gemma":[0.002188428,0.00010333708,0.00032815806,0.00022170684,0.00009099991,0.00022774028,0.000034869365,0.0011245051,0.00012840512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019486265,0.00041904082,0.9220118,0.00013031892,0.00059584796,0.0018955634,0.0020784547,0.00048712973,0.0001769681,0.000055990433,0.020895867,0.031766787],"study_design_scores_gemma":[0.014251318,0.0030495282,0.9360116,0.00018735055,0.00021840786,0.0001293298,0.0007273699,0.00044582272,0.00036014986,0.000015790147,0.044499893,0.000103400984],"about_ca_topic_score_codex":0.13647774,"about_ca_topic_score_gemma":0.1447097,"teacher_disagreement_score":0.031663384,"about_ca_system_score_codex":0.002113145,"about_ca_system_score_gemma":0.0095851645,"threshold_uncertainty_score":0.99602956},"labels":[],"label_agreement":null},{"id":"W4236169968","doi":"10.1200/jco.2002.20.1.42","title":"Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Insulin; Internal medicine; Quartile; Body mass index; Prospective cohort study; Cohort; Endocrinology; Oncology; Diabetes mellitus; Insulin receptor; Insulin-like growth factor; Confidence interval; Cancer; Insulin resistance; Growth factor; Receptor","score_opus":0.13741904731011897,"score_gpt":0.4744873802792335,"score_spread":0.33706833296911454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236169968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563104,0.0002814502,0.0000043539826,0.0020023824,0.0004065236,0.00042420567,0.000024129307,0.000003928366,0.0012219965],"genre_scores_gemma":[0.9981797,0.0008177339,0.00014124728,0.0001829226,0.00042679184,0.00000508599,2.0208614e-7,0.000009939612,0.00023642891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964764,0.00020066007,0.002675344,0.00019043406,0.0002948007,0.00016234996],"domain_scores_gemma":[0.99683714,0.0008968422,0.0016507015,0.00012464625,0.00028508858,0.0002055973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026805298,0.00010457951,0.0015284566,0.00014124015,0.000018046792,0.0000046810264,0.0000790676,0.00017725717,0.000082637824],"category_scores_gemma":[0.0020349538,0.00007304479,0.00016200119,0.00018349613,0.00015098702,0.00007772374,0.000047035977,0.0009605011,0.0000016503316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043879603,0.002010129,0.94836557,0.000016366319,0.00018708219,0.00034822564,0.0009056352,0.0000116661095,0.000009491863,0.0000045179095,0.00009932598,0.043654002],"study_design_scores_gemma":[0.017159143,0.008336872,0.9727742,0.000089950474,0.00017490088,0.000096418094,0.00041485226,0.00011240229,0.0000032448027,0.000013513861,0.00076346507,0.00006105525],"about_ca_topic_score_codex":0.001673081,"about_ca_topic_score_gemma":0.0011279596,"teacher_disagreement_score":0.04359295,"about_ca_system_score_codex":0.00018588058,"about_ca_system_score_gemma":0.00025376867,"threshold_uncertainty_score":0.41729525},"labels":[],"label_agreement":null},{"id":"W4236195741","doi":"10.1200/jco.2005.00.067","title":"Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative‘s Neuro-Oncology Disease Site Group","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Spinal cord compression; Radiation therapy; Surgery; Randomized controlled trial; Myelography; Systematic review; Radiology; Spinal cord; MEDLINE","score_opus":0.36286274477418134,"score_gpt":0.5674847907033129,"score_spread":0.20462204592913158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236195741","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007840906,0.9730162,0.000025244532,0.020325828,0.0012741609,0.0047646775,0.00006061219,0.0000045986912,0.00045027575],"genre_scores_gemma":[0.000078434794,0.9812716,0.0026133729,0.015082943,0.00046056145,0.000341618,0.000013372962,0.00003741439,0.00010066854],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9833206,0.0051946617,0.009545961,0.0004309908,0.0012228988,0.00028488727],"domain_scores_gemma":[0.9724465,0.0064613004,0.017877908,0.0009386753,0.0018142322,0.00046140255],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0073428866,0.0004891427,0.008008335,0.00013882967,0.00007673152,0.000012995606,0.00085498125,0.00025586915,0.00021881914],"category_scores_gemma":[0.013969097,0.00022143731,0.0021650668,0.0003016649,0.00051387347,0.00014251652,0.00057872286,0.0014271574,0.0000037618388],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013583222,0.0010044846,0.0002381535,0.58806944,0.0024890476,0.0010251623,0.00004979162,7.1890656e-7,2.1970843e-8,0.0000957067,0.008788365,0.39688078],"study_design_scores_gemma":[0.0012605865,0.0023696478,0.0020712547,0.41827723,0.056824338,0.00019971914,0.00020444593,0.0000026624477,1.8500538e-8,0.0000062370054,0.5186798,0.00010407725],"about_ca_topic_score_codex":0.000119589015,"about_ca_topic_score_gemma":0.0002509824,"teacher_disagreement_score":0.5098914,"about_ca_system_score_codex":0.00049134187,"about_ca_system_score_gemma":0.0034508344,"threshold_uncertainty_score":0.99433666},"labels":[],"label_agreement":null},{"id":"W4236225208","doi":"10.1200/jco.2017.35.15_suppl.4525","title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Tolerability; Clinical endpoint; Metastatic Urothelial Carcinoma; Oncology; Progression-free survival; Immunotherapy; Urology; Gastroenterology; Surgery; Adverse effect; Cancer; Chemotherapy; Clinical trial; Bladder cancer; Nivolumab; Urothelial carcinoma","score_opus":0.15351026332621126,"score_gpt":0.49104671437415287,"score_spread":0.3375364510479416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236225208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99399334,0.00026887908,0.000051035833,0.0030123163,0.0005939267,0.0003947293,0.000010350909,0.0000037100424,0.0016716897],"genre_scores_gemma":[0.9955849,0.00028016514,0.0031285358,0.00053526997,0.00023544788,0.0000039513525,0.0000012608366,0.000013857468,0.00021661469],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99674875,0.00036931396,0.002175982,0.00021092843,0.00027714812,0.00021787503],"domain_scores_gemma":[0.99626887,0.0010229326,0.001722376,0.00037171738,0.00032498926,0.0002891043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021697083,0.00014285704,0.001884565,0.000085967644,0.00005463508,0.000009837799,0.00020833024,0.00018250628,0.00020885699],"category_scores_gemma":[0.0050918907,0.00008977322,0.00022419973,0.00005736511,0.00045958874,0.00014370427,0.00007489755,0.0005791152,0.000004126324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06804005,0.004861485,0.44829425,0.000110940455,0.0005049809,0.0017296161,0.00022411288,0.00001779626,0.00056740385,0.000049007886,0.0002728894,0.47532746],"study_design_scores_gemma":[0.048423614,0.022154,0.9238525,0.00013041783,0.00046273044,0.0002848073,0.00006646854,0.00006949451,0.00033064254,0.00029713922,0.0038476444,0.0000805266],"about_ca_topic_score_codex":0.0001769577,"about_ca_topic_score_gemma":0.00027841196,"teacher_disagreement_score":0.47555825,"about_ca_system_score_codex":0.00010025924,"about_ca_system_score_gemma":0.0023560869,"threshold_uncertainty_score":0.6095836},"labels":[],"label_agreement":null},{"id":"W4236242001","doi":"10.1200/jco.2018.36.6_suppl.299","title":"Consensus statement on circulating biomarkers for advanced prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Consensus conference; Prostate cancer; Clinical trial; Delphi method; Intensive care medicine; Medical physics; Cancer; Oncology; Family medicine; Internal medicine","score_opus":0.08473667367971845,"score_gpt":0.47400832288594025,"score_spread":0.3892716492062218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236242001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156034,0.00056203856,0.0005105003,0.0035254816,0.002594308,0.00026150618,0.00005240861,0.0000023350638,0.00093110104],"genre_scores_gemma":[0.9863853,0.0011107613,0.0074926224,0.0025869005,0.0022531494,0.000015030248,0.000008486026,0.000019205694,0.0001285848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806225,0.000101493846,0.001300993,0.00020381038,0.000113181006,0.00021825513],"domain_scores_gemma":[0.997176,0.0006269296,0.0012988768,0.00015046645,0.00057411654,0.00017360382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015184692,0.000107441665,0.00043718383,0.000036368256,0.00006252251,0.000009619118,0.00013798833,0.00018349844,0.000017179185],"category_scores_gemma":[0.0028706773,0.000088662935,0.00024564972,0.000042205156,0.00020461011,0.00000195146,0.00004550572,0.000145017,0.0000028263378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019818952,0.0008732208,0.015125892,0.000044212433,0.0010887904,0.000065202395,0.00010524331,0.0012522667,0.10419692,0.00028565657,0.08786583,0.7692778],"study_design_scores_gemma":[0.009651081,0.035564747,0.008233267,0.00007082759,0.00012972794,0.000036969763,0.00016251592,0.0002768173,0.023081062,0.0006776397,0.9218842,0.00023117501],"about_ca_topic_score_codex":0.000010827268,"about_ca_topic_score_gemma":0.00010653731,"teacher_disagreement_score":0.83401835,"about_ca_system_score_codex":0.00007490148,"about_ca_system_score_gemma":0.0012595473,"threshold_uncertainty_score":0.36155695},"labels":[],"label_agreement":null},{"id":"W4236288445","doi":"10.1200/jco.2020.38.4_suppl.768","title":"Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Asymptomatic; Chemotherapy; Cancer; Pancreatic cancer; Lymph node; Logistic regression; Surgery; Retrospective cohort study; Internal medicine","score_opus":0.09957829003136719,"score_gpt":0.48634144860634887,"score_spread":0.38676315857498167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236288445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532866,0.00045464473,0.00010981644,0.0024581065,0.0001753481,0.0003504544,0.000009058673,0.000008638516,0.0011052857],"genre_scores_gemma":[0.99686533,0.0006140733,0.0012987817,0.0006940189,0.00041387705,0.000005199062,0.000004222129,0.000023334293,0.00008114088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640584,0.00053220405,0.0019284647,0.0002005643,0.00061791006,0.0003150231],"domain_scores_gemma":[0.9941675,0.002327511,0.001767276,0.0001837341,0.00090409355,0.00064989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017961033,0.0001634822,0.0028746664,0.000091465976,0.000031605025,0.0000044131693,0.00019688667,0.00031482623,0.00048770703],"category_scores_gemma":[0.005647573,0.000092259004,0.0006827107,0.0003286857,0.00032744,0.00009454438,0.00003769861,0.0009462725,0.000003999082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014241074,0.0010449257,0.95980465,0.00004301566,0.0022955046,0.00024580274,0.00019019964,0.000017187145,0.00012844676,0.000001148362,0.002015212,0.019972835],"study_design_scores_gemma":[0.018043078,0.033028316,0.947244,0.00018651452,0.00046588358,0.000013112436,0.0000362468,0.00042516197,0.0000145716385,0.000012827053,0.00044465694,0.00008562387],"about_ca_topic_score_codex":0.00017947916,"about_ca_topic_score_gemma":0.000057547644,"teacher_disagreement_score":0.03198339,"about_ca_system_score_codex":0.00019860106,"about_ca_system_score_gemma":0.0034162425,"threshold_uncertainty_score":0.67610806},"labels":[],"label_agreement":null},{"id":"W4236359648","doi":"10.1200/jco.2004.22.14_suppl.4655","title":"Change in bone alkaline phosphatase as an outcome predictor in men with hormone-refractory prostate cancer metastasized to bone","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Alkaline phosphatase; Refractory (planetary science); Bone remodeling; Hormone; Cancer; Endocrinology; Urology; Enzyme","score_opus":0.1267942869181265,"score_gpt":0.4918057462744774,"score_spread":0.3650114593563509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236359648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684725,0.0052175997,0.000004964191,0.024553737,0.0003422217,0.0011690486,0.00005104794,0.000012765811,0.00017613536],"genre_scores_gemma":[0.9812562,0.0037463687,0.0034213597,0.010821746,0.00040465017,0.00011675955,0.000022116497,0.00003367348,0.00017716706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545807,0.00031503921,0.0029199992,0.0003153663,0.000484301,0.00050720363],"domain_scores_gemma":[0.9966231,0.00035797214,0.0012497992,0.00025317227,0.00023394586,0.0012820307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029431868,0.00023116065,0.0021954328,0.000340297,0.000026266862,0.0000067432,0.00011019264,0.00030814332,0.00010493797],"category_scores_gemma":[0.001075252,0.00015017792,0.00016390155,0.0003661054,0.00010586853,0.0003048715,0.0000394517,0.0011471906,0.000031866366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11444023,0.01631068,0.65837586,0.0000964764,0.0004141675,0.025902467,0.0016402253,0.000058118512,0.00013081574,0.00007796929,0.0007832479,0.18176971],"study_design_scores_gemma":[0.077561,0.043735113,0.842194,0.00025846672,0.00033825717,0.00044368548,0.00012631489,0.000016702004,0.000037188238,0.00017777931,0.034955367,0.00015610478],"about_ca_topic_score_codex":0.0048811412,"about_ca_topic_score_gemma":0.008491157,"teacher_disagreement_score":0.18381813,"about_ca_system_score_codex":0.00071943976,"about_ca_system_score_gemma":0.0025538371,"threshold_uncertainty_score":0.73788583},"labels":[],"label_agreement":null},{"id":"W4236457854","doi":"10.1200/jco.2020.38.4_suppl.317","title":"Real-world treatment attrition rates in advanced esophagogastric cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cancer; Irinotecan; Ramucirumab; Proportional hazards model; Adenocarcinoma; Oncology; Chemotherapy; Gastroenterology; Surgery; Colorectal cancer","score_opus":0.21507535730796185,"score_gpt":0.5142104876641971,"score_spread":0.29913513035623523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236457854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92883813,0.0008706584,0.000038529408,0.06552433,0.00088468665,0.00028028543,0.0000025400275,0.000013157497,0.0035476577],"genre_scores_gemma":[0.9818638,0.009438213,0.0020614103,0.0041483794,0.0016256507,0.000009383483,0.000002929627,0.000011451339,0.00083875976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768066,0.00015367666,0.0016046187,0.00016346431,0.00020959479,0.0001879816],"domain_scores_gemma":[0.9978885,0.00070168055,0.0009041957,0.00008327734,0.000116841446,0.00030547444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005863913,0.00011659894,0.0012520842,0.00018326442,0.000015784057,0.0000054475986,0.00009070684,0.00010312567,0.0002835677],"category_scores_gemma":[0.0006867533,0.0000830099,0.00034669918,0.00045728806,0.0000533176,0.00009782159,0.000025582953,0.00040411254,0.000014022233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004159156,0.00060089375,0.67047185,0.00002789023,0.00015704375,0.0008636441,0.00007048334,0.000121192745,0.000050270908,0.000050685627,0.003959362,0.31946754],"study_design_scores_gemma":[0.017595313,0.013865834,0.8775626,0.000070031296,0.00030474106,0.000015817954,0.00013281491,0.00016183745,0.00008018126,0.00006957927,0.09007844,0.00006284918],"about_ca_topic_score_codex":0.00015779812,"about_ca_topic_score_gemma":0.0005423599,"teacher_disagreement_score":0.3194047,"about_ca_system_score_codex":0.0004540349,"about_ca_system_score_gemma":0.0007762505,"threshold_uncertainty_score":0.33850455},"labels":[],"label_agreement":null},{"id":"W4236493034","doi":"10.1200/jco.2017.35.15_suppl.2516","title":"A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Asymptomatic; Nausea; Internal medicine; Cmax; Pharmacology","score_opus":0.028755839335996687,"score_gpt":0.35872809854140353,"score_spread":0.32997225920540685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236493034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472636,0.00032132998,0.0000069526977,0.0010657636,0.0030009565,0.00042555455,0.0000097200855,0.0000011558639,0.00044221003],"genre_scores_gemma":[0.9971938,0.00082622544,0.00014825995,0.00021280532,0.0015034392,0.000013127784,0.0000032413463,0.000020591055,0.000078522324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969434,0.00021047865,0.0019667882,0.00029147946,0.00027042476,0.0003173931],"domain_scores_gemma":[0.9969987,0.00012140115,0.0020749932,0.0004928933,0.00017661066,0.00013540284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014142742,0.0001877309,0.001137754,0.000090253336,0.000070225375,0.000012053793,0.00058356696,0.00043721442,0.000011195749],"category_scores_gemma":[0.00074664643,0.0001253457,0.00039499285,0.00007026278,0.0003356747,0.000023305227,0.00008355958,0.00067751354,5.703978e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13272244,0.0057303705,0.82573104,0.00005533468,0.00022143744,0.00007205038,0.00031742468,0.0013895152,0.0029712128,0.000037986534,0.0007355708,0.030015629],"study_design_scores_gemma":[0.09781384,0.007080032,0.8518636,0.00014844298,0.000069629335,0.0000044327726,0.000025344607,0.000014760856,0.001020563,0.00011079994,0.04168724,0.00016132252],"about_ca_topic_score_codex":0.00006253187,"about_ca_topic_score_gemma":0.0068252445,"teacher_disagreement_score":0.04095167,"about_ca_system_score_codex":0.000054126293,"about_ca_system_score_gemma":0.0005758894,"threshold_uncertainty_score":0.51114494},"labels":[],"label_agreement":null},{"id":"W4236688713","doi":"10.1200/jco.2013.31.31_suppl.132","title":"Opportunities for improved end-of-life (EOL) care for adult patients with advanced cancer: Results of a longitudinal assessment of care provided by Quality Oncology Practice Initiative (QOPI) participants.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Palliative care; Referral; Hospice care; Psychological intervention; End-of-life care; Family medicine; Cancer; Quality of life (healthcare); Emergency medicine; Nursing; Internal medicine","score_opus":0.4530028845657584,"score_gpt":0.599564537293914,"score_spread":0.14656165272815563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236688713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838438,0.002033077,0.0012167785,0.006961182,0.0006745951,0.002433365,0.0015762121,0.0000071373784,0.0012538388],"genre_scores_gemma":[0.9605571,0.0020939372,0.03560353,0.0011310859,0.00021370541,0.00021087969,0.00013743357,0.000025012372,0.000027338085],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99332255,0.0008103701,0.0046972577,0.0003023592,0.0004984851,0.000368997],"domain_scores_gemma":[0.95665514,0.014028049,0.010689314,0.00026739214,0.017969254,0.0003908501],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018555457,0.00024616392,0.003297641,0.00012595086,0.000041061925,0.0000035563328,0.00021896459,0.0003968348,0.000024349043],"category_scores_gemma":[0.033738416,0.00017244843,0.0004987666,0.00012547732,0.00056709937,0.00033664133,0.00005972345,0.00050626264,1.2193887e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18730432,0.009704721,0.4500319,0.005995788,0.0056845634,0.000029518027,0.017785504,0.00009738597,0.001274266,0.00060336833,0.0075401245,0.31394854],"study_design_scores_gemma":[0.14120547,0.29672956,0.25621143,0.0042030057,0.004736561,0.0000074046484,0.1678108,0.00024763023,0.008500043,0.00020968547,0.11955421,0.00058416696],"about_ca_topic_score_codex":0.00063280005,"about_ca_topic_score_gemma":0.00075287226,"teacher_disagreement_score":0.31336436,"about_ca_system_score_codex":0.00038548277,"about_ca_system_score_gemma":0.008174777,"threshold_uncertainty_score":0.99744797},"labels":[],"label_agreement":null},{"id":"W4236803962","doi":"10.1200/jco.2016.34.2_suppl.110","title":"Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Prostate-specific antigen; Proportional hazards model; Biochemical recurrence; Urology; Nomogram; Radiation therapy; Stage (stratigraphy); Surgery; Tumor progression; Pathological; Cancer; Internal medicine; Oncology","score_opus":0.08278965795689873,"score_gpt":0.49772983248354424,"score_spread":0.4149401745266455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236803962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227166,0.0010638777,0.0004105874,0.004462644,0.0007342248,0.00058682763,0.00038974558,0.000007429725,0.00007298851],"genre_scores_gemma":[0.9968035,0.0014448578,0.00049382966,0.00018784171,0.0006735134,0.00004406468,0.000033526976,0.000010963306,0.00030787278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731034,0.00022563296,0.0015411216,0.00020559368,0.000448762,0.00026853548],"domain_scores_gemma":[0.99554694,0.0017509701,0.0012268502,0.0001716152,0.0007658711,0.00053773366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014694431,0.00012303228,0.0007050254,0.00013622503,0.00006689111,0.000006240833,0.00011568572,0.00019479431,0.0001326288],"category_scores_gemma":[0.005844287,0.000057714202,0.00046210087,0.000095089155,0.0003980277,0.00021275495,0.000048845366,0.00029537344,0.000005068697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07119689,0.0017081965,0.8261165,0.000054794386,0.00019387892,0.00046154606,0.00030024175,4.154866e-7,0.00022180208,0.000016598151,0.00037558304,0.09935353],"study_design_scores_gemma":[0.028702347,0.0094338795,0.9487378,0.00035390802,0.0001904491,0.000013894937,0.000050081402,0.000009307909,0.0010049177,0.000086826614,0.0113452235,0.0000713538],"about_ca_topic_score_codex":0.0000032396508,"about_ca_topic_score_gemma":0.0000064916644,"teacher_disagreement_score":0.12262129,"about_ca_system_score_codex":0.00019569392,"about_ca_system_score_gemma":0.0022409323,"threshold_uncertainty_score":0.699658},"labels":[],"label_agreement":null},{"id":"W4236818265","doi":"10.1200/jco.2004.22.14_suppl.8009","title":"Providing audiotapes of primary adjuvant treatment consultations to men with prostate cancer: Impact on recall, mood, satisfaction, and quality of life","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Mood; Randomized controlled trial; Quality of life (healthcare); Family medicine; Patient satisfaction; Breast cancer; Cancer; Physical therapy; Clinical psychology; Internal medicine; Nursing","score_opus":0.3930731575537353,"score_gpt":0.5773877042605567,"score_spread":0.18431454670682146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236818265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97570544,0.0010221561,0.000045019526,0.0207307,0.00028654016,0.0013522283,0.00010002422,0.000011078267,0.00074681983],"genre_scores_gemma":[0.98913795,0.0026656555,0.006752743,0.0011384548,0.00013379424,0.00010379747,0.000004582212,0.000016960827,0.000046058307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927344,0.002395864,0.0040313723,0.00020003828,0.00037341434,0.00026495926],"domain_scores_gemma":[0.9838951,0.008257135,0.005455304,0.00034344057,0.0015381902,0.0005108249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001965826,0.00016475642,0.0016403395,0.00015956542,0.00020760999,0.0000029859746,0.00015803712,0.00026650116,0.000030239014],"category_scores_gemma":[0.0052027386,0.00010269085,0.00015447341,0.00022685225,0.00021624815,0.0001547631,0.00007181793,0.0008015672,0.0000032440105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013695683,0.0008375989,0.9232001,0.0003258568,0.00039704985,0.00000261897,0.009081244,0.0015865375,0.00033995064,0.00033540858,0.0003671154,0.04983089],"study_design_scores_gemma":[0.009856347,0.01625006,0.96793294,0.0007284176,0.000100528174,0.000003267119,0.0037149144,0.000010931519,0.00006043955,0.00031530048,0.0009316844,0.00009514541],"about_ca_topic_score_codex":0.0052741496,"about_ca_topic_score_gemma":0.0038284992,"teacher_disagreement_score":0.049735747,"about_ca_system_score_codex":0.0013205543,"about_ca_system_score_gemma":0.011798295,"threshold_uncertainty_score":0.9938039},"labels":[],"label_agreement":null},{"id":"W4236866569","doi":"10.1200/jco.2012.30.15_suppl.lba3500","title":"Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Colorectal cancer; Oncology; Internal medicine; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.08267231040353823,"score_gpt":0.4386455469096126,"score_spread":0.3559732365060744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236866569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923621,0.00036074425,0.00001688233,0.0042392253,0.0012853937,0.0014013378,0.000020185817,0.0000058253045,0.00030832156],"genre_scores_gemma":[0.9967423,0.0013972716,0.0005502382,0.0005608063,0.0004683191,0.00004115129,0.000005622928,0.000022946231,0.00021134349],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970415,0.00021321206,0.0017007062,0.00022894719,0.0005520628,0.00026353652],"domain_scores_gemma":[0.99633723,0.0011217846,0.0018361204,0.00014046721,0.0003938988,0.00017047345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015638798,0.00022166467,0.0015348723,0.00010163698,0.000082362545,0.00000884024,0.00014630267,0.00013081904,0.000052951887],"category_scores_gemma":[0.001112183,0.00009861826,0.0002115247,0.00023453536,0.00027426358,0.00018667927,0.000044993012,0.0005442539,3.8188932e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7682956,0.0056057675,0.12378337,0.000010472386,0.001801475,0.000030220377,0.0014344769,0.00002288668,0.000017661796,0.000004193899,0.00013936231,0.09885453],"study_design_scores_gemma":[0.5289528,0.051528998,0.41283953,0.00034233893,0.00047612388,0.00006416603,0.00028662692,0.000030636933,0.000108214,0.000008877602,0.0052525005,0.000109222594],"about_ca_topic_score_codex":0.00024096917,"about_ca_topic_score_gemma":0.0013271761,"teacher_disagreement_score":0.28905615,"about_ca_system_score_codex":0.00048576354,"about_ca_system_score_gemma":0.0011347425,"threshold_uncertainty_score":0.40215358},"labels":[],"label_agreement":null},{"id":"W4236922292","doi":"10.1200/jco.2019.37.7_suppl.40","title":"Impact of putative chemopreventative agents on prostate cancer diagnosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University Health Network; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Comorbidity; Diabetes mellitus; Cancer; Metformin; Population; Retrospective cohort study; Cancer registry; Endocrinology; Insulin","score_opus":0.06440651341254248,"score_gpt":0.49352775586982395,"score_spread":0.42912124245728145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236922292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895699,0.0009783388,0.000013788046,0.0003994786,0.0076798988,0.00021747354,0.00006890275,0.0000013013173,0.0010708955],"genre_scores_gemma":[0.9843805,0.0072099194,0.00026327532,0.00078187586,0.006509513,0.00002077294,0.0000108373315,0.000017560747,0.0008057347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997916,0.0002908358,0.0011888925,0.00020602514,0.0002017574,0.00019650323],"domain_scores_gemma":[0.9972073,0.0002886357,0.0017509707,0.00016156197,0.0004066058,0.00018496352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010591188,0.00014184002,0.00090774824,0.00005583508,0.00001444536,0.0000042255942,0.00019906527,0.0002590451,0.0002211487],"category_scores_gemma":[0.0007732389,0.0000991304,0.0007092088,0.00007553836,0.00014155326,0.0000088533325,0.00005784631,0.00035621077,0.000012182729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0097251665,0.0023737052,0.67452663,0.000040143204,0.001992133,0.000003914011,0.00060666376,0.0011460675,0.02214357,0.00004384534,0.12631162,0.16108656],"study_design_scores_gemma":[0.006364739,0.017140547,0.6756717,0.00005317222,0.00013677403,0.0000139818985,0.00011614994,0.000009715581,0.008266068,0.00018445935,0.29189247,0.00015023655],"about_ca_topic_score_codex":0.000069275615,"about_ca_topic_score_gemma":0.000021348642,"teacher_disagreement_score":0.16558084,"about_ca_system_score_codex":0.00006820342,"about_ca_system_score_gemma":0.0013517645,"threshold_uncertainty_score":0.40424204},"labels":[],"label_agreement":null},{"id":"W4237011245","doi":"10.1200/jco.2016.34.15_suppl.5079","title":"Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Clinical endpoint; Oncology; Response Evaluation Criteria in Solid Tumors; Proportional hazards model; Prostate-specific antigen; Placebo; Progressive disease; Hazard ratio; Surrogate endpoint; Clinical trial; Cancer; Urology; Confidence interval; Disease; Pathology","score_opus":0.14938310484820938,"score_gpt":0.473387407952784,"score_spread":0.3240043031045746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237011245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882339,0.000062831146,0.0000029261753,0.010043946,0.00011957339,0.0007707877,0.000022126458,0.0000022573702,0.00074163266],"genre_scores_gemma":[0.99748474,0.00041144146,0.00009173318,0.00003776346,0.000093135146,0.000020583351,0.0000020506707,0.000011346766,0.0018471899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702793,0.0009139679,0.0010116918,0.00014222867,0.0007395922,0.0001645922],"domain_scores_gemma":[0.99514484,0.0017666774,0.002036672,0.00014840985,0.00081466185,0.00008870775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032911296,0.00010699049,0.0009253941,0.00012962444,0.000025603902,0.000004376305,0.00009357982,0.000083383005,0.0000344437],"category_scores_gemma":[0.0009625831,0.00004054287,0.00008670088,0.00029748096,0.00013399494,0.00007108676,0.000014630533,0.00028776887,6.708231e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04211641,0.002916709,0.92892265,0.000043351498,0.0010300867,0.0001264982,0.00061132165,0.00003641987,0.0046866387,0.000015865033,0.00017847505,0.01931557],"study_design_scores_gemma":[0.02765857,0.044671837,0.9130027,0.00058417063,0.0006365445,0.000008307953,0.000927055,0.000005018682,0.012072981,0.00003136854,0.00034072303,0.000060680562],"about_ca_topic_score_codex":0.00025548393,"about_ca_topic_score_gemma":0.0034715948,"teacher_disagreement_score":0.04175513,"about_ca_system_score_codex":0.00053364376,"about_ca_system_score_gemma":0.001491128,"threshold_uncertainty_score":0.26451972},"labels":[],"label_agreement":null},{"id":"W4237044476","doi":"10.1200/jco.2016.34.4_suppl.391","title":"Long-term responders to palliative chemotherapy for advanced biliary tract cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Gemcitabine; Capecitabine; Internal medicine; Regimen; Gallbladder cancer; Chemotherapy; Gastroenterology; Surgery; Chemotherapy regimen; Oncology; Cancer; Colorectal cancer","score_opus":0.15869737834405762,"score_gpt":0.511601289388927,"score_spread":0.3529039110448694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237044476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8894995,0.0017000623,0.0013758442,0.10512161,0.0014990774,0.0004299214,0.000015765278,0.000010230407,0.00034800643],"genre_scores_gemma":[0.97785455,0.004412422,0.0027286762,0.011543803,0.002108777,0.00003503107,7.382161e-7,0.00002524816,0.0012907606],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977866,0.00011851282,0.0013550034,0.00023020328,0.00024029087,0.00026938744],"domain_scores_gemma":[0.99497825,0.0030773678,0.0008581256,0.00016911054,0.0005398577,0.00037731233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012946757,0.00014643405,0.0012753442,0.000108786,0.000040038463,0.000004170542,0.0001518942,0.00020867432,0.00014513897],"category_scores_gemma":[0.00247905,0.00008014419,0.0006024413,0.00011170237,0.00014443934,0.00009621776,0.000025867434,0.00030341302,0.000008690752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022494433,0.00059790246,0.37827525,0.000031667296,0.0005200911,0.000150872,0.00037025035,9.091842e-7,0.0025162022,0.000012601956,0.0155762425,0.5794536],"study_design_scores_gemma":[0.01659427,0.014824115,0.89682305,0.00030018916,0.00022802988,0.000041511128,0.00011783323,8.5770375e-7,0.0010549806,0.00014846986,0.06975826,0.00010842446],"about_ca_topic_score_codex":0.0000049400187,"about_ca_topic_score_gemma":0.00007583025,"teacher_disagreement_score":0.57934517,"about_ca_system_score_codex":0.00030665557,"about_ca_system_score_gemma":0.0012684625,"threshold_uncertainty_score":0.32681853},"labels":[],"label_agreement":null},{"id":"W4237067208","doi":"10.1200/jco.2020.38.6_suppl.tps600","title":"PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring <i>FGFR3</i> alterations.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Tolerability; Cisplatin; Internal medicine; Oncology; Placebo; Adjuvant therapy; Urology; Cancer; Gastroenterology; Clinical trial; Chemotherapy; Surgery; Adverse effect; Pathology","score_opus":0.0960230797781937,"score_gpt":0.4147880113532452,"score_spread":0.31876493157505154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237067208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868725,0.00036154134,0.00010961232,0.0038112544,0.0007352895,0.0065476983,0.000015312204,0.000008267902,0.0015385287],"genre_scores_gemma":[0.9942983,0.0003360171,0.00048825511,0.0030104993,0.0015365804,0.00023735112,0.000011707324,0.00003286742,0.000048435442],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936832,0.0009295469,0.0040950663,0.00031380358,0.00069830864,0.00028005088],"domain_scores_gemma":[0.99326706,0.002407719,0.0028967478,0.0002099377,0.0007488639,0.00046968707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002154669,0.00029829965,0.004458152,0.00019103616,0.000043833148,0.000017964554,0.0001990421,0.00030230748,0.00017876823],"category_scores_gemma":[0.002542126,0.000175607,0.0008317322,0.00024700625,0.00025765994,0.00020930593,0.000032410215,0.00092599646,0.000005905708],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9632524,0.007276377,0.011610942,0.000027287258,0.001300777,0.00023908037,0.0008816812,0.000033639753,0.00007438087,0.000038551643,0.00017618875,0.015088686],"study_design_scores_gemma":[0.89787304,0.098037206,0.00086690974,0.00012707447,0.00090253336,0.000019069395,0.00007045834,0.000056645284,0.0010780089,0.000049426217,0.0007859016,0.00013374063],"about_ca_topic_score_codex":0.00010036095,"about_ca_topic_score_gemma":0.00006585091,"teacher_disagreement_score":0.09076083,"about_ca_system_score_codex":0.00010790119,"about_ca_system_score_gemma":0.0047855526,"threshold_uncertainty_score":0.8489365},"labels":[],"label_agreement":null},{"id":"W4237348569","doi":"10.1200/jco.2015.33.15_suppl.lba4","title":"NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Radiosurgery; Radiation therapy; Alliance; Medical physics; Clinical trial; Radiation oncology; Randomized controlled trial; Oncology; Internal medicine","score_opus":0.09733898496823448,"score_gpt":0.4525646395301359,"score_spread":0.35522565456190147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237348569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733671,0.00026538636,0.00071095355,0.022140251,0.0007718365,0.0025764857,0.00005567597,0.000005329854,0.00010696818],"genre_scores_gemma":[0.98561466,0.00010645335,0.0052815555,0.0080652125,0.00062362244,0.00009202214,0.00009263296,0.000025504392,0.0000983278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926563,0.0026033234,0.0035215938,0.00027081202,0.00066273316,0.00028522007],"domain_scores_gemma":[0.9901848,0.0066006104,0.0018950641,0.00023845227,0.00044011636,0.0006409968],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015229839,0.0002109201,0.0033828812,0.00047039552,0.000014777625,0.000009357138,0.00012116659,0.00021287265,0.00012184058],"category_scores_gemma":[0.014681742,0.00013522377,0.0005074726,0.0005631254,0.00011024113,0.00017088484,0.000022850412,0.00048811393,0.0000095629675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75922245,0.009800352,0.004218875,0.0000067956903,0.00038332772,0.00023202493,0.0002655974,0.00021987411,0.000012078564,0.000016869548,0.02668167,0.19894011],"study_design_scores_gemma":[0.8801995,0.05090428,0.016970431,0.00015309427,0.00019581307,0.000014457881,0.000074491,0.000048720165,0.000036694368,0.0001242906,0.05116383,0.00011438982],"about_ca_topic_score_codex":0.000096049705,"about_ca_topic_score_gemma":0.000102685975,"teacher_disagreement_score":0.19882572,"about_ca_system_score_codex":0.0003543006,"about_ca_system_score_gemma":0.0014961112,"threshold_uncertainty_score":0.993618},"labels":[],"label_agreement":null},{"id":"W4237577048","doi":"10.1200/jco.2015.33.15_suppl.e13528","title":"Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to filgrastim.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Filgrastim; Biosimilar; Medicine; Clinical endpoint; Pharmacology; Clinical trial; Oncology; Internal medicine; Neutropenia; Chemotherapy","score_opus":0.27554359687456065,"score_gpt":0.49068665412606977,"score_spread":0.21514305725150912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237577048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777862,0.0002492144,0.0013160442,0.018316109,0.0011896383,0.00046075936,0.000012968162,0.000008132555,0.00066095276],"genre_scores_gemma":[0.9547946,0.0000482578,0.042267695,0.0026918515,0.00015901745,0.0000029292162,0.0000021730887,0.000007749079,0.000025745654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9943777,0.0019347649,0.003014516,0.00028154178,0.0001604723,0.00023100604],"domain_scores_gemma":[0.992322,0.004711437,0.0018516582,0.00021922727,0.0007167722,0.00017885676],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011796711,0.00017781484,0.0013693861,0.00009226481,0.000056388806,0.0000050498443,0.00036354805,0.0005338804,0.00009317037],"category_scores_gemma":[0.009263644,0.00009710389,0.00034433164,0.00022221397,0.0010211243,0.00004137197,0.00011206358,0.0010868516,0.0000061575706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027616713,0.020289958,0.051500987,0.0001693119,0.002466101,0.000048416656,0.00048133568,0.00006427292,0.4384033,0.00084587926,0.0658879,0.39222583],"study_design_scores_gemma":[0.014271128,0.03335224,0.085763134,0.00031528735,0.0012661413,0.00006158311,0.00048414434,0.00062149944,0.76556915,0.0010934978,0.09670706,0.0004951331],"about_ca_topic_score_codex":0.0000018781885,"about_ca_topic_score_gemma":0.000004906127,"teacher_disagreement_score":0.3917307,"about_ca_system_score_codex":0.000044890796,"about_ca_system_score_gemma":0.0017521798,"threshold_uncertainty_score":0.99908173},"labels":[],"label_agreement":null},{"id":"W4237681400","doi":"10.1200/jco.2004.22.14_suppl.3772","title":"Linear regression is a reproducible model of tumor response to pre-operative endorectal brachytherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Brachytherapy; Linear regression; Radiology; Oncology; Nuclear medicine; Internal medicine; Radiation therapy; Statistics","score_opus":0.08667919022008272,"score_gpt":0.5030077746902517,"score_spread":0.41632858447016896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237681400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93280435,0.00022144719,0.007442445,0.058323264,0.0005457396,0.00021732542,0.0000026452674,0.000010165716,0.0004326205],"genre_scores_gemma":[0.88912475,0.0002224039,0.0977383,0.01134518,0.00092319585,0.0000029503417,6.836721e-7,0.000024229275,0.00061829423],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99636,0.0005066622,0.0021234113,0.0003111027,0.00047546646,0.00022335688],"domain_scores_gemma":[0.99607056,0.0012395193,0.001284278,0.0003413192,0.00054585555,0.0005184849],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007975504,0.0001440041,0.0014193717,0.00019685629,0.000045315777,0.000005822326,0.00019494745,0.00019613732,0.00006972297],"category_scores_gemma":[0.02169492,0.00009184433,0.0004314843,0.00019444386,0.00021737517,0.000094907264,0.000061625884,0.0015048698,0.000009203383],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24583137,0.008866279,0.0299094,0.00015006939,0.0011147048,0.003372355,0.013456384,0.04915484,0.31443942,0.00037304996,0.017160738,0.3161714],"study_design_scores_gemma":[0.123592764,0.2348833,0.17277204,0.0058490834,0.0015133313,0.01010036,0.0011127143,0.17077227,0.11211651,0.012835747,0.15318441,0.0012674899],"about_ca_topic_score_codex":0.000022408962,"about_ca_topic_score_gemma":0.0000020314142,"teacher_disagreement_score":0.31490391,"about_ca_system_score_codex":0.00013549668,"about_ca_system_score_gemma":0.0026355141,"threshold_uncertainty_score":0.98654574},"labels":[],"label_agreement":null},{"id":"W4237698423","doi":"10.1200/jco.2004.22.14_suppl.8001","title":"Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Internal medicine; Quality of life (healthcare); Cognition; Chemotherapy; Cancer; Prospective cohort study; Adjuvant chemotherapy; Oncology; Gynecology; Physical therapy; Psychiatry","score_opus":0.049250527410215426,"score_gpt":0.42462944453714524,"score_spread":0.37537891712692983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237698423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292535,0.00095918967,0.00021324985,0.00281269,0.00060887286,0.0022943967,0.000024277553,0.0000075491316,0.00015439966],"genre_scores_gemma":[0.9976645,0.0007123387,0.00014435206,0.00079215935,0.00042001103,0.00018957286,6.4730466e-7,0.000022299877,0.00005412864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973005,0.0001957858,0.00167064,0.0002670354,0.00029896555,0.00026706033],"domain_scores_gemma":[0.9960918,0.0016826517,0.0012044936,0.0000628993,0.0007547549,0.0002034176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022829575,0.00018359024,0.0024654623,0.00018757685,0.000053893153,0.000006945877,0.000045675,0.00015172361,0.00002681458],"category_scores_gemma":[0.0015797475,0.00013866286,0.00018645497,0.00017734156,0.000246316,0.00011394543,0.000036559628,0.0005093651,3.375819e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2724899,0.005914603,0.5930465,0.00006034168,0.011141012,0.00009921493,0.0049264687,0.000009680873,0.0003636839,0.00004770256,0.000050803454,0.111850135],"study_design_scores_gemma":[0.29809234,0.045220193,0.64863753,0.0004977952,0.0016077383,0.00003785638,0.0050361594,0.0000068035442,0.000023956942,0.00072142045,0.000024899738,0.0000932716],"about_ca_topic_score_codex":0.00007180492,"about_ca_topic_score_gemma":0.00029347168,"teacher_disagreement_score":0.11175686,"about_ca_system_score_codex":0.000413609,"about_ca_system_score_gemma":0.00093964406,"threshold_uncertainty_score":0.5654507},"labels":[],"label_agreement":null},{"id":"W4237709015","doi":"10.1200/jco.2004.22.14_suppl.630","title":"A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Anthracycline; Metastatic breast cancer; Ejection fraction; Cardiotoxicity; Trastuzumab; Doxorubicin; Internal medicine; Heart failure; Breast cancer; Cancer; Oncology; Chemotherapy; Gastroenterology; Urology","score_opus":0.1422473115020502,"score_gpt":0.5265052184546788,"score_spread":0.3842579069526286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237709015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043995,0.0012552956,0.00003178978,0.006603307,0.0010958283,0.00044681967,0.000029049279,0.0000064063356,0.00009152367],"genre_scores_gemma":[0.99503076,0.0011781995,0.0022427726,0.0006525,0.0007700377,0.000006375863,0.0000033531153,0.000017583736,0.000098392804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965832,0.0003786921,0.0022874288,0.00021734096,0.00025516588,0.00027817077],"domain_scores_gemma":[0.9970823,0.0007838467,0.0014980165,0.000102932805,0.00019922701,0.00033369518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011025096,0.00018500272,0.0018800473,0.00020264446,0.000039781335,0.000005319939,0.000091832124,0.00025145325,0.00033776846],"category_scores_gemma":[0.00037533362,0.00013405642,0.00035133923,0.00019095534,0.00025266412,0.00012990047,0.000045029385,0.0008000253,0.0000011227272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5181255,0.10322281,0.021914313,0.00016414956,0.0022832528,0.003680516,0.0023287917,0.00025314078,0.050818797,0.00002169203,0.00076142274,0.29642567],"study_design_scores_gemma":[0.86726236,0.06480657,0.059053693,0.0005383471,0.002188121,0.00093372347,0.000259558,0.00035530803,0.0015711962,0.00010655754,0.0027525981,0.00017193721],"about_ca_topic_score_codex":0.00043846926,"about_ca_topic_score_gemma":0.00062989676,"teacher_disagreement_score":0.34913695,"about_ca_system_score_codex":0.00037963895,"about_ca_system_score_gemma":0.002233856,"threshold_uncertainty_score":0.5466662},"labels":[],"label_agreement":null},{"id":"W4238103431","doi":"10.1200/jco.2017.35.15_suppl.6509","title":"Do the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Canadian Agency for Drugs and Technologies in Health; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Nice; Clinical Oncology; Internal medicine; Oncology; Clinical trial; Logistic regression; Family medicine; Cancer","score_opus":0.568359082291044,"score_gpt":0.5899110599553102,"score_spread":0.021551977664266198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238103431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77270526,0.0023103019,0.0009795313,0.2134352,0.0051499456,0.00085459865,0.0001787594,0.000010275043,0.0043761097],"genre_scores_gemma":[0.9062143,0.029256219,0.027777342,0.030369436,0.0062160953,0.000016959251,0.0000044512194,0.00007106641,0.000074136224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.90868396,0.024054488,0.063429385,0.0013772777,0.0014490748,0.0010058266],"domain_scores_gemma":[0.7288549,0.16828333,0.09737774,0.0025926272,0.0018619464,0.0010294489],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.4215171,0.00050080643,0.013934986,0.00011941781,0.0005058858,0.000053925654,0.0042180885,0.0025690156,0.0002983019],"category_scores_gemma":[0.16545257,0.00031830018,0.0057893507,0.00028227267,0.023804957,0.00030375778,0.0012820509,0.006659521,0.00003884461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030935616,0.0029187805,0.70893985,0.00023582026,0.003139402,0.000010033833,0.0016537996,0.00006620664,8.6312986e-7,0.037322573,0.021173153,0.22144595],"study_design_scores_gemma":[0.015151093,0.007828821,0.851106,0.0004102793,0.0005798867,0.000104763094,0.00396907,0.0022937753,0.0000019038882,0.031158991,0.087090075,0.00030534095],"about_ca_topic_score_codex":0.001327141,"about_ca_topic_score_gemma":0.00064863294,"teacher_disagreement_score":0.25606456,"about_ca_system_score_codex":0.00020764688,"about_ca_system_score_gemma":0.006320071,"threshold_uncertainty_score":0.9999269},"labels":[],"label_agreement":null},{"id":"W4238211179","doi":"10.1200/jco.2002.20.2.413","title":"Accuracy of Recorded Tumor, Node, and Metastasis Stage in a Comprehensive Cancer Center","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Stage (stratigraphy); Audit; Malignancy; Confidence interval; Cancer; Clinical audit; Internal medicine","score_opus":0.18252850444528804,"score_gpt":0.5397532008149785,"score_spread":0.35722469636969045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238211179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97928655,0.009107759,0.00013679876,0.008119051,0.0014363661,0.00017661155,0.0000122373485,0.0000037528555,0.0017208714],"genre_scores_gemma":[0.8894103,0.0701783,0.024934728,0.013783354,0.0010347489,0.0000061028363,9.508987e-7,0.000022003609,0.0006294803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972502,0.00041546533,0.0018502807,0.00014738896,0.00015977577,0.00017688457],"domain_scores_gemma":[0.99375117,0.0039047615,0.0017650526,0.00013071483,0.00027351567,0.00017480392],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009091917,0.000110390785,0.0016259009,0.00014191668,0.000018864135,0.0000017027781,0.00010690428,0.000220619,0.0009389836],"category_scores_gemma":[0.0018779306,0.00007527459,0.00022664192,0.00013033932,0.00041849146,0.000112773705,0.000030351517,0.00090874615,0.0000027969922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005636039,0.0027310108,0.4842745,0.00008725885,0.0005515928,0.0013512122,0.00031262657,0.00004943266,0.00038624482,0.00006048972,0.0055852686,0.49897432],"study_design_scores_gemma":[0.023355393,0.009293374,0.2765133,0.0002390172,0.0002223067,0.00081274693,0.00027546656,0.00042703614,0.000110887515,0.00020651783,0.6884232,0.00012072278],"about_ca_topic_score_codex":0.000021422036,"about_ca_topic_score_gemma":0.00007173744,"teacher_disagreement_score":0.68283796,"about_ca_system_score_codex":0.000106149004,"about_ca_system_score_gemma":0.000310515,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W4238219016","doi":"10.1200/jco.2004.22.14_suppl.3104","title":"The BC Cancer Agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gefitinib; Cancer; Lung cancer; Oncology; Internal medicine; Cancer research; Epidermal growth factor receptor","score_opus":0.053792637891429566,"score_gpt":0.4935900234301468,"score_spread":0.4397973855387172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238219016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864854,0.00453986,0.00021891609,0.009076192,0.0011737437,0.00038080002,0.00000353441,0.000005777221,0.0059526362],"genre_scores_gemma":[0.9861612,0.0078853145,0.002481149,0.0018468321,0.00060355186,0.000107522916,7.7709495e-7,0.000017739412,0.0008959457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997953,0.00007802843,0.0012479752,0.00018794132,0.00024601995,0.0002870129],"domain_scores_gemma":[0.9977627,0.00055449083,0.0009432343,0.00017209939,0.00031737852,0.00025009437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005390274,0.00013468096,0.00070045097,0.000056746154,0.0000896185,0.000010390274,0.00016355001,0.00014923624,0.00009825763],"category_scores_gemma":[0.00022969849,0.000070003516,0.00018265645,0.00018896304,0.00017560727,0.00010949605,0.000023352974,0.0006410636,0.0000037175573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049515194,0.0023355873,0.68592703,0.00006736479,0.0005251642,0.0016255305,0.0061735883,0.0036426946,0.00046560337,0.0001312249,0.00075279275,0.29340187],"study_design_scores_gemma":[0.03234413,0.0074889227,0.904401,0.00087519124,0.00079784537,0.00013146142,0.0017218133,0.00007222527,0.00061981566,0.00019503575,0.05115122,0.00020134862],"about_ca_topic_score_codex":0.0006678367,"about_ca_topic_score_gemma":0.0023887255,"teacher_disagreement_score":0.29320052,"about_ca_system_score_codex":0.0005908823,"about_ca_system_score_gemma":0.0057338667,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W4238514467","doi":"10.1200/jco.2019.37.15_suppl.e15753","title":"Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Ontario Institute for Cancer Research; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Vancouver General Hospital; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"","keywords":"Medicine; FOLFIRINOX; KRAS; Oncology; Sunitinib; Internal medicine; Pancreatic cancer; Germline mutation; PARP inhibitor; Cancer; Cancer research; Mutation; Genetics; Colorectal cancer; Gene; Biology","score_opus":0.09350536448579719,"score_gpt":0.42970206085676715,"score_spread":0.33619669637096994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238514467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630326,0.0011754307,0.0007932047,0.0002668533,0.00087329454,0.00027506377,0.000050645947,0.0000014755494,0.00026079518],"genre_scores_gemma":[0.99243945,0.0020917964,0.0044991793,0.0003018365,0.0004217406,0.000004337275,0.000053421893,0.0000146983075,0.00017356407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945313,0.0005492909,0.0041669696,0.00029183546,0.00027842633,0.00018223195],"domain_scores_gemma":[0.9924248,0.0012724964,0.0046835714,0.00037072226,0.0010625811,0.00018586755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024868094,0.00014720771,0.0019817164,0.00019158622,0.000024558114,0.0000068765107,0.00024745901,0.00030239747,0.00014189607],"category_scores_gemma":[0.0023775962,0.00012266205,0.0011098712,0.0002640385,0.00025291514,0.0000110016235,0.0000885892,0.0003449573,0.0000069962302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030487513,0.0017558784,0.8517226,0.00010788889,0.007833926,0.00004130755,0.000057911428,0.0056526475,0.123502426,0.0003117656,0.0022944747,0.0036704117],"study_design_scores_gemma":[0.002928655,0.008841671,0.9724605,0.000025574778,0.0038353843,0.000042345768,0.0002513469,0.0008398708,0.0017299514,0.00029782884,0.008591482,0.00015540764],"about_ca_topic_score_codex":0.000049153918,"about_ca_topic_score_gemma":0.00003052869,"teacher_disagreement_score":0.121772476,"about_ca_system_score_codex":0.00004352566,"about_ca_system_score_gemma":0.0016566702,"threshold_uncertainty_score":0.50020134},"labels":[],"label_agreement":null},{"id":"W4238629480","doi":"10.1200/jco.2020.38.6_suppl.467","title":"Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Checklist; Randomized controlled trial; Quality of life (healthcare); Clinical trial; Physical therapy; Internal medicine; Nursing","score_opus":0.41663105511740783,"score_gpt":0.5600466688396258,"score_spread":0.143415613722218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238629480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853669,0.0031312443,0.0009787127,0.0069953236,0.00069240533,0.0023737021,0.000041289233,0.000007707463,0.00041275308],"genre_scores_gemma":[0.9959872,0.00028606426,0.0020845756,0.0012224715,0.00033926553,0.000030230518,0.0000046060554,0.000021676111,0.00002396068],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9164406,0.02274226,0.059172977,0.0003461064,0.0009610908,0.00033695984],"domain_scores_gemma":[0.8303115,0.0506351,0.116543375,0.00038653502,0.0013799592,0.00074354257],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14296465,0.00026441045,0.030507594,0.00021924745,0.000026891028,0.0000038629623,0.00019016204,0.00032320057,0.0002648164],"category_scores_gemma":[0.423262,0.0001633047,0.0039403513,0.00029680738,0.00042969378,0.0000923077,0.000053472326,0.0009344075,8.5018667e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93333375,0.0044497126,0.023438687,0.0007867679,0.0043658717,0.00012862479,0.0011492665,0.00002993179,0.006097784,0.00014109258,0.00008101527,0.025997473],"study_design_scores_gemma":[0.9634284,0.012358457,0.018281879,0.00025551766,0.0027290378,0.000028183049,0.0006613911,0.0004406718,0.0012656222,0.0004024201,0.000029175864,0.0001192505],"about_ca_topic_score_codex":0.0034117985,"about_ca_topic_score_gemma":0.00007529682,"teacher_disagreement_score":0.28029734,"about_ca_system_score_codex":0.00013388753,"about_ca_system_score_gemma":0.009213634,"threshold_uncertainty_score":0.9964032},"labels":[],"label_agreement":null},{"id":"W4238736514","doi":"10.1200/jco.2004.22.14_suppl.7557","title":"Malignant melanoma in the first three decades of life: A report from the U.S. Surveillance, Epidemiology and End Results (SEER) Program","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Surveillance, Epidemiology, and End Results; Medicine; Epidemiology; Melanoma; Demography; Gerontology; Oncology; Internal medicine; Cancer registry; Cancer research","score_opus":0.12191645807443025,"score_gpt":0.43238221790683407,"score_spread":0.3104657598324038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238736514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8977434,0.0011204032,0.00011537155,0.0976002,0.00074189994,0.0004985115,0.0000057866278,0.000008942787,0.002165452],"genre_scores_gemma":[0.9910126,0.0011806613,0.0024188221,0.004544582,0.00078554306,0.000010799268,0.0000037387297,0.000008283299,0.0000349922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953417,0.00064357894,0.00331177,0.00022552659,0.00025660623,0.00022079155],"domain_scores_gemma":[0.9880329,0.008941001,0.0023448335,0.00035669844,0.00016275053,0.00016186705],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01245241,0.00012241794,0.0013069499,0.0000760766,0.000048677564,0.0000066006523,0.00022971105,0.0002854158,0.000022015916],"category_scores_gemma":[0.01930138,0.000057614336,0.00028296508,0.00016745766,0.00044253084,0.000029062105,0.000074638,0.0008066252,0.0000032344844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008068453,0.0016433933,0.83337176,0.00002842161,0.00049099105,0.0053618858,0.00035447904,0.00005899468,0.000013507039,0.0005298021,0.006759989,0.14331831],"study_design_scores_gemma":[0.0050566397,0.005596843,0.7697215,0.00006828817,0.00010339291,0.0030029058,0.0002076309,0.000026184496,0.0000038217677,0.0020774584,0.2140878,0.000047545946],"about_ca_topic_score_codex":0.0004888475,"about_ca_topic_score_gemma":0.0074785724,"teacher_disagreement_score":0.20732781,"about_ca_system_score_codex":0.000060306873,"about_ca_system_score_gemma":0.0005217162,"threshold_uncertainty_score":0.9889595},"labels":[],"label_agreement":null},{"id":"W4238819712","doi":"10.1200/jco.2006.07.1878","title":"In Reply","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine","score_opus":0.13256440254581456,"score_gpt":0.5020184274082791,"score_spread":0.3694540248624645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238819712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9423785,0.000997035,0.000006919571,0.040627863,0.0006659658,0.00006331807,2.8335802e-7,0.0000025515403,0.015257534],"genre_scores_gemma":[0.98738384,0.00027415997,0.0026197964,0.008056271,0.0012893964,0.0000016407594,4.5004444e-7,0.000005249975,0.00036917056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796194,0.00013018974,0.0015720004,0.000078936486,0.00015026228,0.000106645995],"domain_scores_gemma":[0.99778366,0.0012854261,0.0006178646,0.0000952034,0.00011139895,0.00010645949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014615349,0.00005155076,0.0007848851,0.00008297952,0.0000070021224,0.000002193345,0.000045535282,0.0001291422,0.0001624303],"category_scores_gemma":[0.001101631,0.00003277604,0.0002877392,0.00007629562,0.000052272597,0.000043270447,0.000011869983,0.000370014,0.000033979348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007749616,0.00496065,0.8745543,0.000003695573,0.00005735551,0.0064775115,0.000007829003,0.000004510854,0.000020586642,0.0005027198,0.04832704,0.06430885],"study_design_scores_gemma":[0.005263244,0.0029404396,0.694251,0.000026029264,0.00007162287,0.00048811364,0.000009851428,0.0000054471184,0.000050070514,0.0012438446,0.29562944,0.000020908092],"about_ca_topic_score_codex":0.000084988395,"about_ca_topic_score_gemma":0.000058745638,"teacher_disagreement_score":0.2473024,"about_ca_system_score_codex":0.00009821624,"about_ca_system_score_gemma":0.00044258317,"threshold_uncertainty_score":0.17784978},"labels":[],"label_agreement":null},{"id":"W4238943502","doi":"10.1200/jco.2011.29.18_suppl.lba5006","title":"Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver Coastal Health","funders":"","keywords":"Medicine; Bevacizumab; Interim analysis; Ovarian cancer; Hazard ratio; Carboplatin; Oncology; Internal medicine; Debulking; Chemotherapy; Progression-free survival; Randomized controlled trial; Stage (stratigraphy); Gynecology; Surgery; Cancer; Confidence interval; Cisplatin","score_opus":0.13469147201117654,"score_gpt":0.46080574676548364,"score_spread":0.3261142747543071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238943502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945705,0.00024527014,0.00005729709,0.002424631,0.0004867228,0.0008194478,0.000025615127,0.0000015005917,0.0013690423],"genre_scores_gemma":[0.9966166,0.0019583197,0.0007081963,0.00039614813,0.00022088675,0.00007160793,0.0000031898524,0.000010414075,0.000014626188],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99246716,0.0018167871,0.004797974,0.0002105223,0.00047764136,0.0002299196],"domain_scores_gemma":[0.98823434,0.006582408,0.004304704,0.00033912424,0.0003796745,0.0001597764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009411473,0.00017094596,0.0053397315,0.0004930085,0.000009708348,0.0000031488407,0.00026593087,0.00024502364,0.00039694345],"category_scores_gemma":[0.0027523579,0.00009096101,0.0007854634,0.0006394176,0.0004009593,0.00007498401,0.000034107867,0.0005636938,2.4583605e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92484665,0.014567418,0.019994415,0.000028525077,0.0061055184,0.00046738752,0.003946074,0.000063773325,0.000027381495,0.0002420143,0.00008169643,0.029629176],"study_design_scores_gemma":[0.8218407,0.029531166,0.143292,0.00022952507,0.0038178382,0.000007502187,0.0006411259,0.00008065671,0.0000807825,0.00018350249,0.00022968253,0.000065555956],"about_ca_topic_score_codex":0.0034819792,"about_ca_topic_score_gemma":0.0027821788,"teacher_disagreement_score":0.12329757,"about_ca_system_score_codex":0.00025793523,"about_ca_system_score_gemma":0.0017386681,"threshold_uncertainty_score":0.52637345},"labels":[],"label_agreement":null},{"id":"W4239143346","doi":"10.1200/jco.2003.01.168","title":"Sweet Time Unafflicted","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Latin American and Latino Studies","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine","score_opus":0.1379639911233161,"score_gpt":0.5051193288783582,"score_spread":0.3671553377550421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239143346","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06780887,0.00025082615,0.00024743605,0.013285112,0.0016388318,0.00007148426,4.961605e-7,0.00001986109,0.91667706],"genre_scores_gemma":[0.97637904,0.0009831052,0.010236813,0.0034718807,0.0011344403,8.446217e-7,1.2597903e-7,0.0000070974975,0.0077866353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965329,0.0016716296,0.0011840315,0.00008980068,0.0003103994,0.00021124014],"domain_scores_gemma":[0.99477845,0.0032856422,0.0012387314,0.00008631615,0.00035155306,0.0002592837],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0057471716,0.000063233485,0.00071265426,0.000044967222,0.00015094245,0.000014244476,0.00023180388,0.0001913864,0.0009402603],"category_scores_gemma":[0.017622573,0.000045474102,0.0002650522,0.00021516904,0.00055337604,0.00012912242,0.000023084061,0.00041349974,0.000102345504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030253473,0.0019825238,0.068686016,0.000006021258,0.000706032,0.00037367854,0.009447994,0.00001756064,0.000066555614,0.23293474,0.2145408,0.47093555],"study_design_scores_gemma":[0.00083220506,0.0011094477,0.017783737,0.000006246338,0.000033500903,0.0000094720535,0.0008151318,0.00000539757,0.0000036832687,0.0030027968,0.9763355,0.00006284315],"about_ca_topic_score_codex":0.00004902473,"about_ca_topic_score_gemma":0.00006067117,"teacher_disagreement_score":0.9088904,"about_ca_system_score_codex":0.000070082664,"about_ca_system_score_gemma":0.0016794145,"threshold_uncertainty_score":0.999973},"labels":[],"label_agreement":null},{"id":"W4239258335","doi":"10.1200/jco.2012.30.18_suppl.lba506","title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Neoadjuvant therapy; Exact test; Clinical endpoint; Gastroenterology; Oncology; Cancer; Gynecology; Clinical trial","score_opus":0.45636250260094796,"score_gpt":0.651772909540381,"score_spread":0.19541040693943307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239258335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94013697,0.00091584394,0.00008974701,0.012276723,0.0012081746,0.04212932,0.00004195896,0.0000070123288,0.0031942797],"genre_scores_gemma":[0.9838424,0.00048173394,0.0027831194,0.0008897895,0.0021485768,0.009691785,0.0000022954962,0.00003328781,0.00012705813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936948,0.0013379408,0.0028573277,0.000158161,0.0015871547,0.0003646521],"domain_scores_gemma":[0.99112034,0.0018459149,0.0022361148,0.0002704108,0.0040997355,0.00042748955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024644936,0.00013708453,0.0016154298,0.00013298602,0.000032825636,0.0000043454224,0.0002488505,0.0003251904,0.0016335975],"category_scores_gemma":[0.0034152688,0.000091467584,0.00048161933,0.0001625422,0.0002609333,0.00013134308,0.000045521723,0.0007153476,0.0000077601535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020236887,0.006634393,0.09463601,0.0002627431,0.00066728826,0.000008745417,0.0003462345,0.00011119784,0.005010878,0.00008480216,0.008060211,0.8639406],"study_design_scores_gemma":[0.0700965,0.05195431,0.5099943,0.0012002937,0.0008726258,0.00049257034,0.00036410222,0.0022832728,0.010746404,0.0006732101,0.35109973,0.00022263138],"about_ca_topic_score_codex":0.00033248847,"about_ca_topic_score_gemma":0.00004430386,"teacher_disagreement_score":0.863718,"about_ca_system_score_codex":0.00045304434,"about_ca_system_score_gemma":0.007840122,"threshold_uncertainty_score":0.999279},"labels":[],"label_agreement":null},{"id":"W4239552633","doi":"10.1200/jco.2004.22.14_suppl.7038","title":"Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Clinical endpoint; Neutropenia; Febrile neutropenia; Interim analysis; Lung cancer; Toxicity; Gastroenterology; Placebo; Phases of clinical research; Chemotherapy; Surgery; Oncology; Randomized controlled trial; Cisplatin; Pathology","score_opus":0.04040965542454393,"score_gpt":0.429095674913167,"score_spread":0.3886860194886231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239552633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953039,0.0005601522,0.00033324325,0.0018259445,0.00011418408,0.0014849752,0.000005287698,0.0000070612955,0.00036522988],"genre_scores_gemma":[0.9966743,0.00030652102,0.0022450595,0.00035214753,0.00017019453,0.000063835825,0.000004696152,0.000021026744,0.00016222624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99459857,0.00074228225,0.0035971033,0.00031816927,0.00047846895,0.0002653826],"domain_scores_gemma":[0.9953607,0.0011275706,0.0025188064,0.00019099494,0.00048855937,0.000313406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048028803,0.00024366895,0.0032185214,0.000591563,0.00004308487,0.000009036598,0.000105856285,0.00029315104,0.0000966718],"category_scores_gemma":[0.0014086482,0.00017120579,0.00038569735,0.000531242,0.00022474445,0.00018381786,0.000055914483,0.0010569054,6.38914e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79740465,0.08724327,0.04764573,0.00051138666,0.0016885464,0.0045414744,0.006538179,0.0032028893,0.030015456,0.00007784983,0.00015790555,0.020972678],"study_design_scores_gemma":[0.95544606,0.026338318,0.0086948015,0.0015660672,0.0011915795,0.0000615979,0.0023232333,0.0013463184,0.0026092427,0.00015675164,0.000052781423,0.00021325624],"about_ca_topic_score_codex":0.0007196205,"about_ca_topic_score_gemma":0.0025922589,"teacher_disagreement_score":0.15804142,"about_ca_system_score_codex":0.00029312822,"about_ca_system_score_gemma":0.0013008448,"threshold_uncertainty_score":0.69815695},"labels":[],"label_agreement":null},{"id":"W4239610241","doi":"10.1200/jco.2011.29.7_suppl.318","title":"Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Sorafenib; Internal medicine; Population; Bevacizumab; Targeted therapy; Oncology; Surgery; Cancer; Chemotherapy","score_opus":0.16192317985578475,"score_gpt":0.41148315879596215,"score_spread":0.2495599789401774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239610241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561375,0.0012094667,0.00005845054,0.00095344195,0.00036563844,0.0007838104,0.0000038244993,0.0000026621578,0.0010089336],"genre_scores_gemma":[0.9900589,0.0000970461,0.008988002,0.0005789328,0.00020053599,0.000015827918,0.0000073053056,0.000015426178,0.000038002607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959466,0.00077517604,0.0025479412,0.00015783805,0.0003682171,0.00020424381],"domain_scores_gemma":[0.994333,0.0030171045,0.0019102182,0.000246254,0.00033664439,0.00015675096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026126304,0.0001434396,0.0011886633,0.00015522334,0.000025468928,0.0000031386305,0.00019238156,0.00012516658,0.00008996928],"category_scores_gemma":[0.00090325146,0.00007578328,0.000667038,0.00014865123,0.00010059973,0.00005834597,0.000016011814,0.00048283266,0.0000028298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05897501,0.027596837,0.4647668,0.00015241078,0.0008535827,0.0018293608,0.0086969165,0.000099239405,0.0015926565,0.000277445,0.0060870945,0.42907265],"study_design_scores_gemma":[0.017872492,0.05193563,0.9230694,0.000034358705,0.0003905871,0.00012773054,0.0004138066,0.0000385545,0.003042143,0.0006654343,0.0023367186,0.00007312965],"about_ca_topic_score_codex":0.00014579725,"about_ca_topic_score_gemma":0.000031879612,"teacher_disagreement_score":0.45830262,"about_ca_system_score_codex":0.000095028576,"about_ca_system_score_gemma":0.0005552079,"threshold_uncertainty_score":0.30903527},"labels":[],"label_agreement":null},{"id":"W4239833656","doi":"10.1200/jco.2005.05.358","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine","score_opus":0.13630581783009843,"score_gpt":0.5103470335757675,"score_spread":0.37404121574566906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239833656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8494066,0.00028367658,0.00008462612,0.114111744,0.0008195947,0.000079546706,8.664511e-8,0.000004883946,0.035209224],"genre_scores_gemma":[0.9302607,0.0007832604,0.010404823,0.05032572,0.0036736338,6.977582e-7,2.5165906e-7,0.000006919925,0.0045439745],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979491,0.00016402389,0.0015223558,0.000076972916,0.00016603453,0.00012149783],"domain_scores_gemma":[0.9981973,0.00083850283,0.0006057915,0.000113006754,0.00009065796,0.00015472271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004169126,0.00004878075,0.00068159803,0.00012610285,0.0000071368017,0.0000024068484,0.00009015365,0.00013072598,0.00033691837],"category_scores_gemma":[0.003678405,0.00003413971,0.00022083553,0.00009308354,0.00005506685,0.000095056006,0.00002549325,0.0006193781,0.00008740364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023336082,0.001989081,0.4621606,0.000016544385,0.0001227774,0.0017550315,0.00009720873,0.000023977826,0.00005736409,0.0006065033,0.23533042,0.29550692],"study_design_scores_gemma":[0.003514219,0.0016741892,0.3583066,0.000022218075,0.000043783566,0.000024378738,0.000023474593,0.00011143566,0.000010104895,0.00028917004,0.63595766,0.000022768627],"about_ca_topic_score_codex":0.0000036323986,"about_ca_topic_score_gemma":0.000019651283,"teacher_disagreement_score":0.40062726,"about_ca_system_score_codex":0.00007725281,"about_ca_system_score_gemma":0.00034866564,"threshold_uncertainty_score":0.440366},"labels":[],"label_agreement":null},{"id":"W4239969231","doi":"10.1200/jco.2017.35.4_suppl.189","title":"Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cancer; Proportional hazards model; Gastroesophageal Junction; Hazard ratio; Radiation therapy; Logistic regression; Gastroenterology; Chemotherapy; Esophageal cancer; Surgery; Adenocarcinoma; Confidence interval","score_opus":0.092427492409345,"score_gpt":0.46241804466682823,"score_spread":0.36999055225748323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239969231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974789,0.00020774128,0.00022648096,0.021336678,0.0027095927,0.00047671548,0.000032157284,0.00000758836,0.00021399505],"genre_scores_gemma":[0.99019444,0.0007543264,0.0024840934,0.004442922,0.001326678,0.000031694202,0.0000040446234,0.00001871608,0.00074309815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978143,0.00010249563,0.0011140311,0.00021812283,0.00045619314,0.0002948825],"domain_scores_gemma":[0.99579674,0.0010730539,0.002163554,0.00037872995,0.00034934116,0.00023855455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006743472,0.00015306698,0.0011503067,0.000033576354,0.0001429235,0.000043694115,0.0005643205,0.0001285612,0.00028582083],"category_scores_gemma":[0.0013900908,0.000079753,0.00035717667,0.000041218012,0.0003492472,0.00016223536,0.000118372875,0.0004278363,0.0000026780258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035570762,0.00030457138,0.88456386,0.000010406123,0.0004072676,0.00008104015,0.00018560108,0.000008231178,4.6683115e-7,0.000017906532,0.008444157,0.10241942],"study_design_scores_gemma":[0.014231234,0.0017017442,0.86920357,0.00009656471,0.0004479592,0.0000021582346,0.00015444715,0.000031834734,0.0000044810936,0.00004534607,0.114015624,0.00006502399],"about_ca_topic_score_codex":0.0007210364,"about_ca_topic_score_gemma":0.0010598003,"teacher_disagreement_score":0.10557147,"about_ca_system_score_codex":0.00016599939,"about_ca_system_score_gemma":0.00060054497,"threshold_uncertainty_score":0.3252233},"labels":[],"label_agreement":null},{"id":"W4240003524","doi":"10.1200/jco.2007.25.18_suppl.7553","title":"A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Cisplatin; Hazard ratio; Chemotherapy; Internal medicine; Toxicity; Lung cancer; Radiation therapy; Oncology; Stage (stratigraphy); Proportional hazards model; Adjuvant; Cancer; Survival analysis; Surgery; Confidence interval","score_opus":0.057900440621363854,"score_gpt":0.45773612415526005,"score_spread":0.3998356835338962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240003524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444366,0.00044301964,0.0005264886,0.002563304,0.00052325166,0.00080821617,0.000027420747,0.0000032782564,0.00066134194],"genre_scores_gemma":[0.9967204,0.00015369538,0.0010091137,0.001688222,0.00032488818,0.00001938031,0.0000053561585,0.000018693161,0.000060285565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681026,0.00031027128,0.0020768698,0.00019156402,0.00038075662,0.00023030366],"domain_scores_gemma":[0.98680866,0.009710965,0.0025675443,0.00030280594,0.00042445044,0.00018558957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034028373,0.00016616988,0.002397156,0.0002451419,0.00003213078,0.000002821599,0.00019632532,0.0002567891,0.0000964158],"category_scores_gemma":[0.00085696526,0.00008648554,0.0016867956,0.00047053592,0.0001444075,0.000013050272,0.000017029332,0.0004351181,3.597574e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039875258,0.0032601492,0.88257563,0.00038528396,0.010055028,0.00014758758,0.00014986415,0.0011676681,0.004274864,0.000009931979,0.002916873,0.055181883],"study_design_scores_gemma":[0.031325147,0.031880166,0.8833092,0.0005251132,0.01505832,0.0000029956377,0.000012976054,0.0023057847,0.03417424,0.000006060041,0.0013230563,0.00007695059],"about_ca_topic_score_codex":0.00013753308,"about_ca_topic_score_gemma":0.000599402,"teacher_disagreement_score":0.055104934,"about_ca_system_score_codex":0.00036005815,"about_ca_system_score_gemma":0.000843925,"threshold_uncertainty_score":0.3526778},"labels":[],"label_agreement":null},{"id":"W4240080893","doi":"10.1200/jco.2012.30.18_suppl.lba10008","title":"Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Hazard ratio; GiST; Randomization; Randomized controlled trial; Placebo; Gastroenterology; Surgery; Confidence interval; Cancer; Colorectal cancer; Pathology; Stromal cell","score_opus":0.13901288792292557,"score_gpt":0.4586018462701245,"score_spread":0.3195889583471989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240080893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951425,0.00025562634,0.000087696506,0.00048220583,0.00012965115,0.0037183037,0.000018748533,0.000009297709,0.0001559696],"genre_scores_gemma":[0.96098804,0.0000630573,0.0382336,0.000039612034,0.00040652056,0.000093380564,0.0000175651,0.000034833178,0.00012339633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935546,0.0016554948,0.0029855915,0.0003205225,0.0007777635,0.000706047],"domain_scores_gemma":[0.99013036,0.0049493625,0.0030892685,0.00022158367,0.00055875804,0.0010506359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049332385,0.0003801943,0.0037071735,0.0003008073,0.00009974566,0.000032468768,0.000104996376,0.000060959224,0.000078870566],"category_scores_gemma":[0.0055023152,0.00018898993,0.00030968315,0.0002205242,0.0010699612,0.00027481094,0.000076683464,0.0006572316,0.0000015254368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87460387,0.020713959,0.08508722,0.00009984039,0.00053846644,0.0022231906,0.00011858643,0.0000018692576,0.000032239444,0.000010732333,0.000020841639,0.016549174],"study_design_scores_gemma":[0.6924725,0.29185045,0.008482879,0.0008264293,0.001086145,0.0047433157,0.00018675289,0.00008397222,0.00006562194,0.0000069073917,0.00009469498,0.000100346275],"about_ca_topic_score_codex":0.00007255264,"about_ca_topic_score_gemma":0.00009479978,"teacher_disagreement_score":0.2711365,"about_ca_system_score_codex":0.00035625507,"about_ca_system_score_gemma":0.0017904737,"threshold_uncertainty_score":0.7706786},"labels":[],"label_agreement":null},{"id":"W4240141907","doi":"10.1200/jco.2004.22.14_suppl.3103","title":"Antisense inhibition of methylenetetrahydrofolate reductase (MTHFR) reduces survival of cancer cells in vitro and in vivo","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Methylenetetrahydrofolate reductase; Medicine; In vivo; In vitro; Cancer research; Cancer; Pharmacology; Internal medicine; Genetics; Biology; Gene; Genotype","score_opus":0.04126772261798149,"score_gpt":0.3995135300591283,"score_spread":0.3582458074411468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240141907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951873,0.003605097,0.000019416446,0.00045455617,0.00050210446,0.00009094892,0.00005590787,7.3813186e-7,0.000083925304],"genre_scores_gemma":[0.98784596,0.010195286,0.0015058252,0.00011373448,0.0003132283,0.0000017709009,0.0000049958107,0.00000909064,0.0000101328715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976451,0.0003259298,0.0015510167,0.00018487104,0.00014121,0.0001518878],"domain_scores_gemma":[0.9984776,0.00013421825,0.0009275345,0.000113315895,0.00020000672,0.00014732448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012664272,0.000102466154,0.00066979375,0.00013451437,0.000010073373,0.0000027573221,0.00008494565,0.0002949181,0.000010296714],"category_scores_gemma":[0.00049966894,0.0000940895,0.00017543945,0.00010748778,0.0002736049,0.000008130826,0.000040846568,0.0002113419,1.5445073e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036959432,0.001017003,0.0051084873,0.000042360945,0.00004780648,0.00006304284,0.000045665514,0.000337435,0.9864044,0.0000063294187,0.00009475106,0.0031367715],"study_design_scores_gemma":[0.0060840696,0.0017129884,0.015638571,0.00008476592,0.00005626754,0.000013148338,0.00011217715,0.000006611024,0.97486335,0.0007526439,0.0005843466,0.00009103948],"about_ca_topic_score_codex":0.00010665603,"about_ca_topic_score_gemma":0.0002491274,"teacher_disagreement_score":0.011541033,"about_ca_system_score_codex":0.0000280988,"about_ca_system_score_gemma":0.000710398,"threshold_uncertainty_score":0.38368583},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4240203552","doi":"10.1200/jco.2007.25.18_suppl.6515","title":"Evolution of the randomized controlled trial (RCT) in oncology over three decades","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Internal medicine; Hazard ratio; Sample size determination; Oncology; Breast cancer; Lung cancer; Cancer; Confidence interval","score_opus":0.7350757916366921,"score_gpt":0.6509098452543743,"score_spread":0.08416594638231778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240203552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955269,0.0015873109,0.014330546,0.003820294,0.005953018,0.0026977258,8.476001e-7,9.011828e-7,0.016340379],"genre_scores_gemma":[0.9949404,0.000097292905,0.0024347682,0.00062002445,0.0010221392,0.000016063037,7.92908e-8,0.0000058244086,0.00086340844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.7316197,0.13347165,0.12448744,0.0008357237,0.008968429,0.00061705563],"domain_scores_gemma":[0.45003104,0.43546414,0.1077854,0.0022154788,0.0040838383,0.00042009613],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.69813204,0.00020774642,0.023246761,0.00057450595,0.000049483566,0.00004447024,0.001972103,0.0006461971,0.0024618828],"category_scores_gemma":[0.59603935,0.000068571346,0.011888389,0.0009870649,0.0005560731,0.00015939277,0.00014024788,0.0010473962,0.00007772545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9114302,0.0010949415,0.03238688,0.0000054564753,0.00088723825,0.00003389635,0.00010945434,0.00011383835,0.000024637327,0.0055044577,0.0073513454,0.041057702],"study_design_scores_gemma":[0.8616165,0.0018154022,0.06009092,0.00003386153,0.0010553848,0.000032080778,0.0001833561,0.001388243,0.0000028526006,0.036819033,0.03689179,0.00007058754],"about_ca_topic_score_codex":0.000026004991,"about_ca_topic_score_gemma":0.0011031542,"teacher_disagreement_score":0.30199248,"about_ca_system_score_codex":0.00024864185,"about_ca_system_score_gemma":0.002085677,"threshold_uncertainty_score":0.99845},"labels":[],"label_agreement":null},{"id":"W4240203605","doi":"10.1200/jco.2011.29.4_suppl.511","title":"Associations between county-level surgeon density and colorectal cancer (CRC) mortality.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Demography; Incidence (geometry); Socioeconomic status; Mortality rate; Population; Cancer; Gerontology; Demographics; Internal medicine; Environmental health","score_opus":0.3425276109720428,"score_gpt":0.4770876392922603,"score_spread":0.13456002832021746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240203605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991919,0.0002558268,0.000058835667,0.0014489407,0.0010976397,0.00012353217,0.000085921434,0.000008115312,0.005002178],"genre_scores_gemma":[0.9942378,0.001082492,0.0011184082,0.0022511624,0.0011272529,0.0000018035842,0.000010679496,0.000011129523,0.0001592845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738944,0.00027827403,0.0016803656,0.00016100987,0.00028716945,0.00020377443],"domain_scores_gemma":[0.9961435,0.0014760451,0.0013920069,0.000100591,0.00048244256,0.0004054186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002959635,0.00011031684,0.001419465,0.00007487602,0.000061391656,0.0000054475295,0.00009075837,0.00038823253,0.00041181635],"category_scores_gemma":[0.0018213362,0.00008577899,0.0003013058,0.00008317235,0.00022352408,0.00013478476,0.000041626667,0.0008725362,0.000004947925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007311787,0.00027133216,0.95538175,0.000010393209,0.0007002252,0.00016986796,0.0001810373,3.151662e-7,0.00007592581,0.000040856907,0.0037013076,0.03873579],"study_design_scores_gemma":[0.003441462,0.002182412,0.9808143,0.000024460636,0.00068675674,0.000056501678,0.00004300128,0.000013735696,0.00018488613,0.00023251242,0.012236333,0.000083670835],"about_ca_topic_score_codex":0.00073257857,"about_ca_topic_score_gemma":0.0010130313,"teacher_disagreement_score":0.03865212,"about_ca_system_score_codex":0.0002692492,"about_ca_system_score_gemma":0.0024686805,"threshold_uncertainty_score":0.45091},"labels":[],"label_agreement":null},{"id":"W4240429779","doi":"10.1200/jco.2012.30.27_suppl.99","title":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Anastrozole; Hazard ratio; Aromatase inhibitor; Internal medicine; Letrozole; Breast cancer; Interim analysis; Clinical endpoint; Progression-free survival; Oncology; Population; Cancer; Randomized controlled trial; Tamoxifen; Confidence interval; Chemotherapy","score_opus":0.029476253529622694,"score_gpt":0.4068401066455917,"score_spread":0.37736385311596904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240429779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550974,0.00093786063,0.000041510746,0.0013584804,0.0013619963,0.00044456933,0.00007158739,0.0000026030802,0.00027164494],"genre_scores_gemma":[0.99691534,0.00058543804,0.00046205532,0.00055030483,0.0012656453,0.000021247832,0.000011020236,0.000018260478,0.00017069468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976334,0.00035056644,0.0013547136,0.00015266132,0.0001728053,0.00033587162],"domain_scores_gemma":[0.99695325,0.00026973375,0.0019311478,0.00023020251,0.00034787078,0.00026782483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021210597,0.00014027845,0.0007223451,0.00002968853,0.000051408257,0.0000036355925,0.0002693533,0.0004270938,0.000010789896],"category_scores_gemma":[0.0004986154,0.00007534598,0.0002264331,0.000093102935,0.00019801412,0.00001226871,0.0000617274,0.00039475603,7.90193e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7948122,0.0036051616,0.00069673837,0.000012682811,0.0011072651,0.000008701913,0.000098965706,0.00010214917,0.113558866,0.000021790433,0.006859428,0.079116054],"study_design_scores_gemma":[0.60972625,0.1367279,0.0124729825,0.00009459595,0.00073352916,0.0004767215,0.00020773405,0.000029360557,0.05875467,0.000054721862,0.18036878,0.0003527614],"about_ca_topic_score_codex":0.0000057089233,"about_ca_topic_score_gemma":0.0000045933434,"teacher_disagreement_score":0.18508595,"about_ca_system_score_codex":0.000048856073,"about_ca_system_score_gemma":0.00088176446,"threshold_uncertainty_score":0.32941386},"labels":[],"label_agreement":null},{"id":"W4240475139","doi":"10.1200/jco.2013.31.4_suppl.548","title":"Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Referral; Cancer; Colorectal cancer; Medical record; Internal medicine; Chemotherapy; Surgery; Family medicine","score_opus":0.1077443469896072,"score_gpt":0.46658183287766686,"score_spread":0.35883748588805964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240475139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718793,0.00019051309,0.00024932652,0.026116507,0.0002870953,0.0007434949,0.0000120188115,0.0000030146157,0.0005187189],"genre_scores_gemma":[0.98927796,0.00013096529,0.003968915,0.0050237216,0.00081543665,0.00007592929,0.0000037538944,0.0000131364,0.00069016434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981798,0.00007850241,0.0013255731,0.00011020271,0.00014588468,0.00016004193],"domain_scores_gemma":[0.99647623,0.0018413598,0.00076646317,0.000068533416,0.00064470374,0.00020268733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014338656,0.00007765753,0.0010253194,0.00011111374,0.000013629042,0.0000032615028,0.00009664885,0.00021662396,0.00029046152],"category_scores_gemma":[0.0022372454,0.000055196582,0.000342912,0.000107496235,0.00005043697,0.00006240321,0.00001609958,0.00023417316,0.000012589558],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03633781,0.007920647,0.1153961,0.00021735879,0.0004634373,0.000059622096,0.000514775,0.00004141934,0.01700395,0.0001509515,0.13617222,0.6857217],"study_design_scores_gemma":[0.04010229,0.053611856,0.71241736,0.0003848329,0.00033584042,0.00008964145,0.000101580474,0.0019380369,0.0018033695,0.00167513,0.18736735,0.00017272757],"about_ca_topic_score_codex":0.000054037693,"about_ca_topic_score_gemma":0.00016224154,"teacher_disagreement_score":0.68554896,"about_ca_system_score_codex":0.0001265448,"about_ca_system_score_gemma":0.0007299599,"threshold_uncertainty_score":0.318035},"labels":[],"label_agreement":null},{"id":"W4240488819","doi":"10.1200/jco.2021.39.15_suppl.4541","title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Atezolizumab; Bladder cancer; Cystectomy; Clinical endpoint; Internal medicine; Pathological; Urology; Oncology; Surgery; Clinical trial; Cancer; Immunotherapy; Nivolumab","score_opus":0.1279401219600671,"score_gpt":0.499667704120935,"score_spread":0.3717275821608679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240488819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825929,0.001439533,0.00002565089,0.007987728,0.002910618,0.00048823594,0.000037746348,0.0000060058746,0.004511601],"genre_scores_gemma":[0.98884654,0.0044216975,0.00071628037,0.0028072835,0.0021977348,0.0000239491,0.000007434876,0.00003028289,0.0009487918],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948956,0.0007336269,0.0031553651,0.00032748634,0.00052852783,0.0003593989],"domain_scores_gemma":[0.9938237,0.0025575848,0.001836957,0.0003254861,0.0010086,0.00044765323],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016348378,0.0002306476,0.0025095502,0.00021849369,0.000051377654,0.000007041895,0.00019863511,0.00052066566,0.001149038],"category_scores_gemma":[0.005302321,0.00017597318,0.0008343274,0.00037462552,0.00025318892,0.00013748588,0.000114925184,0.0011101404,0.000016618256],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45451137,0.043844085,0.008300224,0.00011060506,0.0026489561,0.011857465,0.001661476,0.000040223094,0.0069572567,0.000055210345,0.014811563,0.45520157],"study_design_scores_gemma":[0.7025648,0.17186768,0.048126407,0.0006148184,0.0018409506,0.00054148375,0.0008749842,0.000034700988,0.009930608,0.0007033357,0.06261507,0.00028520037],"about_ca_topic_score_codex":0.00022058316,"about_ca_topic_score_gemma":0.0006508267,"teacher_disagreement_score":0.4549164,"about_ca_system_score_codex":0.00036296193,"about_ca_system_score_gemma":0.013195354,"threshold_uncertainty_score":0.999764},"labels":[],"label_agreement":null},{"id":"W4240535532","doi":"10.1200/jco.2018.36.15_suppl.11562","title":"Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Doxorubicin; Adverse effect; Sarcoma; Febrile neutropenia; Anemia; Gastroenterology; Phases of clinical research; Toxicity; Oncology; Surgery; Chemotherapy; Pathology","score_opus":0.025337490249249854,"score_gpt":0.3654284547967453,"score_spread":0.34009096454749543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240535532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989519,0.000019654684,0.00017837618,0.00012293637,0.00017459408,0.00047157888,0.000002944614,0.0000016370328,0.000076378805],"genre_scores_gemma":[0.9975565,0.0000212316,0.0021184224,0.0001626748,0.000099352066,0.0000037152213,0.0000073540255,0.000020399439,0.0000103564225],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9973729,0.00036006156,0.0016121003,0.00023559807,0.00025316927,0.00016614322],"domain_scores_gemma":[0.997585,0.00018692455,0.0013772006,0.00015147205,0.00062599604,0.00007343318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089240907,0.00014796236,0.0008697316,0.00018677012,0.000019742954,0.000003979444,0.00014410904,0.00018493496,0.000012898307],"category_scores_gemma":[0.0005323099,0.000099920966,0.000052060303,0.0003201833,0.0002058811,0.000024245033,0.000044319215,0.00038116943,7.4564787e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24945404,0.08939439,0.52863026,0.00012887326,0.0006110715,0.0004077342,0.0022852984,0.00078626064,0.023645835,0.000024879559,0.00074339216,0.103887945],"study_design_scores_gemma":[0.14792636,0.48739865,0.35265473,0.00024970184,0.00015349025,0.000067078916,0.002049977,0.00045952265,0.0034212884,0.00006218169,0.005290773,0.00026626067],"about_ca_topic_score_codex":0.00006017959,"about_ca_topic_score_gemma":0.005675355,"teacher_disagreement_score":0.39800426,"about_ca_system_score_codex":0.000075705386,"about_ca_system_score_gemma":0.00038143492,"threshold_uncertainty_score":0.40746588},"labels":[],"label_agreement":null},{"id":"W4240638060","doi":"10.1200/jco.2017.35.15_suppl.5085","title":"Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): Results from a controlled registry study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Incidence (geometry); Testosterone (patch); Rectal examination; Prostate; Urology; Internal medicine; Gynecology; Gastroenterology; Cancer","score_opus":0.13079091063366136,"score_gpt":0.47033835688431624,"score_spread":0.3395474462506549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240638060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735302,0.0026758,0.000001478579,0.020378197,0.00032517518,0.00084965315,0.000012088346,0.000005035529,0.0022223943],"genre_scores_gemma":[0.99225366,0.004243132,0.0002516315,0.00030412964,0.0014292661,0.00002385765,0.000001139271,0.000015991174,0.0014771894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996925,0.00034193275,0.0017410569,0.00038462423,0.00038251228,0.0002248904],"domain_scores_gemma":[0.9953761,0.00093964126,0.0025885853,0.00039628954,0.00046933952,0.00023005268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027481762,0.00019364183,0.002404984,0.00006295192,0.0001318997,0.000025872958,0.00018740464,0.00016901207,0.000010283148],"category_scores_gemma":[0.003421293,0.00009760329,0.00013687542,0.00003812375,0.000682954,0.0001310151,0.00009385006,0.00093180506,0.0000012911172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1453915,0.0018632043,0.78450423,0.0000071323384,0.0011933176,0.0011012624,0.00079244765,0.0000012127612,0.00021628589,7.759032e-7,0.00023798204,0.06469066],"study_design_scores_gemma":[0.11511324,0.018396806,0.86429125,0.00019930789,0.00029193988,0.00010229505,0.00053260935,0.000005843491,0.00002467514,0.00005553393,0.000886171,0.00010035238],"about_ca_topic_score_codex":0.00059617264,"about_ca_topic_score_gemma":0.0024489749,"teacher_disagreement_score":0.079786986,"about_ca_system_score_codex":0.00007766286,"about_ca_system_score_gemma":0.00090034533,"threshold_uncertainty_score":0.40958545},"labels":[],"label_agreement":null},{"id":"W4240649963","doi":"10.1200/jco.2013.31.15_suppl.1018","title":"Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer: The SN FNAC study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Hôpital du Saint-Sacrement; Health Sciences Centre; Ottawa Hospital; University Health Network; London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University Health Centre; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Sentinel node; Axilla; Breast cancer; Biopsy; Axillary Dissection; Prospective cohort study; Clinical endpoint; Surgery; Cancer; Radiology; Sentinel lymph node; Clinical trial; Internal medicine","score_opus":0.03089921381056013,"score_gpt":0.3940521671524197,"score_spread":0.36315295334185954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240649963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96491075,0.0009025611,0.000031832376,0.03227821,0.00091717736,0.00041370612,0.000017663806,0.0000051595903,0.00052295486],"genre_scores_gemma":[0.9942242,0.0006287119,0.00047437387,0.0032092833,0.0012819032,0.00006250469,0.0000046127607,0.000030146566,0.00008429406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971201,0.000466332,0.001428121,0.0003517643,0.00025883233,0.00037487902],"domain_scores_gemma":[0.99786717,0.00032269844,0.0010468955,0.00029735075,0.00031601175,0.00014987015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012189233,0.00025384393,0.0009585856,0.00006448442,0.000094031195,0.000025515563,0.00040320386,0.000285183,0.000058825513],"category_scores_gemma":[0.0002721118,0.00015473351,0.0005131437,0.00016026686,0.00020204273,0.000018367857,0.00016473446,0.0005071041,0.000012922414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015866371,0.0027808435,0.93273634,0.000006490215,0.0016573742,0.0001994547,0.00036749942,0.00004086836,0.008596389,0.000006123268,0.002980957,0.049041],"study_design_scores_gemma":[0.007832938,0.0009183704,0.98737097,0.00005536319,0.00018538511,0.0003143113,0.0007595333,0.000029215329,0.00038801692,0.000067349414,0.0019007546,0.00017781007],"about_ca_topic_score_codex":0.00086777896,"about_ca_topic_score_gemma":0.00015581881,"teacher_disagreement_score":0.054634586,"about_ca_system_score_codex":0.0001256137,"about_ca_system_score_gemma":0.0005927284,"threshold_uncertainty_score":0.63098496},"labels":[],"label_agreement":null},{"id":"W4240685591","doi":"10.1200/jco.2012.30.4_suppl.103","title":"Comparison of adjuvant chemoradiation to peri-operative chemotherapy for the treatment of resected gastric and gastroesophageal junction adenocarincoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Chemotherapy; Gastroesophageal Junction; Cancer; Surgery; Adenocarcinoma; Internal medicine; Oncology","score_opus":0.1483966751148379,"score_gpt":0.5031317150333158,"score_spread":0.3547350399184779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240685591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901031,0.0015283163,0.0024302637,0.0045307446,0.00070705195,0.0005607125,0.0000025713466,0.000003034526,0.00013418852],"genre_scores_gemma":[0.9931237,0.00074325845,0.004661053,0.00029168045,0.0009694175,0.000010538205,0.0000025364498,0.000008149507,0.00018966873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824405,0.00010521583,0.0012145843,0.000085265005,0.00019755599,0.0001533575],"domain_scores_gemma":[0.99738455,0.0010681269,0.0010331229,0.00010843274,0.00024783637,0.00015792562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097383244,0.00009470611,0.0010644748,0.00014275472,0.00003063407,0.0000033920137,0.000060446488,0.00009315145,0.00004149903],"category_scores_gemma":[0.00047080728,0.0000533779,0.00024299885,0.00017676379,0.000087652385,0.000063102,0.000012649006,0.00014129016,5.791284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063407896,0.0016361335,0.64536774,0.000026117144,0.0004314875,0.0000020327564,0.0009674085,0.000038380025,0.0003937223,0.000032838754,0.0018575384,0.3429058],"study_design_scores_gemma":[0.009695165,0.033946715,0.93596166,0.000019300398,0.00059576414,0.00002031102,0.000674153,0.00031651536,0.0010686531,0.000007290805,0.017662667,0.00003182507],"about_ca_topic_score_codex":0.000017514812,"about_ca_topic_score_gemma":0.000014071546,"teacher_disagreement_score":0.34287396,"about_ca_system_score_codex":0.0001484314,"about_ca_system_score_gemma":0.00017674435,"threshold_uncertainty_score":0.21766876},"labels":[],"label_agreement":null},{"id":"W4240698369","doi":"10.1200/jco.2019.37.15_suppl.10055","title":"Incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: A population-based study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Institute for Clinical Evaluative Sciences; Kingston Health Sciences Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Cumulative incidence; Incidence (geometry); Confidence interval; Population; Cancer registry; Hazard ratio; Hearing loss; Relative risk; Cancer; Demography; Pediatrics; Audiology; Internal medicine; Environmental health","score_opus":0.08690849598037277,"score_gpt":0.4401409103578889,"score_spread":0.3532324143775161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240698369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969881,0.0005736308,0.000023021365,0.0008624662,0.0009228424,0.00037872308,0.0000026806122,0.0000097782395,0.00023875244],"genre_scores_gemma":[0.99861544,0.00017618119,0.00035092104,0.0002777424,0.00053152355,0.0000066676894,5.626604e-7,0.000015442916,0.00002552362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967579,0.00033105942,0.0019787394,0.00025495669,0.0004542725,0.0002230324],"domain_scores_gemma":[0.995323,0.0023250016,0.001548741,0.00015705639,0.00039579978,0.00025037612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029328007,0.00014839522,0.0017991075,0.00014755539,0.000059815284,0.000009236587,0.00011108522,0.00017583056,0.00003702298],"category_scores_gemma":[0.0019167872,0.000107911634,0.00020624841,0.00017503383,0.00014160681,0.00016564486,0.00008383424,0.00071732485,0.0000011119041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008660548,0.0007627663,0.9899656,0.00010728615,0.00040059816,0.00008155244,0.00052878034,0.00018871807,0.000069342044,0.0000032013238,0.000013323014,0.0070127733],"study_design_scores_gemma":[0.003947925,0.0077527063,0.98588276,0.0009826631,0.0003004541,0.0000125593415,0.00069253455,0.00017041856,0.00004281794,0.000009606156,0.00011148182,0.000094045296],"about_ca_topic_score_codex":0.0025572265,"about_ca_topic_score_gemma":0.0034600014,"teacher_disagreement_score":0.00698994,"about_ca_system_score_codex":0.0001722655,"about_ca_system_score_gemma":0.0009967377,"threshold_uncertainty_score":0.44005087},"labels":[],"label_agreement":null},{"id":"W4240735956","doi":"10.1200/jco.2015.33.15_suppl.tps1102","title":"Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-<i>BRCA</i>-associated locally advanced or metastatic breast cancer (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Veliparib; Medicine; PARP inhibitor; Carboplatin; Internal medicine; Metastatic breast cancer; Oncology; Cancer; Placebo; Chemotherapy; Phases of clinical research; BRCA mutation; Breast cancer; Olaparib; Pathology; Cisplatin; Poly ADP ribose polymerase","score_opus":0.1113354754180309,"score_gpt":0.48724063156258096,"score_spread":0.37590515614455006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240735956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867654,0.0011852719,0.00046891862,0.006263021,0.0013217104,0.0030941444,0.000040033476,0.000015126511,0.00084641017],"genre_scores_gemma":[0.99180084,0.0014766081,0.0037302468,0.0017422142,0.0006474475,0.0002383252,0.0000044614562,0.00004183153,0.0003180468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99072284,0.002764686,0.0050194813,0.0003136364,0.00080466585,0.00037471135],"domain_scores_gemma":[0.985835,0.0070684757,0.004965703,0.00022360233,0.0012501045,0.00065707776],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012585567,0.0003125624,0.006486134,0.00026705817,0.000027606951,0.000011774223,0.0001582218,0.00038060272,0.0001781983],"category_scores_gemma":[0.01119446,0.0001833689,0.0005491195,0.00033219438,0.00071425125,0.00018795973,0.000030681116,0.0011822447,0.000002472359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96197456,0.00618965,0.0014435347,0.0000404745,0.0018102851,0.00042148557,0.00034655503,0.00023597316,0.00014366573,0.000019811187,0.0006250831,0.0267489],"study_design_scores_gemma":[0.960171,0.033452738,0.0007173641,0.00066064944,0.0015294809,0.00037155024,0.0003137617,0.001187741,0.000056271896,0.00034663058,0.0010093534,0.00018347568],"about_ca_topic_score_codex":0.00030257725,"about_ca_topic_score_gemma":0.0010718118,"teacher_disagreement_score":0.027263088,"about_ca_system_score_codex":0.0004956211,"about_ca_system_score_gemma":0.006637239,"threshold_uncertainty_score":0.99899423},"labels":[],"label_agreement":null},{"id":"W4240808556","doi":"10.1200/jco.2006.06.9369","title":"In Reply","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Ontario Clinical Oncology Group; Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Medicine","score_opus":0.6801013047677668,"score_gpt":0.6074018063316424,"score_spread":0.07269949843612433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240808556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66783875,0.0021088615,0.0011287578,0.27731255,0.004636134,0.00020412848,0.000014189309,0.0000086299215,0.046747983],"genre_scores_gemma":[0.8986769,0.0002750836,0.010295217,0.08379893,0.004941491,0.000006670122,0.0000018814142,0.000020940237,0.0019829066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9818165,0.00079793634,0.016830424,0.00022543989,0.00008294313,0.000246804],"domain_scores_gemma":[0.9828674,0.0058016847,0.010831553,0.00022602464,0.00011053038,0.00016277499],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07252319,0.000090349226,0.002191079,0.0003104622,0.000029804702,0.000015157008,0.00026394328,0.00028066113,0.0005241676],"category_scores_gemma":[0.022612663,0.000096905336,0.00031930616,0.0001405879,0.00009252487,0.00040851586,0.000028960265,0.0005886408,0.0008831779],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017455434,0.0010274921,0.4255682,0.000043890643,0.000058252008,0.0000848258,0.00015804496,0.00030621496,0.0000013217417,0.13533115,0.4354702,0.0017758756],"study_design_scores_gemma":[0.0019746376,0.0006338591,0.27043387,0.000021321428,0.0000040218742,0.000032917134,0.00008060667,0.00025352978,7.726814e-7,0.08746736,0.63901126,0.000085842046],"about_ca_topic_score_codex":0.00077413325,"about_ca_topic_score_gemma":0.0003872092,"teacher_disagreement_score":0.23083809,"about_ca_system_score_codex":0.00043472688,"about_ca_system_score_gemma":0.0006785516,"threshold_uncertainty_score":0.99989474},"labels":[],"label_agreement":null},{"id":"W4240924366","doi":"10.1200/jco.2014.32.3_suppl.568","title":"Causes of urban-rural disparities in adjuvant chemotherapy (AC) for rectal cancer (RC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Logistic regression; Quartile; Demography; Internal medicine; Cancer; Colorectal cancer; Confidence interval","score_opus":0.10933204418235218,"score_gpt":0.47580950033287683,"score_spread":0.3664774561505246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240924366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846159,0.0017213046,0.00017380502,0.010388691,0.0016379086,0.00021847259,0.000012856221,0.000004595432,0.0012264617],"genre_scores_gemma":[0.9866302,0.002969837,0.0017274378,0.006418812,0.0017004772,0.000010742609,0.0000032400105,0.000017428267,0.0005218227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973688,0.00018689202,0.001916261,0.00012016148,0.00019273438,0.00021515474],"domain_scores_gemma":[0.99634725,0.0019480526,0.0011200326,0.00012769585,0.00027342237,0.00018355963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018948131,0.00011333098,0.0016718024,0.000109185545,0.000016769047,0.0000031956472,0.00013071808,0.00026654548,0.00026212705],"category_scores_gemma":[0.001830291,0.00008095851,0.00044029186,0.00006994606,0.00022186854,0.00009772855,0.000017180259,0.0005478664,0.0000010591857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014340744,0.0008839042,0.6149031,0.00019215925,0.00037463996,0.00003821493,0.000323474,0.000038432565,0.0013176574,0.0002115767,0.03589209,0.33148402],"study_design_scores_gemma":[0.02139228,0.012082575,0.69505745,0.00028189507,0.0001971614,0.0000663116,0.000179123,0.00045011405,0.0012402836,0.00039624076,0.2685246,0.00013197484],"about_ca_topic_score_codex":0.00019113734,"about_ca_topic_score_gemma":0.00042322942,"teacher_disagreement_score":0.33135203,"about_ca_system_score_codex":0.00016968886,"about_ca_system_score_gemma":0.0014550909,"threshold_uncertainty_score":0.33013922},"labels":[],"label_agreement":null},{"id":"W4240938809","doi":"10.1200/jco.2004.22.14_suppl.5053","title":"Epithelial ovarian cancer (EOC) without macroscopic residual tumour: Long-term, population-based outcomes","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epithelial ovarian cancer; Stage (stratigraphy); Radiation therapy; Incidence (geometry); Internal medicine; Chemotherapy; Population; Ovarian cancer; Oncology; Disease; Gynecology; Surgery; Cancer","score_opus":0.09649344784847107,"score_gpt":0.48111578164589974,"score_spread":0.38462233379742866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240938809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94381183,0.00040518647,0.00020915273,0.05227623,0.0026900084,0.00029505367,0.000022903281,0.000017136665,0.00027247937],"genre_scores_gemma":[0.98564684,0.00030390816,0.0053280876,0.0061198007,0.0023597728,0.000017798453,0.00001147662,0.00003025559,0.00018207886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649346,0.00022851951,0.002186893,0.00027569674,0.00050161796,0.0003137893],"domain_scores_gemma":[0.99654096,0.00087069365,0.0015363209,0.00025273152,0.0003193799,0.00047990412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012001469,0.00021792957,0.0017603283,0.00014088019,0.0000748228,0.000021179074,0.00015988656,0.00036237674,0.0004782835],"category_scores_gemma":[0.0009897898,0.00014521775,0.0005958663,0.0001206436,0.00012619713,0.0001008491,0.000028622122,0.0007427089,0.000034444445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016472318,0.0021833193,0.9682707,0.00003301669,0.0005661675,0.0011403448,0.000033195505,0.0002659213,0.000051154326,0.00015471944,0.00029083915,0.025363376],"study_design_scores_gemma":[0.02656056,0.005355563,0.9645245,0.00032602914,0.00092906377,0.000103960396,0.000007759963,0.0000056353647,0.00035567372,0.00035247378,0.0013527826,0.00012599297],"about_ca_topic_score_codex":0.0006692632,"about_ca_topic_score_gemma":0.0011101923,"teacher_disagreement_score":0.04615643,"about_ca_system_score_codex":0.0007157301,"about_ca_system_score_gemma":0.0038990113,"threshold_uncertainty_score":0.69166785},"labels":[],"label_agreement":null},{"id":"W4241484909","doi":"10.1200/jco.2004.22.14_suppl.6145","title":"Venous thrombosis in breast cancer patients receiving tamoxifen and/or chemotherapy: A systematic review","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Chemotherapy; Venous thrombosis; Oncology; Cancer; Internal medicine; Venous thromboembolism; Thrombosis","score_opus":0.18865759497152587,"score_gpt":0.5531279521266581,"score_spread":0.3644703571551322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241484909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002477073,0.9933073,4.1483594e-7,0.0028472636,0.0011997999,0.0021527219,0.00002216362,0.0000071629897,0.00021549696],"genre_scores_gemma":[0.00014174762,0.9946931,0.0001184327,0.0039368956,0.0007761052,0.00013147283,0.0000068609984,0.000051301864,0.00014406406],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9927147,0.0010958958,0.005260037,0.00030847886,0.00032155265,0.00029931113],"domain_scores_gemma":[0.99153143,0.0022643155,0.0053568585,0.00020866322,0.00029332258,0.00034538502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026566682,0.00038867502,0.012829104,0.00022878188,0.000025841937,0.000007792632,0.00022187272,0.000744786,0.0004261329],"category_scores_gemma":[0.0010965064,0.00021526501,0.0012031541,0.00034445635,0.00013077255,0.00007286166,0.000052927797,0.0015110252,0.000014299849],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041008522,0.0038197886,0.00071462436,0.5924372,0.0017577215,0.00030628836,0.000056316298,5.9432583e-8,4.0476692e-8,7.762963e-7,0.0013520094,0.3991451],"study_design_scores_gemma":[0.007147146,0.007544656,0.0028626958,0.8150718,0.019413702,0.0013328015,0.0000040747586,3.1211326e-7,2.913296e-8,0.000012490217,0.14641927,0.00019102899],"about_ca_topic_score_codex":0.000053032174,"about_ca_topic_score_gemma":0.000046762965,"teacher_disagreement_score":0.39895406,"about_ca_system_score_codex":0.0013507194,"about_ca_system_score_gemma":0.005676363,"threshold_uncertainty_score":0.99996054},"labels":[],"label_agreement":null},{"id":"W4241615461","doi":"10.1200/jco.2018.36.15_suppl.e18608","title":"Physician-reported reasons for non-enrollment of older adults in cancer clinical trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Logistic regression; Cancer; Wilcoxon signed-rank test; Continuous variable; Internal medicine; Medical diagnosis; Exact test; Systemic therapy; Comorbidity; Disease; Mann–Whitney U test; Breast cancer; Pathology","score_opus":0.2229261227544487,"score_gpt":0.6306611230348259,"score_spread":0.40773500028037724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241615461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671061,0.0012999338,0.0043552243,0.012422691,0.011469437,0.0011685325,0.000014946314,0.000008582658,0.0021545643],"genre_scores_gemma":[0.9445958,0.005777832,0.02295405,0.0101777725,0.015965907,0.000038017213,0.0000035327532,0.00003119836,0.00045586273],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9911085,0.0011779944,0.006874424,0.00028357425,0.0002717112,0.00028379445],"domain_scores_gemma":[0.9779439,0.013875639,0.006567345,0.00028027702,0.0010218398,0.0003110255],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020324701,0.00016181746,0.003898806,0.0001421249,0.000035962436,0.0000018907879,0.00020343601,0.00085055706,0.00019334268],"category_scores_gemma":[0.019243808,0.0001058556,0.0011811883,0.00019021808,0.0008736716,0.000089329165,0.000028161447,0.001103084,0.000004196254],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054329116,0.0077659627,0.15724704,0.00006179644,0.0012903883,0.00021758476,0.0002555292,0.0000082130555,0.00016677474,0.00007190321,0.027134068,0.7514516],"study_design_scores_gemma":[0.07771966,0.057620037,0.6265796,0.0010803019,0.0011059326,0.0001544539,0.00025929566,0.0006630596,0.00032596054,0.00096078194,0.23333853,0.00019240486],"about_ca_topic_score_codex":0.000016465576,"about_ca_topic_score_gemma":0.00011417706,"teacher_disagreement_score":0.7512592,"about_ca_system_score_codex":0.00018482904,"about_ca_system_score_gemma":0.0028696838,"threshold_uncertainty_score":0.9890175},"labels":[],"label_agreement":null},{"id":"W4241619766","doi":"10.1200/jco.2004.22.90140.2512","title":"Re-importation of pharmaceuticals may be unsafe: Lessons learned from the RADAR assessment of erythropoietin (EPO)-associated pure red cell aplasia (PRCA)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Erythropoietin; Pure red cell aplasia; Adverse effect; Incidence (geometry); Anemia; Darbepoetin alfa; Epoetin alfa; Internal medicine; Pharmacovigilance; Pediatrics","score_opus":0.2513401943261482,"score_gpt":0.5258195532516994,"score_spread":0.2744793589255512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241619766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.729158,0.002392982,0.0014816643,0.25791755,0.0034740437,0.00054211594,0.00022110975,0.000021255017,0.004791259],"genre_scores_gemma":[0.98523444,0.0022837291,0.009680208,0.0023572787,0.00016613351,0.0000027302997,0.000026661353,0.000017428603,0.00023140069],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99248135,0.0031194375,0.003548667,0.00029067404,0.00021583299,0.00034402654],"domain_scores_gemma":[0.98701215,0.007681478,0.004332166,0.00030667667,0.000557713,0.00010981981],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0079712225,0.00021584528,0.0018261708,0.000078219186,0.00009769694,0.000007653197,0.0005363411,0.0012520313,0.0009968245],"category_scores_gemma":[0.004525372,0.00013304553,0.00077373255,0.00026358585,0.001073419,0.00007487697,0.0001090776,0.0020160084,0.000005452925],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013381918,0.024779161,0.1332226,0.0001507334,0.009422471,0.00039724036,0.0011676515,0.00024979553,0.5677622,0.00984125,0.074723564,0.1649014],"study_design_scores_gemma":[0.03992554,0.01914144,0.44268656,0.0004204936,0.004624504,0.00007319672,0.0030446977,0.000050415718,0.15921776,0.023387995,0.30678725,0.000640121],"about_ca_topic_score_codex":0.00006751109,"about_ca_topic_score_gemma":0.0001119877,"teacher_disagreement_score":0.40854445,"about_ca_system_score_codex":0.00013506856,"about_ca_system_score_gemma":0.0014303576,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W4241696790","doi":"10.1200/jco.2019.37.7_suppl.509","title":"Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"CDKN2A; Copy number analysis; Transcriptome; Genetics; Exon; Copy-number variation; Gene; Biology; BAP1; Cancer research; Medicine; Genome; Gene expression","score_opus":0.089101991097599,"score_gpt":0.42876174340638024,"score_spread":0.3396597523087812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241696790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943123,0.0010587835,0.00041565794,0.0024229519,0.00030613996,0.00015457407,0.000011242887,0.0000041715616,0.0013141712],"genre_scores_gemma":[0.9961608,0.00005546081,0.0021087746,0.0007805238,0.00024961136,9.614519e-7,0.000005364602,0.0000109448465,0.0006275492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996551,0.00030803104,0.0023657023,0.00018877408,0.000369447,0.00021705445],"domain_scores_gemma":[0.99672955,0.001172555,0.001133772,0.0001968766,0.00030980972,0.00045743765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019852037,0.00013172616,0.0023601819,0.00031606018,0.000016560318,0.000004465672,0.00013296286,0.00017681785,0.0007238967],"category_scores_gemma":[0.0006427967,0.00008763508,0.0008561032,0.00041458828,0.0002476092,0.000081323546,0.000030833136,0.00069807033,0.000031664436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012890132,0.004083725,0.91914725,0.000397189,0.010256133,0.013563472,0.0009135041,0.00025819693,0.008205387,0.0009671964,0.00052473386,0.028793063],"study_design_scores_gemma":[0.0066592945,0.010355406,0.9674918,0.000030286628,0.005643387,0.0028204664,0.00019811177,0.00043168565,0.000085151194,0.00028382702,0.005903417,0.00009717884],"about_ca_topic_score_codex":0.000015552767,"about_ca_topic_score_gemma":0.000011089241,"teacher_disagreement_score":0.048344523,"about_ca_system_score_codex":0.00003747092,"about_ca_system_score_gemma":0.00067353906,"threshold_uncertainty_score":0.7926161},"labels":[],"label_agreement":null},{"id":"W4241701342","doi":"10.1200/jco.2018.36.4_suppl.122","title":"Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Esophageal cancer; Hazard ratio; Cancer; Adenocarcinoma; Proportional hazards model; Internal medicine; Radiation therapy; Confidence interval; Gastroenterology; Surgery; Oncology","score_opus":0.31973518995837774,"score_gpt":0.581728887716018,"score_spread":0.2619936977576403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241701342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812737,0.0055549745,0.00059502927,0.007897268,0.0035831276,0.0008622133,0.00011418657,0.000012637901,0.00010683505],"genre_scores_gemma":[0.99105144,0.0022200076,0.0012482876,0.000830539,0.0044335644,0.00007104629,0.000010722976,0.000019936424,0.00011445325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955527,0.0007152163,0.0021692198,0.00035580838,0.0007666075,0.0004404253],"domain_scores_gemma":[0.9921036,0.0038487695,0.0020306616,0.0003688126,0.001180956,0.0004672243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021552409,0.00022165137,0.001682854,0.000054199958,0.00015313592,0.000016891881,0.00040744085,0.00027975102,0.001199639],"category_scores_gemma":[0.0017553355,0.00011632996,0.00055697624,0.0002214976,0.0008727682,0.00014837353,0.00007018942,0.0007362711,0.0000037352668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13315812,0.0022716252,0.71962667,0.00002695085,0.00093776267,0.000078349374,0.0008762985,0.000009338411,0.00006937959,0.00006349025,0.0042381035,0.1386439],"study_design_scores_gemma":[0.03428035,0.03452675,0.9103399,0.00012292946,0.00043942276,0.000010028782,0.00075333624,0.00029663809,0.005938057,0.00019159874,0.01299599,0.00010499439],"about_ca_topic_score_codex":0.0024524743,"about_ca_topic_score_gemma":0.002994387,"teacher_disagreement_score":0.19071323,"about_ca_system_score_codex":0.0005815576,"about_ca_system_score_gemma":0.0046355175,"threshold_uncertainty_score":0.9997134},"labels":[],"label_agreement":null},{"id":"W4241771483","doi":"10.1200/jco.2004.22.14_suppl.4575","title":"Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Placebo; Zoledronic acid; Prostate cancer; Clinical endpoint; Urology; Internal medicine; Exploratory analysis; Cancer; Confidence interval; Surgery; Randomized controlled trial; Pathology","score_opus":0.07053870449685215,"score_gpt":0.4847885505464505,"score_spread":0.41424984604959836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241771483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940396,0.0014257176,0.00039062745,0.0077001583,0.00009517107,0.0007228615,0.000007414948,0.0000017391609,0.00025236473],"genre_scores_gemma":[0.9940034,0.0010744253,0.0045652892,0.00016388188,0.000045875273,0.000044061882,0.0000022496204,0.0000066991092,0.00009410681],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982981,0.0000448434,0.0013279472,0.00007656746,0.00012656313,0.00012595042],"domain_scores_gemma":[0.99738616,0.0005444537,0.0015574193,0.00009830525,0.00032571497,0.000087956636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080047635,0.00005757638,0.0006730993,0.000046387722,0.000017293969,8.160933e-7,0.00005956805,0.000083185485,0.0000071735267],"category_scores_gemma":[0.0002658969,0.00003192812,0.00015530412,0.00008663056,0.000111038746,0.000050783823,0.0000090888725,0.0002509094,3.717021e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014000776,0.0040133125,0.19402783,0.00021644872,0.00060648477,0.000021851021,0.0005209511,0.0014776787,0.0009060786,0.0009330417,0.000054351924,0.7832212],"study_design_scores_gemma":[0.035241228,0.019306952,0.9386352,0.00072968466,0.0004496193,0.000059410177,0.00016316955,0.00008861262,0.0007144896,0.0016411575,0.0029280842,0.00004239131],"about_ca_topic_score_codex":0.00007137784,"about_ca_topic_score_gemma":0.00075731013,"teacher_disagreement_score":0.7831788,"about_ca_system_score_codex":0.00010976597,"about_ca_system_score_gemma":0.0010102477,"threshold_uncertainty_score":0.17921361},"labels":[],"label_agreement":null},{"id":"W4241828587","doi":"10.1200/jco.2019.37.15_suppl.5026","title":"Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; Cancer","score_opus":0.14063196091680283,"score_gpt":0.48479497104042457,"score_spread":0.3441630101236217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241828587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941191,0.00031843188,0.0000045779966,0.000836246,0.00046621112,0.003997499,0.00011291632,0.000013750836,0.0001312391],"genre_scores_gemma":[0.9942558,0.0023722528,0.0006265827,0.00011113636,0.00013601614,0.00015174117,0.000015947178,0.00005050522,0.0022800604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931075,0.0010830509,0.0036209174,0.0006682611,0.0009708817,0.0005493855],"domain_scores_gemma":[0.9936247,0.0018618563,0.0026873979,0.00039878147,0.00087762444,0.0005496268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019034212,0.0004537389,0.003960998,0.0003216601,0.000067169436,0.000029461404,0.00018714718,0.00020569914,0.00014122136],"category_scores_gemma":[0.00045209026,0.00021358926,0.00024154509,0.00045034615,0.0005282058,0.00024047321,0.00007757966,0.0009142236,0.0000039836705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1607388,0.019064419,0.79867524,0.000115795716,0.0031578233,0.0010788341,0.0015665742,0.00006153952,0.000035735055,0.0000055617684,0.00006466588,0.01543502],"study_design_scores_gemma":[0.13295314,0.20671201,0.6572659,0.00033988347,0.0009932163,0.000031579893,0.0012015912,0.00007694728,0.00003788422,0.000008518715,0.00021590243,0.00016345769],"about_ca_topic_score_codex":0.0018476694,"about_ca_topic_score_gemma":0.02711542,"teacher_disagreement_score":0.1876476,"about_ca_system_score_codex":0.0016231127,"about_ca_system_score_gemma":0.0050932965,"threshold_uncertainty_score":0.9906372},"labels":[],"label_agreement":null},{"id":"W4241848341","doi":"10.1200/jco.2019.37.15_suppl.10526","title":"Training of oncologists: Results of a global survey.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Economic shortage; Workload; Family medicine; High income countries; Snowball sampling; Internal medicine; Developing country; Pathology","score_opus":0.23070520020054341,"score_gpt":0.5818012519138812,"score_spread":0.3510960517133378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241848341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96441555,0.0008631748,0.00054013665,0.002305193,0.0038035004,0.00020353886,0.00003723278,0.0000059561166,0.027825726],"genre_scores_gemma":[0.97909886,0.0009949119,0.017510127,0.0012523885,0.00078940194,6.044918e-7,0.0000032671799,0.000008810417,0.00034162882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945812,0.0009413951,0.0037614775,0.00017833187,0.00032690627,0.00021069303],"domain_scores_gemma":[0.98532593,0.008999619,0.00449993,0.0002583035,0.000712127,0.0002040732],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009621848,0.000121264326,0.002684735,0.00006332679,0.000013677158,9.663443e-7,0.00025962107,0.0006818892,0.0001493642],"category_scores_gemma":[0.013652609,0.00008201477,0.00053080666,0.00024083219,0.00071814394,0.00007993672,0.00003605604,0.0008299114,0.000008202588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04837871,0.0025964868,0.66094315,0.000059717735,0.0007559113,0.00029176584,0.00022506017,0.0001145783,0.00036393147,0.00060275785,0.0041426825,0.28152528],"study_design_scores_gemma":[0.022026902,0.047283996,0.8291665,0.00015833462,0.00016705816,0.00059795956,0.0002837528,0.000046309116,0.00006139902,0.0008827376,0.099241406,0.000083659426],"about_ca_topic_score_codex":0.000026679249,"about_ca_topic_score_gemma":0.00008932892,"teacher_disagreement_score":0.2814416,"about_ca_system_score_codex":0.0002373549,"about_ca_system_score_gemma":0.0034915009,"threshold_uncertainty_score":0.9946558},"labels":[],"label_agreement":null},{"id":"W4241919709","doi":"10.1200/jco.2017.35.8_suppl.126","title":"ONCOPRE: A new chemotherapy benefit prediction model to assist treatment decision making.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Microsatellite instability; Medicine; Colorectal cancer; Oncology; Internal medicine; Epidemiology; Adjuvant therapy; Clinical trial; Numeracy; Pathological; Cancer; Intensive care medicine","score_opus":0.19977605874201096,"score_gpt":0.526643531325785,"score_spread":0.326867472583774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241919709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95455605,0.00056265056,0.0029580928,0.026525313,0.0018308881,0.000364091,0.000009928948,0.00001402131,0.013178986],"genre_scores_gemma":[0.9687337,0.0016703866,0.022578102,0.0023064676,0.0019500762,0.000008341475,7.1725594e-7,0.0000170099,0.002735143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99793524,0.000031751693,0.0012993463,0.00021756308,0.00032539415,0.00019073083],"domain_scores_gemma":[0.9972755,0.00050835364,0.0011781544,0.00034788498,0.00027120876,0.00041893192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006623528,0.00015983814,0.0012942355,0.00007982685,0.0001839167,0.000029745013,0.00016878605,0.00023660288,0.00009913889],"category_scores_gemma":[0.0013125816,0.00009757373,0.0005305904,0.000039604074,0.00008064511,0.00010448609,0.000059974303,0.00026826878,0.000016269625],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01425982,0.0013297802,0.07268247,0.0000031315212,0.0005770414,0.00016242672,0.00018633771,0.00016030208,0.000018651583,0.00003724879,0.011081703,0.8995011],"study_design_scores_gemma":[0.015251963,0.040687,0.8269361,0.00021183,0.0005500826,0.00014775968,0.00003269575,0.0012011008,0.0000331026,0.002271027,0.11258979,0.00008752676],"about_ca_topic_score_codex":0.000057486042,"about_ca_topic_score_gemma":0.0003945558,"teacher_disagreement_score":0.8994136,"about_ca_system_score_codex":0.00072716165,"about_ca_system_score_gemma":0.0013069437,"threshold_uncertainty_score":0.3978941},"labels":[],"label_agreement":null},{"id":"W4241951868","doi":"10.1200/jco.2013.31.26_suppl.155","title":"Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Cambridge Memorial Hospital","funders":"","keywords":"Medicine; Exemestane; Discontinuation; Quality of life (healthcare); Breast cancer; Internal medicine; Adverse effect; Clinical endpoint; Cancer; Oncology; Randomized controlled trial; Physical therapy; Tamoxifen","score_opus":0.07385496028442555,"score_gpt":0.44321140298550005,"score_spread":0.3693564427010745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241951868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857933,0.0004973766,0.0000058519886,0.011686397,0.0012320072,0.00018654478,0.0000060346874,0.0000075032376,0.00058500073],"genre_scores_gemma":[0.99483955,0.00044904943,0.00026023918,0.0023376697,0.0019962536,0.000016951655,0.0000074421623,0.000010595307,0.00008226197],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980718,0.00019000118,0.0012120638,0.00017838819,0.00019536143,0.00015240075],"domain_scores_gemma":[0.997635,0.0007361205,0.0010666767,0.000058499685,0.00032114956,0.00018256324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015931042,0.00011597589,0.0009909405,0.0000937525,0.000051533767,0.00000823403,0.000040361403,0.00019813147,0.0005537232],"category_scores_gemma":[0.00012294838,0.00008460161,0.00020083904,0.00010459637,0.00015504737,0.00019137449,0.000030274245,0.00063822785,0.000011182284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005186118,0.0051625026,0.38092324,0.000018323151,0.00091934385,0.000376598,0.001117179,0.00003795809,0.0051010954,0.000042687152,0.010101269,0.59101367],"study_design_scores_gemma":[0.0115909465,0.0036646423,0.9689214,0.00006351308,0.00031635087,0.000121796336,0.00023525108,0.00016745123,0.00004800739,0.0008405862,0.013952266,0.00007776781],"about_ca_topic_score_codex":0.00032339134,"about_ca_topic_score_gemma":0.00011111278,"teacher_disagreement_score":0.59093595,"about_ca_system_score_codex":0.0001836,"about_ca_system_score_gemma":0.0006864068,"threshold_uncertainty_score":0.6062881},"labels":[],"label_agreement":null},{"id":"W4242040300","doi":"10.1200/jco.2021.39.3_suppl.94","title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Irinotecan; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Oxaliplatin; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Immunotherapy","score_opus":0.05796847535692534,"score_gpt":0.4249226621907886,"score_spread":0.36695418683386327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242040300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635386,0.0005312158,0.0000011673685,0.0009929774,0.00034910353,0.0013309859,0.00009300664,0.000010604828,0.00033710033],"genre_scores_gemma":[0.99864405,0.00040026498,0.00011428991,0.00028675067,0.00031651877,0.00006191005,0.000043715136,0.000024435993,0.000108038395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948998,0.00068849884,0.0030331388,0.00040003375,0.0006409475,0.00033757772],"domain_scores_gemma":[0.9934874,0.0023208433,0.0021457737,0.00024763405,0.0015813813,0.00021694483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009087814,0.00026986416,0.0027055116,0.00008385389,0.00011218326,0.000009081282,0.00017073228,0.00020115884,0.00010335903],"category_scores_gemma":[0.0037478413,0.00014652769,0.00024619393,0.0005393225,0.00022518272,0.000078537894,0.00011866784,0.0008963515,0.0000010181617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10523534,0.024427209,0.8428043,0.000009541751,0.0029998557,0.0008087348,0.0029541969,0.000070243164,0.00004593225,4.3002066e-7,0.0005998878,0.02004429],"study_design_scores_gemma":[0.12583818,0.080675036,0.7902893,0.00020773314,0.0014971722,0.000026628108,0.0007510992,0.00012229932,0.00013260856,0.0000026355115,0.00034806642,0.00010927915],"about_ca_topic_score_codex":0.0019189103,"about_ca_topic_score_gemma":0.013390696,"teacher_disagreement_score":0.056247823,"about_ca_system_score_codex":0.0005597643,"about_ca_system_score_gemma":0.0033391365,"threshold_uncertainty_score":0.74723226},"labels":[],"label_agreement":null},{"id":"W4242184364","doi":"10.1200/jco.2019.37.7_suppl.170","title":"Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Enzalutamide; Abiraterone; Prostate cancer; Prednisone; Internal medicine; Pembrolizumab; Oncology; Cohort; Pneumonitis; Cancer; Lung; Immunotherapy","score_opus":0.08204740760807967,"score_gpt":0.43870798409038925,"score_spread":0.3566605764823096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242184364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334556,0.0018226457,0.0000057682055,0.0015782132,0.0004120522,0.0017740196,0.00006320876,0.000016779995,0.0009817452],"genre_scores_gemma":[0.98892236,0.005238987,0.0010174746,0.00044153014,0.00015183858,0.00006567535,0.0000229673,0.000056914025,0.0040822644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946837,0.00070678676,0.0025215726,0.00054707384,0.00084874156,0.00069216924],"domain_scores_gemma":[0.9956047,0.0010461116,0.0015276605,0.00033303234,0.00083776034,0.0006507484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002141823,0.00037647225,0.0025352263,0.00028272494,0.00006238379,0.00004155754,0.00019908106,0.0003040899,0.00030330106],"category_scores_gemma":[0.00069922145,0.00020909724,0.00019805628,0.00044159396,0.00043591348,0.00031795452,0.00009302834,0.0013221644,0.00002240721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21729624,0.0023238738,0.75096476,0.00041499716,0.0014680361,0.003421364,0.00048644925,0.00015996555,0.0006157808,0.000010207629,0.00040052974,0.02243778],"study_design_scores_gemma":[0.11258609,0.0432336,0.83775574,0.0009388126,0.00093289895,0.00033268507,0.00028580023,0.0004310506,0.00039734674,0.000075587996,0.0027503474,0.00028003726],"about_ca_topic_score_codex":0.0004953969,"about_ca_topic_score_gemma":0.0010672797,"teacher_disagreement_score":0.104710154,"about_ca_system_score_codex":0.00099964,"about_ca_system_score_gemma":0.0048279483,"threshold_uncertainty_score":0.8564573},"labels":[],"label_agreement":null},{"id":"W4242192132","doi":"10.1200/jco.2020.38.15_suppl.11518","title":"A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Clinical endpoint; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Progression-free survival; Immune checkpoint; Phases of clinical research; Interim analysis; Cancer; Immunotherapy; Clinical trial; Chemotherapy","score_opus":0.12796546729421232,"score_gpt":0.4439812238453233,"score_spread":0.31601575655111097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242192132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984736,0.0009970941,0.0000103078,0.0118740145,0.00021933697,0.00049392466,0.0000035719358,0.0000136624285,0.0016520544],"genre_scores_gemma":[0.99671125,0.0004876273,0.00017715705,0.0021304837,0.00037808722,0.000004589745,0.0000021170931,0.000022693139,0.00008598103],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9955878,0.00060761045,0.0027846415,0.00030069865,0.0004128343,0.00030641406],"domain_scores_gemma":[0.99660355,0.0008178907,0.0015934642,0.00015470671,0.00027617085,0.00055420405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013083008,0.00019291704,0.0022776627,0.00014264429,0.000046630234,0.000008410102,0.00016535934,0.00041945727,0.000103170714],"category_scores_gemma":[0.0029660666,0.0001486415,0.00035176886,0.0003679667,0.00022974152,0.00010621877,0.00009758782,0.001212226,0.0000025616891],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09414057,0.17283224,0.22825605,0.0001494585,0.0014838605,0.003082984,0.006154639,0.000029046138,0.0025165775,0.000037062055,0.012323764,0.47899377],"study_design_scores_gemma":[0.27520952,0.6535401,0.05079054,0.00022525951,0.0013235584,0.00013979305,0.0038874699,0.0009242996,0.00010347286,0.00016365024,0.013457675,0.00023472095],"about_ca_topic_score_codex":0.0000766961,"about_ca_topic_score_gemma":0.00033607232,"teacher_disagreement_score":0.48070782,"about_ca_system_score_codex":0.00022530291,"about_ca_system_score_gemma":0.00097429904,"threshold_uncertainty_score":0.60614246},"labels":[],"label_agreement":null},{"id":"W4242309384","doi":"10.1200/jco.2009.27.15_suppl.7506","title":"A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Conventional PCI; Radiation therapy; Internal medicine; Clinical endpoint; Surgery; Brain metastasis; Lung cancer; Cumulative incidence; Oncology; Cancer; Metastasis; Cohort; Randomized controlled trial","score_opus":0.08195427920397552,"score_gpt":0.46511825211774704,"score_spread":0.3831639729137715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242309384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964023,0.00038127427,0.0012717276,0.0006718294,0.00047625048,0.0006911757,0.000011412675,0.0000031485004,0.000090868],"genre_scores_gemma":[0.9945908,0.00036800271,0.0044167317,0.00032990973,0.00020274342,0.000009541439,0.00007039234,0.000009386423,0.0000024934832],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99615186,0.0005001281,0.0025798848,0.00019657021,0.00039409145,0.0001774845],"domain_scores_gemma":[0.993922,0.0011331324,0.004057509,0.00015245963,0.00057923404,0.00015564713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226377,0.00015529267,0.0020636106,0.00039271664,0.00002384136,0.0000035409464,0.00009515778,0.00027599747,0.000044814264],"category_scores_gemma":[0.0003665248,0.000111592424,0.00035474027,0.0006406921,0.00008016573,0.00014597733,0.000007782793,0.00046684913,2.4557713e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10216567,0.019132623,0.34957215,0.000025831183,0.0011047649,0.000035206056,0.0003823072,0.0035859183,0.00021141725,0.000009127176,0.000021390128,0.5237536],"study_design_scores_gemma":[0.1307193,0.121471345,0.7377476,0.00004348518,0.0027809662,9.3311314e-7,0.00008860903,0.0067032077,0.00016212807,0.0000077807745,0.0002013765,0.00007326957],"about_ca_topic_score_codex":0.00010905057,"about_ca_topic_score_gemma":0.00029557978,"teacher_disagreement_score":0.5236803,"about_ca_system_score_codex":0.00040463946,"about_ca_system_score_gemma":0.0013241238,"threshold_uncertainty_score":0.45506072},"labels":[],"label_agreement":null},{"id":"W4242384421","doi":"10.1200/jco.2020.38.6_suppl.474","title":"Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Cisplatin; Vinblastine; Gemcitabine; Chemotherapy; Internal medicine; Bladder cancer; Urology; Methotrexate; Gastroenterology; Oncology; Cancer","score_opus":0.20651688930918477,"score_gpt":0.478744517378408,"score_spread":0.27222762806922324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242384421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98142326,0.0013189611,0.0012097495,0.013231671,0.000533498,0.00068251044,0.000082302926,0.000020686797,0.00149735],"genre_scores_gemma":[0.9843117,0.0025738534,0.0057199225,0.0059711323,0.0010271189,0.000023378236,0.000030170304,0.000056345343,0.00028638047],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959422,0.00038586307,0.0024207,0.0004422538,0.0004922436,0.00031678108],"domain_scores_gemma":[0.99170744,0.0044633043,0.0022241075,0.00023735977,0.0007902461,0.00057755515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012556246,0.00029633296,0.0024763772,0.00028297547,0.00006864333,0.00001467652,0.00017932404,0.00043867232,0.00072151015],"category_scores_gemma":[0.0044737007,0.00022115055,0.00079182955,0.00074362283,0.00023049393,0.00012711494,0.000056723133,0.00056292984,0.0000041159674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17839393,0.0037451496,0.06849634,0.00044467853,0.03272995,0.0006011387,0.0047784196,0.0021119518,0.026804667,0.00022733024,0.022939699,0.65872675],"study_design_scores_gemma":[0.15432276,0.09107356,0.5465918,0.0005230726,0.041976325,0.000112561815,0.0022383472,0.013739487,0.015494838,0.00039510158,0.13263863,0.0008935266],"about_ca_topic_score_codex":0.00015211222,"about_ca_topic_score_gemma":0.0002633507,"teacher_disagreement_score":0.6578332,"about_ca_system_score_codex":0.00013836929,"about_ca_system_score_gemma":0.0014634224,"threshold_uncertainty_score":0.9018257},"labels":[],"label_agreement":null},{"id":"W4242429455","doi":"10.1200/jco.2017.35.15_suppl.e18163","title":"Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Cancer; Multivariate analysis; Chemotherapy; Stage (stratigraphy); Oncology; Surgery; Gastroenterology","score_opus":0.14685507219764926,"score_gpt":0.5291919823552195,"score_spread":0.3823369101575702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242429455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95163316,0.0027922539,0.00003316606,0.018927945,0.0017523487,0.00045567748,0.000008026929,0.000014279307,0.024383126],"genre_scores_gemma":[0.9798835,0.010100547,0.004756727,0.0027797632,0.001785743,0.000023098217,0.000008463972,0.000034110733,0.00062807783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99463725,0.0011152896,0.0026492374,0.00036814171,0.0006390784,0.00059098785],"domain_scores_gemma":[0.9919523,0.0033823263,0.0026351393,0.000644157,0.0007847879,0.00060131366],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060471175,0.00022818071,0.0040702457,0.0002165661,0.00020129053,0.000023662782,0.0006914362,0.0010005311,0.00019151813],"category_scores_gemma":[0.008733177,0.00016900855,0.0007206154,0.00013539728,0.0006408965,0.00018350898,0.00016998593,0.0023690904,0.000019549072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009500128,0.0008303229,0.7527274,0.0000776454,0.0005022264,0.0031882462,0.00030073483,0.0000038696785,0.00029186395,0.000011806107,0.0023003994,0.2302654],"study_design_scores_gemma":[0.023386288,0.010663645,0.8992919,0.00041716624,0.00023440458,0.0002039958,0.00021968079,0.00010725071,0.000025139883,0.00010045009,0.065205574,0.0001445523],"about_ca_topic_score_codex":0.0005594145,"about_ca_topic_score_gemma":0.0021731087,"teacher_disagreement_score":0.23012084,"about_ca_system_score_codex":0.001429678,"about_ca_system_score_gemma":0.01064855,"threshold_uncertainty_score":0.99993247},"labels":[],"label_agreement":null},{"id":"W4242436944","doi":"10.1200/jco.2014.32.15_suppl.10528","title":"Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University Health Network; University of Toronto; Mount Sinai Hospital; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Sarcoma; Soft tissue sarcoma; Internal medicine; Trabectedin; Phases of clinical research; Gemcitabine; Pazopanib; Response Evaluation Criteria in Solid Tumors; Progressive disease; Surgery; Oncology; Clinical trial; Cancer; Gastroenterology; Chemotherapy; Pathology; Sunitinib","score_opus":0.0997142638469942,"score_gpt":0.4863031168600618,"score_spread":0.38658885301306756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242436944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554324,0.00008936372,0.00007721286,0.0023787105,0.00055567856,0.00069511647,0.0000048792144,0.000008536644,0.0006472893],"genre_scores_gemma":[0.9931534,0.000033741882,0.0047474066,0.0016394057,0.0002861509,0.000018551156,0.000003812368,0.000024382332,0.00009314481],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996224,0.00043326046,0.0022761377,0.00026431223,0.00054468616,0.0002575894],"domain_scores_gemma":[0.99531513,0.0014597424,0.0016134417,0.00034480484,0.00065606827,0.0006108041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012513081,0.00019992558,0.002001364,0.00015110445,0.0000548361,0.0000051222955,0.00019157754,0.00017631832,0.00013162794],"category_scores_gemma":[0.0022533762,0.00012357072,0.00023178806,0.00016236091,0.00009787576,0.000080455415,0.000092402945,0.00042232242,0.000020053654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011985567,0.087166786,0.31130755,0.000012120302,0.00041397466,0.0003593347,0.00030611383,0.0000065474715,0.000053658045,0.0000116463625,0.0009301574,0.5874466],"study_design_scores_gemma":[0.08118074,0.46159235,0.3802122,0.00011437896,0.000667833,0.000076510194,0.00020565791,0.000010494105,0.00020944435,0.000026833493,0.07560043,0.00010313948],"about_ca_topic_score_codex":0.00002663285,"about_ca_topic_score_gemma":0.00015749641,"teacher_disagreement_score":0.5873434,"about_ca_system_score_codex":0.00010655172,"about_ca_system_score_gemma":0.00040113847,"threshold_uncertainty_score":0.5039068},"labels":[],"label_agreement":null},{"id":"W4242460399","doi":"10.1200/jco.2017.74.6065","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Association for Molecular Pathology; American Society of Clinical Oncology; American Association for Cancer Research","keywords":"Medicine; Atezolizumab; Nivolumab; Pembrolizumab; Oncology; Internal medicine; Lung cancer; Guideline; Docetaxel; Pemetrexed; Chemotherapy; Clinical trial; Cancer; Intensive care medicine; Immunotherapy; Pathology; Cisplatin","score_opus":0.17173911777426318,"score_gpt":0.6087778275094344,"score_spread":0.4370387097351712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242460399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85728806,0.004488583,0.008674434,0.10948297,0.010235643,0.002482694,0.00016389028,0.000030643037,0.0071530924],"genre_scores_gemma":[0.6560702,0.09026978,0.20095018,0.0385616,0.011445527,0.00010668949,0.000034984554,0.00010468069,0.00245637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9870637,0.0011942862,0.010162549,0.0005719644,0.0005153668,0.0004921332],"domain_scores_gemma":[0.96408534,0.0105256615,0.020396052,0.00089106744,0.003268436,0.00083341816],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018309303,0.00032467092,0.0048509166,0.00006719801,0.0002403596,0.000030195415,0.0006985956,0.00095769425,0.00011529208],"category_scores_gemma":[0.0112593025,0.0002228826,0.0027284557,0.000109740795,0.0011607024,0.00028738874,0.00015022911,0.0019510392,0.00000936966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016327629,0.008300833,0.24586107,0.00017270133,0.005490426,0.00028100816,0.00021558104,0.00004878906,0.00009396282,0.000064309264,0.14029853,0.58284515],"study_design_scores_gemma":[0.042530786,0.03173495,0.08790016,0.00021719512,0.0042374013,0.00016792119,0.0009185782,0.0018002064,0.000031640117,0.000035440582,0.8302231,0.00020263813],"about_ca_topic_score_codex":0.0004892409,"about_ca_topic_score_gemma":0.0001279159,"teacher_disagreement_score":0.68992454,"about_ca_system_score_codex":0.0004431918,"about_ca_system_score_gemma":0.015044079,"threshold_uncertainty_score":0.9970693},"labels":[],"label_agreement":null},{"id":"W4242539800","doi":"10.1200/jco.2007.14.6407","title":"In Reply:","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.12408576901502229,"score_gpt":0.5903335612652479,"score_spread":0.46624779225022567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242539800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9064444,0.00041595343,0.00029841755,0.027743595,0.0017241377,0.00009420972,3.7023784e-7,0.0000034230372,0.063275546],"genre_scores_gemma":[0.9797853,0.00017237384,0.005385156,0.012200513,0.001082688,4.655052e-7,3.9213148e-7,0.0000048460115,0.0013682637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983768,0.000048425667,0.0012894208,0.000059727718,0.0001219194,0.00010369143],"domain_scores_gemma":[0.99828666,0.00080880156,0.0005182402,0.00007208814,0.00014302127,0.0001711647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025969006,0.00003706481,0.00050188863,0.00009279463,0.000008305072,0.000001307227,0.000036434336,0.00010978335,0.00013526395],"category_scores_gemma":[0.0015548797,0.000023909875,0.00016414937,0.000090191636,0.000047441572,0.000054712043,0.000007725796,0.00037451097,0.000016870565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038525467,0.0033492884,0.48128474,0.000013338359,0.00036460318,0.008106051,0.00031685355,0.000005498889,0.00011175104,0.00084762817,0.029015612,0.47273207],"study_design_scores_gemma":[0.0055256803,0.004094962,0.5041946,0.00002610061,0.00013205597,0.0003622789,0.000092420916,0.0000026014447,0.000040131432,0.0005430943,0.4849661,0.000019969015],"about_ca_topic_score_codex":0.000021311054,"about_ca_topic_score_gemma":0.000047458067,"teacher_disagreement_score":0.4727121,"about_ca_system_score_codex":0.00015375075,"about_ca_system_score_gemma":0.000950797,"threshold_uncertainty_score":0.18614486},"labels":[],"label_agreement":null},{"id":"W4242570554","doi":"10.1200/jco.2011.29.27_suppl.284","title":"Management of early-stage breast cancer: Are we headed in the right direction?","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Anthracycline; Estrogen receptor; Oncology; Progesterone receptor; Taxane; Stage (stratigraphy); Cancer; Chemotherapy; Hormone receptor; Human Epidermal Growth Factor Receptor 2; Gynecology","score_opus":0.09567210412594637,"score_gpt":0.41857597365424465,"score_spread":0.3229038695282983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242570554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842891,0.0018381163,0.000037775008,0.00692845,0.0008549646,0.00014010267,0.000026666386,0.000002278491,0.0058825286],"genre_scores_gemma":[0.99110794,0.0074490616,0.00046171446,0.0003639398,0.00039146957,0.0000131584875,9.070427e-7,0.000007682861,0.00020413176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831957,0.00030289727,0.0009296037,0.00014821379,0.00015164634,0.0001480723],"domain_scores_gemma":[0.99851865,0.00010809949,0.0009962616,0.0001809156,0.00013866383,0.00005739853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009256865,0.00010313801,0.000505959,0.000040196785,0.00002995253,0.0000025942695,0.00025867345,0.00016070355,0.00006153795],"category_scores_gemma":[0.000036492773,0.00006180488,0.00024127665,0.00009309958,0.00017475631,0.0000054751968,0.000072359566,0.0002335229,0.0000019566025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005678844,0.0033620407,0.9012984,0.00006574,0.0017706762,0.00054836227,0.00059079827,0.000018131837,0.00022957627,0.00040228816,0.0054205214,0.0806146],"study_design_scores_gemma":[0.0022032824,0.0011297568,0.96069366,0.00006789164,0.00013614289,0.00007038213,0.00046105115,6.9210887e-7,0.00040977012,0.00014404878,0.034619737,0.00006357316],"about_ca_topic_score_codex":0.00016733953,"about_ca_topic_score_gemma":0.00047129646,"teacher_disagreement_score":0.08055103,"about_ca_system_score_codex":0.000039184968,"about_ca_system_score_gemma":0.0001354215,"threshold_uncertainty_score":0.25203297},"labels":[],"label_agreement":null},{"id":"W4242579700","doi":"10.1200/jco.2017.35.15_suppl.lba10012","title":"Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical Oncology; Cancer; Chemotherapy; Family medicine; Testicular cancer; Gynecology; Internal medicine; Oncology","score_opus":0.10347763390650425,"score_gpt":0.48962041007728035,"score_spread":0.3861427761707761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242579700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914024,0.00010028573,0.000031579817,0.0074276826,0.00031728303,0.00067557994,0.000016637474,0.0000052320115,0.00002332384],"genre_scores_gemma":[0.9944586,0.000028281138,0.0024121013,0.0028959278,0.000116234645,0.000024701067,0.0000018161162,0.000020172323,0.000042166594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970845,0.00034913313,0.0017615539,0.00021504085,0.00035530707,0.00023446536],"domain_scores_gemma":[0.9948705,0.001391386,0.0025248812,0.00041279805,0.000247324,0.00055313617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085408206,0.00016109289,0.0015258329,0.0001605154,0.000059899754,0.0000066600132,0.0001719619,0.000069229136,0.0000442038],"category_scores_gemma":[0.0049190586,0.00011129396,0.00033130604,0.00011638417,0.0001596559,0.00006924861,0.00003779488,0.00042302546,0.000006058443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035502065,0.0089802295,0.94509953,0.000026206242,0.00034235333,0.00064029987,0.0002629348,0.0002257087,3.495097e-7,6.7124205e-7,0.000027275555,0.04084426],"study_design_scores_gemma":[0.017353741,0.010842783,0.9706614,0.00013241336,0.000326183,0.0000050652857,0.0001487419,0.00013954156,4.6910185e-7,0.000005685223,0.00030167733,0.00008227537],"about_ca_topic_score_codex":0.0042705066,"about_ca_topic_score_gemma":0.03824661,"teacher_disagreement_score":0.040761985,"about_ca_system_score_codex":0.00023376907,"about_ca_system_score_gemma":0.0012632783,"threshold_uncertainty_score":0.9793029},"labels":[],"label_agreement":null},{"id":"W4242603928","doi":"10.1200/jco.2009.27.18_suppl.cra4027","title":"Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; KRAS; Panitumumab; Internal medicine; FOLFIRI; Bevacizumab; Irinotecan; Colorectal cancer; Tolerability; Clinical endpoint; Cetuximab; Oncology; Hazard ratio; Gastroenterology; Chemotherapy; Adverse effect; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.113813598064868,"score_gpt":0.44346528295976523,"score_spread":0.3296516848948972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242603928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474263,0.00032881394,0.0000062614713,0.001827036,0.00052820734,0.0012977503,0.00014144694,0.0000066052003,0.0011212685],"genre_scores_gemma":[0.9979829,0.00034562292,0.001145894,0.00013339783,0.00015205503,0.000058508536,0.000021775479,0.000015529311,0.00014429692],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99633414,0.00029205406,0.0023177422,0.00031588986,0.00041579898,0.00032438728],"domain_scores_gemma":[0.994579,0.0021011282,0.0022031358,0.0001451251,0.0007612886,0.00021027743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008321175,0.00026799313,0.0021198175,0.00016706611,0.000055099536,0.000005720416,0.000107528445,0.00019182377,0.00002904818],"category_scores_gemma":[0.0015701789,0.00015816107,0.00040444024,0.00025975626,0.00021936439,0.000104269755,0.000020530511,0.00044529256,0.0000012440819],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48732907,0.022222117,0.039130412,0.00006142534,0.0037007031,0.00037275994,0.0014104812,0.00010871951,0.000088927416,0.000041922536,0.00062961585,0.44490385],"study_design_scores_gemma":[0.11584193,0.29304823,0.58644986,0.00021267618,0.001625194,0.000021850652,0.0003531605,0.000075239914,0.00045618313,0.00014073268,0.0016343284,0.00014059231],"about_ca_topic_score_codex":0.00020489462,"about_ca_topic_score_gemma":0.0019164119,"teacher_disagreement_score":0.5473195,"about_ca_system_score_codex":0.0015132508,"about_ca_system_score_gemma":0.0019363554,"threshold_uncertainty_score":0.64496213},"labels":[],"label_agreement":null},{"id":"W4242607097","doi":"10.1200/jco.21.00971","title":"Cardio-Oncology","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.1647715590446408,"score_gpt":0.5011092218624866,"score_spread":0.33633766281784583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242607097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9058792,0.0009941822,0.0007228744,0.025198113,0.0029542863,0.000097222255,0.0000015377336,0.000012599914,0.06413999],"genre_scores_gemma":[0.9757256,0.0016567977,0.006278426,0.011189723,0.004215176,0.0000014363586,0.000003454006,0.00001440713,0.0009149684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701846,0.00061454135,0.0017140546,0.00015947304,0.0003125448,0.00018091252],"domain_scores_gemma":[0.9961838,0.0014788811,0.00092483935,0.00020020381,0.0008427655,0.00036947435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031506862,0.0000946862,0.0016319314,0.00006777514,0.0000307147,0.000005932317,0.00008474353,0.0006423445,0.00028131195],"category_scores_gemma":[0.004407765,0.000075072676,0.000991721,0.00015733049,0.00014737625,0.00007590599,0.000032729182,0.0011697512,0.000034880763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002167546,0.0017995705,0.011289304,0.00003872661,0.001346685,0.007412284,0.00023052277,0.000015801912,0.08553054,0.0005105102,0.022652753,0.86700577],"study_design_scores_gemma":[0.009477726,0.0066606547,0.040902473,0.000065097665,0.0005089877,0.008003578,0.00035662643,0.00001480949,0.042589147,0.00092447776,0.89040345,0.000092975046],"about_ca_topic_score_codex":0.0000029345026,"about_ca_topic_score_gemma":0.000009871869,"teacher_disagreement_score":0.8677507,"about_ca_system_score_codex":0.0002486141,"about_ca_system_score_gemma":0.0046398737,"threshold_uncertainty_score":0.8230937},"labels":[],"label_agreement":null},{"id":"W4242690302","doi":"10.1200/jco.2020.38.15_suppl.e24032","title":"Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Depression (economics); Activities of daily living; Comorbidity; Perioperative; Cancer; Physical therapy; Geriatric Depression Scale; Geriatric oncology; Randomized controlled trial; Internal medicine; Anxiety; Surgery; Depressive symptoms; Psychiatry","score_opus":0.09772491008913638,"score_gpt":0.41734124276765056,"score_spread":0.3196163326785142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242690302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9425259,0.00016825942,0.00022021984,0.05566709,0.0006136885,0.0003103688,0.0000024280153,0.000021787286,0.00047023004],"genre_scores_gemma":[0.9839467,0.00017777891,0.0057649706,0.009381699,0.00060638087,0.000008400019,0.0000027370809,0.000031793137,0.00007954234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949604,0.0002926992,0.0034605055,0.000311656,0.00059264246,0.00038207573],"domain_scores_gemma":[0.9896733,0.0061472706,0.0026706397,0.0001864385,0.00061733334,0.0007049973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011490706,0.00021617727,0.00204412,0.00014525342,0.000024002826,0.000009880089,0.00012437213,0.00019694233,0.00030113183],"category_scores_gemma":[0.019410605,0.00014259756,0.00042748376,0.0003044283,0.0001798703,0.00015744264,0.000054472344,0.001454649,0.0000129596465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007526939,0.0010934859,0.9321721,0.0001244566,0.00020387046,0.007213803,0.00039989423,0.00006166304,0.000019481216,0.0000031435109,0.005648454,0.04553268],"study_design_scores_gemma":[0.015123449,0.010282224,0.9667996,0.0024089108,0.00021826931,0.0024698942,0.0005688663,0.00018463115,0.000029312929,0.000015305006,0.0017529731,0.00014651868],"about_ca_topic_score_codex":0.00009778119,"about_ca_topic_score_gemma":0.0008038318,"teacher_disagreement_score":0.04628539,"about_ca_system_score_codex":0.00019914418,"about_ca_system_score_gemma":0.00434633,"threshold_uncertainty_score":0.98884934},"labels":[],"label_agreement":null},{"id":"W4242720353","doi":"10.1200/jco.2006.10.4729","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine","score_opus":0.2537950998688346,"score_gpt":0.6361347659901684,"score_spread":0.3823396661213338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242720353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8822616,0.0010461524,0.00012746472,0.06980266,0.0015852462,0.0001293037,2.441643e-7,0.000004626159,0.045042753],"genre_scores_gemma":[0.97799486,0.0009849065,0.0032815875,0.01392324,0.0024702528,6.802151e-7,9.530037e-8,0.000007311792,0.0013370567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735874,0.00014442595,0.0018411073,0.000090302325,0.0003449738,0.00022042972],"domain_scores_gemma":[0.9956818,0.002975733,0.0006135285,0.000116113966,0.00033966565,0.0002731444],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011753106,0.000050963197,0.00088724366,0.00015961999,0.000011467769,0.0000017639977,0.00009388294,0.00013626128,0.00012448314],"category_scores_gemma":[0.014916431,0.000033086882,0.00022187558,0.00015808166,0.00017371323,0.00006773332,0.00004566909,0.001097404,0.000024885647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011760565,0.0017408945,0.6055884,0.000042560878,0.00031278186,0.013357511,0.0002237722,0.0000018081275,0.0002816692,0.00029610185,0.12740035,0.23899357],"study_design_scores_gemma":[0.0045142886,0.006389709,0.5270732,0.000047084948,0.000033101456,0.00031577333,0.00009548202,0.0000025377074,0.0000786021,0.0004385999,0.46098706,0.000024537627],"about_ca_topic_score_codex":0.000027290082,"about_ca_topic_score_gemma":0.00010638188,"teacher_disagreement_score":0.3335867,"about_ca_system_score_codex":0.00025606868,"about_ca_system_score_gemma":0.0011977345,"threshold_uncertainty_score":0.9933813},"labels":[],"label_agreement":null},{"id":"W4242917661","doi":"10.1200/jco.2004.22.14_suppl.6000","title":"Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Oncology","score_opus":0.8431115334611518,"score_gpt":0.6789057319548245,"score_spread":0.16420580150632724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242917661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9295887,0.006082535,0.027964003,0.0326921,0.0021157,0.0012987758,0.000080829224,0.0000054363486,0.00017195752],"genre_scores_gemma":[0.9894469,0.0006430465,0.0058536623,0.003387931,0.0006115869,0.000011066819,0.0000017815879,0.000018890474,0.000025129484],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.93544716,0.011565118,0.052042264,0.00034463452,0.00026332383,0.0003374857],"domain_scores_gemma":[0.8318217,0.098589405,0.068238266,0.00040928472,0.00049992267,0.00044143733],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.33973774,0.0002197258,0.020072067,0.00042139096,0.00008530236,0.000020882018,0.0002942124,0.0005104969,0.00020646432],"category_scores_gemma":[0.22461028,0.00017826718,0.0018802149,0.00011398609,0.00058898085,0.00027738666,0.000047644487,0.00052046234,0.000013573373],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25445285,0.025806263,0.21827917,0.0010016685,0.021016268,0.00004155132,0.0067613097,0.005082096,0.00067662145,0.45047337,0.0027799977,0.0136288395],"study_design_scores_gemma":[0.8545463,0.008620509,0.010789505,0.0002658859,0.0016316944,0.000040507002,0.0008950031,0.005354183,0.00011284398,0.113080285,0.004318588,0.00034467806],"about_ca_topic_score_codex":0.00018685863,"about_ca_topic_score_gemma":0.000029309911,"teacher_disagreement_score":0.6000935,"about_ca_system_score_codex":0.00033585282,"about_ca_system_score_gemma":0.0012766445,"threshold_uncertainty_score":0.99447596},"labels":[],"label_agreement":null},{"id":"W4243024863","doi":"10.1200/jco.2004.22.14_suppl.6042","title":"Renal safety with pamidronate (PAM) 1-hour infusion for metastatic breast cancer (MBC) and multiple myeloma (MM): A multi-centre, population-based analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Urology; Metastatic breast cancer; Creatinine; Renal function; Population; Randomized controlled trial; Breast cancer; Cancer; Surgery; Internal medicine","score_opus":0.08170321424602131,"score_gpt":0.44240929573447013,"score_spread":0.36070608148844885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243024863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798224,0.00028203343,0.0062218006,0.012804594,0.00020454726,0.00054649235,0.00009225977,0.000012002366,0.000013866526],"genre_scores_gemma":[0.9503199,0.00023203656,0.047163174,0.0020042676,0.00014738434,0.00000896252,0.000040193194,0.000019353825,0.000064725726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971602,0.00020617805,0.001784769,0.00024393029,0.00030769358,0.00029724365],"domain_scores_gemma":[0.99583554,0.0013807574,0.0015212295,0.00014432793,0.0004862226,0.00063192943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011504142,0.00017857309,0.0015781849,0.00023762185,0.00010580854,0.000007907,0.000058829395,0.00019414298,0.000056519882],"category_scores_gemma":[0.0007340253,0.000110385015,0.00040986444,0.00030669363,0.00009247954,0.0000932004,0.0000151522245,0.00041870985,0.0000021399057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018904954,0.0027425676,0.8884123,0.000070033166,0.0020632949,0.00027657047,0.00005163837,0.003472837,0.00001658743,0.000012332922,0.000035773934,0.08394111],"study_design_scores_gemma":[0.053190354,0.004263073,0.9310445,0.00017073109,0.0043066223,0.00015779943,0.000030934225,0.005522185,0.000013526686,0.00005390723,0.0011470917,0.00009927283],"about_ca_topic_score_codex":0.0014119779,"about_ca_topic_score_gemma":0.008110615,"teacher_disagreement_score":0.08384184,"about_ca_system_score_codex":0.00037714367,"about_ca_system_score_gemma":0.0018681062,"threshold_uncertainty_score":0.4525914},"labels":[],"label_agreement":null},{"id":"W4243059760","doi":"10.1200/jco.2002.20.1.205","title":"Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Discontinuation; Chemotherapy; Surgery; Regimen; Prolymphocytic leukemia; Alemtuzumab; Chemotherapy regimen; Adverse effect; Leukemia; Transplantation; Chronic lymphocytic leukemia","score_opus":0.16042065071058748,"score_gpt":0.41533585187470773,"score_spread":0.25491520116412025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243059760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445206,0.0006986566,0.00002943845,0.0016100202,0.00035639174,0.0013349779,0.0000072401303,0.000007940406,0.0015032864],"genre_scores_gemma":[0.9909153,0.0013601173,0.0029317401,0.00047033842,0.0006408999,0.000039009683,0.0000065211375,0.00004846879,0.0035876345],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951057,0.00031465339,0.0030076634,0.00034524046,0.00070194906,0.0005248029],"domain_scores_gemma":[0.9940843,0.0025500823,0.001890224,0.00042460227,0.0005735699,0.0004772276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015216423,0.00023890809,0.0022930682,0.00023728714,0.00006491897,0.000013781063,0.00025359838,0.0005686172,0.00038271502],"category_scores_gemma":[0.0017562393,0.00017497885,0.00067044294,0.00021315577,0.0004741626,0.00009648599,0.000055953547,0.00038323132,0.00004456925],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1449127,0.04735705,0.1294033,0.001062638,0.0023995002,0.0010598324,0.0075248918,0.00022307968,0.0035928446,0.000026386322,0.033113208,0.62932456],"study_design_scores_gemma":[0.6875123,0.13905105,0.062389772,0.00054742256,0.0006858045,0.00021595373,0.00022109438,0.010006547,0.011254248,0.0001224795,0.08762298,0.00037039054],"about_ca_topic_score_codex":0.00013370457,"about_ca_topic_score_gemma":0.00010492886,"teacher_disagreement_score":0.6289542,"about_ca_system_score_codex":0.04875858,"about_ca_system_score_gemma":0.02136623,"threshold_uncertainty_score":0.9841817},"labels":[],"label_agreement":null},{"id":"W4243066995","doi":"10.1200/jco.2012.30.5_suppl.324","title":"Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Seminoma; Hilum (anatomy); Anatomy; Renal hilum; Lymph node; Pelvis; Radiation therapy; Radiology; Nephrectomy; Surgery; Pathology; Kidney; Internal medicine; Chemotherapy","score_opus":0.14513722625120304,"score_gpt":0.4662574816019916,"score_spread":0.3211202553507886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243066995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028796,0.0067451717,0.0006484864,0.0013819475,0.00061153644,0.00009381673,0.0000034939208,0.0000034603418,0.00022414439],"genre_scores_gemma":[0.9907865,0.0005923662,0.0069078943,0.0009903001,0.00068078586,0.0000011606238,0.0000019439638,0.00000861665,0.000030442134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789643,0.00024868283,0.0013908888,0.000078343204,0.00020579674,0.00017986287],"domain_scores_gemma":[0.99716693,0.0013042686,0.001060378,0.000120431,0.00009902672,0.00024894686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015945674,0.000084440035,0.00097370544,0.00011439019,0.000011101895,0.0000022216552,0.000072985626,0.00018738997,0.00014544059],"category_scores_gemma":[0.0015138952,0.000057687572,0.00039336103,0.000074463824,0.000046622306,0.00008611117,0.000020984999,0.0004353104,0.0000019871522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056124333,0.0022338594,0.9210712,0.000046336303,0.00037046798,0.0005219659,0.0003305407,0.000004822623,0.00006656738,0.000041779917,0.00016772552,0.07458353],"study_design_scores_gemma":[0.0063676583,0.0026941213,0.9854577,0.00023382487,0.00026007663,0.0003632447,0.00014623202,0.00002869931,0.000076843105,0.00014387442,0.0041774185,0.000050297676],"about_ca_topic_score_codex":0.000044323748,"about_ca_topic_score_gemma":0.000012472995,"teacher_disagreement_score":0.07453323,"about_ca_system_score_codex":0.00007625276,"about_ca_system_score_gemma":0.0003534814,"threshold_uncertainty_score":0.2352431},"labels":[],"label_agreement":null},{"id":"W4243091502","doi":"10.1200/jco.2013.31.15_suppl.10004","title":"Hyaluronidase synthase 3 (<i>HAS3</i>) variant and anthracycline-related cardiomyopathy: A report from the Children’s Oncology Group.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"","keywords":"Anthracycline; Medicine; Cardiomyopathy; Internal medicine; Oncology; Cancer; Cardiotoxicity; Cardiology; Heart failure; Chemotherapy; Breast cancer","score_opus":0.043843567664108775,"score_gpt":0.3852640079103428,"score_spread":0.341420440246234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243091502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96536165,0.0012672789,0.00050094427,0.02860039,0.0015094802,0.00061270024,0.0000103508755,0.000024843208,0.0021123558],"genre_scores_gemma":[0.9870068,0.0013376409,0.0023640736,0.006383271,0.0027340557,0.000014967586,0.000025945987,0.000030200092,0.000103056715],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948452,0.0010197556,0.0030292762,0.00037204957,0.0004279972,0.00030570079],"domain_scores_gemma":[0.9917928,0.0043726875,0.002382459,0.00045882096,0.00045838745,0.00053481915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004959805,0.00022975275,0.001915717,0.00008498793,0.000116356656,0.000030933206,0.00020365005,0.0008291284,0.00029588287],"category_scores_gemma":[0.006112896,0.00014246222,0.0007410378,0.00015973198,0.0005406487,0.00022500822,0.00008479172,0.0018658747,0.00003586013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029164057,0.0033647248,0.105751716,0.000021515736,0.0037706308,0.011814068,0.00074537593,0.0000171079,0.03122643,0.00019463577,0.020062523,0.82011485],"study_design_scores_gemma":[0.018780828,0.009468579,0.8709516,0.00019081852,0.0017706393,0.03321444,0.00039806048,0.00025623542,0.0015785758,0.002653783,0.060454782,0.00028166035],"about_ca_topic_score_codex":0.00048937957,"about_ca_topic_score_gemma":0.000040695653,"teacher_disagreement_score":0.8198332,"about_ca_system_score_codex":0.00019748608,"about_ca_system_score_gemma":0.0012514008,"threshold_uncertainty_score":0.8106401},"labels":[],"label_agreement":null},{"id":"W4243113348","doi":"10.1200/jco.2017.35.15_suppl.502","title":"Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Tolerability; Clinical endpoint; Gastroenterology; Surgery; Breast cancer; Clinical trial; Cancer; Adverse effect","score_opus":0.3334326856360255,"score_gpt":0.5070968932165508,"score_spread":0.1736642075805253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243113348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98020977,0.0005650212,0.000028753528,0.016056286,0.0004529611,0.0017895281,0.0005192509,0.00000796138,0.00037047226],"genre_scores_gemma":[0.991173,0.0069241044,0.00027814612,0.0003461262,0.001088054,0.00004246767,0.00005492319,0.00003624645,0.000056888664],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99330556,0.0018225679,0.0030388066,0.00041876014,0.0009801674,0.0004341466],"domain_scores_gemma":[0.9888585,0.004729877,0.004244,0.0009252595,0.0010107734,0.00023158526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051129744,0.0003259769,0.00282913,0.000092785696,0.00018377946,0.000045900437,0.00097072567,0.00033552534,0.00009150694],"category_scores_gemma":[0.0009078152,0.00014605928,0.00038674474,0.0002783359,0.0012617077,0.00019101675,0.00006976386,0.0012063382,0.0000032935334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6356883,0.019926824,0.05029601,0.000024162458,0.002036168,0.0004381153,0.00867768,0.000057422712,0.0030376713,0.000029027802,0.0005701836,0.27921844],"study_design_scores_gemma":[0.3224868,0.061033484,0.607914,0.00096137787,0.00029775576,0.000090029105,0.0015078848,0.00031194984,0.0036619783,0.00010339875,0.0014649743,0.00016642957],"about_ca_topic_score_codex":0.009266893,"about_ca_topic_score_gemma":0.00537571,"teacher_disagreement_score":0.55761796,"about_ca_system_score_codex":0.00051168393,"about_ca_system_score_gemma":0.0034276298,"threshold_uncertainty_score":0.9973305},"labels":[],"label_agreement":null},{"id":"W4243385540","doi":"10.1200/jco.2012.30.18_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Gastroenterology; Refractory (planetary science); Tolerability; Breast cancer; Oncology; Cancer; Clinical trial","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243385540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942012,0.0019666222,0.000042958327,0.0013223616,0.00023029612,0.0017039474,0.0002467417,0.000010570448,0.00027530038],"genre_scores_gemma":[0.99424976,0.002383856,0.0024667967,0.00026524335,0.00040675362,0.000061287734,0.000021477239,0.000048426336,0.00009642373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9934989,0.0011873767,0.0033739232,0.00048868824,0.00085595855,0.0005951606],"domain_scores_gemma":[0.99086356,0.0053097066,0.0019090315,0.00031622365,0.0007603456,0.0008411157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032309147,0.00035688566,0.0031006548,0.00027361466,0.000050072318,0.000012633763,0.00018367368,0.00025049088,0.00014467101],"category_scores_gemma":[0.0024290823,0.00022776477,0.00013483106,0.00049582607,0.0005594547,0.00029397378,0.00008639996,0.0013843793,0.000001080625],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5207486,0.02438756,0.05873552,0.00018235228,0.0018934886,0.0029618798,0.0060076504,0.000033075852,0.000839036,0.0000013177698,0.00028505063,0.38392445],"study_design_scores_gemma":[0.29844466,0.15140864,0.5389225,0.0014589467,0.0018579497,0.0009180638,0.005868028,0.00014962952,0.00013057211,0.000004965116,0.0005585541,0.00027752077],"about_ca_topic_score_codex":0.0023609905,"about_ca_topic_score_gemma":0.008142427,"teacher_disagreement_score":0.48018694,"about_ca_system_score_codex":0.00081570173,"about_ca_system_score_gemma":0.003592645,"threshold_uncertainty_score":0.9287978},"labels":[],"label_agreement":null},{"id":"W4243394872","doi":"10.1200/jco.2021.39.15_suppl.e23003","title":"Fostering interspeciality learning in cancer survivorship care: Learning suite results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Juravinski Cancer Centre; McGill University","funders":"","keywords":"Survivorship curve; Medicine; General partnership; Family medicine; Radiation oncologist; Radiation oncology; Psychological intervention; Cancer; Oncology; Nursing; Radiation therapy; Internal medicine","score_opus":0.5845108586498181,"score_gpt":0.6163951200779492,"score_spread":0.031884261428131055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243394872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97070694,0.005966097,0.00010591434,0.0050206278,0.0016321817,0.000057255056,0.0000022777292,0.000009117153,0.016499605],"genre_scores_gemma":[0.98916554,0.0065909587,0.0014591579,0.0005440405,0.0014982229,0.0000013131479,0.000005159742,0.000013539389,0.00072208984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568546,0.0012732287,0.0023188859,0.00019975385,0.0002993792,0.00022327874],"domain_scores_gemma":[0.9930185,0.004282887,0.0014588329,0.000115240975,0.0009260682,0.00019845695],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038873265,0.00011180183,0.0014385096,0.00011930682,0.000026330397,0.00000772193,0.00011215782,0.0003045065,0.00009559554],"category_scores_gemma":[0.029762384,0.000092920105,0.00038958798,0.00023821912,0.00012677902,0.00008648662,0.0001721226,0.0020185316,0.000004356963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003464908,0.0002753758,0.7560484,0.000107077416,0.00017623632,0.0013586659,0.0049554626,0.00033668612,0.0005196361,0.000030868596,0.00026691897,0.23245977],"study_design_scores_gemma":[0.012756031,0.006823054,0.5192396,0.0031105983,0.0002768172,0.00011506886,0.016883364,0.00008656717,0.0021552208,0.00018558792,0.43816388,0.00020418953],"about_ca_topic_score_codex":0.0004311888,"about_ca_topic_score_gemma":0.0022591257,"teacher_disagreement_score":0.43789697,"about_ca_system_score_codex":0.00029620432,"about_ca_system_score_gemma":0.0014863687,"threshold_uncertainty_score":0.97841036},"labels":[],"label_agreement":null},{"id":"W4243504517","doi":"10.1200/jco.2012.30.5_suppl.353","title":"A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical trial; Renal cell carcinoma; Population; Inclusion and exclusion criteria; Surgery; Gastroenterology; Oncology; Confidence interval; Pathology","score_opus":0.31167262159603804,"score_gpt":0.5496005379976042,"score_spread":0.2379279164015662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243504517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648213,0.00021826493,0.000795585,0.0005421788,0.0006663739,0.0010266429,0.00019987219,0.000004483832,0.000064470834],"genre_scores_gemma":[0.97541356,0.000020999241,0.02370052,0.00045699067,0.00026539134,0.000013804656,0.00008155519,0.000025378642,0.00002180411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98553914,0.0036511356,0.009303023,0.00033544237,0.00081350043,0.00035775002],"domain_scores_gemma":[0.96538955,0.022580558,0.009108075,0.0005575564,0.0016914336,0.00067283824],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019816265,0.00029206145,0.0072731813,0.00048385383,0.000031561744,0.0000074016275,0.00021336848,0.00034598555,0.00016105927],"category_scores_gemma":[0.020124476,0.00017011777,0.0033469794,0.00036357518,0.00024109524,0.00014051452,0.00004260668,0.0004419595,0.0000010648961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035192385,0.010779499,0.944186,0.00016759404,0.004966788,0.000018636752,0.000088735855,0.00005678078,0.0000611311,0.000009953386,0.00027710127,0.0041953963],"study_design_scores_gemma":[0.032453302,0.017224813,0.92265725,0.000055461598,0.026036374,0.0000024035169,0.000046410256,0.0006713841,0.0005069075,0.000018515622,0.0002044861,0.00012270329],"about_ca_topic_score_codex":0.00009099645,"about_ca_topic_score_gemma":0.000058103036,"teacher_disagreement_score":0.022904934,"about_ca_system_score_codex":0.0002179026,"about_ca_system_score_gemma":0.0008727874,"threshold_uncertainty_score":0.98812944},"labels":[],"label_agreement":null},{"id":"W4243538454","doi":"10.1200/jco.2018.36.15_suppl.6576","title":"Predicting acute care use following initiation of systemic therapy for solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Lung cancer; Comorbidity; Cancer; Regimen; Logistic regression; Oncology","score_opus":0.15940295916435243,"score_gpt":0.424798257106054,"score_spread":0.2653952979417016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243538454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761755,0.0018895373,0.0035874103,0.00026789762,0.0037094657,0.00021998907,0.00007089144,0.0000063798147,0.0026308978],"genre_scores_gemma":[0.9937595,0.0010708375,0.0022108506,0.00068729866,0.0021807014,0.0000058098803,0.0000027754133,0.000020391139,0.000061836545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594957,0.00004803253,0.0035659098,0.00017928645,0.00003947132,0.00021773245],"domain_scores_gemma":[0.99323785,0.00093625777,0.00512401,0.00015544023,0.00042277618,0.00012367121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026001842,0.00010981795,0.0015586216,0.00015746841,0.0000639309,0.000023876853,0.0002341686,0.0003031011,0.00003257857],"category_scores_gemma":[0.0031157874,0.000104559214,0.0006572276,0.00007862394,0.000112244976,0.0005593175,0.000027520377,0.0002682106,0.000014617775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022423286,0.0003110705,0.9298471,0.00005540864,0.00095790875,0.000022886918,0.002092566,0.00006151202,0.00013571148,0.008952737,0.0016229807,0.05369776],"study_design_scores_gemma":[0.024461318,0.039920412,0.80161965,0.0007024038,0.00031302476,0.00013942992,0.001523624,0.0018148079,0.0010773577,0.02470677,0.10299046,0.0007307445],"about_ca_topic_score_codex":0.00004346869,"about_ca_topic_score_gemma":0.00003052848,"teacher_disagreement_score":0.12822747,"about_ca_system_score_codex":0.00016776453,"about_ca_system_score_gemma":0.00047501476,"threshold_uncertainty_score":0.4263801},"labels":[],"label_agreement":null},{"id":"W4243756399","doi":"10.1200/jco.2016.34.7_suppl.299","title":"Setting quality improvement priorities for women receiving systemic therapy (ST) for early stage breast cancer (EBC) using population level administrative data.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; University of Toronto; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; Health Sciences Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Receipt; Quality management; Operationalization; Population; Family medicine; Breast cancer; Cancer registry; Emergency medicine; Cancer; Environmental health; Internal medicine; Operations management; Accounting","score_opus":0.6504253414392762,"score_gpt":0.6051738722930925,"score_spread":0.04525146914618372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243756399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824825,0.00024987618,0.011324104,0.0034079521,0.0009949792,0.00071481656,0.0007918291,0.0000095155165,0.000024452185],"genre_scores_gemma":[0.98596513,0.00033020726,0.010177221,0.00088920764,0.0023268263,0.000034493583,0.0000071665017,0.000018805744,0.00025093532],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99631315,0.0002691541,0.0023968313,0.00028876573,0.0003695429,0.00036255023],"domain_scores_gemma":[0.993014,0.0028298236,0.0027629896,0.00024982946,0.0009005545,0.00024283283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008270857,0.00014926393,0.0011381482,0.000060316106,0.00010733119,0.000024049383,0.00023742195,0.00024024128,0.000040449242],"category_scores_gemma":[0.0029795903,0.00009283931,0.00024302775,0.00006211732,0.00008545003,0.0004739942,0.00005442883,0.00027494936,3.2466494e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014023574,0.00015678535,0.4232173,0.00019964037,0.00048766288,0.000016477583,0.00038435293,0.000008891332,0.0061894124,0.00010284674,0.00037833495,0.5548347],"study_design_scores_gemma":[0.014241523,0.012000591,0.9613763,0.0015414774,0.00019474857,0.00017105385,0.0024913272,0.00031153872,0.00022914616,0.00073062687,0.0064803897,0.00023127101],"about_ca_topic_score_codex":0.0004527029,"about_ca_topic_score_gemma":0.00023708375,"teacher_disagreement_score":0.55460346,"about_ca_system_score_codex":0.0010226038,"about_ca_system_score_gemma":0.0024829532,"threshold_uncertainty_score":0.44046524},"labels":[],"label_agreement":null},{"id":"W4243762055","doi":"10.1200/jco.2013.31.26_suppl.151","title":"Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Clinical endpoint; Metastatic breast cancer; Aromatase inhibitor; Oncology; Cancer; Surgery; Randomized controlled trial; Aromatase","score_opus":0.04429092118661206,"score_gpt":0.42472936744359124,"score_spread":0.3804384462569792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243762055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880395,0.00010437122,0.00059623754,0.009634042,0.0007755409,0.0007557942,0.000028446018,0.0000057596785,0.000060291102],"genre_scores_gemma":[0.99000835,0.0010837045,0.004737734,0.0031438586,0.000715915,0.000060137067,0.000010142611,0.000033813994,0.00020632373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971418,0.00012553977,0.0021011368,0.00017326802,0.00023530847,0.00022298316],"domain_scores_gemma":[0.9954904,0.00051233947,0.002407067,0.0001479392,0.0012632961,0.0001789881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544994,0.00013836168,0.0014023843,0.00013015677,0.0000184585,0.000003831788,0.00013663904,0.00025706185,0.00032516665],"category_scores_gemma":[0.00056551874,0.00010379239,0.00026373388,0.00014978033,0.00014512952,0.0003178047,0.0000166035,0.0003949231,0.0000027469846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011562173,0.0011922674,0.20473467,0.000057014047,0.00014092412,0.0000027609922,0.00019459179,0.000013877772,0.02424683,0.0000072178623,0.00008098314,0.7577667],"study_design_scores_gemma":[0.02305687,0.0034841516,0.9543131,0.00031300905,0.000055570035,0.000015057208,0.000047545473,0.00007949194,0.001849501,0.00021267809,0.016483044,0.000089978676],"about_ca_topic_score_codex":0.00001744472,"about_ca_topic_score_gemma":0.000016138232,"teacher_disagreement_score":0.7576767,"about_ca_system_score_codex":0.00023008214,"about_ca_system_score_gemma":0.00068692496,"threshold_uncertainty_score":0.42325306},"labels":[],"label_agreement":null},{"id":"W4243820083","doi":"10.1200/jco.2002.20.1.247","title":"Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non–Small-Cell Lung Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":569,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Medicine; Ifosfamide; Confidence interval; Lung cancer; Surgery; Chemotherapy; Stage (stratigraphy); Radiation therapy; Randomized controlled trial; Perioperative; Relative risk; Internal medicine; Gastroenterology; Urology; Cisplatin","score_opus":0.07234392026493715,"score_gpt":0.3936541731063779,"score_spread":0.32131025284144077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243820083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97911876,0.009186462,0.000013855286,0.008847518,0.0004987736,0.0004795676,0.000013661564,0.000008432114,0.0018329412],"genre_scores_gemma":[0.970725,0.02192485,0.00046328394,0.0037981113,0.0004365953,0.000052412666,0.000007900688,0.00003317992,0.0025586723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682426,0.00033566286,0.0017982541,0.00032741108,0.00034153264,0.00037289993],"domain_scores_gemma":[0.9940769,0.0039315303,0.0011534934,0.00019728286,0.00025496475,0.00038580253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018653168,0.0002352721,0.0024344593,0.0001648699,0.00007183457,0.00001751698,0.00008406035,0.00027543466,0.0007204229],"category_scores_gemma":[0.0002547942,0.0001540236,0.00032565265,0.00023020396,0.00016686504,0.00015219723,0.000039596307,0.00072207354,0.0000018172092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038711003,0.003779813,0.81656206,0.00012829031,0.0005697509,0.0006917045,0.00041926178,0.000020732052,0.00009256832,7.081102e-7,0.16616994,0.00769406],"study_design_scores_gemma":[0.030664882,0.008117388,0.90447897,0.001346472,0.0007827341,0.00013311734,0.00018575958,0.00054495083,0.0010619089,0.0000060167404,0.05230217,0.00037560824],"about_ca_topic_score_codex":0.00028603402,"about_ca_topic_score_gemma":0.0005613258,"teacher_disagreement_score":0.113867775,"about_ca_system_score_codex":0.0006764747,"about_ca_system_score_gemma":0.0015364097,"threshold_uncertainty_score":0.7888125},"labels":[],"label_agreement":null},{"id":"W4244060608","doi":"10.1200/jco.2019.37.15_suppl.e23016","title":"Perceptions of medical status and treatment goal in older adults with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Activities of daily living; Performance status; Cancer; Terminally ill; Functional impairment; Internal medicine; Physical therapy; Palliative care","score_opus":0.09268629306402208,"score_gpt":0.5050501444292135,"score_spread":0.4123638513651914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244060608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932416,0.0010825715,0.000016449947,0.0043518324,0.00026303207,0.00019008502,0.000002847938,0.0000023144846,0.00084925344],"genre_scores_gemma":[0.9903412,0.007270817,0.0013059528,0.00076460565,0.00022616175,0.0000043216723,0.0000010155795,0.000005936937,0.00007999083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797547,0.00011337682,0.0011127944,0.00013586119,0.0004789249,0.00018360393],"domain_scores_gemma":[0.9981963,0.0005428435,0.00058890425,0.00009543113,0.00020966119,0.00036684674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084999873,0.00008508034,0.0010037157,0.00007250098,0.0000097274215,0.0000020815708,0.000069790556,0.0002267672,0.00059642893],"category_scores_gemma":[0.00047251736,0.000050505463,0.00012272585,0.000100458725,0.00015620115,0.00008357361,0.000021337892,0.00046790106,0.0000032604162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006124735,0.0004931701,0.7057835,0.000019248437,0.00006998008,0.0001904262,0.00034484762,0.0000295422,0.000025077958,0.000021744303,0.000079935904,0.28681782],"study_design_scores_gemma":[0.019355392,0.024408568,0.9489875,0.0009075187,0.000107919965,0.00020287727,0.0019372394,0.00013552349,0.000011786145,0.000012160597,0.003883366,0.000050137296],"about_ca_topic_score_codex":0.00050013675,"about_ca_topic_score_gemma":0.0019028995,"teacher_disagreement_score":0.2867677,"about_ca_system_score_codex":0.00020761651,"about_ca_system_score_gemma":0.0021343243,"threshold_uncertainty_score":0.6530478},"labels":[],"label_agreement":null},{"id":"W4244139576","doi":"10.1200/jco.2004.22.90140.5019","title":"Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Rash; Internal medicine; Toxicity; Gastroenterology; Neutropenia; Chemotherapy; Erlotinib Hydrochloride; Oncology; Cancer; Surgery; Epidermal growth factor receptor","score_opus":0.1604161750413085,"score_gpt":0.5595969058124701,"score_spread":0.3991807307711616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244139576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950636,0.00049461046,0.000040467097,0.002169232,0.0010565929,0.00087573455,0.000014429973,0.0000052891705,0.00028006462],"genre_scores_gemma":[0.99652916,0.00055955554,0.0017620055,0.0004744798,0.00047864672,0.000070112896,0.00000177834,0.000016500859,0.0001077808],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99629676,0.00029509744,0.0024454491,0.00020150369,0.00047207327,0.00028908957],"domain_scores_gemma":[0.99617493,0.001098574,0.001850209,0.00016653155,0.0003606083,0.00034916744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020218666,0.00015608978,0.0018371231,0.0003741578,0.000045872086,0.0000050445833,0.00013094766,0.00010724194,0.00022889269],"category_scores_gemma":[0.0019098449,0.00008701285,0.00015177217,0.0005899451,0.00012277969,0.000107930224,0.00003825247,0.0006690797,0.0000022410475],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16961189,0.13283506,0.020355357,0.00008991615,0.004315925,0.00308094,0.009849773,0.00048485087,0.00007443563,0.00005135495,0.00039535717,0.65885514],"study_design_scores_gemma":[0.35684454,0.5732414,0.04867267,0.00041932755,0.002511318,0.00023620429,0.0051441523,0.000007309218,0.00005640679,0.00021326242,0.01251231,0.00014107408],"about_ca_topic_score_codex":0.00022229523,"about_ca_topic_score_gemma":0.0009778509,"teacher_disagreement_score":0.65871406,"about_ca_system_score_codex":0.00088717754,"about_ca_system_score_gemma":0.0058024204,"threshold_uncertainty_score":0.99983376},"labels":[],"label_agreement":null},{"id":"W4244259592","doi":"10.1200/jco.2008.17.2494","title":"In Reply","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.3099601706094736,"score_gpt":0.5751988046111001,"score_spread":0.26523863400162645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244259592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520434,0.00085563044,0.000007174629,0.032809343,0.0006317942,0.00007725887,2.810923e-7,0.000002425073,0.013572676],"genre_scores_gemma":[0.982807,0.0043907627,0.0013583159,0.0057486286,0.001052962,0.0000013179648,4.159192e-7,0.0000059154336,0.004634715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826765,0.00015818028,0.0011435365,0.00007675294,0.00021633545,0.00013751545],"domain_scores_gemma":[0.99837655,0.00075347145,0.0003733222,0.00008994643,0.00019039615,0.00021631163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001713207,0.000044405017,0.00069992844,0.00010744346,0.000015362511,9.715803e-7,0.00006393316,0.00013146111,0.00021214907],"category_scores_gemma":[0.0019789075,0.000026662814,0.0002105632,0.00011283706,0.00017226004,0.00006679519,0.000018676514,0.0007141681,0.000036103098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116578415,0.0030067402,0.78086036,0.000018368455,0.00020354771,0.033309717,0.000233806,0.0000027245737,0.000181565,0.0000809345,0.1057878,0.064656585],"study_design_scores_gemma":[0.011860042,0.010165168,0.57402104,0.000038541188,0.00003405225,0.0021270844,0.000036126174,0.000010840896,0.00016601682,0.00039837506,0.40111095,0.00003175209],"about_ca_topic_score_codex":0.00001486085,"about_ca_topic_score_gemma":0.0000060903362,"teacher_disagreement_score":0.29532316,"about_ca_system_score_codex":0.0001235908,"about_ca_system_score_gemma":0.0019437044,"threshold_uncertainty_score":0.34480482},"labels":[],"label_agreement":null},{"id":"W4244355447","doi":"10.1200/jco.2015.33.7_suppl.24","title":"A novel biomarker signature to predict aggressive disease in African-American men with prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; GSTP1; Internal medicine; Biomarker; Oncology; TMPRSS2; Logistic regression; Cohort; Cancer; Gastroenterology; Disease; Genotype; Biology; Gene; Genetics; Coronavirus disease 2019 (COVID-19)","score_opus":0.11713033371959268,"score_gpt":0.48747712595161774,"score_spread":0.37034679223202505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244355447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92872345,0.0028495246,0.00006828601,0.0635604,0.00035822266,0.00087854866,0.00004979171,0.000011345866,0.0035004516],"genre_scores_gemma":[0.9938361,0.0010637537,0.0016047617,0.0014812024,0.00053599564,0.000056505494,0.000005494409,0.000022419155,0.0013937331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973925,0.00024603723,0.0010636444,0.00025779556,0.00065836083,0.00038171367],"domain_scores_gemma":[0.9955163,0.0005732896,0.0011904511,0.0001816712,0.000774913,0.0017633874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016539297,0.00016294689,0.0011587829,0.0002498478,0.000021923554,0.000011068922,0.00017570295,0.00013073551,0.00003606329],"category_scores_gemma":[0.0025845333,0.00008980998,0.00016298975,0.0005723238,0.00040062654,0.00010208299,0.000070001086,0.0008798939,0.000007606226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16516104,0.0031016779,0.6567502,0.000037749698,0.0006843257,0.0089535955,0.00097236375,0.00027136115,0.00021429025,0.000006193721,0.026741004,0.13710617],"study_design_scores_gemma":[0.027796337,0.028981874,0.8818787,0.0006501922,0.00035989666,0.00015414278,0.00095495186,0.00037849334,0.000046560555,0.00008600858,0.058544036,0.00016883355],"about_ca_topic_score_codex":0.00024683826,"about_ca_topic_score_gemma":0.00018803832,"teacher_disagreement_score":0.22512844,"about_ca_system_score_codex":0.00058769214,"about_ca_system_score_gemma":0.0077259387,"threshold_uncertainty_score":0.99789935},"labels":[],"label_agreement":null},{"id":"W4244428853","doi":"10.1200/jco.2015.33.15_suppl.9528","title":"Exploring the preferences for place of death among cancer patients and their caregivers.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Place of death; Palliative care; Psychosocial; Distress; Cancer; Delirium; Family medicine; Gerontology; Psychiatry; Nursing; Internal medicine; Clinical psychology","score_opus":0.7059556714412557,"score_gpt":0.558090426671651,"score_spread":0.14786524476960472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244428853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960955,0.0014063327,0.000046278383,0.00083691423,0.0007341468,0.00012620208,0.0000084298235,0.0000015427413,0.00074465293],"genre_scores_gemma":[0.99554074,0.003304848,0.00058115856,0.00014302495,0.00037301253,0.000006159114,7.6849204e-7,0.0000045846496,0.000045734647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877334,0.0001355634,0.0007802707,0.000070954695,0.00015016262,0.00008969188],"domain_scores_gemma":[0.9957695,0.002309548,0.00093841244,0.000062680076,0.00077480637,0.00014502944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011025267,0.000064608255,0.00072367373,0.000036586673,0.000014052954,0.0000017350202,0.00009412296,0.00008314946,0.0000047880962],"category_scores_gemma":[0.0036821389,0.000031499447,0.00014993078,0.00004104404,0.00018480586,0.00009412457,0.000030246994,0.00022538376,1.5705506e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016846518,0.00022299869,0.9361193,0.00004253822,0.00026377916,0.0000038276544,0.0046631307,0.000012425761,0.000014804215,0.000026857704,0.0019151771,0.05503048],"study_design_scores_gemma":[0.009198146,0.01515248,0.8943176,0.0007305551,0.00038819583,0.0000044757,0.009834205,0.000063841515,0.0015122389,0.00047920214,0.06824301,0.00007605068],"about_ca_topic_score_codex":0.000118834876,"about_ca_topic_score_gemma":0.00009784598,"teacher_disagreement_score":0.06632783,"about_ca_system_score_codex":0.00004616568,"about_ca_system_score_gemma":0.0005152181,"threshold_uncertainty_score":0.440813},"labels":[],"label_agreement":null},{"id":"W4244585987","doi":"10.1200/jco.2007.25.18_suppl.5005","title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Oncology; Cancer; Survival analysis; Chemotherapy","score_opus":0.14606775055517018,"score_gpt":0.5181732919384646,"score_spread":0.37210554138329444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244585987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98294854,0.002105372,0.0002625239,0.008044691,0.002850256,0.003288954,0.00009740345,0.000016349004,0.00038589316],"genre_scores_gemma":[0.9850521,0.0020780207,0.0018503504,0.0003353286,0.0012927633,0.000069179274,0.000010456379,0.000045973076,0.009265842],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942971,0.0005024244,0.003242227,0.00036237863,0.00092978886,0.0006660646],"domain_scores_gemma":[0.9925581,0.0025176995,0.0025810846,0.00042626006,0.0014322483,0.00048459473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060948697,0.00026933895,0.0024009696,0.00015943848,0.00013404328,0.000012493817,0.00044965695,0.00035029682,0.00013715005],"category_scores_gemma":[0.0027191718,0.00013688365,0.000615094,0.0004601051,0.00051046774,0.00015148205,0.00015960832,0.0010997547,0.0000031757074],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5195846,0.014612135,0.22543956,0.00043155148,0.005441083,0.0012724708,0.0024130917,0.0005041057,0.0049140146,0.000059817437,0.0144720115,0.21085557],"study_design_scores_gemma":[0.26828793,0.114682406,0.48598734,0.0006907262,0.0032937513,0.00028133445,0.006150889,0.00056588714,0.007097386,0.00028361098,0.11220323,0.00047552318],"about_ca_topic_score_codex":0.0001033246,"about_ca_topic_score_gemma":0.0010456092,"teacher_disagreement_score":0.26054776,"about_ca_system_score_codex":0.0007922695,"about_ca_system_score_gemma":0.0070803207,"threshold_uncertainty_score":0.9985486},"labels":[],"label_agreement":null},{"id":"W4244999708","doi":"10.1200/jco.2014.32.15_suppl.e17648","title":"A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer (TN-MBC) patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Oncology; Hazard ratio; Vinorelbine; Gemcitabine; Eribulin; Proportional hazards model; Performance status; Breast cancer; Discontinuation; Capecitabine; Chemotherapy; Surgery; Cancer; Confidence interval; Colorectal cancer","score_opus":0.16355271133825136,"score_gpt":0.5159438887030333,"score_spread":0.352391177364782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244999708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966014,0.000177743,0.0002580625,0.000804275,0.0008471158,0.0004367648,0.000052651005,0.0000037148666,0.0008182561],"genre_scores_gemma":[0.9982279,0.00018675541,0.00063465454,0.00064107374,0.00022106338,0.000022121485,0.000010126456,0.000010152268,0.000046159723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99494666,0.0020650204,0.0022111516,0.00022047103,0.0003332228,0.00022349744],"domain_scores_gemma":[0.98944503,0.007083571,0.0023012573,0.00013182515,0.00077638775,0.0002619192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002571531,0.0001823903,0.0035840608,0.00054221315,0.00002215808,0.0000036138383,0.000121421035,0.00017667488,0.00035242416],"category_scores_gemma":[0.0010368266,0.00012789099,0.0007887529,0.0008526761,0.00028471893,0.0000878651,0.000036151094,0.0005858308,0.0000038347816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029011536,0.021357039,0.88687015,0.00010129714,0.014578773,0.00012931778,0.0010699828,0.0014912199,0.0016661629,0.000057791796,0.00053683383,0.043129887],"study_design_scores_gemma":[0.02455625,0.018132135,0.9445951,0.000120489705,0.009056318,0.00001982932,0.0001051381,0.0009996886,0.0010047889,0.00012971075,0.0011767757,0.00010377319],"about_ca_topic_score_codex":0.00021940774,"about_ca_topic_score_gemma":0.00082183786,"teacher_disagreement_score":0.057724945,"about_ca_system_score_codex":0.00059249805,"about_ca_system_score_gemma":0.00082117383,"threshold_uncertainty_score":0.52152437},"labels":[],"label_agreement":null},{"id":"W4245038343","doi":"10.1200/jco.2009.27.15_suppl.5041","title":"Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Sunitinib; Internal medicine; Bevacizumab; Sorafenib; Proportional hazards model; Oncology; Progression-free survival; Population; Clinical endpoint; Gastroenterology; Vascular endothelial growth factor; Hazard ratio; Surgery; Confidence interval; Hepatocellular carcinoma; Overall survival; Clinical trial; Chemotherapy; VEGF receptors","score_opus":0.07290138496579174,"score_gpt":0.3559160573981137,"score_spread":0.283014672432322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245038343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586815,0.00006782186,0.00010902766,0.00021328738,0.00028394102,0.0029615513,0.0003732381,0.000018361914,0.00010464708],"genre_scores_gemma":[0.9967279,0.000014787364,0.002339887,0.00029335177,0.00027016056,0.000023152481,0.00021484941,0.000056539237,0.00005941214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933439,0.0011917943,0.0030878836,0.0006553948,0.0010655249,0.0006555339],"domain_scores_gemma":[0.9917254,0.0040776376,0.0021921967,0.00040144756,0.000964878,0.0006384698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013490486,0.0005232466,0.0026975817,0.00030861603,0.00006375297,0.00002616345,0.00025763837,0.00025829446,0.00006201526],"category_scores_gemma":[0.0030518454,0.00029488417,0.0006062808,0.00022977474,0.000091549424,0.00021935439,0.000037601945,0.000924783,0.0000053461254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07367757,0.02579429,0.8960076,0.000025358962,0.0011974175,0.0016324266,0.00087433116,0.000019751382,0.00007071914,0.0000010484023,0.00008445527,0.0006150073],"study_design_scores_gemma":[0.14187835,0.094286546,0.760681,0.00010211018,0.002000344,0.000004913508,0.00030954555,0.00007105783,0.00027841658,0.000010672143,0.00015694914,0.00022008817],"about_ca_topic_score_codex":0.000289785,"about_ca_topic_score_gemma":0.0002580756,"teacher_disagreement_score":0.13532662,"about_ca_system_score_codex":0.0004971759,"about_ca_system_score_gemma":0.0007957716,"threshold_uncertainty_score":0.99995035},"labels":[],"label_agreement":null},{"id":"W4245050478","doi":"10.1200/jco.2017.35.15_suppl.e18049","title":"A population-based analysis of urban-rural disparities in advanced pancreatic cancer (APC) management and outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Rurality; Pancreatic cancer; Internal medicine; Gemcitabine; Population; Cancer; FOLFIRINOX; Residence; Univariate analysis; Rural area; Demography; Multivariate analysis; Environmental health; Colorectal cancer; Pathology","score_opus":0.0907414009825905,"score_gpt":0.4095549377271247,"score_spread":0.3188135367445342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245050478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134177,0.0018760453,0.00022391422,0.0022662426,0.0007314672,0.0001025568,0.000048194743,0.0000020407385,0.0034077591],"genre_scores_gemma":[0.9957409,0.00214502,0.001047266,0.0006166009,0.000101240454,0.0000075685307,0.0000021389535,0.000008722844,0.0003305796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969736,0.00003661138,0.0025850162,0.00016781504,0.000045297365,0.00019169695],"domain_scores_gemma":[0.99469775,0.0005123386,0.0043225777,0.00027974485,0.00006528955,0.00012230656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016939036,0.00011527376,0.0021849228,0.00041924763,0.000059084156,0.000032013606,0.0002874941,0.000173708,0.000111723624],"category_scores_gemma":[0.0012845396,0.00010664206,0.00042054357,0.00010457763,0.00015378033,0.00034550478,0.000052268675,0.00025595922,0.000002642791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000278389,0.00016197006,0.9665048,0.000023558921,0.00070643437,0.000010279146,0.000030306974,0.00097003835,1.5875925e-7,0.012191941,0.00009441485,0.01902771],"study_design_scores_gemma":[0.0027569255,0.00032197274,0.98686326,0.000043418273,0.00027143795,3.8468457e-7,0.000026012964,0.0014825558,6.227743e-7,0.005484543,0.0026388112,0.000110061505],"about_ca_topic_score_codex":0.0025876411,"about_ca_topic_score_gemma":0.0019800623,"teacher_disagreement_score":0.020358456,"about_ca_system_score_codex":0.00017481334,"about_ca_system_score_gemma":0.00010443472,"threshold_uncertainty_score":0.4348737},"labels":[],"label_agreement":null},{"id":"W4245071987","doi":"10.1200/jco.2012.30.4_suppl.288","title":"Biliary tract cancer: A large institutional experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Cohort; Gallbladder cancer; Ampulla of Vater; Cancer; Internal medicine; Gallbladder; Adenocarcinoma; Klatskin tumor; Radiation therapy; Biliary tract cancer; Gastroenterology; Carcinoma; Gemcitabine; Oncology; Surgery; Resection","score_opus":0.1982081002031606,"score_gpt":0.5087362799872497,"score_spread":0.3105281797840891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245071987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688276,0.01124181,0.000081138576,0.0076174,0.0041170428,0.00008913229,0.0000063075527,0.000008581721,0.00801099],"genre_scores_gemma":[0.98680204,0.002061453,0.00074311544,0.0045975526,0.005552573,0.000008027573,0.0000011892787,0.0000073855854,0.00022668146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978869,0.000120954646,0.0012740969,0.00010423196,0.00031816034,0.00029563427],"domain_scores_gemma":[0.9980066,0.0005569183,0.00064468035,0.000111367866,0.00024825888,0.00043216578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016732601,0.00010051397,0.00092811405,0.00007766444,0.00006883239,0.0000037264067,0.00009995613,0.00020547527,0.00048967154],"category_scores_gemma":[0.0013657676,0.00006601657,0.0004616088,0.000111562505,0.00021628378,0.00022599449,0.000046376044,0.00069628033,0.000022400734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008384535,0.0020353466,0.92842156,0.000015258905,0.00021706706,0.0002310883,0.0008998529,7.6400374e-7,0.000067971,0.0002451104,0.015062095,0.05196541],"study_design_scores_gemma":[0.0027235006,0.0011619235,0.6143245,0.00003507775,0.00015049482,0.0004974066,0.00029324435,0.000004455739,0.000031777978,0.000022038781,0.38070977,0.000045809844],"about_ca_topic_score_codex":0.000024796942,"about_ca_topic_score_gemma":0.000021720969,"teacher_disagreement_score":0.36564767,"about_ca_system_score_codex":0.00017102668,"about_ca_system_score_gemma":0.0014314023,"threshold_uncertainty_score":0.536156},"labels":[],"label_agreement":null},{"id":"W4245100817","doi":"10.1200/jco.2006.24.18_suppl.3524","title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Chemotherapy; Adjuvant; Surgery; Internal medicine; Randomized controlled trial; Cancer; Stage (stratigraphy); Primary tumor; Clinical trial; Gastroenterology; Oncology; Metastasis","score_opus":0.35095931275604364,"score_gpt":0.4946507452496455,"score_spread":0.14369143249360183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245100817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812432,0.013016825,0.001274532,0.0030019972,0.00034719362,0.0006823634,0.00021753038,0.000004352027,0.00021202778],"genre_scores_gemma":[0.99109864,0.0012950625,0.0066030836,0.0003209339,0.000492707,0.00005711474,0.000036378347,0.000013809378,0.00008224455],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9878895,0.0054138266,0.0057761758,0.00022055743,0.0005423518,0.00015758527],"domain_scores_gemma":[0.9802908,0.011997955,0.006408994,0.00016318231,0.0010051874,0.00013388373],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012672552,0.00020389659,0.012650431,0.00040419944,0.000019161645,0.0000064840824,0.00010459149,0.00027229113,0.002394791],"category_scores_gemma":[0.003985095,0.00011227157,0.010210838,0.0004549853,0.0003335619,0.00009241465,0.00001976481,0.00037225467,0.0000013838968],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45533994,0.002570692,0.092728205,0.000015113445,0.43535015,0.00030607465,0.0001368344,0.00005929671,0.0037520835,0.00003066344,0.00059326366,0.009117657],"study_design_scores_gemma":[0.19514313,0.0069146543,0.034898844,0.00002424296,0.73858696,0.000013756897,0.000039552673,0.00067928154,0.021986924,0.00061981555,0.0009855132,0.000107300955],"about_ca_topic_score_codex":0.0020750943,"about_ca_topic_score_gemma":0.0015951897,"teacher_disagreement_score":0.3032368,"about_ca_system_score_codex":0.00007798703,"about_ca_system_score_gemma":0.0008715584,"threshold_uncertainty_score":0.9997017},"labels":[],"label_agreement":null},{"id":"W4245102325","doi":"10.1200/jco.2017.35.15_suppl.2587","title":"A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Selumetinib; Medicine; Colorectal cancer; MEK inhibitor; Internal medicine; KRAS; Rash; Oncology; Adverse effect; Cancer; Pharmacology; MAPK/ERK pathway; Kinase","score_opus":0.055636158484594106,"score_gpt":0.4590854484056294,"score_spread":0.40344928992103535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245102325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981428,0.00011097956,0.0000013529731,0.00033316793,0.00018485423,0.0011173236,0.000008477562,0.0000017952264,0.0000992784],"genre_scores_gemma":[0.99942267,0.00018918686,0.00025124557,0.00004689088,0.000029335451,0.000039412866,0.0000015879695,0.000011726506,0.000007946991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744445,0.00031685294,0.0014384523,0.0002023067,0.00044100944,0.0001569133],"domain_scores_gemma":[0.9963487,0.00036992034,0.0024900017,0.00019239636,0.00048538475,0.00011361744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011521613,0.00015055423,0.0016237696,0.000114105205,0.000065860884,0.00000551023,0.00013968468,0.000068481175,0.000008683379],"category_scores_gemma":[0.0007540288,0.00007772428,0.00007664842,0.00013601645,0.00033912863,0.00017419121,0.00006136878,0.00040637478,5.19741e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038134266,0.019218894,0.90229356,0.000029201907,0.0003872796,0.000114948154,0.0013901764,0.000039039976,0.000055321212,0.0000027041442,0.000004572349,0.03833006],"study_design_scores_gemma":[0.06209265,0.11524174,0.8201505,0.00027629553,0.00043171042,0.000009849911,0.0015293919,0.00006069825,0.00010795906,0.000023234012,0.000012609983,0.00006338805],"about_ca_topic_score_codex":0.00047044698,"about_ca_topic_score_gemma":0.0069170785,"teacher_disagreement_score":0.09602285,"about_ca_system_score_codex":0.000154818,"about_ca_system_score_gemma":0.0006502804,"threshold_uncertainty_score":0.38598922},"labels":[],"label_agreement":null},{"id":"W4245145323","doi":"10.1200/jco.2014.32.15_suppl.tps4150","title":"Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cabozantinib; Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Oncology; Placebo; Tolerability; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Randomized controlled trial; Phases of clinical research; Cancer; Adverse effect; Clinical trial; Pathology","score_opus":0.18161995106099346,"score_gpt":0.4133839541499895,"score_spread":0.23176400308899606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245145323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885959,0.00059846893,0.00013431051,0.0011605341,0.0008235829,0.0060277437,0.0000028936638,0.000017513303,0.0026390566],"genre_scores_gemma":[0.99753577,0.00021920806,0.00078811956,0.00017615274,0.0008034289,0.00015670748,0.0000116178535,0.00006226145,0.00024673695],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888678,0.0036904162,0.005408894,0.0005434303,0.00092722883,0.00056219974],"domain_scores_gemma":[0.98265916,0.0107564805,0.0043275612,0.0005321847,0.0010536389,0.00067098584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011995438,0.0005069973,0.00824981,0.0004935066,0.000076671924,0.000024770963,0.0003369593,0.0006757156,0.00011462594],"category_scores_gemma":[0.0051020267,0.00032268724,0.0012344269,0.00037010264,0.00048999494,0.00016458759,0.00007062283,0.0014830779,0.000013016179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6086626,0.012270621,0.369081,0.000046172478,0.001462957,0.0022055535,0.00058558217,0.000008990908,0.000083381194,0.000025241641,0.000064135,0.0055038016],"study_design_scores_gemma":[0.8951996,0.08328014,0.007442898,0.0001959164,0.004522675,0.00014927956,0.00067977863,0.0065330197,0.0007354424,0.00001734812,0.0009807677,0.0002631227],"about_ca_topic_score_codex":0.00034862285,"about_ca_topic_score_gemma":0.0005478411,"teacher_disagreement_score":0.3616381,"about_ca_system_score_codex":0.00016336882,"about_ca_system_score_gemma":0.0020022814,"threshold_uncertainty_score":0.9999225},"labels":[],"label_agreement":null},{"id":"W4245260718","doi":"10.1200/jco.2004.22.14_suppl.7226","title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Zoledronic acid; Medicine; Placebo; Hazard ratio; Internal medicine; Lung cancer; Pathologic fracture; Surgery; Urology; Oncology; Confidence interval; Pathology","score_opus":0.06257154037284854,"score_gpt":0.4562930126003374,"score_spread":0.3937214722274889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245260718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968156,0.0005722393,0.000067359026,0.0016602913,0.00015942643,0.00025667145,0.000014585621,0.000002491991,0.00045130483],"genre_scores_gemma":[0.9958918,0.00011631652,0.002168661,0.0017121248,0.000058246966,0.000006471326,0.0000040824443,0.000011322207,0.000030978543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665076,0.00015328485,0.0025564611,0.00018163188,0.00029052206,0.00016733652],"domain_scores_gemma":[0.99621695,0.0006883942,0.002240635,0.00021009016,0.00033736878,0.00030658266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010979476,0.00010987406,0.0017024283,0.00026812858,0.000013521265,7.807481e-7,0.000078207995,0.00021166187,0.00006406298],"category_scores_gemma":[0.0004307443,0.00007410436,0.00033934842,0.00019717912,0.00028962467,0.00003710429,0.0000137614015,0.0005478024,9.857803e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003953182,0.0059450846,0.9694828,0.000052110125,0.0006935265,0.000020859414,0.000040890955,0.0003710164,0.0000018830015,0.000032611766,0.000051851846,0.019354232],"study_design_scores_gemma":[0.022150304,0.012115811,0.96271276,0.0002838233,0.0013829875,0.0000040179048,0.000006520423,0.00033627442,0.0000043715563,0.00002728874,0.0009239072,0.000051903295],"about_ca_topic_score_codex":0.00020899969,"about_ca_topic_score_gemma":0.0007707523,"teacher_disagreement_score":0.019302329,"about_ca_system_score_codex":0.0005781294,"about_ca_system_score_gemma":0.0030038327,"threshold_uncertainty_score":0.532867},"labels":[],"label_agreement":null},{"id":"W4245339559","doi":"10.1200/jco.2014.32.4_suppl.438","title":"EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Clinical endpoint; Adverse effect; Internal medicine; Surgery; Renal cell carcinoma; Confidence interval; Clinical trial","score_opus":0.1411817375648806,"score_gpt":0.4584591712089288,"score_spread":0.31727743364404826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245339559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98931533,0.00026074477,0.0006592453,0.0027133825,0.0019447908,0.0021680696,0.000014515865,0.000013844865,0.0029100878],"genre_scores_gemma":[0.98445,0.00030105037,0.008269038,0.0008749346,0.0055000326,0.00006295891,0.000019104757,0.000057778536,0.00046512418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99376357,0.0006888201,0.0038210303,0.00041430152,0.0008345717,0.00047772445],"domain_scores_gemma":[0.9866544,0.006488338,0.004704599,0.00045995298,0.0010698334,0.0006228599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046005957,0.00036388545,0.0029132278,0.00023823103,0.00013096508,0.000011044598,0.00034079395,0.000441243,0.00015386089],"category_scores_gemma":[0.003889548,0.00023574085,0.0012099523,0.00016687368,0.00028014643,0.00015101116,0.00006502511,0.0009597786,0.0000053645704],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87296194,0.012178071,0.00054520275,0.00005542328,0.00044978803,0.00037635554,0.00018431013,0.000086309396,0.0014057156,0.000034016724,0.00046303947,0.11125983],"study_design_scores_gemma":[0.55915946,0.40914184,0.00072660047,0.00008705152,0.0005696015,0.00018447927,0.00005274659,0.00017083253,0.006256685,0.00015675955,0.023361458,0.00013249613],"about_ca_topic_score_codex":0.000041715026,"about_ca_topic_score_gemma":0.000030652205,"teacher_disagreement_score":0.39696378,"about_ca_system_score_codex":0.00021740727,"about_ca_system_score_gemma":0.0020337186,"threshold_uncertainty_score":0.9613233},"labels":[],"label_agreement":null},{"id":"W4245447381","doi":"10.1200/jco.2012.30.18_suppl.lba1000","title":"NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Cyclophosphamide; Gastroenterology; Breast cancer; Gemcitabine; Adjuvant; Paclitaxel; Urology; Cancer; Chemotherapy","score_opus":0.05828094261182096,"score_gpt":0.4145853904945108,"score_spread":0.3563044478826899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245447381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900755,0.004552678,0.00007280096,0.0024783155,0.00025981103,0.0012470112,0.000053628097,0.000009758377,0.0012504533],"genre_scores_gemma":[0.9928295,0.003990918,0.0012821612,0.0011544428,0.0004954463,0.00012310334,0.000008536172,0.000035833233,0.00008002867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949588,0.0010876897,0.0024247486,0.00041203006,0.00049246766,0.0006242355],"domain_scores_gemma":[0.9912679,0.0047409246,0.0024014616,0.00019380856,0.00064048613,0.0007554044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040799477,0.00042022538,0.006761277,0.00052216323,0.00007645545,0.00001924447,0.00012522176,0.00030606138,0.00017836421],"category_scores_gemma":[0.00040063393,0.00023513155,0.00030711602,0.0007610181,0.0011890992,0.00031571116,0.00007655273,0.001080525,9.02773e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7293303,0.0023399757,0.249957,0.00005131647,0.011411476,0.0005299546,0.002246978,0.00028692724,0.000099794815,0.00002514,0.00006525873,0.0036558907],"study_design_scores_gemma":[0.54491156,0.016142562,0.42651346,0.00033422266,0.009826398,0.0006882273,0.0009591738,0.0002387895,0.00004645436,0.000012068409,0.0001251907,0.00020187563],"about_ca_topic_score_codex":0.001011001,"about_ca_topic_score_gemma":0.0013052636,"teacher_disagreement_score":0.18441871,"about_ca_system_score_codex":0.00057293806,"about_ca_system_score_gemma":0.0017942443,"threshold_uncertainty_score":0.95883864},"labels":[],"label_agreement":null},{"id":"W4245472206","doi":"10.1200/jco.2012.30.15_suppl.9570","title":"Preclinical study of a PARP inhibitor in neuroblastoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Neuroblastoma; PARP inhibitor; Poly ADP ribose polymerase; Flow cytometry; Apoptosis; Cancer research; Medicine; Chemotherapy; In vitro; Molecular biology; IC50; Cell culture; Biology; Immunology; DNA; Internal medicine; Polymerase; Biochemistry; Genetics","score_opus":0.2550655916410889,"score_gpt":0.5540228751743285,"score_spread":0.2989572835332396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245472206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630314,0.0001347157,0.0000032607818,0.0010747401,0.00093418406,0.00039283436,0.000001024261,0.0000051514576,0.0011509476],"genre_scores_gemma":[0.9979265,0.000115721865,0.00047622347,0.00037396938,0.0009758477,0.0000055332707,3.1727708e-7,0.000015893096,0.0001100278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946455,0.0011588316,0.0030909658,0.00015972121,0.000576539,0.0003684564],"domain_scores_gemma":[0.9938422,0.003660903,0.0012604083,0.00022940151,0.000273682,0.0007334162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038550342,0.00012530817,0.001577916,0.0002431771,0.000014931659,0.0000030250487,0.0001528739,0.00023421747,0.00007991612],"category_scores_gemma":[0.008096653,0.00008384749,0.00037130187,0.00023378027,0.00016152543,0.00015568471,0.00010204451,0.0013413691,0.000032709308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011387868,0.047849603,0.8959991,0.000024639336,0.000282328,0.0014876636,0.00022074813,0.0000033445026,0.00033628065,0.000010442633,0.0011851122,0.041212868],"study_design_scores_gemma":[0.020219656,0.07883348,0.895925,0.00007212826,0.00017468145,0.0003563386,0.00020228248,0.000011576674,0.00023749548,0.000029961786,0.0038874855,0.00004991059],"about_ca_topic_score_codex":0.000017965729,"about_ca_topic_score_gemma":0.00005948578,"teacher_disagreement_score":0.041162957,"about_ca_system_score_codex":0.00007376773,"about_ca_system_score_gemma":0.0009433241,"threshold_uncertainty_score":0.96930355},"labels":[],"label_agreement":null},{"id":"W4245477772","doi":"10.1200/jco.2012.30.27_suppl.102","title":"Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Bone remodeling; N-terminal telopeptide; Bone resorption; Everolimus; Clinical endpoint; Bisphosphonate; Denosumab; Bone mineral; Exemestane; Osteoclast; Osteoporosis; Endocrinology; Oncology; Breast cancer; Urology; Cancer; Clinical trial; Aromatase; Osteocalcin; Alkaline phosphatase","score_opus":0.031168876565012042,"score_gpt":0.41234507384085245,"score_spread":0.3811761972758404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245477772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992539,0.005455646,0.000024568973,0.0011535204,0.0002826896,0.0004671287,0.000004006394,0.000005088143,0.00006837389],"genre_scores_gemma":[0.99606556,0.0004513317,0.0023005544,0.0008801759,0.00024096895,0.000013850065,0.0000026910457,0.000024156605,0.000020707623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966529,0.0006212312,0.0016921208,0.00019123219,0.0005007409,0.00034176203],"domain_scores_gemma":[0.99543273,0.0021135197,0.0015547231,0.00016302206,0.00017202031,0.00056398386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021909864,0.00018903,0.001662717,0.00031735297,0.000015984608,0.0000027590047,0.000062236606,0.00017300168,0.000023882412],"category_scores_gemma":[0.0024009605,0.00012060217,0.00015929565,0.00021440149,0.00029494244,0.0002398942,0.000050556013,0.0007361259,0.0000020451562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08354434,0.006459715,0.62847006,0.00019590877,0.00012834054,0.00061858335,0.00008623926,0.000010360559,0.00011357649,0.000012434835,0.00007840959,0.280282],"study_design_scores_gemma":[0.03287098,0.014665271,0.947855,0.0012747833,0.00029705075,0.000075796335,0.000043736323,0.000011078474,0.00013911078,0.000089707595,0.002567989,0.00010951531],"about_ca_topic_score_codex":0.000008792539,"about_ca_topic_score_gemma":0.000012355344,"teacher_disagreement_score":0.3193849,"about_ca_system_score_codex":0.0001946418,"about_ca_system_score_gemma":0.00038750627,"threshold_uncertainty_score":0.49180138},"labels":[],"label_agreement":null},{"id":"W4245577852","doi":"10.1200/jco.2012.30.18_suppl.4","title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Bicalutamide; Goserelin; Urology; Oncology; Androgen deprivation therapy; Antiandrogen; Hazard ratio; Castration; Cancer; Androgen receptor; Hormone; Confidence interval","score_opus":0.1729421620923322,"score_gpt":0.5120540794502855,"score_spread":0.33911191735795326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245577852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934441,0.0006219124,0.00001915737,0.0018422384,0.0024052695,0.0009373596,0.00009690278,0.000006126306,0.0006269585],"genre_scores_gemma":[0.99453074,0.0035924108,0.0005045685,0.0002226187,0.0007945776,0.000026524505,0.0001027949,0.00001852907,0.00020721905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952964,0.00063657673,0.0028317615,0.00022820351,0.00064854755,0.00035846536],"domain_scores_gemma":[0.99487585,0.0011759815,0.0021985276,0.00018254592,0.0011285009,0.00043860672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037216102,0.00017376206,0.0013245204,0.00029559268,0.000027542967,0.000010232351,0.00016661161,0.00019182524,0.00004613736],"category_scores_gemma":[0.0034070897,0.000120640965,0.00029177617,0.00018968443,0.00022315986,0.00044417073,0.00007833581,0.00072656514,0.00000547742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68147695,0.011973097,0.03601251,0.000019378656,0.0010948738,0.0002743037,0.0013385097,0.0000066521484,0.00042971558,0.000013358064,0.0013057294,0.26605493],"study_design_scores_gemma":[0.7445533,0.057390727,0.18490441,0.00022063473,0.00064184755,0.00004205645,0.0008200637,0.00019787595,0.0015401971,0.000048629856,0.009474208,0.00016602082],"about_ca_topic_score_codex":0.00015738637,"about_ca_topic_score_gemma":0.00007980786,"teacher_disagreement_score":0.2658889,"about_ca_system_score_codex":0.0005476855,"about_ca_system_score_gemma":0.0009862907,"threshold_uncertainty_score":0.49195957},"labels":[],"label_agreement":null},{"id":"W4245701085","doi":"10.1200/jco.2004.22.14_suppl.8277","title":"A longitudinal assessment of the quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML): A pilot study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Cancer; Physical therapy; Anemia; Cognition; Gerontology; Population; Internal medicine; Psychiatry","score_opus":0.12524729031981305,"score_gpt":0.48500015376294525,"score_spread":0.3597528634431322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245701085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252486,0.0001334173,0.00064252404,0.0045099338,0.00035498585,0.0012224516,0.000015557393,0.0000067784886,0.00058951235],"genre_scores_gemma":[0.99200094,0.0003182322,0.0065237135,0.000600566,0.00043144185,0.000016446336,0.0000016967391,0.000031228305,0.00007574169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903007,0.0015777859,0.005440311,0.00035890756,0.0019168829,0.00040537782],"domain_scores_gemma":[0.9859164,0.004677887,0.005949272,0.0007651977,0.0021427579,0.0005485134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008654574,0.0002679604,0.0034531541,0.00021658083,0.000050404626,0.000005902344,0.0007468673,0.0002923837,0.000099103054],"category_scores_gemma":[0.006964078,0.00014666295,0.00065389375,0.0005934344,0.0010165499,0.00013826926,0.0002921041,0.0022678212,0.0000021989863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046087205,0.020048738,0.9187183,0.0003189883,0.0035862185,0.00071629445,0.0009969403,0.00040453466,0.0015453389,0.00018451558,0.00073025416,0.0066626887],"study_design_scores_gemma":[0.062287506,0.08466046,0.8495586,0.00054879807,0.00086859573,0.00015362383,0.0013128005,0.000035707344,0.00031633105,0.00006104927,0.00008781694,0.00010870218],"about_ca_topic_score_codex":0.0011488487,"about_ca_topic_score_gemma":0.0007959386,"teacher_disagreement_score":0.06915968,"about_ca_system_score_codex":0.0010147427,"about_ca_system_score_gemma":0.020950345,"threshold_uncertainty_score":0.9852681},"labels":[],"label_agreement":null},{"id":"W4245847758","doi":"10.1200/jco.2002.20.3.680","title":"Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hypoxia (environmental); Cervix; Internal medicine; Cancer; Oncology","score_opus":0.10999907893406477,"score_gpt":0.4223830153189353,"score_spread":0.3123839363848705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245847758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922764,0.0004986513,0.0000071447575,0.003086504,0.00084796926,0.00037807165,0.000033822907,0.000008609154,0.0028628318],"genre_scores_gemma":[0.9957496,0.0002712957,0.0005879239,0.0021476455,0.00091672956,0.0000101849,0.0000029451992,0.000023486527,0.00029020448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996386,0.00031649703,0.0019259003,0.00025080246,0.0007664568,0.00035437473],"domain_scores_gemma":[0.9957758,0.0013960054,0.0014715504,0.00017858695,0.0005427019,0.00063533796],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080975686,0.00021780924,0.0017087881,0.00024084204,0.000036421563,0.000013634154,0.00017742878,0.00026428883,0.0044384277],"category_scores_gemma":[0.0021220206,0.00012067265,0.0004318865,0.0004283543,0.00019854047,0.00017042655,0.000046697478,0.0011708097,0.000035707293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014774085,0.0053940415,0.89836544,0.000017900127,0.0006831586,0.0005545345,0.00012760339,0.000029823022,0.0000021348333,0.0000032265068,0.0014715826,0.07857646],"study_design_scores_gemma":[0.047419135,0.029632619,0.91870147,0.00017917842,0.0003783993,0.000058571404,0.000031763975,0.000036055815,0.00000827647,0.00009831015,0.0033470502,0.000109174674],"about_ca_topic_score_codex":0.00034768626,"about_ca_topic_score_gemma":0.0003521624,"teacher_disagreement_score":0.07846728,"about_ca_system_score_codex":0.0008618009,"about_ca_system_score_gemma":0.0014515481,"threshold_uncertainty_score":0.99647164},"labels":[],"label_agreement":null},{"id":"W4245906676","doi":"10.1200/jco.2013.31.26_suppl.108","title":"Taking control of cancer: Why women are choosing mastectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Grounded theory; Mastectomy; Nonprobability sampling; Cancer; Qualitative research; Surgery; Internal medicine; Population","score_opus":0.056134363518623054,"score_gpt":0.4233137366226022,"score_spread":0.36717937310397913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245906676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899715,0.0020886238,0.0024304874,0.003247564,0.0012995873,0.000128952,0.000008648909,0.0000024231967,0.0008222054],"genre_scores_gemma":[0.993361,0.00058094756,0.0019167083,0.0025625357,0.0014540507,0.000021414258,9.492249e-7,0.00001596935,0.000086405715],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977244,0.000280561,0.0014438833,0.000160151,0.00017234156,0.00021865322],"domain_scores_gemma":[0.99571055,0.00027041713,0.002976128,0.00018503204,0.0006955213,0.00016232018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012448805,0.000103342885,0.000697706,0.000059984868,0.000030381652,0.000010124811,0.00026864753,0.00033285044,0.00043390557],"category_scores_gemma":[0.0017284876,0.00008326236,0.0002507578,0.000080778824,0.00017908459,0.000010063741,0.00005486146,0.00034749755,0.000005612627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014834994,0.0007012625,0.3001399,0.00006077829,0.0014221583,0.000031635056,0.00021525938,0.0021911687,0.14059483,0.000033026863,0.02173832,0.53138816],"study_design_scores_gemma":[0.013691733,0.006873768,0.57609475,0.00017351563,0.00026301306,0.00012674465,0.0010689667,0.00038915925,0.021999184,0.00083424634,0.37809226,0.00039264272],"about_ca_topic_score_codex":0.00005963773,"about_ca_topic_score_gemma":0.00006420709,"teacher_disagreement_score":0.53099555,"about_ca_system_score_codex":0.00014604391,"about_ca_system_score_gemma":0.0010984866,"threshold_uncertainty_score":0.4750962},"labels":[],"label_agreement":null},{"id":"W4245977770","doi":"10.1200/jco.2004.22.14_suppl.8014","title":"Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Psychosocial; Breast cancer; Quality of life (healthcare); Chemotherapy; Association (psychology); Distress; Health related quality of life; Oncology; Psychological distress; Cancer; Gerontology; Internal medicine; Clinical psychology; Psychiatry; Disease; Anxiety; Psychotherapist","score_opus":0.05783690621685645,"score_gpt":0.4354651078336763,"score_spread":0.37762820161681987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245977770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8759387,0.0005513587,0.000009820475,0.122936666,0.0002873439,0.00016474666,0.000028474618,0.0000040167397,0.00007884631],"genre_scores_gemma":[0.9948823,0.0018908721,0.00023521954,0.0023238556,0.0006046083,0.000003070638,9.223886e-7,0.000013576888,0.000045577617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667394,0.00035528664,0.0021969115,0.00014799321,0.00046357792,0.0001622781],"domain_scores_gemma":[0.995268,0.0006624728,0.0034673042,0.00013021895,0.00026092338,0.00021109228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039442317,0.00010938018,0.0013636234,0.000040596675,0.000049530674,0.0000064828487,0.00008209153,0.00024588322,0.000054214044],"category_scores_gemma":[0.00055197906,0.00007019521,0.0001776075,0.000111075475,0.00030704887,0.00006920933,0.000024253564,0.00061392295,3.0022252e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007973742,0.0006136454,0.98556644,0.00022229533,0.0007426371,0.000013209982,0.0025241678,0.0000060775465,0.00000862577,0.000038152248,0.00030795916,0.0019830684],"study_design_scores_gemma":[0.014152984,0.0015022792,0.98277116,0.0003960583,0.00012972395,0.000039846593,0.00036149283,7.8518735e-7,0.000006584847,0.00018936681,0.00038573644,0.00006400857],"about_ca_topic_score_codex":0.0031968204,"about_ca_topic_score_gemma":0.012601936,"teacher_disagreement_score":0.12061281,"about_ca_system_score_codex":0.00025775295,"about_ca_system_score_gemma":0.0008170831,"threshold_uncertainty_score":0.7032176},"labels":[],"label_agreement":null},{"id":"W4246008022","doi":"10.1200/jco.2004.22.14_suppl.773","title":"Palliative chemotherapy with vinorelbine or capecitabine in women with anthracycline and taxane refractory metastatic breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Vinorelbine; Capecitabine; Medicine; Anthracycline; Taxane; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.07887157768887255,"score_gpt":0.4760803488222091,"score_spread":0.3972087711333366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246008022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96554744,0.00095881626,0.000043974003,0.032767367,0.00019926777,0.00030157002,0.000014680209,0.0000068780255,0.00016002757],"genre_scores_gemma":[0.9789658,0.011101593,0.0038821395,0.00504928,0.0006585735,0.000029727544,0.0000020495065,0.000027011456,0.00028379247],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978353,0.00015885776,0.0012223495,0.00022766531,0.0002533762,0.00030247952],"domain_scores_gemma":[0.99715763,0.000838756,0.001217458,0.00010906453,0.00028409425,0.00039297197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008651546,0.00020463901,0.0016549879,0.00015321953,0.00002636248,0.000005403294,0.00007762238,0.00014462773,0.0009209123],"category_scores_gemma":[0.0001339789,0.00010351794,0.000071221424,0.00025937255,0.0003997474,0.00013115567,0.000015891063,0.00081204914,0.0000020987165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43287912,0.01854933,0.23100473,0.00016647369,0.0043729865,0.010622286,0.002254036,0.00027429234,0.0013134835,0.00002359312,0.00091068476,0.297629],"study_design_scores_gemma":[0.10438372,0.078323,0.8004852,0.0003953665,0.00073047646,0.002079975,0.00056357,0.000014013811,0.00011990736,0.00010142841,0.012630161,0.00017318879],"about_ca_topic_score_codex":0.00022665507,"about_ca_topic_score_gemma":0.0015642392,"teacher_disagreement_score":0.5694805,"about_ca_system_score_codex":0.00065635354,"about_ca_system_score_gemma":0.0027196533,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W4246016344","doi":"10.1200/jco.2007.25.18_suppl.6537","title":"Quality and consistency of phase III clinical trial abstracts presented at an Annual Meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Interim; MEDLINE; Clinical trial; Family medicine; Inclusion (mineral); Consistency (knowledge bases); Clinical Oncology; Medical physics; Internal medicine; Oncology; Cancer; Psychology","score_opus":0.885265217626877,"score_gpt":0.6935421758454062,"score_spread":0.19172304178147082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246016344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829865,0.00023767268,0.0014326544,0.005937226,0.00095056347,0.00090608763,0.000059962418,0.0000028201546,0.0021743702],"genre_scores_gemma":[0.9861138,0.00027961854,0.011976011,0.0007890025,0.00062632514,0.000004788037,0.0000041535145,0.00001208687,0.00019424541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8412319,0.05961523,0.09284227,0.0011110583,0.0046865693,0.0005130084],"domain_scores_gemma":[0.5233244,0.2393586,0.21778226,0.004163265,0.013865963,0.0015055339],"candidate_categories":["metaresearch","metaepi_broad","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.4717679,0.00031863988,0.015192413,0.00020925899,0.00014856597,0.00004181866,0.0021436801,0.000572925,0.00034749068],"category_scores_gemma":[0.17710765,0.00013389924,0.0062622423,0.001152638,0.0046289857,0.00027301905,0.00038430013,0.0014210265,0.0000051173934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08222887,0.020981735,0.5979628,0.00008175635,0.0045910985,0.000018280936,0.0012521406,0.0001058644,0.0003896853,0.00066641305,0.026451996,0.26526937],"study_design_scores_gemma":[0.050929442,0.023286656,0.8420265,0.000078784135,0.001295374,0.00010516294,0.007125212,0.0009884565,0.000040218503,0.0005767222,0.07335122,0.0001962898],"about_ca_topic_score_codex":0.00009257794,"about_ca_topic_score_gemma":0.0011580659,"teacher_disagreement_score":0.31790748,"about_ca_system_score_codex":0.00007660358,"about_ca_system_score_gemma":0.0032364107,"threshold_uncertainty_score":0.9994281},"labels":[],"label_agreement":null},{"id":"W4246021409","doi":"10.1200/jco.2017.35.6_suppl.72","title":"The diverse genomic landscape of low-risk prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Quartile; Oncology; Cancer; Prostate; Internal medicine; Androgen receptor; Confidence interval","score_opus":0.1336281857188823,"score_gpt":0.5127946063853154,"score_spread":0.3791664206664331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246021409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818192,0.0031433827,0.0000021297556,0.01053718,0.0012694807,0.0001959614,0.000014037686,0.000002377835,0.003016212],"genre_scores_gemma":[0.9506743,0.045627926,0.00014770543,0.00014039122,0.00093707244,0.0000040729524,7.3337765e-7,0.000008616933,0.002459197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980343,0.00020019001,0.0011739171,0.0001032113,0.00027913612,0.00020924583],"domain_scores_gemma":[0.995152,0.0013058697,0.0025311073,0.00031359267,0.00046095852,0.0002364781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030190751,0.00007763516,0.0007513545,0.00004006958,0.00024810125,0.00001840891,0.0003246542,0.0001478453,0.0000952421],"category_scores_gemma":[0.0032617233,0.000036948117,0.00034097256,0.000029538043,0.00059254083,0.00007554537,0.00011668096,0.0007319187,0.00001325031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009001829,0.00037340008,0.7142208,0.000027047803,0.0005253211,0.00030758212,0.000119041215,0.0000065675977,0.00017733825,0.000023390454,0.0068340986,0.26838356],"study_design_scores_gemma":[0.011302043,0.006229298,0.8992973,0.00011089976,0.00032043623,0.000041664618,0.00021714385,0.000068154084,0.00027509147,0.00034747328,0.081743754,0.00004675737],"about_ca_topic_score_codex":0.000092448136,"about_ca_topic_score_gemma":0.00012737606,"teacher_disagreement_score":0.2683368,"about_ca_system_score_codex":0.00009148652,"about_ca_system_score_gemma":0.0020436114,"threshold_uncertainty_score":0.3904823},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4246074465","doi":"10.1200/jco.2004.22.14_suppl.8010","title":"Ten-year breast cancer survival - at what cost in human and physical terms? A case-control study of long-term survivors of breast cancer and their physical and functional well-being","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Oncology; Term (time); Cancer; Internal medicine","score_opus":0.047605701118848,"score_gpt":0.39633031078953196,"score_spread":0.34872460967068397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246074465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662894,0.0005200793,0.000008808544,0.0016404805,0.00067256135,0.00039077963,0.00007454675,0.00000469644,0.000059097405],"genre_scores_gemma":[0.99758613,0.0008107499,0.000003415198,0.00022482523,0.0013117904,0.000015051234,0.0000016519994,0.000024479074,0.000021931453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739987,0.00038183638,0.0012453251,0.0003392798,0.00036898797,0.00026470752],"domain_scores_gemma":[0.9970001,0.001222778,0.00092476263,0.00016559193,0.00033701907,0.00034977242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011425036,0.00024461048,0.0019901905,0.00014829183,0.000068049056,0.000018705152,0.00008053465,0.00020884594,0.000058553378],"category_scores_gemma":[0.00007191645,0.00016897399,0.00023545003,0.00016171177,0.0005601166,0.00025751654,0.000108575885,0.00078540586,2.785135e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006751117,0.0031003093,0.9257481,0.00013120471,0.00055648125,0.00081477297,0.003979432,0.000050064646,0.00069526344,0.000033902,0.000007213042,0.058132127],"study_design_scores_gemma":[0.019979663,0.0038323756,0.9679258,0.00044458194,0.00052507245,0.0027488708,0.0041594384,0.000050683266,0.000051715084,0.00012585249,0.000011737544,0.00014423596],"about_ca_topic_score_codex":0.0028987234,"about_ca_topic_score_gemma":0.041764278,"teacher_disagreement_score":0.057987887,"about_ca_system_score_codex":0.00022086572,"about_ca_system_score_gemma":0.00041381057,"threshold_uncertainty_score":0.975721},"labels":[],"label_agreement":null},{"id":"W4246159133","doi":"10.1200/jco.2015.33.3_suppl.739","title":"Predictive factors and prognostic significance of tumor regression grade in rectal cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Proportional hazards model; Capecitabine; Hazard ratio; Internal medicine; Radiation therapy; Logistic regression; Cancer; Statistical significance; Log-rank test; Concomitant; Oncology; Surgery; Confidence interval","score_opus":0.18697086721822656,"score_gpt":0.46176887325167926,"score_spread":0.2747980060334527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246159133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955294,0.0011594486,0.0000087051185,0.0019111938,0.0005793828,0.00017890753,0.0000041958,0.000003761633,0.00062499824],"genre_scores_gemma":[0.99884146,0.0002218811,0.000295586,0.00015555389,0.0004202319,0.0000035255616,7.175531e-7,0.000006935865,0.00005407706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789643,0.00028235893,0.0012705808,0.00013417978,0.00027820072,0.00013823874],"domain_scores_gemma":[0.9967286,0.0014562783,0.0010566066,0.000060885883,0.00032446397,0.00037315066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014001238,0.00009768168,0.0010966115,0.00010685756,0.000010315547,0.0000020716627,0.00007183041,0.00015490694,0.000015396525],"category_scores_gemma":[0.006102701,0.000056678826,0.0001617179,0.00015343999,0.00025063579,0.00007198673,0.000039873194,0.00068303617,4.841601e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049207993,0.0006679688,0.98276895,0.00003800448,0.000053563286,0.00050635455,0.00034334193,0.0000064491396,0.00084921747,0.000010434368,0.00060996687,0.00922495],"study_design_scores_gemma":[0.004016439,0.020140555,0.9718282,0.00036373816,0.00014454266,0.00017986854,0.0006402928,0.00015998303,0.0009094357,0.00038984965,0.0011714429,0.000055611854],"about_ca_topic_score_codex":0.00010881768,"about_ca_topic_score_gemma":0.00015259579,"teacher_disagreement_score":0.019472586,"about_ca_system_score_codex":0.00012074939,"about_ca_system_score_gemma":0.001550832,"threshold_uncertainty_score":0.7305944},"labels":[],"label_agreement":null},{"id":"W4246309607","doi":"10.1200/jco.2004.22.14_suppl.1534","title":"Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O<sub>2</sub>), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Radiation therapy; Randomized controlled trial; Supplemental oxygen; Whole brain radiotherapy; Internal medicine; Brain metastasis; Oncology; Cancer; Metastasis","score_opus":0.04056882420307413,"score_gpt":0.38717402405283513,"score_spread":0.346605199849761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246309607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796492,0.0001319833,0.00024118058,0.015538573,0.00015917492,0.004035311,0.0001748324,0.000010502083,0.00005926531],"genre_scores_gemma":[0.99264723,0.00007887755,0.0050124726,0.0018434597,0.00017845786,0.000059759368,0.00007175616,0.000050603227,0.0000573687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919112,0.0027440211,0.0031300362,0.00044954993,0.0013602593,0.00040496464],"domain_scores_gemma":[0.9921173,0.002964328,0.0034896568,0.0005217066,0.0005932097,0.00031383513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009616597,0.00039531713,0.003314113,0.0002249088,0.000090296046,0.000022602058,0.0002608332,0.00017797916,0.000030471605],"category_scores_gemma":[0.0019371873,0.00015943627,0.00043516475,0.0005290406,0.0005235035,0.00021048092,0.0000494956,0.0008549866,0.0000018247897],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7383971,0.011091095,0.22268172,0.000020596777,0.0030125978,0.00039322017,0.0010603836,0.00022656862,0.000074110074,0.000019977391,0.00097287615,0.022049712],"study_design_scores_gemma":[0.6319653,0.114289336,0.24799688,0.00023776141,0.0011625026,0.00010878956,0.00090800336,0.000007627136,0.000623627,0.000052379528,0.0024794368,0.00016839932],"about_ca_topic_score_codex":0.00015890584,"about_ca_topic_score_gemma":0.0015648722,"teacher_disagreement_score":0.10643189,"about_ca_system_score_codex":0.00042367648,"about_ca_system_score_gemma":0.002661772,"threshold_uncertainty_score":0.6501622},"labels":[],"label_agreement":null},{"id":"W4246474791","doi":"10.1200/jco.2009.27.18_suppl.lba4505","title":"ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Folinic acid; Gemcitabine; Pancreatic cancer; Chemotherapy; Internal medicine; Fluorouracil; Gastroenterology; Surgery; Adenocarcinoma; Randomized controlled trial; Cancer","score_opus":0.12016273715835939,"score_gpt":0.49128309031717116,"score_spread":0.37112035315881176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246474791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98437876,0.0011571825,0.00017001154,0.0043079536,0.0016628426,0.005173249,0.000014574448,0.0000117676245,0.0031236452],"genre_scores_gemma":[0.99129325,0.001940351,0.0048637358,0.0005521402,0.0008333816,0.0000901745,0.000037271682,0.000027625349,0.00036207787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9876556,0.003008825,0.0069538755,0.0004670749,0.0013288377,0.0005858123],"domain_scores_gemma":[0.9799004,0.011930237,0.005037228,0.00048717007,0.0019944631,0.0006504798],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012401227,0.00038739262,0.009897777,0.0006119695,0.000064123495,0.000032732467,0.0008128059,0.00061626855,0.00046425327],"category_scores_gemma":[0.03721218,0.00023708149,0.0007302751,0.00038234214,0.00072146446,0.00037186945,0.00017934856,0.0017711042,0.000012579936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90436643,0.029520638,0.048612308,0.000024415649,0.0034206968,0.0012768926,0.00017938709,0.0000025533045,0.00010234804,0.00006959189,0.0005485869,0.011876155],"study_design_scores_gemma":[0.80462784,0.12785392,0.061613232,0.00034517515,0.0028533952,0.00007285529,0.000116495816,0.0020611782,0.00001318534,0.000086429725,0.0001922385,0.00016405249],"about_ca_topic_score_codex":0.00007550508,"about_ca_topic_score_gemma":0.000073927426,"teacher_disagreement_score":0.099738576,"about_ca_system_score_codex":0.0004213905,"about_ca_system_score_gemma":0.0031515316,"threshold_uncertainty_score":0.9708978},"labels":[],"label_agreement":null},{"id":"W4246621148","doi":"10.1200/jco.2002.20.3.647","title":"Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Follicular lymphoma; Lymphoma; Immunohistochemistry; Pathology; CD20; Follicular phase; Trunk; Radiation therapy; Internal medicine; Biology","score_opus":0.08091390790361995,"score_gpt":0.454774142752142,"score_spread":0.37386023484852204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246621148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97880435,0.008953134,0.00005548475,0.0032024276,0.0009845779,0.00026565383,0.0000047723693,0.000013285871,0.0077163056],"genre_scores_gemma":[0.96426713,0.008117893,0.022956925,0.0039651385,0.00048458463,0.000006282909,0.0000050580647,0.000021434658,0.00017553086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99439996,0.00093522854,0.0035506904,0.00035090666,0.0005029094,0.00026028682],"domain_scores_gemma":[0.9940862,0.0019335835,0.0025866553,0.00044119157,0.00042444706,0.0005279075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027195318,0.00023098892,0.0027676697,0.00011424563,0.00005361057,0.000012582293,0.00020540401,0.0006333052,0.00014683139],"category_scores_gemma":[0.001719912,0.00015312739,0.0008744321,0.00009914433,0.0004539258,0.00010170892,0.00009464485,0.000530496,0.0000062739578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018720208,0.020949004,0.29180503,0.00007136349,0.0010263693,0.018797606,0.00007737776,0.00001092046,0.0008527111,0.0006906821,0.0039603133,0.6598866],"study_design_scores_gemma":[0.015921015,0.032153737,0.90894157,0.00009520132,0.0012614221,0.0057472833,0.000049565213,0.00009039523,0.00011556121,0.000381238,0.03509235,0.00015068332],"about_ca_topic_score_codex":0.000020116975,"about_ca_topic_score_gemma":0.0000042978454,"teacher_disagreement_score":0.6597359,"about_ca_system_score_codex":0.00026020626,"about_ca_system_score_gemma":0.0008170455,"threshold_uncertainty_score":0.62443537},"labels":[],"label_agreement":null},{"id":"W4246625087","doi":"10.1200/jco.2016.34.15_suppl.lba4500","title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Oncology; Cohort; Internal medicine; Cisplatin; Clinical Oncology; Urothelial carcinoma; Bladder cancer; Cancer; Chemotherapy; Immunotherapy; Nivolumab","score_opus":0.0732569150031822,"score_gpt":0.43176995279368185,"score_spread":0.35851303779049964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246625087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886862,0.0010790329,0.000828346,0.004069373,0.0006627139,0.00054346153,0.000045711688,0.000012300787,0.0040728836],"genre_scores_gemma":[0.9884313,0.006762967,0.002003993,0.0017249,0.00043170343,0.000028186365,0.000008394385,0.000038901228,0.00056967675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426,0.0004385049,0.0037689975,0.00039435056,0.00072300254,0.0004151029],"domain_scores_gemma":[0.993637,0.0027758519,0.002064533,0.00042722342,0.0006653651,0.0004300221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179047,0.00030488012,0.003434036,0.00064847706,0.000036305017,0.000006556434,0.000294331,0.0003317714,0.00083770073],"category_scores_gemma":[0.0016594689,0.0001765429,0.0010912542,0.0007731916,0.00032280677,0.00018044654,0.00005968664,0.0005914538,0.000032770084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02495585,0.0031616848,0.6990369,0.000045737903,0.004218373,0.0012005515,0.00009314463,0.00017335136,0.0013408085,0.00003796743,0.00040054446,0.26533508],"study_design_scores_gemma":[0.040697675,0.025331365,0.9198405,0.0002706157,0.0037208956,0.00024490204,0.00003204127,0.00012718923,0.0016229716,0.00078456127,0.0071088937,0.00021834759],"about_ca_topic_score_codex":0.0002788009,"about_ca_topic_score_gemma":0.00024942763,"teacher_disagreement_score":0.26511672,"about_ca_system_score_codex":0.00041247156,"about_ca_system_score_gemma":0.0034743438,"threshold_uncertainty_score":0.9172236},"labels":[],"label_agreement":null},{"id":"W4246656709","doi":"10.1200/jco.2021.39.15_suppl.tps4596","title":"PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kidney Foundation of Canada; Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"Bristol-Myers Squibb Canada; National Institutes of Health","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Perioperative; Internal medicine; Neoadjuvant therapy; Kidney cancer; Oncology; Adjuvant; Stage (stratigraphy); Surgery; Urology; Immunotherapy; Kidney; Cancer; Breast cancer","score_opus":0.11734380422692563,"score_gpt":0.40725564893423777,"score_spread":0.2899118447073121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246656709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944063,0.0002499829,0.0000817817,0.00039615086,0.0008109617,0.0015321265,0.000001485681,0.000010371945,0.002510828],"genre_scores_gemma":[0.9948585,0.00005159981,0.004131101,0.00021392829,0.0003683188,0.000036396938,0.000023220184,0.000033152086,0.0002837711],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934196,0.001768723,0.003302535,0.00043694724,0.0007138617,0.00035832237],"domain_scores_gemma":[0.99320513,0.003126374,0.0018412282,0.00031098817,0.0011446682,0.00037159567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026319604,0.00030703822,0.0035226434,0.00018549596,0.00008711933,0.000035322773,0.00014815081,0.00022745402,0.00013492149],"category_scores_gemma":[0.0021630283,0.0002110749,0.0004919322,0.00035069845,0.00019054975,0.00025348054,0.00009498487,0.0011881628,0.000010448983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39728177,0.011046171,0.5852471,0.000027189139,0.0004908902,0.0020365203,0.00083305914,0.00010429047,0.000084783795,0.000008572207,0.000050894574,0.0027887507],"study_design_scores_gemma":[0.5248509,0.030227477,0.44235042,0.000091223425,0.00074022164,0.00003769213,0.00077357364,0.00029505987,0.00028357145,0.0000040033233,0.00022349134,0.00012235034],"about_ca_topic_score_codex":0.00010136573,"about_ca_topic_score_gemma":0.00078953535,"teacher_disagreement_score":0.1428967,"about_ca_system_score_codex":0.0008147281,"about_ca_system_score_gemma":0.0032031108,"threshold_uncertainty_score":0.86073846},"labels":[],"label_agreement":null},{"id":"W4246701592","doi":"10.1200/jco.2020.38.15_suppl.tps5596","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.08489063859828656,"score_gpt":0.4675145738132983,"score_spread":0.38262393521501176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246701592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97675127,0.0076656262,0.000010167033,0.0067707216,0.000484682,0.008187864,0.000078574034,0.000014689318,0.00003641761],"genre_scores_gemma":[0.9903456,0.0074747535,0.00061560475,0.00090499065,0.0002722829,0.00022583664,0.000039452676,0.000043829008,0.000077678116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902475,0.002696636,0.0050594714,0.00050575775,0.0009594986,0.0005311626],"domain_scores_gemma":[0.99119735,0.0031818755,0.0032005012,0.00022393005,0.0014197481,0.0007765869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005188732,0.0004228901,0.0055327713,0.00029118915,0.0001434757,0.00003265348,0.00022125065,0.00019619988,0.000110764755],"category_scores_gemma":[0.0053477017,0.00024413712,0.00061052426,0.00035046664,0.0006419176,0.00024390443,0.00009687191,0.0010821053,0.0000017203251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8804176,0.013781619,0.036328528,0.00013493186,0.00275502,0.0008255802,0.0042566513,0.00007528574,0.005680191,0.0000021420713,0.00013630568,0.055606138],"study_design_scores_gemma":[0.8818556,0.07121508,0.04133703,0.0005185717,0.0012450872,0.000021334312,0.0007318127,0.0010876507,0.001360258,0.000014756329,0.00041554007,0.00019728119],"about_ca_topic_score_codex":0.0001967149,"about_ca_topic_score_gemma":0.00019039473,"teacher_disagreement_score":0.05743346,"about_ca_system_score_codex":0.0003954813,"about_ca_system_score_gemma":0.0028774103,"threshold_uncertainty_score":0.99556226},"labels":[],"label_agreement":null},{"id":"W4246805974","doi":"10.1200/jco.2021.39.15_suppl.12116","title":"The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Medicine; Quality of life (healthcare); Pancreatic cancer; Palliative care; Cancer; Performance status; Confidence interval; Ambulatory; Internal medicine; Nursing","score_opus":0.32005180243819553,"score_gpt":0.5983933926156121,"score_spread":0.27834159017741655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246805974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944571,0.0028492326,0.000010034219,0.0015303717,0.00019315242,0.00044017204,0.000060465114,0.0000012878762,0.00045817872],"genre_scores_gemma":[0.99668396,0.0027536417,0.0001475084,0.00022615727,0.00014413927,0.000009170857,0.000002028593,0.0000098688015,0.000023518187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948048,0.001955797,0.0022988974,0.00013561256,0.00064765225,0.0001572692],"domain_scores_gemma":[0.9757978,0.016053276,0.0040458366,0.00034819165,0.00363364,0.00012125409],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020169064,0.00015044984,0.0018253481,0.000032215223,0.000058515394,0.0000032475505,0.00025025144,0.00011714315,0.00004791087],"category_scores_gemma":[0.013839828,0.00005367856,0.0005612012,0.00024450626,0.0005959206,0.00004651614,0.000053423395,0.00067207334,4.0994865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012256608,0.0014901146,0.96178037,0.000044316188,0.0023211273,0.000009618813,0.012039337,0.00012015431,0.00009760528,0.00008929609,0.00015980843,0.009591648],"study_design_scores_gemma":[0.0060256673,0.031184303,0.93872064,0.00052009634,0.0004026182,3.534679e-7,0.022162188,0.000004276117,0.00063495914,0.00007065548,0.0002244273,0.00004983643],"about_ca_topic_score_codex":0.00044394922,"about_ca_topic_score_gemma":0.00045608095,"teacher_disagreement_score":0.029694188,"about_ca_system_score_codex":0.00013511072,"about_ca_system_score_gemma":0.002713658,"threshold_uncertainty_score":0.994467},"labels":[],"label_agreement":null},{"id":"W4246828179","doi":"10.1200/jco.2018.36.6_suppl.tps710","title":"A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Perioperative; Stage (stratigraphy); Internal medicine; Kidney cancer; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy; Kidney","score_opus":0.08311602906615595,"score_gpt":0.3970990932735689,"score_spread":0.31398306420741295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246828179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947223,0.00008893653,0.00042551232,0.00033695,0.00045440684,0.0020604376,8.779105e-7,0.000011810655,0.0018987787],"genre_scores_gemma":[0.99291444,0.000017348879,0.005633099,0.0005667561,0.00057288405,0.000032134907,0.000008947811,0.00003331179,0.00022105177],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934398,0.0016392581,0.0034664972,0.0003913667,0.0007041291,0.00035896344],"domain_scores_gemma":[0.9941129,0.0019413468,0.0021337646,0.00029198817,0.0011422796,0.00037773236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037530274,0.00030675292,0.003763759,0.00025494504,0.00009904946,0.000029012643,0.00017476045,0.0002456398,0.0001507905],"category_scores_gemma":[0.0013210902,0.00019052271,0.0004370058,0.00031255954,0.0004460884,0.00024468295,0.00007375605,0.00095816975,0.000018797424],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41327173,0.011354234,0.57163864,0.00001596951,0.00031894015,0.00040415514,0.0010529243,0.000020258272,0.000048489757,0.000006424851,0.00009221919,0.0017760193],"study_design_scores_gemma":[0.5534419,0.069334425,0.37445945,0.00010413728,0.00068559375,0.000028599046,0.00031932507,0.0008519426,0.00017723789,0.000009331768,0.00046716927,0.0001209439],"about_ca_topic_score_codex":0.00019761873,"about_ca_topic_score_gemma":0.0005777013,"teacher_disagreement_score":0.19717918,"about_ca_system_score_codex":0.0006831147,"about_ca_system_score_gemma":0.0018084671,"threshold_uncertainty_score":0.7769291},"labels":[],"label_agreement":null},{"id":"W4247016860","doi":"10.1200/jco.2004.99.312","title":"In Reply:","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.14731839661788587,"score_gpt":0.5162364027535872,"score_spread":0.3689180061357013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247016860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92562264,0.0003838521,0.000010679706,0.06456424,0.0008442795,0.00006871504,2.5789427e-7,0.0000026081443,0.008502712],"genre_scores_gemma":[0.97978675,0.00066910026,0.003521489,0.015124423,0.0007479104,0.0000016148605,2.5412447e-7,0.0000046005116,0.00014385955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814934,0.000080829785,0.0014181901,0.000084184954,0.00015681474,0.00011063864],"domain_scores_gemma":[0.9983745,0.00063260645,0.00057829544,0.00010390531,0.000108762906,0.00020193761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013776694,0.00005456311,0.00081389403,0.000074976524,0.00000780577,0.000002180898,0.00005129339,0.00014660075,0.000101485704],"category_scores_gemma":[0.0019327191,0.000033904114,0.0002886902,0.00007771198,0.000060047172,0.000058197995,0.00001509831,0.00030843331,0.000053604475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036661027,0.015110266,0.7465234,0.000016229618,0.00036681592,0.024349378,0.00015943272,0.000050464845,0.000058927384,0.0027882934,0.016022692,0.19088802],"study_design_scores_gemma":[0.021784903,0.010775248,0.7429633,0.00008165376,0.00011451048,0.0011289011,0.000031681997,0.0000013464016,0.00018833282,0.002871065,0.22002533,0.000033706347],"about_ca_topic_score_codex":0.000046491426,"about_ca_topic_score_gemma":0.000030955038,"teacher_disagreement_score":0.20400263,"about_ca_system_score_codex":0.00030079755,"about_ca_system_score_gemma":0.0014511246,"threshold_uncertainty_score":0.25742328},"labels":[],"label_agreement":null},{"id":"W4247051977","doi":"10.1200/jco.2013.31.15_suppl.tps8612","title":"Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; ABVD; Dacarbazine; Internal medicine; Oncology; Vinblastine; Chemotherapy regimen; Regimen; Bleomycin; Chemotherapy; Vincristine; CD30; Lymphoma; Cyclophosphamide","score_opus":0.09144301180543674,"score_gpt":0.4451930388676109,"score_spread":0.3537500270621742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247051977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867119,0.0026472292,0.00015112133,0.005421203,0.0014648525,0.0027953098,0.00004984601,0.000035422512,0.0007230725],"genre_scores_gemma":[0.9907259,0.0024744112,0.0037154343,0.0007272876,0.0014215304,0.00022738207,0.000046195586,0.00007616217,0.00058570766],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925458,0.00045821234,0.004591031,0.0009071284,0.00074857,0.0007492827],"domain_scores_gemma":[0.98745984,0.0063447445,0.0030128695,0.0005844104,0.0014132235,0.0011849061],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012898364,0.00076032925,0.00474378,0.00036518584,0.00015571008,0.00005211313,0.00026405603,0.00060469145,0.00019109635],"category_scores_gemma":[0.0032695504,0.0005091321,0.0006828017,0.00025136134,0.00052693405,0.00038332865,0.00020435585,0.00046338548,0.000018682378],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16326317,0.10508201,0.033814177,0.00021585793,0.006793075,0.0015962608,0.0011594762,0.0000900504,0.0077822725,0.00023627978,0.009847754,0.67011964],"study_design_scores_gemma":[0.53342605,0.32919654,0.10752041,0.00033369218,0.0046766438,0.00065265084,0.0015399125,0.002425263,0.0020606474,0.00013117513,0.017571323,0.00046567732],"about_ca_topic_score_codex":0.00042621835,"about_ca_topic_score_gemma":0.00043625102,"teacher_disagreement_score":0.66965395,"about_ca_system_score_codex":0.00073369045,"about_ca_system_score_gemma":0.0016627152,"threshold_uncertainty_score":0.999736},"labels":[],"label_agreement":null},{"id":"W4247156322","doi":"10.1200/jco.2017.35.15_suppl.lba10500","title":"Temporal trends in chronic disease among survivors of childhood cancer diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Childhood cancer; Cancer; Clinical Oncology; Family medicine; Disease; Gerontology; Pediatrics; Internal medicine","score_opus":0.1379309319350012,"score_gpt":0.5133653628192814,"score_spread":0.3754344308842802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247156322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963716,0.008586305,0.000014065287,0.021937076,0.0041968673,0.0010586475,0.00024610144,0.000026647464,0.00021831035],"genre_scores_gemma":[0.989055,0.0025054717,0.00008093432,0.0018391041,0.0061414554,0.000109459674,0.000023618975,0.00008902494,0.00015595065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9880264,0.0016513264,0.0068802475,0.00090293767,0.0017014673,0.0008376388],"domain_scores_gemma":[0.9811494,0.0046726284,0.010293433,0.002124747,0.00068612496,0.0010737175],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011892701,0.0005714788,0.0042376295,0.00021894295,0.00036590168,0.00008583955,0.0017121987,0.0006228217,0.00062737917],"category_scores_gemma":[0.0119520705,0.0003858982,0.0014765454,0.00042423673,0.0013396959,0.0005764775,0.0005235712,0.0029427123,0.000005187746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025544937,0.007342953,0.9210984,0.00003906123,0.0016553038,0.0028075017,0.004148636,0.00009419455,0.000004343723,0.000003462615,0.0025379963,0.057713635],"study_design_scores_gemma":[0.020520724,0.0039709336,0.9659077,0.0010249601,0.0010856749,0.000048184473,0.001465529,0.00004379406,0.000012293851,0.00015513568,0.0054003135,0.00036474486],"about_ca_topic_score_codex":0.1267133,"about_ca_topic_score_gemma":0.6478223,"teacher_disagreement_score":0.52110904,"about_ca_system_score_codex":0.00075869757,"about_ca_system_score_gemma":0.007947769,"threshold_uncertainty_score":0.9998593},"labels":[],"label_agreement":null},{"id":"W4247249647","doi":"10.1200/jco.2004.22.14_suppl.8123","title":"FACT-Gastric: A new international measure of QOL in gastric cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Measure (data warehouse); Internal medicine; Oncology; Gastroenterology; Data mining","score_opus":0.1580850044457385,"score_gpt":0.4830705074917702,"score_spread":0.3249855030460317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247249647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.935115,0.00091861706,0.0026635402,0.049938448,0.0036276348,0.0002531648,0.0000028822758,0.000008445142,0.0074722813],"genre_scores_gemma":[0.9895057,0.0013104903,0.00506568,0.0017729782,0.0015336525,0.0000018116036,9.3121315e-7,0.000009495174,0.0007992318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722004,0.00007426937,0.0018989898,0.00012798785,0.00049844827,0.00018024021],"domain_scores_gemma":[0.9976677,0.00035089088,0.00134574,0.000106786836,0.00028906864,0.00023986195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012778301,0.00010237039,0.0010366548,0.00036983422,0.00000816893,0.000004703039,0.00021853439,0.00017510339,0.00037750506],"category_scores_gemma":[0.0018274307,0.00007517245,0.00038655504,0.00031891954,0.00007072038,0.000105976695,0.00005236439,0.0006929041,0.000006401816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021717981,0.0007864562,0.66653734,0.000018687288,0.00034876552,0.0003636244,0.000088503264,0.00044862277,0.00008181827,0.00012726948,0.007686519,0.32134062],"study_design_scores_gemma":[0.018466227,0.0037627793,0.92224497,0.00019529842,0.00024644204,0.00016534179,0.00010908843,0.000013320606,0.000031199015,0.0004948678,0.05421097,0.000059503105],"about_ca_topic_score_codex":0.00031704918,"about_ca_topic_score_gemma":0.00026795798,"teacher_disagreement_score":0.3212811,"about_ca_system_score_codex":0.0003940353,"about_ca_system_score_gemma":0.0025246292,"threshold_uncertainty_score":0.4478584},"labels":[],"label_agreement":null},{"id":"W4247263729","doi":"10.1200/jco.2004.22.14_suppl.3764","title":"Prognostication using serum levels of components of the folate metabolic pathway in patients (PTS) treated with capecitabine for advanced colorectal cancer (ACRC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Thymidylate synthase; Medicine; Homocysteine; Gastroenterology; Internal medicine; Vitamin B12; Colorectal cancer; Cancer; Fluorouracil","score_opus":0.10361903941469253,"score_gpt":0.41828595469522534,"score_spread":0.3146669152805328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247263729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975166,0.00051339803,0.00003748319,0.0005980399,0.00033911483,0.00085344893,0.000071642724,0.0000024737221,0.000067814915],"genre_scores_gemma":[0.9978447,0.00014685359,0.0017854734,0.000089656605,0.000083821884,0.000021569194,0.0000021737508,0.000013248661,0.000012494592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780935,0.000117969445,0.0014854817,0.00014180798,0.00026994915,0.00017543482],"domain_scores_gemma":[0.9967613,0.0004672354,0.0017660713,0.000095674615,0.0008263541,0.00008336957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048321966,0.00013208047,0.0013232229,0.00008474969,0.00003634765,0.0000016422459,0.00009582754,0.0001245285,0.000011248727],"category_scores_gemma":[0.00074925437,0.000070318194,0.000254664,0.00023934929,0.0001961869,0.00007411864,0.00003370343,0.00023331087,1.2162103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015955571,0.0033788397,0.880341,0.000056439436,0.0007632602,0.0000115278945,0.00030979805,0.00047369784,0.0036530048,0.00005183398,0.0000027625954,0.09500225],"study_design_scores_gemma":[0.027783886,0.01458174,0.9498303,0.00031518814,0.0005031632,0.00001042091,0.00006518937,0.000056332632,0.0064588855,0.00010936837,0.00022428688,0.000061254155],"about_ca_topic_score_codex":0.00013338558,"about_ca_topic_score_gemma":0.000486483,"teacher_disagreement_score":0.094941,"about_ca_system_score_codex":0.0002733538,"about_ca_system_score_gemma":0.00088700943,"threshold_uncertainty_score":0.28674927},"labels":[],"label_agreement":null},{"id":"W4247271096","doi":"10.1200/jco.2004.22.90140.847","title":"Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Interim analysis; Hazard ratio; Internal medicine; Letrozole; Randomized controlled trial; Vasomotor; Placebo; Cancer; Oncology; Surgery; Confidence interval","score_opus":0.00897252141859368,"score_gpt":0.33012705638043166,"score_spread":0.321154534961838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247271096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824405,0.00037679248,0.000017915941,0.00030002877,0.0002196552,0.00067943014,0.000045163997,9.848252e-7,0.0001159686],"genre_scores_gemma":[0.99906886,0.00033465977,0.00013611933,0.00013444682,0.00011554816,0.000032344844,0.0000042052575,0.000011610409,0.0001622209],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99630183,0.0010612346,0.0019851406,0.00016694126,0.0002818263,0.00020301911],"domain_scores_gemma":[0.99628717,0.000502063,0.002576125,0.00022231418,0.0003000879,0.00011224171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028648842,0.00013874364,0.0023561257,0.00016740615,0.000011071293,0.0000033310457,0.0002549406,0.00043237014,0.000053785203],"category_scores_gemma":[0.000558928,0.000078991216,0.00067055854,0.00032979692,0.00046024,0.000007914001,0.0000647703,0.00043958297,3.376566e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9727163,0.0010675086,0.004403344,0.000007786086,0.0061404267,0.000047454305,0.00018163481,0.0035965424,0.011199636,0.000009197932,0.000024356175,0.000605852],"study_design_scores_gemma":[0.90685457,0.011723881,0.07666159,0.00004895032,0.0021638903,0.000014229439,0.00008000508,0.000042137177,0.0021895247,0.000026287184,0.00009306768,0.000101842365],"about_ca_topic_score_codex":0.00018672104,"about_ca_topic_score_gemma":0.00013947823,"teacher_disagreement_score":0.07225824,"about_ca_system_score_codex":0.00006444219,"about_ca_system_score_gemma":0.0011091306,"threshold_uncertainty_score":0.33348346},"labels":[],"label_agreement":null},{"id":"W4247337865","doi":"10.1200/jco.2020.38.15_suppl.e19303","title":"An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; Canadian Agency for Drugs and Technologies in Health; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Oncology; Confidence interval; Cancer; Clinical trial; Disease; Family medicine","score_opus":0.576607370751638,"score_gpt":0.5787913728956122,"score_spread":0.002184002143974184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247337865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860759,0.00038588775,0.010010666,0.0012220427,0.00066576304,0.00071618945,0.00072990125,0.0000016048207,0.00019207805],"genre_scores_gemma":[0.98085165,0.00059144263,0.01708041,0.00057294505,0.00076519547,0.000010477011,0.00010666864,0.000015966232,0.000005257716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99513006,0.00043000796,0.0035774612,0.00030261223,0.00039040012,0.00016947508],"domain_scores_gemma":[0.991522,0.001456183,0.00399479,0.00040475943,0.002414622,0.0002076069],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011971936,0.00012532272,0.0013834919,0.00003708544,0.000022124961,0.0000034520876,0.00048950856,0.0002477641,0.000007860606],"category_scores_gemma":[0.02238902,0.00010518976,0.00045894505,0.00005791583,0.00014865871,0.0000130531735,0.00011626665,0.0002037598,1.2043847e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035377525,0.008915515,0.19073829,0.00084918545,0.0045859306,0.000019681978,0.0005860373,0.0048306533,0.43781808,0.0013635199,0.007511778,0.30740383],"study_design_scores_gemma":[0.07618611,0.19863117,0.30499443,0.00046235163,0.005725041,0.000016875692,0.0024765455,0.033376224,0.31290072,0.003335439,0.06092139,0.0009736823],"about_ca_topic_score_codex":0.0000073461506,"about_ca_topic_score_gemma":0.00038623507,"teacher_disagreement_score":0.30643013,"about_ca_system_score_codex":0.00005399847,"about_ca_system_score_gemma":0.0045691356,"threshold_uncertainty_score":0.9858458},"labels":[],"label_agreement":null},{"id":"W4247355438","doi":"10.1200/jco.2013.49.1118","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":708,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer; Guideline; Deep vein; Intensive care medicine; Pulmonary embolism; Cochrane Library; Randomized controlled trial; Perioperative; Low molecular weight heparin; Clinical trial; MEDLINE; Thrombosis; Internal medicine; Surgery","score_opus":0.16415057401363053,"score_gpt":0.5332278323406828,"score_spread":0.3690772583270523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247355438","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04863467,0.9298244,0.000039879495,0.009563783,0.0045972103,0.005710926,0.00008381252,0.000028648432,0.0015166847],"genre_scores_gemma":[0.0007179165,0.9578322,0.032123864,0.005812816,0.0031595703,0.00012232404,0.000051070663,0.00010936713,0.000070875685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97508824,0.004304404,0.017921269,0.0010166272,0.000967143,0.00070230075],"domain_scores_gemma":[0.96294343,0.009934727,0.023235722,0.000803768,0.002002372,0.0010799592],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.013544141,0.0008140054,0.025915027,0.00025179828,0.00006593921,0.000022358297,0.00052617816,0.0020174624,0.00016165862],"category_scores_gemma":[0.0062753786,0.0004770615,0.0031515597,0.00053162215,0.0017854928,0.00024299677,0.00034344985,0.0039535756,0.000028600261],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018111308,0.037586212,0.014984229,0.0012698416,0.0074879397,0.00031749177,0.00008466718,0.0000025196691,1.4760005e-8,0.000027478505,0.029213365,0.9072151],"study_design_scores_gemma":[0.011836413,0.11631347,0.076971315,0.0025610954,0.010999219,0.00007896072,0.0001380013,0.000008314705,3.929873e-8,0.000015608059,0.78076106,0.00031649915],"about_ca_topic_score_codex":0.0010311562,"about_ca_topic_score_gemma":0.00025396261,"teacher_disagreement_score":0.9068986,"about_ca_system_score_codex":0.00090978376,"about_ca_system_score_gemma":0.012319526,"threshold_uncertainty_score":0.9997681},"labels":[],"label_agreement":null},{"id":"W4247376256","doi":"10.1200/jco.2004.22.14_suppl.8161","title":"Frequency of axillary node dissection and chemotherapy in breast cancer patients over 60 years of age compared with those younger than 60 years of age","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Axillary Dissection; Chemotherapy; Dissection (medical); Axillary Lymph Node Dissection; Oncology; Cancer; Internal medicine; Surgery; Mastectomy; Sentinel lymph node","score_opus":0.028061977479366285,"score_gpt":0.36757570546543383,"score_spread":0.33951372798606755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247376256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99877477,0.0005387523,0.0000100868,0.00027141732,0.00018246591,0.00009375245,0.000043191852,9.988023e-7,0.00008459472],"genre_scores_gemma":[0.9972301,0.0018665367,0.00059743435,0.00016182456,0.00011448168,0.0000029675148,0.000007623859,0.000012653966,0.000006387614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986491,0.000093451716,0.0008267461,0.00014983655,0.00016223249,0.000118586235],"domain_scores_gemma":[0.9986219,0.00007262987,0.00096302293,0.00011987624,0.00016089523,0.000061682884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026671635,0.000101183774,0.0006815452,0.00005572898,0.000008975184,0.0000018364714,0.0000976246,0.00018548834,0.000009814109],"category_scores_gemma":[0.000066231194,0.00008185417,0.00013419286,0.00008395944,0.0003003809,0.000011125438,0.000036468977,0.00015733017,1.162736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003406281,0.0016966761,0.97027,0.00003224724,0.00052519,0.00017375173,0.00036499716,0.00010123147,0.012208032,0.0000075317234,0.00007154954,0.011142536],"study_design_scores_gemma":[0.007694839,0.0016795469,0.9890343,0.0001294451,0.00008032079,0.000027590377,0.00006223573,7.338416e-7,0.0009948858,0.00009513113,0.00012855457,0.00007243088],"about_ca_topic_score_codex":0.0006855027,"about_ca_topic_score_gemma":0.0008736532,"teacher_disagreement_score":0.018764311,"about_ca_system_score_codex":0.000060063787,"about_ca_system_score_gemma":0.00026452518,"threshold_uncertainty_score":0.3337916},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4247435208","doi":"10.1200/jco.2004.22.14_suppl.6153","title":"Development of a QOL module for head and neck cancer patients with enteral feeding tubes","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Head and neck cancer; Larynx; Feeding tube; Enteral administration; Cancer; Radiation therapy; Internal medicine; Physical therapy; Surgery; Parenteral nutrition; Nursing","score_opus":0.11957226754150134,"score_gpt":0.4674364906544131,"score_spread":0.34786422311291176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247435208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603105,0.00036914446,0.00013787858,0.0026473587,0.0004335678,0.00018124298,0.0000024934554,0.0000024296867,0.00019484089],"genre_scores_gemma":[0.97001785,0.00023958216,0.028607717,0.0007551008,0.00033601953,0.000008950127,5.775037e-7,0.00000787622,0.000026353202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984459,0.000019827397,0.0011079011,0.00010023119,0.000181479,0.00014465637],"domain_scores_gemma":[0.9987426,0.00024145536,0.0004126998,0.00003995669,0.00040298342,0.00016032906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000505983,0.00007976082,0.0009923192,0.00005057062,0.00003949082,0.0000021943893,0.000041705778,0.00009257305,0.0000083686045],"category_scores_gemma":[0.00040348084,0.000048196303,0.000102425154,0.000044526627,0.0000952359,0.00005412266,0.000025178777,0.00021345771,2.7211743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075358343,0.001663197,0.856267,0.00013514845,0.0005488373,0.000018504572,0.0010950789,0.000009822973,0.00018365432,0.00003612162,0.00046711866,0.1320397],"study_design_scores_gemma":[0.022915686,0.016303489,0.93994665,0.0006841692,0.00014680414,0.000015695208,0.000093384995,0.000005704801,0.00041599388,0.000055955683,0.019356204,0.000060261384],"about_ca_topic_score_codex":0.000014023268,"about_ca_topic_score_gemma":0.00014036393,"teacher_disagreement_score":0.13197944,"about_ca_system_score_codex":0.00013065616,"about_ca_system_score_gemma":0.0011538024,"threshold_uncertainty_score":0.2046796},"labels":[],"label_agreement":null},{"id":"W4247475439","doi":"10.1200/jco.2018.36.30_suppl.180","title":"Assessing caregiver satisfaction with care on an acute palliative care unit.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palliative care; Family medicine; Nursing; Unit (ring theory); Patient satisfaction; Residence; Psychology","score_opus":0.44320478349166287,"score_gpt":0.6183002900649871,"score_spread":0.17509550657332423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247475439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98983234,0.00055843475,0.00035508754,0.00070051634,0.00093376683,0.00012031817,0.000007919696,0.000011120164,0.007480476],"genre_scores_gemma":[0.9879554,0.00055832963,0.008551652,0.0010115438,0.001849732,0.000001353269,0.000009947527,0.0000191501,0.00004292108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977076,0.00041865892,0.0010589401,0.0001983298,0.00043006492,0.00018638947],"domain_scores_gemma":[0.99442357,0.0010786997,0.0014298226,0.00020157361,0.0025647553,0.00030158286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005046402,0.0001560319,0.0011561363,0.00013745105,0.0000676873,0.000012624471,0.00010953241,0.00033918305,0.000070831906],"category_scores_gemma":[0.00088317425,0.000099836856,0.00023450353,0.00015900293,0.00039348568,0.0002585672,0.000021832233,0.0007894128,0.000010798233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040461062,0.00021717385,0.80581,0.000049450315,0.00059925317,0.0005232257,0.012616753,0.00001012906,0.00019589387,0.0000659133,0.0003878832,0.17547826],"study_design_scores_gemma":[0.0066410555,0.057774305,0.8546458,0.0011637236,0.00093721796,0.000051621922,0.04429183,0.000012992553,0.0012738821,0.000042990832,0.03302738,0.0001371823],"about_ca_topic_score_codex":0.00010733781,"about_ca_topic_score_gemma":0.0006709803,"teacher_disagreement_score":0.17534108,"about_ca_system_score_codex":0.00025242538,"about_ca_system_score_gemma":0.0014462293,"threshold_uncertainty_score":0.40712288},"labels":[],"label_agreement":null},{"id":"W4247519426","doi":"10.1200/jco.2004.22.14_suppl.4508","title":"Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Abbott (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Refractory (planetary science); Internal medicine; Cancer; Prostate; Disease; Cancer research; Biology","score_opus":0.08309949456012075,"score_gpt":0.5086345688209617,"score_spread":0.4255350742608409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247519426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918413,0.0044046547,0.0000031930947,0.0021872297,0.00008157036,0.0013776749,0.00000626168,0.000004525634,0.0000935821],"genre_scores_gemma":[0.9917096,0.007670143,0.00029944666,0.00013626405,0.00009413365,0.000046829184,0.000002781979,0.000011089313,0.00002973759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976124,0.0005199985,0.001032986,0.00021289637,0.0003981178,0.00022358276],"domain_scores_gemma":[0.99734664,0.0012020326,0.0007087423,0.000100112804,0.00014371885,0.0004987693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014486167,0.00014333276,0.0010698385,0.0001601691,0.000026800462,0.0000048779975,0.00007293322,0.00008454732,0.00000955337],"category_scores_gemma":[0.00075349223,0.00007010199,0.00012110889,0.00015853251,0.00036079148,0.00007368155,0.00003178095,0.0006323866,7.14905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29400435,0.037137948,0.42089444,0.00020594806,0.0008475928,0.0147189135,0.0004408907,0.00002049169,0.00091361,0.000009733872,0.0001545744,0.2306515],"study_design_scores_gemma":[0.09157045,0.15761277,0.7487476,0.0005039801,0.00045092378,0.000030954943,0.0003926345,0.000012468045,0.00022120817,0.000116740004,0.0002680615,0.00007223577],"about_ca_topic_score_codex":0.000030019859,"about_ca_topic_score_gemma":0.00001613838,"teacher_disagreement_score":0.3278531,"about_ca_system_score_codex":0.00024222737,"about_ca_system_score_gemma":0.0014788382,"threshold_uncertainty_score":0.2858676},"labels":[],"label_agreement":null},{"id":"W4247541485","doi":"10.1200/jco.2013.31.15_suppl.8028","title":"Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Medicine; KRAS; Internal medicine; Tolerability; Oncology; Lung cancer; Docetaxel; Neutropenia; Mucositis; MEK inhibitor; Adverse effect; Cancer; Chemotherapy; Colorectal cancer; MAPK/ERK pathway","score_opus":0.04455802113006916,"score_gpt":0.4607209968679737,"score_spread":0.4161629757379045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247541485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890942,0.0011679766,0.00007368897,0.0060931128,0.0010045557,0.0015472135,0.000005246139,0.000007632161,0.0010063959],"genre_scores_gemma":[0.9925299,0.0015208753,0.0038270317,0.0013210548,0.000376318,0.0000966802,0.000007752361,0.000026021655,0.00029433877],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99687386,0.00029574477,0.0019476955,0.00029239786,0.00028658393,0.00030370094],"domain_scores_gemma":[0.9969673,0.0008827441,0.0012044704,0.00015079774,0.0004539848,0.00034065876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012375702,0.00020843526,0.001437067,0.00024337578,0.000035631492,0.000022782719,0.00009816888,0.00029245022,0.00012804529],"category_scores_gemma":[0.0006253854,0.00013836031,0.00015319884,0.00037401362,0.00013318095,0.00028371112,0.00002670276,0.0008587268,0.0000040152404],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18366648,0.039601065,0.26716256,0.00037278485,0.0011652501,0.002256102,0.002988757,0.00033796023,0.0063890703,0.0000720636,0.004443323,0.4915446],"study_design_scores_gemma":[0.7760377,0.06703756,0.13483341,0.0011850457,0.0016670933,0.00016471231,0.001052019,0.0014897732,0.0007934336,0.00024146301,0.0151097495,0.00038805127],"about_ca_topic_score_codex":0.00034193974,"about_ca_topic_score_gemma":0.00070690515,"teacher_disagreement_score":0.5923712,"about_ca_system_score_codex":0.00040583964,"about_ca_system_score_gemma":0.0025004204,"threshold_uncertainty_score":0.564217},"labels":[],"label_agreement":null},{"id":"W4247543710","doi":"10.1200/jco.2017.35.8_suppl.215","title":"Delays in access to palliative care services among cancer patients in South Texas.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Referral; Receipt; Family medicine; Cancer; Nursing; Internal medicine","score_opus":0.3892301178978043,"score_gpt":0.6066007543394731,"score_spread":0.21737063644166882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247543710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456894,0.0006472671,0.0000058634323,0.0014831322,0.00083496864,0.0002106329,0.000013825406,0.0000020910754,0.002233253],"genre_scores_gemma":[0.9963087,0.0011922391,0.0005378453,0.0014577386,0.00044935883,0.0000055138876,0.0000025712598,0.000010809674,0.00003525286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744445,0.00018479813,0.0016814246,0.00017725454,0.00029816938,0.00021390602],"domain_scores_gemma":[0.9960168,0.0007138732,0.0020330907,0.0002032215,0.0007709312,0.00026210336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008136775,0.00012250015,0.0013421687,0.00018963989,0.000028937777,0.000016571743,0.0004737399,0.00029716978,0.000050950835],"category_scores_gemma":[0.0030981344,0.000088838264,0.00020285533,0.000105539235,0.00013668153,0.00024760008,0.00016448063,0.0006892269,0.000006648648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014788706,0.00040533495,0.97162074,0.000090027585,0.00008349855,0.00018331525,0.00652277,0.00005033857,0.000003783656,0.0000027903086,0.00015568949,0.019402858],"study_design_scores_gemma":[0.0065713837,0.002472137,0.9813834,0.0018522961,0.000082886334,3.5828222e-7,0.0017285036,0.00002395437,0.00013152491,0.000048174985,0.0056237318,0.00008169513],"about_ca_topic_score_codex":0.0016169974,"about_ca_topic_score_gemma":0.013308266,"teacher_disagreement_score":0.019321164,"about_ca_system_score_codex":0.00023592525,"about_ca_system_score_gemma":0.00062703906,"threshold_uncertainty_score":0.7426325},"labels":[],"label_agreement":null},{"id":"W4247589822","doi":"10.1200/jco.2004.22.14_suppl.8537","title":"Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"CD117; Medicine; GiST; Stromal tumor; Gastroenterology; Population; Internal medicine; PDGFRA; Imatinib mesylate; Gastrointestinal tract; CD34; Exon; Pathology; Imatinib; Stromal cell; Gene","score_opus":0.09480847425614362,"score_gpt":0.45963531132341,"score_spread":0.3648268370672664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247589822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995382,0.00017666267,0.0009703909,0.002619868,0.00020856009,0.00017930036,0.000007530143,0.000007795529,0.00044785376],"genre_scores_gemma":[0.93878734,0.00025300513,0.059568208,0.0002860135,0.0010587189,0.000001436236,0.0000028203797,0.000017329805,0.000025126426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511045,0.0003528127,0.0034117023,0.00023504894,0.0005388889,0.00035110637],"domain_scores_gemma":[0.99463737,0.001387335,0.0020088663,0.00020200144,0.00074466015,0.001019748],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032227607,0.00017676518,0.0017841395,0.00016820966,0.000027023245,0.000008421723,0.00015965868,0.00012110241,0.000044845303],"category_scores_gemma":[0.012662623,0.0001271561,0.00059306726,0.00014291164,0.00062447635,0.00006455304,0.00009578128,0.0013689046,0.0000131451025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040374314,0.003416693,0.9610357,0.00007297001,0.00014159513,0.01606211,0.000008123115,0.0000029554412,0.00028660643,0.00038807385,0.000117802905,0.01442991],"study_design_scores_gemma":[0.0103408545,0.05948266,0.91387016,0.00022852447,0.00044712878,0.0146239195,0.000036943115,0.000013237917,0.00005985875,0.0006298761,0.00019619607,0.00007066134],"about_ca_topic_score_codex":0.000014816061,"about_ca_topic_score_gemma":0.0000027010824,"teacher_disagreement_score":0.058597818,"about_ca_system_score_codex":0.000081332255,"about_ca_system_score_gemma":0.002609592,"threshold_uncertainty_score":0.99565417},"labels":[],"label_agreement":null},{"id":"W4247591112","doi":"10.1200/jco.2004.22.14_suppl.9500","title":"Effect of age and temporal patterns over 5 years in a Magnetic Resonance Imaging (MRI)-based breast surveillance study for BRCA mutation carriers","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetics, Bioinformatics, and Biomedical Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Mammography; BRCA mutation; Magnetic resonance imaging; Cancer; Stage (stratigraphy); Internal medicine; Oncology; Gynecology; Radiology; Obstetrics","score_opus":0.022791920721256718,"score_gpt":0.40012606179993443,"score_spread":0.3773341410786777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247591112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977972,0.00057268556,0.00066764577,0.00034367995,0.00022232259,0.00034525036,0.000030607083,0.000001219036,0.000019411205],"genre_scores_gemma":[0.99856555,0.00014965297,0.0008947457,0.00016950135,0.00018289822,0.0000066375746,0.000011582466,0.00000928419,0.0000101541755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978939,0.00035431725,0.0011289425,0.00016155004,0.0002534573,0.00020781056],"domain_scores_gemma":[0.998593,0.00046672623,0.0004921467,0.0001298004,0.00015637244,0.0001619617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038683892,0.00010176169,0.00054147624,0.00009142646,0.000017345312,0.000010496115,0.000167804,0.00017418007,0.000004497082],"category_scores_gemma":[0.0016748881,0.00007981978,0.00015349273,0.00007164471,0.00024855317,0.0000062905656,0.000053872736,0.00023489409,3.22718e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030714863,0.0004867284,0.7504052,0.00009154641,0.000029607041,0.00019609196,0.00010982236,0.0000627157,0.0012569621,0.0000012567282,0.00011875706,0.24416986],"study_design_scores_gemma":[0.014560046,0.02380891,0.9582392,0.000057869238,0.000026781816,0.00004508285,0.00014936368,0.00033004576,0.0005951397,0.000051105893,0.0020355075,0.00010095225],"about_ca_topic_score_codex":0.00008883594,"about_ca_topic_score_gemma":0.0005049981,"teacher_disagreement_score":0.2440689,"about_ca_system_score_codex":0.00003491337,"about_ca_system_score_gemma":0.0004949764,"threshold_uncertainty_score":0.32549563},"labels":[],"label_agreement":null},{"id":"W4247639575","doi":"10.1200/jco.2017.35.15_suppl.3576","title":"Comparison of 5-FU vs capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Capecitabine; Medicine; Anal cancer; Internal medicine; Adverse effect; Fluorouracil; Cancer; Radiation therapy; Cisplatin; Surgery; Gastroenterology; Oncology; Chemotherapy; Colorectal cancer","score_opus":0.22003845224910615,"score_gpt":0.5309503555624179,"score_spread":0.31091190331331175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247639575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159324,0.0003801812,0.0000061560886,0.006599604,0.00018616115,0.00018536301,0.000002388186,7.190769e-7,0.0010461657],"genre_scores_gemma":[0.9987493,0.0004931819,0.00033053933,0.00010857265,0.00022555317,0.0000045325114,0.0000011238197,0.000004239434,0.00008293348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776495,0.00023143356,0.0015377679,0.00009071254,0.00026442588,0.000110703084],"domain_scores_gemma":[0.9963715,0.0012574402,0.0019273919,0.00015834403,0.00021313968,0.00007217629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011300652,0.00008418713,0.0013537979,0.00011292318,0.000024897026,0.00000378387,0.00015918893,0.00012916661,0.00006091526],"category_scores_gemma":[0.00073002145,0.00003913103,0.0001703519,0.00010673452,0.00022538229,0.000054321314,0.000013447879,0.00033691304,4.6093822e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016999807,0.0052905916,0.8950776,0.000031252122,0.000071321556,0.0005300748,0.00059930584,0.000023248936,0.00014282887,0.00006217509,0.00014808442,0.081023715],"study_design_scores_gemma":[0.014228708,0.06088425,0.92126167,0.00017519495,0.00016352878,0.00008465299,0.00039390725,0.0007898175,0.0003230001,0.00005447449,0.0016044136,0.00003636451],"about_ca_topic_score_codex":0.00092801393,"about_ca_topic_score_gemma":0.019151889,"teacher_disagreement_score":0.08098735,"about_ca_system_score_codex":0.00013396236,"about_ca_system_score_gemma":0.00071562297,"threshold_uncertainty_score":0.99874604},"labels":[],"label_agreement":null},{"id":"W4247765498","doi":"10.1200/jco.2017.35.15_suppl.tps1107","title":"A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Rash; Taxane; Oncology; Placebo; Adverse effect; Trastuzumab; Pertuzumab; Population; Gastroenterology; Cancer; Breast cancer; Colorectal cancer; Pathology","score_opus":0.07203960633910661,"score_gpt":0.4295408083241917,"score_spread":0.3575012019850851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247765498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254936,0.00015183755,0.000017430217,0.0011812049,0.00024324554,0.005277979,0.0000071567706,0.0000054100346,0.0005663729],"genre_scores_gemma":[0.99872386,0.00011842546,0.0005116139,0.00013209545,0.000069213536,0.00019410913,0.0000074394306,0.00002899553,0.00021422678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99488443,0.0011822733,0.002748153,0.00034652677,0.0004990105,0.00033959723],"domain_scores_gemma":[0.9916674,0.003506845,0.0034634878,0.00028874812,0.0007934454,0.00028007012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003193868,0.00030636706,0.0046573584,0.0003665458,0.00007103261,0.000021853946,0.00020771132,0.00019519367,0.00012509555],"category_scores_gemma":[0.0011090755,0.00016781103,0.00018110413,0.0002173466,0.00044280043,0.00027635228,0.000047563066,0.00081495795,8.201924e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5721872,0.019302819,0.39923316,0.000045413184,0.0010006974,0.00044577717,0.00046562823,0.00006365635,0.000004119133,0.0000039333286,0.00001692442,0.0072307037],"study_design_scores_gemma":[0.5268527,0.06520229,0.40585265,0.0001652423,0.0011575607,0.00009534903,0.00038580445,0.00016918627,0.000008094498,0.000011451225,0.000013627185,0.00008599608],"about_ca_topic_score_codex":0.0009898867,"about_ca_topic_score_gemma":0.012532222,"teacher_disagreement_score":0.045899466,"about_ca_system_score_codex":0.00033382117,"about_ca_system_score_gemma":0.001781914,"threshold_uncertainty_score":0.6993274},"labels":[],"label_agreement":null},{"id":"W4247804796","doi":"10.1200/jco.2007.15.6000","title":"In Reply:","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine","score_opus":0.21562305332736192,"score_gpt":0.5172756517223994,"score_spread":0.3016525983950375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247804796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558589,0.00099765,0.0000076106207,0.03548328,0.0009419568,0.000081132785,5.116261e-7,0.0000025001793,0.006626483],"genre_scores_gemma":[0.9760017,0.006736298,0.0018619432,0.014064046,0.0008821742,0.0000027812757,3.6071762e-7,0.0000057082752,0.00044501433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817556,0.000108905704,0.0013714341,0.000085170905,0.0001483647,0.00011057179],"domain_scores_gemma":[0.9981802,0.0007813805,0.0006002953,0.00009950071,0.0001404452,0.0001981659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011139159,0.000052012896,0.00083996315,0.00006876169,0.000011681092,8.7254216e-7,0.00004648715,0.00011312568,0.00016380423],"category_scores_gemma":[0.0014763048,0.0000334896,0.00024424703,0.00007816024,0.000098304765,0.0000603181,0.000014146496,0.00044321863,0.00002654764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001997715,0.003167994,0.8512739,0.000008417031,0.00014395436,0.015813218,0.000113269234,0.000004423598,0.00001982888,0.00009188772,0.06823695,0.059128463],"study_design_scores_gemma":[0.006600533,0.009108322,0.6086865,0.000042762666,0.00005202033,0.0014441223,0.000015934218,0.0000045239403,0.00010822433,0.00026735666,0.37364376,0.000025952842],"about_ca_topic_score_codex":0.000018297109,"about_ca_topic_score_gemma":0.000009965074,"teacher_disagreement_score":0.3054068,"about_ca_system_score_codex":0.00015760942,"about_ca_system_score_gemma":0.0012091742,"threshold_uncertainty_score":0.2145023},"labels":[],"label_agreement":null},{"id":"W4247879458","doi":"10.1200/jco.2017.35.15_suppl.lba3","title":"LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Androgen deprivation therapy; Prednisone; Internal medicine; Abiraterone; Oncology; Clinical trial; Family medicine; Cancer; Androgen receptor","score_opus":0.18564204016041563,"score_gpt":0.5032530866104884,"score_spread":0.31761104645007276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247879458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877079,0.0017134049,0.00023630643,0.004029013,0.0004732638,0.0056981123,0.000030521194,0.000009102936,0.00010235186],"genre_scores_gemma":[0.93872774,0.05743632,0.0023207564,0.00012254257,0.00044667377,0.00042525836,0.000018144856,0.000032627548,0.0004699157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99441975,0.0011709878,0.0030117251,0.00032642542,0.0006817096,0.0003894151],"domain_scores_gemma":[0.99016863,0.0030100173,0.005355313,0.0004155848,0.00069330115,0.00035716745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069685816,0.00027746643,0.0037769505,0.00026141768,0.00013083128,0.000048009766,0.00032406524,0.00025500794,0.00007934757],"category_scores_gemma":[0.0019289178,0.00014233633,0.00039436077,0.00018594555,0.00080258976,0.00038258522,0.00006554482,0.0009757531,0.0000023257617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89850956,0.0041672494,0.0046669506,0.000040817788,0.0028756578,0.0013306105,0.0009708041,0.00024577434,0.00018419985,0.000007790103,0.00018645341,0.08681415],"study_design_scores_gemma":[0.94306713,0.04901784,0.0039648144,0.00023526144,0.0011555462,0.000042985586,0.00012037675,0.0004260209,0.0010137436,0.00017694893,0.0006378891,0.00014143022],"about_ca_topic_score_codex":0.0013675047,"about_ca_topic_score_gemma":0.00083964074,"teacher_disagreement_score":0.086672716,"about_ca_system_score_codex":0.00031263675,"about_ca_system_score_gemma":0.005584161,"threshold_uncertainty_score":0.9906061},"labels":[],"label_agreement":null},{"id":"W4248102444","doi":"10.1200/jco.2005.01.009","title":"Witness","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"","field":"","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine","score_opus":0.2573836196625199,"score_gpt":0.5676999965980919,"score_spread":0.310316376935572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248102444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9388031,0.00035634634,0.0004021279,0.015016146,0.002390193,0.00006751409,0.0000026078349,0.00002493963,0.042937037],"genre_scores_gemma":[0.977035,0.00009370442,0.012322283,0.0031383566,0.006518077,7.072935e-7,3.1935224e-7,0.000032416945,0.00085912936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994842,0.00084134354,0.0034800784,0.00013421083,0.0004347384,0.00026761662],"domain_scores_gemma":[0.9924787,0.003050538,0.003233026,0.00019263817,0.00058275176,0.00046232247],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.009913668,0.000110501875,0.0012971736,0.00013357551,0.000032724107,0.000009824929,0.00044467667,0.00039814028,0.0010892272],"category_scores_gemma":[0.008051648,0.00007863535,0.0005690129,0.00017545385,0.00035796806,0.00032035646,0.000062107036,0.0013168656,0.004996237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003635574,0.003955152,0.041289404,0.0000051156444,0.0003672278,0.0006522238,0.00011630026,0.0004988447,0.00059261674,0.0027272187,0.15538515,0.7907752],"study_design_scores_gemma":[0.004699499,0.0036806753,0.09382332,0.000015810016,0.00011509825,0.00055690773,0.00003585501,0.00015771575,0.00009004296,0.0013334933,0.89539826,0.000093306386],"about_ca_topic_score_codex":0.0000028199424,"about_ca_topic_score_gemma":0.00004209912,"teacher_disagreement_score":0.79068184,"about_ca_system_score_codex":0.00019688073,"about_ca_system_score_gemma":0.0014793786,"threshold_uncertainty_score":0.9998239},"labels":[],"label_agreement":null},{"id":"W4248307030","doi":"10.1200/jco.2011.29.7_suppl.160","title":"Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Temsirolimus; Docetaxel; Prostate cancer; Internal medicine; Oncology; Everolimus; Chemotherapy; Urology; Cancer; PI3K/AKT/mTOR pathway; Clinical trial; Discovery and development of mTOR inhibitors","score_opus":0.16229527574561708,"score_gpt":0.48872050039423237,"score_spread":0.3264252246486153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248307030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889613,0.00089265016,0.0000094096895,0.008423497,0.00020927782,0.0013831728,0.000018856848,0.0000058504643,0.0001611432],"genre_scores_gemma":[0.9943346,0.002539104,0.00071822415,0.0009676824,0.0002299448,0.00012766897,8.747512e-7,0.000029085071,0.0010528252],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964173,0.00046143375,0.0019718637,0.00028649913,0.00049870426,0.00036419957],"domain_scores_gemma":[0.9970456,0.00055049476,0.0009978999,0.000284252,0.0007467837,0.00037501808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002965275,0.00020656211,0.001368929,0.0002776478,0.000048169004,0.0000064652204,0.00017803136,0.00017000662,0.00025408127],"category_scores_gemma":[0.0003998828,0.00011575309,0.00017688115,0.000373773,0.00021632202,0.00011698731,0.000034507102,0.00066713936,0.0000027122046],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7750222,0.035732422,0.11164879,0.000033784443,0.00064008316,0.0033032515,0.0075065205,0.00002097319,0.0030471662,0.0000021311876,0.00041087254,0.062631786],"study_design_scores_gemma":[0.1317457,0.33899033,0.5151653,0.00035452022,0.000121411365,0.00007849835,0.0010171162,0.000015606196,0.0016184105,0.000050841994,0.0106965145,0.00014575716],"about_ca_topic_score_codex":0.00037349717,"about_ca_topic_score_gemma":0.002206543,"teacher_disagreement_score":0.6432765,"about_ca_system_score_codex":0.00026216562,"about_ca_system_score_gemma":0.0019804891,"threshold_uncertainty_score":0.47202742},"labels":[],"label_agreement":null},{"id":"W4248315589","doi":"10.1200/jco.2004.22.14_suppl.5054","title":"A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electron Spin Resonance Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Ovarian cancer; Cancer; Oncology; Internal medicine","score_opus":0.10771411430218164,"score_gpt":0.47578549712869267,"score_spread":0.36807138282651103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248315589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99697566,0.0015140274,0.00001806076,0.000463947,0.00044393475,0.0003298307,0.000010629414,0.000001650711,0.00024228246],"genre_scores_gemma":[0.9974228,0.0013447884,0.00025237587,0.0004943871,0.00036887493,0.000017915576,0.0000041526823,0.000017199098,0.00007748911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970078,0.00035339413,0.0018514674,0.00026572042,0.0002576178,0.00026400117],"domain_scores_gemma":[0.99759805,0.00015446563,0.0016108648,0.00019685795,0.0003189733,0.00012077565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081117585,0.00016881526,0.0009760166,0.000070952905,0.000041548155,0.0000055008345,0.0002504597,0.00021219498,0.000030462792],"category_scores_gemma":[0.00072554516,0.00012853066,0.00023483565,0.00011382235,0.00012725206,0.000007096501,0.0001312202,0.00031733167,0.0000014077001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0245473,0.06138236,0.7160721,0.000020787345,0.0012741783,0.00020111827,0.0015741256,0.0002836265,0.09411619,0.000012754854,0.0014514582,0.09906403],"study_design_scores_gemma":[0.1517908,0.21994503,0.5409704,0.00012615604,0.0001293309,0.00001720813,0.0006563973,0.0000045649017,0.048130434,0.00013058308,0.0377352,0.00036389387],"about_ca_topic_score_codex":0.000065346845,"about_ca_topic_score_gemma":0.0026831625,"teacher_disagreement_score":0.17510167,"about_ca_system_score_codex":0.0001547315,"about_ca_system_score_gemma":0.0006129875,"threshold_uncertainty_score":0.52413285},"labels":[],"label_agreement":null},{"id":"W4248319264","doi":"10.1200/jco.2010.28.15_suppl.6029","title":"A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Cancer; Internal medicine; Clinical Oncology; MEDLINE; Compendium; Breast cancer; Oncology; Family medicine","score_opus":0.9099026406995714,"score_gpt":0.7660324445900648,"score_spread":0.14387019610950658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248319264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96803504,0.00017681876,0.0007879173,0.012540375,0.00928235,0.0008172681,0.00003532551,0.0000026308053,0.008322262],"genre_scores_gemma":[0.9762171,0.0007591711,0.015697388,0.0037240058,0.0032181067,0.0000059963495,0.0000048183815,0.000018872253,0.0003545727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.41618985,0.3329988,0.23996714,0.002075995,0.007890182,0.0008780443],"domain_scores_gemma":[0.09068394,0.72671056,0.17089263,0.0031682393,0.0066967933,0.0018478252],"candidate_categories":["metaresearch","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.8648409,0.00045161476,0.033361718,0.0008587944,0.00006468882,0.00031644345,0.002366731,0.0017748068,0.0055707456],"category_scores_gemma":[0.9166718,0.00019694731,0.009617189,0.0009041819,0.0010072477,0.0006866379,0.0003023933,0.005643991,0.00029642892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009732271,0.010691971,0.23076528,0.000013883642,0.001451303,0.00046246624,0.00010449707,0.000003177312,0.000042507058,0.00073814386,0.10372306,0.64227146],"study_design_scores_gemma":[0.017417232,0.022537041,0.35814875,0.000057522306,0.0014377804,0.0003099692,0.00033659406,0.0011826532,0.0000019094928,0.0020284823,0.5963581,0.00018397148],"about_ca_topic_score_codex":0.000013503815,"about_ca_topic_score_gemma":0.00007932007,"teacher_disagreement_score":0.64208746,"about_ca_system_score_codex":0.00007630042,"about_ca_system_score_gemma":0.004126277,"threshold_uncertainty_score":0.9995211},"labels":[],"label_agreement":null},{"id":"W4248346590","doi":"10.1200/jco.2020.38.15_suppl.5069","title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Renal cell carcinoma; Internal medicine; Proportional hazards model; Discontinuation; Urology; Clear cell renal cell carcinoma; Oncology; Surgery; Gastroenterology; Cancer; Nuclear medicine; Immunotherapy","score_opus":0.0919111155923545,"score_gpt":0.3896725936607971,"score_spread":0.2977614780684426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248346590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98132277,0.0012483856,0.001087422,0.011137964,0.001092571,0.0013492602,0.000019379648,0.00003033603,0.0027119133],"genre_scores_gemma":[0.9818634,0.0009993683,0.009562751,0.00498328,0.0014766941,0.000035877012,0.000038455313,0.00009877591,0.00094141753],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.993539,0.0004897597,0.0040631616,0.00064854714,0.00061737624,0.0006421927],"domain_scores_gemma":[0.99365133,0.0019696946,0.002252313,0.00042418015,0.000637549,0.0010649535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018401161,0.00044553334,0.003061063,0.00023100521,0.00007425171,0.000017200322,0.00041451634,0.00072951213,0.00031489134],"category_scores_gemma":[0.0011901128,0.0003460405,0.001337062,0.0003619821,0.00016972172,0.00016958996,0.00008692584,0.0015790772,0.000059686936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49782708,0.010165321,0.36659575,0.00066663773,0.0011887512,0.008645227,0.0012154473,0.0040471256,0.021074716,0.00005195067,0.03558729,0.05293471],"study_design_scores_gemma":[0.22067,0.14609385,0.4016078,0.00016660376,0.0016960298,0.00041092327,0.0002386238,0.005859682,0.018965118,0.00031680518,0.20326477,0.0007097855],"about_ca_topic_score_codex":0.000044091892,"about_ca_topic_score_gemma":0.000080067446,"teacher_disagreement_score":0.2771571,"about_ca_system_score_codex":0.0005389249,"about_ca_system_score_gemma":0.0017693359,"threshold_uncertainty_score":0.99989915},"labels":[],"label_agreement":null},{"id":"W4248467655","doi":"10.1200/jco.2008.17.2478","title":"In Reply","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine","score_opus":0.18103767032321866,"score_gpt":0.4970623251280943,"score_spread":0.3160246548048756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248467655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9001671,0.00034308046,0.000017431357,0.040911876,0.00093132956,0.000065538115,1.253034e-7,0.0000045784823,0.057558905],"genre_scores_gemma":[0.96106434,0.0015527342,0.0024057818,0.02782809,0.0016695184,8.3268566e-7,2.5928787e-7,0.000009209181,0.005469262],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972019,0.000344603,0.001928118,0.00009789733,0.0002782199,0.00014925035],"domain_scores_gemma":[0.9946553,0.0041830903,0.000581864,0.00013045582,0.00015843917,0.00029083248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003253989,0.00006886887,0.0019318268,0.00010865555,0.000014698502,0.0000013469345,0.00007455175,0.0002267856,0.00021789047],"category_scores_gemma":[0.006915578,0.000044359884,0.0009522704,0.00012281688,0.00016399729,0.00006950521,0.000015095685,0.0007674384,0.00005225516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003775342,0.0012632455,0.90447974,0.00000982692,0.00014409356,0.04286598,0.00012363023,0.0000043376735,0.000029992514,0.0008879715,0.020379378,0.026036453],"study_design_scores_gemma":[0.0032319624,0.001995795,0.46757987,0.000012998491,0.000039900726,0.00563197,0.00001708864,0.0000033329898,0.0000082486495,0.00005313266,0.52139854,0.000027160408],"about_ca_topic_score_codex":0.0000124145845,"about_ca_topic_score_gemma":0.0000036896777,"teacher_disagreement_score":0.5010192,"about_ca_system_score_codex":0.00006317258,"about_ca_system_score_gemma":0.0009447717,"threshold_uncertainty_score":0.8279093},"labels":[],"label_agreement":null},{"id":"W4248533447","doi":"10.1200/jco.2002.20.6.1570","title":"Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Cedars-Sinai Medical Center","keywords":"Ovarian cancer; Medicine; Breast cancer; Oncology; Incidence (geometry); Gynecology; Cancer; Internal medicine; Population; Cohort; BRCA mutation; Cumulative incidence","score_opus":0.06350951092679771,"score_gpt":0.42544422377638613,"score_spread":0.36193471284958845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248533447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946068,0.003457932,0.000055149514,0.0007084145,0.0007411581,0.000082403974,0.000025799332,9.119391e-7,0.00032144372],"genre_scores_gemma":[0.9907669,0.0071368474,0.0010948132,0.00028125086,0.00048874726,0.000014918363,0.0000018726349,0.000010540194,0.00020413953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997416,0.0003637324,0.0016990945,0.00016529366,0.000193831,0.0001620399],"domain_scores_gemma":[0.9968263,0.0002381005,0.002325166,0.00018278003,0.0003331361,0.00009450375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016055737,0.00008681953,0.00062376045,0.00008433297,0.000018256991,0.0000019091387,0.00021858851,0.00033974322,0.00038170262],"category_scores_gemma":[0.0015909818,0.000075603784,0.00017985381,0.00015709898,0.0001494265,0.000008850989,0.0000841482,0.00029059936,0.0000012133684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075207674,0.00033003042,0.87648207,0.000020869084,0.00021413974,0.000008481124,0.00025637497,0.0027681675,0.008649945,0.000010836538,0.0020673366,0.108439684],"study_design_scores_gemma":[0.00306533,0.0021701066,0.97172576,0.00006594353,0.000088300534,0.00001963501,0.00005303062,0.0003537058,0.0044849436,0.0004488225,0.01741241,0.00011202498],"about_ca_topic_score_codex":0.0004177133,"about_ca_topic_score_gemma":0.002611086,"teacher_disagreement_score":0.108327664,"about_ca_system_score_codex":0.00037007852,"about_ca_system_score_gemma":0.00055141666,"threshold_uncertainty_score":0.4179376},"labels":[],"label_agreement":null},{"id":"W4248612104","doi":"10.1200/jco.2005.01.5552","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine","score_opus":0.13976430601001175,"score_gpt":0.5172537019888831,"score_spread":0.3774893959788713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248612104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86973363,0.00074793154,0.000036637648,0.09671317,0.0022611092,0.000053134747,3.740384e-7,0.000004070884,0.030449959],"genre_scores_gemma":[0.9601448,0.00045557617,0.0011371513,0.033015583,0.0038336238,7.16541e-7,1.9818572e-7,0.000006149918,0.0014062065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997971,0.00015883775,0.0014906514,0.00008108178,0.00018165528,0.000116749245],"domain_scores_gemma":[0.9982485,0.00072254473,0.00055448513,0.00011315976,0.00016173795,0.00019953567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002648452,0.000049286195,0.0007625511,0.00008636376,0.0000063213615,0.0000020721477,0.00007476398,0.00017723478,0.0004935325],"category_scores_gemma":[0.0018613007,0.000035107787,0.00028139687,0.00009925252,0.000060817965,0.00008079986,0.00001720014,0.00077782077,0.00004280539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044680936,0.0015706958,0.16677678,0.00001850346,0.000101345395,0.0016675895,0.00042893618,0.000013763893,0.000083351384,0.00034372398,0.08488769,0.7396395],"study_design_scores_gemma":[0.0035318818,0.0030716853,0.11550327,0.000035856832,0.00004713874,0.00037159404,0.00010314414,0.000018132416,0.00004666242,0.00021820066,0.8770199,0.000032586173],"about_ca_topic_score_codex":0.00004649999,"about_ca_topic_score_gemma":0.0007953788,"teacher_disagreement_score":0.79213214,"about_ca_system_score_codex":0.00013031991,"about_ca_system_score_gemma":0.000891739,"threshold_uncertainty_score":0.5403835},"labels":[],"label_agreement":null},{"id":"W4248637744","doi":"10.1200/jco.2002.20.1.237","title":"Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre Hospitalier Universitaire Sainte-Justine; Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Medicine; Concomitant; Radiation therapy; Population; Internal medicine; Incidence (geometry); Cumulative incidence; Prophylactic cranial irradiation; Randomized controlled trial; Toxicity; Surgery; Gastroenterology; Pediatrics; Cohort","score_opus":0.1056811430335067,"score_gpt":0.44715532321745394,"score_spread":0.34147418018394726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248637744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9058898,0.00030667539,0.00032694155,0.012721316,0.0014183954,0.036765706,0.00013954296,0.00004668699,0.04238495],"genre_scores_gemma":[0.9865448,0.0008473507,0.0061263684,0.0009266969,0.0015516629,0.0013273197,0.000008666076,0.000067929395,0.0025992184],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99126846,0.0006683445,0.00599902,0.00039626312,0.0011062352,0.00056165195],"domain_scores_gemma":[0.98763365,0.0055801882,0.0043617003,0.00062368484,0.0010071378,0.0007936586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019244538,0.0003272238,0.0032093083,0.00033065412,0.000035615485,0.0000070776027,0.00040137145,0.00081252324,0.00050942186],"category_scores_gemma":[0.0070281625,0.00021155861,0.0010324843,0.00033268152,0.0008492708,0.0001237727,0.00011274202,0.00076964084,0.00006572567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17622605,0.08250942,0.03891242,0.00093897345,0.024305318,0.023764988,0.0034927274,0.00046863174,0.009124586,0.00044136716,0.18311577,0.45669973],"study_design_scores_gemma":[0.2991561,0.23180105,0.11055308,0.00074080506,0.004849388,0.009313496,0.00024485888,0.004833603,0.0075418167,0.00028638594,0.33016503,0.00051437825],"about_ca_topic_score_codex":0.00007005099,"about_ca_topic_score_gemma":0.000016992073,"teacher_disagreement_score":0.45618537,"about_ca_system_score_codex":0.0021305406,"about_ca_system_score_gemma":0.0065964977,"threshold_uncertainty_score":0.9990352},"labels":[],"label_agreement":null},{"id":"W4248808332","doi":"10.1200/jco.2017.35.6_suppl.4.2017.1.test","title":"Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; DECIPHER; Prostate cancer; Prostate; Metastasis; Disease; Pathology; Cancer; Biopsy; Oncology; Internal medicine; Bioinformatics; Biology","score_opus":0.30499408326372374,"score_gpt":0.5165378263537546,"score_spread":0.21154374309003082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248808332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753476,0.004526109,0.0000152243365,0.005818635,0.0006149449,0.000874183,0.00037667615,0.0000023089792,0.00023716781],"genre_scores_gemma":[0.9943709,0.004628856,0.00032496406,0.00013932717,0.00032132302,0.000035202425,0.000011115993,0.000014256556,0.00015408399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958425,0.000745178,0.0017526249,0.00028666563,0.0011482451,0.00022476699],"domain_scores_gemma":[0.99338156,0.0016690308,0.0022984578,0.0006409491,0.0014686711,0.0005413301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005410493,0.00015263788,0.0014347973,0.00018585271,0.00013074196,0.00002961051,0.00028768324,0.00013250775,0.00035764824],"category_scores_gemma":[0.008159076,0.00008505357,0.0005663174,0.0002632396,0.0007624094,0.00012192211,0.00017128234,0.00038942668,0.0000020687864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038178342,0.0007473524,0.9159532,0.000025632613,0.0065185004,0.0000630717,0.00036593733,0.00028296502,0.0012453885,0.000008882141,0.0009160522,0.07005517],"study_design_scores_gemma":[0.0057395473,0.0011264633,0.9719293,0.00015002342,0.016778896,0.0000027442077,0.00011985223,0.0008629499,0.0003397292,0.0005592688,0.002318716,0.00007247021],"about_ca_topic_score_codex":0.00033058765,"about_ca_topic_score_gemma":0.00030041987,"teacher_disagreement_score":0.06998271,"about_ca_system_score_codex":0.00030613202,"about_ca_system_score_gemma":0.0030893532,"threshold_uncertainty_score":0.9767766},"labels":[],"label_agreement":null},{"id":"W4248908214","doi":"10.1200/jco.2004.22.14_suppl.1556","title":"Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Retinopathy of Prematurity Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Immunostaining; Vascular endothelial growth factor; Pathology; Chemotherapy; Immunohistochemistry; Radiation therapy; Angiogenesis; Glioma; Internal medicine; VEGF receptors; Cancer research","score_opus":0.08458374396705631,"score_gpt":0.41495444195161646,"score_spread":0.33037069798456015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248908214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906375,0.0014832765,0.00002809459,0.004789445,0.0016514396,0.000351122,0.0000020903597,0.000019183555,0.0010378942],"genre_scores_gemma":[0.98629016,0.0013044189,0.009880565,0.0006728192,0.0017457613,0.0000055540895,0.0000011213019,0.000021852691,0.00007774633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562615,0.00030765138,0.0028992186,0.00027851318,0.00050955045,0.00037893344],"domain_scores_gemma":[0.99589556,0.0013276617,0.0016361183,0.00025447473,0.0004866431,0.0003995081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003461043,0.00020580216,0.0019371683,0.00036370754,0.000043066917,0.000009377313,0.00024187089,0.0005906578,0.000014513051],"category_scores_gemma":[0.007648414,0.0001600359,0.0005652674,0.00029835204,0.00025604467,0.00014412277,0.00012106339,0.0017638217,0.000035217145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021399092,0.006030691,0.95602816,0.00014634128,0.00014526243,0.020059979,0.00038937503,0.0000137152065,0.002477632,0.00009448229,0.000830103,0.011644344],"study_design_scores_gemma":[0.011164278,0.008351801,0.9741116,0.00011311103,0.00063036534,0.0035063918,0.00012742924,0.0000036934816,0.0006894622,0.0006055736,0.0005666177,0.00012965807],"about_ca_topic_score_codex":0.0000264597,"about_ca_topic_score_gemma":0.00009182943,"teacher_disagreement_score":0.018083453,"about_ca_system_score_codex":0.000352435,"about_ca_system_score_gemma":0.0021350253,"threshold_uncertainty_score":0.91564184},"labels":[],"label_agreement":null},{"id":"W4248908788","doi":"10.1200/jco.2019.37.7_suppl.195","title":"Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Juravinski Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Enzalutamide; Oncology; Androgen deprivation therapy; Microsatellite instability; KRAS; Cancer; Incidence (geometry); Gastroenterology; Genetics; Androgen receptor; Biology; Allele; Microsatellite","score_opus":0.08544578536697905,"score_gpt":0.5030082362144115,"score_spread":0.41756245084743243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248908788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994127,0.00045313349,0.000006527769,0.004031614,0.0006669238,0.0004934327,0.000015016088,0.000005149257,0.00020123248],"genre_scores_gemma":[0.9939874,0.0036318365,0.000315773,0.0005960068,0.00011665524,0.0000060141297,0.0000064508827,0.000014371438,0.0013254873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641407,0.00030214206,0.0023606864,0.000223366,0.0005032755,0.00019648936],"domain_scores_gemma":[0.99463946,0.0015338586,0.0018700539,0.00019953128,0.0014404816,0.00031664246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393816,0.00011957283,0.001384293,0.00010997998,0.000025452082,0.000008394597,0.00013273407,0.00021656173,0.00011728161],"category_scores_gemma":[0.0016441543,0.0000653476,0.00022421798,0.00016053603,0.0004442679,0.00016270102,0.000057104193,0.00066824164,0.000015013142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006848962,0.0014421339,0.94147563,0.00005130043,0.00065310503,0.00007187783,0.000092856746,0.0000030604901,0.00004643897,0.000010934811,0.00060796406,0.048695743],"study_design_scores_gemma":[0.015290914,0.011901784,0.9682514,0.00012829454,0.00034592176,0.00002296737,0.00008054803,0.000033461125,0.000105682615,0.00008112829,0.0036904914,0.00006738835],"about_ca_topic_score_codex":0.000047950103,"about_ca_topic_score_gemma":0.00004808833,"teacher_disagreement_score":0.048628353,"about_ca_system_score_codex":0.000105217,"about_ca_system_score_gemma":0.0017602636,"threshold_uncertainty_score":0.3122632},"labels":[],"label_agreement":null},{"id":"W4249024289","doi":"10.1200/jco.2004.22.14_suppl.7135","title":"Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Pemetrexed; Medicine; Chemotherapy; Oncology; Internal medicine; Lung cancer; Discontinuation; Surgery; Cisplatin","score_opus":0.05604320246381494,"score_gpt":0.4716940325281952,"score_spread":0.41565083006438025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249024289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950417,0.00043488067,0.00033203798,0.00048909284,0.0015655726,0.0018936654,0.000058584814,0.0000052807145,0.00017913796],"genre_scores_gemma":[0.99777526,0.00024023437,0.0008909967,0.00025000048,0.00058508833,0.00015471921,0.000055953165,0.000018243894,0.000029516706],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948385,0.0008544083,0.0033294351,0.0003001399,0.000473826,0.00020369641],"domain_scores_gemma":[0.99457216,0.0014070914,0.002672621,0.00026349467,0.000788559,0.0002960669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002303358,0.0002038552,0.0031421618,0.00049520686,0.000030672953,0.000013733714,0.00014088764,0.00021331666,0.00016177785],"category_scores_gemma":[0.0012759864,0.00013803692,0.0009523917,0.00047252685,0.00011886312,0.00027641188,0.00003301632,0.00047475635,0.0000017440035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.856545,0.039532945,0.083723806,0.000009632407,0.005873699,0.00018230616,0.004867548,0.00022077977,0.000032283046,0.0000012373745,0.000019387417,0.0089914],"study_design_scores_gemma":[0.83784544,0.023509204,0.11662629,0.000071559945,0.020151947,2.7031024e-7,0.001464348,0.0001454108,0.000034189503,0.000017141956,0.000030573407,0.00010362368],"about_ca_topic_score_codex":0.001682729,"about_ca_topic_score_gemma":0.005986259,"teacher_disagreement_score":0.03290249,"about_ca_system_score_codex":0.0004458247,"about_ca_system_score_gemma":0.0019792682,"threshold_uncertainty_score":0.5628982},"labels":[],"label_agreement":null},{"id":"W4249072217","doi":"10.1200/jco.2012.30.27_suppl.125","title":"BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Memorial Hospital","funders":"","keywords":"Medicine; Exemestane; Internal medicine; Breast cancer; Hazard ratio; Aromatase inhibitor; Everolimus; Placebo; Oncology; Clinical endpoint; Quality of life (healthcare); Proportional hazards model; Interim analysis; Cancer; Randomized controlled trial; Confidence interval; Aromatase; Pathology","score_opus":0.21684305128424827,"score_gpt":0.5177775195784704,"score_spread":0.3009344682942221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249072217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961073,0.0039508524,0.0000029436453,0.0045801713,0.0010136723,0.00038549496,0.000027475035,0.000007848887,0.00042080277],"genre_scores_gemma":[0.99508667,0.0028758908,0.00042067116,0.00121658,0.0002471402,0.000011416506,0.00001216988,0.00002256059,0.00010687733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99499464,0.0009863818,0.003047801,0.00018728344,0.00036191804,0.0004220006],"domain_scores_gemma":[0.9939453,0.0021139386,0.002669023,0.00012781986,0.00035774856,0.0007861887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448508,0.00020750366,0.002373634,0.00020107829,0.00003208539,0.0000031759087,0.000085054344,0.00021711871,0.00034972356],"category_scores_gemma":[0.0005600191,0.00013867255,0.00019769851,0.0002886902,0.00027883166,0.00017388102,0.000030561667,0.00072132837,0.0000035916144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06179852,0.00634926,0.8953944,0.000102815335,0.0011069628,0.00009721019,0.00038523058,0.00000683371,0.000030422027,0.000039953473,0.00088354194,0.033804867],"study_design_scores_gemma":[0.05873028,0.01917427,0.9186315,0.00014847674,0.0007101568,0.00014155926,0.00013986089,0.000013848052,0.000010267305,0.000014674669,0.0021727497,0.000112373295],"about_ca_topic_score_codex":0.0012831542,"about_ca_topic_score_gemma":0.00075108936,"teacher_disagreement_score":0.033692494,"about_ca_system_score_codex":0.00041026445,"about_ca_system_score_gemma":0.0018591387,"threshold_uncertainty_score":0.56549025},"labels":[],"label_agreement":null},{"id":"W4249102013","doi":"10.1200/jco.2020.38.4_suppl.325","title":"Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"University Health Network","keywords":"Medicine; Internal medicine; Esophageal cancer; Chemotherapy; Regimen; Cancer; Gastroenterology; Stage (stratigraphy); Population; Chemotherapy regimen; Adenocarcinoma; Surgery; Oncology","score_opus":0.10016482235262003,"score_gpt":0.4492413592636203,"score_spread":0.34907653691100027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249102013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151486,0.0029707523,0.000011107639,0.0048414436,0.000101981204,0.00027523556,0.000014946159,0.000004952329,0.00026470184],"genre_scores_gemma":[0.9936764,0.002008015,0.002923388,0.0010782678,0.00024892832,0.000004287545,0.0000028750785,0.00000933902,0.000048447302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979996,0.00022231854,0.0010375982,0.00020551866,0.000344218,0.00019073128],"domain_scores_gemma":[0.99729556,0.00094099186,0.00075073726,0.00008958997,0.0002456431,0.0006774634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004973374,0.00014563848,0.0014828512,0.00005970886,0.00002906949,0.0000063547163,0.00006141062,0.00016722555,0.000037039972],"category_scores_gemma":[0.0011629186,0.00007309567,0.00018728685,0.00009354164,0.0003345463,0.000060575174,0.00004421022,0.00046118617,0.0000011670382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072170477,0.0009707565,0.90608007,0.000021679562,0.00034376563,0.0012580379,0.000112024805,0.0000013887504,0.00000249071,0.000017977774,0.0002015229,0.08377325],"study_design_scores_gemma":[0.016857743,0.09640417,0.88575226,0.00002168228,0.0003820363,0.00019078719,0.00004992019,0.0000057948096,0.000018672203,0.00002426552,0.00025257215,0.000040073355],"about_ca_topic_score_codex":0.000038565868,"about_ca_topic_score_gemma":0.000036483598,"teacher_disagreement_score":0.095433414,"about_ca_system_score_codex":0.0001354711,"about_ca_system_score_gemma":0.0007497055,"threshold_uncertainty_score":0.2980755},"labels":[],"label_agreement":null},{"id":"W4249116576","doi":"10.1200/jco.2014.32.3_suppl.581","title":"Efficacy and safety of single agent (SA) or combination (CO) adjuvant chemotherapy (AC) in elderly patients with colon cancer: A Canadian cancer institute experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cancer; Internal medicine; Colorectal cancer; Odds ratio; Toxicity; Chemotherapy; Surgery","score_opus":0.08234617154892031,"score_gpt":0.4303639498721764,"score_spread":0.3480177783232561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249116576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939167,0.00046817918,0.0000098287255,0.0039524226,0.0005762218,0.00037492992,0.00000878825,0.0000025458328,0.0006904152],"genre_scores_gemma":[0.9963253,0.0022097488,0.0002152837,0.0010099139,0.00013894086,0.000019841063,0.000002601438,0.0000090294825,0.000069304675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983376,0.00010602232,0.0009913319,0.00015415091,0.00022401103,0.00018686916],"domain_scores_gemma":[0.9982557,0.00032673654,0.0007610755,0.000081043334,0.000312042,0.0002633926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043858786,0.000118611504,0.0010248723,0.00011875261,0.00004917855,0.00000461202,0.00006568423,0.0001363549,0.00008013982],"category_scores_gemma":[0.00044826383,0.000070916496,0.00007089228,0.00013834595,0.00026462335,0.000084031446,0.000012330957,0.00024653948,3.076469e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014368201,0.0013741956,0.54549533,0.000020091886,0.00019446651,0.000037018937,0.001077365,0.000015004715,0.000021007525,0.000012501977,0.00023547905,0.43714932],"study_design_scores_gemma":[0.026438188,0.028985938,0.89238393,0.00026866584,0.0001153869,0.000008721413,0.00011670394,0.00002598023,0.0000507034,0.000012385508,0.051521312,0.00007205963],"about_ca_topic_score_codex":0.015130954,"about_ca_topic_score_gemma":0.25088537,"teacher_disagreement_score":0.43707725,"about_ca_system_score_codex":0.0006582484,"about_ca_system_score_gemma":0.0016377857,"threshold_uncertainty_score":0.99142736},"labels":[],"label_agreement":null},{"id":"W4249263406","doi":"10.1200/jco.2004.22.14_suppl.8251","title":"Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Cancer; Family medicine; Internal medicine","score_opus":0.10421508308918101,"score_gpt":0.36556001040901515,"score_spread":0.26134492731983416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249263406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915502,0.0002907991,0.00018881245,0.00081860356,0.004486224,0.00014435296,0.0002134128,6.6968767e-7,0.0023068995],"genre_scores_gemma":[0.9975374,0.00049289886,0.0007803752,0.00078845816,0.00025758275,0.000004259219,0.0000038283315,0.000010798297,0.00012441789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596786,0.00001823244,0.003637409,0.00013414113,0.00004253547,0.00019983118],"domain_scores_gemma":[0.9944266,0.00042407034,0.004644177,0.00010639822,0.0002655538,0.00013317079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013143566,0.00009658995,0.0015995597,0.0001059913,0.000013283861,0.000003838642,0.0002207843,0.00022114332,0.00015904386],"category_scores_gemma":[0.0015293183,0.00009798243,0.00023652492,0.00004961507,0.00008454042,0.00014938558,0.000025891883,0.00036360888,0.0000021446394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006842579,0.0005995315,0.96616316,0.00002200036,0.000090204274,0.0000059922613,0.0001695011,0.00007370066,9.94908e-7,0.004226163,0.0016003612,0.026364114],"study_design_scores_gemma":[0.004235414,0.0016540104,0.9026947,0.000055686036,0.000016179583,8.910932e-7,0.000012602593,0.0000070135093,0.000021849435,0.005199539,0.086007886,0.00009421083],"about_ca_topic_score_codex":0.694205,"about_ca_topic_score_gemma":0.96237636,"teacher_disagreement_score":0.26817137,"about_ca_system_score_codex":0.0014845596,"about_ca_system_score_gemma":0.004308379,"threshold_uncertainty_score":0.7642879},"labels":[],"label_agreement":null},{"id":"W4249288009","doi":"10.1200/jco.2019.37.15_suppl.tps6096","title":"Roman: Reduction in oral mucositis with avasopasem manganese (GC4419)—Phase 3 trial in patients receiving chemoradiotherapy for locally-advanced, non-metastatic head and neck cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Northeast Cancer Centre; Health Sciences North","funders":"","keywords":"Mucositis; Medicine; Head and neck cancer; Chemoradiotherapy; Placebo; Radiation therapy; Cisplatin; Internal medicine; Cancer; Gastroenterology; Chemotherapy; Surgery; Pathology","score_opus":0.08606626166967682,"score_gpt":0.5059058958082832,"score_spread":0.41983963413860637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249288009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991858,0.000550561,0.000048272927,0.0035546385,0.0017979863,0.0021286022,0.000007695499,0.0000051576167,0.000049065504],"genre_scores_gemma":[0.97963333,0.0010624658,0.017618483,0.00085726933,0.0006056034,0.000083548206,0.0000072125463,0.00003247529,0.000099601915],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996766,0.00024411232,0.0020220003,0.00030901394,0.00029690948,0.00036202182],"domain_scores_gemma":[0.9972389,0.0007507733,0.0012832291,0.00016494672,0.00024103635,0.00032112605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017597944,0.00018615158,0.0018424958,0.00019575485,0.00002481422,0.0000076834285,0.00007886348,0.00020472184,0.00004894804],"category_scores_gemma":[0.0003689893,0.0001353158,0.00014105909,0.00021766718,0.00009624552,0.00020010879,0.000013988558,0.0006637366,0.0000022831696],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2923108,0.003898646,0.30909935,0.00017073535,0.00010004363,0.00016822355,0.00015176064,0.000101368765,0.000022953462,0.0000015327965,0.00020529816,0.3937693],"study_design_scores_gemma":[0.47183117,0.14099844,0.3821186,0.0009776314,0.00012775928,0.00012592765,0.000102164115,0.00042420768,0.000045976616,0.0000557834,0.0030627784,0.0001295575],"about_ca_topic_score_codex":0.00019376077,"about_ca_topic_score_gemma":0.0008627937,"teacher_disagreement_score":0.3936397,"about_ca_system_score_codex":0.0012258188,"about_ca_system_score_gemma":0.0018305966,"threshold_uncertainty_score":0.5518018},"labels":[],"label_agreement":null},{"id":"W4249335081","doi":"10.1200/jco.2017.35.15_suppl.tps4132","title":"CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Cancer; Refractory (planetary science); Oncology; Phases of clinical research; Chemotherapy; Gastroenterology; Immunotherapy","score_opus":0.11682681699129105,"score_gpt":0.4915325814690506,"score_spread":0.37470576447775955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249335081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140304,0.00089745445,0.00013619495,0.0021574632,0.0013956418,0.003808059,0.00001286731,0.000020822094,0.00016845351],"genre_scores_gemma":[0.9862016,0.007730392,0.0030563616,0.0009701336,0.0005462977,0.00013312187,0.0000062736935,0.00007155877,0.0012843014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924105,0.0011883877,0.004495398,0.0005923964,0.0006882939,0.00062501436],"domain_scores_gemma":[0.98960316,0.0014610671,0.0069402773,0.0007860469,0.0007893487,0.00042009933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005369289,0.00048687612,0.0050632423,0.00033177226,0.00019518775,0.00007191013,0.00086079165,0.00039473118,0.0005996993],"category_scores_gemma":[0.0023609365,0.00028228745,0.0004083474,0.00039926823,0.00069814065,0.00060135167,0.00013740861,0.0011407728,0.0000041777353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7826111,0.02391773,0.013193787,0.000100153935,0.0020951477,0.00149221,0.0006271762,0.000022219914,0.0011811344,4.451557e-7,0.000504763,0.17425415],"study_design_scores_gemma":[0.8459784,0.11822851,0.029774174,0.0011515382,0.0012521637,0.0005302586,0.0006272062,0.00050898467,0.00044821147,0.000005012507,0.0012668776,0.00022867102],"about_ca_topic_score_codex":0.001817597,"about_ca_topic_score_gemma":0.005411487,"teacher_disagreement_score":0.17402548,"about_ca_system_score_codex":0.0007370327,"about_ca_system_score_gemma":0.0032189111,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W4249374804","doi":"10.1200/jco.2004.22.14_suppl.8138","title":"Oncologists' attitudes towards recommending exercise to cancer patients: A Canadian national survey","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cancer; Family medicine; Gerontology; Physical therapy; Internal medicine","score_opus":0.227794771566648,"score_gpt":0.5154839772775656,"score_spread":0.28768920571091755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249374804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550635,0.00035264928,0.0000538694,0.03003545,0.0066995528,0.00028974202,0.000088390916,0.000010788289,0.0074060233],"genre_scores_gemma":[0.98258054,0.00057177205,0.0009206411,0.014527559,0.0011630583,0.00001370224,0.000015619125,0.000016878437,0.00019025049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971258,0.00025939447,0.0015517212,0.00020383953,0.00053782307,0.00032141985],"domain_scores_gemma":[0.9955169,0.00070628,0.00067233853,0.00011279322,0.0018411083,0.0011505742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004290622,0.00013672152,0.0010980243,0.00027904357,0.00006523975,0.000015154904,0.00021204606,0.00035697996,0.00043613938],"category_scores_gemma":[0.0059412043,0.000107430526,0.00032329521,0.00030995868,0.000090629896,0.00010333062,0.000045093006,0.00077942776,0.000031999003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023122726,0.001178251,0.7827023,0.000024394183,0.00020517064,0.00017807425,0.00033780345,0.00011131782,0.0000037348648,0.00007476726,0.026440924,0.18643098],"study_design_scores_gemma":[0.0039490294,0.0043671513,0.85193145,0.00021743754,0.00009193318,0.000023880852,0.00006353863,0.0000012564543,0.0000139915055,0.00015221287,0.13908222,0.00010589977],"about_ca_topic_score_codex":0.15692832,"about_ca_topic_score_gemma":0.7590438,"teacher_disagreement_score":0.60211545,"about_ca_system_score_codex":0.0029251475,"about_ca_system_score_gemma":0.014475345,"threshold_uncertainty_score":0.99111164},"labels":[],"label_agreement":null},{"id":"W4249384979","doi":"10.1200/jco.2019.37.15_suppl.7532","title":"Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; ABVD; Brentuximab vedotin; Population; Dacarbazine; Internal medicine; Nuclear medicine; Oncology; Chemotherapy; Lymphoma; Hodgkin lymphoma; Vincristine; Cyclophosphamide","score_opus":0.06538313009105307,"score_gpt":0.41756307624279165,"score_spread":0.3521799461517386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249384979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851011,0.00011815492,0.000073314135,0.012070716,0.00075005094,0.0010460374,0.000010184331,0.0000064161536,0.0008240289],"genre_scores_gemma":[0.99477404,0.00011827836,0.0025654808,0.0016189287,0.00045195964,0.000015528341,0.0000015731576,0.000026286467,0.00042794418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971829,0.00024127087,0.0016195195,0.0002354857,0.00048156813,0.00023927297],"domain_scores_gemma":[0.9955855,0.0016899044,0.0017366435,0.00040172625,0.00038702574,0.00019917314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018466321,0.00017846275,0.0016473818,0.000060408907,0.000034939072,0.000008988153,0.00026317875,0.000245868,0.0001545363],"category_scores_gemma":[0.00046172726,0.00008518229,0.00065648503,0.00013486609,0.00019270033,0.000060467475,0.000057932753,0.00028804445,0.000019648436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013245069,0.017318344,0.877114,0.00003824743,0.0012818822,0.00010123543,0.000093693154,0.00000815977,0.00006416069,0.00044188992,0.0024924616,0.08780088],"study_design_scores_gemma":[0.0714379,0.03745113,0.83723557,0.00010156332,0.0005985936,0.00009087496,0.00023016984,0.00007036858,0.00049097766,0.00014545028,0.0520578,0.000089623856],"about_ca_topic_score_codex":0.00001740626,"about_ca_topic_score_gemma":0.00008153171,"teacher_disagreement_score":0.08771126,"about_ca_system_score_codex":0.00021776457,"about_ca_system_score_gemma":0.001757542,"threshold_uncertainty_score":0.3473633},"labels":[],"label_agreement":null},{"id":"W4249432793","doi":"10.1200/jco.2012.30.15_suppl.9062","title":"The effect of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A double-blind placebo-controlled trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anorexia; Cachexia; Appetite; Melatonin; Weight loss; Placebo; Internal medicine; Quality of life (healthcare); Interim analysis; Cancer; Randomized controlled trial; Obesity","score_opus":0.022784549183559797,"score_gpt":0.38157381565625487,"score_spread":0.35878926647269505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249432793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434054,0.004120225,0.000004187744,0.00019768113,0.0003602433,0.0007075537,0.000004049749,7.700972e-7,0.00026476348],"genre_scores_gemma":[0.9983457,0.00090638956,0.000052685573,0.00018797559,0.00040676497,0.00003971282,0.0000014484845,0.000010821861,0.000048549045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984198,0.000377221,0.0007696993,0.00012687291,0.00013784647,0.00016851607],"domain_scores_gemma":[0.9982678,0.0006159269,0.0007234254,0.000116804455,0.00009752847,0.00017847242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001590729,0.00011364359,0.0006204664,0.000039204082,0.000028414595,0.0000062567665,0.0000803909,0.00020777865,0.0000035949822],"category_scores_gemma":[0.00047370873,0.00006108609,0.00011686092,0.000034979243,0.00020564761,0.000006148442,0.000028961138,0.0001951008,2.654875e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69590336,0.00046717402,0.2952195,0.0000111328445,0.00017757514,9.133877e-7,0.000014171301,0.000016170587,0.00013256492,0.00001535967,0.00006323148,0.007978823],"study_design_scores_gemma":[0.88956696,0.032064486,0.06848526,0.000070959104,0.00021763866,0.0000033826748,0.000017048455,0.0000039326674,0.0013508253,0.000018032026,0.008097791,0.00010370422],"about_ca_topic_score_codex":0.0000047371377,"about_ca_topic_score_gemma":0.00003896923,"teacher_disagreement_score":0.22673424,"about_ca_system_score_codex":0.000014619808,"about_ca_system_score_gemma":0.00014899386,"threshold_uncertainty_score":0.24910183},"labels":[],"label_agreement":null},{"id":"W4249576449","doi":"10.1200/jco.2017.35.15_suppl.e16509","title":"Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; SABR volatility model; Prostate cancer; Oncology; Abiraterone acetate; Radiation therapy; Internal medicine; Chemotherapy; Lymph; Androgen deprivation therapy; Cancer; Radiology; Urology; Pathology","score_opus":0.17010034977483687,"score_gpt":0.512485317785779,"score_spread":0.3423849680109421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249576449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837153,0.005206889,0.000024283609,0.008833063,0.00033825685,0.0010134651,0.00001776216,0.00000506878,0.00084592646],"genre_scores_gemma":[0.96836907,0.025377419,0.0031418616,0.00032047392,0.00019142588,0.0000537352,0.0000011253792,0.000027019169,0.002517857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963541,0.0005265652,0.0018833699,0.0002891959,0.0005351777,0.0004115823],"domain_scores_gemma":[0.9950567,0.0010669433,0.0025311166,0.00037013425,0.0006168095,0.00035830145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025751404,0.0002046325,0.0014325824,0.00021046064,0.00011441919,0.000048296097,0.0003268847,0.00013040351,0.00019509418],"category_scores_gemma":[0.0009807771,0.00013200447,0.00022577659,0.00014137903,0.00036015635,0.00040444933,0.000056220215,0.0006342157,0.000004130819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07863292,0.004278404,0.6735271,0.00094967696,0.0048225606,0.003176845,0.00511274,0.00048911606,0.033511538,0.00007062557,0.0011214708,0.19430697],"study_design_scores_gemma":[0.032895714,0.025384635,0.92865574,0.0013910118,0.00034998526,0.0000815479,0.0005446941,0.00022916385,0.007747044,0.00044486922,0.0020677452,0.0002078498],"about_ca_topic_score_codex":0.00023565933,"about_ca_topic_score_gemma":0.00029744674,"teacher_disagreement_score":0.2551286,"about_ca_system_score_codex":0.0004695991,"about_ca_system_score_gemma":0.0031801306,"threshold_uncertainty_score":0.5641415},"labels":[],"label_agreement":null},{"id":"W4249624820","doi":"10.1200/jco.2014.32.15_suppl.e15232","title":"FOLFIRINOX in the real world setting: The multicentric experience of six Canadian institutions.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Saint-Luc; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; FOLFIRINOX; Febrile neutropenia; Regimen; Neutropenia; Internal medicine; Performance status; Gemcitabine; Surgery; Cancer; Chemotherapy; Oxaliplatin","score_opus":0.2144056426701395,"score_gpt":0.5333950859759594,"score_spread":0.3189894433058199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249624820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9165853,0.00011744802,0.000053829128,0.029812435,0.00042085742,0.00024430436,9.09944e-7,0.0000017982476,0.0527631],"genre_scores_gemma":[0.9936168,0.00037226902,0.0011447958,0.0039862506,0.0005891438,0.000007657859,6.385512e-7,0.0000042925444,0.0002781049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962988,0.001252391,0.0016665458,0.000109303306,0.00037613284,0.00029682825],"domain_scores_gemma":[0.9895642,0.008770445,0.00076092343,0.00027517948,0.00031039026,0.0003188741],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009026436,0.000078539655,0.00087731186,0.00023294572,0.00008928197,0.000005872076,0.00041420956,0.00019136582,0.00011078895],"category_scores_gemma":[0.0140060885,0.00003737978,0.00019747778,0.0004013443,0.00073969073,0.000052567408,0.00003586548,0.0011551024,0.000013705126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051649247,0.0005189925,0.96362627,0.000011936837,0.00006774046,0.0002484265,0.0012641912,0.000012242671,0.000012767451,0.0031261533,0.0027933603,0.027801447],"study_design_scores_gemma":[0.0028428624,0.0018547956,0.84391826,0.000051804895,0.00013084154,0.00013325979,0.0008810315,0.00055736705,0.000005214592,0.00019143977,0.14939927,0.00003386574],"about_ca_topic_score_codex":0.013149688,"about_ca_topic_score_gemma":0.09912882,"teacher_disagreement_score":0.14660591,"about_ca_system_score_codex":0.00019691004,"about_ca_system_score_gemma":0.0052029258,"threshold_uncertainty_score":0.99429935},"labels":[],"label_agreement":null},{"id":"W4249786531","doi":"10.1200/jco.2013.31.15_suppl.5586","title":"Impact of wait times on survival of women with uterine cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Proportional hazards model; Cancer; Hysterectomy; Cancer registry; Endometrial cancer; Survival analysis; Gynecology; Population; Uterine cancer; Surgery; Internal medicine","score_opus":0.33679038704625974,"score_gpt":0.6202097877194936,"score_spread":0.2834194006732339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249786531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904302,0.000032013264,0.00008144929,0.0075797453,0.0005033117,0.00023891832,0.000009344981,0.0000040146006,0.0011210209],"genre_scores_gemma":[0.9953867,0.000370336,0.0023028888,0.0009272372,0.00080023333,0.0000058278365,0.0000020638986,0.00001668217,0.00018801945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945086,0.00042565298,0.004192519,0.0001377106,0.00049211294,0.00024337735],"domain_scores_gemma":[0.9859007,0.0073804324,0.0046826047,0.00022612908,0.0013932806,0.00041682387],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046929293,0.00012763386,0.0018154244,0.00011565757,0.000011336519,0.0000036888675,0.00014780131,0.0001938857,0.0043985583],"category_scores_gemma":[0.011846836,0.00007345689,0.00036657756,0.0001535726,0.0002217923,0.00018017265,0.00004227527,0.0006893304,0.00001816184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03083099,0.004217891,0.5869956,0.00008741432,0.0020327254,0.000102002305,0.00017426077,0.00019657824,0.0020991962,0.00008364653,0.010904127,0.36227554],"study_design_scores_gemma":[0.010055954,0.07993754,0.9030091,0.00011355481,0.00025211164,0.00008039547,0.00023262858,0.00013785777,0.00009881999,0.00021502934,0.005798759,0.000068214955],"about_ca_topic_score_codex":0.0007634613,"about_ca_topic_score_gemma":0.00006100341,"teacher_disagreement_score":0.36220732,"about_ca_system_score_codex":0.0003371965,"about_ca_system_score_gemma":0.0027067843,"threshold_uncertainty_score":0.9965116},"labels":[],"label_agreement":null},{"id":"W4249825500","doi":"10.1200/jco.2013.31.18_suppl.cra8007","title":"A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Neutropenia; Internal medicine; Gastroenterology; Adenocarcinoma; Febrile neutropenia; Adverse effect; Population; Clinical endpoint; Anemia; Oncology; Randomized controlled trial; Cancer; Chemotherapy","score_opus":0.07307915311204514,"score_gpt":0.4146076731411589,"score_spread":0.3415285200291137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249825500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927518,0.0012564585,0.00033488683,0.0007766619,0.00019199357,0.0045486996,0.0000062672366,0.0000027818787,0.00013049324],"genre_scores_gemma":[0.9969268,0.0002052993,0.0019835583,0.00007570692,0.0003216832,0.00032500774,0.00000955269,0.000031521282,0.00012089831],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99418575,0.0016335826,0.0029889024,0.00034097506,0.0005002605,0.00035056093],"domain_scores_gemma":[0.9954421,0.0012727908,0.0013284029,0.00035645635,0.001390382,0.00020984921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005743255,0.00022969887,0.0021597247,0.00022988488,0.000034008557,0.000013202728,0.00040137715,0.0004853739,0.00008542036],"category_scores_gemma":[0.0034327353,0.00015847078,0.0004135165,0.00021489077,0.00033901562,0.000027686574,0.00010483992,0.0006244569,0.0000013332779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7115364,0.011674525,0.022967933,0.00019689793,0.0016333784,0.000049138962,0.00035149322,0.00013423721,0.23952009,0.00003773278,0.0005912583,0.011306933],"study_design_scores_gemma":[0.74689436,0.12290299,0.018676236,0.0001221229,0.000113661816,0.00003427898,0.00038141574,0.0007489669,0.10890552,0.0002196061,0.0007393689,0.00026146948],"about_ca_topic_score_codex":0.00016364452,"about_ca_topic_score_gemma":0.00031780146,"teacher_disagreement_score":0.13061456,"about_ca_system_score_codex":0.00006711996,"about_ca_system_score_gemma":0.0012952919,"threshold_uncertainty_score":0.6462251},"labels":[],"label_agreement":null},{"id":"W4249861497","doi":"10.1200/jco.2016.34.15_suppl.e16547","title":"The frequency of druggable targets in localized prostate cancer: Initial analysis from the Decipher GRID.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Druggability; Medicine; Prostate cancer; Computational biology; Gene expression profiling; Population; Bioinformatics; Cancer; Gene; Oncology; Gene expression; Biology; Genetics; Internal medicine","score_opus":0.09692976115524495,"score_gpt":0.49111820894542224,"score_spread":0.3941884477901773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249861497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93606806,0.009287547,0.00009545162,0.052037463,0.001011307,0.00032546604,0.000052733718,0.000003844856,0.0011181375],"genre_scores_gemma":[0.9787527,0.018446188,0.00039893863,0.00070151145,0.000994783,0.000020134834,0.000003660921,0.00001110967,0.0006709978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963489,0.0007850705,0.0019390642,0.00016211679,0.0004670414,0.00029778745],"domain_scores_gemma":[0.9907727,0.0071024047,0.0011456594,0.0002581876,0.00052409526,0.00019693666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037332892,0.00011002559,0.0011697205,0.000097022195,0.00006816087,0.000008580779,0.00029356912,0.00019453198,0.00050133414],"category_scores_gemma":[0.0026610058,0.000037490176,0.00053318613,0.00043893105,0.0006261855,0.00008565131,0.000060917107,0.00059551274,0.000008294262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008904478,0.00061914197,0.8026068,0.0000063744124,0.0026621504,0.00034483045,0.0002580835,0.000013174431,0.00039415076,0.000055251643,0.006144846,0.1779907],"study_design_scores_gemma":[0.027239457,0.004727622,0.85149986,0.00029243765,0.0021040328,0.000016149694,0.00040392595,0.00008798996,0.0012728095,0.005996833,0.106235564,0.00012331657],"about_ca_topic_score_codex":0.0011143227,"about_ca_topic_score_gemma":0.0030262328,"teacher_disagreement_score":0.17786738,"about_ca_system_score_codex":0.00024657874,"about_ca_system_score_gemma":0.0025067586,"threshold_uncertainty_score":0.54892576},"labels":[],"label_agreement":null},{"id":"W4249931646","doi":"10.1200/jco.2019.37.7_suppl.171","title":"Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Western University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone; Nausea; Prostate cancer; Pembrolizumab; Cancer; Cohort; Internal medicine; Oncology; Gynecology; Immunotherapy; Androgen receptor","score_opus":0.07638448730761598,"score_gpt":0.439758731083495,"score_spread":0.363374243775879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249931646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919763,0.001124812,0.000006890654,0.0018035488,0.0007057999,0.0016262925,0.000050541992,0.00001900652,0.002686812],"genre_scores_gemma":[0.99272734,0.0021643108,0.00073892664,0.00059887493,0.00020555973,0.00006190714,0.0000339023,0.00006338897,0.0034057621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939106,0.00084095326,0.0028683164,0.0005389782,0.0010607293,0.0007804315],"domain_scores_gemma":[0.9950874,0.0009682248,0.0017629082,0.0004033059,0.0011176936,0.00066046574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025283485,0.0003836393,0.0026402874,0.00039272223,0.000057903253,0.000034172157,0.00027112907,0.00032943458,0.00040956587],"category_scores_gemma":[0.00064056605,0.00023256295,0.0003355065,0.00052792614,0.0003719536,0.00030172674,0.00008243578,0.0016744368,0.00007025866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12287876,0.0025189072,0.8473153,0.00026713614,0.0014498865,0.0035744924,0.00037185106,0.00039334688,0.00075487746,0.000015711346,0.00062510965,0.019834591],"study_design_scores_gemma":[0.08952556,0.03478691,0.8678018,0.00083052716,0.0008118322,0.00017700995,0.00022711689,0.00033987538,0.00057972444,0.0000981317,0.0045337463,0.0002877957],"about_ca_topic_score_codex":0.0006220941,"about_ca_topic_score_gemma":0.0008581684,"teacher_disagreement_score":0.033353206,"about_ca_system_score_codex":0.0016499743,"about_ca_system_score_gemma":0.005743913,"threshold_uncertainty_score":0.9998926},"labels":[],"label_agreement":null},{"id":"W4250119847","doi":"10.1200/jco.2017.35.5_suppl.12","title":"Total and cancer-attributable phase-based costs for adolescent cancer care: A population–based study in British Columbia, Canada.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Institute for Clinical Evaluative Sciences; Centre for Addiction and Mental Health; University of Toronto; BC Children's Hospital; Toronto General Hospital; University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Cancer registry; Population; Cohort; Health care; Total cost; Cohort study; Demography; Internal medicine; Environmental health","score_opus":0.12162223596143411,"score_gpt":0.49218542705920665,"score_spread":0.3705631910977725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250119847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97982836,0.0016159194,0.000053677475,0.014802867,0.0022433088,0.0011749755,0.00025025432,0.0000067740593,0.00002385301],"genre_scores_gemma":[0.9928184,0.00010120879,0.00043522858,0.0050835838,0.0013600093,0.00006792901,0.000012956527,0.000026183754,0.000094497744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960575,0.00040411955,0.0022530544,0.0003381502,0.0005868314,0.00036036214],"domain_scores_gemma":[0.99486774,0.0012761748,0.0022557147,0.000320754,0.00075334095,0.0005262757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026413435,0.0001391999,0.0019052356,0.000055735618,0.00023007613,0.000106938256,0.00023063777,0.00024436184,0.00008571831],"category_scores_gemma":[0.004618315,0.00017769868,0.00022652418,0.00007426133,0.00010930846,0.0001310165,0.000046972742,0.0007622502,1.6518864e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018785922,0.0025111665,0.89792144,0.00016001149,0.00014219667,0.000311596,0.0000682728,0.00008664075,0.0000048656816,2.7197214e-7,0.0062641352,0.09065078],"study_design_scores_gemma":[0.045346797,0.0059298715,0.93717355,0.00081419543,0.00036130758,0.000025701655,0.00038162194,0.00025201967,0.0000055189917,0.000006880904,0.00953908,0.00016345437],"about_ca_topic_score_codex":0.95450443,"about_ca_topic_score_gemma":0.99848765,"teacher_disagreement_score":0.09048732,"about_ca_system_score_codex":0.0018778655,"about_ca_system_score_gemma":0.0158041,"threshold_uncertainty_score":0.98977536},"labels":[],"label_agreement":null},{"id":"W4250130807","doi":"10.1200/jco.2013.31.26_suppl.136","title":"Physical activity and fitness in women with metastatic breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Aerobic exercise; Physical fitness; Physical activity; Internal medicine; Cancer; Metastatic breast cancer; Disease; Physical therapy","score_opus":0.06753255701044164,"score_gpt":0.44535356038684837,"score_spread":0.3778210033764067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250130807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867889,0.00009854455,0.000021647846,0.012278197,0.00029099564,0.00012191289,0.0000033763497,0.0000032333096,0.00039317488],"genre_scores_gemma":[0.99792516,0.00020968953,0.00010625225,0.001124318,0.00051443523,0.00001898931,1.15729854e-7,0.000008729277,0.00009233778],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99878937,0.00021901293,0.00048226665,0.00012017143,0.00020520981,0.00018395692],"domain_scores_gemma":[0.99809,0.00082462013,0.0004652679,0.00008752678,0.00021616557,0.0003164074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007653595,0.00008787749,0.0010650418,0.000059696595,0.000012562564,0.000007773581,0.000059750615,0.00008493307,0.00019180884],"category_scores_gemma":[0.00017962353,0.00005245394,0.00008190616,0.00012556938,0.00017938204,0.00014890207,0.000024338693,0.0006757724,0.0000039169513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00752928,0.0017230496,0.14177461,0.00007127556,0.00024405967,0.0003165519,0.000860021,0.0000085345455,0.00028096343,0.000019330371,0.00047790023,0.8466944],"study_design_scores_gemma":[0.00531122,0.00490439,0.98653305,0.00010260262,0.000113617214,0.0004318522,0.0006497095,0.00010177892,0.000025657882,0.00022852987,0.0015324171,0.00006517571],"about_ca_topic_score_codex":0.0008522333,"about_ca_topic_score_gemma":0.0011111022,"teacher_disagreement_score":0.84662926,"about_ca_system_score_codex":0.00017114337,"about_ca_system_score_gemma":0.0008701581,"threshold_uncertainty_score":0.29359323},"labels":[],"label_agreement":null},{"id":"W4250181945","doi":"10.1200/jco.2004.22.14_suppl.860","title":"Preliminary clinical results of accelerated IMRT with concomitant boost after breast conserving therapy (BCT)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Nuclear medicine; Radiation therapy; Prone position; Breast-conserving surgery; Stage (stratigraphy); Concomitant; Radiology; Mastectomy; Cancer; Surgery; Internal medicine","score_opus":0.07845400968856585,"score_gpt":0.4397908093032171,"score_spread":0.36133679961465126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250181945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97905415,0.00041648888,0.014390713,0.0032964763,0.0005065901,0.0003250776,0.000052691415,0.000025324232,0.0019324672],"genre_scores_gemma":[0.95773804,0.00046630154,0.039493285,0.0010329911,0.0011696798,0.000008759547,0.0000041001545,0.000035736688,0.00005111184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946907,0.00056564517,0.003875991,0.0002902159,0.0002857797,0.0002916577],"domain_scores_gemma":[0.9925487,0.0024735439,0.0036447227,0.00035453463,0.000698204,0.00028028572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028549675,0.00023834525,0.0016984056,0.00009085711,0.000044204713,0.000015167982,0.0004171412,0.00031268806,0.00017142494],"category_scores_gemma":[0.0002023191,0.00015707832,0.00056595175,0.00016736073,0.0006171061,0.00026783015,0.00006000697,0.001265489,0.000002641768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112187296,0.0074198144,0.49253273,0.000017557899,0.0019908561,0.0006099494,0.00036912435,0.00033185325,0.00096841133,0.00086172717,0.002272519,0.38043815],"study_design_scores_gemma":[0.07096241,0.07377696,0.7828298,0.0007770205,0.00032143778,0.0006331947,0.00036647913,0.000106695734,0.00408237,0.006570695,0.058829505,0.0007434248],"about_ca_topic_score_codex":0.00006236383,"about_ca_topic_score_gemma":0.000008837897,"teacher_disagreement_score":0.37969473,"about_ca_system_score_codex":0.00007800596,"about_ca_system_score_gemma":0.0016671522,"threshold_uncertainty_score":0.6405468},"labels":[],"label_agreement":null},{"id":"W4250246459","doi":"10.1200/jco.2017.35.15_suppl.tps4591","title":"S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre","funders":"","keywords":"Medicine; Atezolizumab; Cystectomy; Bladder cancer; Clinical endpoint; Oncology; Internal medicine; Population; Urology; Immunotherapy; Cancer; Pembrolizumab; Randomized controlled trial","score_opus":0.17885300166355622,"score_gpt":0.5346122422509457,"score_spread":0.3557592405873895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250246459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98147935,0.0003573986,0.0000129793525,0.008103156,0.00291107,0.000554072,0.000025634356,0.0000036193917,0.0065527405],"genre_scores_gemma":[0.99338657,0.0021678833,0.00039720218,0.001157085,0.0021686067,0.000019641644,0.0000017472496,0.000021516546,0.0006797748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99624056,0.00033895645,0.00247683,0.00023709428,0.00041610462,0.000290476],"domain_scores_gemma":[0.9939349,0.001445695,0.0032078268,0.00045206244,0.00058587256,0.00037362077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018384897,0.00018489503,0.002100644,0.00017166385,0.0001155549,0.000010858718,0.00036144673,0.00044105918,0.00045631407],"category_scores_gemma":[0.006866776,0.000133027,0.0006247384,0.00008189552,0.0004270196,0.00019330431,0.00012595653,0.00088106963,0.000011951911],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50613475,0.016936352,0.017253038,0.000054621363,0.0014094076,0.0030555294,0.000983747,0.000010292702,0.0019201842,0.000038897608,0.0077097598,0.44449344],"study_design_scores_gemma":[0.5865974,0.16209,0.22033489,0.0004598396,0.0011119563,0.00013951067,0.00027649297,0.000026301965,0.0023139499,0.0006285739,0.025833732,0.00018739278],"about_ca_topic_score_codex":0.00051830854,"about_ca_topic_score_gemma":0.0006736097,"teacher_disagreement_score":0.44430605,"about_ca_system_score_codex":0.00024237827,"about_ca_system_score_gemma":0.006426988,"threshold_uncertainty_score":0.99920565},"labels":[],"label_agreement":null},{"id":"W4250306919","doi":"10.1200/jco.2013.31.4_suppl.lba445","title":"Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Internal medicine; Neutropenia; Bevacizumab; Clinical endpoint; Placebo; Colorectal cancer; Pegfilgrastim; Febrile neutropenia; Gastroenterology; Regimen; Surgery; Oncology; Randomized controlled trial; Chemotherapy; Irinotecan; Oxaliplatin; Cancer; Pathology","score_opus":0.10364740438154886,"score_gpt":0.4599664402436699,"score_spread":0.35631903586212105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250306919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623854,0.00015794412,0.00014405481,0.002979047,0.0019123391,0.007929326,0.000031512056,0.000006212527,0.00060101564],"genre_scores_gemma":[0.9959194,0.0011406387,0.00070747454,0.00018535121,0.0009814843,0.00074457907,0.000007960385,0.000023738081,0.000289386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925312,0.0005174109,0.005960058,0.00028745816,0.00039823542,0.0003056525],"domain_scores_gemma":[0.98249453,0.010956006,0.004716789,0.00017514524,0.0013390172,0.00031851744],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004478093,0.00023133855,0.004969615,0.00033236897,0.000055809924,0.0000109380035,0.00015715207,0.000451725,0.000237917],"category_scores_gemma":[0.010733607,0.00014351103,0.00095231103,0.00024538764,0.0003535192,0.00018237183,0.00005462888,0.0007124313,0.0000013730645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9531503,0.0064698053,0.0017934307,0.00007621145,0.0010541913,0.00001652386,0.00018655331,0.000075100914,0.00008302433,0.000011572895,0.0017948586,0.035288434],"study_design_scores_gemma":[0.9394221,0.054904375,0.0012362893,0.00031304208,0.0015836037,0.000028214192,0.000048102473,0.0005805691,0.00018813896,0.00013310193,0.001441321,0.00012117453],"about_ca_topic_score_codex":0.0004745934,"about_ca_topic_score_gemma":0.0015061025,"teacher_disagreement_score":0.04843457,"about_ca_system_score_codex":0.00019250145,"about_ca_system_score_gemma":0.0017915561,"threshold_uncertainty_score":0.9975994},"labels":[],"label_agreement":null},{"id":"W4250326205","doi":"10.1200/jco.2004.22.14_suppl.4576","title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Medicine; Placebo; Zoledronic acid; Prostate cancer; Hazard ratio; Internal medicine; Surgery; Cancer; Urology; Pathology; Confidence interval","score_opus":0.1011746862801276,"score_gpt":0.4642173471630571,"score_spread":0.3630426608829295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250326205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908025,0.00048830017,0.000681939,0.005965572,0.00037800474,0.0012792866,0.000057647212,0.000003329002,0.00034341664],"genre_scores_gemma":[0.994968,0.0001975874,0.0039741057,0.0006435196,0.00005593506,0.000061800434,0.000025222838,0.000013375918,0.000060438542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633026,0.0001669424,0.0028676088,0.00016387497,0.00030208554,0.00016920829],"domain_scores_gemma":[0.9939433,0.0015713888,0.0032061385,0.0002883158,0.0008197659,0.0001711231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013195096,0.000109813394,0.0010808985,0.000119625176,0.000027352678,6.9545797e-7,0.00014054103,0.00018776141,0.000021954891],"category_scores_gemma":[0.0006050185,0.00006807052,0.00042649833,0.00012427887,0.00043206778,0.000048383496,0.000015273095,0.0004902562,0.0000013116457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010274123,0.020016225,0.8490283,0.00020980371,0.00043366945,0.0000029205173,0.000090532776,0.0010225701,0.000022576725,0.00059676805,0.00032462436,0.1179779],"study_design_scores_gemma":[0.025263702,0.023232361,0.9459777,0.0003826559,0.00042850192,0.0000033449085,0.000012838824,0.00020593367,0.000016086417,0.00036472175,0.0040654605,0.000046724785],"about_ca_topic_score_codex":0.00009759091,"about_ca_topic_score_gemma":0.00040586124,"teacher_disagreement_score":0.11793118,"about_ca_system_score_codex":0.00048387036,"about_ca_system_score_gemma":0.0038947149,"threshold_uncertainty_score":0.6909057},"labels":[],"label_agreement":null},{"id":"W4250491542","doi":"10.1200/jco.2004.22.90140.6588","title":"Long-term follow up of limited stage primary testicular lymphoma: Outcome and patterns of relapse after combined-modality treatment","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Stage (stratigraphy); Chemotherapy; Surgery; Lymphoma; Internal medicine; CHOP; Gastroenterology","score_opus":0.09729579567684771,"score_gpt":0.41592034318740273,"score_spread":0.318624547510555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250491542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557966,0.0007818925,0.00016875919,0.0020853158,0.00073649234,0.00028957915,0.000042169144,0.000006173601,0.0003099754],"genre_scores_gemma":[0.9951169,0.0010252757,0.0015540188,0.0017165641,0.00019121887,0.0000048042816,0.0000137102725,0.000017806295,0.0003597159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607277,0.00023922767,0.0029206243,0.00021643445,0.0003426516,0.00020826406],"domain_scores_gemma":[0.9960097,0.0011610675,0.0018279743,0.00031177636,0.000317479,0.00037196916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012003097,0.0001943323,0.0022220283,0.00013070516,0.000018891984,0.0000039459846,0.00011469442,0.0003436966,0.00014638511],"category_scores_gemma":[0.00088288647,0.00013387171,0.0006503253,0.000080011916,0.00026549725,0.000115596864,0.000058445625,0.00033648606,0.000001765269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012319042,0.0032346917,0.94074816,0.00029449654,0.0006717764,0.0016843533,0.00015581542,0.00001154279,0.00036891602,0.000029061883,0.000023266875,0.040458858],"study_design_scores_gemma":[0.048787724,0.02099877,0.92783725,0.00018231198,0.0007604482,0.00021530488,0.00003849996,0.0000064544834,0.00030507508,0.00006586428,0.00070315896,0.00009910356],"about_ca_topic_score_codex":0.000077706114,"about_ca_topic_score_gemma":0.00008036081,"teacher_disagreement_score":0.040359754,"about_ca_system_score_codex":0.0005077273,"about_ca_system_score_gemma":0.002042546,"threshold_uncertainty_score":0.545913},"labels":[],"label_agreement":null},{"id":"W4250580474","doi":"10.1200/jco.2004.22.14_suppl.6139","title":"Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; The Internet; Intervention (counseling); Family medicine; Internal medicine; World Wide Web; Nursing","score_opus":0.1948323392622773,"score_gpt":0.55349651941195,"score_spread":0.3586641801496727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250580474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811349,0.00023256893,0.0020491024,0.007900086,0.0031495579,0.005027473,0.000023701046,0.000007981518,0.0004746209],"genre_scores_gemma":[0.96646863,0.00017850113,0.00042946576,0.031882275,0.00052785774,0.00045801618,0.000012899783,0.0000049808805,0.00003739974],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9828939,0.0090654,0.00729775,0.00012752865,0.0003917134,0.00022370894],"domain_scores_gemma":[0.9809461,0.0113842925,0.006291522,0.00014848218,0.0009947901,0.00023479214],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02608239,0.00014339505,0.0017161148,0.0000730148,0.00020772974,0.00004831587,0.00021944815,0.00021914564,0.0001536151],"category_scores_gemma":[0.020932024,0.000062320105,0.00035040829,0.00007929653,0.00023973065,0.0013113486,0.00016427446,0.0011024982,0.00001944391],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6589954,0.0002212543,0.0014518143,0.000030289846,0.00011846973,1.7183264e-7,0.043896962,0.000011484147,1.2043023e-7,0.00014674061,0.0006091222,0.29451817],"study_design_scores_gemma":[0.9545351,0.004687027,0.017393615,0.00037360165,0.00015964292,3.852418e-7,0.0032763127,0.004181215,5.7308745e-7,0.0018427402,0.013475606,0.00007417008],"about_ca_topic_score_codex":0.0021012102,"about_ca_topic_score_gemma":0.00063482026,"teacher_disagreement_score":0.29553974,"about_ca_system_score_codex":0.00020930664,"about_ca_system_score_gemma":0.00052641786,"threshold_uncertainty_score":0.98731506},"labels":[],"label_agreement":null},{"id":"W4250599156","doi":"10.1200/jco.2012.30.18_suppl.lba671","title":"Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Interior Health; Ottawa Hospital; Hamilton Health Sciences; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Metastatic breast cancer; Internal medicine; Taxane; Clinical endpoint; Trastuzumab; Lapatinib; Breast cancer; Oncology; Pertuzumab; Interim analysis; Surgery; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.17811336086588878,"score_gpt":0.5349206746260675,"score_spread":0.3568073137601787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250599156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98205435,0.00070023106,0.002573482,0.005142067,0.0007211114,0.008425652,0.00006130563,0.000013467371,0.0003083396],"genre_scores_gemma":[0.98790944,0.0011820191,0.004144889,0.0025289946,0.0011697647,0.0021687117,0.00002446388,0.000056736197,0.0008149933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930134,0.001275507,0.0042184866,0.00036505834,0.00051759306,0.0006099977],"domain_scores_gemma":[0.9831392,0.008726741,0.0063419775,0.0002936758,0.0008214707,0.00067689025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0078026266,0.00047134038,0.011557043,0.00039839002,0.000096005446,0.000028685366,0.00042253383,0.00024317672,0.002797169],"category_scores_gemma":[0.0006000467,0.00023893538,0.0010315706,0.00056513725,0.0005272892,0.0002245381,0.000033775967,0.00065084867,0.0000017234495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8905068,0.040001653,0.001997892,0.00007456607,0.03872723,0.00009661402,0.0005549273,0.00014973045,0.00025273635,0.0000066575058,0.00045477608,0.027176436],"study_design_scores_gemma":[0.8526409,0.12647872,0.0005807919,0.00013942113,0.014728511,0.00016743883,0.00020299929,0.0014783831,0.00034191433,0.000019382729,0.0030004352,0.00022105951],"about_ca_topic_score_codex":0.00029067363,"about_ca_topic_score_gemma":0.00056052534,"teacher_disagreement_score":0.08647706,"about_ca_system_score_codex":0.0005679249,"about_ca_system_score_gemma":0.0042346427,"threshold_uncertainty_score":0.9981144},"labels":[],"label_agreement":null},{"id":"W4250614201","doi":"10.1200/jco.2004.22.90140.6611","title":"A randomized phase I clinical and biologic study of two schedules of BAY 43–9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Nausea; Gastroenterology; Regimen; Vomiting; Oncology; Surgery; Adverse effect","score_opus":0.2024794012292822,"score_gpt":0.55521098114729,"score_spread":0.35273157991800774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250614201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282265,0.00038392894,0.00017322582,0.0005997927,0.00161394,0.004279133,0.00009157678,0.000009423973,0.000026318512],"genre_scores_gemma":[0.99301744,0.0024637391,0.003332868,0.00030975018,0.000656859,0.0001395281,0.0000111410045,0.00003917351,0.000029512743],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9712965,0.008970998,0.016634256,0.0007726108,0.0018045071,0.0005211593],"domain_scores_gemma":[0.96170247,0.024923917,0.009796541,0.00042253852,0.0024977336,0.00065681594],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.051218554,0.00045738564,0.0115532745,0.0007791193,0.000055717894,0.0000113268325,0.0005830922,0.0007777878,0.00013348181],"category_scores_gemma":[0.054276943,0.0002535016,0.0009918801,0.00084844965,0.002895971,0.00030010688,0.00030461457,0.0028305615,0.000001946286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42975104,0.027593069,0.52487713,0.000076873665,0.0056622857,0.00062221417,0.00017371718,0.00028825866,0.00002959359,0.000049726958,0.000035398556,0.010840672],"study_design_scores_gemma":[0.5019066,0.07764101,0.41658285,0.00045501164,0.0026200153,0.000054486092,0.00027036646,0.00012199268,0.000007444793,0.00014648416,0.000051705858,0.000142047],"about_ca_topic_score_codex":0.000900886,"about_ca_topic_score_gemma":0.002923052,"teacher_disagreement_score":0.108294286,"about_ca_system_score_codex":0.0007966036,"about_ca_system_score_gemma":0.015852598,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W4250704120","doi":"10.1200/jco.2013.31.31_suppl.144","title":"Effect of intervention on a quality measure of pain management at Medstar Washington Cancer Institute.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Documentation; Physical therapy; Pain management; Quarter (Canadian coin); Family medicine","score_opus":0.10420943002375828,"score_gpt":0.4853331704945751,"score_spread":0.3811237404708168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250704120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99021184,0.00028055676,0.00044268603,0.003564414,0.0011185863,0.00050674996,0.0000011422213,0.000006423204,0.003867621],"genre_scores_gemma":[0.99672246,0.0005983626,0.00061430695,0.0008871523,0.0003312664,0.000013129719,0.0000025055401,0.00000944173,0.0008213578],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994679,0.0020654907,0.002414431,0.00014665964,0.0005389257,0.000155504],"domain_scores_gemma":[0.9948539,0.0021178764,0.002344129,0.00022411365,0.0002965958,0.00016336671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019325668,0.00012428725,0.0013608361,0.00017138882,0.000019582007,0.000003381191,0.00018924761,0.00020899216,0.00035040043],"category_scores_gemma":[0.004477145,0.00008033454,0.0006920396,0.00012073855,0.00016753709,0.0001076888,0.000090000976,0.00045606482,0.000015091845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009109837,0.0018478772,0.3045296,0.001577796,0.0013695896,0.00008435688,0.00010831007,0.00004877276,0.0004805149,0.00041922755,0.018441295,0.66198283],"study_design_scores_gemma":[0.01658807,0.0330236,0.8965584,0.0019630666,0.0010896636,0.0000029366918,0.00012722652,0.00025174976,0.001169866,0.00033687445,0.048761502,0.00012701518],"about_ca_topic_score_codex":0.00015414668,"about_ca_topic_score_gemma":0.00010866177,"teacher_disagreement_score":0.6618558,"about_ca_system_score_codex":0.00021151971,"about_ca_system_score_gemma":0.00009503729,"threshold_uncertainty_score":0.6697929},"labels":[],"label_agreement":null},{"id":"W4250712221","doi":"10.1200/jco.2004.22.14_suppl.3137","title":"A phase II clinical trial involving the use of low-dose daily oral cyclophosphamide, weekly vinblastine and rofecoxib in patients with advanced solid tumors","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Rofecoxib; Cyclophosphamide; Clinical trial; Placebo; Internal medicine; Chemotherapy; Oncology; Pharmacology; Surgery; Pathology","score_opus":0.09606544889507362,"score_gpt":0.43501264632452663,"score_spread":0.338947197429453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250712221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949297,0.0006686943,0.000027201526,0.0025216592,0.0010759193,0.00073978875,0.000004876293,0.0000079002975,0.00002426187],"genre_scores_gemma":[0.99411386,0.001579877,0.0019070879,0.0014134937,0.0008630928,0.000007940604,0.000003891055,0.000030332303,0.00008043932],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99347544,0.0008071149,0.0045600934,0.00030123218,0.000496646,0.00035944965],"domain_scores_gemma":[0.9919154,0.0036798464,0.003152092,0.00034192688,0.0005326426,0.00037806254],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037328473,0.00024540257,0.0025746336,0.00017626489,0.00008132965,0.000014579527,0.0002205506,0.0003523427,0.000029009763],"category_scores_gemma":[0.012312148,0.00014412457,0.00046163428,0.00027764917,0.0008646513,0.00030917028,0.00010478031,0.0014930391,0.0000017739402],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7086826,0.018839171,0.11056354,0.00004767207,0.0002255472,0.00054032844,0.00026233096,0.00023929763,0.00005467579,0.000013501096,0.0004381687,0.16009319],"study_design_scores_gemma":[0.3548881,0.13933651,0.49628553,0.0006876926,0.00025513588,0.00011398704,0.00011992074,0.000060034945,0.00003210169,0.00004318063,0.008044716,0.0001330653],"about_ca_topic_score_codex":0.00006285491,"about_ca_topic_score_gemma":0.00015449931,"teacher_disagreement_score":0.385722,"about_ca_system_score_codex":0.00014695295,"about_ca_system_score_gemma":0.0026992664,"threshold_uncertainty_score":0.99600756},"labels":[],"label_agreement":null},{"id":"W4250725747","doi":"10.1200/jco.2008.20.1947","title":"Mastering Emasculation","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Shakespeare, Adaptation, and Literary Criticism","field":"Arts and Humanities","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Emasculation; Biology; Botany; Pollination","score_opus":0.3622581526779226,"score_gpt":0.4291667749618332,"score_spread":0.06690862228391059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250725747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88591826,0.00028574636,0.00030589668,0.001462194,0.0037462206,0.000045074525,0.0000016710189,0.000012510403,0.1082224],"genre_scores_gemma":[0.9876686,0.00012917403,0.00094209105,0.001173404,0.0051532513,6.005796e-7,0.000001407785,0.000008300722,0.004923181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980276,0.00020206909,0.0013848927,0.000076198696,0.0001975217,0.000111699395],"domain_scores_gemma":[0.9980738,0.00076298456,0.0006289056,0.00007556442,0.00034881046,0.00010990077],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010597912,0.00006532173,0.00046087088,0.00007738763,0.00012804418,0.000021192438,0.000105987194,0.000084299594,0.001557177],"category_scores_gemma":[0.0005935073,0.000048792645,0.00026879535,0.00001786014,0.00022672651,0.00037245356,0.000012680701,0.00029813807,0.000055644156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021854404,0.0027969263,0.039353,0.000084851425,0.00077419315,0.002520457,0.16707991,0.00029357758,0.000071448165,0.339747,0.05695493,0.38813826],"study_design_scores_gemma":[0.0012292215,0.0013812413,0.039552443,0.000021508777,0.00003927552,0.00018309955,0.0011409314,0.00012347377,0.0000030553897,0.0023660029,0.95388955,0.00007020574],"about_ca_topic_score_codex":0.0000144885935,"about_ca_topic_score_gemma":0.000054380274,"teacher_disagreement_score":0.8969346,"about_ca_system_score_codex":0.000023093842,"about_ca_system_score_gemma":0.0002473394,"threshold_uncertainty_score":0.99935555},"labels":[],"label_agreement":null},{"id":"W4250793702","doi":"10.1200/jco.2013.31.18_suppl.lba509","title":"Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Exemestane; Medicine; Everolimus; PTEN; Oncology; Internal medicine; Breast cancer; Population; Progression-free survival; Hormone receptor; Cancer; Genetics; Tamoxifen; PI3K/AKT/mTOR pathway; Biology; Overall survival","score_opus":0.03618967590298205,"score_gpt":0.4164349621592653,"score_spread":0.38024528625628323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250793702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99086714,0.00044293542,0.00018786991,0.006715051,0.0004006325,0.00045849173,0.00010915673,0.000003684398,0.0008150546],"genre_scores_gemma":[0.994498,0.0011294716,0.0035309773,0.00044255465,0.0002662761,0.000014150546,0.000028768767,0.000012500633,0.000077276636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970555,0.00038888262,0.0019834992,0.00018056226,0.00024194867,0.00014965057],"domain_scores_gemma":[0.9940572,0.002678241,0.0021642302,0.00012904982,0.0007945518,0.000176747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048541502,0.00013027806,0.0012024333,0.00013010048,0.000016347007,0.0000025498796,0.00008722794,0.00022414746,0.00024313608],"category_scores_gemma":[0.0005796069,0.00009373809,0.00019499045,0.00021981617,0.00022923344,0.00015525462,0.000020348225,0.00055785145,0.0000057341613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26725113,0.020695772,0.22308268,0.00005243867,0.004125383,0.00045950053,0.0038499967,0.014927318,0.11197083,0.00011665556,0.008372405,0.3450959],"study_design_scores_gemma":[0.04521683,0.015198171,0.93356633,0.00030544456,0.000498222,0.000041366147,0.00012514052,0.00037411653,0.0040567094,0.00015515112,0.00037715607,0.00008535023],"about_ca_topic_score_codex":0.0014848944,"about_ca_topic_score_gemma":0.00029569693,"teacher_disagreement_score":0.7104837,"about_ca_system_score_codex":0.00020435931,"about_ca_system_score_gemma":0.00096753426,"threshold_uncertainty_score":0.38225284},"labels":[],"label_agreement":null},{"id":"W4250841665","doi":"10.1200/jco.2004.22.14_suppl.6111","title":"The cost of hospitalization secondary to severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Colorectal cancer; Discontinuation; Oxaliplatin; Cohort; Irinotecan; Retrospective cohort study; Chemotherapy; Internal medicine; Cancer; Diarrhea","score_opus":0.05646301878120655,"score_gpt":0.4564091017624467,"score_spread":0.3999460829812401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250841665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98261654,0.0001595857,0.00002270158,0.015270827,0.00088614254,0.0007351097,0.0000071953464,0.0000033333201,0.00029856485],"genre_scores_gemma":[0.995083,0.00038081943,0.0008865179,0.003298944,0.00029476878,0.00002177223,0.0000019829242,0.000016373904,0.000015864573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771386,0.00013864448,0.0014671806,0.00012881361,0.00033391343,0.00021757992],"domain_scores_gemma":[0.99752545,0.0005085816,0.001090459,0.00011576735,0.00047905714,0.00028068892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010287692,0.000104561586,0.000812408,0.00007167524,0.000033283486,0.0000033207953,0.000104720355,0.00020838024,0.000048097085],"category_scores_gemma":[0.00044872367,0.00005812275,0.00010394727,0.0002253258,0.000101104444,0.00006656847,0.000017216027,0.0005368676,0.0000025963159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0147730075,0.0014790207,0.78385115,0.000024581039,0.0001335752,0.000029628203,0.00024550472,0.0001588879,0.000010978162,0.000018899864,0.00035288406,0.19892186],"study_design_scores_gemma":[0.022622816,0.032278806,0.94054097,0.00023183858,0.00005604161,0.000011619707,0.00005009775,0.0000030812962,0.0003647975,0.00010027812,0.0036830213,0.000056651974],"about_ca_topic_score_codex":0.00016247574,"about_ca_topic_score_gemma":0.000997896,"teacher_disagreement_score":0.1988652,"about_ca_system_score_codex":0.0010450416,"about_ca_system_score_gemma":0.0040765735,"threshold_uncertainty_score":0.72316664},"labels":[],"label_agreement":null},{"id":"W4250935423","doi":"10.1200/jco.2004.22.14_suppl.3656","title":"The costs of managing patients with stage 3 and 4 colorectal cancer and the influence of patient factors at presentation","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Colorectal cancer; Presentation (obstetrics); Cancer; Stage (stratigraphy); Oncology; General surgery; Intensive care medicine; Internal medicine; Surgery","score_opus":0.02971451608215515,"score_gpt":0.383100110034559,"score_spread":0.3533855939524039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250935423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982386,0.0003519038,0.000016805858,0.00089924224,0.00016986797,0.00022847662,0.0000029694272,0.0000017990134,0.0000902975],"genre_scores_gemma":[0.99916,0.00059877295,0.00008663432,0.00009751768,0.000037615453,0.0000034274155,3.9034106e-7,0.00000416557,0.000011513107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871814,0.0001377846,0.0007325713,0.00007566497,0.00025810863,0.000077749915],"domain_scores_gemma":[0.9968232,0.0014814505,0.0012228948,0.000057147747,0.0003388827,0.00007643611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006569186,0.00005972339,0.0004225359,0.000034077573,0.0000624802,0.0000040324658,0.00004279782,0.00006760056,0.0000021637352],"category_scores_gemma":[0.0008604344,0.000026337279,0.00006523088,0.00007754037,0.0005223685,0.000060334878,0.00004202229,0.0002521849,5.7255136e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055535674,0.00015523598,0.8880406,0.000024923598,0.0001867268,0.000005783204,0.00090822414,0.0010842909,0.000078010075,0.00006270566,0.000012801217,0.053905018],"study_design_scores_gemma":[0.009003845,0.015816968,0.97349846,0.00011196781,0.00013624679,0.000013569214,0.00039276778,0.000042215972,0.00059272826,0.00008264666,0.00028000347,0.000028554998],"about_ca_topic_score_codex":0.00039700116,"about_ca_topic_score_gemma":0.0006955998,"teacher_disagreement_score":0.08545788,"about_ca_system_score_codex":0.00011690976,"about_ca_system_score_gemma":0.0002273091,"threshold_uncertainty_score":0.19246885},"labels":[],"label_agreement":null},{"id":"W4251177184","doi":"10.1200/jco.2005.03.0171","title":"In Reply","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine","score_opus":0.15748527834970055,"score_gpt":0.5028196473580849,"score_spread":0.3453343690083844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251177184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8413163,0.0021893964,0.00001335124,0.12883848,0.00094857044,0.000059129456,2.5018664e-7,0.0000036740532,0.026630871],"genre_scores_gemma":[0.9649272,0.0007232615,0.002777553,0.027167078,0.0034553176,9.1160774e-7,1.2345963e-7,0.000005576809,0.0009429721],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804825,0.00009875714,0.001475357,0.00008844151,0.00016357769,0.00012560599],"domain_scores_gemma":[0.9984163,0.00064042443,0.0005314277,0.00010194014,0.00015874166,0.00015118252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017541914,0.00005686592,0.0008684243,0.0000900464,0.000010125101,0.0000020549185,0.00006867241,0.000118877964,0.00016316728],"category_scores_gemma":[0.0019193434,0.000038877148,0.0002872719,0.00008668371,0.00008102764,0.00008553441,0.000026069796,0.00064007804,0.000034879944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026823324,0.0012725517,0.5189888,0.00001298885,0.00019721247,0.0016054338,0.0003219217,0.000005979856,0.000078364894,0.00012328956,0.166395,0.30831614],"study_design_scores_gemma":[0.003660546,0.0024207395,0.4808302,0.00002244415,0.000053512544,0.00034757817,0.000052215095,0.0000081182025,0.000026933034,0.00008949813,0.5124633,0.000024945324],"about_ca_topic_score_codex":0.000012474975,"about_ca_topic_score_gemma":0.00008412743,"teacher_disagreement_score":0.3460683,"about_ca_system_score_codex":0.00011255945,"about_ca_system_score_gemma":0.0006093974,"threshold_uncertainty_score":0.27808562},"labels":[],"label_agreement":null},{"id":"W4251233440","doi":"10.1200/jco.2004.22.14_suppl.4519","title":"Long-term effects of conservation therapy for muscle invasive bladder carcinoma","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Radiation therapy; Bladder cancer; Cystoscopy; Urology; Surgery; Salvage therapy; Chemotherapy; Oncology; Internal medicine; Cancer; Urinary system","score_opus":0.10765998591047263,"score_gpt":0.44364298719860124,"score_spread":0.33598300128812864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251233440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917737,0.001047072,0.0005785269,0.004716986,0.0010205568,0.0005776818,0.000003468194,0.0000046037067,0.00027736512],"genre_scores_gemma":[0.99250317,0.0009426225,0.0017170327,0.0039014684,0.0008348208,0.0000136791505,0.0000035343573,0.000015308395,0.000068373556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982215,0.000117091855,0.0012011669,0.00012233571,0.00019458606,0.00014330725],"domain_scores_gemma":[0.99611074,0.002032817,0.0010339639,0.0001308803,0.0005124373,0.00017916632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006087794,0.00010441843,0.0009417666,0.000071362054,0.000023928465,0.0000030243723,0.00008744269,0.00024625123,0.000038686507],"category_scores_gemma":[0.0014365822,0.00007094712,0.0004615614,0.00006856583,0.00014114045,0.00007325547,0.000011789802,0.00026448024,0.0000034568814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011732612,0.005386398,0.8027287,0.0002743173,0.0014175356,0.0006656045,0.00045675295,0.000007686623,0.006952574,0.0001741339,0.0017173383,0.16848633],"study_design_scores_gemma":[0.035612367,0.034794796,0.9144496,0.00013737842,0.00041784125,0.000096402146,0.00002145954,0.000001133052,0.012351515,0.00091675133,0.001145648,0.00005512795],"about_ca_topic_score_codex":0.00003940734,"about_ca_topic_score_gemma":0.00004582358,"teacher_disagreement_score":0.1684312,"about_ca_system_score_codex":0.00011039511,"about_ca_system_score_gemma":0.002416717,"threshold_uncertainty_score":0.42871523},"labels":[],"label_agreement":null},{"id":"W4251242878","doi":"10.1200/jco.2021.39.6_suppl.32","title":"A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Bone scintigraphy; Prostate cancer; Nuclear medicine; Radiology; Stage (stratigraphy); Cancer staging; Positron emission tomography; Cancer; Internal medicine","score_opus":0.08183082847259189,"score_gpt":0.4714340660007631,"score_spread":0.3896032375281712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251242878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957515,0.0008532002,0.0000039674987,0.0019062725,0.00013251929,0.0011651005,0.0001369711,0.000004344141,0.00004613393],"genre_scores_gemma":[0.9983149,0.0008212813,0.000280742,0.00013777077,0.00006795179,0.00010993078,0.000039838826,0.000020370004,0.000207187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579793,0.0007288619,0.0017014146,0.00044323443,0.00097262766,0.0003559521],"domain_scores_gemma":[0.9952992,0.0008128682,0.0017306976,0.00024107106,0.001567529,0.00034859285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015523961,0.00023633592,0.0018546386,0.00049659575,0.00004983868,0.000009729504,0.00014663677,0.000022237846,0.00023425036],"category_scores_gemma":[0.0010983426,0.00013686018,0.00018981843,0.0009989821,0.00035311392,0.00016537413,0.000080519065,0.0007611655,3.8721018e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14633186,0.03551125,0.7926557,0.0001307989,0.0012734598,0.00855154,0.00061277836,0.00009737982,0.000021303898,0.000004139616,0.00008700159,0.014722748],"study_design_scores_gemma":[0.12845697,0.08089221,0.78323287,0.0017381206,0.0015358699,0.000057263216,0.0026349572,0.00027469094,0.0007509413,0.00004819468,0.0001863088,0.00019160617],"about_ca_topic_score_codex":0.0002839993,"about_ca_topic_score_gemma":0.0040638777,"teacher_disagreement_score":0.04538096,"about_ca_system_score_codex":0.000502543,"about_ca_system_score_gemma":0.004514151,"threshold_uncertainty_score":0.80079097},"labels":[],"label_agreement":null},{"id":"W4251266546","doi":"10.1200/jco.2015.33.7_suppl.168","title":"A genomic classifier to identify men with adverse pathology post radical prostatectomy who benefit from adjuvant radiation therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Metastasis; Internal medicine; Cumulative incidence; Adjuvant; Incidence (geometry); Radiation therapy; Oncology; Clinical endpoint; Proportional hazards model; Adjuvant radiotherapy; Adjuvant therapy; Salvage therapy; Prostate cancer; Cancer; Clinical trial; Chemotherapy; Cohort","score_opus":0.1284877817778054,"score_gpt":0.47119199044115356,"score_spread":0.34270420866334816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251266546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786994,0.0020430149,0.0000859487,0.016062541,0.0005519685,0.0006621923,0.000023465122,0.000013591863,0.0018578648],"genre_scores_gemma":[0.9888369,0.0025921639,0.002126174,0.0036279715,0.0015818733,0.000026339541,0.000035631165,0.00003730043,0.0011356411],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99687576,0.0004387452,0.0014462082,0.0003086293,0.00056516076,0.00036548765],"domain_scores_gemma":[0.99633086,0.0007267576,0.0008038229,0.00024634326,0.0008072532,0.0010849443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023295647,0.0001815912,0.0013559229,0.00021290059,0.000044215856,0.000014684271,0.00020059258,0.0003911472,0.00018304531],"category_scores_gemma":[0.00095904135,0.00010584712,0.0002618964,0.00018012198,0.00023879952,0.00014766431,0.00006641105,0.0009613222,0.00009866361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115630046,0.0026688145,0.3518223,0.000016317672,0.0014675668,0.009061946,0.001843327,0.000049973656,0.0048319926,0.00006464793,0.018729435,0.49381363],"study_design_scores_gemma":[0.035296764,0.032561935,0.827611,0.00008185555,0.00024321231,0.0004406251,0.00042855743,0.00006228882,0.0003485419,0.00049115723,0.10230357,0.00013045389],"about_ca_topic_score_codex":0.000072055336,"about_ca_topic_score_gemma":0.000040012852,"teacher_disagreement_score":0.4936832,"about_ca_system_score_codex":0.0005098945,"about_ca_system_score_gemma":0.003345218,"threshold_uncertainty_score":0.5934273},"labels":[],"label_agreement":null},{"id":"W4251270351","doi":"10.1200/jco.2002.20.2.545","title":"Factors Affecting Workload of Cancer Clinical Trials: Results of a Multicenter Study of the National Cancer Institute of Canada Clinical Trials Group","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clinical trial; Medicine; Workload; Protocol (science); Cancer; Data collection; Stage (stratigraphy); Internal medicine; Alternative medicine; Statistics; Pathology","score_opus":0.9155788805400173,"score_gpt":0.6813435236384314,"score_spread":0.23423535690158592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251270351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97353506,0.0019402435,0.000052355746,0.009577478,0.012695748,0.0011452934,0.0005558807,0.0000027665415,0.00049518666],"genre_scores_gemma":[0.99376523,0.001599012,0.00044881136,0.0016722385,0.0023672804,0.000015006075,0.000001473847,0.000019007974,0.00011194147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8836753,0.026024763,0.08835025,0.0006692323,0.0008217716,0.00045870352],"domain_scores_gemma":[0.78432596,0.120953746,0.092698306,0.00046963565,0.0011833358,0.0003690293],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3403962,0.00023866205,0.0097973775,0.00026491852,0.000078714,0.000008796758,0.0007746014,0.0006320184,0.00036828418],"category_scores_gemma":[0.46521145,0.00017659759,0.0018295461,0.00033277815,0.00049730844,0.00026587848,0.00013461757,0.0012307606,0.0000027590063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021515586,0.004585172,0.9561839,0.0001712885,0.0021474082,0.0000018609267,0.0011099739,0.0010706213,0.0000027121678,0.0002250332,0.023366498,0.008983964],"study_design_scores_gemma":[0.02326776,0.0034642154,0.9470667,0.000594288,0.00034146375,0.0000011606653,0.0018035659,0.0016293076,0.000012041211,0.00029295546,0.02133211,0.00019439],"about_ca_topic_score_codex":0.06786837,"about_ca_topic_score_gemma":0.23113339,"teacher_disagreement_score":0.16326502,"about_ca_system_score_codex":0.00061437837,"about_ca_system_score_gemma":0.0040071527,"threshold_uncertainty_score":0.93833876},"labels":[],"label_agreement":null},{"id":"W4251273121","doi":"10.1200/jco.2008.16.9136","title":"In Reply","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; McMaster University; University of Toronto; Mount Sinai Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine","score_opus":0.24258937633338412,"score_gpt":0.5180214534071126,"score_spread":0.27543207707372847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251273121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95871156,0.00090299145,0.00000432814,0.032628294,0.0006752754,0.00005977963,1.9986534e-7,0.0000023788127,0.0070151817],"genre_scores_gemma":[0.98033595,0.0020384241,0.0026594754,0.013882692,0.0007798384,0.0000016112817,2.1135172e-7,0.000005188074,0.00029662054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980502,0.0001436495,0.0014540612,0.00008045194,0.00016600816,0.000105626335],"domain_scores_gemma":[0.99761045,0.0014018088,0.000569542,0.000106316074,0.00012524377,0.00018663745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012028789,0.00005196655,0.0008682274,0.000084102794,0.0000120913965,8.4382526e-7,0.000051115057,0.00012995656,0.0001938617],"category_scores_gemma":[0.0023956036,0.000032896198,0.00030654325,0.00007999059,0.000088599016,0.000048651294,0.000014102064,0.00044586184,0.000047194197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009898376,0.004077275,0.8915902,0.0000027917113,0.00009465793,0.02000227,0.000052994434,0.0000013806936,0.000009524962,0.00007754917,0.034159105,0.04894243],"study_design_scores_gemma":[0.005884106,0.0045958483,0.73038626,0.00002435295,0.00005403064,0.0031966937,0.000015855425,0.000004169468,0.000038798935,0.0001844312,0.25559333,0.00002209947],"about_ca_topic_score_codex":0.00001989269,"about_ca_topic_score_gemma":0.000010441844,"teacher_disagreement_score":0.22143424,"about_ca_system_score_codex":0.000089647976,"about_ca_system_score_gemma":0.0007515306,"threshold_uncertainty_score":0.2867934},"labels":[],"label_agreement":null},{"id":"W4251279045","doi":"10.1200/jco.2004.22.14_suppl.5572","title":"Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Feeding tube; Regimen; Radiation therapy; Chemoradiotherapy; Weight change; Surgery; Internal medicine; Head and neck cancer; Weight loss; Weight gain; Adverse effect; Body weight","score_opus":0.05051975656579242,"score_gpt":0.42152142878661497,"score_spread":0.37100167222082253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251279045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108774,0.0005245418,0.000019606512,0.015854277,0.00058948464,0.0002736506,0.000010569049,0.0000028408977,0.0016372808],"genre_scores_gemma":[0.99592096,0.00068765524,0.0008854136,0.0021851026,0.0002753581,0.000012758292,6.6344643e-7,0.000008528864,0.000023564997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974968,0.00019822932,0.0015178253,0.00016278228,0.0004107655,0.00021363096],"domain_scores_gemma":[0.99748135,0.00078302785,0.0009174124,0.00015099558,0.0004941122,0.0001731259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007777353,0.00011197404,0.001217125,0.000060946928,0.000026096865,0.0000016822596,0.000119235905,0.00014546873,0.000038138358],"category_scores_gemma":[0.001150231,0.000059318547,0.00024009444,0.0001670292,0.0003242285,0.00006520651,0.000042297444,0.00085468125,0.0000010952496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043185532,0.008158041,0.8121131,0.00008004677,0.00028101564,0.00013104215,0.00044222796,0.0002986396,0.0000854253,0.000336602,0.0006570986,0.13423122],"study_design_scores_gemma":[0.030102544,0.031182474,0.93099827,0.0010917266,0.000078713696,0.000017772145,0.00009717338,0.0000035140154,0.00023646627,0.0011973386,0.004930154,0.00006386824],"about_ca_topic_score_codex":0.00011131206,"about_ca_topic_score_gemma":0.0010591208,"teacher_disagreement_score":0.13416734,"about_ca_system_score_codex":0.00056153187,"about_ca_system_score_gemma":0.0022671516,"threshold_uncertainty_score":0.40218294},"labels":[],"label_agreement":null},{"id":"W4251367947","doi":"10.1200/jco.2005.05.384","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine","score_opus":0.13976430601001175,"score_gpt":0.5172537019888831,"score_spread":0.3774893959788713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251367947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86973363,0.00074793154,0.000036637648,0.09671317,0.0022611092,0.000053134747,3.740384e-7,0.000004070884,0.030449959],"genre_scores_gemma":[0.9601448,0.00045557617,0.0011371513,0.033015583,0.0038336238,7.16541e-7,1.9818572e-7,0.000006149918,0.0014062065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997971,0.00015883775,0.0014906514,0.00008108178,0.00018165528,0.000116749245],"domain_scores_gemma":[0.9982485,0.00072254473,0.00055448513,0.00011315976,0.00016173795,0.00019953567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002648452,0.000049286195,0.0007625511,0.00008636376,0.0000063213615,0.0000020721477,0.00007476398,0.00017723478,0.0004935325],"category_scores_gemma":[0.0018613007,0.000035107787,0.00028139687,0.00009925252,0.000060817965,0.00008079986,0.00001720014,0.00077782077,0.00004280539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044680936,0.0015706958,0.16677678,0.00001850346,0.000101345395,0.0016675895,0.00042893618,0.000013763893,0.000083351384,0.00034372398,0.08488769,0.7396395],"study_design_scores_gemma":[0.0035318818,0.0030716853,0.11550327,0.000035856832,0.00004713874,0.00037159404,0.00010314414,0.000018132416,0.00004666242,0.00021820066,0.8770199,0.000032586173],"about_ca_topic_score_codex":0.00004649999,"about_ca_topic_score_gemma":0.0007953788,"teacher_disagreement_score":0.79213214,"about_ca_system_score_codex":0.00013031991,"about_ca_system_score_gemma":0.000891739,"threshold_uncertainty_score":0.5403835},"labels":[],"label_agreement":null},{"id":"W4251379596","doi":"10.1200/jco.2012.30.15_suppl.4538","title":"Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Targeted therapy; Internal medicine; Thrombocytosis; Renal cell carcinoma; Oncology; Odds ratio; Systemic therapy; Confidence interval; Anemia; Cancer; Breast cancer","score_opus":0.12490358618711601,"score_gpt":0.38764103781255194,"score_spread":0.26273745162543594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251379596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640274,0.0012467329,0.000055934335,0.0008068131,0.00045726798,0.00032211796,0.00034978183,0.0000044911008,0.00035412225],"genre_scores_gemma":[0.99614596,0.0011629232,0.0015332402,0.00028176926,0.0005444507,0.0000037509753,0.00022597775,0.000024407507,0.00007752512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955186,0.0006410451,0.0027779283,0.00022797816,0.0005843319,0.0002501064],"domain_scores_gemma":[0.9916995,0.0042127655,0.002690805,0.00039589254,0.00062433304,0.0003766927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024333913,0.00023461904,0.0015828606,0.00011600719,0.0000300339,0.0000089134155,0.00025961723,0.00016352643,0.00012873393],"category_scores_gemma":[0.000966604,0.00012362727,0.00029199393,0.00011269856,0.000513014,0.00014722845,0.000081362705,0.0006087792,0.000002154062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021116892,0.0024263777,0.951936,0.000031963795,0.0011003021,0.00082300376,0.000355234,8.63339e-7,0.01060452,0.0000049006076,0.00023214292,0.011367797],"study_design_scores_gemma":[0.010598538,0.0075241392,0.9623974,0.00012536818,0.0012600911,0.00035294847,0.00010626174,0.000019784911,0.017201534,0.0000029909927,0.00030893882,0.0001019811],"about_ca_topic_score_codex":0.00022723118,"about_ca_topic_score_gemma":0.0000811195,"teacher_disagreement_score":0.011265816,"about_ca_system_score_codex":0.00008934821,"about_ca_system_score_gemma":0.00062357314,"threshold_uncertainty_score":0.5041374},"labels":[],"label_agreement":null},{"id":"W4251402674","doi":"10.1200/jco.2004.22.14_suppl.8150","title":"Prognostic significance of symptoms of advanced cancer patients","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine","score_opus":0.10032471490737374,"score_gpt":0.5171827842584265,"score_spread":0.41685806935105274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251402674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609953,0.00055190234,0.000104141305,0.00142497,0.0004965641,0.00031347177,0.000008483753,0.000002456199,0.000998483],"genre_scores_gemma":[0.99637526,0.00078161573,0.002208346,0.00031255782,0.00021066496,0.000008031561,0.0000020861191,0.000008497412,0.000092934235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968449,0.00015653,0.001954598,0.00011958839,0.0007133975,0.00021098],"domain_scores_gemma":[0.99504465,0.0017403899,0.0015972223,0.00012495363,0.00095246854,0.00054034434],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010281398,0.00008640978,0.0012112648,0.00008663184,0.000011533436,9.434565e-7,0.00013874914,0.00018815677,0.000164786],"category_scores_gemma":[0.015155407,0.00005365399,0.0003088718,0.00015478814,0.00036060635,0.000056791672,0.000029927432,0.0005226079,0.0000063153093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005122877,0.0076557905,0.62635404,0.00014058063,0.00054898753,0.000236705,0.00005440875,0.00003740076,0.0005449001,0.00009133443,0.00023258507,0.3589804],"study_design_scores_gemma":[0.024393642,0.057465035,0.9107818,0.0007092257,0.00033637622,0.000016374246,0.000028463837,0.000005656121,0.001965296,0.00093256764,0.0033116576,0.000053904027],"about_ca_topic_score_codex":0.000035217472,"about_ca_topic_score_gemma":0.000014764022,"teacher_disagreement_score":0.35892648,"about_ca_system_score_codex":0.00014128625,"about_ca_system_score_gemma":0.0032795786,"threshold_uncertainty_score":0.99314034},"labels":[],"label_agreement":null},{"id":"W4251412476","doi":"10.1200/jco.2005.05.0039","title":"In Reply:","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine","score_opus":0.13924725516820705,"score_gpt":0.5286832129648291,"score_spread":0.3894359577966221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251412476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94115764,0.00026123776,0.000044136483,0.03801618,0.0026566791,0.000048553095,5.301522e-7,0.0000042833867,0.017810734],"genre_scores_gemma":[0.9919432,0.00006631314,0.0013352716,0.003286829,0.0022271278,4.1790355e-7,2.0366011e-7,0.000008090372,0.0011325743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703574,0.00052290125,0.0018539398,0.00010450378,0.00026779968,0.00021511342],"domain_scores_gemma":[0.9970607,0.0018740869,0.00070481014,0.00010170156,0.00015871642,0.00009997796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045832815,0.000057001627,0.0006361981,0.00014157296,0.000021720329,0.000010100342,0.00019285585,0.00019478377,0.00016767775],"category_scores_gemma":[0.0028655517,0.000041614025,0.00023206606,0.00015896147,0.00013127134,0.00015594858,0.00002817188,0.0009050234,0.00005759035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00354038,0.0035218408,0.33891726,0.000025863901,0.000037950602,0.0026192097,0.000057614925,0.00006434697,0.002404309,0.00090496475,0.29658282,0.35132346],"study_design_scores_gemma":[0.0029380717,0.003102074,0.4460553,0.000039503895,0.000013674291,0.0001472481,0.00003615108,0.00006165716,0.00033795222,0.0057838005,0.5414296,0.000054994438],"about_ca_topic_score_codex":0.00010691671,"about_ca_topic_score_gemma":0.0001117205,"teacher_disagreement_score":0.35126844,"about_ca_system_score_codex":0.000079991565,"about_ca_system_score_gemma":0.00023963592,"threshold_uncertainty_score":0.39319268},"labels":[],"label_agreement":null},{"id":"W4251544582","doi":"10.1200/jco.2012.30.4_suppl.574","title":"Factors associated with delayed time to adjuvant chemotherapy (AC) in stage III colon cancer: British Columbia Cancer Agency (BCCA) cohort experience.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Stage (stratigraphy); Cancer; Colorectal cancer; Surgery; Population; Referral; Chemotherapy; Internal medicine","score_opus":0.11455130344009797,"score_gpt":0.44668789893414607,"score_spread":0.3321365954940481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251544582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944442,0.0010618068,0.000005579644,0.00097460084,0.0010679973,0.00082609145,0.000056309593,0.00002399184,0.001539403],"genre_scores_gemma":[0.9906066,0.0011084873,0.000111976886,0.0020235376,0.0005183834,0.00011965355,0.000009438794,0.000044077446,0.0054578627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959031,0.0003996799,0.0020088318,0.00033338647,0.0006909901,0.00066406094],"domain_scores_gemma":[0.99577147,0.0011544994,0.0014074349,0.0001845592,0.0004545135,0.0010275184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016961326,0.00022560652,0.0024662563,0.00008929825,0.000067609326,0.000031785068,0.0002188979,0.00048460226,0.0094565535],"category_scores_gemma":[0.0011833104,0.00020690133,0.00035837272,0.0005201564,0.00021501121,0.00022342271,0.00005680549,0.00089635287,0.000013039598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037178134,0.002477393,0.9395247,0.0000070185433,0.0008266292,0.0004827319,0.00069388625,0.000015938267,0.00011678813,2.2904202e-7,0.005275228,0.046861656],"study_design_scores_gemma":[0.012105377,0.009069329,0.94658405,0.0003044782,0.00030280932,0.000036153506,0.00011539471,0.000026832504,0.00006602117,0.0000039269976,0.031175267,0.00021035226],"about_ca_topic_score_codex":0.012486236,"about_ca_topic_score_gemma":0.052522257,"teacher_disagreement_score":0.046651304,"about_ca_system_score_codex":0.0020527125,"about_ca_system_score_gemma":0.001967789,"threshold_uncertainty_score":0.9940897},"labels":[],"label_agreement":null},{"id":"W4251650965","doi":"10.1200/jco.2017.35.6_suppl.142","title":"Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Cohort; Prostatectomy; Oncology; Internal medicine; Prostate cancer; Proportional hazards model; Radiation therapy; Adjuvant therapy; Pathological; Biochemical recurrence; Stage (stratigraphy); Cancer","score_opus":0.09438116764309755,"score_gpt":0.4466428084827843,"score_spread":0.35226164083968675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251650965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745125,0.00055517984,0.00010374075,0.0007886962,0.00009316178,0.00097442046,0.000008643334,8.276484e-7,0.000024064359],"genre_scores_gemma":[0.99504244,0.00064133626,0.0041085323,0.00003993111,0.00004310548,0.000071333336,0.000005384596,0.0000064761825,0.00004144246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998544,0.000107445914,0.0008655035,0.00012848564,0.00020718703,0.00014739831],"domain_scores_gemma":[0.9983746,0.00029982076,0.0009020185,0.00008801308,0.00025545666,0.00008013589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014593967,0.000079033176,0.0005532073,0.00009927095,0.00004421887,0.000013196812,0.00011441706,0.000093649294,0.0000033718266],"category_scores_gemma":[0.000551295,0.000039747694,0.00004923852,0.00003691168,0.00011040961,0.00008464494,0.000049447244,0.0002521123,7.108066e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017941086,0.00062521355,0.82168776,0.00002443867,0.00009788475,0.000008985494,0.0011160009,0.00071684155,0.000710851,0.0000068139984,0.000012675093,0.15705144],"study_design_scores_gemma":[0.013290501,0.005345187,0.97525144,0.00025346904,0.000041440053,0.0000024199433,0.0001379848,0.0012887878,0.0040780245,0.000104822706,0.00016387808,0.000042023694],"about_ca_topic_score_codex":0.000070566704,"about_ca_topic_score_gemma":0.00008376878,"teacher_disagreement_score":0.15700942,"about_ca_system_score_codex":0.00019348472,"about_ca_system_score_gemma":0.00085003185,"threshold_uncertainty_score":0.1620864},"labels":[],"label_agreement":null},{"id":"W4251668037","doi":"10.1200/jco.2021.39.15_suppl.6526","title":"Financial toxicity, symptom burden, illness perceptions, and communication confidence in cancer clinical trial participants.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Marital status; Confidence interval; Population; Adverse effect; Cancer; Physical therapy; Internal medicine; Environmental health","score_opus":0.27305430890683235,"score_gpt":0.47996332636134903,"score_spread":0.20690901745451667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251668037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97683394,0.007147577,0.0003855225,0.009255028,0.003341243,0.0001731356,0.0000310735,0.0000057901575,0.0028266679],"genre_scores_gemma":[0.95922506,0.03527979,0.0008034182,0.0025015047,0.0018600706,0.000015746475,0.0000024121578,0.000014712314,0.00029727235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934287,0.00042777843,0.0053651053,0.00035780246,0.00006672937,0.00035387257],"domain_scores_gemma":[0.9941541,0.001930125,0.0030272752,0.0003388751,0.0002713965,0.00027821536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0084655695,0.0001545565,0.0020092658,0.00013836168,0.000090059904,0.000054380158,0.00036715288,0.0006295116,0.00061116525],"category_scores_gemma":[0.012691644,0.00016131246,0.00040100762,0.00017684135,0.00044877996,0.00046303464,0.0001630262,0.0011771601,0.00005257667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012103346,0.0023655784,0.64786893,0.000036215202,0.000221469,0.00016262064,0.0011009485,0.00017985344,0.000011094307,0.10831484,0.0072242464,0.22041082],"study_design_scores_gemma":[0.037797287,0.0024351547,0.7530115,0.00012684865,0.000060359576,0.000036317277,0.00034202283,0.0004079912,0.000009088989,0.053727437,0.15171564,0.00033035057],"about_ca_topic_score_codex":0.00035816443,"about_ca_topic_score_gemma":0.0015557646,"teacher_disagreement_score":0.22008048,"about_ca_system_score_codex":0.00021555417,"about_ca_system_score_gemma":0.001603765,"threshold_uncertainty_score":0.9956249},"labels":[],"label_agreement":null},{"id":"W4251712217","doi":"10.1200/jco.2005.04.3018","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine","score_opus":0.18397105805896943,"score_gpt":0.5333192794205842,"score_spread":0.3493482213616148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251712217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.873038,0.0010176736,0.000019840889,0.08994338,0.0012721302,0.00009550667,5.4579397e-7,0.0000045216775,0.03460843],"genre_scores_gemma":[0.96375215,0.00073016813,0.0044026794,0.026353808,0.0035288832,0.0000012464857,3.0039558e-7,0.000005980198,0.0012247862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977571,0.00014816754,0.0016719158,0.00008867714,0.00020688566,0.00012728821],"domain_scores_gemma":[0.99773,0.0011879357,0.0006045726,0.00009457055,0.00013144924,0.0002514716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019204369,0.00005697864,0.00093090686,0.0001218694,0.000007214647,0.0000018981075,0.00007025986,0.00015798243,0.0007829885],"category_scores_gemma":[0.0036535163,0.000035479796,0.0003068187,0.0001825632,0.00005386922,0.000085878055,0.000018133427,0.00058215327,0.00007904837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008284595,0.0037843785,0.11886499,0.0000110318,0.00019284057,0.00158258,0.000046529796,0.000009089329,0.000068295725,0.00019816039,0.01658892,0.85036856],"study_design_scores_gemma":[0.016460085,0.008491385,0.2506275,0.00003289923,0.000104812425,0.00029936482,0.000017314896,0.000010668841,0.000103872626,0.00056297117,0.7232542,0.000034911176],"about_ca_topic_score_codex":0.000017532833,"about_ca_topic_score_gemma":0.000033928114,"teacher_disagreement_score":0.8503337,"about_ca_system_score_codex":0.00018041882,"about_ca_system_score_gemma":0.00061115273,"threshold_uncertainty_score":0.8573175},"labels":[],"label_agreement":null},{"id":"W4251830128","doi":"10.1200/jco.2007.25.18_suppl.17000","title":"Redefining evidence","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Multidisciplinary approach; Guideline; Evidence-based practice; Delphi method; Evidence-based medicine; Systematic review; Scientific evidence; Management science; MEDLINE; Alternative medicine; Pathology; Computer science","score_opus":0.7559369596490112,"score_gpt":0.695734790704221,"score_spread":0.060202168944790246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251830128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93887216,0.00057201204,0.010632039,0.038072016,0.0031907598,0.00015423702,3.9299618e-7,0.000015197876,0.008491202],"genre_scores_gemma":[0.9263581,0.0006534689,0.055825442,0.013724967,0.0032373779,3.6126886e-7,7.726953e-7,0.000011877144,0.00018765099],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9921012,0.00036134556,0.0066153277,0.00015276646,0.0005394576,0.00022988765],"domain_scores_gemma":[0.9526174,0.040923208,0.0044966014,0.00022798842,0.0011818497,0.0005529692],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03943843,0.00008740753,0.0010395044,0.00012493039,0.00003075279,0.0000069712,0.00013955668,0.00030810595,0.00033850234],"category_scores_gemma":[0.19646119,0.000064058324,0.00046175398,0.0001818261,0.00014168708,0.0002825931,0.000053843298,0.0013569336,0.000075648175],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076637026,0.00074690895,0.17775005,0.000015884258,0.00016214495,0.0012484721,0.00006779494,0.000004246979,0.0006188631,0.00023387148,0.013953316,0.79753476],"study_design_scores_gemma":[0.007196047,0.018476699,0.6188106,0.00028789014,0.00066060235,0.0018597738,0.00074274,0.000064144835,0.00017370372,0.0006812901,0.35094544,0.0001010406],"about_ca_topic_score_codex":0.000024198842,"about_ca_topic_score_gemma":0.00004808996,"teacher_disagreement_score":0.7974337,"about_ca_system_score_codex":0.00014405533,"about_ca_system_score_gemma":0.0020336763,"threshold_uncertainty_score":0.9891003},"labels":[],"label_agreement":null},{"id":"W4251831405","doi":"10.1200/jco.2004.22.90140.524","title":"Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of British Columbia Hospital","funders":"","keywords":"Medicine; Immunohistochemistry; Tissue microarray; Breast cancer; Stage (stratigraphy); Internal medicine; Vascular endothelial growth factor; Oncology; Cancer; Confidence interval; Angiogenesis; VEGF receptors; Pathology; Biology","score_opus":0.04598440971333615,"score_gpt":0.37551744391613645,"score_spread":0.3295330342028003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251831405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938891,0.00075525127,0.00006928239,0.00040046067,0.00011147485,0.00028900907,0.0044558533,0.0000021654803,0.000027382106],"genre_scores_gemma":[0.99572796,0.002785128,0.00095620286,0.00009379203,0.000249868,0.000006114408,0.00009494617,0.000017511738,0.00006848468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976914,0.00028977904,0.0011943235,0.0003409985,0.00031750108,0.0001660023],"domain_scores_gemma":[0.9960922,0.00049645425,0.002555051,0.0003279642,0.00044675588,0.000081561484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007032062,0.000146576,0.00094592816,0.000017528428,0.0000756114,0.000020933272,0.00027682263,0.0002618615,0.000013319611],"category_scores_gemma":[0.0005047164,0.000108810586,0.00009725864,0.00005722708,0.00043252084,0.000033442717,0.00015825663,0.00024133366,6.9593746e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006981788,0.0006897756,0.950791,0.00006363233,0.0012688102,0.00004070199,0.00022064603,0.000008254859,0.036128365,2.8686014e-7,0.00056085706,0.0032458846],"study_design_scores_gemma":[0.020488711,0.0024439045,0.9614619,0.00036027865,0.00043573676,0.000052023595,0.00021171744,5.235656e-7,0.013532276,0.000004996924,0.00088663894,0.00012131907],"about_ca_topic_score_codex":0.014046943,"about_ca_topic_score_gemma":0.029094033,"teacher_disagreement_score":0.02259609,"about_ca_system_score_codex":0.00006245794,"about_ca_system_score_gemma":0.00063412206,"threshold_uncertainty_score":0.9925186},"labels":[],"label_agreement":null},{"id":"W4251849256","doi":"10.1200/jco.2021.39.6_suppl.tps187","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Enzalutamide; Prostate cancer; Clinical endpoint; Metastatic breast cancer; Oncology; Internal medicine; Nuclear medicine; Cancer; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.06995440332410377,"score_gpt":0.47116281652960146,"score_spread":0.4012084132054977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251849256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768742,0.0128997415,0.000007707776,0.003252397,0.0007274265,0.0061004213,0.000076027536,0.000011218255,0.000050863826],"genre_scores_gemma":[0.9861608,0.011796028,0.00078073,0.00045957475,0.00021696652,0.00023363516,0.00005758607,0.000041968233,0.00025267404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895538,0.0033336116,0.005062378,0.0005168231,0.0009787752,0.0005545978],"domain_scores_gemma":[0.99009484,0.0038100786,0.0029963087,0.00029829264,0.0022184695,0.00058200944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006269233,0.00041117598,0.005492796,0.00034212467,0.00015977111,0.00003799786,0.00018119719,0.00021136011,0.00014819897],"category_scores_gemma":[0.005552865,0.0002430822,0.0006529037,0.000372664,0.00062546553,0.00023697707,0.00010266579,0.001041343,0.0000013007508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8543599,0.022015017,0.04053352,0.0001238372,0.0032420445,0.0017557141,0.0025491538,0.000058268404,0.0077411993,0.0000031619459,0.00009950758,0.06751864],"study_design_scores_gemma":[0.8905936,0.041316714,0.061010245,0.0007618005,0.001355689,0.000059086866,0.00085191434,0.00046896437,0.0029440157,0.000027567054,0.00040998973,0.0002003941],"about_ca_topic_score_codex":0.00020892089,"about_ca_topic_score_gemma":0.00047684196,"teacher_disagreement_score":0.06731824,"about_ca_system_score_codex":0.00051457016,"about_ca_system_score_gemma":0.004492963,"threshold_uncertainty_score":0.99126047},"labels":[],"label_agreement":null},{"id":"W4251871014","doi":"10.1200/jco.2007.14.8437","title":"In Reply","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine","score_opus":0.26972331271421307,"score_gpt":0.5573398424087834,"score_spread":0.28761652969457036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251871014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537817,0.00035765485,0.000032994056,0.028004108,0.0004310038,0.000116760006,3.1782224e-7,0.0000032839346,0.017272176],"genre_scores_gemma":[0.98185796,0.0014622739,0.0018204604,0.011516791,0.0007881864,0.000001458062,3.3328647e-7,0.0000101853075,0.002542386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971055,0.00037135743,0.0018242327,0.000118981996,0.00038774035,0.00019219438],"domain_scores_gemma":[0.99689156,0.0016701496,0.00054379704,0.00014360157,0.00046946437,0.00028142755],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00261386,0.00006676377,0.0010502111,0.00018531209,0.000022416269,0.0000017442143,0.00011288281,0.00019555626,0.00046549624],"category_scores_gemma":[0.01269564,0.00004738181,0.00030294002,0.00018503076,0.00027988735,0.00007251436,0.00003289371,0.0009844311,0.0000699675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00848065,0.0031812158,0.8486831,0.000016324306,0.00014126251,0.037662655,0.0003177714,0.000008823939,0.00036740472,0.00009527837,0.065646246,0.03539923],"study_design_scores_gemma":[0.013393168,0.018176647,0.50158954,0.00005193343,0.0000405573,0.04809461,0.00015832215,0.00013492133,0.00015719038,0.00073996244,0.4173775,0.00008567556],"about_ca_topic_score_codex":0.000027667958,"about_ca_topic_score_gemma":0.00003003603,"teacher_disagreement_score":0.35173124,"about_ca_system_score_codex":0.00016466275,"about_ca_system_score_gemma":0.003178364,"threshold_uncertainty_score":0.99562085},"labels":[],"label_agreement":null},{"id":"W4251972158","doi":"10.1200/jco.2004.22.90140.6087","title":"Severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer: A cost of illness analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Diarrhea; Chemotherapy; Anemia; Internal medicine; Colorectal cancer; Retrospective cohort study; Neutropenia; Cancer; Cohort; Surgery","score_opus":0.045769477663907564,"score_gpt":0.4206567120051923,"score_spread":0.37488723434128474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251972158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637324,0.000041767627,0.000060324273,0.0021601804,0.00042930376,0.00027043495,0.0000068814675,0.0000041214093,0.0006537555],"genre_scores_gemma":[0.9982707,0.00024307186,0.00026289606,0.00094353507,0.00023810279,0.000011676653,0.0000024492974,0.000012213731,0.000015381862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978366,0.00014222118,0.0014074404,0.0001452085,0.0002998875,0.00016863983],"domain_scores_gemma":[0.9975964,0.0003298752,0.0012292225,0.000117551,0.00051511533,0.00021187078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069621316,0.00010888984,0.0015399252,0.00026031942,0.000024442186,0.0000033833937,0.00010304972,0.00023610158,0.00017956183],"category_scores_gemma":[0.000258427,0.000072497736,0.00036507673,0.0007823828,0.00013263684,0.000086109234,0.000014831422,0.0006983031,0.0000017060443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009225476,0.0024630597,0.9454793,0.000011824668,0.0012830438,0.00005723654,0.000187342,0.0007027852,0.00012889548,0.00002031724,0.000061774765,0.04037896],"study_design_scores_gemma":[0.024299892,0.010492711,0.9618816,0.000087616856,0.000961894,0.00002600013,0.00006100263,0.0000048703146,0.0006922046,0.00004347024,0.0013611432,0.00008763183],"about_ca_topic_score_codex":0.00034117806,"about_ca_topic_score_gemma":0.0019025254,"teacher_disagreement_score":0.04029133,"about_ca_system_score_codex":0.00037312787,"about_ca_system_score_gemma":0.0020449387,"threshold_uncertainty_score":0.36276335},"labels":[],"label_agreement":null},{"id":"W4251975905","doi":"10.1200/jco.2013.31.6_suppl.430","title":"First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Temsirolimus; Medicine; Everolimus; Sorafenib; Sunitinib; Renal cell carcinoma; Internal medicine; Oncology; Discovery and development of mTOR inhibitors; Targeted therapy; PI3K/AKT/mTOR pathway; Cancer","score_opus":0.12595325309384883,"score_gpt":0.4106898319392137,"score_spread":0.28473657884536485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251975905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983879,0.00040673435,0.00060916826,0.013404521,0.00059255306,0.00034927108,0.00005333609,0.000006923537,0.00069849164],"genre_scores_gemma":[0.9889935,0.00022990709,0.0064293775,0.0028504452,0.0011099475,0.00001888281,0.00018382215,0.000017704924,0.00016637555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504864,0.0007873348,0.0028982891,0.00034036554,0.0006680954,0.00025726674],"domain_scores_gemma":[0.9929849,0.0037351907,0.0017837625,0.00045391291,0.00057720847,0.00046501815],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00267784,0.00020970727,0.0014491157,0.00032447578,0.000047218702,0.000034513527,0.00026323838,0.00019175334,0.0021372046],"category_scores_gemma":[0.001796953,0.00012442515,0.00069236575,0.00034913208,0.00021338758,0.00033777507,0.00010509569,0.0010135444,0.00008962258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042608953,0.006736403,0.9566675,0.000025321777,0.0022617215,0.005516013,0.0003817792,0.0011197561,0.0034669088,0.000050313545,0.00710897,0.012404449],"study_design_scores_gemma":[0.010094266,0.0057197283,0.9683402,0.000055179815,0.0033418885,0.00020083322,0.0003880052,0.00613896,0.0014871594,0.0003752233,0.0037239476,0.00013457473],"about_ca_topic_score_codex":0.0018048129,"about_ca_topic_score_gemma":0.0022131156,"teacher_disagreement_score":0.012269874,"about_ca_system_score_codex":0.00038387108,"about_ca_system_score_gemma":0.000841032,"threshold_uncertainty_score":0.998775},"labels":[],"label_agreement":null},{"id":"W4251984530","doi":"10.1200/jco.2004.22.14_suppl.6123","title":"Parental perceptions of the informed consent process in pediatric bone marrow transplantation (BMT)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Informed consent; Medicine; Anxiety; Feeling; Family medicine; Phone; Pediatrics; Psychiatry; Alternative medicine; Psychology; Social psychology","score_opus":0.13594947439309543,"score_gpt":0.5221321534493605,"score_spread":0.386182679056265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251984530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806249,0.00037096013,0.000029167826,0.016284728,0.00089081435,0.00020961669,0.0000056206045,0.0000032331734,0.001580968],"genre_scores_gemma":[0.98850405,0.008556065,0.0006632702,0.0012867757,0.0009429429,0.0000029010312,0.0000028873342,0.0000068051845,0.000034324818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675906,0.00023084562,0.0023410935,0.0000933387,0.00041551393,0.00016014991],"domain_scores_gemma":[0.9961899,0.0019150528,0.001171261,0.000111092486,0.00041378426,0.0001989401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021463041,0.00008125608,0.0007108987,0.00014022915,0.000034287994,0.0000029195762,0.00012573999,0.00040001638,0.000049203896],"category_scores_gemma":[0.004553919,0.00005019389,0.00028579537,0.00028483683,0.00019648566,0.00007848808,0.00001410606,0.0015312642,0.0000041854914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012738549,0.0011874107,0.9887364,0.0007631897,0.000028057853,0.00025919924,0.0036137074,0.00021714137,0.00002265412,0.0002866043,0.00022584797,0.0033859669],"study_design_scores_gemma":[0.0072010043,0.0032305203,0.9850732,0.00022564395,0.00027427537,0.0005548356,0.0012999893,0.000008642569,0.000023147257,0.0011584952,0.00089078455,0.00005944851],"about_ca_topic_score_codex":0.00007970635,"about_ca_topic_score_gemma":0.0009783357,"teacher_disagreement_score":0.014997954,"about_ca_system_score_codex":0.0001655106,"about_ca_system_score_gemma":0.008464757,"threshold_uncertainty_score":0.9971563},"labels":[],"label_agreement":null},{"id":"W4252177547","doi":"10.1200/jco.2012.30.15_suppl.tps2104","title":"A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Calgary; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Temozolomide; Medicine; Concomitant; Internal medicine; Regimen; Randomized controlled trial; Hazard ratio; Radiation therapy; Adjuvant; Oncology; Surgery; Confidence interval","score_opus":0.036334405995309016,"score_gpt":0.4111725792789803,"score_spread":0.3748381732836713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252177547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902482,0.002176065,0.00009513706,0.0011853304,0.00071435946,0.005371321,0.000008240513,0.000012356529,0.00018896922],"genre_scores_gemma":[0.99577427,0.0008882437,0.0018213076,0.0005117023,0.00069977663,0.00020876511,0.0000043304267,0.00004962506,0.000041986954],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9918786,0.0015499407,0.004887175,0.00033803438,0.00078594586,0.0005602482],"domain_scores_gemma":[0.9874812,0.007042542,0.0037316112,0.00032594887,0.0005965745,0.00082212256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062592924,0.0004596854,0.010017563,0.00034019595,0.0000504878,0.00001656956,0.00015554954,0.00044873028,0.00014583764],"category_scores_gemma":[0.0021024386,0.00021159019,0.0008565337,0.00024017034,0.00074971764,0.00023369394,0.000025021323,0.00081440515,0.0000014750323],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7749543,0.031008678,0.15968469,0.000019858373,0.003497848,0.0005591159,0.0003004365,0.0000042031384,0.00006364843,0.000020980167,0.00015756121,0.029728647],"study_design_scores_gemma":[0.82310617,0.15321496,0.018005857,0.000351428,0.0038540468,0.00029643046,0.0001745746,0.00016507358,0.00010620467,0.000011965677,0.00051985966,0.0001934094],"about_ca_topic_score_codex":0.000030011703,"about_ca_topic_score_gemma":0.00022725466,"teacher_disagreement_score":0.14167884,"about_ca_system_score_codex":0.0002178455,"about_ca_system_score_gemma":0.0017792751,"threshold_uncertainty_score":0.8628397},"labels":[],"label_agreement":null},{"id":"W4252195682","doi":"10.1200/jco.2018.36.6_suppl.581","title":"Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Renal cell carcinoma; Histology; Nephrectomy; Urology; Papillary renal cell carcinomas; Clear cell; Proportional hazards model; Retrospective cohort study; Internal medicine; Cohort; Gastroenterology; Oncology; Surgery; Kidney; Confidence interval","score_opus":0.12411096762540325,"score_gpt":0.4003767994809201,"score_spread":0.27626583185551684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252195682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97849005,0.001453382,0.00013969262,0.0087178955,0.002491639,0.00063651364,0.00029207655,0.000012876548,0.007765896],"genre_scores_gemma":[0.9766201,0.00021649942,0.016218742,0.0028310402,0.0033391658,0.000018048095,0.00016873851,0.000050858776,0.0005368397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99074304,0.0019666054,0.004738685,0.00073580275,0.0012153486,0.00060049206],"domain_scores_gemma":[0.9855893,0.0083754845,0.0034268438,0.00082200184,0.0010940935,0.0006922741],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0056528947,0.00046761465,0.0021675017,0.00034042608,0.00011254095,0.000042926666,0.0007955887,0.00025735234,0.0005039724],"category_scores_gemma":[0.004230695,0.0002913761,0.00081233354,0.0003896782,0.0009539888,0.00031720835,0.00030770604,0.0020227518,0.00013226051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15879552,0.023965936,0.37678477,0.00021379678,0.004527076,0.073019944,0.007308755,0.00018146443,0.0701602,0.00019164382,0.25415513,0.030695774],"study_design_scores_gemma":[0.06829651,0.030090228,0.7556605,0.0002722138,0.004420042,0.0023291148,0.0027287053,0.00079428003,0.053054158,0.00083273987,0.08087026,0.000651282],"about_ca_topic_score_codex":0.0009840792,"about_ca_topic_score_gemma":0.00044414337,"teacher_disagreement_score":0.3788757,"about_ca_system_score_codex":0.0007339831,"about_ca_system_score_gemma":0.0040951213,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4252577517","doi":"10.1200/jco.2017.35.15_suppl.e15613","title":"Sorafenib treatment in recurrent hepatocellular carcinoma post liver transplantation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Internal medicine; Liver transplantation; Gastroenterology; Hepatitis C; Liver disease; Population; Adverse effect; Surgery; Transplantation; Liver cancer","score_opus":0.2539189499979211,"score_gpt":0.4235836214371172,"score_spread":0.1696646714391961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252577517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866445,0.0017861322,0.00002344214,0.005313629,0.00090312544,0.00041091448,0.000009482906,0.0000065844833,0.0028822303],"genre_scores_gemma":[0.99236643,0.0049966513,0.00122913,0.00031749942,0.000751598,0.000012442744,0.00001299574,0.000018265118,0.00029498385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970425,0.0003644289,0.0018019368,0.00023240491,0.0002907078,0.000268029],"domain_scores_gemma":[0.9968944,0.00061997934,0.0013986147,0.00036148107,0.00031466284,0.00041083543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014501933,0.00019810066,0.0014033578,0.00017149048,0.00010709345,0.000025859996,0.0002133625,0.00037169812,0.00019977709],"category_scores_gemma":[0.0006723167,0.00013576429,0.0007774367,0.00004984983,0.00018346493,0.00018053107,0.000023757091,0.0005260087,0.000059164846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003878526,0.0021162753,0.8288852,0.00004426963,0.00018478038,0.034873117,0.00028916603,2.098909e-7,0.000095244985,0.00004432881,0.00012312223,0.12946574],"study_design_scores_gemma":[0.015173371,0.019889187,0.9430871,0.00011473763,0.00087864854,0.0010411128,0.000050781196,0.00068903697,0.00080539426,0.000069458205,0.018074892,0.00012627454],"about_ca_topic_score_codex":0.00031970284,"about_ca_topic_score_gemma":0.0002619293,"teacher_disagreement_score":0.12933947,"about_ca_system_score_codex":0.00028800784,"about_ca_system_score_gemma":0.0014128571,"threshold_uncertainty_score":0.5536307},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"case_report","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4252596401","doi":"10.1200/jco.2004.22.14_suppl.4195","title":"A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Toxicity; Chemotherapy; Surgery; Radiation therapy; Internal medicine; Cancer; Gastroenterology; Urology","score_opus":0.22569437050080954,"score_gpt":0.5302029612387457,"score_spread":0.3045085907379361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252596401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965186,0.0012092916,0.00001996654,0.007989111,0.00014673136,0.0005081939,0.0000031518446,0.0000027354308,0.00046898238],"genre_scores_gemma":[0.9978424,0.00040702507,0.0004218634,0.000977888,0.00023797217,0.000010857636,5.760559e-7,0.000009655693,0.00009181774],"study_design_codex":"nonrandomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99672556,0.00021495235,0.0023807979,0.00015036181,0.00036835624,0.00015997104],"domain_scores_gemma":[0.9970237,0.0009945194,0.0012134786,0.00029060352,0.00027232905,0.00020539637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001821625,0.00011891998,0.0012489518,0.000063720865,0.000045964698,0.000002306761,0.00031137362,0.00013994699,0.0001444391],"category_scores_gemma":[0.0015770853,0.00006921571,0.000326008,0.00034728344,0.0002632663,0.000053890933,0.000053349675,0.0009426347,0.0000022853574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042742502,0.4255467,0.35921353,0.00034424683,0.0031134752,0.0022084678,0.004910068,0.004372711,0.05192175,0.0008215883,0.0005885412,0.10421642],"study_design_scores_gemma":[0.2778675,0.2187133,0.3880293,0.00043541312,0.0017380423,0.0013832373,0.0017829607,0.00021087613,0.09739584,0.004881789,0.0072860327,0.00027573222],"about_ca_topic_score_codex":0.00004125939,"about_ca_topic_score_gemma":0.000018681349,"teacher_disagreement_score":0.23512499,"about_ca_system_score_codex":0.00008020251,"about_ca_system_score_gemma":0.0010200685,"threshold_uncertainty_score":0.4095331},"labels":[],"label_agreement":null},{"id":"W4252627841","doi":"10.1200/jco.2017.35.15_suppl.10084","title":"Immediate-term chemotherapy-related cognitive impairment (CRCI) following administration of intravenous (IV) chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Chemotherapy; Chemotherapy regimen; Internal medicine; Chemotherapy-induced peripheral neuropathy; Surgery; Anesthesia; Peripheral neuropathy","score_opus":0.07089204889339613,"score_gpt":0.45458445505264766,"score_spread":0.38369240615925154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252627841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798625,0.00045407194,0.00012156895,0.011643832,0.0025777805,0.00074451475,0.000010081421,0.000017672442,0.0045679556],"genre_scores_gemma":[0.99420744,0.002237965,0.0003821366,0.0016166382,0.0011275107,0.0000111716145,0.000006850037,0.000040643314,0.0003696614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99534816,0.00025859463,0.0031263821,0.00029858947,0.0005953453,0.00037295363],"domain_scores_gemma":[0.9918747,0.0013970875,0.0052071004,0.00031028394,0.00084416865,0.00036667945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029040747,0.00027986322,0.0022217054,0.00016358696,0.00018623368,0.000023997287,0.00027887776,0.00057312526,0.0003045435],"category_scores_gemma":[0.00347684,0.00021977801,0.0011245972,0.000098327764,0.00064861093,0.00023585657,0.00007277919,0.0011514993,0.000019399897],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051507052,0.011553981,0.27432376,0.00017629111,0.010868496,0.002672232,0.0027631966,0.0000023312732,0.0024563298,0.00003738624,0.0026263774,0.64101255],"study_design_scores_gemma":[0.041102998,0.038608428,0.9119027,0.0009287233,0.0015302,0.00046828177,0.00067593827,0.000038483613,0.0026534717,0.00034608768,0.0015255893,0.0002190463],"about_ca_topic_score_codex":0.000019399573,"about_ca_topic_score_gemma":0.000020651181,"teacher_disagreement_score":0.6407935,"about_ca_system_score_codex":0.00026325948,"about_ca_system_score_gemma":0.0018672383,"threshold_uncertainty_score":0.89622873},"labels":[],"label_agreement":null},{"id":"W4252683308","doi":"10.1200/jco.2004.22.14_suppl.8058","title":"Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); McMaster University; University of Waterloo","funders":"","keywords":"Medicine; Zoledronic acid; Prostate cancer; Cumulative incidence; Oncology; Incidence (geometry); Breast cancer; Metastatic breast cancer; Bone metastasis; Internal medicine; Prostate; Radiation therapy; Cancer; Cohort","score_opus":0.09205362670657381,"score_gpt":0.4730683217915112,"score_spread":0.3810146950849374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252683308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96633077,0.00018180007,0.00027088376,0.03137891,0.00027890666,0.001503419,0.00003765266,0.0000053164404,0.000012339648],"genre_scores_gemma":[0.9921788,0.00012243698,0.0041309497,0.0032222702,0.000109921806,0.00010450702,0.000012187004,0.000015975846,0.00010296482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674225,0.00034594844,0.0018933159,0.00023402715,0.00043920294,0.00034528662],"domain_scores_gemma":[0.99610204,0.00112145,0.0013516786,0.0001666398,0.00072614773,0.0005320446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018393266,0.00016040058,0.0015374239,0.00035247087,0.00006378517,0.000010169918,0.000097497614,0.00010927807,0.000028530545],"category_scores_gemma":[0.0021537791,0.00008046881,0.00022756791,0.0011424441,0.00006925239,0.00014396168,0.000025898255,0.00040829985,0.000006151707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08675433,0.00365364,0.7331771,0.000052635958,0.0024579205,0.00024001305,0.0018253183,0.007243439,0.000020269128,0.000015513318,0.00020914123,0.16435064],"study_design_scores_gemma":[0.024435157,0.015617114,0.95661664,0.00016590761,0.002162375,0.000034313507,0.0002179901,0.000119395656,0.000027897615,0.00007773862,0.00043689032,0.00008859249],"about_ca_topic_score_codex":0.0008236888,"about_ca_topic_score_gemma":0.0067484304,"teacher_disagreement_score":0.22343948,"about_ca_system_score_codex":0.00069729023,"about_ca_system_score_gemma":0.0030936713,"threshold_uncertainty_score":0.548804},"labels":[],"label_agreement":null},{"id":"W4252709096","doi":"10.1200/jco.2004.22.14_suppl.8266","title":"Physical and psychological well-being in patients with stage IV GI cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Cancer; Internal medicine; Oncology","score_opus":0.07204679316725171,"score_gpt":0.46382505629176807,"score_spread":0.39177826312451636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252709096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200714,0.00009164708,0.00003176862,0.003489845,0.0006430709,0.000118102114,0.0000015305573,0.000005039134,0.0036118368],"genre_scores_gemma":[0.9961254,0.00020747747,0.0002886061,0.0025466369,0.0007298069,0.0000028929537,8.420551e-7,0.000010246444,0.00008807829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983898,0.00013267288,0.0008231132,0.00017754883,0.0002903581,0.000186531],"domain_scores_gemma":[0.99861056,0.00036184513,0.00047597775,0.000104094564,0.00017817237,0.00026933657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006601744,0.00010399118,0.000924159,0.000069192356,0.00001784746,0.000005551705,0.00007610437,0.00020704494,0.000069049514],"category_scores_gemma":[0.00029232248,0.00006282325,0.00014430739,0.00012726992,0.00019048569,0.000075385775,0.00002682308,0.00096525747,0.0000049542896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007202167,0.00280394,0.9392472,0.000020988633,0.00007798603,0.00039232327,0.00043940629,0.000034915618,0.000010323511,0.00022287686,0.0001244522,0.049423445],"study_design_scores_gemma":[0.016185861,0.016938413,0.95724887,0.00014238912,0.00009455998,0.000026340516,0.0001066481,0.0000051900493,0.000011437754,0.00061951287,0.008542421,0.00007834342],"about_ca_topic_score_codex":0.00009969546,"about_ca_topic_score_gemma":0.00075531733,"teacher_disagreement_score":0.0493451,"about_ca_system_score_codex":0.00014703421,"about_ca_system_score_gemma":0.00036293257,"threshold_uncertainty_score":0.4193617},"labels":[],"label_agreement":null},{"id":"W4252738113","doi":"10.1200/jco.2004.22.14_suppl.6090","title":"Medicine and media: The role of journalism in public health education","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Climate Change Communication and Perception","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Journalism; Public health; Public relations; Citizen journalism; Family medicine; Media studies; Nursing; Political science; Sociology; Law","score_opus":0.7626493656573397,"score_gpt":0.6457758400872566,"score_spread":0.11687352557008301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252738113","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4268941,0.004027793,0.000017491893,0.5547707,0.0008392752,0.00007706144,4.7127176e-7,0.0000021036883,0.013370993],"genre_scores_gemma":[0.9322027,0.06272727,0.00030875645,0.003819957,0.0009238331,0.0000010238418,8.3422697e-7,0.0000023814584,0.000013253098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686754,0.0014207602,0.001290907,0.000049066468,0.00025666432,0.00011506598],"domain_scores_gemma":[0.99587077,0.002066583,0.0014577048,0.00009485254,0.00030440642,0.00020566596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01465666,0.00003766495,0.00040309742,0.000121344056,0.00010957243,0.000008556939,0.0002591207,0.00013390352,0.00017057403],"category_scores_gemma":[0.007002819,0.000023106957,0.000065689565,0.00019840494,0.0006137372,0.00013550463,0.000029046003,0.00049888,0.0000017530383],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004540126,0.0005407807,0.017300012,0.0000040416426,0.000011333551,9.051745e-7,0.062422812,0.0000015882875,0.00001676187,0.04238386,0.0007268659,0.8765456],"study_design_scores_gemma":[0.0013749992,0.00079850625,0.20778933,0.00010282523,0.00001144063,0.000021988508,0.08140061,0.000003084332,5.2307536e-7,0.057868082,0.650595,0.00003357776],"about_ca_topic_score_codex":0.0016304844,"about_ca_topic_score_gemma":0.013854116,"teacher_disagreement_score":0.87651205,"about_ca_system_score_codex":0.00018298562,"about_ca_system_score_gemma":0.0029584696,"threshold_uncertainty_score":0.83835346},"labels":[],"label_agreement":null},{"id":"W4252739755","doi":"10.1200/jco.2020.38.15_suppl.tps4121","title":"Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Oncology; FOLFOX; Internal medicine; Colorectal cancer; Clinical endpoint; Chemotherapy; Oxaliplatin; Adjuvant; Stage (stratigraphy); Biomarker; Cancer; Prospective cohort study; Clinical trial","score_opus":0.046103684198474174,"score_gpt":0.4015921796926826,"score_spread":0.35548849549420847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252739755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808705,0.00026517396,0.000043527823,0.00068546145,0.000240898,0.00050169165,0.000043329725,0.0000017907661,0.00013107785],"genre_scores_gemma":[0.9977348,0.00025751113,0.00014699729,0.0015744423,0.00023110402,0.000013409774,0.000009361659,0.000020978101,0.000011431404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973456,0.00021726573,0.0016860244,0.00030020298,0.0002327965,0.00021806062],"domain_scores_gemma":[0.99760914,0.00022723897,0.0015492231,0.00014514689,0.00026873106,0.00020050703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008112739,0.00016237816,0.0009489313,0.00007497187,0.000037914913,0.000005486562,0.0002237416,0.00019730475,0.000038015056],"category_scores_gemma":[0.0010030314,0.00013272124,0.00013608896,0.00018122887,0.00011211295,0.000009585848,0.00015228859,0.00038796652,2.997204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07337486,0.02833725,0.82753617,0.000033114993,0.0006793003,0.0003091683,0.0023160889,0.0017938778,0.015616223,0.000008561915,0.00086698483,0.049128417],"study_design_scores_gemma":[0.12705179,0.26966333,0.5876295,0.000119142416,0.00015389122,0.000008094137,0.001290944,0.00092011876,0.0024935328,0.000025833582,0.010325972,0.00031789133],"about_ca_topic_score_codex":0.00018622195,"about_ca_topic_score_gemma":0.0008509517,"teacher_disagreement_score":0.24132608,"about_ca_system_score_codex":0.000099052115,"about_ca_system_score_gemma":0.0012748487,"threshold_uncertainty_score":0.5412215},"labels":[],"label_agreement":null},{"id":"W4252749574","doi":"10.1200/jco.2004.22.14_suppl.6080","title":"Malignant pleural effusions in lymphoproliferative disorders: A clinico-pathologic study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Dartmouth General Hospital","funders":"","keywords":"Medicine; Thoracentesis; Pleural effusion; Internal medicine; Malignancy; Malignant pleural effusion; Lymphoproliferative disorders; Gastroenterology; Multiple myeloma; Lymphoma; Pleural disease; Odds ratio; Pleurisy; Pathology; Respiratory disease; Lung","score_opus":0.14496618618163537,"score_gpt":0.4967297756653875,"score_spread":0.35176358948375214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252749574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850666,0.00040806492,0.000019526951,0.011462423,0.00089703134,0.00064042455,0.0000026426899,0.000010841768,0.0014924603],"genre_scores_gemma":[0.9941899,0.0011027409,0.0016878593,0.002420847,0.00049651385,0.000029762183,0.000001631767,0.000013307102,0.00005744363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545044,0.0006327899,0.0029692838,0.0002860666,0.00036328565,0.00029815076],"domain_scores_gemma":[0.9961959,0.0017813521,0.0012174312,0.00023386025,0.00020733093,0.00036412996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030395726,0.00019263935,0.0018566694,0.00019273786,0.000052149182,0.000010264574,0.00015820525,0.00031845053,0.00007924273],"category_scores_gemma":[0.0033663444,0.000114476956,0.00060031225,0.00022447553,0.00017734789,0.00009857918,0.000083126346,0.0005907018,0.000050485483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029194038,0.035141576,0.90134525,0.0000063955185,0.00026606154,0.009832218,0.00081789354,0.00006539491,0.000014814894,0.0001890272,0.00017538972,0.0492266],"study_design_scores_gemma":[0.046212316,0.048657145,0.89890665,0.000121699944,0.00035516865,0.00082547654,0.001319177,0.0000111059535,0.000020243688,0.0016296259,0.0018403492,0.000101063066],"about_ca_topic_score_codex":0.00010965471,"about_ca_topic_score_gemma":0.00072783686,"teacher_disagreement_score":0.049125537,"about_ca_system_score_codex":0.0004907675,"about_ca_system_score_gemma":0.0021867377,"threshold_uncertainty_score":0.46682346},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4252790488","doi":"10.1200/jco.2003.99.173","title":"In Reply:","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency","keywords":"Medicine","score_opus":0.11894249604847035,"score_gpt":0.5816968169258487,"score_spread":0.4627543208773784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252790488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7972081,0.004135046,0.0021961364,0.050410923,0.012226207,0.00023229275,4.6169632e-7,0.000010682237,0.1335802],"genre_scores_gemma":[0.80788565,0.0063019167,0.08650794,0.090805165,0.0037693996,0.0000027185463,2.922737e-7,0.000022545495,0.00470436],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746865,0.0004808767,0.0016739056,0.000101183876,0.0001298946,0.0001455128],"domain_scores_gemma":[0.996272,0.0024368959,0.00085375056,0.00012920097,0.0001319712,0.00017612892],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043164934,0.00006386697,0.0010379974,0.00009723474,0.000014305052,9.969034e-7,0.000076544005,0.00031569076,0.00054109335],"category_scores_gemma":[0.008709113,0.00004248286,0.00024590793,0.000118934906,0.00021759783,0.000087360015,0.000005986121,0.0010578227,0.0000199002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009162267,0.006367688,0.59096825,0.000027401957,0.00041835112,0.011782498,0.00023641258,0.000057197427,0.00034304132,0.012174111,0.0870877,0.28137508],"study_design_scores_gemma":[0.0075021773,0.007855619,0.04688272,0.000025388712,0.000041934225,0.0022615134,0.00004962726,0.0000063115754,0.000058664766,0.005260855,0.9300138,0.000041405434],"about_ca_topic_score_codex":0.0000011472791,"about_ca_topic_score_gemma":0.0000059028503,"teacher_disagreement_score":0.8429261,"about_ca_system_score_codex":0.00013557493,"about_ca_system_score_gemma":0.0013856175,"threshold_uncertainty_score":0.99964094},"labels":[],"label_agreement":null},{"id":"W4252867417","doi":"10.1200/jco.20.03570","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Kingston General Hospital; University Health Network; Queen's University","funders":"","keywords":"Medicine; Guideline; Lung cancer; Oncology; Internal medicine; Targeted therapy; T790M; Osimertinib; Stage (stratigraphy); Cancer; Clinical endpoint; Clinical trial; Erlotinib; Epidermal growth factor receptor; Gefitinib; Pathology","score_opus":0.08343939901888191,"score_gpt":0.49462702697377,"score_spread":0.41118762795488806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252867417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93716264,0.006852761,0.013148462,0.039830413,0.00089850416,0.00072740763,0.00004655252,0.000008531597,0.001324727],"genre_scores_gemma":[0.68728006,0.038210645,0.2161298,0.042451005,0.0040869005,0.00016011675,0.0000994141,0.00008279059,0.011499283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811506,0.00009519063,0.0012905172,0.00018705787,0.00015421935,0.00015793834],"domain_scores_gemma":[0.99743897,0.00038556114,0.00080466864,0.0001399655,0.0010010896,0.0002297715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006919357,0.00011783236,0.0007924115,0.000044369513,0.00006934329,0.000018764531,0.000046162077,0.00013815415,0.0003179564],"category_scores_gemma":[0.00022704889,0.00007176162,0.0001978555,0.00007717266,0.00007425682,0.000095276024,0.000019138371,0.00030717463,0.0000015831268],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014387443,0.01086034,0.28244635,0.0004401522,0.010596854,0.0035944742,0.0021943885,0.001494617,0.010254439,0.000895647,0.14330518,0.5195301],"study_design_scores_gemma":[0.05894688,0.013964187,0.07932752,0.00029442954,0.0027935181,0.00034356213,0.0005153062,0.002203127,0.0028366647,0.00021636687,0.8383185,0.00023990787],"about_ca_topic_score_codex":0.000029935052,"about_ca_topic_score_gemma":0.00019492557,"teacher_disagreement_score":0.69501334,"about_ca_system_score_codex":0.00013053774,"about_ca_system_score_gemma":0.003299707,"threshold_uncertainty_score":0.58535385},"labels":[],"label_agreement":null},{"id":"W4252918737","doi":"10.1200/jco.2013.31.6_suppl.52","title":"Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Biochemical recurrence; Prostate cancer; breakpoint cluster region; Internal medicine; Population; Oncology; Cohort; Metastasis; Proportional hazards model; Disease; Context (archaeology); Localized disease; Surgery; Cancer","score_opus":0.11569438920027351,"score_gpt":0.4629404359793572,"score_spread":0.34724604677908366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252918737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960996,0.0008932434,0.000031898868,0.007923311,0.00011696702,0.0009954388,0.000008156425,0.0000057590105,0.00041528195],"genre_scores_gemma":[0.9963616,0.00071481505,0.0024467648,0.00014443489,0.00014103102,0.000047415466,0.000022090877,0.0000142098725,0.00010762806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971215,0.00044621763,0.001364815,0.00021422068,0.0005838426,0.0002693908],"domain_scores_gemma":[0.99692255,0.00081592525,0.0009851704,0.00016548492,0.00051155005,0.0005993018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015701699,0.00013451492,0.00094830757,0.00019250678,0.000020301728,0.0000109917655,0.0001430468,0.0001348238,0.00016960272],"category_scores_gemma":[0.0013680703,0.000072552626,0.00017740083,0.00017374025,0.00052759814,0.0001878126,0.000053746786,0.00078241335,0.000012712037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014676,0.008594826,0.7897411,0.00059042434,0.0007142961,0.0022297525,0.00036164845,0.000013045935,0.016086247,0.000038909817,0.0060977577,0.11538523],"study_design_scores_gemma":[0.02475869,0.019525629,0.94266135,0.0012022421,0.0004599241,0.00022602211,0.00022991924,0.00056484994,0.00840213,0.0005569645,0.0012731188,0.00013918514],"about_ca_topic_score_codex":0.00001381764,"about_ca_topic_score_gemma":0.0000013403417,"teacher_disagreement_score":0.15292022,"about_ca_system_score_codex":0.00020537105,"about_ca_system_score_gemma":0.002845639,"threshold_uncertainty_score":0.5048041},"labels":[],"label_agreement":null},{"id":"W4252970331","doi":"10.1200/jco.2019.37.15_suppl.4069","title":"Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphovascular invasion; Stage (stratigraphy); Resection margin; Cancer; Radiation therapy; Proportional hazards model; Surgery; Chemotherapy; Internal medicine; Neoadjuvant therapy; Retrospective cohort study; Adjuvant therapy; T-stage; Oncology; Metastasis; Resection; Breast cancer","score_opus":0.0347930521195405,"score_gpt":0.4382697299276947,"score_spread":0.4034766778081542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252970331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978257,0.00014173181,0.000065693705,0.00079298136,0.00044381426,0.0006145567,0.0000135389055,0.0000015526438,0.00010043558],"genre_scores_gemma":[0.9976497,0.0001552346,0.0012634834,0.00050203205,0.00025044527,0.000009597875,0.0000035224905,0.000010508288,0.00015544638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836695,0.00010074266,0.0010221147,0.00012248571,0.00021021851,0.00017748434],"domain_scores_gemma":[0.9981189,0.00041338458,0.00087180495,0.000094346746,0.00039543476,0.0001061551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066283194,0.00009501997,0.0009837748,0.00014259198,0.0000065499466,0.000003504635,0.00007047097,0.000116938194,0.00016988639],"category_scores_gemma":[0.00017047845,0.000055142224,0.00034525595,0.000113293616,0.000058014604,0.0000777876,0.000016833395,0.00033693507,0.0000012916448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09674019,0.0009208199,0.8662316,0.00002418532,0.0003267647,0.000025996582,0.00004280386,0.000020399591,0.00003375419,0.0000015782441,0.0004430176,0.03518885],"study_design_scores_gemma":[0.027183546,0.09179884,0.8804316,0.00014582265,0.000090166315,0.0000039958195,0.000012681594,0.000011620286,0.000020930398,0.000012775859,0.00025312637,0.000034927147],"about_ca_topic_score_codex":0.00007198608,"about_ca_topic_score_gemma":0.00010983171,"teacher_disagreement_score":0.090878025,"about_ca_system_score_codex":0.00025427426,"about_ca_system_score_gemma":0.0006620378,"threshold_uncertainty_score":0.22486345},"labels":[],"label_agreement":null},{"id":"W4253002075","doi":"10.1200/jco.2012.30.4_suppl.237","title":"Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); McGill University Health Centre","funders":"","keywords":"Medicine; Everolimus; Sunitinib; Placebo; Internal medicine; Neuroendocrine tumors; Oncology; Randomized controlled trial; Urology; Surgery; Cancer; Pathology","score_opus":0.21156457713355445,"score_gpt":0.5061926296216926,"score_spread":0.29462805248813817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253002075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923541,0.001214177,0.00034179896,0.0028498173,0.0006701638,0.00201237,0.000017378294,0.000020159638,0.00052006333],"genre_scores_gemma":[0.98673314,0.0010001668,0.010621006,0.00041820778,0.0009636809,0.000056670644,0.000006888938,0.000047917336,0.00015233584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9885137,0.0047337105,0.0051258532,0.00025100893,0.00074675446,0.00062894804],"domain_scores_gemma":[0.93911594,0.05409431,0.005060215,0.00024145938,0.00070230983,0.00078575057],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01146701,0.0002903402,0.009141358,0.00030526213,0.00005368727,0.00001253417,0.00020175015,0.000043403757,0.0000620646],"category_scores_gemma":[0.068013154,0.00017694104,0.000843385,0.00017809465,0.00056117715,0.00032190589,0.00008410966,0.0012405716,0.0000031597217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90124726,0.0027346124,0.07761365,0.0004340572,0.001273394,0.00094200775,0.0001630843,0.000058761892,0.0011280227,0.00025071777,0.00074193225,0.013412479],"study_design_scores_gemma":[0.8778415,0.04368353,0.049972046,0.00080437266,0.0037399565,0.006320987,0.00087616243,0.00028894257,0.003631918,0.00075458473,0.011759724,0.00032627734],"about_ca_topic_score_codex":0.000019960822,"about_ca_topic_score_gemma":0.000032663036,"teacher_disagreement_score":0.056546144,"about_ca_system_score_codex":0.00006169749,"about_ca_system_score_gemma":0.000800683,"threshold_uncertainty_score":0.9398374},"labels":[],"label_agreement":null},{"id":"W4253021856","doi":"10.1200/jco.2015.33.15_suppl.tps5610","title":"The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; MEK inhibitor; Internal medicine; Oncology; Clinical endpoint; KRAS; Chemotherapy; Cancer; MAPK/ERK pathway; Clinical trial; Kinase; Colorectal cancer","score_opus":0.14725233005346622,"score_gpt":0.44779431299604044,"score_spread":0.3005419829425742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253021856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984977,0.00071156677,8.104359e-7,0.0063519464,0.0018772878,0.0059586777,0.000036630954,0.0000056362724,0.00008042131],"genre_scores_gemma":[0.9972367,0.000615611,0.00037016065,0.0007903467,0.0005068048,0.00035347452,0.000007255213,0.000050584425,0.00006905028],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917612,0.0023816964,0.0036225545,0.0005337983,0.0012702848,0.00043047144],"domain_scores_gemma":[0.99062526,0.0044180946,0.0031103005,0.0005786696,0.00092146435,0.0003461803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003969006,0.00042495245,0.0033142911,0.00021275546,0.00010532534,0.000034117773,0.0007448902,0.00022506634,0.000019966437],"category_scores_gemma":[0.0019132311,0.00020301093,0.00039057713,0.0007398577,0.0004254093,0.00019037792,0.00022853528,0.0010726153,8.46379e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52754605,0.13817796,0.29182348,0.00007756432,0.0023935693,0.00017117013,0.004540236,0.00009228248,0.000008014165,0.0000047550466,0.00049252075,0.034672383],"study_design_scores_gemma":[0.5543047,0.06642856,0.37353975,0.0005271553,0.0008730307,0.00000952611,0.0031207576,0.00011713155,0.000022741673,0.0000035339629,0.00090059516,0.00015251065],"about_ca_topic_score_codex":0.0018713202,"about_ca_topic_score_gemma":0.0073372433,"teacher_disagreement_score":0.08171628,"about_ca_system_score_codex":0.0011574025,"about_ca_system_score_gemma":0.0050078644,"threshold_uncertainty_score":0.8883736},"labels":[],"label_agreement":null},{"id":"W4253068311","doi":"10.1200/jco.2019.37.15_suppl.e23017","title":"Estimating survival time in older adults receiving chemotherapy for advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Chemotherapy; Proportional hazards model; Internal medicine; Cancer; Performance status; Survival analysis; Oncology","score_opus":0.05624090279665904,"score_gpt":0.46583461570683465,"score_spread":0.4095937129101756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253068311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97911805,0.00026128598,0.00042879905,0.014543433,0.0035320274,0.0006725071,0.0000033081408,0.000013851927,0.001426763],"genre_scores_gemma":[0.9225041,0.00025030054,0.07009243,0.0030391004,0.0020154987,0.000017736336,0.0000035099704,0.000047443886,0.0020298613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967036,0.00018877815,0.002246749,0.0002453391,0.0002984723,0.00031702244],"domain_scores_gemma":[0.9931052,0.0044868826,0.0015247252,0.00019942116,0.0004569015,0.00022689508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031861884,0.0001485218,0.0016598392,0.000113086964,0.000018252456,0.0000061507294,0.0001868404,0.00035970926,0.00052125537],"category_scores_gemma":[0.006067475,0.00011691195,0.0003702712,0.0001438803,0.00006873675,0.00015116266,0.000027588296,0.0008738217,0.000037585763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009942245,0.001127193,0.15310924,0.00019664853,0.00017447643,0.000080642974,0.00045275598,0.00058247574,0.0008769783,0.000007704617,0.0031884671,0.8302612],"study_design_scores_gemma":[0.08946252,0.016437717,0.84229964,0.003951316,0.00015390225,0.00019961291,0.00027186543,0.0271031,0.00036810292,0.00029142297,0.019146003,0.00031477286],"about_ca_topic_score_codex":0.000025117612,"about_ca_topic_score_gemma":0.00007499796,"teacher_disagreement_score":0.8299464,"about_ca_system_score_codex":0.00024675322,"about_ca_system_score_gemma":0.0010408661,"threshold_uncertainty_score":0.72637725},"labels":[],"label_agreement":null},{"id":"W4253095257","doi":"10.1200/jco.2014.32.15_suppl.6519","title":"The toxicity gap: Do real-life patients get hospitalized more during chemotherapy compared to trial patients?","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Observational study; Chemotherapy; Clinical trial; Internal medicine; Lung cancer; Intensive care medicine","score_opus":0.06978940608941775,"score_gpt":0.4461089882026998,"score_spread":0.37631958211328204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253095257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98466223,0.000014376143,0.00003626361,0.0075278566,0.0035319205,0.00061622483,0.0000033704555,0.000014227132,0.003593516],"genre_scores_gemma":[0.992017,0.00029052087,0.00019227836,0.00497256,0.0023327654,0.000015736476,0.0000022937852,0.000020596673,0.00015626237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996508,0.00047620284,0.0020752638,0.00019299485,0.00047516846,0.00027238944],"domain_scores_gemma":[0.995888,0.0011435017,0.0013823749,0.00029027282,0.0007018838,0.00059396983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016740101,0.00014698482,0.0011980566,0.00006908608,0.00016610132,0.000025395424,0.00023229532,0.00021693442,0.000095734234],"category_scores_gemma":[0.0038533972,0.00008737757,0.000510656,0.00014168778,0.000149469,0.000077344295,0.000057141897,0.00066589296,0.000023428709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11738817,0.00340534,0.843162,0.000012315693,0.00032024807,0.000010157454,0.00016113289,0.000016374162,0.000051066032,0.000100740166,0.01442917,0.020943297],"study_design_scores_gemma":[0.110030286,0.015024457,0.80713147,0.00003644874,0.00012671282,0.00000532058,0.000028427241,0.0000061219016,0.000041517746,0.000100080426,0.067385234,0.00008392676],"about_ca_topic_score_codex":0.00001723892,"about_ca_topic_score_gemma":0.000025628176,"teacher_disagreement_score":0.052956067,"about_ca_system_score_codex":0.00019450727,"about_ca_system_score_gemma":0.00048214363,"threshold_uncertainty_score":0.46131545},"labels":[],"label_agreement":null},{"id":"W4253119700","doi":"10.1200/jco.2012.30.5_suppl.172","title":"A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cabazitaxel; Prednisone; Docetaxel; Prostate cancer; Cohort; Internal medicine; Interim analysis; Mitoxantrone; Abiraterone acetate; Cancer; Surgery; Oncology; Androgen deprivation therapy; Clinical trial; Chemotherapy","score_opus":0.16491443993143304,"score_gpt":0.509163103084779,"score_spread":0.3442486631533459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253119700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275357,0.0002852705,0.00008203439,0.0031214072,0.00092035084,0.00241792,0.00016688266,0.000019348587,0.00023324077],"genre_scores_gemma":[0.9776812,0.00021511836,0.019888079,0.00061954005,0.0005227063,0.0003143322,0.00008631121,0.000029825436,0.0006428492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970347,0.00023769663,0.0017390902,0.00021354757,0.00038146833,0.00039344942],"domain_scores_gemma":[0.9949251,0.0014355839,0.0019301777,0.00014545613,0.0010225191,0.0005411787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001170206,0.0002102306,0.0014042347,0.000097975106,0.000068341695,0.000017165363,0.000091085436,0.00013145407,0.000067479006],"category_scores_gemma":[0.0005114281,0.00011510573,0.00021089394,0.0001376203,0.00026268873,0.00029285793,0.00002223307,0.0004912,0.0000024526748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27001205,0.01760405,0.6365766,0.00013291172,0.0034881895,0.00019606731,0.0005747919,0.0000666687,0.00007593948,0.000035126784,0.014960751,0.05627688],"study_design_scores_gemma":[0.06384072,0.098476924,0.70844215,0.00023344254,0.0030623553,0.00012220735,0.000112034395,0.00008750931,0.00005748749,0.0000116729625,0.12539579,0.0001577273],"about_ca_topic_score_codex":0.00011577326,"about_ca_topic_score_gemma":0.00036438546,"teacher_disagreement_score":0.20617135,"about_ca_system_score_codex":0.00045001213,"about_ca_system_score_gemma":0.0023479473,"threshold_uncertainty_score":0.46938753},"labels":[],"label_agreement":null},{"id":"W4253174027","doi":"10.1200/jco.2007.25.18_suppl.6514","title":"The transition from phase II to phase III studies","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Clinical trial; Phase (matter); Phases of clinical research; Regimen; Randomized controlled trial; Internal medicine; Oncology","score_opus":0.8345654492440351,"score_gpt":0.75241606543189,"score_spread":0.0821493838121451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253174027","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5943551,0.00033757786,0.3753672,0.0195674,0.008484536,0.00044386633,0.00003723833,0.000025785528,0.0013812971],"genre_scores_gemma":[0.22141877,0.0007287387,0.76504904,0.005183435,0.0074014096,0.0000070933506,5.898732e-7,0.000031715732,0.00017923003],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9884247,0.0025424045,0.0076808645,0.00027289067,0.0006621286,0.00041696883],"domain_scores_gemma":[0.59343517,0.40163577,0.0029984722,0.0003777738,0.00091959833,0.00063318573],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05525371,0.00019429061,0.0024669962,0.00008006936,0.00024869232,0.00001829976,0.00051525974,0.00044930985,0.0002536615],"category_scores_gemma":[0.41026765,0.00011059622,0.0007189943,0.00021295097,0.0005444898,0.00008105365,0.000120828874,0.0013289589,0.000023720615],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020563245,0.0065566604,0.0000093798035,0.000010591507,0.000998619,0.00043796984,0.0010080647,0.0000019505521,0.00037064543,0.010966844,0.03398375,0.9250923],"study_design_scores_gemma":[0.029733589,0.029662963,0.0001076001,0.00008516446,0.0006939995,0.000026625808,0.0010380262,0.00004061416,0.0005671292,0.8376378,0.100252576,0.00015391018],"about_ca_topic_score_codex":0.00000452112,"about_ca_topic_score_gemma":0.000041771866,"teacher_disagreement_score":0.9249384,"about_ca_system_score_codex":0.00013138852,"about_ca_system_score_gemma":0.00037872247,"threshold_uncertainty_score":0.9728151},"labels":[],"label_agreement":null},{"id":"W4253323776","doi":"10.1200/jco.2013.31.15_suppl.2053","title":"Phase II study of PX-866 in recurrent glioblastoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; BC Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Toronto; University Health Network; Dalhousie University; Cancer Care Ontario; Queen's University","funders":"","keywords":"Medicine; Temozolomide; Nausea; Internal medicine; Gastroenterology; Phases of clinical research; Adverse effect; Oncology; PTEN; Surgery; Toxicity; Chemotherapy; PI3K/AKT/mTOR pathway; Signal transduction","score_opus":0.17804300974857967,"score_gpt":0.5697458970082092,"score_spread":0.39170288725962954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253323776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99144137,0.00034334423,0.0000023336568,0.004719457,0.0016766159,0.0004928,0.0000012500028,0.0000040890573,0.0013187189],"genre_scores_gemma":[0.997601,0.00035968111,0.00021504809,0.00065656775,0.0007838734,0.000014004212,6.314953e-7,0.000008862924,0.00036035557],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9965989,0.00042116395,0.002417132,0.0001409095,0.00023744036,0.00018442854],"domain_scores_gemma":[0.99682784,0.0010706885,0.0013648876,0.0001302266,0.0003348265,0.0002715401],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014209915,0.000110841625,0.0014880053,0.00021488006,0.000019568937,0.0000020901437,0.000123469,0.00019998448,0.0012393008],"category_scores_gemma":[0.00070681446,0.00006819453,0.00027268816,0.00018684023,0.00010940117,0.000084105784,0.000058742455,0.0007896008,0.000024100314],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02756488,0.18234876,0.083205834,0.000029277186,0.00073744403,0.0009382065,0.0012060043,0.000008060557,0.0008604067,0.000012435553,0.03014624,0.67294246],"study_design_scores_gemma":[0.108007245,0.69493675,0.14437242,0.00007876398,0.0006692299,0.00018185232,0.0007310114,0.0000917989,0.00020009115,0.00019528397,0.050446734,0.00008879344],"about_ca_topic_score_codex":0.00008250565,"about_ca_topic_score_gemma":0.0003047041,"teacher_disagreement_score":0.67285365,"about_ca_system_score_codex":0.00013850896,"about_ca_system_score_gemma":0.0007174895,"threshold_uncertainty_score":0.9996737},"labels":[],"label_agreement":null},{"id":"W4253408104","doi":"10.1200/jco.2012.30.27_suppl.98","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Refractory (planetary science); Gastroenterology; Pertuzumab; Breast cancer; Cancer; Oncology; Clinical trial","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253408104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942012,0.0019666222,0.000042958327,0.0013223616,0.00023029612,0.0017039474,0.0002467417,0.000010570448,0.00027530038],"genre_scores_gemma":[0.99424976,0.002383856,0.0024667967,0.00026524335,0.00040675362,0.000061287734,0.000021477239,0.000048426336,0.00009642373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9934989,0.0011873767,0.0033739232,0.00048868824,0.00085595855,0.0005951606],"domain_scores_gemma":[0.99086356,0.0053097066,0.0019090315,0.00031622365,0.0007603456,0.0008411157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032309147,0.00035688566,0.0031006548,0.00027361466,0.000050072318,0.000012633763,0.00018367368,0.00025049088,0.00014467101],"category_scores_gemma":[0.0024290823,0.00022776477,0.00013483106,0.00049582607,0.0005594547,0.00029397378,0.00008639996,0.0013843793,0.000001080625],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5207486,0.02438756,0.05873552,0.00018235228,0.0018934886,0.0029618798,0.0060076504,0.000033075852,0.000839036,0.0000013177698,0.00028505063,0.38392445],"study_design_scores_gemma":[0.29844466,0.15140864,0.5389225,0.0014589467,0.0018579497,0.0009180638,0.005868028,0.00014962952,0.00013057211,0.000004965116,0.0005585541,0.00027752077],"about_ca_topic_score_codex":0.0023609905,"about_ca_topic_score_gemma":0.008142427,"teacher_disagreement_score":0.48018694,"about_ca_system_score_codex":0.00081570173,"about_ca_system_score_gemma":0.003592645,"threshold_uncertainty_score":0.9287978},"labels":[],"label_agreement":null},{"id":"W4253465303","doi":"10.1200/jco.2012.30.18_suppl.lba7500","title":"LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Pemetrexed; Afatinib; Internal medicine; Rash; Lung cancer; Gastroenterology; Adverse effect; Erlotinib; Clinical endpoint; Adenocarcinoma; Oncology; Chemotherapy; Epidermal growth factor receptor; Cisplatin; Cancer; Randomized controlled trial","score_opus":0.1257192747879889,"score_gpt":0.5202801478412544,"score_spread":0.39456087305326554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253465303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417585,0.00077979325,0.00019478747,0.00045672586,0.0006232182,0.0034133017,0.00001744707,0.0000034982438,0.00033536422],"genre_scores_gemma":[0.99313563,0.00010779759,0.0062758066,0.00005503248,0.00017911958,0.0001560842,0.000009672982,0.000020640357,0.000060211296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971076,0.00029280307,0.0019289535,0.00017004556,0.00030283365,0.0001977235],"domain_scores_gemma":[0.9906925,0.0053310604,0.0029815405,0.00019772584,0.00059974415,0.00019743173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011709051,0.0001744088,0.0017281846,0.000098231365,0.00012962666,0.00000888671,0.00012357793,0.00009591366,0.000026518495],"category_scores_gemma":[0.0030843585,0.000092744616,0.00017985904,0.00018030233,0.00015221674,0.0002549251,0.000059281574,0.0002087004,1.5373313e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.510997,0.035624932,0.36433238,0.00009671506,0.00503364,0.000014275526,0.0048185177,0.00011415192,0.000042158,0.00009333482,0.000055284145,0.07877762],"study_design_scores_gemma":[0.844467,0.055713058,0.09202893,0.00023962828,0.0050472803,0.000010683287,0.0015600086,0.00046698368,0.00012465932,0.000016522199,0.00023687685,0.00008836195],"about_ca_topic_score_codex":0.000094164665,"about_ca_topic_score_gemma":0.000037038888,"teacher_disagreement_score":0.33347002,"about_ca_system_score_codex":0.00026201925,"about_ca_system_score_gemma":0.0006641988,"threshold_uncertainty_score":0.37820157},"labels":[],"label_agreement":null},{"id":"W4253473230","doi":"10.1200/jco.2004.22.14_suppl.878","title":"Local accrual pattern of a breast cancer adjuvant chemotherapy clinical trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Cancer; Internal medicine; Oncology; Chemotherapy; Randomized controlled trial; Surgery","score_opus":0.6418777691918434,"score_gpt":0.701061109990532,"score_spread":0.05918334079868859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253473230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.913165,0.00044201623,0.003946641,0.076282874,0.004512904,0.0005410429,0.00002371965,0.000014753468,0.0010710591],"genre_scores_gemma":[0.970339,0.0088151675,0.0024172321,0.011132086,0.006979312,0.000008174501,0.000001702134,0.00004614178,0.0002612003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98644114,0.0012087439,0.00939758,0.00047691335,0.0019455329,0.00053006597],"domain_scores_gemma":[0.95813775,0.033042006,0.0043692593,0.0006319698,0.0025381378,0.001280901],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.033985358,0.0002455662,0.0038720074,0.00017925687,0.000043332406,0.000011285236,0.00072231446,0.0023373973,0.0010084799],"category_scores_gemma":[0.03370409,0.00016662822,0.0020616946,0.00028333577,0.0022738276,0.00012334582,0.0001999858,0.008737703,0.00004812243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2173987,0.01218015,0.065613866,0.000117396216,0.0010860575,0.0008233495,0.00011769245,0.000040878724,0.00006430577,0.00037446243,0.0019490581,0.7002341],"study_design_scores_gemma":[0.39446786,0.07853093,0.49728116,0.0011138564,0.00064829737,0.00076119223,0.00028284165,0.00007643569,0.00018675097,0.010546073,0.015842374,0.00026222397],"about_ca_topic_score_codex":0.00022212634,"about_ca_topic_score_gemma":0.00043145136,"teacher_disagreement_score":0.69997185,"about_ca_system_score_codex":0.00035586004,"about_ca_system_score_gemma":0.0144477375,"threshold_uncertainty_score":0.99990475},"labels":[],"label_agreement":null},{"id":"W4253473443","doi":"10.1200/jco.2019.37.15_suppl.tps5100","title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostatectomy; Prostate cancer; Urology; Antiandrogen; Internal medicine; Placebo; Randomization; Oncology; Randomized controlled trial; Cancer; Pathology","score_opus":0.06609354285625957,"score_gpt":0.44419695264387915,"score_spread":0.3781034097876196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253473443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648053,0.0007378448,0.00029505603,0.001960549,0.0012079552,0.030833159,0.000040938863,0.000023578457,0.00009563655],"genre_scores_gemma":[0.9895268,0.003891933,0.00308288,0.0003710785,0.00053752953,0.0020330064,0.00004302618,0.000081996266,0.00043176874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99085355,0.0016677993,0.0045159557,0.00066283526,0.0015498415,0.00075000804],"domain_scores_gemma":[0.98970765,0.0040053222,0.0036440177,0.0004570155,0.0014445332,0.00074147666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006543547,0.0004964757,0.005679073,0.00056693744,0.00007557576,0.00003206711,0.00036959405,0.00057996437,0.00024172157],"category_scores_gemma":[0.0035539456,0.0002653506,0.00070270617,0.0007078779,0.00056337524,0.00032363227,0.00009459838,0.0016032878,0.000015686508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87957716,0.005479411,0.009977608,0.00011955412,0.0023956918,0.00025392647,0.00045579099,0.0012938086,0.00005696344,0.000012261739,0.00006985836,0.100307986],"study_design_scores_gemma":[0.8909419,0.102469586,0.001117249,0.0006231809,0.00074214756,0.000012104433,0.00010059826,0.00066952856,0.00063352525,0.00005088791,0.002366895,0.0002723781],"about_ca_topic_score_codex":0.0002681743,"about_ca_topic_score_gemma":0.00026675337,"teacher_disagreement_score":0.10003561,"about_ca_system_score_codex":0.0012883381,"about_ca_system_score_gemma":0.010538794,"threshold_uncertainty_score":0.99997985},"labels":[],"label_agreement":null},{"id":"W4253499743","doi":"10.1200/jco.2011.29.15_suppl.e16583","title":"Physician experience and challenges obtaining unfunded oral chemotherapy across Canada.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine; Psychosocial; Psychiatry","score_opus":0.3376887119468509,"score_gpt":0.41123988313451276,"score_spread":0.07355117118766186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253499743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95281243,0.00562915,0.0001880938,0.0037955912,0.0017272448,0.000061421124,0.000012836879,0.0000053219846,0.03576793],"genre_scores_gemma":[0.98287547,0.010097301,0.0013650388,0.0049169855,0.0006022572,0.0000021013798,2.018652e-7,0.00001527065,0.00012538256],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975813,0.000038893344,0.0018119103,0.00021961641,0.000040508312,0.0003077979],"domain_scores_gemma":[0.9971612,0.0002538106,0.0020945182,0.00014958033,0.00008992456,0.00025097147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020329272,0.00012556666,0.0011998059,0.000031375246,0.000062509265,0.000016720789,0.0002879132,0.00021449242,0.00011032567],"category_scores_gemma":[0.000676681,0.00012082221,0.00015355571,0.00005233179,0.000218232,0.0003279385,0.000048740538,0.00039306335,0.000010652633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081609393,0.00042566433,0.1300948,0.000019761546,0.00024405103,0.000090620626,0.0070695183,0.000004208916,0.0000025998722,0.03634329,0.0017451075,0.8231443],"study_design_scores_gemma":[0.0020598017,0.001302515,0.5554429,0.000014886329,0.0000065587346,0.000019990357,0.0010748355,0.000044939203,0.000022419004,0.0132013345,0.4266361,0.00017368008],"about_ca_topic_score_codex":0.01827624,"about_ca_topic_score_gemma":0.04243751,"teacher_disagreement_score":0.8229706,"about_ca_system_score_codex":0.00015604775,"about_ca_system_score_gemma":0.00045704472,"threshold_uncertainty_score":0.98826116},"labels":[],"label_agreement":null},{"id":"W4253674318","doi":"10.1200/jco.2013.31.4_suppl.280","title":"Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Internal medicine; Neutropenia; Liver transplantation; Milan criteria; Gastroenterology; Transplantation; Surgery; Chemotherapy","score_opus":0.10391514629978277,"score_gpt":0.3655726797202157,"score_spread":0.2616575334204329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253674318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683654,0.00045033765,0.00006889436,0.00058385485,0.0007696363,0.0009907564,0.000018008082,0.0000051651377,0.00027679052],"genre_scores_gemma":[0.9962219,0.0012721644,0.001542679,0.00026261053,0.00054541836,0.00004135415,0.000021695025,0.000020518286,0.00007167043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538255,0.0007755304,0.0029470655,0.00020868408,0.00043310103,0.00025304995],"domain_scores_gemma":[0.996205,0.0011309601,0.0015840265,0.00019528529,0.0005308429,0.00035391224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015613433,0.00018540786,0.0016449742,0.00025352428,0.000020515288,0.00000737585,0.00012917927,0.0004531199,0.0006592002],"category_scores_gemma":[0.0007300617,0.00013265254,0.00068473077,0.00017376163,0.00015186038,0.00019466963,0.00001980714,0.0007201686,0.000059926235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079157695,0.010684873,0.8554655,0.00006864609,0.00015938224,0.0022440637,0.00022999491,3.4316466e-7,0.000039295133,0.000007220023,0.00031671728,0.05162627],"study_design_scores_gemma":[0.2779582,0.04414429,0.67440313,0.00007946279,0.0010013117,0.000037737842,0.000026791435,0.0005114405,0.00055460306,0.00013329141,0.0010371736,0.000112566486],"about_ca_topic_score_codex":0.0003603699,"about_ca_topic_score_gemma":0.000031956184,"teacher_disagreement_score":0.19880052,"about_ca_system_score_codex":0.00009678691,"about_ca_system_score_gemma":0.0006144013,"threshold_uncertainty_score":0.721778},"labels":[],"label_agreement":null},{"id":"W4253719807","doi":"10.1200/jco.2016.34.2_suppl.472","title":"Conditional survival of patients with metastatic testicular germ-cell tumors (MT-GCT) treated with first-line curative therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Germ cell tumors; Overall survival; Surgery; Gastroenterology; Chemotherapy","score_opus":0.07362448280307005,"score_gpt":0.39796019129657145,"score_spread":0.3243357084935014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253719807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966473,0.00031995893,0.0010575328,0.0012304694,0.00008834239,0.0003725997,0.000093211704,0.000008779611,0.00018182228],"genre_scores_gemma":[0.996908,0.00015796858,0.0023712963,0.00027437106,0.00011521816,0.0000084017465,0.000034770295,0.000024249748,0.000105718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972715,0.0003331162,0.0014035489,0.00020389857,0.0005839423,0.0002039895],"domain_scores_gemma":[0.99209285,0.0038117478,0.0022945516,0.0001811983,0.0012044284,0.00041522962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004838547,0.00021043804,0.0013950503,0.00009492755,0.000037320187,0.0000043123177,0.00009501913,0.00009723694,0.00028155345],"category_scores_gemma":[0.0017603708,0.00008778032,0.0003103856,0.0001436071,0.00035758372,0.00011721411,0.000016332693,0.0002309177,0.000011314471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013419188,0.010868481,0.9638983,0.00003576396,0.0017186063,0.0015384036,0.00002120191,0.000032895743,0.00003579519,0.0000486515,0.00017546916,0.008207229],"study_design_scores_gemma":[0.04519146,0.04844832,0.90311784,0.00031080848,0.0013095592,0.00011186437,0.000024002044,0.00001734753,0.00015156325,0.0002375454,0.00096835964,0.000111332905],"about_ca_topic_score_codex":0.000012039385,"about_ca_topic_score_gemma":0.000017127864,"teacher_disagreement_score":0.060780477,"about_ca_system_score_codex":0.00009436858,"about_ca_system_score_gemma":0.0014557402,"threshold_uncertainty_score":0.35795775},"labels":[],"label_agreement":null},{"id":"W4253736521","doi":"10.1200/jco.2004.22.14_suppl.8555","title":"Identification of immune evasion strategies of pediatric pre-B acute lymphoblastic leukemia after bone marrow transplantation","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Immune system; Immunology; Bone marrow; Immunosuppression; Leukemia; T cell; Transplantation; Human leukocyte antigen; Acute lymphocytic leukemia; B cell; Oncology; Lymphoblastic Leukemia; Antigen; Antibody; Internal medicine","score_opus":0.03679472496176489,"score_gpt":0.3861622613803333,"score_spread":0.34936753641856844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253736521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823194,0.000506713,0.015566987,0.00037683215,0.0006891909,0.00026096203,0.000011800173,0.000007741641,0.00026037567],"genre_scores_gemma":[0.99248797,0.0042215795,0.002846098,0.00004231142,0.00032453364,0.000005629532,0.000012119019,0.000016444954,0.000043313004],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9944409,0.00022809395,0.004467051,0.00016272507,0.0005455204,0.00015571844],"domain_scores_gemma":[0.995018,0.00095210643,0.003101447,0.0001858733,0.00059513166,0.00014743074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023222975,0.00013614581,0.0011840238,0.00025781593,0.000017783943,0.0000058729343,0.000118287106,0.0003872679,0.00005242875],"category_scores_gemma":[0.00039797425,0.000107916916,0.0004536995,0.00023376067,0.00015971111,0.00023959088,0.000007955841,0.00036861337,0.0000085343545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06364018,0.006074239,0.07514115,0.006971083,0.0018432605,0.003198783,0.0058962777,0.0053046755,0.8104638,0.0016842544,0.000096895834,0.019685416],"study_design_scores_gemma":[0.017094769,0.007846464,0.9115698,0.00058052316,0.004452278,0.0015902013,0.0003492601,0.000114387396,0.054824196,0.0014150726,0.000031410833,0.00013164568],"about_ca_topic_score_codex":0.000016640524,"about_ca_topic_score_gemma":0.000010748475,"teacher_disagreement_score":0.83642864,"about_ca_system_score_codex":0.0001888702,"about_ca_system_score_gemma":0.0027218417,"threshold_uncertainty_score":0.482843},"labels":[],"label_agreement":null},{"id":"W4253819800","doi":"10.1200/jco.2016.34.15_suppl.e18034","title":"Oxaliplatin associated neurotoxicity outcomes among older adults with colorectal cancer: a population-based study.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Women's College Hospital; Queen's University; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Oxaliplatin; Medicine; Hazard ratio; Internal medicine; Regimen; Colorectal cancer; Cancer registry; Cumulative incidence; Population; Cohort; Incidence (geometry); Cancer; Surgery; Oncology; Confidence interval","score_opus":0.06502031611701335,"score_gpt":0.46263581986832353,"score_spread":0.39761550375131016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253819800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187547,0.000029392519,0.000015754245,0.006011635,0.001015045,0.000820965,0.00001320311,0.00002350458,0.00019504367],"genre_scores_gemma":[0.99742705,0.000030239597,0.00012756011,0.0015600811,0.0004810711,0.000046646455,0.0000033148797,0.000022291015,0.00030173396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968237,0.0006379139,0.0016353633,0.00023748183,0.00040653095,0.00025897485],"domain_scores_gemma":[0.99351025,0.0036047031,0.0019694383,0.000114060334,0.00045175554,0.00034979775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011829784,0.00018840474,0.0015889793,0.00012456399,0.000054643806,0.0000056879426,0.000117501346,0.0002802596,0.0007023737],"category_scores_gemma":[0.0015755651,0.0000938737,0.00036435542,0.00016415934,0.000121530065,0.00009912281,0.000021868353,0.0005402873,0.000005748842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011377881,0.0072074602,0.96131533,0.000008760347,0.000892087,0.0005712863,0.00010089726,0.000013035617,0.000053977106,0.0000014310898,0.0008328414,0.017624985],"study_design_scores_gemma":[0.04676094,0.028153602,0.9235077,0.00017992753,0.0008691511,0.000018929184,0.000045526045,0.000042945194,0.00006169949,0.000008817648,0.00024730034,0.000103500504],"about_ca_topic_score_codex":0.0004724913,"about_ca_topic_score_gemma":0.004809037,"teacher_disagreement_score":0.037807696,"about_ca_system_score_codex":0.00042700965,"about_ca_system_score_gemma":0.0012963334,"threshold_uncertainty_score":0.76904994},"labels":[],"label_agreement":null},{"id":"W4253848677","doi":"10.1200/jco.2020.38.15_suppl.5068","title":"Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Calgary; Sunnybrook Hospital; Western University; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; London Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Nephrectomy; Multivariate analysis; Population; Oncology; Kidney","score_opus":0.10023124549084568,"score_gpt":0.4011712840233951,"score_spread":0.3009400385325494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253848677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443406,0.0006972829,0.00012093215,0.0033479766,0.00020219719,0.0006115877,0.00003311051,0.00000426423,0.0005486129],"genre_scores_gemma":[0.99507636,0.00035261293,0.0036440536,0.00042093056,0.0003773842,0.000011211716,0.00007480199,0.000019992836,0.000022658849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932903,0.000988868,0.0042818827,0.00036373033,0.00082760747,0.00024762863],"domain_scores_gemma":[0.99290454,0.0022309269,0.0034508482,0.00048423684,0.0005315917,0.0003978291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019158262,0.00027670377,0.002460446,0.00035638237,0.000021825997,0.000008368565,0.0003664035,0.00014835801,0.00017713563],"category_scores_gemma":[0.00074737705,0.00014749692,0.0011623615,0.00057739846,0.00035228478,0.00014866311,0.000045479053,0.0005747358,0.0000040534264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09418847,0.051486854,0.78663015,0.0002972163,0.008743845,0.010725733,0.013453515,0.0014324156,0.0067696767,0.00005460934,0.00031490278,0.025902627],"study_design_scores_gemma":[0.041111313,0.06301459,0.86697847,0.00014897468,0.006987599,0.00023901286,0.0024930837,0.00085774943,0.017148204,0.0000057803463,0.0008673191,0.00014789838],"about_ca_topic_score_codex":0.00028500723,"about_ca_topic_score_gemma":0.0001364698,"teacher_disagreement_score":0.08034834,"about_ca_system_score_codex":0.00022240955,"about_ca_system_score_gemma":0.0010768294,"threshold_uncertainty_score":0.601475},"labels":[],"label_agreement":null},{"id":"W4253850874","doi":"10.1200/jco.18.02142","title":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Biosimilar; Anemia; Randomized controlled trial; Cancer; Internal medicine; Intensive care medicine; Epoetin alfa; Guideline; Oncology; Cochrane Library; Pathology","score_opus":0.08221512617921757,"score_gpt":0.5030369866052029,"score_spread":0.42082186042598535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253850874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417762,0.0010248295,0.00016195035,0.038896058,0.002005353,0.0005619415,0.000009822268,0.0000253024,0.015538517],"genre_scores_gemma":[0.8735315,0.008518889,0.10722584,0.008211316,0.0009670759,0.0000050753524,0.000020879193,0.000050496834,0.0014689155],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918516,0.0007349058,0.0057646814,0.00038279392,0.000885633,0.00038035365],"domain_scores_gemma":[0.98846453,0.0029663944,0.006130732,0.0004157827,0.0015831041,0.00043947008],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0069544483,0.00026786895,0.0025036563,0.00008440624,0.000050417584,0.000010889612,0.00024836132,0.0005195212,0.0010806897],"category_scores_gemma":[0.0029450841,0.0001756078,0.00067765865,0.0002797805,0.00033369564,0.00018859628,0.00013089678,0.0013054057,0.00006865395],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0142728025,0.013497731,0.6615849,0.0003545062,0.007849337,0.0058770296,0.0001258855,0.00070054183,0.00005662639,0.00031943407,0.064094506,0.23126668],"study_design_scores_gemma":[0.05946742,0.052653857,0.36905885,0.0027398495,0.008012883,0.00064153445,0.0024086821,0.0007370669,0.00009549205,0.00012772209,0.5036209,0.0004356826],"about_ca_topic_score_codex":0.00007769284,"about_ca_topic_score_gemma":0.000031935262,"teacher_disagreement_score":0.43952644,"about_ca_system_score_codex":0.0003459388,"about_ca_system_score_gemma":0.0013345712,"threshold_uncertainty_score":0.99983245},"labels":[],"label_agreement":null},{"id":"W4253956429","doi":"10.1200/jco.2018.36.15_suppl.6004","title":"Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel approach.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Docetaxel; Induction chemotherapy; Neck dissection; Carboplatin; Surgery; Regimen; Cancer; Radiation therapy; Stage (stratigraphy); Internal medicine; Chemotherapy; Cisplatin; Oncology","score_opus":0.18365676065627506,"score_gpt":0.4636832881789709,"score_spread":0.28002652752269586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253956429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924419,0.0006984117,0.0006878986,0.0031325782,0.00091411325,0.0008662349,0.0000135971695,0.000011878493,0.00123339],"genre_scores_gemma":[0.9918425,0.00045713288,0.0038687773,0.0015999491,0.0019436022,0.000048944326,0.0000039632214,0.000028595912,0.00020655215],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9973853,0.00017744229,0.0015784634,0.0003226735,0.0002326784,0.00030343467],"domain_scores_gemma":[0.9967435,0.0014219972,0.00081133796,0.00013202624,0.0005405658,0.00035056061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014173266,0.0002257022,0.0022009686,0.00012603473,0.00016227082,0.000006439493,0.000063170264,0.00025904525,0.00002759587],"category_scores_gemma":[0.0006193632,0.00015420899,0.00043779408,0.00011543974,0.00035145623,0.00010862753,0.000018065588,0.0003792153,0.000001950387],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07730145,0.0525248,0.008290069,0.00007383167,0.00050486904,0.00021584136,0.0040818327,0.0000012129839,0.0017698595,0.00001824339,0.0014416751,0.85377634],"study_design_scores_gemma":[0.15800995,0.761131,0.042261295,0.000052059004,0.0010963969,0.00046850438,0.0029098415,0.00012652697,0.0018380719,0.000072302464,0.031782307,0.00025175532],"about_ca_topic_score_codex":0.00004096546,"about_ca_topic_score_gemma":0.000054323566,"teacher_disagreement_score":0.85352457,"about_ca_system_score_codex":0.0002109767,"about_ca_system_score_gemma":0.0016711098,"threshold_uncertainty_score":0.628846},"labels":[],"label_agreement":null},{"id":"W4254113722","doi":"10.1200/jco.2012.30.4_suppl.217","title":"Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Chemotherapy; Pancreatic cancer; Loss of heterozygosity; Cisplatin; ERCC1; Cancer; DNA repair; Gene","score_opus":0.050417456181828024,"score_gpt":0.37094309058389513,"score_spread":0.3205256344020671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254113722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545985,0.0012155987,0.00085104053,0.0015712662,0.0002871865,0.00014931124,0.000024626173,0.0000028650484,0.00043826102],"genre_scores_gemma":[0.9935708,0.00018273278,0.0039045617,0.0015009362,0.000713229,0.000008876348,0.00004318591,0.00002250241,0.000053144013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980399,0.00022971774,0.0011553135,0.00015376737,0.00016402469,0.0002572828],"domain_scores_gemma":[0.99765825,0.0009121166,0.00084483717,0.00013811527,0.00023363893,0.00021305635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014576822,0.0001423383,0.00057607197,0.00007189288,0.00004042264,0.0000108572,0.000113016016,0.00036573893,0.000061941806],"category_scores_gemma":[0.0015847209,0.00011717461,0.00019680081,0.00012580804,0.0001583036,0.00001518746,0.000013476913,0.0003494953,0.0000020861407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042230864,0.002215416,0.9715872,0.000017716466,0.00045391454,0.0010023112,0.0002954512,0.0014474973,0.0017721172,0.00011881886,0.0012469009,0.015619585],"study_design_scores_gemma":[0.02998906,0.014719653,0.91507816,0.00013148255,0.00044318804,0.005331067,0.0004349837,0.00072591525,0.0036549575,0.00052892306,0.028367257,0.00059532694],"about_ca_topic_score_codex":0.000024739991,"about_ca_topic_score_gemma":0.00055137766,"teacher_disagreement_score":0.056508996,"about_ca_system_score_codex":0.00007924247,"about_ca_system_score_gemma":0.001356542,"threshold_uncertainty_score":0.4778242},"labels":[],"label_agreement":null},{"id":"W4254182661","doi":"10.1200/jco.2013.31.26_suppl.142","title":"Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Exemestane; Medicine; Everolimus; Oncology; Internal medicine; PTEN; Breast cancer; Population; Hormone receptor; Progression-free survival; Cancer; Genetics; PI3K/AKT/mTOR pathway; Biology; Aromatase; Overall survival","score_opus":0.034563522283415374,"score_gpt":0.4159951434199039,"score_spread":0.38143162113648854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254182661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917352,0.00040526275,0.00019523226,0.0058495747,0.00042732348,0.0004623678,0.000119988465,0.0000037452792,0.00080125657],"genre_scores_gemma":[0.99540997,0.00083970465,0.002915517,0.00044324182,0.0002651965,0.000014632584,0.00002858392,0.000012692185,0.00007045518],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99706197,0.00037154177,0.0019834035,0.00018209286,0.00024716282,0.00015384602],"domain_scores_gemma":[0.9941568,0.002653818,0.0021080473,0.00012807031,0.00077177305,0.00018150375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045421478,0.00013456173,0.0012042696,0.0001319289,0.000016735914,0.0000027520052,0.00009140818,0.0002248422,0.0002437474],"category_scores_gemma":[0.0005211714,0.00009651262,0.00021335349,0.00021073161,0.00023326899,0.00016244607,0.00002061877,0.00055224134,0.0000062909708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25276044,0.021328734,0.2722236,0.000055202414,0.004418308,0.0004804898,0.0041439775,0.019945571,0.10417764,0.00013091868,0.008018749,0.31231636],"study_design_scores_gemma":[0.044972192,0.014199071,0.9348795,0.0002872857,0.00051093445,0.00003981808,0.0001273753,0.0004750938,0.0039351718,0.00013943965,0.00034674542,0.00008739402],"about_ca_topic_score_codex":0.0015792495,"about_ca_topic_score_gemma":0.00033226577,"teacher_disagreement_score":0.6626559,"about_ca_system_score_codex":0.00020018988,"about_ca_system_score_gemma":0.00100922,"threshold_uncertainty_score":0.39356703},"labels":[],"label_agreement":null},{"id":"W4254309644","doi":"10.1200/jco.2003.99.184","title":"In Reply:","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine","score_opus":0.16127700030663622,"score_gpt":0.5096696145207001,"score_spread":0.3483926142140639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254309644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8318188,0.00043768552,0.00015526121,0.044917613,0.0034401927,0.00012672784,1.2093618e-7,0.0000049225882,0.11909866],"genre_scores_gemma":[0.9679205,0.00049787,0.004331574,0.022158159,0.0006897628,7.2372217e-7,1.0948347e-7,0.00000600434,0.0043952996],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981043,0.00016982616,0.0013754362,0.00007345461,0.00016082374,0.00011619309],"domain_scores_gemma":[0.9984071,0.00066403777,0.0006060695,0.000098430806,0.00008988558,0.0001344216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031996113,0.000047270354,0.0007466103,0.00011870304,0.0000063046145,0.0000022759482,0.00005746367,0.00009747129,0.0004831946],"category_scores_gemma":[0.0049382094,0.000032621007,0.00023992843,0.00013620539,0.000046950332,0.000060642295,0.000011941741,0.0004983329,0.00002240078],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011647335,0.0009347428,0.80567497,0.000017437882,0.00012828952,0.0024079224,0.0000418292,0.0000056754593,0.0000124488615,0.0024422866,0.11144383,0.0757258],"study_design_scores_gemma":[0.004927572,0.0024940434,0.30955172,0.000015372882,0.0000647404,0.00017143445,0.000051544703,0.0000030096282,0.00000993194,0.00084885664,0.68183947,0.000022305783],"about_ca_topic_score_codex":0.0000066672023,"about_ca_topic_score_gemma":0.000013114586,"teacher_disagreement_score":0.57039565,"about_ca_system_score_codex":0.00008026181,"about_ca_system_score_gemma":0.00055087724,"threshold_uncertainty_score":0.59118545},"labels":[],"label_agreement":null},{"id":"W4254390104","doi":"10.1200/jco.2005.05.302","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine","score_opus":0.14842619539725949,"score_gpt":0.5229542709720655,"score_spread":0.374528075574806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254390104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88202167,0.0005850121,0.000004132093,0.10046267,0.0005743682,0.0000627645,2.611924e-7,0.0000026185767,0.016286526],"genre_scores_gemma":[0.9693107,0.000823986,0.004665093,0.022836955,0.0017782698,0.0000016065513,2.38743e-7,0.000004600361,0.0005785535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799305,0.000120834855,0.0015367043,0.00008246267,0.00015447168,0.00011245446],"domain_scores_gemma":[0.9979718,0.0010140891,0.0006004345,0.00010506421,0.00010723117,0.00020143104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001660752,0.00005402447,0.0008075021,0.00007557115,0.000007257883,0.0000021915125,0.00005257822,0.0001436176,0.00030827476],"category_scores_gemma":[0.0017496949,0.000033637236,0.00028177418,0.000064014,0.000049813152,0.00007390865,0.000015566638,0.00030727216,0.00009158006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014925816,0.005684648,0.4495443,0.0000047028784,0.00014396787,0.0028960465,0.000054715616,0.000008307297,0.000018099021,0.00033753316,0.057865344,0.48194975],"study_design_scores_gemma":[0.0076923044,0.004073635,0.44135776,0.000027443522,0.00007014714,0.0004931017,0.000013332922,0.000015144906,0.000080156315,0.00014071756,0.5460154,0.000020876822],"about_ca_topic_score_codex":0.000013328886,"about_ca_topic_score_gemma":0.00003449971,"teacher_disagreement_score":0.48815003,"about_ca_system_score_codex":0.00022266047,"about_ca_system_score_gemma":0.00078652793,"threshold_uncertainty_score":0.33753926},"labels":[],"label_agreement":null},{"id":"W4254511029","doi":"10.1200/jco.2002.20.1.197","title":"Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Internal medicine; Lymphoma; International Prognostic Index; Surgery; Cancer; Radiation therapy; Large-cell lymphoma; Working Formulation; B symptoms; Oncology; Cyclophosphamide; Non-Hodgkin's lymphoma","score_opus":0.11869513060941014,"score_gpt":0.3949859720411679,"score_spread":0.27629084143175775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254511029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911683,0.00369598,0.000046845173,0.0037188025,0.0006112621,0.00039034596,0.000038918748,0.000011332631,0.0003181793],"genre_scores_gemma":[0.9680889,0.020735022,0.0007741176,0.008078792,0.0012619388,0.00004704559,0.000009542601,0.000021991562,0.0009826286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802315,0.00020082986,0.0010586809,0.00025899918,0.0002270562,0.00023126049],"domain_scores_gemma":[0.9969536,0.0013927182,0.0009043839,0.00021085078,0.00021628979,0.00032212693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054165005,0.0001124566,0.00075459346,0.000018245843,0.00020484922,0.00013287719,0.00013807359,0.00028397993,0.0003808652],"category_scores_gemma":[0.0005487325,0.00009675882,0.0002747628,0.00007937807,0.00015719619,0.00017809976,0.000023142615,0.00016912456,0.0000028043023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051369966,0.01159511,0.6810754,0.000011795256,0.00016696306,0.00026273602,0.0008491554,4.861389e-7,0.00003081109,0.000008835572,0.050444365,0.25504065],"study_design_scores_gemma":[0.041217122,0.0039597214,0.7693754,0.0000695777,0.00021289842,0.000056239576,0.00032627583,0.00044928875,0.00001898718,0.00009484436,0.18412912,0.000090542526],"about_ca_topic_score_codex":0.0044233333,"about_ca_topic_score_gemma":0.009584079,"teacher_disagreement_score":0.2549501,"about_ca_system_score_codex":0.00020019792,"about_ca_system_score_gemma":0.00029679906,"threshold_uncertainty_score":0.66867864},"labels":[],"label_agreement":null},{"id":"W4254584811","doi":"10.1200/jco.2019.37.7_suppl.358","title":"BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Nausea; Internal medicine; Safety profile; Cancer; Oncology; Cohort; Immunotherapy; Adverse effect","score_opus":0.03992822245600391,"score_gpt":0.42550026727157153,"score_spread":0.3855720448155676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254584811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953949,0.00051679707,0.000011343207,0.002153945,0.000649052,0.000875634,0.00001967259,0.000013652943,0.0003650202],"genre_scores_gemma":[0.99587256,0.00058845535,0.0005388817,0.0022997428,0.00034339557,0.000016673182,0.000028908144,0.00003972442,0.0002716905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631613,0.00040798768,0.0020173818,0.00041803336,0.00041502772,0.00042544954],"domain_scores_gemma":[0.99732655,0.00057809317,0.0010799122,0.00025661304,0.0003370961,0.00042173016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016180389,0.00025989598,0.0017688494,0.00018270794,0.000032039567,0.00001525911,0.0001371607,0.00033200294,0.00020737601],"category_scores_gemma":[0.00037209995,0.00018811377,0.00013527855,0.0003014506,0.00018422407,0.00036050775,0.000054940694,0.0011287176,0.000010309642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06288922,0.011133149,0.7787562,0.000078814024,0.0005758305,0.0023829623,0.00085044216,0.00035146117,0.0017070094,0.000025750369,0.00048834505,0.1407608],"study_design_scores_gemma":[0.08751539,0.021885844,0.8788213,0.0002996921,0.00013272342,0.00032066775,0.00027554482,0.00017377564,0.0006276972,0.00004803846,0.009693186,0.00020613069],"about_ca_topic_score_codex":0.00034666774,"about_ca_topic_score_gemma":0.002780004,"teacher_disagreement_score":0.14055467,"about_ca_system_score_codex":0.00042619221,"about_ca_system_score_gemma":0.0013335467,"threshold_uncertainty_score":0.7671057},"labels":[],"label_agreement":null},{"id":"W4254701901","doi":"10.1200/jco.2012.30.5_suppl.15","title":"Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Placebo; Clinical endpoint; Discontinuation; Prostate cancer; Internal medicine; Docetaxel; Tolerability; Prednisone; Randomization; Hazard ratio; Oncology; Urology; Gastroenterology; Chemotherapy; Cancer; Randomized controlled trial; Androgen deprivation therapy; Adverse effect; Confidence interval","score_opus":0.22405257462937547,"score_gpt":0.516633520639768,"score_spread":0.29258094601039253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254701901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307275,0.0048100753,0.0000073816723,0.00052660477,0.00021622067,0.0012496231,0.000066856315,0.0000032169564,0.00004726892],"genre_scores_gemma":[0.99487185,0.0043753437,0.0002965056,0.000031496835,0.000093642455,0.00009870952,0.000011629739,0.000017677294,0.00020316569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948796,0.00070459495,0.0031706765,0.00026266035,0.0005792715,0.00040320796],"domain_scores_gemma":[0.9961268,0.0009876314,0.0018224295,0.00022920694,0.00044808743,0.00038584523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034462258,0.00023182924,0.0031464894,0.00072079897,0.000030784333,0.000008429482,0.00010617199,0.0001371335,0.0000834857],"category_scores_gemma":[0.00025429772,0.00015161867,0.00027258493,0.0007679134,0.00025477514,0.0002529111,0.00004828821,0.0004232025,6.6846127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085291855,0.040865317,0.75866926,0.00023011958,0.010435177,0.0011166816,0.019460013,0.00093750964,0.0046657394,0.000015795702,0.000025613883,0.07828692],"study_design_scores_gemma":[0.15135811,0.038762394,0.7914103,0.00019557805,0.006697717,0.00001809219,0.009305402,0.0009011396,0.00093603745,0.00002760643,0.0002190611,0.00016854616],"about_ca_topic_score_codex":0.001063458,"about_ca_topic_score_gemma":0.010013349,"teacher_disagreement_score":0.07811838,"about_ca_system_score_codex":0.0006488058,"about_ca_system_score_gemma":0.0019254058,"threshold_uncertainty_score":0.61828303},"labels":[],"label_agreement":null},{"id":"W4254791026","doi":"10.1200/jco.2006.08.6157","title":"In Reply","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.10635060987629272,"score_gpt":0.5011863838157462,"score_spread":0.39483577393945346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254791026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8906625,0.000630863,0.00005539513,0.06014943,0.0019048579,0.00013612531,7.334987e-7,0.000006739591,0.046453357],"genre_scores_gemma":[0.9817355,0.00041194915,0.0010362179,0.011886963,0.0027937258,0.0000020148805,4.3151584e-7,0.000008797309,0.0021243917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732745,0.0001769301,0.002011967,0.0001057498,0.00021732037,0.00016057017],"domain_scores_gemma":[0.99715316,0.0013894796,0.0009504903,0.00008191654,0.0003193231,0.00010564121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022215864,0.000072419396,0.0009902589,0.00013749897,0.0000144338765,0.0000021475937,0.00005572183,0.00017034562,0.00019248987],"category_scores_gemma":[0.0035207674,0.000052171777,0.00028813005,0.00014940764,0.00015771361,0.00007433763,0.00002763086,0.0008489789,0.00003779481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006956,0.0037139414,0.59030795,0.000023708475,0.00030273938,0.0042807935,0.000058328147,0.000022982797,0.00017225584,0.00028483037,0.32455602,0.069320425],"study_design_scores_gemma":[0.007815382,0.0062456927,0.6431081,0.00007853702,0.0001284151,0.0004209362,0.000049009697,0.0000101115365,0.00004264593,0.0012799667,0.34077957,0.000041616837],"about_ca_topic_score_codex":0.00006731937,"about_ca_topic_score_gemma":0.000088060224,"teacher_disagreement_score":0.091073014,"about_ca_system_score_codex":0.0001958392,"about_ca_system_score_gemma":0.0007196582,"threshold_uncertainty_score":0.42149416},"labels":[],"label_agreement":null},{"id":"W4254864182","doi":"10.1200/jco.2003.99.240","title":"CORRESPONDENCE","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.20731131467138803,"score_gpt":0.5269878382272908,"score_spread":0.31967652355590276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254864182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.871415,0.0021346826,0.00037318983,0.019632239,0.005107861,0.00017026227,0.0000011581188,0.000008315639,0.10115729],"genre_scores_gemma":[0.98595536,0.0009220378,0.0067650075,0.0042219805,0.0005819551,0.0000016784961,1.7584195e-7,0.000006662885,0.0015451226],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981689,0.00025487816,0.001167281,0.00009183397,0.00020222206,0.000114882685],"domain_scores_gemma":[0.9971215,0.0014895023,0.00073498074,0.00012302892,0.0002377482,0.0002932065],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021501319,0.000060834092,0.0007773381,0.000050753308,0.000015776766,0.000003592048,0.000054593747,0.00016345107,0.0011695296],"category_scores_gemma":[0.004186368,0.000038586117,0.00033188946,0.00007936034,0.000078500016,0.000043066575,0.0000074871464,0.00041673463,0.00010313623],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002853117,0.005078537,0.55599254,0.0000150494025,0.00059199234,0.004354922,0.000059990874,0.000008148346,0.000053272088,0.0062715225,0.07581508,0.34890583],"study_design_scores_gemma":[0.005853102,0.009724839,0.27459875,0.00004478384,0.00024080454,0.00090666977,0.000029618892,0.0000034843897,0.00014241185,0.0006309853,0.7077904,0.00003415433],"about_ca_topic_score_codex":0.0000024135873,"about_ca_topic_score_gemma":0.0000035061983,"teacher_disagreement_score":0.6319753,"about_ca_system_score_codex":0.00010518014,"about_ca_system_score_gemma":0.0018321058,"threshold_uncertainty_score":0.9997435},"labels":[],"label_agreement":null},{"id":"W4254890712","doi":"10.1200/jco.2019.37.15_suppl.2000","title":"Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Temozolomide; Medicine; Glioma; Internal medicine; Isocitrate dehydrogenase; Interim analysis; Oncology; Hazard ratio; IDH1; Randomized controlled trial; Confidence interval; Radiation therapy; Cancer research; Biology","score_opus":0.047358321564473914,"score_gpt":0.42764274213806625,"score_spread":0.38028442057359235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254890712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545234,0.0010452673,0.000055745353,0.0015763447,0.0008189368,0.0008654464,0.00000922019,0.0000023771474,0.00017429425],"genre_scores_gemma":[0.9990633,0.0003565446,0.00006291026,0.00038540966,0.000082412625,0.000017066704,0.00000453379,0.00000976525,0.000018045803],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99607044,0.00075763563,0.0024953352,0.00024577268,0.00027266925,0.00015811817],"domain_scores_gemma":[0.9935604,0.0040186006,0.0018450281,0.0002032114,0.00016631176,0.00020648999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026167557,0.00017736871,0.003335548,0.0004097394,0.000022072834,0.0000088672505,0.00010357344,0.00021328768,0.00018327251],"category_scores_gemma":[0.0021401756,0.00009638851,0.00075735763,0.00027405142,0.00036607636,0.00004855933,0.00007172366,0.0004964801,0.0000014760578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9045487,0.00633243,0.07019822,0.00005607775,0.0058822855,0.00053471496,0.00029858697,0.00012108492,0.0007468877,0.0002710166,0.00022771754,0.010782293],"study_design_scores_gemma":[0.92173004,0.020836739,0.046941333,0.0004212655,0.005409419,0.000108269516,0.00010194586,0.003236507,0.00049759523,0.000068723835,0.00054735277,0.00010083342],"about_ca_topic_score_codex":0.00002679841,"about_ca_topic_score_gemma":0.00037536526,"teacher_disagreement_score":0.02325689,"about_ca_system_score_codex":0.00010260094,"about_ca_system_score_gemma":0.00022208293,"threshold_uncertainty_score":0.39306092},"labels":[],"label_agreement":null},{"id":"W4254989908","doi":"10.1200/jco.2017.35.15_suppl.e16020","title":"Real world outcomes in advanced urothelial cancer and the role of neutrophil to lymphocyte ratio.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Neutrophil to lymphocyte ratio; Proportional hazards model; Overall survival; Urothelial cancer; Cancer; Bladder cancer","score_opus":0.06774151739059532,"score_gpt":0.47023568813214683,"score_spread":0.4024941707415515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254989908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97041595,0.0006158059,0.0000042622028,0.019954996,0.0008655946,0.0003243244,0.0000076112497,0.00000242664,0.0078090364],"genre_scores_gemma":[0.9934823,0.002603264,0.0005959257,0.001819976,0.0006316146,0.000015870468,1.7411418e-7,0.000011304246,0.0008395816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980623,0.0001675228,0.0012702759,0.00013164431,0.0002163995,0.00015183506],"domain_scores_gemma":[0.9974339,0.000802207,0.0011329305,0.00026483167,0.00017220135,0.00019392392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011114732,0.00010604158,0.0013502052,0.00008567731,0.000059174494,0.000010599186,0.00020316547,0.000108671324,0.000045104134],"category_scores_gemma":[0.0011949203,0.000056459376,0.00024052423,0.00004768623,0.00031727614,0.00009051308,0.00006732188,0.00033358153,0.0000028020881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023231046,0.00045050375,0.6886228,0.000008992257,0.0002689531,0.00009243171,0.00022061447,0.000020992176,0.00042684554,0.0005458138,0.000085678636,0.28602538],"study_design_scores_gemma":[0.035251502,0.002973369,0.94092304,0.000086342945,0.00024975542,0.000022742955,0.00006430373,0.00003499278,0.00046336322,0.0010760883,0.01879939,0.00005513895],"about_ca_topic_score_codex":0.0013042042,"about_ca_topic_score_gemma":0.002283263,"teacher_disagreement_score":0.28597024,"about_ca_system_score_codex":0.00012908765,"about_ca_system_score_gemma":0.0012738996,"threshold_uncertainty_score":0.23023465},"labels":[],"label_agreement":null},{"id":"W4255224860","doi":"10.1200/jco.2017.35.18_suppl.lba10001","title":"Managing cancer and living meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Cancer; Distress; Intervention (counseling); Population; Quality of life (healthcare); Clinical endpoint; Psychological intervention; Attrition; Physical therapy; Psychiatry; Clinical psychology; Internal medicine; Nursing","score_opus":0.07562103310577026,"score_gpt":0.49490435624890006,"score_spread":0.41928332314312977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255224860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884296,0.00087382767,0.00083864114,0.0035106027,0.0032182592,0.0020177274,0.000005452839,0.00000492395,0.000687583],"genre_scores_gemma":[0.9955962,0.0020214587,0.0008451444,0.00034594937,0.0008071782,0.00021453432,7.4522154e-7,0.000013395983,0.00015543449],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996746,0.00042404913,0.002172083,0.00019634665,0.0002910927,0.00017043484],"domain_scores_gemma":[0.9903224,0.0037229375,0.00478631,0.00018318638,0.00080393715,0.00018119228],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048178965,0.00013492767,0.0035409287,0.00007842248,0.00007793702,0.000018033605,0.00015604038,0.00020949493,0.0000622724],"category_scores_gemma":[0.010384613,0.00007597001,0.00096994505,0.00002996662,0.00034788685,0.0001250993,0.000045553712,0.0004210275,1.2333727e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7638334,0.0010581295,0.018287038,0.00006414486,0.000646214,0.000010541796,0.00011102884,0.00000368878,0.000004970508,0.000035094454,0.00007817461,0.2158676],"study_design_scores_gemma":[0.9339465,0.024144882,0.037884615,0.0010847094,0.001468213,0.0000071272325,0.00008894302,0.00015157825,0.0000028860031,0.00029650825,0.0008450624,0.000078997014],"about_ca_topic_score_codex":0.00013114206,"about_ca_topic_score_gemma":0.0006392342,"teacher_disagreement_score":0.2157886,"about_ca_system_score_codex":0.00007430224,"about_ca_system_score_gemma":0.00027276407,"threshold_uncertainty_score":0.9979513},"labels":[],"label_agreement":null},{"id":"W4255479527","doi":"10.1200/jco.2004.22.14_suppl.9663","title":"Aglycone Protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Protopanaxadiol; P-glycoprotein; MCF-7; Pharmacology; Cancer cell; Multiple drug resistance; Aglycone; Medicine; Chemistry; Cancer; Ginsenoside; Biochemistry; Ginseng; Internal medicine; Stereochemistry; Glycoside","score_opus":0.034171279591753784,"score_gpt":0.3733129262987917,"score_spread":0.33914164670703795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255479527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987925,0.0012254025,0.000024916893,0.009612415,0.0005107554,0.00040483286,0.000013333968,0.000005751322,0.00027757967],"genre_scores_gemma":[0.9895593,0.0033137945,0.0025935476,0.0025286137,0.0015972864,0.000013129576,0.0000017900979,0.000027192738,0.00036533937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977707,0.00025368595,0.0011035979,0.00035957995,0.00023551448,0.00027690546],"domain_scores_gemma":[0.9981463,0.00025195893,0.0009391832,0.00022673269,0.0002105906,0.00022522121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016289986,0.00021302426,0.0008217325,0.00006719372,0.000080341866,0.000020153886,0.00015516211,0.0004508329,0.000017345665],"category_scores_gemma":[0.00075185875,0.00015431656,0.00029509622,0.00007102785,0.00028663818,0.000012020679,0.000058620524,0.0006079136,0.0000030285437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069519826,0.00047037101,0.000118256685,0.000028222554,0.00024993802,0.00008754105,0.00012927236,0.00006875388,0.89434415,0.00005320672,0.0011381574,0.09636017],"study_design_scores_gemma":[0.005349265,0.0056274706,0.002059306,0.00013130743,0.00005198994,0.000080812395,0.00018117849,0.000007980584,0.92941695,0.00024069646,0.056616515,0.00023649771],"about_ca_topic_score_codex":0.00011445479,"about_ca_topic_score_gemma":0.000085243904,"teacher_disagreement_score":0.09612367,"about_ca_system_score_codex":0.00007897227,"about_ca_system_score_gemma":0.0006541858,"threshold_uncertainty_score":0.6292847},"labels":[],"label_agreement":null},{"id":"W4255506697","doi":"10.1200/jco.2004.22.90140.552","title":"Impact of reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancers","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Breast cancer; Anthracycline; Internal medicine; Population; Oncology; Cyclophosphamide; Retrospective cohort study; Chemotherapy; Surgery; Cancer","score_opus":0.03835756768666998,"score_gpt":0.4281462656102045,"score_spread":0.38978869792353454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255506697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998231,0.00020195518,0.00011535498,0.0009589086,0.00020945922,0.0001632497,0.000084080035,0.0000015333133,0.00003444082],"genre_scores_gemma":[0.9975042,0.00029198223,0.0018154801,0.00019040525,0.00014972736,0.0000025938477,0.000028567885,0.000013208541,0.0000038363755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738723,0.00017606081,0.0018755192,0.00019198148,0.00020576688,0.00016344967],"domain_scores_gemma":[0.9964925,0.00016450026,0.0024417571,0.00022672492,0.00057394704,0.00010056313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011057181,0.00015421493,0.0013401558,0.000113140806,0.000017474655,0.0000010004337,0.00015111249,0.00027288654,0.00003181481],"category_scores_gemma":[0.0006154325,0.000115518276,0.0005565162,0.00014724536,0.00024643046,0.000008116561,0.00003887639,0.00022064315,1.0306495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016263705,0.0024013314,0.9142136,0.00002966592,0.00054603774,0.000016664964,0.000039447506,0.0052445224,0.05318225,0.000002455368,0.00005580288,0.008004519],"study_design_scores_gemma":[0.01308534,0.007019919,0.9587089,0.00011902425,0.00010859645,0.000019698035,0.000026904781,0.00008600963,0.02067463,0.000027836237,0.00003837271,0.00008478663],"about_ca_topic_score_codex":0.0027215926,"about_ca_topic_score_gemma":0.0007467928,"teacher_disagreement_score":0.04449529,"about_ca_system_score_codex":0.00029811714,"about_ca_system_score_gemma":0.002227653,"threshold_uncertainty_score":0.47106987},"labels":[],"label_agreement":null},{"id":"W4255520268","doi":"10.1200/jco.2004.22.14_suppl.5043","title":"Is neoadjuvant chemotherapy a realistic alternative to primary surgery for women with advanced ovarian cancer?","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Carboplatin; Ovarian cancer; Chemotherapy; Stage (stratigraphy); Oncology; Internal medicine; Paclitaxel; Cancer; Surgery; Cisplatin","score_opus":0.10342443646081402,"score_gpt":0.46166550706924525,"score_spread":0.35824107060843124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255520268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8055684,0.00051267206,0.0030238098,0.1873137,0.0014412729,0.0008965619,0.000051404146,0.000013893157,0.0011783033],"genre_scores_gemma":[0.93329954,0.0028409977,0.021743754,0.039677773,0.0019495933,0.00019603547,0.0000037513364,0.00004141246,0.00024711533],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976055,0.00007245163,0.0014120921,0.00027092657,0.0003077225,0.0003313284],"domain_scores_gemma":[0.9959622,0.0015645371,0.0011813863,0.00019807299,0.000500516,0.0005932728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013005651,0.00017293134,0.0017667343,0.00012151332,0.000037620706,0.000009550434,0.00010677884,0.00015940511,0.00012558317],"category_scores_gemma":[0.00057010335,0.00011028655,0.00032044345,0.00015717495,0.0000870257,0.0000784745,0.000016285583,0.00032493024,0.000004841091],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041704047,0.003334652,0.022122668,0.00009020779,0.0019728139,0.0010116189,0.0009978879,0.00046351142,0.000063558335,0.00022209357,0.006963057,0.9210539],"study_design_scores_gemma":[0.04929297,0.053313326,0.66582596,0.00096190505,0.000528234,0.00034051406,0.00018921492,0.000012396613,0.0004848657,0.0029996224,0.22579582,0.0002551545],"about_ca_topic_score_codex":0.00010868209,"about_ca_topic_score_gemma":0.000069186564,"teacher_disagreement_score":0.9207987,"about_ca_system_score_codex":0.0014471109,"about_ca_system_score_gemma":0.0042901537,"threshold_uncertainty_score":0.7610549},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4255585525","doi":"10.1200/jco.2012.30.15_suppl.lba10008","title":"Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Regorafenib; Medicine; Sunitinib; GiST; Imatinib; Internal medicine; Oncology; Randomized controlled trial; Stromal tumor; Clinical trial; Stromal cell; Colorectal cancer; Cancer","score_opus":0.13901288792292557,"score_gpt":0.4586018462701245,"score_spread":0.3195889583471989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255585525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951425,0.00025562634,0.000087696506,0.00048220583,0.00012965115,0.0037183037,0.000018748533,0.000009297709,0.0001559696],"genre_scores_gemma":[0.96098804,0.0000630573,0.0382336,0.000039612034,0.00040652056,0.000093380564,0.0000175651,0.000034833178,0.00012339633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935546,0.0016554948,0.0029855915,0.0003205225,0.0007777635,0.000706047],"domain_scores_gemma":[0.99013036,0.0049493625,0.0030892685,0.00022158367,0.00055875804,0.0010506359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049332385,0.0003801943,0.0037071735,0.0003008073,0.00009974566,0.000032468768,0.000104996376,0.000060959224,0.000078870566],"category_scores_gemma":[0.0055023152,0.00018898993,0.00030968315,0.0002205242,0.0010699612,0.00027481094,0.000076683464,0.0006572316,0.0000015254368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87460387,0.020713959,0.08508722,0.00009984039,0.00053846644,0.0022231906,0.00011858643,0.0000018692576,0.000032239444,0.000010732333,0.000020841639,0.016549174],"study_design_scores_gemma":[0.6924725,0.29185045,0.008482879,0.0008264293,0.001086145,0.0047433157,0.00018675289,0.00008397222,0.00006562194,0.0000069073917,0.00009469498,0.000100346275],"about_ca_topic_score_codex":0.00007255264,"about_ca_topic_score_gemma":0.00009479978,"teacher_disagreement_score":0.2711365,"about_ca_system_score_codex":0.00035625507,"about_ca_system_score_gemma":0.0017904737,"threshold_uncertainty_score":0.7706786},"labels":[],"label_agreement":null},{"id":"W4255717822","doi":"10.1200/jco.2015.33.15_suppl.10010","title":"Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Children’s Oncology Group (COG) study AREN0532.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; Izaak Walton Killam Health Centre","funders":"","keywords":"Cog; Medicine; Wilms' tumor; Oncology; Stage (stratigraphy); Internal medicine; Histology; Wilms tumour; Pediatric oncology; Cancer","score_opus":0.09803741249725176,"score_gpt":0.41892325559040255,"score_spread":0.3208858430931508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255717822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272436,0.0029889469,0.00006180333,0.0013079334,0.0018445187,0.0004966617,0.000011026154,0.0000060570314,0.00055870856],"genre_scores_gemma":[0.99714345,0.00026342904,0.00026455263,0.001249038,0.0007248532,0.000016044667,0.000024287627,0.000022066304,0.000292305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949296,0.0012256124,0.0027403827,0.00046200267,0.00028163372,0.0003607698],"domain_scores_gemma":[0.99599934,0.0009334358,0.0020929347,0.0003439404,0.00023127158,0.000399104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038610864,0.0002481264,0.0013748019,0.00007992406,0.00006632289,0.000016322214,0.0004415192,0.00063042116,0.000025216352],"category_scores_gemma":[0.0044680256,0.00014545933,0.0002751068,0.0001251244,0.00045584497,0.00001528222,0.00022582772,0.00132093,0.0000033329054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018586138,0.001439385,0.98708534,0.0000033173433,0.000533512,0.0019537935,0.00028272683,0.00007629265,0.00030755426,0.000008681552,0.003029209,0.0034215725],"study_design_scores_gemma":[0.010381744,0.019871747,0.9050915,0.000025447565,0.00040345453,0.0013219378,0.0020019312,0.000017723325,0.00006494258,0.00018304566,0.060387507,0.00024897198],"about_ca_topic_score_codex":0.0010239354,"about_ca_topic_score_gemma":0.0020365224,"teacher_disagreement_score":0.081993796,"about_ca_system_score_codex":0.000143856,"about_ca_system_score_gemma":0.0015784133,"threshold_uncertainty_score":0.59316593},"labels":[],"label_agreement":null},{"id":"W4255815021","doi":"10.1200/jco.2011.29.7_suppl.3","title":"A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Androgen deprivation therapy; Clinical endpoint; Prostate cancer; Interim analysis; Internal medicine; Randomized controlled trial; Goserelin; Androgen suppression; Prostatectomy; Urology; Placebo; Progression-free survival; Androgen; Oncology; Cancer; Chemotherapy; Hormone","score_opus":0.15502023248022337,"score_gpt":0.4819053568972396,"score_spread":0.3268851244170162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255815021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852321,0.00084640406,0.00025109612,0.000654899,0.005070106,0.0074284775,0.0000143328425,0.000025861535,0.00047669103],"genre_scores_gemma":[0.9947279,0.00042927818,0.0016203083,0.00022635527,0.0021851684,0.00051484676,0.000060397142,0.000050456598,0.00018529585],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321896,0.001265805,0.0035395669,0.00048888905,0.00085555756,0.0006312189],"domain_scores_gemma":[0.99331254,0.0025209147,0.0023766966,0.00031191012,0.00069399766,0.00078397075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004272749,0.0004057757,0.0039965534,0.00026146704,0.00012903131,0.000050342005,0.00033265082,0.0005335282,0.00043069382],"category_scores_gemma":[0.002381425,0.00021216582,0.0014478957,0.00013152267,0.00096310716,0.00023354474,0.00014940796,0.0012533165,0.000006856948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86604226,0.018885959,0.0073650894,0.000033865283,0.0017975774,0.0005488097,0.000579798,8.150223e-8,0.000033719924,0.0000052811347,0.0014584207,0.10324916],"study_design_scores_gemma":[0.8300812,0.1609655,0.0014288943,0.00045791012,0.0010391166,0.000046522426,0.0001147488,0.00008955519,0.00042163362,0.000049147966,0.005113284,0.00019247584],"about_ca_topic_score_codex":0.000017366967,"about_ca_topic_score_gemma":0.000012795648,"teacher_disagreement_score":0.14207953,"about_ca_system_score_codex":0.00027676346,"about_ca_system_score_gemma":0.0013235587,"threshold_uncertainty_score":0.8651871},"labels":[],"label_agreement":null},{"id":"W4255905899","doi":"10.1200/jco.2013.31.4_suppl.355","title":"Impact of body mass index (BMI) and weight changes on recurrence and survival in stage III colon cancer (CC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Overweight; Body mass index; Internal medicine; Confounding; Obesity; Cancer; Proportional hazards model; Gastroenterology; Stage (stratigraphy); Weight loss; Colorectal cancer","score_opus":0.0499012742309198,"score_gpt":0.4269023279933139,"score_spread":0.3770010537623941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255905899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923785,0.0025272258,0.000023421915,0.00067007256,0.0038231222,0.00013753993,0.00001911847,0.0000010148334,0.00042002887],"genre_scores_gemma":[0.97114456,0.02370352,0.000097725315,0.00023624953,0.0045638033,0.000007861404,0.000002216518,0.000009417881,0.00023462104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838096,0.00027942486,0.0008035699,0.00019978957,0.00013683413,0.00019940322],"domain_scores_gemma":[0.99840224,0.0002602462,0.00080925354,0.00012626284,0.00020050234,0.000201493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001103877,0.00012755612,0.0007891475,0.00007981553,0.000017807226,0.000008369914,0.00012717386,0.00035951956,0.00005343066],"category_scores_gemma":[0.0005093057,0.000092262744,0.00013352951,0.00006112477,0.0002206984,0.000008339524,0.00006193651,0.00038756564,5.6184587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047226,0.0014520318,0.72366935,0.00005140188,0.0003538651,0.000004833277,0.00008551305,0.00003559648,0.059923586,0.000075957425,0.012433927,0.19719133],"study_design_scores_gemma":[0.008937724,0.0074787564,0.84773153,0.000054585667,0.00004329075,0.000013569129,0.00006139929,0.000058752677,0.0007207872,0.00010683987,0.13465571,0.00013702773],"about_ca_topic_score_codex":0.00055212807,"about_ca_topic_score_gemma":0.0013190219,"teacher_disagreement_score":0.1970543,"about_ca_system_score_codex":0.00003372646,"about_ca_system_score_gemma":0.0005658963,"threshold_uncertainty_score":0.37623656},"labels":[],"label_agreement":null},{"id":"W4255993023","doi":"10.1200/jco.2017.35.15_suppl.tps1119","title":"SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with <i>PIK3CA-</i>mutant tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Aromatase inhibitor; Internal medicine; Cancer; Estrogen receptor; Placebo; Palbociclib; PI3K/AKT/mTOR pathway; Clinical endpoint; Oncology; Breast cancer; Cancer research; Randomized controlled trial; Aromatase; Biology; Pathology; Apoptosis; Genetics","score_opus":0.05892864188827659,"score_gpt":0.4421185958734921,"score_spread":0.38318995398521555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255993023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219245,0.00011362405,0.000052110612,0.0029111234,0.00082410825,0.0034965016,0.00031267456,0.000008057302,0.00008932517],"genre_scores_gemma":[0.9967795,0.00022386553,0.0013413054,0.0007527356,0.0004890774,0.00021277629,0.000013712449,0.00005101191,0.00013599476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99510485,0.00069531635,0.0025375995,0.000490864,0.0006694217,0.00050196843],"domain_scores_gemma":[0.99177665,0.0017603699,0.0043228786,0.00044774913,0.0012205146,0.0004718178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013273597,0.00043414006,0.0027989836,0.00014536185,0.00022599469,0.000023503066,0.00045294818,0.00019406657,0.0002221354],"category_scores_gemma":[0.00078576396,0.00021854285,0.00035282096,0.000251627,0.0007284234,0.00029352456,0.00009198926,0.0009629295,0.0000015243583],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6459013,0.057720464,0.20511386,0.00017765124,0.004593698,0.0015994078,0.002603564,0.00033792987,0.0015418425,0.0000127384565,0.0013791919,0.07901833],"study_design_scores_gemma":[0.43369362,0.22724618,0.32664812,0.0010871681,0.0046386546,0.00028500834,0.002063007,0.00013046489,0.0025841217,0.000034850145,0.0011841323,0.0004046731],"about_ca_topic_score_codex":0.0009066277,"about_ca_topic_score_gemma":0.0044944193,"teacher_disagreement_score":0.2122077,"about_ca_system_score_codex":0.0006594067,"about_ca_system_score_gemma":0.004635772,"threshold_uncertainty_score":0.89119184},"labels":[],"label_agreement":null},{"id":"W4256047539","doi":"10.1200/jco.2002.20.6.1584","title":"Time Spent in Hospital in the Last Six Months of Life in Patients Who Died of Cancer in Ontario","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Palliative care; Population; Cancer registry; Hospital bed; Pediatrics; Emergency medicine; Internal medicine","score_opus":0.19403741478365336,"score_gpt":0.4834387068042103,"score_spread":0.289401292020557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256047539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943571,0.0008170016,3.1843243e-7,0.0020515753,0.00026932545,0.00019553905,0.000003471163,4.971186e-7,0.0023051666],"genre_scores_gemma":[0.9982279,0.0010099836,0.00012636748,0.00044244563,0.000106589854,0.0000028578384,9.392988e-7,0.0000056440267,0.00007725299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651945,0.00034578345,0.0025464084,0.00010663543,0.00031762,0.00016408702],"domain_scores_gemma":[0.99678725,0.0016073696,0.0012270482,0.00011372964,0.00017914308,0.0000854847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014242125,0.00009298074,0.0014906082,0.00020330289,0.0000030880851,9.956191e-7,0.00017103464,0.00021517463,0.00028263862],"category_scores_gemma":[0.0032279154,0.000060539784,0.00018129344,0.00020626615,0.00015963752,0.00006114013,0.00003604596,0.00085913617,0.0000035717076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013944384,0.0040740566,0.9820709,0.000021222217,0.000053620475,0.000109991575,0.0047696196,0.00011542016,0.000007347015,0.0000052178602,0.0009789314,0.006399225],"study_design_scores_gemma":[0.010379266,0.006974739,0.97700423,0.00090115104,0.00003372753,6.4993463e-7,0.00044720643,0.00009202143,0.0000194581,0.000032306318,0.004066461,0.00004879402],"about_ca_topic_score_codex":0.011443208,"about_ca_topic_score_gemma":0.23070833,"teacher_disagreement_score":0.21926512,"about_ca_system_score_codex":0.00030112694,"about_ca_system_score_gemma":0.00054398965,"threshold_uncertainty_score":0.99513966},"labels":[],"label_agreement":null},{"id":"W4256062533","doi":"10.1200/jco.2002.20.5.1344","title":"Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non–Small-Cell Lung Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Docetaxel; Medicine; Lung cancer; Chemotherapy; Oncology; Cancer; Clinical trial; Internal medicine; Cost effectiveness; Palliative care; Randomized controlled trial; Radiation therapy; Intensive care medicine; Nursing","score_opus":0.09072873111643139,"score_gpt":0.495878979699561,"score_spread":0.40515024858312965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256062533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983821,0.004629405,0.0000075176067,0.0019899732,0.0020012248,0.00051601033,0.00009518183,0.0000023503444,0.0069373427],"genre_scores_gemma":[0.99152255,0.005274246,0.0003433767,0.00048090273,0.0004849842,0.00001835981,0.000006689755,0.000014872503,0.0018540391],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972035,0.00018058947,0.0020759183,0.00018098178,0.00019242552,0.00016657103],"domain_scores_gemma":[0.994811,0.0010444141,0.0031881807,0.00028299415,0.0004999399,0.00017345182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004777795,0.00014245752,0.001685703,0.00016674412,0.000038298276,0.000003696631,0.00019485892,0.00021477352,0.0022871632],"category_scores_gemma":[0.00030615533,0.00008502595,0.0011641845,0.0002434047,0.00016666655,0.00007082032,0.000027198099,0.0004092214,0.0000048721904],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22853994,0.014112735,0.28061998,0.00028902784,0.06863781,0.0003136966,0.010085187,0.013114113,0.0017840957,0.00009325463,0.008980597,0.37342957],"study_design_scores_gemma":[0.5481724,0.08923743,0.21838073,0.00031815702,0.05189462,0.000033593195,0.006637331,0.0018384287,0.005318002,0.00005113817,0.077691816,0.00042631006],"about_ca_topic_score_codex":0.0002393948,"about_ca_topic_score_gemma":0.0011307858,"teacher_disagreement_score":0.37300324,"about_ca_system_score_codex":0.00038724896,"about_ca_system_score_gemma":0.0019157667,"threshold_uncertainty_score":0.99862486},"labels":[],"label_agreement":null},{"id":"W4256406415","doi":"10.1200/jco.2019.37.7_suppl.519","title":"Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sperm and Testicular Function","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cisplatin; Testicular cancer; Urology; Azoospermia; Semen; Internal medicine; Chemotherapy; Etoposide; Sperm; Gastroenterology; Andrology; Infertility; Pregnancy; Biology","score_opus":0.0820940308195153,"score_gpt":0.4151546073890008,"score_spread":0.3330605765694855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256406415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668837,0.0003870685,0.000030465437,0.00031105688,0.0005800551,0.00018936432,0.000004304638,0.0000025664474,0.0018067743],"genre_scores_gemma":[0.99722964,0.00021908827,0.0022511638,0.00008316925,0.00009426207,0.0000011422478,0.000001974172,0.000008907432,0.000110670975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700224,0.00018960095,0.0022210337,0.00012689001,0.0003297255,0.00013052949],"domain_scores_gemma":[0.9944319,0.0022315492,0.0023451156,0.0001684611,0.00071221765,0.00011074822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001515704,0.00009448519,0.0014866599,0.00014586016,0.000005534469,6.342575e-7,0.00009964978,0.00023599087,0.00026251763],"category_scores_gemma":[0.0049849893,0.000069240625,0.00030640242,0.0002656841,0.00015907089,0.00006114812,0.000025197753,0.00040376102,0.0000024257834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025257,0.0008654361,0.9514543,0.00015615662,0.00018281359,0.00007595431,0.00011021322,0.00096733286,0.028471682,0.000031637694,0.000042542466,0.015116236],"study_design_scores_gemma":[0.007814401,0.012251831,0.97247195,0.0006711458,0.00034157603,0.00007645081,0.00035418101,0.0008787842,0.0045834947,0.000058545804,0.00043479205,0.000062869396],"about_ca_topic_score_codex":0.00022755723,"about_ca_topic_score_gemma":0.00013550691,"teacher_disagreement_score":0.023888187,"about_ca_system_score_codex":0.00007330274,"about_ca_system_score_gemma":0.00073944597,"threshold_uncertainty_score":0.5967858},"labels":[],"label_agreement":null},{"id":"W4256558969","doi":"10.1200/jco.2009.27.18_suppl.cra6501","title":"Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Colonoscopy; Cancer; Population; Breast cancer; Odds ratio; Confidence interval; Mammography; Colorectal cancer; Cancer registry; Cohort; Cancer screening; Internal medicine; Obstetrics","score_opus":0.10048766199695885,"score_gpt":0.4741930810908936,"score_spread":0.37370541909393473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256558969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9166862,0.010250319,0.000049199985,0.0679873,0.00328057,0.0011410965,0.000093948365,0.000030813644,0.0004805667],"genre_scores_gemma":[0.96623033,0.008742709,0.0006889082,0.018584883,0.0055104657,0.000048881815,0.000009623518,0.00006097849,0.00012320818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9865488,0.002246086,0.007902014,0.00077948486,0.0018139251,0.0007096868],"domain_scores_gemma":[0.9852425,0.004900041,0.006863956,0.0009567196,0.0013849813,0.0006518291],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009949588,0.0005160792,0.004423379,0.0002794613,0.00012113418,0.000026082875,0.0009099391,0.0006384446,0.00057997095],"category_scores_gemma":[0.008494178,0.00035427278,0.0011139464,0.0008865283,0.00034656358,0.00031695134,0.00015809613,0.0032299194,0.0000040842374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028457746,0.008230656,0.856883,0.00002212363,0.0016380505,0.00086559367,0.0057088626,0.00027197282,0.000027779375,0.000010994341,0.0054953927,0.117999785],"study_design_scores_gemma":[0.015264228,0.0058126845,0.96221226,0.0012982781,0.001101527,0.00017657045,0.003174955,0.000037198573,0.00006753131,0.00014914435,0.0103746485,0.0003309403],"about_ca_topic_score_codex":0.08700713,"about_ca_topic_score_gemma":0.16985045,"teacher_disagreement_score":0.117668845,"about_ca_system_score_codex":0.0003432273,"about_ca_system_score_gemma":0.006004901,"threshold_uncertainty_score":0.9998909},"labels":[],"label_agreement":null},{"id":"W4256626207","doi":"10.1200/jco.2006.10.3911","title":"In Reply","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"","field":"","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.25290109785997394,"score_gpt":0.5898708259473016,"score_spread":0.3369697280873276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256626207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94777894,0.000171242,0.00019889801,0.0077617425,0.0031728044,0.00006475492,8.075386e-7,0.000009225801,0.040841613],"genre_scores_gemma":[0.97910583,0.000061021085,0.0075693345,0.010210478,0.0025923306,2.6358717e-7,1.5406835e-7,0.000026555184,0.00043400397],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99332005,0.00068154203,0.0051080794,0.00014705902,0.00039380233,0.00034946256],"domain_scores_gemma":[0.98891896,0.0070361784,0.0031075417,0.00018946231,0.00036103994,0.00038679282],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.040938612,0.00009117491,0.00119943,0.000318716,0.000014361539,0.000005148684,0.00033471195,0.00036026989,0.000341933],"category_scores_gemma":[0.021603249,0.0000693159,0.0004018438,0.00033772035,0.00021155187,0.00024562512,0.000052841995,0.0017091089,0.0009912808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014929447,0.0058230213,0.4558074,0.000008229573,0.0002114089,0.018239606,0.0002759547,0.00006245261,0.0015779143,0.0024603524,0.26143202,0.2391722],"study_design_scores_gemma":[0.003967658,0.0035355114,0.39887634,0.000015508247,0.000025612413,0.00045652775,0.00006354144,0.000010153646,0.0000862383,0.0024766242,0.59042716,0.000059129947],"about_ca_topic_score_codex":0.000023561604,"about_ca_topic_score_gemma":0.00032398867,"teacher_disagreement_score":0.32899514,"about_ca_system_score_codex":0.00028145313,"about_ca_system_score_gemma":0.0010985339,"threshold_uncertainty_score":0.99978656},"labels":[],"label_agreement":null},{"id":"W4280556356","doi":"10.1200/jco.22.00333","title":"Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Guideline; Radiosurgery; Radiation therapy; Medical physics; Oncology; Internal medicine; Pathology","score_opus":0.1380771390592393,"score_gpt":0.5074947924660246,"score_spread":0.3694176534067853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280556356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45187637,0.0072008404,0.16596225,0.35828483,0.007466295,0.0053011216,0.00057091645,0.000050985236,0.0032863966],"genre_scores_gemma":[0.4930128,0.0013967454,0.39858449,0.100918256,0.0033441994,0.00015997307,0.0004764305,0.00009729883,0.0020098311],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916395,0.0011106504,0.0058886893,0.00022039414,0.0009027491,0.0002380399],"domain_scores_gemma":[0.99168134,0.0025212076,0.0043378132,0.0003166667,0.00082367595,0.00031927158],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.021357572,0.00015745021,0.001626561,0.00028118718,0.000059474838,0.0000050140184,0.00027787563,0.00007441202,0.0026151147],"category_scores_gemma":[0.009769774,0.00012295073,0.0009480075,0.00019463229,0.000091246904,0.00008408477,0.00010948479,0.00048029918,0.000002832288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011428227,0.0044078175,0.0020636825,0.000048974503,0.0012519753,0.00014061452,0.00005279827,0.0006455905,0.00043767632,0.0005108511,0.5631313,0.41588053],"study_design_scores_gemma":[0.028179364,0.026620386,0.0038854557,0.00001686319,0.000867182,0.00005363839,0.0005145128,0.0018552309,0.00012819596,0.00071468274,0.93707377,0.00009074652],"about_ca_topic_score_codex":0.000012449673,"about_ca_topic_score_gemma":0.0000025737822,"teacher_disagreement_score":0.41578978,"about_ca_system_score_codex":0.0001606448,"about_ca_system_score_gemma":0.0015988891,"threshold_uncertainty_score":0.99857134},"labels":[],"label_agreement":null},{"id":"W4280568048","doi":"10.1200/jco.22.00098","title":"Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Circulating tumor DNA; Liquid biopsy; Wilms' tumor; Urine; Internal medicine; Biomarker; Oncology; Stage (stratigraphy); Cancer; Biology; Genetics","score_opus":0.027978876282252946,"score_gpt":0.352040121269975,"score_spread":0.3240612449877221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280568048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794614,0.00043328112,0.00008591173,0.00030006212,0.00052989385,0.00033123916,0.00011202075,0.0000026651644,0.00025877682],"genre_scores_gemma":[0.99645895,0.0001444152,0.00084463874,0.0020029217,0.00035222867,0.000020482748,0.00013270538,0.000022255454,0.000021385893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996485,0.000702185,0.0017960367,0.00043558716,0.00029671966,0.0002844677],"domain_scores_gemma":[0.9964789,0.0008028208,0.0020429234,0.00027034193,0.00014659199,0.00025842624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019628655,0.00019169452,0.0012468309,0.00021695248,0.00010219337,0.000021518294,0.0002820573,0.00018843978,0.00014812309],"category_scores_gemma":[0.0012772292,0.00016336574,0.00036617042,0.00031295937,0.000175976,0.000009326779,0.00033478555,0.00062262296,0.0000010034463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08181662,0.003805878,0.8881632,0.0000053596937,0.0026191752,0.0006197581,0.00012633837,0.0007261763,0.0010662542,0.00003463074,0.0010140868,0.020002492],"study_design_scores_gemma":[0.077081606,0.030288419,0.8684322,0.000011033831,0.00082197145,0.00006026996,0.00028150465,0.0002199275,0.000027172031,0.00012301422,0.02237137,0.00028147904],"about_ca_topic_score_codex":0.00047703774,"about_ca_topic_score_gemma":0.00094784336,"teacher_disagreement_score":0.02648254,"about_ca_system_score_codex":0.00016568293,"about_ca_system_score_gemma":0.0011596011,"threshold_uncertainty_score":0.66618615},"labels":[],"label_agreement":null},{"id":"W4281289792","doi":"10.1200/jco.21.02278","title":"Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Post-hoc analysis; Internal medicine; Lung cancer; Adverse effect; Incidence (geometry); ALK inhibitor; Oncology","score_opus":0.020435421609981828,"score_gpt":0.43041616336475214,"score_spread":0.4099807417547703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281289792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965951,0.00038612165,0.00005334223,0.001312988,0.00029101997,0.0009184119,0.0002395309,0.0000023001871,0.00020122717],"genre_scores_gemma":[0.9981493,0.0001317649,0.00048125378,0.0009838106,0.00013446707,0.00002342943,0.000047211557,0.000011591528,0.000037215174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973621,0.00042060117,0.0015082068,0.0002132796,0.0003492219,0.00014663723],"domain_scores_gemma":[0.9958157,0.0020451127,0.001443524,0.00016340008,0.0003892374,0.0001430465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081843184,0.00012773964,0.0012782486,0.00014259813,0.00010740573,0.000005815101,0.0001229895,0.000065669316,0.00022479979],"category_scores_gemma":[0.00020180413,0.00007428055,0.00019346748,0.00045893792,0.00010930699,0.00006722573,0.00007255801,0.0006591969,1.6972625e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081173666,0.015240496,0.8005244,0.000005377357,0.005685895,0.0002199675,0.0046983995,0.0014819946,0.000037042864,0.0000014300037,0.000057165453,0.09087416],"study_design_scores_gemma":[0.10060565,0.032346934,0.85381156,0.00003553384,0.0106914835,0.0000029072248,0.001752552,0.00027842107,0.0000036596264,0.0000018238663,0.00040408634,0.00006537609],"about_ca_topic_score_codex":0.00051761395,"about_ca_topic_score_gemma":0.0010811137,"teacher_disagreement_score":0.09080878,"about_ca_system_score_codex":0.00026983832,"about_ca_system_score_gemma":0.0011165865,"threshold_uncertainty_score":0.3029073},"labels":[],"label_agreement":null},{"id":"W4281606747","doi":"10.1200/jco.2022.40.16_suppl.10046","title":"Outcomes of patients with unilateral retinoblastoma: A report from the RIVERBOAT Consortium.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Enucleation; Retinoblastoma; Visual acuity; Pediatrics; Chemotherapy; Surgery","score_opus":0.053131780074060664,"score_gpt":0.4062313964540985,"score_spread":0.35309961638003784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281606747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912683,0.0000691329,0.000011513578,0.006336708,0.0009474404,0.00021162261,0.000020424892,0.000004836631,0.0011300716],"genre_scores_gemma":[0.99594355,0.000016335469,0.0012685551,0.0022140068,0.00014677487,0.0000046003734,0.000018155275,0.000010569167,0.00037743646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967722,0.00070398883,0.0017579647,0.00015273517,0.00047119483,0.00014187091],"domain_scores_gemma":[0.9941196,0.0024528562,0.0026599367,0.00026544364,0.0003614228,0.00014075973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001608665,0.000108656975,0.0012526049,0.000045317745,0.00008675766,0.0000018328334,0.00016829571,0.00014365884,0.0004322723],"category_scores_gemma":[0.0015816509,0.000054404514,0.0003758008,0.000100647616,0.00036077856,0.000046594272,0.00011187813,0.00092601916,0.0000046122486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071047954,0.0031324294,0.9783694,0.0000024361557,0.0014531056,0.003822829,0.000106378204,0.000008278549,0.0000031225604,0.000023977822,0.0020727634,0.0039004774],"study_design_scores_gemma":[0.013023054,0.0144239,0.9323796,0.000013559123,0.00091261254,0.00035700577,0.00010135492,0.0000032189191,0.00001062086,0.00018893978,0.03853986,0.000046275785],"about_ca_topic_score_codex":0.000033940916,"about_ca_topic_score_gemma":0.00002149082,"teacher_disagreement_score":0.04598981,"about_ca_system_score_codex":0.00012320747,"about_ca_system_score_gemma":0.0010738076,"threshold_uncertainty_score":0.47330785},"labels":[],"label_agreement":null},{"id":"W4281609415","doi":"10.1200/jco.2022.40.16_suppl.tps4619","title":"CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Jewish General Hospital; University of British Columbia; McGill University; Princess Margaret Cancer Centre; Ottawa Hospital; Queen's University; Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Durvalumab; Bladder cancer; Cystectomy; Oncology; Radiation therapy; Internal medicine; Clinical endpoint; Cancer; Immunotherapy; Population; Chemotherapy; Urology; Randomized controlled trial; Nivolumab","score_opus":0.13287692024443595,"score_gpt":0.4888937680684552,"score_spread":0.3560168478240192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281609415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949754,0.000342172,0.00025304809,0.004100014,0.001408394,0.0034762712,0.00006345068,0.000026419,0.0008326969],"genre_scores_gemma":[0.9901638,0.00041369526,0.0014069102,0.005255571,0.0014616254,0.00045453478,0.000017092389,0.0000721836,0.0007545884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992779,0.0022824558,0.002647248,0.00052668614,0.0012854604,0.0004791068],"domain_scores_gemma":[0.9927591,0.0026499147,0.0025857445,0.0003883631,0.00086812174,0.00074871915],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033807897,0.0004205511,0.00453548,0.00021938216,0.00035063594,0.00003275311,0.00027069112,0.00022020735,0.0018083097],"category_scores_gemma":[0.0014754932,0.00020955272,0.0007426921,0.00041048773,0.00033847004,0.00023347465,0.00009926676,0.0010264915,0.000003327691],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.860185,0.018776547,0.011399114,0.000014730065,0.0021477176,0.0005697411,0.00076848926,0.000042514872,0.000048838112,0.0000034616796,0.0010579077,0.10498589],"study_design_scores_gemma":[0.7914919,0.18595694,0.011848221,0.00011246841,0.0027497832,0.00010888072,0.00034154416,0.000024078981,0.00007882614,0.000030215544,0.0070265434,0.000230591],"about_ca_topic_score_codex":0.0003268857,"about_ca_topic_score_gemma":0.00018574909,"teacher_disagreement_score":0.16718039,"about_ca_system_score_codex":0.0006796344,"about_ca_system_score_gemma":0.010979846,"threshold_uncertainty_score":0.9991042},"labels":[],"label_agreement":null},{"id":"W4281612751","doi":"10.1200/jco.2022.40.16_suppl.tps613","title":"NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Tamoxifen; Breast-conserving surgery; Internal medicine; Oncology; Stage (stratigraphy); Radiation therapy; Gynecology; Cancer; Mastectomy","score_opus":0.09260431923673264,"score_gpt":0.45677732244228775,"score_spread":0.3641730032055551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281612751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928235,0.0018957014,0.00024162003,0.0023897146,0.0018835075,0.00031718294,0.0003460158,0.0000070382994,0.000095726326],"genre_scores_gemma":[0.9966108,0.0008275911,0.0006061892,0.00024940958,0.0015079498,0.00004755613,0.00006788141,0.000034355544,0.000048270544],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941193,0.0016141839,0.0029277753,0.00035458783,0.00062951166,0.00035465576],"domain_scores_gemma":[0.99341655,0.0013324007,0.0042818836,0.00027216392,0.0005013329,0.00019564628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065516136,0.00023613861,0.0015300122,0.00016555525,0.00017483193,0.000009894407,0.0002886493,0.0002893754,0.00024476222],"category_scores_gemma":[0.001045534,0.00022731,0.001036052,0.00028421645,0.00016838376,0.000032624263,0.00022442214,0.00048850576,5.9917716e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2523782,0.004788924,0.11181668,0.000069560505,0.0031389792,0.000058536407,0.00035291357,0.0015655477,0.053163897,0.000014427714,0.00509739,0.56755495],"study_design_scores_gemma":[0.28500625,0.024523089,0.67189616,0.0003415852,0.0025775095,0.0016021569,0.002254836,0.0016056298,0.0039194147,0.00017276104,0.005192375,0.0009081991],"about_ca_topic_score_codex":0.0005103191,"about_ca_topic_score_gemma":0.0000712424,"teacher_disagreement_score":0.56664675,"about_ca_system_score_codex":0.0003749221,"about_ca_system_score_gemma":0.0030025411,"threshold_uncertainty_score":0.9269433},"labels":[],"label_agreement":null},{"id":"W4281617921","doi":"10.1200/jco.2022.40.16_suppl.9050","title":"Association between lung immune prognostic index, microbiome, and immunotherapy outcomes in non–small cell lung cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Microbiome; Cohort; Lung cancer; Internal medicine; Oncology; Immune system; Gastroenterology; Immunology; Bioinformatics; Biology","score_opus":0.03183581438549636,"score_gpt":0.39634298698970416,"score_spread":0.3645071726042078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281617921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882421,0.0037279634,0.000028647244,0.0058190003,0.0012186967,0.000663342,0.000022484532,0.000011234688,0.00026655392],"genre_scores_gemma":[0.99632293,0.00079640443,0.00081424264,0.0011778881,0.00038713365,0.00006191314,0.0000072361854,0.000030449948,0.00040183027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99548435,0.00083451235,0.0026997437,0.00022747042,0.00041161274,0.0003422907],"domain_scores_gemma":[0.99376464,0.002872263,0.0027292967,0.00016795559,0.0002537749,0.00021208273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058019217,0.00018051756,0.0016137689,0.00032734068,0.000103368424,0.00001543732,0.00024302448,0.0003487782,0.00023791661],"category_scores_gemma":[0.0013446193,0.00015548391,0.00043477336,0.0002784966,0.000092074464,0.00008935296,0.0001747081,0.0014924277,0.0000015661607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017373293,0.0010338873,0.97712433,0.00011362157,0.0012934561,0.00029725523,0.00019823445,0.000010206514,0.00096165657,0.0000010818292,0.001564296,0.015664643],"study_design_scores_gemma":[0.0119705,0.0017770594,0.98009056,0.000094897296,0.00083751185,0.00003311202,0.00013167146,0.00019111954,0.000109952256,0.000028219623,0.004592829,0.0001425694],"about_ca_topic_score_codex":0.000052845717,"about_ca_topic_score_gemma":0.000019927216,"teacher_disagreement_score":0.015522074,"about_ca_system_score_codex":0.0012072603,"about_ca_system_score_gemma":0.0014900151,"threshold_uncertainty_score":0.64839387},"labels":[],"label_agreement":null},{"id":"W4281618634","doi":"10.1200/jco.2022.40.16_suppl.2544","title":"Changes in circulating tumor DNA (ctDNA) and outcomes in solid tumors treated with immune checkpoint inhibitors (ICIs).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Circulating tumor DNA; Meta-analysis; Confidence interval; Cancer","score_opus":0.03674630669360051,"score_gpt":0.3619730845285262,"score_spread":0.3252267778349257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281618634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709696,0.0005418197,0.000005692357,0.0016981156,0.0002741619,0.0001524935,0.000008464041,0.0000017465346,0.00022056577],"genre_scores_gemma":[0.9983461,0.0003045138,0.00024665557,0.0007662687,0.0002573146,0.000020318226,0.0000068219433,0.00001793057,0.000034080065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976773,0.00024573822,0.001484865,0.00021855389,0.0001504964,0.00022302105],"domain_scores_gemma":[0.9982427,0.00033837187,0.0010984149,0.0001334474,0.00007294631,0.000114151284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019817965,0.00013212147,0.0008291357,0.00013529562,0.000043235366,0.00000970294,0.00015085888,0.00011292214,0.00001841921],"category_scores_gemma":[0.0011272961,0.000107742424,0.00014985747,0.00012466765,0.000110520916,0.0000044357053,0.00020177387,0.00052495045,2.8972823e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019239646,0.0010030762,0.9396162,0.000017851075,0.00013299542,0.0011552211,0.00014535298,0.0016076892,0.033487327,0.000024349656,0.00012054509,0.02076542],"study_design_scores_gemma":[0.008476744,0.012252015,0.9605923,0.000051798754,0.000057403024,0.00055150257,0.0008700943,0.00017369936,0.009324009,0.00013894097,0.007232463,0.00027897963],"about_ca_topic_score_codex":0.000116088355,"about_ca_topic_score_gemma":0.0014220878,"teacher_disagreement_score":0.024163317,"about_ca_system_score_codex":0.00010460096,"about_ca_system_score_gemma":0.00048730677,"threshold_uncertainty_score":0.43936086},"labels":[],"label_agreement":null},{"id":"W4281619183","doi":"10.1200/jco.2022.40.16_suppl.e12609","title":"The impact of neoadjuvant treatment (NAT) on surgery in early breast cancer (EBC): A real-world data study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Lumpectomy; Breast cancer; Axillary Lymph Node Dissection; Axilla; Neoadjuvant therapy; Sentinel node; Surgery; Mastectomy; Stage (stratigraphy); Nat; Lymph node; Breast surgery; Breast-conserving surgery; Cancer; Internal medicine; Sentinel lymph node","score_opus":0.1666210635944763,"score_gpt":0.5038565515588903,"score_spread":0.33723548796441405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281619183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479073,0.00076325185,6.0380125e-7,0.0030723207,0.00067646126,0.00021142617,0.00025802938,0.0000019356366,0.00022525962],"genre_scores_gemma":[0.9947084,0.0043598595,0.000017674669,0.000120858655,0.0006117409,0.000038796046,0.000015360809,0.000017225504,0.000110050285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965286,0.001050553,0.0015507089,0.0003101387,0.0002914898,0.0002684799],"domain_scores_gemma":[0.99591917,0.0015970661,0.001622226,0.0005987354,0.00014728967,0.00011552981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026533382,0.00018221227,0.0010806825,0.00010982737,0.0001176028,0.000007902228,0.00051072455,0.00006619011,0.00003263879],"category_scores_gemma":[0.00031319924,0.00010309842,0.0004682963,0.00021518428,0.00020408725,0.000007372325,0.00032142556,0.00037210854,0.0000010066282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010103953,0.0043892404,0.8516252,0.000001378766,0.00142781,0.00016488491,0.00009753085,0.00036980706,0.000068143716,0.0000043076343,0.005534168,0.12621358],"study_design_scores_gemma":[0.0035943543,0.013050273,0.97555757,0.000013892855,0.00013924766,0.000060169852,0.000298439,0.000010913593,0.000026897284,0.000020734236,0.0071376436,0.00008985357],"about_ca_topic_score_codex":0.0078115626,"about_ca_topic_score_gemma":0.016083773,"teacher_disagreement_score":0.12612373,"about_ca_system_score_codex":0.00048471816,"about_ca_system_score_gemma":0.0021091083,"threshold_uncertainty_score":0.9987955},"labels":[],"label_agreement":null},{"id":"W4281619960","doi":"10.1200/jco.2022.40.16_suppl.e22024","title":"Symptom profiles and health care utilization in long-term survivors of Survivors of Childhood Childhood Cancer Survivor (CCSS) study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"National Institutes of Health","keywords":"Medicine; Anxiety; Physical therapy; Depression (economics); Pediatrics; Psychiatry","score_opus":0.1178276235732063,"score_gpt":0.4762185865883002,"score_spread":0.3583909630150939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281619960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816815,0.008879428,0.00002794627,0.0055147996,0.002054672,0.0015247054,0.00011594871,0.000019327523,0.00018162055],"genre_scores_gemma":[0.9949132,0.0026834453,0.00025184246,0.0013767737,0.00060673733,0.00003873247,0.000035594567,0.00006263461,0.000031037573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98724854,0.0036845154,0.0064569563,0.0005808119,0.0015237159,0.00050543994],"domain_scores_gemma":[0.9902165,0.002066144,0.0059286635,0.0005241453,0.00074353075,0.0005210432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011567218,0.00036706653,0.0040025827,0.00065025676,0.00013338124,0.000009664101,0.0004913872,0.00030357204,0.00027171377],"category_scores_gemma":[0.0018330518,0.00032938767,0.0005591105,0.0008718787,0.0003529134,0.00018016036,0.00037284772,0.0018032198,8.116474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015946421,0.009623633,0.9253602,0.00051120535,0.0006226533,0.000082365346,0.016927732,0.00011774176,0.000009671574,0.000042636835,0.00020030253,0.04490719],"study_design_scores_gemma":[0.011797367,0.02067683,0.95297635,0.00047423298,0.0003057122,0.00011541004,0.01284117,0.000011479823,0.000054008142,0.00004116223,0.0004805338,0.0002257268],"about_ca_topic_score_codex":0.0083871065,"about_ca_topic_score_gemma":0.046148248,"teacher_disagreement_score":0.044681463,"about_ca_system_score_codex":0.0005031414,"about_ca_system_score_gemma":0.006005171,"threshold_uncertainty_score":0.99991584},"labels":[],"label_agreement":null},{"id":"W4281620370","doi":"10.1200/jco.2022.40.16_suppl.9053","title":"Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Lung cancer; Internal medicine; Performance status; Nivolumab; Cancer; Cohort; Log-rank test; Medical record; Oncology; Retrospective cohort study; Survival analysis; Immunotherapy","score_opus":0.049555050929143744,"score_gpt":0.4229738043697134,"score_spread":0.37341875344056963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281620370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975505,0.0012340582,0.00000491099,0.00036580887,0.0002519754,0.00044592275,0.000020812888,0.0000033220697,0.00012268807],"genre_scores_gemma":[0.9981172,0.0013857182,0.0001626459,0.00022511295,0.00004103119,0.000009636889,0.000017121063,0.000017414986,0.000024094697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763805,0.00020920957,0.0014521747,0.00015292427,0.00032669998,0.0002209231],"domain_scores_gemma":[0.99752516,0.00018066517,0.0017664686,0.000121529585,0.00026285075,0.00014333152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093034125,0.00014156374,0.0011515556,0.00015874917,0.000051177434,0.0000029040257,0.00006166191,0.000077504745,0.000054430384],"category_scores_gemma":[0.00004660306,0.00008290349,0.00017136653,0.00024201372,0.00008931415,0.00006506258,0.00002563524,0.00056420773,5.9588285e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056176107,0.0012057727,0.87309885,0.000088248504,0.00022711573,0.000013136935,0.00055753684,0.00055204245,0.000048067242,1.6992048e-7,0.000020590416,0.06801237],"study_design_scores_gemma":[0.033071537,0.072608545,0.8930816,0.0002004966,0.00007960821,0.0000048295265,0.000412918,0.000060677172,0.000112528614,1.2934083e-7,0.0002909297,0.00007618643],"about_ca_topic_score_codex":0.0006394828,"about_ca_topic_score_gemma":0.00030970146,"teacher_disagreement_score":0.071402766,"about_ca_system_score_codex":0.0010060583,"about_ca_system_score_gemma":0.0025223047,"threshold_uncertainty_score":0.44744602},"labels":[],"label_agreement":null},{"id":"W4281624214","doi":"10.1200/jco.2022.40.16_suppl.5044","title":"Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Tolerability; Population; Androgen deprivation therapy; Post-hoc analysis; Prostate-specific antigen; Oncology; Urology; Tumor progression; Gastroenterology; Cancer; Adverse effect","score_opus":0.18639553091805627,"score_gpt":0.5445654624035217,"score_spread":0.3581699314854654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281624214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846969,0.011523525,0.000032931322,0.0025833438,0.00045005837,0.00044091835,0.000109179804,0.00000586825,0.00015722736],"genre_scores_gemma":[0.9832232,0.014850338,0.0012360421,0.00026008458,0.00018534895,0.000008915661,0.00003769863,0.000020508774,0.00017785245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99452984,0.0011389945,0.0030481026,0.0002638151,0.00075745676,0.00026176617],"domain_scores_gemma":[0.9941035,0.0023449657,0.0023309374,0.00022782003,0.0006406183,0.0003521898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041567828,0.00015670847,0.0019277092,0.0002097458,0.00006154731,0.0000071819513,0.00020695874,0.00015021648,0.00035445538],"category_scores_gemma":[0.0009823437,0.00009834813,0.0005227308,0.00023148973,0.00057057245,0.00008930539,0.00018282891,0.00098845,0.0000020445777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030231576,0.006641241,0.6052542,0.00020999726,0.002349772,0.000758314,0.0002471019,0.000010824694,0.005031055,0.000017615937,0.0040976154,0.3451507],"study_design_scores_gemma":[0.031098206,0.19951776,0.7116613,0.0005189219,0.002058723,0.00046267486,0.0016225668,0.00020550635,0.005146865,0.00029356618,0.04713925,0.00027470585],"about_ca_topic_score_codex":0.000032274755,"about_ca_topic_score_gemma":0.0000058841433,"teacher_disagreement_score":0.344876,"about_ca_system_score_codex":0.00009313761,"about_ca_system_score_gemma":0.0012403098,"threshold_uncertainty_score":0.42943782},"labels":[],"label_agreement":null},{"id":"W4281624382","doi":"10.1200/jco.2022.40.16_suppl.10024","title":"Menin inhibitors as targeted therapeutics in KMT2a rearranged infant leukemia and the identification of effective treatment combinations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Cancer research; Leukemia; Medicine; Fusion protein; Stromal cell; Context (archaeology); Immunology; Biology; Genetics","score_opus":0.051368950017821505,"score_gpt":0.4365728713667565,"score_spread":0.385203921348935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281624382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878469,0.00066921243,0.00003875487,0.009683812,0.00042104835,0.00073947164,0.0000049066684,0.0000038750113,0.0005919979],"genre_scores_gemma":[0.99798,0.0008723046,0.00015539005,0.00057939184,0.00014200035,0.000057822977,0.00000461556,0.0000112975085,0.00019716474],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949886,0.0020884192,0.002080821,0.00014599881,0.0005456555,0.00015046076],"domain_scores_gemma":[0.990727,0.0071638725,0.0014967244,0.00017909291,0.00032389731,0.000109413966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007577093,0.00009797053,0.00097015064,0.00022332331,0.00007859953,0.000006294027,0.00014273614,0.00014912295,0.000043571654],"category_scores_gemma":[0.0034772793,0.00005768656,0.00022417419,0.00032030026,0.0005024723,0.000052811294,0.000089506175,0.00083799276,0.0000025383315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117205314,0.012849658,0.11834929,0.00013489246,0.004713551,0.001542184,0.0153542,0.000968631,0.037182994,0.0054665166,0.0045432453,0.6816895],"study_design_scores_gemma":[0.23062155,0.06558278,0.6207986,0.00014690607,0.0017584581,0.0015881966,0.004604715,0.0136467535,0.011201011,0.007424546,0.04236643,0.00026005684],"about_ca_topic_score_codex":0.00023029334,"about_ca_topic_score_gemma":0.000031930787,"teacher_disagreement_score":0.68142945,"about_ca_system_score_codex":0.002056215,"about_ca_system_score_gemma":0.003197303,"threshold_uncertainty_score":0.56718785},"labels":[],"label_agreement":null},{"id":"W4281624688","doi":"10.1200/jco.2022.40.17_suppl.lba501","title":"LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T<sub>1</sub>N<sub>0</sub> luminal A breast cancer (BC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; University of Manitoba; Sunnybrook Health Science Centre; University of British Columbia; Centre Hospitalier Universitaire de Sherbrooke; Hôtel-Dieu de Québec; BC Cancer Agency; Northeast Cancer Centre; Royal Victoria Regional Health Centre; Health Sciences North; McMaster University; Toronto General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; Health Sciences Centre; Ottawa Regional Cancer Foundation; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Breast cancer; Breast-conserving surgery; Internal medicine; Radiation therapy; Oncology; Clinical trial; Prospective cohort study; Cohort; Cancer; Adjuvant; Gynecology; Mastectomy","score_opus":0.03668903536459546,"score_gpt":0.3709281839441821,"score_spread":0.33423914857958664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281624688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987437,0.002657467,0.000047817997,0.004919991,0.0042013833,0.0005377006,0.00009854963,0.000015482708,0.00008458781],"genre_scores_gemma":[0.99110484,0.0021439663,0.0001983523,0.001264649,0.0049571916,0.000227925,0.000017573391,0.00007409001,0.0000114102895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371475,0.0015178953,0.0027208521,0.0007304239,0.00058367715,0.00073238136],"domain_scores_gemma":[0.9950898,0.0015686443,0.002366969,0.00033555628,0.0003374063,0.00030162436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045363465,0.00044388158,0.0021359143,0.00025564036,0.00032777738,0.00003318213,0.0004256827,0.00043058803,0.000033053508],"category_scores_gemma":[0.0009598966,0.00041001165,0.0014210164,0.00041528294,0.00033080662,0.00003715001,0.000385566,0.0012954591,0.0000034777715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11522199,0.0039240373,0.6052211,0.00005106483,0.003423777,0.001757384,0.00042878528,0.0002427589,0.08663527,0.000010152641,0.0066762487,0.17640744],"study_design_scores_gemma":[0.089107476,0.006259923,0.8775401,0.0003019725,0.00078589964,0.0045532207,0.0011667492,0.00008153437,0.014162432,0.00014159417,0.0049686595,0.0009304085],"about_ca_topic_score_codex":0.00021761391,"about_ca_topic_score_gemma":0.0007796115,"teacher_disagreement_score":0.27231905,"about_ca_system_score_codex":0.00096716115,"about_ca_system_score_gemma":0.003519917,"threshold_uncertainty_score":0.9998352},"labels":[],"label_agreement":null},{"id":"W4281625396","doi":"10.1200/jco.2022.40.16_suppl.3526","title":"Estimating the impact of reducing the age of colorectal cancer screening on cancer incidence, mortality, and costs in Canada using OncoSim.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; St. Paul's Hospital; Providence Health Care; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Incidence (geometry); Colorectal cancer; Demography; Cancer; Population; Family history; Colonoscopy; Cancer registry; Cancer screening; Gerontology; Environmental health; Internal medicine","score_opus":0.17405705505961913,"score_gpt":0.5007111635938708,"score_spread":0.3266541085342517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281625396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716103,0.0007132062,0.0000605834,0.00078834366,0.00085482287,0.00021248554,0.000014529722,0.0000020687723,0.0001929436],"genre_scores_gemma":[0.9986417,0.000086136046,0.0005728854,0.00031953643,0.00035256054,0.000011510597,5.6898057e-7,0.000010707032,0.0000043740774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695104,0.0006602823,0.0015117634,0.00014600782,0.00054322835,0.00018769142],"domain_scores_gemma":[0.99498755,0.0026591052,0.0019231597,0.00012509739,0.00020453134,0.00010053979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037125426,0.00011028587,0.00092738244,0.00010308473,0.00012804665,0.0000052071628,0.00017151645,0.00007364444,0.00006072599],"category_scores_gemma":[0.0017544709,0.000062841784,0.00022365678,0.00039060554,0.00019159527,0.0000518921,0.00013005502,0.0013237395,1.5663113e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071725836,0.000100798185,0.6325723,0.000016921982,0.0002774339,0.00014832108,0.00031510164,0.28693807,0.0010155567,0.0000020061586,0.00022390216,0.071217],"study_design_scores_gemma":[0.0018809794,0.008137002,0.8832492,0.00037875443,0.00020500614,0.0002514819,0.0005469031,0.104963236,0.00024750907,0.00002015454,0.00005640875,0.00006332223],"about_ca_topic_score_codex":0.91088164,"about_ca_topic_score_gemma":0.6335243,"teacher_disagreement_score":0.2773573,"about_ca_system_score_codex":0.0024689906,"about_ca_system_score_gemma":0.010071451,"threshold_uncertainty_score":0.9955405},"labels":[],"label_agreement":null},{"id":"W4281626159","doi":"10.1200/jco.2022.40.16_suppl.10013","title":"Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Neuroblastoma; Internal medicine; Cog; Gastroenterology; Pediatrics; Oncology","score_opus":0.08744880365876577,"score_gpt":0.41035306148612505,"score_spread":0.32290425782735926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281626159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949475,0.00007458773,0.0000059664885,0.0027016252,0.0007463245,0.0013386488,0.00009500838,0.0000034115621,0.00008694449],"genre_scores_gemma":[0.9986011,0.00013102409,0.00039562807,0.00035263624,0.00031865397,0.00014875778,0.000020574145,0.000020673622,0.000010989703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575835,0.0015569796,0.0015154617,0.0002803859,0.0006299898,0.00025880535],"domain_scores_gemma":[0.99718815,0.0009877298,0.001060556,0.00030048165,0.0002040251,0.00025906568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014080432,0.00014802873,0.0010279238,0.00032716393,0.00003932479,0.000004155907,0.00026171893,0.00012910312,0.0001874091],"category_scores_gemma":[0.0007134407,0.00009460869,0.00018176917,0.00040462066,0.0001433011,0.00009119758,0.0001149839,0.0010701068,0.0000037662803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11287223,0.007717142,0.7062729,0.00000439604,0.00035898993,0.0005034965,0.0010952526,0.000120167366,0.000097198936,0.0000068832046,0.00018458783,0.17076673],"study_design_scores_gemma":[0.016300911,0.087405324,0.8942866,0.000025912497,0.000084413674,0.00002403614,0.00014976136,0.000014071219,0.000044765195,0.0000401445,0.0015697164,0.00005434616],"about_ca_topic_score_codex":0.0008317468,"about_ca_topic_score_gemma":0.007149999,"teacher_disagreement_score":0.18801367,"about_ca_system_score_codex":0.00027053012,"about_ca_system_score_gemma":0.00044427914,"threshold_uncertainty_score":0.46491408},"labels":[],"label_agreement":null},{"id":"W4281626706","doi":"10.1200/jco.2022.40.16_suppl.12018","title":"Psychological mobile app for patients with acute myeloid leukemia (AML): A randomized clinical trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Palliative Care Research Center","keywords":"Medicine; Randomized controlled trial; Hospital Anxiety and Depression Scale; Quality of life (healthcare); Psychoeducation; Psychosocial; Anxiety; Patient Health Questionnaire; Physical therapy; Mood; Internal medicine; Psychological intervention; Psychiatry; Nursing","score_opus":0.09262218604236101,"score_gpt":0.4804174345971489,"score_spread":0.3877952485547879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281626706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98271865,0.00027886365,0.0010823961,0.002295117,0.008896411,0.0027390888,0.000035770856,0.000026749147,0.0019269711],"genre_scores_gemma":[0.98292786,0.00062073104,0.0031708013,0.008265603,0.0033429684,0.0005715317,0.00003649565,0.00004159047,0.0010224009],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99087834,0.0028328982,0.0047171353,0.00042420343,0.0007849404,0.00036249572],"domain_scores_gemma":[0.98241746,0.012636153,0.003269423,0.00036070598,0.00073578634,0.000580494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016855981,0.0002222738,0.0041684886,0.0001298696,0.0001263921,0.00001255919,0.00037046455,0.00046596894,0.00071520463],"category_scores_gemma":[0.0059850174,0.00013463275,0.0023235516,0.00022442412,0.0005066297,0.000075453274,0.00012630071,0.0022575364,0.000009666312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8566517,0.0051233727,0.005656932,0.000012246283,0.0010910246,0.00024529273,0.00008282077,0.000012067204,0.0000012659194,0.00006525501,0.01611732,0.11494069],"study_design_scores_gemma":[0.6497526,0.098202415,0.0043115253,0.00001830121,0.0013940076,0.00014474543,0.0001404728,0.000033352866,8.289721e-7,0.00032089435,0.24555652,0.00012429948],"about_ca_topic_score_codex":0.000013204611,"about_ca_topic_score_gemma":0.000020945763,"teacher_disagreement_score":0.2294392,"about_ca_system_score_codex":0.00035800197,"about_ca_system_score_gemma":0.0022298635,"threshold_uncertainty_score":0.98079973},"labels":[],"label_agreement":null},{"id":"W4281627747","doi":"10.1200/jco.2022.40.16_suppl.7516","title":"Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Internal medicine; Neutropenia; Cohort; Oncology; Cancer; Toxicity; Gastroenterology; Immunotherapy","score_opus":0.13589889030561272,"score_gpt":0.470248609626649,"score_spread":0.3343497193210363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281627747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937603,0.0001491179,0.0000057345915,0.0022772918,0.0012430247,0.0016593008,0.000042618813,0.000021456131,0.00084115454],"genre_scores_gemma":[0.99551827,0.00015627491,0.0009738628,0.0024541873,0.000419886,0.00010300058,0.000045243654,0.00006632391,0.0002629595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99172866,0.0021659178,0.0034904985,0.00070841215,0.0013219756,0.0005845576],"domain_scores_gemma":[0.9932142,0.002143671,0.0026376292,0.0006491945,0.00053435354,0.00082097994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031619642,0.00041460607,0.0033254984,0.00038214884,0.00023830424,0.00005297895,0.0007647435,0.00035710237,0.00053531775],"category_scores_gemma":[0.0015925455,0.00026234673,0.00024947803,0.00053400616,0.00026873723,0.00045992684,0.0005554631,0.0012629033,0.000021759406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13519944,0.23970008,0.4618699,0.000015907828,0.0009297924,0.013957777,0.0005149735,0.000026664926,0.000013832951,0.000041176092,0.003541926,0.14418852],"study_design_scores_gemma":[0.26342598,0.20423476,0.5174322,0.00006263401,0.00057236716,0.00033677224,0.00063697627,0.000119325276,0.0000055922815,0.000017982275,0.012972165,0.00018325738],"about_ca_topic_score_codex":0.0001326464,"about_ca_topic_score_gemma":0.00014229685,"teacher_disagreement_score":0.14400527,"about_ca_system_score_codex":0.0023304198,"about_ca_system_score_gemma":0.0067108157,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W4281629140","doi":"10.1200/jco.2022.40.16_suppl.tps7588","title":"CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Rituximab; Follicular lymphoma; Internal medicine; Refractory (planetary science); Phases of clinical research; Oncology; Neutropenia; Gastroenterology; Lymphoma; Chemotherapy; Multiple myeloma","score_opus":0.13090223204693324,"score_gpt":0.4447035934095154,"score_spread":0.31380136136258213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281629140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387234,0.00231812,0.000014740863,0.0008300374,0.000769179,0.0020695925,0.000029949411,0.0000063205625,0.00008971556],"genre_scores_gemma":[0.9972441,0.0014413401,0.00052934425,0.00027062633,0.00032250863,0.00007585485,0.000019301382,0.000033776494,0.0000631568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99147666,0.002426903,0.004312272,0.00036543686,0.0011070234,0.00031170435],"domain_scores_gemma":[0.9830231,0.0107038645,0.0049688686,0.00043616196,0.0006248883,0.00024313504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061798533,0.00029736818,0.0033773002,0.00020735922,0.00013556702,0.000009493975,0.00027853882,0.00026341187,0.000098696524],"category_scores_gemma":[0.004812642,0.00016030933,0.0004918891,0.0002852501,0.00030158198,0.00009721658,0.00012964233,0.0006571238,6.6737744e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87960887,0.013709534,0.005433188,0.000049448117,0.0015619248,0.00046057225,0.0008791411,0.0011630706,0.00007000665,0.000009061683,0.00018776904,0.09686739],"study_design_scores_gemma":[0.78202176,0.18357545,0.029345913,0.00059218996,0.0011627766,0.00014931415,0.0006807318,0.0013757307,0.000078194505,0.000009731726,0.0008753776,0.00013284879],"about_ca_topic_score_codex":0.00021057104,"about_ca_topic_score_gemma":0.00005644531,"teacher_disagreement_score":0.1698659,"about_ca_system_score_codex":0.0015294425,"about_ca_system_score_gemma":0.0053779436,"threshold_uncertainty_score":0.9540241},"labels":[],"label_agreement":null},{"id":"W4281629374","doi":"10.1200/jco.2022.40.16_suppl.tps5621","title":"OZM-114: Phase Ib expansion study of CX-5461in patients with solid tumors and <i>BRCA2 </i>and/or <i>PALB2 </i>mutation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Montréal; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Oncology; Prostate cancer; Adverse effect; Toxicity; Incidence (geometry); Cohort; Clinical trial; Cancer; Gastroenterology","score_opus":0.03788673541297862,"score_gpt":0.40010088888169426,"score_spread":0.36221415346871566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281629374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985315,0.00041397658,0.000072037394,0.00024882518,0.00039960013,0.00023437485,0.000031010735,0.0000013418726,0.00006730469],"genre_scores_gemma":[0.99795187,0.0004521262,0.0004971141,0.00078362064,0.0002404964,0.000009509067,0.000014774114,0.000015085647,0.00003541481],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99796194,0.00026554745,0.0011848117,0.00021751264,0.00023195577,0.00013823478],"domain_scores_gemma":[0.9978148,0.00040572544,0.0012023323,0.00015168784,0.00025601994,0.00016947066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009533161,0.00011558143,0.0006148224,0.000049490045,0.00008803605,0.000008629784,0.0001426178,0.00009568342,0.000029302577],"category_scores_gemma":[0.0007640725,0.00008517149,0.00008260294,0.000071698174,0.00012780936,0.0000065256613,0.0002125665,0.00030308968,2.4316955e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0726167,0.044674695,0.5487268,0.000102465834,0.0015911427,0.0010040951,0.0023308014,0.0029886684,0.013442849,0.00007500004,0.014200511,0.2982463],"study_design_scores_gemma":[0.10357005,0.4838334,0.30494714,0.00006422536,0.0008855857,0.0004915009,0.005554249,0.00026318943,0.0028643229,0.00031775248,0.09652032,0.0006882762],"about_ca_topic_score_codex":0.000017712797,"about_ca_topic_score_gemma":0.00008222102,"teacher_disagreement_score":0.4391587,"about_ca_system_score_codex":0.000025297166,"about_ca_system_score_gemma":0.0005941665,"threshold_uncertainty_score":0.34731925},"labels":[],"label_agreement":null},{"id":"W4281631797","doi":"10.1200/jco.2022.40.16_suppl.8006","title":"Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Toxicity; Cohort; Antibody; Oncology; Immunology; Cancer; Chimeric antigen receptor; Immunotherapy","score_opus":0.09750823413975031,"score_gpt":0.4644746690344346,"score_spread":0.3669664348946843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281631797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919752,0.00014850801,0.00015674322,0.0015710101,0.0017029974,0.0021688899,0.00022455548,0.000010270699,0.0020418174],"genre_scores_gemma":[0.99503285,0.000543675,0.002024836,0.00031852524,0.001173978,0.00003380976,0.00023691302,0.000047930473,0.0005874793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99218005,0.0014650569,0.004289779,0.0004113121,0.0012185058,0.00043530925],"domain_scores_gemma":[0.99072564,0.0047594495,0.002936235,0.0004096395,0.00083822245,0.00033079679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072161257,0.000227533,0.0018785831,0.0005671217,0.00011492161,0.000012676709,0.00035697376,0.00038217346,0.00077139406],"category_scores_gemma":[0.0039910767,0.00018065528,0.00057354866,0.00048744032,0.00029295767,0.00019333437,0.0001246999,0.0020240357,0.0000045337656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84061193,0.018561851,0.0060265916,0.000058639675,0.00018850397,0.00045525958,0.00032854907,0.00004203807,0.0054578525,0.000008345625,0.0034198032,0.124840654],"study_design_scores_gemma":[0.5726732,0.18655983,0.049713075,0.00007877435,0.00013844877,0.0000697849,0.00028977107,0.0004008899,0.00048452188,0.000036964968,0.18939121,0.00016351353],"about_ca_topic_score_codex":0.00005205762,"about_ca_topic_score_gemma":0.00009676026,"teacher_disagreement_score":0.26793867,"about_ca_system_score_codex":0.00047166186,"about_ca_system_score_gemma":0.0024430186,"threshold_uncertainty_score":0.87935406},"labels":[],"label_agreement":null},{"id":"W4281632216","doi":"10.1200/jco.2022.40.16_suppl.9036","title":"Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Microbiome; Medicine; Lung cancer; Internal medicine; Cohort; Adverse effect; Immune system; Cancer; Oncology; Cohort study; Gastroenterology; Immunology; Biology; Bioinformatics","score_opus":0.010337898891077656,"score_gpt":0.32836648367138566,"score_spread":0.318028584780308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281632216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99868643,0.00043846946,0.000020085206,0.0003105482,0.00015974509,0.00030378872,0.000035364465,0.000002104383,0.00004345765],"genre_scores_gemma":[0.9985179,0.00039839937,0.00045857162,0.00027922788,0.000056363315,0.000008567169,0.000109576664,0.00001781898,0.00015359605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806947,0.0004060366,0.0010133204,0.00018795027,0.000120651464,0.00020258097],"domain_scores_gemma":[0.9979126,0.000087214394,0.0016355542,0.00009678847,0.00018708502,0.000080788086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009032972,0.00012185289,0.00055212126,0.00008151513,0.000084060724,0.0000026614553,0.000118672455,0.00021988936,0.000026886562],"category_scores_gemma":[0.000018973271,0.00009530758,0.00009740686,0.0001258117,0.000035682322,0.00000942397,0.00005311355,0.0005173079,4.4701935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032963608,0.0007396297,0.9499002,0.000013759389,0.00032636424,0.0000078027115,0.000065547305,0.00026836197,0.04314224,1.6693464e-7,0.00008720201,0.002152346],"study_design_scores_gemma":[0.01660576,0.008810562,0.97138035,0.000039426086,0.00013730697,0.000006981196,0.00003887827,0.000007858886,0.0010142728,0.0000016700023,0.0018374928,0.00011942695],"about_ca_topic_score_codex":0.00004910643,"about_ca_topic_score_gemma":0.000046727047,"teacher_disagreement_score":0.042127967,"about_ca_system_score_codex":0.00026927196,"about_ca_system_score_gemma":0.00048369236,"threshold_uncertainty_score":0.38865304},"labels":[],"label_agreement":null},{"id":"W4281633340","doi":"10.1200/jco.2022.40.16_suppl.12100","title":"Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Eosinophilic Disorders and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"National Institutes of Health","keywords":"Medicine; Benralizumab; Rash; Internal medicine; Clinical endpoint; Metastatic breast cancer; Interim analysis; Breast cancer; Oncology; Cancer; Clinical trial; Mepolizumab; Asthma; Eosinophil","score_opus":0.11393533976383019,"score_gpt":0.47372917019499017,"score_spread":0.35979383043116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281633340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897464,0.0006218217,0.0002254421,0.0069301254,0.00030694282,0.0018076495,0.00028022024,0.0000031378188,0.00007828704],"genre_scores_gemma":[0.9986217,0.00016603914,0.0005643607,0.00046375583,0.00007418575,0.000051463852,0.000010705255,0.000018437822,0.000029357341],"study_design_codex":"nonrandomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9947269,0.0012301136,0.0029412827,0.0003071592,0.00055510376,0.00023945942],"domain_scores_gemma":[0.9941088,0.0030654569,0.001702302,0.00022439106,0.00070563465,0.000193403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004902915,0.00018696566,0.0026635414,0.00045906566,0.000076010554,0.00000871977,0.00024564785,0.00006151241,0.00019176574],"category_scores_gemma":[0.0019604582,0.00012375176,0.0005421866,0.0009662022,0.00025770738,0.00007398836,0.00018482473,0.00054026983,2.2540306e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24062695,0.25656372,0.18503281,0.00012379515,0.02846273,0.00037047718,0.02264909,0.0014699232,0.012397253,0.00013263417,0.0015268516,0.25064376],"study_design_scores_gemma":[0.09964713,0.24379513,0.6267058,0.00022786773,0.012179813,0.0003634882,0.014466969,0.0010666912,0.00012563533,0.00024905664,0.00093906565,0.0002333513],"about_ca_topic_score_codex":0.00013155998,"about_ca_topic_score_gemma":0.00034672584,"teacher_disagreement_score":0.44167298,"about_ca_system_score_codex":0.00040839324,"about_ca_system_score_gemma":0.00062923966,"threshold_uncertainty_score":0.504645},"labels":[],"label_agreement":null},{"id":"W4281633703","doi":"10.1200/jco.2022.40.16_suppl.3099","title":"Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i>-fp) solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Cohort; Response Evaluation Criteria in Solid Tumors; Oncology; Progression-free survival; Trk receptor; Phases of clinical research; Clinical trial; Overall survival; Receptor","score_opus":0.0196159395241474,"score_gpt":0.403184964735448,"score_spread":0.3835690252113006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281633703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656475,0.00019616805,0.00008117904,0.0015589413,0.00025863346,0.0004962098,0.0000791705,0.000002669226,0.0007622903],"genre_scores_gemma":[0.9978424,0.0001440399,0.0009042657,0.00095681136,0.000031405885,0.0000070325987,0.000027669652,0.000011283577,0.00007510831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964142,0.0005970661,0.0021367252,0.00019059452,0.00049137394,0.0001700397],"domain_scores_gemma":[0.9951938,0.0015287122,0.0024425755,0.0001951612,0.00048673557,0.00015305605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010665503,0.00013016295,0.001643801,0.00025155535,0.00007668418,0.000002791037,0.00014215607,0.000058205635,0.00017658256],"category_scores_gemma":[0.00072864664,0.00007548024,0.00031205185,0.00094447524,0.00023903258,0.000065476415,0.00010631408,0.00058192195,3.6265573e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027471704,0.010567413,0.8277627,0.000037341426,0.006960444,0.00022083912,0.0014188713,0.011598733,0.000105077954,0.000068082765,0.0004385448,0.1133502],"study_design_scores_gemma":[0.026961239,0.016589016,0.947138,0.00014449014,0.006039965,0.000043978227,0.00060811307,0.0002535975,0.0000766362,0.000046514262,0.0020212098,0.00007723946],"about_ca_topic_score_codex":0.00005046032,"about_ca_topic_score_gemma":0.00010280266,"teacher_disagreement_score":0.11937525,"about_ca_system_score_codex":0.0002274586,"about_ca_system_score_gemma":0.0012910519,"threshold_uncertainty_score":0.30779946},"labels":[],"label_agreement":null},{"id":"W4281633761","doi":"10.1200/jco.2022.40.16_suppl.e12578","title":"Local regional management of the axilla after positive sentinel node biopsy in breast cancer patients clinically downstaged with neoadjuvant therapy: A population-based, real-world analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Axilla; Sentinel node; Breast cancer; Population; Surgery; Biopsy; Neoadjuvant therapy; Radiology; Cancer; Internal medicine","score_opus":0.02266190365164688,"score_gpt":0.3609028205272552,"score_spread":0.3382409168756083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281633761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282885,0.00019560287,0.0000893628,0.0061790184,0.00024686655,0.0001932139,0.00011369329,0.0000018614721,0.000151528],"genre_scores_gemma":[0.99651885,0.0004495194,0.00042133435,0.002335877,0.00012217558,0.00005018654,0.00004139557,0.000015143566,0.000045502555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996743,0.00069991226,0.0015784217,0.0003198031,0.0004528456,0.00020600986],"domain_scores_gemma":[0.9973681,0.00022593168,0.001734232,0.00027066327,0.0003144499,0.00008665294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008918523,0.00017363508,0.0008175874,0.00013545401,0.00008014595,0.0000048407833,0.00027894627,0.00010417847,0.00007156508],"category_scores_gemma":[0.000026224734,0.0001066161,0.00057341787,0.00051406847,0.00024345359,0.0000061672245,0.00019239944,0.00039214385,2.9132167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01810893,0.0019333735,0.9648141,0.000007484213,0.0024529726,0.000083814164,0.000030807645,0.005195494,0.000014005762,0.000010682631,0.00018998157,0.007158346],"study_design_scores_gemma":[0.0067191357,0.0008625833,0.99079347,0.000045317913,0.0005984267,0.000017780381,0.00009621414,0.00006778475,0.000011699099,0.000016694721,0.000655491,0.00011537623],"about_ca_topic_score_codex":0.00062953506,"about_ca_topic_score_gemma":0.0008363605,"teacher_disagreement_score":0.025979389,"about_ca_system_score_codex":0.00020476138,"about_ca_system_score_gemma":0.0004611272,"threshold_uncertainty_score":0.43476784},"labels":[],"label_agreement":null},{"id":"W4281636338","doi":"10.1200/jco.2022.40.16_suppl.e17626","title":"Adjuvant chemotherapy followed by adjuvant radiotherapy for treatment of high risk endometrial cancers: A retrospective review.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Endometrial cancer; Serous fluid; Oncology; Carboplatin; Internal medicine; Chemotherapy; Stage (stratigraphy); Radiation therapy; Hazard ratio; Cancer; Cisplatin; Confidence interval","score_opus":0.07535406918579743,"score_gpt":0.4548630257283078,"score_spread":0.3795089565425104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281636338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7746542,0.1951154,0.00078051415,0.016564997,0.007212676,0.0040295194,0.0009949924,0.000027624446,0.0006200607],"genre_scores_gemma":[0.69950575,0.28694957,0.0049695405,0.0046636728,0.0028838692,0.0002547227,0.00004358693,0.000058136262,0.00067113974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947771,0.0007784035,0.0030101081,0.00035832392,0.00074655976,0.0003295155],"domain_scores_gemma":[0.99121964,0.0036145847,0.004015916,0.0003040886,0.0004574648,0.0003882967],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029648563,0.00026380632,0.004509915,0.00023342842,0.00010098311,0.0000040451782,0.00022503446,0.00019420327,0.0014443565],"category_scores_gemma":[0.0029761426,0.00017330125,0.0019303096,0.0006542087,0.00014751183,0.00005893384,0.000027032365,0.00045050948,0.0000014133102],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10770354,0.009798439,0.043048676,0.0001375953,0.006322642,0.0001927687,0.0001722263,0.000019301826,0.00063215423,0.00005098403,0.05068198,0.7812397],"study_design_scores_gemma":[0.17515035,0.26249027,0.02746873,0.0001905894,0.002944887,0.00013816425,0.000083273764,0.00002574774,0.0008666274,0.000549498,0.52989,0.00020182773],"about_ca_topic_score_codex":0.0005265059,"about_ca_topic_score_gemma":0.000028765271,"teacher_disagreement_score":0.78103787,"about_ca_system_score_codex":0.0030021116,"about_ca_system_score_gemma":0.0019598252,"threshold_uncertainty_score":0.99946845},"labels":[],"label_agreement":null},{"id":"W4281638593","doi":"10.1200/jco.2022.40.16_suppl.tps3166","title":"Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"FOXP3; Medicine; Cancer research; Immune system; Immunosuppression; Context (archaeology); Gene knockdown; Immunology; Oncology; Biology; Cell culture","score_opus":0.06591170919294542,"score_gpt":0.424148845111125,"score_spread":0.3582371359181796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281638593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862546,0.0001589525,0.00006517782,0.00028518657,0.00016544874,0.00066124805,0.0000082207325,0.0000023826926,0.00002792926],"genre_scores_gemma":[0.99799466,0.00009205505,0.0015596508,0.00026731368,0.000044680048,0.0000070477104,0.0000033583206,0.0000104953315,0.00002071297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968195,0.0006197159,0.0019424534,0.00012858576,0.00037100352,0.00011871847],"domain_scores_gemma":[0.99665457,0.0009238142,0.0017995363,0.00010569253,0.00043017344,0.0000862043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018251829,0.0000877424,0.0011100523,0.00017133245,0.000032369684,0.0000016056107,0.00008078665,0.000055029574,0.00009184116],"category_scores_gemma":[0.00071927963,0.00006481201,0.000084684114,0.00032679763,0.00013469647,0.00006489385,0.000032555115,0.00042456377,1.1435746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30230996,0.04255873,0.57214606,0.000044508815,0.00088705897,0.00037441732,0.0011012121,0.0006314758,0.009649796,0.0000034719228,0.00065128837,0.06964201],"study_design_scores_gemma":[0.09764251,0.13295673,0.7673333,0.00006235943,0.00016021138,0.00006974474,0.0007008084,0.00014560706,0.0003742066,0.000014573094,0.00047495187,0.000064937645],"about_ca_topic_score_codex":0.000018893015,"about_ca_topic_score_gemma":0.000025603249,"teacher_disagreement_score":0.20466746,"about_ca_system_score_codex":0.000086930384,"about_ca_system_score_gemma":0.0009489789,"threshold_uncertainty_score":0.2642957},"labels":[],"label_agreement":null},{"id":"W4281638764","doi":"10.1200/jco.2022.40.16_suppl.4537","title":"Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Refractory (planetary science); Population; Immunotherapy; Pembrolizumab; Unison; Oncology; Cancer","score_opus":0.056268137551704185,"score_gpt":0.36679351873605187,"score_spread":0.3105253811843477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281638764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828427,0.0032678647,0.00009776199,0.0010945946,0.0014992623,0.00096845196,0.000034506236,0.000018123563,0.010176749],"genre_scores_gemma":[0.99152714,0.00043261223,0.004820156,0.00040942497,0.00062339555,0.000044645014,0.00004955153,0.00011233857,0.0019807168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98703223,0.002536893,0.006990123,0.00092095643,0.0015872791,0.0009325275],"domain_scores_gemma":[0.99103427,0.0013542323,0.0054349033,0.0010588672,0.0005704077,0.00054731936],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064505935,0.00058924215,0.003670226,0.0009158416,0.00016123323,0.000019100478,0.0008258908,0.0006240403,0.0010439774],"category_scores_gemma":[0.00034000023,0.0005236538,0.0014046371,0.00079026725,0.00039572985,0.0002527526,0.0004129755,0.0037309122,0.000013631843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13222781,0.032476563,0.34157786,0.00059818506,0.00067314954,0.26085523,0.004330617,0.0068427026,0.18431455,0.000052166695,0.003984822,0.032066338],"study_design_scores_gemma":[0.14197728,0.107387386,0.65393263,0.0003383709,0.0012617203,0.01803748,0.0037000563,0.0012708105,0.03714621,0.00045862276,0.033320766,0.0011686855],"about_ca_topic_score_codex":0.0011222417,"about_ca_topic_score_gemma":0.00020437525,"teacher_disagreement_score":0.31235477,"about_ca_system_score_codex":0.0026333376,"about_ca_system_score_gemma":0.0070859315,"threshold_uncertainty_score":0.9998692},"labels":[],"label_agreement":null},{"id":"W4281638918","doi":"10.1200/jco.2022.40.16_suppl.9091","title":"DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Population; Lung cancer; Internal medicine; Cancer","score_opus":0.1710566535487411,"score_gpt":0.5076650051780691,"score_spread":0.336608351629328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281638918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917574,0.00026930714,0.00007100456,0.005817679,0.0009166435,0.00055735203,0.00004644693,0.000011928519,0.00055222184],"genre_scores_gemma":[0.9944482,0.00021672835,0.0023409247,0.0021349795,0.00037277432,0.000010654357,0.000024829444,0.00002689748,0.0004240447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99469995,0.0011229719,0.0029936223,0.0003255253,0.00060809014,0.00024985525],"domain_scores_gemma":[0.99289733,0.0027272883,0.0029649034,0.0003222523,0.00080164825,0.0002865467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044982126,0.00020244705,0.0014561693,0.00020017517,0.0001717561,0.000016467246,0.0001824675,0.00020147167,0.00014583691],"category_scores_gemma":[0.0074056727,0.00011369049,0.00016588916,0.0004717947,0.00024386446,0.00013953808,0.00010493569,0.0013156707,0.0000018440135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13623738,0.012146655,0.81074524,0.00019790971,0.0017073537,0.00036854172,0.0028788948,0.004146579,0.00013746832,0.00029155778,0.002988115,0.02815431],"study_design_scores_gemma":[0.052469164,0.037588038,0.89280075,0.0006568393,0.00092540914,0.00015496704,0.0012470661,0.0016843848,0.000031665477,0.00021944675,0.011973201,0.0002490573],"about_ca_topic_score_codex":0.0003692523,"about_ca_topic_score_gemma":0.00079618755,"teacher_disagreement_score":0.08376822,"about_ca_system_score_codex":0.0004655176,"about_ca_system_score_gemma":0.0033696343,"threshold_uncertainty_score":0.8865817},"labels":[],"label_agreement":null},{"id":"W4281639573","doi":"10.1200/jco.2022.40.16_suppl.4078","title":"Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenvatinib; Medicine; Hazard ratio; Hepatocellular carcinoma; Sorafenib; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Gastroenterology; Nuclear medicine; Confidence interval; Progressive disease; Chemotherapy","score_opus":0.1273829026998968,"score_gpt":0.3592262130248076,"score_spread":0.23184331032491082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281639573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980545,0.00008248836,0.000005949843,0.00066184235,0.000093302726,0.00061812805,0.0000145787435,0.000006183307,0.00046303938],"genre_scores_gemma":[0.9988333,0.00003194567,0.00045407072,0.000309209,0.00007503702,0.00003883365,0.000054043143,0.000029067185,0.00017451638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566746,0.0012728926,0.0019554181,0.00024565792,0.00058625615,0.00027229634],"domain_scores_gemma":[0.99693865,0.00073419855,0.0015955348,0.00020798056,0.00034840027,0.0001752499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023834263,0.00017795445,0.0014522243,0.00052585,0.000043609503,0.000005534975,0.00015479513,0.00013316302,0.00017070817],"category_scores_gemma":[0.0005706242,0.00012235003,0.00016536005,0.00076944596,0.000116342366,0.0001287275,0.000056243258,0.0008436205,0.000001720061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050581254,0.0041646697,0.93581486,0.000039418075,0.000121792335,0.0034107412,0.00020726502,0.0000050053254,0.0025223352,0.000008886683,0.000022442575,0.0031013212],"study_design_scores_gemma":[0.02204895,0.055198517,0.91688555,0.0001216036,0.00019388065,0.00015442942,0.000110723275,0.00029320773,0.0032666852,0.000009445023,0.0016045701,0.00011244239],"about_ca_topic_score_codex":0.00016935544,"about_ca_topic_score_gemma":0.00008755428,"teacher_disagreement_score":0.051033847,"about_ca_system_score_codex":0.00036690402,"about_ca_system_score_gemma":0.0015617658,"threshold_uncertainty_score":0.49892896},"labels":[],"label_agreement":null},{"id":"W4281647552","doi":"10.1200/jco.2022.40.16_suppl.5514","title":"A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Mesothelin; Bevacizumab; Internal medicine; Ovarian cancer; Paclitaxel; Oncology; Refractory (planetary science); Gastroenterology; Progression-free survival; Cancer; Chemotherapy","score_opus":0.16389731666071916,"score_gpt":0.49170786806166683,"score_spread":0.32781055140094767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281647552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783312,0.0019774977,0.000007776701,0.015353778,0.0013370283,0.002540955,0.00006554291,0.000009207816,0.0003770251],"genre_scores_gemma":[0.9942433,0.0018978632,0.0008658736,0.00092256424,0.0007878465,0.00026553165,0.000006388388,0.000035563724,0.00097503455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903006,0.0027592345,0.005317916,0.00044185782,0.00083396706,0.00034644848],"domain_scores_gemma":[0.987649,0.007441778,0.0037930047,0.00036289977,0.00033800534,0.00041528474],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008716464,0.00029963267,0.0050499113,0.0003754232,0.0001461379,0.00001205432,0.00020924713,0.00025068264,0.0022728366],"category_scores_gemma":[0.0045043053,0.00017883057,0.000464662,0.00043858335,0.00025098652,0.00011443933,0.00017848448,0.0013557489,9.3259587e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8596101,0.043967593,0.0013348015,0.00004724928,0.0018760723,0.0047895107,0.0013729573,0.000021979053,0.000051537016,0.000034645927,0.0028723078,0.08402128],"study_design_scores_gemma":[0.73873216,0.2245489,0.007689854,0.00014250613,0.0019040207,0.00021407625,0.001890795,0.000072814095,0.0000058509745,0.000097191085,0.024566852,0.00013495797],"about_ca_topic_score_codex":0.00087030046,"about_ca_topic_score_gemma":0.0019132595,"teacher_disagreement_score":0.18058132,"about_ca_system_score_codex":0.000768725,"about_ca_system_score_gemma":0.0050051226,"threshold_uncertainty_score":0.9986392},"labels":[],"label_agreement":null},{"id":"W4281648011","doi":"10.1200/jco.2022.40.16_suppl.e24081","title":"Physical and psychological symptom burden in patients newly diagnosed with solid organ cancers in a tertiary care centre in India.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Conquer Cancer Foundation","keywords":"Medicine; Breast cancer; Tertiary care; Logistic regression; Cancer; Lung cancer; Physical therapy; Internal medicine","score_opus":0.028812939728452894,"score_gpt":0.3974190315384299,"score_spread":0.368606091809977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281648011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964686,0.00025532083,5.3355126e-7,0.0020415105,0.00055436033,0.00027243313,0.000007893443,0.0000042813626,0.00039504893],"genre_scores_gemma":[0.9972529,0.00013970603,0.000041631,0.002133332,0.00038142275,0.000014781998,0.000007420545,0.000014849091,0.000013991362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973238,0.00062226685,0.001114402,0.00027068012,0.00038414198,0.00028471954],"domain_scores_gemma":[0.9982891,0.0007545143,0.00048194162,0.00012903284,0.00010395767,0.00024141939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069087243,0.00013799926,0.0010838294,0.00022669339,0.000023285076,0.000005468024,0.00014990217,0.0001831726,0.000088652436],"category_scores_gemma":[0.00043123,0.00010155601,0.00012351142,0.00034385352,0.00013159038,0.00006402461,0.000097880344,0.0017688685,0.0000010545373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047009015,0.0015374697,0.9336725,0.000021120111,0.00003360214,0.0022545194,0.0076064677,0.00010066199,0.000006101738,0.000004432665,0.00021498278,0.049847238],"study_design_scores_gemma":[0.020864952,0.0102303345,0.9597242,0.00013464753,0.000047053767,0.000048414982,0.007088612,0.000031408286,0.0000025565917,0.000035274374,0.0016868488,0.00010572996],"about_ca_topic_score_codex":0.00078626047,"about_ca_topic_score_gemma":0.007212203,"teacher_disagreement_score":0.049741507,"about_ca_system_score_codex":0.00085682503,"about_ca_system_score_gemma":0.00090615207,"threshold_uncertainty_score":0.7684952},"labels":[],"label_agreement":null},{"id":"W4281649126","doi":"10.1200/jco.2022.40.16_suppl.e20006","title":"Preliminary efficacy of optimal pharmacotherapy and patient views in multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Internal medicine; Hazard ratio; Population; Oncology; Randomized controlled trial; Clinical endpoint; Progression-free survival; Randomization; Clinical trial; Transplantation; Intensive care medicine; Confidence interval; Chemotherapy; Environmental health","score_opus":0.1814915426467222,"score_gpt":0.4981602613134877,"score_spread":0.3166687186667655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281649126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480844,0.0022670636,0.000008299477,0.0017714337,0.00033676584,0.00042108953,0.00001108414,0.0000030199037,0.0003728077],"genre_scores_gemma":[0.99505013,0.0010726439,0.0028910015,0.00076314213,0.00011147573,0.000023850804,0.000004023803,0.000012965082,0.00007076993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964357,0.0009730592,0.0017302209,0.0001592432,0.00049116724,0.00021059444],"domain_scores_gemma":[0.9956934,0.002803952,0.0009809257,0.00012744681,0.000096354524,0.00029795073],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019212362,0.00009835481,0.001011529,0.0002052715,0.00006589209,0.000002061104,0.00012753787,0.000070648006,0.0010339734],"category_scores_gemma":[0.001373165,0.00007376285,0.00027404306,0.00015345406,0.00014607549,0.000049859114,0.00016889638,0.0010195303,0.0000017818622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054864574,0.009622677,0.24714635,0.000025286896,0.00034217114,0.0025015706,0.00062248536,0.0003744568,0.0012718705,0.0000064470364,0.0018576006,0.68136454],"study_design_scores_gemma":[0.04570084,0.07303377,0.722273,0.000029779816,0.00010724084,0.000715218,0.00047780157,0.0014758739,0.00037454767,0.000018483332,0.15571363,0.00007980347],"about_ca_topic_score_codex":0.000027851305,"about_ca_topic_score_gemma":0.000005500669,"teacher_disagreement_score":0.6812847,"about_ca_system_score_codex":0.00017170014,"about_ca_system_score_gemma":0.0007010154,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W4281650201","doi":"10.1200/jco.2022.40.16_suppl.tps8072","title":"MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Pomalidomide; Internal medicine; Oncology; Multiple myeloma; Bortezomib; Dexamethasone; Progressive disease; Surgery; Chemotherapy","score_opus":0.11914582969451691,"score_gpt":0.4442931853155352,"score_spread":0.32514735562101826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281650201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444544,0.0014881584,0.00001977985,0.0003267968,0.00060560176,0.0027406747,0.00008144046,0.00001378096,0.0002783044],"genre_scores_gemma":[0.9954488,0.00035894196,0.0036186313,0.00013852972,0.00014305605,0.00010290365,0.00003102494,0.00006323838,0.00009483481],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9887942,0.0038394236,0.0044572335,0.00069220085,0.0016214107,0.00059549813],"domain_scores_gemma":[0.97490424,0.018014126,0.004311004,0.0006769769,0.00088215864,0.0012114812],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006609535,0.0004926937,0.005187209,0.0008044469,0.00021827171,0.000022324315,0.00038515287,0.00037402913,0.00012568146],"category_scores_gemma":[0.031407945,0.000334289,0.00034948808,0.0007804399,0.0014437778,0.00035090002,0.00044127996,0.0024761374,0.000001036991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6359456,0.016594823,0.32285327,0.00012300262,0.001798941,0.0012897312,0.0006529168,0.00003070142,0.000081907056,0.00001224446,0.0001716019,0.020445252],"study_design_scores_gemma":[0.61969554,0.08413864,0.29205018,0.00014925905,0.0009876516,0.00009128895,0.0012717004,0.00036196611,0.00005623272,0.000017387792,0.00097484316,0.00020529548],"about_ca_topic_score_codex":0.0006226274,"about_ca_topic_score_gemma":0.0009936396,"teacher_disagreement_score":0.06754382,"about_ca_system_score_codex":0.0005287801,"about_ca_system_score_gemma":0.0027566033,"threshold_uncertainty_score":0.9999109},"labels":[],"label_agreement":null},{"id":"W4281650422","doi":"10.1200/jco.2022.40.16_suppl.e24079","title":"Melatonin supplementation for preventing cancer-related fatigue in patients receiving radiotherapy for early-stage breast cancer: A double-blind placebo-controlled phase III trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Interim analysis; Melatonin; Internal medicine; Breast cancer; Randomization; Cancer; Radiation therapy; Clinical endpoint; Randomized controlled trial; Pathology","score_opus":0.125773310212059,"score_gpt":0.4959016111431434,"score_spread":0.3701283009310844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281650422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98337626,0.0005446565,0.00049361883,0.004620568,0.0047835247,0.005893518,0.00018255494,0.000013323153,0.00009199137],"genre_scores_gemma":[0.99419624,0.000508502,0.0007221688,0.00063400867,0.0011285942,0.0020024602,0.00005775468,0.000043359767,0.0007068861],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99480677,0.0006265031,0.00344496,0.00029806703,0.00045698902,0.00036673664],"domain_scores_gemma":[0.99353886,0.0023264538,0.003316025,0.00013807723,0.000464088,0.000216506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063217953,0.00018881829,0.001977262,0.00027183816,0.00015304805,0.000018611318,0.00018834844,0.00023223239,0.00085257384],"category_scores_gemma":[0.00040057336,0.0001623572,0.0008295761,0.0002716431,0.00004132287,0.00016111479,0.00003468576,0.00084391417,1.3975773e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8610704,0.0032840802,0.04859132,0.00005937968,0.0011054358,0.000013144862,0.0015833343,0.00038313319,0.000038757975,0.000025007064,0.0011109654,0.08273503],"study_design_scores_gemma":[0.9518743,0.022805706,0.006682996,0.00012550688,0.0007858519,0.000011039787,0.0005400785,0.0014622826,0.00003834758,0.000035932662,0.015479675,0.00015823999],"about_ca_topic_score_codex":0.000851856,"about_ca_topic_score_gemma":0.002050031,"teacher_disagreement_score":0.090803936,"about_ca_system_score_codex":0.0012197393,"about_ca_system_score_gemma":0.0022841303,"threshold_uncertainty_score":0.9335085},"labels":[],"label_agreement":null},{"id":"W4281652688","doi":"10.1200/jco.2022.40.16_suppl.7561","title":"Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Internal medicine; Vincristine; CHOP; Placebo; Incidence (geometry); Progression-free survival; Gastroenterology; Oncology; Lymphoma; Chemotherapy; Cyclophosphamide; Pathology","score_opus":0.20937681960913465,"score_gpt":0.5324843172641304,"score_spread":0.3231074976549957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281652688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949838,0.0006228699,0.0000028849115,0.0032984337,0.00060067966,0.00037854214,0.00000548228,0.0000023378875,0.00010499311],"genre_scores_gemma":[0.9956674,0.00017111612,0.00017060684,0.0038337903,0.000115412986,0.0000064342516,0.0000015696504,0.000007923207,0.000025747226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995399,0.0015414797,0.002392832,0.0001890792,0.00033045642,0.00014713388],"domain_scores_gemma":[0.9955611,0.0021623105,0.0018830688,0.00014743544,0.00013223475,0.00011384026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034149573,0.00011196376,0.0016427276,0.0002985321,0.000069937865,0.0000057559437,0.000100485864,0.000089574896,0.00013447618],"category_scores_gemma":[0.00090801826,0.00006901031,0.00036093305,0.00047183223,0.00016821742,0.000051391224,0.00010872593,0.000893545,7.423698e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035516792,0.005502143,0.9594277,0.000005847079,0.0021484648,0.0014012842,0.0021472957,0.00008961188,0.000063174324,0.0000029785754,0.00007768809,0.025582135],"study_design_scores_gemma":[0.008928849,0.0255044,0.9531174,0.0000044361923,0.0060466523,0.00030597203,0.0026015139,0.00068002817,0.0000011966752,0.000028682638,0.0027277905,0.000053105214],"about_ca_topic_score_codex":0.00023525684,"about_ca_topic_score_gemma":0.00026283658,"teacher_disagreement_score":0.02552903,"about_ca_system_score_codex":0.000088659035,"about_ca_system_score_gemma":0.00055158214,"threshold_uncertainty_score":0.3882058},"labels":[],"label_agreement":null},{"id":"W4281653153","doi":"10.1200/jco.2022.40.16_suppl.e22019","title":"Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HR-NB): Response data and efficacy in patient (pt) subgroups.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Phases of clinical research; Progressive disease; Gastroenterology; Clinical trial; Surgery; Oncology; Chemotherapy","score_opus":0.12833963752225622,"score_gpt":0.4588663981835789,"score_spread":0.3305267606613227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281653153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99142545,0.00035103853,0.000016009355,0.006161757,0.00082647585,0.00095107465,0.00020122108,0.000014119189,0.000052824176],"genre_scores_gemma":[0.9962018,0.0008708253,0.0014904108,0.00077593763,0.00032373157,0.000051607272,0.000038166778,0.000042284144,0.00020520137],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99353224,0.002671973,0.0021589135,0.0005455558,0.00061826984,0.00047303629],"domain_scores_gemma":[0.98548234,0.011564596,0.0014446613,0.00067129475,0.0001814708,0.0006556563],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038787841,0.00024534663,0.0015093982,0.0003775037,0.00016835093,0.000016534541,0.00035636863,0.00018058062,0.00010980645],"category_scores_gemma":[0.008632754,0.0001777817,0.0003258507,0.0002474098,0.0001945802,0.00015292277,0.0004279639,0.0013247074,0.000009275945],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3731223,0.03250554,0.029321592,0.000032934207,0.0010464848,0.017243395,0.00039816048,0.00008699407,0.0010891998,0.000026792084,0.009221037,0.53590554],"study_design_scores_gemma":[0.076817766,0.3143229,0.39499474,0.000048182508,0.0005386804,0.0013739048,0.00023683083,0.0005003614,0.00016681588,0.00013526836,0.21069258,0.00017200447],"about_ca_topic_score_codex":0.00007284922,"about_ca_topic_score_gemma":0.00010163489,"teacher_disagreement_score":0.5357336,"about_ca_system_score_codex":0.0006152264,"about_ca_system_score_gemma":0.0019556906,"threshold_uncertainty_score":0.99971795},"labels":[],"label_agreement":null},{"id":"W4281653962","doi":"10.1200/jco.2022.40.16_suppl.7551","title":"Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Tolerability; Gemcitabine; Neutropenia; Diffuse large B-cell lymphoma; Rituximab; Clinical endpoint; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.05272054963104936,"score_gpt":0.428999063772115,"score_spread":0.3762785141410656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281653962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926678,0.00070354296,0.0000051270686,0.002936155,0.0010238241,0.001072358,0.00013008123,0.000006823755,0.0014543057],"genre_scores_gemma":[0.997909,0.0004283884,0.00018200013,0.00080449303,0.0004081612,0.00002055318,0.000013541225,0.000031894087,0.00020196503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921636,0.0020368965,0.003732977,0.0003659086,0.0011968014,0.00050383515],"domain_scores_gemma":[0.9926516,0.003697855,0.0025899436,0.00039730413,0.00036042643,0.00030290746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062258444,0.00023668907,0.0021642689,0.00035517555,0.00015384154,0.000008303412,0.00037719536,0.0002563012,0.000042019987],"category_scores_gemma":[0.0071679973,0.0001502193,0.0003180056,0.0005238964,0.0004314575,0.000156857,0.0005288769,0.0022027828,0.000001425231],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8389443,0.0746349,0.06509681,0.000085461106,0.00029150423,0.0007355252,0.0015833689,0.000014093381,0.000043990272,0.000042504602,0.0025113614,0.01601617],"study_design_scores_gemma":[0.73133457,0.03914619,0.20170212,0.00014637606,0.00015507205,0.000039248145,0.0005996951,0.00010821421,0.000016161537,0.00004002356,0.026592558,0.00011980297],"about_ca_topic_score_codex":0.00034201206,"about_ca_topic_score_gemma":0.0006924275,"teacher_disagreement_score":0.13660531,"about_ca_system_score_codex":0.0013926238,"about_ca_system_score_gemma":0.0040152934,"threshold_uncertainty_score":0.95701176},"labels":[],"label_agreement":null},{"id":"W4281654209","doi":"10.1200/jco.2022.40.16_suppl.2508","title":"Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Mace; Medicine; Internal medicine; Myocarditis; Adverse effect; Oncology; Clinical trial; Cancer; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.18865839977323307,"score_gpt":0.5038805220845376,"score_spread":0.31522212231130453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93964255,0.007169852,0.000016289774,0.04942283,0.0009562522,0.0021266304,0.0006552089,0.0000046595505,0.000005732296],"genre_scores_gemma":[0.9820986,0.006295198,0.00034780434,0.008893891,0.0005994062,0.0014090489,0.0002957741,0.0000195864,0.0000407085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895096,0.004994271,0.0035608248,0.00027042322,0.001436056,0.00022882194],"domain_scores_gemma":[0.9879962,0.006624839,0.0037267199,0.00016760972,0.001360586,0.00012402351],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033859517,0.00020803692,0.0018137334,0.00030729416,0.00019015987,0.00001161049,0.0002706542,0.00016194384,0.00020976813],"category_scores_gemma":[0.0026777147,0.00010916032,0.00076801935,0.0010939403,0.00065526785,0.00008558569,0.000025578553,0.00077060563,2.7007262e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17801522,0.004121037,0.4873772,0.00007846124,0.04100107,0.000017590426,0.0023410995,0.020335967,0.0033136657,0.000030339896,0.014845645,0.24852273],"study_design_scores_gemma":[0.03502738,0.005808579,0.7809939,0.00013164105,0.0062256926,0.000007940727,0.0015664345,0.008411508,0.00027865698,0.000085898224,0.16127251,0.00018990503],"about_ca_topic_score_codex":0.14875673,"about_ca_topic_score_gemma":0.2025632,"teacher_disagreement_score":0.29361665,"about_ca_system_score_codex":0.0009727267,"about_ca_system_score_gemma":0.017942289,"threshold_uncertainty_score":0.9948449},"labels":[],"label_agreement":null},{"id":"W4281654376","doi":"10.1200/jco.2022.40.16_suppl.e16538","title":"Real-world, population-based study of treatments, survival and healthcare use in advanced urothelial carcinoma of the bladder.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Bladder cancer; Proportional hazards model; Cohort; Population; Internal medicine; Comorbidity; Cancer registry; Health care; Cancer; Oncology","score_opus":0.1295840010116572,"score_gpt":0.4545162052505024,"score_spread":0.32493220423884517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964191,0.00014309426,9.739474e-7,0.0017993621,0.0007548542,0.000670176,0.000038797243,0.0000025484296,0.00017109462],"genre_scores_gemma":[0.99909914,0.00005996738,0.00021028289,0.00031547906,0.0001257559,0.00001706554,0.0000036533515,0.000015495714,0.00015316706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960787,0.0012258055,0.00189056,0.00017628071,0.00048079924,0.00014784184],"domain_scores_gemma":[0.9966937,0.0012904053,0.0014512085,0.00024629707,0.00018254692,0.00013588439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010585038,0.000121091005,0.0012441719,0.00016224322,0.000061199324,0.0000022082515,0.00012821541,0.00007743745,0.000070807066],"category_scores_gemma":[0.00045563348,0.00007857836,0.0002415157,0.00028264822,0.000069496724,0.000052576997,0.00006579093,0.0005296127,1.4317085e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00786712,0.0050123446,0.97538173,0.00002204468,0.00022664558,0.00011571037,0.0002604304,0.00019113127,0.000038160215,0.000035078563,0.000026534615,0.01082305],"study_design_scores_gemma":[0.023746558,0.023863142,0.95065933,0.000032101234,0.0003657516,0.000016607079,0.000845968,0.00003125197,0.00003339068,0.00006970447,0.00028818127,0.000048019006],"about_ca_topic_score_codex":0.006916579,"about_ca_topic_score_gemma":0.0075870072,"teacher_disagreement_score":0.024722425,"about_ca_system_score_codex":0.00029503892,"about_ca_system_score_gemma":0.001542303,"threshold_uncertainty_score":0.99969643},"labels":[],"label_agreement":null},{"id":"W4281654580","doi":"10.1200/jco.2022.40.16_suppl.tps7595","title":"TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Medicine; Cancer research; Phagocytosis; Lymphoma; Immune system; CD20; Cancer; Immunology; Internal medicine","score_opus":0.054384069631872596,"score_gpt":0.3744468384151424,"score_spread":0.32006276878326984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956038,0.0013593128,0.000100968835,0.00027513804,0.0020366136,0.00049281836,0.000023661598,0.000010618062,0.00009707873],"genre_scores_gemma":[0.9990179,0.00028171157,0.0003011546,0.00018586409,0.00006456236,0.00002034493,0.000058877864,0.000018681141,0.000050883933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99490523,0.0015728597,0.002653332,0.00030650603,0.0001849885,0.0003770867],"domain_scores_gemma":[0.99485123,0.0014957724,0.0031502882,0.00022443892,0.00020794538,0.00007034023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029707565,0.00021633017,0.001557479,0.0002744804,0.00020710623,0.0000072535972,0.0002526871,0.00041726723,0.00010828903],"category_scores_gemma":[0.0009732532,0.00016371891,0.00025089606,0.00026225107,0.00021881565,0.00027235053,0.00026670727,0.00067097315,0.0000036356253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48590973,0.16979787,0.08764956,0.00010791304,0.0005493387,0.00013018966,0.0012903285,0.00011738333,0.054655246,0.00043680434,0.0012400193,0.19811563],"study_design_scores_gemma":[0.75011665,0.052507233,0.17542545,0.00010949271,0.00020718058,0.000090599206,0.0005184907,0.00009378956,0.0027396677,0.00021508061,0.01769086,0.0002855283],"about_ca_topic_score_codex":0.000012252413,"about_ca_topic_score_gemma":0.000013282965,"teacher_disagreement_score":0.2642069,"about_ca_system_score_codex":0.00021927766,"about_ca_system_score_gemma":0.00051652564,"threshold_uncertainty_score":0.6676264},"labels":[],"label_agreement":null},{"id":"W4281654617","doi":"10.1200/jco.2022.40.16_suppl.e17624","title":"Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); University of Calgary; Western University","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Regimen; Cancer; Incidence (geometry); Cohort; Radiation therapy; Retrospective cohort study; Oncology; Endometrial cancer; Surgery","score_opus":0.2172466783182012,"score_gpt":0.4702099634150809,"score_spread":0.2529632850968797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850029,0.00063992274,0.00003261901,0.008862092,0.0046157395,0.0006134608,0.00016479159,0.0000022892814,0.0000661856],"genre_scores_gemma":[0.9924689,0.0051627476,0.0002172245,0.0014567903,0.0005319922,0.000056517827,0.0000114017275,0.000014092123,0.00008031906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640965,0.00039535924,0.002352112,0.00026462076,0.0003317605,0.00024649405],"domain_scores_gemma":[0.98939145,0.008748072,0.0012630215,0.000096519114,0.000093247734,0.00040771236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011921305,0.00016383194,0.0018461302,0.00016313519,0.00007752868,0.0000071023564,0.000064535416,0.000115509276,0.00013384492],"category_scores_gemma":[0.0035599577,0.000111645255,0.00030410578,0.00014030683,0.00007034056,0.000042805685,0.00007526781,0.0005079542,1.1906945e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011287456,0.001096145,0.6429621,0.000017275113,0.00042933677,0.00015130121,0.00004584085,0.000002537234,6.8709807e-7,0.00003126875,0.0001382378,0.3438378],"study_design_scores_gemma":[0.048263967,0.037949547,0.8707001,0.00005949023,0.0005832786,0.00005597656,0.00036634353,0.000044031967,0.000003404208,0.00015145868,0.041701358,0.00012104439],"about_ca_topic_score_codex":0.05003816,"about_ca_topic_score_gemma":0.29048702,"teacher_disagreement_score":0.34371674,"about_ca_system_score_codex":0.0019657125,"about_ca_system_score_gemma":0.002104113,"threshold_uncertainty_score":0.95628774},"labels":[],"label_agreement":null},{"id":"W4281656035","doi":"10.1200/jco.2022.40.16_suppl.tps8597","title":"Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Clinical endpoint; Lung cancer; Stage (stratigraphy); Placebo; Radiation therapy; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Randomized controlled trial; Surgery; Cancer; Pathology; Immunotherapy","score_opus":0.03614782615214683,"score_gpt":0.42440879605671855,"score_spread":0.3882609699045717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281656035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913069,0.000532523,0.00005075147,0.00063305255,0.0005464459,0.0066993143,0.000022938408,0.00001080958,0.00019726055],"genre_scores_gemma":[0.99600536,0.0005588941,0.00046738485,0.00069935404,0.0002542656,0.00073564355,0.00000570273,0.00006506947,0.0012083427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927261,0.0021453777,0.0032617562,0.00044350908,0.0010025711,0.0004206754],"domain_scores_gemma":[0.9900663,0.0044461447,0.0041314582,0.00039474142,0.00058337586,0.00037798664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003010624,0.00038566027,0.0056888415,0.00037787022,0.00012878233,0.000014377919,0.00027891545,0.00016281777,0.0012027806],"category_scores_gemma":[0.00059866434,0.00018461992,0.0004284272,0.00045851668,0.00016667816,0.00012027877,0.00008634248,0.0012835284,4.2988188e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6034316,0.051140778,0.3369761,0.00007642745,0.0037817408,0.0011614694,0.0012092505,0.00034777462,0.0000047352046,5.45211e-7,0.00027389618,0.001595719],"study_design_scores_gemma":[0.7385396,0.20952427,0.045847066,0.00022755905,0.0035407422,0.000044786862,0.0005849654,0.0010630107,0.000012156944,5.731062e-7,0.0004482329,0.00016706708],"about_ca_topic_score_codex":0.00047650537,"about_ca_topic_score_gemma":0.001766802,"teacher_disagreement_score":0.29112905,"about_ca_system_score_codex":0.0015893395,"about_ca_system_score_gemma":0.005341179,"threshold_uncertainty_score":0.99971026},"labels":[],"label_agreement":null},{"id":"W4281658528","doi":"10.1200/jco.2022.40.16_suppl.10054","title":"Long-term medical and functional outcomes of ependymoma survivors: A population-based, matched cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"Garron Family Cancer Centre","keywords":"Medicine; Ependymoma; National Death Index; Cancer registry; Population; Cohort; Pediatrics; Hazard ratio; Cancer; Internal medicine; Surgery; Confidence interval","score_opus":0.08707822598415547,"score_gpt":0.4412595831547275,"score_spread":0.35418135717057203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281658528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059093,0.00019792723,0.000026509795,0.007717461,0.0010275913,0.0003338332,0.000006381637,0.0000057571733,0.00009358464],"genre_scores_gemma":[0.99837095,0.00002805696,0.000158726,0.0011143186,0.00024023556,0.000024715288,0.000014695218,0.000011393096,0.000036933357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958966,0.00060758926,0.0020549353,0.00018218646,0.0011225414,0.00013616301],"domain_scores_gemma":[0.9945043,0.0035178708,0.0012462799,0.00016240787,0.00022074654,0.00034839244],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00415878,0.000116780844,0.0015543578,0.00016532812,0.000067400426,0.000004263458,0.000094948264,0.00014755463,0.0021136552],"category_scores_gemma":[0.0022690522,0.000079557634,0.00037975147,0.00012229988,0.00009246605,0.000038476563,0.000093715666,0.0006037399,0.000002447684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014011349,0.0105898045,0.97427946,0.000015795264,0.0009999382,0.0031739562,0.000023585522,0.000030887164,0.0000022266681,0.000033471475,0.00029945164,0.009150306],"study_design_scores_gemma":[0.0125458315,0.00855728,0.9770322,0.000021674034,0.00070645486,0.00066518685,0.00010625722,0.00005475608,0.0000031561642,0.000056353372,0.00019353071,0.00005734838],"about_ca_topic_score_codex":0.0001799181,"about_ca_topic_score_gemma":0.00034739377,"teacher_disagreement_score":0.011144697,"about_ca_system_score_codex":0.0001342584,"about_ca_system_score_gemma":0.0008884938,"threshold_uncertainty_score":0.99879855},"labels":[],"label_agreement":null},{"id":"W4281660086","doi":"10.1200/jco.2022.40.16_suppl.526","title":"Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; McMaster University; Sinai Health System; Université Laval","funders":"National Institutes of Health","keywords":"Medicine; Metformin; Placebo; Discontinuation; Internal medicine; Breast cancer; Cancer; Insulin","score_opus":0.15199529384254745,"score_gpt":0.4719469433412135,"score_spread":0.31995164949866606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281660086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164414,0.0023082471,0.000053596003,0.0020585188,0.0011437527,0.0025438669,0.00004128642,0.0000073104798,0.00019925188],"genre_scores_gemma":[0.99386793,0.004136554,0.00064769073,0.00012854139,0.0005288087,0.00044805201,0.000008091076,0.000032484324,0.00020181762],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934038,0.0015945499,0.0035869274,0.0003179055,0.00064470916,0.00045211907],"domain_scores_gemma":[0.99095094,0.0052351877,0.003081943,0.00019300326,0.00026806231,0.00027084714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008873304,0.00025837263,0.0033711484,0.0004608378,0.00005250853,0.000010467572,0.0001924898,0.00019295233,0.00035592483],"category_scores_gemma":[0.0013546391,0.00019337739,0.00045457247,0.0004221943,0.0005364216,0.0004131257,0.00011560437,0.0013932717,8.183449e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89040387,0.0018781883,0.0079835225,0.0000104375395,0.0007984731,0.00022385678,0.0012789379,0.0002267679,0.00039240601,0.00006229228,0.000020621701,0.09672063],"study_design_scores_gemma":[0.9518716,0.012503176,0.031787258,0.00010495149,0.00033418828,0.000082611645,0.0012762777,0.00022752555,0.00045316407,0.000107476575,0.0010836881,0.00016809217],"about_ca_topic_score_codex":0.0009304571,"about_ca_topic_score_gemma":0.00087700575,"teacher_disagreement_score":0.096552536,"about_ca_system_score_codex":0.0005746124,"about_ca_system_score_gemma":0.0011822393,"threshold_uncertainty_score":0.7885701},"labels":[],"label_agreement":null},{"id":"W4281661063","doi":"10.1200/jco.2022.40.16_suppl.8043","title":"Demographic disparities in genomic data and clinical trials for multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Demography; Internal medicine; Oncology; Ethnic group","score_opus":0.27132992418739377,"score_gpt":0.5042745065769797,"score_spread":0.23294458238958593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281661063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896431,0.004341104,0.00088540226,0.0023419822,0.0021366605,0.00028765886,0.0003056841,0.0000014574823,0.000056943743],"genre_scores_gemma":[0.98276085,0.008998266,0.003978424,0.002208191,0.0018948,0.000015847027,0.0000864822,0.000017558372,0.000039595976],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99490815,0.001332889,0.00311953,0.00032258438,0.00011694465,0.00019992169],"domain_scores_gemma":[0.9903976,0.0073400433,0.0016189844,0.00035209907,0.00010493107,0.0001863714],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022037549,0.000104948704,0.0011410557,0.00008038407,0.00007368854,0.0000150265105,0.0005307863,0.00025508783,0.0000147967685],"category_scores_gemma":[0.02697432,0.00009287802,0.00039543514,0.000057292098,0.00019761425,0.000005873317,0.00073826493,0.0005392846,3.4043947e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072064106,0.0011723525,0.7669627,0.000018178449,0.000451043,0.000050499522,0.000015835773,0.00019745123,0.0015756303,0.0001719005,0.029968489,0.19220948],"study_design_scores_gemma":[0.010383448,0.008773029,0.28081292,0.0000074680943,0.00020960212,0.00008044355,0.00013076235,0.0012740948,0.00003612064,0.0010697758,0.69706076,0.00016155136],"about_ca_topic_score_codex":0.000027212332,"about_ca_topic_score_gemma":0.00054582686,"teacher_disagreement_score":0.6670923,"about_ca_system_score_codex":0.0000283686,"about_ca_system_score_gemma":0.0010398477,"threshold_uncertainty_score":0.9812219},"labels":[],"label_agreement":null},{"id":"W4281661179","doi":"10.1200/jco.2022.40.16_suppl.e18835","title":"Choosing Wisely Africa: Insights from the front-lines of clinical care.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Calgary","funders":"Conquer Cancer Foundation","keywords":"Concordance; Medicine; Family medicine; Snowball sampling; Vetting; Front line; Descriptive statistics; Pathology; Internal medicine; Statistics","score_opus":0.7210835632797621,"score_gpt":0.5759492120621326,"score_spread":0.14513435121762952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281661179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9018286,0.017799785,0.00069759774,0.0614227,0.010934377,0.00037357924,0.00020748764,0.000011892095,0.0067239767],"genre_scores_gemma":[0.97509634,0.00073207926,0.004973204,0.01498936,0.0039620446,0.000015666672,0.000009967402,0.000027008957,0.0001943375],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9720362,0.004558477,0.022421261,0.00041716264,0.0002764826,0.00029044924],"domain_scores_gemma":[0.9444222,0.030509936,0.023769105,0.0005697975,0.00038893835,0.00034005553],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05451591,0.00016769563,0.0037707016,0.00017445217,0.00025735178,0.000023361448,0.00093850645,0.00035092293,0.0008762405],"category_scores_gemma":[0.043566864,0.00014354558,0.0009929336,0.0001667598,0.00030219802,0.00027331378,0.00024799627,0.0016265674,0.00019003073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015250674,0.002429311,0.6635624,0.00009547371,0.0013032858,0.000053062726,0.0109394835,0.0016205653,0.0000035869095,0.024488047,0.27187324,0.022106487],"study_design_scores_gemma":[0.0034462672,0.0021576202,0.26123568,0.00003805907,0.00006533744,0.000011254792,0.005296003,0.000810484,8.1019886e-7,0.023594521,0.7031835,0.0001604681],"about_ca_topic_score_codex":0.0004953422,"about_ca_topic_score_gemma":0.0002489443,"teacher_disagreement_score":0.43131027,"about_ca_system_score_codex":0.00040914118,"about_ca_system_score_gemma":0.0019440362,"threshold_uncertainty_score":0.9735748},"labels":[],"label_agreement":null},{"id":"W4281663710","doi":"10.1200/jco.2022.40.16_suppl.e21531","title":"Predictors of complication after groin dissection: A contemporary experience.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Surgery; Seroma; Lymphedema; Complication; Dissection (medical); Lymphadenectomy; Wound dehiscence; Sarcoma; Retrospective cohort study; Groin; Melanoma; Cancer; Internal medicine; Breast cancer","score_opus":0.16257228776733568,"score_gpt":0.4685685004620209,"score_spread":0.30599621269468524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281663710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047744,0.0014137262,0.000026607091,0.004978094,0.0010410303,0.00016085144,0.0000053175677,0.0000050368103,0.0018918947],"genre_scores_gemma":[0.9979406,0.00011046097,0.0003572039,0.0010412469,0.0004211139,0.000051874867,0.0000036523504,0.0000067056785,0.00006712081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977042,0.0002876246,0.0015140182,0.00010825556,0.00030775295,0.00007812102],"domain_scores_gemma":[0.99760014,0.0008304981,0.0011087543,0.00014008718,0.00016365015,0.00015685499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009453778,0.00006443005,0.00073357933,0.00007980283,0.00003568387,0.0000018657062,0.00008234442,0.0000731886,0.0005590615],"category_scores_gemma":[0.0004190135,0.000046094883,0.00035481702,0.000114175426,0.000119884535,0.00005315416,0.000052141368,0.0003746258,0.0000028486547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032571068,0.0043008495,0.9748462,0.0000079751335,0.00021559365,0.0005318624,0.0003336273,0.00000388189,0.00005902887,0.00006078522,0.006384681,0.009998452],"study_design_scores_gemma":[0.0036685679,0.010042442,0.91024774,0.000022787619,0.00012454578,0.00089427544,0.0006109125,0.000015723901,0.00008511376,0.00008919037,0.07416452,0.0000341726],"about_ca_topic_score_codex":0.000013398092,"about_ca_topic_score_gemma":0.0000028485315,"teacher_disagreement_score":0.06777984,"about_ca_system_score_codex":0.00012035393,"about_ca_system_score_gemma":0.00054749014,"threshold_uncertainty_score":0.61213315},"labels":[],"label_agreement":null},{"id":"W4281664001","doi":"10.1200/jco.2022.40.16_suppl.11025","title":"Characterization of industry relationships in oncology.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Mentorship; Medicine; Descriptive statistics; Inclusion (mineral); Oncology; Medical education; Radiation oncology; Internal medicine; Family medicine; Psychology","score_opus":0.28464763379718133,"score_gpt":0.5087859018935396,"score_spread":0.22413826809635823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281664001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9362004,0.000055592423,0.00012509378,0.060581706,0.0011023835,0.00010338637,0.0000029479334,0.0000027178771,0.0018258204],"genre_scores_gemma":[0.99685234,0.000121014964,0.000730823,0.0015671068,0.0004525607,0.00000262293,0.000012461131,0.000006044118,0.00025504362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99617755,0.0010663026,0.0021861293,0.00008714343,0.00038797432,0.00009487132],"domain_scores_gemma":[0.99629045,0.0013189263,0.0019060594,0.00008919483,0.00023300528,0.00016239728],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008704219,0.0000500041,0.0007451508,0.0002236879,0.0000435761,0.0000011359726,0.00009137127,0.000859171,0.0003994576],"category_scores_gemma":[0.0024204138,0.000038635993,0.00017024294,0.0003276249,0.0003370908,0.000053582702,0.000059570903,0.0044366224,0.0000016754177],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059525217,0.007886552,0.44625324,0.00007628083,0.00024555498,0.0007058392,0.0011826602,0.00015604097,0.021667568,0.006988821,0.0013982487,0.5074867],"study_design_scores_gemma":[0.0040462944,0.0065633305,0.85119516,0.000043644348,0.000075870215,0.00025091448,0.00030915427,0.0003380526,0.000065770655,0.0018383277,0.13523577,0.00003769529],"about_ca_topic_score_codex":0.000005860408,"about_ca_topic_score_gemma":0.000010015915,"teacher_disagreement_score":0.507449,"about_ca_system_score_codex":0.00021284529,"about_ca_system_score_gemma":0.0025539573,"threshold_uncertainty_score":0.9978602},"labels":[],"label_agreement":null},{"id":"W4281665305","doi":"10.1200/jco.2022.40.16_suppl.9533","title":"Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute; St Joseph's Health Care; Western University; Université de Montréal; London Health Sciences Centre; Cancer Care Ontario; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Gastroenterology; Transplantation; Immunosuppression; Melanoma; Diarrhea; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.04256337530267586,"score_gpt":0.4007772872969335,"score_spread":0.35821391199425767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281665305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958934,0.0002375554,0.000007807255,0.0024992446,0.00036932496,0.00041417827,0.000054531687,0.0000057824386,0.000518184],"genre_scores_gemma":[0.99834394,0.00052496244,0.00028240166,0.00033898614,0.00013128889,0.00001300444,0.000074078984,0.00001850702,0.0002728186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971616,0.00042768763,0.0013918403,0.00022276997,0.0005118009,0.00028425886],"domain_scores_gemma":[0.9981463,0.00066005456,0.000599283,0.00014862837,0.00019465515,0.00025110706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009361361,0.00014397711,0.0010686135,0.00017573647,0.00006728027,0.0000066211687,0.0001374525,0.00014605145,0.0002768854],"category_scores_gemma":[0.0002281993,0.00010036907,0.00027900742,0.00026184184,0.00007177977,0.00006553607,0.000030546824,0.00086170575,0.000006705216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057834856,0.016947594,0.8052809,0.000043564167,0.00047277292,0.0021313524,0.00025653333,0.00016991243,0.012562755,0.0000064567757,0.004875369,0.09941788],"study_design_scores_gemma":[0.074506074,0.10954144,0.7300185,0.00006568113,0.00042898566,0.00029273203,0.00024676038,0.00003054086,0.004691992,0.000004724772,0.07996965,0.00020289602],"about_ca_topic_score_codex":0.00003759986,"about_ca_topic_score_gemma":0.000036103982,"teacher_disagreement_score":0.099214986,"about_ca_system_score_codex":0.00065723865,"about_ca_system_score_gemma":0.0012800085,"threshold_uncertainty_score":0.40929317},"labels":[],"label_agreement":null},{"id":"W4281666355","doi":"10.1200/jco.22.01003","title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke","funders":"National Cancer Institute; Genentech; Eisai; National Institute for Health and Care Research; MacroGenics; Clovis Oncology; NuCana; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Array BioPharma; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer","keywords":"Medicine; Population; Hazard ratio; Internal medicine; Ovarian cancer; Clinical endpoint; Placebo; Oncology; BRCA mutation; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","score_opus":0.10373829953680314,"score_gpt":0.4865092343933121,"score_spread":0.382770934856509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281666355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725434,0.0004131105,0.0006040084,0.018828822,0.002665017,0.004083162,0.00004043208,0.000018805578,0.0008032287],"genre_scores_gemma":[0.97500145,0.0016161955,0.0021814664,0.016819822,0.0019186864,0.0016889716,0.0000144940495,0.00007036678,0.0006885434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991651,0.0026058725,0.0037345998,0.0004844511,0.0010049081,0.00051919324],"domain_scores_gemma":[0.99234796,0.0033708126,0.002686708,0.00040919316,0.00052354304,0.00066179223],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006626099,0.00035397478,0.0037343255,0.00036379218,0.00012004307,0.000017755996,0.00030009964,0.00023249091,0.0023442411],"category_scores_gemma":[0.0016108013,0.00023197121,0.0008287961,0.00044551678,0.00024623697,0.00012783826,0.000050415012,0.0011675247,0.000017000166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8868774,0.010759607,0.004140001,0.000004653581,0.0010836282,0.0005454744,0.0012287819,0.0011353225,0.00002710477,0.00009323227,0.003099129,0.09100565],"study_design_scores_gemma":[0.8412972,0.07603286,0.0026793734,0.00011309878,0.0004875579,0.000046069006,0.00014625069,0.00020810035,0.00003457932,0.00045005287,0.07829754,0.0002073327],"about_ca_topic_score_codex":0.000775651,"about_ca_topic_score_gemma":0.0002051313,"teacher_disagreement_score":0.09079832,"about_ca_system_score_codex":0.0022774716,"about_ca_system_score_gemma":0.0050729,"threshold_uncertainty_score":0.99856776},"labels":[],"label_agreement":null},{"id":"W4281666844","doi":"10.1200/jco.2022.40.16_suppl.tps5623","title":"KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carboplatin; Medicine; Chemotherapy; Pembrolizumab; Internal medicine; Endometrial cancer; Oncology; Docetaxel; Paclitaxel; Randomization; Trastuzumab; Cancer; Surgery; Cisplatin; Randomized controlled trial; Breast cancer; Immunotherapy","score_opus":0.24721202666134545,"score_gpt":0.5099421291822217,"score_spread":0.26273010252087625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281666844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859526,0.002052007,0.000031228712,0.0022435107,0.004700366,0.0039113415,0.000044119955,0.000021019352,0.0010438194],"genre_scores_gemma":[0.99476135,0.0015094961,0.0016842572,0.0006018528,0.0008577499,0.00029121956,0.000018667915,0.00004787482,0.00022750639],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98884076,0.0023796458,0.0062494837,0.00062501075,0.0013729397,0.000532185],"domain_scores_gemma":[0.9792819,0.015073313,0.0040011634,0.0005504013,0.0005463023,0.0005469381],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009566994,0.0004032108,0.0058419304,0.0007445676,0.00015221351,0.000018623683,0.0007318793,0.00026729837,0.00141112],"category_scores_gemma":[0.014331621,0.00027014228,0.00094529137,0.0017517081,0.00020814843,0.00015982355,0.00046342687,0.0018367515,0.000005250671],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81901234,0.07485774,0.0031903256,0.000055580236,0.0012462103,0.0013970012,0.0007154391,0.00016402558,0.000023215187,0.000018879438,0.00053018983,0.09878904],"study_design_scores_gemma":[0.79426515,0.18702099,0.0012128173,0.0000772293,0.0010421282,0.00014530765,0.0011696318,0.00048365718,0.000045258228,0.00006532347,0.014279613,0.00019291393],"about_ca_topic_score_codex":0.00038409815,"about_ca_topic_score_gemma":0.00040937116,"teacher_disagreement_score":0.11216325,"about_ca_system_score_codex":0.0010957032,"about_ca_system_score_gemma":0.0020095136,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W4281669151","doi":"10.1200/jco.2022.40.16_suppl.e18040","title":"Annual household income and its association with financial toxicity, health utility, and survival in head and neck cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quartile; Socioeconomic status; Proportional hazards model; Generalized estimating equation; Cohort; National Death Index; Prospective cohort study; Household income; Head and neck cancer; Cohort study; Demography; Cancer; Confidence interval; Internal medicine; Environmental health; Hazard ratio; Population; Statistics","score_opus":0.12441793615862642,"score_gpt":0.38677788768162774,"score_spread":0.2623599515230013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281669151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818092,0.006828081,0.000020081816,0.009250499,0.0009286385,0.00013948638,0.00040705147,0.000004316512,0.0006126215],"genre_scores_gemma":[0.99124354,0.0060723205,0.00014870721,0.002005086,0.00038206065,0.0000068400236,9.455251e-7,0.000012901953,0.0001275749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734634,0.00016652294,0.001850592,0.00026962842,0.000074767806,0.00029215586],"domain_scores_gemma":[0.9965792,0.0005673619,0.0024760787,0.000075265554,0.000061210456,0.00024088775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00592166,0.00012333618,0.001405929,0.00017319592,0.00012502178,0.000020204625,0.00012599962,0.00019046428,0.000049493465],"category_scores_gemma":[0.0011433878,0.00012570214,0.000071806724,0.00013889479,0.00008370968,0.00034518028,0.00017099467,0.0008915032,8.971429e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069385837,0.00022623024,0.9749712,0.000020935884,0.000040273386,0.000019533854,0.0002935805,0.00005761468,2.8211093e-7,0.004415338,0.00074367685,0.018517505],"study_design_scores_gemma":[0.0039546085,0.0042814957,0.941157,0.000021355403,0.000008240657,0.000028791581,0.000078792,0.0001803904,5.4271e-7,0.0046078437,0.04555392,0.00012705456],"about_ca_topic_score_codex":0.00075381517,"about_ca_topic_score_gemma":0.0030114825,"teacher_disagreement_score":0.044810243,"about_ca_system_score_codex":0.00050975586,"about_ca_system_score_gemma":0.0007887909,"threshold_uncertainty_score":0.5125984},"labels":[],"label_agreement":null},{"id":"W4281669927","doi":"10.1200/jco.2022.40.16_suppl.2022","title":"Brain metastases in the setting of stable extracranial disease: A systematic review and meta-analysis.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Context (archaeology); Brain metastasis; Meta-analysis; Oncology; Disease; Surgery; Metastasis; Cancer; Confidence interval","score_opus":0.37320787987370163,"score_gpt":0.5485659953034987,"score_spread":0.17535811542979707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281669927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000040330974,0.9902029,0.000023879837,0.0070826896,0.000084313775,0.002314933,0.00021871318,0.000002316384,0.00006621365],"genre_scores_gemma":[0.000037789963,0.9943219,0.0010653319,0.004096277,0.00010098838,0.00017873559,0.000051795847,0.000022290038,0.0001249327],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9767121,0.013870347,0.008060119,0.00032003433,0.00080251717,0.00023489253],"domain_scores_gemma":[0.96235055,0.027255211,0.009295168,0.00063808565,0.00015897048,0.00030201106],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037451964,0.00037033236,0.027323434,0.00036972843,0.00004642293,0.00001314091,0.00038153617,0.00018153088,0.0012911746],"category_scores_gemma":[0.01583283,0.0001599631,0.009516583,0.00093956484,0.00012401362,0.000060014117,0.00011162822,0.0014832625,0.0000021139504],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011463356,0.0018319658,0.000019488056,0.6647967,0.2952034,0.0024473453,0.000029085131,0.0000021993262,2.8964355e-9,0.00011409166,0.0017719009,0.033669177],"study_design_scores_gemma":[0.0006093634,0.001203303,0.000032671207,0.0092484085,0.64890075,0.0005614917,0.000039300692,0.0000014614676,1.4237022e-9,0.000022811264,0.339309,0.00007140759],"about_ca_topic_score_codex":0.000016423071,"about_ca_topic_score_gemma":0.000031548007,"teacher_disagreement_score":0.65554833,"about_ca_system_score_codex":0.000113496615,"about_ca_system_score_gemma":0.0018729431,"threshold_uncertainty_score":0.9996218},"labels":[],"label_agreement":null},{"id":"W4281670144","doi":"10.1200/jco.2022.40.16_suppl.7545","title":"Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Internal medicine; Cohort; Oncology; Clinical endpoint; Neutropenia; Gastroenterology; Cancer; Clinical trial; Toxicity; Immunotherapy","score_opus":0.12424472767676215,"score_gpt":0.46060701607648763,"score_spread":0.3363622883997255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281670144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473184,0.00023796069,0.000002594966,0.0016777787,0.00093444396,0.0017651282,0.000060093233,0.000020422112,0.00056970876],"genre_scores_gemma":[0.9961337,0.00023548378,0.00072852673,0.0017360584,0.00039647275,0.0002483794,0.00004770483,0.00007029594,0.00040336416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99265414,0.0018529703,0.0031443303,0.000716764,0.0010533752,0.00057839154],"domain_scores_gemma":[0.9947141,0.001484858,0.0019784877,0.0006722144,0.00035855576,0.00079180626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001853636,0.00046273135,0.003275373,0.00036876954,0.00018938194,0.00005530693,0.000531946,0.00033374425,0.0006954086],"category_scores_gemma":[0.0006344774,0.0002748677,0.00028653178,0.00044379267,0.0002235061,0.0004411342,0.00035686517,0.0007672394,0.000024061022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16121833,0.23341116,0.43296936,0.000009763897,0.0009107697,0.01630728,0.0004615621,0.000011340685,0.000005835073,0.0000108650975,0.0007030222,0.1539807],"study_design_scores_gemma":[0.26159364,0.23631585,0.48351407,0.000048342536,0.0007278193,0.00028107187,0.00033614424,0.00006491215,0.0000050372882,0.000008760542,0.016938785,0.00016558798],"about_ca_topic_score_codex":0.00015281461,"about_ca_topic_score_gemma":0.0002664794,"teacher_disagreement_score":0.15381512,"about_ca_system_score_codex":0.0032858434,"about_ca_system_score_gemma":0.005454133,"threshold_uncertainty_score":0.9999704},"labels":[],"label_agreement":null},{"id":"W4281670534","doi":"10.1200/jco.2022.40.16_suppl.tps5103","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Ottawa Hospital; McGill University; Queen Elizabeth II Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Randomization; Oncology; Randomized controlled trial; Antiandrogen; Tolerability; Prostatectomy; Urology; Cancer; Adverse effect; Pathology","score_opus":0.12138332810913034,"score_gpt":0.4691233173216555,"score_spread":0.3477399892125252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281670534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97995377,0.0026212425,0.00047823135,0.0040162317,0.0009823674,0.011575643,0.0003123342,0.000008009935,0.000052145784],"genre_scores_gemma":[0.9763156,0.019607168,0.0010196372,0.0008498494,0.00042243683,0.0015447483,0.000031462077,0.000037402468,0.0001716729],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931884,0.0022223555,0.0030285409,0.00031280683,0.00091929076,0.00032860867],"domain_scores_gemma":[0.9869311,0.008067549,0.0037304752,0.00025435412,0.0007661175,0.00025042493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010539158,0.00023831513,0.0032193346,0.00028401133,0.00023577374,0.000017501277,0.00025602512,0.00019573812,0.0001984966],"category_scores_gemma":[0.0031379564,0.00012630528,0.0008209876,0.0003609286,0.00039233064,0.00012635087,0.000095022195,0.000740085,2.571728e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8728983,0.0019958005,0.002392979,0.000025087198,0.0034133343,0.000025014819,0.00059128174,0.00022796306,0.00053232734,0.00006725335,0.00040660353,0.117424056],"study_design_scores_gemma":[0.94932145,0.038720977,0.0005808106,0.00008070202,0.0009527467,0.000013640425,0.00017509426,0.00031628148,0.002803588,0.000619532,0.0063002007,0.00011497872],"about_ca_topic_score_codex":0.00010952213,"about_ca_topic_score_gemma":0.00002659694,"teacher_disagreement_score":0.11730908,"about_ca_system_score_codex":0.000415398,"about_ca_system_score_gemma":0.0041383076,"threshold_uncertainty_score":0.734118},"labels":[],"label_agreement":null},{"id":"W4281670642","doi":"10.1200/jco.2022.40.16_suppl.9016","title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Immunohistochemistry; Cohort; Interim analysis; Oncology; Stage (stratigraphy); Clinical endpoint; Cancer; Lung cancer; Interim; Chemotherapy; Clinical trial; Biology","score_opus":0.030104674396273245,"score_gpt":0.4231097895866135,"score_spread":0.39300511519034026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281670642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209857,0.0028834224,0.00009303816,0.0007382252,0.0006767169,0.00083962234,0.000018870103,0.000013488774,0.002638021],"genre_scores_gemma":[0.9917909,0.0011624126,0.0038714602,0.0021505468,0.00029743422,0.00010216259,0.000018540128,0.000050001167,0.0005565608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968156,0.00036648175,0.0017461076,0.0003185665,0.0003937461,0.0003594577],"domain_scores_gemma":[0.9968876,0.0005403623,0.0017235731,0.00023147059,0.00032712528,0.0002898439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076779944,0.00022299276,0.001295626,0.00021179131,0.00012212025,0.00001450027,0.00019404881,0.00015990443,0.00034666903],"category_scores_gemma":[0.00013716008,0.00015739475,0.00028993658,0.00031043845,0.00007698787,0.00015413211,0.0000562655,0.0010382526,0.0000026531027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012258976,0.0053140284,0.76830035,0.00006213078,0.0005346798,0.00035718095,0.0011505717,0.0028326537,0.00017674179,0.000002571908,0.001829886,0.20718025],"study_design_scores_gemma":[0.13946053,0.05423244,0.7064183,0.0009534655,0.0019431759,0.00008920941,0.0009823831,0.0007478973,0.00036288615,0.000035493453,0.09432333,0.00045089077],"about_ca_topic_score_codex":0.00025488384,"about_ca_topic_score_gemma":0.00011106329,"teacher_disagreement_score":0.20672935,"about_ca_system_score_codex":0.0013488911,"about_ca_system_score_gemma":0.003153681,"threshold_uncertainty_score":0.6418372},"labels":[],"label_agreement":null},{"id":"W4281671615","doi":"10.1200/jco.2022.40.16_suppl.tps5615","title":"ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; MEK inhibitor; Neuroblastoma RAS viral oncogene homolog; Ovarian cancer; Serous fluid; Cancer; Cancer research; Selumetinib; Internal medicine; MAPK/ERK pathway; Kinase; Oncology; Biology","score_opus":0.0909682580429039,"score_gpt":0.456641226699635,"score_spread":0.36567296865673105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281671615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622227,0.0011065346,0.00000830431,0.010484033,0.0010683676,0.0010022915,0.00001565757,0.0000064632814,0.0000860993],"genre_scores_gemma":[0.9972524,0.0011513627,0.00038612858,0.000678901,0.00032001853,0.00014018398,0.000008246333,0.000026042588,0.000036706326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951667,0.0010468229,0.0024987827,0.00037368145,0.00061602006,0.0002979835],"domain_scores_gemma":[0.9958139,0.0015726268,0.0018747695,0.00022285941,0.00022719057,0.0002886595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002853267,0.00022059392,0.0018754102,0.0003653522,0.00006200099,0.0000105081335,0.00013583788,0.00019162048,0.00019043355],"category_scores_gemma":[0.00046480584,0.00016949736,0.00016085811,0.00043395907,0.00012382603,0.00012128479,0.00009847312,0.0015543173,0.0000010572172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030146249,0.08160508,0.7333102,0.0000836484,0.00068004424,0.0026227778,0.0029465782,0.00028870945,0.00005847725,0.000053160886,0.0012670972,0.14693798],"study_design_scores_gemma":[0.14318909,0.096555665,0.75038177,0.00034852038,0.00059654145,0.00026040603,0.0020763713,0.00020756801,0.00007930594,0.000110299414,0.0060157673,0.00017868775],"about_ca_topic_score_codex":0.00092690653,"about_ca_topic_score_gemma":0.0045079603,"teacher_disagreement_score":0.14675929,"about_ca_system_score_codex":0.00080309185,"about_ca_system_score_gemma":0.0017121057,"threshold_uncertainty_score":0.6911902},"labels":[],"label_agreement":null},{"id":"W4281672405","doi":"10.1200/jco.2022.40.16_suppl.11547","title":"Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Circulating tumor DNA; Radiation therapy; Biomarker; Minimal residual disease; Population; Cancer; Gastroenterology; Genetics; Biology","score_opus":0.05955422971865798,"score_gpt":0.4194084173538706,"score_spread":0.3598541876352126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281672405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920283,0.0020484584,0.00026433228,0.004429019,0.0006915162,0.00033039195,0.000007388499,0.00000910695,0.00019148551],"genre_scores_gemma":[0.9976687,0.000058525737,0.0006809982,0.0012941414,0.00021988955,0.000025175032,0.000006197641,0.000024815105,0.00002159274],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995368,0.0011452591,0.0022928359,0.00025788223,0.00067792315,0.00025812507],"domain_scores_gemma":[0.9965311,0.0011139876,0.0015337693,0.00022873457,0.00019610712,0.00039629798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024248138,0.0001571741,0.001254494,0.00029245493,0.00006731994,0.000006792166,0.00014815053,0.00012953847,0.00038343505],"category_scores_gemma":[0.0031928932,0.00013153107,0.0005368212,0.00028289168,0.00014437563,0.00006028062,0.00013653414,0.0007117575,0.0000070564984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02863089,0.016774012,0.23034509,0.00011591033,0.0011594733,0.11245142,0.00013955643,0.0009295844,0.070463605,0.00011974772,0.00055529666,0.5383154],"study_design_scores_gemma":[0.025135472,0.013340997,0.9397455,0.00015089514,0.0012174875,0.0036264816,0.00033668807,0.0013087159,0.003397554,0.0014794883,0.0100607835,0.00019998047],"about_ca_topic_score_codex":0.00011879355,"about_ca_topic_score_gemma":0.00002531879,"teacher_disagreement_score":0.70940036,"about_ca_system_score_codex":0.0003160011,"about_ca_system_score_gemma":0.0012677222,"threshold_uncertainty_score":0.5363681},"labels":[],"label_agreement":null},{"id":"W4281673499","doi":"10.1200/jco.2022.40.16_suppl.e21506","title":"Literature on target therapy of malignant melanoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; Providence Health Care","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Dacarbazine; Oncology; Internal medicine; Combination therapy; Melanoma; Carboplatin; Bevacizumab; Dysgeusia; Mucosal melanoma; Immunotherapy; Surgery; Chemotherapy; Cancer; Adverse effect; Cancer research; Cisplatin","score_opus":0.0987984687595069,"score_gpt":0.4408057179688073,"score_spread":0.34200724920930037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281673499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710603,0.007528213,0.000014163938,0.014757296,0.0024276474,0.00016114817,0.00001604339,0.0000050747935,0.00403011],"genre_scores_gemma":[0.98260057,0.0046858047,0.0010984807,0.010063725,0.0008154171,0.0000039706947,0.0000047049903,0.000013475202,0.0007138442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971956,0.0004993437,0.0016584172,0.00011561537,0.00039852923,0.00013247019],"domain_scores_gemma":[0.997239,0.0008111788,0.0014627267,0.00017319746,0.000193906,0.000120007164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00329552,0.00009128035,0.00097161176,0.00013364146,0.00004238042,0.000003433141,0.0001722796,0.000163355,0.001329776],"category_scores_gemma":[0.00035169607,0.000057519796,0.00068746816,0.0002060169,0.0001104968,0.000033586395,0.000030399378,0.0009742606,0.0000022217976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21586242,0.007791506,0.040040094,0.000042091615,0.0020677382,0.0024871563,0.0008980751,0.000047470407,0.015588191,0.00047751944,0.067125514,0.6475722],"study_design_scores_gemma":[0.012863944,0.060390227,0.08033848,0.00008609171,0.000048389084,0.00072987925,0.00015479828,0.000011340404,0.0012776959,0.0004689821,0.84356004,0.00007012647],"about_ca_topic_score_codex":0.0000051532297,"about_ca_topic_score_gemma":8.5211553e-7,"teacher_disagreement_score":0.77643454,"about_ca_system_score_codex":0.00010670771,"about_ca_system_score_gemma":0.00096059294,"threshold_uncertainty_score":0.9995831},"labels":[],"label_agreement":null},{"id":"W4281673802","doi":"10.1200/jco.2022.40.16_suppl.tps5096","title":"TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Olaparib; PARP inhibitor; Prostate cancer; Placebo; Internal medicine; Androgen receptor; Oncology; Cancer; Pathology; Poly ADP ribose polymerase; Genetics; Biology; Gene","score_opus":0.1576914169105703,"score_gpt":0.4849085811949972,"score_spread":0.32721716428442693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281673802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914437,0.0003535415,0.000108309905,0.00072278274,0.0017579828,0.0052464437,0.00012235518,0.00001597911,0.00022893953],"genre_scores_gemma":[0.99728876,0.0001810725,0.00088462594,0.00056821026,0.0002828894,0.0005830892,0.00006004075,0.000055561195,0.00009574199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903561,0.0026736367,0.004538094,0.00049148937,0.0014827038,0.00045800672],"domain_scores_gemma":[0.98951113,0.0037400972,0.004815754,0.0003269579,0.0012108309,0.00039521887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045264564,0.00037295165,0.0039750934,0.00052442506,0.00013103595,0.00001791486,0.00023423418,0.00016641163,0.00031206492],"category_scores_gemma":[0.0010190519,0.0002855703,0.0004836921,0.0006873584,0.0005035668,0.00025268376,0.00010424146,0.0018843904,0.000003735375],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9526773,0.010786604,0.0063631088,0.00004138565,0.0027694881,0.0016268122,0.004354943,0.017048685,0.00016907926,0.000017536615,0.00022462482,0.0039204345],"study_design_scores_gemma":[0.9386192,0.04987513,0.0040896474,0.0001263038,0.0017484722,0.00016801279,0.0034802908,0.0007090355,0.00049899856,0.000034783177,0.00039875918,0.000251395],"about_ca_topic_score_codex":0.0004053627,"about_ca_topic_score_gemma":0.0005827794,"teacher_disagreement_score":0.03908852,"about_ca_system_score_codex":0.0016636588,"about_ca_system_score_gemma":0.0060661747,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W4281674079","doi":"10.1200/jco.2022.40.16_suppl.8032","title":"A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Oncology; Population; Cytokine release syndrome; Lenalidomide; Multiple myeloma; Gastroenterology; Immunotherapy; Cancer","score_opus":0.1389415827981114,"score_gpt":0.46661091116697845,"score_spread":0.3276693283688671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281674079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619729,0.0012883034,0.0233324,0.0065422566,0.0008347289,0.0051047336,0.0003720874,0.000020541871,0.00053207466],"genre_scores_gemma":[0.9832642,0.000534056,0.013972618,0.0003709908,0.0003573669,0.00029113493,0.00036761296,0.00006132505,0.00078070426],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99543244,0.0005960343,0.0025851452,0.00035356887,0.000667164,0.00036563954],"domain_scores_gemma":[0.98863393,0.007867718,0.0021110987,0.00048898236,0.0007455799,0.00015270537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055570845,0.00022371911,0.001538428,0.00039736243,0.00018957941,0.000014511047,0.00034067302,0.0002491045,0.00012452425],"category_scores_gemma":[0.0010477795,0.00013665734,0.0006454139,0.00048797476,0.0003621587,0.00007754287,0.000025656507,0.00088833395,4.4059888e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57370377,0.08936743,0.001750208,0.00006346217,0.0011866437,0.00012472598,0.0007322015,0.0011748564,0.06773417,0.000077206554,0.0019770518,0.26210827],"study_design_scores_gemma":[0.34951854,0.18620624,0.0067052203,0.000039085822,0.00024893734,0.00012410805,0.0008365262,0.021417335,0.0017893502,0.000029870447,0.43293852,0.00014627066],"about_ca_topic_score_codex":0.000053645028,"about_ca_topic_score_gemma":0.000058033223,"teacher_disagreement_score":0.43096146,"about_ca_system_score_codex":0.0008824071,"about_ca_system_score_gemma":0.002313283,"threshold_uncertainty_score":0.55727243},"labels":[],"label_agreement":null},{"id":"W4281674598","doi":"10.1200/jco.2022.40.16_suppl.508","title":"Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Tamoxifen; Hazard ratio; Oncology; Adjuvant; Randomization; Relative risk; Clinical trial; Randomized controlled trial; Cancer; Gynecology; Confidence interval","score_opus":0.044655869791955564,"score_gpt":0.4023459941710787,"score_spread":0.3576901243791231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281674598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834745,0.010984999,0.000384266,0.0038286336,0.0008347721,0.00041625352,0.00005920502,0.0000049885216,0.000012401714],"genre_scores_gemma":[0.99003315,0.0073622507,0.0014810986,0.00022015652,0.000652404,0.000071581715,0.0000013908045,0.000025758043,0.00015220442],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996537,0.0005165494,0.0020927805,0.00023987233,0.0003777325,0.0002360438],"domain_scores_gemma":[0.99310684,0.003677561,0.0024900376,0.00021369028,0.0003139167,0.00019792456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012326705,0.0001780664,0.0025904495,0.0002996636,0.00004079859,0.0000016771842,0.0001367764,0.00011310692,0.000102420614],"category_scores_gemma":[0.0005944874,0.00012353095,0.0005678508,0.00027393986,0.00017859574,0.000056304023,0.00004695236,0.00053282274,1.552886e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019597154,0.0022729284,0.31597313,0.000051942145,0.0009894667,0.0001428761,0.0002316141,0.00014820108,0.0010810929,0.000022814605,0.000043749973,0.65944505],"study_design_scores_gemma":[0.034044065,0.040024687,0.9031892,0.00009093035,0.0010566353,0.00025361753,0.00009854653,0.000054633783,0.00048109333,0.0006296939,0.019965304,0.00011158401],"about_ca_topic_score_codex":0.001962844,"about_ca_topic_score_gemma":0.00025598853,"teacher_disagreement_score":0.65933347,"about_ca_system_score_codex":0.0012627458,"about_ca_system_score_gemma":0.0008830452,"threshold_uncertainty_score":0.50374454},"labels":[],"label_agreement":null},{"id":"W4281676882","doi":"10.1200/jco.2022.40.16_suppl.102","title":"Largest evaluation of acquired resistance to sotorasib in <i>KRAS</i> p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Amgen","keywords":"KRAS; Medicine; Colorectal cancer; Internal medicine; Oncology; Clinical endpoint; Lung cancer; Progression-free survival; Cancer; Biomarker; Tumor progression; Overall survival; Clinical trial","score_opus":0.07079144942081898,"score_gpt":0.48157992749400935,"score_spread":0.41078847807319036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281676882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921862,0.0027604466,0.00003764144,0.0025485216,0.0006143541,0.00072565576,0.0002011671,0.0000038921544,0.0009221155],"genre_scores_gemma":[0.99757624,0.0006970625,0.0006971574,0.00052537426,0.00008693767,0.00014192874,0.000025643612,0.000017704993,0.00023195511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960577,0.0006544079,0.002109338,0.00027733578,0.0006796369,0.00022161215],"domain_scores_gemma":[0.99571794,0.00093602616,0.0019214916,0.00015561795,0.0010296106,0.00023930792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00329383,0.00015643943,0.0016284672,0.0005392437,0.000060161936,0.0000050176345,0.00014016613,0.0001643872,0.0004817119],"category_scores_gemma":[0.0005691829,0.00012710047,0.0003456679,0.0012204236,0.00012455611,0.000071837974,0.000073594194,0.0002519671,3.493057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010679631,0.0025065313,0.9430735,0.00011259949,0.00489675,0.00011746141,0.001444646,0.007831793,0.010154876,0.0000088858615,0.0033420278,0.01583131],"study_design_scores_gemma":[0.01612562,0.0026852265,0.95108986,0.0001700312,0.014844457,0.000012668971,0.00042568299,0.010400572,0.0015080749,0.000017537783,0.0025874393,0.00013285718],"about_ca_topic_score_codex":0.00094601774,"about_ca_topic_score_gemma":0.0079526445,"teacher_disagreement_score":0.015698453,"about_ca_system_score_codex":0.000944259,"about_ca_system_score_gemma":0.0043004146,"threshold_uncertainty_score":0.7628751},"labels":[],"label_agreement":null},{"id":"W4281677430","doi":"10.1200/jco.2022.40.16_suppl.e19024","title":"Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Azacitidine; Quality of life (healthcare); Placebo; Clinical endpoint; Internal medicine; Myeloid leukemia; Clinical trial; Oncology; Gastroenterology","score_opus":0.10873777328544383,"score_gpt":0.42922506705934815,"score_spread":0.32048729377390434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281677430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764529,0.00027354617,0.000018815548,0.02134822,0.0005320927,0.0010300775,0.00003943566,0.000016418628,0.00028851832],"genre_scores_gemma":[0.99213654,0.0012827115,0.0021641399,0.0035969564,0.00029674068,0.000051609888,0.00003286274,0.000055795757,0.0003826369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98621255,0.0043899748,0.0066714687,0.000471979,0.0014912407,0.00076279574],"domain_scores_gemma":[0.9832765,0.009768237,0.005068625,0.00043151868,0.00062655425,0.00082855823],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01734272,0.0003003925,0.003961542,0.0009069031,0.000093905335,0.000009183029,0.0005274401,0.00044180767,0.0008827082],"category_scores_gemma":[0.017449072,0.0002187424,0.00031516523,0.0013405317,0.00035513,0.00019380098,0.00034989705,0.004444076,0.0000062035215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.098939545,0.0026977283,0.8622422,0.00021490916,0.0005469627,0.0018172618,0.0007221134,0.00058944814,0.0001233744,0.000031892567,0.004145391,0.027929144],"study_design_scores_gemma":[0.07779848,0.03344965,0.88355577,0.00041494222,0.00008980222,0.000121582074,0.00095789065,0.00024423716,0.00003143104,0.00006392061,0.0030626021,0.00020970842],"about_ca_topic_score_codex":0.0014654018,"about_ca_topic_score_gemma":0.0052905967,"teacher_disagreement_score":0.03075192,"about_ca_system_score_codex":0.003916847,"about_ca_system_score_gemma":0.014179489,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W4281678200","doi":"10.1200/jco.2022.40.16_suppl.e18614","title":"Impact of neuroendocrine tumor diagnosis (NET) on quality of life.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biobank; Quality of life (healthcare); Disease; Internal medicine; Institutional review board; Family medicine; Physical therapy; Surgery","score_opus":0.20686631017745158,"score_gpt":0.5578018548869235,"score_spread":0.35093554470947186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281678200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99067974,0.00031224583,0.0000022461502,0.0065929363,0.0006238445,0.00027106097,0.00003470425,0.000007539681,0.001475709],"genre_scores_gemma":[0.9969862,0.0005719448,0.00030913274,0.0014653598,0.00048002138,0.0000146573975,0.0000018054976,0.0000238847,0.00014700527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920407,0.0021950488,0.0039727404,0.00023143142,0.0011970657,0.00036303606],"domain_scores_gemma":[0.9848222,0.009719057,0.0038739473,0.00039268326,0.0005406582,0.00065146387],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026309022,0.00016132483,0.002483885,0.00031995776,0.00004232996,0.0000027128153,0.0004194167,0.000010709057,0.0014700296],"category_scores_gemma":[0.035918605,0.00011448825,0.0013286175,0.00036621065,0.00034579192,0.000087572014,0.00026660718,0.001975324,0.000005990147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029959772,0.009568817,0.91058344,0.000116082454,0.00047220706,0.011457957,0.0000136089375,0.0005875634,0.0009862238,0.00012677824,0.023099085,0.01302848],"study_design_scores_gemma":[0.010479685,0.12733237,0.82871264,0.000041321502,0.00012326725,0.00260158,0.000086486136,0.000025829393,0.00070945494,0.00026175863,0.029537346,0.0000882318],"about_ca_topic_score_codex":0.00011892252,"about_ca_topic_score_gemma":0.000013038227,"teacher_disagreement_score":0.117763564,"about_ca_system_score_codex":0.00019364298,"about_ca_system_score_gemma":0.0027038855,"threshold_uncertainty_score":0.99944276},"labels":[],"label_agreement":null},{"id":"W4281678979","doi":"10.1200/jco.2022.40.16_suppl.tps7583","title":"inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Rituximab; Lenalidomide; Follicular lymphoma; Internal medicine; Phases of clinical research; Oncology; CD20; Lymphoma; Clinical trial; Gastroenterology; Multiple myeloma","score_opus":0.12665443699702822,"score_gpt":0.451538070324499,"score_spread":0.3248836333274708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281678979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077755,0.0033654,0.00010371101,0.0025089385,0.0012890688,0.0016970495,0.000069996146,0.00001448682,0.00017378374],"genre_scores_gemma":[0.9946902,0.0009919512,0.002428567,0.00069351826,0.00064049085,0.0002113724,0.000014938882,0.000048717942,0.00028027935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940551,0.0009693212,0.003114023,0.00056129217,0.00082973705,0.00047053694],"domain_scores_gemma":[0.9884694,0.0075386935,0.0025584735,0.0003868595,0.00041180907,0.000634756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004122395,0.00039044296,0.0035724847,0.0003401447,0.00026387212,0.000026501117,0.00025032985,0.00032490562,0.00016496044],"category_scores_gemma":[0.0027206922,0.0002822549,0.0006067315,0.00022185122,0.00033361628,0.00019361397,0.00029598898,0.0006468651,0.0000036000592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73904353,0.09532422,0.0069226846,0.00019066577,0.0045093093,0.008921503,0.0013828789,0.000044696237,0.00010430378,0.00012896533,0.0052182544,0.13820896],"study_design_scores_gemma":[0.7881477,0.13396315,0.011191539,0.00011263136,0.004011034,0.0023080562,0.004758919,0.00046807944,0.000091508104,0.00006453762,0.054617375,0.0002654757],"about_ca_topic_score_codex":0.0001624941,"about_ca_topic_score_gemma":0.00015151608,"teacher_disagreement_score":0.13794349,"about_ca_system_score_codex":0.0012482966,"about_ca_system_score_gemma":0.0034640336,"threshold_uncertainty_score":0.999963},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4281680466","doi":"10.1200/jco.2022.40.16_suppl.tps8601","title":"TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Medicine; Crizotinib; Pemetrexed; Lung cancer; Internal medicine; Cohort; Oncology; Retrospective cohort study; Cancer; Chemotherapy; Adenocarcinoma; Cisplatin","score_opus":0.06680034650621461,"score_gpt":0.5470637216356914,"score_spread":0.4802633751294768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281680466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845977,0.0010222439,0.000028097651,0.006833416,0.0010339028,0.0009419562,0.00016173396,0.0000061359196,0.0015127741],"genre_scores_gemma":[0.99360996,0.00007359149,0.0004632998,0.0044765593,0.0006073919,0.00013963341,0.000004024936,0.000013525114,0.0006119918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978249,0.00021683049,0.0013148033,0.00020709833,0.00023792984,0.00019841117],"domain_scores_gemma":[0.9981752,0.0005143459,0.0008425303,0.000091034184,0.00016852972,0.00020835965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012988265,0.00011627231,0.0010139511,0.00008063046,0.00024558787,0.000005772992,0.00008075601,0.000079576974,0.00026016604],"category_scores_gemma":[0.00047728157,0.000086120606,0.00021133582,0.00018393755,0.0000796848,0.00005804986,0.000117699405,0.0004647122,2.794802e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02490642,0.04185051,0.6194662,0.000036093257,0.0020227386,0.0015464262,0.00560654,0.00013359963,0.00009614599,0.00015382646,0.012961415,0.29122007],"study_design_scores_gemma":[0.17402413,0.2835262,0.2914404,0.00019568311,0.0039048428,0.0011177728,0.0077342,0.001053528,0.000035435914,0.00045475215,0.23620266,0.00031036197],"about_ca_topic_score_codex":0.00021938862,"about_ca_topic_score_gemma":0.00037734755,"teacher_disagreement_score":0.32802582,"about_ca_system_score_codex":0.0006180133,"about_ca_system_score_gemma":0.0017245052,"threshold_uncertainty_score":0.35118964},"labels":[],"label_agreement":null},{"id":"W4281681049","doi":"10.1200/jco.2022.40.16_suppl.5025","title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Proportional hazards model; Progression-free survival; Androgen deprivation therapy; Cancer; Randomized controlled trial; Overall survival; Confidence interval","score_opus":0.22242967973475058,"score_gpt":0.5031369747882891,"score_spread":0.28070729505353853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281681049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924327,0.0014812865,0.000005120815,0.0049493634,0.00032862023,0.0007073252,0.00008929392,0.0000025341383,0.0000037325694],"genre_scores_gemma":[0.9970429,0.0022455743,0.00038670018,0.00017961433,0.000035775684,0.000030025943,0.000006170186,0.000007542373,0.00006569809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944029,0.0030368108,0.0018141951,0.00016132474,0.00044658364,0.00013821645],"domain_scores_gemma":[0.99250066,0.0054062414,0.0014183066,0.00013441134,0.00039834934,0.00014204411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053780163,0.00010399585,0.0017561724,0.0004873306,0.000045579734,0.0000055834043,0.000080988415,0.00006282841,0.00003848992],"category_scores_gemma":[0.0037654627,0.000059501315,0.00029550242,0.0009847551,0.00016941033,0.000046508387,0.00006133574,0.00036077143,5.0606513e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092461884,0.0005467736,0.8638817,0.000019660103,0.0059425333,0.00011575248,0.0012205911,0.0005215072,0.0026456728,0.0000016462565,0.000022982988,0.032619286],"study_design_scores_gemma":[0.017412324,0.009157393,0.96897215,0.000035130342,0.0031852743,0.000012312521,0.00038441824,0.0002022223,0.0005090792,0.000009594937,0.00007652112,0.000043599997],"about_ca_topic_score_codex":0.00016470761,"about_ca_topic_score_gemma":0.0005501171,"teacher_disagreement_score":0.10509042,"about_ca_system_score_codex":0.00019415613,"about_ca_system_score_gemma":0.001513735,"threshold_uncertainty_score":0.45078826},"labels":[],"label_agreement":null},{"id":"W4281681549","doi":"10.1200/jco.2022.40.16_suppl.e18628","title":"Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gynecologic oncology; Psychological intervention; Hepatitis B virus; Cancer; Oncology; Hepatitis B; Gynecology; Immunology","score_opus":0.1492836367092311,"score_gpt":0.4669587234167426,"score_spread":0.31767508670751154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281681549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752203,0.0001225299,0.000064373206,0.022458708,0.0009019401,0.00067945174,0.00004288068,0.000006915076,0.00050290616],"genre_scores_gemma":[0.9791653,0.0028517758,0.0015636997,0.015843783,0.00036814864,0.00011947622,0.000008679238,0.000018644636,0.000060497066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928765,0.0027455885,0.0031124707,0.00029085076,0.0006611741,0.0003133871],"domain_scores_gemma":[0.9899219,0.005049301,0.004084952,0.00021515577,0.00056118774,0.00016745811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006843267,0.00017019954,0.0014341956,0.00019981102,0.00019219003,0.0000035429516,0.00025228428,0.00018860803,0.00024386788],"category_scores_gemma":[0.007863339,0.000119821096,0.00036787268,0.0002858335,0.00021520931,0.00010834384,0.00035195347,0.0014184258,0.0000017654663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006082835,0.0024022248,0.72951293,0.0000133524945,0.00034291216,0.000039728493,0.0013274181,0.0000532828,0.00049900607,0.0000071549207,0.0037347306,0.25598446],"study_design_scores_gemma":[0.009517843,0.01519406,0.9396917,0.00008738621,0.00010274806,0.000019886505,0.0003121972,0.00006084571,0.00023314373,0.00012408171,0.03455425,0.0001018048],"about_ca_topic_score_codex":0.0034628292,"about_ca_topic_score_gemma":0.008911343,"teacher_disagreement_score":0.25588265,"about_ca_system_score_codex":0.0020259565,"about_ca_system_score_gemma":0.0011342178,"threshold_uncertainty_score":0.941372},"labels":[],"label_agreement":null},{"id":"W4281682418","doi":"10.1200/jco.2022.40.16_suppl.tps4187","title":"PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"3D Printing in Biomedical Research","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemcitabine; Pancreatic cancer; Oncology; Internal medicine; Paclitaxel; Concomitant; Chemotherapy; Cancer","score_opus":0.08262212346181273,"score_gpt":0.44084720927711374,"score_spread":0.358225085815301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281682418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952774,0.0012085972,0.0022743868,0.0002709322,0.00022991505,0.00058871164,0.00001754443,0.000012011109,0.00012052166],"genre_scores_gemma":[0.98790264,0.00016760499,0.0115922745,0.000033897,0.0001669072,0.000059563255,0.0000021604226,0.000025211206,0.000049748083],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9967716,0.0002968719,0.0020296369,0.00017917012,0.00046263728,0.00026013888],"domain_scores_gemma":[0.9939965,0.0044600153,0.0008420664,0.0002063539,0.00028045307,0.00021458487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002007494,0.00015353475,0.0014299166,0.00016289961,0.000053469554,0.000004621229,0.00022244368,0.00009278481,0.00007036263],"category_scores_gemma":[0.001867316,0.00010963718,0.00017097546,0.00020101455,0.00016111565,0.000055333636,0.00008298585,0.00048150236,2.3483047e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023321403,0.02437033,0.24258234,0.000604631,0.0031442733,0.00091544335,0.0029841855,0.014563938,0.0023638387,0.00006701367,0.0004095188,0.6846731],"study_design_scores_gemma":[0.13105649,0.6340709,0.17064738,0.00028729517,0.0013495319,0.00041568006,0.008733513,0.04422175,0.0010402584,0.0005079503,0.0071902466,0.0004790337],"about_ca_topic_score_codex":0.000042277148,"about_ca_topic_score_gemma":0.000048098766,"teacher_disagreement_score":0.684194,"about_ca_system_score_codex":0.00016429188,"about_ca_system_score_gemma":0.000395633,"threshold_uncertainty_score":0.44708744},"labels":[],"label_agreement":null},{"id":"W4281682623","doi":"10.1200/jco.2022.40.16_suppl.e17029","title":"DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Internal medicine; Adverse effect; Interim analysis; Clinical endpoint; Placebo; Oncology; Cancer; Randomized controlled trial","score_opus":0.1871923208535928,"score_gpt":0.4913599537361473,"score_spread":0.30416763288255455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281682623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993785,0.00023172612,0.0000027240283,0.004384264,0.0004042495,0.00093698845,0.00004221801,0.0000043043833,0.00020848967],"genre_scores_gemma":[0.99779826,0.000067437,0.0006050447,0.00066471746,0.00016000462,0.0000919604,0.000024662739,0.000017020924,0.00057086616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612033,0.00065671303,0.0016952278,0.0002130795,0.0010524439,0.00026219],"domain_scores_gemma":[0.99739283,0.00071806816,0.001004807,0.00014260125,0.0005090129,0.00023265922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002679335,0.0001264363,0.00091972004,0.00019345494,0.000106119085,0.000010661478,0.00014154478,0.000056121233,0.00043142057],"category_scores_gemma":[0.0004718865,0.00008169256,0.00013397502,0.00035819234,0.00011877906,0.00014125771,0.000071746545,0.0011022018,0.0000027790657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031048536,0.0078716045,0.94524306,0.000018699466,0.00043334177,0.0009973363,0.00044416395,0.00062812545,0.00002064105,0.000010387612,0.00069259177,0.012591487],"study_design_scores_gemma":[0.029926708,0.039290503,0.9253058,0.00003302188,0.00021121326,0.000016492404,0.0007647681,0.000053372463,0.0000034630038,0.00008003889,0.0042399135,0.00007472721],"about_ca_topic_score_codex":0.00012397591,"about_ca_topic_score_gemma":0.00043225868,"teacher_disagreement_score":0.031418897,"about_ca_system_score_codex":0.00071332266,"about_ca_system_score_gemma":0.0046525323,"threshold_uncertainty_score":0.82533926},"labels":[],"label_agreement":null},{"id":"W4281682739","doi":"10.1200/jco.2022.40.16_suppl.5505","title":"Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Ovarian cancer; Regimen; Internal medicine; Cyclophosphamide; Gastroenterology; Oncology; Urology; Cancer; Chemotherapy; Surgery; Immunotherapy","score_opus":0.03948700336653758,"score_gpt":0.3886118903320324,"score_spread":0.3491248869654948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281682739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977769,0.017055707,0.000010208211,0.0010563456,0.003282391,0.0004177315,0.0002929354,0.0000067943515,0.00010885455],"genre_scores_gemma":[0.9809812,0.017829977,0.0001691863,0.00044185348,0.00013063024,0.00002175173,0.00003323292,0.000018293988,0.00037389898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99344295,0.0026836852,0.0031395424,0.00033214636,0.000111811256,0.00028983646],"domain_scores_gemma":[0.9930847,0.0041402443,0.0023309716,0.00025303333,0.00013000464,0.000061014536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00436691,0.00019694399,0.0017001053,0.00019825797,0.00014777477,0.0000065660283,0.00029346067,0.00037867957,0.00051388366],"category_scores_gemma":[0.0021666042,0.00016345353,0.00023486304,0.00015173515,0.00047651344,0.00014956079,0.0002011903,0.0013784199,0.0000029208231],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62967837,0.002218633,0.0042388225,0.0000079010615,0.00043471754,0.00015215832,0.0005860613,0.00004402997,0.106218815,0.000033170447,0.0003386132,0.2560487],"study_design_scores_gemma":[0.58529043,0.032722637,0.23601066,0.00016853068,0.00025977,0.00028250448,0.00078787305,0.000022797056,0.010727138,0.00048625912,0.13292067,0.0003207091],"about_ca_topic_score_codex":0.0007917482,"about_ca_topic_score_gemma":0.00006949932,"teacher_disagreement_score":0.255728,"about_ca_system_score_codex":0.00011109399,"about_ca_system_score_gemma":0.0011279206,"threshold_uncertainty_score":0.66654414},"labels":[],"label_agreement":null},{"id":"W4281683029","doi":"10.1200/jco.2022.40.16_suppl.7503","title":"First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"ABVD; Dacarbazine; Brentuximab vedotin; Medicine; Vinblastine; Internal medicine; Oncology; Bleomycin; Population; Progression-free survival; Chemotherapy regimen; Chemotherapy; Surgery; Lymphoma; Vincristine; Hodgkin lymphoma; Cyclophosphamide","score_opus":0.04392624238914087,"score_gpt":0.38510317768361135,"score_spread":0.34117693529447046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281683029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943663,0.000040662275,0.00008433847,0.004243502,0.0005227707,0.00046634936,0.00008521804,0.000009576403,0.00018128297],"genre_scores_gemma":[0.99603504,0.00006197559,0.0012850739,0.0020979606,0.00019814231,0.000020664344,0.00011208868,0.000028531065,0.0001605234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951143,0.0005986026,0.0026249408,0.00041445048,0.0008905009,0.00035718744],"domain_scores_gemma":[0.99592793,0.0009143236,0.0018176241,0.00040041763,0.0004178779,0.0005218405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021362645,0.00025040927,0.0028669967,0.0005275401,0.00006016917,0.000010607167,0.0002812107,0.00023094221,0.0006024842],"category_scores_gemma":[0.0003364309,0.00017534746,0.00062211097,0.00084446993,0.000115243594,0.000103405895,0.00013408937,0.00048783177,0.000003105695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04788165,0.035173897,0.8506618,0.000012947986,0.0039444086,0.00059951807,0.0003001263,0.0030477524,0.000025088018,0.00006429555,0.0007163117,0.057572205],"study_design_scores_gemma":[0.08206553,0.043766875,0.8592883,0.00002023841,0.001526554,0.000009202281,0.000106676984,0.0022206556,0.000046152814,0.000017788649,0.010783359,0.00014867802],"about_ca_topic_score_codex":0.00031552592,"about_ca_topic_score_gemma":0.0006999584,"teacher_disagreement_score":0.05742353,"about_ca_system_score_codex":0.0013576623,"about_ca_system_score_gemma":0.0016677476,"threshold_uncertainty_score":0.7150462},"labels":[],"label_agreement":null},{"id":"W4281683135","doi":"10.1200/jco.2022.40.16_suppl.4033","title":"Effect of neutrophil extracellular traps on tumor lymph nodes.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Thoracic Surgery Foundation","keywords":"Neutrophil extracellular traps; Medicine; Metastasis; Lymph; Neutrophil elastase; Cancer; Pathology; Lymphatic system; Cancer cell; Cancer research; Immune system; Inflammation; Immunology; Internal medicine","score_opus":0.043416603762798364,"score_gpt":0.39095390453276835,"score_spread":0.34753730076996997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281683135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759295,0.008468344,0.000027183616,0.0010333102,0.011295651,0.00016724832,0.000013618207,0.000011361238,0.0030537636],"genre_scores_gemma":[0.9969426,0.00025007853,0.00008939279,0.0009360653,0.00029000264,0.000012164347,0.000005470172,0.000026524614,0.0014477129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924662,0.0041684266,0.0026308543,0.00024119418,0.00015114281,0.00034218325],"domain_scores_gemma":[0.9901046,0.0065415762,0.0028054803,0.00034283867,0.00014857858,0.00005692245],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008294496,0.0001979415,0.0017948127,0.00018600024,0.00013886261,0.0000029777204,0.00070302753,0.00035206802,0.0029979667],"category_scores_gemma":[0.0015241021,0.00015124911,0.0008842615,0.00016209087,0.0005124853,0.000053439708,0.00018663098,0.0021566395,0.00010752343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055545963,0.0058302917,0.016355485,0.00013475417,0.0021364868,0.0018176191,0.00029341874,0.001231965,0.26311418,0.0011900752,0.03193216,0.6204176],"study_design_scores_gemma":[0.020707438,0.057419606,0.012545917,0.00005440407,0.00048825177,0.001706553,0.00011088152,0.00001175142,0.052583892,0.00021848604,0.8538985,0.00025431038],"about_ca_topic_score_codex":0.000014163295,"about_ca_topic_score_gemma":6.1472866e-7,"teacher_disagreement_score":0.82196635,"about_ca_system_score_codex":0.00024071413,"about_ca_system_score_gemma":0.00087549863,"threshold_uncertainty_score":0.9979134},"labels":[],"label_agreement":null},{"id":"W4281683594","doi":"10.1200/jco.2022.40.16_suppl.9069","title":"Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with <i>ALK</i>+ advanced non–small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Crizotinib; Medicine; Internal medicine; ALK inhibitor; Clinical endpoint; Progression-free survival; Lung cancer; Randomization; Oncology; Chemotherapy; Randomized controlled trial; Gastroenterology; Surgery","score_opus":0.05485920621376665,"score_gpt":0.46937578439565286,"score_spread":0.4145165781818862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281683594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930524,0.0012130102,0.00007172,0.0017029315,0.0010339075,0.0016372878,0.00022009344,0.0000075237144,0.0010611003],"genre_scores_gemma":[0.99332947,0.0008419742,0.004553661,0.00035753168,0.0004121206,0.00028623283,0.000047053767,0.00003631891,0.00013563213],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99661565,0.0004245007,0.0016690538,0.00031578995,0.00069242064,0.00028255736],"domain_scores_gemma":[0.9956581,0.0011040365,0.002253113,0.00030695793,0.0004336304,0.00024417945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006152464,0.00024159766,0.0016387183,0.00014449538,0.0000800413,0.000007397094,0.00019804429,0.000116274656,0.0003330457],"category_scores_gemma":[0.00016308969,0.00013747979,0.00027125812,0.0002708031,0.00019066603,0.00011317219,0.00005522827,0.00055655895,4.920061e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31955147,0.024563564,0.50915504,0.000033317046,0.0017610975,0.0005797815,0.0022543748,0.00033851422,0.0001506854,0.000007787146,0.00020276674,0.14140157],"study_design_scores_gemma":[0.7257165,0.16384265,0.09495802,0.00042746082,0.0026635332,0.00001549172,0.0014684991,0.0001290037,0.0003578159,0.000057131536,0.010134902,0.00022903166],"about_ca_topic_score_codex":0.0004995005,"about_ca_topic_score_gemma":0.00075794687,"teacher_disagreement_score":0.41419703,"about_ca_system_score_codex":0.0008516356,"about_ca_system_score_gemma":0.004690324,"threshold_uncertainty_score":0.8320433},"labels":[],"label_agreement":null},{"id":"W4281683906","doi":"10.1200/jco.2022.40.16_suppl.e14009","title":"Treatment patterns and outcomes of patients with high-grade glioma during the COVID-19 pandemic.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Ottawa; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Internal medicine; Survival analysis; Coronavirus disease 2019 (COVID-19); Proportional hazards model; Pandemic; Glioma; Oncology; Radiation therapy; Radiosurgery; Retrospective cohort study; Disease","score_opus":0.06418059529165542,"score_gpt":0.43881177957461664,"score_spread":0.3746311842829612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281683906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97885495,0.00008474245,0.000101427206,0.02036057,0.00039285756,0.00015541846,0.0000095739915,0.0000058543264,0.00003457888],"genre_scores_gemma":[0.9958635,0.00017045581,0.00052081794,0.0031448868,0.00018698665,0.0000050440544,0.0000031953064,0.000011526112,0.00009358193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978036,0.0004642554,0.001067873,0.00012572942,0.00039493846,0.0001435651],"domain_scores_gemma":[0.9961256,0.0021966419,0.0011413827,0.00013886463,0.00007300487,0.00032451734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014554871,0.000097942095,0.0009274982,0.0000877255,0.000114777526,0.000004442393,0.00012726437,0.000063836254,0.00012219339],"category_scores_gemma":[0.0019003245,0.000046841746,0.00018112524,0.00007600697,0.0002068179,0.00002896131,0.00008288429,0.000787358,2.8552503e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014740092,0.0010558766,0.9807825,0.000022383634,0.00039165284,0.00039440437,0.00019921579,0.00010905164,0.000018966512,0.000028566146,0.0001326953,0.01539065],"study_design_scores_gemma":[0.015469508,0.008721624,0.9511762,0.000008824142,0.0003007054,0.00068775826,0.00015731878,0.00006304019,0.0000032778903,0.00006705849,0.023298165,0.000046492358],"about_ca_topic_score_codex":0.00015056467,"about_ca_topic_score_gemma":0.000016815005,"teacher_disagreement_score":0.0296063,"about_ca_system_score_codex":0.00023017082,"about_ca_system_score_gemma":0.0004992788,"threshold_uncertainty_score":0.34207225},"labels":[],"label_agreement":null},{"id":"W4281684131","doi":"10.1200/jco.2022.40.16_suppl.e12523","title":"Telehealth delivered Tai Chi intervention for managing aromatase inhibitor-induced arthralgia in breast cancer patients: <i>TaiChi4Joint</i> during the COVID-19 pandemic a Pilot study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Brief Pain Inventory; Physical therapy; Breast cancer; Quality of life (healthcare); Pittsburgh Sleep Quality Index; WOMAC; Attendance; Internal medicine; Cancer; Osteoarthritis; Alternative medicine; Chronic pain; Psychiatry","score_opus":0.14073534185881623,"score_gpt":0.4863820886847931,"score_spread":0.34564674682597685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281684131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256755,0.00036935817,0.000011673167,0.013486311,0.001999438,0.0014250071,0.00009781362,0.000015166586,0.00002767125],"genre_scores_gemma":[0.99144334,0.00039523272,0.0000425051,0.00689378,0.00086637965,0.00025290478,0.000020571095,0.000021940556,0.00006335022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564636,0.0011988566,0.0022103437,0.0002782889,0.000337035,0.00032909878],"domain_scores_gemma":[0.9964847,0.0010780352,0.0017664679,0.00015642543,0.00016775011,0.00034663785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036840597,0.00017049741,0.0010435876,0.00021977154,0.00024086024,0.000008864877,0.00020537827,0.000076191965,0.00038193664],"category_scores_gemma":[0.0004578113,0.000120211094,0.00034124934,0.00024395675,0.00007661169,0.00010172756,0.00015965059,0.00124723,0.0000018232271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0536072,0.019687552,0.88702804,0.00013634335,0.0005899199,0.00035049414,0.0006813131,0.00018844179,0.00036336796,0.0000071403715,0.0054365573,0.031923655],"study_design_scores_gemma":[0.077306196,0.067302495,0.8442017,0.00007144452,0.00063403405,0.00062410237,0.0012454601,0.00011164189,0.0000091723805,0.00015552944,0.008199971,0.00013825395],"about_ca_topic_score_codex":0.00093988643,"about_ca_topic_score_gemma":0.0021034381,"teacher_disagreement_score":0.047614943,"about_ca_system_score_codex":0.0018648512,"about_ca_system_score_gemma":0.0014114203,"threshold_uncertainty_score":0.5418663},"labels":[],"label_agreement":null},{"id":"W4281685079","doi":"10.1200/jco.2022.40.16_suppl.tps5617","title":"ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bevacizumab; Ovarian cancer; Pembrolizumab; Internal medicine; Paclitaxel; Oncology; Chemotherapy; Placebo; Response Evaluation Criteria in Solid Tumors; Surgery; Phases of clinical research; Cancer; Immunotherapy; Pathology","score_opus":0.21759925675284236,"score_gpt":0.5038330728052243,"score_spread":0.2862338160523819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281685079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98050976,0.0016921324,0.00039250212,0.008080707,0.0032760827,0.005042533,0.00018453239,0.000014514371,0.0008072294],"genre_scores_gemma":[0.99344563,0.00047869512,0.0028966544,0.0002734949,0.0014004995,0.0012760415,0.00003705782,0.000045234006,0.00014669105],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931496,0.0010650823,0.0037201517,0.0004894498,0.0011690726,0.0004066615],"domain_scores_gemma":[0.9866385,0.00786265,0.0038897544,0.00037698477,0.00074275007,0.00048934534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005280703,0.0003390431,0.0037042766,0.00027323267,0.00022570623,0.000018264207,0.0002925922,0.00021340771,0.00082694704],"category_scores_gemma":[0.0011692275,0.00023283927,0.00086602755,0.0002817382,0.00025992916,0.00010904258,0.00011866681,0.0011794177,0.0000018422312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.933998,0.020559529,0.0006357044,0.0000747529,0.0056288186,0.0005343914,0.00075313734,0.0020523348,0.000008085603,0.0008923259,0.0019903807,0.03287254],"study_design_scores_gemma":[0.838577,0.13849416,0.0014651266,0.00012743918,0.0046708332,0.00014100014,0.0013483497,0.0005851721,0.0000151578915,0.00010327171,0.014286779,0.00018573175],"about_ca_topic_score_codex":0.00020323343,"about_ca_topic_score_gemma":0.0003823726,"teacher_disagreement_score":0.11793463,"about_ca_system_score_codex":0.0014872064,"about_ca_system_score_gemma":0.0056030652,"threshold_uncertainty_score":0.9939597},"labels":[],"label_agreement":null},{"id":"W4281685654","doi":"10.1200/jco.2022.40.16_suppl.tps9158","title":"Randomized phase 2 study evaluating efficacy and safety of inupadenant in combination with chemotherapy in adults with metastatic non–small cell lung cancer (mNSCLC) who progressed on immunotherapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Oncology; Carboplatin; Tumor microenvironment; Lung cancer; Chemotherapy; Immunotherapy; Regimen; Population; Cancer","score_opus":0.03705372423531692,"score_gpt":0.42339815587601287,"score_spread":0.38634443164069593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281685654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957405,0.0022491666,0.00024340823,0.00042257598,0.00006604925,0.0012334049,0.0000027344206,0.0000011732633,0.000040986997],"genre_scores_gemma":[0.99784166,0.00078521797,0.0009568055,0.00022153955,0.0000658148,0.00007992768,0.000005049946,0.00001927854,0.000024691642],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99634904,0.0015009032,0.0014898768,0.00022550207,0.00027826824,0.0001563844],"domain_scores_gemma":[0.99718624,0.0008407177,0.0016214306,0.00012414558,0.00017107828,0.00005639772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00507621,0.00014693705,0.0011472373,0.00012596647,0.00003988077,0.000005687266,0.00015617486,0.000074547075,0.000026838208],"category_scores_gemma":[0.00026039107,0.00009484036,0.00009775258,0.00017534418,0.00010513857,0.000006882061,0.000038813167,0.0004754001,3.086256e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9122,0.011517878,0.032643907,0.00006489901,0.00060736213,0.00015088517,0.0021997837,0.007052537,0.0044889906,0.000004488656,0.000046515976,0.029022781],"study_design_scores_gemma":[0.9062595,0.06836423,0.01810794,0.00028997828,0.00021764572,0.000032162276,0.0011369259,0.00335597,0.0019263304,0.000012377929,0.000118596814,0.00017835048],"about_ca_topic_score_codex":0.00006563233,"about_ca_topic_score_gemma":0.000047107296,"teacher_disagreement_score":0.056846358,"about_ca_system_score_codex":0.000049066595,"about_ca_system_score_gemma":0.00070123066,"threshold_uncertainty_score":0.38674778},"labels":[],"label_agreement":null},{"id":"W4281690006","doi":"10.1200/jco.2022.40.16_suppl.567","title":"Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine; Breast cancer; Kappa; Oncology; Internal medicine; Adjuvant; Concordance; Cancer","score_opus":0.09464192110889556,"score_gpt":0.40750288461721096,"score_spread":0.3128609635083154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281690006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994426,0.0006912027,0.000059841263,0.0036872386,0.00039535246,0.00058916066,0.000116927826,0.0000059298995,0.000028323611],"genre_scores_gemma":[0.99573356,0.00006093085,0.002164358,0.0010988887,0.00086664216,0.000033206863,0.000008326513,0.000022629676,0.000011435187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967294,0.0008386898,0.0012359106,0.00025747943,0.00071298657,0.00022557605],"domain_scores_gemma":[0.9961551,0.001650182,0.0014320883,0.00019733704,0.00033690798,0.00022838068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016601357,0.00016028038,0.0010882257,0.000061314306,0.000110270514,0.000007862345,0.00017180746,0.00009891847,0.000048999715],"category_scores_gemma":[0.0005214705,0.000093439165,0.00012474894,0.00013861552,0.00022201995,0.00015893995,0.0001730225,0.0012441942,6.8500293e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22370681,0.0010997799,0.73086697,0.0000029222435,0.00023224905,0.00010938151,0.00023728583,0.000068608526,0.0001831962,2.0375053e-7,0.00014167931,0.043350935],"study_design_scores_gemma":[0.081914335,0.016271148,0.90054107,0.000115376126,0.00028291676,0.00004692049,0.0001496115,0.0000066346497,0.000051812454,0.00004889584,0.00047799575,0.00009331317],"about_ca_topic_score_codex":0.00018856364,"about_ca_topic_score_gemma":0.000029595858,"teacher_disagreement_score":0.1696741,"about_ca_system_score_codex":0.00036342704,"about_ca_system_score_gemma":0.00071083725,"threshold_uncertainty_score":0.54054743},"labels":[],"label_agreement":null},{"id":"W4281690443","doi":"10.1200/jco.2022.40.16_suppl.e18536","title":"Health and healthcare equity in the cancer care sector in Canada: Results of a rapid scoping review.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Health care; Health equity; Equity (law); Medicine; Health policy; Multidisciplinary approach; Public relations; Public health; Family medicine; Nursing; Political science; Law","score_opus":0.7551291868113011,"score_gpt":0.6397806267528678,"score_spread":0.1153485600584333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281690443","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31114787,0.25659996,0.000006348066,0.42911452,0.0014129393,0.00092855224,0.0003010326,0.0000013691085,0.0004874166],"genre_scores_gemma":[0.84789515,0.046461467,0.00026178244,0.10501456,0.00029799098,0.000048263184,0.0000060125394,0.0000089203595,0.0000058487585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9806108,0.004273896,0.014313308,0.0002844433,0.0002051001,0.00031249307],"domain_scores_gemma":[0.98177373,0.0060555935,0.011594239,0.00025211656,0.000107592474,0.0002167544],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08119816,0.00009075967,0.0026417882,0.00018053334,0.00008378187,0.000005203149,0.00039622534,0.00007730371,0.00008305008],"category_scores_gemma":[0.013686904,0.00008550254,0.0001234109,0.00025386154,0.000053325264,0.00009886848,0.0001273399,0.0009345125,0.0000012491844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093012146,0.0004579068,0.82876843,0.014952685,0.000086278626,0.000055967284,0.01258763,0.00063909206,9.8497914e-8,0.0030887143,0.073493764,0.06493928],"study_design_scores_gemma":[0.012732412,0.007836405,0.8166114,0.016555233,0.000019611693,0.000102949074,0.029698892,0.000477228,2.5764908e-7,0.0026143051,0.11294523,0.0004060602],"about_ca_topic_score_codex":0.6530713,"about_ca_topic_score_gemma":0.918905,"teacher_disagreement_score":0.5367473,"about_ca_system_score_codex":0.003787886,"about_ca_system_score_gemma":0.02588648,"threshold_uncertainty_score":0.9946212},"labels":[],"label_agreement":null},{"id":"W4281690555","doi":"10.1200/jco.2022.40.16_suppl.1520","title":"Improving supportive care for patients with thoracic cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Psychosocial; Veterans Affairs; Quality of life (healthcare); Randomized controlled trial; Intervention (counseling); Cancer; Physical therapy; Family medicine; Psychiatry; Nursing; Surgery; Internal medicine","score_opus":0.0680349434304363,"score_gpt":0.4724887607071302,"score_spread":0.4044538172766939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281690555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926618,0.0007569329,0.00023065417,0.0020953277,0.0030704234,0.00038368636,0.000068609326,0.000007209518,0.0007254044],"genre_scores_gemma":[0.9959307,0.000048765403,0.00072357093,0.0020853723,0.00091308774,0.000047331512,0.000015042301,0.00001866037,0.00021747233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980864,0.00019010565,0.001012976,0.000148659,0.00037852037,0.00018331695],"domain_scores_gemma":[0.9966915,0.0007024593,0.0013601959,0.000112054506,0.000915918,0.00021787094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010035696,0.000087255175,0.00084721926,0.00006840754,0.00009726538,0.000004222843,0.000118830656,0.00009836595,0.00028769535],"category_scores_gemma":[0.0006281642,0.000060501065,0.00033618248,0.000111415095,0.00006843534,0.000057041016,0.00005695025,0.00074632757,6.6071897e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016562192,0.0006667093,0.44430882,0.00010998581,0.00020579027,0.00011233767,0.0009859897,0.000022497074,0.000007448724,0.000013973158,0.0019964743,0.5350078],"study_design_scores_gemma":[0.016150303,0.09940893,0.3642218,0.00009913996,0.0012615637,0.0000865289,0.0098416135,0.000045264675,0.000059530987,0.00007235978,0.50854105,0.00021188169],"about_ca_topic_score_codex":0.00013506222,"about_ca_topic_score_gemma":0.00060573797,"teacher_disagreement_score":0.5347959,"about_ca_system_score_codex":0.00041246167,"about_ca_system_score_gemma":0.002829152,"threshold_uncertainty_score":0.5018794},"labels":[],"label_agreement":null},{"id":"W4281691525","doi":"10.1200/jco.2022.40.16_suppl.e20579","title":"Meta-analysis of rates and causes of local recurrence in surgically-resected NSCLC and differences in recurrence and survival between Asian and non-Asian populations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medtronic","keywords":"Medicine; Lymphovascular invasion; Relative risk; Internal medicine; Lung cancer; Radiation therapy; Meta-analysis; Surgery; Oncology; Cancer; Confidence interval; Metastasis","score_opus":0.2783214816250098,"score_gpt":0.48656377290594643,"score_spread":0.20824229128093663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281691525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911955,0.0041817934,0.000019651885,0.0042399247,0.00008761267,0.00016520462,0.00003480761,0.0000010761996,0.00007444368],"genre_scores_gemma":[0.99677867,0.0027582613,0.00035892153,0.000047655212,0.000029537978,0.00001027493,0.000006400773,0.0000042079773,0.000006070684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967534,0.0008087132,0.0017673915,0.00024523784,0.0002905889,0.00013467734],"domain_scores_gemma":[0.9956064,0.0029449991,0.001018885,0.00010627647,0.00013760185,0.00018580328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023955498,0.00012506075,0.0027732842,0.00038793654,0.000032880955,0.000006920951,0.00007009102,0.0001200462,0.000056913825],"category_scores_gemma":[0.00063084805,0.00008455007,0.00021867172,0.0004994095,0.00039483845,0.00006845586,0.000103801074,0.00048342047,2.7998125e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005719174,0.0005721237,0.9663501,0.00004667305,0.0058307876,0.00008385797,0.00029416877,0.00000576306,0.0000029834318,0.00006157197,0.000012139306,0.026167927],"study_design_scores_gemma":[0.0030569439,0.004086295,0.97410756,0.000053856686,0.017658543,0.000021677464,0.0004931777,0.00011981819,0.000009859028,0.000271973,0.000056046196,0.00006424149],"about_ca_topic_score_codex":0.000500409,"about_ca_topic_score_gemma":0.0035406812,"teacher_disagreement_score":0.026103685,"about_ca_system_score_codex":0.00006466467,"about_ca_system_score_gemma":0.00029220962,"threshold_uncertainty_score":0.34478518},"labels":[],"label_agreement":null},{"id":"W4281693510","doi":"10.1200/jco.2022.40.16_suppl.1018","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), <i>PIK3CA</i>-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Cohort; Internal medicine; Fulvestrant; Hazard ratio; Oncology; Breast cancer; Cancer; Gastroenterology; Estrogen receptor; Confidence interval; Aromatase","score_opus":0.031121113661462998,"score_gpt":0.39359984602320747,"score_spread":0.3624787323617445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281693510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878187,0.0013775295,0.00009664515,0.0072644744,0.00035893594,0.0024332737,0.00060649845,0.000018154133,0.000025787092],"genre_scores_gemma":[0.99435645,0.0024156808,0.0012803684,0.0011840356,0.00026049858,0.00027362347,0.0001362692,0.00006962487,0.000023422292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881776,0.0051851654,0.0037139861,0.00073477894,0.0016594937,0.00052899745],"domain_scores_gemma":[0.99063927,0.0033113288,0.0040130485,0.00047903953,0.0012579036,0.0002994023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004858315,0.0005437459,0.0025909566,0.0006018536,0.00020333954,0.000026359501,0.00052517565,0.00020590138,0.00038291278],"category_scores_gemma":[0.0010459411,0.00033886472,0.00039272656,0.0015555219,0.00049638376,0.00053476315,0.00018833512,0.0018248635,6.0081373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11455642,0.01760137,0.59073234,0.000018751243,0.0025508031,0.00024131365,0.0030786,0.00012455067,0.009228573,0.00000437244,0.00021028197,0.26165265],"study_design_scores_gemma":[0.07340799,0.031624496,0.8888697,0.00011999261,0.0003515235,0.00005174103,0.003014561,0.00005497303,0.0016826077,0.000044423803,0.00043467645,0.00034328506],"about_ca_topic_score_codex":0.00078936986,"about_ca_topic_score_gemma":0.0013058928,"teacher_disagreement_score":0.29813743,"about_ca_system_score_codex":0.0007383055,"about_ca_system_score_gemma":0.00083029683,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null},{"id":"W4281695484","doi":"10.1200/jco.2022.40.16_suppl.tps9159","title":"AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusion–positive advanced/metastatic NSCLC.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Pemetrexed; Internal medicine; Lung cancer; Oncology; Crizotinib; Response Evaluation Criteria in Solid Tumors; Population; Gemcitabine; Adverse effect; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy; Malignant pleural effusion","score_opus":0.0640521458669212,"score_gpt":0.4968587128532268,"score_spread":0.4328065669863056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281695484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956531,0.00016542974,0.00005165758,0.0017855612,0.00042358777,0.0010878412,0.0000530025,0.0000043611685,0.000775467],"genre_scores_gemma":[0.99765205,0.000054866385,0.0012469549,0.00075367675,0.00008894641,0.000045191184,0.000026298638,0.00001741271,0.00011456996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966762,0.00044892126,0.0019380335,0.0001990805,0.0005566192,0.00018114895],"domain_scores_gemma":[0.9961315,0.0011066999,0.0019171067,0.00017469932,0.00047118214,0.00019881006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067685,0.00013546739,0.0012561289,0.00018528817,0.00007735769,0.0000029838388,0.00012305785,0.000051575564,0.00031046546],"category_scores_gemma":[0.00064289797,0.00009007883,0.00016421321,0.00033682366,0.00007876661,0.00011251084,0.00008237859,0.00070389383,0.0000010213091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040655423,0.0827132,0.7616158,0.00004038589,0.0012273892,0.0010466008,0.0023118104,0.0008410152,0.0000057528946,0.000012193013,0.0011801715,0.10835025],"study_design_scores_gemma":[0.15995337,0.23158456,0.59516126,0.00015700639,0.0017892541,0.000066264045,0.0028121627,0.000115093564,0.000008320174,0.000052344214,0.008176698,0.00012368837],"about_ca_topic_score_codex":0.00002738128,"about_ca_topic_score_gemma":0.00007396415,"teacher_disagreement_score":0.16645457,"about_ca_system_score_codex":0.00029664254,"about_ca_system_score_gemma":0.001049121,"threshold_uncertainty_score":0.36733082},"labels":[],"label_agreement":null},{"id":"W4281695494","doi":"10.1200/jco.2022.40.16_suppl.2009","title":"Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) <i>BRAF</i> V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Trametinib; Internal medicine; Clinical endpoint; Oncology; Cohort; Phases of clinical research; Glioma; Dabrafenib; Surrogate endpoint; Cancer; Clinical trial; Surgery; Cancer research; Metastatic melanoma","score_opus":0.07738325439421567,"score_gpt":0.42337170074754044,"score_spread":0.34598844635332476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281695494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851436,0.00218236,0.000010313682,0.0063225073,0.0017437142,0.0007409069,0.000090908994,0.000016675147,0.00037822998],"genre_scores_gemma":[0.99513394,0.0011071168,0.0008685669,0.0017522513,0.00094558264,0.000065193846,0.000047007554,0.00003880028,0.000041554646],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98977697,0.0018045885,0.006186546,0.00051322195,0.0012350929,0.00048355918],"domain_scores_gemma":[0.98805064,0.0057512415,0.004784517,0.0005308311,0.00028562944,0.0005971678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0066997153,0.00033496227,0.004702954,0.0020838142,0.00012773766,0.000009840636,0.00043123562,0.00046289392,0.00090913655],"category_scores_gemma":[0.002786849,0.00025671872,0.002378922,0.0029523699,0.00020167761,0.00011207141,0.00019321818,0.0020230971,0.000003950849],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22593533,0.52816767,0.06451423,0.00013574144,0.011865336,0.022253225,0.0009180382,0.0010608488,0.006349711,0.00021891978,0.010813601,0.12776738],"study_design_scores_gemma":[0.67369974,0.16079515,0.11284383,0.00004744618,0.023072993,0.00036301644,0.00038434926,0.00021552744,0.0005348526,0.00036007218,0.02730874,0.00037428673],"about_ca_topic_score_codex":0.00006941527,"about_ca_topic_score_gemma":0.00005019258,"teacher_disagreement_score":0.44776443,"about_ca_system_score_codex":0.0006518068,"about_ca_system_score_gemma":0.0024595896,"threshold_uncertainty_score":0.9999885},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4281702604","doi":"10.1200/jco.2022.40.16_suppl.e18057","title":"Osteoradionecrosis in head and neck cancer patients: Risk factors and comparison of grading systems.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osteoradionecrosis; Head and neck cancer; Radiation therapy; Surgery; Retrospective cohort study; Grading (engineering); Fistula","score_opus":0.2003420986851931,"score_gpt":0.5305808281433254,"score_spread":0.3302387294581323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281702604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126303,0.005503459,0.0000018035921,0.0013423471,0.001513873,0.00027874875,0.00003117341,0.0000026118435,0.00006295306],"genre_scores_gemma":[0.99722344,0.0020413816,0.0003494361,0.00021689013,0.00013303912,0.000011282474,0.0000018032799,0.000009736698,0.0000129892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966661,0.0005710768,0.0021444228,0.00014484802,0.00029910327,0.00017447208],"domain_scores_gemma":[0.9959667,0.001477385,0.0020570585,0.000081701444,0.00013469909,0.0002824996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001551393,0.00009769549,0.0015533075,0.00014311621,0.00006474801,0.0000032454466,0.000055738925,0.000120174234,0.00003620623],"category_scores_gemma":[0.000625528,0.00007009442,0.000102161495,0.00013833662,0.000114112634,0.0000528676,0.000062071726,0.0008484389,1.7506957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017950123,0.0014057877,0.9659355,0.00011177712,0.00010464284,0.000023360626,0.0004874656,0.00010110265,0.000003939663,0.00001163981,0.0005451672,0.029474597],"study_design_scores_gemma":[0.00908389,0.023519952,0.9563314,0.00018081034,0.00021262556,0.000023164203,0.00078131224,0.00029736926,0.000009691407,0.000024207813,0.009485662,0.000049938415],"about_ca_topic_score_codex":0.0017997891,"about_ca_topic_score_gemma":0.00025839897,"teacher_disagreement_score":0.02942466,"about_ca_system_score_codex":0.00068304315,"about_ca_system_score_gemma":0.00063315645,"threshold_uncertainty_score":0.3686092},"labels":[],"label_agreement":null},{"id":"W4281703721","doi":"10.1200/jco.2022.40.16_suppl.2510","title":"External validation of the VIGex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Proportional hazards model; Oncology; Internal medicine; Biomarker; Pembrolizumab; Cancer; Cancer research; Immunotherapy; Biology; Confidence interval; Genetics","score_opus":0.05323854368693607,"score_gpt":0.3923489934369064,"score_spread":0.3391104497499703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281703721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881722,0.0014002931,0.006790918,0.0010504788,0.001852921,0.00035031166,0.00015319021,0.000001362585,0.00022837507],"genre_scores_gemma":[0.9952861,0.00060760777,0.0026854873,0.0004124863,0.00075136445,0.000035169676,0.000024373403,0.000015469815,0.00018194976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99807453,0.00020976443,0.0011907072,0.00018337145,0.00020362792,0.00013798133],"domain_scores_gemma":[0.9972846,0.00042832072,0.0017030055,0.00022926995,0.00026690966,0.00008788981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012479431,0.00011346217,0.00044977662,0.00003482766,0.00009929679,0.0000063132143,0.00029715206,0.00022238857,0.00004543298],"category_scores_gemma":[0.0011210348,0.00007523453,0.0006624388,0.00005575489,0.00009539784,0.00000407658,0.00021590058,0.00025347713,3.948538e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054312665,0.0013721625,0.0023557052,0.0000065796603,0.00026869864,0.000006406967,0.000074438925,0.0023459187,0.97947377,0.000047686102,0.0010563317,0.007561056],"study_design_scores_gemma":[0.007983656,0.020701997,0.026055455,0.000028050292,0.00026690273,0.00014349885,0.00015245585,0.00026417934,0.8301824,0.00082513277,0.1132629,0.00013336811],"about_ca_topic_score_codex":0.00001549289,"about_ca_topic_score_gemma":0.0000049318983,"teacher_disagreement_score":0.14929135,"about_ca_system_score_codex":0.00013352225,"about_ca_system_score_gemma":0.0011174062,"threshold_uncertainty_score":0.3067975},"labels":[],"label_agreement":null},{"id":"W4281705317","doi":"10.1200/jco.2022.40.16_suppl.9583","title":"Sentinel lymph node biopsy in Merkel cell carcinoma: A multi-institutional study from the Pan-Canadian Merkel Cell Collaborative.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Memorial University of Newfoundland; Centre Hospitalier de l’Université de Montréal; CARE Canada; University of Northern British Columbia; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Vancouver General Hospital; Mount Sinai Hospital; University of Calgary; Queen's University; McMaster University; University of Manitoba; Health Sciences Centre; Ottawa Hospital; McGill University; University of Ottawa","funders":"","keywords":"Medicine; Merkel cell carcinoma; Sentinel lymph node; Biopsy; Surgery; Proportional hazards model; Carcinoma; Radiation therapy; Dissection (medical); Cancer; Radiology; Internal medicine; Breast cancer","score_opus":0.07900977023024143,"score_gpt":0.39835475622984357,"score_spread":0.31934498599960215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281705317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98416066,0.004242611,0.000011692091,0.0063050827,0.0016236802,0.00038073558,0.00016124731,0.0000067021156,0.0031075664],"genre_scores_gemma":[0.99439883,0.00017090891,0.0004596668,0.0037795804,0.0006626111,0.000019442872,0.000018213306,0.000019375215,0.00047139722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995466,0.0013373442,0.0019759072,0.00029474674,0.0005563808,0.00036961812],"domain_scores_gemma":[0.9960384,0.0016779307,0.0010598671,0.0002682957,0.00028515348,0.0006703596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022681544,0.0002067725,0.001128611,0.0002237413,0.0003121994,0.000015092599,0.00037489532,0.00024800163,0.00053068064],"category_scores_gemma":[0.0009789502,0.00012664027,0.00042677694,0.0005155696,0.00027904735,0.00007573849,0.00014302827,0.0015164424,0.00003985459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020418074,0.0106548015,0.97343206,0.000007753563,0.0002577199,0.007137032,0.0005964087,0.00025944065,0.00036041794,0.000014931334,0.0036194716,0.0016181791],"study_design_scores_gemma":[0.021965398,0.0011168263,0.9504736,0.000018156734,0.00065615505,0.000143706,0.004378217,0.0006345452,0.000018103745,0.000026910096,0.020433439,0.00013493672],"about_ca_topic_score_codex":0.0185004,"about_ca_topic_score_gemma":0.0032448245,"teacher_disagreement_score":0.02295843,"about_ca_system_score_codex":0.0005636415,"about_ca_system_score_gemma":0.011613942,"threshold_uncertainty_score":0.9939893},"labels":[],"label_agreement":null},{"id":"W4281706429","doi":"10.1200/jco.2022.40.16_suppl.12131","title":"Association between unmet needs and utilization of emergency services among cancer survivors in Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Cancer; Logistic regression; Family medicine; Prostate cancer; Breast cancer; Colorectal cancer; Cancer survivor; Health care; Gerontology; Internal medicine","score_opus":0.1187719091850969,"score_gpt":0.3740622120039092,"score_spread":0.2552903028188123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281706429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99182314,0.0021121053,0.00003464688,0.0017006343,0.0022095365,0.00006516079,0.00012763578,0.000001160814,0.0019259779],"genre_scores_gemma":[0.995389,0.003787423,0.00003635892,0.0002861329,0.0002854455,0.0000037932127,0.000003106609,0.000008487672,0.00020025941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969432,0.000111388086,0.002599932,0.0001139544,0.00006788986,0.00016367041],"domain_scores_gemma":[0.9947949,0.00042578008,0.0045153294,0.000071875846,0.000091632166,0.00010046716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003372604,0.00007302197,0.0009923236,0.00020572751,0.00003986214,0.0000043492773,0.00018122641,0.00012294736,0.0005451857],"category_scores_gemma":[0.00052339275,0.000082401806,0.000106338055,0.00025533288,0.00002111052,0.00022009888,0.00006552393,0.00041821148,8.831067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006057055,0.000057179004,0.9869268,0.000015641204,0.0001106392,0.0000024438443,0.00023361793,0.00042132588,4.0811145e-7,0.0007695331,0.0007682125,0.0106336335],"study_design_scores_gemma":[0.0007558889,0.00032720124,0.9226929,0.000006939875,0.000023334214,4.614123e-7,0.00031288769,0.00029043818,0.0000022158533,0.0038814582,0.071630605,0.000075667034],"about_ca_topic_score_codex":0.63135964,"about_ca_topic_score_gemma":0.8719075,"teacher_disagreement_score":0.24054787,"about_ca_system_score_codex":0.0010357498,"about_ca_system_score_gemma":0.00096630823,"threshold_uncertainty_score":0.5969401},"labels":[],"label_agreement":null},{"id":"W4281707764","doi":"10.1200/jco.2022.40.16_suppl.e21172","title":"Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; COPD; Internal medicine; Lung cancer; Nivolumab; Proportional hazards model; Population; Pembrolizumab; Oncology; Comorbidity; Cancer; Immunotherapy","score_opus":0.022828217163813516,"score_gpt":0.3454385561593023,"score_spread":0.3226103389954888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281707764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714524,0.00049033406,0.000048790567,0.0010184739,0.0006094468,0.0005439013,0.00009161361,0.0000015017639,0.000050715913],"genre_scores_gemma":[0.99862725,0.00006981547,0.0005113751,0.00041669482,0.00011355825,0.000091628535,0.00008278186,0.00001592223,0.000070965856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976638,0.00020840342,0.0013184285,0.00020645803,0.00040955903,0.00019334455],"domain_scores_gemma":[0.9965145,0.0012567571,0.0015749718,0.00016594217,0.00029518685,0.00019266267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006065182,0.00012969582,0.0012307217,0.00016611682,0.000056224413,0.0000030095703,0.00011512396,0.000061166545,0.00034663986],"category_scores_gemma":[0.00009253189,0.00009778876,0.00040354396,0.00023103849,0.000026695143,0.000039911978,0.000022102126,0.00044820408,2.1272275e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01102599,0.0022406888,0.9598861,0.000065950495,0.0012984198,0.000114331604,0.000060582155,0.021589976,0.0000014608999,0.0000023956134,0.000119959666,0.0035941445],"study_design_scores_gemma":[0.012484167,0.0033518292,0.9791063,0.00007548166,0.0019903379,6.980051e-7,0.00002273176,0.0016983979,0.0000031252423,0.000014621484,0.0011618701,0.000090424364],"about_ca_topic_score_codex":0.70214796,"about_ca_topic_score_gemma":0.9603452,"teacher_disagreement_score":0.25819722,"about_ca_system_score_codex":0.007778511,"about_ca_system_score_gemma":0.016547805,"threshold_uncertainty_score":0.99603045},"labels":[],"label_agreement":null},{"id":"W4281708097","doi":"10.1200/jco.2022.40.16_suppl.5019","title":"Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Hazard ratio; Internal medicine; Interim analysis; Adverse effect; Clinical endpoint; Placebo; Confidence interval; Enzalutamide; Oncology; Clinical trial; Surgery; Cancer; Pathology","score_opus":0.12185701098343013,"score_gpt":0.44461756509497885,"score_spread":0.3227605541115487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281708097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98443884,0.00012139128,0.00003211236,0.01248439,0.00056718005,0.001865712,0.00030422208,0.0000067845776,0.00017938815],"genre_scores_gemma":[0.99703944,0.00006217183,0.0008474687,0.0015108477,0.00021546627,0.00015183096,0.000039765513,0.00002528821,0.00010769806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932022,0.0017289663,0.0036006174,0.00032224643,0.00089933455,0.00024659716],"domain_scores_gemma":[0.99283814,0.0019995738,0.0038445576,0.00038913768,0.0007417089,0.00018686226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004755991,0.0001978327,0.0016798383,0.00008733591,0.00008607184,0.000011708534,0.00022787589,0.00011136419,0.00037255892],"category_scores_gemma":[0.0007710324,0.000104881416,0.00017875915,0.00035267556,0.00043667664,0.00013977684,0.00004275143,0.0015358969,0.0000010973234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94364685,0.012148623,0.026883032,0.000023386481,0.0006819386,0.00016785464,0.0019261739,0.0009177482,0.00042826726,0.000013006632,0.0012193082,0.0119437985],"study_design_scores_gemma":[0.7433648,0.14324364,0.10387382,0.00025788706,0.0005652058,0.000020311274,0.0010295908,0.00012480134,0.00029834034,0.00021091152,0.006841797,0.00016887137],"about_ca_topic_score_codex":0.0005255336,"about_ca_topic_score_gemma":0.0013128818,"teacher_disagreement_score":0.20028204,"about_ca_system_score_codex":0.00050539535,"about_ca_system_score_gemma":0.0034463496,"threshold_uncertainty_score":0.6672793},"labels":[],"label_agreement":null},{"id":"W4281708993","doi":"10.1200/jco.2022.40.16_suppl.605","title":"Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; University of Ottawa; Canadian Electricity Association; Ontario Institute for Cancer Research; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Clinical endpoint; Cancer; In vivo; Phases of clinical research; Oncology; Clinical trial; Internal medicine; Pathology; Surgery","score_opus":0.10876867856335491,"score_gpt":0.44258848703200215,"score_spread":0.33381980846864723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281708993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078745,0.00017044411,9.219362e-7,0.005609885,0.00077524123,0.0023812351,0.000082212195,0.0000052003284,0.0001873914],"genre_scores_gemma":[0.9984608,0.00015784879,0.00004427144,0.0008789726,0.00019022063,0.00012219376,0.0000032801822,0.000020147358,0.00012225211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98668617,0.0053603584,0.006388175,0.00033860368,0.0008782813,0.00034841202],"domain_scores_gemma":[0.99053425,0.0045281365,0.003863716,0.00044196998,0.00033037152,0.00030157214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023000807,0.00023923769,0.0033764425,0.0004512677,0.000103075545,0.000007808196,0.00049468974,0.00014423546,0.000266112],"category_scores_gemma":[0.003845211,0.0001591579,0.0006751718,0.0008713214,0.00072309765,0.00010542094,0.00030547963,0.002108506,1.7413971e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85202533,0.03186735,0.09364238,0.0000240727,0.0010712591,0.0027498095,0.00821705,0.00009032082,0.0003658442,0.0000019295796,0.0014429776,0.008501665],"study_design_scores_gemma":[0.6045098,0.13225569,0.25210378,0.00013961931,0.0007098918,0.0004904481,0.008553062,0.00012388584,0.00007882657,0.000027978971,0.0008701698,0.0001369047],"about_ca_topic_score_codex":0.014335378,"about_ca_topic_score_gemma":0.009168946,"teacher_disagreement_score":0.2475156,"about_ca_system_score_codex":0.00076451775,"about_ca_system_score_gemma":0.0064879567,"threshold_uncertainty_score":0.9991443},"labels":[],"label_agreement":null},{"id":"W4281709044","doi":"10.1200/jco.2022.40.16_suppl.7517","title":"Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"BCL6; Medicine; Hazard ratio; Internal medicine; Immunohistochemistry; Oncology; Lymphoma; Diffuse large B-cell lymphoma; Proportional hazards model; Univariate analysis; Confidence interval; International Prognostic Index; Cancer research; Multivariate analysis; Immunology; B cell; Antibody; Germinal center","score_opus":0.06113772831689156,"score_gpt":0.4070163829463697,"score_spread":0.34587865462947814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281709044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98196906,0.0034540242,0.000001402997,0.013276494,0.0005387347,0.0003617356,0.000064107706,0.0000050745675,0.00032936622],"genre_scores_gemma":[0.992892,0.0015917339,0.00017664133,0.004845244,0.00015891549,0.000021018917,0.000019773459,0.000012559766,0.00028206903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711186,0.0008282377,0.0013069649,0.00021358297,0.00034031417,0.00019905357],"domain_scores_gemma":[0.9953466,0.0033777435,0.00081607513,0.0001827181,0.000048097867,0.00022878169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017793437,0.00013968747,0.0010628628,0.00006188175,0.00011611703,0.000015181438,0.00011672184,0.00016298157,0.00014049078],"category_scores_gemma":[0.00073212123,0.00007570196,0.00018923714,0.00008275721,0.00008059574,0.000061637664,0.0001934956,0.00034790213,0.000003498684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024193147,0.029686345,0.8903452,0.000004614003,0.00025100197,0.0006891434,0.00027838515,1.3784012e-7,0.00017611255,0.000011443715,0.023983251,0.030381188],"study_design_scores_gemma":[0.3360518,0.005291633,0.5543581,0.000026415853,0.0002480049,0.00003937926,0.0003294727,0.000011525495,0.0000518424,0.00008300638,0.10345382,0.000054965134],"about_ca_topic_score_codex":0.0003156312,"about_ca_topic_score_gemma":0.000047143647,"teacher_disagreement_score":0.3359871,"about_ca_system_score_codex":0.00019132085,"about_ca_system_score_gemma":0.0002880988,"threshold_uncertainty_score":0.30870363},"labels":[],"label_agreement":null},{"id":"W4281709253","doi":"10.1200/jco.2022.40.16_suppl.tps3154","title":"Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Cancer research; Brentuximab vedotin; Antibody-drug conjugate; Pharmacology; Oncology; Internal medicine; Antibody; Immunology; Adverse effect; Monoclonal antibody; Immunohistochemistry","score_opus":0.06244149653943871,"score_gpt":0.46314520347122873,"score_spread":0.40070370693179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281709253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951405,0.00010689726,0.000002594652,0.0019999682,0.0008532521,0.0018045611,0.00002683891,0.000009806294,0.000055563858],"genre_scores_gemma":[0.9973391,0.000016884966,0.0011030257,0.0011728348,0.00021686974,0.00006268111,0.000023606075,0.000022849248,0.00004209612],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9941315,0.0008220112,0.0036021639,0.0003023359,0.0008522538,0.00028973777],"domain_scores_gemma":[0.99587214,0.0008907153,0.0023598876,0.00019649307,0.00041868302,0.00026208884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003758961,0.00019059966,0.001773963,0.00046702137,0.00005145769,0.0000068120844,0.00024637635,0.000096292504,0.000200836],"category_scores_gemma":[0.0014804819,0.00014448157,0.00019208727,0.0007915469,0.0002445595,0.00011838024,0.000094754236,0.0010584509,9.692883e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6274416,0.058800478,0.29233775,0.000020278554,0.00032694123,0.00028008636,0.00075629656,0.0002161311,0.0006993861,0.0000031160055,0.00043507552,0.01868289],"study_design_scores_gemma":[0.4028376,0.12439208,0.4689035,0.00016341425,0.00009409542,0.000024364652,0.0004883093,0.00007675625,0.000056063902,0.000012062398,0.0028317124,0.000120027726],"about_ca_topic_score_codex":0.00008296835,"about_ca_topic_score_gemma":0.0002321238,"teacher_disagreement_score":0.22460398,"about_ca_system_score_codex":0.00033694232,"about_ca_system_score_gemma":0.0021609268,"threshold_uncertainty_score":0.58917874},"labels":[],"label_agreement":null},{"id":"W4281710573","doi":"10.1200/jco.2022.40.16_suppl.3107","title":"First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Pharmacodynamics; Pharmacokinetics; Melanoma; Immune system; Discontinuation; Cancer; Pharmacology; Oncology; Toxicity; Internal medicine; Immunology; Cancer research","score_opus":0.03137461808433421,"score_gpt":0.40204014508579133,"score_spread":0.3706655270014571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281710573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937939,0.0005670941,0.0000018165046,0.0027262205,0.001192308,0.001482748,0.00011164243,0.0000076069723,0.00011663184],"genre_scores_gemma":[0.99828476,0.0005801541,0.000050758863,0.0006951056,0.00025552104,0.000057619625,0.000006046862,0.00003280846,0.000037229685],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9949493,0.0010208002,0.0025209081,0.00041051462,0.0007495508,0.00034891933],"domain_scores_gemma":[0.9958295,0.0010260957,0.002401897,0.00024045349,0.00030869636,0.00019334779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023058786,0.00026746112,0.0014493796,0.00028668277,0.00018544678,0.0000075468297,0.00029277048,0.00012789013,0.00006786162],"category_scores_gemma":[0.0002985902,0.00018447528,0.00024064674,0.0007646817,0.0002936547,0.00016885664,0.00022289372,0.0017948188,1.7392593e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43654138,0.033802524,0.3716244,0.00008307661,0.0008933564,0.00049075077,0.0016584458,0.0011593251,0.008070757,0.000002030354,0.0009256347,0.14474832],"study_design_scores_gemma":[0.21493642,0.06501133,0.71195537,0.00029623738,0.00047983925,0.00004540622,0.000540047,0.00025496128,0.0023121685,0.000016081973,0.0039311233,0.00022103483],"about_ca_topic_score_codex":0.0009405427,"about_ca_topic_score_gemma":0.0023441778,"teacher_disagreement_score":0.34033093,"about_ca_system_score_codex":0.0010953987,"about_ca_system_score_gemma":0.0011144583,"threshold_uncertainty_score":0.7797694},"labels":[],"label_agreement":null},{"id":"W4281713156","doi":"10.1200/jco.2022.40.16_suppl.tps9610","title":"Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre; Canada Health Infoway","funders":"","keywords":"Medicine; Natural history; Informed consent; Biobank; Clinical trial; Institutional review board; Family medicine; Observational study; Natural history study; Data collection; Surgery; Alternative medicine; Internal medicine; Pathology","score_opus":0.07481443550937603,"score_gpt":0.4616758815646279,"score_spread":0.38686144605525186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281713156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767837,0.0021632374,0.0000054980246,0.014428961,0.0037936014,0.00079938344,0.000014465512,0.000010039876,0.002001099],"genre_scores_gemma":[0.9895725,0.00022514632,0.0007749792,0.0086895805,0.00052204984,0.000027434453,0.000005762126,0.0000155815,0.00016694948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9886611,0.006989806,0.002836702,0.0004057534,0.00077065604,0.0003359656],"domain_scores_gemma":[0.9889973,0.0077861813,0.0022381449,0.00034483473,0.00035456973,0.0002789776],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010800683,0.00025449164,0.0020527055,0.000120843346,0.00016254296,0.000012451582,0.00037020273,0.000349737,0.00014456412],"category_scores_gemma":[0.0066660997,0.0001600919,0.00053129153,0.00020997786,0.00033178364,0.00020895155,0.00026494608,0.0031211523,0.0000086123855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060223914,0.011708117,0.9397483,0.000007715972,0.0021355953,0.025636338,0.0010095728,0.0000040111754,4.0777357e-7,0.000105946514,0.0012950372,0.012326552],"study_design_scores_gemma":[0.019219246,0.036768664,0.8660326,0.000013175656,0.0016370098,0.00257477,0.010017575,0.000020856012,2.1713959e-7,0.00009334386,0.06349988,0.00012268097],"about_ca_topic_score_codex":0.00021491667,"about_ca_topic_score_gemma":0.00084272557,"teacher_disagreement_score":0.07371573,"about_ca_system_score_codex":0.001248143,"about_ca_system_score_gemma":0.0024879433,"threshold_uncertainty_score":0.9991787},"labels":[],"label_agreement":null},{"id":"W4281714381","doi":"10.1200/jco.22.00842","title":"Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Gastroenterology; Cytokine release syndrome; Progression-free survival; Oncology; Chimeric antigen receptor; Surgery; Immunotherapy; Chemotherapy; Cancer","score_opus":0.10538137358338813,"score_gpt":0.42759963328509365,"score_spread":0.32221825970170553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281714381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775184,0.0018202633,0.00022930192,0.0021717225,0.0045590596,0.0013448772,0.000046777208,0.000051483363,0.0020246808],"genre_scores_gemma":[0.9775819,0.0050322423,0.005973665,0.0015737487,0.0027433934,0.00005958544,0.00010681334,0.00012351625,0.0068051284],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931665,0.0015746745,0.002788658,0.0005926219,0.0011942518,0.0006832584],"domain_scores_gemma":[0.9935372,0.002158103,0.0021388305,0.0006356935,0.000820089,0.0007101148],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0068612625,0.00034321405,0.0019802975,0.00037796027,0.0003750529,0.000042305037,0.0006530831,0.0005373737,0.0041893567],"category_scores_gemma":[0.0011961802,0.00028966737,0.0011406273,0.0004487903,0.00023239947,0.00031874215,0.00017519957,0.0023213292,0.000054483084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043709017,0.00835889,0.057214297,0.00007416298,0.0006110329,0.00030380648,0.00089110085,0.0001305585,0.7406034,0.000011663969,0.033579167,0.11451292],"study_design_scores_gemma":[0.041736245,0.047503654,0.08018192,0.00002589242,0.0001660369,0.00016370442,0.0008610908,0.0006464586,0.019068746,0.00005061588,0.8092293,0.0003663344],"about_ca_topic_score_codex":0.000045328143,"about_ca_topic_score_gemma":0.000023235747,"teacher_disagreement_score":0.77565014,"about_ca_system_score_codex":0.00046584354,"about_ca_system_score_gemma":0.0030748346,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W4281714680","doi":"10.1200/jco.2022.40.16_suppl.10015","title":"Benefits, harms, and burden of colorectal cancer screening among childhood cancer survivors previously treated with abdominal-pelvic radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; American Cancer Society","keywords":"Medicine; Colonoscopy; Colorectal cancer; Cancer; Cohort; Population; Cumulative incidence; Incidence (geometry); Internal medicine; Environmental health","score_opus":0.043174690697885584,"score_gpt":0.36796641281554404,"score_spread":0.32479172211765844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281714680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895922,0.007502148,0.00007481533,0.0016413651,0.0005101679,0.00036585444,0.000024169942,0.000018116358,0.00027115864],"genre_scores_gemma":[0.9951982,0.002800553,0.0007846107,0.00025442537,0.0007534161,0.000054662483,0.0000047502967,0.000027851336,0.000121543766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970514,0.00043448625,0.0014704556,0.00026474753,0.00052868004,0.00025019146],"domain_scores_gemma":[0.9962024,0.00088737975,0.0020693173,0.00011521384,0.00040266456,0.0003230116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019283402,0.0001740564,0.0013467667,0.00022534475,0.00014485049,0.0000099123845,0.00013134387,0.00018066373,0.00031661603],"category_scores_gemma":[0.0005360999,0.00013198367,0.00026374802,0.00041778572,0.0002174336,0.00012638218,0.00007824064,0.0011046652,3.114233e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025307214,0.00034346996,0.5522208,0.00003236141,0.00069905544,0.000078715566,0.0005926509,0.006672007,0.00007687175,0.0000035014068,0.00033067394,0.41364264],"study_design_scores_gemma":[0.009240726,0.033569448,0.94842076,0.00021101217,0.00096571277,0.0005071333,0.00062236725,0.001837377,0.00034208465,0.000007743816,0.004126937,0.00014868389],"about_ca_topic_score_codex":0.0070967167,"about_ca_topic_score_gemma":0.002971478,"teacher_disagreement_score":0.41349396,"about_ca_system_score_codex":0.0002780823,"about_ca_system_score_gemma":0.0013398349,"threshold_uncertainty_score":0.9995151},"labels":[],"label_agreement":null},{"id":"W4281715825","doi":"10.1200/jco.2022.40.16_suppl.11523","title":"Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iterion Therapeutics","keywords":"Medicine; Internal medicine; Maximum tolerated dose; Adverse effect; Nuclear medicine; Gastroenterology","score_opus":0.07077747817959736,"score_gpt":0.43413814082035546,"score_spread":0.3633606626407581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281715825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707323,0.00027699294,0.0000068893555,0.0006637952,0.0003463104,0.0015317478,0.000029373108,0.0000054156294,0.00006626801],"genre_scores_gemma":[0.9983461,0.000022807977,0.0012641465,0.000068705645,0.00017239427,0.00007394952,0.0000065394506,0.000018918969,0.000026442362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581885,0.00042213575,0.002689217,0.0002528959,0.00060965994,0.00020724737],"domain_scores_gemma":[0.9927331,0.0031546808,0.0029533205,0.00018720655,0.0008104332,0.00016122851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026956522,0.00014748203,0.001576745,0.0002497268,0.0000824488,0.000003083115,0.0000990769,0.00007633948,0.000018348142],"category_scores_gemma":[0.0065706405,0.00010252675,0.00014217198,0.00031978442,0.00020871627,0.00009545691,0.00014843675,0.00057997566,1.5594664e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1745095,0.050867803,0.74183244,0.00022679208,0.00045672184,0.0010080895,0.0031102477,0.000117753014,0.0002380048,0.000006211603,0.0012372766,0.02638919],"study_design_scores_gemma":[0.13378458,0.26965138,0.58837605,0.00032774825,0.0005129577,0.00014019509,0.004358864,0.00029726452,0.00014435308,0.000050644405,0.0022414331,0.00011456141],"about_ca_topic_score_codex":0.000040356368,"about_ca_topic_score_gemma":0.00016648242,"teacher_disagreement_score":0.21878359,"about_ca_system_score_codex":0.00016552905,"about_ca_system_score_gemma":0.0005789858,"threshold_uncertainty_score":0.7866145},"labels":[],"label_agreement":null},{"id":"W4281716671","doi":"10.1200/jco.2022.40.16_suppl.e18704","title":"Life-cycle health technology assessment for precision oncology.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Reimbursement; Stakeholder; Medicine; Health technology; Health care; Precision medicine; Stakeholder engagement; Disinvestment; Process management; Business; Political science; Public relations","score_opus":0.6760200642501228,"score_gpt":0.6437962333821428,"score_spread":0.032223830867980086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281716671","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11363318,0.0045267004,0.026727377,0.83810455,0.010065746,0.0013767304,0.00022767574,0.000041503212,0.0052965675],"genre_scores_gemma":[0.6932749,0.0012609669,0.13088138,0.16981246,0.0034632806,0.00036371368,0.000025076855,0.00007608941,0.00084214046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97861344,0.0023341316,0.017819297,0.00049331965,0.0002116939,0.00052814203],"domain_scores_gemma":[0.96253514,0.012757908,0.023252496,0.0004477818,0.00027658406,0.00073010154],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.12832111,0.00016685227,0.003784504,0.00068639766,0.0004259269,0.00001941257,0.0007348128,0.00043710417,0.000954677],"category_scores_gemma":[0.04421244,0.00018628004,0.00059948437,0.0003015517,0.00016174068,0.00025204167,0.00024252901,0.0014803276,0.00012165705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009763593,0.0043595675,0.04420234,0.00016835128,0.0005894549,0.000023172815,0.00072474685,0.0031973624,0.0000020995415,0.19279917,0.6075955,0.14536184],"study_design_scores_gemma":[0.004657793,0.01391141,0.013092553,0.000018962117,0.000016391288,0.000069399066,0.0021073923,0.003373315,2.492566e-7,0.07065438,0.89194095,0.00015720545],"about_ca_topic_score_codex":0.00006613476,"about_ca_topic_score_gemma":0.000059463044,"teacher_disagreement_score":0.66829205,"about_ca_system_score_codex":0.0028878816,"about_ca_system_score_gemma":0.009571521,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W4281717206","doi":"10.1200/jco.2022.40.16_suppl.e19020","title":"Treatment outcomes for newly diagnosed, untreated <i>TP53</i>-mutated acute myeloid leukemia: A systematic review and meta-analysis.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Internal medicine; Ven; Meta-analysis; Myeloid leukemia; Venetoclax; Oncology; Randomized controlled trial; Leukemia; Gastroenterology; Chronic lymphocytic leukemia","score_opus":0.3036780685263099,"score_gpt":0.5344606692025908,"score_spread":0.23078260067628092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281717206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009708099,0.9846508,0.000053299686,0.0056059607,0.00027742938,0.008785389,0.00036625055,0.000032425032,0.00021874375],"genre_scores_gemma":[0.0000037928512,0.9853699,0.0017723403,0.0047373762,0.00026886316,0.0018930195,0.00031239158,0.00013217141,0.005510096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97938013,0.0055546174,0.012308091,0.00092212326,0.0010848116,0.0007501974],"domain_scores_gemma":[0.95005053,0.03488393,0.011804728,0.0012117203,0.0008690145,0.0011800504],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_broad","research_integrity"],"category_scores_codex":[0.010374131,0.0011355317,0.06388625,0.0010796032,0.00015849997,0.00004544882,0.0008181132,0.0013213248,0.001088152],"category_scores_gemma":[0.015799128,0.00056523696,0.022833718,0.001584332,0.0003060174,0.00013179443,0.00029446563,0.003097176,0.000037793954],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033111998,0.0008207002,0.000015813175,0.27790967,0.66749114,0.005168012,0.000021395144,0.0000015199695,2.6402745e-8,0.000013612358,0.004750877,0.04347611],"study_design_scores_gemma":[0.0040439153,0.007054437,0.0000065168574,0.0037437286,0.56003827,0.002218224,0.000015881937,0.000008929614,3.666626e-8,0.000008270924,0.42264092,0.00022087457],"about_ca_topic_score_codex":0.00007963226,"about_ca_topic_score_gemma":0.00004369108,"teacher_disagreement_score":0.41789004,"about_ca_system_score_codex":0.0046656225,"about_ca_system_score_gemma":0.013731501,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W4281717744","doi":"10.1200/jco.2022.40.16_suppl.e21129","title":"Insights into the advanced non-small cell lung cancer patient journey: Treatment decision-making, preferences, and quality of life considerations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Quality of life (healthcare); Thematic analysis; Palliative care; Lung cancer; Health care; Family medicine; Nursing; Qualitative research; Oncology","score_opus":0.31268162595143956,"score_gpt":0.5497455942042928,"score_spread":0.23706396825285325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281717744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97776294,0.018377712,0.0002019803,0.0017895146,0.0007424822,0.0002535508,0.000007122686,0.0000022383829,0.0008624844],"genre_scores_gemma":[0.9803627,0.011199936,0.006715875,0.0014724765,0.00019605293,0.000018300412,0.0000010922693,0.0000071113113,0.000026439739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629486,0.0007596164,0.0023110372,0.00014982074,0.00037511668,0.00010958028],"domain_scores_gemma":[0.9869836,0.009445692,0.0026302636,0.00017509393,0.0005770514,0.00018828645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001113538,0.00011574291,0.0012380035,0.00008722757,0.00010856756,0.000004704317,0.00009952081,0.000108373744,0.00020477541],"category_scores_gemma":[0.0044731204,0.00006476091,0.0002683437,0.00010290881,0.00018390377,0.00005109694,0.00009164533,0.000507823,3.6505998e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066560237,0.0031589863,0.65372694,0.00012920554,0.0009852342,0.0001243234,0.022465074,0.0013740575,0.0004429635,0.0002726372,0.0041801548,0.3064844],"study_design_scores_gemma":[0.02997006,0.06018177,0.6093584,0.0017818502,0.0017980434,0.000059888618,0.023333756,0.000979278,0.002263509,0.008056817,0.26179796,0.0004186873],"about_ca_topic_score_codex":0.0001846158,"about_ca_topic_score_gemma":0.00063314964,"teacher_disagreement_score":0.30606574,"about_ca_system_score_codex":0.00021339791,"about_ca_system_score_gemma":0.0026048266,"threshold_uncertainty_score":0.5355066},"labels":[],"label_agreement":null},{"id":"W4281718428","doi":"10.1200/jco.22.01026","title":"Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor–Positive Early Breast Cancer?","year":2022,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Estrogen receptor; Breast cancer; Estrogen; Cancer; Cancer research; Oncology; Circulating tumor DNA; Internal medicine; Interception; Biology","score_opus":0.030759214656013615,"score_gpt":0.3569652693478024,"score_spread":0.3262060546917888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281718428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86992145,0.0008338256,0.000024964975,0.12591249,0.0019813452,0.00020937824,0.0009037815,0.0000030547328,0.00020972904],"genre_scores_gemma":[0.61016357,0.003958261,0.000464941,0.37048757,0.013666555,0.000053770418,0.0006554825,0.00012471834,0.0004251506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99617106,0.0006892537,0.001995549,0.0004528769,0.00029487765,0.0003963959],"domain_scores_gemma":[0.99650174,0.0004496364,0.0023450367,0.00023065,0.0003025014,0.0001704348],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011740838,0.00028788074,0.0011439116,0.00012368256,0.00005456899,0.000028550698,0.00044739305,0.0009764019,0.00037491365],"category_scores_gemma":[0.000533097,0.00028253667,0.00059013243,0.000109049826,0.00015596664,0.0000072080074,0.00025969895,0.0028223963,0.0000054932952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023612012,0.00042766775,0.017378021,0.000043853797,0.00073037087,0.001542565,0.00021637774,0.00029732153,0.014682549,0.0000033630752,0.91825384,0.044062857],"study_design_scores_gemma":[0.0044541107,0.008484646,0.02317013,0.00023623377,0.00034882367,0.0006342236,0.00010337311,0.00006220169,0.00034820757,0.00011159577,0.9614135,0.00063292816],"about_ca_topic_score_codex":0.0010396832,"about_ca_topic_score_gemma":0.00041202953,"teacher_disagreement_score":0.25975788,"about_ca_system_score_codex":0.0005820611,"about_ca_system_score_gemma":0.0018584455,"threshold_uncertainty_score":0.9999627},"labels":[],"label_agreement":null},{"id":"W4281719370","doi":"10.1200/jco.2022.40.16_suppl.8018","title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Multiple myeloma; Clinical endpoint; Oncology; Expanded access; Lenalidomide; Phases of clinical research; Discontinuation; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","score_opus":0.05975955941285862,"score_gpt":0.4140060801500837,"score_spread":0.3542465207372251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975726,0.00007463875,0.000017628885,0.0005721012,0.00024695165,0.0010047883,0.000032910444,0.000007964018,0.0004703894],"genre_scores_gemma":[0.9984331,0.0001589993,0.0009294316,0.00014584856,0.00015052542,0.00001271894,0.000011107725,0.000032381333,0.00012589479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99321586,0.0022631509,0.0025489486,0.0004146686,0.0011586598,0.00039869265],"domain_scores_gemma":[0.9915149,0.0049279383,0.0021610183,0.0003663288,0.00043557127,0.0005942208],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004489812,0.00023621232,0.0023171855,0.00028504996,0.00011211524,0.0000064600295,0.00022761503,0.00022471805,0.00015558777],"category_scores_gemma":[0.0028056542,0.00014907215,0.00026705014,0.00029566415,0.00042563214,0.00016033342,0.00025275006,0.0025384964,0.0000028046652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18854704,0.022765588,0.67729247,0.00002082777,0.00083796226,0.0014558672,0.00010712352,0.000012929795,0.0000043622676,0.000002202035,0.000067586654,0.10888604],"study_design_scores_gemma":[0.11014687,0.12489001,0.7624912,0.00005924289,0.00030900675,0.00015033182,0.0002678551,0.00008330217,0.0000050516096,0.0000050595945,0.0014887671,0.00010329968],"about_ca_topic_score_codex":0.00017597665,"about_ca_topic_score_gemma":0.00065304665,"teacher_disagreement_score":0.10878274,"about_ca_system_score_codex":0.00037209498,"about_ca_system_score_gemma":0.001976896,"threshold_uncertainty_score":0.9997627},"labels":[],"label_agreement":null},{"id":"W4281719541","doi":"10.1200/jco.2022.40.16_suppl.1087","title":"Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Concordance; Internal medicine; Breast cancer; Oncology; Immunohistochemistry; Retrospective cohort study; Cancer; Gynecology","score_opus":0.09156177983517647,"score_gpt":0.49356996992915875,"score_spread":0.40200819009398225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870568,0.00052738044,0.00007130762,0.010457159,0.0011316488,0.000582517,0.00009158881,0.000010414551,0.00007120116],"genre_scores_gemma":[0.9956653,0.0004271124,0.00088139065,0.0019908312,0.00071595627,0.000043169366,4.1179348e-7,0.000019944988,0.00025588588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581593,0.00097261876,0.002090249,0.00030848265,0.0005627194,0.00025002274],"domain_scores_gemma":[0.99583083,0.0009794813,0.0019486155,0.0002649701,0.00069042406,0.00028567275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004821246,0.00016594077,0.0015293866,0.00007823759,0.00012317635,0.0000069630382,0.00033146612,0.0000958239,0.00054501306],"category_scores_gemma":[0.0025569275,0.00010187121,0.00023549602,0.00022039068,0.00034860533,0.000083927305,0.00032703596,0.0014590851,0.000003135168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115638515,0.0034792982,0.89146155,0.00007526506,0.0001990208,0.00049325364,0.0010165067,0.000055369524,0.00020979381,0.00004627719,0.00011254369,0.09128727],"study_design_scores_gemma":[0.0038995515,0.02086826,0.970317,0.00010384633,0.00043053727,0.0014620436,0.0006716056,0.000048686496,0.000014231354,0.00015489246,0.0019358055,0.00009352761],"about_ca_topic_score_codex":0.000019093633,"about_ca_topic_score_gemma":0.000016810181,"teacher_disagreement_score":0.09119374,"about_ca_system_score_codex":0.00029098635,"about_ca_system_score_gemma":0.0008153265,"threshold_uncertainty_score":0.63390803},"labels":[],"label_agreement":null},{"id":"W4281719775","doi":"10.1200/jco.2022.40.16_suppl.11562","title":"Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Synovial sarcoma; Clinical endpoint; Oncology; Phases of clinical research; Sarcoma; Surgery; Chemotherapy; Clinical trial; Pathology","score_opus":0.3094605390236914,"score_gpt":0.5609863222026947,"score_spread":0.2515257831790033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947436,0.0025416121,0.0002744457,0.0010513155,0.0003495861,0.00077166944,0.0002139301,0.0000071877466,0.00004665312],"genre_scores_gemma":[0.9979019,0.00078301446,0.0008152282,0.000075384785,0.00016172338,0.000013769595,0.0000700509,0.000027975846,0.00015096097],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9854052,0.006671175,0.0062449914,0.0004079656,0.0009888721,0.0002818095],"domain_scores_gemma":[0.9765147,0.017227693,0.00498348,0.00042006883,0.00047326667,0.00038080552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01827708,0.00024236196,0.0028954714,0.0008739915,0.0000846921,0.000027925693,0.00029045608,0.0002231872,0.000674565],"category_scores_gemma":[0.008334837,0.00019512276,0.0005537857,0.0005853306,0.00048967364,0.00020697029,0.00010503466,0.0011940121,0.0000010260587],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08940199,0.013712711,0.0035811483,0.00006277692,0.00088087743,0.00018845031,0.00094809924,0.00003383764,0.7880501,0.00001073946,0.00007229322,0.103056945],"study_design_scores_gemma":[0.19832547,0.11454652,0.38906342,0.0001583311,0.0058915447,0.00021148166,0.0063779913,0.005678995,0.27497005,0.0008512886,0.0034314936,0.0004934118],"about_ca_topic_score_codex":0.00021141165,"about_ca_topic_score_gemma":0.00004771996,"teacher_disagreement_score":0.51308006,"about_ca_system_score_codex":0.00023630547,"about_ca_system_score_gemma":0.0021483498,"threshold_uncertainty_score":0.99781805},"labels":[],"label_agreement":null},{"id":"W4281721531","doi":"10.1200/jco.2022.40.16_suppl.11024","title":"A needs assessment survey to inform a general practitioner in oncology (GPO) training program in Nepal.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Workforce; Family medicine; Cancer; Internal medicine","score_opus":0.2864187929529738,"score_gpt":0.4849504024833412,"score_spread":0.19853160953036741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281721531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374977,0.00020100447,0.00029868918,0.010283599,0.0028103366,0.00040773972,0.00004926849,0.000007898787,0.048443817],"genre_scores_gemma":[0.9825402,0.00026146052,0.009546717,0.0064654257,0.0005865229,0.000109941946,0.00000904259,0.000021273978,0.0004594125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99433637,0.00037330695,0.0044743624,0.0002518472,0.00008921919,0.00047492184],"domain_scores_gemma":[0.99519014,0.0012669322,0.0029706839,0.00017230444,0.00010588421,0.00029404197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01589336,0.0001522308,0.001859356,0.00092687446,0.00007604689,0.00003170533,0.0004083321,0.00029611253,0.00073388807],"category_scores_gemma":[0.0033075893,0.00016736613,0.0002834291,0.0007810113,0.000081201375,0.00043840433,0.00017796249,0.0017240862,0.00003820122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015463929,0.0025324852,0.55477184,0.000006456175,0.0000976644,0.00021212475,0.001568866,0.0039848485,0.0000022921588,0.022863742,0.0052442006,0.4071691],"study_design_scores_gemma":[0.0028200906,0.0058249785,0.5259709,0.0000055600635,0.0000040658156,0.0000353292,0.0003698987,0.00071900093,1.7112275e-7,0.003245089,0.46088096,0.00012393868],"about_ca_topic_score_codex":0.00088515034,"about_ca_topic_score_gemma":0.0031487083,"teacher_disagreement_score":0.45563677,"about_ca_system_score_codex":0.0018587399,"about_ca_system_score_gemma":0.002384817,"threshold_uncertainty_score":0.80355597},"labels":[],"label_agreement":null},{"id":"W4281722284","doi":"10.1200/jco.2022.40.16_suppl.2522","title":"The association of pre-existing autoimmune disease and immune-related adverse events secondary to immune checkpoint inhibition therapy in a UK multicenter cohort.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Adverse effect; Retrospective cohort study; Cohort study; Cancer; Oncology; Disease; Propensity score matching","score_opus":0.03444418082719999,"score_gpt":0.38759659642076455,"score_spread":0.3531524155935646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876135,0.002729508,0.0000066138305,0.007734745,0.001015408,0.0005767683,0.000008549289,0.0000052447404,0.00030964104],"genre_scores_gemma":[0.99676734,0.0018267647,0.000113667134,0.0007439544,0.00008769728,0.000024461742,0.000008595199,0.0000131446,0.00041438843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952616,0.0008637853,0.0031261141,0.00014715536,0.0004067887,0.00019452884],"domain_scores_gemma":[0.9954712,0.0013191556,0.0027454498,0.00016707966,0.00017489576,0.00012224108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009505636,0.00011073128,0.00078947295,0.00012751715,0.000126819,0.000003958045,0.00011455909,0.00013282432,0.00019997382],"category_scores_gemma":[0.0021549396,0.00007833589,0.00046729465,0.00022102204,0.00009190534,0.00007035084,0.00010075934,0.0010158869,0.0000011145111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12990005,0.0026902345,0.6848706,0.00004260374,0.0018677777,0.00020034201,0.0015158539,0.0001265366,0.035777375,0.000017030863,0.00023851854,0.14275305],"study_design_scores_gemma":[0.018405516,0.0046511274,0.9682113,0.00015381137,0.00013253326,0.000034709974,0.00035426905,0.00016879357,0.00023110282,0.00014164804,0.007442411,0.00007281305],"about_ca_topic_score_codex":0.00011086592,"about_ca_topic_score_gemma":0.000028128434,"teacher_disagreement_score":0.28334063,"about_ca_system_score_codex":0.000606136,"about_ca_system_score_gemma":0.00083144987,"threshold_uncertainty_score":0.44135794},"labels":[],"label_agreement":null},{"id":"W4281722646","doi":"10.1200/jco.2022.40.16_suppl.7061","title":"Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Medicine; Myelofibrosis; Gastroenterology; Internal medicine; Placebo; Clinical endpoint; Anemia; Danazol; Randomization; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.09404202623910829,"score_gpt":0.4406790425051299,"score_spread":0.3466370162660216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474365,0.00020893116,0.0000039323513,0.0007095386,0.00058641454,0.0032152694,0.000016166945,0.00000981532,0.00050631014],"genre_scores_gemma":[0.99848175,0.00028282253,0.00034764115,0.00024087692,0.00017391876,0.00035612678,0.000020814683,0.000033435514,0.00006263707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99160784,0.0025299375,0.0041092196,0.00040688814,0.0009910351,0.00035507287],"domain_scores_gemma":[0.99068445,0.0048270863,0.003252943,0.00031503726,0.00054220017,0.0003782602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036868497,0.00031267863,0.004740037,0.00036383735,0.00009650925,0.000011107631,0.00022222291,0.00015605423,0.00037273127],"category_scores_gemma":[0.0024794561,0.00019742569,0.00060638716,0.0005182681,0.00021167984,0.0001259032,0.00015921074,0.0009770854,0.000003412883],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53540313,0.07599532,0.3725564,0.000031372067,0.0024146975,0.00083112955,0.0012632404,0.00006512914,0.00004259235,0.000022451664,0.00038388322,0.010990667],"study_design_scores_gemma":[0.68933207,0.19761914,0.108056284,0.00012351312,0.0018988793,0.0000486694,0.0013716877,0.00006929527,0.0002015845,0.000009666782,0.0011279254,0.0001412613],"about_ca_topic_score_codex":0.00013383097,"about_ca_topic_score_gemma":0.0002136555,"teacher_disagreement_score":0.26450008,"about_ca_system_score_codex":0.0006405068,"about_ca_system_score_gemma":0.0014536559,"threshold_uncertainty_score":0.80507857},"labels":[],"label_agreement":null},{"id":"W4281723730","doi":"10.1200/jco.2022.40.16_suppl.6519","title":"Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Tolerability; Quality of life (healthcare); Internal medicine; Alternative medicine; Family medicine; Oncology; Adverse effect; Pathology","score_opus":0.566784303406114,"score_gpt":0.5577709644133234,"score_spread":0.009013338992790554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281723730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9050629,0.00443117,0.00046270175,0.08802716,0.00054234604,0.00050611526,0.00006253958,0.0000094265415,0.0008956301],"genre_scores_gemma":[0.979393,0.0004909239,0.009267808,0.010337554,0.00015926293,0.000020315847,0.0000106180005,0.000027918893,0.00029260086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95127547,0.0055494164,0.041620377,0.00072101527,0.00032408914,0.0005096217],"domain_scores_gemma":[0.8893491,0.0142065305,0.09503292,0.0005445052,0.00030440892,0.0005625187],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.17704299,0.00022911423,0.010018772,0.0013009643,0.00013834985,0.000012560419,0.0004454554,0.0003458423,0.00036662436],"category_scores_gemma":[0.04813069,0.00024348244,0.00078620494,0.001172929,0.0003354902,0.00025543888,0.00022151922,0.0014232249,0.000007547325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013830737,0.0013382514,0.951197,0.0005490098,0.0027566268,0.000027058211,0.012718401,0.003968026,0.000001742506,0.01243735,0.0110835815,0.0025398252],"study_design_scores_gemma":[0.015354128,0.0051586335,0.90354866,0.00025968454,0.0004871934,0.00018401306,0.029737525,0.0087045,0.0000052319897,0.015653223,0.020268517,0.0006387171],"about_ca_topic_score_codex":0.008162995,"about_ca_topic_score_gemma":0.0028940146,"teacher_disagreement_score":0.1289123,"about_ca_system_score_codex":0.000895507,"about_ca_system_score_gemma":0.005282749,"threshold_uncertainty_score":0.99844176},"labels":[],"label_agreement":null},{"id":"W4281724494","doi":"10.1200/jco.2022.40.16_suppl.5024","title":"Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Medicine; Standardized uptake value; Prostate cancer; Nuclear medicine; Prostatectomy; Biopsy; Radiology; Cohort; Prostate; Positron emission tomography; PET-CT; Cancer; Urology; Pathology; Internal medicine","score_opus":0.06375505272018468,"score_gpt":0.43579344613662657,"score_spread":0.3720383934164419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281724494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961601,0.001421099,0.000003787925,0.0010763751,0.0001458501,0.00060569163,0.00044265683,0.000004705179,0.00013975623],"genre_scores_gemma":[0.99652237,0.0025403614,0.0004689457,0.00016803617,0.00004244149,0.000021144915,0.00008865347,0.00001613332,0.00013190684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960345,0.0007124716,0.0018150946,0.00035367365,0.0007944978,0.000289782],"domain_scores_gemma":[0.9970044,0.0006600685,0.0013026675,0.00019637475,0.00041714782,0.00041932537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031568864,0.00016698838,0.0018148237,0.000344704,0.00008185805,0.0000170306,0.000105554966,0.00004017488,0.00008983199],"category_scores_gemma":[0.00051206717,0.00010964213,0.00016666613,0.00056736957,0.00030631875,0.00015729168,0.000080145306,0.0008284336,8.2638934e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09786238,0.0022024733,0.8635492,0.000040777755,0.001963195,0.0009386943,0.000255632,0.0002743659,0.00007104543,0.000006195898,0.00074504677,0.032091007],"study_design_scores_gemma":[0.0404151,0.036078557,0.91777426,0.00010134439,0.0017593183,0.00005238965,0.00044073435,0.00048782665,0.000070704475,0.000043849606,0.0026636717,0.00011224965],"about_ca_topic_score_codex":0.00038680204,"about_ca_topic_score_gemma":0.0005622362,"teacher_disagreement_score":0.057447277,"about_ca_system_score_codex":0.00032466854,"about_ca_system_score_gemma":0.0017046881,"threshold_uncertainty_score":0.44710764},"labels":[],"label_agreement":null},{"id":"W4281724669","doi":"10.1200/jco.2022.40.16_suppl.3573","title":"Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Cohort; Medicine; Oxaliplatin; Colorectal cancer; Pembrolizumab; Irinotecan; Oncology; FOLFIRI; Internal medicine; Cancer; Family medicine","score_opus":0.12164807594129175,"score_gpt":0.4555265540163738,"score_spread":0.3338784780750821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281724669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852789,0.0018882866,0.00006425477,0.00945033,0.0010369634,0.0010533422,0.0002895504,0.000019908533,0.00091846363],"genre_scores_gemma":[0.98571587,0.0021262476,0.006597358,0.0033133263,0.00078706624,0.00021609916,0.000026746698,0.000051240033,0.001166071],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962091,0.00036121922,0.0020317952,0.00046945864,0.0005630667,0.00036537496],"domain_scores_gemma":[0.9926824,0.00436442,0.0019690886,0.00018632636,0.00043484644,0.00036290003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018186908,0.0002995255,0.0028111378,0.00012520184,0.0002333081,0.000017808925,0.00016419946,0.00014603249,0.00048823355],"category_scores_gemma":[0.001376376,0.00017838435,0.00038032603,0.00021615035,0.00034812087,0.00008279436,0.00010855142,0.00081141386,0.0000011658353],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7587015,0.003401693,0.05872556,0.000066791305,0.0063381116,0.00088888337,0.0020478189,0.000083622166,0.00022942432,0.000013555517,0.016993385,0.15250963],"study_design_scores_gemma":[0.260092,0.18209903,0.26950678,0.00023688602,0.0052136257,0.0014317405,0.0035209064,0.0014309055,0.0004964117,0.00033044702,0.27505276,0.0005885171],"about_ca_topic_score_codex":0.00063612644,"about_ca_topic_score_gemma":0.00127693,"teacher_disagreement_score":0.49860954,"about_ca_system_score_codex":0.00060164114,"about_ca_system_score_gemma":0.0033311655,"threshold_uncertainty_score":0.7274303},"labels":[],"label_agreement":null},{"id":"W4281727461","doi":"10.1200/jco.2022.40.16_suppl.12002","title":"Impact of age and frailty on acute care use during immune checkpoint inhibitor (ICI) treatment: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Ipilimumab; Population; Emergency department; Retrospective cohort study; Comorbidity; Cohort; Internal medicine; Cancer; Adverse effect; Emergency medicine; Immunotherapy","score_opus":0.11967945695391526,"score_gpt":0.4626707010813241,"score_spread":0.34299124412740883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281727461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977877,0.00017144938,0.0000018984935,0.00084707077,0.00054283795,0.0005157101,0.000044475666,0.000010826892,0.00007804274],"genre_scores_gemma":[0.9987816,0.00004417357,0.00041308196,0.00014860497,0.00036984112,0.000011537278,0.0000186022,0.000024898378,0.00018763005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962437,0.00057448243,0.0022852574,0.0002193953,0.0004717746,0.00020536632],"domain_scores_gemma":[0.9959415,0.0015484678,0.0016963108,0.00030209834,0.00023395116,0.00027764752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080757,0.00018780347,0.001613075,0.00023218368,0.00009766352,0.000008690372,0.00011440715,0.00015780669,0.00017971318],"category_scores_gemma":[0.0017039169,0.00013129019,0.0007708543,0.00016014576,0.00008964911,0.000085891115,0.00008067922,0.00087938947,0.0000016707638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013999646,0.006724757,0.9570272,0.000035242665,0.0013723419,0.003907849,0.0014815229,0.00071707997,0.0014904615,0.000001594396,0.00007323879,0.013169042],"study_design_scores_gemma":[0.022658877,0.08778577,0.88738185,0.0000813109,0.00062968925,0.0001877917,0.0006513989,0.000049342398,0.0001830566,0.000009013957,0.00029480606,0.00008710182],"about_ca_topic_score_codex":0.0005598059,"about_ca_topic_score_gemma":0.00015304098,"teacher_disagreement_score":0.08106102,"about_ca_system_score_codex":0.0010418817,"about_ca_system_score_gemma":0.00087944866,"threshold_uncertainty_score":0.53538585},"labels":[],"label_agreement":null},{"id":"W4281727581","doi":"10.1200/jco.2022.40.16_suppl.e18754","title":"Real-world evidence on predictors of survival for hormone-positive and triple-negative advanced breast cancer by treatment and <i>BRCA</i> status in the United States.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Triple-negative breast cancer; Cohort; Breast cancer; Oncology; Internal medicine; BRCA mutation; Stage (stratigraphy); Proportional hazards model; Cancer; Median follow-up; Medical record; Gynecology; Overall survival","score_opus":0.05646377298844378,"score_gpt":0.4259285794784766,"score_spread":0.3694648064900328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281727581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930826,0.0019181077,0.00005363481,0.0033718797,0.00038679596,0.00038366378,0.0007146927,0.0000010994294,0.000087522094],"genre_scores_gemma":[0.97513777,0.02340915,0.00026538968,0.00077203434,0.00017010835,0.00009186268,0.000043681142,0.0000115605035,0.00009843561],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997826,0.00080593623,0.000825512,0.00020958883,0.00016576979,0.0001672425],"domain_scores_gemma":[0.9963726,0.002345509,0.00085345237,0.00012011234,0.00021906427,0.00008930868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014381823,0.00011521533,0.00047558433,0.00008281978,0.000070634494,0.0000058858764,0.00013573244,0.00008424945,0.0000069806733],"category_scores_gemma":[0.00051663513,0.000079558326,0.00010085882,0.00018201924,0.0002446715,0.000008774044,0.00005842559,0.00025754792,3.170024e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12914996,0.008016885,0.34692907,0.000095927346,0.0036466324,0.00009908717,0.009033017,0.021436531,0.049188584,0.00034616166,0.06062355,0.3714346],"study_design_scores_gemma":[0.03064417,0.087906115,0.6785855,0.00011515669,0.00059261173,0.000096175354,0.0064765834,0.00049866404,0.008787944,0.0006571658,0.18520543,0.00043448008],"about_ca_topic_score_codex":0.0005679104,"about_ca_topic_score_gemma":0.00091953774,"teacher_disagreement_score":0.3710001,"about_ca_system_score_codex":0.00028721214,"about_ca_system_score_gemma":0.0009087941,"threshold_uncertainty_score":0.32442942},"labels":[],"label_agreement":null},{"id":"W4281727653","doi":"10.1200/jco.2022.40.16_suppl.e24066","title":"Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Oncology; Head and neck cancer; Concordance; Cancer","score_opus":0.13518160812579472,"score_gpt":0.4799018621242025,"score_spread":0.3447202539984078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281727653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247533,0.0005791954,0.000054765653,0.0050258795,0.00093217194,0.00052142085,0.00009589576,0.0000046990845,0.00031065743],"genre_scores_gemma":[0.9949155,0.0009077449,0.0010129381,0.0020250152,0.00042812712,0.00018460807,0.0000010823242,0.000016018912,0.0005089716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971251,0.00079415576,0.0014268155,0.00016407334,0.00027753768,0.00021233654],"domain_scores_gemma":[0.99574625,0.0029003778,0.00093235966,0.00014402508,0.000106743304,0.000170212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015583204,0.00013217673,0.0010426486,0.00016237535,0.000057512043,0.0000027059696,0.00015265691,0.00010376624,0.00048871816],"category_scores_gemma":[0.00057878194,0.00008033156,0.00040580475,0.00020794511,0.00010627016,0.000045053177,0.00009744147,0.0007688205,0.0000010213524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021882843,0.002741713,0.8811001,0.000015478805,0.00055792974,0.00036893933,0.0012700902,0.055246413,0.000413491,0.000012336797,0.001628746,0.034761902],"study_design_scores_gemma":[0.032471374,0.056955256,0.80612427,0.000087435445,0.002005837,0.00035043427,0.00077337725,0.032834545,0.00038225952,0.0005467304,0.0672544,0.00021405713],"about_ca_topic_score_codex":0.0013270931,"about_ca_topic_score_gemma":0.003767442,"teacher_disagreement_score":0.074975826,"about_ca_system_score_codex":0.00044913677,"about_ca_system_score_gemma":0.0012488444,"threshold_uncertainty_score":0.53511214},"labels":[],"label_agreement":null},{"id":"W4281728851","doi":"10.1200/jco.2022.40.16_suppl.e18757","title":"Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Rash; Tolerability; Oncology; Internal medicine; Adverse effect; Mixed logit; Confidence interval; Logistic regression; Androgen deprivation therapy; Cancer","score_opus":0.1687419788458399,"score_gpt":0.5115443745390501,"score_spread":0.3428023956932102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281728851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856162,0.0027439822,0.0000017667167,0.0101587055,0.00040122514,0.0007108556,0.000053246997,0.000002867558,0.0003111272],"genre_scores_gemma":[0.9918058,0.005980741,0.00044073685,0.00061633845,0.000120654346,0.00016555708,0.0000057057423,0.000008771111,0.00085569534],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99825346,0.00026312566,0.0009269702,0.00015253133,0.00020599717,0.0001979209],"domain_scores_gemma":[0.99784213,0.0012199325,0.0005157981,0.000064747976,0.00017792672,0.0001794592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089279213,0.00009501531,0.0009802222,0.00011483098,0.00006148243,0.0000051782554,0.00004082622,0.00006737558,0.00003580299],"category_scores_gemma":[0.00036074172,0.00005476233,0.00018472153,0.00007698314,0.00011233618,0.000048018508,0.0000532062,0.00029490882,5.730828e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023916714,0.0027283556,0.4734578,0.00001815704,0.00061924977,0.0005676794,0.0018965624,0.0000374342,0.00013860567,0.000020107944,0.0012895882,0.49530974],"study_design_scores_gemma":[0.030178564,0.107927985,0.783479,0.00003936928,0.000307877,0.0001114196,0.002734901,0.000086625805,0.00024902468,0.00064442994,0.07413226,0.00010857968],"about_ca_topic_score_codex":0.000111524074,"about_ca_topic_score_gemma":0.00012002073,"teacher_disagreement_score":0.49520117,"about_ca_system_score_codex":0.00048500687,"about_ca_system_score_gemma":0.0015086619,"threshold_uncertainty_score":0.26763013},"labels":[],"label_agreement":null},{"id":"W4281732590","doi":"10.1200/jco.2022.40.16_suppl.tps7590","title":"frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"MorphoSys","keywords":"Medicine; Lenalidomide; Internal medicine; CHOP; Diffuse large B-cell lymphoma; Vincristine; Oncology; Phases of clinical research; Clinical endpoint; Rituximab; Gastroenterology; Lymphoma; Randomized controlled trial; Clinical trial; Chemotherapy; Multiple myeloma; Cyclophosphamide","score_opus":0.07088796854688545,"score_gpt":0.4139830785513839,"score_spread":0.34309511000449844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281732590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935723,0.0015970565,0.00016168332,0.0013714544,0.0036724184,0.0035314122,0.00016628281,0.000017529288,0.00012492758],"genre_scores_gemma":[0.9942379,0.0022067258,0.00094051956,0.0006286521,0.0011152261,0.0005846262,0.00003796212,0.00005559301,0.00019281376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99180865,0.001546437,0.0046603847,0.00058069185,0.0008513232,0.00055250444],"domain_scores_gemma":[0.97661144,0.016669475,0.0050358498,0.0004877582,0.00048161254,0.00071388204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0067182123,0.00043490823,0.0056610233,0.0003741737,0.000245124,0.000028073091,0.00034727165,0.00033406893,0.0002181094],"category_scores_gemma":[0.002969601,0.00031013583,0.0012592291,0.00020664801,0.00029390032,0.00016332157,0.0003035961,0.00069225417,0.000005429411],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80735385,0.1374836,0.007640126,0.000037623264,0.0038963498,0.0021312248,0.00096780754,0.000021433301,0.00002260794,0.000067444795,0.0034571784,0.03692078],"study_design_scores_gemma":[0.90414053,0.06973053,0.009727037,0.000048378384,0.008113103,0.000117698044,0.0020789471,0.00022830295,0.00013495874,0.00013664545,0.005311173,0.0002327121],"about_ca_topic_score_codex":0.00084285304,"about_ca_topic_score_gemma":0.0003830644,"teacher_disagreement_score":0.096786685,"about_ca_system_score_codex":0.00054620614,"about_ca_system_score_gemma":0.001275072,"threshold_uncertainty_score":0.9999351},"labels":[],"label_agreement":null},{"id":"W4281733446","doi":"10.1200/jco.2022.40.16_suppl.5555","title":"Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Bevacizumab; Topotecan; Internal medicine; Paclitaxel; Hazard ratio; Oncology; Ovarian cancer; Chemotherapy; Proportional hazards model; Doxorubicin; Progression-free survival; Cancer; Confidence interval","score_opus":0.07656022916424912,"score_gpt":0.4320033288684329,"score_spread":0.35544309970418375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281733446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404479,0.00011283961,0.0000045182483,0.054798055,0.00045445093,0.00041528512,0.000021576152,0.0000141641,0.0037311797],"genre_scores_gemma":[0.99365807,0.00033080988,0.0010547264,0.0037064862,0.00018519262,0.0000685039,0.0000088822935,0.0000344146,0.0009529102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668026,0.00045997225,0.0016933089,0.00025136556,0.000622713,0.0002923749],"domain_scores_gemma":[0.99555457,0.0018440314,0.0019011038,0.00021724345,0.00022116846,0.0002618949],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019263724,0.00019534252,0.0019861052,0.00020547307,0.00008460706,0.000009896142,0.00015858638,0.00012050527,0.0009197507],"category_scores_gemma":[0.0003075822,0.00011750281,0.00022103827,0.00047520507,0.00011875227,0.000060501614,0.00003763168,0.0010972186,0.0000013093195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036891725,0.005839912,0.93172956,0.000010403898,0.0019327361,0.0031790466,0.00018782676,0.00019766808,0.000009963254,0.00038341508,0.0019509328,0.0176868],"study_design_scores_gemma":[0.05466381,0.044422828,0.8870868,0.00015648543,0.00046941158,0.000055084583,0.00013894729,0.000038193804,0.000013787461,0.00012384525,0.012709321,0.000121494966],"about_ca_topic_score_codex":0.00072587247,"about_ca_topic_score_gemma":0.008928548,"teacher_disagreement_score":0.053210143,"about_ca_system_score_codex":0.0016269444,"about_ca_system_score_gemma":0.003347527,"threshold_uncertainty_score":0.99999356},"labels":[],"label_agreement":null},{"id":"W4281733679","doi":"10.1200/jco.2022.40.16_suppl.tps1599","title":"Evaluating the feasibility of using an electronic patient-reported outcome (ePRO) smartphone application (app) and biosensor by patients with cancer undergoing systemic treatments.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech","keywords":"Medicine; Usability; Patient satisfaction; mHealth; Emergency department; Cancer; Observational study; Physical therapy; Emergency medicine; Internal medicine; Surgery; Nursing","score_opus":0.1895623014166875,"score_gpt":0.49365137043552954,"score_spread":0.30408906901884203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281733679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997417,0.00095477427,0.00009826179,0.00045728165,0.00038464705,0.0006403249,0.000017161665,0.0000066139573,0.000023970337],"genre_scores_gemma":[0.99922913,0.000081655926,0.00014460168,0.0003750597,0.00009465863,0.00002855558,0.000011833929,0.000016246084,0.000018257155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964356,0.00080411916,0.001767219,0.00024127122,0.0005576358,0.00019415843],"domain_scores_gemma":[0.99556744,0.00075306563,0.0028330514,0.00026077474,0.00045046135,0.0001352232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025387856,0.00012020752,0.00084458233,0.00005420513,0.00012662786,0.0000051419906,0.000092105234,0.00009321072,0.00002963708],"category_scores_gemma":[0.00046272256,0.00007280813,0.0001470891,0.00019409605,0.000119070726,0.0000701787,0.00005080363,0.0005763656,1.203354e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043377853,0.0012101034,0.9424904,0.000048709302,0.00035093108,0.0000069151024,0.0003691177,0.00020032468,0.0013887936,0.000004776797,0.000014222713,0.049577914],"study_design_scores_gemma":[0.021120891,0.06189404,0.90763456,0.00015128452,0.0027876867,0.0004003408,0.003279952,0.0016722817,0.00018688526,0.00009715048,0.0005520162,0.0002228965],"about_ca_topic_score_codex":0.00057732564,"about_ca_topic_score_gemma":0.00051700795,"teacher_disagreement_score":0.060683936,"about_ca_system_score_codex":0.0008570366,"about_ca_system_score_gemma":0.00162396,"threshold_uncertainty_score":0.29690292},"labels":[],"label_agreement":null},{"id":"W4281733785","doi":"10.1200/jco.2022.40.16_suppl.538","title":"The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Epirubicin; Anthracycline; Breast cancer; Cyclophosphamide; Internal medicine; Oncology; Chemotherapy; Population; Doxorubicin; Cancer; Surgery","score_opus":0.03732208655706,"score_gpt":0.4166207901977058,"score_spread":0.37929870364064583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281733785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987634,0.00329018,0.0000048289194,0.007777603,0.0005500601,0.000109241126,0.000026427175,0.0000014279591,0.0006062145],"genre_scores_gemma":[0.980908,0.017533293,0.0002200615,0.00083847,0.0002917584,0.000035776757,9.925325e-7,0.000010743207,0.0001609276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980145,0.00034971314,0.0010656898,0.00019238866,0.00019286174,0.00018484273],"domain_scores_gemma":[0.9979207,0.00056644424,0.0011245107,0.00015604761,0.00014876449,0.00008353032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001033327,0.000117533345,0.00061988784,0.000036568355,0.00011371539,0.0000045587976,0.00024967492,0.0000753921,0.000040826017],"category_scores_gemma":[0.00023702017,0.00007831092,0.00016147205,0.00014375559,0.00045414115,0.000006188048,0.00018700749,0.0003433571,1.7718835e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009141336,0.00093233975,0.77595335,0.000009159848,0.00049024867,0.00006579381,0.0009962949,0.00015411436,0.0017525344,0.00012194445,0.0020441236,0.20833877],"study_design_scores_gemma":[0.0045372085,0.0016297505,0.96167374,0.000018345856,0.00003709524,0.000083071085,0.0013122911,0.000009702636,0.0012006091,0.0002786506,0.029129112,0.00009044017],"about_ca_topic_score_codex":0.0008197018,"about_ca_topic_score_gemma":0.0022507675,"teacher_disagreement_score":0.20824833,"about_ca_system_score_codex":0.000107226,"about_ca_system_score_gemma":0.0005781344,"threshold_uncertainty_score":0.31934267},"labels":[],"label_agreement":null},{"id":"W4281734609","doi":"10.1200/jco.2022.40.16_suppl.e18615","title":"International approaches to head and neck cancer multidisciplinary tumor board.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Multidisciplinary approach; Head and neck cancer; Head and neck; Attendance; Family medicine; Cancer; Institutional review board; Radiation therapy; Surgery; Internal medicine","score_opus":0.23252192831895044,"score_gpt":0.537181807398802,"score_spread":0.3046598790798515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281734609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9143962,0.0013447843,0.0003440204,0.07361945,0.0054263445,0.0001801707,0.0000086093805,0.000008031886,0.0046723797],"genre_scores_gemma":[0.91379815,0.0016152147,0.059067436,0.017753126,0.0056922943,0.000044882072,0.0000028568006,0.000024970519,0.0020010625],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807763,0.0002564918,0.0010748206,0.00017806592,0.0002625149,0.00015045806],"domain_scores_gemma":[0.9978417,0.0010057151,0.0006894691,0.00010097659,0.00008577165,0.0002763477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016568894,0.00008998259,0.0008113055,0.00011293157,0.00010664676,0.0000031443299,0.00018612744,0.00010582289,0.0005702079],"category_scores_gemma":[0.0006725663,0.0000663795,0.00019412383,0.00009231628,0.0002005426,0.00007025515,0.00017237486,0.0011061841,0.000003263824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017910138,0.002969426,0.529155,0.00001842931,0.00064540334,0.0017329436,0.00067734625,0.0009847815,0.00019060347,0.0004786497,0.01848509,0.42675218],"study_design_scores_gemma":[0.005911249,0.011841531,0.2852063,0.000022962773,0.00007794032,0.001393722,0.000330489,0.00044579006,0.000006473755,0.00039431595,0.694299,0.00007025364],"about_ca_topic_score_codex":0.0000074433437,"about_ca_topic_score_gemma":0.000016497643,"teacher_disagreement_score":0.6758139,"about_ca_system_score_codex":0.00028918375,"about_ca_system_score_gemma":0.00082603353,"threshold_uncertainty_score":0.6243377},"labels":[],"label_agreement":null},{"id":"W4281735399","doi":"10.1200/jco.2022.40.16_suppl.10007","title":"Late mortality and morbidity among adult survivors of childhood glioma treated over three decades: A report from the Childhood Cancer Survivor Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Cumulative incidence; Incidence (geometry); Late effect; Pediatrics; Radiation therapy; Glioma; Cancer; Surgery; Internal medicine; Cohort","score_opus":0.09014402339202375,"score_gpt":0.42804385724407384,"score_spread":0.3378998338520501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281735399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946416,0.0010142189,0.0000015710913,0.0023268373,0.0009725628,0.000753965,0.00011051135,0.00001261539,0.0001660982],"genre_scores_gemma":[0.9984042,0.00040035704,0.000040210267,0.00046363552,0.0005847315,0.000056430963,0.000013427471,0.000025338213,0.000011663432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99466455,0.0010476382,0.0028164205,0.00038859772,0.0008274742,0.0002553082],"domain_scores_gemma":[0.99285835,0.0028452177,0.003054375,0.00050384726,0.00040978182,0.00032845122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036542965,0.00023776328,0.0019158683,0.000107012565,0.00015922078,0.000012871445,0.00025316954,0.00020137815,0.00040285062],"category_scores_gemma":[0.002274381,0.00014026403,0.0005920786,0.00035492977,0.00027619844,0.000089713634,0.00022799257,0.0010705419,8.5728163e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007749018,0.012632805,0.97137135,0.000005720537,0.0033188642,0.004347171,0.0006115195,0.000045524135,0.00003098659,0.0000070655865,0.000677262,0.006176841],"study_design_scores_gemma":[0.011774841,0.0061659883,0.97802746,0.000058075602,0.002313215,0.00028420181,0.0005403129,0.00004574109,0.000068015965,0.00022920748,0.00037653052,0.00011638412],"about_ca_topic_score_codex":0.03275294,"about_ca_topic_score_gemma":0.043890443,"teacher_disagreement_score":0.011137505,"about_ca_system_score_codex":0.00015704043,"about_ca_system_score_gemma":0.0008350546,"threshold_uncertainty_score":0.97368807},"labels":[],"label_agreement":null},{"id":"W4281735746","doi":"10.1200/jco.2022.40.16_suppl.e18631","title":"Mitigating the risk of COVID-19 in a large community oncology clinic and its impact on the patient experience.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Western University; Ottawa Hospital; Brampton Civic Hospital; University of Ottawa; William Osler Health System","funders":"","keywords":"Medicine; Asymptomatic; Pandemic; Personal protective equipment; Internal medicine; Coronavirus disease 2019 (COVID-19); Cancer; Family medicine; Disease; Infectious disease (medical specialty)","score_opus":0.31074216600325777,"score_gpt":0.5946105955058426,"score_spread":0.28386842950258484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281735746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93214846,0.0005844443,0.0000059970744,0.06574888,0.0005296996,0.00045571727,0.000032002856,0.0000047527137,0.0004900833],"genre_scores_gemma":[0.9523066,0.0009308517,0.000044627108,0.046463076,0.0002072832,0.000018403169,0.0000014245858,0.000010499631,0.00001721894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9853044,0.010973566,0.0027431042,0.00014266596,0.00049111166,0.0003451196],"domain_scores_gemma":[0.936341,0.058702804,0.0036617245,0.00039891366,0.00024782924,0.00064775016],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.025656367,0.00014177366,0.0013596906,0.00014933725,0.00047712986,0.000005410595,0.00035379428,0.000235504,0.000712109],"category_scores_gemma":[0.06270161,0.0000690385,0.00045049732,0.0003102916,0.00034407905,0.000049190854,0.0003189741,0.005440003,0.000003061399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014818338,0.006113514,0.8775794,0.000098294164,0.00033838092,0.0005957079,0.04093728,0.000231905,0.00007321753,0.00028801066,0.006689858,0.05223608],"study_design_scores_gemma":[0.007955112,0.07075024,0.81383824,0.00007981021,0.000166137,0.0004993816,0.03058917,0.00045133306,0.000016693126,0.0011120385,0.07445126,0.00009058201],"about_ca_topic_score_codex":0.0009112949,"about_ca_topic_score_gemma":0.00074324117,"teacher_disagreement_score":0.06776141,"about_ca_system_score_codex":0.00095884,"about_ca_system_score_gemma":0.007881673,"threshold_uncertainty_score":0.9977427},"labels":[],"label_agreement":null},{"id":"W4281736048","doi":"10.1200/jco.2022.40.16_suppl.11022","title":"Piloting virtual mentorship: Evaluating acceptability and influence on wellness and professional identity in medical oncology (MO).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Canadian Medical Association; University of Calgary","funders":"","keywords":"Mentorship; Medicine; Medical education; Descriptive statistics; Professional development; Family medicine","score_opus":0.10454935359392979,"score_gpt":0.5850408768745431,"score_spread":0.4804915232806133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281736048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98303473,0.0006019773,0.000090921814,0.012715609,0.0027064765,0.00028530328,0.0000020411321,0.000008372375,0.0005545555],"genre_scores_gemma":[0.9873334,0.00059991353,0.0017380343,0.009290175,0.00090350915,0.00001891028,0.0000011588722,0.0000124138805,0.000102481456],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99257135,0.0035202098,0.00234319,0.0003467056,0.00092891144,0.00028965727],"domain_scores_gemma":[0.98489183,0.012764301,0.0015781585,0.00013678617,0.00018266067,0.00044626594],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.023959106,0.00015100313,0.0014249654,0.00017487752,0.000233787,0.000006111882,0.00025155526,0.0004820877,0.0008929624],"category_scores_gemma":[0.020643413,0.000113053015,0.00013696688,0.0002195878,0.00086074794,0.0002698441,0.00031938648,0.0036025373,0.0000018396339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0087845735,0.0026375584,0.4424967,0.0000275212,0.000094127885,0.0007261101,0.0006354001,0.00017268243,0.0001152824,0.0007889214,0.00015915194,0.54336196],"study_design_scores_gemma":[0.014991106,0.044073347,0.9059343,0.00010589493,0.000103087266,0.0020142389,0.0016867521,0.00096221146,0.000012918452,0.003765675,0.026208382,0.00014210217],"about_ca_topic_score_codex":0.0000123073605,"about_ca_topic_score_gemma":0.00008613983,"teacher_disagreement_score":0.54321986,"about_ca_system_score_codex":0.0006399165,"about_ca_system_score_gemma":0.002865687,"threshold_uncertainty_score":0.9986962},"labels":[],"label_agreement":null},{"id":"W4281738335","doi":"10.1200/jco.2022.40.16_suppl.tps5624","title":"Trial in progress: Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III/NRG-GY024).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health; KWF Kankerbestrijding","keywords":"Medicine; Vulvar cancer; Sentinel lymph node; Clinical endpoint; Sentinel node; Surgery; Radiation therapy; Supraclavicular lymph nodes; Primary tumor; Phases of clinical research; Cancer; Metastasis; Breast cancer; Internal medicine; Vulva; Chemotherapy; Randomized controlled trial","score_opus":0.045777544856682534,"score_gpt":0.41658837074513005,"score_spread":0.3708108258884475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281738335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948372,0.00015610279,0.0000045054676,0.0020249817,0.0012421504,0.0016478746,0.00005271268,0.000005617115,0.000028829934],"genre_scores_gemma":[0.9983841,0.00018834801,0.0001321371,0.00040209678,0.00051951455,0.00029239574,0.000036853304,0.000026464568,0.000018083581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950455,0.0008337368,0.0024606157,0.00044286295,0.00090228784,0.00031502743],"domain_scores_gemma":[0.9967877,0.0007618005,0.0019284856,0.00016145196,0.0002176437,0.00014288933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023098907,0.00025940692,0.0018037526,0.00093537645,0.000040913517,0.000013491614,0.00014840516,0.00016775957,0.0001507238],"category_scores_gemma":[0.00079362735,0.00020482966,0.0001449933,0.0009908638,0.00012109699,0.00023335397,0.00014501094,0.00080723804,4.548046e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44682512,0.024054568,0.5060444,0.000022060916,0.00021932498,0.0003090445,0.00032566706,0.00025013144,0.00003854534,0.0000016686624,0.000006619246,0.021902869],"study_design_scores_gemma":[0.4447886,0.008030633,0.54632246,0.00012553569,0.00017523394,0.0000066610087,0.000096751326,0.00030447784,0.000022876275,0.000015646265,0.000015417172,0.0000956692],"about_ca_topic_score_codex":0.0021966859,"about_ca_topic_score_gemma":0.0006671813,"teacher_disagreement_score":0.04027809,"about_ca_system_score_codex":0.0012266466,"about_ca_system_score_gemma":0.0009504593,"threshold_uncertainty_score":0.8352711},"labels":[],"label_agreement":null},{"id":"W4281738403","doi":"10.1200/jco.2022.40.16_suppl.e24084","title":"Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Palliative care; Randomized controlled trial; Quality of life (healthcare); Cancer; Physical therapy; Internal medicine; Nursing","score_opus":0.139409683531295,"score_gpt":0.5003151181461336,"score_spread":0.3609054346148386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281738403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914598,0.004442375,0.00009073217,0.00024480544,0.0010455771,0.002067633,0.000043005977,0.000006217886,0.0005998828],"genre_scores_gemma":[0.99471694,0.00047762343,0.004144048,0.0001525426,0.00031167237,0.00012380657,0.00002525727,0.000024403851,0.000023681865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99390996,0.0017227997,0.002926068,0.0002375426,0.00094258477,0.00026102655],"domain_scores_gemma":[0.9859814,0.0074476423,0.004335426,0.00016043232,0.0018705534,0.00020451387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016742444,0.00022604929,0.0054681594,0.00023285866,0.000051195595,0.000003309239,0.00019384282,0.00018785839,0.00010160591],"category_scores_gemma":[0.004832452,0.00013720633,0.0007132356,0.000310526,0.00032659958,0.000093219984,0.00006130609,0.0010895065,2.4537022e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7657577,0.0006142157,0.21921204,0.000042427626,0.0016720839,0.00009266096,0.0033447226,0.0006959849,0.0000031403551,0.000009617997,0.000026078722,0.0085293455],"study_design_scores_gemma":[0.8589041,0.08141109,0.048762344,0.00061564124,0.0013033687,7.872388e-7,0.0077584377,0.000037513535,0.000030978063,0.000002895841,0.0010506307,0.00012216125],"about_ca_topic_score_codex":0.00017311327,"about_ca_topic_score_gemma":0.00025995824,"teacher_disagreement_score":0.17044969,"about_ca_system_score_codex":0.0003934521,"about_ca_system_score_gemma":0.0022281324,"threshold_uncertainty_score":0.5785246},"labels":[],"label_agreement":null},{"id":"W4281739223","doi":"10.1200/jco.2022.40.16_suppl.579","title":"Three-year disease-free survival in randomized trials of chemotherapy and HER2-targeted therapy: A meta-analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre; University of Toronto; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Distributed File System; Breast cancer; Trastuzumab; Oncology; Adjuvant therapy; Randomized controlled trial; Clinical trial; Surgery; Chemotherapy; Cancer","score_opus":0.18658708444891442,"score_gpt":0.4511636180631304,"score_spread":0.26457653361421596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281739223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428172,0.040457275,0.00043720132,0.014817794,0.0005348206,0.00058143924,0.00014519806,0.000003503888,0.00020555552],"genre_scores_gemma":[0.99235386,0.0050706565,0.001234515,0.0009387435,0.00028381584,0.00005465686,0.000013544088,0.00001510095,0.0000351226],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923858,0.004013248,0.0028562571,0.0002564041,0.00033033863,0.00015795424],"domain_scores_gemma":[0.9932145,0.003444427,0.0027095594,0.00031788053,0.00018299682,0.0001306486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017734433,0.0001694192,0.0059135538,0.0001493006,0.000041462485,0.0000049418686,0.00030033645,0.00012809927,0.00037196043],"category_scores_gemma":[0.0059125023,0.00010792433,0.003669289,0.0002191271,0.00028812524,0.000004468802,0.00017174927,0.00029125877,2.0548958e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5351944,0.0032243095,0.100593954,0.000012780309,0.34608844,0.000082527615,0.00015724527,0.00042011263,0.00066873885,0.0002352937,0.002470772,0.010851459],"study_design_scores_gemma":[0.5263244,0.0059565576,0.32512844,0.0000042789775,0.11264675,0.000020488902,0.00030324043,0.0000681622,0.00047120862,0.0069919247,0.021714132,0.00037042826],"about_ca_topic_score_codex":0.00010190373,"about_ca_topic_score_gemma":0.00028002737,"teacher_disagreement_score":0.23344168,"about_ca_system_score_codex":0.00002917175,"about_ca_system_score_gemma":0.00050413556,"threshold_uncertainty_score":0.70782447},"labels":[],"label_agreement":null},{"id":"W4281739610","doi":"10.1200/jco.2022.40.16_suppl.e13649","title":"The impact of virtual oncology care on chemotherapy continuity and clinical outcomes in patients treated for colorectal cancer: A pre-post analysis of the COVID-19 pandemic.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Pandemic; Colorectal cancer; Internal medicine; Cancer; Chemotherapy; Odds ratio; Emergency department; Emergency medicine; Incidence (geometry); Coronavirus disease 2019 (COVID-19); Oncology; Disease; Nursing; Infectious disease (medical specialty)","score_opus":0.150963202259676,"score_gpt":0.5753357936613335,"score_spread":0.4243725914016575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281739610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883344,0.000181228,0.000004528572,0.009555255,0.00057973986,0.0010018185,0.00030528835,0.000004669643,0.000033082524],"genre_scores_gemma":[0.99237454,0.0007897921,0.000023553195,0.0065885573,0.0001427376,0.000024268187,0.000011004627,0.000014082567,0.000031463278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934427,0.0021496834,0.0034034124,0.00024882006,0.00045146275,0.0003038866],"domain_scores_gemma":[0.9691859,0.025591597,0.0037429556,0.0002610512,0.000756317,0.00046221173],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0063383966,0.00017773428,0.0029290675,0.00026717663,0.00014753776,0.0000044475223,0.00032307295,0.00040818838,0.00006365008],"category_scores_gemma":[0.02029777,0.0000890288,0.0017457284,0.0005073936,0.00055960944,0.000033020802,0.00011614528,0.0013235704,8.487848e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049766403,0.0023397305,0.8477012,0.000020967003,0.0028904271,0.000010866783,0.0013162704,0.00022811464,0.000017203158,0.000011485237,0.0004923532,0.09520499],"study_design_scores_gemma":[0.02081817,0.08016767,0.89154357,0.000017449538,0.0015113391,0.0000105287945,0.00052260974,0.0001557894,0.0000045288243,0.000025409881,0.005156203,0.000066704924],"about_ca_topic_score_codex":0.0030892098,"about_ca_topic_score_gemma":0.01073397,"teacher_disagreement_score":0.09513828,"about_ca_system_score_codex":0.001794767,"about_ca_system_score_gemma":0.009525423,"threshold_uncertainty_score":0.99608964},"labels":[],"label_agreement":null},{"id":"W4281740120","doi":"10.1200/jco.2022.40.16_suppl.e23000","title":"Gender disparities in multiple myeloma publications.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical and Biological Sciences","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Impact factor; Demography; Citation; MEDLINE; Gender disparity; Family medicine; Library science","score_opus":0.36280793322807553,"score_gpt":0.4912541333492865,"score_spread":0.128446200121211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281740120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92869157,0.0003160661,0.000058002082,0.06266454,0.00088851096,0.00009146715,0.000002085598,0.000006942674,0.007280795],"genre_scores_gemma":[0.98860073,0.00014918734,0.001461694,0.008759596,0.0004932673,0.000008201873,0.0000022174152,0.0000020691803,0.00052306196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973487,0.0004786908,0.0014317625,0.00012675904,0.000433901,0.00018018183],"domain_scores_gemma":[0.99652135,0.002372487,0.0005866522,0.000084280946,0.00011084073,0.00032439007],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053420416,0.000053319134,0.0006394428,0.00009342558,0.00006859899,0.0000049661844,0.00023132584,0.00012723924,0.0020221858],"category_scores_gemma":[0.010215196,0.000029619521,0.00021181215,0.00027920067,0.00029892713,0.000058468682,0.00012513333,0.0010491131,0.000008907466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060288544,0.0016321944,0.8845311,0.0000055485075,0.000025209822,0.00014699358,0.0000241506,0.0000068963454,0.00007565218,0.0013067464,0.010644237,0.10099841],"study_design_scores_gemma":[0.0017849782,0.0033440925,0.744464,0.000004019276,0.000015886872,0.00017114606,0.00014813694,0.00014309218,0.000002893632,0.0027342418,0.24715653,0.000031024527],"about_ca_topic_score_codex":0.000022701308,"about_ca_topic_score_gemma":0.000025601445,"teacher_disagreement_score":0.23651229,"about_ca_system_score_codex":0.0000823249,"about_ca_system_score_gemma":0.00086091884,"threshold_uncertainty_score":0.9988901},"labels":[],"label_agreement":null},{"id":"W4281741466","doi":"10.1200/jco.2022.40.16_suppl.7510","title":"Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Obinutuzumab; Phases of clinical research; Follicular lymphoma; Gastroenterology; Surrogate endpoint; Refractory (planetary science); Randomized controlled trial; Surgery; Clinical trial; Lymphoma; Rituximab","score_opus":0.06847802474352627,"score_gpt":0.4077650418084169,"score_spread":0.3392870170648906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281741466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373543,0.00066222844,0.000012056085,0.00082296436,0.0019053672,0.0019187855,0.00003584019,0.000011061091,0.0008962643],"genre_scores_gemma":[0.99659103,0.0007988941,0.00047163613,0.0014516725,0.00023494166,0.0001670666,0.000043483695,0.000037280934,0.00020400772],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902874,0.0031132852,0.004481662,0.00043078812,0.0013164071,0.0003704298],"domain_scores_gemma":[0.9866905,0.0066601345,0.005238106,0.00069108483,0.00041834617,0.00030182741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005145922,0.00034006988,0.0054519116,0.0005354465,0.0001345006,0.0000126222885,0.0004565405,0.000333204,0.00047607737],"category_scores_gemma":[0.0030018312,0.00017491837,0.0025293163,0.0012985189,0.0003659806,0.000118590346,0.00014623012,0.0007179406,0.0000022941779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.91945255,0.014817398,0.0054697725,0.000015616375,0.011339274,0.00069312233,0.00036192138,0.000895341,0.000008147012,0.00004311178,0.0006866216,0.046217136],"study_design_scores_gemma":[0.86139876,0.06771837,0.04925729,0.00006176868,0.009742784,0.00003467089,0.00018239734,0.000563917,0.000026621692,0.000022972059,0.010827853,0.00016261048],"about_ca_topic_score_codex":0.00019467989,"about_ca_topic_score_gemma":0.000093464696,"teacher_disagreement_score":0.058053795,"about_ca_system_score_codex":0.008476495,"about_ca_system_score_gemma":0.013114641,"threshold_uncertainty_score":0.9953298},"labels":[],"label_agreement":null},{"id":"W4281742541","doi":"10.1200/jco.2022.40.16_suppl.e13579","title":"Using infrared spectroscopy to analyze breath of patients diagnosed with breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Chemical Sensor Technologies","field":"Engineering","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of New Brunswick; Horizon Health Network; Saint John Regional Hospital","funders":"Fondation de la recherche en santé du Nouveau-Brunswick","keywords":"Breast cancer; Population; Medicine; Analytical Chemistry (journal); Cancer; Chromatography; Chemistry; Internal medicine","score_opus":0.04462856772483384,"score_gpt":0.39178250770008216,"score_spread":0.34715393997524835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281742541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976133,0.000092769806,0.0010182962,0.00027927506,0.00044766325,0.000101246675,0.000056752026,0.00004200875,0.00034868647],"genre_scores_gemma":[0.9827672,0.000117783726,0.01675772,0.00017162382,0.00014404298,0.0000055394116,0.0000011252461,0.000024142259,0.00001081324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980133,0.00007383039,0.0012395735,0.00012546609,0.0003181465,0.00022968651],"domain_scores_gemma":[0.99819124,0.00059134886,0.00069488323,0.0001665667,0.00020318065,0.00015276388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024020993,0.00012553875,0.0009001905,0.00013450114,0.000034696623,0.0000034742695,0.00033930226,0.00012478798,0.00015019164],"category_scores_gemma":[0.00047709345,0.000099311284,0.00015415,0.0003841957,0.00010336161,0.00008793711,0.00011195687,0.0008273026,7.590364e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035916064,0.0014715526,0.458477,0.000052536365,0.0006911676,0.0003920201,0.00018186437,0.44315135,0.03400085,0.00004799187,0.0047644977,0.053177588],"study_design_scores_gemma":[0.01755866,0.021741008,0.853666,0.00024587035,0.0007337064,0.00038827388,0.0011592482,0.0062533054,0.049779553,0.0021856707,0.045201883,0.0010868253],"about_ca_topic_score_codex":0.00001647622,"about_ca_topic_score_gemma":0.0000150066335,"teacher_disagreement_score":0.43689805,"about_ca_system_score_codex":0.0004740356,"about_ca_system_score_gemma":0.00010753788,"threshold_uncertainty_score":0.40497968},"labels":[],"label_agreement":null},{"id":"W4281742561","doi":"10.1200/jco.2022.40.16_suppl.108","title":"Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Saskatchewan; Horizon Health Network; Saint John Regional Hospital","funders":"National Institutes of Health","keywords":"Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Oncology; Clinical endpoint; Cumulative incidence; Clinical trial; Hazard ratio; Cancer; Confidence interval; Cohort","score_opus":0.21280575996906073,"score_gpt":0.5514069190639074,"score_spread":0.33860115909484667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281742561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683992,0.0006026374,0.008843991,0.015953079,0.0028273624,0.0008757415,0.000020632948,0.000049884857,0.002427439],"genre_scores_gemma":[0.98598015,0.0023087081,0.0061176107,0.0036897396,0.0011997247,0.00008691912,0.000029474428,0.000075837044,0.00051183027],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9740212,0.015225789,0.008290223,0.00074783847,0.00094561826,0.00076933135],"domain_scores_gemma":[0.9759765,0.013115116,0.009005027,0.0003247417,0.00053260144,0.0010460005],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.055081975,0.00038546836,0.005615438,0.00061235786,0.00025344326,0.000024337658,0.0005254305,0.000445443,0.00031016304],"category_scores_gemma":[0.050629776,0.0003002695,0.0010577586,0.0006378544,0.0010946862,0.00018031619,0.00032848175,0.010859128,0.000011910181],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036726955,0.0069267326,0.071084455,0.000010449924,0.00042227138,0.0034893134,0.0012955425,0.02337324,0.000086555054,0.000019661516,0.0009970356,0.8555678],"study_design_scores_gemma":[0.1027557,0.06325522,0.068284854,0.0000783211,0.0010972383,0.0012005076,0.0020222806,0.5974007,0.0000031819488,0.0005885336,0.16285126,0.00046219846],"about_ca_topic_score_codex":0.00037961555,"about_ca_topic_score_gemma":0.00008940297,"teacher_disagreement_score":0.8551056,"about_ca_system_score_codex":0.0016474021,"about_ca_system_score_gemma":0.00503604,"threshold_uncertainty_score":0.9999449},"labels":[],"label_agreement":null},{"id":"W4281742951","doi":"10.1200/jco.2022.40.16_suppl.7577","title":"Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Population; Leukemia; Proportional hazards model; Confidence interval; Clinical trial","score_opus":0.11348216683812196,"score_gpt":0.4868015602983076,"score_spread":0.37331939346018567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281742951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997941,0.00004538615,0.000014067917,0.0002496118,0.00025108238,0.00032548618,0.0000901717,0.0000061088995,0.0010770389],"genre_scores_gemma":[0.998433,0.000032891374,0.00056136184,0.00047922216,0.00014236948,0.0000047244816,0.000117918025,0.000027227432,0.0002012627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933779,0.0011828536,0.0029655208,0.000455007,0.001600862,0.0004178204],"domain_scores_gemma":[0.99260813,0.0023528477,0.0026771529,0.0014248508,0.00037863594,0.0005584037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00416479,0.00021533604,0.0025175526,0.0005670478,0.00005212594,0.0000088823135,0.000877861,0.0002636221,0.00047096165],"category_scores_gemma":[0.00242172,0.00013633634,0.00061687385,0.0007243029,0.0003089714,0.00018340164,0.0005281895,0.0020660902,0.0000034876164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013265939,0.0077244597,0.9540831,0.000027255335,0.0016609892,0.0010228931,0.00020389387,0.0069589857,0.000004214601,0.0000019267159,0.0028153532,0.012230989],"study_design_scores_gemma":[0.042410843,0.0650472,0.88428706,0.000031252493,0.0007635156,0.000043531694,0.00028059317,0.005823696,0.000007973251,0.000011726486,0.0011676269,0.00012500673],"about_ca_topic_score_codex":0.0010822973,"about_ca_topic_score_gemma":0.00025782973,"teacher_disagreement_score":0.06979606,"about_ca_system_score_codex":0.01467147,"about_ca_system_score_gemma":0.028993534,"threshold_uncertainty_score":0.989111},"labels":[],"label_agreement":null},{"id":"W4281745790","doi":"10.1200/jco.2022.40.16_suppl.584","title":"Real-world outcomes of patients with human epidermal growth factor 2 (HER2)–positive breast cancer receiving neoadjuvant therapy without adjuvant ado-trastuzumab emtansine (T-DM1).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre; University of Toronto; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Trastuzumab; Trastuzumab emtansine; Internal medicine; Oncology; Breast cancer; Neoadjuvant therapy; Taxane; Pertuzumab; Anthracycline; Adjuvant therapy; Chemotherapy; Cancer","score_opus":0.0387784522374028,"score_gpt":0.3932983595810017,"score_spread":0.3545199073435989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281745790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951229,0.00043455913,0.000036366113,0.0025094475,0.0007339804,0.00028475747,0.0004816687,0.0000075126404,0.00038877735],"genre_scores_gemma":[0.9967839,0.0010213436,0.0004954,0.00093150703,0.00050227565,0.00003168532,0.00005333979,0.000048727015,0.00013181739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616784,0.00072329585,0.0017888226,0.00040594875,0.0005373077,0.00037681346],"domain_scores_gemma":[0.9956854,0.00043904645,0.0025846402,0.00027010986,0.00081436074,0.00020643364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007047196,0.00033115866,0.001711113,0.00012442167,0.00021678659,0.000008478431,0.00036780981,0.00015741124,0.000284134],"category_scores_gemma":[0.00019597697,0.00022563178,0.00046334267,0.00017054545,0.00035579607,0.000021042913,0.00023286573,0.0006119624,8.0359905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063726436,0.0023943277,0.95760953,0.000010994394,0.001917304,0.000057825044,0.00019047293,0.00005445004,0.0005406503,0.000018006589,0.0008082341,0.030025575],"study_design_scores_gemma":[0.009849919,0.007865599,0.9794378,0.000039871607,0.00023555258,0.000044413748,0.00014420362,0.0000016179398,0.0005506313,0.00003853892,0.0015555274,0.00023626788],"about_ca_topic_score_codex":0.00068829476,"about_ca_topic_score_gemma":0.0013704018,"teacher_disagreement_score":0.029789308,"about_ca_system_score_codex":0.00029631483,"about_ca_system_score_gemma":0.0010295379,"threshold_uncertainty_score":0.9200997},"labels":[],"label_agreement":null},{"id":"W4281747213","doi":"10.1200/jco.2022.40.16_suppl.11563","title":"Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Adverse effect; Regimen; Internal medicine; Common Terminology Criteria for Adverse Events; Phases of clinical research; Toxicity; Dosing; Clinical trial; Oncology; Surgery","score_opus":0.16313337163550048,"score_gpt":0.5203821345055201,"score_spread":0.3572487628700196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281747213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863467,0.0017366182,0.000010111158,0.010254694,0.0007660615,0.0005106461,0.0000072515422,0.0000063587227,0.00036153273],"genre_scores_gemma":[0.9966457,0.00021338608,0.0011496862,0.0013339557,0.0004856195,0.000021461496,0.0000036588156,0.000018469065,0.00012805486],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99525493,0.00086394616,0.0028652186,0.0002255874,0.00056294753,0.00022739044],"domain_scores_gemma":[0.9951416,0.002516656,0.0015726985,0.00028411852,0.00019714737,0.00028775918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036772862,0.00014242606,0.0018411002,0.00020365026,0.000052786774,0.000003846947,0.00022527558,0.00013354521,0.00094422215],"category_scores_gemma":[0.0014925005,0.00010897308,0.00034504294,0.00023321224,0.000090891255,0.00005029931,0.00014747679,0.0010653278,0.000018025974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006413341,0.21382055,0.3193656,0.000016418273,0.00044911745,0.008819224,0.0006946505,0.000041976502,0.00010807798,0.00001925524,0.0073781637,0.44287363],"study_design_scores_gemma":[0.13193297,0.17601874,0.5591487,0.00005603996,0.0008192501,0.0010763564,0.003781503,0.0001838622,0.00003918973,0.00026615072,0.12654594,0.00013128277],"about_ca_topic_score_codex":0.00019857085,"about_ca_topic_score_gemma":0.00023115595,"teacher_disagreement_score":0.44274235,"about_ca_system_score_codex":0.00020304047,"about_ca_system_score_gemma":0.00090143137,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W4281750499","doi":"10.1200/jco.2022.40.16_suppl.5039","title":"Candidate surrogate endpoints in advanced prostate cancer: Aggregate meta-analysis of 143 randomized trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Randomized controlled trial; Surrogate endpoint; Progression-free survival; Prostate; Urology; Cancer; Confidence interval; Overall survival","score_opus":0.30810223937547704,"score_gpt":0.5556795685582354,"score_spread":0.24757732918275838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281750499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954367,0.025664955,0.000012088635,0.016877733,0.00089241785,0.0013496298,0.0001815336,0.000007360698,0.00064732425],"genre_scores_gemma":[0.9767262,0.01930721,0.0006173674,0.00078973593,0.00014085791,0.00022486706,0.000030820032,0.00002130984,0.0021416834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98449796,0.0076519772,0.0062296386,0.0003112736,0.0009281031,0.0003810168],"domain_scores_gemma":[0.98249704,0.010388202,0.005864724,0.00028922217,0.0005995532,0.00036124964],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.040834177,0.0002084908,0.012977802,0.00096570124,0.000061442704,0.0000072842054,0.00026300072,0.00015329795,0.0028554907],"category_scores_gemma":[0.009545863,0.00012035793,0.005869178,0.0012226212,0.00036315646,0.000108929235,0.0001428229,0.0013938646,0.000002122615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66929615,0.0021388547,0.012940747,0.000055334192,0.26349148,0.0018731346,0.0006513359,0.002932204,0.0003179887,0.000049566235,0.0006797632,0.04557343],"study_design_scores_gemma":[0.56777114,0.008490083,0.0075219832,0.000040250834,0.39098382,0.00006901077,0.00045887366,0.0009325028,0.0010465113,0.00084760203,0.021627298,0.00021095005],"about_ca_topic_score_codex":0.00038700554,"about_ca_topic_score_gemma":0.0005567451,"teacher_disagreement_score":0.12749232,"about_ca_system_score_codex":0.00043846422,"about_ca_system_score_gemma":0.0032801335,"threshold_uncertainty_score":0.9987972},"labels":[],"label_agreement":null},{"id":"W4281750894","doi":"10.1200/jco.2022.40.16_suppl.e21139","title":"The impact of population-based EGFR testing in metastatic non-small cell lung cancer in Alberta.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Population; Lung cancer; Proportional hazards model; Epidermal growth factor receptor; Hazard ratio; Cancer; Confidence interval","score_opus":0.08172151486966567,"score_gpt":0.5107770710693393,"score_spread":0.42905555619967367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281750894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478126,0.0005370463,0.000018559542,0.0028870003,0.00034518878,0.00026772398,0.0000075130774,0.0000011519543,0.0011545831],"genre_scores_gemma":[0.9982442,0.00004799319,0.0011111188,0.00030111836,0.00009383856,0.00002576399,0.0000037594066,0.000009573484,0.00016263568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770117,0.00033863957,0.0015331209,0.000092064,0.00017946953,0.00015556625],"domain_scores_gemma":[0.9925433,0.00590129,0.0012156797,0.00010081255,0.00014173926,0.00009720271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016446133,0.00007578277,0.0006769222,0.00013218862,0.000051908493,0.0000034363568,0.000098868375,0.000045588025,0.00012472783],"category_scores_gemma":[0.0016955052,0.000044411416,0.00025155983,0.00031258288,0.00003352938,0.000033101005,0.000023104954,0.0005708906,4.0758084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069287285,0.0010746759,0.9282329,0.000021089352,0.00015696313,0.00012343729,0.00020205346,0.053181533,0.000035902383,0.000006730815,0.00020921013,0.016062653],"study_design_scores_gemma":[0.007589851,0.0037704082,0.97173834,0.00007534529,0.0003222548,0.00002124714,0.0001721628,0.015793737,0.000006110049,0.000108156026,0.00036142487,0.000040954903],"about_ca_topic_score_codex":0.015610557,"about_ca_topic_score_gemma":0.004803267,"teacher_disagreement_score":0.043505467,"about_ca_system_score_codex":0.0008996051,"about_ca_system_score_gemma":0.0041914205,"threshold_uncertainty_score":0.99094456},"labels":[],"label_agreement":null},{"id":"W4281751456","doi":"10.1200/jco.2022.40.16_suppl.9579","title":"Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Internal medicine; Circulating tumor DNA; Oncology; Liquid biopsy; Melanoma; Adjuvant therapy; Stage (stratigraphy); Clinical endpoint; Prospective cohort study; Clinical trial; Cancer; Cancer research","score_opus":0.04163592212643591,"score_gpt":0.36402254267125345,"score_spread":0.32238662054481754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281751456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615425,0.001528865,0.0012323647,0.0002505118,0.00066518434,0.00012959153,0.000024205658,0.0000011729078,0.000013842014],"genre_scores_gemma":[0.9967564,0.00032077613,0.0021789914,0.00013269027,0.00057058164,0.000014087916,0.0000043676687,0.000014510318,0.000007605065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831814,0.00028407705,0.0009318112,0.0001821811,0.0001422954,0.00014148914],"domain_scores_gemma":[0.9981245,0.0005155788,0.0010143666,0.00010295491,0.00011730739,0.00012530263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017755098,0.00008329599,0.00043828096,0.000072524505,0.00006880957,0.000006697527,0.0001118003,0.00007488879,0.0000044809512],"category_scores_gemma":[0.002592573,0.000085422515,0.00019119568,0.00005464491,0.00006870934,0.000004141306,0.0001194953,0.00029102704,5.063807e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007817728,0.00060760713,0.63166904,0.000076517914,0.00031760958,0.00030631086,0.00021850402,0.013225211,0.28246123,0.00012443536,0.00008922892,0.06308658],"study_design_scores_gemma":[0.022451004,0.016184948,0.88277006,0.00008808246,0.00064779964,0.00019179581,0.0014924039,0.002109376,0.054382585,0.004006173,0.015153852,0.0005219478],"about_ca_topic_score_codex":0.000051326057,"about_ca_topic_score_gemma":0.00001506548,"teacher_disagreement_score":0.251101,"about_ca_system_score_codex":0.00006625839,"about_ca_system_score_gemma":0.00051742664,"threshold_uncertainty_score":0.3483429},"labels":[],"label_agreement":null},{"id":"W4281751565","doi":"10.1200/jco.2022.40.16_suppl.12096","title":"Physical performance limitations and participation restrictions among cancer survivors: A population-based study from NHANES data 2015-2018.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; National Health and Nutrition Examination Survey; Population; Cancer; Demography; Logistic regression; Gerontology; Odds; Odds ratio; Cancer registry; Environmental health; Internal medicine","score_opus":0.2754831293422823,"score_gpt":0.49748788243730624,"score_spread":0.22200475309502393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281751565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939472,0.00023524491,0.00005632002,0.0034903851,0.001852083,0.0002443067,0.000076587494,0.000012694433,0.00008518008],"genre_scores_gemma":[0.9978176,0.00013217542,0.00011755205,0.00045700808,0.0012607827,0.000048608945,0.0000847713,0.000013012273,0.00006851502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997341,0.00071096414,0.0010935274,0.00023710154,0.00047711417,0.00014031585],"domain_scores_gemma":[0.9955867,0.0027614436,0.0008845992,0.0003377709,0.0002162265,0.00021323831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015780038,0.00009813743,0.0006730195,0.00011699752,0.00018857935,0.000013517691,0.00018375096,0.00008644674,0.00012085002],"category_scores_gemma":[0.001301519,0.000081809034,0.00011541356,0.0002700595,0.00006693008,0.00021711737,0.000120029465,0.00083168055,0.0000017572643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092811347,0.0020890764,0.96490765,0.000007855739,0.0001611722,0.000029616707,0.00077076565,0.000981168,0.000007996618,0.0000043746145,0.0010582076,0.02905399],"study_design_scores_gemma":[0.002459785,0.0050072344,0.9728884,0.00002261423,0.0006866779,0.0000046341866,0.0017222703,0.009788345,0.0000022248198,0.00004008986,0.007299609,0.00007811602],"about_ca_topic_score_codex":0.009035177,"about_ca_topic_score_gemma":0.04216793,"teacher_disagreement_score":0.033132754,"about_ca_system_score_codex":0.00016116719,"about_ca_system_score_gemma":0.00084919564,"threshold_uncertainty_score":0.9975637},"labels":[],"label_agreement":null},{"id":"W4281754825","doi":"10.1200/jco.2022.40.16_suppl.11042","title":"Are YouTube videos a reliable information source for young women with metastatic breast cancer?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Breast cancer; Credibility; Metastatic breast cancer; Population; Health professionals; Family medicine; Health care; Cancer; Internal medicine","score_opus":0.19664488399771884,"score_gpt":0.5143334902630637,"score_spread":0.3176886062653449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281754825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9338068,0.00011004192,0.0005438783,0.052551154,0.0112570515,0.0010506879,0.0000372049,0.000020032778,0.00062318135],"genre_scores_gemma":[0.98766905,0.00022630818,0.0025790199,0.0050344486,0.0031056392,0.0012201178,0.0000025261163,0.000014321787,0.00014857475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965048,0.00088913715,0.0014980583,0.00009538011,0.0006507002,0.00036196384],"domain_scores_gemma":[0.9888779,0.005685226,0.00414724,0.00008561966,0.0008384549,0.00036556565],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009834531,0.00007588019,0.0006480508,0.00011764639,0.000600837,0.000029001676,0.00029760163,0.000107982196,0.00037399624],"category_scores_gemma":[0.011425523,0.00006316533,0.00011406093,0.00036746365,0.00020117933,0.0005570424,0.000034221783,0.0006561297,0.00000481998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071682683,0.0011739216,0.30626246,0.000118828146,0.000324984,0.00001724145,0.11700208,0.0016342935,0.0000014764717,0.0010025995,0.030064806,0.535229],"study_design_scores_gemma":[0.0022268048,0.002530214,0.12658294,0.00002676768,0.00009925751,0.000034238758,0.08582365,0.00007244289,2.927395e-7,0.00080035743,0.7817088,0.00009425727],"about_ca_topic_score_codex":0.0019841518,"about_ca_topic_score_gemma":0.0012827532,"teacher_disagreement_score":0.75164396,"about_ca_system_score_codex":0.0017448877,"about_ca_system_score_gemma":0.0068261013,"threshold_uncertainty_score":0.9988043},"labels":[],"label_agreement":null},{"id":"W4281755040","doi":"10.1200/jco.2022.40.16_suppl.1052","title":"Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with <i>PIK3CA</i>-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Genentech","keywords":"Medicine; Neutropenia; Adverse effect; Internal medicine; Letrozole; Gastroenterology; Toxicity; Phases of clinical research; Palbociclib; Fulvestrant; Common Terminology Criteria for Adverse Events; Pharmacology; Oncology; Cancer; Tamoxifen; Breast cancer; Metastatic breast cancer","score_opus":0.07703013949222451,"score_gpt":0.4674175886751332,"score_spread":0.3903874491829087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281755040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624234,0.0005208917,0.00007789389,0.001155722,0.00010691685,0.0018346612,0.000041592226,0.0000086239925,0.000011356958],"genre_scores_gemma":[0.9958478,0.00138545,0.0019917404,0.00049671135,0.00006902681,0.00012836471,0.00001554361,0.0000562639,0.000009095041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936648,0.0023717762,0.0023692206,0.000467103,0.0007572152,0.000369861],"domain_scores_gemma":[0.99487394,0.0018911354,0.0022327588,0.00020248405,0.0005866567,0.0002130389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032380212,0.00033135246,0.0020193225,0.00046087123,0.00008174864,0.00001451691,0.00017767501,0.000087183915,0.00010339975],"category_scores_gemma":[0.00025313208,0.00022919034,0.00007596645,0.00073355425,0.00035725132,0.00049700204,0.00007350367,0.0013494841,1.2240423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15981692,0.017521136,0.577219,0.000021495875,0.00033041614,0.00028960517,0.0033877864,0.00051807443,0.00019684983,0.0000023348966,0.0000011712361,0.24069524],"study_design_scores_gemma":[0.17943735,0.104913466,0.7110791,0.00033358074,0.0001183742,0.000158502,0.003265247,0.00040291323,0.000060869854,0.000045992143,0.000008537883,0.00017602903],"about_ca_topic_score_codex":0.0008936198,"about_ca_topic_score_gemma":0.0036072147,"teacher_disagreement_score":0.24051921,"about_ca_system_score_codex":0.00077565224,"about_ca_system_score_gemma":0.000954871,"threshold_uncertainty_score":0.9346111},"labels":[],"label_agreement":null},{"id":"W4281755690","doi":"10.1200/jco.2022.40.16_suppl.tps3167","title":"Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen","keywords":"Medicine; Protein arginine methyltransferase 5; Cancer research; CDKN2A; Cancer; Tolerability; Pharmacology; Methyltransferase; Internal medicine; Adverse effect; Biology; Biochemistry","score_opus":0.03601285776840743,"score_gpt":0.38417744139351745,"score_spread":0.34816458362511005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281755690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995785,0.0009443604,0.0015937464,0.00031108377,0.00027802525,0.0010562179,0.00001636189,0.0000024990318,0.000012685772],"genre_scores_gemma":[0.99615246,0.00012363993,0.003354002,0.00009954817,0.00014252485,0.000039866594,0.00003961199,0.000023426137,0.000024921183],"study_design_codex":"simulation_or_modeling","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9952059,0.0014262195,0.0023467988,0.0003357962,0.0005071836,0.00017810524],"domain_scores_gemma":[0.9957237,0.0004671766,0.0026916594,0.00020368076,0.00078889856,0.00012483065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024322758,0.00018987867,0.0010709078,0.0001963294,0.000071176044,0.000005835549,0.00016966362,0.00020318161,0.00003503974],"category_scores_gemma":[0.0009664822,0.00016152495,0.000118403244,0.000354821,0.00018028161,0.000031431326,0.0001317554,0.0005503681,2.3257594e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13916105,0.0493506,0.05496219,0.00009765124,0.0017432832,0.00008957374,0.0036169817,0.31688502,0.30022642,0.000029179502,0.0014179393,0.13242008],"study_design_scores_gemma":[0.1505529,0.36080316,0.34011158,0.00018814042,0.0007999107,0.00007940446,0.0021969269,0.0039155125,0.1375439,0.00021122574,0.002862026,0.00073529175],"about_ca_topic_score_codex":0.000020186393,"about_ca_topic_score_gemma":0.000053586624,"teacher_disagreement_score":0.31296954,"about_ca_system_score_codex":0.00012842202,"about_ca_system_score_gemma":0.0011248725,"threshold_uncertainty_score":0.65867966},"labels":[],"label_agreement":null},{"id":"W4281761035","doi":"10.1200/jco.2022.40.16_suppl.e19522","title":"A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Chemoimmunotherapy; Internal medicine; Expanded access; Bruton's tyrosine kinase; Waldenstrom macroglobulinemia; Gastroenterology; Tyrosine kinase; Rituximab; Lymphoma","score_opus":0.15126326786819344,"score_gpt":0.5337357547382141,"score_spread":0.38247248687002067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281761035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965623,0.00007237261,0.000008694982,0.0006859763,0.0005864599,0.0008952202,0.000008468555,0.000007525607,0.0011729561],"genre_scores_gemma":[0.9985105,0.000056164266,0.00029388216,0.00058785186,0.00031704918,0.000026018964,0.0000064274636,0.000027421867,0.00017470986],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99304414,0.0011225095,0.0034854594,0.00033214182,0.0015919874,0.00042376548],"domain_scores_gemma":[0.9942337,0.00197533,0.0022502672,0.00041970483,0.00068792445,0.00043304055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004481306,0.00018562298,0.0020412046,0.00037189655,0.00006374294,0.000011335881,0.00065217144,0.00019261467,0.0007120149],"category_scores_gemma":[0.0028664193,0.00013191403,0.0002722597,0.0006181904,0.0002464856,0.00013793998,0.00052785006,0.0019753962,0.0000047034246],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11465022,0.11555699,0.6157791,0.0000953626,0.0008660157,0.009692049,0.0015955197,0.000345501,0.00006354451,0.000010684078,0.0050251638,0.13631988],"study_design_scores_gemma":[0.5661072,0.26728827,0.1555919,0.00012228625,0.00036318527,0.0010107663,0.0025295112,0.0006716605,0.00010031546,0.000058461486,0.0059627136,0.00019370328],"about_ca_topic_score_codex":0.00027908265,"about_ca_topic_score_gemma":0.0001708295,"teacher_disagreement_score":0.46018717,"about_ca_system_score_codex":0.005214669,"about_ca_system_score_gemma":0.01820285,"threshold_uncertainty_score":0.9986041},"labels":[],"label_agreement":null},{"id":"W4281761203","doi":"10.1200/jco.2022.40.16_suppl.2627","title":"Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Genome Canada","keywords":"Immunohistochemistry; PD-L1; Medicine; Cancer research; Lung cancer; Antibody; Selected reaction monitoring; Peptide; Biomarker; Immunotherapy; Computational biology; Oncology; Cancer; Pathology; Internal medicine; Chemistry; Biology; Mass spectrometry; Immunology; Chromatography; Tandem mass spectrometry; Biochemistry","score_opus":0.1063437348975699,"score_gpt":0.4222033317250409,"score_spread":0.315859596827471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281761203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679416,0.0003234673,0.0012204926,0.00084495934,0.00028004256,0.00033707396,0.0000057845414,0.0000041598937,0.00018983845],"genre_scores_gemma":[0.9937143,0.000084843225,0.0054845493,0.0001358282,0.0004414979,0.000024949273,0.000007991947,0.000012754353,0.000093314244],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99733806,0.00029534067,0.0018164368,0.00015486982,0.00024387789,0.00015143276],"domain_scores_gemma":[0.99655885,0.0013527125,0.0015532486,0.00009986307,0.0003147949,0.00012052256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003205647,0.00009204897,0.00083237176,0.00030629334,0.000076322474,0.000005831227,0.00007162397,0.00014337014,0.000025147017],"category_scores_gemma":[0.0012841444,0.00008305754,0.00035751003,0.00019181773,0.000048119407,0.00009506212,0.000040394465,0.0007176744,6.565349e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007032839,0.0021219486,0.45199525,0.0002898618,0.00018042793,0.00018609536,0.00077163865,0.0004062056,0.5236723,0.000026860738,0.00022804781,0.01308852],"study_design_scores_gemma":[0.028864188,0.01561153,0.8922443,0.0008598576,0.00077704684,0.00022400303,0.0062107285,0.013208351,0.038747218,0.00020236081,0.0027943475,0.0002560829],"about_ca_topic_score_codex":0.00010209308,"about_ca_topic_score_gemma":0.000023398883,"teacher_disagreement_score":0.4849251,"about_ca_system_score_codex":0.00018732745,"about_ca_system_score_gemma":0.000495528,"threshold_uncertainty_score":0.3386988},"labels":[],"label_agreement":null},{"id":"W4281763071","doi":"10.1200/jco.2022.40.16_suppl.tps2078","title":"GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Agile software development; Clinical trial; Randomization; Biomarker; Glioblastoma; Oncology; Protocol (science); Internal medicine; Medical physics; Pathology; Cancer research; Alternative medicine; Computer science","score_opus":0.6883699714316404,"score_gpt":0.658131808954005,"score_spread":0.030238162477635333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281763071","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770418,0.00014899338,0.0067727086,0.0054423437,0.00783052,0.0019010582,0.00019140639,0.000027125292,0.00064408174],"genre_scores_gemma":[0.47831056,0.00020945238,0.5167531,0.00228332,0.0021520795,0.00017175497,9.929289e-7,0.00004641567,0.0000723277],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98422265,0.006615887,0.0069293254,0.0005497696,0.0011373156,0.0005450747],"domain_scores_gemma":[0.797241,0.19722919,0.0038278145,0.0004047411,0.00041975622,0.0008775262],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.036307562,0.0002920204,0.003181439,0.0002029842,0.00011956078,0.000025383953,0.00058630964,0.00038971877,0.00048468],"category_scores_gemma":[0.42832506,0.00021668158,0.0005736419,0.0005733899,0.0002853245,0.00012080359,0.0005903315,0.0021765733,0.000013918611],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4556655,0.010696743,0.00064581394,0.000024243867,0.0003414437,0.0015211751,0.0003009988,0.00008026112,0.000012403882,0.007000196,0.023801433,0.4999098],"study_design_scores_gemma":[0.3445121,0.17579667,0.00182966,0.00014523733,0.0005231844,0.00017110951,0.00063718995,0.0017810902,0.000013498378,0.44068253,0.03351871,0.00038902907],"about_ca_topic_score_codex":0.000019280804,"about_ca_topic_score_gemma":0.00019575388,"teacher_disagreement_score":0.5099804,"about_ca_system_score_codex":0.0006788786,"about_ca_system_score_gemma":0.001406097,"threshold_uncertainty_score":0.9923242},"labels":[],"label_agreement":null},{"id":"W4281763773","doi":"10.1200/jco.2022.40.16_suppl.e20504","title":"Real-world treatment patterns and clinical outcomes in early stage non-small cell lung cancer (eNSCLC) in Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Cohort; Proportional hazards model; Medical record; Retrospective cohort study; Cancer registry; Population; Hazard ratio; Lung cancer; Cancer; Surgery; Confidence interval","score_opus":0.07157574938865965,"score_gpt":0.4787463721276269,"score_spread":0.4071706227389672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281763773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104786,0.00020790595,0.0000038415333,0.005372363,0.0013317721,0.00041212255,0.00006891368,0.0000028269671,0.001552418],"genre_scores_gemma":[0.9920618,0.0028822639,0.00031481034,0.00169624,0.0002479688,0.000044005323,0.0000054687544,0.000017858103,0.0027295987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649507,0.00042366463,0.0022962375,0.00024318798,0.00027051265,0.00027131895],"domain_scores_gemma":[0.9967285,0.0017208424,0.00096975913,0.00015964518,0.00008078343,0.0003405042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011264365,0.00015222248,0.0014852727,0.00018765152,0.000044791217,0.0000059943636,0.000103570164,0.00009462151,0.00024623502],"category_scores_gemma":[0.00014520406,0.00010864799,0.00025008872,0.00015640314,0.00004489275,0.000047256104,0.00006585276,0.00088542333,6.0353767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083535025,0.001935552,0.97465175,0.000019148614,0.00038023456,0.0028377792,0.00034121325,0.00013818554,0.000001018235,0.000006514441,0.00046156085,0.018391676],"study_design_scores_gemma":[0.015986977,0.004941361,0.96545154,0.00004431606,0.00049253134,0.000017200186,0.0004982447,0.00016579562,0.0000025921152,0.000007920959,0.0123033775,0.00008813866],"about_ca_topic_score_codex":0.8679888,"about_ca_topic_score_gemma":0.9795154,"teacher_disagreement_score":0.11152652,"about_ca_system_score_codex":0.0035602974,"about_ca_system_score_gemma":0.012786205,"threshold_uncertainty_score":0.99281037},"labels":[],"label_agreement":null},{"id":"W4281764145","doi":"10.1200/jco.2022.40.16_suppl.tps9137","title":"Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Trastuzumab; KRAS; Metastatic breast cancer; Phases of clinical research; Cancer; Lung cancer; Clinical trial; Breast cancer; Colorectal cancer","score_opus":0.24050476738856874,"score_gpt":0.5669676579238045,"score_spread":0.3264628905352358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281764145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98462147,0.0008883552,0.0008526207,0.0015845574,0.0008849748,0.010797661,0.00006568087,0.000018564999,0.0002861235],"genre_scores_gemma":[0.97504824,0.0007618559,0.01884325,0.00082627,0.0003096525,0.0025958975,0.000028441402,0.00011549884,0.0014708737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98788357,0.004103699,0.0045728013,0.00077969994,0.0018084766,0.0008517576],"domain_scores_gemma":[0.9802392,0.014157096,0.0029036,0.0005276387,0.0012255304,0.00094693626],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011440985,0.0004870117,0.0037780132,0.0004995962,0.00037331437,0.00007961785,0.00084547367,0.0001365182,0.001894327],"category_scores_gemma":[0.011345438,0.00030331902,0.00027242114,0.0009796162,0.0002512277,0.00031592327,0.0004455522,0.0020591721,0.0000067177166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.71539456,0.06462712,0.059914105,0.00025227893,0.0015682002,0.004458996,0.0016869439,0.0139152855,0.000050574952,7.027214e-7,0.00013016995,0.13800104],"study_design_scores_gemma":[0.7399327,0.22731811,0.004396537,0.0006803905,0.0025025066,0.0000963129,0.0023128963,0.021091523,0.000034180743,0.000011472314,0.0013285176,0.00029482835],"about_ca_topic_score_codex":0.0025266642,"about_ca_topic_score_gemma":0.013018596,"teacher_disagreement_score":0.162691,"about_ca_system_score_codex":0.0039829346,"about_ca_system_score_gemma":0.019750057,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4281766312","doi":"10.1200/jco.2022.40.16_suppl.533","title":"Outcomes of patients with T1a,b N0 Her2-positive breast cancer treated with adjuvant trastuzumab in a prospective registry in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Febrile neutropenia; Trastuzumab; Cohort; Ejection fraction; Breast cancer; Cancer; Metastatic breast cancer; Surgery; Heart failure; Oncology; Chemotherapy","score_opus":0.025723894567214974,"score_gpt":0.35572180103437434,"score_spread":0.3299979064671594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281766312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949665,0.000104813145,6.146358e-7,0.003621636,0.00016240672,0.0004893812,0.00012015461,0.0000017187576,0.00053279474],"genre_scores_gemma":[0.9988898,0.000042430995,0.0000978026,0.00065239606,0.000039640938,0.000075029486,0.000010865902,0.000014479461,0.00017757878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754804,0.00020101148,0.0012925694,0.00021925998,0.00052829675,0.00021083528],"domain_scores_gemma":[0.9975755,0.000514957,0.0012746085,0.00013198268,0.00032776187,0.00017516731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040144543,0.00015642712,0.0016415975,0.000113643146,0.000027015565,0.000002328511,0.000091235255,0.000080554295,0.00036573363],"category_scores_gemma":[0.000077967445,0.00009436537,0.00012460379,0.00022722389,0.0001116854,0.000048594346,0.00003286253,0.0009561427,1.1089717e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02212744,0.0071560186,0.9602461,0.000009837861,0.00070723746,0.001993337,0.0004012197,0.00022873902,4.655514e-7,0.000005974526,0.00048565897,0.006638005],"study_design_scores_gemma":[0.027277775,0.017918196,0.9528096,0.00020242654,0.00034610528,0.0001334905,0.00043895503,0.0000035009543,0.000009421365,0.000006683279,0.00076412555,0.00008976329],"about_ca_topic_score_codex":0.8863807,"about_ca_topic_score_gemma":0.99377847,"teacher_disagreement_score":0.10739778,"about_ca_system_score_codex":0.006263083,"about_ca_system_score_gemma":0.012171835,"threshold_uncertainty_score":0.9975517},"labels":[],"label_agreement":null},{"id":"W4281768036","doi":"10.1200/jco.2022.40.16_suppl.2546","title":"Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Biomarker; Circulating tumor DNA; Immunotherapy; Oncology; Liquid biopsy; Cancer; Clinical trial; Melanoma; Surrogate endpoint; Phases of clinical research; Nuclear medicine; Cancer research","score_opus":0.1584307396168753,"score_gpt":0.4919916503322377,"score_spread":0.3335609107153624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281768036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272203,0.0014112793,0.0010946073,0.0005987327,0.00307405,0.0004366045,0.0000797431,0.0000055094415,0.00057746854],"genre_scores_gemma":[0.99375856,0.0004237208,0.0017462405,0.0021681522,0.0017736959,0.000020561709,0.000015625381,0.000057847144,0.00003557852],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9881263,0.004932836,0.005477094,0.00052612124,0.00047241113,0.00046526667],"domain_scores_gemma":[0.99028325,0.004144308,0.004446612,0.00041841663,0.00032536697,0.0003820436],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.021718398,0.00028184341,0.0019486941,0.00019841615,0.00012395557,0.000045766392,0.00055441685,0.00041190808,0.00012993989],"category_scores_gemma":[0.018598588,0.00026302182,0.0012108308,0.00026174777,0.00030357653,0.000014648341,0.00032880125,0.0014901235,0.000004102609],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08792971,0.020298965,0.23439658,0.000047841553,0.004045703,0.006914587,0.0008257809,0.0062157474,0.32968163,0.0003146523,0.0055118296,0.30381697],"study_design_scores_gemma":[0.09411323,0.17723742,0.49227107,0.00020222872,0.0011486217,0.0029492134,0.0011776404,0.011878937,0.0031413103,0.0031894797,0.21106908,0.0016217773],"about_ca_topic_score_codex":0.00012169051,"about_ca_topic_score_gemma":0.000041538147,"teacher_disagreement_score":0.32654032,"about_ca_system_score_codex":0.00025856541,"about_ca_system_score_gemma":0.0028346556,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W4281768533","doi":"10.1200/jco.2022.40.16_suppl.5020","title":"Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; CHEK2; FANCA; Clinical endpoint; Prostate cancer; Abiraterone acetate; Oncology; Internal medicine; PALB2; Cancer research; Carboplatin; Cancer; Gene; Fanconi anemia; DNA repair; Chemotherapy; Clinical trial; Mutation; Genetics; Androgen deprivation therapy; Biology; Germline mutation","score_opus":0.06013094499180042,"score_gpt":0.401546616470539,"score_spread":0.3414156714787386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281768533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635875,0.00062026107,0.000047220423,0.001731539,0.00009493947,0.001067714,0.000058006655,0.000005488933,0.000016067068],"genre_scores_gemma":[0.99616647,0.000534215,0.0024357291,0.00054977706,0.000035204703,0.00018941684,0.000033799864,0.000016146296,0.00003924859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531,0.001603407,0.0019734255,0.00031816252,0.00060226576,0.0001927052],"domain_scores_gemma":[0.99695235,0.000547462,0.0017218655,0.00021608392,0.00045587608,0.0001063827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032306768,0.00017050754,0.0011739226,0.00038451597,0.00010084946,0.000017583692,0.000109749126,0.00006355746,0.000045868223],"category_scores_gemma":[0.00015381014,0.000109836,0.00008597543,0.0007597269,0.00020269949,0.00015405801,0.000036490823,0.0006190288,1.263855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020794677,0.009143085,0.9488753,0.000043235756,0.0020419583,0.00044155697,0.004512558,0.005102714,0.001580725,0.00000436696,0.00018760309,0.0072722244],"study_design_scores_gemma":[0.035723697,0.04677002,0.91318816,0.000035728503,0.0015767603,0.00013144215,0.0015760419,0.0003590994,0.0003520912,0.00006588926,0.000095427364,0.00012562217],"about_ca_topic_score_codex":0.0003792822,"about_ca_topic_score_gemma":0.0033024065,"teacher_disagreement_score":0.037626937,"about_ca_system_score_codex":0.00028309185,"about_ca_system_score_gemma":0.0006098527,"threshold_uncertainty_score":0.4478982},"labels":[],"label_agreement":null},{"id":"W4281769949","doi":"10.1200/jco.2022.40.16_suppl.2500","title":"Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Université Laval; Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Toxicity; Internal medicine; Combination therapy; Renal cell carcinoma; Interleukin 2; Nivolumab; Oncology; CD8; Pharmacology; Cytokine; Immunotherapy; Cancer research; Cancer; Immunology; Immune system","score_opus":0.032399570157146854,"score_gpt":0.38733640719850715,"score_spread":0.3549368370413603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281769949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962082,0.00028304354,0.000025066778,0.002720353,0.00018439238,0.0002863199,0.0000026897983,0.000003776223,0.00028614895],"genre_scores_gemma":[0.99713343,0.00034315154,0.0006582753,0.0017046586,0.00006548591,0.000014989397,0.0000049286214,0.000015024176,0.000060062892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771917,0.00031832996,0.0012879798,0.00016461822,0.00033706962,0.00017286194],"domain_scores_gemma":[0.9983345,0.0003442102,0.0009926915,0.00011128821,0.00011660801,0.00010069536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013363451,0.00010801977,0.0008371818,0.00018538105,0.000035536,0.0000058780615,0.000090799884,0.00008757711,0.000101726415],"category_scores_gemma":[0.0001392703,0.00007497365,0.00007619644,0.00024576017,0.00014488371,0.0001139648,0.000024142371,0.0007838976,3.88978e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1885832,0.0034446642,0.6013199,0.000017417744,0.00011591591,0.0004613269,0.00024408459,0.00016550234,0.00014925783,0.000011300807,0.00021126497,0.20527616],"study_design_scores_gemma":[0.081621125,0.05248317,0.8571415,0.00012413865,0.000031072017,0.0002565305,0.00026035792,0.00011626812,0.000036866415,0.00008226011,0.0077579794,0.00008871392],"about_ca_topic_score_codex":0.00003867355,"about_ca_topic_score_gemma":0.00018525282,"teacher_disagreement_score":0.25582162,"about_ca_system_score_codex":0.00036888942,"about_ca_system_score_gemma":0.0007795475,"threshold_uncertainty_score":0.34056884},"labels":[],"label_agreement":null},{"id":"W4281771147","doi":"10.1200/jco.2022.40.16_suppl.7504","title":"Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Vincristine; Etoposide; Hazard ratio; Regimen; Prednisone; Gastroenterology; Oncology; Surgery; Lymphoma; Cyclophosphamide; Chemotherapy; CD30; Confidence interval","score_opus":0.0271985694545777,"score_gpt":0.36863847134308475,"score_spread":0.34143990188850704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281771147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885817,0.0006144094,0.000033669927,0.008137283,0.00080579007,0.0015911302,0.0001220403,0.000021464208,0.00009249518],"genre_scores_gemma":[0.9955215,0.000611828,0.0011319927,0.0012312775,0.0011514745,0.00014954734,0.00011858288,0.000046983307,0.000036838264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990844,0.0038205076,0.0028444661,0.0006640648,0.0013399811,0.0004869892],"domain_scores_gemma":[0.98622316,0.0075139953,0.0049162526,0.0006740341,0.00027784187,0.00039474232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008095501,0.00038451652,0.0025327823,0.00017870388,0.00027331628,0.000039743245,0.00045470134,0.00032289908,0.00014158648],"category_scores_gemma":[0.003675176,0.00022278292,0.00033865488,0.00042435343,0.00019742848,0.00015420612,0.00032921036,0.0013019998,0.000003888667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011331347,0.03722138,0.8336911,0.0000016696224,0.0036277296,0.007120751,0.0004194203,0.000058163165,0.0000019110198,0.000013661312,0.0025967031,0.10391613],"study_design_scores_gemma":[0.15753491,0.07013766,0.7644752,0.00003789737,0.002398933,0.002402947,0.00076662767,0.00002003759,0.0000041926755,0.00010172852,0.0019381215,0.00018169603],"about_ca_topic_score_codex":0.0072437236,"about_ca_topic_score_gemma":0.005957398,"teacher_disagreement_score":0.14620356,"about_ca_system_score_codex":0.0018306412,"about_ca_system_score_gemma":0.0026056683,"threshold_uncertainty_score":0.9993671},"labels":[],"label_agreement":null},{"id":"W4281771481","doi":"10.1200/jco.2022.40.16_suppl.tps5619","title":"FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital; Université de Montréal; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Gastroenterology; Paclitaxel; Placebo; Ovarian cancer; Oncology; Urology; Surgery; Cancer; Pathology; Cisplatin","score_opus":0.07999690574637143,"score_gpt":0.4582762462387569,"score_spread":0.3782793404923855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281771481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98029447,0.0010307411,0.00009188279,0.008834146,0.002849479,0.0041885036,0.00023675153,0.00003598789,0.0024380346],"genre_scores_gemma":[0.98992056,0.0005282067,0.0037207105,0.0017840733,0.0018825713,0.0004361556,0.000121312485,0.00009786817,0.001508564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98927045,0.0014565632,0.004613677,0.0008710864,0.002775085,0.0010131107],"domain_scores_gemma":[0.9907601,0.0032972828,0.0032645229,0.00058939686,0.0013373852,0.00075133913],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060781445,0.00071534666,0.0039571566,0.0004797099,0.00039502312,0.000052260708,0.0007963172,0.00047119593,0.0026119435],"category_scores_gemma":[0.0011474119,0.0005284677,0.00095566246,0.00089107733,0.0004685969,0.0003496129,0.00027967026,0.0032046253,0.00001638891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7895368,0.017034741,0.08948104,0.000029970142,0.0028002488,0.00056740775,0.000495673,0.0008691429,0.00012251272,0.000117173455,0.0007797762,0.09816554],"study_design_scores_gemma":[0.7893465,0.05096339,0.12425152,0.00009633678,0.00040202794,0.00006829104,0.0008106224,0.0013866104,0.000037163907,0.000095306365,0.032027774,0.00051444717],"about_ca_topic_score_codex":0.0005597995,"about_ca_topic_score_gemma":0.00069417816,"teacher_disagreement_score":0.097651094,"about_ca_system_score_codex":0.0015753021,"about_ca_system_score_gemma":0.0037877623,"threshold_uncertainty_score":0.9997167},"labels":[],"label_agreement":null},{"id":"W4281771845","doi":"10.1200/jco.2022.40.16_suppl.tps10614","title":"Adjusting the TMIST study design to accommodate slower than expected accrual: ECOG-ACRIN EA1151.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Staffing; Mammography; Randomized controlled trial; Breast cancer; Tomosynthesis; Clinical trial; Accrual; Medical physics; Cancer; Surgery; Internal medicine; Nursing; Accounting","score_opus":0.5179859933588322,"score_gpt":0.5552345191777758,"score_spread":0.037248525818943556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281771845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97959894,0.00027627143,0.0016236386,0.013668421,0.0020118156,0.0006506755,0.0000032251291,0.000023572267,0.0021434538],"genre_scores_gemma":[0.9869096,0.00003010023,0.0032277498,0.008198619,0.0012858099,0.000033234486,0.0000010648503,0.000021933738,0.00029184384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99436224,0.0019131049,0.0022154697,0.0002655843,0.0008675482,0.00037604274],"domain_scores_gemma":[0.9945671,0.0028880765,0.0013137767,0.00038074167,0.00041859807,0.00043169496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010473802,0.00016527215,0.0012062112,0.00011926565,0.00029688244,0.000025533738,0.00067216903,0.00011336913,0.0007183108],"category_scores_gemma":[0.006068369,0.00010572883,0.00039834226,0.00042368958,0.00008731811,0.000118348886,0.00044867513,0.0019264055,0.00002525543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036798343,0.0066503165,0.4242306,0.00001667122,0.001487509,0.012368654,0.0058750263,0.0040240777,0.00077127933,0.00007973966,0.11940871,0.38828906],"study_design_scores_gemma":[0.011965647,0.07141362,0.7276079,0.00010171446,0.0010359486,0.0026515725,0.032973427,0.00042758777,0.00007780911,0.0002027884,0.1512223,0.00031969615],"about_ca_topic_score_codex":0.00012251122,"about_ca_topic_score_gemma":0.00013356429,"teacher_disagreement_score":0.38796937,"about_ca_system_score_codex":0.00031603462,"about_ca_system_score_gemma":0.0014070048,"threshold_uncertainty_score":0.836938},"labels":[],"label_agreement":null},{"id":"W4281773151","doi":"10.1200/jco.2022.40.16_suppl.e13054","title":"Supporting patients with metastatic breast cancer during therapy with cyclin-dependent kinase 4/6 (CDK) inhibitors: A needs assessment.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Palbociclib; Discontinuation; Oncology; Breast cancer; Internal medicine; Metastatic breast cancer; Cancer","score_opus":0.044849346532066625,"score_gpt":0.44294296556850393,"score_spread":0.3980936190364373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281773151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270207,0.00039233657,0.00023989171,0.0051961853,0.000753102,0.00047770946,0.000042555865,0.000023690834,0.00017243749],"genre_scores_gemma":[0.9921145,0.00013773085,0.004309739,0.0022078082,0.00088948803,0.000066326174,0.000007053692,0.00006756599,0.00019983295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526894,0.0005666636,0.0022029292,0.0002891507,0.0011970727,0.0004752646],"domain_scores_gemma":[0.99433196,0.00065599295,0.0036278705,0.00026458787,0.0006841692,0.00043543347],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001958476,0.00026985884,0.0015976223,0.00028196897,0.00019240045,0.00001630579,0.00023192517,0.000087328815,0.0010553251],"category_scores_gemma":[0.00014176698,0.0001691349,0.00029186154,0.00041404922,0.00022436724,0.00028837152,0.000105960295,0.0018434267,0.0000016555589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03506455,0.004601592,0.8099456,0.000048371967,0.0016223677,0.0014208704,0.00041468095,0.0011266916,0.00048559584,0.000012169108,0.00009325237,0.14516428],"study_design_scores_gemma":[0.054470923,0.024407933,0.9045181,0.00022733703,0.00063712243,0.0025374405,0.0021790275,0.000031862608,0.00015726955,0.00008550223,0.010451276,0.00029614862],"about_ca_topic_score_codex":0.00005203875,"about_ca_topic_score_gemma":0.000033229404,"teacher_disagreement_score":0.14486812,"about_ca_system_score_codex":0.0008506786,"about_ca_system_score_gemma":0.0029356715,"threshold_uncertainty_score":0.99985784},"labels":[],"label_agreement":null},{"id":"W4281773798","doi":"10.1200/jco.2022.40.16_suppl.2528","title":"Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Rash; Gastroenterology; Adverse effect; Myositis; Pneumonitis; Autoantibody; Optic neuritis; Colitis; Immunology; Antibody","score_opus":0.03472342453510978,"score_gpt":0.3754870551264373,"score_spread":0.3407636305913275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281773798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908259,0.001142119,0.000004957647,0.0026220852,0.004276748,0.00077054376,0.000008520128,0.00002199001,0.00032712118],"genre_scores_gemma":[0.99712026,0.00057619304,0.001126943,0.00052098685,0.0003013446,0.000023615466,0.000009259895,0.00003271024,0.00028867275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99289435,0.00088380993,0.0049386625,0.00030285647,0.00061141275,0.0003689187],"domain_scores_gemma":[0.99609685,0.00080048834,0.002360518,0.00022578679,0.00025257564,0.00026377596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007885218,0.00022424647,0.0017282433,0.00043439242,0.00014168028,0.0000058086553,0.00022400147,0.00029390867,0.00015980474],"category_scores_gemma":[0.0028312735,0.00018236939,0.0007021126,0.00042068257,0.00014719053,0.00015736985,0.00027216514,0.001689815,0.0000058548426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06895663,0.0027688702,0.8294852,0.000070635484,0.000915354,0.00025236953,0.001042023,0.00019273747,0.009872629,0.0000040707355,0.0003861901,0.08605332],"study_design_scores_gemma":[0.04119051,0.011685669,0.9394366,0.0004113039,0.00021613672,0.00010263168,0.00087415776,0.0002243478,0.00075728475,0.00004086662,0.0048740706,0.00018640424],"about_ca_topic_score_codex":0.000106726606,"about_ca_topic_score_gemma":0.000009290124,"teacher_disagreement_score":0.10995145,"about_ca_system_score_codex":0.0006944151,"about_ca_system_score_gemma":0.0008486634,"threshold_uncertainty_score":0.7436808},"labels":[],"label_agreement":null},{"id":"W4281775937","doi":"10.1200/jco.2022.40.16_suppl.e18648","title":"Associations between body composition measurements (BCM) and phase 1 (P1) oncology clinical trial outcomes.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adipose tissue; Proportional hazards model; Internal medicine; Skeletal muscle; SMA*; Cachexia; Body mass index; Sarcopenia; Logistic regression; Lumbar; Cancer; Surgery","score_opus":0.6361724720699012,"score_gpt":0.6497765125779074,"score_spread":0.013604040508006121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281775937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9273347,0.00017533937,0.00020394221,0.06361889,0.0054849256,0.0006689769,0.00006713841,0.000022187029,0.0024239032],"genre_scores_gemma":[0.9750558,0.0002748338,0.0038533008,0.016809791,0.0037727284,0.000014783217,0.00004800848,0.00001862417,0.00015211632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897576,0.0033400967,0.0055685155,0.00025552348,0.00077641173,0.00030186106],"domain_scores_gemma":[0.98859835,0.006135539,0.003853469,0.00016941936,0.00046248347,0.00078072026],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021467663,0.00013951122,0.002629835,0.00022592148,0.00030472674,0.000011167228,0.00016496566,0.000448573,0.0005192004],"category_scores_gemma":[0.004781508,0.00011896022,0.00065577327,0.00016455045,0.0001990336,0.00009394827,0.00012092064,0.0029108473,0.0000148869885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060779016,0.018368747,0.7136614,0.000026100344,0.0010629457,0.00040258217,0.00010500128,0.0000018778177,0.00007234326,0.0001416502,0.029014664,0.17636368],"study_design_scores_gemma":[0.25989398,0.054835,0.45882547,0.00002658165,0.00086482434,0.00015641082,0.0000759386,0.000031084743,0.0000048528887,0.00051153725,0.22467174,0.00010257298],"about_ca_topic_score_codex":0.000011177866,"about_ca_topic_score_gemma":0.0000058537426,"teacher_disagreement_score":0.2548359,"about_ca_system_score_codex":0.0007240092,"about_ca_system_score_gemma":0.0024675562,"threshold_uncertainty_score":0.99938947},"labels":[],"label_agreement":null},{"id":"W4281776870","doi":"10.1200/jco.2022.40.16_suppl.e22512","title":"The BC Generations Project as a tumor tissue resource for cancer research.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health, Environment, Cognitive Aging","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health; University of British Columbia","funders":"","keywords":"Medicine; Cancer registry; Cancer; Surgical pathology; Population; Lung cancer; Breast cancer; Cohort; Biopsy; Molecular pathology; Pathology; Oncology; Internal medicine","score_opus":0.2857549967146767,"score_gpt":0.5662243197993643,"score_spread":0.2804693230846876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281776870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9059789,0.0004502941,0.0006361184,0.071832694,0.0011870966,0.0014655084,0.000025319398,0.000010447623,0.018413622],"genre_scores_gemma":[0.96565914,0.0010403926,0.004834757,0.014923841,0.0023780947,0.0007571662,0.0000036983931,0.00005320429,0.010349719],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99413276,0.003038719,0.0012960011,0.00029038545,0.00079725566,0.00044488348],"domain_scores_gemma":[0.9916587,0.0069657704,0.000872929,0.00023262166,0.00005009062,0.0002199002],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.022492023,0.00008505539,0.00037813192,0.00005533015,0.0012308131,0.000023150591,0.0005428772,0.00007524591,0.0014656159],"category_scores_gemma":[0.0062493733,0.000059052112,0.00016212407,0.00024955792,0.0005782983,0.00010475438,0.0004328864,0.0015641649,0.000082091865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014214347,0.0010220578,0.010776903,0.000007374737,0.000094554875,0.00022593711,0.000995011,0.0034131617,0.0018547951,0.0004576448,0.25288263,0.7268485],"study_design_scores_gemma":[0.00095991616,0.004178121,0.01004051,0.000005021764,0.000025938953,0.00007456994,0.00083824963,0.00043739818,0.00012951053,0.0012486591,0.98199457,0.00006750518],"about_ca_topic_score_codex":0.0005724955,"about_ca_topic_score_gemma":0.00081262557,"teacher_disagreement_score":0.72911197,"about_ca_system_score_codex":0.0009082533,"about_ca_system_score_gemma":0.0011104716,"threshold_uncertainty_score":0.99944717},"labels":[],"label_agreement":null},{"id":"W4281777016","doi":"10.1200/jco.2022.40.16_suppl.1532","title":"Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Cancer; Survivorship curve; Coronavirus disease 2019 (COVID-19); Cancer recurrence; Internal medicine; Disease; Infectious disease (medical specialty)","score_opus":0.11460588877554698,"score_gpt":0.5112122747358033,"score_spread":0.3966063859602563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281777016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680345,0.000055839613,0.00027396454,0.030139878,0.00081517076,0.00057249947,0.000027968215,0.00001582685,0.000064341846],"genre_scores_gemma":[0.99468094,0.00003354047,0.0002554626,0.004231936,0.00068786915,0.00004119149,0.000002416652,0.000017540053,0.00004911085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644655,0.0012422159,0.0010533151,0.00029759298,0.0006632586,0.00029709487],"domain_scores_gemma":[0.9948856,0.0024806391,0.00096338725,0.00019339574,0.00055160734,0.0009253201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026139575,0.00014389899,0.0010203449,0.00038305938,0.00015368678,0.000011028602,0.0001674236,0.00013615153,0.000073315496],"category_scores_gemma":[0.007633494,0.00011131326,0.00018930926,0.00075803127,0.00012710644,0.00027938254,0.00007956173,0.001550242,0.0000027246722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021751732,0.003908375,0.6045249,0.000066750516,0.00013230716,0.00017571295,0.001375394,0.00025645693,0.00021892175,0.000049061364,0.0003540175,0.36718634],"study_design_scores_gemma":[0.008043091,0.028992422,0.95688957,0.00010913686,0.00012058284,0.00010169732,0.00015748128,0.00006345995,0.000030918793,0.00012757654,0.0052539315,0.00011013594],"about_ca_topic_score_codex":0.00064310484,"about_ca_topic_score_gemma":0.0008080857,"teacher_disagreement_score":0.36707622,"about_ca_system_score_codex":0.00215469,"about_ca_system_score_gemma":0.0070420937,"threshold_uncertainty_score":0.9985871},"labels":[],"label_agreement":null},{"id":"W4281777449","doi":"10.1200/jco.2022.40.16_suppl.8014","title":"Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Neutropenia; Cytokine release syndrome; Adverse effect; Oncology; Common Terminology Criteria for Adverse Events; Transplantation; Minimal residual disease; Autologous stem-cell transplantation; Gastroenterology; Immunology; Immunotherapy; Chemotherapy; Chimeric antigen receptor; Bone marrow; Cancer","score_opus":0.06754253009766986,"score_gpt":0.3958977306044321,"score_spread":0.32835520050676226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281777449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937786,0.00047899416,0.00007503088,0.0019313924,0.0011929447,0.0011758767,0.0005544817,0.000036220652,0.0007764583],"genre_scores_gemma":[0.97495556,0.00023070432,0.02111966,0.0007998321,0.0005747684,0.000057625766,0.0006224843,0.000067576235,0.0015717647],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99417526,0.0010306252,0.0028289529,0.00047360756,0.0009640586,0.0005274809],"domain_scores_gemma":[0.98722535,0.008249236,0.0026570167,0.0004443064,0.0008770287,0.0005470486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029023564,0.0002661035,0.0016184417,0.0002495841,0.00028694762,0.00001851531,0.0003447316,0.00029733288,0.00084238435],"category_scores_gemma":[0.008290224,0.00017190473,0.000473822,0.00032011876,0.00015493274,0.00017357623,0.00012317304,0.0017255292,0.000012136631],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.559218,0.014392212,0.12686425,0.000029442828,0.0018151947,0.0021950146,0.00039946564,0.000033945515,0.0012566934,0.0000012101385,0.025348553,0.26844603],"study_design_scores_gemma":[0.2150896,0.09577497,0.4328789,0.00007582008,0.00040242725,0.00008112062,0.00041990567,0.0007185724,0.00023764157,0.00003940917,0.25403607,0.00024556808],"about_ca_topic_score_codex":0.00024466167,"about_ca_topic_score_gemma":0.000109744535,"teacher_disagreement_score":0.3441284,"about_ca_system_score_codex":0.0004989445,"about_ca_system_score_gemma":0.0021276732,"threshold_uncertainty_score":0.99247706},"labels":[],"label_agreement":null},{"id":"W4281779393","doi":"10.1200/jco.2022.40.16_suppl.10025","title":"Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Oncology; Progression-free survival; Temozolomide; Neuroblastoma; Irinotecan; Immunotherapy; Cancer; Chemotherapy","score_opus":0.03405628333367545,"score_gpt":0.37460649417170544,"score_spread":0.34055021083803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281779393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997896,0.000085056716,0.000019665269,0.00065959804,0.00018761774,0.00095761026,0.00014081146,0.00001991367,0.000033722165],"genre_scores_gemma":[0.99842507,0.00010983279,0.0010329233,0.00017219796,0.00007704368,0.000030711355,0.000011402549,0.00006687259,0.000073930925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931915,0.0024562157,0.002033638,0.00046657337,0.0013271882,0.0005249059],"domain_scores_gemma":[0.9918288,0.0044104625,0.002322992,0.00048235545,0.00047759994,0.0004778009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022901741,0.0003451178,0.0020142714,0.00043624427,0.00016159029,0.000017601249,0.0003548063,0.00020673776,0.00016893283],"category_scores_gemma":[0.0022645742,0.00022241798,0.00022960473,0.00044908945,0.00035233964,0.00014804986,0.00027055893,0.001923786,0.000001630471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23934755,0.004973065,0.7246484,0.00003991579,0.00041818054,0.0026417496,0.00009573723,0.00012210634,0.0006164536,0.0000015350207,0.00002539265,0.027069887],"study_design_scores_gemma":[0.062199347,0.15191832,0.7842785,0.00017726983,0.00016488535,0.00015898701,0.000078458506,0.00009817496,0.0005863058,0.00001002825,0.00018684793,0.00014287309],"about_ca_topic_score_codex":0.00022585315,"about_ca_topic_score_gemma":0.0001315372,"teacher_disagreement_score":0.17714821,"about_ca_system_score_codex":0.0003605468,"about_ca_system_score_gemma":0.0010966656,"threshold_uncertainty_score":0.90699416},"labels":[],"label_agreement":null},{"id":"W4281779894","doi":"10.1200/jco.2022.40.16_suppl.e12511","title":"Are we overtreating stage I triple negative breast cancer in Ontario? A population-based study using the ICES database.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Medicine; Triple-negative breast cancer; Hazard ratio; Breast cancer; Stage (stratigraphy); Oncology; Internal medicine; Cancer; Confidence interval; Chemotherapy; Population; Proportional hazards model; Adjuvant chemotherapy; Adjuvant","score_opus":0.1375921511603334,"score_gpt":0.4537004827239551,"score_spread":0.31610833156362167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281779894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995913,0.00039981471,0.000026784024,0.0025478161,0.0006640564,0.0002496349,0.00015269691,0.0000019935053,0.000044178105],"genre_scores_gemma":[0.9983375,0.000042641674,0.00029301748,0.0008171452,0.0003497863,0.00003628808,0.000009186336,0.000013075117,0.000101329744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734175,0.00091409613,0.001043903,0.00023917835,0.00027779414,0.00018325257],"domain_scores_gemma":[0.99705964,0.0005399415,0.0019962436,0.00019774087,0.00014081462,0.00006560668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013684942,0.0001391926,0.0006063317,0.00006141143,0.00021478071,0.000010374434,0.00023778528,0.00007351929,0.00023671189],"category_scores_gemma":[0.00036279834,0.00009519419,0.00019509047,0.00013812979,0.000060211063,0.000010977502,0.00021007289,0.0006066775,1.9313447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002349807,0.0013727174,0.98422855,0.0000039460165,0.00033075776,0.00009422432,0.00031125784,0.008224827,0.00008860751,0.0000017843479,0.00019943863,0.002794064],"study_design_scores_gemma":[0.005409972,0.0012471954,0.9859593,0.000028860597,0.00016003069,0.000028586697,0.0045800777,0.0002039762,0.000023750927,0.000016062091,0.0022426844,0.00009949408],"about_ca_topic_score_codex":0.04645872,"about_ca_topic_score_gemma":0.4052477,"teacher_disagreement_score":0.35878897,"about_ca_system_score_codex":0.00055646774,"about_ca_system_score_gemma":0.0014325996,"threshold_uncertainty_score":0.959891},"labels":[],"label_agreement":null},{"id":"W4281780011","doi":"10.1200/jco.2022.40.16_suppl.7058","title":"Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"CTI Biopharma","keywords":"Medicine; Adverse effect; Internal medicine; Ruxolitinib; Myelofibrosis; Gastroenterology","score_opus":0.0631261125869471,"score_gpt":0.40426387406868175,"score_spread":0.34113776148173464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281780011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951143,0.00014533113,0.00003714346,0.0024867237,0.00028038566,0.00031186477,0.00012352705,0.0000048200113,0.0014958702],"genre_scores_gemma":[0.99618554,0.00056971866,0.0020840121,0.00088837167,0.000118780874,0.00001922732,0.00004344002,0.00001588009,0.00007503825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945131,0.0012565418,0.0029670869,0.00026352087,0.00075465883,0.0002450687],"domain_scores_gemma":[0.992902,0.0031576105,0.0027927884,0.00025045866,0.0006028746,0.0002942926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002948321,0.00017485174,0.00263214,0.00057577516,0.00008060869,0.0000043539635,0.00014973075,0.00016853845,0.0011319059],"category_scores_gemma":[0.0020657547,0.00011665452,0.00073808734,0.0011031386,0.00014774232,0.00006936301,0.000090546135,0.0010649866,0.000003245541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011747872,0.008658776,0.9109757,0.000014023541,0.0036865233,0.0002537821,0.00021758825,0.0007241698,0.0000033949125,0.00006285664,0.0007579986,0.062897295],"study_design_scores_gemma":[0.018974092,0.03171677,0.9311275,0.000051371135,0.004931451,0.000022523975,0.0003535115,0.00021504008,0.000030409716,0.000024226707,0.012458451,0.00009468943],"about_ca_topic_score_codex":0.00011822521,"about_ca_topic_score_gemma":0.00034554838,"teacher_disagreement_score":0.062802605,"about_ca_system_score_codex":0.0004014559,"about_ca_system_score_gemma":0.0008274943,"threshold_uncertainty_score":0.9997812},"labels":[],"label_agreement":null},{"id":"W4281780127","doi":"10.1200/jco.2022.40.16_suppl.10053","title":"Long-term medical and functional outcomes of medulloblastoma survivors: A population-based, matched cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"Garron Family Cancer Centre","keywords":"Medicine; Medulloblastoma; National Death Index; Hazard ratio; Population; Cancer registry; Cohort; Proportional hazards model; Pediatrics; Cancer; Medical record; Internal medicine; Confidence interval","score_opus":0.07004776484964385,"score_gpt":0.4288955004989612,"score_spread":0.3588477356493173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281780127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027556,0.0001823273,0.00002758289,0.008020287,0.0010693885,0.00033840508,0.000006034212,0.0000066760235,0.000073755706],"genre_scores_gemma":[0.9982946,0.00003381291,0.00017035195,0.0011770002,0.00024081932,0.000027575457,0.000011869319,0.000012219269,0.000031731033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99572164,0.0006251168,0.0021056253,0.0001882796,0.0012161558,0.00014320307],"domain_scores_gemma":[0.9943715,0.003549924,0.0012893255,0.00016362543,0.00024403958,0.00038160477],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041136164,0.00012391864,0.0016044045,0.00018064269,0.00006819982,0.000004184196,0.00009891169,0.0001530974,0.0018522658],"category_scores_gemma":[0.0024786368,0.00008455474,0.00039063446,0.00013858262,0.00010979611,0.000038166683,0.00009671036,0.0006114088,0.0000024109409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016701032,0.010647151,0.9759456,0.000017054412,0.0010984503,0.0015401697,0.00002840652,0.000041237327,0.000003927741,0.0000277975,0.00034004456,0.008640072],"study_design_scores_gemma":[0.012285605,0.010125787,0.9758929,0.000026020281,0.00072722055,0.00040283773,0.00012952954,0.000067053596,0.0000041056005,0.000045184734,0.00023392496,0.000059805927],"about_ca_topic_score_codex":0.0001472295,"about_ca_topic_score_gemma":0.00040850916,"teacher_disagreement_score":0.0106155025,"about_ca_system_score_codex":0.00015002214,"about_ca_system_score_gemma":0.0009790107,"threshold_uncertainty_score":0.99906015},"labels":[],"label_agreement":null},{"id":"W4281780509","doi":"10.1200/jco.2022.40.16_suppl.10019","title":"Identifying trends for high symptom burden across the care continuum in adolescents and young adults (AYA) with hematologic malignancies.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Survivorship curve; Quality of life (healthcare); Young adult; Cancer; Gerontology; Family medicine; Internal medicine; Psychiatry","score_opus":0.0720238537935798,"score_gpt":0.4406794232340886,"score_spread":0.3686555694405088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281780509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98333573,0.001990056,0.000068815476,0.012472495,0.0016436463,0.0003664447,0.000024815343,0.000012016908,0.000085991865],"genre_scores_gemma":[0.9958004,0.0001354968,0.000632437,0.0023672208,0.0008495296,0.000036069527,0.0000065334857,0.000023629891,0.00014873286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959964,0.00065144734,0.0020789276,0.00030319727,0.00058945746,0.0003805302],"domain_scores_gemma":[0.9963075,0.0011059529,0.001785799,0.00024557387,0.00034315512,0.00021204512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043277554,0.00017399203,0.001548055,0.00010952186,0.00019480441,0.0000235242,0.00031509894,0.00019103123,0.00003226444],"category_scores_gemma":[0.0013755744,0.00011154843,0.0002943212,0.00024090293,0.00029129157,0.000095707765,0.00021071993,0.0012594269,8.271655e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015772242,0.0008464124,0.91767603,0.00046056247,0.0003296135,0.00088647474,0.01766831,0.000019840716,0.000040518127,0.00010052283,0.0023763985,0.043823086],"study_design_scores_gemma":[0.024576295,0.009992283,0.92090535,0.0008487852,0.0002558481,0.0015603404,0.034236398,0.000023406732,0.000026799016,0.00017588676,0.0072319866,0.00016663787],"about_ca_topic_score_codex":0.00032852544,"about_ca_topic_score_gemma":0.003437794,"teacher_disagreement_score":0.04365645,"about_ca_system_score_codex":0.00024226292,"about_ca_system_score_gemma":0.0006013573,"threshold_uncertainty_score":0.54716533},"labels":[],"label_agreement":null},{"id":"W4281780613","doi":"10.1200/jco.2022.40.16_suppl.3082","title":"Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Peripheral blood mononuclear cell; Oncology; Germline; Gastroenterology; Gene; Genetics; Biology","score_opus":0.026173308514858433,"score_gpt":0.3780055847363402,"score_spread":0.3518322762214818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281780613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979997,0.00032604954,0.0000051948405,0.00038898957,0.0006521053,0.0005478761,0.000031422325,0.0000014856165,0.000047166624],"genre_scores_gemma":[0.9989859,0.00012482621,0.00016947628,0.00043977407,0.0002139481,0.000025603495,0.00001027824,0.00001958908,0.000010633912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965378,0.00069586653,0.0019928822,0.0002591855,0.0002511911,0.00026308277],"domain_scores_gemma":[0.9963,0.0012401709,0.0020147772,0.00025470645,0.000105493134,0.00008484357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026515657,0.00017059511,0.0008820814,0.000091761634,0.00009494115,0.000014667886,0.00037161834,0.00013622244,0.000008893397],"category_scores_gemma":[0.0033673204,0.00010251553,0.00021785265,0.00016997225,0.00016944009,0.000012230251,0.00019960577,0.0006966121,1.7056696e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08681788,0.0060201613,0.73551196,0.00004085042,0.00031190223,0.0005745743,0.0010966173,0.001138071,0.01292141,0.00001243443,0.00044287284,0.15511124],"study_design_scores_gemma":[0.27323458,0.08594246,0.6269776,0.00014446289,0.00030762475,0.00040510253,0.002471811,0.0010644078,0.002619903,0.00020945024,0.006047513,0.0005750503],"about_ca_topic_score_codex":0.00004341469,"about_ca_topic_score_gemma":0.00034151375,"teacher_disagreement_score":0.18641669,"about_ca_system_score_codex":0.00007982549,"about_ca_system_score_gemma":0.0006847945,"threshold_uncertainty_score":0.41804618},"labels":[],"label_agreement":null},{"id":"W4281781116","doi":"10.1200/jco.2022.40.16_suppl.3123","title":"Inference of sample-specific genetic interactions to increase accuracy of indication prioritization in oncology clinical trials and facilitate exploration of combined therapy opportunities.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Medicine; Ipilimumab; Clinical trial; Oncology; Nivolumab; Precision medicine; Drug development; Compendium; Computational biology; Internal medicine; Bioinformatics; Medical physics; Cancer; Drug; Immunotherapy; Pharmacology; Biology","score_opus":0.4667735413359194,"score_gpt":0.5132107662676841,"score_spread":0.04643722493176472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281781116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815318,0.0004997379,0.015820254,0.0010383145,0.0005564435,0.00036519385,0.00006276538,0.000001060939,0.00012440667],"genre_scores_gemma":[0.9839882,0.010512294,0.004909928,0.00034357258,0.00015538001,0.000015540267,0.000056573033,0.0000066267025,0.000011874934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992446,0.0023345603,0.0048023625,0.00014082271,0.00016942175,0.00010685052],"domain_scores_gemma":[0.99017674,0.0044397516,0.0046469187,0.00018936784,0.00041016433,0.0001370847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009952743,0.00009465465,0.0011009426,0.00018831358,0.000030238169,0.000004148385,0.00021054328,0.00022374242,0.000051547206],"category_scores_gemma":[0.0077546253,0.000084527084,0.00021412861,0.0001392306,0.00019467768,0.000024810171,0.00014836944,0.00040586464,2.3836317e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009186181,0.0018785952,0.023138557,0.00003369945,0.00023045293,0.000005568992,0.0009809122,0.0019400935,0.009516582,0.00057805266,0.0012625876,0.9512487],"study_design_scores_gemma":[0.038138766,0.12283606,0.3185762,0.00021152676,0.0003343482,0.00010247101,0.009010954,0.0043954696,0.004415982,0.016132895,0.48513496,0.000710364],"about_ca_topic_score_codex":0.00003319149,"about_ca_topic_score_gemma":0.00005799072,"teacher_disagreement_score":0.95053834,"about_ca_system_score_codex":0.000039396404,"about_ca_system_score_gemma":0.0011290784,"threshold_uncertainty_score":0.9283571},"labels":[],"label_agreement":null},{"id":"W4281781134","doi":"10.1200/jco.2022.40.16_suppl.e15056","title":"An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alpha Cancer Technologies","funders":"","keywords":"Medicine; Cancer; Receptor; Immune system; Immunotherapy; Cancer research; Pharmacology; Immunology; Internal medicine","score_opus":0.10682650102210615,"score_gpt":0.47984886092885404,"score_spread":0.37302235990674787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281781134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263626,0.0036331548,0.00059845624,0.0018661781,0.00061571534,0.00043161472,0.00008685211,0.0000017661563,0.00013000652],"genre_scores_gemma":[0.9951532,0.0016252048,0.0016150995,0.00027758867,0.0009701736,0.00007227626,0.000027091504,0.00001536152,0.00024402534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808276,0.0003973458,0.0009382222,0.00017274696,0.00021199642,0.00019691535],"domain_scores_gemma":[0.99808526,0.0004160712,0.00088216626,0.00024960565,0.00020616625,0.00016074307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229138,0.00010077394,0.0005342583,0.00003359591,0.00014001438,0.000008638498,0.0002603951,0.00008765464,0.0001422997],"category_scores_gemma":[0.00032135987,0.000062185354,0.00040499697,0.000044796878,0.0001707899,0.00000596533,0.00004959957,0.00016708291,0.0000010060952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026719116,0.008373693,0.007846851,0.000019952711,0.001626786,0.00012933204,0.00021687563,0.00058667373,0.28379068,0.000076570235,0.0083975345,0.66221595],"study_design_scores_gemma":[0.008985434,0.09512867,0.003211262,0.000009583879,0.0001397539,0.00008227578,0.00025216618,0.00010028919,0.07419973,0.00018978775,0.81760335,0.0000977216],"about_ca_topic_score_codex":0.00006739821,"about_ca_topic_score_gemma":0.00007620257,"teacher_disagreement_score":0.8092058,"about_ca_system_score_codex":0.00009360608,"about_ca_system_score_gemma":0.0009132402,"threshold_uncertainty_score":0.2535845},"labels":[],"label_agreement":null},{"id":"W4281782152","doi":"10.1200/jco.2022.40.16_suppl.2558","title":"Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Canada's Michael Smith Genome Sciences Centre; McGill University Health Centre","funders":"Terry Fox Research Institute","keywords":"CCL5; CXCL9; Chemokine; Medicine; TIGIT; Immune checkpoint; Immunology; Cancer research; T cell; CXCL10; Immune system; Biology; Immunotherapy; IL-2 receptor","score_opus":0.041281778992316984,"score_gpt":0.4216655925978812,"score_spread":0.3803838136055642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281782152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551946,0.00028947004,0.00005019968,0.0033889292,0.0003608544,0.00023415942,0.000018360884,0.000002450819,0.00013613494],"genre_scores_gemma":[0.99851954,0.00015070087,0.0008816663,0.0002546094,0.00012414754,0.000006898413,0.0000050797835,0.0000067201654,0.0000506135],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969764,0.00046135634,0.0020695666,0.00009865576,0.00030012924,0.00009388771],"domain_scores_gemma":[0.9975065,0.00057856727,0.0015379484,0.00009910339,0.00021047272,0.00006739975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007112699,0.00006520056,0.0006727946,0.0001565873,0.000022842456,0.0000020440239,0.000050611143,0.000118767646,0.00009546793],"category_scores_gemma":[0.0008123487,0.000053706608,0.00017861434,0.00024035343,0.00008490198,0.000055116434,0.000061533705,0.0006350142,1.4835732e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059325427,0.0008523939,0.023353066,0.00006288589,0.00007896247,0.000080953025,0.00056224084,0.00010968662,0.9019037,0.000003499794,0.000094199175,0.013572996],"study_design_scores_gemma":[0.014022483,0.018463098,0.9102717,0.00014394677,0.00006708542,0.00016853478,0.0006396487,0.00015891812,0.050985646,0.00004434667,0.004990254,0.00004431759],"about_ca_topic_score_codex":0.000024307385,"about_ca_topic_score_gemma":0.000013149822,"teacher_disagreement_score":0.88691866,"about_ca_system_score_codex":0.0002896558,"about_ca_system_score_gemma":0.0007637951,"threshold_uncertainty_score":0.2758856},"labels":[],"label_agreement":null},{"id":"W4281784552","doi":"10.1200/jco.2022.40.16_suppl.7539","title":"Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chlorambucil; Medicine; Obinutuzumab; Internal medicine; Gastroenterology; Hazard ratio; Chronic lymphocytic leukemia; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","score_opus":0.13043412768771115,"score_gpt":0.44409590525325937,"score_spread":0.31366177756554825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281784552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874226,0.0018575836,0.000009156461,0.0006245838,0.00402924,0.0007687452,0.00003199357,0.000030208746,0.0052258796],"genre_scores_gemma":[0.9917085,0.0023450889,0.00047699417,0.0003409861,0.0014406063,0.00005979486,0.00002606402,0.000080898666,0.0035210785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990189,0.0013630776,0.0049296436,0.0006696843,0.0017766223,0.0010719529],"domain_scores_gemma":[0.9885758,0.006470025,0.0026785189,0.00086281373,0.0006405699,0.0007722325],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00536145,0.00045451504,0.003681275,0.0006463621,0.00014380238,0.000017709028,0.00085600204,0.0007661037,0.00191784],"category_scores_gemma":[0.0063453387,0.00037251858,0.0014532345,0.0010370141,0.00067937374,0.00020575906,0.00053576415,0.0025181042,0.00010433258],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.56583256,0.0055399844,0.0079492675,0.0011487483,0.009550442,0.040457316,0.00422086,0.052446,0.0036241196,0.0024748093,0.04807367,0.25868222],"study_design_scores_gemma":[0.66964674,0.1528348,0.0034873283,0.00034114593,0.0014117517,0.0030855238,0.0025730638,0.034290038,0.0013111403,0.00041844713,0.13000895,0.0005910358],"about_ca_topic_score_codex":0.0023875844,"about_ca_topic_score_gemma":0.0005537728,"teacher_disagreement_score":0.2580912,"about_ca_system_score_codex":0.47550443,"about_ca_system_score_gemma":0.3827695,"threshold_uncertainty_score":0.9998727},"labels":[],"label_agreement":null},{"id":"W4281786110","doi":"10.1200/jco.2022.40.16_suppl.9547","title":"Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i><sup>V600</sup> mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Vemurafenib; Interim analysis; Internal medicine; Melanoma; Gastroenterology; Oncology; Metastatic melanoma; Cancer; Confidence interval; Randomized controlled trial; Cancer research","score_opus":0.037436212219799016,"score_gpt":0.37055697196171805,"score_spread":0.333120759741919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281786110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826235,0.00010032218,0.00015436941,0.0004346273,0.00015099766,0.00053879747,0.000059096576,0.0000020243194,0.00029739845],"genre_scores_gemma":[0.9991737,0.000051874034,0.0002700372,0.0002473026,0.000060461414,0.000035404188,0.000044171076,0.000016189259,0.00010086067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661505,0.0011348278,0.0014259886,0.00032527608,0.0003016129,0.00019723458],"domain_scores_gemma":[0.997159,0.000903555,0.0013838777,0.00022957397,0.0002231507,0.000100851445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018605326,0.00018287811,0.0010455288,0.00022039961,0.00007540208,0.000010278415,0.00028321758,0.00014284432,0.00010686819],"category_scores_gemma":[0.00057754735,0.00011559802,0.00017157807,0.00046143914,0.00017161675,0.000020421408,0.00018364066,0.0005421657,2.21494e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24854638,0.029454902,0.6035096,0.00011579346,0.006729046,0.002612977,0.0056398367,0.056795143,0.011493206,0.00020539374,0.00030933737,0.034588415],"study_design_scores_gemma":[0.15018348,0.196848,0.62750316,0.00011889994,0.0018224532,0.0005435675,0.0064014276,0.0044526705,0.0045481203,0.0001103933,0.0068432577,0.00062456523],"about_ca_topic_score_codex":0.000059041307,"about_ca_topic_score_gemma":0.006568695,"teacher_disagreement_score":0.1673931,"about_ca_system_score_codex":0.00009013563,"about_ca_system_score_gemma":0.0007305463,"threshold_uncertainty_score":0.47139505},"labels":[],"label_agreement":null},{"id":"W4281787542","doi":"10.1200/jco.2022.40.16_suppl.9573","title":"SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adjuvant; Melanoma; Internal medicine; Clinical endpoint; Adjuvant therapy; Concomitant; Oncology; Radiation therapy; Clinical trial; Surgery; Cancer; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.14525947719671414,"score_gpt":0.460658767907029,"score_spread":0.3153992907103148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281787542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851792,0.0030147408,0.000031447107,0.007390954,0.0026663386,0.0006852988,0.000017003325,0.00000853722,0.0010064915],"genre_scores_gemma":[0.99356484,0.0017872098,0.0009990578,0.0020015182,0.0012321825,0.000021646765,0.000006443331,0.000023693949,0.00036338152],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962027,0.00059975724,0.0023377778,0.00019417293,0.0004352237,0.00023037898],"domain_scores_gemma":[0.9945608,0.0028249228,0.0019044775,0.00018937784,0.00032865518,0.00019179516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004848061,0.00012794611,0.0014535644,0.00015681701,0.00008844398,0.0000063388175,0.00017975889,0.00022568824,0.0005375535],"category_scores_gemma":[0.001992893,0.000094468865,0.0006867518,0.0001660422,0.00027676672,0.00005475384,0.000058489823,0.0007018497,6.8708795e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6494374,0.0048299814,0.0007668402,0.00001826317,0.0006582504,0.00008776177,0.00013488565,0.0000010804783,0.007189239,0.00003702517,0.004983394,0.33185586],"study_design_scores_gemma":[0.3547659,0.32582995,0.012495019,0.00003726185,0.00025449082,0.00059580384,0.00036881233,0.000039879378,0.0008492836,0.00061898236,0.30403492,0.00010969637],"about_ca_topic_score_codex":0.00004757253,"about_ca_topic_score_gemma":0.00002592689,"teacher_disagreement_score":0.33174616,"about_ca_system_score_codex":0.00020640033,"about_ca_system_score_gemma":0.0021480354,"threshold_uncertainty_score":0.58858335},"labels":[],"label_agreement":null},{"id":"W4281787837","doi":"10.1200/jco.2022.40.16_suppl.e21590","title":"Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Université Laval; Hôtel-Dieu de Québec; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Melanoma; Oncology; Proportional hazards model; Biomarker; Univariate analysis; Ipilimumab; Log-rank test; Gastroenterology; Immunotherapy; Cancer; Multivariate analysis; Confidence interval; Cancer research","score_opus":0.07488444548811664,"score_gpt":0.44796856569175497,"score_spread":0.37308412020363835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281787837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925034,0.00081942504,0.000020380388,0.0041340142,0.0005980396,0.00029316684,0.000013550727,0.000006089509,0.0016119299],"genre_scores_gemma":[0.99708956,0.00036041203,0.0013026724,0.00046638568,0.000114533854,0.000008967982,0.000009346934,0.000015847592,0.00063228037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993491,0.0018384123,0.0037319376,0.00026015873,0.0004600524,0.00021844628],"domain_scores_gemma":[0.9919341,0.004101126,0.0029631115,0.0003216346,0.0003288026,0.0003511779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007499699,0.00017019578,0.0026679835,0.001107202,0.00008298511,0.0000031414024,0.00017524256,0.0002395428,0.0004430447],"category_scores_gemma":[0.0034494477,0.00013285721,0.001014442,0.0011898953,0.00033395374,0.000054455522,0.00021970163,0.0005694873,0.0000054309307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2962209,0.011596169,0.5371891,0.000057271896,0.027214045,0.0041584256,0.0010749536,0.00030336872,0.01842323,0.0001936175,0.00093046634,0.1026384],"study_design_scores_gemma":[0.019333921,0.030283159,0.9289572,0.000041049603,0.006665814,0.00026972723,0.00022788843,0.00020588154,0.0022323541,0.00005963726,0.011625562,0.000097781965],"about_ca_topic_score_codex":0.00021357882,"about_ca_topic_score_gemma":0.000103755985,"teacher_disagreement_score":0.3917681,"about_ca_system_score_codex":0.0004632144,"about_ca_system_score_gemma":0.0024062863,"threshold_uncertainty_score":0.54177594},"labels":[],"label_agreement":null},{"id":"W4281789885","doi":"10.1200/jco.2022.40.16_suppl.5519","title":"Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; BRCA mutation; Oncology; Internal medicine; Ovarian cancer; Cancer","score_opus":0.0630377280027824,"score_gpt":0.3949587414549937,"score_spread":0.3319210134522113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281789885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920023,0.00012272783,0.00012335568,0.0051013962,0.0010865304,0.0009780325,0.00034925374,0.000023510449,0.00021291374],"genre_scores_gemma":[0.99287945,0.00020921671,0.001493567,0.0046401164,0.00034694196,0.00006194472,0.00007062486,0.000039597086,0.00025856684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929467,0.002866702,0.0026679111,0.00043739396,0.0007596836,0.0003215953],"domain_scores_gemma":[0.9905575,0.005471596,0.0029416138,0.0002962527,0.000543135,0.00018991527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054032374,0.0002215099,0.001214777,0.00012228516,0.00016036085,0.000016621067,0.00014925144,0.00019864137,0.00026556166],"category_scores_gemma":[0.0033658382,0.00013849926,0.00014479141,0.00030802557,0.00021220773,0.00015577095,0.0000742737,0.0014182855,0.0000023490493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23722664,0.010378634,0.69413084,0.000025706175,0.001680398,0.0017385471,0.008497522,0.0011390389,0.00021919812,0.000050491642,0.017195605,0.027717358],"study_design_scores_gemma":[0.10508625,0.027632397,0.85596144,0.00019473153,0.0003103953,0.00014136595,0.0021503682,0.0008937674,0.000047345136,0.00042418975,0.0069452827,0.00021246493],"about_ca_topic_score_codex":0.0011021587,"about_ca_topic_score_gemma":0.0013202564,"teacher_disagreement_score":0.16183057,"about_ca_system_score_codex":0.0010614924,"about_ca_system_score_gemma":0.0013610543,"threshold_uncertainty_score":0.6161824},"labels":[],"label_agreement":null},{"id":"W4281798152","doi":"10.1200/jco.21.02505","title":"Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Irinotecan; Colorectal cancer; Chemotherapy; Artery; Radiology; Liver cancer; Oncology; Internal medicine; Cancer","score_opus":0.5634665628102268,"score_gpt":0.5191856387713121,"score_spread":0.044280924038914704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281798152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033526968,0.99176604,0.000017578137,0.0022777633,0.0009081012,0.001377905,0.00010801046,0.000007652563,0.00018426706],"genre_scores_gemma":[0.0004789514,0.9943221,0.002026202,0.0008239667,0.0017740926,0.00027104912,0.00008506367,0.000044900455,0.0001736353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948316,0.0014760141,0.0026785424,0.00035745342,0.00039852277,0.0002578612],"domain_scores_gemma":[0.98943913,0.0068285433,0.0027585702,0.00016766501,0.0003906146,0.00041549],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004726656,0.00032781242,0.005401643,0.00016997514,0.00009040571,0.000013562233,0.0001930481,0.0006805903,0.0011945765],"category_scores_gemma":[0.0013411157,0.00020427481,0.0021710026,0.00016261043,0.0001631261,0.0000678276,0.00007313484,0.0014081197,0.0000031854554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023411256,0.0012484326,0.004660867,0.0015330344,0.0033470995,0.00048781515,0.000049954106,4.19863e-8,1.2599118e-7,0.000050295752,0.007923052,0.97835815],"study_design_scores_gemma":[0.0049680904,0.013829698,0.0005711156,0.0008019535,0.0070939427,0.00084851997,0.000016217034,0.00002627356,4.841239e-7,0.00016432998,0.971515,0.00016440192],"about_ca_topic_score_codex":0.000048747203,"about_ca_topic_score_gemma":0.00004446527,"teacher_disagreement_score":0.97819376,"about_ca_system_score_codex":0.00031983212,"about_ca_system_score_gemma":0.006192628,"threshold_uncertainty_score":0.9997185},"labels":[],"label_agreement":null},{"id":"W4281817629","doi":"10.1200/jco.2022.40.16_suppl.5594","title":"Identification of a novel subtype of endometrial cancer with unfavorable outcome using artificial intelligence-based histopathology image analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Histopathology; Subtyping; Medicine; Pathology; H&E stain; Endometrial cancer; Microsatellite instability; Overdiagnosis; Internal medicine; Oncology; Immunohistochemistry; Cancer; Biology; Computer science; Gene","score_opus":0.28968342126371455,"score_gpt":0.5085249397213644,"score_spread":0.21884151845764982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281817629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681025,0.00037655493,0.02855181,0.0011774155,0.0013353335,0.0002541445,0.000061407045,0.0000046961763,0.00013612145],"genre_scores_gemma":[0.9918022,0.000050716248,0.0074279387,0.00027650924,0.00037235505,0.0000096195035,0.0000075455623,0.000013096834,0.000040005558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944073,0.0005046201,0.0039842934,0.00022747813,0.00068428455,0.00019202633],"domain_scores_gemma":[0.9917285,0.0019895511,0.005035937,0.00023462204,0.0008355515,0.00017584303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004426917,0.0001314941,0.0023444574,0.0009828395,0.000056743538,0.000003991344,0.00021388607,0.00014933108,0.0007462921],"category_scores_gemma":[0.0033217622,0.00009400286,0.0008112167,0.0023007148,0.00032539899,0.000065526234,0.000056072135,0.00064071646,8.7438184e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11887949,0.023009708,0.67135113,0.0002285538,0.005319022,0.0006743157,0.00020161776,0.03672537,0.07900644,0.0012507362,0.000049177717,0.063304454],"study_design_scores_gemma":[0.08605871,0.1463836,0.61204004,0.00021178414,0.0627763,0.0006454366,0.0017094456,0.029307466,0.05325693,0.0027664716,0.0038909763,0.0009528677],"about_ca_topic_score_codex":0.0003507893,"about_ca_topic_score_gemma":0.00011046761,"teacher_disagreement_score":0.123373896,"about_ca_system_score_codex":0.00049357757,"about_ca_system_score_gemma":0.0022071986,"threshold_uncertainty_score":0.81713754},"labels":[],"label_agreement":null},{"id":"W4281818131","doi":"10.1200/jco.2022.40.16_suppl.e19553","title":"Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"MorphoSys","keywords":"Medicine; CHOP; Neutropenia; Internal medicine; Lenalidomide; Clinical endpoint; Gastroenterology; Pharmacodynamics; Diffuse large B-cell lymphoma; Pharmacokinetics; Lymphoma; Clinical trial; Toxicity; Multiple myeloma","score_opus":0.054692984075220816,"score_gpt":0.42278285337690696,"score_spread":0.36808986930168613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281818131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413025,0.00024613857,0.000012274066,0.0014151318,0.00042289085,0.003505125,0.00009826101,0.000004247598,0.00016564755],"genre_scores_gemma":[0.9960184,0.00085012516,0.000887645,0.0016397951,0.00010042061,0.00040905928,0.000033769393,0.000036346188,0.000024400284],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99276435,0.001968433,0.0036554348,0.00046965465,0.00070966093,0.0004324702],"domain_scores_gemma":[0.9921347,0.004941698,0.0019821022,0.00024525897,0.0002557222,0.0004405222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044962983,0.0003244017,0.0032404836,0.00064879225,0.00006617769,0.000021762895,0.00034786435,0.00016266108,0.0001427438],"category_scores_gemma":[0.0014816874,0.00024532145,0.00017833944,0.00060353946,0.00010679179,0.00021351916,0.0003736687,0.0006569084,0.0000028057516],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3804439,0.3873913,0.18892217,0.000038316717,0.00038664887,0.004244237,0.0014808717,0.00022161087,0.00002767981,0.0000066121825,0.0005739564,0.0362627],"study_design_scores_gemma":[0.85417193,0.043252464,0.09640925,0.00018121765,0.0007636129,0.00005764387,0.000899145,0.0018511639,0.00004112195,0.000021724813,0.0021565887,0.00019416098],"about_ca_topic_score_codex":0.00035406632,"about_ca_topic_score_gemma":0.0015650915,"teacher_disagreement_score":0.473728,"about_ca_system_score_codex":0.0009818784,"about_ca_system_score_gemma":0.00084094267,"threshold_uncertainty_score":0.9999999},"labels":[],"label_agreement":null},{"id":"W4281825562","doi":"10.1200/jco.2022.40.16_suppl.9128","title":"Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Adenocarcinoma; Stage (stratigraphy); Univariate analysis; Logistic regression; Cancer; Multivariate analysis","score_opus":0.07360579011254115,"score_gpt":0.4469978150138076,"score_spread":0.37339202490126644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281825562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984915,0.00011882683,0.0005336652,0.00053996197,0.0001192335,0.000102156664,0.000029050025,0.0000014455702,0.000064135995],"genre_scores_gemma":[0.9957185,0.000064580025,0.0037218893,0.00038390877,0.00006558944,0.0000016833832,0.000025213158,0.000009213668,0.000009417572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756014,0.00039736123,0.001344741,0.00018232751,0.0003966925,0.00011871177],"domain_scores_gemma":[0.99684906,0.0011630598,0.0014052809,0.0002554478,0.0001734395,0.00015373327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002220013,0.00008333062,0.0012735691,0.00021268295,0.000020730611,0.000003801416,0.00016278356,0.000052309857,0.000023677794],"category_scores_gemma":[0.00229738,0.000055372628,0.00012240124,0.0003084651,0.00010691467,0.00009964937,0.00010896966,0.0005513829,2.3485352e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001212809,0.0015222678,0.8891505,0.000015599206,0.0009149951,0.00016530544,0.00013099813,0.00430178,0.000047330723,0.0000074491186,0.0000067730853,0.102524176],"study_design_scores_gemma":[0.006945337,0.017592851,0.95664346,0.00006197731,0.0019323791,0.000019486728,0.00015429963,0.016230894,0.0000049285663,0.000014757223,0.00035032793,0.000049322774],"about_ca_topic_score_codex":0.0009636554,"about_ca_topic_score_gemma":0.00016788111,"teacher_disagreement_score":0.10247485,"about_ca_system_score_codex":0.00020989058,"about_ca_system_score_gemma":0.0012342283,"threshold_uncertainty_score":0.27503446},"labels":[],"label_agreement":null},{"id":"W4281827731","doi":"10.1200/jco.2022.40.16_suppl.e17588","title":"Evaluating the utility of ctDNA in detecting residual cancer and predicting recurrence in patients with serous ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McMaster University; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Ovarian cancer; Medicine; Serous fluid; Cancer; Minimal residual disease; Oncology; Digital polymerase chain reaction; Germline; Internal medicine; Malignancy; Stage (stratigraphy); Pathology; Cancer research; Polymerase chain reaction; Gene; Biology","score_opus":0.09946209272416091,"score_gpt":0.45197600678074124,"score_spread":0.35251391405658034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281827731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975962,0.0011606587,0.000011519337,0.00053833233,0.00045317935,0.00015089738,0.00002680923,5.484172e-7,0.00006185695],"genre_scores_gemma":[0.998566,0.00046143652,0.00046230992,0.00024807383,0.00023299003,0.000015970476,0.0000019287684,0.0000070806104,0.0000042471843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979486,0.00047133057,0.0010480026,0.00017679448,0.00020375375,0.00015152297],"domain_scores_gemma":[0.99782145,0.0007180513,0.0011136341,0.00011935388,0.0001739733,0.00005351571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038199523,0.00007398972,0.00037376495,0.000039325227,0.000063711115,0.0000050068,0.00017512162,0.000091842645,0.000018226589],"category_scores_gemma":[0.002624861,0.00005425596,0.000049599268,0.0001198689,0.00010631194,0.0000047345548,0.00020029642,0.000591956,1.820268e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002048036,0.00018513859,0.8417166,0.000009055393,0.00003465671,0.0000052426076,0.00015082875,0.002181605,0.00023237654,0.0000019927477,0.00004833258,0.15338612],"study_design_scores_gemma":[0.0038816968,0.006108749,0.9875549,0.000049150312,0.000040356328,0.000007421672,0.0002626193,0.001080408,0.00019515073,0.000065964516,0.00068658387,0.0000669729],"about_ca_topic_score_codex":0.0006992576,"about_ca_topic_score_gemma":0.003911105,"teacher_disagreement_score":0.15331915,"about_ca_system_score_codex":0.0000700192,"about_ca_system_score_gemma":0.0012871944,"threshold_uncertainty_score":0.31423935},"labels":[],"label_agreement":null},{"id":"W4281835206","doi":"10.1200/jco.2022.40.16_suppl.e22027","title":"The implementation of fertility guidelines and impact on the rate of pre-therapy fertility risk discussions in pediatric oncology: A retrospective cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Guideline; Fertility; Cohort; Retrospective cohort study; Cohort study; Family medicine; Gynecology; Population; Internal medicine","score_opus":0.12454574450559881,"score_gpt":0.5244038733204872,"score_spread":0.3998581288148884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281835206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880554,0.0006011498,0.000006266798,0.009423338,0.0004919232,0.0013119633,0.00003021702,0.0000032715025,0.00007647738],"genre_scores_gemma":[0.99793875,0.001518226,0.00004202003,0.00024136316,0.00019043428,0.00004280712,0.0000017458523,0.0000064859946,0.00001817754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9886244,0.0073055616,0.0032017468,0.0003299011,0.00034311568,0.00019525805],"domain_scores_gemma":[0.98968947,0.005779929,0.0031321142,0.00047523808,0.0008126666,0.00011057504],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.038603354,0.0001453091,0.001399497,0.00009586905,0.00021343118,0.0000029043497,0.00023961843,0.0001532408,0.00014277974],"category_scores_gemma":[0.013635667,0.000059779257,0.00039595403,0.00032701113,0.00052762695,0.00005244646,0.00014770452,0.0015177618,2.8260365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06502474,0.0031903707,0.90523374,0.0000043415193,0.00037871522,0.000010589592,0.00055432646,0.0000135587325,0.00008214997,0.000008404484,0.00044244115,0.025056632],"study_design_scores_gemma":[0.004239869,0.03316106,0.9578283,0.0000042554584,0.00027391198,0.000010882087,0.0022198113,0.000028634817,0.00005808393,0.0018076272,0.00032178126,0.000045785873],"about_ca_topic_score_codex":0.00041080007,"about_ca_topic_score_gemma":0.00036332943,"teacher_disagreement_score":0.060784873,"about_ca_system_score_codex":0.00036204647,"about_ca_system_score_gemma":0.0013465662,"threshold_uncertainty_score":0.9946729},"labels":[],"label_agreement":null},{"id":"W4281835697","doi":"10.1200/jco.2022.40.16_suppl.tps6603","title":"A randomized study to measure and enhance the health-related quality of life in patients with cancer receiving immune checkpoint modulators (ME-Q).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Usability; Randomized controlled trial; Adverse effect; Telemedicine; Regret; Clinical trial; Health care; Internal medicine; Nursing","score_opus":0.08657224252246375,"score_gpt":0.44483245686024236,"score_spread":0.3582602143377786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281835697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981402,0.0031479567,0.000017410095,0.013526737,0.00061440276,0.001241763,0.000003490139,0.000003075072,0.00004317307],"genre_scores_gemma":[0.9973675,0.00034430632,0.00014203745,0.0019982026,0.000060587114,0.00003552831,5.797896e-7,0.000011111891,0.000040167182],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9910567,0.0037763037,0.004250955,0.00017143055,0.00057575514,0.00016889835],"domain_scores_gemma":[0.9940636,0.001973678,0.0033527361,0.00019222176,0.0002711718,0.00014657943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0238493,0.000111084126,0.0024504396,0.00009086666,0.0000760144,0.00000348997,0.0001461496,0.00007060245,0.00012592395],"category_scores_gemma":[0.0036633394,0.000060761788,0.00029120778,0.00034150126,0.0001925984,0.00004508084,0.00007480913,0.0009449976,1.6919086e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6009515,0.0025034752,0.37243113,0.000021544953,0.00083257805,0.000005631485,0.0032727954,0.000073280724,0.000048320588,0.0000023066236,0.00007926066,0.01977816],"study_design_scores_gemma":[0.24559589,0.012629983,0.73992246,0.0001093991,0.00008978352,0.0000047615467,0.0013140744,0.000013181259,0.000008125764,0.00002097428,0.00023742065,0.000053971708],"about_ca_topic_score_codex":0.0023694043,"about_ca_topic_score_gemma":0.0007411508,"teacher_disagreement_score":0.3674913,"about_ca_system_score_codex":0.00029425483,"about_ca_system_score_gemma":0.0016414843,"threshold_uncertainty_score":0.8265739},"labels":[],"label_agreement":null},{"id":"W4281837772","doi":"10.1200/jco.2022.40.16_suppl.11560","title":"Synergistic activity of PARP inhibitors (PARPi) in combination with standard chemotherapy (CTx) in leiomyosarcoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Olaparib; Doxorubicin; Cancer research; Temozolomide; Leiomyosarcoma; Pharmacology; Dacarbazine; Combination therapy; Oncology; Internal medicine; Chemotherapy; Melanoma; Poly ADP ribose polymerase; Pathology; Biology; DNA","score_opus":0.08447537777278068,"score_gpt":0.4460339659641407,"score_spread":0.36155858819136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281837772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875566,0.00016839785,0.00041460473,0.009943786,0.0006475087,0.00028477606,0.000008274955,0.0000061898354,0.0009698847],"genre_scores_gemma":[0.99744856,0.00022071412,0.0010104269,0.0009990982,0.00022741336,0.000018304832,0.0000022700526,0.000019771016,0.000053465006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605,0.00087320106,0.0019981076,0.00018588408,0.00068946194,0.00020332298],"domain_scores_gemma":[0.9959239,0.0015384508,0.0019661214,0.00017658158,0.00025454187,0.00014043527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004771581,0.00012673874,0.0014621769,0.0003953947,0.00003050659,0.0000032871474,0.00014654781,0.00016925682,0.00031403085],"category_scores_gemma":[0.00065948657,0.00010301568,0.00020459727,0.0005300368,0.00024992749,0.00011045681,0.000036789457,0.0014341866,8.692452e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10589486,0.013417609,0.6759107,0.00012120544,0.00038508547,0.0017638042,0.0010944152,0.0015946489,0.011742339,0.00074942666,0.0033254812,0.1840004],"study_design_scores_gemma":[0.11136039,0.077597894,0.73179275,0.0005376453,0.00014903645,0.00045628133,0.00075075426,0.0004924022,0.010325184,0.003474983,0.06274167,0.00032102977],"about_ca_topic_score_codex":0.00006226647,"about_ca_topic_score_gemma":0.000115625306,"teacher_disagreement_score":0.18367937,"about_ca_system_score_codex":0.0011274272,"about_ca_system_score_gemma":0.0021470326,"threshold_uncertainty_score":0.6230907},"labels":[],"label_agreement":null},{"id":"W4281843434","doi":"10.1200/jco.2022.40.16_suppl.2539","title":"The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Internal medicine; Cohort; Immunology; Gastroenterology; Chemotherapy; Oncology","score_opus":0.1395545426387361,"score_gpt":0.4665839838991759,"score_spread":0.32702944126043976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281843434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594628,0.0015738426,0.00020639556,0.035940018,0.0009155621,0.0009049126,0.000024961168,0.000006584106,0.0009648725],"genre_scores_gemma":[0.98274386,0.0075181955,0.0019713242,0.005519246,0.0010713302,0.000083739505,0.0000036645822,0.000035107976,0.0010535528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538434,0.0008215433,0.002286082,0.00021670513,0.00094941625,0.00034188927],"domain_scores_gemma":[0.9844965,0.011880984,0.002084768,0.00039499838,0.00096651743,0.00017626802],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010578278,0.00014974558,0.001208861,0.00010406335,0.00024794432,0.0000106852,0.0006323665,0.00013323707,0.0015246683],"category_scores_gemma":[0.0037992105,0.00008244894,0.00078581815,0.00041007757,0.0005693727,0.00005461436,0.00009389222,0.00077154,0.0000016315023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054533448,0.0017135745,0.009070611,0.00004898807,0.0010668256,0.00002596706,0.0015138284,0.00020974963,0.16759534,0.00016771504,0.012769556,0.7512844],"study_design_scores_gemma":[0.017544819,0.04098276,0.06787496,0.00013250898,0.00017065382,0.00013548556,0.0031872485,0.000482108,0.0379396,0.0005788364,0.83079964,0.00017135286],"about_ca_topic_score_codex":0.00003579592,"about_ca_topic_score_gemma":0.000025836163,"teacher_disagreement_score":0.8180301,"about_ca_system_score_codex":0.00025412318,"about_ca_system_score_gemma":0.0017461638,"threshold_uncertainty_score":0.9993881},"labels":[],"label_agreement":null},{"id":"W4281845656","doi":"10.1200/jco.2022.40.16_suppl.tps5609","title":"ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Internal medicine; Oncology; Tolerability; Carboplatin; Chemotherapy; Fallopian tube; Bevacizumab; Cancer; Phases of clinical research; Gastroenterology; Cisplatin; Immunotherapy; Surgery; Adverse effect","score_opus":0.06303458392730951,"score_gpt":0.4184054387971796,"score_spread":0.3553708548698701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281845656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958964,0.00005591305,0.0000063119705,0.0022582756,0.00051421963,0.0010427587,0.000043037962,0.0000042269107,0.00017883511],"genre_scores_gemma":[0.9983154,0.00010491141,0.0007036611,0.00052772515,0.00015681524,0.00010590575,0.000016332853,0.000026992413,0.000042260926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633104,0.0005201927,0.0018930786,0.0002990076,0.0007084752,0.00024819636],"domain_scores_gemma":[0.9972208,0.000684362,0.0014611166,0.000208982,0.0002509402,0.00017376513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093186676,0.00019480915,0.0014314104,0.0002061546,0.000049671962,0.0000081522885,0.0001561722,0.0001130012,0.00030450287],"category_scores_gemma":[0.00016605495,0.0001268194,0.00010598492,0.00032308765,0.0001075069,0.00010234424,0.000050494247,0.0008032251,4.5161397e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3568713,0.05916352,0.53716296,0.000036389734,0.0005494269,0.0014546908,0.00095086923,0.0002409607,0.000021190379,0.00000938753,0.0001075694,0.043431763],"study_design_scores_gemma":[0.27112433,0.14503966,0.58099955,0.00011429961,0.00023289205,0.00001797778,0.0005892174,0.00011166765,0.000014886943,0.0000026086993,0.0016713175,0.000081568316],"about_ca_topic_score_codex":0.0007236442,"about_ca_topic_score_gemma":0.0035725066,"teacher_disagreement_score":0.08587615,"about_ca_system_score_codex":0.0013380373,"about_ca_system_score_gemma":0.0021548318,"threshold_uncertainty_score":0.5171545},"labels":[],"label_agreement":null},{"id":"W4281848198","doi":"10.1200/jco.2022.40.16_suppl.10023","title":"Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; BC Children's Hospital; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Minimal residual disease; Medicine; Concordance; T-cell receptor; Internal medicine; Oncology; Immunology; Acute lymphocytic leukemia; Induction chemotherapy; Leukemia; Chemotherapy; Lymphoblastic Leukemia; T cell; Immune system","score_opus":0.08259697306128469,"score_gpt":0.42370756555382316,"score_spread":0.3411105924925385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281848198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98341864,0.0003464979,0.00015420423,0.013503377,0.00072700926,0.0013207286,0.00021646981,0.000026498963,0.000286569],"genre_scores_gemma":[0.99520975,0.00006485829,0.0005141053,0.0010257104,0.0028015133,0.00007086532,0.000148387,0.0000738329,0.00009097632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9887107,0.002732952,0.0042667664,0.0008092078,0.0026975353,0.0007828484],"domain_scores_gemma":[0.9787684,0.0156059535,0.0031488554,0.0007907738,0.00058081554,0.0011052146],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006243573,0.0004424286,0.0029114971,0.00030040534,0.00031503342,0.00004444741,0.0010369123,0.00037028754,0.00030839792],"category_scores_gemma":[0.0058987252,0.0002870606,0.0005101423,0.00075967255,0.00083516614,0.00020160271,0.0007161485,0.0042974353,0.000025259205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07102673,0.003991935,0.868337,0.0000070386077,0.0056304056,0.029590944,0.0006720274,0.00036889056,0.00002382232,0.000007887843,0.017611042,0.0027323116],"study_design_scores_gemma":[0.055292327,0.03502628,0.89888954,0.00009173241,0.0048902933,0.002107904,0.0014887119,0.0005153405,0.000012960564,0.00005183912,0.0013628532,0.00027024286],"about_ca_topic_score_codex":0.00062662055,"about_ca_topic_score_gemma":0.00020757894,"teacher_disagreement_score":0.031034343,"about_ca_system_score_codex":0.004523646,"about_ca_system_score_gemma":0.019649517,"threshold_uncertainty_score":0.99995816},"labels":[],"label_agreement":null},{"id":"W4281849334","doi":"10.1200/jco.2022.40.16_suppl.3551","title":"Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; Queen's University; University of Ottawa; Genome British Columbia","funders":"","keywords":"Tremelimumab; Medicine; Durvalumab; Internal medicine; Colorectal cancer; Hazard ratio; Subtyping; Oncology; Surgical oncology; Population; Bevacizumab; Refractory (planetary science); Gastroenterology; Confidence interval; Cancer; Immunotherapy; Chemotherapy; Nivolumab","score_opus":0.18568061005052977,"score_gpt":0.5178358373433549,"score_spread":0.33215522729282515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281849334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336016,0.0012342276,7.321495e-7,0.0010348046,0.0013496573,0.00078144117,0.000089259964,0.0000028554293,0.0021468594],"genre_scores_gemma":[0.999189,0.0004130942,0.000044211134,0.000104534876,0.00016078718,0.000053338135,0.000006147455,0.000019043711,0.000009812767],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99453574,0.0017849357,0.0024136088,0.00022281075,0.0007523629,0.0002905458],"domain_scores_gemma":[0.992486,0.005015908,0.0018604517,0.00016106784,0.0003652762,0.00011130283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028174068,0.00020115625,0.0023250803,0.0002636446,0.000055032582,0.000003572083,0.00020205106,0.000113629714,0.00018872501],"category_scores_gemma":[0.0026073202,0.00012709943,0.00084201864,0.00039537597,0.00031768347,0.00002546886,0.00007157294,0.0010476154,8.9344616e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8814464,0.0062592914,0.07182768,0.00006269433,0.0026273318,0.0036468056,0.0048045665,0.002667426,0.00026406773,0.000053654017,0.00026974195,0.026070312],"study_design_scores_gemma":[0.34217665,0.26320195,0.37047276,0.00014692168,0.0015955413,0.00012918733,0.021119291,0.00014134667,0.00018547723,0.0000642964,0.00057595887,0.00019059882],"about_ca_topic_score_codex":0.0018170681,"about_ca_topic_score_gemma":0.003430107,"teacher_disagreement_score":0.5392698,"about_ca_system_score_codex":0.0016552057,"about_ca_system_score_gemma":0.0049359044,"threshold_uncertainty_score":0.8756082},"labels":[],"label_agreement":null},{"id":"W4281856738","doi":"10.1200/jco.2022.40.16_suppl.5579","title":"Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; Ottawa Hospital; Kelowna General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Cmax; Pharmacokinetics; Pharmacodynamics; Internal medicine; Ovarian cancer; Placebo; Gastroenterology; Cancer; Urology; Oncology; Pharmacology; Pathology","score_opus":0.0873480001659174,"score_gpt":0.5068061762553691,"score_spread":0.4194581760894517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281856738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854864,0.0033760092,0.00001551249,0.009529022,0.00071969896,0.00017146477,0.000023650076,0.000002820832,0.000675443],"genre_scores_gemma":[0.9921958,0.0051570144,0.0007070356,0.00167718,0.00014856245,0.000024156643,0.0000037462182,0.000009478575,0.00007704848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972112,0.0003689588,0.0017812256,0.0001807861,0.00030140168,0.00015639224],"domain_scores_gemma":[0.9973733,0.0008893285,0.0012869835,0.000112018235,0.00013166097,0.00020671412],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015335323,0.00009955854,0.001575334,0.00042017957,0.000028146686,0.0000019331865,0.0001035787,0.000066621295,0.0012274694],"category_scores_gemma":[0.00021488247,0.00007943008,0.00039459017,0.0007031558,0.0000817822,0.00004889517,0.00006847623,0.00063522864,3.8308704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046482584,0.0027617423,0.51168835,0.000024995015,0.0036646787,0.00072234974,0.00013338169,0.00517316,0.00072821695,0.000050332565,0.00028984057,0.4701147],"study_design_scores_gemma":[0.018948212,0.006412125,0.9382149,0.00003704349,0.0064818193,0.00006699726,0.00012904286,0.004518803,0.00009856697,0.00005395793,0.024965014,0.00007351434],"about_ca_topic_score_codex":0.0001516056,"about_ca_topic_score_gemma":0.0001556218,"teacher_disagreement_score":0.4700412,"about_ca_system_score_codex":0.00032064962,"about_ca_system_score_gemma":0.00090985076,"threshold_uncertainty_score":0.9996855},"labels":[],"label_agreement":null},{"id":"W4281858899","doi":"10.1200/jco.2022.40.16_suppl.e18618","title":"Altered cancer care delivery during COVID-19: Evaluating the impact of virtual clinics and treatment changes on oncology patient outcomes, quality of life, and satisfaction.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Pandemic; Cancer; Internal medicine; Population; Health care; Coronavirus disease 2019 (COVID-19); Patient satisfaction; Family medicine; Physical therapy; Disease; Oncology; Nursing","score_opus":0.29547142743255533,"score_gpt":0.5020348210433647,"score_spread":0.2065633936108094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281858899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990804,0.0051022293,0.0000107138985,0.0029154085,0.0011413136,0.00024419057,0.00041160197,0.000002735002,0.00026376572],"genre_scores_gemma":[0.9911355,0.0069633983,0.000114081704,0.0014747359,0.0002497594,0.000021466421,0.0000018512603,0.000012552417,0.000026694479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601597,0.00048047796,0.0029673586,0.00024964128,0.00008698395,0.0001995925],"domain_scores_gemma":[0.98994035,0.0033392548,0.006100173,0.00019255673,0.00013923309,0.0002884572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034064325,0.00015711479,0.0018523217,0.0001611374,0.00017983296,0.000008890631,0.0001446123,0.00018125967,0.00021287719],"category_scores_gemma":[0.0038320443,0.00011577161,0.00040405546,0.000077632605,0.00024721213,0.00008296325,0.00012995958,0.00048472226,8.5148855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003406333,0.00033959316,0.7590051,0.000019297104,0.00048587806,0.000004200103,0.0018612681,0.0049209185,0.00001093179,0.0007346349,0.00011223485,0.22909959],"study_design_scores_gemma":[0.0057700947,0.03381227,0.9517902,0.000008425742,0.00004878337,0.000010563052,0.0015255457,0.00020970247,0.0000037316831,0.0007727578,0.0059294435,0.000118456344],"about_ca_topic_score_codex":0.0042086286,"about_ca_topic_score_gemma":0.0015078157,"teacher_disagreement_score":0.22898112,"about_ca_system_score_codex":0.0014219773,"about_ca_system_score_gemma":0.0018403631,"threshold_uncertainty_score":0.6362216},"labels":[],"label_agreement":null},{"id":"W4281859653","doi":"10.1200/jco.2022.40.16_suppl.577","title":"Associations between axillary staging, adjuvant treatment, and survival in older women with early-stage breast cancer: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Proportional hazards model; Stage (stratigraphy); Propensity score matching; Cancer registry; Relative survival; Internal medicine; Population; Adjuvant therapy; Observational study; Cohort; Survival analysis; Oncology; Cancer; Confounding","score_opus":0.045991604506531024,"score_gpt":0.39726022444481224,"score_spread":0.35126861993828123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281859653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721897,0.00026597388,0.000009879712,0.0016184429,0.00021490807,0.0002263493,0.00039553223,0.0000038567887,0.000046120153],"genre_scores_gemma":[0.99902165,0.00013277959,0.00008660445,0.00021710606,0.0003465604,0.0000642981,0.000035768593,0.00001809501,0.000077143224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977514,0.0006517742,0.0008864273,0.00025438555,0.00022119058,0.00023482778],"domain_scores_gemma":[0.998298,0.00035237052,0.00095603435,0.00013819711,0.00011804023,0.0001373409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010826982,0.000154098,0.0008580323,0.00008610003,0.00013610264,0.000010213173,0.0001166673,0.00009613377,0.00005188213],"category_scores_gemma":[0.00009745173,0.00011681674,0.000096448515,0.00013012758,0.000053949054,0.000008730197,0.00009027892,0.0002756616,2.4557454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013551918,0.0014955441,0.9781199,0.000002312978,0.00071195624,0.000062839375,0.0003495435,0.00032643898,0.000009724352,0.0000017549364,0.000035284094,0.017529504],"study_design_scores_gemma":[0.009787262,0.007531494,0.98020333,0.000006501777,0.00015515463,0.000008467596,0.0008119355,0.0000036148642,0.000004000291,0.000009445151,0.0013635014,0.00011529157],"about_ca_topic_score_codex":0.0017601314,"about_ca_topic_score_gemma":0.0024405026,"teacher_disagreement_score":0.017414212,"about_ca_system_score_codex":0.00057254685,"about_ca_system_score_gemma":0.00086816825,"threshold_uncertainty_score":0.47636482},"labels":[],"label_agreement":null},{"id":"W4281861539","doi":"10.1200/jco.2022.40.16_suppl.9516","title":"Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dabrafenib; Medicine; Tolerability; Trametinib; Pembrolizumab; Melanoma; Placebo; Internal medicine; Adverse effect; Metastatic melanoma; Oncology; Dermatology; Vemurafenib; Cancer; Cancer research; Pathology; Immunotherapy; MAPK/ERK pathway; Chemistry","score_opus":0.05212084778346847,"score_gpt":0.35385471353698156,"score_spread":0.3017338657535131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281861539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946299,0.002488807,0.00013878781,0.0007403522,0.0008238873,0.00028776645,0.00004643835,0.000005317102,0.0008387308],"genre_scores_gemma":[0.9967233,0.0012789832,0.00048850686,0.0006720642,0.0005119008,0.000018096174,0.000028823166,0.00003364873,0.0002447067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952243,0.0010717191,0.0023877292,0.0005010471,0.0003825773,0.00043265804],"domain_scores_gemma":[0.9969838,0.00068419403,0.0014433516,0.00035070608,0.00015440947,0.0003835024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030814887,0.00028124533,0.0014896499,0.00016875526,0.000107456835,0.00001838822,0.00041500828,0.00049598893,0.00012191724],"category_scores_gemma":[0.0011981974,0.00024492678,0.00040504176,0.00015173519,0.00036666656,0.000018365574,0.00045656261,0.0009775112,0.0000014231326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06178533,0.00817017,0.52228254,0.00057348533,0.0019248774,0.005708859,0.0025906865,0.0018917597,0.12627271,0.0013392615,0.0071372553,0.26032305],"study_design_scores_gemma":[0.1590518,0.10392458,0.4717102,0.00025615108,0.001220921,0.011769081,0.0021757418,0.0016033956,0.02227527,0.0019985628,0.22195747,0.0020568194],"about_ca_topic_score_codex":0.00002485225,"about_ca_topic_score_gemma":0.00011078368,"teacher_disagreement_score":0.25826624,"about_ca_system_score_codex":0.000064061685,"about_ca_system_score_gemma":0.0011116521,"threshold_uncertainty_score":0.99878246},"labels":[],"label_agreement":null},{"id":"W4281861761","doi":"10.1200/jco.2022.40.16_suppl.e20575","title":"Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Radiation therapy; Radiology; Cancer staging; Computed tomography; Cancer; Adjuvant therapy; T-stage; Internal medicine; Oncology","score_opus":0.04091642380794118,"score_gpt":0.4299737815159568,"score_spread":0.3890573577080156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281861761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76309264,0.00046919566,0.22714977,0.006084993,0.0015347527,0.0011719147,0.000005984677,0.0001073094,0.00038346043],"genre_scores_gemma":[0.8964147,0.000011186237,0.09700226,0.0056431144,0.0007342424,0.00006879437,0.000018835053,0.00004783941,0.000059048107],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99674994,0.00037025518,0.0017550961,0.0003125851,0.00042785163,0.00038427938],"domain_scores_gemma":[0.99523664,0.001975039,0.0016828164,0.00015573479,0.0004570411,0.000492761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043961415,0.00017598222,0.0011004717,0.00036644124,0.00025060604,0.000024620358,0.0002622085,0.00012111476,0.00011879124],"category_scores_gemma":[0.0018415212,0.00015476998,0.0004040975,0.0004243235,0.00010284631,0.000040709823,0.00010457315,0.0018154146,0.0000011164581],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037749847,0.0020351035,0.4483399,0.00038233865,0.0003555452,0.0003096277,0.0004566177,0.3864461,0.008736168,0.000045153716,0.0037435263,0.14537494],"study_design_scores_gemma":[0.0076616644,0.002447071,0.05164242,0.00009332318,0.0005237401,0.000053372278,0.000184406,0.9066194,0.00013398136,0.000012516698,0.030472802,0.0001552866],"about_ca_topic_score_codex":0.000038185473,"about_ca_topic_score_gemma":0.000004086872,"teacher_disagreement_score":0.5201733,"about_ca_system_score_codex":0.0003211111,"about_ca_system_score_gemma":0.0016545296,"threshold_uncertainty_score":0.78871745},"labels":[],"label_agreement":null},{"id":"W4281866980","doi":"10.1200/jco.2022.40.16_suppl.6530","title":"Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"Conquer Cancer Foundation","keywords":"Medicine; Clinical trial; Ethnic group; Family medicine; Internal medicine","score_opus":0.9022345657414026,"score_gpt":0.7702291642372151,"score_spread":0.1320054015041875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281866980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97398746,0.0003025363,0.0015556351,0.019370597,0.002752046,0.0011403096,0.0007052397,0.000009136079,0.00017705653],"genre_scores_gemma":[0.8974848,0.0009771213,0.09094436,0.0063272845,0.0035242348,0.00005491613,0.00019962147,0.00004730131,0.00044037073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9774772,0.0067393365,0.012925423,0.00085881114,0.0016683856,0.00033086204],"domain_scores_gemma":[0.3721689,0.576917,0.027782233,0.0046290783,0.01488815,0.00361467],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18755654,0.00015387015,0.0032893235,0.00013179972,0.000149782,0.000024796946,0.00079374644,0.00062532915,0.0006109593],"category_scores_gemma":[0.63798326,0.00012385026,0.00046685318,0.0002694806,0.0006253758,0.00023609509,0.0012322933,0.0035407883,0.0000012234549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017906275,0.0032639252,0.82275826,0.000070632894,0.00064850505,0.00013777743,0.00010181471,0.000018865567,0.00006116828,0.000058330777,0.02112317,0.13385125],"study_design_scores_gemma":[0.017739955,0.026913496,0.71585244,0.00020241507,0.0009019102,0.000040550505,0.00068323914,0.0012047868,0.000032369353,0.0025577797,0.23369953,0.00017155339],"about_ca_topic_score_codex":0.00030025013,"about_ca_topic_score_gemma":0.0009771417,"teacher_disagreement_score":0.6053083,"about_ca_system_score_codex":0.00014998019,"about_ca_system_score_gemma":0.008547824,"threshold_uncertainty_score":0.9987581},"labels":[],"label_agreement":null},{"id":"W4281868030","doi":"10.1200/jco.2022.40.16_suppl.9067","title":"Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Durvalumab; Nivolumab; Oncology; Chemotherapy; Lung cancer; Population; Bone metastasis; Gastroenterology; Metastasis; Cancer; Immunotherapy","score_opus":0.06106345008876598,"score_gpt":0.44348192977934575,"score_spread":0.3824184796905798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281868030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908288,0.0005954132,0.000010458386,0.0051401304,0.00074477063,0.0025486564,0.000037647314,0.0000047503113,0.00008935232],"genre_scores_gemma":[0.99692917,0.0014850918,0.00030949689,0.00055261864,0.0002840147,0.00012993724,0.0000060714265,0.00002692804,0.000276701],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98826545,0.0057826797,0.0046713944,0.00024205682,0.00077862677,0.00025981254],"domain_scores_gemma":[0.98470783,0.010243916,0.004489899,0.00036558797,0.00009769055,0.00009509081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023719164,0.0002949665,0.0057030297,0.0003697976,0.00006440323,0.0000049221035,0.00019376542,0.00018641012,0.000391008],"category_scores_gemma":[0.0019374773,0.00012787407,0.0014560833,0.00040036073,0.0005185127,0.00005496128,0.000042449283,0.0010663114,4.0036443e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8788184,0.018420568,0.0030176449,0.000036805886,0.0022536237,0.00039471406,0.0010217484,0.000018347338,0.001650112,0.0000063550287,0.000050710816,0.094311],"study_design_scores_gemma":[0.67791885,0.3119946,0.0022990855,0.00010092527,0.0008085836,0.00007996931,0.00049027026,0.00002593792,0.0044006445,0.0000075663565,0.0017888552,0.00008470119],"about_ca_topic_score_codex":0.0009317266,"about_ca_topic_score_gemma":0.00026060053,"teacher_disagreement_score":0.29357404,"about_ca_system_score_codex":0.00045462867,"about_ca_system_score_gemma":0.001198725,"threshold_uncertainty_score":0.82206357},"labels":[],"label_agreement":null},{"id":"W4281874725","doi":"10.1200/jco.2022.40.16_suppl.tps8071","title":"TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; CD47; Multiple myeloma; In vivo; Neutropenia; Pharmacodynamics; Pharmacology; Blockade; Bone marrow; Bortezomib; Phagocytosis; Cancer research; Oncology; Internal medicine; Immunology; Pharmacokinetics; Receptor; Chemotherapy; Biology","score_opus":0.13319477364459895,"score_gpt":0.4655549709589065,"score_spread":0.33236019731430755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281874725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972829,0.0002387028,0.00005651826,0.000781678,0.00041120246,0.0010650002,0.00001844419,0.000009059338,0.0001364548],"genre_scores_gemma":[0.9957013,0.00017111014,0.0036801053,0.00018639516,0.00013533451,0.000041426978,0.00003260583,0.000019364334,0.000032368913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953866,0.00085466914,0.0022455934,0.00030022764,0.0008563684,0.0003565258],"domain_scores_gemma":[0.9950117,0.002298571,0.0017804683,0.0002121903,0.0003227826,0.0003742879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025489137,0.00018685729,0.0016188121,0.000332093,0.00012112375,0.000006768724,0.00014769792,0.00019963978,0.00011325021],"category_scores_gemma":[0.0045418614,0.00012824763,0.00022080618,0.00032442316,0.00019697825,0.00018170539,0.00019467415,0.000934219,0.000001816554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.373129,0.015173314,0.46205267,0.00006094352,0.00022435538,0.00079867407,0.00019853737,0.00005506885,0.0006167235,0.000016146509,0.000120773955,0.14755379],"study_design_scores_gemma":[0.4077615,0.083269045,0.5058681,0.00014546466,0.00013411345,0.000105238025,0.00027338945,0.00059136376,0.00016263813,0.000090419584,0.0014874882,0.000111256246],"about_ca_topic_score_codex":0.00002915356,"about_ca_topic_score_gemma":0.000044758086,"teacher_disagreement_score":0.14744253,"about_ca_system_score_codex":0.00033071605,"about_ca_system_score_gemma":0.0009424575,"threshold_uncertainty_score":0.54373604},"labels":[],"label_agreement":null},{"id":"W4281877857","doi":"10.1200/jco.2022.40.16_suppl.563","title":"Associations of a breast cancer polygenic risk score with tumor characteristics and survival.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Confidence interval; Pathological; Cancer; Logistic regression","score_opus":0.05274540292261171,"score_gpt":0.39872135359530586,"score_spread":0.34597595067269415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281877857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964854,0.0005229515,0.00013455415,0.0012902411,0.0007957244,0.00007142985,0.00055495737,0.0000014826354,0.00014324443],"genre_scores_gemma":[0.99716777,0.00074128277,0.0008589026,0.00047678503,0.00063620904,0.000009900051,0.000013223902,0.000014023173,0.000081895036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809265,0.00045382284,0.0009708672,0.00014517171,0.0002162924,0.00012120467],"domain_scores_gemma":[0.99691314,0.0002603245,0.002208604,0.0001358253,0.00038442813,0.000097679826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016225908,0.00008050145,0.00051657716,0.000047322177,0.00008822376,0.0000048491406,0.00016958754,0.000095827505,0.00010497606],"category_scores_gemma":[0.00062672637,0.00006593099,0.00014053904,0.00010709705,0.00016549615,0.000004324758,0.00012049014,0.00044807707,3.267812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012578146,0.00043633633,0.96530706,0.000007605715,0.000605923,0.000021638663,0.000066886954,0.0002449638,0.0029934135,0.000033463646,0.002177591,0.026847286],"study_design_scores_gemma":[0.0018170458,0.0028428414,0.979407,0.000007682429,0.00022556298,0.00017199972,0.0001409276,0.000031139745,0.00018729565,0.000058397873,0.015024884,0.00008523123],"about_ca_topic_score_codex":0.000057248806,"about_ca_topic_score_gemma":0.00015003707,"teacher_disagreement_score":0.026762055,"about_ca_system_score_codex":0.00010771804,"about_ca_system_score_gemma":0.00223595,"threshold_uncertainty_score":0.39664793},"labels":[],"label_agreement":null},{"id":"W4281895324","doi":"10.1200/jco.2022.40.16_suppl.tps1123","title":"TWT-203: Phase 1b/2 dose-confirming study of CFI-402257 as a single agent in advanced solid tumors and in combination with fulvestrant in patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 and endocrine therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Fulvestrant; Medicine; Breast cancer; Cancer; Internal medicine; Oncology; Population; Pharmacology; Cancer research; Estrogen receptor","score_opus":0.018474655850418645,"score_gpt":0.384068730866191,"score_spread":0.36559407501577235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281895324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984331,0.00047194283,0.0000035393623,0.0002456135,0.00007958239,0.00074093224,0.000017049064,0.0000012242125,0.0000069997723],"genre_scores_gemma":[0.9991018,0.00040928833,0.00015386556,0.00019171987,0.000026123118,0.0000845995,0.000009843242,0.000015893958,0.0000068574045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807894,0.000338072,0.000896948,0.00028804416,0.00021724995,0.00018075631],"domain_scores_gemma":[0.9988514,0.000075336146,0.00072222576,0.00012235275,0.00010641818,0.00012226633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045504366,0.00014810942,0.0005464068,0.0001259765,0.000029551415,0.0000062397194,0.000093930845,0.000057782756,0.000009626864],"category_scores_gemma":[0.00007458315,0.00010680828,0.000041741383,0.00011285937,0.000080712896,0.000017887338,0.00007251715,0.00036264904,3.3317804e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08961961,0.026278641,0.66395617,0.000025128074,0.000057842808,0.00031567164,0.00031238384,0.0006095251,0.0060940804,0.0000010570103,0.0000017181304,0.2127282],"study_design_scores_gemma":[0.05874665,0.05596509,0.88345337,0.00020455488,0.00003139134,0.000031038806,0.00046931568,0.0000614157,0.0005878702,0.000011535746,0.00029679388,0.00014098134],"about_ca_topic_score_codex":0.000026441341,"about_ca_topic_score_gemma":0.00060887035,"teacher_disagreement_score":0.21949722,"about_ca_system_score_codex":0.00007482132,"about_ca_system_score_gemma":0.0003148619,"threshold_uncertainty_score":0.43555152},"labels":[],"label_agreement":null},{"id":"W4281912306","doi":"10.1200/jco.2022.40.16_suppl.7005","title":"Overall survival by <i>IDH2</i> mutant allele (R140 or R172) in patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH2; Medicine; Internal medicine; Myeloid leukemia; Clinical endpoint; Refractory (planetary science); Gastroenterology; Oncology; Randomized controlled trial; IDH1; Mutant; Gene; Biology; Genetics","score_opus":0.07142988887852038,"score_gpt":0.4136009994397066,"score_spread":0.3421711105611862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281912306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236315,0.00014616652,0.000015696423,0.003359906,0.0005822181,0.0024520024,0.0003500832,0.000029059323,0.0007017062],"genre_scores_gemma":[0.9862578,0.00080126146,0.00052642747,0.004075127,0.0005120778,0.0001763444,0.00047274225,0.00013023785,0.0070480085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9878378,0.0038089477,0.004033308,0.0007937408,0.0025622873,0.00096389686],"domain_scores_gemma":[0.98953694,0.005413976,0.002880473,0.00073097006,0.00083206396,0.0006055805],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006378476,0.000554881,0.0029058962,0.00048317644,0.00025073704,0.00004946578,0.0009377822,0.00059992285,0.0021933895],"category_scores_gemma":[0.0025220476,0.00027493434,0.00046886044,0.0011240455,0.0005537006,0.00034392727,0.00026134067,0.0056115417,0.00001366313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9055117,0.009694005,0.02654802,0.00007778083,0.0013417038,0.032131664,0.0010988392,0.00012754777,0.0006608101,0.000016338538,0.019029906,0.003761722],"study_design_scores_gemma":[0.60647255,0.16773976,0.023193054,0.00023556588,0.0008928065,0.0007830341,0.0031788868,0.00015059275,0.00019992312,0.000011396171,0.1966262,0.0005162131],"about_ca_topic_score_codex":0.0003004601,"about_ca_topic_score_gemma":0.001243352,"teacher_disagreement_score":0.2990391,"about_ca_system_score_codex":0.004192565,"about_ca_system_score_gemma":0.0144743025,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W4281929063","doi":"10.1200/jco.2022.40.16_suppl.6501","title":"The PACES Study: A controlled before and after pragmatic trial of a cancer clinic–based intervention to increase early referral to specialist palliative care.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Referral; Palliative care; Intervention (counseling); Population; Cancer; Family medicine; Clinical trial; Clinical nurse specialist; Colorectal cancer; Nursing; Internal medicine","score_opus":0.22630740714431294,"score_gpt":0.5732168280930703,"score_spread":0.3469094209487573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281929063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98979145,0.00094137545,0.000027458276,0.006070477,0.001248891,0.0016084912,0.000033984037,0.00000333641,0.00027455238],"genre_scores_gemma":[0.9967828,0.0001615926,0.00058443344,0.0011161698,0.0009015356,0.00020931239,0.0000019426002,0.00001215829,0.00023008838],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99450177,0.0016919153,0.00289453,0.000178267,0.0005649128,0.00016862318],"domain_scores_gemma":[0.992456,0.004128521,0.0022130134,0.00018061673,0.0007386701,0.00028314802],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005137144,0.00013450706,0.0019724432,0.00014909019,0.000069540176,0.0000101928135,0.00017646723,0.000100916775,0.00018558715],"category_scores_gemma":[0.010652619,0.00008013544,0.00059460616,0.00019681455,0.00014721918,0.000041869695,0.00013157113,0.000604764,0.0000017021176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5589293,0.0024372174,0.39681256,0.000054960088,0.0009511076,0.00011590362,0.007099358,0.000011063466,0.000010388449,0.000013941993,0.00094471086,0.03261943],"study_design_scores_gemma":[0.2138161,0.14057057,0.5969549,0.0005226771,0.0013038138,0.0000021660123,0.014185525,0.000019497294,0.0000128617185,0.00010335612,0.032415334,0.00009321384],"about_ca_topic_score_codex":0.00056481746,"about_ca_topic_score_gemma":0.00539882,"teacher_disagreement_score":0.34511325,"about_ca_system_score_codex":0.00021028543,"about_ca_system_score_gemma":0.0008921451,"threshold_uncertainty_score":0.9976811},"labels":[],"label_agreement":null},{"id":"W4281935189","doi":"10.1200/jco.2022.40.16_suppl.8044","title":"Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Dexamethasone; Population; Nausea; Clinical endpoint; Multiple myeloma; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.05480611066813929,"score_gpt":0.39481319436516243,"score_spread":0.34000708369702315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281935189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563724,0.00025086888,0.00005151655,0.0019524988,0.000093948816,0.0018354511,0.00016002872,0.000007577795,0.000010865561],"genre_scores_gemma":[0.9974216,0.00007325534,0.0021240686,0.00017911757,0.000019015188,0.0000667029,0.000028608629,0.000031166917,0.00005644664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99154115,0.0035225519,0.0027381333,0.00052342785,0.0012708587,0.0004038591],"domain_scores_gemma":[0.98327667,0.012960281,0.0022203191,0.00045532477,0.0005728264,0.0005145839],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00528479,0.00033370152,0.0027054923,0.0009780955,0.00016588673,0.00001957852,0.00019618333,0.0001669853,0.000064198146],"category_scores_gemma":[0.008399831,0.00020162005,0.0002500113,0.0013575909,0.00046920005,0.00018338575,0.0001687218,0.00081055536,5.077954e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4440934,0.0036782825,0.5397373,0.000019269388,0.0029348896,0.0009188411,0.0010905531,0.0002604185,0.00091424224,3.173352e-7,0.000038560476,0.0063139386],"study_design_scores_gemma":[0.16615923,0.04812436,0.7806393,0.000090239446,0.0025429898,0.00009251839,0.0010112288,0.00070243335,0.00035007676,0.00000242433,0.00013455561,0.00015063553],"about_ca_topic_score_codex":0.00044097655,"about_ca_topic_score_gemma":0.001751245,"teacher_disagreement_score":0.27793416,"about_ca_system_score_codex":0.00028995224,"about_ca_system_score_gemma":0.0010776336,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W4281936531","doi":"10.1200/jco.2022.40.16_suppl.105","title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Cancer; Phases of clinical research; Internal medicine; Oncology; Population; Response Evaluation Criteria in Solid Tumors; Antibody; Stage (stratigraphy); Clinical trial; Cancer research; Immunology","score_opus":0.15167348230874803,"score_gpt":0.5658398469977208,"score_spread":0.41416636468897283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281936531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804522,0.003503502,0.00006720963,0.010541207,0.0020510089,0.00051849673,0.000047124722,0.000014802387,0.0028044756],"genre_scores_gemma":[0.98361075,0.010370845,0.002421713,0.0016201625,0.0012352894,0.00000953883,0.000009084844,0.00004684232,0.0006757839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377006,0.0010253799,0.003073339,0.00039813633,0.001189983,0.00054308784],"domain_scores_gemma":[0.9927945,0.0036690226,0.0018742228,0.00043087723,0.0006120173,0.0006193421],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007576654,0.00020004499,0.0020660954,0.00014343207,0.00021617157,0.000011690359,0.00043728307,0.0003061757,0.0015279227],"category_scores_gemma":[0.003919177,0.00016143145,0.00044442306,0.0004930735,0.00065732736,0.000107638916,0.0005434818,0.002719431,0.000010050087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06468201,0.0024655997,0.07475891,0.00021147325,0.00053241267,0.002196904,0.0012126295,0.00041357154,0.008665208,0.00012276146,0.017108334,0.82763016],"study_design_scores_gemma":[0.023147615,0.026913924,0.2527313,0.0002668854,0.00012328605,0.0009348489,0.0011806892,0.00010522826,0.00018511165,0.00010590749,0.6941483,0.00015693097],"about_ca_topic_score_codex":0.00018158427,"about_ca_topic_score_gemma":0.0001265033,"teacher_disagreement_score":0.8274733,"about_ca_system_score_codex":0.0011542992,"about_ca_system_score_gemma":0.0046953782,"threshold_uncertainty_score":0.99958134},"labels":[],"label_agreement":null},{"id":"W4281940408","doi":"10.1200/jco.2022.40.16_suppl.3152","title":"Do early phase trials predict clinical efficacy in subsequent phase III biomarker-enriched randomized trials?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Biomarker; Internal medicine; Clinical trial; Clinical endpoint; Population; Surrogate endpoint; Phases of clinical research; Oncology","score_opus":0.8366637136091927,"score_gpt":0.6655915803232001,"score_spread":0.17107213328599258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281940408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92869765,0.0054211062,0.003187136,0.04467123,0.013027396,0.0031612618,0.00029116997,0.000028342414,0.0015147313],"genre_scores_gemma":[0.98064053,0.0022018827,0.0022297902,0.0103302235,0.004079905,0.00019867157,0.000033176744,0.000054957596,0.00023085314],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.7336783,0.12494829,0.1381332,0.0013771231,0.00076938164,0.0010936948],"domain_scores_gemma":[0.5077593,0.37937418,0.10951424,0.0012160364,0.00051082246,0.0016254949],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.7732013,0.00038776247,0.0238005,0.0011511395,0.00022263426,0.00009500096,0.0010556685,0.00080264936,0.004031824],"category_scores_gemma":[0.56348854,0.0003622253,0.004813984,0.00055612903,0.0005018408,0.0005163618,0.00022967049,0.002666751,0.00024021103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67234594,0.045469508,0.022352073,0.00012773336,0.005834181,0.00046790848,0.0021893047,0.0004843735,0.000015072352,0.02441551,0.12774165,0.09855678],"study_design_scores_gemma":[0.8081696,0.009611966,0.010812291,0.00005734919,0.00038197628,0.000058988127,0.000547571,0.0032946893,7.5641555e-7,0.014210657,0.15245719,0.00039695142],"about_ca_topic_score_codex":0.00026391135,"about_ca_topic_score_gemma":0.00003263905,"teacher_disagreement_score":0.25442588,"about_ca_system_score_codex":0.0012209555,"about_ca_system_score_gemma":0.0034180658,"threshold_uncertainty_score":0.999883},"labels":[],"label_agreement":null},{"id":"W4281944259","doi":"10.1200/jco.2022.40.16_suppl.e22509","title":"Chronic sinusitis in association to increased risk of site-specific cancer: A systematic review and meta-analysis.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Relative risk; Meta-analysis; Cancer; Colorectal cancer; Gastroenterology; Cohort study; Lung cancer; Odds ratio; Confidence interval","score_opus":0.30692823295745825,"score_gpt":0.5339448931014643,"score_spread":0.22701666014400607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281944259","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006823668,0.9957836,0.0000021482278,0.0020128763,0.0002207913,0.0015328772,0.00013953615,0.0000033159902,0.0002365731],"genre_scores_gemma":[0.00006925227,0.99772906,0.00014019496,0.0012540538,0.00032204378,0.00021447071,0.000009489596,0.000021047872,0.00024036606],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9859873,0.0050902986,0.0077111325,0.00032251593,0.0006538869,0.00023487848],"domain_scores_gemma":[0.9769165,0.010609247,0.011475188,0.00033017213,0.00038320286,0.0002856978],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016711203,0.00030070657,0.037040852,0.00053427246,0.00003833272,0.0000055072387,0.00020030004,0.00041235218,0.0011288088],"category_scores_gemma":[0.0124348495,0.00018195044,0.0053870403,0.0011797356,0.000051176867,0.000031400436,0.00012212674,0.0017549797,0.0000072029056],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010718628,0.0004779145,0.00089912897,0.6190888,0.28981116,0.00031289674,0.00007501291,0.0000028385655,5.447428e-8,0.000005331218,0.0051281513,0.08409149],"study_design_scores_gemma":[0.00056730106,0.0019237295,0.0002832305,0.019189484,0.5416835,0.000037031405,0.0000064750384,5.290755e-7,1.17993135e-8,0.0000021397748,0.43622664,0.00007993523],"about_ca_topic_score_codex":0.00025002594,"about_ca_topic_score_gemma":0.0011008949,"teacher_disagreement_score":0.59989935,"about_ca_system_score_codex":0.0022387593,"about_ca_system_score_gemma":0.003113503,"threshold_uncertainty_score":0.9997843},"labels":[],"label_agreement":null},{"id":"W4281945717","doi":"10.1200/jco.2022.40.16_suppl.tps8069","title":"CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pomalidomide; Medicine; Daratumumab; Tolerability; Multiple myeloma; Lenalidomide; Carfilzomib; Internal medicine; Pharmacodynamics; Bortezomib; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Phases of clinical research; Clinical trial; Adverse effect","score_opus":0.16850953554944664,"score_gpt":0.5046144150094214,"score_spread":0.33610487945997475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281945717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656504,0.00009754175,0.00001820165,0.001360018,0.00048647771,0.0013282015,0.000029618512,0.0000045030647,0.00011040309],"genre_scores_gemma":[0.99790233,0.000106973246,0.001285049,0.00028014262,0.00026093906,0.00002925862,0.000009235481,0.000021721944,0.00010431717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994516,0.0022033348,0.0017803073,0.00025200247,0.000923197,0.00032515536],"domain_scores_gemma":[0.98995763,0.0071055503,0.0019779971,0.00023616789,0.00041638233,0.00030628877],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054449015,0.00016577981,0.0012068208,0.0001785363,0.00013444186,0.0000072895996,0.00017405275,0.00011825418,0.00020704584],"category_scores_gemma":[0.009000472,0.000090812435,0.00019650221,0.0001911436,0.0002520912,0.00011601314,0.00018985108,0.0016284273,8.7098306e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.602926,0.0070713954,0.17717513,0.000018168934,0.00040514092,0.00038353406,0.0002699851,0.000024592697,0.00025811716,6.502056e-7,0.000082578365,0.21138468],"study_design_scores_gemma":[0.4509566,0.17638488,0.3670392,0.000073287716,0.0003018399,0.00003483235,0.00029972984,0.002488247,0.00006729016,0.0000035283674,0.002277843,0.00007269457],"about_ca_topic_score_codex":0.00007224733,"about_ca_topic_score_gemma":0.00008472172,"teacher_disagreement_score":0.21131198,"about_ca_system_score_codex":0.00036303516,"about_ca_system_score_gemma":0.0014853858,"threshold_uncertainty_score":0.99934715},"labels":[],"label_agreement":null},{"id":"W4281945968","doi":"10.1200/jco.2022.40.16_suppl.1522","title":"Imaging and physician visits at cancer diagnosis: COVID-19 pandemic impact on cancer care.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Queen's University; Institute of Health Services and Policy Research; University of Toronto","funders":"","keywords":"Medicine; Pandemic; Cancer; Medical diagnosis; Coronavirus disease 2019 (COVID-19); Cohort; Emergency medicine; Internal medicine; Radiology; Disease","score_opus":0.25595197017104193,"score_gpt":0.6085596925311543,"score_spread":0.35260772236011234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281945968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90637165,0.014382843,0.000007334955,0.07700356,0.0016008175,0.00026617834,0.00007948979,0.000018627914,0.00026951308],"genre_scores_gemma":[0.8596373,0.009982759,0.000026807182,0.12813851,0.0020407466,0.000059499027,0.0000034174907,0.00002346282,0.000087511275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967627,0.0006361425,0.0013723591,0.00028418383,0.0005399064,0.00040473187],"domain_scores_gemma":[0.9929314,0.0039016844,0.001367509,0.00018698389,0.00024901613,0.0013633873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020796773,0.0001907538,0.0014086459,0.00019797633,0.000264125,0.0000100404795,0.00015466871,0.00015187412,0.0009713663],"category_scores_gemma":[0.0025307364,0.00013605428,0.00046092176,0.00019490915,0.00012583181,0.00008533832,0.00015909485,0.0016390579,0.0000046950945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00438526,0.00032485154,0.72910106,0.00009010829,0.000173192,0.0006174925,0.0007553555,0.00027478323,0.000043666958,0.0000063978005,0.027041141,0.23718667],"study_design_scores_gemma":[0.0060013253,0.006820479,0.6329773,0.00011073111,0.0003108194,0.00028907423,0.000490911,0.000059374208,0.0000082825545,0.00009082065,0.35273084,0.00011003382],"about_ca_topic_score_codex":0.0024195889,"about_ca_topic_score_gemma":0.0013828473,"teacher_disagreement_score":0.32568967,"about_ca_system_score_codex":0.0053420058,"about_ca_system_score_gemma":0.010409014,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4281946301","doi":"10.1200/jco.2022.40.16_suppl.8013","title":"Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Cohort; Oncology; Clinical endpoint; Gastroenterology; Chimeric antigen receptor; Surgery; Clinical trial; Immunotherapy; Cancer","score_opus":0.05040499462910015,"score_gpt":0.38968772971000076,"score_spread":0.3392827350809006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281946301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996123,0.00045565615,0.0000481366,0.001110081,0.0004930085,0.0009949266,0.00003311898,0.000010293063,0.0007317581],"genre_scores_gemma":[0.9963555,0.00035087005,0.0012619102,0.0008896662,0.00027054906,0.000017422615,0.000022211954,0.000053842716,0.0007780759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948708,0.0010481199,0.0023247502,0.00038509953,0.0009934363,0.00037783963],"domain_scores_gemma":[0.9961616,0.0013676595,0.0012414604,0.00038146327,0.0004628951,0.00038496178],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002977234,0.00022355873,0.0013939708,0.0004971242,0.000074087155,0.000013169073,0.00025059882,0.0003051022,0.0022121526],"category_scores_gemma":[0.0010341968,0.00016982008,0.00025189226,0.0005092343,0.00021691456,0.00012756517,0.0001801607,0.001697665,0.0000107713195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17891303,0.0074365586,0.7289701,0.00006769939,0.00027291372,0.0005840105,0.0009984561,0.000105581814,0.01981823,0.0000026129599,0.0013458984,0.061484925],"study_design_scores_gemma":[0.035026573,0.029401146,0.8056704,0.000102163445,0.000067773035,0.000046916033,0.000251682,0.00004647605,0.0003421525,0.000006211056,0.12889627,0.00014225677],"about_ca_topic_score_codex":0.00003990869,"about_ca_topic_score_gemma":0.00007806703,"teacher_disagreement_score":0.14388646,"about_ca_system_score_codex":0.00038026628,"about_ca_system_score_gemma":0.00077287504,"threshold_uncertainty_score":0.99869996},"labels":[],"label_agreement":null},{"id":"W4281947220","doi":"10.1200/jco.2022.40.16_suppl.7560","title":"Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"MorphoSys","keywords":"Medicine; Lenalidomide; Internal medicine; Hazard ratio; Rituximab; Diffuse large B-cell lymphoma; Bendamustine; Oncology; Clinical endpoint; Neutropenia; Cohort; Refractory (planetary science); Surgery; Lymphoma; Confidence interval; Clinical trial; Multiple myeloma; Toxicity","score_opus":0.08161183968352281,"score_gpt":0.3866761694353465,"score_spread":0.3050643297518237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281947220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979237,0.00033558937,0.0000026340506,0.00021317683,0.00047843036,0.0008599891,0.000030330086,0.000006278072,0.00014991288],"genre_scores_gemma":[0.9991998,0.00017751046,0.00012410434,0.00021636947,0.000104348794,0.00007669425,0.000046505273,0.000023420595,0.000031245097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99376136,0.0015722511,0.002831802,0.00040976025,0.0011404033,0.0002844518],"domain_scores_gemma":[0.99408334,0.0020320616,0.0027411869,0.00041791447,0.0005186614,0.00020681946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036950568,0.00022866929,0.0026837601,0.0006075985,0.00007540937,0.000008698933,0.00024585356,0.00019831685,0.00009912151],"category_scores_gemma":[0.0007100617,0.0001637379,0.00040574002,0.0009313567,0.0000856143,0.00022466324,0.0000980139,0.00057926594,0.0000014822226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035770547,0.13555375,0.82281756,0.000014091993,0.0027408937,0.0007193581,0.0015444394,0.00019880034,0.0000026799905,0.000024362364,0.00006811395,0.00054541073],"study_design_scores_gemma":[0.21455133,0.04214853,0.7367379,0.000037388632,0.0017665323,0.000008984602,0.0044454164,0.000077453595,0.0000017788632,0.000007942561,0.000112455244,0.00010429132],"about_ca_topic_score_codex":0.0004519485,"about_ca_topic_score_gemma":0.0019511407,"teacher_disagreement_score":0.1787808,"about_ca_system_score_codex":0.003279153,"about_ca_system_score_gemma":0.0013131333,"threshold_uncertainty_score":0.8574871},"labels":[],"label_agreement":null},{"id":"W4281951112","doi":"10.1200/jco.2022.40.16_suppl.e18737","title":"The longitudinal impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: Interim analysis from a retrospective chart review.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Cohort; Lung cancer; Retrospective cohort study; Cancer; Interim; Cohort study; Internal medicine; Medical diagnosis; Pediatrics; Pathology","score_opus":0.31488983377634217,"score_gpt":0.5989555511947566,"score_spread":0.28406571741841447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281951112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83511204,0.018804237,0.0000017246733,0.14501558,0.00026694327,0.00042646079,0.00031687017,0.0000017229628,0.00005443115],"genre_scores_gemma":[0.8516133,0.13896394,0.000005245242,0.009045227,0.00028524984,0.00003680016,0.0000057953284,0.000007567646,0.000036864065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964763,0.0009657787,0.0017082769,0.00019610442,0.00039467184,0.0002588882],"domain_scores_gemma":[0.98991627,0.0065973615,0.0020942003,0.00027806792,0.00024143282,0.0008726705],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029612451,0.00014219618,0.0017382912,0.00020991686,0.00019943052,0.000003461751,0.0001949928,0.00013697792,0.0011547979],"category_scores_gemma":[0.006038651,0.000068457135,0.0009786473,0.000415149,0.0002364845,0.000027557488,0.00007267848,0.0008633915,5.720835e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033386424,0.00038108462,0.96295124,0.00004664985,0.0033177217,0.000155376,0.0006882806,0.00001851351,0.0000067835017,0.000017039649,0.017448898,0.01162976],"study_design_scores_gemma":[0.0023792542,0.015499862,0.92183405,0.00023353775,0.0025921187,0.00006376549,0.00014625989,0.00007813624,0.0000052824175,0.000044627337,0.057072975,0.000050106744],"about_ca_topic_score_codex":0.1262527,"about_ca_topic_score_gemma":0.17055488,"teacher_disagreement_score":0.13597035,"about_ca_system_score_codex":0.00668582,"about_ca_system_score_gemma":0.0074595185,"threshold_uncertainty_score":0.9997583},"labels":[],"label_agreement":null},{"id":"W4281951561","doi":"10.1200/jco.2022.40.16_suppl.e13621","title":"Addressing unmet needs of cancer care in a lower middle income country by establishing an electronic hospital based cancer registry.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer registry; Health care; Family medicine; Referral; Cancer; Internal medicine","score_opus":0.08150536354702721,"score_gpt":0.3816906009376848,"score_spread":0.3001852373906576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281951561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691156,0.02288149,0.00008337218,0.0019413305,0.0030118737,0.00015039892,0.00062470813,0.00000616328,0.002185039],"genre_scores_gemma":[0.9956724,0.0016817895,0.00021262892,0.0015586944,0.00064524385,0.000029817951,0.00001667145,0.000035055076,0.00014771594],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959065,0.00014760013,0.0030647013,0.0002696923,0.00011425568,0.00049725536],"domain_scores_gemma":[0.99392813,0.00043222096,0.004972474,0.00027545195,0.00017360336,0.0002180871],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031453639,0.00018352576,0.0016626287,0.0003703392,0.00009895197,0.00004255726,0.00064787065,0.00030612585,0.00095433206],"category_scores_gemma":[0.0009950298,0.00020430468,0.00032646456,0.00044903308,0.00017614216,0.0006546958,0.00010646234,0.0015319224,0.0000021604546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00218436,0.001511065,0.95242715,0.000095306714,0.00021575179,0.000057971545,0.0014424614,0.0071983566,0.000016502416,0.0038085077,0.005060661,0.02598191],"study_design_scores_gemma":[0.011292134,0.012695504,0.19721437,0.0002638933,0.00010020154,0.000012528167,0.002911874,0.0017564811,0.00004142348,0.003919861,0.769053,0.00073878106],"about_ca_topic_score_codex":0.003977473,"about_ca_topic_score_gemma":0.002391051,"teacher_disagreement_score":0.7639923,"about_ca_system_score_codex":0.0018875066,"about_ca_system_score_gemma":0.00306244,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W4281953617","doi":"10.1200/jco.2022.40.16_suppl.7538","title":"Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Tolerability; Gastroenterology; Rituximab; Refractory (planetary science); Toxicity; Progression-free survival; Oncology; Ibrutinib; Leukemia; Overall survival; Adverse effect; Lymphoma","score_opus":0.1575472935405038,"score_gpt":0.46104441983569244,"score_spread":0.30349712629518866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281953617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881307,0.0020113487,0.000005308086,0.0012406139,0.004628369,0.0005158363,0.00005406672,0.000023330771,0.003390454],"genre_scores_gemma":[0.9908279,0.001605281,0.0005908842,0.00054913986,0.0014344056,0.000019811516,0.000029675111,0.00006993071,0.004872955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9891681,0.0014521084,0.0058851363,0.00061028794,0.0020087562,0.00087563344],"domain_scores_gemma":[0.981927,0.012775232,0.0032775495,0.00079153175,0.0005092825,0.0007194522],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010246708,0.00031448907,0.0032318772,0.0005977985,0.000113045266,0.000009403796,0.0008278886,0.00076979224,0.0015469564],"category_scores_gemma":[0.025467524,0.000265312,0.00090610195,0.0009221803,0.00067258434,0.00013581966,0.00095647457,0.0035903659,0.00008292671],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7412454,0.0030974508,0.000845383,0.0004891012,0.0016656558,0.03858717,0.00134142,0.010993209,0.0008309819,0.00014156538,0.08878946,0.11197319],"study_design_scores_gemma":[0.6644254,0.06365177,0.006101202,0.00035238088,0.0006617998,0.003486056,0.0006904094,0.013498424,0.00018172171,0.00006350305,0.24654521,0.0003421322],"about_ca_topic_score_codex":0.0008884569,"about_ca_topic_score_gemma":0.0008375262,"teacher_disagreement_score":0.15775575,"about_ca_system_score_codex":0.21939978,"about_ca_system_score_gemma":0.21308236,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W4281971518","doi":"10.1200/jco.2022.40.16_suppl.tps3632","title":"NSAB C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Stage (stratigraphy); Minimal residual disease; Colorectal cancer; Cancer; Circulating tumor DNA; Primary tumor; Clinical trial; Clinical endpoint; Metastasis; Leukemia","score_opus":0.08639456714582959,"score_gpt":0.43741749873842756,"score_spread":0.35102293159259795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281971518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919766,0.00028222994,0.0005683591,0.0007208571,0.005490701,0.00069038465,0.000170809,0.0000064491574,0.0000935715],"genre_scores_gemma":[0.9923335,0.00005890377,0.0020464512,0.0020696486,0.0033261979,0.000056434266,0.000016585684,0.000036426278,0.000055892655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940673,0.0016491961,0.0027343165,0.00062450184,0.0005164051,0.00040828317],"domain_scores_gemma":[0.99527514,0.0015010359,0.0016290891,0.00030541242,0.000495968,0.0007933761],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0070950403,0.00023441495,0.0009960752,0.00013238042,0.00030501885,0.000041899268,0.0005366227,0.00016197556,0.00020754887],"category_scores_gemma":[0.012626557,0.00023173721,0.00043942418,0.00024958374,0.00010483838,0.000014505696,0.0008822159,0.0008866682,0.0000037209738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03206252,0.0068861195,0.72310895,0.00003992989,0.0011546755,0.0011059232,0.0010432905,0.02806235,0.04205884,0.000010509405,0.03809304,0.12637383],"study_design_scores_gemma":[0.012665005,0.1272467,0.6910362,0.00012905551,0.001219619,0.00040600807,0.0018469152,0.0014677617,0.005043117,0.00015006834,0.15761793,0.0011716106],"about_ca_topic_score_codex":0.00004428144,"about_ca_topic_score_gemma":0.00041727416,"teacher_disagreement_score":0.12520222,"about_ca_system_score_codex":0.00032206235,"about_ca_system_score_gemma":0.004129207,"threshold_uncertainty_score":0.9956905},"labels":[],"label_agreement":null},{"id":"W4281978442","doi":"10.1200/jco.2022.40.16_suppl.e22023","title":"Use and correlates of carotid ultrasound in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiovascular Health and Risk Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Stroke (engine); Heart failure; Myocardial infarction; Cancer; Internal medicine; Poisson regression; Head and neck cancer; Cardiology; Lung cancer; Radiation therapy; Disease; Pediatrics; Population","score_opus":0.07099268589072057,"score_gpt":0.41342553124746506,"score_spread":0.3424328453567445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281978442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871315,0.0066582044,0.0000022618158,0.0014719394,0.0023628382,0.00065469655,0.00009681661,0.0000038538615,0.000036257883],"genre_scores_gemma":[0.9890213,0.009910494,0.00006138421,0.00041180788,0.00052454567,0.000019926205,0.000006744922,0.000019418536,0.00002436278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941058,0.001571647,0.0031314902,0.00025333583,0.0007048432,0.00023285611],"domain_scores_gemma":[0.9887905,0.0076781106,0.0025776946,0.00036501273,0.00032962376,0.00025903576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067552123,0.00015305614,0.0022119991,0.00012434315,0.00007612338,0.0000046700598,0.00019377958,0.00018793879,0.00016455106],"category_scores_gemma":[0.006551762,0.000095072566,0.000624611,0.00032118303,0.00022722092,0.000070244896,0.00011496763,0.0017139567,2.1851136e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011212282,0.0026276142,0.9835573,0.000017327622,0.0012948171,0.00037678683,0.0025886332,0.0002745661,0.000025540101,0.0000017311908,0.0003689362,0.0077455174],"study_design_scores_gemma":[0.0063554454,0.0036684733,0.98194194,0.00009550307,0.0008601321,0.00066876767,0.0027483113,0.000003874911,0.000019511686,0.000029847732,0.0035276406,0.000080564656],"about_ca_topic_score_codex":0.054839116,"about_ca_topic_score_gemma":0.027611999,"teacher_disagreement_score":0.027227117,"about_ca_system_score_codex":0.00016152776,"about_ca_system_score_gemma":0.0033467829,"threshold_uncertainty_score":0.99013156},"labels":[],"label_agreement":null},{"id":"W4281981040","doi":"10.1200/jco.2022.40.16_suppl.9542","title":"The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Adverse effect; Internal medicine; Oncology; Immune checkpoint; Blockade; Clinical endpoint; Proportional hazards model; Melanoma; Metastatic melanoma; Immunotherapy; Cancer; Clinical trial; Cancer research","score_opus":0.04547724419523528,"score_gpt":0.37675807960631336,"score_spread":0.33128083541107806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281981040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976799,0.0004969782,0.0000025143238,0.00078859925,0.00017545963,0.00065119384,0.000005858289,0.000004823647,0.00019468117],"genre_scores_gemma":[0.9993817,0.0002541404,0.00012385486,0.000039101713,0.000014752633,0.000014902218,0.0000149679045,0.000017765955,0.00013881212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995971,0.0007830663,0.0024634167,0.00014323667,0.0004402346,0.00019901062],"domain_scores_gemma":[0.9953185,0.0012857538,0.0028341794,0.00016773875,0.00028647282,0.0001074073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002967581,0.0001515564,0.0010097108,0.00021285558,0.00008781668,0.0000027579524,0.0001261496,0.00006555492,0.00008399564],"category_scores_gemma":[0.00047124628,0.00007742273,0.00033604118,0.00047688533,0.00025705932,0.00007341358,0.00004674936,0.00066830294,4.0103768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060931124,0.0047717765,0.9160466,0.000021318401,0.001881744,0.00014598125,0.00022551157,0.0000991993,0.0007280399,0.0000052414284,0.000013654215,0.015129796],"study_design_scores_gemma":[0.03353511,0.05731311,0.9075719,0.00017267694,0.0005337829,0.00013727207,0.0002310307,0.00011209649,0.000098100645,0.00003793037,0.00017838187,0.000078615056],"about_ca_topic_score_codex":0.00041638818,"about_ca_topic_score_gemma":0.00018325225,"teacher_disagreement_score":0.052541334,"about_ca_system_score_codex":0.00056587736,"about_ca_system_score_gemma":0.00083240675,"threshold_uncertainty_score":0.31572074},"labels":[],"label_agreement":null},{"id":"W4281981306","doi":"10.1200/jco.2022.40.16_suppl.2010","title":"Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Trk receptor; Medicine; Internal medicine; Tropomyosin receptor kinase B; Oncology; Receptor tyrosine kinase; Neuroblastoma; Neurotrophin; Receptor; Neurotrophic factors; Cell culture; Biology","score_opus":0.014079923002584437,"score_gpt":0.30801110948752203,"score_spread":0.2939311864849376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281981306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746865,0.00081780145,0.0000045783418,0.0005394924,0.00031906442,0.000732633,0.000043416974,0.0000036929994,0.00007065725],"genre_scores_gemma":[0.99868053,0.00067261327,0.00025900445,0.00017577819,0.00016480187,0.000016795142,0.000012595084,0.000013644691,0.0000042449046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965004,0.00059774553,0.0020618422,0.00020135066,0.00043670041,0.00020200072],"domain_scores_gemma":[0.9961723,0.0010785093,0.0020260953,0.00012368074,0.00032956767,0.00026983937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00108251,0.00014060852,0.0017185159,0.00019922211,0.00004218243,0.0000030568222,0.00007184071,0.00012559739,0.00003582128],"category_scores_gemma":[0.00048480427,0.00009462896,0.00017096564,0.00018149221,0.000118130876,0.000051235587,0.0000689408,0.0004992654,2.2803833e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018024264,0.00515751,0.9517547,0.00023935709,0.00022622786,0.0005776977,0.0000836167,0.000014025382,0.00006392645,0.000014715279,0.00009591945,0.023748055],"study_design_scores_gemma":[0.037795767,0.020044118,0.94081837,0.00021860705,0.00071121764,0.00012323658,0.000101738995,0.000019473637,0.000025571797,0.0000018286012,0.000070832815,0.00006925278],"about_ca_topic_score_codex":0.000059950617,"about_ca_topic_score_gemma":0.00004001933,"teacher_disagreement_score":0.023678802,"about_ca_system_score_codex":0.00027750313,"about_ca_system_score_gemma":0.00053703174,"threshold_uncertainty_score":0.3858857},"labels":[],"label_agreement":null},{"id":"W4281984015","doi":"10.1200/jco.2022.40.16_suppl.7526","title":"Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"CD20; Medicine; PAX5; Immunohistochemistry; Lymphoma; clone (Java method); B cell; Antibody; Cancer research; Pathology; Immunology; Biology; Gene","score_opus":0.02265403805456371,"score_gpt":0.3389661542117521,"score_spread":0.31631211615718835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281984015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976437,0.00005237652,0.000059326503,0.00070814864,0.0004693434,0.00040587812,0.000020727408,0.000002999263,0.0006375192],"genre_scores_gemma":[0.9975438,0.00011865502,0.0013318247,0.0006398346,0.00010330386,0.00002316463,0.000017770431,0.000018836216,0.0002027992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965711,0.0003764163,0.0020229605,0.00020916692,0.00065139495,0.00016895437],"domain_scores_gemma":[0.99615073,0.00056603574,0.0024785816,0.00023640292,0.00035697804,0.00021129116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011258974,0.0001352546,0.0012504664,0.00021342804,0.00003337562,0.0000023577718,0.00016015365,0.00016475368,0.00014436664],"category_scores_gemma":[0.00041414145,0.00009650179,0.00020601763,0.00024873824,0.00005992922,0.000088634464,0.00009975475,0.00031421334,0.0000033494275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06760066,0.037497297,0.85252565,0.00015936448,0.0002746614,0.0010688478,0.0011610751,0.00006225901,0.02237584,0.0001786315,0.0009116824,0.016184054],"study_design_scores_gemma":[0.03599525,0.042078868,0.8958303,0.00036639092,0.00017569467,0.000023041024,0.00013500603,0.000008870971,0.018652102,0.00012217321,0.0065077133,0.00010459341],"about_ca_topic_score_codex":0.000018241808,"about_ca_topic_score_gemma":0.000013391976,"teacher_disagreement_score":0.043304678,"about_ca_system_score_codex":0.0005248193,"about_ca_system_score_gemma":0.0012727987,"threshold_uncertainty_score":0.39352286},"labels":[],"label_agreement":null},{"id":"W4281986919","doi":"10.1200/jco.2022.40.16_suppl.7549","title":"Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Progressive disease; Progression-free survival; Bruton's tyrosine kinase; Phases of clinical research; Tolerability; Nausea; Ibrutinib; Oncology; Clinical trial; Surgery; Adverse effect; Chronic lymphocytic leukemia; Chemotherapy; Leukemia; Tyrosine kinase","score_opus":0.1423006420353606,"score_gpt":0.48529417237053707,"score_spread":0.34299353033517643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281986919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318445,0.00019206629,0.000018134318,0.0018974231,0.0012008013,0.0014146394,0.000052754538,0.000006777456,0.0020329452],"genre_scores_gemma":[0.9947406,0.00016204656,0.002580212,0.0010737792,0.00041466815,0.00003334821,0.000030542167,0.000040796727,0.00092402],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905964,0.0018510484,0.0049555474,0.0004379166,0.0016303315,0.0005287663],"domain_scores_gemma":[0.9894992,0.0047360673,0.0038326476,0.00056664663,0.0007826117,0.0005828168],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010480465,0.00022787788,0.0024266068,0.00040543868,0.000079096106,0.000014222211,0.0008819035,0.00032929177,0.00035541292],"category_scores_gemma":[0.0093459925,0.00016617743,0.00025593364,0.0005651561,0.00043700062,0.00023606744,0.0007084762,0.0017978478,0.000011543762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.79744947,0.0763676,0.00411243,0.00004981658,0.00038399143,0.0023301595,0.00018570409,0.000017626087,0.000043471733,0.000018755489,0.007829781,0.11121118],"study_design_scores_gemma":[0.76031274,0.1511667,0.013033982,0.00016469012,0.00020597813,0.00016889,0.00016977964,0.0006962142,0.000024419525,0.000016130405,0.07391723,0.00012325271],"about_ca_topic_score_codex":0.0003124359,"about_ca_topic_score_gemma":0.000049016875,"teacher_disagreement_score":0.111087926,"about_ca_system_score_codex":0.008532936,"about_ca_system_score_gemma":0.030652381,"threshold_uncertainty_score":0.9989987},"labels":[],"label_agreement":null},{"id":"W4281991044","doi":"10.1200/jco.2022.40.16_suppl.4057","title":"Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Mount Sinai Hospital; University of Toronto; University Health Network; Toronto General Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Oncology; Proportional hazards model; Esophageal cancer; Performance status; Overall survival","score_opus":0.11568098612232625,"score_gpt":0.4807416017851996,"score_spread":0.36506061566287334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281991044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964173,0.0006192558,0.000033460816,0.0016110973,0.00077862636,0.00036755326,0.000004041923,0.0000041476146,0.00016452106],"genre_scores_gemma":[0.9967256,0.00026117873,0.002074117,0.0006048888,0.00023721,0.00001016836,0.0000025002525,0.000011061808,0.00007324558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621475,0.00039016182,0.0025111446,0.00018275736,0.0005047366,0.000196479],"domain_scores_gemma":[0.9956696,0.001700174,0.002101029,0.00011760368,0.00021476294,0.00019682587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020268268,0.000109558125,0.0016706738,0.00021186002,0.0000340937,0.0000034376808,0.00014506663,0.00008612167,0.000121570956],"category_scores_gemma":[0.0016104343,0.00007792521,0.00019223806,0.00031288102,0.00018501958,0.00006992933,0.00013791939,0.0010634052,4.899129e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008240152,0.0018701728,0.7856868,0.00003546633,0.00014202154,0.00012733217,0.000035771063,0.00018745019,4.1837262e-7,0.000012177899,0.0009129201,0.2027493],"study_design_scores_gemma":[0.02060684,0.037457913,0.93821234,0.00007037701,0.00033691502,0.000017910765,0.00013077602,0.00011856781,7.363213e-7,0.000028059594,0.002963581,0.00005600461],"about_ca_topic_score_codex":0.000017989641,"about_ca_topic_score_gemma":0.00005376158,"teacher_disagreement_score":0.2026933,"about_ca_system_score_codex":0.0001230056,"about_ca_system_score_gemma":0.00073906296,"threshold_uncertainty_score":0.46200255},"labels":[],"label_agreement":null},{"id":"W4281994266","doi":"10.1200/jco.2022.40.16_suppl.10565","title":"An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health","keywords":"Medicine; Hydroxychloroquine; Cancer; Case fatality rate; Intensive care unit; Internal medicine; Tocilizumab; Mortality rate; Epidemiology; Emergency medicine; Intensive care medicine; Coronavirus disease 2019 (COVID-19); Disease; Infectious disease (medical specialty)","score_opus":0.4723548984203999,"score_gpt":0.6097755829883531,"score_spread":0.1374206845679532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281994266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5681585,0.00079020933,0.000026371617,0.4292749,0.0014282145,0.00019689497,0.000087434906,0.000007112604,0.000030393814],"genre_scores_gemma":[0.5900808,0.0054814825,0.00011829255,0.4029128,0.0013505528,0.0000072299567,0.0000062729796,0.000010220199,0.0000323466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902187,0.005686129,0.0031304797,0.00033561606,0.00030032243,0.00032872963],"domain_scores_gemma":[0.9136349,0.0816682,0.0027421087,0.00046912246,0.0001872703,0.0012984254],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021426626,0.00017770947,0.002030298,0.00005424642,0.00033421585,0.000013497366,0.0003010834,0.0003184702,0.0009033985],"category_scores_gemma":[0.06510338,0.00008594503,0.00033601644,0.0000610679,0.0009038678,0.000060117625,0.00019126615,0.003030667,0.0000050105996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004471379,0.00049865874,0.8826607,0.0000138058,0.00029116563,0.00022130723,0.00016656452,0.000004813106,0.0000035786336,0.0009203728,0.037752777,0.07299486],"study_design_scores_gemma":[0.0029864972,0.0051699337,0.63598484,0.000013058584,0.00022035009,0.00011516316,0.00013220146,0.00008753565,1.4534602e-7,0.0024698556,0.35276183,0.000058591544],"about_ca_topic_score_codex":0.0010315388,"about_ca_topic_score_gemma":0.00034132932,"teacher_disagreement_score":0.31500906,"about_ca_system_score_codex":0.00022924173,"about_ca_system_score_gemma":0.003992428,"threshold_uncertainty_score":0.99926937},"labels":[],"label_agreement":null},{"id":"W4282000826","doi":"10.1200/jco.2022.40.16_suppl.9077","title":"Treatment patterns and outcomes in <i>ALK</i> or <i>ROS1</i> altered NSCLC: An ATOMIC Registry Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; ROS1; Medicine; Alectinib; Internal medicine; Discontinuation; ALK inhibitor; Oncology; Ceritinib; Anaplastic lymphoma kinase; Cabozantinib; Lung cancer; Cancer; Adenocarcinoma","score_opus":0.11683352318446201,"score_gpt":0.5224911124055275,"score_spread":0.4056575892210655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282000826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216306,0.00013973845,0.000008010114,0.0056850594,0.0008836119,0.00044162694,0.00002768257,0.0000075715343,0.00064366683],"genre_scores_gemma":[0.99576724,0.00028230448,0.000359555,0.002152234,0.00034335657,0.000041773485,0.0000076027686,0.000015325846,0.0010306389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746966,0.00046146355,0.001434655,0.00021389117,0.00024869014,0.00017164489],"domain_scores_gemma":[0.99791443,0.00072693767,0.0008000581,0.00021903115,0.00006683927,0.0002726737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000820497,0.00013230917,0.0011886937,0.00010600222,0.00007603998,0.00000982722,0.00010283483,0.000086933185,0.00017402056],"category_scores_gemma":[0.00024198381,0.000079386366,0.00019217028,0.0000879917,0.000056239776,0.00008619558,0.000058182122,0.00049823016,0.0000017538708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003643284,0.010394709,0.90180105,0.0000067170668,0.00053011684,0.0027325859,0.0008756241,0.000008751159,0.000007977883,0.000011980088,0.00034657383,0.07964062],"study_design_scores_gemma":[0.03099097,0.058341246,0.86851335,0.000015972599,0.0007250608,0.000916222,0.0033175524,0.00002593801,0.0000034251025,0.00006687796,0.037003145,0.0000802691],"about_ca_topic_score_codex":0.0003572209,"about_ca_topic_score_gemma":0.0010020161,"teacher_disagreement_score":0.07956035,"about_ca_system_score_codex":0.00053201296,"about_ca_system_score_gemma":0.0015014876,"threshold_uncertainty_score":0.3237282},"labels":[],"label_agreement":null},{"id":"W4282011352","doi":"10.1200/jco.2022.40.16_suppl.tps4178","title":"Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Octreotide; Lanreotide; Neuroendocrine tumors; Clinical trial; Randomization; Internal medicine; Randomized controlled trial; Dosing; Somatostatin; Acromegaly; Hormone","score_opus":0.19134980468205656,"score_gpt":0.5185307617796021,"score_spread":0.3271809570975456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282011352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901584,0.00028170834,0.000025395602,0.0074214493,0.0011767762,0.0007969374,0.0000055590544,0.0000036001402,0.0001301836],"genre_scores_gemma":[0.9954963,0.0002944471,0.003085241,0.00079826434,0.00025139598,0.0000065701697,0.0000013881211,0.00002032165,0.00004611892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98505193,0.009415326,0.0040458697,0.00026915365,0.00090165343,0.00031609635],"domain_scores_gemma":[0.9638688,0.03136628,0.003735127,0.00042429677,0.00039405422,0.00021146671],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009515416,0.00014946068,0.0020423052,0.0001335435,0.00008665656,0.00000578995,0.0004952945,0.00005677722,0.00006941898],"category_scores_gemma":[0.025781171,0.00007296107,0.00036438595,0.0003320949,0.0010089717,0.00007571204,0.00040947334,0.002645808,2.8483842e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19650622,0.0037912305,0.74714154,0.000031882784,0.00026462838,0.0014696752,0.000053526037,0.00021683706,0.000040250216,0.0000904133,0.0002889817,0.05010479],"study_design_scores_gemma":[0.083610795,0.061687414,0.84861195,0.00006482822,0.00026510944,0.001255453,0.00023012895,0.0000098242535,0.000039334645,0.00041474216,0.0037484772,0.00006197046],"about_ca_topic_score_codex":0.000040326104,"about_ca_topic_score_gemma":0.0000975404,"teacher_disagreement_score":0.11289543,"about_ca_system_score_codex":0.000089506815,"about_ca_system_score_gemma":0.0014266375,"threshold_uncertainty_score":0.9996551},"labels":[],"label_agreement":null},{"id":"W4282017622","doi":"10.1200/jco.2022.40.16_suppl.e16047","title":"Adjuvant immunotherapy in patients with resected esophageal and gastroesophageal junction cancer: Real-world evidence from Nova Scotia.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority; Nova Scotia Health Authority","funders":"","keywords":"Medicine; Population; Nivolumab; Esophageal cancer; Disease; Cancer; Surgery; Internal medicine; General surgery; Immunotherapy","score_opus":0.08574634608827679,"score_gpt":0.44836694415406486,"score_spread":0.36262059806578806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282017622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938996,0.007075415,0.000015812277,0.0021319147,0.0007367111,0.00046654095,0.000024430732,0.0000092379,0.00014998941],"genre_scores_gemma":[0.995456,0.0018961517,0.0011447865,0.0007249958,0.0005155155,0.000018781991,0.00001577048,0.000024237303,0.00020377457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604315,0.0008569135,0.0014929317,0.00032455506,0.0009315277,0.00035090419],"domain_scores_gemma":[0.99672586,0.0013224701,0.0010157713,0.00022414462,0.00031951652,0.00039226454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019338836,0.00017480686,0.0012382998,0.00038922092,0.00008145994,0.000013317483,0.00017399617,0.00009667185,0.0011866353],"category_scores_gemma":[0.00040168833,0.00012139293,0.00016806772,0.0005257958,0.00020011359,0.00019835347,0.00010471781,0.0016459692,0.000003910921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046808302,0.0015756822,0.85314304,0.000011643228,0.000325159,0.001723888,0.000088528075,0.000077628254,0.000019576362,0.000004803945,0.0007248463,0.095496885],"study_design_scores_gemma":[0.02315107,0.03827918,0.93751395,0.00016647668,0.00013650788,0.000030906394,0.000036553916,0.000041753006,0.00004113794,0.000046547615,0.00048631825,0.00006961806],"about_ca_topic_score_codex":0.0064291744,"about_ca_topic_score_gemma":0.006216918,"teacher_disagreement_score":0.09542727,"about_ca_system_score_codex":0.0010687849,"about_ca_system_score_gemma":0.0022131684,"threshold_uncertainty_score":0.9997264},"labels":[],"label_agreement":null},{"id":"W4282018957","doi":"10.1200/jco.2022.40.16_suppl.7548","title":"Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Phases of clinical research; Chemoimmunotherapy; Adverse effect; Refractory (planetary science); Oncology; Clinical trial; Cancer; Immunotherapy","score_opus":0.21426952189194884,"score_gpt":0.5364124915908745,"score_spread":0.32214296969892564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282018957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893605,0.0030534111,0.000017127579,0.0010848778,0.0011873699,0.0043591596,0.000027978114,0.000013120272,0.00089645525],"genre_scores_gemma":[0.9949788,0.0020597917,0.0015749102,0.00072626525,0.00017412758,0.00019547022,0.000011274685,0.00007540202,0.00020396727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9796891,0.00893813,0.007761789,0.00077717303,0.0021726745,0.0006611309],"domain_scores_gemma":[0.98029095,0.012828631,0.0045217914,0.0007159382,0.0010733623,0.0005693231],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.034645695,0.00042512058,0.0061393636,0.00056483684,0.00015723388,0.00004085244,0.00063494715,0.00043023512,0.0007424413],"category_scores_gemma":[0.008075761,0.00029694507,0.0006098222,0.0006283142,0.0005603367,0.00021324171,0.0005796015,0.0029720187,0.0000019858087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5303931,0.055115175,0.082753226,0.000028152634,0.0009005684,0.00266904,0.0020548077,0.000009408277,0.00019443876,0.000004837699,0.000102897706,0.3257743],"study_design_scores_gemma":[0.6753554,0.29911104,0.012730275,0.00009449552,0.00036975782,0.00009988177,0.0072587123,0.00018743021,0.0000387213,0.00003949356,0.004510767,0.00020404578],"about_ca_topic_score_codex":0.00013629755,"about_ca_topic_score_gemma":0.00046596452,"teacher_disagreement_score":0.32557026,"about_ca_system_score_codex":0.0008204192,"about_ca_system_score_gemma":0.0062172874,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W4282021311","doi":"10.1200/jco.2022.40.16_suppl.5508","title":"COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Cancer; Intensive care unit; Cervical cancer; Ovarian cancer; Mechanical ventilation; Odds ratio; Endometrial cancer; Logistic regression; Lung cancer","score_opus":0.2172379124766714,"score_gpt":0.5326260566856762,"score_spread":0.3153881442090048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282021311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7614963,0.0024215744,0.000030066703,0.23410179,0.0011279929,0.0006372872,0.00008091163,0.00001364739,0.00009041122],"genre_scores_gemma":[0.7925652,0.0015852025,0.00015145713,0.20494136,0.00053226826,0.00006696231,0.000013827623,0.000016670765,0.00012700363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947546,0.0013455327,0.0024238427,0.0003931214,0.0006910176,0.0003919012],"domain_scores_gemma":[0.9800211,0.01457494,0.0028863407,0.00035794315,0.00031764514,0.0018419923],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053263246,0.00019229644,0.0015019911,0.00014978182,0.0002549879,0.000010659041,0.000256505,0.00028297602,0.0017699278],"category_scores_gemma":[0.034951616,0.00011480559,0.00019468385,0.0003008511,0.00043467327,0.000085554646,0.0002215335,0.002105102,0.0000013611154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020347403,0.001158966,0.9063933,0.00008070602,0.000208592,0.0051168716,0.0006621026,0.00038935113,0.0000017810994,0.000009908738,0.04600961,0.019621393],"study_design_scores_gemma":[0.010708293,0.011819549,0.62641853,0.000028816872,0.00024574282,0.00038904187,0.00031152362,0.000023884473,3.2388093e-7,0.00020409843,0.34976485,0.000085342544],"about_ca_topic_score_codex":0.0115489345,"about_ca_topic_score_gemma":0.007785936,"teacher_disagreement_score":0.30375522,"about_ca_system_score_codex":0.0029656966,"about_ca_system_score_gemma":0.04274288,"threshold_uncertainty_score":0.9991426},"labels":[],"label_agreement":null},{"id":"W4282021936","doi":"10.1200/jco.2022.40.16_suppl.e12614","title":"A novel immune cell signature predicts pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer patients in the Q-CROC3 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Tumor-infiltrating lymphocytes; Breast cancer; Internal medicine; Stromal cell; FOXP3; Immune system; Cancer; Pathology; Immunology; Immunotherapy","score_opus":0.07438614511012666,"score_gpt":0.409740350759453,"score_spread":0.33535420564932633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282021936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590714,0.00046590777,0.000012177151,0.037453357,0.0014842466,0.001265019,0.00010945236,0.0000051478,0.00013327808],"genre_scores_gemma":[0.97717106,0.0004171365,0.0003957403,0.021357603,0.00042196963,0.00009227583,0.0000052242535,0.000017545362,0.00012144062],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939059,0.0023165436,0.0025410878,0.0002690597,0.0006398597,0.00032753794],"domain_scores_gemma":[0.99490184,0.0031556056,0.0013553044,0.00022273751,0.00020828773,0.00015620474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009696444,0.00018376736,0.0013667468,0.00024738454,0.00007965243,0.000010682407,0.00044928447,0.00028035796,0.00053703325],"category_scores_gemma":[0.0014018586,0.00011068255,0.0004969494,0.00066894054,0.00016581602,0.000060224524,0.00009409795,0.0021894611,0.0000019107376],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9131324,0.0098157935,0.011103299,0.000008345571,0.00010184059,0.0004710218,0.0019339739,0.000060929164,0.009200727,0.0000015995687,0.004126073,0.05004395],"study_design_scores_gemma":[0.21443772,0.032527268,0.7207914,0.0000631679,0.000045257122,0.00018154815,0.0007175024,0.00005467503,0.000041922165,0.0000251294,0.031011153,0.00010327771],"about_ca_topic_score_codex":0.00020221996,"about_ca_topic_score_gemma":0.000110917674,"teacher_disagreement_score":0.70968807,"about_ca_system_score_codex":0.0006099048,"about_ca_system_score_gemma":0.0014732464,"threshold_uncertainty_score":0.951224},"labels":[],"label_agreement":null},{"id":"W4282022545","doi":"10.1200/jco.2022.40.16_suppl.9522","title":"Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Placebo; Oncology; Gastroenterology; Cancer; Immunotherapy; Pathology","score_opus":0.043367404318560704,"score_gpt":0.3662485159631802,"score_spread":0.3228811116446195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282022545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782944,0.00017148016,0.000067736204,0.00015125333,0.00073298253,0.00034363067,0.000025173971,0.0000028948646,0.0006754087],"genre_scores_gemma":[0.9985451,0.00011912382,0.0004702896,0.0002126719,0.00023782332,0.00004516714,0.0000698046,0.000023183338,0.00027682644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973206,0.0004788087,0.0014021234,0.00028465255,0.00021018894,0.0003036458],"domain_scores_gemma":[0.99831307,0.0002540231,0.00093654526,0.000189464,0.00016934313,0.00013753131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014552771,0.00015309258,0.00083922525,0.00011313756,0.000047938418,0.000005341499,0.0003007204,0.00022804538,0.000032943048],"category_scores_gemma":[0.00052985817,0.00012519016,0.00021641552,0.00012527591,0.000071796465,0.0000094454745,0.00013093943,0.00045984113,0.000001312949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021589026,0.0020720125,0.94355804,0.000024215607,0.00011455263,0.0002972059,0.000051127277,0.00032763596,0.0029603483,0.000027362943,0.0002097789,0.028768698],"study_design_scores_gemma":[0.04289931,0.047902893,0.8921627,0.000031326166,0.000056404173,0.00007953693,0.000112790454,0.000061784034,0.0013569916,0.000050375747,0.015028735,0.0002571672],"about_ca_topic_score_codex":0.000016129408,"about_ca_topic_score_gemma":0.0005502817,"teacher_disagreement_score":0.051395353,"about_ca_system_score_codex":0.00015866816,"about_ca_system_score_gemma":0.0008146453,"threshold_uncertainty_score":0.5105107},"labels":[],"label_agreement":null},{"id":"W4282023107","doi":"10.1200/jco.2022.40.16_suppl.e18043","title":"Spatial transcriptomics unravels novel signaling patterns at the leading edge of oral squamous cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Transcriptome; Cancer research; Head and neck squamous-cell carcinoma; Cancer; Gene; Head and neck cancer; Tumor progression; Metastasis; Medicine; Gene expression; Biology; Internal medicine; Genetics","score_opus":0.1392049277454933,"score_gpt":0.4035629628286871,"score_spread":0.2643580350831938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282023107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892099,0.00053691264,0.0018419615,0.0052622054,0.00201849,0.000204048,0.000033846372,0.000004653045,0.00088797975],"genre_scores_gemma":[0.9954926,0.00008534806,0.0004670882,0.0028060996,0.00077027996,0.000008531169,0.000004135938,0.000025677682,0.00034028088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634004,0.00043229767,0.0022178143,0.00019239524,0.00055252295,0.00026494052],"domain_scores_gemma":[0.99643666,0.0012418294,0.0016604498,0.00019887624,0.0002512581,0.0002109599],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003443098,0.00014233534,0.0012898059,0.00009292624,0.00013610815,0.0000061047513,0.0003080755,0.00017362367,0.00097383274],"category_scores_gemma":[0.00034482824,0.00009497696,0.000802479,0.0001357003,0.00017212793,0.00004480747,0.00013096939,0.0013453605,0.0000040435834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011189195,0.006050166,0.7812374,0.00020527573,0.0003896769,0.00039302674,0.0021541163,0.0012856497,0.080105096,0.00007927676,0.007966036,0.108945064],"study_design_scores_gemma":[0.048890464,0.073511355,0.4759834,0.00013077023,0.0038871944,0.0014943619,0.0039622793,0.0025127488,0.075749606,0.00010389859,0.31317654,0.00059737894],"about_ca_topic_score_codex":0.00015879716,"about_ca_topic_score_gemma":0.0001031534,"teacher_disagreement_score":0.305254,"about_ca_system_score_codex":0.00033560744,"about_ca_system_score_gemma":0.0010796144,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W4282028151","doi":"10.1200/jco.2022.40.16_suppl.589","title":"Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Clinical endpoint; Anastrozole; Palbociclib; Internal medicine; Urology; Estrogen receptor; Breast cancer; Gastroenterology; Confidence interval; Phases of clinical research; Neoadjuvant therapy; Oncology; Gynecology; Cancer; Randomized controlled trial; Tamoxifen; Chemotherapy; Metastatic breast cancer","score_opus":0.0776512974025615,"score_gpt":0.4460083337624238,"score_spread":0.36835703635986233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282028151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945165,0.0002108332,0.00008451539,0.007099514,0.0009800856,0.0015197621,0.00043578597,0.000011903413,0.00020597842],"genre_scores_gemma":[0.99696934,0.00016637833,0.0011574642,0.00084058405,0.00029925996,0.00023704986,0.000029126651,0.000046390498,0.00025440412],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992408,0.0024037699,0.0029783465,0.0005210505,0.0011664566,0.00052239985],"domain_scores_gemma":[0.99217343,0.0029019127,0.0031745527,0.00039301472,0.00097408803,0.00038297934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034302727,0.00039261373,0.0038704535,0.0004380152,0.00017237531,0.000037428876,0.001012891,0.00016497962,0.0016883301],"category_scores_gemma":[0.00073382375,0.00024965376,0.00036497376,0.001488851,0.0008055127,0.00032829374,0.000398332,0.0016653768,0.0000020734162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87630767,0.009276284,0.043214034,0.000008457953,0.01667407,0.0008238595,0.0024685252,0.011870693,0.00030476454,0.000048255977,0.00007260808,0.038930755],"study_design_scores_gemma":[0.73440593,0.040397782,0.21210866,0.00014352394,0.004172539,0.00030432147,0.004439049,0.0021312744,0.000054664968,0.000032701424,0.0015164271,0.00029309661],"about_ca_topic_score_codex":0.0035114551,"about_ca_topic_score_gemma":0.0012706306,"teacher_disagreement_score":0.16889462,"about_ca_system_score_codex":0.0026276277,"about_ca_system_score_gemma":0.0044213524,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W4282036173","doi":"10.1200/jco.2022.40.16_suppl.tps10062","title":"FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with <i>RAF</i>-altered recurrent or progressive low-grade glioma or advanced solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Oncology; Internal medicine; Adverse effect; Glioma; Cancer research","score_opus":0.07504121689368846,"score_gpt":0.4745597762813039,"score_spread":0.39951855938761544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282036173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317616,0.000572768,0.00000218821,0.0028763786,0.0005891634,0.0027249723,0.000030655174,0.0000070730594,0.000020653435],"genre_scores_gemma":[0.998526,0.0001598413,0.00036867903,0.0004506586,0.0003202115,0.00012844568,0.000007465961,0.00002625328,0.000012490614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99410546,0.0013134029,0.0029538302,0.00038138212,0.00089870224,0.00034724086],"domain_scores_gemma":[0.99345845,0.0032977774,0.0020521071,0.00032194518,0.0004469476,0.0004227581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028565226,0.0002580619,0.0019807364,0.00030603356,0.00012159973,0.000011023651,0.00026472303,0.00007336671,0.00014115161],"category_scores_gemma":[0.0032728002,0.00012161533,0.00023470727,0.00079757924,0.00012427948,0.000077222365,0.00024267862,0.0008310619,0.0000019733527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26432815,0.12558797,0.3912444,0.00007802679,0.0007416376,0.00553965,0.0021732762,0.00032437683,0.00002881861,0.0000028274446,0.000691389,0.20925947],"study_design_scores_gemma":[0.123681515,0.20547879,0.6672685,0.0001626299,0.0010715856,0.00020054687,0.00071702746,0.00005489763,0.000055628756,0.000010249387,0.0011610548,0.00013753184],"about_ca_topic_score_codex":0.0000074721042,"about_ca_topic_score_gemma":0.00006552326,"teacher_disagreement_score":0.27602413,"about_ca_system_score_codex":0.0002914467,"about_ca_system_score_gemma":0.0014230108,"threshold_uncertainty_score":0.49593294},"labels":[],"label_agreement":null},{"id":"W4282037661","doi":"10.1200/jco.2022.40.16_suppl.1545","title":"Impact of proactive symptom monitoring on quality of life (QoL) and treatment toxicity in patients with cancer receiving chemotherapy: A meta-analysis of randomized clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Minimal clinically important difference; Quality of life (healthcare); Clinical trial; MEDLINE; Strictly standardized mean difference; Internal medicine; Odds ratio; Cancer; Physical therapy","score_opus":0.42822123247110955,"score_gpt":0.6059991463496031,"score_spread":0.1777779138784935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282037661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968662,0.00091817597,0.0000076217098,0.00080450036,0.00028716616,0.00096556015,0.00007759607,0.0000019852616,0.00007118652],"genre_scores_gemma":[0.9975774,0.0017051223,0.00028357885,0.00014245533,0.00018260506,0.00006519384,0.0000043595687,0.000011512698,0.000027743472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98302966,0.009890754,0.0061621177,0.00025342553,0.0005055072,0.00015851382],"domain_scores_gemma":[0.9648023,0.025460683,0.008852686,0.00018956502,0.00045707394,0.0002376457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023408126,0.00019674104,0.012757508,0.00038283985,0.000023379032,0.0000018641464,0.00009779342,0.0001865055,0.00065098784],"category_scores_gemma":[0.0060744584,0.00010434263,0.0045276396,0.0004330425,0.00028865616,0.000048513848,0.000035652316,0.00060490455,4.6966804e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3235583,0.008361249,0.47862166,0.000008532735,0.17900588,0.0000046761047,0.00028042414,0.0003069039,0.000028577335,0.0000017175392,0.000014014515,0.0098080775],"study_design_scores_gemma":[0.20681433,0.030745521,0.6588725,0.000010833297,0.10328356,7.338238e-7,0.000056617253,0.00005276506,0.000084654195,0.000011043092,0.000015704287,0.000051749033],"about_ca_topic_score_codex":0.0010790884,"about_ca_topic_score_gemma":0.00012566708,"teacher_disagreement_score":0.18025082,"about_ca_system_score_codex":0.0005529948,"about_ca_system_score_gemma":0.0018665125,"threshold_uncertainty_score":0.87207776},"labels":[],"label_agreement":null},{"id":"W4282047752","doi":"10.1200/jco.2022.40.16_suppl.e14044","title":"Efficacy of Gemcitabine in recurrent meningioma: A phase II study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Research Institute","keywords":"Medicine; Gemcitabine; Common Terminology Criteria for Adverse Events; Adverse effect; Progression-free survival; Internal medicine; Phases of clinical research; Chemotherapy; Oncology; Radiation therapy; Surgery","score_opus":0.1885548469309659,"score_gpt":0.5161420882940101,"score_spread":0.3275872413630442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282047752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991248,0.00039432172,0.000027076407,0.0032986682,0.0013667409,0.0005039524,0.0000019773543,0.0000059825084,0.0031532936],"genre_scores_gemma":[0.9980897,0.000013509271,0.0010582892,0.00016431471,0.0003513076,0.000013929882,0.000002593668,0.0000102851445,0.00029611547],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9945939,0.00087857427,0.003433515,0.00020349762,0.0006703989,0.00022006688],"domain_scores_gemma":[0.99633,0.0010922757,0.0019296219,0.00023878418,0.00017872376,0.00023054569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008173193,0.00012046445,0.0016110921,0.00042880452,0.000068852736,0.000002784671,0.00025549228,0.0000799333,0.0005840478],"category_scores_gemma":[0.0024369736,0.00009447385,0.000444807,0.00042873734,0.00007890592,0.000051320425,0.0003471499,0.0010816563,0.0000027937795],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09421838,0.20000564,0.1069579,0.00009889941,0.0019018349,0.047070775,0.0039981483,0.00028126314,0.00085668324,0.0009451963,0.019660955,0.52400434],"study_design_scores_gemma":[0.1317425,0.4168776,0.31174538,0.00009623248,0.0009713925,0.0015059754,0.0025779412,0.00045619963,0.00003375985,0.0002254998,0.13358021,0.00018731882],"about_ca_topic_score_codex":0.000012554548,"about_ca_topic_score_gemma":0.0000051737456,"teacher_disagreement_score":0.523817,"about_ca_system_score_codex":0.00018925493,"about_ca_system_score_gemma":0.00080320693,"threshold_uncertainty_score":0.6394914},"labels":[],"label_agreement":null},{"id":"W4282979697","doi":"10.1200/jco.22.01054","title":"Reply to W.L. Lee et al","year":2022,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.19633739867309016,"score_gpt":0.5230404048062763,"score_spread":0.32670300613318615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282979697","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012573822,0.0040315096,0.00030848617,0.9004798,0.067422375,0.0006445091,0.00009073213,0.000028584234,0.0144202085],"genre_scores_gemma":[0.0010682825,0.003266257,0.006859389,0.9217059,0.055957254,0.000020064264,0.0000457906,0.00015694067,0.010920114],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96990514,0.011145725,0.013423054,0.0010751706,0.0031864897,0.0012644421],"domain_scores_gemma":[0.95370775,0.031396583,0.010388243,0.0013052383,0.0011551382,0.0020470624],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.044444803,0.0007377828,0.008005328,0.0006072282,0.00016617673,0.000046862307,0.0015757016,0.001919214,0.016504664],"category_scores_gemma":[0.050787024,0.00066669984,0.003476316,0.00055223086,0.0006577585,0.00023317027,0.0008742725,0.023226762,0.0009884018],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00668185,0.0023618685,0.0051741144,0.00020905466,0.0020974874,0.0145435175,0.0010311177,0.00007062052,0.000009087131,0.00017949044,0.9139226,0.053719163],"study_design_scores_gemma":[0.008434352,0.053059347,0.021348253,0.001027187,0.0013829439,0.0031798687,0.0005132648,0.000009125561,0.0000036109366,0.00037504194,0.91013557,0.00053145096],"about_ca_topic_score_codex":0.0007007087,"about_ca_topic_score_gemma":0.0002290735,"teacher_disagreement_score":0.05318771,"about_ca_system_score_codex":0.0018377153,"about_ca_system_score_gemma":0.015965037,"threshold_uncertainty_score":0.9997894},"labels":[],"label_agreement":null},{"id":"W4283211705","doi":"10.1200/jco.22.00705","title":"Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Docetaxel; Cancer; Prostate; Oncology; Prostate cancer; Internal medicine; Hormone","score_opus":0.14967188929207503,"score_gpt":0.5055826342452931,"score_spread":0.3559107449532181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283211705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611879,0.0059011616,0.000023954683,0.026272094,0.0007850393,0.0005575541,0.000060287457,0.0000065058116,0.00520549],"genre_scores_gemma":[0.97461367,0.015207468,0.0021771737,0.0020793532,0.00021307833,0.000035676967,0.000006095875,0.000018670986,0.005648812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678147,0.000406572,0.0016482896,0.0001755884,0.00072440866,0.00026367544],"domain_scores_gemma":[0.99726355,0.0005283627,0.0013405322,0.00016446691,0.0004316431,0.00027143265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026067817,0.000118132695,0.001273523,0.000171844,0.000074591044,0.000004361234,0.00015320127,0.000058683425,0.00044395027],"category_scores_gemma":[0.00012643506,0.00008102798,0.00045816717,0.00029660153,0.00021975867,0.00006658312,0.00017542801,0.00087609916,0.0000069449766],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081999555,0.009833176,0.023133757,0.00055881235,0.014376287,0.02452316,0.0034893171,0.00027533047,0.0012007845,0.0006954342,0.10560995,0.7343044],"study_design_scores_gemma":[0.09665092,0.11064693,0.22479025,0.0005040772,0.0074446755,0.0018248213,0.029351868,0.0006078359,0.004268781,0.0033286978,0.5200583,0.0005228758],"about_ca_topic_score_codex":0.0000829444,"about_ca_topic_score_gemma":0.0000034421942,"teacher_disagreement_score":0.7337816,"about_ca_system_score_codex":0.00034816473,"about_ca_system_score_gemma":0.0013518689,"threshold_uncertainty_score":0.48609442},"labels":[],"label_agreement":null},{"id":"W4283220315","doi":"10.1200/jco.22.00868","title":"Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Metastasectomy; Sunitinib; Asymptomatic; Clear cell renal cell carcinoma; Systemic therapy; Guideline; Pazopanib; Kidney cancer; Nephrectomy; Cancer; Metastasis; Pathology; Kidney","score_opus":0.2803893385683397,"score_gpt":0.4979387979693033,"score_spread":0.2175494594009636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283220315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009925705,0.96811056,0.00006737067,0.00029165324,0.001632325,0.0011033169,0.00003055954,0.000009391664,0.027762271],"genre_scores_gemma":[0.0008556843,0.9716727,0.022694902,0.00030264942,0.0008796624,0.000029951263,0.00007398883,0.00010816046,0.0033823045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9841761,0.0021824802,0.011272136,0.0005573867,0.0013362692,0.00047560924],"domain_scores_gemma":[0.98372614,0.0030711703,0.011241587,0.00082933134,0.00043329113,0.00069844734],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0076566143,0.00061426265,0.010220001,0.00054180424,0.000054461725,0.000008780274,0.00070746784,0.0005415886,0.0024463707],"category_scores_gemma":[0.00045533472,0.0004114847,0.0049466263,0.0004660813,0.00022319025,0.0000613441,0.00044734232,0.002893514,0.00008874333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014118167,0.004988695,0.000046124438,0.017456032,0.0022898684,0.023336533,0.000024004148,0.000009880936,0.0000014957242,0.000026280008,0.020502355,0.9299069],"study_design_scores_gemma":[0.0063287993,0.025613844,0.00015609675,0.0018252954,0.026199019,0.0016034519,0.000118470714,0.0000062857926,0.000011345589,0.000035739406,0.93785596,0.00024569954],"about_ca_topic_score_codex":0.00001965179,"about_ca_topic_score_gemma":0.0000016564898,"teacher_disagreement_score":0.9296612,"about_ca_system_score_codex":0.00093625276,"about_ca_system_score_gemma":0.004234041,"threshold_uncertainty_score":0.9998337},"labels":[],"label_agreement":null},{"id":"W4283269985","doi":"10.1200/jco.21.02543","title":"Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University; University of Calgary","funders":"National Cancer Institute","keywords":"Lomustine; Procarbazine; Medicine; Oligodendroglial Tumor; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Vincristine; Radiation therapy; Chemotherapy; Clinical trial; Glioma; Oligodendroglioma; Confidence interval; Cancer research","score_opus":0.15953746859711318,"score_gpt":0.467163835070124,"score_spread":0.3076263664730108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283269985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201995,0.00063154893,0.00035154127,0.0056125917,0.00037570787,0.00081230205,0.00003407272,0.000007068683,0.00015523797],"genre_scores_gemma":[0.991724,0.00023981502,0.006532581,0.0005876008,0.00072740886,0.00006333062,0.0000152319735,0.000024148954,0.00008586248],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952251,0.0002977252,0.0035613694,0.0002853217,0.0004113677,0.00021917054],"domain_scores_gemma":[0.99214804,0.002925525,0.0039880527,0.00016578665,0.00041789675,0.0003546919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005423521,0.00019466337,0.002976992,0.00018560025,0.00008578463,0.000008254504,0.000070523405,0.000121627156,0.00010659615],"category_scores_gemma":[0.005393442,0.00012397708,0.00036829553,0.00014003314,0.00024967507,0.000048739206,0.000053422606,0.00046685166,1.6956854e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3960923,0.044462454,0.13273717,0.000810951,0.007822841,0.045567602,0.00065932417,0.000190645,0.009706099,0.0007633721,0.02819544,0.3329918],"study_design_scores_gemma":[0.3975413,0.3081141,0.1734879,0.0004927583,0.0064943996,0.05057248,0.0005898585,0.0013957642,0.0041198446,0.0007124945,0.056018278,0.00046077836],"about_ca_topic_score_codex":0.000022448572,"about_ca_topic_score_gemma":0.000018690522,"teacher_disagreement_score":0.33253103,"about_ca_system_score_codex":0.00008956688,"about_ca_system_score_gemma":0.0011641629,"threshold_uncertainty_score":0.6456844},"labels":[],"label_agreement":null},{"id":"W4283311019","doi":"10.1200/jco.22.00205","title":"Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Durvalumab; Metastatic Urothelial Carcinoma; Olaparib; Urothelial cancer; Oncology; Urothelial carcinoma; Internal medicine; Multicenter trial; Multicenter study; Urology; Gynecology; Randomized controlled trial; Bladder cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.07433443946184327,"score_gpt":0.4213825141518132,"score_spread":0.34704807468996995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283311019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204385,0.0005551688,0.000078324796,0.0010568397,0.0017691961,0.0033857939,0.00006444165,0.000015611095,0.0010307904],"genre_scores_gemma":[0.99584,0.00013540531,0.0013686575,0.001267949,0.0006376074,0.00021502223,0.000038663118,0.00004750845,0.000449158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923843,0.0021522858,0.003661177,0.00038580672,0.0009438921,0.00047253098],"domain_scores_gemma":[0.994478,0.0020831004,0.0023172365,0.00029188386,0.0003745191,0.0004552564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039878804,0.00032386833,0.003787873,0.00032667606,0.00016252273,0.000014605629,0.00025932657,0.00015638678,0.0007407921],"category_scores_gemma":[0.0023363247,0.00020929896,0.00081240945,0.00033179673,0.0002508481,0.00015421052,0.00014593551,0.0014175577,0.000009511712],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93843627,0.021794703,0.022147056,0.000033752658,0.0011351941,0.00148949,0.0007581304,0.00014911061,0.00000407682,0.000015301652,0.000821285,0.013215615],"study_design_scores_gemma":[0.8917668,0.09674093,0.003150742,0.00006877373,0.0024580653,0.00018764369,0.00016293272,0.00048403876,0.000012407115,0.00007921591,0.0047214986,0.00016697508],"about_ca_topic_score_codex":0.00044271504,"about_ca_topic_score_gemma":0.00012104814,"teacher_disagreement_score":0.074946225,"about_ca_system_score_codex":0.0007843397,"about_ca_system_score_gemma":0.004306323,"threshold_uncertainty_score":0.8534964},"labels":[],"label_agreement":null},{"id":"W4283390621","doi":"10.1200/jco.21.02741","title":"Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Prostate-specific antigen; Internal medicine; Surrogate endpoint; Hazard ratio; Urology; Radiation therapy; Clinical endpoint; Biochemical recurrence; Prostate; Salvage therapy; Stage (stratigraphy); Cancer; Clinical trial; Chemotherapy; Confidence interval","score_opus":0.10869204179453774,"score_gpt":0.4688955939346918,"score_spread":0.3602035521401541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283390621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94521046,0.0018039243,0.000014339074,0.050232314,0.0013294052,0.0006798707,0.0005289743,0.0000061307314,0.00019459196],"genre_scores_gemma":[0.99051356,0.004136376,0.0013691197,0.003246543,0.0003627331,0.00019939215,0.000059671696,0.000022289118,0.000090329166],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99477816,0.0005945008,0.0032110573,0.000407863,0.00060450187,0.00040389106],"domain_scores_gemma":[0.9932064,0.0030286724,0.0025931208,0.00025433744,0.00054725324,0.00037025783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045265504,0.00021891945,0.00307579,0.00045663895,0.00005294776,0.000006126709,0.00022481667,0.00026628058,0.0008273245],"category_scores_gemma":[0.0011454737,0.0001695517,0.0013833544,0.0006032569,0.0001975623,0.00006903158,0.00016003098,0.0011217772,0.0000012782746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05884602,0.018164052,0.6163054,0.00022962855,0.012648757,0.0013088814,0.0020770992,0.00080464175,0.0018257714,0.0003209759,0.039521106,0.24794763],"study_design_scores_gemma":[0.054317605,0.06871175,0.42089626,0.00026141354,0.010953048,0.000121562625,0.0012011221,0.0013815901,0.0036518928,0.0006507856,0.43743676,0.00041622456],"about_ca_topic_score_codex":0.00019698784,"about_ca_topic_score_gemma":0.00065729563,"teacher_disagreement_score":0.39791563,"about_ca_system_score_codex":0.001562907,"about_ca_system_score_gemma":0.0032314193,"threshold_uncertainty_score":0.90586233},"labels":[],"label_agreement":null},{"id":"W4283698841","doi":"10.1200/jco.21.02698","title":"Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Autologous stem-cell transplantation; Hazard ratio; Cohort; Bendamustine; Chemoimmunotherapy; Oncology; Cytarabine; Retrospective cohort study; Transplantation; Surgery; Lymphoma; Chemotherapy; Confidence interval","score_opus":0.025955125559323392,"score_gpt":0.34530363848414874,"score_spread":0.31934851292482536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283698841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974103,0.00031966076,0.0000016393693,0.0010237372,0.00010092075,0.00035224986,0.00020285575,0.000003824057,0.000584825],"genre_scores_gemma":[0.9959578,0.0030956608,0.0005178241,0.00018730517,0.000028410313,0.000013593931,0.000073343625,0.000010030432,0.000116068506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772847,0.00027867846,0.0013644866,0.00021386465,0.00024946537,0.00016503429],"domain_scores_gemma":[0.997375,0.0012144524,0.0010398519,0.00012109096,0.00009983439,0.00014976782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000554321,0.00013781297,0.0012809362,0.0001191676,0.000039879236,0.000004247776,0.000043096556,0.00007651195,0.00001854588],"category_scores_gemma":[0.0000946123,0.00008218385,0.00011242961,0.00009205881,0.0000745182,0.000053549877,0.000023880128,0.00011552558,5.354895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01834176,0.016185675,0.93865263,0.000017962724,0.00028821934,0.0010281894,0.00047154227,0.0000056206454,0.0000016266779,0.000018789602,0.00009113391,0.024896832],"study_design_scores_gemma":[0.1516279,0.013996667,0.8321147,0.00007686498,0.00063039665,0.000038008206,0.00011663801,0.000023481118,0.000040879535,0.000032792672,0.0012435452,0.000058123886],"about_ca_topic_score_codex":0.0007423665,"about_ca_topic_score_gemma":0.0016183213,"teacher_disagreement_score":0.13328615,"about_ca_system_score_codex":0.0003212966,"about_ca_system_score_gemma":0.00035400045,"threshold_uncertainty_score":0.335136},"labels":[],"label_agreement":null},{"id":"W4285007047","doi":"10.1200/jco.22.00581","title":"Ki67 as a Companion Diagnostic: Good or Bad News?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Dermatology","score_opus":0.06451593407112884,"score_gpt":0.42435416398907544,"score_spread":0.3598382299179466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285007047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318094,0.0014223141,0.00042043015,0.005270467,0.003929671,0.00015849233,0.00003356101,0.000004062588,0.0055800593],"genre_scores_gemma":[0.98359704,0.003284041,0.0013316154,0.0083154235,0.0025980542,0.000012054409,0.000020354295,0.000022637903,0.0008187826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975025,0.00041847798,0.0013829594,0.00022129441,0.000249991,0.00022475238],"domain_scores_gemma":[0.9961646,0.0019924205,0.0011314885,0.00023782389,0.0001942637,0.0002793728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015721568,0.00012498416,0.0006331677,0.00005239419,0.00010807859,0.000014831692,0.00039949833,0.00020592388,0.000571373],"category_scores_gemma":[0.008063215,0.00010113681,0.00038202782,0.00009385032,0.000106011146,0.0000040090163,0.0003734012,0.0006030094,0.000020738005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01287071,0.0063382685,0.11210033,0.00002687601,0.0010125313,0.0022295255,0.00017703012,0.003596978,0.009380506,0.0025377888,0.45534715,0.3943823],"study_design_scores_gemma":[0.0034626278,0.018617908,0.01662225,0.0000070090773,0.00009908066,0.0006144693,0.00019333838,0.000026607935,0.00043955725,0.00054059346,0.95923436,0.00014218323],"about_ca_topic_score_codex":0.00005175077,"about_ca_topic_score_gemma":0.00016257999,"teacher_disagreement_score":0.50388724,"about_ca_system_score_codex":0.00008002892,"about_ca_system_score_gemma":0.002055594,"threshold_uncertainty_score":0.9653003},"labels":[],"label_agreement":null},{"id":"W4285013864","doi":"10.1200/jco.22.00824","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Guideline; Anaplastic lymphoma kinase; Ceritinib; Alectinib; Lung cancer; Oncology; Intensive care medicine; Clinical trial; Internal medicine; Pathology","score_opus":0.29180651902451915,"score_gpt":0.5659930437473555,"score_spread":0.27418652472283633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285013864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97276247,0.0063081095,0.010446032,0.0074629756,0.0011299353,0.0005129046,0.000030825104,0.000007729758,0.0013390346],"genre_scores_gemma":[0.8659807,0.015663756,0.089160725,0.018983072,0.00414361,0.00012246567,0.000019099594,0.00006252326,0.005864066],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973438,0.000267351,0.001747171,0.00015688613,0.00030415173,0.0001806759],"domain_scores_gemma":[0.99429095,0.0030055344,0.0015689192,0.00014625871,0.0008208381,0.00016748422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025278653,0.00011568136,0.0010319534,0.00010306781,0.00008148093,0.0000053963327,0.00016049756,0.00010891758,0.0007862734],"category_scores_gemma":[0.001138636,0.00007853535,0.00033595518,0.00012137391,0.00008114895,0.00007140069,0.00004958214,0.0006279938,8.4446077e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01105897,0.0038065824,0.8004184,0.00017985818,0.0018038179,0.0004212375,0.0033177626,0.0038762973,0.0023139385,0.000110026274,0.10527988,0.06741323],"study_design_scores_gemma":[0.013772407,0.022229692,0.024033956,0.00041442647,0.0005069039,0.00004070274,0.0015115484,0.0038721808,0.0005156921,0.000037593752,0.9329128,0.00015207642],"about_ca_topic_score_codex":0.000054647084,"about_ca_topic_score_gemma":0.00007675171,"teacher_disagreement_score":0.82763296,"about_ca_system_score_codex":0.00016751909,"about_ca_system_score_gemma":0.0020982993,"threshold_uncertainty_score":0.86091423},"labels":[],"label_agreement":null},{"id":"W4285043434","doi":"10.1200/jco.22.00825","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Atezolizumab; Oncology; Internal medicine; Guideline; Lung cancer; Chemotherapy; Cancer; Clinical trial; Randomized controlled trial; Immunotherapy; Pathology","score_opus":0.10364059094424469,"score_gpt":0.4805426847156378,"score_spread":0.37690209377139317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285043434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96700585,0.0066900216,0.005263888,0.015276479,0.0038138235,0.00093979074,0.000034943103,0.000014536952,0.0009606726],"genre_scores_gemma":[0.911392,0.010308644,0.019621,0.04241209,0.0048774183,0.00018966262,0.000014904703,0.00007075587,0.011113526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964247,0.00035670627,0.0024371597,0.000207921,0.00032998272,0.00024354384],"domain_scores_gemma":[0.9958417,0.0015197489,0.001777002,0.00020013942,0.0004822322,0.00017918293],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005126186,0.000144298,0.0010040147,0.00012719868,0.00017613696,0.000014566231,0.00022208992,0.00016056414,0.0023899851],"category_scores_gemma":[0.0005272438,0.00010789902,0.00068646873,0.00014403989,0.00009196483,0.000087626715,0.000060476646,0.00079844025,0.0000013134126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053914994,0.005606599,0.26319858,0.00013568779,0.0028824783,0.00025589098,0.0015465523,0.0011553754,0.017849332,0.0000386765,0.24488828,0.40852752],"study_design_scores_gemma":[0.021864086,0.014935403,0.04044252,0.000106451625,0.00035761023,0.00010473818,0.00046917968,0.004558553,0.0002843806,0.000025752615,0.91667956,0.00017176729],"about_ca_topic_score_codex":0.00008501461,"about_ca_topic_score_gemma":0.00008537981,"teacher_disagreement_score":0.67179126,"about_ca_system_score_codex":0.00036781156,"about_ca_system_score_gemma":0.0030732981,"threshold_uncertainty_score":0.998522},"labels":[],"label_agreement":null},{"id":"W4285491618","doi":"10.1200/jco.21.02707","title":"Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Gene signature; Gene expression profiling; Peripheral T-cell lymphoma; Cohort; Pathology; Lymphoma; Transcriptome; Oncology; Internal medicine; Gene expression; Bioinformatics; Computational biology; Gene; T cell; Immunology; Biology","score_opus":0.11950702309088221,"score_gpt":0.47054557871177616,"score_spread":0.3510385556208939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285491618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95380217,0.0071264375,0.000052508276,0.03543752,0.001991067,0.00067685975,0.00002276651,0.0000042306133,0.0008864316],"genre_scores_gemma":[0.9816327,0.0051977322,0.00306944,0.008626283,0.001158123,0.0001834281,0.0000058350392,0.000014393452,0.000112026915],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99402744,0.002107073,0.002820388,0.00020391124,0.000614526,0.00022669033],"domain_scores_gemma":[0.9576197,0.03880797,0.002757263,0.00031977476,0.00037042986,0.00012481722],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010313718,0.00014630455,0.0011480522,0.00006639638,0.00015861631,0.000016001002,0.0004234854,0.00021159793,0.00017713911],"category_scores_gemma":[0.008827566,0.000069395326,0.0009043798,0.00015302247,0.00022119065,0.000116489544,0.00015109256,0.00067799434,0.0000014100774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032359116,0.06006174,0.53974766,0.000081027254,0.0013258138,0.0021269973,0.0021530217,0.0008275309,0.00019796488,0.00048741268,0.11157976,0.24905199],"study_design_scores_gemma":[0.034692913,0.02684439,0.44295263,0.000067533445,0.0014134598,0.00048164077,0.0049660476,0.0002243283,0.001067473,0.0002516657,0.48691916,0.00011874112],"about_ca_topic_score_codex":0.00005087472,"about_ca_topic_score_gemma":0.000017046195,"teacher_disagreement_score":0.37533942,"about_ca_system_score_codex":0.00019829675,"about_ca_system_score_gemma":0.0012549824,"threshold_uncertainty_score":0.9995215},"labels":[],"label_agreement":null},{"id":"W4285491831","doi":"10.1200/jco.21.02514","title":"Moving the Needle on Precision Medicine in Pancreatic Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Pancreatic cancer; Medicine; Precision medicine; Pancreatic ductal adenocarcinoma; Germline; Personalized medicine; Germline mutation; Homologous recombination; Cancer; Bioinformatics; Cancer research; Mutation; Internal medicine; Genetics; Biology; Gene; Pathology; Colorectal cancer","score_opus":0.2108715449826536,"score_gpt":0.5439291058351822,"score_spread":0.3330575608525286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285491831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91225696,0.0013404802,0.000030273955,0.06582623,0.0010912311,0.0003042525,0.0000015094621,0.000004343105,0.019144695],"genre_scores_gemma":[0.9862527,0.0018044561,0.0003357703,0.008149779,0.001328304,0.00003952203,0.0000010098081,0.000012802221,0.0020756116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995098,0.0016227247,0.0020439285,0.00016343301,0.0008028504,0.00026908028],"domain_scores_gemma":[0.98727125,0.011051511,0.0010026164,0.0002413987,0.00019894307,0.00023430369],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01204469,0.00010393081,0.0016157319,0.00023375191,0.0001269984,0.000002781942,0.0003085351,0.00015998633,0.0026541047],"category_scores_gemma":[0.009611288,0.00005378449,0.00022175856,0.00034877326,0.00033001896,0.00003835052,0.00013547242,0.0024476312,0.000012833499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011022428,0.0018195045,0.79872644,0.000024394465,0.0003202918,0.0013212748,0.00086892134,0.00029285427,0.00016786387,0.00041080487,0.036682244,0.14834295],"study_design_scores_gemma":[0.01071485,0.03105907,0.84436744,0.0002218599,0.00040536202,0.0005123624,0.0017365016,0.0014671803,0.0000059789404,0.0013714166,0.1080706,0.000067402165],"about_ca_topic_score_codex":0.00027453667,"about_ca_topic_score_gemma":0.00007513521,"teacher_disagreement_score":0.14827555,"about_ca_system_score_codex":0.000504319,"about_ca_system_score_gemma":0.0023146502,"threshold_uncertainty_score":0.9998538},"labels":[],"label_agreement":null},{"id":"W4285492196","doi":"10.1200/jco.21.02615","title":"Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":276,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences","keywords":"Medicine; Circulating tumor DNA; Liquid biopsy; Colorectal cancer; Minimal residual disease; Oncology; Biomarker; Internal medicine; Circulating tumor cell; DNA methylation; Risk stratification; Disease; Personalized medicine; Profiling (computer programming); Precision medicine; Bioinformatics; Cancer; Pathology; Gene; Metastasis","score_opus":0.28981203367804953,"score_gpt":0.5445730461990795,"score_spread":0.25476101252103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285492196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039921496,0.9570688,0.000014929717,0.000043206215,0.0025518772,0.00021886153,0.000025848605,0.0000011869549,0.00015377955],"genre_scores_gemma":[0.0025521517,0.99417466,0.0008093024,0.00010643166,0.0022925253,0.000015630778,0.000012585157,0.000033434957,0.0000032943067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960459,0.00074286154,0.002449487,0.00034108825,0.00018204271,0.00023862717],"domain_scores_gemma":[0.9901865,0.0019849334,0.007407505,0.00012740477,0.00011783865,0.00017579265],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028892194,0.0002279407,0.0021264306,0.00013018562,0.000062845174,0.000028441973,0.00027918487,0.0003498122,0.000055804838],"category_scores_gemma":[0.00957097,0.00019797627,0.0005491074,0.00013000418,0.000106447245,0.0000085135225,0.00036099245,0.0013103517,4.516282e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096471595,0.00025259188,0.0020568077,0.00087450474,0.0002032967,0.00018578382,0.000014713876,0.000052237345,0.000059954404,0.000008285755,0.0003515822,0.99584377],"study_design_scores_gemma":[0.00076252286,0.001137563,0.00036909647,0.0011368365,0.00063269,0.00057895406,0.000034576646,0.0000946093,0.0000033599629,0.000021179796,0.9950229,0.00020573699],"about_ca_topic_score_codex":0.000069508686,"about_ca_topic_score_gemma":0.00020078136,"teacher_disagreement_score":0.995638,"about_ca_system_score_codex":0.00028659333,"about_ca_system_score_gemma":0.00623754,"threshold_uncertainty_score":0.99939615},"labels":[],"label_agreement":null},{"id":"W4285803599","doi":"10.1200/jco.21.02488","title":"Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Cancer; Stage (stratigraphy); Adjuvant therapy; Clinical endpoint; AJCC staging system; Cohort; Surgery; Clinical trial; Confidence interval","score_opus":0.1311454640012218,"score_gpt":0.48271803109723527,"score_spread":0.3515725670960135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285803599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035263,0.000059865084,0.0005879995,0.0067345155,0.0008977353,0.0008877578,0.0004088357,0.0000052344963,0.000065425615],"genre_scores_gemma":[0.9958819,0.0010145833,0.0019775867,0.0006999063,0.00017153562,0.0000782648,0.000015248724,0.000011196545,0.00014978109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968962,0.00055349607,0.0019516059,0.00021565972,0.00028868133,0.000094359166],"domain_scores_gemma":[0.9947651,0.0018992262,0.0025948843,0.00034802707,0.0002227285,0.00017005634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021045457,0.000100373436,0.0007502904,0.00011126757,0.00009677208,0.000009101035,0.00023376469,0.000030534273,0.00015393896],"category_scores_gemma":[0.00038715856,0.000066995985,0.00035202704,0.000084953375,0.00021542201,0.0000433393,0.00013098175,0.00039842617,5.370968e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056561194,0.0050933016,0.8057197,0.000013239159,0.0025274886,0.000023842953,0.00011883711,0.00010545088,0.000020357842,0.00019616862,0.00029250616,0.18023299],"study_design_scores_gemma":[0.00511284,0.009830705,0.9643986,0.000015264995,0.0017124914,0.0000029622477,0.0019875767,0.000263024,0.000005427993,0.000090475674,0.016527077,0.000053523683],"about_ca_topic_score_codex":0.00043239217,"about_ca_topic_score_gemma":0.0002211844,"teacher_disagreement_score":0.18017946,"about_ca_system_score_codex":0.00008057324,"about_ca_system_score_gemma":0.00013540973,"threshold_uncertainty_score":0.27320167},"labels":[],"label_agreement":null},{"id":"W4286293114","doi":"10.1200/jco.2022.40.16_suppl.12031","title":"Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University; University of Calgary","funders":"","keywords":"Medicine; Cohort; Palliative care; Context (archaeology); Population; End-of-life care; Retrospective cohort study; Multiple myeloma; Internal medicine; Emergency medicine; Nursing","score_opus":0.23297592073719228,"score_gpt":0.5253754011652463,"score_spread":0.29239948042805397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806094,0.00028650305,0.00042706705,0.00024858702,0.00021154819,0.00031446805,0.00029581322,0.000002616934,0.00015243753],"genre_scores_gemma":[0.99017036,0.00003991987,0.009299877,0.00021420885,0.000087775414,0.0000091194825,0.00015746486,0.000010581508,0.0000106905345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953959,0.000572645,0.0030674024,0.00015294696,0.0006827843,0.00012833254],"domain_scores_gemma":[0.98629475,0.006956958,0.0047135428,0.00021997985,0.0016549913,0.0001598036],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020601302,0.00010565484,0.0026322426,0.00031010315,0.000029878856,7.941928e-7,0.00014971607,0.00014111174,0.00015530182],"category_scores_gemma":[0.010539657,0.00007782797,0.000922633,0.0004041429,0.00016143387,0.000034808716,0.000037428894,0.00031230753,1.185718e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013341922,0.0017275471,0.97597647,0.00020931097,0.0026102904,0.00000447383,0.00048309224,0.0012871603,0.000031707663,0.000037179205,0.00011985308,0.0041709715],"study_design_scores_gemma":[0.011952226,0.011286075,0.9690364,0.00010231965,0.0023690164,2.9648444e-7,0.0012284406,0.00036384517,0.00006369101,0.000019828722,0.0035122435,0.00006563829],"about_ca_topic_score_codex":0.00051197107,"about_ca_topic_score_gemma":0.00055806985,"teacher_disagreement_score":0.009558529,"about_ca_system_score_codex":0.00013158449,"about_ca_system_score_gemma":0.0011973524,"threshold_uncertainty_score":0.997795},"labels":[],"label_agreement":null},{"id":"W4286293512","doi":"10.1200/jco.2022.40.16_suppl.5055","title":"Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living North; Abbotsford Veterinary Clinic; BC Cancer Agency; Kelowna General Hospital; University of British Columbia","funders":"","keywords":"PTEN; Prostate cancer; Medicine; Loss of heterozygosity; Internal medicine; Oncology; Cancer; Androgen deprivation therapy; Cancer research; Allele; Biology; Gene; Genetics; Apoptosis","score_opus":0.12466618231781888,"score_gpt":0.5212195107989226,"score_spread":0.3965533284811037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96168995,0.0025784674,8.123552e-7,0.034711443,0.0004066687,0.00050192676,0.00004225378,0.0000021380054,0.00006636815],"genre_scores_gemma":[0.9930418,0.004395021,0.00050987507,0.0012157003,0.00012777376,0.000038621813,0.0000044706144,0.000010679062,0.0006560448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594265,0.0009806887,0.0021155782,0.00021671978,0.0005027366,0.00024165404],"domain_scores_gemma":[0.99460024,0.0030511168,0.001719164,0.000085778236,0.00028971164,0.0002540153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005100183,0.000115431,0.0014406391,0.00028485633,0.000043191856,0.000011393854,0.00008705257,0.00013498153,0.000056714875],"category_scores_gemma":[0.005096663,0.00007938592,0.00016090664,0.00025318214,0.00014048263,0.00007841812,0.00010376161,0.0010689143,5.6889354e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009470413,0.0012461009,0.9512337,0.000050393686,0.0003825148,0.0014601888,0.00053666363,0.0000496628,0.0001567944,0.000028059083,0.0012020776,0.03418342],"study_design_scores_gemma":[0.014133238,0.008213206,0.9735817,0.00011604992,0.00019176753,0.00008016464,0.0006201346,0.000041306797,0.00003383976,0.00031360943,0.0026037593,0.00007125217],"about_ca_topic_score_codex":0.00039256734,"about_ca_topic_score_gemma":0.00203554,"teacher_disagreement_score":0.034112167,"about_ca_system_score_codex":0.00044960665,"about_ca_system_score_gemma":0.0017874131,"threshold_uncertainty_score":0.610155},"labels":[],"label_agreement":null},{"id":"W4286293550","doi":"10.1200/jco.2022.40.16_suppl.e18017","title":"Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Contraindication; Cancer; Cancer registry; Head and neck cancer; Radiation therapy; Proportional hazards model; Confidence interval; Oncology; Chemotherapy; Surgery; Immunotherapy","score_opus":0.1230429459821802,"score_gpt":0.4312034245061363,"score_spread":0.3081604785239561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864628,0.00032346256,7.012069e-8,0.0059207943,0.00096415856,0.00032816784,0.000002625016,0.0000013566384,0.0059965905],"genre_scores_gemma":[0.99680156,0.000033375425,0.0000536095,0.001489291,0.00009645026,0.000008812894,2.0384513e-7,0.000008535848,0.0015081819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962988,0.0005976645,0.0022951008,0.00016112765,0.00043138562,0.00021592237],"domain_scores_gemma":[0.9975159,0.0012117858,0.00085639005,0.00018308115,0.000091905895,0.0001409249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024673897,0.00010498072,0.0016621484,0.00013777833,0.00005561621,0.000001673836,0.00017265786,0.000064246444,0.000117694646],"category_scores_gemma":[0.0006238571,0.00006961217,0.00014745431,0.00026975572,0.00009416296,0.000024673116,0.00021458961,0.0017699148,1.553176e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002000225,0.002147009,0.9891711,0.00001986879,0.000033939108,0.0010682818,0.0012636635,0.000027451013,0.000007826791,0.0000059290887,0.0027045347,0.0015502004],"study_design_scores_gemma":[0.013485781,0.011868621,0.9522087,0.000026595082,0.00009092516,0.000057356032,0.0017086115,0.000009920563,0.0000033431072,0.000022194452,0.020461226,0.000056702604],"about_ca_topic_score_codex":0.92329144,"about_ca_topic_score_gemma":0.99930525,"teacher_disagreement_score":0.076013826,"about_ca_system_score_codex":0.001453337,"about_ca_system_score_gemma":0.00786751,"threshold_uncertainty_score":0.99775696},"labels":[],"label_agreement":null},{"id":"W4286293721","doi":"10.1200/jco.2022.40.16_suppl.e18577","title":"Efficacy of an educational comic book for HPV vaccination information in Nigeria.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Comics; Medicine; Cervical cancer; Family medicine; Cancer; Medical education; Internal medicine; Political science","score_opus":0.21323315243281188,"score_gpt":0.5775688223868274,"score_spread":0.3643356699540155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518985,0.000120013145,0.00006487988,0.03294269,0.01240352,0.0008561463,0.000005883497,0.000004100558,0.0017042368],"genre_scores_gemma":[0.9938517,0.00014370019,0.0020973966,0.0014936724,0.0022057581,0.00015514216,0.000017527254,0.0000047252984,0.000030379131],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99597573,0.0014073909,0.0019913882,0.00006691317,0.00040628805,0.00015228042],"domain_scores_gemma":[0.9813543,0.015448673,0.0024652544,0.00006866099,0.0005108879,0.00015221658],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0105405245,0.000044763223,0.00041082603,0.00021611141,0.00019180478,0.000008452142,0.00026496715,0.00015623002,0.00092682394],"category_scores_gemma":[0.03300559,0.000047341706,0.0001258743,0.00024350939,0.00008387571,0.00063669746,0.000020766653,0.0004197289,0.0000029124058],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020389587,0.0026969402,0.043792833,0.000032414868,0.000028372937,7.798833e-7,0.039256617,0.000492846,0.0000053201456,0.00913376,0.0095955925,0.89292556],"study_design_scores_gemma":[0.0024932022,0.0019144437,0.6351489,0.000004204831,0.000014252503,0.000002010555,0.0052815382,0.000086483844,0.0000028963227,0.004042493,0.35096306,0.000046531604],"about_ca_topic_score_codex":0.00026519908,"about_ca_topic_score_gemma":0.0005646531,"teacher_disagreement_score":0.892879,"about_ca_system_score_codex":0.0007521335,"about_ca_system_score_gemma":0.007801664,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W4286293745","doi":"10.1200/jco.2022.40.16_suppl.12113","title":"Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent <i>clostridioides difficile</i> infection: Data from ECOSPOR III, a phase 3 randomized trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"Seres Therapeutics","keywords":"Medicine; Placebo; Internal medicine; Clinical endpoint; Clostridium difficile; Population; Randomized controlled trial; Surgery; Antibiotics; Pathology","score_opus":0.2355751553004312,"score_gpt":0.4961658340741805,"score_spread":0.2605906787737493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98797107,0.0020855258,0.00036331615,0.0050026546,0.0015671065,0.002168944,0.000741092,0.000014050036,0.00008623863],"genre_scores_gemma":[0.99191916,0.0026147733,0.0014344958,0.0008299274,0.0022370166,0.00006343178,0.00077469193,0.0000340584,0.00009242799],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99276257,0.0017179962,0.004024556,0.0004905513,0.0006937717,0.00031058624],"domain_scores_gemma":[0.98429453,0.011501624,0.0025321352,0.00058880454,0.0005456817,0.0005372489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010450317,0.0002411811,0.0028881312,0.00025922692,0.00019988563,0.000021176977,0.00045670668,0.00026599996,0.0006066632],"category_scores_gemma":[0.006437208,0.0001855695,0.00064035127,0.0003271678,0.00062683923,0.00016585014,0.00035155256,0.0013147605,0.0000018253016],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.912317,0.009983506,0.00020346424,0.000045652025,0.0011597237,0.000047189635,0.00009860623,0.00003164438,0.0075264443,0.00007132714,0.0044350945,0.06408034],"study_design_scores_gemma":[0.8798438,0.03912509,0.00055056147,0.000079605605,0.0014080052,0.00017000148,0.000109212226,0.0017977909,0.0020021168,0.00039492338,0.07434663,0.00017226733],"about_ca_topic_score_codex":0.000088070396,"about_ca_topic_score_gemma":0.000028401304,"teacher_disagreement_score":0.06991154,"about_ca_system_score_codex":0.0002327585,"about_ca_system_score_gemma":0.0033569792,"threshold_uncertainty_score":0.77064043},"labels":[],"label_agreement":null},{"id":"W4286293751","doi":"10.1200/jco.2022.40.16_suppl.e13512","title":"Globalization of oncology clinical trials: Which lower-middle and upper-middle income countries are participating?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cohort; Low and middle income countries; Randomized controlled trial; Cohort study; Global health; Clinical trial; Cancer; Family medicine; Internal medicine; Developing country; Public health; Economic growth; Pathology","score_opus":0.31078682811072544,"score_gpt":0.544348003948391,"score_spread":0.23356117583766556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715007,0.0019814484,0.00008716696,0.017274199,0.006469568,0.0003920203,0.000043831657,0.000016461365,0.002234584],"genre_scores_gemma":[0.9865333,0.0023317968,0.0012049577,0.008213355,0.0015619043,0.000019595878,0.000007006051,0.000019078763,0.00010900204],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9807858,0.007751518,0.009804067,0.00033273903,0.00080528436,0.00052061625],"domain_scores_gemma":[0.96506363,0.022229586,0.009627662,0.00033370097,0.0015743055,0.0011711395],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.058352757,0.00019648782,0.0046047135,0.00018934977,0.00016633465,0.000009590417,0.0002165865,0.0006770985,0.00064843753],"category_scores_gemma":[0.07673062,0.00015191575,0.0007474135,0.00043587197,0.0004494016,0.000115793715,0.00022466212,0.0018033404,0.000010047272],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020695103,0.0033210912,0.9260232,0.000258995,0.00036701057,0.0005537662,0.0001509244,0.000050301052,0.0000035587589,0.0008988704,0.010400785,0.03727642],"study_design_scores_gemma":[0.013308301,0.041269634,0.44930613,0.00032539078,0.0007596841,0.0007834332,0.0010113061,0.00057881937,0.000006183738,0.0009684864,0.49152222,0.00016039505],"about_ca_topic_score_codex":0.000046162742,"about_ca_topic_score_gemma":0.00011106476,"teacher_disagreement_score":0.48112145,"about_ca_system_score_codex":0.00035079126,"about_ca_system_score_gemma":0.0056519047,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W4286293765","doi":"10.1200/jco.2022.40.16_suppl.e13536","title":"Survival trends in hilar and extrahepatic cholangiocarcinoma based on Facility type: A National Cancer Database analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cypress Health Region; Saskatchewan Health Authority","funders":"","keywords":"Medicine; Cancer; Internal medicine; Survival analysis; Survival rate; Biliary tract cancer; Cancer registry; Oncology; Gastroenterology; Gemcitabine","score_opus":0.21145231033729564,"score_gpt":0.48463543732228936,"score_spread":0.2731831269849937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98607886,0.0016794099,0.000023132276,0.008995004,0.00079868984,0.000085489475,0.00012177398,0.0000057428974,0.0022119181],"genre_scores_gemma":[0.9961122,0.00014991064,0.0002004509,0.002970281,0.0003293249,0.000012288716,0.000044023567,0.0000063122197,0.00017518498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709064,0.00057566556,0.0012049015,0.00025584246,0.000691687,0.0001812687],"domain_scores_gemma":[0.9976631,0.0011626369,0.00055881706,0.00016104041,0.00025705015,0.0001973955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036252653,0.00012426099,0.0012378719,0.00062373024,0.00007122407,0.000006112366,0.00011635371,0.00008929423,0.0008489589],"category_scores_gemma":[0.0010700763,0.00009870053,0.00040245897,0.0008576504,0.000113395494,0.00005763884,0.000082171544,0.0009835103,0.0000016171537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003871014,0.0010624293,0.9642508,0.000014572268,0.0007006836,0.0004745116,0.00010330749,0.0005123001,0.000021273147,0.000022649472,0.003975719,0.024990715],"study_design_scores_gemma":[0.0056509273,0.00354012,0.96784246,0.000011683409,0.0008100888,0.000032465116,0.00010409066,0.0024627722,0.0000023328437,0.000022237922,0.019436356,0.00008447199],"about_ca_topic_score_codex":0.0001862928,"about_ca_topic_score_gemma":0.0006548083,"teacher_disagreement_score":0.024906242,"about_ca_system_score_codex":0.0003893876,"about_ca_system_score_gemma":0.0010983918,"threshold_uncertainty_score":0.92955047},"labels":[],"label_agreement":null},{"id":"W4286293775","doi":"10.1200/jco.2022.40.16_suppl.5057","title":"Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cholesterol side-chain cleavage enzyme; Androgen receptor; CYP17A1; Medicine; Internal medicine; Endocrinology; Androgen; Pregnenolone; Glucocorticoid receptor; Pharmacology; Hormone; Steroid; CYP3A4; Chemistry; Receptor; Prostate cancer; Cytochrome P450; Enzyme; Cancer; Biochemistry","score_opus":0.05253178606062217,"score_gpt":0.44546713280245953,"score_spread":0.3929353467418374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538934,0.000054480624,0.000005660474,0.0031343065,0.00012656089,0.0011018038,0.00015190935,0.0000032672428,0.000032669337],"genre_scores_gemma":[0.99847484,0.000058464306,0.0010562157,0.00018366108,0.00005308585,0.000089927555,0.000009349092,0.000018808276,0.00005566822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969828,0.00080764724,0.0011086403,0.0002761619,0.00053871865,0.00028599866],"domain_scores_gemma":[0.99544317,0.0027827732,0.00076886563,0.000106175576,0.00057777093,0.00032124564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023258182,0.00016052464,0.0009583053,0.00047971637,0.0000868356,0.000008886254,0.000058184927,0.000055185752,0.000027451446],"category_scores_gemma":[0.0025549012,0.0001108674,0.00011736365,0.00068702723,0.000089901776,0.00013844954,0.000057686735,0.00074525335,7.1253737e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.322248,0.0035986286,0.61683303,0.00003886001,0.00059586845,0.00065691996,0.004710802,0.014631713,0.010711429,0.0000027852282,0.00017837336,0.025793586],"study_design_scores_gemma":[0.020249506,0.071957275,0.9023452,0.0003255391,0.00006817351,0.000018803225,0.0006915882,0.00014971066,0.0038270329,0.000029287408,0.00022310225,0.00011481511],"about_ca_topic_score_codex":0.00026251408,"about_ca_topic_score_gemma":0.00082501967,"teacher_disagreement_score":0.3019985,"about_ca_system_score_codex":0.0016771001,"about_ca_system_score_gemma":0.0028878793,"threshold_uncertainty_score":0.5122974},"labels":[],"label_agreement":null},{"id":"W4286293776","doi":"10.1200/jco.2022.40.16_suppl.5060","title":"Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Brief Pain Inventory; Placebo; Prednisone; Abiraterone acetate; Quality of life (healthcare); Internal medicine; Percentile; Oncology; Cancer; Androgen deprivation therapy; Physical therapy; Pathology; Chronic pain","score_opus":0.10602322050026562,"score_gpt":0.4325382791948476,"score_spread":0.32651505869458197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319303,0.0010125788,0.000016706359,0.004355352,0.000076891316,0.0013004984,0.000030088206,0.000004430691,0.000010413893],"genre_scores_gemma":[0.99720013,0.0005202287,0.0014169696,0.00071009947,0.000016616736,0.000100200516,0.000010311612,0.0000123466625,0.000013104387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921255,0.004170821,0.0028229295,0.0002433631,0.00047773976,0.00015962683],"domain_scores_gemma":[0.9954381,0.0012137691,0.0027183802,0.00015551844,0.00035521222,0.000119005854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009915648,0.0001360277,0.0012691804,0.00019880741,0.00008089962,0.0000083697305,0.00006746115,0.000059727266,0.00001812874],"category_scores_gemma":[0.0005921036,0.00008834973,0.000041924708,0.0003178629,0.00027079656,0.00012326367,0.000030984815,0.0006194919,3.3767048e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032632492,0.007425714,0.93188524,0.00021612502,0.000477256,0.00009793985,0.0083040325,0.0008748136,0.00022462069,0.000027412541,0.00010906821,0.017725285],"study_design_scores_gemma":[0.037959125,0.06593437,0.8924679,0.00011261982,0.00012688704,0.00006335036,0.0028613221,0.000189744,0.000014916296,0.00015731703,0.000034740613,0.00007767435],"about_ca_topic_score_codex":0.0010619428,"about_ca_topic_score_gemma":0.0045099757,"teacher_disagreement_score":0.058508653,"about_ca_system_score_codex":0.00018991523,"about_ca_system_score_gemma":0.001026353,"threshold_uncertainty_score":0.36027974},"labels":[],"label_agreement":null},{"id":"W4286293800","doi":"10.1200/jco.2022.40.16_suppl.e13651","title":"The impact of face-to-face evaluation in the clinical assessment of cancer patients.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Physical examination; Observational study; Cancer; Breast cancer; Prostate cancer; Prospective cohort study; Internal medicine; Head and neck cancer; Family medicine; Physical therapy","score_opus":0.23454203055993547,"score_gpt":0.5302165349370165,"score_spread":0.295674504377081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986265,0.001306036,0.00012117776,0.0037566859,0.0021146387,0.0003879136,0.00009778372,9.3469e-7,0.005949825],"genre_scores_gemma":[0.99742985,0.0013451339,0.0001373703,0.0006955037,0.00030345478,0.000026994265,0.0000017881537,0.000009543135,0.000050368893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937251,0.00069876015,0.0049895276,0.00018512279,0.00017442166,0.00022703169],"domain_scores_gemma":[0.9906653,0.0028716105,0.0058121337,0.00026814447,0.00027576316,0.00010702029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025670657,0.000104164945,0.0012674744,0.00013744991,0.000083197505,0.000012625065,0.0007156123,0.00014335636,0.00036963756],"category_scores_gemma":[0.0044147954,0.000067461995,0.0007078154,0.00024531447,0.00017350711,0.0001349089,0.0001294333,0.0009309666,0.000005594262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053906976,0.0011688529,0.8812036,0.0000031281222,0.00018133293,0.0000014143536,0.00030992128,0.01246098,6.733369e-7,0.0030486013,0.0054795556,0.09560288],"study_design_scores_gemma":[0.00278782,0.006839575,0.94376856,0.000008165065,0.000030619394,0.0000012985469,0.00023514628,0.0020590054,6.348316e-7,0.0057356977,0.03846256,0.0000709064],"about_ca_topic_score_codex":0.0005130901,"about_ca_topic_score_gemma":0.00020920331,"teacher_disagreement_score":0.09553197,"about_ca_system_score_codex":0.00061590836,"about_ca_system_score_gemma":0.0017190627,"threshold_uncertainty_score":0.88969886},"labels":[],"label_agreement":null},{"id":"W4286293801","doi":"10.1200/jco.2022.40.16_suppl.3600","title":"Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; University of Ottawa; McGill University Health Centre; University of Saskatchewan; Université de Montréal; Horizon Health Network; Centre hospitalier universitaire de Québec; Saskatchewan Cancer Agency; Ottawa Hospital; Nova Scotia Cancer Centre; Hôpital Charles-Le Moyne; Université de Sherbrooke; St. John’s Health Sciences Centre; Jewish General Hospital; Queen's University","funders":"","keywords":"Tremelimumab; Durvalumab; Medicine; Blockade; Internal medicine; Hazard ratio; Clinical endpoint; Colorectal cancer; Oncology; Immune checkpoint; Refractory (planetary science); Cancer; Surgical oncology; Gastroenterology; Randomized controlled trial; Immunotherapy; Confidence interval; Nivolumab; Ipilimumab","score_opus":0.09198383425691793,"score_gpt":0.45645490672142286,"score_spread":0.36447107246450494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872187,0.0098854685,0.0000016965064,0.0010495246,0.00070354965,0.00067211327,0.000042295156,0.000006956059,0.00041968937],"genre_scores_gemma":[0.99394315,0.0051805484,0.00031840816,0.00013921493,0.00018065741,0.00008576217,0.000003858286,0.000025217783,0.00012319976],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952828,0.0009465461,0.002727225,0.00024033111,0.0005457169,0.00025734474],"domain_scores_gemma":[0.9910461,0.0059230863,0.0024920204,0.000156919,0.00020816419,0.00017373981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015488511,0.00023650867,0.0029320342,0.00027678531,0.000058919653,0.0000022808993,0.00014755838,0.00009507913,0.00038506647],"category_scores_gemma":[0.0016856281,0.00015567271,0.0009639912,0.0002657893,0.0002682971,0.00004124599,0.000086411266,0.0006616856,0.0000026825353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20235237,0.120615594,0.0924491,0.0007669117,0.01934335,0.011096675,0.0047167405,0.0010497867,0.041062016,0.00010080959,0.001520458,0.5049262],"study_design_scores_gemma":[0.03863626,0.15829915,0.74693936,0.00022934379,0.0029469933,0.00016062043,0.00041530054,0.000042331343,0.036362197,0.000036074594,0.015781753,0.00015061034],"about_ca_topic_score_codex":0.00078402425,"about_ca_topic_score_gemma":0.0003012561,"teacher_disagreement_score":0.6544903,"about_ca_system_score_codex":0.0010366115,"about_ca_system_score_gemma":0.0014846651,"threshold_uncertainty_score":0.63481486},"labels":[],"label_agreement":null},{"id":"W4286293804","doi":"10.1200/jco.2022.40.16_suppl.6598","title":"National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Cancer Society","keywords":"Medicine; Cancer drugs; Medical prescription; Drug prices; Cancer; Observational study; Competition (biology); Drug; Cohort; Ordinary least squares; Internal medicine; Oncology; Pharmacology; Public economics; Econometrics","score_opus":0.15504623829462838,"score_gpt":0.46430494089556673,"score_spread":0.30925870260093835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96678716,0.0050136815,0.000006468868,0.017236168,0.0008925273,0.00007220765,0.00018118994,0.000001348316,0.009809229],"genre_scores_gemma":[0.991918,0.0052120574,0.00007496393,0.0020537137,0.00042945083,0.000010520519,0.0000031546606,0.0000070270603,0.00029109739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975149,0.00018648729,0.0019441557,0.00014262802,0.000058801383,0.00015301706],"domain_scores_gemma":[0.9968342,0.0007992642,0.0021086757,0.00007582056,0.00007612075,0.000105927094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004945603,0.00008011545,0.000803073,0.00022266121,0.000048181744,0.000013723281,0.0002470675,0.00007446424,0.002148838],"category_scores_gemma":[0.0004898211,0.00005991082,0.00036507507,0.0001719544,0.00015665052,0.00013196823,0.00011921242,0.0005855017,0.000005947995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008407999,0.0030029502,0.52595264,0.00003183959,0.0014787205,0.000031735548,0.0019326435,0.03165951,0.000060850478,0.09058986,0.20968111,0.12717013],"study_design_scores_gemma":[0.007299778,0.0010998538,0.79305136,0.00000328512,0.00002328036,0.000038413236,0.000051597835,0.017706107,0.0000019529427,0.025449056,0.15516523,0.00011007316],"about_ca_topic_score_codex":0.00096871535,"about_ca_topic_score_gemma":0.0001410921,"teacher_disagreement_score":0.26709872,"about_ca_system_score_codex":0.00029509902,"about_ca_system_score_gemma":0.00043660827,"threshold_uncertainty_score":0.9987633},"labels":[],"label_agreement":null},{"id":"W4286293820","doi":"10.1200/jco.2022.40.16_suppl.e17018","title":"Pilot trial of physical and cognitive changes related to fall risk in enzalutamide patients with castration-resistant prostate cancer (CRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Physical therapy; Montreal Cognitive Assessment; Cancer; Oncology; Internal medicine; Disease; Androgen receptor; Cognitive impairment","score_opus":0.09699072246260514,"score_gpt":0.4671761462542567,"score_spread":0.37018542379165154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958342,0.00027682257,6.654922e-7,0.0023483548,0.00025243525,0.0009908387,0.00009123613,0.0000026352616,0.00020286388],"genre_scores_gemma":[0.9988819,0.00041011948,0.00007306465,0.00020428338,0.00015160356,0.00006680205,0.000008808845,0.000011889145,0.00019153357],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976736,0.00057629676,0.0009018344,0.00017353956,0.00048668036,0.00018805095],"domain_scores_gemma":[0.9970428,0.0014004577,0.00087475695,0.00006676062,0.00039611862,0.00021911264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001358254,0.0000992288,0.0008736687,0.0001661793,0.000050918254,0.0000040335244,0.000060436527,0.000049739312,0.000039350576],"category_scores_gemma":[0.0010582326,0.00006253203,0.000084445484,0.00024029486,0.00017267201,0.00004784337,0.00006188763,0.0008742477,6.7933235e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5573051,0.0053742924,0.37987188,0.000027597564,0.0004626906,0.0003064052,0.0014520044,0.000046722314,0.0002036384,0.000011462135,0.0001264616,0.054811746],"study_design_scores_gemma":[0.17399713,0.18780129,0.6360245,0.00015206284,0.0003603374,0.000009568759,0.00051502604,0.000026232185,0.000095664014,0.000119668875,0.0008273949,0.000071129456],"about_ca_topic_score_codex":0.0002934739,"about_ca_topic_score_gemma":0.00091305055,"teacher_disagreement_score":0.383308,"about_ca_system_score_codex":0.00019500048,"about_ca_system_score_gemma":0.0013255813,"threshold_uncertainty_score":0.379822},"labels":[],"label_agreement":null},{"id":"W4286293830","doi":"10.1200/jco.2022.40.16_suppl.tps1118","title":"KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Metastatic breast cancer; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Placebo; Immunotherapy; Pathology","score_opus":0.07995130304151785,"score_gpt":0.4552754857975471,"score_spread":0.3753241827560293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900392,0.0006867844,0.00033093707,0.0027867358,0.0008484522,0.0051606544,0.0000287959,0.000012934615,0.000105496256],"genre_scores_gemma":[0.9962495,0.0002946383,0.00093239156,0.0013520758,0.00030386413,0.0005998916,0.0000060929156,0.000060855044,0.00020071573],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910008,0.0022189398,0.004662701,0.00041939263,0.0012460637,0.00045210432],"domain_scores_gemma":[0.99105513,0.0028551337,0.0043870527,0.0003657563,0.000969257,0.00036769683],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005644348,0.00037761612,0.006356704,0.00042646768,0.0000928133,0.000011720943,0.00040193537,0.00013562432,0.0013882845],"category_scores_gemma":[0.00067685265,0.00022327958,0.0005789105,0.0005882421,0.00034762264,0.00019902158,0.000099648336,0.0018257734,0.0000016218902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.862376,0.030326948,0.006744324,0.000054119,0.003276696,0.0003633017,0.0012831481,0.004446819,0.000006533595,0.000007578245,0.00007588446,0.09103866],"study_design_scores_gemma":[0.9208191,0.06873747,0.004758952,0.00018849249,0.0014997912,0.00028153067,0.0015658572,0.00063822215,0.0000058927926,0.00003778321,0.0012600934,0.0002068122],"about_ca_topic_score_codex":0.000225996,"about_ca_topic_score_gemma":0.0003878339,"teacher_disagreement_score":0.090831846,"about_ca_system_score_codex":0.0011314077,"about_ca_system_score_gemma":0.0051848963,"threshold_uncertainty_score":0.9995246},"labels":[],"label_agreement":null},{"id":"W4286293841","doi":"10.1200/jco.2022.40.16_suppl.2545","title":"Baseline peripheral T-cell composition in relation to radiographic phenotypes of immune-related pneumonitis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Pneumonitis; Immune system; CD8; T cell; CXCR3; Immunology; Internal medicine; Gastroenterology; Chemokine; Lung; Chemokine receptor","score_opus":0.04137695127662742,"score_gpt":0.38370161056652324,"score_spread":0.3423246592898958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890167,0.0019252088,0.00011076516,0.0065354635,0.0010845357,0.000210948,0.000004948343,0.000005612038,0.0011058344],"genre_scores_gemma":[0.99685365,0.00057545607,0.0010602404,0.0012216099,0.00015093271,0.000004903695,0.000011271831,0.000011892767,0.000110053974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590695,0.0007888575,0.0027439352,0.00012068637,0.0003066968,0.00013287165],"domain_scores_gemma":[0.997592,0.00065192796,0.0013624101,0.00012109851,0.0001649555,0.000107655025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046269945,0.00008550596,0.000866091,0.00034330023,0.000044894696,0.0000025826841,0.00011594791,0.0001523603,0.0006329996],"category_scores_gemma":[0.00024472864,0.00007413516,0.00051962637,0.00052032585,0.00009837339,0.000059603546,0.00003432112,0.0008687791,0.0000018008077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11246082,0.009923691,0.30804673,0.000104398576,0.00092774484,0.0009388743,0.0015999218,0.0045255665,0.28907114,0.0001381724,0.002771019,0.2694919],"study_design_scores_gemma":[0.019685995,0.02315529,0.93426406,0.00012438478,0.00021369733,0.00046134996,0.00035121088,0.0007114021,0.0006673192,0.00018366345,0.020058135,0.0001234794],"about_ca_topic_score_codex":0.000068772,"about_ca_topic_score_gemma":0.0000132381165,"teacher_disagreement_score":0.6262173,"about_ca_system_score_codex":0.0002313595,"about_ca_system_score_gemma":0.00053812674,"threshold_uncertainty_score":0.69309014},"labels":[],"label_agreement":null},{"id":"W4286294073","doi":"10.1200/jco.2022.40.16_suppl.tps5110","title":"CCTG PR21: A randomized phase II study of [<sup>177</sup>lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; McMaster University; Western University; Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Université Laval; Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Tolerability; Taxane; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Adverse effect; Progression-free survival; Chemotherapy; Population; Progressive disease; Cancer; Urology; Breast cancer","score_opus":0.068962979691834,"score_gpt":0.45872948020305576,"score_spread":0.38976650051122175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992627,0.0014374265,0.000004024112,0.0023080371,0.00017582045,0.0031496906,0.00020232555,0.0000058566434,0.00008977552],"genre_scores_gemma":[0.9981994,0.0005495957,0.0002436071,0.00024181629,0.000107266875,0.00028474614,0.000037068257,0.000026979025,0.00030949878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99406046,0.0017123381,0.0024531882,0.00036535197,0.0010418944,0.00036674843],"domain_scores_gemma":[0.99498725,0.0018483188,0.0017078761,0.00021508778,0.0006845533,0.0005569269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033273303,0.00025149845,0.0024774515,0.00032708247,0.00018545969,0.000015859914,0.00015424569,0.000068037334,0.00017233602],"category_scores_gemma":[0.0012120508,0.00015497855,0.0002817906,0.00037199297,0.00045756146,0.00018521083,0.00014811647,0.0010402278,6.475173e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8229222,0.033388436,0.11467056,0.000113308204,0.0022675144,0.0026234512,0.0039745453,0.0005413253,0.000028049666,0.000014540564,0.00022957995,0.01922645],"study_design_scores_gemma":[0.7382433,0.09167261,0.16209759,0.00019572304,0.0025848618,0.000027841825,0.003949442,0.0005698632,0.000021247255,0.00013311826,0.00033389893,0.00017055332],"about_ca_topic_score_codex":0.0002561589,"about_ca_topic_score_gemma":0.00014301705,"teacher_disagreement_score":0.084678985,"about_ca_system_score_codex":0.00041080167,"about_ca_system_score_gemma":0.003398041,"threshold_uncertainty_score":0.63198423},"labels":[],"label_agreement":null},{"id":"W4286294091","doi":"10.1200/jco.2022.40.16_suppl.tps8074","title":"MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Pfizer","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Combination therapy; Oncology; Clinical endpoint; Pomalidomide; Phases of clinical research; Multiple myeloma; Regimen; Dexamethasone; Refractory (planetary science); Pharmacology; Clinical trial","score_opus":0.07689841356222658,"score_gpt":0.45274538678816556,"score_spread":0.37584697322593896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959984,0.00018396512,0.000010656574,0.0003991855,0.00012793201,0.0031430863,0.000010774084,0.0000038337425,0.00012219793],"genre_scores_gemma":[0.99793947,0.00016687986,0.0014775791,0.00019192572,0.00002369375,0.00010008281,0.000027081585,0.000025558405,0.000047721307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994004,0.0027330858,0.0019568058,0.0003089414,0.0007519504,0.0002452236],"domain_scores_gemma":[0.99543285,0.0022005863,0.001462216,0.00025074717,0.0003506564,0.00030293377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003763626,0.00018022416,0.0020479704,0.00041778845,0.00007215465,0.000015546275,0.0002666494,0.0001103216,0.00010967871],"category_scores_gemma":[0.0014627952,0.00011629911,0.000053120635,0.00028170642,0.00022335017,0.00034401796,0.00012620026,0.0010885061,7.5654066e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5178946,0.09012409,0.3430912,0.000010323963,0.000302938,0.00077707716,0.00052341376,0.00001543254,0.000022368025,0.0000031304714,0.000014079049,0.047221348],"study_design_scores_gemma":[0.5051446,0.14540757,0.34775,0.00004179633,0.000094867006,0.000018263196,0.00055394357,0.00076688325,0.00000484614,0.000013554821,0.00014649854,0.000057182424],"about_ca_topic_score_codex":0.0005202483,"about_ca_topic_score_gemma":0.0009462654,"teacher_disagreement_score":0.05528348,"about_ca_system_score_codex":0.00024232762,"about_ca_system_score_gemma":0.00069212145,"threshold_uncertainty_score":0.474254},"labels":[],"label_agreement":null},{"id":"W4286294211","doi":"10.1200/jco.2022.40.16_suppl.11524","title":"A report on the review of archived osteosarcoma and EWING sarcoma specimens at the Biopathology Center, BONE Sarcoma Committee, Children’s Oncology Group.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"B.C. Women's Hospital & Health Centre","funders":"","keywords":"Medicine; Sarcoma; Biorepository; Osteosarcoma; Medical physics; Quality assurance; Pathology; Bioinformatics; Biobank","score_opus":0.09168260471630847,"score_gpt":0.41072254545473114,"score_spread":0.3190399407384227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.850794,0.03273735,0.0000034409447,0.111689836,0.0008668211,0.0009022009,0.000037150254,0.000009995449,0.0029591923],"genre_scores_gemma":[0.9410629,0.028376563,0.00072464475,0.028852662,0.00065734424,0.00007932855,0.00003944306,0.000038073435,0.00016898497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907158,0.0038914771,0.0038239602,0.00042192457,0.0007218596,0.00042497268],"domain_scores_gemma":[0.98455906,0.010126858,0.004008361,0.0007964772,0.00020371663,0.00030554074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009307194,0.0002937702,0.0026362012,0.00016533564,0.00034837038,0.0000071631803,0.00043229602,0.0001865403,0.0006310811],"category_scores_gemma":[0.0028863393,0.00015303116,0.0010203987,0.00019495939,0.0009021387,0.000038796963,0.00075912755,0.001963067,0.000011718477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004720456,0.013126256,0.74615943,0.00018304429,0.0012830924,0.019615008,0.00022708414,0.0000011759216,0.0003005469,0.0010032183,0.036029845,0.17735086],"study_design_scores_gemma":[0.0075057284,0.020789094,0.6521698,0.0006168992,0.0008101617,0.062038083,0.00014910856,0.000004143795,0.000057143156,0.00028149053,0.25546432,0.00011402076],"about_ca_topic_score_codex":0.00004013916,"about_ca_topic_score_gemma":0.00009265983,"teacher_disagreement_score":0.21943447,"about_ca_system_score_codex":0.0004380917,"about_ca_system_score_gemma":0.00058157626,"threshold_uncertainty_score":0.85286593},"labels":[],"label_agreement":null},{"id":"W4286294233","doi":"10.1200/jco.2022.40.16_suppl.10045","title":"Outcomes of patients with bilateral retinoblastoma: A report from the RIVERBOAT Consortium.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Enucleation; Retinoblastoma; Visual acuity; Pediatrics; Surgery","score_opus":0.05491785469255673,"score_gpt":0.4079018242220167,"score_spread":0.35298396952946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913133,0.00008878677,0.000011116453,0.0064047053,0.0010097459,0.00022385565,0.00002315907,0.000004945629,0.000920416],"genre_scores_gemma":[0.99590695,0.000016445887,0.0013495113,0.0022240835,0.0001612176,0.000005390733,0.000016265136,0.000010702684,0.0003094295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967375,0.00066790596,0.0018112261,0.0001588181,0.000480994,0.00014357759],"domain_scores_gemma":[0.99401194,0.0025184879,0.0027101138,0.0002681601,0.0003505969,0.00014072357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016400898,0.00010966874,0.0012773145,0.000048434627,0.000085532396,0.0000019018797,0.00016573248,0.00014469081,0.00048855535],"category_scores_gemma":[0.0016969555,0.0000537077,0.0004001688,0.00010146065,0.00035695636,0.000046894475,0.000111099536,0.0009071735,0.0000055154123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077946866,0.0033463538,0.97648335,0.0000025035572,0.001488244,0.0038380004,0.00010712984,0.0000070487063,0.000003866895,0.000014716756,0.0023354609,0.004578615],"study_design_scores_gemma":[0.013117323,0.015722713,0.93623894,0.000013422358,0.000913689,0.00038600198,0.000092374634,0.0000031067934,0.000013757476,0.0001791351,0.033272643,0.00004687445],"about_ca_topic_score_codex":0.00003672867,"about_ca_topic_score_gemma":0.000020523654,"teacher_disagreement_score":0.04024441,"about_ca_system_score_codex":0.00011839634,"about_ca_system_score_gemma":0.0010427627,"threshold_uncertainty_score":0.53493387},"labels":[],"label_agreement":null},{"id":"W4286294249","doi":"10.1200/jco.2022.40.16_suppl.tps11591","title":"ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"National Institutes of Health","keywords":"Medicine; Vinorelbine; Cyclophosphamide; Vincristine; Maintenance therapy; Rhabdomyosarcoma; Surgery; Internal medicine; Chemotherapy; Randomized controlled trial; Sarcoma; Pathology; Cisplatin","score_opus":0.10281248392510003,"score_gpt":0.41546596443513495,"score_spread":0.31265348051003494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621993,0.00017896063,0.00003506608,0.001984294,0.00028171795,0.0012301513,0.00005747876,0.0000038378394,0.0000085466645],"genre_scores_gemma":[0.9932458,0.00016883298,0.0052466677,0.0011223147,0.00011334864,0.00005828804,0.0000037880432,0.000017025794,0.000023934139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753845,0.00040487468,0.0013131966,0.00019474124,0.00037607868,0.00017266037],"domain_scores_gemma":[0.99478936,0.0029382005,0.001323254,0.00019323317,0.00050958904,0.0002463607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011568291,0.00012639262,0.0013232903,0.000111963534,0.000074762866,0.000006716197,0.00010667391,0.0000335452,0.000040903768],"category_scores_gemma":[0.00087876315,0.00007519023,0.00020663904,0.00012936833,0.00008467751,0.000053804728,0.00007592429,0.00039956646,6.462895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02549104,0.02434478,0.8949095,0.000005183453,0.0007370547,0.00016304378,0.0002965867,0.000025906676,0.0000016167916,0.000026948737,0.0016951255,0.05230321],"study_design_scores_gemma":[0.03251499,0.12938583,0.82494783,0.00002884786,0.00035893283,0.000028560895,0.00023725868,0.000009556551,0.0000039203364,0.00006457894,0.012359972,0.00005975009],"about_ca_topic_score_codex":0.00021725752,"about_ca_topic_score_gemma":0.00008296896,"teacher_disagreement_score":0.10504104,"about_ca_system_score_codex":0.00010255966,"about_ca_system_score_gemma":0.00024833326,"threshold_uncertainty_score":0.30661687},"labels":[],"label_agreement":null},{"id":"W4286294352","doi":"10.1200/jco.2022.40.16_suppl.e19062","title":"Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naïve, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Internal medicine; Meta-analysis; Observational study; Retrospective cohort study; Randomized controlled trial; Prospective cohort study; Relative risk; Myelodysplastic syndromes; Oncology; Confidence interval; Bone marrow","score_opus":0.1736590505472295,"score_gpt":0.48266296518030205,"score_spread":0.30900391463307253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60129166,0.2931293,0.001048241,0.09078715,0.0013490195,0.010895897,0.00102568,0.00011860979,0.00035445037],"genre_scores_gemma":[0.8462577,0.101776704,0.009708501,0.025972592,0.00058505224,0.0011595769,0.00017340026,0.00018887153,0.014177646],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9867633,0.0054428168,0.0057012835,0.0005985848,0.0009802774,0.0005137165],"domain_scores_gemma":[0.96488166,0.026932636,0.0057504377,0.00062970445,0.0010449921,0.0007605999],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015920583,0.00046510182,0.014534028,0.0004934813,0.00021201652,0.000039073173,0.0004032554,0.00048121889,0.00062884705],"category_scores_gemma":[0.011244091,0.00024242989,0.0050237053,0.0011720301,0.00030040136,0.00014682193,0.000112119276,0.0020250003,0.000005621599],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074486863,0.0057797194,0.09182352,0.007150046,0.8715689,0.0067963563,0.00012207712,0.000079798236,0.0000028032052,0.00011325516,0.0077655776,0.0013492407],"study_design_scores_gemma":[0.021470994,0.06115027,0.10591013,0.0008190719,0.8001315,0.0021810178,0.000057144774,0.00029127894,4.9900245e-7,0.00012560368,0.00756236,0.00030010598],"about_ca_topic_score_codex":0.000011535242,"about_ca_topic_score_gemma":0.000034366258,"teacher_disagreement_score":0.244966,"about_ca_system_score_codex":0.0007838883,"about_ca_system_score_gemma":0.0017191676,"threshold_uncertainty_score":0.9970846},"labels":[],"label_agreement":null},{"id":"W4286294356","doi":"10.1200/jco.2022.40.16_suppl.11052","title":"Female representation in oncology leadership in Africa: Analysis of trends in the African organization for cancer research and training in cancer (AORTIC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Representation (politics); Workforce; Medicine; Session (web analytics); Descriptive statistics; Cancer; Internal medicine; Medical education; Oncology; Family medicine; Political science","score_opus":0.6144707541246163,"score_gpt":0.6285102400009321,"score_spread":0.014039485876315871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686521,0.0012925138,0.000067932495,0.028811952,0.00034180185,0.0002567083,0.000005900751,0.0000015014768,0.00056957017],"genre_scores_gemma":[0.99670535,0.0013394785,0.0006161586,0.00090396375,0.0002300528,0.00007460819,0.0000069312255,0.0000101531305,0.00011327324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954169,0.0020083848,0.0017609893,0.00022125072,0.000295056,0.00029741868],"domain_scores_gemma":[0.9919486,0.0068278904,0.00084979634,0.00011778025,0.00019577003,0.000060144263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011065256,0.00007643871,0.0012746213,0.0016738358,0.00004783782,0.0000025171707,0.00019114425,0.00024089427,0.0002787568],"category_scores_gemma":[0.002602086,0.000056791323,0.00011014565,0.004169298,0.00035619465,0.00008021138,0.000035529592,0.0014674091,5.007768e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004919312,0.0015572344,0.7372326,0.000015562451,0.0002155745,0.00021330053,0.028872382,0.0061045787,0.00016848669,0.00022340818,0.00019370846,0.22028384],"study_design_scores_gemma":[0.008532259,0.007623673,0.91754353,0.000037222755,0.00022708086,0.00003656571,0.054513842,0.0016626277,0.00001510029,0.00065085024,0.009091319,0.00006590801],"about_ca_topic_score_codex":0.0003460324,"about_ca_topic_score_gemma":0.015383924,"teacher_disagreement_score":0.22021793,"about_ca_system_score_codex":0.000994535,"about_ca_system_score_gemma":0.0014066831,"threshold_uncertainty_score":0.85845906},"labels":[],"label_agreement":null},{"id":"W4286294365","doi":"10.1200/jco.2022.40.16_suppl.2041","title":"Population-based retrospective analysis of response assessment criteria in patients with glioblastoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; CancerCare Manitoba; University of Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Medicine; Radiation oncologist; Glioblastoma; Radiation therapy; Neurosurgery; Population; Cohort; Oncology; Internal medicine; Cancer; Retrospective cohort study; Progression-free survival; Medical physics; Radiology; Chemotherapy","score_opus":0.0409162105192905,"score_gpt":0.45263434784833323,"score_spread":0.4117181373290427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974596,0.000017372791,0.000018489794,0.0020192033,0.00021561804,0.00017215751,0.000024003326,0.0000024622168,0.000071128816],"genre_scores_gemma":[0.99802274,0.0000025098648,0.0014287293,0.0004716961,0.00003629116,0.0000108016475,0.000013921291,0.000007871269,0.000005418493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964276,0.001118904,0.0016024965,0.00015024807,0.00058362324,0.00011712832],"domain_scores_gemma":[0.99590814,0.0017679011,0.0016247341,0.00016978971,0.0003978274,0.00013162337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031629207,0.00008678966,0.0014639638,0.00072459644,0.00003356495,0.0000031469663,0.000077924466,0.00007793218,0.0005474053],"category_scores_gemma":[0.0011712511,0.00006016114,0.0003994132,0.0008631677,0.00004560808,0.000039175622,0.000031941992,0.00043836536,3.3671557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02848062,0.008382313,0.9583415,0.0000036803415,0.0013764903,0.00028137857,0.00003147536,0.0014826249,0.000020574233,0.00002368628,0.00012220559,0.0014535023],"study_design_scores_gemma":[0.014560886,0.040902615,0.941691,0.00002249949,0.0018250465,0.0000034365337,0.000051210267,0.0006007531,0.000011147967,0.00002590606,0.0002589657,0.000046525056],"about_ca_topic_score_codex":0.00004305009,"about_ca_topic_score_gemma":0.00010140966,"teacher_disagreement_score":0.0325203,"about_ca_system_score_codex":0.00080996176,"about_ca_system_score_gemma":0.00083728915,"threshold_uncertainty_score":0.59937036},"labels":[],"label_agreement":null},{"id":"W4286294367","doi":"10.1200/jco.2022.40.16_suppl.tps12144","title":"The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ear and Head Tumors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Western University; Ontario Clinical Oncology Group; Cancer Care Ontario; McMaster University; London Health Sciences Centre","funders":"Academic Medical Organization of Southwestern Ontario","keywords":"Medicine; Ototoxicity; Tolerability; Head and neck squamous-cell carcinoma; Oncology; Cisplatin; Randomized controlled trial; Internal medicine; Quality of life (healthcare); Hazard ratio; Head and neck cancer; Hearing loss; Radiation therapy; Adverse effect; Confidence interval; Chemotherapy; Audiology","score_opus":0.07987995410677115,"score_gpt":0.46936546336990204,"score_spread":0.38948550926313086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795034,0.00055494445,0.012100345,0.0035588695,0.0009914793,0.0030324033,0.000014274034,0.0000038529156,0.00024043847],"genre_scores_gemma":[0.9924348,0.00007832165,0.0064439727,0.0004200711,0.00038162983,0.00015219419,0.000006740855,0.0000151204795,0.00006714447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99650365,0.0007312809,0.0021256634,0.00016070878,0.0002967959,0.00018187819],"domain_scores_gemma":[0.98407453,0.012691598,0.0025657103,0.000102018144,0.00040669748,0.00015944087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006482244,0.00012155862,0.001826431,0.000058492482,0.00015321127,0.000008798709,0.00010170545,0.000090227535,0.00001481732],"category_scores_gemma":[0.0030242421,0.000069890724,0.00050494645,0.00006743049,0.00025339203,0.00006076501,0.000036301368,0.000661819,5.804943e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9534061,0.0013709153,0.004874173,0.00011274971,0.00017813533,0.000020086422,0.00039282368,0.00021117617,0.0002547521,0.00047062937,0.00066127547,0.038047194],"study_design_scores_gemma":[0.8873063,0.077382594,0.014811876,0.00005940387,0.0006322315,0.00008735634,0.00055182073,0.012245921,0.00043256304,0.0002523523,0.006146132,0.00009147202],"about_ca_topic_score_codex":0.000006705957,"about_ca_topic_score_gemma":0.000021215426,"teacher_disagreement_score":0.07601168,"about_ca_system_score_codex":0.00021110875,"about_ca_system_score_gemma":0.0017357384,"threshold_uncertainty_score":0.36205187},"labels":[],"label_agreement":null},{"id":"W4286294385","doi":"10.1200/jco.2022.40.16_suppl.3119","title":"Clinical utility of tumor next-generational sequencing (NGS) panel testing to inform treatment decisions for patients with advanced solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; Precision medicine; Cancer; Companion diagnostic; Family medicine; Pathology","score_opus":0.19048666912548062,"score_gpt":0.43843466699285694,"score_spread":0.2479479978673763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996402,0.00009257396,0.0017082652,0.00029811973,0.000752443,0.00038276945,0.00016095492,0.0000020348534,0.00020083369],"genre_scores_gemma":[0.95423824,0.0000723236,0.043647144,0.0012999143,0.0006091989,0.0000374571,0.000052691892,0.000015822316,0.000027197797],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967342,0.00015564631,0.0023758255,0.00025646912,0.0002619718,0.00021588017],"domain_scores_gemma":[0.99441475,0.002481513,0.0017039081,0.00022416614,0.0008960976,0.00027955917],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018603147,0.00013765752,0.0008290237,0.000055637764,0.00015015685,0.00000989355,0.0002449593,0.00010691927,0.000027974858],"category_scores_gemma":[0.010737173,0.00010680224,0.00034532457,0.00011845032,0.00010189038,0.00000970438,0.00017480414,0.0002511597,7.2850173e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014616306,0.0042774878,0.33974513,0.000015197467,0.000468743,0.000045897792,0.000095141586,0.018179461,0.004383909,0.000108638116,0.0034199806,0.6146441],"study_design_scores_gemma":[0.022330666,0.19753608,0.48769143,0.000072596624,0.0003666599,0.0001199812,0.00046177953,0.0025079548,0.0026286556,0.0006414213,0.28512648,0.0005162942],"about_ca_topic_score_codex":0.000010895595,"about_ca_topic_score_gemma":0.000060595354,"teacher_disagreement_score":0.6141278,"about_ca_system_score_codex":0.00014664365,"about_ca_system_score_gemma":0.0035091862,"threshold_uncertainty_score":0.9975958},"labels":[],"label_agreement":null},{"id":"W4286294387","doi":"10.1200/jco.2022.40.16_suppl.12062","title":"Prevalence of pain symptoms among U.S. adult cancer survivors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Cancer; Breast cancer; Population; Physical therapy; Back pain; Prostate cancer; Internal medicine; Cancer pain; Pathology","score_opus":0.0676659185469602,"score_gpt":0.4372555924011358,"score_spread":0.3695896738541756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825735,0.0007810399,0.00029361004,0.006647162,0.0014170973,0.00026922123,0.000019965195,0.000008042917,0.0023064862],"genre_scores_gemma":[0.9907916,0.00079793145,0.0010957734,0.0050237086,0.0003556201,0.000019208723,0.000001739603,0.000015757738,0.0018986374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944406,0.0018396209,0.002495106,0.00017442308,0.00085455866,0.00019570295],"domain_scores_gemma":[0.9939997,0.0022281385,0.0026837187,0.00025113692,0.00049849803,0.00033877644],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010934026,0.000107773274,0.0011900625,0.00014779367,0.0000392182,0.0000027740978,0.00029931738,0.00008492344,0.003564028],"category_scores_gemma":[0.007878339,0.00008526544,0.0005146654,0.00018605952,0.00023880378,0.000075169446,0.00015757357,0.0008484901,0.0000034723876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025201282,0.0023928115,0.87193376,0.0004484137,0.00052839593,0.00051411317,0.00011179535,0.00013023661,0.000017971826,0.00020578073,0.017277343,0.10391922],"study_design_scores_gemma":[0.0059487424,0.010653938,0.9527665,0.00015250251,0.0012692556,0.00004356309,0.00042234958,0.0011146846,0.000010399323,0.00030310027,0.027214902,0.00010010875],"about_ca_topic_score_codex":0.0001713601,"about_ca_topic_score_gemma":0.000057938865,"teacher_disagreement_score":0.10381911,"about_ca_system_score_codex":0.00012593876,"about_ca_system_score_gemma":0.0011221208,"threshold_uncertainty_score":0.9973469},"labels":[],"label_agreement":null},{"id":"W4286294392","doi":"10.1200/jco.2022.40.16_suppl.11541","title":"Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Tolerability; Sunitinib; Adverse effect; Internal medicine; Clinical endpoint; Quality of life (healthcare); GiST; Gastroenterology; Surgery; Randomized controlled trial; Cancer; Stromal cell","score_opus":0.2290711850459004,"score_gpt":0.5292887835417361,"score_spread":0.30021759849583574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520427,0.000060383085,7.189756e-7,0.0018588213,0.00042496726,0.0019134418,0.000013892589,0.0000054287616,0.00051809486],"genre_scores_gemma":[0.9979377,0.000027371434,0.0014722121,0.00023927583,0.000043462132,0.000216058,0.000009972746,0.00001592748,0.000038069968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327767,0.0019071769,0.003449747,0.00037914334,0.0006083088,0.00037794744],"domain_scores_gemma":[0.9943338,0.0030969388,0.0014844658,0.00031363463,0.00030227719,0.00046886486],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0044188597,0.0002123575,0.0018575228,0.00028088686,0.000066342494,0.000022674714,0.00016127608,0.000067561225,0.00023321887],"category_scores_gemma":[0.0100580435,0.00014918906,0.00015374112,0.0002836091,0.00012469484,0.00013335476,0.00039894896,0.0011061864,0.000002117509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065637395,0.08263019,0.72607666,0.000008627398,0.000207328,0.0077116536,0.00055105594,0.0000030351173,0.0000014892054,0.0000013440616,0.000039095557,0.117132135],"study_design_scores_gemma":[0.1431874,0.1800789,0.67477614,0.00004795848,0.000119817385,0.00014522151,0.00095947314,0.000031478714,0.0000022009185,0.000036138335,0.00054594484,0.00006930097],"about_ca_topic_score_codex":0.0003310068,"about_ca_topic_score_gemma":0.0005097657,"teacher_disagreement_score":0.11706283,"about_ca_system_score_codex":0.0011193109,"about_ca_system_score_gemma":0.0012335253,"threshold_uncertainty_score":0.99828064},"labels":[],"label_agreement":null},{"id":"W4286294457","doi":"10.1200/jco.2022.40.16_suppl.e17570","title":"Evaluating the use of machine learning use in ovarian cancer: A systematic review.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Malignancy; Machine learning; Ovarian cancer; Cancer; Artificial intelligence; Oncology; Internal medicine; Computer science","score_opus":0.2857747185906214,"score_gpt":0.5445571691338327,"score_spread":0.25878245054321125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9165583,0.024245875,0.0005534897,0.055494536,0.0017329471,0.0012607197,0.000004945584,0.000011438295,0.00013771583],"genre_scores_gemma":[0.9485425,0.015222754,0.01010609,0.024521664,0.00056142,0.00005583694,0.0000049654136,0.00004306576,0.00094170053],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99082,0.004529554,0.0035743346,0.00014679469,0.0007372619,0.00019205864],"domain_scores_gemma":[0.98566324,0.009968295,0.003696287,0.00023604135,0.00027034135,0.00016582724],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0217785,0.00010663517,0.0021534394,0.00013677895,0.000092295086,0.000010665508,0.00025406355,0.000078350444,0.00023798853],"category_scores_gemma":[0.081150085,0.00006193942,0.00043314003,0.00031498354,0.00012860015,0.00009751281,0.0001490949,0.0035611019,0.0000011223934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054334784,0.0033900114,0.74062806,0.06007502,0.002033603,0.0027913554,0.0013989594,0.06256231,0.0012859813,0.00046772146,0.008171682,0.1117618],"study_design_scores_gemma":[0.023068395,0.033235386,0.11441183,0.10078072,0.007989086,0.005558551,0.00055992877,0.6321619,0.000009774442,0.00025290696,0.08152222,0.00044932103],"about_ca_topic_score_codex":0.00039246143,"about_ca_topic_score_gemma":0.000029198318,"teacher_disagreement_score":0.62621623,"about_ca_system_score_codex":0.00019662366,"about_ca_system_score_gemma":0.001105912,"threshold_uncertainty_score":0.99873775},"labels":[],"label_agreement":null},{"id":"W4286294460","doi":"10.1200/jco.2022.40.16_suppl.3143","title":"Rapid access to biomarker data in a community setting: Integration of next-generation sequencing into routine pathologic workflow.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; William Osler Health System; University of Toronto","funders":"Pfizer Canada","keywords":"Medicine; Biomarker; Turnaround time; Lung cancer; Oncology; Workflow; Biomarker discovery; Cancer; Internal medicine; Database; Computer science","score_opus":0.3561444716787875,"score_gpt":0.4723952387430519,"score_spread":0.1162507670642644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317604,0.0005520052,0.002798379,0.0022553145,0.0008519477,0.00014256197,0.00003241125,0.0000015166597,0.00018983585],"genre_scores_gemma":[0.98877925,0.0005502492,0.0073892865,0.00262681,0.0004435058,0.0000069977837,0.00018474148,0.000009532001,0.0000096036],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966366,0.0013731726,0.0015155115,0.00018415866,0.0001576515,0.00013287866],"domain_scores_gemma":[0.9975909,0.00056992413,0.0010700461,0.00046888363,0.00020208088,0.00009818109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077296286,0.000093167844,0.00046876987,0.00011108444,0.000089482994,0.000021412787,0.0008290153,0.00016567482,0.00003323824],"category_scores_gemma":[0.006816713,0.00008355359,0.00011395635,0.00019093172,0.000068414876,0.000018877785,0.0011728632,0.0006506621,5.0712407e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002006026,0.0011339881,0.03393774,0.000018375546,0.000103064805,0.00008931303,0.00047436164,0.003582137,0.41635397,0.000041486175,0.012793042,0.5294665],"study_design_scores_gemma":[0.021320367,0.07038442,0.40135854,0.00028877435,0.0005789151,0.0008790265,0.008341476,0.03222917,0.056886822,0.0045214416,0.4016286,0.0015824105],"about_ca_topic_score_codex":0.00021610166,"about_ca_topic_score_gemma":0.0014665006,"teacher_disagreement_score":0.5278841,"about_ca_system_score_codex":0.00014571846,"about_ca_system_score_gemma":0.0010246574,"threshold_uncertainty_score":0.8160735},"labels":[],"label_agreement":null},{"id":"W4286294464","doi":"10.1200/jco.2022.40.16_suppl.5544","title":"Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; PARP inhibitor; Oncology; BRCA mutation; Placebo; Clinical endpoint; Ovarian cancer; Cancer; Clinical trial; Pathology; Poly ADP ribose polymerase; Genetics; Gene","score_opus":0.06077571247806247,"score_gpt":0.3681802976767992,"score_spread":0.30740458519873676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631405,0.000072496034,0.00011655768,0.0018354774,0.00043971796,0.0004579249,0.00006511954,0.0000054665325,0.0006931742],"genre_scores_gemma":[0.9981698,0.00010214841,0.0010396676,0.0005122136,0.00006238456,0.000014332453,0.000041343406,0.000014203051,0.000043934604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673885,0.0007920123,0.001594571,0.00024616468,0.00043239768,0.00019597347],"domain_scores_gemma":[0.99472547,0.002334227,0.0022154844,0.00014482252,0.00043914316,0.00014085337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014161743,0.00014984621,0.0011949855,0.00014716455,0.0000696902,0.0000037195605,0.000078539764,0.00014747094,0.00006973415],"category_scores_gemma":[0.0009586243,0.00010008181,0.000105621955,0.00023949833,0.00025052647,0.000058465077,0.000032758388,0.0007369812,4.6460514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10830764,0.010142429,0.81198525,0.000008426345,0.0004144954,0.0006343896,0.0013433874,0.0002989756,0.00007177011,0.00016277416,0.00024291773,0.06638757],"study_design_scores_gemma":[0.058423303,0.064116985,0.87575483,0.00016872896,0.00018531975,0.00010026313,0.00021237753,0.00013247869,0.00009850953,0.00013591355,0.00057868153,0.000092584196],"about_ca_topic_score_codex":0.00014357513,"about_ca_topic_score_gemma":0.00017430657,"teacher_disagreement_score":0.06629498,"about_ca_system_score_codex":0.0011446611,"about_ca_system_score_gemma":0.0012138659,"threshold_uncertainty_score":0.40812176},"labels":[],"label_agreement":null},{"id":"W4286294471","doi":"10.1200/jco.2022.40.16_suppl.3031","title":"BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Alberta Health Services; McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"FOLFOX; Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Interim analysis; Pharmacodynamics; Gastroenterology; Regimen; Pharmacokinetics; Pharmacology; Colorectal cancer; Oxaliplatin; Cancer; Adverse effect; Clinical trial","score_opus":0.04238617727844382,"score_gpt":0.3963305953709731,"score_spread":0.3539444180925293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998141,0.000023093302,0.00010588566,0.0005025373,0.00029807017,0.00088107964,0.000012142571,0.000009958117,0.00002621735],"genre_scores_gemma":[0.998505,0.000009896833,0.0012082211,0.00017406349,0.0000484217,0.000024046754,0.000004600322,0.000020271997,0.000005502867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947101,0.0012486891,0.0026763312,0.00037535033,0.000678699,0.00031086817],"domain_scores_gemma":[0.9954494,0.0014176157,0.0023264464,0.00022956621,0.00041064798,0.00016627522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003994328,0.00019330361,0.0012246869,0.00026283282,0.00006858078,0.000017316897,0.0002954483,0.000067357076,0.00015741064],"category_scores_gemma":[0.00064317335,0.00015200766,0.00006833944,0.000446152,0.00024346361,0.00036749546,0.00013646304,0.0006670235,0.0000010451057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121000096,0.15990184,0.6516212,0.000036744674,0.000055990087,0.0001795509,0.001441245,0.011947298,0.008991012,0.000013204152,0.000050985695,0.04476082],"study_design_scores_gemma":[0.14164764,0.25225207,0.6022813,0.00017481971,0.00006351298,0.000049508926,0.0010052102,0.0012370382,0.0009542761,0.000068181806,0.000074390766,0.0001921183],"about_ca_topic_score_codex":0.0002591048,"about_ca_topic_score_gemma":0.0009070428,"teacher_disagreement_score":0.092350215,"about_ca_system_score_codex":0.0007420391,"about_ca_system_score_gemma":0.0008715705,"threshold_uncertainty_score":0.61986923},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4286294473","doi":"10.1200/jco.2022.40.16_suppl.10052","title":"Associations between global longitudinal strain (GLS), N-terminal-prohormone brain natriuretic peptide (NT-proBNP) and subsequent cardiomyopathy (CM) in a clinically assessed cohort of childhood cancer survivors exposed to cardiotoxic therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Hazard ratio; Cohort; Proportional hazards model; Ejection fraction; Heart failure; Confidence interval; Cardiology","score_opus":0.09054600251274955,"score_gpt":0.42286524290875044,"score_spread":0.3323192403960009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884441,0.0008420412,0.00018492842,0.0078696385,0.00065141614,0.0012469147,0.0003287678,0.000017072041,0.00041510948],"genre_scores_gemma":[0.99502707,0.00087570964,0.00079816463,0.0020937384,0.0010343873,0.000061513725,0.000041498166,0.000034585,0.000033348057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991864,0.0019689593,0.004035078,0.00051614974,0.0011597343,0.00045605795],"domain_scores_gemma":[0.993795,0.0023326445,0.0023949787,0.0003443991,0.0005664397,0.00056654273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0122601185,0.00029962495,0.003295819,0.0002820004,0.000120209035,0.00002049807,0.0003225228,0.00049913843,0.00006951131],"category_scores_gemma":[0.0041408124,0.00027670403,0.0010750788,0.00078036333,0.00020408274,0.00013089043,0.00013998958,0.0017448476,0.0000011099385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001967656,0.0014469365,0.9456608,0.000026329533,0.0016137315,0.00049399276,0.0005307046,0.00028438497,0.006633676,0.000032820495,0.00040013742,0.040908806],"study_design_scores_gemma":[0.010657823,0.0103293145,0.9753519,0.00010314157,0.0005454864,0.00030958164,0.00032820582,0.000022107768,0.000565662,0.00042310404,0.0011271737,0.00023648323],"about_ca_topic_score_codex":0.0004191807,"about_ca_topic_score_gemma":0.00042263305,"teacher_disagreement_score":0.040672325,"about_ca_system_score_codex":0.0011668704,"about_ca_system_score_gemma":0.003835595,"threshold_uncertainty_score":0.9999685},"labels":[],"label_agreement":null},{"id":"W4286294474","doi":"10.1200/jco.2022.40.16_suppl.e21549","title":"Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Adverse effect; Melanoma; Regimen; Population; Adjuvant; Internal medicine; Ipilimumab; Surgery; Retrospective cohort study; Immunotherapy; Cancer","score_opus":0.06041713287285471,"score_gpt":0.3908551932033071,"score_spread":0.33043806033045237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919746,0.0010376591,0.000008832831,0.003930168,0.0013936887,0.00021011232,0.000004238108,0.0000060600373,0.0014346237],"genre_scores_gemma":[0.9964424,0.0003199891,0.0002545388,0.0019997512,0.00049425516,0.000010133771,0.000005936492,0.000016878306,0.0004561349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652046,0.00036581722,0.0023160388,0.00014491349,0.00044196346,0.00021077799],"domain_scores_gemma":[0.99761033,0.0005124272,0.0014213339,0.00015805717,0.00016508783,0.00013278119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025837822,0.00011970913,0.0010778598,0.00018101133,0.000053962623,0.000005742964,0.00016250725,0.00013869687,0.00087801774],"category_scores_gemma":[0.00033561073,0.00008167242,0.00040505594,0.00020298598,0.00025431174,0.000079749516,0.00007941803,0.0011202869,0.0000032021198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06471877,0.003914673,0.813715,0.000037697457,0.00043390997,0.0012435813,0.0004900139,0.0000093749395,0.00097594684,0.000011766044,0.0008987234,0.11355058],"study_design_scores_gemma":[0.022847356,0.04197097,0.9161143,0.000114881535,0.000100263765,0.00042885874,0.00051838264,0.000004506543,0.0004652124,0.000025182513,0.017309258,0.00010085248],"about_ca_topic_score_codex":0.00004191909,"about_ca_topic_score_gemma":0.000088947476,"teacher_disagreement_score":0.11344973,"about_ca_system_score_codex":0.0004416551,"about_ca_system_score_gemma":0.001172583,"threshold_uncertainty_score":0.96136785},"labels":[],"label_agreement":null},{"id":"W4286294475","doi":"10.1200/jco.2022.40.16_suppl.10535","title":"The role of health information technology in improving awareness of HPV and HPV vaccine among U.S. adults: Insights from the health information national trends survey.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Health Information National Trends Survey; Logistic regression; HPV vaccines; Vaccination; Cervical cancer; Family medicine; Health care; Human papilloma virus; Environmental health; Cancer; HPV infection; Health information; Immunology; Internal medicine","score_opus":0.05739146808281959,"score_gpt":0.4430592706351592,"score_spread":0.3856678025523396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616209,0.0038889388,0.00013759782,0.032483775,0.0003902131,0.00034364263,0.00007819436,0.0000061852857,0.0010505208],"genre_scores_gemma":[0.99730456,0.0012079926,0.0000945221,0.0012172693,0.00009980919,0.000011184111,0.000057546335,0.0000036833549,0.0000034521609],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99493814,0.0009839153,0.0031210142,0.000076507495,0.00069854123,0.0001818745],"domain_scores_gemma":[0.993043,0.0029791198,0.0028628733,0.00014339513,0.0008584064,0.000113187285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008807201,0.00007730541,0.00083061674,0.0003816218,0.0001719388,0.0000089973455,0.0002510053,0.00013773769,0.00015567461],"category_scores_gemma":[0.0041222135,0.000044431887,0.000102024154,0.00063679385,0.00017458387,0.00032617833,0.0001870784,0.0011686429,4.3070156e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028381655,0.0001609892,0.21714504,0.000035814315,0.000040896804,6.0104804e-7,0.00066215533,0.00003995572,9.1669443e-7,0.00037250042,0.00031826875,0.7783847],"study_design_scores_gemma":[0.0048651453,0.005606718,0.96740097,0.00001734478,0.000010156894,0.0000143081,0.0026942326,0.0019674222,0.000007785387,0.001389635,0.015993172,0.0000331145],"about_ca_topic_score_codex":0.0042342884,"about_ca_topic_score_gemma":0.0049476675,"teacher_disagreement_score":0.7783516,"about_ca_system_score_codex":0.00034684324,"about_ca_system_score_gemma":0.0038004862,"threshold_uncertainty_score":0.6741899},"labels":[],"label_agreement":null},{"id":"W4286294477","doi":"10.1200/jco.2022.40.16_suppl.4513","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Clinical endpoint; Population; Internal medicine; Hazard ratio; Oncology; Pembrolizumab; Discontinuation; Cancer; Clinical trial; Confidence interval; Immunotherapy","score_opus":0.11094462871210896,"score_gpt":0.4268923143727819,"score_spread":0.31594768566067294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886141,0.004751151,0.00003886001,0.0026540593,0.0009837771,0.001548747,0.00006147536,0.000017117378,0.0013307349],"genre_scores_gemma":[0.9925219,0.0035332188,0.0019986362,0.00069452985,0.00052006304,0.00026921317,0.000085605374,0.00008198535,0.00029486994],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99243075,0.0010400885,0.0040703313,0.0006473477,0.0011398384,0.00067166303],"domain_scores_gemma":[0.9902175,0.004417338,0.003435482,0.0006469012,0.0007296681,0.0005531068],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031774936,0.00047425475,0.0032894122,0.00091142376,0.00017114785,0.000015373043,0.0004988082,0.0004480873,0.0012843761],"category_scores_gemma":[0.0006078161,0.00035802368,0.0022278312,0.00097454176,0.00028151277,0.00013320903,0.00016982785,0.0015524033,0.000006596179],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81490946,0.0148839755,0.094941854,0.00019989212,0.0020543905,0.004442783,0.0015303286,0.00917034,0.0021949033,0.000022460092,0.0006274443,0.05502216],"study_design_scores_gemma":[0.2051217,0.2750613,0.44777092,0.00014219261,0.0029205438,0.0002163509,0.0008778603,0.0019736437,0.010979792,0.00009992409,0.054253202,0.00058258156],"about_ca_topic_score_codex":0.00010439698,"about_ca_topic_score_gemma":0.00024888176,"teacher_disagreement_score":0.60978776,"about_ca_system_score_codex":0.0011649869,"about_ca_system_score_gemma":0.0022543871,"threshold_uncertainty_score":0.99988717},"labels":[],"label_agreement":null},{"id":"W4286294580","doi":"10.1200/jco.2022.40.16_suppl.tps9146","title":"EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences","keywords":"Medicine; Carboplatin; Lung cancer; Internal medicine; Chemotherapy; Oncology; Pembrolizumab; Cisplatin; Cancer; Phases of clinical research; Paclitaxel; Immunotherapy","score_opus":0.0822613191702985,"score_gpt":0.44876321393303004,"score_spread":0.36650189476273154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371725,0.0012933704,0.00032174223,0.0019204635,0.0006919316,0.0015929792,0.000029697123,0.000012401955,0.00042018192],"genre_scores_gemma":[0.99463105,0.0008108688,0.0013154326,0.0018572317,0.00037489692,0.000119026336,0.00000455866,0.000064142456,0.00082281453],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99396306,0.00071929785,0.0036395474,0.0004122037,0.0008268702,0.00043899767],"domain_scores_gemma":[0.99418104,0.0014233015,0.003380188,0.00038723458,0.00033288545,0.0002953379],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003345583,0.0003453552,0.0030159024,0.00039911893,0.00011074942,0.00001182494,0.00041397865,0.00017137169,0.0015631344],"category_scores_gemma":[0.00025608955,0.00022753088,0.00046627523,0.00071647146,0.00022337247,0.00010666537,0.00008913212,0.0016399227,8.5325996e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75310904,0.032177504,0.09467998,0.00042483452,0.0034016802,0.0027733662,0.008142796,0.0022375588,0.0022389116,0.0000021860342,0.0016910689,0.099121064],"study_design_scores_gemma":[0.6188801,0.28302145,0.05733882,0.00065549323,0.0027448377,0.0014546376,0.0093513625,0.009131739,0.00067673385,0.000019335765,0.016122693,0.0006028013],"about_ca_topic_score_codex":0.0011124031,"about_ca_topic_score_gemma":0.0040870337,"teacher_disagreement_score":0.25084394,"about_ca_system_score_codex":0.0011688937,"about_ca_system_score_gemma":0.006447024,"threshold_uncertainty_score":0.9993496},"labels":[],"label_agreement":null},{"id":"W4286294884","doi":"10.1200/jco.2022.40.16_suppl.7042","title":"Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Azacitidine; Gastroenterology; Internal medicine; Placebo; Bone marrow; Population; Platelet; Surgery; Pathology","score_opus":0.05185352637567781,"score_gpt":0.38777019628409265,"score_spread":0.33591666990841484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896398,0.000053327924,0.0002050614,0.007029562,0.0004678893,0.0016519978,0.000040438586,0.00002927959,0.0008826085],"genre_scores_gemma":[0.9823797,0.000076497454,0.009762371,0.0067094844,0.00036610384,0.00013839189,0.00005059276,0.000069669266,0.000447232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99273944,0.00095085514,0.0031085806,0.00059326657,0.0017456274,0.00086224475],"domain_scores_gemma":[0.99320936,0.0024709825,0.0018537892,0.0005174142,0.0008852615,0.001063174],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0037681672,0.0003959536,0.002929307,0.00068273034,0.00015951453,0.000024018545,0.000696389,0.00028732003,0.00056118995],"category_scores_gemma":[0.0019282991,0.00026550103,0.00030579,0.0010282301,0.0003080904,0.00023328797,0.0004916598,0.0033445754,0.00003549767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13757071,0.00488656,0.8056258,0.000066994915,0.0013661826,0.012797004,0.000311911,0.001423065,0.00042710933,0.000044410386,0.020170111,0.015310124],"study_design_scores_gemma":[0.1612525,0.106643796,0.702741,0.0002584751,0.00067884004,0.0010555694,0.000986961,0.00045235522,0.00032806757,0.00008492921,0.024987848,0.0005296655],"about_ca_topic_score_codex":0.00013294852,"about_ca_topic_score_gemma":0.00024173073,"teacher_disagreement_score":0.102884814,"about_ca_system_score_codex":0.0033170683,"about_ca_system_score_gemma":0.005740809,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W4286294892","doi":"10.1200/jco.2022.40.16_suppl.11009","title":"Assessing the landscape in medical oncology medical education scholarship: A scoping study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Scholarship; Specialty; Medicine; Medical education; MEDLINE; Curriculum; Oncology; Family medicine; Psychology; Pedagogy","score_opus":0.1369151036034087,"score_gpt":0.6214437676744681,"score_spread":0.4845286640710594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8921629,0.0030869062,0.00023353175,0.09117255,0.0076739127,0.00048922846,3.064561e-7,0.000012288842,0.005168352],"genre_scores_gemma":[0.9533193,0.0013735561,0.0019470999,0.039281387,0.0038669182,0.000048477763,0.000002113075,0.000020134901,0.00014098833],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98952246,0.0052796253,0.003092081,0.00027412298,0.0015115292,0.0003201556],"domain_scores_gemma":[0.98590297,0.011018172,0.0019150573,0.0002919883,0.000275905,0.00059589854],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031200493,0.00014356185,0.001587521,0.0002570324,0.0002546724,0.000013325062,0.0006694589,0.0006290178,0.0040675793],"category_scores_gemma":[0.029857485,0.00008856776,0.000301634,0.00044260567,0.00048481725,0.00022530637,0.00022597452,0.0064556696,0.0000070976257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016178116,0.0104864305,0.41427934,0.000016193344,0.00017364525,0.003442546,0.0004888922,0.000029824338,0.0000037478812,0.00013590956,0.002719447,0.5666062],"study_design_scores_gemma":[0.027239835,0.04618107,0.6002294,0.000760853,0.00032780538,0.017568745,0.011811254,0.00073913985,0.0000017141194,0.0016687377,0.2932457,0.00022575758],"about_ca_topic_score_codex":0.000010061184,"about_ca_topic_score_gemma":0.00018894697,"teacher_disagreement_score":0.56638044,"about_ca_system_score_codex":0.0006806268,"about_ca_system_score_gemma":0.038577806,"threshold_uncertainty_score":0.997583},"labels":[],"label_agreement":null},{"id":"W4286294933","doi":"10.1200/jco.2022.40.16_suppl.2042","title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Alberta Children's Hospital; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Université Laval; Hospital for Sick Children; BC Children's Hospital; University of Toronto; SickKids Foundation; Centre hospitalier de l'Université Laval; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Neurofibromatosis; Trametinib; Dysgeusia; Internal medicine; Gastroenterology; Progressive disease; Refractory (planetary science); Glioma; Surgery; Adverse effect; MAPK/ERK pathway; Oncology; Pathology; Disease; Cancer research","score_opus":0.08662136118785654,"score_gpt":0.43331365857666904,"score_spread":0.34669229738881246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840915,0.000011150287,0.0000055812193,0.00025576024,0.00011707444,0.0011373612,0.000029086797,0.000002797853,0.000032037464],"genre_scores_gemma":[0.9992632,0.000007576937,0.00042862928,0.00011168139,0.00010683729,0.000030256302,0.000002260725,0.000017285147,0.00003223963],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975066,0.00040037642,0.0011080778,0.00016033495,0.0006657375,0.00015883031],"domain_scores_gemma":[0.9952717,0.0020128575,0.0019515223,0.00017553961,0.00040984448,0.00017856657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007657632,0.000108040105,0.0007936467,0.00016636394,0.000076764954,0.0000031521254,0.00013286961,0.000043208624,0.000032645257],"category_scores_gemma":[0.00150827,0.00005028311,0.00012759586,0.00032289105,0.00011346303,0.0000824098,0.00007223941,0.00052000734,1.1381381e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39857233,0.10426368,0.4489257,0.00020145546,0.0007585725,0.0008372305,0.00043604444,0.000010797198,0.0008417861,0.000007758489,0.0003942537,0.0447504],"study_design_scores_gemma":[0.06461113,0.46844545,0.46495727,0.000023525026,0.00033275003,0.0001534155,0.00036785132,0.000011731759,0.0003511569,0.000012875099,0.0006927064,0.00004013291],"about_ca_topic_score_codex":0.00000792698,"about_ca_topic_score_gemma":0.000009138595,"teacher_disagreement_score":0.3641818,"about_ca_system_score_codex":0.00006171301,"about_ca_system_score_gemma":0.0012397266,"threshold_uncertainty_score":0.2259202},"labels":[],"label_agreement":null},{"id":"W4286294937","doi":"10.1200/jco.2022.40.16_suppl.e14017","title":"Real-world analysis of outcomes of patients receiving bevacizumab for recurrent glioblastoma in British Columbia.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Temozolomide; Demographics; Internal medicine; Proportional hazards model; Oncology; Glioblastoma; Multivariate analysis; Progression-free survival; Retrospective cohort study; Chemotherapy; Radiosurgery; Overall survival; Surgery; Radiation therapy","score_opus":0.06459525051494117,"score_gpt":0.4327033120342623,"score_spread":0.3681080615193212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977671,0.00012989966,0.0000026347266,0.00087450835,0.0006195425,0.00033311278,0.000095402516,0.0000025652935,0.00017522908],"genre_scores_gemma":[0.9986599,0.00027028716,0.00069189817,0.00017284676,0.00005844922,0.000030038454,0.00001749345,0.000011151785,0.00008793827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552387,0.00038774795,0.0032596164,0.00017964473,0.0004692225,0.00017988893],"domain_scores_gemma":[0.9930514,0.0032418033,0.002872263,0.00016959742,0.0005088821,0.00015606618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022913378,0.000078884,0.0024894725,0.00047434526,0.000038592552,0.0000064892147,0.00014720448,0.00009775993,0.00033976842],"category_scores_gemma":[0.0028449297,0.00008096753,0.0011593394,0.0008354015,0.00007700602,0.000043018572,0.00008982773,0.00038815223,2.3764456e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001954418,0.008525941,0.84207416,0.000026255764,0.0021470375,0.000113940754,0.000052699896,0.00010259127,0.0000032563623,0.000005269045,0.0018337825,0.14316066],"study_design_scores_gemma":[0.012557277,0.02492311,0.9546349,0.0000698672,0.0028522634,0.000007723208,0.00012007392,0.00016244476,0.000009909131,0.00008130383,0.0045228866,0.000058222544],"about_ca_topic_score_codex":0.0013481443,"about_ca_topic_score_gemma":0.11263116,"teacher_disagreement_score":0.14310242,"about_ca_system_score_codex":0.00036848368,"about_ca_system_score_gemma":0.0004889141,"threshold_uncertainty_score":0.903561},"labels":[],"label_agreement":null},{"id":"W4286294939","doi":"10.1200/jco.2022.40.16_suppl.2052","title":"Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Hospital for Sick Children; University of Toronto; SickKids Foundation; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Trk receptor; Medicine; Internal medicine; Oncology; Ependymoma; Gastroenterology; Pathology; Surgery; Neurotrophin; Receptor","score_opus":0.03604645718126428,"score_gpt":0.36955425197417385,"score_spread":0.3335077947929096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754244,0.00027277114,0.000007959734,0.00075140945,0.0007517085,0.00044059873,0.00014058572,0.00000512571,0.00008741561],"genre_scores_gemma":[0.99782246,0.00025892715,0.0011339119,0.00048679922,0.00022411319,0.000008626049,0.000030568375,0.000018260007,0.000016353722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486303,0.00068301114,0.0034654113,0.00023001718,0.00052154745,0.00023699296],"domain_scores_gemma":[0.994411,0.001434702,0.0031471052,0.00019083984,0.00037198325,0.00044438394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025389208,0.00015911614,0.0024243023,0.000117113195,0.00006289472,0.0000042675924,0.00010125375,0.0001682983,0.000080115096],"category_scores_gemma":[0.0009937726,0.000103657054,0.0003111915,0.000112077396,0.0002602134,0.000046970483,0.00016655811,0.0006820196,6.1382383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063841087,0.0076112803,0.9604594,0.00018642245,0.00048115835,0.0005375056,0.000050891453,8.4846454e-7,0.000025794165,0.000080542835,0.0004622366,0.023719817],"study_design_scores_gemma":[0.01564841,0.021989355,0.95672196,0.00016262874,0.00089081185,0.0001294649,0.00017029185,0.00002546037,0.000010261246,0.000003346986,0.0041668476,0.00008114854],"about_ca_topic_score_codex":0.000015796253,"about_ca_topic_score_gemma":0.000004634386,"teacher_disagreement_score":0.023638668,"about_ca_system_score_codex":0.00017543639,"about_ca_system_score_gemma":0.0004990336,"threshold_uncertainty_score":0.42270118},"labels":[],"label_agreement":null},{"id":"W4286295042","doi":"10.1200/jco.2022.40.16_suppl.8033","title":"Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cohort; Visual analogue scale; Quality of life (healthcare); Refractory (planetary science); Progressive disease; Clinical trial; Oncology; Surgery; Disease","score_opus":0.09080855741906677,"score_gpt":0.42029281233436727,"score_spread":0.32948425491530053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964775,0.00030363706,0.00000860383,0.0013423305,0.00022824146,0.0013433292,0.00005000228,0.000017599694,0.00022877699],"genre_scores_gemma":[0.99820846,0.00014211648,0.001003278,0.00027201403,0.000031332504,0.000024966244,0.00018273511,0.000040798215,0.00009431597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98987937,0.0022623257,0.005559757,0.00043405598,0.001352036,0.00051244185],"domain_scores_gemma":[0.990678,0.0020316658,0.0056692953,0.00043078273,0.0006276569,0.0005626129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003170366,0.0002954164,0.002976374,0.0007231391,0.0000987286,0.000010087859,0.00019633022,0.0002890289,0.00012967488],"category_scores_gemma":[0.0028984975,0.00019334904,0.0003021545,0.0008252551,0.00023766397,0.00020581242,0.00009399425,0.00182206,0.0000039933657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07320663,0.01720519,0.89457136,0.00007964105,0.00052325457,0.0011687323,0.0002817068,0.000088889785,0.00013319454,0.000002948045,0.00010439395,0.0126340585],"study_design_scores_gemma":[0.07359406,0.03461929,0.8903295,0.00013926536,0.000060843162,0.0000427788,0.00042011222,0.000086479085,0.000027408376,0.000008524666,0.0005202105,0.00015155431],"about_ca_topic_score_codex":0.0014960028,"about_ca_topic_score_gemma":0.0010935812,"teacher_disagreement_score":0.0174141,"about_ca_system_score_codex":0.00079690624,"about_ca_system_score_gemma":0.0029493987,"threshold_uncertainty_score":0.7916045},"labels":[],"label_agreement":null},{"id":"W4286295068","doi":"10.1200/jco.2022.40.16_suppl.e12547","title":"Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Montreal Clinical Research Institute; Université Laval","funders":"","keywords":"Medicine; Breast cancer; PCSK9; Internal medicine; Stage (stratigraphy); Oncology; Cancer; Triglyceride; Breast disease; Gastroenterology; Cholesterol; Lipoprotein; LDL receptor","score_opus":0.07571733667242873,"score_gpt":0.41526961592420003,"score_spread":0.3395522792517713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910808,0.0025219969,0.00007564972,0.00052133907,0.004736766,0.00007833401,0.000059716098,0.0000012574073,0.00092414557],"genre_scores_gemma":[0.99276733,0.0008162364,0.0004889899,0.000661804,0.0049541635,0.000003814649,0.0000030664576,0.000011228019,0.0002933915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779266,0.00036786817,0.0012954712,0.00017926755,0.00018883379,0.00017590164],"domain_scores_gemma":[0.9983316,0.00016759672,0.0011116759,0.00013756727,0.00012552582,0.00012603309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00228166,0.00008798415,0.0007000417,0.00009300554,0.000049197137,0.0000052304727,0.00017453945,0.0001635225,0.00013998462],"category_scores_gemma":[0.00043559523,0.00008386647,0.00020500686,0.00010257002,0.00016419949,0.00000622872,0.00017656392,0.00047328658,2.0222228e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057937154,0.0012424949,0.10144983,0.00010183795,0.0006214832,0.000057548972,0.0007708383,0.0034447436,0.24648952,0.0005188949,0.019367805,0.62014127],"study_design_scores_gemma":[0.0062240385,0.002693356,0.21043748,0.000018686902,0.00006106093,0.0005073929,0.000697405,0.00007763214,0.00041645364,0.00010546244,0.7786134,0.0001476359],"about_ca_topic_score_codex":0.00035593088,"about_ca_topic_score_gemma":0.0007279183,"teacher_disagreement_score":0.7592456,"about_ca_system_score_codex":0.000079117184,"about_ca_system_score_gemma":0.0015075086,"threshold_uncertainty_score":0.34199756},"labels":[],"label_agreement":null},{"id":"W4286295221","doi":"10.1200/jco.2022.40.16_suppl.e20602","title":"Population kinetics assessment of limited small cell lung cancer (L-SCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Population; Internal medicine; Survival analysis; Area under the curve; Proportional hazards model; Progression-free survival; Nuclear medicine; Oncology; Overall survival","score_opus":0.1782929049983703,"score_gpt":0.5676061630957456,"score_spread":0.3893132580973753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98099166,0.0020257595,0.00016238281,0.010681537,0.0015901086,0.0003003217,0.000011830763,0.000006541446,0.0042298767],"genre_scores_gemma":[0.99164677,0.0016462,0.0042630346,0.0010585042,0.00079636526,0.000017308175,0.0000046546857,0.000014962018,0.0005521988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964147,0.0006183718,0.0019064277,0.0001391306,0.00071570044,0.00020566102],"domain_scores_gemma":[0.9957334,0.0015209469,0.0017926281,0.00016336402,0.0005826232,0.0002070845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029310442,0.00009167038,0.0011668133,0.00016292611,0.000056170666,0.0000031700731,0.00017823598,0.00010910933,0.0005091517],"category_scores_gemma":[0.0013116766,0.00006997089,0.00034106584,0.0002207743,0.00009722389,0.00003414005,0.00021035712,0.0012770068,4.9534367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017006997,0.0023904804,0.95283574,0.00019099124,0.0005521988,0.00024028386,0.00012176698,0.0012330718,0.0014363222,0.00006663833,0.01388805,0.025343781],"study_design_scores_gemma":[0.006089033,0.013826835,0.9344984,0.000066129345,0.000563142,0.00004674938,0.00018691322,0.0015746483,0.000094115574,0.00007151554,0.042914104,0.00006839619],"about_ca_topic_score_codex":0.00015063988,"about_ca_topic_score_gemma":0.0000803916,"teacher_disagreement_score":0.029026054,"about_ca_system_score_codex":0.00080356945,"about_ca_system_score_gemma":0.0019616163,"threshold_uncertainty_score":0.55748546},"labels":[],"label_agreement":null},{"id":"W4286295232","doi":"10.1200/jco.2022.40.16_suppl.2589","title":"The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Oncology; Melanoma; Adverse effect; Cancer; Immunotherapy; Breast cancer; Immune system; Immunology; Cancer research","score_opus":0.1164887187995321,"score_gpt":0.489061600304296,"score_spread":0.3725728815047639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98146844,0.00065942353,4.1950116e-7,0.011711685,0.0043846085,0.00077248435,0.000003838196,0.0000026658452,0.0009964213],"genre_scores_gemma":[0.9934385,0.0012304503,0.000010885824,0.0044040494,0.00077488687,0.000047463625,0.0000012769275,0.000014545779,0.000077965866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98919845,0.0051111095,0.004565156,0.00019515639,0.0006594823,0.00027066979],"domain_scores_gemma":[0.9820027,0.015030758,0.0024573593,0.00032125806,0.00009189808,0.000096060554],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02473898,0.0001414705,0.0015539431,0.00015836088,0.00009898103,0.000008350051,0.00041697366,0.00025429612,0.000107704596],"category_scores_gemma":[0.0075268145,0.00007033252,0.0008789941,0.0003759326,0.0002852312,0.0000478501,0.00006993578,0.0026111354,0.0000023793061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22473061,0.0009542736,0.46557122,0.000009669122,0.00011648922,0.00007552082,0.000098599296,0.00000950861,0.0000016390303,0.0000065985087,0.0009367374,0.30748913],"study_design_scores_gemma":[0.12959978,0.07147972,0.7489308,0.00007967964,0.00008866272,0.000027807604,0.00010416324,0.000012533508,0.000002520103,0.000022989887,0.049596116,0.000055215507],"about_ca_topic_score_codex":0.00009599818,"about_ca_topic_score_gemma":0.00025945256,"teacher_disagreement_score":0.3074339,"about_ca_system_score_codex":0.00040712158,"about_ca_system_score_gemma":0.0009005006,"threshold_uncertainty_score":0.9996899},"labels":[],"label_agreement":null},{"id":"W4286295262","doi":"10.1200/jco.2022.40.16_suppl.e18803","title":"Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Osimertinib; Stage (stratigraphy); Clinical endpoint; Oncology; Interim analysis; Medical record; Population; Clinical trial; Erlotinib; Cancer; Epidermal growth factor receptor","score_opus":0.13300075310156162,"score_gpt":0.5004411818494514,"score_spread":0.3674404287478898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948891,0.000048498696,0.00001580368,0.0025459786,0.00039233884,0.00028286967,0.000023816394,0.000004243388,0.001797354],"genre_scores_gemma":[0.9973279,0.0002116038,0.00014017677,0.0003187508,0.00007713878,0.000010453426,0.0000021840763,0.0000059624344,0.0019058328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967943,0.00048699288,0.0019498575,0.00018715663,0.00039977915,0.0001819464],"domain_scores_gemma":[0.9975786,0.00081020524,0.0011770884,0.00020125246,0.00008360112,0.00014921336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018615612,0.00011801152,0.002124029,0.00047828804,0.000028490862,0.000007600432,0.00014251057,0.000048539878,0.00042691123],"category_scores_gemma":[0.00031927714,0.00008289667,0.0005085825,0.0008032719,0.000055181106,0.000058358262,0.00019209446,0.00036717264,4.857713e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033384417,0.003546408,0.96592623,0.000010075369,0.0035503078,0.0009999801,0.00032461472,0.000057793703,0.0000012318917,0.000056302615,0.00010438151,0.022084218],"study_design_scores_gemma":[0.0102917105,0.02642201,0.95572823,0.0000086814525,0.0026240908,0.000008447585,0.0017886958,0.000071923154,4.895642e-7,0.00001802928,0.0029863955,0.0000513119],"about_ca_topic_score_codex":0.006988615,"about_ca_topic_score_gemma":0.023667555,"teacher_disagreement_score":0.022875603,"about_ca_system_score_codex":0.0006752532,"about_ca_system_score_gemma":0.0003607571,"threshold_uncertainty_score":0.99962395},"labels":[],"label_agreement":null},{"id":"W4286295274","doi":"10.1200/jco.2022.40.16_suppl.5050","title":"Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Abiraterone; Abiraterone acetate; Placebo; Internal medicine; Pharmacokinetics; Urology; Oncology; Pharmacology; Cancer; Androgen deprivation therapy; Androgen receptor; Chemistry; Pathology","score_opus":0.3205997998601303,"score_gpt":0.5146648703228783,"score_spread":0.194065070462748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.924477,0.003570867,0.000070335074,0.06805882,0.0011483923,0.0018201014,0.00029527608,0.000012200692,0.0005470029],"genre_scores_gemma":[0.9759597,0.010646445,0.0013962328,0.009464469,0.0016816715,0.0002195584,0.00009130378,0.00004435494,0.0004962621],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99466044,0.0013206151,0.0025767293,0.00034657473,0.0008269764,0.00026866453],"domain_scores_gemma":[0.9943628,0.002342023,0.002229776,0.0005453831,0.0003124523,0.00020757124],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005050593,0.00019778276,0.0013151332,0.00008504818,0.0001382405,0.000025546231,0.0006084176,0.00007904205,0.0015100826],"category_scores_gemma":[0.0005383856,0.00011104108,0.0001378047,0.00032476112,0.0002596643,0.00017066387,0.00013071713,0.0016019035,0.0000069171942],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87067086,0.005259044,0.005806425,0.000030311992,0.0020116426,0.0021511912,0.0015145646,0.005598471,0.0024415336,0.000035078818,0.045541625,0.058939252],"study_design_scores_gemma":[0.44730628,0.062156454,0.013795983,0.00018638097,0.0007906917,0.00031912507,0.0009597921,0.0028113595,0.0004727871,0.00065863266,0.4702807,0.00026179277],"about_ca_topic_score_codex":0.00070342136,"about_ca_topic_score_gemma":0.000866526,"teacher_disagreement_score":0.4247391,"about_ca_system_score_codex":0.0005056091,"about_ca_system_score_gemma":0.005529054,"threshold_uncertainty_score":0.9994027},"labels":[],"label_agreement":null},{"id":"W4286295289","doi":"10.1200/jco.2022.40.16_suppl.e13644","title":"Iron surveillance and management in gastrointestinal oncology patients: A national survey of physician practice.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; St. Michael's Hospital; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Anemia; Ferritin; Malignancy; Population; Internal medicine; Demographics; Gastrointestinal cancer; Cancer; Iron deficiency; Iron-deficiency anemia; Family medicine; Pediatrics; Environmental health","score_opus":0.09101167811956434,"score_gpt":0.45780767948499845,"score_spread":0.3667960013654341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787224,0.00028029355,0.00005732788,0.0046291277,0.0005109821,0.00023835117,0.000018953699,0.0000027419478,0.015539827],"genre_scores_gemma":[0.98975784,0.00040336014,0.0055226777,0.0040921327,0.00013791957,0.000005455557,0.000015505058,0.000008922242,0.00005619779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957535,0.0017373246,0.0016464726,0.00015261513,0.0005466064,0.0001634716],"domain_scores_gemma":[0.9941363,0.0031867442,0.001822493,0.00008456531,0.0006468264,0.0001231228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008266878,0.00008612287,0.00089619856,0.0001808773,0.00003173554,0.0000023147081,0.000113728696,0.00006134505,0.000064512555],"category_scores_gemma":[0.0073754163,0.00007402943,0.0001091159,0.000220127,0.00016363696,0.00008792327,0.00012408609,0.0007156301,0.0000018325111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011606727,0.007856132,0.8681672,0.000062852596,0.00006283877,0.0002923151,0.00008653637,0.00014400316,0.000012911819,0.000540528,0.0053115045,0.10585641],"study_design_scores_gemma":[0.010656518,0.010321351,0.94193566,0.000019672543,0.000056446912,0.00016267732,0.00040176613,0.00004427191,4.1025302e-7,0.00015847257,0.036191046,0.000051687577],"about_ca_topic_score_codex":0.00009156811,"about_ca_topic_score_gemma":0.00014379545,"teacher_disagreement_score":0.10580472,"about_ca_system_score_codex":0.00017090382,"about_ca_system_score_gemma":0.0009674324,"threshold_uncertainty_score":0.88295954},"labels":[],"label_agreement":null},{"id":"W4286295316","doi":"10.1200/jco.2022.40.16_suppl.e24097","title":"Patient and caregiver-reported acceptability of an automatic phone call offering supportive and palliative care referral for advanced non-small cell lung cancer patients.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Alberta Health Services; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Palliative care; Referral; Family medicine; Psychological intervention; Lung cancer; Likert scale; Distress; Nursing; Internal medicine","score_opus":0.16664038068766462,"score_gpt":0.5048861052261611,"score_spread":0.33824572453849644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962893,0.0018066481,0.00010724391,0.00017183424,0.00060411886,0.000683632,0.00012884832,0.0000059227987,0.00020242794],"genre_scores_gemma":[0.9925093,0.0005607409,0.0065192045,0.0002074807,0.0000955115,0.00004377038,0.000028932658,0.000017596769,0.0000174775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966898,0.00031237674,0.0021736333,0.00027381844,0.00033788133,0.00021247617],"domain_scores_gemma":[0.993944,0.0013776046,0.002968968,0.00016118129,0.0012630378,0.00028521073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078494166,0.0001693778,0.0016030669,0.00010125568,0.00006435651,0.0000029282612,0.000098283424,0.00015479371,0.00009613623],"category_scores_gemma":[0.0015415425,0.00013614507,0.00026232106,0.00010980867,0.0002016759,0.00010305782,0.00013536186,0.00052764575,4.9464898e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038615759,0.0013334489,0.8354404,0.0007786519,0.00041440912,0.000071143375,0.023650432,0.00011141173,0.0004447647,0.0000018659338,0.00020452266,0.1336874],"study_design_scores_gemma":[0.0144795785,0.028240737,0.92804056,0.00026410478,0.0009681844,0.000008883476,0.020344064,0.0012864462,0.0033173927,0.000033456854,0.002833605,0.00018298942],"about_ca_topic_score_codex":0.00016825547,"about_ca_topic_score_gemma":0.00014270197,"teacher_disagreement_score":0.13350442,"about_ca_system_score_codex":0.00032947128,"about_ca_system_score_gemma":0.00095151505,"threshold_uncertainty_score":0.5551835},"labels":[],"label_agreement":null},{"id":"W4286295329","doi":"10.1200/jco.2022.40.16_suppl.e13598","title":"Study design of a global molecular disease characterization initiative (MDCI) in oncology clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Protocol (science); Informed consent; Medical physics; Patient recruitment; Compassionate Use; Oncology; Family medicine; Alternative medicine; Internal medicine; Pathology","score_opus":0.2448329620535235,"score_gpt":0.5217701496896715,"score_spread":0.276937187636148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987272,0.0005024447,0.008004757,0.0013270701,0.0019806544,0.0006192092,0.000112362104,0.000001951773,0.0001795545],"genre_scores_gemma":[0.9950997,0.0008980269,0.00096907216,0.0022069619,0.0007308497,0.000035921825,0.000035283934,0.000015087068,0.000009069454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.984786,0.009695132,0.004674634,0.0003280569,0.0003024062,0.00021380078],"domain_scores_gemma":[0.99259967,0.002521808,0.003944018,0.00026275436,0.00034466712,0.00032708718],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020418195,0.00015323372,0.0016697485,0.00007450929,0.00004205959,0.0000073826423,0.0004036685,0.00029448405,0.000054497385],"category_scores_gemma":[0.02212183,0.00014032393,0.0005858516,0.00020800713,0.0001864167,0.0000074550117,0.0003512883,0.0006879579,0.0000014558585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052988905,0.027765235,0.71981066,0.000019500876,0.001408002,0.00320151,0.0002556699,0.008324082,0.008841649,0.0005755301,0.0029192492,0.17389002],"study_design_scores_gemma":[0.02645552,0.09497477,0.81608355,0.000023039946,0.00078053446,0.00010346191,0.0010188085,0.00048190786,0.00023770158,0.0016594884,0.057805687,0.00037550577],"about_ca_topic_score_codex":0.000009903189,"about_ca_topic_score_gemma":0.000032010787,"teacher_disagreement_score":0.17351452,"about_ca_system_score_codex":0.00020795492,"about_ca_system_score_gemma":0.005396496,"threshold_uncertainty_score":0.9861153},"labels":[],"label_agreement":null},{"id":"W4286295482","doi":"10.1200/jco.2022.40.16_suppl.e23555","title":"Metastasectomy in synovial sarcoma: A systematic review.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Metastasectomy; Cohort; Checklist; Sarcoma; MEDLINE; Cohort study; Malignancy; Surgery; Retrospective cohort study; Systematic review; Internal medicine; Metastasis; Cancer; Pathology","score_opus":0.13712709831136985,"score_gpt":0.48685670904620665,"score_spread":0.34972961073483677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7970665,0.15696767,0.00001881603,0.038617726,0.002119713,0.0021060824,0.000014578575,0.000014969671,0.0030739524],"genre_scores_gemma":[0.9823206,0.004578026,0.0008414124,0.011807939,0.00026475417,0.00009198195,0.0000033307076,0.000013073324,0.0000788993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942904,0.0016109736,0.00327886,0.00013956631,0.00050607906,0.00017410249],"domain_scores_gemma":[0.99464154,0.0030114888,0.0017737395,0.00022017446,0.00013765883,0.00021541781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073382272,0.00010760817,0.0029006768,0.0001672889,0.000035354937,0.0000031537688,0.00016370161,0.000073938405,0.000569798],"category_scores_gemma":[0.0049808207,0.00006957064,0.00074675493,0.00025263813,0.00004821013,0.000040734285,0.00008783661,0.00092652516,0.000021632235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00821915,0.08370182,0.5368072,0.10612759,0.0062245866,0.111271895,0.00033856774,0.00004714838,0.00005025943,0.0017554645,0.10209122,0.043365117],"study_design_scores_gemma":[0.10258674,0.110744394,0.42049184,0.09198083,0.026407449,0.045679115,0.0014288354,0.0002142451,0.000051055078,0.0017300243,0.19789301,0.00079248095],"about_ca_topic_score_codex":0.000015697238,"about_ca_topic_score_gemma":0.000014948511,"teacher_disagreement_score":0.18525408,"about_ca_system_score_codex":0.00035986598,"about_ca_system_score_gemma":0.0009560173,"threshold_uncertainty_score":0.62388885},"labels":[],"label_agreement":null},{"id":"W4286295489","doi":"10.1200/jco.2022.40.16_suppl.e16159","title":"A systematic literature review of the economic evidence for transarterial radioembolization for the treatment of hepatocellular carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Systematic review; Economic evaluation; MEDLINE; Internal medicine; Oncology; Pathology","score_opus":0.1678502282671501,"score_gpt":0.3954657820031051,"score_spread":0.22761555373595502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295489","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2575353,0.7113515,0.007363915,0.0091633815,0.009268518,0.0042763576,0.0007906246,0.0000031378604,0.00024726635],"genre_scores_gemma":[0.88080955,0.116827495,0.00033332253,0.00084010366,0.00083182025,0.0001972651,0.0000031692093,0.000015822916,0.00014145515],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596435,0.00015903144,0.003558184,0.00014704955,0.000039198025,0.00013218833],"domain_scores_gemma":[0.9914031,0.0027241902,0.0054056314,0.00028062597,0.00013585963,0.000050618353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043389383,0.00010565446,0.0018129754,0.000060968607,0.00009131326,0.000010027264,0.00042870746,0.00010295663,0.0000763851],"category_scores_gemma":[0.0015433531,0.000066368535,0.0012286672,0.000081820785,0.00009551587,0.00012901766,0.000017636878,0.00013854096,9.732549e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026941322,0.007849809,0.19120213,0.2626688,0.00960052,0.00003794657,0.01273289,0.009121502,0.00018071404,0.35228696,0.052076716,0.07530067],"study_design_scores_gemma":[0.027731167,0.059363402,0.034925457,0.03182194,0.003254933,0.0002458492,0.00042786694,0.032634955,0.0003368035,0.03120245,0.77725357,0.0008016254],"about_ca_topic_score_codex":0.000018812272,"about_ca_topic_score_gemma":0.000008196341,"teacher_disagreement_score":0.7251768,"about_ca_system_score_codex":0.00041716194,"about_ca_system_score_gemma":0.00063749956,"threshold_uncertainty_score":0.27064303},"labels":[],"label_agreement":null},{"id":"W4286295491","doi":"10.1200/jco.2022.40.16_suppl.4136","title":"Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Nivolumab; Medicine; Mesothelin; Gemcitabine; Internal medicine; Oncology; Pancreatic cancer; Immunotherapy; Ipilimumab; Tolerability; Deoxycytidine; Gastroenterology; Cancer; Adverse effect","score_opus":0.09108027032456575,"score_gpt":0.47385303167211024,"score_spread":0.38277276134754445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288684,0.002078699,0.0001544959,0.0023737743,0.00021778248,0.001897187,0.000004183529,0.000009409377,0.00037762788],"genre_scores_gemma":[0.9936076,0.002214658,0.00225538,0.0011955891,0.00011339482,0.00012731273,0.000005911416,0.00004879376,0.0004313645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922196,0.002390104,0.0036608789,0.00035630027,0.0009422936,0.0004307765],"domain_scores_gemma":[0.9924873,0.0039905272,0.002400188,0.00041716555,0.00051750545,0.00018728856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006500674,0.00027048725,0.0036993711,0.0006765814,0.000080765094,0.0000064971337,0.00042670764,0.0002642248,0.0008653473],"category_scores_gemma":[0.00089037867,0.00018536228,0.0002486633,0.00087764644,0.00030819935,0.00013279566,0.00005783723,0.0019803818,0.0000023323735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31773204,0.06294539,0.50786906,0.000055710116,0.001313011,0.0035748356,0.008742303,0.00022249002,0.0023727957,0.000054979675,0.00012569774,0.09499168],"study_design_scores_gemma":[0.28153184,0.20613854,0.49726596,0.00008419513,0.00019644598,0.00056694436,0.011464953,0.0009570221,0.00003893772,0.00022928893,0.0013620902,0.00016378412],"about_ca_topic_score_codex":0.0002780981,"about_ca_topic_score_gemma":0.00033043523,"teacher_disagreement_score":0.14319316,"about_ca_system_score_codex":0.0010529385,"about_ca_system_score_gemma":0.0048977355,"threshold_uncertainty_score":0.94749457},"labels":[],"label_agreement":null},{"id":"W4286295495","doi":"10.1200/jco.2022.40.16_suppl.5546","title":"Validation of the integrated prediction model algorithm for outcome of cytoreduction in advanced ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Retrospective cohort study; Ovarian cancer; Cohort; Triage; Stage (stratigraphy); Surgery; Oncology; Youden's J statistic; Cancer; Internal medicine; Algorithm; Predictive value; Emergency medicine","score_opus":0.13366408298817567,"score_gpt":0.4752023374431294,"score_spread":0.3415382544549537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98311085,0.00019590645,0.0045691105,0.008504653,0.0028219724,0.00056883733,0.00013010214,0.000003353282,0.000095233125],"genre_scores_gemma":[0.9871511,0.00020944113,0.012013035,0.0002143939,0.00024227606,0.00006861249,0.000008825683,0.000008675486,0.000083626706],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99745387,0.00022547724,0.001863957,0.000111413334,0.00025756255,0.00008772641],"domain_scores_gemma":[0.9972373,0.00039728658,0.0018402276,0.000121419434,0.00034847943,0.00005528711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017308944,0.00006768434,0.0007536065,0.0000997818,0.000031962663,0.0000011654615,0.00009095733,0.000102934675,0.000055328517],"category_scores_gemma":[0.00056349084,0.000043756427,0.00032835337,0.00020528212,0.00006216603,0.00006271165,0.000028584305,0.0004164858,6.798793e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041948804,0.004083213,0.28173876,0.00005153558,0.0004419956,0.000010309208,0.00026113287,0.058258917,0.0011793486,0.00023757799,0.00097283814,0.6485695],"study_design_scores_gemma":[0.041464828,0.02555688,0.79538554,0.00029213098,0.0015717063,0.00011847266,0.0009456213,0.11435754,0.006524117,0.0020589347,0.0115935085,0.00013072498],"about_ca_topic_score_codex":0.000086575856,"about_ca_topic_score_gemma":0.000023399369,"teacher_disagreement_score":0.64843875,"about_ca_system_score_codex":0.0005578874,"about_ca_system_score_gemma":0.0012976482,"threshold_uncertainty_score":0.23019722},"labels":[],"label_agreement":null},{"id":"W4286295522","doi":"10.1200/jco.2022.40.16_suppl.4559","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Chemotherapy; Carboplatin; Gemcitabine; Oncology; Progressive disease; Chemotherapy regimen; Neutropenia; Bladder cancer; Gastroenterology; Cisplatin; Urothelial carcinoma; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.08168948695276965,"score_gpt":0.41989050533008004,"score_spread":0.3382010183773104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493114,0.00067954755,0.0009979083,0.04541693,0.0019438134,0.0011664997,0.0003390147,0.000019197741,0.00012573536],"genre_scores_gemma":[0.9746945,0.0002907402,0.0045844563,0.017320849,0.00076818775,0.00018517087,0.000037074813,0.00008114683,0.0020378705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948894,0.000638493,0.0027738905,0.00053429493,0.0005930388,0.0005708952],"domain_scores_gemma":[0.9931162,0.004456658,0.0011645178,0.00042397567,0.00031085074,0.00052778795],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002739735,0.00035161548,0.0022506323,0.00024533147,0.00012843864,0.000014013786,0.00043189703,0.0003099511,0.0011792091],"category_scores_gemma":[0.003182833,0.00027600638,0.00078416336,0.00027041635,0.00012783744,0.000103579274,0.00012809299,0.0010881085,0.000020993453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29998228,0.008068592,0.54008436,0.000038501163,0.0009997148,0.0016207789,0.00081361295,0.00012942459,0.00302289,0.000015138211,0.016732559,0.12849213],"study_design_scores_gemma":[0.08190148,0.03556336,0.8032546,0.000081724014,0.00037392526,0.00017266271,0.00015863405,0.00006368115,0.0006071073,0.0003635695,0.07714102,0.0003182587],"about_ca_topic_score_codex":0.00017374301,"about_ca_topic_score_gemma":0.00040542183,"teacher_disagreement_score":0.2631702,"about_ca_system_score_codex":0.0008848465,"about_ca_system_score_gemma":0.0018850621,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W4286295529","doi":"10.1200/jco.2022.40.16_suppl.12057","title":"Using CT-based body composition metrics and frailty index in predicting survival among older adults with cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Simon Fraser University","funders":"","keywords":"Medicine; Proportional hazards model; Cancer; Internal medicine; Sarcopenia; Body mass index; Geriatric oncology; Survival analysis; Gerontology","score_opus":0.1090159546830337,"score_gpt":0.44257263471719116,"score_spread":0.33355668003415745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994735,0.0003218671,0.00079838984,0.0024823935,0.0010919359,0.00032402645,0.000012425734,0.000012185322,0.00022180326],"genre_scores_gemma":[0.9960001,0.000067171146,0.0023891546,0.0009923833,0.0004885842,0.000009511451,0.000006368571,0.000024174082,0.000022546215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962674,0.0007279881,0.0017605834,0.00024929683,0.0007270189,0.00026770477],"domain_scores_gemma":[0.99513745,0.0024767595,0.0016118414,0.00014541729,0.00032168726,0.000306868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031434847,0.00014959369,0.001178484,0.00037849782,0.00010142232,0.000010717447,0.00013649816,0.00014837188,0.00013476943],"category_scores_gemma":[0.001403149,0.000120919045,0.00014809426,0.0005556582,0.00022558434,0.0001392198,0.00009289093,0.0020859954,2.7826061e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004585375,0.0012098348,0.96964455,0.00006488139,0.00013813777,0.0015030283,0.00021876353,0.0034882734,0.00005539755,0.0000027399012,0.00018770709,0.018901331],"study_design_scores_gemma":[0.021261664,0.006253055,0.92193097,0.0005081364,0.0002487886,0.0005450133,0.000627387,0.047892638,0.00004187107,0.0000105440495,0.0005619275,0.00011798284],"about_ca_topic_score_codex":0.0007840804,"about_ca_topic_score_gemma":0.00065402885,"teacher_disagreement_score":0.047713537,"about_ca_system_score_codex":0.0005407367,"about_ca_system_score_gemma":0.0015271995,"threshold_uncertainty_score":0.90627277},"labels":[],"label_agreement":null},{"id":"W4286295642","doi":"10.1200/jco.2022.40.16_suppl.e18604","title":"Association between control group therapy and magnitude of clinical benefit of cancer drugs.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Randomized controlled trial; Placebo; Cancer; Oncology; Clinical Oncology; Logistic regression; Clinical endpoint; Alternative medicine; Pathology","score_opus":0.13749556092351323,"score_gpt":0.41688235798779566,"score_spread":0.27938679706428243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835039,0.006418007,0.000099422155,0.003839611,0.0020152528,0.0001456019,0.00029654856,0.000002874564,0.003678829],"genre_scores_gemma":[0.98700035,0.009594497,0.00044296318,0.001435267,0.0012067416,0.000007287367,0.0000020533766,0.00001537896,0.00029547527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993699,0.0002019221,0.005564916,0.0002149778,0.00010529377,0.00021389793],"domain_scores_gemma":[0.98572475,0.0028622411,0.0108680455,0.00014645976,0.00022625593,0.00017224504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011537002,0.00011590169,0.0026108995,0.00014959589,0.000054918924,0.000008366386,0.00030813506,0.00032501656,0.00062249426],"category_scores_gemma":[0.0021961061,0.00011487764,0.00061551254,0.00010902185,0.00015514258,0.00019008349,0.000078374906,0.000859744,0.000004385425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008214206,0.00045546782,0.84576166,0.000008748173,0.00071643374,0.000002357716,0.00009693514,0.000054227487,0.0000022645302,0.0052836733,0.0013739503,0.14542285],"study_design_scores_gemma":[0.006817248,0.004264031,0.8161776,0.000008906574,0.000078186786,0.000001281924,0.00004727749,0.0000663135,0.0000041833127,0.011732991,0.160705,0.00009696418],"about_ca_topic_score_codex":0.00039410035,"about_ca_topic_score_gemma":0.00007144569,"teacher_disagreement_score":0.15933105,"about_ca_system_score_codex":0.00021685386,"about_ca_system_score_gemma":0.0003576941,"threshold_uncertainty_score":0.6815875},"labels":[],"label_agreement":null},{"id":"W4286295659","doi":"10.1200/jco.2022.40.16_suppl.12114","title":"Patient-reported hope, quality of life (QOL), symptom burden, and coping mechanisms in early phase clinical trial participants.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Coping (psychology); Quality of life (healthcare); Lung cancer; Physical therapy; Clinical trial; Breast cancer; Internal medicine; Cancer; Clinical psychology","score_opus":0.34510368600404184,"score_gpt":0.479676291716037,"score_spread":0.13457260571199514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905923,0.0011742498,0.000632144,0.0020071652,0.00398905,0.00032447826,0.000057966718,0.000005456119,0.0012171692],"genre_scores_gemma":[0.99618125,0.0008375746,0.0006315026,0.0014661122,0.00080043374,0.000015627476,0.0000019915792,0.000018442359,0.000047057132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9875413,0.0005979941,0.010997867,0.00037081534,0.00011796303,0.00037406903],"domain_scores_gemma":[0.98664355,0.0022602885,0.010262446,0.0002679841,0.00013838323,0.00042736338],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017299203,0.00015671416,0.0029862432,0.00024077641,0.000073909534,0.00002077951,0.00028964708,0.0003291624,0.0003374154],"category_scores_gemma":[0.013925104,0.00016488989,0.0005535576,0.00019163106,0.00024026273,0.0002889743,0.00020591644,0.0011602433,0.000009384423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13731016,0.007675718,0.61249524,0.000058712045,0.001180814,0.00024998622,0.0015382518,0.00049397594,0.00002346129,0.06325885,0.0028716712,0.17284316],"study_design_scores_gemma":[0.24044912,0.056885358,0.5168119,0.000048830603,0.00012780204,0.000028644197,0.0006208398,0.0007971414,0.000010550323,0.06012647,0.123480126,0.0006132408],"about_ca_topic_score_codex":0.00045228057,"about_ca_topic_score_gemma":0.00005658138,"teacher_disagreement_score":0.17222992,"about_ca_system_score_codex":0.00016833216,"about_ca_system_score_gemma":0.001033208,"threshold_uncertainty_score":0.994381},"labels":[],"label_agreement":null},{"id":"W4286295669","doi":"10.1200/jco.2022.40.16_suppl.11530","title":"Real-world experience of tyrosine kinase inhibitors in patients (pt) with recurrent bone tumours (BT): A CanSaRCC study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Saskatchewan Cancer Agency; McGill University Health Centre; Hôtel-Dieu de Québec; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Sarcoma; Mucositis; Univariate analysis; Regorafenib; Progression-free survival; Surgery; Gastroenterology; Oncology; Overall survival; Chemotherapy; Cancer; Multivariate analysis; Pathology","score_opus":0.076013502387822,"score_gpt":0.431415457594392,"score_spread":0.35540195520657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962326,0.00043413712,5.2940396e-7,0.0017376032,0.00071672996,0.00054078357,0.000007642966,0.000004457598,0.00032547943],"genre_scores_gemma":[0.9987765,0.00016910581,0.00037713198,0.00035513588,0.0001842137,0.000058341597,0.0000047779745,0.000016602955,0.000058164886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957429,0.0006088653,0.0024112232,0.00023905229,0.0007628937,0.00023507224],"domain_scores_gemma":[0.99655026,0.0008620973,0.001776225,0.00022577183,0.00029863225,0.00028702093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016877657,0.00015630046,0.0015203491,0.00032568537,0.000049686634,0.000003701364,0.00014457614,0.00006148194,0.00015805184],"category_scores_gemma":[0.0006807029,0.00010490872,0.00024541328,0.00046235256,0.00013474461,0.00006219346,0.00011561826,0.0008196124,0.0000013294745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008046954,0.03357246,0.9108645,0.000010104794,0.0001104453,0.0022679267,0.0009139261,0.000025306741,0.000008485785,0.000017803522,0.0010294876,0.04313263],"study_design_scores_gemma":[0.01972043,0.057914194,0.9157833,0.00011220646,0.00023485874,0.00005787756,0.0016642119,0.0000065355835,0.000066203575,0.000012829374,0.0043429127,0.00008446893],"about_ca_topic_score_codex":0.0006529199,"about_ca_topic_score_gemma":0.0012827704,"teacher_disagreement_score":0.043048162,"about_ca_system_score_codex":0.0005650443,"about_ca_system_score_gemma":0.00095529336,"threshold_uncertainty_score":0.42780536},"labels":[],"label_agreement":null},{"id":"W4286295684","doi":"10.1200/jco.2022.40.16_suppl.tps9593","title":"A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncolytic virus; Nivolumab; Pembrolizumab; Radiation therapy; Phases of clinical research; Oncology; Internal medicine; Clinical trial; Dermatology; Immunotherapy; Cancer","score_opus":0.04996168488206171,"score_gpt":0.42721297695134225,"score_spread":0.37725129206928054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956037,0.0006463104,0.000014720292,0.00017734991,0.00032786228,0.0025206178,0.000019178331,0.0000018424171,0.00068845326],"genre_scores_gemma":[0.9987993,0.00008091717,0.00024796874,0.0003911084,0.000124794,0.00013942788,0.000013208806,0.0000354864,0.00016776008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99168706,0.0040600896,0.0028849116,0.0003748627,0.000649006,0.00034407483],"domain_scores_gemma":[0.99483186,0.0014174506,0.0025896374,0.0004144324,0.0005319479,0.00021469616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005928728,0.00021826528,0.00292728,0.00017408734,0.00008647449,0.000013503318,0.00093813596,0.00017899534,0.00014341174],"category_scores_gemma":[0.00162702,0.00015539117,0.0003019745,0.00019882251,0.00020949313,0.00001107451,0.0005015756,0.0009201488,0.000001409341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9349833,0.03713641,0.010423794,0.000008771259,0.00030353898,0.00033448,0.00011291371,0.00097611477,0.0031178386,0.000001253536,0.00024266781,0.012358901],"study_design_scores_gemma":[0.71666926,0.28054264,0.00046270055,0.0000037229545,0.00015072992,0.00003207664,0.0003315542,0.000085191525,0.0007256579,0.000015612624,0.00085091,0.00012995329],"about_ca_topic_score_codex":0.00003124911,"about_ca_topic_score_gemma":0.00015999751,"teacher_disagreement_score":0.24340625,"about_ca_system_score_codex":0.00010960015,"about_ca_system_score_gemma":0.0014951495,"threshold_uncertainty_score":0.6336668},"labels":[],"label_agreement":null},{"id":"W4286295687","doi":"10.1200/jco.2022.40.16_suppl.4149","title":"Comparison of systematic inflammatory prognostic scores in patients with advanced pancreatic adenocarcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ontario Institute for Cancer Research; McGill University Health Centre; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Toronto General Hospital; University of Toronto; Dalhousie University; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Proportional hazards model; Hazard ratio; Oncology; Population; Confidence interval; Pancreatic cancer; Clinical endpoint; Clinical trial; Cancer","score_opus":0.07017949937170496,"score_gpt":0.4163667655716693,"score_spread":0.3461872661999643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996123,0.0016334209,0.000010680819,0.00018635104,0.0004994694,0.0013342297,0.0000047280064,0.000010214051,0.00019786597],"genre_scores_gemma":[0.99778706,0.000017235474,0.0017956585,0.00018840352,0.00008518647,0.00008410603,0.000004973257,0.00002555504,0.000011818168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927416,0.0013568387,0.0044688806,0.00020358576,0.0009724326,0.0002566798],"domain_scores_gemma":[0.99178016,0.0026635374,0.0043963017,0.00031485962,0.00057028554,0.000274832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033102322,0.00017669202,0.002688073,0.00035765787,0.000052532334,0.0000045986917,0.00030334637,0.00014905966,0.00010118103],"category_scores_gemma":[0.0056268875,0.0001266741,0.00034016665,0.0003177667,0.00026150688,0.00010986404,0.00013196966,0.0009598647,0.0000036369215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014080536,0.0038073156,0.9738183,0.0051803603,0.00050485117,0.00036998268,0.00023128228,0.00014568864,0.000010950831,0.00002778085,0.00016992244,0.0016530444],"study_design_scores_gemma":[0.012273211,0.017539676,0.96485335,0.0031393445,0.0011071075,0.000049618415,0.0006306204,0.00017167535,0.00002301383,0.0000384916,0.000060323084,0.000113561444],"about_ca_topic_score_codex":0.0000016863278,"about_ca_topic_score_gemma":0.000004706931,"teacher_disagreement_score":0.013732361,"about_ca_system_score_codex":0.00033170928,"about_ca_system_score_gemma":0.0015854385,"threshold_uncertainty_score":0.67363167},"labels":[],"label_agreement":null},{"id":"W4286295696","doi":"10.1200/jco.2022.40.16_suppl.11001","title":"Challenges faced by female oncologists in sub-Saharan Africa.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia, Okanagan Campus; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Thematic analysis; Focus group; Delphi method; Descriptive statistics; Delphi; Terminology; Medical education; Family medicine; Qualitative research","score_opus":0.2066642743936782,"score_gpt":0.5306666004801863,"score_spread":0.32400232608650814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79910743,0.10118497,0.00024223606,0.056580905,0.006751954,0.00055256725,0.000014982736,0.00003229411,0.035532665],"genre_scores_gemma":[0.9192986,0.06854701,0.003498257,0.0057484177,0.001422429,0.00003396089,0.0000048603324,0.000029234534,0.0014172372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955026,0.001336307,0.0021580893,0.00026973002,0.00039262592,0.00034066214],"domain_scores_gemma":[0.9938752,0.0039847945,0.0015205038,0.0002184178,0.00012738786,0.0002737004],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060871574,0.00015286844,0.0017819303,0.00018105346,0.00008945279,0.000002324475,0.00032887858,0.00043225658,0.0005425238],"category_scores_gemma":[0.0023604082,0.00011774678,0.00039626344,0.00020638296,0.00038444373,0.00009272329,0.00009442866,0.0025462662,0.000016234348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014288706,0.009719802,0.030481271,0.000036670153,0.00043493806,0.0052337055,0.0006518231,0.00025943544,0.0016107726,0.00020390528,0.14324747,0.7938315],"study_design_scores_gemma":[0.01049641,0.025486698,0.06330402,0.000022706221,0.00007416507,0.0010041486,0.00039178142,0.000032538985,0.000040826104,0.00059740926,0.89843774,0.00011156952],"about_ca_topic_score_codex":0.0000027847304,"about_ca_topic_score_gemma":0.000038547423,"teacher_disagreement_score":0.79371995,"about_ca_system_score_codex":0.00066981226,"about_ca_system_score_gemma":0.0014032788,"threshold_uncertainty_score":0.9997549},"labels":[],"label_agreement":null},{"id":"W4286295706","doi":"10.1200/jco.2022.40.16_suppl.7002","title":"MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Medicine; Anemia; Clinical endpoint; Placebo; Myelofibrosis; Gastroenterology; Internal medicine; Randomization; Hematocrit; Ruxolitinib; Randomized controlled trial; Surgery; Urology; Bone marrow; Pathology","score_opus":0.061160090670637865,"score_gpt":0.4143125339813228,"score_spread":0.3531524433106849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615157,0.0002900054,0.0000022214629,0.0005810744,0.0003259734,0.00243022,0.000010126339,0.000008470971,0.00020035279],"genre_scores_gemma":[0.99881256,0.00035276616,0.00027859467,0.00015647519,0.000099026685,0.00022792896,0.000013658273,0.000024753866,0.00003422266],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936061,0.0018526996,0.0032379234,0.0003212004,0.0007121553,0.0002699226],"domain_scores_gemma":[0.99194205,0.0047149924,0.0024606674,0.00021550198,0.00033941437,0.00032738416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027843784,0.00025940148,0.0034673973,0.00033421983,0.00007826463,0.000009455363,0.00012414067,0.00012780579,0.00011512467],"category_scores_gemma":[0.0017959683,0.00016523615,0.0002995209,0.00035473544,0.0002000903,0.0000948885,0.000107897904,0.00067741214,0.0000011838358],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36749178,0.042409264,0.57435334,0.00006183586,0.0016701281,0.00056763645,0.001408526,0.00004755302,0.000032346707,0.000011552297,0.00020706932,0.011739011],"study_design_scores_gemma":[0.70441246,0.15326704,0.13808747,0.00018171115,0.0018671291,0.000085676955,0.0014156094,0.0002126894,0.00009781309,0.0000134348875,0.00023155971,0.00012740734],"about_ca_topic_score_codex":0.00007340449,"about_ca_topic_score_gemma":0.00008098542,"teacher_disagreement_score":0.43626583,"about_ca_system_score_codex":0.00036180232,"about_ca_system_score_gemma":0.0006292471,"threshold_uncertainty_score":0.67381346},"labels":[],"label_agreement":null},{"id":"W4286295712","doi":"10.1200/jco.2022.40.16_suppl.3614","title":"Adiposity in resectable colorectal cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Alberta Health Services","keywords":"Medicine; Sarcopenia; Cohort; Adipose tissue; Internal medicine; Colorectal cancer; Hazard ratio; Retrospective cohort study; Cancer; Proportional hazards model; Quartile; Obesity; Gastroenterology; Oncology","score_opus":0.25423790325939494,"score_gpt":0.5682340303487425,"score_spread":0.3139961270893476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95335215,0.0011896082,0.000006192563,0.036953975,0.0019849562,0.0001303799,0.0000032778992,0.0000055683904,0.0063738725],"genre_scores_gemma":[0.9879806,0.0006738575,0.0011721839,0.008964726,0.0008568897,0.000011242746,0.0000010180933,0.000006776888,0.00033269776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973257,0.0005696658,0.0015266577,0.00009863555,0.00029192888,0.00018738331],"domain_scores_gemma":[0.9978293,0.0009521696,0.00074426737,0.000061033472,0.00015160156,0.00026163255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004836551,0.000049402835,0.00082646863,0.00015173916,0.000076770324,0.0000023462567,0.000105730214,0.00010765424,0.0014445055],"category_scores_gemma":[0.0011103919,0.000042018957,0.00017772305,0.00021752295,0.000064786975,0.00004257997,0.00006576803,0.0018669654,0.0000048575885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011866901,0.0026771852,0.89798886,0.00005727805,0.0000807344,0.001840062,0.00015209596,0.00006727581,0.00049797725,0.0002725643,0.037553523,0.046945542],"study_design_scores_gemma":[0.009542163,0.010857274,0.5904842,0.00006183177,0.000059269652,0.0007014865,0.00016702381,0.00018232342,0.000074897,0.00056411495,0.38725722,0.00004818837],"about_ca_topic_score_codex":0.00013214498,"about_ca_topic_score_gemma":0.00021874109,"teacher_disagreement_score":0.3497037,"about_ca_system_score_codex":0.00051052147,"about_ca_system_score_gemma":0.0023866808,"threshold_uncertainty_score":0.9994683},"labels":[],"label_agreement":null},{"id":"W4286295746","doi":"10.1200/jco.2022.40.16_suppl.2584","title":"Factors associated with acute kidney injury among patients with cancer treated with immune checkpoint inhibitor therapy: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Acute kidney injury; Internal medicine; Interquartile range; Kidney disease; Nephrology; Cancer; Renal replacement therapy; Dialysis; Population; Adverse effect; Creatinine; Oncology","score_opus":0.05894117129586121,"score_gpt":0.3887593888572356,"score_spread":0.3298182175613744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972679,0.000066223525,0.0000049773093,0.0011905977,0.00042388384,0.00088372827,0.00009263267,0.000024907127,0.00004514656],"genre_scores_gemma":[0.99795556,0.000029308027,0.00004818444,0.0014691163,0.00014883842,0.000055049648,0.000097928074,0.00004978945,0.00014622505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961188,0.00068632385,0.0017612099,0.00027125512,0.0008828062,0.0002796454],"domain_scores_gemma":[0.99544126,0.00043392967,0.0029995088,0.00022936314,0.00057438825,0.0003215355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014214983,0.00027289122,0.001518556,0.00020248399,0.00018315435,0.000015456586,0.00017301046,0.00016971798,0.0006197122],"category_scores_gemma":[0.00027682562,0.00014069099,0.00032570376,0.0005694787,0.00016723412,0.00012409738,0.00002830953,0.0010974465,2.457867e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10535745,0.0057103354,0.87878007,0.000004577714,0.0045038993,0.00015229176,0.00018759284,0.000032119053,0.000102606355,1.1761583e-7,0.0003141587,0.004854777],"study_design_scores_gemma":[0.04494175,0.08905416,0.8633776,0.00015171454,0.00083097466,0.0000047504864,0.00018594865,0.000015688458,0.00014503858,9.70831e-7,0.0011162396,0.00017520074],"about_ca_topic_score_codex":0.00079259963,"about_ca_topic_score_gemma":0.00030253382,"teacher_disagreement_score":0.083343826,"about_ca_system_score_codex":0.0008919785,"about_ca_system_score_gemma":0.002881615,"threshold_uncertainty_score":0.6785414},"labels":[],"label_agreement":null},{"id":"W4286295755","doi":"10.1200/jco.2022.40.16_suppl.5531","title":"Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cervical cancer; Oncology; Stage (stratigraphy); Internal medicine; Progression-free survival; Lymph node; Gynecology; Randomized controlled trial; Population; Cancer; Overall survival","score_opus":0.12274704029529901,"score_gpt":0.48269932928276404,"score_spread":0.359952288987465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96853095,0.0013057394,0.000015320484,0.020176169,0.0049449224,0.0010587424,0.000089469926,0.000016501956,0.0038621975],"genre_scores_gemma":[0.9928037,0.0011600166,0.0004824969,0.0024121841,0.002784338,0.00009484846,0.000017237353,0.00004361067,0.00020160332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933873,0.0017818495,0.002035622,0.00046505276,0.0017392116,0.00059099577],"domain_scores_gemma":[0.98944086,0.0078479815,0.0014268666,0.00046117566,0.0002649179,0.00055820314],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046654623,0.0003598952,0.0020919475,0.0002105401,0.00017997598,0.000032281387,0.00055971975,0.0002692219,0.0014383787],"category_scores_gemma":[0.0028566113,0.00018605273,0.00055092026,0.0005235784,0.00026929888,0.00015645032,0.0002547743,0.002459606,0.0000066393786],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8123123,0.0049597323,0.064747356,0.00003943905,0.0008601154,0.001852327,0.0001821978,0.00060014887,0.000010222581,0.00011048575,0.0049803373,0.109345354],"study_design_scores_gemma":[0.4889157,0.15199648,0.31829202,0.00024227364,0.0006846091,0.00013347606,0.0006665123,0.000116471645,0.00000912461,0.00043153125,0.038183436,0.00032834738],"about_ca_topic_score_codex":0.00038212838,"about_ca_topic_score_gemma":0.00058121484,"teacher_disagreement_score":0.32339656,"about_ca_system_score_codex":0.00081322424,"about_ca_system_score_gemma":0.0024450317,"threshold_uncertainty_score":0.99984175},"labels":[],"label_agreement":null},{"id":"W4286295779","doi":"10.1200/jco.2022.40.16_suppl.5073","title":"Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Overweight; Body mass index; Underweight; Internal medicine; Subgroup analysis; Testosterone (patch); Androgen deprivation therapy; Randomized controlled trial; Gynecology; Cancer; Confidence interval","score_opus":0.05860357441995731,"score_gpt":0.46429011962309996,"score_spread":0.4056865452031426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881195,0.0011070587,0.00011750924,0.008119794,0.00019981145,0.0020022683,0.00006714805,0.0000057192456,0.0002612261],"genre_scores_gemma":[0.99702704,0.0016835573,0.00031362174,0.00043528125,0.00018539086,0.0001613873,0.000028153629,0.00002066,0.00014491014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931797,0.0031612604,0.0021430703,0.00034709775,0.00088183983,0.00028706886],"domain_scores_gemma":[0.9852921,0.012308484,0.0015236661,0.00032616,0.00029787802,0.00025171877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008960761,0.00020264779,0.0026159866,0.0003182888,0.00010036324,0.0000090060585,0.0002147847,0.00010140877,0.00029589253],"category_scores_gemma":[0.002152234,0.00010432842,0.00039130446,0.00080551207,0.00036593078,0.00006579898,0.000078115154,0.001435128,4.4193283e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7742444,0.0056649046,0.18825926,0.00001062955,0.0036220113,0.0008150385,0.0002953443,0.007198111,0.000047571146,0.000002258106,0.00013805192,0.019702418],"study_design_scores_gemma":[0.8113387,0.03685403,0.13036844,0.00008324934,0.003803732,0.000005201193,0.0015026956,0.014502797,0.00003338432,0.000026161593,0.0013730739,0.00010851794],"about_ca_topic_score_codex":0.0006273373,"about_ca_topic_score_gemma":0.000539195,"teacher_disagreement_score":0.05789081,"about_ca_system_score_codex":0.00042338547,"about_ca_system_score_gemma":0.0018682719,"threshold_uncertainty_score":0.6234997},"labels":[],"label_agreement":null},{"id":"W4286295785","doi":"10.1200/jco.2022.40.16_suppl.tps6107","title":"A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV<sup>+</sup>) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Ganciclovir; Cancer research; Tolerability; Pembrolizumab; Internal medicine; Oncology; Immunology; Virus; Cancer; Immunotherapy; Radiation therapy; Adverse effect","score_opus":0.02019828733133715,"score_gpt":0.35343665774943883,"score_spread":0.33323837041810167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980051,0.00024629987,0.0000028657573,0.00019739964,0.0000765835,0.0013702223,0.00004293273,0.0000036107401,0.000054981396],"genre_scores_gemma":[0.99940526,0.00003744801,0.00015483455,0.0002924031,0.000012587066,0.000033856522,0.000032068303,0.000027387794,0.00000413096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958808,0.000917832,0.0017639518,0.00035475887,0.0007600605,0.00032263435],"domain_scores_gemma":[0.99695253,0.00059947924,0.0016940563,0.00012879456,0.00041059838,0.00021451007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001108859,0.0002402875,0.0016924501,0.00048751355,0.000062432635,0.000007999933,0.00010801396,0.00008414752,0.0000150437045],"category_scores_gemma":[0.00046232605,0.0001747856,0.000058168127,0.000574546,0.00018734815,0.00023330019,0.00006807173,0.001102094,1.400324e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112351075,0.0292049,0.83109605,0.000042944837,0.0001800915,0.00045568895,0.0029409195,0.00061209605,0.0000026818652,0.0000031128104,0.000017135933,0.023093304],"study_design_scores_gemma":[0.21387446,0.16785377,0.6146037,0.00014820065,0.00018057616,0.00001183411,0.0028838264,0.0003004554,0.0000034176712,0.00002067592,0.000004354895,0.00011470315],"about_ca_topic_score_codex":0.00025392452,"about_ca_topic_score_gemma":0.000972286,"teacher_disagreement_score":0.21649233,"about_ca_system_score_codex":0.0005610083,"about_ca_system_score_gemma":0.0009192562,"threshold_uncertainty_score":0.71275496},"labels":[],"label_agreement":null},{"id":"W4286295814","doi":"10.1200/jco.2022.40.16_suppl.e13587","title":"Canadian oncology residents’ knowledge of and attitudes towards artificial intelligence and machine learning.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Artificial intelligence; Oncology; Radiation oncology; Thematic analysis; Curriculum; Internal medicine; Medical education; Perception; Family medicine; Psychology; Qualitative research; Radiation therapy; Computer science","score_opus":0.4808149758248864,"score_gpt":0.573191379401539,"score_spread":0.09237640357665255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686804,0.0035047464,0.00010260796,0.024432968,0.0014877185,0.00016076425,0.000004214918,0.0000046498303,0.0016219474],"genre_scores_gemma":[0.9950724,0.002278201,0.0008220317,0.0009292262,0.0006600666,0.000004384526,0.0000029854002,0.0000097659085,0.00022092977],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99662423,0.00076046644,0.0020429508,0.00017127486,0.00018489249,0.00021619035],"domain_scores_gemma":[0.9960137,0.0019000592,0.00095303403,0.00010028222,0.00046283295,0.00057011493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052103694,0.00009097732,0.0008683281,0.00028736974,0.000168939,0.0000063759962,0.00012026459,0.00022370844,0.00040930777],"category_scores_gemma":[0.005055846,0.00007788123,0.0001217796,0.00018691596,0.00030367103,0.000058205376,0.00009404623,0.0014143459,0.000005638783],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011063768,0.0006541393,0.17221119,0.000048732385,0.00007278467,0.000109529086,0.0018283934,0.000037197715,0.00004492127,0.0005924282,0.00050152873,0.82279277],"study_design_scores_gemma":[0.00064932654,0.08002512,0.5626979,0.00020773833,0.00060690247,0.0029223948,0.015144573,0.0034787795,0.001063002,0.015767954,0.31709054,0.0003457805],"about_ca_topic_score_codex":0.033670906,"about_ca_topic_score_gemma":0.058863364,"teacher_disagreement_score":0.822447,"about_ca_system_score_codex":0.00044086683,"about_ca_system_score_gemma":0.0069827233,"threshold_uncertainty_score":0.99864674},"labels":[],"label_agreement":null},{"id":"W4286295815","doi":"10.1200/jco.2022.40.16_suppl.5092","title":"Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Surgery; Chemotherapy; Regimen; Progressive disease; Etoposide; Metastasectomy; Cancer; Docetaxel; Malignancy; Internal medicine; Metastasis; Oncology","score_opus":0.13473257032819377,"score_gpt":0.4766543075741527,"score_spread":0.341921737245959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97810626,0.0032446154,0.000080955055,0.016785387,0.0012828131,0.0002542459,0.000028990167,0.0000051026586,0.00021162914],"genre_scores_gemma":[0.98794806,0.00028426174,0.0007025427,0.009587603,0.0009444591,0.0000761012,0.0000036058045,0.000021563059,0.0004318254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664086,0.00047514663,0.0020295437,0.00019065585,0.00036840336,0.0002953742],"domain_scores_gemma":[0.99517983,0.0033062743,0.00094820623,0.000121648845,0.00017016033,0.00027387723],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003348343,0.00012998813,0.0013923987,0.00016125305,0.0000455122,0.000004857821,0.00012647588,0.00010716954,0.0042128307],"category_scores_gemma":[0.0011113355,0.00009274271,0.00075708283,0.00021508016,0.00011164309,0.000053761847,0.000044334356,0.001302407,0.000007377717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093953304,0.0077193887,0.43645808,0.00014385393,0.00088119134,0.016863562,0.0009508877,0.00006028253,0.000028038048,0.00011051534,0.04843237,0.3943985],"study_design_scores_gemma":[0.01297909,0.010906699,0.7557734,0.00019979033,0.00039581716,0.0048477114,0.0004975601,0.00071706605,0.00006139569,0.0017202164,0.21169963,0.00020158869],"about_ca_topic_score_codex":0.000021738239,"about_ca_topic_score_gemma":0.00004589404,"teacher_disagreement_score":0.39419693,"about_ca_system_score_codex":0.0001844887,"about_ca_system_score_gemma":0.0021219654,"threshold_uncertainty_score":0.9966974},"labels":[],"label_agreement":null},{"id":"W4286295817","doi":"10.1200/jco.2022.40.16_suppl.11536","title":"Second primary malignancies (SPM) in patients with gastrointestinal stromal tumors (GIST): 10-year experience from the Ottawa Hospital (TOH).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; GiST; Cancer; Internal medicine; Stromal tumor; Oncology; Cancer registry; Colorectal cancer; Cohort; Melanoma; Gastroenterology; Stromal cell; Cancer research","score_opus":0.03214689705471082,"score_gpt":0.33579312524414234,"score_spread":0.30364622818943154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933788,0.0001167107,0.000016713302,0.0024744465,0.00063434907,0.00028341758,0.00006202506,0.0000077396135,0.0030258042],"genre_scores_gemma":[0.99127865,0.000008785898,0.0035172582,0.004217929,0.0005426543,0.00001559431,0.00003174123,0.000020857718,0.0003665352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631405,0.0004909247,0.0018654874,0.000287123,0.00070624193,0.00033617803],"domain_scores_gemma":[0.9964399,0.001331227,0.0014457302,0.00027412956,0.00024399164,0.00026504247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014704647,0.00018057607,0.0010989839,0.00007913906,0.000113762464,0.000013602926,0.0004139662,0.00007670285,0.0055903657],"category_scores_gemma":[0.0010436048,0.00011493141,0.0002767554,0.00016503259,0.00041137243,0.0001920307,0.00017624376,0.0016072126,0.000008244439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009015986,0.0014587793,0.9716017,0.000010725662,0.000082229795,0.0010125219,0.0005491904,0.000037377933,0.000056324287,0.000017869284,0.010302351,0.0058549],"study_design_scores_gemma":[0.011532351,0.026813684,0.9243987,0.00007396079,0.000057695575,0.00018139482,0.0013914959,0.000014456703,0.000008262481,0.000023619628,0.035387512,0.000116820134],"about_ca_topic_score_codex":0.000057375077,"about_ca_topic_score_gemma":0.00006804245,"teacher_disagreement_score":0.047203,"about_ca_system_score_codex":0.0004902534,"about_ca_system_score_gemma":0.0025336395,"threshold_uncertainty_score":0.99531865},"labels":[],"label_agreement":null},{"id":"W4286296027","doi":"10.1200/jco.2022.40.16_suppl.e17043","title":"Real-world associations between bone-targeted agents and palliative bone radiotherapy in prostate cancer decedents: A province-wide population study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Enzalutamide; Zoledronic acid; Denosumab; Docetaxel; Oncology; Internal medicine; Abiraterone acetate; Palliative care; Cancer; Androgen deprivation therapy; Radiation therapy; Population; Osteoporosis; Androgen receptor","score_opus":0.13510126777588183,"score_gpt":0.49402637502753605,"score_spread":0.3589251072516542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98492724,0.00039390352,0.000017970971,0.012643721,0.0004284727,0.0013346698,0.000050709463,0.000011545122,0.00019178749],"genre_scores_gemma":[0.99399585,0.0009086568,0.0015189268,0.0022193121,0.00025404675,0.00006508796,0.000040432766,0.00002406647,0.0009736037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944873,0.0015388681,0.0026706583,0.00026405443,0.0007925619,0.00024655732],"domain_scores_gemma":[0.99513817,0.0014662787,0.0027719538,0.00015424236,0.00018497753,0.00028435365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054581943,0.00014859058,0.0014905734,0.00041348653,0.00010223549,0.000015135082,0.0001138886,0.000060799648,0.0002871124],"category_scores_gemma":[0.0024369208,0.0001286961,0.00019716284,0.0003993601,0.000054546443,0.00014942465,0.00010401489,0.00086079363,0.0000010623988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022422518,0.0030322822,0.9694271,0.000025733063,0.000706415,0.0007841108,0.00067048374,0.00011485567,0.0000033599722,0.000027769001,0.0033343441,0.0196313],"study_design_scores_gemma":[0.015265937,0.0045674113,0.9718499,0.000044294862,0.0006759943,0.0000030877936,0.0006498954,0.00025878087,4.0904817e-7,0.00035184657,0.0062281974,0.00010423993],"about_ca_topic_score_codex":0.00091944187,"about_ca_topic_score_gemma":0.0020056276,"teacher_disagreement_score":0.019527059,"about_ca_system_score_codex":0.0010992471,"about_ca_system_score_gemma":0.0009136187,"threshold_uncertainty_score":0.52480745},"labels":[],"label_agreement":null},{"id":"W4286296031","doi":"10.1200/jco.2022.40.16_suppl.4024","title":"Molecular characterization of long-term and short-term survivors of advanced pancreatic ductal adenocarcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McGill University Health Centre; Ontario Institute for Cancer Research; Genome British Columbia; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Internal medicine; Oncology; Pancreatic cancer; Gemcitabine; Chemotherapy; Chemotherapy regimen; Regimen; Clinical trial; Cancer","score_opus":0.08058431793753569,"score_gpt":0.44226283194190447,"score_spread":0.3616785140043688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968797,0.0008529115,0.00021548031,0.00087801355,0.00038419932,0.00031881474,0.0000121918465,0.0000039306206,0.00045478102],"genre_scores_gemma":[0.9975398,0.0012138602,0.0007079406,0.00019317832,0.0001725964,0.000009752295,0.000017646758,0.000016532898,0.0001286839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959698,0.00082446815,0.0022648347,0.00018536451,0.00054123416,0.00021435549],"domain_scores_gemma":[0.99641263,0.0012354428,0.0014586692,0.00021512667,0.00040860905,0.00026954105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028260713,0.00012290345,0.0020169106,0.00021045268,0.00004687963,0.0000023441812,0.00018153212,0.00019564517,0.00029207073],"category_scores_gemma":[0.001395406,0.000099816905,0.00028942619,0.00018928981,0.00043599328,0.00007891093,0.00015785347,0.00079115346,8.974305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003962812,0.0011676475,0.91542244,0.00015011139,0.0005048216,0.0012318626,0.00017699906,0.000003238009,0.06289482,0.00006454668,0.000011167978,0.014409559],"study_design_scores_gemma":[0.0040051737,0.015032984,0.9776115,0.0000821985,0.00079663954,0.0011893162,0.0001434019,0.00007242589,0.00086997973,0.000043044496,0.000082852544,0.00007051434],"about_ca_topic_score_codex":0.000010253746,"about_ca_topic_score_gemma":0.000006377026,"teacher_disagreement_score":0.062189054,"about_ca_system_score_codex":0.0000976309,"about_ca_system_score_gemma":0.0012370991,"threshold_uncertainty_score":0.40704152},"labels":[],"label_agreement":null},{"id":"W4286296035","doi":"10.1200/jco.2022.40.16_suppl.e18630","title":"Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Triage; Adverse effect; Medical emergency; Prioritization; Internal medicine","score_opus":0.17393629695017787,"score_gpt":0.5376151559304593,"score_spread":0.3636788589802814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990258,0.00017616103,0.00015773752,0.0052567828,0.0028106023,0.0010293402,0.000012633981,0.00001077712,0.00028799602],"genre_scores_gemma":[0.84983337,0.00024102432,0.14693066,0.0012747437,0.001358108,0.00007950387,0.000040520765,0.000026913141,0.00021513723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539095,0.0003036349,0.0032328104,0.00018997384,0.0005536208,0.00032899986],"domain_scores_gemma":[0.9947708,0.00094391085,0.0032525708,0.00011521611,0.0005998925,0.00031758254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030225448,0.000120569384,0.001193852,0.00014670867,0.00013339373,0.0000018469235,0.00016448446,0.00015233735,0.0003197831],"category_scores_gemma":[0.00089127943,0.00009565226,0.00022952682,0.00015601271,0.00006770481,0.000046015175,0.000149829,0.00057849335,0.0000012247444],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003852036,0.0014843843,0.30312404,0.00009832117,0.00020483744,0.000035266992,0.0007133452,0.0000032403173,0.000039557723,0.0000060511516,0.0031392123,0.6872997],"study_design_scores_gemma":[0.011144451,0.014621156,0.35277835,0.000051571576,0.00018324736,0.000033855387,0.0005876377,0.0000323343,0.000347534,0.000022904986,0.6201399,0.000057063866],"about_ca_topic_score_codex":0.000041259304,"about_ca_topic_score_gemma":0.0001774132,"teacher_disagreement_score":0.6872426,"about_ca_system_score_codex":0.0012601832,"about_ca_system_score_gemma":0.0035320036,"threshold_uncertainty_score":0.62656224},"labels":[],"label_agreement":null},{"id":"W4286296056","doi":"10.1200/jco.2022.40.16_suppl.12056","title":"Remote symptom monitoring (RSM) during treatment for metastatic prostate cancer (mPC) in older men: Feasibility and efficacy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Cohort; Mood; Anxiety; Prospective cohort study; Cohort study; Physical therapy; Psychological intervention; Internal medicine; Cancer; Psychiatry","score_opus":0.22121105787326412,"score_gpt":0.5433773381928398,"score_spread":0.3221662803195757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987786,0.0040387264,0.000004626159,0.0056723976,0.0012928854,0.0010392267,0.000018050156,0.000007909544,0.0001401886],"genre_scores_gemma":[0.99227244,0.0042518186,0.0015595447,0.00026104992,0.0007299571,0.000078396835,0.000002919447,0.000019547982,0.0008243217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737966,0.00042133243,0.0014492292,0.00026667255,0.00020264217,0.00028047056],"domain_scores_gemma":[0.99701035,0.0016857529,0.0008154495,0.00012013528,0.00011383149,0.00025449682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016570719,0.00015510552,0.0012900457,0.00013983966,0.00009920311,0.000005747532,0.00007400942,0.000080495534,0.00017901152],"category_scores_gemma":[0.00032037892,0.00011539873,0.000312079,0.00012967816,0.00008981689,0.000059729955,0.00005953805,0.00052673306,6.229899e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036736734,0.008592379,0.68696785,0.00014939507,0.0014531049,0.0013384768,0.0017188512,0.0004197655,0.0017594995,0.000006161164,0.00051669125,0.2603411],"study_design_scores_gemma":[0.08267266,0.028176596,0.8626962,0.000086522516,0.0014150275,0.00043679195,0.00046777335,0.00028494498,0.0006987016,0.00016909934,0.022755908,0.00013977707],"about_ca_topic_score_codex":0.00013317965,"about_ca_topic_score_gemma":0.00006471492,"teacher_disagreement_score":0.26020133,"about_ca_system_score_codex":0.0014560327,"about_ca_system_score_gemma":0.001073506,"threshold_uncertainty_score":0.47058237},"labels":[],"label_agreement":null},{"id":"W4286296062","doi":"10.1200/jco.2022.40.16_suppl.e14042","title":"Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Bevacizumab; Regimen; Progression-free survival; Proportional hazards model; Internal medicine; Log-rank test; Glioblastoma; Oncology; Nuclear medicine; Overall survival; Surgery; Chemotherapy","score_opus":0.09889350733138935,"score_gpt":0.4598800816353836,"score_spread":0.3609865743039942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989973,0.00093308964,0.0000025361219,0.006503943,0.0014708074,0.00022523463,0.0000055818696,0.0000044506723,0.0008813713],"genre_scores_gemma":[0.9985454,0.0003209047,0.00032179581,0.00045145876,0.0002950034,0.000011709967,0.0000015430361,0.000012056574,0.000040096267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959545,0.00056247896,0.0025497312,0.0001669603,0.0005746877,0.00019162633],"domain_scores_gemma":[0.9957155,0.002043705,0.0016325468,0.00019219129,0.00017630358,0.00023973182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028050148,0.00010822647,0.0013887488,0.00028494376,0.00003096155,0.000002513761,0.00017101834,0.00012723973,0.00063071196],"category_scores_gemma":[0.001823508,0.00007155682,0.0005506134,0.00023998553,0.00008023258,0.000036009897,0.00013352161,0.0009877421,0.000009781097],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034255084,0.043422993,0.16297303,0.00004247407,0.00073459145,0.00708816,0.00034665913,0.00048319285,0.00042235115,0.00028361485,0.0062953564,0.74365246],"study_design_scores_gemma":[0.058193285,0.10112417,0.75356966,0.00013484001,0.0005647309,0.0011070332,0.0003960647,0.000092915085,0.00065049465,0.000327443,0.08371508,0.00012425348],"about_ca_topic_score_codex":0.000014511321,"about_ca_topic_score_gemma":0.00005745506,"teacher_disagreement_score":0.74352825,"about_ca_system_score_codex":0.0003921589,"about_ca_system_score_gemma":0.0010261979,"threshold_uncertainty_score":0.6905853},"labels":[],"label_agreement":null},{"id":"W4286296163","doi":"10.1200/jco.2022.40.16_suppl.5511","title":"Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Karyopharm Therapeutics","keywords":"Endometrial cancer; Microsatellite instability; Internal medicine; Medicine; Oncology; Placebo; Hazard ratio; Randomization; Cancer; Randomized controlled trial; Pathology; Biology; Confidence interval; Gene; Microsatellite; Genetics","score_opus":0.13704866950052047,"score_gpt":0.5075401047607437,"score_spread":0.37049143526022327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520797,0.0016016412,0.00018834393,0.0007008047,0.00080980494,0.0011733065,0.00004717233,0.0000043887753,0.00026655156],"genre_scores_gemma":[0.99783605,0.0012687809,0.0003264864,0.00011956254,0.0002851656,0.00009789073,0.000009363086,0.000014985006,0.000041684852],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920239,0.002350946,0.0042271432,0.0003219446,0.0008071664,0.00026894207],"domain_scores_gemma":[0.9852818,0.00982807,0.0037350305,0.00028047914,0.00053680333,0.00033778374],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077881017,0.00020847975,0.004757801,0.0012288191,0.00004231574,0.0000052779033,0.00023974416,0.00016149657,0.0006262336],"category_scores_gemma":[0.009902859,0.00013829597,0.0015443068,0.002541569,0.0002539429,0.0000753022,0.000111794776,0.000900175,4.0561724e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8912053,0.012680201,0.057324708,0.000020953716,0.010940473,0.00036858194,0.00033792306,0.0006456788,0.0006953045,0.000033828128,0.0000889379,0.025658099],"study_design_scores_gemma":[0.8993211,0.038553726,0.05187555,0.000023483104,0.0079198405,0.000024631307,0.00096019846,0.0008552552,0.000082923856,0.000051345734,0.00022637063,0.00010557583],"about_ca_topic_score_codex":0.0017606543,"about_ca_topic_score_gemma":0.00027378093,"teacher_disagreement_score":0.025873527,"about_ca_system_score_codex":0.00057661027,"about_ca_system_score_gemma":0.0013037645,"threshold_uncertainty_score":0.99843717},"labels":[],"label_agreement":null},{"id":"W4286296167","doi":"10.1200/jco.2022.40.16_suppl.e13583","title":"The need for artificial intelligence curriculum in medical education: A Canadian cross-sectional study of future oncology trainees.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Hamilton Health Sciences; Western University; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Curriculum; Likert scale; Medical education; Context (archaeology); Oncology; Internal medicine; Thematic analysis; Health care; Workforce; Narrative; Test (biology); Family medicine; Qualitative research; Psychology","score_opus":0.3262165673108167,"score_gpt":0.600381602941495,"score_spread":0.2741650356306783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262082,0.00034000835,0.00007383071,0.060026135,0.01228754,0.0007035039,0.000004026346,0.0000031713475,0.0003536064],"genre_scores_gemma":[0.99127203,0.0001474855,0.00028306505,0.0029891331,0.005114351,0.00010898955,0.0000065730264,0.000010381235,0.000067979214],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99406403,0.00080463605,0.004000361,0.00020034856,0.0006230901,0.0003075463],"domain_scores_gemma":[0.99287397,0.0037152765,0.0014054105,0.00018563712,0.00120474,0.00061497465],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011230028,0.000101311874,0.00075698196,0.00029610939,0.00030936397,0.000011719035,0.00036711813,0.00036494207,0.00057347433],"category_scores_gemma":[0.010593726,0.00007280128,0.0002756148,0.00046411733,0.00025794443,0.000061383565,0.000041461808,0.001740673,0.0000033446636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023450158,0.0078223385,0.36992943,0.000016699987,0.000079952144,0.00007202132,0.0023154423,0.00018729398,0.0000018634904,0.0022664617,0.0033963055,0.61156714],"study_design_scores_gemma":[0.0010972718,0.055221174,0.43989164,0.0000443497,0.00015208809,0.0012129645,0.17898579,0.0031515418,0.000018159573,0.013590117,0.30643627,0.0001986155],"about_ca_topic_score_codex":0.015368233,"about_ca_topic_score_gemma":0.1440066,"teacher_disagreement_score":0.61136854,"about_ca_system_score_codex":0.0009645469,"about_ca_system_score_gemma":0.042317715,"threshold_uncertainty_score":0.99774045},"labels":[],"label_agreement":null},{"id":"W4286296168","doi":"10.1200/jco.2022.40.16_suppl.5542","title":"Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Vancouver Coastal Health","funders":"","keywords":"Medicine; Ovarian cancer; Biomarker; Stage (stratigraphy); Cancer; Serous fluid; Extracellular vesicle; Internal medicine; Oncology; Cohort; Cancer research; Gastroenterology; Microvesicles; microRNA; Biology","score_opus":0.07713148515859228,"score_gpt":0.40839241666148485,"score_spread":0.3312609315028926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9228628,0.008512675,0.0640584,0.0019414657,0.0020509267,0.00037757523,0.0000720735,0.0000043931423,0.00011966629],"genre_scores_gemma":[0.99674267,0.00016098507,0.0014292354,0.00042451234,0.00063389674,0.000047748617,0.000007162453,0.000025933767,0.0005278565],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689984,0.0009548074,0.0014277643,0.00021566085,0.0002942787,0.00020763159],"domain_scores_gemma":[0.99630404,0.001091173,0.0018269166,0.0003419272,0.00028693335,0.00014901003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005954409,0.00012102427,0.00045311984,0.00005596378,0.00015654307,0.000008561244,0.00050173677,0.00022177065,0.00012757441],"category_scores_gemma":[0.0018275047,0.00009238138,0.0006684541,0.00012145857,0.00023180315,0.000006048946,0.0001250938,0.00044941605,7.952284e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009809444,0.0012457278,0.00975954,0.000036001486,0.00057156844,0.000061329854,0.00002529733,0.002707401,0.79521185,0.00015982555,0.0013029804,0.17910904],"study_design_scores_gemma":[0.008324241,0.012418136,0.046033658,0.000015422691,0.00055387564,0.000043628523,0.00022927263,0.004522615,0.114251375,0.00027890323,0.81306493,0.00026394567],"about_ca_topic_score_codex":0.000036397334,"about_ca_topic_score_gemma":0.000035896213,"teacher_disagreement_score":0.811762,"about_ca_system_score_codex":0.00007172429,"about_ca_system_score_gemma":0.0011798161,"threshold_uncertainty_score":0.3767203},"labels":[],"label_agreement":null},{"id":"W4286296171","doi":"10.1200/jco.2022.40.16_suppl.tps11593","title":"TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Doxorubicin; Medicine; Phagocytosis; Monoclonal antibody; Cancer research; Macrophage; Immune system; Antibody; Internal medicine; Immunology; Chemotherapy; In vitro; Biology","score_opus":0.1245483292626334,"score_gpt":0.4765491561945884,"score_spread":0.352000826931955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947529,0.00011153172,0.000012677935,0.0035284543,0.0002233695,0.0010428693,0.000018563684,0.0000048064308,0.0003048219],"genre_scores_gemma":[0.9976452,0.000048554564,0.0011426698,0.00047875044,0.00009009442,0.000039023493,0.000021441501,0.000025863055,0.0005084278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933399,0.0017344849,0.002570361,0.00031177228,0.0016084927,0.00043499627],"domain_scores_gemma":[0.9952056,0.002384399,0.001456813,0.0002396889,0.00040772994,0.0003057746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038713515,0.00021857503,0.0020555786,0.00070565485,0.000112295544,0.000008780275,0.00036144044,0.000100866906,0.0004860335],"category_scores_gemma":[0.00095597515,0.0001277757,0.00014973046,0.0009895664,0.00023711631,0.00016743815,0.00024445812,0.0019259125,0.0000020797886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12624289,0.09998405,0.74847156,0.00010244617,0.00062046136,0.0037243904,0.0009368117,0.00031956763,0.00015386526,0.00012394198,0.0005517925,0.018768225],"study_design_scores_gemma":[0.098857805,0.30404672,0.591483,0.00012918987,0.0002234635,0.00012611217,0.001497743,0.00024667932,0.00006750039,0.00011580619,0.0030739172,0.00013205723],"about_ca_topic_score_codex":0.00084354973,"about_ca_topic_score_gemma":0.001427341,"teacher_disagreement_score":0.20406267,"about_ca_system_score_codex":0.000245775,"about_ca_system_score_gemma":0.0016929657,"threshold_uncertainty_score":0.8367238},"labels":[],"label_agreement":null},{"id":"W4286296182","doi":"10.1200/jco.2022.40.16_suppl.2550","title":"Methylated circulating tumor DNA (cfMeDIP) as a predictive biomarker of clinical outcome in pan-cancer patients (pts) treated with pembrolizumab (P).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute of Cancer Research; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cohort; Biomarker; Proportional hazards model; Cancer; Pembrolizumab; Immunotherapy; Genetics; Biology","score_opus":0.0746302075059749,"score_gpt":0.43517960799127353,"score_spread":0.3605494004852986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698895,0.00045282822,0.000045679786,0.00031066427,0.0009971249,0.00028320932,0.00008998259,0.0000033968236,0.000828151],"genre_scores_gemma":[0.99773926,0.00039465702,0.00032479793,0.00097608933,0.00042217187,0.000026732065,0.00003289404,0.000032169035,0.000051203642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99418813,0.0009734059,0.0037509017,0.0003873044,0.0004044664,0.0002957692],"domain_scores_gemma":[0.9943598,0.001244617,0.0033691563,0.00025341703,0.000530964,0.0002420692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031273258,0.00020022209,0.001430545,0.00013942068,0.000056682115,0.000007269238,0.0003590978,0.00030792443,0.00013052675],"category_scores_gemma":[0.005043873,0.0001597752,0.0004969526,0.00025694526,0.00027088498,0.000009381807,0.00026756193,0.0008498415,0.000001601725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01655202,0.0026835066,0.94945526,0.000016692713,0.0006314932,0.00022178634,0.000052485728,0.0009288074,0.0018870443,0.000012430264,0.0005518813,0.027006602],"study_design_scores_gemma":[0.020014526,0.03250218,0.9300894,0.000043876993,0.00032181718,0.000070265894,0.00016887226,0.00052326906,0.0006105077,0.00011007384,0.015301039,0.00024414263],"about_ca_topic_score_codex":0.00018889831,"about_ca_topic_score_gemma":0.00016307546,"teacher_disagreement_score":0.029818676,"about_ca_system_score_codex":0.00012954247,"about_ca_system_score_gemma":0.0020899717,"threshold_uncertainty_score":0.65154433},"labels":[],"label_agreement":null},{"id":"W4286296187","doi":"10.1200/jco.2022.40.16_suppl.5056","title":"Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"PTEN; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Cancer; Prednisone; Placebo; Oncology; Interim analysis; Gastroenterology; Pathology; Randomized controlled trial; PI3K/AKT/mTOR pathway","score_opus":0.40071639978436796,"score_gpt":0.49403444143841113,"score_spread":0.09331804165404317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536926,0.00017656214,0.000007431784,0.0023549956,0.0002472586,0.0015106298,0.00032162544,0.0000025713775,0.000009671882],"genre_scores_gemma":[0.9987336,0.00021156491,0.00016151088,0.00032929025,0.0001072183,0.00008533638,0.00025122054,0.000014042685,0.000106254214],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960201,0.0012115934,0.001716303,0.00025614514,0.0006054068,0.00019047737],"domain_scores_gemma":[0.9968262,0.0010532953,0.0014711665,0.00032427398,0.00023029477,0.0000948075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024387795,0.00014223675,0.00095016795,0.00010941336,0.00011735237,0.00002159486,0.00024123369,0.000067116605,0.00010352476],"category_scores_gemma":[0.0009157577,0.000061825245,0.00008023881,0.00034018728,0.00016226857,0.00030895072,0.00012740835,0.0006878942,1.85706e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3235236,0.0044631595,0.6187274,0.00003213828,0.0006800341,0.00017414185,0.0015137036,0.00033840028,0.0061883815,0.0000037367663,0.00031392853,0.04404139],"study_design_scores_gemma":[0.5258449,0.03676937,0.42012125,0.00040161808,0.0010821013,0.000018946304,0.0037064159,0.0068619633,0.0037674373,0.000061910745,0.0011340695,0.00023004755],"about_ca_topic_score_codex":0.0033196418,"about_ca_topic_score_gemma":0.007287641,"teacher_disagreement_score":0.20232126,"about_ca_system_score_codex":0.00048370636,"about_ca_system_score_gemma":0.0033154439,"threshold_uncertainty_score":0.5881455},"labels":[],"label_agreement":null},{"id":"W4286296188","doi":"10.1200/jco.2022.40.16_suppl.3521","title":"Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cohort; FOLFIRI; Pembrolizumab; Internal medicine; Colorectal cancer; Neutropenia; Oncology; Oxaliplatin; Cancer; Chemotherapy","score_opus":0.15561355809020025,"score_gpt":0.47624915382276123,"score_spread":0.32063559573256095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901633,0.0021345026,0.00015706358,0.0019780817,0.0041766,0.0011076985,0.0000560718,0.000008574099,0.00021810841],"genre_scores_gemma":[0.9942083,0.0009465446,0.0025772443,0.0011319323,0.00043518125,0.0001693082,0.0000069861935,0.00004655895,0.0004779834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946461,0.0006421888,0.003180746,0.00038631016,0.00069970376,0.00044495446],"domain_scores_gemma":[0.9917956,0.0049477895,0.002188143,0.00021437582,0.00046276732,0.0003913117],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034130954,0.00025744332,0.002778723,0.00031293693,0.000078977595,0.000008591538,0.0003005607,0.0002671713,0.0010355299],"category_scores_gemma":[0.00442423,0.00019530981,0.00059461955,0.00032954031,0.00036483127,0.000081488615,0.00023174385,0.0012157849,0.0000010168046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17112239,0.0024993506,0.6983969,0.0005890784,0.0017119929,0.0018482123,0.0009994744,0.0006721316,0.0026369805,0.000047477002,0.006989444,0.11248658],"study_design_scores_gemma":[0.06746082,0.051943358,0.866213,0.0002201049,0.0016481132,0.0015314176,0.00032794278,0.0007704296,0.0008362602,0.0004352855,0.0083043305,0.0003089106],"about_ca_topic_score_codex":0.00010648543,"about_ca_topic_score_gemma":0.0016770537,"teacher_disagreement_score":0.16781613,"about_ca_system_score_codex":0.0009154456,"about_ca_system_score_gemma":0.006071535,"threshold_uncertainty_score":0.99987763},"labels":[],"label_agreement":null},{"id":"W4286296209","doi":"10.1200/jco.2022.40.16_suppl.e17022","title":"Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Internal medicine; Prostate; Metastasis; Clinical endpoint; Oncology; Radiation therapy; Clinical trial","score_opus":0.06887974090385791,"score_gpt":0.40731526398732854,"score_spread":0.33843552308347064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916254,0.00059962826,0.000003378556,0.007127599,0.00011481666,0.00034380335,0.00012542264,0.0000043198593,0.0000556132],"genre_scores_gemma":[0.9934933,0.0019264995,0.0005801088,0.0023533287,0.00005954666,0.00005380528,0.000012048066,0.000019466335,0.0015019048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972635,0.00042540242,0.001593099,0.00018970353,0.0002844672,0.00024384534],"domain_scores_gemma":[0.9976465,0.00037882524,0.0013858824,0.00011606998,0.00024729525,0.00022544373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005700781,0.00016612248,0.0013644125,0.00021437481,0.000042859872,0.0000044863045,0.00007050133,0.00002723534,0.00091178477],"category_scores_gemma":[0.00013021461,0.0001016887,0.00022738928,0.00022721708,0.00012530945,0.00005901979,0.000045112913,0.0004766747,4.3359464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005973122,0.0040825917,0.9585051,0.000059324037,0.0007696291,0.0006139872,0.00050882215,0.0004724921,0.0002871323,0.0000027978867,0.00013594877,0.028589033],"study_design_scores_gemma":[0.033286866,0.02108963,0.9337923,0.00009547648,0.00085726345,0.00006507343,0.0007499887,0.00013133786,0.0004463465,0.000040292005,0.009318246,0.00012716194],"about_ca_topic_score_codex":0.0002337948,"about_ca_topic_score_gemma":0.001883522,"teacher_disagreement_score":0.028461872,"about_ca_system_score_codex":0.00023151627,"about_ca_system_score_gemma":0.0010925297,"threshold_uncertainty_score":0.9983404},"labels":[],"label_agreement":null},{"id":"W4286296236","doi":"10.1200/jco.2022.40.16_suppl.8570","title":"Stereotactic radiosurgery (SRS) versus whole brain radiation therapy (WBRT) in patients with small cell lung cancer (SCLC) and intracranial metastatic disease (IMD): A systematic review and meta-analysis.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Radiosurgery; Meta-analysis; Hazard ratio; Internal medicine; Confidence interval; Oncology; Radiation therapy","score_opus":0.24485543690621728,"score_gpt":0.5107754946513745,"score_spread":0.26592005774515726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007742194,0.9914428,0.000006088332,0.0033252786,0.0002665798,0.0040772366,0.0000874174,0.0000054678308,0.000014940434],"genre_scores_gemma":[0.00024798562,0.99711025,0.00013806987,0.001618176,0.00014582575,0.0004990405,0.000032933996,0.000048928752,0.00015879024],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98778546,0.0057670376,0.0046237623,0.00051717693,0.0009376528,0.00036892918],"domain_scores_gemma":[0.9778428,0.014912654,0.005863513,0.00042951788,0.00032669786,0.00062478974],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008492271,0.0004984641,0.018084208,0.00066938746,0.000072527306,0.000034632303,0.00024167109,0.00014771003,0.00029317223],"category_scores_gemma":[0.0071001076,0.00026791438,0.0022933176,0.00092213415,0.00018723133,0.00015736114,0.00012225006,0.0018281993,0.0000012246661],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038094714,0.0015260978,0.0034221164,0.5942401,0.32058096,0.001363096,0.00009179184,0.000003974563,4.8351607e-9,0.0000015314357,0.0014595473,0.0735013],"study_design_scores_gemma":[0.008885003,0.0039433334,0.0028092887,0.010565014,0.85193586,0.000039683946,0.00001814312,0.00001364853,2.3294684e-9,0.000002414302,0.121522814,0.00026479905],"about_ca_topic_score_codex":0.000031375144,"about_ca_topic_score_gemma":0.000071477116,"teacher_disagreement_score":0.5836751,"about_ca_system_score_codex":0.00082741026,"about_ca_system_score_gemma":0.0036468965,"threshold_uncertainty_score":0.9999773},"labels":[],"label_agreement":null},{"id":"W4286296240","doi":"10.1200/jco.2022.40.16_suppl.2505","title":"Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Pharmacokinetics; Internal medicine; Pharmacology; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.05910397734427379,"score_gpt":0.457865669327313,"score_spread":0.3987616919830392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962918,0.00024378762,0.0000049761643,0.0024150023,0.00017505696,0.0006349558,0.0000032776488,0.0000037829648,0.0002273694],"genre_scores_gemma":[0.99903834,0.00037847873,0.00011896409,0.00033563052,0.000059599453,0.000018740247,0.0000055387463,0.000013810103,0.000030914092],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960965,0.0005823509,0.0025770946,0.00021473654,0.00036471014,0.00016463958],"domain_scores_gemma":[0.99735326,0.00069435034,0.0016085894,0.0001537411,0.000114185656,0.000075885284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033930328,0.00012002454,0.0011485124,0.00044467676,0.000043744367,0.0000051357883,0.00011342231,0.000110838584,0.00006432939],"category_scores_gemma":[0.00036208538,0.00009575299,0.00009741874,0.0004087396,0.0001129261,0.00013508699,0.000031568994,0.00079362944,1.8787765e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.499809,0.052090976,0.32042968,0.000050007537,0.00024040438,0.0016034864,0.00440378,0.001424752,0.0043438324,0.00003251178,0.0001018668,0.11546968],"study_design_scores_gemma":[0.23288378,0.102149926,0.66100305,0.00014855977,0.00003832104,0.0001407392,0.0019913716,0.00043843494,0.000111692134,0.00019804311,0.0008118919,0.00008417871],"about_ca_topic_score_codex":0.00027678514,"about_ca_topic_score_gemma":0.001361689,"teacher_disagreement_score":0.34057337,"about_ca_system_score_codex":0.00034348076,"about_ca_system_score_gemma":0.0005127526,"threshold_uncertainty_score":0.39046937},"labels":[],"label_agreement":null},{"id":"W4286296256","doi":"10.1200/jco.2022.40.16_suppl.5506","title":"Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Adenosquamous carcinoma; Oncology; Internal medicine; Cervical cancer; Population; Chemotherapy; Adenocarcinoma; Hazard ratio; Cisplatin; Cancer; Confidence interval; Immunotherapy","score_opus":0.08432459763388121,"score_gpt":0.4298550331995215,"score_spread":0.3455304355656403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450964,0.0008937972,0.000022349604,0.003533534,0.00055437005,0.00027053518,0.000037504782,0.000004141367,0.00017415948],"genre_scores_gemma":[0.99597245,0.0009591734,0.00051649945,0.002236582,0.00011175147,0.000013951979,0.000015597847,0.000018443945,0.00015556012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957555,0.00063552725,0.0024274455,0.00022751895,0.00071058015,0.00024346022],"domain_scores_gemma":[0.99619174,0.0008828697,0.0022062627,0.00022220219,0.00030916507,0.00018773433],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022046925,0.00015723704,0.0021455018,0.00054900924,0.000045944525,0.0000046751243,0.00024409719,0.000110156194,0.0029416198],"category_scores_gemma":[0.00027537526,0.00009930582,0.0011210637,0.001255243,0.00020293477,0.00006836003,0.00004648475,0.00087860774,5.479121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25171766,0.0053622182,0.6283721,0.000043759956,0.008499597,0.00011945015,0.00032102177,0.00020812199,0.00002278762,0.0000052174005,0.0007524794,0.10457565],"study_design_scores_gemma":[0.043312572,0.041689206,0.8898517,0.000060217855,0.0039073634,0.00003836435,0.00037741396,0.00039436552,0.0000077123,0.000007776751,0.020237112,0.000116217234],"about_ca_topic_score_codex":0.00020701904,"about_ca_topic_score_gemma":0.000563537,"teacher_disagreement_score":0.26147965,"about_ca_system_score_codex":0.0005705979,"about_ca_system_score_gemma":0.0016748552,"threshold_uncertainty_score":0.9979698},"labels":[],"label_agreement":null},{"id":"W4286296262","doi":"10.1200/jco.2022.40.16_suppl.4049","title":"A 107-gene Nanostring assay effectively characterizes complex multiomic gastric cancer molecular classification in a translational patient-derived organoid model.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Organoid; Concordance; Transcriptome; Computational biology; Microsatellite instability; Medicine; Cancer; Precision medicine; Biology; Cancer research; Gene; Oncology; Pathology; Internal medicine; Gene expression; Genetics; Microsatellite","score_opus":0.0917033664434126,"score_gpt":0.41095075451265206,"score_spread":0.31924738806923947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957823,0.0005247582,0.039386142,0.0012657419,0.0004525737,0.00040002726,0.00006351541,0.000005298136,0.000078940786],"genre_scores_gemma":[0.99507374,0.00039735745,0.003432302,0.0006675781,0.00019949437,0.000093953975,0.00008141596,0.000037123948,0.000017020406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99577785,0.0014826603,0.0014716352,0.00039344843,0.00053767464,0.00033673953],"domain_scores_gemma":[0.9979559,0.00021998356,0.0010771939,0.00020451666,0.00034975118,0.00019265304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020724363,0.00018623732,0.00064657355,0.0002625431,0.000104112034,0.0000140620705,0.0003557274,0.00030908067,0.0001352626],"category_scores_gemma":[0.0008609526,0.00018410955,0.0003646437,0.00031651036,0.00010080053,0.000014037763,0.00017918994,0.0009872703,0.0000019746528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023694232,0.00059555145,0.00062719407,0.000008836024,0.00018441246,0.000105449115,0.00006430312,0.021130662,0.93764895,0.000021810438,0.00012535817,0.03711806],"study_design_scores_gemma":[0.018994255,0.012960437,0.064462,0.00006134842,0.00023501908,0.00064555963,0.0002443064,0.08323545,0.80558914,0.0003698519,0.012471123,0.00073151407],"about_ca_topic_score_codex":0.000030407264,"about_ca_topic_score_gemma":0.000041061685,"teacher_disagreement_score":0.13205981,"about_ca_system_score_codex":0.00030966502,"about_ca_system_score_gemma":0.0021067513,"threshold_uncertainty_score":0.75077695},"labels":[],"label_agreement":null},{"id":"W4286296265","doi":"10.1200/jco.2022.40.16_suppl.5000","title":"TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Cancer; Overall survival; Urology; Nuclear medicine; Clinical trial; Confidence interval; Androgen deprivation therapy","score_opus":0.13108514094083001,"score_gpt":0.46336823419059714,"score_spread":0.3322830932497671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842944,0.0060332697,0.0000039892384,0.0064517017,0.0018620075,0.0007964169,0.00013508566,0.000010243116,0.00041289316],"genre_scores_gemma":[0.9946898,0.0015377827,0.0012250602,0.0004148722,0.0005608284,0.0002625787,0.000022623057,0.000052170293,0.0012342854],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9938333,0.0011889276,0.0025759768,0.0004125752,0.001342043,0.00064714625],"domain_scores_gemma":[0.9959214,0.0013740446,0.0013762076,0.0003154681,0.0005383507,0.00047457518],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037022675,0.00029319926,0.0018122221,0.00039146774,0.000084688276,0.000034235472,0.000292451,0.00019932698,0.0013081855],"category_scores_gemma":[0.00078985404,0.00021958273,0.00061828917,0.0004400877,0.00045669178,0.0002648004,0.00015680773,0.0016904982,0.0000071418262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3818743,0.0062837475,0.3479719,0.00047464843,0.0044403537,0.024141392,0.009528857,0.00091866014,0.0010259672,0.000054430122,0.002214426,0.22107136],"study_design_scores_gemma":[0.14934494,0.039502993,0.74730283,0.000858326,0.0022059858,0.00030598397,0.0065413574,0.00075175054,0.0003253368,0.0008499588,0.051258385,0.00075216574],"about_ca_topic_score_codex":0.00033980788,"about_ca_topic_score_gemma":0.0013557728,"teacher_disagreement_score":0.39933094,"about_ca_system_score_codex":0.0008273744,"about_ca_system_score_gemma":0.0050034653,"threshold_uncertainty_score":0.99960476},"labels":[],"label_agreement":null},{"id":"W4286296271","doi":"10.1200/jco.2022.40.16_suppl.e20028","title":"Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Dexamethasone; Oncology; Daratumumab; TEC; Gastroenterology; Surgery; Lenalidomide","score_opus":0.18829153612612937,"score_gpt":0.43592106167785666,"score_spread":0.2476295255517273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941525,0.0010972902,0.00022675983,0.0007836182,0.0012798407,0.001994255,0.0002533785,0.000018699408,0.00019364944],"genre_scores_gemma":[0.9930531,0.00058028236,0.005271495,0.000113061156,0.00034232595,0.00017340426,0.000090927766,0.0000583527,0.00031708408],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9930616,0.0012692426,0.003419186,0.00040194156,0.001321708,0.0005263384],"domain_scores_gemma":[0.97742283,0.016468583,0.0040051835,0.00056280335,0.0010698506,0.00047077466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002579539,0.00036080435,0.0029267855,0.00034394386,0.0002101248,0.000009668381,0.00040627952,0.0003173026,0.00026213564],"category_scores_gemma":[0.003499673,0.00020994544,0.0009793807,0.00043800546,0.00043148192,0.000105601706,0.000103411345,0.0011066347,0.000004018505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34912884,0.03556789,0.3130005,0.00012948272,0.005062305,0.00033873957,0.0015153935,0.00026523898,0.00038957837,0.000013770231,0.0010210121,0.29356727],"study_design_scores_gemma":[0.20363455,0.22698642,0.48360127,0.00010431886,0.002195933,0.000051722815,0.0024302942,0.0016672806,0.0012055449,0.000030691728,0.07785342,0.00023856948],"about_ca_topic_score_codex":0.00016920689,"about_ca_topic_score_gemma":0.00037365,"teacher_disagreement_score":0.2933287,"about_ca_system_score_codex":0.0009474826,"about_ca_system_score_gemma":0.001894584,"threshold_uncertainty_score":0.8561327},"labels":[],"label_agreement":null},{"id":"W4286296403","doi":"10.1200/jco.2022.40.16_suppl.2045","title":"Digital monitoring and assessments in patients with glioblastoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Karyopharm Therapeutics","keywords":"Medicine; Temozolomide; Quality of life (healthcare); Oncology; Clinical trial; Bevacizumab; Internal medicine; Radiation therapy; Chemotherapy","score_opus":0.057561820404960766,"score_gpt":0.43949641583156196,"score_spread":0.3819345954266012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980211,0.000076764125,0.0000013927626,0.0006332892,0.00036858293,0.00007328095,0.0000023407529,0.000001852019,0.0008213959],"genre_scores_gemma":[0.99939364,0.000020791387,0.00031784363,0.00011505518,0.00012301833,0.0000049029554,9.53369e-7,0.0000063097827,0.000017511318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988155,0.0000762079,0.0006462076,0.00008450839,0.00028255724,0.0000950205],"domain_scores_gemma":[0.99883187,0.00044397393,0.00045115847,0.000056906967,0.000076742755,0.00013937161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046622768,0.00005265967,0.00043905026,0.000092186536,0.000026970312,0.0000079187985,0.00004086671,0.00004474831,0.00003712369],"category_scores_gemma":[0.00022980745,0.000036090863,0.00007213388,0.00008727019,0.00003600751,0.000085679145,0.000059665057,0.00039029578,9.549419e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022910098,0.0030786833,0.884406,0.0000028405684,0.00011481454,0.0005681819,0.000014629532,0.000012673442,0.0000017872965,0.000007816256,0.00013207221,0.10936951],"study_design_scores_gemma":[0.013103801,0.030581323,0.9505468,0.000029081515,0.00007478408,0.000059669386,0.000095926516,0.0000064953106,0.000012837072,0.000022911978,0.005435775,0.00003061558],"about_ca_topic_score_codex":0.0000016677018,"about_ca_topic_score_gemma":0.0000014683792,"teacher_disagreement_score":0.109338894,"about_ca_system_score_codex":0.00011125105,"about_ca_system_score_gemma":0.00023348136,"threshold_uncertainty_score":0.16956627},"labels":[],"label_agreement":null},{"id":"W4286296404","doi":"10.1200/jco.2022.40.16_suppl.7056","title":"Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Anemia; Clinical endpoint; Placebo; Neutropenia; Lenalidomide; Surgery; Clinical trial; Bone marrow; Chemotherapy; Multiple myeloma","score_opus":0.10514348294514825,"score_gpt":0.42207269695300415,"score_spread":0.3169292140078559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959407,0.00024900597,0.000055434644,0.0023067396,0.00072820403,0.00054857216,0.000035500387,0.0000042681686,0.00013157605],"genre_scores_gemma":[0.99781775,0.00089875987,0.00022073815,0.00052868924,0.00031613902,0.000012200546,0.000024928513,0.000022426231,0.00015836158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596846,0.0008707776,0.0018542062,0.00023971245,0.0008288617,0.00023799766],"domain_scores_gemma":[0.9926546,0.004623149,0.0018118403,0.00027125602,0.000369351,0.00026978593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003285694,0.0001448259,0.0012787925,0.00017292601,0.00008641139,0.000010587808,0.0003112203,0.000200281,0.0006547518],"category_scores_gemma":[0.004524442,0.000084925916,0.00017630134,0.00029167897,0.0003138687,0.000097358505,0.00023841135,0.0016422012,0.0000031517284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104583934,0.0019029451,0.8334767,0.000022137216,0.0003122824,0.00042769767,0.00023600124,0.0000764189,0.000008144241,0.000015742302,0.0006630159,0.058274962],"study_design_scores_gemma":[0.08378794,0.034244634,0.8792793,0.00009960343,0.00035865058,0.00009295051,0.0001525011,0.000271901,0.0000046719806,0.000116236515,0.0015179798,0.0000735892],"about_ca_topic_score_codex":0.0001709068,"about_ca_topic_score_gemma":0.00030932698,"teacher_disagreement_score":0.058201373,"about_ca_system_score_codex":0.00039639318,"about_ca_system_score_gemma":0.0012897186,"threshold_uncertainty_score":0.71690726},"labels":[],"label_agreement":null},{"id":"W4286296434","doi":"10.1200/jco.2022.40.16_suppl.e18776","title":"Trends and disparities in the treatment of older adults with colon cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cohort; Comorbidity; Proportional hazards model; Logistic regression; Cancer; Population; Cancer registry; Internal medicine; Retrospective cohort study; Colorectal cancer; Medical record; Hazard ratio; Gerontology; Confidence interval","score_opus":0.07566138458126964,"score_gpt":0.44644655549494516,"score_spread":0.3707851709136755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95959693,0.0019423419,0.0000018229854,0.037195187,0.00033972066,0.00014818933,0.000010384685,0.0000019517825,0.00076345535],"genre_scores_gemma":[0.995412,0.0022713207,0.00024284353,0.001256284,0.00025846023,0.000029865829,0.0000020592213,0.000007003505,0.00052017946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980704,0.00038570334,0.0010034841,0.00010512687,0.00030626619,0.0001290132],"domain_scores_gemma":[0.9973906,0.0015801188,0.0007252479,0.000119731405,0.000093093484,0.0000911574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009055836,0.000082192295,0.000853262,0.0001116071,0.000033718028,0.0000026002663,0.00009918379,0.00007869449,0.00018679889],"category_scores_gemma":[0.0002061924,0.0000425466,0.00013623683,0.00016727213,0.00021858048,0.00003340287,0.000019611021,0.00045227192,2.060142e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011379894,0.004892606,0.511174,0.000034738987,0.00022315417,0.0006889989,0.0037192693,0.00004602744,0.0000057415127,0.0000475981,0.0041445186,0.46364343],"study_design_scores_gemma":[0.017786818,0.062605195,0.86950326,0.00010787995,0.0002475995,0.00064538635,0.0014875277,0.000059964546,0.000011979235,0.00002962823,0.04747005,0.000044692177],"about_ca_topic_score_codex":0.0003656194,"about_ca_topic_score_gemma":0.0012619329,"teacher_disagreement_score":0.46359873,"about_ca_system_score_codex":0.00016512212,"about_ca_system_score_gemma":0.00048523466,"threshold_uncertainty_score":0.2045317},"labels":[],"label_agreement":null},{"id":"W4286296437","doi":"10.1200/jco.2022.40.16_suppl.1573","title":"Interface software can markedly reduce time and improve accuracy for clinical trial data transfer from EMR to EDC: The results of two measure of work time studies comparing commercially available clinical data transfer software to current practice manual data transfer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electronic Health Records Systems","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Data entry; Electronic data capture; Clinical trial; Transfer (computing); Demographics; Medical record; Medical physics; Surgery; Computer science; Database; Internal medicine","score_opus":0.6863036870456535,"score_gpt":0.6561498057262362,"score_spread":0.03015388131941732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74287355,0.014659641,0.02501265,0.11873011,0.03455512,0.020355096,0.0434789,0.00012594077,0.0002089937],"genre_scores_gemma":[0.790884,0.02627155,0.094657704,0.031385995,0.04564554,0.0010279435,0.0068186284,0.0008931449,0.0024154694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9433513,0.03070935,0.020636676,0.0021926372,0.0017092247,0.0014007579],"domain_scores_gemma":[0.7629529,0.22342227,0.003928845,0.0058333087,0.0024344488,0.0014282208],"candidate_categories":["metaresearch","metaepi_narrow","open_science","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.13201955,0.00057823776,0.006138969,0.00018913219,0.0007847605,0.000031962863,0.007513649,0.0007810316,0.0002508509],"category_scores_gemma":[0.15782195,0.0004310219,0.0005308656,0.0005656792,0.00059580535,0.00080799503,0.0037972508,0.008379945,0.00004919265],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.316111,0.003782788,0.003495117,0.00036448336,0.0022593467,0.00002273944,0.0024255526,0.000035745856,0.000034628116,0.000008449769,0.41984192,0.25161824],"study_design_scores_gemma":[0.09779114,0.027420877,0.0026303204,0.0016282828,0.0030095442,0.00002917484,0.0023651293,0.00084317476,0.0000067231144,0.00007641179,0.8636308,0.0005684657],"about_ca_topic_score_codex":0.00083094597,"about_ca_topic_score_gemma":0.004109239,"teacher_disagreement_score":0.44378883,"about_ca_system_score_codex":0.00045305456,"about_ca_system_score_gemma":0.015550944,"threshold_uncertainty_score":0.99981415},"labels":[],"label_agreement":null},{"id":"W4286296441","doi":"10.1200/jco.2022.40.16_suppl.10014","title":"Modifiable risk factors for late mortality among five-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Underweight; Body mass index; Dyslipidemia; Population; Cancer; Diabetes mellitus; Cause of death; Demography; Confidence interval; Obesity; Pediatrics; Overweight; Internal medicine; Environmental health; Disease; Endocrinology","score_opus":0.11556146447377327,"score_gpt":0.45330862541958955,"score_spread":0.33774716094581625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845812,0.0013152313,0.00006088289,0.0045000487,0.005886392,0.002059055,0.0012763351,0.000036953323,0.00028390577],"genre_scores_gemma":[0.99427176,0.0010841466,0.00031508305,0.0011184237,0.0025899652,0.00017710381,0.00004931587,0.00008601711,0.0003081932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9871886,0.003316993,0.0062546236,0.0007665434,0.0018581332,0.00061512826],"domain_scores_gemma":[0.9779151,0.0100276405,0.009467092,0.0010918936,0.00090577814,0.0005924986],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016405286,0.0004539811,0.0038993617,0.000164672,0.00043634212,0.000024415267,0.0009690566,0.00037200222,0.000863654],"category_scores_gemma":[0.009927694,0.00031769776,0.0017472812,0.00054396875,0.00045994806,0.00021106866,0.00042410017,0.002996147,0.0000017546444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002094871,0.0072997618,0.9660726,0.000035025947,0.004826765,0.00016485571,0.0075983307,0.0039740438,0.0000061356664,0.000010384133,0.005112864,0.0028043631],"study_design_scores_gemma":[0.01119528,0.0072336206,0.9594597,0.000119078526,0.0027929358,0.0000341566,0.008799323,0.0001844079,0.000033071152,0.0005600236,0.009287892,0.0003004706],"about_ca_topic_score_codex":0.18665491,"about_ca_topic_score_gemma":0.03759597,"teacher_disagreement_score":0.14905894,"about_ca_system_score_codex":0.00046662893,"about_ca_system_score_gemma":0.005199171,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W4286296447","doi":"10.1200/jco.2022.40.16_suppl.4561","title":"Health-related quality of life (HRQoL) for patients with advanced/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Discontinuation; Quality of life (healthcare); Pembrolizumab; Cisplatin; Nausea; Internal medicine; Performance status; Oncology; Clinical trial; Tolerability; Visual analogue scale; Carboplatin; Chemotherapy; Cancer; Surgery; Adverse effect; Nursing","score_opus":0.09338075154397162,"score_gpt":0.4274998481295275,"score_spread":0.3341190965855559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915846,0.0008509004,0.0002685589,0.0045815255,0.00095170125,0.0013264524,0.000171032,0.000008879601,0.00025632762],"genre_scores_gemma":[0.9931755,0.00011946831,0.0036851475,0.0024925487,0.0001990529,0.00005092093,0.000026130729,0.000039280432,0.00021194757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926418,0.0011836404,0.004680159,0.0003121982,0.0007720175,0.00041019393],"domain_scores_gemma":[0.99197716,0.0017958478,0.004946454,0.00024994244,0.0005937821,0.0004367944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033329872,0.00022934708,0.0033401777,0.00027040095,0.00010537564,0.000005006372,0.00021996298,0.00015448748,0.0001856969],"category_scores_gemma":[0.0027236142,0.00016809377,0.00054335775,0.00034012232,0.00014360613,0.00010481065,0.00008576718,0.0009969291,0.0000017489649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114697,0.007316931,0.8395232,0.0002538579,0.0007828602,0.00014765024,0.00044151326,0.0008156339,0.000023304854,0.000044331136,0.0014924039,0.034461338],"study_design_scores_gemma":[0.10034258,0.050292645,0.8454304,0.00016158533,0.0002779181,0.00003786935,0.00035462712,0.00007766421,0.000010217567,0.000519678,0.0023434677,0.00015140166],"about_ca_topic_score_codex":0.0002654753,"about_ca_topic_score_gemma":0.0001880372,"teacher_disagreement_score":0.042975713,"about_ca_system_score_codex":0.00039048394,"about_ca_system_score_gemma":0.0048961663,"threshold_uncertainty_score":0.8685589},"labels":[],"label_agreement":null},{"id":"W4286296468","doi":"10.1200/jco.2022.40.16_suppl.6590","title":"Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Internal medicine; Proportional hazards model; Clinical endpoint; Cohort; Oncology; Clear cell renal cell carcinoma; Cancer; Confidence interval; Clinical trial","score_opus":0.09682740337617424,"score_gpt":0.37434232149698016,"score_spread":0.2775149181208059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940001,0.00077657687,0.0006695145,0.0012349167,0.0009798382,0.0003338037,0.00036964627,0.0000014174836,0.001634216],"genre_scores_gemma":[0.9961938,0.00006193398,0.0025070366,0.0009413093,0.00013235769,0.000025387038,0.000028427221,0.000018176032,0.00009152544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653554,0.00010486903,0.002704792,0.0002745474,0.00012491959,0.0002553578],"domain_scores_gemma":[0.9942622,0.0014212556,0.0038492943,0.00022537436,0.0001320464,0.00010979784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028169756,0.00016033994,0.0014502531,0.00023192035,0.000081612634,0.000017916731,0.00059905247,0.000079882215,0.00013951448],"category_scores_gemma":[0.0005169071,0.00012588449,0.00026602414,0.000115217255,0.00012424718,0.0002888646,0.00014165192,0.0006757997,0.00000306514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016714006,0.0014703266,0.98876566,0.0000305571,0.000065533495,0.000013276685,0.00042405052,0.0005994804,0.000017031176,0.0010636421,0.0027476898,0.0031313302],"study_design_scores_gemma":[0.010902531,0.009861641,0.94334906,0.000008582013,0.00006652551,0.0000061383034,0.0003962265,0.0010252688,0.00003595463,0.0009784291,0.03320468,0.00016497562],"about_ca_topic_score_codex":0.00008505285,"about_ca_topic_score_gemma":0.00011154003,"teacher_disagreement_score":0.04541663,"about_ca_system_score_codex":0.00023340402,"about_ca_system_score_gemma":0.00038800997,"threshold_uncertainty_score":0.513342},"labels":[],"label_agreement":null},{"id":"W4286296843","doi":"10.1200/jco.2022.40.16_suppl.7019","title":"Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH1; Medicine; Isocitrate dehydrogenase; Azacitidine; Myeloid leukemia; Peripheral blood mononuclear cell; Bone marrow; Internal medicine; Gastroenterology; Oncology; Mutation; Biology","score_opus":0.05165808764749978,"score_gpt":0.397512320340821,"score_spread":0.3458542326933212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926406,0.000015774773,0.0003775267,0.0050283675,0.00029573994,0.0013845449,0.00008231399,0.000021282549,0.00015386479],"genre_scores_gemma":[0.9933955,0.0000835261,0.0031694365,0.0026337705,0.0002847493,0.00006298955,0.00012703416,0.000074972864,0.00016800153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9884532,0.0039807837,0.0048811887,0.00055630726,0.0015557098,0.0005728172],"domain_scores_gemma":[0.9892508,0.0048996485,0.0030071957,0.00055302255,0.0013612453,0.0009280896],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008450767,0.00034526514,0.0033230248,0.00077388133,0.00008438923,0.000015145164,0.000535349,0.00039693076,0.00024845128],"category_scores_gemma":[0.0057259994,0.0002504554,0.0004270269,0.001215626,0.0003977353,0.00020682736,0.00027418026,0.0027847174,0.000011667644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4365799,0.0028846858,0.539045,0.000025681322,0.00082834106,0.00562566,0.00015236354,0.0007359023,0.0064279945,0.000008507176,0.0008248069,0.006861175],"study_design_scores_gemma":[0.07442457,0.07273662,0.8452028,0.00019120892,0.0004814425,0.00020295287,0.00015456478,0.00050559425,0.0009389426,0.0000051036895,0.0049252976,0.00023087084],"about_ca_topic_score_codex":0.00006418924,"about_ca_topic_score_gemma":0.000037495738,"teacher_disagreement_score":0.36215535,"about_ca_system_score_codex":0.0014923067,"about_ca_system_score_gemma":0.0074402597,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4286296848","doi":"10.1200/jco.2022.40.16_suppl.2524","title":"Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Tolerability; Medicine; Internal medicine; Lung cancer; Colorectal cancer; Cancer; Oncology; Adverse effect; Melanoma; Gastroenterology; Cancer research","score_opus":0.06912738098116634,"score_gpt":0.440825409337411,"score_spread":0.37169802835624466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342966,0.00041548215,0.00000299437,0.0049114134,0.00018646137,0.0009443654,0.000024442106,0.000002605981,0.00008255341],"genre_scores_gemma":[0.9986878,0.00019361996,0.0003872128,0.0005251663,0.0001616556,0.000011707306,0.0000044411977,0.000014712431,0.000013681659],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960843,0.0007797779,0.0021342884,0.00027702007,0.0005468275,0.00017783625],"domain_scores_gemma":[0.99455106,0.003072832,0.0018112664,0.00027748634,0.00016689488,0.00012044413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046353852,0.00014257673,0.0013491696,0.00006931075,0.00014011022,0.0000053865247,0.00014909403,0.000060378698,0.000021914488],"category_scores_gemma":[0.0014317286,0.00006906123,0.000090374815,0.0002601022,0.000244576,0.000055090073,0.00017469781,0.0011286399,7.6697916e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6201515,0.016754352,0.17030105,0.00006542742,0.00039544562,0.0008614096,0.011824718,0.0015029603,0.0017345804,0.0000063092516,0.00023150453,0.17617072],"study_design_scores_gemma":[0.23869243,0.1120486,0.6395636,0.00085313845,0.00042620985,0.00012305767,0.0067590266,0.00026768382,0.00018706825,0.000024103665,0.0009494286,0.0001056344],"about_ca_topic_score_codex":0.00025397202,"about_ca_topic_score_gemma":0.0023845755,"teacher_disagreement_score":0.46926257,"about_ca_system_score_codex":0.00012763299,"about_ca_system_score_gemma":0.00063365925,"threshold_uncertainty_score":0.49034417},"labels":[],"label_agreement":null},{"id":"W4286296857","doi":"10.1200/jco.2022.40.16_suppl.5084","title":"Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Population; Internal medicine; Bicalutamide; Urology; Oncology; Goserelin; Radiation therapy; Hormonal therapy; Randomized controlled trial; Cancer","score_opus":0.10210199417347897,"score_gpt":0.47783163263754,"score_spread":0.37572963846406104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981154,0.0021801903,0.00001130824,0.0020179553,0.00037861874,0.0055762064,0.000009851424,0.0000058561154,0.000008502452],"genre_scores_gemma":[0.9891683,0.009489383,0.000087660024,0.00054733496,0.00015135744,0.0004695842,0.0000314046,0.000020958154,0.000034017772],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948375,0.0017479975,0.002160289,0.00028674226,0.0007081658,0.00025927246],"domain_scores_gemma":[0.99637437,0.001324007,0.0016015584,0.00020769522,0.00033822877,0.00015412965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003627398,0.0001852955,0.0013254763,0.00038518992,0.00009839444,0.000015461472,0.00016146549,0.00013398839,0.000099642384],"category_scores_gemma":[0.00056137313,0.00010295544,0.00013227992,0.00066360884,0.000064870226,0.00013864186,0.000050175473,0.00080295786,6.5266346e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3974696,0.00402537,0.3275784,0.0000075832286,0.00023544891,0.00014487449,0.0019471716,0.0015091283,0.00012417651,0.0000017925421,0.000024052079,0.2669324],"study_design_scores_gemma":[0.44211242,0.065115996,0.49041706,0.00005546477,0.000121704536,0.000022164673,0.0009790412,0.0004479337,0.00015005209,0.000054267195,0.0004259421,0.00009795938],"about_ca_topic_score_codex":0.00067099347,"about_ca_topic_score_gemma":0.001993661,"teacher_disagreement_score":0.26683444,"about_ca_system_score_codex":0.00048618164,"about_ca_system_score_gemma":0.0011269387,"threshold_uncertainty_score":0.41984013},"labels":[],"label_agreement":null},{"id":"W4286296877","doi":"10.1200/jco.2022.40.16_suppl.5078","title":"Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Hazard ratio; Prostate-specific antigen; Internal medicine; Oncology; Population; Androgen deprivation therapy; Confidence interval; Cancer","score_opus":0.10449796444811289,"score_gpt":0.4477058098119922,"score_spread":0.3432078453638793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761374,0.001008368,0.0000025516745,0.009259592,0.00046306965,0.0012453378,0.00037491007,0.0000034148516,0.000028993554],"genre_scores_gemma":[0.9962427,0.0027052592,0.00016606822,0.00034922187,0.00017324793,0.00003410231,0.000044096552,0.000018419933,0.00026690785],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943662,0.0027790274,0.0014680786,0.00022535687,0.00088549335,0.00027579343],"domain_scores_gemma":[0.99158,0.005680895,0.001845093,0.00015046768,0.0005686859,0.00017487461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006396691,0.00014040948,0.0012036309,0.00013076591,0.00008073784,0.000012674995,0.00009831812,0.00008458864,0.00006803469],"category_scores_gemma":[0.001799896,0.000080358564,0.00016216123,0.00024237002,0.00019236444,0.00010680639,0.00007550553,0.00095866626,9.785492e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7199899,0.0033921562,0.26262483,0.0000070269543,0.00087071053,0.0004396755,0.0016278214,0.00004430704,0.00039702252,0.0000031775587,0.002096727,0.008506662],"study_design_scores_gemma":[0.22981434,0.04016629,0.71766824,0.000047326397,0.0002852633,0.000004555918,0.0007627594,0.000037098194,0.000079851416,0.00008145712,0.010975514,0.00007732859],"about_ca_topic_score_codex":0.00015906009,"about_ca_topic_score_gemma":0.00008915487,"teacher_disagreement_score":0.49017555,"about_ca_system_score_codex":0.0006434449,"about_ca_system_score_gemma":0.0018459813,"threshold_uncertainty_score":0.41649812},"labels":[],"label_agreement":null},{"id":"W4286297006","doi":"10.1200/jco.2022.40.16_suppl.12028","title":"Medical assistance in dying (MAiD) in patients with cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Cancer; Population; Cancer registry; Internal medicine; Disease; Lung cancer","score_opus":0.27672321252303095,"score_gpt":0.5653771557122299,"score_spread":0.28865394318919896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992188,0.0011549833,0.00002067874,0.0045573055,0.0006677625,0.00008706477,0.0000030964907,0.0000021044325,0.0013190224],"genre_scores_gemma":[0.99581814,0.000718507,0.0010446431,0.0021150939,0.00023089435,0.0000062684303,0.0000018721363,0.000008229643,0.000056345692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969168,0.00043617078,0.001639857,0.00011930783,0.0007236982,0.00016420087],"domain_scores_gemma":[0.99689764,0.0016474569,0.0009876085,0.00008732278,0.00019387969,0.00018606761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026977852,0.00007271689,0.0010991675,0.00014611856,0.000016644093,0.0000013157479,0.00015354491,0.0001361943,0.00050347217],"category_scores_gemma":[0.0034698404,0.00005122129,0.00011543111,0.00027054068,0.00012324084,0.000051075993,0.000058976384,0.0013529228,9.1344907e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050975652,0.0013435418,0.95070785,0.000019511299,0.00006683356,0.00071658153,0.0002659524,0.000064199434,0.000002763717,0.000025425637,0.0009025811,0.040787183],"study_design_scores_gemma":[0.013208081,0.006920569,0.9189602,0.0005402786,0.000044272347,0.000012841652,0.00033087164,0.0000594719,0.0000058223936,0.000049029455,0.05981548,0.00005307345],"about_ca_topic_score_codex":0.00010049295,"about_ca_topic_score_gemma":0.0005286022,"teacher_disagreement_score":0.0589129,"about_ca_system_score_codex":0.00034896165,"about_ca_system_score_gemma":0.0019683687,"threshold_uncertainty_score":0.5877852},"labels":[],"label_agreement":null},{"id":"W4286297020","doi":"10.1200/jco.2022.40.16_suppl.e24105","title":"Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Hypomagnesemia; Medicine; Hypokalemia; Hyponatremia; Internal medicine; Hazard ratio; Cisplatin; Gastroenterology; Acute kidney injury; Incidence (geometry); Furosemide; Retrospective cohort study; Confidence interval; Chemotherapy","score_opus":0.031972476554493194,"score_gpt":0.3549968437425993,"score_spread":0.3230243671881061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432564,0.0000244199,0.0000027216263,0.00443071,0.00014773053,0.00034454063,0.000047817815,0.000017440536,0.0006589571],"genre_scores_gemma":[0.9945036,0.000049282935,0.0007177134,0.004217753,0.0001563103,0.000008231325,0.00004062954,0.00004245489,0.00026401746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966436,0.0005596606,0.0015574421,0.00028071846,0.000680182,0.00027840515],"domain_scores_gemma":[0.9957228,0.0008470583,0.0023340913,0.00018142312,0.00042561328,0.00048904197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016237126,0.0002073587,0.0013947834,0.0002754064,0.00008219628,0.0000098455575,0.00014279193,0.0003230512,0.00022158417],"category_scores_gemma":[0.0025884232,0.00014933596,0.00013054305,0.00054046954,0.00019682314,0.00014793879,0.00006706586,0.0018822999,0.0000017701434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013218612,0.0021165777,0.9561526,0.000011085681,0.00049347023,0.001028617,0.00014037322,0.000003278264,0.0011765284,0.0000023313924,0.0038241113,0.021832393],"study_design_scores_gemma":[0.026599878,0.03075389,0.9390679,0.00015476186,0.00044733577,0.00038757856,0.00009785192,0.0000544873,0.0007306112,0.000054793287,0.001485661,0.00016523218],"about_ca_topic_score_codex":0.000019884992,"about_ca_topic_score_gemma":0.000030185134,"teacher_disagreement_score":0.028637312,"about_ca_system_score_codex":0.00071957026,"about_ca_system_score_gemma":0.0015655925,"threshold_uncertainty_score":0.8177761},"labels":[],"label_agreement":null},{"id":"W4286297054","doi":"10.1200/jco.2022.40.16_suppl.3006","title":"CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring <i>NRG1</i> fusions.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Cohort; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Internal medicine; Discontinuation; Cancer; Targeted therapy; Phases of clinical research; Clinical trial","score_opus":0.07209854940977523,"score_gpt":0.501764807270861,"score_spread":0.4296662578610858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092466,0.0005881119,0.000019816209,0.0041930443,0.0007638344,0.00019105342,0.000010617449,0.0000042226343,0.0033046522],"genre_scores_gemma":[0.9973232,0.00050633267,0.0008416429,0.00091785844,0.0003073485,0.000006000107,0.000003437881,0.000010267306,0.000083904895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99745,0.00028186452,0.0017459572,0.00012263635,0.00025602127,0.00014352218],"domain_scores_gemma":[0.997544,0.0010986702,0.00094087236,0.000105029816,0.0001281913,0.00018322002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014690867,0.0000802606,0.0009649133,0.00014401836,0.00006935114,0.0000026040536,0.000081985534,0.00008324356,0.000196826],"category_scores_gemma":[0.001053277,0.000062486644,0.00015771305,0.00016407737,0.00012854481,0.00006092598,0.00009953426,0.0007596737,0.0000010015673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048545487,0.016978152,0.3465996,0.00017916875,0.001613238,0.009538159,0.0034815543,0.0018001775,0.0022542975,0.0015866904,0.00456684,0.5628566],"study_design_scores_gemma":[0.03332085,0.01942233,0.88503796,0.00019363144,0.0005979894,0.0011343622,0.0008065416,0.000113557115,0.00013773462,0.00028782533,0.05883948,0.00010776637],"about_ca_topic_score_codex":0.000043491513,"about_ca_topic_score_gemma":0.000018053574,"teacher_disagreement_score":0.56274885,"about_ca_system_score_codex":0.0001949309,"about_ca_system_score_gemma":0.0018505445,"threshold_uncertainty_score":0.33004466},"labels":[],"label_agreement":null},{"id":"W4286297227","doi":"10.1200/jco.2022.40.16_suppl.2513","title":"A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tolerability; Internal medicine; Clinical endpoint; Rash; Adverse effect; Pharmacodynamics; Phases of clinical research; Oncology; Head and neck squamous-cell carcinoma; Pharmacokinetics; Gastroenterology; Toxicity; Pharmacology; Surgery; Clinical trial; Head and neck cancer; Cancer; Immunotherapy","score_opus":0.03620175007699712,"score_gpt":0.37153577562168394,"score_spread":0.33533402554468683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650997,0.00003539515,0.000005333802,0.0023238764,0.00020727758,0.0007177941,0.0000033988665,0.0000018378922,0.00019509206],"genre_scores_gemma":[0.9994317,0.0000071602794,0.00013033375,0.0002427843,0.00009615104,0.000023114537,0.0000041780727,0.000007361794,0.000057163183],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976281,0.0004209937,0.0011875761,0.00013233985,0.0005113091,0.000119703865],"domain_scores_gemma":[0.99813783,0.0003350489,0.0011425783,0.00008077575,0.00021493154,0.00008880749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001292772,0.0000856929,0.00080428785,0.00015726179,0.00004365207,0.0000022345291,0.000078110614,0.00006806,0.00005505036],"category_scores_gemma":[0.0006934542,0.000046911875,0.00009992882,0.0003025623,0.00014498593,0.000074224205,0.000074518146,0.0008408122,1.749391e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7783807,0.015392999,0.17433211,0.000026303089,0.00004485432,0.00016412324,0.00011329462,0.00008418178,0.00041058657,0.0000398855,0.000036184396,0.030974776],"study_design_scores_gemma":[0.3117628,0.12741312,0.5596945,0.00010904675,0.000049910966,0.00007302852,0.00010122904,0.00012744822,0.000051946914,0.00014957318,0.0004216792,0.000045672252],"about_ca_topic_score_codex":0.0000177041,"about_ca_topic_score_gemma":0.000116230956,"teacher_disagreement_score":0.46661788,"about_ca_system_score_codex":0.00016651224,"about_ca_system_score_gemma":0.0009265957,"threshold_uncertainty_score":0.36529574},"labels":[],"label_agreement":null},{"id":"W4286297236","doi":"10.1200/jco.2022.40.16_suppl.tps4607","title":"MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Cabozantinib; Oncology; Internal medicine; Chemotherapy; Avelumab; Maintenance therapy; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.05547294590462917,"score_gpt":0.41005076293859727,"score_spread":0.35457781703396807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918498,0.00039661632,0.00022472448,0.0027972518,0.0015531695,0.0027367165,0.00016594613,0.00000736369,0.00026840626],"genre_scores_gemma":[0.9944634,0.0006821927,0.001899314,0.0017565198,0.00043013872,0.00047923738,0.000010584707,0.000047321617,0.00023131687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99459517,0.00082987297,0.0030138344,0.00037233796,0.0007997832,0.00038897886],"domain_scores_gemma":[0.9938825,0.0027216894,0.0025070228,0.00026372523,0.00034371164,0.00028136343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027380597,0.00030974878,0.0033875527,0.00016629152,0.00007018982,0.000008911379,0.00018993179,0.0001535571,0.0012381369],"category_scores_gemma":[0.0011899382,0.00021033865,0.0005090909,0.00026493307,0.00045941235,0.0000993053,0.000047928646,0.0009614021,0.0000014150605],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96075916,0.009776956,0.0061410433,0.00005064966,0.0009175147,0.00038098724,0.00022786547,0.0001341303,0.0000033715448,0.000010236111,0.0002691729,0.021328893],"study_design_scores_gemma":[0.92638487,0.06018504,0.0073752915,0.00017960819,0.0010276599,0.000018903047,0.00005465335,0.00030624363,0.00003575168,0.00005144944,0.00420184,0.00017867633],"about_ca_topic_score_codex":0.00017121182,"about_ca_topic_score_gemma":0.00028824943,"teacher_disagreement_score":0.050408084,"about_ca_system_score_codex":0.000342597,"about_ca_system_score_gemma":0.0028802364,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W4286297240","doi":"10.1200/jco.2022.40.16_suppl.5574","title":"Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"ImmunoGen","keywords":"Medicine; Tolerability; Ovarian cancer; Internal medicine; Adverse effect; Gastroenterology; Population; Oncology; Phases of clinical research; Folate receptor; Nausea; Cancer; Toxicity; Surgery; Cancer cell","score_opus":0.14832471963709895,"score_gpt":0.47356855325880187,"score_spread":0.32524383362170295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98380876,0.0019333084,0.0000669126,0.009802078,0.0026405074,0.0009483528,0.0005801033,0.0000066438665,0.00021333556],"genre_scores_gemma":[0.99093395,0.0042862636,0.002852966,0.001144411,0.00053034385,0.00002635686,0.00014217787,0.000032840235,0.0000506605],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9893515,0.0038080153,0.005605984,0.00039467358,0.00056523154,0.00027455887],"domain_scores_gemma":[0.99014056,0.004391043,0.0040992266,0.00022285998,0.00066143845,0.00048485494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010824381,0.00024364555,0.0035019459,0.00023064224,0.00006521302,0.000008935927,0.00014296411,0.00027045462,0.00066740107],"category_scores_gemma":[0.0032487686,0.00016094148,0.0005781211,0.00036769517,0.0002638223,0.000096480355,0.00010748395,0.0015855149,0.000001127932],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103110895,0.028567629,0.2984393,0.000022258115,0.0015429475,0.00028823785,0.000117625175,0.000009969842,0.00001684524,0.00003048302,0.0030507478,0.56480306],"study_design_scores_gemma":[0.15101252,0.16448773,0.5971072,0.00072325976,0.0020707096,0.00004334395,0.00017090118,0.00009161213,0.00004519637,0.000059771595,0.08398429,0.00020348566],"about_ca_topic_score_codex":0.00015881733,"about_ca_topic_score_gemma":0.00018176076,"teacher_disagreement_score":0.5645996,"about_ca_system_score_codex":0.0009759481,"about_ca_system_score_gemma":0.0024986558,"threshold_uncertainty_score":0.73075736},"labels":[],"label_agreement":null},{"id":"W4286297247","doi":"10.1200/jco.2022.40.16_suppl.tps5605","title":"ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Radical Hysterectomy; Cervical cancer; Surgery; Stage (stratigraphy); Perioperative; Randomized controlled trial; Laparoscopy; Hysterectomy; Cancer; Internal medicine","score_opus":0.21870152696086242,"score_gpt":0.5189242622034704,"score_spread":0.300222735242608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96884733,0.00063972356,0.0007343318,0.008513229,0.012345376,0.004688651,0.00007353849,0.000014146594,0.004143655],"genre_scores_gemma":[0.99134636,0.00042016362,0.0031641347,0.0011610289,0.0027319484,0.00041891064,0.000011443165,0.000034040495,0.0007119861],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924193,0.0017145985,0.0042082616,0.00036644124,0.0008798842,0.00041153628],"domain_scores_gemma":[0.981821,0.013837956,0.0028954668,0.00031076494,0.00046914638,0.00066567224],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0084006,0.0002490707,0.00564816,0.00020089306,0.0001337386,0.000021908998,0.0006944939,0.00035491114,0.0021326733],"category_scores_gemma":[0.008743665,0.0001728838,0.0020859644,0.00043445185,0.00036384028,0.000137014,0.00043273123,0.0013921442,0.0000047699473],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9594912,0.00475987,0.003414661,0.00008866454,0.0020385308,0.00021996598,0.000086541215,0.00008039905,0.000028052265,0.00017967299,0.00084155943,0.028770898],"study_design_scores_gemma":[0.8948142,0.06689425,0.0069245268,0.00006228134,0.002335864,0.00003709619,0.00008731829,0.00026270712,0.000051914827,0.0003514167,0.028030965,0.00014746972],"about_ca_topic_score_codex":0.0007558048,"about_ca_topic_score_gemma":0.00009872337,"teacher_disagreement_score":0.06467699,"about_ca_system_score_codex":0.0006089566,"about_ca_system_score_gemma":0.0038974679,"threshold_uncertainty_score":0.99960613},"labels":[],"label_agreement":null},{"id":"W4286297253","doi":"10.1200/jco.2022.40.16_suppl.e16239","title":"The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Biobank; Oncology; Cancer; Biomarker; Disease; Data sharing; Internal medicine; Bioinformatics; Pathology; Genetics; Biology","score_opus":0.13558366121239296,"score_gpt":0.4992311965434322,"score_spread":0.3636475353310392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937295,0.00034220016,0.000058481222,0.0021820043,0.0008923534,0.00096169714,0.000024545165,0.000005552778,0.0018036743],"genre_scores_gemma":[0.99382097,0.002671206,0.001401682,0.00018950204,0.00063501496,0.00015092139,0.0000018781221,0.000016011296,0.0011127958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935768,0.0019454978,0.0026228207,0.00024409655,0.0013212373,0.00028949685],"domain_scores_gemma":[0.98845035,0.0074218605,0.002872189,0.00029213112,0.0006945409,0.00026894288],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0076963976,0.00014397745,0.0018018029,0.00014285727,0.00026120414,0.000010430711,0.00050239556,0.00013005052,0.000994091],"category_scores_gemma":[0.005094655,0.000073301795,0.00021897857,0.00024831295,0.00059404934,0.000045590743,0.00022641828,0.0016239692,0.0000031507502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01930996,0.0039711935,0.9541294,0.000011692303,0.004503506,0.00054881664,0.000376135,0.00014688476,0.00000632585,0.0000122860165,0.0018993912,0.015084421],"study_design_scores_gemma":[0.012661338,0.052970167,0.9207475,0.00003420361,0.0026074483,0.00088421674,0.002425478,0.0002946117,0.0000023752248,0.00006648012,0.007236186,0.00006996785],"about_ca_topic_score_codex":0.00049296074,"about_ca_topic_score_gemma":0.0011130446,"teacher_disagreement_score":0.048998974,"about_ca_system_score_codex":0.0003140327,"about_ca_system_score_gemma":0.0051903496,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W4286297269","doi":"10.1200/jco.2022.40.16_suppl.4553","title":"Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; London Health Sciences Centre; St Joseph's Health Care; Western University","funders":"","keywords":"Medicine; Renal cell carcinoma; Clinical endpoint; Adverse effect; Immunotherapy; Internal medicine; Oncology; Immune system; Transplantation; Cancer; Gastroenterology; Immunology; Surgery; Clinical trial","score_opus":0.043059140389493794,"score_gpt":0.38476211469932614,"score_spread":0.3417029743098323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989788,0.000041312254,0.000050372244,0.000056884695,0.00020351009,0.00048106033,0.00014180702,0.0000022473262,0.00004398993],"genre_scores_gemma":[0.9981743,0.000025318188,0.0010371888,0.0002009656,0.00021844871,0.0000051545676,0.00028974348,0.000024187191,0.00002469696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967759,0.0008173571,0.001579073,0.00032999975,0.0002281957,0.00026947423],"domain_scores_gemma":[0.99794906,0.00011561649,0.0014680817,0.00018115257,0.00016755912,0.00011850616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00139419,0.00018181744,0.00062324904,0.000110277266,0.00013993974,0.000004457294,0.00021613538,0.0001807813,0.00004329508],"category_scores_gemma":[0.000034722172,0.00013850271,0.00015047831,0.00013797737,0.000061255894,0.000016730257,0.000049961847,0.0006854634,6.0142366e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17155875,0.011755894,0.74191844,0.000016468406,0.00026854855,0.00030786076,0.0008536824,0.00064872653,0.06882263,1.2444039e-7,0.000056201152,0.0037926943],"study_design_scores_gemma":[0.12641075,0.059911925,0.8087689,0.000044433637,0.00021483112,0.00008341504,0.00052743236,0.000054989185,0.0030310561,0.00000129988,0.0007244936,0.00022643716],"about_ca_topic_score_codex":0.00030057863,"about_ca_topic_score_gemma":0.00026430012,"teacher_disagreement_score":0.066850506,"about_ca_system_score_codex":0.00013935938,"about_ca_system_score_gemma":0.0010512822,"threshold_uncertainty_score":0.5647977},"labels":[],"label_agreement":null},{"id":"W4286297405","doi":"10.1200/jco.2022.40.16_suppl.5558","title":"OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Oncology; BRCA mutation; Cancer; Gynecology; Internal medicine; Gynecologic cancer; Poly ADP ribose polymerase","score_opus":0.20796135304604615,"score_gpt":0.4907434038774964,"score_spread":0.28278205083145025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99000734,0.0005138894,0.00010978586,0.0066457517,0.0015083201,0.0008458252,0.00006878085,0.00000720036,0.00029313247],"genre_scores_gemma":[0.9960358,0.00091522606,0.0006321064,0.0017455332,0.0004917994,0.0001300346,0.0000030353503,0.000027204678,0.000019234714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402165,0.0013111915,0.0033259788,0.000323626,0.0007254245,0.0002921451],"domain_scores_gemma":[0.9933663,0.0009937665,0.0039956747,0.0004524698,0.0007684449,0.0004233519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005835776,0.00019613338,0.0025410922,0.00043161758,0.00010056463,0.0000075897183,0.00028867717,0.00020720644,0.00044850504],"category_scores_gemma":[0.0015994349,0.00012622183,0.0011841655,0.000951507,0.00023355619,0.00012381077,0.00019995528,0.0011741784,4.4835858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20711434,0.010773479,0.54531074,0.00013559074,0.01948468,0.00027990056,0.009947181,0.0068654413,0.011430456,0.00016897469,0.014231349,0.17425787],"study_design_scores_gemma":[0.08363086,0.09388689,0.79116315,0.0006066981,0.006049863,0.00013294967,0.006071766,0.0010424401,0.0017491363,0.00039070434,0.014856771,0.00041880034],"about_ca_topic_score_codex":0.0001786167,"about_ca_topic_score_gemma":0.00017911503,"teacher_disagreement_score":0.24585238,"about_ca_system_score_codex":0.00085681205,"about_ca_system_score_gemma":0.0028416815,"threshold_uncertainty_score":0.5147177},"labels":[],"label_agreement":null},{"id":"W4286297417","doi":"10.1200/jco.2022.40.16_suppl.e18840","title":"Phase-specific costs of care in diffuse large B-cell lymphoma in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Cohort; Diffuse large B-cell lymphoma; Cancer registry; Cancer; Health care; Lymphoma; Pediatrics; Emergency medicine; Internal medicine","score_opus":0.07041149630699811,"score_gpt":0.3367472137608768,"score_spread":0.2663357174538787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97041,0.0044606593,0.000022222206,0.0006092486,0.0022358873,0.00011241625,0.00013280175,0.0000012544557,0.022015495],"genre_scores_gemma":[0.9977602,0.00061964476,0.00014120755,0.001006728,0.00015611929,0.000005779289,0.000005296035,0.00001403409,0.00029101392],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957648,0.000106062864,0.0035312106,0.00021443608,0.00007012194,0.00031337058],"domain_scores_gemma":[0.996374,0.0005061709,0.0027114237,0.00018153452,0.000070315196,0.00015655301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002471415,0.00011585697,0.0015825215,0.00028137057,0.000037617363,0.0000068540785,0.00038897627,0.00016441676,0.0007621979],"category_scores_gemma":[0.00037105803,0.00013250731,0.00024204492,0.00017103634,0.000055260665,0.00014691836,0.00010649957,0.0007848605,0.000006400024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047557736,0.025017293,0.86873055,0.000026143949,0.00007735888,0.0007582644,0.002094298,0.0003862049,0.000004779069,0.018566864,0.01800483,0.061577637],"study_design_scores_gemma":[0.04036466,0.0035107187,0.23512761,0.000013299665,0.0000049602713,0.000011379078,0.0006118679,0.000051323128,0.0000059033855,0.0010957686,0.7190662,0.0001363132],"about_ca_topic_score_codex":0.47571912,"about_ca_topic_score_gemma":0.9661495,"teacher_disagreement_score":0.70106137,"about_ca_system_score_codex":0.004411167,"about_ca_system_score_gemma":0.0040976806,"threshold_uncertainty_score":0.99941075},"labels":[],"label_agreement":null},{"id":"W4286297624","doi":"10.1200/jco.2022.40.16_suppl.12112","title":"Alleviating breathlessness in patients with cancer with dexamethasone (ABCD): A parallel-group, double-blind, randomized clinical trial (RCT).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Randomized controlled trial; Dexamethasone; Randomization; Placebo; Internal medicine; Adverse effect; Ambulatory; Physical therapy","score_opus":0.1376378387101562,"score_gpt":0.4637631109652709,"score_spread":0.3261252722551147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98916155,0.000663621,0.00044151748,0.003326393,0.0034199306,0.0020629808,0.0000093833705,0.000016317541,0.0008983155],"genre_scores_gemma":[0.9927901,0.0004745494,0.0017594812,0.002427918,0.001983015,0.00033132397,0.000020165931,0.000052022562,0.0001614118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9886668,0.004084131,0.004959749,0.0004916551,0.0013343454,0.00046333877],"domain_scores_gemma":[0.98615396,0.008111437,0.0041610594,0.00036997936,0.00067242,0.000531139],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0194266,0.000301893,0.0049381857,0.00025163052,0.00010871445,0.00001980183,0.00036217822,0.0003944257,0.000634758],"category_scores_gemma":[0.0020842138,0.00018614615,0.0009451876,0.0005173539,0.00044679854,0.00015477046,0.00015782811,0.0033047586,0.0000025786728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69934016,0.0041307737,0.25240177,0.000024540626,0.0007828576,0.00038322445,0.00031009142,0.00020073552,1.6687913e-7,0.000045933688,0.00019438866,0.042185344],"study_design_scores_gemma":[0.8972309,0.03572984,0.05527156,0.00017415351,0.0011101281,0.0000639023,0.00060841563,0.00007159585,4.336626e-7,0.000047534875,0.009469586,0.00022192627],"about_ca_topic_score_codex":0.0008282851,"about_ca_topic_score_gemma":0.0045050387,"teacher_disagreement_score":0.19789076,"about_ca_system_score_codex":0.0004364511,"about_ca_system_score_gemma":0.0032795027,"threshold_uncertainty_score":0.99899465},"labels":[],"label_agreement":null},{"id":"W4286297736","doi":"10.1200/jco.2022.40.16_suppl.e21575","title":"Real-world changes in the clinical management of resected stage III melanoma at high risk of local recurrence in the era of modern systemic therapies.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Melanoma; Systemic therapy; Stage (stratigraphy); Adjuvant therapy; Lymph node; Adjuvant; Cancer; Dissection (medical); Radiation therapy; Surgery; Medical record; Internal medicine; Retrospective cohort study; Oncology; Breast cancer","score_opus":0.09095725202580443,"score_gpt":0.4155777017828459,"score_spread":0.3246204497570415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908642,0.00058397185,0.00018404971,0.004802194,0.0009059463,0.0007606565,0.000016659718,0.0000043599016,0.001877958],"genre_scores_gemma":[0.99122375,0.007339074,0.00033807312,0.0005525776,0.00017268323,0.000027799477,0.000003082219,0.000011617849,0.00033134848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9908179,0.0042230636,0.0036349038,0.00023107626,0.0008756968,0.0002173635],"domain_scores_gemma":[0.9912813,0.0043650386,0.0035995066,0.0005029222,0.0001761123,0.00007514342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015947424,0.00014072702,0.0015189685,0.00026705343,0.00005037728,0.0000031094044,0.0006068534,0.0001464846,0.00021835467],"category_scores_gemma":[0.00042617455,0.00008100338,0.00038843622,0.00057870534,0.00035777962,0.000028861943,0.00025831466,0.0018485715,0.0000011817776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05386942,0.011623257,0.20773631,0.00095537415,0.0026055232,0.0054804035,0.0069334116,0.001967234,0.00027527293,0.0077341674,0.004038817,0.6967808],"study_design_scores_gemma":[0.021281632,0.036212597,0.88833165,0.00075185474,0.0010505589,0.0007402211,0.021855064,0.0013482505,0.00009033085,0.0015434751,0.026591286,0.00020308713],"about_ca_topic_score_codex":0.0005241874,"about_ca_topic_score_gemma":0.0036046244,"teacher_disagreement_score":0.6965777,"about_ca_system_score_codex":0.00025070348,"about_ca_system_score_gemma":0.00026931253,"threshold_uncertainty_score":0.8031226},"labels":[],"label_agreement":null},{"id":"W4286297765","doi":"10.1200/jco.2022.40.16_suppl.tps4605","title":"TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Phases of clinical research; Clear cell renal cell carcinoma; Urology; Gastroenterology; Clinical trial; Cancer; Immunotherapy","score_opus":0.14702469632031276,"score_gpt":0.4409735268817561,"score_spread":0.2939488305614434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98502636,0.0013085781,0.0001319733,0.0034611905,0.00023640908,0.009676855,0.000010474315,0.000013350326,0.00013483521],"genre_scores_gemma":[0.9909934,0.00010478037,0.0069000246,0.0005560131,0.00024126258,0.0007785915,0.000017192951,0.00009168786,0.0003170773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98831964,0.004031619,0.0052361283,0.00067414757,0.0012203334,0.00051813445],"domain_scores_gemma":[0.99219906,0.0025278784,0.003301332,0.0005382397,0.00089432695,0.0005391394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009664431,0.0005162811,0.007453195,0.0007577405,0.0001280584,0.00006607718,0.0005786792,0.00012145932,0.000094045026],"category_scores_gemma":[0.0007298546,0.00032789633,0.0004499741,0.000763457,0.00018894736,0.000269076,0.00019915737,0.0013569482,0.0000014726402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7742681,0.15118201,0.050245773,0.00004970274,0.0011711575,0.0031607712,0.0049824486,0.00040941543,0.0056101913,0.0000021944616,0.000022535787,0.0088957045],"study_design_scores_gemma":[0.7567201,0.21194951,0.020136094,0.00066293974,0.0006193374,0.00008342625,0.0035230822,0.0016939744,0.0042344015,0.000006979863,0.00009737184,0.00027272987],"about_ca_topic_score_codex":0.0016846869,"about_ca_topic_score_gemma":0.009034368,"teacher_disagreement_score":0.060767498,"about_ca_system_score_codex":0.00073972787,"about_ca_system_score_gemma":0.002320004,"threshold_uncertainty_score":0.9999173},"labels":[],"label_agreement":null},{"id":"W4286297779","doi":"10.1200/jco.2022.40.16_suppl.7032","title":"Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia (R/R AML).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Quality of life (healthcare); Refractory (planetary science); IDH2; Randomized controlled trial; Clinical trial; Oncology; Gastroenterology; IDH1; Mutant","score_opus":0.09316453831724156,"score_gpt":0.43260420948397377,"score_spread":0.33943967116673224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170846,0.00040473553,0.00002138203,0.0052117268,0.00088219094,0.0009131528,0.00011808391,0.000021203507,0.0007190426],"genre_scores_gemma":[0.99450403,0.00037082855,0.001552766,0.0018968881,0.00020290197,0.000027126738,0.00012299593,0.000067635294,0.0012548314],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9887157,0.0029819224,0.005108571,0.0005242828,0.002020598,0.0006488888],"domain_scores_gemma":[0.9869124,0.0047213174,0.005596343,0.00053761376,0.0013553075,0.0008769739],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006052485,0.0003241755,0.0031380353,0.00045217815,0.0001624803,0.000009133106,0.00047067806,0.00048467732,0.0010080393],"category_scores_gemma":[0.0037209638,0.00021744461,0.00044011854,0.0007781928,0.00063326804,0.0002238226,0.00025212343,0.004767833,0.000010049603],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.52028245,0.005202415,0.44579518,0.0004413118,0.0034193222,0.0049780253,0.0022114157,0.0010965717,0.00020941961,0.00014458838,0.008070501,0.00814883],"study_design_scores_gemma":[0.1750108,0.08917916,0.7116809,0.00034737034,0.00042337316,0.00018047792,0.0034549462,0.00008079693,0.00004389088,0.000016967422,0.019228496,0.0003528251],"about_ca_topic_score_codex":0.00054874003,"about_ca_topic_score_gemma":0.0007473767,"teacher_disagreement_score":0.34527162,"about_ca_system_score_codex":0.0046671364,"about_ca_system_score_gemma":0.028773423,"threshold_uncertainty_score":0.99990517},"labels":[],"label_agreement":null},{"id":"W4286298010","doi":"10.1200/jco.2022.40.16_suppl.3036","title":"Test performance and clinical validity of circulating tumor DNA (ctDNA) in predicting relapse in solid tumors treated with curative intent therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Landmark; Circulating tumor DNA; Internal medicine; Oncology; Meta-analysis; Odds ratio; Cancer; Artificial intelligence","score_opus":0.07818553057709571,"score_gpt":0.3956230946297622,"score_spread":0.3174375640526665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99879813,0.00024149529,0.000017110486,0.0003049314,0.00023511001,0.00016385366,0.000013067412,0.000001455068,0.0002248548],"genre_scores_gemma":[0.9975793,0.0013877584,0.00036613672,0.00038816634,0.00024005372,0.000008067157,0.000005757875,0.000013886656,0.000010904926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968251,0.0005149916,0.0020711673,0.00023805548,0.00016545298,0.00018522199],"domain_scores_gemma":[0.99630696,0.0015574892,0.0017012766,0.00013939758,0.00017924224,0.00011561451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036555484,0.00012035074,0.00080598035,0.00008280044,0.000045303113,0.0000057453685,0.00017249821,0.00012971037,0.000010627235],"category_scores_gemma":[0.0038993305,0.00009661052,0.00014925339,0.00013853394,0.00019158861,0.000009113231,0.00016485552,0.00081375067,1.395466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020822985,0.0010557137,0.9816163,0.000008792566,0.00005968799,0.0001592103,0.00009773412,0.0010468842,0.0023729417,0.0000042882134,0.00008321923,0.011412919],"study_design_scores_gemma":[0.006973158,0.032000195,0.9545009,0.0000867113,0.000037456408,0.0002789746,0.0005743742,0.0022742646,0.0015101037,0.000038866598,0.0015854726,0.00013949264],"about_ca_topic_score_codex":0.000043228854,"about_ca_topic_score_gemma":0.00019230408,"teacher_disagreement_score":0.030944481,"about_ca_system_score_codex":0.000079129786,"about_ca_system_score_gemma":0.00092615216,"threshold_uncertainty_score":0.46681446},"labels":[],"label_agreement":null},{"id":"W4286298026","doi":"10.1200/jco.2022.40.16_suppl.1015","title":"Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Oncology; Aromatase inhibitor; Letrozole; Progression-free survival; Cancer; Breast cancer; Aromatase; Overall survival","score_opus":0.1017267633768129,"score_gpt":0.45310265736838784,"score_spread":0.35137589399157493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839031,0.0015223266,0.0008854741,0.008821865,0.001585905,0.0013533996,0.0017183934,0.00007314379,0.00013637572],"genre_scores_gemma":[0.99237895,0.00063880585,0.0040096794,0.0012184855,0.0011409529,0.0001512413,0.00022886466,0.00013522278,0.00009780482],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9878971,0.0025960186,0.006120849,0.00085867837,0.0017185679,0.00080877193],"domain_scores_gemma":[0.9811519,0.005855633,0.0095366575,0.0006342446,0.0017938215,0.0010277819],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023082036,0.00082832837,0.0064136083,0.00041247107,0.00037199247,0.000018603778,0.00057634903,0.00054251135,0.0012447654],"category_scores_gemma":[0.0014548217,0.00064947776,0.0010279004,0.00080352917,0.0011072656,0.0006408494,0.0002651133,0.0026384566,0.000009737322],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7401887,0.021490645,0.08936571,0.00066475547,0.013500589,0.00060698093,0.0070492476,0.012167806,0.036368515,0.00027328127,0.0024737427,0.075849995],"study_design_scores_gemma":[0.2169949,0.12536682,0.6168635,0.0009490689,0.002346189,0.00054015085,0.0052996553,0.00046105206,0.023405178,0.00062243274,0.0056130816,0.0015380093],"about_ca_topic_score_codex":0.0023069587,"about_ca_topic_score_gemma":0.0010874502,"teacher_disagreement_score":0.52749777,"about_ca_system_score_codex":0.0042826817,"about_ca_system_score_gemma":0.0052786036,"threshold_uncertainty_score":0.99966824},"labels":[],"label_agreement":null},{"id":"W4286298030","doi":"10.1200/jco.2022.40.16_suppl.8035","title":"Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Population; Oncology; Refractory (planetary science); Clinical trial; Surgery","score_opus":0.17223124497874664,"score_gpt":0.426324916349482,"score_spread":0.25409367137073535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365824,0.00094361394,0.00007679367,0.00082966994,0.0012472572,0.0025141253,0.00037352488,0.000019694524,0.00033707844],"genre_scores_gemma":[0.99551326,0.000836769,0.0022917558,0.00007452577,0.00030243254,0.00022696081,0.00016968684,0.00006294223,0.0005216627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327326,0.0011368787,0.0033493072,0.00044253873,0.0012090667,0.0005889617],"domain_scores_gemma":[0.98217714,0.012089566,0.003967002,0.0006021883,0.0006822002,0.00048188958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015460555,0.0004347385,0.0030760812,0.00036425263,0.00029065777,0.000011322091,0.0003952026,0.00030728534,0.0002564233],"category_scores_gemma":[0.0012737304,0.00024446694,0.0011541191,0.0003648454,0.0003961546,0.000097597695,0.00009144895,0.00076812523,0.000005094439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2723545,0.046711743,0.34102386,0.00008915726,0.0065708295,0.00043142232,0.0016036463,0.0001987346,0.00030819976,0.000022443359,0.00082034257,0.3298651],"study_design_scores_gemma":[0.21071772,0.29753247,0.41464013,0.00008080389,0.0023778167,0.000069895555,0.0020815053,0.00071839406,0.0018210952,0.000022194741,0.06972818,0.0002098048],"about_ca_topic_score_codex":0.00030096935,"about_ca_topic_score_gemma":0.0007600621,"teacher_disagreement_score":0.32965532,"about_ca_system_score_codex":0.0018319489,"about_ca_system_score_gemma":0.00207096,"threshold_uncertainty_score":0.9969072},"labels":[],"label_agreement":null},{"id":"W4286298041","doi":"10.1200/jco.2022.40.16_suppl.e14547","title":"Efficacy of the novel treatments of BCC with bone metastasis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; Providence Health Care","funders":"","keywords":"Vismodegib; Medicine; Basal cell carcinoma; Radiation therapy; Metastasis; Oncology; Dermatology; Internal medicine; Chemotherapy; Adverse effect; Basal cell; Cancer","score_opus":0.1178438574894156,"score_gpt":0.42310642634026296,"score_spread":0.30526256885084735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971542,0.00080673,0.00019289371,0.0007853179,0.00041700472,0.000111416455,0.000026856855,9.338349e-7,0.0005046516],"genre_scores_gemma":[0.99731356,0.00011030515,0.00186387,0.00032132346,0.00017580546,0.000003898199,0.0000022310483,0.000010831409,0.00019818613],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774027,0.00041411145,0.0012911849,0.00013628212,0.00029162897,0.00012654805],"domain_scores_gemma":[0.9970761,0.0004200776,0.0019577385,0.0002385968,0.0002414394,0.00006603497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017389132,0.00009725143,0.0007687629,0.00003719086,0.00005999085,0.0000012468308,0.00030733072,0.00009448895,0.000024232333],"category_scores_gemma":[0.0011040461,0.000055463042,0.0004409706,0.000119478675,0.00028970098,0.000002006027,0.00024514445,0.00030889493,3.4508852e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019105826,0.016085636,0.0796777,0.00006350023,0.009114996,0.00014145431,0.0005299675,0.0041166525,0.77681965,0.00024213089,0.0069186683,0.087183796],"study_design_scores_gemma":[0.038713828,0.0840022,0.32195216,0.000088383385,0.0025116885,0.00076614594,0.0011318871,0.00003048436,0.21675777,0.00013993101,0.33349872,0.0004067997],"about_ca_topic_score_codex":0.000008253678,"about_ca_topic_score_gemma":0.000011569399,"teacher_disagreement_score":0.5600619,"about_ca_system_score_codex":0.000026508265,"about_ca_system_score_gemma":0.00076064956,"threshold_uncertainty_score":0.22617173},"labels":[],"label_agreement":null},{"id":"W4286298060","doi":"10.1200/jco.2022.40.16_suppl.5509","title":"Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Internal medicine; Microsatellite instability; Oncology; Regimen; Discontinuation; Cohort; Interim analysis; Population; Endometrial cancer; Cancer; Clinical trial","score_opus":0.1477863281919131,"score_gpt":0.46961964950248314,"score_spread":0.3218333213105701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777823,0.0036727474,0.0000146731245,0.0037249166,0.011507898,0.0027360064,0.00008284003,0.00003886694,0.0004397633],"genre_scores_gemma":[0.9932283,0.0012025078,0.0014040933,0.0017903538,0.0009816419,0.0003133254,0.000009481997,0.000058393354,0.001011898],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888594,0.0026567786,0.0050598215,0.00081791467,0.001722105,0.00088394],"domain_scores_gemma":[0.988503,0.0069082305,0.0026221655,0.0007803272,0.0007324724,0.00045382231],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0123766195,0.0004218159,0.0026300754,0.00046932814,0.00027018815,0.00003400364,0.00083434716,0.0003202863,0.0036867715],"category_scores_gemma":[0.010832984,0.00024023604,0.00076699565,0.001921149,0.00048244337,0.00013257095,0.00066438346,0.003511773,0.0000124889875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26043895,0.030208496,0.49553058,0.00024732004,0.0009927948,0.0027538566,0.005037113,0.0063589234,0.0008191145,0.00003641967,0.010159585,0.18741684],"study_design_scores_gemma":[0.054941412,0.121969365,0.19918273,0.0002727854,0.00095237716,0.0008475211,0.010620407,0.00041357442,0.00039446072,0.00017467492,0.60964566,0.0005850495],"about_ca_topic_score_codex":0.00032943414,"about_ca_topic_score_gemma":0.0025117928,"teacher_disagreement_score":0.59948605,"about_ca_system_score_codex":0.0023018427,"about_ca_system_score_gemma":0.008046461,"threshold_uncertainty_score":0.99878716},"labels":[],"label_agreement":null},{"id":"W4286298149","doi":"10.1200/jco.2022.40.16_suppl.4564","title":"Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Metastatic Urothelial Carcinoma; Oncology; Post-hoc analysis; Chemotherapy; Gastroenterology; Cisplatin; Proportional hazards model; Cancer; Immunotherapy; Urothelial carcinoma; Bladder cancer; Nivolumab","score_opus":0.09915499778419397,"score_gpt":0.4290532779881926,"score_spread":0.32989828020399864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969409,0.000099454315,0.000009256658,0.00035975414,0.000063300286,0.0022166166,0.000053317497,0.0000061689457,0.00025123823],"genre_scores_gemma":[0.9987128,0.000012219164,0.0006855894,0.0002470543,0.00007175639,0.00016876179,0.000009289964,0.000046861005,0.000045679684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365777,0.002226851,0.002151069,0.00033890887,0.001239957,0.00038542436],"domain_scores_gemma":[0.9956689,0.0015946428,0.0017463829,0.00037506915,0.00040030247,0.00021470884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028359785,0.0003282125,0.0026264659,0.00041182333,0.000071779854,0.000011645672,0.00026768012,0.00007099275,0.00025648184],"category_scores_gemma":[0.0006340569,0.0001348257,0.00027907774,0.0009482968,0.0002534523,0.00013337912,0.000051649775,0.0011482442,0.0000011519899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15319595,0.018706508,0.8155888,0.000025554908,0.0015377041,0.0030033884,0.0012185349,0.00022179558,0.000002390372,0.0000012171618,0.000046604167,0.0064515867],"study_design_scores_gemma":[0.069273464,0.22208937,0.7034818,0.00007836022,0.0024117918,0.00053341984,0.0019232803,0.000032014006,0.000005281272,0.000005302655,0.000053532585,0.000112404785],"about_ca_topic_score_codex":0.0012294885,"about_ca_topic_score_gemma":0.0019560624,"teacher_disagreement_score":0.20338285,"about_ca_system_score_codex":0.0005125173,"about_ca_system_score_gemma":0.00462485,"threshold_uncertainty_score":0.82042855},"labels":[],"label_agreement":null},{"id":"W4286298155","doi":"10.1200/jco.2022.40.16_suppl.e18785","title":"Breast cancer after reduction mammoplasty: A population-based analysis of incidence, treatment, and screening patterns.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary; University of Toronto","funders":"","keywords":"Reduction Mammoplasty; Medicine; Mammoplasty; Augmentation Mammoplasty; Breast cancer; Population; Breast reduction; Mammography; Surgery; Incidence (geometry); Cancer; Mammaplasty; Internal medicine; Breast augmentation","score_opus":0.06314261004700047,"score_gpt":0.41827193772463894,"score_spread":0.3551293276776385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973233,0.00014739185,0.00020549646,0.0014757279,0.00067893777,0.00007522142,0.000072904346,0.0000037750528,0.000017250926],"genre_scores_gemma":[0.9983297,0.00009120371,0.00093840715,0.00010406636,0.0004554504,0.0000079607735,0.000016411333,0.000006003726,0.00005079183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817413,0.00026355416,0.0011476818,0.00012143322,0.00019781665,0.000095378455],"domain_scores_gemma":[0.9980558,0.0002905933,0.0012932313,0.00007493105,0.00015107504,0.00013433673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007794853,0.00007741722,0.00091426953,0.0004298693,0.00004895983,0.000003464742,0.000033670527,0.00010749236,0.0006010782],"category_scores_gemma":[0.00003479268,0.000055853612,0.00036839303,0.00030676645,0.00006219011,0.00006877306,0.000018833605,0.0003196422,1.9026045e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036833656,0.00022178247,0.6490982,0.0000070286796,0.00090143055,0.00004266058,0.000025259162,0.000400592,0.000017271417,0.0000016915307,0.00001856562,0.34558213],"study_design_scores_gemma":[0.002879332,0.0018690395,0.9760858,0.00003898745,0.0035447902,0.013703188,0.00015094422,0.0014553694,0.000009617299,0.000009559293,0.00020605908,0.000047332673],"about_ca_topic_score_codex":0.0006475612,"about_ca_topic_score_gemma":0.0002798183,"teacher_disagreement_score":0.3455348,"about_ca_system_score_codex":0.00016126923,"about_ca_system_score_gemma":0.00043483335,"threshold_uncertainty_score":0.6581385},"labels":[],"label_agreement":null},{"id":"W4286298168","doi":"10.1200/jco.2022.40.16_suppl.e21559","title":"Whose mitochondria are more stable, male or female ones? Response of neurosteroid status of mitochondria of cerebral cortex cells to melanoma development in presense of chronic pain.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Estrone; Internal medicine; Endocrinology; Testosterone (patch); Medicine; Hormone; Cerebral cortex; Subcutaneous injection","score_opus":0.0911648732861474,"score_gpt":0.43104749565425093,"score_spread":0.3398826223681035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495345,0.0010496299,0.000019490435,0.0013551835,0.0015844612,0.00083998137,0.000117524476,0.0000034090567,0.00007683752],"genre_scores_gemma":[0.994182,0.00039302,0.0030751051,0.0005012297,0.00021306278,0.000033369324,0.000008436713,0.00003028208,0.0015634957],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9923032,0.0021995057,0.0040967925,0.0003085209,0.00063690136,0.00045511077],"domain_scores_gemma":[0.9903958,0.004510252,0.0038221567,0.00033503212,0.0005242475,0.00041250818],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028684267,0.00022406552,0.002548533,0.0004950969,0.0000310712,0.0000021475896,0.00030220195,0.00022825578,0.0015697058],"category_scores_gemma":[0.001634252,0.00017935624,0.00040290836,0.0005079827,0.000272408,0.00007151722,0.00025468966,0.000791874,0.0000020511434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28995064,0.0144875115,0.32508534,0.0006302759,0.0009183827,0.0026242586,0.0035829253,0.0007243843,0.3324498,0.000005078486,0.018823033,0.010718387],"study_design_scores_gemma":[0.03121622,0.08830548,0.7388864,0.0003751041,0.00046739614,0.00033047586,0.0013998057,0.00010785605,0.058184173,0.000009771536,0.08051023,0.00020705115],"about_ca_topic_score_codex":0.00010626325,"about_ca_topic_score_gemma":0.00035843163,"teacher_disagreement_score":0.41380107,"about_ca_system_score_codex":0.00059164234,"about_ca_system_score_gemma":0.0058610216,"threshold_uncertainty_score":0.9997748},"labels":[],"label_agreement":null},{"id":"W4286298185","doi":"10.1200/jco.2022.40.16_suppl.tps4614","title":"A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Bladder cancer; Pembrolizumab; Cystectomy; Internal medicine; Cohort; Carcinoma in situ; Oncology; Urology; Concomitant; Cancer; Surgery; Gastroenterology; Immunotherapy","score_opus":0.05761441077137525,"score_gpt":0.3880984322002823,"score_spread":0.33048402142890704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98700756,0.000097959484,0.000009806783,0.0006060997,0.001119547,0.010878535,0.00017953636,0.0000124112985,0.00008857178],"genre_scores_gemma":[0.9971253,0.000024383417,0.00037116595,0.0005466632,0.00044642316,0.0011179928,0.000010823134,0.000063550506,0.00029366597],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99393106,0.0015575278,0.0022967763,0.0004947811,0.0012814733,0.00043836498],"domain_scores_gemma":[0.9935543,0.0015726866,0.00295192,0.0005011723,0.0010652606,0.0003546777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017965,0.00033734366,0.0018302592,0.00015223808,0.00031123424,0.000017230728,0.0003980114,0.00015799928,0.00015043684],"category_scores_gemma":[0.0014982676,0.00020229332,0.00045036295,0.0003725266,0.00017497035,0.000072159164,0.00022896142,0.001181865,0.0000021695305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07867917,0.22281948,0.64927757,0.000052939846,0.0027887202,0.001371076,0.0018146426,0.00008234821,0.00034710488,6.9589885e-7,0.000837063,0.04192921],"study_design_scores_gemma":[0.13023297,0.5525438,0.30481815,0.00007022778,0.0040296544,0.00007603701,0.0038278068,0.0000105796535,0.0004948216,0.000019457888,0.0036675273,0.0002089803],"about_ca_topic_score_codex":0.0017071313,"about_ca_topic_score_gemma":0.0014444311,"teacher_disagreement_score":0.3444594,"about_ca_system_score_codex":0.0007622591,"about_ca_system_score_gemma":0.0041355113,"threshold_uncertainty_score":0.82492816},"labels":[],"label_agreement":null},{"id":"W4286298199","doi":"10.1200/jco.2022.40.16_suppl.5058","title":"Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Disease; Androgen receptor; Transcriptome; Cancer; Oncology; Bioinformatics; Cancer research; Internal medicine; Genetics; Biology; Gene; Gene expression","score_opus":0.14846742324663345,"score_gpt":0.48801363054230923,"score_spread":0.33954620729567575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311846,0.0031472372,0.000039563303,0.0021949292,0.00040920242,0.00022034899,0.00003123115,0.0000029946568,0.0008360541],"genre_scores_gemma":[0.9925636,0.00060622266,0.005711751,0.00024023214,0.00013601575,0.000009624596,0.0000040508403,0.00001184119,0.00071663485],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963648,0.00049412914,0.0021834306,0.00012956059,0.0006462163,0.0001818732],"domain_scores_gemma":[0.9969951,0.00079136505,0.0014545155,0.0001433651,0.00046077895,0.00015487446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003463263,0.000086877095,0.0012981112,0.00016547534,0.000039712057,0.0000016649187,0.00017091131,0.00012261765,0.00021891293],"category_scores_gemma":[0.0010075539,0.00006303611,0.00048629683,0.00019111148,0.00028753196,0.000047779755,0.00005143617,0.0006305936,8.5651374e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048822213,0.0048521976,0.45608738,0.00083617156,0.0012187614,0.0036034097,0.00059977424,0.00009085001,0.4579374,0.0010275512,0.0014939057,0.023430385],"study_design_scores_gemma":[0.04425882,0.048025418,0.6280504,0.00094306556,0.0016384468,0.0010831791,0.0029498672,0.0001344961,0.23655532,0.011765235,0.02424346,0.00035229395],"about_ca_topic_score_codex":0.0000055247574,"about_ca_topic_score_gemma":0.000004523104,"teacher_disagreement_score":0.22138207,"about_ca_system_score_codex":0.00014503713,"about_ca_system_score_gemma":0.0017703671,"threshold_uncertainty_score":0.31405553},"labels":[],"label_agreement":null},{"id":"W4286298407","doi":"10.1200/jco.2022.40.16_suppl.11528","title":"A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Refractory (planetary science); Chondrosarcoma; Cancer; Gastroenterology; Surgery; Immunotherapy; Nivolumab","score_opus":0.13544740700773397,"score_gpt":0.5229142548348268,"score_spread":0.38746684782709284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958854,0.00078726583,0.0000011260622,0.0021725309,0.0005328549,0.00034349956,0.0000073848764,0.000003671248,0.0002662938],"genre_scores_gemma":[0.99870414,0.0005007366,0.00018504231,0.0003859533,0.00013868092,0.000009128784,0.0000035988053,0.0000130309845,0.000059722337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964706,0.00063684507,0.0021415467,0.00018713433,0.00038150378,0.0001824221],"domain_scores_gemma":[0.99721247,0.0009852762,0.0013157694,0.00016780908,0.000096937634,0.0002217629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019264286,0.00011703627,0.0017149777,0.00023609566,0.000047140846,0.0000037110715,0.00011896601,0.000083920255,0.00014657684],"category_scores_gemma":[0.0006325078,0.00008706828,0.00022084755,0.00023106164,0.00011483956,0.00006383847,0.00012251112,0.0008888819,0.000001598493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036970165,0.09781261,0.86777335,0.000019071673,0.00035741806,0.0076180412,0.0004331062,0.000008887455,0.00038879286,0.000032162654,0.00050620775,0.021353334],"study_design_scores_gemma":[0.06867424,0.08985805,0.8333663,0.000037437487,0.00037644865,0.0011140222,0.0010409231,0.00004849256,0.00003824012,0.00011494364,0.005267071,0.0000638826],"about_ca_topic_score_codex":0.0001048826,"about_ca_topic_score_gemma":0.000035674067,"teacher_disagreement_score":0.06497722,"about_ca_system_score_codex":0.00009638432,"about_ca_system_score_gemma":0.00045425358,"threshold_uncertainty_score":0.3861799},"labels":[],"label_agreement":null},{"id":"W4286298413","doi":"10.1200/jco.2022.40.16_suppl.11515","title":"INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer; Internal medicine; Nausea; Combination therapy; Gastroenterology; Adverse effect; Vomiting; Common Terminology Criteria for Adverse Events; Oncology","score_opus":0.09199061574928084,"score_gpt":0.4698823754610562,"score_spread":0.37789175971177535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805474,0.000746468,0.00012025812,0.016808862,0.00051422534,0.00043594697,0.000006405066,0.000009607925,0.00081081735],"genre_scores_gemma":[0.99453527,0.0013341844,0.00058608403,0.0019910175,0.00031505877,0.000008502983,0.000004138004,0.000035522866,0.0011901995],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953546,0.0009707404,0.0020996458,0.00030961513,0.0008705564,0.00039485245],"domain_scores_gemma":[0.9952159,0.002253323,0.0014690933,0.0003291471,0.00042099712,0.0003115176],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006248058,0.0001846583,0.0018060064,0.00029177495,0.00009193774,0.00001281081,0.00027579482,0.00027707245,0.0013404931],"category_scores_gemma":[0.0011564196,0.00014570034,0.00023534909,0.00038521897,0.00056483713,0.00013799426,0.00018373042,0.0026738015,0.000004131447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16645157,0.011640949,0.28001237,0.00013339601,0.0008964923,0.003077297,0.0036669285,0.000120592355,0.032196954,0.00008801225,0.0044861757,0.49722928],"study_design_scores_gemma":[0.05108101,0.0838832,0.64023393,0.00016256304,0.00013278848,0.0025930994,0.0024126042,0.0005391884,0.0021032672,0.0013607419,0.21522728,0.00027034097],"about_ca_topic_score_codex":0.00020513734,"about_ca_topic_score_gemma":0.0005249907,"teacher_disagreement_score":0.4969589,"about_ca_system_score_codex":0.00056628336,"about_ca_system_score_gemma":0.0013132793,"threshold_uncertainty_score":0.99962705},"labels":[],"label_agreement":null},{"id":"W4286298419","doi":"10.1200/jco.2022.40.16_suppl.3039","title":"Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Lung Health Foundation","keywords":"Medicine; Lung cancer; Cohort; Liquid biopsy; Biopsy; Stage (stratigraphy); Clinical endpoint; Internal medicine; Lung; Cancer; Oncology; Pathology; Gastroenterology; Clinical trial","score_opus":0.08662869958223099,"score_gpt":0.43107391299901954,"score_spread":0.3444452134167886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983484,0.004352687,0.00026004497,0.0061604013,0.003771254,0.00012384933,0.00007028188,0.0000037554223,0.0017736824],"genre_scores_gemma":[0.97809756,0.010430226,0.003269175,0.0044526737,0.0034394488,0.00011056863,0.000013699077,0.000028990924,0.0001576734],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975885,0.00023893124,0.0014356298,0.00025167424,0.00023000978,0.00025525308],"domain_scores_gemma":[0.99731517,0.0007822991,0.0013217337,0.00020660467,0.00020893331,0.00016523707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013198038,0.00013821594,0.0006087676,0.00003917344,0.00021084827,0.000017585555,0.00040977515,0.0002258376,0.00058363617],"category_scores_gemma":[0.0017621462,0.00012661707,0.00042040687,0.00010522477,0.000099989105,0.000007959844,0.0004126813,0.00062936416,0.0000021935807],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010741656,0.0037674066,0.2995698,0.00008292833,0.001880313,0.0008314823,0.0006085238,0.019776355,0.008883733,0.0010374916,0.5602728,0.09254753],"study_design_scores_gemma":[0.0029827338,0.008710407,0.0036089253,0.000017721735,0.00015349856,0.00018466334,0.00017463596,0.00025181097,0.0028930584,0.00007855515,0.98074085,0.00020313851],"about_ca_topic_score_codex":0.000074721,"about_ca_topic_score_gemma":0.00017492626,"teacher_disagreement_score":0.42046806,"about_ca_system_score_codex":0.0001363405,"about_ca_system_score_gemma":0.0013616793,"threshold_uncertainty_score":0.63904065},"labels":[],"label_agreement":null},{"id":"W4286298426","doi":"10.1200/jco.2022.40.16_suppl.8052","title":"Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Daratumumab; Clinical endpoint; Oncology; Dexamethasone; Subgroup analysis; Clinical trial; Confidence interval","score_opus":0.15148787291625726,"score_gpt":0.45750047916652814,"score_spread":0.3060126062502709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675494,0.0007748758,0.000010934652,0.00077076466,0.00026018434,0.00133846,0.000060137238,0.0000070118526,0.000022705643],"genre_scores_gemma":[0.99729264,0.0006836387,0.0011625604,0.00036264086,0.00006815281,0.00013495627,0.00001741909,0.00004296543,0.00023500614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99215215,0.0029263096,0.0027013542,0.00050587876,0.0011960819,0.00051823055],"domain_scores_gemma":[0.9905915,0.0060846615,0.0020450035,0.0004245914,0.0005357735,0.00031843325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004083091,0.0003559451,0.0029422801,0.0012551305,0.00011560828,0.000015844089,0.00028219048,0.00028176626,0.00019473046],"category_scores_gemma":[0.005838659,0.00017648311,0.000280105,0.0022052424,0.00062899635,0.00026259778,0.00020353572,0.0021025632,8.3663446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40631077,0.0070972615,0.547127,0.000039401446,0.0023440244,0.005880752,0.0020480312,0.00020992891,0.000043051707,0.0000010184386,0.000029294935,0.028869454],"study_design_scores_gemma":[0.19120851,0.060782462,0.7439207,0.00025731997,0.0007435882,0.00011399035,0.0011758575,0.0013443754,0.00003703608,0.000007866589,0.00024295,0.00016533061],"about_ca_topic_score_codex":0.0007609,"about_ca_topic_score_gemma":0.020784708,"teacher_disagreement_score":0.21510226,"about_ca_system_score_codex":0.0015722193,"about_ca_system_score_gemma":0.0028973792,"threshold_uncertainty_score":0.9970834},"labels":[],"label_agreement":null},{"id":"W4286298670","doi":"10.1200/jco.2022.40.16_suppl.tps7072","title":"Emotion and symptom-focused engagement (EASE): A multisite randomized controlled trial of an intervention for individuals with acute leukemia.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Randomized controlled trial; Psychosocial; Psychological intervention; Palliative care; Distress; Intervention (counseling); Psychiatry; Physical therapy; Clinical psychology; Nursing; Internal medicine","score_opus":0.07777380951158785,"score_gpt":0.45710751168431346,"score_spread":0.3793337021727256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866451,0.00021971663,0.0029253466,0.004343573,0.0013205733,0.004421432,0.000024861667,0.000011461475,0.000087943954],"genre_scores_gemma":[0.98568285,0.00016176829,0.0114423325,0.0013358343,0.0009643616,0.00024715223,0.000023578452,0.000022644943,0.0001195057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98834425,0.0059156884,0.004560271,0.00023942854,0.0007598116,0.00018052167],"domain_scores_gemma":[0.9833355,0.0098801,0.0058879703,0.00020335669,0.00041109129,0.00028195756],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03796704,0.0001651919,0.0046352874,0.0002393369,0.00009560214,0.000012406466,0.00015748377,0.00017267988,0.00011619817],"category_scores_gemma":[0.008312177,0.00011178836,0.0012773804,0.00010615556,0.00022337891,0.00014302989,0.00008707133,0.00086899207,3.3385535e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96426636,0.0033394182,0.00088941853,0.000065796026,0.004167894,0.000057606223,0.0010517046,0.000042570297,0.000030054027,0.00009792928,0.00031152496,0.025679717],"study_design_scores_gemma":[0.921629,0.06650919,0.003053083,0.00013976342,0.0041298065,0.00014515303,0.0007189335,0.00071815687,0.000026876229,0.00040045145,0.0024334402,0.00009614867],"about_ca_topic_score_codex":0.000051792464,"about_ca_topic_score_gemma":0.00003347563,"teacher_disagreement_score":0.06316977,"about_ca_system_score_codex":0.00023241148,"about_ca_system_score_gemma":0.0011821553,"threshold_uncertainty_score":0.9951053},"labels":[],"label_agreement":null},{"id":"W4286298696","doi":"10.1200/jco.2022.40.16_suppl.4560","title":"Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Avelumab; Medicine; Internal medicine; Metastatic Urothelial Carcinoma; Discontinuation; Maintenance therapy; Randomization; Gemcitabine; Oncology; Bladder cancer; Surgery; Gastroenterology; Chemotherapy; Urology; Nivolumab; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy","score_opus":0.1344244734599757,"score_gpt":0.4257519701847146,"score_spread":0.2913274967247389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541354,0.00040794304,0.0001685147,0.0015998587,0.00075360964,0.0010999014,0.00027094877,0.000025072752,0.00026058042],"genre_scores_gemma":[0.9923361,0.00041904495,0.001997313,0.002337619,0.0005606557,0.00013643995,0.0000856025,0.00009719404,0.0020300199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457103,0.0006636553,0.0026066583,0.0006762804,0.00087009865,0.00061228883],"domain_scores_gemma":[0.99500734,0.001182063,0.0021281815,0.00055671786,0.0005823217,0.0005433681],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007034164,0.0005580435,0.003460245,0.00032642667,0.00017761218,0.000019373923,0.0003385177,0.00025939418,0.0020824107],"category_scores_gemma":[0.00044645282,0.00031026418,0.00047774953,0.00040379365,0.00029525196,0.00028853107,0.000111917674,0.0011995302,0.000013991475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096419126,0.0071906354,0.8658486,0.000022502776,0.0020024243,0.0021465078,0.00060257793,0.00028099882,0.000019768253,9.3396096e-7,0.00015974038,0.025306191],"study_design_scores_gemma":[0.09575445,0.08901289,0.8097873,0.00017700586,0.0013474543,0.00009726583,0.0003438921,0.00006458422,0.00013553894,0.000024707375,0.002937256,0.00031767014],"about_ca_topic_score_codex":0.00022752001,"about_ca_topic_score_gemma":0.0052109044,"teacher_disagreement_score":0.081822254,"about_ca_system_score_codex":0.0011024734,"about_ca_system_score_gemma":0.003128018,"threshold_uncertainty_score":0.999935},"labels":[],"label_agreement":null},{"id":"W4286298705","doi":"10.1200/jco.2022.40.16_suppl.2023","title":"Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and to better predict intracranial tumor response in patients with non–small cell lung cancer with brain metastases: A prospective cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Liquid biopsy; Cerebrospinal fluid; Concordance; Lung cancer; Internal medicine; Circulating tumor cell; Brain tumor; Cell-free fetal DNA; Oncology; Cancer; Primary tumor; Circulating tumor DNA; Pathology; Metastasis; Biology","score_opus":0.012566644823849742,"score_gpt":0.3470967485761972,"score_spread":0.3345301037523475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968136,0.000112023234,0.00066162,0.0002921718,0.0001875169,0.0017810357,0.00014607968,0.0000017735283,0.0000041997764],"genre_scores_gemma":[0.9889032,0.000008156262,0.010375322,0.00038943405,0.000097938,0.00017720435,0.000005653238,0.00003648695,0.0000065758704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645483,0.0008374696,0.0016209409,0.0004220919,0.0003915651,0.00027311448],"domain_scores_gemma":[0.9971183,0.0006828246,0.0013275453,0.0002297855,0.0004194136,0.00022215597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027933281,0.00021466298,0.0010321331,0.00020958312,0.00005913076,0.000014602473,0.00026804936,0.000051245195,0.000010587926],"category_scores_gemma":[0.0013382025,0.00017847256,0.00011108215,0.0002744653,0.000109885645,0.00001070811,0.0002702692,0.00041046838,9.3338244e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019187884,0.0012643028,0.94072217,0.000071659575,0.0003617879,0.0002594232,0.00039709976,0.0073884604,0.029639767,5.061099e-7,0.00004786051,0.0006590674],"study_design_scores_gemma":[0.0062370296,0.039921083,0.94958925,0.00012418439,0.0003024657,0.000053928357,0.0006799582,0.00020616311,0.0026669123,0.000007938731,0.0000261739,0.00018493288],"about_ca_topic_score_codex":0.00015732503,"about_ca_topic_score_gemma":0.00028210424,"teacher_disagreement_score":0.03865678,"about_ca_system_score_codex":0.00021658192,"about_ca_system_score_gemma":0.0016241303,"threshold_uncertainty_score":0.72779},"labels":[],"label_agreement":null},{"id":"W4286298719","doi":"10.1200/jco.2022.40.16_suppl.8019","title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Cohort; Adverse effect; Internal medicine; Gastroenterology; Pharmacology; Oncology; Surgery","score_opus":0.029723395850542424,"score_gpt":0.36360403092387455,"score_spread":0.33388063507333215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975255,0.0001092986,0.000013841218,0.0002201313,0.00030850878,0.0017076614,0.000016724583,0.000008130992,0.000090214264],"genre_scores_gemma":[0.99898285,0.000035989084,0.00057866913,0.000104252314,0.00007979467,0.00007876335,0.00004338922,0.000036508238,0.00005976591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940366,0.0018113981,0.0021269703,0.0003510711,0.001255896,0.0004180354],"domain_scores_gemma":[0.9923871,0.004762371,0.0017291093,0.00029699056,0.00040266773,0.00042171727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024045643,0.00024586543,0.0016968023,0.00062299863,0.00006606964,0.00000764593,0.00021744803,0.00016632784,0.000065024615],"category_scores_gemma":[0.0042310227,0.0001677975,0.00016979456,0.0005385939,0.00021892959,0.00016049232,0.00013996492,0.0017039932,0.0000044802932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07024161,0.042485222,0.85136116,0.00016026828,0.00037708378,0.009438407,0.0003990303,0.00010804703,0.000094266594,0.0000048153024,0.00007841049,0.025251705],"study_design_scores_gemma":[0.12665096,0.105347864,0.76651174,0.0003148128,0.00017819967,0.00003878289,0.00041324325,0.0001890648,0.00008347263,0.0000124288545,0.00014681392,0.00011259333],"about_ca_topic_score_codex":0.00020670175,"about_ca_topic_score_gemma":0.0008144578,"teacher_disagreement_score":0.08484937,"about_ca_system_score_codex":0.0007320188,"about_ca_system_score_gemma":0.001636939,"threshold_uncertainty_score":0.7403097},"labels":[],"label_agreement":null},{"id":"W4286298899","doi":"10.1200/jco.2022.40.16_suppl.e13526","title":"Canadian medical oncology workforce and cancer incidence trends: Supply and proxy demand analyses from 1994 to 2020.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Workforce; Cancer incidence; Incidence (geometry); Cancer registry; Cohort; Demography; Population; Cancer; Proxy (statistics); Family medicine; Environmental health; Internal medicine; Statistics; Economic growth","score_opus":0.12860106752037218,"score_gpt":0.43722333562952914,"score_spread":0.30862226810915694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91283506,0.020204734,0.00018120818,0.05147006,0.0024591002,0.00014416507,0.00031071398,0.000006294585,0.012388675],"genre_scores_gemma":[0.9691872,0.009436096,0.0013303165,0.01779227,0.0013976193,0.00002608484,0.0000043111017,0.000020510402,0.000805617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646175,0.0001759762,0.002444885,0.00040052706,0.00011375627,0.000403129],"domain_scores_gemma":[0.99552315,0.0011043053,0.0016282098,0.00016563425,0.00006144916,0.0015172374],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004024931,0.00016614216,0.0016859637,0.00035173487,0.00018129508,0.000036767375,0.00041412306,0.00039254088,0.0046763383],"category_scores_gemma":[0.0023442765,0.0001656897,0.00019518206,0.0002645779,0.00021125351,0.00024543251,0.00022437394,0.0011278432,0.000018158695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057932077,0.00016266615,0.43417266,0.000004632534,0.00023631791,0.00037839156,0.00051348266,0.00023958363,0.0000027933145,0.002210338,0.02944028,0.53205955],"study_design_scores_gemma":[0.0016894017,0.0022656803,0.18810472,0.000019894858,0.000046426387,0.00008997219,0.0001672559,0.00044564635,0.0000015032836,0.0041730427,0.80281544,0.00018099525],"about_ca_topic_score_codex":0.07769935,"about_ca_topic_score_gemma":0.13358624,"teacher_disagreement_score":0.77337515,"about_ca_system_score_codex":0.0008184482,"about_ca_system_score_gemma":0.002871023,"threshold_uncertainty_score":0.9962335},"labels":[],"label_agreement":null},{"id":"W4286298929","doi":"10.1200/jco.2022.40.16_suppl.e18530","title":"Variations in Ewing sarcoma and rhabdomyosarcoma patient outcomes based on treatment center volume.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Rhabdomyosarcoma; Sarcoma; Ewing's sarcoma; Cancer; Proportional hazards model; Retrospective cohort study; Surgery; Internal medicine; Pathology","score_opus":0.0997866183177801,"score_gpt":0.4279913151365361,"score_spread":0.32820469681875597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95940703,0.00027962655,0.000024236373,0.038301013,0.00072057225,0.00030264878,0.000015424966,0.00000648237,0.0009429427],"genre_scores_gemma":[0.9906869,0.00010130523,0.002188958,0.0067926245,0.000108806606,0.000044573124,0.0000072239955,0.000013641121,0.000055970442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997105,0.00060170994,0.0015358981,0.00019594094,0.00035941292,0.00020203085],"domain_scores_gemma":[0.99619544,0.0025882425,0.0007194045,0.00018324274,0.000074948766,0.00023872689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096704595,0.00014907682,0.0011495132,0.00025277396,0.000088056535,0.000007985846,0.000070075635,0.000095933014,0.0003214183],"category_scores_gemma":[0.0006827855,0.00009752973,0.00042900257,0.00012356625,0.00005317757,0.000040704857,0.000056362725,0.0004889686,0.00000621184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011248029,0.013857959,0.763366,0.0000024653887,0.00017975672,0.0016329767,0.0001223841,0.00009166002,0.0000022980287,0.00007444435,0.0006559265,0.21888937],"study_design_scores_gemma":[0.017057369,0.0263872,0.86656785,0.000029233195,0.0001874966,0.0002146684,0.00013992628,0.0011164624,0.000006779076,0.00010334867,0.08812095,0.00006873525],"about_ca_topic_score_codex":0.00004825297,"about_ca_topic_score_gemma":0.00003682331,"teacher_disagreement_score":0.21882063,"about_ca_system_score_codex":0.0007297362,"about_ca_system_score_gemma":0.0005674155,"threshold_uncertainty_score":0.3977147},"labels":[],"label_agreement":null},{"id":"W4286298930","doi":"10.1200/jco.2022.40.16_suppl.e24120","title":"Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Asymptomatic; Population; Internal medicine; Cohort; Breast cancer; Disease; Environmental health","score_opus":0.19853488419119875,"score_gpt":0.5111715247900571,"score_spread":0.3126366405988584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870954,0.0002128495,0.000048800724,0.011736908,0.00031840263,0.0005011515,0.000018880173,0.0000025763266,0.000064990556],"genre_scores_gemma":[0.99494827,0.00021569473,0.00014576103,0.0045152353,0.00013282764,0.000010975483,5.752906e-7,0.0000070391134,0.000023628716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974102,0.0005337854,0.001234572,0.00013194823,0.0005613293,0.00012817432],"domain_scores_gemma":[0.9956498,0.000845052,0.0024938276,0.00014923386,0.00059192814,0.00027011824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022926552,0.00007880253,0.000843829,0.00006654713,0.00008377165,0.0000015724332,0.00012955107,0.00010698866,0.00016997194],"category_scores_gemma":[0.005513584,0.000044273944,0.00015181901,0.00018771486,0.00032548496,0.000055875083,0.00007129335,0.0008379871,1.1730563e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046461276,0.00063178944,0.9650582,0.0001372876,0.00009140457,0.000018259449,0.0006399132,0.00004469032,0.00021189866,0.000009648314,0.00052527554,0.027985519],"study_design_scores_gemma":[0.004937749,0.017273666,0.9729496,0.00009692506,0.00014820363,0.000039577553,0.000555038,0.000011199187,0.000022696428,0.00013191068,0.00379175,0.000041655712],"about_ca_topic_score_codex":0.0007365611,"about_ca_topic_score_gemma":0.0007802374,"teacher_disagreement_score":0.027943864,"about_ca_system_score_codex":0.00036843988,"about_ca_system_score_gemma":0.0060108365,"threshold_uncertainty_score":0.99962413},"labels":[],"label_agreement":null},{"id":"W4286298951","doi":"10.1200/jco.2022.40.16_suppl.10051","title":"The relationship between chronic health conditions and employment transitions among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Childhood cancer; Socioeconomic status; Poisson regression; Demography; Cancer; Population; Internal medicine; Environmental health","score_opus":0.14863841126538113,"score_gpt":0.4856757084781737,"score_spread":0.3370372972127926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8525257,0.011452944,0.000039363866,0.13230829,0.0016886308,0.0013570416,0.00054042455,0.000021252668,0.000066344524],"genre_scores_gemma":[0.9915096,0.0022304896,0.00005657337,0.003445236,0.0023629952,0.00018139355,0.000058847283,0.000044009434,0.00011083282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9880365,0.0046250867,0.0051454445,0.00045491615,0.0013022815,0.00043577125],"domain_scores_gemma":[0.97661835,0.016755069,0.00503549,0.00069756835,0.0003731499,0.000520379],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013217847,0.00027210845,0.0020762924,0.00012924241,0.0011944493,0.000025543499,0.0004924464,0.00018054279,0.00030119802],"category_scores_gemma":[0.003290119,0.00017867403,0.00064697437,0.00051296636,0.00070829375,0.000156166,0.00018772167,0.0027942844,0.0000012668463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031260887,0.002670833,0.972749,0.000019601948,0.0016911742,0.00007243717,0.00811865,0.00015123593,0.0000011744157,0.00006726468,0.006955114,0.007190901],"study_design_scores_gemma":[0.006283329,0.007318099,0.9574962,0.00019816382,0.0010938891,0.00014126432,0.0076982514,0.000006618266,0.0000017215193,0.0005583579,0.019051688,0.0001524017],"about_ca_topic_score_codex":0.024024317,"about_ca_topic_score_gemma":0.102107786,"teacher_disagreement_score":0.1389839,"about_ca_system_score_codex":0.0007128377,"about_ca_system_score_gemma":0.008732394,"threshold_uncertainty_score":0.9995063},"labels":[],"label_agreement":null},{"id":"W4286298970","doi":"10.1200/jco.2022.40.16_suppl.5047","title":"Tolerability of [<sup>177</sup>Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Prostate cancer; Adverse effect; Taxane; Internal medicine; Urology; Gastroenterology; Clinical trial; Cancer; Breast cancer","score_opus":0.07360753000731195,"score_gpt":0.4581354245937601,"score_spread":0.38452789458644815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957408,0.00090329413,0.0000054886,0.0014686442,0.00011730775,0.0015375924,0.00015974353,0.0000053597373,0.0000617754],"genre_scores_gemma":[0.9987354,0.00026182312,0.0003006716,0.00011394672,0.000060327682,0.00014517401,0.00007050718,0.000019075353,0.00029303523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99372584,0.001589267,0.002764896,0.00040968205,0.0011574466,0.0003528895],"domain_scores_gemma":[0.99610794,0.0009800239,0.0016166014,0.00034116078,0.00062287285,0.0003314209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030414504,0.00024008467,0.002356598,0.00037387374,0.00010762502,0.000013961391,0.00017851332,0.00009207353,0.00036906052],"category_scores_gemma":[0.00030295548,0.00014309646,0.00045796295,0.0008974038,0.00021181033,0.00014493617,0.00007517838,0.0007744864,8.19558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04185062,0.027995395,0.8950417,0.000042318024,0.0036607592,0.00051106495,0.0018061976,0.002504202,0.00005753935,0.0000016711981,0.00025670603,0.026271837],"study_design_scores_gemma":[0.038916886,0.12358579,0.8297384,0.000038998485,0.0027362905,0.00000806516,0.0036228383,0.00027158967,0.000033224496,0.000024124882,0.00090872234,0.00011512034],"about_ca_topic_score_codex":0.00079480297,"about_ca_topic_score_gemma":0.0013380246,"teacher_disagreement_score":0.09559039,"about_ca_system_score_codex":0.0013003885,"about_ca_system_score_gemma":0.0023923728,"threshold_uncertainty_score":0.5835304},"labels":[],"label_agreement":null},{"id":"W4286299131","doi":"10.1200/jco.2022.40.16_suppl.2587","title":"Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Kelowna General Hospital","funders":"","keywords":"Medicine; Microsatellite instability; Internal medicine; Oncology; Cohort; Cancer; Discontinuation; Colorectal cancer","score_opus":0.0513029500556739,"score_gpt":0.41039273397851095,"score_spread":0.359089783922837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811816,0.00019829292,0.0000034641228,0.0005180199,0.00019712573,0.00065368984,0.000010592194,0.0000023463808,0.00029831094],"genre_scores_gemma":[0.9991457,0.00006411377,0.00034965837,0.0003736514,0.000033409025,0.000011271269,0.0000043549344,0.000009365286,0.0000084828425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943911,0.0013303705,0.002979789,0.00023239956,0.0008721414,0.00019419237],"domain_scores_gemma":[0.99472237,0.002682264,0.0019017308,0.00029808178,0.00029155935,0.00010400812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064310567,0.00012573705,0.0020195134,0.00042515507,0.0000301595,0.0000023386885,0.0002196842,0.00009745749,0.00013353214],"category_scores_gemma":[0.0018193222,0.0000764632,0.0002796289,0.0010048096,0.00022478538,0.000023682362,0.00013953229,0.0009400897,1.696363e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019846039,0.00959926,0.9592662,0.000022724087,0.0008066739,0.00021553841,0.0022831813,0.0041118427,0.000012245143,0.0000029682124,0.00018815005,0.0036452156],"study_design_scores_gemma":[0.01415995,0.04731991,0.9336808,0.000050697035,0.0013396183,0.000033762703,0.0025034065,0.0002756257,0.0000069970074,0.000011590417,0.0005554378,0.00006224745],"about_ca_topic_score_codex":0.00013077309,"about_ca_topic_score_gemma":0.00061473117,"teacher_disagreement_score":0.037720654,"about_ca_system_score_codex":0.00025070802,"about_ca_system_score_gemma":0.000764426,"threshold_uncertainty_score":0.40842742},"labels":[],"label_agreement":null},{"id":"W4286299145","doi":"10.1200/jco.2022.40.16_suppl.7015","title":"Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Anemia; Gastroenterology; Clinical trial; Oncology; Bone marrow","score_opus":0.0949849504133424,"score_gpt":0.45899286883157475,"score_spread":0.3640079184182323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361604,0.0002808326,0.0000025387012,0.0028043478,0.0004529088,0.0024941782,0.000029533358,0.0000050280664,0.00031456005],"genre_scores_gemma":[0.99677837,0.00020239042,0.0011224836,0.0014636323,0.00018712046,0.00014893325,0.000018793939,0.000025486894,0.000052803505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946886,0.0013523006,0.0026605565,0.00042165318,0.0005489859,0.00032791053],"domain_scores_gemma":[0.9950601,0.00274861,0.0013436121,0.00021213802,0.00025571638,0.0003798489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024838634,0.00024271556,0.001977098,0.0002468962,0.00011111498,0.000021684593,0.00022878704,0.00014797898,0.00010136903],"category_scores_gemma":[0.0013586583,0.00017015336,0.000103243336,0.00028176184,0.0001408452,0.00019273302,0.000447562,0.001391714,0.0000030157262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12820071,0.10281509,0.7060651,0.000021647924,0.0002924073,0.0025055762,0.0015836828,0.000042088093,0.000004412832,0.000018427198,0.0003612416,0.05808963],"study_design_scores_gemma":[0.22082601,0.13646834,0.63745403,0.00024027248,0.00021469795,0.000073176634,0.0011733723,0.00014787201,0.000006848206,0.000007659313,0.003279232,0.000108482294],"about_ca_topic_score_codex":0.000111882386,"about_ca_topic_score_gemma":0.00014325586,"teacher_disagreement_score":0.092625305,"about_ca_system_score_codex":0.00076043856,"about_ca_system_score_gemma":0.001279585,"threshold_uncertainty_score":0.6938653},"labels":[],"label_agreement":null},{"id":"W4286299150","doi":"10.1200/jco.2022.40.16_suppl.e18780","title":"COVID-19 vaccine humoral response and treatment effect in patients with hematologic malignancy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Titer; Vaccination; Gastroenterology; Immunology; Hematologic malignancy; Serology; Antibody titer; Antibody","score_opus":0.06993593062474698,"score_gpt":0.4419147618172505,"score_spread":0.3719788311925035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829377,0.0006495973,0.0000033604174,0.01032246,0.00030959494,0.00034644082,0.000004525677,0.000005342561,0.00006489867],"genre_scores_gemma":[0.99376,0.00017449998,0.0002284851,0.005625314,0.00006991973,0.000015634241,0.0000029297137,0.000008857099,0.00011437561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969349,0.0013809232,0.0011387485,0.00015389732,0.00023409697,0.00015747064],"domain_scores_gemma":[0.99622154,0.002514625,0.0008049507,0.00012106157,0.000051444073,0.000286353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003864711,0.00011639191,0.0011351018,0.00015584475,0.000059712045,0.000003419218,0.00007200885,0.0001034333,0.00037575117],"category_scores_gemma":[0.0015205889,0.000064501684,0.00019080123,0.00016218446,0.00008288514,0.00003399126,0.000037078247,0.00040723247,8.965609e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3251581,0.0014378323,0.65107495,0.000012629074,0.00018113093,0.0013410577,0.00009422109,0.000006882707,0.000037458634,0.000002917543,0.0008629902,0.019789826],"study_design_scores_gemma":[0.056281887,0.14140192,0.76345265,0.000023595632,0.00012266627,0.00044744668,0.00006888061,0.0000037765749,0.000015997244,0.000025404726,0.038098846,0.000056908495],"about_ca_topic_score_codex":0.000042533902,"about_ca_topic_score_gemma":0.000051302068,"teacher_disagreement_score":0.2688762,"about_ca_system_score_codex":0.0007926284,"about_ca_system_score_gemma":0.0016355001,"threshold_uncertainty_score":0.41142118},"labels":[],"label_agreement":null},{"id":"W4286299170","doi":"10.1200/jco.2022.40.16_suppl.5051","title":"On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Prospective cohort study; Progression-free survival; Cancer; Overall survival; Urology","score_opus":0.07396152325729093,"score_gpt":0.43107750911942205,"score_spread":0.3571159858621311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961249,0.0005612378,0.000008889011,0.00225273,0.00063455524,0.00018773804,0.00007652807,0.0000010867549,0.00015231206],"genre_scores_gemma":[0.99407315,0.0044448613,0.000460981,0.0005150771,0.00017688014,0.000052948144,0.000013670041,0.000010115255,0.00025231592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984903,0.00021549998,0.0008613588,0.00017781982,0.000120745935,0.0001342791],"domain_scores_gemma":[0.998466,0.00059979863,0.00065844145,0.0001074798,0.00005610188,0.00011215529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048854185,0.00011918313,0.00054722105,0.000059969785,0.00006506844,0.00001055464,0.000063338775,0.00006487449,0.000039953284],"category_scores_gemma":[0.00034948258,0.00008613462,0.00016448635,0.000041282867,0.000049716065,0.000003874147,0.00003561629,0.00016482767,8.873066e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021275464,0.01109599,0.31363678,0.00001780439,0.0020878082,0.0012434139,0.0004985085,0.02894266,0.017006887,0.00060159166,0.0030091049,0.60058403],"study_design_scores_gemma":[0.029360466,0.16351004,0.30860895,0.00002136345,0.000483755,0.00020998232,0.0010439608,0.000506049,0.003449076,0.001361866,0.49100837,0.00043613426],"about_ca_topic_score_codex":0.00027394807,"about_ca_topic_score_gemma":0.0023223534,"teacher_disagreement_score":0.60014784,"about_ca_system_score_codex":0.00042123502,"about_ca_system_score_gemma":0.0011419704,"threshold_uncertainty_score":0.3512468},"labels":[],"label_agreement":null},{"id":"W4286299175","doi":"10.1200/jco.2022.40.16_suppl.e24043","title":"Patients' perspectives and safety of COVID-19 vaccination among cancer patients: A prospective single-center study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Vaccination; Tolerability; Lung cancer; Cancer; Common Terminology Criteria for Adverse Events; Population; Malignancy; Confidence interval; Immunology","score_opus":0.06046458249867042,"score_gpt":0.43211973444953944,"score_spread":0.371655151950869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534506,0.00043888646,0.000019286013,0.0020691457,0.00078040373,0.00080029585,0.00002795773,0.0000050066424,0.0005139502],"genre_scores_gemma":[0.9982883,0.00033338863,0.000070051414,0.0010105089,0.00017673692,0.000024282308,0.0000033678825,0.000011005698,0.0000823893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970704,0.0006054534,0.0015635053,0.00019385375,0.0004424954,0.0001243388],"domain_scores_gemma":[0.9964301,0.0006891245,0.0019224328,0.00009733942,0.00068006915,0.00018093236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018495793,0.000102092774,0.00080846885,0.00015005974,0.00010359383,0.0000047477415,0.00009691816,0.00008967408,0.0006707442],"category_scores_gemma":[0.0019717584,0.00007727926,0.000250409,0.0001960014,0.00015331052,0.00011000055,0.00008728037,0.00053874135,1.8541378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03815703,0.015144511,0.9031433,0.00002312093,0.00063086825,0.000019780593,0.004553884,0.000006111643,0.000019054758,0.000010054263,0.0011069045,0.037185412],"study_design_scores_gemma":[0.036822546,0.0432084,0.90117985,0.00002076649,0.00020254283,0.000012951552,0.006014809,0.000006262308,0.0000059482254,0.00003961971,0.012420194,0.000066109686],"about_ca_topic_score_codex":0.000112866845,"about_ca_topic_score_gemma":0.00015361526,"teacher_disagreement_score":0.037119303,"about_ca_system_score_codex":0.0012645781,"about_ca_system_score_gemma":0.0009224401,"threshold_uncertainty_score":0.7344179},"labels":[],"label_agreement":null},{"id":"W4286299180","doi":"10.1200/jco.2022.40.16_suppl.2520","title":"Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Cancer; Vomiting; Internal medicine; Pembrolizumab; Gastroenterology; Adverse effect; Immunotherapy","score_opus":0.053420525828164714,"score_gpt":0.42683596112054406,"score_spread":0.37341543529237936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970955,0.0002924262,0.000008255935,0.0010550186,0.00037388524,0.001068427,0.00008755341,0.0000057223733,0.000013168435],"genre_scores_gemma":[0.9994215,0.00009179714,0.0001604693,0.00016751135,0.000091523325,0.000015177319,0.0000054898182,0.000021441385,0.000025105805],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99263513,0.0028702992,0.0034134034,0.00031992566,0.0005689958,0.00019222472],"domain_scores_gemma":[0.9919778,0.0028969147,0.004237947,0.00031820472,0.00040229986,0.0001668494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008359463,0.0002240135,0.0027111,0.00024535955,0.00006308228,0.0000054118113,0.00015878597,0.000121074554,0.0000256814],"category_scores_gemma":[0.002915451,0.00014677116,0.0002708707,0.0002197048,0.00047575365,0.000075111675,0.000110048255,0.000931616,1.6915716e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8611103,0.0067213443,0.035563696,0.00018420178,0.0010760421,0.00034594382,0.0022933022,0.00001156254,0.08241996,3.4676518e-7,0.000114255134,0.010159037],"study_design_scores_gemma":[0.17271557,0.4867341,0.32237038,0.0015232424,0.0011889539,0.0012049611,0.0027649303,0.00033970186,0.01096897,0.0000042286133,0.000052181473,0.0001327836],"about_ca_topic_score_codex":0.00047722727,"about_ca_topic_score_gemma":0.000045412235,"teacher_disagreement_score":0.6883947,"about_ca_system_score_codex":0.00017761596,"about_ca_system_score_gemma":0.00065446197,"threshold_uncertainty_score":0.5985154},"labels":[],"label_agreement":null},{"id":"W4286299192","doi":"10.1200/jco.2022.40.16_suppl.5585","title":"Outcomes of recurrent and metastatic endometrial cancer (RMEC) treated with systemic progestins.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Hormonal therapy; Endometrial cancer; Internal medicine; Progestin; Oncology; Chemotherapy; Cancer; Progression-free survival; Gynecology; Hormone; Prostate cancer","score_opus":0.17443040946666052,"score_gpt":0.47881777866680975,"score_spread":0.3043873692001492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899537,0.006468394,0.000011658348,0.0018484591,0.0008619325,0.0004587312,0.000032451277,0.000006951134,0.00035771154],"genre_scores_gemma":[0.9968274,0.0012204788,0.0010957574,0.00037922742,0.00027335546,0.000045513683,0.0000032183827,0.000013975974,0.00014104588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644727,0.0006265854,0.001980167,0.00017533083,0.00059328927,0.00017737181],"domain_scores_gemma":[0.99399406,0.00320237,0.0020658446,0.000120380086,0.0003164698,0.00030085104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020432894,0.00014004158,0.002221154,0.00027958277,0.000046169393,0.0000036496672,0.00011029764,0.000071043054,0.00030813878],"category_scores_gemma":[0.0025907264,0.00007747278,0.0003261455,0.0005341293,0.00014267668,0.000045786393,0.00006750805,0.00063406734,9.561693e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02857503,0.0027438633,0.72932756,0.0001152541,0.002993682,0.00062813057,0.000057439614,0.000021538657,0.000065402506,0.000050162336,0.00018051939,0.23524144],"study_design_scores_gemma":[0.11772766,0.14255963,0.7114215,0.0003000568,0.008336333,0.001998027,0.00039930583,0.00003625101,0.0002356327,0.00015363733,0.016619934,0.00021206525],"about_ca_topic_score_codex":0.00012946421,"about_ca_topic_score_gemma":0.000020452087,"teacher_disagreement_score":0.23502937,"about_ca_system_score_codex":0.0002571715,"about_ca_system_score_gemma":0.0011775951,"threshold_uncertainty_score":0.33739036},"labels":[],"label_agreement":null},{"id":"W4286299193","doi":"10.1200/jco.2022.40.16_suppl.2021","title":"CSF proteomics for differentiation of brain malignancies.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Cerebrospinal fluid; Brain biopsy; Liquid biopsy; Proteomics; Brain tumor; Malignancy; Biopsy; Oncology; Pathology; Cancer; Internal medicine; Biology","score_opus":0.12193466006055696,"score_gpt":0.4523782625407163,"score_spread":0.3304436024801593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97767735,0.00018904996,0.0005147816,0.020201594,0.0007946611,0.00040367918,0.000014983001,0.000002659764,0.00020122343],"genre_scores_gemma":[0.99323756,0.000057662044,0.0046464615,0.0015630107,0.0003430466,0.000042432184,0.000007437419,0.000008609742,0.00009379052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979765,0.00018823535,0.0014117359,0.00008632538,0.00023219966,0.00010499338],"domain_scores_gemma":[0.99593765,0.0019953556,0.0015730889,0.00009731052,0.0002857348,0.000110842724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018599345,0.000059717087,0.00082141283,0.000084126295,0.000039617287,0.000002173912,0.000078461155,0.00009086954,0.00017224763],"category_scores_gemma":[0.0029053697,0.000042645912,0.00047937853,0.000071733775,0.000046850986,0.000029322922,0.00004234659,0.00027019499,8.610231e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016447015,0.030773476,0.5038854,0.00024066877,0.0024722454,0.00058500434,0.00046065266,0.00028423592,0.035021935,0.0056230626,0.112268314,0.29193798],"study_design_scores_gemma":[0.03695615,0.06514477,0.6599604,0.000081331484,0.0011377917,0.00035783456,0.00029854712,0.0005491993,0.0077604344,0.003975253,0.22365148,0.00012680248],"about_ca_topic_score_codex":0.0000033866334,"about_ca_topic_score_gemma":0.0000039472193,"teacher_disagreement_score":0.29181117,"about_ca_system_score_codex":0.00012748712,"about_ca_system_score_gemma":0.00061805965,"threshold_uncertainty_score":0.34782088},"labels":[],"label_agreement":null},{"id":"W4286437560","doi":"10.1200/jco.2022.40.17_suppl.lba7502","title":"Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Neutropenia; Bendamustine; Phases of clinical research; Placebo; Ibrutinib; Chemoimmunotherapy; Rituximab; Surgery; Population; Hazard ratio; Gastroenterology; Chemotherapy; Randomized controlled trial; Confidence interval; Leukemia; Lymphoma; Chronic lymphocytic leukemia; Pathology","score_opus":0.07259979377230029,"score_gpt":0.4085435094493707,"score_spread":0.3359437156770704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286437560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156594,0.00022546425,0.000040819214,0.0029909012,0.00018791211,0.004510669,0.00007680606,0.0000058890028,0.0003956005],"genre_scores_gemma":[0.99811125,0.00012622785,0.0004684164,0.000405398,0.00016471179,0.00023505819,0.00008471121,0.000030362393,0.00037385416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953917,0.00048915605,0.0025004756,0.00040008425,0.0008814421,0.0003371321],"domain_scores_gemma":[0.9891035,0.007568791,0.0021949525,0.00036176795,0.0005782036,0.00019280166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032680586,0.00023384787,0.0019912107,0.00016337537,0.00013637445,0.0000136149865,0.00025401695,0.00013996309,0.000047640773],"category_scores_gemma":[0.0009473416,0.0001211201,0.00017899186,0.0002596971,0.00022252955,0.00009520156,0.0001449875,0.0005146428,9.490804e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.90138865,0.06637237,0.006904038,0.00003940439,0.0006922664,0.00052430114,0.0015738677,0.0002855935,0.000005159125,0.000013296437,0.0004639428,0.02173713],"study_design_scores_gemma":[0.8386011,0.13861507,0.015529447,0.00011649714,0.00071279454,0.000119362754,0.0012389582,0.0022560952,0.00001995817,0.000038882103,0.0026475233,0.00010428123],"about_ca_topic_score_codex":0.0010905414,"about_ca_topic_score_gemma":0.00091817655,"teacher_disagreement_score":0.0722427,"about_ca_system_score_codex":0.004103345,"about_ca_system_score_gemma":0.00750645,"threshold_uncertainty_score":0.99971974},"labels":[],"label_agreement":null},{"id":"W4286602972","doi":"10.1200/jco.22.00221","title":"Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network; McGill University; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Gastroenterology; Lenvatinib; Phases of clinical research; Oncology; Immunotherapy; Toxicity; Cancer","score_opus":0.12266143385166989,"score_gpt":0.46588470242273133,"score_spread":0.34322326857106145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286602972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987153,0.00018164724,0.000045174304,0.0031567558,0.00034885682,0.008955527,0.000010133847,0.000023023424,0.0001258584],"genre_scores_gemma":[0.99462825,0.00006112114,0.0024427949,0.0005272862,0.0002600561,0.0013580584,0.000017043247,0.000053885695,0.0006515229],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9947486,0.00080824236,0.0027919703,0.00040142497,0.0008413247,0.00040842473],"domain_scores_gemma":[0.99470955,0.0010980851,0.0032031797,0.000266056,0.00048320214,0.00023993617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003608563,0.0002953129,0.0018463327,0.00034387,0.00018517926,0.000018396933,0.00027259637,0.00027343584,0.000103781735],"category_scores_gemma":[0.0007367804,0.00017203792,0.00033436142,0.00045233616,0.0001705039,0.00010119235,0.000062852545,0.0009993267,5.0936706e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6223753,0.07721262,0.005404952,0.00013665119,0.00053206744,0.0006825212,0.0019664995,0.000008688543,0.0026739165,0.000016836459,0.00023381603,0.28875613],"study_design_scores_gemma":[0.29951826,0.66335773,0.004993401,0.00035816804,0.00025472054,0.0002501477,0.002268022,0.00016561439,0.0045748423,0.00006053908,0.024011066,0.00018750834],"about_ca_topic_score_codex":0.0001118653,"about_ca_topic_score_gemma":0.00021045598,"teacher_disagreement_score":0.5861451,"about_ca_system_score_codex":0.00056587363,"about_ca_system_score_gemma":0.005092242,"threshold_uncertainty_score":0.9033418},"labels":[],"label_agreement":null},{"id":"W4287833514","doi":"10.1200/jco.22.00230","title":"A Population-Based Study of the Long-Term Risk of Infections Associated With Hospitalization in Childhood Cancer Survivors","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Chronic Disease Prevention and Health Promotion; National Cancer Institute; bluebird bio; Washington State University; Pfizer","keywords":"Medicine; Incidence (geometry); Poisson regression; Cancer; Pediatrics; Rate ratio; Population; Retrospective cohort study; Malignancy; Epidemiology; Multivariate analysis; Internal medicine; Confidence interval","score_opus":0.055348534205921014,"score_gpt":0.4266977258191059,"score_spread":0.3713491916131849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287833514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964229,0.0001064272,0.00003885587,0.0017840833,0.0009588275,0.00060974516,0.000026396052,0.0000066953066,0.00004606368],"genre_scores_gemma":[0.99924546,0.000036294354,0.000028646302,0.00047147312,0.00015782524,0.000019476387,0.0000073856927,0.000018124327,0.000015317582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99341893,0.0028224217,0.0026212547,0.00016420228,0.0008329562,0.00014024567],"domain_scores_gemma":[0.9914314,0.0025665814,0.0051848628,0.00026005358,0.00045673474,0.00010036219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049923677,0.000117431795,0.0013527975,0.00021437346,0.00009193537,0.0000028976406,0.0002027531,0.0001310776,0.00013416084],"category_scores_gemma":[0.0058150715,0.00008019187,0.00032112052,0.00081882504,0.000086686276,0.00006196533,0.00006787223,0.0011013215,1.2433281e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008299097,0.014624973,0.97003007,0.000021346012,0.000588224,0.000014812983,0.001487259,0.011036349,0.0000015692519,0.000005933318,0.000034116132,0.0013254366],"study_design_scores_gemma":[0.010882461,0.015878387,0.9714093,0.00019018243,0.0006666436,0.000008759938,0.0007452242,0.00007839613,0.000004957587,0.00004230459,0.000020724667,0.00007265941],"about_ca_topic_score_codex":0.0066653895,"about_ca_topic_score_gemma":0.083536975,"teacher_disagreement_score":0.07687159,"about_ca_system_score_codex":0.00038470473,"about_ca_system_score_gemma":0.0020497185,"threshold_uncertainty_score":0.99994934},"labels":[],"label_agreement":null},{"id":"W4288061296","doi":"10.1200/jco.2022.40.17_suppl.lba5004","title":"Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Hazard ratio; Oncology; Internal medicine; Prostate cancer; Cohort; Cancer; Confidence interval; Androgen receptor","score_opus":0.16276056201978895,"score_gpt":0.515166324359394,"score_spread":0.3524057623396051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288061296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057645,0.0003625992,0.000007038684,0.006051651,0.0016149322,0.00086180406,0.00013507169,0.0000050293397,0.0003854427],"genre_scores_gemma":[0.9953574,0.002386999,0.00051099673,0.0008098576,0.00023643194,0.00006881933,0.00006910329,0.000021475096,0.00053890276],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9938629,0.0021708438,0.0025597187,0.0002849662,0.00080969546,0.00031186375],"domain_scores_gemma":[0.99588954,0.0018837716,0.0013249619,0.00016845281,0.00050547224,0.00022782269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005470246,0.0001792777,0.0020298937,0.00047143933,0.00003551169,0.000010949689,0.0002480662,0.000114904105,0.0002857575],"category_scores_gemma":[0.0019260343,0.00012725686,0.00030607302,0.0003418912,0.00024287075,0.00028932962,0.00014933436,0.0015043078,0.0000019228737],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66607964,0.016142052,0.27940336,0.000028179116,0.002291909,0.0059539834,0.003328005,0.0015003764,0.0018529281,0.00037357843,0.0009400756,0.02210589],"study_design_scores_gemma":[0.32847956,0.05773552,0.5973358,0.00007976646,0.0003541992,0.00009131553,0.0028910022,0.0008352298,0.00026036144,0.00054699084,0.011158541,0.00023171303],"about_ca_topic_score_codex":0.00071363524,"about_ca_topic_score_gemma":0.0008451249,"teacher_disagreement_score":0.3376001,"about_ca_system_score_codex":0.000858537,"about_ca_system_score_gemma":0.0024960202,"threshold_uncertainty_score":0.6535553},"labels":[],"label_agreement":null},{"id":"W4289820683","doi":"10.1200/jco.2022.40.17_suppl.lba8511","title":"Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pathological; Clinical endpoint; Internal medicine; Oncology; Nivolumab; Lung cancer; Neoadjuvant therapy; Receiver operating characteristic; Post-hoc analysis; Stage (stratigraphy); Chemotherapy; non-small cell lung cancer (NSCLC); Surrogate endpoint; Cancer; Clinical trial; Immunotherapy; Breast cancer","score_opus":0.06948997712028145,"score_gpt":0.4151919174606839,"score_spread":0.34570194034040247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289820683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987472,0.0012198974,0.0002081115,0.0068838354,0.0021159349,0.00084037706,0.000047819645,0.000012878948,0.0011991424],"genre_scores_gemma":[0.9908065,0.002065479,0.0030735563,0.0011506818,0.00089678273,0.00009945105,0.000022733393,0.000058032663,0.0018267663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99518126,0.00057176535,0.0025386112,0.00038429498,0.00082267966,0.0005013851],"domain_scores_gemma":[0.9929471,0.002148407,0.0038438386,0.0003746475,0.00049976434,0.00018624635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007813046,0.00026276647,0.001980906,0.00018356416,0.00011790588,0.000012274581,0.00046779195,0.0005111937,0.00053481385],"category_scores_gemma":[0.0011464701,0.00018949904,0.00063664507,0.00041183885,0.00012801096,0.00011151334,0.00014417528,0.0014466521,5.326268e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55872357,0.005681894,0.31105554,0.00038417845,0.0013355128,0.0005021235,0.0010524016,0.0005323229,0.034211613,0.000015253566,0.030087607,0.056417983],"study_design_scores_gemma":[0.46719494,0.075314924,0.3663355,0.0013529751,0.0012586945,0.00022428867,0.0021084545,0.004704134,0.018746775,0.00021994529,0.061633047,0.0009063213],"about_ca_topic_score_codex":0.00023144642,"about_ca_topic_score_gemma":0.00046770438,"teacher_disagreement_score":0.09152862,"about_ca_system_score_codex":0.0016301994,"about_ca_system_score_gemma":0.0026070725,"threshold_uncertainty_score":0.7727546},"labels":[],"label_agreement":null},{"id":"W4290879625","doi":"10.1200/jco.21.02815","title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Internal medicine; Dexamethasone; Refractory (planetary science); Clinical endpoint; Multiple myeloma; Hazard ratio; Ixazomib; Progression-free survival; Oncology; Surgery; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval; Carfilzomib","score_opus":0.1882167091889099,"score_gpt":0.47928399839735003,"score_spread":0.29106728920844016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290879625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869807,0.0019355224,0.0011242939,0.006026139,0.001510273,0.0019524888,0.00017691094,0.000013726747,0.00027995804],"genre_scores_gemma":[0.99100643,0.00060313405,0.004650307,0.000981144,0.0015953518,0.00020816892,0.00011821889,0.00002992227,0.00080731564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907555,0.0043209083,0.0030426255,0.0004268579,0.0009838325,0.00047028932],"domain_scores_gemma":[0.9489982,0.04722657,0.00234612,0.00040729548,0.00038263603,0.00063918106],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012984682,0.00026539652,0.0039391206,0.00027349973,0.00047454354,0.000027498,0.0003421758,0.0002685036,0.00082764967],"category_scores_gemma":[0.026242776,0.00015884108,0.002274047,0.00031160068,0.00045706925,0.000109317705,0.00028921195,0.00161665,0.0000032800865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9234996,0.006278227,0.004796439,0.000007569386,0.011854666,0.0007670277,0.0002603142,0.000058569633,0.000078319244,0.00008482899,0.0017828438,0.05053162],"study_design_scores_gemma":[0.90216947,0.03599601,0.01720917,0.0000141603105,0.006775934,0.0000821421,0.0002956259,0.004156029,0.000012458861,0.00040059316,0.032752052,0.00013637052],"about_ca_topic_score_codex":0.0005421002,"about_ca_topic_score_gemma":0.00017816278,"teacher_disagreement_score":0.050395247,"about_ca_system_score_codex":0.0005049942,"about_ca_system_score_gemma":0.0023905158,"threshold_uncertainty_score":0.9819596},"labels":[],"label_agreement":null},{"id":"W4290879678","doi":"10.1200/jco.21.02831","title":"Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Clinical endpoint; Radiation therapy; Prostate cancer; Clinical trial; Adverse effect; Endometrial cancer; Internal medicine; Urinary system; Quality of life (healthcare); Cancer; Surgery; Oncology","score_opus":0.1164874476356977,"score_gpt":0.4376565768534813,"score_spread":0.3211691292177836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290879678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929853,0.0011478995,0.000020534006,0.002703448,0.0018463267,0.00097578013,0.000040432184,0.000017172686,0.0002631195],"genre_scores_gemma":[0.99680454,0.0010126507,0.0001088686,0.00077062927,0.0008933514,0.000023055858,0.0003134311,0.000016299698,0.00005718825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99427885,0.00097292475,0.0034176735,0.00027651212,0.0008457723,0.00020824395],"domain_scores_gemma":[0.9927416,0.00092513853,0.0050574136,0.00019897365,0.0008232001,0.0002536903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002461528,0.00017870832,0.0017102531,0.00028187936,0.00010765277,0.000007907699,0.00013921547,0.0001850654,0.0007221456],"category_scores_gemma":[0.00096157903,0.000120615245,0.0005050339,0.0006501709,0.00016919538,0.00011782157,0.000033447854,0.0007690165,0.0000015224107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74394757,0.011233281,0.0013948336,0.0000048358384,0.0020659822,0.00020847868,0.00018258339,0.00015556513,0.0039630127,0.0000048972965,0.0015698284,0.23526911],"study_design_scores_gemma":[0.75837624,0.17134078,0.037684172,0.000034050616,0.00045484788,0.00022132036,0.00012731561,0.0005136332,0.00510766,0.00012086263,0.025880657,0.00013846954],"about_ca_topic_score_codex":0.0000763935,"about_ca_topic_score_gemma":0.000009251076,"teacher_disagreement_score":0.23513064,"about_ca_system_score_codex":0.000597815,"about_ca_system_score_gemma":0.0024973592,"threshold_uncertainty_score":0.79069877},"labels":[],"label_agreement":null},{"id":"W4290994344","doi":"10.1200/jco.22.00597","title":"Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Janssen Biotech; National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Genentech; Janssen Scientific Affairs; Karyopharm Therapeutics; Conquer Cancer Foundation; Gilead Sciences; Sanofi; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; American Society of Clinical Oncology; GlaxoSmithKline; Amgen","keywords":"Medicine; Lenalidomide; Ibrutinib; Rituximab; Chemoimmunotherapy; Internal medicine; Chemotherapy; Diffuse large B-cell lymphoma; Oncology; International Prognostic Index; Surgery; Lymphoma; Gastroenterology; Multiple myeloma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.047371172100373934,"score_gpt":0.3881505520512346,"score_spread":0.34077937995086066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290994344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994672,0.00045002822,0.00001911111,0.0020305056,0.0004903273,0.00040835672,0.000014669483,0.000007839981,0.0019071897],"genre_scores_gemma":[0.9949972,0.0002142294,0.001188721,0.0028620707,0.00030435776,0.000013759299,0.000009712583,0.00003025418,0.00037971724],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951923,0.0009164735,0.002056108,0.00030211516,0.0010211065,0.00051188265],"domain_scores_gemma":[0.9943185,0.0034883735,0.0010547558,0.00027516816,0.00032999253,0.0005332041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005266212,0.00016993562,0.0016021678,0.00026211745,0.00009476714,0.00001335825,0.00024535286,0.00021039665,0.0004332629],"category_scores_gemma":[0.0024848725,0.00012342725,0.00022227837,0.00031474087,0.00024175658,0.00012641777,0.00031661484,0.0011822485,0.000017347205],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.056937948,0.03456409,0.8219319,0.0001182232,0.00031645378,0.00885826,0.00042779767,0.000044731114,0.000010376334,0.000089197216,0.016620887,0.060080107],"study_design_scores_gemma":[0.5057991,0.025713636,0.35093585,0.00006413332,0.00014451676,0.00036178614,0.00029347345,0.00055937946,0.000012091108,0.00009192513,0.11588406,0.00014005249],"about_ca_topic_score_codex":0.00014207215,"about_ca_topic_score_gemma":0.00013308124,"teacher_disagreement_score":0.47099608,"about_ca_system_score_codex":0.0048815203,"about_ca_system_score_gemma":0.017060168,"threshold_uncertainty_score":0.99893856},"labels":[],"label_agreement":null},{"id":"W4291019548","doi":"10.1200/jco.22.00843","title":"Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Provincial Health Services Authority; Centre hospitalier universitaire de Québec","funders":"National Cancer Institute","keywords":"Rituximab; Medicine; Lenalidomide; Follicular lymphoma; Internal medicine; Hazard ratio; Clinical endpoint; Progression-free survival; Oncology; Chemotherapy; Lymphoma; Clinical trial; Gastroenterology; Confidence interval; Multiple myeloma","score_opus":0.04292526790811107,"score_gpt":0.3750719490034204,"score_spread":0.3321466810953093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291019548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751423,0.0040048747,0.00003549867,0.016077803,0.0017293498,0.00080963154,0.00034774074,0.000053032556,0.0017997897],"genre_scores_gemma":[0.982417,0.00550872,0.0062760324,0.004118389,0.00070506264,0.00010007605,0.00019006696,0.00008994887,0.00059472217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910872,0.0012762609,0.0046152486,0.00093831326,0.0012204557,0.00086251687],"domain_scores_gemma":[0.988595,0.0068174843,0.0026671747,0.0007873636,0.00045661617,0.00067633693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031649747,0.00055796746,0.0041019763,0.00028385795,0.00020289481,0.000031255615,0.00058771466,0.00057954725,0.00043569636],"category_scores_gemma":[0.0055445177,0.0004522667,0.0013273166,0.0006347516,0.00030767906,0.00025878428,0.00020834546,0.0012400516,0.00010258019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52506405,0.06554961,0.027289916,0.000045636283,0.0037278617,0.022310112,0.0009881516,0.002090654,0.0004282963,0.00027262024,0.13728587,0.21494724],"study_design_scores_gemma":[0.59912586,0.016332284,0.015850611,0.00024821408,0.0007145063,0.00032665805,0.0009351415,0.0013921524,0.00042903295,0.00034945854,0.36386475,0.00043135765],"about_ca_topic_score_codex":0.0007347241,"about_ca_topic_score_gemma":0.00012568058,"teacher_disagreement_score":0.22657886,"about_ca_system_score_codex":0.0036123057,"about_ca_system_score_gemma":0.0027369778,"threshold_uncertainty_score":0.99979293},"labels":[],"label_agreement":null},{"id":"W4291021297","doi":"10.1200/jco.21.02613","title":"Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Cohort; Hazard ratio; Radiation therapy; Proportional hazards model; Framingham Risk Score; Anthracycline; Cumulative incidence; Hodgkin lymphoma; Cohort study; Cancer; Disease; Lymphoma; Confidence interval; Breast cancer","score_opus":0.10809120818624754,"score_gpt":0.424639050781617,"score_spread":0.3165478425953695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291021297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98486954,0.00078227586,0.0019916703,0.011017592,0.00042331053,0.00070422795,0.0002002187,0.0000063884822,0.0000047790018],"genre_scores_gemma":[0.95957905,0.0001459456,0.038107976,0.0014993635,0.00046026296,0.00013546905,0.000031147974,0.000015122714,0.000025673433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975256,0.00034313792,0.0015236512,0.00019678578,0.0002790253,0.00013180767],"domain_scores_gemma":[0.99664366,0.0019466406,0.000814604,0.00010780648,0.00018340551,0.00030389722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026620377,0.00010855654,0.0008673048,0.000084948,0.000094460294,0.000004919493,0.00003489152,0.000099211604,0.000021098926],"category_scores_gemma":[0.0007462557,0.00008904298,0.00023716982,0.000041614338,0.00008489653,0.000097975855,0.00004505992,0.0001425241,1.5371756e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115481764,0.008238354,0.66320187,0.00049991923,0.001667979,0.00005504762,0.005073969,0.00097164995,0.00013780291,0.00017312785,0.0143076815,0.19019087],"study_design_scores_gemma":[0.020919297,0.019399155,0.79787195,0.00008812504,0.0009301341,0.00018630509,0.0007530378,0.0010932343,0.00012299961,0.0021903438,0.15633835,0.000107075575],"about_ca_topic_score_codex":0.000014687057,"about_ca_topic_score_gemma":0.00002843956,"teacher_disagreement_score":0.19008379,"about_ca_system_score_codex":0.00023953205,"about_ca_system_score_gemma":0.0013923447,"threshold_uncertainty_score":0.36310676},"labels":[],"label_agreement":null},{"id":"W4292228059","doi":"10.1200/jco.22.00184","title":"Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; CancerCare Manitoba; Juravinski Cancer Centre; Queen's University; St. Paul's Hospital; Health Sciences North; University of Manitoba; Ottawa Hospital","funders":"","keywords":"Medicine; Total mesorectal excision; Oxaliplatin; Surgery; Colorectal cancer; Folinic acid; Capecitabine; Chemotherapy; Clinical endpoint; Rectum; Neoadjuvant therapy; Cancer; Fluorouracil; Randomized controlled trial; Internal medicine","score_opus":0.19738608042926228,"score_gpt":0.5044359961536334,"score_spread":0.3070499157243711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292228059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490285,0.0008058594,0.000052885054,0.04542406,0.0024832461,0.0012852508,0.000084974585,0.000012925731,0.0008222972],"genre_scores_gemma":[0.9869572,0.0014808006,0.0011064911,0.006596379,0.002843854,0.00016129267,0.000028427654,0.000030469182,0.0007951123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579734,0.00061317254,0.0023738907,0.00030725298,0.00064675824,0.0002616163],"domain_scores_gemma":[0.9919525,0.005272239,0.0019315967,0.00022117046,0.00032911374,0.00029342898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056091137,0.00017324275,0.001346349,0.00008267214,0.0002929936,0.0000146687225,0.000201293,0.00019788834,0.00032687947],"category_scores_gemma":[0.0027832915,0.00010658544,0.0005435258,0.00019420897,0.00020117236,0.00011695267,0.00012508563,0.0009929644,0.0000010356858],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4819497,0.0028288802,0.0019367271,0.000009422112,0.00034145202,0.00018227249,0.00036247817,0.0000076191277,0.00017933472,0.00001655418,0.012109865,0.5000757],"study_design_scores_gemma":[0.31743345,0.15916209,0.09795208,0.00004128126,0.00038295853,0.00030432173,0.00011631653,0.00015087945,0.000074770796,0.00078449136,0.42347926,0.000118121396],"about_ca_topic_score_codex":0.00007403741,"about_ca_topic_score_gemma":0.000026519416,"teacher_disagreement_score":0.4999576,"about_ca_system_score_codex":0.0006180786,"about_ca_system_score_gemma":0.0017649935,"threshold_uncertainty_score":0.4346428},"labels":[],"label_agreement":null},{"id":"W4292411141","doi":"10.1200/jco.22.00171","title":"Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Medicine; Internal medicine; Colorectal cancer; Oxaliplatin; Metabolic equivalent; Chemotherapy; Surgery; Gastroenterology; Prospective cohort study; Cancer; Physical activity; Physical therapy","score_opus":0.13114558690586794,"score_gpt":0.49633223991697556,"score_spread":0.36518665301110764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292411141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807031,0.00054738,0.000027004613,0.011995784,0.0034834375,0.0002034615,0.000022287988,0.000010314987,0.003007185],"genre_scores_gemma":[0.9928863,0.0006926045,0.000054884462,0.0026858773,0.0017645652,0.000029383646,0.0000017292265,0.000018351711,0.0018662759],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969735,0.0007651675,0.0011072656,0.00024104126,0.0006080518,0.00030497077],"domain_scores_gemma":[0.9967737,0.001352237,0.0011494907,0.00020249005,0.00018956963,0.000332475],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025348184,0.00013877216,0.001658314,0.00009325282,0.00006861112,0.000005797457,0.0002334819,0.00018922622,0.00087610283],"category_scores_gemma":[0.0005687737,0.00011615033,0.0005425151,0.0003303238,0.00015724063,0.00009655076,0.00014641116,0.0026295169,0.000006035305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038141035,0.011607823,0.26234636,0.00014027189,0.00050849555,0.005624107,0.0023758067,0.00079528906,0.0025008444,0.00046761724,0.019783894,0.65570843],"study_design_scores_gemma":[0.015549912,0.016605418,0.3003672,0.00008497897,0.00028518183,0.0001619596,0.0013150066,0.00079766044,0.0003764888,0.00021286597,0.6640126,0.00023073274],"about_ca_topic_score_codex":0.0012653513,"about_ca_topic_score_gemma":0.0042024124,"teacher_disagreement_score":0.6554777,"about_ca_system_score_codex":0.0009208015,"about_ca_system_score_gemma":0.0029835298,"threshold_uncertainty_score":0.99967146},"labels":[],"label_agreement":null},{"id":"W4292565458","doi":"10.1200/jco.22.00294","title":"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Deciphera Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Sunitinib; GiST; Internal medicine; Hazard ratio; Imatinib; Clinical endpoint; Gastroenterology; Tyrosine-kinase inhibitor; Imatinib mesylate; Oncology; Progression-free survival; Surgery; Randomized controlled trial; Confidence interval; Cancer; Stromal cell; Chemotherapy","score_opus":0.10621829567524453,"score_gpt":0.4614978297003581,"score_spread":0.35527953402511353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292565458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929849,0.00006972727,0.00007471799,0.0011679496,0.00033942933,0.0041142623,0.00005799128,0.000013932153,0.0011771009],"genre_scores_gemma":[0.9712725,0.00001610334,0.027267456,0.00025896128,0.0003015344,0.00064841297,0.000050597264,0.00004595846,0.00013846876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926674,0.0019942056,0.002988629,0.00048007752,0.0011471524,0.0007225368],"domain_scores_gemma":[0.99102426,0.004573721,0.0024712826,0.00035994445,0.0006631864,0.00090761954],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037462732,0.00041015816,0.0035100759,0.00030733077,0.0001296369,0.000041170475,0.00035842994,0.000050106704,0.0009233601],"category_scores_gemma":[0.0031584771,0.00023860589,0.00037193816,0.00034307846,0.0005255138,0.000224537,0.00022608037,0.001574027,0.000009207019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8895627,0.04409621,0.030583994,0.000013400918,0.00055295177,0.01653389,0.000060128677,0.000024501953,0.000005371237,0.000020273073,0.00008077673,0.018465772],"study_design_scores_gemma":[0.590372,0.40094924,0.0054597952,0.00019232063,0.00048698942,0.0015365509,0.00020032897,0.00007945462,0.0000047143453,0.000015365778,0.0005900983,0.00011312058],"about_ca_topic_score_codex":0.00010183721,"about_ca_topic_score_gemma":0.00010846885,"teacher_disagreement_score":0.35685304,"about_ca_system_score_codex":0.00093696365,"about_ca_system_score_gemma":0.003964107,"threshold_uncertainty_score":0.9999899},"labels":[],"label_agreement":null},{"id":"W4292978844","doi":"10.1200/jco.22.00644","title":"Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"National Cancer Institute; Astellas Pharma; AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Prostate cancer; Clinical endpoint; Cancer; Clinical trial; Confidence interval","score_opus":0.30776712836981457,"score_gpt":0.5398081416264104,"score_spread":0.23204101325659587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292978844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912127,0.0044988566,0.0000056002564,0.003257608,0.0003477171,0.00058581086,0.00008407701,0.0000036002482,0.000003994621],"genre_scores_gemma":[0.9902135,0.008610933,0.0008375091,0.00014989989,0.000041821633,0.00003761893,0.000008881365,0.000009740036,0.000090090485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942523,0.002578121,0.0023489548,0.00018206422,0.00047192856,0.00016661786],"domain_scores_gemma":[0.99127674,0.0065096603,0.0015313098,0.00013883061,0.0003280353,0.00021539991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077978116,0.00011293776,0.0024556844,0.00085736363,0.00003074683,0.000004851505,0.0000938704,0.00007388477,0.000106001746],"category_scores_gemma":[0.0043810215,0.00007367962,0.00030364536,0.0010014476,0.00014925198,0.000051970936,0.00006787361,0.00034985348,8.592576e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11447661,0.000706334,0.81507725,0.00003320911,0.0050427117,0.00014432253,0.00061798823,0.00028582322,0.0014421641,9.182123e-7,0.000042570548,0.062130123],"study_design_scores_gemma":[0.023090394,0.017072905,0.95634854,0.000034178265,0.0024029305,0.000007573731,0.00019722342,0.00011337887,0.000261181,0.000012484794,0.0004073868,0.000051817617],"about_ca_topic_score_codex":0.00012421144,"about_ca_topic_score_gemma":0.00019879879,"teacher_disagreement_score":0.14127132,"about_ca_system_score_codex":0.00019374843,"about_ca_system_score_gemma":0.0012549415,"threshold_uncertainty_score":0.5244809},"labels":[],"label_agreement":null},{"id":"W4293074115","doi":"10.1200/jco.2022.40.16_suppl.6052","title":"Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Cancer; Lung cancer; Head and neck cancer; Cancer research","score_opus":0.03754380128616392,"score_gpt":0.3725184672614961,"score_spread":0.3349746659753322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293074115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972954,0.0015548347,0.0000624685,0.00032131554,0.0004226169,0.0001358368,0.000054790464,0.0000012598438,0.00015150357],"genre_scores_gemma":[0.9974292,0.0002614389,0.001009974,0.0010060612,0.00019664307,0.000012599531,0.000029237097,0.000015692778,0.000039172894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978258,0.00035188498,0.0010975134,0.0002630326,0.0002478322,0.00021391326],"domain_scores_gemma":[0.99793714,0.00036871602,0.0012004662,0.00014086213,0.00017846505,0.00017436218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010415802,0.0001300614,0.00078405597,0.0001386925,0.00007141421,0.0000128529,0.00016307793,0.0000696572,0.00010624627],"category_scores_gemma":[0.0005951149,0.00011076797,0.00026179638,0.00025474184,0.00010161616,0.0000053595904,0.00013834327,0.00043956874,4.1960044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003918945,0.0014775366,0.9761501,0.00002288892,0.00041616036,0.0001125307,0.00011699116,0.004244436,0.00041047772,0.000012957456,0.0006995054,0.012417475],"study_design_scores_gemma":[0.02100326,0.01697138,0.92258203,0.000018411709,0.0011228801,0.000033473443,0.00028526358,0.0007113985,0.00007833475,0.000072220006,0.03680753,0.0003138169],"about_ca_topic_score_codex":0.000083032086,"about_ca_topic_score_gemma":0.00054456445,"teacher_disagreement_score":0.05356806,"about_ca_system_score_codex":0.000111148904,"about_ca_system_score_gemma":0.0008500134,"threshold_uncertainty_score":0.45169866},"labels":[],"label_agreement":null},{"id":"W4293074142","doi":"10.1200/jco.2022.40.16_suppl.6082","title":"Impact of intensive multimodal treatment on the outcomes of patients with anaplastic thyroid cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Propensity score matching; Cohort; Cancer; Internal medicine; Radiation therapy; Thyroid cancer; Anaplastic thyroid cancer; Malignancy; Proportional hazards model; Clinical trial; Multivariate analysis; Surgery","score_opus":0.08228916221044025,"score_gpt":0.45348281489046227,"score_spread":0.371193652680022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293074142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383104,0.0003087687,0.000002333518,0.0048041893,0.00047496977,0.00033286685,0.000103925624,0.0000020239875,0.00013987388],"genre_scores_gemma":[0.998386,0.0003753057,0.00009184916,0.0009480167,0.00011290022,0.000030420693,0.000004222118,0.000012174766,0.000039093095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776584,0.00028057038,0.0012454096,0.00012838012,0.00043149546,0.00014832769],"domain_scores_gemma":[0.9936118,0.0032277228,0.0019974702,0.00019755684,0.0008127543,0.0001526681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042289123,0.0001435251,0.0014431414,0.00008626258,0.0000430391,0.0000015246718,0.00011715369,0.00006245023,0.00037720092],"category_scores_gemma":[0.0010540793,0.000059451762,0.00069176184,0.00011335293,0.00016535755,0.000023907258,0.000039672053,0.00038514004,0.0000011258574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017866852,0.008062639,0.9455797,0.0000046844816,0.0034530365,0.000093713104,0.00021248311,0.0010935364,0.000011914009,0.00003095645,0.0021442727,0.021446235],"study_design_scores_gemma":[0.014163338,0.17433321,0.80964833,0.00003136976,0.0007435938,0.000011358295,0.00021541526,0.000023923785,0.00005244885,0.000015643947,0.0007209945,0.0000403494],"about_ca_topic_score_codex":0.00031343466,"about_ca_topic_score_gemma":0.000087295746,"teacher_disagreement_score":0.16627058,"about_ca_system_score_codex":0.0007969841,"about_ca_system_score_gemma":0.0014908061,"threshold_uncertainty_score":0.41300854},"labels":[],"label_agreement":null},{"id":"W4293074212","doi":"10.1200/jco.2022.40.16_suppl.6092","title":"Prognostic factors in sinonasal cancers: A multicenter pooled analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Surgical Oncology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Histology; Internal medicine; Oncology; Hazard ratio; Stage (stratigraphy); Adenoid cystic carcinoma; Radiation therapy; Adenocarcinoma; Proportional hazards model; Carcinoma; Cancer; Confidence interval","score_opus":0.12158025224848559,"score_gpt":0.4775028856926541,"score_spread":0.3559226334441685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293074212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893052,0.00026628133,0.000033388216,0.0065659457,0.0016237547,0.00022779738,0.0000060150264,0.000009009221,0.0019626024],"genre_scores_gemma":[0.99413425,0.00008718912,0.00051738153,0.004362301,0.00062280346,0.000010849634,0.000007476142,0.000012962604,0.00024481612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99463797,0.0013644629,0.0028896001,0.00024145984,0.0005070048,0.00035950824],"domain_scores_gemma":[0.99289083,0.004932523,0.0012999605,0.00016079294,0.00021784428,0.00049805944],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041044285,0.00014191432,0.0025375322,0.0005149285,0.000052835454,0.0000045670463,0.00020505892,0.00026350428,0.0019240427],"category_scores_gemma":[0.0048327227,0.00010065774,0.0010085866,0.0008244102,0.00015431365,0.00006930952,0.000119923716,0.0021015583,0.000009204826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047576637,0.0033630899,0.97329336,0.000010875673,0.0014540346,0.003879866,0.00021126268,0.00046231964,0.000089899964,0.000034103767,0.0012179042,0.011225637],"study_design_scores_gemma":[0.00925668,0.0131773995,0.8582251,0.000017790957,0.0020886643,0.00014467745,0.00037137786,0.0009247582,0.0000086415575,0.000046992263,0.11564623,0.00009169399],"about_ca_topic_score_codex":0.000117076466,"about_ca_topic_score_gemma":0.0003335661,"teacher_disagreement_score":0.11506825,"about_ca_system_score_codex":0.00078511034,"about_ca_system_score_gemma":0.0030612065,"threshold_uncertainty_score":0.99898833},"labels":[],"label_agreement":null},{"id":"W4293074253","doi":"10.1200/jco.2022.40.16_suppl.6067","title":"Transoral robotic surgery (TORS)-guided radiotherapy (RT) volume de-intensification in p16-positive unknown primary squamous cell carcinoma (SCC) of the neck: A phase 2 trial (FIND).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tonsil; Swallowing; Radiation therapy; Transoral robotic surgery; Neck dissection; Dysphagia; Head and neck cancer; Surgery; Basal cell; Cancer; Nuclear medicine; Internal medicine","score_opus":0.1224924231663354,"score_gpt":0.4310474329360159,"score_spread":0.3085550097696805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293074253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806959,0.0015927375,0.00013092133,0.01376421,0.0026277637,0.0005827064,0.000008099339,0.0000061923406,0.00059144356],"genre_scores_gemma":[0.9942829,0.00033454754,0.0004295331,0.003493088,0.0010313177,0.00002190745,0.0000043439672,0.00002337966,0.00037895478],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994233,0.0017929218,0.0029314957,0.00022859573,0.0004908044,0.0003231983],"domain_scores_gemma":[0.9941264,0.0033410627,0.0017320787,0.00024271754,0.00035257472,0.00020517835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048387395,0.00017719126,0.0024826515,0.00020246727,0.000101076526,0.0000043115933,0.00022520221,0.00021985843,0.00015699086],"category_scores_gemma":[0.0017971991,0.00011806293,0.0010111515,0.00035706587,0.00027630222,0.00006394155,0.000045850593,0.0014066015,0.00000101944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46890083,0.031548914,0.29544047,0.00033005505,0.0006946867,0.002418575,0.006702282,0.0010202166,0.011418822,0.00008149363,0.06283611,0.118607536],"study_design_scores_gemma":[0.22813623,0.05467504,0.68107283,0.0001282953,0.0008337848,0.0006999409,0.00081681035,0.0013332183,0.00074453646,0.000092829425,0.03119188,0.0002746037],"about_ca_topic_score_codex":0.000103753046,"about_ca_topic_score_gemma":0.00003586475,"teacher_disagreement_score":0.38563237,"about_ca_system_score_codex":0.0008759982,"about_ca_system_score_gemma":0.0048093926,"threshold_uncertainty_score":0.8531656},"labels":[],"label_agreement":null},{"id":"W4293083608","doi":"10.1200/jco.2022.40.17_suppl.lba2002","title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600–mutant pediatric low-grade glioma (pLGG).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Trametinib; Internal medicine; Clinical endpoint; Dabrafenib; Phases of clinical research; Oncology; Randomized controlled trial; Progression-free survival; Carboplatin; Cancer; Surgery; Clinical trial; Chemotherapy; Metastatic melanoma; Vemurafenib; Cisplatin; Kinase; MAPK/ERK pathway","score_opus":0.08595484011169645,"score_gpt":0.44389021965536163,"score_spread":0.35793537954366517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293083608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929636,0.0011286801,0.000015085845,0.0037347716,0.00106377,0.00067101367,0.00008997133,0.000007698162,0.00032540856],"genre_scores_gemma":[0.99709517,0.00071339397,0.0006517697,0.000758001,0.0006741869,0.000037648566,0.000029117145,0.000024453548,0.000016280434],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99082386,0.0012463077,0.006065125,0.00037080966,0.0011222274,0.00037165868],"domain_scores_gemma":[0.98973095,0.0044422564,0.004699678,0.00041204446,0.00028805027,0.0004270262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005553362,0.00025586938,0.0046868697,0.0017298245,0.00006815247,0.000005243421,0.00036655538,0.00033866597,0.00050664495],"category_scores_gemma":[0.0023407654,0.0001942484,0.002405292,0.0026499238,0.00020874983,0.00008586611,0.00017026452,0.0012228024,0.0000012614827],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38252518,0.38302743,0.07170697,0.00026677805,0.012227657,0.013672771,0.0014245515,0.0023888038,0.008409873,0.00017137502,0.0030925116,0.12108611],"study_design_scores_gemma":[0.73769265,0.16138321,0.06878547,0.00006765575,0.02279388,0.0003328574,0.00049759203,0.00081332267,0.0014725932,0.00022331542,0.0056413948,0.00029605848],"about_ca_topic_score_codex":0.00005581124,"about_ca_topic_score_gemma":0.000045145087,"teacher_disagreement_score":0.35516748,"about_ca_system_score_codex":0.00045524223,"about_ca_system_score_gemma":0.002830907,"threshold_uncertainty_score":0.79212195},"labels":[],"label_agreement":null},{"id":"W4293083622","doi":"10.1200/jco.2022.40.17_suppl.lba5500","title":"ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; BRCA mutation; Clinical endpoint; Population; Oncology; Placebo; Ovarian cancer; PARP inhibitor; Cancer; Surgery; Clinical trial; Pathology","score_opus":0.2784281856441137,"score_gpt":0.5579846632316603,"score_spread":0.2795564775875466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293083622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92633086,0.0006436216,0.0018006318,0.05986158,0.005509777,0.005332982,0.000030606458,0.000036867266,0.00045304294],"genre_scores_gemma":[0.97618216,0.00084803096,0.0063637067,0.0102517,0.0029886463,0.0025387874,0.000016115515,0.00012167199,0.0006891633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98790514,0.004206278,0.005172579,0.00069769943,0.0013043996,0.0007138876],"domain_scores_gemma":[0.9775993,0.01737311,0.003347343,0.0005887938,0.00037503228,0.0007163722],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024114804,0.0005164164,0.0042610075,0.00063846895,0.00027846373,0.00003535918,0.00044340713,0.00042686716,0.0019019477],"category_scores_gemma":[0.005156356,0.00041191856,0.0019629644,0.0007567266,0.0002138905,0.0001436122,0.00005608645,0.0016787761,0.00001696693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9266429,0.0058596833,0.0001932913,0.000010113373,0.0015139277,0.0008748999,0.0015547702,0.009828616,0.0013049775,0.000043447817,0.0007799549,0.051393397],"study_design_scores_gemma":[0.8378996,0.106951505,0.000048583122,0.00021632733,0.00051164965,0.00008138158,0.0002807611,0.0038200254,0.0006906146,0.00022359278,0.048965648,0.0003102968],"about_ca_topic_score_codex":0.0003877806,"about_ca_topic_score_gemma":0.00023405229,"teacher_disagreement_score":0.101091824,"about_ca_system_score_codex":0.004257562,"about_ca_system_score_gemma":0.008934733,"threshold_uncertainty_score":0.9998333},"labels":[],"label_agreement":null},{"id":"W4293094498","doi":"10.1200/jco.22.00364","title":"Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital; Queen's University; University of British Columbia","funders":"BC Cancer Foundation; Michael Smith Health Research BC; Terry Fox Research Institute; AstraZeneca","keywords":"Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Epidermal growth factor receptor; Internal medicine; Panitumumab; Oncology; Targeted therapy; Cancer research; Cetuximab; EGFR inhibitors; Cancer","score_opus":0.05956573017385619,"score_gpt":0.3845516860664789,"score_spread":0.3249859558926227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293094498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959071,0.0012999487,0.000038289476,0.00096685777,0.001359833,0.00018010198,0.00012950474,0.0000017345529,0.0001166137],"genre_scores_gemma":[0.99663854,0.0011348185,0.0007242378,0.000983603,0.00042490076,0.000018962019,0.000009892264,0.000016371274,0.00004866476],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99744755,0.00043736532,0.0014278576,0.00022803555,0.00024418996,0.00021502147],"domain_scores_gemma":[0.99763185,0.0006058392,0.0012333449,0.00012553426,0.0002618018,0.00014160827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013673536,0.0001226989,0.0007626106,0.00010616082,0.00006248455,0.000010046839,0.0003068336,0.00008048748,0.00021537927],"category_scores_gemma":[0.002051253,0.00011189468,0.0002839431,0.0001729282,0.00008984343,0.000008778556,0.00019851628,0.00019677448,0.0000011542667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009543894,0.0013931826,0.30653775,0.000053817595,0.00061452325,0.00040250033,0.0007492591,0.0022602302,0.64609194,0.000079217396,0.017813789,0.014459924],"study_design_scores_gemma":[0.015987406,0.017090589,0.7468599,0.00010911645,0.0001858524,0.00013324244,0.0025178487,0.00013723531,0.13258876,0.00046109685,0.08320376,0.0007252114],"about_ca_topic_score_codex":0.00007582105,"about_ca_topic_score_gemma":0.00045342155,"teacher_disagreement_score":0.5135032,"about_ca_system_score_codex":0.00008196306,"about_ca_system_score_gemma":0.0010361605,"threshold_uncertainty_score":0.45629326},"labels":[],"label_agreement":null},{"id":"W4293372485","doi":"10.1200/jco.21.02839","title":"Postmortem Tissue Donation: Giving Families the Ability to Choose","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Organ Donation and Transplantation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Tissue Donation; Donation; Surgery; Organ donation; Transplantation","score_opus":0.09636303341016667,"score_gpt":0.4704831808275332,"score_spread":0.37412014741736654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293372485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8986683,0.00008761429,0.00029097244,0.09510549,0.0015427539,0.00020532096,0.0000058304176,0.000010052519,0.004083647],"genre_scores_gemma":[0.98674625,0.00007581243,0.0010508437,0.010751676,0.0006887808,0.000004955648,0.0000030195279,0.000006901377,0.00067178695],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99768263,0.00048243054,0.0011921242,0.00010404006,0.0004424854,0.00009626481],"domain_scores_gemma":[0.997258,0.0016506121,0.00052514847,0.00012656872,0.00028147144,0.00015820295],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039921175,0.00005890603,0.00042648325,0.000086748376,0.00012065715,0.000006541241,0.00014224235,0.00006878124,0.0011805263],"category_scores_gemma":[0.001861553,0.000038123944,0.00015695057,0.0002034521,0.00006461361,0.00006150467,0.000039097074,0.0007359197,0.000023870416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00497852,0.002434887,0.14823195,0.000065497145,0.0002620627,0.0006221358,0.0030710953,0.00040661215,0.002587654,0.0016887237,0.014291012,0.8213599],"study_design_scores_gemma":[0.0018165099,0.0031601142,0.68824446,0.0000069432795,0.00008780427,0.00042679984,0.0005942203,0.000031365573,0.000087705586,0.00019659774,0.30531302,0.00003447857],"about_ca_topic_score_codex":0.000012498355,"about_ca_topic_score_gemma":0.000024492807,"teacher_disagreement_score":0.82132536,"about_ca_system_score_codex":0.00013465984,"about_ca_system_score_gemma":0.000664238,"threshold_uncertainty_score":0.99973255},"labels":[],"label_agreement":null},{"id":"W4295078726","doi":"10.1200/jco.22.01549","title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":475,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; NRG Oncology; Sanofi; AstraZeneca","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Ovarian cancer; Hazard ratio; Clinical endpoint; Oncology; Placebo; Cancer; Veliparib; BRCA mutation; Clinical trial; Surgery; Poly ADP ribose polymerase; Confidence interval; Pathology","score_opus":0.0555831528157147,"score_gpt":0.3980408485949811,"score_spread":0.34245769577926644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295078726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829684,0.00018509774,0.0001138045,0.013383229,0.002006334,0.0008550347,0.000021339718,0.000008842786,0.00045791984],"genre_scores_gemma":[0.99239784,0.00022855356,0.0011162886,0.005045392,0.0006198644,0.0001348221,0.0000080438285,0.000029995375,0.00041919266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99651206,0.00073105295,0.0014366048,0.00028911393,0.0007279065,0.00030328933],"domain_scores_gemma":[0.9952398,0.0023183767,0.0016285571,0.0002185164,0.00036813846,0.00022660538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179637,0.0001772311,0.0011600049,0.00009441567,0.00014780885,0.000012173125,0.00017588309,0.00013641245,0.000448143],"category_scores_gemma":[0.0009345552,0.000103304,0.00017499531,0.00025047452,0.00029440483,0.00013396172,0.00007866536,0.0012334168,0.0000018156851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7321832,0.0016133755,0.23983485,0.000015385967,0.00046773604,0.0007390929,0.00079766905,0.00113173,0.000012151402,0.00028968597,0.003683691,0.019231418],"study_design_scores_gemma":[0.54100716,0.035552334,0.39654776,0.00013442678,0.0001942548,0.00012625223,0.00033481134,0.000052066156,0.0000042494084,0.00050210307,0.025393337,0.00015123165],"about_ca_topic_score_codex":0.00010060441,"about_ca_topic_score_gemma":0.00090589636,"teacher_disagreement_score":0.19117604,"about_ca_system_score_codex":0.0007488106,"about_ca_system_score_gemma":0.0019944229,"threshold_uncertainty_score":0.53586507},"labels":[],"label_agreement":null},{"id":"W429551751","doi":"10.1200/jco.2006.24.18_suppl.3016","title":"Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Pharmacokinetics; Internal medicine; Refractory (planetary science); Dysgeusia; Cohort; Pharmacodynamics; Gastroenterology; Adverse effect; Urology; Pharmacology","score_opus":0.06641904893265617,"score_gpt":0.42355253041354257,"score_spread":0.3571334814808864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W429551751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981596,0.00008206487,0.00017708883,0.00025471303,0.0006666786,0.0004936529,0.00005691588,0.000002782826,0.00010653789],"genre_scores_gemma":[0.9981141,0.000047257887,0.00077467505,0.00012629034,0.0008494488,0.00000603028,0.000019655477,0.000021896241,0.000040641346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953382,0.0006176399,0.0030466814,0.00042734316,0.00034933526,0.0002207878],"domain_scores_gemma":[0.99660236,0.0004095412,0.0022237885,0.00032551942,0.00026983666,0.00016897618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016513554,0.0002007076,0.00086999283,0.000076765384,0.000051267245,0.000014325042,0.0003049207,0.00037332228,0.000008150441],"category_scores_gemma":[0.0008201684,0.00013711368,0.00017339454,0.00016183153,0.00019739718,0.00001889863,0.00017095129,0.0007131318,6.131684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063633166,0.017817393,0.5513802,0.000015854934,0.0003231362,0.000048216385,0.00022186401,0.0050119734,0.27339745,0.0000017460173,0.0014438077,0.086705185],"study_design_scores_gemma":[0.046575397,0.021049326,0.9194633,0.00014013362,0.00013493508,0.000010087486,0.0002575144,0.00015515885,0.009236547,0.000013033956,0.0027747455,0.00018985284],"about_ca_topic_score_codex":0.0001247438,"about_ca_topic_score_gemma":0.00036115714,"teacher_disagreement_score":0.36808303,"about_ca_system_score_codex":0.000049539984,"about_ca_system_score_gemma":0.0005285266,"threshold_uncertainty_score":0.55913335},"labels":[],"label_agreement":null},{"id":"W4297021340","doi":"10.1200/jco.22.01401","title":"Reply to D.J. Benedetti et al","year":2022,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.07003031137667919,"score_gpt":0.4323239830103335,"score_spread":0.3622936716336543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297021340","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032413386,0.005821734,0.00049570383,0.93438584,0.019706177,0.00028757646,0.00024661986,0.0000032260286,0.0066397623],"genre_scores_gemma":[0.004300714,0.01478083,0.0060491716,0.9558084,0.014854783,0.00001689293,0.00015333199,0.00009011124,0.003945765],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99219567,0.0015443694,0.004319948,0.000727898,0.0005914559,0.0006206482],"domain_scores_gemma":[0.99120945,0.0028630856,0.0038112183,0.000732525,0.0006980376,0.000685663],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.006310056,0.00043967695,0.0022107405,0.00017016513,0.00011480826,0.000049881666,0.0010988866,0.001447355,0.0014037091],"category_scores_gemma":[0.01001958,0.00042677906,0.0016809833,0.0001581858,0.0002771873,0.0000076056276,0.0009591122,0.004630455,0.000077517754],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022626934,0.0007221246,0.0009802899,0.000024590518,0.0007094964,0.001767655,0.000041390944,0.00066198123,0.0005760103,0.00014490787,0.93741524,0.05469363],"study_design_scores_gemma":[0.0024761918,0.033294868,0.0014170149,0.000054778233,0.0003472606,0.0006970189,0.00004511226,0.000008875532,0.00016359384,0.00021815716,0.9608462,0.00043096967],"about_ca_topic_score_codex":0.00011347176,"about_ca_topic_score_gemma":0.00014315802,"teacher_disagreement_score":0.05426266,"about_ca_system_score_codex":0.00034893194,"about_ca_system_score_gemma":0.0068490915,"threshold_uncertainty_score":0.99984896},"labels":[],"label_agreement":null},{"id":"W4297094017","doi":"10.1200/jco.22.00533","title":"Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Pasteur; Pharmacyclics; EMD Serono; Genentech; Aptitude Health; Qbiotics; Italfarmaco; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Astellas Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Array BioPharma; Five Prime Therapeutics; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Sun Pharma; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Endocyte; Sanofi; GlaxoSmithKline; Amgen; Celgene; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Hazard ratio; Internal medicine; Adjuvant; Population; Melanoma; Adjuvant therapy; Adverse effect; Randomized controlled trial; Stage (stratigraphy); Gastroenterology; Oncology; Surgery; Cancer; Immunotherapy; Confidence interval; Cancer research","score_opus":0.08196171607296819,"score_gpt":0.3946335868003538,"score_spread":0.3126718707273856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297094017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959553,0.0004707821,0.000011890009,0.0011123136,0.0010792505,0.00075026584,0.000059945487,0.000016457234,0.000543779],"genre_scores_gemma":[0.9965641,0.0006498019,0.0007258782,0.0006579944,0.00011849653,0.000020216507,0.000027495435,0.000051343166,0.0011846769],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99454474,0.00094108836,0.0026896314,0.0003403056,0.00106292,0.0004213261],"domain_scores_gemma":[0.99456275,0.0013018962,0.0028745192,0.00044720882,0.0005668976,0.00024673017],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027903419,0.0002723797,0.0021767332,0.00033181484,0.00010039192,0.00000951573,0.00037694027,0.00023886161,0.0019112821],"category_scores_gemma":[0.00045906694,0.00016709357,0.00032776265,0.0006770403,0.0004297446,0.00015088561,0.00009731777,0.0014410651,0.0000019835898],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79757345,0.0062008123,0.16036421,0.00004243068,0.001348068,0.00088052306,0.0003333401,0.000054787743,0.00034286338,0.000008815844,0.0009012944,0.031949434],"study_design_scores_gemma":[0.23003778,0.23046045,0.5136012,0.00011666815,0.00012260517,0.000045031742,0.000723558,0.000059637383,0.00014638883,0.0000046561427,0.024503913,0.00017810527],"about_ca_topic_score_codex":0.0003125585,"about_ca_topic_score_gemma":0.0010325406,"teacher_disagreement_score":0.56753564,"about_ca_system_score_codex":0.00064343034,"about_ca_system_score_gemma":0.00317068,"threshold_uncertainty_score":0.9990011},"labels":[],"label_agreement":null},{"id":"W4298109746","doi":"10.1200/jco.2022.40.28_suppl.248","title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 randomized clinical trial (RCT).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; CancerCare Manitoba; Ottawa Hospital; Queen's University","funders":"","keywords":"Medicine; Cetuximab; Randomized controlled trial; Colorectal cancer; Toxicity; Population; Cancer; Internal medicine; Clinical trial","score_opus":0.8035221349837114,"score_gpt":0.6779323277369244,"score_spread":0.12558980724678703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298109746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88691515,0.002090109,0.00007504197,0.10318349,0.0031771432,0.0018369651,0.00008349443,0.0000042087645,0.0026344017],"genre_scores_gemma":[0.9579069,0.001577118,0.0012848896,0.032965742,0.004603391,0.00050403655,0.000008254336,0.000028585495,0.0011210823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.93193144,0.03524202,0.031423997,0.00048271526,0.00048156388,0.00043824044],"domain_scores_gemma":[0.8692261,0.1063392,0.023560267,0.00054122193,0.00016752638,0.00016568296],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3906432,0.00016869161,0.0049419627,0.00018733685,0.00022239223,0.000023486704,0.000835777,0.00025382472,0.0021243566],"category_scores_gemma":[0.07095739,0.0001090937,0.0014294221,0.00020905912,0.0004288037,0.0001355038,0.000093281014,0.0011977748,0.00008639205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7134636,0.0133581925,0.08051295,0.00008168106,0.0028975753,0.000045203727,0.008178624,0.008873244,0.0000042935617,0.016196424,0.103756845,0.05263137],"study_design_scores_gemma":[0.7549453,0.022577103,0.023575569,0.000041458195,0.00026572528,0.000033198023,0.0017615887,0.01989189,0.0000012505667,0.015990559,0.16065766,0.00025873183],"about_ca_topic_score_codex":0.0006334167,"about_ca_topic_score_gemma":0.00026562865,"teacher_disagreement_score":0.31968582,"about_ca_system_score_codex":0.0008489476,"about_ca_system_score_gemma":0.0027647032,"threshold_uncertainty_score":0.9987878},"labels":[],"label_agreement":null},{"id":"W4298109774","doi":"10.1200/jco.2022.40.28_suppl.355","title":"Screening for supportive care services in the neuro-oncology patient: A quality improvement project.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Quality of life (healthcare); Psychological intervention; Family medicine; MEDLINE; Nursing","score_opus":0.4277408631143845,"score_gpt":0.6017217053121101,"score_spread":0.17398084219772564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298109774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883485,0.0009989411,0.0001422518,0.007370308,0.0008489088,0.0008035943,0.00004737067,0.0000045117076,0.0014356177],"genre_scores_gemma":[0.9840428,0.0002589255,0.004207524,0.01088117,0.0004840079,0.000079864454,0.000018947369,0.000011319399,0.000015401953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532294,0.0013029705,0.002506595,0.00018621095,0.0004512505,0.00023002147],"domain_scores_gemma":[0.9902315,0.0064072004,0.0025759703,0.00016699398,0.00052492146,0.00009342539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004509065,0.00011222031,0.0012351202,0.00013381986,0.00007163072,0.000003792032,0.00026954024,0.00014691245,0.000045155804],"category_scores_gemma":[0.002652446,0.000071491,0.00047792573,0.00019308015,0.00011016433,0.000060717266,0.00013130021,0.0009761311,4.330665e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019000381,0.003303975,0.27703008,0.00044531983,0.00046149612,0.0007862483,0.043598305,0.000080086094,0.00067390857,0.00023812237,0.0037888596,0.6505932],"study_design_scores_gemma":[0.010848418,0.07647943,0.045731068,0.00012851186,0.00030580143,0.00009049573,0.13956,0.00008848529,0.00023399857,0.0002376781,0.7261939,0.00010222966],"about_ca_topic_score_codex":0.00018512883,"about_ca_topic_score_gemma":0.00022396934,"teacher_disagreement_score":0.722405,"about_ca_system_score_codex":0.0002068882,"about_ca_system_score_gemma":0.0014376641,"threshold_uncertainty_score":0.42408583},"labels":[],"label_agreement":null},{"id":"W4298124740","doi":"10.1200/jco.22.00572","title":"Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Childhood cancer; Worry; Finance; Cancer; Demography; Gerontology; Family medicine; Psychiatry; Internal medicine; Anxiety","score_opus":0.054194045665423365,"score_gpt":0.4487576000213288,"score_spread":0.39456355435590545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298124740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96832496,0.0015917331,0.0000016333152,0.025263269,0.0028275778,0.0015624705,0.0002951314,0.0000045334546,0.00012871221],"genre_scores_gemma":[0.9920697,0.00035096434,0.000056048088,0.005961222,0.0012560659,0.00024701154,0.000010835926,0.0000303443,0.000017794497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98856175,0.0041547697,0.004808774,0.0003986731,0.0016846246,0.00039141116],"domain_scores_gemma":[0.99100775,0.003318607,0.004248961,0.0007502187,0.00057151506,0.00010296164],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01052541,0.00026164716,0.001854864,0.00014612512,0.00013789436,0.000012216029,0.0009292826,0.00019815515,0.000665707],"category_scores_gemma":[0.00333083,0.00014474757,0.00071314815,0.0008177224,0.00023127388,0.00012868954,0.0003270658,0.002616908,5.6101385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001970581,0.003335294,0.92577064,0.000034387587,0.00030178155,0.00018820028,0.049614467,0.00021048677,0.000006748289,0.000013137404,0.0009903052,0.01756398],"study_design_scores_gemma":[0.009339125,0.003121113,0.93251866,0.00020988613,0.0004434306,0.000065368506,0.05126054,0.000003370961,0.00003731303,0.00015933276,0.0027111287,0.00013071754],"about_ca_topic_score_codex":0.084171325,"about_ca_topic_score_gemma":0.51859266,"teacher_disagreement_score":0.43442133,"about_ca_system_score_codex":0.00047121535,"about_ca_system_score_gemma":0.00758707,"threshold_uncertainty_score":0.9996841},"labels":[],"label_agreement":null},{"id":"W4298139026","doi":"10.1200/jco.2022.40.28_suppl.332","title":"Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gynecologic oncology; Psychological intervention; Hepatitis B virus; Cancer; Oncology; Hepatitis B; Gynecology; Immunology","score_opus":0.1492836367092311,"score_gpt":0.4669587234167426,"score_spread":0.31767508670751154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752203,0.0001225299,0.000064373206,0.022458708,0.0009019401,0.00067945174,0.00004288068,0.000006915076,0.00050290616],"genre_scores_gemma":[0.9791653,0.0028517758,0.0015636997,0.015843783,0.00036814864,0.00011947622,0.000008679238,0.000018644636,0.000060497066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928765,0.0027455885,0.0031124707,0.00029085076,0.0006611741,0.0003133871],"domain_scores_gemma":[0.9899219,0.005049301,0.004084952,0.00021515577,0.00056118774,0.00016745811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006843267,0.00017019954,0.0014341956,0.00019981102,0.00019219003,0.0000035429516,0.00025228428,0.00018860803,0.00024386788],"category_scores_gemma":[0.007863339,0.000119821096,0.00036787268,0.0002858335,0.00021520931,0.00010834384,0.00035195347,0.0014184258,0.0000017654663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006082835,0.0024022248,0.72951293,0.0000133524945,0.00034291216,0.000039728493,0.0013274181,0.0000532828,0.00049900607,0.0000071549207,0.0037347306,0.25598446],"study_design_scores_gemma":[0.009517843,0.01519406,0.9396917,0.00008738621,0.00010274806,0.000019886505,0.0003121972,0.00006084571,0.00023314373,0.00012408171,0.03455425,0.0001018048],"about_ca_topic_score_codex":0.0034628292,"about_ca_topic_score_gemma":0.008911343,"teacher_disagreement_score":0.25588265,"about_ca_system_score_codex":0.0020259565,"about_ca_system_score_gemma":0.0011342178,"threshold_uncertainty_score":0.941372},"labels":[],"label_agreement":null},{"id":"W4298139084","doi":"10.1200/jco.2022.40.28_suppl.421","title":"Nursing strategies to improve alert closure for remote symptom monitoring.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health","keywords":"Medicine; PDCA; Quality management; Medical emergency; Workforce; Nursing; Management system; Operations management","score_opus":0.20478661420787578,"score_gpt":0.5773199361404165,"score_spread":0.37253332193254074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528365,0.0007435723,0.0032116445,0.031281542,0.005075801,0.0007045201,0.000014312484,0.000015601172,0.0061164848],"genre_scores_gemma":[0.98013526,0.00018730569,0.014176055,0.001173944,0.0029711751,0.000013958035,0.000003055196,0.000018707258,0.0013205404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997136,0.00029879206,0.0013037282,0.00018471619,0.000729668,0.00034711458],"domain_scores_gemma":[0.99539775,0.0025758315,0.0005438748,0.0001697388,0.00036877804,0.0009440139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032476608,0.00010059612,0.0009270307,0.0001237811,0.000109430934,0.000012084872,0.00019363643,0.0001557675,0.00018023353],"category_scores_gemma":[0.0070601176,0.00007099977,0.0004398616,0.00013477357,0.00010408312,0.000065410226,0.00006164096,0.001116514,0.000010430643],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012855127,0.0023296892,0.01265626,0.00003985147,0.0005980807,0.0012106323,0.00017787033,0.000019249732,0.0006307796,0.00024196175,0.020032195,0.9492083],"study_design_scores_gemma":[0.035512958,0.20785134,0.17202538,0.00050401955,0.0009378579,0.0010310804,0.0028336493,0.0004037928,0.00060936465,0.0132806795,0.5647508,0.00025908335],"about_ca_topic_score_codex":0.000011766452,"about_ca_topic_score_gemma":0.000001716892,"teacher_disagreement_score":0.9489492,"about_ca_system_score_codex":0.00038544735,"about_ca_system_score_gemma":0.0034387314,"threshold_uncertainty_score":0.845213},"labels":[],"label_agreement":null},{"id":"W4298139105","doi":"10.1200/jco.2022.40.28_suppl.258","title":"Patient-reported satisfaction with care and care coordination: Results from an online survey conducted in Manitoba, Canada during the COVID-19 pandemic.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Family medicine; Patient satisfaction; Health care; Test (biology); Post-hoc analysis; Demography; Pandemic; Disease; Coronavirus disease 2019 (COVID-19); Nursing; Internal medicine","score_opus":0.40060722748795763,"score_gpt":0.5234416862665136,"score_spread":0.12283445877855592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98980415,0.00030905253,0.000004392774,0.0043253405,0.0033414105,0.0007350408,0.0014210747,0.000018090503,0.000041478834],"genre_scores_gemma":[0.9954234,0.00011342357,0.00017090351,0.0034620964,0.00034210566,0.0000404513,0.00041131963,0.00001972209,0.000016588536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98513776,0.010011774,0.0035315845,0.00033812283,0.00067368953,0.00030708674],"domain_scores_gemma":[0.982943,0.010632563,0.004451332,0.00030559063,0.0011878855,0.00047962906],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028659503,0.00015738561,0.0008037576,0.00013512114,0.0009920396,0.000005329127,0.00016782992,0.000280598,0.00013801978],"category_scores_gemma":[0.008044543,0.00011299209,0.000051009243,0.00031666193,0.00011155359,0.00016697923,0.00013199146,0.0032239137,5.169057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004992398,0.00005218046,0.97577244,0.000048444053,0.00006062702,0.00022887903,0.006108908,0.0007361998,0.0000044017283,0.0000018876264,0.0012993333,0.01069432],"study_design_scores_gemma":[0.0075003505,0.0022560966,0.8852631,0.00003948627,0.00003825663,0.0000833629,0.091099195,0.000027164271,2.8274084e-7,0.000016885473,0.013568926,0.000106883206],"about_ca_topic_score_codex":0.89381623,"about_ca_topic_score_gemma":0.9966791,"teacher_disagreement_score":0.102862924,"about_ca_system_score_codex":0.004776046,"about_ca_system_score_gemma":0.014263659,"threshold_uncertainty_score":0.9990757},"labels":[],"label_agreement":null},{"id":"W4298139108","doi":"10.1200/jco.2022.40.28_suppl.228","title":"The association between medical cannabis and prescription opioid medication use in patients with early-stage cancer: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"M.S.I. Foundation","keywords":"Medicine; Poisson regression; Medical prescription; Cancer; Population; Cannabis; Prior authorization; Stage (stratigraphy); Opioid; Cancer registry; Pharmacy; Retrospective cohort study; Internal medicine; Emergency medicine; Family medicine; Psychiatry; Environmental health; Pharmacology","score_opus":0.0544409036262644,"score_gpt":0.4233114814502166,"score_spread":0.36887057782395216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677522,0.00008580038,0.0000091909305,0.03112699,0.00040782263,0.0005792458,0.000015057616,0.000004634791,0.000019032645],"genre_scores_gemma":[0.99781424,0.000068015564,0.000026834436,0.000672127,0.00035090648,0.00007124053,0.000016466232,0.000012396349,0.0009677458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99499166,0.0012330086,0.0014265927,0.00017726747,0.0019481467,0.00022331037],"domain_scores_gemma":[0.9969931,0.0007277521,0.0012874637,0.00014746723,0.0005138664,0.00033029655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076940055,0.0000886478,0.0006247029,0.00015647843,0.0001856872,0.000025979884,0.00015832743,0.00017221023,0.00012910018],"category_scores_gemma":[0.0060206447,0.000054774257,0.000097414886,0.00025061925,0.00007160664,0.00011638603,0.000075684315,0.0014569262,3.994578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022547974,0.0010384346,0.9574828,0.000009761454,0.00014166695,0.000031681044,0.0001330467,0.000035303077,3.372638e-7,0.00000799655,0.004639316,0.034224853],"study_design_scores_gemma":[0.009170609,0.008902351,0.9321776,0.000025197067,0.00013499259,0.0000013119321,0.00015192527,0.00014169142,3.9433485e-7,0.000012726716,0.04923242,0.000048778962],"about_ca_topic_score_codex":0.0031551947,"about_ca_topic_score_gemma":0.003931537,"teacher_disagreement_score":0.044593103,"about_ca_system_score_codex":0.0010551312,"about_ca_system_score_gemma":0.0027426102,"threshold_uncertainty_score":0.7207709},"labels":[],"label_agreement":null},{"id":"W4298139160","doi":"10.1200/jco.2022.40.28_suppl.126","title":"Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 &gt; 50%: Comparison between clinical trials and the real world.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Progression-free survival; Cancer; Oncology; Retrospective cohort study; Univariate analysis; Chemotherapy; Multivariate analysis; Surgery; Immunotherapy","score_opus":0.12152832720090546,"score_gpt":0.46121229726665824,"score_spread":0.3396839700657528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906547,0.0031799423,0.00004994732,0.0036355213,0.00071361015,0.0013011942,0.000102687285,0.0000059454046,0.00035643397],"genre_scores_gemma":[0.99029416,0.00549285,0.0005223765,0.002109188,0.0009433042,0.00006525252,0.000011459068,0.000040892995,0.0005205331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903778,0.0022493468,0.005939016,0.00037708334,0.00069449184,0.00036229537],"domain_scores_gemma":[0.9876966,0.006373911,0.0049313344,0.00036287704,0.0003745805,0.0002607032],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015282282,0.00029228503,0.004182402,0.00022353501,0.00009069997,0.00001472893,0.00030620297,0.00024991087,0.0011821936],"category_scores_gemma":[0.00039255124,0.00015070206,0.0006138081,0.00039345585,0.0008044675,0.0000858308,0.00010060361,0.0019583711,4.601764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3301611,0.0016905919,0.63075316,0.00005352273,0.0009079419,0.00004615375,0.00026458275,0.00006747943,0.0000078729245,0.0000019381014,0.00047019141,0.03557547],"study_design_scores_gemma":[0.12840903,0.023234615,0.80719733,0.00017201135,0.00070673705,0.0000060279185,0.00011497794,0.00016393981,0.000020706242,0.000008523317,0.039817844,0.00014827696],"about_ca_topic_score_codex":0.00027762583,"about_ca_topic_score_gemma":0.004074489,"teacher_disagreement_score":0.20175207,"about_ca_system_score_codex":0.0002562049,"about_ca_system_score_gemma":0.0020698293,"threshold_uncertainty_score":0.9997309},"labels":[],"label_agreement":null},{"id":"W4298139203","doi":"10.1200/jco.2022.40.28_suppl.199","title":"The PaCES (Palliative Care Early and Systematic) Project: Impact of individual components of a multi-faceted intervention on early referral to specialist palliative care.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Referral; Palliative care; Clinical nurse specialist; Intervention (counseling); Family medicine; Nursing","score_opus":0.47488771930568463,"score_gpt":0.5776056362351999,"score_spread":0.10271791692951526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488974,0.002842983,0.000029807305,0.00032725028,0.0005398385,0.00091387256,0.00019740818,0.0000043925997,0.0002547406],"genre_scores_gemma":[0.9982995,0.00036102487,0.00096704764,0.0000763293,0.00019257178,0.000021100548,0.000016410704,0.00001585231,0.000050182363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943796,0.0016823527,0.002697494,0.00019602141,0.00083562214,0.00020890238],"domain_scores_gemma":[0.9912514,0.003214138,0.0038894974,0.00019997738,0.0012632671,0.00018169421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002192942,0.00019153298,0.002033857,0.0002448883,0.00008954862,0.000012246885,0.0003083815,0.0001700392,0.000019750349],"category_scores_gemma":[0.004679108,0.00011564052,0.00074593804,0.00027577262,0.00028312736,0.00006706659,0.00018765462,0.0008165348,0.00000122111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018514842,0.0021529717,0.85537064,0.0028902083,0.0039996277,0.00013256149,0.10776966,0.00008387816,0.0006215974,0.00013955098,0.00065616623,0.0076682777],"study_design_scores_gemma":[0.007223412,0.04943232,0.89983076,0.0045371093,0.000630855,0.0000054576467,0.03729489,0.000023727769,0.0002339353,0.000022697208,0.0006644986,0.00010035603],"about_ca_topic_score_codex":0.0007153018,"about_ca_topic_score_gemma":0.00024589975,"teacher_disagreement_score":0.07047477,"about_ca_system_score_codex":0.00040432782,"about_ca_system_score_gemma":0.00056448707,"threshold_uncertainty_score":0.5601668},"labels":[],"label_agreement":null},{"id":"W4298139317","doi":"10.1200/jco.2022.40.28_suppl.238","title":"Bone mineral density testing and the risk of fractures in men initiating androgen-deprivation therapy: Population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Bone mineral; Incidence (geometry); Cohort; Prostate cancer; Internal medicine; Population; Retrospective cohort study; Cohort study; Osteoporosis; Surgery; Physical therapy; Cancer","score_opus":0.14026530696661274,"score_gpt":0.4744846231375586,"score_spread":0.3342193161709459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964658,0.0005954699,0.0000073620063,0.0023205532,0.00008785782,0.00037989966,0.0000019724391,0.0000024607345,0.00013862064],"genre_scores_gemma":[0.9985634,0.00012284738,0.00070230913,0.00041929915,0.00016524213,0.000009137251,0.0000024643807,0.000005768554,0.000009530535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702924,0.0013404647,0.0011069184,0.000093803705,0.00033193076,0.00009762974],"domain_scores_gemma":[0.99202263,0.006419648,0.001215643,0.00008613782,0.00019614244,0.000059772898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064617447,0.000060341874,0.0006553793,0.00010885991,0.00010172046,0.000004439059,0.000059392758,0.000056462497,0.000031364772],"category_scores_gemma":[0.00636097,0.00003276352,0.00010540427,0.00018165197,0.00008121723,0.000037247464,0.000048589463,0.0007758137,8.3882206e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008805118,0.0009476155,0.94326365,0.0000055364903,0.00014098527,0.00013797385,0.00035113035,0.0003698017,0.00007057459,0.00000471838,0.000031236716,0.045871682],"study_design_scores_gemma":[0.024158593,0.00557671,0.96727335,0.000015544412,0.00009995175,0.00003437777,0.00048944453,0.0016647404,0.000031676,0.00057620136,0.000051385286,0.000028001226],"about_ca_topic_score_codex":0.00036480336,"about_ca_topic_score_gemma":0.00006738419,"teacher_disagreement_score":0.04584368,"about_ca_system_score_codex":0.00010000198,"about_ca_system_score_gemma":0.0005258857,"threshold_uncertainty_score":0.7615135},"labels":[],"label_agreement":null},{"id":"W4298139318","doi":"10.1200/jco.2022.40.28_suppl.037","title":"A novel PA-led urgent care model for medical oncology patients at a large academic cancer center.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Triage; Emergency department; Cancer; Psychological intervention; Emergency medicine; Internal medicine; Medical emergency; Nursing","score_opus":0.3876305071018086,"score_gpt":0.6031830303817522,"score_spread":0.21555252327994368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97061974,0.0040155305,0.0031109385,0.016147846,0.0041431612,0.00059816515,0.00043233772,0.000012543982,0.0009197187],"genre_scores_gemma":[0.9684299,0.0058280826,0.004965133,0.018335026,0.001622521,0.00010296384,0.00007742412,0.000039637926,0.00059929123],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.995276,0.00037241715,0.0027769906,0.0002608995,0.0009047667,0.00040893006],"domain_scores_gemma":[0.9933838,0.002601042,0.0021479796,0.00015554293,0.0009149388,0.0007966849],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026740148,0.00017007517,0.0019207903,0.00013747075,0.000103312836,0.00000126639,0.00034305008,0.00060864585,0.00084626395],"category_scores_gemma":[0.00842735,0.00012994102,0.00080480945,0.00012431876,0.00016032596,0.00005098714,0.00034421353,0.0018146551,0.0000030944636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026080647,0.009078805,0.77195865,0.000268916,0.0013157495,0.00034055937,0.0064472985,0.0005244087,0.00025050226,0.00022458092,0.08460055,0.09890935],"study_design_scores_gemma":[0.0381326,0.014344572,0.013820968,0.00030178294,0.00055607193,0.00009939322,0.0011874654,0.012578389,0.000037887337,0.00008154507,0.9187123,0.00014697935],"about_ca_topic_score_codex":0.0000195638,"about_ca_topic_score_gemma":0.00017436004,"teacher_disagreement_score":0.8341118,"about_ca_system_score_codex":0.0013755228,"about_ca_system_score_gemma":0.005514478,"threshold_uncertainty_score":0.9999251},"labels":[],"label_agreement":null},{"id":"W4298139337","doi":"10.1200/jco.2022.40.28_suppl.270","title":"Trajectory of symptoms reported in remote symptom monitoring over the course of oncology treatment for gynecologic cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social and Behavioral Studies","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Interquartile range; Gynecologic oncology; Cancer; Internal medicine; Gynecologic cancer; Stage (stratigraphy); Physical therapy; Ovarian cancer","score_opus":0.2951787469395832,"score_gpt":0.5485195792349367,"score_spread":0.2533408322953535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050266,0.0008820469,0.0000036067725,0.0031262771,0.0038328057,0.00037977425,0.0000116415,0.000005400491,0.0012557957],"genre_scores_gemma":[0.99713284,0.0014424054,0.00024561133,0.00013040601,0.0008473744,0.00002539148,5.035442e-7,0.000006987004,0.00016850005],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956926,0.0014092936,0.0020896215,0.00015295905,0.00038118116,0.0002743166],"domain_scores_gemma":[0.98982686,0.0064748432,0.0031773283,0.0001110538,0.0003148302,0.00009509332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006353063,0.000105473686,0.0012781904,0.00006870105,0.00029325034,0.0000032989979,0.00033594813,0.0002465179,0.000112774695],"category_scores_gemma":[0.0020606776,0.00006764256,0.0005670007,0.00028576134,0.00072824943,0.000054537533,0.000074962125,0.00047719886,2.0615052e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012257281,0.002273187,0.47669592,0.000006601329,0.0004649497,0.00011206423,0.0106735015,0.00017564929,0.00013868728,0.00024096562,0.0008167539,0.507176],"study_design_scores_gemma":[0.0044523766,0.019642891,0.7973123,0.00002147451,0.00043891757,0.000009785488,0.02412866,0.000013226322,0.00005796476,0.0012690013,0.15254508,0.00010827383],"about_ca_topic_score_codex":0.004670267,"about_ca_topic_score_gemma":0.006498681,"teacher_disagreement_score":0.5070677,"about_ca_system_score_codex":0.0017618922,"about_ca_system_score_gemma":0.0042740605,"threshold_uncertainty_score":0.7582},"labels":[],"label_agreement":null},{"id":"W4298139438","doi":"10.1200/jco.2022.40.28_suppl.444","title":"Feasibility and usability of an electronic patient (pt)-reported outcome (ePRO) smartphone application (app) and biosensor for pts with cancer undergoing systemic therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Usability; mHealth; Patient satisfaction; Cancer; Observational study; Physical therapy; Internal medicine; Surgery; Nursing; Psychological intervention","score_opus":0.16451552070093628,"score_gpt":0.5016482407432397,"score_spread":0.3371327200423034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933806,0.0009676289,0.00047842285,0.0036451982,0.00017880191,0.0013180287,0.00001386237,0.000008364665,0.000009094804],"genre_scores_gemma":[0.9969145,0.00055930356,0.0011737976,0.0010747381,0.00016846177,0.00008082017,0.000011416135,0.000011476725,0.0000054893435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996607,0.00039339563,0.00226351,0.0002449763,0.00029341798,0.0001977129],"domain_scores_gemma":[0.99549437,0.0012777096,0.0024719706,0.00018454265,0.00036868337,0.0002026996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004147267,0.00010098067,0.00095657475,0.00007764546,0.00008418495,0.0000026651962,0.00004987031,0.00008520673,0.000024872534],"category_scores_gemma":[0.0007336231,0.000068596644,0.00008467101,0.00012533033,0.00011709823,0.00006748765,0.000025145328,0.0004333566,4.5942617e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007914764,0.0008654298,0.7697747,0.0002004468,0.00015580135,0.000008345121,0.00024260837,0.000009974817,0.00086349,0.000034072073,0.00004249552,0.21988788],"study_design_scores_gemma":[0.018634016,0.0543821,0.9193767,0.000037557347,0.00033748918,0.0007484242,0.001436883,0.0002475711,0.00019776095,0.00032602088,0.004191018,0.00008448093],"about_ca_topic_score_codex":0.00016147671,"about_ca_topic_score_gemma":0.00047156384,"teacher_disagreement_score":0.2198034,"about_ca_system_score_codex":0.00035590495,"about_ca_system_score_gemma":0.0015920165,"threshold_uncertainty_score":0.2824169},"labels":[],"label_agreement":null},{"id":"W4298139442","doi":"10.1200/jco.2022.40.28_suppl.175","title":"Assessing the needs of those who serve the underserved: A national survey among cancer care clinicians.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Family medicine; Health care; Best practice; Needs assessment; Nursing; MEDLINE","score_opus":0.3367519218827459,"score_gpt":0.47085422597989995,"score_spread":0.13410230409715407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622499,0.007395478,0.00019552598,0.008840134,0.004055544,0.00018185,0.00022272162,0.0000040309314,0.016854817],"genre_scores_gemma":[0.99274987,0.0014123007,0.00006682161,0.0044046068,0.0009612926,0.000014359165,0.0000043576483,0.000020064439,0.00036633518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953244,0.00062885915,0.003479998,0.0001665025,0.0001457902,0.00025448302],"domain_scores_gemma":[0.98922634,0.0038382858,0.0060927733,0.00024406989,0.0004890506,0.00010950355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01585277,0.00013506491,0.001263324,0.00016442138,0.00029395148,0.00005740148,0.0008418087,0.00020228168,0.000550455],"category_scores_gemma":[0.0037866614,0.000095443094,0.000625025,0.00037091898,0.00041810764,0.00043359937,0.00020442261,0.0013303417,0.000007950166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026329872,0.00024094943,0.94877845,0.000013123807,0.0003163518,0.0000055505297,0.0016748486,0.0034970061,4.195277e-7,0.013726895,0.012906647,0.018576454],"study_design_scores_gemma":[0.0012914606,0.00079645315,0.86558807,0.000021968839,0.000034553603,0.000006808414,0.0044480856,0.0004084691,0.0000016009777,0.008540709,0.11874599,0.00011582181],"about_ca_topic_score_codex":0.0021176762,"about_ca_topic_score_gemma":0.002301619,"teacher_disagreement_score":0.10583934,"about_ca_system_score_codex":0.0004878509,"about_ca_system_score_gemma":0.0016989959,"threshold_uncertainty_score":0.60270965},"labels":[],"label_agreement":null},{"id":"W4298139448","doi":"10.1200/jco.2022.40.28_suppl.286","title":"Impact of the COVID-19 pandemic on patient perceptions of the quality of their cancer care.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pandemic; Family medicine; Logistic regression; Cancer; Coronavirus disease 2019 (COVID-19); Health care; Disease; Internal medicine","score_opus":0.4695094099347966,"score_gpt":0.643557380423838,"score_spread":0.17404797048904141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755992,0.0003538452,0.0000072200833,0.022320943,0.000996677,0.00032578807,0.00016221948,0.0000027601814,0.00023131273],"genre_scores_gemma":[0.9885962,0.00044555296,0.000016782253,0.010658949,0.00023659818,0.0000054215557,9.977881e-7,0.000008550477,0.000030948722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943394,0.0022135756,0.0025112266,0.00011811435,0.0006425835,0.0001751093],"domain_scores_gemma":[0.98956484,0.0053914348,0.0037463761,0.0004250746,0.00054534595,0.0003269154],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036940302,0.0001039531,0.0012275273,0.000083349114,0.000110758774,0.0000010309936,0.0003212829,0.00017380007,0.0006505374],"category_scores_gemma":[0.009200191,0.000046938276,0.0013318376,0.00025337614,0.00037501825,0.000021959873,0.00016039007,0.0013734158,3.655471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00399922,0.001125514,0.9598216,0.00012891044,0.00021561045,0.0000038950175,0.0041485815,0.0010647168,0.0009852836,0.00004095337,0.0029271226,0.025538586],"study_design_scores_gemma":[0.003089205,0.013403088,0.96759534,0.000071040435,0.00015475674,0.000054292443,0.002376242,0.000009062149,0.000027983613,0.00019654201,0.012982046,0.00004042303],"about_ca_topic_score_codex":0.0031778484,"about_ca_topic_score_gemma":0.0014132636,"teacher_disagreement_score":0.025498163,"about_ca_system_score_codex":0.0014412602,"about_ca_system_score_gemma":0.0153404735,"threshold_uncertainty_score":0.99914575},"labels":[],"label_agreement":null},{"id":"W4298139451","doi":"10.1200/jco.2022.40.28_suppl.135","title":"Falling off the treatment wagon: Barriers to cancer treatment and care for people experiencing health and social inequities.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Victoria","funders":"","keywords":"Medicine; Health equity; Health care; Social determinants of health; Poverty; Context (archaeology); Nursing; Gerontology; Public health; Economic growth","score_opus":0.2538436100715615,"score_gpt":0.5249800988356204,"score_spread":0.2711364887640589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9535233,0.0117109725,0.00003583834,0.03361321,0.00057772413,0.000428666,0.000022027381,0.000004218436,0.00008404683],"genre_scores_gemma":[0.98467374,0.0036917143,0.0006338376,0.009699776,0.0010809158,0.00012446141,0.0000026798098,0.000009651884,0.0000831984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837804,0.00018571461,0.0008447081,0.00016182884,0.00019834972,0.00023136799],"domain_scores_gemma":[0.99826413,0.00057959306,0.00049954624,0.00006785909,0.0001350024,0.0004538871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008984619,0.000106936815,0.0009660289,0.0000444313,0.0005407748,0.000011933243,0.00006650981,0.000063356296,0.000056868455],"category_scores_gemma":[0.0002932302,0.00006445479,0.00020399076,0.00006783054,0.00007327794,0.000039922215,0.00004561192,0.0002189524,1.1243554e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004958566,0.0001503001,0.04772755,0.00003379475,0.00026945097,0.000049264618,0.1357633,0.0001576918,0.000020557176,0.00006838736,0.0019360763,0.8088651],"study_design_scores_gemma":[0.007093807,0.06710821,0.011153898,0.000042051914,0.00025753488,0.0001698252,0.25614995,0.000099968645,0.000019463196,0.000035912082,0.65777844,0.00009095377],"about_ca_topic_score_codex":0.0007640901,"about_ca_topic_score_gemma":0.0021593107,"teacher_disagreement_score":0.8087741,"about_ca_system_score_codex":0.0013833037,"about_ca_system_score_gemma":0.0035665433,"threshold_uncertainty_score":0.6326895},"labels":[],"label_agreement":null},{"id":"W4298139476","doi":"10.1200/jco.2022.40.28_suppl.330","title":"What is the prognostic value of lymph node yield on the outcomes of patients with oral cavity squamous cell carcinoma?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lymph node; Proportional hazards model; Retrospective cohort study; Neck dissection; Stage (stratigraphy); Lymph; Cohort; Internal medicine; Dissection (medical); Carcinoma; Cancer; Survival analysis; Oncology; Primary tumor; Surgery; Pathology; Metastasis","score_opus":0.08269848992631351,"score_gpt":0.3916761546825978,"score_spread":0.3089776647562843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724117,0.00041661097,0.0000017552555,0.025592515,0.0008635804,0.00038437574,0.000022410115,0.00000162942,0.00030542945],"genre_scores_gemma":[0.993023,0.00012000683,0.00006759517,0.006577658,0.0000958912,0.000020736372,0.0000017278238,0.000011207429,0.00008217049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743843,0.0004415994,0.0012165688,0.00013157999,0.0006238716,0.00014794417],"domain_scores_gemma":[0.9901244,0.0075853313,0.0016207921,0.00028800662,0.00027642265,0.00010501778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014355273,0.00011582918,0.0009992262,0.00004582096,0.00007119124,0.000005433233,0.0002076965,0.00007944155,0.00027640956],"category_scores_gemma":[0.0009221317,0.00004812552,0.00043759757,0.00011213735,0.00020268511,0.000043180517,0.00008882665,0.0005316097,0.0000018089245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026307933,0.0067109773,0.9806509,0.000020395037,0.00025324937,0.00007069672,0.00032183545,0.000101528756,0.0000020286207,0.00006320447,0.0020343496,0.007140039],"study_design_scores_gemma":[0.0065560094,0.019600395,0.9697823,0.00003893286,0.0008806484,0.000014892357,0.00052803685,0.000020864301,0.00012967519,0.000061198254,0.0023423645,0.000044661723],"about_ca_topic_score_codex":0.00021367632,"about_ca_topic_score_gemma":0.00003543079,"teacher_disagreement_score":0.020611314,"about_ca_system_score_codex":0.00017943874,"about_ca_system_score_gemma":0.0008286202,"threshold_uncertainty_score":0.30264908},"labels":[],"label_agreement":null},{"id":"W4298139504","doi":"10.1200/jco.2022.40.28_suppl.389","title":"Virtual care beyond COVID-19: Patient and physician perspectives.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Feeling; Logistic regression; Pandemic; Coronavirus disease 2019 (COVID-19); Internal medicine; Psychology","score_opus":0.09630328605190049,"score_gpt":0.5019543125812085,"score_spread":0.405651026529308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555143,0.0015148013,0.0001418506,0.03940828,0.0009706645,0.0002614289,0.000014320644,0.000009645706,0.0021647138],"genre_scores_gemma":[0.947416,0.00024858376,0.0007098574,0.050546985,0.0010071908,0.0000076055235,0.000009373186,0.000009721768,0.000044656237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741405,0.00044875895,0.0013778649,0.00015598982,0.00043355496,0.00016975842],"domain_scores_gemma":[0.99683505,0.0010155602,0.0011716235,0.00009768531,0.0002497197,0.00063035206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013861316,0.00008329294,0.00074378744,0.00013159815,0.00015543525,0.0000031908176,0.00006737761,0.00007207014,0.00044606082],"category_scores_gemma":[0.002025648,0.00006561768,0.00016672096,0.00012790597,0.00014174405,0.000056516023,0.00008136686,0.0008976705,0.000002013882],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039112163,0.0013188192,0.048124615,0.00005622168,0.00022822675,0.000979829,0.021213768,0.000029971892,0.00005339106,0.0013593055,0.0519314,0.8707932],"study_design_scores_gemma":[0.010128519,0.060156427,0.06063839,0.000008003871,0.0002409913,0.0005947362,0.14791569,0.000017867318,0.00000824695,0.00037134177,0.719849,0.00007081354],"about_ca_topic_score_codex":0.000040297673,"about_ca_topic_score_gemma":0.000020410713,"teacher_disagreement_score":0.8707224,"about_ca_system_score_codex":0.0004838452,"about_ca_system_score_gemma":0.0027944555,"threshold_uncertainty_score":0.4957244},"labels":[],"label_agreement":null},{"id":"W4298139506","doi":"10.1200/jco.2022.40.28_suppl.275","title":"Patient-reported hope, quality of life, symptom burden, coping, and financial toxicity in early-phase clinical trial participants.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Coping (psychology); Clinical trial; Denial; Internal medicine; Physical therapy; Clinical psychology; Nursing","score_opus":0.29697850040645357,"score_gpt":0.4735330369966519,"score_spread":0.17655453659019832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082154,0.0013527813,0.0001362534,0.0014213634,0.0042531616,0.000347638,0.00009130238,0.0000056495505,0.0015702961],"genre_scores_gemma":[0.9958736,0.00086725806,0.0002713097,0.0018047811,0.0010867888,0.000016448212,0.0000022969673,0.00001691535,0.000060632672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.986959,0.0006510302,0.011431413,0.00041171024,0.00012863682,0.00041820348],"domain_scores_gemma":[0.98670566,0.0021119735,0.010263755,0.00030007004,0.00016059238,0.00045794438],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015984166,0.00017722682,0.0032075294,0.0002516279,0.00008672494,0.000019594021,0.00032800395,0.00041079614,0.00035508888],"category_scores_gemma":[0.025627535,0.00018790769,0.00063442165,0.00023256631,0.00037199812,0.00029653223,0.00024734857,0.0013780287,0.000009465276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07233002,0.005407393,0.840171,0.000028225126,0.0002847202,0.00011556681,0.0006970193,0.00017540863,0.000004559554,0.009072007,0.0041486253,0.06756549],"study_design_scores_gemma":[0.1028497,0.025659809,0.7336849,0.000021314805,0.00004979096,0.000011986122,0.00012298464,0.0001741834,0.000004341478,0.009424539,0.12768832,0.00030812167],"about_ca_topic_score_codex":0.00053613377,"about_ca_topic_score_gemma":0.00014448208,"teacher_disagreement_score":0.12353969,"about_ca_system_score_codex":0.0001922261,"about_ca_system_score_gemma":0.0015575138,"threshold_uncertainty_score":0.98258},"labels":[],"label_agreement":null},{"id":"W4298139508","doi":"10.1200/jco.2022.40.28_suppl.272","title":"Adaptation of remote symptom monitoring using electronic patient-reported outcomes for implementation in real-world settings.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Workflow; Psychological intervention; Adaptation (eye); Intervention (counseling); Formative assessment; Medical emergency; Medical education; Process management; Nursing; Computer science","score_opus":0.24815936707773248,"score_gpt":0.6122470737257302,"score_spread":0.3640877066479977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052984,0.00013685327,0.0018108608,0.0031830731,0.0020039992,0.0021233545,0.00001565676,0.000011258092,0.00018509048],"genre_scores_gemma":[0.9821976,0.00048143623,0.015265931,0.0011262387,0.00045143164,0.00038767242,0.000014933308,0.000022037604,0.000052737105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991548,0.0014032432,0.0059785484,0.00019300691,0.0003516172,0.0005255872],"domain_scores_gemma":[0.98682326,0.0042677755,0.00798526,0.00017422278,0.00053181767,0.00021766336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008664286,0.00010328436,0.00096405105,0.00033708324,0.00039923203,0.0000015089455,0.0001556075,0.00015664504,0.000100780766],"category_scores_gemma":[0.0014732934,0.00009566736,0.000214509,0.00039096948,0.000029920146,0.00009916988,0.000070364644,0.0014008542,9.301086e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010112354,0.0002869734,0.6467046,0.00013211003,0.00006004882,0.0000053472327,0.0007876217,0.000726054,0.0000674007,0.00095475145,0.00057433324,0.34868953],"study_design_scores_gemma":[0.011889497,0.0056235436,0.69923955,0.00013944745,0.00020427493,0.000013004868,0.011097155,0.0042687086,0.000024380837,0.0038605842,0.26348236,0.00015748746],"about_ca_topic_score_codex":0.0015648925,"about_ca_topic_score_gemma":0.0015748988,"teacher_disagreement_score":0.34853205,"about_ca_system_score_codex":0.00130271,"about_ca_system_score_gemma":0.0072989324,"threshold_uncertainty_score":0.99832875},"labels":[],"label_agreement":null},{"id":"W4298139516","doi":"10.1200/jco.2022.40.28_suppl.169","title":"Social determinants of health—to screen or not to screen? How, when, and what to do next are really the questions.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Food Security and Health in Diverse Populations","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Social determinants of health; Family medicine; Health care; Quarter (Canadian coin); Social media; Inclusion (mineral); Breast cancer; Gerontology; Public health; Cancer; Nursing; Psychology; Social psychology","score_opus":0.5656435479812495,"score_gpt":0.6274280717862142,"score_spread":0.061784523804964686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54449147,0.00027893475,0.00011546741,0.45179388,0.0020331547,0.0010691267,0.00008806986,0.0000100503285,0.00011983555],"genre_scores_gemma":[0.88625276,0.000685292,0.004976746,0.10601593,0.0014915506,0.000060719154,0.0000031364775,0.000023875433,0.00049002154],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9900689,0.0050963033,0.0033825133,0.00027420378,0.0006304412,0.0005476111],"domain_scores_gemma":[0.9901595,0.004913563,0.003113119,0.00028137123,0.0007100728,0.00082234235],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0134672,0.00015166476,0.0014651604,0.0002716165,0.0020663,0.000034731944,0.00056347786,0.00028365836,0.0003981336],"category_scores_gemma":[0.006964941,0.000107201995,0.00020038089,0.00039041106,0.00013280706,0.0003327669,0.00069880224,0.0021164597,0.00003728384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014135805,0.0011936936,0.08779514,0.00026130662,0.00013704035,0.00012869087,0.03597748,0.0001126946,0.000005624796,0.003730842,0.3705231,0.48599857],"study_design_scores_gemma":[0.0017020004,0.009724338,0.50254047,0.00035811486,0.00005428326,0.000026872669,0.029647458,0.00002604135,3.3733508e-7,0.0008341117,0.45497248,0.00011351183],"about_ca_topic_score_codex":0.000839534,"about_ca_topic_score_gemma":0.009760181,"teacher_disagreement_score":0.48588505,"about_ca_system_score_codex":0.0003610552,"about_ca_system_score_gemma":0.0036606982,"threshold_uncertainty_score":0.9992329},"labels":[],"label_agreement":null},{"id":"W4298139548","doi":"10.1200/jco.2022.40.28_suppl.167","title":"Factors associated with timely receipt of COVID vaccination in patients with cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Vaccination; Cancer; Population; Internal medicine; Proportional hazards model; Cohort; Retrospective cohort study; Immunology; Environmental health","score_opus":0.12340707136672682,"score_gpt":0.44213401985282136,"score_spread":0.3187269484860945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948227,0.000071392365,0.000009990168,0.0026610259,0.00043657667,0.00013635558,0.000009458133,0.000004129224,0.0018484197],"genre_scores_gemma":[0.99925613,0.00007242881,0.000034132394,0.00033129076,0.000105031555,0.0000031172156,0.0000034989082,0.0000066903394,0.00018764754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969826,0.001153585,0.001018242,0.000103886014,0.00057534594,0.00016637828],"domain_scores_gemma":[0.9955837,0.0016088395,0.0021502555,0.0000595798,0.00047248937,0.00012513944],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003170174,0.000068416724,0.0006526748,0.00011690343,0.00013665107,0.0000059508266,0.00023182803,0.00011684637,0.0012256957],"category_scores_gemma":[0.0028243423,0.000046856738,0.00009800417,0.00041034602,0.000026313668,0.00018884384,0.00003222118,0.00057341106,3.8329293e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001068382,0.0009778708,0.98626256,0.000002408708,0.00008295639,0.000013094561,0.0014763325,0.00028769608,4.2225898e-7,0.000088492634,0.0014751471,0.008264632],"study_design_scores_gemma":[0.0042504696,0.0067756264,0.9770556,0.00002027438,0.000054927965,1.6047744e-7,0.0008975799,0.000004047232,0.0000022264594,0.00019682462,0.010680622,0.000061655424],"about_ca_topic_score_codex":0.00028394235,"about_ca_topic_score_gemma":0.0064043626,"teacher_disagreement_score":0.00920698,"about_ca_system_score_codex":0.0006005726,"about_ca_system_score_gemma":0.0027391433,"threshold_uncertainty_score":0.9996873},"labels":[],"label_agreement":null},{"id":"W4298139633","doi":"10.1200/jco.2022.40.28_suppl.040","title":"Comparing chair time required for systemic agent drug reaction (DR) management to allocated chair time for systemic protocol.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Island Health; BC Cancer Agency","funders":"","keywords":"Medicine; Regimen; Surgery","score_opus":0.6319275583430035,"score_gpt":0.6184079064705147,"score_spread":0.013519651872488825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139633","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07359836,0.00008021361,0.5569289,0.027090337,0.011729466,0.32576677,0.00018551628,0.0004891729,0.0041312855],"genre_scores_gemma":[0.032021888,0.000013358776,0.8678697,0.0022761193,0.003766722,0.087597474,0.000011251876,0.00019342109,0.006250073],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.985158,0.0042110807,0.00849175,0.00062320195,0.0008974061,0.00061854126],"domain_scores_gemma":[0.9253084,0.066858426,0.005952804,0.00055932347,0.00079716515,0.0005238564],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.045288615,0.00034385337,0.003699431,0.0002753189,0.00025657096,0.000034904322,0.0009320525,0.00036001543,0.0001729567],"category_scores_gemma":[0.053439096,0.00029020116,0.001096639,0.00031487903,0.000112569716,0.00010293871,0.00035370776,0.0009774377,0.00008977693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09083619,0.013180248,0.000360527,0.008683664,0.0065301647,0.0010929019,0.00090632046,0.0015886571,0.010677453,0.06178827,0.72681576,0.07753985],"study_design_scores_gemma":[0.05903693,0.040911987,0.00047772215,0.0030950736,0.0033948752,0.002403825,0.0011497826,0.019772163,0.0003441935,0.5311067,0.3368072,0.0014995363],"about_ca_topic_score_codex":0.0000034664479,"about_ca_topic_score_gemma":0.000001343812,"teacher_disagreement_score":0.46931845,"about_ca_system_score_codex":0.0011457846,"about_ca_system_score_gemma":0.0005231231,"threshold_uncertainty_score":0.999955},"labels":[],"label_agreement":null},{"id":"W4298139704","doi":"10.1200/jco.2022.40.28_suppl.168","title":"Patient-reported outcomes in a linguistically diverse cancer population: Addressing barriers to access.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; First language; Population; Language barrier; Family medicine; Ethnic group; Demography; Linguistics; Environmental health; Pathology","score_opus":0.38158616459432326,"score_gpt":0.637614743551324,"score_spread":0.2560285789570007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96277577,0.00012252721,0.00003088399,0.024562053,0.00769305,0.00036298027,0.000016028103,0.00001810897,0.004418589],"genre_scores_gemma":[0.9754375,0.00004759895,0.0010508115,0.022685094,0.00046835473,0.00009940368,0.0000031355532,0.000014700521,0.00019338212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904283,0.004439431,0.004178514,0.00017915957,0.0004475057,0.00032706876],"domain_scores_gemma":[0.98913276,0.006142804,0.0031618043,0.00031404514,0.00068791106,0.0005606449],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0055310787,0.00010234461,0.00094446767,0.00022434424,0.0007107905,0.0000080433365,0.0005370447,0.00023338092,0.0025774813],"category_scores_gemma":[0.04038021,0.00008557453,0.00020522295,0.00028338144,0.000050665178,0.00007867568,0.00069778,0.0031064712,0.000008636692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011054018,0.00017742698,0.96273476,0.000021253638,0.000052781892,0.00011394712,0.0032771633,0.0006511042,9.408892e-7,0.0002145793,0.00477139,0.02687924],"study_design_scores_gemma":[0.002060189,0.0017345655,0.87130046,0.00029749135,0.00005340475,0.00001138977,0.008809157,0.00024733803,3.066821e-7,0.00092744996,0.1144313,0.00012696756],"about_ca_topic_score_codex":0.002109222,"about_ca_topic_score_gemma":0.0011345085,"teacher_disagreement_score":0.10965991,"about_ca_system_score_codex":0.0008262403,"about_ca_system_score_gemma":0.0036572698,"threshold_uncertainty_score":0.99919343},"labels":[],"label_agreement":null},{"id":"W4298139915","doi":"10.1200/jco.2022.40.28_suppl.041","title":"Staff experiences with remote work in a comprehensive cancer center during the COVID-19 pandemic.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Respondent; Medicine; Personal protective equipment; Descriptive statistics; Pandemic; Health care; Family medicine; Logistic regression; Nursing; Work (physics); Patient safety; Coronavirus disease 2019 (COVID-19); Medical emergency; Disease","score_opus":0.265712875586701,"score_gpt":0.5477696191517794,"score_spread":0.28205674356507837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95512867,0.00037396522,0.000067685076,0.043361563,0.0006914264,0.00027755246,0.000002780902,0.000006721853,0.00008965279],"genre_scores_gemma":[0.97491026,0.00036183494,0.00051345874,0.023477921,0.0006034527,0.000022945274,0.00000192681,0.00000812537,0.000100048564],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970756,0.0006512513,0.0014760286,0.00013628385,0.00043574962,0.00022504071],"domain_scores_gemma":[0.99673504,0.0015409522,0.0011915385,0.00011215467,0.00012498404,0.00029533124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018112103,0.00008232832,0.00067702844,0.0001066063,0.00012763577,0.0000034737213,0.00014057511,0.000058987767,0.00085486623],"category_scores_gemma":[0.00069054664,0.0000451582,0.00009903712,0.0002864322,0.00016963368,0.000047540994,0.00006469991,0.0011123709,7.287391e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011710979,0.00041800967,0.9276625,0.000036916554,0.00009975761,0.00093170936,0.009619855,0.00011773782,0.00001240433,0.0000044607737,0.006981593,0.04240411],"study_design_scores_gemma":[0.014397801,0.008400586,0.4494396,0.000038076007,0.00006708208,0.0015384903,0.050782826,0.000019099552,0.0000025730817,0.000021059544,0.47523487,0.000057952468],"about_ca_topic_score_codex":0.00022405907,"about_ca_topic_score_gemma":0.0004793112,"teacher_disagreement_score":0.47822288,"about_ca_system_score_codex":0.0004925479,"about_ca_system_score_gemma":0.0020410486,"threshold_uncertainty_score":0.9360186},"labels":[],"label_agreement":null},{"id":"W4298142751","doi":"10.1200/jco.2022.40.28_suppl.341","title":"Evaluating nurses' time to response by severity and cancer stage in a remote symptom monitoring program.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Stage (stratigraphy); Breast cancer; Confidence interval; Logistic regression; Cancer; Odds ratio; Randomized controlled trial; Emergency medicine; Physical therapy; Internal medicine","score_opus":0.2646454342485577,"score_gpt":0.6677738373337316,"score_spread":0.40312840308517395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298142751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96353686,0.00071349525,0.000019990008,0.031017022,0.001647774,0.002446979,0.000040520114,0.000023668865,0.0005537202],"genre_scores_gemma":[0.8691544,0.0036825978,0.046101224,0.041528028,0.0043358803,0.009938533,0.000013972844,0.00014823899,0.025097106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98891634,0.0065416964,0.003224028,0.00028720635,0.00044687858,0.00058387755],"domain_scores_gemma":[0.9882108,0.008431557,0.0019841078,0.00021396189,0.00030165017,0.0008579013],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024269927,0.00011704417,0.0009229188,0.0001656218,0.00056665466,0.0000045094257,0.0002480961,0.00026362808,0.0010610673],"category_scores_gemma":[0.0065881824,0.00010668046,0.00009122077,0.0003752824,0.000060207203,0.000071273884,0.0002174903,0.0029086967,0.000041161795],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008021424,0.00057418924,0.06762357,0.00007315097,0.000019090805,0.000027067947,0.0008109378,0.00009786844,0.00021859219,0.000011400976,0.022709426,0.8998133],"study_design_scores_gemma":[0.0031577037,0.004935482,0.14973834,0.000115571056,0.000023401406,0.000009963398,0.00079761137,0.00097246794,0.0000016990585,0.00008130356,0.84008354,0.00008291003],"about_ca_topic_score_codex":0.0004399105,"about_ca_topic_score_gemma":0.00007053138,"teacher_disagreement_score":0.8997304,"about_ca_system_score_codex":0.00083733513,"about_ca_system_score_gemma":0.0067505217,"threshold_uncertainty_score":0.9998521},"labels":[],"label_agreement":null},{"id":"W4298142784","doi":"10.1200/jco.2022.40.28_suppl.351","title":"Identification of target population in the implementation of navigator-delivered home ePRO for patients with cancer receiving treatment.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Population; Cancer; Disease; Stage (stratigraphy); Internal medicine; Family medicine; Physical therapy","score_opus":0.08169249563776833,"score_gpt":0.4102740948993806,"score_spread":0.3285815992616123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298142784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726766,0.0003615007,0.00024740846,0.0007574045,0.0006378343,0.00033342265,0.00031710064,8.826176e-7,0.00007678016],"genre_scores_gemma":[0.99901205,0.00026652543,0.00038803942,0.00012122772,0.00011855772,0.000041432846,0.000023141907,0.000007898571,0.000021104619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726295,0.00008460872,0.0023716898,0.00012085271,0.000054067146,0.00010585505],"domain_scores_gemma":[0.9944433,0.00038923335,0.0049031586,0.00010486876,0.00012971433,0.000029713838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023615696,0.00006382845,0.00066173694,0.00011827686,0.000046138524,0.000005766124,0.00016438423,0.00006062735,0.00013865814],"category_scores_gemma":[0.00023353059,0.000051099156,0.00016358105,0.00012158301,0.00003842652,0.00021550381,0.000015101293,0.00013736253,5.3836976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007138531,0.000507734,0.96435606,0.000011558475,0.00007800266,4.800361e-7,0.00060408126,0.0006669646,0.0000051914035,0.0022413759,0.00020484209,0.030609844],"study_design_scores_gemma":[0.0043268595,0.004006919,0.97865796,0.0000075791077,0.000027243657,7.5049286e-7,0.00039875213,0.00012533172,0.000017901293,0.006749317,0.005624065,0.00005732555],"about_ca_topic_score_codex":0.0006906313,"about_ca_topic_score_gemma":0.00024047881,"teacher_disagreement_score":0.03055252,"about_ca_system_score_codex":0.0003493997,"about_ca_system_score_gemma":0.00020810276,"threshold_uncertainty_score":0.20837632},"labels":[],"label_agreement":null},{"id":"W4298142795","doi":"10.1200/jco.2022.40.28_suppl.427","title":"Delivery of cancer care via an outpatient telephone support line: A cross-sectional study of oncology nursing perspectives on quality and challenges.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Nursing; Referral; Cross-sectional study; Family medicine; Oncology nursing; Patient satisfaction; Nurse education","score_opus":0.29386537388859424,"score_gpt":0.4871128733011826,"score_spread":0.19324749941258834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298142795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98407763,0.009655266,0.000027760674,0.0007023942,0.0020526997,0.00021717903,0.00013449677,0.0000035544128,0.003129036],"genre_scores_gemma":[0.9938466,0.005126782,0.00017016203,0.00023603831,0.0005588454,0.000013582321,0.0000021637125,0.000016251064,0.00002957189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952973,0.00030915663,0.0036973173,0.00036703964,0.00012075127,0.00020840182],"domain_scores_gemma":[0.9932945,0.0007120509,0.0051642,0.00020761097,0.00043934048,0.00018229829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040858714,0.00014175162,0.0017340599,0.0002668845,0.000107302585,0.000008198235,0.00027066088,0.00025930873,0.000383804],"category_scores_gemma":[0.000640678,0.00014791035,0.00029544128,0.00009557846,0.00033586292,0.00021323573,0.000090847185,0.0008397061,0.0000022617353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055438154,0.009750548,0.82446903,0.000041238556,0.00036005693,0.00002266381,0.019637428,0.001818097,0.000007476856,0.0037851986,0.00007468333,0.13448973],"study_design_scores_gemma":[0.0050877444,0.055358455,0.9135673,0.000010419576,0.00003336791,0.000015573303,0.016038774,0.00007103069,0.000006052185,0.0015829572,0.0080883,0.00013999952],"about_ca_topic_score_codex":0.0007341475,"about_ca_topic_score_gemma":0.00046318397,"teacher_disagreement_score":0.13434973,"about_ca_system_score_codex":0.0011108537,"about_ca_system_score_gemma":0.0009359462,"threshold_uncertainty_score":0.6031609},"labels":[],"label_agreement":null},{"id":"W4298147104","doi":"10.1200/jco.2022.40.28_suppl.268","title":"Sociodemographic difference in patients who enroll and decline remote symptom monitoring (RSM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Interquartile range; Medicaid; Demography; Internal medicine; Physical therapy; Family medicine; Health care","score_opus":0.0911968639740277,"score_gpt":0.3648920743823263,"score_spread":0.2736952104082986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905873,0.0022658186,0.00012294433,0.0019365012,0.0023609328,0.00009597677,0.000023130275,0.0000040709824,0.0026033379],"genre_scores_gemma":[0.9946987,0.0028209747,0.00062654365,0.0011055969,0.0005358377,0.0000022863935,9.506971e-7,0.0000152184575,0.00019388023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965295,0.000119286546,0.002759495,0.00024985368,0.00006969045,0.0002721478],"domain_scores_gemma":[0.996397,0.0006941091,0.002493747,0.00014750978,0.000072949595,0.00019468604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036601603,0.00012454319,0.0013496826,0.0002863438,0.00009645348,0.000021352764,0.00032557573,0.00020124413,0.000107001746],"category_scores_gemma":[0.0014344095,0.00013293774,0.00026045786,0.0001590923,0.00012684676,0.00019735821,0.0002339736,0.0010698978,0.000008386003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035516007,0.0002873873,0.9158695,0.0000052184405,0.000044503402,0.000013748727,0.00012994326,0.000054801192,4.3802322e-7,0.0015939394,0.0002392342,0.08140614],"study_design_scores_gemma":[0.0038813131,0.0022945062,0.9346161,0.000014972016,0.000009556009,0.0000058815936,0.000042975524,0.0002676341,6.861938e-7,0.0281067,0.030630335,0.00012932961],"about_ca_topic_score_codex":0.00011321388,"about_ca_topic_score_gemma":0.000026919988,"teacher_disagreement_score":0.08127681,"about_ca_system_score_codex":0.00024879066,"about_ca_system_score_gemma":0.00019497266,"threshold_uncertainty_score":0.54210436},"labels":[],"label_agreement":null},{"id":"W4298147203","doi":"10.1200/jco.2022.40.28_suppl.028","title":"International comparison of the impact of COVID on adherence with supportive care focused Choosing Wisely recommendations (CWR).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Colorectal cancer; Cancer; Pandemic; Internal medicine; Economic shortage; Disease; Infectious disease (medical specialty)","score_opus":0.6899590673822006,"score_gpt":0.6263443518311803,"score_spread":0.06361471555102027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496759,0.00026538435,0.0006418762,0.039734095,0.002186827,0.00037683747,0.00044739436,0.0000042660517,0.0066674096],"genre_scores_gemma":[0.9962762,0.00004408983,0.0017406808,0.0016159763,0.0002460463,0.000011644098,0.000010750976,0.000011456745,0.000043178214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903918,0.0012544665,0.007806553,0.00019621673,0.00019488919,0.0001561074],"domain_scores_gemma":[0.9768866,0.004624727,0.017782945,0.0002513764,0.0003095364,0.00014485857],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012796129,0.00010408454,0.001618885,0.00022189535,0.0001297709,0.000010053146,0.0005551953,0.00010704632,0.0012047394],"category_scores_gemma":[0.0088211605,0.00008351449,0.00046972584,0.00018052138,0.00016164682,0.00017327485,0.00009758393,0.0007361112,0.000012000846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012129261,0.0017223977,0.94231683,0.00005262751,0.0005891418,0.0000025802578,0.005307007,0.011575923,0.0000061443843,0.0044459966,0.024718966,0.008049435],"study_design_scores_gemma":[0.009826348,0.02912378,0.8371135,0.00023287503,0.00008768669,0.00004444361,0.01803396,0.0042048907,0.000038962033,0.004649603,0.09631682,0.00032712915],"about_ca_topic_score_codex":0.0003710998,"about_ca_topic_score_gemma":0.00009847534,"teacher_disagreement_score":0.10520335,"about_ca_system_score_codex":0.0008997896,"about_ca_system_score_gemma":0.002128219,"threshold_uncertainty_score":0.9997083},"labels":[],"label_agreement":null},{"id":"W4298147263","doi":"10.1200/jco.2022.40.28_suppl.112","title":"Promoting prostate cancer screening equity: Findings from a quality improvement education initiative implemented in 3 sites.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Genentech","keywords":"Medicine; Family medicine; Intervention (counseling); Prostate cancer screening; Health equity; Health care; Quality management; Nursing; Prostate cancer; Public health; Cancer; Prostate-specific antigen; Internal medicine","score_opus":0.5725901069045072,"score_gpt":0.6603167425896221,"score_spread":0.08772663568511496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94894665,0.00019710927,0.00019119807,0.048381265,0.0011739491,0.00081969134,0.00006983967,0.000011165568,0.0002091098],"genre_scores_gemma":[0.97359776,0.00019160852,0.00631791,0.018705966,0.0008981918,0.000099936384,0.00011240804,0.000022231283,0.0000539647],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9896643,0.001596355,0.007147028,0.00034850242,0.00090024347,0.00034357476],"domain_scores_gemma":[0.9865466,0.00659918,0.0055302093,0.0001991338,0.00081905344,0.00030584162],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.019949108,0.00015912276,0.0012495995,0.00022735972,0.000120622404,0.00002021324,0.00021358112,0.00013103097,0.0014550127],"category_scores_gemma":[0.02381336,0.00014276587,0.00032441216,0.00039192397,0.00007762795,0.00035420153,0.00050663465,0.002062834,0.0000033916563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032058025,0.002294517,0.43341944,0.000027225775,0.00024585455,0.00006979002,0.0014014709,0.000022276521,0.002149583,0.000019579797,0.002547271,0.5545972],"study_design_scores_gemma":[0.020503903,0.01397011,0.89592856,0.00019323132,0.00057079026,0.000049613995,0.013169722,0.00093825575,0.00030739585,0.002195884,0.051943786,0.00022873309],"about_ca_topic_score_codex":0.0019633358,"about_ca_topic_score_gemma":0.00096046645,"teacher_disagreement_score":0.55436844,"about_ca_system_score_codex":0.0011329333,"about_ca_system_score_gemma":0.006798156,"threshold_uncertainty_score":0.9994578},"labels":[],"label_agreement":null},{"id":"W4298147309","doi":"10.1200/jco.2022.40.28_suppl.013","title":"Medicare coverage and cost-sharing for abiraterone following generic entry.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conquer Cancer Foundation","keywords":"Medicine; Beneficiary; Formulary; Medicare Part D; Cost sharing; Prescription drug; Market share; Generic drug; Product (mathematics); Competition (biology); Medical prescription; Marketing; Business; Family medicine; Drug; Finance; Pharmacology; Mathematics","score_opus":0.2614241358421591,"score_gpt":0.450878591896307,"score_spread":0.1894544560541479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067363,0.004020707,0.0021070044,0.014758396,0.005863854,0.00029845137,0.00015756777,0.000007904019,0.012112502],"genre_scores_gemma":[0.98560154,0.0013927154,0.0007938787,0.010858305,0.00091899093,0.000024598901,0.0000047593203,0.000018876517,0.00038630728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997275,0.000062298815,0.0021392251,0.00022967003,0.000041308722,0.00025250536],"domain_scores_gemma":[0.9970869,0.00092703634,0.0015454938,0.00011900693,0.000028512075,0.0002930841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004710939,0.00009525941,0.0010293192,0.00012363089,0.00013482485,0.000027155205,0.00029985484,0.00012156094,0.00054438773],"category_scores_gemma":[0.0010752389,0.00010038925,0.0004055952,0.000072400224,0.000055810742,0.0001274653,0.0002141775,0.0005837338,0.000015240237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002607255,0.0022148974,0.31788117,0.00011728865,0.0022058792,0.0004247524,0.0009967941,0.0021646095,0.00010404939,0.17254971,0.073334225,0.4253994],"study_design_scores_gemma":[0.004826217,0.0014938457,0.008800233,0.0000040085765,0.000035377732,0.00004502813,0.000042323853,0.004144947,0.000003986584,0.031985644,0.948493,0.00012535603],"about_ca_topic_score_codex":0.000014324165,"about_ca_topic_score_gemma":0.0000048788247,"teacher_disagreement_score":0.8751588,"about_ca_system_score_codex":0.00018264668,"about_ca_system_score_gemma":0.00017609948,"threshold_uncertainty_score":0.5960664},"labels":[],"label_agreement":null},{"id":"W4298147379","doi":"10.1200/jco.2022.40.28_suppl.408","title":"An exploratory comparative effectiveness analysis of febrile neutropenia incidence among patients with cancer receiving granulocyte colony stimulating factors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Pegfilgrastim; Filgrastim; Medicine; Febrile neutropenia; Internal medicine; Oncology; Neutropenia; Chemotherapy","score_opus":0.1064224285459139,"score_gpt":0.46079978491983475,"score_spread":0.35437735637392087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833226,0.00008048148,0.00020231804,0.000054981203,0.0007278827,0.0003845405,0.00003186179,0.000010567585,0.00017508735],"genre_scores_gemma":[0.999394,0.00003168709,0.00015977213,0.00017859253,0.00014891065,0.000041913812,0.000015137514,0.000016883241,0.000013094488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954855,0.0018669857,0.0015829486,0.00026921314,0.0005903094,0.00020504398],"domain_scores_gemma":[0.993446,0.0024701464,0.0025526586,0.0002344367,0.001001265,0.00029550385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022169868,0.00016504872,0.002285384,0.00035038238,0.00020910229,0.000010373071,0.00020492528,0.00010536662,0.00043953132],"category_scores_gemma":[0.00035546307,0.00012032454,0.00042643351,0.0010337748,0.00027110658,0.0003324377,0.000088762245,0.0010883798,5.856458e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005526767,0.0014233249,0.9420347,0.000020024374,0.001925085,0.000047518584,0.00073841104,0.046195976,0.00046534112,0.000006796406,0.00006781925,0.0015482034],"study_design_scores_gemma":[0.0048523764,0.016446473,0.97314966,0.00008376017,0.0032555514,0.0000059246095,0.0005751473,0.000895983,0.0001898879,0.000006163165,0.00042021132,0.000118865435],"about_ca_topic_score_codex":0.00048083195,"about_ca_topic_score_gemma":0.0013295414,"teacher_disagreement_score":0.045299992,"about_ca_system_score_codex":0.0005201018,"about_ca_system_score_gemma":0.0013395941,"threshold_uncertainty_score":0.49066922},"labels":[],"label_agreement":null},{"id":"W4298147396","doi":"10.1200/jco.2022.40.28_suppl.290","title":"Evaluation of a virtual, nurse practitioner–led, pre-counselling seminar for mainstream germline genetic testing using a patient-reported outcomes measure (PROM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Provincial Health Services Authority; BC Cancer Agency","funders":"","keywords":"Medicine; Genetic counseling; Family medicine; Genetic testing; Attendance; Population; Internal medicine","score_opus":0.1349034609756953,"score_gpt":0.45983827213829737,"score_spread":0.32493481116260203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98624104,0.0013000575,0.010070057,0.00034555525,0.00137331,0.00055324583,0.000032697153,0.0000042142797,0.00007982855],"genre_scores_gemma":[0.9589769,0.00007239897,0.039936006,0.00029930632,0.00055455905,0.00007380251,0.000023300763,0.000030109488,0.00003359139],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99516386,0.0010582486,0.0024158857,0.00029561936,0.00086416927,0.00020224563],"domain_scores_gemma":[0.9916023,0.0008605348,0.0042751,0.00027549756,0.0028801097,0.00010647951],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008084484,0.00015070647,0.0006406965,0.00011447886,0.00015131447,0.000009521989,0.00020982143,0.0002380172,0.000047189795],"category_scores_gemma":[0.010046267,0.0001414894,0.000370316,0.00018774097,0.00010357125,0.000015396485,0.000049534745,0.00039449724,2.7257872e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032128075,0.0030955104,0.028521344,0.00004063549,0.002365251,0.000047645706,0.0005193663,0.36867467,0.12284656,0.000013884873,0.002097775,0.46856454],"study_design_scores_gemma":[0.0811682,0.15200534,0.15756242,0.000618795,0.025869694,0.008200696,0.008931784,0.3593639,0.058574554,0.0074121705,0.1374759,0.0028165225],"about_ca_topic_score_codex":0.000013026896,"about_ca_topic_score_gemma":0.000016283791,"teacher_disagreement_score":0.465748,"about_ca_system_score_codex":0.00032894168,"about_ca_system_score_gemma":0.005165834,"threshold_uncertainty_score":0.9982925},"labels":[],"label_agreement":null},{"id":"W4298147445","doi":"10.1200/jco.2022.40.28_suppl.234","title":"Developing a standardized approach to prevention and outpatient management of febrile neutropenia.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Quality management; Multidisciplinary approach; Patient education; Febrile neutropenia; Ambulatory care; Family medicine; MEDLINE; Intensive care medicine; Best practice; Health care; Nursing; Medical emergency; Neutropenia; Surgery; Management system; Pathology","score_opus":0.16437001727404082,"score_gpt":0.47828012804257286,"score_spread":0.31391011076853204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97799736,0.00020517976,0.0065471726,0.003036001,0.00092820794,0.00050760125,0.000004380665,0.00000576704,0.010768356],"genre_scores_gemma":[0.967986,0.00027899124,0.029974917,0.000989486,0.00017267332,0.000033107568,0.0000018802817,0.0000099624485,0.000553023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978352,0.0003072984,0.0012861614,0.00013198242,0.00032641168,0.00011292981],"domain_scores_gemma":[0.99862885,0.00014562419,0.00077170227,0.00010441448,0.00018933226,0.00016005042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020747955,0.0000665839,0.00076097215,0.0001087109,0.00007021505,0.0000043435393,0.00008487346,0.00005126355,0.00010969462],"category_scores_gemma":[0.00010321661,0.000053177806,0.00020652049,0.00018071383,0.000045815006,0.000042784162,0.0001737707,0.0004226981,0.000001651136],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033146463,0.009132689,0.06597139,0.00066066306,0.0030444774,0.00050699484,0.0011620086,0.0014506762,0.0006350053,0.018906988,0.020559324,0.8448233],"study_design_scores_gemma":[0.01804816,0.03464081,0.2509313,0.00018910883,0.001002025,0.00076760456,0.0018456875,0.0000385603,0.00016899602,0.0008329139,0.69137543,0.00015938483],"about_ca_topic_score_codex":0.0000056877543,"about_ca_topic_score_gemma":0.0000025213576,"teacher_disagreement_score":0.8446639,"about_ca_system_score_codex":0.00024224959,"about_ca_system_score_gemma":0.0006616691,"threshold_uncertainty_score":0.2168528},"labels":[],"label_agreement":null},{"id":"W4298147478","doi":"10.1200/jco.2022.40.28_suppl.244","title":"Are YouTube videos a reliable information source for young women with metastatic breast cancer?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Credibility; Population; Health professionals; Family medicine; Health care; Cancer; Internal medicine","score_opus":0.19664488399771884,"score_gpt":0.5143334902630637,"score_spread":0.3176886062653449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9338068,0.00011004192,0.0005438783,0.052551154,0.0112570515,0.0010506879,0.0000372049,0.000020032778,0.00062318135],"genre_scores_gemma":[0.98766905,0.00022630818,0.0025790199,0.0050344486,0.0031056392,0.0012201178,0.0000025261163,0.000014321787,0.00014857475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965048,0.00088913715,0.0014980583,0.00009538011,0.0006507002,0.00036196384],"domain_scores_gemma":[0.9888779,0.005685226,0.00414724,0.00008561966,0.0008384549,0.00036556565],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009834531,0.00007588019,0.0006480508,0.00011764639,0.000600837,0.000029001676,0.00029760163,0.000107982196,0.00037399624],"category_scores_gemma":[0.011425523,0.00006316533,0.00011406093,0.00036746365,0.00020117933,0.0005570424,0.000034221783,0.0006561297,0.00000481998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071682683,0.0011739216,0.30626246,0.000118828146,0.000324984,0.00001724145,0.11700208,0.0016342935,0.0000014764717,0.0010025995,0.030064806,0.535229],"study_design_scores_gemma":[0.0022268048,0.002530214,0.12658294,0.00002676768,0.00009925751,0.000034238758,0.08582365,0.00007244289,2.927395e-7,0.00080035743,0.7817088,0.00009425727],"about_ca_topic_score_codex":0.0019841518,"about_ca_topic_score_gemma":0.0012827532,"teacher_disagreement_score":0.75164396,"about_ca_system_score_codex":0.0017448877,"about_ca_system_score_gemma":0.0068261013,"threshold_uncertainty_score":0.9988043},"labels":[],"label_agreement":null},{"id":"W4298147607","doi":"10.1200/jco.2022.40.28_suppl.017","title":"Real-world cost effectiveness of first-line pembrolizumab for advanced melanoma: A population-based study by the Canadian Real-world Evidence Value for Cancer Drugs (CanREValue) Collaboration.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Ipilimumab; Pembrolizumab; Population; Quality of life (healthcare); Demography; Internal medicine; Cancer; Environmental health","score_opus":0.41251703988492056,"score_gpt":0.563294581362455,"score_spread":0.15077754147753447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9106024,0.0016491396,0.0010302726,0.07095417,0.0044597504,0.008185012,0.0024545637,0.00001464543,0.0006500765],"genre_scores_gemma":[0.99189633,0.00017914399,0.0012633282,0.0035504117,0.0006475758,0.0018438267,0.00006025077,0.000044716064,0.000514439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98622704,0.0033983719,0.009160029,0.0004999431,0.0002805131,0.000434131],"domain_scores_gemma":[0.9432147,0.04407582,0.011041895,0.00044937196,0.0008563955,0.00036183192],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07586458,0.00022044504,0.0026874058,0.0005477926,0.0007314327,0.000042245938,0.00064636534,0.00015452277,0.00017711172],"category_scores_gemma":[0.019890668,0.00021622353,0.00046054975,0.00064993615,0.00009872852,0.00032789027,0.000050212424,0.00053015933,0.0000055332357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006138644,0.0014566182,0.84072655,0.00063333614,0.00058807485,0.0000034443872,0.0009542006,0.10471419,0.0000020669677,0.018957108,0.023680216,0.0021455458],"study_design_scores_gemma":[0.021981265,0.011583725,0.7120577,0.00035946854,0.00036103654,0.000003542765,0.0015777276,0.030794812,0.000009541662,0.011368128,0.20932017,0.0005828464],"about_ca_topic_score_codex":0.23387577,"about_ca_topic_score_gemma":0.75266707,"teacher_disagreement_score":0.51879126,"about_ca_system_score_codex":0.007487665,"about_ca_system_score_gemma":0.0075328895,"threshold_uncertainty_score":0.9980935},"labels":[],"label_agreement":null},{"id":"W4303457093","doi":"10.1200/jco.22.01273","title":"Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Chemoimmunotherapy; Irinotecan; Temozolomide; Progressive disease; Neuroblastoma; Granulocyte colony-stimulating factor; Oncology; Progression-free survival; Gastroenterology; Surgery; Cancer; Chemotherapy; Cyclophosphamide","score_opus":0.03646536451102339,"score_gpt":0.3768109796344001,"score_spread":0.3403456151233767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303457093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981677,0.000030714258,0.000018347335,0.0006467921,0.00016911258,0.000795282,0.0001245469,0.000015036217,0.000032473934],"genre_scores_gemma":[0.9985813,0.00003663295,0.0010827865,0.000108467575,0.000058243193,0.000020665782,0.000008934733,0.00004588614,0.00005706708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336666,0.002804426,0.0018072802,0.0003917494,0.0012043024,0.0004255793],"domain_scores_gemma":[0.9914376,0.005175207,0.0020708768,0.0003814521,0.00042512093,0.00050975155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021517703,0.0002621797,0.00171216,0.00039325506,0.0001288439,0.000011099313,0.0002589679,0.00017002616,0.00009424662],"category_scores_gemma":[0.0038411405,0.00016491325,0.00017410061,0.0003870255,0.00028214755,0.00011952879,0.0002652204,0.001814397,0.0000012483905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23913512,0.0042062006,0.73934054,0.000033347234,0.00026589306,0.00407372,0.000059215214,0.00015072072,0.00020018236,0.0000016850788,0.000026828307,0.012506559],"study_design_scores_gemma":[0.059183728,0.1802229,0.7595836,0.00014381735,0.00016844484,0.0001359921,0.000056219338,0.00009952807,0.00020657765,0.000009106244,0.000089038294,0.00010103231],"about_ca_topic_score_codex":0.00014382559,"about_ca_topic_score_gemma":0.00013663078,"teacher_disagreement_score":0.17995138,"about_ca_system_score_codex":0.00028910904,"about_ca_system_score_gemma":0.0010413481,"threshold_uncertainty_score":0.7882753},"labels":[],"label_agreement":null},{"id":"W4304474516","doi":"10.1200/jco.21.02508","title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":490,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Institute for Health and Care Research; Cancer Research UK","keywords":"Pembrolizumab; Medicine; Internal medicine; Hazard ratio; Oncology; Head and neck squamous-cell carcinoma; Chemotherapy; Interquartile range; Cetuximab; Head and neck cancer; Population; Radiation therapy; Cancer; Immunotherapy; Confidence interval","score_opus":0.13058326158297728,"score_gpt":0.4718791313295498,"score_spread":0.3412958697465725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304474516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258524,0.0005744791,0.0000036741935,0.0049968264,0.00047681795,0.00082444266,0.000016300568,0.0000046265664,0.0005175855],"genre_scores_gemma":[0.99756813,0.00018898162,0.00037692045,0.0011764019,0.0001524087,0.000019844574,0.0000015508273,0.000019247234,0.00049652497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99562687,0.0009804969,0.002375758,0.00025479123,0.00051901484,0.0002430553],"domain_scores_gemma":[0.9963793,0.0013028418,0.001638405,0.0002585311,0.00023024576,0.00019065525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002767106,0.00017743073,0.0021917894,0.00012449866,0.000096519805,0.000004271195,0.0001967862,0.00006852365,0.0001214105],"category_scores_gemma":[0.00086448627,0.00008208537,0.000163123,0.0004018406,0.00022264237,0.000045724562,0.00012109122,0.001193971,3.9658713e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7308723,0.030338714,0.1816182,0.00010418521,0.00040191598,0.002106203,0.0067497543,0.000024277415,0.00009647038,0.000002780914,0.0060478067,0.04163741],"study_design_scores_gemma":[0.37572077,0.30172777,0.2872694,0.00009657333,0.00077509193,0.0007955179,0.005804202,0.00026114655,0.00009852204,0.000012641733,0.027283398,0.00015496928],"about_ca_topic_score_codex":0.00015701228,"about_ca_topic_score_gemma":0.0013765391,"teacher_disagreement_score":0.3551515,"about_ca_system_score_codex":0.00018940459,"about_ca_system_score_gemma":0.002440582,"threshold_uncertainty_score":0.51872766},"labels":[],"label_agreement":null},{"id":"W4306247953","doi":"10.1200/jco.21.02873","title":"Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McGill University Health Centre; University of Toronto; Western University; London Health Sciences Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre; Mount Sinai Hospital; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Germline; Medicine; Microsatellite; Microsatellite instability; Germline mutation; DNA mismatch repair; Cancer; Genetics; Oncology; Internal medicine; Mutation; Biology; Gene; Allele; Colorectal cancer","score_opus":0.062250524706438846,"score_gpt":0.4450766673061232,"score_spread":0.3828261425996844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306247953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972329,0.02361264,0.0000141846795,0.0013321601,0.002213216,0.00020350204,0.00005850683,0.000009872838,0.00022687206],"genre_scores_gemma":[0.98386353,0.010550562,0.0038317358,0.001051319,0.00041377314,0.00000801975,0.0000022029315,0.000020131549,0.00025869385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609,0.0007006837,0.0022774832,0.0002481021,0.00045543842,0.0002282731],"domain_scores_gemma":[0.99495745,0.0019005844,0.002336558,0.0002222457,0.00034107256,0.00024211704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040706974,0.00013896555,0.0012544531,0.00015188013,0.00008665017,0.0000046626346,0.00021459066,0.00024563918,0.0007531514],"category_scores_gemma":[0.0019271299,0.00010868749,0.0005341436,0.00018304362,0.00034601998,0.000029861825,0.00020393322,0.001647643,0.000002129557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005161361,0.0009479255,0.93032324,0.00008937182,0.0005472925,0.0002870793,0.00034671833,0.0005104959,0.015181541,0.0000076057086,0.008674081,0.03792327],"study_design_scores_gemma":[0.003546191,0.008868486,0.9286737,0.00003802706,0.0008422402,0.0004580033,0.00018864972,0.00011516234,0.0009023161,0.00036880584,0.0558925,0.000105925006],"about_ca_topic_score_codex":0.0001742383,"about_ca_topic_score_gemma":0.00012395384,"teacher_disagreement_score":0.04721842,"about_ca_system_score_codex":0.00025875212,"about_ca_system_score_gemma":0.0018338576,"threshold_uncertainty_score":0.824648},"labels":[],"label_agreement":null},{"id":"W4306661079","doi":"10.1200/jco.22.01207","title":"Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Center, University of Colorado; Walter Reed National Military Medical Center; SUNY Downstate Medical Center; Cancer Institute, University of Pittsburgh; University of Oklahoma Health Sciences Center; Medical Center, University of Pittsburgh; University of Texas MD Anderson Cancer Center; EMD Serono; Saitama Medical University; Clovis Oncology; Seoul National University Hospital; Case Western Reserve University; Celldex Therapeutics; Exelixis; Regeneron Pharmaceuticals; Ludwig Institute for Cancer Research; Astellas Pharma; University of Oklahoma; Eisai; Virginia Commonwealth University; Barbara Ann Karmanos Cancer Institute; Stryker; AstraZeneca; Genentech; University of Cincinnati; Pennsylvania State University; GlaxoSmithKline; Stony Brook University; University of Pittsburgh; University of Minnesota; Roswell Park Cancer Institute; Cleveland Clinic Foundation; Brody School of Medicine; Bristol-Myers Squibb; York University; Moffitt Cancer Center; Cleveland Clinic; Array BioPharma; Ohio State University; Wake Forest University; NRG Oncology; Memorial Sloan-Kettering Cancer Center; Rush University; Amgen; University of Pennsylvania; University of North Carolina at Chapel Hill; Wayne State University; PharmaMar; Northwestern University; Seoul National University; Yale University; Sanofi; Edwards Lifesciences; Pfizer","keywords":"Medicine; Bevacizumab; Internal medicine; Hazard ratio; Oncology; Ovarian cancer; Carboplatin; Progression-free survival; Placebo; Clinical endpoint; Cancer; Chemotherapy; Randomized controlled trial; Pathology; Cisplatin; Confidence interval","score_opus":0.06551143553526073,"score_gpt":0.3779583636623471,"score_spread":0.31244692812708635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306661079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94917953,0.000102328755,0.000008771676,0.049244925,0.00045543964,0.00090440543,0.00005027402,0.0000024433705,0.000051888637],"genre_scores_gemma":[0.9973988,0.000069222755,0.00002281514,0.0020243418,0.00035289195,0.0001070424,0.000007251364,0.000012943566,0.0000046989276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960394,0.0011658246,0.0017071215,0.00021484935,0.0007238454,0.00014896796],"domain_scores_gemma":[0.9894258,0.006948952,0.0027227376,0.0004976964,0.0003644167,0.000040427578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005448709,0.0001438321,0.00071555143,0.00005802078,0.00024012392,0.00001598528,0.0003460703,0.000054389868,0.00011446149],"category_scores_gemma":[0.00082272297,0.00005433662,0.00021640373,0.0003365103,0.00015668197,0.00006303819,0.000095944844,0.0007674904,7.254267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004824868,0.008522588,0.8767222,0.000013119565,0.00079598336,0.000057976966,0.012605872,0.0013502274,0.000050153594,0.00015505095,0.00038109877,0.09452086],"study_design_scores_gemma":[0.0054659047,0.0054932036,0.9779226,0.00007779993,0.0004968519,0.000009283891,0.008257152,0.00013114458,0.0010691414,0.00014670174,0.000876621,0.000053551717],"about_ca_topic_score_codex":0.0006673694,"about_ca_topic_score_gemma":0.000834699,"teacher_disagreement_score":0.10120044,"about_ca_system_score_codex":0.00033257037,"about_ca_system_score_gemma":0.000434046,"threshold_uncertainty_score":0.33344066},"labels":[],"label_agreement":null},{"id":"W4306724295","doi":"10.1200/jco.21.02947","title":"Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Novartis Institutes for BioMedical Research; EMD Serono; Genentech; Sierra Oncology; PharmaMar; Astellas Pharma; Eisai; G1 Therapeutics; National Institute of Environmental Health Sciences; MacroGenics; Silverback Therapeutics; INOVIO Pharmaceuticals; Cardinal Health; Puma Biotechnology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Agios Pharmaceuticals; Ipsen; Array BioPharma; Five Prime Therapeutics; Halozyme; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; PTC Therapeutics; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Invitae; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Hazard ratio; PARP inhibitor; Oncology; Urology; Progression-free survival; Clinical endpoint; Randomized controlled trial; Cancer; Gastroenterology; Overall survival; Poly ADP ribose polymerase; Confidence interval","score_opus":0.27304451516687994,"score_gpt":0.5330496930102513,"score_spread":0.26000517784337135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306724295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95238817,0.0015943565,0.000113253736,0.036239844,0.0028938677,0.004702331,0.0012569409,0.000008445305,0.0008027771],"genre_scores_gemma":[0.9895,0.002093617,0.0027666292,0.0008601725,0.0015788763,0.0008598447,0.000080682665,0.00002125535,0.002238934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99502355,0.0009269883,0.0025366826,0.00022391485,0.0010664073,0.00022245875],"domain_scores_gemma":[0.9890518,0.0068389806,0.0026108597,0.0001480177,0.0011746071,0.00017574341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074472534,0.00014771496,0.0019433306,0.000108025364,0.00017778817,0.000013580901,0.00020402478,0.00007563251,0.00019072632],"category_scores_gemma":[0.0042070146,0.00006560229,0.00044463723,0.00022693846,0.00058671867,0.000118246026,0.000043878186,0.0007396054,4.4897334e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9837683,0.0012022622,0.0003802398,0.0000341587,0.0024203013,0.00011959177,0.00050718384,0.0006804765,0.00013455849,0.00015621156,0.0032694729,0.007327239],"study_design_scores_gemma":[0.92902356,0.017477859,0.0005108135,0.00010494278,0.0015752671,0.000037581995,0.0003772866,0.00065459235,0.00013100749,0.00074571266,0.049281742,0.00007963689],"about_ca_topic_score_codex":0.0009935194,"about_ca_topic_score_gemma":0.001839004,"teacher_disagreement_score":0.054744747,"about_ca_system_score_codex":0.00041025665,"about_ca_system_score_gemma":0.015284167,"threshold_uncertainty_score":0.9902983},"labels":[],"label_agreement":null},{"id":"W4306888875","doi":"10.1200/jco.2022.40.36_suppl.390226","title":"Mepitel Film for the prevention of acute radiation dermatitis in breast cancer: A randomized multi-centre open-label phase 3 trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital; Health Sciences North; Essar Steel Algoma (Canada); Sunnybrook Health Science Centre; University of Waterloo; McMaster University; Queen's University; Health Sciences Centre","funders":"","keywords":"Medicine; Lumpectomy; Common Terminology Criteria for Adverse Events; Clinical endpoint; Breast cancer; Surgery; Seroma; Mastectomy; Adverse effect; Randomized controlled trial; Radiation therapy; Internal medicine; Cancer; Complication","score_opus":0.15406917231565248,"score_gpt":0.5267028761925728,"score_spread":0.37263370387692035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306888875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87591815,0.004254917,0.0026545909,0.10385419,0.0059745926,0.006819776,0.00032649664,0.0000061143005,0.00019116854],"genre_scores_gemma":[0.9833315,0.0073306733,0.0047508157,0.002328737,0.0012376029,0.0005243841,0.000014456395,0.000021065875,0.00046077557],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535745,0.0013475771,0.0026838214,0.00014243778,0.00030602963,0.0001626667],"domain_scores_gemma":[0.9904531,0.006010114,0.0030471878,0.00013551388,0.0002675614,0.0000864719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060821474,0.0001034155,0.0020521688,0.00010382832,0.00009029933,0.0000073425554,0.00027667015,0.00010561119,0.0002850879],"category_scores_gemma":[0.0020488147,0.00006624565,0.00046356858,0.00016562038,0.00015905153,0.000112300964,0.00014718952,0.00056922063,5.962068e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7934914,0.0070142443,0.002223885,0.000027178408,0.0018840552,0.00006353221,0.00040295214,0.0000539627,0.000033420176,0.000038608963,0.012925734,0.18184103],"study_design_scores_gemma":[0.96110594,0.006332713,0.009960186,0.00007428097,0.0017919445,0.00015899519,0.00022441911,0.004030361,0.000023263443,0.0001865984,0.016050143,0.00006116608],"about_ca_topic_score_codex":0.000112776834,"about_ca_topic_score_gemma":0.00013607078,"teacher_disagreement_score":0.18177986,"about_ca_system_score_codex":0.00032877282,"about_ca_system_score_gemma":0.0016907357,"threshold_uncertainty_score":0.31215125},"labels":[],"label_agreement":null},{"id":"W4306921840","doi":"10.1200/jco.22.00574","title":"Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Population; Cost effectiveness; Guideline; Mammography; Quality of life (healthcare); Cancer; Pediatrics; Internal medicine; Environmental health; Pathology","score_opus":0.15908003600990855,"score_gpt":0.47458276426242324,"score_spread":0.3155027282525147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306921840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97162247,0.0045579174,0.00073651044,0.020362455,0.001250142,0.000943839,0.0003472457,0.000018321585,0.00016112272],"genre_scores_gemma":[0.98949933,0.0014000093,0.004766002,0.0034417734,0.00075451523,0.000057292673,0.00003668548,0.000033575092,0.000010797774],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99534094,0.0010552439,0.0025198718,0.0003057216,0.0003871458,0.00039109148],"domain_scores_gemma":[0.99214613,0.0038192566,0.002490863,0.00015123295,0.0008903344,0.0005021773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009199758,0.00020360491,0.0023498149,0.0003590138,0.00014474528,0.000010176165,0.00021184685,0.00019106807,0.000030649004],"category_scores_gemma":[0.0014543671,0.00016581903,0.0006255185,0.00042630566,0.0003026942,0.00017328498,0.00012329075,0.00054754544,1.881735e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009316385,0.0013853832,0.25948298,0.00008847748,0.0005947839,0.000039077753,0.000034041135,0.0002564916,0.000027855205,0.00013767353,0.0008704907,0.7277664],"study_design_scores_gemma":[0.015955675,0.01630023,0.94462234,0.00032864342,0.0003208061,0.004437469,0.0001699269,0.00031813304,0.000010312117,0.0001223523,0.017274322,0.00013977588],"about_ca_topic_score_codex":0.00082556927,"about_ca_topic_score_gemma":0.00016239984,"teacher_disagreement_score":0.7276266,"about_ca_system_score_codex":0.00029838088,"about_ca_system_score_gemma":0.002068922,"threshold_uncertainty_score":0.6761904},"labels":[],"label_agreement":null},{"id":"W4307027551","doi":"10.1200/jco.22.00970","title":"Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Ottawa Hospital","funders":"Cilag; National Cancer Institute; PharmaMar; Astellas Pharma; Clovis Oncology; National Institute for Health and Care Research; Genentech; Janssen Scientific Affairs; Janssen Biotech; Medical Research Council; Les Laboratories Pierre Fabre; Accuray; Royal Marsden NHS Foundation Trust; Foundation Medicine; Genomic Health; Ipsen; Varian Medical Systems; ViewRay; Sanofi; Prostate Cancer Foundation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Cancer Research UK; Boston Scientific Corporation","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Oncology; Randomized controlled trial; Internal medicine; Androgen; Prostate; Pooled analysis; Cancer; Urology; Gynecology; Meta-analysis; Hormone","score_opus":0.3172983636502488,"score_gpt":0.530759032529385,"score_spread":0.21346066887913623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307027551","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020920292,0.97241175,0.0011242381,0.00025544185,0.00035518286,0.004683424,0.0002280576,0.000003216078,0.000018406337],"genre_scores_gemma":[0.0038241039,0.9906211,0.004410177,0.00011530933,0.00021550976,0.000622527,0.00013527904,0.000037911832,0.000018068482],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866794,0.002797123,0.009504346,0.00027740916,0.0005694939,0.00017223497],"domain_scores_gemma":[0.96510315,0.016417727,0.017360754,0.0002712202,0.0007069363,0.00014024068],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.017300902,0.00031260276,0.019573415,0.0007211249,0.00002830419,0.0000048591723,0.00015053285,0.0002869511,0.00023905934],"category_scores_gemma":[0.0037503936,0.00016682279,0.004753556,0.00065366534,0.00022751372,0.00008023216,0.00001448766,0.00042731027,3.692006e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12117199,0.0011399941,0.0013941284,0.0021356218,0.07051188,0.00002599098,0.00027696294,0.00018016613,0.000028517583,0.000014825132,0.00006102869,0.8030589],"study_design_scores_gemma":[0.3572506,0.042519797,0.0006823505,0.008687287,0.25456256,0.00008779174,0.00015199666,0.00046147485,0.00036677107,0.00008632566,0.33477327,0.0003697852],"about_ca_topic_score_codex":0.00006481027,"about_ca_topic_score_gemma":0.000036413338,"teacher_disagreement_score":0.80268914,"about_ca_system_score_codex":0.00072712987,"about_ca_system_score_gemma":0.007075716,"threshold_uncertainty_score":0.9985532},"labels":[],"label_agreement":null},{"id":"W4307340144","doi":"10.1200/jco.22.01749","title":"Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Oncology; Cancer; Oncology; Statement (logic); Nicotine; Internal medicine; Family medicine; Medical physics","score_opus":0.25741103816965594,"score_gpt":0.5865230218156791,"score_spread":0.3291119836460231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307340144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341499,0.0002791474,0.000056371424,0.064177535,0.00066271296,0.0005594108,0.00006171283,0.000006999341,0.000046159534],"genre_scores_gemma":[0.9874953,0.004320527,0.00017514409,0.005262859,0.0024245202,0.00007936758,0.000039450828,0.000019510348,0.0001833302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9893727,0.0059648217,0.0030580994,0.0002611381,0.0009346715,0.00040860486],"domain_scores_gemma":[0.9754049,0.01579603,0.0069804136,0.00026870548,0.0013521276,0.00019780106],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.03637546,0.00011614721,0.0018879798,0.00008502261,0.00026326848,0.000016251863,0.00033551085,0.00015393985,0.000046179874],"category_scores_gemma":[0.0029157551,0.00006641084,0.00050168065,0.0004996419,0.0011540073,0.00006699806,0.00014629717,0.0024692235,3.2197494e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027559841,0.0026925784,0.76001525,0.000011804967,0.0017676913,0.000008128849,0.0007325568,0.00011523655,0.00030615903,0.0006119438,0.048310604,0.15786819],"study_design_scores_gemma":[0.013304339,0.037599094,0.7111559,0.000018180062,0.00086107507,0.000021817763,0.0070311404,0.0009011469,0.000020783107,0.00050848525,0.22849922,0.00007881144],"about_ca_topic_score_codex":0.008371617,"about_ca_topic_score_gemma":0.0005742052,"teacher_disagreement_score":0.18018861,"about_ca_system_score_codex":0.001776216,"about_ca_system_score_gemma":0.006786682,"threshold_uncertainty_score":0.9998321},"labels":[],"label_agreement":null},{"id":"W4307583466","doi":"10.1200/jco.22.01482","title":"Oligometastases: Emerging Evidence","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Randomized controlled trial; Observational study; Context (archaeology); Disease; Intensive care medicine; Medical physics; Surgery; Internal medicine","score_opus":0.6107009890162114,"score_gpt":0.6252916984323568,"score_spread":0.014590709416145375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307583466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013977295,0.990645,0.00010894349,0.001166531,0.003254235,0.00066607236,0.000013613301,0.000015035347,0.0041165836],"genre_scores_gemma":[0.000005226239,0.99013585,0.0047065415,0.0022242025,0.0015387484,0.000027980113,0.000016909162,0.000059090664,0.0012854446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9874362,0.0029782606,0.0075549623,0.00039568896,0.0012815214,0.00035340307],"domain_scores_gemma":[0.9751424,0.013557075,0.009527762,0.0006543949,0.00026178712,0.0008565551],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016502911,0.00037956305,0.009054456,0.0006672188,0.000059906808,0.000017095703,0.0006753397,0.00035131027,0.00855916],"category_scores_gemma":[0.039356783,0.00026181247,0.0042199786,0.00056110544,0.00017613523,0.0001645706,0.00038817196,0.0032011236,0.00013116233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042516165,0.0012716292,0.000029952194,0.010821114,0.0020010613,0.0062741404,0.00001572167,7.0674105e-7,9.727396e-9,0.00007330134,0.02722883,0.95185834],"study_design_scores_gemma":[0.0016763089,0.0057696537,0.00004354836,0.010060638,0.020710573,0.0010085119,0.00011394768,0.0000042546308,8.0350775e-9,0.00005443024,0.96037376,0.00018435788],"about_ca_topic_score_codex":0.0000035824555,"about_ca_topic_score_gemma":8.0942607e-7,"teacher_disagreement_score":0.951674,"about_ca_system_score_codex":0.00039372954,"about_ca_system_score_gemma":0.0075170617,"threshold_uncertainty_score":0.99998343},"labels":[],"label_agreement":null},{"id":"W4307804562","doi":"10.1200/jco.22.01928","title":"Reply to S. Rossi et al and P. Palassin et al","year":2022,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Conquer Cancer Foundation","keywords":"Medicine","score_opus":0.11288508398988809,"score_gpt":0.4824033575385294,"score_spread":0.3695182735486413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307804562","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02697035,0.009989829,0.00008509636,0.9370693,0.021939581,0.00037720494,0.00006320438,0.00001126878,0.0034941481],"genre_scores_gemma":[0.0014420366,0.02255808,0.0022424178,0.9613902,0.0056361603,0.00001383567,0.000028796892,0.00007397417,0.006614506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884819,0.0037410632,0.00539058,0.0006437445,0.0010566284,0.000686122],"domain_scores_gemma":[0.9857896,0.008657167,0.0040006177,0.0004770338,0.00035823038,0.000717341],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0187311,0.00046045,0.003434377,0.00031704106,0.00013457339,0.00006513232,0.00048540984,0.0010394007,0.0056098914],"category_scores_gemma":[0.0053870226,0.0003607411,0.0014126201,0.00028707265,0.0008038975,0.0001612533,0.00031061994,0.009871043,0.000049044003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02444671,0.0007962306,0.005476465,0.00004387282,0.0013409334,0.0064600026,0.00022854346,0.0000049930704,0.0002004939,0.00002531611,0.7920576,0.16891883],"study_design_scores_gemma":[0.012122679,0.03867673,0.061802108,0.00053101196,0.0005210006,0.0035038071,0.00013712622,0.000013173856,0.000006267517,0.00006146259,0.8823154,0.00030922037],"about_ca_topic_score_codex":0.00026272293,"about_ca_topic_score_gemma":0.00009337768,"teacher_disagreement_score":0.16860962,"about_ca_system_score_codex":0.00078601495,"about_ca_system_score_gemma":0.006393028,"threshold_uncertainty_score":0.9998844},"labels":[],"label_agreement":null},{"id":"W4307842003","doi":"10.1200/jco.22.00478","title":"Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Prednisone; Vincristine; Cyclophosphamide; Oncology; Internal medicine; Lymphoma; Chemotherapy","score_opus":0.05108753602228596,"score_gpt":0.4074900151700494,"score_spread":0.35640247914776346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307842003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921377,0.0034823627,0.00020331459,0.00008333246,0.00043161318,0.0019321016,0.001703931,0.0000049618266,0.000020686175],"genre_scores_gemma":[0.9900961,0.007679954,0.0016900324,0.00007759999,0.000113982955,0.00006508005,0.00012829292,0.000042004547,0.00010696799],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959841,0.00080289645,0.0018988209,0.0003683753,0.0006321149,0.0003136929],"domain_scores_gemma":[0.99228114,0.0038655703,0.0021090338,0.0003289398,0.001046065,0.0003692508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014309864,0.00026145906,0.0035651298,0.0005177316,0.00007692299,0.0000052801474,0.00018171231,0.000189182,0.00060862326],"category_scores_gemma":[0.0004502982,0.00017181953,0.00053522916,0.00059516926,0.00025649773,0.00005852575,0.00011416204,0.00025979377,2.2589329e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5491804,0.021630406,0.28521413,0.00019051752,0.0043906565,0.000028367855,0.0014950841,0.000072705676,0.0030283825,0.0000013830627,0.00006011027,0.13470788],"study_design_scores_gemma":[0.26079383,0.31800303,0.3905113,0.00004981048,0.0021153719,0.0000027446488,0.0011361019,0.00012640284,0.012304646,0.0000042946976,0.014804061,0.0001484126],"about_ca_topic_score_codex":0.00014696682,"about_ca_topic_score_gemma":0.00034368254,"teacher_disagreement_score":0.2963726,"about_ca_system_score_codex":0.00056408043,"about_ca_system_score_gemma":0.0010636636,"threshold_uncertainty_score":0.7006597},"labels":[],"label_agreement":null},{"id":"W4308254239","doi":"10.1200/jco.21.02937","title":"Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"MacroGenics; University of Washington","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Internal medicine; Overall survival; Randomized controlled trial; Cancer","score_opus":0.1259646493750785,"score_gpt":0.49088681888886,"score_spread":0.3649221695137815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308254239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98637676,0.00029084654,0.0000144222595,0.0065408405,0.002746196,0.002388209,0.0007599599,0.00001459058,0.0008681607],"genre_scores_gemma":[0.9963772,0.0004919127,0.0006135613,0.000530442,0.0013992972,0.00017941091,0.00014472395,0.00005135143,0.00021207689],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98878026,0.004553455,0.0038788556,0.00055149157,0.0016399833,0.00059593096],"domain_scores_gemma":[0.9857798,0.009928395,0.002535134,0.00034216058,0.00082899735,0.0005854835],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007288229,0.000308475,0.0039615575,0.0002762503,0.00010020337,0.000017409116,0.00036930587,0.00028407158,0.0011857679],"category_scores_gemma":[0.005524334,0.00021936196,0.000712285,0.00041889772,0.0003961465,0.0001639788,0.0001396899,0.002836173,0.000005514202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.909203,0.013476157,0.0068646227,0.000012110549,0.0011095814,0.0013282464,0.00028264787,0.00018547503,0.000008276739,0.0000052505216,0.0012335295,0.06629109],"study_design_scores_gemma":[0.8586609,0.075942405,0.06062006,0.00018511574,0.0006355839,0.00003159595,0.00009915153,0.00018257988,0.0000071712434,0.00004109848,0.0034108078,0.0001835732],"about_ca_topic_score_codex":0.0012553356,"about_ca_topic_score_gemma":0.0004404641,"teacher_disagreement_score":0.06610751,"about_ca_system_score_codex":0.0021405246,"about_ca_system_score_gemma":0.0059270244,"threshold_uncertainty_score":0.9997273},"labels":[],"label_agreement":null},{"id":"W4308341362","doi":"10.1200/jco.22.01812","title":"Achieving a Cure Without Total Mesorectal Excision in Rectal Adenocarcinoma","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Total mesorectal excision; Context (archaeology); Colorectal cancer; Clinical trial; Quality of life (healthcare); Intensive care medicine; Disease; General surgery; Radiation therapy; Presentation (obstetrics); Medical physics; Surgery; Cancer; Internal medicine; Nursing","score_opus":0.36871092982335424,"score_gpt":0.5659188091126705,"score_spread":0.1972078792893162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308341362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02640198,0.96265054,0.0000032546832,0.00040278494,0.0036224436,0.0009652092,0.000015057476,0.000020979109,0.0059177633],"genre_scores_gemma":[0.004629868,0.99140334,0.0008377817,0.00020271172,0.0022399705,0.00006489486,0.000026208092,0.00009722567,0.00049802527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886417,0.0027406742,0.006357684,0.0006511941,0.0010707006,0.0005380704],"domain_scores_gemma":[0.9866985,0.007323632,0.004688931,0.00041290378,0.00016208971,0.0007139506],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0053774063,0.0005852839,0.010488186,0.0006861562,0.0000655242,0.000017524768,0.00045790663,0.0013496676,0.0018393646],"category_scores_gemma":[0.006460012,0.00039715267,0.0037660934,0.0007883321,0.00020423054,0.00014395332,0.00044074337,0.006427191,0.000047220034],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038545101,0.0018751054,0.013577341,0.0011497787,0.00084885285,0.011207027,0.000054285807,0.0000010327017,1.3824331e-7,0.0000066113794,0.00062709587,0.96679825],"study_design_scores_gemma":[0.00595629,0.021006674,0.019087654,0.005695837,0.002779007,0.013675554,0.000041315678,0.000006650661,7.3324784e-8,0.000022161825,0.9314372,0.00029158517],"about_ca_topic_score_codex":0.000025400857,"about_ca_topic_score_gemma":0.000029810682,"teacher_disagreement_score":0.96650666,"about_ca_system_score_codex":0.002253619,"about_ca_system_score_gemma":0.006846336,"threshold_uncertainty_score":0.9999468},"labels":[],"label_agreement":null},{"id":"W4308834775","doi":"10.1200/jco.22.01637","title":"Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Common Terminology Criteria for Adverse Events; Oxaliplatin; Colorectal cancer; Cancer; Adverse effect; Peripheral neuropathy; Odds ratio; Oncology; Surgery; Diabetes mellitus","score_opus":0.09447792420464099,"score_gpt":0.45060245459565806,"score_spread":0.3561245303910171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308834775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98493415,0.0024414298,0.000007591938,0.005285754,0.006553382,0.0003982836,0.00019947698,0.0000109875045,0.00016893541],"genre_scores_gemma":[0.9895018,0.004710455,0.00028422248,0.0033986971,0.0017674078,0.000036667156,0.000037199447,0.000033445656,0.00023013231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495316,0.0010462311,0.0026602484,0.0003623267,0.000624985,0.0003530403],"domain_scores_gemma":[0.99565,0.0016165031,0.0019922499,0.00020040522,0.0001925897,0.00034825515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013621243,0.00024038392,0.0022658685,0.00014644262,0.000080476,0.0000063946773,0.00033093637,0.00031775222,0.0072344244],"category_scores_gemma":[0.0003001699,0.00019732505,0.0005750256,0.0002655648,0.00017719138,0.000099978985,0.00012596522,0.0018985936,0.0000035659984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07161017,0.0077531105,0.6883034,0.000019929003,0.0014678689,0.00638514,0.002751679,0.00065471133,0.107128225,0.000017359134,0.007927709,0.10598071],"study_design_scores_gemma":[0.07114356,0.041343153,0.8244853,0.000071108014,0.0007561404,0.00006821854,0.0008018201,0.0007245542,0.0035138398,0.0001952542,0.056607127,0.000289952],"about_ca_topic_score_codex":0.0033414087,"about_ca_topic_score_gemma":0.000903498,"teacher_disagreement_score":0.13618189,"about_ca_system_score_codex":0.0006285589,"about_ca_system_score_gemma":0.002510958,"threshold_uncertainty_score":0.9936731},"labels":[],"label_agreement":null},{"id":"W4309028333","doi":"10.1200/jco.22.01000","title":"Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600–Mutant Low-Grade Glioma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Brain Tumour Charity; Novartis Pharmaceuticals Corporation","keywords":"Trametinib; Dabrafenib; Medicine; Oncology; Dosing; Internal medicine; MEK inhibitor; Adverse effect; Pharmacology; Cancer; MAPK/ERK pathway; Kinase; Biology; Metastatic melanoma","score_opus":0.057300248598997884,"score_gpt":0.40279409561246426,"score_spread":0.34549384701346636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309028333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916982,0.0006066791,0.000008365284,0.0068985606,0.00021829543,0.0004561128,0.000004800878,0.000003881505,0.00010507837],"genre_scores_gemma":[0.9969712,0.0015962722,0.0007579604,0.000507119,0.0001245687,0.000017139202,0.0000029592668,0.000015805897,0.000006995309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966198,0.00055570615,0.0020619738,0.00019347825,0.00038547616,0.00018353769],"domain_scores_gemma":[0.99533653,0.0029816185,0.0012848857,0.00013175304,0.00009644048,0.00016874401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023258424,0.00012968817,0.0013016186,0.00043909822,0.000029993897,0.0000042902957,0.0001086495,0.00014433435,0.00010621963],"category_scores_gemma":[0.0007136009,0.00008264915,0.00014800784,0.0006285014,0.00010024409,0.00006147589,0.000038584934,0.0007195581,5.7240385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055555124,0.040741,0.7625342,0.00006868646,0.00025698202,0.0060895965,0.0005323439,0.0004707562,0.00060012686,0.00019884329,0.0001963927,0.13275596],"study_design_scores_gemma":[0.10198045,0.04195095,0.85149014,0.000075605225,0.00022092077,0.00065592217,0.00019596347,0.000112843845,0.0002948834,0.00013822761,0.0027950283,0.00008904489],"about_ca_topic_score_codex":0.000027251168,"about_ca_topic_score_gemma":0.000093529365,"teacher_disagreement_score":0.13266693,"about_ca_system_score_codex":0.00017854356,"about_ca_system_score_gemma":0.0007653902,"threshold_uncertainty_score":0.33703348},"labels":[],"label_agreement":null},{"id":"W4309411030","doi":"10.1200/jco.22.00642","title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Lymphoblastic Leukemia; Refractory (planetary science); Oncology; Young adult; Pediatrics; Internal medicine; Leukemia","score_opus":0.04583295466574167,"score_gpt":0.38603387227293473,"score_spread":0.34020091760719307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309411030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710256,0.00018543296,0.000009465925,0.00090717187,0.0006431332,0.00052818895,0.000007967496,0.0000024723174,0.0006135927],"genre_scores_gemma":[0.9971432,0.0013069097,0.00022458412,0.000654456,0.0005389578,0.0000139326,0.000004313023,0.00002036826,0.00009327727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958494,0.0009158649,0.0018499172,0.00020338502,0.000913288,0.00026817602],"domain_scores_gemma":[0.9960063,0.0022155975,0.0011234642,0.00023253958,0.00025965623,0.0001624064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004600054,0.00012419488,0.0010355253,0.0003728585,0.000041437033,0.0000069220305,0.00029972792,0.0001858767,0.00040392575],"category_scores_gemma":[0.0015681596,0.00007710081,0.0001851329,0.0005296888,0.00018264845,0.000082170714,0.0001162002,0.0018840298,0.0000037031277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2215448,0.0024221523,0.748802,0.000028684311,0.00018182545,0.0009481128,0.00035244925,0.000037525137,0.00005908086,0.00002747891,0.0019765997,0.023619272],"study_design_scores_gemma":[0.16406457,0.04032029,0.7919285,0.00002689845,0.00028285576,0.00012870424,0.00022489703,0.00013112667,0.0000031925133,0.0001453118,0.002658744,0.00008487225],"about_ca_topic_score_codex":0.00010900203,"about_ca_topic_score_gemma":0.0004405515,"teacher_disagreement_score":0.057480223,"about_ca_system_score_codex":0.00060482905,"about_ca_system_score_gemma":0.002818517,"threshold_uncertainty_score":0.8185277},"labels":[],"label_agreement":null},{"id":"W4309658164","doi":"10.1200/jco.22.01632","title":"Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Adverse effect; Cannabidiol; Anxiety; Distress; Depression (economics); Quality of life (healthcare); Opioid; Randomized controlled trial; Nausea; Internal medicine; Anesthesia; Psychiatry; Cannabis","score_opus":0.10276834909914252,"score_gpt":0.5042183069792973,"score_spread":0.40144995788015475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309658164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737078,0.0030373223,0.000030234814,0.017423026,0.0015127243,0.0035383417,0.000023121218,0.0000047251724,0.0007227328],"genre_scores_gemma":[0.99120235,0.0009852329,0.00009528705,0.00055229693,0.00071935856,0.001563108,0.0000026933544,0.000035106426,0.0048445803],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910801,0.001721013,0.0052853073,0.0003160882,0.0011596348,0.0004378327],"domain_scores_gemma":[0.9898265,0.0042902157,0.0040424294,0.0004042257,0.0011303689,0.00030626016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019115787,0.00022116129,0.00448093,0.00037957972,0.00012794242,0.000008012271,0.00050717714,0.00021555716,0.00046012312],"category_scores_gemma":[0.006965357,0.00013006611,0.0013053016,0.00048247527,0.0004654623,0.00007316377,0.00018878294,0.0018826809,3.9426283e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84904295,0.012094633,0.0020416374,0.00008599905,0.0012986701,0.000100520025,0.0009153415,0.002818301,0.0002696411,0.000059653223,0.0065815365,0.12469111],"study_design_scores_gemma":[0.9232266,0.040735133,0.0014829874,0.000092257054,0.0011071429,0.00006499191,0.0030837825,0.0014754965,0.00007994237,0.00004945611,0.028489549,0.00011267442],"about_ca_topic_score_codex":0.0008372609,"about_ca_topic_score_gemma":0.0011541222,"teacher_disagreement_score":0.12457843,"about_ca_system_score_codex":0.00037308587,"about_ca_system_score_gemma":0.0047495724,"threshold_uncertainty_score":0.84255373},"labels":[],"label_agreement":null},{"id":"W4311018631","doi":"10.1200/jco.22.01873","title":"Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital; Queen's University; McMaster University; Health Sciences North; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Common Terminology Criteria for Adverse Events; Breast cancer; Clinical endpoint; Adverse effect; Lumpectomy; Internal medicine; Odds ratio; Surgery; Mastectomy; Radiation therapy; Cancer","score_opus":0.07927515681087716,"score_gpt":0.5041688425382151,"score_spread":0.424893685727338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311018631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9277236,0.0008412632,0.0019567735,0.060366124,0.003291475,0.0055781268,0.00011885366,0.0000054045067,0.000118404016],"genre_scores_gemma":[0.99196786,0.0014995092,0.0018419626,0.0031401769,0.00087514916,0.00042513615,0.00002055967,0.000014920122,0.00021474481],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99439794,0.0020285284,0.002943601,0.00013057208,0.00035354006,0.00014582726],"domain_scores_gemma":[0.9865398,0.009284098,0.003609638,0.00014678278,0.0003082112,0.00011151452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009884921,0.000096523996,0.0017899557,0.0001443329,0.00007248589,0.000010356228,0.00028930814,0.00014075029,0.00035700912],"category_scores_gemma":[0.0033949832,0.00006289977,0.00048391655,0.00015870389,0.000108219094,0.00019634704,0.000079737474,0.0006555884,7.2793546e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8406033,0.005689635,0.0005943578,0.00002502927,0.0011642243,0.000038038987,0.00025908634,0.00022342782,0.00017546231,0.00005973031,0.011862152,0.13930559],"study_design_scores_gemma":[0.9532737,0.011476568,0.004291786,0.00005529578,0.0016498686,0.00012813506,0.0000833349,0.018702643,0.000038316073,0.00015883449,0.010086153,0.000055378212],"about_ca_topic_score_codex":0.00007051478,"about_ca_topic_score_gemma":0.000035176992,"teacher_disagreement_score":0.1392502,"about_ca_system_score_codex":0.00022847018,"about_ca_system_score_gemma":0.0014239952,"threshold_uncertainty_score":0.40643573},"labels":[],"label_agreement":null},{"id":"W4311018682","doi":"10.1200/jco.22.01065","title":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cilag; NIHR Cambridge Biomedical Research Centre; Genentech; National Institutes of Health; Ipsen; MorphoSys; Astellas Pharma; Eisai; National Institute for Health and Care Research; Cancer Research UK; Merck KGaA; ECOG-ACRIN Cancer Research Group; BeiGene; Medical Research Council; Les Laboratories Pierre Fabre; TG Therapeutics; Daiichi-Sankyo; Celldex Therapeutics; Celgene; NRG Oncology; American College of Radiology Imaging Network; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Oncosuisse; GlaxoSmithKline; National Cancer Research Institute; National Health and Medical Research Council; EUSA Pharma; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Plexxikon; Relay Therapeutics; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Amgen; Breast Cancer Research Foundation; Sanofi","keywords":"Exemestane; Tamoxifen; Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Gynecology; Cancer; Confidence interval","score_opus":0.043856912938356495,"score_gpt":0.389506704370043,"score_spread":0.3456497914316865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311018682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164176,0.002855649,0.000008281078,0.003112456,0.0013711142,0.00012805949,0.0001169098,0.0000037408722,0.00076201826],"genre_scores_gemma":[0.9916604,0.0055149696,0.0003101144,0.00092680444,0.0013131379,0.000010017206,0.000037312493,0.000018288689,0.00020895006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705726,0.0007844826,0.0014179406,0.0002566265,0.00024420727,0.00023949794],"domain_scores_gemma":[0.99824244,0.00034046074,0.0009529975,0.00019558362,0.00009996463,0.00016857032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017181896,0.00012813968,0.00061621243,0.00005757608,0.00005567342,0.0000060512575,0.00032795616,0.00022509339,0.00014958587],"category_scores_gemma":[0.0004124176,0.00009906964,0.00023224136,0.000080671394,0.00009006614,0.000005564493,0.00017379108,0.0010277956,0.00000415075],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090890214,0.0046540215,0.13045779,0.000007262708,0.0013569002,0.0017972161,0.00019572057,0.0031089203,0.19774635,0.000037862937,0.036889657,0.5328581],"study_design_scores_gemma":[0.04916534,0.046267796,0.33876014,0.000048870752,0.00015403623,0.0008841535,0.00026324313,0.00018685183,0.0092676,0.00039318146,0.5541329,0.00047591017],"about_ca_topic_score_codex":0.0001852719,"about_ca_topic_score_gemma":0.000073322946,"teacher_disagreement_score":0.5323822,"about_ca_system_score_codex":0.00007020191,"about_ca_system_score_gemma":0.0009214431,"threshold_uncertainty_score":0.44653174},"labels":[],"label_agreement":null},{"id":"W4311115665","doi":"10.1200/jco.22.02473","title":"The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Associazione Italiana per la Ricerca sul Cancro; University College London; Cancer Research UK","keywords":"Medicine; International Prognostic Index; Internal medicine; Stage (stratigraphy); Proportional hazards model; Hazard ratio; Oncology; Prognostic variable; Multivariate analysis; Lymphoma; Rituximab; Confidence interval","score_opus":0.15409362817916955,"score_gpt":0.454837998927281,"score_spread":0.30074437074811144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311115665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957527,0.0005076234,0.00055310025,0.0067227487,0.0019259143,0.00031580296,0.00004546765,0.000006264669,0.00034780157],"genre_scores_gemma":[0.9955131,0.000821527,0.0020217716,0.0009631713,0.00046484367,0.000047598263,0.000022679813,0.000009526143,0.00013577913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99565417,0.00060779735,0.0028026036,0.00019355818,0.00060607214,0.00013578181],"domain_scores_gemma":[0.98968303,0.0074110827,0.002239283,0.00017546923,0.00033317597,0.00015796455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00424362,0.0001091209,0.0007133704,0.000044326367,0.00017675561,0.000014943559,0.000210074,0.00012896635,0.000042712374],"category_scores_gemma":[0.0055910894,0.000058782858,0.0002504477,0.000074948715,0.00024011933,0.00007169762,0.00017036282,0.00040994643,0.0000017625576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034973263,0.0021134443,0.6603601,0.000004652833,0.00064165564,0.000092479146,0.00019151396,0.0010460991,0.000006534601,0.00032356093,0.0011370768,0.33058554],"study_design_scores_gemma":[0.0107165715,0.0030848489,0.9143857,0.00004657177,0.00036593174,0.00010995748,0.0005148962,0.007697246,0.000054336066,0.00053657906,0.062435143,0.00005223834],"about_ca_topic_score_codex":0.000016515942,"about_ca_topic_score_gemma":0.000017912216,"teacher_disagreement_score":0.3305333,"about_ca_system_score_codex":0.00024956753,"about_ca_system_score_gemma":0.0024001144,"threshold_uncertainty_score":0.66934603},"labels":[],"label_agreement":null},{"id":"W4311274646","doi":"10.1200/jco.22.00023","title":"Use of Instrumental Variable Analyses for Evaluating Comparative Effectiveness in Empirical Applications of Oncology: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; Women's College Hospital; University of Toronto; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Instrumental variable; Oncology; Medical physics; Internal medicine; Statistics","score_opus":0.9553191728226137,"score_gpt":0.7508432072186777,"score_spread":0.204475965603936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311274646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022122992,0.98782575,0.0026487522,0.0005562445,0.0006930675,0.00720875,0.00048680176,0.000004308873,0.00035512197],"genre_scores_gemma":[0.00017584872,0.98188275,0.014440462,0.0013116597,0.00021653525,0.0018412728,0.0000647521,0.0000350561,0.000031674645],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.94510335,0.014806688,0.038957514,0.0005483302,0.00026798152,0.00031613043],"domain_scores_gemma":[0.83487153,0.10632403,0.0576813,0.00052227953,0.00040808125,0.0001927693],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14169917,0.00033386605,0.025320387,0.00083582435,0.000074808384,0.000012906353,0.000721872,0.0006539928,0.0002250409],"category_scores_gemma":[0.07134894,0.0003081561,0.0020119436,0.00081637915,0.00022843503,0.00029136363,0.00015525034,0.001163929,0.000023174047],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017348405,0.0023788302,0.00069307623,0.960595,0.002475948,0.00000318784,0.0002194395,0.00017038999,7.981181e-8,0.0038349177,0.0018426515,0.027613001],"study_design_scores_gemma":[0.0023260023,0.0059280326,0.00015879117,0.16543053,0.0031816845,0.000075398384,0.0003513881,0.00066866935,1.0077434e-7,0.0021998212,0.8193323,0.0003472581],"about_ca_topic_score_codex":0.0001077132,"about_ca_topic_score_gemma":0.000033027067,"teacher_disagreement_score":0.8174897,"about_ca_system_score_codex":0.0023562522,"about_ca_system_score_gemma":0.0063490276,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W4311658410","doi":"10.1200/jco.22.01007","title":"Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University; Université de Montréal; Royal Columbian Hospital; Sinai Health System; McMaster University; University Health Network; Health Sciences Centre; Ottawa Hospital; BC Cancer Agency; Jewish General Hospital; Sunnybrook Health Science Centre; Regional Municipality of Durham; McGill University; Princess Margaret Cancer Centre; Mount Sinai Hospital; University of Calgary; Lakeridge Health; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Randomized controlled trial; Geriatric oncology; Cancer; Internal medicine; Clinical trial; Performance status; Physical therapy; Nursing","score_opus":0.07671591818668182,"score_gpt":0.49259964610324153,"score_spread":0.4158837279165597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311658410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935986,0.00042805218,0.0005260149,0.006306231,0.0007778735,0.0022521934,0.00005742772,0.0000033935114,0.000288948],"genre_scores_gemma":[0.99618083,0.0019425878,0.0010176343,0.00036176035,0.00031747116,0.00008945474,0.000007291821,0.000012219379,0.000070754715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953134,0.001519681,0.0023173613,0.00017255126,0.00053338386,0.00014361467],"domain_scores_gemma":[0.9885197,0.007923396,0.0028782717,0.00017892168,0.0003334644,0.00016624066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00809454,0.00012656316,0.0020646523,0.00011836944,0.00006522367,0.000005824946,0.00013214846,0.000095511605,0.00007284325],"category_scores_gemma":[0.0022953977,0.00006746496,0.00042495143,0.00015573003,0.00025687407,0.00004037075,0.00009095638,0.0003897439,3.9314074e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91284657,0.003906594,0.06369599,0.00022365473,0.002124824,0.000014367357,0.00027325033,0.0002801194,0.000003185471,0.0004399739,0.0022832938,0.013908157],"study_design_scores_gemma":[0.5802631,0.02726906,0.39070228,0.000089557325,0.00068091555,0.000012253909,0.00035517808,0.00022947679,0.0000017999142,0.000117624826,0.0002210063,0.00005776155],"about_ca_topic_score_codex":0.00014501048,"about_ca_topic_score_gemma":0.0000596195,"teacher_disagreement_score":0.3325835,"about_ca_system_score_codex":0.00014407969,"about_ca_system_score_gemma":0.0010182757,"threshold_uncertainty_score":0.28054222},"labels":[],"label_agreement":null},{"id":"W4311672560","doi":"10.1200/jco.22.01134","title":"Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Bristol-Myers Squibb","keywords":"Medicine; Nab-paclitaxel; Gemcitabine; Pancreatic ductal adenocarcinoma; Adjuvant; Oncology; Internal medicine; Paclitaxel; Open label; Adenocarcinoma; Pancreatic cancer; Randomized controlled trial; Chemotherapy; Cancer","score_opus":0.23006368320376133,"score_gpt":0.5178463876754167,"score_spread":0.2877827044716553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311672560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96713656,0.0031883446,0.00006817816,0.014658386,0.0020122426,0.0031179024,0.00012865239,0.000016719143,0.009672983],"genre_scores_gemma":[0.9870878,0.0016456937,0.0044765053,0.0023254182,0.0020128377,0.0002444227,0.00011246263,0.000041134415,0.0020537253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98062086,0.008200103,0.008445524,0.00066620746,0.0013294223,0.0007378843],"domain_scores_gemma":[0.96376216,0.02991166,0.0040452993,0.00070644834,0.00065720465,0.000917224],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032886725,0.00033154077,0.008437509,0.00051103614,0.00020842279,0.000032670516,0.0010079815,0.0005390699,0.0016256276],"category_scores_gemma":[0.049067985,0.00024058232,0.0006684596,0.0006949784,0.0008459516,0.00023117354,0.00084052933,0.0042474163,0.000026625548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93570083,0.018584779,0.009862562,0.000014460113,0.0014204064,0.010382961,0.0004987727,0.0000053046624,0.00023245474,0.00012906437,0.018171458,0.004996953],"study_design_scores_gemma":[0.9107102,0.061168775,0.010304659,0.00011637135,0.0019060501,0.0008667213,0.0007248708,0.0018247633,0.000006103368,0.0016491647,0.010520341,0.00020197769],"about_ca_topic_score_codex":0.0014146144,"about_ca_topic_score_gemma":0.00020542268,"teacher_disagreement_score":0.042583995,"about_ca_system_score_codex":0.0007576297,"about_ca_system_score_gemma":0.009592536,"threshold_uncertainty_score":0.999287},"labels":[],"label_agreement":null},{"id":"W4311675987","doi":"10.1200/jco.22.01064","title":"Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; University of Calgary","funders":"Eisai; National Cancer Institute; Cancer Research UK; AstraZeneca; Ipsen; Pfizer","keywords":"Exemestane; Medicine; Breast cancer; Internal medicine; Tamoxifen; Hazard ratio; Oncology; Population; Gynecology; Clinical endpoint; Cancer; Clinical trial; Confidence interval","score_opus":0.039487348790926455,"score_gpt":0.38268670063299554,"score_spread":0.34319935184206907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311675987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517655,0.0017307013,0.000021626667,0.0017369238,0.00096215593,0.0002597516,0.000019094194,0.0000014002316,0.00009179264],"genre_scores_gemma":[0.99843085,0.0008473022,0.00009235331,0.00022532733,0.00020958329,0.0000104031005,0.0000056873832,0.0000131359575,0.00016538618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964638,0.0015853558,0.0013645897,0.00017782263,0.00024001162,0.00016845272],"domain_scores_gemma":[0.99761677,0.0004191324,0.0015497555,0.00017618085,0.00011561495,0.00012256118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035252625,0.00011830962,0.000905919,0.000044194,0.00006756408,0.0000053464823,0.00025932386,0.00024734085,0.00005761089],"category_scores_gemma":[0.0005766241,0.000064895314,0.00019983503,0.00010174235,0.00018138098,0.000005932185,0.00022282146,0.0006877529,1.6259591e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05872334,0.0020226028,0.58664787,0.00005609986,0.0009542302,0.00033612808,0.00014483772,0.0003597136,0.24345782,0.000049771614,0.0024590825,0.10478853],"study_design_scores_gemma":[0.03344059,0.028484235,0.9207034,0.00018948791,0.00054403837,0.0012847747,0.00011365036,0.000061058934,0.011140707,0.00008747172,0.0037308573,0.00021971119],"about_ca_topic_score_codex":0.000023429828,"about_ca_topic_score_gemma":0.000059410846,"teacher_disagreement_score":0.33405557,"about_ca_system_score_codex":0.000035414774,"about_ca_system_score_gemma":0.0009069455,"threshold_uncertainty_score":0.29879823},"labels":[],"label_agreement":null},{"id":"W4311916201","doi":"10.1200/jco.22.00272","title":"Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Crizotinib; Chemotherapy; Oncology; Internal medicine; Pediatric oncology; Anaplastic lymphoma kinase; Lymphoma; Anaplastic large-cell lymphoma; Cancer; Lung cancer","score_opus":0.030733638649790996,"score_gpt":0.36043339663175894,"score_spread":0.32969975798196793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311916201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321204,0.00013551037,0.000045851142,0.0039400277,0.00071452884,0.0015387316,0.000055744753,0.0000050580575,0.00035251325],"genre_scores_gemma":[0.99697924,0.00017386358,0.0010837773,0.0010393946,0.0005164465,0.00009281313,0.000060887513,0.000022721293,0.000030871797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618155,0.000659383,0.0020858946,0.00025322373,0.00054623466,0.00027372647],"domain_scores_gemma":[0.9913009,0.005054638,0.0029131402,0.00020335683,0.00037504162,0.00015294206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030514766,0.00017149348,0.0013569476,0.00020242065,0.000099615194,0.0000055500127,0.00020122941,0.00018619606,0.000027472724],"category_scores_gemma":[0.00093802344,0.00009179877,0.00029289845,0.00033638757,0.00011883182,0.00006552598,0.000049086473,0.000381568,9.032822e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43590605,0.07001601,0.45733097,0.000019178171,0.00033016058,0.00010496531,0.00019732682,0.000038847516,6.67513e-7,0.0000929878,0.0029446175,0.033018194],"study_design_scores_gemma":[0.39640304,0.15572986,0.44044515,0.000011205958,0.0004040628,0.000034335324,0.00008236352,0.000026304184,0.000005761657,0.000033870318,0.006768518,0.00005553881],"about_ca_topic_score_codex":0.000027671287,"about_ca_topic_score_gemma":0.00008253569,"teacher_disagreement_score":0.08571385,"about_ca_system_score_codex":0.0004911024,"about_ca_system_score_gemma":0.0017790308,"threshold_uncertainty_score":0.37434453},"labels":[],"label_agreement":null},{"id":"W4312019909","doi":"10.1200/jco.22.02121","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"Genentech; Pfizer; Bristol-Myers Squibb","keywords":"Guideline; Medicine; Clinical Practice; Family medicine; Schedule; Stage (stratigraphy); Medical physics; Pathology","score_opus":0.07129517158464499,"score_gpt":0.5037843898540751,"score_spread":0.43248921826943015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312019909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96676844,0.0039661564,0.0058161835,0.015315023,0.004142911,0.0012004258,0.00008612893,0.000016023876,0.002688674],"genre_scores_gemma":[0.93270284,0.005019115,0.024086995,0.01606928,0.0031426859,0.00025216653,0.000049538903,0.000057332643,0.01862003],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976119,0.00022212387,0.0014814327,0.00019303756,0.0002997518,0.00019180111],"domain_scores_gemma":[0.99682796,0.0010899402,0.0011875397,0.0001578708,0.00053362834,0.00020305334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017495421,0.000119340504,0.0007264331,0.00011609101,0.00022970515,0.00001197467,0.0001361819,0.00011383677,0.0016948826],"category_scores_gemma":[0.0004335003,0.00008835009,0.00041063028,0.00011695615,0.000043850425,0.00010283205,0.000057337296,0.000566113,0.0000032890855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007034057,0.0067483746,0.44151345,0.00010605589,0.0026440732,0.00032005386,0.0021275722,0.0054677827,0.0017629208,0.0000969924,0.37819043,0.15398826],"study_design_scores_gemma":[0.020624913,0.013381545,0.0422577,0.000103097474,0.0012654755,0.000053832868,0.0009436435,0.0072556273,0.000098105294,0.000046116922,0.91381675,0.00015319602],"about_ca_topic_score_codex":0.00008457386,"about_ca_topic_score_gemma":0.000052734173,"teacher_disagreement_score":0.53562635,"about_ca_system_score_codex":0.0005239908,"about_ca_system_score_gemma":0.0034283672,"threshold_uncertainty_score":0.9992177},"labels":[],"label_agreement":null},{"id":"W4312065326","doi":"10.1200/jco.22.01732","title":"Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Cumulative incidence; Incidence (geometry); Proportional hazards model; Neuroblastoma; Late effect; Radiation therapy; Pediatrics; Cancer; Internal medicine; Surgery; Confidence interval; Cohort","score_opus":0.09167047179970336,"score_gpt":0.4543000658693397,"score_spread":0.36262959406963635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312065326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970669,0.000253733,0.0000014012871,0.0008770048,0.00097475573,0.0007006948,0.000043116976,0.0000101889855,0.000072195566],"genre_scores_gemma":[0.998768,0.0004040954,0.00001567163,0.00020393044,0.00048122142,0.000041397645,0.0000041239655,0.000022556449,0.00005902108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99450856,0.0017983513,0.002145118,0.0003362695,0.00093404663,0.00027762627],"domain_scores_gemma":[0.9934989,0.0033372734,0.0020566126,0.00044792192,0.0002578106,0.00040145454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030546705,0.0001729689,0.001371045,0.0000938653,0.00016498756,0.000011357781,0.00027001894,0.000093375296,0.00024434755],"category_scores_gemma":[0.0032536355,0.00011090183,0.00036874245,0.00023223834,0.00031895147,0.000106434265,0.00041001616,0.0015318906,9.373098e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002294129,0.006748198,0.96202004,0.000017108609,0.0012281332,0.023888608,0.00033998134,0.000018236844,0.000098620774,3.700683e-7,0.00011785911,0.0032287429],"study_design_scores_gemma":[0.009145295,0.009002137,0.98016876,0.000042700583,0.00054632133,0.0006309622,0.00019362786,0.000007233397,0.00009746903,0.00002175349,0.00006905111,0.000074681535],"about_ca_topic_score_codex":0.0044747735,"about_ca_topic_score_gemma":0.012949639,"teacher_disagreement_score":0.023257645,"about_ca_system_score_codex":0.00008612058,"about_ca_system_score_gemma":0.0010983747,"threshold_uncertainty_score":0.72262025},"labels":[],"label_agreement":null},{"id":"W4312114336","doi":"10.1200/jco.22.02124","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Guideline; Clinical Practice; Family medicine; Schedule; Stage (stratigraphy); Pathology","score_opus":0.06123616474840071,"score_gpt":0.48610858152854763,"score_spread":0.4248724167801469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96889895,0.0030708862,0.0065578776,0.015604748,0.0022389663,0.001119759,0.00007270224,0.000013335775,0.0024227775],"genre_scores_gemma":[0.928258,0.0043169013,0.03218013,0.016247397,0.002631197,0.00028601155,0.000052483712,0.000061724306,0.015966173],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980257,0.00016896705,0.0011681519,0.00017639737,0.00028735012,0.0001734347],"domain_scores_gemma":[0.9970464,0.0010596387,0.0010444138,0.00014144572,0.0005280881,0.00017998155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013036573,0.000110144625,0.0006299327,0.00010200148,0.00020733097,0.000010656547,0.000114303904,0.00008884597,0.0013802965],"category_scores_gemma":[0.00023134473,0.000073729614,0.00027776367,0.0001240161,0.000044484445,0.00009633382,0.000040541498,0.00050095486,0.000001945916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015098684,0.009205879,0.4088041,0.00013812885,0.0040333774,0.00074288977,0.0026957833,0.012147032,0.0014544037,0.00013372049,0.39962032,0.1459257],"study_design_scores_gemma":[0.025847033,0.026050366,0.042633396,0.0001313959,0.001459998,0.00008395616,0.0012522368,0.004849071,0.00009752608,0.000029577575,0.89740247,0.00016295427],"about_ca_topic_score_codex":0.000078552635,"about_ca_topic_score_gemma":0.00007101493,"teacher_disagreement_score":0.49778217,"about_ca_system_score_codex":0.00044835164,"about_ca_system_score_gemma":0.0035612949,"threshold_uncertainty_score":0.9995326},"labels":[],"label_agreement":null},{"id":"W4312114812","doi":"10.1200/jco.21.02968","title":"Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Approaches: An International Cohort Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Princess Margaret Cancer Centre; University Health Network; University of Alberta; University of Toronto; Western University; BC Children's Hospital; Université Laval; Hospital for Sick Children; Université de Montréal; Dalhousie University; Centre Hospitalier Universitaire Sainte-Justine; SickKids Foundation; University of British Columbia; Alberta Children's Hospital; Stollery Children's Hospital; Izaak Walton Killam Health Centre","funders":"Brain Tumour Charity; Cancer Research UK","keywords":"Medicine; Medulloblastoma; Cohort; Neurocognitive; Proportional hazards model; Propensity score matching; Salvage therapy; Hazard ratio; Chemotherapy; Internal medicine; Oncology; Pediatrics; Surgery; Confidence interval; Pathology","score_opus":0.07871412418263195,"score_gpt":0.41383360308021794,"score_spread":0.335119478897586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976299,0.000055839737,0.000009114649,0.0008993274,0.00056947966,0.0004427614,0.000010411001,0.000005380854,0.00037779743],"genre_scores_gemma":[0.9984694,0.00002438165,0.0008396211,0.0003284245,0.00025566583,0.000049239312,0.000008143945,0.000013969424,0.000011138011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997307,0.00035077654,0.0013789729,0.00021048926,0.0006247116,0.00012804237],"domain_scores_gemma":[0.997993,0.000334982,0.0011295149,0.0001594006,0.00017069458,0.00021244094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018003162,0.00012525906,0.001020516,0.00018706673,0.000057360074,0.000010369217,0.00013892358,0.00008452987,0.00017413401],"category_scores_gemma":[0.00046867706,0.000085388485,0.0001588317,0.000097443604,0.000110971974,0.00016119915,0.00009903842,0.00054525636,6.816159e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004814405,0.007695375,0.9750158,0.0000028595955,0.0022649,0.0004347654,0.00043308485,0.000057939767,0.0000027781214,0.000023852435,0.000023499208,0.009230733],"study_design_scores_gemma":[0.014825413,0.024360117,0.9585672,0.000014008426,0.0007324979,0.000753133,0.0004561325,0.00009684937,0.0000038071046,0.000024193758,0.000093881186,0.00007276938],"about_ca_topic_score_codex":0.00004560824,"about_ca_topic_score_gemma":0.000093455295,"teacher_disagreement_score":0.016664742,"about_ca_system_score_codex":0.00011839305,"about_ca_system_score_gemma":0.00036669808,"threshold_uncertainty_score":0.34820414},"labels":[],"label_agreement":null},{"id":"W4313544410","doi":"10.1200/jco.22.00940","title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute","keywords":"Lenalidomide; Medicine; Daratumumab; Dexamethasone; Multiple myeloma; Oncology; Internal medicine","score_opus":0.23679982054285367,"score_gpt":0.5162298201272686,"score_spread":0.27942999958441495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313544410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124056,0.0004914388,0.000054795066,0.0026254563,0.00045704184,0.0033086387,0.000013565074,0.000025674159,0.0017828072],"genre_scores_gemma":[0.9931166,0.0021940656,0.002720736,0.00031880723,0.00046856637,0.000115477575,0.000024133855,0.000041160034,0.0010004308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99214506,0.0028008681,0.0032500182,0.00045060253,0.00071467826,0.000638762],"domain_scores_gemma":[0.98306644,0.0136859,0.0015772721,0.00032042532,0.00040122974,0.00094870426],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0126693165,0.0003116644,0.004753676,0.0004554769,0.00009220602,0.000062504776,0.0003195423,0.000419507,0.00012788107],"category_scores_gemma":[0.017121222,0.00018573318,0.00033213967,0.00054623734,0.00057854387,0.000297921,0.00021359477,0.001266217,0.000025196927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90187144,0.00721743,0.016499402,0.000028871336,0.0014749041,0.007961342,0.00014124018,0.0000038139453,0.00012119129,0.000047250403,0.0008535204,0.06377956],"study_design_scores_gemma":[0.930879,0.04567247,0.017915182,0.00024806126,0.0005063513,0.00037577908,0.00008826867,0.0013952181,0.00004844574,0.00013796966,0.0025715488,0.0001617244],"about_ca_topic_score_codex":0.0004416663,"about_ca_topic_score_gemma":0.00073038123,"teacher_disagreement_score":0.06361784,"about_ca_system_score_codex":0.00020576469,"about_ca_system_score_gemma":0.0018449848,"threshold_uncertainty_score":0.991158},"labels":[],"label_agreement":null},{"id":"W4313544673","doi":"10.1200/jco.22.01096","title":"Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Universiteit van Amsterdam; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Brachytherapy; Magnetic resonance imaging; Cervical cancer; Radiation therapy; Proportional hazards model; External beam radiotherapy; Radiology; Nuclear medicine; Internal medicine; Cancer","score_opus":0.07557243701981974,"score_gpt":0.44062573261341714,"score_spread":0.3650532955935974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313544673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98258185,0.0027768144,0.00014207947,0.012475296,0.0009532416,0.0009290471,0.000074452604,0.000019299981,0.00004791537],"genre_scores_gemma":[0.9939337,0.0028035785,0.0012173064,0.000981991,0.00088612194,0.000046489586,0.000017139522,0.000025793159,0.00008787572],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99604046,0.0005787454,0.0022335667,0.0003805527,0.00045122093,0.00031547507],"domain_scores_gemma":[0.9867322,0.011530787,0.0010046113,0.00022636923,0.00023319061,0.00027286282],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003015462,0.00020087011,0.0014290555,0.00012399981,0.00009793266,0.000019993302,0.00019522772,0.00028838648,0.000034347744],"category_scores_gemma":[0.008692461,0.000118128984,0.000415469,0.0006145461,0.00014722877,0.00014314594,0.000055466164,0.00085382117,0.000004639715],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020980678,0.0010858242,0.41716734,0.000011873416,0.00028998603,0.00029757957,0.00081703794,0.0001818046,0.00005972862,0.0000046265254,0.0010870646,0.5580164],"study_design_scores_gemma":[0.0636298,0.012709399,0.9118688,0.00010490065,0.0004447281,0.0000071725312,0.0017437952,0.0010240603,0.000038277227,0.0006679111,0.007648273,0.00011289278],"about_ca_topic_score_codex":0.00087349245,"about_ca_topic_score_gemma":0.00221451,"teacher_disagreement_score":0.5579035,"about_ca_system_score_codex":0.00024160779,"about_ca_system_score_gemma":0.00066604547,"threshold_uncertainty_score":0.99965775},"labels":[],"label_agreement":null},{"id":"W4313546351","doi":"10.1200/jco.22.00655","title":"Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research; Gunnar Nilssons Cancerstiftelse; Lunds Universitet; Cancerfonden","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cohort; Hazard ratio; Proportional hazards model; Breast-conserving surgery; Tamoxifen; Radiation therapy; Adjuvant; Estrogen receptor; Cancer; Mastectomy; Confidence interval","score_opus":0.06752263489636273,"score_gpt":0.42491590205087326,"score_spread":0.35739326715451053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313546351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665135,0.0008798806,0.0004418043,0.0016414735,0.00022072403,0.00013014974,0.000017420325,7.317717e-7,0.00001644721],"genre_scores_gemma":[0.99682814,0.0018964566,0.0009912334,0.000061881234,0.0001744941,0.000015164997,0.000008218202,0.000004990161,0.00001941596],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989451,0.00007330343,0.0007496959,0.00008304567,0.000072583076,0.00007622958],"domain_scores_gemma":[0.99873924,0.00035241345,0.00069097226,0.000051861174,0.00013419124,0.00003129965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009768351,0.000051080824,0.0003165385,0.00003824727,0.00001812996,0.0000010989671,0.00006272055,0.00010584708,0.0000039495712],"category_scores_gemma":[0.00018219928,0.000031818072,0.000073501156,0.00005066349,0.00009345119,0.000003121098,0.000044271957,0.00006558318,3.7940256e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024425657,0.00030293985,0.12814651,0.000056023757,0.00036625454,0.0000028267011,0.00034875737,0.00069697644,0.023704037,0.000021472348,0.0019282879,0.8419833],"study_design_scores_gemma":[0.0029885944,0.00057861867,0.96163523,0.000034445737,0.0000653149,0.000012109397,0.00034747025,0.00016432333,0.023458382,0.000035541194,0.010649213,0.000030741023],"about_ca_topic_score_codex":0.000018922678,"about_ca_topic_score_gemma":0.0000397251,"teacher_disagreement_score":0.8419526,"about_ca_system_score_codex":0.000040005816,"about_ca_system_score_gemma":0.0005653279,"threshold_uncertainty_score":0.12975033},"labels":[],"label_agreement":null},{"id":"W4313553529","doi":"10.1200/jco.22.02331","title":"Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Trastuzumab; Ramucirumab; Oncology; Ipilimumab; Cancer; Targeted therapy; Esophageal cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Immunotherapy; Progressive disease; Breast cancer","score_opus":0.23759490594763785,"score_gpt":0.5638737964619235,"score_spread":0.3262788905142856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313553529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014336125,0.9914524,0.0002596072,0.003366737,0.003218019,0.0013863255,0.000038044156,0.000027539983,0.00010798951],"genre_scores_gemma":[0.000006808333,0.9845546,0.007122494,0.0020729727,0.0041317707,0.000085712054,0.000034456505,0.00009085203,0.0019003386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99356055,0.00027871647,0.005109276,0.00033609624,0.0003457603,0.0003696266],"domain_scores_gemma":[0.99188656,0.002553839,0.004538354,0.00026084986,0.0004616337,0.00029874794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038387673,0.00037878772,0.0067078033,0.00034108481,0.00005585404,0.000015766056,0.00028895232,0.00058030966,0.00013107192],"category_scores_gemma":[0.001291988,0.00023915837,0.0020657098,0.00027241462,0.00015490736,0.00007304627,0.00006137466,0.0011094236,0.0000064251262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001900531,0.00021811071,0.00025672824,0.0015315108,0.0021802187,0.00016142814,0.000008793194,0.0000015729252,4.0768575e-7,0.000015622565,0.030299922,0.96342516],"study_design_scores_gemma":[0.011929553,0.009427892,0.0010572858,0.002293872,0.0017266232,0.00010509118,0.000017387292,0.0000073666233,2.2694164e-7,0.000080303435,0.97321254,0.00014186614],"about_ca_topic_score_codex":0.000015217002,"about_ca_topic_score_gemma":0.000012368623,"teacher_disagreement_score":0.9632833,"about_ca_system_score_codex":0.00023210752,"about_ca_system_score_gemma":0.002587721,"threshold_uncertainty_score":0.97525954},"labels":[],"label_agreement":null},{"id":"W4315471489","doi":"10.1200/jco.22.01542","title":"Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; National Institutes of Health; LEO Pharma; Incyte; American Heart Association; Sanofi; Cancer Prevention and Research Institute of Texas; Servier; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Cancer; Intensive care medicine; Thrombosis; Internal medicine","score_opus":0.2399188490831667,"score_gpt":0.5821119881672215,"score_spread":0.3421931390840548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315471489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98781013,0.0002857226,0.0022033057,0.007620787,0.0010305827,0.0008822037,0.00003163646,0.000013286161,0.00012234335],"genre_scores_gemma":[0.983284,0.012570774,0.0026754418,0.0010094616,0.00034770815,0.000051768828,0.000026235262,0.000017079326,0.000017520038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99464357,0.00093897217,0.0036782683,0.00020954119,0.00030808165,0.00022154339],"domain_scores_gemma":[0.9928205,0.0023556051,0.003812157,0.00013396797,0.00067506125,0.00020273545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010496307,0.00011038007,0.0022926338,0.000201531,0.000049099643,0.000009463435,0.00008850389,0.00023967685,0.0000047426306],"category_scores_gemma":[0.0032677087,0.00008846825,0.00029964326,0.00023166505,0.000075548094,0.000091327805,0.00005176337,0.00054707634,4.659948e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055103155,0.002659776,0.9133879,0.00045824636,0.0007920496,0.000014395997,0.0007780756,0.017480135,0.000022169988,0.0008873454,0.006859623,0.056109253],"study_design_scores_gemma":[0.009204357,0.006873034,0.89482313,0.0004526731,0.00047525237,0.0000019843137,0.0006985951,0.085351974,0.00000873627,0.00038704273,0.0016491972,0.000074011055],"about_ca_topic_score_codex":0.0008895093,"about_ca_topic_score_gemma":0.0013382875,"teacher_disagreement_score":0.06787184,"about_ca_system_score_codex":0.0003986261,"about_ca_system_score_gemma":0.0023529113,"threshold_uncertainty_score":0.41739637},"labels":[],"label_agreement":null},{"id":"W4317565732","doi":"10.1200/jco.22.01229","title":"Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"vaccines and immunoinformatics approaches","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Sanofi Genzyme; Takeda Oncology; Health Resources and Services Administration; MorphoSys; José Carreras Leukämie-Stiftung; TG Therapeutics; bluebird bio; Kiadis Pharma; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Medac; Jazz Pharmaceuticals; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; HistoGenetics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Amgen; StemCyte; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Human leukocyte antigen; Hazard ratio; Transplantation; Proportional hazards model; Hematopoietic cell; Immunology; Graft-versus-host disease; Hematopoietic stem cell transplantation; Internal medicine; Oncology; Antigen; Haematopoiesis; Biology; Stem cell; Genetics","score_opus":0.04495652827376074,"score_gpt":0.37633100756416854,"score_spread":0.3313744792904078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317565732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857324,0.00006095298,0.0000207813,0.00008265641,0.00059013424,0.00009869694,0.000024908453,0.0000013720294,0.0005472428],"genre_scores_gemma":[0.9988495,0.0007999142,0.00007049558,0.000056895904,0.00010758071,0.0000016014841,0.0000233434,0.000009382012,0.00008127847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978706,0.00022069256,0.0015257858,0.000076969955,0.0001777748,0.00012817493],"domain_scores_gemma":[0.99790025,0.00022317258,0.0013604773,0.00019470474,0.0002703191,0.00005106169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011620184,0.000098082994,0.000491482,0.000056797475,0.000019716523,0.0000034799048,0.00024662007,0.00028324442,0.000016912787],"category_scores_gemma":[0.00054666476,0.000055015164,0.0006081744,0.00014189827,0.00008286287,0.000008282755,0.00005332693,0.00028435563,0.000004347533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023823738,0.0018294487,0.88110656,0.00016863158,0.0021588993,0.000015367952,0.0005943177,0.0047828197,0.03772941,0.00006159421,0.00344025,0.044288944],"study_design_scores_gemma":[0.00350289,0.0073623173,0.98563737,0.00004920332,0.00008540747,0.0000063673488,0.000039685383,0.000094835974,0.0023103738,0.000036490004,0.0008125588,0.00006253048],"about_ca_topic_score_codex":0.000013973089,"about_ca_topic_score_gemma":0.0000063334996,"teacher_disagreement_score":0.10453076,"about_ca_system_score_codex":0.000033933968,"about_ca_system_score_gemma":0.00050692173,"threshold_uncertainty_score":0.22434533},"labels":[],"label_agreement":null},{"id":"W4317565739","doi":"10.1200/jco.22.02423","title":"Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Dexrazoxane; Medicine; Childhood cancer; Cancer; Term (time); Oncology; Internal medicine; Pediatrics; Breast cancer; Anthracycline","score_opus":0.0922238082597881,"score_gpt":0.4516663067950726,"score_spread":0.3594424985352845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317565739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929102,0.00035175963,0.000029175708,0.0055745435,0.0007828762,0.00011877617,0.0000013637372,0.000006933434,0.00022439488],"genre_scores_gemma":[0.9954038,0.0026895262,0.00008124065,0.0010632339,0.0006670099,0.0000019932177,0.0000021291955,0.000008587266,0.00008247715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835134,0.000170888,0.0010702452,0.000102184604,0.00018897466,0.000116401134],"domain_scores_gemma":[0.9984807,0.00066899933,0.00050211366,0.00007830882,0.00014026051,0.00012962414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021355993,0.000064246065,0.00082278793,0.00016273536,0.000012783803,0.000002306948,0.000036437537,0.00026472795,0.00005256896],"category_scores_gemma":[0.00071390846,0.000050836574,0.00020472241,0.00023050533,0.00009280124,0.00006468214,0.000015905525,0.00048903085,0.0000033010842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012896898,0.0004739724,0.8227478,0.00005293193,0.00018318143,0.00008751262,0.00017668749,0.000021854989,0.017841753,0.000019281499,0.0004740771,0.15663125],"study_design_scores_gemma":[0.004504076,0.0030747326,0.98680896,0.00016131077,0.00010520479,0.0001371001,0.00006336849,0.0000145319955,0.0033214525,0.00013994751,0.0016283555,0.00004098265],"about_ca_topic_score_codex":0.000045828645,"about_ca_topic_score_gemma":0.0003509317,"teacher_disagreement_score":0.16406111,"about_ca_system_score_codex":0.000056315785,"about_ca_system_score_gemma":0.0004989872,"threshold_uncertainty_score":0.21246228},"labels":[],"label_agreement":null},{"id":"W4317776100","doi":"10.1200/jco.22.02224","title":"Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; Pediatric Oncology Group","funders":"Astellas Pharma; National Institute for Health and Care Research; Gilead Sciences; AstraZeneca; Pediatric Oncology Group of Ontario; Pfizer","keywords":"Medicine; Guideline; Intensive care medicine; Febrile neutropenia; Empiric therapy; Neutropenia; Transplantation; Randomized controlled trial; Internal medicine; Chemotherapy; Pathology; Alternative medicine","score_opus":0.05324916365716414,"score_gpt":0.41727674857600616,"score_spread":0.364027584918842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317776100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932313,0.00036329837,0.00014620459,0.005207957,0.0004629983,0.0003867251,0.000011535646,0.0000026193138,0.00018736479],"genre_scores_gemma":[0.97134626,0.026116125,0.0011206213,0.0009377922,0.00021953223,0.000027781842,0.0000061257765,0.000011070279,0.00021469896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985962,0.000051098723,0.0009983862,0.00010485461,0.00014474838,0.00010473968],"domain_scores_gemma":[0.9987072,0.00042107792,0.00053193775,0.00006758272,0.00019695981,0.00007524433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090770866,0.00006399242,0.0004205568,0.000077148434,0.000027961982,0.0000038272874,0.000050506813,0.000064942826,0.00002728531],"category_scores_gemma":[0.000028984927,0.000035955458,0.0000625626,0.00021374028,0.000057476474,0.00005750481,0.000018403678,0.00019820055,0.00000139973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045086555,0.00051505613,0.944965,0.00039143045,0.00019938633,0.0000783734,0.00010691174,0.00020194048,0.000011982007,0.00006180049,0.009614097,0.03934533],"study_design_scores_gemma":[0.0113157835,0.0019233251,0.9700916,0.000084041865,0.0009133681,0.000012970547,0.000065671426,0.00003478304,0.0000124061835,0.00006995383,0.015434784,0.000041323015],"about_ca_topic_score_codex":0.000015806392,"about_ca_topic_score_gemma":0.00007315496,"teacher_disagreement_score":0.03930401,"about_ca_system_score_codex":0.000027540611,"about_ca_system_score_gemma":0.00013619039,"threshold_uncertainty_score":0.14662209},"labels":[],"label_agreement":null},{"id":"W4317776104","doi":"10.1200/jco.22.01978","title":"Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Medical Research and Materiel Command; National Institute on Aging; Servicio Gallego de Salud; Institute of Biomedical Sciences, Academia Sinica; Instituto de Salud Carlos III; Cancer Council Western Australia; Cancer Council NSW; Cancer Council Victoria; World Cancer Research Fund; Medical Research Council; Manchester Biomedical Research Centre; Division of Cancer Prevention, National Cancer Institute; National Institutes of Health; Hellenic Health Foundation; Universitätsklinikum Hamburg-Eppendorf; Xunta de Galicia; Rheinische Friedrich-Wilhelms-Universität Bonn; Mutuelle Générale de l'Education Nationale; Imperial Experimental Cancer Medicine Centre; Institut Gustave-Roussy; Center for Agroforestry, University of Missouri; Oulun Yliopisto; National Health and Medical Research Council; Ministry of Education, Science and Technology; Academia Sinica; Deutsche Krebshilfe; National Institute for Health and Care Research; Centers for Disease Control and Prevention; Cancer Council South Australia; Memorial Sloan-Kettering Cancer Center; Centre International de Recherche sur le Cancer; Kreftforeningen; Institut National Du Cancer; Sanofi; Leids Universitair Medisch Centrum; Karolinska Institutet; Associazione Italiana per la Ricerca sul Cancro; KWF Kankerbestrijding; Syöpäsäätiö; Vetenskapsrådet; National Medical Research Council; Norges Forskningsråd; Stockholms Läns Landsting; University of Westminster; Ligue Contre le Cancer; California Department of Public Health; National Research Foundation of Korea; Korea Health Industry Development Institute; Japan Agency for Medical Research and Development; Deutsche Gesetzliche Unfallversicherung; King's College London; Gentofte Hospital; University of Southern California; Cancerfonden; American Cancer Society; Cancer Australia; Russian Foundation for Basic Research; Kuopion Yliopistollinen Sairaala; Erasmus Universiteit Rotterdam; National Heart, Lung, and Blood Institute; Universiteit Leiden; University of Crete; Institut National de la Santé et de la Recherche Médicale; Agency for Science, Technology and Research; Canadian Institutes of Health Research; European Commission; European Organisation for Research and Treatment of Cancer; Cancer Institute NSW; Kerry Group Kuok Foundation; Stavros Niarchos Foundation; Fondation de France; National Research Foundation; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; University of Utah; Breast Cancer Campaign; National Breast Cancer Foundation; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; National Institute of Environmental Health Sciences; Swedish Cancer Foundation; Programme Grants for Applied Research; Robert Bosch Stiftung; Harvard T.H. Chan School of Public Health; Huntsman Cancer Foundation; University of California, San Francisco; Intermountain Healthcare; Consejo Nacional de Ciencia y Tecnología; Sundhed og Sygdom, Det Frie Forskningsråd; National Center for Chronic Disease Prevention and Health Promotion; Unicancer; Deutsches Krebsforschungszentrum; National Research Foundation Singapore; Academy of Finland; James S. McDonnell Foundation; Agence Nationale de la Recherche; Wellcome Trust; Fondation du cancer du sein du Québec; Brigham and Women's Hospital; U.S. Department of Defense; Cancer Research UK; U.S. Army; Ministry of Science and Higher Education of the Russian Federation; Eli Lilly and Company; Lon V. Smith Foundation; Genome Canada; Cancer Council Tasmania; Itä-Suomen Yliopisto; National Cancer Institute; European Regional Development Fund; Ministerio de Sanidad, Servicios Sociales e Igualdad; Government of Canada; University of Cambridge; Breast Cancer Research Foundation; U.S. Department of Health and Human Services; National Cancer Research Institute; F. Hoffmann-La Roche; Freistaat Sachsen; Fonds Wetenschappelijk Onderzoek; Huntsman Cancer Institute; Ministerio de Economía y Competitividad; Bundesministerium für Bildung und Forschung; Ministry of Education, Culture, Sports, Science and Technology; Ovarian Cancer Research Fund; Susan G. Komen for the Cure; Taiwan Biobank","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Polygenic risk score; Cancer; Single-nucleotide polymorphism; Gene; Genetics; Genotype; Biology","score_opus":0.06613917808660164,"score_gpt":0.418115325158246,"score_spread":0.3519761470716444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317776104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970819,0.0002066602,0.00010932749,0.001358071,0.00073532906,0.000061010807,0.00032554122,0.000003279912,0.00011891755],"genre_scores_gemma":[0.99623036,0.0018056775,0.0006526083,0.00023301494,0.00094481464,0.0000042427428,0.000015098475,0.000014814402,0.00009935678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983466,0.00024732965,0.0009534319,0.00014129528,0.00017065956,0.00014068313],"domain_scores_gemma":[0.99724257,0.00033703318,0.0016918943,0.00012850268,0.00048781783,0.00011220824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014725114,0.00008383869,0.00052740687,0.00006089325,0.000042472075,0.0000061779983,0.0001333961,0.00017751595,0.00002497239],"category_scores_gemma":[0.00110014,0.00006393364,0.00013631205,0.00016141431,0.00019939437,0.0000051889783,0.0000641789,0.00029409665,0.0000021165415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069545547,0.00016780819,0.9625392,0.000010521,0.00053036,0.00002385285,0.000050383773,0.00008011456,0.0036153733,0.00002367295,0.0025804979,0.029682785],"study_design_scores_gemma":[0.0014434755,0.0013985649,0.9917159,0.000019707468,0.00017946285,0.00006268535,0.00007142679,0.0000451372,0.00030616042,0.00006431969,0.004619002,0.00007414015],"about_ca_topic_score_codex":0.000041242252,"about_ca_topic_score_gemma":0.00022739239,"teacher_disagreement_score":0.029608645,"about_ca_system_score_codex":0.000051005827,"about_ca_system_score_gemma":0.0017233301,"threshold_uncertainty_score":0.30571136},"labels":[],"label_agreement":null},{"id":"W4317862685","doi":"10.1200/jco.2023.41.4_suppl.lba294","title":"INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University Health Centre","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Hazard ratio; Placebo; Population; Progression-free survival; Clinical endpoint; Cancer; Oncology; Clinical trial; Gastroenterology; Confidence interval; Colorectal cancer; Chemotherapy; Pathology","score_opus":0.22269149000110042,"score_gpt":0.5219122760889366,"score_spread":0.2992207860878362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98840743,0.00020996731,0.00007325539,0.0030903453,0.003193639,0.0046038916,0.000010695896,0.000033817276,0.0003769544],"genre_scores_gemma":[0.99616617,0.0003372167,0.00020143142,0.0001780686,0.0012035029,0.0002005087,0.000011936913,0.000041177304,0.0016600143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9886009,0.002617755,0.0065778154,0.0005209218,0.0010418333,0.00064076664],"domain_scores_gemma":[0.9851058,0.008312783,0.0051996037,0.0004913934,0.00046468378,0.00042572105],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019269949,0.00043078608,0.0046330066,0.0005925615,0.00009531236,0.00003132966,0.00061912334,0.00024957614,0.00032516202],"category_scores_gemma":[0.0062157395,0.00026225488,0.0008789438,0.0010091946,0.00028319,0.00024654466,0.00017827128,0.0023613551,0.000009385236],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8146711,0.011987922,0.11489503,0.00003594956,0.0017859549,0.0018101629,0.00096008414,0.00025044178,0.00018903456,0.0000064728542,0.0064495457,0.046958275],"study_design_scores_gemma":[0.8444107,0.069879435,0.05709449,0.00014246436,0.002249501,0.000039010018,0.02209931,0.00011557248,0.00002141812,0.000008064177,0.0037827247,0.00015729842],"about_ca_topic_score_codex":0.0004657316,"about_ca_topic_score_gemma":0.0022205357,"teacher_disagreement_score":0.05789151,"about_ca_system_score_codex":0.00045006745,"about_ca_system_score_gemma":0.0010731337,"threshold_uncertainty_score":0.99998295},"labels":[],"label_agreement":null},{"id":"W4317862689","doi":"10.1200/jco.2023.41.4_suppl.662","title":"Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Israel Cancer Association; Gateway for Cancer Research","keywords":"Medicine; Brief Pain Inventory; Clinical endpoint; Quality of life (healthcare); Celiac plexus; Pancreatic cancer; Minimal clinically important difference; Abdominal pain; Palliative care; Cancer pain; Cancer; Clinical trial; Internal medicine; Surgery; Randomized controlled trial; Physical therapy; Chronic pain","score_opus":0.3478222454132207,"score_gpt":0.594419364093887,"score_spread":0.24659711868066625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548215,0.00032090032,0.00045195277,0.03871049,0.0038035503,0.0014413594,0.000051491606,0.000024694878,0.00037405948],"genre_scores_gemma":[0.9769177,0.0029658163,0.0073444527,0.010844531,0.00048435217,0.0001245205,0.00009048283,0.000036873054,0.0011912687],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902863,0.0016324859,0.0067387037,0.00029465623,0.0007172164,0.00033062234],"domain_scores_gemma":[0.990109,0.0042803576,0.0044031176,0.00031313815,0.0003160627,0.0005783261],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032167863,0.00016911868,0.0026132064,0.00053821644,0.000039621395,0.0000059942417,0.00029731836,0.00016106475,0.00026881424],"category_scores_gemma":[0.016465347,0.0001378544,0.0007378496,0.0003549793,0.00011249201,0.00017169582,0.000095075884,0.00046774006,0.0000035634032],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18698548,0.01556911,0.045498792,0.00049276464,0.0020970504,0.0003629471,0.00018362244,0.00037085277,0.000013154375,0.0010425866,0.027505731,0.7198779],"study_design_scores_gemma":[0.44702795,0.032070123,0.41992137,0.00028450915,0.00048511164,0.0000037541117,0.0010250508,0.003504538,0.0000018637642,0.0020893528,0.09336243,0.00022394175],"about_ca_topic_score_codex":0.00007264373,"about_ca_topic_score_gemma":0.000055566103,"teacher_disagreement_score":0.71965396,"about_ca_system_score_codex":0.00026459774,"about_ca_system_score_gemma":0.001370733,"threshold_uncertainty_score":0.99658686},"labels":[],"label_agreement":null},{"id":"W4317862744","doi":"10.1200/jco.2023.41.4_suppl.252","title":"AI-powered multi-omic signature to predict treatment response of patients with colorectal cancer liver metastasis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; McGill University","funders":"","keywords":"Medicine; Colorectal cancer; Metastasis; Liquid biopsy; Biomarker; Transcriptome; Oncology; Cancer; Internal medicine; Pathology; Bioinformatics; Gene; Biology; Gene expression","score_opus":0.05747260751210537,"score_gpt":0.4507144880441809,"score_spread":0.39324188053207554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825574,0.00023325192,0.00023191991,0.015610347,0.0009009599,0.00036196984,0.00003094733,0.000016288524,0.000056910703],"genre_scores_gemma":[0.99041474,0.0004946352,0.0050397054,0.0033189151,0.00038580684,0.000010382803,0.000008990249,0.000026496662,0.0003003452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699384,0.0006533523,0.0014079098,0.00021374684,0.000466112,0.00026500967],"domain_scores_gemma":[0.9955805,0.0022365486,0.00097367173,0.00014659186,0.0005184923,0.00054417626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028153674,0.00016136012,0.0014298678,0.00026581454,0.000035393263,0.0000057508396,0.00015343331,0.0002501319,0.00015971977],"category_scores_gemma":[0.0056674373,0.000094475436,0.00035509898,0.00031963462,0.0001971794,0.000057455305,0.000049338123,0.0009348144,0.000016045205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10010385,0.004154266,0.64962304,0.000054504515,0.0020929596,0.001695218,0.0007948591,0.00097190513,0.0017440184,0.000009701295,0.023507534,0.21524817],"study_design_scores_gemma":[0.016216662,0.02990179,0.9010085,0.00016626662,0.0006756155,0.000039550894,0.000051403727,0.001851701,0.00022320567,0.000007016656,0.04976539,0.00009290548],"about_ca_topic_score_codex":0.00004263257,"about_ca_topic_score_gemma":0.000026343243,"teacher_disagreement_score":0.25138548,"about_ca_system_score_codex":0.0002556217,"about_ca_system_score_gemma":0.0015839624,"threshold_uncertainty_score":0.67848617},"labels":[],"label_agreement":null},{"id":"W4317862749","doi":"10.1200/jco.2023.41.4_suppl.291","title":"Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; FOLFOX; Ipilimumab; Cancer; Gastroesophageal Junction; Randomized controlled trial; Adenocarcinoma; Immunotherapy; Oxaliplatin; Colorectal cancer","score_opus":0.08883121524277672,"score_gpt":0.42292600852385553,"score_spread":0.33409479328107883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96742904,0.0023403075,0.00074196863,0.019647252,0.007831969,0.001433147,0.000097642005,0.00014189133,0.00033678676],"genre_scores_gemma":[0.95511407,0.016438546,0.0036527116,0.003419415,0.008268882,0.00026823438,0.00013163724,0.00014321711,0.0125632975],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99437994,0.00016358045,0.002918369,0.0007740487,0.0008112369,0.0009528464],"domain_scores_gemma":[0.994472,0.0012589219,0.0024532704,0.0005033774,0.0005937117,0.00071867974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012980592,0.0005945868,0.0031630262,0.0004577752,0.00020278887,0.00004148152,0.00044122658,0.00057378283,0.0010006092],"category_scores_gemma":[0.00079602655,0.00047841633,0.0015527542,0.00080628507,0.0002010558,0.00027550056,0.00011488927,0.0008800708,0.000085473686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07694628,0.0016120926,0.2821933,0.00022856468,0.0039047902,0.00135287,0.0005491328,0.0014230318,0.00039844692,0.000040638573,0.05022277,0.58112806],"study_design_scores_gemma":[0.17367488,0.039254546,0.6652889,0.00039091913,0.003661057,0.00014845644,0.0005514546,0.0032954852,0.001338835,0.00049643446,0.11133863,0.00056039233],"about_ca_topic_score_codex":0.0012759423,"about_ca_topic_score_gemma":0.00104068,"teacher_disagreement_score":0.58056766,"about_ca_system_score_codex":0.0026315989,"about_ca_system_score_gemma":0.0025403767,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W4317862760","doi":"10.1200/jco.2023.41.4_suppl.7","title":"Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health","keywords":"Medicine; Clinical endpoint; Colorectal cancer; Randomized controlled trial; FOLFOX; Capecitabine; Internal medicine; Total mesorectal excision; Phases of clinical research; Surgery; Gastroenterology; Cancer; Clinical trial; Oxaliplatin","score_opus":0.35935716779455956,"score_gpt":0.5727178297137407,"score_spread":0.21336066191918118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857752,0.0011586123,0.00003037801,0.003050104,0.008048378,0.001245809,0.00007193843,0.000057030342,0.0005625941],"genre_scores_gemma":[0.98523146,0.0065217963,0.0013302433,0.0011141599,0.005341206,0.000037043752,0.000049960978,0.00006319378,0.0003109566],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98936516,0.0008663732,0.007293075,0.00076809584,0.00096106896,0.0007462403],"domain_scores_gemma":[0.98690236,0.008112644,0.00310978,0.00045805276,0.00046147875,0.000955664],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062615755,0.00042323532,0.0037533194,0.00034756193,0.00010777782,0.00002285648,0.00036142758,0.001069461,0.0004264779],"category_scores_gemma":[0.008011484,0.000305512,0.0015172203,0.0007683046,0.00042322552,0.00032030497,0.00024242501,0.0026496928,0.00003831276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46903616,0.006413846,0.02694957,0.00000641343,0.00061598065,0.007053644,0.00015680393,0.00010040401,0.00020445324,0.0000017516662,0.0003202265,0.48914075],"study_design_scores_gemma":[0.59531283,0.101979285,0.29229048,0.0006631587,0.00038819524,0.00028164446,0.00007026144,0.0015535828,0.00014179155,0.00016965778,0.006828295,0.00032080873],"about_ca_topic_score_codex":0.00025440575,"about_ca_topic_score_gemma":0.0006321975,"teacher_disagreement_score":0.48881996,"about_ca_system_score_codex":0.0009286224,"about_ca_system_score_gemma":0.0046575395,"threshold_uncertainty_score":0.9999397},"labels":[],"label_agreement":null},{"id":"W4317862782","doi":"10.1200/jco.2023.41.4_suppl.489","title":"NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Clinical endpoint; Internal medicine; Adverse effect; Randomized controlled trial; Quality of life (healthcare); Oncology; Proportional hazards model; Interim analysis; Progression-free survival; Nuclear medicine; Overall survival; Gastroenterology","score_opus":0.15168990675317187,"score_gpt":0.42427901292216696,"score_spread":0.2725891061689951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905628,0.0025453009,0.00003080066,0.0027359077,0.001053427,0.002766622,0.0000082383995,0.00003543365,0.00026146934],"genre_scores_gemma":[0.99597436,0.0024220967,0.00008404369,0.0004239231,0.0005111261,0.00009621579,0.00005094976,0.000056649096,0.00038064038],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9896405,0.0032604013,0.0052848677,0.00044853333,0.00085790036,0.0005077956],"domain_scores_gemma":[0.9902977,0.0051116925,0.0032021326,0.0004374152,0.00045903958,0.0004920383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009899427,0.00039054672,0.0051140203,0.0007093771,0.00007118097,0.000021148382,0.00030373764,0.00056608074,0.00024439543],"category_scores_gemma":[0.002566992,0.00028255323,0.0013883741,0.0008782262,0.0002146252,0.00022683389,0.00006422158,0.0011114503,0.000042931253],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23393546,0.010714024,0.72805387,0.000035981666,0.0013591293,0.0037516777,0.0010750871,0.0000011773658,0.0012903588,0.000008215038,0.0033118404,0.016463181],"study_design_scores_gemma":[0.87622315,0.038770366,0.0690503,0.00008303209,0.0018708212,0.00010224657,0.00048696232,0.0054602446,0.0015988394,0.00013218519,0.0059311786,0.00029069258],"about_ca_topic_score_codex":0.00020121144,"about_ca_topic_score_gemma":0.000029978548,"teacher_disagreement_score":0.65900356,"about_ca_system_score_codex":0.00025646272,"about_ca_system_score_gemma":0.0012196767,"threshold_uncertainty_score":0.9999627},"labels":[],"label_agreement":null},{"id":"W4317862788","doi":"10.1200/jco.2023.41.4_suppl.255","title":"Twitterchats as a means to educate patients with CRC and caregivers and stimulate collaborations.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Session (web analytics); Medicine; Medical education; Clinical trial; World Wide Web; Internal medicine; Computer science","score_opus":0.27738145339106574,"score_gpt":0.5559247713037084,"score_spread":0.2785433179126427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.941389,0.00003828238,0.000005773066,0.053440165,0.00416832,0.00044777346,0.0000021615303,0.000010954776,0.000497546],"genre_scores_gemma":[0.99580544,0.00044649438,0.0009452221,0.0016227867,0.0010653149,0.000020632382,0.0000014971918,0.000008219965,0.00008441055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980114,0.00063944276,0.0006552695,0.00013391006,0.0003496297,0.00021033568],"domain_scores_gemma":[0.992341,0.005634154,0.00055736606,0.000060469116,0.0008157889,0.0005912378],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027625358,0.00006298056,0.00039849413,0.00014155511,0.00022341791,0.00002873375,0.000103833605,0.00017887288,0.000024422876],"category_scores_gemma":[0.017257808,0.00005132796,0.00003161188,0.00054197473,0.00033731828,0.00016516306,0.000027882565,0.00027651197,0.000020683277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070565357,0.00032200175,0.69482607,0.000015996657,0.000070680195,0.0000247268,0.09585916,0.0000311452,0.0000013831136,0.0008389516,0.013608116,0.1936961],"study_design_scores_gemma":[0.0013838351,0.0027514216,0.784665,0.00004814682,0.000050375125,0.0000013484262,0.014708116,0.0000051909437,4.8453e-7,0.0008056952,0.19550753,0.000072841525],"about_ca_topic_score_codex":0.00073326426,"about_ca_topic_score_gemma":0.0018707761,"teacher_disagreement_score":0.19362324,"about_ca_system_score_codex":0.0001693028,"about_ca_system_score_gemma":0.0035983266,"threshold_uncertainty_score":0.99102026},"labels":[],"label_agreement":null},{"id":"W4317862821","doi":"10.1200/jco.2023.41.4_suppl.249","title":"A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"KRAS; Medicine; Microsatellite instability; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Pembrolizumab; Oncology; Internal medicine; Indel; Exact test; Cancer; Population; MLH1; Cancer research; DNA mismatch repair; Microsatellite; Genotype; Immunotherapy; Gene; Single-nucleotide polymorphism; Genetics; Biology; Allele","score_opus":0.01737283250456966,"score_gpt":0.32817249118641484,"score_spread":0.31079965868184517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985711,0.00030989043,0.00009605402,0.00031598486,0.00026980482,0.000104117455,0.00027925379,0.0000024274866,0.000051358278],"genre_scores_gemma":[0.9970976,0.00060878124,0.0014688905,0.0002538269,0.00036254418,0.0000061559554,0.00014921295,0.000015181002,0.000037776208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998368,0.000105618274,0.0009501123,0.00021354278,0.00017663074,0.00018604954],"domain_scores_gemma":[0.99770075,0.00055285054,0.0010481724,0.00010708238,0.00043146752,0.00015965526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062815985,0.000119627875,0.00068175653,0.00015888878,0.000037040063,0.000013175433,0.0001433486,0.00016858058,0.000056034984],"category_scores_gemma":[0.00040087424,0.00009390727,0.0002129493,0.00026180028,0.0001650161,0.0000051585193,0.0000669303,0.00017773599,0.0000022093104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005461692,0.00035660077,0.9570109,0.000026029564,0.001547914,0.0000537653,0.000043572618,0.018326586,0.009258683,0.000014043731,0.0011348627,0.0067653335],"study_design_scores_gemma":[0.0059408313,0.0043245354,0.9710174,0.000014251136,0.000719991,0.0000060775137,0.000041219802,0.0009241213,0.005367988,0.00004537318,0.011450106,0.00014809542],"about_ca_topic_score_codex":0.00010336633,"about_ca_topic_score_gemma":0.00049827783,"teacher_disagreement_score":0.017402465,"about_ca_system_score_codex":0.000034131655,"about_ca_system_score_gemma":0.0011535578,"threshold_uncertainty_score":0.38294274},"labels":[],"label_agreement":null},{"id":"W4317862877","doi":"10.1200/jco.2023.41.4_suppl.505","title":"Real-world treatments and outcomes of resected biliary tract cancers in British Columbia, Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"Incyte","keywords":"Medicine; Gemcitabine; Gallbladder cancer; Capecitabine; Cancer; Population; Internal medicine; Surgery; Adjuvant therapy; Oncology; Colorectal cancer","score_opus":0.08840316758310654,"score_gpt":0.428635678763622,"score_spread":0.34023251118051545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286383,0.0005622472,7.574333e-8,0.0038732092,0.00070028426,0.0001420058,0.000019311488,0.000005868248,0.0018331934],"genre_scores_gemma":[0.9929085,0.0039240182,0.00009353203,0.0005723412,0.0001948975,0.0000043682985,0.0000031242585,0.000010315753,0.0022889462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997719,0.00016354336,0.0014816382,0.0001494448,0.00028557394,0.00020080191],"domain_scores_gemma":[0.9971672,0.0017045261,0.0006354558,0.00010489634,0.00018412633,0.00020376976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009518046,0.00007179994,0.0014385219,0.00011167123,0.00002734083,0.0000071514805,0.00007244985,0.00011670142,0.000048862632],"category_scores_gemma":[0.0014280748,0.000075517484,0.0001734759,0.00035461396,0.00014769075,0.000046076173,0.00003845762,0.00042998174,5.0518815e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028019154,0.00023762725,0.9265311,0.000027600403,0.00040270804,0.0027034974,0.000075226046,0.0000017795961,0.000015280686,5.0035965e-7,0.027849285,0.04187521],"study_design_scores_gemma":[0.0062472667,0.0020485166,0.98541594,0.00012011169,0.00022424235,0.00010210107,0.00032720872,0.000008877511,0.0000037829025,0.000042592474,0.005403475,0.00005587605],"about_ca_topic_score_codex":0.8953613,"about_ca_topic_score_gemma":0.9968314,"teacher_disagreement_score":0.10147007,"about_ca_system_score_codex":0.00050822744,"about_ca_system_score_gemma":0.0043563456,"threshold_uncertainty_score":0.77279705},"labels":[],"label_agreement":null},{"id":"W4317862891","doi":"10.1200/jco.2023.41.4_suppl.687","title":"Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Internal medicine; Cancer; Ethnic group; Oncology","score_opus":0.21041301194133977,"score_gpt":0.5286024331635134,"score_spread":0.31818942122217364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637703,0.0014015562,0.000080795355,0.0331673,0.001188744,0.0002256323,0.000025446345,0.000038862356,0.000101379344],"genre_scores_gemma":[0.9726955,0.018185398,0.0003225198,0.0069166366,0.0015879459,0.000008157759,0.00000600625,0.000024393836,0.0002534293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960677,0.0009216074,0.0019299398,0.00021752641,0.000452585,0.0004106402],"domain_scores_gemma":[0.9799022,0.017384669,0.0015977443,0.00018186195,0.0002545107,0.00067901524],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006758607,0.00016339192,0.0017859747,0.00025669293,0.00011190456,0.00001957516,0.00011303589,0.00048319102,0.00010451837],"category_scores_gemma":[0.016091475,0.00012052378,0.0002683262,0.00032177748,0.0003417111,0.00011107758,0.000057893874,0.0013059485,0.000010125241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059801503,0.00017805335,0.9131128,0.00022563174,0.00025255524,0.00028077574,0.0002057569,0.00008833116,0.000007157945,0.00002917735,0.004826048,0.08019567],"study_design_scores_gemma":[0.006075878,0.0053713773,0.97847086,0.00033162482,0.0003132757,0.000025685553,0.00017802208,0.00022693997,0.000013638961,0.0007810213,0.008098179,0.000113466966],"about_ca_topic_score_codex":0.0018984382,"about_ca_topic_score_gemma":0.007608634,"teacher_disagreement_score":0.08008221,"about_ca_system_score_codex":0.00021332153,"about_ca_system_score_gemma":0.004971112,"threshold_uncertainty_score":0.9921964},"labels":[],"label_agreement":null},{"id":"W4317862985","doi":"10.1200/jco.2023.41.4_suppl.320","title":"Integrating patient-reported-outcomes into prognostication in gastroesophageal cancer: Results of a population-based retrospective cohort analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Cancer; Retrospective cohort study; Univariate analysis; Population; Performance status; Stage (stratigraphy); Oncology; Multivariate analysis","score_opus":0.07160230193151976,"score_gpt":0.4873387986264606,"score_spread":0.41573649669494084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317862985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489075,0.00023503005,0.00008322033,0.0039034446,0.00022661986,0.00045139363,0.00001726276,0.000013920101,0.0001783504],"genre_scores_gemma":[0.99680674,0.00013331819,0.002578683,0.00018842764,0.0001393639,0.00003523804,0.00007754266,0.0000101191445,0.000030588682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99524766,0.00040284498,0.0031454542,0.0002481084,0.00072097854,0.00023494018],"domain_scores_gemma":[0.9940343,0.0022116585,0.0024326507,0.00021293934,0.0008454073,0.00026306222],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034260035,0.00012303007,0.0016906171,0.0006803391,0.000030978783,0.000005921778,0.000096736745,0.00016991387,0.000036940786],"category_scores_gemma":[0.015383532,0.000083628314,0.0005286478,0.0013485635,0.000102162565,0.00007760889,0.000029864219,0.0006695876,0.0000026028226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033351018,0.00087263156,0.96698457,0.000023086795,0.0014612637,0.00086954527,0.00012069805,0.0006147418,0.000009507088,0.00003020888,0.0001405468,0.025538117],"study_design_scores_gemma":[0.006435902,0.0071345456,0.983088,0.000100074976,0.00095072977,0.000007689873,0.000074006144,0.0017477574,0.00007655911,0.00032039545,0.000021666687,0.0000426723],"about_ca_topic_score_codex":0.0025603517,"about_ca_topic_score_gemma":0.0022857944,"teacher_disagreement_score":0.025495443,"about_ca_system_score_codex":0.0008052203,"about_ca_system_score_gemma":0.0016870742,"threshold_uncertainty_score":0.9929103},"labels":[],"label_agreement":null},{"id":"W4317863022","doi":"10.1200/jco.2023.41.4_suppl.332","title":"Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux des Laurentides; Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; McGill University","funders":"","keywords":"Docetaxel; Medicine; Neoadjuvant therapy; Oxaliplatin; Esophageal cancer; Internal medicine; Regimen; Oncology; Taxane; Esophagectomy; Chemotherapy; Adenocarcinoma; Cancer; Gastroenterology; Colorectal cancer","score_opus":0.2345634129739334,"score_gpt":0.5366262983611576,"score_spread":0.3020628853872242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850017,0.0066143065,0.00040019111,0.0068087354,0.00042716367,0.0005977781,0.000055407254,0.000018943723,0.000075776916],"genre_scores_gemma":[0.994031,0.0007044934,0.002305097,0.0022701959,0.00039353155,0.000028071829,0.000032132022,0.00002297641,0.00021249782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959486,0.0003872855,0.0023012192,0.00027061257,0.00067971536,0.00041256787],"domain_scores_gemma":[0.98974663,0.0070450692,0.0015727952,0.00028145505,0.00084545574,0.0005085945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002242635,0.00019837152,0.0030930247,0.0008853028,0.000062269166,0.000009791518,0.00021722708,0.00028534335,0.00017905168],"category_scores_gemma":[0.0021677476,0.00012596932,0.0022432576,0.001026468,0.00022854409,0.00006895643,0.00004272619,0.00064464257,0.000008137283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01625655,0.001729655,0.9262697,0.00006666036,0.010032314,0.0022574551,0.00014405347,0.0005109995,0.00007605659,0.000067676774,0.0035838392,0.039005045],"study_design_scores_gemma":[0.029657261,0.020926695,0.94033474,0.00004290931,0.0026475778,0.000022012078,0.00009371441,0.0024984414,0.00020412315,0.00014724277,0.0033461114,0.00007917854],"about_ca_topic_score_codex":0.00005113501,"about_ca_topic_score_gemma":0.000026473714,"teacher_disagreement_score":0.038925868,"about_ca_system_score_codex":0.00017857463,"about_ca_system_score_gemma":0.0018966709,"threshold_uncertainty_score":0.51368797},"labels":[],"label_agreement":null},{"id":"W4317863036","doi":"10.1200/jco.2023.41.4_suppl.302","title":"Pre-diagnostic delay among patients with curative esophageal and gastric cancer during the COVID-19 pandemic.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Proportional hazards model; Hazard ratio; Retrospective cohort study; Cohort; Internal medicine; Incidence (geometry); Stage (stratigraphy); Cancer; Pandemic; Confidence interval; Gastroenterology; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.10475290846190702,"score_gpt":0.4806335728456903,"score_spread":0.3758806643837833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310344,0.0018659196,0.00002943123,0.004189408,0.00022259787,0.00048121493,0.000016483731,0.00001716471,0.000074337804],"genre_scores_gemma":[0.99463826,0.003124072,0.0000967651,0.0012980872,0.00044591285,0.000041788786,0.0000040874984,0.000014698022,0.0003363207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976953,0.0004299976,0.0008749258,0.00019060027,0.00049802696,0.00031110985],"domain_scores_gemma":[0.9915526,0.0065139276,0.00070196216,0.00013081875,0.00030028907,0.00080038275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014294825,0.00012889545,0.0007068369,0.00012349754,0.00012825098,0.000012940341,0.00011897812,0.00014019356,0.000118485055],"category_scores_gemma":[0.006498512,0.00006286315,0.00013946605,0.00030513268,0.00041816148,0.00011149272,0.00007410736,0.00090363255,0.000008258082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004159683,0.0003638935,0.9785914,0.0000415114,0.0004472328,0.0025256546,0.0002111897,0.00012764597,7.7027613e-7,0.0000054154057,0.0016425148,0.011883113],"study_design_scores_gemma":[0.012108057,0.009992822,0.97560364,0.000060157745,0.00025239892,0.00025999756,0.000062027284,0.00003567284,0.0000033264998,0.000078247256,0.0014933933,0.000050250226],"about_ca_topic_score_codex":0.00016113266,"about_ca_topic_score_gemma":0.00041088383,"teacher_disagreement_score":0.011832862,"about_ca_system_score_codex":0.0004075362,"about_ca_system_score_gemma":0.0018456538,"threshold_uncertainty_score":0.77797955},"labels":[],"label_agreement":null},{"id":"W4317863062","doi":"10.1200/jco.2023.41.4_suppl.333","title":"Treatment selection and outcomes of locally advanced esophageal cancer in octo- and nonagenarians: Is a curative intent multimodal approach feasible?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Esophageal cancer; Internal medicine; Neoadjuvant therapy; Tolerability; Oncology; Chemoradiotherapy; Cancer; Surgery; Adverse effect","score_opus":0.12428365141152391,"score_gpt":0.5027541373919628,"score_spread":0.3784704859804389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887491,0.0031383825,0.00009099851,0.0070327376,0.0001630102,0.0005397804,0.000014614345,0.000008163405,0.0002632169],"genre_scores_gemma":[0.9897202,0.007362234,0.0021201083,0.0003121524,0.000111027846,0.00004378537,0.0000026346622,0.000011258894,0.00031656347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786514,0.00023996833,0.0011349145,0.00023187118,0.00029107893,0.00023704473],"domain_scores_gemma":[0.99795693,0.0008497538,0.00053581846,0.000079728736,0.00026350925,0.00031425795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007676468,0.00015033362,0.001268252,0.00023764321,0.000029837578,0.0000060711986,0.000052057956,0.00017741464,0.000025722655],"category_scores_gemma":[0.00059808115,0.00009320333,0.00019153573,0.0002695281,0.00017875791,0.000107275286,0.000042364976,0.0004321555,0.0000015540488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005702248,0.0016126727,0.74019396,0.00005942062,0.00068769534,0.0006188912,0.00065199385,0.000113567614,0.000061747895,0.000046874222,0.000088150344,0.25016278],"study_design_scores_gemma":[0.019047683,0.02083003,0.95515513,0.00008126754,0.00018758104,0.00014031511,0.0005009841,0.0033491175,0.00023379154,0.00012271375,0.00028975098,0.000061621846],"about_ca_topic_score_codex":0.00024834534,"about_ca_topic_score_gemma":0.00034588884,"teacher_disagreement_score":0.25010118,"about_ca_system_score_codex":0.0003723814,"about_ca_system_score_gemma":0.0010628749,"threshold_uncertainty_score":0.38007215},"labels":[],"label_agreement":null},{"id":"W4317863112","doi":"10.1200/jco.2023.41.4_suppl.349","title":"Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Internal medicine; Cancer; Gastroenterology; Oncology; Esophageal cancer; Adverse effect; Antigen; Immunology","score_opus":0.14423713882392886,"score_gpt":0.4446103898628588,"score_spread":0.3003732510389299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944516,0.00083496876,0.000047516518,0.001893167,0.0013170193,0.001315878,0.00003077619,0.000012373186,0.00009673861],"genre_scores_gemma":[0.98172224,0.014343053,0.0005513927,0.00045795902,0.0019133582,0.00002516601,0.000054205953,0.00004019497,0.0008924611],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949618,0.0011886545,0.0023663426,0.0003360086,0.0008024508,0.00034472466],"domain_scores_gemma":[0.99208266,0.0049562585,0.0016817662,0.00030518824,0.000669481,0.00030463265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00350462,0.00021796358,0.0014464963,0.00029861848,0.0000764128,0.000019656462,0.00023685716,0.0003041351,0.0009004503],"category_scores_gemma":[0.0019104077,0.00012041513,0.00025628196,0.001122664,0.00024680828,0.00017163115,0.000055052733,0.0011512948,0.000008996559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5282518,0.0060210987,0.03668603,0.000015008466,0.00021937587,0.00007871096,0.00019994356,0.00016577591,0.007842659,6.734876e-7,0.0039489507,0.41656995],"study_design_scores_gemma":[0.6683839,0.12665272,0.18015535,0.00011279246,0.00025394492,0.000011058686,0.00023408464,0.0004158119,0.0012027088,0.000008821073,0.022401007,0.0001678166],"about_ca_topic_score_codex":0.00011931876,"about_ca_topic_score_gemma":0.00011491547,"teacher_disagreement_score":0.41640213,"about_ca_system_score_codex":0.00023165593,"about_ca_system_score_gemma":0.0024250294,"threshold_uncertainty_score":0.9859299},"labels":[],"label_agreement":null},{"id":"W4317863129","doi":"10.1200/jco.2023.41.4_suppl.31","title":"A single center survival analysis of patients with colorectal cancer who underwent next generation sequencing.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; KRAS; Colorectal cancer; Internal medicine; Oncology; Cancer; Single Center; DNA sequencing; Gene","score_opus":0.24704837718176417,"score_gpt":0.44615862218205377,"score_spread":0.1991102450002896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996423,0.00015643575,0.000030566156,0.0014308355,0.00081502803,0.00015777157,0.000028943903,0.00000792424,0.0009494795],"genre_scores_gemma":[0.998296,0.00059194415,0.00019892662,0.00032448565,0.00040040206,0.000006931078,0.000028370525,0.000010513458,0.00014242176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779445,0.00017835568,0.0012461675,0.00016483958,0.00043769632,0.0001785084],"domain_scores_gemma":[0.99734324,0.00053477206,0.0011124797,0.00008831694,0.00076698954,0.00015419428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006919507,0.00011678768,0.0014931316,0.00026310378,0.000042572326,0.000007288821,0.00006352872,0.00013213475,0.00012960442],"category_scores_gemma":[0.00042933735,0.00007072544,0.00043907997,0.0006942532,0.00013792081,0.00007832919,0.000039415016,0.00024336265,0.0000021451563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004436636,0.0013588371,0.9473918,0.000014233059,0.0066118385,0.00009576655,0.0003231397,0.00030375828,0.00031249636,0.000009642147,0.0013005519,0.037841287],"study_design_scores_gemma":[0.005976895,0.014900516,0.97072893,0.00004529479,0.0033788185,0.0000041928047,0.00022195851,0.0010369022,0.00010977474,0.0000079119245,0.003518206,0.00007060704],"about_ca_topic_score_codex":0.00011187812,"about_ca_topic_score_gemma":0.0026303334,"teacher_disagreement_score":0.03777068,"about_ca_system_score_codex":0.0005083316,"about_ca_system_score_gemma":0.000791245,"threshold_uncertainty_score":0.28840998},"labels":[],"label_agreement":null},{"id":"W4317863160","doi":"10.1200/jco.2023.41.4_suppl.56","title":"Real-world use of biologics and its association with outcomes in RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) in Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); University of Calgary","funders":"Amgen","keywords":"Medicine; FOLFOX; FOLFIRI; Bevacizumab; Internal medicine; Colorectal cancer; Oncology; Panitumumab; Population; Irinotecan; Chemotherapy; Systemic therapy; Cancer; KRAS; Oxaliplatin","score_opus":0.1698860173818171,"score_gpt":0.4599984992628806,"score_spread":0.29011248188106353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926116,0.00027579552,1.465298e-7,0.0061814673,0.00049290335,0.00023323599,0.000016614846,0.000004112325,0.0001841532],"genre_scores_gemma":[0.9936066,0.0052711805,0.00017820504,0.000462424,0.000059184924,0.000006595519,0.0000032201385,0.000008342993,0.0004042088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767536,0.0003002968,0.0013696008,0.00014589397,0.00028741886,0.00022144889],"domain_scores_gemma":[0.993339,0.005023668,0.0011438119,0.000051640283,0.00032697924,0.00011490099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012702578,0.00012184703,0.0016687681,0.0002085353,0.000019823703,0.00000362514,0.000050479437,0.000100325786,0.000030072795],"category_scores_gemma":[0.004777744,0.00007325966,0.000086171254,0.0004310564,0.00005527649,0.00007310961,0.000040114275,0.00044273527,6.1474714e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003361156,0.00026484104,0.9884637,0.000019847468,0.0006381534,0.0005870153,0.00015078633,0.00011590115,0.000065384746,0.000011145759,0.0009558126,0.0053662644],"study_design_scores_gemma":[0.0052239485,0.0044312184,0.9879409,0.00010887853,0.0002807949,0.000013626417,0.00023117763,0.00014847111,0.00006342462,0.000041561027,0.0014493928,0.00006662552],"about_ca_topic_score_codex":0.23585185,"about_ca_topic_score_gemma":0.97298145,"teacher_disagreement_score":0.7371296,"about_ca_system_score_codex":0.0015303778,"about_ca_system_score_gemma":0.0042247986,"threshold_uncertainty_score":0.7692367},"labels":[],"label_agreement":null},{"id":"W4317863163","doi":"10.1200/jco.2023.41.4_suppl.793","title":"Use of positron emission tomography-computed tomography (PET-CT) scan in patients with gastrointestinal (GI) cancer at the University Hospital of Montreal (CHUM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Positron emission tomography; Computed tomography; Nuclear medicine; Radiology; Cancer; Retrospective cohort study; Internal medicine","score_opus":0.02291272173716744,"score_gpt":0.3394756930266791,"score_spread":0.31656297128951166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963587,0.000047433026,0.00006499207,0.002960538,0.0002689893,0.00015991986,0.000007925878,0.000008433026,0.00012305148],"genre_scores_gemma":[0.9975773,0.00009038753,0.0019567546,0.00016603214,0.00010606598,3.378166e-7,0.000006988891,0.000011469466,0.00008462879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782616,0.0003181754,0.0010371185,0.00016301942,0.00043597692,0.00021957271],"domain_scores_gemma":[0.9966162,0.0012876187,0.0013212285,0.00015418496,0.0003675633,0.00025320772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011798338,0.00011570655,0.0008555571,0.0003198665,0.00004542652,0.000004174663,0.0001958211,0.000042320895,0.00003294992],"category_scores_gemma":[0.0009738636,0.00006959292,0.00034112824,0.00060871977,0.0004899117,0.0000890627,0.00009726821,0.00088393997,4.5302738e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003636273,0.0008850124,0.9650137,0.000028622453,0.00015007702,0.00064023456,0.00006747028,0.00041839152,0.00011111925,0.000005592581,0.002966569,0.026076948],"study_design_scores_gemma":[0.0058846,0.007210625,0.9827539,0.0005055335,0.00020116015,0.000107459586,0.00007642195,0.0017798286,0.000025047759,0.000014778117,0.0013800381,0.000060620605],"about_ca_topic_score_codex":0.0005829808,"about_ca_topic_score_gemma":0.00012644057,"teacher_disagreement_score":0.026016327,"about_ca_system_score_codex":0.00010716062,"about_ca_system_score_gemma":0.0004580633,"threshold_uncertainty_score":0.38403285},"labels":[],"label_agreement":null},{"id":"W4317863183","doi":"10.1200/jco.22.02111","title":"Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities; American Society of Clinical Oncology","keywords":"Medicine; Cumulative incidence; Internal medicine; Population; Relative risk; Incidence (geometry); Cumulative dose; Wilms' tumor; Cancer; Rate ratio; Pediatrics; Surgery; Confidence interval; Cohort","score_opus":0.054623003387600774,"score_gpt":0.43132459889435637,"score_spread":0.3767015955067556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319136,0.0011739358,0.000014310017,0.0028256627,0.0023444416,0.00032444898,0.000029568484,0.00000793461,0.00008830923],"genre_scores_gemma":[0.9943513,0.0031895163,0.000039743056,0.0013375443,0.00084048207,0.00001484309,0.0000129918035,0.000024354898,0.0001892015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995891,0.0006879985,0.0024245293,0.00030760615,0.00039362928,0.00029526526],"domain_scores_gemma":[0.99510497,0.0011915475,0.002889271,0.00037093126,0.00021531367,0.00022796099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040235706,0.00018291926,0.001183452,0.000055386798,0.00007784662,0.0000101407795,0.00045842308,0.0003029745,0.00003451646],"category_scores_gemma":[0.0019281306,0.00010032741,0.0005979772,0.00024052018,0.0002651176,0.000008742698,0.00015449735,0.00070839666,0.000003810376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039512035,0.00068138714,0.9815598,0.0000061251376,0.0012738106,0.00042002808,0.00022086581,0.00037865745,0.00015531474,0.0000012792002,0.0053188056,0.009588785],"study_design_scores_gemma":[0.0029894623,0.0030729994,0.98682487,0.000059142523,0.00014288921,0.000020115496,0.0003360472,0.000016608432,0.00010117044,0.000107276195,0.0062159738,0.00011346154],"about_ca_topic_score_codex":0.0067157187,"about_ca_topic_score_gemma":0.02576956,"teacher_disagreement_score":0.019053841,"about_ca_system_score_codex":0.00004086537,"about_ca_system_score_gemma":0.0015583491,"threshold_uncertainty_score":0.9998987},"labels":[],"label_agreement":null},{"id":"W4317863218","doi":"10.1200/jco.2023.41.4_suppl.307","title":"Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"FOLFIRI; Medicine; Irinotecan; Internal medicine; FOLFOX; Oncology; Proportional hazards model; Capecitabine; Cancer; Surgery; Gastroenterology; Oxaliplatin; Colorectal cancer","score_opus":0.07573812732351219,"score_gpt":0.44332281317177336,"score_spread":0.36758468584826115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289536,0.000036313777,0.000027045082,0.0035338113,0.0004168882,0.0002930366,0.0000073133324,0.000024477753,0.0027657442],"genre_scores_gemma":[0.9930413,0.00081127114,0.0018066106,0.0006735072,0.0002182778,0.000008920557,0.000008790099,0.00002521329,0.0034061256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973573,0.000100782665,0.0015497857,0.00017549234,0.00054975227,0.00026690713],"domain_scores_gemma":[0.9961878,0.0009705508,0.0018518531,0.00019685009,0.0005540682,0.00023889817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073076657,0.00016052222,0.0016986752,0.00042483793,0.000024554125,0.000004086191,0.00014514415,0.00009919279,0.00015879827],"category_scores_gemma":[0.00044937612,0.00008608314,0.0002763769,0.00095963635,0.00014918111,0.000105329374,0.00004269909,0.00041762844,0.0000071891955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068427227,0.0005690977,0.907474,0.000034839955,0.00079698116,0.00020475363,0.000020319903,0.000105916166,0.0000027965036,0.000018824094,0.0041517364,0.07977805],"study_design_scores_gemma":[0.01783567,0.012835205,0.95472085,0.000111560454,0.0008603607,0.0000047020712,0.000056857134,0.00001584904,0.000008994586,0.000016483813,0.013454688,0.00007874905],"about_ca_topic_score_codex":0.00010983335,"about_ca_topic_score_gemma":0.00043292754,"teacher_disagreement_score":0.0796993,"about_ca_system_score_codex":0.00015339119,"about_ca_system_score_gemma":0.00066750875,"threshold_uncertainty_score":0.35103688},"labels":[],"label_agreement":null},{"id":"W4317863223","doi":"10.1200/jco.2023.41.4_suppl.522","title":"Trends in incidence, treatments, and clinical outcomes of cholangiocarcinoma diagnosed in British Columbia, Canada, from 2005 through 2019.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"Incyte","keywords":"Medicine; Internal medicine; Incidence (geometry); Gallbladder cancer; Interquartile range; Population; Cancer registry; Cancer; Gastroenterology","score_opus":0.08403312008261335,"score_gpt":0.42384539975281976,"score_spread":0.33981227967020644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905551,0.0033276707,4.780871e-7,0.0042152954,0.0010855087,0.00014648413,0.00006146136,0.0000067708743,0.00060120074],"genre_scores_gemma":[0.98964465,0.0069587016,0.00029569052,0.0015153411,0.0004460039,0.0000063765588,0.000016151456,0.000016422742,0.0011006902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953783,0.000392438,0.003168695,0.00031073028,0.00040437377,0.00034547303],"domain_scores_gemma":[0.99390715,0.004465373,0.0010213257,0.00020193722,0.0001397034,0.00026452748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018305883,0.00013521747,0.0025245722,0.00016651182,0.000027689151,0.000015447487,0.00016592673,0.0003461096,0.00014109813],"category_scores_gemma":[0.0024927794,0.0001441619,0.00045012363,0.0004248794,0.00026318815,0.00012980928,0.00011303451,0.00083468825,0.0000029699802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003110037,0.00071541785,0.856747,0.000007390807,0.00049190223,0.0052660243,0.00011985227,9.3176516e-7,0.0000011781369,8.555379e-7,0.05983031,0.07650817],"study_design_scores_gemma":[0.01409636,0.0022155098,0.9741645,0.00015783474,0.00032235155,0.00007770385,0.00042554285,0.0000117492455,7.10855e-7,0.00009535643,0.008323401,0.00010898248],"about_ca_topic_score_codex":0.8297234,"about_ca_topic_score_gemma":0.9911455,"teacher_disagreement_score":0.16142207,"about_ca_system_score_codex":0.0002861552,"about_ca_system_score_gemma":0.0018279504,"threshold_uncertainty_score":0.5878752},"labels":[],"label_agreement":null},{"id":"W4317863229","doi":"10.1200/jco.2023.41.4_suppl.347","title":"Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Gastroenterology; Cohort; Chemotherapy; Interquartile range; Surgery; Oncology; Adverse effect","score_opus":0.10153986570574992,"score_gpt":0.448687866644014,"score_spread":0.3471480009382641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890947,0.0012982971,0.0031234762,0.0047879815,0.0011937203,0.00034531642,0.000027285845,0.0000133817675,0.00011588203],"genre_scores_gemma":[0.9873637,0.0020617035,0.0059876945,0.00058191404,0.0028378654,0.00002330232,0.00011237858,0.000044948716,0.0009865095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975883,0.00021168002,0.0014059391,0.00029706905,0.00019212138,0.00030493492],"domain_scores_gemma":[0.99769795,0.00044855766,0.0011340237,0.00026501424,0.00024178975,0.00021269232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012983999,0.00018526742,0.00075549143,0.00009467633,0.00008079267,0.000018065351,0.0002127553,0.0003170163,0.000053492513],"category_scores_gemma":[0.00077853276,0.00014783596,0.0005868036,0.00012827993,0.000113004106,0.0000109974435,0.00004825183,0.00019495358,0.000020719464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022318318,0.0033770392,0.0192361,0.000117875075,0.003992793,0.00044472085,0.00031384028,0.021834752,0.05760418,0.000101264544,0.0605578,0.81010133],"study_design_scores_gemma":[0.04186191,0.083203614,0.10489801,0.00012262438,0.0010162622,0.0007553846,0.00020415081,0.004194929,0.056277744,0.001638608,0.7052874,0.0005393348],"about_ca_topic_score_codex":0.000011729102,"about_ca_topic_score_gemma":0.00004820304,"teacher_disagreement_score":0.80956197,"about_ca_system_score_codex":0.000113089314,"about_ca_system_score_gemma":0.00085316494,"threshold_uncertainty_score":0.60285753},"labels":[],"label_agreement":null},{"id":"W4317863234","doi":"10.1200/jco.2023.41.4_suppl.tps259","title":"Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Oncology; Colorectal cancer; Internal medicine; FOLFOX; Clinical endpoint; Chemotherapy; Oxaliplatin; Stage (stratigraphy); Adjuvant; KRAS; Cancer; Prospective cohort study; Biomarker; Clinical trial","score_opus":0.044563657483168276,"score_gpt":0.4167230142475589,"score_spread":0.37215935676439066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984496,0.0001628499,0.00001443103,0.00028502097,0.0004064252,0.0004983285,0.000047330683,0.0000029787245,0.00013303093],"genre_scores_gemma":[0.998779,0.0004074753,0.00007197954,0.00045311463,0.0001797523,0.00002154179,0.000016020824,0.00002306646,0.00004804199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973128,0.0002200178,0.0016631657,0.00028978917,0.00025176862,0.00026246358],"domain_scores_gemma":[0.9976432,0.00032758375,0.0014277066,0.00018533072,0.0002751178,0.00014109396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014237652,0.00015877195,0.00089071546,0.0001659955,0.000047281635,0.000005567329,0.00021698761,0.00021177073,0.000028936312],"category_scores_gemma":[0.0009096442,0.00012966701,0.00013624044,0.0002950879,0.00011788242,0.000009244711,0.0001672825,0.00034784977,6.128888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04165068,0.024567354,0.8611803,0.000026482094,0.0006167664,0.0003715735,0.0014059688,0.0022116238,0.010933763,0.000008987495,0.0012512415,0.055775255],"study_design_scores_gemma":[0.077944994,0.12545986,0.78742296,0.000110716544,0.00008947188,0.0000066545363,0.0009960362,0.0005844438,0.0011826985,0.00004270914,0.005942047,0.00021741552],"about_ca_topic_score_codex":0.0002675466,"about_ca_topic_score_gemma":0.001678563,"teacher_disagreement_score":0.10089251,"about_ca_system_score_codex":0.00012117712,"about_ca_system_score_gemma":0.0012439071,"threshold_uncertainty_score":0.52876675},"labels":[],"label_agreement":null},{"id":"W4317863296","doi":"10.1200/jco.2023.41.4_suppl.106","title":"A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Tolerability; Adverse effect; Response Evaluation Criteria in Solid Tumors; Internal medicine; Colorectal cancer; Pharmacokinetics; Pharmacodynamics; Oncology; Cancer; Pharmacology; Phases of clinical research; Clinical trial","score_opus":0.08887203526624725,"score_gpt":0.5075697103502357,"score_spread":0.4186976750839884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715215,0.0000135046575,0.0000074474083,0.0005598716,0.0008111798,0.0012338823,0.0000100542065,0.000017522902,0.00019436116],"genre_scores_gemma":[0.99913543,0.000033516422,0.0002512582,0.000044678553,0.00028572,0.00009586032,0.000040122188,0.000023251578,0.00009018074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663025,0.00031323015,0.0021670414,0.00023755452,0.0004167664,0.00023517369],"domain_scores_gemma":[0.99660075,0.00035402976,0.002238207,0.00009444733,0.0005270982,0.00018545934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010195841,0.0001591993,0.0011339709,0.00041997488,0.00006634468,0.00000902803,0.00007993997,0.0001530077,0.000058602956],"category_scores_gemma":[0.00074220664,0.00011312989,0.0001335669,0.0006758278,0.000071111455,0.00030198236,0.00004591572,0.00063580385,0.0000071158374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040982172,0.029398022,0.79367226,0.00006499611,0.0011241891,0.00052179524,0.002969839,0.0010632256,0.0051609254,0.0000070986657,0.0005182911,0.124517195],"study_design_scores_gemma":[0.14972326,0.16149561,0.67533606,0.0015558002,0.0010638086,0.00004011911,0.0043323957,0.0011517579,0.0039542685,0.000032353528,0.0010626845,0.00025187037],"about_ca_topic_score_codex":0.00012556706,"about_ca_topic_score_gemma":0.0005466089,"teacher_disagreement_score":0.13209759,"about_ca_system_score_codex":0.00067822856,"about_ca_system_score_gemma":0.0011487982,"threshold_uncertainty_score":0.46133032},"labels":[],"label_agreement":null},{"id":"W4317877703","doi":"10.1200/jco.2023.41.4_suppl.tps260","title":"NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; Natera","keywords":"Medicine; Irinotecan; Internal medicine; Oxaliplatin; Oncology; Cohort; Regimen; Randomized controlled trial; Clinical endpoint; Colorectal cancer; Prospective cohort study; Chemotherapy; Stage (stratigraphy); Adjuvant; Cancer; Surgery","score_opus":0.11558722527029774,"score_gpt":0.4654234957018605,"score_spread":0.34983627043156273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317877703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994644,0.0004152351,0.00009235936,0.0030157273,0.0010259553,0.0001787354,0.000028658276,0.000003638893,0.00059569493],"genre_scores_gemma":[0.99514306,0.0011280779,0.00024945932,0.002246998,0.0011067875,0.000006189214,0.00004322951,0.000019059684,0.000057128073],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99753237,0.0004396891,0.0011939475,0.00020609683,0.00045548243,0.0001724343],"domain_scores_gemma":[0.9971856,0.0006427938,0.0010425604,0.00026955135,0.00062928285,0.00023022415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004715154,0.00011220599,0.0005271336,0.00008997964,0.000030054733,0.0000066460593,0.00020131528,0.00027443838,0.000058732425],"category_scores_gemma":[0.0051254057,0.000094967574,0.0003378958,0.000114193695,0.00012903292,0.0000031121403,0.000041599447,0.0002269216,0.0000102951435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032232553,0.0049536955,0.15019415,0.00010582927,0.0008778903,0.00029044072,0.00008946063,0.17342699,0.05238888,0.0002536423,0.12540883,0.45977765],"study_design_scores_gemma":[0.015198802,0.0138812745,0.7998824,0.000080456906,0.0004626434,0.000009114348,0.000038195685,0.015678873,0.0068916194,0.0011279683,0.14648943,0.00025923338],"about_ca_topic_score_codex":0.0000064930605,"about_ca_topic_score_gemma":0.000025041858,"teacher_disagreement_score":0.64968824,"about_ca_system_score_codex":0.000064169086,"about_ca_system_score_gemma":0.0026621113,"threshold_uncertainty_score":0.61359596},"labels":[],"label_agreement":null},{"id":"W4317877786","doi":"10.1200/jco.2023.41.4_suppl.553","title":"Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Lenvatinib; Hepatocellular carcinoma; Bevacizumab; Progression-free survival; Overall survival; Oncology; Gastroenterology; Chemotherapy","score_opus":0.1301184676285087,"score_gpt":0.36353514782354895,"score_spread":0.23341668019504025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317877786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815227,0.00066432595,0.000014872279,0.016087785,0.00034548691,0.001043125,0.000021018986,0.000011043143,0.00028964828],"genre_scores_gemma":[0.9968341,0.00047022363,0.00049290736,0.0016970523,0.00023938398,0.00003334557,0.000032342472,0.00003214646,0.00016846911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956205,0.0009713906,0.0021247447,0.00027625693,0.00062278076,0.00038433666],"domain_scores_gemma":[0.99500275,0.0028472745,0.0010840415,0.00046440234,0.00037115676,0.00023037885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032048842,0.00027860628,0.0018516178,0.0002972421,0.00009442613,0.00002020084,0.0003459156,0.00027395695,0.00011694547],"category_scores_gemma":[0.00068018393,0.00012908831,0.00039900944,0.0007052427,0.0002618565,0.00009590176,0.00006207981,0.00085946586,0.00003288743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046686707,0.0013885658,0.9646029,0.000020932604,0.00050475274,0.0004729309,0.0012247167,0.0000035910023,0.00003501482,0.000016679276,0.002753357,0.024307894],"study_design_scores_gemma":[0.01363243,0.0089536775,0.94984525,0.00006642706,0.00034420867,0.000030685653,0.00029372826,0.00032876566,0.00008271895,0.00003884616,0.026255146,0.00012809355],"about_ca_topic_score_codex":0.00022909995,"about_ca_topic_score_gemma":0.00014206926,"teacher_disagreement_score":0.0241798,"about_ca_system_score_codex":0.00008421709,"about_ca_system_score_gemma":0.0005201796,"threshold_uncertainty_score":0.5264068},"labels":[],"label_agreement":null},{"id":"W4317891151","doi":"10.1200/jco.2023.41.4_suppl.689","title":"Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Cohort; Pancreatic cancer; Pancreas; Internal medicine; Cancer; Oncology; Pancreatic ductal adenocarcinoma","score_opus":0.11747493045172404,"score_gpt":0.4984733129767491,"score_spread":0.38099838252502505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317891151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982501,0.0008022441,0.00038905407,0.012658125,0.0011705552,0.0016965463,0.00008073048,0.000041892607,0.00065988983],"genre_scores_gemma":[0.98751605,0.0040520593,0.0027420276,0.0014388127,0.0021671378,0.0002571989,0.000020643165,0.000046793382,0.0017592746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99445176,0.0012171546,0.0025534094,0.000383302,0.00067342987,0.00072097004],"domain_scores_gemma":[0.97919744,0.018011019,0.0013327755,0.00044186378,0.000634665,0.00038221272],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01398393,0.00023139446,0.0028952067,0.00014257382,0.00031383068,0.000031123243,0.00044049343,0.00030596458,0.00045282283],"category_scores_gemma":[0.017629933,0.00013614111,0.0005507992,0.00044533054,0.00028662325,0.00013001337,0.00016014703,0.0014473605,0.00007840701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034966231,0.0013416627,0.9443581,0.00003561423,0.002443934,0.00027689975,0.0005275281,0.000006132189,0.000036118447,0.000042791045,0.032783326,0.014651263],"study_design_scores_gemma":[0.0147260325,0.0073163924,0.9483346,0.0001974554,0.0050275647,0.000056388428,0.0023131326,0.0027217253,0.000007874078,0.0014068886,0.017765785,0.00012616582],"about_ca_topic_score_codex":0.0018363798,"about_ca_topic_score_gemma":0.0009395964,"teacher_disagreement_score":0.016793864,"about_ca_system_score_codex":0.00031302482,"about_ca_system_score_gemma":0.0024016756,"threshold_uncertainty_score":0.990645},"labels":[],"label_agreement":null},{"id":"W4317891402","doi":"10.1200/jco.2023.41.4_suppl.tps816","title":"A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; T cell; Tolerability; Cancer; Immunotherapy; Clinical trial; Cancer research; Oncology; Internal medicine; Immune system; Immunology; Adverse effect","score_opus":0.16911744821216934,"score_gpt":0.5104959826276299,"score_spread":0.3413785344154605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317891402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013174,0.00019655573,0.000006594726,0.0073753344,0.00090524927,0.0005980965,0.000003233419,0.00001711105,0.00076611724],"genre_scores_gemma":[0.9943537,0.0009954463,0.0009481751,0.000841153,0.0016072685,0.0000052385876,0.0000028959876,0.000031516964,0.001214568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99299896,0.0017576775,0.00404091,0.00024265336,0.0005577647,0.0004020563],"domain_scores_gemma":[0.97873974,0.018013982,0.0023080246,0.0002615378,0.00028947004,0.00038723057],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016707368,0.00015629566,0.002006584,0.000260578,0.00010139655,0.0000085452475,0.00026166145,0.00041684858,0.00039053982],"category_scores_gemma":[0.03527804,0.00009017349,0.00036536003,0.00057205424,0.0007019557,0.00005861391,0.00018632907,0.002527927,0.000007935311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4562477,0.0073142704,0.0019794344,0.00012568373,0.00045629247,0.003184854,0.0026169573,0.00014570184,0.10288568,0.000024720192,0.0063880114,0.4186307],"study_design_scores_gemma":[0.630706,0.22938599,0.021730758,0.00083204784,0.0003876229,0.00058945967,0.0022034063,0.004812969,0.004553754,0.00040265772,0.1040835,0.00031184207],"about_ca_topic_score_codex":0.000031863943,"about_ca_topic_score_gemma":0.000029442737,"teacher_disagreement_score":0.41831887,"about_ca_system_score_codex":0.00014988672,"about_ca_system_score_gemma":0.002735978,"threshold_uncertainty_score":0.99977326},"labels":[],"label_agreement":null},{"id":"W4317891429","doi":"10.1200/jco.2023.41.4_suppl.563","title":"The impact of peri-operative chemotherapy on the outcomes of patients with non-metastatic cholangiocarcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Perioperative; Cancer; Malignancy; Surgery; Adenocarcinoma; Cohort; Internal medicine; Proportional hazards model; Oncology","score_opus":0.09448969755730614,"score_gpt":0.46705589743734655,"score_spread":0.3725661998800404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317891429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99021506,0.00018014786,0.000005675068,0.007954717,0.00026436918,0.00030058992,0.000011284279,0.00000373638,0.0010643891],"genre_scores_gemma":[0.9984377,0.0003482186,0.000084211264,0.00076716667,0.00015977619,0.000005987924,0.0000018055381,0.00001542958,0.00017971713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977336,0.00025064882,0.0012734545,0.00011479351,0.00043292038,0.00019461276],"domain_scores_gemma":[0.9933847,0.004377161,0.001264127,0.00025863465,0.0006081549,0.000107204694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001727538,0.00014686614,0.001269796,0.0000859777,0.00007569981,0.0000062554154,0.00020959548,0.00007495072,0.000049367383],"category_scores_gemma":[0.0015625809,0.0000514463,0.00070293865,0.00026270363,0.0004302657,0.000044373046,0.000038681992,0.0005120402,0.00000690015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043846136,0.0007370602,0.9707289,0.000010243668,0.002498791,0.000032678836,0.0010978254,0.000020236515,0.000025420215,0.000029345487,0.007352184,0.013082701],"study_design_scores_gemma":[0.0065065897,0.019057812,0.97243285,0.000048425674,0.00023972084,0.000007758811,0.0008226262,0.000029116141,0.000057310175,0.000056322657,0.0006913546,0.00005011965],"about_ca_topic_score_codex":0.00003292252,"about_ca_topic_score_gemma":0.00001669322,"teacher_disagreement_score":0.01832075,"about_ca_system_score_codex":0.0000772874,"about_ca_system_score_gemma":0.00070532964,"threshold_uncertainty_score":0.22245884},"labels":[],"label_agreement":null},{"id":"W4317891455","doi":"10.1200/jco.2023.41.4_suppl.82","title":"Diagnostics and treatment for HER2+ mG&amp;CRC: Learning outcomes of GetSMART.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Daiichi-Sankyo","keywords":"McNemar's test; Medicine; Confidence interval; Family medicine; Test (biology); Accreditation; Internal medicine; Oncology; Medical education","score_opus":0.24926125345807543,"score_gpt":0.5194070009653468,"score_spread":0.2701457475072713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317891455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800685,0.00030154304,0.00025510337,0.017199662,0.0011316016,0.0002531561,0.00000291967,0.000014725071,0.00077278074],"genre_scores_gemma":[0.9681225,0.012669114,0.0065501877,0.0013215109,0.0011591853,0.000012411196,0.000009049421,0.00002449996,0.010131539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981254,0.00009563975,0.0012993157,0.00011036002,0.00017902078,0.00019027214],"domain_scores_gemma":[0.9921235,0.0065197125,0.00090714725,0.00009490662,0.00017374752,0.00018097676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016353232,0.00009889902,0.0012792035,0.00015181564,0.000030862884,0.000004770491,0.000060910326,0.00013779032,0.000040813913],"category_scores_gemma":[0.007225519,0.00006386681,0.00042281562,0.000112991154,0.0000965951,0.00003684502,0.000043519703,0.00024392872,0.000008161118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000720457,0.00033433005,0.78069264,0.000036934234,0.00052571966,0.000081637554,0.000094054434,0.000027776254,0.0000071535774,0.00009581506,0.008789802,0.20859371],"study_design_scores_gemma":[0.0061885244,0.008399962,0.6136816,0.000025865387,0.00050560426,0.000015972502,0.00014619998,0.000059366695,0.0000043555856,0.00017578139,0.37076086,0.00003592479],"about_ca_topic_score_codex":0.000017243641,"about_ca_topic_score_gemma":0.00006663499,"teacher_disagreement_score":0.36197105,"about_ca_system_score_codex":0.00007717499,"about_ca_system_score_gemma":0.0002897432,"threshold_uncertainty_score":0.8650143},"labels":[],"label_agreement":null},{"id":"W4317892023","doi":"10.1200/jco.2023.41.4_suppl.647","title":"Liver-directed therapy of neuroendocrine liver metastases.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Neuroendocrine tumors; Poisson regression; Retrospective cohort study; Internal medicine; Embolization; Comorbidity; Cohort; Population; Relative risk; Surgery; Confidence interval","score_opus":0.2043806085465516,"score_gpt":0.5061436562230898,"score_spread":0.30176304767653817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317892023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869498,0.0021201721,0.000010594806,0.007842458,0.0010174396,0.00033250084,0.000010315042,0.000072482704,0.001644247],"genre_scores_gemma":[0.94766974,0.0460085,0.0024462806,0.0015948648,0.0010309991,0.000005483692,0.000004795576,0.000038938455,0.00120037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953206,0.0009858153,0.0022829184,0.00022787524,0.0007644746,0.00041830528],"domain_scores_gemma":[0.9918621,0.005071215,0.0014467828,0.0002993169,0.00080442283,0.0005161534],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016810226,0.00016083714,0.0017452512,0.00042346868,0.00002991736,0.000005740174,0.00031460077,0.000026206728,0.0005547142],"category_scores_gemma":[0.011976105,0.00010984647,0.00068887015,0.00068769284,0.0003766122,0.00015413282,0.00013021388,0.0012297466,0.00010003546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019753322,0.0048787002,0.034563344,0.0001723805,0.001113181,0.24766134,0.00004742598,0.000049349226,0.0078775855,0.00021046802,0.11442172,0.5692512],"study_design_scores_gemma":[0.016702488,0.04308557,0.233455,0.0001048124,0.00022289173,0.011844218,0.00008437256,0.0004808393,0.010166859,0.0003291677,0.68336916,0.00015460236],"about_ca_topic_score_codex":0.000029400471,"about_ca_topic_score_gemma":0.00001668904,"teacher_disagreement_score":0.56909657,"about_ca_system_score_codex":0.00004397696,"about_ca_system_score_gemma":0.0010582204,"threshold_uncertainty_score":0.9963464},"labels":[],"label_agreement":null},{"id":"W4318154232","doi":"10.1200/jco.22.02863","title":"Prognostic Tests in Early-Stage Hormone Receptor–Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care","year":2023,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cancer; Breast cancer; Stage (stratigraphy); Oncology; Hormone receptor; Internal medicine; Gynecology","score_opus":0.09898571761593765,"score_gpt":0.4427627469808154,"score_spread":0.34377702936487775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318154232","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5407332,0.004297017,0.000004921898,0.44869447,0.0026428814,0.00061333383,0.0027518515,0.000019337927,0.00024298723],"genre_scores_gemma":[0.28502482,0.03523219,0.0014208754,0.6190622,0.050946884,0.0007935509,0.001840199,0.00046425062,0.0052150385],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9951944,0.0009790085,0.0019548396,0.000740736,0.00050199375,0.000629031],"domain_scores_gemma":[0.99533737,0.0006368182,0.0018539676,0.0003880331,0.0011822014,0.0006016277],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009812295,0.00051029405,0.0020628762,0.00021854385,0.000083709085,0.00002419523,0.000564813,0.0017667424,0.0001240876],"category_scores_gemma":[0.0016974887,0.00042168522,0.00056323863,0.00027551063,0.00033203923,0.00001573722,0.00028128165,0.0024364272,0.000016881208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006606288,0.00074625213,0.16226378,0.00011244247,0.0018761115,0.0028990142,0.00075507374,0.000047363832,0.00052425865,0.0000017840199,0.7600726,0.06409501],"study_design_scores_gemma":[0.003960088,0.005813384,0.5033019,0.000370439,0.00045494558,0.00009178922,0.0002555386,9.114429e-7,0.00003844847,0.0000070440583,0.48527226,0.0004332339],"about_ca_topic_score_codex":0.002603316,"about_ca_topic_score_gemma":0.0055032354,"teacher_disagreement_score":0.34103814,"about_ca_system_score_codex":0.0006788275,"about_ca_system_score_gemma":0.0048055793,"threshold_uncertainty_score":0.999865},"labels":[],"label_agreement":null},{"id":"W4318168322","doi":"10.1200/jco.22.02466","title":"The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto; SickKids Foundation; Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Medicine; Medulloblastoma; Hazard ratio; Cumulative incidence; Population; Cohort; Incidence (geometry); Cancer registry; Pediatrics; Internal medicine; Cancer; Confidence interval","score_opus":0.04930126122981097,"score_gpt":0.3872826315588139,"score_spread":0.3379813703290029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318168322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908822,0.000049721042,5.2951543e-7,0.0076136957,0.0007969779,0.00041124612,0.0000015250039,0.000004260943,0.00023980577],"genre_scores_gemma":[0.9994582,0.000021021735,0.00006148095,0.00017479026,0.00020687871,0.000013031921,0.0000038151557,0.000009908995,0.00005090459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967349,0.0003864959,0.0020094847,0.00013208558,0.0005425532,0.00019447334],"domain_scores_gemma":[0.9935148,0.004841806,0.0010605091,0.00019287464,0.0002170701,0.00017296773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038462428,0.00009949613,0.0011417058,0.00011395305,0.000046046873,0.0000053536405,0.00013476169,0.000112975344,0.000072984854],"category_scores_gemma":[0.0025899415,0.00005861335,0.00021355896,0.0002496402,0.000038303693,0.000024431889,0.000036188074,0.0005301528,0.0000025880013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034397864,0.0017229153,0.9905937,0.0000040419177,0.00040737138,0.0008939718,0.00019751528,0.00081772055,0.0000030129997,0.0000066245775,0.0012207178,0.0037884421],"study_design_scores_gemma":[0.0064098486,0.0030930168,0.98813796,0.000070113165,0.00026029997,0.000025267804,0.0007524891,0.00012849527,0.0000059871695,0.000054974855,0.001017326,0.0000442465],"about_ca_topic_score_codex":0.9051508,"about_ca_topic_score_gemma":0.99302685,"teacher_disagreement_score":0.08787608,"about_ca_system_score_codex":0.000633078,"about_ca_system_score_gemma":0.0056682616,"threshold_uncertainty_score":0.99996865},"labels":[],"label_agreement":null},{"id":"W4318484838","doi":"10.1200/jco.2023.41.36_suppl.397784","title":"Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Sunitinib; Medicine; GiST; Imatinib; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Stromal tumor; Exon; Population; Imatinib mesylate; Gastroenterology; Cancer; Cancer research; Stromal cell; Gene; Genetics; Biology","score_opus":0.06797431653573303,"score_gpt":0.42116125139408617,"score_spread":0.3531869348583531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318484838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99869746,0.00003326539,0.000088565386,0.0006237605,0.000040951116,0.0002442605,0.00012100675,0.00000682969,0.00014390092],"genre_scores_gemma":[0.9764028,0.000013261904,0.023350084,0.00004480986,0.00008498687,0.0000033670497,0.00006958229,0.000012502822,0.000018567704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957759,0.0005281107,0.0023853253,0.00025183917,0.0007583367,0.00030050476],"domain_scores_gemma":[0.9916306,0.004865981,0.0020138135,0.00019950615,0.0008949761,0.00039509122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001859183,0.00016653568,0.0017276789,0.0005137115,0.000024728692,0.000006205049,0.00014920931,0.000059227837,0.000101310485],"category_scores_gemma":[0.007335527,0.00011738218,0.00035485908,0.0007343122,0.00048183024,0.00007879688,0.00007097197,0.0006339793,0.0000036604963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026366796,0.0024825458,0.967117,0.00005521078,0.0006821975,0.0013042955,0.00004128882,0.000087965585,0.000074967946,0.000024658288,0.00007582841,0.0016872117],"study_design_scores_gemma":[0.01796677,0.020651208,0.95958406,0.00043953425,0.0006322383,0.00011922978,0.000084703264,0.00017728104,0.00013193233,0.000119773096,0.000029870544,0.00006341163],"about_ca_topic_score_codex":0.000068243084,"about_ca_topic_score_gemma":0.00021519024,"teacher_disagreement_score":0.02326152,"about_ca_system_score_codex":0.00008400062,"about_ca_system_score_gemma":0.0008450146,"threshold_uncertainty_score":0.8781841},"labels":[],"label_agreement":null},{"id":"W4318693852","doi":"10.1200/jco.22.02186","title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Medicine; Afatinib; Clinical endpoint; Internal medicine; Oncology; Osimertinib; Lung cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy); Adenocarcinoma; Confidence interval; Erlotinib; Epidermal growth factor receptor","score_opus":0.10840297314600988,"score_gpt":0.5189698770640995,"score_spread":0.4105669039180896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318693852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675907,0.0008045755,0.00048213528,0.020850962,0.0043654903,0.004163289,0.00073682924,0.00005984211,0.0009462112],"genre_scores_gemma":[0.9824337,0.0024509123,0.0013908022,0.0029769707,0.0039458754,0.00032229314,0.0009439206,0.00006423175,0.00547129],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930717,0.0010559765,0.00457662,0.00039159227,0.0004511279,0.00045297926],"domain_scores_gemma":[0.9798626,0.014922036,0.0034084932,0.0003795526,0.0009883463,0.0004390093],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061268313,0.00026259877,0.0029442688,0.00016008575,0.00019268245,0.000030104457,0.00030833494,0.00042151785,0.0002928297],"category_scores_gemma":[0.008428186,0.00014294544,0.001101028,0.00049565727,0.00026284638,0.00009924053,0.00006753308,0.0009711326,0.000016350648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89708036,0.0018015526,0.0001590921,0.000017978185,0.0031869712,0.0004542609,0.0009144054,0.00012817595,0.00054941815,0.000009812089,0.07624538,0.019452568],"study_design_scores_gemma":[0.91358954,0.008790943,0.0010347838,0.00016186395,0.00575361,0.0000103001485,0.00043026646,0.007671444,0.0003718648,0.00010365823,0.06194002,0.0001416835],"about_ca_topic_score_codex":0.00089573325,"about_ca_topic_score_gemma":0.0002996278,"teacher_disagreement_score":0.019310886,"about_ca_system_score_codex":0.00030248906,"about_ca_system_score_gemma":0.0049660453,"threshold_uncertainty_score":0.99992424},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4318904012","doi":"10.1200/jco.2023.41.4_suppl.164","title":"Extended criteria liver resection: Can noncurative intent resection of colorectal liver metastasis improve survival?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Debulking; Tumor Debulking; Surgery; Ablative case; Stage (stratigraphy); Chemotherapy; Hepatectomy; Metastasis; Resection; Cancer; Internal medicine; Radiation therapy; Ovarian cancer","score_opus":0.31955487131747906,"score_gpt":0.4565202202860046,"score_spread":0.13696534896852552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901835,0.0004555125,0.00006658801,0.003159537,0.003663944,0.00041167185,0.0000231444,0.000023466857,0.002012646],"genre_scores_gemma":[0.994972,0.0018753206,0.0011894105,0.00016679581,0.0011130684,0.000016946447,0.000016231175,0.00002294874,0.00062731333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957237,0.0011886077,0.0020338541,0.00026479585,0.00050819357,0.00028084652],"domain_scores_gemma":[0.9945821,0.002161241,0.0014150662,0.0001878524,0.0013000561,0.00035369155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042883875,0.00018287159,0.0015260912,0.00033658036,0.000067633744,0.000011354712,0.00013406797,0.00040771937,0.00058146054],"category_scores_gemma":[0.0036710496,0.00013029229,0.0008547905,0.00052069285,0.000273005,0.00014129379,0.0000916941,0.00084200926,0.000039106868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08181716,0.007589449,0.42161164,0.0005639122,0.008735295,0.01714239,0.0036804113,0.000004246572,0.026955381,0.00047532335,0.030402407,0.40102237],"study_design_scores_gemma":[0.019540139,0.1649516,0.7301544,0.00037255144,0.0037768916,0.0009375361,0.002502094,0.005103366,0.045142043,0.00053446274,0.026583647,0.00040126394],"about_ca_topic_score_codex":0.00021322994,"about_ca_topic_score_gemma":0.00041442944,"teacher_disagreement_score":0.40062112,"about_ca_system_score_codex":0.00025551426,"about_ca_system_score_gemma":0.0009781142,"threshold_uncertainty_score":0.63665855},"labels":[],"label_agreement":null},{"id":"W4318904034","doi":"10.1200/jco.2023.41.4_suppl.124","title":"Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Transverse colon; KRAS; Internal medicine; Splenic flexure; Rectum; Cetuximab; Oncology; Randomized controlled trial; Multivariate analysis; Cohort; Clinical endpoint; Gastroenterology; Cancer; Colonoscopy","score_opus":0.12560684137360376,"score_gpt":0.4836043072537022,"score_spread":0.3579974658800984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846307,0.0052917637,0.000018605157,0.008097491,0.00037983985,0.001000569,0.00026394118,0.000005639394,0.00031144315],"genre_scores_gemma":[0.9943768,0.0048795533,0.00012584984,0.0003136963,0.0001808171,0.000040214512,0.000008416585,0.000008572478,0.00006607757],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948601,0.0022257771,0.002162176,0.00018794741,0.0004065988,0.00015741496],"domain_scores_gemma":[0.96272254,0.03436335,0.0023232189,0.000109826025,0.0003606819,0.000120386794],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062254644,0.00016207578,0.004510494,0.00014502757,0.00009632968,0.000010019463,0.00011074682,0.00015155859,0.00006376512],"category_scores_gemma":[0.013330596,0.00006977966,0.0011141746,0.00052625133,0.0011695109,0.00004241104,0.00004529072,0.0004991417,1.6454946e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5117792,0.0012733849,0.3269101,0.000086785345,0.10635925,0.00021823504,0.008160155,0.00023542788,0.0010661826,0.000033549008,0.006607703,0.037270024],"study_design_scores_gemma":[0.10279478,0.004399529,0.826505,0.00016368221,0.0628235,0.00002209817,0.0015278154,0.00073364266,0.00020635161,0.0002538252,0.0005082857,0.0000615],"about_ca_topic_score_codex":0.00030587133,"about_ca_topic_score_gemma":0.0013075555,"teacher_disagreement_score":0.4995949,"about_ca_system_score_codex":0.00006836045,"about_ca_system_score_gemma":0.000763242,"threshold_uncertainty_score":0.9949805},"labels":[],"label_agreement":null},{"id":"W4318904035","doi":"10.1200/jco.2023.41.4_suppl.86","title":"Reflex testing for RAS and BRAF mutations in metastatic colorectal cancer: A single Canadian academic oncology center experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Reflex; Pathological; Cancer; KRAS","score_opus":0.33428148533444246,"score_gpt":0.548434544920429,"score_spread":0.21415305958598652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811057,0.00067382446,0.0000043005107,0.015072649,0.0009104611,0.00041192237,0.000027417429,0.000011271825,0.0017824438],"genre_scores_gemma":[0.99506,0.0007251367,0.0019703126,0.0015618213,0.00040948953,0.00010756746,0.0000058887713,0.00001448507,0.00014525266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771184,0.00017267435,0.0014001634,0.0002017399,0.00014679591,0.00036681138],"domain_scores_gemma":[0.99457824,0.0040470986,0.00061848626,0.00005154093,0.00029774074,0.00040690083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287845,0.00012314793,0.0011215687,0.00030680434,0.00009664699,0.0000066170523,0.000079457765,0.00021277978,0.000036182384],"category_scores_gemma":[0.00569983,0.00009204632,0.00015372419,0.00038729285,0.00025622864,0.00008594382,0.00003799461,0.00059099024,0.0000032117819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024508438,0.0005478092,0.53722787,0.00003783164,0.0003607347,0.001195118,0.0029563077,0.000022908152,0.0006434273,0.000034316832,0.002924257,0.45159855],"study_design_scores_gemma":[0.012784481,0.024833532,0.8684268,0.0001900351,0.00041072493,0.00058858603,0.0035194,0.00044633067,0.00007591422,0.00067998946,0.087901615,0.00014258282],"about_ca_topic_score_codex":0.004484171,"about_ca_topic_score_gemma":0.115909606,"teacher_disagreement_score":0.45145598,"about_ca_system_score_codex":0.0008666634,"about_ca_system_score_gemma":0.0032958305,"threshold_uncertainty_score":0.9002227},"labels":[],"label_agreement":null},{"id":"W4318904046","doi":"10.1200/jco.2023.41.4_suppl.lba492","title":"Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of Toronto; Hamilton Health Sciences; University Health Network; Royal Victoria Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Dr. H. Bliss Murphy Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Hôtel-Dieu de Montréal","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Liver cancer; Radiation therapy; Cancer; Gastroenterology; Randomized controlled trial; Colorectal cancer; Quality of life (healthcare)","score_opus":0.33541306456164943,"score_gpt":0.48027383915800526,"score_spread":0.14486077459635582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98980206,0.0048355926,0.00012780045,0.002355414,0.000547232,0.0022285436,0.000069364905,0.000010787,0.000023220671],"genre_scores_gemma":[0.9946702,0.0027140619,0.0012306976,0.00045032895,0.00064368825,0.00012805428,0.000017364833,0.000030493436,0.00011511247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99483883,0.0012723444,0.0029732196,0.00025681496,0.00032861205,0.00033019923],"domain_scores_gemma":[0.9917397,0.0049708355,0.0019798,0.00019028588,0.0004089833,0.00071039033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0079217795,0.00021544308,0.0032525887,0.00043613467,0.0000761467,0.000011560084,0.00012829635,0.00027323834,0.00018463991],"category_scores_gemma":[0.0020117057,0.0001482942,0.0007289833,0.00032872558,0.00011434597,0.00007997446,0.00002204079,0.00035193312,0.0000022349536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064063505,0.0030411303,0.89736146,0.00012202231,0.0043169376,0.0020500668,0.0014893203,0.0000013066443,0.00029568013,0.00002300442,0.0027195679,0.08217314],"study_design_scores_gemma":[0.2771254,0.16943169,0.4585947,0.0004029274,0.018219054,0.00017716663,0.0037642117,0.031821072,0.0009526148,0.0003050294,0.038659886,0.0005462517],"about_ca_topic_score_codex":0.013213128,"about_ca_topic_score_gemma":0.011813825,"teacher_disagreement_score":0.43876675,"about_ca_system_score_codex":0.00030966307,"about_ca_system_score_gemma":0.001997223,"threshold_uncertainty_score":0.99335796},"labels":[],"label_agreement":null},{"id":"W4318904227","doi":"10.1200/jco.2023.41.4_suppl.131","title":"Phase II trial of rosuvastatin combined with chemoradiation therapy (CRT) in the treatment of high-risk locally advanced rectal cancer (STARC trial).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Alberta Cancer Foundation","keywords":"Medicine; Colorectal cancer; Rosuvastatin; Internal medicine; Hazard ratio; Radiation therapy; Surgery; Urology; Cancer; Stage (stratigraphy); Oncology; Capecitabine; Gastroenterology; Confidence interval","score_opus":0.05462650368132326,"score_gpt":0.42599224806564395,"score_spread":0.3713657443843207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234706,0.0009883,0.00006360511,0.00096728734,0.0048616687,0.0006821678,0.000040053696,0.0000025257439,0.000047328445],"genre_scores_gemma":[0.95959216,0.033015374,0.0004057399,0.00020332646,0.0065814992,0.000060654078,0.0000263611,0.000015382182,0.00009951391],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971519,0.0006392887,0.001599675,0.00018400153,0.0002488165,0.00017632924],"domain_scores_gemma":[0.99693376,0.0005406967,0.0019897507,0.00021428862,0.00024191783,0.00007957966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018829022,0.00013908728,0.0010380525,0.00008104735,0.00003388975,0.0000038262897,0.00019103022,0.00022318643,0.000016776718],"category_scores_gemma":[0.00059592,0.00008070557,0.00033908803,0.00021606823,0.00018689476,0.000008031428,0.000015945558,0.00020314759,3.7453717e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6363587,0.006769108,0.00025436442,0.000005054439,0.00026011484,0.000002264708,0.00032447212,0.00040857046,0.0072613154,0.000014760883,0.0019469558,0.34639433],"study_design_scores_gemma":[0.60313743,0.26358247,0.0022519657,0.000016601894,0.0001271283,0.000003657758,0.00016638132,0.000032523643,0.0061486103,0.0001156331,0.12433114,0.00008643065],"about_ca_topic_score_codex":0.00020081572,"about_ca_topic_score_gemma":0.0007353464,"teacher_disagreement_score":0.34630787,"about_ca_system_score_codex":0.00004434719,"about_ca_system_score_gemma":0.0013852216,"threshold_uncertainty_score":0.32910776},"labels":[],"label_agreement":null},{"id":"W4318904237","doi":"10.1200/jco.2023.41.4_suppl.183","title":"Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bausch Health (Canada); Hôpital du Sacré-Cœur de Montréal; Juravinski Cancer Centre; Cancer Care Nova Scotia; Jewish General Hospital; Hôpital Charles-Le Moyne; St. John’s Health Sciences Centre; BC Cancer Agency; Hôtel-Dieu de Québec; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; Moncton Hospital","funders":"","keywords":"Medicine; Hazard ratio; Colorectal cancer; Internal medicine; Oncology; Biomarker; Refractory (planetary science); Proportional hazards model; Gastroenterology; Cancer; Confidence interval","score_opus":0.07469459667457762,"score_gpt":0.43831413433587135,"score_spread":0.36361953766129373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608666,0.00022750832,0.000008080982,0.0014288456,0.0005548439,0.0011896711,0.00010084659,0.000009732002,0.00039378952],"genre_scores_gemma":[0.998866,0.00045386117,0.00012364912,0.00012754246,0.0001002858,0.00014773513,0.000024412986,0.00001921195,0.0001373043],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966233,0.00031924286,0.002156618,0.00021304471,0.0004679359,0.00021987472],"domain_scores_gemma":[0.9944528,0.0023508254,0.002267452,0.00013536922,0.00067834684,0.00011521005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018675631,0.00016994125,0.002039649,0.00033831885,0.00005908198,0.000004555812,0.00007649598,0.00013106303,0.000099101926],"category_scores_gemma":[0.002787348,0.00008886628,0.00080573,0.0010946792,0.00028381665,0.000073816875,0.0000490979,0.00037800273,0.0000016600184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6492895,0.005034056,0.31052434,0.000048352194,0.014324353,0.000099562894,0.0005411024,0.00016196958,0.00013809613,0.000007391391,0.00074648054,0.019084781],"study_design_scores_gemma":[0.09844021,0.04554297,0.84754235,0.00015949075,0.0057776705,0.000005291603,0.00031737916,0.00046728883,0.00071542594,0.000044165386,0.0009133932,0.00007436653],"about_ca_topic_score_codex":0.00022713731,"about_ca_topic_score_gemma":0.0008752914,"teacher_disagreement_score":0.5508493,"about_ca_system_score_codex":0.0004931996,"about_ca_system_score_gemma":0.0012550872,"threshold_uncertainty_score":0.3623862},"labels":[],"label_agreement":null},{"id":"W4318904247","doi":"10.1200/jco.2023.41.4_suppl.180","title":"Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Ottawa Hospital; Queen's University; Providence Health Care; BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; KRAS; Buffy coat; Germline; Oxaliplatin; Oncology; Chemotherapy; Internal medicine; Cancer; Surgery; Gene; Biology; Genetics","score_opus":0.10933166846213783,"score_gpt":0.4513977569303293,"score_spread":0.3420660884681915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965891,0.000043625547,0.00012653583,0.0024453267,0.00020983358,0.00052007794,0.00001615309,0.0000015020086,0.0000478386],"genre_scores_gemma":[0.99756014,0.00024699353,0.0008491544,0.0010487199,0.00024348701,0.000012064749,0.000016613203,0.000011426032,0.000011377443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978541,0.00029537367,0.0012883234,0.00021116465,0.00020550401,0.00014551694],"domain_scores_gemma":[0.99735945,0.0011155054,0.0009618999,0.00016257665,0.00033110735,0.00006947336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026341863,0.00009863345,0.0004613393,0.00007459658,0.00004071491,0.000010177628,0.00016024451,0.00013421124,0.0000056199583],"category_scores_gemma":[0.0069072936,0.000069539514,0.000072615774,0.00026747212,0.00006988586,0.00001661839,0.000068454334,0.0002103457,1.9968071e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04313719,0.0021253282,0.90813315,0.000031503478,0.000088771776,0.000020618178,0.0011491929,0.0019857753,0.00969098,0.000019136058,0.0017433658,0.031874962],"study_design_scores_gemma":[0.0582717,0.013703484,0.9242009,0.00010150356,0.000026604395,0.0000025405093,0.00030562517,0.00029537344,0.0011956423,0.00031577962,0.0014732737,0.000107575666],"about_ca_topic_score_codex":0.00013202366,"about_ca_topic_score_gemma":0.0014317747,"teacher_disagreement_score":0.031767387,"about_ca_system_score_codex":0.0001001878,"about_ca_system_score_gemma":0.00088612706,"threshold_uncertainty_score":0.8269174},"labels":[],"label_agreement":null},{"id":"W4318904300","doi":"10.1200/jco.2023.41.4_suppl.394","title":"Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Cancer; Clinical endpoint; Adverse effect; Clinical trial; Oncology; Discontinuation; Immunotherapy","score_opus":0.13587131473590172,"score_gpt":0.5253662221665132,"score_spread":0.38949490743061144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318904300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98319846,0.00026671673,0.00003890991,0.010253556,0.0042975717,0.0005093121,0.0000056488125,0.000012022606,0.0014178146],"genre_scores_gemma":[0.99353933,0.0035818291,0.00020112561,0.00078719656,0.0011605613,0.0000072321413,0.000002875239,0.000015307403,0.0007045339],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99610776,0.00030699096,0.0025483305,0.00018222257,0.0005399663,0.00031472632],"domain_scores_gemma":[0.9962457,0.0011595027,0.0019542715,0.00025939048,0.00022298425,0.00015815297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002489077,0.0001390731,0.0017425562,0.00035361524,0.000030770098,0.0000055204696,0.0003208427,0.00019913547,0.00010956743],"category_scores_gemma":[0.0029518805,0.00008542178,0.00067636056,0.0010600367,0.00017344012,0.00009446281,0.000131235,0.00085423683,0.000008727328],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25557998,0.0054969033,0.17947698,0.00017854836,0.00061845174,0.0012684077,0.00020188719,0.0008188285,0.00129128,0.00012406659,0.014170587,0.5407741],"study_design_scores_gemma":[0.44738775,0.018439692,0.50242347,0.00020689926,0.0004668602,0.00006872544,0.0002281573,0.0005536965,0.000055667464,0.00011588365,0.029961472,0.00009171616],"about_ca_topic_score_codex":0.00004704038,"about_ca_topic_score_gemma":0.000054792818,"teacher_disagreement_score":0.5406824,"about_ca_system_score_codex":0.00023853198,"about_ca_system_score_gemma":0.001953786,"threshold_uncertainty_score":0.37112814},"labels":[],"label_agreement":null},{"id":"W4319068412","doi":"10.1200/jco.22.01990","title":"Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":512,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Carboplatin; Internal medicine; Hazard ratio; Lung cancer; Placebo; Chemotherapy; Oncology; Population; Clinical trial; Phases of clinical research; Cancer; Surgery; Confidence interval; Pathology; Immunotherapy; Cisplatin","score_opus":0.06809060181907818,"score_gpt":0.45897296203500015,"score_spread":0.390882360215922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319068412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842347,0.0007865348,0.000017045511,0.007465809,0.0017910074,0.00076906907,0.000006747158,0.0000116765195,0.0007286336],"genre_scores_gemma":[0.9927728,0.0033273553,0.000083271014,0.0024063585,0.00068324397,0.000014380007,0.0000013109643,0.000029190307,0.00068209384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958783,0.0004388987,0.0026977414,0.00022545457,0.0004422045,0.0003173961],"domain_scores_gemma":[0.9965092,0.0009112374,0.0018152032,0.00035774335,0.00024136866,0.00016526449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00384867,0.00017815453,0.0015952969,0.0002134469,0.000046489273,0.000007423046,0.00041229418,0.00031144003,0.000326031],"category_scores_gemma":[0.00038635265,0.00011045406,0.0006688491,0.0006602047,0.00021501751,0.000056328,0.00007812581,0.0010467803,0.000006510775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29794303,0.017449277,0.40707475,0.00026502032,0.0020401347,0.0014709358,0.004679912,0.00033485075,0.0088086175,0.0000129338405,0.03226704,0.22765353],"study_design_scores_gemma":[0.3414296,0.023713598,0.5937942,0.0003069689,0.0007979144,0.00011475443,0.0021880735,0.0015546619,0.0015790446,0.000051488285,0.03421496,0.0002547035],"about_ca_topic_score_codex":0.00033780193,"about_ca_topic_score_gemma":0.00045099357,"teacher_disagreement_score":0.22739883,"about_ca_system_score_codex":0.00036114603,"about_ca_system_score_gemma":0.002912971,"threshold_uncertainty_score":0.51674855},"labels":[],"label_agreement":null},{"id":"W4321018302","doi":"10.1200/jco.23.00041","title":"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bayer HealthCare","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Androgen deprivation therapy; Placebo; Oncology; Hormone therapy; Cancer; Pathology; Confidence interval; Breast cancer","score_opus":0.13009900985133552,"score_gpt":0.4793231230773755,"score_spread":0.34922411322603997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321018302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814925,0.0064938134,0.000008895338,0.010627133,0.00017094091,0.0011078451,0.0000721722,0.0000061199617,0.000020586613],"genre_scores_gemma":[0.9024942,0.09653679,0.000045130364,0.00048103297,0.00023275534,0.000047866684,0.000022360935,0.000012061466,0.00012777971],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969644,0.00097022596,0.0011975514,0.00022795414,0.00035779644,0.00028209807],"domain_scores_gemma":[0.9970301,0.0017990378,0.00063868257,0.00011816539,0.00013322878,0.000280808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004487393,0.00013716659,0.0009434316,0.0002056533,0.00005919768,0.000021255753,0.00007068708,0.00010571666,0.000009220934],"category_scores_gemma":[0.0013349373,0.00007740729,0.00012574643,0.00035761806,0.0003215752,0.00013658473,0.000033313787,0.0008165777,0.0000019891547],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59571505,0.0028460827,0.19611366,0.000035874957,0.00066793466,0.005104761,0.0034967114,0.000044065255,0.0004101517,0.000013738387,0.004342862,0.19120912],"study_design_scores_gemma":[0.4199222,0.014064035,0.55420595,0.00007991456,0.00040076437,0.00006767528,0.001203221,0.0035568834,0.000041954358,0.0006761822,0.005653342,0.00012786803],"about_ca_topic_score_codex":0.00023243931,"about_ca_topic_score_gemma":0.00016979457,"teacher_disagreement_score":0.35809228,"about_ca_system_score_codex":0.00015454795,"about_ca_system_score_gemma":0.0010697956,"threshold_uncertainty_score":0.35476694},"labels":[],"label_agreement":null},{"id":"W4321033178","doi":"10.1200/jco.22.01926","title":"Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Cohort; Dialysis; Kidney transplantation; Internal medicine; Proportional hazards model; Kidney cancer; Kidney disease; Cancer; Hazard ratio; Pediatrics; Transplantation; Confidence interval","score_opus":0.11918431756485869,"score_gpt":0.45373659315411263,"score_spread":0.33455227558925393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321033178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898983,0.00011805431,0.0014187131,0.0075027896,0.00059969694,0.00037189937,0.000041567062,0.00000947031,0.00003947711],"genre_scores_gemma":[0.99166507,0.00060187007,0.0066051437,0.0006103057,0.000399587,0.000016327858,0.000026350845,0.000017269698,0.000058066882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960583,0.00020266935,0.0029886558,0.00017765464,0.0004006742,0.00017207835],"domain_scores_gemma":[0.99630046,0.0010416694,0.0018716062,0.00012418217,0.00040325103,0.00025885124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050481926,0.00011204883,0.001272816,0.00027795232,0.000019958721,0.0000027902383,0.0001023576,0.0003046937,0.00001638223],"category_scores_gemma":[0.0033792295,0.00009416781,0.00021779536,0.00024360498,0.00011016204,0.000108827044,0.000046626992,0.00039814165,6.017626e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027194526,0.0016270061,0.9350511,0.0008369749,0.0005448214,0.000018769731,0.006024588,0.0008146407,0.0004836158,0.000060788276,0.002651591,0.04916664],"study_design_scores_gemma":[0.009282472,0.0023009274,0.9820668,0.0009090005,0.00022211153,0.00002572914,0.00030213772,0.0021974822,0.0011856866,0.00026067626,0.0011608474,0.00008610792],"about_ca_topic_score_codex":0.000059553313,"about_ca_topic_score_gemma":0.0011520721,"teacher_disagreement_score":0.049080532,"about_ca_system_score_codex":0.00011121669,"about_ca_system_score_gemma":0.0031459057,"threshold_uncertainty_score":0.5580701},"labels":[],"label_agreement":null},{"id":"W4321436832","doi":"10.1200/jco.22.01989","title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Grifols; Y-mAbs Therapeutics; Shionogi; Actuate Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Mirati Therapeutics; Les Laboratories Pierre Fabre; Helsinn; Merck KGaA; Sanofi; GlaxoSmithKline; Helsinn Therapeutics; Amgen; Celgene; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Pemetrexed; Medicine; Pembrolizumab; Carboplatin; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Hazard ratio; Phases of clinical research; Clinical trial; Surgery; Cisplatin; Chemotherapy; Cancer; Confidence interval; Immunotherapy","score_opus":0.11470995085224713,"score_gpt":0.4737687742129537,"score_spread":0.3590588233607066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321436832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870902,0.0013047737,0.000014394876,0.008936661,0.001498601,0.0006797449,0.000021059199,0.00001548937,0.000439105],"genre_scores_gemma":[0.9944464,0.002043131,0.00016564355,0.0020756754,0.00075659057,0.000019046938,0.0000039796923,0.000024422105,0.00046512348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964613,0.00049099885,0.0021136361,0.00025739486,0.00037599177,0.00030068675],"domain_scores_gemma":[0.99367285,0.004652299,0.0010607371,0.0002658516,0.00014480154,0.0002034516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003434363,0.0001894673,0.0015293881,0.0001805908,0.000071781265,0.000020104402,0.00025522054,0.0002755033,0.0002743461],"category_scores_gemma":[0.0011481735,0.00011141347,0.00038192613,0.0003992664,0.00017418519,0.00006509524,0.000097558455,0.0011139022,0.000010035911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032896627,0.0023273965,0.8705879,0.000025692902,0.0008116397,0.0011915575,0.0019768383,0.000022476226,0.00040680607,0.0000012226573,0.007744926,0.08200692],"study_design_scores_gemma":[0.10098632,0.008653657,0.880575,0.00009088382,0.00055445125,0.000028924333,0.002725719,0.00084606424,0.000031012936,0.00002211147,0.005364005,0.000121875266],"about_ca_topic_score_codex":0.0011767944,"about_ca_topic_score_gemma":0.0020410724,"teacher_disagreement_score":0.08188504,"about_ca_system_score_codex":0.00025953766,"about_ca_system_score_gemma":0.0015929029,"threshold_uncertainty_score":0.48394126},"labels":[],"label_agreement":null},{"id":"W4321612001","doi":"10.1200/jco.2023.41.4_suppl.tps284","title":"NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Circulating tumor DNA; Minimal residual disease; Microsatellite instability; Cancer; Stage (stratigraphy); Primary tumor; Surgical oncology; Disease; Metastasis; Microsatellite; Leukemia","score_opus":0.1064744249561399,"score_gpt":0.4555206512265185,"score_spread":0.3490462262703786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321612001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251467,0.00014961866,0.00049473956,0.0008056133,0.0051868227,0.00063945155,0.0001101449,0.00001288733,0.00008607367],"genre_scores_gemma":[0.9923287,0.00014296365,0.001665462,0.001271804,0.0044390736,0.000030982686,0.000016017637,0.00003946483,0.000065500615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947154,0.0010196011,0.0027499993,0.00062331004,0.0004267709,0.0004649025],"domain_scores_gemma":[0.9948896,0.0019124252,0.0013587341,0.00030583327,0.00063004723,0.00090336514],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006767814,0.0002469216,0.0010307012,0.00016768063,0.00017053138,0.000051879746,0.00045347,0.0002726829,0.00006733574],"category_scores_gemma":[0.020566264,0.0002302254,0.00043405758,0.00036581943,0.00012152593,0.00001710721,0.00053290353,0.00063197577,0.00001814257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017402835,0.003016075,0.7184269,0.000053063537,0.0010043716,0.0010663244,0.0007578926,0.010846383,0.046438877,0.0000074406476,0.048938792,0.15204108],"study_design_scores_gemma":[0.006121834,0.04206861,0.9006549,0.00018214874,0.0006276215,0.00010070829,0.0006291336,0.0010600927,0.0046820333,0.00010477694,0.043121524,0.00064658443],"about_ca_topic_score_codex":0.000034466662,"about_ca_topic_score_gemma":0.0005878729,"teacher_disagreement_score":0.18222806,"about_ca_system_score_codex":0.00017425221,"about_ca_system_score_gemma":0.0032552534,"threshold_uncertainty_score":0.9876839},"labels":[],"label_agreement":null},{"id":"W4321765041","doi":"10.1200/jco.22.00074","title":"Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Antibiotics; Proportional hazards model; Cancer; Retrospective cohort study; Cohort; Population; Medical prescription; Confidence interval; Pharmacology; Environmental health","score_opus":0.06076598604988435,"score_gpt":0.4486368202333411,"score_spread":0.38787083418345675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321765041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973088,0.000060749895,0.0000012289977,0.0011595772,0.00072865665,0.00061880134,0.000010778012,0.000011562062,0.00009986454],"genre_scores_gemma":[0.99915344,0.00010531258,0.000034398596,0.00007082081,0.0005211366,0.000011254281,0.000008068287,0.000019673922,0.00007592715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730027,0.00028822076,0.0017080281,0.00018341177,0.00032068123,0.0001994177],"domain_scores_gemma":[0.9977447,0.0005398217,0.0010945902,0.00019522545,0.00024923222,0.0001764474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008922725,0.00015719264,0.001416181,0.00025800348,0.000027443708,0.0000045413353,0.00006800093,0.00016081949,0.000109796805],"category_scores_gemma":[0.0002648866,0.00008953489,0.0005000686,0.00034804194,0.00004423491,0.000052386255,0.000012952738,0.00047479488,0.000004536693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013748176,0.007888301,0.9572608,0.00002965667,0.00045946173,0.00043078233,0.00032746565,0.0016017447,0.00010244632,0.0000027239944,0.00004235324,0.018106088],"study_design_scores_gemma":[0.029075,0.10717499,0.86250836,0.000530881,0.00024851487,0.000017932165,0.00020637506,0.00005389176,0.000086484695,0.0000052857918,0.000030037847,0.000062259256],"about_ca_topic_score_codex":0.002423191,"about_ca_topic_score_gemma":0.004007007,"teacher_disagreement_score":0.09928669,"about_ca_system_score_codex":0.0006782778,"about_ca_system_score_gemma":0.0018191787,"threshold_uncertainty_score":0.3663156},"labels":[],"label_agreement":null},{"id":"W4323352826","doi":"10.1200/jco.22.01972","title":"MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Medical Research Council; Cancer Research UK","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Discontinuation; Internal medicine; Gastroenterology; Cohort; Clinical endpoint; Surgery; Clinical trial; Bone marrow","score_opus":0.14049935953026033,"score_gpt":0.4583511375790651,"score_spread":0.31785177804880477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323352826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164636,0.00015200909,0.00003281108,0.015162467,0.00060353114,0.0008716294,0.00002073539,0.000020877489,0.0014896026],"genre_scores_gemma":[0.99301624,0.000928675,0.0033226584,0.0007485406,0.00089379225,0.00013492264,0.000038650676,0.000030123829,0.0008863791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997063,0.0002715342,0.0017502886,0.0002673285,0.0003176848,0.00033019422],"domain_scores_gemma":[0.9942204,0.0038453087,0.000967496,0.00016269648,0.00046331502,0.00034079998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014386531,0.00020786865,0.0014662857,0.00031142533,0.000058653986,0.000015171501,0.000077154604,0.0003047253,0.00006358646],"category_scores_gemma":[0.0014972105,0.00012959274,0.0003976636,0.00030203332,0.00011575332,0.000115836825,0.000021952002,0.00033685047,0.000047260553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017730035,0.012121985,0.7355753,0.000107011714,0.0008944557,0.004008695,0.0004892224,0.000040915613,0.00019007073,0.0019966594,0.0070071537,0.2198385],"study_design_scores_gemma":[0.04648079,0.08596678,0.810272,0.00033171065,0.0005440967,0.0003142065,0.00034164827,0.00020479404,0.0012529936,0.00074012415,0.053400885,0.00015002108],"about_ca_topic_score_codex":0.0000343841,"about_ca_topic_score_gemma":0.00020287812,"teacher_disagreement_score":0.21968849,"about_ca_system_score_codex":0.00042967667,"about_ca_system_score_gemma":0.0012058775,"threshold_uncertainty_score":0.52846384},"labels":[],"label_agreement":null},{"id":"W4324027514","doi":"10.1200/jco.22.00624","title":"Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences","keywords":"Medicine; Retroperitoneal lymph node dissection; Seminoma; Testicular cancer; Lymph node; Radiation therapy; Surgery; Chemotherapy; Retroperitoneal space; Dissection (medical); Internal medicine","score_opus":0.12481592593201406,"score_gpt":0.4408074869296148,"score_spread":0.31599156099760073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324027514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965841,0.00065339095,0.000115047726,0.00089616916,0.00091243524,0.00073084794,0.000037956957,0.000027763785,0.000042286814],"genre_scores_gemma":[0.9958881,0.00018272712,0.0027799527,0.00013979488,0.00077526603,0.000053429205,0.000047270132,0.000045439883,0.00008798052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955645,0.00040508035,0.002781008,0.00032824188,0.0005334189,0.00038771145],"domain_scores_gemma":[0.99330896,0.0035129383,0.0018900865,0.0002754154,0.00053806877,0.00047453778],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022420592,0.00024464904,0.002283713,0.00043284142,0.000070693844,0.000012282528,0.00012094784,0.0002680787,0.000016369084],"category_scores_gemma":[0.0091328295,0.00016468475,0.0007774414,0.00067243155,0.00022140608,0.00014515508,0.000047441994,0.00032726798,0.00000463535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39039955,0.028496617,0.49438807,0.0003582795,0.0017485634,0.015561538,0.0002369354,0.00006970618,0.0013215507,0.00001892938,0.00082450366,0.06657577],"study_design_scores_gemma":[0.23820138,0.090449154,0.66358364,0.0006768107,0.002854548,0.0014642469,0.00021357708,0.0014528355,0.00026266545,0.00006518612,0.00055437145,0.0002216145],"about_ca_topic_score_codex":0.00006727261,"about_ca_topic_score_gemma":0.000010275438,"teacher_disagreement_score":0.16919555,"about_ca_system_score_codex":0.0002664745,"about_ca_system_score_gemma":0.0022199703,"threshold_uncertainty_score":0.99921364},"labels":[],"label_agreement":null},{"id":"W4324136146","doi":"10.1200/jco.2023.41.6_suppl.653","title":"2022 Global patient survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary; Kidney Foundation of Canada","funders":"","keywords":"Medicine; Psychosocial; Family medicine; Quality of life (healthcare); Best practice; Kidney cancer; Cancer; Renal cell carcinoma; Nursing; Oncology; Internal medicine; Psychiatry","score_opus":0.1485751672798912,"score_gpt":0.3877245480185314,"score_spread":0.2391493807386402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850938,0.0024821928,0.00010237922,0.00036908282,0.0011768123,0.000114658265,0.00013256383,0.000004044819,0.0105244685],"genre_scores_gemma":[0.9915066,0.0075535784,0.00038904243,0.00016196398,0.00016575128,0.000005721389,0.0000037213815,0.000008800774,0.00020487295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570805,0.00008966968,0.0036841074,0.0002338655,0.00006886806,0.0002154312],"domain_scores_gemma":[0.9938085,0.0006082426,0.005039208,0.00021771515,0.00015446715,0.00017183622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003173676,0.00010931724,0.0013220635,0.00015644345,0.000026026726,0.000008254105,0.00024217994,0.00020429537,0.00013811723],"category_scores_gemma":[0.0015887016,0.000108841254,0.0002567593,0.0002911436,0.00024166447,0.00017038186,0.00014716646,0.00022617973,0.000013419125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039772433,0.00032674504,0.95461977,0.00003674,0.00016355624,0.00010291241,0.00031742654,0.00012770304,0.000004268247,0.0023850119,0.010401842,0.031116307],"study_design_scores_gemma":[0.0015854039,0.0023750984,0.94120985,0.000026339003,0.00002845945,0.000009180096,0.00023037253,0.00011192556,0.00005522209,0.0058047264,0.04845132,0.00011209949],"about_ca_topic_score_codex":0.00058302854,"about_ca_topic_score_gemma":0.00008038788,"teacher_disagreement_score":0.038049478,"about_ca_system_score_codex":0.000094474606,"about_ca_system_score_gemma":0.00016857297,"threshold_uncertainty_score":0.44384176},"labels":[],"label_agreement":null},{"id":"W4324136162","doi":"10.1200/jco.2023.41.6_suppl.15","title":"Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Disease; Prostate cancer; Proportional hazards model; Androgen deprivation therapy; Oncology; Cancer","score_opus":0.08111143485991455,"score_gpt":0.4650320885907761,"score_spread":0.38392065373086154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98831284,0.002190602,0.000013050831,0.0085567525,0.00004167381,0.0008403383,0.000025738822,0.0000040939613,0.000014924262],"genre_scores_gemma":[0.98525286,0.014403913,0.000026318718,0.00019263926,0.000056549863,0.00001156164,0.000014471659,0.000008469575,0.000033196524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778426,0.0006910257,0.0008625425,0.00018638572,0.0003224545,0.00015335265],"domain_scores_gemma":[0.99736154,0.0015876574,0.0004811311,0.00012965054,0.00011578629,0.0003242093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029775072,0.00010250807,0.0006081852,0.00017554233,0.000049515646,0.000011864193,0.000061742125,0.00006877162,0.000006310531],"category_scores_gemma":[0.0016086829,0.000056093657,0.00004790835,0.00028368496,0.00031635768,0.0001057264,0.000031276493,0.00046047563,4.4493106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04535007,0.0049401526,0.88596565,0.00002702724,0.00012501053,0.0006801335,0.0005488471,0.000009380772,0.000041586023,0.000011187882,0.00028379943,0.062017154],"study_design_scores_gemma":[0.07246203,0.010926702,0.913882,0.00007577386,0.00016767648,0.000014759894,0.0004435399,0.00065800454,0.000004621502,0.00041809864,0.00089639716,0.000050370505],"about_ca_topic_score_codex":0.000029918336,"about_ca_topic_score_gemma":0.000029010804,"teacher_disagreement_score":0.061966784,"about_ca_system_score_codex":0.000050509225,"about_ca_system_score_gemma":0.00049464166,"threshold_uncertainty_score":0.2287433},"labels":[],"label_agreement":null},{"id":"W4324136172","doi":"10.1200/jco.2023.41.6_suppl.654","title":"Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Clear cell; Clear cell renal cell carcinoma; Odds ratio; Proportional hazards model; Oncology; Logistic regression","score_opus":0.06000292314472487,"score_gpt":0.3742030261254033,"score_spread":0.3142001029806784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970542,0.000051161085,0.00011460994,0.001106384,0.00043658423,0.0007978112,0.00002284582,0.000037536,0.00037886304],"genre_scores_gemma":[0.9962358,0.00037994966,0.0018213021,0.0005534478,0.0003278164,0.00001919129,0.00016010371,0.00007629655,0.00042612568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99342597,0.0006090219,0.0042269905,0.00045011562,0.0008777161,0.00041016843],"domain_scores_gemma":[0.9899901,0.0025666934,0.005152155,0.0005535311,0.0012425397,0.00049496396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019135473,0.00038870279,0.0031671172,0.00033350542,0.000067090376,0.000009741938,0.00023895029,0.00050809735,0.00011570378],"category_scores_gemma":[0.0007528968,0.00022366176,0.0008009848,0.00055928744,0.00048529427,0.00020070166,0.00003851369,0.00091466255,0.00001815186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032261018,0.004309547,0.94850904,0.000080552054,0.00061791774,0.0010891656,0.00005208541,0.00014959583,0.0012653245,0.0000011787498,0.00012548568,0.01153908],"study_design_scores_gemma":[0.04689177,0.067031115,0.87976825,0.0002504288,0.00065181614,0.000026590636,0.000018177056,0.00013333895,0.0036650451,0.000003247741,0.0013712932,0.00018889812],"about_ca_topic_score_codex":0.000049086662,"about_ca_topic_score_gemma":0.00006809839,"teacher_disagreement_score":0.06874077,"about_ca_system_score_codex":0.00020687675,"about_ca_system_score_gemma":0.0016141316,"threshold_uncertainty_score":0.91206616},"labels":[],"label_agreement":null},{"id":"W4324136173","doi":"10.1200/jco.2023.41.6_suppl.45","title":"Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with <sup>18</sup>F-DCFPyL PSMA-PET: A regional cohort analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Western University; St. Joseph’s Healthcare Hamilton; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Lymph node; Biochemical recurrence; Radiation therapy; Stage (stratigraphy); Cohort; Adjuvant; Internal medicine; Urology; Nuclear medicine; Cancer; Oncology; Prostatectomy","score_opus":0.06048129559350125,"score_gpt":0.43402948002501357,"score_spread":0.37354818443151233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096066,0.00031338082,0.000023749044,0.0077995146,0.00007901238,0.00070370064,0.000050540442,0.00001117709,0.00005825785],"genre_scores_gemma":[0.99473965,0.0023129273,0.00066213,0.00082103495,0.00028653888,0.000076491844,0.000053154716,0.000035695302,0.0010123837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962109,0.0004336167,0.0016469002,0.0003384261,0.00094052014,0.00042965927],"domain_scores_gemma":[0.9968468,0.00068090373,0.0010870895,0.00027998097,0.00075186737,0.0003533773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018711223,0.00021836093,0.0019482147,0.00063281506,0.000031929172,0.000010328634,0.00016889666,0.00019947121,0.0005461999],"category_scores_gemma":[0.00016403031,0.00011984481,0.0003817627,0.0010901889,0.00026261967,0.0001357239,0.000034137698,0.0010133641,0.000003702741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053517047,0.0013073195,0.9308487,0.000072443836,0.0043656933,0.0018675575,0.00045699775,0.0010532193,0.000005507885,0.0000013667559,0.0021945653,0.0043095867],"study_design_scores_gemma":[0.024778163,0.012742389,0.95491385,0.00033283624,0.0010273306,0.00002108348,0.0002508461,0.00027286215,0.000011499409,0.0000117794025,0.005510941,0.00012642103],"about_ca_topic_score_codex":0.0001573276,"about_ca_topic_score_gemma":0.00096450903,"teacher_disagreement_score":0.028738884,"about_ca_system_score_codex":0.00038041722,"about_ca_system_score_gemma":0.0018113579,"threshold_uncertainty_score":0.5980506},"labels":[],"label_agreement":null},{"id":"W4324136177","doi":"10.1200/jco.2023.41.6_suppl.410","title":"European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Pathological; Proportional hazards model; Testicular cancer; Stage (stratigraphy); Internal medicine; Pagetoid; Oncology; Hazard ratio; Nomogram; Rete testis; Pathological staging; Cancer; Gynecology; Urology; Chemotherapy; Confidence interval","score_opus":0.2109341375656655,"score_gpt":0.4787112081718409,"score_spread":0.2677770706061754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959183,0.00026141404,0.00036442807,0.0018763917,0.0006306325,0.0007264646,0.00016537256,0.00001973611,0.00003729384],"genre_scores_gemma":[0.9958655,0.0008432651,0.0021489977,0.0002723089,0.0006461179,0.000016894503,0.000079127094,0.000031058997,0.00009672512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537504,0.0010296783,0.0026640769,0.00028762853,0.00038178134,0.00026177312],"domain_scores_gemma":[0.9862059,0.007537538,0.0044435286,0.00017488476,0.0013100704,0.00032808818],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026830854,0.0001617677,0.0012605338,0.00014528172,0.000028450306,0.0000059723975,0.000119200624,0.00028723493,0.000026065069],"category_scores_gemma":[0.043052066,0.00010884232,0.00038841725,0.0002709706,0.00008614188,0.00007599136,0.00003478145,0.00049476506,0.0000082177885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003721921,0.0021357078,0.8571317,0.00003274455,0.0006173207,0.00010667811,0.00003124493,0.000060381157,0.000007764053,0.000006276333,0.0010190743,0.13512915],"study_design_scores_gemma":[0.0165274,0.013198087,0.96374613,0.000100253164,0.00077861967,0.0000043101513,0.000037428505,0.0006940046,9.4665825e-7,0.00006866417,0.00475382,0.00009035721],"about_ca_topic_score_codex":0.00008381237,"about_ca_topic_score_gemma":0.00022748199,"teacher_disagreement_score":0.1350388,"about_ca_system_score_codex":0.00022422597,"about_ca_system_score_gemma":0.0012492663,"threshold_uncertainty_score":0.96500874},"labels":[],"label_agreement":null},{"id":"W4324136183","doi":"10.1200/jco.2023.41.6_suppl.300","title":"Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cégep de Rimouski; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"AstraZeneca Canada","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Cancer; Urology; Stage (stratigraphy); Logistic regression; Internal medicine; Surgery","score_opus":0.2033276439089874,"score_gpt":0.4985545941071959,"score_spread":0.2952269501982085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912292,0.0020877346,0.000023252749,0.004955195,0.00027055782,0.0013167837,0.00008163564,0.000011556398,0.000024127314],"genre_scores_gemma":[0.9733914,0.024109574,0.000467518,0.00035255338,0.000703818,0.000048687063,0.00037267752,0.00003189142,0.00052184623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575615,0.0013454332,0.001948633,0.00030171953,0.00041440848,0.0002336434],"domain_scores_gemma":[0.9926692,0.005176859,0.001362155,0.00027080753,0.00026130097,0.000259662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037672166,0.0001774694,0.0028867635,0.00019124652,0.000032542015,0.000025085914,0.00013590019,0.00014759015,0.00012428054],"category_scores_gemma":[0.0015206828,0.00007996596,0.0001279096,0.00022169037,0.00028860112,0.0002073153,0.000053147447,0.0005408465,0.000002270914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40461835,0.0005025773,0.53269583,0.000014553362,0.0009819906,0.00032785724,0.00005898406,0.0000050604576,0.000015552936,1.9898658e-7,0.00030618263,0.06047285],"study_design_scores_gemma":[0.37997955,0.007932613,0.61093765,0.00031499326,0.00047861875,0.000008726163,0.000010889748,0.00010445917,0.000019326357,0.000017179047,0.00013430287,0.00006170351],"about_ca_topic_score_codex":0.00012939994,"about_ca_topic_score_gemma":0.0006135257,"teacher_disagreement_score":0.07824182,"about_ca_system_score_codex":0.00021419297,"about_ca_system_score_gemma":0.0008910658,"threshold_uncertainty_score":0.3260917},"labels":[],"label_agreement":null},{"id":"W4324136206","doi":"10.1200/jco.2023.41.6_suppl.636","title":"The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Regional Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Sunitinib; Internal medicine; Ipilimumab; Regimen; Nivolumab; Oncology; Proportional hazards model; Clear cell renal cell carcinoma; Progression-free survival; Cancer; Surgery; Immunotherapy; Chemotherapy","score_opus":0.11396875939156738,"score_gpt":0.43938296977762364,"score_spread":0.3254142103860563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837122,0.0012226879,0.00001010342,0.010820329,0.0012494245,0.0004461587,0.0000062728927,0.0000061109754,0.0025267329],"genre_scores_gemma":[0.99498713,0.0025485104,0.00031499827,0.0007485453,0.00029152498,0.000020633202,0.0000024700441,0.000027374545,0.0010588289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946447,0.0012278613,0.0025899997,0.00024180593,0.0008528247,0.0004428325],"domain_scores_gemma":[0.99141616,0.0058769835,0.0017554502,0.00045281532,0.00031007986,0.00018853176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004492298,0.00023185351,0.0016500634,0.00014088136,0.00009218704,0.000017966431,0.00060500775,0.00017773778,0.00015543483],"category_scores_gemma":[0.00051784137,0.0001069649,0.0007058685,0.00042756693,0.0003850653,0.000078183235,0.00008548811,0.001077113,0.000020557141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047413623,0.0017242165,0.9685785,0.00006932453,0.00034552708,0.0019166948,0.0037557643,0.00011374102,0.0014393443,0.00003677205,0.0028003466,0.014478388],"study_design_scores_gemma":[0.008077001,0.00455389,0.9686937,0.0000439237,0.00024542763,0.000042854783,0.0044890298,0.00012366023,0.0018177832,0.00007945637,0.0117298905,0.00010341897],"about_ca_topic_score_codex":0.00035203432,"about_ca_topic_score_gemma":0.00034090635,"teacher_disagreement_score":0.0143749695,"about_ca_system_score_codex":0.00021072275,"about_ca_system_score_gemma":0.0013454001,"threshold_uncertainty_score":0.46795797},"labels":[],"label_agreement":null},{"id":"W4324136255","doi":"10.1200/jco.2023.41.6_suppl.460","title":"FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Gemcitabine; Cisplatin; Neoadjuvant therapy; Chemotherapy; Vinblastine; Chemoradiotherapy; Radiology; Positron emission tomography; Prospective cohort study; Internal medicine; Oncology; Nuclear medicine; Cancer; Urology; Breast cancer","score_opus":0.10934851904634206,"score_gpt":0.5055802606982742,"score_spread":0.39623174165193215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98093975,0.00013164725,0.000029646442,0.016494771,0.00089831627,0.0009461972,0.0000056757985,0.000022440607,0.0005315439],"genre_scores_gemma":[0.99288887,0.000101555175,0.00070673745,0.0055895788,0.0004271635,0.000080204816,0.0000012412735,0.000044698147,0.00015995359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957258,0.0009695572,0.0020394304,0.0004022225,0.00044474064,0.00041823942],"domain_scores_gemma":[0.99544173,0.0029293823,0.0007781456,0.00023304082,0.00029634312,0.00032133603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043222834,0.00023344679,0.001519685,0.0006545504,0.000042108833,0.0000285322,0.00019298516,0.00006929062,0.00021226592],"category_scores_gemma":[0.0034406155,0.00017973401,0.00028402187,0.0007992222,0.00010914914,0.0001659099,0.00006515406,0.0010341618,0.000024893936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02237134,0.0036420696,0.82389843,0.000018470375,0.00021525062,0.018181486,0.0018706275,0.00024014624,0.0021076861,0.0000010005598,0.000857132,0.12659638],"study_design_scores_gemma":[0.028739749,0.009863107,0.95524335,0.0005456346,0.00013432287,0.00015254281,0.0028910337,0.0003025401,0.00039536934,0.000092543996,0.0014848013,0.00015501853],"about_ca_topic_score_codex":0.00056087587,"about_ca_topic_score_gemma":0.002118806,"teacher_disagreement_score":0.13134491,"about_ca_system_score_codex":0.001086671,"about_ca_system_score_gemma":0.0049584378,"threshold_uncertainty_score":0.8796056},"labels":[],"label_agreement":null},{"id":"W4324136257","doi":"10.1200/jco.2023.41.6_suppl.673","title":"Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; BC Cancer Agency; University of Alberta; University of Calgary","funders":"Pfizer","keywords":"Medicine; Sunitinib; Cabozantinib; Axitinib; Pazopanib; Nivolumab; Ipilimumab; Internal medicine; Oncology; Renal cell carcinoma; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.09932302570924442,"score_gpt":0.43582544593874145,"score_spread":0.33650242022949706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968469,0.000093574075,0.000009934272,0.00051501824,0.000691746,0.00059109647,0.000020011621,0.0000088723555,0.0012228289],"genre_scores_gemma":[0.998498,0.00018388868,0.0008045663,0.000056516114,0.0001609631,0.000012018069,0.00006172056,0.00003885056,0.00018344817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99455494,0.0008379384,0.003246128,0.00029861025,0.00067950954,0.00038284875],"domain_scores_gemma":[0.99194276,0.0040534344,0.002750695,0.0003360667,0.0006294564,0.00028757416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020583586,0.00032808195,0.002977992,0.0004361449,0.000032770047,0.0000046979944,0.00017164918,0.00030614948,0.00011088812],"category_scores_gemma":[0.0009631904,0.00019933592,0.0011847924,0.00043483556,0.00015369445,0.00011471437,0.00005556633,0.0005259796,0.000018077066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021411207,0.013208187,0.9513428,0.00007203495,0.0012736119,0.0012232867,0.0002830021,0.0011283504,0.00034489797,0.000015904938,0.00018844697,0.009508261],"study_design_scores_gemma":[0.04770579,0.13347605,0.81645155,0.00015539421,0.00094117236,0.000040260296,0.000055800363,0.00017638634,0.0005700185,0.00010833687,0.00020200375,0.00011722077],"about_ca_topic_score_codex":0.00045497375,"about_ca_topic_score_gemma":0.0001651908,"teacher_disagreement_score":0.13489123,"about_ca_system_score_codex":0.0016411077,"about_ca_system_score_gemma":0.0020586692,"threshold_uncertainty_score":0.8128683},"labels":[],"label_agreement":null},{"id":"W4324136259","doi":"10.1200/jco.2023.41.6_suppl.690","title":"Outcomes of partial nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian multi-institutional collaborative.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; McGill University Health Centre; University of Ottawa; Université Laval; Sunnybrook Health Science Centre; St. Boniface Hospital; Ottawa Hospital; St. Joseph’s Healthcare Hamilton; University of Manitoba; Dalhousie University; University of Toronto; McMaster University; University of British Columbia","funders":"","keywords":"Medicine; Chromophobe cell; Nephrectomy; Renal cell carcinoma; Clear cell; Histology; Internal medicine; Urology; Cancer; Kidney cancer; Pathological; Gastroenterology; Surgery; Kidney","score_opus":0.17107211845663586,"score_gpt":0.45926812666341765,"score_spread":0.2881960082067818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838645,0.000097704025,0.00031407096,0.008091008,0.0011686741,0.0007644802,0.00054547435,0.000010982069,0.00062116893],"genre_scores_gemma":[0.9685143,0.00007563734,0.029307654,0.0007860687,0.00077129586,0.000034981113,0.00011845367,0.000018811541,0.00037275057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556184,0.00030887246,0.003079306,0.00026110234,0.00043890093,0.0003500011],"domain_scores_gemma":[0.9908441,0.005507106,0.0017130796,0.00022230815,0.00092334993,0.0007901079],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026642343,0.00019856985,0.002019575,0.00034181835,0.00007322239,0.000008788072,0.00017162092,0.00022477661,0.00006326355],"category_scores_gemma":[0.0108388085,0.00012942177,0.0006659037,0.00038713255,0.00029408,0.000094658906,0.000032138472,0.0004833355,0.000042392934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081516325,0.008983649,0.66909254,0.0002522075,0.012316417,0.027849847,0.0029122375,0.0022561653,0.0047705863,0.0006280086,0.09181539,0.09760664],"study_design_scores_gemma":[0.04210693,0.011100505,0.87056446,0.00021549399,0.00098034,0.00012999373,0.00037812252,0.0018665055,0.0012996474,0.0002466941,0.070954666,0.00015661864],"about_ca_topic_score_codex":0.004711219,"about_ca_topic_score_gemma":0.014223425,"teacher_disagreement_score":0.20147195,"about_ca_system_score_codex":0.00038853724,"about_ca_system_score_gemma":0.010879134,"threshold_uncertainty_score":0.9974933},"labels":[],"label_agreement":null},{"id":"W4324136271","doi":"10.1200/jco.2023.41.6_suppl.600","title":"Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Sunitinib; Pazopanib; Cohort; Internal medicine; Brain metastasis; Oncology; Clear cell renal cell carcinoma; Cancer; Urology; Gastroenterology; Database; Metastasis","score_opus":0.09916175054994858,"score_gpt":0.36863244658691724,"score_spread":0.26947069603696866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846402,0.00037362505,0.00011216574,0.010245369,0.00041856704,0.00064953533,0.0030714073,0.00002348386,0.00046565846],"genre_scores_gemma":[0.99026924,0.00013918451,0.0053812475,0.0015040141,0.00044503107,0.000018077095,0.0017109594,0.00006118234,0.00047104948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929111,0.0010410402,0.0035556774,0.0006117395,0.0014435669,0.00043689494],"domain_scores_gemma":[0.97554815,0.018215362,0.0038800554,0.000824114,0.0010521065,0.00048020604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002312359,0.00048762647,0.0024133655,0.00027738215,0.00009967274,0.000029095456,0.00062941236,0.00019926393,0.00034431444],"category_scores_gemma":[0.0023781369,0.0002374532,0.0006244729,0.00042355948,0.0005532313,0.00021052998,0.00017718943,0.00097320764,0.00003162035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044831157,0.0039533917,0.9254457,0.000033690558,0.0026756246,0.003430443,0.00059428497,0.00019898669,0.0007012245,0.000004811495,0.016172696,0.001958001],"study_design_scores_gemma":[0.04850193,0.018444752,0.91682535,0.00013468374,0.0029166788,0.000036542304,0.00052927574,0.00014140675,0.0056653027,0.000044214303,0.0065301214,0.0002297513],"about_ca_topic_score_codex":0.0016560033,"about_ca_topic_score_gemma":0.0010209524,"teacher_disagreement_score":0.017362924,"about_ca_system_score_codex":0.0002287472,"about_ca_system_score_gemma":0.0015760732,"threshold_uncertainty_score":0.96830606},"labels":[],"label_agreement":null},{"id":"W4324136309","doi":"10.1200/jco.2023.41.6_suppl.19","title":"Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Placebo; Interim analysis; Internal medicine; Pembrolizumab; Randomization; Abiraterone acetate; Oncology; Prednisone; Randomized controlled trial; Androgen deprivation therapy; Surgery; Cancer","score_opus":0.21805030031091002,"score_gpt":0.538259259351251,"score_spread":0.32020895904034097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879789,0.00052446884,0.00008092022,0.0044281958,0.0008920458,0.005728362,0.00007841203,0.000024942403,0.00026377323],"genre_scores_gemma":[0.99438596,0.001056214,0.0007970362,0.0002495708,0.00059168634,0.00062103535,0.00007463136,0.000045383236,0.0021784885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949591,0.0005694353,0.0026732401,0.0003538971,0.00092691946,0.0005173687],"domain_scores_gemma":[0.9925087,0.0032342377,0.0017599023,0.00023852596,0.001721201,0.0005374001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046587996,0.0002665655,0.002756926,0.0003411428,0.00014273408,0.000040528994,0.00018712008,0.00015715588,0.00011881602],"category_scores_gemma":[0.0015215733,0.00014520557,0.00062020356,0.00046918847,0.00037620735,0.00021138729,0.000048358248,0.00074084784,0.000017653083],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9564133,0.0067371135,0.008569205,0.0001379909,0.0031661908,0.0009657637,0.0005924656,0.00013762305,0.000019904872,0.00003424853,0.001969626,0.021256559],"study_design_scores_gemma":[0.93775994,0.043979254,0.009901082,0.0001447451,0.0026054138,0.000028117662,0.0005167478,0.00036369002,0.000038113692,0.0001831141,0.004325646,0.0001541173],"about_ca_topic_score_codex":0.00008706662,"about_ca_topic_score_gemma":0.00020291367,"teacher_disagreement_score":0.03724214,"about_ca_system_score_codex":0.00042010527,"about_ca_system_score_gemma":0.005305507,"threshold_uncertainty_score":0.9411742},"labels":[],"label_agreement":null},{"id":"W4324136360","doi":"10.1200/jco.2023.41.6_suppl.660","title":"Improved health-related quality of life (HR-QOL) with use of an online mindfulness tool in patients with metastatic renal cell carcinoma (mRCC) receiving immunotherapy (IO).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Mindfulness; Quality of life (healthcare); Anxiety; Population; Internal medicine; Cancer; Psychological intervention; Worry; Nivolumab; Ipilimumab; Physical therapy; Oncology; Immunotherapy; Clinical psychology; Psychiatry; Nursing","score_opus":0.15220887129809124,"score_gpt":0.4205057916142931,"score_spread":0.26829692031620184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775916,0.00015681333,0.000114279916,0.0010470777,0.00043826268,0.00040634436,0.00005389861,0.000009217471,0.000014937967],"genre_scores_gemma":[0.9972858,0.00003458123,0.001756911,0.00066796585,0.00010354853,0.000005871426,0.000042218373,0.000033799748,0.000069318616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929636,0.001536322,0.004334222,0.00025365473,0.0006002668,0.00031190473],"domain_scores_gemma":[0.9917368,0.0023798672,0.004365158,0.00036509053,0.0008659184,0.0002871325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047584316,0.00019441468,0.002599873,0.0002913462,0.000026777278,0.0000060698976,0.00017274592,0.00023042221,0.00006690544],"category_scores_gemma":[0.0015051177,0.00012770224,0.00027684038,0.0006499434,0.00022876286,0.0001992083,0.000034330435,0.0009987262,6.714909e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06689795,0.0053346623,0.8185429,0.00036569714,0.00046823296,0.000117918484,0.0013858723,0.000167951,0.00021564803,0.0000083113155,0.000113948714,0.1063809],"study_design_scores_gemma":[0.024103332,0.035580367,0.9382499,0.0002816067,0.00013587206,0.0000126833165,0.00082768605,0.0001785815,0.0002704049,0.00003319063,0.00019566728,0.00013070078],"about_ca_topic_score_codex":0.0027286017,"about_ca_topic_score_gemma":0.0069859736,"teacher_disagreement_score":0.119707,"about_ca_system_score_codex":0.00017125436,"about_ca_system_score_gemma":0.0031991315,"threshold_uncertainty_score":0.5675122},"labels":[],"label_agreement":null},{"id":"W4324136387","doi":"10.1200/jco.2023.41.6_suppl.449","title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment-weighted analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Dalhousie University; Queen's University; McMaster University; University of British Columbia; McGill University Health Centre; McGill University; University of Ottawa; University of Calgary; Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital; Université de Sherbrooke; Western University; University of Toronto","funders":"","keywords":"Medicine; Bladder cancer; Radiation therapy; Urology; Pelvis; Lymph node; Confounding; Internal medicine; Oncology; Randomized controlled trial; Cancer; Surgery","score_opus":0.09554304253305543,"score_gpt":0.42880769995618473,"score_spread":0.3332646574231293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673647,0.00007906271,0.000047580404,0.001615641,0.00038800464,0.000787181,0.00018987797,0.000016299178,0.00013991016],"genre_scores_gemma":[0.99602747,0.00059822644,0.0019724995,0.00044911102,0.000501618,0.000056532783,0.0001601105,0.000022746975,0.0002116871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735945,0.00019503878,0.001571454,0.00028252302,0.0003535649,0.00023798404],"domain_scores_gemma":[0.9956515,0.001099782,0.0015935479,0.00026259653,0.0010309762,0.00036161617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007175437,0.0001791886,0.0016535642,0.00029089648,0.000048081238,0.0000059377835,0.00010634391,0.00026065428,0.00011887136],"category_scores_gemma":[0.000563634,0.00011107945,0.0006627274,0.0006394157,0.00015089718,0.0001672285,0.000014286672,0.00019598003,0.0000048096954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006055786,0.0042485194,0.8117891,0.00003935386,0.0055471165,0.000031235515,0.00034593945,0.00025861646,0.00003169292,0.000013590447,0.00064589083,0.17099316],"study_design_scores_gemma":[0.023274617,0.042950667,0.9177215,0.00003663647,0.00835838,0.0000023805858,0.00009851165,0.00039698617,0.00014615175,0.00044624228,0.0064684665,0.00009944843],"about_ca_topic_score_codex":0.00023366074,"about_ca_topic_score_gemma":0.0015460287,"teacher_disagreement_score":0.17089371,"about_ca_system_score_codex":0.00038206,"about_ca_system_score_gemma":0.0018523147,"threshold_uncertainty_score":0.45296884},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4324136398","doi":"10.1200/jco.2023.41.6_suppl.22","title":"Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Cabazitaxel; Nivolumab; Docetaxel; Abiraterone acetate; Prostate cancer; Cohort; Prednisone; Randomized controlled trial; Oncology; Taxane; Chemotherapy; Clinical trial; Cancer; Androgen deprivation therapy; Breast cancer; Immunotherapy","score_opus":0.2058361179828932,"score_gpt":0.5215913805671609,"score_spread":0.3157552625842677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8843901,0.0046380716,0.00004844168,0.094455205,0.0017687224,0.006257697,0.008245488,0.000021451748,0.00017482367],"genre_scores_gemma":[0.87043655,0.101957165,0.0026219403,0.0028547966,0.006410008,0.0026166034,0.0025982969,0.00011229757,0.010392358],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951853,0.00084333506,0.0028191644,0.00024619338,0.00059449364,0.0003114956],"domain_scores_gemma":[0.96406525,0.03242926,0.002103156,0.0002868059,0.00092453224,0.0001909701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00446789,0.00020367983,0.0019925851,0.00009546932,0.0001634526,0.000023060664,0.00019957557,0.0001405275,0.00070191995],"category_scores_gemma":[0.00441867,0.00008443536,0.0011965085,0.00024258035,0.0006144302,0.00007647073,0.00001601568,0.00033814294,0.000009433057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8844651,0.0024215186,0.000008326997,0.000017164464,0.0038757783,0.00013478316,0.00093871437,0.00006679007,0.00034829404,0.000030989308,0.02147735,0.0862152],"study_design_scores_gemma":[0.8709097,0.03232145,0.00088694395,0.00011718381,0.0017509493,0.000013988558,0.00063385017,0.0014103258,0.00041736016,0.0006451143,0.09081685,0.000076286684],"about_ca_topic_score_codex":0.00036378065,"about_ca_topic_score_gemma":0.00028014756,"teacher_disagreement_score":0.0973191,"about_ca_system_score_codex":0.0003892407,"about_ca_system_score_gemma":0.0049913856,"threshold_uncertainty_score":0.88545036},"labels":[],"label_agreement":null},{"id":"W4324136427","doi":"10.1200/jco.2023.41.6_suppl.436","title":"Who coauthors Cochrane Reviews related to genitourinary cancers? A 1998-2022 analysis of country and gender diversity.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Systematic review; MEDLINE; Family medicine; Urology; Gynecology; Political science","score_opus":0.19668700825861882,"score_gpt":0.4880865601830759,"score_spread":0.2913995519244571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627352,0.0017292948,0.000037187696,0.028189141,0.001736591,0.00020765224,0.00001182475,0.000019877678,0.005333237],"genre_scores_gemma":[0.8798862,0.027858257,0.00037245057,0.088517524,0.0026339912,0.0000072665193,0.00003242175,0.000026466923,0.0006653842],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592215,0.00035452214,0.0027997363,0.00022539456,0.0002996872,0.00039849326],"domain_scores_gemma":[0.99511904,0.0015411553,0.0026712085,0.00018914534,0.00033044495,0.00014898673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01247519,0.00014230462,0.00240942,0.00078909437,0.00015893622,0.000015413902,0.00034224222,0.00034216628,0.00017444574],"category_scores_gemma":[0.006886208,0.00010989929,0.00046167625,0.0023217944,0.00017533374,0.00025998053,0.00065428397,0.0005716703,0.00006825992],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059336703,0.00016582885,0.18283309,0.00033765353,0.0014718372,0.00019904604,0.00023764788,0.002898086,0.000007137944,0.0038343084,0.79240006,0.015021917],"study_design_scores_gemma":[0.0007242896,0.00031159708,0.28304124,0.00003736353,0.0010604069,0.000008872159,0.00022294311,0.004031595,2.3051008e-8,0.0007319326,0.7097437,0.00008602819],"about_ca_topic_score_codex":0.0023574831,"about_ca_topic_score_gemma":0.00036540133,"teacher_disagreement_score":0.100208156,"about_ca_system_score_codex":0.00010547694,"about_ca_system_score_gemma":0.0002571158,"threshold_uncertainty_score":0.82439315},"labels":[],"label_agreement":null},{"id":"W4324136455","doi":"10.1200/jco.2023.41.6_suppl.363","title":"Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Dose fractionation; Urology; Retrospective cohort study; Toxicity; Radiosurgery; Radiation therapy; Cancer; Internal medicine; Nuclear medicine","score_opus":0.06902400250732574,"score_gpt":0.4753972413860362,"score_spread":0.40637323887871046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591064,0.0008100879,0.000017872206,0.0018111739,0.00037677767,0.0005629795,0.0004990512,0.0000037339303,0.0000076498045],"genre_scores_gemma":[0.9829595,0.01641686,0.000040447325,0.00018554102,0.00012606494,0.00007046793,0.000032983287,0.000012828998,0.00015527068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772865,0.00018505126,0.001308627,0.00020372219,0.00035245108,0.00022152768],"domain_scores_gemma":[0.9955355,0.0015576672,0.0017206009,0.0001258597,0.000692217,0.00036814492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008795617,0.00011376995,0.0012030822,0.00049515656,0.000038294675,0.000005627441,0.000086496664,0.00012004468,0.000090145775],"category_scores_gemma":[0.0020906306,0.00007709195,0.0003502887,0.0003982798,0.000272739,0.0001273427,0.000020789483,0.00024726242,3.518952e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027668677,0.0003475808,0.9514229,0.000050704642,0.0032199332,0.000042069143,0.0007159012,0.00016525183,0.0007896153,0.000003584168,0.00022662696,0.015347099],"study_design_scores_gemma":[0.013473729,0.0021406715,0.9751079,0.00007125227,0.0013304407,0.0000015436613,0.00013168278,0.006321273,0.0010748575,0.00004974014,0.0002324634,0.000064412015],"about_ca_topic_score_codex":0.0045986003,"about_ca_topic_score_gemma":0.006846165,"teacher_disagreement_score":0.023684978,"about_ca_system_score_codex":0.00078656856,"about_ca_system_score_gemma":0.002095253,"threshold_uncertainty_score":0.6951739},"labels":[],"label_agreement":null},{"id":"W4324136456","doi":"10.1200/jco.2023.41.6_suppl.25","title":"Social determinants of health (SDOH) and survival among patients with metastatic prostate cancer (mPC): A systematic literature review (SLR).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; MEDLINE; Systematic review; Population; Internal medicine; Cochrane Library; Residence; Demography; Oncology; Gerontology; Cancer; Family medicine; Environmental health","score_opus":0.2185110608012534,"score_gpt":0.5365843704958443,"score_spread":0.3180733096945909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96309423,0.032342993,0.000006139497,0.0033073598,0.00038539642,0.0007827906,0.00001766233,0.000007971057,0.000055469365],"genre_scores_gemma":[0.95344096,0.04365121,0.00037708977,0.0021764196,0.00020541083,0.000018060196,0.00000552266,0.000017182094,0.00010815095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517953,0.00091832096,0.0028533381,0.00016446116,0.00062647235,0.00025787647],"domain_scores_gemma":[0.9944049,0.0007545549,0.0036743565,0.00011362626,0.0008073048,0.00024523205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006124214,0.00014115675,0.0029540595,0.00010606966,0.000057145164,0.000009773432,0.000109150795,0.000113306516,0.000011554019],"category_scores_gemma":[0.0022320922,0.00008166206,0.00023953318,0.00044442955,0.00018421645,0.00015057082,0.000042986132,0.0005486679,0.0000017779387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014513347,0.00025813095,0.8974913,0.060903676,0.0003908861,0.00052412605,0.000621812,0.000002097146,8.4966166e-7,0.000010810081,0.003411541,0.034933463],"study_design_scores_gemma":[0.00466812,0.007596009,0.8748683,0.111057274,0.000842495,0.00010090596,0.0002372287,0.00003479974,0.0000010451996,0.00004528467,0.00045965557,0.00008890198],"about_ca_topic_score_codex":0.000045578185,"about_ca_topic_score_gemma":0.00016174756,"teacher_disagreement_score":0.0501536,"about_ca_system_score_codex":0.00009743483,"about_ca_system_score_gemma":0.0012377729,"threshold_uncertainty_score":0.33300823},"labels":[],"label_agreement":null},{"id":"W4324136468","doi":"10.1200/jco.2023.41.6_suppl.349","title":"Two-fraction stereotactic MRI-guided ablative radiotherapy with simultaneous boost to dominant intraprostatic lesion: Results from the 2SMART phase 2 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"SABR volatility model; Medicine; Prostate cancer; Prostate; Ablative case; Nuclear medicine; Clinical endpoint; Magnetic resonance imaging; Radiation therapy; Radiosurgery; Radiology; Urology; Cancer; Clinical trial; Internal medicine","score_opus":0.15264440451134856,"score_gpt":0.49817259506254713,"score_spread":0.34552819055119854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92759514,0.00032822916,0.00035930666,0.06825482,0.0016692805,0.001459046,0.00005920561,0.000019663334,0.00025532945],"genre_scores_gemma":[0.9825283,0.0039900006,0.003150519,0.0071992436,0.0026792572,0.000053210195,0.000031725736,0.00003563641,0.00033207744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99585897,0.0006852779,0.0023443354,0.0003304624,0.00048710147,0.00029386848],"domain_scores_gemma":[0.9775803,0.019294905,0.001872227,0.00034912425,0.00047216588,0.00043129234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030355917,0.00020981196,0.0014575147,0.000110608176,0.000105590414,0.000029830288,0.00014979925,0.0001621828,0.000083921164],"category_scores_gemma":[0.005654988,0.00010424881,0.00030300836,0.00036335594,0.00015703647,0.00011838105,0.000029017225,0.0007379886,0.00005052516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6744706,0.004862556,0.002390862,0.000012388965,0.0021588933,0.00811683,0.0014799301,0.0008473167,0.0004182206,0.00001597242,0.042766638,0.26245978],"study_design_scores_gemma":[0.57433075,0.16025616,0.017036853,0.000650003,0.0016030319,0.00053109607,0.0011159881,0.0018345886,0.0008635828,0.00031904888,0.24119706,0.00026183837],"about_ca_topic_score_codex":0.00015022636,"about_ca_topic_score_gemma":0.00012666339,"teacher_disagreement_score":0.26219797,"about_ca_system_score_codex":0.0004966128,"about_ca_system_score_gemma":0.0013731752,"threshold_uncertainty_score":0.6769957},"labels":[],"label_agreement":null},{"id":"W4324136522","doi":"10.1200/jco.2023.41.6_suppl.517","title":"Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Leukapheresis; Internal medicine; Oncology; Cohort; Cancer; Adverse effect; Immunotherapy; Clinical trial; Antigen; Immunology; CD34; Stem cell","score_opus":0.13308871601389985,"score_gpt":0.4393163791348133,"score_spread":0.30622766312091343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935196,0.00047863752,0.000015429152,0.0021208832,0.0024207283,0.0007492821,0.000031063897,0.000023163988,0.00064118503],"genre_scores_gemma":[0.99085855,0.004266646,0.0019389885,0.0014647616,0.0008028946,0.000034378143,0.00002228894,0.00004487303,0.00056661357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948931,0.0006617279,0.0031877114,0.0003541348,0.000558219,0.00034516107],"domain_scores_gemma":[0.99532235,0.0014513566,0.0020760887,0.00028804934,0.0005427193,0.00031944233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001759571,0.00025362291,0.00214176,0.0002253161,0.00003847176,0.0000072439652,0.0002235601,0.0005098294,0.00018909913],"category_scores_gemma":[0.00082528614,0.00016188216,0.0005523986,0.00034028495,0.00023921914,0.00017257612,0.000050728955,0.0009319192,0.00003077241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023965927,0.005807933,0.7732674,0.000030458885,0.00031112446,0.000108349974,0.00014473026,0.00009401343,0.0004228255,0.000002155859,0.0030908436,0.19275425],"study_design_scores_gemma":[0.045078047,0.076117665,0.8711341,0.000095221265,0.00027559104,0.000006540736,0.00007384991,0.0000778833,0.00055458467,0.000024616957,0.0064145946,0.00014731081],"about_ca_topic_score_codex":0.000077400284,"about_ca_topic_score_gemma":0.00006527965,"teacher_disagreement_score":0.19260694,"about_ca_system_score_codex":0.00016423623,"about_ca_system_score_gemma":0.0024196594,"threshold_uncertainty_score":0.6601363},"labels":[],"label_agreement":null},{"id":"W4324136525","doi":"10.1200/jco.2023.41.6_suppl.89","title":"Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of the Fraser Valley; University of British Columbia; University of Alberta; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Multivariate analysis; Univariate analysis; Oncology; Population; Radiation therapy; Metastasis; Cancer; Urology; Surgery","score_opus":0.46024789426579193,"score_gpt":0.5820325619540767,"score_spread":0.12178466768828478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574083,0.0012172068,0.000009071554,0.0019910254,0.00055240863,0.00042144634,0.000046519097,0.000006168155,0.000015307629],"genre_scores_gemma":[0.9750951,0.023267683,0.0004644494,0.00018114182,0.000113525566,0.000020775773,0.000028616867,0.000011588027,0.0008171504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964029,0.0005366046,0.0022530945,0.00016034234,0.00041911955,0.00022790868],"domain_scores_gemma":[0.9956807,0.0022723258,0.0012251864,0.00014843883,0.00048343386,0.00018992372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026375968,0.00010490598,0.0016450492,0.00076583325,0.000018011851,0.0000073626156,0.000102659724,0.00011184227,0.00015475611],"category_scores_gemma":[0.0018020935,0.000057318066,0.00045726355,0.0013254728,0.00008686567,0.000114449664,0.000028703484,0.00046023005,0.0000057985176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017337916,0.0010462739,0.8704661,0.0000840501,0.0033690939,0.0006472036,0.0004419778,0.0004760677,0.00013428576,0.0000046407768,0.000553086,0.10543928],"study_design_scores_gemma":[0.012101341,0.0042326194,0.9781299,0.0003756526,0.0012278154,0.000017718217,0.0003004591,0.0025897885,0.000037309823,0.00002145976,0.0009102519,0.000055634304],"about_ca_topic_score_codex":0.0004144278,"about_ca_topic_score_gemma":0.0009902784,"teacher_disagreement_score":0.10766383,"about_ca_system_score_codex":0.00027097677,"about_ca_system_score_gemma":0.001156581,"threshold_uncertainty_score":0.23373629},"labels":[],"label_agreement":null},{"id":"W4324136549","doi":"10.1200/jco.2023.41.6_suppl.605","title":"Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Exelixis","keywords":"Medicine; Clinical endpoint; Population; Internal medicine; Placebo; Hazard ratio; Ipilimumab; Surgery; Nivolumab; Randomized controlled trial; Urology; Gastroenterology; Confidence interval; Cancer; Immunotherapy","score_opus":0.2303979398076087,"score_gpt":0.574612994244477,"score_spread":0.3442150544368683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819864,0.00035029423,0.00005642771,0.008861995,0.00090939493,0.0012434623,0.0000599452,0.000011755032,0.00030808427],"genre_scores_gemma":[0.98732275,0.009519271,0.0012680923,0.0010352824,0.00041197048,0.000050221406,0.000012330332,0.000026266653,0.00035378902],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907723,0.002962614,0.0045483317,0.00035649523,0.00079439825,0.000565849],"domain_scores_gemma":[0.9685292,0.027513912,0.0029807852,0.00032842022,0.0003371815,0.00031045105],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022019524,0.00024809223,0.003355854,0.0004498707,0.00009201742,0.000011212115,0.0004167495,0.0005061731,0.00016283838],"category_scores_gemma":[0.04370489,0.00014092405,0.00040496443,0.00055915787,0.0006542206,0.00013721958,0.00016857764,0.0025886558,0.000018804136],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45634416,0.0038676322,0.39494935,0.00009494525,0.00046270515,0.0011250707,0.0014562504,0.00005115281,0.000076607444,0.00000719289,0.0066786148,0.13488634],"study_design_scores_gemma":[0.5878016,0.068389945,0.32026282,0.00028428185,0.0007584244,0.0001442818,0.0020908855,0.014232747,0.000015170333,0.0004942643,0.0053629735,0.00016264676],"about_ca_topic_score_codex":0.00032491065,"about_ca_topic_score_gemma":0.0014691665,"teacher_disagreement_score":0.1347237,"about_ca_system_score_codex":0.00022389396,"about_ca_system_score_gemma":0.0027717208,"threshold_uncertainty_score":0.9997124},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4324136559","doi":"10.1200/jco.2023.41.6_suppl.489","title":"Quality of life after radical treatment for muscle invasive bladder cancer: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Urinary diversion; Systematic review; Quality of life (healthcare); Meta-analysis; Surgery; MEDLINE; Intensive care medicine; Cancer; Internal medicine","score_opus":0.5681781195811048,"score_gpt":0.5940124811918732,"score_spread":0.025834361610768464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016786058,0.99304885,0.000022094217,0.0021456743,0.00023723514,0.004029793,0.00043771474,0.0000075553066,0.000054279208],"genre_scores_gemma":[0.00006607582,0.99408174,0.00045053856,0.002749867,0.0004198768,0.0013856704,0.00002126009,0.00004990286,0.0007750995],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98722774,0.0024121902,0.009168391,0.0004319001,0.0004962582,0.00026350736],"domain_scores_gemma":[0.9791869,0.01057661,0.008487395,0.0005114939,0.0005955471,0.00064207305],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0053115324,0.0004891873,0.040361185,0.00028857664,0.000026962065,0.0000082011,0.00020628245,0.00069752795,0.00043780546],"category_scores_gemma":[0.0074500507,0.00023928814,0.013906832,0.0004518116,0.00023516116,0.000047004985,0.00005511781,0.00056546205,0.000010581582],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003146638,0.0008212276,0.000030001775,0.49413007,0.4861083,0.00009604795,0.000023188191,1.4020331e-7,1.1858061e-8,0.000007767731,0.0007854042,0.017683163],"study_design_scores_gemma":[0.0026232211,0.004974344,0.00013657004,0.02070151,0.86345226,0.000045479796,0.00001205849,3.1232068e-7,5.6794363e-8,0.000030890475,0.10787811,0.00014521764],"about_ca_topic_score_codex":0.0001139024,"about_ca_topic_score_gemma":0.00030468556,"teacher_disagreement_score":0.47342858,"about_ca_system_score_codex":0.00033830773,"about_ca_system_score_gemma":0.006880812,"threshold_uncertainty_score":0.99874926},"labels":[],"label_agreement":null},{"id":"W4324136563","doi":"10.1200/jco.2023.41.6_suppl.85","title":"First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; University of British Columbia; McMaster University; BC Cancer Agency","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Cancer registry; Ethnic group; Socioeconomic status; Cohort; Disease; Cancer; Disease registry; Quality of life (healthcare); Internal medicine; Demography; Gerontology; Environmental health; Population","score_opus":0.16263299207011864,"score_gpt":0.5039225942459716,"score_spread":0.341289602175853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9103731,0.00035702187,0.000011377039,0.088005126,0.00038477863,0.000479386,0.000053954787,0.0000036766357,0.00033157523],"genre_scores_gemma":[0.98362154,0.008212741,0.00017167146,0.0006913062,0.00057162135,0.00009234691,0.00002027655,0.000014260842,0.0066042445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809015,0.00012240362,0.0011084955,0.00012068091,0.0003269491,0.00023130166],"domain_scores_gemma":[0.9957229,0.002674124,0.00095411245,0.0001686231,0.00037050797,0.00010975369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030433454,0.00007942796,0.0005775309,0.00005242186,0.000051940155,0.000005750281,0.00021408097,0.000085620406,0.000079199715],"category_scores_gemma":[0.0023095391,0.000033452856,0.00013558989,0.00014166761,0.00033403514,0.00004644937,0.000074645606,0.00040446484,0.0000045581655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057627704,0.0009946224,0.7737721,0.0001545817,0.0007857801,0.00055608817,0.0007844297,0.000491551,0.00042321504,0.000036207824,0.036948744,0.12742493],"study_design_scores_gemma":[0.017240983,0.006985232,0.77003855,0.00041800266,0.00026733952,0.000040476134,0.0007061801,0.0033743114,0.000530473,0.00015301019,0.20017041,0.0000750484],"about_ca_topic_score_codex":0.000021993672,"about_ca_topic_score_gemma":0.0004060216,"teacher_disagreement_score":0.16322167,"about_ca_system_score_codex":0.00021978925,"about_ca_system_score_gemma":0.0010458806,"threshold_uncertainty_score":0.2764901},"labels":[],"label_agreement":null},{"id":"W4324136570","doi":"10.1200/jco.2023.41.6_suppl.61","title":"Changes in planned disease management after piflufolastat F<sup>18</sup> PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Prostate; Cancer; Radiology; Internal medicine","score_opus":0.09118491147118293,"score_gpt":0.4418453356488163,"score_spread":0.3506604241776333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844564,0.0012019161,3.2083875e-7,0.012757121,0.00006511576,0.00091961405,0.0004498959,0.000005351392,0.00014424365],"genre_scores_gemma":[0.9938049,0.0050835456,0.00006941737,0.00035806073,0.00010341392,0.000119294695,0.000056721277,0.000013244059,0.00039143045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969939,0.00045731384,0.0014191188,0.00034639364,0.0004807205,0.00030253516],"domain_scores_gemma":[0.9968635,0.0018384964,0.000607218,0.00023088307,0.00017410728,0.0002858081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024757544,0.00016627752,0.0012330248,0.0004596303,0.00002279082,0.000012729231,0.00015587076,0.000033771703,0.00010213883],"category_scores_gemma":[0.00048407266,0.00008710038,0.00015439828,0.0008702477,0.00024805337,0.000060784696,0.0001430953,0.0006660047,0.000001751148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.122251466,0.0023025356,0.8084442,0.000110527086,0.004189879,0.01776199,0.0017876324,0.00016911482,0.00002036998,8.143204e-7,0.0020362372,0.040925223],"study_design_scores_gemma":[0.027126068,0.0056491643,0.9595568,0.00051961746,0.0016679352,0.000010013411,0.0032265305,0.0011827081,0.000027597043,0.000041927335,0.0008989363,0.00009269402],"about_ca_topic_score_codex":0.00016032251,"about_ca_topic_score_gemma":0.0030898023,"teacher_disagreement_score":0.1511126,"about_ca_system_score_codex":0.00018885724,"about_ca_system_score_gemma":0.0008041893,"threshold_uncertainty_score":0.35518503},"labels":[],"label_agreement":null},{"id":"W4324136592","doi":"10.1200/jco.2023.41.6_suppl.tps750","title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Population Health Research Institute; McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; Ottawa Hospital; Health Sciences Centre; Ontario Clinical Oncology Group; Grand River Hospital; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Renal cell carcinoma; Sunitinib; Kidney cancer; Internal medicine; Oncology; Nephrectomy; Immunotherapy; Urology; Cancer; Kidney","score_opus":0.1758098658183557,"score_gpt":0.49934697921114257,"score_spread":0.3235371133927869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860363,0.00024950664,0.00036176844,0.009925047,0.0018627095,0.0013020604,0.000029449233,0.000018662007,0.00021447058],"genre_scores_gemma":[0.9935693,0.0007972291,0.003281395,0.0005479093,0.0008999049,0.000083371175,0.000028783406,0.00003822786,0.0007538937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965203,0.00042584218,0.0020556243,0.00023297875,0.00052795047,0.00023731172],"domain_scores_gemma":[0.9930402,0.0025257159,0.002727593,0.00019649668,0.0011211307,0.00038886906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020780938,0.00018340058,0.0017664698,0.00032374932,0.00007792787,0.0000064376295,0.00011539628,0.00018410594,0.0001554273],"category_scores_gemma":[0.0021207125,0.0001222362,0.0005371475,0.00032563834,0.00021552588,0.00022507168,0.000018579944,0.0005110405,0.0000039881184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7973086,0.029597377,0.00094706274,0.00019476416,0.006285643,0.0006063334,0.00039938127,0.000110150024,0.0052819313,0.00018859739,0.009612158,0.14946797],"study_design_scores_gemma":[0.62090206,0.34059432,0.007928395,0.0001910832,0.0026260496,0.0003720226,0.00030750653,0.0010237881,0.0027204307,0.0004599434,0.022724014,0.00015037632],"about_ca_topic_score_codex":0.000043557317,"about_ca_topic_score_gemma":0.000009757301,"teacher_disagreement_score":0.31099695,"about_ca_system_score_codex":0.00059652847,"about_ca_system_score_gemma":0.003700291,"threshold_uncertainty_score":0.65641576},"labels":[],"label_agreement":null},{"id":"W4324136600","doi":"10.1200/jco.2023.41.6_suppl.209","title":"Prognostic biomarkers and clinical outcomes in neuroendocrine prostate cancer (NEPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Stage (stratigraphy); Internal medicine; Proportional hazards model; Androgen deprivation therapy; Immunohistochemistry; Cancer; Adenocarcinoma; Oncology; Biopsy; Prostate; Log-rank test; Pathology; Gastroenterology","score_opus":0.18071229396248417,"score_gpt":0.5528733898621524,"score_spread":0.3721610958996682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95458746,0.00088315,0.0000010365758,0.04231554,0.0013502319,0.00046379006,0.0000071591253,0.000019511428,0.0003721093],"genre_scores_gemma":[0.9679557,0.02810461,0.00027180617,0.0012782381,0.00049487734,0.000021224017,0.000004512518,0.000023151415,0.0018458881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612737,0.0005160336,0.0023343824,0.00025841003,0.00036149358,0.00040230254],"domain_scores_gemma":[0.994095,0.004341916,0.00068371877,0.00014099035,0.00023650861,0.00050185027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031257407,0.00014117456,0.0014794796,0.0003106276,0.000031285203,0.0000115944285,0.0001168882,0.0001465792,0.00006304002],"category_scores_gemma":[0.0065176524,0.000085553715,0.0003650036,0.00040508388,0.00041758467,0.00009658467,0.000110851004,0.0011014567,0.000024973375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004406084,0.0008532996,0.8136939,0.00004111084,0.0004872752,0.006378569,0.000030447129,0.0000018704125,0.0000152346,0.000007815048,0.0035520159,0.17053238],"study_design_scores_gemma":[0.014989391,0.008741783,0.95652086,0.00012493238,0.00023477981,0.0002014654,0.000090853806,0.00017026452,0.000010267611,0.00026838496,0.018574456,0.00007256649],"about_ca_topic_score_codex":0.000058238522,"about_ca_topic_score_gemma":0.00011699099,"teacher_disagreement_score":0.17045982,"about_ca_system_score_codex":0.000106072264,"about_ca_system_score_gemma":0.0017171619,"threshold_uncertainty_score":0.78027093},"labels":[],"label_agreement":null},{"id":"W4324136609","doi":"10.1200/jco.2023.41.6_suppl.506","title":"A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cohort; Cancer; Immunotherapy","score_opus":0.16250859558715813,"score_gpt":0.4724198347077909,"score_spread":0.3099112391206328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600625,0.00031246812,0.000005151871,0.0010915569,0.00078412413,0.0004661068,0.0000066753405,0.000009406888,0.0013182473],"genre_scores_gemma":[0.99819875,0.00044854853,0.0002611814,0.00037912797,0.00039491244,0.00001081269,0.0000011034409,0.000019907371,0.00028563774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690735,0.00037722843,0.0019266153,0.00020506853,0.00035366093,0.0002300924],"domain_scores_gemma":[0.9974178,0.0011414108,0.00079243566,0.00017522475,0.00022191403,0.00025123177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014640986,0.00013712588,0.0014823219,0.00028407702,0.000022563063,0.0000037081193,0.00011302882,0.00009784519,0.000072901516],"category_scores_gemma":[0.0013875975,0.00009854954,0.00014831299,0.00032310514,0.00012571372,0.0000796075,0.00006447901,0.0005844101,0.000011137277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033672284,0.008229133,0.8472629,0.000055201574,0.00033987666,0.0021194092,0.0008534845,0.000018903202,0.00081832317,0.000020114221,0.0007448352,0.105865486],"study_design_scores_gemma":[0.04566516,0.13937424,0.8110412,0.00006046816,0.00026276583,0.00016020678,0.00082099304,0.00002962134,0.000066444154,0.00018958776,0.002264294,0.00006504598],"about_ca_topic_score_codex":0.00023776562,"about_ca_topic_score_gemma":0.000431132,"teacher_disagreement_score":0.1311451,"about_ca_system_score_codex":0.00009076174,"about_ca_system_score_gemma":0.0010990073,"threshold_uncertainty_score":0.40187338},"labels":[],"label_agreement":null},{"id":"W4324136624","doi":"10.1200/jco.2023.41.6_suppl.477","title":"Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; Chemotherapy; Proportional hazards model; Immunotherapy; Bladder cancer; Cohort; Cancer; Logistic regression","score_opus":0.1806858237803709,"score_gpt":0.48682957261763793,"score_spread":0.306143748837267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821532,0.00023107808,0.00026539585,0.013329082,0.001649506,0.001325779,0.000070995564,0.000020790385,0.00095419324],"genre_scores_gemma":[0.9898915,0.0025704158,0.00078388443,0.0015215662,0.000638501,0.000094961986,0.000008051972,0.00003957216,0.0044515324],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99697506,0.00025152316,0.0018989275,0.00020303104,0.00037732988,0.00029411472],"domain_scores_gemma":[0.99603194,0.0017547394,0.0013792752,0.00031528453,0.00036021598,0.00015853508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012634186,0.00019881631,0.0014075261,0.00016675159,0.00010465046,0.000007766465,0.00021904158,0.0001459898,0.00035832025],"category_scores_gemma":[0.0005598017,0.0001007311,0.0008881754,0.00041589994,0.00018574808,0.00007185332,0.000029348266,0.00023772297,0.0000072756293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10016024,0.028818484,0.3481378,0.0002952191,0.007711852,0.0005873797,0.009653893,0.000060735812,0.0018583585,0.0014528767,0.01587072,0.48539245],"study_design_scores_gemma":[0.12105046,0.07679575,0.52927965,0.00019794173,0.0015663076,0.00018004279,0.0008904016,0.00074145844,0.005847166,0.002104951,0.26109666,0.00024921345],"about_ca_topic_score_codex":0.0001737816,"about_ca_topic_score_gemma":0.00058551575,"teacher_disagreement_score":0.48514324,"about_ca_system_score_codex":0.00026599958,"about_ca_system_score_gemma":0.0018235209,"threshold_uncertainty_score":0.4107695},"labels":[],"label_agreement":null},{"id":"W4324136629","doi":"10.1200/jco.2023.41.6_suppl.309","title":"Patterns of failure with <sup>18</sup>F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; St. Joseph’s Healthcare Hamilton; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"Cancer Care Ontario","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Lymph node; Cohort; Stage (stratigraphy); Prospective cohort study; Pathological; Cancer registry; Incidence (geometry); Urology; Proportional hazards model; Cancer; Nuclear medicine; Radiology; Internal medicine","score_opus":0.09783272336616256,"score_gpt":0.4596731295079382,"score_spread":0.36184040614177565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067804,0.000117029536,0.000013509275,0.03812223,0.00006668222,0.00044321537,0.000020506099,0.000010692645,0.0005280854],"genre_scores_gemma":[0.99648196,0.0006908807,0.00034768184,0.0014819435,0.00034741638,0.000021524209,0.00006259863,0.000017676131,0.0005483213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958828,0.00078540324,0.0017708289,0.00026184207,0.00090931647,0.000389821],"domain_scores_gemma":[0.9947074,0.0030272303,0.0010191704,0.00031127577,0.00069003116,0.00024485815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005733935,0.00016886776,0.0015624153,0.00056497904,0.000050509898,0.000013654583,0.000312284,0.00007606705,0.00025422042],"category_scores_gemma":[0.0011400009,0.00008341581,0.0006358554,0.0011940011,0.0002565001,0.000093028124,0.00006326898,0.0013477313,0.000019318319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043457025,0.00085169706,0.96855444,0.000059879225,0.002367631,0.013961424,0.00032758556,0.00038733846,0.00002087524,0.000021671336,0.005883739,0.003218045],"study_design_scores_gemma":[0.009394585,0.008326698,0.961594,0.00015603368,0.0014467564,0.0013408269,0.0023403305,0.00068810594,0.000023344026,0.000085741165,0.014509972,0.00009362707],"about_ca_topic_score_codex":0.00012142186,"about_ca_topic_score_gemma":0.00029505586,"teacher_disagreement_score":0.036640283,"about_ca_system_score_codex":0.00013900409,"about_ca_system_score_gemma":0.0018195377,"threshold_uncertainty_score":0.5855297},"labels":[],"label_agreement":null},{"id":"W4324136640","doi":"10.1200/jco.2023.41.6_suppl.332","title":"Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer HealthCare","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Adverse effect; Oncology; Cancer; Androgen receptor; Clinical trial","score_opus":0.24014668830663125,"score_gpt":0.5210510775349937,"score_spread":0.28090438922836247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916468,0.0004328,0.000028407112,0.0059098415,0.00060178724,0.00092439156,0.00012928486,0.000015273812,0.00031137062],"genre_scores_gemma":[0.9733061,0.013189321,0.005804959,0.00042216905,0.0005757194,0.000070537804,0.000027501952,0.00004407378,0.006559572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631494,0.00023887966,0.002304319,0.00025938082,0.00047951093,0.00040297507],"domain_scores_gemma":[0.99269617,0.004405557,0.0013962872,0.00019743058,0.000877597,0.00042693556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029828516,0.00017667405,0.0015297448,0.00041856687,0.00007289929,0.000022080532,0.00010923686,0.00015180779,0.000046192377],"category_scores_gemma":[0.0023900904,0.00011995535,0.0003663485,0.0004958008,0.00041482365,0.00021324899,0.000059020473,0.00054509594,0.0000052445466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073551185,0.0027234196,0.5321557,0.0019837974,0.0041276836,0.00330378,0.001195115,0.00059109076,0.03196168,0.0006511114,0.044311658,0.30344376],"study_design_scores_gemma":[0.021356288,0.016252909,0.90667176,0.00066018925,0.0011623404,0.00008692823,0.00035817164,0.0019988199,0.0016521908,0.0015381072,0.048055395,0.00020687829],"about_ca_topic_score_codex":0.0003649929,"about_ca_topic_score_gemma":0.0008603515,"teacher_disagreement_score":0.37451607,"about_ca_system_score_codex":0.00019496627,"about_ca_system_score_gemma":0.0030951833,"threshold_uncertainty_score":0.54907227},"labels":[],"label_agreement":null},{"id":"W4324136654","doi":"10.1200/jco.2023.41.6_suppl.5","title":"Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Nivolumab; Internal medicine; Pembrolizumab; Discontinuation; Adverse effect; Cohort; Ipilimumab; Oncology; Hazard ratio; Cancer; Immunotherapy; Confidence interval","score_opus":0.06080808873022766,"score_gpt":0.42575040446987894,"score_spread":0.3649423157396513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526423,0.00089042744,0.0000027397555,0.0021702815,0.0007733263,0.00045258616,0.00006139982,0.000007435242,0.0003775861],"genre_scores_gemma":[0.9985268,0.0000969606,0.00039444465,0.00028438226,0.0006320557,0.0000030958356,0.000019650435,0.000011579542,0.00003101311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954681,0.00045489662,0.0031742803,0.00021828641,0.00045719405,0.0002272663],"domain_scores_gemma":[0.9956053,0.0018524791,0.0015656202,0.00024468274,0.00032485466,0.00040704943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023756216,0.00014213641,0.0010879721,0.0000631902,0.000042818665,0.000003890418,0.0002650633,0.00018311704,0.000062392726],"category_scores_gemma":[0.0017046469,0.000096814605,0.00048241724,0.0002622623,0.00022438129,0.000112467234,0.00017892875,0.00065918255,0.0000036293154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019286206,0.005683094,0.9620016,0.00008545726,0.00003789784,0.0005378055,0.0010730783,0.00010523188,0.0002711491,0.0000041689555,0.00028618,0.010628114],"study_design_scores_gemma":[0.021383224,0.012950743,0.9579725,0.000035465837,0.00015779409,0.000051772946,0.0065702964,0.00027037133,0.00010813621,0.00011092585,0.0003193268,0.00006943957],"about_ca_topic_score_codex":0.00039613803,"about_ca_topic_score_gemma":0.0000886274,"teacher_disagreement_score":0.010558674,"about_ca_system_score_codex":0.00016153343,"about_ca_system_score_gemma":0.0013657557,"threshold_uncertainty_score":0.3947985},"labels":[],"label_agreement":null},{"id":"W4324136665","doi":"10.1200/jco.2023.41.6_suppl.316","title":"Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Medicine; Prostatectomy; Nomogram; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Salvage therapy; Biochemical recurrence; Oncology; Internal medicine; Urology; Odds ratio; Post-hoc analysis; Surgery; Cancer; Chemotherapy","score_opus":0.08919680025866426,"score_gpt":0.49517546282303976,"score_spread":0.4059786625643755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98169595,0.00028057123,0.00008272942,0.014580383,0.00021079928,0.0030966497,0.00004153377,0.000005364632,0.000006048135],"genre_scores_gemma":[0.996931,0.0016247437,0.0002988427,0.000637623,0.000107200285,0.00031303964,0.000017622036,0.000011505936,0.000058417674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980143,0.00019907,0.0012047326,0.00016026753,0.00026905385,0.00015261119],"domain_scores_gemma":[0.99604875,0.00094536954,0.0012842498,0.00013752065,0.001489491,0.00009461016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012380686,0.00008967001,0.0007955717,0.00035444385,0.000044497825,0.000004588281,0.000075709606,0.00007949498,0.0000027060742],"category_scores_gemma":[0.0017310691,0.000047766305,0.00054990867,0.00075743254,0.000066932575,0.000041938278,0.000011257531,0.00010515758,3.6572263e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2484084,0.0015223572,0.031997256,0.000043590237,0.0022262456,0.000004915836,0.0009954463,0.006205884,0.030383442,0.000021984522,0.0003061737,0.6778843],"study_design_scores_gemma":[0.11772894,0.19021909,0.5801898,0.00024658084,0.0035124496,0.0000051082193,0.00040270545,0.006699137,0.08845678,0.00018377755,0.012214844,0.00014077222],"about_ca_topic_score_codex":0.00006540483,"about_ca_topic_score_gemma":0.00003296979,"teacher_disagreement_score":0.67774355,"about_ca_system_score_codex":0.00039634074,"about_ca_system_score_gemma":0.0013752991,"threshold_uncertainty_score":0.24397215},"labels":[],"label_agreement":null},{"id":"W4324136672","doi":"10.1200/jco.2023.41.6_suppl.407","title":"Longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Orchiectomy; Stage (stratigraphy); Internal medicine; Biomarker; Testicular cancer; Minimal residual disease; Germ cell tumors; Log-rank test; Oncology; Exact test; Gastroenterology; Survival analysis; Surgery; Cancer; Chemotherapy","score_opus":0.15747000340210068,"score_gpt":0.47080590821605045,"score_spread":0.3133359048139498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973561,0.0008296911,0.000006348754,0.0010911266,0.0002420336,0.00028686062,0.000015992222,0.000006376142,0.00016543425],"genre_scores_gemma":[0.9981194,0.000112000795,0.0013524351,0.000062066974,0.00025313487,0.0000053717013,0.0000028778597,0.000012681639,0.000080041325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968975,0.0003873174,0.0016634217,0.00017858694,0.0007106742,0.00016248022],"domain_scores_gemma":[0.9956335,0.0014902913,0.0014074122,0.00017014456,0.0006638635,0.00063479535],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002812878,0.00010860488,0.00095505494,0.00019349698,0.000021306108,0.0000038273524,0.0000796104,0.00012652209,0.00004670998],"category_scores_gemma":[0.009069652,0.00007945795,0.0003224546,0.00019622428,0.00014165323,0.00005539806,0.000060882863,0.00024063497,0.000013608606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011785589,0.0014791614,0.9212012,0.00014332574,0.00040340185,0.0015457044,0.00009371701,0.00008268605,0.0005479419,0.00001401107,0.0011002326,0.061603017],"study_design_scores_gemma":[0.008959844,0.013246365,0.9738397,0.00019628195,0.0025618128,0.00006556542,0.000042491556,0.00020862925,0.00032646864,0.0003302073,0.00016473925,0.000057885067],"about_ca_topic_score_codex":0.000020410902,"about_ca_topic_score_gemma":0.000010824539,"teacher_disagreement_score":0.061545134,"about_ca_system_score_codex":0.00006101964,"about_ca_system_score_gemma":0.001728953,"threshold_uncertainty_score":0.99927735},"labels":[],"label_agreement":null},{"id":"W4324136676","doi":"10.1200/jco.2023.41.6_suppl.148","title":"Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Dosing; Pharmacokinetics; Discontinuation; Internal medicine","score_opus":0.0895156565479519,"score_gpt":0.4494159933776046,"score_spread":0.35990033682965267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938486,0.0011162848,0.000005839743,0.003521876,0.000059795813,0.0013979839,0.000014075258,0.0000041749126,0.000031357547],"genre_scores_gemma":[0.97227633,0.027198035,0.000105731735,0.00031399034,0.000040623472,0.000018822571,0.000010971186,0.000015351914,0.000020138757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974849,0.0006396194,0.000970837,0.00018912862,0.00050934276,0.00020612674],"domain_scores_gemma":[0.9976133,0.0010369638,0.000741562,0.00010427014,0.00040878836,0.00009511397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023853043,0.00014301903,0.00083814317,0.00026174655,0.000038434813,0.000012824417,0.00006843336,0.00006516654,0.0000032659648],"category_scores_gemma":[0.00015412283,0.00007072709,0.00004468946,0.00050437223,0.00030233178,0.0001244998,0.000023478744,0.0005210601,2.7050362e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05139629,0.0030357158,0.88050926,0.000020814086,0.0004898216,0.00036195814,0.004271286,0.00007632304,0.00015032866,0.0000076442,0.000045057393,0.05963549],"study_design_scores_gemma":[0.06569961,0.026639134,0.9054821,0.00009734299,0.0001276946,0.000022898505,0.0010911829,0.00018865279,0.00016644566,0.00009626071,0.00031944143,0.00006923903],"about_ca_topic_score_codex":0.00008415809,"about_ca_topic_score_gemma":0.00012232459,"teacher_disagreement_score":0.059566252,"about_ca_system_score_codex":0.00009245349,"about_ca_system_score_gemma":0.0004680523,"threshold_uncertainty_score":0.28841668},"labels":[],"label_agreement":null},{"id":"W4324136686","doi":"10.1200/jco.2023.41.6_suppl.570","title":"Comprehensive gene sequencing to identify progression predictors to muscle-invasive bladder cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu Grace Healthcare; Windsor Regional Hospital; Western University; University of Windsor","funders":"","keywords":"Bladder cancer; Medicine; Oncology; Cancer; Internal medicine; Transitional cell carcinoma","score_opus":0.2163602581421605,"score_gpt":0.5354659678048062,"score_spread":0.3191057096626456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794657,0.0003714636,0.00009849559,0.014835174,0.0036085711,0.00065535214,0.00002409803,0.00004890541,0.0008921908],"genre_scores_gemma":[0.9815333,0.001105925,0.0031418025,0.010243473,0.0032538068,0.00005113024,0.0000067382366,0.000042429678,0.00062142656],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966314,0.00027726224,0.0017370759,0.00032231607,0.00062964123,0.00040231794],"domain_scores_gemma":[0.99606,0.001089266,0.0007195091,0.00023447524,0.0008488042,0.0010479273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009973908,0.00019530045,0.0013056484,0.0002923428,0.00007606088,0.000015130151,0.00020974241,0.00030901082,0.00022159156],"category_scores_gemma":[0.0018081618,0.00013812019,0.00042760244,0.0005611087,0.00008965575,0.00009750255,0.00013777649,0.0006360461,0.00022745755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0085119875,0.0014636863,0.16622773,0.00019823574,0.003107226,0.008906398,0.0031646062,0.0009988204,0.06967228,0.000018483253,0.1318836,0.60584694],"study_design_scores_gemma":[0.0068397103,0.020348066,0.8523492,0.0006069118,0.00075276854,0.00024043627,0.0006835924,0.000027033757,0.0052047796,0.00013951161,0.11261665,0.00019132647],"about_ca_topic_score_codex":0.00008715323,"about_ca_topic_score_gemma":0.00008045159,"teacher_disagreement_score":0.68612146,"about_ca_system_score_codex":0.0005113293,"about_ca_system_score_gemma":0.0033367288,"threshold_uncertainty_score":0.5919213},"labels":[],"label_agreement":null},{"id":"W4324136691","doi":"10.1200/jco.2023.41.6_suppl.366","title":"Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual patient data meta-analysis from the MARCAP Consortium.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Radiation therapy; Urology; Androgen; Internal medicine; Randomized controlled trial; Prostate; Oncology; Gynecology; Cancer; Hormone","score_opus":0.3237556577422082,"score_gpt":0.48914129670789985,"score_spread":0.16538563896569164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96288395,0.0150980465,0.000028387178,0.020675758,0.00043422342,0.00042240813,0.00037881106,0.000013242018,0.00006518107],"genre_scores_gemma":[0.983283,0.010965847,0.0019455862,0.002406652,0.00039347034,0.000015277194,0.0004983239,0.000025901909,0.0004659411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963842,0.0007080354,0.0016401605,0.0003382087,0.0006569802,0.00027242868],"domain_scores_gemma":[0.9939843,0.00419377,0.0008698768,0.0005164002,0.00013309527,0.00030256063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043293745,0.00015582178,0.0020111022,0.0001704538,0.00009469337,0.00002449084,0.00029983209,0.00020706601,0.00027958513],"category_scores_gemma":[0.0008106058,0.00007409809,0.0010287487,0.00043668857,0.00022033301,0.00019771139,0.00016082951,0.000693797,0.000005372162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008290849,0.0008933329,0.516104,0.000020712074,0.3289575,0.003308973,0.0009083759,0.00004602026,0.00036963442,0.0000017666322,0.021874005,0.11922487],"study_design_scores_gemma":[0.0130831525,0.01069833,0.6303033,0.00004911066,0.26225427,0.00009363327,0.00058719213,0.000294525,0.0002213192,0.00032258095,0.08189339,0.00019915459],"about_ca_topic_score_codex":0.00007704414,"about_ca_topic_score_gemma":0.00006847465,"teacher_disagreement_score":0.11902571,"about_ca_system_score_codex":0.000043658507,"about_ca_system_score_gemma":0.000747442,"threshold_uncertainty_score":0.3061261},"labels":[],"label_agreement":null},{"id":"W4324136701","doi":"10.1200/jco.2023.41.6_suppl.508","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Avelumab; Randomization; Regimen; Internal medicine; Metastatic Urothelial Carcinoma; Clinical endpoint; Chemotherapy; Oncology; Maintenance therapy; Chemotherapy regimen; Cisplatin; Urology; Surgery; Bladder cancer; Randomized controlled trial; Cancer; Nivolumab; Urothelial carcinoma; Immunotherapy","score_opus":0.07867984464162421,"score_gpt":0.3967172159134745,"score_spread":0.3180373712718503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865708,0.0009381661,0.0007017294,0.008529544,0.0012556941,0.0011264276,0.0007909455,0.000013593679,0.00007311293],"genre_scores_gemma":[0.9906604,0.004486816,0.0011859213,0.001770234,0.0010917218,0.000043154414,0.00019430174,0.000064249165,0.00050317467],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99480504,0.00043666858,0.003151736,0.0005253188,0.00060461136,0.00047663916],"domain_scores_gemma":[0.9908389,0.00577461,0.0021923913,0.0005075988,0.00042635223,0.00026018618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002346272,0.00036232086,0.003353361,0.00024865087,0.0000609546,0.000013618912,0.0003813904,0.00050481857,0.00038691462],"category_scores_gemma":[0.0013759944,0.0002429547,0.001185312,0.00055392104,0.0003323478,0.00011511765,0.00006603225,0.0006117715,0.0000027809076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45711926,0.0036254067,0.45578954,0.000055673154,0.010512378,0.00014144194,0.0013485779,0.000050022674,0.0030998026,0.000027833408,0.0056386874,0.06259137],"study_design_scores_gemma":[0.2928242,0.013684083,0.6838836,0.00015129385,0.0030676753,0.0000056404965,0.00016140443,0.0006069147,0.001111668,0.00083264394,0.0034341353,0.00023674448],"about_ca_topic_score_codex":0.0012585112,"about_ca_topic_score_gemma":0.0024499893,"teacher_disagreement_score":0.22809404,"about_ca_system_score_codex":0.00019424061,"about_ca_system_score_gemma":0.0009261501,"threshold_uncertainty_score":0.9907405},"labels":[],"label_agreement":null},{"id":"W4324136707","doi":"10.1200/jco.2023.41.6_suppl.646","title":"Real-world outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving dual immune checkpoint inhibitor (ICI-ICI) regimens or immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) combinations as first-line therapy: A British Columbia (BC) population-based analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Sunitinib; Nivolumab; Ipilimumab; Renal cell carcinoma; Internal medicine; Pembrolizumab; Axitinib; Oncology; Population; Tyrosine-kinase inhibitor; Proportional hazards model; Cancer; Immunotherapy","score_opus":0.05497399050232772,"score_gpt":0.3487207684273048,"score_spread":0.2937467779249771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929781,0.00044914256,0.000010324408,0.0038341817,0.00075396505,0.001641295,0.00007029657,0.00006883906,0.0001938721],"genre_scores_gemma":[0.9939591,0.0003861569,0.0019691482,0.00038091754,0.0004299461,0.000090406924,0.00037211718,0.00012287113,0.002289302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.989348,0.0011185838,0.006457559,0.00086868845,0.0013856125,0.0008215662],"domain_scores_gemma":[0.98973536,0.003484983,0.004112082,0.0007085509,0.0011871014,0.0007719414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042713736,0.0005973929,0.004450906,0.0012511546,0.00030695705,0.00015885038,0.00026264778,0.000441227,0.00032334775],"category_scores_gemma":[0.0026653518,0.0005225626,0.0012286193,0.002618485,0.00050232594,0.00033248082,0.00018104602,0.0016050815,0.000019145155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008080722,0.00927531,0.9723347,0.00018431195,0.0015385842,0.0035164366,0.00030927817,0.00043581333,0.00060787715,0.000004290717,0.0005193179,0.0031933933],"study_design_scores_gemma":[0.04595107,0.022046559,0.9259455,0.0006702663,0.0024160722,0.00008226682,0.00023085807,0.0006069014,0.0012058332,0.00008878004,0.00029114963,0.00046474728],"about_ca_topic_score_codex":0.021644656,"about_ca_topic_score_gemma":0.05183289,"teacher_disagreement_score":0.046389166,"about_ca_system_score_codex":0.0012278778,"about_ca_system_score_gemma":0.0017338296,"threshold_uncertainty_score":0.9997226},"labels":[],"label_agreement":null},{"id":"W4324136720","doi":"10.1200/jco.2023.41.6_suppl.72","title":"Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Docetaxel; Taxane; Cabazitaxel; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Cancer; Androgen deprivation therapy; Clinical trial; Breast cancer","score_opus":0.16528388220811646,"score_gpt":0.46729792203362736,"score_spread":0.3020140398255109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405623,0.00086210086,0.000033290253,0.010679528,0.0004696442,0.0035828569,0.0002619323,0.000016593385,0.000037816648],"genre_scores_gemma":[0.9859834,0.010817702,0.0011707775,0.00033242189,0.00012589413,0.0005326419,0.00014000782,0.000052917523,0.0008442677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946974,0.0005427537,0.0029274472,0.00044646394,0.0008163809,0.00056954165],"domain_scores_gemma":[0.9914203,0.0019780342,0.0028087015,0.0002724661,0.0031839134,0.00033653982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027266545,0.00033994456,0.002194736,0.0004254949,0.00010366125,0.000029673583,0.00016594211,0.00014715106,0.000045810564],"category_scores_gemma":[0.0016476822,0.00021037352,0.00036661027,0.000686561,0.0004023945,0.00030397685,0.000028669889,0.0006496853,0.0000039526067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061992366,0.0034770924,0.83886695,0.00065749686,0.0037125621,0.0005947006,0.004672209,0.0015353513,0.0010812304,0.0000429335,0.0014517034,0.08191543],"study_design_scores_gemma":[0.03964828,0.02036721,0.9322902,0.0008564082,0.0008574565,0.000024792453,0.0015922438,0.0008440986,0.0014989411,0.00015348078,0.0016209101,0.00024597993],"about_ca_topic_score_codex":0.0008530911,"about_ca_topic_score_gemma":0.0058491887,"teacher_disagreement_score":0.09342327,"about_ca_system_score_codex":0.000751849,"about_ca_system_score_gemma":0.0035753176,"threshold_uncertainty_score":0.8578783},"labels":[],"label_agreement":null},{"id":"W4324136732","doi":"10.1200/jco.2023.41.6_suppl.232","title":"Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Medicine; Receiver operating characteristic; Cell-free fetal DNA; Genotyping; Prostate cancer; Internal medicine; Oncology; Area under the curve; Cancer; Genotype; Biology; Genetics","score_opus":0.07925642358073769,"score_gpt":0.41340020728486215,"score_spread":0.33414378370412445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413204,0.00032123082,0.003097423,0.0007742277,0.00090413215,0.0002090588,0.00003312652,0.0000061223814,0.0005226658],"genre_scores_gemma":[0.99368846,0.0002482698,0.0043598185,0.0005802617,0.0010122701,0.0000072009684,0.000017984792,0.000019692303,0.000066021676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776036,0.00017068791,0.0015119056,0.00019037459,0.00014357778,0.00022309789],"domain_scores_gemma":[0.9969705,0.0011951083,0.0011276577,0.000173695,0.00032741664,0.00020566992],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029190308,0.00010312801,0.00065404957,0.0000746144,0.000050768336,0.000007773819,0.00022947164,0.0001934388,0.000017423006],"category_scores_gemma":[0.013635221,0.00009149203,0.0004015351,0.000116902454,0.00007011155,0.0000033353726,0.00014107928,0.0002525791,0.0000048174525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065465732,0.0014543218,0.34527153,0.0005532453,0.001367572,0.00018177078,0.0005686677,0.012680455,0.20846277,0.00036462015,0.027056448,0.39549202],"study_design_scores_gemma":[0.009833817,0.027041344,0.3673474,0.0002175325,0.0004957865,0.00018212823,0.00053926656,0.03794793,0.017548298,0.0031374763,0.53514,0.000569024],"about_ca_topic_score_codex":0.000010736849,"about_ca_topic_score_gemma":0.000033583347,"teacher_disagreement_score":0.5080835,"about_ca_system_score_codex":0.000021402273,"about_ca_system_score_gemma":0.0007569443,"threshold_uncertainty_score":0.9946734},"labels":[],"label_agreement":null},{"id":"W4324136745","doi":"10.1200/jco.2023.41.6_suppl.528","title":"A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre; University Health Network; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Medicine; Interim analysis; Cystoscopy; Bladder cancer; Carcinoma in situ; Clinical endpoint; Interim; Adverse effect; Urology; Clinical trial; Surgery; Photodynamic therapy; Internal medicine; Carcinoma; Cancer; Urinary system","score_opus":0.1173005526692258,"score_gpt":0.5202315740592199,"score_spread":0.40293102138999415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766296,0.000049369442,0.00002664107,0.00069244666,0.000547064,0.0008055135,0.000015061884,0.000011963075,0.00018900252],"genre_scores_gemma":[0.9982883,0.00031948677,0.0002206813,0.0007794344,0.00021779655,0.000011886999,0.0000112672815,0.000023454593,0.00012771794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387026,0.0011759992,0.0036975353,0.00034048228,0.0006243557,0.00029134692],"domain_scores_gemma":[0.99498284,0.0019410482,0.001726773,0.0003387239,0.000630374,0.0003802328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031960807,0.00021103559,0.0029721898,0.0005838442,0.00003679547,0.0000055984992,0.00022875109,0.0003201443,0.00020095386],"category_scores_gemma":[0.0014980978,0.00012930356,0.0006612708,0.0011527272,0.00025693473,0.00008508277,0.000077588105,0.0010709419,0.000010470106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09812674,0.0733761,0.7343011,0.000006870076,0.0049752486,0.00090564846,0.0007207338,0.000017802047,0.00002862099,0.0000017123426,0.0003240298,0.08721539],"study_design_scores_gemma":[0.086865835,0.2767843,0.6339769,0.000038363,0.0012633839,0.000009075704,0.0004063258,0.00012829741,0.0000089594505,0.000022867596,0.000423433,0.000072277806],"about_ca_topic_score_codex":0.00004978886,"about_ca_topic_score_gemma":0.00023752567,"teacher_disagreement_score":0.2034082,"about_ca_system_score_codex":0.00014897806,"about_ca_system_score_gemma":0.0013441142,"threshold_uncertainty_score":0.5272846},"labels":[],"label_agreement":null},{"id":"W4324136749","doi":"10.1200/jco.2023.41.6_suppl.549","title":"Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Pembrolizumab; Oncology; Internal medicine; Neoadjuvant therapy; Gene expression profiling; Gene expression; Immunotherapy; Cancer; Gene; Biology; Breast cancer","score_opus":0.06726500618780332,"score_gpt":0.4353241490489515,"score_spread":0.36805914286114816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563813,0.00026665517,0.000015206627,0.00248886,0.0007743377,0.0005613215,0.000014686385,0.000010171356,0.00023061069],"genre_scores_gemma":[0.9976583,0.00030045942,0.00005367023,0.0011436583,0.0006436713,0.000037674065,0.000005984368,0.000019964089,0.00013662428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963777,0.00088876433,0.0016494575,0.00025766587,0.00055776327,0.0002686306],"domain_scores_gemma":[0.9977775,0.0009960474,0.0005892366,0.000247173,0.00012457544,0.0002654567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00199983,0.0001675018,0.0011076507,0.00015165126,0.00005335599,0.000020334592,0.00019048864,0.0002538482,0.00011224707],"category_scores_gemma":[0.0010025669,0.000089848916,0.00024519782,0.00019042907,0.00012533237,0.00010379283,0.000116250696,0.0009648693,0.000022583861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054225405,0.002737647,0.96977884,0.000025241892,0.00014569527,0.0034114085,0.0008964621,5.6147593e-7,0.000020771195,9.110768e-7,0.0019663665,0.01559354],"study_design_scores_gemma":[0.024105338,0.011233398,0.9605658,0.00011773758,0.00045224844,0.00020205165,0.00033106213,0.0000077660525,0.0000146456605,0.00010026849,0.0027905798,0.00007908574],"about_ca_topic_score_codex":0.000039858613,"about_ca_topic_score_gemma":0.00010168718,"teacher_disagreement_score":0.018682798,"about_ca_system_score_codex":0.00009723786,"about_ca_system_score_gemma":0.00030575736,"threshold_uncertainty_score":0.41919306},"labels":[],"label_agreement":null},{"id":"W4324136759","doi":"10.1200/jco.2023.41.6_suppl.129","title":"Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Placebo; Prostate cancer; Randomization; Population; Internal medicine; Urology; Gynecology; Oncology; Cancer; Clinical trial; Alternative medicine","score_opus":0.1430674295185643,"score_gpt":0.48837286328871127,"score_spread":0.345305433770147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091357,0.0003343,0.000018528399,0.00567558,0.0008173416,0.0018459286,0.00007344254,0.000025056614,0.00029622807],"genre_scores_gemma":[0.9951144,0.00088566676,0.0014487177,0.0005375444,0.00018165766,0.00024710112,0.000065577595,0.00004631678,0.001473037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948865,0.00030185757,0.0029641057,0.00037856665,0.00085860083,0.0006103804],"domain_scores_gemma":[0.99432874,0.0018115827,0.001925045,0.00024932175,0.0012303289,0.00045501275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017897144,0.00027169997,0.0018975917,0.00042037954,0.00009031436,0.000027065142,0.00014705781,0.0002079598,0.00007126122],"category_scores_gemma":[0.0024735285,0.00015954599,0.0004259687,0.00057458435,0.00023534523,0.0002229892,0.00005361315,0.00077786954,0.000012113029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10479498,0.004471401,0.77313584,0.00041221522,0.0022978408,0.0038773683,0.0011254871,0.00051495456,0.00021267576,0.00005037206,0.0047237473,0.10438313],"study_design_scores_gemma":[0.10474855,0.03335952,0.84729195,0.00038876076,0.0008538845,0.00008120968,0.0005678393,0.00051953556,0.00014728034,0.00042729668,0.011361596,0.00025260632],"about_ca_topic_score_codex":0.00017801294,"about_ca_topic_score_gemma":0.0005831424,"teacher_disagreement_score":0.10413053,"about_ca_system_score_codex":0.0007352019,"about_ca_system_score_gemma":0.0052288715,"threshold_uncertainty_score":0.92757934},"labels":[],"label_agreement":null},{"id":"W4324136789","doi":"10.1200/jco.2023.41.6_suppl.18","title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Docetaxel; Population; Progression-free survival; Interim analysis; Cancer; Randomized controlled trial; Chemotherapy; Androgen receptor","score_opus":0.2779043447976356,"score_gpt":0.49502006637751983,"score_spread":0.21711572157988424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892908,0.0013407685,0.000113956405,0.0053174854,0.0025516364,0.0010158101,0.0002326247,0.000022282335,0.000114637645],"genre_scores_gemma":[0.98837525,0.0043016486,0.002807799,0.0011939518,0.0023139252,0.000106154825,0.000055825436,0.000049030656,0.00079643313],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.995214,0.00052917347,0.0031469476,0.00032862503,0.00045798757,0.00032327135],"domain_scores_gemma":[0.9936503,0.0027053487,0.0022864158,0.00021142035,0.00081615173,0.00033037405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036841817,0.00024497721,0.0018381684,0.0002369471,0.00008250385,0.000030506884,0.000132866,0.000265687,0.00038474146],"category_scores_gemma":[0.0014472349,0.00017008274,0.00045767258,0.00026699342,0.00025228,0.00022118456,0.000031283453,0.0005361956,0.000003566575],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18051352,0.0051424936,0.0077859396,0.0007834155,0.004001401,0.00058743905,0.0026002966,0.0002850202,0.5386808,0.0009417705,0.04111544,0.21756247],"study_design_scores_gemma":[0.22705969,0.11013368,0.10041767,0.0012904727,0.0015061137,0.0007508597,0.0013048061,0.0020329836,0.1451413,0.002435411,0.40689942,0.0010275929],"about_ca_topic_score_codex":0.000032736654,"about_ca_topic_score_gemma":0.0003747955,"teacher_disagreement_score":0.3935395,"about_ca_system_score_codex":0.0001790654,"about_ca_system_score_gemma":0.0030182947,"threshold_uncertainty_score":0.6935773},"labels":[],"label_agreement":null},{"id":"W4324136809","doi":"10.1200/jco.2023.41.6_suppl.115","title":"A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Docetaxel; Febrile neutropenia; Internal medicine; Neutropenia; Chemotherapy; Gemcitabine; Etoposide; Carboplatin; Oncology; Cancer; Surgery; Cisplatin","score_opus":0.1681566355874772,"score_gpt":0.4761490487553787,"score_spread":0.3079924131679015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010728665,0.9764071,0.00038881556,0.0038898773,0.00044598817,0.007889255,0.000197359,0.00002404295,0.000028858047],"genre_scores_gemma":[0.0014416839,0.99406326,0.00094775134,0.0012932,0.0013460184,0.00073215464,0.00001449779,0.00006832386,0.00009308547],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965712,0.00035389757,0.0022065633,0.00033068052,0.00028699456,0.00025066547],"domain_scores_gemma":[0.9867168,0.007402841,0.004252738,0.00037215368,0.0010581791,0.00019728192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021809645,0.0003006476,0.0034023053,0.00010660686,0.00032695243,0.0000148251165,0.00026888063,0.00031587319,0.000011756475],"category_scores_gemma":[0.0025684298,0.00012584504,0.0008219449,0.00039302153,0.00034558086,0.00007766427,0.000055966128,0.0010605816,3.226181e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003940469,0.0006119005,0.25425884,0.0920373,0.0027912327,0.000011499262,0.00012010163,0.000002953648,0.000003280334,0.00003385208,0.0011603172,0.64502823],"study_design_scores_gemma":[0.005373561,0.016300343,0.40209466,0.019594464,0.0038590648,0.00055375294,0.000026832511,5.0360876e-7,1.4793804e-7,0.000077213685,0.55193955,0.00017992717],"about_ca_topic_score_codex":0.0000058360533,"about_ca_topic_score_gemma":0.000037499616,"teacher_disagreement_score":0.64484835,"about_ca_system_score_codex":0.00067295384,"about_ca_system_score_gemma":0.0035936134,"threshold_uncertainty_score":0.6374916},"labels":[],"label_agreement":null},{"id":"W4324136813","doi":"10.1200/jco.2023.41.6_suppl.702","title":"Cross-sectional study of patients' (pts) and physicians' needs and the financial toxicity of systemic treatment for metastatic renal cell carcinoma (mRCC) in Japan.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Renal cell carcinoma; Observational study; Internal medicine; Quality of life (healthcare); Cross-sectional study; Toxicity; Clinical endpoint; Cancer; Disease; Oncology; Family medicine; Clinical trial; Pathology; Nursing","score_opus":0.11145133065096935,"score_gpt":0.37538950102366375,"score_spread":0.2639381703726944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976282,0.0006913324,0.000083764244,0.00013726896,0.00065574737,0.00045858117,0.000104155944,0.0000015804162,0.00023937362],"genre_scores_gemma":[0.9990518,0.0004474809,0.000077557874,0.00008911345,0.00022029816,0.0000189188,0.000001905096,0.0000092339005,0.00008369275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668086,0.00009955202,0.0028299366,0.00016958897,0.000048549737,0.00017152583],"domain_scores_gemma":[0.99516296,0.0017097425,0.002810047,0.0001142295,0.00013895807,0.00006403493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029864237,0.000113876304,0.0015114514,0.00024233057,0.000045588655,0.000012971406,0.0001366309,0.00013326367,0.000009911977],"category_scores_gemma":[0.001114893,0.00008676456,0.0002550019,0.00017186825,0.00026032113,0.00014572688,0.000043575757,0.00019549429,0.0000018005813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023433012,0.0012364594,0.9826912,0.000046133955,0.000092911374,0.0000025735972,0.0016195909,0.00026813513,0.0000050939575,0.002472444,0.00007442851,0.009147678],"study_design_scores_gemma":[0.018786097,0.008627686,0.9675343,0.000013121577,0.000046707682,0.0000029255093,0.00049988343,0.00047599728,0.000015390577,0.0033405004,0.0005826969,0.00007468859],"about_ca_topic_score_codex":0.00024803923,"about_ca_topic_score_gemma":0.00022685004,"teacher_disagreement_score":0.016442796,"about_ca_system_score_codex":0.000120253775,"about_ca_system_score_gemma":0.00019804706,"threshold_uncertainty_score":0.35381562},"labels":[],"label_agreement":null},{"id":"W4324136818","doi":"10.1200/jco.2023.41.6_suppl.329","title":"Patient opinions on controversies: In regard to low-risk prostate cancer, is Gleason 6 the old Gleason 5?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; Guideline; Cancer; Prostate; Anxiety; Family medicine; Gynecology; Oncology; Internal medicine; Pathology; Psychiatry","score_opus":0.4394151456877865,"score_gpt":0.5477447598364261,"score_spread":0.10832961414863962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6845339,0.0007703141,0.00003354167,0.30857015,0.003937713,0.0006564843,0.0002788105,0.000011655055,0.0012074708],"genre_scores_gemma":[0.8610042,0.006068208,0.00049686217,0.12964177,0.0016007925,0.00011005895,0.0000070589717,0.00004120653,0.0010298919],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98829067,0.0012818543,0.009364324,0.00039960013,0.00019689374,0.00046663554],"domain_scores_gemma":[0.9727669,0.01796839,0.008281542,0.00041354334,0.00018093573,0.0003887124],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03572783,0.00017115215,0.0020178705,0.0003927435,0.00013520694,0.000039023664,0.0004095727,0.00030686348,0.00022892773],"category_scores_gemma":[0.05720754,0.00014598761,0.00041067836,0.0004351423,0.00010511173,0.00016906981,0.000087491644,0.0009808919,0.0015744951],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010519793,0.00058854866,0.20824833,0.00006928981,0.00022816757,0.000024261257,0.0052702483,0.00465074,5.7678193e-7,0.008257669,0.7517246,0.0198856],"study_design_scores_gemma":[0.0030109868,0.0030727952,0.20956482,0.00024142,0.000014163704,0.000003826403,0.0018094244,0.0017337331,0.0000014083121,0.004671345,0.7757131,0.00016301172],"about_ca_topic_score_codex":0.0015934686,"about_ca_topic_score_gemma":0.0009999595,"teacher_disagreement_score":0.17892836,"about_ca_system_score_codex":0.00094414037,"about_ca_system_score_gemma":0.0008880152,"threshold_uncertainty_score":0.9992029},"labels":[],"label_agreement":null},{"id":"W4324136820","doi":"10.1200/jco.2023.41.6_suppl.76","title":"Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Western University; University of Toronto; University of Calgary; Mount Sinai Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; Jewish General Hospital; McGill University; University of Ottawa; McMaster University; University of Alberta; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Population; Cohort; Cabazitaxel; Cancer; Androgen receptor","score_opus":0.1275548431199656,"score_gpt":0.4888571245861799,"score_spread":0.36130228146621435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994231,0.00009095059,0.000007699259,0.0049003805,0.00018307354,0.00046797955,0.000026060703,0.0000039773545,0.00008889628],"genre_scores_gemma":[0.9961892,0.0030990613,0.00033997028,0.00012446617,0.000082063576,0.00001409479,0.000023067383,0.000008582774,0.00011954296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982606,0.00027868175,0.00094782753,0.00012698039,0.00024937248,0.0001365237],"domain_scores_gemma":[0.9967322,0.0012858253,0.00087813404,0.00007698018,0.0008822418,0.00014464156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009767581,0.00008299316,0.00067526224,0.0001672774,0.000016317796,0.000004245005,0.00002654157,0.00006500965,0.0000071226486],"category_scores_gemma":[0.0010889242,0.000046987636,0.000064193766,0.00020803596,0.00013778942,0.00013699465,0.0000129208665,0.00024877893,0.0000014952191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012612705,0.0011409009,0.93213207,0.000039763483,0.00061450765,0.00033162892,0.0010033911,0.00003437014,0.000029261946,0.0000073426104,0.00010390137,0.05195017],"study_design_scores_gemma":[0.013236674,0.027437316,0.956533,0.00016269187,0.00040416955,0.00002891722,0.0012417219,0.00007479256,0.00014049275,0.000014382152,0.0006891057,0.000036711383],"about_ca_topic_score_codex":0.0002111582,"about_ca_topic_score_gemma":0.00018790421,"teacher_disagreement_score":0.05191346,"about_ca_system_score_codex":0.0002758746,"about_ca_system_score_gemma":0.0013249542,"threshold_uncertainty_score":0.2350412},"labels":[],"label_agreement":null},{"id":"W4324136846","doi":"10.1200/jco.2023.41.6_suppl.671","title":"Adjuvant immunotherapy in renal cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adjuvant; Renal cell carcinoma; Internal medicine; Meta-analysis; Oncology; Immunotherapy; Randomized controlled trial; Adjuvant therapy; Systematic review; Clinical trial; Placebo; Kidney cancer; MEDLINE; Cancer; Pathology","score_opus":0.5534088171674288,"score_gpt":0.5817157849324555,"score_spread":0.028306967765026614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116505274,0.9909747,0.000024847259,0.00077010354,0.0004205952,0.007391683,0.0000470712,0.00000848048,0.00024597242],"genre_scores_gemma":[0.00032167562,0.9966449,0.00078101293,0.00077644404,0.0002987935,0.00033135278,0.000032569616,0.00008206029,0.0007311495],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.884929,0.064697765,0.04828118,0.00068491034,0.0010225354,0.00038459906],"domain_scores_gemma":[0.8276881,0.12630922,0.04339159,0.0011007199,0.0008693408,0.0006410454],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.21820934,0.0008245305,0.17732733,0.0016673655,0.000022178521,0.000014821998,0.0005464868,0.0016377843,0.00033010845],"category_scores_gemma":[0.07561468,0.00038654683,0.05754172,0.0015433929,0.0005553123,0.00006123432,0.00014157084,0.003102252,0.00002487034],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013031523,0.0016776756,0.000025829677,0.48698705,0.47802094,0.0019451585,0.000024494355,7.160362e-7,1.0197435e-7,0.0000125240285,0.00041918433,0.017854817],"study_design_scores_gemma":[0.06801051,0.0039341976,0.00007034285,0.031867493,0.8860136,0.00034652694,0.000011902299,0.000010126169,1.7496231e-7,0.000025207763,0.009489621,0.00022029974],"about_ca_topic_score_codex":0.000046575482,"about_ca_topic_score_gemma":0.000025077508,"teacher_disagreement_score":0.45511955,"about_ca_system_score_codex":0.00031470408,"about_ca_system_score_gemma":0.004116096,"threshold_uncertainty_score":0.9998586},"labels":[],"label_agreement":null},{"id":"W4324136849","doi":"10.1200/jco.2023.41.6_suppl.tps582","title":"Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Astellas Pharma; Seagen","keywords":"Medicine; Bladder cancer; Cystectomy; Tolerability; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Carcinoma in situ; Urology; Cancer; Adverse effect; Immunotherapy","score_opus":0.1589544761568458,"score_gpt":0.5099200195524446,"score_spread":0.3509655433955988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937224,0.00006500491,0.000003710922,0.00048159313,0.00076458853,0.004840911,0.000049459733,0.000006740529,0.000065624394],"genre_scores_gemma":[0.9986211,0.00011373566,0.000182277,0.000066609835,0.0006057495,0.00031859093,0.000011579453,0.000029762825,0.000050612678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958311,0.00029404133,0.0026919271,0.0002940908,0.0005882463,0.00030064106],"domain_scores_gemma":[0.9956742,0.0013956352,0.0017843536,0.00024270006,0.00065022113,0.00025288897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009453162,0.00022875755,0.0023332918,0.00026855213,0.000030219608,0.000004770705,0.00014883644,0.0001955589,0.0000642062],"category_scores_gemma":[0.00060427556,0.0001381972,0.00032767648,0.00036000746,0.00018084446,0.00008356969,0.000030661577,0.00024963642,0.0000017202814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18350424,0.117882736,0.5798951,0.000037995127,0.0020212901,0.00038566336,0.0030129983,0.00001930184,0.000009952143,0.0000014428574,0.00027056743,0.1129587],"study_design_scores_gemma":[0.2700709,0.2973015,0.42959315,0.000051088227,0.0010401479,0.000002262163,0.0015345669,0.000009281644,0.00008137633,0.000012955685,0.00024379457,0.000058979327],"about_ca_topic_score_codex":0.00019505923,"about_ca_topic_score_gemma":0.00093024527,"teacher_disagreement_score":0.17941877,"about_ca_system_score_codex":0.0002758919,"about_ca_system_score_gemma":0.0030187895,"threshold_uncertainty_score":0.5635518},"labels":[],"label_agreement":null},{"id":"W4324136858","doi":"10.1200/jco.2023.41.6_suppl.tps287","title":"CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Clinical endpoint; Oncology; Internal medicine; Enzalutamide; Taxane; Chemotherapy; Cancer; Clinical trial; Androgen receptor; Breast cancer","score_opus":0.250652462958183,"score_gpt":0.5513524197459858,"score_spread":0.3006999567878028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262184,0.0029128545,0.0000010632095,0.0029532462,0.00037500556,0.00094655657,0.000021482107,0.000007683636,0.00016024116],"genre_scores_gemma":[0.9918226,0.0072866697,0.0001646631,0.00007311375,0.00014251852,0.00003708983,0.0000054039847,0.000015604775,0.00045230685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996602,0.0004381277,0.0019359726,0.0002577575,0.00045468623,0.00031145566],"domain_scores_gemma":[0.9962404,0.0020150188,0.0008935096,0.00014723594,0.0003239239,0.000379922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002839923,0.00016465028,0.0014600867,0.00033770618,0.00005351889,0.000015081736,0.00008854068,0.00011844357,0.000051037732],"category_scores_gemma":[0.0011104341,0.000111057176,0.00011916014,0.00039355713,0.0003067718,0.00013629015,0.00006519072,0.00066045224,0.0000023586133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5387797,0.022306513,0.19528016,0.0009182162,0.0052496768,0.020372761,0.01671161,0.00022927167,0.009647687,0.00011080205,0.003552877,0.18684076],"study_design_scores_gemma":[0.5533216,0.12712651,0.28928393,0.00050999346,0.002270939,0.00024346034,0.021605616,0.0012169715,0.0007283336,0.0004559177,0.0029150276,0.0003216779],"about_ca_topic_score_codex":0.0006178428,"about_ca_topic_score_gemma":0.0020691394,"teacher_disagreement_score":0.18651909,"about_ca_system_score_codex":0.00014116718,"about_ca_system_score_gemma":0.0016922479,"threshold_uncertainty_score":0.45287803},"labels":[],"label_agreement":null},{"id":"W4324136905","doi":"10.1200/jco.2023.41.6_suppl.338","title":"Pelvic clinical node-positive prostate cancer: Impact of radiotherapy and nodal disease burden.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Context (archaeology); Radiation therapy; Internal medicine; Hazard ratio; Oncology; Univariate analysis; Prostate; Proportional hazards model; Population; Cancer; Multivariate analysis; Urology; Confidence interval","score_opus":0.12091008707411777,"score_gpt":0.554328276363233,"score_spread":0.43341818928911524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97866595,0.005017371,0.000008062608,0.014901065,0.0007087423,0.00038379923,0.00006417154,0.000013519367,0.00023732717],"genre_scores_gemma":[0.93398356,0.06222879,0.00038972465,0.00044515304,0.0018533702,0.000008841592,0.000011482432,0.00002676608,0.0010523326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632496,0.0005639111,0.0020742,0.00024810727,0.00043859717,0.00035022406],"domain_scores_gemma":[0.99460727,0.0026229566,0.001119836,0.00018420209,0.00048239809,0.0009833407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032846835,0.00016315327,0.0016668012,0.00020625863,0.000045595043,0.00001030884,0.00013293629,0.0002591186,0.00016760005],"category_scores_gemma":[0.0015052627,0.00009715949,0.0008803326,0.0002982355,0.0006883731,0.00010488449,0.000063024636,0.000958787,0.000008736902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033236895,0.00095801253,0.7617868,0.00007309009,0.001579065,0.0019512416,0.00026909544,0.000051425606,0.00027400276,0.000011055394,0.0072922735,0.192517],"study_design_scores_gemma":[0.01774757,0.018477416,0.95653576,0.00024168864,0.0004232355,0.00008115037,0.00008812536,0.0007269912,0.000027290454,0.00020767293,0.005350384,0.0000927296],"about_ca_topic_score_codex":0.00011165304,"about_ca_topic_score_gemma":0.000008861794,"teacher_disagreement_score":0.19474891,"about_ca_system_score_codex":0.00027414804,"about_ca_system_score_gemma":0.0048427503,"threshold_uncertainty_score":0.85908306},"labels":[],"label_agreement":null},{"id":"W4324136907","doi":"10.1200/jco.2023.41.6_suppl.tps283","title":"NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"SABR volatility model; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Radiation therapy; Oncology; Prostate; Internal medicine; Urology; Prostatectomy; Cancer; Surgery; Pathology","score_opus":0.1913529550231457,"score_gpt":0.5169976281634783,"score_spread":0.3256446731403326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262614,0.0015659772,0.000050692506,0.0058111176,0.00055423874,0.009190277,0.00002486705,0.000034064742,0.00014263553],"genre_scores_gemma":[0.96703583,0.025483977,0.003076251,0.00042009293,0.0005580876,0.0011751073,0.000023800134,0.00009160267,0.002135233],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926749,0.0010857787,0.0038923637,0.0004721438,0.0011712917,0.00070352206],"domain_scores_gemma":[0.9930998,0.0022090052,0.002935287,0.00036793985,0.00090409897,0.00048385814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008456009,0.00039823004,0.00403298,0.0012319527,0.00009844962,0.000028263737,0.0002840332,0.0002954803,0.00022641126],"category_scores_gemma":[0.00100107,0.00020964682,0.00052258803,0.001835338,0.00046590393,0.00030233664,0.00005146523,0.0011061999,0.0000058225423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8318784,0.0071950904,0.016373059,0.00016961031,0.0027157192,0.0008192067,0.0020898874,0.00016007418,0.0010403635,0.000008488144,0.00023331068,0.13731675],"study_design_scores_gemma":[0.8556812,0.13494606,0.0021273755,0.0004126765,0.0005483678,0.00013355345,0.00037036344,0.00096440996,0.0013964006,0.0002035485,0.0030076166,0.00020842215],"about_ca_topic_score_codex":0.00010405577,"about_ca_topic_score_gemma":0.00016050016,"teacher_disagreement_score":0.13710833,"about_ca_system_score_codex":0.0004354041,"about_ca_system_score_gemma":0.007281517,"threshold_uncertainty_score":0.99834627},"labels":[],"label_agreement":null},{"id":"W4324136914","doi":"10.1200/jco.2023.41.6_suppl.tps591","title":"Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Bladder cancer; Oncology; Internal medicine; Cancer; Urology; Immunotherapy","score_opus":0.06530937548472666,"score_gpt":0.4273297818045215,"score_spread":0.3620204063197949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989838,0.00017045708,0.00081266556,0.0035111948,0.001750546,0.002428603,0.00065683236,0.000070082744,0.0007616088],"genre_scores_gemma":[0.98598003,0.0031611645,0.0034279572,0.0035297237,0.0019496458,0.00036533433,0.000109302455,0.0001740765,0.0013027414],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934909,0.00061998813,0.00277969,0.000855497,0.0012344124,0.0010195494],"domain_scores_gemma":[0.98780274,0.0051960982,0.002860706,0.0006046777,0.0024726011,0.0010631644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016273216,0.0006715395,0.0033401803,0.0005184591,0.00025870078,0.000038377246,0.00040674134,0.0006999907,0.00048489735],"category_scores_gemma":[0.0034834794,0.0003913928,0.0007354839,0.0008208669,0.00055392645,0.00029937766,0.00011194137,0.0015133884,0.00008631397],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38162997,0.014822576,0.16695963,0.00026077364,0.00966046,0.0059542716,0.0008571207,0.0002887712,0.0001614743,0.000021910913,0.024313774,0.39506924],"study_design_scores_gemma":[0.2574298,0.27497727,0.40932268,0.000600953,0.007651118,0.00052905147,0.0005069209,0.00018863298,0.0005722888,0.000109814035,0.047418844,0.00069262384],"about_ca_topic_score_codex":0.0006823004,"about_ca_topic_score_gemma":0.0013373904,"teacher_disagreement_score":0.39437664,"about_ca_system_score_codex":0.0008306696,"about_ca_system_score_gemma":0.008743779,"threshold_uncertainty_score":0.9998538},"labels":[],"label_agreement":null},{"id":"W4324136925","doi":"10.1200/jco.2023.41.6_suppl.488","title":"Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Proportional hazards model; Internal medicine; Interquartile range; Oncology; Hazard ratio; Comorbidity; Cancer registry; Cancer; Urology; Confidence interval","score_opus":0.1614066650767347,"score_gpt":0.47534668525430473,"score_spread":0.31394002017757006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800818,0.0002882407,0.000020144354,0.0096331155,0.0014354374,0.0005043984,0.00012913735,0.000040811294,0.007866926],"genre_scores_gemma":[0.99306214,0.0017921504,0.00024156495,0.0010477331,0.0008868468,0.000023041692,0.00003750491,0.000037090955,0.0028719106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958565,0.00043804012,0.0022991977,0.0003278823,0.00070253067,0.00037582905],"domain_scores_gemma":[0.99309444,0.002867212,0.002219105,0.000263873,0.0010740487,0.00048130215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009987612,0.00031087323,0.003190123,0.0003163089,0.00006092623,0.000011308287,0.0002019636,0.00025917654,0.0004500342],"category_scores_gemma":[0.00056290237,0.00019628256,0.00058187806,0.0006811582,0.00043594168,0.00014133725,0.000046464724,0.0007469723,0.00005483992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042350106,0.0021235459,0.9353838,0.00006333223,0.0053407685,0.0006045242,0.00073017506,0.00011604511,0.00017544157,0.0001015158,0.0192782,0.03184765],"study_design_scores_gemma":[0.018847818,0.010445976,0.9483618,0.00016737841,0.0019129189,0.00003648828,0.0005116913,0.00006329179,0.0006524628,0.000045857538,0.018773496,0.00018083416],"about_ca_topic_score_codex":0.0007047924,"about_ca_topic_score_gemma":0.0029515547,"teacher_disagreement_score":0.03166681,"about_ca_system_score_codex":0.00030222922,"about_ca_system_score_gemma":0.0044218595,"threshold_uncertainty_score":0.80041707},"labels":[],"label_agreement":null},{"id":"W4324136935","doi":"10.1200/jco.2023.41.6_suppl.lba441","title":"Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Metastatic Urothelial Carcinoma; Atezolizumab; Interim analysis; Gemcitabine; Oncology; Population; Phases of clinical research; Urology; Clinical trial; Chemotherapy; Cancer; Pembrolizumab; Bladder cancer; Urothelial carcinoma; Immunotherapy","score_opus":0.17186929022796524,"score_gpt":0.48820594336400025,"score_spread":0.316336653136035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411434,0.00027607763,0.00017679222,0.0036258183,0.00059907057,0.00085898646,0.00013161254,0.0000234106,0.00019391773],"genre_scores_gemma":[0.99553245,0.0012300551,0.00060856075,0.0016998921,0.00045159066,0.000038660743,0.000032175187,0.000051474817,0.00035511047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99386716,0.0011930409,0.0032857202,0.00044411563,0.0007709733,0.00043898923],"domain_scores_gemma":[0.99258214,0.0044531636,0.0017302097,0.00050768116,0.00043261884,0.00029419892],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024923761,0.00035982116,0.0035557775,0.0004594357,0.000058103135,0.000016912245,0.0004356162,0.00025394233,0.0012314259],"category_scores_gemma":[0.0011644441,0.00020408745,0.0010284042,0.001535107,0.00024734755,0.00012561798,0.000052725358,0.00083712867,0.0000193307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24676473,0.014430006,0.51644385,0.000025234342,0.016873019,0.0037118301,0.0021268586,0.000787931,0.0009408314,0.000013230215,0.0009349447,0.19694754],"study_design_scores_gemma":[0.12572438,0.030789353,0.8311994,0.000075768556,0.005681554,0.000034084176,0.0009064376,0.0023387792,0.0005164988,0.00019217364,0.00233292,0.00020866877],"about_ca_topic_score_codex":0.0017931731,"about_ca_topic_score_gemma":0.0017951463,"teacher_disagreement_score":0.31475556,"about_ca_system_score_codex":0.00028354098,"about_ca_system_score_gemma":0.002545107,"threshold_uncertainty_score":0.9996816},"labels":[],"label_agreement":null},{"id":"W4324136951","doi":"10.1200/jco.2023.41.6_suppl.lba442","title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cohort; Bladder cancer; Cystectomy; Pembrolizumab; Internal medicine; Oncology; Cancer; Metastasis; Urology; Surgery; Immunotherapy","score_opus":0.07345774090978048,"score_gpt":0.43161687563576606,"score_spread":0.3581591347259856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845811,0.000113497714,0.00022366298,0.0068888883,0.0030970823,0.0031007791,0.0016919703,0.000021507403,0.00028151812],"genre_scores_gemma":[0.9903817,0.0014336515,0.0013863735,0.0035730596,0.0021295147,0.00020497416,0.000054284592,0.000081230326,0.00075518177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99403244,0.00084318995,0.003116636,0.0005869808,0.0009100761,0.00051067624],"domain_scores_gemma":[0.9867183,0.0074753747,0.003079431,0.0006522567,0.0014979928,0.0005766381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019652313,0.00038581868,0.0024279132,0.0002493196,0.00013660413,0.00001574704,0.00044759727,0.0005051275,0.00015472437],"category_scores_gemma":[0.0068754293,0.00022146551,0.00088317884,0.00058205565,0.00029282089,0.000112457536,0.00009210043,0.0008886566,0.000023621451],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7402162,0.0050375615,0.030593188,0.000027681832,0.004260093,0.00019693695,0.00091201573,0.0003339873,0.000309706,0.000007653994,0.02450579,0.1935992],"study_design_scores_gemma":[0.46748668,0.10747745,0.3910487,0.00031258253,0.0026253022,0.000010689421,0.00018185144,0.000055740085,0.001419411,0.0002807128,0.028841441,0.000259465],"about_ca_topic_score_codex":0.0021609792,"about_ca_topic_score_gemma":0.0011504695,"teacher_disagreement_score":0.36045548,"about_ca_system_score_codex":0.0004563806,"about_ca_system_score_gemma":0.004315968,"threshold_uncertainty_score":0.90311015},"labels":[],"label_agreement":null},{"id":"W4324136961","doi":"10.1200/jco.2023.41.6_suppl.lba16","title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Hazard ratio; Abiraterone acetate; Placebo; Progression-free survival; Interim analysis; Oncology; Prednisone; Confidence interval; Androgen deprivation therapy; Cancer; Surgery; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.31049066337092945,"score_gpt":0.5159334548274083,"score_spread":0.2054427914564788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775956,0.002322041,0.000010288487,0.017690692,0.00085043296,0.0013123159,0.000058652313,0.000016318147,0.00014365281],"genre_scores_gemma":[0.9722468,0.023976931,0.0009688081,0.00038921274,0.0005604217,0.000162333,0.00003330282,0.000043526285,0.001618646],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967788,0.00035909208,0.0015894811,0.00035761629,0.0004317627,0.00048325298],"domain_scores_gemma":[0.9961047,0.0022900105,0.00067536195,0.00014450369,0.0004004156,0.00038501027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031156025,0.0002374431,0.0013352975,0.00022802567,0.000105263476,0.00004545525,0.000106520085,0.00021235443,0.000087642926],"category_scores_gemma":[0.001022061,0.00015501722,0.00015487162,0.0002260974,0.00033291374,0.0002082857,0.00005610674,0.00070823525,0.000013718774],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.652523,0.0037038578,0.10499051,0.0008642571,0.0026651644,0.004016977,0.0018402273,0.00035763843,0.006430954,0.00031404538,0.0062089497,0.21608444],"study_design_scores_gemma":[0.30102357,0.099494934,0.5214996,0.0006543318,0.0007494215,0.00020677003,0.0007945013,0.0017369173,0.0011159581,0.0024416924,0.069766924,0.00051538774],"about_ca_topic_score_codex":0.00020117882,"about_ca_topic_score_gemma":0.0014323946,"teacher_disagreement_score":0.41650906,"about_ca_system_score_codex":0.00023142394,"about_ca_system_score_gemma":0.0018757858,"threshold_uncertainty_score":0.6321419},"labels":[],"label_agreement":null},{"id":"W4324136966","doi":"10.1200/jco.2023.41.6_suppl.lba440","title":"Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Placebo; Gemcitabine; Metastatic Urothelial Carcinoma; Urology; Oncology; Gastroenterology; Randomized controlled trial; Chemotherapy; Cancer; Pembrolizumab; Urothelial carcinoma; Bladder cancer; Immunotherapy; Pathology","score_opus":0.20118079705618278,"score_gpt":0.48444036288816095,"score_spread":0.2832595658319782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808897,0.0007231509,0.0016046229,0.0076236636,0.0020504629,0.006173908,0.00060885353,0.000053938602,0.00027171563],"genre_scores_gemma":[0.9905446,0.001212088,0.0033241927,0.00087993173,0.0018974545,0.0007183886,0.00008046331,0.00010027101,0.0012426218],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99133724,0.0014485433,0.005061574,0.0006103562,0.0008801526,0.00066211756],"domain_scores_gemma":[0.97093487,0.024124447,0.0029842139,0.0006163732,0.00080888113,0.00053119473],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004083594,0.0006103588,0.0055316077,0.00023876365,0.00019699842,0.000024626928,0.00048412674,0.000329891,0.0007483453],"category_scores_gemma":[0.008733754,0.00031546463,0.0017220493,0.00045895085,0.00052102894,0.00016108023,0.00011369882,0.0007496341,0.00004801847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8618201,0.010560381,0.0037990615,0.00008160376,0.00582256,0.001821278,0.001251469,0.00036837955,0.00013729703,0.000028560376,0.0024651827,0.11184414],"study_design_scores_gemma":[0.8501127,0.11498415,0.008514798,0.00025807146,0.008888788,0.00020831531,0.0010327643,0.0025642253,0.0007172628,0.0007462228,0.011663993,0.00030872377],"about_ca_topic_score_codex":0.00040666186,"about_ca_topic_score_gemma":0.00080682925,"teacher_disagreement_score":0.111535415,"about_ca_system_score_codex":0.0004269444,"about_ca_system_score_gemma":0.003942101,"threshold_uncertainty_score":0.9999297},"labels":[],"label_agreement":null},{"id":"W4324136969","doi":"10.1200/jco.2023.41.6_suppl.tps396","title":"DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; Jewish General Hospital","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Docetaxel; Placebo; Internal medicine; Salvage therapy; Randomization; Prostatectomy; Oncology; Randomized controlled trial; Antiandrogen; Urology; Surgery; Cancer; Chemotherapy; Pathology","score_opus":0.2047591432241928,"score_gpt":0.5064863245693975,"score_spread":0.30172718134520465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989336,0.0014899197,0.0004948129,0.004501131,0.00049508316,0.003551018,0.000070729366,0.000015016201,0.000046274297],"genre_scores_gemma":[0.9152064,0.081959315,0.00119799,0.00026692887,0.0007548872,0.0003124632,0.00006970018,0.00002998582,0.00020238366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964735,0.00063735753,0.0019696373,0.0002366278,0.0004251864,0.00025770822],"domain_scores_gemma":[0.9894129,0.0073659797,0.0021967038,0.00013357912,0.0006527643,0.00023806399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00623136,0.00016274986,0.0020231514,0.00026193797,0.00007449718,0.000014974504,0.0000815331,0.00026923147,0.00003313367],"category_scores_gemma":[0.003066335,0.00008587003,0.0003266792,0.00036760754,0.0004873311,0.00014673197,0.000023102088,0.0004982855,0.0000013627322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7745846,0.001143256,0.0022127198,0.00004728083,0.0014248918,0.00012916522,0.00027213412,0.00002214646,0.0000979929,0.00006065544,0.00033611283,0.21966907],"study_design_scores_gemma":[0.9410628,0.04970524,0.0012859859,0.00013439305,0.00090070633,0.000030945936,0.000119228294,0.0005459678,0.0013445917,0.0008085546,0.0039724545,0.00008913009],"about_ca_topic_score_codex":0.00009937502,"about_ca_topic_score_gemma":0.000038052713,"teacher_disagreement_score":0.21957995,"about_ca_system_score_codex":0.0001240347,"about_ca_system_score_gemma":0.0028427227,"threshold_uncertainty_score":0.5042868},"labels":[],"label_agreement":null},{"id":"W4324136974","doi":"10.1200/jco.2023.41.6_suppl.169","title":"Comparative outcomes of metastatic prostate cancer (mPC) patients (pts) with DNA damage response gene alterations (DDR-a): A single-center experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Clinical endpoint; Oncology; Cancer; Progression-free survival; Overall survival; Clinical trial; Androgen receptor","score_opus":0.2792048131138515,"score_gpt":0.5362127304498683,"score_spread":0.2570079173360168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936668,0.00011774095,0.000019986908,0.004813027,0.00047719164,0.00060380035,0.00007029237,0.0000115998655,0.00021952714],"genre_scores_gemma":[0.99586904,0.00029593435,0.0015393277,0.0005191505,0.00011386746,0.000057987458,0.00002489805,0.000017269467,0.0015625028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652785,0.00072538573,0.0016335347,0.00020560285,0.00060012663,0.00030749082],"domain_scores_gemma":[0.9953515,0.0020033782,0.0011383558,0.0001929381,0.0009850537,0.00032875492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014683947,0.0001614775,0.0014735155,0.00026957973,0.00006953294,0.000013507209,0.00014235856,0.000090920556,0.0001430218],"category_scores_gemma":[0.0009511418,0.00009050651,0.0002566625,0.00042160947,0.00047910478,0.00017963712,0.00006087414,0.00045639413,0.000016188329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051555872,0.006455421,0.920007,0.00005439735,0.0016707605,0.0010978067,0.0056604315,0.00010522537,0.003526962,0.00000799326,0.00398464,0.0058734794],"study_design_scores_gemma":[0.031888627,0.032883856,0.9176225,0.00023117966,0.00043091807,0.000051297735,0.0016094523,0.0001900387,0.0043619303,0.000043416647,0.010542132,0.00014466581],"about_ca_topic_score_codex":0.000017479075,"about_ca_topic_score_gemma":0.000064414315,"teacher_disagreement_score":0.026428433,"about_ca_system_score_codex":0.0002459841,"about_ca_system_score_gemma":0.0017091805,"threshold_uncertainty_score":0.36907482},"labels":[],"label_agreement":null},{"id":"W4324136985","doi":"10.1200/jco.2023.41.6_suppl.177","title":"Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Enzalutamide; Adverse effect; Pharmacokinetics; Internal medicine; Oncology; Pharmacodynamics; Antiandrogen; Pharmacology; Abiraterone acetate; Abiraterone; Tolerability; Cancer; Androgen deprivation therapy","score_opus":0.1872818187061182,"score_gpt":0.5233139718776647,"score_spread":0.3360321531715465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908303,0.00023423895,0.0000024310634,0.007705114,0.00038256854,0.00040916048,0.000015781407,0.000009342575,0.00041108255],"genre_scores_gemma":[0.9967707,0.0007890138,0.0007684856,0.00035660717,0.00016506578,0.000019269708,0.000018703371,0.000016265658,0.0010959349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740726,0.00028197435,0.0013427674,0.00015766363,0.00050550187,0.00030480957],"domain_scores_gemma":[0.9977656,0.0006916486,0.00064931693,0.000111566944,0.0004943601,0.00028748915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019354096,0.00010929202,0.00095172116,0.00022354837,0.000033023687,0.00000999912,0.000088314395,0.00009693932,0.00011065052],"category_scores_gemma":[0.00075455493,0.00006170643,0.00014373157,0.0004726935,0.00017170691,0.0001222042,0.000026271518,0.00064287113,0.000024484236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024369478,0.0015029153,0.88580877,0.00006388858,0.00043783005,0.0022588538,0.00019400366,0.00008696539,0.0000458023,0.000023986766,0.0034593425,0.081748195],"study_design_scores_gemma":[0.023667201,0.016815504,0.9509384,0.00016221605,0.00018520474,0.000013057568,0.00014595562,0.000054386786,0.000035205754,0.00018488133,0.007731421,0.00006655315],"about_ca_topic_score_codex":0.000084401174,"about_ca_topic_score_gemma":0.00039832795,"teacher_disagreement_score":0.08168164,"about_ca_system_score_codex":0.0002665847,"about_ca_system_score_gemma":0.0027878033,"threshold_uncertainty_score":0.49454433},"labels":[],"label_agreement":null},{"id":"W4324136996","doi":"10.1200/jco.2023.41.6_suppl.299","title":"Patient-level data meta-analysis of a multi-modal artificial intelligence (MMAI) prognostic biomarker in high-risk prostate cancer: Results from six NRG/RTOG phase III randomized trials.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Prostate cancer; Biomarker; Oncology; Internal medicine; Radiation therapy; Cohort; Randomized controlled trial; Prostate; Cumulative incidence; Cancer","score_opus":0.4715789308372614,"score_gpt":0.5536479833131753,"score_spread":0.08206905247591395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671418,0.0016286677,0.010645663,0.015983608,0.0017761737,0.0012778203,0.0014979518,0.000023749684,0.000024546493],"genre_scores_gemma":[0.9792789,0.0035186314,0.015690023,0.00056428637,0.0004077316,0.0000357093,0.00042358568,0.000028295253,0.000052810105],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97908086,0.0065196687,0.012458182,0.00064364314,0.0008833386,0.00041428296],"domain_scores_gemma":[0.9288459,0.059053846,0.010189487,0.000741854,0.0006409016,0.0005280057],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.057553932,0.00028698164,0.010881008,0.0009516011,0.000054656495,0.000025322728,0.0005493459,0.00038985495,0.00026642645],"category_scores_gemma":[0.2878852,0.00017468087,0.0027031372,0.0014999278,0.0006446138,0.00015542537,0.00027084816,0.0019405701,0.000008913937],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3191654,0.0033495275,0.0031243018,0.00002256518,0.10861854,0.0009987922,0.0007678174,0.0036837615,0.00025245245,0.000030795654,0.0011841215,0.55880195],"study_design_scores_gemma":[0.21549504,0.0021081183,0.0100538945,0.0001017793,0.26220727,0.000012327596,0.0002561728,0.50695914,0.00006306266,0.0010180232,0.00152004,0.00020515207],"about_ca_topic_score_codex":0.0041771447,"about_ca_topic_score_gemma":0.00081260654,"teacher_disagreement_score":0.5585968,"about_ca_system_score_codex":0.00008219919,"about_ca_system_score_gemma":0.0015174989,"threshold_uncertainty_score":0.9704465},"labels":[],"label_agreement":null},{"id":"W4324136998","doi":"10.1200/jco.2023.41.6_suppl.391","title":"Biochemical recurrence (BCR) surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate (BCRSCRAP): A meta-analysis from MARCAP Consortium.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Censoring (clinical trials); Hazard ratio; Prostate cancer; Proportional hazards model; Clinical endpoint; Oncology; Meta-analysis; Internal medicine; Biochemical recurrence; Randomized controlled trial; Radiation therapy; Survival analysis; Clinical trial; Confidence interval; Cancer; Prostatectomy","score_opus":0.2985716304873846,"score_gpt":0.5183122075337184,"score_spread":0.21974057704633382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94776964,0.009668414,0.00031573419,0.038391188,0.0014544682,0.001680474,0.00068646634,0.000014237805,0.00001936347],"genre_scores_gemma":[0.9793868,0.0057189474,0.009093506,0.0043362733,0.0006757688,0.00039625823,0.00004172086,0.00003504429,0.00031565386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937704,0.00061508705,0.0043359185,0.0004656179,0.00044446543,0.00036850144],"domain_scores_gemma":[0.97878295,0.016605912,0.0028799355,0.000548691,0.00081472116,0.00036778938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004912162,0.000262609,0.0048394944,0.00018296976,0.000047387908,0.00001360987,0.0003401985,0.0004114982,0.00020284548],"category_scores_gemma":[0.0055441516,0.00013581097,0.008694777,0.0004888094,0.0005401282,0.00007246851,0.00007846755,0.00056763284,0.0000039514534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008705705,0.0017164596,0.8604387,0.000047691214,0.10337475,0.00006446967,0.00009501953,0.0000059728777,0.000022368587,0.000033260112,0.01749795,0.007997638],"study_design_scores_gemma":[0.01179566,0.006700701,0.83180135,0.000031488285,0.11660695,0.000010466737,0.000057443303,0.00012939662,0.00028925494,0.0008255742,0.03162175,0.00012998456],"about_ca_topic_score_codex":0.000030136915,"about_ca_topic_score_gemma":0.00004054014,"teacher_disagreement_score":0.034054913,"about_ca_system_score_codex":0.00012243069,"about_ca_system_score_gemma":0.0012787377,"threshold_uncertainty_score":0.8768916},"labels":[],"label_agreement":null},{"id":"W4324137009","doi":"10.1200/jco.2023.41.6_suppl.tps274","title":"PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; Prostate cancer; MSH2; PALB2; MSH6; Genetic testing; Oncology; PTEN; Germline; MLH1; Internal medicine; Cancer; Germline mutation; Genetics; DNA mismatch repair; Mutation; Gene; Colorectal cancer; Biology","score_opus":0.16414880134387766,"score_gpt":0.5276381257444269,"score_spread":0.36348932440054926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98491234,0.0010859211,0.000017670158,0.012443071,0.00036042056,0.0009851535,0.00009211693,0.000010117677,0.00009316442],"genre_scores_gemma":[0.98686796,0.009049832,0.0009307814,0.00006922055,0.0003178624,0.00014956864,0.000026317553,0.000021423668,0.0025670305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832195,0.00019781351,0.0009515285,0.0001880736,0.00014203042,0.00019862822],"domain_scores_gemma":[0.99537104,0.0030257844,0.0008187558,0.0001314571,0.00040407098,0.0002488933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017323784,0.00012245304,0.0012355131,0.00010722235,0.000048379432,0.000008148158,0.000050537637,0.00017151189,0.000006609193],"category_scores_gemma":[0.0020517798,0.00007184919,0.00022734606,0.00013117124,0.00034603418,0.00005388646,0.00003206099,0.00022579056,4.1529742e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025599118,0.0014110588,0.6903384,0.00056872144,0.0019972953,0.00030510154,0.00030266962,0.000008537823,0.003264093,0.00007639458,0.00066464837,0.27546397],"study_design_scores_gemma":[0.036281183,0.018317662,0.93263257,0.0002052569,0.0007065041,0.00006426121,0.00024711207,0.00028485036,0.0007331167,0.0007151785,0.009726233,0.00008607846],"about_ca_topic_score_codex":0.00008430369,"about_ca_topic_score_gemma":0.00007350055,"teacher_disagreement_score":0.2753779,"about_ca_system_score_codex":0.0001449232,"about_ca_system_score_gemma":0.0016759986,"threshold_uncertainty_score":0.29731497},"labels":[],"label_agreement":null},{"id":"W4324137014","doi":"10.1200/jco.2023.41.6_suppl.tps279","title":"TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; PARP inhibitor; Prostate cancer; Internal medicine; Placebo; Oncology; Cancer; Androgen receptor; Cancer research; Pathology; Poly ADP ribose polymerase; Genetics; Biology; Gene","score_opus":0.14805231365607274,"score_gpt":0.4902022351030057,"score_spread":0.34214992144693296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920579,0.00018666696,0.00013745685,0.001067039,0.0010353231,0.0052379277,0.00008686921,0.000032061802,0.00015874866],"genre_scores_gemma":[0.997092,0.00044898028,0.0007843924,0.0006558574,0.0003608147,0.00036094853,0.00006441378,0.00006370877,0.00016888672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99080706,0.0018595156,0.0050354614,0.0005080255,0.0012562759,0.0005336556],"domain_scores_gemma":[0.9894305,0.0037575602,0.004384754,0.00033596088,0.0016292473,0.00046199333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049569146,0.0004048834,0.0045392783,0.0007031952,0.000076524695,0.000023353028,0.00020557977,0.0002838746,0.00010902346],"category_scores_gemma":[0.0014470143,0.00028844672,0.0004950944,0.001012645,0.0005878513,0.00030532962,0.00006510156,0.001424761,0.000017238766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95353574,0.006647633,0.017435286,0.00008321133,0.0024519002,0.002080868,0.0044357665,0.008150993,0.00032133248,0.000013473133,0.0004298577,0.0044139656],"study_design_scores_gemma":[0.94638836,0.027068648,0.019772451,0.00042589905,0.0014918948,0.0001495914,0.0017998077,0.0011781382,0.0011664478,0.00007396875,0.00021544323,0.00026934873],"about_ca_topic_score_codex":0.0003244792,"about_ca_topic_score_gemma":0.00070485513,"teacher_disagreement_score":0.020421015,"about_ca_system_score_codex":0.00084073294,"about_ca_system_score_gemma":0.0049439543,"threshold_uncertainty_score":0.9999568},"labels":[],"label_agreement":null},{"id":"W4324137016","doi":"10.1200/jco.2023.41.6_suppl.136","title":"Radiographic progression-free survival (rPFS) and time to radiographic progression (TTrP) as surrogate endpoints in docetaxel-naïve metastatic castrate resistant prostate cancer (mCRPC): A pooled analysis of COU-AA-302 and ACIS.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Docetaxel; Placebo; Internal medicine; Enzalutamide; Progression-free survival; Oncology; Prostate cancer; Population; Clinical endpoint; Proportional hazards model; Randomized controlled trial; Cancer; Overall survival; Pathology","score_opus":0.08520076043534967,"score_gpt":0.4857800125696871,"score_spread":0.4005792521343374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835807,0.0065477095,0.0000024787716,0.007980975,0.00024024834,0.0012793008,0.00012532948,0.000024772158,0.0002184766],"genre_scores_gemma":[0.9801556,0.017812386,0.0010303598,0.00019254822,0.00013488707,0.00010262924,0.000037585465,0.00004200465,0.00049201335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935624,0.0012570869,0.0027458214,0.0005830189,0.0011653516,0.0006863108],"domain_scores_gemma":[0.9942193,0.0021519968,0.001575561,0.0003997317,0.00069106114,0.0009623618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0079481965,0.0003467832,0.0031037712,0.0027659582,0.00009728962,0.000040492665,0.00027977893,0.0002972153,0.00018296458],"category_scores_gemma":[0.002099669,0.00022448874,0.0006350057,0.0044127144,0.0007518794,0.00019408565,0.00021721957,0.0009973891,0.0000102990025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063584074,0.0037983176,0.69130534,0.0007255025,0.016587105,0.012030386,0.0014824711,0.00011929541,0.008092885,0.000046984755,0.0020310218,0.20019664],"study_design_scores_gemma":[0.028001796,0.021672726,0.93554467,0.0015172438,0.0074234186,0.00019187137,0.00053356535,0.001306588,0.0005172167,0.0007190226,0.0022295786,0.00034230895],"about_ca_topic_score_codex":0.00013998881,"about_ca_topic_score_gemma":0.000446341,"teacher_disagreement_score":0.24423935,"about_ca_system_score_codex":0.00013930869,"about_ca_system_score_gemma":0.0015009892,"threshold_uncertainty_score":0.91543853},"labels":[],"label_agreement":null},{"id":"W4324137050","doi":"10.1200/jco.2023.41.6_suppl.166","title":"Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Internal medicine; Cohort; Clinical endpoint; Docetaxel; Androgen receptor; Oncology; Cancer; Androgen deprivation therapy; Clinical trial","score_opus":0.08534680067596,"score_gpt":0.4606475781123941,"score_spread":0.3753007774364341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934285,0.00051985186,0.0000063985376,0.0026626012,0.0004636646,0.0025579908,0.0003387899,0.00001009399,0.000012082214],"genre_scores_gemma":[0.99579537,0.00234719,0.00058899896,0.00031514192,0.00033809993,0.00020671047,0.00008836091,0.00004388749,0.000276247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962814,0.00034405402,0.0017837912,0.00042781455,0.00081578246,0.0003471661],"domain_scores_gemma":[0.9957371,0.0015402592,0.0014762143,0.00016562412,0.0007910715,0.00028974662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015877149,0.00026164058,0.001185627,0.00037251363,0.00006120252,0.000029323059,0.0001577569,0.00011752407,0.00019538177],"category_scores_gemma":[0.0008127401,0.00016365582,0.00018420733,0.0002881774,0.00020700663,0.00022929882,0.00006992124,0.0005716863,0.000005315089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42655453,0.013549963,0.49205768,0.00026991538,0.0027535923,0.0018699021,0.0035351673,0.00031906736,0.000777156,0.00000836643,0.000666646,0.057638012],"study_design_scores_gemma":[0.19433953,0.1486555,0.63436574,0.005786911,0.0006139431,0.000033405333,0.0015895845,0.0009602814,0.0037603134,0.0000950802,0.009375045,0.00042465836],"about_ca_topic_score_codex":0.00006446762,"about_ca_topic_score_gemma":0.0005288971,"teacher_disagreement_score":0.232215,"about_ca_system_score_codex":0.00023553958,"about_ca_system_score_gemma":0.00070303975,"threshold_uncertainty_score":0.66736907},"labels":[],"label_agreement":null},{"id":"W4324137081","doi":"10.1200/jco.2023.41.6_suppl.394","title":"The landscape of prostate cancer research in Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Movember Canada","keywords":"Medicine; Prostate cancer; Investment (military); Cancer; Cancer registry; Disease; Family medicine; Database; Gerontology; Political science; Internal medicine","score_opus":0.6362756902591336,"score_gpt":0.6820773536302881,"score_spread":0.045801663371154544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8619082,0.00023970114,0.0000011794117,0.13585083,0.0011405116,0.0001810192,0.0000041550275,0.0000019931376,0.0006724108],"genre_scores_gemma":[0.99160427,0.0060199355,0.00016168033,0.0012318778,0.000689279,0.0000063813013,0.0000019083332,0.000008686159,0.00027596627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938433,0.0010705468,0.0039428393,0.00010670328,0.00076742726,0.00026914294],"domain_scores_gemma":[0.96405846,0.032980982,0.0014858582,0.00016248759,0.0011270989,0.00018509547],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02662781,0.000051243413,0.000673537,0.00013679289,0.00003831311,0.00000421373,0.00016947059,0.00010384125,0.00008277113],"category_scores_gemma":[0.03906081,0.000029539084,0.00011920729,0.00063330145,0.00014673428,0.00006256358,0.00007599909,0.0013862433,0.000009156135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034906697,0.00015693817,0.54739136,0.000021248772,0.000087445944,0.00039246108,0.00006083658,0.00008412819,0.000056007288,0.00003870503,0.095250964,0.35296926],"study_design_scores_gemma":[0.004910291,0.0028730799,0.7883898,0.00009492053,0.000060019927,0.00003779289,0.0022545762,0.0004643664,0.000032044656,0.00069598097,0.20015433,0.00003278743],"about_ca_topic_score_codex":0.24804707,"about_ca_topic_score_gemma":0.84143245,"teacher_disagreement_score":0.5933854,"about_ca_system_score_codex":0.00032666823,"about_ca_system_score_gemma":0.023577074,"threshold_uncertainty_score":0.9819583},"labels":[],"label_agreement":null},{"id":"W4327573670","doi":"10.1200/jco.2023.41.6_suppl.218","title":"Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Jewish General Hospital; Western University; London Health Sciences Centre; McMaster University; Juravinski Cancer Centre; McGill University; Centre Hospitalier de l’Université de Montréal; University of British Columbia; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; PTEN; Prostate cancer; Oncology; Internal medicine; Clinical endpoint; Cancer; Biomarker; Clinical trial; PI3K/AKT/mTOR pathway; Biology","score_opus":0.1983996801879875,"score_gpt":0.5153342638053399,"score_spread":0.3169345836173524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327573670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992319,0.0014929619,0.0000501546,0.0031203714,0.0011148683,0.0016475518,0.00019576687,0.0000033511412,0.000055999462],"genre_scores_gemma":[0.9935995,0.003698325,0.00027587425,0.00042957225,0.001289371,0.0004457996,0.000022707753,0.000023447375,0.00021543461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969667,0.0005402498,0.0017108112,0.0002941073,0.00015010778,0.00033798817],"domain_scores_gemma":[0.9971754,0.000952409,0.0011809112,0.000119088574,0.00036158907,0.00021063641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045484086,0.00017054533,0.0008906823,0.0001304294,0.000252998,0.000036386882,0.0001541504,0.00016844863,0.0000192553],"category_scores_gemma":[0.0021282183,0.00011477149,0.00031321953,0.00023226072,0.00008094664,0.000008144659,0.0000331737,0.00020150215,0.0000011663427],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034339756,0.008937499,0.079545744,0.000090226546,0.006092427,0.00041445548,0.0044930787,0.021250255,0.09860267,0.00047472902,0.017419912,0.72833925],"study_design_scores_gemma":[0.08853224,0.1559425,0.27113026,0.00016854543,0.0030282235,0.00006889442,0.0030986,0.0026544996,0.011536492,0.002400117,0.46047273,0.0009669015],"about_ca_topic_score_codex":0.03144972,"about_ca_topic_score_gemma":0.8196643,"teacher_disagreement_score":0.7882146,"about_ca_system_score_codex":0.0007030383,"about_ca_system_score_gemma":0.006065102,"threshold_uncertainty_score":0.9995696},"labels":[],"label_agreement":null},{"id":"W4327700855","doi":"10.1200/jco.22.01916","title":"Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Multiple myeloma; Internal medicine; Hazard ratio; AL amyloidosis; Gastroenterology; Clinical significance; Bone marrow; Phenotype; Pathology; Monoclonal; Oncology; Immunology; Monoclonal antibody; Immunoglobulin light chain; Antibody; Confidence interval; Biology","score_opus":0.12955596645445286,"score_gpt":0.4218574056104702,"score_spread":0.29230143915601736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327700855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977895,0.000100998994,0.00002034731,0.0008269827,0.00039763158,0.00047666408,0.00002888083,0.0000060258567,0.0003529573],"genre_scores_gemma":[0.9964261,0.00046148157,0.0026864687,0.00016542872,0.00017510305,0.000009156184,0.00000905331,0.000017152512,0.000050066425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952896,0.00079001696,0.0026598484,0.00025153704,0.0007197766,0.00028921428],"domain_scores_gemma":[0.9930457,0.0039393995,0.0018624577,0.0002506511,0.00061010435,0.00029170688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030052052,0.00016157058,0.001440887,0.00020050869,0.000034984285,0.0000049138102,0.00019944085,0.0002759065,0.000027988619],"category_scores_gemma":[0.00359317,0.00009291173,0.00034951733,0.00042381947,0.0008222551,0.000095249285,0.000093054485,0.0008431611,0.00000514689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014095467,0.0022446867,0.9410581,0.000074043885,0.00026663448,0.00018267144,0.00006018353,0.000010584655,0.0000970036,0.00006492468,0.00017421826,0.041671496],"study_design_scores_gemma":[0.015713843,0.013580545,0.9689107,0.00022551273,0.00018884437,0.000016672459,0.00007715897,0.00020237225,0.00010178686,0.0006816189,0.00022518364,0.00007576434],"about_ca_topic_score_codex":0.000048974107,"about_ca_topic_score_gemma":0.00009642533,"teacher_disagreement_score":0.04159573,"about_ca_system_score_codex":0.00008449071,"about_ca_system_score_gemma":0.0015376738,"threshold_uncertainty_score":0.43016195},"labels":[],"label_agreement":null},{"id":"W4360608257","doi":"10.1200/jco.22.01649","title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":319,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Cohort; Placebo; Hazard ratio; Internal medicine; Prednisone; Oncology; Clinical endpoint; Urology; Progression-free survival; Androgen deprivation therapy; Androgen receptor; Cancer; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.2899895319608854,"score_gpt":0.5543641495000348,"score_spread":0.26437461753914937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360608257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97131693,0.0018402648,0.000039824514,0.025302764,0.00065391924,0.00058096566,0.00003776594,0.000014046944,0.00021351078],"genre_scores_gemma":[0.97882336,0.010215785,0.0036042437,0.00084844814,0.0006614148,0.000082876235,0.000018836765,0.000027237676,0.005717766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978606,0.00015745699,0.0012843146,0.00016255937,0.0002562234,0.00027884523],"domain_scores_gemma":[0.997283,0.0011940922,0.0006442029,0.0000907738,0.00046727786,0.00032067538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025866996,0.00010487194,0.00094696827,0.00014535498,0.00006408044,0.000016932694,0.00006303902,0.000103282015,0.00004602591],"category_scores_gemma":[0.00087969645,0.00006448111,0.00020728784,0.00018608393,0.0002110673,0.00010301504,0.00002766956,0.00036483354,0.00000993173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06785408,0.0019887844,0.07667806,0.0010136135,0.004141139,0.0037954082,0.0014564367,0.00012511421,0.020284515,0.00044055824,0.057602428,0.7646199],"study_design_scores_gemma":[0.078267634,0.057575203,0.5324579,0.00051819254,0.0023512424,0.00041975512,0.0012689208,0.001206166,0.0029207622,0.0054346398,0.3172293,0.00035031227],"about_ca_topic_score_codex":0.000024047933,"about_ca_topic_score_gemma":0.00008096982,"teacher_disagreement_score":0.76426953,"about_ca_system_score_codex":0.00009670948,"about_ca_system_score_gemma":0.0017041327,"threshold_uncertainty_score":0.30230582},"labels":[],"label_agreement":null},{"id":"W4360825582","doi":"10.1200/jco.23.00280","title":"Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Adjuvant; Oncology; Adjuvant therapy; Internal medicine; Clinical trial; Urothelial cancer; Kidney cancer; Bladder cancer","score_opus":0.5047290868562413,"score_gpt":0.5790289443396136,"score_spread":0.07429985748337231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360825582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98579997,0.002662664,0.00005149754,0.009748326,0.00050947303,0.00079797115,0.00003230419,0.000013179794,0.00038462933],"genre_scores_gemma":[0.98959935,0.003394515,0.004174906,0.0005937246,0.0014013974,0.000057107827,0.000009818032,0.000035940706,0.0007332225],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946855,0.00069779356,0.0034582524,0.00022367774,0.0006619843,0.00027282466],"domain_scores_gemma":[0.9846011,0.009689834,0.003868272,0.0002477146,0.00133546,0.00025763063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012607828,0.00016480181,0.0031487518,0.00018032624,0.00004460229,0.0000059178305,0.00016041467,0.00028350955,0.00040291122],"category_scores_gemma":[0.00623726,0.000087618355,0.00088810665,0.00035342877,0.00010010181,0.00005074394,0.00003089805,0.00048308197,0.000005600804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09779237,0.0017158588,0.1376179,0.00020068615,0.0043281363,0.00046027027,0.0010262543,0.0006533569,0.017629683,0.000050954244,0.012745552,0.725779],"study_design_scores_gemma":[0.049963783,0.12599248,0.7919757,0.00077163836,0.001998271,0.00021211884,0.00040617894,0.0013114852,0.013562787,0.001041205,0.012596385,0.00016799051],"about_ca_topic_score_codex":0.00009452158,"about_ca_topic_score_gemma":0.00018437009,"teacher_disagreement_score":0.725611,"about_ca_system_score_codex":0.00016802772,"about_ca_system_score_gemma":0.0025949946,"threshold_uncertainty_score":0.7467034},"labels":[],"label_agreement":null},{"id":"W4361252724","doi":"10.1200/jco.22.02120","title":"Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Children's Cancer and Leukaemia Group","keywords":"Medicine; Myeloid leukemia; Disease; Oncology; Internal medicine; Leukemia","score_opus":0.061764803794376405,"score_gpt":0.40195570795067576,"score_spread":0.3401909041562994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361252724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862285,0.00052052503,0.000007788366,0.010116039,0.0009712088,0.0015875387,0.000050702172,0.000030600375,0.00048706195],"genre_scores_gemma":[0.9943235,0.0029429153,0.00006671796,0.0005996342,0.0010753283,0.00005240639,0.00002379072,0.00004749305,0.00086819974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99143076,0.0030106036,0.002536052,0.0006175027,0.0018835035,0.0005215921],"domain_scores_gemma":[0.9930914,0.0042199986,0.0010631594,0.00045077183,0.00039936585,0.00077527884],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019194234,0.00030647576,0.0015028442,0.00038954808,0.00020379687,0.00007757368,0.00055031345,0.0003857403,0.00005995249],"category_scores_gemma":[0.006774529,0.0001901207,0.00023155432,0.00048411512,0.00038840517,0.00030966193,0.0006626484,0.003795754,0.000018851628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015005638,0.0046509253,0.9355787,0.000013686042,0.0017879173,0.0038614057,0.0017805921,0.00001403621,0.00014534147,0.0000051755474,0.014492924,0.02266366],"study_design_scores_gemma":[0.039145757,0.011621928,0.93879515,0.00007342537,0.0011456148,0.0002444594,0.005125391,0.00034355145,0.0000053882254,0.0001534367,0.003185142,0.0001607707],"about_ca_topic_score_codex":0.00033132255,"about_ca_topic_score_gemma":0.0011056293,"teacher_disagreement_score":0.024140118,"about_ca_system_score_codex":0.0004835439,"about_ca_system_score_gemma":0.0017867285,"threshold_uncertainty_score":0.99850255},"labels":[],"label_agreement":null},{"id":"W4362676637","doi":"10.1200/jco.23.00281","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; Pathology","score_opus":0.08184180362781925,"score_gpt":0.507410448665457,"score_spread":0.4255686450376378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362676637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714732,0.0012230877,0.005069458,0.016442975,0.0019292003,0.0009722299,0.000044540226,0.000025673284,0.0028195991],"genre_scores_gemma":[0.87003285,0.01750085,0.046935495,0.014638364,0.0062215338,0.0002270021,0.00009903447,0.00010701842,0.04423785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814016,0.00009074641,0.0011762436,0.00017295647,0.00021837109,0.00020154043],"domain_scores_gemma":[0.99670386,0.0014202478,0.00082955393,0.00013800588,0.0007005304,0.00020777735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001157299,0.00011636535,0.0006553384,0.00013201556,0.00010032658,0.000013947039,0.00009243087,0.00016422861,0.0003723422],"category_scores_gemma":[0.00041450502,0.0000725256,0.00027178315,0.00019198243,0.000052924544,0.00011636675,0.000021787893,0.00031687494,0.000016547776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065354872,0.003065134,0.3278011,0.00017887824,0.0031216855,0.0006497558,0.001433286,0.004236935,0.0011588352,0.000070749025,0.5308414,0.12090675],"study_design_scores_gemma":[0.029763795,0.018674962,0.18905167,0.0005626334,0.0017773464,0.000041274216,0.00087991153,0.009319601,0.00019345108,0.00004822051,0.7494724,0.00021472595],"about_ca_topic_score_codex":0.00007330967,"about_ca_topic_score_gemma":0.00012136656,"teacher_disagreement_score":0.218631,"about_ca_system_score_codex":0.0002138087,"about_ca_system_score_gemma":0.0026676932,"threshold_uncertainty_score":0.47323734},"labels":[],"label_agreement":null},{"id":"W4362677699","doi":"10.1200/jco.23.00282","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Clinical Practice; Family medicine; Schedule; Medical physics; Pathology","score_opus":0.10246977257888533,"score_gpt":0.49752046239889086,"score_spread":0.3950506898200055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362677699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97127193,0.0019682501,0.00095302274,0.02048582,0.0032085103,0.0008802561,0.00003016819,0.00002308217,0.0011789465],"genre_scores_gemma":[0.9136783,0.0429997,0.0131233,0.011751578,0.0062195905,0.00018897829,0.0000345474,0.000069896036,0.011934148],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973771,0.00015319827,0.0016982432,0.00023357425,0.00027916423,0.00025872496],"domain_scores_gemma":[0.9954706,0.0023541718,0.0010686696,0.00019095001,0.0006430013,0.00027260045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022390909,0.00015001697,0.0009914698,0.00013833062,0.00008912191,0.000016790194,0.00012948473,0.00024695238,0.00053009804],"category_scores_gemma":[0.00077363825,0.00010142388,0.000531345,0.00016755199,0.000053413074,0.0001030058,0.00004367381,0.00040469953,0.00003340556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020352872,0.0017675441,0.52621514,0.00010276197,0.0009521684,0.00020988719,0.00025778997,0.00059872423,0.0002632646,0.000018331639,0.41660222,0.050976895],"study_design_scores_gemma":[0.02433345,0.013476184,0.3282016,0.00078506756,0.001121608,0.000021997108,0.00026507812,0.0094813965,0.00041043924,0.000047883786,0.62164783,0.0002074668],"about_ca_topic_score_codex":0.00009008143,"about_ca_topic_score_gemma":0.0001617848,"teacher_disagreement_score":0.20504561,"about_ca_system_score_codex":0.0004240718,"about_ca_system_score_gemma":0.0019292989,"threshold_uncertainty_score":0.5804202},"labels":[],"label_agreement":null},{"id":"W4362694490","doi":"10.1200/jco.22.01579","title":"Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Fluid-attenuated inversion recovery; Glioblastoma; Immunotherapy; Internal medicine; Radiation therapy; Oncology; Glioma; Magnetic resonance imaging; Progression-free survival; Clinical trial; Nuclear medicine; Radiology; Surgery; Overall survival; Cancer; Cancer research","score_opus":0.11714325160101495,"score_gpt":0.5034581160782827,"score_spread":0.38631486447726776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362694490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93074447,0.00072605745,0.000027983855,0.063524485,0.0018838948,0.002842684,0.000043909382,0.00002955715,0.00017694672],"genre_scores_gemma":[0.98913324,0.0060510132,0.0020609763,0.0019585486,0.0001787437,0.00051176216,0.0000103544135,0.0000854326,0.000009925104],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.93318534,0.053242646,0.008712212,0.001422312,0.0021832876,0.0012542102],"domain_scores_gemma":[0.91997975,0.07401442,0.0036393523,0.00071567163,0.000990651,0.00066018355],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.098170124,0.00070871436,0.0046679853,0.0036505559,0.000097648626,0.00004418626,0.00045439202,0.0013794878,0.00009998346],"category_scores_gemma":[0.031582322,0.0005835233,0.00048259643,0.0019699365,0.0007840254,0.00035339416,0.0004214654,0.004391349,0.000003909924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.39064512,0.01546189,0.34211195,0.00006035306,0.000358095,0.017374223,0.0015438104,0.0025920304,0.045351796,0.00008550203,0.00103577,0.18337949],"study_design_scores_gemma":[0.08849806,0.10309653,0.7820495,0.0003806967,0.00037281754,0.00043757638,0.0016255577,0.00823466,0.00016220834,0.00049359957,0.014328716,0.00032010122],"about_ca_topic_score_codex":0.00017483301,"about_ca_topic_score_gemma":0.003743211,"teacher_disagreement_score":0.43993753,"about_ca_system_score_codex":0.007055428,"about_ca_system_score_gemma":0.02165282,"threshold_uncertainty_score":0.9999169},"labels":[],"label_agreement":null},{"id":"W4364374948","doi":"10.1200/jco.22.02661","title":"External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Yale University; Celgene; AstraZeneca; Active Biotech; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Overall survival; Chemotherapy; Cancer; Prognostic model; Castration; Hormone","score_opus":0.19259416196254225,"score_gpt":0.49401133627255367,"score_spread":0.3014171743100114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364374948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543786,0.00024599236,0.00013045596,0.0030884396,0.000114256465,0.0005020173,0.0000215899,0.000004712422,0.0004546511],"genre_scores_gemma":[0.9954552,0.0017198689,0.0019854787,0.000055537002,0.00010493728,0.000023030889,0.0000073287015,0.000016459426,0.0006321815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971598,0.00025771884,0.0016278299,0.00014599814,0.00059550896,0.00021319183],"domain_scores_gemma":[0.9970124,0.0009079767,0.0012238261,0.00011034176,0.0005971432,0.00014835833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023443399,0.00011095709,0.0010825054,0.00021345534,0.000014619213,0.0000050822864,0.00009513192,0.000093728275,0.00004882824],"category_scores_gemma":[0.0005104236,0.00006801786,0.00016440681,0.00028581056,0.00018267272,0.00011009488,0.000019902065,0.0003915836,0.0000014809418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08914637,0.004836266,0.78172106,0.00088378636,0.0021070472,0.0013570677,0.0026863664,0.020036776,0.054151785,0.0003364224,0.0006779473,0.042059112],"study_design_scores_gemma":[0.051008653,0.026193522,0.8834365,0.0013522793,0.000809496,0.000050495575,0.0007827509,0.020502253,0.012449926,0.0030478926,0.00017297655,0.00019323122],"about_ca_topic_score_codex":0.000107125285,"about_ca_topic_score_gemma":0.000105637315,"teacher_disagreement_score":0.10171547,"about_ca_system_score_codex":0.00015416533,"about_ca_system_score_gemma":0.0031195343,"threshold_uncertainty_score":0.553392},"labels":[],"label_agreement":null},{"id":"W4365503784","doi":"10.1200/jco.22.02152","title":"Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Genentech; PharmaMar; Eisai; Fujirebio US; Puma Biotechnology; Incyte; Clovis Oncology; Karyopharm Therapeutics; Gilead Sciences; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Lenvatinib; Clinical endpoint; Internal medicine; Endometrial cancer; Oncology; Phases of clinical research; Randomized controlled trial; Clinical trial; Cancer; Immunotherapy","score_opus":0.11258114695601837,"score_gpt":0.4825073820538253,"score_spread":0.369926235097807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365503784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98642343,0.0027527465,0.000019041305,0.005469279,0.001657505,0.0030819154,0.000038197475,0.000042925076,0.0005149344],"genre_scores_gemma":[0.9838013,0.013185099,0.00012840737,0.0009073522,0.0015689528,0.00010273567,0.000049862123,0.000032673517,0.00022361908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911995,0.002694961,0.004496321,0.00045822427,0.00068756513,0.00046340725],"domain_scores_gemma":[0.969588,0.0271279,0.0021417276,0.00032934232,0.0003372773,0.00047575394],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00711297,0.00032628234,0.0049545416,0.00039796563,0.000104693674,0.000023412647,0.00031120973,0.00036580252,0.00044889763],"category_scores_gemma":[0.018534087,0.00017519026,0.0006637396,0.0017074053,0.00034642627,0.0001354041,0.00013773952,0.0013301297,0.000017424838],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73370606,0.0036572048,0.013628356,0.000009207606,0.0017183935,0.0008669796,0.00051418657,0.0000659858,0.000048019116,0.0000082253455,0.0004804054,0.24529697],"study_design_scores_gemma":[0.8546623,0.016148772,0.12062668,0.00015672499,0.0021342584,0.000029085675,0.0003222917,0.00020294175,0.000031849217,0.00012374872,0.0054197614,0.00014157954],"about_ca_topic_score_codex":0.0011484756,"about_ca_topic_score_gemma":0.00059910497,"teacher_disagreement_score":0.24515538,"about_ca_system_score_codex":0.00042422162,"about_ca_system_score_gemma":0.0014322111,"threshold_uncertainty_score":0.9897332},"labels":[],"label_agreement":null},{"id":"W4366339435","doi":"10.1200/jco.22.01792","title":"Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Foundation Medicine; Genentech; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; G1 Therapeutics; GlaxoSmithKline; UroGen Pharma; Bavarian Nordic; Silverback Therapeutics; Ipsen; Mirati Therapeutics; Clovis Oncology; Janssen Biotech; Les Laboratories Pierre Fabre; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Gilead Sciences; Exelixis; Sanofi; Amgen; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Avelumab; Medicine; Clinical endpoint; Metastatic Urothelial Carcinoma; Hazard ratio; Internal medicine; Bladder cancer; Clinical trial; Progression-free survival; Oncology; Urothelial carcinoma; Chemotherapy; Cancer; Immunotherapy; Confidence interval; Nivolumab","score_opus":0.1206717529403053,"score_gpt":0.42870129326904377,"score_spread":0.30802954032873847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366339435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97697544,0.00037195368,0.00021925684,0.014585818,0.00583259,0.0010928491,0.00047518773,0.000017162878,0.00042976983],"genre_scores_gemma":[0.98890626,0.00077732996,0.0015417789,0.0020204387,0.004639117,0.00006154245,0.000027711214,0.000040638988,0.0019851923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99579155,0.00026035352,0.0028140503,0.00031636519,0.0004643901,0.00035327132],"domain_scores_gemma":[0.99114233,0.0061953543,0.0015062244,0.0003958628,0.000516953,0.00024325309],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024496072,0.00019092733,0.001530716,0.00009010969,0.000050259194,0.000008023585,0.00028541216,0.0003767373,0.00013220837],"category_scores_gemma":[0.008368188,0.000119011005,0.0010427525,0.00022255899,0.00024101185,0.000075654636,0.00007087217,0.0006315042,0.000043372434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.801528,0.0012921335,0.0041123666,0.00002396038,0.0010514773,0.00057255186,0.00075500907,0.00004072047,0.00010343014,0.000022089138,0.0353446,0.1551537],"study_design_scores_gemma":[0.5368831,0.035904743,0.1979698,0.00023580613,0.0014673818,0.000050423576,0.0002812745,0.00017176142,0.0002621177,0.0016747181,0.22489823,0.00020061716],"about_ca_topic_score_codex":0.00015173227,"about_ca_topic_score_gemma":0.00028710373,"teacher_disagreement_score":0.26464483,"about_ca_system_score_codex":0.000117128984,"about_ca_system_score_gemma":0.0017144922,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W4366446437","doi":"10.1200/jco.23.00294","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Apixaban; Medicine; Rivaroxaban; Guideline; Randomized controlled trial; Venous thromboembolism; Intensive care medicine; Perioperative; Cochrane Library; Dabigatran; MEDLINE; Surgery; Internal medicine; Warfarin; Thrombosis","score_opus":0.1395609783394468,"score_gpt":0.48438725880918615,"score_spread":0.34482628046973934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366446437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013712887,0.9807306,0.0000027647272,0.0012623029,0.0016269422,0.0021965029,0.000046135418,0.000020502228,0.0004013633],"genre_scores_gemma":[0.0002313928,0.9967549,0.00071456505,0.00061104965,0.0013321049,0.00008745944,0.000044861426,0.0000883401,0.00013533999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99342793,0.00047780096,0.0047314167,0.00045399024,0.0005031244,0.0004057162],"domain_scores_gemma":[0.9944422,0.00079894415,0.0036002256,0.00035068145,0.00039165554,0.00041627258],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020720493,0.0004650359,0.010678494,0.00036715524,0.000046715584,0.000017588056,0.00021700039,0.00072255713,0.000080508486],"category_scores_gemma":[0.0006239842,0.0002582239,0.0007516124,0.00035662408,0.00019932612,0.000073863215,0.00012644945,0.0011209274,0.000035657642],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034722438,0.006356759,0.002317764,0.0020285572,0.002551953,0.0007783965,0.00004081801,0.000003428529,3.877457e-9,0.00003171323,0.004654109,0.98088926],"study_design_scores_gemma":[0.006204598,0.03444319,0.05081862,0.007405361,0.00551204,0.00003819809,0.000015212984,0.0000013967439,2.5661148e-8,0.000034993314,0.895317,0.00020934292],"about_ca_topic_score_codex":0.00029029764,"about_ca_topic_score_gemma":0.00035599413,"teacher_disagreement_score":0.9806799,"about_ca_system_score_codex":0.00072236895,"about_ca_system_score_gemma":0.0033696203,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W4366448658","doi":"10.1200/jco.23.00293","title":"Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Partenariat Canadien Contre Le Cancer; American Society of Clinical Oncology","keywords":"Medicine; Psychosocial; Anxiety; Psychological intervention; Guideline; Depression (economics); Cognitive behavioral therapy; Randomized controlled trial; Psychiatry; Physical therapy; Clinical psychology; Internal medicine","score_opus":0.13140279929504117,"score_gpt":0.5172604837641015,"score_spread":0.3858576844690603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366448658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005328132,0.9902652,0.000017587869,0.0005408235,0.0025557657,0.00042193066,0.000048097572,0.000005706372,0.00081676495],"genre_scores_gemma":[0.0007206432,0.997605,0.00055470585,0.00019991181,0.0006732069,0.000013358435,0.000015742036,0.000036695463,0.00018072083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921653,0.0005598235,0.0063090017,0.00027932678,0.00048056853,0.00020594834],"domain_scores_gemma":[0.99290115,0.00096303545,0.0049301283,0.0002969599,0.00067710766,0.00023160085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004508302,0.00024303109,0.005632025,0.00025500666,0.00001120188,0.00000250986,0.0002567217,0.00073656515,0.00006576759],"category_scores_gemma":[0.0007595521,0.0001629511,0.0010203947,0.00043532977,0.0001686418,0.000039874358,0.00019658817,0.0011677189,0.0000025250536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006186548,0.00029780716,0.010859404,0.015041897,0.00083642197,0.00033567846,0.000030352552,0.0000027809544,1.17531854e-7,0.000031763502,0.0018138204,0.9701313],"study_design_scores_gemma":[0.0025686882,0.0009549398,0.0056195664,0.033469256,0.002996084,0.00007387709,0.00017178194,0.00000825917,0.0000011455345,0.00004069087,0.95396996,0.0001257787],"about_ca_topic_score_codex":0.0011489247,"about_ca_topic_score_gemma":0.004053655,"teacher_disagreement_score":0.9700055,"about_ca_system_score_codex":0.00015082955,"about_ca_system_score_gemma":0.0012638505,"threshold_uncertainty_score":0.6644953},"labels":[],"label_agreement":null},{"id":"W4366453256","doi":"10.1200/jco.23.00042","title":"Intensive Caring: Reminding Patients They Matter","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.323180719490392,"score_gpt":0.5146898815755554,"score_spread":0.1915091620851634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366453256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758382,0.000018582063,0.000011867775,0.007827068,0.0022373458,0.00009614041,0.000001874636,0.000011940667,0.0139569985],"genre_scores_gemma":[0.9904323,0.00009888527,0.00034691882,0.007698043,0.0007292977,7.8532827e-7,0.000005542538,0.000011510198,0.0006767003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977506,0.00021270748,0.0014435381,0.00011277847,0.00028169932,0.00019871753],"domain_scores_gemma":[0.9959495,0.0018137636,0.000984241,0.00014329373,0.0008440823,0.0002650926],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001742237,0.00008146284,0.0008316621,0.00017075028,0.00003442661,0.0000052912537,0.00013881661,0.00025705865,0.00016524381],"category_scores_gemma":[0.011131147,0.00005663599,0.00035081606,0.00013220886,0.00007357057,0.0000915566,0.00010091831,0.0008798594,0.0005717832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011252224,0.00034658954,0.91232455,0.000017889342,0.00016126658,0.00040219244,0.0005095864,0.000002875536,0.000046124183,0.000020210246,0.054128677,0.030914826],"study_design_scores_gemma":[0.0041700476,0.0047606872,0.9165478,0.00014174085,0.00015828622,0.00007709787,0.00029047483,0.000020363765,0.00003992812,0.00086864026,0.072864205,0.000060774724],"about_ca_topic_score_codex":0.0000066781076,"about_ca_topic_score_gemma":0.0000030433785,"teacher_disagreement_score":0.03085405,"about_ca_system_score_codex":0.000076724515,"about_ca_system_score_gemma":0.0003664547,"threshold_uncertainty_score":0.9971985},"labels":[],"label_agreement":null},{"id":"W4366977243","doi":"10.1200/jco.22.01946","title":"Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Neuroblastoma; Medicine; Internal medicine; Pediatric oncology; Cog; Cutoff; Stage (stratigraphy); Oncology; Pediatrics; Gastroenterology; Cancer","score_opus":0.11797693712033351,"score_gpt":0.4393053416662598,"score_spread":0.32132840454592626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366977243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538416,0.000012493409,0.0000050015415,0.0027109846,0.00032360392,0.0014208222,0.000028484848,0.0000050646836,0.000109380344],"genre_scores_gemma":[0.9987626,0.00018180501,0.00024753262,0.00053251284,0.00014026598,0.000073007286,0.0000065960394,0.000022002723,0.000033647386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957092,0.0013466834,0.0016856339,0.0002710247,0.000661673,0.00032577908],"domain_scores_gemma":[0.9969561,0.0011146736,0.0010522875,0.0003253918,0.00021800927,0.00033354101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001800707,0.00015950168,0.0011045538,0.0004263055,0.000019783609,0.0000045812512,0.0002481774,0.00018996057,0.000042528114],"category_scores_gemma":[0.0012405425,0.00009355511,0.00019675384,0.0006852868,0.00015046567,0.000080042904,0.00010215637,0.00074259145,0.000008348205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023621293,0.005838449,0.9053604,0.000010201995,0.00018351947,0.00034629318,0.0004095214,0.000043021722,0.000993868,0.0000051488346,0.00018354735,0.063004754],"study_design_scores_gemma":[0.011357896,0.048127767,0.93938214,0.00011205409,0.000053586864,0.00000953136,0.00004080911,0.000009684903,0.00040899482,0.000028815697,0.00040642134,0.000062304185],"about_ca_topic_score_codex":0.0001509714,"about_ca_topic_score_gemma":0.001786157,"teacher_disagreement_score":0.06294245,"about_ca_system_score_codex":0.00022165904,"about_ca_system_score_gemma":0.0005387913,"threshold_uncertainty_score":0.38150665},"labels":[],"label_agreement":null},{"id":"W4366997708","doi":"10.1200/jco.22.02524","title":"Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; European Society for Medical Oncology; Shanghai Jiao Tong University; Revolution Medicines; Jiangsu Hengrui Medicine; Calithera Biosciences; BeiGene; Mirati Therapeutics; McGill University; Moderna; Memorial Sloan-Kettering Cancer Center; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; KRAS; Clinical endpoint; Tolerability; Internal medicine; Clinical trial; Lung cancer; Oncology; Discontinuation; Phases of clinical research; Surrogate endpoint; Cancer; Adverse effect; Colorectal cancer","score_opus":0.03039771911843098,"score_gpt":0.43100504387916794,"score_spread":0.40060732476073696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366997708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984507,0.00028567275,0.000029289975,0.0003489014,0.00019941418,0.00045414656,0.000033056254,0.0000083492605,0.00019047891],"genre_scores_gemma":[0.9988849,0.0004804892,0.000256035,0.00014543837,0.000019569514,0.000007912951,0.000055928198,0.00001841552,0.00013131347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749076,0.00014942652,0.0016674658,0.00019912775,0.00030171665,0.00019147525],"domain_scores_gemma":[0.9966319,0.00093505596,0.0015088448,0.0001732868,0.00054964115,0.0002012561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049232517,0.0001605635,0.0018535316,0.0004971076,0.000019039053,0.000004637352,0.00009717089,0.0002160391,0.000056633267],"category_scores_gemma":[0.00033826957,0.00010231083,0.00033562473,0.0009958808,0.00015557713,0.000057311274,0.00003629472,0.00033198745,0.0000010181777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002733191,0.0025274868,0.9837051,0.000083328625,0.00614132,0.0002503576,0.00031108927,0.0009501102,0.00006800479,0.0000019813479,0.000104886516,0.0031231213],"study_design_scores_gemma":[0.021569755,0.0046287193,0.9619693,0.00022764012,0.010818429,0.0000031163972,0.000055262382,0.00047233127,0.00015809548,0.00000249705,0.000013740317,0.00008109702],"about_ca_topic_score_codex":0.00017847172,"about_ca_topic_score_gemma":0.00017407163,"teacher_disagreement_score":0.021735808,"about_ca_system_score_codex":0.00013444487,"about_ca_system_score_gemma":0.00081189,"threshold_uncertainty_score":0.41721144},"labels":[],"label_agreement":null},{"id":"W4367173078","doi":"10.1200/jco.22.02390","title":"Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Oncology; Prostate; Internal medicine; Androgen; Cancer; Urology; Hormone","score_opus":0.12903100958468114,"score_gpt":0.47913766780678985,"score_spread":0.35010665822210874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367173078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371415,0.00027426297,0.00061634585,0.0026507843,0.0007835329,0.0018053415,0.00013484614,0.000013151433,0.000007601159],"genre_scores_gemma":[0.9864002,0.010422301,0.0022516658,0.00017039159,0.00038449923,0.00018095713,0.00013116923,0.000016160559,0.00004265496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964712,0.0002058872,0.0026241688,0.00021794596,0.0002845495,0.00019620828],"domain_scores_gemma":[0.99570256,0.0017851777,0.0017565717,0.00011749229,0.0004686544,0.00016955078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00260053,0.00014208439,0.0012862559,0.00024617554,0.000037996135,0.00000660261,0.00008233063,0.00020798945,0.0000130123335],"category_scores_gemma":[0.0018923271,0.0000828354,0.00022650578,0.00033146882,0.00018546624,0.00012545893,0.0000152076445,0.00034408655,6.040337e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5777108,0.0075777266,0.09269324,0.000045641045,0.00071985106,0.0003880931,0.00042005614,0.00024727784,0.00029624542,0.000009312176,0.0005345537,0.31935722],"study_design_scores_gemma":[0.681563,0.07579569,0.23408796,0.00043889435,0.00041258385,0.00004160244,0.000058651556,0.0034851565,0.0010923513,0.00005246805,0.0028750033,0.00009662767],"about_ca_topic_score_codex":0.000064161664,"about_ca_topic_score_gemma":0.00046040092,"teacher_disagreement_score":0.3192606,"about_ca_system_score_codex":0.0004146024,"about_ca_system_score_gemma":0.0021772555,"threshold_uncertainty_score":0.38623577},"labels":[],"label_agreement":null},{"id":"W4367173202","doi":"10.1200/jco.22.02389","title":"Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Hormonal therapy; Clinical endpoint; Randomized controlled trial; Urology; Radiation therapy; Androgen suppression; Internal medicine; Oncology; Cancer","score_opus":0.07489647229290873,"score_gpt":0.43207221493483206,"score_spread":0.3571757426419233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367173202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865946,0.0007541728,0.00005547807,0.0045328354,0.0031474803,0.004768889,0.00009005183,0.00003771879,0.000018735913],"genre_scores_gemma":[0.9746263,0.022446098,0.00040267635,0.00044912795,0.00056690455,0.0009199424,0.0005184277,0.00003930359,0.0000312186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99356806,0.0012712531,0.0039560962,0.0003920378,0.0004682389,0.00034428242],"domain_scores_gemma":[0.98678136,0.008624647,0.003700816,0.00019066341,0.00041076023,0.0002917636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037073651,0.00027423073,0.002979304,0.00033992343,0.0000680807,0.0000225485,0.000097374425,0.0004976564,0.00008635142],"category_scores_gemma":[0.0038936746,0.00015525895,0.00054050906,0.00032848265,0.00017092329,0.0002466311,0.00003141454,0.0006041286,0.0000026256714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4607474,0.0022686862,0.18876353,0.000009106722,0.0009471452,0.00028916012,0.00048157971,0.000047677997,0.00005255753,0.0000013619048,0.00056493457,0.34582686],"study_design_scores_gemma":[0.59048516,0.038707964,0.36704573,0.00012618136,0.00070673745,0.000020253567,0.00009588117,0.0008707281,0.00029311367,0.0001494109,0.0013819574,0.00011689828],"about_ca_topic_score_codex":0.00023991449,"about_ca_topic_score_gemma":0.0002925469,"teacher_disagreement_score":0.34570998,"about_ca_system_score_codex":0.000660021,"about_ca_system_score_gemma":0.001618282,"threshold_uncertainty_score":0.6331276},"labels":[],"label_agreement":null},{"id":"W4376870566","doi":"10.1200/jco.22.02546","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Febrile neutropenia; Lung cancer; Chemotherapy; Regimen; Oncology; Phases of clinical research; Chemotherapy regimen; Dexamethasone; Gastroenterology; Surgery; Cisplatin","score_opus":0.057080918598974816,"score_gpt":0.4704023204420486,"score_spread":0.4133214018430738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376870566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947822,0.00018219383,0.00004271296,0.0012052445,0.00051605474,0.0019401923,0.00000780681,0.000010154086,0.0013134107],"genre_scores_gemma":[0.99685717,0.001198816,0.000741717,0.00026011167,0.0003076819,0.00007873897,0.000020058567,0.00002651644,0.0005091693],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99713564,0.0002776762,0.0018225887,0.0001856174,0.00035118763,0.0002273113],"domain_scores_gemma":[0.9956347,0.0016237281,0.0018798176,0.00015902102,0.0004917937,0.00021095094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014583751,0.00016719147,0.0023592962,0.000242531,0.000023697867,0.0000051444513,0.00009571631,0.00017924266,0.00010866353],"category_scores_gemma":[0.00043765808,0.0000892852,0.00034434436,0.00046806879,0.00016047854,0.00007011845,0.000011676192,0.0003819833,0.0000016910506],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9227839,0.0062357886,0.050320107,0.000044058426,0.0021926374,0.00013803241,0.00037731492,0.000059503498,0.000007641596,0.0000021016401,0.000682292,0.017156607],"study_design_scores_gemma":[0.93379754,0.038445476,0.023376584,0.00023261365,0.0030788777,0.0000027469025,0.00007669548,0.00018933564,0.000055822067,0.0000034066,0.00065669086,0.000084210566],"about_ca_topic_score_codex":0.00020793229,"about_ca_topic_score_gemma":0.00014264786,"teacher_disagreement_score":0.032209687,"about_ca_system_score_codex":0.00023487772,"about_ca_system_score_gemma":0.002174379,"threshold_uncertainty_score":0.3857255},"labels":[],"label_agreement":null},{"id":"W4378417256","doi":"10.1200/jco.23.00249","title":"Impact of <sup>18</sup>F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Sunnybrook Health Science Centre; St. Michael's Hospital; NOSM University; Public Health Ontario; Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; Western University; University of Toronto; Ottawa Hospital; Health Sciences Centre; University Health Network; Hamilton Health Sciences; McMaster University; Ontario Clinical Oncology Group; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Nuclear medicine; Radiology; Stage (stratigraphy); Positron emission tomography; Radiation therapy; Asymptomatic; Cancer; Abdomen; Surgery; Internal medicine","score_opus":0.0431784161238915,"score_gpt":0.4392578454359969,"score_spread":0.3960794293121054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378417256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546254,0.00007353366,0.0006418575,0.0030443007,0.00017744639,0.00041472298,0.0000442267,0.00004524026,0.00009612324],"genre_scores_gemma":[0.99081707,0.0001676199,0.008480647,0.00022963567,0.000199462,0.000016966027,0.000045505076,0.000022781816,0.000020329164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968121,0.00020561277,0.0018052286,0.00025423363,0.00059982814,0.0003229859],"domain_scores_gemma":[0.9963947,0.0008625838,0.0011806489,0.00022587954,0.0008599752,0.00047620566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012844258,0.00018143332,0.001130334,0.00048725694,0.000039518323,0.0000067286123,0.00021766959,0.00024024784,0.00019459482],"category_scores_gemma":[0.00041049314,0.00012144713,0.0005512427,0.0010435337,0.00026781778,0.00012647049,0.0000663111,0.0009196058,0.0000021789622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016406773,0.003053208,0.8975604,0.000050802668,0.0004856961,0.000068637935,0.000034733497,0.00043205844,0.00064489874,0.000025703086,0.006280949,0.07495613],"study_design_scores_gemma":[0.021958338,0.008606904,0.9640944,0.00069514854,0.00021216761,0.000017962098,0.00002413461,0.003519679,0.00007319773,0.00009665957,0.00058293436,0.00011847287],"about_ca_topic_score_codex":0.00005990399,"about_ca_topic_score_gemma":0.000004787627,"teacher_disagreement_score":0.074837655,"about_ca_system_score_codex":0.00016887535,"about_ca_system_score_gemma":0.0011258107,"threshold_uncertainty_score":0.495247},"labels":[],"label_agreement":null},{"id":"W4378802651","doi":"10.1200/jco.22.02200","title":"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Seattle Children's Research Institute; Children's Hospital of Philadelphia","keywords":"Blinatumomab; Medicine; Chemotherapy; Internal medicine; Oncology; Leukemia; Surgery; Lymphoblastic Leukemia","score_opus":0.03294594451113258,"score_gpt":0.397294345372739,"score_spread":0.3643484008616064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378802651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551046,0.00027113286,0.000032935797,0.001810753,0.00070504675,0.001335511,0.000017779643,0.00001775846,0.0002986267],"genre_scores_gemma":[0.99230444,0.005298836,0.00069946534,0.00037379176,0.001156357,0.000017779224,0.00002709886,0.000047375543,0.000074859214],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928198,0.0011289343,0.0039996556,0.0005194629,0.00084412354,0.0006880557],"domain_scores_gemma":[0.9932774,0.002872912,0.0025198124,0.00036213096,0.0003288638,0.00063889456],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006782419,0.00030216097,0.0027427224,0.0009408278,0.000042478776,0.000009686111,0.00040515533,0.000987618,0.000032796306],"category_scores_gemma":[0.005181288,0.0002195492,0.00034062698,0.000877767,0.0006378512,0.00016781416,0.0002459638,0.0032821365,0.000016690792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41329736,0.01629929,0.5319235,0.00011308956,0.00036630555,0.0040159547,0.0004923439,0.00003055102,0.00004052675,0.000009806147,0.0030050257,0.030406276],"study_design_scores_gemma":[0.4877348,0.05146634,0.45711708,0.0006758692,0.00028490828,0.0010902949,0.00016117323,0.0007834416,0.000021114533,0.000036348087,0.0004849579,0.00014366388],"about_ca_topic_score_codex":0.00054071605,"about_ca_topic_score_gemma":0.0013408537,"teacher_disagreement_score":0.07480637,"about_ca_system_score_codex":0.00085203606,"about_ca_system_score_gemma":0.003248733,"threshold_uncertainty_score":0.99901736},"labels":[],"label_agreement":null},{"id":"W4379280591","doi":"10.1200/jco.2023.41.16_suppl.9072","title":"Outcomes of patients with advanced EGFR mutant lung cancer treated with first line (1L) osimertinib (osi) who would not have met eligibility criteria for the FLAURA trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Discontinuation; Performance status; Hazard ratio; Anemia; Proportional hazards model; Oncology; Creatinine; Clinical trial; Cancer; Confidence interval","score_opus":0.09955501633614276,"score_gpt":0.5343672649270595,"score_spread":0.4348122485909168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98357606,0.00020352623,0.00023487862,0.013104539,0.0007495295,0.0018216114,0.00017852815,0.000017854185,0.00011346525],"genre_scores_gemma":[0.99602574,0.00066072715,0.0009513788,0.0013932234,0.00035502698,0.00016681652,0.00003009933,0.000032349955,0.00038465098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968866,0.00015376229,0.0020015761,0.00026376938,0.00041702605,0.0002772837],"domain_scores_gemma":[0.99201626,0.0044315336,0.001881802,0.0003112083,0.0011385486,0.00022062837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012062677,0.00021218286,0.0017663377,0.00010472811,0.00010755009,0.000010330296,0.00015765456,0.00026340352,0.00009110248],"category_scores_gemma":[0.0021338842,0.00009360768,0.0004005484,0.0002550399,0.00024482483,0.00011412019,0.000029806246,0.0005167852,0.0000010658555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23166785,0.0025869042,0.71457064,0.00013278727,0.0047533293,0.00007006003,0.00041992418,0.0004452173,0.00003827903,0.000016075219,0.0027625759,0.04253633],"study_design_scores_gemma":[0.14703071,0.03380366,0.79772663,0.0002670591,0.0044831294,0.000006114685,0.00017307365,0.00044375547,0.0002425761,0.000026822681,0.015671454,0.00012499855],"about_ca_topic_score_codex":0.000103482365,"about_ca_topic_score_gemma":0.00042611395,"teacher_disagreement_score":0.084637135,"about_ca_system_score_codex":0.00030135986,"about_ca_system_score_gemma":0.0015063379,"threshold_uncertainty_score":0.38172105},"labels":[],"label_agreement":null},{"id":"W4379280592","doi":"10.1200/jco.2023.41.16_suppl.12039","title":"Defining an abnormal geriatric assessment for older adults with cancer: Which deficits matter most?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Logistic regression; Univariate; Univariate analysis; Cohort; Retrospective cohort study; Geriatric oncology; Multivariate analysis; Cancer; Multivariate statistics; Internal medicine; Statistics","score_opus":0.05470628664069272,"score_gpt":0.4493228923069172,"score_spread":0.3946166056662245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97134846,0.00023303826,0.0008261856,0.02252882,0.002197476,0.00059982424,0.00002649507,0.000045836405,0.0021938684],"genre_scores_gemma":[0.9694534,0.0004809522,0.022246746,0.0047796257,0.0020646625,0.00009869627,0.0000360699,0.00006614557,0.0007737234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961121,0.00026190726,0.0022277315,0.00033773924,0.00054685184,0.00051366666],"domain_scores_gemma":[0.9937164,0.0026024266,0.0015673517,0.0002769589,0.00129633,0.0005405222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029256523,0.00021581135,0.0014705202,0.0002638367,0.00008027985,0.000021697455,0.00024276657,0.00044393598,0.00041983603],"category_scores_gemma":[0.0013444292,0.0001487575,0.00026849637,0.00058789714,0.00009202308,0.00024867043,0.000060310304,0.0011160739,0.00007000916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00948597,0.0016484254,0.58749235,0.00030377015,0.00059956015,0.0006888081,0.00051685574,0.00055088045,0.000023433362,0.0001198668,0.08160369,0.3169664],"study_design_scores_gemma":[0.020921657,0.0150132,0.94103223,0.00053389673,0.00059509696,0.0006645443,0.0005385668,0.00165343,0.000021010626,0.000084496016,0.018742934,0.00019892963],"about_ca_topic_score_codex":0.00006242567,"about_ca_topic_score_gemma":0.00033973096,"teacher_disagreement_score":0.3535399,"about_ca_system_score_codex":0.00020919609,"about_ca_system_score_gemma":0.0031320087,"threshold_uncertainty_score":0.6066155},"labels":[],"label_agreement":null},{"id":"W4379280618","doi":"10.1200/jco.2023.41.16_suppl.e18858","title":"Characterizing of adverse events across 30,000 peer reviewed case report publications.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Pharmacovigilance; MedDRA; Clinical trial; MEDLINE; Internal medicine; Oncology","score_opus":0.4588446939620104,"score_gpt":0.6311208187385584,"score_spread":0.17227612477654802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97493714,0.0001575131,0.00003108413,0.012400594,0.0066084163,0.00028372824,0.000119287564,0.000057393467,0.005404864],"genre_scores_gemma":[0.9861878,0.0030531732,0.0002444373,0.003506478,0.0016334286,0.00002261408,0.000039366027,0.000025748102,0.0052869283],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937773,0.0011574748,0.003895932,0.00028502234,0.00039781738,0.00048647352],"domain_scores_gemma":[0.9904159,0.0030290529,0.0043888143,0.00031172915,0.0012965227,0.000557996],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01464686,0.00020085703,0.0013310348,0.00021735037,0.00021565921,0.0000039128054,0.0004078778,0.00061584683,0.0017218114],"category_scores_gemma":[0.0075471248,0.00016979907,0.0007217882,0.0006530091,0.00029942408,0.00045524584,0.0001526017,0.0021660116,0.00037363332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035512121,0.007907464,0.30596125,0.00041759788,0.003954308,0.16385888,0.0024345242,0.00095415325,0.021004813,0.0005156067,0.26639512,0.22304505],"study_design_scores_gemma":[0.0034883216,0.00043789524,0.040528458,0.000047835143,0.00042234274,0.016659837,0.0005215915,0.00025920462,0.0008416956,0.00013190616,0.9364937,0.00016724519],"about_ca_topic_score_codex":0.000012565768,"about_ca_topic_score_gemma":0.000007964683,"teacher_disagreement_score":0.67009854,"about_ca_system_score_codex":0.000114025606,"about_ca_system_score_gemma":0.0009098277,"threshold_uncertainty_score":0.99919075},"labels":[],"label_agreement":null},{"id":"W4379280628","doi":"10.1200/jco.2023.41.16_suppl.e18840","title":"Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in patients with non-small cell lung cancer receiving first-line treatment.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pembrolizumab; Medicine; Pharmacovigilance; Adverse effect; Internal medicine; Lung cancer; Oncology; Cohort; Population; Clinical trial; Adverse Event Reporting System; Intensive care medicine; Cancer; Immunotherapy","score_opus":0.07976227313535207,"score_gpt":0.40686519276608746,"score_spread":0.3271029196307354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780005,0.00008881665,0.000058163325,0.00025609374,0.00062360946,0.0010665503,0.00002130944,0.000010593593,0.000074788746],"genre_scores_gemma":[0.9973468,0.00077014405,0.0011228457,0.00021757386,0.00012435066,0.000047849397,0.000043025488,0.00003177214,0.0002956274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612963,0.00012659687,0.0028578772,0.000312671,0.0002773272,0.00029589923],"domain_scores_gemma":[0.9940871,0.00077918207,0.0042199353,0.00024356133,0.0004869013,0.00018334652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002104731,0.00018447898,0.0012598064,0.00029601852,0.000050413182,0.000004923866,0.00007194613,0.000254227,0.00012653379],"category_scores_gemma":[0.00034118665,0.00013468276,0.00033880907,0.00045663468,0.0000742788,0.000302616,0.000028337581,0.00030248938,4.3273067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062367428,0.0037631246,0.9009248,0.00035009373,0.0012403892,0.0014669787,0.0008580498,0.0021147989,0.0020048912,7.691604e-7,0.0004199219,0.02448877],"study_design_scores_gemma":[0.1608186,0.031849664,0.77916104,0.0018422684,0.0024374041,0.0007719032,0.0002986973,0.008267398,0.0064402274,0.00006603564,0.0076287836,0.0004179876],"about_ca_topic_score_codex":0.0016330502,"about_ca_topic_score_gemma":0.00049528544,"teacher_disagreement_score":0.12176376,"about_ca_system_score_codex":0.0003866604,"about_ca_system_score_gemma":0.0010376743,"threshold_uncertainty_score":0.5492204},"labels":[],"label_agreement":null},{"id":"W4379280640","doi":"10.1200/jco.2023.41.16_suppl.12055","title":"Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Prospective cohort study; Generalizability theory; Enzalutamide; Logistic regression; Cohort; Internal medicine; Physical therapy; Activities of daily living; Cancer; Oncology","score_opus":0.1251830953723007,"score_gpt":0.47940212098810686,"score_spread":0.35421902561580615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997435,0.00008766175,0.0000069419016,0.0018385107,0.00019839594,0.00032459677,0.000022520866,0.0000070960828,0.00007931999],"genre_scores_gemma":[0.9990994,0.00040286957,0.0001654028,0.00002937136,0.00021709743,0.000018131721,0.0000013349342,0.000008968163,0.000057444246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985589,0.00027006367,0.0005652803,0.00016405138,0.00028340993,0.0001583387],"domain_scores_gemma":[0.9974078,0.0012658293,0.0007790531,0.00010828542,0.00027295898,0.00016606084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091338484,0.00010221489,0.0011053423,0.00007435452,0.000022011009,0.0000040564855,0.000039527004,0.00007400689,0.0000051148977],"category_scores_gemma":[0.0003778111,0.0000597559,0.00012506664,0.00029336082,0.00012840741,0.00009090633,0.000016843194,0.00038292457,3.8919185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007328471,0.002136221,0.91270006,0.00006792113,0.00025693653,0.00016280818,0.0026453247,0.000042589265,0.000088649576,0.0000024111355,0.000016568005,0.07455203],"study_design_scores_gemma":[0.010603803,0.010316028,0.97646505,0.00026951794,0.0003350851,0.000017561395,0.0012877354,0.00009376438,0.00048475695,0.00002689818,0.00004452221,0.00005528201],"about_ca_topic_score_codex":0.00083791977,"about_ca_topic_score_gemma":0.0046008993,"teacher_disagreement_score":0.074496746,"about_ca_system_score_codex":0.00036296202,"about_ca_system_score_gemma":0.0011500622,"threshold_uncertainty_score":0.256741},"labels":[],"label_agreement":null},{"id":"W4379280653","doi":"10.1200/jco.2023.41.16_suppl.12109","title":"Patient-reported hope, prognostic understanding, quality of life, symptom burden, coping mechanisms, and financial wellbeing in early phase clinical trial participants.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Coping (psychology); Quality of life (healthcare); Physical therapy; Clinical trial; Breast cancer; Cancer; Internal medicine; Family medicine; Clinical psychology; Nursing","score_opus":0.39961098805216266,"score_gpt":0.4709977756171639,"score_spread":0.07138678756500122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990768,0.0005328304,0.0023393976,0.0012723882,0.0037322487,0.00042663235,0.000032227606,0.000014335848,0.0008819391],"genre_scores_gemma":[0.9963447,0.0015808099,0.0005268835,0.00058876514,0.0008858747,0.000009773193,0.000002758059,0.00002282957,0.000037628564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888211,0.00035087412,0.009797239,0.00041170133,0.00011348956,0.0005056083],"domain_scores_gemma":[0.9879583,0.0034855974,0.0077296603,0.00023029865,0.00014470649,0.00045139977],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014290351,0.0001927723,0.0028615738,0.00039163665,0.00006544755,0.000035474386,0.00023389251,0.0006134899,0.000054808304],"category_scores_gemma":[0.03618607,0.0001962854,0.00049895165,0.0003649736,0.0003242089,0.0003712479,0.00012258852,0.00088311714,0.000024780873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046940017,0.0027894648,0.80728686,0.00011256685,0.00054965686,0.0002878524,0.0012435437,0.00018187011,0.0000140601205,0.10244209,0.0026616603,0.035490386],"study_design_scores_gemma":[0.1158046,0.020040995,0.7291674,0.00019108129,0.00010775873,0.000009134022,0.00036715838,0.0008748237,0.0000058963997,0.120375305,0.012590786,0.00046503893],"about_ca_topic_score_codex":0.00024466458,"about_ca_topic_score_gemma":0.00013906547,"teacher_disagreement_score":0.078119405,"about_ca_system_score_codex":0.00018762959,"about_ca_system_score_gemma":0.0011455045,"threshold_uncertainty_score":0.97193253},"labels":[],"label_agreement":null},{"id":"W4379280656","doi":"10.1200/jco.2023.41.16_suppl.e18827","title":"Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Internal medicine; Refractory (planetary science); Pediatrics","score_opus":0.25324802302955485,"score_gpt":0.49543075120540486,"score_spread":0.24218272817585001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850658,0.00044590904,0.000001607467,0.013014066,0.00030609244,0.0008634046,0.00012945961,0.000011556681,0.00016205727],"genre_scores_gemma":[0.9586276,0.03070074,0.00004800964,0.0021914549,0.000328354,0.000033273398,0.00013679029,0.000029283683,0.007904543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953271,0.0010297021,0.002245559,0.0002523848,0.0007711276,0.00037413702],"domain_scores_gemma":[0.9915496,0.0054025073,0.0014166514,0.00034281623,0.00080827693,0.0004801374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025902733,0.0002137147,0.001534698,0.0001377544,0.00010597645,0.0000115167895,0.00021089741,0.00009494144,0.000064490065],"category_scores_gemma":[0.003292321,0.00011665646,0.00023735,0.00048134784,0.00017286933,0.000075063836,0.000120662095,0.0005723304,0.0000096471085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002136736,0.0017235171,0.9546652,0.00015903449,0.0010172334,0.002197881,0.00020932018,0.000005553072,0.000012074615,0.0000052297964,0.0041436246,0.03372462],"study_design_scores_gemma":[0.009568566,0.008468467,0.7906363,0.00032796132,0.00026768039,0.00007496735,0.00019407539,0.00018187985,0.00000763557,0.000004504313,0.19020069,0.00006726966],"about_ca_topic_score_codex":0.08494602,"about_ca_topic_score_gemma":0.43415868,"teacher_disagreement_score":0.34921265,"about_ca_system_score_codex":0.00038796783,"about_ca_system_score_gemma":0.002677015,"threshold_uncertainty_score":0.9211474},"labels":[],"label_agreement":null},{"id":"W4379280659","doi":"10.1200/jco.2023.41.16_suppl.e18826","title":"Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Refractory (planetary science); Salvage therapy; Internal medicine; Retrospective cohort study; Pediatrics; Chemotherapy","score_opus":0.11932301477636917,"score_gpt":0.45885474674368393,"score_spread":0.3395317319673148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946492,0.00003828896,0.0000019868805,0.0036279948,0.0004288349,0.0007427915,0.00014218499,0.00001673943,0.0003520009],"genre_scores_gemma":[0.98892146,0.0021302414,0.000029339752,0.00037856834,0.00036715993,0.000019490994,0.000041663614,0.000033922934,0.008078133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955846,0.00097579404,0.0018951742,0.00031267936,0.00075247267,0.0004792777],"domain_scores_gemma":[0.99287456,0.0040663993,0.0013403401,0.00038536207,0.0007591536,0.0005742035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002323,0.00024411596,0.001580443,0.00022597246,0.00013289796,0.000017484053,0.00021471868,0.00013443835,0.00004489901],"category_scores_gemma":[0.002534276,0.00013535564,0.00024058734,0.00050839916,0.00026172597,0.00007306425,0.00014737595,0.00077818864,0.000009308672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005353052,0.0022716646,0.96735233,0.000023720795,0.0014903942,0.004043062,0.00090013543,0.000007566037,0.000036904923,0.0000047794288,0.0013748377,0.017141556],"study_design_scores_gemma":[0.017382624,0.02156514,0.91643333,0.000070410715,0.00025179298,0.00007868076,0.0011044416,0.00025934857,0.00005392351,0.000010724304,0.04269873,0.0000908598],"about_ca_topic_score_codex":0.2064951,"about_ca_topic_score_gemma":0.71375257,"teacher_disagreement_score":0.50725746,"about_ca_system_score_codex":0.0007708222,"about_ca_system_score_gemma":0.0021643636,"threshold_uncertainty_score":0.7987889},"labels":[],"label_agreement":null},{"id":"W4379280693","doi":"10.1200/jco.2023.41.16_suppl.12038","title":"Association of sarcopenia and treatment tolerability in older adults with advanced cancer: Secondary analysis of a nationwide NCI Community Oncology Research Program (NCORP) randomized clinical trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Simon Fraser University","funders":"National Institutes of Health","keywords":"Medicine; Sarcopenia; Common Terminology Criteria for Adverse Events; Tolerability; Internal medicine; Geriatric oncology; Randomized controlled trial; Adverse effect; Cancer; Performance status","score_opus":0.30773580954029306,"score_gpt":0.6239108044290156,"score_spread":0.3161749948887225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810315,0.0003132322,0.000008861624,0.0154747935,0.0003705319,0.0022116418,0.00001554614,0.000011847711,0.0005620861],"genre_scores_gemma":[0.9871055,0.008451958,0.0034998124,0.00042838842,0.00021471534,0.00016451236,0.000022130242,0.000010154254,0.000102817896],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9790117,0.014188755,0.0056728814,0.00022588293,0.00060690887,0.0002938283],"domain_scores_gemma":[0.94642675,0.04707359,0.0039396067,0.00024830227,0.0020045699,0.00030715537],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.064887136,0.00012218647,0.004815664,0.00082011154,0.000075638054,0.0000051019824,0.00013450382,0.0005181321,0.00011313286],"category_scores_gemma":[0.023323571,0.00008244305,0.00062621315,0.0014235763,0.0006030191,0.00008630668,0.00005883003,0.0021793407,9.878819e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43594706,0.007163286,0.2561861,0.000116487114,0.001269889,0.000031843818,0.00062056363,0.000016068278,0.000004086857,0.00000985678,0.00023146532,0.2984033],"study_design_scores_gemma":[0.47157148,0.026366612,0.49627855,0.00027118585,0.0010531635,0.000004474986,0.0007066419,0.00073743117,0.000008899009,0.00014039132,0.0028184357,0.0000427399],"about_ca_topic_score_codex":0.0006710071,"about_ca_topic_score_gemma":0.008744217,"teacher_disagreement_score":0.29836056,"about_ca_system_score_codex":0.00081155315,"about_ca_system_score_gemma":0.0042481953,"threshold_uncertainty_score":0.9849034},"labels":[],"label_agreement":null},{"id":"W4379280702","doi":"10.1200/jco.2023.41.16_suppl.e21200","title":"The impact of COVID-19 on the survival outcome of lung cancer at a Canadian academic centre: A real-world data analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Internal medicine; Retrospective cohort study; Cancer; Cohort; Cancer registry; Coronavirus disease 2019 (COVID-19); Cohort study; Oncology; Disease","score_opus":0.3588928223894947,"score_gpt":0.6086505214041281,"score_spread":0.2497576990146334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8622131,0.00048969034,0.0000014011747,0.1351179,0.00065178546,0.00028227476,0.00026997834,0.0000050137633,0.000968897],"genre_scores_gemma":[0.9859477,0.011148825,0.000013059611,0.0017419424,0.00048138332,0.0000057776483,0.000022881182,0.000012530831,0.00062589825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609363,0.0007027965,0.0021617233,0.00021897999,0.0004853468,0.0003375094],"domain_scores_gemma":[0.98348284,0.01258657,0.002228438,0.00070673093,0.00022972035,0.00076570694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070562405,0.00013975565,0.0016652865,0.00028968268,0.00009892477,0.000005103908,0.00058031955,0.00016834463,0.0003254852],"category_scores_gemma":[0.0058277487,0.00005998535,0.00088039675,0.0010182628,0.00032201997,0.000043276148,0.0001414206,0.0008120608,0.000007116664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013890511,0.00019268888,0.89380103,0.000019185622,0.00570938,0.00018612498,0.00010658911,0.00047935548,0.0000016829771,0.0002448458,0.09497607,0.0028940197],"study_design_scores_gemma":[0.002490822,0.0013549706,0.95679015,0.000058411762,0.003417379,0.0000075124703,0.000106701584,0.0007872479,0.0000036387246,0.000068562935,0.034863044,0.000051565214],"about_ca_topic_score_codex":0.1913784,"about_ca_topic_score_gemma":0.7233578,"teacher_disagreement_score":0.53197944,"about_ca_system_score_codex":0.0025707015,"about_ca_system_score_gemma":0.0069310223,"threshold_uncertainty_score":0.9986988},"labels":[],"label_agreement":null},{"id":"W4379280704","doi":"10.1200/jco.2023.41.16_suppl.11514","title":"Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Springworks Therapeutics","keywords":"Medicine; Clinical endpoint; Hyperintensity; Placebo; Magnetic resonance imaging; Hazard ratio; Nuclear medicine; Surrogate endpoint; Internal medicine; Radiology; Randomized controlled trial; Pathology; Confidence interval","score_opus":0.06999060030941875,"score_gpt":0.4140665784396552,"score_spread":0.3440759781302365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940543,0.00035635076,0.0000077139,0.002842254,0.0007366711,0.0018554433,0.000010855844,0.000016068056,0.00012031275],"genre_scores_gemma":[0.99757665,0.000347344,0.0007607531,0.000624259,0.0005142581,0.00004258978,0.000005433337,0.000020177724,0.000108552034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995306,0.0009278705,0.002800714,0.00023110799,0.0004769192,0.00025738258],"domain_scores_gemma":[0.9876045,0.008739435,0.0025434794,0.00016721449,0.00067922584,0.00026616198],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051370203,0.0001995687,0.006767718,0.00027709623,0.000035110053,0.000006761229,0.000092433394,0.00014096637,0.000050341256],"category_scores_gemma":[0.024312442,0.000118852164,0.00045203557,0.00022177116,0.00084773015,0.00006141936,0.00007823942,0.0006416122,0.0000083891655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8414394,0.0021508508,0.14820248,0.000021936992,0.0006877107,0.0017545138,0.0002596584,0.0000012594058,0.00001373605,0.0000044498283,0.00045961956,0.005004369],"study_design_scores_gemma":[0.7735925,0.024516987,0.19958326,0.00016763368,0.0009157554,0.0000679384,0.00024206119,0.000083983316,0.000010021539,0.00008639869,0.0006530513,0.000080405356],"about_ca_topic_score_codex":0.00009023022,"about_ca_topic_score_gemma":0.00014964286,"teacher_disagreement_score":0.06784692,"about_ca_system_score_codex":0.0000671728,"about_ca_system_score_gemma":0.0006040574,"threshold_uncertainty_score":0.9839062},"labels":[],"label_agreement":null},{"id":"W4379280711","doi":"10.1200/jco.2023.41.16_suppl.11564","title":"Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Springworks Therapeutics","keywords":"Medicine; Brief Pain Inventory; Placebo; Pain scale; Quality of life (healthcare); Physical therapy; Clinical endpoint; Chronic pain; Clinical trial; Internal medicine; Alternative medicine; Nursing","score_opus":0.11666602005707004,"score_gpt":0.4869831672524884,"score_spread":0.37031714719541836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968386,0.00008332332,0.0000020479492,0.0018725222,0.00032375153,0.00058643345,0.00005563155,0.000017313261,0.00022035396],"genre_scores_gemma":[0.9987682,0.00008220942,0.00016300862,0.0005394671,0.00036595936,0.000006390315,0.000014262931,0.000025322874,0.000035187633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99462825,0.0013500727,0.0027257423,0.00026530644,0.0007151168,0.00031553782],"domain_scores_gemma":[0.97880256,0.01793278,0.0020769802,0.0003762331,0.00055616995,0.0002553032],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006674454,0.0002099402,0.001815587,0.00020955366,0.00004832373,0.0000060372736,0.00022550164,0.00013799251,0.000033515546],"category_scores_gemma":[0.028216787,0.0001044783,0.0003837472,0.00056176644,0.00031223212,0.00006434651,0.00008442502,0.0010602755,0.000028316956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047636103,0.007947768,0.90637136,0.000006447375,0.0007733528,0.002542894,0.0017038478,0.000070385824,0.00000425779,0.0000016557506,0.006151647,0.026790263],"study_design_scores_gemma":[0.04962947,0.1208318,0.8270359,0.00031990488,0.0002835935,0.000020449017,0.0012592211,0.00002799953,0.0000029259936,0.000041991963,0.0004684301,0.00007828259],"about_ca_topic_score_codex":0.00024509302,"about_ca_topic_score_gemma":0.0002345895,"teacher_disagreement_score":0.11288403,"about_ca_system_score_codex":0.00023001348,"about_ca_system_score_gemma":0.0010469017,"threshold_uncertainty_score":0.97996897},"labels":[],"label_agreement":null},{"id":"W4379280715","doi":"10.1200/jco.2023.41.16_suppl.11513","title":"Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Pregnancy; Observational study; Logistic regression; Retrospective cohort study; Obstetrics; Fibromatosis; Multivariate analysis; Gynecology; Surgery; Internal medicine","score_opus":0.24869752973467837,"score_gpt":0.5310005077524699,"score_spread":0.2823029780177915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978879,0.00007247844,0.0000038594703,0.00085398095,0.00035789705,0.0002597114,0.000007273847,0.000015829884,0.00054104306],"genre_scores_gemma":[0.9984372,0.00017520909,0.0008267493,0.00008532577,0.0003612933,0.000017531682,0.0000026180344,0.000015424035,0.00007862207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970951,0.00026254248,0.0017092869,0.00018125218,0.0005469321,0.00020487387],"domain_scores_gemma":[0.99652195,0.0011269673,0.0012345636,0.00016505145,0.000761338,0.00019011082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020759664,0.00011949752,0.0012740167,0.00028826128,0.00001981331,0.0000044667804,0.00017177666,0.000112337606,0.00013438563],"category_scores_gemma":[0.0046365694,0.00007845151,0.00018064927,0.00047549294,0.00016727143,0.00022907561,0.00006387344,0.0005511754,0.0000074244767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071915756,0.0029593226,0.9782871,0.0000125151955,0.001021986,0.0017041194,0.0016339875,0.00005792957,0.00006922209,0.000021604837,0.00032990487,0.006710713],"study_design_scores_gemma":[0.008311996,0.05249128,0.93646735,0.00032979497,0.00008592574,0.00021845427,0.0015968166,0.000044581262,0.0000059450063,0.00030609558,0.000079206664,0.00006255835],"about_ca_topic_score_codex":0.000036439884,"about_ca_topic_score_gemma":0.000052204796,"teacher_disagreement_score":0.04953196,"about_ca_system_score_codex":0.00052195694,"about_ca_system_score_gemma":0.001281129,"threshold_uncertainty_score":0.55507416},"labels":[],"label_agreement":null},{"id":"W4379280728","doi":"10.1200/jco.2023.41.16_suppl.e18800","title":"Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pandemic; Hazard ratio; Regimen; Rituximab; Confidence interval; Population; Internal medicine; Retrospective cohort study; Proportional hazards model; Cohort; Emergency medicine; Pediatrics; Coronavirus disease 2019 (COVID-19); Lymphoma; Disease; Infectious disease (medical specialty); Environmental health","score_opus":0.15023235682813965,"score_gpt":0.48221588343745514,"score_spread":0.3319835266093155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830973,0.00009032589,0.00001848988,0.016422968,0.00018451973,0.00014609373,0.000009317687,0.000006185313,0.000024802726],"genre_scores_gemma":[0.9910891,0.00008946726,0.00012864929,0.008510297,0.00006306538,0.000001817576,0.00002160409,0.00000592324,0.00009005138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971974,0.00035404653,0.0016178524,0.00013388641,0.0005049139,0.00019190629],"domain_scores_gemma":[0.99188673,0.0055391514,0.0016056158,0.000105844585,0.00039262287,0.0004700542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002478233,0.00009245447,0.0015186458,0.0004441717,0.000029465533,0.0000033311107,0.000058215857,0.00026908214,0.00003893455],"category_scores_gemma":[0.0071787103,0.00006508117,0.00019737323,0.00038726718,0.000028957296,0.000040338207,0.000017030834,0.00042905868,3.3470877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015999035,0.00015146215,0.98874027,0.00007958795,0.0005670894,0.0003097083,0.00045941313,0.0011116639,0.0000013559072,0.0000020362513,0.0004012082,0.006576335],"study_design_scores_gemma":[0.008317547,0.0020769564,0.98440915,0.00005090323,0.0008524198,0.000012078088,0.00037974401,0.00016187041,6.1806566e-7,0.000016261149,0.0036668065,0.000055622113],"about_ca_topic_score_codex":0.9293579,"about_ca_topic_score_gemma":0.9987941,"teacher_disagreement_score":0.06943623,"about_ca_system_score_codex":0.006165393,"about_ca_system_score_gemma":0.03926818,"threshold_uncertainty_score":0.9976498},"labels":[],"label_agreement":null},{"id":"W4379280787","doi":"10.1200/jco.2023.41.16_suppl.9579","title":"A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McGill University; Ottawa Hospital; Jewish General Hospital; University of Ottawa; Royal Victoria Hospital; Health Sciences Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Vemurafenib; Melanoma; Internal medicine; Neoadjuvant therapy; Lymph node; Surgery; Oncology; Cancer; Metastatic melanoma; Breast cancer; Cancer research","score_opus":0.09954392322007363,"score_gpt":0.35462500954589155,"score_spread":0.25508108632581794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854445,0.00003505259,0.00003213646,0.00016240476,0.0005242964,0.00040576645,0.00009586832,0.000003378561,0.00019664248],"genre_scores_gemma":[0.9991519,0.000048617952,0.0004295956,0.00011078186,0.00012418233,0.0000063386096,0.000023025375,0.00002316616,0.000082387705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99565125,0.0010960645,0.002173128,0.00030067202,0.0004956669,0.00028323062],"domain_scores_gemma":[0.9958142,0.0007478464,0.002294294,0.00048682225,0.0005126326,0.00014420725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026709943,0.00019495143,0.0012089083,0.00011120609,0.000038068625,0.000008340604,0.00042489625,0.00014413515,0.0000064115034],"category_scores_gemma":[0.0019684513,0.00010517908,0.00017346327,0.00036749005,0.00023377743,0.000013792316,0.00020831599,0.0003497897,0.0000017364415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049007483,0.007902771,0.9274249,0.000038788305,0.00089815084,0.000246709,0.00021103908,0.0023200635,0.00867138,0.00003130086,0.0007655929,0.002481802],"study_design_scores_gemma":[0.029493634,0.07247621,0.89223224,0.000097509386,0.00022855376,0.000023722874,0.00039663527,0.000034287135,0.0021829605,0.000010672141,0.002670974,0.00015262402],"about_ca_topic_score_codex":0.0002289292,"about_ca_topic_score_gemma":0.0010842802,"teacher_disagreement_score":0.06457344,"about_ca_system_score_codex":0.000034944638,"about_ca_system_score_gemma":0.0011657329,"threshold_uncertainty_score":0.42890784},"labels":[],"label_agreement":null},{"id":"W4379280905","doi":"10.1200/jco.2023.41.16_suppl.8567","title":"EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable <i>EGFR</i>-mutant non-small-cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Erlotinib; Durvalumab; non-small cell lung cancer (NSCLC); Lung cancer; Hazard ratio; Cancer; Nivolumab; Epidermal growth factor receptor; Confidence interval; Immunotherapy","score_opus":0.0736198032207939,"score_gpt":0.4727268993844826,"score_spread":0.39910709616368867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97832364,0.0022861704,0.000060613773,0.006758367,0.009268522,0.0005970349,0.000017592469,0.000032345957,0.002655733],"genre_scores_gemma":[0.9942041,0.0023055177,0.00031476555,0.00066414237,0.0017561006,0.000049883787,0.00003449854,0.000041904586,0.00062905793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624354,0.0002475348,0.0021764885,0.00033936588,0.0005068731,0.00048617888],"domain_scores_gemma":[0.99635,0.001445957,0.0012110282,0.00021363817,0.00032679722,0.00045256288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020057927,0.00023992389,0.0013902836,0.00034158904,0.00009305028,0.000024852316,0.00016710756,0.00036374066,0.00011552122],"category_scores_gemma":[0.0013255745,0.00017468362,0.000599056,0.0007731588,0.00008230931,0.00021200419,0.000071645845,0.0009322083,0.000036593497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012158625,0.0085463775,0.65324855,0.0005998345,0.0032310383,0.00893086,0.0024645065,0.0035270185,0.010531759,0.00010842048,0.045662336,0.2509907],"study_design_scores_gemma":[0.2650151,0.02428702,0.5450773,0.0030596885,0.008131722,0.0001469745,0.0024286562,0.0148723805,0.008402169,0.0001233374,0.12733763,0.001117963],"about_ca_topic_score_codex":0.00037208642,"about_ca_topic_score_gemma":0.0004533224,"teacher_disagreement_score":0.2528565,"about_ca_system_score_codex":0.0015412034,"about_ca_system_score_gemma":0.004376651,"threshold_uncertainty_score":0.7763991},"labels":[],"label_agreement":null},{"id":"W4379280920","doi":"10.1200/jco.2023.41.16_suppl.7523","title":"Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Diffuse large B-cell lymphoma; Oncology; Gastroenterology; Lymphoma; Nuclear medicine; Confidence interval","score_opus":0.035003053264597815,"score_gpt":0.37982385187909773,"score_spread":0.34482079861449993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99858546,0.00015120859,0.000005887148,0.0003369967,0.0003600207,0.00040906502,0.000017074199,0.0000035327184,0.0001307613],"genre_scores_gemma":[0.9977073,0.00068506005,0.00010817994,0.0011961744,0.00023125765,0.000007112653,0.000017364879,0.000021703827,0.000025813171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963176,0.00081974326,0.0018839022,0.00031867565,0.000244189,0.000415851],"domain_scores_gemma":[0.9966859,0.0016958046,0.000992058,0.00027350168,0.00015455658,0.00019815646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036749437,0.00017640885,0.0008820768,0.000106395775,0.000048554044,0.000029204124,0.00026942985,0.00025259025,0.000002737582],"category_scores_gemma":[0.003629564,0.000111829555,0.00020150543,0.00021247227,0.000121302815,0.000008969595,0.00018341902,0.00044061677,0.000003458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011136371,0.012475323,0.9771786,0.0000076032397,0.00011687798,0.00038254118,0.00020564909,0.000014773083,0.000017528992,0.000007191795,0.00022126044,0.008259018],"study_design_scores_gemma":[0.043396965,0.011921085,0.93990546,0.000019283969,0.00009651415,0.000015478194,0.0005999705,0.0000503299,0.0000061802784,0.000035227302,0.0038230468,0.00013044117],"about_ca_topic_score_codex":0.00012537757,"about_ca_topic_score_gemma":0.002441905,"teacher_disagreement_score":0.042283326,"about_ca_system_score_codex":0.00006502957,"about_ca_system_score_gemma":0.00073256757,"threshold_uncertainty_score":0.4560277},"labels":[],"label_agreement":null},{"id":"W4379280923","doi":"10.1200/jco.2023.41.16_suppl.tps9144","title":"KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS <sup>G12C</sup> inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, <i>KRAS G12C</i> -mutated NSCLC.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"KRAS; Docetaxel; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Context (archaeology); Lung cancer; Cancer research; Colorectal cancer; Biology","score_opus":0.04660133977478886,"score_gpt":0.38008856713473615,"score_spread":0.3334872273599473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666375,0.0002724853,0.00021485468,0.0011507968,0.000395707,0.0012129361,0.00002837282,0.0000063063153,0.00005477174],"genre_scores_gemma":[0.99668545,0.00076298177,0.00059751765,0.0014119952,0.00037570472,0.000026097703,0.00001778017,0.000032610922,0.0000898942],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959642,0.0008290933,0.0021374803,0.0003275309,0.00037565146,0.00036599522],"domain_scores_gemma":[0.9964019,0.00094085326,0.0017656839,0.00031738973,0.00035464385,0.00021951504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026005364,0.00026056744,0.0011257153,0.00006858908,0.000105479594,0.000020717496,0.0003827301,0.0002566083,0.000013408777],"category_scores_gemma":[0.0018027346,0.00012793066,0.00027984474,0.00038522386,0.00043905244,0.00001758582,0.00015789724,0.0006037929,0.0000010772638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63465464,0.005181749,0.0059424955,0.00009564674,0.0019691996,0.00011350024,0.0011533671,0.0030914526,0.030048257,0.00010741088,0.0010340876,0.3166082],"study_design_scores_gemma":[0.801536,0.11655505,0.015264805,0.00077925465,0.0015624727,0.000094204144,0.0008652348,0.0011459542,0.023865227,0.0004460249,0.03717258,0.0007131649],"about_ca_topic_score_codex":0.000022706097,"about_ca_topic_score_gemma":0.00017295235,"teacher_disagreement_score":0.31589505,"about_ca_system_score_codex":0.000048660288,"about_ca_system_score_gemma":0.001279573,"threshold_uncertainty_score":0.5216861},"labels":[],"label_agreement":null},{"id":"W4379280924","doi":"10.1200/jco.2023.41.16_suppl.e21076","title":"Serum tumor biomarkers as a surrogate for radiographic assessment of non-small cell lung cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Surrogate endpoint; Stage (stratigraphy); Response Evaluation Criteria in Solid Tumors; Population; Gastroenterology; Cancer; Oncology; Regimen; Progressive disease; Surgery; Disease","score_opus":0.0543517897463957,"score_gpt":0.4895864810916594,"score_spread":0.4352346913452637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97566926,0.0005369861,0.0017099397,0.017327204,0.0025322987,0.0004093674,0.000008071076,0.000018675184,0.0017881775],"genre_scores_gemma":[0.9783435,0.0025732475,0.015251488,0.0023739499,0.0010509886,0.000017349399,0.0000041562503,0.000035714354,0.0003496127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965992,0.000282521,0.0021744785,0.00021650056,0.00037228764,0.00035498952],"domain_scores_gemma":[0.99365956,0.003276412,0.0019727356,0.00017760189,0.0004186407,0.00049504265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075188763,0.0001479526,0.0015592366,0.00039193244,0.00005258705,0.000008663271,0.00024143637,0.00021274776,0.00008067253],"category_scores_gemma":[0.0028431076,0.00010930172,0.0009095193,0.0004716411,0.00023971044,0.00004934234,0.000057911573,0.0010840219,0.0000025974034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016930235,0.0010077874,0.84682506,0.00069821475,0.0014185279,0.0011053081,0.00011620932,0.00043526303,0.003480218,0.00006825013,0.025981221,0.11717091],"study_design_scores_gemma":[0.020345803,0.010750435,0.80770385,0.00076993223,0.0014905663,0.0002856684,0.0002624941,0.11342451,0.00023175999,0.00029537643,0.04424648,0.00019314898],"about_ca_topic_score_codex":0.00007231598,"about_ca_topic_score_gemma":0.000011578772,"teacher_disagreement_score":0.11697776,"about_ca_system_score_codex":0.00010179552,"about_ca_system_score_gemma":0.0027363517,"threshold_uncertainty_score":0.48541704},"labels":[],"label_agreement":null},{"id":"W4379280931","doi":"10.1200/jco.2023.41.16_suppl.e18824","title":"Utility of Brock model for risk stratification in patients with high-risk pulmonary nodules: A single center study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nodule (geology); Malignancy; Lung cancer; Lung cancer screening; Radiology; Radiological weapon; Population; Lung; Receiver operating characteristic; Internal medicine","score_opus":0.07433639514919821,"score_gpt":0.4188765587079318,"score_spread":0.34454016355873357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937342,0.000012176227,0.004693453,0.0006748885,0.00030205867,0.00045000287,0.00001721922,0.000009005328,0.00010699031],"genre_scores_gemma":[0.99348795,0.00007094454,0.0060146865,0.00013827323,0.0001861435,0.000004838093,0.000016031798,0.000015942993,0.000065190026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969826,0.00040484307,0.0018708978,0.00020086393,0.0003592361,0.00018160028],"domain_scores_gemma":[0.9959632,0.0014402601,0.0018121618,0.00019094802,0.0004183039,0.00017514007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027383498,0.0000999843,0.0009454762,0.00015906927,0.000033300686,0.0000048958923,0.00013301166,0.0001544067,0.00000939743],"category_scores_gemma":[0.0060294634,0.00006673332,0.00018468245,0.00018697354,0.00012783533,0.00007787364,0.000031915188,0.0009766631,0.0000017638063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042052763,0.0075162738,0.86698526,0.000033214674,0.00011894294,0.000022836328,0.00014652804,0.0012850385,0.00001615714,0.000005524641,0.0005944089,0.11907052],"study_design_scores_gemma":[0.010172834,0.009062699,0.849559,0.0000739879,0.00021002258,0.000005938341,0.00016743498,0.12998788,0.0000026264786,0.0005163298,0.00019138194,0.00004984166],"about_ca_topic_score_codex":0.000048380134,"about_ca_topic_score_gemma":0.000058363992,"teacher_disagreement_score":0.12870285,"about_ca_system_score_codex":0.000043650172,"about_ca_system_score_gemma":0.0002981229,"threshold_uncertainty_score":0.7218266},"labels":[],"label_agreement":null},{"id":"W4379280969","doi":"10.1200/jco.2023.41.16_suppl.9008","title":"Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"Docetaxel; KRAS; Medicine; Clinical endpoint; Internal medicine; Oncology; Biomarker; Cancer; Lung cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Phases of clinical research; Randomized controlled trial; Clinical trial; Chemotherapy; Colorectal cancer","score_opus":0.1010531826313901,"score_gpt":0.5176842000167955,"score_spread":0.4166310173854054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577856,0.00035452246,0.000061363906,0.00036898884,0.0011667946,0.0010880886,0.000102980935,0.000013860823,0.0010648293],"genre_scores_gemma":[0.99776816,0.00083205826,0.0007153535,0.00012923121,0.00015638661,0.00004338942,0.00009127128,0.0000319217,0.00023220424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99590087,0.00029300156,0.0026959628,0.00029075428,0.0004910595,0.00032835794],"domain_scores_gemma":[0.99429834,0.0013701078,0.0027641219,0.0002483572,0.0010188553,0.0003002343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008959641,0.00024536558,0.0020666255,0.00043915227,0.000031412612,0.0000055679357,0.00016632873,0.0002982722,0.000112519505],"category_scores_gemma":[0.00077982066,0.00016022955,0.00044839492,0.0010322253,0.00020350376,0.00014377113,0.000036956426,0.00044003665,0.0000030053761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64276326,0.014858267,0.30855674,0.00019709702,0.0033184679,0.00045171977,0.0004234454,0.00051200984,0.0024139343,0.0000013485985,0.0023863688,0.024117323],"study_design_scores_gemma":[0.66954935,0.060685784,0.25996387,0.00061735837,0.0046878983,0.000007490271,0.00024227938,0.00091890007,0.0020539295,0.0000059384993,0.0010745374,0.00019268515],"about_ca_topic_score_codex":0.00046448206,"about_ca_topic_score_gemma":0.00033443107,"teacher_disagreement_score":0.04859287,"about_ca_system_score_codex":0.00035303002,"about_ca_system_score_gemma":0.0027922809,"threshold_uncertainty_score":0.6533972},"labels":[],"label_agreement":null},{"id":"W4379281001","doi":"10.1200/jco.2023.41.16_suppl.e20046","title":"Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Observational study; Adverse effect; Incidence (geometry); Refractory (planetary science); Retrospective cohort study; Surgery","score_opus":0.3787009502811558,"score_gpt":0.5351315061661807,"score_spread":0.15643055588502486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872912,0.00008875233,0.00006258351,0.008436314,0.0013604683,0.0013324807,0.00005546206,0.00005902907,0.0013136825],"genre_scores_gemma":[0.98617464,0.0006135346,0.0051320638,0.00097391725,0.0019766123,0.00008321634,0.0001260173,0.000053178774,0.0048668445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944221,0.00068562577,0.002978766,0.00039423298,0.00092506525,0.0005942113],"domain_scores_gemma":[0.98670244,0.009735378,0.001481771,0.00037157102,0.0009330505,0.0007758069],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0057050143,0.00024581983,0.0017740693,0.00040619055,0.00015429524,0.000020599875,0.00031806252,0.0003389146,0.00027808693],"category_scores_gemma":[0.0113565475,0.00017719826,0.0007562687,0.000569892,0.00016889564,0.00019819922,0.00013802618,0.0011928151,0.0002587195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017221918,0.006429733,0.8396711,0.000047062167,0.0013592206,0.0027559905,0.000104091414,0.000013415381,0.0001564669,0.0001253711,0.041586313,0.090529315],"study_design_scores_gemma":[0.035379104,0.018450798,0.8392665,0.00006857452,0.00034638733,0.00009329512,0.00026309924,0.0007111841,0.00003574746,0.00033677818,0.10492488,0.00012369105],"about_ca_topic_score_codex":0.00009318796,"about_ca_topic_score_gemma":0.00085104,"teacher_disagreement_score":0.09040562,"about_ca_system_score_codex":0.0003476082,"about_ca_system_score_gemma":0.0024761755,"threshold_uncertainty_score":0.9969712},"labels":[],"label_agreement":null},{"id":"W4379281020","doi":"10.1200/jco.2023.41.16_suppl.8002","title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Neutropenia; Oncology; Multiple myeloma; Lenalidomide; Regimen; Alemtuzumab; Bortezomib; Chemotherapy; Transplantation","score_opus":0.05943540418970244,"score_gpt":0.37962879687662415,"score_spread":0.3201933926869217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948539,0.00015970114,0.000004793378,0.0030100746,0.00028688967,0.0012040217,0.0000649962,0.000041857933,0.00037375887],"genre_scores_gemma":[0.99728155,0.0003369054,0.0012424698,0.00027720613,0.0004878254,0.000023613911,0.00005958938,0.00005264884,0.00023817888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943528,0.0009526147,0.0024178403,0.0005753377,0.001114361,0.0005870154],"domain_scores_gemma":[0.98041064,0.016358651,0.0015281809,0.00046856265,0.00066228095,0.0005716605],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037603183,0.00032721454,0.0015796975,0.0002371165,0.00020910992,0.000038855138,0.00030601234,0.00033644994,0.00003182086],"category_scores_gemma":[0.02044264,0.00016898505,0.00018036134,0.0005695823,0.0004127256,0.00019227879,0.00017472035,0.0018902902,0.000033568278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07728489,0.005409875,0.845004,0.00001940861,0.0007781324,0.009455337,0.0010791878,0.00013355071,0.000014714351,6.5348337e-7,0.0014664163,0.059353817],"study_design_scores_gemma":[0.080609515,0.042727478,0.8620149,0.00029496357,0.00024472622,0.00007951787,0.0015765314,0.0012217053,0.000009510492,0.000014835355,0.011041498,0.00016480916],"about_ca_topic_score_codex":0.00073550915,"about_ca_topic_score_gemma":0.005015454,"teacher_disagreement_score":0.05918901,"about_ca_system_score_codex":0.00030826734,"about_ca_system_score_gemma":0.0007816147,"threshold_uncertainty_score":0.9878086},"labels":[],"label_agreement":null},{"id":"W4379281044","doi":"10.1200/jco.2023.41.16_suppl.9053","title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease: A systematic review and meta-analysis in non-small cell lung cancer.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Meta-analysis; Oncology; Cancer; Adverse effect; Population","score_opus":0.10919054630018293,"score_gpt":0.4567624176956659,"score_spread":0.34757187139548296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070239445,0.9893498,0.000002610105,0.00047986035,0.0001298499,0.0029340747,0.00006078871,0.0000039283855,0.000015131808],"genre_scores_gemma":[0.0015413476,0.99779654,0.000102439284,0.00015906242,0.00005467785,0.00012146002,0.000013943798,0.000040091658,0.00017044449],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.989422,0.0010312534,0.00851773,0.00040916263,0.00036390938,0.00025589258],"domain_scores_gemma":[0.9881604,0.0026885394,0.008326087,0.00032941657,0.00025885072,0.00023672586],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0068737245,0.00042264108,0.017155489,0.0005162179,0.000029576206,0.0000116287765,0.0001696729,0.00037057762,0.000041512292],"category_scores_gemma":[0.0014787443,0.0002366451,0.0019626147,0.001031747,0.00024436112,0.000062448955,0.00012078974,0.0011088055,1.5744621e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038800053,0.00075637765,0.012241459,0.8492984,0.08820334,0.000122033176,0.0001284054,0.000006858402,2.8487264e-7,4.9950773e-7,0.000017290477,0.04534503],"study_design_scores_gemma":[0.007431554,0.0013630206,0.15541677,0.22213832,0.6109479,0.000013724695,0.000015825846,0.00002059449,1.0542077e-7,6.225142e-7,0.0024181204,0.00023343615],"about_ca_topic_score_codex":0.000512475,"about_ca_topic_score_gemma":0.00041324316,"teacher_disagreement_score":0.6271601,"about_ca_system_score_codex":0.0003669242,"about_ca_system_score_gemma":0.0017193464,"threshold_uncertainty_score":0.99743587},"labels":[],"label_agreement":null},{"id":"W4379281047","doi":"10.1200/jco.2023.41.16_suppl.8537","title":"Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mesothelin; Medicine; Mesothelioma; Cancer research; Oncology; Ovarian cancer; Internal medicine; Cancer; Gastroenterology; Immunology; Pathology","score_opus":0.1679472589828233,"score_gpt":0.5078129524008199,"score_spread":0.3398656934179966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958021,0.00023694399,0.000014170055,0.00093184056,0.0004188254,0.0006849795,0.000015948173,0.000017921198,0.001877264],"genre_scores_gemma":[0.995262,0.00085067586,0.0007237453,0.00046442426,0.00094408344,0.000015606647,0.000004834756,0.000065855136,0.001668774],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99472696,0.0008741756,0.0028487775,0.0003276862,0.0007907442,0.00043164307],"domain_scores_gemma":[0.9948467,0.002246776,0.0017585319,0.00035040206,0.0003459749,0.00045163438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041271714,0.00024608427,0.0023946974,0.00057630864,0.00004241909,0.000014254159,0.00018307885,0.00037218296,0.0005448939],"category_scores_gemma":[0.0014141959,0.00015764423,0.0003755761,0.00039286003,0.00041944362,0.000104428094,0.00006567668,0.0007961294,0.000015384307],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44197443,0.025732752,0.03387544,0.00008055943,0.0009469735,0.0015352076,0.0008973098,0.00002472227,0.024966778,0.000010016469,0.0010821806,0.46887365],"study_design_scores_gemma":[0.6379598,0.24207427,0.03300424,0.0005868001,0.00044557932,0.0001452396,0.00034197568,0.0005073417,0.0056631197,0.00012483083,0.07888478,0.00026205063],"about_ca_topic_score_codex":0.000053362328,"about_ca_topic_score_gemma":0.000034799734,"teacher_disagreement_score":0.4686116,"about_ca_system_score_codex":0.0003407625,"about_ca_system_score_gemma":0.0017344638,"threshold_uncertainty_score":0.6428545},"labels":[],"label_agreement":null},{"id":"W4379281125","doi":"10.1200/jco.2023.41.16_suppl.e18916","title":"Receipt of financial drug assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Geriatric oncology; Cohort; Lung cancer; Cancer; Targeted therapy; Internal medicine; Finance","score_opus":0.04652476666434791,"score_gpt":0.34930717045471255,"score_spread":0.30278240379036464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863286,0.0043465914,0.001944975,0.0012041965,0.002915387,0.0006224396,0.00017182704,0.00001670407,0.0024492573],"genre_scores_gemma":[0.9847814,0.007977796,0.0041314065,0.0008963503,0.000945948,0.00007101268,0.000007380396,0.00005519111,0.0011335562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956337,0.00005906683,0.0032935194,0.00042135286,0.00007593833,0.0005164038],"domain_scores_gemma":[0.9928095,0.00088774867,0.0053084213,0.0002690097,0.0004599636,0.00026537525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029432916,0.00025441375,0.0021959147,0.00026334065,0.000080491234,0.000020551575,0.00047091683,0.0004182216,0.00015381863],"category_scores_gemma":[0.0010015167,0.0002238392,0.0006072223,0.00036171736,0.00022926285,0.00041684372,0.000042325246,0.0006292871,0.000015362008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010426889,0.0010072298,0.78747755,0.00022059667,0.0003455492,0.000046165733,0.0013898602,0.0012432064,0.000031432006,0.0013349361,0.041781187,0.1546954],"study_design_scores_gemma":[0.01565833,0.0031058376,0.9175508,0.00027239145,0.000046040597,0.00000221679,0.00013089369,0.0011839323,0.00027704312,0.0014398148,0.059969526,0.00036317552],"about_ca_topic_score_codex":0.00015433725,"about_ca_topic_score_gemma":0.0005678309,"teacher_disagreement_score":0.15433224,"about_ca_system_score_codex":0.00020015519,"about_ca_system_score_gemma":0.0012245836,"threshold_uncertainty_score":0.9127898},"labels":[],"label_agreement":null},{"id":"W4379281140","doi":"10.1200/jco.2023.41.16_suppl.11557","title":"Metronomic dosing of selinexor in select soft tissue sarcomas (STS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Nausea; Dosing; Adverse effect; Dysgeusia; Leiomyosarcoma; Pharmacokinetics; Internal medicine; Toxicity; Neutropenia; Constipation; Gastroenterology; Oncology; Surgery","score_opus":0.15481991202598133,"score_gpt":0.5004697707607743,"score_spread":0.3456498587347929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842746,0.0016371154,0.000035044704,0.00841179,0.0006501916,0.00015777715,0.0000021222313,0.000011298014,0.00066721154],"genre_scores_gemma":[0.9944559,0.0010096423,0.0031590518,0.00061522046,0.0006241241,0.000003998464,0.0000029541065,0.000016627144,0.00011253584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966876,0.0003241482,0.0023611686,0.00015541693,0.00023402991,0.00023762934],"domain_scores_gemma":[0.9942799,0.0040715463,0.0010886163,0.00015813916,0.00019206162,0.000209716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031614364,0.00011306502,0.0015608678,0.00034888388,0.000015946303,0.0000037670984,0.00012110656,0.00024462354,0.00011721825],"category_scores_gemma":[0.0029291396,0.00008034886,0.00037666337,0.00038208248,0.00009601624,0.000056248256,0.000045491986,0.00055503106,0.00006878458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010219282,0.0025664838,0.6017856,0.000027521799,0.00033199895,0.0013149242,0.00007415035,0.000070653936,0.00066868914,0.000054199645,0.0055920477,0.3864918],"study_design_scores_gemma":[0.009485874,0.007244389,0.9230082,0.00016428204,0.00035750872,0.00026590496,0.00010891314,0.00030504088,0.0011933594,0.00032435433,0.05746376,0.00007840034],"about_ca_topic_score_codex":0.00005515004,"about_ca_topic_score_gemma":0.00007635329,"teacher_disagreement_score":0.3864134,"about_ca_system_score_codex":0.00019360145,"about_ca_system_score_gemma":0.0009608132,"threshold_uncertainty_score":0.35066652},"labels":[],"label_agreement":null},{"id":"W4379281157","doi":"10.1200/jco.2023.41.16_suppl.8003","title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"Janssen Research and Development","keywords":"Medicine; Daratumumab; Internal medicine; Refractory (planetary science); CD38; Oncology; Tolerability; Gastroenterology; Proteasome inhibitor; Lenalidomide; Multiple myeloma; Adverse effect; CD34","score_opus":0.1027499321914212,"score_gpt":0.4408975407525841,"score_spread":0.3381476085611629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984054,0.000107849395,0.0000098295895,0.004347916,0.0012569732,0.0006069799,0.00002278311,0.000049281192,0.009544353],"genre_scores_gemma":[0.9913082,0.00053487293,0.0005629877,0.00085575273,0.0007926479,0.000009653102,0.00009570947,0.00006748085,0.005772686],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99277025,0.0011301964,0.0037057898,0.00047457067,0.0012526205,0.0006665859],"domain_scores_gemma":[0.99223775,0.0038267232,0.001762348,0.0005585922,0.000954899,0.000659688],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006891201,0.00027722443,0.0020930343,0.0007391335,0.00007342294,0.00002066575,0.00041203966,0.0007779043,0.000529738],"category_scores_gemma":[0.008776086,0.00019397547,0.00049737754,0.001169497,0.0004301819,0.00024040726,0.00014330263,0.0034354732,0.00023939017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19995457,0.008048778,0.29590532,0.00005450675,0.0008662594,0.0068422835,0.00041699328,0.00008307042,0.0022096168,0.000019485753,0.053941302,0.43165782],"study_design_scores_gemma":[0.07580209,0.03203242,0.5981579,0.00015325386,0.00010947801,0.00013157271,0.00015152083,0.00026730006,0.00021396698,0.000050669052,0.29275507,0.00017477534],"about_ca_topic_score_codex":0.00005152814,"about_ca_topic_score_gemma":0.0002367697,"teacher_disagreement_score":0.43148306,"about_ca_system_score_codex":0.0006162488,"about_ca_system_score_gemma":0.0025605417,"threshold_uncertainty_score":0.9995734},"labels":[],"label_agreement":null},{"id":"W4379281186","doi":"10.1200/jco.2023.41.16_suppl.tps8070","title":"A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Carfilzomib; Internal medicine; Dexamethasone; Lenalidomide; Clinical endpoint; Multiple myeloma; Oncology; Cmax; Pharmacokinetics; Pharmacology; Urology; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.19663143277498835,"score_gpt":0.5185551004945744,"score_spread":0.3219236677195861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382716,0.0018645144,0.000023097577,0.0008905776,0.0008307326,0.0019929253,0.000035405385,0.000032079057,0.0005035247],"genre_scores_gemma":[0.9927043,0.0033902046,0.0028641245,0.00012340477,0.00039156343,0.00007560094,0.0000144411,0.00005802677,0.00037837544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98942095,0.0038216945,0.004325649,0.0006581307,0.0010397318,0.00073385454],"domain_scores_gemma":[0.960503,0.034914177,0.0023440984,0.0004923318,0.0006516109,0.0010948117],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013259349,0.00044482597,0.005361778,0.0010197129,0.00010286662,0.000028451635,0.00029437497,0.0005415946,0.00010838577],"category_scores_gemma":[0.041050423,0.00031951768,0.0005848542,0.0008245414,0.00093977683,0.00024271778,0.00030892904,0.0019288802,0.000012677298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68825024,0.011540555,0.17851602,0.000133746,0.0025805277,0.00578746,0.0011979359,0.000038681028,0.0011011356,0.000022039796,0.0002612717,0.11057038],"study_design_scores_gemma":[0.849849,0.033758447,0.108029075,0.00019128989,0.0010448322,0.00014104877,0.0023336823,0.0027903316,0.00024305226,0.0000806128,0.0013050459,0.00023357614],"about_ca_topic_score_codex":0.0011197168,"about_ca_topic_score_gemma":0.0022626866,"teacher_disagreement_score":0.16159876,"about_ca_system_score_codex":0.0002598548,"about_ca_system_score_gemma":0.0013092879,"threshold_uncertainty_score":0.9999257},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4379281197","doi":"10.1200/jco.2023.41.16_suppl.12069","title":"The effect of exercise on physical function and medication adherence in women receiving endocrine therapy for breast cancer: The breast cancer endocrine therapy fitness (BE-FIT) randomized controlled trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Foundation","keywords":"Medicine; Breast cancer; Randomized controlled trial; Physical therapy; Aerobic exercise; Cancer; Regimen; Internal medicine","score_opus":0.05194554238897886,"score_gpt":0.4371213079362251,"score_spread":0.38517576554724625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95305836,0.0028433336,0.000011261027,0.03716241,0.0031714113,0.003669327,0.00002665045,0.000014000132,0.000043248383],"genre_scores_gemma":[0.9354262,0.05958901,0.0000020218242,0.0006650325,0.0018738304,0.0022646985,0.0000020207606,0.00002211287,0.00015508334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99506617,0.0019241687,0.0019047351,0.00024443076,0.00052351766,0.00033695906],"domain_scores_gemma":[0.9739924,0.02341307,0.0017899486,0.00023555066,0.00039882056,0.00017019098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010168523,0.0002217851,0.0032387876,0.000127977,0.00010288882,0.000017207449,0.00021952082,0.0001381567,0.00009240221],"category_scores_gemma":[0.0019405144,0.00009394902,0.0007490902,0.00031950697,0.00041908797,0.000075202835,0.000028395176,0.0007156986,7.1319425e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60471356,0.00028250343,0.002591964,0.000030307845,0.0004348633,0.0000062709355,0.00029692202,0.00002012222,0.0001022664,0.000017229302,0.0004424988,0.39106148],"study_design_scores_gemma":[0.9134971,0.012373565,0.06956454,0.00041498718,0.0004043332,0.000041148935,0.00036505747,0.00059943926,0.00009342104,0.0003603305,0.002190146,0.00009592651],"about_ca_topic_score_codex":0.00034130792,"about_ca_topic_score_gemma":0.00031208398,"teacher_disagreement_score":0.39096555,"about_ca_system_score_codex":0.00018317265,"about_ca_system_score_gemma":0.0007982455,"threshold_uncertainty_score":0.383113},"labels":[],"label_agreement":null},{"id":"W4379281203","doi":"10.1200/jco.2023.41.16_suppl.9116","title":"Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"LUNGevity Foundation","keywords":"Medicine; Internal medicine; Oncology; Proportional hazards model; Lung cancer; Osimertinib; Chemotherapy; Cancer; Medical record; Adenocarcinoma","score_opus":0.07240415758148412,"score_gpt":0.46693052407450025,"score_spread":0.39452636649301615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432456,0.00034795378,0.00046658996,0.0022028412,0.0012851354,0.00033059236,0.000040921706,0.000012345998,0.00098908],"genre_scores_gemma":[0.9938198,0.0027100078,0.0014328696,0.0005147932,0.00053831626,0.000015067635,0.000018927976,0.00003104452,0.00091921113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722654,0.00016124449,0.0018404481,0.00017814385,0.00033254214,0.00026110324],"domain_scores_gemma":[0.9958335,0.0011349239,0.001922848,0.00019441238,0.0005809664,0.00033331654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011307846,0.00016104171,0.0014889197,0.00017408167,0.000038944654,0.000007714569,0.00013579887,0.00014699608,0.00019251314],"category_scores_gemma":[0.00034488394,0.000099917466,0.00032599233,0.00030054865,0.00015490664,0.000068930836,0.000035140543,0.00051188207,0.000014293602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018575412,0.0017430539,0.9448481,0.0004346602,0.0018121846,0.0035926597,0.00060061,0.000053507774,0.0005008723,0.000014429031,0.00075350795,0.04378883],"study_design_scores_gemma":[0.008068462,0.0057407273,0.9789995,0.00041024847,0.0039788596,0.00017948278,0.00016235995,0.00019849143,0.00036523317,0.000015277488,0.0017700276,0.00011132589],"about_ca_topic_score_codex":0.00013297063,"about_ca_topic_score_gemma":0.00029811438,"teacher_disagreement_score":0.043677505,"about_ca_system_score_codex":0.00019040622,"about_ca_system_score_gemma":0.0029770692,"threshold_uncertainty_score":0.52811927},"labels":[],"label_agreement":null},{"id":"W4379281207","doi":"10.1200/jco.2023.41.16_suppl.e18623","title":"Real world evidence for continuing HER2-directed therapy for metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Metastatic breast cancer; Cohort; Breast cancer; Systemic therapy; Cancer; Internal medicine; Pharmacy; Oncology; Family medicine","score_opus":0.29597170892414887,"score_gpt":0.5694901139097674,"score_spread":0.2735184049856186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.907888,0.0043528555,0.004171305,0.0756117,0.005161095,0.0022779237,0.00012364371,0.00021607413,0.00019741524],"genre_scores_gemma":[0.9041307,0.01548109,0.06223017,0.0050768023,0.00826382,0.00041540372,0.000012804156,0.00013991301,0.0042493106],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966795,0.00025617643,0.0020777106,0.000263276,0.00030886548,0.0004144729],"domain_scores_gemma":[0.984202,0.012244328,0.0018524948,0.00019207125,0.0012009203,0.0003081331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040952777,0.00018151478,0.0017860866,0.00022081187,0.000057800004,0.000011829958,0.00021338018,0.00014351639,0.000121606754],"category_scores_gemma":[0.0035210229,0.00012919755,0.00073296635,0.00043691063,0.00020595304,0.00019957944,0.000025497407,0.00049853866,0.000005816557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041398343,0.00045488751,0.017301949,0.00010900986,0.00094934873,0.000098886434,0.0002147005,0.00008105501,0.0017839408,0.00009751217,0.006573515,0.9309369],"study_design_scores_gemma":[0.042251393,0.015102686,0.6108886,0.0018427497,0.0010319784,0.0004625342,0.0004099845,0.0016232535,0.00054968084,0.0041138227,0.32139248,0.0003308458],"about_ca_topic_score_codex":0.00006116442,"about_ca_topic_score_gemma":0.00023081218,"teacher_disagreement_score":0.930606,"about_ca_system_score_codex":0.0002767539,"about_ca_system_score_gemma":0.0015237546,"threshold_uncertainty_score":0.52685237},"labels":[],"label_agreement":null},{"id":"W4379281224","doi":"10.1200/jco.2023.41.16_suppl.e18798","title":"Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Gilead Sciences (Canada)","funders":"","keywords":"Medicine; Internal medicine; Population; Taxane; Oncology; Triple-negative breast cancer; Breast cancer; Cancer","score_opus":0.1317608025608072,"score_gpt":0.48175530173972303,"score_spread":0.34999449917891584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7402819,0.00046262998,0.000098523364,0.2514483,0.0037387148,0.0020922173,0.0015403177,0.00004798005,0.0002894273],"genre_scores_gemma":[0.9663804,0.004741344,0.0042580585,0.016995622,0.0013178237,0.00033144144,0.00005519102,0.00011317254,0.0058069276],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948651,0.00057561585,0.0027585705,0.00038670594,0.000511084,0.0009029142],"domain_scores_gemma":[0.9878113,0.008922705,0.0017907616,0.00029127754,0.0005583715,0.000625582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041631893,0.00032959218,0.0019107345,0.00046391346,0.00014369066,0.000029005045,0.00040393168,0.0002071917,0.0003332313],"category_scores_gemma":[0.0041998723,0.00017261089,0.0004218224,0.0009976793,0.00025593094,0.00023453086,0.000049858885,0.0015262767,0.000015196502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030768879,0.00083648233,0.28856495,0.00019931926,0.0011987457,0.0013788436,0.003634173,0.00023149564,0.0000116088095,0.000055736025,0.02260837,0.6505114],"study_design_scores_gemma":[0.021345263,0.006748321,0.79352283,0.00070645794,0.00055763806,0.00018804807,0.00090177235,0.00043352428,0.000015735102,0.0015096366,0.17375849,0.00031226836],"about_ca_topic_score_codex":0.0197579,"about_ca_topic_score_gemma":0.54814416,"teacher_disagreement_score":0.6501991,"about_ca_system_score_codex":0.001194557,"about_ca_system_score_gemma":0.005400112,"threshold_uncertainty_score":0.9867696},"labels":[],"label_agreement":null},{"id":"W4379281242","doi":"10.1200/jco.2023.41.16_suppl.11560","title":"Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Soft tissue sarcoma; Context (archaeology); Clinical trial; Sarcoma; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Incidence (geometry); Adverse effect; Phases of clinical research; Surgery; Pathology","score_opus":0.32274826970421994,"score_gpt":0.5535054830943374,"score_spread":0.2307572133901175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963515,0.0013832904,0.000001586393,0.0010511266,0.0001551264,0.0010112404,0.000003999416,0.000007440251,0.00003472791],"genre_scores_gemma":[0.9953727,0.0034797026,0.00073378487,0.00022620858,0.000117660806,0.00003178391,0.000011737096,0.000020375559,0.0000060248913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99130005,0.0039805057,0.003513367,0.00022419119,0.00079113076,0.00019075778],"domain_scores_gemma":[0.9915222,0.0052488763,0.0021417346,0.00019008147,0.0007173039,0.00017983752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023592724,0.00015971035,0.0023363307,0.00034125574,0.000017176695,0.0000059030785,0.00008002665,0.00032153475,0.00007707795],"category_scores_gemma":[0.00450735,0.00007418089,0.00024035817,0.0004953142,0.0001839528,0.00008940819,0.000014846139,0.00054566615,0.0000023603673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053086054,0.008732819,0.514599,0.0000031229592,0.0003210182,0.00019134222,0.00006695968,0.000003763548,0.000008873203,0.000001047359,0.000038321024,0.42294767],"study_design_scores_gemma":[0.15347126,0.06611546,0.7790714,0.00031186925,0.00031404672,0.000014865273,0.00005512041,0.00023152296,0.000045070905,0.000035136785,0.00027289285,0.000061376086],"about_ca_topic_score_codex":0.000045459226,"about_ca_topic_score_gemma":0.0000632578,"teacher_disagreement_score":0.42288628,"about_ca_system_score_codex":0.00012175441,"about_ca_system_score_gemma":0.0011472566,"threshold_uncertainty_score":0.81768143},"labels":[],"label_agreement":null},{"id":"W4379281274","doi":"10.1200/jco.2023.41.16_suppl.e21065","title":"Prognostic effects of <i>TP53</i> variants co-occuring in patients with <i>HER2</i>-mutated non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Oncology; Lung cancer; Proportional hazards model; Progression-free survival; Adenocarcinoma; Stage (stratigraphy); Cancer; Overall survival; Gastroenterology","score_opus":0.016187047812253167,"score_gpt":0.3460881710566787,"score_spread":0.32990112324442555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975439,0.00044424526,0.00017636422,0.000119493576,0.00093121163,0.00036667686,0.00002586912,0.0000035314013,0.00038872167],"genre_scores_gemma":[0.9971835,0.0014157089,0.0004419463,0.00045041676,0.00039866415,0.000014724665,0.00002437204,0.00002887414,0.00004179073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977964,0.00017586393,0.0012796914,0.0002474092,0.00019258645,0.00030800654],"domain_scores_gemma":[0.9971705,0.00094042666,0.0011827921,0.00018641891,0.00032816405,0.00019169386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008662755,0.00016267624,0.00075346284,0.00010759586,0.000024870675,0.000008930084,0.0002569059,0.00032502835,0.0000074696645],"category_scores_gemma":[0.001166625,0.00013035916,0.00018037045,0.00021267297,0.00009623201,0.000006561232,0.00010162448,0.00038684247,0.0000030730066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018820593,0.0011653517,0.97790307,0.00018376131,0.00020552285,0.00017840657,0.0000720762,0.0012915309,0.006644566,0.0000025750542,0.0036996116,0.0067714746],"study_design_scores_gemma":[0.012128396,0.00866512,0.96263546,0.00028801663,0.00023053656,0.0000051593634,0.000021285956,0.00018594728,0.012103564,0.000020768832,0.0035040025,0.00021176477],"about_ca_topic_score_codex":0.000051795563,"about_ca_topic_score_gemma":0.0001317244,"teacher_disagreement_score":0.015267626,"about_ca_system_score_codex":0.000051285544,"about_ca_system_score_gemma":0.001339825,"threshold_uncertainty_score":0.5315892},"labels":[],"label_agreement":null},{"id":"W4379281300","doi":"10.1200/jco.2023.41.16_suppl.10628","title":"Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Outreach; Medicine; Family medicine; Prostate cancer; Cancer registry; Genetic testing; Medical education; Cancer; Internal medicine; Political science","score_opus":0.18823952650303352,"score_gpt":0.45043890590668106,"score_spread":0.26219937940364757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7875989,0.0012515952,0.00024048986,0.2040616,0.0023387377,0.0009454653,0.00025106594,0.000038123373,0.0032740366],"genre_scores_gemma":[0.9632997,0.004364671,0.0041658813,0.011999078,0.003209572,0.00038244305,0.000013260558,0.00007678931,0.012488584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955291,0.00011424748,0.003094993,0.00054431823,0.00011489268,0.0006024126],"domain_scores_gemma":[0.9950448,0.0007068719,0.0028152333,0.0005903312,0.00018628835,0.00065642886],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030462814,0.0002381936,0.001570267,0.00020497844,0.00012142728,0.00012393249,0.00089826516,0.0003519904,0.00020795694],"category_scores_gemma":[0.005092523,0.00019161617,0.00049899507,0.00042588348,0.00014297258,0.0001523504,0.00022490519,0.0008208655,0.0008586599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017271715,0.0006117996,0.21508121,0.000017989067,0.000421113,0.00015805227,0.0011055912,0.0023137883,0.000008320397,0.00068929757,0.23273772,0.5451279],"study_design_scores_gemma":[0.0015464907,0.0017877537,0.3511087,0.000044599812,0.00003253721,0.0000069887237,0.00009786858,0.0001855791,0.000005523495,0.0034837932,0.6415348,0.0001653779],"about_ca_topic_score_codex":0.0020017307,"about_ca_topic_score_gemma":0.001647872,"teacher_disagreement_score":0.5449626,"about_ca_system_score_codex":0.00043128623,"about_ca_system_score_gemma":0.0010305048,"threshold_uncertainty_score":0.9999193},"labels":[],"label_agreement":null},{"id":"W4379281331","doi":"10.1200/jco.2023.41.16_suppl.5578","title":"Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Olaparib; Chemotherapy; Oncology; Progression-free survival; Cancer; Ovarian cancer; Retrospective cohort study; Poly ADP ribose polymerase","score_opus":0.11437305139472029,"score_gpt":0.47365586000055415,"score_spread":0.35928280860583384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78942126,0.00015489034,0.000018092805,0.20752262,0.00233823,0.00037392942,0.000031642183,0.000015959955,0.0001233899],"genre_scores_gemma":[0.98219866,0.0007320355,0.0020758193,0.0129285,0.0018161886,0.000054344393,0.000006500597,0.000031283995,0.00015665064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99611294,0.0006648496,0.0021418054,0.00028703563,0.00044005873,0.00035329768],"domain_scores_gemma":[0.9952326,0.0027901845,0.00083806826,0.00023361249,0.00034107186,0.00056450756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050433064,0.00017964277,0.0013480271,0.00036680233,0.00003256846,0.000011957034,0.00014425653,0.00031203282,0.00037925263],"category_scores_gemma":[0.0028695373,0.00013046451,0.00044109323,0.00052077044,0.00008057155,0.000049060567,0.000031663923,0.000696442,0.00008925569],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13088194,0.0043535805,0.1605008,0.000042175212,0.0004683095,0.0051567615,0.00056434976,0.00039726493,0.0030213844,0.000059586808,0.025216283,0.6693376],"study_design_scores_gemma":[0.024502097,0.02253259,0.7678568,0.0004417111,0.000117182586,0.000041425938,0.000069611146,0.00009546747,0.0010709217,0.00008067136,0.18307054,0.00012099818],"about_ca_topic_score_codex":0.00014762618,"about_ca_topic_score_gemma":0.00041837536,"teacher_disagreement_score":0.6692166,"about_ca_system_score_codex":0.00085872767,"about_ca_system_score_gemma":0.004977326,"threshold_uncertainty_score":0.88295627},"labels":[],"label_agreement":null},{"id":"W4379281340","doi":"10.1200/jco.2023.41.16_suppl.e18694","title":"Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; McMaster University; Ontario Clinical Oncology Group; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Feeding tube; Dysphagia; Cohort; Gastrostomy; Surgery; Retrospective cohort study; Cancer; Internal medicine","score_opus":0.11788834271752892,"score_gpt":0.41500981377030954,"score_spread":0.29712147105278064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780643,0.00007258177,0.0000012264138,0.0010812086,0.00037883528,0.0005581971,0.0000038878165,0.000007698738,0.00008995003],"genre_scores_gemma":[0.99906003,0.000056043515,0.00030593298,0.00022621927,0.00021494203,0.000005210419,0.0000015952771,0.000014127739,0.00011591119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745154,0.00038899336,0.0014016045,0.00020910236,0.0003389773,0.00020980238],"domain_scores_gemma":[0.9966868,0.0017132562,0.0008227071,0.0001078543,0.00047298713,0.00019637101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015459778,0.00012036697,0.0013937466,0.00023956576,0.000021917302,0.000005309214,0.000064810236,0.00020392414,0.000020142512],"category_scores_gemma":[0.002729258,0.00007683546,0.00009987734,0.00032445247,0.00021060956,0.00015774377,0.00005973118,0.0007394711,0.0000025276402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067353,0.0038233816,0.96931785,0.00004084519,0.00023323052,0.001792296,0.00046644034,0.0000089792675,0.00008472774,0.000004722956,0.00009711689,0.017395109],"study_design_scores_gemma":[0.008788515,0.027327767,0.9628651,0.000111645786,0.00035275368,0.000041018437,0.00026910487,0.000032933734,0.000037182246,0.000022827939,0.00009415315,0.00005699463],"about_ca_topic_score_codex":0.00006502203,"about_ca_topic_score_gemma":0.00011344825,"teacher_disagreement_score":0.023504384,"about_ca_system_score_codex":0.00011704622,"about_ca_system_score_gemma":0.00046477426,"threshold_uncertainty_score":0.3267374},"labels":[],"label_agreement":null},{"id":"W4379281361","doi":"10.1200/jco.2023.41.16_suppl.6623","title":"Financial toxicity, quality of life, symptom burden, and access to resources in early-phase clinical trial (EP-CT) participants.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Toxicity; Internal medicine; Finance; Clinical trial; Physical therapy; Nursing","score_opus":0.46909572073591665,"score_gpt":0.5404443154155059,"score_spread":0.0713485946795892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98839283,0.00048886164,0.00009562206,0.0056435913,0.003158231,0.00034314976,0.00007152433,0.00001131236,0.0017948798],"genre_scores_gemma":[0.9932163,0.0015703406,0.00018787949,0.0017941138,0.0030462125,0.00001116697,0.0000012193321,0.000020287616,0.00015249656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98932886,0.00040441766,0.009193392,0.00044084445,0.00011056174,0.00052192295],"domain_scores_gemma":[0.9902349,0.0037758537,0.004921053,0.0003036855,0.00015131432,0.00061318174],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020025771,0.00019086165,0.0033323986,0.0004750197,0.00004995771,0.00006304402,0.0006523943,0.00044450577,0.000117307376],"category_scores_gemma":[0.041465443,0.00018853528,0.0005937284,0.00046304206,0.00035050616,0.00049192813,0.00032877113,0.0009007213,0.0000976221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0400276,0.0013735867,0.86584073,0.000040143197,0.00017063961,0.000086639004,0.0005542044,0.00014496683,0.000003905555,0.00772692,0.0071795806,0.076851085],"study_design_scores_gemma":[0.044497862,0.0077152615,0.85661846,0.00004349738,0.000023440813,0.0000025557417,0.000052862306,0.00012560435,0.0000053197973,0.014220593,0.07648179,0.00021278053],"about_ca_topic_score_codex":0.0005362713,"about_ca_topic_score_gemma":0.0005463683,"teacher_disagreement_score":0.0766383,"about_ca_system_score_codex":0.00010395406,"about_ca_system_score_gemma":0.00081192545,"threshold_uncertainty_score":0.9666087},"labels":[],"label_agreement":null},{"id":"W4379281373","doi":"10.1200/jco.2023.41.16_suppl.8056","title":"Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Imaging for Blood Diseases","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics; University of Manitoba","funders":"","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Oncology; Internal medicine; Tumor progression; Disease; Risk stratification; Telomere; Cancer; Monoclonal; Immunology; Monoclonal antibody; Genetics; Biology; Antibody","score_opus":0.08638838182639255,"score_gpt":0.4239433698228404,"score_spread":0.3375549879964479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935559,0.00014179229,0.0032507698,0.0013642024,0.0011238913,0.00021529189,0.0000072093117,0.000055070082,0.00028586425],"genre_scores_gemma":[0.91593,0.000016046022,0.08364645,0.00018469144,0.00019206526,0.0000062853856,0.0000010277176,0.0000113594415,0.0000121048915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661404,0.00021856446,0.0019995023,0.00027879028,0.0005762117,0.0003128764],"domain_scores_gemma":[0.99507785,0.0026704282,0.0013118963,0.00028226356,0.00030455613,0.00035303095],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003393814,0.00012613145,0.0007774335,0.00037575964,0.000035285786,0.000032366304,0.0007841259,0.0001380682,0.000003581711],"category_scores_gemma":[0.008621044,0.00009629633,0.0002947003,0.00076504104,0.000113052716,0.0005405076,0.00057404616,0.0005161779,0.00002723745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003048562,0.00084132154,0.60943097,0.000023616685,0.00006317691,0.00042726885,0.000051918447,0.0035329831,0.000249049,0.00020371412,0.0012036179,0.38366753],"study_design_scores_gemma":[0.0029624181,0.0034849008,0.9286663,0.00041668117,0.000039970186,0.00006132454,0.00002902831,0.056469128,0.0013638107,0.004886848,0.0014553001,0.0001642967],"about_ca_topic_score_codex":0.000014721354,"about_ca_topic_score_gemma":0.00003956717,"teacher_disagreement_score":0.38350323,"about_ca_system_score_codex":0.000051787716,"about_ca_system_score_gemma":0.0008699155,"threshold_uncertainty_score":0.99972975},"labels":[],"label_agreement":null},{"id":"W4379281376","doi":"10.1200/jco.2023.41.16_suppl.e18077","title":"Re-irradiation for recurrent head and neck cancer: Freedom from cancer recurrence rate.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Head and neck cancer; Cancer; Surgery; Retrospective cohort study; Internal medicine; Cohort; Oncology; Randomized controlled trial","score_opus":0.24536121551004125,"score_gpt":0.533669281469328,"score_spread":0.28830806595928676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9183229,0.01353942,0.000039284365,0.05985413,0.007405294,0.00031316912,0.000083584506,0.000019800555,0.0004224023],"genre_scores_gemma":[0.80870533,0.1741834,0.00257634,0.0046545644,0.009248694,0.00011537383,0.000018592647,0.000032040596,0.00046565363],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975416,0.00020062912,0.001572759,0.00023256487,0.0002031996,0.00024924442],"domain_scores_gemma":[0.9949848,0.0031537705,0.0010093295,0.00011418223,0.00043091492,0.0003070095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021121253,0.00012620253,0.0013818117,0.00009337864,0.000075118995,0.000008354533,0.000090875066,0.00024091273,0.00009413224],"category_scores_gemma":[0.0038771979,0.00009158952,0.00024620135,0.00019704195,0.00014051427,0.00008580395,0.00004206974,0.000571184,0.000008254785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054318924,0.00027396993,0.13133644,0.000078259276,0.00036282954,0.000057402423,0.0004149252,0.000025135381,0.00008643532,0.00003168811,0.1898429,0.67205817],"study_design_scores_gemma":[0.007913456,0.010039099,0.59177065,0.0006362985,0.00032240365,0.0000060894467,0.00016041945,0.00092115963,0.000027128948,0.0006121663,0.38749197,0.00009917763],"about_ca_topic_score_codex":0.00040444743,"about_ca_topic_score_gemma":0.0031780833,"teacher_disagreement_score":0.671959,"about_ca_system_score_codex":0.00018768934,"about_ca_system_score_gemma":0.0014796689,"threshold_uncertainty_score":0.46416482},"labels":[],"label_agreement":null},{"id":"W4379281424","doi":"10.1200/jco.2023.41.16_suppl.12026","title":"Interventions to improve outcomes for caregivers of patients with advanced cancer: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Kingston Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychological intervention; CINAHL; Quality of life (healthcare); Family caregivers; Mental health; Meta-analysis; MEDLINE; Anxiety; Randomized controlled trial; Caregiver burden; Palliative care; Physical therapy; Psychiatry; Nursing; Internal medicine; Disease; Dementia","score_opus":0.3564766688451994,"score_gpt":0.5828462370150539,"score_spread":0.22636956816985448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281424","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012878182,0.9933497,0.000077429526,0.0012306401,0.0007764078,0.004018333,0.0004609954,0.0000071211316,0.00006654232],"genre_scores_gemma":[0.000029049532,0.9970913,0.00079156604,0.00044750233,0.00005743326,0.0004938223,0.000008457808,0.000025067737,0.0010558212],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9910396,0.001905049,0.0059300205,0.00030208705,0.0005748231,0.00024843268],"domain_scores_gemma":[0.9775441,0.009326672,0.011093907,0.00030528233,0.0014028344,0.00032714708],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008698782,0.0002635482,0.020200074,0.0003490849,0.00008253481,0.000015303864,0.0006502557,0.0003625507,0.00007779314],"category_scores_gemma":[0.015582238,0.00014272665,0.008072483,0.00082003156,0.00025597392,0.00012618711,0.00009962809,0.00045618735,0.000003359574],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039502233,0.00028468677,0.00020350373,0.81002265,0.15919136,0.000009054091,0.00021349995,0.000002576209,3.0626224e-10,0.00015212312,0.0008346018,0.029046461],"study_design_scores_gemma":[0.00052606163,0.0013325283,0.00008023609,0.030381888,0.8572817,4.239445e-7,0.00030112092,5.794068e-8,1.5064745e-9,0.000029622523,0.10991381,0.00015253662],"about_ca_topic_score_codex":0.00015591395,"about_ca_topic_score_gemma":0.0025856243,"teacher_disagreement_score":0.77964073,"about_ca_system_score_codex":0.000254617,"about_ca_system_score_gemma":0.0020559824,"threshold_uncertainty_score":0.9943461},"labels":[],"label_agreement":null},{"id":"W4379281427","doi":"10.1200/jco.2023.41.16_suppl.9063","title":"Management of patients with <i>ALK</i>-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Pfizer","keywords":"Crizotinib; Medicine; ALK inhibitor; Lung cancer; Radiation therapy; Internal medicine; Brain metastasis; Randomization; Tyrosine-kinase inhibitor; Post-hoc analysis; Oncology; Surgery; Cancer; Gastroenterology; Randomized controlled trial; Metastasis","score_opus":0.04846021177409551,"score_gpt":0.49410377674524425,"score_spread":0.44564356497114876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900474,0.00014292912,0.0000470082,0.0043473244,0.0004890838,0.002348185,0.000016719483,0.0000047563353,0.0025565808],"genre_scores_gemma":[0.99538785,0.00087630627,0.0005273518,0.00211599,0.00023060889,0.000104749335,0.000009594903,0.000018802119,0.00072873227],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99759513,0.00043620603,0.0012408593,0.00018563568,0.00036430825,0.00017784782],"domain_scores_gemma":[0.99696875,0.0014259471,0.0010784623,0.00018699221,0.0002375525,0.000102306374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014793441,0.00013041242,0.0009184627,0.00014214483,0.000039774946,0.0000060820025,0.0001484494,0.00008796809,0.00003708163],"category_scores_gemma":[0.00010913338,0.00006903044,0.00018166845,0.0003509011,0.000065904336,0.000054066695,0.000015104578,0.00040720456,0.000001444704],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3707882,0.050998908,0.23390158,0.00011781734,0.0038908068,0.0020390989,0.007638687,0.0010828247,0.000034678513,0.000019051313,0.008574855,0.32091352],"study_design_scores_gemma":[0.31710202,0.07011937,0.60386384,0.00029821144,0.0008589604,0.0000015883486,0.0017245511,0.000057030917,0.00001813543,0.000008130501,0.0058786096,0.00006955445],"about_ca_topic_score_codex":0.000029414967,"about_ca_topic_score_gemma":0.000057613182,"teacher_disagreement_score":0.36996228,"about_ca_system_score_codex":0.0002505237,"about_ca_system_score_gemma":0.0005609635,"threshold_uncertainty_score":0.28149796},"labels":[],"label_agreement":null},{"id":"W4379281441","doi":"10.1200/jco.2023.41.16_suppl.12005","title":"Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Capecitabine; Medicine; Diclofenac; Placebo; Adverse effect; Randomized controlled trial; Celecoxib; Randomization; Internal medicine; Incidence (geometry); Surgery; Anesthesia; Cancer; Colorectal cancer","score_opus":0.10454778977138701,"score_gpt":0.4422506921034259,"score_spread":0.33770290233203887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556434,0.00006452861,0.000025537027,0.0007765234,0.00068443303,0.0023266098,6.083235e-7,0.0000073084675,0.0005501138],"genre_scores_gemma":[0.9991881,0.00015646427,0.00019695146,0.00005556312,0.00011731442,0.000031538948,0.000002281001,0.000017888113,0.00023389517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99108857,0.0019431541,0.005894094,0.0002228566,0.0006068174,0.00024450725],"domain_scores_gemma":[0.9902943,0.006075245,0.0029243077,0.00021605763,0.00033270335,0.00015738422],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011665573,0.00016230105,0.0045341263,0.0006096643,0.000016188771,0.000003934485,0.00019080604,0.0005101424,0.00009423114],"category_scores_gemma":[0.008857421,0.000115698924,0.00070299953,0.0005966757,0.0002047788,0.00008893675,0.0000636825,0.0011850504,0.0000038412177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7284741,0.009274828,0.25389317,0.000038298098,0.00058307714,0.0002332275,0.0007383779,0.000095597636,0.00012513631,0.000008366906,0.000039731047,0.0064961067],"study_design_scores_gemma":[0.61905456,0.009371327,0.37032425,0.00028395883,0.00025433354,0.00002013472,0.00021144249,0.0001637691,0.00006985629,0.00017981025,0.000013735354,0.00005280953],"about_ca_topic_score_codex":0.000071048504,"about_ca_topic_score_gemma":0.00041890534,"teacher_disagreement_score":0.116431095,"about_ca_system_score_codex":0.00019414682,"about_ca_system_score_gemma":0.0005164041,"threshold_uncertainty_score":0.9994914},"labels":[],"label_agreement":null},{"id":"W4379281451","doi":"10.1200/jco.2023.41.16_suppl.9017","title":"Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; ROS1; Internal medicine; Oncology; Lung cancer; Cohort; Cancer; Adenocarcinoma","score_opus":0.037452175759279754,"score_gpt":0.4448131267924545,"score_spread":0.4073609510331747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225086,0.0039284783,0.00007629424,0.0013010661,0.0010063893,0.0010278627,0.00006648809,0.00001101483,0.00033154903],"genre_scores_gemma":[0.99577016,0.0030204745,0.00040944715,0.0002966603,0.0003812656,0.00004019352,0.00000988508,0.000019611842,0.000052291238],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960347,0.00069771585,0.002338355,0.00029252304,0.00030227812,0.00033442897],"domain_scores_gemma":[0.99432784,0.0035585612,0.001485142,0.00017525334,0.0002153444,0.0002378519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021638027,0.00019580733,0.0015496833,0.00026327206,0.00006161585,0.000016764372,0.00013080874,0.00019690793,0.000008172879],"category_scores_gemma":[0.0008888077,0.00012250325,0.0002446991,0.0004814488,0.00013715857,0.00011742865,0.000051001607,0.0006678938,9.2825985e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030739848,0.009640275,0.39314604,0.0021595436,0.0020651184,0.015147275,0.01454738,0.001886232,0.013986652,0.00011436661,0.0015824649,0.5149848],"study_design_scores_gemma":[0.09577339,0.010933294,0.8685023,0.0033263622,0.004103659,0.002723409,0.010042062,0.0026695684,0.00077527895,0.000019864216,0.00084709335,0.00028369922],"about_ca_topic_score_codex":0.00044294752,"about_ca_topic_score_gemma":0.00046478742,"teacher_disagreement_score":0.51470107,"about_ca_system_score_codex":0.00030717114,"about_ca_system_score_gemma":0.0013323069,"threshold_uncertainty_score":0.49955374},"labels":[],"label_agreement":null},{"id":"W4379281462","doi":"10.1200/jco.2023.41.16_suppl.8045","title":"Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Multiple myeloma; CD38; Plasma cell; Internal medicine; Oncology; Cohort; Proteasome inhibitor; Immunology; Biology; Stem cell; Genetics","score_opus":0.13802688268702376,"score_gpt":0.535442610703193,"score_spread":0.3974157280161692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534667,0.00019697673,0.000022992186,0.0037497396,0.00014389127,0.00037544878,0.000014253329,0.0000041852845,0.00014584759],"genre_scores_gemma":[0.9959163,0.0005488328,0.0022809897,0.00032395206,0.00007950225,0.000011461628,0.000002011007,0.000010086569,0.0008268569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641293,0.00070786645,0.0019312825,0.00023314748,0.00043568073,0.00027909037],"domain_scores_gemma":[0.99587625,0.0024872588,0.00050784537,0.00023994358,0.00025088995,0.000637814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061820643,0.00010462455,0.0015299161,0.0010376502,0.000020495792,0.0000073436636,0.00015650652,0.00016353844,0.000083008665],"category_scores_gemma":[0.0082977675,0.00007755284,0.00027376588,0.0010309292,0.000087941524,0.000043633758,0.0001253118,0.00035311832,0.000047413483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030753687,0.0004190416,0.92990744,0.000025818743,0.0006345685,0.0035264683,0.000109025794,0.000016821059,0.0014899715,0.0000021527449,0.0011780341,0.03193695],"study_design_scores_gemma":[0.0051399185,0.0051864316,0.9853614,0.000085974236,0.00045219657,0.000033585035,0.00007473639,0.0000919209,0.0001159263,0.000050989474,0.0033504833,0.000056412657],"about_ca_topic_score_codex":0.00007388076,"about_ca_topic_score_gemma":0.0018705145,"teacher_disagreement_score":0.055453967,"about_ca_system_score_codex":0.0001767736,"about_ca_system_score_gemma":0.0006380477,"threshold_uncertainty_score":0.9933802},"labels":[],"label_agreement":null},{"id":"W4379281468","doi":"10.1200/jco.2023.41.16_suppl.6005","title":"Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Head and neck squamous-cell carcinoma; Cohort; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Head and neck cancer; Progressive disease; Chemotherapy; Cancer; Clinical trial; Immunotherapy","score_opus":0.044206503035995014,"score_gpt":0.3784376208988284,"score_spread":0.3342311178628334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340636,0.00011275623,0.000024806135,0.005086885,0.00068324234,0.00023534533,0.000005502694,0.000006259773,0.0004388325],"genre_scores_gemma":[0.9974028,0.00005539818,0.0015607128,0.00055310735,0.00026532452,0.000002386335,0.000008152291,0.000018132578,0.00013400232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969894,0.00044294042,0.0015381031,0.00021110114,0.0005985683,0.00021983442],"domain_scores_gemma":[0.9962861,0.0016865677,0.001292388,0.0001787906,0.00030569694,0.00025046166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021574234,0.00013525199,0.0009021252,0.00019613406,0.00004578803,0.0000068589025,0.000117807125,0.00011782166,0.000011369929],"category_scores_gemma":[0.0033160509,0.00006747955,0.00013697355,0.000384115,0.0003103173,0.000079612466,0.0000661454,0.0013235116,0.0000023036084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033376664,0.0018902221,0.9271731,0.00012437285,0.00006554203,0.00028913657,0.0003126288,0.00043779422,0.000053345262,0.000012265005,0.0037366885,0.032528237],"study_design_scores_gemma":[0.0477602,0.01752898,0.9293714,0.0002727166,0.00020282192,0.00009920522,0.00010786338,0.001243961,0.000014175279,0.000046721743,0.0032797374,0.000072193645],"about_ca_topic_score_codex":0.00004701794,"about_ca_topic_score_gemma":0.000037873328,"teacher_disagreement_score":0.032456044,"about_ca_system_score_codex":0.00007997608,"about_ca_system_score_gemma":0.00095614797,"threshold_uncertainty_score":0.57500726},"labels":[],"label_agreement":null},{"id":"W4379281493","doi":"10.1200/jco.2023.41.16_suppl.tps5625","title":"FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Placebo; Paclitaxel; Oncology; Gastroenterology; Ovarian cancer; Cohort; Cancer; Urology; Cisplatin; Pathology","score_opus":0.0798111814400133,"score_gpt":0.46988640323913194,"score_spread":0.39007522179911863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790237,0.0007384155,0.000054532415,0.011278499,0.0014118853,0.004916314,0.00017691145,0.000060105303,0.002339669],"genre_scores_gemma":[0.98528993,0.0024256834,0.0022872656,0.0016926932,0.0019876263,0.0004173549,0.00015371916,0.000103829,0.0056419256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907644,0.0009396329,0.004344115,0.0008594655,0.002011174,0.0010812153],"domain_scores_gemma":[0.99143714,0.0031218838,0.0026206095,0.0005700136,0.0013938226,0.00085651025],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042361096,0.0007813539,0.004346735,0.0005232205,0.00023392322,0.000061251114,0.00052636984,0.0006740919,0.0013065805],"category_scores_gemma":[0.0010847192,0.00051419844,0.00097183074,0.00085715204,0.00047753833,0.00032494887,0.00012421615,0.0015593464,0.00010818251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69618773,0.015865773,0.13743924,0.00003601085,0.0030922568,0.0008741828,0.0006450861,0.00047227024,0.00018868504,0.000077492594,0.0006723911,0.14444888],"study_design_scores_gemma":[0.697876,0.06324263,0.2080229,0.00022457435,0.00042142818,0.00006684552,0.0005066202,0.0017856673,0.00015603908,0.00018538423,0.027023807,0.0004881333],"about_ca_topic_score_codex":0.0011232955,"about_ca_topic_score_gemma":0.0012821496,"teacher_disagreement_score":0.14396073,"about_ca_system_score_codex":0.0012814585,"about_ca_system_score_gemma":0.0038651605,"threshold_uncertainty_score":0.99973094},"labels":[],"label_agreement":null},{"id":"W4379281497","doi":"10.1200/jco.2023.41.16_suppl.e17604","title":"GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of ovarian cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Ovarian cancer; Stage (stratigraphy); Cancer; Cohort; Internal medicine; Retrospective cohort study; Biomarker; Immunohistochemistry; Pathology; Oncology; Gastroenterology","score_opus":0.08970683819463547,"score_gpt":0.4792280001840072,"score_spread":0.3895211619893717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928333,0.0016764625,0.00007941642,0.004780354,0.0002320765,0.0001735143,0.000019453073,0.0000024995284,0.00020290511],"genre_scores_gemma":[0.98942196,0.008858733,0.0007426687,0.00036308944,0.00029016595,0.000010049438,0.000007512104,0.0000098052415,0.00029603028],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987462,0.00017006938,0.00066138274,0.00014526276,0.00012261907,0.00015442308],"domain_scores_gemma":[0.99765474,0.0014323251,0.00042067395,0.000087433786,0.00023802413,0.00016681328],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00177472,0.00007162582,0.00037238334,0.000085891916,0.000030635238,0.0000094443985,0.00009957211,0.00022938299,0.000028664877],"category_scores_gemma":[0.008625088,0.000055523753,0.00011138905,0.00007984324,0.00021196187,0.0000056334034,0.0000767506,0.00013607208,0.0000016920153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011566006,0.00064467004,0.34964797,0.0003506834,0.0018917877,0.00025313385,0.00020368674,0.00007945772,0.18849787,0.0007897791,0.0464112,0.39966375],"study_design_scores_gemma":[0.009425036,0.022039795,0.559529,0.00010901868,0.00020713775,0.00013148296,0.00032624917,0.00021532305,0.04369495,0.0028540334,0.36120912,0.00025885762],"about_ca_topic_score_codex":0.0000519363,"about_ca_topic_score_gemma":0.00014281158,"teacher_disagreement_score":0.39940488,"about_ca_system_score_codex":0.000007932501,"about_ca_system_score_gemma":0.000364781,"threshold_uncertainty_score":0.9997257},"labels":[],"label_agreement":null},{"id":"W4379281518","doi":"10.1200/jco.2023.41.16_suppl.8011","title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Clinical endpoint; Surrogate endpoint; Multiple myeloma; Cytokine release syndrome; Oncology; Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Chimeric antigen receptor","score_opus":0.07838029115917072,"score_gpt":0.41537985051176585,"score_spread":0.3369995593525951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704427,0.00020871476,0.000044409575,0.00047867995,0.0010707421,0.00065092486,0.00005595996,0.000023769826,0.0004225326],"genre_scores_gemma":[0.9966487,0.00083464634,0.0013379119,0.00010002825,0.00037611846,0.0000073114857,0.0002614367,0.000042896572,0.000390914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951499,0.00053343584,0.0024994148,0.00037502678,0.0009740793,0.00046811442],"domain_scores_gemma":[0.99407184,0.0025070328,0.0018401713,0.00041271566,0.0006882363,0.0004799981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014435194,0.00025103163,0.001696288,0.00054993713,0.000054411827,0.000017545131,0.00026880243,0.0005066718,0.00016898388],"category_scores_gemma":[0.0023312503,0.00017219911,0.00042108746,0.0005489982,0.00025431308,0.00025600783,0.0001008651,0.001141838,0.00009939013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030841261,0.004291613,0.9198414,0.00006843426,0.0003943139,0.0019952166,0.0001256578,0.0000044668886,0.00169667,0.0000019242798,0.0008141277,0.039924897],"study_design_scores_gemma":[0.055182,0.011829036,0.93041927,0.00035704867,0.00014343818,0.000016349892,0.00008126938,0.00009735605,0.00042017407,0.000028118144,0.0012906833,0.0001352876],"about_ca_topic_score_codex":0.00010848404,"about_ca_topic_score_gemma":0.0003932946,"teacher_disagreement_score":0.03978961,"about_ca_system_score_codex":0.00023984937,"about_ca_system_score_gemma":0.0011100221,"threshold_uncertainty_score":0.7022076},"labels":[],"label_agreement":null},{"id":"W4379281534","doi":"10.1200/jco.2023.41.16_suppl.e18742","title":"Implementation and assessment of a provincial early palliative care initiative for patients with pancreatic cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Medicine; Referral; Palliative care; Pancreatic cancer; Family medicine; Cancer; Emergency medicine; Internal medicine; Nursing","score_opus":0.36940074324936467,"score_gpt":0.6228161902829947,"score_spread":0.25341544703363006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773407,0.00023796907,0.00024985062,0.00060993823,0.00020572133,0.00052449334,0.000105790845,0.000003778669,0.0003283832],"genre_scores_gemma":[0.99059767,0.001109902,0.0077855703,0.00017620581,0.00025574936,0.000028595425,0.000025406895,0.000010003677,0.000010885898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981273,0.00016181031,0.0011815542,0.00011195359,0.0002895633,0.00012782913],"domain_scores_gemma":[0.9943705,0.0022087975,0.0017579843,0.000055875735,0.0014944267,0.00011241846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006075192,0.00008932434,0.0010022948,0.00010430459,0.000023323304,0.0000024609258,0.00004966743,0.00010761617,0.000016128073],"category_scores_gemma":[0.0010287,0.00005886561,0.00014315534,0.00014190571,0.00013627017,0.00007889271,0.000023203667,0.00022495842,2.447946e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022864908,0.00023764088,0.9374008,0.00020029387,0.00048683945,0.000013254961,0.0028438081,0.0000026708083,0.000017342656,0.000077884484,0.0002700242,0.05616294],"study_design_scores_gemma":[0.011062632,0.029595828,0.9505151,0.000522751,0.00057678134,4.6953886e-7,0.0051681194,0.000025125943,0.00013522203,0.00012364726,0.002221171,0.00005315265],"about_ca_topic_score_codex":0.00010900988,"about_ca_topic_score_gemma":0.00026233806,"teacher_disagreement_score":0.056109786,"about_ca_system_score_codex":0.00013218207,"about_ca_system_score_gemma":0.0017187207,"threshold_uncertainty_score":0.30489367},"labels":[],"label_agreement":null},{"id":"W4379281543","doi":"10.1200/jco.2023.41.16_suppl.e17583","title":"Levels of ANGPTL3 and characterization of other circulating cholesterol-related factors in high-grade serous ovarian cancers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Montreal Clinical Research Institute; Université Laval","funders":"","keywords":"Medicine; Serous ovarian cancer; Serous fluid; Internal medicine; Ovarian cancer; Cancer; Cholesterol; Endocrinology; Oncology","score_opus":0.0724683064074298,"score_gpt":0.38433078898481543,"score_spread":0.31186248257738564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599284,0.00012395931,0.000066901266,0.00028605346,0.0033710976,0.000078939476,0.000032205975,0.0000024448282,0.000045537006],"genre_scores_gemma":[0.9973309,0.0005415418,0.00013572111,0.00017287041,0.0017244209,0.0000011257864,0.000012105142,0.000013908326,0.00006737357],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99798244,0.00023711204,0.0013730126,0.00014591898,0.00012062029,0.00014089976],"domain_scores_gemma":[0.9982323,0.00012544218,0.0013195351,0.00011288779,0.00012571491,0.00008412687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011151391,0.000092175644,0.00068553846,0.000110013716,0.0000136745375,0.0000033813421,0.00010673983,0.00035825532,0.000016292017],"category_scores_gemma":[0.00045850876,0.00007750253,0.00014003471,0.0001606856,0.00012253618,0.000010339769,0.00004507394,0.00022876215,3.7513678e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002548231,0.00014200379,0.16647997,0.000034624572,0.00016473579,0.000001541892,0.00031049785,0.00013900742,0.8121768,0.000048035155,0.00014677443,0.020101158],"study_design_scores_gemma":[0.0027647882,0.00085802446,0.9745279,0.00004890347,0.000047900354,0.000013998851,0.0000774432,0.00004205026,0.008539825,0.000072819435,0.012930309,0.000076013894],"about_ca_topic_score_codex":0.00016883589,"about_ca_topic_score_gemma":0.00014835272,"teacher_disagreement_score":0.80804795,"about_ca_system_score_codex":0.000023175673,"about_ca_system_score_gemma":0.00040225018,"threshold_uncertainty_score":0.31604615},"labels":[],"label_agreement":null},{"id":"W4379281566","doi":"10.1200/jco.2023.41.16_suppl.tps5633","title":"The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN14<sup>2</sup>): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Clinical endpoint; Endometrial cancer; Radiation therapy; Internal medicine; Interim analysis; Oncology; Durvalumab; Hazard ratio; Cancer; Surgery; Urology; Randomized controlled trial; Immunotherapy; Pembrolizumab; Confidence interval","score_opus":0.08732168933804182,"score_gpt":0.43913163184910203,"score_spread":0.35180994251106024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809779,0.0002239896,0.000019937337,0.011382406,0.0035002455,0.0034583334,0.0001937345,0.000020774336,0.00022269414],"genre_scores_gemma":[0.98732924,0.002293057,0.0001483016,0.0015296426,0.008144896,0.00023937304,0.000033011278,0.000048120964,0.00023437079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911963,0.0023921698,0.0038628215,0.00042100044,0.0015653532,0.0005623677],"domain_scores_gemma":[0.9753802,0.02015746,0.002904898,0.00048488058,0.0005663674,0.0005062258],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008150906,0.00034500516,0.0027941242,0.00061527087,0.00018133399,0.000025433525,0.00050468056,0.00043332865,0.0006544492],"category_scores_gemma":[0.014054439,0.00016061429,0.000885927,0.0020423362,0.00033090805,0.000112223184,0.000071060975,0.0015246752,0.000022133221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69772583,0.0042392923,0.0019988294,0.000007854855,0.0010408835,0.00008536187,0.00021398978,0.00015972393,0.000005261128,0.00004759474,0.0042784973,0.2901969],"study_design_scores_gemma":[0.7700936,0.17902508,0.021881176,0.00016077774,0.0006645491,0.0000049947016,0.00016362872,0.000083877756,0.000036787766,0.00022463524,0.027512977,0.00014791919],"about_ca_topic_score_codex":0.00071095646,"about_ca_topic_score_gemma":0.00022117366,"teacher_disagreement_score":0.290049,"about_ca_system_score_codex":0.00066407234,"about_ca_system_score_gemma":0.0017237769,"threshold_uncertainty_score":0.9942506},"labels":[],"label_agreement":null},{"id":"W4379281572","doi":"10.1200/jco.2023.41.16_suppl.6650","title":"Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: A cost consequence analysis using linked administrative data.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; Health Sciences Centre; University of Toronto; University Health Network; McGill University Health Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Propensity score matching; Clinical endpoint; Clinical trial; Internal medicine; Reimbursement; Oncology; Health care; Gerontology; Demography","score_opus":0.8869488620836262,"score_gpt":0.6662045509663783,"score_spread":0.2207443111172479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858249,0.0002725666,0.007141264,0.004129345,0.0005684435,0.00061804027,0.0013843811,0.000011548609,0.000049528302],"genre_scores_gemma":[0.9460614,0.00018639669,0.051231217,0.0021848173,0.000221721,0.000015039773,0.00003670715,0.000019029052,0.00004371188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98905784,0.00062468153,0.0094119,0.00044384872,0.00011591733,0.00034583706],"domain_scores_gemma":[0.95225835,0.03334599,0.013123922,0.00045450145,0.00048458477,0.00033265256],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03577171,0.00018700614,0.0036350708,0.00052864343,0.000105016785,0.000026558677,0.00040827176,0.00028453788,0.000022803935],"category_scores_gemma":[0.098586336,0.00017265421,0.0004294283,0.00051139423,0.00025701942,0.00035027083,0.00009278283,0.00035155835,0.00002053137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081357866,0.00079313177,0.97622794,0.00015271279,0.0031900983,0.000055218363,0.0006246994,0.009688329,0.00016889349,0.00079403474,0.00073832495,0.0067530693],"study_design_scores_gemma":[0.0047269277,0.0037357304,0.8725076,0.000120728044,0.00029163074,0.000036313075,0.0009523464,0.11561889,0.000012455849,0.0012245565,0.00053871743,0.00023410592],"about_ca_topic_score_codex":0.00019437588,"about_ca_topic_score_gemma":0.00014830797,"teacher_disagreement_score":0.10593056,"about_ca_system_score_codex":0.0004445317,"about_ca_system_score_gemma":0.001596913,"threshold_uncertainty_score":0.99287593},"labels":[],"label_agreement":null},{"id":"W4379281575","doi":"10.1200/jco.2023.41.16_suppl.e24181","title":"Differential efficacy of antidepressants in the treatment of hormone mediated depression in patients with ER+ breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Escitalopram; Internal medicine; Depression (economics); Oncology; Montreal Cognitive Assessment; Beck Depression Inventory; Anxiety; Cancer; Psychiatry; Antidepressant; Disease; Dementia","score_opus":0.06353248988997418,"score_gpt":0.43057731109829467,"score_spread":0.3670448212083205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996904,0.00036154213,0.0000028115041,0.0018011451,0.00032706128,0.0004664822,0.000036345955,0.0000044893955,0.00009612304],"genre_scores_gemma":[0.9947798,0.004887324,0.000018291594,0.000082798826,0.0001874654,0.000011561919,0.00000899389,0.000011186889,0.000012570433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970305,0.0003835449,0.0017411574,0.00015029928,0.0004883332,0.0002061834],"domain_scores_gemma":[0.9954971,0.0025741763,0.0013720053,0.00013391189,0.00033281842,0.000089987996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006203907,0.0001338313,0.0013793012,0.00025132255,0.000017478136,0.0000015949721,0.00011494619,0.0001769875,0.000036624948],"category_scores_gemma":[0.0007436727,0.000066912784,0.00020116215,0.00046408433,0.00024077768,0.000049015303,0.000032680622,0.00039490723,0.0000018199132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025935156,0.007989011,0.9144957,0.000015693637,0.00042858825,0.00013707129,0.00046659552,0.000039094662,0.00011757568,4.6296887e-7,0.0005563242,0.0498187],"study_design_scores_gemma":[0.044997804,0.016510574,0.9372704,0.0003497608,0.0003722066,0.000012136668,0.00015920667,0.000044498087,0.00007357245,0.0000069632224,0.000150102,0.000052780455],"about_ca_topic_score_codex":0.00013883768,"about_ca_topic_score_gemma":0.00018143334,"teacher_disagreement_score":0.04976592,"about_ca_system_score_codex":0.00015296691,"about_ca_system_score_gemma":0.00038975768,"threshold_uncertainty_score":0.27286243},"labels":[],"label_agreement":null},{"id":"W4379281611","doi":"10.1200/jco.2023.41.16_suppl.4577","title":"Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Abbotsford Veterinary Clinic; Surrey Place Centre; Kelowna General Hospital; University of British Columbia","funders":"Bladder Cancer Canada","keywords":"Medicine; Fibroblast growth factor receptor; Somatic cell; Targeted therapy; Oncology; Cancer; Cancer research; Context (archaeology); Cell-free fetal DNA; Internal medicine; Fibroblast growth factor; Gene; Biology; Receptor; Genetics","score_opus":0.18723083376356847,"score_gpt":0.45611063431441046,"score_spread":0.268879800550842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983874,0.0002809966,0.000009244889,0.00073105074,0.00030414242,0.00023577489,0.000025863998,6.659684e-7,0.000024856748],"genre_scores_gemma":[0.99788636,0.0005352167,0.00017861214,0.0011299202,0.00023952656,0.000008414001,0.000004883242,0.000011118079,0.000005954239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977228,0.00052638154,0.0012358654,0.00012414154,0.00023863482,0.00015218822],"domain_scores_gemma":[0.996541,0.0016396873,0.001299945,0.00018053631,0.0003037142,0.00003511813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025443302,0.00008606161,0.00046125418,0.000054465705,0.0000220238,0.000006640847,0.0002492174,0.000117437914,0.000010843024],"category_scores_gemma":[0.0032278593,0.0000463661,0.00014897124,0.00018555303,0.00013823889,0.0000055430737,0.000053413365,0.00030121137,3.4954613e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004623092,0.0006893383,0.8480472,0.000014324121,0.00017077649,0.000021382446,0.0006369272,0.00935036,0.01788822,0.000033173634,0.00052945124,0.11799578],"study_design_scores_gemma":[0.0065789716,0.007877168,0.9786321,0.00006551314,0.000038811348,0.000004109612,0.0003182355,0.000716553,0.00153718,0.00006356931,0.004086463,0.0000813153],"about_ca_topic_score_codex":0.00017165692,"about_ca_topic_score_gemma":0.00065286923,"teacher_disagreement_score":0.13058494,"about_ca_system_score_codex":0.000026023565,"about_ca_system_score_gemma":0.0008559231,"threshold_uncertainty_score":0.3864282},"labels":[],"label_agreement":null},{"id":"W4379281628","doi":"10.1200/jco.2023.41.16_suppl.9085","title":"Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; Queen's University; University of Toronto; University Health Network; Institute of Health Services and Policy Research","funders":"Pfizer","keywords":"Medicine; Cohort; Biomarker; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Lung cancer; Biopsy; Retrospective cohort study","score_opus":0.03744327701679611,"score_gpt":0.3948653433724385,"score_spread":0.3574220663556424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614656,0.00019221003,0.00036863107,0.00014641494,0.0005881696,0.00033748613,0.00005919588,0.000015166681,0.002146141],"genre_scores_gemma":[0.995951,0.00031790062,0.0017986922,0.00051066827,0.001094543,0.00002156362,0.000028539696,0.00006517046,0.00021191056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973774,0.000117521704,0.0013001398,0.00039857434,0.00026189975,0.0005444559],"domain_scores_gemma":[0.9961566,0.0011326959,0.0014620945,0.0003139056,0.00058649824,0.00034822253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015311678,0.00030458215,0.00084536657,0.00010075615,0.0001442955,0.00006085441,0.00040037592,0.00053090655,0.000035199922],"category_scores_gemma":[0.0012399333,0.0002183059,0.00040581822,0.00026411575,0.00022653655,0.000014984637,0.0002269056,0.000623624,0.000014416726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025333227,0.00081432983,0.90348834,0.000043717602,0.00036620782,0.00023255342,0.000099679295,0.0020945217,0.015467452,3.77842e-7,0.0099861175,0.0648734],"study_design_scores_gemma":[0.0055721784,0.016918994,0.96303463,0.00021740311,0.00022450234,0.00003314434,0.000026278442,0.0044536907,0.0055586076,0.000024371802,0.0034558873,0.00048030456],"about_ca_topic_score_codex":0.00016861358,"about_ca_topic_score_gemma":0.00010914679,"teacher_disagreement_score":0.064393096,"about_ca_system_score_codex":0.00017820272,"about_ca_system_score_gemma":0.0014468698,"threshold_uncertainty_score":0.8902256},"labels":[],"label_agreement":null},{"id":"W4379281638","doi":"10.1200/jco.2023.41.16_suppl.e17589","title":"A DMBA-induced ovarian cancer model: Could it be clinically useful to test OncoTherad and erythropoietin as anticancer approaches?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Ovarian cancer; Medicine; Ovarian carcinoma; Context (archaeology); Serous fluid; Immunohistochemistry; KRAS; Erythropoietin; Cancer; Ovary; Cancer research; Pathology; Oncology; Internal medicine; Biology; Colorectal cancer","score_opus":0.44756353311683394,"score_gpt":0.5529489784331576,"score_spread":0.10538544531632366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72950655,0.00014816473,0.0006024309,0.26317912,0.0014547331,0.000507892,0.000021530279,0.00006028435,0.004519318],"genre_scores_gemma":[0.9128738,0.0068585705,0.0074368324,0.068292536,0.0032602255,0.000060773684,0.0000037304524,0.00008761443,0.0011258807],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939831,0.00042773486,0.0036861757,0.0005491225,0.00081663707,0.0005372384],"domain_scores_gemma":[0.9920998,0.003936075,0.0017878335,0.00043742155,0.00061690103,0.0011219248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065148897,0.00029812654,0.0021873727,0.0003956456,0.00009595929,0.000030967825,0.00030398308,0.000826384,0.0006966227],"category_scores_gemma":[0.0053940853,0.00023455381,0.000523581,0.00079714914,0.0003608444,0.00014883991,0.000118549535,0.0018982167,0.00012896596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036944035,0.00975359,0.19829643,0.000282966,0.002939529,0.0026410883,0.0043375646,0.002854143,0.01399574,0.00076009735,0.38042158,0.34677324],"study_design_scores_gemma":[0.05684964,0.07040024,0.16863352,0.0015256703,0.0015087825,0.0013461513,0.0016484029,0.019382792,0.0013068891,0.0046314793,0.67159534,0.0011711251],"about_ca_topic_score_codex":0.00008598039,"about_ca_topic_score_gemma":0.00010481042,"teacher_disagreement_score":0.34560212,"about_ca_system_score_codex":0.00030778666,"about_ca_system_score_gemma":0.004053327,"threshold_uncertainty_score":0.9564827},"labels":[],"label_agreement":null},{"id":"W4379281653","doi":"10.1200/jco.2023.41.16_suppl.e17547","title":"Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oncology; Internal medicine; PARP inhibitor; BRCA mutation; Chemotherapy; Cancer; Progression-free survival; Ovarian cancer; Maintenance therapy; Response Evaluation Criteria in Solid Tumors; Progressive disease; Poly ADP ribose polymerase; Biology","score_opus":0.12067771473555423,"score_gpt":0.4522124393765086,"score_spread":0.3315347246409544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8711821,0.00028332445,0.0009064977,0.123279534,0.0030538077,0.0011231033,0.00005538495,0.000069860966,0.00004638776],"genre_scores_gemma":[0.9752803,0.0033817678,0.0022598593,0.01689674,0.0012385977,0.00009999448,0.000008599494,0.00010245556,0.0007316815],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.992278,0.0018535814,0.0035000273,0.00069563335,0.00084041903,0.0008323444],"domain_scores_gemma":[0.9916189,0.0046035666,0.0016211004,0.0005121517,0.00086225773,0.0007820252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012860744,0.00041375952,0.0019493735,0.000903721,0.00015890626,0.000033105523,0.00041134167,0.0007854974,0.0002474358],"category_scores_gemma":[0.0059605986,0.00034359234,0.0004163476,0.001950429,0.00026683914,0.00017339035,0.00008309272,0.0014880451,0.000043892866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5572085,0.0064914064,0.038641702,0.000084657695,0.00047714272,0.0043946314,0.0035751637,0.007910985,0.16500764,0.000029483224,0.08688032,0.12929842],"study_design_scores_gemma":[0.07744805,0.07625929,0.6001886,0.0025872758,0.00015202182,0.001288268,0.00039152452,0.0019681705,0.015691422,0.0013000371,0.22177012,0.0009552028],"about_ca_topic_score_codex":0.00020786886,"about_ca_topic_score_gemma":0.00022308918,"teacher_disagreement_score":0.5615469,"about_ca_system_score_codex":0.0020233076,"about_ca_system_score_gemma":0.0030016515,"threshold_uncertainty_score":0.9999016},"labels":[],"label_agreement":null},{"id":"W4379281663","doi":"10.1200/jco.2023.41.16_suppl.4538","title":"Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of British Columbia; Dalhousie University; University of Toronto; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Renal cell carcinoma; Oncology; Systemic therapy; Performance status; Progressive disease; Cancer; Expanded access; Disease; Immunotherapy","score_opus":0.16417140236697905,"score_gpt":0.4356573498684445,"score_spread":0.2714859475014655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864115,0.0006497773,0.000026744987,0.017903686,0.0015409298,0.00069705,0.00016968003,0.000014471765,0.0003565208],"genre_scores_gemma":[0.9922212,0.00088878,0.0033494383,0.0019150571,0.0011852192,0.000040318013,0.00013848879,0.000034128832,0.00022738552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936977,0.00082244776,0.00374329,0.00043712722,0.00092558144,0.0003738735],"domain_scores_gemma":[0.992546,0.0038562568,0.002137724,0.0005292396,0.0005544612,0.00037627574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043009687,0.00027055515,0.0015397914,0.00033252878,0.00003873692,0.000022219161,0.00047797078,0.00020502412,0.00014598279],"category_scores_gemma":[0.0023104541,0.00015967527,0.00051413843,0.00037966284,0.00021635463,0.00016381558,0.00023453377,0.00095983566,0.000048350892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28584144,0.007384336,0.37099084,0.00014942461,0.0015344884,0.025060266,0.004993257,0.0002355089,0.13243303,0.000021366654,0.011991235,0.15936483],"study_design_scores_gemma":[0.03507785,0.011604013,0.9135584,0.0006169001,0.0003467017,0.00020572358,0.0005943017,0.00063127815,0.022436794,0.00006019356,0.014667473,0.00020032545],"about_ca_topic_score_codex":0.00026005667,"about_ca_topic_score_gemma":0.0002118017,"teacher_disagreement_score":0.5425676,"about_ca_system_score_codex":0.00043350473,"about_ca_system_score_gemma":0.0018344568,"threshold_uncertainty_score":0.6511368},"labels":[],"label_agreement":null},{"id":"W4379281665","doi":"10.1200/jco.2023.41.16_suppl.tps5623","title":"Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Triple-negative breast cancer; Medicine; Ovarian cancer; PARP inhibitor; PALB2; Cancer research; Cancer; BRCA mutation; Oncology; Breast cancer; Internal medicine; Germline mutation; Biology; Mutation; Genetics","score_opus":0.09415033928534335,"score_gpt":0.4692976871396335,"score_spread":0.37514734785429016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823722,0.00013954248,0.0000068602135,0.015955951,0.0008990977,0.00051129516,0.00005624952,0.000004424848,0.0000543271],"genre_scores_gemma":[0.9966026,0.0021634987,0.00011701711,0.0005705634,0.0004260419,0.000043703338,8.933226e-7,0.000012116563,0.00006355369],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99754906,0.00043370403,0.0013788821,0.00014742535,0.00032592102,0.00016503946],"domain_scores_gemma":[0.9963455,0.0012828561,0.0018063686,0.0001172345,0.0002968513,0.00015117465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018525013,0.00010446735,0.0011255312,0.00013948743,0.000030208488,0.000004285014,0.00008639511,0.0001966006,0.000055653225],"category_scores_gemma":[0.0004523026,0.00006444326,0.00007822104,0.00044275954,0.0004302504,0.00010500793,0.000029426656,0.000608851,1.98544e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69954956,0.0051105125,0.048358813,0.00019400002,0.001129541,0.00028358752,0.0044944533,0.0001090198,0.0043991096,0.00033305906,0.0020480016,0.23399034],"study_design_scores_gemma":[0.39948454,0.020370053,0.5746072,0.0006332262,0.00020169807,0.00029944902,0.0007165831,0.00012131669,0.0008912858,0.0018020731,0.00078320195,0.00008939248],"about_ca_topic_score_codex":0.0006891785,"about_ca_topic_score_gemma":0.0003951425,"teacher_disagreement_score":0.52624834,"about_ca_system_score_codex":0.00031197947,"about_ca_system_score_gemma":0.0016354833,"threshold_uncertainty_score":0.29012772},"labels":[],"label_agreement":null},{"id":"W4379281669","doi":"10.1200/jco.2023.41.16_suppl.6065","title":"Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Minimal residual disease; Liquid biopsy; Digital polymerase chain reaction; Stage (stratigraphy); Radiation therapy; Head and neck cancer; Cancer; Polymerase chain reaction; Gene; Bone marrow","score_opus":0.022472595168704243,"score_gpt":0.3539098016828768,"score_spread":0.3314372065141725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980648,0.00079166057,0.0001007965,0.0003640668,0.00033191606,0.0001244245,0.00001235494,0.0000019035888,0.00020805991],"genre_scores_gemma":[0.99801934,0.0008852238,0.0006782064,0.00018968548,0.00018007711,0.0000051318975,0.000006866469,0.000015726431,0.000019723118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802214,0.00025448747,0.0011742206,0.00022188284,0.0001280394,0.00019925635],"domain_scores_gemma":[0.99840045,0.00061030494,0.0005232741,0.00014770513,0.00011607604,0.00020221081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010001782,0.00011312856,0.00049945014,0.00014027648,0.000013613675,0.0000057826364,0.00013364376,0.00030395106,0.0000026753587],"category_scores_gemma":[0.0023177285,0.000109073684,0.00014567803,0.00013749472,0.00013226138,0.000005959479,0.00011178961,0.00035558818,0.0000013720404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027454272,0.00236885,0.40525132,0.0001824908,0.000060337643,0.0030006606,0.0001716998,0.028511139,0.32292825,0.00006724016,0.000493239,0.20951049],"study_design_scores_gemma":[0.021478552,0.009348582,0.9126482,0.000048996368,0.000060558214,0.00004365905,0.00014187435,0.0023081845,0.047447372,0.0004413339,0.0057997294,0.0002329613],"about_ca_topic_score_codex":0.000059603022,"about_ca_topic_score_gemma":0.0008285535,"teacher_disagreement_score":0.5073969,"about_ca_system_score_codex":0.000040836956,"about_ca_system_score_gemma":0.0007712799,"threshold_uncertainty_score":0.4447896},"labels":[],"label_agreement":null},{"id":"W4379281682","doi":"10.1200/jco.2023.41.16_suppl.e17075","title":"Darolutamide and time to pain progression by disease volume in ARASENS.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Hazard ratio; Prostate cancer; Placebo; Oncology; Confidence interval; Cancer; Pathology","score_opus":0.0763143164530647,"score_gpt":0.5133563349878346,"score_spread":0.4370420185347699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93688196,0.0004924329,0.0000087487615,0.06143202,0.00034330823,0.00024211296,0.0000073072315,0.000014440329,0.0005776876],"genre_scores_gemma":[0.98265624,0.00072181213,0.00048131874,0.008834443,0.0009302737,0.00001417694,0.000014852215,0.000017817296,0.0063290396],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799764,0.00049120846,0.0009819254,0.0001528731,0.00017307764,0.00020326504],"domain_scores_gemma":[0.99743474,0.0014131389,0.00034423222,0.00007751561,0.000074892625,0.0006555026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029558653,0.00008753242,0.00076467445,0.00015582373,0.000018974735,0.000004213084,0.000058260113,0.00015083014,0.00042215915],"category_scores_gemma":[0.0022813964,0.0000627945,0.00013638235,0.00020864919,0.00009372716,0.00004251567,0.00004523562,0.00041130654,0.00019326134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007489643,0.0013724361,0.25662282,0.000022350845,0.000088733104,0.0026532174,0.0000532974,0.000008798104,0.0007573697,0.0000021318438,0.44155034,0.28937885],"study_design_scores_gemma":[0.007480832,0.012957102,0.47231057,0.000110866284,0.00019226577,0.000052475007,0.000019174307,0.0009942424,0.000020988404,0.00014732165,0.50564134,0.00007284988],"about_ca_topic_score_codex":0.000005429519,"about_ca_topic_score_gemma":0.000005985919,"teacher_disagreement_score":0.28930598,"about_ca_system_score_codex":0.000100150166,"about_ca_system_score_gemma":0.0005636903,"threshold_uncertainty_score":0.46223465},"labels":[],"label_agreement":null},{"id":"W4379281689","doi":"10.1200/jco.2023.41.16_suppl.e16237","title":"Real world sequence of peptide receptor radionucleotide therapy (PRRT) and chemotherapy in patients with metastatic pancreatic neuroendocrine tumors (pNETs).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Ottawa Hospital; London Health Sciences Centre; St Joseph's Health Care; University of Ottawa","funders":"Ipsen","keywords":"Medicine; Radionuclide therapy; Internal medicine; Neuroendocrine tumors; Oncology; Chemotherapy; Octreotide; Cancer; Somatostatin","score_opus":0.09304424224061221,"score_gpt":0.44236725394993875,"score_spread":0.34932301170932656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925891,0.00008442862,0.000002178245,0.0062902407,0.00017048304,0.00055003836,0.000007576193,0.000019493322,0.00028645637],"genre_scores_gemma":[0.9873191,0.006644984,0.0043070186,0.0010055155,0.00017571037,0.000010407767,0.0000068124587,0.000046717083,0.00048374844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957104,0.0007079009,0.0021562018,0.00029125533,0.0006932344,0.0004410621],"domain_scores_gemma":[0.9946975,0.0029217997,0.0013549825,0.00025553285,0.00035862395,0.0004115516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012816167,0.0002059943,0.0018419871,0.00055815675,0.000026531532,0.000008402679,0.00021520474,0.000013220234,0.00012270028],"category_scores_gemma":[0.0025143165,0.00013528221,0.00018754686,0.0008277514,0.0005142555,0.00020279289,0.000053006264,0.00095231197,0.000008709523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02127442,0.0013836876,0.93222433,0.00010100485,0.00023339313,0.0058096414,0.00005188797,0.000048491736,0.0007671613,0.000037541966,0.0020113327,0.0360571],"study_design_scores_gemma":[0.022402367,0.025547318,0.9407235,0.0002606859,0.00006449452,0.00041793572,0.00008011066,0.00008340242,0.00036795574,0.0001941472,0.009744214,0.000113878625],"about_ca_topic_score_codex":0.000076790915,"about_ca_topic_score_gemma":0.00009366758,"teacher_disagreement_score":0.03594322,"about_ca_system_score_codex":0.00009907855,"about_ca_system_score_gemma":0.0007296455,"threshold_uncertainty_score":0.5516649},"labels":[],"label_agreement":null},{"id":"W4379281703","doi":"10.1200/jco.2023.41.16_suppl.6063","title":"The impact of genetic predisposition to depression on quality of life in patients with head and neck cancer immediately post-treatment: A longitudinal study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Psychosocial; Head and neck cancer; Quality of life (healthcare); Depression (economics); Cancer; Genetic predisposition; Suicidal ideation; Prospective cohort study; Internal medicine; Psychiatry; Disease; Poison control; Injury prevention; Emergency medicine","score_opus":0.1526069818676899,"score_gpt":0.5185050351344056,"score_spread":0.3658980532667157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827874,0.00007072161,0.0000014245617,0.0007214746,0.0003877937,0.0004221022,0.000020321522,0.0000029839287,0.00009445757],"genre_scores_gemma":[0.9994698,0.0002557517,0.0000456695,0.000055484194,0.00014581865,0.0000102478025,0.0000010187555,0.000005906817,0.0000102893955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966478,0.0010998948,0.0014196921,0.0001402954,0.0004957933,0.00019654959],"domain_scores_gemma":[0.9949497,0.0030188933,0.0012787271,0.00011594395,0.00041029602,0.00022641475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028403366,0.000086640306,0.0007005881,0.00010011229,0.00008813319,0.00000875614,0.00016976328,0.00012998114,0.000013939403],"category_scores_gemma":[0.0028709348,0.00004523411,0.00013136014,0.0003025716,0.00022946137,0.00008392631,0.000043032236,0.00020004179,0.0000013584709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007910131,0.0017750085,0.9587359,0.000004330242,0.00012072105,0.000012461192,0.0025637986,0.00035297725,0.0000036422368,0.0000058852884,0.000079623496,0.028435545],"study_design_scores_gemma":[0.003904726,0.02167501,0.97288203,0.00006033674,0.00003496685,2.3938586e-7,0.001290383,0.0000060730035,0.0000015374284,0.000055361586,0.000043048818,0.0000463079],"about_ca_topic_score_codex":0.010874754,"about_ca_topic_score_gemma":0.020755097,"teacher_disagreement_score":0.028389238,"about_ca_system_score_codex":0.00021239187,"about_ca_system_score_gemma":0.0013356518,"threshold_uncertainty_score":0.9971136},"labels":[],"label_agreement":null},{"id":"W4379281712","doi":"10.1200/jco.2023.41.16_suppl.5525","title":"Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Olaparib; PARP inhibitor; Oncology; Biomarker; Ovarian cancer; Internal medicine; Endometrial cancer; PALB2; Somatic cell; Circulating tumor cell; Multiplex; Loss of heterozygosity; Cancer; Germline mutation; Bioinformatics; Gene; Metastasis; Poly ADP ribose polymerase; Biology; Mutation","score_opus":0.07966472871351292,"score_gpt":0.4464484640246096,"score_spread":0.36678373531109665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489903,0.00019803009,0.00002661476,0.003316032,0.0010862089,0.00025745775,0.0001374252,0.000010269183,0.00006893661],"genre_scores_gemma":[0.9967246,0.0004545216,0.0018794378,0.00055452087,0.00033169836,0.000007019832,0.00001295861,0.000016770988,0.000018481589],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960795,0.00073836197,0.002300367,0.00022141448,0.00046134074,0.00019898804],"domain_scores_gemma":[0.98011893,0.017165309,0.0019029895,0.00017266536,0.0003906477,0.00024947536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035543565,0.00012335677,0.0012489004,0.0005304475,0.000017880355,0.0000034227355,0.000097010576,0.000243567,0.000054279095],"category_scores_gemma":[0.013888174,0.00008864685,0.0001555656,0.0006887431,0.00029262438,0.00007234517,0.000021925614,0.0005232673,0.000002724463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60239583,0.0010138758,0.3626523,0.000016876465,0.00040612638,0.00030183265,0.00008472191,0.0003545104,0.0011248933,0.0000015498417,0.00063953234,0.031007934],"study_design_scores_gemma":[0.1544326,0.027105125,0.8142067,0.0004627686,0.00021721757,0.0000060668153,0.000038327278,0.00008439937,0.0007045842,0.000059993356,0.002605115,0.00007709775],"about_ca_topic_score_codex":0.000059011243,"about_ca_topic_score_gemma":0.000054746415,"teacher_disagreement_score":0.45155442,"about_ca_system_score_codex":0.00014017282,"about_ca_system_score_gemma":0.0019406187,"threshold_uncertainty_score":0.99441826},"labels":[],"label_agreement":null},{"id":"W4379281722","doi":"10.1200/jco.2023.41.16_suppl.4544","title":"Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clear cell renal cell carcinoma; Renal cell carcinoma; Oncology; DNA methylation; Internal medicine; Immunotherapy; Methylation; Biomarker; Cancer; Cancer research; Gene; Biology; Gene expression","score_opus":0.06259786080241296,"score_gpt":0.3744640109322438,"score_spread":0.3118661501298308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980229,0.0003344126,0.00012669875,0.00040629142,0.000100748606,0.0004295704,0.000006304496,0.0000143490415,0.00055873673],"genre_scores_gemma":[0.99690497,0.00006931121,0.0026991798,0.00011626837,0.00009763948,0.0000075928606,0.000021058191,0.00002098699,0.00006301736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996923,0.000477232,0.0015215668,0.0002541167,0.0005473167,0.00027673243],"domain_scores_gemma":[0.99717057,0.0007433185,0.0012734532,0.00022044507,0.00034801324,0.0002442207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015768257,0.00019514783,0.0011313998,0.00025460537,0.000040063594,0.000013157234,0.000095206226,0.00016878905,0.000034566117],"category_scores_gemma":[0.00032404021,0.000121278375,0.00014965377,0.0005554836,0.00012810099,0.00016187527,0.000032685806,0.000371866,0.0000047218546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068505662,0.0009745941,0.9678132,0.000035584195,0.00029688215,0.00070391333,0.000096007265,0.00019274886,0.00021744774,0.000008313203,0.00008473079,0.022726022],"study_design_scores_gemma":[0.032047853,0.025061792,0.9413583,0.00009743653,0.00043297853,0.00010461013,0.000091624956,0.00031103016,0.00014851174,0.00014829732,0.00008994837,0.00010760671],"about_ca_topic_score_codex":0.00009333928,"about_ca_topic_score_gemma":0.000094582516,"teacher_disagreement_score":0.026454877,"about_ca_system_score_codex":0.0005400063,"about_ca_system_score_gemma":0.00057835324,"threshold_uncertainty_score":0.49455887},"labels":[],"label_agreement":null},{"id":"W4379281725","doi":"10.1200/jco.2023.41.16_suppl.e17095","title":"Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Interim analysis; Incidence (geometry); Cancer; Oncology; Clinical trial","score_opus":0.21190454391267297,"score_gpt":0.5100699996184069,"score_spread":0.29816545570573394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963432,0.00008984721,0.000005103125,0.002423505,0.00025708848,0.000655212,0.000042607382,0.000008543229,0.00017491357],"genre_scores_gemma":[0.99809813,0.0001111793,0.00037244204,0.00030877517,0.0001392945,0.000033793574,0.000056518817,0.000014410661,0.0008654541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964291,0.00041657142,0.0019306835,0.0002387664,0.0006980688,0.0002868048],"domain_scores_gemma":[0.997058,0.000886865,0.00097187946,0.00016331438,0.00065411953,0.00026581995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026618547,0.00014021838,0.001344388,0.000537906,0.00004486034,0.000017669061,0.0001280774,0.00010108241,0.0002952933],"category_scores_gemma":[0.0005877226,0.00008623602,0.00023670438,0.0012363942,0.0001391291,0.00017354432,0.00004462379,0.00069455104,0.000011569355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014857196,0.0030431363,0.96936834,0.000030190376,0.002561385,0.0008764548,0.0004311872,0.00037819316,0.000029091549,0.0000041406142,0.0006225498,0.007798127],"study_design_scores_gemma":[0.018590424,0.019136643,0.95926905,0.00005552899,0.00095170684,0.0000034460666,0.00051568536,0.00020923004,0.000007713723,0.000053965246,0.001130427,0.00007616675],"about_ca_topic_score_codex":0.000082664505,"about_ca_topic_score_gemma":0.0027542112,"teacher_disagreement_score":0.016093506,"about_ca_system_score_codex":0.00034741274,"about_ca_system_score_gemma":0.0024306234,"threshold_uncertainty_score":0.43118215},"labels":[],"label_agreement":null},{"id":"W4379281728","doi":"10.1200/jco.2023.41.16_suppl.e17112","title":"Biochemical recurrence (BCR) and outcomes in patients (pts) with prostate cancer (PC) following radical prostatectomy (RP).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer","keywords":"Medicine; Biochemical recurrence; Prostate cancer; Prostatectomy; Internal medicine; breakpoint cluster region; Urology; Oncology; Hazard ratio; Cohort; Metastasis; Cancer; Surgery; Confidence interval","score_opus":0.08702810657634075,"score_gpt":0.4838215263645555,"score_spread":0.39679341978821475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900905,0.00064248656,0.0000017297848,0.0079268385,0.0005202397,0.0005744856,0.000009631373,0.00001675252,0.00021736171],"genre_scores_gemma":[0.9961203,0.002377412,0.0004220587,0.00040949893,0.0001682556,0.00003705613,0.000010795373,0.0000210004,0.0004336429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714935,0.0002217996,0.001327331,0.00028490872,0.000581997,0.00043460907],"domain_scores_gemma":[0.9976521,0.0010157357,0.0004971196,0.00012885508,0.00024666026,0.0004595347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018322808,0.00016785598,0.001275723,0.00024984762,0.00004247092,0.000014103034,0.000118408076,0.00024826315,0.000025837113],"category_scores_gemma":[0.0016245741,0.00009505329,0.00021050681,0.0004473902,0.0003459566,0.00013220265,0.00008554236,0.0010997656,0.000010059665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009277122,0.0010279628,0.91944593,0.000060164126,0.0002936458,0.0011158752,0.00017193054,0.0000019031789,0.00004892152,0.000005628351,0.0015878644,0.06696307],"study_design_scores_gemma":[0.029921608,0.009961846,0.95246327,0.00045416973,0.00015417513,0.00002754078,0.00009199473,0.000040054292,0.00020264355,0.00014844777,0.006414192,0.00012004406],"about_ca_topic_score_codex":0.000028737959,"about_ca_topic_score_gemma":0.000019260693,"teacher_disagreement_score":0.066843025,"about_ca_system_score_codex":0.0002473716,"about_ca_system_score_gemma":0.0015741984,"threshold_uncertainty_score":0.47779956},"labels":[],"label_agreement":null},{"id":"W4379281733","doi":"10.1200/jco.2023.41.16_suppl.e17035","title":"Retrospective review of 250 gallium-68 PSMA scans in prostate cancer patients in Health Canada Special Access Program.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Malignancy; Prostate; Cancer; Metastasis; Radiology; Oncology; Internal medicine; Nuclear medicine","score_opus":0.1567586231304603,"score_gpt":0.5714267706640235,"score_spread":0.4146681475335632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94171983,0.0016816421,5.560235e-7,0.05266248,0.00061047147,0.0009680446,0.00003644998,0.0000070501223,0.0023134775],"genre_scores_gemma":[0.93020904,0.0631466,0.00015330628,0.004985346,0.0012372932,0.00006349068,0.000015037727,0.000013097622,0.00017677045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630547,0.0002059356,0.0026457391,0.0001770396,0.00039581562,0.00027002304],"domain_scores_gemma":[0.9973515,0.00039428493,0.0014138411,0.00011661104,0.00038456643,0.00033917345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002057839,0.000097880606,0.0013088112,0.00006998337,0.000018020375,0.0000031684608,0.00019238093,0.000104832914,0.00017987704],"category_scores_gemma":[0.0022741274,0.00007626674,0.0001465142,0.00077315635,0.00012244676,0.00006078388,0.000043552776,0.0009983832,0.0000020233538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085901615,0.0018812532,0.8661321,0.002155916,0.00006310568,0.00021514553,0.00004293185,0.000022656206,0.000012126279,0.000026558631,0.04633782,0.08225141],"study_design_scores_gemma":[0.0036547466,0.0014120514,0.86401963,0.0029395835,0.000043152453,0.000012621925,0.000020575111,0.000044355427,0.000059021986,0.000092800765,0.1276402,0.00006124609],"about_ca_topic_score_codex":0.015891872,"about_ca_topic_score_gemma":0.07483744,"teacher_disagreement_score":0.08219016,"about_ca_system_score_codex":0.00087768206,"about_ca_system_score_gemma":0.0066726035,"threshold_uncertainty_score":0.99895865},"labels":[],"label_agreement":null},{"id":"W4379281742","doi":"10.1200/jco.2023.41.16_suppl.e16293","title":"Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Israel Cancer Association; Gateway for Cancer Research","keywords":"Medicine; Clinical endpoint; Quality of life (healthcare); Brief Pain Inventory; Celiac plexus; Minimal clinically important difference; Pancreatic cancer; Palliative care; Abdominal pain; Clinical trial; Internal medicine; Cancer; Surgery; Randomized controlled trial; Physical therapy; Chronic pain","score_opus":0.3478222454132207,"score_gpt":0.594419364093887,"score_spread":0.24659711868066625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548215,0.00032090032,0.00045195277,0.03871049,0.0038035503,0.0014413594,0.000051491606,0.000024694878,0.00037405948],"genre_scores_gemma":[0.9769177,0.0029658163,0.0073444527,0.010844531,0.00048435217,0.0001245205,0.00009048283,0.000036873054,0.0011912687],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902863,0.0016324859,0.0067387037,0.00029465623,0.0007172164,0.00033062234],"domain_scores_gemma":[0.990109,0.0042803576,0.0044031176,0.00031313815,0.0003160627,0.0005783261],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032167863,0.00016911868,0.0026132064,0.00053821644,0.000039621395,0.0000059942417,0.00029731836,0.00016106475,0.00026881424],"category_scores_gemma":[0.016465347,0.0001378544,0.0007378496,0.0003549793,0.00011249201,0.00017169582,0.000095075884,0.00046774006,0.0000035634032],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18698548,0.01556911,0.045498792,0.00049276464,0.0020970504,0.0003629471,0.00018362244,0.00037085277,0.000013154375,0.0010425866,0.027505731,0.7198779],"study_design_scores_gemma":[0.44702795,0.032070123,0.41992137,0.00028450915,0.00048511164,0.0000037541117,0.0010250508,0.003504538,0.0000018637642,0.0020893528,0.09336243,0.00022394175],"about_ca_topic_score_codex":0.00007264373,"about_ca_topic_score_gemma":0.000055566103,"teacher_disagreement_score":0.71965396,"about_ca_system_score_codex":0.00026459774,"about_ca_system_score_gemma":0.001370733,"threshold_uncertainty_score":0.99658686},"labels":[],"label_agreement":null},{"id":"W4379281744","doi":"10.1200/jco.2023.41.16_suppl.tps5635","title":"GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients' expectations and assessment of care.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Life expectancy; Family medicine; Patient satisfaction; Cancer; Nursing; Internal medicine; Population","score_opus":0.29871600776039975,"score_gpt":0.601500533734368,"score_spread":0.3027845259739682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98773134,0.001529474,0.00007867906,0.0035346416,0.0012456733,0.0002778228,0.000016818578,0.000011986394,0.005573538],"genre_scores_gemma":[0.9853919,0.005993805,0.0075913984,0.00038965256,0.0004400752,0.000010957295,0.000048393213,0.000016213273,0.0001175651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995902,0.00053217285,0.0026707696,0.00021131714,0.00045479517,0.00022893376],"domain_scores_gemma":[0.99215287,0.004545277,0.001977831,0.00016301975,0.0009276096,0.00023341677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017062369,0.0001473896,0.0016312931,0.00033520523,0.000031043215,0.000004226198,0.00013601707,0.00041240396,0.0000988827],"category_scores_gemma":[0.005448843,0.00011774791,0.00028525662,0.00041767926,0.00024255321,0.00011508056,0.00007420539,0.00081492605,0.00000909871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008525178,0.0015719285,0.88360894,0.00015195324,0.00027517672,0.0002760169,0.0031235237,0.000055582997,0.00015496675,0.00034174733,0.0040506176,0.10553705],"study_design_scores_gemma":[0.011185619,0.012828336,0.8963525,0.00033440642,0.0002928336,0.000014278244,0.0067598107,0.00032256808,0.00009438658,0.00020947616,0.07149838,0.00010735309],"about_ca_topic_score_codex":0.000050776267,"about_ca_topic_score_gemma":0.00024552696,"teacher_disagreement_score":0.105429694,"about_ca_system_score_codex":0.0003060118,"about_ca_system_score_gemma":0.0014252989,"threshold_uncertainty_score":0.65231675},"labels":[],"label_agreement":null},{"id":"W4379281748","doi":"10.1200/jco.2023.41.16_suppl.4541","title":"Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Saskatchewan","funders":"National Institutes of Health","keywords":"Medicine; Concordance; Perioperative; Nivolumab; Nephrectomy; Biopsy; Internal medicine; Surgery; Radiology; Kidney; Immunotherapy; Cancer","score_opus":0.1284391337867495,"score_gpt":0.374694729662386,"score_spread":0.24625559587563647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976829,0.0006268399,0.0000029853043,0.0007059458,0.00016117285,0.00055546395,0.000005684074,0.0000080476475,0.0002509032],"genre_scores_gemma":[0.99659944,0.0010222052,0.0021613515,0.00009373162,0.00005870502,0.000007356078,0.000009459852,0.0000235187,0.000024260005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679273,0.0005564291,0.0017332502,0.00036603786,0.00027143167,0.00028011526],"domain_scores_gemma":[0.996233,0.0022389125,0.0010233527,0.00013456261,0.00020322086,0.00016694565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012216303,0.00023160384,0.0012986291,0.00033008397,0.000056168312,0.000014117673,0.0000870534,0.00031862082,0.000016648002],"category_scores_gemma":[0.0013606371,0.00016632823,0.00008400419,0.00041951195,0.00036560002,0.00023656599,0.000083279665,0.0008545004,7.7813763e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033015672,0.00077252707,0.9547639,0.00006750376,0.000084041596,0.000741257,0.00259084,0.000043697775,0.001405926,0.000041847088,0.00000968497,0.0064631],"study_design_scores_gemma":[0.040354077,0.022772199,0.93374723,0.00026237516,0.000076274606,0.00014362909,0.001459066,0.00085562305,0.00008545674,0.000022565355,0.00009065587,0.00013086735],"about_ca_topic_score_codex":0.00033681342,"about_ca_topic_score_gemma":0.0008412764,"teacher_disagreement_score":0.02199967,"about_ca_system_score_codex":0.00045910187,"about_ca_system_score_gemma":0.0006519221,"threshold_uncertainty_score":0.6782668},"labels":[],"label_agreement":null},{"id":"W4379281754","doi":"10.1200/jco.2023.41.16_suppl.e18504","title":"Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Pandemic; Socioeconomic status; Demography; Coronavirus disease 2019 (COVID-19); Population; Palliative care; Cohort; Gerontology; Environmental health; Disease; Internal medicine","score_opus":0.24349761320283844,"score_gpt":0.5172485705380119,"score_spread":0.2737509573351734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634326,0.00043621773,0.000018320254,0.0026281376,0.00016847732,0.00020111595,0.000086898195,0.000006210863,0.00011136395],"genre_scores_gemma":[0.99097544,0.007620474,0.0002668226,0.0003880047,0.00042135172,0.0000054380225,0.000008011565,0.000014610663,0.0002998671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978998,0.0002780349,0.0011966258,0.00013864192,0.00029209742,0.00019483318],"domain_scores_gemma":[0.99192035,0.004045047,0.003041068,0.000112344795,0.0006768609,0.0002043434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010026161,0.00011570332,0.0013769289,0.00009116101,0.000048078986,0.00000542922,0.00007826407,0.00021299606,0.00004738432],"category_scores_gemma":[0.0031929144,0.00006572224,0.00016991499,0.00014938989,0.00036920243,0.00010754116,0.000040605482,0.00047519436,5.758908e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029464453,0.00007469932,0.9809548,0.00021150197,0.0008887525,0.000033968543,0.012327781,0.00024016477,0.000027754513,0.000018213983,0.0009092451,0.001366642],"study_design_scores_gemma":[0.005593908,0.0030706828,0.9730903,0.00035977495,0.00052864704,0.000004415834,0.006861568,0.000028180033,0.00005988786,0.00003962528,0.010301142,0.00006187588],"about_ca_topic_score_codex":0.0011810845,"about_ca_topic_score_gemma":0.027122375,"teacher_disagreement_score":0.02594129,"about_ca_system_score_codex":0.00059667655,"about_ca_system_score_gemma":0.0015005638,"threshold_uncertainty_score":0.9906301},"labels":[],"label_agreement":null},{"id":"W4379281756","doi":"10.1200/jco.2023.41.16_suppl.tps6114","title":"CCTG HN11: SPECT-CT guided elective contralateral neck treatment (SELECT) for patients with lateralized oropharyngeal cancer—A phase III randomized controlled trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Queen's University; London Health Sciences Centre; Western University; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Head and neck cancer; Swallowing; Hazard ratio; Confidence interval; Radiation therapy; Randomized controlled trial; Adverse effect; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Radiology; Surgery","score_opus":0.09218040947009737,"score_gpt":0.48754248066925376,"score_spread":0.3953620711991564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815635,0.00050653564,0.000037104674,0.0063301944,0.0026795869,0.007816801,0.000026621983,0.00003950745,0.0010001585],"genre_scores_gemma":[0.9888571,0.003854273,0.0003517699,0.0013854789,0.0021993665,0.0010039804,0.00003529458,0.000045847024,0.0022669162],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933799,0.000976425,0.0042279917,0.00036076113,0.0004602415,0.00059471274],"domain_scores_gemma":[0.9889303,0.0066992627,0.0026992476,0.00017161094,0.0010321819,0.00046738653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032472638,0.0003744649,0.011003235,0.00022750859,0.00013220616,0.000017933773,0.0001284923,0.0001521896,0.00022121446],"category_scores_gemma":[0.004188965,0.00019195264,0.0019003561,0.0002754336,0.00025560704,0.00011179801,0.000022682972,0.00046694724,0.000008016562],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95763075,0.0049424125,0.0027023565,0.000021709442,0.007322666,0.00058911403,0.00021267757,0.000007794375,0.000053377084,0.000027522337,0.009066883,0.017422728],"study_design_scores_gemma":[0.8879253,0.092916496,0.004147234,0.00011389748,0.0035907577,0.000042988315,0.000025099333,0.0003530944,0.00012169419,0.00013979764,0.010449894,0.0001736992],"about_ca_topic_score_codex":0.00013459881,"about_ca_topic_score_gemma":0.00009873124,"teacher_disagreement_score":0.08797409,"about_ca_system_score_codex":0.0006097454,"about_ca_system_score_gemma":0.002820191,"threshold_uncertainty_score":0.78276014},"labels":[],"label_agreement":null},{"id":"W4379281765","doi":"10.1200/jco.2023.41.16_suppl.7550","title":"Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Post-hoc analysis; Regimen; Phases of clinical research; Nuclear medicine; Clinical endpoint; Internal medicine; Toxicity; Urology; Surgery; Clinical trial","score_opus":0.14952030056499643,"score_gpt":0.5083827260818493,"score_spread":0.3588624255168529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949997,0.0009923094,0.000035352106,0.0016193244,0.0006162546,0.0005431761,0.000016765587,0.000029734709,0.0011473639],"genre_scores_gemma":[0.99216354,0.0021380582,0.00047079573,0.00074134074,0.00078876433,0.000015415606,0.000012409677,0.0000536898,0.0036160043],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99497753,0.0011005785,0.0021069977,0.00045377138,0.00083465717,0.00052645575],"domain_scores_gemma":[0.9938801,0.0038491616,0.0009816013,0.00039872996,0.00031644455,0.0005739899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004837918,0.0002697906,0.0021655292,0.00055032433,0.00009429014,0.000023899705,0.00025849725,0.00043105482,0.0007118282],"category_scores_gemma":[0.0013296729,0.0001821896,0.0004224233,0.0006810144,0.00021152431,0.00016735135,0.00013127214,0.0011980683,0.000024714835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17426562,0.06614592,0.21556999,0.000038429454,0.002462871,0.017327044,0.002952576,0.000005679735,0.018821718,0.000006629813,0.0061441376,0.4962594],"study_design_scores_gemma":[0.40237117,0.13748512,0.40068352,0.00015750343,0.00058307976,0.0002311549,0.0030442658,0.0005306962,0.00035576278,0.0002116675,0.054058224,0.00028782195],"about_ca_topic_score_codex":0.00019028231,"about_ca_topic_score_gemma":0.0007965136,"teacher_disagreement_score":0.49597156,"about_ca_system_score_codex":0.0002498033,"about_ca_system_score_gemma":0.0015206675,"threshold_uncertainty_score":0.7794019},"labels":[],"label_agreement":null},{"id":"W4379281789","doi":"10.1200/jco.2023.41.16_suppl.6640","title":"Palliative care as a component of high-value and cost-saving care during hospitalization for metastatic cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palliative care; Receipt; Emergency medicine; Cancer; Population; Odds ratio; Randomized controlled trial; Quality of life (healthcare); Logistic regression; Odds; Intensive care medicine; Internal medicine; Nursing; Environmental health","score_opus":0.3295869857274058,"score_gpt":0.5850418027921991,"score_spread":0.2554548170647933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99015117,0.007089912,0.00027961217,0.0012585336,0.00064578006,0.00039153543,0.00005148502,0.0000078238045,0.00012416621],"genre_scores_gemma":[0.98828644,0.006726093,0.004396409,0.00017524956,0.0003206967,0.000016085867,0.000023662968,0.000015245892,0.000040115545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785715,0.00018169812,0.0014005101,0.00014012774,0.0002656841,0.00015480256],"domain_scores_gemma":[0.99497294,0.0021850471,0.0014446649,0.00008741285,0.0011505953,0.00015932508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058672397,0.00010744908,0.0013103836,0.00013404156,0.000036049794,0.0000031084237,0.00007738215,0.00013392784,0.00001406097],"category_scores_gemma":[0.0036539924,0.000082299455,0.0002627885,0.0001625081,0.00014430373,0.000059265993,0.000040898143,0.00024048566,0.00000106278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063342866,0.00053240586,0.87784415,0.0036173502,0.0021210473,0.00042663867,0.025982996,0.001903717,0.0024065897,0.001184163,0.0009821999,0.07666444],"study_design_scores_gemma":[0.017046759,0.013110391,0.91924006,0.0034010313,0.00168006,0.00001750901,0.026251694,0.0004124826,0.0057049864,0.0006464811,0.012310385,0.0001781685],"about_ca_topic_score_codex":0.00019187317,"about_ca_topic_score_gemma":0.00010340986,"teacher_disagreement_score":0.07648627,"about_ca_system_score_codex":0.00017062522,"about_ca_system_score_gemma":0.00064113335,"threshold_uncertainty_score":0.43744344},"labels":[],"label_agreement":null},{"id":"W4379281793","doi":"10.1200/jco.2023.41.16_suppl.e18533","title":"Evidence-based cost estimation of essential medicines for pediatric cancer care in Peru.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Health care; Essential medicines; Cancer registry; Unit (ring theory); Incidence (geometry); Environmental health; Population; Public health; Economic growth; Nursing","score_opus":0.4379964756465755,"score_gpt":0.6309777323155042,"score_spread":0.19298125666892874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9255498,0.010226779,0.00035557165,0.06107474,0.0021163048,0.00043782435,0.000008278412,0.000007733146,0.00022296299],"genre_scores_gemma":[0.9762107,0.019019222,0.0009794637,0.0017053696,0.0020339692,0.000018601688,0.0000026779312,0.000007277739,0.00002270647],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99771184,0.00021754048,0.0015067151,0.00010571433,0.00029792322,0.00016024594],"domain_scores_gemma":[0.9867986,0.011300803,0.0011305884,0.00006245025,0.00054961455,0.0001579646],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031077787,0.00007250403,0.0008920991,0.00014982006,0.000027533239,0.0000026832054,0.00008768592,0.00016560085,0.000111186135],"category_scores_gemma":[0.017621512,0.000048209244,0.00024452384,0.00031982624,0.00010444721,0.000111613976,0.00002469251,0.00044794404,0.000003846711],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015120737,0.000628814,0.3499702,0.0010138437,0.0001827374,0.00020573271,0.00033188442,0.0026077793,0.0001361989,0.000025532514,0.012775217,0.6170013],"study_design_scores_gemma":[0.023658577,0.01662983,0.83644706,0.0011686995,0.0027727482,0.000029547518,0.0010715468,0.021118365,0.00041167391,0.00021233284,0.09632179,0.00015783633],"about_ca_topic_score_codex":0.000038215832,"about_ca_topic_score_gemma":0.00009377072,"teacher_disagreement_score":0.61684346,"about_ca_system_score_codex":0.000089353816,"about_ca_system_score_gemma":0.0013991967,"threshold_uncertainty_score":0.99065346},"labels":[],"label_agreement":null},{"id":"W4379281805","doi":"10.1200/jco.2023.41.16_suppl.5047","title":"Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Cabazitaxel; Internal medicine; Progression-free survival; Confidence interval; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Oncology; Hormonal therapy; Cancer; Progressive disease; Urology; Surgery; Androgen deprivation therapy","score_opus":0.11962850468057874,"score_gpt":0.46088185585892416,"score_spread":0.34125335117834543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471396,0.002629692,0.0000056482486,0.0014248375,0.000226357,0.00072072947,0.00024384298,0.000006243379,0.000028703069],"genre_scores_gemma":[0.98898,0.010493751,0.00024086543,0.000052511383,0.000061170635,0.000035023633,0.000039915463,0.000020329067,0.00007644659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946867,0.001743267,0.0019645134,0.0003529862,0.0008872324,0.0003652669],"domain_scores_gemma":[0.99254304,0.0042807017,0.0016623393,0.00021390073,0.0009736675,0.00032635283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067439694,0.0002464893,0.0021125632,0.00094569894,0.00005580784,0.000014615878,0.00014643196,0.00015851631,0.00003546047],"category_scores_gemma":[0.0017217011,0.00015134156,0.00032853166,0.0012900536,0.0007617317,0.00015150357,0.00007769185,0.00065489183,2.9444806e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15240641,0.0018821245,0.803553,0.00011669582,0.0047191284,0.0004244114,0.00082912226,0.00011623575,0.001885702,0.000019418694,0.00012883986,0.03391891],"study_design_scores_gemma":[0.03481465,0.019212835,0.9431195,0.00026706714,0.0010689251,0.000009410828,0.00035404804,0.00037972978,0.00033770007,0.000099534846,0.00020693598,0.00012965036],"about_ca_topic_score_codex":0.0002826668,"about_ca_topic_score_gemma":0.0008935338,"teacher_disagreement_score":0.13956651,"about_ca_system_score_codex":0.00018293489,"about_ca_system_score_gemma":0.0022576558,"threshold_uncertainty_score":0.617153},"labels":[],"label_agreement":null},{"id":"W4379281846","doi":"10.1200/jco.2023.41.16_suppl.e17113","title":"Investigating the association (assoc) between mental health illness (MHI) and development of prostate cancer (PC) in a nationwide matched cohort of &gt;5,000,000 US Veterans.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health disparities and outcomes","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Veterans Affairs; Logistic regression; Cohort; Demography; Prostate cancer; Comorbidity; Gerontology; Cancer; Internal medicine","score_opus":0.12893807218475548,"score_gpt":0.4904191238107463,"score_spread":0.36148105162599087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519434,0.00016065074,0.0000038006697,0.046674084,0.00069923495,0.00029638383,0.000027841998,0.0000053138024,0.00018928635],"genre_scores_gemma":[0.99517393,0.0020008874,0.0005516482,0.0018986494,0.0002450345,0.000011602184,0.0000036560305,0.0000062037457,0.0001083638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951427,0.0013062593,0.002517793,0.000107821776,0.00060559664,0.0003198313],"domain_scores_gemma":[0.99258256,0.004098909,0.0028148757,0.0000484832,0.00025698374,0.00019818533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020040676,0.00007215107,0.0008830514,0.00009545664,0.0002520956,0.000013156356,0.00016870875,0.00019555866,0.00002023528],"category_scores_gemma":[0.004184898,0.000052434105,0.00008146067,0.00032100335,0.00020331926,0.00012289154,0.000047697227,0.00040793637,8.093282e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033303615,0.000048851936,0.9286439,0.000061321865,0.00007346023,0.0000011680329,0.024295416,0.000013987049,0.0000026163345,0.00010919883,0.0006452791,0.046071522],"study_design_scores_gemma":[0.0011150547,0.0001760901,0.9624665,0.00015129389,0.000015832655,3.442557e-7,0.0048640184,0.000017492845,0.000012462414,0.00030046026,0.030829977,0.000050516013],"about_ca_topic_score_codex":0.0065784757,"about_ca_topic_score_gemma":0.019223195,"teacher_disagreement_score":0.046021007,"about_ca_system_score_codex":0.0005963087,"about_ca_system_score_gemma":0.003978713,"threshold_uncertainty_score":0.99867344},"labels":[],"label_agreement":null},{"id":"W4379281866","doi":"10.1200/jco.2023.41.16_suppl.5023","title":"Clinical analysis of optimized neural network risk models to predict clinically significant prostate cancer and avoid unnecessary prostate biopsies.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Calgary; University of Alberta; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Prostate Cancer Canada","keywords":"Medicine; Overdiagnosis; Prostate cancer; Cohort; Cancer; Internal medicine; Artificial neural network; Oncology; Artificial intelligence","score_opus":0.07760661196714504,"score_gpt":0.4543973577004853,"score_spread":0.37679074573334026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722059,0.0005596374,0.0018614787,0.022372102,0.0019960105,0.0006016721,0.000053443084,0.00005193651,0.00029784776],"genre_scores_gemma":[0.94401735,0.02776885,0.021107651,0.0046264376,0.0019847744,0.0000210661,0.000024386867,0.000056592522,0.0003928618],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98885196,0.0017342571,0.0074007004,0.0006043485,0.0007765299,0.0006322208],"domain_scores_gemma":[0.9829201,0.009983931,0.0044473168,0.00041744404,0.0008183988,0.0014128104],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02483762,0.00029536997,0.0044277175,0.0005684158,0.00010536442,0.000027952956,0.0003791733,0.0005295242,0.0000637479],"category_scores_gemma":[0.014571856,0.00020480841,0.0013849827,0.0017273689,0.0008474694,0.00015862969,0.00028103436,0.0031785981,0.00000594904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008582975,0.0005473251,0.52433276,0.000051800445,0.0035247712,0.00045844575,0.00024635138,0.27532628,0.000021560138,0.000015123158,0.009469282,0.17742333],"study_design_scores_gemma":[0.008144374,0.0073729404,0.41264966,0.00022617642,0.0056053433,0.000027885428,0.00013665274,0.560079,0.0000014720114,0.00046017903,0.005120368,0.00017594975],"about_ca_topic_score_codex":0.0001372348,"about_ca_topic_score_gemma":0.000018224973,"teacher_disagreement_score":0.28475273,"about_ca_system_score_codex":0.000066674846,"about_ca_system_score_gemma":0.0014980226,"threshold_uncertainty_score":0.9991211},"labels":[],"label_agreement":null},{"id":"W4379281872","doi":"10.1200/jco.2023.41.16_suppl.7555","title":"Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Adverse effect; Follicular lymphoma; Regimen; Phases of clinical research; Refractory (planetary science); Surgery; Lymphoma; Gastroenterology; Clinical trial","score_opus":0.0552513847129782,"score_gpt":0.3780557654255918,"score_spread":0.32280438071261364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947213,0.00010539795,2.122627e-7,0.0036678235,0.000598026,0.00071628095,0.000027959919,0.0000065393206,0.00015643897],"genre_scores_gemma":[0.9986059,0.00036118075,0.000077113706,0.0005021306,0.0003602885,0.0000053093263,0.00000850631,0.000015533959,0.00006405077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961609,0.0007865987,0.0020867714,0.00024053908,0.00054353924,0.00018164814],"domain_scores_gemma":[0.9902402,0.0074554808,0.0015132698,0.00040271,0.00023000767,0.00015829176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020224191,0.00014936882,0.0011393318,0.00006400798,0.000067023735,0.000007876409,0.00018992556,0.00020818715,0.000017278297],"category_scores_gemma":[0.00496481,0.000058392256,0.00019331268,0.00033028013,0.00020130911,0.00005922082,0.00012337982,0.0003634481,0.0000075957832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04877756,0.01180946,0.8976751,0.00000550568,0.0005676467,0.00036717247,0.00082871254,0.00002218074,0.0000031925015,0.000004794068,0.0030372115,0.036901437],"study_design_scores_gemma":[0.11141225,0.026856255,0.85010517,0.00022484874,0.00042091627,0.0000076157453,0.00068808335,0.000008011417,0.0000116503925,0.0000069851826,0.010203004,0.00005518964],"about_ca_topic_score_codex":0.00020106477,"about_ca_topic_score_gemma":0.0004112528,"teacher_disagreement_score":0.062634684,"about_ca_system_score_codex":0.00024412025,"about_ca_system_score_gemma":0.0009876301,"threshold_uncertainty_score":0.59436995},"labels":[],"label_agreement":null},{"id":"W4379281877","doi":"10.1200/jco.2023.41.16_suppl.e24078","title":"Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Pomalidomide; Multiple myeloma; Oncology; Confidence interval; Surgery; Lenalidomide","score_opus":0.22361293536407767,"score_gpt":0.47960702118392706,"score_spread":0.2559940858198494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01065131,0.9859321,0.000004882479,0.00019374512,0.00008058087,0.0029276535,0.00013167043,0.000009186953,0.000068830115],"genre_scores_gemma":[0.0038553302,0.993486,0.0017524627,0.00029469442,0.000060649243,0.00009509914,0.000065349945,0.000052486772,0.0003379647],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98703176,0.0026483329,0.008131044,0.00055096357,0.0011684184,0.00046945832],"domain_scores_gemma":[0.9787992,0.010340545,0.008700927,0.00060364185,0.0010755922,0.0004800784],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008043545,0.000580146,0.03012343,0.0010296876,0.000047623224,0.000020169662,0.0004284584,0.00056489976,0.0001345806],"category_scores_gemma":[0.012626962,0.00030140957,0.0037584766,0.0011969957,0.00038182925,0.00020305235,0.00026115775,0.0014763385,0.00001567428],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043005624,0.0012991133,0.060393013,0.71941465,0.20578198,0.0014097934,0.00003123216,0.0000011061352,1.411981e-7,0.0000023422479,0.00017741416,0.011059168],"study_design_scores_gemma":[0.003883936,0.004052444,0.21345267,0.113898285,0.6614224,0.00023901636,0.00001691517,0.0000058472297,2.5598996e-7,0.00000814933,0.0027406488,0.00027946898],"about_ca_topic_score_codex":0.000030023744,"about_ca_topic_score_gemma":0.00025745403,"teacher_disagreement_score":0.6055164,"about_ca_system_score_codex":0.0002804044,"about_ca_system_score_gemma":0.00236797,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W4379281880","doi":"10.1200/jco.2023.41.16_suppl.tps7586","title":"SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Gemcitabine; Phases of clinical research; Antibody-drug conjugate; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Lymphoma; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Antibody; Immunology; Monoclonal antibody; Colorectal cancer","score_opus":0.0704012691811073,"score_gpt":0.44661518105052217,"score_spread":0.3762139118694149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965983,0.0002413114,0.000016095273,0.0009792291,0.00024921782,0.0016726098,0.000005547155,0.000007397646,0.0002302908],"genre_scores_gemma":[0.9985871,0.00040926042,0.00044295425,0.00012958069,0.00019779797,0.00001684141,0.000016145239,0.000035559606,0.00016476837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945282,0.0013044515,0.0024901857,0.0003331727,0.0009777432,0.00036624484],"domain_scores_gemma":[0.9885821,0.0077494946,0.002614143,0.00026880324,0.0005490532,0.00023643019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006940499,0.00022382452,0.0018675104,0.00046366843,0.00007054705,0.000016270955,0.00018124294,0.00034287223,0.00006568875],"category_scores_gemma":[0.004132876,0.00013456627,0.00011777189,0.00070765644,0.00052092917,0.00015777432,0.00011496685,0.0012669452,0.0000018429891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7951437,0.008363641,0.039100613,0.00007210707,0.00019946191,0.0003596518,0.0014504403,0.00011205096,0.00048084874,0.0000092414775,0.00007964517,0.15462856],"study_design_scores_gemma":[0.5783959,0.10828539,0.3085821,0.00043532674,0.00014573708,0.000040192914,0.00030366765,0.0034209762,0.00003242439,0.00003840214,0.00021869756,0.00010117316],"about_ca_topic_score_codex":0.00011235308,"about_ca_topic_score_gemma":0.0001589423,"teacher_disagreement_score":0.26948148,"about_ca_system_score_codex":0.00046638233,"about_ca_system_score_gemma":0.0024144154,"threshold_uncertainty_score":0.55043167},"labels":[],"label_agreement":null},{"id":"W4379281884","doi":"10.1200/jco.2023.41.16_suppl.4160","title":"Impact of positive resection margins on recurrence and survival following resection and adjuvant chemotherapy in pancreatic cancer: Results of the PRODIGE 24-CCTG PA-6 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pancreatic cancer; Resection margin; Lymphovascular invasion; Pancreas; Adjuvant therapy; Superior mesenteric vein; Surgery; Radiology; Oncology; Internal medicine; Cancer; Chemotherapy; Resection; Portal vein; Metastasis","score_opus":0.16483388515723563,"score_gpt":0.5247978508876707,"score_spread":0.3599639657304351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931237,0.00030079798,0.0000041032354,0.004085115,0.0009117569,0.0006956781,0.000013096651,0.0000034668308,0.00086229615],"genre_scores_gemma":[0.99223846,0.0070265727,0.000079559024,0.0000522498,0.00034434168,0.000011258032,0.0000018859771,0.000009842153,0.00023580166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960663,0.0013291133,0.0017333413,0.00020808584,0.00043742952,0.00022574174],"domain_scores_gemma":[0.9925666,0.0055505214,0.0012591548,0.00017860906,0.00029409985,0.0001509998],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008242263,0.000114770926,0.00159205,0.00025907208,0.00004933086,0.000004212583,0.000101170925,0.0003041814,0.000010557942],"category_scores_gemma":[0.010260488,0.00006597332,0.00031049448,0.0005088558,0.00031737957,0.00006989602,0.00004817088,0.0009168969,5.631246e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22714962,0.0008492458,0.74276245,0.000056528537,0.00047942932,0.00007970414,0.0005665587,0.000010493358,0.0008250453,0.000020141111,0.00056829443,0.026632464],"study_design_scores_gemma":[0.056204773,0.03849646,0.90316993,0.00079582434,0.00019481899,0.000028911743,0.00021724122,0.0003126613,0.00015401123,0.00027704067,0.0001012676,0.000047036094],"about_ca_topic_score_codex":0.000782019,"about_ca_topic_score_gemma":0.00065816694,"teacher_disagreement_score":0.17094485,"about_ca_system_score_codex":0.00025548282,"about_ca_system_score_gemma":0.0017670837,"threshold_uncertainty_score":0.9980765},"labels":[],"label_agreement":null},{"id":"W4379281889","doi":"10.1200/jco.2023.41.16_suppl.tps7582","title":"BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Idelalisib; Rituximab; Medicine; Venetoclax; Internal medicine; Pharmacology; Oncology; Immunology; Leukemia; Lymphoma; Tyrosine kinase","score_opus":0.33510161085826223,"score_gpt":0.5299669314419019,"score_spread":0.19486532058363965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98886263,0.0018515001,0.000031927975,0.0005651716,0.0024625643,0.0051816637,0.000056663976,0.000097546974,0.00089030754],"genre_scores_gemma":[0.99351543,0.0020044765,0.00117897,0.00048022025,0.0014973859,0.00021740889,0.0000559161,0.00019144815,0.0008587403],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97678256,0.0047413786,0.012939738,0.0013377137,0.0025163407,0.0016822603],"domain_scores_gemma":[0.9563737,0.03096801,0.0070737083,0.0015729996,0.0020582736,0.001953296],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018579543,0.0009833918,0.0123415645,0.0018482478,0.00015007553,0.000077250654,0.0022303094,0.0015233901,0.0002988411],"category_scores_gemma":[0.085416645,0.0007390899,0.0010451518,0.0038262089,0.0022640303,0.0005538252,0.0015354563,0.001786139,0.000110675384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9276685,0.020656977,0.00031105473,0.0015178109,0.0041225534,0.012551383,0.0017408403,0.00358075,0.0008991203,0.0000766561,0.0061983173,0.020676041],"study_design_scores_gemma":[0.80504394,0.054208957,0.00030580745,0.0016813949,0.0024076777,0.00077588274,0.0010953312,0.13165294,0.00093529484,0.00007416449,0.0013244206,0.0004941832],"about_ca_topic_score_codex":0.01230086,"about_ca_topic_score_gemma":0.0039058912,"teacher_disagreement_score":0.2506033,"about_ca_system_score_codex":0.1453475,"about_ca_system_score_gemma":0.3959508,"threshold_uncertainty_score":0.99977285},"labels":[],"label_agreement":null},{"id":"W4379281896","doi":"10.1200/jco.2023.41.16_suppl.5013","title":"Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Placebo; Prostate cancer; Internal medicine; Quality of life (healthcare); Cancer; Oncology; Alternative medicine; Androgen receptor; Nursing; Pathology","score_opus":0.19302331313074272,"score_gpt":0.5105133045419311,"score_spread":0.3174899914111884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316705,0.0004799259,0.000014678651,0.00847995,0.0012332322,0.005442623,0.0007409922,0.00007934187,0.00036219333],"genre_scores_gemma":[0.991014,0.0015550534,0.0007858489,0.00026019115,0.0006121197,0.00092433725,0.00035419446,0.00008558155,0.0044086976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910708,0.0007336522,0.0053113895,0.000842896,0.0011885496,0.00085270114],"domain_scores_gemma":[0.9867749,0.006995498,0.003693568,0.0005683601,0.001084325,0.00088331907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041649356,0.0005474313,0.0030107812,0.000431159,0.00031110138,0.00007737985,0.00023626845,0.0003119638,0.00015409982],"category_scores_gemma":[0.008112264,0.00035091137,0.00089048437,0.0005711981,0.00031393557,0.00033334934,0.000115894036,0.0008510888,0.000026576081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34251767,0.03155621,0.40162185,0.00019763673,0.016220514,0.017619396,0.009256061,0.0009034386,0.0018260909,0.000010695728,0.006675484,0.17159493],"study_design_scores_gemma":[0.33621016,0.17892757,0.43860734,0.0007736881,0.006648872,0.00014197803,0.0070837378,0.002869188,0.0029153798,0.000692857,0.024395851,0.0007334017],"about_ca_topic_score_codex":0.0021135367,"about_ca_topic_score_gemma":0.003290425,"teacher_disagreement_score":0.17086153,"about_ca_system_score_codex":0.0012413412,"about_ca_system_score_gemma":0.0038904792,"threshold_uncertainty_score":0.99989426},"labels":[],"label_agreement":null},{"id":"W4379281910","doi":"10.1200/jco.2023.41.16_suppl.e18873","title":"Real world challenges in defining oligometastatic disease in clinical practice.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; North York General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Family medicine; Disease; Comprehension; Quality of life (healthcare); Academic institution; Descriptive statistics; Medical physics; Internal medicine; Nursing","score_opus":0.3601135950582786,"score_gpt":0.5746320365243027,"score_spread":0.2145184414660241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89466023,0.0039289054,0.0000011861327,0.090650216,0.001542408,0.00022334213,0.000003255092,0.000014647054,0.008975776],"genre_scores_gemma":[0.88647956,0.10846023,0.0022954426,0.0018079968,0.00078384124,0.000019481222,0.0000037298123,0.000018981795,0.00013075909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942755,0.00096911023,0.0037866076,0.000271542,0.000392882,0.0003043318],"domain_scores_gemma":[0.98067737,0.016954327,0.0014067418,0.00021805278,0.0001725511,0.0005709887],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0102698505,0.00013013513,0.001699754,0.0005252897,0.000014694466,0.000007182633,0.00011091598,0.00017399105,0.000072450704],"category_scores_gemma":[0.018667921,0.00009639883,0.0004928695,0.0005241896,0.00012264606,0.00013526465,0.00006536789,0.0012150562,0.00010580475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004169723,0.0044156597,0.63871014,0.000039992476,0.00020054326,0.013760379,0.000118345684,0.00005471765,2.5347853e-7,0.00087573566,0.002232101,0.33542243],"study_design_scores_gemma":[0.010013737,0.0046992544,0.90521795,0.00038075287,0.00035094883,0.000047746777,0.00030813538,0.00012420981,3.8380628e-7,0.00084136135,0.07794377,0.00007172953],"about_ca_topic_score_codex":0.00011064458,"about_ca_topic_score_gemma":0.0018266962,"teacher_disagreement_score":0.3353507,"about_ca_system_score_codex":0.00028787574,"about_ca_system_score_gemma":0.0020633773,"threshold_uncertainty_score":0.9895983},"labels":[],"label_agreement":null},{"id":"W4379281948","doi":"10.1200/jco.2023.41.16_suppl.tps5617","title":"CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Immunotherapy; Internal medicine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Biomarker; Ovarian cancer; Progression-free survival; Clinical trial; Cancer; Phases of clinical research; Chemotherapy","score_opus":0.19965416869474437,"score_gpt":0.5005382425116133,"score_spread":0.3008840738168689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818761,0.00047544183,0.000009554126,0.014257889,0.0022224593,0.00071111077,0.000018472,0.00003824328,0.0003907554],"genre_scores_gemma":[0.99361384,0.0016371337,0.00089020294,0.0017978038,0.0016169212,0.00007738133,0.000009032756,0.000053276708,0.0003044172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508065,0.00037536316,0.0030045067,0.0004134914,0.0006335176,0.0004924687],"domain_scores_gemma":[0.9960663,0.0013958327,0.0014066066,0.00041504347,0.0002629859,0.00045327013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034619556,0.00028062824,0.00211021,0.00036021945,0.00008432123,0.000029126353,0.00028329482,0.00043050904,0.0005068373],"category_scores_gemma":[0.00046129798,0.00019770584,0.00034845347,0.00057813054,0.000115878254,0.00022472169,0.000057703455,0.001212539,0.000041359475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013754744,0.017817145,0.73326415,0.00004045965,0.001745153,0.010302645,0.0019850184,0.00016753639,0.00024779068,0.00047863484,0.0043071387,0.21588956],"study_design_scores_gemma":[0.03231283,0.03184121,0.9154345,0.00015826039,0.00038037286,0.000115886825,0.0008773879,0.000055900317,0.00006180488,0.0011839664,0.017399052,0.00017887444],"about_ca_topic_score_codex":0.0015054676,"about_ca_topic_score_gemma":0.003241185,"teacher_disagreement_score":0.21571068,"about_ca_system_score_codex":0.0007137456,"about_ca_system_score_gemma":0.0021492047,"threshold_uncertainty_score":0.806221},"labels":[],"label_agreement":null},{"id":"W4379281954","doi":"10.1200/jco.2023.41.16_suppl.5504","title":"Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Internal medicine; Clinical endpoint; Placebo; Endometrial cancer; Randomized controlled trial; Quality of life (healthcare); Chemotherapy; Urology; Gastroenterology; Cancer; Surgery; Nuclear medicine; Cisplatin","score_opus":0.1570218913015609,"score_gpt":0.4735090099771405,"score_spread":0.3164871186755796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861022,0.00026871072,0.0000066058146,0.004213142,0.00289343,0.0055820798,0.00010668485,0.000031121916,0.0007960019],"genre_scores_gemma":[0.9936198,0.0006467572,0.0008330436,0.0029140322,0.00077119534,0.000840257,0.00011003515,0.00005125566,0.00021360513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917293,0.0009592784,0.004797481,0.00058324763,0.0012095436,0.0007211143],"domain_scores_gemma":[0.9832261,0.0124895,0.0025703174,0.00040254564,0.0007623178,0.0005492275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033579874,0.00043270332,0.003624136,0.00094749243,0.000079151294,0.000026693211,0.00033830683,0.00040973618,0.0001173738],"category_scores_gemma":[0.019895688,0.00022274129,0.00066678587,0.0027082916,0.00012585816,0.00017197193,0.00009672006,0.0010984329,0.000013537409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5789342,0.0060862163,0.18763979,0.000066086635,0.0006827117,0.0007118015,0.00057587435,0.00011651138,0.000020044867,0.0000062685253,0.0009541545,0.22420634],"study_design_scores_gemma":[0.4536304,0.09094022,0.4349879,0.00033671068,0.0006498421,0.000027179582,0.0005318358,0.00002868932,0.000032250657,0.00006854382,0.018510375,0.00025605407],"about_ca_topic_score_codex":0.0006910794,"about_ca_topic_score_gemma":0.001573115,"teacher_disagreement_score":0.24734811,"about_ca_system_score_codex":0.0016300981,"about_ca_system_score_gemma":0.0027127028,"threshold_uncertainty_score":0.98836017},"labels":[],"label_agreement":null},{"id":"W4379281959","doi":"10.1200/jco.2023.41.16_suppl.7012","title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Myeloid leukemia; Gastroenterology; Placebo; IDH1; IDH2; Pathology","score_opus":0.10253138610034464,"score_gpt":0.420495168032642,"score_spread":0.31796378193229735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896156,0.000034872344,0.000035460012,0.007307946,0.00017746392,0.0023520289,0.00023638942,0.000050014452,0.000190179],"genre_scores_gemma":[0.99538577,0.0002608242,0.0012707798,0.001649286,0.00052160345,0.000024823163,0.0006350218,0.000067509376,0.00018438141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99361527,0.0013946628,0.0025144392,0.0007298262,0.0011072467,0.0006385815],"domain_scores_gemma":[0.98674774,0.009560603,0.0010407428,0.0011069035,0.0007142681,0.00082974986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004293624,0.00037826915,0.002375025,0.0003571224,0.00013687229,0.000050695115,0.0009949718,0.000316466,0.00015465541],"category_scores_gemma":[0.0039628716,0.00020258145,0.00010120972,0.0013971801,0.00040746466,0.00029669586,0.0006689848,0.0021628437,0.00007937918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111635536,0.0020478447,0.8297119,0.000007468075,0.0016930068,0.004384073,0.0004226011,0.00028181888,0.000063433086,0.0000014858387,0.039100077,0.010650718],"study_design_scores_gemma":[0.10720682,0.02053365,0.86198896,0.00021317872,0.00083241775,0.000054158332,0.00088600296,0.00076152704,0.00001620783,0.00000523682,0.0072994167,0.0002024108],"about_ca_topic_score_codex":0.0007738371,"about_ca_topic_score_gemma":0.0026027665,"teacher_disagreement_score":0.032277033,"about_ca_system_score_codex":0.0007467842,"about_ca_system_score_gemma":0.0028005773,"threshold_uncertainty_score":0.93966},"labels":[],"label_agreement":null},{"id":"W4379281982","doi":"10.1200/jco.2023.41.16_suppl.12056","title":"Associations between sarcopenia and clinical outcomes in men with metastatic castrate-resistant prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Sarcopenia; Medicine; Prostate cancer; Internal medicine; Grip strength; Observational study; Geriatric oncology; Cancer; Oncology; Surgery","score_opus":0.3039813988042344,"score_gpt":0.5776280471310021,"score_spread":0.2736466483267677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416452,0.00014203995,0.000007574235,0.056796808,0.0002744531,0.0003274031,0.00004172916,0.000014521954,0.00075027626],"genre_scores_gemma":[0.9906843,0.0023296268,0.003697453,0.0021620519,0.00043414463,0.00000799862,0.000009776782,0.000017295344,0.0006574068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99548036,0.00065073307,0.0030979265,0.00017240824,0.00032335147,0.0002752361],"domain_scores_gemma":[0.99271464,0.0049812538,0.0014808564,0.000095122086,0.00027855596,0.0004495695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007460087,0.000104937855,0.0019056797,0.00020016069,0.000054241675,0.000012328711,0.00007714729,0.00016700618,0.00004037417],"category_scores_gemma":[0.0026049123,0.00006833997,0.00017841363,0.00030743663,0.00017628759,0.0000898915,0.00003209799,0.0011664733,0.000012892537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013342315,0.00042263936,0.97619087,0.000041565778,0.00035282853,0.00074308785,0.000092599774,0.0000030627778,0.000005008,0.000041879666,0.003096616,0.017675588],"study_design_scores_gemma":[0.01231982,0.005343572,0.9741648,0.0001895873,0.00037578313,0.000029904724,0.0002234344,0.000050764746,0.0000019970055,0.000497754,0.0067363,0.00006629403],"about_ca_topic_score_codex":0.00016721214,"about_ca_topic_score_gemma":0.00090430083,"teacher_disagreement_score":0.054634754,"about_ca_system_score_codex":0.00016197054,"about_ca_system_score_gemma":0.0019658313,"threshold_uncertainty_score":0.50678104},"labels":[],"label_agreement":null},{"id":"W4379282010","doi":"10.1200/jco.2023.41.16_suppl.4518","title":"First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Pembrolizumab; Medicine; Chromophobe cell; Clear cell; Lenvatinib; Renal cell carcinoma; Histology; Internal medicine; Oncology; Clinical endpoint; Cabozantinib; Cancer; Clinical trial; Immunotherapy","score_opus":0.16724848101688072,"score_gpt":0.46749150508458487,"score_spread":0.30024302406770415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934126,0.00028176387,0.000013457076,0.0041413098,0.0012938525,0.0011432675,0.000074298536,0.0000241749,0.0036866234],"genre_scores_gemma":[0.9920943,0.0006771888,0.00039429482,0.00028379448,0.0012672292,0.000020801306,0.000014566128,0.000056354635,0.0051915166],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9922889,0.00080915,0.0047682887,0.00051948015,0.000988688,0.0006254953],"domain_scores_gemma":[0.9906635,0.003427874,0.0037126222,0.0009496033,0.0006596287,0.0005867496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00364605,0.00041418994,0.0026229357,0.00018882762,0.00017608504,0.000016466103,0.0005021055,0.00046605445,0.00007695792],"category_scores_gemma":[0.0015605206,0.00023162899,0.0015259561,0.000613749,0.00037948746,0.00009192457,0.0002502903,0.0011193841,0.00010425458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3248878,0.14783032,0.291005,0.00065285544,0.004169731,0.028067848,0.0162672,0.0039772703,0.017721254,0.00000876761,0.039443664,0.12596828],"study_design_scores_gemma":[0.18420918,0.22848706,0.5290249,0.00019111423,0.001991068,0.00033412655,0.001933709,0.00072167674,0.02025986,0.000044090943,0.03251343,0.00028976644],"about_ca_topic_score_codex":0.0002289545,"about_ca_topic_score_gemma":0.00022788953,"teacher_disagreement_score":0.23801991,"about_ca_system_score_codex":0.00059504935,"about_ca_system_score_gemma":0.0019121873,"threshold_uncertainty_score":0.94455564},"labels":[],"label_agreement":null},{"id":"W4379282018","doi":"10.1200/jco.2023.41.16_suppl.6606","title":"The safety of seasonal influenza vaccination among patients prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke; McGill University; Western University; Public Health Ontario; Dalhousie University; University of Toronto","funders":"Canadian Immunization Research Network","keywords":"Medicine; Vaccination; Poisson regression; Adverse effect; Incidence (geometry); Rate ratio; Influenza vaccine; Seasonal influenza; Population; Internal medicine; Immunology; Confidence interval; Environmental health; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.14974235888975182,"score_gpt":0.47345569402657084,"score_spread":0.323713335136819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962617,0.00031783665,0.000008730827,0.0010116268,0.0011776334,0.0010642116,0.000025266878,0.000015269445,0.00011773713],"genre_scores_gemma":[0.99864036,0.00029467136,0.0003473174,0.00011885317,0.0005057604,0.000009004424,0.000009478579,0.00001523791,0.00005929163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939468,0.0010780172,0.0040494977,0.00020025927,0.0005131452,0.00021231585],"domain_scores_gemma":[0.9923184,0.002661847,0.0035881244,0.00037155743,0.000913327,0.00014674602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009334828,0.0001571613,0.0013646819,0.000110585934,0.00016478171,0.000020718226,0.0002543579,0.00021470265,0.00003837929],"category_scores_gemma":[0.0053105415,0.0000920452,0.00046789303,0.00034765044,0.00018449745,0.000341251,0.00015865224,0.00062756473,0.0000014377208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30015042,0.007703556,0.6094116,0.00007709279,0.006944234,0.0027035351,0.0029408718,0.000024601168,0.0005713654,0.000011198192,0.0011170136,0.06834454],"study_design_scores_gemma":[0.06600912,0.020632744,0.90172714,0.00013100171,0.0010010026,0.0006287885,0.0045932326,0.0007742401,0.00015649019,0.00003509867,0.0042000655,0.00011109569],"about_ca_topic_score_codex":0.00007966042,"about_ca_topic_score_gemma":0.00026268236,"teacher_disagreement_score":0.29231554,"about_ca_system_score_codex":0.00020406392,"about_ca_system_score_gemma":0.0017754085,"threshold_uncertainty_score":0.6357598},"labels":[],"label_agreement":null},{"id":"W4379282038","doi":"10.1200/jco.2023.41.16_suppl.8039","title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Discontinuation; Refractory (planetary science); Adverse effect; Gastroenterology; Surgery","score_opus":0.09237953159947176,"score_gpt":0.4317053603468726,"score_spread":0.33932582874740086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938338,0.00027632818,0.00014808562,0.0027552936,0.000912913,0.0017976784,0.00008360992,0.000028128092,0.00016415794],"genre_scores_gemma":[0.99509645,0.0010571242,0.0020876555,0.00023116697,0.0006813903,0.000040428193,0.00026836703,0.000037878337,0.00049953215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962096,0.0006003872,0.0016377519,0.0004104688,0.00075731735,0.0003844754],"domain_scores_gemma":[0.99243647,0.0049059563,0.0012062656,0.000346471,0.0006832333,0.00042162207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018370964,0.00024306879,0.0010413995,0.00018529635,0.00021169172,0.000055937202,0.00021164078,0.00030999153,0.00006234679],"category_scores_gemma":[0.0030219564,0.00013872908,0.00028648748,0.00029298416,0.00020790703,0.00025257815,0.00006791418,0.0007277912,0.000033773253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050446704,0.0069446363,0.75045127,0.000038936545,0.0007558214,0.000931644,0.00045998822,0.0000017187275,0.0008792615,0.000006982981,0.0070668412,0.18201621],"study_design_scores_gemma":[0.048601594,0.049902912,0.8835539,0.00007548386,0.0003303911,0.00003612927,0.00086626125,0.00046846663,0.0000960589,0.000084789266,0.015860518,0.00012349893],"about_ca_topic_score_codex":0.00008634424,"about_ca_topic_score_gemma":0.00058681733,"teacher_disagreement_score":0.18189271,"about_ca_system_score_codex":0.000108763896,"about_ca_system_score_gemma":0.0009963186,"threshold_uncertainty_score":0.5657208},"labels":[],"label_agreement":null},{"id":"W4379282039","doi":"10.1200/jco.2023.41.16_suppl.6050","title":"Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Western University; Jewish General Hospital; London Health Sciences Centre; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Tremelimumab; Clinical endpoint; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Phases of clinical research; Head and neck cancer; Adverse effect; Radiation therapy; Nivolumab; Clinical trial; Immunotherapy; Cancer; Ipilimumab","score_opus":0.23514552807841463,"score_gpt":0.5088777108746165,"score_spread":0.27373218279620193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876744,0.00201303,0.00006548383,0.008286347,0.0011310839,0.00067838124,0.000036231355,0.000008759493,0.000106267085],"genre_scores_gemma":[0.99199045,0.0038062378,0.0020131094,0.00077576993,0.000905247,0.00001112041,0.00000810426,0.000021482387,0.00046847307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629664,0.0003421037,0.0026311984,0.00021779163,0.00027999823,0.00023226927],"domain_scores_gemma":[0.99452895,0.0031829635,0.0016599126,0.00017519762,0.00022958353,0.00022341432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046244906,0.00015226331,0.0017322839,0.0002093344,0.00006999266,0.000009675191,0.00009302551,0.0001941342,0.000026165968],"category_scores_gemma":[0.002200938,0.00010776311,0.0004678059,0.00018771732,0.00031470117,0.000093980605,0.000027150112,0.00039207956,4.846327e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78466517,0.0026332615,0.0004120758,0.00010668425,0.0010021836,0.00021230767,0.00035997242,9.4778187e-7,0.0014241197,0.000015956844,0.004088131,0.2050792],"study_design_scores_gemma":[0.68773186,0.22707929,0.026178764,0.0001109744,0.00073682,0.00047955217,0.00015441852,0.0008015584,0.000100691934,0.00014373024,0.05637915,0.00010318172],"about_ca_topic_score_codex":0.00003947543,"about_ca_topic_score_gemma":0.000025712223,"teacher_disagreement_score":0.22444603,"about_ca_system_score_codex":0.000116225565,"about_ca_system_score_gemma":0.0013851288,"threshold_uncertainty_score":0.4394452},"labels":[],"label_agreement":null},{"id":"W4379282068","doi":"10.1200/jco.2023.41.16_suppl.e24003","title":"Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Juravinski Hospital","funders":"","keywords":"Modalities; Medicine; Coaching; Psychological intervention; MEDLINE; Inclusion (mineral); Patient education; Family medicine; Nursing; Psychology; Psychotherapist","score_opus":0.7892770475780096,"score_gpt":0.6988212050513154,"score_spread":0.09045584252669425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007408512,0.9637423,0.0000018909142,0.01920643,0.0037406322,0.011921576,0.000113165,0.000038610597,0.0004945459],"genre_scores_gemma":[0.00068025547,0.98030335,0.00033844367,0.013445691,0.00046949016,0.0044372934,0.00008490084,0.000107913154,0.00013264192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9732488,0.014972549,0.0103602335,0.00039511858,0.00050101755,0.0005222839],"domain_scores_gemma":[0.8984271,0.08236828,0.015960254,0.0015851054,0.0012479532,0.00041128055],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009436058,0.00051650207,0.0061638243,0.0003226087,0.0009623357,0.000020583002,0.0012592173,0.0012770285,0.000058506488],"category_scores_gemma":[0.031422257,0.00028234618,0.001709453,0.00033511422,0.00029396647,0.00013107213,0.0003399103,0.0050314637,0.000060912214],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015416864,0.0004858145,0.00019310284,0.026717277,0.000221768,0.0000023598102,0.0024122908,8.8779194e-7,1.457711e-9,0.00063864887,0.0067124465,0.96246123],"study_design_scores_gemma":[0.0008645199,0.0040472466,0.0006797561,0.43046778,0.0009750855,0.000016414899,0.0051891357,0.0000043711752,5.425258e-9,0.0005928329,0.5568944,0.00026844835],"about_ca_topic_score_codex":0.00010546269,"about_ca_topic_score_gemma":0.00012996954,"teacher_disagreement_score":0.9621928,"about_ca_system_score_codex":0.00094975886,"about_ca_system_score_gemma":0.019666603,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W4379282075","doi":"10.1200/jco.2023.41.16_suppl.5027","title":"AI-enabled analysis of H&amp;E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Metastasis; Prostatectomy; Oncology; Internal medicine; Androgen deprivation therapy; Cancer; Prostate; Placebo; Disease; Urology; Pathology","score_opus":0.11432942091504984,"score_gpt":0.5153988634597378,"score_spread":0.401069442544688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051356,0.0007304546,0.000471478,0.0039446,0.00028016954,0.0025666705,0.001447973,0.0000142522795,0.000030828996],"genre_scores_gemma":[0.983153,0.0038493655,0.01051721,0.0001877223,0.00017762174,0.00042556855,0.00019248539,0.000058979713,0.0014380488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460745,0.00046406258,0.0029795298,0.00045700502,0.0008914606,0.00060048676],"domain_scores_gemma":[0.9909219,0.002073192,0.003141423,0.00035620388,0.0029700582,0.00053722254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022639043,0.0003395851,0.0031855903,0.0010298413,0.00013146052,0.000034251058,0.00017062151,0.00014833387,0.00012189845],"category_scores_gemma":[0.001208963,0.0002030908,0.00081831426,0.0020324118,0.00029065894,0.00025273158,0.000043992335,0.00034737313,0.0000029439032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07237062,0.0058418377,0.56507385,0.00080673833,0.03219397,0.00036021456,0.003091405,0.010385724,0.0049064816,0.0000045753845,0.0017304908,0.3032341],"study_design_scores_gemma":[0.038504954,0.044912465,0.867841,0.000538255,0.029165609,0.0000042069705,0.0011737535,0.000840301,0.0057184245,0.00008308288,0.010894974,0.0003229594],"about_ca_topic_score_codex":0.00092852756,"about_ca_topic_score_gemma":0.001748396,"teacher_disagreement_score":0.30291113,"about_ca_system_score_codex":0.0008080582,"about_ca_system_score_gemma":0.004921697,"threshold_uncertainty_score":0.8730879},"labels":[],"label_agreement":null},{"id":"W4379282095","doi":"10.1200/jco.2023.41.16_suppl.e15094","title":"A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Neutropenia; Pharmacology; Cancer; Lymphoma; Pharmacokinetics; Refractory (planetary science); Toxicity; Internal medicine; Cancer research; Oncology; Biology","score_opus":0.08867594655244497,"score_gpt":0.4542369393706819,"score_spread":0.3655609928182369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978302,0.000031941116,0.0000031168308,0.00088066247,0.00019362541,0.00043677105,0.000013361465,0.000010188918,0.0006001318],"genre_scores_gemma":[0.9978935,0.00012889026,0.0006085148,0.00068519224,0.0002865575,0.000009565311,0.000042833813,0.000024051245,0.0003208785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953041,0.0005121423,0.0031160726,0.0003099581,0.00046280696,0.00029491485],"domain_scores_gemma":[0.99627984,0.00068241195,0.002002727,0.00023663374,0.00036211713,0.00043624637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029703004,0.00018812192,0.002122918,0.00052371563,0.000047805937,0.000015850259,0.00020521277,0.00030893154,0.00012439083],"category_scores_gemma":[0.0014463678,0.00012791042,0.00014501304,0.0005288632,0.0002544358,0.00040677443,0.000111222886,0.0008003784,0.000008088498],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59336424,0.15639223,0.14113164,0.00022777583,0.00033678347,0.004729876,0.0006212679,0.00011084493,0.0030820007,0.000050909417,0.0060976758,0.09385478],"study_design_scores_gemma":[0.79824066,0.11480388,0.079334036,0.0008785876,0.00020995135,0.000024716484,0.00026877364,0.00032966162,0.00017266866,0.00016071308,0.005374391,0.00020193361],"about_ca_topic_score_codex":0.0000505968,"about_ca_topic_score_gemma":0.00036628122,"teacher_disagreement_score":0.20487647,"about_ca_system_score_codex":0.00016127649,"about_ca_system_score_gemma":0.00097417436,"threshold_uncertainty_score":0.5216036},"labels":[],"label_agreement":null},{"id":"W4379282151","doi":"10.1200/jco.2023.41.16_suppl.e17001","title":"Circulating levels of PCSK9, ANGPTL3, and other lipid-related factors in men with high-grade prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute; Université Laval","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Internal medicine; PCSK9; Oncology; Leptin; Prostate; Cohort; Metastasis; Endocrinology; Cholesterol; Obesity; Lipoprotein; LDL receptor","score_opus":0.0708109451932615,"score_gpt":0.4019586233540388,"score_spread":0.3311476781607773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959362,0.00074324926,0.000011045899,0.0006590989,0.002192194,0.00012619933,0.000028770737,0.000004318558,0.00029890778],"genre_scores_gemma":[0.99523133,0.0012672858,0.00023307864,0.00022056201,0.0026861995,0.0000040025,0.0000037157492,0.000021258682,0.0003325495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979738,0.0002453017,0.001202152,0.00020073564,0.00015839176,0.00021962586],"domain_scores_gemma":[0.9983549,0.00022573496,0.0010263534,0.00012399656,0.0001297316,0.00013924629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001342161,0.0001253221,0.000762707,0.00010082817,0.000023591316,0.000005629827,0.00012645671,0.00031362576,0.000024401139],"category_scores_gemma":[0.0005135899,0.000088875975,0.00013497015,0.00019014713,0.00019891476,0.00000837731,0.000057644873,0.00033946402,6.8622563e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018550516,0.00048379262,0.73956597,0.00008505401,0.0007796782,0.000017695369,0.0011303376,0.0019995673,0.17971608,0.00013389644,0.007983484,0.06624937],"study_design_scores_gemma":[0.0073892595,0.0028200508,0.81026465,0.00010841604,0.00011975123,0.000049280567,0.00051876134,0.00008636168,0.0041086706,0.00020113343,0.17413476,0.00019889658],"about_ca_topic_score_codex":0.00022012423,"about_ca_topic_score_gemma":0.00045981116,"teacher_disagreement_score":0.17560741,"about_ca_system_score_codex":0.00002394135,"about_ca_system_score_gemma":0.00062167115,"threshold_uncertainty_score":0.3624257},"labels":[],"label_agreement":null},{"id":"W4379282163","doi":"10.1200/jco.2023.41.16_suppl.11509","title":"Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"Natera; Conquer Cancer Foundation","keywords":"Medicine; Circulating tumor DNA; Internal medicine; Oncology; Adjuvant; Minimal residual disease; Population; Cancer; Clinical endpoint; Sarcoma; Gastroenterology; Pathology; Clinical trial; Leukemia","score_opus":0.06661750532639654,"score_gpt":0.4166488437109175,"score_spread":0.35003133838452094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355805,0.00069768715,0.0036050582,0.00072163873,0.0010930939,0.00015547006,0.0000137285915,0.000008535909,0.00014671173],"genre_scores_gemma":[0.9962801,0.00028473936,0.0011088569,0.0009498465,0.0012959196,0.000004709622,0.000015187372,0.00003588572,0.000024777375],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99698627,0.00047132073,0.0016069728,0.00032276462,0.00026079494,0.000351887],"domain_scores_gemma":[0.9976226,0.0005864985,0.0009600743,0.00025658778,0.00022214692,0.0003521036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002433099,0.00017211564,0.000675669,0.00016966692,0.000062852305,0.00002468468,0.000242928,0.0003277449,0.000014856442],"category_scores_gemma":[0.0066888044,0.00016911201,0.00030299023,0.00024390893,0.00013607083,0.000009633935,0.0001805225,0.00047578517,0.000009933276],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047797696,0.0009369367,0.05097211,0.0000788842,0.00030712073,0.0061055445,0.00006471999,0.035836924,0.7853462,0.00013486973,0.0010502577,0.11438663],"study_design_scores_gemma":[0.037004106,0.021273915,0.443964,0.0005685326,0.001294581,0.0013920688,0.0007333497,0.051947393,0.16987075,0.010531503,0.2590809,0.002338918],"about_ca_topic_score_codex":0.00004999714,"about_ca_topic_score_gemma":0.0001855943,"teacher_disagreement_score":0.6154755,"about_ca_system_score_codex":0.00011854135,"about_ca_system_score_gemma":0.0013504733,"threshold_uncertainty_score":0.8007607},"labels":[],"label_agreement":null},{"id":"W4379282230","doi":"10.1200/jco.2023.41.16_suppl.4055","title":"Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastro-esophageal adenocarcinoma: A phase II trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Adenocarcinoma; Docetaxel; Perioperative; Gastroenterology; Clinical endpoint; Chemotherapy; Esophageal cancer; Surgery; Cancer; Oncology; Clinical trial","score_opus":0.10153319328979075,"score_gpt":0.47926730085487845,"score_spread":0.3777341075650877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262954,0.0006957051,0.00018404791,0.012189559,0.0018560619,0.0006622689,0.0000025174058,0.00002791966,0.001752386],"genre_scores_gemma":[0.98670655,0.0014112431,0.0022109398,0.003157233,0.0014954593,0.00002031591,0.00000677068,0.000028396496,0.004963105],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958391,0.00033490488,0.0027046818,0.0002704599,0.00044416037,0.0004066631],"domain_scores_gemma":[0.9971979,0.00088464946,0.0011229023,0.00023581772,0.0002763288,0.00028240218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033148518,0.00020390745,0.0019047958,0.0004066279,0.00006696131,0.000013846447,0.0002521109,0.00025722664,0.00038891725],"category_scores_gemma":[0.0019300189,0.00015353873,0.00060488854,0.00060075463,0.00018653597,0.00016717287,0.00010575541,0.0011680885,0.00004379044],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30440572,0.0067988886,0.03765937,0.000050632792,0.00070735835,0.0059240633,0.0012116209,0.00009321031,0.0005500031,0.00019382492,0.009854785,0.63255054],"study_design_scores_gemma":[0.56850934,0.112929456,0.25000393,0.00014872751,0.00026238264,0.0001706722,0.0010943683,0.00043694212,0.000064146676,0.00012182904,0.06607811,0.00018012473],"about_ca_topic_score_codex":0.000012336234,"about_ca_topic_score_gemma":0.000025590134,"teacher_disagreement_score":0.6323704,"about_ca_system_score_codex":0.00026139847,"about_ca_system_score_gemma":0.0014397388,"threshold_uncertainty_score":0.62611276},"labels":[],"label_agreement":null},{"id":"W4379282232","doi":"10.1200/jco.2023.41.16_suppl.5533","title":"Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Saskatchewan Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Radiation therapy; Clinical endpoint; Cervical cancer; Sexual function; Internal medicine; Logistic regression; Repeated measures design; Clinical trial; Oncology; Cancer","score_opus":0.1096764400448195,"score_gpt":0.4374613537497762,"score_spread":0.32778491370495666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930373,0.00033893134,0.000019293722,0.0035251286,0.0020280215,0.0001784274,0.000013841519,0.00003820665,0.0008208625],"genre_scores_gemma":[0.99521524,0.00055436353,0.00008388432,0.0024473527,0.0011728321,0.000007631131,0.000063477906,0.00001660359,0.00043862354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965859,0.0003818721,0.0019655675,0.00026909893,0.0005802662,0.00021727588],"domain_scores_gemma":[0.9950803,0.0024074134,0.0017159614,0.00022555808,0.00024420346,0.00032656503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010901182,0.00016144032,0.0015983556,0.0006038366,0.0000623931,0.000011561478,0.00007524347,0.00031729083,0.0009574298],"category_scores_gemma":[0.002228956,0.000103839004,0.0008180724,0.0011440481,0.00005001564,0.000106384556,0.000028391243,0.00073140627,0.00008550711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011675986,0.0010940186,0.5791443,0.0000069150233,0.0072353287,0.0005853476,0.000107533386,0.00006904071,0.00019213384,0.0000028469176,0.0006469716,0.3992396],"study_design_scores_gemma":[0.020769183,0.01306513,0.9552475,0.00001332679,0.002377865,0.000014653975,0.00016558554,0.00005324799,0.00009493672,0.00014921432,0.00796462,0.00008473589],"about_ca_topic_score_codex":0.00011458879,"about_ca_topic_score_gemma":0.00005307276,"teacher_disagreement_score":0.39915487,"about_ca_system_score_codex":0.00022839855,"about_ca_system_score_gemma":0.0005133423,"threshold_uncertainty_score":0.99995583},"labels":[],"label_agreement":null},{"id":"W4379282237","doi":"10.1200/jco.2023.41.16_suppl.6091","title":"Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Trk receptor; Internal medicine; Thyroid cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Gastroenterology; Progressive disease; Disease; Neurotrophin; Receptor","score_opus":0.05328036846583633,"score_gpt":0.3944418620765917,"score_spread":0.3411614936107554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99158734,0.0007981787,0.0000030479027,0.00576832,0.00078463176,0.00052871037,0.000008892189,0.000018962482,0.00050194183],"genre_scores_gemma":[0.9947722,0.0034112092,0.00032363905,0.00061580184,0.0005802087,0.000013881564,0.000021370359,0.000029876563,0.00023183798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967627,0.00041441896,0.0017255429,0.00033279904,0.0004232783,0.00034125624],"domain_scores_gemma":[0.9965151,0.0015560758,0.000975713,0.00022765758,0.00025752073,0.00046794422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014237141,0.00021409987,0.0014055326,0.0002437162,0.00006188455,0.00001248345,0.0001152463,0.00031133922,0.00013399041],"category_scores_gemma":[0.00095061306,0.0001380317,0.00023102139,0.000352316,0.00016730967,0.00010217889,0.00008240554,0.00082785916,0.000039476996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014436056,0.0038083033,0.8103894,0.000031631203,0.00015962946,0.00097199297,0.0001392351,0.000005137321,0.00005910628,0.0000098032715,0.002523274,0.16746643],"study_design_scores_gemma":[0.048018884,0.036106374,0.90715766,0.0002964424,0.00023973273,0.00006898168,0.00005657739,0.0000059425324,0.00011755867,0.00001214067,0.007799113,0.000120593235],"about_ca_topic_score_codex":0.00004080375,"about_ca_topic_score_gemma":0.00021136715,"teacher_disagreement_score":0.16734584,"about_ca_system_score_codex":0.0003652797,"about_ca_system_score_gemma":0.00064873684,"threshold_uncertainty_score":0.5628769},"labels":[],"label_agreement":null},{"id":"W4379282239","doi":"10.1200/jco.2023.41.16_suppl.tps5116","title":"PSMAddition: A phase 3 trial to compare treatment with <sup>177</sup>Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Oncology; Internal medicine; Enzalutamide; Urology; Cancer; Randomized controlled trial; Androgen receptor","score_opus":0.11165875529990572,"score_gpt":0.47914637269810373,"score_spread":0.367487617398198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322164,0.00066442764,0.000011753641,0.0033224532,0.0001175599,0.0019719924,0.00057569944,0.0000114273635,0.00010303804],"genre_scores_gemma":[0.9965178,0.0018096368,0.00084322836,0.00017032966,0.00025304407,0.00009795733,0.00014058602,0.000028053539,0.00013940273],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968361,0.00038308714,0.00137925,0.00030651386,0.00071334705,0.0003816519],"domain_scores_gemma":[0.996572,0.0008998337,0.00080280023,0.00016575992,0.0010551555,0.00050443655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007783045,0.00023749952,0.0023211557,0.00030093838,0.00006507449,0.000013461717,0.00007490352,0.00009419854,0.000035268295],"category_scores_gemma":[0.00025679174,0.0001332351,0.00017545697,0.0004683158,0.00035339216,0.00011400015,0.000043296805,0.00046471157,0.0000034460782],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86568826,0.0026514118,0.034610182,0.000117404335,0.0015214831,0.0025210427,0.0057287845,0.00036350611,0.000010118457,0.000003817651,0.0016516838,0.08513227],"study_design_scores_gemma":[0.5805897,0.336958,0.06970036,0.00061509246,0.0011524641,0.000045875826,0.0070550027,0.00013621344,0.0001937425,0.000025939706,0.0033408161,0.00018680446],"about_ca_topic_score_codex":0.00013501565,"about_ca_topic_score_gemma":0.0005984125,"teacher_disagreement_score":0.33430657,"about_ca_system_score_codex":0.00095444935,"about_ca_system_score_gemma":0.0034411214,"threshold_uncertainty_score":0.6104402},"labels":[],"label_agreement":null},{"id":"W4379282240","doi":"10.1200/jco.2023.41.16_suppl.5096","title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): Updated individual patient data meta-analyses from the MARCAP consortium.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; McGill University Health Centre; University of Ottawa; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Androgen; Randomized controlled trial; Radiation therapy; Urology; Prostate; Internal medicine; Cancer; Hormone","score_opus":0.4338375755924066,"score_gpt":0.5274865139207717,"score_spread":0.09364893832836513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96763694,0.011077559,0.000017861115,0.019757943,0.00061673945,0.00045176997,0.0003496418,0.00001736879,0.0000741811],"genre_scores_gemma":[0.9816887,0.011709484,0.0021340828,0.0026164455,0.0004878517,0.000013730528,0.0008272304,0.000033881348,0.0004885945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621147,0.00078893447,0.001737471,0.00033305408,0.00063989626,0.00028919757],"domain_scores_gemma":[0.9947808,0.0033618324,0.00091430196,0.00048208397,0.0001546784,0.00030633432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003698362,0.0001738632,0.0016121692,0.00011730147,0.00010070355,0.000026331132,0.00031098034,0.00021886305,0.00028310332],"category_scores_gemma":[0.0009889466,0.000080407895,0.0005136145,0.00026077684,0.0002500415,0.0002375348,0.00017005486,0.0007532781,0.0000073931633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021432307,0.0017748085,0.44948474,0.00004133872,0.07890999,0.0076230518,0.0012247172,0.000045217104,0.005772286,0.0000027388755,0.1464197,0.28726912],"study_design_scores_gemma":[0.02976274,0.020912481,0.65490204,0.0002182316,0.039680112,0.00031469698,0.0010710747,0.00035251534,0.0022168406,0.00071920065,0.24949993,0.00035012641],"about_ca_topic_score_codex":0.00007684601,"about_ca_topic_score_gemma":0.00003645185,"teacher_disagreement_score":0.28691897,"about_ca_system_score_codex":0.0000470899,"about_ca_system_score_gemma":0.00093952083,"threshold_uncertainty_score":0.32789388},"labels":[],"label_agreement":null},{"id":"W4379282252","doi":"10.1200/jco.2023.41.16_suppl.e21118","title":"An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Afatinib; Osimertinib; Gefitinib; Erlotinib; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Hazard ratio; Confidence interval; Proportional hazards model; Clinical endpoint; Performance status; Clinical trial; Cancer","score_opus":0.19225506038499515,"score_gpt":0.485844825525819,"score_spread":0.2935897651408238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957583,0.00067266735,0.00013081235,0.0016959645,0.00031700838,0.0003709279,0.0007991912,0.000020737974,0.00023441142],"genre_scores_gemma":[0.9933016,0.00029412206,0.0049550603,0.0006097787,0.00031388254,0.000043443808,0.00018533973,0.000031255597,0.00026554763],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957719,0.00053413934,0.0024291573,0.0003160544,0.00062851794,0.0003202441],"domain_scores_gemma":[0.9943091,0.0014106245,0.002580137,0.00023562311,0.0009524697,0.0005120191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011584994,0.00025443156,0.0033825007,0.00072259764,0.00006765787,0.000015237501,0.00017213174,0.00025342562,0.0008941578],"category_scores_gemma":[0.00039544096,0.00014648272,0.0016290344,0.0012259391,0.00016581843,0.00020269603,0.00004190138,0.00051706005,0.0000053149183],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002635869,0.004093866,0.5436153,0.000083052255,0.4176132,0.00055085705,0.0018218323,0.00090963294,0.00080419914,0.000009114284,0.0067648804,0.021098178],"study_design_scores_gemma":[0.008220284,0.01717557,0.38300517,0.00003249249,0.58497113,0.000024926938,0.00074568787,0.00034544192,0.003293834,0.000004886492,0.0019675693,0.00021298556],"about_ca_topic_score_codex":0.00047019363,"about_ca_topic_score_gemma":0.0002300065,"teacher_disagreement_score":0.16735794,"about_ca_system_score_codex":0.00017913544,"about_ca_system_score_gemma":0.0019150053,"threshold_uncertainty_score":0.9790401},"labels":[],"label_agreement":null},{"id":"W4379282258","doi":"10.1200/jco.2023.41.16_suppl.e16516","title":"Characteristics and outcomes of 795 patients with renal cell cancer following hospitalization for acute myocardial infarction.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Myocardial infarction; Internal medicine; Percutaneous coronary intervention; Odds ratio; Cardiology; Conventional PCI; Population; Cancer; Surgery","score_opus":0.044379127709354906,"score_gpt":0.4195478630284488,"score_spread":0.3751687353190939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649084,0.000042572377,0.0002563116,0.0012960039,0.0015105401,0.00022075298,0.000039754977,0.0000057538164,0.00013749438],"genre_scores_gemma":[0.9958406,0.000835216,0.0012717197,0.0013535691,0.00044451212,0.000007437178,0.00003555245,0.000014525314,0.00019685684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984304,0.00005766432,0.0010685931,0.00010578586,0.0002149446,0.00012261195],"domain_scores_gemma":[0.9978124,0.00064047193,0.0009955048,0.0000715126,0.00034364386,0.0001364664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006331459,0.00008164578,0.00096467213,0.000095552066,0.000031051848,0.0000042311835,0.00004741403,0.00015018479,0.000022001863],"category_scores_gemma":[0.0005570166,0.000054677497,0.00026772034,0.000095193864,0.00006832173,0.00010690619,0.000020425457,0.00021852211,6.6548887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024577728,0.00017267444,0.9610243,0.000032150678,0.00096476136,0.000022670294,0.000089327514,0.000010253243,0.000095914096,0.0000048695424,0.0017058881,0.033419427],"study_design_scores_gemma":[0.009806618,0.0061605936,0.9705302,0.000038619735,0.00097501057,0.000002703671,0.000024527024,0.00009870619,0.000029399347,0.000019560955,0.012257265,0.00005678991],"about_ca_topic_score_codex":0.000007433846,"about_ca_topic_score_gemma":0.00000524626,"teacher_disagreement_score":0.03336264,"about_ca_system_score_codex":0.00006905875,"about_ca_system_score_gemma":0.0007157265,"threshold_uncertainty_score":0.22296835},"labels":[],"label_agreement":null},{"id":"W4379282265","doi":"10.1200/jco.2023.41.16_suppl.3561","title":"Determinants of permanent liver limited disease (pLLD) in metastatic colorectal cancer (mCRC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Disease; Metastasis; Multivariate analysis; Oncology; Logistic regression; Univariate analysis; Imputation (statistics); Liver disease; Cancer; Gastroenterology; Surgery; Missing data","score_opus":0.28562823900125967,"score_gpt":0.4619672177052568,"score_spread":0.17633897870399712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609,0.0012162683,0.0000013519794,0.0017012461,0.0005277232,0.0002682422,0.000013014695,0.000008316384,0.0001738562],"genre_scores_gemma":[0.99592364,0.0030047572,0.000279912,0.0003229354,0.0002480796,0.000016379323,0.0000063304983,0.000014937906,0.00018301999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970519,0.0004405259,0.0018076989,0.00014990992,0.00031999534,0.0002299545],"domain_scores_gemma":[0.99679714,0.0015528485,0.0008998864,0.00010795529,0.00022835124,0.00041383915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017440878,0.00012117821,0.0012973628,0.0002709604,0.000017093393,0.0000031977693,0.0001064863,0.00014226638,0.00023077523],"category_scores_gemma":[0.0016770866,0.00008449533,0.00050750765,0.00032611945,0.00014122651,0.00006725977,0.000046450885,0.00041350527,0.00003822276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003561735,0.0012818886,0.91099,0.00009264167,0.00018972423,0.011723402,0.00015572699,0.0000053077006,0.00014811421,0.0000056093136,0.0007620893,0.071083784],"study_design_scores_gemma":[0.0057954644,0.0048281145,0.9801228,0.00020685013,0.000841814,0.00008481427,0.00006681546,0.0042650006,0.00036617866,0.00006224106,0.0032860942,0.00007380731],"about_ca_topic_score_codex":0.0000696271,"about_ca_topic_score_gemma":0.00019169149,"teacher_disagreement_score":0.07100998,"about_ca_system_score_codex":0.00010975206,"about_ca_system_score_gemma":0.00136684,"threshold_uncertainty_score":0.34456196},"labels":[],"label_agreement":null},{"id":"W4379282289","doi":"10.1200/jco.2023.41.16_suppl.4132","title":"ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Initial safety analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Nuclear medicine; Adverse effect; Internal medicine; Somatostatin receptor 2; Somatostatin receptor; Somatostatin; Radionuclide therapy; Toxicity; Pharmacokinetics; Gastroenterology; Oncology; Pharmacology; Urology","score_opus":0.1190048836507754,"score_gpt":0.4956917116793705,"score_spread":0.3766868280285951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941475,0.00022134726,0.00009899463,0.0036545123,0.00054980797,0.0010409391,0.000070128146,0.000062413535,0.0001543595],"genre_scores_gemma":[0.9932307,0.0013876655,0.0032714722,0.0005236213,0.0012349653,0.000059605656,0.00008797844,0.0000850888,0.00011891146],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9876497,0.0031068265,0.006082822,0.000655488,0.001404638,0.0011005239],"domain_scores_gemma":[0.98963535,0.0046782657,0.003694556,0.00054857857,0.00064101786,0.00080223905],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029113488,0.000478416,0.003922831,0.0017332471,0.000105736704,0.000059941092,0.00046069862,0.00008219595,0.00041844224],"category_scores_gemma":[0.009610389,0.00037949646,0.0011758292,0.0020807085,0.00073661853,0.0005800776,0.00019635666,0.002265413,0.000028218024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5116776,0.009312959,0.32316947,0.00034616937,0.001994664,0.044117175,0.00038810886,0.0015535866,0.0031545465,0.00000973182,0.0019621146,0.102313876],"study_design_scores_gemma":[0.56973755,0.12858865,0.24348253,0.0023798128,0.0029579161,0.006667673,0.0046336013,0.013881949,0.0076896884,0.00039867504,0.018540898,0.00104105],"about_ca_topic_score_codex":0.000048871363,"about_ca_topic_score_gemma":0.00008399321,"teacher_disagreement_score":0.11927569,"about_ca_system_score_codex":0.0002336324,"about_ca_system_score_gemma":0.001909693,"threshold_uncertainty_score":0.9998657},"labels":[],"label_agreement":null},{"id":"W4379282320","doi":"10.1200/jco.2023.41.16_suppl.e16243","title":"Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Staining; Immunohistochemistry; Tissue microarray; Pathology; Neuroendocrine tumors; Medicine; Stomach; Duodenum; Internal medicine; Biology; Gastroenterology","score_opus":0.12494599352825986,"score_gpt":0.4598218344127951,"score_spread":0.33487584088453526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929316,0.000108669396,0.000318144,0.0046240096,0.0004206955,0.0004781494,0.0000046234445,0.000094075476,0.0010200359],"genre_scores_gemma":[0.9737021,0.00032462893,0.023444952,0.00101092,0.00092783023,0.000018541763,0.000010519583,0.00006747472,0.0004930631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99193627,0.0013682023,0.0042061573,0.0005903371,0.00092002115,0.0009790369],"domain_scores_gemma":[0.9872616,0.008246644,0.0027478565,0.00041895788,0.0005351371,0.0007897858],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0041523906,0.00035231202,0.0022414844,0.00065572443,0.00009999544,0.000025578202,0.00041532432,0.00004146438,0.00015507724],"category_scores_gemma":[0.034053203,0.00023791772,0.00037251142,0.0009905675,0.00040104505,0.00035885588,0.00032076836,0.0034631644,0.000068709225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008895053,0.0012989199,0.74376684,0.00010818151,0.000030727377,0.22279839,0.00002653456,0.0030884324,0.007451865,0.000016116319,0.0024901433,0.010028776],"study_design_scores_gemma":[0.030819865,0.08410006,0.73051476,0.004274639,0.00018041824,0.13122518,0.0015745198,0.01027253,0.0018920539,0.0005535002,0.004126794,0.00046566376],"about_ca_topic_score_codex":0.000028347007,"about_ca_topic_score_gemma":0.000038447935,"teacher_disagreement_score":0.09157321,"about_ca_system_score_codex":0.00014118022,"about_ca_system_score_gemma":0.0014184082,"threshold_uncertainty_score":0.99883586},"labels":[],"label_agreement":null},{"id":"W4379282338","doi":"10.1200/jco.2023.41.16_suppl.e17111","title":"Biochemical recurrence (BCR) among patients (pts) with prostate cancer (PC) after radiation therapy (RT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Androgen deprivation therapy; Internal medicine; Radiation therapy; Oncology; breakpoint cluster region; Prostate-specific antigen; Cohort; Retrospective cohort study; Urology; Cancer; Prostatectomy","score_opus":0.0962726000690626,"score_gpt":0.47961277484898784,"score_spread":0.3833401747799252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915533,0.0015447832,0.0000030627225,0.005357233,0.0007415478,0.00042362665,0.000013239476,0.000016506287,0.00034668934],"genre_scores_gemma":[0.97878486,0.018824175,0.00011753204,0.0006440977,0.00072911865,0.000057443922,0.00002125933,0.000019753103,0.00080173474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977285,0.00020964403,0.0010195446,0.00021184213,0.00051588315,0.0003145691],"domain_scores_gemma":[0.99765414,0.0005537547,0.00068342796,0.00013897697,0.0006002765,0.00036941134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011826333,0.00013129026,0.0007221947,0.00015430128,0.00003659577,0.0000118684275,0.00011030652,0.00023757557,0.00017028062],"category_scores_gemma":[0.0005752362,0.00007302083,0.00020153356,0.00037095085,0.00030303677,0.00013664647,0.000033384706,0.00076788454,0.000033613644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016935777,0.0007357682,0.724632,0.00002085907,0.0002365987,0.0003013861,0.00017757263,0.0000030291892,0.000048278038,0.0000011526391,0.011032164,0.24587539],"study_design_scores_gemma":[0.0148786465,0.011100807,0.9336455,0.00019069,0.00009403092,0.0000118766875,0.00003401665,0.000045183016,0.00062053243,0.00006343187,0.039227046,0.000088265646],"about_ca_topic_score_codex":0.00002518975,"about_ca_topic_score_gemma":0.000014156099,"teacher_disagreement_score":0.24578711,"about_ca_system_score_codex":0.00023232476,"about_ca_system_score_gemma":0.0014134418,"threshold_uncertainty_score":0.3336119},"labels":[],"label_agreement":null},{"id":"W4379282347","doi":"10.1200/jco.2023.41.16_suppl.3545","title":"Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bausch Health (Canada); Hôpital du Sacré-Cœur de Montréal; Jewish General Hospital; Juravinski Cancer Centre; Hôpital Charles-Le Moyne; St. John’s Health Sciences Centre; BC Cancer Agency; Hôtel-Dieu de Québec; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; Dalhousie University; Moncton Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Biomarker; Immune system; Colorectal cancer; Post-hoc analysis; Proportional hazards model; Cancer; Gastroenterology; Cancer research; Immunology; Confidence interval; Biology","score_opus":0.10498592062238005,"score_gpt":0.47535596303189404,"score_spread":0.370370042409514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805147,0.00018428531,0.000052703523,0.016555805,0.0012061811,0.0012499355,0.00013097528,0.000012099239,0.0000933385],"genre_scores_gemma":[0.99796504,0.0004821087,0.00019520405,0.0006913541,0.00019364615,0.00012502827,0.000012910379,0.000023366585,0.00031135464],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99451715,0.0011366273,0.0033730438,0.00023714534,0.00044885595,0.00028716185],"domain_scores_gemma":[0.9920141,0.005006269,0.0021615103,0.00020902306,0.00042665828,0.00018244227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011982158,0.00016604505,0.00196994,0.0008741702,0.000049215843,0.000007868795,0.00017097284,0.00023832973,0.00019536975],"category_scores_gemma":[0.007618218,0.00010344303,0.0013894545,0.0021919124,0.00028212456,0.000069078844,0.00005250136,0.00047135566,0.000004746796],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89279974,0.0010587631,0.0064359903,0.00003042371,0.006157075,0.00012832879,0.0006871297,0.00028614,0.07851603,0.0000036028437,0.0016093164,0.012287451],"study_design_scores_gemma":[0.14265807,0.03128079,0.7909899,0.00034611745,0.004213668,0.000058825815,0.00082001387,0.0027607314,0.014265842,0.00009058256,0.012364663,0.00015081394],"about_ca_topic_score_codex":0.00038460412,"about_ca_topic_score_gemma":0.0011922038,"teacher_disagreement_score":0.7845539,"about_ca_system_score_codex":0.00047191896,"about_ca_system_score_gemma":0.0027901945,"threshold_uncertainty_score":0.9120269},"labels":[],"label_agreement":null},{"id":"W4379282394","doi":"10.1200/jco.2023.41.16_suppl.tps3634","title":"Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Irinotecan; Internal medicine; Oxaliplatin; Oncology; Cohort; Regimen; Randomized controlled trial; Clinical endpoint; Prospective cohort study; Chemotherapy; Stage (stratigraphy); Adjuvant; Colorectal cancer; Cancer; Surgery","score_opus":0.11318594279038119,"score_gpt":0.46510485792373196,"score_spread":0.3519189151333508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945571,0.00041592238,0.000098124015,0.0029282332,0.0010441988,0.00018473633,0.000029821203,0.000003758702,0.00073810935],"genre_scores_gemma":[0.99505544,0.0011243279,0.00026144917,0.0023051775,0.0011146,0.0000063251105,0.000046373843,0.000019553794,0.00006677324],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99748594,0.00045057165,0.0012142382,0.00020918778,0.00046455063,0.00017552968],"domain_scores_gemma":[0.9971596,0.0006561769,0.0010579622,0.0002738624,0.0006182547,0.00023413295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004812437,0.000114314156,0.00053555693,0.000092501854,0.000030622617,0.000006837108,0.00020571647,0.00027866446,0.000067849396],"category_scores_gemma":[0.004998033,0.00009687675,0.00034384243,0.00012081017,0.00013051966,0.0000032160424,0.000042594544,0.00023135771,0.000012548748],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034506388,0.005333044,0.16745664,0.00011007484,0.00091867906,0.00030503966,0.00008611651,0.14908439,0.053428743,0.00029158156,0.1534353,0.435044],"study_design_scores_gemma":[0.014716675,0.013716286,0.788009,0.00007879716,0.00045020116,0.000009110948,0.000036779726,0.013825316,0.0064083315,0.0011247024,0.16137193,0.00025285524],"about_ca_topic_score_codex":0.000006654702,"about_ca_topic_score_gemma":0.000029338167,"teacher_disagreement_score":0.62055236,"about_ca_system_score_codex":0.00006576705,"about_ca_system_score_gemma":0.0026693621,"threshold_uncertainty_score":0.5983473},"labels":[],"label_agreement":null},{"id":"W4379282451","doi":"10.1200/jco.2023.41.16_suppl.5033","title":"Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Jewish General Hospital; Université de Sherbrooke; Université Laval","funders":"Cancer Research Society","keywords":"Medicine; Prostate cancer; Nuclear medicine; Imaging biomarker; Positron emission tomography; Lesion; Pet imaging; Biopsy; Radiology; Target lesion; Cancer; Internal medicine; Magnetic resonance imaging; Pathology","score_opus":0.1359790741629398,"score_gpt":0.5024908946381167,"score_spread":0.3665118204751769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938181,0.00012189018,0.000010120953,0.004174371,0.000817229,0.00078207254,0.000013845623,0.000006395928,0.00025595335],"genre_scores_gemma":[0.9986169,0.00026424322,0.0001354948,0.00071942765,0.00009982335,0.000020816638,0.0000036060856,0.000013222548,0.00012651592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577,0.0011490504,0.0019536263,0.00020465678,0.0006542309,0.0002684819],"domain_scores_gemma":[0.9954301,0.002730351,0.0009777357,0.0002643607,0.00040163274,0.00019579454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037968901,0.00013160497,0.00088064204,0.00028178538,0.000032116997,0.000006788543,0.00022959715,0.00005426961,0.00009621202],"category_scores_gemma":[0.0034947363,0.000069467635,0.000312655,0.00036017617,0.00024409876,0.00006396853,0.00007793259,0.0008608609,0.000017279555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078336755,0.0077244686,0.9089874,0.00010054906,0.00016862301,0.0009649245,0.00033902147,0.00007280205,0.000026190157,0.0000015626051,0.0016071761,0.07217361],"study_design_scores_gemma":[0.015674677,0.029370744,0.9512074,0.00023230167,0.0001983563,0.000019754409,0.00039920126,0.0013936537,0.0001833193,0.00005218652,0.0012076326,0.000060795242],"about_ca_topic_score_codex":0.0000148891895,"about_ca_topic_score_gemma":0.000023865683,"teacher_disagreement_score":0.07211281,"about_ca_system_score_codex":0.0002088157,"about_ca_system_score_gemma":0.0008687545,"threshold_uncertainty_score":0.41837782},"labels":[],"label_agreement":null},{"id":"W4379282452","doi":"10.1200/jco.2023.41.16_suppl.tps10067","title":"LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating <i>RAF</i> alteration.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Regimen; Tolerability; Internal medicine; Chemotherapy regimen; Lomustine; Glioma; Chemotherapy; Oncology; Interim analysis; Progression-free survival; Randomized controlled trial; Hazard ratio; Bedaquiline; Adverse effect; Surgery; Vincristine; Pathology; Cancer research; Confidence interval","score_opus":0.04503749390740588,"score_gpt":0.40923877696052147,"score_spread":0.3642012830531156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601936,0.0001000849,0.000028964874,0.001988607,0.00063637935,0.0011559218,0.000004791996,0.000015910962,0.00004998188],"genre_scores_gemma":[0.99604857,0.001216455,0.0012993943,0.0003681064,0.0009665256,0.00005458617,0.0000142173585,0.00002782116,0.0000043229406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956607,0.0006693793,0.0026458679,0.00027631788,0.00047793062,0.00026978983],"domain_scores_gemma":[0.9927168,0.0041532842,0.002199258,0.00017956497,0.0004295861,0.00032151752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026528134,0.00021219222,0.0023310515,0.0004365536,0.00004443564,0.000020652393,0.00010306006,0.00025086777,0.00001554045],"category_scores_gemma":[0.0041542803,0.00013660036,0.00033966685,0.0005221401,0.00013345033,0.00024333401,0.000026970058,0.00048006471,0.0000013154315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7723374,0.013544359,0.18544367,0.0000509261,0.00034162772,0.0009054925,0.00046089198,0.000035115056,0.00023435896,0.000020033238,0.0001619881,0.026464159],"study_design_scores_gemma":[0.83384633,0.021421762,0.14298871,0.00013950809,0.00038544496,0.000025026113,0.000060258626,0.0005229192,0.00039703381,0.000060418857,0.000047031932,0.00010555968],"about_ca_topic_score_codex":0.00006455135,"about_ca_topic_score_gemma":0.000042619802,"teacher_disagreement_score":0.061508954,"about_ca_system_score_codex":0.00009789182,"about_ca_system_score_gemma":0.0005124889,"threshold_uncertainty_score":0.5570401},"labels":[],"label_agreement":null},{"id":"W4379282483","doi":"10.1200/jco.2023.41.16_suppl.7068","title":"Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"CTI Biopharma","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; Gastroenterology; Exacerbation; Spleen; Bone marrow","score_opus":0.08983051127285616,"score_gpt":0.4316969737022216,"score_spread":0.34186646242936547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958977,0.00009015543,0.000011302299,0.0029422564,0.00022871832,0.0004518543,0.00002003483,0.0000029177584,0.00035502922],"genre_scores_gemma":[0.9953938,0.0005318013,0.0037640722,0.00009915082,0.00012263782,0.000015066967,0.000009362928,0.000010408244,0.000053697047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769187,0.00016049239,0.0016446136,0.00014470101,0.00022756873,0.00013073476],"domain_scores_gemma":[0.99618894,0.0017253837,0.0011693409,0.00010532824,0.00068074116,0.00013025572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012137991,0.000094161805,0.0013392301,0.00016311574,0.000018324617,0.000002448249,0.00004598822,0.0001669,0.0000166066],"category_scores_gemma":[0.0015105755,0.00006053792,0.00017223207,0.00016827103,0.00020581167,0.00006262274,0.000023478986,0.00019500437,8.174656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075013544,0.0017665635,0.9417272,0.0001189177,0.00033689322,0.000027792388,0.00017942676,0.0000040734226,0.000082361774,0.00028578858,0.00090976583,0.047059823],"study_design_scores_gemma":[0.017132739,0.023890821,0.9557796,0.0003961879,0.0003306287,0.000029226578,0.00021851825,0.000012661444,0.0008138543,0.00019600595,0.0011491507,0.000050595714],"about_ca_topic_score_codex":0.000014091519,"about_ca_topic_score_gemma":0.000020754649,"teacher_disagreement_score":0.047009226,"about_ca_system_score_codex":0.00004649086,"about_ca_system_score_gemma":0.00045491676,"threshold_uncertainty_score":0.24686648},"labels":[],"label_agreement":null},{"id":"W4379282499","doi":"10.1200/jco.2023.41.16_suppl.e24127","title":"Symptom severity, specialty palliative care, and subsequent symptom control among adolescents and young adults with cancer: A population-based study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; Southlake Regional Health Center; Hospital for Sick Children; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Terry Fox Research Institute","keywords":"Medicine; Specialty; Cancer; Palliative care; Population; Cohort; Young adult; Disease; Internal medicine; Family medicine","score_opus":0.05563187651675316,"score_gpt":0.42249805718296485,"score_spread":0.3668661806662117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420726,0.0005549604,0.000035620316,0.0030643558,0.0010745304,0.00092178676,0.000032057047,0.00003349934,0.00007593581],"genre_scores_gemma":[0.9960692,0.0005752812,0.00017876217,0.0016801126,0.001416551,0.000018417895,0.000009577691,0.000030042758,0.000022076347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995719,0.0007939338,0.0019840028,0.00038641025,0.0008019827,0.0003146532],"domain_scores_gemma":[0.99536616,0.0014251934,0.0017533787,0.00020775311,0.0006417201,0.00060581526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022529648,0.00023871817,0.0018392716,0.00018211543,0.000102327496,0.00002627813,0.00013056904,0.00027116202,0.000024536954],"category_scores_gemma":[0.0014201738,0.00017839753,0.00020297673,0.00026423525,0.00023051446,0.00012561287,0.00005775419,0.0009106625,0.0000024960846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007494687,0.00076437875,0.97654176,0.0002462001,0.00049316825,0.00039532382,0.002460436,0.00004058478,8.979657e-7,0.0000046378473,0.00021816796,0.0113397455],"study_design_scores_gemma":[0.029170217,0.009825094,0.9557263,0.0013151285,0.0007668536,0.000022676002,0.002465089,0.000298984,0.0000015183952,0.000027402963,0.00020784071,0.00017286795],"about_ca_topic_score_codex":0.0027051922,"about_ca_topic_score_gemma":0.023861356,"teacher_disagreement_score":0.021675529,"about_ca_system_score_codex":0.00034483033,"about_ca_system_score_gemma":0.0013297345,"threshold_uncertainty_score":0.9939506},"labels":[],"label_agreement":null},{"id":"W4379282509","doi":"10.1200/jco.2023.41.16_suppl.4025","title":"Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Ipilimumab; FOLFOX; Cancer; Gastroesophageal Junction; Randomized controlled trial; Overall survival; Adenocarcinoma; Immunotherapy; Oxaliplatin; Colorectal cancer","score_opus":0.08883121524277672,"score_gpt":0.42292600852385553,"score_spread":0.33409479328107883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96742904,0.0023403075,0.00074196863,0.019647252,0.007831969,0.001433147,0.000097642005,0.00014189133,0.00033678676],"genre_scores_gemma":[0.95511407,0.016438546,0.0036527116,0.003419415,0.008268882,0.00026823438,0.00013163724,0.00014321711,0.0125632975],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99437994,0.00016358045,0.002918369,0.0007740487,0.0008112369,0.0009528464],"domain_scores_gemma":[0.994472,0.0012589219,0.0024532704,0.0005033774,0.0005937117,0.00071867974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012980592,0.0005945868,0.0031630262,0.0004577752,0.00020278887,0.00004148152,0.00044122658,0.00057378283,0.0010006092],"category_scores_gemma":[0.00079602655,0.00047841633,0.0015527542,0.00080628507,0.0002010558,0.00027550056,0.00011488927,0.0008800708,0.000085473686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07694628,0.0016120926,0.2821933,0.00022856468,0.0039047902,0.00135287,0.0005491328,0.0014230318,0.00039844692,0.000040638573,0.05022277,0.58112806],"study_design_scores_gemma":[0.17367488,0.039254546,0.6652889,0.00039091913,0.003661057,0.00014845644,0.0005514546,0.0032954852,0.001338835,0.00049643446,0.11133863,0.00056039233],"about_ca_topic_score_codex":0.0012759423,"about_ca_topic_score_gemma":0.00104068,"teacher_disagreement_score":0.58056766,"about_ca_system_score_codex":0.0026315989,"about_ca_system_score_gemma":0.0025403767,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W4379282537","doi":"10.1200/jco.2023.41.16_suppl.tps3625","title":"Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Oncology; Internal medicine; Colorectal cancer; FOLFOX; Chemotherapy; Clinical endpoint; Stage (stratigraphy); Oxaliplatin; Adjuvant; KRAS; Cancer; Biomarker; Prospective cohort study; Clinical trial","score_opus":0.044563657483168276,"score_gpt":0.4167230142475589,"score_spread":0.37215935676439066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984496,0.0001628499,0.00001443103,0.00028502097,0.0004064252,0.0004983285,0.000047330683,0.0000029787245,0.00013303093],"genre_scores_gemma":[0.998779,0.0004074753,0.00007197954,0.00045311463,0.0001797523,0.00002154179,0.000016020824,0.00002306646,0.00004804199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973128,0.0002200178,0.0016631657,0.00028978917,0.00025176862,0.00026246358],"domain_scores_gemma":[0.9976432,0.00032758375,0.0014277066,0.00018533072,0.0002751178,0.00014109396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014237652,0.00015877195,0.00089071546,0.0001659955,0.000047281635,0.000005567329,0.00021698761,0.00021177073,0.000028936312],"category_scores_gemma":[0.0009096442,0.00012966701,0.00013624044,0.0002950879,0.00011788242,0.000009244711,0.0001672825,0.00034784977,6.128888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04165068,0.024567354,0.8611803,0.000026482094,0.0006167664,0.0003715735,0.0014059688,0.0022116238,0.010933763,0.000008987495,0.0012512415,0.055775255],"study_design_scores_gemma":[0.077944994,0.12545986,0.78742296,0.000110716544,0.00008947188,0.0000066545363,0.0009960362,0.0005844438,0.0011826985,0.00004270914,0.005942047,0.00021741552],"about_ca_topic_score_codex":0.0002675466,"about_ca_topic_score_gemma":0.001678563,"teacher_disagreement_score":0.10089251,"about_ca_system_score_codex":0.00012117712,"about_ca_system_score_gemma":0.0012439071,"threshold_uncertainty_score":0.52876675},"labels":[],"label_agreement":null},{"id":"W4379282610","doi":"10.1200/jco.2023.41.16_suppl.10004","title":"Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Glioma; Phases of clinical research; Oncology; Adverse effect; Clinical trial; Surgery; Cancer research","score_opus":0.1904794271642859,"score_gpt":0.5175572452701831,"score_spread":0.3270778181058972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98483217,0.00016561747,0.0000019828742,0.012809719,0.0013377329,0.0006368722,0.000016095331,0.00000641001,0.0001933912],"genre_scores_gemma":[0.997385,0.0003750055,0.00009045349,0.00033460048,0.0017613786,0.000016526446,0.0000025083086,0.000012853642,0.000021654343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99319935,0.0017574466,0.0036562157,0.0002497068,0.0008989471,0.00023831117],"domain_scores_gemma":[0.98593307,0.010001097,0.0030950368,0.00044744142,0.00035061242,0.00017273318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008530758,0.00017095015,0.001620909,0.00022085597,0.000052082454,0.000007715737,0.0003919958,0.00035107954,0.000040972962],"category_scores_gemma":[0.007090293,0.00008547093,0.0010260588,0.0009274703,0.00033470683,0.000082325,0.00010446835,0.0011447502,0.000008037274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037207366,0.06729704,0.8859174,0.000056710905,0.00044489268,0.0015981109,0.00031217514,0.000018712342,0.0005727423,0.00008458776,0.008147652,0.031829193],"study_design_scores_gemma":[0.023064436,0.01985708,0.9533129,0.00006993029,0.000723252,0.0001111399,0.0003605852,0.000053247397,0.0005683178,0.0002600538,0.0015505416,0.00006851246],"about_ca_topic_score_codex":0.00003404565,"about_ca_topic_score_gemma":0.00013590704,"teacher_disagreement_score":0.067395456,"about_ca_system_score_codex":0.00007713364,"about_ca_system_score_gemma":0.0014670582,"threshold_uncertainty_score":0.8488255},"labels":[],"label_agreement":null},{"id":"W4379282619","doi":"10.1200/jco.2023.41.16_suppl.e22021","title":"Congenital anomalies and health outcomes among survivors of childhood cancer: A report from the childhood cancer survivor study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Hazard ratio; Pediatrics; Cancer; Common Terminology Criteria for Adverse Events; Confidence interval; Internal medicine","score_opus":0.15122955626799603,"score_gpt":0.4949005945480021,"score_spread":0.3436710382800061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9311122,0.0038138586,0.0000062563117,0.059889972,0.003820034,0.000973719,0.00014170553,0.000051174553,0.00019108636],"genre_scores_gemma":[0.987497,0.004665302,0.00017398303,0.0050495854,0.0022815114,0.000036547885,0.000015826632,0.000058782753,0.00022148625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9900114,0.0017398889,0.005872163,0.00056498026,0.0012669392,0.0005446499],"domain_scores_gemma":[0.9854629,0.0067782383,0.0057481895,0.0006886747,0.00062582904,0.0006961415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013544834,0.00038376046,0.004072847,0.0002149917,0.00017663655,0.000027962917,0.00048517092,0.00036793723,0.00016336335],"category_scores_gemma":[0.005733261,0.0002452466,0.00081462506,0.00058003847,0.00071255036,0.00019744683,0.00028677852,0.0015913286,0.000006046748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005090069,0.00242341,0.9549501,0.000041591764,0.0030697924,0.00047827128,0.0072510885,0.000013060005,0.0000023015536,0.000009348141,0.005341073,0.025910987],"study_design_scores_gemma":[0.008167887,0.00499473,0.97410536,0.0002863303,0.00076598616,0.00016268615,0.0070579294,0.000009613017,0.0000073182023,0.00015519092,0.0040775575,0.00020942498],"about_ca_topic_score_codex":0.06454784,"about_ca_topic_score_gemma":0.14861602,"teacher_disagreement_score":0.08406819,"about_ca_system_score_codex":0.00018872893,"about_ca_system_score_gemma":0.0051486325,"threshold_uncertainty_score":1},"labels":[],"label_agreement":null},{"id":"W4379282660","doi":"10.1200/jco.2023.41.16_suppl.tps5632","title":"CCTG EN10: A phase II study of tailored adjuvant therapy in <i>POLE</i>-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Saskatchewan Health Authority; Vancouver Coastal Health; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of British Columbia; University of Alberta; Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Endometrial cancer; Lymphovascular invasion; Stage (stratigraphy); Oncology; Hysterectomy; Internal medicine; Clinical endpoint; Adjuvant therapy; Brachytherapy; Cancer; Clinical trial; Metastasis; Surgery; Radiation therapy","score_opus":0.1725754803686325,"score_gpt":0.5041996955573087,"score_spread":0.33162421518867624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346215,0.002441575,0.000002774342,0.0020493837,0.0010541235,0.00080938335,0.000027823367,0.00001635592,0.00013645944],"genre_scores_gemma":[0.98629665,0.011887821,0.00008099321,0.00062946504,0.0007990866,0.000029233359,0.0000049234704,0.000026019185,0.00024579602],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955261,0.0006493028,0.0025606197,0.0003490199,0.00055572606,0.0003592725],"domain_scores_gemma":[0.9942378,0.0034718786,0.0013146014,0.0001856173,0.00030115375,0.000488995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028699362,0.00023807133,0.0024603484,0.0006388108,0.00006306051,0.000011255318,0.00015009826,0.00033710845,0.00021771199],"category_scores_gemma":[0.0032919387,0.00015647348,0.00026765637,0.001259778,0.0002491471,0.00011881747,0.00012598521,0.00085829,0.000003377404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08967185,0.017729996,0.30306336,0.000059944246,0.0019020899,0.0027854207,0.0030241972,0.000023866167,0.0034169029,0.000012863546,0.0004364525,0.57787305],"study_design_scores_gemma":[0.27527705,0.19521862,0.5174502,0.00015526084,0.000570983,0.000069566435,0.0013753053,0.00008633251,0.00046712309,0.00012596359,0.009005189,0.00019839368],"about_ca_topic_score_codex":0.0007983258,"about_ca_topic_score_gemma":0.0003614915,"teacher_disagreement_score":0.5776747,"about_ca_system_score_codex":0.000118997006,"about_ca_system_score_gemma":0.00072216033,"threshold_uncertainty_score":0.63808036},"labels":[],"label_agreement":null},{"id":"W4379282676","doi":"10.1200/jco.2023.41.16_suppl.e21535","title":"Efficacy and safety of BRAF/MEK inhibitor rechallenge in patients with advanced melanoma: Systematic review and meta-analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Meta-analysis; Melanoma; Adverse effect; Cochrane Library; Confidence interval; Targeted therapy; Randomized controlled trial; Cancer; Cancer research","score_opus":0.08060896918441193,"score_gpt":0.3887397324274803,"score_spread":0.3081307632430683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975729,0.02272255,0.0000384553,0.00075440854,0.00007676029,0.0005300008,0.000015757852,0.0000024998176,0.00013060267],"genre_scores_gemma":[0.987652,0.011091552,0.0007078141,0.0004128522,0.00004415957,0.000010674022,0.000014917396,0.000010431502,0.00005560863],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.996918,0.00065615214,0.0019066047,0.00021331642,0.00017082297,0.00013507658],"domain_scores_gemma":[0.99741715,0.000553606,0.0014788342,0.00021488655,0.00020101467,0.00013448395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028349187,0.00012983632,0.0028351494,0.000111112495,0.000016595137,0.0000030988158,0.00012231263,0.00018778234,0.000010711589],"category_scores_gemma":[0.0018676651,0.00007766072,0.00038055397,0.00022082795,0.00009537616,0.000007800297,0.00008375035,0.00021349927,0.0000011971505],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036678072,0.012525012,0.20053616,0.17965549,0.53409547,0.0010657291,0.00087863783,0.00053979864,0.007735288,0.00089701265,0.0051841317,0.020209182],"study_design_scores_gemma":[0.02780868,0.042515654,0.5196608,0.0024831418,0.40265357,0.0000883373,0.00015953099,0.000017420918,0.00056208996,0.000115646835,0.0032229146,0.00071225595],"about_ca_topic_score_codex":0.000001401902,"about_ca_topic_score_gemma":0.000036058605,"teacher_disagreement_score":0.31912458,"about_ca_system_score_codex":0.0000089198,"about_ca_system_score_gemma":0.00012066576,"threshold_uncertainty_score":0.31669122},"labels":[],"label_agreement":null},{"id":"W4379282682","doi":"10.1200/jco.2023.41.16_suppl.3146","title":"Tumor-agnostic genomic and clinical analysis of solid tumors with <i>BRAF </i>fusions.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Fusion gene; Cancer research; Exon; DNA sequencing; Oncology; Gene; Internal medicine; Biology; Genetics","score_opus":0.047194185315729595,"score_gpt":0.41668085423173995,"score_spread":0.36948666891601034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732333,0.0004967549,0.00029298037,0.00095518405,0.00052670715,0.000095017094,0.000051645668,0.000004076042,0.00025430846],"genre_scores_gemma":[0.9905566,0.006273849,0.0010668318,0.0012200451,0.00077104877,0.000002078784,0.00002202342,0.000019683424,0.00006784076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966221,0.00027960257,0.0023740323,0.0002956228,0.00019080557,0.00023787725],"domain_scores_gemma":[0.99499947,0.0022153158,0.0018105878,0.00029152996,0.0003518949,0.00033121355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028665764,0.00014709079,0.0014314159,0.00022863182,0.000042829153,0.000008678279,0.000269258,0.00027310522,0.0000259526],"category_scores_gemma":[0.0045801774,0.00011147361,0.0005939005,0.00041657223,0.00043436151,0.0000045792876,0.00022136066,0.00040338867,0.0000060183916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00482361,0.0016565714,0.8809528,0.000042443193,0.0076117017,0.00097186083,0.00007512686,0.008008516,0.013014454,0.00018153667,0.021816928,0.060844474],"study_design_scores_gemma":[0.0033509443,0.013025986,0.9405585,0.000034275945,0.0024225398,0.0001178814,0.00010334718,0.0009766042,0.000493739,0.00015435467,0.03856613,0.00019572901],"about_ca_topic_score_codex":0.000021194912,"about_ca_topic_score_gemma":0.00027768034,"teacher_disagreement_score":0.060648743,"about_ca_system_score_codex":0.000020249534,"about_ca_system_score_gemma":0.0012268074,"threshold_uncertainty_score":0.5483231},"labels":[],"label_agreement":null},{"id":"W4379282685","doi":"10.1200/jco.2023.41.16_suppl.4038","title":"Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cancer; Quality of life (healthcare); Population; Randomized controlled trial; Gastroenterology; Visual analogue scale; Gastroesophageal Junction; Esophageal cancer; Chemotherapy; Surgery; Adenocarcinoma","score_opus":0.1121092006435373,"score_gpt":0.4326053091283922,"score_spread":0.3204961084848549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99008083,0.0012611466,0.00004139445,0.005082212,0.0025498813,0.0007279556,0.00009968684,0.000031877207,0.00012501086],"genre_scores_gemma":[0.9940308,0.0031237674,0.0010744508,0.0006569515,0.0005466102,0.000021812464,0.0000562874,0.00004447972,0.0004448858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99166435,0.0006408286,0.0056420253,0.00047624472,0.0010100224,0.00056654157],"domain_scores_gemma":[0.99034613,0.0015487897,0.0066431225,0.00038522264,0.0005967862,0.00047995106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002931489,0.00032831397,0.003502867,0.000512179,0.000049979957,0.0000074505474,0.00031973477,0.00035251677,0.00020113816],"category_scores_gemma":[0.0017864698,0.0002373678,0.00045430523,0.0013114606,0.00025868713,0.00021060907,0.00008956699,0.0010533814,0.0000050076897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26969257,0.0011055447,0.58718026,0.00017092821,0.00090506906,0.00013342593,0.0004312572,0.0014879775,0.000012000382,0.000003723768,0.00359463,0.1352826],"study_design_scores_gemma":[0.12691465,0.022980383,0.8481697,0.00033310772,0.00027026975,0.000003207718,0.00032847715,0.00036992066,0.000018431418,0.000014238822,0.00047571538,0.00012189619],"about_ca_topic_score_codex":0.007782272,"about_ca_topic_score_gemma":0.0053663575,"teacher_disagreement_score":0.26098946,"about_ca_system_score_codex":0.0011972717,"about_ca_system_score_gemma":0.0039931512,"threshold_uncertainty_score":0.998825},"labels":[],"label_agreement":null},{"id":"W4379282697","doi":"10.1200/jco.2023.41.16_suppl.4008","title":"Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Cohort; Internal medicine; Biliary tract cancer; Gemcitabine; Gallbladder cancer; Oncology; Clinical endpoint; Cancer; Metastatic breast cancer; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Trastuzumab; Surgery; Phases of clinical research; Clinical trial","score_opus":0.2021545997385521,"score_gpt":0.49464389825382776,"score_spread":0.29248929851527566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97116387,0.0020160663,0.0000027949507,0.023134971,0.0018197637,0.00079893274,0.00014502845,0.000043521017,0.00087508204],"genre_scores_gemma":[0.99124837,0.0033518297,0.00007172529,0.00204966,0.0027479085,0.000038220405,0.000046297264,0.0000378574,0.0004081239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421215,0.0009303953,0.0032760552,0.0004963293,0.00059091847,0.000494167],"domain_scores_gemma":[0.9912201,0.006174969,0.0014289095,0.000536977,0.00029100224,0.00034802573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043736417,0.00028981705,0.0020674814,0.00015954132,0.00010233888,0.000025930178,0.00041741057,0.0003509492,0.00016895637],"category_scores_gemma":[0.004889819,0.00017253078,0.0005573769,0.00065315515,0.0002606368,0.00014347742,0.00017712294,0.0017800854,0.000054706026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02497765,0.009100222,0.7174847,0.000024513958,0.0014486108,0.0065733893,0.0034254119,0.000018529363,0.00030114368,0.0000025255194,0.086719185,0.14992411],"study_design_scores_gemma":[0.040261112,0.0139503265,0.90199405,0.00021179022,0.00077660475,0.00009103628,0.0025999262,0.00007440496,0.00003398554,0.00005837979,0.039782956,0.00016541245],"about_ca_topic_score_codex":0.0028770661,"about_ca_topic_score_gemma":0.0054161497,"teacher_disagreement_score":0.18450937,"about_ca_system_score_codex":0.0002789621,"about_ca_system_score_gemma":0.0014812066,"threshold_uncertainty_score":0.7733684},"labels":[],"label_agreement":null},{"id":"W4379282782","doi":"10.1200/jco.2023.41.16_suppl.3567","title":"Reversion of <i>RAS</i> mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency; Ottawa Hospital; Queen's University; Pancreas Centre (Canada); University of British Columbia","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Medicine; KRAS; Colorectal cancer; Internal medicine; Cetuximab; Oncology; Cancer; Panitumumab; Mutation; Cancer research; Genetics; Biology; Gene","score_opus":0.1362001860192569,"score_gpt":0.5035358244269232,"score_spread":0.36733563840766636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945454,0.0004319804,0.00003096243,0.002885416,0.0014356534,0.0002581974,0.00003064429,0.0000017264175,0.00038002062],"genre_scores_gemma":[0.99028414,0.0075648967,0.0003338348,0.0010251896,0.0007146084,0.00001480487,0.0000124221015,0.000012039722,0.000038058068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961415,0.00091493246,0.0023963242,0.00017569706,0.00019087397,0.0001806712],"domain_scores_gemma":[0.9949029,0.0035114298,0.0011815679,0.00015096033,0.00016413722,0.00008899445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007107574,0.00009090674,0.0007326205,0.000106666026,0.00002189471,0.000006528089,0.00031032876,0.00026184818,0.000023966862],"category_scores_gemma":[0.00703571,0.00006485327,0.00037224704,0.00027838632,0.00022237682,0.0000053666904,0.000066614564,0.0005153379,0.000007055352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13375041,0.011689715,0.41902235,0.00011938436,0.0011097126,0.0013524379,0.0010640492,0.008970687,0.020215793,0.00061713805,0.19060357,0.21148475],"study_design_scores_gemma":[0.1264485,0.036283597,0.569973,0.0001384293,0.00043590742,0.00008229266,0.0016949195,0.0005377175,0.0026171906,0.0022851021,0.2591227,0.0003806545],"about_ca_topic_score_codex":0.00006687893,"about_ca_topic_score_gemma":0.001120988,"teacher_disagreement_score":0.21110408,"about_ca_system_score_codex":0.000037569815,"about_ca_system_score_gemma":0.0015571758,"threshold_uncertainty_score":0.84229106},"labels":[],"label_agreement":null},{"id":"W4379282849","doi":"10.1200/jco.2023.41.16_suppl.8521","title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Surgery; Clinical endpoint; Oncology; Phases of clinical research; Neoadjuvant therapy; Chemotherapy; Randomized controlled trial; Gastroenterology; Cancer; Breast cancer","score_opus":0.11363242936900166,"score_gpt":0.4904432246227921,"score_spread":0.37681079525379046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779733,0.000107379754,0.000020766232,0.018702466,0.0010567495,0.00078906066,0.00016311588,0.000023987075,0.0011632113],"genre_scores_gemma":[0.9910575,0.0013889221,0.0005752028,0.0053078216,0.00068445643,0.00003254627,0.00017163092,0.00004594902,0.0007359819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99444664,0.0008163299,0.0033461666,0.00039726458,0.0006054051,0.00038822796],"domain_scores_gemma":[0.9807467,0.015633894,0.0023320839,0.00038502962,0.000563022,0.00033927488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004745242,0.00023334385,0.002201914,0.00013198749,0.00008661085,0.000023080447,0.0001891424,0.00032642297,0.00006752003],"category_scores_gemma":[0.00647848,0.000110945,0.00048355846,0.00044896573,0.0003245929,0.00015833102,0.000034469173,0.0010627359,0.000031922504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35405454,0.0066001066,0.50764215,0.0000047435333,0.0013526793,0.0004715615,0.00029368172,0.0000056719255,0.0000010072406,0.0000040090626,0.042938404,0.08663144],"study_design_scores_gemma":[0.34641674,0.031017162,0.5900144,0.00025824324,0.0005415053,0.000011088855,0.00023659588,0.000019366555,0.0000067185238,0.000065854634,0.031294145,0.00011818996],"about_ca_topic_score_codex":0.00042919288,"about_ca_topic_score_gemma":0.0003558395,"teacher_disagreement_score":0.08651324,"about_ca_system_score_codex":0.00023751167,"about_ca_system_score_gemma":0.0027525877,"threshold_uncertainty_score":0.7755814},"labels":[],"label_agreement":null},{"id":"W4379282852","doi":"10.1200/jco.2023.41.16_suppl.tps3153","title":"TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Prostate cancer; Internal medicine; Oncology; Cancer; Combination therapy; Bevacizumab; Cancer research; Immunotherapy; Chemotherapy","score_opus":0.139887455660775,"score_gpt":0.5423854401283179,"score_spread":0.4024979844675429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997433,0.000058110858,0.000031694373,0.0010957421,0.00016240933,0.001152115,0.0000057497073,0.0000070347332,0.000054133725],"genre_scores_gemma":[0.9981279,0.0006650956,0.0006793529,0.00037643744,0.0000513655,0.000030097643,0.000005654943,0.00003373355,0.000030390524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570805,0.0006823279,0.0021134436,0.00030833564,0.00083387544,0.0003539823],"domain_scores_gemma":[0.9967336,0.001126731,0.0011626285,0.00023706027,0.00046428625,0.00027569267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001958447,0.00017503182,0.001551975,0.0005373468,0.000026025813,0.000010282724,0.00018016019,0.00009082345,0.00006634484],"category_scores_gemma":[0.0014279262,0.000117257965,0.00006514731,0.0006421987,0.00021820772,0.00018729077,0.000058089303,0.0008844517,0.0000054022375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032054365,0.018510206,0.85917526,0.00010897778,0.00020765516,0.0018056735,0.00089939695,0.00013390562,0.000052888674,0.000003885254,0.00010635402,0.086941406],"study_design_scores_gemma":[0.117394485,0.08059835,0.7981028,0.00063925196,0.00009384136,0.000036648977,0.0013730905,0.0011585681,0.00009251937,0.00007230382,0.00033447353,0.00010366916],"about_ca_topic_score_codex":0.0001171046,"about_ca_topic_score_gemma":0.0006489973,"teacher_disagreement_score":0.08683774,"about_ca_system_score_codex":0.0002670426,"about_ca_system_score_gemma":0.0012177739,"threshold_uncertainty_score":0.4781641},"labels":[],"label_agreement":null},{"id":"W4379282862","doi":"10.1200/jco.2023.41.16_suppl.4004","title":"Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Discontinuation; Internal medicine; Adverse effect; Proportional hazards model; Tremelimumab; Oncology; Confidence interval; Gastroenterology; Cancer; Immunotherapy; Ipilimumab","score_opus":0.11499127931369861,"score_gpt":0.4508944703931721,"score_spread":0.3359031910794735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566644,0.0006320322,0.0000061623955,0.0022056333,0.0004961448,0.0008291451,0.00002725849,0.000008945847,0.00012823583],"genre_scores_gemma":[0.99876094,0.00046759748,0.000039180504,0.0005144289,0.00006284527,0.0000222354,0.000019016412,0.000015243232,0.00009849187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421024,0.0011521648,0.0032560872,0.0002522815,0.00075449987,0.00037474005],"domain_scores_gemma":[0.99512386,0.0025134832,0.0016458367,0.00036103366,0.00022324549,0.00013256643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007985446,0.00021091288,0.0018253825,0.00037061883,0.000035748304,0.0000036181075,0.0004458926,0.00023157592,0.000103385304],"category_scores_gemma":[0.001642009,0.000120855075,0.00041647494,0.0010578128,0.0002333717,0.00013062266,0.000058576992,0.0010718968,0.000010136253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041947413,0.006863757,0.9395368,0.00003778633,0.00034882702,0.0019656797,0.0011485283,0.000020361804,0.00078228716,9.1406184e-7,0.0011234701,0.0062241647],"study_design_scores_gemma":[0.099355906,0.025726287,0.86711603,0.00015135971,0.00019232323,0.00009076233,0.004093585,0.0006053999,0.0000890983,0.000010582257,0.0024425995,0.00012606222],"about_ca_topic_score_codex":0.0008211858,"about_ca_topic_score_gemma":0.00044758653,"teacher_disagreement_score":0.07242078,"about_ca_system_score_codex":0.00029985877,"about_ca_system_score_gemma":0.001893615,"threshold_uncertainty_score":0.4928327},"labels":[],"label_agreement":null},{"id":"W4379282877","doi":"10.1200/jco.2023.41.16_suppl.5002","title":"Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Proportional hazards model; Internal medicine; Randomization; Oncology; Radiation therapy; Stage (stratigraphy); Surrogate endpoint; Randomized controlled trial; Clinical endpoint; Hazard ratio; Urology; Survival analysis; Cancer; Confidence interval","score_opus":0.2661617005470177,"score_gpt":0.553959838353273,"score_spread":0.2877981378062553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402673,0.005891011,0.00023251396,0.0023738632,0.00038359684,0.003176993,0.0038994304,0.000007171636,0.000008695782],"genre_scores_gemma":[0.9901258,0.006261727,0.0022377037,0.00018228574,0.00034699254,0.0001706791,0.0006169141,0.000025763882,0.000032174572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98893356,0.0045826933,0.0050817095,0.00030522174,0.00081503176,0.00028178174],"domain_scores_gemma":[0.9685347,0.02258821,0.006215609,0.0004902197,0.0019059009,0.00026533325],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018547928,0.00021546583,0.0064110286,0.0004278909,0.000044930715,0.000015131447,0.0004014192,0.00028422207,0.00024615368],"category_scores_gemma":[0.01493834,0.00010466284,0.0015290886,0.0012354746,0.0008396839,0.00016990886,0.000075747244,0.0004307086,4.0835369e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7031616,0.001983129,0.20592938,0.00008851121,0.044589575,0.000055509903,0.004362567,0.0009824655,0.0012733851,0.0000088816305,0.004057975,0.033507038],"study_design_scores_gemma":[0.45876497,0.036330808,0.44677362,0.00058853545,0.031495754,0.00000606368,0.0016644272,0.021141114,0.00090038095,0.0005546027,0.001555315,0.00022439238],"about_ca_topic_score_codex":0.0009974769,"about_ca_topic_score_gemma":0.0007735184,"teacher_disagreement_score":0.2443966,"about_ca_system_score_codex":0.00017464574,"about_ca_system_score_gemma":0.004130104,"threshold_uncertainty_score":0.99335927},"labels":[],"label_agreement":null},{"id":"W4379282883","doi":"10.1200/jco.2023.41.16_suppl.11007","title":"Remote delivery of a mindfulness-based intervention to decrease stress levels and promote coping among health-care workers during the COVID-19 pandemic.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and Mental Health","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Western University","funders":"","keywords":"Mindfulness; Medicine; Psychological intervention; Burnout; Coping (psychology); Intervention (counseling); Health care; Clinical psychology; Family medicine; Physical therapy; Nursing","score_opus":0.2961240709057198,"score_gpt":0.5639005269190157,"score_spread":0.2677764560132959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432636,0.0006196641,0.0021904258,0.0108584445,0.0013421181,0.0005528504,0.000036758145,0.000024904117,0.000048462516],"genre_scores_gemma":[0.9913715,0.000035370762,0.00034093298,0.007769825,0.000310984,0.000011423143,0.0000046777727,0.000018331559,0.00013692272],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99501145,0.00167382,0.0023533616,0.00029189265,0.00028146876,0.00038798066],"domain_scores_gemma":[0.9923524,0.004044911,0.0020095746,0.00025085174,0.00018016457,0.0011620637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005930397,0.00014951803,0.000914367,0.00026797527,0.0001654108,0.000011637095,0.0002915017,0.00028801287,0.00017952683],"category_scores_gemma":[0.0036651744,0.00011012608,0.00034940077,0.00034893263,0.00024919733,0.0000705406,0.00012622672,0.0007359491,0.000009916727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007282041,0.00047272813,0.48178148,0.000891226,0.0001790144,0.00031075178,0.0031331305,0.00021651841,0.000015446445,0.000030120456,0.0019488198,0.5037387],"study_design_scores_gemma":[0.0111890575,0.006893104,0.95004106,0.0008979728,0.00010896543,0.00012307586,0.0072639575,0.00013122857,0.00007771358,0.00025410808,0.022839313,0.00018044368],"about_ca_topic_score_codex":0.0022593075,"about_ca_topic_score_gemma":0.0037387041,"teacher_disagreement_score":0.5035583,"about_ca_system_score_codex":0.00068101095,"about_ca_system_score_gemma":0.0034462293,"threshold_uncertainty_score":0.6113463},"labels":[],"label_agreement":null},{"id":"W4379282903","doi":"10.1200/jco.2023.41.16_suppl.4516","title":"Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Avelumab; Medicine; Discontinuation; Internal medicine; Metastatic Urothelial Carcinoma; Adverse effect; Oncology; Surgery; Bladder cancer; Urothelial carcinoma; Immunotherapy; Nivolumab; Cancer","score_opus":0.14046921801371734,"score_gpt":0.4619004423937132,"score_spread":0.32143122437999583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97356194,0.000430634,0.00066011626,0.019455057,0.0027442588,0.0018738982,0.00006658898,0.000014767635,0.001192757],"genre_scores_gemma":[0.9917666,0.0018500732,0.00084451155,0.0022278985,0.0022338647,0.000068749156,0.000014300848,0.000035448393,0.0009585591],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9952475,0.00039785393,0.003182294,0.0002816651,0.00047505606,0.00041566906],"domain_scores_gemma":[0.9932518,0.0042110435,0.001506871,0.00035586464,0.0004704388,0.00020397117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041784393,0.00021706558,0.0018096867,0.0001927674,0.00006185331,0.0000069594234,0.00036759328,0.00037236954,0.0001501251],"category_scores_gemma":[0.0040566367,0.00012861355,0.00085676863,0.00036447385,0.00024475498,0.00008965,0.000052696407,0.00077406864,0.000022479991],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5809984,0.006824144,0.08632373,0.0002702241,0.0010759424,0.0018748353,0.0010363404,0.00018496478,0.00022917085,0.00026784927,0.010746233,0.31016815],"study_design_scores_gemma":[0.34143135,0.051548757,0.5640695,0.0003445772,0.000847176,0.00028633693,0.0002748076,0.0001769239,0.00024882975,0.0010859886,0.039477646,0.00020811094],"about_ca_topic_score_codex":0.000036219044,"about_ca_topic_score_gemma":0.00026357043,"teacher_disagreement_score":0.47774577,"about_ca_system_score_codex":0.00018069557,"about_ca_system_score_gemma":0.0018136818,"threshold_uncertainty_score":0.5244708},"labels":[],"label_agreement":null},{"id":"W4379282910","doi":"10.1200/jco.2023.41.16_suppl.3089","title":"Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Docetaxel; Tolerability; Pharmacokinetics; Oncology; Adverse effect; Internal medicine; Drug; Pharmacology; Cancer","score_opus":0.17533644675191873,"score_gpt":0.4953780951590365,"score_spread":0.3200416484071178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945125,0.00010574106,0.000015645695,0.0024475888,0.0006237183,0.0016610106,0.00018373245,0.000025030653,0.00042502378],"genre_scores_gemma":[0.99478835,0.0004007385,0.0029691034,0.00026558977,0.00050923973,0.000050911895,0.00021517019,0.000053628126,0.0007472617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919388,0.0005657571,0.005271225,0.00059634045,0.0010006637,0.0006271774],"domain_scores_gemma":[0.99162793,0.0027290275,0.003529287,0.0003987417,0.0011382852,0.0005767363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050970307,0.00031754843,0.0025624325,0.00039498386,0.00009007638,0.00002942125,0.0004764486,0.00023349801,0.00012479817],"category_scores_gemma":[0.0066622137,0.00021486367,0.00023732724,0.0008352139,0.00029607004,0.00046592267,0.0002748007,0.0013575692,0.000053069893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18163665,0.0665109,0.6515449,0.0000716979,0.0014824651,0.0014818774,0.0016112598,0.00021538167,0.0025116277,0.00000498081,0.0065860418,0.086342216],"study_design_scores_gemma":[0.33720127,0.054148823,0.598874,0.0010848372,0.00043472814,0.000010334082,0.0017946989,0.00074431003,0.0010887707,0.00007640318,0.0042358143,0.0003060667],"about_ca_topic_score_codex":0.00022962484,"about_ca_topic_score_gemma":0.00034966067,"teacher_disagreement_score":0.15556462,"about_ca_system_score_codex":0.0002946199,"about_ca_system_score_gemma":0.002507986,"threshold_uncertainty_score":0.8761886},"labels":[],"label_agreement":null},{"id":"W4379282925","doi":"10.1200/jco.2023.41.16_suppl.e19069","title":"Stopping study in chronic myeloid leukemia: Defining a new paradigm for Ontario CML1.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Windsor; Western University; Windsor Regional Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Myeloid leukemia; Internal medicine; Cohort; Quality of life (healthcare); Cancer; Incidence (geometry); Oncology; Clinical trial","score_opus":0.18085906819872577,"score_gpt":0.46733339883324565,"score_spread":0.2864743306345199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915727,0.00062379707,0.00011136092,0.002815207,0.0015382026,0.0009530183,0.0000017988303,0.00003594414,0.00234799],"genre_scores_gemma":[0.99034077,0.00035820494,0.0024804354,0.0009350871,0.0018685003,0.00003536647,0.0000104275505,0.00004838938,0.0039228476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950451,0.00029009875,0.0032415236,0.00038115293,0.00045264818,0.00058946386],"domain_scores_gemma":[0.99341965,0.0041258843,0.0014613312,0.0003285604,0.00013561909,0.0005289871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004715942,0.00024088447,0.0022298805,0.00040196563,0.000059521186,0.00001440273,0.00026271894,0.00048681072,0.00016724085],"category_scores_gemma":[0.0033695155,0.00019228482,0.00061904744,0.0004238563,0.000083264706,0.00014628335,0.00010505513,0.0017766503,0.00011046895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007000181,0.0021090352,0.6499048,0.00009482016,0.0015177852,0.0059335744,0.0030052941,0.00095960096,0.000095901814,0.00032059688,0.01993674,0.30912167],"study_design_scores_gemma":[0.062112916,0.033781834,0.7653368,0.000338402,0.0006896164,0.00045510143,0.0005905877,0.0005885775,0.000013502357,0.00086505746,0.13503474,0.00019287893],"about_ca_topic_score_codex":0.0033803429,"about_ca_topic_score_gemma":0.03688939,"teacher_disagreement_score":0.3089288,"about_ca_system_score_codex":0.014977055,"about_ca_system_score_gemma":0.043770492,"threshold_uncertainty_score":0.9888043},"labels":[],"label_agreement":null},{"id":"W4379282944","doi":"10.1200/jco.2023.41.16_suppl.2635","title":"Multisystem immune-related adverse events from dual agent immunotherapy use.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Adverse effect; Internal medicine; Cancer; Cohort; Immunotherapy","score_opus":0.1364889781021885,"score_gpt":0.45279909526999446,"score_spread":0.316310117167806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868569,0.0014741697,0.00005258154,0.0038640413,0.0070301006,0.00029475792,0.000018055765,0.00005061938,0.00035878885],"genre_scores_gemma":[0.9891331,0.004703745,0.0007557388,0.0017129504,0.0009148904,0.0000053788463,0.000023893073,0.00004058035,0.0027097322],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99423,0.00065751787,0.004059088,0.00022945367,0.00051108014,0.00031286146],"domain_scores_gemma":[0.9945876,0.00219318,0.002332635,0.00033301962,0.00029327406,0.0002603062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004037821,0.00019270377,0.0015942534,0.00020939634,0.000063898005,0.0000065143295,0.00020008904,0.00059118925,0.00070518104],"category_scores_gemma":[0.0012032508,0.00013834662,0.0014341684,0.0003645765,0.00016542044,0.00017298503,0.000053244912,0.0009600499,0.00026068097],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08261456,0.0035982071,0.2727962,0.000058587993,0.011302804,0.006387003,0.0011889494,0.00009583428,0.04336584,0.000052054103,0.027278079,0.5512619],"study_design_scores_gemma":[0.023519248,0.0048487815,0.8006773,0.00025660644,0.0002423425,0.00028050435,0.00029764243,0.00016309324,0.00019447684,0.000110599,0.16927543,0.00013398284],"about_ca_topic_score_codex":0.00022845095,"about_ca_topic_score_gemma":0.000023638466,"teacher_disagreement_score":0.5511279,"about_ca_system_score_codex":0.00028157767,"about_ca_system_score_gemma":0.0009839032,"threshold_uncertainty_score":0.7721238},"labels":[],"label_agreement":null},{"id":"W4379282952","doi":"10.1200/jco.2023.41.16_suppl.e24193","title":"How did the COVID-19 pandemic affect the management of patients with cancer? What is the impact of anti-cancer medications on the immune response to the COVID-19 vaccinations?.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Moncton Hospital","funders":"","keywords":"Medicine; Cancer; Internal medicine; Vaccination; Pandemic; Radiation therapy; Coronavirus disease 2019 (COVID-19); Oncology; Disease; Immunology; Infectious disease (medical specialty)","score_opus":0.2525952345957814,"score_gpt":0.5702085816503789,"score_spread":0.3176133470545975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282952","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48785257,0.00079343456,0.000097169424,0.5096825,0.00038900215,0.0011088899,0.00004976905,0.000008671861,0.000018004472],"genre_scores_gemma":[0.9063194,0.014798051,0.000013171829,0.078061864,0.0003472077,0.00011372533,0.000004086887,0.000020674448,0.00032182186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99376595,0.0030104495,0.00152888,0.00023768659,0.0010729149,0.00038409047],"domain_scores_gemma":[0.9594471,0.035956472,0.0024204683,0.0010077785,0.00064082036,0.00052736903],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017242497,0.00021547255,0.00094322255,0.0001822918,0.00051673624,0.000044835462,0.0010059199,0.00018950371,0.0002458211],"category_scores_gemma":[0.012436071,0.00006552499,0.00057898747,0.0011286545,0.00050491974,0.00012008699,0.00018848824,0.0012366632,0.0000079143365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047530424,0.0020601985,0.5802719,0.00042856083,0.0063538784,0.00008539354,0.014084215,0.0050997185,0.0001556176,0.00074141345,0.2180638,0.12512486],"study_design_scores_gemma":[0.0040968647,0.005452506,0.84714943,0.00021461936,0.00062368985,0.000020866482,0.002787821,0.00007735046,0.000013632713,0.00020168103,0.13929014,0.00007141492],"about_ca_topic_score_codex":0.00092177326,"about_ca_topic_score_gemma":0.0006470659,"teacher_disagreement_score":0.4316206,"about_ca_system_score_codex":0.0010162095,"about_ca_system_score_gemma":0.007246557,"threshold_uncertainty_score":0.99838144},"labels":[],"label_agreement":null},{"id":"W4379282976","doi":"10.1200/jco.2023.41.16_suppl.e15555","title":"Real-world safety and effectiveness of MVASI in metastatic colorectal cancer patients in Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Markham Stouffville Hospital; Southlake Regional Health Center; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Victoria Hospital; Ottawa Hospital; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Nova Scotia Health Authority; Centre Intégré de Santé et de Services Sociaux des Laurentides; London Health Sciences Centre; Amgen (Canada); Grand River Hospital","funders":"Amgen","keywords":"Medicine; Bevacizumab; Colorectal cancer; Internal medicine; Biosimilar; Adverse effect; Oncology; Medical record; Cancer; Surgery; Chemotherapy","score_opus":0.06881814776288293,"score_gpt":0.4400968442127952,"score_spread":0.3712786964499123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972124,0.00026254673,0.0000038170715,0.00066459854,0.0012346787,0.00014352158,0.00002997685,0.0000020561122,0.0004463851],"genre_scores_gemma":[0.9975225,0.0020584986,0.00018619059,0.00014675455,0.000022642153,0.0000030697624,0.0000033494025,0.0000063589932,0.000050657974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950845,0.002590977,0.0018502771,0.00015833441,0.00006697489,0.00024888554],"domain_scores_gemma":[0.98963016,0.0093371095,0.0007648837,0.00006120973,0.00014802399,0.00005863994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005620278,0.00010467848,0.0014402356,0.00022195264,0.000016771079,0.0000014327076,0.00014335268,0.0002097681,0.00009437841],"category_scores_gemma":[0.0023596883,0.00007399419,0.00011737909,0.00047256958,0.0002408641,0.000041068983,0.00007563237,0.0007386623,0.0000015691842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046857004,0.00038510605,0.9550286,0.000050627827,0.00020560338,0.00009011103,0.000026947817,0.000026426367,0.0010960493,0.0001366582,0.0003569809,0.03791118],"study_design_scores_gemma":[0.0052157217,0.0014787486,0.98829377,0.00012768754,0.000075659125,0.00000535673,0.000052252006,0.000024479132,0.0012693179,0.00035749158,0.0030267432,0.00007275411],"about_ca_topic_score_codex":0.19344182,"about_ca_topic_score_gemma":0.77781534,"teacher_disagreement_score":0.58437353,"about_ca_system_score_codex":0.00032603514,"about_ca_system_score_gemma":0.0022858272,"threshold_uncertainty_score":0.8119291},"labels":[],"label_agreement":null},{"id":"W4379282977","doi":"10.1200/jco.2023.41.16_suppl.tps5103","title":"SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Observational study; Interim analysis; Biomarker; Oncology; Interim; Internal medicine; Clinical trial; Seminoma; Chemotherapy","score_opus":0.5887588118999613,"score_gpt":0.48082834315819845,"score_spread":0.10793046874176282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97888553,0.00014568084,0.0002690985,0.018910898,0.00088491786,0.0006727744,0.00006082338,0.000008562221,0.00016174192],"genre_scores_gemma":[0.98621815,0.0008344889,0.009706227,0.002053587,0.0007961785,0.000009729157,0.00013131565,0.00003229538,0.0002180239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99341005,0.0017014069,0.0035274625,0.00031196047,0.0008096886,0.00023940713],"domain_scores_gemma":[0.98276746,0.01361301,0.0025020663,0.00036502138,0.00041583166,0.00033662794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00954286,0.0001906374,0.0013372363,0.00042294626,0.00007206386,0.000019184266,0.00049173285,0.00022535212,0.00018843931],"category_scores_gemma":[0.0076587508,0.00013502667,0.00023508945,0.00053424167,0.0006634665,0.000386766,0.00020089763,0.00141781,9.161367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0877814,0.010885484,0.73222345,0.00028622744,0.0010923464,0.0013340296,0.0017743785,0.0078322105,0.0029916398,0.00023612226,0.07614675,0.07741599],"study_design_scores_gemma":[0.057765234,0.0053158505,0.91312534,0.00018200709,0.00036780996,0.000055426794,0.00034510548,0.015152217,0.000033969864,0.00020108541,0.0073269573,0.00012898378],"about_ca_topic_score_codex":0.0001678127,"about_ca_topic_score_gemma":0.00014947118,"teacher_disagreement_score":0.18090193,"about_ca_system_score_codex":0.000054719592,"about_ca_system_score_gemma":0.0047823805,"threshold_uncertainty_score":0.91687936},"labels":[],"label_agreement":null},{"id":"W4379283040","doi":"10.1200/jco.2023.41.16_suppl.2519","title":"A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Chimeric antigen receptor; Breast cancer; Immunotherapy; Cancer; Cancer research; Leukapheresis; T cell; Oncology; Internal medicine; Immunology; Immune system; Stem cell; CD34","score_opus":0.2245488059784758,"score_gpt":0.54106261968792,"score_spread":0.3165138137094442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157685,0.00014105109,0.00000615804,0.005546326,0.0007866855,0.00053036277,0.0000037711284,0.00002092845,0.0013878448],"genre_scores_gemma":[0.9937527,0.00097072934,0.0010771508,0.0007368769,0.0014227533,0.000005139744,0.000004103916,0.000032939166,0.0019975798],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932646,0.0012602073,0.0042677517,0.00026022195,0.000561495,0.00038572683],"domain_scores_gemma":[0.9855097,0.011317888,0.0020599363,0.0002639398,0.00030898582,0.0005395596],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011668635,0.00015768319,0.0025142627,0.00043863617,0.00005729997,0.000006124189,0.00020753357,0.00053318375,0.0005794711],"category_scores_gemma":[0.04261397,0.000109481014,0.0003651439,0.0006164806,0.0006401785,0.000068828915,0.00015734257,0.0022523727,0.000009940634],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44985962,0.007401102,0.0025802823,0.000087043714,0.00031881596,0.0036984275,0.0008790796,0.00002487777,0.018109145,0.000030167252,0.0023341684,0.5146773],"study_design_scores_gemma":[0.60847855,0.2701399,0.058193456,0.0006564194,0.00024827546,0.0008260886,0.0005517745,0.0015584581,0.00069624186,0.0003630169,0.058082785,0.00020501205],"about_ca_topic_score_codex":0.000030506184,"about_ca_topic_score_gemma":0.000050833343,"teacher_disagreement_score":0.51447225,"about_ca_system_score_codex":0.0001910044,"about_ca_system_score_gemma":0.0037389807,"threshold_uncertainty_score":0.97855633},"labels":[],"label_agreement":null},{"id":"W4379283059","doi":"10.1200/jco.2023.41.16_suppl.e23006","title":"Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Academic Publishing and Open Access","field":"Decision Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; MEDLINE; Systematic review; Oncology; Family medicine; Internal medicine","score_opus":0.5421390908204856,"score_gpt":0.6198680837637089,"score_spread":0.07772899294322333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97737443,0.0026756797,0.0000978359,0.016330263,0.0014586655,0.00015757093,0.000017754084,0.000008518285,0.0018792524],"genre_scores_gemma":[0.9896145,0.008265468,0.000674246,0.0009115779,0.0002907477,0.000004809941,9.68728e-7,0.0000045100137,0.00023318898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97859824,0.01013025,0.008009786,0.000583143,0.0022038743,0.0004747239],"domain_scores_gemma":[0.9046034,0.085970126,0.00760876,0.00063668477,0.00064826297,0.00053275266],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15308571,0.0001710517,0.0042573665,0.0017789198,0.00008861891,0.00006035987,0.003966583,0.00093545945,0.00031007806],"category_scores_gemma":[0.32258987,0.00011937074,0.0011769646,0.010352697,0.00041280556,0.0012422156,0.0017295192,0.0020895456,0.00010639259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001119363,0.00043235088,0.78493285,0.000011768751,0.00018950726,0.0008903169,0.00039419782,0.00048999407,0.0000049845385,0.00006585121,0.025007842,0.186461],"study_design_scores_gemma":[0.00083597185,0.0010007487,0.9617203,0.00025140858,0.0006182811,0.00003287461,0.00066053023,0.0016621887,0.0000025714498,0.0073862406,0.025706658,0.00012225563],"about_ca_topic_score_codex":0.00048016018,"about_ca_topic_score_gemma":0.0020615272,"teacher_disagreement_score":0.18633874,"about_ca_system_score_codex":0.0005849053,"about_ca_system_score_gemma":0.0017193435,"threshold_uncertainty_score":0.90781516},"labels":[],"label_agreement":null},{"id":"W4379283073","doi":"10.1200/jco.2023.41.16_suppl.2514","title":"Association of common inherited <i>NOD2</i> mutations with exceptional response to immune checkpoint inhibitors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; NOD2; Lung cancer; Oncology; Internal medicine; Immune system; Melanoma; Colorectal cancer; Cohort; Immunology; Cancer; Cancer research; Innate immune system","score_opus":0.07366329743773874,"score_gpt":0.4402658457155609,"score_spread":0.3666025482778221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534261,0.00008220973,0.00004586009,0.045183625,0.0006951013,0.00017514758,0.000009706665,0.000015262449,0.0003669543],"genre_scores_gemma":[0.995427,0.00017508883,0.0013412206,0.0013967701,0.00049850455,0.000005839119,0.000011202572,0.000014514717,0.0011298544],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964345,0.0005524652,0.002272394,0.00010618339,0.00047736042,0.00015709411],"domain_scores_gemma":[0.9945576,0.0026532991,0.0018916641,0.000127044,0.0006101586,0.00016019058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007714718,0.00008744562,0.0008638421,0.00024436796,0.000037758993,0.0000056006193,0.000090139874,0.0002581378,0.00015209359],"category_scores_gemma":[0.0031651268,0.00006319112,0.00039595607,0.0006189114,0.00011636921,0.00006869341,0.000027391576,0.000496974,0.000025913963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28571454,0.0034203466,0.213369,0.00006719552,0.0023826323,0.0004622223,0.0012737411,0.00018407723,0.3546532,0.000013592306,0.04260063,0.09585882],"study_design_scores_gemma":[0.009769508,0.01353901,0.8797575,0.00017828557,0.00018027704,0.00010153352,0.00028205285,0.000021435988,0.0019601863,0.000065664586,0.09407602,0.000068485504],"about_ca_topic_score_codex":0.000034127308,"about_ca_topic_score_gemma":0.000059655693,"teacher_disagreement_score":0.6663885,"about_ca_system_score_codex":0.0003252859,"about_ca_system_score_gemma":0.0012372144,"threshold_uncertainty_score":0.3789181},"labels":[],"label_agreement":null},{"id":"W4379283093","doi":"10.1200/jco.2023.41.16_suppl.e16264","title":"Impact of homelessness on outcomes among pancreatic cancer hospitalization: Insight from the 2016-2020 National Inpatient Sample.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Healthcare Cost and Utilization Project; Medicaid; Odds ratio; Confidence interval; Logistic regression; Cancer; Pulmonary embolism; Pancreatic cancer; Odds; Diagnosis code; Retrospective cohort study; Health care; Emergency medicine; Demography; Internal medicine; Population; Environmental health","score_opus":0.10205988320647816,"score_gpt":0.48305345664944677,"score_spread":0.3809935734429686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204123,0.00012527313,0.00016826238,0.005832892,0.00095347996,0.00024734178,0.000093099145,0.000011431082,0.00052698323],"genre_scores_gemma":[0.9961624,0.0012046186,0.00021369499,0.0009843243,0.0012303102,0.000013133607,0.000031917967,0.000021508371,0.0001380941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959678,0.0004657504,0.0019288443,0.00018225587,0.0012150662,0.00024029329],"domain_scores_gemma":[0.9792379,0.017535796,0.0015308844,0.00022025754,0.0011914433,0.00028371354],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001872675,0.00015089066,0.0013697036,0.0001481726,0.000051613708,0.00001086276,0.00030489662,0.00028720807,0.0005182701],"category_scores_gemma":[0.017094113,0.0000751746,0.00058205606,0.000523997,0.0003529354,0.000103630126,0.00010332821,0.0006723917,0.000032686465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016457917,0.0006189774,0.9603795,0.00001585857,0.0011059114,0.00012230834,0.0003912884,0.00066260615,0.000015291656,0.000077507466,0.02548038,0.009484573],"study_design_scores_gemma":[0.00633217,0.00523733,0.9838736,0.00020663875,0.000199135,0.000008568849,0.0001272693,0.0015081725,0.000013390409,0.00069393823,0.0017290446,0.000070751375],"about_ca_topic_score_codex":0.00088031974,"about_ca_topic_score_gemma":0.00014530809,"teacher_disagreement_score":0.023751335,"about_ca_system_score_codex":0.0010017148,"about_ca_system_score_gemma":0.0071925833,"threshold_uncertainty_score":0.99843574},"labels":[],"label_agreement":null},{"id":"W4379283094","doi":"10.1200/jco.2023.41.16_suppl.10057","title":"Outcomes among survivors of childhood cancer in low- and middle-income countries: A systematic review.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hospital for Sick Children","funders":"","keywords":"Medicine; Low and middle income countries; Childhood cancer; Cancer; High income countries; Cohort study; Demography; Cohort; Observational study; Developing country; Environmental health; Pathology; Internal medicine","score_opus":0.08095344182457336,"score_gpt":0.45920323292601467,"score_spread":0.3782497911014413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690555,0.012059744,0.0000045435922,0.016510064,0.0012566417,0.0008734475,0.000017557992,0.00002032838,0.00020220947],"genre_scores_gemma":[0.951099,0.042240098,0.00012960233,0.0058855065,0.0003846478,0.000025362426,0.0000016766973,0.000031424075,0.0002027302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99077684,0.0012423524,0.006585835,0.00025254115,0.0008201716,0.00032228592],"domain_scores_gemma":[0.98707217,0.0075038713,0.0041945283,0.0003693011,0.0004634798,0.0003966522],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0146326525,0.0002221763,0.00549012,0.0003445916,0.000026509122,0.0000072674684,0.00027211194,0.0003504076,0.00009208744],"category_scores_gemma":[0.01845031,0.00015464277,0.0006175811,0.00055671897,0.0003513207,0.0001447509,0.00010446119,0.0009728699,0.000015765741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027370598,0.0004580565,0.86291945,0.13418412,0.0006037316,0.00025017365,0.0008593488,0.0000070270835,4.93507e-7,0.000036463745,0.00026676102,0.00014065689],"study_design_scores_gemma":[0.0040809647,0.0014599145,0.80947673,0.18338302,0.00072806206,0.000073994,0.0004241074,0.000024107452,0.0000032090686,0.00010764028,0.00012380983,0.000114459275],"about_ca_topic_score_codex":0.0005810401,"about_ca_topic_score_gemma":0.0031172824,"teacher_disagreement_score":0.05344274,"about_ca_system_score_codex":0.00015527243,"about_ca_system_score_gemma":0.0014563287,"threshold_uncertainty_score":0.9898177},"labels":[],"label_agreement":null},{"id":"W4379283124","doi":"10.1200/jco.2023.41.16_suppl.e21529","title":"Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: A systematic review of clinical trials.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Clinical trial; Oncology; Refractory (planetary science); Immunotherapy; Gastroenterology; Cancer","score_opus":0.36525618465451337,"score_gpt":0.5638272574325883,"score_spread":0.19857107277807495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283124","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023524533,0.9858706,0.0000029122848,0.000834249,0.007063986,0.0044919536,0.000026453683,0.000015758618,0.0014588254],"genre_scores_gemma":[0.0011477021,0.9932467,0.00042420748,0.0004527812,0.0039571812,0.00012636885,0.000011154374,0.00013603827,0.0004978645],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9157829,0.017589236,0.06404356,0.00070764497,0.0012776817,0.0005989272],"domain_scores_gemma":[0.860414,0.08138953,0.05519662,0.0011988711,0.0010849889,0.0007159481],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.099853024,0.000787002,0.06327002,0.00070053234,0.000032251195,0.00000892743,0.00084703934,0.002305473,0.00010552221],"category_scores_gemma":[0.2325803,0.00047553508,0.013775673,0.0009693899,0.0005342096,0.00005944153,0.00042412864,0.006188404,0.00014844922],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062779203,0.0017526274,0.00038772955,0.8610435,0.0011025757,0.007862386,0.000031209864,1.3587189e-7,9.0538165e-8,0.000003914755,0.0033606999,0.1238273],"study_design_scores_gemma":[0.006193182,0.010943358,0.00032109223,0.74290353,0.028867539,0.0039625615,0.00006757281,0.0000017507093,8.142268e-7,0.000024376814,0.2063762,0.00033802312],"about_ca_topic_score_codex":0.000047037112,"about_ca_topic_score_gemma":0.00003114226,"teacher_disagreement_score":0.20301549,"about_ca_system_score_codex":0.0008002565,"about_ca_system_score_gemma":0.011449444,"threshold_uncertainty_score":0.9997696},"labels":[],"label_agreement":null},{"id":"W4379283135","doi":"10.1200/jco.2023.41.16_suppl.9115","title":"Implementation strategies for monitoring adherence in real time (iSMART): A pilot randomized trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Chatbot; Usability; Quality of life (healthcare); Physical therapy; Lung cancer; Distress; Internal medicine; Artificial intelligence; Nursing","score_opus":0.5432867711967909,"score_gpt":0.6508600414659074,"score_spread":0.10757327026911645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97008497,0.000032561253,0.000038031434,0.008328309,0.017888656,0.0023183397,0.0000013183165,0.000024510797,0.0012833037],"genre_scores_gemma":[0.9839755,0.0022634242,0.0022696513,0.00009811825,0.010508848,0.0007656275,0.000002554019,0.000011326209,0.00010490248],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99378735,0.0029123323,0.0024903386,0.00012574013,0.00037314062,0.0003110971],"domain_scores_gemma":[0.94603604,0.05152815,0.0018195723,0.000058951482,0.00036920977,0.00018810043],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031121632,0.00006845144,0.0010120281,0.00016989336,0.00013177816,0.000033034,0.00020765202,0.00021965698,0.00008795898],"category_scores_gemma":[0.037992146,0.000059924354,0.00024452448,0.0003915037,0.00024851604,0.00029961296,0.00001530066,0.0003412125,0.000026855987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6505701,0.00070932845,0.015403904,0.00003139488,0.00009357808,0.000016676426,0.022767391,0.00001810269,0.000058213926,0.006454166,0.0041957083,0.29968145],"study_design_scores_gemma":[0.8694172,0.008602719,0.039131746,0.000067593064,0.00009998859,7.005901e-7,0.03033403,0.000054676748,0.000006619324,0.0346501,0.017508177,0.00012643769],"about_ca_topic_score_codex":0.0031673515,"about_ca_topic_score_gemma":0.0017641904,"teacher_disagreement_score":0.29955503,"about_ca_system_score_codex":0.00030735286,"about_ca_system_score_gemma":0.006765725,"threshold_uncertainty_score":0.998865},"labels":[],"label_agreement":null},{"id":"W4379283164","doi":"10.1200/jco.2023.41.16_suppl.6582","title":"Proportion of patients in phase I solid tumor oncology trials receiving treatments that are clinically efficacious.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Population; Internal medicine; Regimen; Clinical endpoint; Surrogate endpoint; Phases of clinical research; Quality of life (healthcare); Randomized controlled trial; Oncology","score_opus":0.15791369243174436,"score_gpt":0.5046102087168033,"score_spread":0.34669651628505893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644536,0.00016856172,0.000087228145,0.0007005148,0.0019177184,0.00035902552,0.00005492577,0.000004585254,0.00026207106],"genre_scores_gemma":[0.9932746,0.0043906677,0.00071464496,0.0006084172,0.0008535249,0.000012888683,0.000058797614,0.000022762484,0.000063668725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336946,0.0010537363,0.004712495,0.00030207227,0.00027176665,0.00029046412],"domain_scores_gemma":[0.99048847,0.0023869865,0.00617466,0.00024551715,0.00047510545,0.00022924713],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008728853,0.00016960155,0.0019881555,0.00016917859,0.000029767101,0.000007777802,0.00027484554,0.0005401372,0.000026849613],"category_scores_gemma":[0.02619678,0.00013356205,0.0006531917,0.00017183855,0.00017296552,0.000008211449,0.00013784025,0.00042148712,0.000010654003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015271446,0.010143757,0.6597777,0.000041158128,0.00061718095,0.00040948758,0.00009891434,0.0004108573,0.0058548264,0.000012637474,0.01024569,0.2971163],"study_design_scores_gemma":[0.045979027,0.06215497,0.8033326,0.00015992206,0.00046751733,0.000035632456,0.00026258224,0.00013821643,0.0062507414,0.0005395468,0.08035216,0.00032703282],"about_ca_topic_score_codex":0.000012286481,"about_ca_topic_score_gemma":0.00011982298,"teacher_disagreement_score":0.2967893,"about_ca_system_score_codex":0.00012142176,"about_ca_system_score_gemma":0.001491384,"threshold_uncertainty_score":0.98200595},"labels":[],"label_agreement":null},{"id":"W4379283170","doi":"10.1200/jco.2023.41.16_suppl.e17587","title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Population; Oncology; PARP inhibitor; Cancer; Ovarian cancer; Meta-analysis; Confidence interval; Poly ADP ribose polymerase","score_opus":0.22325241492691433,"score_gpt":0.489723068872906,"score_spread":0.2664706539459917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000853187,0.9898597,0.000044377815,0.0051138094,0.00028295812,0.004401264,0.00013942324,0.000023280943,0.00004986605],"genre_scores_gemma":[0.00010226174,0.9888829,0.0007470811,0.008365985,0.00055762357,0.0008093671,0.000031853026,0.00012393104,0.0003789924],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9865173,0.003050005,0.00808207,0.00073930254,0.0010684191,0.0005428753],"domain_scores_gemma":[0.98160744,0.004586587,0.011420674,0.00081069156,0.00088612025,0.0006885161],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005876052,0.00082345784,0.031590518,0.0008662355,0.00005306217,0.000032348817,0.00042024392,0.0007440586,0.0002837676],"category_scores_gemma":[0.0016521404,0.0003944071,0.0036312446,0.0021907182,0.00037743003,0.00016739848,0.00005740217,0.0023260005,0.000014258802],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055101775,0.0033333192,0.0015294884,0.41876292,0.49843135,0.0029028596,0.000096908334,0.0000036979977,3.6590873e-8,0.00003033499,0.0038606268,0.06553827],"study_design_scores_gemma":[0.016809786,0.010626744,0.0007127197,0.14832003,0.7265706,0.00024239632,0.000016601736,0.0000012412385,1.2949296e-7,0.000011044104,0.096209876,0.00047881607],"about_ca_topic_score_codex":0.00013221234,"about_ca_topic_score_gemma":0.0003333044,"teacher_disagreement_score":0.2704429,"about_ca_system_score_codex":0.00060185074,"about_ca_system_score_gemma":0.0047403956,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W4379283180","doi":"10.1200/jco.2023.41.16_suppl.2580","title":"The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada)","funders":"","keywords":"Medicine; Oncolytic virus; Pharmacokinetics; Internal medicine; Gastroenterology; Colorectal cancer; Pharmacodynamics; Carcinoembryonic antigen; Cancer","score_opus":0.07195290089014271,"score_gpt":0.4714039475880513,"score_spread":0.3994510466979086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849814,0.000097679476,0.000034104898,0.00034371088,0.00040705412,0.00046575395,0.000030902433,0.000003104849,0.00011955642],"genre_scores_gemma":[0.99869347,0.00047996198,0.00020864783,0.00011517313,0.00038811087,0.0000150793985,0.000021969283,0.000025621453,0.000051941537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99554986,0.0006860374,0.0026485645,0.00028767457,0.0004862032,0.0003416445],"domain_scores_gemma":[0.9957454,0.0007827006,0.0023601837,0.0003650362,0.00055666,0.00018999014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043392833,0.00016930686,0.0010822883,0.00014648357,0.00006255457,0.000011856596,0.00032908103,0.00030385447,0.000009216281],"category_scores_gemma":[0.0033386475,0.00011163882,0.0002253771,0.0002511912,0.00052665314,0.000015603366,0.00015905316,0.00057473336,0.00000126175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63349724,0.0033085775,0.0087831,0.000038786817,0.00044809,0.00066537946,0.00015319465,0.00021934541,0.1947396,0.000001274957,0.00079933496,0.1573461],"study_design_scores_gemma":[0.38244176,0.3611581,0.05176567,0.00038115744,0.00023291605,0.00015616346,0.00045633796,0.000407809,0.19240293,0.00019925907,0.009895083,0.00050279923],"about_ca_topic_score_codex":0.000012575321,"about_ca_topic_score_gemma":0.00014948823,"teacher_disagreement_score":0.35784954,"about_ca_system_score_codex":0.00003796453,"about_ca_system_score_gemma":0.0016665303,"threshold_uncertainty_score":0.4552499},"labels":[],"label_agreement":null},{"id":"W4379283210","doi":"10.1200/jco.2023.41.16_suppl.tps5627","title":"ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Karyopharm Therapeutics","keywords":"Medicine; Clinical endpoint; Internal medicine; Placebo; Oncology; Phases of clinical research; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Maintenance therapy; Cancer; Clinical trial; Gastroenterology; Surgery; Pathology","score_opus":0.1379598362240812,"score_gpt":0.478609204240197,"score_spread":0.3406493680161158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97929496,0.0011984936,0.00010034759,0.0007785433,0.002615209,0.015903383,0.00004974731,0.000016564698,0.00004277051],"genre_scores_gemma":[0.9881173,0.007081414,0.0014059254,0.00023857385,0.0013513449,0.0014221701,0.0000507445,0.000060651677,0.00027188775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909288,0.0016187571,0.0051809424,0.0005072604,0.0010361279,0.0007280703],"domain_scores_gemma":[0.9791275,0.01466526,0.0033774297,0.0004126295,0.0018478287,0.00056934264],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0087968465,0.0004282275,0.005525438,0.00088412187,0.000049478414,0.000020388718,0.00031360166,0.00044448467,0.00011422285],"category_scores_gemma":[0.013838844,0.0002157027,0.0013850536,0.0007437564,0.0002987184,0.00016432916,0.000049465885,0.00097548484,0.000011520528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84561485,0.012729783,0.015899558,0.00007937435,0.0021157956,0.00062822335,0.00019630858,0.000017899263,0.000044662924,0.000002900912,0.00024424426,0.122426406],"study_design_scores_gemma":[0.90702575,0.08536949,0.0030726665,0.00044099626,0.00041518052,0.00003998023,0.0001264442,0.00065737026,0.000060492323,0.0000128350475,0.0026006815,0.00017809992],"about_ca_topic_score_codex":0.000034918907,"about_ca_topic_score_gemma":0.00007472235,"teacher_disagreement_score":0.12224831,"about_ca_system_score_codex":0.00029720762,"about_ca_system_score_gemma":0.0022783566,"threshold_uncertainty_score":0.99446803},"labels":[],"label_agreement":null},{"id":"W4379283217","doi":"10.1200/jco.2023.41.16_suppl.12016","title":"Long-term outcomes of adolescents and young adults with testicular germ cell tumors: A population-based retrospective matched cohort study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Interquartile range; Population; Cumulative incidence; Internal medicine; Retrospective cohort study; Proportional hazards model; Germ cell tumors; Cohort; Surgery; Chemotherapy; Confidence interval","score_opus":0.03872511693993979,"score_gpt":0.4006318436623977,"score_spread":0.3619067267224579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998632,0.00012080833,0.000025816356,0.00023625576,0.00021097694,0.0007155712,0.000008233004,0.000020343068,0.000030008181],"genre_scores_gemma":[0.9991736,0.00003165465,0.000470343,0.00013133558,0.00011029175,0.000009308301,0.00001255841,0.000022162809,0.00003873648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741614,0.00020602248,0.001406763,0.00024153486,0.0005441769,0.00018538987],"domain_scores_gemma":[0.9967293,0.0005822452,0.0016630975,0.00021292898,0.00046390944,0.0003484829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008457535,0.00016891569,0.0015558235,0.000142632,0.00003464967,0.000007850625,0.00007896826,0.0001321531,0.000018118217],"category_scores_gemma":[0.0021279664,0.00010462875,0.00027555073,0.00021264832,0.000101822385,0.000053764266,0.000034001954,0.00033990524,0.0000056826293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027398176,0.0054595214,0.985846,0.00013531336,0.00060476875,0.0037709516,0.000058208774,0.0000137631305,0.0000055417563,0.0000010473627,0.000015488193,0.0013495691],"study_design_scores_gemma":[0.017883314,0.012209465,0.96724236,0.0005065396,0.0017513162,0.00009860833,0.00010595319,0.000085281055,0.0000066069915,0.000022383376,6.633101e-7,0.00008751739],"about_ca_topic_score_codex":0.00009517833,"about_ca_topic_score_gemma":0.00007425346,"teacher_disagreement_score":0.018603656,"about_ca_system_score_codex":0.00012605214,"about_ca_system_score_gemma":0.0005477896,"threshold_uncertainty_score":0.42666367},"labels":[],"label_agreement":null},{"id":"W4379283222","doi":"10.1200/jco.2023.41.16_suppl.tps2670","title":"A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Barrier Structure and Function Studies","field":"Neuroscience","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Tolerability; Radioimmunotherapy; Antibody; Internal medicine; Chemotherapy; Adverse effect; Immunology; Monoclonal antibody","score_opus":0.11100165793756535,"score_gpt":0.4566002010796958,"score_spread":0.34559854314213045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974627,0.000020750807,0.00006966541,0.0010982318,0.0007011388,0.00045132625,0.000009931362,0.000007066818,0.00017920558],"genre_scores_gemma":[0.99899703,0.00012227238,0.00015845512,0.00047945505,0.00019985037,0.0000035836504,0.0000012626459,0.000008174084,0.000029925508],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970979,0.0005923482,0.0015411682,0.00025602663,0.0003466738,0.00016587629],"domain_scores_gemma":[0.9956201,0.002897713,0.0010048874,0.00009279154,0.00020731565,0.00017721526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017244827,0.000118224394,0.0009057072,0.00020856483,0.000105906,0.000007427585,0.00007951281,0.00013915804,0.000012628009],"category_scores_gemma":[0.005595165,0.000078616606,0.000081511236,0.0003468412,0.00023399391,0.00015509374,0.00014681637,0.0004000453,0.0000017043978],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6670351,0.0027723387,0.014442947,0.000016187118,0.000064059546,0.00010582624,0.0018813714,0.00017963482,0.0016782989,0.000046181816,0.0006864572,0.31109163],"study_design_scores_gemma":[0.13124306,0.10366369,0.7633584,0.00008794348,0.0000954971,0.000016754959,0.00009707892,0.00021350023,0.0004432183,0.00016295869,0.0005260269,0.00009185541],"about_ca_topic_score_codex":0.0000028459508,"about_ca_topic_score_gemma":0.000004230381,"teacher_disagreement_score":0.74891543,"about_ca_system_score_codex":0.000034274228,"about_ca_system_score_gemma":0.00021322032,"threshold_uncertainty_score":0.6698339},"labels":[],"label_agreement":null},{"id":"W4379283236","doi":"10.1200/jco.2023.41.16_suppl.3125","title":"Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; Medicine; HRAS; MAPK/ERK pathway; Cancer research; Cancer; Colorectal cancer; Mutation; Mutant; Melanoma; Lung cancer; Kinase; Oncology; Internal medicine; Biology; Gene; Genetics","score_opus":0.2124749365452833,"score_gpt":0.4693900631818412,"score_spread":0.2569151266365579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0135696605,0.9825427,0.000031105323,0.000087613924,0.00029067337,0.0032996018,0.00014819718,0.000005703951,0.00002476075],"genre_scores_gemma":[0.0055838837,0.9930438,0.00042627114,0.00021206516,0.00014109575,0.00021055814,0.00010192077,0.000068338784,0.0002121131],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98426956,0.006401647,0.007801414,0.00067414116,0.0005061636,0.0003470879],"domain_scores_gemma":[0.98484063,0.0014028936,0.012045202,0.00066771585,0.0006675183,0.00037602842],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008438638,0.0005842683,0.019525083,0.00038712856,0.000028648767,0.000013520925,0.00048644113,0.0008928924,0.000028561622],"category_scores_gemma":[0.006187402,0.00033572433,0.0042611626,0.00092301535,0.00029663017,0.00001747993,0.00020378514,0.0012780258,0.000004714721],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013710982,0.0024660141,0.00034980185,0.57502615,0.3942736,0.00037568496,0.000018011908,0.0000063062867,0.000033452736,0.0000074622526,0.0008883244,0.02518406],"study_design_scores_gemma":[0.0037735535,0.012501173,0.00025929004,0.029193904,0.92548025,0.00004323909,0.0000131153765,0.0000021818018,0.00007249871,0.00001781836,0.028000502,0.00064246915],"about_ca_topic_score_codex":0.000041854022,"about_ca_topic_score_gemma":0.00015978154,"teacher_disagreement_score":0.5458323,"about_ca_system_score_codex":0.00010531546,"about_ca_system_score_gemma":0.002787685,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W4379283245","doi":"10.1200/jco.2023.41.16_suppl.2515","title":"Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Microbiome; Gastroenterology; Melanoma; Progressive disease; Adjuvant; Colorectal cancer; Immune system; Oncology; Disease; Cancer; Immunology; Cancer research; Bioinformatics; Biology","score_opus":0.09736325671866872,"score_gpt":0.4256533730893036,"score_spread":0.3282901163706349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806319,0.0002228818,0.000068280344,0.017657964,0.0009979694,0.0001602032,0.000009863451,0.000017783119,0.00023318188],"genre_scores_gemma":[0.99604475,0.0012274629,0.00027798326,0.0012736138,0.00066388224,0.000004221211,0.00006955518,0.000014879853,0.00042362243],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99672997,0.00024717444,0.0024951412,0.00013946043,0.00020236237,0.00018586632],"domain_scores_gemma":[0.9978455,0.00042356865,0.0012207226,0.0001270248,0.00020775045,0.00017547287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003688222,0.000097291406,0.0007376387,0.00031921826,0.000025240506,0.000008761705,0.00007337773,0.00017726031,0.00013816213],"category_scores_gemma":[0.0016897244,0.00007418069,0.0004034918,0.0005008129,0.00015231135,0.000103485785,0.00003346761,0.00052816357,0.00003250322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04805512,0.0010813418,0.03159469,0.000085042295,0.00012631017,0.0018817298,0.00010238488,0.0000021232752,0.84837776,0.000026609643,0.0008323892,0.06783448],"study_design_scores_gemma":[0.0072947517,0.00368129,0.9535844,0.0005646264,0.00007691797,0.00015640674,0.00006191923,0.00006925491,0.0020781131,0.00013584005,0.032220937,0.000075562755],"about_ca_topic_score_codex":0.00001305223,"about_ca_topic_score_gemma":0.000012658677,"teacher_disagreement_score":0.9219897,"about_ca_system_score_codex":0.0002357006,"about_ca_system_score_gemma":0.0010070283,"threshold_uncertainty_score":0.30250007},"labels":[],"label_agreement":null},{"id":"W4379283247","doi":"10.1200/jco.2023.41.16_suppl.10048","title":"Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) report.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Psychosocial; Sibling; Demography; Logistic regression; Ethnic group; National Health Interview Survey; Marital status; Health and Retirement Study; Gerontology; Household income; Finance; Psychology; Psychiatry; Environmental health; Population; Developmental psychology","score_opus":0.12437909302941884,"score_gpt":0.4810666729856726,"score_spread":0.3566875799562538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841766,0.0013535583,0.000029210667,0.0064529553,0.006226543,0.001230588,0.00009453722,0.00007071338,0.0003652951],"genre_scores_gemma":[0.99107665,0.0029155465,0.00019881033,0.001042838,0.004254159,0.0000476633,0.000018715307,0.000101157326,0.00034446345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9847656,0.001675011,0.009758442,0.00079812884,0.002207151,0.00079570507],"domain_scores_gemma":[0.98109895,0.0043537915,0.0107914535,0.00096647325,0.002005155,0.0007842063],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016705317,0.0005389928,0.005783948,0.00087983126,0.00011175687,0.00001929622,0.0008452953,0.0008819753,0.0004049514],"category_scores_gemma":[0.018497422,0.00045305336,0.0018020299,0.0018038999,0.000753863,0.00031141963,0.00034000515,0.0024601398,0.000012855362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023808763,0.009064194,0.94751745,0.0003371954,0.001830638,0.0023074043,0.0038485543,0.00010203653,0.00005615613,0.000016097198,0.0027584666,0.029780952],"study_design_scores_gemma":[0.012679058,0.011134746,0.97050947,0.0012730419,0.0014722388,0.00030314902,0.00092912593,0.000013423906,0.00028287532,0.00014492481,0.0008959525,0.00036199106],"about_ca_topic_score_codex":0.0074325656,"about_ca_topic_score_gemma":0.032987572,"teacher_disagreement_score":0.029418962,"about_ca_system_score_codex":0.00027776297,"about_ca_system_score_gemma":0.009003782,"threshold_uncertainty_score":0.9998412},"labels":[],"label_agreement":null},{"id":"W4379283294","doi":"10.1200/jco.2023.41.16_suppl.3036","title":"Longitudinal mutational analysis of <i>TP53</i> in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Circulating tumor DNA; Mdm2; Internal medicine; Somatic cell; Oncology; Mutation; Cancer research; Gene; Cancer; Genetics; Biology","score_opus":0.058946878093820154,"score_gpt":0.42576158674096526,"score_spread":0.3668147086471451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994335,0.00002545082,0.000023850844,0.00006543837,0.00015446263,0.00020393252,0.00004489391,0.0000013327817,0.00004710142],"genre_scores_gemma":[0.999418,0.000045595585,0.00025274782,0.00008364857,0.00011053385,0.000007370313,0.0000647442,0.000014426959,0.0000028935372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626464,0.00033492234,0.0025527433,0.00030276514,0.000306205,0.00023873031],"domain_scores_gemma":[0.9970437,0.00055254047,0.0017686306,0.00019488197,0.000311106,0.00012910727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019718346,0.0001450494,0.0012599733,0.00061557966,0.00001864407,0.0000075319354,0.00023146436,0.00015716307,0.000009362716],"category_scores_gemma":[0.00142215,0.0001284037,0.00020674395,0.0009549591,0.00013156612,0.000013810337,0.000090191694,0.00033680777,4.496423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035889465,0.0076295016,0.9477236,0.000015495743,0.00038215952,0.00047276128,0.00034615668,0.033449937,0.00219016,0.000007777109,0.000023164659,0.0041703065],"study_design_scores_gemma":[0.016712077,0.02090715,0.95653707,0.000046128436,0.0002649583,0.000013848281,0.00092022534,0.0037112236,0.0006635063,0.00003920452,0.000048508333,0.00013609401],"about_ca_topic_score_codex":0.00020520102,"about_ca_topic_score_gemma":0.0066609634,"teacher_disagreement_score":0.029738715,"about_ca_system_score_codex":0.00008233796,"about_ca_system_score_gemma":0.0009141468,"threshold_uncertainty_score":0.52361506},"labels":[],"label_agreement":null},{"id":"W4379283340","doi":"10.1200/jco.2023.41.16_suppl.e14570","title":"Efficacy and safety study of a novel alpha-fetoprotein (AFP)-maytansine conjugate in an ovarian xenograft model.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Alpha Cancer Technologies","funders":"","keywords":"Medicine; Ovarian cancer; Cancer research; Conjugate; Cancer; Internal medicine; Oncology","score_opus":0.15649444812781935,"score_gpt":0.4993262605804959,"score_spread":0.3428318124526766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984053,0.00014974507,0.00024828728,0.00057522365,0.00011019077,0.00035344693,0.000015582475,0.0000023466582,0.00013988666],"genre_scores_gemma":[0.99829465,0.0005717278,0.00072229136,0.00011749091,0.00019570054,0.000007584486,0.000011878462,0.000013486164,0.00006517302],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977554,0.00029360357,0.0012599041,0.00023977784,0.00021846249,0.00023285807],"domain_scores_gemma":[0.9986363,0.00018644196,0.0005193864,0.00021364211,0.00019420416,0.00025000746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020108973,0.00011383632,0.00067543326,0.00012569332,0.000031052365,0.000008108077,0.00018653179,0.00021696171,0.000009220186],"category_scores_gemma":[0.00069768255,0.0000893445,0.00011315751,0.00015738439,0.00014164453,0.0000110062165,0.00013561115,0.00033482484,0.0000013142458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10821354,0.05394274,0.26406237,0.00010241489,0.0028679273,0.0021261554,0.0014178882,0.012406948,0.26749325,0.00023116048,0.001444663,0.28569096],"study_design_scores_gemma":[0.11430424,0.11380245,0.750295,0.00009609355,0.00022794028,0.00014937161,0.00069171865,0.00716526,0.0039600027,0.00042173048,0.008509396,0.0003768441],"about_ca_topic_score_codex":0.00015183997,"about_ca_topic_score_gemma":0.0016372782,"teacher_disagreement_score":0.4862326,"about_ca_system_score_codex":0.00002762054,"about_ca_system_score_gemma":0.00058104086,"threshold_uncertainty_score":0.3643363},"labels":[],"label_agreement":null},{"id":"W4379283341","doi":"10.1200/jco.2023.41.16_suppl.5028","title":"Building a predictive model for outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Univariate; Logistic regression; Univariate analysis; Oncology; Predictive value; Internal medicine; Multivariate analysis; Multivariate statistics; Cancer; Statistics","score_opus":0.24238683400862732,"score_gpt":0.5266294923762522,"score_spread":0.2842426583676249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927554,0.00018573656,0.0013361933,0.0034500905,0.00014285414,0.0015590533,0.0005214855,0.000016678667,0.00003249978],"genre_scores_gemma":[0.97326386,0.00032529182,0.025498228,0.00019213917,0.000174056,0.00006111312,0.00015376974,0.000044013832,0.00028753164],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9961754,0.0002578279,0.0018773612,0.00045581016,0.0007649113,0.00046869437],"domain_scores_gemma":[0.9954107,0.0018818895,0.0012095828,0.00034360294,0.0008420295,0.00031224324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002849604,0.00022845408,0.0013362913,0.00033484056,0.00010640452,0.000027024413,0.00023311771,0.00015820436,0.000003988389],"category_scores_gemma":[0.001489042,0.00012622078,0.00014310151,0.00042082687,0.0002466337,0.00051225384,0.0001238428,0.0007248614,8.628607e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4371894,0.0037674906,0.35264513,0.00036585677,0.0021679127,0.0013844795,0.0017943567,0.16497836,0.00007859465,0.000022018881,0.002161989,0.033444427],"study_design_scores_gemma":[0.06544279,0.05367884,0.40019292,0.0011928324,0.0012610132,0.000029617753,0.0009869939,0.47634217,0.000024841105,0.00027592434,0.00036431296,0.00020775251],"about_ca_topic_score_codex":0.00008951946,"about_ca_topic_score_gemma":0.00017239078,"teacher_disagreement_score":0.3717466,"about_ca_system_score_codex":0.00047480143,"about_ca_system_score_gemma":0.003993588,"threshold_uncertainty_score":0.7084453},"labels":[],"label_agreement":null},{"id":"W4379283347","doi":"10.1200/jco.2023.41.16_suppl.e24059","title":"Subjective and objective hearing loss among US adult cancer survivors: A national cross-sectional study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Audiometry; Hearing loss; Tinnitus; Population; Logistic regression; National Health and Nutrition Examination Survey; Cross-sectional study; Cancer; Audiology; Young adult; Internal medicine; Pathology","score_opus":0.21217582786864564,"score_gpt":0.5092305380666451,"score_spread":0.29705471019799945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472696,0.000025676649,0.000039359773,0.00045915018,0.00282037,0.00029129506,0.000017858167,0.000039806226,0.0015795047],"genre_scores_gemma":[0.99668604,0.00027056603,0.00014034574,0.0008695309,0.0015721102,0.000017536286,4.6007926e-7,0.000029150578,0.00041424512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99461305,0.0012199287,0.0020921347,0.0005407129,0.001104645,0.00042951934],"domain_scores_gemma":[0.98961526,0.0070854453,0.0013729209,0.0001444776,0.0014269158,0.0003550047],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056385184,0.00019413103,0.0008070736,0.00032628264,0.00025594042,0.00009708585,0.00034414366,0.00036851616,0.000068818124],"category_scores_gemma":[0.028227843,0.00017168807,0.00024870952,0.0006804063,0.0007408887,0.0003230633,0.00029486767,0.0015382676,0.000046379013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071241905,0.0005985414,0.99401486,0.000008860173,0.000084637715,0.00033549446,0.0005618967,0.0013369535,0.0005771896,0.00012152484,0.00013204491,0.0015155987],"study_design_scores_gemma":[0.0026414986,0.002617357,0.9909637,0.000022835828,0.000026741202,0.00020474884,0.00022919159,0.0009214456,0.00043840395,0.0010832533,0.0006888734,0.00016198176],"about_ca_topic_score_codex":0.0010883538,"about_ca_topic_score_gemma":0.0039774906,"teacher_disagreement_score":0.022589324,"about_ca_system_score_codex":0.00036242112,"about_ca_system_score_gemma":0.0019037516,"threshold_uncertainty_score":0.9799578},"labels":[],"label_agreement":null},{"id":"W4379283386","doi":"10.1200/jco.2023.41.16_suppl.4002","title":"Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Population; Internal medicine; Adverse effect; Atezolizumab; Oncology; Randomized controlled trial; Cancer","score_opus":0.0569313940728409,"score_gpt":0.38558290673978524,"score_spread":0.3286515126669443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966564,0.0002475572,0.00000685979,0.0008200995,0.00088774593,0.0012015533,0.00014815107,0.000007584894,0.000024006142],"genre_scores_gemma":[0.9988551,0.0008325478,0.00005900737,0.000040622803,0.0001039183,0.000017909273,0.00004961703,0.000014524639,0.00002672287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955907,0.0006862063,0.0025786741,0.00031428525,0.0006210756,0.00020907834],"domain_scores_gemma":[0.99178374,0.0041373274,0.0031642925,0.00027175323,0.00045482928,0.00018803161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012706371,0.00019894139,0.0019411485,0.000116912975,0.00011438323,0.000004666709,0.00009342346,0.0001459432,0.000021224354],"category_scores_gemma":[0.005411386,0.00010185664,0.00035619072,0.00035772467,0.00021530475,0.00008678525,0.00011521657,0.00044234697,5.373787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43776542,0.0013611924,0.5307545,0.000010327677,0.0006723667,0.00020859083,0.0003782035,0.00001976487,0.0000024043322,8.396015e-7,0.000041552616,0.028784804],"study_design_scores_gemma":[0.19566663,0.032748025,0.77021587,0.00014217582,0.00059669017,0.0000029874761,0.00015264128,0.00014928861,0.000031338735,0.000031875312,0.00018434094,0.0000781257],"about_ca_topic_score_codex":0.0007848923,"about_ca_topic_score_gemma":0.0007935145,"teacher_disagreement_score":0.24209881,"about_ca_system_score_codex":0.0003490681,"about_ca_system_score_gemma":0.0007399724,"threshold_uncertainty_score":0.6478326},"labels":[],"label_agreement":null},{"id":"W4379283389","doi":"10.1200/jco.2023.41.16_suppl.3110","title":"First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melanoma; Internal medicine; Cancer; Hematology; Cohort; Dosing; Response Evaluation Criteria in Solid Tumors; Oncology; Gastroenterology; Pharmacology; Phases of clinical research; Toxicity; Cancer research","score_opus":0.05513052242782712,"score_gpt":0.3994851417478971,"score_spread":0.34435461932007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728745,0.00024339919,0.0000011226688,0.00097022933,0.00055154,0.00089628133,0.000021738688,0.0000045201937,0.00002369223],"genre_scores_gemma":[0.9992943,0.00026534093,0.00005126183,0.00022630485,0.00010531905,0.000022173304,0.0000096394815,0.0000143066045,0.000011374167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965272,0.00025233702,0.0024169357,0.0002014341,0.00039621798,0.00020588537],"domain_scores_gemma":[0.9974428,0.0004305065,0.0016189198,0.00019097605,0.00022360748,0.00009318573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016230552,0.00015467302,0.0010709679,0.0002515263,0.00003698828,0.0000058378882,0.0001265476,0.00018165741,0.00003439673],"category_scores_gemma":[0.00029364548,0.00010249509,0.00013856111,0.0005472865,0.00020302403,0.00018774066,0.00005505838,0.00043229258,3.757219e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03400003,0.004416613,0.9279417,0.00007705157,0.00013674377,0.00006929026,0.000765371,0.0004842581,0.00026844168,0.0000025231607,0.00017522318,0.031662747],"study_design_scores_gemma":[0.062675714,0.015375098,0.91888654,0.00068697473,0.00010115994,0.0000052658766,0.00026614117,0.0004894137,0.00031353865,0.000011459945,0.0010975108,0.00009116073],"about_ca_topic_score_codex":0.0005819595,"about_ca_topic_score_gemma":0.0089354515,"teacher_disagreement_score":0.031571586,"about_ca_system_score_codex":0.0002665068,"about_ca_system_score_gemma":0.0003838749,"threshold_uncertainty_score":0.49861914},"labels":[],"label_agreement":null},{"id":"W4379283397","doi":"10.1200/jco.2023.41.16_suppl.5097","title":"Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Adverse effect; Proportional hazards model; Cohort; Oncology; Cancer; Androgen receptor","score_opus":0.2668486127059642,"score_gpt":0.5243409152184116,"score_spread":0.2574923025124474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873609,0.00034417433,0.000017139677,0.009996718,0.00022856997,0.0017210164,0.00009569772,0.00001536656,0.00022042205],"genre_scores_gemma":[0.98918366,0.007356212,0.00068845274,0.0016680862,0.0002187778,0.00018400716,0.000081071536,0.000029278763,0.0005904587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552435,0.0009477501,0.0017915786,0.00036939498,0.00083443406,0.0005325102],"domain_scores_gemma":[0.9869689,0.0105165085,0.0011479795,0.00024400667,0.0007953943,0.00032721827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004129899,0.00026482105,0.001379431,0.0005555679,0.00014936012,0.00004466771,0.0002269009,0.00013061542,0.000020884125],"category_scores_gemma":[0.001627744,0.00014124216,0.00018088729,0.0010713673,0.0005153093,0.0002084864,0.000043739787,0.000983887,0.000008929111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1510177,0.0051471824,0.7657062,0.00075978896,0.0019877688,0.0025878535,0.012727734,0.005206988,0.00042144218,0.00035598027,0.016635532,0.03744583],"study_design_scores_gemma":[0.021364912,0.038013734,0.9195725,0.0015905588,0.00056609506,0.000030378133,0.003161735,0.0021937578,0.00014682412,0.0006551265,0.012478317,0.00022609744],"about_ca_topic_score_codex":0.00068474095,"about_ca_topic_score_gemma":0.004329845,"teacher_disagreement_score":0.15386626,"about_ca_system_score_codex":0.00048248353,"about_ca_system_score_gemma":0.0020056567,"threshold_uncertainty_score":0.57596874},"labels":[],"label_agreement":null},{"id":"W4379283399","doi":"10.1200/jco.2023.41.16_suppl.tps2671","title":"Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; T-cell receptor; CD8; Antigen; Immunology; Cytokine release syndrome; Cancer research; T cell; Pharmacology; Oncology; Internal medicine; Immune system; Chimeric antigen receptor; Adverse effect","score_opus":0.057827630948723535,"score_gpt":0.43414341595895894,"score_spread":0.37631578501023544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516594,0.000081251725,0.0000037044585,0.0009027962,0.00073104474,0.0027111073,0.000026777743,0.000019270046,0.000358115],"genre_scores_gemma":[0.9974018,0.00076499063,0.00021635636,0.00018723155,0.0007382478,0.00004303924,0.000084753665,0.00006775049,0.0004958467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99294084,0.0012587,0.0033788823,0.0005413994,0.001300068,0.00058008643],"domain_scores_gemma":[0.9941689,0.0020393792,0.0018734825,0.000286087,0.0012255863,0.00040657833],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037161252,0.00035292332,0.0022627534,0.0010497774,0.00007517233,0.00001575048,0.00021284369,0.00038276357,0.0013555308],"category_scores_gemma":[0.0017050891,0.00024665083,0.0003896279,0.0014069012,0.00019649054,0.00015724785,0.00007034163,0.0013474617,0.00003574732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54294515,0.07703579,0.35097376,0.000033779324,0.0005773166,0.00081942487,0.0015130857,0.00010513005,0.01623584,8.430467e-7,0.001047295,0.008712606],"study_design_scores_gemma":[0.42255232,0.34737232,0.22070044,0.0001479395,0.00010988558,0.000011251054,0.001190309,0.00017326046,0.0025861945,0.000012931807,0.0049405205,0.00020261153],"about_ca_topic_score_codex":0.00055535807,"about_ca_topic_score_gemma":0.0004976713,"teacher_disagreement_score":0.27033654,"about_ca_system_score_codex":0.0008827131,"about_ca_system_score_gemma":0.002850479,"threshold_uncertainty_score":0.99999857},"labels":[],"label_agreement":null},{"id":"W4379283403","doi":"10.1200/jco.2023.41.16_suppl.10002","title":"A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"St. Baldrick's Foundation","keywords":"Medicine; Internal medicine; Melphalan; Carboplatin; Busulfan; ThioTEPA; Transplantation; Oncology; Surgery; Chemotherapy; Cyclophosphamide; Hematopoietic stem cell transplantation; Cisplatin","score_opus":0.06469210767394869,"score_gpt":0.4603786648885649,"score_spread":0.3956865572146162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964963,0.000043261367,0.000008792824,0.00057381985,0.0011137443,0.0016344618,0.000008009552,0.000027296088,0.000094310104],"genre_scores_gemma":[0.99840707,0.00018995335,0.00013302478,0.00041987989,0.00040860276,0.000051993935,0.0000018621787,0.00004037292,0.00034726513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99325424,0.0028070984,0.002274468,0.00038175198,0.0008413939,0.00044105505],"domain_scores_gemma":[0.9916,0.005507679,0.0013073336,0.00034693332,0.000626041,0.0006120326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024703909,0.00025152945,0.0020242867,0.00036948718,0.00006826363,0.000013858825,0.00021923952,0.0001845224,0.00007782433],"category_scores_gemma":[0.0049244277,0.0001625586,0.00040593368,0.00050767726,0.00020457686,0.00013909674,0.00023103239,0.0015285877,0.0001770577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05540505,0.07024612,0.7843517,0.0000995499,0.0043400573,0.051390756,0.0015803613,0.000086971304,0.0007480852,0.000003020542,0.0019244815,0.029823814],"study_design_scores_gemma":[0.043903798,0.19760548,0.75623125,0.000080816666,0.00096408,0.00006373694,0.0004671691,0.00014494981,0.00010841432,0.000015115661,0.00033607302,0.00007910852],"about_ca_topic_score_codex":0.000092766364,"about_ca_topic_score_gemma":0.00038344742,"teacher_disagreement_score":0.12735936,"about_ca_system_score_codex":0.00007639428,"about_ca_system_score_gemma":0.00039959262,"threshold_uncertainty_score":0.6641038},"labels":[],"label_agreement":null},{"id":"W4379283421","doi":"10.1200/jco.2023.41.16_suppl.4517","title":"The impact of surgery on patients with VHL-associated tumors: An international patient survey.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merck","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Hemangioblastoma; Surgery; Pediatrics","score_opus":0.08470603852163096,"score_gpt":0.4291160218878838,"score_spread":0.34440998336625284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967902,0.00007417258,0.000004182028,0.00012477959,0.002680546,0.00007140722,0.00006440237,0.000002840574,0.00018752248],"genre_scores_gemma":[0.99771094,0.0009411371,0.000017139017,0.00015148455,0.0009998566,0.0000021082685,0.000102638405,0.000013261624,0.00006145933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975124,0.0006930738,0.0011522773,0.00014409058,0.0003085827,0.0001895651],"domain_scores_gemma":[0.99613273,0.0011431554,0.0015968219,0.00018441895,0.00078938116,0.00015348652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031535141,0.00010388401,0.00053932006,0.00006962568,0.000042674274,0.000010455543,0.00024201661,0.00019119117,0.000013404905],"category_scores_gemma":[0.005511289,0.000056856803,0.00039322133,0.00013434463,0.00012843875,0.000009134704,0.000053065047,0.0002659049,0.0000029514938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006609716,0.0015241435,0.863309,0.0000016751001,0.0006854096,0.000008542915,0.000035557827,0.00035861056,0.00040037555,0.0000057418656,0.026279971,0.10078123],"study_design_scores_gemma":[0.0015811274,0.007489236,0.97236425,0.000017584129,0.00002148768,0.0000038339963,0.000023067409,0.000017424461,0.00014039884,0.000023855706,0.018249014,0.00006869349],"about_ca_topic_score_codex":0.000070328366,"about_ca_topic_score_gemma":0.00019927554,"teacher_disagreement_score":0.10905526,"about_ca_system_score_codex":0.000042281717,"about_ca_system_score_gemma":0.0009975923,"threshold_uncertainty_score":0.6597926},"labels":[],"label_agreement":null},{"id":"W4379283423","doi":"10.1200/jco.2023.41.16_suppl.6618","title":"An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"Pfizer","keywords":"Cohort; Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Biology","score_opus":0.11470470744722208,"score_gpt":0.47846226075161813,"score_spread":0.3637575533043961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939804,0.00031171524,0.000076040575,0.0022873832,0.00097174,0.00083058863,0.00013097342,0.000044955264,0.0013662018],"genre_scores_gemma":[0.9950652,0.00054141664,0.0016051438,0.0004245054,0.00077148224,0.000024296009,0.000043060936,0.000058644575,0.0014662115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98656446,0.006641359,0.004387647,0.00058958173,0.0010618859,0.00075507007],"domain_scores_gemma":[0.96866393,0.026229734,0.0027951028,0.0005914114,0.0006484522,0.0010713966],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011919174,0.0003811547,0.0038220836,0.0012275057,0.00007489618,0.000024604045,0.0005138004,0.0006418975,0.00039937612],"category_scores_gemma":[0.01721082,0.00029721583,0.00072451413,0.00072460755,0.00052305905,0.00030958737,0.0001023173,0.0024469325,0.000110456545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2373404,0.0039997,0.66808724,0.000027943843,0.0007285242,0.0056438246,0.0005402581,0.000075966884,0.0105770575,0.000009426583,0.0012508897,0.07171875],"study_design_scores_gemma":[0.05394179,0.025728246,0.9062606,0.00029342694,0.00030914435,0.000048302096,0.00042400789,0.0066867354,0.0015040139,0.00027576322,0.004323692,0.00020428191],"about_ca_topic_score_codex":0.00094307004,"about_ca_topic_score_gemma":0.0033315748,"teacher_disagreement_score":0.23817334,"about_ca_system_score_codex":0.00078912254,"about_ca_system_score_gemma":0.0029979763,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W4379283431","doi":"10.1200/jco.2023.41.16_suppl.tps10071","title":"Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; St. Baldrick's Foundation","keywords":"Medicine; Clinical trial; Oncology; Cog; Refractory (planetary science); Internal medicine; Pediatrics","score_opus":0.07864758137944391,"score_gpt":0.4418208690745673,"score_spread":0.36317328769512336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761284,0.00035197323,0.0001812677,0.0059931017,0.0036297264,0.0020497025,0.00008827819,0.000035440964,0.00005767177],"genre_scores_gemma":[0.9818859,0.0026423694,0.0019067667,0.002831587,0.010458938,0.00006756841,0.000039618524,0.000057665256,0.000109570894],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960048,0.00029654565,0.002319375,0.00040472278,0.00054626237,0.00042826805],"domain_scores_gemma":[0.9936947,0.002235667,0.0026088997,0.00022987464,0.0006735889,0.00055725774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040105064,0.00023161717,0.0020041969,0.00022205159,0.000094489464,0.000014541715,0.00018001029,0.0004525423,0.000016455522],"category_scores_gemma":[0.0044156075,0.00017307291,0.00049329526,0.00023997553,0.00017406148,0.0001675448,0.000055423792,0.00089554675,0.0000059093836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6722468,0.002044243,0.20593011,0.00055279146,0.0013318463,0.00014251786,0.0011694765,0.0000074929026,0.000005992712,0.000018706389,0.057673566,0.058876436],"study_design_scores_gemma":[0.21872415,0.045074046,0.71790004,0.00044613332,0.0018864651,0.000208751,0.00055960147,0.00003781479,0.000016646394,0.00024073894,0.014642847,0.00026277406],"about_ca_topic_score_codex":0.00010697269,"about_ca_topic_score_gemma":0.00044695335,"teacher_disagreement_score":0.5119699,"about_ca_system_score_codex":0.00023964109,"about_ca_system_score_gemma":0.0028784573,"threshold_uncertainty_score":0.70577085},"labels":[],"label_agreement":null},{"id":"W4379283433","doi":"10.1200/jco.2023.41.16_suppl.e24027","title":"Examination of real-world data from geriatric assessments in a comprehensive cancer center to explore predominant and cancer-specific domains for intervention.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Geriatric oncology; Cancer; Internal medicine; Depression (economics); Geriatrics; Physical therapy; Psychiatry","score_opus":0.4218854716891127,"score_gpt":0.5642937494975934,"score_spread":0.14240827780848064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942655,0.00040495335,0.00039967627,0.0071745757,0.0016590032,0.00059517485,0.00026465242,0.000006872006,0.00006853525],"genre_scores_gemma":[0.98477995,0.0075745774,0.005854296,0.00032217547,0.0009725242,0.000056804238,0.00009872878,0.00002116793,0.00031978582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968519,0.00033804608,0.0020490545,0.00028774116,0.00028043694,0.00019277816],"domain_scores_gemma":[0.9949891,0.0027213532,0.0013679051,0.00028105304,0.0004518791,0.00018871161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017091781,0.00011250682,0.0011682607,0.00038178434,0.000016597156,0.000007667087,0.00024495317,0.00012522298,0.00008527502],"category_scores_gemma":[0.0009346701,0.00009010009,0.0001522847,0.00039128718,0.000106488376,0.00014699543,0.00021340139,0.00036092458,0.000003678808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006672652,0.0016488672,0.28484076,0.00019580981,0.00045235964,0.00019776073,0.00089325465,0.000050447125,0.00071161956,0.000016098671,0.04598363,0.65833676],"study_design_scores_gemma":[0.012957127,0.0035380707,0.9335345,0.0007503179,0.00016559545,0.00000810382,0.0007831888,0.0008009886,0.000058529502,0.000109142056,0.047223445,0.00007098941],"about_ca_topic_score_codex":0.0006371407,"about_ca_topic_score_gemma":0.004839665,"teacher_disagreement_score":0.65826577,"about_ca_system_score_codex":0.000275976,"about_ca_system_score_gemma":0.00036738455,"threshold_uncertainty_score":0.3674175},"labels":[],"label_agreement":null},{"id":"W4379283504","doi":"10.1200/jco.2023.41.16_suppl.e14639","title":"Prognostic value of human leukocyte antigen G (HLA-G) expression in solid tumors: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Reproductive System and Pregnancy","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Human leukocyte antigen; Meta-analysis; Colorectal cancer; Oncology; Internal medicine; Antigen; Major histocompatibility complex; Cancer; Immunology","score_opus":0.34895955106199833,"score_gpt":0.53040192791786,"score_spread":0.18144237685586168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006938059,0.9966777,0.0000130870085,0.000112735535,0.00046736424,0.0024724253,0.000028125638,0.000011873729,0.00014732187],"genre_scores_gemma":[0.0007262081,0.99785006,0.00007657465,0.0000924675,0.000103978186,0.0001449908,0.000028910521,0.00004211528,0.00093468407],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9719497,0.013803395,0.013059157,0.0006513689,0.00016428901,0.00037207323],"domain_scores_gemma":[0.97547346,0.006557047,0.016589506,0.00080485054,0.00048119167,0.0000939591],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.018284153,0.00053775666,0.037331667,0.0008099186,0.00006246502,0.000009973116,0.0007820761,0.0012794747,0.00017158914],"category_scores_gemma":[0.010709985,0.00029774057,0.006363383,0.0008539386,0.00038030843,0.00011103159,0.00026574588,0.0018285342,0.000085674554],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030622883,0.0005923295,0.00016528576,0.79070973,0.20513669,0.00029220793,0.00008558472,0.0000015815025,0.000017281813,0.00009906207,0.0006485123,0.0022211233],"study_design_scores_gemma":[0.00068028877,0.0020005833,0.00032242827,0.20641778,0.77316225,0.00063657993,0.000032957025,8.546528e-8,0.0000083677005,0.0001428984,0.016289674,0.00030611537],"about_ca_topic_score_codex":0.000019278892,"about_ca_topic_score_gemma":0.000018246728,"teacher_disagreement_score":0.58429193,"about_ca_system_score_codex":0.00007936435,"about_ca_system_score_gemma":0.0011137066,"threshold_uncertainty_score":0.9999475},"labels":[],"label_agreement":null},{"id":"W4379283505","doi":"10.1200/jco.2023.41.16_suppl.tps2673","title":"A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Queen's University; McMaster University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; Juravinski Cancer Centre","funders":"AstraZeneca Canada","keywords":"Durvalumab; Medicine; Tolerability; Discontinuation; Adverse effect; Internal medicine; Oncology; Tremelimumab; Prednisone; Leukocytopenia; Toxicity; Cancer; Surgery; Nivolumab; Immunotherapy; Ipilimumab","score_opus":0.10086411216741632,"score_gpt":0.46395260846125325,"score_spread":0.36308849629383694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932607,0.00029234323,0.0000027896394,0.0037540938,0.0009075113,0.0015831498,0.000010909885,0.00001738085,0.00017111156],"genre_scores_gemma":[0.99795705,0.00085747807,0.00012696731,0.00033969144,0.00018177753,0.000028826958,0.000007597942,0.000027879614,0.00047271463],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993574,0.0007613286,0.004513711,0.0003056759,0.0005147764,0.0003304782],"domain_scores_gemma":[0.99614453,0.0007091062,0.0021727358,0.00038620082,0.00033703778,0.00025038104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004036248,0.00023316959,0.0024051454,0.00037180952,0.000065475324,0.0000075313033,0.00022950124,0.00035498163,0.00015125982],"category_scores_gemma":[0.0013864221,0.00015604439,0.0006238407,0.000732135,0.00013492735,0.00010051617,0.00009700395,0.00062497036,0.000008374988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18038777,0.09460063,0.1190967,0.000022502649,0.0023240156,0.0007576881,0.008422041,0.000014171535,0.00948431,0.0000017949562,0.00073763286,0.58415073],"study_design_scores_gemma":[0.1241095,0.22525945,0.6456199,0.00018255696,0.00013594475,0.000017454084,0.00079095404,0.000022681903,0.0012673474,0.00002497771,0.002466809,0.00010236709],"about_ca_topic_score_codex":0.0001903541,"about_ca_topic_score_gemma":0.0002565778,"teacher_disagreement_score":0.5840484,"about_ca_system_score_codex":0.0004698683,"about_ca_system_score_gemma":0.00083965674,"threshold_uncertainty_score":0.63633054},"labels":[],"label_agreement":null},{"id":"W4379283528","doi":"10.1200/jco.2023.41.16_suppl.2602","title":"Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"University of Toronto","keywords":"Medicine; Internal medicine; Oncology; Melanoma; Immunotherapy; Cancer; Primary tumor; Cancer research; Metastasis","score_opus":0.06197621445913011,"score_gpt":0.3991467992697854,"score_spread":0.3371705848106553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98381674,0.0075709727,0.000396564,0.00715559,0.00018985152,0.00012968962,0.000005929555,0.0000187082,0.00071593054],"genre_scores_gemma":[0.9763365,0.015340427,0.0034466882,0.0029062044,0.00033623236,0.000004343821,0.0000065281083,0.000024988118,0.0015981233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978463,0.00017032638,0.0013027173,0.00020265671,0.00026936358,0.00020865412],"domain_scores_gemma":[0.9981447,0.0006672354,0.00067771145,0.00016938579,0.00014281338,0.00019818236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002499628,0.00013017764,0.0013141934,0.00025190113,0.000060715545,0.000018501154,0.00009558282,0.00020156146,0.000058718248],"category_scores_gemma":[0.00010671635,0.00008733552,0.0003316375,0.00065851054,0.00035695973,0.00011555466,0.000017417467,0.00029003038,0.0000018697023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15699638,0.0009983041,0.1835796,0.00027071906,0.019772286,0.0022152371,0.0021276185,0.00003949974,0.2698053,0.00003632423,0.0017735166,0.36238518],"study_design_scores_gemma":[0.009830301,0.0038371189,0.83103883,0.00007061518,0.00082776777,0.00013908744,0.00019065429,0.00002535828,0.000033909593,0.00004441262,0.15386283,0.000099087694],"about_ca_topic_score_codex":0.000009745826,"about_ca_topic_score_gemma":0.000076786666,"teacher_disagreement_score":0.64745927,"about_ca_system_score_codex":0.00008643607,"about_ca_system_score_gemma":0.0004299075,"threshold_uncertainty_score":0.3561439},"labels":[],"label_agreement":null},{"id":"W4379283554","doi":"10.1200/jco.2023.41.16_suppl.2502","title":"Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Pharmacodynamics; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; Oncology; Nausea; Pancreatic cancer; Toxicity; Chills; Tolerability; Phases of clinical research; Gastroenterology; Pharmacokinetics","score_opus":0.055033909224283875,"score_gpt":0.43084518347711925,"score_spread":0.3758112742528354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733925,0.000116368676,8.39059e-7,0.00057287083,0.0011261374,0.00064218946,0.000030992684,0.00001270747,0.00015864926],"genre_scores_gemma":[0.99887323,0.00013265565,0.000118542775,0.00025802903,0.0005214463,0.000010850185,0.00003473724,0.000028428862,0.00002209469],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9940492,0.00033573268,0.0044384166,0.00032384324,0.0005564657,0.00029634644],"domain_scores_gemma":[0.9954806,0.0013406571,0.0024313272,0.0003139819,0.00025988472,0.00017354624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026845776,0.00020362678,0.0019228723,0.00042925338,0.00003433679,0.000005351493,0.00020827063,0.00028202558,0.000058902973],"category_scores_gemma":[0.001363244,0.00015092344,0.00026116127,0.0005325356,0.00019812034,0.00014885551,0.000060943054,0.001002387,0.000005114373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45964962,0.029926505,0.42556834,0.000039263163,0.0007954883,0.0012096288,0.0025072843,0.00014668547,0.0037849084,8.300839e-7,0.0009964773,0.075374976],"study_design_scores_gemma":[0.16797744,0.07849565,0.7501918,0.0006108461,0.000092710856,0.000004918042,0.0007258704,0.00004862259,0.00042492736,0.000024088362,0.0012681743,0.0001349098],"about_ca_topic_score_codex":0.00028630058,"about_ca_topic_score_gemma":0.0006068199,"teacher_disagreement_score":0.3246235,"about_ca_system_score_codex":0.00029726914,"about_ca_system_score_gemma":0.0007913395,"threshold_uncertainty_score":0.61544794},"labels":[],"label_agreement":null},{"id":"W4379283577","doi":"10.1200/jco.2023.41.16_suppl.tps2084","title":"Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Microbubbles; Biopsy; Liquid biopsy; Brain tumor; Radiology; Biomarker; Ultrasound; Pathology; Oncology; Internal medicine; Cancer","score_opus":0.05983556324942811,"score_gpt":0.40771759427676135,"score_spread":0.3478820310273332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805063,0.00012605876,0.00068246113,0.015571807,0.0018294181,0.0011495247,0.000043657023,0.000038296752,0.00005250376],"genre_scores_gemma":[0.99109036,0.0004964258,0.0038594757,0.0022582794,0.0017145713,0.00011591121,0.000009725121,0.000065500084,0.00038975707],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996144,0.0002415217,0.0024270357,0.0003805161,0.00031966565,0.0004872519],"domain_scores_gemma":[0.98759633,0.009262524,0.0014675816,0.00026802687,0.0009737665,0.0004317678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052200416,0.00022757718,0.001916673,0.00037774822,0.00006556343,0.00001867578,0.00019211364,0.0005761164,0.000033917928],"category_scores_gemma":[0.0054971147,0.00016503541,0.0005749973,0.0005071225,0.0002239657,0.00013901999,0.000035314686,0.0006594137,0.000015345613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25745723,0.0056258207,0.3888441,0.0025388005,0.0033665912,0.002966103,0.0014724603,0.0011781498,0.13297778,0.00031136133,0.18984412,0.013417469],"study_design_scores_gemma":[0.1936259,0.3715908,0.15744495,0.009434646,0.005574176,0.01720368,0.0027267546,0.0016215289,0.07272395,0.0019300387,0.16427743,0.0018461597],"about_ca_topic_score_codex":0.000015925014,"about_ca_topic_score_gemma":0.00022798385,"teacher_disagreement_score":0.36596495,"about_ca_system_score_codex":0.0003495448,"about_ca_system_score_gemma":0.001579593,"threshold_uncertainty_score":0.6729949},"labels":[],"label_agreement":null},{"id":"W4379283594","doi":"10.1200/jco.2023.41.16_suppl.e14656","title":"Quantitation of the PD-1/PD-L1 axis in non-small cell lung cancer by immuno-multiple reaction monitoring.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Research Manitoba; McGill University","funders":"","keywords":"PD-L1; Medicine; Glycosylation; Lung cancer; Immunohistochemistry; Tumor microenvironment; Antibody; Cancer research; Cancer; Internal medicine; Oncology; Immunotherapy; Immunology; Chemistry; Biochemistry","score_opus":0.07425049357207787,"score_gpt":0.46780609548667834,"score_spread":0.3935556019146005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659574,0.0013479432,0.00002421594,0.00061223353,0.0010417524,0.00013925147,0.0000144745,0.0000015956527,0.00022279848],"genre_scores_gemma":[0.9932137,0.005881892,0.00009984152,0.000045741395,0.00035163073,0.000013587136,0.000010840842,0.00000806834,0.00037469176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985262,0.00022042924,0.0007775012,0.00013248128,0.00017177104,0.00017162088],"domain_scores_gemma":[0.99866533,0.00027227716,0.0006560132,0.00014992824,0.00018132212,0.00007514991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009818918,0.000074258714,0.00031339872,0.000055080276,0.00003076909,0.0000051186594,0.00019016556,0.00021514045,0.000005882605],"category_scores_gemma":[0.0006884551,0.000051847204,0.00022148466,0.00016142872,0.00006667012,0.0000072674043,0.00007213185,0.00032335692,0.0000022251681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016513264,0.000506319,0.5944232,0.000029674256,0.00016681686,0.000016885318,0.000060809733,0.00014163532,0.37730473,0.0000010420963,0.006658995,0.019038603],"study_design_scores_gemma":[0.0047998615,0.0024320728,0.86285996,0.00006981887,0.000057201072,0.000006164427,0.00015408569,0.00017308368,0.10954276,0.000028369002,0.019795287,0.00008133978],"about_ca_topic_score_codex":0.00090222433,"about_ca_topic_score_gemma":0.00074582704,"teacher_disagreement_score":0.2684368,"about_ca_system_score_codex":0.00009172611,"about_ca_system_score_gemma":0.0006050062,"threshold_uncertainty_score":0.21142676},"labels":[],"label_agreement":null},{"id":"W4379283603","doi":"10.1200/jco.2023.41.16_suppl.tps2680","title":"Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Abatacept; Placebo; Internal medicine; Mace; Myocarditis; Adverse effect; Population; Myocardial infarction; Rituximab; Pathology; Percutaneous coronary intervention","score_opus":0.049994155593255936,"score_gpt":0.392043112508057,"score_spread":0.3420489569148011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760055,0.0006232777,0.000057781057,0.0059920875,0.002194429,0.014738893,0.00024027728,0.00006190102,0.00008587898],"genre_scores_gemma":[0.99678093,0.00041634386,0.00028909472,0.0010845296,0.0005317825,0.0005551036,0.00015623626,0.00010323987,0.0000827301],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98323625,0.005056558,0.008716357,0.0006870128,0.0014681183,0.0008356931],"domain_scores_gemma":[0.97770333,0.014275198,0.004645226,0.00058185775,0.0019704245,0.00082393223],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03450967,0.00066907174,0.008107866,0.0006865791,0.0002195366,0.00006297948,0.0004764762,0.0005516525,0.00006670173],"category_scores_gemma":[0.05321697,0.00042620485,0.0018713295,0.0014507754,0.000689767,0.00021907734,0.00025028564,0.0013404051,0.000011217999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95475066,0.008302046,0.014837197,0.00006063612,0.0094645405,0.00015724103,0.002754903,0.0001672424,0.0020325244,0.000001934233,0.0031789567,0.0042921253],"study_design_scores_gemma":[0.65054464,0.027364232,0.3163195,0.00093944295,0.0020628478,0.000014481708,0.0011840448,0.00025947497,0.00046206507,0.000021786951,0.0004871005,0.00034041214],"about_ca_topic_score_codex":0.00024534596,"about_ca_topic_score_gemma":0.00017067276,"teacher_disagreement_score":0.30420604,"about_ca_system_score_codex":0.00088790315,"about_ca_system_score_gemma":0.0022203575,"threshold_uncertainty_score":0.999819},"labels":[],"label_agreement":null},{"id":"W4379283617","doi":"10.1200/jco.2023.41.16_suppl.e13598","title":"Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Queen's University; Children's Hospital of Eastern Ontario; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Accrual; Clinical trial; Cancer; Lung cancer; Internal medicine; Gerontology; Oncology; Demography","score_opus":0.27569083966442626,"score_gpt":0.5667722670620134,"score_spread":0.2910814273975872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97324276,0.0009276686,0.000009481663,0.019822795,0.005520596,0.00031525944,0.00001658728,0.000008114159,0.00013675181],"genre_scores_gemma":[0.9870065,0.005851882,0.00038976318,0.004120438,0.002545918,0.0000046447753,0.0000027425165,0.00002123095,0.000056915975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98431647,0.004136201,0.010048709,0.00031837283,0.0008422137,0.00033803095],"domain_scores_gemma":[0.9816011,0.011784965,0.0050887647,0.00026221,0.00051586947,0.000747091],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.039424516,0.00017557888,0.004593295,0.00022241965,0.000023948662,0.0000052961327,0.00025110756,0.00046520415,0.000075545155],"category_scores_gemma":[0.060194515,0.00013579999,0.00058809435,0.00037355736,0.00026491948,0.00009431586,0.00013617401,0.0016417487,0.0000047625294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007997778,0.0005484077,0.81898546,0.00020952793,0.00027760284,0.0003898559,0.0004315368,0.000005615087,0.000020906093,0.000007775123,0.014713817,0.15641169],"study_design_scores_gemma":[0.017379103,0.002991219,0.96788263,0.0014366439,0.0002559839,0.000059841637,0.0011067776,0.00009940305,0.000025016296,0.0001428718,0.008506549,0.000113948496],"about_ca_topic_score_codex":0.3762594,"about_ca_topic_score_gemma":0.8832436,"teacher_disagreement_score":0.50698423,"about_ca_system_score_codex":0.00042127306,"about_ca_system_score_gemma":0.015689177,"threshold_uncertainty_score":0.98989093},"labels":[],"label_agreement":null},{"id":"W4379283672","doi":"10.1200/jco.2023.41.16_suppl.tps2083","title":"Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Novocure","keywords":"Medicine; Temozolomide; Concomitant; Oncology; Clinical endpoint; Internal medicine; Radiation therapy; Progression-free survival; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.0680415118100119,"score_gpt":0.4293803540714433,"score_spread":0.3613388422614314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98762983,0.0005540804,0.000022509212,0.010261809,0.0004335878,0.00074842386,0.0000039757124,0.000023731958,0.00032204035],"genre_scores_gemma":[0.99549794,0.0014051447,0.0002706682,0.0021553775,0.00048298074,0.000040636496,0.0000024619035,0.00002344818,0.00012133954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642974,0.00037391097,0.0021259193,0.00033317157,0.00037387526,0.00036338388],"domain_scores_gemma":[0.9934591,0.004411445,0.0012261608,0.0002453765,0.00028664037,0.00037125044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023049307,0.00023937627,0.0016999395,0.00029687365,0.00006274008,0.000027563152,0.00013972737,0.0002742169,0.0000808163],"category_scores_gemma":[0.0027164416,0.0001515829,0.00024256822,0.00046398892,0.000119098666,0.00012771982,0.000044479686,0.00083889783,0.00001046098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01582992,0.0153756365,0.77742296,0.000027601753,0.0007646874,0.02404861,0.001435329,0.00011585551,0.00016034792,0.000025507636,0.009384941,0.15540862],"study_design_scores_gemma":[0.21235092,0.12561108,0.64901674,0.00037155437,0.0005010643,0.00072613475,0.004913785,0.00089978025,0.0007204822,0.00018894195,0.004402088,0.00029742892],"about_ca_topic_score_codex":0.00014634755,"about_ca_topic_score_gemma":0.000893184,"teacher_disagreement_score":0.196521,"about_ca_system_score_codex":0.00014563951,"about_ca_system_score_gemma":0.00071987894,"threshold_uncertainty_score":0.6181371},"labels":[],"label_agreement":null},{"id":"W4379283675","doi":"10.1200/jco.2023.41.16_suppl.5010","title":"Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Proportional hazards model; Internal medicine; Nuclear medicine; Oncology; Cancer; Radiology","score_opus":0.04646587833407486,"score_gpt":0.40587083656753464,"score_spread":0.3594049582334598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593776,0.00023536652,0.0000025926893,0.001462059,0.00070684205,0.0014557865,0.00014600217,0.000016416097,0.000037157188],"genre_scores_gemma":[0.99385464,0.005145121,0.00028098148,0.00007166922,0.00026731953,0.000047463032,0.00008987883,0.00003327691,0.00020964892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960629,0.0005947425,0.0014784189,0.0004933499,0.0009912639,0.00037936677],"domain_scores_gemma":[0.997072,0.00035295813,0.0009699719,0.00021519761,0.00074202265,0.0006478943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018961084,0.00024912227,0.0010005117,0.00041834472,0.00010708281,0.000059222315,0.00015396411,0.00008719738,0.00004527031],"category_scores_gemma":[0.00035569223,0.00015692906,0.00015738799,0.00035783078,0.000219322,0.00040684428,0.000078185854,0.000800283,0.000003457181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06566353,0.0055323984,0.9176953,0.000045964436,0.00062599237,0.0023267348,0.00081103377,0.00008724482,0.00043536702,0.0000062056833,0.00011434146,0.006655883],"study_design_scores_gemma":[0.036043193,0.018487237,0.9435798,0.00026593768,0.0002642574,0.000007675552,0.00052829774,0.00021585067,0.00010182951,0.00007369473,0.0002808074,0.00015144884],"about_ca_topic_score_codex":0.00025617125,"about_ca_topic_score_gemma":0.0004348453,"teacher_disagreement_score":0.029620338,"about_ca_system_score_codex":0.00042515792,"about_ca_system_score_gemma":0.00075505755,"threshold_uncertainty_score":0.6399381},"labels":[],"label_agreement":null},{"id":"W4379283716","doi":"10.1200/jco.2023.41.16_suppl.e13033","title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab-deruxtecan in patients with breast cancer: A systematic review and single-arm meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Trastuzumab; Metastatic breast cancer; Cohort; Population; Incidence (geometry); Lung cancer; Interstitial lung disease; Cancer; Lung","score_opus":0.2038903981286359,"score_gpt":0.5079035114256127,"score_spread":0.30401311329697683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018443157,0.9950457,0.000010913103,0.00056031876,0.000112710135,0.0022315138,0.00017156171,0.0000052777814,0.000017691862],"genre_scores_gemma":[0.013680734,0.98546183,0.00007064092,0.00043390453,0.00013370709,0.00013128023,0.000015016343,0.000031894877,0.000040965853],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99372345,0.0014330555,0.0037841345,0.00038438445,0.0004541127,0.00022085622],"domain_scores_gemma":[0.9916639,0.0022139414,0.0049190884,0.0002486751,0.00046064306,0.00049379625],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0022345793,0.0003978135,0.019282438,0.00044035277,0.000021753685,0.00000862377,0.00016408549,0.00025536804,0.00008143478],"category_scores_gemma":[0.00059090497,0.0001976262,0.0017953471,0.000695519,0.00037653788,0.00008677411,0.000074130854,0.000911238,5.352779e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003310481,0.0028160287,0.013939505,0.6469779,0.31170204,0.0009730571,0.000046575948,0.000004488737,1.7352257e-8,0.000002466429,0.00015802318,0.020069387],"study_design_scores_gemma":[0.003252011,0.0077154175,0.008598577,0.09486191,0.884286,0.0002293295,0.000008295272,0.0000040944847,1.5336862e-8,0.0000025850559,0.0008784266,0.00016332597],"about_ca_topic_score_codex":0.000102804974,"about_ca_topic_score_gemma":0.0006069115,"teacher_disagreement_score":0.572584,"about_ca_system_score_codex":0.00046975721,"about_ca_system_score_gemma":0.0022576342,"threshold_uncertainty_score":0.99527735},"labels":[],"label_agreement":null},{"id":"W4379283721","doi":"10.1200/jco.2023.41.16_suppl.1541","title":"Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Psychological intervention; Prehabilitation; Interim analysis; Interim; Randomized controlled trial; Physical therapy; Cancer; Surgery; Internal medicine; Nursing","score_opus":0.0873897671730822,"score_gpt":0.5138039621702424,"score_spread":0.42641419499716016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927405,0.0002430327,0.000024233006,0.0036360289,0.0009881171,0.0019149508,0.000092033486,0.000009860983,0.00035120582],"genre_scores_gemma":[0.99670607,0.0013180668,0.0010768255,0.00022011591,0.00038975434,0.000058891517,0.000040174345,0.000021737675,0.00016837085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924833,0.0010585932,0.005149339,0.00031370524,0.0006941851,0.00030084254],"domain_scores_gemma":[0.98860884,0.0071520475,0.00307975,0.00022081313,0.0007328719,0.00020565365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035393573,0.00022426467,0.0037491533,0.00015660698,0.000019803318,0.000007356595,0.0001622995,0.0003573461,0.00014794958],"category_scores_gemma":[0.0027255698,0.00013849445,0.00055744895,0.00028065784,0.00050254824,0.00021494145,0.00010228857,0.00071944686,0.0000012955317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9031419,0.0022695428,0.047378443,0.00013704687,0.00057527696,0.00045533877,0.0026227846,0.000023201701,0.0000033026151,0.000017345916,0.0010626074,0.042313177],"study_design_scores_gemma":[0.9151584,0.019020114,0.059039995,0.00055027625,0.0004774038,0.00003984822,0.0008351708,0.000066770786,0.00004774039,0.000029206738,0.004614247,0.00012082815],"about_ca_topic_score_codex":0.0003236769,"about_ca_topic_score_gemma":0.00052177184,"teacher_disagreement_score":0.042192347,"about_ca_system_score_codex":0.00013875496,"about_ca_system_score_gemma":0.0009056761,"threshold_uncertainty_score":0.56476396},"labels":[],"label_agreement":null},{"id":"W4379283735","doi":"10.1200/jco.2023.41.16_suppl.e13506","title":"Patient decision aid for chemotherapy or exclusion in cisplatin-intolerant patients with locally advanced cervical cancer (CECIL): Development, alpha testing, and peer-validation.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Philippine Council for Health Research and Development","keywords":"Medicine; Cervical cancer; Decision aids; Gynecologic oncology; Delphi method; Oncology; Family medicine; Medical physics; Cancer; Internal medicine; Alternative medicine; Pathology","score_opus":0.2522191085484327,"score_gpt":0.5296169045560852,"score_spread":0.2773977960076525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951183,0.00019324495,0.0020293884,0.0017277142,0.0003897541,0.00044483683,0.000007078463,0.000009689635,0.00007997253],"genre_scores_gemma":[0.784915,0.0013277504,0.21121977,0.002025737,0.00028496375,0.00003198123,0.000018894794,0.000030986164,0.00014492363],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99705106,0.000097816424,0.0018732464,0.00021567573,0.00054802926,0.00021418408],"domain_scores_gemma":[0.9922047,0.004917674,0.0011698522,0.00009906125,0.0013925649,0.00021612155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013177217,0.00014592342,0.0010445283,0.00017453115,0.000043032735,0.0000056364393,0.000087630186,0.0002112139,0.00005172473],"category_scores_gemma":[0.007972915,0.00008728043,0.000095302785,0.00032843134,0.00009407038,0.00009786934,0.000052847237,0.00033170995,0.000002151175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013611323,0.00045076886,0.45757362,0.000043837474,0.00005969401,0.00004393005,0.00045337464,0.00010452709,0.000036626716,0.0000012689636,0.0007649534,0.52685606],"study_design_scores_gemma":[0.03167744,0.015002788,0.7526741,0.0023398884,0.00007822638,0.000013069213,0.000233466,0.0007525299,0.0006277332,0.00011046715,0.19634494,0.00014535633],"about_ca_topic_score_codex":0.000017036173,"about_ca_topic_score_gemma":0.00014389094,"teacher_disagreement_score":0.52671075,"about_ca_system_score_codex":0.00015602577,"about_ca_system_score_gemma":0.0011843406,"threshold_uncertainty_score":0.95448995},"labels":[],"label_agreement":null},{"id":"W4379283750","doi":"10.1200/jco.2023.41.16_suppl.2062","title":"Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Chimeric antigen receptor; Oncolytic virus; Cancer research; Medicine; Glioma; Immunotherapy; Immune system; Antigen; Population; T cell; CD8; Cytotoxic T cell; Epitope; Tumor microenvironment; Immunology; Biology; In vitro","score_opus":0.12369999698428902,"score_gpt":0.4475433971989874,"score_spread":0.3238434002146984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930684,0.00048908027,0.001750851,0.0014738283,0.0014348159,0.0011143488,0.000025573756,0.000026954067,0.00061616744],"genre_scores_gemma":[0.99075407,0.0021905764,0.0028098463,0.00023598963,0.0014012046,0.000031234504,0.0000112096695,0.000081470855,0.0024843935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946211,0.0004855726,0.0031222228,0.00035190803,0.0009328928,0.00048633528],"domain_scores_gemma":[0.98665285,0.008817645,0.0025364487,0.0005770146,0.001072776,0.00034326242],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004014387,0.0002475168,0.0025885366,0.0005218102,0.000058702353,0.000009936345,0.0003053508,0.0005153071,0.0010341804],"category_scores_gemma":[0.0010658292,0.00017604283,0.00079831743,0.000999487,0.0005522323,0.00010703079,0.000055615263,0.001151873,0.000018422877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11131609,0.0027567595,0.00022741765,0.0001274324,0.0014331321,0.00017090802,0.00028529324,0.00059904705,0.8237289,0.000049192025,0.005441257,0.053864546],"study_design_scores_gemma":[0.07147487,0.08569822,0.05080511,0.0004662831,0.00057006016,0.00018479387,0.0005568816,0.0001524575,0.64370364,0.0004995709,0.1455906,0.0002975103],"about_ca_topic_score_codex":0.00008760691,"about_ca_topic_score_gemma":0.000026265276,"teacher_disagreement_score":0.18002528,"about_ca_system_score_codex":0.00026268684,"about_ca_system_score_gemma":0.0019958103,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W4379283755","doi":"10.1200/jco.2023.41.16_suppl.e13593","title":"A bibliometric analysis of immuno-oncology research: Is a new global leader emerging?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; China; Cancer; Oncology; Library science; Internal medicine; Political science","score_opus":0.47145745755442675,"score_gpt":0.6163869865647756,"score_spread":0.1449295290103489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436153,0.005686116,0.000104525745,0.04350228,0.0016112833,0.00018505412,0.000015284402,0.000019408535,0.005260751],"genre_scores_gemma":[0.96928275,0.020596676,0.0015280121,0.004725533,0.0014240602,0.0000037212808,0.000007986298,0.000021941009,0.0024093504],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936361,0.000945721,0.0035531898,0.00026540615,0.0011059598,0.0004936575],"domain_scores_gemma":[0.9913511,0.0045370203,0.0019421754,0.00038063305,0.0013164934,0.0004725646],"candidate_categories":["bibliometrics","insufficient_payload"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.01511479,0.00014381361,0.0024942744,0.046733707,0.000056363006,0.000011831136,0.00041414952,0.000658422,0.0015049333],"category_scores_gemma":[0.0071134386,0.00010474267,0.0018615662,0.19315,0.00057803106,0.00010225265,0.00012709986,0.00105656,0.00005720283],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015805893,0.0010509632,0.10148842,0.000028473394,0.009813891,0.00053320854,0.00034867116,0.0000122714455,0.0010675873,0.000032812663,0.17480677,0.695011],"study_design_scores_gemma":[0.0071498854,0.012571309,0.54663604,0.000048569254,0.0017822767,0.0001210071,0.00058399054,0.00014217682,0.000069550166,0.0002587097,0.43056527,0.00007124373],"about_ca_topic_score_codex":0.0004459424,"about_ca_topic_score_gemma":0.00015331927,"teacher_disagreement_score":0.6949398,"about_ca_system_score_codex":0.0004973088,"about_ca_system_score_gemma":0.0056732027,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W4379283756","doi":"10.1200/jco.2023.41.16_suppl.4105","title":"Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; McMaster University; Juravinski Cancer Centre; University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Esophagogastroduodenoscopy; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Cirrhosis; Esophageal varices; Varices; Surgery; Portal hypertension; Endoscopy","score_opus":0.10311514564959642,"score_gpt":0.36887125960808,"score_spread":0.26575611395848353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975915,0.00030051242,0.000026632766,0.001107198,0.000052441465,0.0005926637,0.000031219803,0.000028132774,0.000269693],"genre_scores_gemma":[0.99625117,0.0005070125,0.002808206,0.00006916905,0.00009680249,0.000010023935,0.00011879486,0.000033198172,0.0001056099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673086,0.00026740556,0.001774854,0.0004030836,0.00048728153,0.0003364889],"domain_scores_gemma":[0.99564725,0.00126695,0.0015187856,0.00030645117,0.00073212583,0.0005284434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008915565,0.00027724038,0.0022149172,0.0008360616,0.00010706357,0.00001846649,0.000120798206,0.0002117953,0.000045196048],"category_scores_gemma":[0.00026790757,0.00018016843,0.0003218998,0.0013977695,0.0003811505,0.00010168644,0.000063465704,0.0004425695,0.0000041132453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077937464,0.0010691549,0.9750798,0.000058737533,0.0036358193,0.000550372,0.00024576034,0.000014068592,0.00004703103,0.000034152712,0.00009914177,0.011372265],"study_design_scores_gemma":[0.018365892,0.008584862,0.9546834,0.00012692725,0.01031542,0.000028195762,0.00012460505,0.007006019,0.00015881522,0.000006102825,0.00046302524,0.00013671315],"about_ca_topic_score_codex":0.00012009541,"about_ca_topic_score_gemma":0.00010289822,"teacher_disagreement_score":0.020396328,"about_ca_system_score_codex":0.000120871104,"about_ca_system_score_gemma":0.0003874578,"threshold_uncertainty_score":0.7347055},"labels":[],"label_agreement":null},{"id":"W4379283773","doi":"10.1200/jco.2023.41.16_suppl.3071","title":"Large retrospective validation study of metabolomic biomarkers for resectable lung cancer detection and risk assessment.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Biomarker; Stage (stratigraphy); Adenocarcinoma; Pathology","score_opus":0.05259541201615695,"score_gpt":0.4636769617179346,"score_spread":0.4110815497017776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545217,0.00094722887,0.0018068913,0.00021027081,0.001063783,0.00035273153,0.000043532076,0.0000038732333,0.00011953047],"genre_scores_gemma":[0.98849845,0.01008633,0.000792985,0.000026641079,0.0004625441,0.00002840981,0.000004994273,0.000012960704,0.000086679494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792075,0.00044274816,0.001055347,0.00023546812,0.00015750578,0.00018817287],"domain_scores_gemma":[0.99739265,0.00036617648,0.0015469398,0.00013326359,0.00048546167,0.00007550205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005035632,0.00010412675,0.0007493435,0.00015454328,0.00009488506,0.0000089906625,0.00011010684,0.00019982537,0.000008784846],"category_scores_gemma":[0.0026817606,0.00008250496,0.00020331863,0.00022591652,0.000060042024,0.0000111840245,0.000107958214,0.0002443475,1.8659769e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003547807,0.0012430873,0.81998575,0.000042602587,0.0050322204,0.000006208727,0.0002008773,0.00007842101,0.15268156,0.00008126509,0.0040153144,0.013084861],"study_design_scores_gemma":[0.008198543,0.012432287,0.9545933,0.000009214159,0.0009582774,0.000005579193,0.001617332,0.0007649356,0.011884594,0.00047937635,0.008925267,0.00013131776],"about_ca_topic_score_codex":0.000047968093,"about_ca_topic_score_gemma":0.00036274022,"teacher_disagreement_score":0.14079697,"about_ca_system_score_codex":0.000041355244,"about_ca_system_score_gemma":0.00026440885,"threshold_uncertainty_score":0.33644545},"labels":[],"label_agreement":null},{"id":"W4379283793","doi":"10.1200/jco.2023.41.16_suppl.e13646","title":"Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical endpoint; Stakeholder; Confounding; Value (mathematics); Clinical trial; Family medicine; Oncology; Internal medicine; Public relations","score_opus":0.6661001126112539,"score_gpt":0.6010472307491245,"score_spread":0.06505288186212943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90119153,0.00014585297,0.0012764155,0.092522524,0.0014785462,0.0005873229,0.00010457974,0.000012391194,0.0026808237],"genre_scores_gemma":[0.9748365,0.00023362084,0.007472918,0.01643482,0.0008694617,0.000028409193,0.0000014481758,0.000025014086,0.00009778472],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9881158,0.0011394359,0.009663871,0.00045737214,0.00019822938,0.00042530158],"domain_scores_gemma":[0.9388458,0.05215974,0.007865037,0.0004186347,0.00039101535,0.0003197571],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07254272,0.00017387475,0.0022645844,0.00034352968,0.000272735,0.000055515062,0.00033427178,0.000390531,0.00042972204],"category_scores_gemma":[0.111308426,0.00014824735,0.00030672245,0.0002894638,0.0003405759,0.00026866994,0.00017219184,0.00079691416,0.00041680632],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017967208,0.0030751878,0.15271032,0.0002620187,0.0013080108,0.0002601955,0.11497103,0.003365114,0.000029816603,0.43081722,0.24442537,0.04697901],"study_design_scores_gemma":[0.0058678417,0.014983559,0.6801205,0.00049213367,0.0000669525,0.00022308211,0.071927495,0.003997931,0.000010683149,0.14246517,0.0793096,0.00053501705],"about_ca_topic_score_codex":0.000039069233,"about_ca_topic_score_gemma":0.00019457721,"teacher_disagreement_score":0.5274102,"about_ca_system_score_codex":0.00045818972,"about_ca_system_score_gemma":0.0013359615,"threshold_uncertainty_score":0.95501244},"labels":[],"label_agreement":null},{"id":"W4379283830","doi":"10.1200/jco.2023.41.16_suppl.e13544","title":"Predicting which cancer patients will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Referral; Psychosocial; Radiation oncologist; Medical diagnosis; Artificial intelligence; Family medicine; Natural language processing; Psychiatry; Internal medicine; Computer science; Pathology; Radiation therapy","score_opus":0.281183226784225,"score_gpt":0.591157506219587,"score_spread":0.30997427943536193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826441,0.0007707211,0.00007463522,0.00806841,0.007852593,0.00035902945,0.000019670926,0.000031757972,0.00017908505],"genre_scores_gemma":[0.99017084,0.00094814046,0.0011608619,0.0021394962,0.0054058004,0.000012848655,0.000043950913,0.000021441903,0.00009662694],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99605244,0.00045905242,0.0025620924,0.00023751038,0.00038150224,0.00030742103],"domain_scores_gemma":[0.99144727,0.004187205,0.002196578,0.00011140331,0.001769099,0.0002884493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020943084,0.00014743271,0.00090177247,0.00017215677,0.00014459548,0.000021915548,0.00013266306,0.00044696755,0.00019809797],"category_scores_gemma":[0.0080176545,0.00009849078,0.00016278979,0.00050309475,0.000141467,0.00026882897,0.000028374983,0.001087185,0.000019495403],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008326261,0.0010810111,0.19800407,0.00010280243,0.00021404037,0.00010233591,0.012619035,0.00009213322,0.00017819459,0.0000026572366,0.0026441396,0.7766333],"study_design_scores_gemma":[0.020195482,0.06404892,0.57567453,0.0042649684,0.0035760098,0.000627538,0.12317263,0.09761037,0.002558908,0.0031533486,0.10378994,0.001327349],"about_ca_topic_score_codex":0.0011618133,"about_ca_topic_score_gemma":0.0038819348,"teacher_disagreement_score":0.775306,"about_ca_system_score_codex":0.0005097919,"about_ca_system_score_gemma":0.007966746,"threshold_uncertainty_score":0.9976572},"labels":[],"label_agreement":null},{"id":"W4379283863","doi":"10.1200/jco.2023.41.16_suppl.e13528","title":"Assessing the feasibility of recording smartphone-based patient-reported outcomes in patients with cancer: A pilot study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Conquer Cancer Foundation","keywords":"Medicine; Interquartile range; Nausea; Anxiety; Hospital Anxiety and Depression Scale; Depression (economics); Cancer; Quality of life (healthcare); Physical therapy; Internal medicine; Psychiatry","score_opus":0.24777300136930497,"score_gpt":0.5093542617623448,"score_spread":0.2615812603930398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944781,0.000032789347,0.000012001026,0.0028784373,0.0019263146,0.0005030677,0.000003532671,0.00001115961,0.00015456829],"genre_scores_gemma":[0.9990481,0.00001618967,0.00008605687,0.0006768256,0.00012373134,0.000012084209,0.0000021793555,0.000014578124,0.00002023637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995809,0.00075579557,0.0024276224,0.00019376565,0.0006087147,0.00020509538],"domain_scores_gemma":[0.9938576,0.0027522324,0.0022610037,0.00028544816,0.00069625856,0.0001474356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041333525,0.00012381627,0.0013997835,0.00016786683,0.000039756545,0.0000106308025,0.00013531618,0.00009424386,0.000047990234],"category_scores_gemma":[0.003352872,0.000065550645,0.00022410911,0.0005613989,0.00014277035,0.00010697902,0.000044974986,0.00077274436,0.0000010440186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062672943,0.0042593563,0.9430774,0.000026406036,0.00023325108,0.00012708298,0.00028517804,0.000050801602,0.00000825219,5.021287e-7,0.00016985086,0.045494657],"study_design_scores_gemma":[0.012621245,0.035004593,0.9502585,0.00016482205,0.0002667365,0.0000032408386,0.0013442327,0.000029426363,0.000008594706,0.000021451846,0.00021335423,0.00006380372],"about_ca_topic_score_codex":0.0012029544,"about_ca_topic_score_gemma":0.005197591,"teacher_disagreement_score":0.045430854,"about_ca_system_score_codex":0.00025615105,"about_ca_system_score_gemma":0.0019661468,"threshold_uncertainty_score":0.40139434},"labels":[],"label_agreement":null},{"id":"W4379283867","doi":"10.1200/jco.2023.41.16_suppl.tps3161","title":"FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Fibroblast activation protein, alpha; Pancreatic cancer; Cancer; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; DOTA; Tumor microenvironment; Cancer research; Phases of clinical research; Oncology; Clinical trial; Internal medicine; Adverse effect; In vivo","score_opus":0.15199138756568836,"score_gpt":0.5253792704416357,"score_spread":0.3733878828759473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642366,0.000030049876,0.00018347324,0.00068680244,0.000097345444,0.0024663582,0.000054752272,0.000007719986,0.00004986652],"genre_scores_gemma":[0.998606,0.000039955885,0.0008843694,0.00015326666,0.00015507304,0.00002777519,0.000024717861,0.0000164575,0.00009236715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99515635,0.0007289992,0.0030744632,0.00032197652,0.0005106841,0.00020752725],"domain_scores_gemma":[0.99533695,0.0012841626,0.0017967133,0.0002610499,0.0009545146,0.00036660553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044332026,0.00018771719,0.0027862864,0.0003112918,0.00006772345,0.000011844147,0.00013436982,0.0001061086,0.00004681045],"category_scores_gemma":[0.0016895264,0.00011919791,0.0002118883,0.00051353936,0.00011631896,0.00012274517,0.00007345843,0.00017392295,0.0000018590546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04969291,0.100854054,0.74910355,0.00004547522,0.0019016832,0.00007541241,0.0013080434,0.0000683777,0.0004082256,0.0000015927011,0.00062993274,0.09591074],"study_design_scores_gemma":[0.10452315,0.23614863,0.6549994,0.00011729238,0.0016356969,0.000006602489,0.0011989151,0.0007194338,0.00036379046,0.000037295722,0.00015418025,0.000095637624],"about_ca_topic_score_codex":0.000034976525,"about_ca_topic_score_gemma":0.000074535594,"teacher_disagreement_score":0.13529459,"about_ca_system_score_codex":0.00018171116,"about_ca_system_score_gemma":0.00063024095,"threshold_uncertainty_score":0.48607498},"labels":[],"label_agreement":null},{"id":"W4379283901","doi":"10.1200/jco.2023.41.16_suppl.e13667","title":"Use of adjuvant bisphosphonate therapy in breast cancer by Indian oncologists: An implementation science study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Snowball sampling; Breast cancer; Hormonal therapy; Family medicine; Internal medicine; Oncology; Adjuvant therapy; Hormone therapy; Cancer; Gynecology; Pathology","score_opus":0.28758025533249354,"score_gpt":0.5983234989120486,"score_spread":0.3107432435795551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293727,0.00011971562,7.5380467e-7,0.0056921323,0.000727792,0.00045966037,0.000033816348,0.000008000913,0.000020861828],"genre_scores_gemma":[0.9944436,0.0034180703,0.00022063458,0.001778614,0.000066311375,0.000016030435,0.000006167155,0.000009775272,0.00004081874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967301,0.00032460768,0.0019733373,0.00020179235,0.00046261185,0.0003075377],"domain_scores_gemma":[0.9969834,0.0006804232,0.0013492304,0.00015310435,0.00040592914,0.00042789878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004220716,0.00009956956,0.00094932,0.00030344442,0.000048014776,0.0000078475,0.00014322664,0.00014548785,0.00012404006],"category_scores_gemma":[0.00043131612,0.00006652572,0.00010872219,0.0007514545,0.0002904452,0.00028841314,0.000034275243,0.0004691085,0.0000058628975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023857155,0.002657854,0.62980473,0.0000053677254,0.000057898742,0.0003345002,0.00038060223,0.0000037065597,0.00019233146,0.000002584409,0.0009762651,0.36319846],"study_design_scores_gemma":[0.012203425,0.020485712,0.9625568,0.000034919947,0.000051778017,0.00006817477,0.0009721694,0.000027893288,0.00013471163,0.000046711324,0.0033692156,0.00004853455],"about_ca_topic_score_codex":0.0059601525,"about_ca_topic_score_gemma":0.0043488396,"teacher_disagreement_score":0.36314994,"about_ca_system_score_codex":0.0003935434,"about_ca_system_score_gemma":0.004567999,"threshold_uncertainty_score":0.90100074},"labels":[],"label_agreement":null},{"id":"W4379283904","doi":"10.1200/jco.2023.41.16_suppl.e13001","title":"Serial multiomic analysis in advanced breast cancer: A novel platform to inform therapeutic decisions.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Internal medicine; Multiplex; Targeted therapy; Biopsy; Bioinformatics","score_opus":0.08729205356903277,"score_gpt":0.4531535403146253,"score_spread":0.3658614867455925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464744,0.00018369725,0.0009722713,0.0025227955,0.0013181006,0.00013142043,0.00008090464,0.0000037646628,0.00013962801],"genre_scores_gemma":[0.9918789,0.0031637377,0.0017869001,0.0021814296,0.00086345326,0.000011971909,0.000018831073,0.000014415135,0.00008034355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99781007,0.000039347116,0.0014986353,0.00020986264,0.00017834936,0.00026376123],"domain_scores_gemma":[0.9979569,0.0006661187,0.0006459897,0.0002135864,0.00026404712,0.0002533759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014454372,0.00012378648,0.00075148983,0.00032278712,0.0000375314,0.000014978601,0.00030384702,0.00031663958,0.00003736358],"category_scores_gemma":[0.0015090114,0.00010224438,0.00043408072,0.0007985105,0.00005455493,0.000009304046,0.00014971831,0.00028353126,0.00001609646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009214561,0.0007327959,0.08109867,0.000006000654,0.0012464217,0.00006761091,0.00013914898,0.06835591,0.036157686,0.00010871864,0.0030200009,0.7998525],"study_design_scores_gemma":[0.007450424,0.002905105,0.8316323,0.000028276945,0.00032722828,0.000038260085,0.00016837764,0.0014435645,0.00061266276,0.00018796638,0.15497354,0.00023229448],"about_ca_topic_score_codex":0.000075367105,"about_ca_topic_score_gemma":0.0025333648,"teacher_disagreement_score":0.7996202,"about_ca_system_score_codex":0.00010848718,"about_ca_system_score_gemma":0.001103585,"threshold_uncertainty_score":0.4169405},"labels":[],"label_agreement":null},{"id":"W4379283972","doi":"10.1200/jco.2023.41.16_suppl.2034","title":"A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Metastatic breast cancer; Breast cancer; Neratinib; Targeted therapy; Palbociclib; Confidence interval; Cancer; Randomized controlled trial","score_opus":0.22987811967722435,"score_gpt":0.497840903758899,"score_spread":0.2679627840816746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015642901,0.9943527,0.000013026983,0.00047605907,0.00015334964,0.002275913,0.0011565954,0.000003971012,0.000004092521],"genre_scores_gemma":[0.0012799482,0.9967301,0.0013856811,0.00019562393,0.00006339083,0.0001917655,0.00008041263,0.000044119613,0.000028943945],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909252,0.0017774252,0.006179805,0.00033688627,0.0005370417,0.00024363032],"domain_scores_gemma":[0.9832967,0.0067078983,0.008584401,0.0003437596,0.0008516907,0.00021555806],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005404378,0.0004272327,0.024107894,0.00055197015,0.000017097078,0.00000699582,0.00022201861,0.00029125425,0.00012358598],"category_scores_gemma":[0.001179865,0.0002056402,0.004772194,0.0007480207,0.00020122604,0.000068323454,0.00005779434,0.00056869304,7.9261196e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023413925,0.0016175791,0.00047151107,0.28805494,0.6719503,0.000102537175,0.00003397955,0.0000062964564,1.2970157e-8,0.000019914633,0.000082603314,0.035318952],"study_design_scores_gemma":[0.005903247,0.008229102,0.00086987606,0.032376405,0.95007014,0.000036293237,0.000031379073,0.000006141324,9.978367e-8,0.000006746066,0.00232253,0.00014803738],"about_ca_topic_score_codex":0.0001491287,"about_ca_topic_score_gemma":0.00020057261,"teacher_disagreement_score":0.27811986,"about_ca_system_score_codex":0.00017799967,"about_ca_system_score_gemma":0.0010779821,"threshold_uncertainty_score":0.9903802},"labels":[],"label_agreement":null},{"id":"W4379283976","doi":"10.1200/jco.2023.41.16_suppl.4502","title":"Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Renal cell carcinoma; Urology; Sunitinib; Gastroenterology; Confidence interval; Everolimus; Hazard ratio; Clinical trial","score_opus":0.11529768167133961,"score_gpt":0.3854609462312064,"score_spread":0.27016326455986683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934572,0.0000776448,0.000017229679,0.00034711589,0.00049801543,0.00045829205,0.000046139274,0.000012647829,0.005085697],"genre_scores_gemma":[0.9975259,0.00016758188,0.0011911867,0.00011113308,0.00021500331,0.000008163284,0.00007903417,0.000044412496,0.0006576106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927406,0.00092369004,0.0040875385,0.0004421571,0.001295747,0.0005102662],"domain_scores_gemma":[0.99141157,0.0030051623,0.0034560293,0.0005371188,0.0011551306,0.00043497735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024819071,0.00032986794,0.0038013766,0.0011490153,0.000034761866,0.000007389792,0.00036516873,0.00042324897,0.00031456785],"category_scores_gemma":[0.001541072,0.00024243983,0.0011933139,0.0014060907,0.00031831366,0.00015160158,0.00013813717,0.0010834046,0.000014805726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17810783,0.0030795778,0.8033289,0.00015207623,0.0018172981,0.0010579843,0.00047768423,0.0019717037,0.00046145293,0.000080925274,0.00080971606,0.008654856],"study_design_scores_gemma":[0.07014952,0.043331075,0.8812637,0.00012702431,0.0023833015,0.000016039767,0.00026401356,0.0003241684,0.00090197724,0.000033959037,0.0010338787,0.00017136439],"about_ca_topic_score_codex":0.0001308089,"about_ca_topic_score_gemma":0.0003016546,"teacher_disagreement_score":0.10795831,"about_ca_system_score_codex":0.00040943146,"about_ca_system_score_gemma":0.0019128516,"threshold_uncertainty_score":0.9886409},"labels":[],"label_agreement":null},{"id":"W4379283978","doi":"10.1200/jco.2023.41.16_suppl.4165","title":"Meta-analyses of factors associated with long-term survival after resection of pancreatic ductal adenocarcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Meta-analysis; Pancreatic ductal adenocarcinoma; Pancreatic cancer; Cancer","score_opus":0.5700919829858108,"score_gpt":0.5560122353437926,"score_spread":0.014079747642018137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680036,0.0010202733,0.00006460601,0.0007863581,0.00032647565,0.00022695186,0.000016428019,0.000010092815,0.00074847165],"genre_scores_gemma":[0.9978753,0.00057122146,0.000238648,0.000059307335,0.00026715125,0.0000078238,0.000014763561,0.000020738866,0.00094507996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940521,0.0015463559,0.0029336677,0.00021113963,0.000937837,0.0003188935],"domain_scores_gemma":[0.9869665,0.008600534,0.0026192518,0.0002740531,0.0012149719,0.0003246928],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0062837345,0.00018220155,0.0045034178,0.00043953265,0.000031961914,0.0000039163588,0.00018674154,0.00047754293,0.00067376374],"category_scores_gemma":[0.010029074,0.00010073352,0.0011399267,0.0006522169,0.00065481354,0.00009708517,0.00006710906,0.00091513584,0.0000085121155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070014163,0.001113711,0.9575959,0.00009098052,0.03207099,0.000946809,0.00014707506,0.000006659944,0.0006237954,0.000008520051,0.00020986017,0.00018432403],"study_design_scores_gemma":[0.004755258,0.01886966,0.94114053,0.0001113408,0.03425413,0.00008471329,0.00021672939,0.000032472333,0.0003725915,0.00007125007,0.00001751965,0.00007380804],"about_ca_topic_score_codex":0.000081235456,"about_ca_topic_score_gemma":0.00020864348,"teacher_disagreement_score":0.01775595,"about_ca_system_score_codex":0.00013068944,"about_ca_system_score_gemma":0.0018149831,"threshold_uncertainty_score":0.99830985},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4379284034","doi":"10.1200/jco.2023.41.16_suppl.1532","title":"Best practices study to enhance the quality of multi-disciplinary teams in lung cancer care.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Best practice; Health care; Lung cancer; Maturity (psychological); Family medicine; Nursing; Psychology; Oncology; Management","score_opus":0.25948320000092057,"score_gpt":0.689914745405848,"score_spread":0.4304315454049274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97532487,0.0032105981,0.00013460698,0.017501889,0.002625414,0.00058512314,0.0000035153998,0.000007732208,0.0006062259],"genre_scores_gemma":[0.98964906,0.003624768,0.0028103562,0.0016141394,0.0014009101,0.000025022158,5.711907e-7,0.0000135159235,0.0008616459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538094,0.0013957905,0.0024525656,0.00021075904,0.00034190572,0.00021802573],"domain_scores_gemma":[0.9872565,0.008721626,0.003201701,0.0002668012,0.000394907,0.00015846323],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00850338,0.00011317026,0.0013808585,0.00013730464,0.000063648,0.0000026992927,0.00031294816,0.00023182562,0.00006656185],"category_scores_gemma":[0.0099046985,0.00006403349,0.00023168813,0.0004436833,0.00029972245,0.00011167331,0.000103811355,0.0012781254,0.000009595096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006946932,0.005763262,0.8581618,0.0000815608,0.00037792875,0.0004749387,0.0076969704,0.0007258164,0.00037713422,0.000011865209,0.0016137146,0.117768064],"study_design_scores_gemma":[0.005908677,0.017491441,0.9322821,0.00018382013,0.0002353696,0.000043408134,0.022319874,0.00016908212,0.00006179203,0.00004740947,0.021162009,0.00009504725],"about_ca_topic_score_codex":0.00021701521,"about_ca_topic_score_gemma":0.0031727382,"teacher_disagreement_score":0.11767302,"about_ca_system_score_codex":0.00026519396,"about_ca_system_score_gemma":0.0016322284,"threshold_uncertainty_score":0.9984353},"labels":[],"label_agreement":null},{"id":"W4379284089","doi":"10.1200/jco.2023.41.16_suppl.tps616","title":"lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Letrozole; Tamoxifen; Internal medicine; Anastrozole; Oncology; Exemestane; Fulvestrant; Breast cancer; Tolerability; Estrogen receptor; Hazard ratio; Adverse effect; Cancer; Gynecology; Confidence interval","score_opus":0.05948224414837465,"score_gpt":0.43914211620900123,"score_spread":0.37965987206062657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576503,0.00019571703,0.000016702195,0.0022009131,0.0005079483,0.0010949636,0.00009175028,0.000021073565,0.00010592334],"genre_scores_gemma":[0.9972687,0.0007319758,0.0005293083,0.0005765178,0.0006804559,0.00004930615,0.000008693757,0.00006547293,0.00008959278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943778,0.00071938004,0.003065218,0.0004367348,0.00089977786,0.0005010751],"domain_scores_gemma":[0.9928982,0.0016771147,0.003361691,0.00034599603,0.0013832471,0.0003337226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095607596,0.00037909282,0.0030520235,0.0003126391,0.00004939062,0.0000074689033,0.0003275004,0.00019927966,0.00015616202],"category_scores_gemma":[0.00034075804,0.0002658832,0.00038421774,0.0007541048,0.0004969056,0.00030942485,0.00006762891,0.0011756244,0.0000061787223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088703945,0.019487202,0.52030766,0.000051472354,0.0019071617,0.00035133128,0.0024689788,0.00025432935,0.0008301105,0.0000072216185,0.0001676628,0.36546296],"study_design_scores_gemma":[0.09735624,0.062863156,0.8344183,0.0006800945,0.00028190322,0.000037619546,0.0013973088,0.000021529471,0.0017958774,0.000055736007,0.00089263124,0.00019961192],"about_ca_topic_score_codex":0.0034360385,"about_ca_topic_score_gemma":0.0007159912,"teacher_disagreement_score":0.36526334,"about_ca_system_score_codex":0.0003826539,"about_ca_system_score_gemma":0.001296968,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W4379284114","doi":"10.1200/jco.2023.41.16_suppl.tps1123","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Fulvestrant; Tolerability; Regimen; Internal medicine; Everolimus; Oncology; Pharmacology; Cancer; Adverse effect; Breast cancer; Estrogen receptor","score_opus":0.045631715074727526,"score_gpt":0.4278713048804936,"score_spread":0.38223958980576606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337476,0.0003004527,0.00030333365,0.002750302,0.0007460605,0.002101949,0.00019089178,0.00006259278,0.00016966017],"genre_scores_gemma":[0.9935795,0.0015023332,0.0032736764,0.00080818275,0.0003649432,0.00012696687,0.0000368345,0.00012962506,0.00017790595],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99004984,0.0018085339,0.005019305,0.0008010998,0.0014387199,0.0008824929],"domain_scores_gemma":[0.9881695,0.0038013146,0.0043791793,0.00053035875,0.0023589353,0.0007607125],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026900063,0.00069998915,0.004469831,0.00065411726,0.00010374166,0.000023546769,0.0005486154,0.00042165903,0.00022525544],"category_scores_gemma":[0.0015214863,0.00047406222,0.0004336855,0.002119811,0.0009520731,0.00072533387,0.00016894795,0.0023465052,0.000015762802],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48862943,0.039188243,0.04670381,0.0002097196,0.0035603186,0.0053414833,0.005423759,0.002351508,0.00088054244,0.00001545006,0.00074627134,0.4069495],"study_design_scores_gemma":[0.26491943,0.14398755,0.57463384,0.0018262834,0.0013916014,0.0007204055,0.0090349475,0.000233644,0.00035500654,0.00013356352,0.00211083,0.00065290934],"about_ca_topic_score_codex":0.0007017375,"about_ca_topic_score_gemma":0.0014349939,"teacher_disagreement_score":0.52793,"about_ca_system_score_codex":0.000989487,"about_ca_system_score_gemma":0.0033297008,"threshold_uncertainty_score":0.9999551},"labels":[],"label_agreement":null},{"id":"W4379284260","doi":"10.1200/jco.2023.41.16_suppl.581","title":"Characteristics associated with spatially resolved immune landscapes in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Breast Cancer Research Foundation","keywords":"Triple-negative breast cancer; Medicine; Immune system; Breast cancer; Tumor-infiltrating lymphocytes; CD8; Cohort; Oncology; Stromal cell; Internal medicine; Cancer research; Immunology; Cancer","score_opus":0.06959085374094032,"score_gpt":0.4230436699381012,"score_spread":0.3534528161971609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841052,0.00023879018,0.000002131842,0.013903221,0.000918307,0.0005404757,0.000033940774,0.0000071816826,0.00025074094],"genre_scores_gemma":[0.99171335,0.005996792,0.000035043762,0.0012688092,0.0006969893,0.000021933034,0.000009579839,0.000013815279,0.00024367543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959497,0.00096954114,0.0023419617,0.0001680272,0.00033446573,0.00023628959],"domain_scores_gemma":[0.9927019,0.005217208,0.0016659711,0.00013100945,0.00019698401,0.00008691627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009097066,0.00013263476,0.0013818524,0.00017939128,0.000034441407,0.000014633119,0.0001521611,0.00033642363,0.00018954187],"category_scores_gemma":[0.0035674635,0.000072967974,0.00021879436,0.0004999619,0.00021305581,0.00006462457,0.00002600666,0.001105823,0.0000030839387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36261168,0.0009840118,0.56971174,0.000014367505,0.0005158559,0.0007832108,0.00046598134,0.0000020850682,0.000058509402,0.0000021403237,0.00087903824,0.0639714],"study_design_scores_gemma":[0.11342845,0.007186155,0.87710977,0.00026860033,0.00020219419,0.0000803417,0.00022414804,0.00011115911,0.000002954309,0.00003146721,0.0012780399,0.00007674051],"about_ca_topic_score_codex":0.0002987475,"about_ca_topic_score_gemma":0.002856862,"teacher_disagreement_score":0.30739802,"about_ca_system_score_codex":0.00014894389,"about_ca_system_score_gemma":0.0014296606,"threshold_uncertainty_score":0.4804312},"labels":[],"label_agreement":null},{"id":"W4379284394","doi":"10.1200/jco.2023.41.16_suppl.1110","title":"Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Hazard ratio; Internal medicine; Breast cancer; Discontinuation; Oncology; Odds ratio; Adverse effect; Progression-free survival; Cancer; Confidence interval; Overall survival","score_opus":0.12906726759457574,"score_gpt":0.547813829062053,"score_spread":0.41874656146747724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887911,0.0019381717,0.00017870065,0.0072731883,0.0004564368,0.0013052195,0.000013226561,0.000015833382,0.000028141794],"genre_scores_gemma":[0.99651194,0.0012592018,0.0009961124,0.00015622878,0.00081400713,0.0001923084,0.0000046995337,0.00001945011,0.00004608171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938239,0.0019730988,0.0034225157,0.00024184427,0.00027506013,0.00026358658],"domain_scores_gemma":[0.9918795,0.005139886,0.0025498779,0.0001090643,0.000113973234,0.00020770173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009299552,0.00018469816,0.0047581056,0.00023558203,0.000020379104,0.000008530418,0.000071548384,0.00022014542,0.00002622993],"category_scores_gemma":[0.0031021642,0.00011054117,0.00039762273,0.00021196871,0.00033725263,0.00022171206,0.00002061067,0.0004315196,0.0000015022811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15038984,0.0004541914,0.5331496,0.00000608011,0.000189118,0.000102744336,0.00034536407,0.000052471583,0.0011005908,0.0000026476418,0.0000033786414,0.314204],"study_design_scores_gemma":[0.3307481,0.0024679801,0.6648275,0.00045612903,0.00016915395,0.000033750846,0.00034202286,0.00028373167,0.00034734965,0.000115859184,0.0001368525,0.00007154373],"about_ca_topic_score_codex":0.000078589685,"about_ca_topic_score_gemma":0.000104012826,"teacher_disagreement_score":0.31413245,"about_ca_system_score_codex":0.00044592711,"about_ca_system_score_gemma":0.00051350944,"threshold_uncertainty_score":0.45077384},"labels":[],"label_agreement":null},{"id":"W4379284398","doi":"10.1200/jco.2023.41.16_suppl.1028","title":"Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University Health Centre; Western University; Hôpital Charles-Le Moyne; Université de Sherbrooke; University of Toronto; University Health Network; London Health Sciences Centre; Université Laval; Royal Victoria Regional Health Centre; Statistics Canada; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Liquid biopsy; Concordance; Biopsy; Circulating tumor cell; Cancer; Breast cancer; Pathology; Metastatic breast cancer; Internal medicine; Oncology; Metastasis","score_opus":0.08155842286322046,"score_gpt":0.437272413481729,"score_spread":0.35571399061850856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949299,0.001120173,0.000057566624,0.003025185,0.0006030342,0.00010927374,0.000059826187,0.0000034745317,0.00009154678],"genre_scores_gemma":[0.9880491,0.009758205,0.0003642213,0.00043297687,0.0013204216,0.0000114134145,0.000009336446,0.000016142672,0.000038167753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981562,0.00015727417,0.0010374787,0.00022899055,0.00012697554,0.00029307848],"domain_scores_gemma":[0.99812764,0.00062120135,0.00066183315,0.0001422381,0.00016148311,0.00028562866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011947168,0.0001220167,0.0006515862,0.0000642756,0.000026547188,0.000010674251,0.00016515107,0.00023497142,0.0000127261155],"category_scores_gemma":[0.00082964567,0.00009527421,0.00007757874,0.00016058149,0.00019378534,0.0000061676715,0.00010375828,0.00031139044,0.000004732545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052880896,0.00035849487,0.7187553,0.000029316023,0.00022202916,0.00060772774,0.00009113798,0.0003749722,0.0065477593,0.00003743458,0.0036968053,0.26399094],"study_design_scores_gemma":[0.0059842654,0.0119394045,0.9144004,0.000117638214,0.00010438394,0.00011282639,0.00010246089,0.000034312736,0.0015883747,0.00008900095,0.06532635,0.0002006175],"about_ca_topic_score_codex":0.00011354479,"about_ca_topic_score_gemma":0.0009007768,"teacher_disagreement_score":0.26379034,"about_ca_system_score_codex":0.000040760773,"about_ca_system_score_gemma":0.0009420484,"threshold_uncertainty_score":0.38851696},"labels":[],"label_agreement":null},{"id":"W4379284501","doi":"10.1200/jco.2023.41.16_suppl.e13558","title":"Impact of breast density on classification of infrared spectroscopy for breath-based breast cancer screening.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Chemical Sensor Technologies","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick; Horizon Health Network; Saint John Regional Hospital","funders":"Fondation de la recherche en santé du Nouveau-Brunswick","keywords":"Breast cancer; Medicine; Cancer; Internal medicine","score_opus":0.09507586633535742,"score_gpt":0.4476073287031837,"score_spread":0.3525314623678263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992304,0.000034621844,0.005868368,0.00093721267,0.000289323,0.0001352111,0.00016853663,0.00009943805,0.00016324932],"genre_scores_gemma":[0.99275506,0.000168921,0.006754798,0.000031157124,0.00023927727,0.000005518283,0.0000056907584,0.000026104986,0.000013465963],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978391,0.000052156836,0.0015082881,0.00013722933,0.00021759224,0.00024563345],"domain_scores_gemma":[0.9961743,0.0019757214,0.0010897464,0.00022344213,0.0004167918,0.00012003906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004706554,0.00014817601,0.0010271592,0.00019372429,0.000017788081,0.0000031821612,0.00027106935,0.00041329843,0.000028902292],"category_scores_gemma":[0.0011143312,0.00011468026,0.0005553481,0.00033654322,0.00022160716,0.000077849894,0.000023914386,0.0005549389,0.0000023696637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073060486,0.00085576455,0.13560462,0.00016699615,0.0008230677,0.00003573481,0.000029685898,0.090136066,0.5896585,0.0001703903,0.011270681,0.16394247],"study_design_scores_gemma":[0.0029735025,0.0025021438,0.92069274,0.00014388975,0.0001052151,0.00004485355,0.000034127155,0.015759287,0.05598785,0.0012559784,0.00036071576,0.00013969425],"about_ca_topic_score_codex":0.000012921507,"about_ca_topic_score_gemma":0.000008814573,"teacher_disagreement_score":0.7850881,"about_ca_system_score_codex":0.0002484723,"about_ca_system_score_gemma":0.00015259183,"threshold_uncertainty_score":0.46765253},"labels":[],"label_agreement":null},{"id":"W4379284511","doi":"10.1200/jco.2023.41.16_suppl.534","title":"Real-world impact of TAILORx on chemotherapy use and SOFT/TEXT on ovarian function suppression uptake in a population based-cohort of women 40 years and under with HR-positive, HER2-negative, axillary lymph node negative breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency; Western University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Cohort; Gynecology; Population; Hormone therapy; Cancer","score_opus":0.03120094645655303,"score_gpt":0.3709059868350041,"score_spread":0.33970504037845106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99875027,0.000025738618,0.000022401102,0.000789652,0.000102624464,0.00016927953,0.00007397778,0.0000033305378,0.00006270846],"genre_scores_gemma":[0.9982326,0.0010008588,0.00024898138,0.00031756648,0.00012241505,0.000012301716,0.000017872304,0.000020443038,0.00002696345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983631,0.0002878245,0.00070948486,0.00025679776,0.00018893399,0.00019385859],"domain_scores_gemma":[0.9980478,0.0006064046,0.0009070108,0.00012968005,0.00019090742,0.00011817431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000632002,0.00016616887,0.0007052281,0.00016471438,0.000032391596,0.0000073151764,0.000056956633,0.00020007002,0.000021135436],"category_scores_gemma":[0.00019340347,0.00011768775,0.00011643496,0.00021463342,0.00018349224,0.00002299226,0.000034536246,0.00018775294,3.0868347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0325443,0.00048598167,0.94153816,0.000015459153,0.00065687357,0.00001747975,0.0001543505,0.0017708038,0.0011537316,0.0000106358975,0.00010352936,0.02154869],"study_design_scores_gemma":[0.00640287,0.0047055064,0.9876819,0.0002023731,0.00007739238,0.0000143488905,0.00010206694,0.00010028053,0.00044722998,0.00013773906,0.000028156368,0.00010011818],"about_ca_topic_score_codex":0.0024915938,"about_ca_topic_score_gemma":0.0007209752,"teacher_disagreement_score":0.046143755,"about_ca_system_score_codex":0.00029892608,"about_ca_system_score_gemma":0.00042109593,"threshold_uncertainty_score":0.4799167},"labels":[],"label_agreement":null},{"id":"W4379284512","doi":"10.1200/jco.2023.41.16_suppl.1567","title":"Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Queen's University; University of Toronto; London Health Sciences Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Randomized controlled trial; Clinical trial; Dysgeusia; Colorectal cancer; Cancer; Internal medicine; Oncology; Intensive care medicine","score_opus":0.900708865580246,"score_gpt":0.7184210677067275,"score_spread":0.18228779787351845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284512","genre_codex":"review","genre_gemma":"review","domain_codex":"methods","domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0260409,0.9504176,0.00011881351,0.00040984133,0.0015967147,0.021106515,0.00022209529,0.0000059714525,0.00008159255],"genre_scores_gemma":[0.00083320314,0.9949073,0.0004802325,0.00021988012,0.0010078339,0.0013016957,0.000013726021,0.00005260787,0.0011835017],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.14636357,0.5380735,0.30825248,0.0017782566,0.0049258242,0.0006064044],"domain_scores_gemma":[0.031927705,0.6121451,0.35117385,0.0012832718,0.0028315198,0.0006385286],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.9021582,0.001111887,0.3004664,0.0013484017,0.00012153608,0.0002850893,0.0013518042,0.001483597,0.0010775635],"category_scores_gemma":[0.97823215,0.0004425867,0.03671081,0.0017696348,0.00078742334,0.0003813602,0.0005090671,0.0022041933,0.000018919145],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055902924,0.0011715548,0.0045511117,0.5966044,0.086474895,0.00090244197,0.00055055163,0.0000016432625,0.000002939509,0.000030743347,0.0097145075,0.24409229],"study_design_scores_gemma":[0.20441143,0.001123971,0.00022801408,0.5653611,0.21902841,0.00023193023,0.0004686189,0.00033796293,4.785433e-7,0.00013506995,0.008153482,0.0005195395],"about_ca_topic_score_codex":0.00023778185,"about_ca_topic_score_gemma":0.001020283,"teacher_disagreement_score":0.26375556,"about_ca_system_score_codex":0.00036059608,"about_ca_system_score_gemma":0.004886194,"threshold_uncertainty_score":0.9998356},"labels":[],"label_agreement":null},{"id":"W4379284520","doi":"10.1200/jco.2023.41.16_suppl.e12581","title":"Reflex MammaPrint testing on breast core biopsies: A single center experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Cancer; Retrospective cohort study","score_opus":0.28882395038927,"score_gpt":0.4863552853791417,"score_spread":0.1975313349898717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911099,0.00007507273,0.00001749171,0.0027872664,0.0012440612,0.00006688656,0.00001662409,0.00001494886,0.0046677254],"genre_scores_gemma":[0.9955257,0.00019814148,0.0011905824,0.0012081915,0.0016252893,0.000007844394,0.000007636276,0.000018503531,0.00021809999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809486,0.00013259996,0.0010433495,0.00025598452,0.00020104981,0.0002721402],"domain_scores_gemma":[0.99805945,0.0004841951,0.0007812532,0.00021435937,0.00029115894,0.00016959614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007469775,0.0001493392,0.0005535653,0.00007039807,0.00006758256,0.000009522744,0.00022725487,0.00024294895,0.000021723301],"category_scores_gemma":[0.0019616515,0.00010898219,0.0002736182,0.00017197173,0.000234087,0.0000052399896,0.00017630948,0.0002781599,0.000047694943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004705323,0.0028909852,0.52256393,0.000022501756,0.0007073127,0.0007712018,0.00036941955,0.000090843,0.02614966,0.000067568246,0.022282401,0.41937888],"study_design_scores_gemma":[0.005971079,0.011280147,0.823507,0.00013288076,0.00007502389,0.00146231,0.00096333225,0.000025482103,0.0023333493,0.00021166596,0.15375191,0.0002857824],"about_ca_topic_score_codex":0.000008554711,"about_ca_topic_score_gemma":0.000022813305,"teacher_disagreement_score":0.41909307,"about_ca_system_score_codex":0.00006962063,"about_ca_system_score_gemma":0.00023123664,"threshold_uncertainty_score":0.44441646},"labels":[],"label_agreement":null},{"id":"W4379284572","doi":"10.1200/jco.2023.41.16_suppl.e12595","title":"Informative tools to optimize neoadjuvant therapy in ER positive, HER2 negative breast cancers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Foundation","keywords":"Medicine; Breast cancer; Nat; Internal medicine; Oncology; Neoadjuvant therapy; Biopsy; Cancer; Pathological; Chemotherapy; Gynecology","score_opus":0.07457581712649966,"score_gpt":0.4305560753139689,"score_spread":0.35598025818746926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98513925,0.00020653545,0.00009707557,0.010255112,0.00088386843,0.00028333694,0.00008196213,0.000008049524,0.0030448113],"genre_scores_gemma":[0.98890084,0.0029226923,0.002337275,0.0047917743,0.00082762755,0.00002981134,0.00001696951,0.000018800429,0.0001542316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977559,0.00030193225,0.0012408305,0.0002055359,0.00019496774,0.0003008216],"domain_scores_gemma":[0.99788326,0.00067288213,0.00071040617,0.00015177215,0.0003848579,0.00019680941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011175026,0.00017432102,0.00081703474,0.00012188613,0.000044786728,0.000013907892,0.00023451043,0.00025706264,0.000033886343],"category_scores_gemma":[0.0009404124,0.00012807998,0.00027658045,0.0002865062,0.00015654416,0.000022766615,0.00014635,0.0003655977,0.000036364654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023056677,0.001071824,0.06201908,0.000011532068,0.002081254,0.00051527534,0.0030017851,0.004935628,0.0013071292,0.000077000426,0.04580942,0.8561134],"study_design_scores_gemma":[0.008347078,0.0066055674,0.95876276,0.00007010587,0.0000360361,0.00013861986,0.001066566,0.00002924542,0.0015287724,0.00013281594,0.023082703,0.00019972141],"about_ca_topic_score_codex":0.000202559,"about_ca_topic_score_gemma":0.00043337012,"teacher_disagreement_score":0.8967437,"about_ca_system_score_codex":0.00018949587,"about_ca_system_score_gemma":0.0009953438,"threshold_uncertainty_score":0.522295},"labels":[],"label_agreement":null},{"id":"W4379285481","doi":"10.1200/jco.2023.41.16_suppl.509","title":"Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University","funders":"Hologic","keywords":"Medicine; Breast cancer; Hazard ratio; Internal medicine; Tamoxifen; Proportional hazards model; Oncology; Stage (stratigraphy); Confidence interval; Exemestane; Cancer","score_opus":0.027749604048949213,"score_gpt":0.40954301599619247,"score_spread":0.38179341194724326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996559,0.00054698455,0.0000073854294,0.0016214065,0.00023311944,0.00023185129,0.0006923603,0.0000016019771,0.00010628382],"genre_scores_gemma":[0.9893038,0.01020326,0.000046693767,0.00016179707,0.00018563255,0.000052920226,0.0000048339025,0.000012335755,0.000028679136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973957,0.00057041406,0.001227205,0.00025118218,0.0002839533,0.00027157785],"domain_scores_gemma":[0.9975839,0.0005107801,0.0014558563,0.00016061,0.00019531157,0.000093529176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020485907,0.00016635816,0.00088330486,0.00008013009,0.0000273439,0.000007039366,0.00022598123,0.00019568308,0.000022354316],"category_scores_gemma":[0.00014688824,0.000099015386,0.000081553575,0.00022743444,0.0003176117,0.0000135347545,0.000107001644,0.0004678124,1.6472188e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034188263,0.0011445372,0.94091964,0.00002664678,0.0004908565,0.00003570121,0.00035739786,0.00026857507,0.00081595185,0.000011365651,0.00040582326,0.02133523],"study_design_scores_gemma":[0.021962272,0.0040916568,0.97245145,0.000100647034,0.00008667284,0.000025800024,0.00034367177,0.000024680536,0.000028767332,0.00007619126,0.00070819,0.000100029865],"about_ca_topic_score_codex":0.0016896831,"about_ca_topic_score_gemma":0.0023225895,"teacher_disagreement_score":0.03153177,"about_ca_system_score_codex":0.00014349105,"about_ca_system_score_gemma":0.0009841897,"threshold_uncertainty_score":0.403773},"labels":[],"label_agreement":null},{"id":"W4379285568","doi":"10.1200/jco.2023.41.16_suppl.1554","title":"Can synthetic data accurately mimic oncology clinical trials?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McMaster University; University of Ottawa; Agricultural Research Institute of Ontario","funders":"CHEO Research Institute","keywords":"Custodians; Data sharing; Medicine; Clinical trial; Synthetic data; Confidence interval; Computer science; Clinical endpoint; Metric (unit); Data mining; Medical physics; Artificial intelligence; Internal medicine; Alternative medicine","score_opus":0.9702328098062203,"score_gpt":0.808878059487289,"score_spread":0.16135475031893132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49156162,0.00080802466,0.00023951613,0.46131113,0.019889448,0.0011817161,0.00011773428,0.00014766284,0.024743147],"genre_scores_gemma":[0.9162481,0.038866512,0.007903808,0.017831828,0.014243012,0.000013887384,0.000073866875,0.000110272806,0.0047087157],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.949927,0.02202187,0.02276489,0.0013430268,0.0027385305,0.0012047015],"domain_scores_gemma":[0.124930605,0.8475799,0.013557708,0.004315571,0.005109503,0.00450673],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.38706592,0.00032582055,0.007331166,0.00051409315,0.00012684839,0.000045641395,0.0026199957,0.0044665993,0.0010732661],"category_scores_gemma":[0.83762157,0.00022136183,0.0020469616,0.0008833996,0.002187666,0.00024384035,0.0016169698,0.017620364,0.0010259746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0144474,0.0048757945,0.02777973,0.00016382516,0.0019314612,0.009276143,0.00009518286,0.000009439013,0.00013198234,0.001921516,0.21606429,0.72330326],"study_design_scores_gemma":[0.023967441,0.04650198,0.11135062,0.00063040777,0.0021050253,0.0014505193,0.00070637633,0.0023365812,0.000035386583,0.03973811,0.7708095,0.0003680606],"about_ca_topic_score_codex":0.00004762963,"about_ca_topic_score_gemma":0.0005368185,"teacher_disagreement_score":0.825558,"about_ca_system_score_codex":0.0003669083,"about_ca_system_score_gemma":0.027694566,"threshold_uncertainty_score":0.9998399},"labels":[],"label_agreement":null},{"id":"W4379285617","doi":"10.1200/jco.2023.41.16_suppl.e13616","title":"Design, reporting, and disparities of advanced non–small cell lung cancer phase 3 clinical trials in the era of immunotherapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Population; Internal medicine; Ethnic group; Oncology; Family medicine; Environmental health","score_opus":0.21021761547945003,"score_gpt":0.5775891799436152,"score_spread":0.3673715644641652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804824,0.0030134015,0.002422571,0.012460695,0.0010489434,0.0003849731,0.0000019327758,0.0000051416782,0.00017994145],"genre_scores_gemma":[0.96692765,0.021788187,0.008249814,0.0021548711,0.00074488146,0.000009822827,0.0000015431683,0.000018557575,0.00010467418],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9863124,0.0030412772,0.009909947,0.00017734418,0.00034208316,0.00021693346],"domain_scores_gemma":[0.9600056,0.026693434,0.012579491,0.00023659709,0.00029956436,0.00018534875],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.080951765,0.00011985089,0.003103958,0.00012884311,0.00002769299,0.000006989175,0.00020913588,0.00026627164,0.000040077237],"category_scores_gemma":[0.06536782,0.000068412985,0.00060418417,0.00022173846,0.00040963409,0.000051568903,0.000042822885,0.0020484019,3.7934012e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061478484,0.0018101766,0.33927667,0.00022097763,0.0003747153,0.00068035204,0.0008257054,0.00042218462,0.004746552,0.000019728544,0.0044685067,0.6410066],"study_design_scores_gemma":[0.07287901,0.023256758,0.84792113,0.0023679107,0.001479034,0.00039500874,0.0013504962,0.028899794,0.0009544462,0.0010194636,0.019206846,0.00027010805],"about_ca_topic_score_codex":0.00007731251,"about_ca_topic_score_gemma":0.000008814609,"teacher_disagreement_score":0.64073646,"about_ca_system_score_codex":0.000027479973,"about_ca_system_score_gemma":0.0012868774,"threshold_uncertainty_score":0.94635355},"labels":[],"label_agreement":null},{"id":"W4379285629","doi":"10.1200/jco.2023.41.16_suppl.533","title":"Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Ottawa Hospital","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Oncology; Internal medicine; Population; Tamoxifen; Lymph node; Concordance; Cancer; Gynecology","score_opus":0.03771371628662702,"score_gpt":0.387941283862577,"score_spread":0.35022756757594997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939152,0.00015112538,0.0000652906,0.0020982577,0.0021814243,0.0002641994,0.00038468113,0.00003636129,0.0009034392],"genre_scores_gemma":[0.99094075,0.0019017609,0.0009772645,0.0035151818,0.001969781,0.000072855015,0.00037592405,0.000021192525,0.00022529876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955544,0.0006394339,0.0026317064,0.00034318672,0.00041068174,0.00042058414],"domain_scores_gemma":[0.9950371,0.0015138236,0.0022665348,0.00031817413,0.00063533423,0.00022902522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025827214,0.00026830923,0.0010289262,0.00021421949,0.00013234655,0.000019014618,0.00040062494,0.00073428324,0.00019224056],"category_scores_gemma":[0.0068094386,0.00016015366,0.0005583566,0.00026846127,0.00062863925,0.000063553496,0.00028684508,0.0006914456,0.00015500208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00497439,0.0014514825,0.64294946,0.00005228506,0.00090032344,0.00065937924,0.00022041003,0.00036152377,0.0008979034,0.00012569787,0.2624977,0.08490943],"study_design_scores_gemma":[0.0038792598,0.004032063,0.7673363,0.000041650103,0.00013150819,0.00019345169,0.00018355921,0.000023110213,0.00009673785,0.00084678177,0.22306477,0.00017078141],"about_ca_topic_score_codex":0.000010993113,"about_ca_topic_score_gemma":0.00013627778,"teacher_disagreement_score":0.12438685,"about_ca_system_score_codex":0.00008244933,"about_ca_system_score_gemma":0.0012565624,"threshold_uncertainty_score":0.8152026},"labels":[],"label_agreement":null},{"id":"W4379285655","doi":"10.1200/jco.2023.41.16_suppl.e13113","title":"Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer; Metastatic breast cancer; Meta-analysis; Randomized controlled trial; Antibody-drug conjugate; Antibody; Monoclonal antibody; Immunology","score_opus":0.6540924356858592,"score_gpt":0.6992106650388575,"score_spread":0.04511822935299836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046456717,0.9867222,0.000007652381,0.005453005,0.00049985334,0.006939455,0.00025007717,0.000007661029,0.00007367019],"genre_scores_gemma":[0.00007467786,0.99801415,0.00021705066,0.0006609893,0.00045052578,0.00024174768,0.000022035952,0.00006576434,0.0002530419],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.87486756,0.07184647,0.05065355,0.0006661664,0.0015210679,0.00044516256],"domain_scores_gemma":[0.6777756,0.27409887,0.044061024,0.0010833688,0.0021399872,0.00084114354],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.31317115,0.0005845967,0.16453372,0.0016380941,0.00001838409,0.000013402826,0.00079094496,0.0012740085,0.0008064193],"category_scores_gemma":[0.2579738,0.00029282665,0.033809472,0.0024640895,0.0012867355,0.000062598905,0.0002438536,0.0038411105,0.000013018162],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011469788,0.0009885022,0.0000955271,0.5622572,0.39761338,0.0002653845,0.000016217575,0.0000011283274,5.267221e-8,0.000020833928,0.0010265002,0.026245521],"study_design_scores_gemma":[0.046348207,0.0007690238,0.000085923566,0.16938838,0.77217305,0.00017888052,0.000011684093,0.000021832846,4.443287e-8,0.000017285614,0.010855988,0.00014969116],"about_ca_topic_score_codex":0.0002324811,"about_ca_topic_score_gemma":0.000094801144,"teacher_disagreement_score":0.39286882,"about_ca_system_score_codex":0.00023303897,"about_ca_system_score_gemma":0.009092478,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W4379285657","doi":"10.1200/jco.2023.41.16_suppl.103","title":"Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Akkermansia muciniphila; Medicine; Internal medicine; Dysbiosis; Oncology; Gut flora; Cancer; Gastroenterology; Immunology; Disease","score_opus":0.07187441173212379,"score_gpt":0.43935275882743297,"score_spread":0.3674783470953092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872247,0.0007992824,0.0001391461,0.0095203975,0.0012118267,0.000111058034,0.0000048919787,0.000008078227,0.0009806489],"genre_scores_gemma":[0.9901069,0.0013267925,0.0046830853,0.0015949645,0.0012573653,0.0000025881336,0.000007473821,0.000022410562,0.0009984435],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972486,0.00027655545,0.0017327269,0.00027456105,0.00015004032,0.00031753295],"domain_scores_gemma":[0.9980607,0.00022936573,0.0008959312,0.00021676517,0.00025958082,0.00033767315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031589628,0.00013824298,0.0006892576,0.00011088893,0.0000970049,0.000028193192,0.00020837106,0.00043743209,0.00001735341],"category_scores_gemma":[0.0019864975,0.00011266452,0.00026752552,0.00020241542,0.00014547519,0.00001138308,0.00019907884,0.0004731965,0.000024259978],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008097851,0.00024956686,0.021241581,0.000057199544,0.00013169466,0.00012295769,0.00009194704,0.000007770936,0.92275006,0.000078908284,0.041705646,0.012752885],"study_design_scores_gemma":[0.0021372878,0.003699423,0.46589652,0.00016111271,0.00006365707,0.000083643106,0.00028720632,0.000002895663,0.01981687,0.0001841819,0.5074552,0.00021196653],"about_ca_topic_score_codex":0.00000919914,"about_ca_topic_score_gemma":0.0000966858,"teacher_disagreement_score":0.9029332,"about_ca_system_score_codex":0.000040980332,"about_ca_system_score_gemma":0.0007490211,"threshold_uncertainty_score":0.4594326},"labels":[],"label_agreement":null},{"id":"W4379285679","doi":"10.1200/jco.2023.41.16_suppl.1012","title":"BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech","keywords":"Medicine; Internal medicine; Clinical endpoint; Metastatic breast cancer; Oncology; Breast cancer; Cohort; Cancer; Everolimus; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy; Randomized controlled trial","score_opus":0.05960428248022853,"score_gpt":0.4296832217146817,"score_spread":0.3700789392344532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631226,0.00039144707,0.000019804316,0.002797005,0.00007674349,0.00024782823,0.000010206296,0.000003188166,0.0001415445],"genre_scores_gemma":[0.998287,0.00095541833,0.00017134177,0.00030738107,0.00014750675,0.00002970951,0.000009248857,0.000018079261,0.000074273834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797463,0.0005912837,0.0006729534,0.00023567231,0.00026237598,0.00026306533],"domain_scores_gemma":[0.9986224,0.0003365362,0.00051320874,0.00017856859,0.00018077639,0.0001685124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002242488,0.00012613011,0.00046188518,0.0001287968,0.000046556426,0.000022383265,0.00016530516,0.00014040845,0.000017223341],"category_scores_gemma":[0.00029008946,0.00007402466,0.00005609657,0.00025994584,0.00023151911,0.00002834821,0.00006555266,0.00053955166,0.0000024869403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012231478,0.0015168252,0.77932733,0.00006349514,0.00057783443,0.0013705577,0.00072682335,0.0007741202,0.0025821049,0.000082482235,0.0007859834,0.19996095],"study_design_scores_gemma":[0.010315832,0.009209281,0.9760633,0.00010718335,0.000072072944,0.00018912819,0.0006829231,0.00020791919,0.00019024765,0.00019201334,0.0026365283,0.00013354004],"about_ca_topic_score_codex":0.00066103437,"about_ca_topic_score_gemma":0.022043148,"teacher_disagreement_score":0.19982742,"about_ca_system_score_codex":0.0001227998,"about_ca_system_score_gemma":0.0014389883,"threshold_uncertainty_score":0.99580204},"labels":[],"label_agreement":null},{"id":"W4379285686","doi":"10.1200/jco.2023.41.16_suppl.e13649","title":"Cancer research in vulnerable populations: A call for collaboration and sustainability from MENATC countries.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Vulnerability (computing); Pandemic; Cancer; Scarcity; Family medicine; Environmental health; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.3217403126041786,"score_gpt":0.530004345292926,"score_spread":0.20826403268874732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573174,0.0036278644,0.0004454468,0.03502609,0.0016646176,0.00037939407,0.00019400213,0.000006690007,0.0013384755],"genre_scores_gemma":[0.99256665,0.0047534406,0.0006158255,0.0006121687,0.0008296411,0.000048363552,0.0000062620065,0.000012277191,0.0005553494],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971323,0.00015584813,0.0021383313,0.00023265716,0.00005180286,0.00028904915],"domain_scores_gemma":[0.99534696,0.0026951763,0.0010713348,0.00012535499,0.0006226773,0.00013850143],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012526692,0.000074949625,0.00090301235,0.00032930187,0.000104246,0.000045242705,0.0001461375,0.0003081568,0.00006892228],"category_scores_gemma":[0.008922111,0.000075873395,0.00010031986,0.00037303896,0.00017187613,0.00039487978,0.000044338547,0.0005658431,0.000017302918],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017343587,0.0002938342,0.79994524,0.00006294489,0.00009721574,0.00002929717,0.00094645366,0.0014628757,0.0000022085935,0.11530659,0.042438596,0.03768038],"study_design_scores_gemma":[0.0022877145,0.0006715863,0.2985099,0.000018219573,0.0000065691543,6.7495426e-7,0.0003090511,0.0016553154,0.000002182121,0.34863794,0.3478243,0.0000765542],"about_ca_topic_score_codex":0.0022936463,"about_ca_topic_score_gemma":0.0042300005,"teacher_disagreement_score":0.50143534,"about_ca_system_score_codex":0.00072082115,"about_ca_system_score_gemma":0.0013722175,"threshold_uncertainty_score":0.9994262},"labels":[],"label_agreement":null},{"id":"W4379285694","doi":"10.1200/jco.2023.41.16_suppl.1530","title":"Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer; Stage (stratigraphy); Referral; Population; Cancer registry; Triple-negative breast cancer; Cohort; Family medicine","score_opus":0.039701471113064775,"score_gpt":0.4592711388449616,"score_spread":0.41956966773189686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893256,0.00069533003,0.000058151032,0.00907767,0.00029931602,0.0002165443,0.0002382446,0.0000023715813,0.000086780936],"genre_scores_gemma":[0.9845233,0.014169119,0.00045928056,0.00044745952,0.00034814276,0.000014846763,0.000014385207,0.000011935697,0.000011522814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982386,0.0002555819,0.0009613248,0.00019433859,0.00019106592,0.00015907669],"domain_scores_gemma":[0.996274,0.0017465601,0.0012236902,0.0000777157,0.00051844824,0.00015957291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012553226,0.00012922463,0.0009178364,0.00009561849,0.000034994824,0.0000025836894,0.000099879486,0.00038939607,0.00001637244],"category_scores_gemma":[0.0013461465,0.00009011331,0.00029301323,0.00011788703,0.00057269924,0.0000061952023,0.000048888618,0.00019626888,1.9218696e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031664927,0.0014259244,0.21489313,0.000044819837,0.0034582105,0.000028911067,0.0005803291,0.000030356357,0.0037601022,0.00007033148,0.0045714183,0.73947155],"study_design_scores_gemma":[0.014651646,0.020450758,0.9610161,0.0000876579,0.00016831186,0.00010399158,0.0002765605,0.00005344945,0.0016133981,0.00031863461,0.0011742867,0.000085184],"about_ca_topic_score_codex":0.00023494085,"about_ca_topic_score_gemma":0.00012818862,"teacher_disagreement_score":0.74612296,"about_ca_system_score_codex":0.000048309263,"about_ca_system_score_gemma":0.0009366593,"threshold_uncertainty_score":0.3674714},"labels":[],"label_agreement":null},{"id":"W4379285707","doi":"10.1200/jco.2023.41.16_suppl.1073","title":"Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Fulvestrant; Dysgeusia; Internal medicine; Pharmacodynamics; Oncology; Aromatase inhibitor; Metastatic breast cancer; Exemestane; Tolerability; Adverse effect; Cancer; Breast cancer; Pharmacology; Estrogen receptor; Pharmacokinetics; Aromatase","score_opus":0.03716716879121391,"score_gpt":0.39312068510171766,"score_spread":0.35595351631050376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843913,0.000021551445,0.0002851358,0.00030557718,0.00014143126,0.00071749504,0.000068081674,0.0000046171217,0.000016971702],"genre_scores_gemma":[0.99762875,0.00009364512,0.0020653545,0.00005753381,0.000048414684,0.000017020064,0.0000427588,0.000023242632,0.000023308887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642897,0.00059738604,0.0020663051,0.0003265786,0.00037835015,0.00020242383],"domain_scores_gemma":[0.9955779,0.0006507183,0.0027718698,0.00017361928,0.0006617609,0.00016418796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013656311,0.00021596992,0.0012738217,0.00012421665,0.00005670295,0.0000070491433,0.0001430232,0.000103724975,0.000010598358],"category_scores_gemma":[0.0008275045,0.00012954457,0.00011581398,0.00035471763,0.00038704774,0.000038647897,0.000069122754,0.0004493271,2.431878e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04777054,0.006808659,0.9221304,0.0000273824,0.00081949175,0.00009595906,0.00014687135,0.0005590294,0.00025719064,0.000008767005,0.000026451322,0.021349255],"study_design_scores_gemma":[0.039317098,0.12594222,0.83258885,0.00016991202,0.00024033047,0.00003748248,0.0009178504,0.00047750972,0.00013756813,0.0000117914,0.000008156501,0.0001512343],"about_ca_topic_score_codex":0.00009649961,"about_ca_topic_score_gemma":0.0013180894,"teacher_disagreement_score":0.119133554,"about_ca_system_score_codex":0.000057840523,"about_ca_system_score_gemma":0.00072600844,"threshold_uncertainty_score":0.52826744},"labels":[],"label_agreement":null},{"id":"W4379285726","doi":"10.1200/jco.2023.41.16_suppl.1075","title":"Impact of pathogenic germline <i>BRCA1/2</i> and <i>PALB2</i> mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Palbociclib; Oncology; Breast cancer; Cancer; Internal medicine; Germline; Metastatic breast cancer; Gene; Biology; Genetics","score_opus":0.03512793821252162,"score_gpt":0.40659574631437717,"score_spread":0.37146780810185553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787503,0.00041411608,0.000017632747,0.0010993856,0.0000829174,0.00036047463,0.00011665959,0.000014420066,0.000019337116],"genre_scores_gemma":[0.9979398,0.0003163981,0.0011668373,0.0003204959,0.00016399044,0.000014204142,0.000013946257,0.000038863447,0.000025468564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733764,0.0002400309,0.0015225178,0.00025329273,0.00035969264,0.00028679843],"domain_scores_gemma":[0.99654436,0.00090278353,0.0014637479,0.00015362122,0.0005894615,0.0003460285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007998983,0.00022301966,0.00155218,0.00028311886,0.00003260363,0.0000068688064,0.00007261672,0.000103738595,0.00004231837],"category_scores_gemma":[0.00026887227,0.00013019002,0.0001530653,0.0006074347,0.000503435,0.00019977853,0.000032874534,0.00056571607,0.0000011683384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013811993,0.0011778503,0.93273664,0.00006783287,0.00065949315,0.00046406058,0.00018360683,0.00026969233,0.00039830038,0.0000020625198,0.0000534075,0.05017507],"study_design_scores_gemma":[0.0236214,0.0147055285,0.95944864,0.0003636346,0.00054624816,0.0007639756,0.0001285947,0.00006918872,0.000033331202,0.000049401526,0.00014205642,0.00012798759],"about_ca_topic_score_codex":0.00017425139,"about_ca_topic_score_gemma":0.00024239528,"teacher_disagreement_score":0.05004708,"about_ca_system_score_codex":0.00016454936,"about_ca_system_score_gemma":0.001101357,"threshold_uncertainty_score":0.5308995},"labels":[],"label_agreement":null},{"id":"W4379285779","doi":"10.1200/jco.2023.41.16_suppl.525","title":"Long-term oncologic outcomes after omitting axillary surgery in older women with early stage, node-negative breast cancer: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Meta-analysis; Stage (stratigraphy); Sentinel lymph node; Randomized controlled trial; Observational study; Axilla; Internal medicine; Oncology; Cancer","score_opus":0.15846221307060848,"score_gpt":0.46852906775920955,"score_spread":0.31006685468860107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285779","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005298654,0.99203235,0.000005739661,0.0009508329,0.00017394903,0.001277109,0.00023973596,0.000007574457,0.000014061401],"genre_scores_gemma":[0.002776032,0.99379534,0.000110509965,0.0015587264,0.00019754343,0.00113224,0.000016521843,0.00006617398,0.00034692543],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99039173,0.002753149,0.0052451473,0.0007080439,0.00038924426,0.0005127137],"domain_scores_gemma":[0.9873605,0.0042359685,0.0071729505,0.0005068302,0.00043833765,0.00028544271],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0054832776,0.0007195229,0.02281996,0.00038209054,0.00004946255,0.000030019688,0.0003707261,0.00076069427,0.00009981914],"category_scores_gemma":[0.0017448807,0.0003740904,0.0036401604,0.00068629853,0.00030023977,0.000018767165,0.00030184406,0.0009074703,0.0000068061386],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057916675,0.00074891857,0.104758546,0.3278762,0.54819566,0.0019018045,0.000088004934,0.000003625966,1.6463922e-8,6.1411197e-7,0.00018100401,0.015666414],"study_design_scores_gemma":[0.0013073143,0.000785132,0.2432029,0.026551891,0.72531074,0.00041165683,0.000051921932,1.1109216e-7,5.0792618e-8,0.0000032739013,0.0018284282,0.00054656964],"about_ca_topic_score_codex":0.00008359957,"about_ca_topic_score_gemma":0.0008325412,"teacher_disagreement_score":0.3013243,"about_ca_system_score_codex":0.00037263814,"about_ca_system_score_gemma":0.0018520681,"threshold_uncertainty_score":0.9998711},"labels":[],"label_agreement":null},{"id":"W4379285819","doi":"10.1200/jco.2023.41.16_suppl.e13112","title":"Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Proportional hazards model; Oncology; Breast cancer; Internal medicine; Cohort; Population; Cancer; Log-rank test; Disease","score_opus":0.07430403723859035,"score_gpt":0.4999019569320717,"score_spread":0.4255979196934813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975667,0.000042201395,0.000054509117,0.0016426465,0.00023052232,0.00027801865,0.00009018705,0.000008911019,0.00008630457],"genre_scores_gemma":[0.99785846,0.000022344744,0.0015056115,0.00037060896,0.000078632635,0.0000068042727,0.000024932087,0.000020682215,0.00011191863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634445,0.00025870756,0.0025030447,0.00014170361,0.0005432341,0.00020887682],"domain_scores_gemma":[0.9945584,0.0019266534,0.0027155648,0.00017317885,0.0004821591,0.00014403583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014004811,0.00013004093,0.0023371505,0.00034461258,0.000013747942,0.000001444321,0.000113050795,0.00009454937,0.0003418627],"category_scores_gemma":[0.0005154852,0.00008583761,0.00024541223,0.00052816106,0.00012215364,0.000087533066,0.000023344317,0.00043626927,0.0000036354247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007026801,0.0020841397,0.97825074,0.00007010768,0.00047509634,0.000029967667,0.000057696678,0.0011498504,0.000013959484,0.00002109744,0.00014206195,0.01067847],"study_design_scores_gemma":[0.014664188,0.0022244079,0.98114806,0.00025707053,0.0003506266,0.0000028226602,0.00003177158,0.0007623793,0.000013270381,0.00007476103,0.00039957426,0.00007105942],"about_ca_topic_score_codex":0.0003816259,"about_ca_topic_score_gemma":0.0012380496,"teacher_disagreement_score":0.01060741,"about_ca_system_score_codex":0.00023887349,"about_ca_system_score_gemma":0.0008889893,"threshold_uncertainty_score":0.3743157},"labels":[],"label_agreement":null},{"id":"W4379285839","doi":"10.1200/jco.2023.41.16_suppl.1584","title":"Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetics, Bioinformatics, and Biomedical Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clinical trial; Medicine; Government (linguistics); Revenue; Stakeholder; Oncology; Internal medicine; Family medicine; Business; Public relations; Finance; Political science","score_opus":0.1563141061695462,"score_gpt":0.5095642624845064,"score_spread":0.35325015631496015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8760729,0.002930058,0.022281352,0.08520342,0.0068598627,0.0009227168,0.00033080587,0.00004101132,0.005357885],"genre_scores_gemma":[0.94729614,0.03514204,0.009779464,0.003844958,0.0027272522,0.000013807681,0.00019843107,0.00001851137,0.0009793828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934885,0.001167813,0.004264282,0.00028111774,0.00044673434,0.00035154124],"domain_scores_gemma":[0.99436295,0.0015879461,0.0025632742,0.00032530562,0.0007896222,0.00037087945],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01241375,0.00015114348,0.0013108575,0.00023446957,0.000051507042,0.000023504977,0.0008173678,0.0008636875,0.00009139455],"category_scores_gemma":[0.02321272,0.00009690809,0.0009681195,0.00076064817,0.00044331592,0.000012802336,0.00042631393,0.00050430093,0.000028039563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014344518,0.0003828156,0.011945548,0.000009525864,0.0018130691,0.000011724293,0.000025276984,0.00028449297,0.00025420674,0.00003382278,0.24034643,0.7434586],"study_design_scores_gemma":[0.0028241782,0.007662797,0.0060831085,0.0000194075,0.00056184747,0.000018566037,0.00065524946,0.0013490285,0.00071776746,0.0011198298,0.97885764,0.00013058094],"about_ca_topic_score_codex":0.000103306375,"about_ca_topic_score_gemma":0.00023682743,"teacher_disagreement_score":0.74332803,"about_ca_system_score_codex":0.00013556961,"about_ca_system_score_gemma":0.002137762,"threshold_uncertainty_score":0.98501515},"labels":[],"label_agreement":null},{"id":"W4379285848","doi":"10.1200/jco.2023.41.16_suppl.e13630","title":"Decentralized elements within oncology trials: Labcorp experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pandemic; Telemedicine; Coronavirus disease 2019 (COVID-19); Clinical trial; Digital health; Quality of life (healthcare); Quality (philosophy); Family medicine; Oncology; Health care; Internal medicine; Nursing; Disease","score_opus":0.5189509914270882,"score_gpt":0.6292564234761482,"score_spread":0.11030543204905996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8780867,0.00035322047,0.00035884767,0.10952994,0.009126705,0.000340718,0.0000033676554,0.00004126293,0.0021592502],"genre_scores_gemma":[0.97030383,0.0047062584,0.010510052,0.010015031,0.0032523645,0.000009905212,0.000016516238,0.000024985427,0.0011610675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911387,0.0016426675,0.0059868204,0.00020030385,0.0007218179,0.00030970696],"domain_scores_gemma":[0.98948103,0.0051721544,0.003933971,0.0001772421,0.0005357373,0.00069984613],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028803103,0.0001256541,0.002289302,0.00021798327,0.00005876691,0.0000089123005,0.00018907675,0.0010502327,0.00060374464],"category_scores_gemma":[0.023042234,0.00007573189,0.00066293793,0.00044326237,0.0008487168,0.000076152995,0.00007044667,0.0013778629,0.00009121699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00983493,0.0023251201,0.014478213,0.00004517066,0.00084996823,0.0020240413,0.0017814329,0.000028255701,0.0018809069,0.0029483205,0.049584545,0.9142191],"study_design_scores_gemma":[0.017802386,0.0114683695,0.05369538,0.00012681444,0.00037508016,0.0002854879,0.000750877,0.001062232,0.00022331074,0.005115282,0.9089889,0.00010588294],"about_ca_topic_score_codex":0.00001032628,"about_ca_topic_score_gemma":0.000015358224,"teacher_disagreement_score":0.9141132,"about_ca_system_score_codex":0.00017432781,"about_ca_system_score_gemma":0.0032015727,"threshold_uncertainty_score":0.9982638},"labels":[],"label_agreement":null},{"id":"W4379285864","doi":"10.1200/jco.2023.41.16_suppl.tps1121","title":"TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Fulvestrant; Metastatic breast cancer; Breast cancer; Internal medicine; Oncology; Cancer; Estrogen receptor; Palbociclib","score_opus":0.12521894117043925,"score_gpt":0.49614112231660895,"score_spread":0.3709221811461697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933914,0.00079951435,0.00013365959,0.0028016716,0.0003691913,0.002357291,0.0000644959,0.000036194982,0.000046611243],"genre_scores_gemma":[0.98773015,0.0011002038,0.0096775,0.00036323076,0.00038583,0.00036738178,0.0000068779486,0.00009907159,0.0002697616],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943423,0.0008368888,0.0029668147,0.0005145624,0.0007692203,0.0005701834],"domain_scores_gemma":[0.9940577,0.0013741485,0.003257406,0.0003463118,0.00056814245,0.00039625794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016884872,0.00041384052,0.0031748626,0.00040443137,0.00007172554,0.000009614931,0.00027451702,0.0001828839,0.0003855373],"category_scores_gemma":[0.00078358984,0.0002564113,0.00036593698,0.0012287745,0.0003264082,0.00030908143,0.00006060113,0.000991637,0.000009997498],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23229568,0.042401925,0.21904401,0.00023437467,0.007242964,0.0013894129,0.0022030405,0.00084856723,0.008952607,0.00001419581,0.00011332382,0.4852599],"study_design_scores_gemma":[0.47073233,0.22529393,0.2639521,0.0028341855,0.0057194387,0.0009126097,0.015182048,0.00087220635,0.004602733,0.0002831889,0.008575032,0.0010401804],"about_ca_topic_score_codex":0.0002121098,"about_ca_topic_score_gemma":0.00022656024,"teacher_disagreement_score":0.48421973,"about_ca_system_score_codex":0.0005189302,"about_ca_system_score_gemma":0.0019084355,"threshold_uncertainty_score":0.9999888},"labels":[],"label_agreement":null},{"id":"W4379328412","doi":"10.1200/jco.2023.41.16_suppl.573","title":"Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Ottawa Hospital; University of Ottawa; McMaster University; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Oncology; Biopsy; Internal medicine; Cancer; Pathology","score_opus":0.14429373958511077,"score_gpt":0.49485442827497106,"score_spread":0.3505606886898603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299437,0.0009224651,0.000006233698,0.0021006386,0.0020232226,0.0018760982,0.000014255833,0.0000066579446,0.00005604038],"genre_scores_gemma":[0.996082,0.002550545,0.000083205276,0.00040788436,0.0007247849,0.000043494838,0.0000020940463,0.000015405994,0.00009059849],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924345,0.0027252226,0.003943699,0.0001733431,0.0004905764,0.00023267428],"domain_scores_gemma":[0.98743373,0.008243702,0.0035831034,0.00023954202,0.00031219985,0.00018774057],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02456397,0.00016122757,0.002826284,0.00028147158,0.000056612927,0.000007133484,0.00019938206,0.0002947699,0.00008308647],"category_scores_gemma":[0.009545914,0.00009580577,0.0007337797,0.00043857243,0.00080780766,0.00011471655,0.00008860171,0.00097152765,3.9363678e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8728966,0.002435732,0.0013071286,0.00010750677,0.00073703827,0.00010924635,0.00045478262,0.000003499234,0.014557902,0.0000104655965,0.00015107032,0.10722904],"study_design_scores_gemma":[0.89515656,0.064507134,0.037481736,0.00038748616,0.00049304665,0.000044986966,0.00015134923,0.00018698192,0.0012154253,0.0001205921,0.00017787762,0.000076841854],"about_ca_topic_score_codex":0.0005616821,"about_ca_topic_score_gemma":0.00008208232,"teacher_disagreement_score":0.1071522,"about_ca_system_score_codex":0.00014389,"about_ca_system_score_gemma":0.003993896,"threshold_uncertainty_score":0.9987971},"labels":[],"label_agreement":null},{"id":"W4379328597","doi":"10.1200/jco.2023.41.16_suppl.tps620","title":"A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; Toronto General Hospital; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; St Mary's Hospital Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Neratinib; Medicine; Oncology; Internal medicine; Trastuzumab emtansine; Lapatinib; Trastuzumab; Breast cancer; Clinical endpoint; Minimal residual disease; Adjuvant; Adjuvant therapy; Cancer; Clinical trial; Leukemia","score_opus":0.08444538164440572,"score_gpt":0.44990916660006175,"score_spread":0.365463784955656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897073,0.00069417927,0.00068866316,0.0067297486,0.0007272588,0.0006946069,0.0005904285,0.0000039148426,0.00016388156],"genre_scores_gemma":[0.99200565,0.0018381439,0.0025291007,0.0015584142,0.0017318751,0.000048596725,0.00008379164,0.00004425812,0.00016014655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975358,0.00022689831,0.0013593831,0.00036960517,0.00021325632,0.00029504686],"domain_scores_gemma":[0.9968474,0.0006943721,0.0011905772,0.00023521855,0.0006273318,0.00040512925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011665158,0.0002085328,0.00092094234,0.00006949299,0.000100936944,0.000039204857,0.0003135538,0.00028422585,0.000014661941],"category_scores_gemma":[0.0014852394,0.00016647538,0.00018649106,0.00013138202,0.0003133422,0.000015014838,0.00025828442,0.00026614644,5.520744e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6407856,0.033463854,0.0008375154,0.00013044047,0.0020386449,0.0009079106,0.00019771684,0.00059877033,0.11279821,0.0006424259,0.03532022,0.17227872],"study_design_scores_gemma":[0.5235636,0.37984335,0.0057562636,0.00039239068,0.001834216,0.0002497026,0.00027880407,0.000537522,0.0150979385,0.0012003529,0.070412144,0.0008336989],"about_ca_topic_score_codex":0.000060989405,"about_ca_topic_score_gemma":0.00024394234,"teacher_disagreement_score":0.3463795,"about_ca_system_score_codex":0.00005356922,"about_ca_system_score_gemma":0.0027990867,"threshold_uncertainty_score":0.6788669},"labels":[],"label_agreement":null},{"id":"W4379328789","doi":"10.1200/jco.2023.41.16_suppl.1557","title":"An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interquartile range; Cohort; Cancer registry; Cancer; Nomogram; Internal medicine","score_opus":0.12583964316569932,"score_gpt":0.494114734523482,"score_spread":0.3682750913577827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586933,0.00013912625,0.03655091,0.0032988633,0.0008359383,0.00020402961,0.0000036010013,0.00003506595,0.00023915208],"genre_scores_gemma":[0.98773706,0.0024974938,0.006832141,0.00037182219,0.0008917566,0.000007899059,0.000007022059,0.000036235386,0.001618584],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9971346,0.00032229465,0.0017704173,0.0001871037,0.0003273148,0.0002582347],"domain_scores_gemma":[0.99636525,0.0013344015,0.0013701874,0.00013930336,0.00042502026,0.00036585832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055381632,0.00011787696,0.0010931017,0.00022608979,0.0000656611,0.0000062496574,0.00016587964,0.00025620928,0.00006409141],"category_scores_gemma":[0.0044267825,0.000089657755,0.00041346613,0.00021391344,0.000110213135,0.000111676185,0.000031157157,0.0011571796,0.000009425306],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054699066,0.0013180784,0.052587297,0.00016342806,0.00064192864,0.00008460845,0.000523186,0.0835761,0.06618474,0.00008927633,0.0010571684,0.78830427],"study_design_scores_gemma":[0.0035657194,0.008960066,0.023719817,0.0001749794,0.00036890362,0.00005528981,0.00008066813,0.9566592,0.0007027427,0.0013701747,0.0042469073,0.00009554049],"about_ca_topic_score_codex":0.00019411644,"about_ca_topic_score_gemma":0.000016254296,"teacher_disagreement_score":0.8730831,"about_ca_system_score_codex":0.00013611517,"about_ca_system_score_gemma":0.0008115041,"threshold_uncertainty_score":0.5299592},"labels":[],"label_agreement":null},{"id":"W4379328792","doi":"10.1200/jco.2023.41.16_suppl.tps623","title":"NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Internal medicine; Breast-conserving surgery; Stage (stratigraphy); Radiation therapy; Regimen; Cancer; Gynecology; Mastectomy","score_opus":0.1325680739143401,"score_gpt":0.49626301296204933,"score_spread":0.3636949390477092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424,0.00061835954,0.00023997907,0.0024611573,0.0018455411,0.00027960446,0.00019343574,0.000012333427,0.00010959869],"genre_scores_gemma":[0.99650764,0.0009175802,0.0003733634,0.00018938298,0.0018402367,0.000024319854,0.00005259959,0.000034382185,0.000060503844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948856,0.0009918909,0.0028805705,0.00034243285,0.0005076263,0.00039187126],"domain_scores_gemma":[0.9936189,0.0018055546,0.0034949356,0.0002698093,0.0006017242,0.00020910034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006052823,0.00023781654,0.0015474707,0.00020617252,0.0000978867,0.000011949528,0.0002441373,0.00044106264,0.0000863725],"category_scores_gemma":[0.0016781361,0.00021518087,0.0010598457,0.00037459706,0.00018678742,0.00003498524,0.0001392527,0.00033622008,0.0000020141301],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11890074,0.0022223846,0.22101131,0.00012718029,0.0027983154,0.0000984083,0.00025590096,0.0010230887,0.02206832,0.00001420911,0.003020132,0.62846],"study_design_scores_gemma":[0.122934,0.005901613,0.86217266,0.0005015222,0.0013490486,0.0005503861,0.00067686435,0.0017428063,0.0027508016,0.0001544481,0.00083905814,0.00042679466],"about_ca_topic_score_codex":0.000431742,"about_ca_topic_score_gemma":0.00015789426,"teacher_disagreement_score":0.6411613,"about_ca_system_score_codex":0.00018875506,"about_ca_system_score_gemma":0.0028127257,"threshold_uncertainty_score":0.8774821},"labels":[],"label_agreement":null},{"id":"W4379328967","doi":"10.1200/jco.2023.41.16_suppl.tps1115","title":"HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Internal medicine; Metastatic breast cancer; Capecitabine; Oncology; Trastuzumab; Neratinib; Taxane; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","score_opus":0.13449861670288013,"score_gpt":0.5150052673203316,"score_spread":0.3805066506174515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98800457,0.00032699524,0.00023955041,0.009618373,0.0003530867,0.0013780282,0.00002491787,0.000014566461,0.000039891696],"genre_scores_gemma":[0.995699,0.001135269,0.0016604451,0.0008230567,0.00020781554,0.00012611083,0.0000033881092,0.00003861251,0.00030631793],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99684244,0.00037636593,0.0018460777,0.0002655043,0.0003793102,0.00029029546],"domain_scores_gemma":[0.9941221,0.0032265189,0.001637346,0.0001730808,0.0006315704,0.00020940538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002353773,0.00019635941,0.0017336406,0.00024190191,0.00004164372,0.0000071329628,0.00014762445,0.00011957336,0.000080096965],"category_scores_gemma":[0.0010175187,0.00011728635,0.00014550469,0.00044393088,0.00025764204,0.00016662403,0.000022290033,0.0005365252,0.0000011957159],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23240605,0.015388002,0.021471262,0.00012806233,0.001007488,0.0006153982,0.0029874705,0.00014274767,0.00020869893,0.00005072334,0.00040357976,0.7251905],"study_design_scores_gemma":[0.34215328,0.26090294,0.36135116,0.00073604437,0.0005586186,0.002606437,0.020464242,0.00093293,0.00009983593,0.0009749238,0.008947102,0.00027249954],"about_ca_topic_score_codex":0.00011742412,"about_ca_topic_score_gemma":0.0005031635,"teacher_disagreement_score":0.724918,"about_ca_system_score_codex":0.00028555674,"about_ca_system_score_gemma":0.0020591815,"threshold_uncertainty_score":0.47827986},"labels":[],"label_agreement":null},{"id":"W4379329045","doi":"10.1200/jco.2023.41.16_suppl.e12611","title":"Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; Breast cancer; BRCA mutation; Meta-analysis; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Cisplatin; Biology; Genetics; Poly ADP ribose polymerase; Polymerase","score_opus":0.24861264601890962,"score_gpt":0.5261196172802644,"score_spread":0.2775069712613547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379329045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020225089,0.993918,0.000012582489,0.002207477,0.00030594476,0.0030979905,0.0002051266,0.000017102366,0.000033514287],"genre_scores_gemma":[0.00029921794,0.99653894,0.00042237111,0.001546598,0.00038558067,0.0005242142,0.000022792541,0.000077938086,0.00018237458],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9868243,0.0025543063,0.00888392,0.0005248345,0.0008732705,0.0003393921],"domain_scores_gemma":[0.98213625,0.004935163,0.01080669,0.00044289904,0.0012290031,0.00044999056],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005905407,0.00055631856,0.024511065,0.0008479384,0.000043980384,0.00002497537,0.0002501352,0.0005870395,0.00023765792],"category_scores_gemma":[0.002472369,0.00030437755,0.0035236944,0.0018345249,0.0002734821,0.00018819906,0.00006371081,0.0021351392,0.000020305883],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062359695,0.001485476,0.0025030316,0.5729662,0.38997567,0.00071827247,0.00013493246,0.000017272123,9.423003e-9,0.000012924067,0.000616047,0.030946527],"study_design_scores_gemma":[0.003847896,0.0020408689,0.006043354,0.16345853,0.8160761,0.00015035433,0.000016103299,0.0000021814058,3.7851745e-8,0.000028105524,0.00804195,0.00029453755],"about_ca_topic_score_codex":0.00012882765,"about_ca_topic_score_gemma":0.00018684253,"teacher_disagreement_score":0.42610043,"about_ca_system_score_codex":0.0006593296,"about_ca_system_score_gemma":0.0025879783,"threshold_uncertainty_score":0.9999408},"labels":[],"label_agreement":null},{"id":"W4379329068","doi":"10.1200/jco.2023.41.16_suppl.1078","title":"Alpelisib + endocrine therapy in patients with <i>PIK3CA</i>-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Fulvestrant; Internal medicine; Tolerability; Breast cancer; Cohort; Oncology; Cancer; Metastatic breast cancer; Adverse effect; Gynecology; Aromatase; Estrogen receptor","score_opus":0.0445158908315171,"score_gpt":0.4085474749493247,"score_spread":0.3640315841178076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379329068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528533,0.00025733074,0.000016251848,0.002554107,0.00044063458,0.0010353997,0.0002981133,0.000017993965,0.00009482547],"genre_scores_gemma":[0.9970475,0.0012352617,0.00074947433,0.0005915819,0.00019857033,0.000031110438,0.00003210446,0.00004938699,0.00006503421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365383,0.0010631019,0.003377606,0.00042699743,0.0010206205,0.00045781338],"domain_scores_gemma":[0.9912144,0.0018809949,0.0043431013,0.0004202332,0.0018664269,0.0002748506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013100698,0.0003537413,0.0034107624,0.0005836113,0.00005895285,0.0000054116363,0.0004318578,0.00020249178,0.0003034782],"category_scores_gemma":[0.00071667414,0.00021012363,0.00070298836,0.0022137284,0.0006013599,0.00027375453,0.00011840626,0.0010811025,0.0000019527079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029207012,0.0049030916,0.88539886,0.000018209132,0.006855586,0.000057333706,0.00092395546,0.0007475707,0.0024478515,0.000006372149,0.00022361141,0.06921055],"study_design_scores_gemma":[0.030114887,0.014665154,0.95150065,0.00016186123,0.0011055791,0.000012723436,0.00051751215,0.000021313936,0.0011843588,0.000034103818,0.00049679814,0.00018508047],"about_ca_topic_score_codex":0.00035639206,"about_ca_topic_score_gemma":0.00036771238,"teacher_disagreement_score":0.06902547,"about_ca_system_score_codex":0.00037211413,"about_ca_system_score_gemma":0.00070388056,"threshold_uncertainty_score":0.8568593},"labels":[],"label_agreement":null},{"id":"W4379329451","doi":"10.1200/jco.2023.41.16_suppl.1056","title":"Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Palbociclib; Fulvestrant; Internal medicine; Oncology; Breast cancer; Tamoxifen; Odds ratio; Adverse effect; Tolerability; Gynecology; Cancer; Metastatic breast cancer","score_opus":0.15844072831483,"score_gpt":0.505342744608513,"score_spread":0.346902016293683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379329451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962953,0.00027714405,0.00001229779,0.0021610176,0.00059981394,0.0005231952,0.00002730506,0.0000044896706,0.00009945105],"genre_scores_gemma":[0.9977004,0.0015728062,0.00039294927,0.00013358722,0.00014438275,0.000016839671,0.000007929523,0.000014413629,0.00001669902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942642,0.0010429136,0.0038515325,0.00017229396,0.00044825076,0.0002208132],"domain_scores_gemma":[0.9927357,0.003223677,0.0032473402,0.00011932349,0.000578994,0.000094966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003726553,0.00014896286,0.0031101834,0.000517547,0.000006739283,0.0000014351995,0.00012152003,0.0001417404,0.00004814917],"category_scores_gemma":[0.0011628746,0.00010312717,0.00019927748,0.0006883628,0.00021288163,0.00018646565,0.000027486523,0.000649746,6.460863e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051366944,0.002908468,0.80393195,0.000036862035,0.00013853176,0.000078688965,0.000611552,0.0016764586,0.00079378596,0.000050152958,0.000027956621,0.13837866],"study_design_scores_gemma":[0.064910956,0.009683793,0.9223898,0.00056969316,0.000024891202,0.000010789177,0.0004273569,0.000063390406,0.00075974996,0.00050372863,0.00057896925,0.000076875636],"about_ca_topic_score_codex":0.00026390544,"about_ca_topic_score_gemma":0.0013820934,"teacher_disagreement_score":0.13830179,"about_ca_system_score_codex":0.00031437073,"about_ca_system_score_gemma":0.0009624998,"threshold_uncertainty_score":0.4205404},"labels":[],"label_agreement":null},{"id":"W4379330247","doi":"10.1200/jco.2023.41.16_suppl.e13088","title":"Identifying the education, information and support needs of Canadians diagnosed with breast cancer: A Canadian Breast Cancer Network (CBCN) assessment project.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Breast Cancer Network","funders":"","keywords":"Breast cancer; Medicine; Focus group; Family medicine; Population; Information needs; Social support; Cancer; Oncology; Internal medicine; Psychology; Library science; Psychotherapist","score_opus":0.1150959129867347,"score_gpt":0.4815359980013761,"score_spread":0.36644008501464137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341995,0.0004152195,0.000047284873,0.06004665,0.0017078753,0.0005413424,0.0001437641,0.000011652337,0.0028866976],"genre_scores_gemma":[0.9894704,0.0021537459,0.00029789525,0.0066098534,0.0012499824,0.000039170896,0.00001289393,0.000010265057,0.0001557707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976934,0.00014737876,0.001331663,0.000088142566,0.0003887737,0.00035059536],"domain_scores_gemma":[0.9967209,0.00039859506,0.0012091085,0.00014485845,0.0010098361,0.0005166873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022463044,0.000118211115,0.0006756433,0.0002877598,0.00012821172,0.000030902727,0.00017107805,0.00016786368,0.00014797725],"category_scores_gemma":[0.00020407503,0.00007343528,0.000117541305,0.0008008142,0.00018335617,0.0003766097,0.000027887078,0.00060758373,0.0000025035918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003439959,0.000043051525,0.76883,0.000045794353,0.000217087,0.000072507544,0.00096688024,0.00025526484,0.0000014133121,0.00010876646,0.057854433,0.17126077],"study_design_scores_gemma":[0.0014195438,0.0008480398,0.9445667,0.00043077458,0.00032536645,0.0011006185,0.0056578736,0.00013103662,3.5562778e-7,0.000037815353,0.045404483,0.00007738672],"about_ca_topic_score_codex":0.5682103,"about_ca_topic_score_gemma":0.7072596,"teacher_disagreement_score":0.17573668,"about_ca_system_score_codex":0.00063858525,"about_ca_system_score_gemma":0.041133653,"threshold_uncertainty_score":0.96430224},"labels":[],"label_agreement":null},{"id":"W4379330364","doi":"10.1200/jco.2023.41.16_suppl.e16566","title":"AI-based pathologic biomarker for pathologic downstaging in patients with muscle-invasive bladder cancer undergoing cystectomy after neoadjuvant nivolumab, gemcitabine, and cisplatin: BLAAST-1 Trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Gemcitabine; Cystectomy; Bladder cancer; Biomarker; Nivolumab; Neoadjuvant therapy; Cisplatin; Cancer; Oncology; Urology; Internal medicine; Radiology; Pathology; Chemotherapy; Immunotherapy; Breast cancer","score_opus":0.07790973581627869,"score_gpt":0.4174531822234907,"score_spread":0.339543446407212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202657,0.00040430663,0.0002853102,0.0045783627,0.0010013704,0.0014340279,0.000052420895,0.000031195075,0.000186463],"genre_scores_gemma":[0.99291694,0.0003265238,0.0018033214,0.004200238,0.00040417266,0.00019470092,0.000016650822,0.000043557524,0.00009386432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963836,0.0004187056,0.0018429058,0.00045532477,0.0004008815,0.00049856375],"domain_scores_gemma":[0.99508584,0.0027915377,0.0011073552,0.00022288902,0.0004908466,0.0003015196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018020095,0.0002973172,0.0016128046,0.00038527424,0.00007038201,0.000022420036,0.00012104409,0.00042111054,0.00009635908],"category_scores_gemma":[0.001734477,0.00018820124,0.0003539942,0.0003973992,0.00024973226,0.0001586245,0.00005857553,0.0006501305,0.000006634409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13917032,0.0019237567,0.75846046,0.00017428384,0.00045152556,0.003634579,0.00020242689,0.000094729425,0.00005905992,0.0000045356855,0.0010455345,0.09477879],"study_design_scores_gemma":[0.20295489,0.025603512,0.76842123,0.0004117346,0.00061874755,0.000046410936,0.000168652,0.00018260504,0.000016534508,0.0001795582,0.001196177,0.0001999419],"about_ca_topic_score_codex":0.000025358147,"about_ca_topic_score_gemma":0.00032553833,"teacher_disagreement_score":0.09457885,"about_ca_system_score_codex":0.00024225657,"about_ca_system_score_gemma":0.0019447397,"threshold_uncertainty_score":0.7674624},"labels":[],"label_agreement":null},{"id":"W4379330365","doi":"10.1200/jco.2023.41.16_suppl.5502","title":"Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Cervical cancer; Clinical endpoint; Cisplatin; Oncology; Ribonucleotide reductase; Internal medicine; Randomized controlled trial; Urology; Brachytherapy; Tolerability; Interim analysis; Cancer; Chemotherapy; Radiation therapy; Adverse effect","score_opus":0.1088375194101865,"score_gpt":0.4717391893382906,"score_spread":0.36290166992810413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834304,0.0005643845,0.0027819206,0.009796139,0.000978839,0.002057064,0.00012367721,0.000020085376,0.0002474915],"genre_scores_gemma":[0.98798877,0.0022146006,0.0069000996,0.0005960918,0.0018580197,0.000113928516,0.00014798019,0.000021297006,0.000159236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99484354,0.00046400997,0.0037073926,0.00029585688,0.00048414842,0.00020507343],"domain_scores_gemma":[0.9849528,0.010011671,0.0037857876,0.0001602919,0.0007375045,0.00035195722],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047216513,0.00018618842,0.0032913857,0.0002334432,0.000041971063,0.000009381087,0.000099604375,0.0003212711,0.000059729253],"category_scores_gemma":[0.00972928,0.00011447899,0.00045670176,0.0005228971,0.00023691781,0.00014002327,0.000027981148,0.00042029735,0.0000020526081],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77672577,0.0012904798,0.000246823,0.00003691612,0.0006755997,0.00006210478,0.00008638299,0.000070319715,0.00022337465,0.00005274684,0.00033981874,0.22018969],"study_design_scores_gemma":[0.94993496,0.038555726,0.002963478,0.00021032435,0.0016175049,0.000015150484,0.000062529696,0.0022984624,0.0004394949,0.0018846182,0.0019145815,0.000103142294],"about_ca_topic_score_codex":0.00016402172,"about_ca_topic_score_gemma":0.00010271632,"teacher_disagreement_score":0.22008654,"about_ca_system_score_codex":0.00014965645,"about_ca_system_score_gemma":0.0015998292,"threshold_uncertainty_score":0.99861217},"labels":[],"label_agreement":null},{"id":"W4379330376","doi":"10.1200/jco.2023.41.16_suppl.6521","title":"Curating clinical trials: Helping patients find hope by exploring clinical trial opportunities.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Windsor","funders":"","keywords":"Medicine; Clinical trial; Referral; Patient recruitment; Family medicine; Alternative medicine; Disadvantage; Internal medicine; Pathology","score_opus":0.9784761195624883,"score_gpt":0.770259507718971,"score_spread":0.20821661184351725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9408657,0.00031124087,0.00020580782,0.029069846,0.023892548,0.0012607399,0.000030033654,0.000100022466,0.0042640436],"genre_scores_gemma":[0.84519136,0.08240595,0.006260025,0.015982846,0.043488882,0.00010763971,0.00010130736,0.00024673552,0.006215245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9319345,0.02289391,0.038592093,0.0012105075,0.0040122424,0.0013567924],"domain_scores_gemma":[0.18236515,0.78111476,0.022148414,0.001877167,0.0070216097,0.005472901],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.3774876,0.00044796578,0.008088195,0.00049228576,0.00024357745,0.00009242891,0.0011321263,0.003547629,0.0005231709],"category_scores_gemma":[0.7825972,0.00033219883,0.0045983037,0.0007165428,0.001637891,0.00054955244,0.00079688296,0.017881671,0.00034765436],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09708757,0.006408642,0.11553426,0.000120127734,0.0012422107,0.0012688588,0.000093663984,0.0000041680037,0.000010855657,0.00041554292,0.11285138,0.6649627],"study_design_scores_gemma":[0.32345104,0.11161653,0.12727149,0.0016419367,0.0015036792,0.00007253912,0.0015683607,0.00065093645,0.000021745225,0.0059301355,0.42558414,0.00068746705],"about_ca_topic_score_codex":0.000015181389,"about_ca_topic_score_gemma":0.00001865915,"teacher_disagreement_score":0.75822085,"about_ca_system_score_codex":0.0002599618,"about_ca_system_score_gemma":0.010601007,"threshold_uncertainty_score":0.999913},"labels":[],"label_agreement":null},{"id":"W4379330790","doi":"10.1200/jco.2023.41.16_suppl.tps7592","title":"Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Rituximab; Diffuse large B-cell lymphoma; Internal medicine; Vincristine; Cytokine release syndrome; CHOP; Oncology; Prednisone; Phases of clinical research; International Prognostic Index; Cyclophosphamide; Lymphoma; Gastroenterology; Discontinuation; CD20; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.10362165935719093,"score_gpt":0.45996181553981313,"score_spread":0.3563401561826222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192995,0.00011644192,0.000014146335,0.001094361,0.0030889525,0.0011217552,0.00003697151,0.000030660456,0.0025667679],"genre_scores_gemma":[0.99484086,0.0013321264,0.00031728018,0.00039954073,0.0015560895,0.00002089182,0.000027758833,0.00008077352,0.0014246689],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923208,0.001058075,0.0037837415,0.0004670499,0.0015273333,0.0008430157],"domain_scores_gemma":[0.9859727,0.009593224,0.002105987,0.0005991649,0.00088991644,0.00083899853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004714005,0.00034204352,0.0028003163,0.00069578417,0.000057911315,0.000019420459,0.0005052816,0.00075592566,0.0004920367],"category_scores_gemma":[0.0074156285,0.00025059504,0.00083530654,0.0010283098,0.0003655881,0.00015843015,0.00015845636,0.0015304429,0.000093917886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.680355,0.12140177,0.015737051,0.000071281924,0.00043270274,0.011401039,0.00028896163,0.000005941582,0.0003164162,0.000016612486,0.0034167797,0.16655646],"study_design_scores_gemma":[0.777863,0.16929454,0.015787352,0.0001386444,0.0002944992,0.00012290047,0.00030096312,0.00017027558,0.000087184286,0.000039478156,0.03570944,0.00019170449],"about_ca_topic_score_codex":0.00005986014,"about_ca_topic_score_gemma":0.00015069662,"teacher_disagreement_score":0.16636476,"about_ca_system_score_codex":0.0005805387,"about_ca_system_score_gemma":0.0027930934,"threshold_uncertainty_score":0.99999464},"labels":[],"label_agreement":null},{"id":"W4379330912","doi":"10.1200/jco.2023.41.16_suppl.5012","title":"Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Prostate cancer; Hazard ratio; Confidence interval; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Cancer; Physical therapy; Chronic pain","score_opus":0.266717536119669,"score_gpt":0.528010711439331,"score_spread":0.261293175319662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738275,0.0008376914,0.0000048677416,0.0222533,0.00022750055,0.0027370425,0.00008252431,0.0000060763296,0.000023525028],"genre_scores_gemma":[0.99548244,0.0032130603,0.00038055447,0.00049195194,0.00006626722,0.00013808909,0.000028047381,0.0000170416,0.00018255715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99475104,0.0018376482,0.0024128484,0.00025773578,0.0004251621,0.00031556652],"domain_scores_gemma":[0.99118733,0.0063320245,0.0016529158,0.00013363227,0.00037515681,0.00031896337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010032139,0.00017423843,0.0018105523,0.00015323187,0.000099574296,0.000022433442,0.0000811492,0.00013443117,0.000009885529],"category_scores_gemma":[0.0046512824,0.00008879741,0.00010294232,0.00024122352,0.0004220676,0.00012887814,0.000030818966,0.00053166255,4.7612608e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8084542,0.0024983054,0.11615857,0.00052893424,0.0010140393,0.000080120655,0.0026836349,0.000010509107,0.000053068256,0.0000268757,0.0014518063,0.0670399],"study_design_scores_gemma":[0.5565403,0.07844234,0.36058345,0.0002949657,0.00034816234,0.000006516691,0.0017976257,0.0002930833,0.000010165985,0.00015308423,0.0014100561,0.00012022742],"about_ca_topic_score_codex":0.00038649654,"about_ca_topic_score_gemma":0.001216471,"teacher_disagreement_score":0.25191393,"about_ca_system_score_codex":0.00014151988,"about_ca_system_score_gemma":0.0019145099,"threshold_uncertainty_score":0.55683553},"labels":[],"label_agreement":null},{"id":"W4379331646","doi":"10.1200/jco.2023.41.16_suppl.2029","title":"Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: A real-world analysis of outcomes, clinical and pathologic characteristics.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Histology; Brain metastasis; Adenocarcinoma; Cancer; Proportional hazards model; Cohort; Oncology; Gastroenterology; Carcinoma; Signet ring cell; Metastasis","score_opus":0.13806467491617977,"score_gpt":0.4761318657105468,"score_spread":0.338067190794367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379331646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387294,0.00032110992,0.000019915127,0.005070202,0.0002981125,0.00020808289,0.00009104955,0.000011998898,0.00010657656],"genre_scores_gemma":[0.99424833,0.0010901621,0.0033750653,0.00093806814,0.00018797276,0.000006355484,0.000036307727,0.000016431819,0.00010132139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99335325,0.001518645,0.004060494,0.00037396385,0.00035056518,0.00034310753],"domain_scores_gemma":[0.9898981,0.007224199,0.0019131211,0.0002640128,0.00019812753,0.0005024317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010154791,0.00022800593,0.00428743,0.0011192458,0.000035027297,0.000010976848,0.00011334057,0.00025202264,0.000058799855],"category_scores_gemma":[0.0041889767,0.00015423237,0.0008768192,0.0009800426,0.0005468935,0.00007386937,0.00014793641,0.0007797737,0.0000026488913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012653819,0.0011116258,0.9527701,0.000045625806,0.0021402007,0.006257635,0.00009986373,0.0000033344318,0.000013539969,0.000115591065,0.0004480714,0.03572902],"study_design_scores_gemma":[0.00819249,0.00671846,0.9786373,0.00003524091,0.0050741676,0.00017765875,0.00016034469,0.00033597325,0.000004705205,0.0000741511,0.0005017331,0.000087787295],"about_ca_topic_score_codex":0.00016584339,"about_ca_topic_score_gemma":0.0003170004,"teacher_disagreement_score":0.035641234,"about_ca_system_score_codex":0.000063109765,"about_ca_system_score_gemma":0.0004582779,"threshold_uncertainty_score":0.62894136},"labels":[],"label_agreement":null},{"id":"W4379332762","doi":"10.1200/jco.2023.41.16_suppl.4073","title":"Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; STRIDE; Regimen; Adverse effect; Internal medicine; Oncology; Surgery; Gastroenterology; Physical medicine and rehabilitation","score_opus":0.11774840846087462,"score_gpt":0.43704786002037305,"score_spread":0.31929945155949846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379332762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965181,0.00032554558,0.000009731381,0.0016042385,0.00047048146,0.0009183178,0.000012305837,0.000009403282,0.00013188916],"genre_scores_gemma":[0.9988642,0.00033854827,0.000048011952,0.00037220863,0.00019616622,0.000022612634,0.000017443044,0.000025370848,0.000115486146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939002,0.0013231551,0.0033994608,0.00025083948,0.0007457679,0.00038061675],"domain_scores_gemma":[0.9960158,0.0015512318,0.0016922384,0.00037454325,0.00022864623,0.00013754219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008750144,0.00020734654,0.0017105503,0.00047093496,0.000034491244,0.0000037840036,0.00039939763,0.00025698135,0.0001387217],"category_scores_gemma":[0.0008757529,0.00012280693,0.0004445731,0.0009246837,0.00015026281,0.0001281367,0.000062123436,0.0011169098,0.000009101119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060885042,0.006477391,0.91940486,0.000054957858,0.0003432339,0.0054396037,0.0015092564,0.0000321038,0.0006277733,0.0000011206713,0.00015316428,0.0050714836],"study_design_scores_gemma":[0.10046895,0.032904442,0.8575121,0.0002332045,0.00018499805,0.00017435862,0.0062903943,0.00086047914,0.00007813247,0.000011320434,0.001166975,0.00011464161],"about_ca_topic_score_codex":0.0021248802,"about_ca_topic_score_gemma":0.0016854191,"teacher_disagreement_score":0.061892767,"about_ca_system_score_codex":0.00034234623,"about_ca_system_score_gemma":0.002108907,"threshold_uncertainty_score":0.5007921},"labels":[],"label_agreement":null},{"id":"W4379332778","doi":"10.1200/jco.2023.41.16_suppl.5035","title":"Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Biotech","keywords":"Medicine; Prostate cancer; Placebo; Internal medicine; Proportional hazards model; Randomized controlled trial; Biopsy; Oncology; Androgen deprivation therapy; Cancer; Urology; Pathology","score_opus":0.04946033413308798,"score_gpt":0.45113482799378074,"score_spread":0.40167449386069276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379332778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539596,0.00006908289,0.0012193413,0.0013529729,0.00062060077,0.0012744159,0.000021682083,0.000009826361,0.000036136717],"genre_scores_gemma":[0.99576896,0.00010726797,0.0037527604,0.00008249127,0.00019436078,0.000041526353,0.000024157796,0.000015856975,0.000012623249],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99451,0.0009406451,0.0035295128,0.00022752312,0.0005383281,0.0002539825],"domain_scores_gemma":[0.993091,0.003610382,0.002697264,0.00012376238,0.00026898977,0.00020858625],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071889474,0.00015068006,0.0021361818,0.00043889275,0.000028815428,0.000012393849,0.00012362379,0.00016073791,0.000020962661],"category_scores_gemma":[0.017313732,0.00009259711,0.00029682546,0.00039136692,0.0006700073,0.00011607559,0.000026201846,0.0012183496,0.000001312952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.643854,0.0031835304,0.11683323,0.000041712607,0.00006706727,0.00051339075,0.00021400854,0.0022771477,0.000043550765,0.000007957347,0.000019652438,0.23294471],"study_design_scores_gemma":[0.7900711,0.02203001,0.11132552,0.0008187462,0.00035724964,0.00000906434,0.00010156412,0.0747437,0.00002977263,0.0003469928,0.000057856767,0.00010841906],"about_ca_topic_score_codex":0.00007113377,"about_ca_topic_score_gemma":0.0000726624,"teacher_disagreement_score":0.23283629,"about_ca_system_score_codex":0.00012963782,"about_ca_system_score_gemma":0.0019090095,"threshold_uncertainty_score":0.9909639},"labels":[],"label_agreement":null},{"id":"W4379332790","doi":"10.1200/jco.2023.41.16_suppl.tps4206","title":"STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; FOLFOX; Internal medicine; Oncology; Oxaliplatin; Chemotherapy; Gastroenterology; Cancer; Immunotherapy; Colorectal cancer","score_opus":0.11238046023711853,"score_gpt":0.4602107707478902,"score_spread":0.3478303105107716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379332790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981994,0.0027053922,0.00028460985,0.003654495,0.0007613059,0.0026235145,0.000009432207,0.00001931167,0.00012196926],"genre_scores_gemma":[0.9533189,0.032989237,0.010927189,0.0012645301,0.00045657397,0.00006324797,0.00001389482,0.000057403173,0.0009090143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99477327,0.00076085824,0.0029902158,0.0004780502,0.0004871741,0.0005104179],"domain_scores_gemma":[0.9930712,0.004103571,0.0018326745,0.00024897783,0.0002999555,0.00044360769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053069307,0.00034681,0.0035804824,0.0005050801,0.0000661666,0.000055683828,0.00024214263,0.00019806146,0.00015407144],"category_scores_gemma":[0.002587584,0.00024308455,0.00023149414,0.0006195077,0.00055206276,0.00035673217,0.00017695704,0.00068682124,0.000002287028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84258986,0.0026212782,0.011385652,0.00017163152,0.0011321746,0.0009574098,0.00019031092,0.000008919968,0.000018483004,0.000019639343,0.0012518342,0.1396528],"study_design_scores_gemma":[0.91853935,0.055776317,0.02046704,0.00018588034,0.0012045339,0.00017408935,0.0004013113,0.0015340095,0.000012674817,0.00009382705,0.0014705692,0.0001403761],"about_ca_topic_score_codex":0.00017767942,"about_ca_topic_score_gemma":0.0002046248,"teacher_disagreement_score":0.13951242,"about_ca_system_score_codex":0.00016166385,"about_ca_system_score_gemma":0.00077937805,"threshold_uncertainty_score":0.99127},"labels":[],"label_agreement":null},{"id":"W4379332798","doi":"10.1200/jco.2023.41.16_suppl.4098","title":"BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Jewish General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"FOLFOX; Medicine; Internal medicine; Clinical endpoint; Cohort; Gastroenterology; Oncology; Cancer; Phases of clinical research; Progressive disease; Chemotherapy; Surgery; Clinical trial; Colorectal cancer; Oxaliplatin","score_opus":0.04174982015737085,"score_gpt":0.4195633865741152,"score_spread":0.37781356641674435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379332798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741596,0.00064471544,0.0000048989023,0.0009264993,0.000080459286,0.0008601218,0.000011040512,0.000009862635,0.00004645424],"genre_scores_gemma":[0.99753755,0.0020767434,0.00009128194,0.00015095378,0.00005703248,0.000018187684,0.000014407377,0.000017519595,0.00003629917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970808,0.00029416173,0.001685071,0.00031464518,0.00038807446,0.00023724843],"domain_scores_gemma":[0.99708045,0.0010934818,0.0011648714,0.00016345744,0.0003224014,0.00017531835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011932002,0.0001959179,0.0019549448,0.00071636244,0.000034733443,0.0000057322927,0.000082123384,0.0001439162,0.000015775755],"category_scores_gemma":[0.0003029,0.00012650613,0.00010570922,0.0016231982,0.00015668594,0.00013414826,0.00003368798,0.0005477736,1.9083447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03570781,0.028383277,0.8535832,0.000035343743,0.001152189,0.00018557635,0.00088387384,0.00009029463,0.000016171252,5.3490476e-7,0.00008149089,0.07988025],"study_design_scores_gemma":[0.14435011,0.06474329,0.78890616,0.00012937142,0.0010545503,0.000010222629,0.00041990163,0.00011161019,0.000007232727,0.000004059742,0.000171728,0.00009179076],"about_ca_topic_score_codex":0.00034942184,"about_ca_topic_score_gemma":0.0016101759,"teacher_disagreement_score":0.1086423,"about_ca_system_score_codex":0.00016400845,"about_ca_system_score_gemma":0.00034807698,"threshold_uncertainty_score":0.515877},"labels":[],"label_agreement":null},{"id":"W4379333019","doi":"10.1200/jco.2023.41.16_suppl.4568","title":"Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Seagen","keywords":"Medicine; Internal medicine; Clinical endpoint; Cohort; Pembrolizumab; Oncology; Cancer; Cisplatin; Urology; Progression-free survival; Chemotherapy; Randomized controlled trial; Immunotherapy","score_opus":0.10170508381080158,"score_gpt":0.4359688664735234,"score_spread":0.33426378266272183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165183,0.00009834052,0.00010693207,0.001310226,0.00073697703,0.0022094408,0.0015839328,0.00007058528,0.0022317225],"genre_scores_gemma":[0.9894386,0.0010538124,0.0020781723,0.0019120419,0.00061701244,0.00032558283,0.00059348234,0.00012743085,0.0038538906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946553,0.0005461263,0.0022928258,0.0006711492,0.0012172859,0.00061731046],"domain_scores_gemma":[0.9933861,0.0027338576,0.0019808593,0.0005728024,0.0007508244,0.0005755645],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012871573,0.00047462535,0.0027995394,0.00035312423,0.00009187222,0.000030224115,0.00042113467,0.00028902898,0.001872589],"category_scores_gemma":[0.0025170078,0.00025031433,0.00021299049,0.00075899414,0.00029178333,0.00034566416,0.00008061461,0.0011211812,0.00005096149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3260014,0.0034628026,0.5742044,0.00015212833,0.002277914,0.003957394,0.00015525974,0.0005902223,0.0000027232236,0.000014131309,0.023012504,0.0661691],"study_design_scores_gemma":[0.16992892,0.0773772,0.7108776,0.003953288,0.0028424596,0.00048296788,0.00021883889,0.0008464629,0.000046003275,0.000050970702,0.032860022,0.0005152425],"about_ca_topic_score_codex":0.00024463038,"about_ca_topic_score_gemma":0.0053235744,"teacher_disagreement_score":0.15607248,"about_ca_system_score_codex":0.00052759075,"about_ca_system_score_gemma":0.0093204705,"threshold_uncertainty_score":0.99999493},"labels":[],"label_agreement":null},{"id":"W4379333134","doi":"10.1200/jco.2023.41.16_suppl.5001","title":"Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Prostate cancer; Biomarker; Oncology; Radiation therapy; Androgen deprivation therapy; Internal medicine; Randomized controlled trial; Cumulative incidence; Biopsy; Cancer; Cohort","score_opus":0.06611430162671936,"score_gpt":0.4499989975432892,"score_spread":0.3838846959165698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072295,0.0001534231,0.006343053,0.0018964742,0.00012011825,0.0007250838,0.000021958704,0.000013900792,0.000003011412],"genre_scores_gemma":[0.98594886,0.0009970715,0.01243821,0.0003903253,0.000109636385,0.000028106275,0.000051374576,0.000027399441,0.0000090346775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964836,0.00041558224,0.0022340305,0.0002555062,0.00038507566,0.00022617962],"domain_scores_gemma":[0.9959084,0.001299734,0.0020416738,0.0001501706,0.00032891502,0.0002711252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005995306,0.0001645331,0.0015893169,0.00023211123,0.00004123948,0.000016332684,0.00011155426,0.00018778574,0.000012470412],"category_scores_gemma":[0.0020341536,0.00009997555,0.00010007424,0.0003288726,0.0002783734,0.00015397812,0.000022306354,0.00043872933,1.8077496e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04039095,0.0008334741,0.525813,0.000029272134,0.00033172118,0.00020449208,0.00090197724,0.0015661519,0.005222002,5.051647e-7,0.000016476011,0.42468998],"study_design_scores_gemma":[0.119356,0.013362478,0.84201604,0.0005427338,0.00015626472,0.00009109108,0.00015639882,0.01074796,0.012810931,0.000021364744,0.0005843826,0.00015434352],"about_ca_topic_score_codex":0.00006173137,"about_ca_topic_score_gemma":0.00008440214,"teacher_disagreement_score":0.42453563,"about_ca_system_score_codex":0.00009224046,"about_ca_system_score_gemma":0.0008570708,"threshold_uncertainty_score":0.40768847},"labels":[],"label_agreement":null},{"id":"W4379333138","doi":"10.1200/jco.2023.41.16_suppl.5503","title":"Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Carboplatin; Endometrial cancer; Microsatellite instability; Oncology; Paclitaxel; Placebo; Randomized controlled trial; Progression-free survival; Cancer; Overall survival; Gynecology; Chemotherapy; Cisplatin; Pathology","score_opus":0.11455992045018204,"score_gpt":0.46715122274199783,"score_spread":0.3525913022918158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9383135,0.025386125,0.00018981418,0.012296586,0.019961732,0.0027003677,0.0008797654,0.000010965497,0.0002611424],"genre_scores_gemma":[0.5583731,0.41615444,0.0019163135,0.0140324375,0.0077839536,0.0003085251,0.00023003672,0.00011990941,0.0010813012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494046,0.00046829396,0.003204153,0.00039313082,0.00049579184,0.0004981792],"domain_scores_gemma":[0.99296063,0.0026371195,0.0031332346,0.00043919613,0.00053398835,0.0002958365],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032757528,0.00027043282,0.0017773112,0.00009370595,0.00007957973,0.000016531812,0.00072608184,0.0005118595,0.00008435446],"category_scores_gemma":[0.015296294,0.00016834516,0.0013718448,0.000322803,0.00020344365,0.000012096108,0.0003071118,0.0006315302,0.0000027303872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21198952,0.002975828,0.0074194376,0.00059174676,0.0017141057,0.000039047,0.000068911846,0.00015600014,0.0101708,0.00010004308,0.30624005,0.4585345],"study_design_scores_gemma":[0.10354479,0.014595634,0.008960691,0.00033025403,0.0006238043,0.000018457093,0.000043457745,0.000009600051,0.0033391544,0.00020204879,0.868034,0.00029808338],"about_ca_topic_score_codex":0.000025479814,"about_ca_topic_score_gemma":0.0001976288,"teacher_disagreement_score":0.561794,"about_ca_system_score_codex":0.000180234,"about_ca_system_score_gemma":0.00357107,"threshold_uncertainty_score":0.9929983},"labels":[],"label_agreement":null},{"id":"W4379333203","doi":"10.1200/jco.2023.41.16_suppl.e18929","title":"Cost-effectiveness analysis of a circulating tumor DNA-based molecular residual disease assay to guide adjuvant chemotherapy decisions in patients with resectable early stage colorectal cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Oncology; Colorectal cancer; Internal medicine; Stage (stratigraphy); Observational study; Cost effectiveness; Adjuvant; Adjuvant chemotherapy; Disease; Chemotherapy; Cancer","score_opus":0.055843359957450406,"score_gpt":0.4285267242014579,"score_spread":0.3726833642440075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736005,0.0001026306,0.0013347978,0.0002999364,0.00020470083,0.00043832927,0.00020056225,0.0000033233118,0.000055680364],"genre_scores_gemma":[0.9981326,0.00010799561,0.00095040567,0.000563626,0.00011265957,0.00003920791,0.00005410404,0.000026082465,0.000013324382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715275,0.0005335292,0.0013215502,0.0003299719,0.00036992005,0.00029225368],"domain_scores_gemma":[0.9961362,0.0016879817,0.0009175623,0.00026028696,0.00064444856,0.00035351285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026684562,0.00015586156,0.0009900761,0.00035314367,0.000036005065,0.000014122794,0.0002639385,0.00016091092,0.00001717111],"category_scores_gemma":[0.006143797,0.00012901712,0.00034757305,0.000901023,0.000098918266,0.0000068670734,0.000096073694,0.00024601625,0.0000010568638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010735264,0.00065961294,0.8434615,0.000011049761,0.00072470715,0.0002000206,0.000031550233,0.12773125,0.008620088,0.000009847609,0.0002528639,0.0075622047],"study_design_scores_gemma":[0.005788432,0.004997155,0.98040664,0.00008490754,0.0003710414,5.034946e-7,0.00002752227,0.001091931,0.0049336134,0.000018336092,0.0021263778,0.00015356424],"about_ca_topic_score_codex":0.00022247306,"about_ca_topic_score_gemma":0.0009412188,"teacher_disagreement_score":0.13694507,"about_ca_system_score_codex":0.00016695423,"about_ca_system_score_gemma":0.002292184,"threshold_uncertainty_score":0.7355143},"labels":[],"label_agreement":null},{"id":"W4379333310","doi":"10.1200/jco.2023.41.16_suppl.2035","title":"HER2-low breast cancer brain metastases: Incidence and treatment implications.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Statistics Canada; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Trastuzumab; Immunohistochemistry; Internal medicine; Cancer; Estrogen receptor; Cohort; Incidence (geometry); Triple-negative breast cancer; Disease; Gynecology","score_opus":0.13916651994930493,"score_gpt":0.508628078309755,"score_spread":0.36946155836045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85619235,0.0008356723,0.000056988483,0.14189982,0.00041467068,0.00025504344,0.000087920525,0.000020158219,0.00023739535],"genre_scores_gemma":[0.98254734,0.0077781193,0.0028186566,0.0052404697,0.00091519556,0.000035302422,0.000013470659,0.000019830335,0.00063161954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99763644,0.00039302462,0.0013259334,0.00021251013,0.00020943214,0.00022267435],"domain_scores_gemma":[0.99567854,0.0025963665,0.0007982457,0.00021070564,0.00025337073,0.00046276857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023165327,0.00014323046,0.0011302915,0.00013329825,0.000059054248,0.000011277685,0.00008239682,0.00015342866,0.00020004039],"category_scores_gemma":[0.00092698034,0.00008759599,0.00037222382,0.00025677928,0.00018152082,0.000084019535,0.000045412202,0.00028903614,0.00003928054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011568016,0.0015600822,0.15655367,0.000022623502,0.0010750064,0.0010192319,0.00008404442,0.000020380618,0.0001038603,0.00030543894,0.01955733,0.8185415],"study_design_scores_gemma":[0.0068266722,0.00691391,0.8824018,0.00008547751,0.00079237367,0.0018714719,0.00012920809,0.000058219393,0.000034131408,0.00045349027,0.10035409,0.00007914437],"about_ca_topic_score_codex":0.00015485416,"about_ca_topic_score_gemma":0.0001521653,"teacher_disagreement_score":0.8184624,"about_ca_system_score_codex":0.00021482544,"about_ca_system_score_gemma":0.0012530427,"threshold_uncertainty_score":0.35720608},"labels":[],"label_agreement":null},{"id":"W4379333378","doi":"10.1200/jco.2023.41.16_suppl.4161","title":"Tandem duplicator phenotype: A novel targetable subgroup in pancreatic cancer?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McGill University Health Centre; Mount Sinai Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Germline mutation; Germline; Cancer; Breast cancer; Oncology; Internal medicine; Somatic cell; Cancer research; Gene; Genetics; Mutation; Biology","score_opus":0.0683165215975913,"score_gpt":0.41153387842384587,"score_spread":0.34321735682625454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932817,0.0019033334,0.0004333487,0.0020674653,0.0013323345,0.00010915758,0.000017671542,0.0000048709903,0.0008500865],"genre_scores_gemma":[0.9863246,0.0086951535,0.0012142102,0.0015364467,0.001840395,0.00001436127,0.000012252381,0.00002173953,0.00034082172],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801826,0.000089685534,0.0012619271,0.00021213808,0.00014164938,0.00027636145],"domain_scores_gemma":[0.9982338,0.0004996928,0.0007114367,0.00018971489,0.00016686873,0.00019846403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001797592,0.000113029484,0.00067399297,0.00008565816,0.000028007646,0.000010508005,0.0002583314,0.00033942997,0.00004207578],"category_scores_gemma":[0.0022586114,0.00009678075,0.00023976606,0.00022376074,0.000091083006,0.000004879326,0.000110771194,0.00035007545,0.000020125373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002782053,0.0020614916,0.6838745,0.000058395693,0.00063257525,0.00030381358,0.00012253082,0.0041506444,0.142146,0.0010735434,0.08393361,0.07886085],"study_design_scores_gemma":[0.0059271837,0.0036048268,0.39592403,0.000046411216,0.000115973075,0.00003566501,0.00009074792,0.00056683377,0.0019154132,0.00071459805,0.5908186,0.00023975807],"about_ca_topic_score_codex":0.00009575131,"about_ca_topic_score_gemma":0.0005231019,"teacher_disagreement_score":0.50688493,"about_ca_system_score_codex":0.00007154237,"about_ca_system_score_gemma":0.0013645765,"threshold_uncertainty_score":0.39466044},"labels":[],"label_agreement":null},{"id":"W4379333379","doi":"10.1200/jco.2023.41.16_suppl.4523","title":"Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: Analysis of NRG RTOG 0524 and 0712.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Immune system; Bladder cancer; Medicine; Tumor microenvironment; CD8; Cancer research; Oncology; Cancer; Internal medicine; Immunology","score_opus":0.08197830074176479,"score_gpt":0.4020741608459205,"score_spread":0.3200958601041557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969026,0.0008991129,0.000026029089,0.0006559741,0.000077978024,0.00044508756,0.000040628383,0.0000057280413,0.00094688585],"genre_scores_gemma":[0.9960627,0.0031514608,0.00042713818,0.00011824616,0.00008254964,0.0000382273,0.00002153045,0.0000121395215,0.00008603352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976367,0.0002251248,0.0015112311,0.00019055855,0.0002830556,0.0001533285],"domain_scores_gemma":[0.9960681,0.0016777576,0.0015029237,0.00012852374,0.00049066776,0.00013202924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006299723,0.00013731724,0.0014575045,0.0003790713,0.000017477447,0.0000036404615,0.000058156056,0.00017923566,0.00008898112],"category_scores_gemma":[0.00059804576,0.00009372037,0.00022711608,0.0010758339,0.0001958168,0.00008711624,0.000015413092,0.00025028418,0.0000014973932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035828475,0.0017035126,0.9709723,0.00008745988,0.0032274802,0.00022581662,0.00082176155,0.0007308684,0.002006741,0.000007833984,0.000055144163,0.01657826],"study_design_scores_gemma":[0.0094716,0.011325827,0.9656761,0.00017907553,0.0052517885,0.000009424843,0.00042419008,0.00024825567,0.007251187,0.000037380687,0.000052615196,0.00007254158],"about_ca_topic_score_codex":0.0005537677,"about_ca_topic_score_gemma":0.0007723244,"teacher_disagreement_score":0.01650572,"about_ca_system_score_codex":0.00015081126,"about_ca_system_score_gemma":0.0015781799,"threshold_uncertainty_score":0.38218057},"labels":[],"label_agreement":null},{"id":"W4379333485","doi":"10.1200/jco.2023.41.16_suppl.4088","title":"Characterizing <i>KRAS</i> allele variants within biliary tract cancers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"KRAS; Medicine; Internal medicine; Cancer; Oncology; Gallbladder cancer; Biliary tract cancer; Colorectal cancer; Gemcitabine","score_opus":0.1582577499380623,"score_gpt":0.44865106098162383,"score_spread":0.29039331104356153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96348053,0.0007646377,0.000011859376,0.02453095,0.0036526972,0.00014716326,0.000005985637,0.000039860915,0.007366289],"genre_scores_gemma":[0.9843995,0.0023515185,0.0007239337,0.008131689,0.0034881143,0.000005125403,0.0000057839748,0.000024430452,0.00086988125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968823,0.00021546248,0.0019964327,0.00021900449,0.00038042254,0.0003063469],"domain_scores_gemma":[0.99676955,0.0011280251,0.0012608418,0.00019576428,0.0002889501,0.00035687548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032312754,0.0001498789,0.0014689083,0.00015868113,0.00006644344,0.0000107759815,0.0001672195,0.00028447283,0.00012828643],"category_scores_gemma":[0.0021221484,0.00010588651,0.00053724565,0.00031069544,0.00015485125,0.00014891474,0.00007346777,0.0010832562,0.00007642858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060471254,0.0016649084,0.58562404,0.00016535196,0.0021423474,0.012039449,0.0028627263,0.00002126224,0.0076252064,0.00008429876,0.23217659,0.14954671],"study_design_scores_gemma":[0.004620799,0.0045015253,0.83690774,0.000103311046,0.000344281,0.0006880615,0.00047491325,0.00007942985,0.00013105664,0.00011486791,0.15192519,0.000108795684],"about_ca_topic_score_codex":0.000052487492,"about_ca_topic_score_gemma":0.00005309863,"teacher_disagreement_score":0.25128374,"about_ca_system_score_codex":0.00019491767,"about_ca_system_score_gemma":0.0020239227,"threshold_uncertainty_score":0.47062692},"labels":[],"label_agreement":null},{"id":"W4379333780","doi":"10.1200/jco.2023.41.16_suppl.tps7590","title":"MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BeiGene","keywords":"Medicine; Obinutuzumab; Lenalidomide; Rituximab; Internal medicine; Ibrutinib; Oncology; Idelalisib; Follicular lymphoma; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Gastroenterology; Lymphoma; Leukemia; Multiple myeloma; Tyrosine kinase","score_opus":0.11818073334886847,"score_gpt":0.4680301710243539,"score_spread":0.34984943767548543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529815,0.0001548556,0.00007066557,0.0015892345,0.0012898067,0.0011987437,0.000025266334,0.000031845215,0.0003414083],"genre_scores_gemma":[0.9939958,0.0012659932,0.0016576012,0.0004826616,0.0010508791,0.000016804612,0.000031165222,0.00006992921,0.0014291579],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910991,0.0011325758,0.004633226,0.00051148277,0.0018049406,0.00081863574],"domain_scores_gemma":[0.98864585,0.0062884395,0.0028378987,0.0005954256,0.0009833033,0.0006490965],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068680034,0.00036808953,0.0043648873,0.000791115,0.00007053538,0.000019321202,0.0004993326,0.0007660447,0.00031757946],"category_scores_gemma":[0.014463886,0.00021596016,0.00064719573,0.0011009914,0.00079996313,0.00025433983,0.00022970646,0.0012566576,0.000065953885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9301945,0.013890411,0.0043297797,0.00029723716,0.0009279969,0.01764075,0.00025734806,0.000056277713,0.000070611524,0.00001675449,0.0053230296,0.026995294],"study_design_scores_gemma":[0.864,0.0898437,0.022847356,0.00079427805,0.0005427056,0.0005364217,0.0002554998,0.0018621061,0.00011031581,0.000022659584,0.018953525,0.00023142784],"about_ca_topic_score_codex":0.00023317117,"about_ca_topic_score_gemma":0.00014126011,"teacher_disagreement_score":0.07595329,"about_ca_system_score_codex":0.0069065588,"about_ca_system_score_gemma":0.055417124,"threshold_uncertainty_score":0.99690574},"labels":[],"label_agreement":null},{"id":"W4379333898","doi":"10.1200/jco.2023.41.16_suppl.e16112","title":"Costs and health care resource utilization (HCRU) for patients with advanced biliary tract (aBTC) cancer using administrative databases in Ontario, 2010 to 2020.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; AstraZeneca (Canada); Sunnybrook Hospital","funders":"AstraZeneca Canada","keywords":"Medicine; Gemcitabine; Gallbladder cancer; Population; Cancer; Pharmacoeconomics; Biliary tract cancer; Emergency medicine; Ampulla of Vater; Indirect costs; Activity-based costing; Internal medicine; Oncology; Intensive care medicine; Carcinoma; Environmental health","score_opus":0.3463381377702627,"score_gpt":0.5339147406864414,"score_spread":0.18757660291617873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908109,0.0012764012,0.000043455726,0.006574289,0.00048039688,0.0006602648,0.000053858857,0.000006524888,0.00009392187],"genre_scores_gemma":[0.9938645,0.00054218346,0.0028245896,0.0023497392,0.00026459075,0.000020121222,0.000047839323,0.000016224856,0.00007021739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982268,0.000110027286,0.0009978274,0.0002302761,0.00021261352,0.00022242061],"domain_scores_gemma":[0.9978685,0.00077028567,0.00063423475,0.00010522724,0.000358774,0.00026300017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007029747,0.00012069171,0.0009077604,0.00011819456,0.00006375539,0.0000053447848,0.00005418542,0.00007282778,0.000015395788],"category_scores_gemma":[0.00067400356,0.0000862686,0.00009043433,0.00021920858,0.00007590953,0.000106699095,0.000040998766,0.00042050588,5.022399e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005431673,0.00036767873,0.89991957,0.00005692262,0.00008609037,0.000076961274,0.0016308711,0.000039277707,0.0000059243785,0.000002630147,0.0069576316,0.085424796],"study_design_scores_gemma":[0.0070897583,0.010697924,0.9332032,0.00038267163,0.00010872911,0.000016902228,0.0018912717,0.0000213309,0.000008233602,0.0000028649317,0.046498712,0.00007839212],"about_ca_topic_score_codex":0.003942698,"about_ca_topic_score_gemma":0.18575975,"teacher_disagreement_score":0.18181705,"about_ca_system_score_codex":0.00066577527,"about_ca_system_score_gemma":0.002859652,"threshold_uncertainty_score":0.829098},"labels":[],"label_agreement":null},{"id":"W4379333933","doi":"10.1200/jco.2023.41.16_suppl.4553","title":"Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Lenvatinib; Tolerability; Internal medicine; Clinical endpoint; Renal cell carcinoma; Oncology; Phases of clinical research; Adverse effect; Clear cell renal cell carcinoma; Urology; Cancer; Surgery; Clinical trial","score_opus":0.06792469037048972,"score_gpt":0.4135502440189556,"score_spread":0.3456255536484659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574226,0.00022658799,0.0000028760853,0.00079461717,0.00046765443,0.0020854427,0.00005260877,0.00000996247,0.00061801064],"genre_scores_gemma":[0.99776417,0.00007700629,0.0013132904,0.00016366554,0.0003104257,0.00006143309,0.000013608511,0.000043671098,0.000252748],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995171,0.0005450564,0.002721623,0.00041918256,0.00080663554,0.00033650442],"domain_scores_gemma":[0.99312735,0.0023145995,0.0030755228,0.0004687121,0.00068911206,0.00032473044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017824592,0.0002821671,0.0015421489,0.00020110015,0.000071612114,0.0000059011863,0.00020303437,0.00028701572,0.000008978578],"category_scores_gemma":[0.0010468796,0.00015352042,0.00043204083,0.00028815423,0.00033517784,0.000082104234,0.00016437941,0.0007503807,0.0000028881118],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7059098,0.04257451,0.16135082,0.0006243383,0.00035248837,0.0010611558,0.0029121302,0.00012154301,0.0025507982,0.0000021003352,0.0035100991,0.07903023],"study_design_scores_gemma":[0.08558629,0.41630396,0.48257393,0.0005634416,0.0007536642,0.000032739816,0.0006148421,0.00009967202,0.011169552,0.00001717433,0.0021555158,0.00012921532],"about_ca_topic_score_codex":0.000009061336,"about_ca_topic_score_gemma":0.000015168921,"teacher_disagreement_score":0.6203235,"about_ca_system_score_codex":0.00018171775,"about_ca_system_score_gemma":0.0008936046,"threshold_uncertainty_score":0.6260381},"labels":[],"label_agreement":null},{"id":"W4379334158","doi":"10.1200/jco.2023.41.16_suppl.tps5104","title":"AGCT1531: Evaluating the utility of circulating microRNA in the management of children, adolescents, and adults with malignant germ cell tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Seminoma; Germ cell tumors; Oncology; Biomarker; Internal medicine; Clinical endpoint; Prospective cohort study; Stage (stratigraphy); Clinical trial; Chemotherapy","score_opus":0.09273951183679753,"score_gpt":0.43626285290864425,"score_spread":0.34352334107184673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768287,0.0009051625,0.000008804077,0.0007141288,0.000060954182,0.0004260652,0.000004258906,0.0000029010187,0.00019485339],"genre_scores_gemma":[0.99874306,0.00026843758,0.0007072015,0.0001941923,0.00006723595,0.0000033605834,0.0000024328847,0.0000075399657,0.0000065411905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748737,0.00043198024,0.0013939851,0.00014097398,0.00039416854,0.00015150572],"domain_scores_gemma":[0.9972642,0.00068647665,0.0016060771,0.00020515468,0.0001515606,0.000086513326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032585103,0.00009482174,0.000652169,0.00005180566,0.00003151065,0.0000037377417,0.00013491513,0.00006501592,0.000010004205],"category_scores_gemma":[0.00042887757,0.00004268357,0.00019383614,0.00020397143,0.00017070543,0.000024334322,0.00006306352,0.00031946623,0.0000011595472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001780764,0.001409147,0.91067183,0.00033049894,0.0002709883,0.0006320845,0.00026192516,0.00001822245,0.00004666431,0.000009610552,0.000036158912,0.0845321],"study_design_scores_gemma":[0.007333745,0.0037881325,0.9849489,0.001383358,0.00072818506,0.0002000452,0.0008115198,0.0006586925,0.000027203092,0.0000749693,0.000009035712,0.000036218913],"about_ca_topic_score_codex":0.000040724583,"about_ca_topic_score_gemma":0.000009419802,"teacher_disagreement_score":0.08449588,"about_ca_system_score_codex":0.00002027326,"about_ca_system_score_gemma":0.0002529708,"threshold_uncertainty_score":0.17405854},"labels":[],"label_agreement":null},{"id":"W4379334167","doi":"10.1200/jco.2023.41.16_suppl.e14531","title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Cohort; Internal medicine; Sarcoma; Cytokine release syndrome; Fludarabine; Gastroenterology; Oncology; Surgery; Cyclophosphamide; Chemotherapy; Cancer; Pathology; Immunotherapy; Chimeric antigen receptor","score_opus":0.060239172461123786,"score_gpt":0.4539872028012736,"score_spread":0.3937480303401498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964953,0.0001653716,0.000018582714,0.0013465654,0.00068074657,0.00090381224,0.000054279626,0.000013690675,0.00032164427],"genre_scores_gemma":[0.9976663,0.00090638665,0.0003352915,0.00014050219,0.0002465043,0.000013164562,0.00003144774,0.000039611004,0.00062079413],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9917185,0.0010011122,0.0045935786,0.00036004637,0.0016648332,0.00066196994],"domain_scores_gemma":[0.9893608,0.0053388495,0.003040616,0.00064774655,0.0011545958,0.0004573977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008179289,0.0002555761,0.0036281543,0.0007217112,0.00007455484,0.000013110235,0.0004905053,0.00043742015,0.00020657881],"category_scores_gemma":[0.005045153,0.00015489769,0.0011422168,0.0025550982,0.0007493143,0.00013560103,0.00015247698,0.0014546335,0.000009505285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4654973,0.006387127,0.3398898,0.00006868944,0.007290996,0.0013315198,0.00021678754,0.00071440917,0.0018500816,0.000015341288,0.00026611972,0.17647187],"study_design_scores_gemma":[0.12367968,0.04996077,0.8206858,0.00015396894,0.0019141043,0.0000313807,0.00020318557,0.00051282113,0.00016796886,0.000044776883,0.0025143484,0.00013117405],"about_ca_topic_score_codex":0.00010250751,"about_ca_topic_score_gemma":0.00046499388,"teacher_disagreement_score":0.48079604,"about_ca_system_score_codex":0.0002985064,"about_ca_system_score_gemma":0.0019374435,"threshold_uncertainty_score":0.631974},"labels":[],"label_agreement":null},{"id":"W4379334471","doi":"10.1200/jco.2023.41.16_suppl.3540","title":"Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Indel; KRAS; Colorectal cancer; Medicine; Neuroblastoma RAS viral oncogene homolog; Somatic cell; Microsatellite instability; Cancer research; Liquid biopsy; Oncology; Genotype; V600E; Circulating tumor DNA; Cancer; Mutation; Internal medicine; Allele; Single-nucleotide polymorphism; Biology; Genetics; Gene; Microsatellite","score_opus":0.0744419537187974,"score_gpt":0.4355758523876607,"score_spread":0.3611338986688633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305433,0.000104655504,0.00006547725,0.0009491409,0.005251677,0.00011479178,0.00029187975,0.000005747345,0.00016230183],"genre_scores_gemma":[0.99266756,0.00058846246,0.0011781165,0.0002458982,0.0049802754,0.00004462763,0.00013225924,0.000018967325,0.00014381146],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997879,0.00020087951,0.0012545404,0.00021771318,0.00020480537,0.00024304981],"domain_scores_gemma":[0.9977163,0.00095403154,0.0008173844,0.00009878534,0.00026393737,0.00014955642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011375013,0.00011608114,0.0004820785,0.0001111068,0.00008431524,0.00003445101,0.00016620976,0.00015805576,0.00033738755],"category_scores_gemma":[0.003147732,0.000089866226,0.00025000828,0.00015906432,0.000089143556,0.00002009888,0.000092994625,0.00023925568,0.000011971134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048298966,0.0017522173,0.16621086,0.00009732763,0.0014650571,0.0013177324,0.00030021378,0.040750224,0.65256363,0.00028042824,0.083764836,0.04666759],"study_design_scores_gemma":[0.009279795,0.0037954466,0.7813952,0.00023559098,0.00030048788,0.00023554367,0.000776222,0.0019048112,0.047329064,0.0033596484,0.15078035,0.0006078098],"about_ca_topic_score_codex":0.000062753265,"about_ca_topic_score_gemma":0.00051129324,"teacher_disagreement_score":0.61518437,"about_ca_system_score_codex":0.000120770506,"about_ca_system_score_gemma":0.0015848788,"threshold_uncertainty_score":0.37683567},"labels":[],"label_agreement":null},{"id":"W4379334501","doi":"10.1200/jco.2023.41.16_suppl.5069","title":"Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Univariate analysis; Proportional hazards model; Cancer; Multivariate analysis","score_opus":0.06814075112185157,"score_gpt":0.4346734287969608,"score_spread":0.3665326776751092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849528,0.00012100296,0.0000070104606,0.014055543,0.00028510066,0.0003247786,0.0000152045195,0.00001062037,0.00022791946],"genre_scores_gemma":[0.99618435,0.0016641421,0.0013920451,0.00052604463,0.00008903104,0.000022104381,0.0000046999244,0.0000150376045,0.000102552294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963602,0.0011917953,0.0014968596,0.000172392,0.00043590288,0.00034283995],"domain_scores_gemma":[0.994626,0.0031439152,0.0015874831,0.000091817754,0.00036802635,0.00018278214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008931108,0.00012379156,0.0013193664,0.00033845438,0.00001341724,0.0000036516014,0.00009672446,0.00027468812,0.000024753972],"category_scores_gemma":[0.0049186787,0.00008889438,0.0001681097,0.0005550482,0.00016766253,0.00006361143,0.000044167526,0.00073636055,0.0000035310654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025018407,0.0006117166,0.9516891,0.000078234356,0.0006247486,0.003895554,0.00027012365,0.00008091024,0.0006122242,0.000005511693,0.00030295766,0.016810473],"study_design_scores_gemma":[0.008824561,0.005179141,0.9830238,0.00020368476,0.00035189724,0.000061749066,0.0007517044,0.0011204967,0.000063985724,0.00012057289,0.0002188961,0.000079488585],"about_ca_topic_score_codex":0.000039712733,"about_ca_topic_score_gemma":0.0025337015,"teacher_disagreement_score":0.031334683,"about_ca_system_score_codex":0.00075478345,"about_ca_system_score_gemma":0.0014111327,"threshold_uncertainty_score":0.5888473},"labels":[],"label_agreement":null},{"id":"W4379334626","doi":"10.1200/jco.2023.41.16_suppl.5567","title":"Proactive assessment of patient reported outcomes in patients with ovarian cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Observational study; MEDLINE; Ovarian cancer; Quartile; Cancer; Quality of life (healthcare); Clinical trial; Internal medicine; Confidence interval","score_opus":0.1074612622490358,"score_gpt":0.49483671187199757,"score_spread":0.3873754496229618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070144,0.000025286216,0.000006958461,0.0069538387,0.0007068553,0.00044569565,0.000007610641,0.0000061727687,0.0011461705],"genre_scores_gemma":[0.9972884,0.00018049667,0.0018824874,0.00045001294,0.00009902716,0.000029591389,0.0000049684722,0.000012688194,0.00005231054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968313,0.00019125482,0.0021413756,0.0001751967,0.00048696538,0.0001739301],"domain_scores_gemma":[0.9960327,0.0008083468,0.0022883078,0.00017895234,0.0005062518,0.00018541278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010710483,0.00011311368,0.0014534022,0.00018439721,0.000014327187,0.0000028912361,0.00006199276,0.00015577082,0.00007701338],"category_scores_gemma":[0.00068929396,0.00006541501,0.0002351993,0.00030092016,0.00008016649,0.0000650047,0.000031777807,0.00045059298,0.0000015197351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019474664,0.0053922613,0.9133261,0.000016364193,0.0012826141,0.0005621041,0.00009517583,0.00006494783,0.0000011718391,0.000052155563,0.00045254536,0.07680713],"study_design_scores_gemma":[0.017010959,0.02039179,0.9597726,0.0001628208,0.0004295046,0.00000886358,0.00008574689,0.00002224633,0.000020645346,0.00006194036,0.0019760712,0.000056812143],"about_ca_topic_score_codex":0.00011226567,"about_ca_topic_score_gemma":0.000081945436,"teacher_disagreement_score":0.07675031,"about_ca_system_score_codex":0.00040306442,"about_ca_system_score_gemma":0.0022941027,"threshold_uncertainty_score":0.40696394},"labels":[],"label_agreement":null},{"id":"W4379334637","doi":"10.1200/jco.2023.41.16_suppl.4530","title":"Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Calgary","funders":"Ipsen","keywords":"Medicine; Cabozantinib; Internal medicine; Clinical endpoint; Oncology; Renal cell carcinoma; Hazard ratio; Discontinuation; Confidence interval; Clinical trial","score_opus":0.061048986354388095,"score_gpt":0.37100721815226234,"score_spread":0.30995823179787424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550253,0.00020150025,0.000006820998,0.0009443964,0.00049132586,0.0011034214,0.000029559234,0.00006167303,0.0016587435],"genre_scores_gemma":[0.9907884,0.0002518303,0.0025354463,0.00071556185,0.00058033376,0.00007070918,0.000029332328,0.00014340134,0.004884992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939739,0.00056580215,0.0030821837,0.0005938424,0.0010874831,0.00069679646],"domain_scores_gemma":[0.99366665,0.0014915349,0.0025776757,0.0005515537,0.00086626934,0.0008463012],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013777844,0.0006031336,0.0027376916,0.0005982933,0.00008166691,0.000030151416,0.00020968275,0.00027741323,0.00040646226],"category_scores_gemma":[0.0004098527,0.00029674303,0.0006559302,0.0009164451,0.0004536331,0.00028154897,0.000077248376,0.0011104103,0.00006585328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0442178,0.0038305516,0.9273049,0.000080582664,0.00058980583,0.008091422,0.0001514335,0.000039442362,0.00022843589,0.00000155947,0.00126936,0.01419471],"study_design_scores_gemma":[0.03936915,0.045392748,0.9040373,0.00038389637,0.00079970894,0.00007636927,0.000119273194,0.000016517748,0.004246066,0.0000073114343,0.005228691,0.0003229539],"about_ca_topic_score_codex":0.00022798819,"about_ca_topic_score_gemma":0.00054119737,"teacher_disagreement_score":0.041562196,"about_ca_system_score_codex":0.00036169178,"about_ca_system_score_gemma":0.0012806894,"threshold_uncertainty_score":0.99994844},"labels":[],"label_agreement":null},{"id":"W4379334895","doi":"10.1200/jco.2023.41.16_suppl.e15003","title":"Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Perforation; Carcinoembryonic antigen; Internal medicine; Oncology; Surgery; Gastroenterology; Ophthalmology; Cancer","score_opus":0.0696800325846888,"score_gpt":0.49284928820567564,"score_spread":0.42316925562098684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984018,0.000035842924,0.000012584154,0.00042219213,0.00039146002,0.0005280022,0.000037027785,0.0000068621766,0.00016422603],"genre_scores_gemma":[0.9992011,0.0001357311,0.0002095363,0.00019852794,0.00011453222,0.000005455897,0.00004447257,0.000013975434,0.00007666543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954009,0.00048877165,0.0032053504,0.00021290511,0.0004601545,0.00023189644],"domain_scores_gemma":[0.9949918,0.0013757565,0.0025767141,0.00020127295,0.0006346275,0.00021987357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001665609,0.00015905254,0.0029732457,0.0007682009,0.000017568658,5.2268996e-7,0.00013823484,0.00015660835,0.00024080365],"category_scores_gemma":[0.00070925185,0.000109800974,0.00045117232,0.0015423328,0.00013265105,0.0000843851,0.00004726351,0.0005085131,0.0000032053633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08928014,0.04820324,0.8277271,0.000025478923,0.0064548515,0.0005727677,0.00045884613,0.0018245179,0.00013033714,0.0000022265333,0.00015609761,0.025164424],"study_design_scores_gemma":[0.11848128,0.10205845,0.77173185,0.00006672786,0.006415815,0.000004997252,0.0005086409,0.00034444235,0.000042401643,0.000008083144,0.0002712179,0.00006610953],"about_ca_topic_score_codex":0.000044965698,"about_ca_topic_score_gemma":0.00028538628,"teacher_disagreement_score":0.055995226,"about_ca_system_score_codex":0.00018691628,"about_ca_system_score_gemma":0.0008323078,"threshold_uncertainty_score":0.4477554},"labels":[],"label_agreement":null},{"id":"W4379335543","doi":"10.1200/jco.2023.41.16_suppl.4167","title":"The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Periampullary cancer; Adenocarcinoma; Cohort; Pancreatic cancer; Gastroenterology; Incidence (geometry); Pancreas; Pancreatic ductal adenocarcinoma; Cancer; Histopathology; Oncology; Pathology","score_opus":0.1886452620425605,"score_gpt":0.5222542033844666,"score_spread":0.3336089413419061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98224837,0.00006478884,0.000031004744,0.010755193,0.004168431,0.00072625675,0.000009707415,0.000025327958,0.0019709268],"genre_scores_gemma":[0.9867962,0.005982132,0.00014007074,0.0014263471,0.0026636708,0.000047771562,0.000013248364,0.000024165916,0.002906373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468565,0.0010299856,0.002414841,0.0003260552,0.0010875323,0.0004559155],"domain_scores_gemma":[0.99090683,0.006257402,0.0010697418,0.00038558277,0.0008088717,0.0005715462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049619256,0.00021382706,0.0017701288,0.00024320593,0.00019855006,0.000039869446,0.0005852784,0.0003388012,0.00028419294],"category_scores_gemma":[0.0062429085,0.00011212274,0.00045529744,0.00016808615,0.0004818123,0.00012434748,0.00025759355,0.0016076778,0.00006574372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072783744,0.0024791004,0.96327865,0.00001458094,0.0016503481,0.00080228254,0.0007205831,0.000009397478,0.00012220228,0.000039784627,0.0035147022,0.020090016],"study_design_scores_gemma":[0.009238008,0.011532697,0.95620406,0.00005714891,0.00068324903,0.00008408982,0.0058845156,0.003889378,0.000014660777,0.000055097036,0.012257261,0.000099841745],"about_ca_topic_score_codex":0.0001663095,"about_ca_topic_score_gemma":0.0004840696,"teacher_disagreement_score":0.019990172,"about_ca_system_score_codex":0.0005990439,"about_ca_system_score_gemma":0.0013402438,"threshold_uncertainty_score":0.7473796},"labels":[],"label_agreement":null},{"id":"W4379335592","doi":"10.1200/jco.2023.41.16_suppl.5053","title":"Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Anemia; Enzalutamide; Population; Adverse effect; Placebo; Internal medicine; Prostate cancer; Phases of clinical research; Cancer; Clinical trial; Oncology; Androgen receptor; Pathology","score_opus":0.25554562833408717,"score_gpt":0.5647169066209956,"score_spread":0.30917127828690844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97258955,0.0022846211,0.0002264155,0.018383577,0.0018492221,0.0037524006,0.0001402472,0.000038814575,0.0007351733],"genre_scores_gemma":[0.99117476,0.00315023,0.0006460449,0.002508758,0.001362513,0.0004578943,0.00003017965,0.00004485973,0.00062475353],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9871398,0.0044205487,0.0064030616,0.00045698095,0.0010807432,0.0004988414],"domain_scores_gemma":[0.97298163,0.021778196,0.0038101608,0.00043376727,0.00061399303,0.00038224456],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0153105315,0.0003658022,0.0051503554,0.00035086198,0.0001455218,0.000048658287,0.00034825335,0.00023765865,0.000639218],"category_scores_gemma":[0.009591021,0.00020896997,0.0012667826,0.0008327637,0.0006057152,0.00023417256,0.00007029939,0.0016614923,0.00004216203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95453006,0.0031529036,0.005148006,0.00002644216,0.0045352275,0.002875966,0.0020144316,0.0055173435,0.002435232,0.00006437554,0.004143815,0.015556226],"study_design_scores_gemma":[0.957874,0.0059783435,0.016217012,0.00031558063,0.0030968532,0.00009242351,0.002977896,0.0045344033,0.00025250035,0.0011910867,0.007225564,0.00024431033],"about_ca_topic_score_codex":0.00090142543,"about_ca_topic_score_gemma":0.0024391324,"teacher_disagreement_score":0.018585239,"about_ca_system_score_codex":0.0006928869,"about_ca_system_score_gemma":0.004670123,"threshold_uncertainty_score":0.99875164},"labels":[],"label_agreement":null},{"id":"W4379335619","doi":"10.1200/jco.2023.41.16_suppl.5500","title":"KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Chemotherapy; Cervical cancer; Placebo; Internal medicine; Oncology; Interim analysis; Gemcitabine; Cancer; Cisplatin; Surgery; Randomized controlled trial; Immunotherapy; Pathology","score_opus":0.30500281861651696,"score_gpt":0.5088345386815675,"score_spread":0.20383172006505051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98025715,0.0011889689,0.00013029444,0.0127182435,0.0018218608,0.0034581595,0.00032125448,0.00002141575,0.00008266663],"genre_scores_gemma":[0.9755306,0.020230602,0.00088327035,0.0006694833,0.0014732522,0.00019704804,0.0000897788,0.00006612803,0.0008598241],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919514,0.000809223,0.0055750655,0.0004963426,0.0007402735,0.00042771557],"domain_scores_gemma":[0.9837626,0.010319041,0.0044194045,0.00045073908,0.00071828143,0.00032991156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004745277,0.00041840892,0.005440368,0.00032161883,0.000075989505,0.000013712854,0.00032704422,0.00035413765,0.0004901985],"category_scores_gemma":[0.001244558,0.00025748237,0.0030133354,0.000443589,0.00039891448,0.00009302659,0.000030272206,0.0004427287,0.000002580033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8664819,0.021669706,0.00064117444,0.00011274264,0.01158191,0.00013192036,0.0020608176,0.00014938791,0.0001471928,0.0000036526078,0.0017193469,0.09530027],"study_design_scores_gemma":[0.8455556,0.13014264,0.0020110242,0.00024855096,0.0031725203,0.000042290452,0.00071493105,0.0020340101,0.00032599823,0.000059394366,0.015497522,0.00019551996],"about_ca_topic_score_codex":0.00091352855,"about_ca_topic_score_gemma":0.0010727941,"teacher_disagreement_score":0.10847294,"about_ca_system_score_codex":0.00041801378,"about_ca_system_score_gemma":0.0020620578,"threshold_uncertainty_score":0.9999877},"labels":[],"label_agreement":null},{"id":"W4379335699","doi":"10.1200/jco.2023.41.16_suppl.tps4609","title":"MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Avelumab; Chemotherapy; Internal medicine; Oncology; Maintenance therapy; Cabozantinib; Cancer; Surgery; Immunotherapy; Pembrolizumab","score_opus":0.07253974970556581,"score_gpt":0.43133282188382527,"score_spread":0.35879307217825945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917005,0.00022913195,0.0002023807,0.0034192926,0.0014792666,0.0025666538,0.000101663594,0.000014625079,0.00028648728],"genre_scores_gemma":[0.9935957,0.002274979,0.0015345735,0.0012709148,0.00060240825,0.00030460957,0.000011462423,0.00005411328,0.0003512049],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99478585,0.000557129,0.0031273228,0.00039147478,0.0006792377,0.00045901485],"domain_scores_gemma":[0.9933767,0.0034329079,0.0021498203,0.0002725948,0.00043715537,0.00033085514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027268017,0.00033834262,0.0035654027,0.00020859209,0.000041548596,0.000011611937,0.00017046912,0.00026203346,0.00040359484],"category_scores_gemma":[0.001978907,0.00021848001,0.00052411074,0.0003832621,0.0005356029,0.000115701936,0.000031251337,0.00070997805,0.0000075148605],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95407325,0.0055560316,0.0043322155,0.000081825325,0.0009489878,0.00050845597,0.00022003801,0.00006665964,0.0000058496175,0.000007779718,0.0005042996,0.033694636],"study_design_scores_gemma":[0.9428878,0.042670965,0.009124953,0.0004669133,0.0010010053,0.000013250968,0.000042566557,0.00056732324,0.000084296385,0.000066675675,0.0028873298,0.00018695873],"about_ca_topic_score_codex":0.0001647633,"about_ca_topic_score_gemma":0.00053048634,"teacher_disagreement_score":0.037114933,"about_ca_system_score_codex":0.00021885161,"about_ca_system_score_gemma":0.0023582254,"threshold_uncertainty_score":0.8909356},"labels":[],"label_agreement":null},{"id":"W4379335757","doi":"10.1200/jco.2023.41.16_suppl.6625","title":"Efficacy-effectiveness gap with immune checkpoint inhibitors in solid cancers: A population based cohort study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Formulary; Cohort; Population; Randomized controlled trial; Internal medicine; Real world data; Cancer; Family medicine; Oncology","score_opus":0.10763988971676725,"score_gpt":0.4053628881865086,"score_spread":0.2977229984697414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338,0.00027188033,0.00022376669,0.0007652062,0.0017264513,0.0005587164,0.000009231859,0.00001657078,0.0030481692],"genre_scores_gemma":[0.9987327,0.00019887315,0.00016984668,0.00019972766,0.0005781719,0.000028651608,0.000004524454,0.000026773832,0.000060762188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955483,0.00020823197,0.0035110356,0.0003246047,0.00007885142,0.00032898347],"domain_scores_gemma":[0.9952313,0.0012299204,0.003022849,0.0002277897,0.00011850938,0.00016968793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01033455,0.00016820406,0.0019844433,0.0004612542,0.00004895284,0.000026867876,0.00024526636,0.0002829149,0.00010789291],"category_scores_gemma":[0.0027368923,0.00015090776,0.00033906987,0.00047168453,0.00008767476,0.00031437833,0.000044955337,0.00069529796,0.00008764419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001809749,0.0007122621,0.978428,0.000014964823,0.00014873118,0.0001018943,0.00009593983,0.007294482,0.0000032291443,0.00039810434,0.000114220624,0.010878422],"study_design_scores_gemma":[0.007689643,0.004450746,0.98173827,0.00008861331,0.000027117887,0.000005755235,0.00008080272,0.00097297586,0.000012715163,0.0018616656,0.0028920886,0.000179613],"about_ca_topic_score_codex":0.0017859313,"about_ca_topic_score_gemma":0.0009910187,"teacher_disagreement_score":0.010698809,"about_ca_system_score_codex":0.0009131763,"about_ca_system_score_gemma":0.0007056669,"threshold_uncertainty_score":0.6153839},"labels":[],"label_agreement":null},{"id":"W4379335761","doi":"10.1200/jco.2023.41.16_suppl.3053","title":"CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine; Colorectal cancer; Lung cancer; KRAS; Targeted therapy; Population; ROS1; Cancer; Adenocarcinoma","score_opus":0.06595717553733264,"score_gpt":0.4985419576020871,"score_spread":0.4325847820647544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938316,0.00012194732,0.00022382065,0.008597271,0.0005401521,0.00025915974,0.000017611108,0.000008149819,0.0008487394],"genre_scores_gemma":[0.99721485,0.00014161969,0.0013032875,0.0008788601,0.00019604222,0.000009136674,0.000005086634,0.000010482571,0.00024060413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972674,0.00029111843,0.0018175967,0.000120000055,0.00031472606,0.0001891206],"domain_scores_gemma":[0.9952867,0.0024769956,0.0015414117,0.00016582716,0.00043415552,0.00009490351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002903944,0.0000830606,0.00079468184,0.00010928929,0.00006773901,0.0000039283227,0.00013992193,0.00017428459,0.000024618505],"category_scores_gemma":[0.005166968,0.00005122369,0.00029989504,0.00035509208,0.000131947,0.00007247132,0.000041028856,0.00032001015,0.000007107363],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027969865,0.010853573,0.1081153,0.0006997805,0.0025851887,0.0044240365,0.042217273,0.00051869726,0.43570974,0.0024816212,0.0039655166,0.36045942],"study_design_scores_gemma":[0.013791592,0.011660279,0.9370766,0.00055596617,0.0005629405,0.00024364617,0.012970843,0.00026860074,0.011763612,0.0056682224,0.0053243623,0.00011333521],"about_ca_topic_score_codex":0.00009915784,"about_ca_topic_score_gemma":0.00087063,"teacher_disagreement_score":0.8289613,"about_ca_system_score_codex":0.00011027686,"about_ca_system_score_gemma":0.0007980248,"threshold_uncertainty_score":0.61857164},"labels":[],"label_agreement":null},{"id":"W4379335762","doi":"10.1200/jco.2023.41.16_suppl.e16012","title":"The prognostic value of degree of pre- and post-treatment anemia in patients with advanced gastroesophageal cancers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Anemia; Proportional hazards model; Oncology; Cancer; Chemotherapy; Neutrophil to lymphocyte ratio; Progression-free survival; Overall survival","score_opus":0.03625168588571483,"score_gpt":0.38550049918887797,"score_spread":0.34924881330316315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813974,0.00034501098,0.0000016391691,0.00063319743,0.00024405919,0.0005038721,0.000011123915,0.00000488134,0.00011649901],"genre_scores_gemma":[0.99769986,0.00038035595,0.0017014109,0.000090046124,0.00008014479,0.000013164654,0.0000034256102,0.00001191299,0.000019693478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749994,0.00028301237,0.0015407836,0.00013149969,0.00034064442,0.0002041215],"domain_scores_gemma":[0.9955909,0.0021738757,0.0013782904,0.00015991314,0.0005099137,0.000187079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001285625,0.000112297625,0.00084434415,0.00011377224,0.000026218322,0.0000024454862,0.00011147438,0.00013513128,0.0000072489515],"category_scores_gemma":[0.002516535,0.00006042046,0.00015420615,0.00018699047,0.00041673836,0.00005505289,0.000045449135,0.00026468057,7.837709e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019628052,0.00064593065,0.88146186,0.0000738285,0.0002670337,0.00018842853,0.00010654601,0.000032958396,0.00004755672,0.000012729023,0.00005827678,0.097476795],"study_design_scores_gemma":[0.010636125,0.026479384,0.9617672,0.0002328342,0.00033800595,0.000016500506,0.000112920476,0.00004257418,0.000114580194,0.000035249894,0.0001852945,0.000039325616],"about_ca_topic_score_codex":0.00001568531,"about_ca_topic_score_gemma":0.00005123913,"teacher_disagreement_score":0.09743747,"about_ca_system_score_codex":0.00018561973,"about_ca_system_score_gemma":0.0014865088,"threshold_uncertainty_score":0.30127093},"labels":[],"label_agreement":null},{"id":"W4379335780","doi":"10.1200/jco.2023.41.16_suppl.4519","title":"Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Pazopanib; Internal medicine; Renal cell carcinoma; Sunitinib; Oncology; Proportional hazards model; Gastroenterology","score_opus":0.07453684115200986,"score_gpt":0.3569206041753232,"score_spread":0.2823837630233133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930838,0.0005014781,0.00012946806,0.003715886,0.00054897025,0.0011208445,0.00043156042,0.000017838012,0.00045019423],"genre_scores_gemma":[0.9892245,0.0003414431,0.008298328,0.0009930532,0.0002777973,0.000020365313,0.000402027,0.00008240554,0.00036011077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99176294,0.0010850269,0.004516951,0.0007092858,0.0013363499,0.00058946037],"domain_scores_gemma":[0.98244596,0.011533501,0.0038800365,0.00091530813,0.0007171773,0.000508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036635841,0.0005302611,0.002393673,0.0005012346,0.00010806431,0.000032250995,0.0006781895,0.00022344495,0.0001849615],"category_scores_gemma":[0.0015030574,0.00030897505,0.00058241095,0.00058694015,0.0005769547,0.00018637012,0.00020736583,0.0014152053,0.000032145268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22525178,0.014530817,0.73071116,0.0002821643,0.0010801671,0.0075693172,0.0011599207,0.0010837278,0.005425878,0.000004157916,0.009310267,0.0035906576],"study_design_scores_gemma":[0.11261188,0.0289897,0.83974177,0.00031824363,0.0011384137,0.00007132453,0.00032972847,0.0019011912,0.011936543,0.000021411692,0.0026232773,0.00031651586],"about_ca_topic_score_codex":0.0005398436,"about_ca_topic_score_gemma":0.000283892,"teacher_disagreement_score":0.112639904,"about_ca_system_score_codex":0.00033171146,"about_ca_system_score_gemma":0.0020400141,"threshold_uncertainty_score":0.9999362},"labels":[],"label_agreement":null},{"id":"W4379335781","doi":"10.1200/jco.2023.41.16_suppl.4022","title":"Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Foundation","keywords":"Medicine; Neuroendocrine tumors; Nuclear medicine; Positron emission tomography; Prospective cohort study; Pet imaging; PET-CT; Population; DOTA; Standardized uptake value; Radiology; Internal medicine; In vivo","score_opus":0.139677346620512,"score_gpt":0.5054487847444988,"score_spread":0.3657714381239868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027306,0.0002395792,0.0000015103979,0.0069836415,0.0006657017,0.0015124448,0.000007012532,0.000007005406,0.0003100511],"genre_scores_gemma":[0.99927586,0.00029995546,0.000039175808,0.00015234102,0.000136891,0.000028310355,7.7899176e-7,0.000015247264,0.000051455794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926883,0.0030029952,0.0023817096,0.0002820495,0.0012909347,0.00035398503],"domain_scores_gemma":[0.99333155,0.0035667506,0.0017046877,0.00037160687,0.0008553986,0.00017002442],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058557563,0.00016282102,0.0012785232,0.00018565405,0.00004960528,0.000008598558,0.00032261395,0.0000018242539,0.00006803408],"category_scores_gemma":[0.016677843,0.00008691602,0.00028186708,0.0004507545,0.0007388447,0.0001208162,0.00029701638,0.0011857355,0.0000023190164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018845906,0.001536265,0.97668064,0.00006404952,0.00011218045,0.007649339,0.00006018361,0.000056283745,0.00013937344,0.0000122638,0.00068832014,0.0111165345],"study_design_scores_gemma":[0.010529287,0.007236075,0.9615291,0.00014576134,0.00040563496,0.012912641,0.0013473749,0.004907026,0.00024876645,0.00038355513,0.000310881,0.00004392572],"about_ca_topic_score_codex":0.000057951944,"about_ca_topic_score_gemma":0.0002641726,"teacher_disagreement_score":0.015151545,"about_ca_system_score_codex":0.00010162738,"about_ca_system_score_gemma":0.00093259494,"threshold_uncertainty_score":0.9916051},"labels":[],"label_agreement":null},{"id":"W4379335961","doi":"10.1200/jco.2023.41.16_suppl.7066","title":"Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Quality of life (healthcare); Post-hoc analysis; Ruxolitinib; Anemia; Population; Myelofibrosis; Health related quality of life; Internal medicine; Bone marrow","score_opus":0.09369376429611907,"score_gpt":0.4527289621501644,"score_spread":0.3590351978540453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967223,0.00021560247,0.000008200439,0.00257269,0.00007510205,0.00028998716,0.00005106484,0.0000038842454,0.00006119858],"genre_scores_gemma":[0.9973146,0.0022212546,0.00020585812,0.00016656263,0.000038434016,0.0000030854621,0.000030512456,0.000010630144,0.000009082028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538565,0.0006540205,0.003138629,0.00022126918,0.00042261655,0.00017784159],"domain_scores_gemma":[0.993087,0.0033599744,0.0025254476,0.00014835878,0.0005573789,0.00032187227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023464586,0.00015568969,0.0027732097,0.0006012294,0.00003464239,0.000003342942,0.000048259124,0.00024068015,0.00008175282],"category_scores_gemma":[0.001722452,0.00009587736,0.0004303257,0.0007990358,0.00018979807,0.00006443316,0.00002496461,0.00039131808,8.714708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023988325,0.0020668143,0.9195051,0.00009907367,0.0028031731,0.00001314979,0.00068702275,0.00056994916,0.0001302745,0.000020762112,0.00009156994,0.050024793],"study_design_scores_gemma":[0.0142249605,0.07391656,0.9100956,0.00028758176,0.00087368255,0.000004186125,0.00025185864,0.00021006462,0.00003255319,0.00002069374,0.000022239523,0.0000600191],"about_ca_topic_score_codex":0.0011363508,"about_ca_topic_score_gemma":0.000594139,"teacher_disagreement_score":0.07184975,"about_ca_system_score_codex":0.00012895725,"about_ca_system_score_gemma":0.0007162453,"threshold_uncertainty_score":0.39097652},"labels":[],"label_agreement":null},{"id":"W4379336010","doi":"10.1200/jco.2023.41.16_suppl.e18512","title":"UK cancer healthcare professionals collaborating with colleagues in low- and middle-income counties: Mapping the extent and nature of partnerships.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Government (linguistics); Health care; Family medicine; Promotion (chess); Nursing; Economic growth; Political science; Politics","score_opus":0.20317889068253464,"score_gpt":0.5015848647094507,"score_spread":0.2984059740269161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9144272,0.0074891755,7.1238765e-7,0.07702286,0.000662495,0.00029724243,0.000010182519,0.0000044170183,0.000085715794],"genre_scores_gemma":[0.9867676,0.005328686,0.00024882797,0.0071159247,0.0003684702,0.000010552955,0.0000014652052,0.000007647688,0.000150831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706084,0.0004998592,0.0016586048,0.00014301477,0.00035925343,0.0002784414],"domain_scores_gemma":[0.993791,0.0039791474,0.0011601679,0.00009418591,0.0006736511,0.0003018813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006012224,0.0000978335,0.0011040592,0.0001353896,0.00007296606,0.0000056429617,0.00006447711,0.00036689977,0.000010849566],"category_scores_gemma":[0.0029497622,0.000050903967,0.000066777255,0.0005268745,0.0002460897,0.000053457014,0.000043197706,0.001166723,4.8504506e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036954647,0.0001715393,0.986627,0.0011304975,0.00009670331,0.00040384106,0.0007110276,0.0000060779275,0.0000065421896,0.00029159634,0.0022541222,0.004605606],"study_design_scores_gemma":[0.0035283666,0.0021971443,0.97521794,0.005714819,0.000045116474,0.00012533144,0.0069800485,0.00013671648,0.000006662747,0.00024736542,0.0057382374,0.00006227522],"about_ca_topic_score_codex":0.00006853715,"about_ca_topic_score_gemma":0.0006822419,"teacher_disagreement_score":0.07234039,"about_ca_system_score_codex":0.00009006818,"about_ca_system_score_gemma":0.003315566,"threshold_uncertainty_score":0.5881672},"labels":[],"label_agreement":null},{"id":"W4379336150","doi":"10.1200/jco.2023.41.16_suppl.tps5630","title":"Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Endometrial cancer; Clinical endpoint; Internal medicine; Oncology; Randomized controlled trial; Chemotherapy; Radiation therapy; Cancer; Paclitaxel; Surgery; Cisplatin","score_opus":0.16951544864782392,"score_gpt":0.49988804699641476,"score_spread":0.33037259834859084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360604,0.00073197024,0.000016354486,0.0019412516,0.0064578108,0.006860954,0.000020021236,0.000038849954,0.0003267738],"genre_scores_gemma":[0.99527204,0.0021668368,0.00026495336,0.00032155472,0.001367868,0.0004464346,0.00002885264,0.000058162786,0.00007329537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9869905,0.0023817664,0.0076154955,0.0007289948,0.0014612831,0.0008219608],"domain_scores_gemma":[0.97419554,0.021051701,0.0032507707,0.00042931468,0.00046985372,0.000602807],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013093223,0.0005200317,0.0072463234,0.0015855075,0.00010666554,0.000034538323,0.00044346985,0.00019673236,0.00036227],"category_scores_gemma":[0.019457512,0.0003684469,0.0010764188,0.002982182,0.00020937332,0.00021426273,0.00019439142,0.001785417,0.00002836655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8114705,0.055499434,0.050736405,0.000034651912,0.00167634,0.0014419623,0.00080268143,0.0007277913,0.0000046255714,0.000002083716,0.00019423357,0.0774093],"study_design_scores_gemma":[0.8826872,0.07929332,0.033036172,0.0001624146,0.0012926521,0.0000088398465,0.0011749036,0.0005037326,0.000008944015,0.000049719874,0.001521776,0.00026033708],"about_ca_topic_score_codex":0.00058974186,"about_ca_topic_score_gemma":0.0017972181,"teacher_disagreement_score":0.07714896,"about_ca_system_score_codex":0.0011634616,"about_ca_system_score_gemma":0.001225905,"threshold_uncertainty_score":0.99987674},"labels":[],"label_agreement":null},{"id":"W4379336228","doi":"10.1200/jco.2023.41.16_suppl.e17630","title":"Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Internal medicine; Endometrial cancer; Oncology; Meta-analysis; Cancer; Immunotherapy; Thyroid cancer","score_opus":0.5084981135942951,"score_gpt":0.5814257263023181,"score_spread":0.07292761270802306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012223627,0.99323124,0.0000040587,0.0011884231,0.00044713484,0.004850158,0.00010927972,0.000014849091,0.00014263275],"genre_scores_gemma":[0.000025231579,0.9959049,0.00039979175,0.0005437259,0.00045564875,0.0012275034,0.000028687382,0.00005953767,0.001354943],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9865195,0.0025136159,0.009100308,0.00063538627,0.0008114113,0.00041977514],"domain_scores_gemma":[0.97568166,0.013853089,0.008902848,0.00051200716,0.00041135005,0.000639055],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003790507,0.0007325804,0.05068367,0.0013444253,0.00003436716,0.000017633307,0.00029059022,0.00061062723,0.00047317523],"category_scores_gemma":[0.008011844,0.0002921942,0.007039283,0.0038619512,0.00013847298,0.00008331705,0.0000779711,0.0012714812,0.000019590165],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005979654,0.001140506,0.00001059264,0.3788635,0.3565205,0.0022120597,0.000014880479,0.0000017209702,2.3480704e-9,0.0000060005277,0.000054137974,0.25519642],"study_design_scores_gemma":[0.01873632,0.027940353,0.000011628561,0.04850848,0.7873028,0.0005316246,0.000011330812,0.0000013255948,1.941888e-8,0.0000056309873,0.11674681,0.00020369294],"about_ca_topic_score_codex":0.00010673603,"about_ca_topic_score_gemma":0.0007474211,"teacher_disagreement_score":0.4307823,"about_ca_system_score_codex":0.0017646349,"about_ca_system_score_gemma":0.0063691526,"threshold_uncertainty_score":0.99995303},"labels":[],"label_agreement":null},{"id":"W4379336249","doi":"10.1200/jco.2023.41.16_suppl.4099","title":"A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Durvalumab; Internal medicine; PARP inhibitor; Oncology; Interim analysis; Intrahepatic Cholangiocarcinoma; Phases of clinical research; Gastroenterology; Surgery; Cancer; Chemotherapy; Clinical trial; Immunotherapy; Poly ADP ribose polymerase; Nivolumab","score_opus":0.10437422885994299,"score_gpt":0.45197953897474114,"score_spread":0.3476053101147981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975432,0.0002699584,0.0000011791118,0.0010549987,0.0003060766,0.00039438307,0.0000040006107,0.000010081499,0.0004161031],"genre_scores_gemma":[0.9992758,0.00009600683,0.000085125896,0.00026334854,0.00017603164,0.000005588817,0.000003914456,0.0000146899565,0.00007949908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729425,0.0002411876,0.0016517703,0.00019833779,0.00040341445,0.0002110202],"domain_scores_gemma":[0.9977251,0.0006099913,0.00089428906,0.00016300706,0.00041029588,0.00019730539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015846305,0.00013314457,0.0015011253,0.0003010063,0.000043842716,0.0000040517484,0.00009729795,0.00014500118,0.000015554562],"category_scores_gemma":[0.001001577,0.00008740653,0.00014279284,0.0004554116,0.00015635115,0.000087658045,0.00010854465,0.0006231189,0.0000025854188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011371311,0.011428882,0.93273926,0.000028605522,0.0005195794,0.00059771264,0.002141858,0.0000035827095,0.000014847728,0.00000260879,0.0011527775,0.039998986],"study_design_scores_gemma":[0.077197224,0.11133714,0.8089165,0.00007362317,0.00034474165,0.000027888942,0.0013542417,0.000021546519,0.0000060629577,0.000016414364,0.00063894177,0.000065643755],"about_ca_topic_score_codex":0.00006962398,"about_ca_topic_score_gemma":0.00017712484,"teacher_disagreement_score":0.12382272,"about_ca_system_score_codex":0.000064575834,"about_ca_system_score_gemma":0.00042111852,"threshold_uncertainty_score":0.35643348},"labels":[],"label_agreement":null},{"id":"W4379336470","doi":"10.1200/jco.2023.41.16_suppl.4511","title":"Fibroblast growth factor receptor 3 (<i>FGFR3</i>) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Tolerability; Internal medicine; Placebo; Oncology; Metastatic Urothelial Carcinoma; Adjuvant therapy; Cancer; Randomized controlled trial; Surgery; Adverse effect; Bladder cancer; Urothelial carcinoma; Pathology","score_opus":0.08624236105440229,"score_gpt":0.4171832021538532,"score_spread":0.3309408410994509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995073,0.000048179223,0.000011918553,0.0017027648,0.0006561473,0.0017789467,0.000086399625,0.00001086605,0.0006317641],"genre_scores_gemma":[0.9975482,0.0003139703,0.000304874,0.0007616592,0.0007755805,0.00007467957,0.00003503895,0.000034988458,0.00015098738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99521613,0.00060782244,0.0028963077,0.00030830252,0.00059945765,0.00037199986],"domain_scores_gemma":[0.99615794,0.0011749212,0.0015438374,0.00022190866,0.0005849419,0.00031642962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009820366,0.00025848363,0.0018667356,0.00045266474,0.00003940476,0.0000114936565,0.0001930117,0.000338297,0.00030021946],"category_scores_gemma":[0.0020029647,0.00017047898,0.00035431664,0.0005905024,0.00019548507,0.00020758311,0.00004135097,0.0008413619,0.000021266676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5996459,0.019783791,0.31232977,0.00007774058,0.0005656256,0.00054797373,0.0031449827,0.00002307655,0.0015759616,0.000038534905,0.0021533456,0.060113266],"study_design_scores_gemma":[0.5572351,0.19243667,0.24401557,0.00048649308,0.00011108198,0.000026312202,0.00025885116,0.000020292653,0.0039072377,0.0001628079,0.0011548074,0.00018474847],"about_ca_topic_score_codex":0.0003050907,"about_ca_topic_score_gemma":0.00067136355,"teacher_disagreement_score":0.17265287,"about_ca_system_score_codex":0.00022332695,"about_ca_system_score_gemma":0.004215425,"threshold_uncertainty_score":0.74779826},"labels":[],"label_agreement":null},{"id":"W4379336528","doi":"10.1200/jco.2023.41.16_suppl.tps5629","title":"A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; Durvalumab; Oncology; Clinical endpoint; Internal medicine; PARP inhibitor; Pharmacology; Randomized controlled trial; Cancer; Nivolumab; Immunotherapy","score_opus":0.2684857014458186,"score_gpt":0.4735416012764046,"score_spread":0.20505589983058597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97868925,0.0040779575,0.0002311224,0.00765398,0.0037504362,0.0050006304,0.00010319542,0.00009381557,0.00039962213],"genre_scores_gemma":[0.9899603,0.006275369,0.00071260944,0.0011717218,0.0009804593,0.0005337322,0.00003359735,0.00012774729,0.00020443839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98134625,0.005735954,0.0081009,0.0011293594,0.0023789986,0.0013085367],"domain_scores_gemma":[0.97356874,0.017208388,0.0058308393,0.0008075313,0.0013578818,0.0012266112],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022815939,0.0009256852,0.008583974,0.0015514025,0.0005274698,0.00012605597,0.0007349532,0.00050102634,0.00030029292],"category_scores_gemma":[0.013933194,0.00058887596,0.0010732835,0.0024907838,0.0029266633,0.0005363419,0.00040893728,0.0027271963,0.000008191438],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88383514,0.03582397,0.0054906798,0.0005275741,0.008391891,0.0009522774,0.018295357,0.00031061156,0.0011608159,0.00019123212,0.002577422,0.04244302],"study_design_scores_gemma":[0.8962279,0.070430905,0.004194872,0.0014075151,0.0051645525,0.000630519,0.011046662,0.004451835,0.0001876918,0.00041323516,0.0051976,0.0006467324],"about_ca_topic_score_codex":0.00048037322,"about_ca_topic_score_gemma":0.00083217025,"teacher_disagreement_score":0.041796286,"about_ca_system_score_codex":0.0014340035,"about_ca_system_score_gemma":0.002661763,"threshold_uncertainty_score":0.9997868},"labels":[],"label_agreement":null},{"id":"W4379336529","doi":"10.1200/jco.2023.41.16_suppl.e17110","title":"Impact of obesity on admissions for COVID-19 with concurrent prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Prostate cancer; Obesity; Cancer; Retrospective cohort study; Population; Comorbidity; Pulmonary embolism; Internal medicine","score_opus":0.45990084791797486,"score_gpt":0.6697279335816271,"score_spread":0.2098270856636522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92717886,0.00018173413,0.00013133006,0.07090446,0.0007672851,0.00062704633,0.00008252108,0.000019422821,0.00010733225],"genre_scores_gemma":[0.9894048,0.0015148467,0.0002109305,0.0077744685,0.00077207736,0.0000116993815,0.0000071361665,0.000016459238,0.00028760603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728364,0.00024050489,0.0016232838,0.00017043247,0.00035876365,0.00032335677],"domain_scores_gemma":[0.988694,0.006604043,0.0016900359,0.00017218664,0.0006747895,0.0021649147],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030321816,0.00013142244,0.0014391176,0.00020524465,0.00006583383,0.0000037660902,0.00011478572,0.00024952556,0.0001874882],"category_scores_gemma":[0.024399498,0.00007332864,0.0005802945,0.0002862121,0.0001409359,0.000047589147,0.00002732639,0.00074015063,0.000006452857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0311878,0.00251064,0.71682405,0.0006119212,0.00062835735,0.000557318,0.0005506309,0.000567641,0.00013560832,0.00014069352,0.10337628,0.14290908],"study_design_scores_gemma":[0.013228747,0.081596196,0.7866362,0.00038055572,0.00028286022,0.00009292791,0.00008901123,0.00015978022,0.000028959232,0.00025226537,0.11717174,0.00008075399],"about_ca_topic_score_codex":0.00029381443,"about_ca_topic_score_gemma":0.00023678683,"teacher_disagreement_score":0.14282833,"about_ca_system_score_codex":0.0007012734,"about_ca_system_score_gemma":0.034842484,"threshold_uncertainty_score":0.9838184},"labels":[],"label_agreement":null},{"id":"W4379336686","doi":"10.1200/jco.2023.41.16_suppl.tps3639","title":"Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Clinical endpoint; Oncology; Microsatellite instability; Cancer; Population; Adverse effect; Phases of clinical research; Chemoradiotherapy; Clinical trial; Stage (stratigraphy); Surgery","score_opus":0.14355133449377774,"score_gpt":0.4913713116795473,"score_spread":0.3478199771857695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467283,0.00067112286,0.0000037220643,0.001365698,0.0005497508,0.001859213,0.000027742102,0.000019715873,0.0008302191],"genre_scores_gemma":[0.99621856,0.001731662,0.00037855114,0.0004506907,0.00012757222,0.00007741471,0.000009409081,0.000035093944,0.00097107136],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99590003,0.00031964606,0.0024724174,0.0003807762,0.00052902475,0.00039811106],"domain_scores_gemma":[0.99600226,0.0007789317,0.0019360118,0.00024616538,0.000774709,0.00026195406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011896349,0.00028031733,0.0025107749,0.00023907579,0.0001293819,0.00001116646,0.00028334785,0.00019026062,0.00013714454],"category_scores_gemma":[0.00057691464,0.00017821445,0.00014590698,0.0007124567,0.00018778435,0.00020360172,0.00023619177,0.00063635333,0.0000015029635],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17329524,0.1674638,0.18639949,0.000030822644,0.0018635445,0.0010369472,0.0033887126,0.00010493815,0.00013559821,0.000002242652,0.0008715719,0.4654071],"study_design_scores_gemma":[0.30900034,0.5595362,0.12345757,0.0003669909,0.00047679723,0.00000957748,0.0014516462,0.000075462405,0.000069525224,0.000017656128,0.005365462,0.00017272295],"about_ca_topic_score_codex":0.0005707951,"about_ca_topic_score_gemma":0.0053687324,"teacher_disagreement_score":0.46523437,"about_ca_system_score_codex":0.0005496539,"about_ca_system_score_gemma":0.0013348423,"threshold_uncertainty_score":0.72673744},"labels":[],"label_agreement":null},{"id":"W4379336689","doi":"10.1200/jco.2023.41.16_suppl.tps5612","title":"ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre; Hamilton Health Sciences","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Ovarian cancer; Oncology; Chemotherapy; Fallopian tube; Phases of clinical research; Cancer; Fallopian tube cancer; Carboplatin; Serous carcinoma; Response Evaluation Criteria in Solid Tumors; Endometrial cancer; Immunotherapy; Gynecology; Adverse effect; Cisplatin","score_opus":0.065304763447694,"score_gpt":0.42476654696221133,"score_spread":0.35946178351451735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968599,0.000046027308,0.000010576221,0.0013543852,0.00061880786,0.00095267553,0.000027150256,0.000010960792,0.00011952041],"genre_scores_gemma":[0.9984808,0.00024790966,0.00039799197,0.00048530515,0.00022174612,0.000031426247,0.000018108314,0.000033594544,0.00008312145],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960533,0.00041130322,0.0022490774,0.00029151596,0.00067662704,0.00031820845],"domain_scores_gemma":[0.99703157,0.00085648143,0.0013859585,0.00022527379,0.00034074925,0.00015993886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014622279,0.00022245674,0.0014208438,0.00032768547,0.00003455851,0.00001114218,0.00018260018,0.00025138943,0.0001513164],"category_scores_gemma":[0.00031355958,0.000140428,0.00013595066,0.000592374,0.00020600187,0.00014851184,0.000031389292,0.0007604885,0.0000013595842],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57033795,0.01385718,0.3556135,0.0000604712,0.000589965,0.00058194,0.0011548898,0.000047829482,0.0005116871,0.0000022923866,0.00014270733,0.05709955],"study_design_scores_gemma":[0.2756224,0.06635255,0.6551873,0.00027044068,0.00013165844,0.000008865737,0.00058064493,0.00015989781,0.000055354347,0.0000020560428,0.0015175948,0.000111241985],"about_ca_topic_score_codex":0.00065687596,"about_ca_topic_score_gemma":0.004756926,"teacher_disagreement_score":0.29957378,"about_ca_system_score_codex":0.0005574967,"about_ca_system_score_gemma":0.0017633487,"threshold_uncertainty_score":0.57264876},"labels":[],"label_agreement":null},{"id":"W4379336690","doi":"10.1200/jco.2023.41.16_suppl.4596","title":"A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Urology; Tolerability; Internal medicine; Interim analysis; Oncology; Adverse effect; Cancer; Clinical trial","score_opus":0.0865494763517485,"score_gpt":0.4815242672372223,"score_spread":0.3949747908854738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645513,0.00002473908,0.000003931203,0.0006918311,0.0008255057,0.0016178197,0.000078364035,0.000008921702,0.00029372994],"genre_scores_gemma":[0.9988325,0.00020292336,0.00009801498,0.00020858434,0.00051266566,0.00003130903,0.00003312876,0.000034626642,0.000046211964],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9938413,0.00057680305,0.0041378373,0.00039381126,0.000666859,0.00038341805],"domain_scores_gemma":[0.99521583,0.0011763811,0.0023800617,0.0003546561,0.00052093755,0.00035214168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026144374,0.0002693433,0.002511943,0.0004593681,0.000033666955,0.000008185891,0.00028074702,0.0002713078,0.00008930587],"category_scores_gemma":[0.0014021691,0.00018759527,0.00030393084,0.00049791654,0.00032604,0.00020790058,0.00006439883,0.00095341966,0.0000037404154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49545783,0.05559169,0.42159444,0.0001216638,0.0010560303,0.0013997214,0.005228096,0.00011171312,0.00058240874,0.0000061177466,0.00069593854,0.018154372],"study_design_scores_gemma":[0.33643243,0.12741674,0.53392434,0.00045711754,0.00038545186,0.0000055936957,0.0007036357,0.00006366622,0.0003063678,0.000038942057,0.00015306128,0.00011264643],"about_ca_topic_score_codex":0.0013184515,"about_ca_topic_score_gemma":0.0048068915,"teacher_disagreement_score":0.15902539,"about_ca_system_score_codex":0.00024706085,"about_ca_system_score_gemma":0.0025224085,"threshold_uncertainty_score":0.76499134},"labels":[],"label_agreement":null},{"id":"W4379336973","doi":"10.1200/jco.2023.41.16_suppl.e16111","title":"Examining the treatment journey of patients diagnosed with hepatocellular carcinoma (HCC) using retrospective real-world data in British Columbia, Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Sunnybrook Hospital","funders":"Eisai Canada","keywords":"Medicine; Hepatocellular carcinoma; Retrospective cohort study; Pharmacy; Population; Medical record; Cancer; Liver cancer; Health care; Internal medicine; Family medicine; Emergency medicine; Oncology; Environmental health","score_opus":0.20980005626348586,"score_gpt":0.3572878606882384,"score_spread":0.14748780442475257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965271,0.00030116382,0.00001590043,0.00029701437,0.00093240844,0.00021038513,0.00031635555,0.0000032564092,0.0013964641],"genre_scores_gemma":[0.99677926,0.0020511658,0.00023097763,0.00022594974,0.00039782605,0.0000035045941,0.000013799578,0.000022716467,0.000274822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652404,0.00011142104,0.002639981,0.00030908285,0.000094097115,0.0003214024],"domain_scores_gemma":[0.9945748,0.0010218772,0.0036622533,0.0004030233,0.00017310401,0.00016493455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028689674,0.000110414185,0.0016367752,0.00013448238,0.00007637777,0.000053276894,0.0005029721,0.00012067528,0.00006701444],"category_scores_gemma":[0.0015023318,0.00011856454,0.00011859335,0.000434326,0.000211611,0.00027051938,0.00009376206,0.000445327,0.0000035083717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012611925,0.00031448065,0.9876968,0.0000057046664,0.0001247555,0.00029477573,0.00012063497,0.00007452463,1.4673704e-7,0.00006268071,0.0023559295,0.008823414],"study_design_scores_gemma":[0.00332068,0.0024013773,0.97439736,0.00004767589,0.00003614949,0.0000070261312,0.00020636687,0.0011577813,6.855086e-7,0.00047858365,0.017821554,0.00012477119],"about_ca_topic_score_codex":0.8371498,"about_ca_topic_score_gemma":0.9851006,"teacher_disagreement_score":0.14795087,"about_ca_system_score_codex":0.0011792688,"about_ca_system_score_gemma":0.0019779732,"threshold_uncertainty_score":0.48349214},"labels":[],"label_agreement":null},{"id":"W4379337120","doi":"10.1200/jco.2023.41.16_suppl.5006","title":"Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Orchiectomy; Stage (stratigraphy); Seminoma; Internal medicine; Testicular cancer; Urology; Gastroenterology; Surgery; Oncology; Cancer; Chemotherapy","score_opus":0.05442890426921665,"score_gpt":0.4079769689529613,"score_spread":0.35354806468374467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987333,0.000050389757,0.00003624296,0.00017384275,0.0004701686,0.0003970372,0.000031337935,0.000017047252,0.00009063296],"genre_scores_gemma":[0.9984046,0.00005905865,0.000973804,0.00021772926,0.00011931954,0.000006781373,0.0000254999,0.000028672082,0.0001645002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949136,0.00071571744,0.0029015716,0.00038815147,0.0007483748,0.0003325804],"domain_scores_gemma":[0.9920496,0.004267119,0.0021147367,0.00041597607,0.00042730887,0.0007253083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022986822,0.00022262621,0.0023329207,0.00064027664,0.00003108905,0.000009152086,0.00019032587,0.0003118673,0.000058320573],"category_scores_gemma":[0.0066885957,0.00014097181,0.00095167564,0.0010785825,0.00012289343,0.000064085376,0.000081912505,0.0007005337,0.000033011165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014124927,0.0032962426,0.96153516,0.00003809609,0.0010602247,0.0028679257,0.000039421928,0.00041170255,0.000031808915,7.3147754e-7,0.00013745157,0.016456325],"study_design_scores_gemma":[0.02008503,0.026750889,0.9508194,0.0003231791,0.0015993874,0.0000044879293,0.000018594747,0.00010364902,0.00007123824,0.0000056379276,0.00009366077,0.0001248589],"about_ca_topic_score_codex":0.000028186521,"about_ca_topic_score_gemma":0.00010460222,"teacher_disagreement_score":0.023454646,"about_ca_system_score_codex":0.00012906082,"about_ca_system_score_gemma":0.00064587774,"threshold_uncertainty_score":0.8007357},"labels":[],"label_agreement":null},{"id":"W4379337128","doi":"10.1200/jco.2023.41.16_suppl.tps7088","title":"EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Tolerability; Anagrelide; Myelofibrosis; Thrombocytosis; Internal medicine; Polycythemia vera; Interferon alfa; Myeloproliferative neoplasm; Oncology; Alpha interferon; Surgery; Gastroenterology; Immunology; Bone marrow; Adverse effect; Platelet; Interferon","score_opus":0.10602229858724463,"score_gpt":0.4481146316255874,"score_spread":0.34209233303834274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872147,0.000027647086,0.000053353153,0.011106453,0.00024676992,0.0011273273,0.000008244906,0.000009874661,0.00020561767],"genre_scores_gemma":[0.99793506,0.00026219056,0.0005129695,0.0010010798,0.00022368005,0.000019726951,0.0000038549997,0.000021264343,0.000020204745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960191,0.00083662703,0.0020599072,0.00034599542,0.00045814944,0.000280203],"domain_scores_gemma":[0.99344456,0.0043754512,0.0011749368,0.00028681877,0.00041902522,0.0002991817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025074568,0.00021687307,0.001955721,0.00014981726,0.00004536924,0.000016361808,0.00017724097,0.00007522312,0.000033977987],"category_scores_gemma":[0.0017976823,0.00011290112,0.00020496524,0.00044940066,0.00035787842,0.00007634315,0.00015883638,0.0007249058,0.0000075505936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026598,0.020246863,0.90738684,0.000031468855,0.00053617207,0.00043528504,0.003420762,0.00016490751,0.00003296999,0.0000081855205,0.00015160574,0.040986933],"study_design_scores_gemma":[0.015360177,0.065077536,0.9152491,0.00019346585,0.00031371458,0.000050277467,0.0027121787,0.00012320954,0.00010645402,0.0000035161033,0.0007172874,0.00009304862],"about_ca_topic_score_codex":0.0002258665,"about_ca_topic_score_gemma":0.012022797,"teacher_disagreement_score":0.044830672,"about_ca_system_score_codex":0.00017291216,"about_ca_system_score_gemma":0.0004458786,"threshold_uncertainty_score":0.6709003},"labels":[],"label_agreement":null},{"id":"W4379337241","doi":"10.1200/jco.2023.41.16_suppl.4555","title":"Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Cancer Care Ontario; Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Oncology; Proportional hazards model; Pembrolizumab; Logistic regression; Lung cancer; Cancer; Immunotherapy","score_opus":0.1260057301905067,"score_gpt":0.4047002711503722,"score_spread":0.2786945409598655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922716,0.00018589562,0.00004967993,0.003842312,0.00077666005,0.0011765211,0.000894048,0.000018900426,0.00078437175],"genre_scores_gemma":[0.9962988,0.00033354343,0.0014900845,0.00053929724,0.00025271432,0.000027764814,0.000752308,0.00006956057,0.00023592735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9883607,0.0025732475,0.0059928256,0.00067901367,0.001720154,0.0006740529],"domain_scores_gemma":[0.95557725,0.032687705,0.008295935,0.0010840748,0.0018764548,0.0004785681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006707142,0.00057931786,0.003173568,0.00048502258,0.00015272033,0.000027398662,0.0007586982,0.00030088145,0.00017267621],"category_scores_gemma":[0.006574168,0.0002639212,0.0011866968,0.0007357392,0.0009980095,0.00021260178,0.00025025845,0.001729188,0.000015518874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061200574,0.00833865,0.91517884,0.000049234237,0.0037834353,0.0015494893,0.000516713,0.0005425266,0.00027314582,0.000020675243,0.0059746783,0.0025720329],"study_design_scores_gemma":[0.04886779,0.06304881,0.8806514,0.00021365768,0.0036927778,0.00006256916,0.0004590325,0.0003500066,0.0014237448,0.000057339847,0.00095723785,0.0002156402],"about_ca_topic_score_codex":0.0012831542,"about_ca_topic_score_gemma":0.0004752532,"teacher_disagreement_score":0.05471016,"about_ca_system_score_codex":0.0008021994,"about_ca_system_score_gemma":0.003869249,"threshold_uncertainty_score":0.9999813},"labels":[],"label_agreement":null},{"id":"W4379337291","doi":"10.1200/jco.2023.41.16_suppl.4508","title":"SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health","keywords":"Medicine; Cystectomy; Bladder cancer; Lymphadenectomy; Surgery; Randomized controlled trial; Hazard ratio; Urothelial cancer; Urology; Cancer; Internal medicine; Confidence interval","score_opus":0.16550752834126867,"score_gpt":0.5093724658990231,"score_spread":0.3438649375577544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99162996,0.00027193874,0.00002668551,0.0034960583,0.001962379,0.0019264979,0.00024201762,0.000018229273,0.00042623893],"genre_scores_gemma":[0.99523395,0.00055208703,0.00037997554,0.0004140686,0.002745615,0.00016336709,0.000017995626,0.000044065473,0.0004488631],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947937,0.00055564527,0.002848372,0.0003473139,0.0010102415,0.000444724],"domain_scores_gemma":[0.9912324,0.005566376,0.0012824836,0.00035825607,0.00090327486,0.0006572079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042564343,0.0002535903,0.0025300193,0.00020932317,0.00010662623,0.0000080679365,0.000370158,0.00039938444,0.00087309413],"category_scores_gemma":[0.0032358065,0.00015265345,0.0010713328,0.00038764282,0.00041524446,0.00009683135,0.00011057297,0.000407392,0.000017851235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9000761,0.0025410715,0.00039316915,0.000066881126,0.001490547,0.00032905763,0.0006591506,0.000058304875,0.0025903867,0.000037002337,0.0030830011,0.08867532],"study_design_scores_gemma":[0.75641334,0.18905985,0.005326085,0.00022400482,0.0026576878,0.00016354007,0.0002505212,0.0004179053,0.005820293,0.00020021184,0.03927012,0.0001964323],"about_ca_topic_score_codex":0.00009920283,"about_ca_topic_score_gemma":0.00017985865,"teacher_disagreement_score":0.18651879,"about_ca_system_score_codex":0.00051601045,"about_ca_system_score_gemma":0.005728958,"threshold_uncertainty_score":0.9999076},"labels":[],"label_agreement":null},{"id":"W4379337304","doi":"10.1200/jco.2023.41.16_suppl.e15144","title":"Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; ROS1; Immunohistochemistry; Lung cancer; Adenocarcinoma; Population; Pembrolizumab; Biomarker; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; Cancer; Pathology; Histology; Immunotherapy; Biology","score_opus":0.026041316998926454,"score_gpt":0.42986271819090716,"score_spread":0.4038214011919807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787104,0.00025915226,0.000026464415,0.0005278883,0.0001811853,0.00030138285,0.000009576154,0.0000053783174,0.0008179491],"genre_scores_gemma":[0.99869096,0.00027802394,0.00068993884,0.00006719554,0.00012615861,0.000018472674,0.000020471092,0.000013709744,0.00009507832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862814,0.000052124888,0.0008497675,0.00014363593,0.00019035855,0.00013596061],"domain_scores_gemma":[0.99815834,0.00024630668,0.0011340677,0.00009203774,0.00023876243,0.0001305161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037160423,0.00010961097,0.0005451543,0.00015510267,0.000028841678,0.0000045639363,0.000028730377,0.00014328201,0.00003249295],"category_scores_gemma":[0.00013836286,0.00006613191,0.00012263589,0.00022432495,0.00005540172,0.00008325057,0.000011546508,0.0002846163,6.78594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010390555,0.0014747987,0.9589416,0.0001332539,0.00091708597,0.00019871056,0.0005556981,0.002065658,0.007861056,0.0000024342983,0.0008290131,0.01663016],"study_design_scores_gemma":[0.0096724015,0.010573473,0.9767998,0.0004811235,0.00038198053,0.000045699886,0.00020322474,0.0005046964,0.001146067,0.000012735512,0.000105042134,0.00007378807],"about_ca_topic_score_codex":0.00075688615,"about_ca_topic_score_gemma":0.00007678763,"teacher_disagreement_score":0.017858192,"about_ca_system_score_codex":0.00072253164,"about_ca_system_score_gemma":0.0014591125,"threshold_uncertainty_score":0.26967812},"labels":[],"label_agreement":null},{"id":"W4379337518","doi":"10.1200/jco.2023.41.16_suppl.2022","title":"Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Clinical endpoint; Bevacizumab; Internal medicine; Debulking; Temozolomide; Concordance; Oncology; Nuclear medicine; Surgery; Clinical trial; Cancer; Chemotherapy; Ovarian cancer","score_opus":0.03366958217915085,"score_gpt":0.39021211645256576,"score_spread":0.3565425342734149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996452,0.00049965235,0.000023560291,0.0012647994,0.0012639831,0.0002312604,0.000005269453,0.000009225053,0.00025030493],"genre_scores_gemma":[0.99646264,0.0017268305,0.000387729,0.00043412377,0.0006707338,0.000009124555,0.000021369324,0.000026919815,0.00026050338],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996944,0.00039285587,0.0015636781,0.00034027002,0.00037585243,0.00038331826],"domain_scores_gemma":[0.9975708,0.00021951199,0.0013663686,0.00019456427,0.00037692857,0.00027182832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000977623,0.00020089108,0.0008247355,0.00016156408,0.00006458164,0.00001556239,0.00028378647,0.0006198023,0.000027414713],"category_scores_gemma":[0.0009158499,0.00012122816,0.00026884864,0.00035614136,0.00021901425,0.000014813504,0.00013484228,0.0008292528,0.000022339329],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13999692,0.0039697797,0.076200835,0.000120080695,0.0009974483,0.0022713114,0.00032386836,0.001466215,0.004136763,0.000011578478,0.021304246,0.74920094],"study_design_scores_gemma":[0.08980228,0.2945304,0.37862226,0.0023196214,0.00062268175,0.0008055901,0.0005549101,0.0007162982,0.017879019,0.0004001713,0.2123737,0.0013730593],"about_ca_topic_score_codex":0.000007853267,"about_ca_topic_score_gemma":0.000098789846,"teacher_disagreement_score":0.7478279,"about_ca_system_score_codex":0.00011622485,"about_ca_system_score_gemma":0.00068855984,"threshold_uncertainty_score":0.49435407},"labels":[],"label_agreement":null},{"id":"W4379337520","doi":"10.1200/jco.2023.41.16_suppl.e19029","title":"Use of daunorubicin and cytarabine in adults with acute myeloid leukemia and associated risk factors for inpatient mortality: National inpatient sample review.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Daunorubicin; Myeloid leukemia; Odds ratio; Leukemia","score_opus":0.15922450178369418,"score_gpt":0.460501352641641,"score_spread":0.3012768508579468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961864,0.00030201118,0.00006453357,0.0021885769,0.00014085138,0.0008473317,0.00023392681,0.000009010344,0.000027409556],"genre_scores_gemma":[0.9587041,0.037078574,0.0027974744,0.0010627719,0.00012985,0.000022016035,0.00012880463,0.000026411457,0.000049981703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99576217,0.0005277806,0.0023861013,0.0002698875,0.00075513736,0.00029893278],"domain_scores_gemma":[0.9868022,0.009542357,0.0020644476,0.00014973253,0.0011101143,0.00033110738],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00494971,0.00017329218,0.0016986007,0.00034750038,0.000041882628,0.000007105464,0.00010869999,0.00030961807,0.000015637674],"category_scores_gemma":[0.02971576,0.000114297196,0.00018513041,0.0005071018,0.00030332303,0.00017488142,0.00011100095,0.0010178199,8.6313497e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059812823,0.0005537247,0.9715699,0.0004027344,0.00085697975,0.00013819548,0.000335966,0.00007072342,0.000066764405,0.000033299326,0.005006191,0.014984243],"study_design_scores_gemma":[0.011837658,0.015398367,0.9645233,0.0012170175,0.0005273665,0.00004277429,0.00013125471,0.0023589202,0.000057350167,0.00024009582,0.0035526776,0.000113187714],"about_ca_topic_score_codex":0.0004977994,"about_ca_topic_score_gemma":0.00048414193,"teacher_disagreement_score":0.03748223,"about_ca_system_score_codex":0.00072233594,"about_ca_system_score_gemma":0.0027313773,"threshold_uncertainty_score":0.97845733},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4379337628","doi":"10.1200/jco.2023.41.16_suppl.4569","title":"Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Atezolizumab; Discontinuation; Clinical endpoint; Internal medicine; Metastatic Urothelial Carcinoma; Adverse effect; Urology; Population; Oncology; Clinical trial; Surgery; Immunotherapy; Gastroenterology; Cancer; Urothelial carcinoma; Bladder cancer; Nivolumab","score_opus":0.1421393444483367,"score_gpt":0.43814280452401,"score_spread":0.2960034600756733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932397,0.000049900023,0.0000068250356,0.00083806267,0.0007552455,0.00063426065,0.00012267029,0.00001945738,0.0043339],"genre_scores_gemma":[0.9981303,0.000243933,0.0006772652,0.00016625808,0.00023595312,0.000015548929,0.000089566296,0.00003399941,0.0004071549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950001,0.00047390704,0.0030436164,0.0003914056,0.0007889554,0.00030201316],"domain_scores_gemma":[0.9951395,0.0017629833,0.0019195133,0.00027789525,0.0006187202,0.00028141864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000933443,0.00024774674,0.0016121014,0.00048452147,0.000030293242,0.000009263936,0.00025820074,0.00015358161,0.00011000775],"category_scores_gemma":[0.0011406317,0.0001727245,0.00024434275,0.00057410996,0.00014163087,0.00018755667,0.00007275893,0.00077374687,0.000020206642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07850079,0.04895038,0.76662517,0.000025497717,0.000833402,0.007077291,0.0009271834,0.00031073444,0.000020345811,0.0000018446983,0.00047965502,0.096247725],"study_design_scores_gemma":[0.074213974,0.12018426,0.8030378,0.00032212818,0.0004900979,0.00008318351,0.00043582523,0.000121740006,0.000038409813,0.00009763422,0.0008613682,0.000113544105],"about_ca_topic_score_codex":0.0010471242,"about_ca_topic_score_gemma":0.0012811464,"teacher_disagreement_score":0.096134186,"about_ca_system_score_codex":0.00049312494,"about_ca_system_score_gemma":0.0013706313,"threshold_uncertainty_score":0.70435005},"labels":[],"label_agreement":null},{"id":"W4379337784","doi":"10.1200/jco.2023.41.16_suppl.10058","title":"Subsequent meningiomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Meningioma; Confidence interval; Incidence (geometry); Cumulative incidence; Radiation therapy; Cancer; Childhood cancer; Pediatrics; Internal medicine; Surgery; Cohort","score_opus":0.13853771687687294,"score_gpt":0.46547015459884505,"score_spread":0.3269324377219721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819485,0.0024367133,0.000008307444,0.010820382,0.0029144255,0.00082357234,0.00001689905,0.000024129857,0.0010070923],"genre_scores_gemma":[0.9963887,0.000948163,0.00015662643,0.0005498044,0.001348209,0.000051850835,0.000009377392,0.000034032666,0.00051325554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99275047,0.0010888976,0.0043706363,0.00040427453,0.0009612107,0.0004245153],"domain_scores_gemma":[0.9924585,0.0032705865,0.0030469634,0.0005358465,0.0003813591,0.0003067334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009870276,0.00023901442,0.002165909,0.00029806595,0.00006464384,0.000013996574,0.000466319,0.0002635325,0.00026055318],"category_scores_gemma":[0.003932065,0.00014833361,0.0005983451,0.00088971603,0.00016404515,0.00011185308,0.00021400015,0.0011345157,0.000012882312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006919336,0.0036382757,0.9511837,0.000017665368,0.0016516418,0.015573711,0.0028592113,0.00017063682,0.000073274336,0.000019526451,0.010047172,0.014073273],"study_design_scores_gemma":[0.0069296844,0.003823966,0.9678309,0.00021952802,0.00070138933,0.00029801598,0.0022674215,0.00005588991,0.000044489374,0.00014663218,0.017578831,0.000103258935],"about_ca_topic_score_codex":0.007116174,"about_ca_topic_score_gemma":0.0065544555,"teacher_disagreement_score":0.016647216,"about_ca_system_score_codex":0.00019869092,"about_ca_system_score_gemma":0.0019137964,"threshold_uncertainty_score":0.9994955},"labels":[],"label_agreement":null},{"id":"W4379337801","doi":"10.1200/jco.2023.41.16_suppl.e22000","title":"Outcomes among children with hearing loss admitted with acute lymphocytic leukemia.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Hearing loss; Medicaid; Pediatrics; Healthcare Cost and Utilization Project; Medical diagnosis; Population; Diagnosis code; Retrospective cohort study; Sensorineural hearing loss; Health care; Audiology; Internal medicine","score_opus":0.12960621822314305,"score_gpt":0.43204815204243535,"score_spread":0.3024419338192923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996483,0.000011461934,0.00019763403,0.0012263461,0.00068142853,0.00024474916,0.000003971971,0.000102562684,0.0010488202],"genre_scores_gemma":[0.9935282,0.0002675897,0.0020069727,0.0026865278,0.00048484834,0.0000047362846,0.0000010040276,0.00006187137,0.00095828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953529,0.0006264369,0.0019991463,0.00048290275,0.00086154445,0.00067706185],"domain_scores_gemma":[0.99386525,0.003090303,0.0017260171,0.00044629446,0.00024122183,0.0006309389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023006045,0.00027972393,0.0014489029,0.00028980486,0.00015008521,0.000059952217,0.0007282487,0.00038084708,0.000043676202],"category_scores_gemma":[0.0048189736,0.00018121659,0.000288427,0.00082991703,0.0007386061,0.00025010444,0.00024956334,0.0014237745,0.00016387642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011099906,0.00015848235,0.98361856,0.000008293197,0.0002859447,0.0036249568,0.00012673478,0.0027878752,0.00043211962,0.000049568072,0.000784748,0.0070127207],"study_design_scores_gemma":[0.0064725853,0.005553405,0.9809664,0.00007227657,0.00023334971,0.0019366264,0.00003734898,0.0009197753,0.0012735515,0.00010043493,0.0021877494,0.00024648002],"about_ca_topic_score_codex":0.00007646112,"about_ca_topic_score_gemma":0.00012283798,"teacher_disagreement_score":0.0067662406,"about_ca_system_score_codex":0.0007152878,"about_ca_system_score_gemma":0.005889349,"threshold_uncertainty_score":0.9997463},"labels":[],"label_agreement":null},{"id":"W4379338102","doi":"10.1200/jco.2023.41.16_suppl.10042","title":"Reduction in curie score in neuroblastoma patients treated with naxitamab.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Internal medicine; Clinical endpoint; Interim analysis; Bone marrow; Phases of clinical research; Granulocyte colony-stimulating factor; Confidence interval; Gastroenterology; Clinical trial; Surgery; Chemotherapy","score_opus":0.12165218330828766,"score_gpt":0.4596841081793691,"score_spread":0.33803192487108147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962769,0.0000137727075,5.371664e-7,0.0022270468,0.00028452105,0.00027029155,0.000001698109,0.000014576656,0.0009106447],"genre_scores_gemma":[0.99900186,0.00020453462,0.000102952916,0.00017811645,0.00018095055,0.0000070019046,0.0000060346656,0.000018569965,0.00029999888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733377,0.000411859,0.0013271556,0.0002002456,0.00041474553,0.00031221847],"domain_scores_gemma":[0.99815154,0.0006301643,0.0005237978,0.00013337046,0.00024414348,0.00031698248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009586382,0.00011539976,0.0008435749,0.0005801655,0.00001761989,0.000005665219,0.00009128268,0.00017699343,0.000032913737],"category_scores_gemma":[0.0017692382,0.000075381395,0.0001448749,0.0008237407,0.00013622348,0.00013219981,0.000035858153,0.0009606695,0.00006291506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013663083,0.0035258285,0.9231077,0.000019546816,0.0000847779,0.009189215,0.000046912315,0.00003417397,0.00018036744,0.0000060242287,0.0013423589,0.048800047],"study_design_scores_gemma":[0.01906478,0.031424507,0.9472355,0.0001782536,0.00004140356,0.0003030401,0.000034048815,0.000059063772,0.00018774522,0.00005768645,0.0013625909,0.00005138315],"about_ca_topic_score_codex":0.000031589327,"about_ca_topic_score_gemma":0.00012438219,"teacher_disagreement_score":0.048748665,"about_ca_system_score_codex":0.00017550282,"about_ca_system_score_gemma":0.0007412814,"threshold_uncertainty_score":0.41736844},"labels":[],"label_agreement":null},{"id":"W4379338170","doi":"10.1200/jco.2023.41.16_suppl.tps8604","title":"NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Durvalumab; Medicine; Tolerability; Clinical endpoint; Adjuvant; Neoadjuvant therapy; Chemotherapy; Phases of clinical research; Cisplatin; Oncology; Internal medicine; Cancer; Radiology; Immunotherapy; Clinical trial; Adverse effect; Pembrolizumab; Breast cancer","score_opus":0.06079098764279891,"score_gpt":0.4049117923564123,"score_spread":0.3441208047136134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997647,0.004279611,0.00003644503,0.0019231269,0.0009916823,0.0026279076,0.000092299684,0.000029061473,0.000043390664],"genre_scores_gemma":[0.985359,0.011929228,0.00045590053,0.00088931236,0.0003555391,0.00023732318,0.000024733816,0.00012540487,0.0006235498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349463,0.00035444595,0.0035513085,0.0007836062,0.0010329101,0.00078312436],"domain_scores_gemma":[0.9916129,0.004015122,0.0026592927,0.000515117,0.00060973084,0.00058779866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031319181,0.00061921834,0.004647813,0.0005582312,0.00013661457,0.00004045922,0.0002888263,0.00027897616,0.00016993133],"category_scores_gemma":[0.00076508167,0.00037772054,0.00036268454,0.00078718935,0.000365151,0.00025533323,0.00017537033,0.0010491917,0.0000023476066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19528045,0.030369138,0.7011387,0.00042591078,0.004193139,0.0024833975,0.0040131863,0.0002280009,0.00045232623,9.985569e-7,0.015061188,0.04635357],"study_design_scores_gemma":[0.4139161,0.042452633,0.5319374,0.0017087929,0.0014137633,0.00022887762,0.0020196517,0.0018788642,0.0003343614,0.0000022980012,0.0035775763,0.00052961404],"about_ca_topic_score_codex":0.005356529,"about_ca_topic_score_gemma":0.006003051,"teacher_disagreement_score":0.21863568,"about_ca_system_score_codex":0.001446154,"about_ca_system_score_gemma":0.006199114,"threshold_uncertainty_score":0.9998675},"labels":[],"label_agreement":null},{"id":"W4379338189","doi":"10.1200/jco.2023.41.16_suppl.e21124","title":"Circulating tumour DNA (ctDNA) as a predictor of clinical outcome in non-small cell lung cancer undergoing targeted therapies: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Lung cancer; Hazard ratio; Publication bias; Liquid biopsy; Population; Clinical trial; Confidence interval; Cancer","score_opus":0.2093908932844684,"score_gpt":0.4961860749999855,"score_spread":0.2867951817155171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030040652,0.99444455,0.00010548519,0.00026628497,0.0005319886,0.0014577316,0.000109691406,0.0000037047685,0.00007649047],"genre_scores_gemma":[0.0033194106,0.99408585,0.00053937524,0.0010967866,0.00053918536,0.00012001356,0.000030433612,0.00006992928,0.00019900413],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9843506,0.002295492,0.0120577505,0.000620503,0.00032457648,0.00035107398],"domain_scores_gemma":[0.97910047,0.006725155,0.012841615,0.0005610069,0.00043756908,0.00033421567],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01174448,0.0005019895,0.019126963,0.0002910157,0.00003380723,0.000023239962,0.00064096734,0.001165097,0.000047074936],"category_scores_gemma":[0.013711184,0.0003390617,0.0070377905,0.00051585905,0.00015249103,0.000007116602,0.00030725263,0.0012389818,0.0000032805765],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011283085,0.0007615353,0.0034996935,0.76418364,0.22609818,0.00038768788,0.00005645232,0.00012390496,0.000010362465,0.00001714335,0.0008564927,0.0038920506],"study_design_scores_gemma":[0.0020819441,0.002240328,0.0005333214,0.028770741,0.94561255,0.00009495906,0.00006202112,0.00008085206,0.0000018858015,0.00004112701,0.019909585,0.0005707104],"about_ca_topic_score_codex":0.000065084365,"about_ca_topic_score_gemma":0.0004927168,"teacher_disagreement_score":0.73541296,"about_ca_system_score_codex":0.00010270669,"about_ca_system_score_gemma":0.0040232167,"threshold_uncertainty_score":0.9999061},"labels":[],"label_agreement":null},{"id":"W4379338428","doi":"10.1200/jco.2023.41.16_suppl.10015","title":"Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Chromosomal translocation; ETV6; Oncology; Uniparental disomy; Cohort; Pediatrics; Genetics; Karyotype; Chromosome; Biology; Gene","score_opus":0.1028610708479253,"score_gpt":0.47195819887326024,"score_spread":0.36909712802533495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962862,0.00007889982,0.00004784536,0.0010001597,0.0013340065,0.00073481543,0.000010874917,0.000025099878,0.00048210457],"genre_scores_gemma":[0.9963925,0.00054681936,0.0011404513,0.0007252907,0.00079330837,0.000019481555,0.000004309323,0.000052942578,0.00032493816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902344,0.0012172431,0.0064277984,0.0004492083,0.0009188591,0.0007525223],"domain_scores_gemma":[0.9882005,0.0074998206,0.0027515478,0.0004711651,0.00043638333,0.00064061553],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009215318,0.00029190638,0.004056756,0.0010248984,0.000044878114,0.00000825913,0.0006817807,0.00091079064,0.000112562375],"category_scores_gemma":[0.009323167,0.00021585348,0.0007096408,0.0008800049,0.0005322227,0.00013174611,0.00047015818,0.0018655678,0.00018998062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0074228197,0.0030502456,0.91177934,0.00004786379,0.00071796606,0.012862248,0.00031780844,0.00006139102,0.0004581764,0.000011865113,0.0015874313,0.06168285],"study_design_scores_gemma":[0.033817716,0.03801732,0.9214072,0.00010527908,0.00070159696,0.0028115013,0.00039611012,0.0014073644,0.00003164975,0.000106604224,0.0010475639,0.00015005651],"about_ca_topic_score_codex":0.00021421621,"about_ca_topic_score_gemma":0.0003921739,"teacher_disagreement_score":0.061532795,"about_ca_system_score_codex":0.004039853,"about_ca_system_score_gemma":0.009431902,"threshold_uncertainty_score":0.99978346},"labels":[],"label_agreement":null},{"id":"W4379338490","doi":"10.1200/jco.2023.41.16_suppl.e18511","title":"Real-world associations among patient-physician sex concordance, treatment practices, and cancer outcomes.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Concordance; Cohort; Internal medicine; Proportional hazards model; Cancer; Population; Disease; Logistic regression; Medical record; Hazard ratio; Retrospective cohort study; Lung cancer; Confidence interval","score_opus":0.18785686525694914,"score_gpt":0.4477173302840783,"score_spread":0.2598604650271291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93637586,0.0007209158,0.000013999025,0.0062708743,0.0025795738,0.00016913569,0.0001531,0.000020311361,0.053696238],"genre_scores_gemma":[0.97515345,0.015944926,0.00034399057,0.0021945208,0.0011123935,0.000020931679,0.000006463125,0.000027722555,0.005195625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662936,0.0000860379,0.0026423722,0.00026845298,0.000056272398,0.0003174955],"domain_scores_gemma":[0.9893799,0.0016252589,0.008431429,0.00017450396,0.00012416541,0.00026478758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017952566,0.00016313318,0.0017111795,0.00025433244,0.0000996897,0.000042895073,0.00016312032,0.00023236017,0.00009678096],"category_scores_gemma":[0.001997919,0.00014665144,0.00037910455,0.0002640299,0.00016859153,0.00053144735,0.00005177814,0.0004202305,0.00011451894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007075397,0.0002686979,0.8773256,0.0000040316822,0.0003734265,0.000031789827,0.00021686772,0.00005805055,0.0000010234493,0.0066894908,0.007744557,0.1072157],"study_design_scores_gemma":[0.0013611643,0.0010323233,0.6778925,0.000010103561,0.00004406361,0.0000011077885,0.000073453055,0.00016500626,0.0000035355988,0.0050156103,0.31428573,0.000115424125],"about_ca_topic_score_codex":0.0027265481,"about_ca_topic_score_gemma":0.0026953763,"teacher_disagreement_score":0.30654114,"about_ca_system_score_codex":0.00058713154,"about_ca_system_score_gemma":0.0005367827,"threshold_uncertainty_score":0.5980272},"labels":[],"label_agreement":null},{"id":"W4379338513","doi":"10.1200/jco.2023.41.16_suppl.e21524","title":"Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Pembrolizumab; Progressive disease; Oncology; Response Evaluation Criteria in Solid Tumors; Context (archaeology); Retrospective cohort study; Cohort; Cancer; Immunotherapy; Disease","score_opus":0.05065080828758043,"score_gpt":0.41441770345213397,"score_spread":0.3637668951645535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998404,0.00006074227,0.0000071264058,0.008137797,0.00085995597,0.00075094623,0.000003207093,0.000014467864,0.00018175054],"genre_scores_gemma":[0.9980455,0.000032275104,0.0006487168,0.0008531454,0.00022814113,0.000018975476,0.000004223275,0.000018371496,0.00015062401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963147,0.0004511119,0.0022108094,0.00022721256,0.0005739605,0.00022222174],"domain_scores_gemma":[0.99705285,0.0009994068,0.001013438,0.00018293936,0.00058193563,0.00016944545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007829184,0.00012737261,0.0010751974,0.0003217055,0.000036501642,0.000007445423,0.00012002352,0.000106152664,0.000053377833],"category_scores_gemma":[0.004041582,0.00008852601,0.00024567606,0.0007526054,0.00010029065,0.00012824699,0.000053497028,0.0006276185,0.000012208503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14310193,0.0015285711,0.8370129,0.0000035601454,0.00024816132,0.00032344594,0.00025923684,0.000015076819,0.0006560352,8.2863943e-7,0.0003890001,0.016461251],"study_design_scores_gemma":[0.025191722,0.023548227,0.9473033,0.00013306108,0.00007470802,0.00001802795,0.00041114318,0.000010677681,0.00004887441,0.00002249066,0.0031452987,0.000092492446],"about_ca_topic_score_codex":0.000036570687,"about_ca_topic_score_gemma":0.000053201846,"teacher_disagreement_score":0.117910214,"about_ca_system_score_codex":0.0006502677,"about_ca_system_score_gemma":0.0010886752,"threshold_uncertainty_score":0.4838443},"labels":[],"label_agreement":null},{"id":"W4379338578","doi":"10.1200/jco.2023.41.16_suppl.10047","title":"Adherence to surveillance guidelines in survivors of hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Survivorship curve; Internal medicine; Cancer; Odds ratio; Cohort; Pediatrics","score_opus":0.22560426467412212,"score_gpt":0.5287655810131487,"score_spread":0.30316131633902665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94884336,0.0018543359,0.000040089577,0.043617908,0.004385029,0.0008806448,0.00005438668,0.00003664311,0.00028758947],"genre_scores_gemma":[0.98674697,0.0016890719,0.0007309856,0.0074080783,0.0029595967,0.000038298185,0.000008603157,0.0000487214,0.00036968812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98659444,0.0025387432,0.008276634,0.00060586806,0.0014789891,0.0005053361],"domain_scores_gemma":[0.9814702,0.011409692,0.004118832,0.0009288344,0.0015733663,0.00049902016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025405472,0.00031836727,0.003403743,0.00028146963,0.00005803453,0.00001610571,0.0008017114,0.00037578042,0.00020004323],"category_scores_gemma":[0.04108004,0.00021236703,0.0006755119,0.0014867183,0.00023649164,0.00013211906,0.00030493585,0.0009193069,0.00003974048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021642554,0.0025921036,0.8988491,0.00002402594,0.0005802788,0.0014742682,0.0023190244,0.0001534348,0.00003256861,0.0000040563295,0.033350185,0.058456693],"study_design_scores_gemma":[0.008146596,0.0064049903,0.93991184,0.00038826928,0.00016040604,0.00013644603,0.002607287,0.00003460664,0.000023887584,0.000118931835,0.04187278,0.00019395807],"about_ca_topic_score_codex":0.042578556,"about_ca_topic_score_gemma":0.14253424,"teacher_disagreement_score":0.099955685,"about_ca_system_score_codex":0.00020713125,"about_ca_system_score_gemma":0.004303645,"threshold_uncertainty_score":0.9669973},"labels":[],"label_agreement":null},{"id":"W4379338732","doi":"10.1200/jco.2023.41.16_suppl.10052","title":"Mortality and the burden of subsequent malignant neoplasms in survivors of childhood cancer beyond age 50: A report from the Childhood Cancer Survivor Study (CCSS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Cancer; Confidence interval; Population; Incidence (geometry); Cumulative incidence; Demography; Standardized mortality ratio; Mortality rate; Pediatrics; Internal medicine; Cohort; Environmental health","score_opus":0.1285341905980374,"score_gpt":0.4610103543726973,"score_spread":0.3324761637746599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558873,0.0057598636,0.000005964324,0.033895407,0.0025727022,0.0014512921,0.00013931937,0.000019483014,0.00026863464],"genre_scores_gemma":[0.9878246,0.0074704005,0.00007961765,0.0021127816,0.0022707512,0.00006310793,0.00001344247,0.000049449016,0.00011580675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98683107,0.0034178498,0.007021693,0.00060104224,0.0016171596,0.00051118224],"domain_scores_gemma":[0.98186934,0.010534918,0.005676608,0.0009884657,0.00055982225,0.00037085736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022598282,0.00038449065,0.004087279,0.00020954435,0.00009340504,0.000019456598,0.0007159439,0.00042626404,0.00019755532],"category_scores_gemma":[0.0074762804,0.00021280139,0.0008609916,0.00080966414,0.0011853955,0.0001478572,0.00036245797,0.0018237743,0.0000029067646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033793044,0.0033773088,0.95644027,0.00008620933,0.003192789,0.0014868607,0.022812642,0.0003526041,0.00006940922,0.000054041804,0.0026977118,0.006050828],"study_design_scores_gemma":[0.016642865,0.0023875749,0.9661869,0.0005722003,0.0013435931,0.00014858556,0.008265486,0.000051817417,0.00006386548,0.0007890439,0.0033506074,0.00019748328],"about_ca_topic_score_codex":0.15775448,"about_ca_topic_score_gemma":0.12605608,"teacher_disagreement_score":0.03193731,"about_ca_system_score_codex":0.00018646925,"about_ca_system_score_gemma":0.0036394736,"threshold_uncertainty_score":0.8950346},"labels":[],"label_agreement":null},{"id":"W4379338742","doi":"10.1200/jco.2023.41.16_suppl.11535","title":"Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Proportional hazards model; Sarcoma; Univariate analysis; Chemotherapy; Internal medicine; Retrospective cohort study; Cohort; Induction chemotherapy; Lung; Progressive disease; Oncology; Surgery; Radiology; Gastroenterology; Multivariate analysis; Pathology","score_opus":0.1500337107342064,"score_gpt":0.43322342300620803,"score_spread":0.2831897122720016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433416,0.0004640361,0.000012038679,0.004199846,0.00043517823,0.00035047054,0.000043651828,0.000010560695,0.00015006783],"genre_scores_gemma":[0.99703515,0.00055887504,0.0017046005,0.00048355552,0.00013019425,0.00001074814,0.000015681951,0.000026106885,0.00003510154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940833,0.001925151,0.0027320867,0.00023047517,0.0007034773,0.00032554826],"domain_scores_gemma":[0.98278,0.014612402,0.0016982271,0.0002522683,0.00035552133,0.00030162637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060960585,0.00020641887,0.002738844,0.00062505424,0.000030633888,0.000005798052,0.00017443171,0.00012742096,0.00006182273],"category_scores_gemma":[0.004803322,0.00012552842,0.0005787557,0.0006596268,0.00014105314,0.00011002147,0.00008657272,0.0006135573,0.000019058887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021453897,0.0067010676,0.933499,0.000047555066,0.0007023744,0.0038737806,0.000074638716,0.000023105407,0.000007342454,0.00001597316,0.00030671756,0.033294592],"study_design_scores_gemma":[0.017041879,0.01287762,0.96736974,0.00008440944,0.0011086201,0.000060790317,0.00013815777,0.00006660672,0.000007528601,0.00008377224,0.0010605565,0.00010033462],"about_ca_topic_score_codex":0.000021973727,"about_ca_topic_score_gemma":0.000023508072,"teacher_disagreement_score":0.033870768,"about_ca_system_score_codex":0.00012599619,"about_ca_system_score_gemma":0.0008168342,"threshold_uncertainty_score":0.5750372},"labels":[],"label_agreement":null},{"id":"W4379338780","doi":"10.1200/jco.2023.41.16_suppl.e21542","title":"Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Adjuvant therapy; Meta-analysis; Randomized controlled trial; Neoadjuvant therapy; Melanoma; Relative risk; Stage (stratigraphy); Adjuvant; Surgery; Cancer; Confidence interval; Breast cancer","score_opus":0.3404217630581205,"score_gpt":0.5004558199483272,"score_spread":0.16003405689020672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008766405,0.9946134,0.000009259502,0.0004959044,0.0004404326,0.003964343,0.000020880803,0.00001831884,0.00034981163],"genre_scores_gemma":[0.00005865107,0.99238485,0.00018002749,0.0009019868,0.00012042786,0.00013408378,0.000017890154,0.000056624463,0.006145434],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9895505,0.0021190266,0.006732786,0.00047907085,0.00077602925,0.00034260494],"domain_scores_gemma":[0.98763067,0.004259515,0.006630976,0.0006297276,0.00044562604,0.00040348354],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.007144565,0.00049354485,0.02666757,0.0008410876,0.000040301642,0.000022481983,0.0003027745,0.00050820323,0.0005604629],"category_scores_gemma":[0.0033057015,0.0002196227,0.0033636778,0.0012741466,0.0001283543,0.0000706444,0.00011944963,0.0015601863,0.00004095251],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007900016,0.0017236323,0.000041536918,0.47967124,0.455451,0.0050682807,0.00003583261,0.0000025270638,3.512154e-9,0.00001522932,0.0015827154,0.048507977],"study_design_scores_gemma":[0.007284501,0.017036228,0.0000692286,0.019700646,0.6455189,0.00016731766,0.000038457674,0.000002693828,4.866218e-9,0.0000015124801,0.30999064,0.00018983694],"about_ca_topic_score_codex":0.000033026525,"about_ca_topic_score_gemma":0.00039597315,"teacher_disagreement_score":0.4599706,"about_ca_system_score_codex":0.00030938996,"about_ca_system_score_gemma":0.0012799298,"threshold_uncertainty_score":0.98778254},"labels":[],"label_agreement":null},{"id":"W4379338861","doi":"10.1200/jco.2023.41.16_suppl.10056","title":"Outcomes of childhood, adolescent, and young adult cancer survivors (CAYACS) with solid organ transplants: A population-based study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hepatoblastoma; Interquartile range; Cancer; Population; Internal medicine; Pediatrics; Kidney cancer; Lung cancer; Liver cancer","score_opus":0.058801358164849896,"score_gpt":0.44550788486479453,"score_spread":0.38670652669994465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471986,0.000047473673,0.000102669954,0.0041600694,0.00045517043,0.00040426207,0.000020564838,0.000018033079,0.00007190513],"genre_scores_gemma":[0.9979597,0.0003227361,0.00036172115,0.0008778118,0.00031822087,0.0000065296126,0.0000066297025,0.000030029287,0.0001166457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647385,0.00039370282,0.0018560918,0.0002204354,0.00076126563,0.00029467832],"domain_scores_gemma":[0.9957137,0.0020178605,0.0010213116,0.00019234145,0.0006728003,0.0003819754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019057177,0.00016348113,0.0016434677,0.0002739261,0.000049094542,0.0000068867234,0.0001710302,0.00024243163,0.000063949934],"category_scores_gemma":[0.0023811548,0.00009916559,0.0001962197,0.00039742448,0.00016667112,0.000073104566,0.000032681124,0.0007701926,0.0000052283795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003779204,0.0019396292,0.9856811,0.00009510965,0.0006862205,0.00070646644,0.00036524236,0.00008928826,0.000029941924,0.0000051309257,0.00035479962,0.00626785],"study_design_scores_gemma":[0.02065527,0.007642629,0.96945715,0.0003008334,0.00054614444,0.00014090439,0.00055272767,0.000510648,0.000027439139,0.000013461017,0.00006171983,0.00009107586],"about_ca_topic_score_codex":0.0016615432,"about_ca_topic_score_gemma":0.006453103,"teacher_disagreement_score":0.016876066,"about_ca_system_score_codex":0.00023490835,"about_ca_system_score_gemma":0.0028668914,"threshold_uncertainty_score":0.50857425},"labels":[],"label_agreement":null},{"id":"W4379338875","doi":"10.1200/jco.2023.41.16_suppl.10016","title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Refractory (planetary science); Interim analysis; CD22; Gastroenterology; Minimal residual disease; Surgery; Chemotherapy; Randomized controlled trial; Leukemia; Lymphoma; CD20","score_opus":0.11795961857088606,"score_gpt":0.49575143501116953,"score_spread":0.3777918164402835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98352295,0.00008993503,0.0014266657,0.0071269986,0.0036766012,0.0016445179,0.0017053226,0.000045702203,0.0007613179],"genre_scores_gemma":[0.98012567,0.0014124806,0.008137962,0.0015379086,0.0076331585,0.000030433202,0.00053219614,0.00007433647,0.00051588495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98838365,0.001684935,0.007550658,0.0006365454,0.0009774127,0.00076678506],"domain_scores_gemma":[0.95881647,0.033181652,0.005585534,0.0006305816,0.0008751027,0.00091064966],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.013027253,0.00034926107,0.0040668435,0.0005925817,0.00009391162,0.000013109316,0.0006538643,0.0014143968,0.0003776393],"category_scores_gemma":[0.036150772,0.00026209312,0.001226941,0.0004768828,0.00065566547,0.00017590648,0.00024848158,0.0023683384,0.00007316865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6861229,0.01421365,0.00032100358,0.00003286369,0.0022254817,0.0010755559,0.00028782643,0.000014777905,0.0012514251,0.00012033443,0.059708603,0.23462556],"study_design_scores_gemma":[0.6970455,0.18873748,0.005999174,0.000100568934,0.0014125314,0.00019699075,0.00013817356,0.0012342943,0.00047530132,0.0011700802,0.10330689,0.00018297484],"about_ca_topic_score_codex":0.00036897382,"about_ca_topic_score_gemma":0.00028243993,"teacher_disagreement_score":0.23444258,"about_ca_system_score_codex":0.0016432606,"about_ca_system_score_gemma":0.008562448,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W4379338876","doi":"10.1200/jco.2023.41.16_suppl.e18537","title":"Engine failures: A critical analysis of current clinical trial websites' search engines.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Windsor","funders":"","keywords":"Clinical trial; Medicine; MEDLINE; Medical physics; Internal medicine","score_opus":0.8403261242939453,"score_gpt":0.763777617993248,"score_spread":0.07654850630069732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379338876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417829,0.0010233261,0.0021508585,0.04439774,0.0077871988,0.00069992396,0.000039174312,0.00006904315,0.0020498438],"genre_scores_gemma":[0.9782755,0.008363462,0.004868719,0.00093701365,0.006586822,0.00001115893,0.000021701768,0.000048818718,0.0008868384],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98069537,0.0031983273,0.011426855,0.0006501516,0.0032230893,0.00080621534],"domain_scores_gemma":[0.72568214,0.26332766,0.0021427195,0.0010757733,0.005709734,0.0020619568],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.0933805,0.00026912164,0.0054316465,0.0016650289,0.00006722921,0.000024139172,0.00088045734,0.0019961882,0.0011765067],"category_scores_gemma":[0.47638392,0.0001956743,0.004418431,0.0034555222,0.0019507176,0.00013605179,0.00047397948,0.011911845,0.00026487824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24915317,0.02688755,0.26709262,0.0010709799,0.018056048,0.004179897,0.00031442687,0.0006015243,0.00015225525,0.016840514,0.027203228,0.3884478],"study_design_scores_gemma":[0.18409969,0.1302345,0.37067187,0.0013138537,0.0207325,0.00015909827,0.00070499035,0.018431656,0.00014458277,0.012351757,0.26040253,0.00075297686],"about_ca_topic_score_codex":0.000014063656,"about_ca_topic_score_gemma":0.0000745887,"teacher_disagreement_score":0.38769484,"about_ca_system_score_codex":0.00015634476,"about_ca_system_score_gemma":0.00851276,"threshold_uncertainty_score":0.99973655},"labels":[],"label_agreement":null},{"id":"W4379339033","doi":"10.1200/jco.2023.41.16_suppl.tps10636","title":"Metformin for chemoprevention of lung cancer in high-risk overweight or obese individuals.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Lung cancer; Metformin; Overweight; Oncology; Internal medicine; Cancer; Diabetes mellitus; Lung; Obesity; Endocrinology; Insulin","score_opus":0.05935521631229222,"score_gpt":0.4591342143746568,"score_spread":0.39977899806236455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621461,0.035626497,0.00018329655,0.00013740115,0.0015608359,0.00019223744,0.00007665694,0.000002576509,0.00007441912],"genre_scores_gemma":[0.7163725,0.27774447,0.0021761633,0.0004963617,0.002376972,0.00005285162,0.000031240164,0.000028677901,0.0007207937],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974821,0.00027404752,0.0016265077,0.00018913423,0.00018935621,0.0002388192],"domain_scores_gemma":[0.9974163,0.0004610223,0.0015989348,0.00015682916,0.00024945918,0.000117457734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003983772,0.00011256161,0.0008605378,0.000119817356,0.00002197997,0.0000046805553,0.0002406381,0.00043378808,0.00013700347],"category_scores_gemma":[0.0025443465,0.00008076755,0.00039823758,0.00020444901,0.00008614314,0.000011393776,0.00007418785,0.00028823677,0.0000017003117],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002049877,0.00056371134,0.08475414,0.00011905594,0.0005713735,0.000014316522,0.000069054455,0.00018407812,0.0025563024,0.000116421055,0.023620352,0.88538134],"study_design_scores_gemma":[0.011128132,0.004751611,0.14648579,0.000132039,0.0004949305,0.000009378898,0.00009186741,0.00024382808,0.024633033,0.0019971803,0.8098033,0.00022887968],"about_ca_topic_score_codex":0.000036386504,"about_ca_topic_score_gemma":0.00031385705,"teacher_disagreement_score":0.88515246,"about_ca_system_score_codex":0.00003587748,"about_ca_system_score_gemma":0.0009820589,"threshold_uncertainty_score":0.33457708},"labels":[],"label_agreement":null},{"id":"W4379339089","doi":"10.1200/jco.2023.41.16_suppl.7545","title":"Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"BeiGene","keywords":"Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Rituximab; Clinical endpoint; International Prognostic Index; Oncology; Refractory (planetary science); Progression-free survival; Neutropenia; Salvage therapy; Surgery; Gastroenterology; Chemotherapy; Lymphoma; Randomized controlled trial","score_opus":0.0636855480645238,"score_gpt":0.3946122477324434,"score_spread":0.3309266996679196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688065,0.000108413245,0.0000011468376,0.0004934058,0.0012622452,0.00061914115,0.00001656526,0.000016207105,0.0006022146],"genre_scores_gemma":[0.99919415,0.00012079042,0.0000995009,0.00026324778,0.00013693946,0.000015520107,0.000032380198,0.000023997973,0.00011346986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99477845,0.0007590953,0.002792217,0.00034383524,0.0009741746,0.00035224005],"domain_scores_gemma":[0.99407345,0.0020737625,0.0023953116,0.00059571647,0.0005863843,0.000275376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00203205,0.0002497632,0.0025812567,0.00056118105,0.00006369601,0.000010198,0.00033880025,0.0003645284,0.000087193635],"category_scores_gemma":[0.0017144593,0.00013421685,0.0010322544,0.002302494,0.00020588501,0.00010812234,0.00014587522,0.00046500986,0.000019320869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02270824,0.0072537083,0.9439244,0.0000103854845,0.009535316,0.0009609842,0.00038233088,0.0013783386,0.0000024203882,0.000025460744,0.0015907218,0.012227653],"study_design_scores_gemma":[0.09931315,0.024707545,0.864498,0.00006398183,0.0070642564,0.000008098338,0.00047756892,0.00033755507,0.000013585441,0.0000096788635,0.003397169,0.000109414774],"about_ca_topic_score_codex":0.00023021591,"about_ca_topic_score_gemma":0.00045342793,"teacher_disagreement_score":0.079426445,"about_ca_system_score_codex":0.003494008,"about_ca_system_score_gemma":0.0056034285,"threshold_uncertainty_score":0.9940241},"labels":[],"label_agreement":null},{"id":"W4379339266","doi":"10.1200/jco.2023.41.16_suppl.e20602","title":"Importance of <i>DICER1 </i>pathogenic variants in non-small cell lung cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University","funders":"","keywords":"Wnt signaling pathway; Somatic cell; Lung cancer; Cancer research; Adenocarcinoma; Immunohistochemistry; Biology; Missense mutation; Medicine; Pathology; Gene; Genetics; Cancer; Mutation","score_opus":0.08329539115087871,"score_gpt":0.4430632211597281,"score_spread":0.35976783000884943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865758,0.0016407897,0.000024919571,0.004258471,0.0011944433,0.0002732306,0.000009999045,0.000010038976,0.006012337],"genre_scores_gemma":[0.9925906,0.0040789675,0.0011346285,0.0010223967,0.0005664379,0.000011655075,0.000001238507,0.000021232248,0.0005728267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956763,0.0002382219,0.0032339562,0.0001912181,0.00034549725,0.0003148323],"domain_scores_gemma":[0.9949271,0.0023930676,0.001823999,0.00021541551,0.0003785621,0.00026182694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004118789,0.00014102874,0.0018924851,0.0002228317,0.000019050003,0.0000028459021,0.00020891643,0.0002598095,0.00015372009],"category_scores_gemma":[0.003276171,0.00010868182,0.00045185027,0.00052341836,0.00016729436,0.00005969634,0.00011516068,0.0008379903,0.000029608527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009052589,0.0008364022,0.9374907,0.00029532672,0.00034872734,0.0023285463,0.0004654864,0.000035474324,0.0024954423,0.000010142345,0.00595558,0.048832912],"study_design_scores_gemma":[0.006294158,0.0020499,0.9871632,0.00027300185,0.00041270687,0.0000726928,0.00024309356,0.0008274038,0.000073144976,0.00013879016,0.0023597293,0.000092179034],"about_ca_topic_score_codex":0.000050883482,"about_ca_topic_score_gemma":0.0006100258,"teacher_disagreement_score":0.0496725,"about_ca_system_score_codex":0.00014768682,"about_ca_system_score_gemma":0.0018961057,"threshold_uncertainty_score":0.44319162},"labels":[],"label_agreement":null},{"id":"W4379339399","doi":"10.1200/jco.2023.41.16_suppl.11567","title":"Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"University Health Network","keywords":"Olaparib; Medicine; Oncology; PARP inhibitor; Internal medicine; Proportional hazards model; Transcriptome; Immune checkpoint; Immune system; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Hazard ratio; Cohort; Biomarker; Bevacizumab; Cancer research; Progressive disease; Immunotherapy; Cancer; Immunology; Disease; Chemotherapy; Poly ADP ribose polymerase; Biology; Overall survival; Confidence interval; Gene expression; Gene","score_opus":0.09993577892613789,"score_gpt":0.41242827236065693,"score_spread":0.312492493434519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968172,0.00027269474,0.00000916021,0.0019031522,0.00020938025,0.0006766597,0.000026689573,0.000015934884,0.00006915024],"genre_scores_gemma":[0.9991397,0.00012876702,0.00020809473,0.00026629373,0.000094612595,0.000020112395,0.000036103575,0.00002806713,0.000078224104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950688,0.0006697161,0.002941231,0.00029079398,0.0007363448,0.00029310593],"domain_scores_gemma":[0.99334085,0.004114288,0.0015094236,0.0004191696,0.00041636196,0.00019992239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018720719,0.00024931796,0.003016176,0.0003821059,0.00005137887,0.000011273294,0.00026952085,0.00023235196,0.00019701339],"category_scores_gemma":[0.0007009234,0.0001049456,0.000596402,0.0015628058,0.0002316654,0.000093867246,0.000040152652,0.0007651812,0.000013833913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025278274,0.0096898815,0.9470492,0.0000073204383,0.008721698,0.0015273378,0.0007042309,0.00017340983,0.000004264216,0.0000034142984,0.00009022072,0.0067507206],"study_design_scores_gemma":[0.04998219,0.024845164,0.9152377,0.00010160007,0.008215333,0.000016943002,0.0011292376,0.00014059168,0.000007744804,0.0000068978607,0.000209726,0.00010684211],"about_ca_topic_score_codex":0.0007940563,"about_ca_topic_score_gemma":0.0016099988,"teacher_disagreement_score":0.031811498,"about_ca_system_score_codex":0.00018184599,"about_ca_system_score_gemma":0.00048585408,"threshold_uncertainty_score":0.42795572},"labels":[],"label_agreement":null},{"id":"W4379339623","doi":"10.1200/jco.2023.41.16_suppl.e24126","title":"Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Psychological intervention; Discontinuation; Breast cancer; Logistic regression; Physical therapy; Prospective cohort study; Internal medicine; Cancer","score_opus":0.19586223253320784,"score_gpt":0.511135638950515,"score_spread":0.3152734064173071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931074,0.000058430996,0.00021375237,0.0043373103,0.0013547845,0.0007708332,0.000079834346,0.00001412343,0.00006357113],"genre_scores_gemma":[0.99684864,0.000019829053,0.0014220283,0.0010627998,0.00036905878,0.00010139065,0.000012826921,0.00002379907,0.00013960636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968549,0.0005511912,0.0017054563,0.00021350259,0.00041055674,0.00026436633],"domain_scores_gemma":[0.9965127,0.0013572,0.00086021476,0.00016632414,0.00077857403,0.00032494756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036363704,0.00011528483,0.0009550546,0.0003237963,0.00003338962,0.000009184318,0.00013188999,0.00016205358,0.00005119401],"category_scores_gemma":[0.0025094536,0.00008098498,0.0005012613,0.00043794262,0.000053921794,0.00007681932,0.000058981856,0.00043384175,0.000006110396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09979376,0.0021787235,0.5533372,0.00013766991,0.00029983302,0.00003750816,0.00081138813,0.00015295038,0.000023968738,0.000005545695,0.001707175,0.34151426],"study_design_scores_gemma":[0.017227912,0.0324483,0.9439702,0.0009840416,0.00024272721,0.0000237171,0.00048690822,0.00027081554,0.000003029202,0.000018249104,0.0042313384,0.00009278132],"about_ca_topic_score_codex":0.000051680337,"about_ca_topic_score_gemma":0.00032812374,"teacher_disagreement_score":0.39063296,"about_ca_system_score_codex":0.00033507435,"about_ca_system_score_gemma":0.0010304296,"threshold_uncertainty_score":0.33024716},"labels":[],"label_agreement":null},{"id":"W4379339637","doi":"10.1200/jco.2023.41.16_suppl.e21506","title":"Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Ipilimumab; Melanoma; Dabrafenib; Trametinib; Internal medicine; Nivolumab; Oncology; Metastatic melanoma; Targeted therapy; Retrospective cohort study; Gastroenterology; Vemurafenib; Cancer; Cancer research; Immunotherapy; Kinase","score_opus":0.2015642610219666,"score_gpt":0.44122866727246157,"score_spread":0.23966440625049498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802184,0.000050759565,0.000026263568,0.0009827729,0.00029945272,0.00020470422,0.00032328806,0.0000029442172,0.000088003195],"genre_scores_gemma":[0.9915407,0.0046044337,0.00030293394,0.00092256715,0.00023856314,0.000011729385,0.002307395,0.000013952161,0.000057764548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967815,0.0010615117,0.0014612201,0.00027574095,0.00015990529,0.0002600983],"domain_scores_gemma":[0.9971713,0.001495128,0.00076397444,0.00036460045,0.00007576078,0.00012922469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017841898,0.0001537373,0.0007320356,0.00020149467,0.000027548187,0.000021544214,0.00031097388,0.00012208881,0.0000413694],"category_scores_gemma":[0.00096484134,0.00008796065,0.000077991805,0.0003482217,0.00009185699,0.000010077007,0.00016039105,0.00030714495,0.000004220796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009608265,0.0031351466,0.8518017,0.000040467563,0.00076628185,0.00856648,0.0018356199,0.00016394757,0.002493651,0.00004053383,0.0074255983,0.11412233],"study_design_scores_gemma":[0.006480422,0.017390935,0.8644727,0.00007363332,0.0001531894,0.00007597453,0.0017085173,0.0018626993,0.00044323565,0.0001756944,0.10695814,0.00020484213],"about_ca_topic_score_codex":0.0023006424,"about_ca_topic_score_gemma":0.024009952,"teacher_disagreement_score":0.11391749,"about_ca_system_score_codex":0.000043483058,"about_ca_system_score_gemma":0.0004524822,"threshold_uncertainty_score":0.9937993},"labels":[],"label_agreement":null},{"id":"W4379339717","doi":"10.1200/jco.2023.41.16_suppl.6054","title":"Association between locoregional failure and <i>NFE2L2/KEAP1/CUL3 </i>pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cumulative incidence; Oncology; Internal medicine; Glottis; Hazard ratio; Confidence interval; Larynx; Surgery; Cohort","score_opus":0.08298177096268915,"score_gpt":0.42132881107503745,"score_spread":0.3383470401123483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785179,0.00018352583,0.00012724256,0.01850915,0.0010461503,0.0007363264,0.000017064483,0.000011801689,0.0008508216],"genre_scores_gemma":[0.9973292,0.00037369327,0.00048384795,0.00029492954,0.0010977089,0.000052163952,0.00006827793,0.000013875568,0.00028633352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994772,0.0010436806,0.0029839806,0.00022672047,0.000758243,0.00021533466],"domain_scores_gemma":[0.984278,0.0124019245,0.0023889488,0.00007991799,0.00070957036,0.00014159526],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0073084272,0.00014716075,0.0019279156,0.0006354899,0.000054789012,0.000008949667,0.00007014099,0.00047662776,0.00006446681],"category_scores_gemma":[0.010351369,0.00012530417,0.00042954658,0.00046580838,0.00016535578,0.00024460044,0.00003103711,0.00090503163,0.000011690885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32131487,0.0024250268,0.66095454,0.00014107562,0.0003496517,0.00014539999,0.0005347192,0.00022832026,0.00022039574,0.0003502834,0.004479785,0.008855971],"study_design_scores_gemma":[0.47355217,0.002763585,0.5163193,0.00006681111,0.00030131426,0.000021058722,0.00023691748,0.00063292676,0.00005392554,0.00116352,0.004805383,0.00008313341],"about_ca_topic_score_codex":0.00010032641,"about_ca_topic_score_gemma":0.00034597542,"teacher_disagreement_score":0.1522373,"about_ca_system_score_codex":0.000581493,"about_ca_system_score_gemma":0.0014959114,"threshold_uncertainty_score":0.9979849},"labels":[],"label_agreement":null},{"id":"W4379339923","doi":"10.1200/jco.2023.41.16_suppl.12012","title":"Cost-utility of geriatric assessment in older adults with cancer: Results from the 5C trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Bruyère; University of Calgary; Western University; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Confidence interval; Guideline; Randomized controlled trial; Quality-adjusted life year; Health care; Imputation (statistics); Cost effectiveness; Demography; Gerontology; Missing data; Internal medicine; Statistics","score_opus":0.6431964274911245,"score_gpt":0.598384548890255,"score_spread":0.04481187860086944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90507454,0.0007133213,0.00023498411,0.08809644,0.0027870897,0.000990175,0.00040334655,0.000008692055,0.0016913948],"genre_scores_gemma":[0.990627,0.0020052076,0.0013496577,0.0042428733,0.0015598416,0.00005502351,0.000016880113,0.000016152724,0.00012737972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9821427,0.0019472528,0.015025394,0.00038158312,0.00019680875,0.0003062671],"domain_scores_gemma":[0.9593861,0.025033258,0.014716114,0.00043855855,0.00022944885,0.00019649009],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08029395,0.00013522695,0.0025563082,0.00023809988,0.000056640307,0.000017347795,0.00046933547,0.0003305645,0.00032716262],"category_scores_gemma":[0.023553051,0.0001032759,0.00030224488,0.00045685985,0.00015694117,0.00021474808,0.00006599433,0.0008761134,0.00008767589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05437498,0.0027646904,0.7304039,0.00016350157,0.0006331539,0.000049405015,0.0045827874,0.001133299,3.1195404e-7,0.0026778188,0.16768493,0.035531227],"study_design_scores_gemma":[0.05948479,0.0016151022,0.8947488,0.00016368098,0.000025940197,0.0000020578739,0.0013844365,0.0027116314,3.878137e-7,0.002739669,0.037012257,0.00011125835],"about_ca_topic_score_codex":0.0036308009,"about_ca_topic_score_gemma":0.0029973604,"teacher_disagreement_score":0.16434489,"about_ca_system_score_codex":0.00037909352,"about_ca_system_score_gemma":0.0024293528,"threshold_uncertainty_score":0.98467195},"labels":[],"label_agreement":null},{"id":"W4379339971","doi":"10.1200/jco.2023.41.16_suppl.7515","title":"Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cohort; Salvage therapy; Anthracycline; Chemotherapy; Cancer; Breast cancer","score_opus":0.021160036168766737,"score_gpt":0.32007736944883763,"score_spread":0.2989173332800709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955983,0.0013272351,0.00006650908,0.0013947963,0.00039602278,0.0009892747,0.000024467154,0.000090192785,0.00011316138],"genre_scores_gemma":[0.9861614,0.012145285,0.000714816,0.0005178376,0.00019474079,0.00004146722,0.000027975335,0.0000847879,0.00011165637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943981,0.0013050599,0.0022649122,0.00064902054,0.00076094846,0.0006219552],"domain_scores_gemma":[0.9954393,0.001138506,0.0022116958,0.00039507577,0.00030328624,0.0005121632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023082378,0.00049743336,0.0022249524,0.00047760623,0.00013060527,0.00003542362,0.00022463751,0.0006418701,0.000024108025],"category_scores_gemma":[0.00030419225,0.00032405625,0.00031765515,0.0005351915,0.00042525667,0.00021218532,0.000037643065,0.0008967143,0.000030040275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14567123,0.005210621,0.78174543,0.00012238463,0.00051652995,0.0039192946,0.0009926399,0.00006415914,0.00016455112,0.0000039529486,0.00022977601,0.061359394],"study_design_scores_gemma":[0.121760495,0.025052369,0.84528995,0.0017145262,0.0006372665,0.003707096,0.00030095238,0.00054213544,0.00036209653,0.000017456941,0.00031773385,0.00029791502],"about_ca_topic_score_codex":0.0002512901,"about_ca_topic_score_gemma":0.00044507722,"teacher_disagreement_score":0.0635445,"about_ca_system_score_codex":0.000663143,"about_ca_system_score_gemma":0.0025027767,"threshold_uncertainty_score":0.99992114},"labels":[],"label_agreement":null},{"id":"W4379339972","doi":"10.1200/jco.2023.41.16_suppl.10011","title":"Medicaid enrollment changes among U.S. adult survivors of childhood cancer following medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicaid; Medicine; Demography; Population; Cohort; Ethnic group; Cancer; Patient Protection and Affordable Care Act; Cohort study; Gerontology; Health care; Environmental health; Internal medicine","score_opus":0.08864839900342854,"score_gpt":0.38477999825073594,"score_spread":0.2961315992473074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379339972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95518845,0.009789128,0.00004109698,0.02120263,0.0113425385,0.0005659933,0.0002052142,0.00002854997,0.0016363674],"genre_scores_gemma":[0.9715614,0.020446274,0.00007449149,0.003473547,0.003935185,0.00009101972,0.000011277661,0.000056107147,0.0003507068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99261403,0.00030958856,0.005505232,0.0006258055,0.0003497349,0.0005955982],"domain_scores_gemma":[0.98889387,0.0025264455,0.0071661337,0.00063163775,0.00030708074,0.00047480967],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009786157,0.00034320384,0.0030987659,0.0002752137,0.00016876661,0.000036073874,0.0009812906,0.0005369677,0.0009986927],"category_scores_gemma":[0.0069258553,0.00025869784,0.00094265916,0.0005393835,0.00034093595,0.00039625878,0.00025614872,0.0012068457,0.000050061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022727625,0.0014141393,0.9307427,0.000010715645,0.0018359612,0.0003762138,0.0036291254,0.00010256143,0.0000025071538,0.00015382505,0.016275218,0.045229778],"study_design_scores_gemma":[0.004588515,0.0017164919,0.92790174,0.00017141741,0.00021016032,0.000012370449,0.0014913782,0.00006181717,0.000012698606,0.0014598045,0.062098052,0.00027553603],"about_ca_topic_score_codex":0.016492851,"about_ca_topic_score_gemma":0.027135976,"teacher_disagreement_score":0.045822833,"about_ca_system_score_codex":0.0002687715,"about_ca_system_score_gemma":0.0014002176,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W4379340099","doi":"10.1200/jco.2023.41.16_suppl.11524","title":"Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Sunitinib; GiST; Discontinuation; Internal medicine; Imatinib; Adverse effect; Interim analysis; Clinical endpoint; Oncology; Population; Imatinib mesylate; Tyrosine-kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Cancer; Stromal cell","score_opus":0.0876221049838368,"score_gpt":0.44013897513082545,"score_spread":0.3525168701469886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831283,0.00003951347,0.00013539629,0.00073539774,0.000047983827,0.0005062811,0.000031337466,0.000030480644,0.00016077666],"genre_scores_gemma":[0.98735,0.000054320037,0.012132616,0.00008356689,0.00013864413,0.0000067086025,0.00015413036,0.000030870837,0.00004916654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961987,0.00050478353,0.0017350125,0.0003635129,0.00065852766,0.00053943077],"domain_scores_gemma":[0.9956291,0.0016507844,0.0011624611,0.00021537626,0.0006186037,0.000723714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010592506,0.00027468876,0.0017334907,0.00028294374,0.00004509848,0.000021278523,0.000143599,0.00006352173,0.000112728485],"category_scores_gemma":[0.0019141246,0.00015815812,0.00016776554,0.0003988342,0.00029256087,0.00017134681,0.00007689171,0.0009851735,0.00001374331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055678044,0.0020206464,0.920106,0.000025721067,0.00034458988,0.011683171,0.000013333925,0.000044994318,0.000085166444,0.000003784583,0.00007330943,0.009921231],"study_design_scores_gemma":[0.035154972,0.06795937,0.89449614,0.0008106416,0.00032884537,0.00089140615,0.000051298706,0.00013180239,0.000025089576,0.000021882708,0.000019904748,0.0001086598],"about_ca_topic_score_codex":0.000109062225,"about_ca_topic_score_gemma":0.00028416436,"teacher_disagreement_score":0.06593872,"about_ca_system_score_codex":0.00021623261,"about_ca_system_score_gemma":0.000905652,"threshold_uncertainty_score":0.6449501},"labels":[],"label_agreement":null},{"id":"W4379340103","doi":"10.1200/jco.2023.41.16_suppl.e22003","title":"Novel biomarkers to predict chronic kidney disease and hypertension at 3 and 12 months post-cisplatin.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; University of Manitoba; CancerCare Manitoba; BC Children's Hospital; McGill University Health Centre; University of British Columbia; Hospital for Sick Children","funders":"","keywords":"Medicine; Renal function; Kidney disease; Lipocalin; Acute kidney injury; Internal medicine; Creatinine; Cisplatin; Urology; Nephrotoxicity; Gastroenterology; Biomarker; Kidney; Chemotherapy","score_opus":0.07510347908231652,"score_gpt":0.39294391494819925,"score_spread":0.31784043586588273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9274115,0.00022324434,0.00003823416,0.071349084,0.0005262279,0.000286201,0.000019295037,0.000024987783,0.000121202575],"genre_scores_gemma":[0.98407716,0.00092018105,0.0015766284,0.012062756,0.0010628713,0.0000025295562,0.00001435148,0.000029964714,0.00025357533],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99796325,0.00011253576,0.0011400313,0.00024532404,0.00031742308,0.00022146119],"domain_scores_gemma":[0.9963521,0.001230868,0.00053397455,0.00016504017,0.00023257373,0.0014854926],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014931078,0.00013596934,0.0007862865,0.00019824762,0.00006226713,0.000009386529,0.00007053334,0.0002768967,0.00008622752],"category_scores_gemma":[0.008506841,0.00010355165,0.00016425409,0.00017747062,0.0001793194,0.000094727584,0.00010794089,0.0004065047,0.000022761335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013744322,0.00086399016,0.103595726,0.00017859832,0.0007378566,0.0011686418,0.0002827684,0.000010449551,0.6013896,0.0000132757,0.06980492,0.20820989],"study_design_scores_gemma":[0.012227747,0.007950218,0.95143807,0.0002950027,0.0004256129,0.00074152066,0.00006738801,0.0018937151,0.0018735086,0.000066042514,0.022892656,0.00012849936],"about_ca_topic_score_codex":0.000016581742,"about_ca_topic_score_gemma":0.00004110354,"teacher_disagreement_score":0.84784234,"about_ca_system_score_codex":0.0002263456,"about_ca_system_score_gemma":0.0011585002,"threshold_uncertainty_score":0.9998449},"labels":[],"label_agreement":null},{"id":"W4379340293","doi":"10.1200/jco.2023.41.16_suppl.e18661","title":"Examination of current status of cross-provincial border access for clinical trials for patients with cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Windsor; Western University","funders":"National Research Council Canada; TD Bank","keywords":"Clinical trial; Medicine; Referral; Cancer; CLARITY; Family medicine; Internal medicine","score_opus":0.8964569137876871,"score_gpt":0.8064212177429483,"score_spread":0.09003569604473882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886954,0.00033898372,0.0017009929,0.0022972461,0.0044235974,0.001993964,0.0003124699,0.000009587044,0.00022777452],"genre_scores_gemma":[0.98029757,0.011609203,0.0037840784,0.00038018666,0.0034144605,0.00009939037,0.00005096972,0.000046850757,0.00031729505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98504436,0.0019786493,0.010536309,0.00038911184,0.0015231617,0.00052840094],"domain_scores_gemma":[0.6905198,0.2828455,0.010748053,0.00041223058,0.014705862,0.00076858274],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09211927,0.0001589855,0.0035069576,0.00026619423,0.00005338044,0.000016933664,0.00048537907,0.0010341895,0.00010182584],"category_scores_gemma":[0.5759447,0.00010218568,0.0012296734,0.00038188475,0.0010909147,0.00019670321,0.00017839823,0.0022345209,0.0000017290515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030422032,0.003267297,0.4836655,0.0006816848,0.00042267703,0.0000047165568,0.00004299912,0.000016681726,0.000008739916,0.0005337898,0.0024726815,0.4784612],"study_design_scores_gemma":[0.034658913,0.04405929,0.8795457,0.0005080753,0.00060215185,8.4115203e-7,0.00003784698,0.00023372253,0.00008369012,0.004066801,0.03610877,0.00009418249],"about_ca_topic_score_codex":0.000025852203,"about_ca_topic_score_gemma":0.00019255755,"teacher_disagreement_score":0.48382545,"about_ca_system_score_codex":0.00017574523,"about_ca_system_score_gemma":0.0112815825,"threshold_uncertainty_score":0.99432355},"labels":[],"label_agreement":null},{"id":"W4379340344","doi":"10.1200/jco.2023.41.16_suppl.12084","title":"Social determinants of health and neurocognitive and psychosocial outcomes in adult childhood cancer survivors: A report from the childhood cancer survivor study (CCSS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Neurocognitive; Psychosocial; Quality of life (healthcare); Anxiety; Somatization; Pediatric cancer; Depression (economics); Cancer; Psychiatry; Gerontology; Clinical psychology; Cognition; Internal medicine","score_opus":0.1548463025667613,"score_gpt":0.5288021134280056,"score_spread":0.37395581086124435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342851,0.0018476907,0.0000018530383,0.060841873,0.00181346,0.0010382582,0.00010408407,0.000018418374,0.000049252096],"genre_scores_gemma":[0.9811612,0.005825092,0.000043290132,0.010808083,0.002017963,0.000047166697,0.0000062342183,0.000045822668,0.00004515925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903837,0.0026591362,0.004994731,0.000560144,0.0009226974,0.00047958182],"domain_scores_gemma":[0.988481,0.005743352,0.004542845,0.00026862053,0.00055842806,0.00040577239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00800534,0.00032272693,0.0036308658,0.00020171212,0.00017495143,0.000020036034,0.00027185588,0.00036163663,0.00003783724],"category_scores_gemma":[0.008327387,0.0002222314,0.00042321777,0.0005027356,0.00046704727,0.00016744941,0.00019561627,0.0015324033,0.000001891932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011518507,0.0029268365,0.90235347,0.0000470149,0.00066979555,0.00036264735,0.021881402,5.890006e-7,0.000001774549,0.00000266315,0.0018426699,0.0687593],"study_design_scores_gemma":[0.012770426,0.0044524726,0.9692954,0.00039384328,0.00033659468,0.00009345133,0.011005749,0.000006882221,0.0000032236971,0.00022098438,0.0012420976,0.0001788959],"about_ca_topic_score_codex":0.027211921,"about_ca_topic_score_gemma":0.12079105,"teacher_disagreement_score":0.09357913,"about_ca_system_score_codex":0.000120994,"about_ca_system_score_gemma":0.003575827,"threshold_uncertainty_score":0.99692625},"labels":[],"label_agreement":null},{"id":"W4379340377","doi":"10.1200/jco.2023.41.16_suppl.8503","title":"Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer research; Cancer; Immunotherapy","score_opus":0.39782845581144777,"score_gpt":0.6052007752304426,"score_spread":0.2073723194189948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278,0.0004302927,0.00011882556,0.0047009173,0.0007897564,0.00082057534,0.000040597562,0.000009944175,0.00030903541],"genre_scores_gemma":[0.9978484,0.00054471235,0.00018681273,0.00052463484,0.00031666056,0.000028041966,0.0000027868398,0.000019942981,0.0005280271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99485236,0.00083781267,0.002865058,0.00024428076,0.00089088466,0.00030962515],"domain_scores_gemma":[0.988925,0.0059212404,0.0023950366,0.00049211987,0.00202496,0.00024168107],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058024153,0.00015312951,0.0026984185,0.0005157594,0.00007566591,0.000004596357,0.00037116223,0.00019387738,0.00006475961],"category_scores_gemma":[0.014897692,0.000088005945,0.0013022382,0.0015117561,0.0005242266,0.0000826837,0.00025133826,0.0006301601,0.0000029522614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18300794,0.032809086,0.3857148,0.001185368,0.104071036,0.0028177176,0.011655224,0.0027388625,0.016574526,0.00017848975,0.117830314,0.14141664],"study_design_scores_gemma":[0.076601684,0.0476495,0.8240867,0.00020769835,0.013637347,0.00002296631,0.011903855,0.004475902,0.000789327,0.00013964188,0.020309707,0.00017563792],"about_ca_topic_score_codex":0.000044574295,"about_ca_topic_score_gemma":0.00021178476,"teacher_disagreement_score":0.43837193,"about_ca_system_score_codex":0.0002495694,"about_ca_system_score_gemma":0.002415312,"threshold_uncertainty_score":0.9934002},"labels":[],"label_agreement":null},{"id":"W4379340490","doi":"10.1200/jco.2023.41.16_suppl.e18034","title":"PORTO-001 study: Changes in the oral microbiome and matrix metalloproteinases in patients with oropharyngeal squamous cell carcinoma undergoing definitive chemoradiotherapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Mucositis; Medicine; Internal medicine; Gastroenterology; Head and neck cancer; Chemoradiotherapy; Cancer; Population; Stage (stratigraphy); Oncology; Saliva; Radiation therapy","score_opus":0.0808311032665748,"score_gpt":0.40751802156330463,"score_spread":0.3266869182967298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427754,0.0008549642,3.9056803e-7,0.003816833,0.00019247086,0.0005461978,0.0000046676614,0.000006343928,0.00030056562],"genre_scores_gemma":[0.9978613,0.00044839876,0.00021719674,0.001178456,0.0001842679,0.000014520252,0.000003449307,0.000016864738,0.00007551537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978231,0.00046537456,0.0009684369,0.0001968802,0.00027548868,0.0002706892],"domain_scores_gemma":[0.99735415,0.001745002,0.0005361996,0.000111576475,0.00014640158,0.000106658095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002304656,0.00014927801,0.0014593625,0.00025248958,0.00004320857,0.000009017621,0.000110728,0.00012740116,0.00002048761],"category_scores_gemma":[0.0004925713,0.00008259706,0.00008304837,0.0004163016,0.00015908177,0.00006198849,0.000047895464,0.0006097613,0.0000034473399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004588851,0.0035584008,0.97656614,0.000067959176,0.000086796,0.0025315697,0.0013317908,0.000001347913,0.00006752876,0.000003046868,0.0004656108,0.0107309725],"study_design_scores_gemma":[0.027422622,0.039633777,0.9291473,0.000054597847,0.00014893015,0.000057719826,0.0021680177,0.0000037073228,0.00003099544,0.000017172759,0.0012294034,0.00008576117],"about_ca_topic_score_codex":0.00013417169,"about_ca_topic_score_gemma":0.0030904287,"teacher_disagreement_score":0.04741883,"about_ca_system_score_codex":0.000111030444,"about_ca_system_score_gemma":0.0005243326,"threshold_uncertainty_score":0.33682102},"labels":[],"label_agreement":null},{"id":"W4379340492","doi":"10.1200/jco.2023.41.16_suppl.12135","title":"Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Queen's University","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Gemcitabine; Toxicity; Internal medicine; Randomized controlled trial; Cancer; Oncology; Surgery","score_opus":0.31545422589029176,"score_gpt":0.4544405815159518,"score_spread":0.13898635562566003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97151273,0.000999602,0.000015830363,0.008299543,0.0015570661,0.00021946526,0.000020034004,0.000003884649,0.017371826],"genre_scores_gemma":[0.9945216,0.0025143106,0.00005019293,0.0012700313,0.0008747083,0.000012159661,9.0427346e-7,0.000009692166,0.00074635295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965688,0.00016616557,0.0028199765,0.00014928872,0.00005807099,0.00023772134],"domain_scores_gemma":[0.9948489,0.0019570875,0.0028497549,0.00021953094,0.000052145835,0.00007256736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007284751,0.000102714286,0.0013356269,0.0001397103,0.00005090991,0.000018078777,0.00053611235,0.00020073575,0.0002022227],"category_scores_gemma":[0.0018179041,0.00006342263,0.0004155881,0.00022675918,0.00017792237,0.00016252903,0.000057096622,0.00049895566,0.00013800185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014752584,0.0023831956,0.8478293,0.000023106626,0.0008531834,0.00008030126,0.001588646,0.0019563395,0.000014135576,0.02297977,0.037667878,0.069871604],"study_design_scores_gemma":[0.023312794,0.002586807,0.8380974,0.000028544866,0.00005059098,0.000005820594,0.00011257265,0.0010120183,0.000012106278,0.016695844,0.117974706,0.0001107967],"about_ca_topic_score_codex":0.00034663238,"about_ca_topic_score_gemma":0.00045571467,"teacher_disagreement_score":0.08030683,"about_ca_system_score_codex":0.00016103932,"about_ca_system_score_gemma":0.00030491524,"threshold_uncertainty_score":0.25862998},"labels":[],"label_agreement":null},{"id":"W4379340511","doi":"10.1200/jco.2023.41.16_suppl.tps9160","title":"Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital; BC Cancer Agency; William Osler Health System; Lions Gate Hospital; Grand River Hospital; McMaster University; University of Toronto; University Health Network; Western University","funders":"","keywords":"Osimertinib; Medicine; Pemetrexed; T790M; Oncology; Lung cancer; Docetaxel; Internal medicine; Chemotherapy; Erlotinib; Gefitinib; Epidermal growth factor receptor; Cancer; Cisplatin","score_opus":0.11977918865227226,"score_gpt":0.5251163492424061,"score_spread":0.40533716059013386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92612463,0.0020612762,0.00006394092,0.06570437,0.0009153784,0.0005175663,0.000008532519,0.00005732732,0.0045469906],"genre_scores_gemma":[0.9808234,0.009910587,0.0013569411,0.005131867,0.0009863755,0.000044309705,0.000012543976,0.000053564363,0.0016804375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968618,0.00024664635,0.001897536,0.00026356874,0.00037503033,0.00035540815],"domain_scores_gemma":[0.99681526,0.0011130418,0.0011543976,0.00021164988,0.0003908246,0.00031481162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018515898,0.00019400785,0.0013437546,0.00024521112,0.00004772329,0.000008645317,0.00015682254,0.00033152383,0.00030269087],"category_scores_gemma":[0.00057810405,0.00011844572,0.00027604876,0.0005451753,0.00013851315,0.000116650444,0.00002688222,0.0009165855,0.00002765665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02378889,0.0059937215,0.45897844,0.00018447831,0.0054859864,0.003728059,0.0044580353,0.001452851,0.0007883017,0.00016271586,0.040166147,0.45481238],"study_design_scores_gemma":[0.05036097,0.016674235,0.8428669,0.0008797604,0.00165634,0.0002620863,0.00098312,0.0016619012,0.0004978882,0.0003525532,0.08348652,0.0003177355],"about_ca_topic_score_codex":0.0001266626,"about_ca_topic_score_gemma":0.0001745511,"teacher_disagreement_score":0.45449463,"about_ca_system_score_codex":0.00034282877,"about_ca_system_score_gemma":0.0025591503,"threshold_uncertainty_score":0.48300764},"labels":[],"label_agreement":null},{"id":"W4379340597","doi":"10.1200/jco.2023.41.16_suppl.tps12137","title":"The FARGO study: Frailty assessment for risk prediction in gynecologic oncology.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; Princess Margaret Cancer Centre; Hamilton Health Sciences; University Health Network; Credit Valley Hospital; Health Sciences Centre; Sinai Health System; Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Medicine; Gynecologic oncology; Perioperative; Biomarker; Internal medicine; Population; Malignancy; Risk assessment; Oncology; Intensive care medicine; Surgery","score_opus":0.22172334442143243,"score_gpt":0.547736739252483,"score_spread":0.3260133948310506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95632434,0.00011337444,0.00036595066,0.032636236,0.0057117552,0.0014848725,0.000017336139,0.000045892586,0.0033002154],"genre_scores_gemma":[0.9905431,0.0013538055,0.0033894936,0.0012012783,0.0017140795,0.00011515916,0.0000069868383,0.000024239765,0.0016518191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99360365,0.001622979,0.003553976,0.00028396593,0.0004963522,0.0004390595],"domain_scores_gemma":[0.9703269,0.026244655,0.0022622216,0.0003194554,0.00056366395,0.0002830859],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021407446,0.0001630007,0.0014861645,0.00021609748,0.00016776222,0.000015111231,0.00033820063,0.00060688145,0.00007239596],"category_scores_gemma":[0.032909382,0.00009627716,0.0005035914,0.00041106227,0.00026037928,0.00009958465,0.0001166104,0.0022335171,0.000052072395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023897525,0.0033811864,0.55030364,0.000013752003,0.0004055359,0.00048540672,0.00023262335,0.00017025541,0.000019084466,0.000051044386,0.049325064,0.39322263],"study_design_scores_gemma":[0.01349489,0.044222496,0.703524,0.000030237305,0.0002979851,0.000072307004,0.0015608267,0.0016580599,0.0000025593538,0.0015327226,0.23354669,0.00005722569],"about_ca_topic_score_codex":0.0000282186,"about_ca_topic_score_gemma":0.00089566177,"teacher_disagreement_score":0.3931654,"about_ca_system_score_codex":0.0007267035,"about_ca_system_score_gemma":0.0027553292,"threshold_uncertainty_score":0.97523683},"labels":[],"label_agreement":null},{"id":"W4379340800","doi":"10.1200/jco.2023.41.16_suppl.10005","title":"Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Stollery Children's Hospital","funders":"","keywords":"Medicine; Vincristine; Nephrectomy; Wilms' tumor; Etoposide; Stage (stratigraphy); Radiation therapy; Chemotherapy; Cyclophosphamide; Surgery; Internal medicine; Oncology; Kidney","score_opus":0.07960359844800521,"score_gpt":0.4307159259402512,"score_spread":0.35111232749224597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860873,0.008748068,0.00004291179,0.0030174966,0.0016563785,0.00018283293,0.00002080816,0.000006070772,0.00023808407],"genre_scores_gemma":[0.97818726,0.01902471,0.0003077719,0.00053633784,0.0016953433,0.00001315113,0.000035193367,0.000017056094,0.00018317635],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969391,0.00043498946,0.0018384774,0.00032472503,0.00020926344,0.00025343557],"domain_scores_gemma":[0.9961675,0.0013885474,0.0017558415,0.00025839414,0.00022396835,0.00020579592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010658709,0.00019181691,0.0011613482,0.000055617456,0.00007244335,0.0000064958704,0.00022103332,0.00042963022,0.000011046859],"category_scores_gemma":[0.001817116,0.00010391115,0.00046322026,0.00014226712,0.0006479834,0.000005856297,0.00012633979,0.00037966346,0.0000050967324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016045727,0.003694845,0.2908965,0.000046179106,0.017089522,0.009068682,0.0009668264,0.0007452982,0.015450319,0.000083630475,0.08108786,0.56482464],"study_design_scores_gemma":[0.018431127,0.1033277,0.5098692,0.00018087914,0.0022287483,0.006244011,0.0018715545,0.00017879334,0.0029751852,0.0014942075,0.35269794,0.0005006349],"about_ca_topic_score_codex":0.00007721076,"about_ca_topic_score_gemma":0.00024586404,"teacher_disagreement_score":0.56432396,"about_ca_system_score_codex":0.000082629136,"about_ca_system_score_gemma":0.0008100099,"threshold_uncertainty_score":0.42373738},"labels":[],"label_agreement":null},{"id":"W4379341007","doi":"10.1200/jco.2023.41.16_suppl.12001","title":"Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Mount Sinai Hospital","funders":"National Institutes of Health","keywords":"Medicine; Breast cancer; Weight loss; Weight change; Body mass index; Internal medicine; Cancer; Randomized controlled trial; Obesity; Gynecology","score_opus":0.036754753902847624,"score_gpt":0.4060768622442863,"score_spread":0.3693221083414387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97200036,0.00036192816,0.000007347285,0.023149591,0.002775938,0.00078643434,0.0007377215,0.000022988097,0.00015769422],"genre_scores_gemma":[0.9923434,0.003006893,0.000016916494,0.0008679214,0.0032995506,0.00010170963,0.0000199443,0.000051673363,0.00029194297],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99344987,0.0014076727,0.0032138373,0.00049419265,0.000873098,0.00056134374],"domain_scores_gemma":[0.9896211,0.006117237,0.0029872025,0.00048094685,0.00033490575,0.000458586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005408856,0.00036346522,0.002471957,0.0002895558,0.000076741366,0.000016620183,0.00040594948,0.0005251414,0.00067203696],"category_scores_gemma":[0.00065915554,0.00019051539,0.0007420325,0.00062090706,0.0004760589,0.00013555032,0.00009348926,0.0015762971,0.000025414678],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5469909,0.0011249619,0.31041586,0.000056674133,0.00064437924,0.0007547224,0.00035900838,0.00007775738,0.00005934894,0.0000023941072,0.0059573282,0.13355672],"study_design_scores_gemma":[0.17599109,0.024307122,0.78104895,0.0017027613,0.00047482384,0.0001019235,0.000038278045,0.00009200491,0.00031687407,0.00003791848,0.015709285,0.00017897882],"about_ca_topic_score_codex":0.0071144076,"about_ca_topic_score_gemma":0.008150757,"teacher_disagreement_score":0.4706331,"about_ca_system_score_codex":0.0015019713,"about_ca_system_score_gemma":0.001600399,"threshold_uncertainty_score":0.9994973},"labels":[],"label_agreement":null},{"id":"W4379341012","doi":"10.1200/jco.2023.41.16_suppl.12100","title":"Patient- versus clinician-reported symptoms in the POLARIX study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); University of Alberta","funders":"","keywords":"Medicine; Constipation; Nausea; Adverse effect; Vomiting; Placebo; Common Terminology Criteria for Adverse Events; Incidence (geometry); MedDRA; Quality of life (healthcare); Internal medicine; Diarrhea; Clinical trial; Physical therapy; Pharmacovigilance; Alternative medicine","score_opus":0.2938817515610744,"score_gpt":0.5797884005485378,"score_spread":0.2859066489874634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977811,0.00020077321,7.373311e-7,0.011801362,0.0054044933,0.00043108503,0.0000017334805,0.000015374531,0.0043334425],"genre_scores_gemma":[0.9946382,0.00032639495,0.000045578876,0.0033190984,0.0014133886,0.000011625669,0.000004364411,0.000011874116,0.00022949411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564064,0.0009439899,0.0025801896,0.00017459727,0.0004002987,0.00026029727],"domain_scores_gemma":[0.9922622,0.0058128703,0.0013361439,0.00021386895,0.0001978369,0.00017709345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004845752,0.00011916438,0.0011081805,0.00021245782,0.000040031588,0.0000067746814,0.00017321877,0.00026079742,0.0002032934],"category_scores_gemma":[0.0027948064,0.000068694426,0.00042875775,0.00052897044,0.0001258587,0.000059640803,0.000051316136,0.0012045183,0.00009082427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020616896,0.010951843,0.7165704,0.0000071308586,0.0014204135,0.0121312635,0.0015449726,0.000013092221,0.000033475666,0.000030215688,0.029839074,0.20684123],"study_design_scores_gemma":[0.028450623,0.06724744,0.78772646,0.000019207959,0.00090091117,0.00020313579,0.0016799805,0.000028900753,0.000004017592,0.00009721147,0.11357972,0.000062395186],"about_ca_topic_score_codex":0.00006540481,"about_ca_topic_score_gemma":0.00028680704,"teacher_disagreement_score":0.20677884,"about_ca_system_score_codex":0.00012943111,"about_ca_system_score_gemma":0.0011419966,"threshold_uncertainty_score":0.52330995},"labels":[],"label_agreement":null},{"id":"W4379341100","doi":"10.1200/jco.2023.41.16_suppl.e20021","title":"Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Neutropenia; KRAS; Oncology; Adverse effect; Minimal residual disease; Gastroenterology; Bone marrow; Immunology; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.09913919666111909,"score_gpt":0.471155325907031,"score_spread":0.37201612924591193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926976,0.00021622537,0.0000835742,0.0051687527,0.00058856636,0.0010602025,0.00003141438,0.000014433041,0.00013926366],"genre_scores_gemma":[0.98749447,0.0006609143,0.010102964,0.0006731036,0.00019457725,0.00006364655,0.0000339718,0.000030669416,0.0007457057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737763,0.00024172696,0.0014237306,0.00024495987,0.0003268205,0.00038509932],"domain_scores_gemma":[0.98813677,0.010326133,0.00061804237,0.0001608695,0.00038239703,0.00037580312],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020810906,0.00015521856,0.0012473318,0.00030713357,0.000051880506,0.000012644192,0.00012456575,0.00035863864,0.000018181501],"category_scores_gemma":[0.037686918,0.00009581021,0.00037126226,0.00017024754,0.00010109253,0.00011162551,0.00005845121,0.00053270475,0.000004578758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02095516,0.0014400115,0.60061663,0.00012064573,0.00033892976,0.0007554113,0.00007410798,0.000004479032,0.00015636941,0.000015771504,0.0060449736,0.36947754],"study_design_scores_gemma":[0.047296897,0.019735415,0.91547966,0.00010844542,0.00012016759,0.000036337315,0.00007786017,0.0004938449,0.00004443015,0.00022656698,0.016295893,0.000084476866],"about_ca_topic_score_codex":0.000018219056,"about_ca_topic_score_gemma":0.00018290395,"teacher_disagreement_score":0.36939305,"about_ca_system_score_codex":0.00012758045,"about_ca_system_score_gemma":0.000561133,"threshold_uncertainty_score":0.97041905},"labels":[],"label_agreement":null},{"id":"W4379341117","doi":"10.1200/jco.2023.41.16_suppl.6593","title":"Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cohort; Toxicity; Cancer; Population; Colorectal cancer; Acute toxicity; Emergency medicine; Internal medicine; Environmental health","score_opus":0.40066355382058505,"score_gpt":0.5053217211604071,"score_spread":0.10465816733982203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936568,0.0018902516,0.00025070095,0.0020541584,0.0011526486,0.00022288956,0.000067650944,0.000004763654,0.0007001034],"genre_scores_gemma":[0.9968767,0.0016885448,0.00011661552,0.0007503143,0.00051665725,0.00001986024,0.000005251429,0.0000089069745,0.000017125818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562293,0.00035785747,0.0034716262,0.00017010584,0.00020082125,0.0001766421],"domain_scores_gemma":[0.99301404,0.0020195665,0.00423571,0.00013601917,0.00054739945,0.00004729581],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.029769188,0.000088909954,0.0009420269,0.00019414758,0.00005367183,0.000023185046,0.000290926,0.00022676379,0.00008008414],"category_scores_gemma":[0.005887366,0.00007364872,0.00031600648,0.00031594574,0.00005774733,0.0003129644,0.00001668359,0.00031699974,0.000024373017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002706725,0.00026253329,0.95311075,0.000023067305,0.000104582585,0.0000016286372,0.00065316417,0.02016917,0.000035325098,0.0060522053,0.00035254552,0.018964376],"study_design_scores_gemma":[0.0028804215,0.00027204552,0.9808087,0.000039869767,0.000006754495,0.0000013002716,0.00012256109,0.004148583,0.00000523814,0.010857143,0.00077579304,0.00008160963],"about_ca_topic_score_codex":0.00065227994,"about_ca_topic_score_gemma":0.00014685259,"teacher_disagreement_score":0.027697952,"about_ca_system_score_codex":0.00038423514,"about_ca_system_score_gemma":0.00081281987,"threshold_uncertainty_score":0.9990568},"labels":[],"label_agreement":null},{"id":"W4379341221","doi":"10.1200/jco.2023.41.16_suppl.8523","title":"Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Oncology; KRAS; Lung cancer; Gemcitabine; Hazard ratio; Ipilimumab; Exact test; Cancer; Confidence interval; Immunotherapy; Colorectal cancer","score_opus":0.07769800303543296,"score_gpt":0.4769410763487024,"score_spread":0.39924307331326947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629655,0.0012316045,0.00009185404,0.03219971,0.0016693522,0.0007227955,0.000014215825,0.000021975784,0.001083027],"genre_scores_gemma":[0.9886258,0.0014564645,0.0029160662,0.003770491,0.00096274423,0.00008827712,0.000007260914,0.000045592853,0.0021272597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610746,0.00054913544,0.0022633332,0.00028605293,0.00036816663,0.00042584245],"domain_scores_gemma":[0.9960152,0.0018556495,0.0009138544,0.0002881141,0.00045611098,0.00047106124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037532677,0.000193163,0.0013352982,0.00047306833,0.000061322295,0.000013000492,0.00019902526,0.00032569276,0.00018722728],"category_scores_gemma":[0.0011711713,0.00013760576,0.0004999549,0.0006684432,0.000087796114,0.00007008047,0.00005609838,0.0007867043,0.000055527467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13875902,0.008973107,0.3381705,0.00019485867,0.0015387058,0.009109395,0.005364609,0.011813833,0.2799408,0.000008016447,0.037414603,0.16871254],"study_design_scores_gemma":[0.06190703,0.034834057,0.7138554,0.001262059,0.0005995665,0.00006355454,0.0009099695,0.0027428288,0.022136662,0.000037074693,0.1612966,0.00035520334],"about_ca_topic_score_codex":0.00035900756,"about_ca_topic_score_gemma":0.0003212182,"teacher_disagreement_score":0.3756849,"about_ca_system_score_codex":0.0008223631,"about_ca_system_score_gemma":0.0072952653,"threshold_uncertainty_score":0.99833244},"labels":[],"label_agreement":null},{"id":"W4379341253","doi":"10.1200/jco.2023.41.16_suppl.7518","title":"Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC","funders":"","keywords":"Medicine; Vincristine; Internal medicine; Rituximab; Prednisone; Hazard ratio; CHOP; International Prognostic Index; Cyclophosphamide; Gastroenterology; Diffuse large B-cell lymphoma; Confidence interval; Lymphoma; Surgery; Oncology; Chemotherapy","score_opus":0.07306567624849852,"score_gpt":0.44908758379917674,"score_spread":0.3760219075506782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973834,0.000111589085,0.000007779849,0.0013935221,0.00021710599,0.00039669932,0.000020348525,0.000006738709,0.00046280003],"genre_scores_gemma":[0.9985762,0.00022162465,0.00009788329,0.0008618295,0.00013538434,0.000012754703,0.00002126285,0.000012574646,0.000060491628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959635,0.00072900526,0.0021263957,0.00021531575,0.00068027136,0.00028548858],"domain_scores_gemma":[0.9947515,0.0028768736,0.0014864905,0.00034189806,0.0003284071,0.00021480175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003328962,0.0001614867,0.0018169228,0.00051932206,0.000042404172,0.000010663383,0.00023747933,0.00019215763,0.000042130952],"category_scores_gemma":[0.00087740936,0.00008037981,0.0006421092,0.001371328,0.000095048425,0.00007683923,0.000049825852,0.00028983256,0.000015741043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002992659,0.19158822,0.7599975,0.0000100255,0.0020629752,0.0017483557,0.0007658801,0.000003528528,0.000003563828,0.000017240567,0.0007294947,0.040080573],"study_design_scores_gemma":[0.14315797,0.04674938,0.80029076,0.000027315642,0.004510616,0.000015498697,0.0011594968,0.00010310983,0.000008858056,0.000012353489,0.0039035885,0.00006106027],"about_ca_topic_score_codex":0.00014136282,"about_ca_topic_score_gemma":0.00065505935,"teacher_disagreement_score":0.14483884,"about_ca_system_score_codex":0.00017166756,"about_ca_system_score_gemma":0.0005797332,"threshold_uncertainty_score":0.32777935},"labels":[],"label_agreement":null},{"id":"W4379341453","doi":"10.1200/jco.2023.41.16_suppl.e18016","title":"Chronotherapy in head and neck cancer (HNC): A systematic review.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Dalhousie University; McGill University Health Centre","funders":"","keywords":"Medicine; Chronotherapy (sleep phase); Radiation therapy; Randomized controlled trial; Head and neck cancer; Systematic review; Internal medicine; Cancer; Oncology; Chemotherapy; Clinical trial; Adverse effect; CINAHL; Psychological intervention; MEDLINE; Morning","score_opus":0.19447922034292023,"score_gpt":0.559438125921726,"score_spread":0.36495890557880584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341453","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8282219,0.11338681,0.0000030795086,0.05562769,0.0008875694,0.00052146503,0.0000018157587,0.000011815558,0.0013378282],"genre_scores_gemma":[0.33394185,0.6387745,0.00032727668,0.024850454,0.0010199206,0.000048323316,5.0962194e-7,0.000019683348,0.0010174989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972071,0.00028292165,0.0020301696,0.00011365754,0.00019479364,0.00017137922],"domain_scores_gemma":[0.997621,0.0012181621,0.0007402016,0.00010672574,0.00014378884,0.0001701454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033827052,0.00008631788,0.0026368925,0.000103681865,0.000018589442,0.000002544269,0.000065233704,0.00013503159,0.00005923623],"category_scores_gemma":[0.0027768076,0.00005271833,0.0002079898,0.00024634006,0.00008709992,0.00004163243,0.000025055204,0.0004924593,0.000019365632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041687908,0.0019141207,0.4078149,0.24462526,0.001899943,0.0040410073,0.0013564718,0.0000071347613,0.00018127065,0.00013902743,0.19420567,0.13964643],"study_design_scores_gemma":[0.016408995,0.015787395,0.67766523,0.21336673,0.000906022,0.00042931124,0.00021147857,0.00012944582,0.000009414358,0.00020250204,0.07470867,0.00017480942],"about_ca_topic_score_codex":0.000037477304,"about_ca_topic_score_gemma":0.0002915053,"teacher_disagreement_score":0.5253877,"about_ca_system_score_codex":0.00011829724,"about_ca_system_score_gemma":0.0007981853,"threshold_uncertainty_score":0.33242986},"labels":[],"label_agreement":null},{"id":"W4379341468","doi":"10.1200/jco.2023.41.16_suppl.e20636","title":"Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Conventional PCI; Prophylactic cranial irradiation; Hazard ratio; Internal medicine; Meta-analysis; Retrospective cohort study; Lung cancer; Oncology; Magnetic resonance imaging; Surgery; Radiology; Confidence interval; Myocardial infarction","score_opus":0.23733862060632313,"score_gpt":0.540150651919288,"score_spread":0.30281203131296486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013098326,0.99301475,7.1793835e-7,0.0027498698,0.00013746762,0.0038767282,0.000021367629,0.0000023680989,0.000065728986],"genre_scores_gemma":[0.0007822834,0.9976182,0.00008214467,0.00081954384,0.00012728863,0.00041394957,0.0000036470128,0.000024901185,0.00012804318],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9878635,0.0044913907,0.006370136,0.000321482,0.0006756122,0.00027789018],"domain_scores_gemma":[0.9872053,0.0064890548,0.0052427384,0.00036337055,0.00057201344,0.00012749305],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011627051,0.00029193528,0.0154868355,0.00047135004,0.00002103685,0.000011753341,0.0003956567,0.00023770193,0.000041701514],"category_scores_gemma":[0.010638293,0.00013961594,0.0022414196,0.0014375884,0.00017373964,0.000060055998,0.00010186053,0.0022652908,0.0000029038154],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012971992,0.000803443,0.0040419814,0.95343083,0.013481409,0.00034506095,0.0001679403,0.0000011088599,1.1104812e-8,0.0000030723606,0.0004669466,0.02712849],"study_design_scores_gemma":[0.0022167885,0.002153386,0.016763303,0.06270133,0.9041354,0.000036242967,0.000027648124,0.00003187557,7.3838105e-9,0.000018144421,0.011760765,0.00015510558],"about_ca_topic_score_codex":0.00022175218,"about_ca_topic_score_gemma":0.0006901363,"teacher_disagreement_score":0.8907295,"about_ca_system_score_codex":0.00046954027,"about_ca_system_score_gemma":0.0024845263,"threshold_uncertainty_score":0.9991293},"labels":[],"label_agreement":null},{"id":"W4379341601","doi":"10.1200/jco.2023.41.16_suppl.8596","title":"Brain metastasis burden and management in small cell lung cancer: An analysis of 8705 patients.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University Health Network; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiosurgery; Hazard ratio; Brain metastasis; Confidence interval; Lung cancer; Internal medicine; Radiation therapy; Incidence (geometry); Chemotherapy; Population; Oncology; Cancer; Metastasis; Surgery","score_opus":0.1354225464933262,"score_gpt":0.5332530314402404,"score_spread":0.3978304849469142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698145,0.000964481,0.000016376438,0.010632149,0.00021351724,0.0002642632,0.000013527861,0.00000579398,0.0009084448],"genre_scores_gemma":[0.9826712,0.014826542,0.0010928544,0.00068082183,0.00027791914,0.000014621708,0.00000705503,0.000012148431,0.00041683295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970852,0.000462441,0.0016224051,0.0002000298,0.00038447542,0.00024540763],"domain_scores_gemma":[0.9968886,0.0015195563,0.00082513463,0.0001730841,0.00033699517,0.00025667562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040939874,0.00009900591,0.001578926,0.00084072707,0.00002192761,0.0000050227372,0.00015641189,0.000114989,0.00007097768],"category_scores_gemma":[0.0012389186,0.000071430004,0.00032114814,0.0010160895,0.0001557186,0.00006478992,0.00016977513,0.00045489438,0.000001395435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013938663,0.0005718364,0.81026363,0.00023706756,0.005019278,0.00039661545,0.00047857853,0.0004494541,0.000024661875,0.000029534507,0.0044730376,0.17666245],"study_design_scores_gemma":[0.006447448,0.003959392,0.9690324,0.00007705991,0.0039791963,0.0000015416523,0.000595619,0.0020906662,0.000016977374,0.000045739806,0.013690395,0.0000635353],"about_ca_topic_score_codex":0.00038064204,"about_ca_topic_score_gemma":0.0013319895,"teacher_disagreement_score":0.1765989,"about_ca_system_score_codex":0.00022294025,"about_ca_system_score_gemma":0.00034709155,"threshold_uncertainty_score":0.2912831},"labels":[],"label_agreement":null},{"id":"W4379341611","doi":"10.1200/jco.2023.41.16_suppl.8008","title":"Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Adverse effect; Surgery; Gastroenterology; Oncology","score_opus":0.05691125985349645,"score_gpt":0.40425127325656196,"score_spread":0.34734001340306553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995839,0.002234191,0.000015422873,0.0010927974,0.00015955362,0.000529005,0.000016407928,0.000017191549,0.00009641161],"genre_scores_gemma":[0.9889269,0.0090521015,0.0014172025,0.00017061643,0.00014370975,0.0000037713708,0.000029805242,0.000022660492,0.00023324392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621475,0.00077600626,0.0019019285,0.00030352856,0.00056224194,0.00024152025],"domain_scores_gemma":[0.9917636,0.005977537,0.0011686311,0.00024270006,0.0006211295,0.00022639922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002357609,0.00017241576,0.00190084,0.0005817469,0.000045748184,0.000009900868,0.00011891303,0.0003192432,0.0002075538],"category_scores_gemma":[0.002545183,0.00011652311,0.00020423876,0.0009206145,0.0003365932,0.00011292446,0.00008095159,0.0008501547,0.0000030167241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0651968,0.0017919567,0.6755541,0.000051869825,0.004116849,0.00019704022,0.0016253135,0.000016625785,0.0027559863,7.895014e-7,0.0002946577,0.248398],"study_design_scores_gemma":[0.04373744,0.009197646,0.9425158,0.00012347054,0.0009887614,0.0000042563897,0.00056475407,0.0004674442,0.00008273834,0.000024660403,0.0021925592,0.0001004901],"about_ca_topic_score_codex":0.000085784115,"about_ca_topic_score_gemma":0.00030018805,"teacher_disagreement_score":0.2669617,"about_ca_system_score_codex":0.00012126403,"about_ca_system_score_gemma":0.0004095609,"threshold_uncertainty_score":0.47516742},"labels":[],"label_agreement":null},{"id":"W4379341619","doi":"10.1200/jco.2023.41.16_suppl.12022","title":"Neurocognitive function outcomes in NRG/RTOG 0534, the SPPORT trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Institutes of Health","keywords":"Medicine; Androgen deprivation therapy; Statistical significance; Prostate cancer; Neurocognitive; Quality of life (healthcare); Internal medicine; Gerontology; Cognition; Cancer","score_opus":0.13302836798510112,"score_gpt":0.5032844862240917,"score_spread":0.37025611823899063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95923203,0.000038929167,0.01986319,0.008263174,0.0033839403,0.0005745173,0.0000057012744,0.000046304027,0.008592232],"genre_scores_gemma":[0.99423856,0.00012303842,0.0011342219,0.0016407773,0.0020098523,0.000025619303,0.000002095231,0.000020227078,0.0008056011],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997452,0.00048691782,0.0015506507,0.00013116012,0.00019169156,0.0001875587],"domain_scores_gemma":[0.99504656,0.0033965635,0.0012004178,0.00013553964,0.00014053391,0.00008041217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030421992,0.00010460443,0.00077276106,0.000111596906,0.00004184418,0.000009911689,0.00021487223,0.00011554472,0.00020845306],"category_scores_gemma":[0.0006062812,0.000061403734,0.0004125294,0.00023300735,0.00011487852,0.00014221712,0.00003951981,0.0009208637,0.000018554936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0147147,0.0013357284,0.36335364,0.000002630303,0.00039188497,0.000118225274,0.00012656736,0.00009727099,0.00007799985,0.0024649813,0.010052759,0.6072636],"study_design_scores_gemma":[0.05098752,0.011567158,0.5444158,0.000029905385,0.00014814593,0.000010853677,0.00046463026,0.00017996323,0.000087610286,0.042193465,0.34969664,0.00021834839],"about_ca_topic_score_codex":0.000013741788,"about_ca_topic_score_gemma":0.0000062162762,"teacher_disagreement_score":0.60704523,"about_ca_system_score_codex":0.00003377451,"about_ca_system_score_gemma":0.00035713584,"threshold_uncertainty_score":0.40007457},"labels":[],"label_agreement":null},{"id":"W4379341627","doi":"10.1200/jco.2023.41.16_suppl.9542","title":"Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Progression-free survival; Placebo; Melanoma; Overall survival; Cancer; Immunotherapy; Pathology; Cancer research","score_opus":0.06243232627494016,"score_gpt":0.41519514953864695,"score_spread":0.3527628232637068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959283,0.00008029093,0.000009373086,0.0010968928,0.0014471522,0.00035094674,0.000016723996,0.000011833372,0.0010584698],"genre_scores_gemma":[0.9966334,0.0008968294,0.0009876894,0.0005142997,0.00039851273,0.000017708207,0.000022167571,0.00003668525,0.0004927105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99518126,0.0008512681,0.002529475,0.0005200875,0.00042821612,0.0004897043],"domain_scores_gemma":[0.9965547,0.0011860337,0.0012534517,0.00045806498,0.00021894307,0.0003288223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038829735,0.00027576863,0.0015134835,0.00018810369,0.00005272294,0.000016441134,0.00047070315,0.0007061672,0.00002937834],"category_scores_gemma":[0.005121899,0.00017597036,0.0002672055,0.00024409506,0.00024341857,0.000023856961,0.00029032628,0.0008872699,0.000018032537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018833168,0.0021448086,0.91183436,0.00002933258,0.00014205484,0.0004903893,0.000037228787,0.000042307896,0.00023705095,0.000036585578,0.0013199046,0.06485282],"study_design_scores_gemma":[0.029642168,0.03458882,0.92469215,0.00014060213,0.000036247977,0.000027897817,0.00012178981,0.00004100853,0.00027200117,0.00016018281,0.010028362,0.00024877785],"about_ca_topic_score_codex":0.000013480802,"about_ca_topic_score_gemma":0.00073701347,"teacher_disagreement_score":0.064604044,"about_ca_system_score_codex":0.000056144003,"about_ca_system_score_gemma":0.0007878597,"threshold_uncertainty_score":0.7175863},"labels":[],"label_agreement":null},{"id":"W4379341789","doi":"10.1200/jco.2023.41.16_suppl.e18653","title":"Medical terminology and interpretation of results in plain language summaries published by oncology journals.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Text Mining and Ontologies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Syncrude (Canada)","funders":"","keywords":"Readability; Terminology; Medicine; Medical terminology; Context (archaeology); Medical physics; Computer science; Linguistics","score_opus":0.05592858290550649,"score_gpt":0.4539058598675796,"score_spread":0.3979772769620731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766116,0.0026260018,0.00018918255,0.018161496,0.0009426458,0.000064645596,0.00002487958,0.00000853398,0.0013709875],"genre_scores_gemma":[0.9923271,0.0047458154,0.0012442133,0.0009962276,0.0004330047,0.0000029809155,0.0000419959,0.0000105284025,0.00019815567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956307,0.0009999,0.0025300025,0.0002511013,0.0003106872,0.00027762994],"domain_scores_gemma":[0.9955934,0.0022883017,0.001498965,0.00016211694,0.000191685,0.00026552615],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008619713,0.0001247717,0.0010325606,0.00024203575,0.000024583203,0.000011465279,0.00038193414,0.0012516319,0.000037039295],"category_scores_gemma":[0.039260827,0.00009244732,0.0001776419,0.00021230744,0.0008570715,0.000012945259,0.00022588349,0.0009538201,0.000002966399],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036236648,0.00041564304,0.013163257,0.000022503336,0.0001506001,0.00048020246,0.00049482065,0.0000046633004,0.0049461178,0.000027030155,0.0632215,0.91345],"study_design_scores_gemma":[0.02076068,0.030257687,0.15364115,0.0003246688,0.00012803952,0.0011716032,0.0041830917,0.0013817898,0.003567635,0.0014727154,0.7827052,0.00040578868],"about_ca_topic_score_codex":0.000034848385,"about_ca_topic_score_gemma":0.0003069038,"teacher_disagreement_score":0.9130442,"about_ca_system_score_codex":0.00002954488,"about_ca_system_score_gemma":0.00110829,"threshold_uncertainty_score":0.9688319},"labels":[],"label_agreement":null},{"id":"W4379341825","doi":"10.1200/jco.2023.41.16_suppl.tps8611","title":"Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE),compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Amgen","keywords":"Topotecan; Medicine; Refractory (planetary science); Internal medicine; Discontinuation; Oncology; Chemotherapy; Lung cancer; Cancer; Malignancy","score_opus":0.08975948839399366,"score_gpt":0.4811738018165464,"score_spread":0.39141431342255273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933936,0.001874845,0.000026885707,0.00073090056,0.00068401755,0.0027284385,0.00004835307,0.000014020311,0.00049896503],"genre_scores_gemma":[0.99737424,0.0009075171,0.001045836,0.00011763293,0.00030238894,0.0000667885,0.000010377139,0.00004258648,0.00013262211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917106,0.0020927822,0.004083272,0.00038436984,0.0012409256,0.00048804094],"domain_scores_gemma":[0.98876816,0.0057578194,0.0024749658,0.00033605847,0.0022433915,0.00041958713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008313868,0.00026181887,0.004595212,0.0005676135,0.00006194049,0.00000789084,0.0003214071,0.00020210986,0.000103836675],"category_scores_gemma":[0.0058225337,0.00017045047,0.000455223,0.0009062198,0.0002611074,0.000080235346,0.00019962921,0.0015542129,0.0000032275811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64273375,0.005627542,0.3321461,0.0005684929,0.0008313057,0.0004052279,0.009208512,0.00091854663,0.00028836072,8.363341e-7,0.0046139546,0.0026573644],"study_design_scores_gemma":[0.86915606,0.05605631,0.059057064,0.0008316616,0.0011060038,0.0000014618652,0.010275121,0.00018611965,0.00070011494,0.000006193688,0.0024156177,0.00020827983],"about_ca_topic_score_codex":0.00019550671,"about_ca_topic_score_gemma":0.0004913763,"teacher_disagreement_score":0.27308905,"about_ca_system_score_codex":0.0005547925,"about_ca_system_score_gemma":0.0021612966,"threshold_uncertainty_score":0.69705373},"labels":[],"label_agreement":null},{"id":"W4379341829","doi":"10.1200/jco.2023.41.16_suppl.e22020","title":"Primary care utilization and cardiovascular screening in adult-aged survivors of childhood cancer: A report from the childhood cancer survivor study (CCSS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Cancer; Diabetes mellitus; Medical record; Pediatric cancer; Internal medicine; Pediatrics; Physical therapy","score_opus":0.12728594790495543,"score_gpt":0.4422114847047186,"score_spread":0.3149255367997632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658123,0.025468657,0.000054827313,0.0052838293,0.0018894601,0.0011603682,0.000081183985,0.00004116097,0.00020816844],"genre_scores_gemma":[0.97740537,0.01759282,0.00033137124,0.0024165479,0.002061775,0.00004601504,0.000050701045,0.000063904474,0.000031504245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902038,0.0026141154,0.0045937016,0.0006411637,0.001519433,0.00042780305],"domain_scores_gemma":[0.9912604,0.003959375,0.002671606,0.0007986494,0.0009496269,0.00036035833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010651728,0.00033686732,0.0034163275,0.00028115883,0.00012025093,0.00001996375,0.00041862475,0.00045258593,0.0000611161],"category_scores_gemma":[0.0063992,0.00024354686,0.0009906023,0.00096552673,0.00029391568,0.00021547644,0.00025574066,0.0017146305,0.0000019952731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010649888,0.0013326092,0.8761444,0.00011302369,0.0027909672,0.00077620713,0.012363028,0.00032684483,0.0000080216705,0.0000018124643,0.0010757862,0.104002304],"study_design_scores_gemma":[0.0122169955,0.002076705,0.9634035,0.00093814003,0.001423742,0.0001238324,0.01391787,0.000031963107,0.000021054513,0.000027340377,0.0056072124,0.00021165184],"about_ca_topic_score_codex":0.02797459,"about_ca_topic_score_gemma":0.047589406,"teacher_disagreement_score":0.10379065,"about_ca_system_score_codex":0.00018799632,"about_ca_system_score_gemma":0.0030642955,"threshold_uncertainty_score":0.9931553},"labels":[],"label_agreement":null},{"id":"W4379344523","doi":"10.1200/jco.2023.41.16_suppl.11536","title":"Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Sunitinib; GiST; Internal medicine; Imatinib; Oncology; Gastroenterology; Tyrosine-kinase inhibitor; Stromal tumor; Cancer; Stromal cell","score_opus":0.08702355214595854,"score_gpt":0.44692430361761426,"score_spread":0.35990075147165573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379344523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436235,0.0000066324437,0.00002893097,0.004480205,0.00009306572,0.0009002227,0.000010081647,0.000014188995,0.00010432388],"genre_scores_gemma":[0.9964587,0.0000056224217,0.0027874066,0.00048350787,0.00015511783,0.000026331973,0.000008968251,0.000020542644,0.000053776792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948819,0.0011881174,0.0021627813,0.0002826111,0.0009339117,0.00055063126],"domain_scores_gemma":[0.992985,0.004941304,0.0008942167,0.00027156738,0.0005371501,0.00037076313],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004825687,0.00022307706,0.0014891953,0.00041053447,0.00003986663,0.000014179283,0.00029195758,0.00004889462,0.000033513097],"category_scores_gemma":[0.016983155,0.000113685244,0.00021421612,0.000524569,0.00017984174,0.00010122749,0.000088681496,0.0017821235,0.000019965571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018406287,0.00800116,0.94565374,0.000012439576,0.00007849668,0.01641402,0.00006416124,0.00006191918,0.000011450196,0.0000023720106,0.0001566306,0.011137349],"study_design_scores_gemma":[0.03001145,0.09719914,0.87077963,0.0002565167,0.00008320241,0.0006310594,0.00068318966,0.00019796597,0.0000068365375,0.000019234278,0.0000614886,0.00007028793],"about_ca_topic_score_codex":0.000075621654,"about_ca_topic_score_gemma":0.0008869707,"teacher_disagreement_score":0.08919798,"about_ca_system_score_codex":0.00022040521,"about_ca_system_score_gemma":0.0009119445,"threshold_uncertainty_score":0.9912972},"labels":[],"label_agreement":null},{"id":"W4379344533","doi":"10.1200/jco.2023.41.16_suppl.12053","title":"The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Body mass index; Comorbidity; Retrospective cohort study; Population; Emergency department; Acute care; Ipilimumab; Emergency medicine; Adverse effect; Internal medicine; Cancer; Health care; Immunotherapy","score_opus":0.08150562680345796,"score_gpt":0.4363362661063142,"score_spread":0.35483063930285624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379344533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703395,0.00006280167,6.6879755e-7,0.001716236,0.00026220124,0.0008357663,0.000019505756,0.000012823607,0.000056033226],"genre_scores_gemma":[0.99922067,0.000200493,0.000049826136,0.00014440868,0.00021762871,0.000013194308,0.0000064671162,0.000023410988,0.00012392897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959216,0.0007464585,0.0023691494,0.00021741215,0.00050174724,0.0002436464],"domain_scores_gemma":[0.98545516,0.011322929,0.002097068,0.00047871988,0.00046322294,0.00018288523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019775052,0.00021440869,0.001277299,0.00015491317,0.00010569013,0.000015673668,0.00020436471,0.0002594667,0.000015962973],"category_scores_gemma":[0.0082944585,0.0000989611,0.0006016627,0.000296126,0.00031660992,0.00009610936,0.000056681187,0.00080115313,0.0000033028516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005794149,0.0017976706,0.9533773,0.00003768841,0.0010010685,0.00045560583,0.0045024646,0.0017700652,0.00036901963,0.000002832819,0.00018031498,0.030711839],"study_design_scores_gemma":[0.008972398,0.032076564,0.955029,0.0009415675,0.000302255,0.000014767237,0.0019250454,0.00026035807,0.00034265226,0.000018488861,0.000041540872,0.00007536969],"about_ca_topic_score_codex":0.0010480142,"about_ca_topic_score_gemma":0.0005408287,"teacher_disagreement_score":0.030636469,"about_ca_system_score_codex":0.00029576232,"about_ca_system_score_gemma":0.00052254513,"threshold_uncertainty_score":0.992984},"labels":[],"label_agreement":null},{"id":"W4379344732","doi":"10.1200/jco.2023.41.16_suppl.e24018","title":"The role of Chinese acupuncture plus herbal decoction for chemotherapy induced cognitive impairment in elderly cancer patients.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acupuncture; Decoction; Montreal Cognitive Assessment; Electroacupuncture; Cancer; Internal medicine; Neurocognitive; Traditional Chinese medicine; Quality of life (healthcare); Cohort; Traditional medicine; Cognition; Cognitive impairment; Alternative medicine; Psychiatry; Disease","score_opus":0.05169977170882057,"score_gpt":0.45993728534513,"score_spread":0.40823751363630945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379344732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940057,0.00052850833,0.000016402028,0.0070882384,0.0016321715,0.0010223091,0.00001731261,0.0000109636885,0.0002835076],"genre_scores_gemma":[0.9954228,0.0024377536,0.000043895616,0.001041276,0.0008392416,0.000086889275,0.0000063097714,0.000018210487,0.00010366462],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99723756,0.0002019185,0.0017591977,0.00017191979,0.0003472218,0.00028219965],"domain_scores_gemma":[0.99335897,0.0038819772,0.0014915528,0.00008104926,0.0010517607,0.00013467627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018973622,0.00018159953,0.0012304644,0.00015075687,0.000072619376,0.000005261797,0.00010309709,0.00030854373,0.000032132473],"category_scores_gemma":[0.0035718956,0.00009147155,0.00049974496,0.0003861556,0.00016594671,0.000073465446,0.00004094111,0.00072287925,0.000003610063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026648622,0.0013391123,0.44918615,0.000034513516,0.001084438,0.000018406092,0.0011582355,0.000020669775,0.00019316227,0.000005679039,0.002040828,0.5182702],"study_design_scores_gemma":[0.028635764,0.025391402,0.93294686,0.00025227145,0.00028786124,0.000012004509,0.0014920675,0.00022020534,0.00023905213,0.0010387313,0.009391024,0.00009276812],"about_ca_topic_score_codex":0.00005128871,"about_ca_topic_score_gemma":0.00043062895,"teacher_disagreement_score":0.5181774,"about_ca_system_score_codex":0.0004385184,"about_ca_system_score_gemma":0.0011489645,"threshold_uncertainty_score":0.42761508},"labels":[],"label_agreement":null},{"id":"W4379345208","doi":"10.1200/jco.2023.41.16_suppl.e18693","title":"Use of antibiotics and outcomes of patients presenting to emergency department with non-neutropenic fever and/or suspected infection.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; Juravinski Hospital","funders":"","keywords":"Medicine; Emergency department; Cefepime; Febrile neutropenia; Neutropenia; Internal medicine; Cancer; Antibiotics; Retrospective cohort study; Piperacillin; Tazobactam; Pediatrics; Chemotherapy; Antibiotic resistance","score_opus":0.12722038535242558,"score_gpt":0.4557597575859942,"score_spread":0.3285393722335686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804133,0.000011176722,0.000036324862,0.0009038237,0.0005913846,0.0002792385,0.000006196975,0.0000065097274,0.00012403776],"genre_scores_gemma":[0.99767566,0.00095347274,0.0007630736,0.00014893923,0.00010876887,5.7177556e-7,0.0000017560121,0.000011543763,0.00033618865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981033,0.000109716915,0.0013126467,0.00012443663,0.00021316914,0.00013669633],"domain_scores_gemma":[0.9976689,0.0006032945,0.0008862721,0.00011409114,0.00052499986,0.00020240706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046959525,0.00009063013,0.00089362514,0.00017046422,0.000033338085,0.0000042071483,0.000039837494,0.000101026366,0.000056941895],"category_scores_gemma":[0.0011277625,0.00005429531,0.00012857605,0.00031998692,0.00009277126,0.00010762353,0.00007735294,0.00025403858,0.000002317477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011445966,0.0007468948,0.99241,0.000054716475,0.00038963906,0.000042839376,0.000055096523,0.00003399108,0.00026759697,0.000015178273,0.0016111339,0.0032283054],"study_design_scores_gemma":[0.003151461,0.007489099,0.98321354,0.00004597984,0.00040827628,0.00003330686,0.000022107253,0.000018406039,0.0004376467,0.0000105609315,0.0051170513,0.000052556526],"about_ca_topic_score_codex":0.000054302265,"about_ca_topic_score_gemma":0.00022752373,"teacher_disagreement_score":0.009196464,"about_ca_system_score_codex":0.00003120561,"about_ca_system_score_gemma":0.00022883645,"threshold_uncertainty_score":0.22140986},"labels":[],"label_agreement":null},{"id":"W4379345342","doi":"10.1200/jco.2023.41.16_suppl.12092","title":"The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University Health Network","funders":"National Institutes of Health","keywords":"Single-nucleotide polymorphism; Allele; Population; Allele frequency; Expression quantitative trait loci; Ancestry-informative marker; Genome-wide association study; Oncology; Genetics; Medicine; Biology; Pharmacogenomics; Internal medicine; Genotype; Gene; Environmental health","score_opus":0.1847579850841918,"score_gpt":0.5206790500866666,"score_spread":0.33592106500247476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962278,0.00029903755,0.0000014781124,0.0017495293,0.0009231323,0.00017318889,0.000012027257,0.000010258753,0.0006035736],"genre_scores_gemma":[0.9908293,0.0075619966,0.0000874254,0.00031169405,0.0009870604,0.0000021636845,0.0000053949866,0.00001472441,0.00020023002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997693,0.00059852924,0.0012113772,0.00012641508,0.00018225155,0.00018841594],"domain_scores_gemma":[0.99528325,0.0029301052,0.0013076591,0.00010677079,0.00017514994,0.00019704348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001954319,0.0001188953,0.00076845457,0.00009321868,0.000090918555,0.0000065026084,0.000080084596,0.0001602681,0.00007647964],"category_scores_gemma":[0.0011205121,0.00006724821,0.00042094264,0.00012285361,0.00013084078,0.000048541828,0.000029121229,0.0007038538,0.0000071912123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017071389,0.0011240755,0.6613487,0.000016685417,0.0015873208,0.000639614,0.00046186804,0.00079559046,0.026178535,0.00004212841,0.008636873,0.28209722],"study_design_scores_gemma":[0.007630196,0.02397742,0.9608481,0.000012793659,0.00054349244,0.00023080753,0.00008962063,0.0018076573,0.00027537116,0.00027394478,0.0042447574,0.00006583348],"about_ca_topic_score_codex":0.00018776109,"about_ca_topic_score_gemma":0.00004160584,"teacher_disagreement_score":0.29949942,"about_ca_system_score_codex":0.00016121917,"about_ca_system_score_gemma":0.00046191958,"threshold_uncertainty_score":0.30579334},"labels":[],"label_agreement":null},{"id":"W4379345411","doi":"10.1200/jco.2023.41.16_suppl.11021","title":"How reliable are post-mastectomy breast reconstruction videos on YouTube?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Calgary; McGill University","funders":"","keywords":"Medicine; Thematic analysis; Breast cancer; Mastectomy; Narrative; Breast reconstruction; Health professionals; Health care; Qualitative research; Cancer; Internal medicine","score_opus":0.29665184527361355,"score_gpt":0.5290365478526594,"score_spread":0.23238470257904587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7656118,0.00004771305,0.0000062967156,0.19498236,0.03549943,0.00032636398,0.000004665446,0.000048693997,0.0034726697],"genre_scores_gemma":[0.97830397,0.0010970128,0.00085212954,0.0019743212,0.016992288,0.000038644615,0.0000020314358,0.000020513902,0.00071910647],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961596,0.0013224665,0.0013353893,0.00018907966,0.00060883036,0.0003846043],"domain_scores_gemma":[0.9843355,0.011425924,0.0023440232,0.00014049801,0.001254195,0.00049990363],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008348632,0.00009641135,0.0007231666,0.0002374538,0.00031329715,0.00004936336,0.0002918518,0.000604018,0.00014449004],"category_scores_gemma":[0.0615052,0.00008105765,0.00028218477,0.0006630678,0.000403889,0.0004135267,0.000024760775,0.0010357356,0.00017388772],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058771984,0.00034173578,0.12671591,0.00001935869,0.000058491594,0.00006042255,0.0032631387,0.000012817254,0.000014312234,0.0009879404,0.01327396,0.8546642],"study_design_scores_gemma":[0.0013384101,0.0020502661,0.5470622,0.00014451373,0.000054998898,0.0000668649,0.020432282,0.000014251921,0.000005682547,0.0023327996,0.42637694,0.00012075789],"about_ca_topic_score_codex":0.0004991148,"about_ca_topic_score_gemma":0.0009791567,"teacher_disagreement_score":0.85454345,"about_ca_system_score_codex":0.00050533994,"about_ca_system_score_gemma":0.0035423008,"threshold_uncertainty_score":0.94640017},"labels":[],"label_agreement":null},{"id":"W4379345488","doi":"10.1200/jco.2023.41.16_suppl.8044","title":"Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine; Cohort; Internal medicine; Cytokine release syndrome; Immunology; Gastroenterology; Pharmacology; Immune system; T cell","score_opus":0.07945615037243428,"score_gpt":0.44949109181036945,"score_spread":0.37003494143793514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768674,0.00010645847,0.000033403943,0.0017854944,0.000070083675,0.00019965647,0.000048954986,0.000008004182,0.00006120504],"genre_scores_gemma":[0.99839246,0.00070771505,0.00021374004,0.000048096397,0.000031085237,0.000004296284,0.000030099238,0.000010250695,0.0005622402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962539,0.00079038925,0.0020378332,0.00016434614,0.00058435206,0.00016914777],"domain_scores_gemma":[0.9920379,0.0045939977,0.0020041652,0.00021164729,0.00086317986,0.0002891239],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006159478,0.00009475403,0.0016171891,0.0007541595,0.000024056546,0.000004222372,0.000094318864,0.0002004428,0.00006676865],"category_scores_gemma":[0.0160767,0.00006252635,0.00031222717,0.0012971291,0.00031106983,0.00006639541,0.000038776983,0.00032236957,0.000004131103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022913475,0.0012631741,0.95122945,0.000034259614,0.007082343,0.0022644412,0.000043070024,0.00005206297,0.0053984565,0.000007618102,0.000323471,0.009388152],"study_design_scores_gemma":[0.0066133747,0.01135537,0.9756781,0.00008555431,0.0040439237,0.00014651731,0.00005366166,0.0013434669,0.00042855548,0.000027784365,0.00017948152,0.000044214554],"about_ca_topic_score_codex":0.00003086348,"about_ca_topic_score_gemma":0.000047941645,"teacher_disagreement_score":0.024448618,"about_ca_system_score_codex":0.00007409434,"about_ca_system_score_gemma":0.00066856766,"threshold_uncertainty_score":0.9922113},"labels":[],"label_agreement":null},{"id":"W4379345526","doi":"10.1200/jco.2023.41.16_suppl.e21159","title":"Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Erlotinib; Oncology; Lung cancer; Meta-analysis; Cochrane Library; Epidermal growth factor receptor; Clinical trial; Cancer","score_opus":0.17527750369452477,"score_gpt":0.5179745255713109,"score_spread":0.3426970218767861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000275918,0.99059176,0.000010022431,0.0011086272,0.00024446254,0.0074764253,0.00006272843,0.0000095363175,0.00022053476],"genre_scores_gemma":[0.00016487349,0.9938234,0.00086283276,0.00179203,0.00017996231,0.0012501735,0.000040264375,0.0000671829,0.001819251],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99138856,0.0011024205,0.0061027873,0.0005386221,0.0005153121,0.00035230487],"domain_scores_gemma":[0.9908185,0.0018663151,0.005582502,0.00047390626,0.0006178065,0.0006409954],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002633757,0.00054439745,0.021247938,0.0005923456,0.00003813893,0.000021568507,0.00022017976,0.00045700304,0.00008648826],"category_scores_gemma":[0.0010442551,0.00026603337,0.0032620062,0.0011542266,0.000054669206,0.00006598636,0.00008197176,0.000890736,0.000020256977],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014509485,0.0022977097,0.0011238279,0.68938595,0.29338023,0.0009465941,0.0002393029,0.0000059036843,1.3209646e-8,0.000001923631,0.0021816033,0.010291868],"study_design_scores_gemma":[0.0028561158,0.0056271446,0.00023044407,0.0928457,0.8734711,0.000043329546,0.000022063612,0.0000016322473,6.829807e-8,0.0000014405589,0.02470092,0.00020004569],"about_ca_topic_score_codex":0.00008731958,"about_ca_topic_score_gemma":0.0005397617,"teacher_disagreement_score":0.5965402,"about_ca_system_score_codex":0.001371177,"about_ca_system_score_gemma":0.0037034396,"threshold_uncertainty_score":0.9999792},"labels":[],"label_agreement":null},{"id":"W4379345563","doi":"10.1200/jco.2023.41.16_suppl.11563","title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Internal medicine; Cohort; Oncology; Sarcoma; Interim analysis; Clinical endpoint; Fludarabine; Progression-free survival; Surgery; Gastroenterology; Cyclophosphamide; Chemotherapy; Clinical trial; Pathology","score_opus":0.1710643192867094,"score_gpt":0.5202117515068317,"score_spread":0.34914743222012234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884755,0.0003874303,0.0000301298,0.004184115,0.0017884098,0.00049042195,0.000016064996,0.000011803162,0.004244089],"genre_scores_gemma":[0.9913886,0.0044645197,0.00046133352,0.0001840293,0.0010160931,0.000007693459,0.000010889123,0.000032037206,0.002434773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9912404,0.0015172703,0.0049704476,0.00029424843,0.0014243143,0.00055332785],"domain_scores_gemma":[0.9839119,0.011901736,0.0025133719,0.0005548166,0.00075912545,0.00035910163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014530582,0.00020709712,0.0033843399,0.00096666324,0.000048904676,0.00001059256,0.0005586405,0.00048041684,0.00044503616],"category_scores_gemma":[0.0079656625,0.00013454809,0.0018488417,0.0019632932,0.00058094,0.00010645636,0.00015102154,0.00157451,0.0000147535875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4418058,0.005196823,0.073300324,0.00008124348,0.0072003095,0.00083068165,0.00033423188,0.0009887993,0.026436057,0.00033171524,0.0014950939,0.4419989],"study_design_scores_gemma":[0.16009101,0.04190423,0.74787337,0.00013950258,0.0021051727,0.000028517008,0.00056206324,0.0032330323,0.0007668446,0.00057375885,0.042516988,0.0002055319],"about_ca_topic_score_codex":0.00017784466,"about_ca_topic_score_gemma":0.0008795487,"teacher_disagreement_score":0.674573,"about_ca_system_score_codex":0.0002561319,"about_ca_system_score_gemma":0.00274757,"threshold_uncertainty_score":0.9536218},"labels":[],"label_agreement":null},{"id":"W4379345743","doi":"10.1200/jco.2023.41.16_suppl.e18030","title":"Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Immune system; Oncology; Internal medicine; Paclitaxel; CDKN2A; Chemotherapy; Cancer; Immunology","score_opus":0.05026273937400142,"score_gpt":0.40831075219027435,"score_spread":0.3580480128162729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965441,0.00022857712,0.000003505479,0.0016213651,0.0009629191,0.00022409872,0.000006974826,0.000007144769,0.00040131956],"genre_scores_gemma":[0.9988601,0.00050926005,0.000105158964,0.00030644846,0.00017319852,0.0000017376356,0.000010356329,0.000013392219,0.000020329155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646515,0.00035199238,0.0023152926,0.00019123046,0.00046506137,0.00021128991],"domain_scores_gemma":[0.99569994,0.002069375,0.001558272,0.00021599275,0.00028254458,0.00017389354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037308245,0.00013872131,0.0017946431,0.0005618235,0.000024519812,0.000006011766,0.00012301133,0.00028984636,0.000042130625],"category_scores_gemma":[0.0014301146,0.0000905142,0.00052180485,0.001060171,0.00036329162,0.00006339044,0.000035161236,0.0005186246,0.00000342134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12190674,0.0033369532,0.81076837,0.000034699562,0.0055049714,0.00015162112,0.00011206729,0.000014976821,0.00044790827,0.00007462489,0.0009792519,0.0566678],"study_design_scores_gemma":[0.03796463,0.020713583,0.937532,0.00012503455,0.0009214323,0.000006551511,0.000068829715,0.000019144385,0.00013190402,0.00007591192,0.0023570326,0.00008396271],"about_ca_topic_score_codex":0.000055511216,"about_ca_topic_score_gemma":0.000029667772,"teacher_disagreement_score":0.1267636,"about_ca_system_score_codex":0.00010614724,"about_ca_system_score_gemma":0.00048566706,"threshold_uncertainty_score":0.3691062},"labels":[],"label_agreement":null},{"id":"W4379345749","doi":"10.1200/jco.2023.41.16_suppl.e20017","title":"Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Discontinuation; Multiple myeloma; Refractory (planetary science); Lenalidomide; Cohort; Gastroenterology; Oncology; Surgery","score_opus":0.04056370450328561,"score_gpt":0.37855677151527556,"score_spread":0.33799306701198994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983305,0.00023965124,0.00004333789,0.0005949691,0.00017687354,0.00039423237,0.000109333196,0.000011887843,0.000099220735],"genre_scores_gemma":[0.99535453,0.0014779906,0.002720106,0.00008762975,0.00015454814,0.000004540335,0.0001103357,0.00002130783,0.0000689983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956208,0.00077611185,0.0022091425,0.00032901193,0.00071560766,0.0003493457],"domain_scores_gemma":[0.990647,0.006595145,0.0015078374,0.00032927224,0.00038955803,0.0005311453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001954303,0.00019009219,0.0020750288,0.000705445,0.000044440185,0.000007804078,0.00016901431,0.00035656197,0.00018574044],"category_scores_gemma":[0.005564525,0.00012463007,0.00034602924,0.00096570957,0.00028937706,0.00013820798,0.000097610544,0.0010675956,0.000019599483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04386494,0.0026707714,0.8084025,0.000016886928,0.0025189053,0.0007455263,0.00008962613,0.000047015863,0.00001997636,0.0000034905456,0.00017870948,0.14144164],"study_design_scores_gemma":[0.077296875,0.016806096,0.90268004,0.000095623145,0.0014857096,0.000004706792,0.00005756904,0.00038184295,0.000014846197,0.000047182017,0.0010368144,0.00009271566],"about_ca_topic_score_codex":0.0009801162,"about_ca_topic_score_gemma":0.0011356748,"teacher_disagreement_score":0.14134893,"about_ca_system_score_codex":0.00014423642,"about_ca_system_score_gemma":0.00053052884,"threshold_uncertainty_score":0.66616577},"labels":[],"label_agreement":null},{"id":"W4379345771","doi":"10.1200/jco.2023.41.16_suppl.e24088","title":"Barriers to offering female fertility preservation to pediatric and young adult oncology patients: A national survey of pediatric hematology oncology providers in the United States and Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fertility preservation; Medicine; Fertility; Oncofertility; Infertility; Candidacy; Reproductive medicine; Family medicine; Gynecology; Pregnancy; Oncology; Internal medicine; Population","score_opus":0.11617523976683361,"score_gpt":0.4257067375634668,"score_spread":0.30953149779663314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98340476,0.000098586774,0.00002135496,0.014975601,0.0007032704,0.0006656442,0.00003306673,0.0000065075906,0.00009118706],"genre_scores_gemma":[0.99540466,0.00043879313,0.00025856277,0.0035822922,0.00023037466,0.000024321336,0.000036283127,0.0000088263705,0.000015910038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99410164,0.0026551208,0.0021641154,0.00038312853,0.00038018287,0.00031578902],"domain_scores_gemma":[0.9888294,0.0073332265,0.0010012831,0.00018888766,0.0021895217,0.00045773134],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01058439,0.00015312531,0.0012259326,0.0004847313,0.000073046846,0.0000049579216,0.00020206609,0.00042650703,0.000012316516],"category_scores_gemma":[0.07993252,0.00010599725,0.00007040727,0.0009985243,0.00022217662,0.0001125999,0.0001419743,0.0007787955,0.0000012823544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012306187,0.00043685964,0.9793493,0.00007962361,0.0000743985,0.00006238216,0.0010525372,0.000068387526,0.000008310549,0.000018057917,0.0046827313,0.0018611887],"study_design_scores_gemma":[0.0029304412,0.0074312524,0.986475,0.000008856801,0.000107618056,0.000041774794,0.0008276733,0.00014158225,0.000006573944,0.00017959898,0.001766861,0.00008276121],"about_ca_topic_score_codex":0.064362176,"about_ca_topic_score_gemma":0.3007803,"teacher_disagreement_score":0.23641814,"about_ca_system_score_codex":0.00037218753,"about_ca_system_score_gemma":0.005754295,"threshold_uncertainty_score":0.99988216},"labels":[],"label_agreement":null},{"id":"W4379345905","doi":"10.1200/jco.2023.41.16_suppl.8561","title":"Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Durvalumab; Medicine; Pneumonitis; Internal medicine; Lung cancer; Radiation therapy; Oncology; Cancer; Lung; Pembrolizumab; Immunotherapy","score_opus":0.021213238515244634,"score_gpt":0.36598598011295885,"score_spread":0.3447727415977142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716914,0.00010069811,0.00020314683,0.0005087447,0.00045386865,0.0014656677,0.00007704701,0.0000122157935,0.000009475654],"genre_scores_gemma":[0.997508,0.00033207345,0.0017189828,0.00019541885,0.000089613975,0.000041955118,0.000040152052,0.000035164834,0.000038639795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969419,0.0002264519,0.0019480482,0.00024411167,0.0004122525,0.00022722912],"domain_scores_gemma":[0.9943018,0.0016716828,0.0027968336,0.00017582158,0.0008838486,0.00017003888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013398485,0.00021594348,0.0012885568,0.0002155378,0.00006879859,0.000011522851,0.0001089977,0.00020683638,0.000013716933],"category_scores_gemma":[0.0005334499,0.00013243686,0.0003131301,0.00025107455,0.00013999599,0.0001398978,0.000026506557,0.00044447384,3.3805162e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04424923,0.0017968405,0.9381836,0.00010317475,0.0012314413,0.00004123567,0.00048665956,0.00015860732,0.00045961046,1.0222885e-7,0.000017068725,0.013272449],"study_design_scores_gemma":[0.054415707,0.024047347,0.9179469,0.00036476305,0.0014098557,0.0000033106658,0.00045118344,0.0008484861,0.00032200234,0.0000013153112,0.000048947004,0.00014022116],"about_ca_topic_score_codex":0.0007018835,"about_ca_topic_score_gemma":0.00052730076,"teacher_disagreement_score":0.022250507,"about_ca_system_score_codex":0.00022906574,"about_ca_system_score_gemma":0.0011293816,"threshold_uncertainty_score":0.54006183},"labels":[],"label_agreement":null},{"id":"W4379345936","doi":"10.1200/jco.2023.41.16_suppl.10503","title":"Second primary breast cancer in young breast cancer survivors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Cancer; Proportional hazards model; Internal medicine; Oncology; Genetic testing; Prospective cohort study; Cohort; Quartile; Cancer registry; Gynecology; Confidence interval","score_opus":0.07792445159145578,"score_gpt":0.442798516397978,"score_spread":0.36487406480652224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581054,0.00072858814,0.000004453194,0.02472407,0.004816329,0.00020562278,0.00023349066,0.000026061716,0.011156014],"genre_scores_gemma":[0.97600484,0.008659652,0.00014402941,0.008329024,0.0037155075,0.000019195899,0.000012937904,0.00004350635,0.0030712923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958912,0.0003649584,0.00251518,0.00030236496,0.00045905146,0.00046721217],"domain_scores_gemma":[0.9966148,0.0010730536,0.0011773218,0.00022609398,0.00040800354,0.0005006839],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003218088,0.00020222712,0.0019439644,0.00034130635,0.00004187059,0.000011495509,0.00024998863,0.00046863095,0.007149633],"category_scores_gemma":[0.00025029472,0.00015477094,0.0005103469,0.00052150094,0.00022048909,0.0002645794,0.00009127168,0.0016614846,0.000052712207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046357415,0.00042937478,0.736311,0.00012398275,0.00032053704,0.0010967308,0.00017883212,0.00008308651,0.00051346404,0.000012428489,0.018261382,0.2380334],"study_design_scores_gemma":[0.007670975,0.00073211576,0.9384886,0.00019544031,0.00014365208,0.0013357366,0.00013999578,0.00019635368,0.000012282237,0.00004776509,0.050888795,0.0001483043],"about_ca_topic_score_codex":0.0009783852,"about_ca_topic_score_gemma":0.013629316,"teacher_disagreement_score":0.2378851,"about_ca_system_score_codex":0.00082813966,"about_ca_system_score_gemma":0.0058667837,"threshold_uncertainty_score":0.99976903},"labels":[],"label_agreement":null},{"id":"W4379346094","doi":"10.1200/jco.2023.41.16_suppl.e23005","title":"Global impact of a video education platform on oncology education amongst healthcare professionals.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Audience measurement; Medicine; Socioeconomic status; Health care; Demographics; Citation; Family medicine; Medical education; Library science; Demography; Economic growth; Political science; Environmental health","score_opus":0.34082325225512,"score_gpt":0.6654326824420626,"score_spread":0.32460943018694255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8866695,0.00027509232,0.0000032874655,0.06802101,0.035886176,0.00085373974,0.000008437472,0.000027061222,0.008255667],"genre_scores_gemma":[0.98747164,0.0012023489,0.0006612054,0.0023254796,0.008009563,0.00012707249,0.0000149826255,0.000013593062,0.0001740963],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99369854,0.0021280854,0.0027082833,0.00022630296,0.00079359155,0.0004452236],"domain_scores_gemma":[0.98066187,0.012212313,0.0042370935,0.00019664005,0.0018828774,0.0008092107],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010164616,0.00013942874,0.0010510243,0.0003096563,0.0002627674,0.000012827891,0.00043990018,0.0009412689,0.00016710126],"category_scores_gemma":[0.04373222,0.00011393874,0.00049036444,0.0012490492,0.0004526215,0.00030965614,0.000041599622,0.00085350295,0.00008332826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065855717,0.0029321106,0.19218796,0.00003900171,0.00005431758,0.0000035512394,0.005593205,0.000008586273,0.0000019650624,0.008173019,0.058448616,0.7318991],"study_design_scores_gemma":[0.0007333105,0.0059273695,0.8199117,0.00021597288,0.000045842935,0.000008662188,0.013039889,0.000006239881,0.0000016615312,0.0130572505,0.1469555,0.000096571064],"about_ca_topic_score_codex":0.007622037,"about_ca_topic_score_gemma":0.0037924852,"teacher_disagreement_score":0.7318025,"about_ca_system_score_codex":0.003756623,"about_ca_system_score_gemma":0.112964585,"threshold_uncertainty_score":0.9989863},"labels":[],"label_agreement":null},{"id":"W4379346102","doi":"10.1200/jco.2023.41.16_suppl.e18618","title":"Does community size impact survival with breast cancer? Data from a large population-based cohort in British Columbia.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Cohort; Population; Cancer; Lymphovascular invasion; Mastectomy; Rural area; Radiation therapy; Demography; Internal medicine; Oncology; Metastasis; Environmental health; Pathology","score_opus":0.2252163985883568,"score_gpt":0.51246211452598,"score_spread":0.2872457159376232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946338,0.00006589944,0.000022512737,0.0033590016,0.00072845875,0.00018230536,0.00086417183,0.000020827285,0.00012305858],"genre_scores_gemma":[0.99647045,0.00022916582,0.00046828884,0.0017133211,0.0008399695,0.0000039586653,0.00018862638,0.00001629365,0.000069912225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963899,0.0009770865,0.0015415878,0.00020826173,0.0005618761,0.0003212631],"domain_scores_gemma":[0.99290395,0.0049402206,0.0009570188,0.00047147096,0.0003785282,0.0003488365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068858834,0.00009829782,0.0013985483,0.000048727237,0.000101164325,0.000054538792,0.00046224348,0.0002678593,0.00084101956],"category_scores_gemma":[0.0043868567,0.00007810263,0.00019086525,0.00041214775,0.00010759846,0.0002418027,0.0001385562,0.0016260731,0.000006573264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002031554,0.0005360577,0.97659856,0.0000130383105,0.00024703378,0.0012742812,0.00001883896,0.000108023305,0.0000040589052,2.4777648e-7,0.0070307464,0.0121375825],"study_design_scores_gemma":[0.0071860277,0.0017717744,0.9873564,0.00052976207,0.00024150603,0.00012586759,0.0003741092,0.0009793242,2.0574038e-7,0.00011182726,0.0012237057,0.00009947524],"about_ca_topic_score_codex":0.43895674,"about_ca_topic_score_gemma":0.817992,"teacher_disagreement_score":0.3790352,"about_ca_system_score_codex":0.0003589462,"about_ca_system_score_gemma":0.002800535,"threshold_uncertainty_score":0.9208574},"labels":[],"label_agreement":null},{"id":"W4379346220","doi":"10.1200/jco.2023.41.16_suppl.e21519","title":"Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world evidence.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Progression-free survival; Discontinuation; Population; Adverse effect; Hazard ratio; Cohort; Proportional hazards model; Log-rank test; Exact test; Cancer; Immunotherapy; Overall survival; Confidence interval","score_opus":0.1081467984445015,"score_gpt":0.4475976401977972,"score_spread":0.3394508417532957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726741,0.0029315527,0.0000031941267,0.009291085,0.0034932676,0.00031622322,0.0000016650382,0.000027589274,0.011261334],"genre_scores_gemma":[0.9908274,0.0037409882,0.0010705894,0.0005104478,0.001787781,0.000012386704,0.0000012960679,0.000036795347,0.0020123448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402755,0.00041337614,0.004189331,0.0003287598,0.0005479463,0.00049304997],"domain_scores_gemma":[0.99071604,0.006221257,0.002025228,0.00034083097,0.00035132666,0.00034529853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038948122,0.00022584909,0.0022647083,0.000510495,0.00005017908,0.000007259037,0.0002613537,0.0003176548,0.00011425616],"category_scores_gemma":[0.0065719164,0.00017512712,0.00069182535,0.00084520463,0.0002780606,0.00013949472,0.00019797838,0.0016828083,0.00012785851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071451454,0.0011751219,0.89492947,0.00018893823,0.00009014281,0.021353336,0.0005957693,0.0001466356,0.0020889828,0.000017428065,0.007454747,0.064814284],"study_design_scores_gemma":[0.008228903,0.011696083,0.95391375,0.00036078863,0.00020666634,0.0007018801,0.0006197327,0.000058941114,0.0019655894,0.00020361751,0.021857854,0.00018619545],"about_ca_topic_score_codex":0.0002600485,"about_ca_topic_score_gemma":0.0007781154,"teacher_disagreement_score":0.06462809,"about_ca_system_score_codex":0.0007414716,"about_ca_system_score_gemma":0.0018747757,"threshold_uncertainty_score":0.78676724},"labels":[],"label_agreement":null},{"id":"W4379346323","doi":"10.1200/jco.2023.41.16_suppl.10012","title":"Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; Rally Foundation","keywords":"Medicine; Cog; Logistic regression; Cardiomyopathy; Internal medicine; Nuclear medicine; Ejection fraction; Body surface area; Cardiology; Heart failure","score_opus":0.07403849476494273,"score_gpt":0.4190733946718723,"score_spread":0.3450348999069296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974055,0.0022342121,0.00046761165,0.0023957319,0.0035677978,0.00049723225,0.000052565585,0.00007562896,0.0009686399],"genre_scores_gemma":[0.98321164,0.012332354,0.00062901666,0.000641399,0.0029515715,0.000021998647,0.00008690288,0.00003904011,0.0000861007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941143,0.00092400634,0.0036423334,0.0003816926,0.0006178515,0.00031983215],"domain_scores_gemma":[0.9935254,0.0019193725,0.0031937128,0.00038377356,0.0006672343,0.00031052565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006750263,0.0002162337,0.002569512,0.0002818224,0.000058462316,0.000008138176,0.00017635492,0.0010200667,0.00008876787],"category_scores_gemma":[0.0022908447,0.00017490218,0.001434381,0.00063655793,0.00025816282,0.00013137775,0.000046375742,0.0013267229,0.000009942102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033559247,0.00080408657,0.5042235,0.000027757482,0.005044736,0.0013242109,0.0004993183,0.00018322447,0.10368092,0.00001124335,0.0023755126,0.3784695],"study_design_scores_gemma":[0.011497446,0.0068168403,0.9435005,0.0002328979,0.0005635301,0.0010072592,0.00020280079,0.000100632926,0.013582463,0.00045319909,0.021897059,0.00014534281],"about_ca_topic_score_codex":0.00050414307,"about_ca_topic_score_gemma":0.0001715774,"teacher_disagreement_score":0.43927696,"about_ca_system_score_codex":0.00035083268,"about_ca_system_score_gemma":0.0015747766,"threshold_uncertainty_score":0.78676885},"labels":[],"label_agreement":null},{"id":"W4379346404","doi":"10.1200/jco.2023.41.16_suppl.8018","title":"A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Interim analysis; Tolerability; Bortezomib; Multiple myeloma; Adverse effect; Internal medicine; Dexamethasone; Clinical endpoint; Gastroenterology; Surgery; Clinical trial","score_opus":0.11451876890469877,"score_gpt":0.5070437614309877,"score_spread":0.392524992526289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989249,0.00006302443,0.0000233155,0.00023156898,0.000068082394,0.0005705619,0.000049735354,0.00000422563,0.00006456146],"genre_scores_gemma":[0.99912983,0.00013098854,0.0006139458,0.000016098644,0.000028733024,0.000010931713,0.000046902027,0.000012023343,0.000010563344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552655,0.00087490096,0.0025454308,0.0001952379,0.00064756174,0.00021034294],"domain_scores_gemma":[0.99460745,0.0026402103,0.0015459183,0.00023794179,0.0007512958,0.00021717692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002455086,0.00012367677,0.0024321,0.0014119735,0.000011898565,0.0000027246201,0.00016615418,0.0001649326,0.000039622897],"category_scores_gemma":[0.0032443656,0.00008595412,0.00026680462,0.0014685636,0.00015124511,0.00009719373,0.00005721247,0.00048672545,6.892457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06449442,0.025173433,0.8257967,0.000077588185,0.0015836505,0.002107207,0.0037289513,0.00022438393,0.00023379983,0.0000037463099,0.000016772607,0.07655932],"study_design_scores_gemma":[0.09923573,0.14658196,0.74187255,0.0001580465,0.0007532401,0.0000065663185,0.009443718,0.0014877351,0.000380205,0.000008059128,0.000027448248,0.00004471748],"about_ca_topic_score_codex":0.00073046907,"about_ca_topic_score_gemma":0.0174624,"teacher_disagreement_score":0.12140854,"about_ca_system_score_codex":0.0002334479,"about_ca_system_score_gemma":0.0008236618,"threshold_uncertainty_score":0.9744429},"labels":[],"label_agreement":null},{"id":"W4379346499","doi":"10.1200/jco.2023.41.16_suppl.e18691","title":"Use of positron emission tomography-computed tomography (PET-CT) scan in cancer patients: A single Canadian academic oncology center experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Cegep regional de Lanaudiere","funders":"","keywords":"Medicine; Positron emission tomography; Nuclear medicine; Computed tomography; Radiology; Positron Emission Tomography-Computed Tomography; Medical physics","score_opus":0.08845606377034693,"score_gpt":0.44941031402596304,"score_spread":0.3609542502556161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859578,0.00023105938,0.00001800547,0.010967302,0.002122188,0.00021809986,0.000009009514,0.000017275475,0.0004592698],"genre_scores_gemma":[0.99314415,0.00084070495,0.0012613017,0.0041547245,0.0004824545,0.0000068017066,0.000015964706,0.000025672121,0.00006820658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956373,0.00055985706,0.0025480553,0.0002826644,0.00044583433,0.00052631483],"domain_scores_gemma":[0.99563223,0.0014139531,0.0013901506,0.00017175364,0.00038103815,0.0010108738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020221833,0.00017898603,0.0014256733,0.0012513441,0.000052513795,0.000010883033,0.00029722156,0.0002313825,0.00009631049],"category_scores_gemma":[0.0036201777,0.00013836593,0.00048262448,0.0010448237,0.00038669026,0.0001873021,0.00007917134,0.0022906074,0.0000028633788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071172504,0.0010427763,0.85659593,0.000028582042,0.0001212988,0.0012113757,0.0003456918,0.000079632526,0.0008928123,0.000009274218,0.010288094,0.12867282],"study_design_scores_gemma":[0.006029589,0.005450798,0.8330496,0.0006662475,0.000119786455,0.0002703391,0.00017606904,0.0020756365,0.00014432345,0.0000723249,0.15179996,0.00014530217],"about_ca_topic_score_codex":0.009252065,"about_ca_topic_score_gemma":0.0037461892,"teacher_disagreement_score":0.14151187,"about_ca_system_score_codex":0.00048649922,"about_ca_system_score_gemma":0.001994052,"threshold_uncertainty_score":0.9973454},"labels":[],"label_agreement":null},{"id":"W4379346591","doi":"10.1200/jco.2023.41.16_suppl.9126","title":"Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Pharmacokinetics; Cancer; Surgery","score_opus":0.04505073144794957,"score_gpt":0.4709536166532698,"score_spread":0.4259028852053202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931231,0.000045417753,0.0000137253965,0.005389738,0.00049412926,0.00071565347,0.000017682903,0.000006747352,0.00019381153],"genre_scores_gemma":[0.9988739,0.00033174196,0.00006690318,0.00043567774,0.000060340702,0.000008898171,0.000012601135,0.0000107738015,0.0001991524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973728,0.00037351268,0.0016809305,0.00014635318,0.00028356528,0.00014285938],"domain_scores_gemma":[0.9970464,0.00083257706,0.0014503229,0.00022865807,0.0003601328,0.00008191093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013032941,0.00009710426,0.0006566611,0.00007912803,0.00007532214,0.0000068585887,0.00013528648,0.000089239504,0.000017999479],"category_scores_gemma":[0.0007861506,0.00004469445,0.00010730331,0.0003657772,0.00013759473,0.000072261166,0.00004313343,0.0003513708,0.0000025383495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031947173,0.013111462,0.56131524,0.000043885637,0.0013842628,0.00053611776,0.0035537805,0.00023209454,0.0005862407,0.000059464714,0.0015427243,0.38568753],"study_design_scores_gemma":[0.03130881,0.01747079,0.9447099,0.00008766993,0.0005584264,0.000075816795,0.0019531643,0.0001011126,0.000065301174,0.00009258618,0.0035238916,0.000052541833],"about_ca_topic_score_codex":0.000015792175,"about_ca_topic_score_gemma":0.000117552874,"teacher_disagreement_score":0.385635,"about_ca_system_score_codex":0.0001411837,"about_ca_system_score_gemma":0.0005125014,"threshold_uncertainty_score":0.18225868},"labels":[],"label_agreement":null},{"id":"W4379346636","doi":"10.1200/jco.2023.41.16_suppl.e22548","title":"Outcomes for patients with Lynch Syndrome in Manitoba.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Lynch syndrome; Medicine; MSH6; PMS2; MSH2; MLH1; Cancer; Internal medicine; Oncology; Colorectal cancer; Endometrial cancer; Cancer registry; Gynecology; DNA mismatch repair","score_opus":0.13880373480588976,"score_gpt":0.4645096022472412,"score_spread":0.32570586744135144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931545,0.000022521283,0.000024339215,0.004095676,0.00185243,0.00038182322,0.0000043952414,0.000010344252,0.0004539701],"genre_scores_gemma":[0.99518424,0.00004812117,0.003196172,0.0011095785,0.00019923295,0.000013751927,0.0000033702393,0.000018430006,0.00022709458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977766,0.00010348848,0.0014121378,0.00014063092,0.00033666645,0.00023044071],"domain_scores_gemma":[0.9959706,0.00268648,0.0006683951,0.00012774055,0.00035508958,0.00019170779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015338177,0.000099749544,0.0011279659,0.0001866123,0.000015234682,0.0000035437674,0.00012869741,0.00024772275,0.0000513587],"category_scores_gemma":[0.003927875,0.00006146599,0.00024188345,0.00022543375,0.000094472845,0.000041841344,0.000035414367,0.0004894776,0.000026481079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026411705,0.0007042198,0.96736616,0.000027331957,0.00013517609,0.00031728885,0.000023582967,0.000018559565,0.0000032381636,0.000011356294,0.0033970776,0.025354825],"study_design_scores_gemma":[0.01149314,0.02322403,0.95074904,0.00006458099,0.000103016,0.000070001144,0.000055784854,0.000026540616,0.0000045069582,0.0003191452,0.013827444,0.0000627542],"about_ca_topic_score_codex":0.000008126448,"about_ca_topic_score_gemma":0.000158518,"teacher_disagreement_score":0.02529207,"about_ca_system_score_codex":0.00018789544,"about_ca_system_score_gemma":0.00076060643,"threshold_uncertainty_score":0.47023168},"labels":[],"label_agreement":null},{"id":"W4379346645","doi":"10.1200/jco.2023.41.16_suppl.6550","title":"Disparities in clinical trial enrolment at a Canadian comprehensive cancer centre: A 15-year retrospective study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Odds ratio; Retrospective cohort study; Population; Confidence interval; Context (archaeology); Cancer; Demography; Clinical trial; Internal medicine; Environmental health","score_opus":0.22384726499061797,"score_gpt":0.4414607711075236,"score_spread":0.2176135061169056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747142,0.0008040436,0.0000036095537,0.007933993,0.008123602,0.0005600312,0.00013037348,0.0000112521975,0.007718868],"genre_scores_gemma":[0.9903346,0.0037508379,0.000068894115,0.002107402,0.0023222952,0.000020273012,0.000003302134,0.000027412381,0.0013649871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99321866,0.0002791518,0.005349551,0.0004499152,0.00009572016,0.0006070092],"domain_scores_gemma":[0.99489754,0.0010626971,0.002918304,0.0002675021,0.00020838258,0.00064555055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060296436,0.00020195526,0.0026094397,0.0004834467,0.000090937196,0.000037449627,0.00040364533,0.0005081763,0.00077990396],"category_scores_gemma":[0.0037395223,0.00020106402,0.0006522326,0.00034564073,0.00024226813,0.00024541223,0.00013550115,0.001162119,0.0005148471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0094603095,0.0008011223,0.953426,0.000005627706,0.00028657788,0.00031065065,0.00029779575,0.00006605929,9.283718e-8,0.0043052305,0.025706807,0.005333748],"study_design_scores_gemma":[0.036351427,0.0041685663,0.8052168,0.000020048068,0.000026061833,0.0000043067193,0.00026631253,0.00007502745,1.6776396e-7,0.005167223,0.14852804,0.00017601004],"about_ca_topic_score_codex":0.040085558,"about_ca_topic_score_gemma":0.25421086,"teacher_disagreement_score":0.2141253,"about_ca_system_score_codex":0.0017849407,"about_ca_system_score_gemma":0.0015523457,"threshold_uncertainty_score":0.96630657},"labels":[],"label_agreement":null},{"id":"W4379346764","doi":"10.1200/jco.2023.41.16_suppl.12054","title":"Understanding treatment toxicity patterns through remote symptom monitoring and examining the effect of frailty in older men with metastatic prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Cohort; Prospective cohort study; Internal medicine; Cancer; Geriatric oncology; Physical therapy","score_opus":0.2851889427448995,"score_gpt":0.4826334702792292,"score_spread":0.19744452753432973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938588,0.00025619555,0.00026331955,0.004387758,0.00035732437,0.00052118086,0.0000056517533,0.000011731779,0.00033804702],"genre_scores_gemma":[0.9965459,0.0022701956,0.00066213455,0.00007812447,0.00026430408,0.000008977635,0.000001071426,0.000020752168,0.00014850599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971872,0.000655819,0.0013284619,0.0001982944,0.00036090726,0.00026932935],"domain_scores_gemma":[0.9919376,0.006668142,0.0010047881,0.00017405082,0.00007934004,0.00013610382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026560682,0.0001712259,0.0013544033,0.00010534034,0.000045801593,0.000009684017,0.00010023928,0.00012410815,0.0000150672895],"category_scores_gemma":[0.0010822479,0.000086001026,0.00012581462,0.0002618294,0.00020336565,0.000115958064,0.000049197217,0.0005893543,9.620109e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002572882,0.00016458188,0.931888,0.00016661624,0.0006950215,0.00079362764,0.0029261007,0.00029611628,0.0002525866,0.0000044232474,0.00013105314,0.060109034],"study_design_scores_gemma":[0.019568555,0.031560827,0.94025725,0.0018097891,0.0007457444,0.00022787302,0.0026035886,0.0007719249,0.002011648,0.00014904558,0.00018867182,0.000105056315],"about_ca_topic_score_codex":0.00036890875,"about_ca_topic_score_gemma":0.00026894515,"teacher_disagreement_score":0.06000398,"about_ca_system_score_codex":0.0004955751,"about_ca_system_score_gemma":0.00038849993,"threshold_uncertainty_score":0.35070202},"labels":[],"label_agreement":null},{"id":"W4379512894","doi":"10.1200/jco.23.00566","title":"Reply to V. Nardone et al","year":2023,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine","score_opus":0.11005358029564095,"score_gpt":0.4688016490665829,"score_spread":0.35874806877094195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379512894","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017133344,0.0030118742,0.00023146386,0.963143,0.013605847,0.00024009125,0.00012304573,0.000010762727,0.0025005592],"genre_scores_gemma":[0.00575463,0.009881221,0.0042132274,0.95495594,0.018282838,0.00002288669,0.00010714727,0.00011500422,0.006667135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924325,0.0016476237,0.003897245,0.00076377165,0.0005771536,0.0006817494],"domain_scores_gemma":[0.9924519,0.002233677,0.0032287189,0.00061577716,0.0009582036,0.0005117146],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0045484398,0.00052789383,0.0028572683,0.00017492725,0.00008930303,0.000026592623,0.00071218854,0.0017887282,0.00013578573],"category_scores_gemma":[0.007255498,0.0004364058,0.0016676185,0.00022131328,0.00048096702,0.000009100972,0.0006340428,0.0030874494,0.0005143558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002202868,0.00066973054,0.0046555856,0.000035144487,0.0028579917,0.0026773808,0.00007669018,0.000047101174,0.0001793921,0.000023641693,0.9342372,0.05233732],"study_design_scores_gemma":[0.0035933596,0.012379026,0.030084169,0.00018875072,0.0005915105,0.0006968761,0.00006660734,0.0000013180949,0.0001024834,0.00012279142,0.9518088,0.00036432297],"about_ca_topic_score_codex":0.00013967037,"about_ca_topic_score_gemma":0.0001956962,"teacher_disagreement_score":0.051972996,"about_ca_system_score_codex":0.0002748047,"about_ca_system_score_gemma":0.0029239412,"threshold_uncertainty_score":0.9998088},"labels":[],"label_agreement":null},{"id":"W4379644950","doi":"10.1200/jco.2023.41.16_suppl.11568","title":"Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Sarcoma; Oncology; Vinblastine; Leiomyosarcoma; Adverse effect; Chemotherapy; Gastroenterology; Pathology","score_opus":0.08268008088990014,"score_gpt":0.4032064166453766,"score_spread":0.32052633575547645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379644950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929614,0.00025391244,0.000033473025,0.007826665,0.00033644412,0.000687424,0.000009199556,0.00004778813,0.0015089642],"genre_scores_gemma":[0.9920524,0.0006511697,0.005590455,0.00079127075,0.00051881355,0.000039911818,0.000024232357,0.00006114568,0.00027064187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951469,0.00058538024,0.0023872298,0.00047013644,0.00082644465,0.00058396056],"domain_scores_gemma":[0.9925844,0.0042224615,0.0016814969,0.0003657602,0.00059555826,0.0005502866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028528972,0.00035844138,0.002507862,0.00033613644,0.00007340642,0.000019005316,0.00021564934,0.00035021943,0.00018197733],"category_scores_gemma":[0.0016969825,0.00017529896,0.000192583,0.0009256623,0.00039068804,0.000224848,0.00006571431,0.0016937993,0.000036323097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20798013,0.005803983,0.7120188,0.00009430721,0.0007027657,0.024558071,0.00026350023,0.00012955902,0.000014059894,0.00003641668,0.0014297888,0.046968628],"study_design_scores_gemma":[0.053353507,0.07912253,0.8565413,0.0013708759,0.00044473223,0.0017528862,0.0006233744,0.00020438642,0.00003071999,0.00002544601,0.0063084885,0.00022180147],"about_ca_topic_score_codex":0.00012175096,"about_ca_topic_score_gemma":0.0053077536,"teacher_disagreement_score":0.15462662,"about_ca_system_score_codex":0.0003537936,"about_ca_system_score_gemma":0.003123713,"threshold_uncertainty_score":0.7358809},"labels":[],"label_agreement":null},{"id":"W4379645897","doi":"10.1200/jco.2023.41.17_suppl.lba8505","title":"IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Surrey Memorial Hospital; University of Ottawa; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pemetrexed; Carboplatin; Pembrolizumab; Internal medicine; Lung cancer; Oncology; Tolerability; Progression-free survival; Neutropenia; Cancer; Chemotherapy; Cisplatin; Adverse effect; Immunotherapy","score_opus":0.10570444244188702,"score_gpt":0.45400903663092607,"score_spread":0.34830459418903903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379645897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981642,0.000047834128,0.0000053773642,0.00027926048,0.00018813812,0.0010928769,0.00001934588,0.000012559002,0.0001904264],"genre_scores_gemma":[0.99877614,0.00008413261,0.00038400653,0.0002555454,0.00020395746,0.000023832772,0.000016190334,0.000031534186,0.00022468012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958034,0.0004351615,0.002293806,0.0003185874,0.0008628031,0.00028623533],"domain_scores_gemma":[0.99637,0.0011699463,0.0016755878,0.00021560637,0.00015654396,0.0004122788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013597124,0.0002429692,0.0018885407,0.0004023976,0.00004843383,0.000009099875,0.00014533011,0.00017871495,0.00011345949],"category_scores_gemma":[0.0007222005,0.00012996145,0.00015627767,0.00051987567,0.0002702176,0.00016202571,0.00008149643,0.00050066825,0.0000071849745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4215111,0.014613397,0.5536306,0.000034172528,0.00032390587,0.00062418985,0.00023377809,0.000018705556,0.00003051951,0.0000021404842,0.00020368378,0.008773814],"study_design_scores_gemma":[0.30925968,0.13736835,0.55148476,0.00016485201,0.00048618185,0.00006355503,0.00075362314,0.00011820984,0.0000135879545,0.0000131279385,0.00017536386,0.00009868802],"about_ca_topic_score_codex":0.000086808424,"about_ca_topic_score_gemma":0.00031318262,"teacher_disagreement_score":0.12275496,"about_ca_system_score_codex":0.00012423894,"about_ca_system_score_gemma":0.00068296643,"threshold_uncertainty_score":0.5299674},"labels":[],"label_agreement":null},{"id":"W4379645953","doi":"10.1200/jco.2023.41.17_suppl.lba500","title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Clinical endpoint; Tolerability; Internal medicine; Anastrozole; Population; Oncology; Interim analysis; Goserelin; Cancer; Surgery; Gynecology; Randomized controlled trial; Tamoxifen; Adverse effect","score_opus":0.07422391342854126,"score_gpt":0.4508825997255233,"score_spread":0.37665868629698207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379645953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796555,0.0013468929,0.000003914434,0.017001314,0.00070820213,0.0008796942,0.0002164745,0.00002105465,0.0001669518],"genre_scores_gemma":[0.9886286,0.0067374185,0.0002820543,0.0024043492,0.0015526284,0.00004322954,0.000044253142,0.000036133333,0.0002712983],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99653333,0.00043116775,0.0019118183,0.00032472808,0.0004766503,0.00032230516],"domain_scores_gemma":[0.9946154,0.0030759147,0.0014416768,0.0003032858,0.0002831328,0.00028063636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011260228,0.0002321772,0.0015936447,0.00010696385,0.000058254853,0.000012916347,0.00017752228,0.00016462534,0.00007170611],"category_scores_gemma":[0.0004131212,0.00011629027,0.00021235568,0.0002736806,0.00033605134,0.0001691755,0.00004757347,0.0006973994,0.000009418523],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4239222,0.0022249676,0.073802985,0.0000025206498,0.0004818736,0.0004218074,0.00039284135,0.000006899409,0.000025714922,0.000002992803,0.00020546372,0.49850973],"study_design_scores_gemma":[0.3718432,0.02681236,0.57405925,0.00011451922,0.00012928319,0.000061589446,0.00009906081,0.0000045582055,0.000018760978,0.00011424717,0.026663654,0.00007953325],"about_ca_topic_score_codex":0.0010467157,"about_ca_topic_score_gemma":0.0002622869,"teacher_disagreement_score":0.50025624,"about_ca_system_score_codex":0.0003838703,"about_ca_system_score_gemma":0.0013702617,"threshold_uncertainty_score":0.47421795},"labels":[],"label_agreement":null},{"id":"W4379645970","doi":"10.1200/jco.2023.41.17_suppl.lba4","title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Brentuximab vedotin; Clinical endpoint; Oncology; Nivolumab; Randomized controlled trial; Chemotherapy; Cancer; Lymphoma; Hodgkin lymphoma; Immunotherapy","score_opus":0.12644087717551697,"score_gpt":0.4876273556058542,"score_spread":0.36118647843033724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379645970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900252,0.00067769317,0.000005784942,0.0026161154,0.0028445616,0.0012992636,0.000008021078,0.000035805937,0.0024875274],"genre_scores_gemma":[0.9954596,0.0024857935,0.00040086696,0.00043441582,0.00048654433,0.00008024386,0.000008281112,0.00004225946,0.0006019538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99143773,0.0017597405,0.0049055186,0.00045923877,0.00090903795,0.00052875263],"domain_scores_gemma":[0.98386914,0.011623905,0.003080279,0.00047577062,0.00046885654,0.00048202617],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058819847,0.00034054488,0.0049627223,0.00054771185,0.00005556142,0.000014771767,0.00032675997,0.00044990168,0.00022994904],"category_scores_gemma":[0.009458716,0.00024040465,0.0011882868,0.00070434285,0.00033385004,0.00016089292,0.0001671799,0.00057966,0.00013050772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5509346,0.03039364,0.12168983,0.00007778219,0.0025393653,0.008231326,0.0011573404,0.00016323637,0.000067285546,0.0002002928,0.0023958744,0.28214937],"study_design_scores_gemma":[0.6954478,0.03642843,0.25613275,0.00020896281,0.0010574458,0.00009324559,0.0024785858,0.00029111354,0.00008390184,0.00016286467,0.0074482523,0.00016665622],"about_ca_topic_score_codex":0.0003126217,"about_ca_topic_score_gemma":0.00052956847,"teacher_disagreement_score":0.28198272,"about_ca_system_score_codex":0.0006720052,"about_ca_system_score_gemma":0.0023147357,"threshold_uncertainty_score":0.99888504},"labels":[],"label_agreement":null},{"id":"W4379646000","doi":"10.1200/jco.2023.41.17_suppl.lba1","title":"INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Servier","keywords":"Medicine; Glioma; Internal medicine; Clinical endpoint; Interim analysis; Oligodendroglioma; Placebo; Randomization; Hazard ratio; Randomized controlled trial; Surgery; Oncology; Astrocytoma; Pathology; Confidence interval","score_opus":0.12675541746533447,"score_gpt":0.5069442630659087,"score_spread":0.3801888456005742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379646000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955151,0.00003909993,0.00009096287,0.002017983,0.00086890644,0.0013218888,0.000003886364,0.000019938567,0.00012222015],"genre_scores_gemma":[0.9970385,0.000044912977,0.0022773785,0.0001638143,0.000400232,0.000020868772,0.000015775999,0.000024375418,0.000014130899],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99434435,0.0012782807,0.0027066108,0.0003043708,0.0010484883,0.00031789122],"domain_scores_gemma":[0.9929451,0.0035415103,0.0022861394,0.00024055461,0.0005200949,0.0004666186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064637004,0.00020945983,0.0023209762,0.0004192842,0.000049633618,0.000019347757,0.00024439392,0.00020868632,0.000036025573],"category_scores_gemma":[0.006178341,0.00011545187,0.00016103993,0.0009094266,0.00039535703,0.00018769523,0.000053354837,0.0013415357,0.0000037972045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85002315,0.010902595,0.102912195,0.000031818647,0.0007240699,0.0033384517,0.00077293394,0.0004143608,0.0000012091461,0.000023917302,0.00035581682,0.0304995],"study_design_scores_gemma":[0.80890256,0.0984575,0.08869707,0.00021336827,0.00081750884,0.00016985895,0.0016795899,0.0007245635,0.0000031215204,0.00006467458,0.00015151236,0.00011867713],"about_ca_topic_score_codex":0.00013984728,"about_ca_topic_score_gemma":0.0003621304,"teacher_disagreement_score":0.08755491,"about_ca_system_score_codex":0.00016323644,"about_ca_system_score_gemma":0.0017173523,"threshold_uncertainty_score":0.7396498},"labels":[],"label_agreement":null},{"id":"W4379646019","doi":"10.1200/jco.2023.41.17_suppl.lba9016","title":"Intracranial efficacy of sotorasib versus docetaxel in pretreated<i> KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Medicine; Docetaxel; Oncology; KRAS; Internal medicine; Randomized controlled trial; Lung cancer; Brain metastasis; Cancer; Chemotherapy; Metastasis","score_opus":0.08553337113873839,"score_gpt":0.5350344985612282,"score_spread":0.4495011274224898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379646019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788584,0.0022889597,0.00040752825,0.0034458858,0.0058920737,0.0051553594,0.00026279362,0.000032523654,0.0036564579],"genre_scores_gemma":[0.98455507,0.0066528795,0.005526846,0.0005470313,0.002009298,0.0001940166,0.00029696675,0.000039473933,0.00017842623],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99253917,0.00087611325,0.005128827,0.00042949762,0.00059840793,0.0004279642],"domain_scores_gemma":[0.974307,0.01893417,0.005091203,0.0005092594,0.00074121315,0.0004171521],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049826102,0.00032605595,0.005121889,0.00022923046,0.000058498645,0.00002431364,0.00043277143,0.0004619562,0.00017529386],"category_scores_gemma":[0.021929193,0.00021885427,0.0009110252,0.0006064686,0.00022149792,0.00049336575,0.0001334032,0.0009233407,0.000014228042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9482684,0.0061184764,0.0013682834,0.00004450491,0.0044880635,0.0013807721,0.0003374807,0.00035009187,0.00014591233,0.0000062208373,0.0013585638,0.03613324],"study_design_scores_gemma":[0.967919,0.008601876,0.0010550792,0.00040209448,0.011112072,0.000032846176,0.00038993216,0.006686658,0.00004099749,0.000026325,0.003566124,0.00016697923],"about_ca_topic_score_codex":0.00077297166,"about_ca_topic_score_gemma":0.00036305902,"teacher_disagreement_score":0.035966262,"about_ca_system_score_codex":0.000563558,"about_ca_system_score_gemma":0.00714029,"threshold_uncertainty_score":0.9984883},"labels":[],"label_agreement":null},{"id":"W4379662191","doi":"10.1200/jco.2023.41.17_suppl.lba5511","title":"An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Centre Hospitalier de l’Université de Montréal; University of British Columbia; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Medicine; Clinical endpoint; Surgery; Randomized controlled trial; Cervical cancer; Stage (stratigraphy); Hysterectomy; Dissection (medical); Cancer; Gynecology; Internal medicine","score_opus":0.07525559909361731,"score_gpt":0.44774736447856567,"score_spread":0.3724917653849483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908257,0.00032777654,0.000037788068,0.0016609277,0.0033744331,0.003520135,0.00014793547,0.000036600773,0.00006866948],"genre_scores_gemma":[0.9960337,0.0009957493,0.000034019406,0.0005773083,0.0015287446,0.0006299034,0.00008347094,0.000052025698,0.00006503612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902234,0.0039377743,0.003595579,0.00073208706,0.00087964657,0.0006314852],"domain_scores_gemma":[0.99009925,0.0058856267,0.0024274483,0.00027167544,0.00039891372,0.0009171122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072576394,0.00047942207,0.004099593,0.00060997275,0.0002973321,0.00014599194,0.00035084703,0.0004806884,0.0006564313],"category_scores_gemma":[0.003515334,0.00027510038,0.00048010607,0.00073663925,0.00042068528,0.00041751377,0.00011315147,0.0016913816,0.000003168932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44253868,0.002985412,0.5243016,0.000033360877,0.0013647415,0.00013115958,0.00045445125,0.00004742726,0.000018247852,0.000002447504,0.0000971812,0.028025324],"study_design_scores_gemma":[0.48334423,0.009825707,0.5026474,0.00014423895,0.0011401535,0.000012043509,0.00026467995,0.002057585,0.000005776133,0.000022919497,0.00035272975,0.00018256901],"about_ca_topic_score_codex":0.12947553,"about_ca_topic_score_gemma":0.4934451,"teacher_disagreement_score":0.36396956,"about_ca_system_score_codex":0.0014530785,"about_ca_system_score_gemma":0.0010419005,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W4379662208","doi":"10.1200/jco.2023.41.17_suppl.lba5507","title":"Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"ImmunoGen","keywords":"Medicine; Clinical endpoint; Tolerability; Internal medicine; Progression-free survival; Oncology; Fallopian tube; Chemotherapy; Ovarian cancer; Topotecan; Paclitaxel; Nausea; Randomized controlled trial; Urology; Surgery; Cancer; Adverse effect","score_opus":0.07782574795674795,"score_gpt":0.4396865665417338,"score_spread":0.36186081858498587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103415,0.0002944711,0.00018222224,0.0055010235,0.0014905276,0.0012610498,0.000105080544,0.0000586459,0.00007281413],"genre_scores_gemma":[0.97247756,0.0006077314,0.023531301,0.0013517835,0.0015520679,0.00006133755,0.00004787898,0.00013125398,0.0002391149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990888,0.00080206036,0.0056918818,0.000706457,0.0012605642,0.0006510491],"domain_scores_gemma":[0.9894425,0.0025876216,0.0055725067,0.0007139587,0.00094201806,0.00074137055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002992005,0.00054129696,0.0044248495,0.0005156022,0.00008704724,0.0000118328335,0.0004951949,0.0005935038,0.00024456985],"category_scores_gemma":[0.0032733306,0.00038702035,0.00036541832,0.0011483191,0.0009873849,0.00043320408,0.00011202579,0.0017031922,0.0000022039746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44889256,0.015655339,0.026258014,0.00055029755,0.0028124163,0.011150309,0.0030929805,0.0007184833,0.37102717,0.00005489649,0.0019380894,0.11784944],"study_design_scores_gemma":[0.4491597,0.15520748,0.2704618,0.003712829,0.0011037582,0.001211523,0.0026286452,0.00009548066,0.053320304,0.0005868135,0.061349522,0.0011621373],"about_ca_topic_score_codex":0.00075935695,"about_ca_topic_score_gemma":0.00070788775,"teacher_disagreement_score":0.31770688,"about_ca_system_score_codex":0.00073341775,"about_ca_system_score_gemma":0.007889159,"threshold_uncertainty_score":0.99985814},"labels":[],"label_agreement":null},{"id":"W4379662222","doi":"10.1200/jco.2023.41.17_suppl.lba4501","title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Renal cell carcinoma; Temsirolimus; Population; Pembrolizumab; Internal medicine; Sunitinib; Interim analysis; Discontinuation; Oncology; Urology; Clinical trial; Cancer","score_opus":0.16010111005953448,"score_gpt":0.4468035488967355,"score_spread":0.28670243883720103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876574,0.0007546662,0.000095556614,0.002554492,0.0011347211,0.00066566037,0.00005198087,0.00003235754,0.007053163],"genre_scores_gemma":[0.9921916,0.0023179143,0.0024840678,0.00039364593,0.0010186955,0.000024158751,0.00009019386,0.00006736988,0.0014123518],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942162,0.00045677906,0.0034858203,0.0004728058,0.00078542944,0.0005829513],"domain_scores_gemma":[0.9871531,0.0075679715,0.0029040494,0.00056190975,0.0011606974,0.0006522551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026991812,0.00035474246,0.0033041763,0.0008366517,0.00009707754,0.000012093795,0.00038065304,0.0005896211,0.00045204206],"category_scores_gemma":[0.002052345,0.00026893485,0.0025528218,0.0011599105,0.0002791082,0.00010561954,0.000095051946,0.0009527904,0.000072738694],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8253824,0.012317495,0.035608303,0.0006467761,0.011911099,0.006414789,0.0016032828,0.012914785,0.010618753,0.0002797565,0.014871303,0.06743127],"study_design_scores_gemma":[0.2589084,0.26288265,0.3391598,0.00013621803,0.015532336,0.00015808796,0.0016382755,0.003067304,0.026846953,0.00034972932,0.090621635,0.0006986074],"about_ca_topic_score_codex":0.000054789074,"about_ca_topic_score_gemma":0.00004816175,"teacher_disagreement_score":0.56647396,"about_ca_system_score_codex":0.00038915811,"about_ca_system_score_gemma":0.0021474638,"threshold_uncertainty_score":0.9999763},"labels":[],"label_agreement":null},{"id":"W4379662223","doi":"10.1200/jco.2023.41.17_suppl.lba100","title":"KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Randomization; Tolerability; Lung cancer; Population; Internal medicine; Stage (stratigraphy); Oncology; Surgery; Clinical trial; Cancer; Adverse effect; Pathology; Immunotherapy","score_opus":0.1590405190309529,"score_gpt":0.48809078074049345,"score_spread":0.32905026170954055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915726,0.00028718243,0.0011474127,0.0027392872,0.0013445569,0.0049591493,0.000047759422,0.000048693877,0.00026867195],"genre_scores_gemma":[0.99184406,0.0010016445,0.00047410306,0.0009378056,0.00078376627,0.00022012745,0.000023177201,0.00008024834,0.0046350732],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99305636,0.0010137461,0.0041820253,0.00047873062,0.0007756307,0.0004935158],"domain_scores_gemma":[0.9844734,0.010957647,0.00322397,0.00037679757,0.00057325285,0.0003949104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009193695,0.00038537133,0.0037262214,0.00050536625,0.00014991146,0.000039042236,0.00028292573,0.00068466243,0.00041445182],"category_scores_gemma":[0.0030493715,0.00024055634,0.0009958755,0.0005977463,0.0004670811,0.00018429157,0.000043701948,0.0009297668,0.000003914456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95581114,0.004272858,0.0007157712,0.00017420965,0.0023356008,0.00028320524,0.0008754626,0.000056601555,0.0013200875,0.0000036364675,0.011156799,0.022994598],"study_design_scores_gemma":[0.8892904,0.09058868,0.00078945915,0.00019712852,0.0009229418,0.00012215995,0.0011078726,0.0018374118,0.00084549625,0.00001562163,0.014049272,0.00023356371],"about_ca_topic_score_codex":0.00020675204,"about_ca_topic_score_gemma":0.00035915422,"teacher_disagreement_score":0.086315826,"about_ca_system_score_codex":0.00032683706,"about_ca_system_score_gemma":0.0031268843,"threshold_uncertainty_score":0.9809603},"labels":[],"label_agreement":null},{"id":"W4379662232","doi":"10.1200/jco.2023.41.17_suppl.lba3","title":"Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; T790M; Hazard ratio; Adjuvant; Clinical endpoint; Placebo; Lung cancer; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Confidence interval; Clinical trial; Cancer; Adenocarcinoma; Pathology","score_opus":0.05934005480903422,"score_gpt":0.44847918798046527,"score_spread":0.38913913317143106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954206,0.00020943343,0.000050232797,0.0017580792,0.0010740284,0.00075515406,0.00014975276,0.000011524511,0.00057121634],"genre_scores_gemma":[0.99772775,0.00041331572,0.00028293414,0.0004700965,0.0004659115,0.00002233845,0.00012098773,0.000025314574,0.00047137847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957996,0.00060688466,0.0023953405,0.00027626762,0.00061249913,0.0003094036],"domain_scores_gemma":[0.9938004,0.0028193956,0.002115583,0.00031304045,0.00071202876,0.00023954353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015461823,0.00019140894,0.0018346442,0.00028545925,0.000051598123,0.000011240822,0.00022580363,0.00025832182,0.00029039418],"category_scores_gemma":[0.0008718159,0.000104412975,0.00052498665,0.0010911605,0.00013050898,0.00008533204,0.000060196227,0.0007888163,0.0000047939125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08851994,0.002414928,0.89566576,0.000021566197,0.004648251,0.00022416445,0.00070044975,0.0011711634,0.000055338056,0.000003058141,0.001434258,0.0051411074],"study_design_scores_gemma":[0.13707511,0.007400044,0.8480046,0.00012993933,0.0050608516,4.3642217e-7,0.00021214536,0.0008644851,0.00003449256,0.000013983511,0.0011093757,0.00009456164],"about_ca_topic_score_codex":0.0026676138,"about_ca_topic_score_gemma":0.0027554142,"teacher_disagreement_score":0.04855518,"about_ca_system_score_codex":0.00029651396,"about_ca_system_score_gemma":0.0026408301,"threshold_uncertainty_score":0.4684719},"labels":[],"label_agreement":null},{"id":"W4379662235","doi":"10.1200/jco.2023.41.17_suppl.lba7505","title":"Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Medicine; Clinical endpoint; Rituximab; Hazard ratio; Internal medicine; Randomization; Randomized controlled trial; Regimen; Radiation therapy; Lymphoma; Nuclear medicine; Oncology; Radiology; Confidence interval","score_opus":0.06727258392776242,"score_gpt":0.3905714880302037,"score_spread":0.3232989041024413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648318,0.00026305357,0.00007354546,0.03213914,0.00079823914,0.0016824092,0.000009386376,0.000014974648,0.000187434],"genre_scores_gemma":[0.9766867,0.0017448654,0.0055978196,0.01481547,0.00070283894,0.00011528714,0.000021912578,0.000041132906,0.0002739781],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945678,0.0018548404,0.0023714092,0.00021453704,0.0007186117,0.00027278453],"domain_scores_gemma":[0.9835011,0.014171395,0.0013816828,0.0002723464,0.00043458954,0.00023892704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01084334,0.00019174692,0.002343519,0.00022551548,0.00005654345,0.000018706216,0.00020027348,0.00020124005,0.00005518128],"category_scores_gemma":[0.0034527634,0.00009518368,0.00049319,0.00044849853,0.0002096824,0.00007744513,0.000030467254,0.00028242337,0.000015826228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8667347,0.0032947955,0.04703211,0.000009783073,0.00038481326,0.00025221467,0.0003160894,0.000018763045,0.000063920226,0.000007404783,0.00321897,0.07866644],"study_design_scores_gemma":[0.52894276,0.020043472,0.42307556,0.00007884339,0.0001300579,0.000014546391,0.000025603576,0.000025401278,0.00001987236,0.000027166026,0.027560143,0.000056582656],"about_ca_topic_score_codex":0.000023015526,"about_ca_topic_score_gemma":0.000010594842,"teacher_disagreement_score":0.37604344,"about_ca_system_score_codex":0.0007258345,"about_ca_system_score_gemma":0.002190587,"threshold_uncertainty_score":0.413353},"labels":[],"label_agreement":null},{"id":"W4379662243","doi":"10.1200/jco.2023.41.17_suppl.lba107","title":"Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Interim analysis; Refractory (planetary science); Intention-to-treat analysis; Censoring (clinical trials); Oncology; Survival analysis; Cumulative incidence; Confidence interval; Proportional hazards model; Randomized controlled trial; Surgery; Cohort","score_opus":0.13418231096971184,"score_gpt":0.4891123781802256,"score_spread":0.3549300672105138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934047,0.0012409819,0.000011567205,0.00043908725,0.0011583713,0.00097080425,0.00004527698,0.000007748708,0.0027214815],"genre_scores_gemma":[0.99453294,0.0045253765,0.000082410974,0.00013567017,0.00022795849,0.000010065828,0.000011992288,0.000031035026,0.00044254775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9890759,0.0042645484,0.004389308,0.00028884422,0.0016211027,0.00036032574],"domain_scores_gemma":[0.9819065,0.012934662,0.003148939,0.00066318305,0.0011254074,0.00022132008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01602267,0.00021823522,0.0055136066,0.0008694689,0.00003758683,0.0000049657087,0.0005349146,0.00040564509,0.00062317046],"category_scores_gemma":[0.0041433712,0.00013393344,0.002270516,0.0016002043,0.0004403717,0.000057613175,0.00017756817,0.0009881388,0.0000020736275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8685289,0.023015754,0.02731079,0.000090684305,0.00706943,0.00028535683,0.0022498101,0.00014637869,0.006993024,0.0000153592,0.00028457795,0.064009935],"study_design_scores_gemma":[0.8397578,0.053138345,0.095379256,0.00007355458,0.002485632,0.000003267299,0.0026864568,0.0002238625,0.0010582176,0.00003157861,0.005049707,0.00011234201],"about_ca_topic_score_codex":0.00007912237,"about_ca_topic_score_gemma":0.0002813331,"teacher_disagreement_score":0.06806847,"about_ca_system_score_codex":0.0004061827,"about_ca_system_score_gemma":0.0028683005,"threshold_uncertainty_score":0.682328},"labels":[],"label_agreement":null},{"id":"W4379662245","doi":"10.1200/jco.2023.41.17_suppl.lba5506","title":"Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Bevacizumab; Internal medicine; Carboplatin; Taxane; Population; Oncology; Paclitaxel; BRCA mutation; Ovarian cancer; Urology; Cancer; Chemotherapy; Cisplatin; Breast cancer","score_opus":0.032711900382277684,"score_gpt":0.39351388607395377,"score_spread":0.3608019856916761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98107624,0.0006456696,0.0005064607,0.010511565,0.0009833218,0.005775509,0.000209748,0.000043535194,0.00024795477],"genre_scores_gemma":[0.99249846,0.001585932,0.0016479071,0.0025098638,0.0006193147,0.0006811095,0.0000865944,0.000081077276,0.00028977136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99022496,0.0025613746,0.0047147362,0.0008116028,0.0010512127,0.000636122],"domain_scores_gemma":[0.97469383,0.018321525,0.0052103954,0.00047507705,0.00075726735,0.00054187357],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009345078,0.00054332905,0.004866627,0.00026437867,0.00019035532,0.00006723715,0.00025444562,0.00042246512,0.00006190777],"category_scores_gemma":[0.012464691,0.00030994145,0.00041701752,0.00059279543,0.0008810122,0.00039430166,0.0000635865,0.0015657736,0.0000043241344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96267784,0.0016423385,0.0046500587,0.000022988537,0.0012607173,0.00071297976,0.001286225,0.00026032768,0.00011725527,0.000016898666,0.004493875,0.02285848],"study_design_scores_gemma":[0.95379174,0.020023583,0.017881634,0.0011194636,0.0012082749,0.00009163793,0.00058671273,0.0035184764,0.000048220016,0.00038227788,0.000994512,0.00035349664],"about_ca_topic_score_codex":0.00080717885,"about_ca_topic_score_gemma":0.0015056152,"teacher_disagreement_score":0.022504983,"about_ca_system_score_codex":0.000518295,"about_ca_system_score_gemma":0.0022320899,"threshold_uncertainty_score":0.99993527},"labels":[],"label_agreement":null},{"id":"W4379791997","doi":"10.1200/jco.23.00233","title":"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Olaparib; Prostate cancer; Pembrolizumab; Oncology; Internal medicine; Randomized controlled trial; Biomarker; Open label; PARP inhibitor; Metastatic breast cancer; Cancer; Immunotherapy; Breast cancer; Poly ADP ribose polymerase","score_opus":0.18578888301456287,"score_gpt":0.51321039237129,"score_spread":0.3274215093567271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379791997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984359,0.0010565576,0.000027227074,0.0054141073,0.000475629,0.008432508,0.000082090846,0.000019556168,0.0001332913],"genre_scores_gemma":[0.9913104,0.004638003,0.00058113295,0.00035624093,0.00031238844,0.0008160268,0.00016569062,0.000040936942,0.0017791406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953399,0.0010929919,0.002277609,0.0003179305,0.00050854863,0.0004630392],"domain_scores_gemma":[0.99082685,0.005648832,0.0017174416,0.00020126619,0.0011997832,0.0004058252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004965931,0.00024049828,0.0024713753,0.00018136557,0.00022427867,0.00008390643,0.00024219048,0.00016261822,0.000048946],"category_scores_gemma":[0.0028510885,0.000110378896,0.0002406238,0.0005058957,0.00057323836,0.00019809714,0.000065659755,0.0005534405,0.0000025444624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9354349,0.003082188,0.00048364082,0.000075335345,0.0026217096,0.00024917055,0.00029569317,0.0000036813258,0.00011093732,0.00002811852,0.004214456,0.053400204],"study_design_scores_gemma":[0.9307252,0.057041273,0.0023488866,0.00016849839,0.0024746342,0.000040739687,0.000094375384,0.0010382842,0.000035441997,0.00016793165,0.0057443334,0.000120401375],"about_ca_topic_score_codex":0.0001848044,"about_ca_topic_score_gemma":0.00027682862,"teacher_disagreement_score":0.053959087,"about_ca_system_score_codex":0.00025680166,"about_ca_system_score_gemma":0.004660472,"threshold_uncertainty_score":0.8267477},"labels":[],"label_agreement":null},{"id":"W4379984464","doi":"10.1200/jco.2023.41.16_suppl.tps4204","title":"Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Pancreatic cancer; Clinical endpoint; Perioperative; FOLFIRINOX; Neoadjuvant therapy; Oncology; Internal medicine; Cancer; Surgery; Adverse effect; Adjuvant therapy; Randomized controlled trial; Clinical trial; Oxaliplatin; Breast cancer; Colorectal cancer","score_opus":0.5331988781864347,"score_gpt":0.6513751795581946,"score_spread":0.11817630137175983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379984464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98110604,0.0020546704,0.00018869322,0.008986563,0.0027978737,0.0019597113,0.000017024075,0.000025365598,0.0028640786],"genre_scores_gemma":[0.93605745,0.027806932,0.011258551,0.0019728132,0.010355385,0.0006416775,0.000032604643,0.00007673363,0.011797874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99456495,0.0010653518,0.0027343198,0.00033507086,0.00070998113,0.0005903543],"domain_scores_gemma":[0.98258597,0.013798273,0.0014853664,0.00025420968,0.0013625212,0.00051365694],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012373527,0.00020310457,0.0030183252,0.00015025586,0.00017758725,0.00001730358,0.00026889498,0.00046793767,0.0008233305],"category_scores_gemma":[0.021183051,0.00013640361,0.0006458153,0.0004105516,0.00045888207,0.00012831896,0.00005688594,0.0011209926,0.000045479108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80082947,0.0021674756,0.004019405,0.000048288603,0.0016372239,0.00036200727,0.0006304536,0.000021306621,0.0009794029,0.00009716364,0.015611129,0.17359665],"study_design_scores_gemma":[0.68685967,0.2286768,0.0058126934,0.0002426764,0.0010484946,0.000055507935,0.0011300357,0.010938254,0.00013008573,0.00024133205,0.06469932,0.00016514823],"about_ca_topic_score_codex":0.00006773128,"about_ca_topic_score_gemma":0.000065923865,"teacher_disagreement_score":0.22650932,"about_ca_system_score_codex":0.00035318616,"about_ca_system_score_gemma":0.009374295,"threshold_uncertainty_score":0.9962416},"labels":[],"label_agreement":null},{"id":"W4379984958","doi":"10.1200/jco.2023.41.16_suppl.e20006","title":"Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Pomalidomide; Medicine; Lenalidomide; Dexamethasone; Refractory (planetary science); Internal medicine; Bortezomib; Daratumumab; Multiple myeloma; Gastroenterology; Cohort","score_opus":0.10937720769085078,"score_gpt":0.44787935980253124,"score_spread":0.33850215211168044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379984958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993642,0.0003901257,0.000019902,0.005230756,0.00009729755,0.0004980768,0.000006967523,0.000009115581,0.00010577226],"genre_scores_gemma":[0.99194354,0.0031672684,0.0043833954,0.00019417795,0.0000980297,0.0000074924424,0.000007493705,0.000018162382,0.0001804439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664074,0.0007326222,0.00170654,0.00026493607,0.00036682675,0.0002883444],"domain_scores_gemma":[0.9881298,0.0103085935,0.0008017379,0.00014975258,0.00023217141,0.00037797235],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003854199,0.00015224084,0.0013682331,0.0004051783,0.00003480437,0.0000076045617,0.00008033291,0.00030465916,0.000017768001],"category_scores_gemma":[0.012282264,0.0000991892,0.00006936771,0.00038333112,0.0003513213,0.00011896457,0.00008163974,0.00090093137,0.0000026187122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12160219,0.0021568034,0.6773887,0.00011396693,0.00020511192,0.003130073,0.0002959412,0.000012682896,0.0011466407,0.000014971502,0.00012606927,0.1938068],"study_design_scores_gemma":[0.08576725,0.018385189,0.89107734,0.00045231124,0.0000797482,0.000274441,0.00023964896,0.0022848197,0.000070422975,0.000060805793,0.001228529,0.000079512625],"about_ca_topic_score_codex":0.00014538951,"about_ca_topic_score_gemma":0.00094459864,"teacher_disagreement_score":0.21368857,"about_ca_system_score_codex":0.00013432889,"about_ca_system_score_gemma":0.0007275289,"threshold_uncertainty_score":0.9960377},"labels":[],"label_agreement":null},{"id":"W4380355515","doi":"10.1200/jco.22.02320","title":"Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Coronary artery disease; Cardiology; Internal medicine; Ventricle; Heart failure; Cumulative incidence; Cancer; Radiation therapy; Cohort","score_opus":0.03667664061782985,"score_gpt":0.3970711349017339,"score_spread":0.360394494283904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380355515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909809,0.004235246,0.0000015837151,0.0020053424,0.0017804067,0.0007238195,0.00022966205,0.000009378046,0.00003361225],"genre_scores_gemma":[0.9744794,0.024005102,0.0000279343,0.00012605592,0.0012791847,0.000018170813,0.000021203945,0.000021186665,0.000021802825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99573666,0.0012491557,0.0020519544,0.00026268375,0.0005139157,0.00018561399],"domain_scores_gemma":[0.99458027,0.0022394212,0.0023157047,0.0003243615,0.00029880024,0.00024145049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004711527,0.00016308484,0.0018098524,0.00013089272,0.000043930635,0.0000061136107,0.00012806612,0.0002793014,0.000020542675],"category_scores_gemma":[0.0027464111,0.00010909553,0.00060686504,0.00044665576,0.00016269981,0.0000882525,0.00004593967,0.0009130963,4.9164925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010762076,0.0005634873,0.9242814,0.00001982921,0.0016892425,0.00011708421,0.0026004764,0.00033799498,0.0006371235,0.0000020615266,0.000203988,0.068471104],"study_design_scores_gemma":[0.005135578,0.0008802347,0.99001914,0.00013555528,0.001435527,0.0000057455536,0.0007036761,0.000029600053,0.0004825094,0.00022353294,0.000857553,0.000091372625],"about_ca_topic_score_codex":0.007957693,"about_ca_topic_score_gemma":0.0027602918,"teacher_disagreement_score":0.06837973,"about_ca_system_score_codex":0.000111123816,"about_ca_system_score_gemma":0.0015950982,"threshold_uncertainty_score":0.9986484},"labels":[],"label_agreement":null},{"id":"W4380562973","doi":"10.1200/jco.22.01856","title":"Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Interior Health","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Brachytherapy; Prostate cancer; Urology; Clinical endpoint; Prostate; Radiation therapy; External beam radiotherapy; Prostate-specific antigen; Randomized controlled trial; Internal medicine; Cancer; Oncology","score_opus":0.09237329880463416,"score_gpt":0.5014962855885621,"score_spread":0.4091229867839279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380562973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97596616,0.00570232,0.0002418203,0.0041013244,0.008756772,0.0050641582,0.00006635575,0.000041585765,0.00005948569],"genre_scores_gemma":[0.77785665,0.2141156,0.0008777611,0.0009954502,0.005083028,0.0008587211,0.000042168125,0.00007722779,0.000093373805],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98841745,0.0041596573,0.005708287,0.00053484313,0.0006282298,0.0005515629],"domain_scores_gemma":[0.9409421,0.05021277,0.0072308052,0.00035650717,0.00072748814,0.00053032994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.025278555,0.00042762535,0.006348879,0.0003041432,0.00009034954,0.000019883873,0.00027371553,0.00072670385,0.000103772814],"category_scores_gemma":[0.007845865,0.0002462235,0.0021856164,0.00035561743,0.0008343513,0.00018254055,0.00003614451,0.0012938478,0.000010272578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5131918,0.0018609778,0.034001365,0.000037518294,0.0026569408,0.00016951402,0.00017020847,0.000053212803,0.000037654405,0.0000066191933,0.0012068629,0.4466073],"study_design_scores_gemma":[0.67489433,0.2815655,0.01815177,0.0001830734,0.0014553999,0.000036862093,0.000027239934,0.00025945666,0.0010687554,0.00013555033,0.022067716,0.00015434907],"about_ca_topic_score_codex":0.00008788459,"about_ca_topic_score_gemma":0.00006985504,"teacher_disagreement_score":0.44645295,"about_ca_system_score_codex":0.0004407669,"about_ca_system_score_gemma":0.003399578,"threshold_uncertainty_score":0.999999},"labels":[],"label_agreement":null},{"id":"W4380740721","doi":"10.1200/jco.23.00570","title":"Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Vancouver General Hospital; Terry Fox Research Institute; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Queen's University; Spinal Cord Injury BC; Princess Margaret Cancer Centre; Simon Fraser University","funders":"National Cancer Institute","keywords":"Medicine; Concordance; Oncology; Cohort; Diffuse large B-cell lymphoma; Exome sequencing; Internal medicine; Somatic evolution in cancer; Autologous stem-cell transplantation; Exome; Population; Lymphoma; Biopsy; Cancer; Mutation; Gene; Biology","score_opus":0.07014261780382237,"score_gpt":0.39890226877294815,"score_spread":0.3287596509691258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380740721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887727,0.00020507618,0.0000125327015,0.0067212414,0.00046704427,0.00014581301,0.0000241348,0.00002289819,0.0036285433],"genre_scores_gemma":[0.9964005,0.0004913042,0.00040107017,0.0013292491,0.00023545054,0.0000073305214,0.0000370487,0.000021284528,0.0010767751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972465,0.000281278,0.0015503467,0.00019976066,0.0003916214,0.00033046142],"domain_scores_gemma":[0.9952308,0.0029980172,0.0010756654,0.00016786001,0.00023132504,0.00029636646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00182916,0.0001467846,0.0011707857,0.00019458846,0.000052115243,0.0000067010897,0.000107976906,0.0003615049,0.00005119873],"category_scores_gemma":[0.0025168771,0.0000962196,0.0003399073,0.0004063323,0.00009973541,0.00007982328,0.000064431755,0.0003685489,0.00007034498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017196012,0.029729022,0.9300631,0.000015473912,0.00032947995,0.00975825,0.00010615176,0.0000037082575,0.0000014160939,0.00011718045,0.0121105695,0.016046006],"study_design_scores_gemma":[0.06668158,0.0059875916,0.9143802,0.00023157505,0.0003544066,0.00026539582,0.00020993639,0.003931996,0.0000050671892,0.00017618574,0.007681052,0.00009500046],"about_ca_topic_score_codex":0.000036072586,"about_ca_topic_score_gemma":0.00032284265,"teacher_disagreement_score":0.06496198,"about_ca_system_score_codex":0.0015494501,"about_ca_system_score_gemma":0.0013406421,"threshold_uncertainty_score":0.4051758},"labels":[],"label_agreement":null},{"id":"W4381487700","doi":"10.1200/jco.22.02555","title":"Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"National Cancer Institute","keywords":"Medicine; Wilms' tumor; Chemotherapy; Incidence (geometry); Radiation therapy; Internal medicine; Demographics; Grading (engineering); Pediatrics; Surgery","score_opus":0.0472836705084622,"score_gpt":0.436726411250155,"score_spread":0.38944274074169277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381487700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907353,0.0038229004,0.0000029265486,0.0038420055,0.0012969027,0.00008317659,0.000005323654,0.0000027534213,0.00020870232],"genre_scores_gemma":[0.9603413,0.035882868,0.00036386293,0.0012390168,0.0010313502,0.0000046897053,0.0000026407274,0.000009424002,0.001124862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975988,0.0003416016,0.0014915694,0.00021135632,0.00022278416,0.00013383263],"domain_scores_gemma":[0.99825525,0.00038968658,0.00083574076,0.0000962101,0.00033814262,0.00008499337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032135884,0.000102406324,0.0007141352,0.00011195312,0.000016907154,0.000003248971,0.00011598328,0.00032575976,0.0000075802136],"category_scores_gemma":[0.0024337715,0.000067941146,0.00028689712,0.00015354963,0.00031234886,0.000009186803,0.000060947095,0.00046828657,0.000002068781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004898509,0.0003616035,0.92919254,0.00010360318,0.00076208793,0.00011630724,0.00009239359,0.00014520685,0.001566901,0.000055205182,0.024487004,0.038218617],"study_design_scores_gemma":[0.0037058315,0.0030757685,0.9641937,0.00008708857,0.000060128885,0.0002088155,0.00010745247,0.00001420588,0.00042957976,0.0007176117,0.027288502,0.0001113388],"about_ca_topic_score_codex":0.0000022629379,"about_ca_topic_score_gemma":0.000015104608,"teacher_disagreement_score":0.038107276,"about_ca_system_score_codex":0.000026673524,"about_ca_system_score_gemma":0.00043896702,"threshold_uncertainty_score":0.29136276},"labels":[],"label_agreement":null},{"id":"W4381612716","doi":"10.1200/jco.22.02746","title":"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Sanofi","keywords":"Medicine; Internal medicine; Hazard ratio; Estrogen receptor; Oncology; Breast cancer; Fulvestrant; Cancer; Progression-free survival; Clinical endpoint; Gynecology; Clinical trial; Confidence interval; Chemotherapy","score_opus":0.08678585079797575,"score_gpt":0.4766479143054478,"score_spread":0.38986206350747205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381612716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893228,0.0006797048,0.00014645323,0.0051564714,0.0017244561,0.0024012031,0.00044147452,0.00007109533,0.00005634491],"genre_scores_gemma":[0.99009186,0.0020472312,0.0060176323,0.00029183464,0.0010986527,0.00021369403,0.000036884725,0.00011783496,0.00008439898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98979944,0.0028525863,0.004720294,0.00072827697,0.0010401258,0.0008592951],"domain_scores_gemma":[0.9878008,0.005484255,0.0039475206,0.00034564198,0.0017940636,0.00062776514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029542702,0.00064222753,0.0058354577,0.00062150817,0.00017798254,0.000014833891,0.00043946493,0.00039476008,0.00073427794],"category_scores_gemma":[0.00277203,0.0005008311,0.0010838766,0.0011121281,0.0008647178,0.0004860281,0.000108334585,0.0019538607,0.000009822061],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76128936,0.006644517,0.01655972,0.000040427018,0.004131047,0.00026829797,0.0034174111,0.00020687778,0.013675268,0.000068805355,0.00025404894,0.1934442],"study_design_scores_gemma":[0.854488,0.09287938,0.026574029,0.0004284439,0.0008718411,0.00013779233,0.004264681,0.000059688115,0.017583072,0.0003408486,0.00179415,0.00057806674],"about_ca_topic_score_codex":0.00041848354,"about_ca_topic_score_gemma":0.0002241604,"teacher_disagreement_score":0.19286613,"about_ca_system_score_codex":0.0013530997,"about_ca_system_score_gemma":0.002196241,"threshold_uncertainty_score":0.99974436},"labels":[],"label_agreement":null},{"id":"W4381612727","doi":"10.1200/jco.22.01599","title":"Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Melanoma; Oncology; Clinical trial; Confidence interval; Cancer; Immunotherapy; Cancer research","score_opus":0.10690249198560138,"score_gpt":0.47226073629170395,"score_spread":0.3653582443061026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381612727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933595,0.0002553355,0.0000037350735,0.0035338711,0.004898727,0.00043681197,0.0000054648826,0.000011944699,0.0015181493],"genre_scores_gemma":[0.99785066,0.0004963338,0.00009386005,0.00041562223,0.00045458417,0.000006822812,0.0000017166839,0.00001928117,0.00066113996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99596137,0.00055251265,0.002526491,0.00019591123,0.00049465493,0.0002690847],"domain_scores_gemma":[0.99583393,0.001965284,0.0014875876,0.0003426989,0.00022783052,0.00014269419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035155842,0.00014555232,0.0014116623,0.00019400376,0.00004276351,0.0000044986505,0.0003263045,0.00027405765,0.0001489273],"category_scores_gemma":[0.0020596888,0.000090896916,0.00074147753,0.00062942813,0.0002216479,0.000081074875,0.000089524074,0.0008765715,0.000012809942],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6464722,0.005901374,0.04787516,0.000040270756,0.0013803354,0.0007409999,0.001343541,0.000031974345,0.002608959,0.000032391454,0.0067359596,0.2868368],"study_design_scores_gemma":[0.49832147,0.05706531,0.3956355,0.00019987318,0.0004829921,0.00009296902,0.0035122817,0.00007090131,0.00043340196,0.00013446776,0.043900244,0.00015058904],"about_ca_topic_score_codex":0.00005645562,"about_ca_topic_score_gemma":0.00037477823,"teacher_disagreement_score":0.34776035,"about_ca_system_score_codex":0.00022619797,"about_ca_system_score_gemma":0.0015682239,"threshold_uncertainty_score":0.3808316},"labels":[],"label_agreement":null},{"id":"W4382198144","doi":"10.1200/jco.22.02887","title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; Regeneron Pharmaceuticals; National Institutes of Health; Astellas Pharma; G1 Therapeutics; Pharmacyclics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Clovis Oncology; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Seagen; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Neutropenia; Internal medicine; Rash; Oncology; Urothelial cancer; Adverse effect; Metastatic Urothelial Carcinoma; Cisplatin; Cancer; Nausea; Chemotherapy; Bladder cancer; Urothelial carcinoma; Immunotherapy","score_opus":0.09489864755430755,"score_gpt":0.45565051426684977,"score_spread":0.3607518667125422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382198144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579805,0.00013098541,0.000103237595,0.0010966287,0.00044884044,0.0012948981,0.000029540948,0.000045063618,0.0010527415],"genre_scores_gemma":[0.99171233,0.00088117894,0.003097324,0.0013459483,0.00032902742,0.00009554383,0.000018344239,0.00007747998,0.0024428004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582803,0.0003059835,0.002173977,0.00038185925,0.00074593804,0.00056417997],"domain_scores_gemma":[0.99613893,0.001002141,0.0014266474,0.00027328642,0.00066103996,0.00049795356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088439585,0.000346871,0.002311931,0.00031442213,0.000054174852,0.000016609809,0.00020538103,0.00021240089,0.0005113484],"category_scores_gemma":[0.00093212834,0.00016563092,0.00020198648,0.0008383399,0.00021441792,0.00021409412,0.000042933327,0.0008244307,0.000036429687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24707918,0.002292501,0.6341034,0.0001370633,0.0010662586,0.003149974,0.00033565832,0.0006044622,0.000012342539,0.0000062554072,0.0007657427,0.110447146],"study_design_scores_gemma":[0.21976879,0.13162018,0.62975913,0.0019609635,0.002362977,0.0006151086,0.000304311,0.0006018493,0.00013395373,0.000064399195,0.012351135,0.0004572029],"about_ca_topic_score_codex":0.00029898266,"about_ca_topic_score_gemma":0.0032976593,"teacher_disagreement_score":0.12932768,"about_ca_system_score_codex":0.00038126344,"about_ca_system_score_gemma":0.0086098695,"threshold_uncertainty_score":0.9970104},"labels":[],"label_agreement":null},{"id":"W4383199379","doi":"10.1200/jco.23.00759","title":"Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Context (archaeology); Clinical trial; Cancer; Oncology; Population; Palbociclib; Letrozole; Targeted therapy; Internal medicine; Bioinformatics; Aromatase; Biology","score_opus":0.18503550709040315,"score_gpt":0.5029483626875648,"score_spread":0.31791285559716165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383199379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024842964,0.9716289,0.000025044385,0.001337309,0.0008727614,0.00086973445,0.00030404195,0.00002866935,0.000090591406],"genre_scores_gemma":[0.010485186,0.9849924,0.002710377,0.00026475018,0.0012477514,0.0000379077,0.000014596021,0.000112113536,0.00013494103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99229693,0.0012024617,0.0050702477,0.0004767012,0.0004703684,0.00048331212],"domain_scores_gemma":[0.98709565,0.005111291,0.006237058,0.00024140975,0.00094937504,0.000365214],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015586386,0.00054613315,0.008476072,0.00059419003,0.000049138842,0.0000069316993,0.00024380138,0.0006291004,0.00014294476],"category_scores_gemma":[0.0024557377,0.00037982877,0.0010237863,0.00055425166,0.00073340227,0.00025296237,0.00012644046,0.0025073178,0.0000053740714],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023318408,0.00027371963,0.0006394114,0.0030273849,0.0019616685,0.00066013884,0.00042075285,0.0000034123254,0.0003573601,0.00004579838,0.00006898205,0.9902095],"study_design_scores_gemma":[0.049389794,0.025332103,0.17846563,0.08348509,0.0065108156,0.008110578,0.003528806,0.000016431059,0.0003498532,0.002147911,0.6403238,0.0023391675],"about_ca_topic_score_codex":0.00015812049,"about_ca_topic_score_gemma":0.00011951951,"teacher_disagreement_score":0.98787034,"about_ca_system_score_codex":0.0009578887,"about_ca_system_score_gemma":0.0032159663,"threshold_uncertainty_score":0.99986535},"labels":[],"label_agreement":null},{"id":"W4383895788","doi":"10.1200/jco.23.01055","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Guideline; Clinical Practice; Family medicine; Schedule; Clinical Oncology; Medical physics; Cancer; Pathology; Internal medicine","score_opus":0.08184180362781925,"score_gpt":0.507410448665457,"score_spread":0.4255686450376378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383895788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971317,0.0012377168,0.005186316,0.016498042,0.0019272423,0.0009583167,0.000044069726,0.000026113465,0.0028052016],"genre_scores_gemma":[0.87410736,0.016984474,0.044632636,0.013848945,0.0060242657,0.00021613736,0.00009541751,0.000103862,0.043986905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981405,0.00009200463,0.0011746287,0.00017313841,0.00021826821,0.00020145699],"domain_scores_gemma":[0.9966898,0.0014321617,0.0008289524,0.00013830689,0.0007028715,0.00020789841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011694962,0.000116244526,0.00065508846,0.00013206697,0.00010120024,0.000013935903,0.000091937305,0.00016418146,0.00036224927],"category_scores_gemma":[0.00042352846,0.00007246189,0.00027123638,0.00019200542,0.000052784926,0.00011449608,0.000021553984,0.0003188687,0.000016412243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006404683,0.003058146,0.32479095,0.00017793284,0.0031207975,0.00064536324,0.0014468101,0.004418344,0.001103208,0.00006920991,0.53143495,0.12332961],"study_design_scores_gemma":[0.030196566,0.018860925,0.1862356,0.00058033783,0.001807731,0.00004245405,0.00092968415,0.009782303,0.00019407089,0.00004834253,0.75110364,0.00021834606],"about_ca_topic_score_codex":0.00007444601,"about_ca_topic_score_gemma":0.00011970076,"teacher_disagreement_score":0.2196687,"about_ca_system_score_codex":0.00021384489,"about_ca_system_score_gemma":0.0026592293,"threshold_uncertainty_score":0.47173584},"labels":[],"label_agreement":null},{"id":"W4383896730","doi":"10.1200/jco.23.00435","title":"Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Genentech; Bavarian Nordic; Siemens Healthineers; Eisai; National Center for Advancing Translational Sciences; Seagen; Puma Biotechnology; Advanced Accelerator Applications; Gilead Sciences; Daiichi Sankyo Europe; Exelixis; Sanofi; Astellas Pharma; Mylan; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Breast cancer; Clinical trial; Neoadjuvant therapy; Clinical endpoint; Oncology; Cancer; Surrogate endpoint; Internal medicine; Medical physics; Surgery","score_opus":0.3488729579279656,"score_gpt":0.5602541676005899,"score_spread":0.2113812096726243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383896730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552195,0.0017182068,0.00079643395,0.03322123,0.0069298325,0.0006986707,0.00091623113,0.000020715524,0.00047919637],"genre_scores_gemma":[0.97575504,0.014521487,0.0026836745,0.0018563844,0.0048645344,0.00009165715,0.00006894232,0.00004357112,0.00011473344],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931652,0.0018402626,0.0040093,0.0003666857,0.00023996852,0.00037860428],"domain_scores_gemma":[0.9897368,0.007308408,0.0019639744,0.00023547874,0.00049271795,0.00026261073],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014925229,0.00020232632,0.0021064538,0.00013229866,0.000075311335,0.000013320123,0.000259759,0.00054892595,0.000075604694],"category_scores_gemma":[0.017034322,0.00014966243,0.001277446,0.00020475226,0.00029799892,0.000009540224,0.00013467406,0.00050395064,0.000015244198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030444564,0.0026805196,0.11881454,0.0000256802,0.002283625,0.00021304635,0.000105448766,0.00011982058,0.0005766455,0.000200915,0.06621594,0.77831924],"study_design_scores_gemma":[0.04480111,0.0049848435,0.80470246,0.00013731519,0.00063239154,0.0001623978,0.000245596,0.00003531685,0.0002487106,0.0016207024,0.14215657,0.00027258095],"about_ca_topic_score_codex":0.0000307573,"about_ca_topic_score_gemma":0.00037700185,"teacher_disagreement_score":0.77804667,"about_ca_system_score_codex":0.00009780611,"about_ca_system_score_gemma":0.001798488,"threshold_uncertainty_score":0.9912456},"labels":[],"label_agreement":null},{"id":"W4384024547","doi":"10.1200/jco.23.01280","title":"Cancer Cachexia: ASCO Guideline Rapid Recommendation Update","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"American Society of Clinical Oncology","keywords":"Guideline; Medicine; Dissemination; Cancer; MEDLINE; Family medicine; Medical physics; Pathology; Internal medicine; Computer science","score_opus":0.3878660763563588,"score_gpt":0.6182902435172055,"score_spread":0.23042416716084674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384024547","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18651116,0.0006581056,0.0006194988,0.7974666,0.0074020335,0.00022426354,0.000010245955,0.0000603045,0.0070477915],"genre_scores_gemma":[0.60274535,0.07226465,0.040175494,0.2586319,0.022730302,0.000024145585,0.00014626217,0.00007783454,0.0032040544],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962992,0.00031613273,0.0028289745,0.00012523997,0.00021488835,0.0002155486],"domain_scores_gemma":[0.9967836,0.0008276087,0.0013221622,0.00010274856,0.0005806463,0.00038322454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006782651,0.00007807813,0.0009100927,0.00015630075,0.000050728635,0.000005119283,0.00008338927,0.0002594259,0.0025622107],"category_scores_gemma":[0.0023346636,0.000058754264,0.00026334988,0.00026656466,0.00006402161,0.00008236937,0.00003295896,0.00095468387,0.00018266497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083818135,0.00027558403,0.013294436,0.00003227519,0.000086253924,0.00015054623,0.000021148777,0.0000057538145,0.00006280894,0.000071819435,0.5114177,0.4737435],"study_design_scores_gemma":[0.0057396414,0.0019323026,0.055500433,0.00009970297,0.000116391864,0.00013717497,0.0000719921,0.000558096,0.000040797167,0.000622304,0.93513054,0.000050617902],"about_ca_topic_score_codex":0.000017383109,"about_ca_topic_score_gemma":0.000027158412,"teacher_disagreement_score":0.5388347,"about_ca_system_score_codex":0.00015587143,"about_ca_system_score_gemma":0.0013299298,"threshold_uncertainty_score":0.9983496},"labels":[],"label_agreement":null},{"id":"W4384488712","doi":"10.1200/jco.23.00428","title":"Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Cumulative incidence; Oncology; Hazard ratio; Cohort; Cancer; Incidence (geometry); Proportional hazards model; Breast cancer; Confidence interval","score_opus":0.056810800784341656,"score_gpt":0.43351736500150384,"score_spread":0.3767065642171622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384488712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802964,0.003884601,0.0000028712577,0.010414817,0.0022197065,0.002907924,0.00005999002,0.00009251687,0.00012118962],"genre_scores_gemma":[0.98232603,0.014032736,0.00008473743,0.0016548664,0.001319598,0.00013888672,0.00000996526,0.00010752644,0.00032564517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98755324,0.002779609,0.006355142,0.001087079,0.0014405337,0.0007844128],"domain_scores_gemma":[0.9908334,0.0029600875,0.004045204,0.00071829965,0.00055191334,0.0008911055],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02221686,0.0005819778,0.0043354207,0.0006371741,0.00017295317,0.00005362262,0.00037661663,0.0006103042,0.00018797048],"category_scores_gemma":[0.005185208,0.00047129646,0.0004994863,0.001199046,0.000432644,0.00025135383,0.00028275442,0.0025301618,0.000010591979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014535805,0.009581968,0.95544016,0.000048156875,0.0031653119,0.0024904609,0.010141781,0.000028920824,0.000010873523,0.000002743765,0.00074472884,0.016891282],"study_design_scores_gemma":[0.021364355,0.01028638,0.95714474,0.00037311544,0.001418668,0.00066547294,0.0064852047,0.00003806949,0.0000063546895,0.00014297472,0.0016505307,0.0004241176],"about_ca_topic_score_codex":0.024037648,"about_ca_topic_score_gemma":0.074646205,"teacher_disagreement_score":0.050608553,"about_ca_system_score_codex":0.00038921516,"about_ca_system_score_gemma":0.0032789716,"threshold_uncertainty_score":0.99977386},"labels":[],"label_agreement":null},{"id":"W4384498679","doi":"10.1200/jco.23.00933","title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":421,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute on Minority Health and Health Disparities; National Cancer Institute; National Institute on Aging","keywords":"Medicine; Guideline; Geriatric oncology; Polypharmacy; Psychological intervention; Randomized controlled trial; Clinical trial; MEDLINE; Geriatrics; Family medicine; Population; Cancer; Gerontology; Intensive care medicine; Internal medicine; Psychiatry; Pathology","score_opus":0.29371972622551945,"score_gpt":0.593498540390338,"score_spread":0.29977881416481855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384498679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051153563,0.9839403,0.000075031305,0.005002375,0.0033037735,0.0019850808,0.000026539878,0.000015887756,0.00053566863],"genre_scores_gemma":[0.0006448508,0.9903967,0.0073085465,0.000449994,0.00067350274,0.00007083924,0.00002048469,0.000063647894,0.00037143164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98822993,0.0017493662,0.008551801,0.0003971204,0.0007496312,0.0003221675],"domain_scores_gemma":[0.9877707,0.005119341,0.0057470943,0.00037152597,0.00071846554,0.00027287024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008743603,0.0003535065,0.006285201,0.00029820195,0.000021554215,0.000012299198,0.00023801354,0.0007870453,0.00012548883],"category_scores_gemma":[0.0025088834,0.00023215287,0.0007432297,0.00030977873,0.00021077626,0.00011934931,0.0002053769,0.00223027,0.000008294055],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002783544,0.001371451,0.0078896275,0.01857438,0.0017663297,0.0005422331,0.000043358395,0.000003341386,4.5472852e-8,0.00005004431,0.012934024,0.9565468],"study_design_scores_gemma":[0.008993726,0.0042978846,0.030008283,0.083456166,0.0025202557,0.00034624283,0.00017584482,0.000025973543,1.0142775e-7,0.000063325344,0.86987853,0.00023369472],"about_ca_topic_score_codex":0.000038824983,"about_ca_topic_score_gemma":0.000058232657,"teacher_disagreement_score":0.95631313,"about_ca_system_score_codex":0.0007641,"about_ca_system_score_gemma":0.0030378643,"threshold_uncertainty_score":0.9689538},"labels":[],"label_agreement":null},{"id":"W4384520841","doi":"10.1200/jco.22.02760","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Chemotherapy; Placebo; Capecitabine; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.10099132118663944,"score_gpt":0.48503122228144663,"score_spread":0.3840399010948072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384520841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851435,0.00052509655,0.000013939428,0.011594349,0.00036487807,0.0020733306,0.0000035891226,0.000017337803,0.00026400783],"genre_scores_gemma":[0.9952333,0.0031369806,0.00019932781,0.0009149828,0.0001362908,0.0002664523,0.000006104988,0.000022049322,0.000084485706],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996039,0.0007741612,0.0022278388,0.00024229572,0.00046021814,0.00025650277],"domain_scores_gemma":[0.9934811,0.0047483547,0.0012078657,0.000106596584,0.00031360867,0.00014246564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00443902,0.00021178201,0.0030806996,0.00040810424,0.00004952099,0.000009192484,0.00010189066,0.000119317,0.00016130046],"category_scores_gemma":[0.0013023708,0.00012472388,0.00033160776,0.0007289452,0.00020550229,0.000068303496,0.000017154473,0.000596211,0.000003865957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7555528,0.016963368,0.088000804,0.000017262291,0.0013795677,0.0019211705,0.0018953879,0.0003839817,0.000024755089,0.000009848652,0.00013496907,0.13371608],"study_design_scores_gemma":[0.74237055,0.07871794,0.17446868,0.00012178029,0.00031612502,0.000030118856,0.000700966,0.0022782753,0.000050649927,0.0001950785,0.00064811745,0.00010174336],"about_ca_topic_score_codex":0.0006169221,"about_ca_topic_score_gemma":0.005328243,"teacher_disagreement_score":0.13361433,"about_ca_system_score_codex":0.00040927724,"about_ca_system_score_gemma":0.0016160661,"threshold_uncertainty_score":0.50860924},"labels":[],"label_agreement":null},{"id":"W4384819754","doi":"10.1200/jco.23.00402","title":"Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sumitomo Dainippon Pharma Oncology; Sierra Oncology; Bavarian Nordic; PharmaMar; Eisai; Springworks Therapeutics; Seagen; MacroGenics; Pfizer; Incyte; Moderna; Puma Biotechnology; Agios Pharmaceuticals; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Calithera Biosciences; AstraZeneca; Novocure; Ipsen; Jazz Pharmaceuticals; Array BioPharma; Exelixis; Karyopharm Therapeutics; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Temozolomide; Internal medicine; Oncology; Neutropenia; Clinical endpoint; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","score_opus":0.25019151630043096,"score_gpt":0.6109909192460797,"score_spread":0.3607994029456488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384819754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715398,0.000025828942,0.00021629097,0.004753278,0.00059240253,0.02251875,0.000013203604,0.000023388715,0.00031703763],"genre_scores_gemma":[0.982593,0.00010650883,0.005037497,0.0012533709,0.0012976874,0.008999393,0.00000354069,0.00003563173,0.00067339843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996196,0.00026692866,0.0027726653,0.00021661211,0.00031826808,0.00022957708],"domain_scores_gemma":[0.9950946,0.001892211,0.001962295,0.00022519765,0.0005446171,0.000281078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003316945,0.0001420338,0.0016179959,0.00021043008,0.000066368775,0.000004221631,0.00014197352,0.0002110631,0.000087214],"category_scores_gemma":[0.002010772,0.00010529119,0.00027989075,0.00024138446,0.00019218588,0.00011182331,0.000081745966,0.00051131885,0.000003506098],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12147525,0.03617193,0.017141527,0.00045246465,0.0011201508,0.0007798698,0.0008898972,0.000039455037,0.028397875,0.00012931104,0.026073707,0.76732856],"study_design_scores_gemma":[0.21405515,0.3318891,0.018085226,0.0001929654,0.0002143608,0.00030182864,0.0005560329,0.00022476235,0.0024336695,0.00090400013,0.43100834,0.00013455623],"about_ca_topic_score_codex":0.0000036532178,"about_ca_topic_score_gemma":0.000012651675,"teacher_disagreement_score":0.76719403,"about_ca_system_score_codex":0.000082003724,"about_ca_system_score_gemma":0.00074387935,"threshold_uncertainty_score":0.429365},"labels":[],"label_agreement":null},{"id":"W4384923116","doi":"10.1200/jco.23.00429","title":"Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Deep vein; Thrombosis; Cancer; Presentation (obstetrics); Surgery; Internal medicine; Oncology","score_opus":0.08589697068769593,"score_gpt":0.4718669680710094,"score_spread":0.3859699973833135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384923116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941841,0.00006500999,0.00004902979,0.0041005663,0.0009180387,0.00031390841,0.000012720421,0.000016564629,0.00034007232],"genre_scores_gemma":[0.99648416,0.0020599542,0.00030533638,0.0008386602,0.00017437423,0.0000062328986,0.00001981305,0.000017746397,0.000093738694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652743,0.00036765638,0.0022861694,0.00018467911,0.00042700858,0.00020707207],"domain_scores_gemma":[0.995047,0.0019803613,0.002050754,0.00013312815,0.00054014043,0.000248648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021194287,0.00012398606,0.001976451,0.00012898401,0.000038368275,0.0000075101834,0.00010351152,0.0002654321,0.000092955685],"category_scores_gemma":[0.002645742,0.00007928548,0.00030454743,0.00025474772,0.0002336673,0.00010765038,0.000080645346,0.00046616507,0.0000053446583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093461754,0.0040440527,0.94754666,0.000035960416,0.0016664297,0.000039140195,0.00013400587,0.000019522711,0.00000460788,0.000036595564,0.0046203644,0.04091806],"study_design_scores_gemma":[0.009456333,0.012860025,0.9738026,0.00009873857,0.00110356,0.0000011227561,0.00015002531,0.00025250658,0.000003386591,0.0000914552,0.002104861,0.00007537572],"about_ca_topic_score_codex":0.000086061686,"about_ca_topic_score_gemma":0.00022615367,"teacher_disagreement_score":0.040842682,"about_ca_system_score_codex":0.000067954235,"about_ca_system_score_gemma":0.00032705715,"threshold_uncertainty_score":0.32331678},"labels":[],"label_agreement":null},{"id":"W4385303851","doi":"10.1200/jco.2023.41.36_suppl.427956","title":"Long-term follow up of selinexor maintenance in patients with <i>TP53</i>wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Subgroup analysis; Internal medicine; Oncology; Endometrial cancer; Maintenance therapy; Phases of clinical research; Surrogate endpoint; Clinical trial; Cancer; Chemotherapy; Confidence interval; Pathology","score_opus":0.14961426728585525,"score_gpt":0.4993738082871081,"score_spread":0.34975954100125284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385303851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369323,0.00089938,0.000063515006,0.0018617847,0.00169034,0.0015903715,0.00014741086,0.0000146550465,0.00003933513],"genre_scores_gemma":[0.9929753,0.00506713,0.00021903942,0.00018630608,0.00085863634,0.00008708001,0.000070206086,0.00002783631,0.00050848845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940698,0.0009362963,0.002895492,0.00045762453,0.0011194455,0.00052132504],"domain_scores_gemma":[0.9903074,0.0058188257,0.0020500778,0.0004676731,0.0009769097,0.0003791365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033857333,0.0002674736,0.0025970922,0.00060533156,0.000066612316,0.000016965412,0.00045860402,0.00021392084,0.00027307234],"category_scores_gemma":[0.004364868,0.0001272093,0.00069276534,0.0028094675,0.00027520122,0.00014939823,0.00012903569,0.0012356964,0.000005821398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20153673,0.0060933344,0.62934834,0.000019655456,0.0029617294,0.0006381383,0.0006127185,0.000044065357,0.000022335424,0.0000011319005,0.0007300622,0.15799178],"study_design_scores_gemma":[0.14305353,0.037102267,0.814671,0.00024711806,0.0020950395,0.0000037362051,0.00041030155,0.00007095436,0.00006138913,0.0000131885345,0.0021515328,0.00011997596],"about_ca_topic_score_codex":0.00019183742,"about_ca_topic_score_gemma":0.002865557,"teacher_disagreement_score":0.18532266,"about_ca_system_score_codex":0.0004478972,"about_ca_system_score_gemma":0.0017544891,"threshold_uncertainty_score":0.53685546},"labels":[],"label_agreement":null},{"id":"W4385334309","doi":"10.1200/jco.23.00775","title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Obinutuzumab; Internal medicine; Neutropenia; Gastroenterology; Clinical endpoint; Rituximab; Phases of clinical research; Hazard ratio; Adverse effect; Surgery; Randomized controlled trial; Lymphoma; Chemotherapy; Confidence interval","score_opus":0.11398352335244477,"score_gpt":0.4717419386539264,"score_spread":0.3577584153014816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385334309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552566,0.00016420218,0.00001606653,0.00026707922,0.0012592167,0.002316333,0.0000062058893,0.000033435877,0.00041177942],"genre_scores_gemma":[0.9976581,0.0005348389,0.00046963984,0.00022723954,0.0004150802,0.000057421206,0.000013411919,0.00006940696,0.0005548936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99019474,0.0020752253,0.004912849,0.0004884346,0.0016963126,0.0006324524],"domain_scores_gemma":[0.98414636,0.01069847,0.002986367,0.00069071696,0.00093247124,0.0005455979],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008413794,0.00034976713,0.0049094013,0.0007025294,0.00008210764,0.0000123037125,0.00048967876,0.00061928463,0.00019127839],"category_scores_gemma":[0.012441195,0.00020891815,0.0007371102,0.0011356854,0.0005295814,0.00018908881,0.00018879429,0.0011079506,0.000022688622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9468335,0.010501414,0.0009876152,0.000059566068,0.0020956434,0.0039664577,0.0018347767,0.00044427582,0.000022812246,0.00001163931,0.0013480315,0.031894293],"study_design_scores_gemma":[0.806012,0.1797688,0.004505471,0.00021476422,0.0005834261,0.00006604572,0.000946593,0.0047304,0.000023313218,0.000027181266,0.0029517743,0.00017024085],"about_ca_topic_score_codex":0.00047682037,"about_ca_topic_score_gemma":0.0002253496,"teacher_disagreement_score":0.16926739,"about_ca_system_score_codex":0.027196573,"about_ca_system_score_gemma":0.07010876,"threshold_uncertainty_score":0.99587744},"labels":[],"label_agreement":null},{"id":"W4385567526","doi":"10.1200/jco.23.00348","title":"Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Government of Canada; Statistics Canada; University of Ottawa","funders":"","keywords":"Medicine; Demography; Breast cancer; Incidence (geometry); Cohort; Cancer registry; Age groups; Cancer; Gerontology; Internal medicine","score_opus":0.23422744754118194,"score_gpt":0.5229709030962428,"score_spread":0.28874345555506087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385567526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278486,0.00005096687,0.0000016109959,0.0023805613,0.0005475686,0.00008886334,0.00004106443,0.000006753541,0.004097772],"genre_scores_gemma":[0.99753284,0.00025056975,0.00014158813,0.0008266658,0.0009027777,0.0000026117682,0.0000037788486,0.000015581283,0.000323571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719495,0.00025878585,0.0013931784,0.00016098084,0.00044342986,0.0005486609],"domain_scores_gemma":[0.9973135,0.00073260005,0.0006827491,0.00015463137,0.00023897726,0.00087753177],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042769313,0.00011626568,0.0012054628,0.00040358066,0.00002084502,0.00000761842,0.00020119859,0.0002939092,0.0009575308],"category_scores_gemma":[0.001617056,0.00009053376,0.00037751623,0.00053844444,0.00012012615,0.00008816963,0.000035973364,0.0008676202,0.000046730896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067229294,0.00014678585,0.91445094,0.00001077666,0.00026161966,0.0037105638,0.00023571309,0.0011010164,0.000050861097,0.000021097401,0.011886515,0.061401185],"study_design_scores_gemma":[0.003590198,0.00552244,0.9800763,0.00024093631,0.00004337843,0.00008999154,0.00037928883,0.00009954323,0.0000013526312,0.000059001533,0.009822084,0.00007548456],"about_ca_topic_score_codex":0.10036914,"about_ca_topic_score_gemma":0.095704734,"teacher_disagreement_score":0.06562536,"about_ca_system_score_codex":0.000976035,"about_ca_system_score_gemma":0.004769582,"threshold_uncertainty_score":0.9999557},"labels":[],"label_agreement":null},{"id":"W4385690625","doi":"10.1200/jco.23.00126","title":"Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Internal medicine; Endocrine system; Hormone receptor; Cancer; Gynecology; Hormone; Metastatic breast cancer","score_opus":0.080194030517838,"score_gpt":0.4702822198798135,"score_spread":0.39008818936197553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385690625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957517,0.00017357012,0.000012718172,0.0028188308,0.00025574744,0.0008786935,0.000026149208,0.000010101891,0.0000725349],"genre_scores_gemma":[0.9971803,0.0011098507,0.00047944093,0.0004028571,0.0007025908,0.00003604611,0.000004588651,0.00003927898,0.00004504175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622464,0.0007358238,0.0017605507,0.00023994457,0.00064587337,0.00039319374],"domain_scores_gemma":[0.99505097,0.0022062038,0.0017783092,0.000235327,0.00055651285,0.00017269964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00197719,0.00023266814,0.0017690061,0.00025619025,0.000028221706,0.000009214503,0.00024534584,0.00017652058,0.00011415576],"category_scores_gemma":[0.00050360744,0.00010143069,0.00025445136,0.00086677057,0.00032680173,0.00021355636,0.000028585022,0.0011763611,0.0000027568944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39462605,0.0012987445,0.5360111,0.0000050119506,0.00036764267,0.00012437241,0.0007049103,0.00006235866,0.00004850855,0.0000012562873,0.00006735036,0.06668267],"study_design_scores_gemma":[0.17131658,0.057125356,0.7704671,0.00032551176,0.00007192705,0.00008553421,0.0002550009,0.000007637807,0.000009786694,0.00002493574,0.00021249926,0.00009811947],"about_ca_topic_score_codex":0.00039794575,"about_ca_topic_score_gemma":0.0006251216,"teacher_disagreement_score":0.23445599,"about_ca_system_score_codex":0.00037418195,"about_ca_system_score_gemma":0.001918721,"threshold_uncertainty_score":0.5110769},"labels":[],"label_agreement":null},{"id":"W4385829606","doi":"10.1200/jco.23.00857","title":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Canadian College of Naturopathic Medicine; University of Manitoba; University of Calgary","funders":"National Center for Complementary and Integrative Health","keywords":"Medicine; Integrative medicine; Anxiety; Guideline; Reflexology; Randomized controlled trial; Music therapy; Aromatherapy; MEDLINE; Psychological intervention; Quality of life (healthcare); Palliative care; Alternative medicine; Physical therapy; Nursing; Internal medicine; Psychiatry; Massage","score_opus":0.10844664231100169,"score_gpt":0.5214908097372791,"score_spread":0.4130441674262774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385829606","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005725066,0.9875895,0.00021025298,0.0007822091,0.002382179,0.0019952743,0.00037541336,0.000013241663,0.0009268634],"genre_scores_gemma":[0.002175479,0.9920368,0.0036017234,0.0004141069,0.001269495,0.00018917062,0.000102947146,0.00007364361,0.00013659877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907818,0.0011114079,0.006652844,0.0005944795,0.00046819996,0.0003912836],"domain_scores_gemma":[0.9796088,0.007554596,0.008653931,0.00032551447,0.003486109,0.00037106054],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0039870637,0.0005666877,0.011085605,0.00034675567,0.00003748492,0.0000041256644,0.00039048638,0.0023883383,0.000040894545],"category_scores_gemma":[0.0033500523,0.00031374797,0.002591064,0.0006373913,0.000878764,0.000093214265,0.00018458584,0.0030715242,7.168744e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061101927,0.0007094174,0.0038296324,0.010962089,0.0020897025,0.000107536645,0.005830545,0.000003895738,0.0000011667344,0.000025655452,0.005281515,0.9650487],"study_design_scores_gemma":[0.010847843,0.034304686,0.0005254184,0.05589022,0.004863694,0.00025797487,0.018890195,0.000034617697,0.000008939867,0.00004720247,0.87405294,0.0002762746],"about_ca_topic_score_codex":0.0007711657,"about_ca_topic_score_gemma":0.015407331,"teacher_disagreement_score":0.9647724,"about_ca_system_score_codex":0.0015912887,"about_ca_system_score_gemma":0.016770447,"threshold_uncertainty_score":0.99993145},"labels":[],"label_agreement":null},{"id":"W4386211636","doi":"10.1200/jco.23.00617","title":"Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"National Cancer Institute; ViewRay","keywords":"Medicine; Radiation therapy; Prostate cancer; Prostate; Adenocarcinoma; Biochemical recurrence; Oncology; Internal medicine; Cancer; Prostatectomy","score_opus":0.1953171748966815,"score_gpt":0.5228171113928758,"score_spread":0.3274999364961943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386211636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96183884,0.002559394,0.00010097539,0.031243132,0.002890092,0.0012517856,0.00007892022,0.000009462949,0.000027397698],"genre_scores_gemma":[0.98320806,0.0069988873,0.0050071212,0.0031060015,0.001180543,0.00018292366,0.000007705224,0.000027918044,0.0002808343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962759,0.00023241916,0.0027164952,0.00024216011,0.00025632165,0.00027672367],"domain_scores_gemma":[0.9889516,0.008373207,0.0015782124,0.0002800972,0.00056771206,0.00024914872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037895893,0.00014684707,0.0016377392,0.00006898323,0.00003312765,0.000005944366,0.00021205572,0.00030298973,0.000022730514],"category_scores_gemma":[0.0060115177,0.00007750086,0.0016920144,0.0001683279,0.00035960175,0.00005135165,0.000049667306,0.0004334606,0.0000029180549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007953545,0.0012802471,0.89368105,0.00008535651,0.00065030006,0.00003871895,0.00007686159,0.0000010724656,0.000025009334,0.00005142947,0.036399156,0.05975723],"study_design_scores_gemma":[0.014548849,0.0120694665,0.8735318,0.0001669196,0.00046949604,0.000029913954,0.000038264192,0.000050296043,0.0003454902,0.00060099555,0.09807575,0.00007271562],"about_ca_topic_score_codex":0.0000028651755,"about_ca_topic_score_gemma":0.000004238936,"teacher_disagreement_score":0.061676595,"about_ca_system_score_codex":0.00011332602,"about_ca_system_score_gemma":0.0013234769,"threshold_uncertainty_score":0.7196782},"labels":[],"label_agreement":null},{"id":"W4386244466","doi":"10.1200/jco.23.00558","title":"Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600–Mutant Pediatric High-Grade Glioma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Brain Tumour Charity","keywords":"Trametinib; Dabrafenib; Medicine; Internal medicine; Oncology; Refractory (planetary science); Adverse effect; Discontinuation; Phases of clinical research; Rash; Clinical trial; Cancer; Vemurafenib; MAPK/ERK pathway; Biology","score_opus":0.11489134300308251,"score_gpt":0.4559964426832014,"score_spread":0.3411050996801189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386244466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855258,0.00056275347,0.0000036821682,0.0094498275,0.0034921863,0.00060470414,0.000021862226,0.000026450294,0.00031275008],"genre_scores_gemma":[0.9942142,0.0019445367,0.00047110207,0.0005794585,0.0026678669,0.000022043809,0.000011686373,0.000035546513,0.00005355962],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930478,0.00071590923,0.004698133,0.00033981467,0.0007539964,0.00044435644],"domain_scores_gemma":[0.99024385,0.0057065766,0.0028635166,0.00035532375,0.0002773975,0.00055335264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047091753,0.0002552815,0.0028396305,0.00087908184,0.000052192347,0.0000074478644,0.00026540394,0.0006846602,0.00015715414],"category_scores_gemma":[0.0062535126,0.00018064491,0.001005005,0.0011399644,0.00019712844,0.000097690376,0.000102631566,0.0012699284,0.000039162023],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3543687,0.27656388,0.026187584,0.00024347373,0.0018024372,0.0442101,0.00088128826,0.0002807178,0.008210914,0.0005869969,0.032493338,0.25417057],"study_design_scores_gemma":[0.77379644,0.16797426,0.031792387,0.00013599212,0.0014935094,0.00027724807,0.00017794226,0.00012015379,0.001543921,0.0008393648,0.021631371,0.00021741525],"about_ca_topic_score_codex":0.000041515243,"about_ca_topic_score_gemma":0.000030325746,"teacher_disagreement_score":0.41942775,"about_ca_system_score_codex":0.00025833727,"about_ca_system_score_gemma":0.0021548097,"threshold_uncertainty_score":0.748649},"labels":[],"label_agreement":null},{"id":"W4386316145","doi":"10.1200/jco.23.00058","title":"Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Cancer; Colorectal cancer; Hazard ratio; Internal medicine; Prostate cancer; Lung cancer; Cause of death; Physical therapy; Oncology; Confidence interval; Disease","score_opus":0.18802326867465477,"score_gpt":0.5302207402796117,"score_spread":0.34219747160495695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386316145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264765,0.0017257271,0.000009502207,0.0038538596,0.001029324,0.00007205921,0.000018436303,0.0000079869305,0.0006354828],"genre_scores_gemma":[0.9780812,0.020433024,0.00006102657,0.00086192193,0.00038470697,0.0000044551,0.0000035515216,0.000007203813,0.00016288547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976992,0.00016488347,0.0015451919,0.00013701511,0.00031699936,0.00013670181],"domain_scores_gemma":[0.996624,0.0015580215,0.0010031799,0.00016496245,0.000405978,0.00024386295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024809104,0.000078522164,0.0017622914,0.0003165774,0.000016016555,0.0000035109908,0.00008610304,0.00023388928,0.000286027],"category_scores_gemma":[0.0011514388,0.000056611218,0.00071670854,0.00088956096,0.0001671782,0.00004975142,0.000047239184,0.0003893529,0.000004062289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081237854,0.00028009634,0.8119945,0.000043582637,0.002137124,0.00016241682,0.00021278462,0.000014961627,0.000059324837,0.000019706742,0.0026226547,0.18164048],"study_design_scores_gemma":[0.0014554468,0.0015498324,0.9790695,0.00010069669,0.007782943,0.0000073929855,0.00032749254,0.000112561225,0.00008141375,0.00011132224,0.009351077,0.00005035717],"about_ca_topic_score_codex":0.00048084516,"about_ca_topic_score_gemma":0.0015595021,"teacher_disagreement_score":0.18159012,"about_ca_system_score_codex":0.00004279459,"about_ca_system_score_gemma":0.0005337007,"threshold_uncertainty_score":0.3131795},"labels":[],"label_agreement":null},{"id":"W4386447675","doi":"10.1200/jco.22.02906","title":"Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; PharmaMar; Swedish Orphan Biovitrum; Eisai; G1 Therapeutics; MacroGenics; AstraZeneca España; Amgen; Radius Health; Syndax Pharmaceuticals; BeiGene; Clovis Oncology; Pfizer; Incyte; NuCana; AstraZeneca; Novocure; Ipsen; Jazz Pharmaceuticals; Taiho Pharmaceutical; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi; GlaxoSmithKline; Plexxikon; Seagen; Relay Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Endometrial cancer; Chemotherapy; Oncology; Maintenance therapy; Internal medicine; Gynecologic cancer; Cancer; Gynecology; Ovarian cancer","score_opus":0.08886164544139567,"score_gpt":0.4607676338415168,"score_spread":0.3719059884001211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386447675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835249,0.0010795301,0.0009775589,0.0075011933,0.006407587,0.00036547682,0.000026146903,0.000011573818,0.00010601263],"genre_scores_gemma":[0.9321606,0.04282309,0.004781336,0.007724846,0.009831439,0.0000778258,0.000025979012,0.000059251917,0.0025156275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816823,0.00012098873,0.0010614708,0.00024255567,0.00015439473,0.00025235492],"domain_scores_gemma":[0.9981412,0.00039692177,0.0007588663,0.00016538767,0.00039211113,0.0001454941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013052471,0.00014576042,0.0006261757,0.00007893003,0.00004407106,0.000010095398,0.00019081507,0.00036989496,0.00022225633],"category_scores_gemma":[0.0022050808,0.00009151606,0.0004577919,0.00018844925,0.00008629478,0.000008680842,0.000034644472,0.0002869291,0.000011898502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10241956,0.00028244266,0.0017582548,0.000013295924,0.00028593247,0.00003563781,0.000029374698,0.00009841654,0.0061917817,0.000013423388,0.04111553,0.8477563],"study_design_scores_gemma":[0.015171904,0.020451322,0.007614098,0.000023414901,0.000040184193,0.000036976384,0.000024016172,0.0000649039,0.0022412413,0.0003661481,0.953836,0.00012975985],"about_ca_topic_score_codex":0.000004420312,"about_ca_topic_score_gemma":0.00012454174,"teacher_disagreement_score":0.9127205,"about_ca_system_score_codex":0.00003436776,"about_ca_system_score_gemma":0.00052180444,"threshold_uncertainty_score":0.37319165},"labels":[],"label_agreement":null},{"id":"W4386608505","doi":"10.1200/jco.23.00296","title":"Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Statistics Canada; Juravinski Cancer Centre; University of British Columbia; McMaster University; Queen's University; Princess Margaret Cancer Centre; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; BC Cancer Agency; University Health Network; University of Toronto","funders":"National Cancer Institute; Genentech; National Institute for Health and Care Research; Cancer Research UK; Seagen; MacroGenics; Puma Biotechnology; Clovis Oncology; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Cilag; Mylan; GlaxoSmithKline; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Metformin; Breast cancer; Placebo; Clinical endpoint; Internal medicine; Cancer; Hazard ratio; Oncology; Randomized controlled trial; Gynecology; Confidence interval; Pathology; Insulin","score_opus":0.0946734792280245,"score_gpt":0.47558886193226,"score_spread":0.38091538270423553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386608505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97607183,0.019079112,0.000006046237,0.00021958597,0.0028244348,0.0012144553,0.00022127383,0.0000022968559,0.00036097525],"genre_scores_gemma":[0.9490759,0.048426308,0.000044695847,0.00037932748,0.0016778295,0.0002039553,0.00006320667,0.000027842023,0.00010095495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916397,0.002868202,0.004216871,0.00037923985,0.00038889586,0.0005071291],"domain_scores_gemma":[0.99220973,0.0036803952,0.0031348132,0.00027142075,0.00019444386,0.0005092146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021611892,0.00027307367,0.0056063132,0.0011035999,0.000022664095,0.000010159117,0.00037669786,0.00067655405,0.00033784067],"category_scores_gemma":[0.0026184514,0.00020235729,0.0016445467,0.0010994079,0.00023403646,0.00002062658,0.000050944287,0.0006689372,0.0000010031999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7326243,0.00020738468,0.0007624638,0.000032938726,0.003486308,0.000033968277,0.00008637268,0.00082614814,0.00055100437,0.000009008428,0.00092398666,0.26045614],"study_design_scores_gemma":[0.9709762,0.007895002,0.0017293079,0.00009742693,0.0033527303,0.0000017916983,0.000030094992,0.00013076169,0.0018648802,0.000015007775,0.013717111,0.00018968347],"about_ca_topic_score_codex":0.14226994,"about_ca_topic_score_gemma":0.41505873,"teacher_disagreement_score":0.2727888,"about_ca_system_score_codex":0.0004912527,"about_ca_system_score_gemma":0.011466912,"threshold_uncertainty_score":0.99413717},"labels":[],"label_agreement":null},{"id":"W4386647810","doi":"10.1200/jco.23.01204","title":"Playing by Eye: Using Music as a Parallel to Clinical Oncology","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Music Therapy and Health","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Parallels; Clinical Oncology; Medical physics; Internal medicine; Oncology; Cancer","score_opus":0.5301479850742232,"score_gpt":0.6431936183089678,"score_spread":0.11304563323474459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386647810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93960905,0.0003356293,0.00090831245,0.022817962,0.020093624,0.00038391168,0.000010066308,0.000066280976,0.015775139],"genre_scores_gemma":[0.8951944,0.0007645003,0.010422777,0.076679714,0.012429871,0.000019590205,0.000008097721,0.000100865785,0.004380188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9875679,0.0040390585,0.006390408,0.00058678724,0.00048666762,0.00092920463],"domain_scores_gemma":[0.985213,0.009159612,0.0034279467,0.0005022498,0.00034077978,0.0013564194],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.021576941,0.00028351,0.0028964053,0.00035030968,0.00021473448,0.000020396128,0.0007717109,0.0017270566,0.0037943637],"category_scores_gemma":[0.0045443145,0.00023385593,0.00095158047,0.0006067254,0.00036197974,0.00012985522,0.00019157077,0.0030875038,0.0022310817],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012720135,0.0031231858,0.058055244,0.000015528825,0.00083328935,0.0018099758,0.0016317065,0.00010109795,0.00011087874,0.0018948787,0.49416435,0.42553973],"study_design_scores_gemma":[0.009791374,0.02509752,0.21613246,0.00004925418,0.00016652471,0.00024501138,0.0007047889,0.00012725584,0.0000010737757,0.0014934648,0.7459338,0.00025747536],"about_ca_topic_score_codex":0.00018774132,"about_ca_topic_score_gemma":0.000107932035,"teacher_disagreement_score":0.42528227,"about_ca_system_score_codex":0.000289855,"about_ca_system_score_gemma":0.0031503418,"threshold_uncertainty_score":0.99956894},"labels":[],"label_agreement":null},{"id":"W4386764738","doi":"10.1200/jco.23.00170","title":"Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Chemotherapy; Cancer; Oncology; Population; Esophageal cancer; Quality of life (healthcare); Adenocarcinoma; Gastroenterology; Immunotherapy; Nursing","score_opus":0.08815538424877481,"score_gpt":0.4211214824627632,"score_spread":0.33296609821398837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386764738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916762,0.0011648939,0.000073819385,0.0051592584,0.0012011382,0.0006195127,0.00003058869,0.00003311038,0.000041477113],"genre_scores_gemma":[0.9936672,0.0019394385,0.0018896359,0.0018476392,0.0003925313,0.000015633632,0.000034498433,0.0000555424,0.00015789579],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99426216,0.0005432632,0.0035646504,0.00038858963,0.00076962734,0.00047169562],"domain_scores_gemma":[0.9939074,0.0009800053,0.0039496995,0.00030889254,0.0004578523,0.00039614638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022872526,0.00029715855,0.0026433584,0.00028028892,0.00005460705,0.000008761404,0.00021687368,0.00037660787,0.00040025564],"category_scores_gemma":[0.0003727554,0.0001884375,0.0003504122,0.0009263275,0.00033825944,0.00018471174,0.000023448352,0.0009678563,0.0000046718055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4424859,0.0010248813,0.4359347,0.000047861948,0.0010111512,0.00008447466,0.0003092318,0.00015202892,0.00005940631,0.0000011980661,0.00059968827,0.11828946],"study_design_scores_gemma":[0.15582494,0.03805108,0.8048807,0.00025267203,0.00009066072,0.0000115201,0.00020882837,0.000093208255,0.00005016787,0.0000074413647,0.00040542323,0.00012336602],"about_ca_topic_score_codex":0.0014158067,"about_ca_topic_score_gemma":0.0009842338,"teacher_disagreement_score":0.368946,"about_ca_system_score_codex":0.0008406764,"about_ca_system_score_gemma":0.004584932,"threshold_uncertainty_score":0.8133472},"labels":[],"label_agreement":null},{"id":"W4386915712","doi":"10.1200/jco.23.01423","title":"Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Anticancer drug; Oncology; End point; Progression-free survival; Overall survival; Internal medicine; Pharmacology; Drug; Clinical trial","score_opus":0.7421747698617622,"score_gpt":0.6165159011575854,"score_spread":0.12565886870417686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386915712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51642936,0.0003790448,0.0016823614,0.4682337,0.0044897185,0.0008769155,0.00024311892,0.000028215283,0.007637578],"genre_scores_gemma":[0.9281304,0.00092363846,0.019666856,0.045927804,0.0038766977,0.000085593245,0.000047724538,0.00006605336,0.0012752267],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98549193,0.0007570729,0.012585037,0.0003504319,0.0004747137,0.0003407837],"domain_scores_gemma":[0.9600348,0.025298312,0.013572419,0.00045065308,0.00036180537,0.00028203565],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.12331254,0.00014732094,0.0026511892,0.0003189152,0.000080670834,0.000023776704,0.00048603158,0.00045985845,0.0002866598],"category_scores_gemma":[0.075061284,0.00014760012,0.0005771283,0.00021684263,0.00022818684,0.00037146255,0.00008784647,0.00047984297,0.00010015597],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005058636,0.002828878,0.09595671,0.001725449,0.0012729551,0.00004958593,0.004000679,0.00030402318,0.00013747765,0.39532387,0.45665452,0.036687214],"study_design_scores_gemma":[0.018370483,0.010451003,0.2558966,0.00040880623,0.00013680894,0.000034467303,0.0024680237,0.0036275848,0.000117176874,0.18167761,0.526209,0.00060244143],"about_ca_topic_score_codex":0.000111037036,"about_ca_topic_score_gemma":0.000108803855,"teacher_disagreement_score":0.4223059,"about_ca_system_score_codex":0.00037954166,"about_ca_system_score_gemma":0.002073948,"threshold_uncertainty_score":0.9327299},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"methods","study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"evaluation","study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4387163062","doi":"10.1200/jco.23.01059","title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":462,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Glioma; Magnetic resonance imaging; Tumor progression; Radiation therapy; Clinical trial; Glioblastoma; Radiology; Oncology; Internal medicine; Nuclear medicine; Cancer; Cancer research","score_opus":0.09423328660314903,"score_gpt":0.49618787779595364,"score_spread":0.40195459119280463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387163062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78922594,0.000111548434,0.000012643334,0.2089096,0.0010954362,0.0005941128,0.000009105829,0.0000067764536,0.000034863362],"genre_scores_gemma":[0.9902973,0.0006149453,0.0015753413,0.0068999417,0.0004826377,0.00009304397,0.0000043919044,0.00001791919,0.000014467545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957847,0.001436161,0.0019586144,0.00026406033,0.00022409423,0.00033236123],"domain_scores_gemma":[0.987304,0.011449952,0.00058218243,0.00020168378,0.00016061768,0.00030156795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008390871,0.00014300553,0.0012894517,0.00047433918,0.000036255777,0.000012652638,0.0001559903,0.00028274528,0.000033592973],"category_scores_gemma":[0.0063175852,0.000086876105,0.000207312,0.00046587788,0.00010078192,0.00005820259,0.00009874048,0.00061644666,0.000016179332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17938308,0.014049489,0.44444668,0.00017493436,0.0006204664,0.029658351,0.0015085252,0.00023225414,0.008119075,0.0013500437,0.069212705,0.2512444],"study_design_scores_gemma":[0.031053297,0.017781423,0.87577015,0.00016799697,0.00011033034,0.0001992213,0.00020910973,0.00035736317,0.00012167787,0.0005324454,0.073624544,0.000072463685],"about_ca_topic_score_codex":0.00003299154,"about_ca_topic_score_gemma":0.00048639535,"teacher_disagreement_score":0.43132347,"about_ca_system_score_codex":0.0002362925,"about_ca_system_score_gemma":0.00093828054,"threshold_uncertainty_score":0.75631964},"labels":[],"label_agreement":null},{"id":"W4387163071","doi":"10.1200/jco.23.01529","title":"Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Sunitinib; Everolimus; Neuroendocrine tumors; Radionuclide therapy; Oncology; Internal medicine; Systemic therapy; Chemotherapy; Targeted therapy; Response Evaluation Criteria in Solid Tumors; Cancer; Progressive disease; Breast cancer","score_opus":0.11030489510178978,"score_gpt":0.4812814346831032,"score_spread":0.3709765395813134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387163071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98220843,0.0005005805,0.0005363097,0.014085311,0.0009202803,0.0015854537,0.000021743059,0.000056325225,0.000085575484],"genre_scores_gemma":[0.9917052,0.0011798176,0.0017060755,0.0039949683,0.0008124338,0.00008840722,0.000017764236,0.000067188565,0.0004281684],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99149954,0.0013281158,0.0052485433,0.00039443676,0.00068372465,0.00084565266],"domain_scores_gemma":[0.9912027,0.0049498403,0.0021105986,0.00034582478,0.0007862136,0.00060480204],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031367529,0.00029776257,0.0031301097,0.00069778186,0.00004160776,0.000022162872,0.00039673745,0.000018940727,0.00013429218],"category_scores_gemma":[0.011837897,0.00020593834,0.00077109947,0.00052954507,0.00019831784,0.00018706259,0.00006750095,0.001288218,0.00006194128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1250738,0.009871715,0.4646883,0.0012719943,0.002431439,0.22623833,0.000073454794,0.0015260538,0.024684587,0.000120627185,0.1073564,0.036663305],"study_design_scores_gemma":[0.3073432,0.17684293,0.27020815,0.0025534488,0.0014615696,0.087416686,0.001218497,0.032957207,0.002370169,0.0020010993,0.11487594,0.0007510714],"about_ca_topic_score_codex":0.000024322417,"about_ca_topic_score_gemma":0.000032042375,"teacher_disagreement_score":0.19448012,"about_ca_system_score_codex":0.00015411043,"about_ca_system_score_gemma":0.0011509004,"threshold_uncertainty_score":0.9964858},"labels":[],"label_agreement":null},{"id":"W4387329458","doi":"10.1200/jco.23.00307","title":"Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital; University of British Columbia","funders":"Society for Immunotherapy of Cancer","keywords":"Bladder cancer; Medicine; Clinical trial; Cancer; Cystectomy; Multidisciplinary approach; Immunotherapy; Disease; Clinical study design; Oncology; Family medicine; Internal medicine; Medical physics","score_opus":0.3129307591216636,"score_gpt":0.5244787903783332,"score_spread":0.2115480312566696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387329458","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53866893,0.015111618,0.0017147653,0.4291021,0.009894913,0.0031562045,0.002108838,0.000023400175,0.00021920251],"genre_scores_gemma":[0.2942658,0.6287984,0.016089873,0.042960722,0.015232459,0.0017537758,0.00016212533,0.00010110669,0.00063571305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699897,0.00030998714,0.0019844503,0.000246674,0.00025601182,0.00020390526],"domain_scores_gemma":[0.9821215,0.015780887,0.0013500866,0.00016464389,0.00045300863,0.0001298533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003981862,0.00015591415,0.0010599499,0.000040653988,0.000176884,0.000024048244,0.00021713233,0.0002862559,0.00039674088],"category_scores_gemma":[0.0013764361,0.0000829755,0.0011157583,0.00010878826,0.0006612176,0.000088665765,0.00005562819,0.000526122,8.353025e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14899199,0.0014070453,0.03921775,0.000026377393,0.017706651,0.0000045520273,0.0009906992,0.0000057601546,0.00007943541,0.002022461,0.19341694,0.5961303],"study_design_scores_gemma":[0.38234994,0.009682923,0.11812413,0.00025491675,0.0061261756,0.000019523219,0.0013225735,0.0008620476,0.000057048124,0.020864276,0.46011358,0.00022287056],"about_ca_topic_score_codex":0.0009370757,"about_ca_topic_score_gemma":0.0014579552,"teacher_disagreement_score":0.6136868,"about_ca_system_score_codex":0.00010930179,"about_ca_system_score_gemma":0.0015537539,"threshold_uncertainty_score":0.43440345},"labels":[],"label_agreement":null},{"id":"W4387379962","doi":"10.1200/jco.23.00365","title":"High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Methotrexate; Aggressive lymphoma; Lymphoma; Oncology; Internal medicine; Intensive care medicine; Rituximab","score_opus":0.06900215192948117,"score_gpt":0.42950592537063864,"score_spread":0.36050377344115747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387379962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896063,0.0007597968,0.0000058727373,0.0061014346,0.002059095,0.0003493301,0.000013129826,0.000029541205,0.0010754559],"genre_scores_gemma":[0.98700345,0.0070904237,0.0028218965,0.0011278989,0.0010626124,0.000025914636,0.000010077767,0.00003777778,0.0008199391],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99494016,0.0009912226,0.0027328972,0.00035845826,0.00054027064,0.0004369725],"domain_scores_gemma":[0.99024844,0.0052238386,0.0032681338,0.00034419264,0.00034875656,0.0005666515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035598306,0.00024748896,0.0021863594,0.00045741696,0.00005653573,0.000015165409,0.00021848215,0.00056814513,0.0002469808],"category_scores_gemma":[0.0068552922,0.00016584074,0.00072930334,0.00062996586,0.00019529561,0.0000991125,0.00012056166,0.0007086727,0.0006543479],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004554217,0.009202446,0.16956414,0.00003665289,0.00054155034,0.030367946,0.00018168258,0.00007169302,0.00009540796,0.00017857354,0.0070178616,0.7781878],"study_design_scores_gemma":[0.04218871,0.025663937,0.9059523,0.00021524784,0.00058773096,0.00057972665,0.00016744748,0.000051356234,0.00085081963,0.002254721,0.021329453,0.00015857643],"about_ca_topic_score_codex":0.0007381464,"about_ca_topic_score_gemma":0.00015409024,"teacher_disagreement_score":0.77802926,"about_ca_system_score_codex":0.00047062867,"about_ca_system_score_gemma":0.002050185,"threshold_uncertainty_score":0.84105366},"labels":[],"label_agreement":null},{"id":"W4387517250","doi":"10.1200/jco.23.01435","title":"Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Hamilton Health Sciences; Windsor Regional Hospital; Western University; Juravinski Cancer Centre","funders":"Hamilton Health Sciences; Brown University; American Society of Clinical Oncology; University of California","keywords":"Medicine; Guideline; Lung cancer; Systemic therapy; Randomized controlled trial; Systematic review; Intensive care medicine; Radiation therapy; Cancer; Evidence-based medicine; Oncology; MEDLINE; Quality of life (healthcare); Family medicine; Disease; Internal medicine; Alternative medicine; Pathology; Nursing; Breast cancer","score_opus":0.22785546923338496,"score_gpt":0.5706298294869827,"score_spread":0.34277436025359775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387517250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8776369,0.052972272,0.00018215836,0.059751295,0.005763509,0.0021935543,0.00005212414,0.000053871285,0.0013942934],"genre_scores_gemma":[0.7170854,0.19482131,0.008772266,0.029667322,0.01687616,0.00091803743,0.000077381796,0.00021723045,0.03156485],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945241,0.00033527598,0.0034335535,0.00036798554,0.0006553081,0.0006837769],"domain_scores_gemma":[0.9933441,0.0016882471,0.0020683326,0.00030125986,0.0019748358,0.0006232128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005103402,0.0002422159,0.0025506865,0.00022540097,0.0001719076,0.000015438989,0.00034190193,0.000335005,0.0003330248],"category_scores_gemma":[0.0009165072,0.00016668758,0.00081877684,0.00024489878,0.00015223623,0.000073979965,0.00011057638,0.0015778516,0.000009503831],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0072325203,0.00046167322,0.51847386,0.0007397365,0.0014845448,0.0002303597,0.0047317166,0.0002589453,0.00008903694,0.00001054342,0.34110904,0.12517802],"study_design_scores_gemma":[0.021203358,0.015368994,0.12548728,0.0009431882,0.00038770222,0.00008312979,0.0014121232,0.00013137655,0.000047458212,0.000041988256,0.8347101,0.00018328431],"about_ca_topic_score_codex":0.1853998,"about_ca_topic_score_gemma":0.653929,"teacher_disagreement_score":0.49360108,"about_ca_system_score_codex":0.0078047924,"about_ca_system_score_gemma":0.04469162,"threshold_uncertainty_score":0.99600405},"labels":[],"label_agreement":null},{"id":"W4387722601","doi":"10.1200/jco.22.02770","title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Internal medicine; Pancreatic cancer; Oncology; Erlotinib Hydrochloride; Hazard ratio; Adverse effect; Placebo; Clinical endpoint; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.22827661898477386,"score_gpt":0.5345134374092202,"score_spread":0.30623681842444633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387722601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901187,0.00019940524,0.000032505934,0.005150357,0.0018375425,0.0020583535,0.00011021458,0.000007236924,0.00048569616],"genre_scores_gemma":[0.99588954,0.0009884735,0.0009926478,0.0006696578,0.00097605493,0.00010729846,0.000023772054,0.000025211939,0.00032732094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98847264,0.0021349434,0.0068058795,0.0003365628,0.001778138,0.00047184038],"domain_scores_gemma":[0.9822309,0.009442739,0.005642629,0.000294991,0.0019346849,0.0004540663],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015407285,0.00025258897,0.005899948,0.0002613741,0.0000697606,0.0000041707776,0.00040165868,0.00035099714,0.00018175523],"category_scores_gemma":[0.018755786,0.00013320628,0.00044025984,0.0009512407,0.0010050469,0.00014000373,0.00009896304,0.0013600711,9.026128e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4644217,0.0042775236,0.51161236,0.00010492656,0.00170475,0.00011327982,0.00009412294,0.0005951812,0.000029627623,0.00004467246,0.003966194,0.013035682],"study_design_scores_gemma":[0.40725097,0.02081652,0.5655262,0.0006100405,0.00095083116,0.000012489412,0.00008216611,0.0007339057,0.000009105247,0.00004113269,0.0038607004,0.00010595784],"about_ca_topic_score_codex":0.017165253,"about_ca_topic_score_gemma":0.14188525,"teacher_disagreement_score":0.12471999,"about_ca_system_score_codex":0.0007634933,"about_ca_system_score_gemma":0.029085044,"threshold_uncertainty_score":0.98950964},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","score_opus":0.16127771494674698,"score_gpt":0.5034432526818972,"score_spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387865238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931667,0.000114297305,0.000019537503,0.0050256113,0.00040877974,0.0007727908,0.00005661087,0.0000117441405,0.0004239492],"genre_scores_gemma":[0.9968565,0.0002679252,0.0012532031,0.0004551395,0.0010680418,0.0000061402166,0.000026200798,0.000027813681,0.00003901472],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939156,0.0011156189,0.0034036005,0.00030302457,0.00087999227,0.00038211656],"domain_scores_gemma":[0.9861416,0.01095005,0.0017932979,0.0003393481,0.00040596182,0.00036974385],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0070592784,0.00016646921,0.0017003256,0.00016714302,0.00009474322,0.000012879208,0.00030034324,0.00024495117,0.000041014755],"category_scores_gemma":[0.014887613,0.00009589279,0.00017045574,0.00041790985,0.0006147417,0.00009530571,0.00017908461,0.0016623155,0.0000038688813],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6577554,0.0069367224,0.04236623,0.000041240088,0.00022709426,0.0005646164,0.00088508043,0.000046090776,0.00026963142,0.000002465625,0.0032335988,0.28767186],"study_design_scores_gemma":[0.31613505,0.061380845,0.6166926,0.0010224745,0.0001291059,0.000021785152,0.00014757055,0.00007495884,0.00007253753,0.00006735818,0.0041697407,0.00008599097],"about_ca_topic_score_codex":0.00010454838,"about_ca_topic_score_gemma":0.000054712054,"teacher_disagreement_score":0.57432634,"about_ca_system_score_codex":0.00024600577,"about_ca_system_score_gemma":0.0033193324,"threshold_uncertainty_score":0.9934104},"labels":[],"label_agreement":null},{"id":"W4387871549","doi":"10.1200/jco.23.00930","title":"Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With Cancer: Economic Evaluation Within 5C Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health; University Health Network; Toronto General Hospital; University of Toronto; University of Calgary; Alberta Health Services","funders":"Canadian Institutes of Health Research; Alberta Health Services","keywords":"Medicine; Guideline; Quality-adjusted life year; Randomized controlled trial; Cost–utility analysis; Cost-effectiveness analysis; Health care; Quality of life (healthcare); Cost effectiveness; Demography; Gerontology; Internal medicine","score_opus":0.17340827514881235,"score_gpt":0.5362958490697342,"score_spread":0.3628875739209218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387871549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331105,0.00012665223,0.00006137323,0.0034897318,0.0009793824,0.0012653209,0.000008976636,0.0000065519657,0.0007509483],"genre_scores_gemma":[0.9958856,0.0017729957,0.0016830598,0.000200029,0.0002917591,0.00005444696,0.000013705446,0.000009209909,0.00008917578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958419,0.00061976677,0.0026137843,0.0002604423,0.0004909192,0.00017318621],"domain_scores_gemma":[0.9959699,0.0013351677,0.0020037205,0.00021554678,0.00029413612,0.00018154268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009164937,0.000116600284,0.0015803052,0.0006866817,0.000016760372,0.0000063093426,0.00010784482,0.00019908721,0.00029588965],"category_scores_gemma":[0.00060302106,0.00008422084,0.0002554681,0.00068319374,0.00012662513,0.00009049691,0.0000526136,0.00048442202,0.0000028434577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08076681,0.0017127306,0.488123,0.00014836388,0.0046333866,0.00022222573,0.0005520915,0.0057649673,0.0000024213402,0.000031349176,0.0019623148,0.41608036],"study_design_scores_gemma":[0.10159874,0.004745796,0.8438732,0.00013409929,0.0045207287,0.000008854719,0.00040479726,0.044198595,0.0000028033965,0.0000445903,0.00040435855,0.00006345309],"about_ca_topic_score_codex":0.00018400747,"about_ca_topic_score_gemma":0.0020775255,"teacher_disagreement_score":0.4160169,"about_ca_system_score_codex":0.0005074953,"about_ca_system_score_gemma":0.0015848681,"threshold_uncertainty_score":0.34344262},"labels":[],"label_agreement":null},{"id":"W4387969063","doi":"10.1200/jco.23.00389","title":"Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; Children's Hospital of Philadelphia","keywords":"Medicine; Internal medicine; Cumulative incidence; Gastroenterology; Cohort; Hazard ratio; Proportional hazards model; Incidence (geometry); Oncology; Confidence interval","score_opus":0.0372843631416352,"score_gpt":0.39753980510575504,"score_spread":0.36025544196411985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387969063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836848,0.00030627524,0.000022939428,0.0148900775,0.0003711228,0.0005583158,0.000012788282,0.000020454809,0.00013326733],"genre_scores_gemma":[0.994218,0.001881623,0.0008807836,0.0023874678,0.00047130822,0.000009886677,0.000023678027,0.00002927453,0.00009796727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583435,0.0006038333,0.0020813656,0.00041120301,0.0006270672,0.0004421947],"domain_scores_gemma":[0.99447626,0.0033564775,0.0011681869,0.00032644265,0.00018475617,0.0004878867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003961848,0.0002135506,0.0017764088,0.00020172904,0.000056967023,0.00001834475,0.0002576383,0.00051888166,0.000026041198],"category_scores_gemma":[0.00483997,0.00011238894,0.00017593538,0.00029097655,0.0006611216,0.000117049916,0.00026695023,0.0018182925,0.000014349779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004053162,0.0006849228,0.9560172,0.000012476859,0.0008651042,0.013491011,0.00020180138,0.0000012226291,0.000007264907,0.000008722431,0.0025388792,0.022118215],"study_design_scores_gemma":[0.022062222,0.007948327,0.9263445,0.00029733375,0.00037361984,0.04120332,0.00019360549,0.000075879434,8.018113e-7,0.000101213314,0.0012912275,0.00010791372],"about_ca_topic_score_codex":0.00084214006,"about_ca_topic_score_gemma":0.00065566663,"teacher_disagreement_score":0.029672682,"about_ca_system_score_codex":0.0003446353,"about_ca_system_score_gemma":0.0016006684,"threshold_uncertainty_score":0.7899677},"labels":[],"label_agreement":null},{"id":"W4388124188","doi":"10.1200/jco.23.00914","title":"First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Hazard ratio; Clinical endpoint; Chemotherapy; Placebo; Internal medicine; Cervical cancer; Clinical trial; Surgery; Oncology; Confidence interval; Cancer; Immunotherapy; Pathology","score_opus":0.2622251498244805,"score_gpt":0.4862756760409937,"score_spread":0.22405052621651322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388124188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91811264,0.0015998246,0.0003179958,0.07006754,0.0075489213,0.0012645889,0.00024007677,0.000053489086,0.0007949474],"genre_scores_gemma":[0.91641,0.058288507,0.0066586738,0.0058430713,0.0060137613,0.00010002363,0.0001027602,0.0001818812,0.0064012916],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437517,0.0003603611,0.0036484296,0.0004072091,0.0006833413,0.0005254742],"domain_scores_gemma":[0.98913324,0.0067121093,0.0027147965,0.0003597794,0.00070734514,0.0003727593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004631672,0.00032426786,0.0024446754,0.00026554486,0.00008758566,0.000014629138,0.0003853398,0.0004324699,0.00056562835],"category_scores_gemma":[0.0028819446,0.00022349178,0.0019490537,0.00048440555,0.0003646408,0.000110320136,0.00004271696,0.00079304876,0.0000083893165],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7909551,0.0017628095,0.0008561086,0.00027098536,0.003132611,0.000120876466,0.00032155088,0.00012682105,0.00027504924,0.00002294141,0.029815786,0.17233932],"study_design_scores_gemma":[0.37648365,0.08311993,0.03336552,0.00054471084,0.0012796427,0.00017564863,0.0003444088,0.0030793173,0.00039979903,0.00018372663,0.5006567,0.00036693196],"about_ca_topic_score_codex":0.00012449147,"about_ca_topic_score_gemma":0.00050758774,"teacher_disagreement_score":0.47084093,"about_ca_system_score_codex":0.00039845912,"about_ca_system_score_gemma":0.002711614,"threshold_uncertainty_score":0.911373},"labels":[],"label_agreement":null},{"id":"W4388662516","doi":"10.1200/jco.22.02668","title":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Gemcitabine; Internal medicine; Folinic acid; Hazard ratio; Oxaliplatin; Population; Oncology; Pancreatic cancer; Irinotecan; Adenocarcinoma; Adjuvant therapy; Gastroenterology; Cancer; Fluorouracil; Colorectal cancer; Confidence interval","score_opus":0.40558186386206574,"score_gpt":0.5186904279081003,"score_spread":0.11310856404603453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388662516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934218,0.0003930189,0.00003059341,0.0017941484,0.001885861,0.0021886218,0.000014408569,0.00001306184,0.00025849103],"genre_scores_gemma":[0.9970133,0.00046978905,0.00039050105,0.00019704989,0.0017336431,0.000015892121,0.0000038811113,0.000024652327,0.00015131367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9846205,0.0080454,0.0052793603,0.00038561755,0.0011970922,0.0004720305],"domain_scores_gemma":[0.9842421,0.010765172,0.002933166,0.00076600956,0.000989525,0.0003040402],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.034246363,0.00020834022,0.0032453244,0.00027656893,0.0001214043,0.000007702274,0.0004044918,0.0007552455,0.00003832185],"category_scores_gemma":[0.023845382,0.00010944446,0.0006000117,0.0009899755,0.000843517,0.000156134,0.00026857812,0.0028632977,0.0000024421397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07078132,0.00729659,0.91349196,0.00007268409,0.0006520347,0.00063550955,0.0008069416,0.0001552094,0.0013062609,0.000010517115,0.00078560365,0.004005396],"study_design_scores_gemma":[0.06374055,0.04330191,0.88013494,0.0002032884,0.0012459165,0.0001862603,0.0022019474,0.008530937,0.0000583036,0.00017069762,0.00015387427,0.00007139615],"about_ca_topic_score_codex":0.00032590763,"about_ca_topic_score_gemma":0.0006399977,"teacher_disagreement_score":0.036005322,"about_ca_system_score_codex":0.00020803987,"about_ca_system_score_gemma":0.0043019643,"threshold_uncertainty_score":0.99943715},"labels":[],"label_agreement":null},{"id":"W4388662575","doi":"10.1200/jco.23.00339","title":"Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; National Institute for Health and Care Research; AstraZeneca","keywords":"Olaparib; Medicine; Prostate cancer; Oncology; Internal medicine; PARP inhibitor; Cancer; Clinical trial; Prostate; Gynecology; Poly ADP ribose polymerase","score_opus":0.20027265815935,"score_gpt":0.501004182842899,"score_spread":0.300731524683549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388662575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98574275,0.00046055022,0.000022412527,0.011409499,0.0003096051,0.0019773287,0.000046819867,0.000002171043,0.00002886503],"genre_scores_gemma":[0.99467564,0.0029807724,0.0005672158,0.0010082973,0.0002719103,0.00037626814,0.000008086107,0.000009590788,0.00010219726],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979269,0.00028127435,0.0013126513,0.000120415505,0.0002232252,0.00013555573],"domain_scores_gemma":[0.99434304,0.004536141,0.0007521476,0.000103973645,0.0002049086,0.000059806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017955487,0.00009194258,0.00065037597,0.000086715685,0.00004993441,0.000012854215,0.00005379563,0.00005932796,0.000009826947],"category_scores_gemma":[0.0004310602,0.00003807205,0.00008257081,0.00022971658,0.00020519688,0.00007824699,0.0000051922425,0.0001994323,2.2874299e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7464764,0.009391191,0.10070356,0.00016941254,0.0011369326,0.00022233705,0.009911883,0.00044606705,0.00026802087,0.00046148757,0.0028118212,0.1280009],"study_design_scores_gemma":[0.35667643,0.09157249,0.50311494,0.00024924916,0.0007270996,0.000037299797,0.0016063773,0.0003835728,0.0000849438,0.0007706861,0.04466157,0.00011535558],"about_ca_topic_score_codex":0.000068213274,"about_ca_topic_score_gemma":0.0023914578,"teacher_disagreement_score":0.40241134,"about_ca_system_score_codex":0.00010640496,"about_ca_system_score_gemma":0.0010482274,"threshold_uncertainty_score":0.18595104},"labels":[],"label_agreement":null},{"id":"W4388724082","doi":"10.1200/jco.23.00954","title":"Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Digital polymerase chain reaction; Cervical cancer; Internal medicine; Oncology; Cancer; Stage (stratigraphy); Gastroenterology; Polymerase chain reaction; Biology","score_opus":0.19480380342222756,"score_gpt":0.5349917637318983,"score_spread":0.3401879603096707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388724082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972595,0.00015726032,0.000071194925,0.0014332733,0.00052078423,0.00038098264,0.00001898419,0.000008594797,0.0001494299],"genre_scores_gemma":[0.9975461,0.00015092983,0.0001445765,0.00027284346,0.0017889657,0.00003681921,0.000009409382,0.000020051717,0.000030326546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99506325,0.00050884194,0.0033775293,0.00022777331,0.0005700755,0.00025251677],"domain_scores_gemma":[0.9946812,0.0024815549,0.0014377172,0.00017164764,0.00085088867,0.00037702444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057587638,0.00010589887,0.0012519638,0.0002898063,0.000029811088,0.000007165809,0.00012389326,0.00028820755,0.00031220663],"category_scores_gemma":[0.006798449,0.000087100045,0.0005550896,0.00041092373,0.00020057462,0.00013818919,0.000055549706,0.00074308296,0.0000041192025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020538991,0.0011485165,0.7760145,0.00044645136,0.00015246977,0.00016165561,0.0001330399,0.000062305924,0.007147099,0.000024898327,0.00011300375,0.19405709],"study_design_scores_gemma":[0.008083338,0.0065089236,0.97945493,0.00010776144,0.00023272376,0.000005516454,0.000055689718,0.0006612097,0.003716473,0.00076482724,0.00033601356,0.00007256513],"about_ca_topic_score_codex":0.00016285367,"about_ca_topic_score_gemma":0.00029238945,"teacher_disagreement_score":0.20344047,"about_ca_system_score_codex":0.00018544507,"about_ca_system_score_gemma":0.0012482731,"threshold_uncertainty_score":0.81388694},"labels":[],"label_agreement":null},{"id":"W4389275881","doi":"10.1200/jco.23.02219","title":"CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Chugai Pharmaceutical; GlaxoSmithKline; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Chemotherapy; Lung cancer; Epidermal growth factor receptor; Hazard ratio; Brain metastasis; Cancer; Metastasis; Erlotinib; Confidence interval","score_opus":0.06908951526366378,"score_gpt":0.48588338280253934,"score_spread":0.4167938675388756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389275881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205947,0.00024228518,0.00010354127,0.0056486498,0.00059634313,0.0005913162,0.000013682201,0.000019811392,0.0007248913],"genre_scores_gemma":[0.9916492,0.0018974508,0.0036220988,0.0011625517,0.0003628439,0.000026407168,0.000009140881,0.00004016064,0.0012301401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715865,0.00017767957,0.0018531423,0.00022914367,0.00027825622,0.0003031562],"domain_scores_gemma":[0.99611026,0.0014959436,0.001503123,0.00015717467,0.0004453533,0.00028814696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006651804,0.00018300825,0.0015678158,0.0002151125,0.000030048795,0.0000046037903,0.00013580215,0.00023661717,0.00035866883],"category_scores_gemma":[0.00070244196,0.00010688785,0.00025428107,0.00053931517,0.00013688256,0.00010061702,0.00002145584,0.00060470466,0.000009162595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024546485,0.0030988115,0.884462,0.00017561634,0.0012537729,0.00050145516,0.0017474977,0.00038935483,0.0028919645,0.000004537785,0.0022136131,0.07871487],"study_design_scores_gemma":[0.06821755,0.01524081,0.9025011,0.0007235263,0.00090524013,0.00006681545,0.00047102763,0.00070618314,0.0041232486,0.000012900199,0.006831056,0.00020054632],"about_ca_topic_score_codex":0.0001205464,"about_ca_topic_score_gemma":0.00015426968,"teacher_disagreement_score":0.07851432,"about_ca_system_score_codex":0.00024552643,"about_ca_system_score_gemma":0.0033164883,"threshold_uncertainty_score":0.5883308},"labels":[],"label_agreement":null},{"id":"W4389417749","doi":"10.1200/jco.22.02776","title":"Interpreting the Significance of Changes in Health-Related Quality-of-Life Scores","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Quality of life (healthcare); Concordance; Clinical significance; Statistical significance; Health related quality of life; Cancer; Demography; Internal medicine; Disease","score_opus":0.26337676098042473,"score_gpt":0.5253150424491456,"score_spread":0.2619382814687209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389417749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94427156,0.0012566359,0.000021510908,0.05200235,0.0015244458,0.00015558275,0.0000036801453,0.0000066866182,0.00075753586],"genre_scores_gemma":[0.99580586,0.0011921427,0.00006804522,0.0025064347,0.00029577926,0.0000033930914,0.0000010368249,0.000008704314,0.00011860893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99474305,0.0013057888,0.0033489706,0.00010792086,0.00031949524,0.00017476275],"domain_scores_gemma":[0.9891182,0.0072698463,0.003040092,0.00016006762,0.00025602276,0.0001557345],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013193522,0.000071757815,0.0014724514,0.00015267963,0.00001634599,0.0000017516726,0.00018157133,0.00018887615,0.00007765159],"category_scores_gemma":[0.011565949,0.000044232213,0.00029148033,0.000442341,0.0002640839,0.000025577307,0.000052276104,0.00083489163,0.0000037458758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008907651,0.0007079284,0.7828606,0.00078419375,0.00037047648,0.0001243269,0.0069584204,0.00012313112,0.0008939914,0.0009877048,0.004991595,0.19229002],"study_design_scores_gemma":[0.004921101,0.009167964,0.95889163,0.0013027941,0.00006386991,0.000029087405,0.006303715,0.00018657044,0.000212108,0.0010835842,0.017746747,0.000090799236],"about_ca_topic_score_codex":0.001135303,"about_ca_topic_score_gemma":0.0051408005,"teacher_disagreement_score":0.19219922,"about_ca_system_score_codex":0.0000702713,"about_ca_system_score_gemma":0.0014956697,"threshold_uncertainty_score":0.9967601},"labels":[],"label_agreement":null},{"id":"W4389428319","doi":"10.1200/jco.23.01941","title":"ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Flatiron Health; American Society of Clinical Oncology; AstraZeneca","keywords":"Medicine; Economic shortage; Oncology; Clinical Oncology; Drug development; Drug; Medical physics; Internal medicine; Pharmacology; Cancer","score_opus":0.7813826350739537,"score_gpt":0.6674149115257141,"score_spread":0.11396772354823959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389428319","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.072278365,0.0018389123,0.013405075,0.8926458,0.0072353515,0.0010563461,0.00007809507,0.000027459988,0.011434638],"genre_scores_gemma":[0.83015484,0.009854938,0.073800676,0.07672836,0.0054782964,0.0002073729,0.000011650969,0.00008157047,0.0036822928],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98384225,0.0015773268,0.013618962,0.00034701338,0.00020768361,0.0004067361],"domain_scores_gemma":[0.9341289,0.05355905,0.011295791,0.00042190307,0.00033208542,0.0002623051],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.14522277,0.00014389152,0.0025166392,0.000212727,0.00012638916,0.000019060273,0.00057336065,0.00066943147,0.00020428166],"category_scores_gemma":[0.040579308,0.00011983872,0.00066650123,0.000251042,0.00037252315,0.00019194277,0.000111376496,0.0013034946,0.00039343216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006741769,0.0007438226,0.015494131,0.0003785198,0.0010719885,0.00005747195,0.00063692254,0.0004564762,0.0000011221398,0.34856713,0.6127446,0.01917359],"study_design_scores_gemma":[0.002641787,0.0019168395,0.078715175,0.00008390205,0.00009395059,0.000030488838,0.0017809835,0.0027168386,0.000002366569,0.034772854,0.8771121,0.00013269672],"about_ca_topic_score_codex":0.000040000992,"about_ca_topic_score_gemma":0.00007542258,"teacher_disagreement_score":0.8159174,"about_ca_system_score_codex":0.00035701416,"about_ca_system_score_gemma":0.001117677,"threshold_uncertainty_score":0.9675023},"labels":[],"label_agreement":null},{"id":"W4389542099","doi":"10.1200/jco.23.01574","title":"CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"CD5; Diffuse large B-cell lymphoma; Cancer research; Biology; B cell; breakpoint cluster region; Lymphoma; Gene; Genetics; Immunology; Antibody","score_opus":0.0603212062346504,"score_gpt":0.4085103311707689,"score_spread":0.34818912493611853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389542099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813718,0.00034914265,0.000061841245,0.014990147,0.0016407386,0.0003032968,0.000051110965,0.000041404135,0.0011905084],"genre_scores_gemma":[0.9875025,0.0010197846,0.0008385834,0.0076449965,0.0015629871,0.000010454002,0.000052520198,0.000027747677,0.0013403986],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9967898,0.00033857062,0.0017057678,0.00029604675,0.00049006747,0.00037976247],"domain_scores_gemma":[0.9959517,0.0016944597,0.0008930493,0.00023474763,0.00059364206,0.00063240266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019800935,0.00020643328,0.0013457156,0.00028683283,0.000082550265,0.00002431011,0.000085437125,0.0004783778,0.00009053095],"category_scores_gemma":[0.0020845497,0.00014617041,0.0006267005,0.00042114392,0.00008856621,0.00011777243,0.00012259884,0.0004442055,0.0004244619],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015781242,0.07655659,0.09350098,0.0002341388,0.0021410522,0.11690944,0.0018255484,0.00009701058,0.06718972,0.0008425397,0.5437498,0.08117192],"study_design_scores_gemma":[0.07019264,0.016158124,0.74523646,0.00040422767,0.0011201784,0.0013569896,0.00056958315,0.0001318217,0.068772204,0.0003958882,0.09533557,0.000326324],"about_ca_topic_score_codex":0.000017860322,"about_ca_topic_score_gemma":0.000039515,"teacher_disagreement_score":0.6517355,"about_ca_system_score_codex":0.00035748567,"about_ca_system_score_gemma":0.00084355986,"threshold_uncertainty_score":0.59606564},"labels":[],"label_agreement":null},{"id":"W4389574711","doi":"10.1200/jco.23.01101","title":"International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Physical Activity and Health","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; School of Public Health, Imperial College London; NIHR Imperial Biomedical Research Centre; Instituto de Salud Carlos III; Marshfield Clinic Research Foundation; World Cancer Research Fund; Medical Research Council; National Institutes of Health; Institut Gustave-Roussy; Deutsche Krebshilfe; Vetenskapsrådet; Institut National de la Santé et de la Recherche Médicale; Cancerfonden; Agence Nationale de la Recherche; Associazione Italiana per la Ricerca sul Cancro; Imperial College London; Deutsches Krebsforschungszentrum; Ligue Contre le Cancer; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; Breast Cancer Research Foundation; World Health Organization; Cancer Research UK","keywords":"Medicine; Breast cancer; Oncology; Physical activity; Cancer; Gynecology; Leisure time; Obstetrics; Demography; Gerontology; Internal medicine; Physical therapy","score_opus":0.08894632789063817,"score_gpt":0.4883061767275761,"score_spread":0.3993598488369379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389574711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876817,0.000016632284,0.000010588198,0.011533337,0.00024869273,0.00008847729,0.000100096666,0.0000075650582,0.00031290032],"genre_scores_gemma":[0.998308,0.00045391324,0.000046525092,0.00023549239,0.0008811573,0.000004377614,0.000005081534,0.0000069254284,0.000058500897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803305,0.000319296,0.0008652308,0.00019001347,0.00039295226,0.0001994456],"domain_scores_gemma":[0.9960435,0.0023966257,0.0009331751,0.00010413888,0.00018133028,0.0003412534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015132895,0.00009645157,0.0022954422,0.00028942403,0.000016812002,0.0000046152004,0.000106696425,0.00017257677,0.00024715177],"category_scores_gemma":[0.0006054444,0.00007261855,0.00024438454,0.0005288083,0.0001623544,0.00014436386,0.00007579968,0.0007389196,0.0000061041555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014528437,0.009804533,0.64514554,0.000040873812,0.0070144883,0.00027757886,0.00064880226,0.000276951,0.020609148,0.000036082805,0.0006508714,0.30096668],"study_design_scores_gemma":[0.0032144785,0.0020660833,0.9849929,0.000054310363,0.0011362338,0.000009510797,0.000037145044,0.007186609,0.000070374284,0.0004368389,0.0007386077,0.00005687512],"about_ca_topic_score_codex":0.00044310093,"about_ca_topic_score_gemma":0.00014591399,"teacher_disagreement_score":0.33984736,"about_ca_system_score_codex":0.00026217627,"about_ca_system_score_gemma":0.0008513338,"threshold_uncertainty_score":0.3210279},"labels":[],"label_agreement":null},{"id":"W4389763605","doi":"10.1200/jco.23.00838","title":"Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Bendamustine; Obinutuzumab; Vincristine; Hazard ratio; Follicular lymphoma; Rituximab; CHOP; Cyclophosphamide; Prednisone; Chemotherapy; Oncology; Induction chemotherapy; Gastroenterology; Minimal residual disease; Surgery; Lymphoma; Confidence interval; Leukemia","score_opus":0.05636821618870117,"score_gpt":0.42493185501344843,"score_spread":0.36856363882474724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389763605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734235,0.00010340357,0.0000012678848,0.00078514696,0.0002103677,0.0014131954,0.000053113563,0.000012385958,0.00007877706],"genre_scores_gemma":[0.9993948,0.00007054894,0.00006658839,0.00019335772,0.00010303613,0.000044730266,0.000028638187,0.00001678015,0.000081522565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516135,0.0006589453,0.0026298743,0.0003179542,0.00087495934,0.0003569309],"domain_scores_gemma":[0.9955065,0.001172819,0.001846036,0.00038879644,0.0005906815,0.00049511896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00157253,0.0002092258,0.0022225883,0.0004285481,0.000045814377,0.000008938758,0.00017512779,0.00014839844,0.000028710236],"category_scores_gemma":[0.0023796025,0.000104643186,0.00067222817,0.0015673516,0.00018883456,0.000082242266,0.00009837378,0.0002449216,0.000004066838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029798135,0.040523835,0.91659904,0.000017122078,0.006788339,0.0017302622,0.0005534686,0.00014227463,5.7021583e-7,0.000006665796,0.00025549522,0.003584825],"study_design_scores_gemma":[0.109607294,0.02695748,0.8504422,0.00008150078,0.012260936,0.0000034089485,0.0002898431,0.0001282534,0.0000042354986,0.000010284715,0.00013677013,0.00007779224],"about_ca_topic_score_codex":0.000130617,"about_ca_topic_score_gemma":0.00032963778,"teacher_disagreement_score":0.07980916,"about_ca_system_score_codex":0.0005380556,"about_ca_system_score_gemma":0.0018430249,"threshold_uncertainty_score":0.42672253},"labels":[],"label_agreement":null},{"id":"W4389942753","doi":"10.1200/jco.23.01115","title":"Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Terry Fox Research Institute; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of British Columbia; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Seagen; BC Cancer Foundation; Genome British Columbia; BeiGene; Regeneron Pharmaceuticals; Genome Canada; Kanae Foundation for the Promotion of Medical Science; National Cancer Institute; Strong; Genentech; AstraZeneca; Pfizer","keywords":"Tumor microenvironment; Medicine; Lymphoma; Oncology; Internal medicine; Cancer research; Pathology; Cancer","score_opus":0.0919978999920369,"score_gpt":0.4107195557820578,"score_spread":0.31872165579002093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389942753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859003,0.0005086127,0.0000037350528,0.01057097,0.001300686,0.000421797,0.00001148049,0.00002664796,0.0012557679],"genre_scores_gemma":[0.9923399,0.0028681485,0.0011422185,0.001972841,0.00057623244,0.000036662954,0.0000112299795,0.000030388814,0.0010223486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955406,0.00045390974,0.0027865868,0.00031930444,0.0004905787,0.0004090184],"domain_scores_gemma":[0.9949879,0.0027565248,0.0013339814,0.00033784733,0.00008101097,0.0005027448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017727617,0.0002604012,0.0021123432,0.00030407612,0.000040194394,0.000009515265,0.00015585985,0.00032094857,0.00014368206],"category_scores_gemma":[0.0015560059,0.00016435368,0.0007843576,0.00018743327,0.00016388598,0.000063401654,0.000073881296,0.00028007606,0.00023561654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023706143,0.012192531,0.77637416,0.000013030402,0.0006493324,0.012139862,0.00014769573,0.000040130013,0.00013060133,0.00001729305,0.0031275651,0.19279721],"study_design_scores_gemma":[0.034853008,0.025842523,0.8411765,0.0001149404,0.0003886287,0.00024118008,0.00008056518,0.000052590323,0.00021760003,0.00007574414,0.09685316,0.00010354072],"about_ca_topic_score_codex":0.00011452459,"about_ca_topic_score_gemma":0.00017865875,"teacher_disagreement_score":0.19269367,"about_ca_system_score_codex":0.0015875977,"about_ca_system_score_gemma":0.0016814083,"threshold_uncertainty_score":0.6702149},"labels":[],"label_agreement":null},{"id":"W43900738","doi":"10.1200/jco.2008.26.15_suppl.638","title":"Clinical-pathologic characteristics of true interval and screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Family history; Breast cancer screening; Population; Confidence interval; Mammography; Stage (stratigraphy); Cancer; Internal medicine; Gynecology","score_opus":0.10008413342725529,"score_gpt":0.43344545840574195,"score_spread":0.33336132497848664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W43900738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778545,0.0003199472,0.00003006597,0.0006304819,0.00036830778,0.00053700496,0.0002996523,0.000006850949,0.000022252614],"genre_scores_gemma":[0.9980045,0.0004244326,0.0005890986,0.00027371536,0.000622775,0.00004621276,0.000005380324,0.000024421732,0.000009476903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99480206,0.0012641831,0.0028014374,0.0004046745,0.00018359332,0.0005440838],"domain_scores_gemma":[0.9963024,0.0005105228,0.0017645406,0.000255135,0.00054804597,0.0006193439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027037184,0.00025900087,0.0017029438,0.00015789288,0.00009389016,0.000010138958,0.00022209715,0.00047572964,0.000020541014],"category_scores_gemma":[0.0014883442,0.00020217393,0.00031761566,0.00018633876,0.00073276623,0.000018210805,0.00011530608,0.00065395574,6.174407e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002494307,0.0017205854,0.8237057,0.000008167883,0.0006740891,0.005994597,0.00015353801,0.0000061383803,0.000033457145,3.1323145e-7,0.000036654976,0.16517249],"study_design_scores_gemma":[0.0095593985,0.0062594884,0.9757881,0.00008039275,0.0004193801,0.0071460754,0.000313853,0.00012119137,0.0000043742943,0.000002234429,0.0001334291,0.00017207598],"about_ca_topic_score_codex":0.048550077,"about_ca_topic_score_gemma":0.31793037,"teacher_disagreement_score":0.2693803,"about_ca_system_score_codex":0.000084223095,"about_ca_system_score_gemma":0.0012986601,"threshold_uncertainty_score":0.9577857},"labels":[],"label_agreement":null},{"id":"W4390732429","doi":"10.1200/jco.23.01796","title":"Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; VIVA Foundation for Children with Cancer; American Lebanese Syrian Associated Charities","keywords":"Medicine; Ejection fraction; Internal medicine; Cardiomyopathy; Hazard ratio; Natriuretic peptide; Heart failure; Cardiology; Proportional hazards model; Cumulative incidence; Cohort; Confidence interval","score_opus":0.08958753645345267,"score_gpt":0.4284127894471966,"score_spread":0.3388252529937439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390732429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920523,0.00417403,0.0005605907,0.0006028639,0.0018721159,0.0005359363,0.000067842455,0.000015506404,0.000118787546],"genre_scores_gemma":[0.9934294,0.0035540403,0.0011191205,0.00023512889,0.0016200605,0.000005306426,0.0000029055473,0.000022055514,0.000011967197],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99679196,0.0005038888,0.0017509809,0.00032055547,0.00038692594,0.00024567323],"domain_scores_gemma":[0.9980756,0.0004887514,0.0006351671,0.00017147584,0.0003368822,0.0002921052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035541728,0.000192796,0.0014758501,0.00022527747,0.000034059238,0.000018975828,0.000098305616,0.0004493564,0.000018807208],"category_scores_gemma":[0.0008930425,0.00015594765,0.0005428515,0.0005155021,0.00013206768,0.00014080181,0.00003030105,0.0009258782,5.3859685e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051204734,0.0007024924,0.38624036,0.00018566204,0.0016222023,0.0008297451,0.0011361043,0.000616733,0.15308838,0.000017801804,0.000122011865,0.450318],"study_design_scores_gemma":[0.00819014,0.012422546,0.96275854,0.0008681262,0.0007818982,0.0017831379,0.00042122853,0.0015913447,0.009350674,0.00027539695,0.0013528746,0.00020410612],"about_ca_topic_score_codex":0.00029362683,"about_ca_topic_score_gemma":0.0002853033,"teacher_disagreement_score":0.5765182,"about_ca_system_score_codex":0.00044822428,"about_ca_system_score_gemma":0.001781364,"threshold_uncertainty_score":0.635936},"labels":[],"label_agreement":null},{"id":"W4390788419","doi":"10.1200/jco.23.01306","title":"Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre Hospitalier de l’Université de Montréal; Surrey Memorial Hospital; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"National Cancer Institute; Sanofi; AstraZeneca; Pfizer; Cook Medical; Bristol-Myers Squibb","keywords":"Medicine; Clinical endpoint; Lung cancer; Cumulative incidence; Population; Cancer; Clinical trial; Incidence (geometry); Surgery; Stage (stratigraphy); Internal medicine; Oncology; Cohort","score_opus":0.061062696815833574,"score_gpt":0.44079531234608926,"score_spread":0.37973261553025567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390788419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95747834,0.032396577,0.00003572143,0.0022724248,0.005922861,0.00088549237,0.00054730626,0.00000456259,0.00045670345],"genre_scores_gemma":[0.96790457,0.028944705,0.00036396706,0.00054148154,0.0017384114,0.00012784125,0.000018508712,0.000029353367,0.00033116475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962613,0.0002987103,0.002473742,0.0003820606,0.0003377423,0.00024645822],"domain_scores_gemma":[0.9932685,0.003441378,0.0022483068,0.00029561124,0.0005467168,0.00019948972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018485012,0.00022353914,0.0023625684,0.000181786,0.0000457013,0.000011893377,0.00020409832,0.00041417388,0.0006246025],"category_scores_gemma":[0.00027768547,0.00014286872,0.0012311647,0.00048731774,0.0002582966,0.00012926522,0.000076473276,0.0007022301,1.7945018e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3346564,0.0026568614,0.47396556,0.0047671124,0.057904236,0.00012408684,0.00094458443,0.0016515418,0.005461361,0.00009416572,0.035489235,0.08228486],"study_design_scores_gemma":[0.16068041,0.01519185,0.7309972,0.0024030616,0.05839781,0.000005238911,0.00016135344,0.005164188,0.006251853,0.00010100166,0.020362735,0.00028329805],"about_ca_topic_score_codex":0.0032387306,"about_ca_topic_score_gemma":0.015976356,"teacher_disagreement_score":0.25703165,"about_ca_system_score_codex":0.0017711718,"about_ca_system_score_gemma":0.005923043,"threshold_uncertainty_score":0.99971247},"labels":[],"label_agreement":null},{"id":"W4390902638","doi":"10.1200/jco.23.01569","title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University; Juravinski Cancer Centre","funders":"Cilag; EMD Serono; Genentech; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Chugai Pharmaceutical; AstraZeneca; EUSA Pharma; Seagen; LG Chem; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; BeiGene; Tizona Therapeutics; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Sunitinib; Clinical endpoint; Renal cell carcinoma; Internal medicine; Hazard ratio; Pembrolizumab; Discontinuation; Oncology; Phases of clinical research; Clinical trial; Confidence interval; Cancer; Sorafenib; Immunotherapy; Hepatocellular carcinoma","score_opus":0.24905172738378725,"score_gpt":0.4762400422636671,"score_spread":0.22718831487987987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390902638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926637,0.0020363014,0.00003865078,0.00051732705,0.0010042612,0.0008213614,0.000048695907,0.000012120495,0.0028576148],"genre_scores_gemma":[0.9974073,0.00078764075,0.0006473955,0.000026270605,0.0005062063,0.000021054017,0.000037572532,0.00003566237,0.0005308752],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99250853,0.0008384227,0.0049072015,0.000495869,0.0008570024,0.00039294877],"domain_scores_gemma":[0.9908697,0.0056649037,0.0020242382,0.0005070361,0.0005363981,0.00039773982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019833443,0.00037391548,0.0043761823,0.0010624162,0.000032802094,0.000011347572,0.0002404536,0.00033494664,0.00038665993],"category_scores_gemma":[0.00073145126,0.00026823254,0.0016931752,0.0009692255,0.0002282133,0.00012608005,0.00007528141,0.0007490755,0.000005018711],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7115575,0.07573561,0.06760972,0.00035041588,0.014360355,0.021802017,0.0047009047,0.009288128,0.0015837207,0.0001281637,0.00034787168,0.092535555],"study_design_scores_gemma":[0.27790627,0.30486262,0.39114442,0.00016097646,0.01502938,0.00009039714,0.0013145916,0.0031044693,0.0015611466,0.00003052175,0.0045363638,0.000258863],"about_ca_topic_score_codex":0.00038645155,"about_ca_topic_score_gemma":0.0010935926,"teacher_disagreement_score":0.43365127,"about_ca_system_score_codex":0.0010007003,"about_ca_system_score_gemma":0.0023916876,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4391090926","doi":"10.1200/jco.2024.42.3_suppl.485","title":"Defining ablative radiotherapy in patients with hepatocellular carcinoma: An expert consensus.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ablative case; Hepatocellular carcinoma; External beam radiotherapy; Radiation therapy; Delphi method; Nuclear medicine; Medical physics; Radiology; Brachytherapy; Internal medicine","score_opus":0.11978588596541397,"score_gpt":0.3977059256057551,"score_spread":0.2779200396403411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391090926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933524,0.006822703,0.00007461085,0.0020021843,0.00058992923,0.00032602233,0.0000036697793,0.000019087156,0.0008265404],"genre_scores_gemma":[0.9909724,0.00023921988,0.007355429,0.00083273154,0.00047732255,0.000006996241,0.000012155037,0.00003686219,0.00006687822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969635,0.000543956,0.0015825704,0.00027550728,0.00036783845,0.00026660023],"domain_scores_gemma":[0.9973736,0.0013264302,0.0004548436,0.00017784922,0.00028178518,0.00038552622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017989635,0.00019472915,0.0013053134,0.00026690462,0.000029302346,0.000019844592,0.000098212,0.00033943114,0.00015390772],"category_scores_gemma":[0.00036203887,0.00012316658,0.00033628833,0.00025109836,0.00018383127,0.00013090268,0.000015402196,0.0008647324,0.000014306566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041029025,0.001546512,0.9336086,0.000022540478,0.00041992246,0.005601187,0.000650227,0.0000013798788,0.000021033835,0.00013649795,0.00054834795,0.053340882],"study_design_scores_gemma":[0.01520329,0.03448752,0.91997266,0.0002798431,0.0003266253,0.00023621366,0.0001679086,0.0046774927,0.00012848181,0.000089272085,0.02424378,0.00018693627],"about_ca_topic_score_codex":0.000049840695,"about_ca_topic_score_gemma":0.000014310137,"teacher_disagreement_score":0.053153947,"about_ca_system_score_codex":0.00026120528,"about_ca_system_score_gemma":0.0015212096,"threshold_uncertainty_score":0.5022587},"labels":[],"label_agreement":null},{"id":"W4391090938","doi":"10.1200/jco.2024.42.3_suppl.247","title":"Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Cohort; Interim; Cancer; Internal medicine; Adjuvant; Interim analysis; Oncology; Clinical trial","score_opus":0.07270202975508602,"score_gpt":0.469063524211494,"score_spread":0.396361494456408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391090938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997647,0.0040620244,0.0003730324,0.003377407,0.0015198815,0.00052430626,0.000004504342,0.000011212189,0.00015115616],"genre_scores_gemma":[0.9916952,0.006559408,0.00020673711,0.0008732722,0.00038486958,0.000012747467,0.0000017175772,0.000016714612,0.00024932294],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99662375,0.00036883674,0.00199885,0.00031692072,0.00044087847,0.0002507767],"domain_scores_gemma":[0.9978883,0.0007020359,0.00081925374,0.00021060764,0.00017112303,0.00020863784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017883485,0.00020401955,0.0018925319,0.00078796595,0.000037257007,0.000024524,0.00016989061,0.00013540265,0.00015345079],"category_scores_gemma":[0.00045015704,0.000121105295,0.00046396776,0.0011563281,0.00021353144,0.00014267715,0.000121548816,0.00085359707,9.1033894e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021874228,0.0012477104,0.21179964,0.00004682699,0.002269971,0.0006897212,0.00045346754,0.0005478733,0.00014771336,0.000018006875,0.00035893996,0.7605459],"study_design_scores_gemma":[0.034245726,0.0354361,0.91561097,0.0002170813,0.0033327525,0.00014702193,0.00069391035,0.005962002,0.000022725715,0.000046775913,0.0041896068,0.00009532856],"about_ca_topic_score_codex":0.00017580418,"about_ca_topic_score_gemma":0.00052862696,"teacher_disagreement_score":0.76045054,"about_ca_system_score_codex":0.00027192777,"about_ca_system_score_gemma":0.0008965596,"threshold_uncertainty_score":0.49385306},"labels":[],"label_agreement":null},{"id":"W4391090940","doi":"10.1200/jco.2024.42.3_suppl.591","title":"Quality of surveillance in patients with completely resected gastroenteropancreatic neuroendocrine tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Neuroendocrine tumors; Stage (stratigraphy); Incidence (geometry); Population; Internal medicine; Cohort; Colorectal cancer; Disease; Surveillance, Epidemiology, and End Results; Retrospective cohort study; General surgery; Cancer; Surgery; Cancer registry","score_opus":0.11525702795952839,"score_gpt":0.4797180262774592,"score_spread":0.3644609983179308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391090940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955489,0.0002258762,0.00002801789,0.0029248577,0.00037784418,0.00030699177,0.0000141898945,0.0000153467,0.00055795105],"genre_scores_gemma":[0.99796975,0.00015018746,0.0012309363,0.00029521744,0.00022957925,0.0000031668521,0.000005177209,0.000025469133,0.000090547044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939642,0.0013308802,0.0032162266,0.0002661895,0.0008316902,0.000390823],"domain_scores_gemma":[0.994003,0.0036437644,0.0010976165,0.00026411552,0.0006474218,0.00034409767],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017605178,0.00015775209,0.0020819409,0.0003347045,0.00001299334,0.000009911467,0.00022733417,0.000015356041,0.000082876184],"category_scores_gemma":[0.008711866,0.00010190497,0.0002760223,0.00043547095,0.00036764916,0.00015664291,0.00008319809,0.0013951769,0.0000071455615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018516926,0.0016433923,0.96046567,0.00030299876,0.00012920833,0.010301344,0.000008664067,0.000016339865,0.00019802741,0.00004616532,0.0007674477,0.0076037897],"study_design_scores_gemma":[0.009642239,0.031296972,0.95462734,0.00037834162,0.000028998942,0.00083213893,0.000019496563,0.00005617943,0.00007617175,0.00009026866,0.0028922865,0.00005958244],"about_ca_topic_score_codex":0.000047316764,"about_ca_topic_score_gemma":0.00016485278,"teacher_disagreement_score":0.029653579,"about_ca_system_score_codex":0.000115830466,"about_ca_system_score_gemma":0.00084909017,"threshold_uncertainty_score":0.9996382},"labels":[],"label_agreement":null},{"id":"W4391091096","doi":"10.1200/jco.2024.42.3_suppl.33","title":"Outcomes of elderly patients with node-positive colon cancer: A multi-center population-based cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"University of Saskatchewan","keywords":"Medicine; Internal medicine; Cohort; Colorectal cancer; Population; Anemia; Cancer; Gastroenterology; Proportional hazards model; Chemotherapy; Surgery","score_opus":0.06649157005208194,"score_gpt":0.46509720845145053,"score_spread":0.3986056383993686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956866,0.00016070841,0.00006192398,0.001599148,0.001272212,0.00090856367,0.00003957081,0.000014853811,0.00025641065],"genre_scores_gemma":[0.9980092,0.000033883392,0.0010695207,0.00055176846,0.00015311097,0.000031259242,0.0000138482155,0.000022964516,0.00011445913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684584,0.00033725126,0.0017680086,0.00025309803,0.000612005,0.00018380253],"domain_scores_gemma":[0.9959298,0.002065864,0.00092247414,0.00015195277,0.0006774007,0.00025250117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089340453,0.00017480146,0.001726309,0.00015374088,0.000026264523,0.000009006365,0.00010081511,0.00019756121,0.00015032502],"category_scores_gemma":[0.00069655734,0.00010206082,0.00042952312,0.00021886105,0.0001026448,0.0000889814,0.000027331393,0.0005888195,0.0000058878063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008162604,0.01188423,0.94712526,0.000035480596,0.0020593614,0.00053782546,0.00007092435,0.000036857575,0.0000011572058,0.0000026461241,0.00012445402,0.02995921],"study_design_scores_gemma":[0.023770815,0.032488655,0.9412561,0.00026799698,0.001138556,0.000010714589,0.000023056708,0.00018638502,0.0000068250174,0.000005374705,0.0007621167,0.00008338279],"about_ca_topic_score_codex":0.00035949232,"about_ca_topic_score_gemma":0.0004942349,"teacher_disagreement_score":0.029875826,"about_ca_system_score_codex":0.0005215789,"about_ca_system_score_gemma":0.0011596641,"threshold_uncertainty_score":0.41619194},"labels":[],"label_agreement":null},{"id":"W4391091122","doi":"10.1200/jco.2024.42.3_suppl.tps419","title":"First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Radioimmunotherapy; Cancer research; Oncology; Internal medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.21684933801765216,"score_gpt":0.5891909108825557,"score_spread":0.37234157286490355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821911,0.00081654236,0.000067867804,0.0066172485,0.0031858864,0.0010386849,0.000008599626,0.00002850384,0.0060455548],"genre_scores_gemma":[0.991035,0.0004711911,0.0010157241,0.00090356055,0.004324812,0.00002580943,0.0000060460147,0.000057102443,0.0021607545],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908735,0.0018919873,0.0050476356,0.00050102064,0.000985969,0.0006998846],"domain_scores_gemma":[0.9887789,0.008806296,0.001097804,0.00033055054,0.00042540755,0.0005610756],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017840836,0.0002735095,0.002880072,0.00080872385,0.00006564508,0.00004864167,0.00036385242,0.00070274225,0.00249989],"category_scores_gemma":[0.006136658,0.00021450601,0.0008677827,0.00062268967,0.000397781,0.00017707153,0.0001230808,0.0043254546,0.000086531254],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29806265,0.013624428,0.002197019,0.00029727034,0.00089320494,0.05089756,0.002014446,0.00040418722,0.05678502,0.00024954035,0.007749169,0.5668255],"study_design_scores_gemma":[0.5423758,0.31974876,0.013954427,0.0034825734,0.0008781564,0.0030827883,0.00094716816,0.03165707,0.006748776,0.003595195,0.07277315,0.000756158],"about_ca_topic_score_codex":0.000103100465,"about_ca_topic_score_gemma":0.00023370414,"teacher_disagreement_score":0.56606936,"about_ca_system_score_codex":0.0009798347,"about_ca_system_score_gemma":0.0041632317,"threshold_uncertainty_score":0.99841195},"labels":[],"label_agreement":null},{"id":"W4391091163","doi":"10.1200/jco.2024.42.3_suppl.85","title":"The impact of multidisciplinary care for locally advanced rectal cancer referrals: A systems perspective.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Radiation oncologist; Multidisciplinary approach; Radiation oncology; Colorectal cancer; Cancer; Radiation therapy; Internal medicine; Medical record; Oncology","score_opus":0.4137686811158595,"score_gpt":0.6748760079225026,"score_spread":0.26110732680664306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9295476,0.031681854,0.0021462853,0.026564632,0.007304648,0.0014843654,0.00008126548,0.000027820231,0.0011615492],"genre_scores_gemma":[0.9908198,0.0037506155,0.0024296944,0.00013994997,0.0025694761,0.00003283974,0.0000051900424,0.000030625433,0.00022180149],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99445415,0.00052362366,0.004186961,0.00023166703,0.00036613276,0.00023746397],"domain_scores_gemma":[0.9738362,0.02076252,0.0021172406,0.00021445731,0.0028224695,0.00024713975],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006180102,0.00014652252,0.0012631365,0.00009822922,0.00007920212,0.00002178792,0.0001801641,0.00028087033,0.000038555372],"category_scores_gemma":[0.02920822,0.000077387806,0.0011822456,0.00018964703,0.00021934802,0.00021177602,0.00005987067,0.0010117679,0.0000041884778],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052163586,0.0015318798,0.015799493,0.0005811127,0.0039121998,0.00042440463,0.0022983884,0.003176311,0.0022536183,0.001100143,0.027871951,0.8888869],"study_design_scores_gemma":[0.055434115,0.21629618,0.26810086,0.0053195357,0.006641587,0.002276997,0.1115905,0.045766164,0.0002380244,0.0047096745,0.28287387,0.0007524918],"about_ca_topic_score_codex":0.0004572824,"about_ca_topic_score_gemma":0.00031273553,"teacher_disagreement_score":0.8881344,"about_ca_system_score_codex":0.0009428266,"about_ca_system_score_gemma":0.007002649,"threshold_uncertainty_score":0.9986267},"labels":[],"label_agreement":null},{"id":"W4391091175","doi":"10.1200/jco.2024.42.3_suppl.521","title":"Comparing resection and stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion: A propensity score matched study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Propensity score matching; Hepatocellular carcinoma; Surgery; Cirrhosis; Log-rank test; Population; Incidence (geometry); Cumulative incidence; Radiation therapy; Internal medicine; Survival analysis; Radiology","score_opus":0.31393284844736397,"score_gpt":0.39836148807241,"score_spread":0.08442863962504604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920608,0.0038517353,0.00019801613,0.0015868449,0.0004842515,0.001720739,8.564751e-7,0.000021705497,0.00007509635],"genre_scores_gemma":[0.9978731,0.00063414744,0.000435879,0.00016948133,0.00074063655,0.000040268,0.0000070624283,0.000029687326,0.000069720605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975613,0.00045977076,0.0011538165,0.00030248068,0.00033120424,0.00019142727],"domain_scores_gemma":[0.99794674,0.0007961433,0.00047988864,0.00018506013,0.0003384546,0.00025371576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003264406,0.00017429338,0.0012504403,0.00017327293,0.00008556387,0.000055603443,0.000070309354,0.0002100569,0.000019962315],"category_scores_gemma":[0.00031223975,0.000106775806,0.00034578593,0.0001829582,0.0000867573,0.00019381834,0.00002939207,0.00058449246,0.0000036628817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00960324,0.0012670681,0.9552617,0.00015362797,0.0012108432,0.0024326611,0.00037481883,3.7545553e-7,0.00026322398,0.000013375123,0.00014450058,0.029274544],"study_design_scores_gemma":[0.013860505,0.0467756,0.9263722,0.00018853758,0.00130636,0.0011287172,0.00013146602,0.0046594325,0.00080028945,0.00006792963,0.0045863045,0.00012266914],"about_ca_topic_score_codex":0.000058243757,"about_ca_topic_score_gemma":0.000037098394,"teacher_disagreement_score":0.045508534,"about_ca_system_score_codex":0.00014180272,"about_ca_system_score_gemma":0.0007988898,"threshold_uncertainty_score":0.4354191},"labels":[],"label_agreement":null},{"id":"W4391091197","doi":"10.1200/jco.2024.42.3_suppl.83","title":"Real-world adoption of 3 months of adjuvant oxaliplatin chemotherapy in patients with stage III colorectal cancer (CRC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"FOLFOX; Medicine; Oxaliplatin; Colorectal cancer; Internal medicine; Oncology; Univariate analysis; Population; Stage (stratigraphy); Cohort; Capecitabine; Cancer; Surgery; Multivariate analysis; Environmental health","score_opus":0.048586313327491075,"score_gpt":0.4210041315058274,"score_spread":0.3724178181783363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945237,0.0002182934,0.000031894666,0.0014341887,0.0007583104,0.0002883801,0.000008608373,0.0000059659706,0.0027306485],"genre_scores_gemma":[0.9964354,0.0013919906,0.0008702097,0.00022589808,0.00028006535,0.00000308341,0.0000043063956,0.000014525771,0.0007745117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974323,0.00009843289,0.0018051735,0.00013449685,0.00038500343,0.00014462159],"domain_scores_gemma":[0.99783987,0.00056377356,0.00115832,0.000093310366,0.00024472104,0.00009998229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011127986,0.00010605391,0.001231686,0.00029463455,0.000006628156,0.0000033061447,0.000089732384,0.00012551137,0.00027550294],"category_scores_gemma":[0.00015743761,0.000068845686,0.00023205233,0.00035210914,0.00012426732,0.000104012586,0.000024505724,0.00047150484,0.0000015248389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011594137,0.00082233467,0.9051411,0.000145584,0.00036439812,0.00007948346,0.00015907672,0.00009356309,0.000057098398,0.00012302674,0.001378554,0.08004161],"study_design_scores_gemma":[0.012618183,0.008587456,0.9694756,0.0004135593,0.00023491848,0.0000016134838,0.000084071726,0.00019057328,0.00009021961,0.000023719836,0.008224597,0.000055478573],"about_ca_topic_score_codex":0.00034678538,"about_ca_topic_score_gemma":0.0011648663,"teacher_disagreement_score":0.07998613,"about_ca_system_score_codex":0.00021402744,"about_ca_system_score_gemma":0.00074676407,"threshold_uncertainty_score":0.3016564},"labels":[],"label_agreement":null},{"id":"W4391091200","doi":"10.1200/jco.2024.42.3_suppl.528","title":"The role of pre-operative ctDNA in resectable intrahepatic cholangiocarcinoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Natera","keywords":"Medicine; IDH1; Circulating tumor DNA; Internal medicine; Confidence interval; Gastroenterology; Stage (stratigraphy); Oncology; Cancer; Mutation; Gene","score_opus":0.06434620071322406,"score_gpt":0.454905245943585,"score_spread":0.39055904523036095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9353796,0.043874558,0.000013660639,0.0065695727,0.0010980294,0.000192919,0.0000022057113,0.0000072076705,0.012862221],"genre_scores_gemma":[0.9951951,0.002817975,0.00025399585,0.00031670305,0.0009317844,0.0000075024827,6.331593e-7,0.000012866751,0.00046347213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971999,0.00032980044,0.0017942557,0.00015492114,0.00030223717,0.0002188725],"domain_scores_gemma":[0.9958518,0.0031558517,0.00041390234,0.00017558741,0.00026772654,0.00013509917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030070446,0.0001093185,0.0010152834,0.00013660948,0.000041571628,0.000017187336,0.00017287806,0.00017758258,0.00004338468],"category_scores_gemma":[0.002323556,0.00005956715,0.00040109022,0.00026815632,0.00026453374,0.000107466956,0.000068508285,0.0010711666,0.000008911299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004820779,0.0006943487,0.65465754,0.000110074274,0.0010537793,0.00091852003,0.003414867,0.000011704878,0.00088044914,0.001373006,0.0076927403,0.3243722],"study_design_scores_gemma":[0.0025556332,0.0070481957,0.87264186,0.00036132106,0.00029383376,0.00026027684,0.0014635469,0.00048311497,0.00055358827,0.0019443928,0.112316765,0.000077455945],"about_ca_topic_score_codex":0.00010347367,"about_ca_topic_score_gemma":0.0003515165,"teacher_disagreement_score":0.32429475,"about_ca_system_score_codex":0.00014517707,"about_ca_system_score_gemma":0.0014012959,"threshold_uncertainty_score":0.46537456},"labels":[],"label_agreement":null},{"id":"W4391091257","doi":"10.1200/jco.2024.42.3_suppl.158","title":"Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Panitumumab; Colorectal cancer; Antibody; Internal medicine; Oncology; Indel; Circulating tumor DNA; Cancer; MAPK/ERK pathway; Immunology; Genotype; Kinase","score_opus":0.08638271925348104,"score_gpt":0.47889451577829134,"score_spread":0.3925117965248103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902596,0.0020695913,0.0004421376,0.0018524687,0.004628136,0.00028437993,0.00010063778,0.000004881142,0.0003581523],"genre_scores_gemma":[0.9918564,0.0010589929,0.0041995076,0.0010530544,0.0017335544,0.000010535591,0.000006862546,0.000026414726,0.00005465965],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99515516,0.00054198265,0.00321701,0.00047501957,0.00027486854,0.0003359884],"domain_scores_gemma":[0.9966879,0.0014349051,0.0008807636,0.00024720156,0.0004001037,0.00034913447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004929786,0.00019280701,0.0013854766,0.00014125896,0.00003437675,0.00003523318,0.00037798347,0.00027462706,0.000056912097],"category_scores_gemma":[0.008288877,0.00017188542,0.00055410253,0.00027758352,0.00022383526,0.000014054993,0.00025020118,0.00038185975,0.000007443718],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012901179,0.0022230865,0.38367137,0.00047495702,0.001543993,0.0016592199,0.0005198498,0.0018302876,0.4664146,0.0003176549,0.04034288,0.0881009],"study_design_scores_gemma":[0.003551357,0.0054722787,0.871019,0.00052604097,0.0003343213,0.00007305704,0.00023280783,0.00029835085,0.021354029,0.0006074959,0.09612278,0.00040846682],"about_ca_topic_score_codex":0.000070947826,"about_ca_topic_score_gemma":0.0023006662,"teacher_disagreement_score":0.48734763,"about_ca_system_score_codex":0.00008320698,"about_ca_system_score_gemma":0.0022683628,"threshold_uncertainty_score":0.9923159},"labels":[],"label_agreement":null},{"id":"W4391091258","doi":"10.1200/jco.2024.42.3_suppl.397","title":"Prognostic role of platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in advanced gastric cancer treated with immunotherapy: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Neutrophil to lymphocyte ratio; Subgroup analysis; Lymphocyte; Cancer; Immunotherapy; Context (archaeology); Oncology; Publication bias","score_opus":0.0867589358310258,"score_gpt":0.4438157979486968,"score_spread":0.357056862117671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023758886,0.9904306,0.000025403573,0.0006076272,0.000116228504,0.0063125174,0.00007363564,0.000018025165,0.000040096336],"genre_scores_gemma":[0.0017159315,0.99398595,0.0014992314,0.001308218,0.00012794108,0.0011159293,0.000015355885,0.00010036034,0.00013107283],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9875963,0.002271087,0.008245047,0.0007672212,0.00068091875,0.0004394576],"domain_scores_gemma":[0.9895837,0.0025299154,0.005763899,0.00064534496,0.0007622784,0.00071488525],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004677599,0.00081955985,0.023393892,0.0014827047,0.00004192663,0.000041661755,0.00038210856,0.0006143362,0.000095658135],"category_scores_gemma":[0.0024105746,0.0004550819,0.0028626618,0.0024421287,0.00023466923,0.00013257453,0.00013613894,0.000986787,0.000012301948],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037254894,0.0008757296,0.0009929645,0.59700185,0.2846318,0.0021042682,0.00010464919,0.000036358815,0.0000075636976,0.000017519138,0.00014502932,0.1103568],"study_design_scores_gemma":[0.0035787781,0.0048905117,0.00077722094,0.08693952,0.87890965,0.0010557655,0.00002798116,0.00005167214,0.0000025569254,0.000008324862,0.023340527,0.0004174882],"about_ca_topic_score_codex":0.000027806047,"about_ca_topic_score_gemma":0.000058562182,"teacher_disagreement_score":0.59427786,"about_ca_system_score_codex":0.0007522341,"about_ca_system_score_gemma":0.00482619,"threshold_uncertainty_score":0.9997901},"labels":[],"label_agreement":null},{"id":"W4391091309","doi":"10.1200/jco.2024.42.3_suppl.531","title":"Genomic characterization of cholangiocarcinoma with autoimmune etiologies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Etiology; Primary sclerosing cholangitis; Autoimmune disease; Ankylosing spondylitis; Immunology; Autoimmune hepatitis; Cohort; Population; Internal medicine; Disease","score_opus":0.10032702548946894,"score_gpt":0.41656106392142794,"score_spread":0.316234038431959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857603,0.004544376,0.0002577303,0.005724638,0.0012512783,0.0001265689,0.00000494379,0.000020088928,0.0023100998],"genre_scores_gemma":[0.995846,0.0014420175,0.0007887276,0.00058630854,0.0009682293,0.0000027589726,0.000006558416,0.000016469476,0.0003429386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997926,0.00012219127,0.0014450296,0.00015155209,0.00020810471,0.00014710688],"domain_scores_gemma":[0.9981962,0.000538319,0.0006988416,0.00015303011,0.00030728267,0.00010636919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011943041,0.000112419686,0.0011548765,0.0001560918,0.000020481932,0.000008731587,0.000111352936,0.00019924095,0.00007666909],"category_scores_gemma":[0.0003967799,0.00006801763,0.000382648,0.00017277479,0.00022500822,0.00009804904,0.000045020814,0.00060381915,0.000012456095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005399438,0.0007400343,0.6715872,0.0003189249,0.0022737477,0.0018199662,0.000764319,0.000005121167,0.054289084,0.00038358817,0.0026356622,0.25978288],"study_design_scores_gemma":[0.002081863,0.007831033,0.94018596,0.00021467109,0.00046824344,0.00062326103,0.000084127205,0.000043645574,0.00032381964,0.000042923995,0.048036367,0.00006409173],"about_ca_topic_score_codex":0.000008934643,"about_ca_topic_score_gemma":0.0000040755763,"teacher_disagreement_score":0.26859874,"about_ca_system_score_codex":0.00009836978,"about_ca_system_score_gemma":0.0011873931,"threshold_uncertainty_score":0.27736783},"labels":[],"label_agreement":null},{"id":"W4391091316","doi":"10.1200/jco.2024.42.3_suppl.tps243","title":"NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Natera","keywords":"Medicine; Irinotecan; Internal medicine; Oxaliplatin; Oncology; Cohort; Regimen; Chemotherapy; Clinical endpoint; Randomized controlled trial; Colorectal cancer; Prospective cohort study; Cancer; Surgery","score_opus":0.0788650787455616,"score_gpt":0.4455083510090546,"score_spread":0.366643272263493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914189,0.0028276423,0.00061816786,0.002975665,0.001350107,0.00018115895,0.000050051192,0.0000036685021,0.00057466864],"genre_scores_gemma":[0.99410766,0.001673397,0.0004866183,0.0022817357,0.0013348683,0.0000058687797,0.00004711869,0.000020960082,0.000041786683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760634,0.00039881113,0.0011791177,0.0002390461,0.00042464997,0.0001520398],"domain_scores_gemma":[0.9976949,0.0006492677,0.0006924593,0.00024469913,0.0004878014,0.00023084252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022813173,0.0001246097,0.00052523724,0.00007943343,0.000022977583,0.000013298486,0.00018418183,0.00020654523,0.000078810146],"category_scores_gemma":[0.0027206254,0.00010072088,0.00038173524,0.00010100705,0.00016443976,0.0000043639902,0.000032089534,0.00029314205,0.0000067118285],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011644077,0.0026977682,0.027531171,0.00010252816,0.00070687325,0.00023821525,0.00007837001,0.07000602,0.008152792,0.00011225496,0.047883667,0.83084625],"study_design_scores_gemma":[0.010317529,0.023775997,0.2840442,0.00019976651,0.0011160288,0.000022443977,0.000053774696,0.041062403,0.0030896137,0.0009170621,0.63499403,0.00040711116],"about_ca_topic_score_codex":0.000008022289,"about_ca_topic_score_gemma":0.000034179073,"teacher_disagreement_score":0.83043915,"about_ca_system_score_codex":0.00008463492,"about_ca_system_score_gemma":0.0035152866,"threshold_uncertainty_score":0.6235967},"labels":[],"label_agreement":null},{"id":"W4391091344","doi":"10.1200/jco.2024.42.3_suppl.638","title":"Vascular resection for pancreas cancer: Ten-year real-world experience from a single high-volume center.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Perioperative; Pancreaticoduodenectomy; Cancer; Adenocarcinoma; Surgery; Single Center; Pancreas; Pancreatic cancer; Internal medicine","score_opus":0.1699832340692588,"score_gpt":0.5159581187213744,"score_spread":0.3459748846521156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97897017,0.0017634883,0.0013748233,0.009473262,0.0034836985,0.0004305506,0.000034330296,0.000034489094,0.0044352054],"genre_scores_gemma":[0.96867955,0.0069397097,0.012325103,0.0008523899,0.0065020067,0.0000698609,0.000016336377,0.000038034304,0.0045770304],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99642307,0.000468109,0.0018866905,0.00034365917,0.00049735245,0.00038111926],"domain_scores_gemma":[0.99447066,0.003669494,0.0005573215,0.00025878282,0.0005586141,0.00048514886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029627827,0.00015272321,0.001731779,0.00022939262,0.00007597578,0.000027941242,0.00020616512,0.0004211175,0.00091035827],"category_scores_gemma":[0.0034231085,0.00010861065,0.0006367088,0.00027754004,0.0003358303,0.0001579667,0.00006144641,0.0010441417,0.00004759659],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01498575,0.002489819,0.8093987,0.00018352502,0.0021927035,0.0011117237,0.00051856355,0.000006068817,0.0013107643,0.0006324496,0.058249295,0.108920656],"study_design_scores_gemma":[0.009539217,0.020359736,0.4786064,0.0007603679,0.0012423442,0.000125382,0.0003615165,0.001606197,0.00018380843,0.001762473,0.4852924,0.0001601346],"about_ca_topic_score_codex":0.0013988949,"about_ca_topic_score_gemma":0.00093705155,"teacher_disagreement_score":0.4270431,"about_ca_system_score_codex":0.000580981,"about_ca_system_score_gemma":0.0024519812,"threshold_uncertainty_score":0.9967784},"labels":[],"label_agreement":null},{"id":"W4391091357","doi":"10.1200/jco.2024.42.3_suppl.748","title":"Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Sunitinib; GiST; Discontinuation; Imatinib; Internal medicine; Clinical endpoint; Interim analysis; Adverse effect; Imatinib mesylate; Population; Oncology; Tyrosine-kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Cancer; Stromal cell","score_opus":0.09268520678837064,"score_gpt":0.434354382403186,"score_spread":0.34166917561481536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972918,0.00020349995,0.00043652704,0.00086765626,0.000060099406,0.00066678016,0.000054026183,0.00003240181,0.00038721756],"genre_scores_gemma":[0.975997,0.000065758075,0.023374636,0.00010143586,0.00024404842,0.000012827996,0.00008561758,0.000048939768,0.000069793794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955601,0.0005928814,0.0018507297,0.00052003807,0.0008533588,0.0006228888],"domain_scores_gemma":[0.99435353,0.002909369,0.0009479199,0.00025145963,0.0007019044,0.0008358104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011208914,0.0004074885,0.0019757664,0.0002985557,0.000055871336,0.000060706185,0.00017154736,0.000079568985,0.00017885014],"category_scores_gemma":[0.001418658,0.0002197585,0.00020290108,0.00032885344,0.00052562385,0.00027584462,0.00006620563,0.0016298256,0.000007290016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11048638,0.0023161632,0.85158515,0.00010376333,0.0005273676,0.022704551,0.000031363594,0.000038279122,0.000034583347,0.000013136505,0.000032125805,0.012127135],"study_design_scores_gemma":[0.029138926,0.1309762,0.8312254,0.0036673497,0.00066110847,0.0038798938,0.000063383544,0.00012838561,0.000026458547,0.000017851695,0.000053567557,0.00016150154],"about_ca_topic_score_codex":0.00013871405,"about_ca_topic_score_gemma":0.00049809576,"teacher_disagreement_score":0.12866004,"about_ca_system_score_codex":0.00028344672,"about_ca_system_score_gemma":0.0019256738,"threshold_uncertainty_score":0.89614916},"labels":[],"label_agreement":null},{"id":"W4391091436","doi":"10.1200/jco.2024.42.3_suppl.747","title":"A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Internal medicine; Immunotherapy; Refractory (planetary science); T cell; Oncology; Pharmacokinetics; Chemotherapy; Leukapheresis; Gastroenterology; Immunology; Immune system; Cancer; Stem cell; CD34","score_opus":0.1868673389277022,"score_gpt":0.5374342180194681,"score_spread":0.3505668790917659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925644,0.00099013,0.000020108517,0.0059215296,0.0012262483,0.000499601,0.000004034971,0.00001813618,0.0020637945],"genre_scores_gemma":[0.9929837,0.001044612,0.001640767,0.00066924834,0.00185873,0.000004071623,0.000002244482,0.000033487162,0.0017631542],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936056,0.001101991,0.004174935,0.00028394675,0.0005107118,0.00032280257],"domain_scores_gemma":[0.98672205,0.011085878,0.0012081565,0.00023159914,0.0002468097,0.00050549314],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009806014,0.00016375101,0.0023219066,0.00037887535,0.000041751813,0.0000121160665,0.00017985151,0.0005343781,0.00086590945],"category_scores_gemma":[0.025583822,0.000108655746,0.00040968606,0.00040513134,0.0006398387,0.00008797592,0.00011727595,0.0027963363,0.000005990804],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32849014,0.006486535,0.00059698033,0.00016203658,0.00040098923,0.004900928,0.0008385487,0.000009382794,0.015042985,0.00007370121,0.0015402326,0.64145756],"study_design_scores_gemma":[0.47756246,0.3380775,0.012418158,0.0018533333,0.00047573182,0.002285002,0.00039670014,0.0027526126,0.00090255914,0.00055496744,0.16247389,0.00024710532],"about_ca_topic_score_codex":0.000028116627,"about_ca_topic_score_gemma":0.000041753217,"teacher_disagreement_score":0.64121044,"about_ca_system_score_codex":0.00025304605,"about_ca_system_score_gemma":0.0051377835,"threshold_uncertainty_score":0.99950427},"labels":[],"label_agreement":null},{"id":"W4391091447","doi":"10.1200/jco.2024.42.3_suppl.282","title":"De novo metastatic versus recurrent gastroesophageal cancer: A single-centre retrospective analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Toronto General Hospital; University Health Network; University of Toronto; Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cohort; Retrospective cohort study; Cancer; Proportional hazards model; Progression-free survival; Overall survival","score_opus":0.15094890869120225,"score_gpt":0.4840463247286766,"score_spread":0.33309741603747434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455921,0.006172268,0.0024998547,0.030612025,0.009566793,0.00033098785,0.0000196923,0.000052498013,0.0051537952],"genre_scores_gemma":[0.9911156,0.0008361809,0.0039648614,0.00097595627,0.001955359,0.0000036322076,0.0000032052174,0.00001609599,0.0011291039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715394,0.00025389018,0.0015828006,0.00023896001,0.00045010945,0.0003202811],"domain_scores_gemma":[0.997209,0.0012766118,0.0007164633,0.00014798,0.00027794385,0.00037201215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021246772,0.00014962837,0.0016029276,0.0004099571,0.000026888161,0.00003654281,0.00014196138,0.00011515947,0.00089927984],"category_scores_gemma":[0.0016365412,0.000107196356,0.0011863983,0.0008058481,0.00011345069,0.000102810096,0.000051504114,0.00095215935,0.000017812286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010076905,0.0019572529,0.49994072,0.0001671185,0.022080902,0.009865544,0.00036260585,0.00020791483,0.0000330717,0.00075405935,0.033833507,0.4207204],"study_design_scores_gemma":[0.01643097,0.02225798,0.75971997,0.00026528683,0.034794282,0.00020735202,0.00040379263,0.00219043,0.000016877877,0.0004014441,0.16312522,0.00018642179],"about_ca_topic_score_codex":0.00001890895,"about_ca_topic_score_gemma":0.0002457438,"teacher_disagreement_score":0.42053396,"about_ca_system_score_codex":0.0010737429,"about_ca_system_score_gemma":0.001379776,"threshold_uncertainty_score":0.98464835},"labels":[],"label_agreement":null},{"id":"W4391091452","doi":"10.1200/jco.2024.42.3_suppl.tps240","title":"AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Colorectal cancer; FOLFOX; Microsatellite instability; Oncology; Perioperative; Internal medicine; Clinical endpoint; Cancer; Stage (stratigraphy); Neoadjuvant therapy; Randomized controlled trial; Oxaliplatin; Surgery; Breast cancer","score_opus":0.09934647020094547,"score_gpt":0.5109368179126034,"score_spread":0.4115903477116579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891799,0.0031477802,0.000010046102,0.0005112428,0.0005167638,0.005609422,0.00014128888,0.000013567545,0.00086995424],"genre_scores_gemma":[0.9957844,0.0020905854,0.0005384536,0.00016541724,0.00011104947,0.00022490519,0.000014481022,0.000047093752,0.0010236233],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99270755,0.0018309249,0.003771029,0.0004751958,0.0008464224,0.00036890473],"domain_scores_gemma":[0.9918829,0.0038848708,0.0019218103,0.00030013957,0.0016802339,0.00033004244],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030752989,0.00034521776,0.0061491453,0.0003026738,0.000052600008,0.00003482426,0.00033369835,0.0003012201,0.0011537211],"category_scores_gemma":[0.0014213884,0.00018958944,0.0002890775,0.0007921516,0.00039791368,0.0002809294,0.00013288674,0.00093279796,0.0000013207956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9110688,0.017037002,0.03279237,0.00017426621,0.0030211085,0.001851338,0.0071811303,0.00006197833,0.000066652705,0.000007739369,0.00020072913,0.026536899],"study_design_scores_gemma":[0.68638706,0.30235642,0.003327931,0.001156814,0.0011224642,0.000014653578,0.001473172,0.0001816299,0.00023331931,0.0000046001587,0.00359913,0.00014277177],"about_ca_topic_score_codex":0.0015134097,"about_ca_topic_score_gemma":0.0062770653,"teacher_disagreement_score":0.28531942,"about_ca_system_score_codex":0.0012122749,"about_ca_system_score_gemma":0.0058184243,"threshold_uncertainty_score":0.99981767},"labels":[],"label_agreement":null},{"id":"W4391092147","doi":"10.1200/jco.2024.42.3_suppl.306","title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Ipilimumab; Chemo-radiotherapy; Cancer; Gastroesophageal Junction; Chemotherapy; Adenocarcinoma; Immunotherapy","score_opus":0.07172661690654751,"score_gpt":0.42666343019450076,"score_spread":0.35493681328795323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391092147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640897,0.009170756,0.0013533162,0.015154218,0.008142896,0.0013295048,0.000062721454,0.00008136016,0.0006155296],"genre_scores_gemma":[0.9660475,0.014520805,0.0037423044,0.0013855854,0.004774935,0.00012918879,0.00002887871,0.000102163576,0.009268642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99507976,0.00012089953,0.0028642486,0.00060331565,0.0006708506,0.0006609296],"domain_scores_gemma":[0.9959279,0.0008912658,0.0017619843,0.0003810077,0.0005537324,0.00048415246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013059953,0.00048023372,0.002682973,0.00046850747,0.000095010895,0.000032874304,0.0003265647,0.00045457302,0.0008652991],"category_scores_gemma":[0.00048677524,0.00036989365,0.0015810012,0.00063940114,0.00021701527,0.0002579091,0.00007097335,0.0007734497,0.000022805509],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0475251,0.0021772156,0.14474039,0.000925635,0.0042203246,0.00090708304,0.0004560948,0.0004595564,0.00067094155,0.00016283618,0.027664857,0.77009],"study_design_scores_gemma":[0.15599284,0.102470815,0.44953445,0.001600671,0.008356164,0.0006632807,0.00056148117,0.0036015748,0.006260733,0.00075158506,0.26939785,0.0008085735],"about_ca_topic_score_codex":0.0003832232,"about_ca_topic_score_gemma":0.00032052133,"teacher_disagreement_score":0.7692814,"about_ca_system_score_codex":0.0016496709,"about_ca_system_score_gemma":0.0024477057,"threshold_uncertainty_score":0.9998753},"labels":[],"label_agreement":null},{"id":"W4391094949","doi":"10.1200/jco.2024.42.3_suppl.78","title":"Impact of revising colorectal cancer screening guidelines on health care resources in Canada.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; St. Paul's Hospital; Alberta Health Services; Providence Health Care; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Colonoscopy; Population; Incidence (geometry); Colorectal cancer; Cumulative incidence; Demography; Health care; Microsimulation; Cohort study; Cancer; Gerontology; Environmental health; Internal medicine","score_opus":0.16831647240223663,"score_gpt":0.538842015067165,"score_spread":0.3705255426649284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391094949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97398394,0.015330203,0.00007092898,0.008631047,0.0012535282,0.0001305676,0.000011444855,0.000009668988,0.0005786429],"genre_scores_gemma":[0.9949426,0.0012517846,0.0013322361,0.0010008682,0.001430441,0.0000022195484,0.0000013318827,0.000015962745,0.000022577391],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99655557,0.00029061022,0.0023333505,0.00018311338,0.00041741694,0.0002199568],"domain_scores_gemma":[0.9969469,0.0012326587,0.00095597585,0.00008960326,0.00050559425,0.00026928753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020859079,0.00012281077,0.0012945824,0.00024906892,0.000028370443,0.000008560163,0.000088753324,0.00015485086,0.00005332916],"category_scores_gemma":[0.0025242248,0.00008377309,0.00043519324,0.0003737848,0.000054057575,0.00005540307,0.000024869745,0.0010351446,5.398382e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014761347,0.00007058104,0.10481957,0.00012668358,0.00023617432,0.00033996438,0.00038085046,0.0017686225,0.000057746813,0.0000027072278,0.010187857,0.8672479],"study_design_scores_gemma":[0.0033476888,0.052297447,0.88970155,0.0043428983,0.00015235473,0.0003665931,0.00089381565,0.002558627,0.00012279254,0.00001601253,0.046067458,0.00013277735],"about_ca_topic_score_codex":0.5441377,"about_ca_topic_score_gemma":0.6642628,"teacher_disagreement_score":0.86711514,"about_ca_system_score_codex":0.0022523988,"about_ca_system_score_gemma":0.01855307,"threshold_uncertainty_score":0.98701084},"labels":[],"label_agreement":null},{"id":"W4391095158","doi":"10.1200/jco.2024.42.3_suppl.137","title":"Real-world data of TAS-102 therapy in refractory metastatic colorectal cancer (mCRC): The experience of the University Hospital of Montreal (CHUM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; KRAS; Univariate analysis; Refractory (planetary science); Oncology; Proportional hazards model; Population; Progression-free survival; Performance status; Multivariate analysis; Cancer; Chemotherapy","score_opus":0.1347906399030432,"score_gpt":0.466576971073403,"score_spread":0.3317863311703598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903447,0.0028532587,0.0000020120663,0.0037592757,0.00087501586,0.00024875265,0.00006979801,0.000002694047,0.001844478],"genre_scores_gemma":[0.9881477,0.011290117,0.00012483534,0.000077406876,0.00013364854,0.0000022158101,0.0000013041537,0.000007204478,0.00021556842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977716,0.00038212727,0.0011999113,0.00017509481,0.00033716013,0.00013411138],"domain_scores_gemma":[0.996019,0.0022469228,0.0011495106,0.0002865974,0.00023250734,0.00006546102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012285102,0.00010890685,0.0011188493,0.00009412628,0.00003215239,0.0000024598662,0.00043613283,0.00006486377,0.00008081132],"category_scores_gemma":[0.00055789575,0.000052177034,0.00030576,0.00040988156,0.000960925,0.000107360625,0.00017959416,0.0004943458,2.8791575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015521047,0.004329922,0.6395185,0.00013263381,0.0031639282,0.0006051493,0.011952046,0.00003324918,0.0011177289,0.00034746068,0.0060216333,0.3172567],"study_design_scores_gemma":[0.0030080439,0.009010583,0.9669342,0.0002058046,0.0004392344,0.000014444348,0.0030945148,0.00012231353,0.0003459716,0.000080207414,0.016691066,0.000053640942],"about_ca_topic_score_codex":0.0046284827,"about_ca_topic_score_gemma":0.016942574,"teacher_disagreement_score":0.32741567,"about_ca_system_score_codex":0.00020879127,"about_ca_system_score_gemma":0.0015462224,"threshold_uncertainty_score":0.94543535},"labels":[],"label_agreement":null},{"id":"W4391095160","doi":"10.1200/jco.2024.42.3_suppl.169","title":"Clonal hematopoiesis of indeterminate potential (CHIP), treatment outcomes and adverse events in gastrointestinal cancers: A pooled analysis of clinical trial and real-world data.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University Health Network; Ottawa Hospital; University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Oncology; Internal medicine; Adverse effect; Colorectal cancer; Cohort; Cancer; Germline mutation; Gastrointestinal cancer; Mutation; Gene; Biology; Genetics","score_opus":0.1090078014296683,"score_gpt":0.4782764493223831,"score_spread":0.3692686478927148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99816644,0.0004534006,0.0001421013,0.00035532773,0.0005222746,0.00014835504,0.00015851692,0.0000013215897,0.000052264797],"genre_scores_gemma":[0.99241346,0.004075488,0.0028603002,0.000089235065,0.00046913436,0.0000029183782,0.000036017795,0.000010683154,0.000042757292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613154,0.00035668825,0.002814523,0.00035382848,0.00017644982,0.00016699983],"domain_scores_gemma":[0.9965315,0.0014353016,0.0014315352,0.0002803989,0.00013153933,0.00018973801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002557924,0.00015469661,0.0016832956,0.0002716132,0.000014338752,0.000005103286,0.00021023858,0.00016785623,0.000012711982],"category_scores_gemma":[0.001804238,0.0001176655,0.0005365354,0.00020206186,0.00031912443,0.00001176582,0.00022215715,0.0002613059,2.2363281e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034143176,0.0012532339,0.9108465,0.00005131545,0.0038936688,0.00029043466,0.000034108976,0.00023765146,0.000577007,0.000060752158,0.00018327369,0.048428915],"study_design_scores_gemma":[0.027313186,0.016589297,0.9477989,0.00013114621,0.0038190847,0.00007788571,0.000090587535,0.002312337,0.000114135335,0.00014963224,0.0014552078,0.00014859166],"about_ca_topic_score_codex":0.0006747591,"about_ca_topic_score_gemma":0.0068473495,"teacher_disagreement_score":0.048280325,"about_ca_system_score_codex":0.0000561665,"about_ca_system_score_gemma":0.0015313965,"threshold_uncertainty_score":0.479826},"labels":[],"label_agreement":null},{"id":"W4391095249","doi":"10.1200/jco.2024.42.3_suppl.5","title":"Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; FOLFOX; Oncology; Oxaliplatin; Clinical endpoint; Colorectal cancer; Chemotherapy; Phases of clinical research; Adjuvant; KRAS; Stage (stratigraphy); Cancer; Gastroenterology; Randomized controlled trial","score_opus":0.03918961208690408,"score_gpt":0.4224455366819951,"score_spread":0.383255924595091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651027,0.0010241736,0.000046182173,0.00064201857,0.0006923133,0.0005876817,0.00023326094,0.0000039575607,0.00026014668],"genre_scores_gemma":[0.9982747,0.000580804,0.00017161923,0.00048505343,0.00032602926,0.000021193817,0.000032405824,0.00002996753,0.0000782344],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9964952,0.0002444387,0.0022491054,0.0004267681,0.00029185545,0.00029264798],"domain_scores_gemma":[0.99757266,0.00042260476,0.0012873315,0.00022695096,0.00030488637,0.00018554518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019317281,0.00021518717,0.0009987167,0.00017998536,0.000066242705,0.000012352349,0.00024073385,0.0002674117,0.00003219471],"category_scores_gemma":[0.0012141954,0.00017166689,0.00020982273,0.00025904283,0.00017763094,0.00001644799,0.00019547563,0.00051484385,4.1502625e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29446384,0.10727399,0.11481108,0.000121438025,0.0026574791,0.0019750192,0.0046677943,0.0017355053,0.052012537,0.000044812037,0.0062519633,0.41398457],"study_design_scores_gemma":[0.27828798,0.5124101,0.12945628,0.000694708,0.000445581,0.000037998543,0.000980766,0.0025393055,0.0075186947,0.00011322878,0.066886336,0.00062900654],"about_ca_topic_score_codex":0.00024222076,"about_ca_topic_score_gemma":0.0011306227,"teacher_disagreement_score":0.41335556,"about_ca_system_score_codex":0.00018065685,"about_ca_system_score_gemma":0.002168587,"threshold_uncertainty_score":0.7000373},"labels":[],"label_agreement":null},{"id":"W4391095254","doi":"10.1200/jco.2024.42.3_suppl.208","title":"Comparative genomic analysis to identify a signature of sporadic colorectal cancer development in young adults.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu Grace Healthcare; Western University; Windsor Regional Hospital; University of Windsor; Lakehead University","funders":"Windsor Cancer Centre Foundation","keywords":"Medicine; Colorectal cancer; Cancer; Incidence (geometry); Oncology; Population; Cancer registry; Disease; Internal medicine; Environmental health","score_opus":0.09151699468966065,"score_gpt":0.49180209746868203,"score_spread":0.4002851027790214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919949,0.0034595921,0.00013295398,0.0011606547,0.002252201,0.00032643066,0.000009572354,0.000007700404,0.0006559783],"genre_scores_gemma":[0.99409467,0.00030981548,0.004710331,0.00032344,0.00042931794,0.00001715858,0.0000035007815,0.000014555074,0.000097209275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960691,0.00024675755,0.0026707551,0.00029373408,0.00047827367,0.00024140689],"domain_scores_gemma":[0.99723125,0.0010729937,0.00078339287,0.00011630611,0.00047123514,0.00032484863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002151782,0.00016824936,0.0021563,0.00074907386,0.000015869568,0.000009753703,0.00021584587,0.00038738668,0.00047678375],"category_scores_gemma":[0.00066837476,0.00012606684,0.0005489307,0.0011928664,0.00014635349,0.000052691285,0.00007494022,0.0011785331,0.000017119008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01664746,0.0014728741,0.868368,0.00023778089,0.008656969,0.0013438916,0.010762602,0.0027343626,0.020790951,0.00002578098,0.004624097,0.064335175],"study_design_scores_gemma":[0.002048762,0.003955027,0.9815665,0.00034992766,0.0011915708,0.000072997515,0.0003938962,0.00051807094,0.0030147883,0.000033691344,0.006733544,0.000121264195],"about_ca_topic_score_codex":0.00013477156,"about_ca_topic_score_gemma":0.0038661475,"teacher_disagreement_score":0.1131984,"about_ca_system_score_codex":0.0008876483,"about_ca_system_score_gemma":0.0042116214,"threshold_uncertainty_score":0.7471236},"labels":[],"label_agreement":null},{"id":"W4391095388","doi":"10.1200/jco.2024.42.3_suppl.162","title":"Development of an improved risk stratification scheme for stage II and III colorectal cancers through incorporation of the digital pathology biomarker QuantCRC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Risk stratification; Oncology; Stage (stratigraphy); Biomarker; Cohort; Colorectal cancer; Log-rank test; Proportional hazards model; Cancer; Confidence interval","score_opus":0.07902622233437456,"score_gpt":0.44862327910188066,"score_spread":0.3695970567675061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877205,0.00023546131,0.009058827,0.0017368371,0.0007828632,0.00025896463,0.000013640862,0.000005597918,0.00018730719],"genre_scores_gemma":[0.95410556,0.0001465244,0.045374155,0.00012354294,0.00018347244,0.0000050428403,0.000009816003,0.000010348005,0.000041530922],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977396,0.00015048865,0.0016711712,0.00015419045,0.00017803215,0.00010649672],"domain_scores_gemma":[0.99722517,0.00083238655,0.0015093754,0.0001012723,0.00023241999,0.00009938368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029424173,0.00008437419,0.0006174089,0.000058427442,0.00006501065,0.000010700623,0.00009889154,0.00019297255,0.000008893656],"category_scores_gemma":[0.0027600052,0.000050870563,0.00016125596,0.00010630145,0.0003693747,0.0001701138,0.000042968633,0.0005379883,1.2879497e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039031564,0.0007939622,0.026261674,0.00025236214,0.00059944915,0.00003877207,0.0021790778,0.000037971633,0.076863274,0.0016227219,0.00029848036,0.8871491],"study_design_scores_gemma":[0.020631084,0.029724,0.5699579,0.00090982026,0.0012026813,0.0006537394,0.003007133,0.28484654,0.010181961,0.0046159476,0.07386302,0.00040617157],"about_ca_topic_score_codex":0.000019292154,"about_ca_topic_score_gemma":0.000040888186,"teacher_disagreement_score":0.88674295,"about_ca_system_score_codex":0.00009192429,"about_ca_system_score_gemma":0.002243952,"threshold_uncertainty_score":0.3980674},"labels":[],"label_agreement":null},{"id":"W4391095415","doi":"10.1200/jco.2024.42.3_suppl.32","title":"Applying the fragility index to randomized controlled trials evaluating total neoadjuvant therapy for rectal cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Colorectal cancer; Neoadjuvant therapy; Sample size determination; Internal medicine; Surgery; Cancer; Breast cancer; Statistics","score_opus":0.6436043033534936,"score_gpt":0.6974140371941839,"score_spread":0.05380973384069032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69275564,0.008232127,0.03670327,0.22053859,0.018749945,0.022317866,0.000024530309,0.000047158323,0.00063086505],"genre_scores_gemma":[0.9556698,0.0020190603,0.009647658,0.01788972,0.011443101,0.002738042,0.0000055370506,0.000039431667,0.0005476389],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97594273,0.008465497,0.014122731,0.00032669585,0.0008452997,0.00029702234],"domain_scores_gemma":[0.5548349,0.43530893,0.00704591,0.0003229016,0.0020287684,0.0004585835],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2278048,0.00020868944,0.00774511,0.00014562924,0.000083970386,0.00006477223,0.00018520064,0.00033767172,0.00042005206],"category_scores_gemma":[0.5253976,0.000094378025,0.0037974033,0.0002127102,0.00018887033,0.00016239406,0.000052967836,0.0014294471,0.000009537511],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4356679,0.00025380097,0.00029024322,0.000017085535,0.0019115581,0.00002416791,0.000120199125,0.0001744712,0.00036029902,0.000042953594,0.006031886,0.55510545],"study_design_scores_gemma":[0.81956077,0.014371852,0.0024447255,0.00036201612,0.0053789583,0.0001984454,0.00061496394,0.052861996,0.000038034006,0.0034011174,0.10060251,0.0001646149],"about_ca_topic_score_codex":0.00011021949,"about_ca_topic_score_gemma":0.0000448717,"teacher_disagreement_score":0.5549408,"about_ca_system_score_codex":0.00029718401,"about_ca_system_score_gemma":0.0064105215,"threshold_uncertainty_score":0.9992222},"labels":[],"label_agreement":null},{"id":"W4391095417","doi":"10.1200/jco.2024.42.3_suppl.563","title":"Surrogate endpoints for overall survival in advanced hepatocellular carcinoma: A meta-analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; Internal medicine; Oncology; Hepatocellular carcinoma; Hazard ratio; Meta-analysis; Progression-free survival; Randomized controlled trial; Clinical trial; Overall survival; Confidence interval","score_opus":0.14581906971095818,"score_gpt":0.4364676470625984,"score_spread":0.2906485773516402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978137,0.014003407,0.0036042025,0.0018201892,0.0016698205,0.0002031125,0.00007010972,0.0000031390275,0.0004890131],"genre_scores_gemma":[0.9941283,0.0012777409,0.0027768554,0.0006878703,0.0007643214,0.000015452113,0.000026849308,0.000019937306,0.0003026821],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973739,0.00025139938,0.0016680642,0.0003170217,0.00015294203,0.000236693],"domain_scores_gemma":[0.9975944,0.0012434323,0.0005344682,0.00022202282,0.00023129329,0.00017436245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033147726,0.00015140486,0.001610495,0.00014956956,0.000018609746,0.000022846245,0.0002306326,0.0003163972,0.000051960727],"category_scores_gemma":[0.001689624,0.00011742626,0.0024796866,0.00015776334,0.00007028756,0.0000072280054,0.000078056066,0.00033498817,0.0000036499077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023313949,0.006601655,0.29960755,0.00054069853,0.44476888,0.005611971,0.00046875002,0.023887169,0.06736365,0.012829085,0.036088794,0.078917876],"study_design_scores_gemma":[0.008537198,0.01116806,0.026843438,0.000013211063,0.08057967,0.00007864864,0.00008263866,0.005592348,0.0057996227,0.004407865,0.85632515,0.00057215936],"about_ca_topic_score_codex":0.000028228875,"about_ca_topic_score_gemma":0.0003992798,"teacher_disagreement_score":0.8202363,"about_ca_system_score_codex":0.000052530053,"about_ca_system_score_gemma":0.0009730922,"threshold_uncertainty_score":0.4788504},"labels":[],"label_agreement":null},{"id":"W4391095466","doi":"10.1200/jco.2024.42.3_suppl.tps232","title":"A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with <i>KRAS</i> G12C mutant advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Medicine; Internal medicine; Cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Phases of clinical research; Gastroenterology; Clinical trial; Colorectal cancer","score_opus":0.10241900380241814,"score_gpt":0.516742404990561,"score_spread":0.41432340118814287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954971,0.0009990502,0.000010656479,0.0016567259,0.00018036508,0.0013371641,0.0000027507901,0.0000064736982,0.00030972357],"genre_scores_gemma":[0.99766165,0.00026641827,0.0009332411,0.0009412576,0.00006018031,0.000053087602,0.0000011229786,0.00002339354,0.000059662954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773926,0.0003308857,0.0011790554,0.00025089513,0.00032560746,0.00017428126],"domain_scores_gemma":[0.99834377,0.00071819854,0.0005127617,0.00009319587,0.00023834709,0.00009372163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014972533,0.000168392,0.0011732203,0.00014418368,0.00003657729,0.000033206747,0.000085034255,0.00007083337,0.00004162969],"category_scores_gemma":[0.00026064878,0.000089646666,0.00004021802,0.00019662829,0.00011155469,0.00020615563,0.000041518546,0.00046661944,0.0000014832286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0812611,0.030055366,0.58757716,0.000024578143,0.00077329297,0.0005840796,0.0039174915,0.000011979546,0.00009469478,0.0000074888994,0.000017328986,0.29567543],"study_design_scores_gemma":[0.20465791,0.26223034,0.5285323,0.00076126953,0.00024646294,0.00002331353,0.0018640376,0.00042291687,0.000025341684,0.00009621791,0.0010136457,0.00012623324],"about_ca_topic_score_codex":0.00007036288,"about_ca_topic_score_gemma":0.0008357523,"teacher_disagreement_score":0.29554918,"about_ca_system_score_codex":0.00021202413,"about_ca_system_score_gemma":0.0004758301,"threshold_uncertainty_score":0.3655685},"labels":[],"label_agreement":null},{"id":"W4391095740","doi":"10.1200/jco.2024.42.3_suppl.129","title":"A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nausea; Tolerability; Internal medicine; Adverse effect; Gastroenterology; Cancer; Vomiting; Refractory (planetary science); Colorectal cancer; Oncology","score_opus":0.13944598514296183,"score_gpt":0.5023822377590372,"score_spread":0.3629362526160754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951681,0.00086126174,0.00015694895,0.0012293853,0.0014688922,0.0008732949,0.000025712709,0.000016875352,0.00019955335],"genre_scores_gemma":[0.9876557,0.00023568035,0.0105722295,0.00043002702,0.0009316355,0.000045561268,0.000008679332,0.000061436614,0.00005906311],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947895,0.00041352244,0.0032474932,0.00046791352,0.0006136034,0.0004679634],"domain_scores_gemma":[0.99590313,0.0009961572,0.0018582776,0.00028679537,0.00055663555,0.00039900694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023979987,0.000298775,0.0022167412,0.0004248633,0.000051359933,0.000022951135,0.00040047624,0.00022511357,0.00013753017],"category_scores_gemma":[0.0011457257,0.00022245238,0.00015679274,0.00051437627,0.00039915892,0.0009542356,0.00013633074,0.0019852319,0.0000015607363],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62790996,0.014664082,0.09050667,0.00021325995,0.00024608732,0.00160615,0.000623332,0.00063677615,0.0009810107,0.000081316044,0.00023879501,0.26229253],"study_design_scores_gemma":[0.6893762,0.21076094,0.071473084,0.005989053,0.00032326035,0.00017587554,0.00039057012,0.00038935812,0.00009841306,0.000547089,0.020117566,0.00035859706],"about_ca_topic_score_codex":0.00044302692,"about_ca_topic_score_gemma":0.003334667,"teacher_disagreement_score":0.26193395,"about_ca_system_score_codex":0.0017561903,"about_ca_system_score_gemma":0.0051758736,"threshold_uncertainty_score":0.9181777},"labels":[],"label_agreement":null},{"id":"W4391095774","doi":"10.1200/jco.2024.42.3_suppl.166","title":"Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Cancer; Retrospective cohort study; Progression-free survival; V600E; Overall survival; Mutation","score_opus":0.1669075625742355,"score_gpt":0.5323606022496141,"score_spread":0.3654530396753786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993977,0.0012936675,0.0000031894494,0.0016615432,0.0015555728,0.0004979697,0.000013398963,0.0000069294565,0.0009907206],"genre_scores_gemma":[0.9972404,0.0019139438,0.00030565725,0.00016479568,0.00022480851,0.000017774015,0.000004965913,0.000016283677,0.000111358735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953438,0.000745227,0.0027539243,0.00025791393,0.00071254687,0.00018656929],"domain_scores_gemma":[0.9941433,0.003751101,0.0010880039,0.00010318461,0.00071224314,0.00020218216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056349863,0.00016811508,0.0021693287,0.00022632837,0.000024298926,0.000009780193,0.000074326534,0.0001353584,0.00012887726],"category_scores_gemma":[0.0020264748,0.00009578658,0.000344813,0.0002787011,0.00032408797,0.00011618871,0.000050636452,0.00063510897,0.0000016661614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055247247,0.001382099,0.7696287,0.00006789005,0.0014453857,0.00016193332,0.00012285914,0.000008100592,7.3624255e-7,0.000016824448,0.00010965068,0.22153106],"study_design_scores_gemma":[0.013857195,0.016020935,0.96690744,0.00033671025,0.002242494,0.000013485641,0.000047106972,0.00012987191,0.0000037177863,0.000080516395,0.00027775532,0.000082771956],"about_ca_topic_score_codex":0.00044461468,"about_ca_topic_score_gemma":0.022527799,"teacher_disagreement_score":0.22144829,"about_ca_system_score_codex":0.00028479536,"about_ca_system_score_gemma":0.0021439053,"threshold_uncertainty_score":0.9953085},"labels":[],"label_agreement":null},{"id":"W4391096120","doi":"10.1200/jco.2024.42.3_suppl.lba246","title":"Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Docetaxel; Oxaliplatin; Gastroenterology; Population; Cancer; Oncology; Perioperative; Taxane; Surgery; Colorectal cancer; Breast cancer","score_opus":0.15852899901770198,"score_gpt":0.4617092112320652,"score_spread":0.3031802122143632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802664,0.0015684683,0.0036337203,0.01252194,0.00044707503,0.001468611,0.000015270321,0.00002217564,0.000056358585],"genre_scores_gemma":[0.9945996,0.0009604201,0.0011431739,0.0014661922,0.0006328795,0.00008689739,0.000009931492,0.000024718103,0.001076223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943276,0.0019719745,0.0021529265,0.00056440034,0.0006072618,0.0003758237],"domain_scores_gemma":[0.9931893,0.0051655737,0.0008196867,0.00028183445,0.00018548075,0.00035813698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008255066,0.00030179002,0.002720106,0.00062334473,0.00010183697,0.00012500127,0.00018280494,0.00019554474,0.00016411018],"category_scores_gemma":[0.0010385686,0.00015091473,0.00032062587,0.001383975,0.0003124568,0.00022092617,0.00013507312,0.0011676227,0.0000031515524],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64793766,0.00069060666,0.32262906,0.000019739604,0.001501891,0.0019874272,0.00037986774,0.000057683712,0.00003961356,0.0000036575411,0.0035034446,0.021249378],"study_design_scores_gemma":[0.5295857,0.022866288,0.4284795,0.00022371222,0.008382921,0.0005842191,0.0012918687,0.0018960977,0.0000044011476,0.00003293454,0.0064445734,0.00020776565],"about_ca_topic_score_codex":0.0010830684,"about_ca_topic_score_gemma":0.0020910825,"teacher_disagreement_score":0.1183519,"about_ca_system_score_codex":0.00024654035,"about_ca_system_score_gemma":0.0004498469,"threshold_uncertainty_score":0.6154124},"labels":[],"label_agreement":null},{"id":"W4391096236","doi":"10.1200/jco.2024.42.3_suppl.697","title":"Characterizing the genomic landscape of locally advanced pancreatic cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University Health Centre; Mount Sinai Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Internal medicine; Pancreatic cancer; Oncology; Cancer; Colorectal cancer","score_opus":0.036550347774366276,"score_gpt":0.39344906701868415,"score_spread":0.3568987192443179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97676855,0.01653107,0.00037285275,0.0030556023,0.0021513782,0.000087978784,0.000020123614,0.0000023744788,0.0010100476],"genre_scores_gemma":[0.97573924,0.020342695,0.00054941355,0.001269652,0.0019388098,0.0000048195675,0.0000043729524,0.000016038906,0.00013498249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983488,0.00011898127,0.0011355489,0.00014539619,0.00010740101,0.00014389341],"domain_scores_gemma":[0.9982828,0.0006455054,0.0006346943,0.00017219089,0.00016710111,0.00009770704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001204129,0.00009334145,0.0005003242,0.000034197685,0.000025155266,0.000014777405,0.00025899353,0.0001882758,0.00004419809],"category_scores_gemma":[0.0008126322,0.000059351238,0.00032279955,0.0000650814,0.00012839222,0.000004529281,0.000084772786,0.0003158861,0.000004365923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025377427,0.00033741788,0.016375551,0.00011986705,0.0010314649,0.00013474154,0.00016986794,0.00089524116,0.40072268,0.000521674,0.012057106,0.5650967],"study_design_scores_gemma":[0.002201252,0.007059354,0.062342424,0.00021662899,0.00039053085,0.00015962608,0.00017318122,0.00049050397,0.012200518,0.00039468196,0.9141747,0.00019661995],"about_ca_topic_score_codex":0.000012987615,"about_ca_topic_score_gemma":0.000053403175,"teacher_disagreement_score":0.90211755,"about_ca_system_score_codex":0.000028006494,"about_ca_system_score_gemma":0.0014928906,"threshold_uncertainty_score":0.26483238},"labels":[],"label_agreement":null},{"id":"W4391096241","doi":"10.1200/jco.2024.42.3_suppl.660","title":"Does metformin use effect overall survival for patients with pancreatic cancer?","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Metformin; Medicine; Retrospective cohort study; Pancreatic cancer; Internal medicine; Cancer; Incidence (geometry); Oncology; Overall survival; Insulin","score_opus":0.039977169167844884,"score_gpt":0.4068261611475139,"score_spread":0.366848991979669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681974,0.026297936,0.00043034626,0.000120955134,0.0045697163,0.0002423548,0.000052118117,0.0000049956107,0.00008419308],"genre_scores_gemma":[0.9485266,0.043196227,0.0018113184,0.0010397112,0.0046158526,0.000053648953,0.0000344206,0.0000498142,0.0006723924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981183,0.00029324862,0.00090924953,0.00023707429,0.00020368851,0.00023847373],"domain_scores_gemma":[0.9977547,0.0011220764,0.00048083768,0.00015683008,0.0003048639,0.00018067897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016293533,0.00015524206,0.00084029214,0.000044430013,0.000030519263,0.00003300176,0.0001716327,0.0002882,0.000043282856],"category_scores_gemma":[0.0014260906,0.00007395648,0.00041168657,0.000052335774,0.00009965165,0.000019203455,0.000036433896,0.0002747019,0.00000220669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005862241,0.0005408828,0.10714498,0.00017642103,0.0015144234,0.000028304528,0.000025623616,0.000041878062,0.00048379917,0.000120172845,0.010177057,0.8738842],"study_design_scores_gemma":[0.004545107,0.011990074,0.026752943,0.00009355035,0.0005632666,0.0000038536655,0.000006425812,0.000034009103,0.0017381993,0.00018975361,0.953924,0.00015879738],"about_ca_topic_score_codex":0.000018444156,"about_ca_topic_score_gemma":0.00008804422,"teacher_disagreement_score":0.943747,"about_ca_system_score_codex":0.000038862974,"about_ca_system_score_gemma":0.0007328739,"threshold_uncertainty_score":0.30158576},"labels":[],"label_agreement":null},{"id":"W4391096243","doi":"10.1200/jco.2024.42.3_suppl.143","title":"BOLD-100-001 (TRIO039): A phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX—Efficacy and safety analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; McGill University; Jewish General Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; Hamilton Health Sciences; University Health Network; Health Sciences Centre","funders":"","keywords":"FOLFOX; Medicine; Colorectal cancer; Internal medicine; Phases of clinical research; Progressive disease; Surgery; Oncology; Gastroenterology; Oxaliplatin; Cancer; Chemotherapy","score_opus":0.04292805712188189,"score_gpt":0.4315394046302656,"score_spread":0.38861134750838366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648106,0.00101552,0.000017776209,0.0005327465,0.00009755556,0.0013769133,0.0000099356885,0.000012655133,0.0004558643],"genre_scores_gemma":[0.9988456,0.000575005,0.00026323044,0.00008746078,0.000049813276,0.000033519045,0.000019065312,0.000023901932,0.00010244458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963118,0.000366937,0.0020959855,0.00040882078,0.00053619605,0.00028026119],"domain_scores_gemma":[0.9968544,0.0011837868,0.0010654939,0.00019887257,0.00048960303,0.00020782082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011546657,0.00027338654,0.0025239012,0.00062729936,0.000042258314,0.000012485733,0.00009390485,0.00015596725,0.000039647588],"category_scores_gemma":[0.00033111183,0.00014951405,0.00015252377,0.0013553358,0.00019136736,0.00018818866,0.000041657167,0.0006542031,5.715227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08074101,0.047088545,0.78565514,0.00006194349,0.0039951717,0.000996024,0.0011154871,0.00014042945,0.0000030729686,0.000010519605,0.000051187217,0.08014146],"study_design_scores_gemma":[0.0977937,0.22263607,0.6747351,0.00035695315,0.0031591705,0.000021306127,0.0004738066,0.00009313604,0.000004221002,0.0000074232785,0.0006073333,0.000111775065],"about_ca_topic_score_codex":0.00023620337,"about_ca_topic_score_gemma":0.003884069,"teacher_disagreement_score":0.17554753,"about_ca_system_score_codex":0.0003852547,"about_ca_system_score_gemma":0.0006164744,"threshold_uncertainty_score":0.60970056},"labels":[],"label_agreement":null},{"id":"W4391096671","doi":"10.1200/jco.2024.42.3_suppl.lba588","title":"[<sup>177</sup>Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Neuroendocrine tumors; Radionuclide therapy; Nuclear medicine; Progression-free survival; Internal medicine; Octreotide; Randomized controlled trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Gastroenterology; Urology; Somatostatin; Clinical trial; Overall survival","score_opus":0.033401229344990506,"score_gpt":0.40301160991177937,"score_spread":0.36961038056678885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318206,0.0005028164,0.00004253622,0.003992096,0.00026811642,0.0019221287,0.000022351089,0.000023923296,0.00004395848],"genre_scores_gemma":[0.997382,0.00093466346,0.00043088646,0.0008798968,0.00015822546,0.000052586696,0.00002031863,0.000051459396,0.0000900053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905391,0.0032125262,0.0039329734,0.0005741753,0.0011177384,0.0006235389],"domain_scores_gemma":[0.99050707,0.0064324113,0.0017311841,0.00048142532,0.00034255974,0.00050533505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014425959,0.00040790575,0.004693026,0.00094686757,0.000051515788,0.000039942963,0.00042201122,0.000027067426,0.00007420432],"category_scores_gemma":[0.0043680733,0.00022133278,0.0009438538,0.0013711369,0.0007283313,0.00030993152,0.00021907024,0.0018711527,0.0000018428152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19130547,0.015918959,0.7426498,0.0003017182,0.0053858166,0.030867351,0.00025225503,0.001626928,0.0002483367,0.000005470372,0.0003985974,0.011039294],"study_design_scores_gemma":[0.37521723,0.022534663,0.5895873,0.00054392166,0.0060930327,0.0006109068,0.00034985397,0.004404485,0.00007886116,0.00005495937,0.0003658147,0.00015896892],"about_ca_topic_score_codex":0.000055962533,"about_ca_topic_score_gemma":0.00012762996,"teacher_disagreement_score":0.18391177,"about_ca_system_score_codex":0.00014920556,"about_ca_system_score_gemma":0.00047489756,"threshold_uncertainty_score":0.90256894},"labels":[],"label_agreement":null},{"id":"W4391096676","doi":"10.1200/jco.2024.42.3_suppl.689","title":"The prognostic value of mutational signatures in pancreatic cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Population; Pancreatic cancer; Cancer; Cohort; CHEK2; Log-rank test; Bioinformatics; Survival analysis; Biology; Mutation; Genetics; Gene; Germline mutation","score_opus":0.036928484135712016,"score_gpt":0.42407913264529734,"score_spread":0.3871506485095853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96964437,0.025145523,0.00018376957,0.0026220477,0.0016443209,0.0000925373,0.000013048833,0.0000011660336,0.00065322313],"genre_scores_gemma":[0.9901272,0.007846276,0.00049014523,0.00036867842,0.001039285,0.0000067425485,0.0000025476618,0.000008686967,0.000110459936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842745,0.00016704315,0.0010447444,0.00011073071,0.0001324252,0.000117585376],"domain_scores_gemma":[0.99677557,0.002498961,0.00040542733,0.00008739391,0.00016576237,0.00006686534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001484889,0.00006689959,0.0003248139,0.00003823061,0.000020489311,0.000012837793,0.00017622185,0.00019220941,0.000014585296],"category_scores_gemma":[0.003578989,0.00004249487,0.00020364927,0.000080368016,0.00015983546,0.0000028747363,0.00004316251,0.00031893607,0.0000010731695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056019966,0.0017911958,0.2698428,0.00030305728,0.0022110925,0.000954621,0.00035354155,0.04269838,0.032271087,0.02865918,0.07570018,0.5396129],"study_design_scores_gemma":[0.0030369086,0.0098757185,0.47183818,0.0003628217,0.0003787936,0.00011635432,0.00018290167,0.0034749275,0.003670167,0.010471818,0.49634507,0.00024633534],"about_ca_topic_score_codex":0.000030021642,"about_ca_topic_score_gemma":0.00022574278,"teacher_disagreement_score":0.53936654,"about_ca_system_score_codex":0.000033429165,"about_ca_system_score_gemma":0.0019932752,"threshold_uncertainty_score":0.4284643},"labels":[],"label_agreement":null},{"id":"W4391096767","doi":"10.1200/jco.2024.42.3_suppl.437","title":"Prognostic factors of gallbladder cancer (GBC) in patients diagnosed over a period of 20 years: A Canadian province experience.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"University of Saskatchewan","keywords":"Medicine; Gallbladder cancer; Internal medicine; Cancer; Stage (stratigraphy); Cohort; Retrospective cohort study; Pathological; Population; Proportional hazards model; Disease; Gastroenterology; Pediatrics","score_opus":0.07239226802153154,"score_gpt":0.4211916329448718,"score_spread":0.34879936492334024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391096767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942759,0.0024619529,0.0000010123875,0.0012974988,0.0011765038,0.0003039679,0.000026771948,0.0000042163497,0.00045213944],"genre_scores_gemma":[0.99875605,0.00036777937,0.0000813987,0.0003741302,0.000298048,0.000012676006,0.0000024729509,0.000015818878,0.0000916472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974363,0.000115877374,0.0016331068,0.00019201181,0.00037019185,0.00025250154],"domain_scores_gemma":[0.9980109,0.0007189506,0.0005358242,0.00013082862,0.00029917163,0.00030433226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049982994,0.0001316089,0.0011632448,0.00029036944,0.0000130894205,0.0000069386997,0.00014066408,0.0002156588,0.00027711783],"category_scores_gemma":[0.0018585986,0.00009512218,0.00034590228,0.00025356124,0.0002590378,0.000108885055,0.00004044836,0.0005709299,0.0000018361528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052400987,0.0005895247,0.9764187,0.00010654866,0.00030255516,0.0006436724,0.0038062257,0.0000025969766,0.000031647636,0.000010742388,0.0036716564,0.013892154],"study_design_scores_gemma":[0.0029320274,0.0042248797,0.9779983,0.00052272185,0.00020587143,0.000010242814,0.0005846468,0.000015905263,0.000037120608,0.000012775559,0.013374705,0.00008079408],"about_ca_topic_score_codex":0.00983706,"about_ca_topic_score_gemma":0.06591666,"teacher_disagreement_score":0.0560796,"about_ca_system_score_codex":0.0003200719,"about_ca_system_score_gemma":0.005190813,"threshold_uncertainty_score":0.9967565},"labels":[],"label_agreement":null},{"id":"W4391301902","doi":"10.1200/jco.2024.42.4_suppl.116","title":"Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Hormonal therapy; Internal medicine; Subgroup analysis; Cancer; Pathology; Alternative medicine; Androgen receptor","score_opus":0.0822781094013292,"score_gpt":0.43054497577940876,"score_spread":0.3482668663780796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391301902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933037,0.0010956638,0.000036025147,0.0015258514,0.000103069804,0.0036453197,0.00011657037,0.000011821674,0.00016196314],"genre_scores_gemma":[0.9980402,0.00041568128,0.00059501117,0.00020498103,0.000044543376,0.00042506258,0.000069004775,0.00004156729,0.00016393102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938389,0.00062103575,0.002725975,0.00055337464,0.0017492493,0.0005114683],"domain_scores_gemma":[0.9953124,0.0017081298,0.001650075,0.00038788767,0.0006856624,0.0002558374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023025966,0.00042755815,0.002515432,0.0007664729,0.00006848942,0.000058387464,0.00022132442,0.00014993918,0.00005949429],"category_scores_gemma":[0.00022446574,0.00018439507,0.00034373076,0.0017251027,0.00040727094,0.0002813837,0.00004357239,0.00106371,6.532644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11080472,0.008273557,0.8490464,0.000081163205,0.013506675,0.0036529296,0.0054193847,0.0023854407,0.000052225256,0.000015602907,0.000048197067,0.0067137023],"study_design_scores_gemma":[0.055022,0.05077218,0.8855529,0.00029557463,0.0041363533,0.000046708145,0.0026906112,0.00096493325,0.00006263974,0.000011695026,0.00024889395,0.00019553998],"about_ca_topic_score_codex":0.0010952922,"about_ca_topic_score_gemma":0.0074367044,"teacher_disagreement_score":0.05578272,"about_ca_system_score_codex":0.0012123361,"about_ca_system_score_gemma":0.0051870323,"threshold_uncertainty_score":0.92015725},"labels":[],"label_agreement":null},{"id":"W4391301910","doi":"10.1200/jco.2024.42.4_suppl.598","title":"Role of thromboprophylaxis during neoadjuvant chemotherapy before radical cystectomy in patients with bladder cancer: Results of a multicenter retrospective cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Chemotherapy; Retrospective cohort study; Oncology; Urothelial cancer; Cancer; Cohort; Multicenter study; Urology; Internal medicine; Surgery; Randomized controlled trial","score_opus":0.01570662997873549,"score_gpt":0.3658043565948304,"score_spread":0.3500977266160949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391301910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996603,0.0003314971,0.0000041598055,0.0009186387,0.00048204264,0.0011328456,0.000017411532,0.0000084726325,0.000501907],"genre_scores_gemma":[0.9986645,0.00044243364,0.00035130008,0.00013814379,0.000320992,0.000017190041,0.0000024091885,0.000027489927,0.000035544814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960245,0.0002107216,0.0025124683,0.00031095286,0.0007092219,0.00023216402],"domain_scores_gemma":[0.9976162,0.00028431133,0.001212081,0.00024284577,0.00048283415,0.00016173122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017959368,0.00017096971,0.0023491995,0.00025343077,0.000018162118,0.0000063068546,0.00015742774,0.00019742911,0.00010364102],"category_scores_gemma":[0.0005008251,0.00010666712,0.00030669142,0.00029362005,0.00023230987,0.00009544448,0.000063116124,0.0007690727,0.0000021053806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009157787,0.011129349,0.95535135,0.0001268978,0.0022193976,0.00021582466,0.0015569057,0.00002019197,0.00010239981,0.000016884274,0.0002148813,0.019888103],"study_design_scores_gemma":[0.025496233,0.03240824,0.93951064,0.00067329325,0.0005510241,0.0000068174413,0.00036469116,0.00006577481,0.00014813284,0.000040930827,0.00065379316,0.000080443824],"about_ca_topic_score_codex":0.00036593506,"about_ca_topic_score_gemma":0.00041719014,"teacher_disagreement_score":0.021278892,"about_ca_system_score_codex":0.00034624056,"about_ca_system_score_gemma":0.00050484505,"threshold_uncertainty_score":0.4349759},"labels":[],"label_agreement":null},{"id":"W4391301985","doi":"10.1200/jco.2024.42.4_suppl.586","title":"Thromboembolic events associated with neoadjuvant chemotherapy for muscle invasive cancer of the bladder.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Bladder cancer; Cancer; Neoadjuvant therapy; Oncology; Internal medicine; Breast cancer","score_opus":0.09253284493630053,"score_gpt":0.44434921390521925,"score_spread":0.3518163689689187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391301985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96932095,0.0013351934,0.0001101811,0.025401592,0.0019992287,0.000664358,0.0000138404,0.000011805192,0.0011428263],"genre_scores_gemma":[0.98955494,0.0034123024,0.00036991722,0.0054832543,0.000802499,0.000025415367,0.0000017011934,0.000030538864,0.0003194545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99770826,0.00017350112,0.0013507548,0.0001798093,0.0003689527,0.00021874119],"domain_scores_gemma":[0.9965472,0.0015634754,0.0011252972,0.0001922574,0.00043045808,0.00014128191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019019854,0.00013193025,0.0015073026,0.00007379748,0.000042231175,0.0000076054425,0.00021000429,0.00022052333,0.00018900831],"category_scores_gemma":[0.0015203306,0.000067491244,0.0006295833,0.00020838158,0.0001702152,0.000069024616,0.00004435876,0.0004899177,0.0000025461416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026679276,0.0154016465,0.07711301,0.00078971655,0.016852187,0.00034206678,0.0026538374,0.00032944203,0.0031217914,0.002817472,0.24852291,0.629388],"study_design_scores_gemma":[0.0064196973,0.008932743,0.9012288,0.0013231768,0.0018061529,0.000022618022,0.00018834473,0.000116834475,0.0005155469,0.00117328,0.07817681,0.0000960007],"about_ca_topic_score_codex":0.000044343462,"about_ca_topic_score_gemma":0.00025764175,"teacher_disagreement_score":0.8241158,"about_ca_system_score_codex":0.00016436663,"about_ca_system_score_gemma":0.0020649347,"threshold_uncertainty_score":0.36631054},"labels":[],"label_agreement":null},{"id":"W4391301992","doi":"10.1200/jco.2024.42.4_suppl.106","title":"Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; External beam radiation; Radiation therapy; External beam radiotherapy; Oncology; Radium; Internal medicine; Prostate; Cancer; Urology; Bone metastasis; Radiochemistry","score_opus":0.0628498156280137,"score_gpt":0.4379534022943611,"score_spread":0.37510358666634736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391301992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193186,0.0034701654,0.00002082768,0.0032409804,0.00040229372,0.00076018943,0.000033150736,0.000015255991,0.00012527469],"genre_scores_gemma":[0.9964408,0.0018510537,0.00056746375,0.00029086662,0.00016407616,0.00003020547,0.000030673185,0.000033151668,0.0005916861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969732,0.00033356834,0.0014189121,0.00026265153,0.00069591374,0.0003157138],"domain_scores_gemma":[0.99787253,0.00084528705,0.0005589931,0.0001377196,0.0003091601,0.00027628115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014967327,0.00020813527,0.0012043157,0.00024091227,0.000058060177,0.000040199226,0.000092505215,0.00013553712,0.00007014738],"category_scores_gemma":[0.00020392465,0.00010339736,0.00026788563,0.0003654419,0.00011881085,0.0002811396,0.000010795443,0.0007789864,0.0000034459006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033209134,0.0013942848,0.9044232,0.00004104988,0.0017378399,0.0023540433,0.00019792771,0.00009727108,0.00009764824,0.0000060449124,0.00012601944,0.056315545],"study_design_scores_gemma":[0.03406002,0.015884941,0.94552976,0.0004924128,0.0005433771,0.00003291671,0.00005061307,0.00007669268,0.00015032613,0.000027259302,0.0030370774,0.000114589],"about_ca_topic_score_codex":0.00025347972,"about_ca_topic_score_gemma":0.00034149812,"teacher_disagreement_score":0.05620096,"about_ca_system_score_codex":0.00059425033,"about_ca_system_score_gemma":0.0027200866,"threshold_uncertainty_score":0.48253167},"labels":[],"label_agreement":null},{"id":"W4391302039","doi":"10.1200/jco.2024.42.4_suppl.589","title":"Clinical outcomes with split-dose cisplatin-based regimens in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a systematic literature review (SLR) and network meta-analysis (NMA).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Metastatic Urothelial Carcinoma; Oncology; Cisplatin; Internal medicine; Urothelial carcinoma; Urology; Chemotherapy; Cancer; Bladder cancer","score_opus":0.12442925419844507,"score_gpt":0.4530283069035779,"score_spread":0.32859905270513284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69151235,0.2694449,0.0018893989,0.020996341,0.0015976555,0.01215279,0.0005459376,0.00008631511,0.0017743113],"genre_scores_gemma":[0.9738861,0.0063675544,0.015744017,0.0033040107,0.00017520065,0.00009871217,0.000019236508,0.00005233231,0.0003528775],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98963106,0.0026838232,0.005956608,0.00055013044,0.00084569835,0.00033271097],"domain_scores_gemma":[0.9839777,0.011439865,0.0028804543,0.00055903825,0.0007038676,0.00043910727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007303763,0.00041934772,0.008785317,0.00032272603,0.000030197985,0.00003107228,0.00020565647,0.000292184,0.000062711886],"category_scores_gemma":[0.004345035,0.00018566196,0.0018769001,0.0012176745,0.00031652977,0.00014783267,0.000038996204,0.0012281624,0.0000028530183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13202967,0.007808999,0.4905934,0.06811,0.26826057,0.014381686,0.00039569568,0.0007872636,7.366939e-7,0.00013717687,0.0018962808,0.015598535],"study_design_scores_gemma":[0.051525846,0.06189723,0.31073874,0.040320676,0.5326604,0.00043763642,0.00005788449,0.0005162069,0.0000020355321,0.000065123364,0.0013885034,0.00038969514],"about_ca_topic_score_codex":0.000021687452,"about_ca_topic_score_gemma":0.00024484342,"teacher_disagreement_score":0.28237373,"about_ca_system_score_codex":0.00010933976,"about_ca_system_score_gemma":0.0024688193,"threshold_uncertainty_score":0.7571075},"labels":[],"label_agreement":null},{"id":"W4391302045","doi":"10.1200/jco.2024.42.4_suppl.105","title":"Patient-reported outcomes (PRO) in patients (pts) with <i>BRCA1/2</i>-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Abiraterone; Internal medicine; Oncology; Cancer; Castration; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.09669820922149745,"score_gpt":0.4317309454260764,"score_spread":0.3350327362045789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927142,0.0006887634,0.00003335627,0.003819753,0.00091940304,0.0014886742,0.00014107386,0.00003475075,0.00015997842],"genre_scores_gemma":[0.9940606,0.00042164064,0.004149099,0.0007937551,0.0002196737,0.000089781286,0.00003103112,0.00005830966,0.00017612796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933597,0.00072750525,0.0039836555,0.000633057,0.00090292166,0.0003931848],"domain_scores_gemma":[0.99465346,0.0015557571,0.0023640567,0.0003378111,0.0007154029,0.00037348006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002168916,0.00036262744,0.001948103,0.00028212072,0.00006680985,0.00007994082,0.00011821922,0.00016423267,0.00007221679],"category_scores_gemma":[0.0008063032,0.00022275482,0.00014587956,0.00039976527,0.00028546026,0.0004053407,0.00004585266,0.0011864398,0.0000040311393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08345566,0.004854341,0.8245428,0.00012874053,0.0032955552,0.0034000569,0.0053719915,0.00026372244,0.00062171684,0.0000027821507,0.0007404088,0.07332222],"study_design_scores_gemma":[0.061078236,0.034857243,0.8984747,0.0012793109,0.0010648714,0.0000940516,0.0008650427,0.00010088249,0.00014038601,0.000083979314,0.0017089937,0.00025228542],"about_ca_topic_score_codex":0.00058121997,"about_ca_topic_score_gemma":0.003196457,"teacher_disagreement_score":0.07393192,"about_ca_system_score_codex":0.000416078,"about_ca_system_score_gemma":0.0019171693,"threshold_uncertainty_score":0.9083678},"labels":[],"label_agreement":null},{"id":"W4391302082","doi":"10.1200/jco.2024.42.4_suppl.15","title":"Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.10673379587228134,"score_gpt":0.5226580841497942,"score_spread":0.4159242882775129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808421,0.0051461975,0.000004112424,0.012014088,0.00030102785,0.0012178986,0.000029788685,0.000007968453,0.00043681392],"genre_scores_gemma":[0.9819087,0.016520452,0.00021887066,0.00021033996,0.0003157389,0.00008930047,0.000004472213,0.000021176646,0.0007109924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657315,0.0006967535,0.0016447728,0.00025868948,0.00055449095,0.0002721342],"domain_scores_gemma":[0.9967292,0.0019283149,0.00067279034,0.00023694933,0.00024556433,0.00018719926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002590561,0.0002003086,0.00148392,0.0001903535,0.00003050983,0.00001810893,0.00019140741,0.00014275553,0.00011069247],"category_scores_gemma":[0.00029321466,0.000081739505,0.00031905167,0.0002990213,0.00023179028,0.0000732637,0.000023531655,0.00081849186,0.000002970366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037765432,0.014040013,0.56531906,0.000056114786,0.003534365,0.0025361627,0.004118629,0.0000136914405,0.0003105429,0.000040005405,0.0018673051,0.37039867],"study_design_scores_gemma":[0.11303853,0.20312005,0.6528098,0.00063096225,0.0023363573,0.00012464848,0.003557012,0.00020647954,0.0031982919,0.0008397242,0.019894922,0.00024323903],"about_ca_topic_score_codex":0.00043362577,"about_ca_topic_score_gemma":0.0004021036,"teacher_disagreement_score":0.37015542,"about_ca_system_score_codex":0.00047126692,"about_ca_system_score_gemma":0.0024386975,"threshold_uncertainty_score":0.43261448},"labels":[],"label_agreement":null},{"id":"W4391302286","doi":"10.1200/jco.2024.42.4_suppl.110","title":"Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Toxicity; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Clinical trial; Adverse effect; Cancer; Confidence interval","score_opus":0.741817832009525,"score_gpt":0.6914602367720749,"score_spread":0.05035759523745009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302286","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93876445,0.0010995303,0.050171424,0.0016649074,0.0069769938,0.0005193635,0.00022818222,0.000043052303,0.00053208997],"genre_scores_gemma":[0.28774282,0.0016972403,0.7077492,0.00043518288,0.0020922364,0.00001212951,9.3095105e-7,0.000051164694,0.00021908],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97956,0.0054132724,0.013161548,0.0005023971,0.0009252963,0.00043747269],"domain_scores_gemma":[0.76469636,0.22630015,0.007053723,0.0004372297,0.001054164,0.0004584006],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0564492,0.0003057724,0.007987604,0.000652097,0.000053816406,0.000042617117,0.0005342694,0.0007403979,0.0010699498],"category_scores_gemma":[0.31341445,0.00020695993,0.0028933315,0.0016691949,0.00042484023,0.00021010422,0.0001620023,0.0015417736,0.000005015388],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008090063,0.003361236,0.008053753,0.0007339196,0.026417581,0.00064822333,0.00040502258,0.0020484799,0.009643158,0.04886169,0.0018525077,0.88988435],"study_design_scores_gemma":[0.0067687714,0.006169799,0.007010848,0.0014374432,0.030079508,0.00003266364,0.00019074678,0.016459893,0.005949271,0.91871506,0.0066375113,0.0005484972],"about_ca_topic_score_codex":0.000021684875,"about_ca_topic_score_gemma":0.00004576111,"teacher_disagreement_score":0.8893359,"about_ca_system_score_codex":0.00030040677,"about_ca_system_score_gemma":0.0015965449,"threshold_uncertainty_score":0.9998432},"labels":[],"label_agreement":null},{"id":"W4391302332","doi":"10.1200/jco.2024.42.4_suppl.581","title":"Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Javelin; Urothelial carcinoma; Avelumab; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Urology; Carcinoma; Bladder cancer; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.13518270733900614,"score_gpt":0.48475030112486694,"score_spread":0.3495675937858608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682185,0.0016206212,0.0010377512,0.020356916,0.0055789812,0.002531067,0.000062288804,0.000026600435,0.0005672394],"genre_scores_gemma":[0.99054825,0.00065898034,0.000912148,0.0046384535,0.002126156,0.00017985319,0.000017992286,0.000053559936,0.0008646092],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99435973,0.00034708442,0.003788554,0.0004464372,0.0005730974,0.0004851089],"domain_scores_gemma":[0.9942607,0.0033633234,0.0012375473,0.00040906938,0.0004325889,0.0002967564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026532218,0.00032688837,0.0019084761,0.00021534276,0.00007808851,0.000037478127,0.00029777948,0.00041122586,0.00022933343],"category_scores_gemma":[0.0037031423,0.00018021256,0.0011621609,0.00026822364,0.00020896186,0.00017357216,0.000044925288,0.0011366814,0.000022051523],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25562313,0.013113927,0.05135579,0.00022748527,0.0019203502,0.009736097,0.0010951442,0.000023060722,0.000118520926,0.000116188516,0.008647592,0.6580227],"study_design_scores_gemma":[0.603428,0.12460978,0.13620085,0.0007009946,0.0030341097,0.0018371034,0.0003404576,0.00041895595,0.00030501565,0.0014083778,0.12722825,0.0004881098],"about_ca_topic_score_codex":0.000035101562,"about_ca_topic_score_gemma":0.000155824,"teacher_disagreement_score":0.6575346,"about_ca_system_score_codex":0.00029862483,"about_ca_system_score_gemma":0.0024676998,"threshold_uncertainty_score":0.7348855},"labels":[],"label_agreement":null},{"id":"W4391302371","doi":"10.1200/jco.2024.42.4_suppl.109","title":"Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Homologous recombination; Cohort; Oncology; Internal medicine; Gene; Cancer; Genetics; Biology","score_opus":0.07261226795548535,"score_gpt":0.45086850354280084,"score_spread":0.37825623558731547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105316,0.000915999,0.000029262092,0.004031289,0.0010428869,0.0026435195,0.00017505317,0.000042694573,0.00006614289],"genre_scores_gemma":[0.99758786,0.00027141944,0.0005737255,0.00032753285,0.00010694584,0.00023835128,0.0002305728,0.00003538622,0.00062821695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99519384,0.00063864863,0.0025037578,0.00043631328,0.00092184974,0.0003055953],"domain_scores_gemma":[0.99527496,0.001911654,0.0012365469,0.00028990486,0.0010019032,0.00028503904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021895058,0.00024054572,0.0010923,0.00015194474,0.00017620884,0.000072880146,0.00012505947,0.0001400447,0.00012007614],"category_scores_gemma":[0.001394689,0.00012167924,0.00034374243,0.00037161994,0.00032715284,0.00030225737,0.000047682075,0.00092899206,0.000004852973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005981064,0.0076690703,0.94948137,0.000033996337,0.004899728,0.0025401006,0.0020363894,0.000026683125,0.00008376493,0.0000026625808,0.005984958,0.021260187],"study_design_scores_gemma":[0.021522585,0.02897362,0.9426563,0.0002137537,0.002982317,0.000045576253,0.0013635622,0.00026417826,0.00013327754,0.00012854871,0.0015617958,0.00015453622],"about_ca_topic_score_codex":0.0005834188,"about_ca_topic_score_gemma":0.00033949685,"teacher_disagreement_score":0.02130455,"about_ca_system_score_codex":0.000581866,"about_ca_system_score_gemma":0.0019220368,"threshold_uncertainty_score":0.49619353},"labels":[],"label_agreement":null},{"id":"W4391302427","doi":"10.1200/jco.2024.42.4_suppl.328","title":"Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; University of Ottawa; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Cancer; Disease; Prostate; Androgen; Hormone","score_opus":0.09829980145780604,"score_gpt":0.49146646231312974,"score_spread":0.3931666608553237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844229,0.006192673,0.000074319185,0.0057933894,0.00112096,0.0016450366,0.0007175406,0.000013388437,0.000019794374],"genre_scores_gemma":[0.9621487,0.03593111,0.00064337254,0.0002800172,0.00051481253,0.00010621569,0.000040105795,0.000038838643,0.00029679792],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.990956,0.0030566643,0.0044969223,0.00042754205,0.0006157869,0.0004470815],"domain_scores_gemma":[0.9856272,0.010369086,0.0023681733,0.00026518517,0.00063252496,0.00073784793],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011372695,0.00029627598,0.003942618,0.00035479467,0.000041961157,0.00001693945,0.00015760338,0.00033271642,0.00027974404],"category_scores_gemma":[0.016700985,0.00016897655,0.00049294817,0.00038043523,0.0005541158,0.00013038579,0.000073123185,0.0010866828,0.000006623137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38299197,0.0036006568,0.09834753,0.001054369,0.001890076,0.00231259,0.0004171775,0.000063851796,0.0032497533,0.000051870134,0.0010136525,0.5050065],"study_design_scores_gemma":[0.16873513,0.09476549,0.6550683,0.011154766,0.0052831597,0.00006086739,0.00034685462,0.0033231229,0.019616287,0.0010434478,0.039929062,0.00067354867],"about_ca_topic_score_codex":0.00010505793,"about_ca_topic_score_gemma":0.00006587182,"teacher_disagreement_score":0.55672073,"about_ca_system_score_codex":0.0003273088,"about_ca_system_score_gemma":0.004496297,"threshold_uncertainty_score":0.99158174},"labels":[],"label_agreement":null},{"id":"W4391302496","doi":"10.1200/jco.2024.42.4_suppl.320","title":"Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Salvage therapy; Prostate; Urology; Surgery; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.06960715960634782,"score_gpt":0.45225148390489134,"score_spread":0.3826443242985435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942107,0.0015193125,0.000012845926,0.0023968334,0.00053312373,0.0010964584,0.000026491523,0.000016908909,0.00018732769],"genre_scores_gemma":[0.9908099,0.00799148,0.00025158506,0.00018360463,0.00031722672,0.000012406742,0.000074921,0.000033257133,0.00032558132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963727,0.00044074774,0.0020462656,0.00028265483,0.00055606716,0.00030155593],"domain_scores_gemma":[0.9968886,0.001046667,0.0010832549,0.00017542737,0.00057961163,0.00022645765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025771454,0.00017538026,0.0011529628,0.0004036128,0.000033485074,0.000026747937,0.000108346154,0.00025231027,0.000030431951],"category_scores_gemma":[0.0012397364,0.000095766634,0.00020187178,0.0004804677,0.00018050203,0.00028439955,0.000024076113,0.0007936989,0.000005325535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04287332,0.0010855191,0.6517233,0.00011058322,0.00033778482,0.00044869058,0.0007301112,0.0000068874706,0.00033602543,0.0000012795646,0.00015046084,0.302196],"study_design_scores_gemma":[0.03919473,0.03322443,0.9220322,0.00074273185,0.00014733567,0.000051681614,0.000050290513,0.00012711805,0.003054678,0.000015828346,0.0012538175,0.00010517651],"about_ca_topic_score_codex":0.000035087967,"about_ca_topic_score_gemma":0.00009988138,"teacher_disagreement_score":0.30209082,"about_ca_system_score_codex":0.00036308597,"about_ca_system_score_gemma":0.002747347,"threshold_uncertainty_score":0.48736757},"labels":[],"label_agreement":null},{"id":"W4391302587","doi":"10.1200/jco.2024.42.4_suppl.204","title":"Impact of androgen deprivation therapy (ADT) on circulating tumor DNA (ctDNA) detection in <i>de novo</i> metastatic castration-sensitive prostate cancer (mCSPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Castration; Oncology; Internal medicine; Androgen; Cancer research; Cancer; Hormone","score_opus":0.05740354167708947,"score_gpt":0.43124629386886504,"score_spread":0.37384275219177554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975555,0.00092689594,0.00051118614,0.0002346124,0.0004705582,0.0001617945,0.000030488822,0.00000223379,0.00010673043],"genre_scores_gemma":[0.9967509,0.002036495,0.00037368064,0.00029214093,0.00050645164,0.0000074542054,0.000007828055,0.000016385977,0.0000086522],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983317,0.00021037193,0.0010064027,0.0001764956,0.00011979852,0.00015517778],"domain_scores_gemma":[0.9984427,0.00051390607,0.00063949067,0.00009737108,0.00021870914,0.00008779839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012184108,0.00010916898,0.000428155,0.00009305263,0.000020502906,0.000017029048,0.00007069154,0.0001263198,0.000008243507],"category_scores_gemma":[0.0009120096,0.000087469154,0.00028628606,0.00012932692,0.00006333681,0.000010299686,0.00001807063,0.00029634673,0.0000010099865],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036113448,0.00062992447,0.039912414,0.00003916772,0.00066641386,0.00037572815,0.00032104205,0.015832622,0.6149477,0.00004931716,0.00021022123,0.32340413],"study_design_scores_gemma":[0.011534489,0.035502017,0.5158422,0.00043299972,0.0003358411,0.001104519,0.00029721973,0.0068736244,0.41711342,0.0014684339,0.008943538,0.000551717],"about_ca_topic_score_codex":0.00013034491,"about_ca_topic_score_gemma":0.0003536926,"teacher_disagreement_score":0.47592977,"about_ca_system_score_codex":0.00017180415,"about_ca_system_score_gemma":0.0019773657,"threshold_uncertainty_score":0.35668886},"labels":[],"label_agreement":null},{"id":"W4391302647","doi":"10.1200/jco.2024.42.4_suppl.208","title":"Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Cancer; Hormone","score_opus":0.2339183130763819,"score_gpt":0.5423661705284767,"score_spread":0.3084478574520948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882728,0.0010390093,0.004684287,0.0037608547,0.0003356238,0.0013777545,0.00047549207,0.0000123075015,0.00004186557],"genre_scores_gemma":[0.95942366,0.00029402407,0.039597113,0.0001457033,0.00017444325,0.00003803745,0.00006586477,0.000034947683,0.0002262007],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969059,0.00017873863,0.0015955105,0.00040451816,0.00059027533,0.00032505777],"domain_scores_gemma":[0.99662375,0.0015607282,0.0007086315,0.0002522813,0.000615951,0.00023864824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022547983,0.0001879348,0.0010678286,0.00024723884,0.00006293432,0.000037594313,0.0001657655,0.00012534518,0.0000040630243],"category_scores_gemma":[0.0007970738,0.00009705182,0.00012776894,0.000246368,0.00020250923,0.0005310979,0.00007478061,0.0007133125,3.9056468e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.637482,0.005525719,0.22525033,0.00096776185,0.00408717,0.0027583167,0.0018429077,0.034985434,0.0001814068,0.00008710909,0.0022856356,0.0845462],"study_design_scores_gemma":[0.06702447,0.09824536,0.35196775,0.0037778998,0.0027300706,0.00007793546,0.00046992514,0.47357476,0.00005314411,0.0005362952,0.0012611724,0.00028121533],"about_ca_topic_score_codex":0.00006794573,"about_ca_topic_score_gemma":0.00019283064,"teacher_disagreement_score":0.5704575,"about_ca_system_score_codex":0.0005089382,"about_ca_system_score_gemma":0.005015042,"threshold_uncertainty_score":0.88964695},"labels":[],"label_agreement":null},{"id":"W4391302671","doi":"10.1200/jco.2024.42.4_suppl.209","title":"11-Ketotestosterone and time to castration resistance in patients with recurrent non-metastatic prostate cancer receiving androgen deprivation therapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; McGill University; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen deprivation therapy; Testosterone (patch); Internal medicine; Androgen receptor; Androgen; Dihydrotestosterone; Endocrinology; Bicalutamide; Cohort; Urology; Oncology; Cancer; Hormone","score_opus":0.07317815419877942,"score_gpt":0.4411291755949603,"score_spread":0.36795102139618086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894666,0.0026427023,0.000022667786,0.006903839,0.00019708757,0.0005994711,0.00000747694,0.0000054565353,0.00015471934],"genre_scores_gemma":[0.9955711,0.0014308468,0.0019318908,0.00026638733,0.00015611641,0.000023069853,0.000007920465,0.000015872823,0.0005968372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834263,0.0001628695,0.0008431712,0.00018966194,0.00029631364,0.00016532734],"domain_scores_gemma":[0.9987272,0.00046290414,0.00027013075,0.000079180085,0.0002699715,0.00019062098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012414671,0.000099254736,0.000530657,0.00017220143,0.000024305797,0.000023862141,0.000044936947,0.00007265659,0.00005245431],"category_scores_gemma":[0.00030832476,0.000060050897,0.000050920924,0.00025370752,0.000056456345,0.00016494787,0.000018014362,0.00037863114,0.000008645472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014532229,0.000628082,0.5829659,0.00011271049,0.00020246676,0.0002992254,0.0005301175,0.000012979539,0.0002159517,0.0000048425845,0.0011306092,0.3993649],"study_design_scores_gemma":[0.008464101,0.011467265,0.97009045,0.0011354559,0.00008404503,0.000015675034,0.000021304602,0.000094131035,0.00008477976,0.00010119042,0.008364769,0.0000768404],"about_ca_topic_score_codex":0.000012619026,"about_ca_topic_score_gemma":0.00018356842,"teacher_disagreement_score":0.39928806,"about_ca_system_score_codex":0.00024835856,"about_ca_system_score_gemma":0.00096819876,"threshold_uncertainty_score":0.24488045},"labels":[],"label_agreement":null},{"id":"W4391302681","doi":"10.1200/jco.2024.42.4_suppl.323","title":"Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Bristol-Myers Squibb Foundation","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Cohort; Oncology; Prostate; Internal medicine; Radiosurgery; Prospective cohort study; Randomized controlled trial; Clinical trial; Cancer","score_opus":0.14295998657361347,"score_gpt":0.47687874480035325,"score_spread":0.3339187582267398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699352,0.0036984459,0.00021291283,0.021663094,0.0032475109,0.0009602623,0.00022373023,0.000007694198,0.00005117417],"genre_scores_gemma":[0.9921718,0.005167452,0.0003275374,0.0006441101,0.00084667,0.000046669156,0.00004913687,0.000014067616,0.0007325156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975837,0.00033487054,0.0013051308,0.00019143698,0.00042120885,0.00016365074],"domain_scores_gemma":[0.99424374,0.004268921,0.0008113042,0.00019559507,0.00036149027,0.00011897233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012035641,0.0001488149,0.00074764894,0.00006921182,0.000094310286,0.00003060677,0.00023137173,0.00015358103,0.00015969906],"category_scores_gemma":[0.0011416172,0.000056988785,0.00068110874,0.00008712565,0.00034783038,0.000107265936,0.000038822167,0.00044627188,0.0000063535676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066228886,0.0012825646,0.84642327,0.000015483542,0.0024875442,0.00013743085,0.00023511802,0.0000073352544,0.00012401193,0.00013345332,0.0005900182,0.14194085],"study_design_scores_gemma":[0.023915222,0.004972929,0.9549199,0.000094576084,0.0005665235,0.00004506416,0.000031136093,0.00054549857,0.00075481914,0.00023983656,0.013861243,0.00005327361],"about_ca_topic_score_codex":0.00019234522,"about_ca_topic_score_gemma":0.00007094844,"teacher_disagreement_score":0.14188758,"about_ca_system_score_codex":0.0004732103,"about_ca_system_score_gemma":0.002826806,"threshold_uncertainty_score":0.50146323},"labels":[],"label_agreement":null},{"id":"W4391302763","doi":"10.1200/jco.2024.42.4_suppl.325","title":"Every-other-day or once-a-week: Long-term efficacy outcomes of the multicenter randomised PATRIOT prostate SBRT trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; CancerCare Manitoba","funders":"","keywords":"Medicine; Term (time); Prostate cancer; Prostate; Randomized controlled trial; Internal medicine; Cancer","score_opus":0.19466731613974858,"score_gpt":0.524018911751432,"score_spread":0.3293515956116834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97596395,0.0022120124,0.00003544162,0.0144781545,0.004475084,0.0019399651,0.000014874055,0.000016794887,0.0008637514],"genre_scores_gemma":[0.981534,0.0024242983,0.00016750158,0.0010563179,0.0012736096,0.000021683481,0.000002384834,0.0000353606,0.013484862],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950237,0.0010222715,0.0027053386,0.00024512224,0.0006669646,0.00033655026],"domain_scores_gemma":[0.9895067,0.008429989,0.0010551864,0.0003186854,0.00037289498,0.00031650244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049364637,0.00020057785,0.0019026425,0.00014993889,0.000050766128,0.000025784864,0.00030976345,0.00031910997,0.0005131983],"category_scores_gemma":[0.006142046,0.00008122324,0.0014036114,0.00024442893,0.00042969547,0.00010703665,0.000096722215,0.0012367867,0.000036966536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6445016,0.0059236838,0.17032464,0.0002299302,0.0024985622,0.0017787309,0.00051649445,0.00000492781,0.00020332684,0.00001224962,0.00639066,0.16761515],"study_design_scores_gemma":[0.58364713,0.018508816,0.35199404,0.0008647353,0.0014557933,0.0001064889,0.000060307284,0.00008023228,0.00064544566,0.00005057705,0.042453185,0.0001332826],"about_ca_topic_score_codex":0.000010591858,"about_ca_topic_score_gemma":0.000025157407,"teacher_disagreement_score":0.1816694,"about_ca_system_score_codex":0.0002559522,"about_ca_system_score_gemma":0.003196571,"threshold_uncertainty_score":0.7353046},"labels":[],"label_agreement":null},{"id":"W4391302789","doi":"10.1200/jco.2024.42.4_suppl.214","title":"Chromatin modifications on plasma ctDNA as a tool to phenotype castration-resistant prostate cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Foundation","keywords":"Epigenomics; Prostate cancer; Medicine; Liquid biopsy; Cancer research; DNA methylation; Cell-free fetal DNA; Phenotype; Oncology; Cancer; Internal medicine; Biology; Gene; Genetics; Gene expression","score_opus":0.06097212507725887,"score_gpt":0.43018224899383695,"score_spread":0.3692101239165781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985173,0.00087116763,0.0001940785,0.008876268,0.001807647,0.000196986,0.00007226722,0.00000589358,0.002802718],"genre_scores_gemma":[0.9920228,0.0014091945,0.0019916163,0.0019770635,0.0018010732,0.00002366268,0.0000113891065,0.000019700445,0.00074351736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982686,0.000088440116,0.0010810974,0.00023283601,0.0001612246,0.00016777436],"domain_scores_gemma":[0.99862283,0.00040240903,0.00034899762,0.00018819376,0.00023456308,0.00020302123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075850735,0.000113906106,0.00035797493,0.00006354545,0.000047449983,0.00004471119,0.00018037125,0.00020502237,0.000063100575],"category_scores_gemma":[0.0017436879,0.00009311085,0.00020848948,0.0001050407,0.00006209553,0.0000053332615,0.000045093864,0.00029214233,0.00006751144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006304337,0.0011771056,0.0004757451,0.00007742015,0.0007190909,0.00036609272,0.00037013515,0.010035625,0.32398298,0.008085679,0.14728189,0.5011239],"study_design_scores_gemma":[0.0015819519,0.014832458,0.008598209,0.00012643065,0.00014250769,0.000057798898,0.00008184975,0.000520672,0.01185664,0.00097785,0.96098626,0.00023735987],"about_ca_topic_score_codex":0.000046022047,"about_ca_topic_score_gemma":0.00026938855,"teacher_disagreement_score":0.8137044,"about_ca_system_score_codex":0.00009047461,"about_ca_system_score_gemma":0.002486134,"threshold_uncertainty_score":0.4410295},"labels":[],"label_agreement":null},{"id":"W4391302877","doi":"10.1200/jco.2024.42.4_suppl.156","title":"Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Cancer; Internal medicine; breakpoint cluster region; Androgen receptor; Receptor","score_opus":0.08249207575034151,"score_gpt":0.4634647410781154,"score_spread":0.3809726653277739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97274965,0.005786381,0.00000776744,0.019400544,0.0008711528,0.0005671913,0.00003909283,0.000020512327,0.00055768894],"genre_scores_gemma":[0.97117233,0.026374076,0.00085311657,0.00019229743,0.00042796976,0.00003553434,0.000042397445,0.000025980937,0.0008763217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691975,0.00040123795,0.0015438003,0.00033398517,0.000500542,0.00030068783],"domain_scores_gemma":[0.99668425,0.0018855756,0.0006090232,0.00017628551,0.00031417175,0.00033071553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013408951,0.00021016963,0.0013166192,0.00023620536,0.000035482855,0.00002623047,0.00010863091,0.00026638716,0.00015570778],"category_scores_gemma":[0.0005427565,0.000109912085,0.00028660736,0.00023899427,0.0001770522,0.00012626367,0.00004183948,0.0009475436,0.000019336476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015644442,0.0028175812,0.56561756,0.000047018133,0.0012547529,0.0026561006,0.00046704191,0.000018501309,0.000826862,0.00005388294,0.002654876,0.40794137],"study_design_scores_gemma":[0.03984851,0.041192774,0.892213,0.0011982962,0.0012436452,0.00007289266,0.00028125427,0.0005563787,0.004980808,0.0021724268,0.016015299,0.00022474512],"about_ca_topic_score_codex":0.0009551246,"about_ca_topic_score_gemma":0.000527313,"teacher_disagreement_score":0.40771663,"about_ca_system_score_codex":0.0013361704,"about_ca_system_score_gemma":0.002546344,"threshold_uncertainty_score":0.4517105},"labels":[],"label_agreement":null},{"id":"W4391302892","doi":"10.1200/jco.2024.42.4_suppl.395","title":"Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Expanded access; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.11448769709135011,"score_gpt":0.4236837089006565,"score_spread":0.3091960118093064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787989,0.0016704473,0.000061631334,0.015847083,0.0016540856,0.00029455862,0.00014794874,0.0000122729725,0.0015130378],"genre_scores_gemma":[0.9918803,0.0015205899,0.00416223,0.0010132327,0.0008214653,0.000007335805,0.000084673484,0.00003272334,0.00047747567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495935,0.0005955311,0.0030911064,0.00042186526,0.00065023033,0.00028191472],"domain_scores_gemma":[0.99147093,0.00624482,0.0011571452,0.000449337,0.00029108973,0.00038665632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002993575,0.00026935406,0.0017146231,0.00033219103,0.000041194307,0.000035879155,0.0003951439,0.00016424224,0.00045328218],"category_scores_gemma":[0.0010923246,0.00016097588,0.0004519798,0.0002372261,0.00039994196,0.00026423935,0.0001990335,0.0012716849,0.000016786727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009572946,0.003478165,0.9436425,0.00013280095,0.0013499294,0.009173701,0.0004888759,0.000052735904,0.000972797,0.00028200247,0.007198452,0.02365512],"study_design_scores_gemma":[0.017410876,0.0071177413,0.94509697,0.00032749327,0.0017645672,0.00039119384,0.00036715527,0.0026677272,0.0011042545,0.00064398133,0.022906223,0.000201817],"about_ca_topic_score_codex":0.0011292846,"about_ca_topic_score_gemma":0.006078565,"teacher_disagreement_score":0.023453303,"about_ca_system_score_codex":0.00031776697,"about_ca_system_score_gemma":0.0013292073,"threshold_uncertainty_score":0.65644056},"labels":[],"label_agreement":null},{"id":"W4391303024","doi":"10.1200/jco.2024.42.4_suppl.151","title":"Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"Cancer Council Australia; Pfizer","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Cancer; Gynecology","score_opus":0.10347654656899868,"score_gpt":0.5266114866556074,"score_spread":0.42313494008660874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605425,0.023117607,0.00007645012,0.013085162,0.0012119225,0.0016961758,0.00006456077,0.0000257803,0.00017983263],"genre_scores_gemma":[0.9820181,0.013849324,0.0018986176,0.0003623949,0.0014046805,0.00014118107,0.00003066619,0.0000326309,0.00026242048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942014,0.0016266985,0.0021858688,0.0005064258,0.0010307294,0.000448856],"domain_scores_gemma":[0.9947551,0.002878415,0.0011412821,0.00028893386,0.00056232535,0.0003739767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057202633,0.0002662528,0.0022644722,0.0006654304,0.00008205192,0.000069960704,0.00020965928,0.00029689018,0.00008818937],"category_scores_gemma":[0.0018677366,0.00012658186,0.0011664244,0.0020563602,0.00060463743,0.00022212414,0.00008622239,0.002253482,0.000008314561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2644105,0.0026460958,0.43399712,0.00005355566,0.012374173,0.006300963,0.0025196716,0.000022874157,0.00041089067,0.000030259627,0.004017232,0.27321666],"study_design_scores_gemma":[0.10348218,0.033705056,0.83260846,0.0015575956,0.011646395,0.00011651056,0.0008909071,0.0030370925,0.00029905478,0.0016170413,0.010749852,0.00028987892],"about_ca_topic_score_codex":0.00019138747,"about_ca_topic_score_gemma":0.00030695804,"teacher_disagreement_score":0.39861134,"about_ca_system_score_codex":0.0005618057,"about_ca_system_score_gemma":0.0028914884,"threshold_uncertainty_score":0.97903824},"labels":[],"label_agreement":null},{"id":"W4391303050","doi":"10.1200/jco.2024.42.4_suppl.390","title":"Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Clear cell renal cell carcinoma; Cancer research","score_opus":0.1440181782252977,"score_gpt":0.4280044634524601,"score_spread":0.2839862852271624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786434,0.0061129113,0.00413293,0.005926984,0.0023622676,0.0008909106,0.00071486813,0.000037809623,0.0011778945],"genre_scores_gemma":[0.97004694,0.0007187287,0.024317304,0.0005901911,0.0019143971,0.00011895835,0.00039986815,0.00008880925,0.0018047796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99228,0.0010689966,0.00405026,0.0008889867,0.0010536828,0.0006580659],"domain_scores_gemma":[0.98987436,0.005587361,0.0016343168,0.0010481857,0.0008702402,0.0009855235],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033627995,0.0006419595,0.0033468513,0.0009570474,0.00010526604,0.00010705635,0.000643163,0.0002667723,0.00092186395],"category_scores_gemma":[0.00096618367,0.00042444584,0.0026675835,0.00055523345,0.0003885529,0.00053410523,0.000158847,0.0009214706,0.000040208037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.100794144,0.04614445,0.6147981,0.002004305,0.050638184,0.105420806,0.003686522,0.0017391215,0.007757806,0.0007830787,0.012126302,0.05410716],"study_design_scores_gemma":[0.07971268,0.12263501,0.5429673,0.00021607048,0.099617995,0.0027749387,0.0012089345,0.015041733,0.010561765,0.0014376855,0.12243473,0.00139115],"about_ca_topic_score_codex":0.00020690866,"about_ca_topic_score_gemma":0.00084645906,"teacher_disagreement_score":0.11030842,"about_ca_system_score_codex":0.00078440947,"about_ca_system_score_gemma":0.0024782699,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W4391303054","doi":"10.1200/jco.2024.42.4_suppl.393","title":"Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; McGill University Health Centre; Health Sciences Centre; University Health Network; CancerCare Manitoba; Ottawa Hospital; Hôtel-Dieu de Québec; BC Cancer Agency; Juravinski Cancer Centre; Institute of Cancer Research; University of Manitoba; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Nivolumab; Axitinib; Medicine; Ipilimumab; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Population; Metastatic melanoma; Immunotherapy; Cancer; Sunitinib","score_opus":0.10268332968470205,"score_gpt":0.4055934135473228,"score_spread":0.30291008386262075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98400974,0.0033729281,0.00005319678,0.0043717963,0.0016920262,0.00050793734,0.000030175042,0.000020112484,0.005942069],"genre_scores_gemma":[0.9919371,0.000060871287,0.004624992,0.001749482,0.0010678056,0.000014232103,0.000051556013,0.000049045375,0.0004449059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434274,0.0007093885,0.003351727,0.0004824636,0.0006112257,0.00050245353],"domain_scores_gemma":[0.9948176,0.002175793,0.00061840564,0.00036999918,0.00031016607,0.0017080118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011144868,0.00030697443,0.0021524176,0.0009708648,0.00005475319,0.00004590685,0.00027172084,0.00033851468,0.00043561205],"category_scores_gemma":[0.0009802156,0.00023398355,0.000661334,0.00055073836,0.0000992891,0.00017764268,0.000058581754,0.0013566143,0.00023394865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032751307,0.0077679115,0.4930758,0.00060910446,0.002928635,0.19559231,0.0062226304,0.0021523063,0.0036581773,0.0012070418,0.04927285,0.20476194],"study_design_scores_gemma":[0.0122335255,0.008516598,0.93485016,0.0003623354,0.0008666011,0.00066372054,0.00029564113,0.0014732259,0.00029722473,0.0012467913,0.038934957,0.00025922988],"about_ca_topic_score_codex":0.07673532,"about_ca_topic_score_gemma":0.14235382,"teacher_disagreement_score":0.44177434,"about_ca_system_score_codex":0.002091082,"about_ca_system_score_gemma":0.0056623244,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W4391303131","doi":"10.1200/jco.2024.42.4_suppl.126","title":"Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate-specific antigen; Prostate cancer; Oncology; Internal medicine; Prostate; Hormone; Cancer","score_opus":0.10834649701347598,"score_gpt":0.47152638440485967,"score_spread":0.3631798873913837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992426,0.0013018344,0.000017432365,0.0029813864,0.001109456,0.0015519297,0.00025413063,0.000015393834,0.00034243788],"genre_scores_gemma":[0.9959621,0.0027141469,0.00009667719,0.00015734196,0.00033311482,0.00007354902,0.000049825256,0.000040630166,0.00057262974],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99295956,0.003002187,0.002212799,0.00050201925,0.0008672869,0.00045617172],"domain_scores_gemma":[0.98895097,0.009236534,0.0008130508,0.00030777798,0.00030493154,0.00038671438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042222166,0.00035412997,0.003127678,0.0014282601,0.000039631457,0.000039267714,0.00012696034,0.00024503045,0.0002509853],"category_scores_gemma":[0.0008732493,0.00020500446,0.0013503789,0.00088707864,0.000275773,0.000106737214,0.000029578521,0.0011151383,0.00001554245],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9034572,0.0042977794,0.009464962,0.0000809829,0.0074694837,0.007227041,0.0008129125,0.00035679314,0.003922833,0.000018390108,0.00035224837,0.06253935],"study_design_scores_gemma":[0.14515822,0.27832767,0.5627129,0.00049755775,0.003953294,0.000011496815,0.00010225847,0.0024670472,0.0024165863,0.00004400752,0.0040873243,0.0002216302],"about_ca_topic_score_codex":0.00015998413,"about_ca_topic_score_gemma":0.0001078648,"teacher_disagreement_score":0.758299,"about_ca_system_score_codex":0.0012013022,"about_ca_system_score_gemma":0.0031796978,"threshold_uncertainty_score":0.83598393},"labels":[],"label_agreement":null},{"id":"W4391303156","doi":"10.1200/jco.2024.42.4_suppl.382","title":"Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; Université Laval; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; CancerCare Manitoba; University Health Network; Dalhousie University; University of Alberta; University of Calgary; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Manitoba; Centre hospitalier universitaire de Québec; University of Ottawa; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Kidney cancer; Renal carcinoma; Cancer treatment; Immunotherapy; Sunitinib","score_opus":0.05276805426933315,"score_gpt":0.39429339450685746,"score_spread":0.34152534023752434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976654,0.0005558669,5.773007e-7,0.017026575,0.0005450117,0.0008236754,0.000029330271,0.0000059595955,0.004359029],"genre_scores_gemma":[0.99719876,0.0005113337,0.00029841077,0.0011803329,0.00033910054,0.000054319036,0.00002014695,0.000034685203,0.0003628843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958198,0.00049306895,0.0022261073,0.00038456463,0.00045104758,0.00062541786],"domain_scores_gemma":[0.99672085,0.0017644061,0.000660815,0.00026661172,0.00015964815,0.000427669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013795025,0.00030612238,0.0016765889,0.00073407445,0.000038586873,0.000020683294,0.00020755352,0.00022634777,0.000061584324],"category_scores_gemma":[0.000282147,0.00016707099,0.00032497392,0.00051524356,0.00010697965,0.00012817925,0.000027226728,0.0011951425,0.0000065737877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005626997,0.0010412359,0.94011194,0.000056210178,0.00011993081,0.007979577,0.0012794764,0.00075326744,0.0000015019241,0.000010384333,0.00024844383,0.042771045],"study_design_scores_gemma":[0.025978109,0.013995127,0.9490392,0.00059897086,0.00021823193,0.000047167516,0.00020831321,0.00031902295,0.000024329614,0.000023842706,0.009408633,0.0001390027],"about_ca_topic_score_codex":0.15291862,"about_ca_topic_score_gemma":0.7884442,"teacher_disagreement_score":0.6355256,"about_ca_system_score_codex":0.0063428753,"about_ca_system_score_gemma":0.004788246,"threshold_uncertainty_score":0.9974716},"labels":[],"label_agreement":null},{"id":"W4391303168","doi":"10.1200/jco.2024.42.4_suppl.482","title":"Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Renal cell carcinoma; Meta-analysis; Oncology; Internal medicine; Hepatocellular carcinoma; Cancer; Immunotherapy; Sorafenib","score_opus":0.40977554878475164,"score_gpt":0.49290238542084375,"score_spread":0.0831268366360921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980791,0.00390156,0.008088055,0.0015383335,0.0003028918,0.0017476274,0.00007598684,0.000013698772,0.0035409026],"genre_scores_gemma":[0.9372228,0.000075793505,0.06096521,0.00024887265,0.0002874496,0.00008083683,0.0000311537,0.000038557286,0.0010493727],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99445873,0.0004530248,0.0034728954,0.0004920054,0.0007357532,0.00038760176],"domain_scores_gemma":[0.9919709,0.004131593,0.0022316459,0.00049537513,0.0007432169,0.0004273005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016107593,0.00038957034,0.0059541278,0.00036985855,0.00004756861,0.00001226308,0.0002807106,0.00019631987,0.0002171002],"category_scores_gemma":[0.00008812248,0.0002310581,0.0028393154,0.0008298797,0.00019871435,0.00008367392,0.00007837366,0.00042078324,0.0000072753737],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13179229,0.011060128,0.01938419,0.0012363286,0.56056607,0.002249394,0.0012726834,0.25933424,0.00047188465,0.00047729237,0.004198197,0.007957296],"study_design_scores_gemma":[0.048246805,0.08019394,0.2554967,0.00033737067,0.596028,0.00012179306,0.00048010843,0.0025370715,0.0034954895,0.00014922366,0.012521079,0.0003924324],"about_ca_topic_score_codex":0.000032994547,"about_ca_topic_score_gemma":0.00009310887,"teacher_disagreement_score":0.25679716,"about_ca_system_score_codex":0.00039260427,"about_ca_system_score_gemma":0.00072542747,"threshold_uncertainty_score":0.9422276},"labels":[],"label_agreement":null},{"id":"W4391303197","doi":"10.1200/jco.2024.42.4_suppl.131","title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Clinical endpoint; Enzalutamide; Internal medicine; Surgery; Oncology; Randomized controlled trial; Cancer; Androgen receptor","score_opus":0.047664306498826095,"score_gpt":0.40599287676845164,"score_spread":0.35832857026962556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465543,0.0011174561,0.00014120761,0.0024963391,0.0007635406,0.00047208538,0.0000505761,0.000018657043,0.00028472464],"genre_scores_gemma":[0.99487793,0.00071744097,0.0033764318,0.00014820205,0.0006724253,0.000009274356,0.00012749719,0.00003095691,0.000039823077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600595,0.0004841464,0.0021601438,0.00036487196,0.00070723664,0.00027762062],"domain_scores_gemma":[0.9934678,0.0045452057,0.000962666,0.00021728381,0.00050922355,0.00029780297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020133113,0.00018089423,0.0011287313,0.00029850387,0.000035382385,0.000020179275,0.00013043387,0.00036474175,0.000019618567],"category_scores_gemma":[0.0059771077,0.00010725523,0.00024098676,0.0004470163,0.00033850316,0.00022219744,0.00004251808,0.0015528848,0.000006586208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15382698,0.004029462,0.71675175,0.00022683687,0.0027715266,0.0050088083,0.0016306218,0.000085399115,0.0012226035,0.00013588987,0.0024532315,0.11185688],"study_design_scores_gemma":[0.096429355,0.0265296,0.8617504,0.0033787608,0.0012814072,0.000058727226,0.00044603625,0.00034598762,0.0050997455,0.0006881964,0.0037178486,0.00027391856],"about_ca_topic_score_codex":0.00012943408,"about_ca_topic_score_gemma":0.00006427413,"teacher_disagreement_score":0.14499865,"about_ca_system_score_codex":0.00044727864,"about_ca_system_score_gemma":0.0028780664,"threshold_uncertainty_score":0.71555877},"labels":[],"label_agreement":null},{"id":"W4391303198","doi":"10.1200/jco.2024.42.4_suppl.141","title":"Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"ESSA Pharma","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen receptor; Internal medicine; Urology; Regimen; Oncology; Pharmacology; Metastatic breast cancer; Concomitant; Pharmacokinetics; Docetaxel; Tolerability; Chemotherapy; Cancer; Adverse effect; Breast cancer","score_opus":0.17280411001997317,"score_gpt":0.5116431645062401,"score_spread":0.33883905448626694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931866,0.0006028183,0.00024353457,0.0030770055,0.0002935402,0.0023764728,0.00016900795,0.000008728058,0.0000422933],"genre_scores_gemma":[0.9955481,0.00031913054,0.0036159756,0.0001415171,0.00009509764,0.00007796136,0.000076021584,0.000026757529,0.00009943359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99529,0.0007615391,0.0025302116,0.0003593321,0.00070659973,0.00035236313],"domain_scores_gemma":[0.99619114,0.0017387348,0.0008916081,0.00016190024,0.0006057206,0.00041091788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034839245,0.00023176162,0.0016068766,0.0005858281,0.000036328685,0.000033165998,0.00010417341,0.00012861332,0.00003172762],"category_scores_gemma":[0.0010375857,0.00014116964,0.00010510228,0.00068938476,0.0002779078,0.00029734222,0.00002694785,0.0007527486,0.0000015384235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8638802,0.026837043,0.0034232808,0.00015171879,0.0005878738,0.002393749,0.0011267324,0.00018896106,0.0008292046,0.00001757022,0.00039703597,0.10016664],"study_design_scores_gemma":[0.785791,0.19693393,0.011087466,0.0011152243,0.00063041266,0.00003480236,0.00026486765,0.0014254636,0.0009030115,0.000114780494,0.0015254398,0.00017364202],"about_ca_topic_score_codex":0.0002604831,"about_ca_topic_score_gemma":0.0009456674,"teacher_disagreement_score":0.17009687,"about_ca_system_score_codex":0.00045118298,"about_ca_system_score_gemma":0.0030648534,"threshold_uncertainty_score":0.5756731},"labels":[],"label_agreement":null},{"id":"W4391303212","doi":"10.1200/jco.2024.42.4_suppl.262","title":"Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Vetenskapsrådet","keywords":"Medicine; Prostate cancer; Prospective cohort study; Cohort; Cancer; Prostate; Oncology; Gynecology; Internal medicine","score_opus":0.14412154296887295,"score_gpt":0.5400226121622324,"score_spread":0.39590106919335943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96313244,0.002021215,0.016277289,0.010328283,0.005879224,0.0021324423,0.00000492349,0.0000313612,0.00019280399],"genre_scores_gemma":[0.98776615,0.0012549568,0.0073412,0.00080742524,0.0018950626,0.00016512405,0.0000028922866,0.000031096642,0.00073608826],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996965,0.0003237412,0.0019232419,0.00027340013,0.00028219447,0.00023243648],"domain_scores_gemma":[0.9968005,0.0018134005,0.0006959715,0.00010569344,0.00034722546,0.00023725515],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0060571404,0.00012702103,0.0010334909,0.00022263377,0.000033892335,0.000023750785,0.000094779636,0.00025827732,0.000051010327],"category_scores_gemma":[0.008359657,0.00009093943,0.0004541777,0.00023985992,0.0001288045,0.0001345546,0.000025303718,0.0016482386,0.000005458541],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057516314,0.0020082507,0.07567103,0.0002314669,0.00072044076,0.00052371685,0.0006640804,0.00030442845,0.0009228045,0.000034103934,0.0010039329,0.8603994],"study_design_scores_gemma":[0.26577166,0.029113384,0.40601796,0.0016233898,0.0017052626,0.00056562544,0.00034374287,0.18790646,0.0004918142,0.0006715308,0.10546156,0.00032762074],"about_ca_topic_score_codex":0.00005823754,"about_ca_topic_score_gemma":0.00009491189,"teacher_disagreement_score":0.86007184,"about_ca_system_score_codex":0.0004273967,"about_ca_system_score_gemma":0.0012565299,"threshold_uncertainty_score":0.9999933},"labels":[],"label_agreement":null},{"id":"W4391303220","doi":"10.1200/jco.2024.42.4_suppl.363","title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Sunitinib; Ipilimumab; Internal medicine; Renal cell carcinoma; Oncology; Immunotherapy; Cancer","score_opus":0.25596672697664336,"score_gpt":0.4770844221774215,"score_spread":0.22111769520077812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759309,0.008988561,0.00056668004,0.006033394,0.004846812,0.0022490278,0.0007276786,0.000033188084,0.0006237195],"genre_scores_gemma":[0.98652804,0.003106222,0.0020983848,0.0003826297,0.0050272136,0.00007731284,0.00071174104,0.00009369101,0.0019747475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927072,0.0006631071,0.0045099985,0.000792219,0.0007348376,0.0005926496],"domain_scores_gemma":[0.9843202,0.010712689,0.0022891064,0.0014698821,0.00058758544,0.0006205268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025816802,0.000528049,0.0034088076,0.00020316264,0.00013180738,0.000044051467,0.00084580237,0.0005435362,0.00044317372],"category_scores_gemma":[0.001717989,0.0003109349,0.0017246187,0.00026519198,0.0003999549,0.00026635668,0.00021999124,0.00083332154,0.000038965227],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65774214,0.013554334,0.0038554547,0.00042041135,0.0031337,0.0062353495,0.0007095411,0.00006728976,0.0017256488,0.000035470843,0.009337935,0.3031827],"study_design_scores_gemma":[0.63785976,0.21603154,0.0216596,0.0006751752,0.0088448385,0.0005622485,0.00024397763,0.0021963613,0.0070267604,0.0002675897,0.10421233,0.00041983387],"about_ca_topic_score_codex":0.00013087296,"about_ca_topic_score_gemma":0.00052799465,"teacher_disagreement_score":0.30276287,"about_ca_system_score_codex":0.000946557,"about_ca_system_score_gemma":0.0042059915,"threshold_uncertainty_score":0.99993426},"labels":[],"label_agreement":null},{"id":"W4391303262","doi":"10.1200/jco.2024.42.4_suppl.366","title":"Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Princess Margaret Cancer Centre; University of Calgary; McMaster University; Sunnybrook Health Science Centre; University of Manitoba; Juravinski Cancer Centre; University of Ottawa; McGill University Health Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Centre hospitalier universitaire de Québec; University Health Network; Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Toxicity; Kidney cancer; Oncology; Cancer; Internal medicine; Kidney","score_opus":0.057788766818501945,"score_gpt":0.38178262200828855,"score_spread":0.32399385518978663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794467,0.00027706724,0.000004483921,0.014158094,0.001107592,0.0006335122,0.00032518542,0.0000116907095,0.004035648],"genre_scores_gemma":[0.99774957,0.00023527621,0.00040294306,0.0010253496,0.00019111583,0.000016236061,0.000103116516,0.000020351728,0.0002560356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569756,0.0008585619,0.0023718926,0.00023973703,0.00053733477,0.00029489698],"domain_scores_gemma":[0.9932059,0.004242749,0.0012397368,0.00024367029,0.00038436317,0.000683597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019108863,0.00024414883,0.0012391362,0.00029247053,0.00007164029,0.00006708447,0.00011730892,0.00019221738,0.000035750058],"category_scores_gemma":[0.0010961758,0.000121487596,0.00020659571,0.0002529631,0.00009501373,0.0004183766,0.000031098385,0.00078936166,0.000014036508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035231425,0.00071008253,0.98088574,0.00008001257,0.0009053023,0.0021101418,0.001267864,0.00002868344,0.0000019632778,0.00003086293,0.0011651645,0.009291009],"study_design_scores_gemma":[0.021359088,0.004927276,0.96353513,0.00042016272,0.0018263398,0.00006983272,0.0005613914,0.00020380023,0.00003202842,0.0000059909357,0.0069448617,0.000114077746],"about_ca_topic_score_codex":0.24687245,"about_ca_topic_score_gemma":0.29265276,"teacher_disagreement_score":0.045780312,"about_ca_system_score_codex":0.0022822162,"about_ca_system_score_gemma":0.004887767,"threshold_uncertainty_score":0.8670689},"labels":[],"label_agreement":null},{"id":"W4391303267","doi":"10.1200/jco.2024.42.4_suppl.389","title":"Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Sunnybrook Health Science Centre; University of Calgary; McMaster University; University of British Columbia; Université de Sherbrooke; University of Toronto; University of Manitoba; Trillium Health Centre; St. Joseph’s Healthcare Hamilton; Ottawa Hospital; CancerCare Manitoba; Hotel Dieu Hospital; University of Ottawa; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Université Laval; Dalhousie University","funders":"","keywords":"Medicine; Renal cell carcinoma; Kidney cancer; Chromophobe cell; Cancer; Oncology; Kidney; Internal medicine; Kidney disease; Pathology; Clear cell","score_opus":0.06188277802279362,"score_gpt":0.37032861790919114,"score_spread":0.3084458398863975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97883993,0.0016241692,0.000005014581,0.007109254,0.002030108,0.00033637573,0.00016375222,0.0000063266934,0.009885064],"genre_scores_gemma":[0.9978744,0.0007055305,0.0003369043,0.0005605207,0.00036731805,0.000007922378,0.000018615832,0.0000080803275,0.000120732104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669075,0.00026963156,0.0023102062,0.00016123404,0.0003682782,0.00019990101],"domain_scores_gemma":[0.9970432,0.0012254354,0.0008667723,0.00020867202,0.00017993667,0.00047600627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022059996,0.00013748817,0.0008432845,0.00024949235,0.00003522947,0.000022210737,0.00016141674,0.00023304613,0.000021783457],"category_scores_gemma":[0.0007665934,0.00007799052,0.00021119943,0.00021278231,0.00014256542,0.00019982163,0.0000481987,0.00069750176,0.000008227637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022983302,0.0001815641,0.94017565,0.0004786443,0.00054330064,0.0027397547,0.00155479,0.000033897137,0.00002167732,0.00015155226,0.018682143,0.033138685],"study_design_scores_gemma":[0.0052308217,0.001663368,0.95189345,0.00076906604,0.0005434266,0.00008115782,0.0003732836,0.00023704907,0.00011866298,0.000020770813,0.039003756,0.0000651711],"about_ca_topic_score_codex":0.037451226,"about_ca_topic_score_gemma":0.022314532,"teacher_disagreement_score":0.03307351,"about_ca_system_score_codex":0.0008176411,"about_ca_system_score_gemma":0.0029808835,"threshold_uncertainty_score":0.99552566},"labels":[],"label_agreement":null},{"id":"W4391303268","doi":"10.1200/jco.2024.42.4_suppl.120","title":"Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: Secondary analysis of the LATITUDE study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Concomitant; Oncology; Internal medicine; Overall survival; Prostate; Cancer","score_opus":0.03509505456332665,"score_gpt":0.4501880095331972,"score_spread":0.41509295496987053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303436,0.0036265925,0.000016975671,0.0010025168,0.0019914315,0.0002138394,0.000053403262,9.013193e-7,0.00005995801],"genre_scores_gemma":[0.99572176,0.003423618,0.000070279624,0.00009532015,0.0005688886,0.000014891455,0.0000019976248,0.000006330635,0.00009692571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673223,0.0018391629,0.0010346549,0.00014592365,0.00014677826,0.00010126693],"domain_scores_gemma":[0.9970134,0.002144326,0.00051553367,0.00016639108,0.000080880716,0.000079498015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049590147,0.000092916314,0.0009045235,0.0001365469,0.000015856625,0.0000040740474,0.00011907664,0.00009375246,0.000015984593],"category_scores_gemma":[0.0011894119,0.000050545146,0.0003414569,0.00023402933,0.00018162813,0.0000034666336,0.000036868267,0.00021764553,1.3181791e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03234502,0.0027630802,0.68078196,0.0001412235,0.016292742,0.000031196596,0.0024101096,0.002102706,0.045208275,0.00009662934,0.0011051802,0.2167219],"study_design_scores_gemma":[0.0071638282,0.022815505,0.90629923,0.00007147727,0.0050267396,0.00001850926,0.00028691272,0.00018124333,0.0031694772,0.000030124942,0.054852024,0.00008491083],"about_ca_topic_score_codex":0.00012793063,"about_ca_topic_score_gemma":0.0023204596,"teacher_disagreement_score":0.22551732,"about_ca_system_score_codex":0.0000666685,"about_ca_system_score_gemma":0.0016796946,"threshold_uncertainty_score":0.29797062},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4391303271","doi":"10.1200/jco.2024.42.4_suppl.516","title":"Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour: A multicenter retrospective cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Retroperitoneal lymph node dissection; Germ cell; Retrospective cohort study; Dissection (medical); Stage (stratigraphy); Lymph node; Germ cell tumors; Oncology; Surgery; Radiology; Testicular cancer; Internal medicine; Chemotherapy","score_opus":0.020606331257810577,"score_gpt":0.3821119603954536,"score_spread":0.361505629137643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500835,0.00065701053,0.00003571302,0.0005108543,0.0006027292,0.00068964117,0.00001093993,0.000021848673,0.0024629103],"genre_scores_gemma":[0.9975831,0.000114587136,0.00073066226,0.00035873742,0.00034266018,0.00003939805,0.0000050972467,0.0000371434,0.00078864093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971398,0.00024562856,0.0014909629,0.00035381012,0.00051678816,0.00025298755],"domain_scores_gemma":[0.998126,0.0005335031,0.0005942845,0.00021125251,0.00020236943,0.00033261525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010878239,0.00021775837,0.0014841715,0.00017188562,0.000026460215,0.000028875465,0.00008892561,0.00018622541,0.000087908375],"category_scores_gemma":[0.00040019784,0.00012697285,0.0003937595,0.0001642254,0.00010205376,0.00015197172,0.000055424935,0.00070314325,0.000028137929],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006422113,0.007097075,0.9543579,0.0001042708,0.00082920055,0.029223895,0.00020459034,0.000005985739,0.000041429335,9.2562163e-7,0.00013445318,0.0015781623],"study_design_scores_gemma":[0.012022401,0.0063220905,0.97905535,0.00024747607,0.0012184262,0.000304473,0.00026756382,0.00025897217,0.00001162073,0.0000055091514,0.00016703001,0.00011911483],"about_ca_topic_score_codex":0.000104316205,"about_ca_topic_score_gemma":0.00005626549,"teacher_disagreement_score":0.028919421,"about_ca_system_score_codex":0.00095479947,"about_ca_system_score_gemma":0.00095943315,"threshold_uncertainty_score":0.51778024},"labels":[],"label_agreement":null},{"id":"W4391303280","doi":"10.1200/jco.2024.42.4_suppl.tps356","title":"ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Window of opportunity; Oncology; Randomized controlled trial; Open label; Internal medicine; Cancer","score_opus":0.19313651286179898,"score_gpt":0.532625601221301,"score_spread":0.339489088359502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979739,0.00080538983,0.00013414619,0.012637491,0.00023375577,0.006375772,0.000014911048,0.000007802847,0.00005170599],"genre_scores_gemma":[0.99462277,0.0013587587,0.0014794655,0.001860519,0.0001264383,0.00048198126,0.000005142677,0.000020079522,0.00004482582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943714,0.0022154103,0.0025592977,0.00029610965,0.00032428867,0.00023348107],"domain_scores_gemma":[0.9900995,0.00796356,0.001018715,0.00017450248,0.00038342,0.00036031785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012806458,0.0001750173,0.0023452956,0.00027155108,0.000031367337,0.000020778903,0.00022515882,0.00017338117,0.000020881782],"category_scores_gemma":[0.006513081,0.00008521701,0.00007371185,0.000537306,0.00073990895,0.00022379139,0.00007500963,0.0007670814,2.5578152e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90446603,0.01637465,0.019407414,0.00039805286,0.0006975865,0.0008649533,0.0030430022,0.000057010933,0.006111344,0.00023208733,0.0008758532,0.04747201],"study_design_scores_gemma":[0.81318563,0.14957272,0.024525495,0.0016667433,0.00046388022,0.0001447631,0.0006947483,0.0011572107,0.0029329942,0.0037656247,0.0017189154,0.00017127347],"about_ca_topic_score_codex":0.00026813502,"about_ca_topic_score_gemma":0.0004587205,"teacher_disagreement_score":0.13319805,"about_ca_system_score_codex":0.00017829568,"about_ca_system_score_gemma":0.003118297,"threshold_uncertainty_score":0.77972364},"labels":[],"label_agreement":null},{"id":"W4391303281","doi":"10.1200/jco.2024.42.4_suppl.367","title":"Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; McGill University Health Centre; McMaster University; Université Laval; Centre Hospitalier de l’Université de Montréal; University of Calgary; Princess Margaret Cancer Centre; University of Manitoba; Ottawa Hospital; BC Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Toxicity; Oncology; Internal medicine; Metastatic melanoma; Performance status; Immunotherapy; Overall survival; Cancer","score_opus":0.0803915643702765,"score_gpt":0.39809327686299806,"score_spread":0.31770171249272156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592066,0.0028025846,0.0000048831776,0.00035031946,0.00013326031,0.00042097922,0.000015730055,0.0000029742057,0.00034862504],"genre_scores_gemma":[0.99371326,0.0049959137,0.0010899031,0.000017868408,0.00006980386,0.000003590264,0.000009163851,0.000014983036,0.000085522144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677825,0.00023652354,0.0022497827,0.00023216067,0.0003030102,0.00020028216],"domain_scores_gemma":[0.9965584,0.001681548,0.001126972,0.00013973888,0.00023504853,0.00025825395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007963622,0.00017919824,0.0015808372,0.00035184334,0.000019188978,0.000005154782,0.00004148912,0.00013012266,0.000020764986],"category_scores_gemma":[0.00034110338,0.00012338994,0.00016972894,0.00020358902,0.00025733377,0.00010404657,0.0000345076,0.00025916658,4.3808453e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009528138,0.0039430074,0.84254164,0.00079150015,0.0002648506,0.00025174604,0.00074581953,0.000039397382,0.0012810515,0.00001707456,0.000023716955,0.14057207],"study_design_scores_gemma":[0.01747461,0.08711676,0.8874668,0.0003251227,0.00085567025,0.00007392827,0.000057707934,0.00083706644,0.0054177702,0.000060043065,0.00024139605,0.00007311247],"about_ca_topic_score_codex":0.00069045776,"about_ca_topic_score_gemma":0.00066360243,"teacher_disagreement_score":0.14049897,"about_ca_system_score_codex":0.00024825401,"about_ca_system_score_gemma":0.00061098894,"threshold_uncertainty_score":0.5031696},"labels":[],"label_agreement":null},{"id":"W4391303315","doi":"10.1200/jco.2024.42.4_suppl.674","title":"Application of artificial intelligence (AI) features of nuclear morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Gemcitabine; Cystectomy; Bladder cancer; Nivolumab; Cisplatin; Oncology; Internal medicine; Clinical endpoint; Biomarker; Chemotherapy; Urology; Cancer; Immunotherapy; Clinical trial","score_opus":0.04359644702124354,"score_gpt":0.39548858770279194,"score_spread":0.3518921406815484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958009,0.0007456282,0.0016418938,0.00077230285,0.00041364893,0.00041368938,0.000030690928,0.000005012365,0.00017620111],"genre_scores_gemma":[0.9973817,0.0002601172,0.0018247069,0.00018704603,0.00030360755,0.000006481315,0.0000044865756,0.000020919018,0.0000109343555],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997141,0.0002170439,0.00193843,0.00022736612,0.00033157232,0.00014457568],"domain_scores_gemma":[0.9967709,0.0014837359,0.0011825219,0.0001371699,0.0003241308,0.00010150628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068869704,0.00013605246,0.0012445772,0.0002079987,0.000014949097,0.000005198459,0.000103186256,0.00029088507,0.00010070286],"category_scores_gemma":[0.00034119037,0.00009653323,0.0001764296,0.00023178369,0.00027816134,0.00008980774,0.000037035734,0.0005687026,0.0000010131927],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18019901,0.003909242,0.29209578,0.00037428323,0.0018585266,0.00013983426,0.00096485676,0.0002847556,0.0054899524,0.0005426162,0.00028495202,0.5138562],"study_design_scores_gemma":[0.06073707,0.05079271,0.8754547,0.0016793024,0.0019965663,0.000050763567,0.00053019956,0.0024759136,0.0022392438,0.0030958564,0.0006949274,0.00025271604],"about_ca_topic_score_codex":0.00066872046,"about_ca_topic_score_gemma":0.00058901764,"teacher_disagreement_score":0.58335894,"about_ca_system_score_codex":0.00009733246,"about_ca_system_score_gemma":0.00089361425,"threshold_uncertainty_score":0.39365107},"labels":[],"label_agreement":null},{"id":"W4391303316","doi":"10.1200/jco.2024.42.4_suppl.313","title":"EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Post-hoc analysis; Post hoc; Oncology; Internal medicine","score_opus":0.29736328481147134,"score_gpt":0.543237928412474,"score_spread":0.24587464360100264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824143,0.0020918625,0.000085115054,0.0066677686,0.0011493443,0.00020304612,0.000020497395,0.00001532291,0.0015255791],"genre_scores_gemma":[0.997408,0.0005262734,0.00031541457,0.00036633605,0.00040335636,0.0000034129364,0.000009136982,0.00001568717,0.00095243],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99576944,0.00043365,0.0024338483,0.00025661645,0.00084184046,0.00026459162],"domain_scores_gemma":[0.9953953,0.0018044983,0.0011441279,0.00026484046,0.00096822355,0.00042301498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036351006,0.00014513319,0.0020179125,0.00077844254,0.00003133092,0.000013738183,0.0001289432,0.000351757,0.00027559898],"category_scores_gemma":[0.0032075506,0.00008757421,0.0008924002,0.0010448489,0.00026271955,0.00012795886,0.00006273212,0.0011657858,0.0000110201],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015259553,0.002679426,0.30606118,0.00015062641,0.018514479,0.005187244,0.00032747842,0.00002393783,0.0038039319,0.000028967108,0.0022528807,0.6457103],"study_design_scores_gemma":[0.007166624,0.04825209,0.8905778,0.00012217388,0.015926335,0.0003163173,0.0003403171,0.0006863206,0.0007217436,0.000076012475,0.03564959,0.00016468643],"about_ca_topic_score_codex":0.000052509822,"about_ca_topic_score_gemma":0.000073376286,"teacher_disagreement_score":0.6455456,"about_ca_system_score_codex":0.00028190666,"about_ca_system_score_gemma":0.0026749827,"threshold_uncertainty_score":0.50648236},"labels":[],"label_agreement":null},{"id":"W4391303377","doi":"10.1200/jco.2024.42.4_suppl.600","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Javelin; Urothelial carcinoma; Body mass index; Avelumab; Internal medicine; Oncology; Urology; Bladder cancer; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.07156124318769336,"score_gpt":0.4065718662245334,"score_spread":0.33501062303684004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798133,0.0004112206,0.0012481775,0.011228801,0.005056739,0.0018608356,0.00016619473,0.000022114726,0.00019266928],"genre_scores_gemma":[0.992132,0.00030828934,0.0011817968,0.0025256437,0.0029894814,0.00009782307,0.000036761016,0.00006980459,0.0006583767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552524,0.00030060852,0.0025681711,0.00048968074,0.0006303206,0.0004860046],"domain_scores_gemma":[0.9940065,0.0039123595,0.00094056356,0.00038426006,0.00044398682,0.0003123162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012624573,0.00036337564,0.0019472485,0.00014469573,0.00007643205,0.000038318638,0.00035590693,0.00046173937,0.00031685625],"category_scores_gemma":[0.0016057071,0.0001897181,0.00068469916,0.00020297099,0.000246092,0.00018616264,0.000058625214,0.0012573864,0.000025483552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2221624,0.0025790276,0.70542544,0.0000480553,0.0012192914,0.00076980446,0.000112677044,0.00003470866,0.000009563884,0.000037796348,0.0017915842,0.06580969],"study_design_scores_gemma":[0.218188,0.029606156,0.7437297,0.00031917368,0.0008257958,0.000026863825,0.00003751431,0.00010832109,0.000033904285,0.0005119458,0.0064325174,0.0001800965],"about_ca_topic_score_codex":0.00019789262,"about_ca_topic_score_gemma":0.0005891941,"teacher_disagreement_score":0.065629594,"about_ca_system_score_codex":0.00045625903,"about_ca_system_score_gemma":0.0021288118,"threshold_uncertainty_score":0.773648},"labels":[],"label_agreement":null},{"id":"W4391303387","doi":"10.1200/jco.2024.42.4_suppl.78","title":"Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Radioligand; Glutamate carboxypeptidase II; Oncology; Internal medicine; Prostate; Circulating tumor cell; Prostate-specific antigen; Urology; Cancer; Metastasis; Receptor","score_opus":0.09463349629339564,"score_gpt":0.46919856485776784,"score_spread":0.3745650685643722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816904,0.0103315655,0.0000052596683,0.0045051994,0.00081644254,0.0024668316,0.00004390753,0.000024826457,0.00011554167],"genre_scores_gemma":[0.96686316,0.030876786,0.0006801877,0.00047471185,0.00041858098,0.0001553108,0.000021799468,0.000068015936,0.00044144315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943214,0.0008836935,0.002658261,0.0005596373,0.0010576457,0.0005193813],"domain_scores_gemma":[0.99615586,0.0014512351,0.0010202082,0.00030989054,0.0006183989,0.00044442996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003033525,0.00038430715,0.0020869595,0.00034070792,0.00006372213,0.0000766659,0.00018030708,0.00024483536,0.00011488391],"category_scores_gemma":[0.00013736135,0.0001735482,0.00039129253,0.00041768068,0.00045726923,0.00026102114,0.00002379028,0.0014792177,0.000014609042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12314913,0.0027687794,0.73951143,0.00014846143,0.0014812228,0.003636412,0.000523317,0.000027081014,0.000093205264,0.0000055317823,0.00033400516,0.12832141],"study_design_scores_gemma":[0.04011145,0.05318727,0.89322335,0.002533511,0.00016532971,0.00008871347,0.0001278456,0.000022272961,0.00021068804,0.000031096843,0.010084095,0.00021438395],"about_ca_topic_score_codex":0.000029212548,"about_ca_topic_score_gemma":0.00007509824,"teacher_disagreement_score":0.1537119,"about_ca_system_score_codex":0.0003960718,"about_ca_system_score_gemma":0.0030775885,"threshold_uncertainty_score":0.707709},"labels":[],"label_agreement":null},{"id":"W4391303394","doi":"10.1200/jco.2024.42.4_suppl.296","title":"Weight variation during androgen deprivation therapy in patients with localized prostate cancer: Data from two prospective randomized trials.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Cégep de l'Outaouais; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Randomized controlled trial; Androgen; Internal medicine; Cancer; Urology; Hormone","score_opus":0.13856799279096224,"score_gpt":0.49214647304898723,"score_spread":0.35357848025802496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879582,0.00545046,0.00019965213,0.0035966774,0.0008720595,0.0017646862,0.00005565254,0.000014404984,0.000088242174],"genre_scores_gemma":[0.9838056,0.013358406,0.0013279305,0.00013541021,0.0010857928,0.000050372815,0.0001161691,0.000022545912,0.00009775498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99532783,0.0015059735,0.0021713933,0.00031992284,0.00048633348,0.00018854534],"domain_scores_gemma":[0.99401575,0.0041504414,0.0010187865,0.0002313432,0.00042368256,0.00015999578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077235876,0.00013868813,0.0021620705,0.00019511806,0.000031873107,0.000031345688,0.0001552117,0.00016981424,0.00017995093],"category_scores_gemma":[0.003571239,0.00007027367,0.0002306014,0.0002748803,0.00014364616,0.0003298577,0.000053532654,0.000723017,0.000005257304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49786943,0.00068218954,0.43001655,0.000021702355,0.0017062128,0.00019770824,0.0003084449,0.000016208605,0.0000420892,0.000015994568,0.00014245379,0.06898099],"study_design_scores_gemma":[0.55280524,0.0030106667,0.43857214,0.00041189225,0.0005416677,0.000005651848,0.000014599712,0.0010319687,0.00021790012,0.0012060407,0.0021044142,0.00007781614],"about_ca_topic_score_codex":0.00020791923,"about_ca_topic_score_gemma":0.00008415917,"teacher_disagreement_score":0.06890318,"about_ca_system_score_codex":0.00041673073,"about_ca_system_score_gemma":0.0021239521,"threshold_uncertainty_score":0.4275365},"labels":[],"label_agreement":null},{"id":"W4391303403","doi":"10.1200/jco.2024.42.4_suppl.179","title":"The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Homologous recombination; Cancer; Oncology; Castration; Overall survival; Internal medicine; Gynecology; Hormone; Genetics; Gene; Biology","score_opus":0.11020932669797454,"score_gpt":0.47406908573934015,"score_spread":0.3638597590413656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754892,0.0012486049,0.00037230895,0.021352787,0.00012716552,0.0007643454,0.0000309421,0.000022783272,0.00059183623],"genre_scores_gemma":[0.9943156,0.0012443843,0.002320591,0.00020168483,0.00013341858,0.00020385032,0.00000620789,0.000023114775,0.0015511231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980363,0.00013691677,0.000903099,0.00028852833,0.00035613775,0.00027896694],"domain_scores_gemma":[0.99692136,0.0016104534,0.0005847173,0.0001388069,0.00048034792,0.00026430888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097635295,0.00019385769,0.0007954777,0.000040367868,0.00019296212,0.00006728505,0.00012740064,0.0000940471,0.000030282084],"category_scores_gemma":[0.0002442787,0.00008568263,0.00009249591,0.00023144232,0.0006715685,0.00014451338,0.000013845725,0.00047143042,4.046495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03999701,0.0023921675,0.81529385,0.00080813555,0.0040456364,0.00074213475,0.0026343423,0.0005437688,0.0032680302,0.0024598278,0.0014483954,0.12636667],"study_design_scores_gemma":[0.053337477,0.027934058,0.7172295,0.0019363476,0.009122865,0.0025681742,0.011573628,0.007525695,0.011248982,0.0008541423,0.15550022,0.0011689115],"about_ca_topic_score_codex":0.0000885517,"about_ca_topic_score_gemma":0.0005460165,"teacher_disagreement_score":0.15405181,"about_ca_system_score_codex":0.00018488384,"about_ca_system_score_gemma":0.0015378312,"threshold_uncertainty_score":0.34940362},"labels":[],"label_agreement":null},{"id":"W4391303450","doi":"10.1200/jco.2024.42.4_suppl.416","title":"Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; McMaster University; Ottawa Hospital; McGill University Health Centre; McGill University; University of Ottawa; Hôtel-Dieu de Québec; BC Cancer Agency; Sunnybrook Health Science Centre; Université Laval; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Immunotherapy; Nephrectomy; Internal medicine; Urology; Oncology; Database; Kidney; Cancer research; Cancer","score_opus":0.16167583484499456,"score_gpt":0.46841458877793224,"score_spread":0.3067387539329377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931545,0.003736623,0.000020182742,0.0017881412,0.00036813208,0.0002489002,0.0001278629,0.0000028910242,0.00055274996],"genre_scores_gemma":[0.99600625,0.0006283512,0.0028949487,0.0001403261,0.00023428797,0.0000023563941,0.000011806193,0.000017827924,0.00006381916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962409,0.0006413641,0.0023608918,0.00022540084,0.00036205843,0.00016935063],"domain_scores_gemma":[0.98707074,0.011127662,0.0011951241,0.0003036335,0.00016500983,0.00013783206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025542006,0.00017720302,0.0016372938,0.00019783882,0.0000153129,0.0000071913128,0.0001485516,0.00012359148,0.000058203328],"category_scores_gemma":[0.0015038926,0.00008662088,0.0006328387,0.00017857492,0.00025549298,0.00008895705,0.000044859094,0.0008387948,0.00000263018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06882569,0.006474628,0.76695913,0.00014422018,0.0050630323,0.004895347,0.0048664934,0.00016734832,0.030452896,0.000049060567,0.004902188,0.10719996],"study_design_scores_gemma":[0.011833569,0.018835098,0.9625654,0.00033721147,0.0006618947,0.00013506346,0.00028186868,0.0001669799,0.004359553,0.00018703232,0.00056376174,0.00007256644],"about_ca_topic_score_codex":0.0008250337,"about_ca_topic_score_gemma":0.000040151062,"teacher_disagreement_score":0.19560626,"about_ca_system_score_codex":0.00023957984,"about_ca_system_score_gemma":0.0012787824,"threshold_uncertainty_score":0.36441928},"labels":[],"label_agreement":null},{"id":"W4391303451","doi":"10.1200/jco.2024.42.4_suppl.701","title":"Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Medicine; Bladder cancer; Cystectomy; Gemcitabine; Cohort; tar (computing); Carcinoma in situ; Internal medicine; Urology; Cancer; Oncology; Surgery","score_opus":0.08216404500659064,"score_gpt":0.44272863594382383,"score_spread":0.3605645909372332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98877263,0.0006518974,0.0003954503,0.004452929,0.0016327812,0.0031045293,0.0009042772,0.000014889091,0.0000706143],"genre_scores_gemma":[0.9944876,0.00046937124,0.0018963924,0.0011277412,0.0014965214,0.0002954538,0.000023063692,0.000058040674,0.0001458056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99477506,0.00093709794,0.0026245792,0.0005885006,0.00064457505,0.00043021498],"domain_scores_gemma":[0.97987163,0.017007856,0.0012764923,0.00045458076,0.0010183573,0.00037111167],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030253867,0.00033913428,0.0022472974,0.00017126932,0.00008408867,0.000019779394,0.00033031884,0.00045360916,0.00016844412],"category_scores_gemma":[0.008356826,0.00017073737,0.00062857126,0.0003835403,0.00044920275,0.00013081527,0.00007971431,0.0011942051,0.000004177809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13359863,0.008196819,0.711267,0.00017769396,0.0051012044,0.0006112663,0.0015614408,0.000054557782,0.000040654177,0.000029714223,0.010616231,0.12874478],"study_design_scores_gemma":[0.0551818,0.081783965,0.8433683,0.0005611907,0.003501867,0.000024882052,0.0007687479,0.000087780805,0.000111305024,0.00040585978,0.01400312,0.00020119683],"about_ca_topic_score_codex":0.0029466958,"about_ca_topic_score_gemma":0.010660558,"teacher_disagreement_score":0.13210127,"about_ca_system_score_codex":0.00056036207,"about_ca_system_score_gemma":0.0061324774,"threshold_uncertainty_score":0.9999962},"labels":[],"label_agreement":null},{"id":"W4391303459","doi":"10.1200/jco.2024.42.4_suppl.529","title":"Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Atezolizumab; Oncology; Internal medicine; Proportional hazards model; Urinary system; Urology; Cancer; Immunotherapy","score_opus":0.06428930445296924,"score_gpt":0.4078801022914252,"score_spread":0.3435907978384559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522084,0.002504813,0.00009943596,0.00034206646,0.00030922098,0.00058560615,0.00009891564,0.000005095995,0.00083400443],"genre_scores_gemma":[0.99521875,0.0032457593,0.001113466,0.00008374042,0.00015432602,0.000017615097,0.000007971073,0.000024926056,0.00013345675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699074,0.00043202055,0.0018013718,0.00024609533,0.0003442259,0.00018553958],"domain_scores_gemma":[0.99480194,0.001952379,0.0019313889,0.0001925757,0.00097015913,0.00015156393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005306386,0.00018977924,0.001608788,0.00028394695,0.000017254373,0.000002825503,0.00011810448,0.00025300236,0.00017798154],"category_scores_gemma":[0.0003758646,0.00011776552,0.0002383489,0.0003965424,0.000435567,0.0001014687,0.000034686716,0.00074134534,0.00000441255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08529037,0.0036368533,0.80542374,0.0006912392,0.004041427,0.0022226488,0.0027838165,0.00216177,0.004522901,0.000032595726,0.000982975,0.08820966],"study_design_scores_gemma":[0.012430501,0.049324244,0.92939407,0.0023404954,0.0016584304,0.00028802833,0.00058020937,0.0005366659,0.0028485209,0.00008403177,0.00039703594,0.000117767275],"about_ca_topic_score_codex":0.00059241324,"about_ca_topic_score_gemma":0.00021420198,"teacher_disagreement_score":0.12397033,"about_ca_system_score_codex":0.00023097846,"about_ca_system_score_gemma":0.004643818,"threshold_uncertainty_score":0.82379335},"labels":[],"label_agreement":null},{"id":"W4391303478","doi":"10.1200/jco.2024.42.4_suppl.199","title":"Fragmentomics of cell-free DNA from targeted panels in genitourinary malignancies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Genitourinary system; Bladder cancer; Cohort; Internal medicine; Cell-free fetal DNA; Prostate; Renal cell carcinoma; Cancer research; Pathology; Biology; Genetics","score_opus":0.043691826396021205,"score_gpt":0.3690602101281196,"score_spread":0.3253683837320984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878169,0.0076687955,0.00043433753,0.00075780065,0.0021981753,0.00007500936,0.00008540831,0.0000022985744,0.0009613051],"genre_scores_gemma":[0.9871018,0.006801136,0.0037519578,0.00055560225,0.0016293835,0.0000021837386,0.000017924398,0.000019101848,0.000120900586],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977084,0.00015109917,0.0016000771,0.00020879578,0.0001511486,0.00018047636],"domain_scores_gemma":[0.9981608,0.00068899844,0.00059035484,0.00026879937,0.00014711723,0.00014392697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011050355,0.00011761762,0.0006249991,0.00008693452,0.000011029206,0.000011614518,0.00037728326,0.000427694,0.00005918421],"category_scores_gemma":[0.0012140841,0.00010210096,0.000354725,0.000094724885,0.000116451054,0.0000056589447,0.00020042573,0.00039569422,0.0000054885986],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002684788,0.0019768775,0.021269126,0.000108160384,0.0005421045,0.0015354673,0.00026873237,0.00059999,0.877104,0.000240601,0.049099833,0.044570353],"study_design_scores_gemma":[0.009746883,0.01520364,0.093922675,0.0002567032,0.00038149895,0.00013517663,0.00041607948,0.00054626155,0.31330454,0.009164266,0.55638576,0.00053653296],"about_ca_topic_score_codex":0.000058251866,"about_ca_topic_score_gemma":0.00007244496,"teacher_disagreement_score":0.56379944,"about_ca_system_score_codex":0.000052830877,"about_ca_system_score_gemma":0.0013314869,"threshold_uncertainty_score":0.41635564},"labels":[],"label_agreement":null},{"id":"W4391303528","doi":"10.1200/jco.2024.42.4_suppl.tps714","title":"MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cabozantinib; Medicine; Urothelial cancer; Chemotherapy; Metastatic Urothelial Carcinoma; Avelumab; Oncology; Cancer; Internal medicine; Urothelial carcinoma; Bladder cancer; Immunotherapy","score_opus":0.0465595784971834,"score_gpt":0.41487149972707943,"score_spread":0.36831192122989603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876595,0.0012572221,0.00062568305,0.005628707,0.0016230794,0.0027599137,0.00012894592,0.000014217041,0.0003027261],"genre_scores_gemma":[0.99020666,0.003029818,0.0024371936,0.0025731085,0.0009097209,0.00028846375,0.000007437543,0.00006104845,0.00048655577],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946003,0.0005685586,0.0033424231,0.00043879138,0.0006349638,0.00041499257],"domain_scores_gemma":[0.99472564,0.0028130687,0.0014876586,0.00025322166,0.0003853015,0.00033511655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002703415,0.0003654202,0.0036678165,0.00019370193,0.00003316897,0.000021988288,0.00015999856,0.0002751303,0.0006807232],"category_scores_gemma":[0.0011540838,0.00022273246,0.00059623626,0.00028229633,0.00055030105,0.00015025564,0.000024922405,0.00089654175,0.000005273486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9436985,0.006145613,0.0041314205,0.00019137983,0.0010826405,0.0007696874,0.00025168931,0.000035057426,0.00001090669,0.000016593009,0.0006320115,0.04303449],"study_design_scores_gemma":[0.9475146,0.03630811,0.00393223,0.0012395072,0.0013235759,0.00004186668,0.000021706137,0.000772733,0.00013671222,0.00012268788,0.008387585,0.00019866525],"about_ca_topic_score_codex":0.00018006343,"about_ca_topic_score_gemma":0.00044773516,"teacher_disagreement_score":0.042835824,"about_ca_system_score_codex":0.00022815198,"about_ca_system_score_gemma":0.0029085223,"threshold_uncertainty_score":0.9082766},"labels":[],"label_agreement":null},{"id":"W4391303529","doi":"10.1200/jco.2024.42.4_suppl.400","title":"Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Clinical endpoint; Cancer research; Immune checkpoint; Immunotherapy; Clinical trial; Cancer","score_opus":0.20245774741973144,"score_gpt":0.4760169792886244,"score_spread":0.27355923186889297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946704,0.00083329936,0.00009317547,0.00086614484,0.0012830334,0.001572298,0.000010988479,0.00002788604,0.0006427923],"genre_scores_gemma":[0.9937834,0.0000550565,0.004324993,0.00016114532,0.0011083521,0.00006446774,0.000024379375,0.00008402752,0.00039417672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914635,0.0016921094,0.004771711,0.00061919,0.0008862431,0.00056728075],"domain_scores_gemma":[0.99310327,0.0036864108,0.0016488058,0.00040969744,0.00055477145,0.0005970745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010750977,0.00043652076,0.0027683603,0.0005350949,0.000052993233,0.000049844683,0.00026222682,0.00026708425,0.00012854322],"category_scores_gemma":[0.0016205638,0.00027624748,0.00087766326,0.00033653624,0.00019978303,0.00028728956,0.000094756935,0.0015350399,0.000017799404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12037703,0.03680755,0.51307255,0.0014063086,0.005061791,0.062061343,0.0069247875,0.00087673374,0.050681304,0.000056636076,0.00075501355,0.20191896],"study_design_scores_gemma":[0.05198651,0.21578486,0.7066022,0.0006972115,0.0038145601,0.001029924,0.0019811161,0.0048306403,0.011976174,0.000255329,0.0006160544,0.00042538578],"about_ca_topic_score_codex":0.00024086332,"about_ca_topic_score_gemma":0.0003318267,"teacher_disagreement_score":0.20149358,"about_ca_system_score_codex":0.0008743214,"about_ca_system_score_gemma":0.0025283543,"threshold_uncertainty_score":0.99996895},"labels":[],"label_agreement":null},{"id":"W4391303561","doi":"10.1200/jco.2024.42.4_suppl.2","title":"First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Clear cell; Phases of clinical research; Cancer research; Cancer; Clinical trial; Immunotherapy","score_opus":0.1359062445362326,"score_gpt":0.4478767421619031,"score_spread":0.31197049762567053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98531705,0.0014274201,0.00054862874,0.0051281736,0.0036680335,0.001613639,0.000028570117,0.000020865387,0.002247634],"genre_scores_gemma":[0.9914349,0.00022604462,0.0016003429,0.00048509636,0.00201179,0.00003666688,0.0000063048415,0.00006872796,0.0041301264],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9938226,0.0005049829,0.0038989955,0.00047763053,0.0008425451,0.00045328835],"domain_scores_gemma":[0.99219996,0.004152087,0.0018200423,0.00063297356,0.0007204982,0.00047444546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033048105,0.00035639488,0.0024582047,0.00023544129,0.000111562375,0.000022948976,0.0004734709,0.00044948037,0.0001927229],"category_scores_gemma":[0.0022336405,0.00020541038,0.0020433478,0.0003391162,0.0003105201,0.000115201634,0.00017074782,0.0014263625,0.000021649503],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42011288,0.07020184,0.05125053,0.0036497132,0.011830853,0.01999427,0.0082177175,0.001122422,0.01822382,0.00052063435,0.08701813,0.30785722],"study_design_scores_gemma":[0.280255,0.35295904,0.19733912,0.0012441212,0.011601324,0.0018743185,0.0013656572,0.0103797335,0.011179338,0.0011520204,0.12997402,0.000676314],"about_ca_topic_score_codex":0.00004730579,"about_ca_topic_score_gemma":0.00009969868,"teacher_disagreement_score":0.30718088,"about_ca_system_score_codex":0.00051823515,"about_ca_system_score_gemma":0.0036310605,"threshold_uncertainty_score":0.8376392},"labels":[],"label_agreement":null},{"id":"W4391303586","doi":"10.1200/jco.2024.42.4_suppl.tps719","title":"Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Bladder cancer; Cohort; Bacillus (shape); Oncology; Internal medicine; Urology; Cancer; Immunotherapy; Microbiology","score_opus":0.049694772448061,"score_gpt":0.426308802879533,"score_spread":0.376614030431472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868783,0.0008507188,0.0022239094,0.0038226866,0.0024531386,0.002223048,0.0007404507,0.000053839114,0.00075391424],"genre_scores_gemma":[0.9863877,0.002516281,0.004400331,0.0029860195,0.002296403,0.00024338358,0.000063968546,0.00015420152,0.0009516875],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9945554,0.00044871308,0.0024091392,0.0007946168,0.0010293252,0.0007627803],"domain_scores_gemma":[0.9905536,0.0046409606,0.0015884929,0.00047172516,0.0018591307,0.00088605663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012086527,0.0005974932,0.002800344,0.0003973124,0.00016799134,0.00005775676,0.00030323552,0.00061041943,0.0006901148],"category_scores_gemma":[0.0019543406,0.00032818518,0.00070618844,0.0004969759,0.0004884807,0.0003263544,0.000071037626,0.0015978009,0.000043588832],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2973897,0.010099054,0.12176123,0.00038923064,0.012718891,0.007156838,0.0006690913,0.00011898926,0.00007533628,0.000043919998,0.016353799,0.5332239],"study_design_scores_gemma":[0.1744562,0.2945626,0.39991465,0.0013706397,0.013962609,0.00089593173,0.0002905723,0.0002446791,0.00041501233,0.00016225466,0.112950034,0.000774802],"about_ca_topic_score_codex":0.00044923235,"about_ca_topic_score_gemma":0.0008539402,"teacher_disagreement_score":0.5324491,"about_ca_system_score_codex":0.0008618985,"about_ca_system_score_gemma":0.010508571,"threshold_uncertainty_score":0.99991703},"labels":[],"label_agreement":null},{"id":"W4391303614","doi":"10.1200/jco.2024.42.4_suppl.294","title":"Influential factors impacting treatment (tx) decision making (TDM) and decision regret (DR) in patients (pts) with localized or locally advanced prostate cancer (LPC/LAPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Regret; Prostate cancer; Prostatectomy; Family medicine; Gynecology; Internal medicine; Cancer","score_opus":0.3930220746293773,"score_gpt":0.5729655051690452,"score_spread":0.17994343053966788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98747045,0.002827419,0.003183565,0.0030834747,0.002567029,0.00064573355,0.00006329652,0.000015980657,0.00014305944],"genre_scores_gemma":[0.98355466,0.0020230727,0.012212204,0.0016578363,0.00040274652,0.000022563267,0.0000041950843,0.00004352738,0.00007918471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890921,0.00047320663,0.009231784,0.00055117236,0.00022332228,0.0004283793],"domain_scores_gemma":[0.9832063,0.010878088,0.0051247748,0.00024037305,0.00020177155,0.00034871243],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014126179,0.00027354815,0.0024371303,0.00053384464,0.00009934857,0.00010853926,0.00020392858,0.00038091576,0.00022638778],"category_scores_gemma":[0.0111067295,0.00019750884,0.00024568848,0.0002885042,0.00012663574,0.00078169606,0.00006799046,0.0006222648,0.000045535562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006454446,0.0004877572,0.5877194,0.00010014648,0.00021908457,0.000073516676,0.0010402998,0.0020710991,3.6169666e-7,0.00022720851,0.0010164502,0.40059024],"study_design_scores_gemma":[0.03375319,0.021979101,0.77788526,0.0046795453,0.00014022828,0.00007667371,0.0012453749,0.01349764,0.0000041257763,0.012194803,0.1337935,0.0007505289],"about_ca_topic_score_codex":0.00022314063,"about_ca_topic_score_gemma":0.0014163859,"teacher_disagreement_score":0.3998397,"about_ca_system_score_codex":0.0018575917,"about_ca_system_score_gemma":0.0017248485,"threshold_uncertainty_score":0.99722314},"labels":[],"label_agreement":null},{"id":"W4391303641","doi":"10.1200/jco.2024.42.4_suppl.90","title":"Trends in local therapy utilization and survival of patients with de-novo metastatic prostate cancer treated by hormone therapy with or without systemic therapy intensification with chemotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Systemic therapy; Prostate cancer; Oncology; Chemotherapy; Hormone therapy; Internal medicine; Hormonal therapy; Cancer; Overall survival; Breast cancer","score_opus":0.13566366543201502,"score_gpt":0.46693036480939226,"score_spread":0.33126669937737724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98207533,0.014824117,0.00042865434,0.0017860861,0.00006882418,0.0007396743,0.000020708065,0.00001523976,0.000041368556],"genre_scores_gemma":[0.93721145,0.06177475,0.00025802653,0.0002314675,0.000061827195,0.00004883114,0.000035001678,0.000047449037,0.0003311959],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975157,0.000406788,0.0010467517,0.0002850767,0.00048169948,0.00026400844],"domain_scores_gemma":[0.99784267,0.00041937234,0.0006612022,0.00015067027,0.0007347345,0.00019135108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011835666,0.00023304379,0.0012628834,0.0003090738,0.000027783302,0.00002136469,0.00008601646,0.0001535579,0.000050191997],"category_scores_gemma":[0.000034187462,0.0000994983,0.00008222377,0.00065205985,0.00046075485,0.00016677921,0.00000631963,0.0004931552,3.135038e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12805071,0.0013389308,0.41860777,0.000045664874,0.0010390884,0.00011843778,0.0008401846,0.000009547804,0.00046298458,0.0000028004595,0.00010881329,0.44937506],"study_design_scores_gemma":[0.0964084,0.10516739,0.7884602,0.0010653214,0.00029447637,0.0002754618,0.0008092172,0.0011310419,0.0018046233,0.00001926805,0.0043078484,0.00025676988],"about_ca_topic_score_codex":0.00013552903,"about_ca_topic_score_gemma":0.00014701592,"teacher_disagreement_score":0.4491183,"about_ca_system_score_codex":0.00027202294,"about_ca_system_score_gemma":0.0014631042,"threshold_uncertainty_score":0.4057423},"labels":[],"label_agreement":null},{"id":"W4391303668","doi":"10.1200/jco.2024.42.4_suppl.76","title":"Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of the Fraser Valley; University of Alberta; Abbotsford Veterinary Clinic; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Clinical trial; Cancer; Internal medicine; Standard of care","score_opus":0.38987340184040364,"score_gpt":0.6506472274266518,"score_spread":0.2607738255862482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577575,0.03638462,0.000010675842,0.0037621886,0.0010498075,0.0008457137,0.00014999065,0.0000052459004,0.000034269146],"genre_scores_gemma":[0.9121394,0.0858457,0.0012533886,0.00014301226,0.0005176832,0.000016549537,0.000007556754,0.000018858502,0.000057838075],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99238795,0.0023195927,0.004338869,0.00025820863,0.00044709712,0.00024828565],"domain_scores_gemma":[0.99280226,0.0046860906,0.0011009304,0.00018037244,0.00068555435,0.0005447771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014736923,0.00016119755,0.0033006964,0.00025222122,0.000014678456,0.000015324504,0.00013219602,0.00021226707,0.0002684523],"category_scores_gemma":[0.0050591193,0.000077343575,0.0007006569,0.00033536844,0.00025117688,0.00012787717,0.000042508258,0.0009257318,0.0000014809256],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12301365,0.0010827613,0.15264262,0.00019511298,0.0011781296,0.0006459857,0.000874902,0.0000167892,0.00009430927,0.000011517398,0.0012967761,0.7189474],"study_design_scores_gemma":[0.03963293,0.48229474,0.44591886,0.0018772349,0.00095561217,0.00012120565,0.0010493592,0.00006224896,0.00039331484,0.00046721165,0.02705857,0.00016871434],"about_ca_topic_score_codex":0.000048061458,"about_ca_topic_score_gemma":0.00017080993,"teacher_disagreement_score":0.7187787,"about_ca_system_score_codex":0.00023994785,"about_ca_system_score_gemma":0.007937187,"threshold_uncertainty_score":0.99768686},"labels":[],"label_agreement":null},{"id":"W4391303701","doi":"10.1200/jco.2024.42.4_suppl.165","title":"Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Abiraterone; Homologous recombination; PARP inhibitor; Internal medicine; Oncology; Enzalutamide; Placebo; Cancer research; Gene; Urology; Cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics; Pathology; Polymerase; Biology","score_opus":0.14794484308262323,"score_gpt":0.44795023381165994,"score_spread":0.3000053907290367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252397,0.00046849073,0.00009442367,0.0035109478,0.0008882321,0.0021156117,0.000020387432,0.000018280616,0.000359662],"genre_scores_gemma":[0.996186,0.000158537,0.0028734047,0.0002558426,0.00018784768,0.00018641396,0.000022139333,0.000029003895,0.00010077754],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99537283,0.0010229992,0.0024230375,0.00029703972,0.0006320259,0.0002520692],"domain_scores_gemma":[0.9950094,0.0026853366,0.0014069286,0.00022071465,0.0005613702,0.000116238094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032198115,0.0001918283,0.0011345218,0.00033277847,0.000041696596,0.000025540592,0.00014229494,0.00015667849,0.000048283677],"category_scores_gemma":[0.0010729758,0.000109839784,0.00018139138,0.0006643536,0.00032794473,0.00022027463,0.000014372778,0.0009043236,0.0000032693185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94289243,0.008311389,0.0033662987,0.00025774082,0.0010866948,0.0017683847,0.0047555594,0.0062168795,0.0005462296,0.00013732458,0.0006730068,0.029988049],"study_design_scores_gemma":[0.7394571,0.15372261,0.0971169,0.0018325989,0.0013570184,0.00026069765,0.0012536534,0.0014924739,0.0006296258,0.00026870592,0.0022891974,0.00031944326],"about_ca_topic_score_codex":0.00017427802,"about_ca_topic_score_gemma":0.0015258013,"teacher_disagreement_score":0.20343538,"about_ca_system_score_codex":0.0012398585,"about_ca_system_score_gemma":0.0047722785,"threshold_uncertainty_score":0.8465817},"labels":[],"label_agreement":null},{"id":"W4391303703","doi":"10.1200/jco.2024.42.4_suppl.31","title":"Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Jewish General Hospital; Hôpital Fleurimont; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Positron emission tomography; Pet imaging; Internal medicine; Radiology","score_opus":0.12331357639596299,"score_gpt":0.5106027960481183,"score_spread":0.38728921965215535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782883,0.008619403,0.00000866925,0.011290474,0.0006645737,0.00044832256,0.00003005087,0.0000076260303,0.00064261275],"genre_scores_gemma":[0.99261814,0.0051455675,0.001195084,0.00029113746,0.00021335288,0.000020538177,0.0000050752383,0.000019352126,0.0004917629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970907,0.0002970103,0.0017243982,0.00022424376,0.00040234847,0.00026127958],"domain_scores_gemma":[0.9970428,0.0018667757,0.0004824587,0.00010475478,0.00025823608,0.00024499238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025282486,0.00013804874,0.0009317988,0.00028179874,0.000025226056,0.00002327254,0.00007560248,0.00004367022,0.00006938531],"category_scores_gemma":[0.0011499464,0.00008615909,0.00018439724,0.00023495093,0.00027303013,0.0001339138,0.000028740971,0.0007729151,0.000005160133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025408316,0.0034045458,0.26246065,0.0018057454,0.0016723681,0.052624878,0.0016875976,0.00034023222,0.0073704654,0.0017072071,0.002833631,0.63868433],"study_design_scores_gemma":[0.018578328,0.020158129,0.9226952,0.0038811592,0.0014110169,0.0016368369,0.0008931334,0.0045602145,0.0007476166,0.0034820046,0.021712659,0.00024366115],"about_ca_topic_score_codex":0.000105173385,"about_ca_topic_score_gemma":0.00013618341,"teacher_disagreement_score":0.6602346,"about_ca_system_score_codex":0.0001947629,"about_ca_system_score_gemma":0.0029294977,"threshold_uncertainty_score":0.5196803},"labels":[],"label_agreement":null},{"id":"W4391303712","doi":"10.1200/jco.2024.42.4_suppl.50","title":"Survival and fracture risk with radium-223 therapy in metastatic castrate-resistant prostate cancer (mCRPC): A real-world analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Radium-223; Internal medicine; Prostate; Bone metastasis","score_opus":0.12100971359601917,"score_gpt":0.5166939524884578,"score_spread":0.39568423889243864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98016423,0.00354055,0.00012592509,0.014419865,0.00012879053,0.0002299377,0.000025820898,0.000012333907,0.0013525481],"genre_scores_gemma":[0.98422253,0.013201457,0.0010620945,0.0005813013,0.00041055892,0.000016611297,0.000004555041,0.000014946937,0.00048593755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759114,0.00030490753,0.0013701066,0.0002547974,0.0002697713,0.00020925957],"domain_scores_gemma":[0.99681073,0.001954996,0.00056183594,0.00014128463,0.00014748579,0.00038369175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002187947,0.00015160601,0.001302522,0.00017360951,0.000034325814,0.000026061614,0.000086449305,0.00012660597,0.00019374255],"category_scores_gemma":[0.00022994618,0.00008772075,0.0002717003,0.00081852375,0.00024665648,0.000078318764,0.0000110234805,0.0015039593,0.0000022896202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042040613,0.005614173,0.70176446,0.0005410727,0.020874029,0.012627721,0.000918737,0.003147164,0.006200915,0.0007694558,0.004204042,0.20129763],"study_design_scores_gemma":[0.012080963,0.0047601084,0.82168686,0.0002477847,0.0067720623,0.0002732059,0.00026720698,0.0031339691,0.0008629013,0.0007687603,0.14889829,0.00024790148],"about_ca_topic_score_codex":0.0002921051,"about_ca_topic_score_gemma":0.0010184742,"teacher_disagreement_score":0.20104972,"about_ca_system_score_codex":0.00011457914,"about_ca_system_score_gemma":0.0011777985,"threshold_uncertainty_score":0.6534038},"labels":[],"label_agreement":null},{"id":"W4391303714","doi":"10.1200/jco.2024.42.4_suppl.280","title":"Association between artificial intelligence–derived tumor volume and oncologic outcomes in localized prostate cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Prostate; Volume (thermodynamics); Internal medicine","score_opus":0.14270486388965267,"score_gpt":0.4842449739684548,"score_spread":0.34154011007880214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94192445,0.0027839981,0.00007039401,0.053147685,0.0014977402,0.00036232529,0.000020571217,0.000016178126,0.00017664362],"genre_scores_gemma":[0.99114925,0.0056623193,0.00079386757,0.0012372863,0.00079472427,0.000033314853,0.000003888898,0.000014116802,0.00031123922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967635,0.0003113723,0.0021561298,0.000230066,0.0002860508,0.00025286627],"domain_scores_gemma":[0.99598545,0.0026170164,0.0008621382,0.00007782819,0.00020861278,0.00024895472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002843031,0.00014224864,0.0015694565,0.00015369622,0.000026189045,0.000030268655,0.000068521906,0.00025945244,0.00014570147],"category_scores_gemma":[0.0022043637,0.000093276925,0.00028619968,0.00018786454,0.00011540486,0.00011453961,0.0000398675,0.0008252812,0.000020265703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057689135,0.0005157371,0.67099565,0.000041706913,0.00055372715,0.0009142014,0.00014884537,0.000012805797,0.000019851708,0.000045060682,0.0008460219,0.3253295],"study_design_scores_gemma":[0.0024087094,0.011637526,0.9395552,0.00038274232,0.0009566011,0.000040601073,0.00019783844,0.00046992933,0.00026175738,0.0041252077,0.03984097,0.00012287888],"about_ca_topic_score_codex":0.00010552889,"about_ca_topic_score_gemma":0.0002263503,"teacher_disagreement_score":0.32520664,"about_ca_system_score_codex":0.0011232853,"about_ca_system_score_gemma":0.0016406897,"threshold_uncertainty_score":0.38037226},"labels":[],"label_agreement":null},{"id":"W4391303716","doi":"10.1200/jco.2024.42.4_suppl.287","title":"Detection and delineation of intraprostatic lesions (IPLs) using multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen positron emission tomography (PSMA PET) for patients with prostate cancer: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Magnetic resonance imaging; Positron emission tomography; Nuclear medicine; Meta-analysis; Prostate; Radiation therapy; Radiology; Histopathology; Cancer; Receiver operating characteristic; Internal medicine; Pathology","score_opus":0.1506478707525152,"score_gpt":0.4812907334608733,"score_spread":0.3306428627083581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009088261,0.9837944,0.00012602367,0.0002896837,0.00009508331,0.0064368397,0.00016018792,0.000007999458,0.0000015430282],"genre_scores_gemma":[0.002796787,0.9936267,0.0030027237,0.000064418935,0.00005994443,0.00023381907,0.000039282324,0.000051130864,0.000125173],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9939688,0.000843611,0.0038009405,0.0005634255,0.000515397,0.00030786602],"domain_scores_gemma":[0.993284,0.001687109,0.003353446,0.0002510488,0.001085176,0.000339246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003077622,0.00045073018,0.009130111,0.0011641679,0.000102845544,0.00004900212,0.00010016547,0.00019200315,0.000007579096],"category_scores_gemma":[0.0009279189,0.0002315764,0.0012425991,0.0014610492,0.00030849883,0.00015612521,0.000069277834,0.00075647444,2.2056683e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001738163,0.0004915394,0.0021931904,0.5431887,0.02511491,0.000122069716,0.00009022184,0.000001955289,0.0000070372416,9.725354e-7,0.00003938013,0.42701185],"study_design_scores_gemma":[0.004499283,0.007080706,0.0013847714,0.0818619,0.89272475,0.0004005294,0.00004005997,0.0008250992,0.0000061463447,0.00001662161,0.010835968,0.00032414912],"about_ca_topic_score_codex":0.000025510999,"about_ca_topic_score_gemma":0.0000125180195,"teacher_disagreement_score":0.86760986,"about_ca_system_score_codex":0.00019008797,"about_ca_system_score_gemma":0.0008070454,"threshold_uncertainty_score":0.9443411},"labels":[],"label_agreement":null},{"id":"W4391303726","doi":"10.1200/jco.2024.42.4_suppl.59","title":"A real-world observational study characterizing patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with or without androgen receptor pathway inhibitors (ARPIs).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary; University of Alberta","funders":"AstraZeneca Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Docetaxel; Logistic regression; Cohort; Cancer; Referral; Oncology; Retrospective cohort study; Family medicine","score_opus":0.20658985672378094,"score_gpt":0.47709178138388847,"score_spread":0.27050192466010753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948132,0.00013522657,0.000005554897,0.0026467333,0.00044323574,0.0015484764,0.000083993415,0.000030362347,0.00029323596],"genre_scores_gemma":[0.99354494,0.000556198,0.0012702178,0.00030695234,0.00068459567,0.000109530905,0.00008594181,0.000053021962,0.0033885974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625164,0.00052037055,0.001649626,0.00039268695,0.0008340908,0.000351588],"domain_scores_gemma":[0.9961361,0.001026972,0.00093568687,0.00015170268,0.0013300783,0.0004194036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00145306,0.00027392016,0.0014376647,0.00028870263,0.000098312885,0.000059684884,0.00008582233,0.00010769181,0.00015990812],"category_scores_gemma":[0.00027674434,0.00013412804,0.00017218376,0.0006582103,0.00023965581,0.00039061636,0.000030381196,0.0008878649,0.000012988936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04403533,0.0034416523,0.8981788,0.00012253757,0.0030224083,0.005161842,0.0013056422,0.000009329063,0.0003971929,0.000008018755,0.00060689653,0.043710344],"study_design_scores_gemma":[0.034439575,0.08839498,0.8553559,0.0018938471,0.002054645,0.00037077593,0.0015685465,0.00023209918,0.0017501671,0.0000122910205,0.013580539,0.00034659755],"about_ca_topic_score_codex":0.00030499627,"about_ca_topic_score_gemma":0.0016985629,"teacher_disagreement_score":0.08495332,"about_ca_system_score_codex":0.00062582054,"about_ca_system_score_gemma":0.0055611203,"threshold_uncertainty_score":0.98651886},"labels":[],"label_agreement":null},{"id":"W4391303738","doi":"10.1200/jco.2024.42.4_suppl.69","title":"Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Ottawa Hospital; University of Ottawa; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cohort; Internal medicine; Population; Cancer; Gynecology","score_opus":0.371127075384124,"score_gpt":0.5450453315106891,"score_spread":0.17391825612656514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98125,0.00028220983,0.0072246855,0.00863021,0.000616246,0.0018871137,0.000020898873,0.000011866587,0.00007680726],"genre_scores_gemma":[0.99698377,0.00032286346,0.0018393351,0.00018205642,0.00029688355,0.0001502891,0.00003144486,0.000016188185,0.00017715125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977924,0.0003456786,0.001213783,0.00020686397,0.00025049766,0.00019075722],"domain_scores_gemma":[0.9967062,0.0022628915,0.000414777,0.00008423292,0.0003916025,0.00014032096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027606718,0.000110236746,0.000723643,0.0002809112,0.000045156357,0.000027273809,0.00003308253,0.00010126302,0.000022180166],"category_scores_gemma":[0.0009343766,0.00007412114,0.0001975832,0.0002396867,0.0000457879,0.000113307404,0.0000049341024,0.00029305022,0.0000017730433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009034711,0.002619348,0.9575928,0.00011265025,0.0014673182,0.0010925931,0.0019576496,0.0014287282,0.00037878085,0.00043511757,0.00013859571,0.023741705],"study_design_scores_gemma":[0.011089224,0.011765975,0.9545022,0.0002455018,0.0010806615,0.00006957155,0.0010832517,0.018510964,0.000081613245,0.0011842281,0.00030900483,0.0000777807],"about_ca_topic_score_codex":0.0004331944,"about_ca_topic_score_gemma":0.0011868133,"teacher_disagreement_score":0.023663925,"about_ca_system_score_codex":0.003520836,"about_ca_system_score_gemma":0.0038047621,"threshold_uncertainty_score":0.9206863},"labels":[],"label_agreement":null},{"id":"W4391303761","doi":"10.1200/jco.2024.42.4_suppl.166","title":"Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Placebo; Oncology; Internal medicine; Prostate cancer; Chemotherapy; Cancer; Pathology","score_opus":0.1025656710349568,"score_gpt":0.44005449297768734,"score_spread":0.33748882194273055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987466,0.00153214,0.0016079933,0.0062086736,0.0001610401,0.00052504375,0.000014352233,0.0000125303695,0.000063591724],"genre_scores_gemma":[0.99419504,0.0037425207,0.0012815765,0.0003417723,0.00033210448,0.000012913744,0.000035135294,0.000018330302,0.000040603838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979764,0.00039058464,0.000790523,0.00026352308,0.000374373,0.00020459041],"domain_scores_gemma":[0.9957418,0.0032229724,0.0004384524,0.000114106515,0.00034704106,0.00013563967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033989171,0.00013919664,0.0010263145,0.00029639865,0.000042286643,0.000045715657,0.000042221836,0.00017655767,0.000016179862],"category_scores_gemma":[0.000279325,0.00007785652,0.00019809495,0.000355462,0.00012854565,0.00019795573,0.000013416934,0.0005349731,5.8170957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06758786,0.0011559414,0.8541718,0.000033905588,0.0041987156,0.0012416532,0.00036906818,0.00018820676,0.0009942995,0.00009245509,0.00007296047,0.06989312],"study_design_scores_gemma":[0.040414426,0.013191959,0.9317584,0.00019263466,0.00078919675,0.00010246593,0.00014489476,0.008761946,0.000651868,0.0006164925,0.0032425881,0.0001331146],"about_ca_topic_score_codex":0.0001671224,"about_ca_topic_score_gemma":0.0006314019,"teacher_disagreement_score":0.0775866,"about_ca_system_score_codex":0.00021075922,"about_ca_system_score_gemma":0.00094869355,"threshold_uncertainty_score":0.31748968},"labels":[],"label_agreement":null},{"id":"W4391333672","doi":"10.1200/jco.2024.42.4_suppl.308","title":"Prostate Cancer Supportive Care (PCSC) Program: A model for meeting an unmet need for patients with PC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Prostate Cancer Canada; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Internal medicine; Intensive care medicine; Family medicine","score_opus":0.3825510620887835,"score_gpt":0.6723473763992209,"score_spread":0.28979631431043745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391333672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958481,0.0012518142,0.0019310003,0.022505412,0.0064919284,0.007592358,0.00047660782,0.00007819891,0.0011916641],"genre_scores_gemma":[0.96774334,0.00020608472,0.025722556,0.0018636952,0.0025548432,0.001063725,0.000036326128,0.0000619216,0.0007475105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943266,0.0015356872,0.0030004727,0.00029112538,0.0002991179,0.0005469816],"domain_scores_gemma":[0.9852456,0.008784024,0.0027224235,0.00013922356,0.0026293113,0.00047940965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074918745,0.00016203999,0.0011248448,0.000106330685,0.00031311502,0.000023192655,0.00016862339,0.0005279054,0.000029926741],"category_scores_gemma":[0.004097724,0.0000988461,0.00026632872,0.00013522051,0.000068312605,0.00045017814,0.00003354875,0.0013414262,0.000003787848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013664423,0.0010824018,0.18574297,0.003801174,0.0005459411,0.000038002483,0.02401698,0.00027579023,0.0000032145506,0.00062336377,0.016998846,0.7532069],"study_design_scores_gemma":[0.008881575,0.039832275,0.012191239,0.001876381,0.000497805,0.000004902028,0.012800475,0.02146943,0.000001269358,0.0008533801,0.9013354,0.00025583315],"about_ca_topic_score_codex":0.00021795601,"about_ca_topic_score_gemma":0.0021340384,"teacher_disagreement_score":0.8843366,"about_ca_system_score_codex":0.00032417805,"about_ca_system_score_gemma":0.009623357,"threshold_uncertainty_score":0.9959912},"labels":[],"label_agreement":null},{"id":"W4391333733","doi":"10.1200/jco.2024.42.4_suppl.617","title":"Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Urothelial carcinoma; Cohort; Oncology; Solid tumor; Internal medicine; Targeted therapy; Carcinoma; Urothelial cancer; Cancer; Bladder cancer","score_opus":0.061673013247210036,"score_gpt":0.40888773095158637,"score_spread":0.34721471770437634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391333733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020064,0.00036813656,0.000020488003,0.0072303344,0.00043907078,0.0011467017,0.000026479544,0.000011052277,0.0005570942],"genre_scores_gemma":[0.9962755,0.00044424637,0.0004035093,0.0022734022,0.00045218293,0.000039041468,0.000020128004,0.00003095166,0.00006103857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651384,0.0006739293,0.0015782099,0.00031534678,0.0006719758,0.00024670898],"domain_scores_gemma":[0.9962342,0.002427175,0.00065880443,0.00031451604,0.00025733263,0.000107983156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019507933,0.00021258269,0.0010429773,0.00010543937,0.000051069717,0.00003339327,0.00024317195,0.00018206179,0.000028452],"category_scores_gemma":[0.00051638455,0.00007864459,0.00014312645,0.00034092186,0.00020049285,0.00019054282,0.000023295572,0.0011036693,0.0000061419605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11610721,0.0033199717,0.8032315,0.000009982268,0.00025215323,0.00087479554,0.0021930854,0.000033638975,0.000017383054,0.000015425669,0.00026433915,0.07368054],"study_design_scores_gemma":[0.05559227,0.04312542,0.8981054,0.000555273,0.00019849338,0.00006788095,0.00043668682,0.00012465012,0.00004179261,0.00014297907,0.0015112666,0.00009791428],"about_ca_topic_score_codex":0.00035014906,"about_ca_topic_score_gemma":0.0006671235,"teacher_disagreement_score":0.094873905,"about_ca_system_score_codex":0.0002218686,"about_ca_system_score_gemma":0.0019673542,"threshold_uncertainty_score":0.47949556},"labels":[],"label_agreement":null},{"id":"W4391333745","doi":"10.1200/jco.2024.42.4_suppl.509","title":"North American patterns of care in clinical stage I testicular cancer from SWOG S1823.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Testicular cancer; Oncology; Cancer; Stage (stratigraphy); Internal medicine; Gynecology","score_opus":0.08731779590181986,"score_gpt":0.5104595847796042,"score_spread":0.4231417888777843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391333745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888822,0.008204614,0.00007067455,0.0011478767,0.0012312934,0.00017163898,0.00015801989,0.0000122205165,0.00012148202],"genre_scores_gemma":[0.99439657,0.0023855884,0.0012859767,0.00078229053,0.0010547203,0.000005292778,0.000020141755,0.00002319305,0.000046243316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607164,0.00037730532,0.002720124,0.0002726209,0.00036020123,0.00019813687],"domain_scores_gemma":[0.99499613,0.0028668153,0.0011857917,0.00023183723,0.00024763358,0.0004718204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064466335,0.00015289253,0.0017671839,0.00012222791,0.000011490148,0.000008362607,0.00013902811,0.00017219328,0.00016464626],"category_scores_gemma":[0.0022385588,0.00010324426,0.00081431604,0.00022141877,0.00021831786,0.00005836968,0.00005494186,0.00091792474,0.00001232631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010459633,0.0013477925,0.74851984,0.00009276876,0.00061491935,0.0059227073,0.000070450405,0.000032911707,0.0000026440434,0.000009271665,0.00013598225,0.24220474],"study_design_scores_gemma":[0.0044248034,0.010598728,0.97128797,0.0005541666,0.0013110423,0.0000308748,0.00019595992,0.00017625223,0.0000069009225,0.00003134107,0.0112980185,0.000083923864],"about_ca_topic_score_codex":0.0011593963,"about_ca_topic_score_gemma":0.0036459363,"teacher_disagreement_score":0.24212082,"about_ca_system_score_codex":0.00018425776,"about_ca_system_score_gemma":0.0024545991,"threshold_uncertainty_score":0.43543535},"labels":[],"label_agreement":null},{"id":"W4391333747","doi":"10.1200/jco.2024.42.4_suppl.625","title":"Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Tolerability; Cisplatin; Internal medicine; Oncology; Nausea; Chemotherapy; Adverse effect; Carboplatin; Pharmacology","score_opus":0.08707493923184538,"score_gpt":0.4415278125938331,"score_spread":0.3544528733619877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391333747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258053,0.00050106,0.0016383054,0.0020143667,0.001400594,0.0013469442,0.00006279506,0.000015826035,0.00043958487],"genre_scores_gemma":[0.9873032,0.00006789225,0.010657236,0.00032589768,0.001348149,0.00008104196,0.000012438688,0.000045697805,0.00015842528],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967098,0.00023499878,0.0020795069,0.0002814337,0.00042800762,0.0002662509],"domain_scores_gemma":[0.9959262,0.0024652905,0.0008365805,0.00016750411,0.00026034168,0.000344058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011647643,0.00023831261,0.0016349547,0.00018443845,0.00007381006,0.000030788706,0.00009178826,0.00015897286,0.000057670142],"category_scores_gemma":[0.00074908877,0.00014473528,0.0004719338,0.00017374367,0.00021722664,0.00013992071,0.000017801498,0.0005124489,0.0000017506349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7564685,0.011550236,0.015231469,0.0006850614,0.0076026004,0.0046562073,0.001668827,0.00007502618,0.0015578247,0.00046991787,0.0027825367,0.19725184],"study_design_scores_gemma":[0.5893654,0.3798134,0.0050185756,0.0008893754,0.009025913,0.0012240275,0.0004092319,0.0012796303,0.0026453002,0.00061698107,0.00939462,0.0003175247],"about_ca_topic_score_codex":0.000035877776,"about_ca_topic_score_gemma":0.000066313,"teacher_disagreement_score":0.36826316,"about_ca_system_score_codex":0.00009021942,"about_ca_system_score_gemma":0.004019758,"threshold_uncertainty_score":0.71308786},"labels":[],"label_agreement":null},{"id":"W4391333856","doi":"10.1200/jco.2024.42.4_suppl.629","title":"Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Urothelial cancer; Placebo; Oncology; Randomized controlled trial; Internal medicine; Cancer; Bladder cancer; Pathology","score_opus":0.0711555961690205,"score_gpt":0.4587715160747748,"score_spread":0.3876159199057543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391333856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969731,0.0003164754,0.00026949056,0.00064583094,0.00060102233,0.00097536755,0.0000347944,0.0000058175733,0.00017812714],"genre_scores_gemma":[0.9982443,0.000121419595,0.0005234483,0.00015153241,0.0007363334,0.00005616559,0.000063990905,0.00002133755,0.00008147282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99520916,0.0020816664,0.0015653854,0.000343244,0.00056778337,0.00023273577],"domain_scores_gemma":[0.9947941,0.0037798355,0.000642856,0.00024304447,0.0004022733,0.00013790923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035739369,0.0001675271,0.0010608863,0.00018471257,0.000056826604,0.000053854717,0.0003279611,0.0002740754,0.00020807656],"category_scores_gemma":[0.0048299334,0.000085599284,0.00036357966,0.00057715096,0.00021817264,0.000020609472,0.0001408079,0.0008741441,0.000003408556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88281673,0.0018591215,0.07659907,0.000017348564,0.0043942784,0.00022291359,0.00042841278,0.00036681906,0.0016338881,0.0000020043049,0.0005429623,0.031116439],"study_design_scores_gemma":[0.6396301,0.034198374,0.3176973,0.00015174854,0.002120167,0.000005440728,0.00037957175,0.0011400816,0.0006752914,0.000021996846,0.0036963641,0.0002836244],"about_ca_topic_score_codex":0.00021363686,"about_ca_topic_score_gemma":0.0031112055,"teacher_disagreement_score":0.24318668,"about_ca_system_score_codex":0.00010914695,"about_ca_system_score_gemma":0.0018119043,"threshold_uncertainty_score":0.57822305},"labels":[],"label_agreement":null},{"id":"W4391339917","doi":"10.1200/jco.23.02259","title":"Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies","year":2024,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital; University of Toronto; University of Calgary; University of Ottawa","funders":"","keywords":"Medicine; Clinical endpoint; Expanded access; Drug; Progression-free survival; Oncology; End point; Surrogate endpoint; Intensive care medicine; Medical physics; Internal medicine; Overall survival; Clinical trial; Pharmacology","score_opus":0.2902808959613531,"score_gpt":0.4476403663145367,"score_spread":0.1573594703531836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391339917","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007521292,0.0021972007,0.00031028336,0.9630408,0.011114844,0.0009386962,0.0007339258,0.000021374064,0.014121584],"genre_scores_gemma":[0.010883231,0.0030406662,0.0033398964,0.9692978,0.011580416,0.00013164384,0.000113230824,0.00012752564,0.001485553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934818,0.00018325297,0.0048320824,0.00066446717,0.00019121917,0.0006471626],"domain_scores_gemma":[0.9910074,0.0025512408,0.005190568,0.0005610071,0.00023829695,0.00045152762],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005885046,0.00041804538,0.00274521,0.00049094675,0.000104081184,0.0004036455,0.0012939079,0.0011168587,0.0004126026],"category_scores_gemma":[0.0018071784,0.00036537088,0.0011411449,0.0001873963,0.00015270636,0.0003729267,0.00040437718,0.0028214678,0.00008282844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007022697,0.00026690142,0.00060034654,0.00020147415,0.00056076556,0.00015849395,0.00023311765,0.00003495783,0.0000013666545,0.0040856567,0.978364,0.014790656],"study_design_scores_gemma":[0.0017209814,0.0015941549,0.0004505709,0.00012580505,0.00008817374,0.000022749868,0.00004570133,0.0001561988,0.000027055572,0.08920828,0.9061883,0.00037202524],"about_ca_topic_score_codex":0.00014740504,"about_ca_topic_score_gemma":0.000101661964,"teacher_disagreement_score":0.08512263,"about_ca_system_score_codex":0.00062702835,"about_ca_system_score_gemma":0.0013156045,"threshold_uncertainty_score":0.99987984},"labels":[],"label_agreement":null},{"id":"W4391559535","doi":"10.1200/jco.2024.42.36_suppl.439572","title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Bortezomib; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Refractory (planetary science); Oncology","score_opus":0.10140309870037255,"score_gpt":0.4550800140791745,"score_spread":0.3536769153788019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391559535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842729,0.008237328,0.00007109807,0.0037606312,0.0008356554,0.0021894423,0.00012445367,0.00002897157,0.0004795351],"genre_scores_gemma":[0.9910036,0.0048944284,0.002615417,0.00030952753,0.0007310001,0.000046749297,0.000043486558,0.000060514645,0.0002952988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98780525,0.0041747354,0.0055093938,0.0008319723,0.0010511714,0.00062745047],"domain_scores_gemma":[0.944094,0.052012797,0.0020071089,0.0006420592,0.00042561934,0.00081841985],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014534551,0.00048699282,0.0046953796,0.0004829061,0.00012282962,0.00006744163,0.00037016798,0.00068350893,0.000103731974],"category_scores_gemma":[0.025919916,0.00028957112,0.0006144313,0.0005043353,0.0010670071,0.0002500966,0.0002860665,0.0030294894,0.000010385677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65896964,0.012258375,0.07144131,0.00007776551,0.00409737,0.0069773453,0.0032586798,0.000004716668,0.0006226208,0.000030599887,0.0018186137,0.24044296],"study_design_scores_gemma":[0.7091485,0.022805428,0.25431165,0.0006185431,0.0018848091,0.00048202358,0.0019594983,0.0037738562,0.0001734527,0.00022170976,0.0043730163,0.00024750523],"about_ca_topic_score_codex":0.0027423229,"about_ca_topic_score_gemma":0.0026767813,"teacher_disagreement_score":0.24019545,"about_ca_system_score_codex":0.0002185998,"about_ca_system_score_gemma":0.0014128004,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W4391676744","doi":"10.1200/jco.23.01615","title":"Mental Disorders Among Adolescents and Young Adults With Cancer: A Canadian Population–Based and Sibling Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of Calgary; Hospital for Sick Children; Manitoba Health; University of Manitoba; SickKids Foundation; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine; Population; Anxiety; Mood disorders; Cohort; Cohort study; Cancer; Mood; Incidence (geometry); Sibling; Psychiatry; Pediatrics; Internal medicine; Psychology","score_opus":0.04216858583204014,"score_gpt":0.4268869604346474,"score_spread":0.38471837460260727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391676744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959154,0.0012003685,0.000014638154,0.007102167,0.0012630249,0.0006388176,0.000010364572,0.000013810063,0.00016525926],"genre_scores_gemma":[0.9971418,0.0005828351,0.00021474136,0.0013966558,0.0005942355,0.000008286135,0.0000047132257,0.000022516084,0.00003425432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975569,0.0002869464,0.0012421026,0.00027654596,0.00042193997,0.00021552354],"domain_scores_gemma":[0.99822813,0.0003863026,0.0004406708,0.00011109111,0.0001205763,0.0007131981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002215011,0.00014276386,0.00090776157,0.00024992737,0.00007672676,0.00003391968,0.00006813151,0.00015997174,0.000033749384],"category_scores_gemma":[0.00050401327,0.000105713436,0.0001079024,0.00018090314,0.00014584746,0.00014578414,0.000022877239,0.00076276925,7.924752e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013547826,0.00039002538,0.96660554,0.00012067565,0.0003571796,0.00022719309,0.0009358389,0.000008295654,3.5029913e-7,0.0000023385996,0.00036148593,0.029636268],"study_design_scores_gemma":[0.006286123,0.004899174,0.9834613,0.0013299448,0.0004946317,0.000084968706,0.0012110373,0.00072779815,2.7771128e-7,0.000015920858,0.0013788521,0.00010997878],"about_ca_topic_score_codex":0.17106047,"about_ca_topic_score_gemma":0.7747146,"teacher_disagreement_score":0.60365415,"about_ca_system_score_codex":0.0002879297,"about_ca_system_score_gemma":0.0018391168,"threshold_uncertainty_score":0.8344595},"labels":[],"label_agreement":null},{"id":"W4391694006","doi":"10.1200/jco.23.01134","title":"ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Helsinn Therapeutics; Regeneron Pharmaceuticals; Springworks Therapeutics; Novocure; Celgene; Bristol-Myers Squibb; American Society of Clinical Oncology; Helsinn; National Cancer Institute; Kaiser Permanente; Children's National Hospital; American Academy of Neurology; Ono Pharmaceutical","keywords":"Medicine; Glioma; Progressive disease; Clinical endpoint; Radiation therapy; Surgery; Internal medicine; Gastroenterology; Urology; Nuclear medicine; Chemotherapy; Randomized controlled trial; Cancer research","score_opus":0.134791375236248,"score_gpt":0.4833792657145425,"score_spread":0.34858789047829447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391694006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600909,0.007318664,0.00002076798,0.027418934,0.0037775293,0.0002498473,0.0000063332373,0.000022885408,0.0010941521],"genre_scores_gemma":[0.9937392,0.0024935596,0.0009610797,0.0008947442,0.0017704372,0.000011228953,0.000004849924,0.000026077305,0.00009881422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958775,0.0003035199,0.0027914078,0.00028588952,0.00042636515,0.0003152972],"domain_scores_gemma":[0.99617994,0.0022183212,0.0006276194,0.00022413026,0.00026334307,0.0004866478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025066375,0.00019401984,0.0015816927,0.0003964707,0.000021466496,0.000022047703,0.00014573286,0.00037326917,0.00029643008],"category_scores_gemma":[0.0024623494,0.000121582845,0.0006242188,0.00045185338,0.00013436994,0.00010485834,0.000061698935,0.001197789,0.00012451179],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004678515,0.027026035,0.08942736,0.00018981622,0.0011763935,0.074374534,0.00028490546,0.0000142385625,0.0026847194,0.0009993362,0.023679983,0.7754642],"study_design_scores_gemma":[0.030884402,0.034741707,0.38163263,0.0018759586,0.0013770808,0.004121448,0.00015642731,0.0011766058,0.001392812,0.0017064391,0.54063404,0.00030046614],"about_ca_topic_score_codex":0.00002457299,"about_ca_topic_score_gemma":0.00009591524,"teacher_disagreement_score":0.7751637,"about_ca_system_score_codex":0.0003799791,"about_ca_system_score_gemma":0.0013498635,"threshold_uncertainty_score":0.5203864},"labels":[],"label_agreement":null},{"id":"W4391846018","doi":"10.1200/jco.23.01291","title":"Machine Learning to Allocate Palliative Care Consultations During Cancer Treatment","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer; Palliative care; Intensive care medicine; Nursing; Internal medicine","score_opus":0.36490396742460124,"score_gpt":0.5984340566589451,"score_spread":0.23353008923434387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391846018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96046984,0.026743796,0.000160257,0.008938256,0.0010807067,0.000166592,0.00002305004,0.00001873109,0.0023987615],"genre_scores_gemma":[0.97466636,0.019426586,0.0032174569,0.00044318187,0.000883789,0.000010159932,0.0000061579244,0.000015714922,0.0013305986],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814034,0.00018629135,0.0011809659,0.00014769203,0.00019573061,0.00014900696],"domain_scores_gemma":[0.9966065,0.0020557763,0.00042142085,0.000070035145,0.0005786422,0.00026757744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003983287,0.000113392874,0.00095225254,0.00014264065,0.000035621753,0.0000067236656,0.000062953324,0.00014362743,0.00015111026],"category_scores_gemma":[0.0024724456,0.000074669806,0.00034384686,0.00018493521,0.00008168118,0.00004704746,0.000022582171,0.00052273885,0.000025778249],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037255152,0.00073345075,0.6056862,0.00039218797,0.0031071731,0.0023837187,0.02821332,0.00195913,0.0018941433,0.00023317008,0.0010335227,0.3506385],"study_design_scores_gemma":[0.006576607,0.014583289,0.16049671,0.0024102447,0.0012004675,0.00004563819,0.0050780973,0.00045879508,0.0024868737,0.00006415019,0.80644804,0.00015105584],"about_ca_topic_score_codex":0.0001695873,"about_ca_topic_score_gemma":0.00024231151,"teacher_disagreement_score":0.80541456,"about_ca_system_score_codex":0.00040317932,"about_ca_system_score_gemma":0.0012626854,"threshold_uncertainty_score":0.30449462},"labels":[],"label_agreement":null},{"id":"W4392091243","doi":"10.1200/jco.23.01601","title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Esophageal adenocarcinoma; Chemotherapy; Internal medicine; Gastric adenocarcinoma; Adenocarcinoma; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Immunotherapy","score_opus":0.06358621870465926,"score_gpt":0.4120272378043416,"score_spread":0.34844101909968234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392091243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700074,0.0025094564,0.0049012275,0.013220661,0.0077854507,0.001305084,0.000013776797,0.000026589525,0.00023032044],"genre_scores_gemma":[0.9885749,0.0010309684,0.0027721645,0.00093209126,0.0033868183,0.000020266833,0.0000044795247,0.0000339667,0.0032443418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99660444,0.00012776638,0.002255099,0.00028660017,0.00041714215,0.0003089585],"domain_scores_gemma":[0.9969183,0.0011123682,0.0011775397,0.00024152147,0.00031060414,0.00023962352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002148737,0.00021088918,0.0015938323,0.00018499403,0.000079987396,0.000021932057,0.00021996305,0.0002344867,0.00014999951],"category_scores_gemma":[0.0011578538,0.00013308477,0.0009635846,0.00029946005,0.00023571093,0.00014749396,0.00007604214,0.00068773597,0.0000025886159],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6242429,0.0023015272,0.01778634,0.0006832978,0.00232082,0.00047339514,0.0004993078,0.00012026606,0.0001605029,0.0005213005,0.045987684,0.30490267],"study_design_scores_gemma":[0.8275675,0.053140763,0.04931566,0.00028663882,0.0024163178,0.00035003942,0.00025619924,0.0018752534,0.00017916349,0.00069858076,0.06374113,0.00017275634],"about_ca_topic_score_codex":0.000010525852,"about_ca_topic_score_gemma":0.000022392785,"teacher_disagreement_score":0.3047299,"about_ca_system_score_codex":0.00020277526,"about_ca_system_score_gemma":0.0010022816,"threshold_uncertainty_score":0.5427039},"labels":[],"label_agreement":null},{"id":"W4392186176","doi":"10.1200/jco.23.01730","title":"Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Capecitabine; Diclofenac; Randomized controlled trial; Double blind; Foot (prosody); Dermatology; Internal medicine; Cancer; Pharmacology; Alternative medicine; Colorectal cancer; Placebo; Pathology","score_opus":0.11412582579354162,"score_gpt":0.4739152298721753,"score_spread":0.3597894040786337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392186176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97615856,0.001582785,0.0023170079,0.009237587,0.0046108947,0.005007513,0.0000043600835,0.000024194413,0.0010571014],"genre_scores_gemma":[0.9936113,0.0004625563,0.0014314359,0.00034620153,0.0014748645,0.00012019076,0.000007797249,0.00003181065,0.0025138934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99201685,0.0011316761,0.0057877544,0.0002543724,0.0005404855,0.00026888345],"domain_scores_gemma":[0.98041946,0.015762456,0.0026752776,0.0001786377,0.00067486457,0.00028931638],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013023574,0.0002069926,0.0064238827,0.00025498113,0.000040274994,0.00002260662,0.0001645507,0.0010162671,0.00037087928],"category_scores_gemma":[0.01649665,0.00012891754,0.0038980918,0.00023599481,0.00039313166,0.000098098855,0.000027604696,0.0012486796,0.0000056856015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9768478,0.003721141,0.000055604745,0.000081178965,0.0052811718,0.0002761034,0.000098165474,0.0000049262335,0.00044863243,0.00042893423,0.0018919162,0.010864395],"study_design_scores_gemma":[0.9614643,0.025617843,0.00022352912,0.00053850515,0.00370877,0.00031599,0.000018442164,0.0008050837,0.00031001447,0.0026552347,0.004238476,0.000103829974],"about_ca_topic_score_codex":0.000007872404,"about_ca_topic_score_gemma":0.000021675192,"teacher_disagreement_score":0.021896701,"about_ca_system_score_codex":0.00022443358,"about_ca_system_score_gemma":0.0019340039,"threshold_uncertainty_score":0.9917878},"labels":[],"label_agreement":null},{"id":"W4392229930","doi":"10.1200/jco.23.02744","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Astellas Pharma; Eisai; G1 Therapeutics; NGM Biopharmaceuticals; Tarveda Therapeutics; Moderna; Pfizer; Incyte; Agios Pharmaceuticals; BeiGene; Mirati Therapeutics; GlaxoSmithKline; Tizona Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Merck KGaA; Apollomics; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Genentech; Aeglea BioTherapeutics; Amgen; Celgene","keywords":"Guideline; Medicine; Randomized controlled trial; Systematic review; Family medicine; Evidence-based practice; MEDLINE; Alternative medicine; Pathology","score_opus":0.13876197309369276,"score_gpt":0.5291187612858572,"score_spread":0.39035678819216446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392229930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003559524,0.9910742,0.0003218262,0.0024012467,0.0031974474,0.0017780113,0.000090698246,0.000011240521,0.0007693612],"genre_scores_gemma":[0.000048353137,0.98343897,0.0055567995,0.0015333369,0.0043865875,0.00023673911,0.00003770162,0.000079117046,0.004682421],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953267,0.00028102205,0.0033158672,0.00043282882,0.0003514435,0.00029211544],"domain_scores_gemma":[0.9927056,0.0032440543,0.0027026634,0.00029761138,0.000704896,0.00034516773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020628069,0.00040286628,0.004145597,0.00022173862,0.000065171,0.000036616002,0.00021289084,0.0006591784,0.00048494842],"category_scores_gemma":[0.0003581196,0.000211606,0.0017967351,0.00018986347,0.00007357232,0.00008250343,0.00005866314,0.0012344333,0.000030046096],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006294878,0.0015815687,0.0014418956,0.0078899115,0.0038497765,0.00057327485,0.000060221213,0.00002077469,2.2964986e-7,0.000010910928,0.2693347,0.71460724],"study_design_scores_gemma":[0.0044803736,0.010094111,0.00017552299,0.028118486,0.012530274,0.00007260621,0.000022032558,0.00010723275,8.795285e-7,0.0000044347826,0.9442061,0.00018789934],"about_ca_topic_score_codex":0.0000558163,"about_ca_topic_score_gemma":0.00014418537,"teacher_disagreement_score":0.71441936,"about_ca_system_score_codex":0.001185138,"about_ca_system_score_gemma":0.0089429105,"threshold_uncertainty_score":0.9966755},"labels":[],"label_agreement":null},{"id":"W4392243479","doi":"10.1200/jco.23.02746","title":"Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Guideline; Medicine; Randomized controlled trial; Systematic review; Family medicine; Evidence-based practice; MEDLINE; Alternative medicine; Internal medicine; Pathology","score_opus":0.15762656148621587,"score_gpt":0.5461024975880412,"score_spread":0.3884759361018253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392243479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036355355,0.98822343,0.00028789887,0.0023533558,0.0058979555,0.0018992415,0.00010738938,0.000013530622,0.0008536648],"genre_scores_gemma":[0.000063887856,0.9802952,0.0049056034,0.0017822518,0.0061290623,0.0002442918,0.00004176514,0.00008622542,0.0064517413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942744,0.00036914292,0.004194791,0.00047278937,0.00036610203,0.0003228127],"domain_scores_gemma":[0.99217254,0.0033281979,0.0030657577,0.00033196757,0.0007122144,0.00038929412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027645167,0.00043562806,0.0047601,0.00025244075,0.000072470546,0.000041160387,0.00025343828,0.00084303063,0.0005957106],"category_scores_gemma":[0.00067322515,0.00025331255,0.0026470725,0.00017899927,0.000072584604,0.000088327986,0.000082969804,0.0013928027,0.000050750838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034064232,0.0013415901,0.0018728958,0.006926254,0.0029143197,0.0002847417,0.000055687462,0.000010913494,3.304394e-7,0.000009174968,0.28120825,0.7050352],"study_design_scores_gemma":[0.0041184947,0.005932185,0.00020155184,0.025090583,0.012439858,0.000053456173,0.00001930187,0.00018728821,0.0000010290912,0.000007996335,0.9517453,0.00020296221],"about_ca_topic_score_codex":0.000060072245,"about_ca_topic_score_gemma":0.00010703227,"teacher_disagreement_score":0.70483226,"about_ca_system_score_codex":0.0013819396,"about_ca_system_score_gemma":0.008593912,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W4392691757","doi":"10.1200/jco.23.00762","title":"Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Radiation therapy; Urology; Androgen deprivation therapy; Prostate-specific antigen; Internal medicine; Prostate; Randomized controlled trial; Oncology; Cancer; Confidence interval","score_opus":0.18223907637416828,"score_gpt":0.5103644010103067,"score_spread":0.3281253246361384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392691757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93379956,0.061215516,0.000041643554,0.0011689098,0.00059267535,0.0021689257,0.000987357,0.000008176562,0.000017249024],"genre_scores_gemma":[0.9210359,0.076761544,0.0014518228,0.00014918497,0.0002435432,0.00013694227,0.00018011319,0.0000294242,0.000011561479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98867255,0.0028531482,0.006999734,0.00047958392,0.0006708707,0.00032413722],"domain_scores_gemma":[0.986996,0.007995461,0.0035988223,0.00055704557,0.0004691134,0.00038356925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014903657,0.00027982294,0.007998235,0.00079316145,0.00001660533,0.00002453935,0.00027141353,0.00028875773,0.0005362392],"category_scores_gemma":[0.0034359577,0.00015643184,0.0021079995,0.00087779184,0.00042100306,0.00024348301,0.0001062115,0.0005161876,0.00000110344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2969184,0.0031537118,0.50441176,0.000091198184,0.021746246,0.0008151741,0.0015672348,0.0007409664,0.00012574755,0.000004725441,0.0009617519,0.1694631],"study_design_scores_gemma":[0.20224676,0.030619847,0.7373548,0.0010883387,0.016945262,0.000034943616,0.00012828659,0.0047445404,0.0002891556,0.00011012048,0.006217789,0.00022013222],"about_ca_topic_score_codex":0.0004147793,"about_ca_topic_score_gemma":0.0002988232,"teacher_disagreement_score":0.23294306,"about_ca_system_score_codex":0.00061557774,"about_ca_system_score_gemma":0.002807215,"threshold_uncertainty_score":0.6379105},"labels":[],"label_agreement":null},{"id":"W4392745023","doi":"10.1200/jco.23.02596","title":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute on Drug Abuse; Genentech; Association of Community Cancer Centers","keywords":"Medicine; Cannabis; Guideline; Cannabinoid; Cancer; Oncology; Internal medicine; Pharmacology; Psychiatry; Pathology; Receptor","score_opus":0.1187324837119717,"score_gpt":0.538122426205369,"score_spread":0.4193899424933973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392745023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005562791,0.9577468,0.0000023613427,0.038097978,0.0013412527,0.0008505343,0.000054740212,0.00001200547,0.0013380242],"genre_scores_gemma":[0.000026751337,0.9838838,0.00032832017,0.0009157491,0.0031728384,0.00009824924,0.00001595971,0.000099411765,0.011458919],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913566,0.0006202553,0.0060167448,0.0005972024,0.0008312737,0.0005778907],"domain_scores_gemma":[0.9951736,0.00018245292,0.0022272617,0.00037535984,0.0010226861,0.0010186639],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005446896,0.00051885046,0.0076333815,0.00086014724,0.000036595742,0.000033939934,0.00034109442,0.001327591,0.00019549273],"category_scores_gemma":[0.002046115,0.00028456,0.001202452,0.0007669916,0.00056371494,0.00008546406,0.00018829986,0.005180363,0.000014684186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010018656,0.00031932132,0.00018751188,0.009399741,0.00048200283,0.0037608854,0.0000365338,6.514774e-7,4.0639186e-8,0.000023388224,0.32464677,0.6601413],"study_design_scores_gemma":[0.0037815124,0.009502279,0.0005199892,0.03163354,0.0031337377,0.0032811924,0.00006986229,0.00001546244,1.0763319e-7,0.000023336506,0.9477791,0.00025986583],"about_ca_topic_score_codex":0.0014682874,"about_ca_topic_score_gemma":0.0027463906,"teacher_disagreement_score":0.6598814,"about_ca_system_score_codex":0.000885011,"about_ca_system_score_gemma":0.02515797,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W4392795497","doi":"10.1200/jco.23.01241","title":"How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Clinical trial; Medical physics; Oncology; Intensive care medicine; Internal medicine","score_opus":0.40261462867987136,"score_gpt":0.5663841718660045,"score_spread":0.16376954318613318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392795497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9240934,0.0050274604,0.01128836,0.056262225,0.0022592598,0.0006590755,0.000007465178,0.00006635484,0.0003363584],"genre_scores_gemma":[0.9790003,0.0023828798,0.008802061,0.0014505967,0.007970391,0.000016721686,0.000004056465,0.000035289962,0.00033771014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926183,0.00085838966,0.0052858465,0.00048718706,0.00037359513,0.0003766745],"domain_scores_gemma":[0.98973405,0.0058084973,0.002739162,0.00030829388,0.00031847568,0.0010915325],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01464133,0.00024979352,0.0018648282,0.00009293926,0.000108718035,0.000119265416,0.00020344998,0.0006501445,0.00007814402],"category_scores_gemma":[0.012954759,0.00016310463,0.0009326553,0.00020146454,0.00068012293,0.00016405448,0.00006994453,0.002992575,0.0000038713147],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07063763,0.0026995826,0.00021843272,0.00015487586,0.0010408484,0.003824144,0.00010504493,0.000003599251,0.040729474,0.00014669418,0.0026204211,0.87781924],"study_design_scores_gemma":[0.29934895,0.064232215,0.002559874,0.0005941813,0.0072072158,0.024612572,0.0011938984,0.034792062,0.01235228,0.003817184,0.548349,0.0009405489],"about_ca_topic_score_codex":0.0000019206957,"about_ca_topic_score_gemma":4.4844487e-7,"teacher_disagreement_score":0.8768787,"about_ca_system_score_codex":0.000103852704,"about_ca_system_score_gemma":0.0019632392,"threshold_uncertainty_score":0.9993076},"labels":[],"label_agreement":null},{"id":"W4392978770","doi":"10.1200/jco.23.02086","title":"Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nasopharyngeal cancer; Radiation therapy; Cancer; Randomized controlled trial; Oncology; Open label; Nuclear medicine; Internal medicine; Nasopharyngeal carcinoma","score_opus":0.11750052029752703,"score_gpt":0.4876263936029576,"score_spread":0.37012587330543056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392978770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889381,0.00084397395,0.000008964206,0.0047216862,0.0035046656,0.0014355058,0.00011960277,0.000014245147,0.0004132828],"genre_scores_gemma":[0.99506384,0.0013313213,0.00145896,0.0006278018,0.0012321619,0.000024342995,0.00012839271,0.00002462654,0.000108550215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937968,0.0010581254,0.0040735085,0.0003586409,0.00046316136,0.00024975967],"domain_scores_gemma":[0.9950195,0.0018910139,0.0018652165,0.00022733986,0.0006479813,0.00034894256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004125647,0.00020227827,0.0038033326,0.00019655826,0.000039801253,0.000028445433,0.000270218,0.00032145748,0.000106804284],"category_scores_gemma":[0.0026215713,0.0001327138,0.00019297496,0.00030120206,0.00028309686,0.00041166449,0.000096103126,0.0009852422,0.000003355865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93706536,0.009598776,0.005511421,0.000025363423,0.0009818579,0.0002182329,0.000612349,0.000007308208,0.00013336941,0.0000098487035,0.0033367982,0.04249931],"study_design_scores_gemma":[0.90237176,0.04419556,0.04333456,0.0006965363,0.00089254545,0.0000024710819,0.00005496705,0.002320096,0.000032076427,0.000032694134,0.0059475577,0.0001191758],"about_ca_topic_score_codex":0.001545482,"about_ca_topic_score_gemma":0.00072488026,"teacher_disagreement_score":0.042380136,"about_ca_system_score_codex":0.00030139752,"about_ca_system_score_gemma":0.0031031165,"threshold_uncertainty_score":0.55047953},"labels":[],"label_agreement":null},{"id":"W4393201929","doi":"10.1200/jco.23.01655","title":"International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Radiation therapy; Lymphoma; Hazard ratio; Proportional hazards model; Stage (stratigraphy); Hodgkin lymphoma; Gastroenterology","score_opus":0.1277191329791658,"score_gpt":0.47341353432658,"score_spread":0.34569440134741425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393201929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546299,0.005144503,0.0010625378,0.023532057,0.010176682,0.0006583487,0.000027273045,0.000037549,0.004731151],"genre_scores_gemma":[0.98352337,0.0020866306,0.008276241,0.0017397519,0.0037144376,0.00004503039,0.000014378446,0.000028250864,0.00057192583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711066,0.00011446232,0.0018954908,0.00026214612,0.00038157342,0.00023566971],"domain_scores_gemma":[0.9950233,0.0034218526,0.00059958984,0.00015786297,0.00046566967,0.0003317076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018845065,0.00016251659,0.0010963646,0.00017879426,0.000034818127,0.000037800986,0.00018214654,0.00031099978,0.00023759025],"category_scores_gemma":[0.0034600012,0.00010287162,0.0009654672,0.00011040937,0.00013266288,0.000114465474,0.00005261455,0.00017733709,0.00008011982],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037118478,0.003446661,0.0541389,0.00009732488,0.0016314589,0.0049127145,0.00007092516,0.0000066769003,0.00009193011,0.0013081438,0.025811817,0.9047716],"study_design_scores_gemma":[0.018254047,0.011979832,0.1376323,0.0006200863,0.0011701498,0.0029461877,0.00004377109,0.0015105953,0.0003760139,0.00069730636,0.82465637,0.00011335024],"about_ca_topic_score_codex":0.0000090495805,"about_ca_topic_score_gemma":0.000004566191,"teacher_disagreement_score":0.90465826,"about_ca_system_score_codex":0.0006934452,"about_ca_system_score_gemma":0.003031215,"threshold_uncertainty_score":0.5377245},"labels":[],"label_agreement":null},{"id":"W4393252428","doi":"10.1200/jco.23.02329","title":"Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Clinical endpoint; Internal medicine; Phases of clinical research; Clinical trial; Lymphoma; Non-Hodgkin's lymphoma; Oncology","score_opus":0.08335546380125415,"score_gpt":0.4715924011792489,"score_spread":0.38823693737799475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393252428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920761,0.0036413441,0.000017080773,0.0012124783,0.0007262353,0.00073537295,0.000006067928,0.000011159452,0.0015741632],"genre_scores_gemma":[0.99238783,0.0020296127,0.0005167757,0.00021787906,0.0003756445,0.000018117631,0.0000012390562,0.000043194104,0.0044097183],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99464846,0.0012340193,0.0025363262,0.00039097987,0.0008215387,0.00036868034],"domain_scores_gemma":[0.9923086,0.0050814133,0.0013757115,0.00034375733,0.00046340047,0.00042709894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006456516,0.0002295962,0.0019771957,0.0006359733,0.0000473355,0.000019199826,0.00022045302,0.0003766549,0.00049836375],"category_scores_gemma":[0.0030021733,0.00015111153,0.00032972769,0.00047823327,0.000413403,0.00013204903,0.00013532727,0.0017592354,0.0000058660557],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3023654,0.03589046,0.028282113,0.00031460964,0.0015466606,0.0432778,0.0056131696,0.000011311293,0.03171798,0.000014092608,0.0026274999,0.5483389],"study_design_scores_gemma":[0.26460475,0.57932997,0.10732671,0.0024865929,0.0011177429,0.0036678214,0.0065422216,0.0007877222,0.003403023,0.00026340815,0.030081011,0.00038904417],"about_ca_topic_score_codex":0.00007191792,"about_ca_topic_score_gemma":0.00014619628,"teacher_disagreement_score":0.54794985,"about_ca_system_score_codex":0.00038566854,"about_ca_system_score_gemma":0.004854974,"threshold_uncertainty_score":0.8612515},"labels":[],"label_agreement":null},{"id":"W4393307028","doi":"10.1200/jco.23.02330","title":"Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Université Laval; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Randomized controlled trial; Cognition; Cancer; Cognitive impairment; Insomnia; Physical therapy; Psychiatry; Internal medicine","score_opus":0.11346995498819747,"score_gpt":0.5019580998848923,"score_spread":0.3884881448966948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393307028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678064,0.0053322697,0.000102885424,0.0046065147,0.005700281,0.015817115,0.00021549575,0.00003828243,0.0003807475],"genre_scores_gemma":[0.98015964,0.014276184,0.00012971631,0.0013425269,0.0010933301,0.0025869906,0.00001475593,0.00006278076,0.00033405717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990232,0.002115225,0.005859676,0.00052095065,0.00074584014,0.0005263165],"domain_scores_gemma":[0.9733015,0.02079028,0.00238653,0.00011402066,0.0029632882,0.00044440402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0079902,0.0004536595,0.0076244273,0.00072278857,0.00006521472,0.000020872443,0.00018065104,0.0006490235,0.00047797678],"category_scores_gemma":[0.0071495385,0.000307594,0.0024480228,0.00054286106,0.0005913585,0.00016274523,0.00007186083,0.0013843953,0.0000071406475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9075161,0.008232704,0.0019901318,0.00007879175,0.008500696,0.0002695592,0.003720152,0.00002877079,0.00015468999,0.000011479695,0.0005340015,0.068962924],"study_design_scores_gemma":[0.90548,0.06159411,0.020558193,0.0030566333,0.0062459516,0.000028087026,0.0016471962,0.00042503435,0.00012220052,0.00010316219,0.00046560145,0.00027377577],"about_ca_topic_score_codex":0.0009507469,"about_ca_topic_score_gemma":0.0017133912,"teacher_disagreement_score":0.06868915,"about_ca_system_score_codex":0.00078023836,"about_ca_system_score_gemma":0.005084039,"threshold_uncertainty_score":0.9999376},"labels":[],"label_agreement":null},{"id":"W4393901659","doi":"10.1200/jco.23.01935","title":"Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Complete response; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.05246330153503596,"score_gpt":0.3973789799301017,"score_spread":0.3449156783950657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393901659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349445,0.0021578062,0.00005580387,0.0033231357,0.0006421123,0.00015283775,0.000077463024,0.0000069133475,0.00008945892],"genre_scores_gemma":[0.99678004,0.0007627537,0.001533278,0.00036740943,0.00046153084,0.000015703048,0.000007723401,0.000022749005,0.0000488172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977534,0.00054033665,0.0009682534,0.00030422767,0.00017502255,0.0002587842],"domain_scores_gemma":[0.998599,0.00046680606,0.00044509902,0.00016216509,0.00019638996,0.00013057161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009541604,0.00019788933,0.0007457664,0.00010171729,0.00004326995,0.00001987251,0.00014585069,0.0002179327,0.000020118514],"category_scores_gemma":[0.00019831349,0.00012009394,0.000248302,0.0001125007,0.00016182747,0.000013317019,0.000076192286,0.00030486242,0.000005067099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032921664,0.0014310871,0.8352857,0.000013213226,0.0008218236,0.0010410094,0.00030163105,0.00030751637,0.0010589507,0.000008074479,0.00023208404,0.1265772],"study_design_scores_gemma":[0.0054762242,0.0113760345,0.97445816,0.00014128201,0.00015933436,0.00015082741,0.00005266403,0.00001057728,0.00004845669,0.000008960621,0.007984275,0.00013322069],"about_ca_topic_score_codex":0.00007071277,"about_ca_topic_score_gemma":0.00014956956,"teacher_disagreement_score":0.1391724,"about_ca_system_score_codex":0.00026134858,"about_ca_system_score_gemma":0.0007845445,"threshold_uncertainty_score":0.48972887},"labels":[],"label_agreement":null},{"id":"W4393928263","doi":"10.1200/jco.23.02536","title":"Prevalence and Cancer-Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Logistic regression; Behavioral Risk Factor Surveillance System; Bathing; Odds ratio; Gerontology; Activities of daily living; Physical therapy; Internal medicine; Population; Environmental health","score_opus":0.11613798137191504,"score_gpt":0.44319765332654293,"score_spread":0.3270596719546279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393928263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961601,0.025134059,0.00013387161,0.004086306,0.008409053,0.00014564917,0.000099718505,0.000011634137,0.00037867748],"genre_scores_gemma":[0.9639332,0.03234551,0.000024855359,0.00033796896,0.0026162972,0.0000143247025,0.0000026953242,0.00001529759,0.00070984155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970716,0.0003345662,0.0016272146,0.00029203313,0.00048081754,0.00019376386],"domain_scores_gemma":[0.99669707,0.0017761141,0.0006474691,0.00019814086,0.00036699083,0.00031422672],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023787909,0.00013998794,0.0010140416,0.00006868161,0.000030945565,0.000012695896,0.000121809724,0.00028488546,0.0018991485],"category_scores_gemma":[0.00036861253,0.00010118847,0.00042441022,0.00015060902,0.00048465445,0.0001459511,0.00006614624,0.0010298786,0.000002449032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012049762,0.00031065827,0.8801199,0.00055091584,0.000236616,0.000116464544,0.00018088816,0.000013534387,0.0000712366,0.00006423722,0.0029143938,0.11421617],"study_design_scores_gemma":[0.0010597748,0.0015996358,0.9114536,0.0005376262,0.00032404685,0.00008268903,0.00013578491,0.00006654515,0.000038328173,0.00010241051,0.08451406,0.00008550793],"about_ca_topic_score_codex":0.0029429717,"about_ca_topic_score_gemma":0.014542683,"teacher_disagreement_score":0.11413066,"about_ca_system_score_codex":0.00026746138,"about_ca_system_score_gemma":0.0011309155,"threshold_uncertainty_score":0.99901325},"labels":[],"label_agreement":null},{"id":"W4394711037","doi":"10.1200/jco.23.01989","title":"Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute; Children's National Hospital; National Institutes of Health; Children's Hospital of Philadelphia","keywords":"Medicine; Neurocognitive; Cohort; Prospective cohort study; Propofol; Socioeconomic status; Anesthesiology; Pediatrics; Internal medicine; Anesthesia; Population; Cognition; Psychiatry","score_opus":0.10425880615601561,"score_gpt":0.4778533901343757,"score_spread":0.3735945839783601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394711037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967758,0.000027598937,0.0000106384805,0.0011355159,0.00024108909,0.0015607831,0.000021059464,0.000024666864,0.00020283004],"genre_scores_gemma":[0.9985249,0.00026484288,0.00006934387,0.00074673694,0.00027654326,0.000028942042,8.810302e-7,0.00004303391,0.00004479281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99127305,0.0045682895,0.0021690512,0.0006112192,0.0008790071,0.00049937575],"domain_scores_gemma":[0.98905003,0.008859256,0.0013030542,0.00028559612,0.00015550153,0.00034654883],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033179203,0.0003050316,0.0019202742,0.0005610315,0.00006041717,0.000037493217,0.00067812443,0.0003515439,0.00006565472],"category_scores_gemma":[0.006040525,0.00017288516,0.0006177323,0.0005729308,0.0005351486,0.00025675757,0.00012936148,0.0032206355,0.00003329884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053023254,0.011574201,0.9460384,0.000005661788,0.00043606604,0.0029179987,0.0002556336,0.000063820975,0.00063039776,0.00008908047,0.00009297935,0.032593384],"study_design_scores_gemma":[0.0056955926,0.18395402,0.80843306,0.00004145601,0.00016195321,0.0009498988,0.00004560677,0.000022067981,0.00035569133,0.00014418375,0.00006462506,0.00013187945],"about_ca_topic_score_codex":0.00019192303,"about_ca_topic_score_gemma":0.00009535533,"teacher_disagreement_score":0.17237982,"about_ca_system_score_codex":0.00017854408,"about_ca_system_score_gemma":0.001505624,"threshold_uncertainty_score":0.999079},"labels":[],"label_agreement":null},{"id":"W4394711050","doi":"10.1200/jco.23.01841","title":"Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Daunorubicin; Medicine; Mitoxantrone; Flow cytometry; Minimal residual disease; Risk stratification; Internal medicine; Oncology; Stratification (seeds); Leukemia; Pharmacology; Immunology; Chemotherapy","score_opus":0.14548876113930462,"score_gpt":0.449249650039506,"score_spread":0.30376088890020136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394711050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316216,0.0006748881,0.0006736117,0.004057575,0.0008256581,0.00031803743,0.000018175955,0.000008173321,0.00026173235],"genre_scores_gemma":[0.994027,0.0006116692,0.0035381482,0.000050600764,0.001722433,0.000005249168,0.000007034198,0.000019927813,0.000017944854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995097,0.00088107743,0.002146643,0.00025438154,0.0014052113,0.00021567888],"domain_scores_gemma":[0.9947417,0.0026812255,0.0011677878,0.0002821455,0.0007928342,0.00033434472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064429427,0.00013851254,0.0009588819,0.0008737039,0.000019638072,0.000007230239,0.00015910243,0.00028542854,0.00005999551],"category_scores_gemma":[0.008126786,0.00009466665,0.00023577728,0.0008135948,0.00019805133,0.000113497656,0.000023120114,0.0017194321,0.0000064018764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2718311,0.009904749,0.46892914,0.0011416137,0.0013180766,0.0021710747,0.00019360728,0.007107994,0.008578904,0.00013955428,0.0063571148,0.22232707],"study_design_scores_gemma":[0.018677494,0.03525625,0.93333006,0.00039254667,0.0013058616,0.00002223399,0.00014209232,0.008698818,0.0016205555,0.00005502745,0.00039134867,0.0001077171],"about_ca_topic_score_codex":0.00003868,"about_ca_topic_score_gemma":0.000058401023,"teacher_disagreement_score":0.46440092,"about_ca_system_score_codex":0.00074685516,"about_ca_system_score_gemma":0.0071694264,"threshold_uncertainty_score":0.998459},"labels":[],"label_agreement":null},{"id":"W4394742399","doi":"10.1200/jco.23.01621","title":"Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Cerebrospinal fluid; Biomarker discovery; Liquid biopsy; Bench to bedside; Biomarker; Lumbar puncture; Oncology; Bioinformatics; Pathology; Internal medicine; Proteomics; Medical physics; Cancer","score_opus":0.12661907113025214,"score_gpt":0.531999019790208,"score_spread":0.40537994865995586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394742399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029274242,0.9917754,0.00026455562,0.002893887,0.0011454466,0.0034213334,0.00003729985,0.0000077255945,0.0001615915],"genre_scores_gemma":[0.0004508743,0.9967777,0.0005884312,0.0014445886,0.00048657172,0.00015888717,0.000026160553,0.00004573224,0.00002106251],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9847849,0.0023971936,0.01152897,0.0005136977,0.00054261804,0.0002326451],"domain_scores_gemma":[0.98670703,0.005921646,0.0059282403,0.00048001553,0.0004999638,0.00046311883],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011352231,0.0003896608,0.012574918,0.0005057582,0.000018518676,0.0000208157,0.00023616641,0.000933694,0.000015099293],"category_scores_gemma":[0.014723166,0.00022595905,0.0021729998,0.00067099405,0.00018194126,0.00010204467,0.00016296386,0.0011992949,0.00002927647],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003141468,0.0019472206,0.00065563776,0.55890673,0.0016410542,0.00059093046,0.000008298467,1.9434431e-7,8.49091e-7,0.00009049489,0.0035766482,0.43226779],"study_design_scores_gemma":[0.0020226433,0.00830976,0.0009855289,0.55301213,0.023513379,0.0008338925,0.000010173507,0.0000119448605,2.1906153e-7,0.00003344794,0.41112748,0.0001394117],"about_ca_topic_score_codex":0.0000057152224,"about_ca_topic_score_gemma":0.000017543472,"teacher_disagreement_score":0.43212837,"about_ca_system_score_codex":0.0005679025,"about_ca_system_score_gemma":0.0035689934,"threshold_uncertainty_score":0.9935762},"labels":[],"label_agreement":null},{"id":"W4394993360","doi":"10.1200/jco.23.02353","title":"Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Sodium thiosulfate; Cisplatin; Food and drug administration; Cancer; Pharmacokinetics; Regulatory agency; Intensive care medicine; Drug; Ototoxicity; International agency; Pharmacology; Chemotherapy; Surgery; Internal medicine","score_opus":0.2060857741570339,"score_gpt":0.4718048834864121,"score_spread":0.26571910932937814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394993360","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060764167,0.935591,0.0000010697219,0.00040580815,0.00077454903,0.0020940874,0.00012698637,0.000010328682,0.00023200567],"genre_scores_gemma":[0.0031210675,0.9950077,0.0003979116,0.0010232314,0.00019944459,0.000025435205,0.0000040189166,0.00006786618,0.00015334105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903177,0.0031313074,0.004782659,0.0005133237,0.00091774005,0.00033725207],"domain_scores_gemma":[0.98900425,0.0020760056,0.007250071,0.00067918864,0.00076355966,0.00022691063],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00224015,0.0004578421,0.0049899034,0.00025465986,0.000036145153,0.00004128249,0.0009064629,0.0007120959,0.000032534652],"category_scores_gemma":[0.0055067246,0.00020634658,0.00070534955,0.0013881964,0.0005013059,0.00016925449,0.0002098177,0.0035072565,0.0000046179603],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004159539,0.0046839896,0.010086953,0.1225131,0.00084991736,0.001342956,0.00053683977,0.000021922071,0.000046016794,0.000116704614,0.0017499272,0.85389215],"study_design_scores_gemma":[0.0019228912,0.011156382,0.0027523604,0.3357895,0.0020544708,0.00029634975,0.0000046481396,0.0000071478885,0.00004557083,0.00003177771,0.6456278,0.00031109183],"about_ca_topic_score_codex":0.00005420555,"about_ca_topic_score_gemma":0.000111510235,"teacher_disagreement_score":0.8535811,"about_ca_system_score_codex":0.0002192305,"about_ca_system_score_gemma":0.0047334987,"threshold_uncertainty_score":0.9987917},"labels":[],"label_agreement":null},{"id":"W4395083112","doi":"10.1200/jco.23.01983","title":"<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Else Kröner-Fresenius-Stiftung; Rheinische Friedrich-Wilhelms-Universität Bonn; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft","keywords":"Gene duplication; Bladder cancer; Medicine; Copy-number variation; Cancer; Oncology; Fluorescence in situ hybridization; Internal medicine; Metastatic breast cancer; Cancer research; Breast cancer; Chromosome; Biology; Genome; Gene; Genetics","score_opus":0.1263294054098523,"score_gpt":0.49340585196090614,"score_spread":0.36707644655105387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395083112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819893,0.003236664,0.000075109434,0.012654257,0.001082596,0.00035783483,0.000024364703,0.000011269435,0.00056857266],"genre_scores_gemma":[0.99386734,0.0020540203,0.0005508666,0.0027289274,0.00050152786,0.000029481487,0.0000015373232,0.000021564523,0.0002447633],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967495,0.00050898944,0.0019700336,0.00024902463,0.0002938048,0.00022859788],"domain_scores_gemma":[0.99744445,0.001630312,0.00044322,0.00012843759,0.00011104645,0.00024252708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003356324,0.00014287456,0.0010428107,0.00029655892,0.000017415901,0.000017423654,0.000084747575,0.00016887416,0.00016753438],"category_scores_gemma":[0.0014918866,0.000103457336,0.00018668661,0.00024654783,0.00012497594,0.00012787688,0.000024655877,0.0008670129,0.000011493394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089858174,0.0044751475,0.3451035,0.000517037,0.0013157864,0.011315002,0.0056621647,0.00017364387,0.0043256963,0.00029456653,0.0068535605,0.5301057],"study_design_scores_gemma":[0.020354342,0.020193955,0.9017489,0.0016118478,0.000719219,0.0011233758,0.00039476258,0.0010678775,0.00117478,0.0021585324,0.049236313,0.00021611726],"about_ca_topic_score_codex":0.00037577652,"about_ca_topic_score_gemma":0.00030708246,"teacher_disagreement_score":0.5566454,"about_ca_system_score_codex":0.00040005642,"about_ca_system_score_gemma":0.0041011325,"threshold_uncertainty_score":0.7275233},"labels":[],"label_agreement":null},{"id":"W4396562490","doi":"10.1200/jco.23.02750","title":"Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Guideline; Systematic review; Observational study; Family medicine; Osteoradionecrosis; Psychological intervention; MEDLINE; Radiation therapy; Nursing; Surgery; Internal medicine; Pathology","score_opus":0.08567149998520775,"score_gpt":0.48897729084087366,"score_spread":0.4033057908556659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396562490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734224,0.0064117885,0.000030752326,0.005329138,0.00019630369,0.0005755287,0.0000055836263,0.0000056356034,0.00010300616],"genre_scores_gemma":[0.97594124,0.018335044,0.005014307,0.00043797033,0.00012637016,0.000017489867,0.0000068631834,0.000015405625,0.00010533285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979712,0.0001406333,0.0013343102,0.00017674225,0.00024176178,0.00013539683],"domain_scores_gemma":[0.9987799,0.00018284502,0.0006039225,0.0000888157,0.00018459259,0.00015991995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088451384,0.00010922619,0.000747312,0.00013124711,0.0000155764,0.0000062145623,0.00002958022,0.00012275414,0.000032021686],"category_scores_gemma":[0.000024102917,0.00006273902,0.00005703751,0.00019332903,0.000089975576,0.000104983024,0.000012325771,0.00024560836,4.4961143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007457409,0.00071689184,0.55670154,0.00016787901,0.0003287724,0.00006616689,0.00004888141,0.0000133609565,0.0000014540765,0.000010867072,0.00026107414,0.43422568],"study_design_scores_gemma":[0.022485178,0.039449234,0.9246665,0.0015216175,0.00037950653,0.000021066753,0.000032170195,0.00012161838,0.000021532745,0.000038432703,0.011208252,0.000054885135],"about_ca_topic_score_codex":0.00015748478,"about_ca_topic_score_gemma":0.00019216578,"teacher_disagreement_score":0.43417078,"about_ca_system_score_codex":0.00030034312,"about_ca_system_score_gemma":0.0005017608,"threshold_uncertainty_score":0.2558423},"labels":[],"label_agreement":null},{"id":"W4396568956","doi":"10.1200/jco.23.01951","title":"Development and Standardization of an Osteoradionecrosis Classification System in Head and Neck Cancer: Implementation of a Risk-Based Model","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Dental and Craniofacial Research","keywords":"Medicine; Osteoradionecrosis; Head and neck cancer; Logistic regression; Radiation therapy; Internal medicine; Stage (stratigraphy); Oncology","score_opus":0.20588506427211084,"score_gpt":0.5576283900954752,"score_spread":0.3517433258233643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396568956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947143,0.0013043055,0.0022814595,0.0011371537,0.00023299704,0.00026707357,0.000033518692,0.000005072364,0.000024084404],"genre_scores_gemma":[0.96068186,0.0009687404,0.03818282,0.00006877497,0.00006946667,0.00001232157,0.00000630776,0.000008111609,0.0000016136057],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974262,0.00019546907,0.0019159262,0.00013497965,0.00023252884,0.000094888084],"domain_scores_gemma":[0.9980763,0.0003846393,0.0010750905,0.00007096884,0.00024098522,0.00015199237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022737705,0.00007078408,0.0006903493,0.00017035757,0.00001886546,0.0000043426726,0.000027002265,0.00013325659,0.0000056112362],"category_scores_gemma":[0.00011356957,0.000053949025,0.0000502725,0.00013509733,0.000065344466,0.00009065315,0.000008570814,0.00020558585,9.501235e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026718276,0.00037558397,0.3093238,0.0011281315,0.000107261454,0.000020668851,0.0010565472,0.0012276323,0.00024843216,0.00026949475,0.000036125697,0.6835345],"study_design_scores_gemma":[0.010465598,0.007318336,0.91425306,0.001569191,0.0003937674,0.000034236833,0.0017092437,0.06029411,0.0022318703,0.000084892206,0.0015752381,0.00007044159],"about_ca_topic_score_codex":0.00020354058,"about_ca_topic_score_gemma":0.0014416111,"teacher_disagreement_score":0.68346405,"about_ca_system_score_codex":0.00074614,"about_ca_system_score_gemma":0.0037700622,"threshold_uncertainty_score":0.66879284},"labels":[],"label_agreement":null},{"id":"W4396604922","doi":"10.1200/jco.23.00934","title":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Adaptive Biotechnologies; Astellas Pharma; bluebird bio; Kiadis Pharma; Omeros Corporation; Pfizer; Incyte; Jazz Pharmaceuticals; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Celgene; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; GlaxoSmithKline; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US; National Institute of Allergy and Infectious Diseases; Roswell Park Cancer Institute","keywords":"Medicine; Minimal residual disease; Internal medicine; Multiple myeloma; Oncology; Hazard ratio; Lenalidomide; Hematopoietic stem cell transplantation; Transplantation; Progression-free survival; Surgery; Gastroenterology; Bone marrow; Overall survival; Confidence interval","score_opus":0.0611446475342914,"score_gpt":0.39033018106175177,"score_spread":0.3291855335274604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396604922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609596,0.0012437695,0.000051833576,0.0018231216,0.00025533486,0.00029065466,0.000069859845,0.000015910453,0.00015354595],"genre_scores_gemma":[0.99733496,0.0014062227,0.00051454996,0.00018096941,0.0002007718,0.000013400016,0.000026152504,0.000025286712,0.0002977021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719167,0.00052421994,0.0011195346,0.00028440615,0.00045557308,0.00042460934],"domain_scores_gemma":[0.9960326,0.0026278386,0.00039811543,0.00011692636,0.00018011124,0.0006444279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146547,0.0001733397,0.00094966416,0.00017923806,0.0000264393,0.000028713797,0.00006988452,0.00021935666,0.00007396641],"category_scores_gemma":[0.001617452,0.00011312459,0.00018504562,0.000119110264,0.00023503405,0.00014205271,0.000025123294,0.00079893786,0.000012209826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036903337,0.0010795349,0.9051391,0.00025688566,0.00033274206,0.051360797,0.00017365979,0.000006288849,0.00003859977,0.000008446679,0.00016091848,0.004539697],"study_design_scores_gemma":[0.018988676,0.0037738609,0.9750339,0.0010024763,0.0004121663,0.00023941255,0.000067405526,0.00017733255,0.000030633026,0.00005678138,0.00010983502,0.0001075265],"about_ca_topic_score_codex":0.000024619116,"about_ca_topic_score_gemma":0.0006436762,"teacher_disagreement_score":0.0698948,"about_ca_system_score_codex":0.00022350696,"about_ca_system_score_gemma":0.0011880734,"threshold_uncertainty_score":0.46130866},"labels":[],"label_agreement":null},{"id":"W4396939189","doi":"10.1200/jco.24.00542","title":"Palliative Care for Patients With Cancer: ASCO Guideline Update","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":279,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University","funders":"","keywords":"Medicine; Guideline; Palliative care; Family medicine; Psychological intervention; MEDLINE; Systematic review; Nursing; Pathology","score_opus":0.2797672943753287,"score_gpt":0.5939021769326539,"score_spread":0.3141348825573252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396939189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9347506,0.034520563,0.003613626,0.019197727,0.004286022,0.0006499464,0.00022311663,0.000025680853,0.0027326986],"genre_scores_gemma":[0.9177227,0.017407443,0.055999354,0.0043507577,0.004009928,0.000020392337,0.000076628916,0.000049790695,0.0003629982],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974778,0.000093875744,0.0017976234,0.00016212271,0.00030375295,0.0001648101],"domain_scores_gemma":[0.995004,0.0017964535,0.00087283866,0.00010635278,0.0020151562,0.00020522937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077559426,0.00012176358,0.0012143746,0.00007700012,0.00002283082,0.000005469111,0.000108324544,0.0002102193,0.00009830047],"category_scores_gemma":[0.0022374082,0.00007149943,0.00039593084,0.0001252043,0.00014266509,0.000076145516,0.000022865901,0.00046732853,0.0000057230586],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008281468,0.0007765973,0.5337092,0.00045936907,0.0017391944,0.00023250103,0.0011201015,0.000043915465,0.000013331585,0.00031376196,0.07085488,0.38245565],"study_design_scores_gemma":[0.0061717248,0.013750968,0.04870089,0.0014230199,0.00075874664,0.0000033366753,0.00040844112,0.000091105925,0.00010149624,0.00017637068,0.92833185,0.00008207299],"about_ca_topic_score_codex":0.000029160243,"about_ca_topic_score_gemma":0.00006736918,"teacher_disagreement_score":0.85747695,"about_ca_system_score_codex":0.00016804862,"about_ca_system_score_gemma":0.0017054245,"threshold_uncertainty_score":0.302535},"labels":[],"label_agreement":null},{"id":"W4396948218","doi":"10.1200/jco.24.00541","title":"Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Clinical Oncology; Internal medicine; Oncology; Cancer; Cancer-related fatigue; Pathology","score_opus":0.19354768088057345,"score_gpt":0.5662116812695283,"score_spread":0.3726640003889548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396948218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003372677,0.98660815,0.00044267808,0.0032385131,0.0060724793,0.0012260942,0.00026095487,0.000007364972,0.0018065169],"genre_scores_gemma":[0.00019136653,0.99073267,0.0064809537,0.0006631109,0.0011943474,0.00010546405,0.00006272613,0.00005915802,0.00051021687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98862475,0.0006693431,0.0094401855,0.00043392484,0.00049641426,0.00033537621],"domain_scores_gemma":[0.9881497,0.0027215208,0.0067435317,0.00035094772,0.0017724013,0.00026192577],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006374598,0.00044581434,0.009608878,0.0002879889,0.0000155577,0.000004414224,0.00048658912,0.0014064641,0.000109313296],"category_scores_gemma":[0.0009975288,0.0002793706,0.0053350665,0.0006325828,0.00038948897,0.00005181041,0.00016995902,0.0022177945,0.000003288923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012052536,0.0008856708,0.00012395265,0.024631355,0.00508773,0.0002806366,0.00031716403,0.0000044513195,1.9266095e-7,0.0006708375,0.02367488,0.94311786],"study_design_scores_gemma":[0.0032878933,0.006587152,0.000046921272,0.031216895,0.01130631,0.0000588114,0.0010306154,0.00003169135,0.0000021128049,0.00024892925,0.9459981,0.00018458793],"about_ca_topic_score_codex":0.001058732,"about_ca_topic_score_gemma":0.009329412,"teacher_disagreement_score":0.94293326,"about_ca_system_score_codex":0.0009780696,"about_ca_system_score_gemma":0.0060956245,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W4396996859","doi":"10.1200/jco.23.02445","title":"Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McMaster University; Cancer Care Ontario","funders":"National Cancer Institute","keywords":"Medicine; Clinical endpoint; Hazard ratio; Prostate cancer; Internal medicine; Cumulative incidence; Randomized controlled trial; Radiation therapy; Oncology; Dose fractionation; Clinical trial; Cancer; Urology; Confidence interval; Cohort","score_opus":0.08089638849077009,"score_gpt":0.5309293230211334,"score_spread":0.4500329345303633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584943,0.0010288757,0.00023241177,0.0007319502,0.00064683735,0.0013266038,0.000018037717,0.0000106001235,0.00015526247],"genre_scores_gemma":[0.99729407,0.0018775692,0.0003405211,0.00006120728,0.0002528379,0.00005993111,0.000031784144,0.000015595539,0.000066487104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946408,0.0013230675,0.0028358938,0.00029870056,0.00064448797,0.00025699637],"domain_scores_gemma":[0.99334687,0.0034622343,0.0018096955,0.0001636875,0.00097616686,0.0002413342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005966092,0.00017748478,0.003433868,0.00088993716,0.00004823806,0.00001924221,0.00011826169,0.00019368654,0.00017347842],"category_scores_gemma":[0.001391074,0.00010512915,0.0005562364,0.0009165122,0.00035634803,0.00021622532,0.00005455348,0.001352553,0.000002703952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2774708,0.008943829,0.6432717,0.000048337515,0.00746288,0.00042106444,0.00050195487,0.00039097806,0.000006932324,0.000007916352,0.000011686868,0.06146195],"study_design_scores_gemma":[0.35882518,0.010296122,0.621227,0.00020900623,0.0059336,0.0000041420617,0.0001258386,0.0031972558,0.000016030574,0.000024179386,0.00007404701,0.00006758441],"about_ca_topic_score_codex":0.00046740944,"about_ca_topic_score_gemma":0.0020323927,"teacher_disagreement_score":0.08135438,"about_ca_system_score_codex":0.0007819578,"about_ca_system_score_gemma":0.0028662556,"threshold_uncertainty_score":0.58762455},"labels":[],"label_agreement":null},{"id":"W4397011150","doi":"10.1200/jco.23.02639","title":"Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; University of Toronto; National Institute for Health and Care Research; Princess Margaret Cancer Foundation","keywords":"Medicine; Placebo; Methylphenidate; Adverse effect; Clinical endpoint; Internal medicine; Randomized controlled trial; Anesthesia; Attention deficit hyperactivity disorder; Psychiatry","score_opus":0.11176075469853798,"score_gpt":0.47412073243594316,"score_spread":0.3623599777374052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397011150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760463,0.0016235217,0.0006858978,0.0022779566,0.011556885,0.0065592336,0.00001386613,0.000022970637,0.0012133387],"genre_scores_gemma":[0.9942147,0.0005866018,0.0017953757,0.0003082802,0.0019679072,0.000800312,0.000014440315,0.000043646472,0.0002686952],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99497944,0.0007461571,0.0031083773,0.00033544181,0.00048091827,0.0003496825],"domain_scores_gemma":[0.98187435,0.015622846,0.001475023,0.00017022227,0.00055253034,0.0003050415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056711566,0.00025471233,0.0037092343,0.00027074345,0.000039667597,0.000029801868,0.00015694513,0.00035911615,0.00009699372],"category_scores_gemma":[0.004065772,0.00015342205,0.0011359822,0.0002244641,0.00015392574,0.00019699182,0.00002888264,0.0010277831,0.0000026900725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90860605,0.0010395144,0.0012431532,0.000095900206,0.0016736112,0.000080589554,0.00037948362,0.00021219406,0.0000036638107,0.000045654422,0.00017124816,0.08644892],"study_design_scores_gemma":[0.9713182,0.018874831,0.00015512029,0.00054133125,0.0021995537,0.0000033100669,0.00022858164,0.0010790644,0.000023991866,0.000026545362,0.00539729,0.00015218848],"about_ca_topic_score_codex":0.00014561521,"about_ca_topic_score_gemma":0.0018134243,"teacher_disagreement_score":0.08629673,"about_ca_system_score_codex":0.00040391574,"about_ca_system_score_gemma":0.0019120963,"threshold_uncertainty_score":0.62563694},"labels":[],"label_agreement":null},{"id":"W4399071479","doi":"10.1200/jco.23.02475","title":"Surveillance Imaging After Curative-Intent Treatment for Cancer: Benefits, Harms, and Evidence","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","score_opus":0.265175740569886,"score_gpt":0.5760310266439186,"score_spread":0.31085528607403257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399071479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002061054,0.98002696,0.00020766474,0.015565057,0.003287321,0.0006158328,0.000024798488,0.000013096211,0.00005318672],"genre_scores_gemma":[0.0003635334,0.9920383,0.0023509657,0.0012993992,0.0033293841,0.00009615602,0.000005410641,0.00005884201,0.00045798134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99547005,0.0004575719,0.0030415084,0.00043585204,0.00028482015,0.0003102295],"domain_scores_gemma":[0.9914031,0.0054214452,0.0020910318,0.0001987378,0.00037027945,0.00051540905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037790544,0.00037601168,0.0052371556,0.00019662912,0.00004070905,0.0000439306,0.00017298984,0.00034308375,0.00004363867],"category_scores_gemma":[0.006000979,0.00020524104,0.0015973086,0.00012274053,0.00026313993,0.000091717004,0.0000821924,0.001735152,0.000008453656],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045818067,0.00018920374,0.0017201,0.005397188,0.00094627205,0.0006886242,0.000047054717,0.000001133201,1.2808646e-7,0.000029151128,0.003706376,0.9868166],"study_design_scores_gemma":[0.0015330196,0.0030238037,0.00051560055,0.04014501,0.0049926597,0.001402744,0.00001638076,0.00045198144,7.790515e-8,0.000041550327,0.9477104,0.0001667637],"about_ca_topic_score_codex":0.00003849718,"about_ca_topic_score_gemma":0.000023306291,"teacher_disagreement_score":0.9866498,"about_ca_system_score_codex":0.0005269662,"about_ca_system_score_gemma":0.0032977345,"threshold_uncertainty_score":0.8369487},"labels":[],"label_agreement":null},{"id":"W4399071580","doi":"10.1200/jco.23.01462","title":"Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; AstraZeneca","keywords":"Tremelimumab; Durvalumab; Medicine; Sorafenib; Hepatocellular carcinoma; Regimen; Internal medicine; Oncology; Surgery; Cancer; Immunotherapy; Nivolumab; Ipilimumab","score_opus":0.22743119253941496,"score_gpt":0.4282499582866636,"score_spread":0.20081876574724866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399071580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904675,0.0039320895,0.000020773938,0.0024351615,0.0013950333,0.0010536897,0.000011622307,0.000018772647,0.0006653409],"genre_scores_gemma":[0.9986509,0.00017652065,0.0001984915,0.0003075393,0.00043297664,0.000025861289,0.00001398661,0.00003487071,0.00015883613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930392,0.0011120252,0.0043854876,0.00036917292,0.0007632008,0.00033092676],"domain_scores_gemma":[0.9931885,0.004313122,0.0013790114,0.0004687401,0.00035645714,0.00029415017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032493223,0.00026896747,0.002472175,0.00025745895,0.00005046669,0.000023176686,0.00024150361,0.0003522534,0.00039576902],"category_scores_gemma":[0.0018501169,0.00015216785,0.0008762561,0.00046043948,0.0001548421,0.00014274791,0.00010322541,0.0012273573,0.00001386145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068204454,0.008029633,0.91278255,0.000028913668,0.0016019623,0.01631904,0.0021598313,0.000004031557,0.00018811414,0.000010678987,0.0007739851,0.051280815],"study_design_scores_gemma":[0.09822699,0.054820772,0.8154146,0.00033543428,0.004186014,0.0003416765,0.004188106,0.010423097,0.0005898272,0.00019310844,0.011012995,0.0002673886],"about_ca_topic_score_codex":0.0018398579,"about_ca_topic_score_gemma":0.00030098498,"teacher_disagreement_score":0.09736795,"about_ca_system_score_codex":0.00030637116,"about_ca_system_score_gemma":0.0021530949,"threshold_uncertainty_score":0.62052244},"labels":[],"label_agreement":null},{"id":"W4399117432","doi":"10.1200/jco.23.02292","title":"Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Sunnybrook Health Science Centre","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; National Institutes of Health; American College of Radiology Imaging Network; NRG Oncology; Rising Tide Foundation; Rising Tide Foundation for Clinical Cancer Research; Eli Lilly and Company; AstraZeneca; Gateway for Cancer Research; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Breast Cancer Research Foundation","keywords":"Medicine; Pregnancy; Fertility preservation; Gynecology; Breast cancer; Obstetrics; Cumulative incidence; Embryo transfer; Fertility; Cancer; Population; Internal medicine; Cohort","score_opus":0.13801101376026467,"score_gpt":0.4686959038321765,"score_spread":0.3306848900719118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399117432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98198545,0.0023412243,0.000057924848,0.014149005,0.00095135125,0.00040850224,0.0000044901335,0.000012246102,0.00008981851],"genre_scores_gemma":[0.9984015,0.00025834015,0.00042721693,0.00038326372,0.00040602218,0.000012334233,0.0000029521184,0.000008826454,0.00009952318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976562,0.0003895752,0.0012326837,0.00041145974,0.00016558809,0.00014448712],"domain_scores_gemma":[0.9984146,0.0003212938,0.00037917614,0.00022166818,0.00053099915,0.00013227956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020643338,0.000104333594,0.0007070208,0.0001083997,0.000022590939,0.0000075055727,0.000060890987,0.00014323973,0.00004948984],"category_scores_gemma":[0.001990261,0.00006096494,0.00009031063,0.0001954009,0.00012751967,0.00023796537,0.00003772605,0.00068468624,0.0000015472237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020233074,0.00064608513,0.6058582,0.00003656075,0.00010857298,0.000030057601,0.00009247302,0.0000021457329,0.00015575337,0.0000016231503,0.000075429096,0.37276],"study_design_scores_gemma":[0.003295569,0.0056997454,0.987052,0.0006257036,0.00006069376,0.00006551154,0.000021646452,0.000026434775,0.00007580156,0.00006794411,0.002952372,0.00005657556],"about_ca_topic_score_codex":0.000059831582,"about_ca_topic_score_gemma":0.00006442465,"teacher_disagreement_score":0.38119376,"about_ca_system_score_codex":0.00014825445,"about_ca_system_score_gemma":0.00037668634,"threshold_uncertainty_score":0.2974659},"labels":[],"label_agreement":null},{"id":"W4399117481","doi":"10.1200/jco.23.02335","title":"LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Surgery; Cervical cancer; Invasive surgery; Clinical endpoint; Radical Hysterectomy; Hysterectomy; Open surgery; Hazard ratio; Radical surgery; Laparoscopy; Clinical trial; Randomized controlled trial; Overall survival; Cancer; Confidence interval; Internal medicine","score_opus":0.3905927765772268,"score_gpt":0.5398693198398935,"score_spread":0.1492765432626667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399117481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97612625,0.00069093925,0.00011820361,0.007815198,0.006645281,0.0009984815,0.000051324198,0.00002369879,0.0075306296],"genre_scores_gemma":[0.9908156,0.0005411713,0.0014147002,0.001477355,0.0042205113,0.00007518426,0.000020543357,0.000035629946,0.0013992984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951231,0.00061470614,0.0026433095,0.00049854815,0.0007023256,0.0004180511],"domain_scores_gemma":[0.9837117,0.01403446,0.0009351028,0.00025271662,0.00035866644,0.0007073193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031993652,0.00027236072,0.0033058878,0.00042254748,0.00006822043,0.00011320202,0.0005025329,0.00046757914,0.0010254724],"category_scores_gemma":[0.004096443,0.00018215261,0.0019200953,0.0007192827,0.00016277599,0.00019318832,0.0001764476,0.001184966,0.000033665714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8745983,0.0037153738,0.055017836,0.00019983,0.01587587,0.0015882712,0.000103881925,0.000105795945,0.00003214114,0.0010521741,0.0032831514,0.044427346],"study_design_scores_gemma":[0.44177142,0.10420318,0.2732685,0.00050171936,0.013386143,0.000024516052,0.00008187472,0.0005811493,0.00011398584,0.00035885867,0.16534485,0.00036383476],"about_ca_topic_score_codex":0.00050736667,"about_ca_topic_score_gemma":0.0011919601,"teacher_disagreement_score":0.43282694,"about_ca_system_score_codex":0.00061437185,"about_ca_system_score_gemma":0.0033638878,"threshold_uncertainty_score":0.9998877},"labels":[],"label_agreement":null},{"id":"W4399118516","doi":"10.1200/jco.2024.42.16_suppl.e13562","title":"Similarities and differences of lung cancer (LC) multidisciplinary teams (MDTs) in China compared to Europe and Canada.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; China; Multidisciplinary approach; Family medicine; Oncology","score_opus":0.13273349462632278,"score_gpt":0.4867570489609132,"score_spread":0.35402355433459043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399118516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98016936,0.006875302,0.000018375515,0.011262245,0.00064188737,0.000101824866,0.000011233072,0.0000032262242,0.0009165788],"genre_scores_gemma":[0.99608916,0.0020944607,0.0005801949,0.0007771563,0.00032762715,0.000001935007,4.7333097e-7,0.00000628393,0.00012270897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817824,0.00014030977,0.0011209854,0.00015017956,0.00025726834,0.00015300732],"domain_scores_gemma":[0.9985151,0.00075849134,0.0002560633,0.00006340016,0.00014260528,0.00026429226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010439692,0.000092194976,0.0009385397,0.000094964555,0.000023463583,0.000010292966,0.00008549469,0.000101714046,0.00003509427],"category_scores_gemma":[0.0008469363,0.00006302672,0.0000599054,0.00013471235,0.0001486587,0.0000776299,0.00008793101,0.00056243764,1.5440365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012336953,0.000085070365,0.96975166,0.00019076471,0.000113313654,0.0010033062,0.0005715487,0.000040155846,0.00008506296,0.00007309546,0.0055033523,0.02134896],"study_design_scores_gemma":[0.0012258643,0.0016725762,0.9880613,0.0011194991,0.00013327859,0.00016065255,0.0005437924,0.002114819,0.000012703487,0.000063964995,0.0048269136,0.00006463929],"about_ca_topic_score_codex":0.09445427,"about_ca_topic_score_gemma":0.3531144,"teacher_disagreement_score":0.2586601,"about_ca_system_score_codex":0.0001252389,"about_ca_system_score_gemma":0.0025731793,"threshold_uncertainty_score":0.91157585},"labels":[],"label_agreement":null},{"id":"W4399118532","doi":"10.1200/jco.2024.42.16_suppl.e13570","title":"Retrospective study on the correlation between MASCC score and the evolution of febrile neutropenia for patients with solid cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Febrile neutropenia; Retrospective cohort study; Cancer; Internal medicine; Neutropenia; Oncology; Chemotherapy","score_opus":0.07791766994629522,"score_gpt":0.4430866803413428,"score_spread":0.36516901039504757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399118532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123305,0.00020410847,0.00037597417,0.005544733,0.0009874015,0.0010340651,0.000014155475,0.0000052833216,0.0006012099],"genre_scores_gemma":[0.99857605,0.000078303594,0.000030670533,0.00020666086,0.0009407043,0.000034969897,0.0000010734792,0.000011387417,0.000120188175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839544,0.00028083488,0.00084685296,0.00013209955,0.00024889596,0.000095870826],"domain_scores_gemma":[0.9968513,0.0018195738,0.0006662302,0.00011969686,0.0004761378,0.00006702288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016353835,0.00008152007,0.0006906057,0.000058294438,0.00008975832,0.000012546825,0.0000651737,0.00009046084,0.000023997029],"category_scores_gemma":[0.0006431745,0.000034035587,0.00017691667,0.00016163754,0.00026632662,0.00007318359,0.00002212186,0.0006260141,0.0000016102258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006834141,0.0004917196,0.9826075,0.000016090631,0.0005912468,0.000006237646,0.00027081312,0.000035578025,0.000006484562,0.0018350191,0.0012495233,0.0060556764],"study_design_scores_gemma":[0.00866025,0.024170218,0.9628529,0.00016514705,0.001168108,0.000011729378,0.00032528737,0.0000856453,0.0000060490966,0.0007535747,0.0017649916,0.00003609347],"about_ca_topic_score_codex":0.000057330504,"about_ca_topic_score_gemma":0.000081713624,"teacher_disagreement_score":0.023678498,"about_ca_system_score_codex":0.0002785544,"about_ca_system_score_gemma":0.00071901054,"threshold_uncertainty_score":0.27197546},"labels":[],"label_agreement":null},{"id":"W4399118536","doi":"10.1200/jco.2024.42.16_suppl.e13591","title":"Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Text Mining and Ontologies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Provincial Health Services Authority","keywords":"Medicine; Computed tomography; Breast cancer; Radiology; Cancer; Oncology; Medical physics; Internal medicine","score_opus":0.05514140096302278,"score_gpt":0.45301280522436466,"score_spread":0.3978714042613419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399118536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97152203,0.022131568,0.0021739514,0.0021871135,0.0017959595,0.000103685605,0.0000068104478,0.00003294651,0.000045906072],"genre_scores_gemma":[0.9953243,0.0004129515,0.0035572308,0.00015527422,0.0005128944,0.000007419901,0.0000056510335,0.000006043384,0.000018234012],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875283,0.00010775131,0.00076837704,0.00018464524,0.00007636497,0.00011000677],"domain_scores_gemma":[0.9991514,0.00018800196,0.0004018749,0.000056909943,0.00013736032,0.00006445694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012499552,0.00006815,0.00028284916,0.000086196866,0.000023393595,0.00001878305,0.00006238838,0.0002914869,0.0000014719835],"category_scores_gemma":[0.00067926524,0.000049195045,0.000106488,0.00013928644,0.00014878913,0.0000073498823,0.000022345272,0.0003272344,1.4311755e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003129813,0.00007560652,0.004928607,0.000057443212,0.0000439229,0.00005025626,0.00005272313,0.000003968881,0.01745455,0.000002036952,0.0010070597,0.97601086],"study_design_scores_gemma":[0.0019151864,0.0031655428,0.82289106,0.0005330945,0.00012402928,0.0021760135,0.00037589963,0.08863542,0.0015373834,0.00015642603,0.078244686,0.0002452347],"about_ca_topic_score_codex":0.000011058162,"about_ca_topic_score_gemma":0.0001123246,"teacher_disagreement_score":0.9757656,"about_ca_system_score_codex":0.000021221887,"about_ca_system_score_gemma":0.00036964728,"threshold_uncertainty_score":0.2248214},"labels":[],"label_agreement":null},{"id":"W4399118543","doi":"10.1200/jco.2024.42.16_suppl.e13567","title":"From what works to what matters: Whole person cancer care and the integrative oncology leadership collaborative (IOLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Inclusion (mineral); Workflow; Oncology; Nursing; Internal medicine; Medical education; Psychology; Management","score_opus":0.17753826838827627,"score_gpt":0.41462919017748445,"score_spread":0.23709092178920818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399118543","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19427203,0.41752017,0.0006631135,0.37186363,0.012359144,0.0004137966,0.00009025269,0.00001446923,0.0028034055],"genre_scores_gemma":[0.79928386,0.13592722,0.0014256871,0.057356745,0.005231004,0.0000557518,0.00000649402,0.000048643124,0.00066461175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969304,0.0002744626,0.0019673568,0.00042749228,0.00005991887,0.00034036933],"domain_scores_gemma":[0.99430925,0.0035750829,0.0013408883,0.00019208596,0.00027073835,0.0003119822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026273327,0.00023274479,0.0019424801,0.00020037289,0.00008972429,0.0007827919,0.00038207337,0.0005479989,0.0004057715],"category_scores_gemma":[0.0011327454,0.00016194784,0.00041693664,0.00025296275,0.0005913341,0.0027501818,0.000071385366,0.0013088307,0.0002141832],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002349708,0.00008170469,0.0012930763,0.000028103075,0.0006525517,0.00008256755,0.060650237,0.00007801951,0.0000033646718,0.0053914683,0.045302264,0.8840869],"study_design_scores_gemma":[0.0034996832,0.0025897848,0.0032641,0.0012233774,0.00010736666,0.000013705259,0.16725129,0.00024829566,0.000009501194,0.009372734,0.8121788,0.00024137867],"about_ca_topic_score_codex":0.00038459903,"about_ca_topic_score_gemma":0.0010891642,"teacher_disagreement_score":0.88384557,"about_ca_system_score_codex":0.00074386,"about_ca_system_score_gemma":0.0010098609,"threshold_uncertainty_score":0.754848},"labels":[],"label_agreement":null},{"id":"W4399118591","doi":"10.1200/jco.2024.42.16_suppl.e13626","title":"Reliability of YouTube content targeting Arabic-speaking patients with breast cancer regarding post-mastectomy reconstruction.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; St Mary's Hospital Centre; McGill University","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Arabic; Breast reconstruction; Reliability (semiconductor); Cancer; Oncology; Internal medicine","score_opus":0.12615295940017474,"score_gpt":0.5055267811370193,"score_spread":0.3793738217368446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399118591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524165,0.00021816752,0.00068036193,0.003737139,0.0067034736,0.00050167687,0.00007752538,0.000029006043,0.00281097],"genre_scores_gemma":[0.99191636,0.00013342446,0.0046639196,0.0020688954,0.0011224544,0.000014230563,0.000005373079,0.00001475343,0.000060573002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98941475,0.0018483112,0.007700033,0.00023313308,0.00043416943,0.0003696286],"domain_scores_gemma":[0.9812564,0.0049968534,0.005025144,0.00021895856,0.008165637,0.00033696648],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013359149,0.00015004023,0.001189316,0.0001695124,0.00024367523,0.000014370711,0.0002169004,0.0004302778,0.00090867333],"category_scores_gemma":[0.014474502,0.0000790888,0.0003058147,0.0002823815,0.00021478323,0.0027994232,0.00008104764,0.0025164147,0.00001970872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002516048,0.00020192208,0.8125673,0.0006624851,0.00008478323,0.0000046390437,0.0012703036,0.000031410233,0.000009316115,0.00010027812,0.00068759953,0.18186393],"study_design_scores_gemma":[0.004208441,0.0011899266,0.9480923,0.0020625745,0.000089415174,0.000021668733,0.0021396019,0.00067799573,0.000004414909,0.00013023248,0.041269694,0.00011378176],"about_ca_topic_score_codex":0.00025834556,"about_ca_topic_score_gemma":0.00006512536,"teacher_disagreement_score":0.18175015,"about_ca_system_score_codex":0.00054607366,"about_ca_system_score_gemma":0.00414452,"threshold_uncertainty_score":0.9997848},"labels":[{"model":"gemma","categories":["metaresearch","scholarly_communication"],"domain":"evaluation","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4399121788","doi":"10.1200/jco.2024.42.16_suppl.515","title":"Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"Exact Sciences Corporation","keywords":"Medicine; Ethnic group; Internal medicine; Demography; Breast cancer; Cancer; Race (biology); Proportional hazards model; Oncology; Biology","score_opus":0.10334647653270163,"score_gpt":0.462894742433962,"score_spread":0.3595482659012604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399121788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602788,0.024703978,0.000052045118,0.014053645,0.0006612432,0.0001234505,0.000010787237,0.0000018744561,0.000114191265],"genre_scores_gemma":[0.9865204,0.0111425705,0.00031068147,0.0015570879,0.00038879138,0.000007760953,0.000002600327,0.000006766774,0.000063308755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984037,0.00042085184,0.00071952055,0.00020436669,0.00012383578,0.00012769314],"domain_scores_gemma":[0.9983988,0.001167703,0.00020108347,0.000108941545,0.00005819833,0.00006527919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019284737,0.00011021891,0.0005127906,0.000032513897,0.00003509127,0.000021431575,0.00013384558,0.00019842004,0.000004586224],"category_scores_gemma":[0.0013936918,0.00006017741,0.00012476361,0.000060090304,0.000296326,0.00000812718,0.00008935143,0.000364978,7.964905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023715138,0.0016600029,0.56155795,0.000076205746,0.001341473,0.00032709882,0.0008655655,0.0000057536636,0.004335836,0.00028526434,0.07242935,0.33340034],"study_design_scores_gemma":[0.024183298,0.0068878573,0.8631353,0.00009301784,0.00025096769,0.00031242837,0.00026355337,0.000012266973,0.0007478198,0.0010039575,0.10291398,0.00019554306],"about_ca_topic_score_codex":0.000028566055,"about_ca_topic_score_gemma":0.00012783319,"teacher_disagreement_score":0.3332048,"about_ca_system_score_codex":0.000015863397,"about_ca_system_score_gemma":0.00023621976,"threshold_uncertainty_score":0.24539636},"labels":[],"label_agreement":null},{"id":"W4399121831","doi":"10.1200/jco.2024.42.16_suppl.505","title":"Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Hope Foundation; Breast Cancer Research Foundation; Exact Sciences Corporation","keywords":"Anti-Müllerian hormone; Medicine; Breast cancer; Ovarian reserve; Hormone receptor; Hormone; Internal medicine; Adjuvant; Correlation; Cancer; Gynecology; Receptor; Oncology; Endocrinology; Infertility; Biology","score_opus":0.03407251763736503,"score_gpt":0.37179306735341394,"score_spread":0.3377205497160489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399121831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98641217,0.00068485155,0.00032305997,0.009360149,0.0007631752,0.000851986,0.0014196583,0.000009229582,0.00017571232],"genre_scores_gemma":[0.99584657,0.0016204424,0.0011222003,0.0008154323,0.00038511556,0.00002681024,0.00005214154,0.000044201177,0.000087112705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959855,0.00026872847,0.0024294467,0.00043823855,0.0006327146,0.00024534186],"domain_scores_gemma":[0.9954519,0.0012395548,0.0017774969,0.00022315174,0.0010414633,0.00026638428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007685681,0.00026919987,0.0015396839,0.00029271116,0.000033693905,0.000017229542,0.00014125001,0.00033390944,0.00019799413],"category_scores_gemma":[0.0002312409,0.00019622318,0.00019855218,0.0004898364,0.00015214318,0.00023069652,0.000033266322,0.00060648145,0.00001538134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050785057,0.0150511805,0.3938722,0.00009887376,0.0043003582,0.0002197808,0.0033721647,0.0016459505,0.018139124,0.00016295446,0.0033791317,0.50897324],"study_design_scores_gemma":[0.012885886,0.02233956,0.9567964,0.0015059463,0.00053198513,0.000013879053,0.00015569328,0.00024431077,0.005042906,0.00008683676,0.00023463911,0.00016194039],"about_ca_topic_score_codex":0.0007510755,"about_ca_topic_score_gemma":0.00026574542,"teacher_disagreement_score":0.5629242,"about_ca_system_score_codex":0.00083743624,"about_ca_system_score_gemma":0.0009744318,"threshold_uncertainty_score":0.8001749},"labels":[],"label_agreement":null},{"id":"W4399121921","doi":"10.1200/jco.2024.42.16_suppl.567","title":"Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Non-Destructive Testing Techniques","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; BC Cancer Agency; Ontario Institute for Cancer Research; Queen's University","funders":"","keywords":"Medicine; Adjuvant; Internal medicine; Oncology; Cancer research","score_opus":0.07982037673378764,"score_gpt":0.4464117560613898,"score_spread":0.3665913793276021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399121921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76772594,0.0013215925,0.22545733,0.0002990948,0.0016330981,0.00015316824,0.00004632769,0.00011048897,0.0032529435],"genre_scores_gemma":[0.7911038,0.00038015257,0.20836759,0.000018262286,0.00010555886,0.0000010830704,0.0000017929684,0.000018645378,0.000003134871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978148,0.0002414801,0.0015003424,0.00012019842,0.00018598727,0.00013723609],"domain_scores_gemma":[0.9961108,0.0032555216,0.0002457896,0.00007504561,0.0002126649,0.00010020964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022359993,0.00010655097,0.00079097354,0.00020214863,0.000007615375,0.000011225992,0.00008944745,0.00021916597,0.000041993142],"category_scores_gemma":[0.0033441177,0.000083977335,0.00008102744,0.00019782137,0.00019551464,0.00014749583,0.000032065658,0.0007337845,0.0000022970523],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041877325,0.0013610127,0.2842124,0.0014817455,0.0016848071,0.0049752337,0.0015606985,0.00551236,0.013439646,0.30944845,0.02508651,0.3470494],"study_design_scores_gemma":[0.0039455756,0.010248222,0.57894987,0.0012182096,0.00032235333,0.00037206488,0.00013923162,0.028879125,0.00071145885,0.36681536,0.0079754405,0.00042308288],"about_ca_topic_score_codex":0.000013588061,"about_ca_topic_score_gemma":0.00003152793,"teacher_disagreement_score":0.34662628,"about_ca_system_score_codex":0.00014126916,"about_ca_system_score_gemma":0.00030743098,"threshold_uncertainty_score":0.40034628},"labels":[],"label_agreement":null},{"id":"W4399121924","doi":"10.1200/jco.2024.42.16_suppl.531","title":"PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Genetic testing; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.10453447063581303,"score_gpt":0.4549896726979898,"score_spread":0.35045520206217673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399121924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743784,0.0005461006,0.000033585573,0.009755453,0.0006613497,0.000629275,0.00000958568,0.000019122454,0.0009076821],"genre_scores_gemma":[0.99445444,0.00060916337,0.0005802793,0.0027471385,0.0014592712,0.00005969215,4.5459353e-7,0.000022028964,0.000067536545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960615,0.0010833528,0.0016976225,0.00031558823,0.0005222285,0.00031969653],"domain_scores_gemma":[0.98941606,0.008867878,0.0007326964,0.0002704438,0.00043803337,0.00027487267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040193005,0.00018205371,0.0011882886,0.00016683136,0.00005027954,0.000030474286,0.00025710842,0.00019723366,0.00030265737],"category_scores_gemma":[0.0015867378,0.00009982101,0.00017158013,0.0006127893,0.0003354126,0.00013253289,0.000036863763,0.0014155278,0.000009884677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009560622,0.0018263914,0.87760603,0.000050179857,0.00055987306,0.010306415,0.0032098042,0.00031964137,0.00010362198,0.000006834569,0.0018907156,0.09455989],"study_design_scores_gemma":[0.017780283,0.015785534,0.9576795,0.00043452735,0.00027816344,0.0011944465,0.003674602,0.00010582139,0.0000072734856,0.00025678662,0.0026914645,0.00011161006],"about_ca_topic_score_codex":0.0003360005,"about_ca_topic_score_gemma":0.0011092873,"teacher_disagreement_score":0.09444828,"about_ca_system_score_codex":0.0008734994,"about_ca_system_score_gemma":0.004703077,"threshold_uncertainty_score":0.83430564},"labels":[],"label_agreement":null},{"id":"W4399122010","doi":"10.1200/jco.2024.42.16_suppl.1005","title":"Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer; Gynecology","score_opus":0.1377817727281921,"score_gpt":0.5451264201042444,"score_spread":0.4073446473760523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93946314,0.005955674,0.0000212871,0.045775335,0.0037770444,0.00072002714,0.00025963117,0.000021726275,0.004006134],"genre_scores_gemma":[0.98123354,0.013443392,0.00035702818,0.0011645115,0.0024808105,0.00004478759,0.0000023892126,0.000051775005,0.0012217495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941801,0.00069215044,0.0031925638,0.0004464924,0.00093993865,0.0005487946],"domain_scores_gemma":[0.993878,0.0033108767,0.001011773,0.00026347965,0.0008543061,0.0006815409],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053212135,0.00026305264,0.002334462,0.00044174626,0.000036781952,0.000026718724,0.0002798578,0.00059474463,0.0027676767],"category_scores_gemma":[0.0018067625,0.0001923091,0.0004391945,0.00064676185,0.00077421207,0.00021400671,0.000095367985,0.002768139,0.000015816062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009361668,0.0011987846,0.4714575,0.00069057243,0.0009795795,0.0036255042,0.0007607604,0.000048225305,0.00041145962,0.00014609196,0.026994381,0.48432547],"study_design_scores_gemma":[0.008434697,0.0039172173,0.9469662,0.0028538096,0.00041278757,0.0023060394,0.0003106329,0.00064230734,0.00022010122,0.00043854179,0.033294834,0.00020286908],"about_ca_topic_score_codex":0.006647034,"about_ca_topic_score_gemma":0.0049844133,"teacher_disagreement_score":0.4841226,"about_ca_system_score_codex":0.0010578857,"about_ca_system_score_gemma":0.012057471,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W4399122015","doi":"10.1200/jco.2024.42.16_suppl.tps611","title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Rising Tide Foundation for Clinical Cancer Research; Agendia; Swiss Cancer Research Foundation; Freiwillige Akademische Gesellschaft","keywords":"Medicine; Breast cancer; Axillary Lymph Node Dissection; Lymph node; Radiation therapy; Axillary Dissection; Dissection (medical); Axilla; Oncology; Internal medicine; Radiology; Cancer; Surgery; Mastectomy; Sentinel lymph node","score_opus":0.024766196027086112,"score_gpt":0.3672187278846096,"score_spread":0.34245253185752345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884408,0.0037562915,0.00067080115,0.004347168,0.0018109877,0.00044152787,0.00020743726,0.00002982388,0.00029512326],"genre_scores_gemma":[0.9878475,0.0066090673,0.0010600137,0.0024442098,0.001378302,0.00006296794,0.00015942502,0.000119797325,0.0003186854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468344,0.0007633875,0.0024731844,0.000864437,0.00059369067,0.0006218407],"domain_scores_gemma":[0.99588025,0.0011490055,0.0015235039,0.00039569862,0.0006520919,0.00039946314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015710575,0.0005701196,0.0021119588,0.00019756366,0.00012465958,0.000058516755,0.00032339126,0.00077183323,0.00012587845],"category_scores_gemma":[0.00036885118,0.00035473998,0.0005915158,0.00042785573,0.00055736885,0.000065749475,0.000101482445,0.00079231,0.000008191707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059645552,0.002010195,0.8890293,0.000056325796,0.002775403,0.00040635883,0.00008823782,0.00008543002,0.0003347197,0.0000018416938,0.01043666,0.035129942],"study_design_scores_gemma":[0.016049225,0.008768208,0.95974165,0.00075317017,0.000662022,0.00053464377,0.00016840294,0.00006202336,0.00021882194,0.000011084042,0.012364431,0.0006663346],"about_ca_topic_score_codex":0.00019281136,"about_ca_topic_score_gemma":0.00055846205,"teacher_disagreement_score":0.0707123,"about_ca_system_score_codex":0.00059018587,"about_ca_system_score_gemma":0.0026973798,"threshold_uncertainty_score":0.99989045},"labels":[],"label_agreement":null},{"id":"W4399122083","doi":"10.1200/jco.2024.42.16_suppl.e12664","title":"Trends and outcomes in patients receiving neoadjuvant chemotherapy for breast cancer in Ontario: A population-based study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Chemotherapy; Internal medicine; Neoadjuvant therapy; Population; Cancer; Environmental health","score_opus":0.037138252744362804,"score_gpt":0.4172799214966643,"score_spread":0.3801416687523015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949487,0.00029915138,0.000013868128,0.0038859413,0.0006526578,0.00014455627,0.000021771337,0.0000020216596,0.00003137311],"genre_scores_gemma":[0.99894243,0.00006596756,0.00028826966,0.00042069313,0.00015561563,0.000024158622,0.00000593704,0.000012608068,0.000084306615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855167,0.000109267734,0.0008930042,0.00020757059,0.00009832308,0.00014018381],"domain_scores_gemma":[0.9991971,0.00031556017,0.0002742482,0.00007573442,0.00008046452,0.00005688246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065268774,0.00011457343,0.00060485705,0.00013069586,0.000017570557,0.000009987701,0.00007119008,0.00014956966,0.00002584456],"category_scores_gemma":[0.00015621926,0.00008285814,0.00015734634,0.00007682661,0.000026832626,0.00000755301,0.00002435089,0.00021616243,1.5433187e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012777477,0.0008399803,0.74731964,0.000005271715,0.00015950136,0.000008778182,0.00009347591,0.000044630408,0.000005734004,0.000001213927,0.0000776245,0.25016645],"study_design_scores_gemma":[0.008867882,0.0022791957,0.9874463,0.000057584406,0.000054218177,0.0000029622088,0.000035174577,0.000028450124,0.0000038125302,0.00003827053,0.0011073918,0.00007876185],"about_ca_topic_score_codex":0.0048051313,"about_ca_topic_score_gemma":0.25077567,"teacher_disagreement_score":0.25008768,"about_ca_system_score_codex":0.00022795852,"about_ca_system_score_gemma":0.0004732176,"threshold_uncertainty_score":0.7628957},"labels":[],"label_agreement":null},{"id":"W4399122099","doi":"10.1200/jco.2024.42.16_suppl.1007","title":"Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Pertuzumab; Trastuzumab; Eribulin; Taxane; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Paclitaxel; Anthracycline; Cancer","score_opus":0.11762713107934504,"score_gpt":0.5248258775869272,"score_spread":0.4071987465075822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96708935,0.0010857296,0.00090694404,0.024669986,0.000500458,0.005515408,0.00017899631,0.000011102572,0.000042007727],"genre_scores_gemma":[0.98476017,0.010322798,0.0033031395,0.0005159322,0.00030197954,0.0003970867,0.000019579438,0.000047763133,0.00033153288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940108,0.0008810529,0.0036797135,0.0004640686,0.0005391289,0.00042525973],"domain_scores_gemma":[0.9883208,0.009361271,0.0011976159,0.00020024442,0.0005716397,0.00034842445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005286548,0.00032035817,0.0035628318,0.00039330605,0.00003606792,0.00002595008,0.00014960027,0.00025698973,0.00014049637],"category_scores_gemma":[0.003463821,0.00017922717,0.00040622044,0.00044827678,0.00046951062,0.00017848452,0.00003079166,0.0008472663,0.0000014753867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67592937,0.008344154,0.0001475017,0.0003403154,0.0008025427,0.0007905263,0.00084906706,0.00007488629,0.000116380834,0.0000062851805,0.000038996408,0.31255996],"study_design_scores_gemma":[0.8293004,0.14027199,0.0011944931,0.0022688063,0.00086541,0.00051272876,0.00022644152,0.022078369,0.00029540007,0.00006728755,0.0027607922,0.00015789102],"about_ca_topic_score_codex":0.0015008885,"about_ca_topic_score_gemma":0.006666228,"teacher_disagreement_score":0.31240207,"about_ca_system_score_codex":0.0013264411,"about_ca_system_score_gemma":0.0062170215,"threshold_uncertainty_score":0.9994168},"labels":[],"label_agreement":null},{"id":"W4399122113","doi":"10.1200/jco.2024.42.16_suppl.536","title":"Sexual health and therapy adherence of hormone-sensitive breast cancer survivors on maintenance endocrine therapy: The SHE-CAN project in Toronto, Canada.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Hormone therapy; Breast cancer; Endocrine system; Reproductive health; Sex therapy; Hormonal therapy; Oncology; Cancer; Maintenance therapy; Gynecology; Hormone; Family medicine; Internal medicine; Sexual dysfunction; Chemotherapy; Population; Environmental health","score_opus":0.11777278363842013,"score_gpt":0.46750764458037253,"score_spread":0.3497348609419524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93601006,0.009411852,0.0000036491238,0.048583616,0.0025501056,0.00040075424,0.000069072354,0.0000077447785,0.0029631243],"genre_scores_gemma":[0.952482,0.042046476,0.000040814684,0.0045221746,0.0006287145,0.000009561253,6.241594e-7,0.000012019457,0.00025765426],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959037,0.0016554343,0.0013023767,0.00022392483,0.0005421781,0.0003724275],"domain_scores_gemma":[0.9947233,0.0038777792,0.00079824176,0.00012589028,0.0002708902,0.00020386987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052119545,0.00013459723,0.00080770656,0.000048338105,0.00010288316,0.000021389133,0.00031061238,0.00013102344,0.000056363817],"category_scores_gemma":[0.00073801714,0.0000781182,0.000097625925,0.00024495774,0.00060304446,0.00013811774,0.000032271684,0.00072478084,3.2282966e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026593285,0.0003910673,0.040488,0.000015954662,0.00020380197,0.0003238723,0.014199956,0.000011467084,0.000026194335,0.0023291232,0.023672301,0.9156789],"study_design_scores_gemma":[0.0031035147,0.009330066,0.60634595,0.0002469337,0.000019587605,0.00012114226,0.07054208,0.00009668274,0.000014678474,0.0004999538,0.30940136,0.00027806358],"about_ca_topic_score_codex":0.936858,"about_ca_topic_score_gemma":0.9877044,"teacher_disagreement_score":0.91540086,"about_ca_system_score_codex":0.0009469862,"about_ca_system_score_gemma":0.01936884,"threshold_uncertainty_score":0.98619044},"labels":[],"label_agreement":null},{"id":"W4399122128","doi":"10.1200/jco.2024.42.16_suppl.103","title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous <i>EGFR</i> wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Oncology; Population; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.022615103615234937,"score_gpt":0.3832729628268702,"score_spread":0.36065785921163523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950096,0.0007675715,0.00039430876,0.0015251166,0.00075568113,0.00049254013,0.000002923105,0.00001215889,0.001040123],"genre_scores_gemma":[0.99503684,0.00029528246,0.002750767,0.0014730864,0.00029629088,0.0000039864763,0.000007372486,0.000027760158,0.00010858922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605364,0.00058670173,0.0022441351,0.0002807179,0.0005793225,0.00025549962],"domain_scores_gemma":[0.9956409,0.0021513612,0.0014368147,0.00031000155,0.0002512121,0.0002097112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002838181,0.00018377462,0.0020144873,0.0003550992,0.000041481686,0.000020239257,0.0002722427,0.00025456035,0.000035342913],"category_scores_gemma":[0.0020352781,0.00009997947,0.00073233433,0.0009397771,0.00023818022,0.00013668578,0.0000522459,0.0016560052,0.0000011706799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060521517,0.0024816021,0.60364413,0.00009251513,0.0017584855,0.00018678886,0.00024928592,0.0011259781,0.00035917122,0.000008148673,0.00053755596,0.3290348],"study_design_scores_gemma":[0.08331026,0.012600813,0.88744926,0.0009227265,0.0032855072,0.000019296296,0.000027809703,0.0048944536,0.00006317291,0.000028207947,0.007252738,0.00014574223],"about_ca_topic_score_codex":0.000060750284,"about_ca_topic_score_gemma":0.000018213334,"teacher_disagreement_score":0.32888904,"about_ca_system_score_codex":0.00029016292,"about_ca_system_score_gemma":0.0012753075,"threshold_uncertainty_score":0.7194611},"labels":[],"label_agreement":null},{"id":"W4399123713","doi":"10.1200/jco.2024.42.16_suppl.1606","title":"Global disparities in immunotherapy clinical trials: A comprehensive analysis of low- and middle-income countries over the past decade.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Population; Low and middle income countries; Cancer; Developing country; Demography; Environmental health; Internal medicine; Economic growth","score_opus":0.19470086968884395,"score_gpt":0.4657013935249846,"score_spread":0.2710005238361406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399123713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94961625,0.040443126,0.00051168475,0.0051166373,0.0026817718,0.00014942982,0.00021038913,0.0000052221185,0.0012654902],"genre_scores_gemma":[0.9654155,0.03146321,0.00025366043,0.0018885608,0.0008978174,0.0000038048195,0.0000014903334,0.0000117304235,0.00006425594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99135417,0.0005285894,0.0075100386,0.0002829157,0.00007283187,0.0002514416],"domain_scores_gemma":[0.9855213,0.010380779,0.0035785928,0.00022645548,0.00014536397,0.00014747008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015691793,0.00017015733,0.0038556885,0.00036291577,0.000038756432,0.00008525864,0.00034779464,0.00047360736,0.00019451523],"category_scores_gemma":[0.0039321226,0.000121609155,0.0013186911,0.00050652213,0.0007344605,0.00032484162,0.00007403908,0.00071064784,0.000012864578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012528988,0.00019776922,0.9269455,0.0000697847,0.0027558366,0.00003868207,0.00013057912,0.00014410041,1.1562768e-7,0.054407492,0.0007995623,0.013257692],"study_design_scores_gemma":[0.0021419327,0.0009403781,0.896827,0.00014923347,0.00027702513,0.000010445706,0.00006601817,0.0013556697,2.00115e-7,0.016897596,0.08121579,0.00011870761],"about_ca_topic_score_codex":0.00032406053,"about_ca_topic_score_gemma":0.0005064242,"teacher_disagreement_score":0.080416225,"about_ca_system_score_codex":0.00018426156,"about_ca_system_score_gemma":0.0004401941,"threshold_uncertainty_score":0.54384935},"labels":[],"label_agreement":null},{"id":"W4399123749","doi":"10.1200/jco.2024.42.16_suppl.580","title":"A retrospective look: Industry partnership and transparency in phase III randomized clinical trials of breast cancer targeted therapies across two decades.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Clinical trial; Transparency (behavior); Internal medicine; General partnership; Cancer; Intensive care medicine","score_opus":0.1860640989025555,"score_gpt":0.5718642440831567,"score_spread":0.38580014518060124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399123749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91710097,0.018392878,0.0002436964,0.061760463,0.0016670547,0.0004913531,0.00002751736,0.000022760845,0.00029332744],"genre_scores_gemma":[0.9708088,0.026786277,0.00026265247,0.0010204281,0.00096069556,0.000012067423,0.0000017165953,0.000015515992,0.0001318263],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98856,0.0033457607,0.0072476533,0.00031332282,0.0002447231,0.0002885374],"domain_scores_gemma":[0.9872362,0.00985278,0.0021982554,0.0001630752,0.0002696493,0.00028006083],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.044591792,0.00019214507,0.0056124227,0.00021545094,0.00003193443,0.000009565821,0.00015365073,0.007666231,0.00037841743],"category_scores_gemma":[0.010957046,0.000112391404,0.001132141,0.0003591553,0.0018166665,0.00010184589,0.000031425086,0.012981282,0.000001612443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5276725,0.0035606413,0.1029792,0.00013180608,0.0061460924,0.0018549334,0.002024473,0.0000061341884,0.00065400795,0.0021082328,0.0017809138,0.35108104],"study_design_scores_gemma":[0.85094404,0.008319383,0.11991094,0.0020319533,0.0032089879,0.0012540277,0.0011885624,0.0006705189,0.00045456295,0.0053534806,0.006394239,0.0002693032],"about_ca_topic_score_codex":0.000053109547,"about_ca_topic_score_gemma":0.0000830936,"teacher_disagreement_score":0.35081175,"about_ca_system_score_codex":0.00007670648,"about_ca_system_score_gemma":0.0016300986,"threshold_uncertainty_score":0.99737406},"labels":[],"label_agreement":null},{"id":"W4399127309","doi":"10.1200/jco.2024.42.16_suppl.1043","title":"Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Circulating tumor DNA; Circulating tumor cell; HER2 negative; Cancer research; Breast cancer; Cancer; Metastasis","score_opus":0.11459226726504335,"score_gpt":0.4771240423921294,"score_spread":0.36253177512708606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399127309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993874,0.008074168,0.00038765412,0.00072335487,0.00062546565,0.00020417199,0.00003539132,0.0000032069381,0.000007850734],"genre_scores_gemma":[0.98881274,0.0021801256,0.008185269,0.00023814058,0.000546892,0.000005261607,0.0000019913427,0.000026538533,0.0000030127837],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99619806,0.0015176521,0.0014559116,0.00032926403,0.0002588028,0.00024030112],"domain_scores_gemma":[0.9924512,0.005959834,0.0009803184,0.0001320479,0.00031578718,0.00016079286],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008853202,0.00017356139,0.000814594,0.0001994838,0.000047231588,0.000037518526,0.000073125244,0.000117335905,0.0000087301105],"category_scores_gemma":[0.011964664,0.00014091564,0.0001526057,0.0002560716,0.0001772404,0.000017085187,0.00014077232,0.00045180783,1.3611574e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052302224,0.00046399265,0.066490404,0.00017928846,0.0003058867,0.001433201,0.00015943339,0.0017125062,0.63362336,0.000022669281,0.00005791458,0.29032114],"study_design_scores_gemma":[0.013470495,0.017233495,0.81259173,0.0035220494,0.0008410527,0.009625316,0.0004594464,0.07987477,0.059071306,0.0008585562,0.0015861233,0.0008656398],"about_ca_topic_score_codex":0.00014697146,"about_ca_topic_score_gemma":0.000114070644,"teacher_disagreement_score":0.7461013,"about_ca_system_score_codex":0.00010744997,"about_ca_system_score_gemma":0.0015773928,"threshold_uncertainty_score":0.996358},"labels":[],"label_agreement":null},{"id":"W4399127422","doi":"10.1200/jco.2024.42.16_suppl.1579","title":"Racial disparities in the immunotherapeutic outcomes of patients with non-small cell lung cancer (NSCLC): An in-depth systematic review and meta-analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Meta-analysis; Oncology; Internal medicine","score_opus":0.15693279296178267,"score_gpt":0.5092593889879565,"score_spread":0.3523265960261739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399127422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60214055,0.3771995,0.00008296055,0.01631404,0.00022623445,0.0023752106,0.00002376438,0.000005236208,0.0016324723],"genre_scores_gemma":[0.986181,0.009201841,0.000075135154,0.0043386295,0.00005446531,0.000046369987,0.000001745259,0.000010588338,0.000090192356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604833,0.0009499009,0.0021899454,0.00015854514,0.000478253,0.00017502275],"domain_scores_gemma":[0.9963487,0.0024395331,0.00059092365,0.00021641611,0.00029460454,0.000109820394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050534233,0.00012764362,0.0041619213,0.00022706673,0.000014855539,0.00001760411,0.00020943259,0.00012373338,0.00039540877],"category_scores_gemma":[0.00041882612,0.00005363278,0.00075324177,0.0004656353,0.00014136221,0.00008633035,0.00003061424,0.00089447346,7.672289e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015266932,0.0020638304,0.85293525,0.090319015,0.04923144,0.00019080249,0.00094873254,0.000016012404,0.0000011077757,0.000065489774,0.00010133522,0.0026002903],"study_design_scores_gemma":[0.0020821437,0.0023551963,0.80334955,0.00066932285,0.1911997,0.000004637906,0.00008364731,0.00009822197,7.5284953e-7,0.000030358007,0.00006866364,0.000057802543],"about_ca_topic_score_codex":0.00021975189,"about_ca_topic_score_gemma":0.002394029,"teacher_disagreement_score":0.38404047,"about_ca_system_score_codex":0.00008388856,"about_ca_system_score_gemma":0.0007061379,"threshold_uncertainty_score":0.43294486},"labels":[],"label_agreement":null},{"id":"W4399149960","doi":"10.1200/jco.2024.42.16_suppl.tps622","title":"NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Breast-conserving surgery; Tamoxifen; Oncology; Internal medicine; Stage (stratigraphy); Radiation therapy; Lymphovascular invasion; Gynecology; Cancer; Metastasis; Surgery; Mastectomy","score_opus":0.10797263554618532,"score_gpt":0.49326496587965496,"score_spread":0.38529233033346966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399149960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904381,0.0031117408,0.0006257277,0.0025957085,0.0026216658,0.00025608554,0.00019382077,0.000010383459,0.00014673955],"genre_scores_gemma":[0.9958462,0.0009697318,0.00054550695,0.00017272559,0.0023264529,0.000019624802,0.000030983134,0.000034352397,0.000054413893],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952643,0.0008572338,0.0027538645,0.00035110326,0.00045011783,0.00032339268],"domain_scores_gemma":[0.99518657,0.0017268305,0.0021848215,0.00023062772,0.00048233735,0.00018880013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051437775,0.00023388423,0.0014032495,0.00017478268,0.0000715197,0.000019712414,0.0002064074,0.0004310035,0.00011261537],"category_scores_gemma":[0.0010575891,0.00020346045,0.0011309573,0.0002550016,0.00018010668,0.000040455034,0.00010322572,0.00038445945,0.0000011953093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09007847,0.0019684485,0.07229999,0.00020828165,0.0033592249,0.00011894745,0.00024932215,0.00043687105,0.019773861,0.000028817873,0.002075867,0.80940187],"study_design_scores_gemma":[0.20710753,0.016023727,0.7461931,0.0025838965,0.005003964,0.0027473012,0.0011244385,0.0059201396,0.0074019087,0.00047500117,0.004349068,0.001069935],"about_ca_topic_score_codex":0.00038159953,"about_ca_topic_score_gemma":0.00012454293,"teacher_disagreement_score":0.80833197,"about_ca_system_score_codex":0.00022752483,"about_ca_system_score_gemma":0.0036172904,"threshold_uncertainty_score":0.82968765},"labels":[],"label_agreement":null},{"id":"W4399150010","doi":"10.1200/jco.2024.42.16_suppl.e13771","title":"Value of a multidisciplinary geriatric oncology committee on patient care in a community-based, academic cancer center.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multidisciplinary approach; Center (category theory); Geriatric oncology; Clinical Oncology; Oncology; Cancer; Family medicine; Internal medicine; Medical physics","score_opus":0.08825863976784491,"score_gpt":0.5467960305490188,"score_spread":0.4585373907811739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399150010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96769077,0.012110513,0.0001738899,0.010957439,0.005903535,0.00039006182,0.0000312965,0.000017830796,0.0027246957],"genre_scores_gemma":[0.9793231,0.00802618,0.0051517007,0.0060102395,0.0013722267,0.000020503698,0.000009023329,0.000031641688,0.000055397035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993828,0.002488245,0.0028688544,0.00020649824,0.0003116774,0.00029672138],"domain_scores_gemma":[0.98818195,0.00975114,0.0012880713,0.00027188685,0.00026358126,0.00024338166],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031366027,0.00020070425,0.0019263824,0.00046052274,0.00007132156,0.0000023781645,0.00032616596,0.0010886306,0.000102997416],"category_scores_gemma":[0.0010377879,0.00014081484,0.000559026,0.0003666394,0.0005952727,0.00008261828,0.00008819475,0.006163532,0.000009189355],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026226087,0.007108079,0.1943907,0.0006584405,0.00052038685,0.0031201867,0.0052171764,0.003032401,0.00027061068,0.00036095377,0.005632304,0.7534627],"study_design_scores_gemma":[0.024704993,0.1556453,0.10617788,0.0026423533,0.0005257221,0.0008126352,0.0025420007,0.0014870781,0.00022067296,0.0011219832,0.7038381,0.00028126157],"about_ca_topic_score_codex":0.00004283664,"about_ca_topic_score_gemma":0.00014094396,"teacher_disagreement_score":0.7531814,"about_ca_system_score_codex":0.0012612768,"about_ca_system_score_gemma":0.0043238318,"threshold_uncertainty_score":0.9961293},"labels":[],"label_agreement":null},{"id":"W4399150145","doi":"10.1200/jco.2024.42.16_suppl.1601","title":"Racial/ethnic representation and disparities in preclinical cancer models.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Ethnic group; Cancer; Oncology; Internal medicine","score_opus":0.611265956079529,"score_gpt":0.636543770636527,"score_spread":0.025277814556997957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399150145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94929284,0.025850724,0.0004359791,0.019800562,0.0019267455,0.00012299402,0.0000022960864,0.000012293578,0.00255555],"genre_scores_gemma":[0.97956,0.01541531,0.0012100624,0.00215726,0.0013648395,0.000005464537,8.0976633e-7,0.000008481256,0.00027775147],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973654,0.0002471922,0.0017476574,0.00019070793,0.0002884714,0.00016055517],"domain_scores_gemma":[0.99717593,0.002000447,0.00035015118,0.0000905266,0.00016819633,0.00021472915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00307237,0.00007907732,0.00086917216,0.00011363039,0.000015011855,0.000016707989,0.00007535384,0.0002942719,0.00007014545],"category_scores_gemma":[0.0024775784,0.000057185458,0.00023981821,0.00018933517,0.00018243464,0.00031049977,0.00004313894,0.0010697987,0.000003846498],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003563499,0.00025106827,0.20759502,0.000096874974,0.0001934504,0.0018657802,0.00041577808,0.00044067204,0.000038638584,0.001530131,0.006109504,0.77789956],"study_design_scores_gemma":[0.0050518876,0.007041976,0.91792387,0.001504854,0.000531108,0.00081210944,0.0003788307,0.018972509,0.00002682564,0.022050673,0.025549317,0.00015605001],"about_ca_topic_score_codex":0.00029222123,"about_ca_topic_score_gemma":0.0006947101,"teacher_disagreement_score":0.7777435,"about_ca_system_score_codex":0.00012396945,"about_ca_system_score_gemma":0.0012437248,"threshold_uncertainty_score":0.46478027},"labels":[],"label_agreement":null},{"id":"W4399150161","doi":"10.1200/jco.2024.42.16_suppl.e13639","title":"Auto-machine learning for opportunistic thyroid nodule detection in lung cancer screening chest CT.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Lung cancer screening; Radiology; Lung cancer; Context (archaeology); Thyroid nodules; Thyroid cancer; Artificial intelligence; National Lung Screening Trial; Colorectal cancer; Machine learning; Thyroid; Nuclear medicine; Cancer; Computed tomography; Computer science; Pathology; Internal medicine","score_opus":0.08138901625536003,"score_gpt":0.4727752139493028,"score_spread":0.39138619769394273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399150161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6506469,0.010007836,0.276495,0.051894497,0.00797194,0.0006354276,0.000006868078,0.00011774778,0.0022237715],"genre_scores_gemma":[0.98619586,0.0016931248,0.0072766696,0.0014214135,0.0024984344,0.000012344054,0.0000067891206,0.00004131222,0.00085405033],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9971186,0.00027872878,0.0017840869,0.00024235451,0.00028456614,0.00029164273],"domain_scores_gemma":[0.99575627,0.0029677495,0.00065892783,0.00009354037,0.00016819892,0.00035532765],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0061776815,0.00014194126,0.0010577852,0.00028208707,0.00006871195,0.000029975414,0.0001254954,0.0001802682,0.00010520758],"category_scores_gemma":[0.010443067,0.00010650702,0.00042957283,0.00021419495,0.00012419836,0.00012045519,0.00003915722,0.0029256071,0.0000028973445],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090683985,0.00025670158,0.042854197,0.00029371353,0.00030746486,0.0017131865,0.0001042628,0.0010939898,0.0017927069,0.00012432998,0.0013858518,0.9491668],"study_design_scores_gemma":[0.0037597562,0.0027050048,0.033171706,0.00067654584,0.00041659226,0.0007339177,0.00004680096,0.7042116,0.000036075704,0.00012653615,0.25400794,0.00010754169],"about_ca_topic_score_codex":0.000121434976,"about_ca_topic_score_gemma":0.00006389216,"teacher_disagreement_score":0.9490592,"about_ca_system_score_codex":0.00022675427,"about_ca_system_score_gemma":0.0010794891,"threshold_uncertainty_score":0.9993747},"labels":[],"label_agreement":null},{"id":"W4399150452","doi":"10.1200/jco.2024.42.16_suppl.1596","title":"Racial disparities in presentation and survival for lobular breast cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Breast cancer; Mastectomy; Hazard ratio; Invasive lobular carcinoma; Proportional hazards model; Population; Cancer; Oncology; Cohort; Stage (stratigraphy); Internal medicine; Radiation therapy; Ductal carcinoma; Gynecology; Invasive ductal carcinoma; Confidence interval","score_opus":0.06744667285283096,"score_gpt":0.4717265635164948,"score_spread":0.4042798906636638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399150452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768023,0.0076707196,0.00060498377,0.012251856,0.0022928882,0.00012639778,0.000072142866,0.0000032292064,0.00017549821],"genre_scores_gemma":[0.993593,0.003670137,0.00036278623,0.0002340103,0.0020282601,0.000017052089,0.000006641027,0.000009428696,0.00007869812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989178,0.00011816039,0.0006140621,0.00014722555,0.00008288218,0.00011984682],"domain_scores_gemma":[0.9992008,0.000384047,0.00019053923,0.000048651804,0.000113178474,0.00006276002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073498016,0.000077106895,0.000385408,0.000038335053,0.000022761049,0.000013532569,0.00006224595,0.00016424675,0.000007767489],"category_scores_gemma":[0.0003136702,0.000058935337,0.00013819274,0.00003951044,0.00012863093,0.000008833956,0.000041621242,0.00014813976,4.4836113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006613036,0.00076577434,0.54234934,0.00016532058,0.0010867168,0.00012835681,0.00021749534,0.00012558691,0.0015107946,0.00084875023,0.010162922,0.43602592],"study_design_scores_gemma":[0.004226764,0.0021901235,0.930091,0.00008580126,0.00019613176,0.00013264944,0.00014056609,0.00011623186,0.00032947864,0.0011460854,0.061220165,0.0001249708],"about_ca_topic_score_codex":0.00008748742,"about_ca_topic_score_gemma":0.00070564734,"teacher_disagreement_score":0.43590093,"about_ca_system_score_codex":0.000036628146,"about_ca_system_score_gemma":0.0004102397,"threshold_uncertainty_score":0.24033132},"labels":[],"label_agreement":null},{"id":"W4399150691","doi":"10.1200/jco.2024.42.16_suppl.1612","title":"Association of socioeconomic status with aggressive end-of-life care in patients with cancer before and during the COVID-19 pandemic.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Ottawa; University Health Network; University of Toronto; McMaster University; Queen's University","funders":"Canadian Institutes of Health Research; Peterborough K. M. Hunter Charitable Foundation","keywords":"Medicine; Socioeconomic status; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; End-of-life care; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Gerontology; Demography; Environmental health; Internal medicine; Palliative care; Disease; Virology; Outbreak; Population; Nursing; Infectious disease (medical specialty)","score_opus":0.1220284038985465,"score_gpt":0.4988099158730807,"score_spread":0.37678151197453424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399150691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923655,0.0052031316,0.0000071311806,0.001881308,0.00023546087,0.00014964421,0.00004986979,0.0000028891377,0.00010510965],"genre_scores_gemma":[0.9950088,0.0040260777,0.00022677443,0.00047917088,0.00020027855,0.000003318161,0.0000042945603,0.000009558498,0.00004171228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821496,0.00020566411,0.0010963205,0.00011189169,0.00023286964,0.00013827362],"domain_scores_gemma":[0.9950287,0.0022391083,0.002108208,0.000070610244,0.0003886066,0.00016477509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008139555,0.000086807384,0.0009215388,0.00009213104,0.000017136728,0.0000029654789,0.00006261441,0.00018313546,0.000051389234],"category_scores_gemma":[0.0022434655,0.000045879202,0.00011025777,0.000076087956,0.00022630885,0.00006940544,0.000024082425,0.0005127257,3.670146e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003492953,0.00010704779,0.9788579,0.00030948952,0.0006267464,0.000036856793,0.0043889387,0.0000737103,0.000005389767,0.000009761074,0.00020681528,0.011884398],"study_design_scores_gemma":[0.007887128,0.0049555358,0.97287095,0.00086707354,0.00033079882,0.0000062980534,0.0018477328,0.000011634426,0.000019626254,0.000040894378,0.011115972,0.000046381512],"about_ca_topic_score_codex":0.00022019637,"about_ca_topic_score_gemma":0.0025999555,"teacher_disagreement_score":0.011838016,"about_ca_system_score_codex":0.00063037215,"about_ca_system_score_gemma":0.0029428483,"threshold_uncertainty_score":0.52204865},"labels":[],"label_agreement":null},{"id":"W4399150704","doi":"10.1200/jco.2024.42.16_suppl.1040","title":"<i>CCNE1</i> amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"","keywords":"Cyclin E1; Medicine; Internal medicine; Gene duplication; Breast cancer; Cancer research; Oncology; Cancer; Biology; Gene; Cyclin; Genetics; Cell cycle","score_opus":0.0407926585524997,"score_gpt":0.409803535397823,"score_spread":0.3690108768453233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399150704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822001,0.009382114,0.0009287026,0.0059264563,0.0009081657,0.00014076117,0.000058011763,0.0000021075648,0.00045362313],"genre_scores_gemma":[0.9873934,0.0093328925,0.0016604112,0.0010800943,0.00045285266,0.000009531863,0.000005044046,0.000013596809,0.000052224237],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854887,0.00007434225,0.0009696571,0.00018514878,0.00009698356,0.00012499295],"domain_scores_gemma":[0.998831,0.00036341813,0.00044359345,0.00008821893,0.00017615802,0.00009765897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094376196,0.000089407105,0.0004123275,0.000055456923,0.000011897888,0.000011309277,0.000118333664,0.00022510339,0.000025736499],"category_scores_gemma":[0.00038728333,0.0000723764,0.00014583436,0.000088137254,0.000119298005,0.000007213287,0.00004831744,0.00023934971,0.0000010985175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038427198,0.0012464935,0.11690977,0.000124712,0.0004566568,0.000041098283,0.00006820889,0.0003491591,0.3133739,0.001377028,0.0024534184,0.5597568],"study_design_scores_gemma":[0.00577992,0.0072305608,0.5805147,0.0003039199,0.00026774892,0.00041016893,0.00017034251,0.000747982,0.017057784,0.0027823644,0.38439173,0.00034274836],"about_ca_topic_score_codex":0.000037628313,"about_ca_topic_score_gemma":0.00007850322,"teacher_disagreement_score":0.5594141,"about_ca_system_score_codex":0.000034684013,"about_ca_system_score_gemma":0.00092034566,"threshold_uncertainty_score":0.29514238},"labels":[],"label_agreement":null},{"id":"W4399153733","doi":"10.1200/jco.24.00762","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Guideline; Medicine; Clinical Practice; Family medicine; Schedule; Stage (stratigraphy); Clinical Oncology; Cancer; Pathology; Internal medicine","score_opus":0.06257167324106218,"score_gpt":0.5001184062087508,"score_spread":0.43754673296768865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399153733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8977576,0.015695494,0.030553294,0.03763621,0.0074643395,0.0016905488,0.000085070504,0.00004136259,0.009076064],"genre_scores_gemma":[0.8618705,0.012310134,0.060918793,0.00972618,0.0061784363,0.00012975733,0.00003316147,0.000089165085,0.04874383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998261,0.0000758967,0.0011229053,0.00018688093,0.00018863691,0.00016472745],"domain_scores_gemma":[0.9973354,0.0013707457,0.00045805812,0.00011625742,0.0005279193,0.00019164725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088980224,0.000119352255,0.00059291295,0.000111762376,0.0000794662,0.00002774222,0.00007632398,0.00015715428,0.0007690882],"category_scores_gemma":[0.00021411631,0.000070624534,0.00030453596,0.00013720106,0.000050179682,0.00014299554,0.000015412685,0.0004052837,0.000008933849],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00596013,0.0035241353,0.1370521,0.0005043941,0.00487105,0.0012250545,0.0023455129,0.0023215988,0.0011142286,0.00024702842,0.5874888,0.253346],"study_design_scores_gemma":[0.009052144,0.011327902,0.021521261,0.0007483049,0.0016809682,0.000053274893,0.00030277163,0.007717442,0.00012869963,0.000037637878,0.94730425,0.00012532233],"about_ca_topic_score_codex":0.000050735438,"about_ca_topic_score_gemma":0.00008248048,"teacher_disagreement_score":0.3598155,"about_ca_system_score_codex":0.0002816678,"about_ca_system_score_gemma":0.003518484,"threshold_uncertainty_score":0.84209764},"labels":[],"label_agreement":null},{"id":"W4399218247","doi":"10.1200/jco.24.00581","title":"Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Grifols; Lunit; Sociedad Española de Oncología Médica; BeiGene; Taiho Pharmaceutical; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Lung cancer; Internal medicine; Oncology; ALK inhibitor","score_opus":0.04732648856136055,"score_gpt":0.475723419983027,"score_spread":0.4283969314216664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399218247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895454,0.00072063215,0.00005155528,0.003145871,0.0026305236,0.0010475133,0.0000730552,0.000012099628,0.002773357],"genre_scores_gemma":[0.99722207,0.00015922067,0.0007424542,0.0010584369,0.00050437014,0.00003575871,0.000018532275,0.000026953507,0.00023223675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750155,0.00023023758,0.0014157932,0.00027332315,0.00035383532,0.00022523286],"domain_scores_gemma":[0.9954353,0.0031844145,0.00065538916,0.00019996571,0.0003196508,0.00020525765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063360657,0.00018705694,0.0010828136,0.0000811808,0.00006090284,0.000024949011,0.0001540306,0.00013495878,0.00015809196],"category_scores_gemma":[0.000328907,0.000095863565,0.00025657922,0.00021162332,0.000101103986,0.00014002105,0.000042578184,0.0008930327,0.000008185379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025969837,0.0079272,0.877073,0.000017559609,0.0020864888,0.00066443614,0.0028581088,0.00008209845,0.000005852109,0.00000824,0.001694543,0.08161263],"study_design_scores_gemma":[0.12595417,0.027688636,0.83566004,0.00027078527,0.0029955865,0.0000019760741,0.0015710535,0.00007681934,0.000013900649,0.000010359805,0.0056423545,0.000114306014],"about_ca_topic_score_codex":0.00026217956,"about_ca_topic_score_gemma":0.000561389,"teacher_disagreement_score":0.09998433,"about_ca_system_score_codex":0.00035854033,"about_ca_system_score_gemma":0.0019079689,"threshold_uncertainty_score":0.39092028},"labels":[],"label_agreement":null},{"id":"W4399218268","doi":"10.1200/jco.24.00733","title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Centro de Investigación Biomédica en Red de Cáncer; European Commission; National Institute on Minority Health and Health Disparities; Comunidad de Madrid; Instituto de Salud Carlos III; Gilead Sciences","keywords":"Medicine; Docetaxel; Open label; Lung cancer; Oncology; Randomized controlled trial; Internal medicine; Phases of clinical research; Cancer; Chemotherapy","score_opus":0.15434764482793675,"score_gpt":0.5628618517731004,"score_spread":0.4085142069451637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399218268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950586,0.014282485,0.0029340521,0.009357557,0.0055756965,0.013735237,0.000103416096,0.00004424276,0.0033812777],"genre_scores_gemma":[0.98028404,0.0035723476,0.00558533,0.0011472544,0.0009310402,0.0012917545,0.000019059591,0.000064599306,0.0071046036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99545515,0.0006683721,0.0027777927,0.00039240374,0.0003276486,0.00037861918],"domain_scores_gemma":[0.9879049,0.009480164,0.0014136032,0.00032432482,0.00049294607,0.00038407618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041144216,0.0002946598,0.0029197996,0.00013823307,0.00016295527,0.00009175643,0.00040791614,0.00014739491,0.00024200472],"category_scores_gemma":[0.0019673132,0.00013984974,0.0006260956,0.00033671045,0.00019690093,0.00022859048,0.00008188832,0.0007275683,0.0000068217073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70615757,0.013350011,0.0002081066,0.00025232788,0.0110168895,0.0013581138,0.00178969,0.00009424976,0.000060510985,0.00007820011,0.008171345,0.257463],"study_design_scores_gemma":[0.8772753,0.0464113,0.0001037456,0.0003576764,0.029377574,0.00011498966,0.0013323227,0.0038898082,0.000046196634,0.00009065014,0.040830906,0.00016956904],"about_ca_topic_score_codex":0.0002915636,"about_ca_topic_score_gemma":0.00074702495,"teacher_disagreement_score":0.25729346,"about_ca_system_score_codex":0.0007097402,"about_ca_system_score_gemma":0.0063082865,"threshold_uncertainty_score":0.99932504},"labels":[],"label_agreement":null},{"id":"W4399273953","doi":"10.1200/jco.24.00835","title":"Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Essar Steel Algoma (Canada); London Health Sciences Centre; Queen's University; McMaster University; Canadian Cancer Society; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Strong; Canadian Cancer Society Research Institute; Government of Ontario","keywords":"Medicine; Anastrozole; Exemestane; Oncology; Breast cancer; Cancer; Internal medicine; Adjuvant; Estrogen receptor; Clinical trial; Gynecology; Postmenopausal women; Hormone receptor; Estrogen; Aromatase","score_opus":0.04773259264113607,"score_gpt":0.43468616542297206,"score_spread":0.386953572781836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399273953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98542607,0.007981415,0.00022689298,0.0011278378,0.0034310282,0.0005394907,0.0011842718,0.0000029639411,0.00008004294],"genre_scores_gemma":[0.9883606,0.008372909,0.0020019386,0.000057243473,0.0010239229,0.000021300408,0.000103751234,0.00002843819,0.00002991641],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99606586,0.0010347958,0.0020592646,0.00027844013,0.00026111648,0.00030050345],"domain_scores_gemma":[0.9974675,0.00069192547,0.0010116504,0.000118579475,0.00031375088,0.00039659586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036189454,0.00017972176,0.001292841,0.00015876304,0.000021432028,0.000011890097,0.000129859,0.00055892556,0.00009766278],"category_scores_gemma":[0.0014306565,0.0001345769,0.00019854151,0.00016245722,0.00027788596,0.000018640563,0.000043896016,0.000490541,9.2341395e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45413765,0.0014712319,0.012557173,0.00023945128,0.0033657437,0.00023086228,0.00019732033,0.00027057654,0.16751854,0.0011592339,0.007961898,0.35089034],"study_design_scores_gemma":[0.3745792,0.26784968,0.046558004,0.0024492224,0.00469052,0.00042167772,0.00079148985,0.0007973466,0.05810482,0.00041763516,0.24174131,0.0015990756],"about_ca_topic_score_codex":0.004482443,"about_ca_topic_score_gemma":0.008402884,"teacher_disagreement_score":0.34929127,"about_ca_system_score_codex":0.00023325803,"about_ca_system_score_gemma":0.004251487,"threshold_uncertainty_score":0.7541956},"labels":[],"label_agreement":null},{"id":"W4399280180","doi":"10.1200/jco.2024.42.16_suppl.e23513","title":"Localized GIST in Hispanic population in North and South America.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; GiST; Population; Demography; Internal medicine; Environmental health; Stromal cell","score_opus":0.057049016479963154,"score_gpt":0.4257786971227731,"score_spread":0.36872968064281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332124,0.0045370776,0.000894924,0.00053224363,0.00044988573,0.00005810561,0.0000017997993,0.0000016627163,0.00020304497],"genre_scores_gemma":[0.99594307,0.0023548834,0.0010929767,0.00018527944,0.0003566611,0.0000013219974,0.00001033081,0.000008612899,0.00004683776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830353,0.00026298198,0.0010698489,0.00016081707,0.00009137343,0.00011145429],"domain_scores_gemma":[0.9993035,0.00017872431,0.00030919313,0.00007884116,0.000047932175,0.00008179122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009782601,0.000070570924,0.0003783172,0.000105564955,0.000008901782,0.000011162206,0.00006888903,0.00022351964,0.000008421416],"category_scores_gemma":[0.00088405417,0.00005768538,0.000101374964,0.00013836712,0.00006436294,0.0000053532835,0.00003656827,0.00031018376,0.0000022227355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005187533,0.00018626676,0.7712617,0.000022746795,0.000041096253,0.0001077042,0.00010914644,0.0006465395,0.0040331124,0.000052595467,0.00010693854,0.2229134],"study_design_scores_gemma":[0.0014486253,0.0022406064,0.94381046,0.000029091076,0.000023089446,0.000009940715,0.00004551596,0.0012019548,0.00015256586,0.00044999554,0.050500855,0.00008732415],"about_ca_topic_score_codex":0.00004890951,"about_ca_topic_score_gemma":0.0009262738,"teacher_disagreement_score":0.22282606,"about_ca_system_score_codex":0.00003026915,"about_ca_system_score_gemma":0.00021465415,"threshold_uncertainty_score":0.23523417},"labels":[],"label_agreement":null},{"id":"W4399280225","doi":"10.1200/jco.2024.42.16_suppl.e23266","title":"Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Standard of care; Oncology; Lung cancer; Health care; Healthcare system; Internal medicine; Intensive care medicine","score_opus":0.10058853251565913,"score_gpt":0.4898858693503855,"score_spread":0.3892973368347264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790805,0.0046660556,0.000100847705,0.012615857,0.00038725688,0.00052050216,0.000035784473,0.000018676728,0.0025745193],"genre_scores_gemma":[0.9858256,0.011799906,0.0006380465,0.00048582707,0.00036277642,0.000008266209,0.000035229765,0.000028284303,0.00081604504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955246,0.0006715002,0.0025000158,0.00035037487,0.00060736266,0.0003461908],"domain_scores_gemma":[0.99635744,0.001114314,0.0010488048,0.00020901588,0.0009129933,0.0003574296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002599934,0.00018644436,0.0019092383,0.00081109593,0.000045009758,0.000010119296,0.0001424478,0.00023036033,0.00012547559],"category_scores_gemma":[0.00082806003,0.0001237919,0.00026074523,0.0018635753,0.00023148296,0.000097183416,0.00010896344,0.0012377533,9.858172e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00904289,0.0006788855,0.9584203,0.00060041744,0.0018831441,0.00021605972,0.00047914268,0.00022336257,0.000017607388,0.000050526338,0.0068777734,0.021509925],"study_design_scores_gemma":[0.0071418937,0.0060499595,0.9398206,0.000705893,0.0018761468,0.0000053279514,0.00014210671,0.0023195725,0.00004260128,0.000014550251,0.041764412,0.00011693906],"about_ca_topic_score_codex":0.0015321001,"about_ca_topic_score_gemma":0.017771693,"teacher_disagreement_score":0.034886636,"about_ca_system_score_codex":0.0006591228,"about_ca_system_score_gemma":0.0017955218,"threshold_uncertainty_score":0.9917022},"labels":[],"label_agreement":null},{"id":"W4399280226","doi":"10.1200/jco.2024.42.16_suppl.e23188","title":"Longitudinal changes in patient-reported outcomes (PROs) among early phase cancer clinical trial (EP-CT) participants.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Cancer; Oncology; Internal medicine","score_opus":0.3639042410832089,"score_gpt":0.5019303714133655,"score_spread":0.1380261303301566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97294897,0.0039561247,0.00012448973,0.004518837,0.015499171,0.00039574027,0.000058804682,0.000021770898,0.00247612],"genre_scores_gemma":[0.9921496,0.0033367383,0.00015685326,0.001097423,0.0027006718,0.00004271173,0.000002009104,0.00003874164,0.0004752797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904184,0.00019912515,0.008070262,0.00057104364,0.00011194905,0.00062923454],"domain_scores_gemma":[0.9928986,0.0018609097,0.0042856885,0.00030236886,0.0001381506,0.00051430066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008643084,0.00026848415,0.0030641202,0.00041685658,0.000049246326,0.00010279324,0.00036775778,0.00046847877,0.0007601686],"category_scores_gemma":[0.0064159464,0.0002341841,0.00093595136,0.00028279316,0.0003832066,0.0006379448,0.00009461889,0.0015830181,0.00013406448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008310071,0.0017227968,0.85925627,0.000018721985,0.00060286286,0.0012330115,0.00019151866,0.00001727216,5.659964e-7,0.003819669,0.0029892377,0.121838],"study_design_scores_gemma":[0.04502091,0.010888224,0.82202333,0.00011944,0.00014505969,0.000027412087,0.00004578018,0.0003346856,0.000007640622,0.008636243,0.11241711,0.0003341556],"about_ca_topic_score_codex":0.00075387163,"about_ca_topic_score_gemma":0.001898513,"teacher_disagreement_score":0.121503845,"about_ca_system_score_codex":0.00034919239,"about_ca_system_score_gemma":0.0010196597,"threshold_uncertainty_score":0.95497507},"labels":[],"label_agreement":null},{"id":"W4399280239","doi":"10.1200/jco.2024.42.16_suppl.e23096","title":"Childhood Cancer in Cameroon and Kenya: Preliminary findings of an implementation effectiveness study for early detection of childhood cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer; Childhood cancer; Environmental health; Internal medicine","score_opus":0.0708005336545692,"score_gpt":0.5081169841013813,"score_spread":0.4373164504468121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935154,0.0023650115,0.00012163578,0.0011430358,0.0013885824,0.0013931864,0.000050128303,0.000010568484,0.000012457588],"genre_scores_gemma":[0.99805796,0.00060972234,0.00024539832,0.00014726724,0.00084013515,0.000061655024,0.000002985236,0.000030303061,0.0000045938045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995658,0.0008266992,0.0025702226,0.00032483294,0.00040842846,0.00021184988],"domain_scores_gemma":[0.9953875,0.0027420241,0.0011944296,0.00015349705,0.00033340423,0.00018912986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058858874,0.00017403017,0.0016233266,0.000331902,0.00003215326,0.000009965843,0.00012501,0.00024769423,0.00003092279],"category_scores_gemma":[0.000970292,0.00014594024,0.00030004568,0.00029981538,0.00012843202,0.0002656252,0.000047562287,0.0006962861,2.701329e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070993197,0.0039188955,0.58755726,0.00064184633,0.00092755206,0.00004201162,0.006822907,0.000045882036,0.0014407651,0.000011366161,0.000028726849,0.39146346],"study_design_scores_gemma":[0.011805059,0.05676897,0.9236888,0.00093338423,0.0008248524,0.000054075103,0.0024002616,0.000058244386,0.00304616,0.00019692852,0.00011485082,0.0001083969],"about_ca_topic_score_codex":0.0024642379,"about_ca_topic_score_gemma":0.004240783,"teacher_disagreement_score":0.39135507,"about_ca_system_score_codex":0.00024876048,"about_ca_system_score_gemma":0.001558538,"threshold_uncertainty_score":0.59512705},"labels":[],"label_agreement":null},{"id":"W4399280247","doi":"10.1200/jco.2024.42.16_suppl.e23184","title":"Understanding breast cancer (BC) from the patient (pt) perspective: A qualitative study of symptoms, impacts and health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative (HR+, HER2–) BC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Breast cancer; Perspective (graphical); Quality of life (healthcare); Hormone receptor; Health related quality of life; Cancer; Oncology; Internal medicine; Hormone; Gerontology; Gynecology; Family medicine; Disease; Nursing","score_opus":0.22766241118193264,"score_gpt":0.5252653460637992,"score_spread":0.2976029348818665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95747495,0.01099136,0.00015438437,0.029811261,0.00054526195,0.0007185129,0.00016801663,0.000012178984,0.00012408785],"genre_scores_gemma":[0.99625224,0.0023402763,0.0003605388,0.00071765546,0.0002688049,0.000013042127,0.0000027878023,0.00003180384,0.000012878806],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9909015,0.0038039063,0.003935479,0.00038477895,0.0006630692,0.00031124573],"domain_scores_gemma":[0.9845545,0.0107979635,0.0033002135,0.00021482585,0.0007556132,0.00037685814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005707482,0.00026230194,0.0025591594,0.00019185542,0.00006396244,0.000011878556,0.00015876912,0.0002715229,0.00011657764],"category_scores_gemma":[0.0023356038,0.00016636755,0.0003038387,0.00055778044,0.0007940757,0.0002286969,0.00008776822,0.0015977977,0.0000013097476],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07734206,0.00955299,0.176357,0.00031935194,0.01068927,0.00020710901,0.6671388,0.00021745176,0.00061540585,0.002912396,0.0013777477,0.053270377],"study_design_scores_gemma":[0.010570067,0.016169887,0.6556931,0.0012886274,0.00021301632,0.000037811955,0.31162447,0.000037565183,0.000019661578,0.0041568787,0.000057558824,0.00013132054],"about_ca_topic_score_codex":0.029852055,"about_ca_topic_score_gemma":0.006028796,"teacher_disagreement_score":0.47933614,"about_ca_system_score_codex":0.0023077358,"about_ca_system_score_gemma":0.0030120967,"threshold_uncertainty_score":0.9766082},"labels":[],"label_agreement":null},{"id":"W4399280301","doi":"10.1200/jco.2024.42.16_suppl.e23080","title":"Exploring sexual and reproductive health among adolescent and young adult patients with cancer: A patient-oriented qualitative study using novel, serial focus groups.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; BC Children's Hospital; BC Cancer Agency; Ottawa Hospital; University of British Columbia","funders":"Social Sciences and Humanities Research Council of Canada; Canadian Institutes of Health Research","keywords":"Medicine; Reproductive health; Focus group; Qualitative research; Family medicine; Gynecology; Population","score_opus":0.23284413697857373,"score_gpt":0.48888545748306944,"score_spread":0.2560413205044957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912441,0.0003603514,0.0001527963,0.001337454,0.0061145066,0.00069317565,0.000023531997,0.000021111904,0.00005299263],"genre_scores_gemma":[0.9971697,0.0003061495,0.0009807539,0.00016377239,0.0013257969,0.000018897043,0.000001108605,0.000022935488,0.000010926639],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99477035,0.00184638,0.0017348062,0.00051458663,0.00075472204,0.0003791711],"domain_scores_gemma":[0.9961172,0.0010584742,0.0014209003,0.00012954006,0.0008475487,0.00042636704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052935407,0.00018240618,0.0009809164,0.00014734792,0.00032168409,0.00006916393,0.00012685153,0.00014035309,0.000009090446],"category_scores_gemma":[0.0024633158,0.00013718268,0.00007197642,0.0003698004,0.0007678759,0.000965661,0.00011446214,0.0008330398,3.9011644e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018426471,0.0017388331,0.5385768,0.000046303583,0.00033805773,0.000074261734,0.3783244,0.000011289538,0.0000029794412,0.00033054734,0.00013342247,0.0785805],"study_design_scores_gemma":[0.0043201204,0.013110922,0.44199014,0.00034846558,0.00019711103,0.000011469117,0.53843516,0.00004143186,0.0000019402453,0.00012117707,0.0011811986,0.00024086259],"about_ca_topic_score_codex":0.010382781,"about_ca_topic_score_gemma":0.013093002,"teacher_disagreement_score":0.16011079,"about_ca_system_score_codex":0.0005498073,"about_ca_system_score_gemma":0.0018708975,"threshold_uncertainty_score":0.9962072},"labels":[],"label_agreement":null},{"id":"W4399280309","doi":"10.1200/jco.2024.42.16_suppl.e23274","title":"Real world outcomes of 2,339 patients with early-stage triple-negative breast cancer (TNBC) treated in British Columbia.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Oncology; Stage (stratigraphy); Internal medicine; Cancer; Gynecology","score_opus":0.03029519893394185,"score_gpt":0.3834471964773274,"score_spread":0.35315199754338555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727213,0.00035415936,0.000004258002,0.00059543096,0.0006189087,0.00019103641,0.00030617943,0.0000057013003,0.00065221294],"genre_scores_gemma":[0.9965309,0.0011052835,0.00027778326,0.00016912594,0.00028379695,0.000017549622,0.000013148419,0.000024963012,0.0015774665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762905,0.00025999534,0.0013459314,0.0002901721,0.00023999505,0.00023484704],"domain_scores_gemma":[0.99812955,0.00043527776,0.00076306687,0.00014178077,0.00039801633,0.00013233976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050578907,0.00014221093,0.0010595522,0.00008104722,0.000030387977,0.000029854284,0.0001690488,0.00022416639,0.00011703368],"category_scores_gemma":[0.00028018278,0.000133149,0.00029460632,0.0002492113,0.00029737497,0.000016874148,0.00007383672,0.00037122102,0.0000016564276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014101906,0.0009395571,0.95728743,0.000020828524,0.0010843443,0.00022567838,0.000049995408,0.000010790172,0.000020757194,0.000002866517,0.0017732214,0.037174344],"study_design_scores_gemma":[0.0069512273,0.002325589,0.9873151,0.00017494617,0.00019810999,0.000018982322,0.000056064928,0.0000032211906,0.000050600782,0.000027355089,0.0027500268,0.0001287745],"about_ca_topic_score_codex":0.027355209,"about_ca_topic_score_gemma":0.30152196,"teacher_disagreement_score":0.27416676,"about_ca_system_score_codex":0.00014982092,"about_ca_system_score_gemma":0.00070366997,"threshold_uncertainty_score":0.97912174},"labels":[],"label_agreement":null},{"id":"W4399280312","doi":"10.1200/jco.2024.42.16_suppl.e23233","title":"An international expert consensus on improving the quality of care in patients with cancer by optimal central vascular access device selection.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Selection (genetic algorithm); Cancer; Vascular access; Intensive care medicine; Consensus conference; Quality (philosophy); Oncology; Internal medicine; Artificial intelligence; Computer science","score_opus":0.1285111487329294,"score_gpt":0.5496744656931577,"score_spread":0.4211633169602283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946669,0.00045608825,0.00010196093,0.0022516868,0.0020489783,0.00024605147,0.00003946428,0.0000066899497,0.00018222308],"genre_scores_gemma":[0.9972391,0.00032888152,0.00033289543,0.0013580037,0.0006931812,0.000010130215,0.000008302504,0.0000124976905,0.000017009608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961549,0.0012835375,0.0017253795,0.0001836752,0.00038940273,0.00026307118],"domain_scores_gemma":[0.9961858,0.0019593094,0.0010125058,0.00011984726,0.0005759632,0.00014661442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020297277,0.000098881384,0.00064408936,0.00008157794,0.00010560499,0.0000148796635,0.0003157192,0.00023553852,0.0002111025],"category_scores_gemma":[0.0005504185,0.00005555347,0.00023360725,0.00014583822,0.00009207115,0.00014035507,0.000043319567,0.0011904119,0.0000016677868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045861555,0.0011710599,0.9002863,0.00008463086,0.000397548,0.000010535233,0.0036831615,0.0009778085,0.000058790098,0.00008818057,0.001994751,0.08666107],"study_design_scores_gemma":[0.0039281533,0.0037637565,0.9652446,0.00024220928,0.0001126255,8.93232e-7,0.0015897654,0.0008557409,0.000027975493,0.000011957233,0.024121596,0.0001007068],"about_ca_topic_score_codex":0.0012661152,"about_ca_topic_score_gemma":0.0017298431,"teacher_disagreement_score":0.08656037,"about_ca_system_score_codex":0.0005315532,"about_ca_system_score_gemma":0.0018526617,"threshold_uncertainty_score":0.51718134},"labels":[],"label_agreement":null},{"id":"W4399280332","doi":"10.1200/jco.2024.42.16_suppl.e23246","title":"Improving symptom screening rates for patients with head and neck cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck cancer; Head and neck; Cancer; Internal medicine; Oncology; Surgery","score_opus":0.10013079896692421,"score_gpt":0.4969974762724058,"score_spread":0.3968666773054816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490137,0.0051963404,0.0005337074,0.007796729,0.0010493331,0.00019833556,0.0000068050053,0.000011219329,0.00030615862],"genre_scores_gemma":[0.98637927,0.0012390523,0.009191295,0.0014999593,0.0014763155,0.000010523974,0.000001217524,0.000017829783,0.0001845654],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986123,0.00004774991,0.0008657654,0.00014746716,0.00015501455,0.00017169317],"domain_scores_gemma":[0.9974509,0.0016324759,0.00033573536,0.000052948246,0.00032890963,0.00019904884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083607406,0.000091447684,0.00093190686,0.000061365514,0.000050385122,0.000013740442,0.00004117416,0.00012579936,0.000016365879],"category_scores_gemma":[0.0010143624,0.000052795796,0.00014880426,0.00007427716,0.000109686356,0.00009650589,0.000026641113,0.0004282797,7.76385e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032169996,0.00020503813,0.3963426,0.00016501086,0.00039540627,0.00006542017,0.00011267295,0.0000016971329,0.000019103778,0.000030564406,0.0032046793,0.5962408],"study_design_scores_gemma":[0.012933041,0.045383923,0.78968334,0.0015549865,0.0006658971,0.00005922664,0.00012066224,0.0008024182,0.000027961942,0.00007202838,0.14858103,0.000115456176],"about_ca_topic_score_codex":0.000030982264,"about_ca_topic_score_gemma":0.0000666424,"teacher_disagreement_score":0.5961253,"about_ca_system_score_codex":0.00006224999,"about_ca_system_score_gemma":0.0008447488,"threshold_uncertainty_score":0.215295},"labels":[],"label_agreement":null},{"id":"W4399280403","doi":"10.1200/jco.2024.42.16_suppl.e23150","title":"EHR documentation of cost discussions and financial interventions for a cohort of patients with advanced cancer: Findings from a retrospective chart review-based study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Documentation; Psychological intervention; Chart; Retrospective cohort study; Cancer; Cohort; Medical physics; Oncology; Internal medicine; Nursing","score_opus":0.07662179420226478,"score_gpt":0.4322118726201299,"score_spread":0.3555900784178651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839193,0.008331199,0.0030434134,0.0015009223,0.0010867008,0.0009686288,0.0009777979,0.000003584824,0.00016843004],"genre_scores_gemma":[0.9940426,0.004354606,0.0010225937,0.0002857143,0.00014784909,0.00006753455,0.000014447763,0.00001338024,0.00005130261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970731,0.000041756877,0.002476808,0.00022902968,0.00005560237,0.0001236746],"domain_scores_gemma":[0.99679345,0.00055493147,0.0021824972,0.00011110418,0.00026272,0.00009529455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015227693,0.000108261745,0.0014718041,0.00015078964,0.000034327993,0.000012435312,0.00012351951,0.0001112825,0.00018240583],"category_scores_gemma":[0.0017702971,0.00008439011,0.0003905661,0.000137692,0.00011706897,0.00033182616,0.000025622678,0.00026016496,0.0000020330122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010848021,0.0009090337,0.96306103,0.00028450968,0.0002879788,0.0000022627453,0.0001661027,0.000018997325,0.0000016029126,0.0020485278,0.001699692,0.03043547],"study_design_scores_gemma":[0.0039587463,0.006410356,0.9747191,0.0015535104,0.00022451591,2.589476e-7,0.000044426626,0.00005820859,0.0000072622197,0.002740807,0.010185575,0.00009724936],"about_ca_topic_score_codex":0.00009355888,"about_ca_topic_score_gemma":0.00024964908,"teacher_disagreement_score":0.030338222,"about_ca_system_score_codex":0.0001949264,"about_ca_system_score_gemma":0.000340293,"threshold_uncertainty_score":0.34413287},"labels":[],"label_agreement":null},{"id":"W4399280425","doi":"10.1200/jco.2024.42.16_suppl.e23169","title":"The Progress Tracker Breast Cancer Registry: Feasibility of a longitudinal patient-led, patient-reported outcomes (PROM) registry.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Breast Cancer Society of Canada","keywords":"Medicine; Prom; Cancer registry; Breast cancer; Cancer; Patient registry; Medical physics; Internal medicine; Obstetrics","score_opus":0.21131887313934458,"score_gpt":0.5118680957883336,"score_spread":0.300549222648989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963964,0.0048448653,0.000021030377,0.027232211,0.0026151384,0.00037874747,0.00003903996,0.000021147356,0.00088382437],"genre_scores_gemma":[0.9973403,0.00046894536,0.00067612535,0.0005973204,0.0006597722,0.000015274902,0.0000033653553,0.00001818641,0.00022070794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943532,0.00032871537,0.003633486,0.0003520833,0.00096787553,0.00036465],"domain_scores_gemma":[0.9934777,0.0012680948,0.0031033433,0.000504333,0.0012592376,0.00038726258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029596172,0.0002106361,0.0014835164,0.000069561094,0.0000878249,0.000040868625,0.00029015198,0.00036207997,0.00013920703],"category_scores_gemma":[0.0036848453,0.00011351177,0.00085887354,0.0003118671,0.00078026974,0.0001882794,0.000089646535,0.0013344288,0.0000045855923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046583307,0.0005614836,0.71950376,0.00008017948,0.000689667,0.0017559401,0.000112126014,0.0000046006203,0.000013011303,0.000069929876,0.011570774,0.26098022],"study_design_scores_gemma":[0.002589266,0.0061055273,0.9423931,0.00080437853,0.0008009904,0.0032263473,0.0005079522,0.00006914375,0.00003141045,0.00035088844,0.042995714,0.00012522869],"about_ca_topic_score_codex":0.00020781804,"about_ca_topic_score_gemma":0.00024198182,"teacher_disagreement_score":0.260855,"about_ca_system_score_codex":0.00035712429,"about_ca_system_score_gemma":0.003633409,"threshold_uncertainty_score":0.64455116},"labels":[],"label_agreement":null},{"id":"W4399280447","doi":"10.1200/jco.2024.42.16_suppl.e23241","title":"Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Mental Health Interventions","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Victoria; University of Calgary; Impact; University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre; McMaster University; University Health Network; Canadian Cancer Society; University of Toronto","funders":"","keywords":"Medicine; Physical therapy","score_opus":0.3552527084089198,"score_gpt":0.5769867386486223,"score_spread":0.22173403023970245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280447","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20454611,0.0031523472,0.7391579,0.022337986,0.014522427,0.0033843187,0.0003454363,0.00021860431,0.01233488],"genre_scores_gemma":[0.8940593,0.00002410783,0.10327759,0.0009953021,0.00046691566,0.00041252287,0.000044370816,0.000046484256,0.0006734267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995859,0.00069671776,0.0025154913,0.00035745584,0.0002236186,0.00034769328],"domain_scores_gemma":[0.99417555,0.0038988711,0.0009745612,0.00027414545,0.00022981047,0.00044706758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047583985,0.00016983789,0.0010345496,0.00025330042,0.00010232716,0.00007122714,0.0002925265,0.00022846683,0.0005454323],"category_scores_gemma":[0.00039646277,0.00012431483,0.00049829035,0.00027092415,0.00020253417,0.0004768262,0.000020346648,0.00060481357,0.00005184167],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010803047,0.017904928,0.0006964732,0.00030900363,0.00060228043,0.0003217288,0.0032356388,0.0002699989,0.000019693063,0.007903695,0.09194798,0.8659855],"study_design_scores_gemma":[0.020228533,0.15671468,0.0035642742,0.0020259155,0.0016498204,0.0015526685,0.022360204,0.008482228,0.00046481375,0.009093615,0.77290046,0.0009628124],"about_ca_topic_score_codex":0.000024414552,"about_ca_topic_score_gemma":0.000030763687,"teacher_disagreement_score":0.8650227,"about_ca_system_score_codex":0.00015930916,"about_ca_system_score_gemma":0.0008825047,"threshold_uncertainty_score":0.5972101},"labels":[],"label_agreement":null},{"id":"W4399280462","doi":"10.1200/jco.2024.42.16_suppl.e23087","title":"Investigations of the quality of fertility preservation education provided to patients with cancer at a large community hospital.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Windsor","funders":"","keywords":"Medicine; Fertility preservation; Fertility; Quality (philosophy); Cancer; Family medicine; Intensive care medicine; Gynecology; Environmental health; Internal medicine; Population","score_opus":0.1712558017813923,"score_gpt":0.5059812281108207,"score_spread":0.33472542632942837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865357,0.00021839091,0.00006075461,0.011345306,0.00097569055,0.00055299205,0.000026095553,0.0000044029152,0.00028062024],"genre_scores_gemma":[0.99843824,0.000016393413,0.00054641976,0.0006857878,0.0001295543,0.000014520975,0.0000072919584,0.0000046211853,0.00015716178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996443,0.0015376195,0.0015578269,0.0001303962,0.00024282436,0.000088356435],"domain_scores_gemma":[0.99555224,0.0012585107,0.0011113036,0.00040011678,0.0015579409,0.00011990492],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049926294,0.000070846385,0.0006304363,0.000044313816,0.00006153216,0.0000019340134,0.00016163144,0.00017812825,0.000039255094],"category_scores_gemma":[0.015581783,0.000037349106,0.00019245499,0.0002357168,0.00032866307,0.00012291102,0.00009622265,0.00071621564,9.992913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006205676,0.0036479686,0.9800781,0.0001957422,0.00017649977,2.1547343e-7,0.00072426477,0.0000033220003,0.00040288808,0.00013366136,0.0012178731,0.007213776],"study_design_scores_gemma":[0.0010634292,0.0034029563,0.9879318,0.00020227273,0.00015332697,8.3097655e-7,0.00008865936,0.0000092493665,0.00062658044,0.001224328,0.0052624787,0.00003407294],"about_ca_topic_score_codex":0.00037869424,"about_ca_topic_score_gemma":0.0006278365,"teacher_disagreement_score":0.011902502,"about_ca_system_score_codex":0.00018494944,"about_ca_system_score_gemma":0.0026585786,"threshold_uncertainty_score":0.9927104},"labels":[],"label_agreement":null},{"id":"W4399280485","doi":"10.1200/jco.2024.42.16_suppl.e23195","title":"Impact of early phase study enrollment for pediatric oncology patients on symptom burden and quality of life (QOL): Early report of trial-in-progress results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; London Health Sciences Centre; McMaster University; Children's Hospital of Eastern Ontario; University of Calgary; Hospital for Sick Children; CancerCare Manitoba; BC Children's Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Pediatric oncology; Internal medicine; Clinical trial; Oncology; Intensive care medicine; Cancer; Pediatrics","score_opus":0.20964086741928642,"score_gpt":0.5748771221779716,"score_spread":0.36523625475868515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245864,0.0007124035,0.000017292621,0.0025388105,0.0019572265,0.0020022339,0.00011432795,0.000009569621,0.00018952103],"genre_scores_gemma":[0.9969371,0.00025277538,0.00051425153,0.000109882094,0.0020897873,0.000021714977,0.000008842227,0.000028936844,0.00003670766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98492557,0.0020251519,0.0111465,0.00047960473,0.0011038169,0.00031937278],"domain_scores_gemma":[0.9771937,0.012752041,0.007917605,0.0004803591,0.0011382074,0.00051804644],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021928819,0.00025909094,0.004362139,0.00053725275,0.000021310067,0.000009280935,0.0002560646,0.0005145334,0.000016637789],"category_scores_gemma":[0.02271663,0.00018834036,0.0011612014,0.0003902581,0.00031917373,0.00010680621,0.000097579396,0.0009885869,9.2979656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33580625,0.0206315,0.60212785,0.00038991956,0.0014591548,0.00026500144,0.0030937532,0.000008583223,0.00001334075,0.000025452659,0.00057265133,0.035606578],"study_design_scores_gemma":[0.15394466,0.2474428,0.5968447,0.00017546675,0.00062952534,0.00001577934,0.0002749591,0.000008850758,0.0000082002425,0.00008641788,0.0004738978,0.00009478653],"about_ca_topic_score_codex":0.0010427563,"about_ca_topic_score_gemma":0.000116705014,"teacher_disagreement_score":0.22681129,"about_ca_system_score_codex":0.00032899433,"about_ca_system_score_gemma":0.005033198,"threshold_uncertainty_score":0.9855154},"labels":[],"label_agreement":null},{"id":"W4399280524","doi":"10.1200/jco.2024.42.16_suppl.e23103","title":"Time-to-first treatment for new cancer diagnoses before and during the COVID-19 pandemic in Manitoba, Canada.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Internal medicine; Outbreak; Disease; Infectious disease (medical specialty)","score_opus":0.2508852690811006,"score_gpt":0.5306683263075423,"score_spread":0.27978305722644176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7238952,0.002595622,0.000014233641,0.27235237,0.0006575047,0.00042452317,0.00001742522,0.000007550917,0.00003559698],"genre_scores_gemma":[0.95811415,0.0041872044,0.00011550811,0.032584514,0.0032902772,0.000028971359,0.0000013314357,0.000019169742,0.001658896],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982533,0.000106424835,0.0010444631,0.0001641844,0.00017585342,0.00025578213],"domain_scores_gemma":[0.9918791,0.006726724,0.00024390347,0.000104180675,0.00007389582,0.00097217085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011826003,0.0001128728,0.000789473,0.00010723582,0.000066743014,0.000012076181,0.00008309549,0.00016932552,0.00012536625],"category_scores_gemma":[0.0051757833,0.00006186834,0.00014660734,0.000121316814,0.00006397542,0.00003981874,0.000027164966,0.00043107368,0.0000043651844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031272974,0.00019871419,0.66759986,0.0003777368,0.00027662495,0.0015698968,0.00092522736,0.00013182919,0.000012432504,0.000016663405,0.05893749,0.26682624],"study_design_scores_gemma":[0.0031505802,0.0037865154,0.38942894,0.00017657565,0.00014291034,0.00032722083,0.00010361151,0.000058510355,0.0000022108513,0.00011000649,0.6026722,0.000040686064],"about_ca_topic_score_codex":0.28425774,"about_ca_topic_score_gemma":0.97229534,"teacher_disagreement_score":0.68803763,"about_ca_system_score_codex":0.003140888,"about_ca_system_score_gemma":0.024702705,"threshold_uncertainty_score":0.9808263},"labels":[],"label_agreement":null},{"id":"W4399280638","doi":"10.1200/jco.2024.42.16_suppl.tps11588","title":"Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Unum Therapeutics","keywords":"Sunitinib; Medicine; GiST; Stromal tumor; Stromal cell; Internal medicine; Sunitinib malate; Gastrointestinal tract; Oncology; Gastroenterology; Pathology; Cancer","score_opus":0.26774522995793537,"score_gpt":0.5397139872383176,"score_spread":0.2719687572803823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950822,0.000054407687,0.00009239433,0.0005235926,0.00044799157,0.0034464183,0.000033572243,0.000015651105,0.0003038016],"genre_scores_gemma":[0.99459785,0.000023704579,0.00493368,0.00005903223,0.00020850716,0.000046204535,0.00003167099,0.000043934317,0.000055442688],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899519,0.003201207,0.0048151487,0.00055649865,0.0009766419,0.0004985971],"domain_scores_gemma":[0.98579204,0.009875663,0.0018629922,0.00031147897,0.0013344538,0.0008233967],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009598861,0.00036447676,0.0034425063,0.00047940022,0.00006754078,0.00007639905,0.00037449188,0.000106659856,0.0000659202],"category_scores_gemma":[0.013980408,0.00023712633,0.00026122574,0.00040075064,0.00076216855,0.0002986921,0.0003182942,0.0021453116,0.00000793505],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36264083,0.14694165,0.47387698,0.000044328754,0.0006248017,0.0057692747,0.0001548951,0.0000012902323,0.0000019313334,0.000026809505,0.00007348511,0.009843737],"study_design_scores_gemma":[0.45530173,0.22952747,0.31194964,0.0005932184,0.00053968956,0.0004401208,0.0011747079,0.000348189,5.3006715e-7,0.000010630243,0.0000346144,0.000079432364],"about_ca_topic_score_codex":0.0001380513,"about_ca_topic_score_gemma":0.0003874275,"teacher_disagreement_score":0.16192733,"about_ca_system_score_codex":0.00018371003,"about_ca_system_score_gemma":0.001765593,"threshold_uncertainty_score":0.9943253},"labels":[],"label_agreement":null},{"id":"W4399280818","doi":"10.1200/jco.2024.42.16_suppl.e23242","title":"Implementation of a hepatitis B screening program in patients receiving systemic anti-cancer therapy: A Canadian single center retrospective review.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Systemic therapy; Single Center; Cancer; Retrospective cohort study; Hepatitis B; Cancer therapy; Hepatitis B virus; Center (category theory); Oncology; Internal medicine; Virology; Virus; Breast cancer","score_opus":0.11069822735168984,"score_gpt":0.49247594768138103,"score_spread":0.3817777203296912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848831,0.009751782,0.000015336107,0.0030315507,0.0009361317,0.0007970035,0.000027623164,0.000010909408,0.0005465551],"genre_scores_gemma":[0.9512784,0.046352096,0.0008302694,0.0011539867,0.00031569676,0.000025541362,0.0000054962607,0.000018639188,0.000019869876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658746,0.00037838222,0.0022733428,0.00017901738,0.00033085307,0.0002509685],"domain_scores_gemma":[0.9978118,0.00033208827,0.0009273446,0.00009921156,0.0006365299,0.00019301941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020360542,0.000116578216,0.0013349839,0.00025256918,0.000025212588,0.000009415854,0.000083278195,0.00014315477,0.00013634928],"category_scores_gemma":[0.0012325221,0.000088340144,0.000282018,0.00032013934,0.00007864884,0.00013614047,0.000025402593,0.0005803392,0.0000035304367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080420075,0.00029040512,0.6545082,0.00023524555,0.00023357183,0.000083762905,0.00019822532,2.5804192e-7,0.000027429916,0.0000036124045,0.0020213556,0.34231755],"study_design_scores_gemma":[0.0029066026,0.006920273,0.9689015,0.0073574875,0.00012495891,0.000031594318,0.00005717948,0.000017572056,0.000036742105,0.000010217017,0.013566814,0.00006902864],"about_ca_topic_score_codex":0.04295004,"about_ca_topic_score_gemma":0.22144124,"teacher_disagreement_score":0.34224853,"about_ca_system_score_codex":0.0008298076,"about_ca_system_score_gemma":0.001297582,"threshold_uncertainty_score":0.963423},"labels":[],"label_agreement":null},{"id":"W4399280965","doi":"10.1200/jco.2024.42.16_suppl.e23303","title":"Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2- early breast cancer in the real-world setting.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Moncton Hospital; Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.05384784892070495,"score_gpt":0.43555563111410167,"score_spread":0.38170778219339674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931066,0.0007847096,0.0000017461854,0.0041479436,0.00048833195,0.00020046259,0.00008538791,9.892834e-7,0.0011838495],"genre_scores_gemma":[0.998666,0.00064877747,0.000045462064,0.00029243034,0.000258654,0.000019760506,0.0000082753395,0.000008776349,0.000051886127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975602,0.0008138228,0.0008864961,0.0001930302,0.00032890562,0.00021751989],"domain_scores_gemma":[0.9984905,0.0002732322,0.00047969495,0.00013761567,0.0005236254,0.00009531339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054546334,0.00010942008,0.00039558357,0.00013179578,0.000032078733,0.000008807887,0.00018379517,0.00013423803,0.000043693464],"category_scores_gemma":[0.00038705225,0.00006667495,0.00009328459,0.00024999486,0.00013212913,0.0000119860115,0.000035874324,0.00036056974,8.423218e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007610946,0.0003308157,0.8823578,0.0000115849225,0.00021104788,0.000034578108,0.00039688635,0.00023419126,0.000026971133,0.000021733227,0.00078960386,0.11482372],"study_design_scores_gemma":[0.0027564636,0.0012846234,0.98915726,0.00016815196,0.00015131061,0.0000044537765,0.00008641801,0.000066613495,0.000027913093,0.000056309796,0.0061701196,0.00007037871],"about_ca_topic_score_codex":0.060283367,"about_ca_topic_score_gemma":0.7035736,"teacher_disagreement_score":0.6432902,"about_ca_system_score_codex":0.00032175033,"about_ca_system_score_gemma":0.004058119,"threshold_uncertainty_score":0.9459743},"labels":[],"label_agreement":null},{"id":"W4399281014","doi":"10.1200/jco.2024.42.16_suppl.11101","title":"Associations of symptom burden with patient-reported outcomes (PROs) and clinical outcomes among early-phase cancer clinical trial (EP-CT) participants.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Clinical trial; Quality of life (healthcare); Intensive care medicine; Internal medicine","score_opus":0.24939361616866051,"score_gpt":0.4896000004485675,"score_spread":0.24020638427990698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865645,0.0016099437,0.00018701567,0.0027100625,0.006761203,0.0004594001,0.000199057,0.000023059785,0.0014857588],"genre_scores_gemma":[0.99446213,0.0023534799,0.00047224283,0.0007237445,0.0014969303,0.000018993469,0.0000041770563,0.00004293568,0.00042538802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98711914,0.00030744832,0.011357663,0.00056206214,0.00015934661,0.0004943372],"domain_scores_gemma":[0.98471785,0.005816933,0.008195556,0.0003597082,0.00030640987,0.00060355064],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009601526,0.00029063525,0.0042523323,0.00025726118,0.00007702047,0.00009107753,0.00033029937,0.0005803659,0.00023848301],"category_scores_gemma":[0.011933722,0.000223768,0.0013252519,0.00021207721,0.0007504712,0.0006291316,0.000113026435,0.0014498725,0.000034207143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038490265,0.0013225477,0.93055093,0.000013745248,0.0026461044,0.0001443597,0.00016278993,0.000013672975,1.2243693e-7,0.0034366183,0.0013318314,0.056528226],"study_design_scores_gemma":[0.036572825,0.010086208,0.9305134,0.000075862656,0.00052980887,0.000009534539,0.000046414865,0.00022749543,0.0000011338187,0.004728931,0.016948132,0.00026028027],"about_ca_topic_score_codex":0.00085870735,"about_ca_topic_score_gemma":0.0005596217,"teacher_disagreement_score":0.056267947,"about_ca_system_score_codex":0.00020199694,"about_ca_system_score_gemma":0.0013823927,"threshold_uncertainty_score":0.99638915},"labels":[],"label_agreement":null},{"id":"W4399281048","doi":"10.1200/jco.2024.42.16_suppl.11093","title":"Enhancing the patient journey to clinical trial enrollment with navigation to optimize accrual: A pilot study for a pragmatic multicentre, stepped wedge, cluster randomized controlled trial (The CTN Pilot Trial).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Manitoba; University of Windsor","funders":"","keywords":"Medicine; Pilot trial; Randomized controlled trial; Accrual; Clinical trial; Observational study; Medical physics; Physical therapy; Surgery; Internal medicine","score_opus":0.5983308606511375,"score_gpt":0.646737011405918,"score_spread":0.0484061507547805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8324506,0.000444378,0.0026142574,0.06140559,0.03218114,0.070571415,0.000025333893,0.00005426524,0.00025298432],"genre_scores_gemma":[0.95359755,0.00023306062,0.0013169926,0.025242677,0.012779371,0.0060504344,0.000006334479,0.00007154349,0.0007020443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9469615,0.037728935,0.012488469,0.00076178694,0.0010331627,0.0010261246],"domain_scores_gemma":[0.8584415,0.13462985,0.0037495454,0.00044661507,0.0010820309,0.0016505198],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.094071954,0.00059986854,0.005796042,0.00023919228,0.0006217297,0.00019731515,0.0009794661,0.0008089735,0.00043869732],"category_scores_gemma":[0.0439636,0.00028320547,0.0016973466,0.0005107014,0.0005086749,0.00023411369,0.00025513678,0.0070964093,0.00010039797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94121784,0.021108704,0.000022741908,0.00006602577,0.0050281687,0.00018992949,0.0019537117,0.0019037245,0.000035033307,0.000110607885,0.009354676,0.019008864],"study_design_scores_gemma":[0.74132717,0.19827877,0.000014958691,0.000171773,0.005021387,0.000040071587,0.0010859763,0.0040089083,0.000029164748,0.00015262043,0.049614705,0.00025447024],"about_ca_topic_score_codex":0.000022905358,"about_ca_topic_score_gemma":0.0001567639,"teacher_disagreement_score":0.19989063,"about_ca_system_score_codex":0.0003834133,"about_ca_system_score_gemma":0.00373557,"threshold_uncertainty_score":0.99996203},"labels":[],"label_agreement":null},{"id":"W4399281058","doi":"10.1200/jco.2024.42.16_suppl.11098","title":"Quality of life and testosterone recovery after androgen deprivation therapy in patients with high-risk prostate cancer: Long-term data from a phase III trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Quality of life (healthcare); Oncology; Androgen; Internal medicine; Prostate; Cancer; Term (time); Antiandrogen; Hormone","score_opus":0.17770989970535347,"score_gpt":0.4998605126675258,"score_spread":0.3221506129621723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954225,0.0074316734,0.000022994655,0.0014613121,0.00044510496,0.0007572722,0.0003264296,0.000004717851,0.0000082481065],"genre_scores_gemma":[0.9786579,0.02022886,0.0003029253,0.0002275906,0.0003871806,0.000019573974,0.00012410326,0.0000140599495,0.000037790134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695253,0.00047665634,0.0017891264,0.0002686645,0.00036179446,0.00015122394],"domain_scores_gemma":[0.99664444,0.0017275533,0.00093183503,0.0002651216,0.00022570656,0.0002053755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024072302,0.000113123526,0.0010836968,0.00012558201,0.0000151732,0.000016132622,0.00011860509,0.00016947479,0.00010105244],"category_scores_gemma":[0.0010405726,0.000064269785,0.00008176503,0.00014607834,0.00016729705,0.0002653478,0.00007462311,0.0005631295,0.0000011541886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29686958,0.0016133393,0.4914881,0.000029976542,0.00045146825,0.0000859439,0.000066574605,4.8232783e-7,0.000015882912,2.2960334e-7,0.000108192966,0.20927024],"study_design_scores_gemma":[0.21581037,0.028338691,0.7548482,0.00025387312,0.00014441655,0.0000016680929,0.000010659619,0.000014543606,0.00003548602,0.000080736165,0.00040712036,0.000054272758],"about_ca_topic_score_codex":0.0003527132,"about_ca_topic_score_gemma":0.0003779828,"teacher_disagreement_score":0.26336005,"about_ca_system_score_codex":0.00011749915,"about_ca_system_score_gemma":0.0016720685,"threshold_uncertainty_score":0.29661778},"labels":[],"label_agreement":null},{"id":"W4399281099","doi":"10.1200/jco.2024.42.16_suppl.tps10622","title":"Blood-based colorectal cancer (CRC) screening implementation into clinical practice in the outpatient clinical setting in the Appalachian highlands.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Cancer; Oncology; Clinical Practice; Family medicine","score_opus":0.11326013338962425,"score_gpt":0.5397215490507542,"score_spread":0.42646141566112994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9371838,0.0014217311,0.000670692,0.055886596,0.00330538,0.0006363819,0.0000039662254,0.000023173878,0.000868265],"genre_scores_gemma":[0.97903085,0.00070765335,0.005195642,0.010999656,0.00397337,0.000053072505,0.000008899156,0.000021920254,0.000008909704],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9877992,0.0055160723,0.0050422186,0.00042228223,0.000860591,0.00035960504],"domain_scores_gemma":[0.9687818,0.028790934,0.0016719397,0.00023050178,0.0003264491,0.00019834479],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04001758,0.00020491147,0.0011542389,0.0002564532,0.000102554455,0.00007496595,0.00035364556,0.00054262666,0.000050224822],"category_scores_gemma":[0.013638682,0.00011412135,0.00076720794,0.0006837887,0.00025748173,0.00023524383,0.000059755377,0.004526407,0.000006893189],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012010096,0.0011056076,0.41520366,0.00003952779,0.00024303893,0.0010713232,0.0015902112,0.000103667146,0.00000684017,0.000044399476,0.0026249925,0.56595665],"study_design_scores_gemma":[0.010676985,0.041541833,0.845665,0.00042616113,0.0010576054,0.0005548996,0.005185931,0.004376828,0.00001751398,0.00012581065,0.0902068,0.00016466712],"about_ca_topic_score_codex":0.0007885248,"about_ca_topic_score_gemma":0.0045812484,"teacher_disagreement_score":0.56579196,"about_ca_system_score_codex":0.00018350517,"about_ca_system_score_gemma":0.0024365024,"threshold_uncertainty_score":0.9977702},"labels":[],"label_agreement":null},{"id":"W4399281115","doi":"10.1200/jco.2024.42.16_suppl.12092","title":"Novel genome-wide significant germline genetic variants associated with venous thrombo-embolism (VTE) and arterial embolism (ATE) risk in patients with <i>ALK</i> and <i>ROS1</i> fusion non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Pulmonary embolism; Venous thromboembolism; Germline; Internal medicine; Oncology; Cardiology; Thrombosis; Genetics; Gene","score_opus":0.017677674896626368,"score_gpt":0.3451939423154888,"score_spread":0.3275162674188624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944507,0.002005434,0.0005236373,0.0008542841,0.0009769828,0.00068755343,0.00011184094,0.000014430558,0.00037512535],"genre_scores_gemma":[0.99398196,0.0023445748,0.0019220641,0.00095337274,0.000610897,0.00001947459,0.000024298857,0.00004994558,0.000093410206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973704,0.00017939815,0.0013511449,0.0004051098,0.00033693534,0.00035701552],"domain_scores_gemma":[0.9973646,0.0008117568,0.0009450026,0.00015462379,0.00033511923,0.0003889269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076117297,0.00026605392,0.0013467768,0.00016593594,0.000084262676,0.000046494744,0.000088672605,0.00031550968,0.00003847988],"category_scores_gemma":[0.00021212253,0.00016593907,0.000109472356,0.00022137706,0.00018067192,0.00012323339,0.000049935716,0.0008129329,0.0000015770382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005709029,0.0066081,0.9505357,0.00019837948,0.0019257966,0.0013237483,0.002478336,0.00024250893,0.0010700357,0.000005591533,0.0005058298,0.029396908],"study_design_scores_gemma":[0.025585117,0.007673313,0.9614444,0.00064102135,0.002623447,0.000052769054,0.000054838285,0.00045319216,0.000017104612,0.000037889404,0.0012275344,0.00018939965],"about_ca_topic_score_codex":0.00032515227,"about_ca_topic_score_gemma":0.00033299995,"teacher_disagreement_score":0.029207509,"about_ca_system_score_codex":0.00028701447,"about_ca_system_score_gemma":0.0019957596,"threshold_uncertainty_score":0.67667985},"labels":[],"label_agreement":null},{"id":"W4399281276","doi":"10.1200/jco.2024.42.16_suppl.10565","title":"Adverse childhood experiences and cancer: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Meta-analysis; Cancer; Adverse effect; Childhood cancer; Oncology; Internal medicine","score_opus":0.41253230775601674,"score_gpt":0.6256693956908188,"score_spread":0.21313708793480207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000044705403,0.9905434,0.0000015646328,0.0074573588,0.00054364506,0.0011657882,0.000019692454,0.000007089198,0.0002569952],"genre_scores_gemma":[0.0000585375,0.99281514,0.00031306877,0.005243986,0.0008376125,0.00014659307,0.0000031006425,0.000024209348,0.0005577414],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9900436,0.0019781126,0.0068655396,0.00040065954,0.00050204416,0.00021003993],"domain_scores_gemma":[0.98949176,0.0043073054,0.004768868,0.0003360382,0.00043165765,0.0006643794],"candidate_categories":["metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011230981,0.0003628984,0.028814252,0.00033874388,0.000040848892,0.000017750095,0.00021509206,0.0009988383,0.0002519431],"category_scores_gemma":[0.0077487617,0.00016913925,0.005265448,0.0006183902,0.00025812563,0.000061277606,0.000118789234,0.0035076444,0.000009151025],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000064052024,0.00011091239,0.0000036196182,0.8216473,0.14891773,0.0005551577,0.00040864042,1.677241e-8,1.05669085e-10,0.000056864345,0.0009608213,0.027332539],"study_design_scores_gemma":[0.00012252237,0.00081001996,0.0000019082022,0.03689537,0.5825669,0.00057616935,0.00012413775,4.328368e-7,4.38715e-10,0.000018784389,0.3788041,0.00007963269],"about_ca_topic_score_codex":0.000033681186,"about_ca_topic_score_gemma":0.000025080084,"teacher_disagreement_score":0.78475195,"about_ca_system_score_codex":0.00009256311,"about_ca_system_score_gemma":0.0038514223,"threshold_uncertainty_score":0.9987913},"labels":[],"label_agreement":null},{"id":"W4399281283","doi":"10.1200/jco.2024.42.16_suppl.10540","title":"Cancer screening in sexual and gender minority populations: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Sex and Gender in Healthcare","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Meta-analysis; Sexual minority; Systematic review; Oncology; Gynecology; MEDLINE; Internal medicine; Lesbian; Biology","score_opus":0.8431962283126858,"score_gpt":0.6784180081824666,"score_spread":0.16477822013021926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014150684,0.9955188,0.000015890339,0.002867743,0.00027237323,0.0012230787,0.000025221589,0.000005057094,0.000057682748],"genre_scores_gemma":[0.000044978988,0.9950296,0.0012805832,0.0028282632,0.0003944683,0.00007943948,0.000009538583,0.000018741883,0.00031434203],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.990027,0.0024056737,0.0065811826,0.00041813645,0.0003651624,0.0002028074],"domain_scores_gemma":[0.9935746,0.0024946462,0.002965878,0.00031216623,0.00027887398,0.00037382063],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010076601,0.00031261647,0.02082305,0.00050717866,0.000026591573,0.000015291123,0.0001228473,0.00071413396,0.00010313809],"category_scores_gemma":[0.0037084662,0.00016608837,0.0023930485,0.0006392436,0.000088557936,0.00005403704,0.000080500264,0.002116168,0.0000033481097],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000138343075,0.000079575206,0.00047015422,0.7961229,0.1260466,0.00034241285,0.00003685216,2.3900583e-7,4.729305e-10,0.000027434215,0.0006111817,0.07624879],"study_design_scores_gemma":[0.0002904217,0.00046856777,0.00049242866,0.021263115,0.9262847,0.0009447508,0.00006181958,0.0000102956665,2.1545658e-10,0.00009483058,0.049971413,0.00011769878],"about_ca_topic_score_codex":0.000111397574,"about_ca_topic_score_gemma":0.00045920684,"teacher_disagreement_score":0.8002381,"about_ca_system_score_codex":0.00010574327,"about_ca_system_score_gemma":0.0013938564,"threshold_uncertainty_score":0.99371386},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4399281317","doi":"10.1200/jco.2024.42.16_suppl.10024","title":"Comparing the impact of insufficient physical activity on cardiovascular disease in survivors of childhood Hodgkin lymphoma and sibling controls: A report from the Childhood Cancer Survivor Study (CCSS).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"","keywords":"Medicine; Childhood cancer; Disease; Sibling; Hodgkin lymphoma; Cancer; Lymphoma; Oncology; Pediatrics; Internal medicine; Developmental psychology","score_opus":0.11530267717549171,"score_gpt":0.46182190704892245,"score_spread":0.34651922987343076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844185,0.009853686,0.000041999883,0.0034911248,0.0010091596,0.0010262929,0.000056739915,0.000015553263,0.000086919026],"genre_scores_gemma":[0.9971112,0.00087487546,0.000017374881,0.00030244418,0.0016294002,0.000019226243,0.0000027651363,0.000038226495,0.0000044977373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99208575,0.00296407,0.0027316555,0.0005348285,0.0013433766,0.00034030195],"domain_scores_gemma":[0.9851616,0.011473173,0.0018109876,0.0008549371,0.00031546017,0.00038386858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011915276,0.00033550148,0.0034534167,0.00020956833,0.00007285375,0.000032014224,0.00040681465,0.00018524533,0.000015748808],"category_scores_gemma":[0.006469602,0.00017539907,0.0020382716,0.00059092895,0.00045608587,0.000150745,0.0001928951,0.0014324372,0.0000011313701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053380053,0.019832062,0.91210407,0.00006873644,0.008300939,0.0008893681,0.0076431353,0.005799588,0.000030809988,0.000017634327,0.00016719243,0.03980849],"study_design_scores_gemma":[0.0089011965,0.005436266,0.97871566,0.0008039339,0.0018457773,0.000081882456,0.0010989225,0.0023668557,0.000023287788,0.00008842502,0.0004852635,0.0001525167],"about_ca_topic_score_codex":0.022540266,"about_ca_topic_score_gemma":0.0026984368,"teacher_disagreement_score":0.06661163,"about_ca_system_score_codex":0.00029548182,"about_ca_system_score_gemma":0.0034333451,"threshold_uncertainty_score":0.98396873},"labels":[],"label_agreement":null},{"id":"W4399281323","doi":"10.1200/jco.2024.42.16_suppl.10012","title":"Access for adolescents and young adults with hard-to-cure cancer to PROFYLE: The pan-Canadian precision oncology pipeline.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Hospital for Sick Children; Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Oncology; Precision oncology; Internal medicine; Precision medicine; Cancer; Pipeline (software); Pathology","score_opus":0.13679172836157394,"score_gpt":0.5055261244730199,"score_spread":0.368734396111446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66927505,0.0018749062,0.0016184476,0.3185006,0.0059637045,0.0021301326,0.00006146994,0.000023478167,0.0005522057],"genre_scores_gemma":[0.95007,0.0010505198,0.0034429587,0.03928968,0.0052925358,0.00009433371,0.000003703146,0.00005173773,0.0007044894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99607694,0.00046193972,0.002012161,0.00045728098,0.0005323925,0.00045931162],"domain_scores_gemma":[0.9947197,0.0021712845,0.0006387236,0.00029473106,0.00083655067,0.001339018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051850737,0.00022382067,0.0014334704,0.000277424,0.00010862876,0.00007211145,0.00044661673,0.00044931239,0.000069618916],"category_scores_gemma":[0.0042503,0.00012827618,0.00028750175,0.00037709903,0.0001631053,0.000180618,0.00011971409,0.0013281527,0.000019357423],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018909339,0.00057788834,0.09818036,0.00044358766,0.00041317477,0.00039959367,0.0029650885,0.000029892159,0.000022622296,0.00004455502,0.21699806,0.66101587],"study_design_scores_gemma":[0.005609986,0.013559178,0.33822745,0.0030135168,0.0005469368,0.00042485204,0.0005384929,0.00022657112,0.00002413009,0.00013853482,0.63751686,0.00017347839],"about_ca_topic_score_codex":0.0069547747,"about_ca_topic_score_gemma":0.20243779,"teacher_disagreement_score":0.66084236,"about_ca_system_score_codex":0.0005613968,"about_ca_system_score_gemma":0.0077241347,"threshold_uncertainty_score":0.999658},"labels":[],"label_agreement":null},{"id":"W4399281370","doi":"10.1200/jco.2024.42.16_suppl.10006","title":"Outcome of children and young adults with localized extremity rhabdomyosarcoma treated on Children's Oncology Group trials.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Rhabdomyosarcoma; Pediatric oncology; Pediatrics; Clinical trial; Oncology; Internal medicine; Cancer; Sarcoma; Pathology","score_opus":0.09171732378957578,"score_gpt":0.4430172618121664,"score_spread":0.35129993802259063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883371,0.004555931,0.000057702444,0.004781136,0.00074678066,0.000715612,0.0000382596,0.000029701929,0.00073774933],"genre_scores_gemma":[0.993718,0.0020613747,0.0024251454,0.000769981,0.0008982565,0.000012477385,0.00002640899,0.000035374243,0.000052959327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993702,0.0012790308,0.0038347153,0.00041745044,0.00047119003,0.0002956124],"domain_scores_gemma":[0.9907164,0.0065314686,0.0017412478,0.00027880605,0.00023371582,0.00049834204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004496435,0.00030750394,0.004019686,0.00031001025,0.00004175831,0.000016556865,0.00015111946,0.00060772826,0.00014406128],"category_scores_gemma":[0.0029523436,0.00016775413,0.00089284225,0.00024559742,0.0004205039,0.00009174704,0.00005415149,0.0011576855,0.0000098643395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0141093815,0.004507606,0.6810656,0.000024524303,0.0019581958,0.0016193532,0.000071610826,0.0000015238879,0.000008240001,0.00020602837,0.0012816625,0.2951463],"study_design_scores_gemma":[0.032804284,0.039346885,0.91759026,0.00056651677,0.0026710373,0.0038360567,0.00003886393,0.00004115622,0.000095266056,0.00010032789,0.0027664683,0.00014290505],"about_ca_topic_score_codex":0.0002367501,"about_ca_topic_score_gemma":0.00011917049,"teacher_disagreement_score":0.29500338,"about_ca_system_score_codex":0.00024136971,"about_ca_system_score_gemma":0.00058471074,"threshold_uncertainty_score":0.6840815},"labels":[],"label_agreement":null},{"id":"W4399281392","doi":"10.1200/jco.2024.42.16_suppl.10016","title":"Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood &amp; Marrow Transplant Research (CIBMTR) registry results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Blinatumomab; Bone marrow transplant; Hematopoietic cell; Acute lymphocytic leukemia; Bone marrow; Oncology; Bone transplantation; Pediatrics; Leukemia; Internal medicine; Bone marrow transplantation; Stem cell; Surgery; Haematopoiesis","score_opus":0.14603389688117718,"score_gpt":0.46044773126579247,"score_spread":0.3144138343846153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889353,0.002950978,0.0010751421,0.0022665376,0.002768359,0.0009975557,0.0006025494,0.000008836927,0.00039474122],"genre_scores_gemma":[0.9374718,0.049834978,0.0022618514,0.00006940398,0.0033617772,0.000048480542,0.000057513847,0.000043706,0.0068504578],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959703,0.00039292182,0.002215825,0.00032865774,0.0007485265,0.0003437587],"domain_scores_gemma":[0.9825937,0.013890515,0.0008035045,0.00032079697,0.0021464399,0.00024505093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004257105,0.00016503266,0.0008719848,0.00037305424,0.000058199137,0.000025157024,0.0002728525,0.0004186795,0.0000618242],"category_scores_gemma":[0.004493979,0.00010317629,0.0006942013,0.00020032292,0.00039008458,0.00012204315,0.000033815697,0.00070857484,0.0000026454766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41417044,0.026798658,0.115354694,0.0026509059,0.01642812,0.0014578312,0.0055225445,0.00013603727,0.13876267,0.0007206189,0.13048637,0.14751111],"study_design_scores_gemma":[0.12833293,0.11484606,0.06900065,0.00082078006,0.008865106,0.0014492534,0.0005205751,0.006621842,0.004714278,0.00082060136,0.6636152,0.0003927026],"about_ca_topic_score_codex":0.00011504514,"about_ca_topic_score_gemma":0.00013553734,"teacher_disagreement_score":0.53312886,"about_ca_system_score_codex":0.0008832704,"about_ca_system_score_gemma":0.002564168,"threshold_uncertainty_score":0.5380037},"labels":[],"label_agreement":null},{"id":"W4399281417","doi":"10.1200/jco.2024.42.16_suppl.10035","title":"Testicular germ cell tumor survival among children, adolescents, and young adults: A population-based retrospective cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Retrospective cohort study; Germ cell; Testicular Germ Cell Tumor; Young adult; Cohort; Oncology; Population; Testicular cancer; Pediatrics; Internal medicine; Cancer; Genetics; Environmental health","score_opus":0.020587872584558766,"score_gpt":0.37178943525090086,"score_spread":0.3512015626663421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958824,0.0017996035,0.00006157786,0.0002182722,0.0011222848,0.0007454288,0.000014701641,0.000032954507,0.00012278283],"genre_scores_gemma":[0.9985266,0.00006793757,0.0004147642,0.00019308394,0.00071093964,0.000008641244,0.00001436511,0.000028820534,0.00003486211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715316,0.00033537624,0.0014242028,0.00034765332,0.0005365508,0.00020303587],"domain_scores_gemma":[0.99759287,0.0005886072,0.000804434,0.0001923733,0.0003345023,0.00048720802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013347495,0.00019120856,0.001203544,0.00012888732,0.000053565716,0.00003306536,0.00007865825,0.0001536234,0.000045151017],"category_scores_gemma":[0.0030884726,0.00013170375,0.00042190257,0.00017280922,0.00011188489,0.00009007795,0.000035096942,0.0007061351,0.00000989377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009447801,0.00432838,0.9863518,0.00007817274,0.0006056605,0.0040674326,0.000024507184,0.000008272085,0.0000014999376,0.0000072532835,0.00010504018,0.0034772414],"study_design_scores_gemma":[0.008001311,0.007612372,0.9801493,0.00056309655,0.0024844923,0.00024294644,0.000052607,0.00069914485,0.000001521728,0.000052554944,0.000028846614,0.00011177668],"about_ca_topic_score_codex":0.00037795556,"about_ca_topic_score_gemma":0.0000987893,"teacher_disagreement_score":0.007056531,"about_ca_system_score_codex":0.00025740225,"about_ca_system_score_gemma":0.0008003001,"threshold_uncertainty_score":0.5370723},"labels":[],"label_agreement":null},{"id":"W4399281478","doi":"10.1200/jco.2024.42.16_suppl.10014","title":"Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Bone marrow; Peripheral blood; Oncology; Antibody; Pediatric oncology; Internal medicine; Cancer; Immunology","score_opus":0.0819843434298011,"score_gpt":0.4552698508456327,"score_spread":0.3732855074158316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768115,0.010708258,0.000113412636,0.010346162,0.0012743983,0.00037772884,0.0000069469797,0.00001380766,0.00034777683],"genre_scores_gemma":[0.986359,0.0039487937,0.006802246,0.000793418,0.0019930927,0.0000066445,0.000014795518,0.000033392753,0.000048621463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922419,0.0012198954,0.0049041077,0.00045431318,0.000709051,0.00047071234],"domain_scores_gemma":[0.9883864,0.009172611,0.0015383522,0.00035409603,0.0002647561,0.00028377568],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0074923965,0.00023470644,0.0025692664,0.00030452627,0.000030693423,0.000023813938,0.00033643766,0.0008025809,0.00012422037],"category_scores_gemma":[0.0069210865,0.00015311371,0.0003243659,0.00058798894,0.00048728278,0.0001618882,0.00026371106,0.0032196026,0.000006575193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047286325,0.0021256534,0.9365204,0.000093582996,0.0006823411,0.025253797,0.0012391869,0.00009189435,0.0011007055,0.00013195131,0.0039289417,0.024102943],"study_design_scores_gemma":[0.016578784,0.013042471,0.9526998,0.00035941022,0.0010202898,0.008455486,0.0005523742,0.0017123539,0.000050149523,0.0008041094,0.004548312,0.00017646597],"about_ca_topic_score_codex":0.0017443644,"about_ca_topic_score_gemma":0.00081584626,"teacher_disagreement_score":0.023926476,"about_ca_system_score_codex":0.0015309036,"about_ca_system_score_gemma":0.007487289,"threshold_uncertainty_score":0.99908},"labels":[],"label_agreement":null},{"id":"W4399281491","doi":"10.1200/jco.2024.42.16_suppl.10036","title":"Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Glioma; Oncology; Gastroenterology; Cancer research; Biology","score_opus":0.09920939744627026,"score_gpt":0.4479339066055135,"score_spread":0.34872450915924325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798212,0.005768821,7.9120326e-7,0.011043509,0.0022918943,0.00058697513,0.000004750021,0.000012018469,0.0004700464],"genre_scores_gemma":[0.99357086,0.0030722423,0.00022346119,0.00093642937,0.0021191854,0.000022860106,0.0000060835723,0.000020654441,0.000028236664],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951385,0.0010177725,0.0026876836,0.00032165187,0.00048643627,0.00034795047],"domain_scores_gemma":[0.9923202,0.0063450783,0.00067293644,0.00022609562,0.00015988915,0.0002758113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053019268,0.0002149579,0.0014148873,0.0008152342,0.000040846066,0.000021779095,0.00023736666,0.00051043154,0.00014111225],"category_scores_gemma":[0.00803228,0.00013254087,0.00048041967,0.0014362123,0.00010816097,0.00016233933,0.00007134287,0.0016598006,0.000028611315],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18696523,0.15087306,0.33384612,0.00055190065,0.0006985471,0.13034086,0.002036465,0.00003768686,0.0008254056,0.000585146,0.105056874,0.0881827],"study_design_scores_gemma":[0.5147513,0.09369206,0.3202848,0.0014857679,0.0015311055,0.0010765713,0.00063175434,0.00029399633,0.0007469042,0.002163531,0.06282601,0.0005162016],"about_ca_topic_score_codex":0.00012490542,"about_ca_topic_score_gemma":0.00026052826,"teacher_disagreement_score":0.3277861,"about_ca_system_score_codex":0.0004969755,"about_ca_system_score_gemma":0.002199293,"threshold_uncertainty_score":0.96159697},"labels":[],"label_agreement":null},{"id":"W4399281523","doi":"10.1200/jco.2024.42.16_suppl.10057","title":"The role of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Blockade; Meta-analysis; Immune checkpoint; Immune system; Oncology; Immunology; Internal medicine; Receptor","score_opus":0.05968354540550545,"score_gpt":0.40163851932705785,"score_spread":0.3419549739215524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004050729,0.99747366,0.0000019384668,0.00028046945,0.0011462439,0.0009543903,0.000008756295,0.000004901986,0.0000891353],"genre_scores_gemma":[0.0014359812,0.9972139,0.000009711599,0.00013336724,0.00004709162,0.0000401571,0.000014978925,0.000019528277,0.0010852936],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98770624,0.003475222,0.008221612,0.00029886104,0.0000821138,0.00021592033],"domain_scores_gemma":[0.9909925,0.0013669195,0.0069885654,0.00036873226,0.00023733426,0.000045947814],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0075261043,0.0003561309,0.012984664,0.00035729512,0.000057620247,0.000018773366,0.0003585453,0.0008174967,0.00011989345],"category_scores_gemma":[0.002616742,0.00016788061,0.004569935,0.00037662254,0.00030188772,0.0000716089,0.00017128415,0.0025498967,0.00004388608],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041332777,0.0008981769,0.00014848009,0.39038783,0.5346454,0.000024282665,0.00010341838,1.6680521e-7,0.000009561301,0.00009368744,0.0008078626,0.0724678],"study_design_scores_gemma":[0.0005780178,0.00076332036,0.00012718888,0.03881549,0.7480457,0.0014255521,0.000084773266,8.398382e-7,0.0000024180674,0.000020116855,0.20999204,0.00014458623],"about_ca_topic_score_codex":0.0000541697,"about_ca_topic_score_gemma":0.000038103495,"teacher_disagreement_score":0.35157233,"about_ca_system_score_codex":0.00007187037,"about_ca_system_score_gemma":0.00034204454,"threshold_uncertainty_score":0.99975127},"labels":[],"label_agreement":null},{"id":"W4399281543","doi":"10.1200/jco.2024.42.16_suppl.10554","title":"Risk of subsequent primary cancers among adult cancer survivors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine; Primary cancer","score_opus":0.07439936143624962,"score_gpt":0.4380478404294067,"score_spread":0.3636484789931571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711241,0.007889478,0.00011376474,0.0029407388,0.0056265835,0.00018803154,0.000044364446,0.000017290493,0.012055619],"genre_scores_gemma":[0.9625719,0.030478448,0.00092396233,0.0029357842,0.0021648759,0.0000074325408,0.000005748901,0.000030009636,0.0008818167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959258,0.0004051814,0.0026926997,0.00024151913,0.0004768983,0.00025789562],"domain_scores_gemma":[0.99535197,0.0019057925,0.0014903122,0.00021546078,0.00061514456,0.00042130318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028715811,0.00016346677,0.0017781007,0.00018659623,0.000027691562,0.000008775085,0.00018992001,0.0003853358,0.0008946054],"category_scores_gemma":[0.0010659926,0.00011386109,0.0008769517,0.00022375752,0.00043277637,0.00019176859,0.000043566997,0.0016229787,0.0000092977325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038634674,0.0003444683,0.60634667,0.00045584308,0.0019306918,0.0010536285,0.00034902833,0.0002487465,0.00044327741,0.00012836972,0.022371609,0.3624642],"study_design_scores_gemma":[0.005189308,0.0060214875,0.81635135,0.00068343093,0.0014529059,0.00019572572,0.00017508134,0.0008369035,0.00045471292,0.00015383429,0.16830844,0.00017680146],"about_ca_topic_score_codex":0.004571413,"about_ca_topic_score_gemma":0.0038875856,"teacher_disagreement_score":0.36228737,"about_ca_system_score_codex":0.0009810758,"about_ca_system_score_gemma":0.009132346,"threshold_uncertainty_score":0.99648494},"labels":[],"label_agreement":null},{"id":"W4399281547","doi":"10.1200/jco.2024.42.16_suppl.10003","title":"Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Neuroblastoma; Stage (stratigraphy); Staging system; Oncology; Internal medicine; Pediatric oncology; Cancer","score_opus":0.04178863206831531,"score_gpt":0.41280699349096694,"score_spread":0.37101836142265165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972934,0.000053171,0.000104766004,0.00013855529,0.0010538534,0.00080399815,0.00012711287,0.00002999446,0.0003951098],"genre_scores_gemma":[0.9989723,0.00010033905,0.00025010234,0.000061826875,0.0005147788,0.0000138290825,0.000034939047,0.00004658826,0.000005281765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937565,0.0018516198,0.0026247469,0.00045615493,0.0009992729,0.00031172737],"domain_scores_gemma":[0.9922004,0.0036960489,0.0028648644,0.00037888542,0.00057352573,0.00028631053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025034426,0.000268291,0.0014292013,0.0004866181,0.000051428873,0.000026909569,0.0003156254,0.00022889259,0.00002008136],"category_scores_gemma":[0.0012022181,0.00015018634,0.000501626,0.00037047177,0.00020839937,0.00034370038,0.00008306467,0.00157239,0.0000037049363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03226318,0.004637726,0.9266759,0.000062378225,0.0018758049,0.0051926346,0.0003144749,0.00042236544,0.0003143068,0.000054934593,0.000034196742,0.028152097],"study_design_scores_gemma":[0.012772047,0.08223294,0.9020684,0.00093347934,0.0001895121,0.00048628575,0.00019197345,0.0008812645,0.000113425034,0.000009767449,0.00003702692,0.00008390821],"about_ca_topic_score_codex":0.0007202048,"about_ca_topic_score_gemma":0.0001958728,"teacher_disagreement_score":0.07759521,"about_ca_system_score_codex":0.001089031,"about_ca_system_score_gemma":0.0012682291,"threshold_uncertainty_score":0.68313396},"labels":[],"label_agreement":null},{"id":"W4399281554","doi":"10.1200/jco.2024.42.16_suppl.10516","title":"Accurate parent-of-origin variant assignment for multiple hereditary cancer syndromes using proband-only blood sample analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Vancouver General Hospital; University of British Columbia; Canada's Michael Smith Genome Sciences Centre; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Proband; Medicine; Cancer; Genetics; Blood cancer; Sample (material); Oncology; Internal medicine; Mutation; Gene; Biology","score_opus":0.18252516611360467,"score_gpt":0.49039779197767336,"score_spread":0.3078726258640687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8882652,0.0065059597,0.10057575,0.0008716151,0.003233112,0.00025573213,0.00024220214,0.000005352654,0.000045100867],"genre_scores_gemma":[0.96349895,0.0011990855,0.03323601,0.00022296551,0.001683255,0.000023785204,0.000037812944,0.000022071821,0.00007603618],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738073,0.00023441369,0.0016587364,0.00030179447,0.00020423255,0.00022008864],"domain_scores_gemma":[0.9972889,0.0010769571,0.0009288025,0.00020353297,0.0003626092,0.00013922068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017323325,0.00014618346,0.0008234579,0.00013481536,0.000043379565,0.000019742432,0.0002451907,0.00033239395,0.00008499332],"category_scores_gemma":[0.0013017547,0.000114324204,0.00072616787,0.00024794135,0.0001282858,0.000012938806,0.000069419955,0.0002718259,6.731851e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061493143,0.005490047,0.30897418,0.0010487282,0.0766514,0.0011037085,0.00056030223,0.22860062,0.08430922,0.00057614007,0.037832025,0.2487043],"study_design_scores_gemma":[0.017244125,0.02302147,0.06323193,0.0006794635,0.029838532,0.0016152755,0.0005850829,0.08017695,0.019200789,0.0029968522,0.76002175,0.0013877599],"about_ca_topic_score_codex":0.00007676737,"about_ca_topic_score_gemma":0.00025502002,"teacher_disagreement_score":0.7221897,"about_ca_system_score_codex":0.00012858161,"about_ca_system_score_gemma":0.003912651,"threshold_uncertainty_score":0.69408745},"labels":[],"label_agreement":null},{"id":"W4399281563","doi":"10.1200/jco.2024.42.16_suppl.10517","title":"Prevalence of obesity and its impact on outcome in children diagnosed with cancer in Canada: A population-based study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Kingston Health Sciences Centre; Montreal Children's Hospital; Children's Hospital of Eastern Ontario; Alberta Children's Hospital; Stollery Children's Hospital; Izaak Walton Killam Health Centre; BC Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; Dalhousie University; Saskatchewan Cancer Agency; CancerCare Manitoba; Janeway Children's Health and Rehabilitation Centre; Centre Hospitalier Universitaire de Sherbrooke; London Health Sciences Centre; McMaster Children's Hospital","funders":"Fonds de Recherche du Québec - Santé; Leukemia and Lymphoma Society of Canada","keywords":"Medicine; Obesity; Cancer; Population; Outcome (game theory); Pediatrics; Demography; Environmental health; Internal medicine","score_opus":0.07739568002561432,"score_gpt":0.4799806090349106,"score_spread":0.40258492900929627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944376,0.0012349018,0.0000016100539,0.0034818556,0.00031433487,0.0004787472,0.000029769253,0.0000037179814,0.0000174759],"genre_scores_gemma":[0.9985886,0.00016956417,0.000044195775,0.0009463972,0.00022072074,0.000005873916,9.447746e-7,0.000012191569,0.000011492028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644953,0.0005679459,0.002076551,0.0002156491,0.00051760254,0.00017274976],"domain_scores_gemma":[0.9953787,0.0034116118,0.0007346275,0.0001340872,0.00011721781,0.00022379875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029476942,0.00013642189,0.0013678598,0.00020118285,0.00001019441,0.0000043385758,0.000110888956,0.000117116295,0.00009020055],"category_scores_gemma":[0.001996811,0.00008791477,0.00012902501,0.00024690406,0.00003321081,0.000070105874,0.000020093823,0.0009258883,4.5431054e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020517686,0.0013053508,0.9907545,0.00018814392,0.00018854764,0.0004495372,0.00021308922,0.0008937018,0.0000010097051,0.0000043873047,0.00005823717,0.003891763],"study_design_scores_gemma":[0.0063097468,0.00708522,0.98492134,0.0009770861,0.00018302485,0.000027905624,0.00008971471,0.00030346183,0.0000034244672,0.000010625146,0.000008114427,0.00008031498],"about_ca_topic_score_codex":0.56942916,"about_ca_topic_score_gemma":0.8561799,"teacher_disagreement_score":0.2867507,"about_ca_system_score_codex":0.0010269441,"about_ca_system_score_gemma":0.008821816,"threshold_uncertainty_score":0.99679726},"labels":[],"label_agreement":null},{"id":"W4399304545","doi":"10.1200/jco.2024.42.16_suppl.10011","title":"Communicating cardiovascular health information and improving coordination with primary care: A Childhood Cancer Survivor Study randomized trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Randomized controlled trial; Childhood cancer; Cancer; Primary care; Family medicine; Pediatrics; Internal medicine","score_opus":0.06256426761012762,"score_gpt":0.4336289849662315,"score_spread":0.37106471735610386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9355507,0.039619837,0.0015125822,0.017697064,0.0017534497,0.0032410687,0.000008117641,0.00005456702,0.00056264934],"genre_scores_gemma":[0.9894111,0.0032315769,0.0028762964,0.0031666216,0.0011941069,0.000066954795,0.000014088647,0.000025097757,0.000014116114],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99151,0.0033271334,0.0038733806,0.00021738515,0.00084762945,0.00022449947],"domain_scores_gemma":[0.99185306,0.0046652197,0.002146684,0.0003864968,0.00062798377,0.00032056906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026763098,0.00019489515,0.0035050407,0.00023556345,0.00011809694,0.00006890943,0.00017475653,0.00020115759,0.000008073663],"category_scores_gemma":[0.0039706402,0.00013021754,0.0007417212,0.00027053076,0.0002153328,0.0005051142,0.000105175066,0.0014247568,0.0000019167628],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29178417,0.0010708608,0.0033546733,0.000874516,0.004066356,0.000046817284,0.017055519,0.00003690604,7.858655e-7,0.00003514989,0.00029063507,0.6813836],"study_design_scores_gemma":[0.9181269,0.019581165,0.034189284,0.0011844964,0.0024063266,0.00023837297,0.0069903717,0.00024266343,0.0000015449299,0.000036136316,0.016813967,0.00018878099],"about_ca_topic_score_codex":0.0023539325,"about_ca_topic_score_gemma":0.00065152405,"teacher_disagreement_score":0.68119484,"about_ca_system_score_codex":0.0005014714,"about_ca_system_score_gemma":0.0061843195,"threshold_uncertainty_score":0.9994497},"labels":[],"label_agreement":null},{"id":"W4399304614","doi":"10.1200/jco.2024.42.16_suppl.10022","title":"Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Solid tumor; Oncology; Internal medicine; Cancer","score_opus":0.040032194962885834,"score_gpt":0.43847416982381215,"score_spread":0.3984419748609263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372566,0.00058336597,0.000022429207,0.0033257764,0.00059833983,0.0002446535,0.00009177394,0.000010054401,0.0013979448],"genre_scores_gemma":[0.996025,0.0006262722,0.0020930034,0.0003073755,0.00074120116,0.0000014084903,0.000083418716,0.000016071905,0.000106218286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970068,0.00018694355,0.0022241191,0.00021418999,0.0002279079,0.00014006082],"domain_scores_gemma":[0.99645734,0.0020863358,0.0008532784,0.00014301829,0.00024812555,0.00021192344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007705812,0.000113153976,0.0009925492,0.00016635502,0.000017239456,0.000009014453,0.00007259302,0.0001775745,0.000049294737],"category_scores_gemma":[0.0013789458,0.00006897956,0.00012494865,0.00025417472,0.00009687985,0.00012072513,0.000028423166,0.0005714179,0.0000048931274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04606782,0.005211708,0.78655577,0.00011557709,0.0012765119,0.0009991134,0.002270346,0.000065837055,0.000024220133,0.000055929588,0.006623111,0.15073408],"study_design_scores_gemma":[0.027041372,0.008871844,0.95544255,0.00032249306,0.0008641079,0.000022078271,0.00006277694,0.00010030567,0.00001072103,0.00008016043,0.007114415,0.00006720117],"about_ca_topic_score_codex":0.000044507764,"about_ca_topic_score_gemma":0.00002922488,"teacher_disagreement_score":0.16888678,"about_ca_system_score_codex":0.00011737171,"about_ca_system_score_gemma":0.0015035908,"threshold_uncertainty_score":0.2812905},"labels":[],"label_agreement":null},{"id":"W4399304659","doi":"10.1200/jco.2024.42.16_suppl.10513","title":"Tracking uncertainty in germline genetic testing for hereditary cancer syndromes: Sources, attributes, and resolution of variants of uncertain significance in over 1 million individuals.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Invitae","keywords":"Germline; Medicine; Hereditary Cancer; Genetic testing; Genetics; Germline mutation; Cancer; Computational biology; Mutation; Internal medicine; Gene; Biology; Breast cancer","score_opus":0.11552614025418245,"score_gpt":0.4276754270286964,"score_spread":0.3121492867745139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97497,0.022442438,0.0010617633,0.0005543369,0.00062393676,0.0002212143,0.00010737058,0.0000020187315,0.000016963955],"genre_scores_gemma":[0.9885734,0.0016318093,0.009110418,0.00010717552,0.00051022216,0.000020428015,0.000014622692,0.000017306773,0.00001461896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997103,0.00030435054,0.0019329917,0.00027909153,0.00017644659,0.0002041653],"domain_scores_gemma":[0.9972255,0.0013911667,0.0008964978,0.00012540423,0.0002922057,0.00006919362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028621843,0.00012420428,0.00067302026,0.00019117701,0.000017685032,0.000007259688,0.00017042365,0.0003854052,0.000010766035],"category_scores_gemma":[0.0028002276,0.00011038845,0.00013968235,0.00032233566,0.00020601181,0.000014239783,0.00005868388,0.00035309847,9.3714284e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017128193,0.0008464097,0.49996847,0.000845147,0.0005525303,0.00019992221,0.0004898559,0.10046952,0.059922036,0.00005613076,0.0026358445,0.33230132],"study_design_scores_gemma":[0.0043267016,0.005012047,0.9623439,0.0011049536,0.00017920618,0.00016391465,0.00022403464,0.013589244,0.0022489168,0.0013117939,0.009263025,0.0002322977],"about_ca_topic_score_codex":0.00028282573,"about_ca_topic_score_gemma":0.00064508687,"teacher_disagreement_score":0.4623754,"about_ca_system_score_codex":0.00016954166,"about_ca_system_score_gemma":0.0019424075,"threshold_uncertainty_score":0.45015106},"labels":[],"label_agreement":null},{"id":"W4399304688","doi":"10.1200/jco.2024.42.16_suppl.10001","title":"Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; MAPK/ERK pathway; Glioma; Oncology; Cancer research; Internal medicine; Signal transduction","score_opus":0.09219530182431585,"score_gpt":0.451528682929528,"score_spread":0.3593333811052122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954456,0.0014102544,0.000027408538,0.0016088801,0.00047194547,0.0008981941,0.000027523158,0.00001397007,0.0000962439],"genre_scores_gemma":[0.99859625,0.00008561558,0.0005263459,0.00021460398,0.00048744076,0.000028080021,0.0000042361116,0.000030265266,0.000027160173],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974402,0.00020809073,0.0016041292,0.00025915328,0.00029284987,0.0001955397],"domain_scores_gemma":[0.99706304,0.0014173351,0.00084515923,0.00016790503,0.00020299321,0.00030358482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192998,0.000180488,0.0014041886,0.00021848854,0.00003380782,0.000014464764,0.00008730674,0.00017660005,0.000036018697],"category_scores_gemma":[0.0005021689,0.00010216793,0.00029613412,0.00021039466,0.0001282544,0.000070510505,0.000030381241,0.00047841822,0.0000022411293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03250293,0.17239927,0.302765,0.0003380441,0.0107946,0.0046982,0.0018433081,0.000017379532,0.007725177,0.0006272987,0.005648456,0.46064034],"study_design_scores_gemma":[0.17271365,0.43132862,0.34369075,0.0016677201,0.004115204,0.0019659372,0.0008805429,0.0001743999,0.015543313,0.00033441247,0.027237268,0.00034816866],"about_ca_topic_score_codex":0.00002057011,"about_ca_topic_score_gemma":0.000037095502,"teacher_disagreement_score":0.46029216,"about_ca_system_score_codex":0.00006658639,"about_ca_system_score_gemma":0.0006055924,"threshold_uncertainty_score":0.41662872},"labels":[],"label_agreement":null},{"id":"W4399304690","doi":"10.1200/jco.2024.42.16_suppl.10032","title":"Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Adverse effect; Internal medicine; Neuroblastoma; Oncology","score_opus":0.037030278562639414,"score_gpt":0.4098771567904975,"score_spread":0.3728468782278581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747306,0.00024887445,0.0000033689103,0.0008031085,0.0008702478,0.00041198102,0.000025372028,0.000024452282,0.00013951486],"genre_scores_gemma":[0.9979689,0.0008523174,0.00046968058,0.00015025568,0.00014540587,0.0000074154427,0.000007401747,0.000040511946,0.00035808753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630916,0.0006092244,0.0017804124,0.00037879607,0.00053042494,0.00039199827],"domain_scores_gemma":[0.9966308,0.0015855493,0.0007800202,0.00020890763,0.00019232856,0.0006023965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011358047,0.00024881467,0.001181469,0.00024312292,0.000059663274,0.000011157687,0.00010179388,0.00030785025,0.000042824933],"category_scores_gemma":[0.0010488429,0.00014577314,0.0002690941,0.00026838438,0.00026262738,0.00025174534,0.00006379774,0.0013891361,0.000051768577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017183444,0.0064560263,0.85202616,0.00004559696,0.001172811,0.008034699,0.00043106265,0.00006247236,0.000025372274,0.000017154704,0.00014914475,0.114396065],"study_design_scores_gemma":[0.030992107,0.06733551,0.89891726,0.00034998465,0.00028197133,0.00024204415,0.00008489637,0.000089073765,0.000034942022,0.00017385623,0.0013966904,0.00010169907],"about_ca_topic_score_codex":0.00007265856,"about_ca_topic_score_gemma":0.00017727993,"teacher_disagreement_score":0.11429437,"about_ca_system_score_codex":0.0003644454,"about_ca_system_score_gemma":0.0009784152,"threshold_uncertainty_score":0.6035182},"labels":[],"label_agreement":null},{"id":"W4399304712","doi":"10.1200/jco.2024.42.16_suppl.10535","title":"Are cancer screening recommendations from top US cancer centers concordant with the USPSTF guidelines?","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Family medicine; Internal medicine; Oncology","score_opus":0.2721463880739692,"score_gpt":0.4618736005459208,"score_spread":0.18972721247195162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63007635,0.036891587,0.010916091,0.30450875,0.0114692,0.0002277038,0.00071089034,0.000027447908,0.005171971],"genre_scores_gemma":[0.9394384,0.020900676,0.003926522,0.027213229,0.0068488717,0.000032195672,0.000006188444,0.000053893276,0.001580005],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99661034,0.00007362466,0.0026459706,0.00031375227,0.00006337513,0.00029295112],"domain_scores_gemma":[0.994916,0.0010742341,0.0033004011,0.00021358785,0.00027951214,0.00021625297],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022382552,0.00017617269,0.0012052254,0.00012822273,0.00010322017,0.00010389978,0.0004067904,0.00022651308,0.001481134],"category_scores_gemma":[0.0009591858,0.00011934473,0.0004062976,0.00018010837,0.00019786751,0.00043561214,0.000062590894,0.0009164441,0.000064665925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067009905,0.00015021833,0.38665995,0.000016789047,0.0012415623,0.00014227115,0.0002423544,0.0013893424,0.0000043557266,0.0053367056,0.32544285,0.2787035],"study_design_scores_gemma":[0.0011831693,0.00038909185,0.13266788,0.00023320771,0.00008494023,0.00001274677,0.00017438625,0.0012172959,0.00000528774,0.0017839819,0.8620923,0.00015569836],"about_ca_topic_score_codex":0.0028936781,"about_ca_topic_score_gemma":0.0034607593,"teacher_disagreement_score":0.53664947,"about_ca_system_score_codex":0.0003105885,"about_ca_system_score_gemma":0.00068936666,"threshold_uncertainty_score":0.99943167},"labels":[],"label_agreement":null},{"id":"W4399304742","doi":"10.1200/jco.2024.42.16_suppl.e22000","title":"Efficacy and safety of dinutuximab in the management of high-risk neuroblastoma: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Oncology; Internal medicine","score_opus":0.22538668968210182,"score_gpt":0.5244454560737357,"score_spread":0.29905876639163387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002582907,0.99591756,0.000004926382,0.0010492888,0.000063026295,0.0025265927,0.000037050853,0.000002400946,0.00014087412],"genre_scores_gemma":[0.0022632908,0.9969311,0.0003222808,0.00023744893,0.000036073834,0.000050457078,0.0000035583143,0.000021182037,0.00013462544],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98853314,0.0039005713,0.0063665807,0.00033666985,0.0006598084,0.00020321022],"domain_scores_gemma":[0.9877692,0.0063653947,0.0049383123,0.0005267175,0.00018108112,0.00021929364],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008268107,0.00033536734,0.019559072,0.00050718844,0.00001810594,0.000009541301,0.00032406877,0.00024018272,0.000030985557],"category_scores_gemma":[0.0017155883,0.00013782608,0.0035826853,0.0009109391,0.00025603565,0.00003759746,0.00020174864,0.0015170337,0.0000058178357],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034237988,0.0012762916,0.0000044291696,0.6958595,0.26870874,0.002404022,0.000012756508,3.4338274e-7,9.201262e-9,0.00010837602,0.00019558283,0.031087602],"study_design_scores_gemma":[0.002498066,0.0054947217,0.0004093392,0.050760675,0.92712,0.0007906507,0.000010406147,0.000001415155,2.9776633e-8,0.00004696619,0.012798496,0.00006926127],"about_ca_topic_score_codex":0.000010409407,"about_ca_topic_score_gemma":0.00001219509,"teacher_disagreement_score":0.65841126,"about_ca_system_score_codex":0.000059067337,"about_ca_system_score_gemma":0.00040641814,"threshold_uncertainty_score":0.9949966},"labels":[],"label_agreement":null},{"id":"W4399304747","doi":"10.1200/jco.2024.42.16_suppl.10033","title":"Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Neuroblastoma; Oncology; Internal medicine","score_opus":0.04914244612573484,"score_gpt":0.4229556134096565,"score_spread":0.37381316728392167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773306,0.000049223738,0.00007032614,0.00069668714,0.0007406359,0.0005972784,0.000048830534,0.000011124881,0.000052844538],"genre_scores_gemma":[0.99885684,0.00008725206,0.00041557066,0.0002211367,0.00021637532,0.000018735924,0.000008447243,0.000039352522,0.00013631459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962819,0.0006730134,0.0019157272,0.00027889325,0.0005225316,0.0003279065],"domain_scores_gemma":[0.99278563,0.005586308,0.0007958626,0.00019222789,0.00030071996,0.00033926876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020057769,0.00018023688,0.0011873104,0.00042069983,0.000028232696,0.0000118006765,0.00012697835,0.000227057,0.000033992426],"category_scores_gemma":[0.0036710012,0.000115344,0.00052277325,0.00020394938,0.00007140574,0.00016065962,0.000047211597,0.0009882543,0.000006781063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27548343,0.008647677,0.5629589,0.00018029925,0.0016697325,0.006846433,0.00011122323,0.000014755125,0.0014388006,0.000011391456,0.00046576868,0.14217159],"study_design_scores_gemma":[0.03641887,0.23767874,0.721851,0.00050043676,0.00047833717,0.00004408893,0.000030363775,0.000056624005,0.00123088,0.00003330479,0.0015944275,0.00008295401],"about_ca_topic_score_codex":0.000051144278,"about_ca_topic_score_gemma":0.00004821379,"teacher_disagreement_score":0.23906456,"about_ca_system_score_codex":0.00025299058,"about_ca_system_score_gemma":0.0013745886,"threshold_uncertainty_score":0.4703592},"labels":[],"label_agreement":null},{"id":"W4399304802","doi":"10.1200/jco.2024.42.16_suppl.10514","title":"Gene-environment interactions between clonal hematopoiesis of indeterminate potential and air pollution in non-small cell lung cancer among non-smokers.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Carcinogens and Genotoxicity Assessment","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"Canadian Institutes of Health Research; National Institutes of Health; Physicians' Services Incorporated Foundation; Burroughs Wellcome Fund","keywords":"Medicine; Indeterminate; Lung cancer; Haematopoiesis; Cancer; Gene; Cancer research; Oncology; Genetics; Internal medicine; Biology; Stem cell","score_opus":0.024080272407906826,"score_gpt":0.37266705120687577,"score_spread":0.34858677879896893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463403,0.00095002487,0.002502527,0.0009927137,0.0006143978,0.00013948958,0.00003178167,0.0000012962342,0.00013371349],"genre_scores_gemma":[0.99640113,0.0015315512,0.0010359087,0.00019722621,0.0006957027,0.0000075107537,0.000007470995,0.000012972706,0.00011053057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981322,0.00014141467,0.0011750209,0.00022794855,0.00015149881,0.00017189019],"domain_scores_gemma":[0.99904186,0.000108237844,0.00053796574,0.00011503403,0.00006056245,0.00013635287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094904256,0.00012481198,0.0005432212,0.0001213585,0.000028129263,0.000010058368,0.00012159515,0.00030569188,0.000031773012],"category_scores_gemma":[0.00003815086,0.00010785943,0.00030861123,0.000060072405,0.0001463758,0.000012141682,0.0001388353,0.00045123787,7.863629e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008448214,0.0010634125,0.5943894,0.0003330297,0.000985146,0.00044146107,0.0003946096,0.004078665,0.3267042,0.0000057958814,0.0022038347,0.06855567],"study_design_scores_gemma":[0.0015102947,0.0016697254,0.93776894,0.000111459114,0.00029426027,0.0000629438,0.00014223611,0.001004966,0.053791415,0.000031029867,0.0034647973,0.00014791843],"about_ca_topic_score_codex":0.00009388917,"about_ca_topic_score_gemma":0.00014898444,"teacher_disagreement_score":0.3433796,"about_ca_system_score_codex":0.00009160433,"about_ca_system_score_gemma":0.00036412117,"threshold_uncertainty_score":0.439838},"labels":[],"label_agreement":null},{"id":"W4399304891","doi":"10.1200/jco.2024.42.16_suppl.10007","title":"Radiation dose escalation and local control for intermediate-risk rhabdomyosarcoma on ARST1431: A report from the Children’s Oncology Group","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Rhabdomyosarcoma; Radiation oncology; Oncology; Radiation therapy; Internal medicine; Nuclear medicine; Sarcoma; Pathology","score_opus":0.04969632549857694,"score_gpt":0.4214391323161194,"score_spread":0.37174280681754246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588244,0.0045749983,0.0047661257,0.028390689,0.0024773576,0.00075310154,0.00004440406,0.00001974931,0.00014919098],"genre_scores_gemma":[0.9903998,0.0019776002,0.00095399463,0.0033466157,0.003194374,0.000048368518,0.00004317874,0.000021287167,0.000014807956],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99668145,0.00058242684,0.001974714,0.00030044696,0.0002670798,0.00019390888],"domain_scores_gemma":[0.9800676,0.018138926,0.0011962332,0.00019872797,0.00014957077,0.00024890376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034683947,0.0001647293,0.0011349602,0.00010278026,0.00006874871,0.000026034526,0.00009617754,0.00042225435,0.000041253366],"category_scores_gemma":[0.004190913,0.00009036624,0.0005593954,0.00007758503,0.00025236412,0.00008842374,0.000026143676,0.00088383723,0.000013541578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040837247,0.0013881825,0.3001132,0.0000060571956,0.0009265512,0.0011584566,0.000092509166,0.000010521484,0.000007784193,0.00024306688,0.006632341,0.6853376],"study_design_scores_gemma":[0.013951032,0.01770502,0.89622736,0.0001317273,0.0016495262,0.001208421,0.00006230747,0.0020450912,0.000012649919,0.0019846875,0.0649471,0.00007507009],"about_ca_topic_score_codex":0.00008894862,"about_ca_topic_score_gemma":0.000103981576,"teacher_disagreement_score":0.68526256,"about_ca_system_score_codex":0.0003321675,"about_ca_system_score_gemma":0.0006738347,"threshold_uncertainty_score":0.5017217},"labels":[],"label_agreement":null},{"id":"W4399304904","doi":"10.1200/jco.2024.42.16_suppl.10555","title":"Utility of colposcopy for the screening and management of cervical cancer in Africa: A cross-sectional analysis of providers’ training and practices.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Colposcopy; Medicine; Cross-sectional study; Cervical cancer; Cervical cancer screening; Family medicine; Gynecology; Obstetrics; Cancer; Internal medicine; Pathology","score_opus":0.4642595669409164,"score_gpt":0.6085444938992781,"score_spread":0.1442849269583617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806282,0.009179078,0.0017046562,0.0060595353,0.00023541077,0.0004925691,0.000039937666,0.0000025347883,0.0016580862],"genre_scores_gemma":[0.99534535,0.0022941078,0.0020681657,0.00008136841,0.00014563742,0.000011427344,7.802233e-7,0.000005162891,0.000047979385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752724,0.00016655747,0.0016066096,0.00016861476,0.00038699096,0.00014398311],"domain_scores_gemma":[0.9920797,0.006342472,0.0009288084,0.00009157159,0.0004376022,0.00011988302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00583188,0.00006573504,0.0009966409,0.00022346994,0.00002257056,0.000011593407,0.00009255975,0.00015029772,0.00035258546],"category_scores_gemma":[0.0015962387,0.00004036372,0.00031766552,0.0005085502,0.0004569991,0.00008353176,0.0000707348,0.0005332163,3.628731e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008818311,0.00039768513,0.67632073,0.001188163,0.0037251806,0.000037210542,0.0005685122,0.00008884897,0.000034735083,0.000300297,0.000084709674,0.3084356],"study_design_scores_gemma":[0.0029368452,0.00244596,0.96801347,0.000106785155,0.0018389928,0.00001188107,0.00062535756,0.019777771,0.000017019313,0.0001871976,0.004009252,0.000029458912],"about_ca_topic_score_codex":0.00018414571,"about_ca_topic_score_gemma":0.00058199937,"teacher_disagreement_score":0.30840614,"about_ca_system_score_codex":0.00003523779,"about_ca_system_score_gemma":0.0007162568,"threshold_uncertainty_score":0.38605633},"labels":[],"label_agreement":null},{"id":"W4399304908","doi":"10.1200/jco.2024.42.16_suppl.10531","title":"E-cigarette use and United States Preventive Services Task Force (USPSTF) lung cancer screening (LCS) eligibility.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Task force; Lung cancer screening; Lung cancer; Family medicine; Cancer; Cigarette smoking; Oncology; Internal medicine","score_opus":0.09362545802010405,"score_gpt":0.4950479606680435,"score_spread":0.40142250264793944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612742,0.017329542,0.00027662597,0.01950695,0.0010904099,0.00020191459,0.000024599143,0.000026547066,0.00026919617],"genre_scores_gemma":[0.96658236,0.021813737,0.0011697711,0.008101267,0.0012541306,0.000008859849,0.000009302867,0.000025706222,0.0010348466],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732167,0.00030814824,0.0015349038,0.00026865437,0.00030390196,0.00026275154],"domain_scores_gemma":[0.99515057,0.0033502409,0.0005234732,0.0001285872,0.00051511225,0.0003320412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022361767,0.00016053807,0.0013061607,0.00018152612,0.00006984579,0.0000408489,0.00009602327,0.00024638913,0.000060072605],"category_scores_gemma":[0.0009151497,0.00010779157,0.0002886438,0.00027235982,0.00020363319,0.00029912856,0.000101069825,0.0010360384,0.0000017415181],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064827274,0.00072155945,0.70378095,0.0016788016,0.0062809014,0.0021602644,0.004020205,0.00013982029,0.00025298735,0.00014778654,0.03837394,0.23596004],"study_design_scores_gemma":[0.0063275304,0.008779079,0.4791035,0.0046493285,0.0028609822,0.00029938688,0.0013922738,0.013080076,0.00011829363,0.0005470531,0.48256972,0.00027277233],"about_ca_topic_score_codex":0.00029766836,"about_ca_topic_score_gemma":0.00028918646,"teacher_disagreement_score":0.44419578,"about_ca_system_score_codex":0.00012252797,"about_ca_system_score_gemma":0.0006713146,"threshold_uncertainty_score":0.4501129},"labels":[],"label_agreement":null},{"id":"W4399305020","doi":"10.1200/jco.2024.42.16_suppl.e23018","title":"Progress Tracker Breast Cancer Registry: A Breast Cancer Canada initiative.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Cancer registry; Cancer; Oncology; Gynecology; Family medicine; Internal medicine","score_opus":0.21243190545564603,"score_gpt":0.5169567206665904,"score_spread":0.3045248152109443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7314745,0.0160592,0.000034879908,0.24166913,0.0066332077,0.00025258117,0.0003654834,0.000033631302,0.0034773543],"genre_scores_gemma":[0.98144233,0.0021533212,0.0003131296,0.010017702,0.005574148,0.000016501523,0.0000027878461,0.000025162317,0.00045490908],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99662405,0.00021289935,0.0017683401,0.0002784435,0.0007347334,0.00038153218],"domain_scores_gemma":[0.99681485,0.0006138054,0.00092254975,0.00017204823,0.0008691018,0.0006076676],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001505856,0.00018982706,0.0012453755,0.00008247458,0.000052045918,0.000033130458,0.00023149623,0.00031721473,0.001142059],"category_scores_gemma":[0.0003831256,0.00012911145,0.0003554267,0.0003278211,0.00029080122,0.00023983225,0.00004619227,0.0015598699,0.000007844031],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004125245,0.00025434824,0.3398358,0.00013992538,0.00085637986,0.008116107,0.00010317961,0.000025157455,0.000016565136,0.00011314451,0.20697725,0.4394369],"study_design_scores_gemma":[0.0021702358,0.0011202905,0.7296302,0.0016225298,0.0006439622,0.008030345,0.00028762073,0.00021606391,0.000016539298,0.000083505525,0.25601977,0.00015892759],"about_ca_topic_score_codex":0.08712047,"about_ca_topic_score_gemma":0.20750335,"teacher_disagreement_score":0.439278,"about_ca_system_score_codex":0.0010999972,"about_ca_system_score_gemma":0.027130852,"threshold_uncertainty_score":0.99977106},"labels":[],"label_agreement":null},{"id":"W4399305103","doi":"10.1200/jco.2024.42.16_suppl.e23028","title":"Reduced time to efficacy signals in advanced cancer trials using Chauhan weighted trajectory analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Trajectory","score_opus":0.26803958941622663,"score_gpt":0.572184460458182,"score_spread":0.3041448710419554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7923288,0.0011823388,0.1971144,0.006248999,0.0025561256,0.0002484304,0.000005222561,0.000031554126,0.00028414486],"genre_scores_gemma":[0.7684143,0.00011407457,0.2279052,0.0016745178,0.0016348475,0.000009830352,0.0000014423309,0.000022966266,0.00022283055],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9897771,0.0047161058,0.0041406597,0.00048063952,0.0005714234,0.00031409692],"domain_scores_gemma":[0.97606647,0.021633742,0.0013474907,0.0002674622,0.00032484706,0.00036001403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022535011,0.00018743955,0.0025650552,0.0012102007,0.000034602956,0.000097534605,0.00085285446,0.00023295164,0.0002764898],"category_scores_gemma":[0.0069442894,0.00014455157,0.0011320496,0.002700627,0.000060847873,0.0005292355,0.00016918204,0.00079533015,0.000046455152],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006686747,0.0005518751,0.00015652689,0.000012219015,0.0012501715,0.00042624888,0.0003504369,0.45921376,0.008568846,0.00034571812,0.0007587405,0.5276968],"study_design_scores_gemma":[0.0031807418,0.0022019222,0.037362594,0.00030163245,0.0008691042,0.00005431843,0.00001675315,0.93431675,0.001065946,0.0039119553,0.016357765,0.0003605333],"about_ca_topic_score_codex":0.000019965068,"about_ca_topic_score_gemma":0.000023501261,"teacher_disagreement_score":0.52733624,"about_ca_system_score_codex":0.00041793328,"about_ca_system_score_gemma":0.0035778866,"threshold_uncertainty_score":0.83134645},"labels":[],"label_agreement":null},{"id":"W4399305131","doi":"10.1200/jco.2024.42.16_suppl.e22555","title":"Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Li–Fraumeni syndrome; Oncology; Internal medicine; Germline mutation; Mutation","score_opus":0.31459171756443927,"score_gpt":0.5387352649662988,"score_spread":0.2241435474018595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305131","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008152217,0.99421304,0.00035385622,0.0025514343,0.0005948413,0.0021230434,0.000066669345,0.000014332256,0.00007463206],"genre_scores_gemma":[0.00007895951,0.9960011,0.0012506446,0.0018734502,0.00025646435,0.000055364537,0.000026627287,0.000086146145,0.00037122655],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.980335,0.005579379,0.012278517,0.0006816179,0.00073829835,0.00038718255],"domain_scores_gemma":[0.9860586,0.0043464666,0.007729967,0.00081796915,0.0004917989,0.00055519573],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_broad","research_integrity"],"category_scores_codex":[0.023714537,0.0006655762,0.044383463,0.0011204756,0.00002419665,0.000029565173,0.00037452194,0.001343708,0.0002256809],"category_scores_gemma":[0.010070781,0.0003844629,0.010412217,0.0019459008,0.00017880705,0.000073269664,0.00018026968,0.004240286,0.00006552548],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041780957,0.00038759626,0.0000045465154,0.7347505,0.24947101,0.010701201,0.00000681759,0.00001028594,1.7772487e-7,0.000008622732,0.0010690963,0.0035483805],"study_design_scores_gemma":[0.00061705895,0.0011235349,0.0000044555027,0.09916505,0.6998257,0.009892001,0.0000031288128,0.00010787068,1.0993047e-8,0.000010782021,0.18904023,0.00021015244],"about_ca_topic_score_codex":0.00001957876,"about_ca_topic_score_gemma":0.0000641095,"teacher_disagreement_score":0.6355854,"about_ca_system_score_codex":0.00061800616,"about_ca_system_score_gemma":0.0038663365,"threshold_uncertainty_score":0.99995273},"labels":[],"label_agreement":null},{"id":"W4399305137","doi":"10.1200/jco.2024.42.16_suppl.e23076","title":"Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Cancer drugs; Cancer; Cancer survival; Cohort; Oncology; Population; Internal medicine; Environmental health","score_opus":0.10685569826907657,"score_gpt":0.4906044053077352,"score_spread":0.3837487070386586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822451,0.00039749304,0.00003058206,0.01537329,0.00041877443,0.00082481536,0.000013171688,0.000011499944,0.00068528455],"genre_scores_gemma":[0.9973665,0.0001605573,0.0004786863,0.0011276867,0.0006783864,0.000035856374,0.000009444464,0.000023344213,0.00011953473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99500656,0.0010816492,0.0024260078,0.00026209242,0.0010171918,0.0002064686],"domain_scores_gemma":[0.9937865,0.0043497486,0.0012585054,0.00022838994,0.00021447848,0.00016234085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067086513,0.00017626192,0.001629175,0.00041030045,0.000019359311,0.000018698236,0.00018698556,0.00015554471,0.00015520603],"category_scores_gemma":[0.000684019,0.000097190205,0.0001507085,0.0010075972,0.00010980279,0.00013637809,0.000015839994,0.0010547024,9.850974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033828765,0.0013607051,0.9803715,0.000082143575,0.0004918321,0.00016160279,0.0021238278,0.0019630797,0.0000010136397,0.00004663394,0.0006033419,0.009411456],"study_design_scores_gemma":[0.009391726,0.004974078,0.9816025,0.0014717218,0.00062162726,0.000010199973,0.0007479866,0.00032710275,0.0000039664865,0.00007782314,0.000667494,0.00010375987],"about_ca_topic_score_codex":0.07685527,"about_ca_topic_score_gemma":0.3242202,"teacher_disagreement_score":0.24736494,"about_ca_system_score_codex":0.00048339655,"about_ca_system_score_gemma":0.004939279,"threshold_uncertainty_score":0.929292},"labels":[],"label_agreement":null},{"id":"W4399305240","doi":"10.1200/jco.2024.42.16_suppl.e22553","title":"Adherence to cancer screening for patients with Li-Fraumeni syndrome: A report on our experience at Fred Hutchinson Cancer Center.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Li–Fraumeni syndrome; Center (category theory); Oncology; Family medicine; Internal medicine; Gerontology; Mutation; Genetics; Germline mutation","score_opus":0.13004915608594106,"score_gpt":0.4958860091938646,"score_spread":0.3658368531079236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414993,0.00086659164,0.001867177,0.0070294174,0.0049720793,0.0008144141,0.00005247198,0.000032491585,0.00021541219],"genre_scores_gemma":[0.98977757,0.0002855491,0.0051927497,0.0022776162,0.0008979157,0.00015769653,0.000009741241,0.0000584281,0.0013427162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964102,0.00012129585,0.0019475241,0.00050847285,0.000615003,0.0003975374],"domain_scores_gemma":[0.99694145,0.00043848078,0.0010929969,0.00030831495,0.00059393386,0.0006248471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009765388,0.0002341336,0.0012456228,0.00018059144,0.00007112947,0.000022147582,0.00020687681,0.0003393308,0.00013816089],"category_scores_gemma":[0.001659649,0.00016257704,0.0004481194,0.000287352,0.00007238622,0.00011786452,0.0000837646,0.0009663691,0.000014267893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04218795,0.0033443898,0.38563013,0.00032688412,0.0024037934,0.016648913,0.0016909441,0.0011747052,0.0010430155,0.000036489833,0.06633154,0.47918123],"study_design_scores_gemma":[0.020909464,0.08740863,0.3134804,0.00731634,0.0010469004,0.0036490948,0.0002909797,0.0005536039,0.00064270414,0.000034818946,0.564109,0.0005580203],"about_ca_topic_score_codex":0.00014998883,"about_ca_topic_score_gemma":0.0003648864,"teacher_disagreement_score":0.4977775,"about_ca_system_score_codex":0.0008555474,"about_ca_system_score_gemma":0.001857648,"threshold_uncertainty_score":0.6629699},"labels":[],"label_agreement":null},{"id":"W4399305286","doi":"10.1200/jco.2024.42.16_suppl.e23165","title":"Patients’ voices matter: Translating pretreatment patient-reported outcomes into high and low health-related quality of life provides a new clinical aspect on prognosis and survival in patients with previously untreated diffuse large B‐cell lymphoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Quality of life (healthcare); Intensive care medicine; Overall survival; Internal medicine; Nursing","score_opus":0.052483682107085095,"score_gpt":0.3913854228204668,"score_spread":0.3389017407133817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921956,0.0016098134,0.000002670363,0.0040657534,0.00046957273,0.0015281484,0.000026962522,0.000024670706,0.000076823366],"genre_scores_gemma":[0.9976572,0.00058669306,0.00083070225,0.00073615025,0.00006647583,0.000023283026,0.00003688938,0.000037847618,0.000024752571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99107814,0.0013266497,0.005961742,0.00058086694,0.0006621278,0.0003904983],"domain_scores_gemma":[0.99156684,0.0039941296,0.0031140004,0.0002477566,0.00030072336,0.00077657925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002370161,0.00037932262,0.0031797532,0.00023466986,0.000056298388,0.0000339899,0.000086492335,0.00038695798,0.000022565559],"category_scores_gemma":[0.001661298,0.00022092984,0.00040706788,0.0002563216,0.00020372929,0.00017350701,0.000056769735,0.00042986328,0.0000037585694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076405955,0.039602224,0.8350819,0.0003928072,0.0015140992,0.0001644819,0.0010096607,0.0000012163897,3.0146072e-7,0.00001726111,0.00019672977,0.11437877],"study_design_scores_gemma":[0.08700089,0.041417304,0.86936885,0.0010563046,0.000664347,0.0000076005626,0.000093520284,0.000029289788,0.000009341328,0.000058928654,0.00013623029,0.00015738298],"about_ca_topic_score_codex":0.0015182212,"about_ca_topic_score_gemma":0.0007341562,"teacher_disagreement_score":0.11422139,"about_ca_system_score_codex":0.00037163327,"about_ca_system_score_gemma":0.0019282376,"threshold_uncertainty_score":0.90092576},"labels":[],"label_agreement":null},{"id":"W4399305396","doi":"10.1200/jco.2024.42.16_suppl.12041","title":"The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Body mass index; Internal medicine; Population; Oncology; Immune system; Immunology; Environmental health","score_opus":0.048425392446149594,"score_gpt":0.4182693096533779,"score_spread":0.3698439172072283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938321,0.00011001211,0.000016656953,0.00087313505,0.002410412,0.00063331815,0.000002451574,0.000015557292,0.0021063574],"genre_scores_gemma":[0.9989315,0.00006026618,0.000052245843,0.00006948894,0.0005234652,0.000010674935,0.000008820933,0.000024867299,0.00031863598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956813,0.0005058095,0.0027397391,0.00020057306,0.0006179144,0.00025470587],"domain_scores_gemma":[0.9949001,0.00294259,0.0014390368,0.0002583016,0.00026515155,0.00019483041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004240904,0.00019028502,0.0011453055,0.00021570119,0.00005743557,0.000033982524,0.00016381913,0.00018911419,0.000073924275],"category_scores_gemma":[0.002095078,0.00010142917,0.0010794264,0.00019042482,0.00007899211,0.00011428829,0.00005434783,0.0007439218,0.000008466715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025705013,0.0036988212,0.9411964,0.000028359289,0.0015741828,0.00013030095,0.000033500317,0.00036087382,0.000015328449,0.000026977004,0.000836291,0.04952848],"study_design_scores_gemma":[0.0072874334,0.023594094,0.96641225,0.00027405008,0.00048799245,7.4464367e-7,0.00006974226,0.0009452261,0.000016231446,0.00019341629,0.00063759554,0.00008122422],"about_ca_topic_score_codex":0.00021623512,"about_ca_topic_score_gemma":0.00005885756,"teacher_disagreement_score":0.049447257,"about_ca_system_score_codex":0.00048804472,"about_ca_system_score_gemma":0.00043493067,"threshold_uncertainty_score":0.41361615},"labels":[],"label_agreement":null},{"id":"W4399305435","doi":"10.1200/jco.2024.42.16_suppl.11581","title":"Fragility index analysis of systemic therapy clinical trials in soft tissue sarcoma (STS).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Soft tissue sarcoma; Systemic therapy; Fragility; Soft tissue; Sarcoma; Oncology; Clinical trial; Internal medicine; Surgery; Pathology; Cancer; Breast cancer","score_opus":0.33105257293480816,"score_gpt":0.5906034073479546,"score_spread":0.2595508344131464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96251225,0.02857694,0.00046706546,0.005983717,0.0017498323,0.00039708184,0.000010735058,0.000013208885,0.00028915558],"genre_scores_gemma":[0.98404956,0.013302576,0.00059428,0.0009666675,0.0010119885,0.0000075691432,0.000005261698,0.00001643726,0.000045661156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98471653,0.004774708,0.009409267,0.00035052237,0.00051487,0.00023407656],"domain_scores_gemma":[0.95797014,0.038093105,0.002764884,0.00039685494,0.00038617227,0.0003888646],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.045427144,0.00018702258,0.006757097,0.00058484107,0.00001726772,0.000014812679,0.00021042848,0.00075497513,0.0007398042],"category_scores_gemma":[0.017292071,0.00011574045,0.0030099275,0.00074164453,0.00025241927,0.000075013806,0.00004468405,0.0013098719,0.000030226298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022413274,0.0037267772,0.55598664,0.000035883688,0.0053091515,0.0014730925,0.000108564884,0.000026310425,0.000037404516,0.000035602763,0.0012043755,0.4298149],"study_design_scores_gemma":[0.009068814,0.0078072236,0.9525565,0.00044243826,0.004754023,0.00020139125,0.00016101512,0.0011982082,0.000026761978,0.00038870695,0.023305006,0.000089949885],"about_ca_topic_score_codex":0.00015527512,"about_ca_topic_score_gemma":0.00018789308,"teacher_disagreement_score":0.42972493,"about_ca_system_score_codex":0.0001774226,"about_ca_system_score_gemma":0.0018768035,"threshold_uncertainty_score":0.9909857},"labels":[],"label_agreement":null},{"id":"W4399305446","doi":"10.1200/jco.2024.42.16_suppl.tps11589","title":"Randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs adjuvant chemotherapy alone for localized soft tissue sarcoma (NACLESS, JCOG2102).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Center Japan","keywords":"Medicine; Adjuvant chemotherapy; Adjuvant; Chemotherapy; Soft tissue sarcoma; Sarcoma; Soft tissue; Oncology; Randomized controlled trial; Internal medicine; Cancer; Pathology; Breast cancer","score_opus":0.07647029941662178,"score_gpt":0.46652710935634195,"score_spread":0.39005680993972014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91489726,0.03584651,0.0044737975,0.037264805,0.0031158442,0.0040199817,0.000041465348,0.000052227657,0.00028808357],"genre_scores_gemma":[0.96001494,0.024542363,0.00762103,0.0044826423,0.002746807,0.00014634455,0.000025496041,0.00009871578,0.00032165096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925944,0.0007337012,0.005032303,0.0005318727,0.0006301309,0.00047758946],"domain_scores_gemma":[0.98578626,0.010630891,0.0020826345,0.00038496402,0.00050179026,0.0006134449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006774685,0.00045422977,0.007422489,0.00029120664,0.00006757028,0.00003619772,0.00023481103,0.00065032643,0.00038118436],"category_scores_gemma":[0.0023297172,0.00028550453,0.001853583,0.00021838449,0.00072276813,0.00013820436,0.000049255836,0.0007938973,0.00000939311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53225005,0.006833293,0.00020999351,0.0001027239,0.0019182283,0.00061361544,0.00018659634,0.0000014248466,0.0003361115,0.00016072199,0.0053092823,0.45207798],"study_design_scores_gemma":[0.7853239,0.03100207,0.00060764875,0.00051730504,0.0023183227,0.00048220798,0.00007124941,0.0011842174,0.0021787088,0.0015676372,0.17452952,0.00021720711],"about_ca_topic_score_codex":0.000057985006,"about_ca_topic_score_gemma":0.000020582678,"teacher_disagreement_score":0.4518608,"about_ca_system_score_codex":0.00017583827,"about_ca_system_score_gemma":0.0015816528,"threshold_uncertainty_score":0.9999597},"labels":[],"label_agreement":null},{"id":"W4399305524","doi":"10.1200/jco.2024.42.16_suppl.e23292","title":"Cancer burden across South Asia in 2020: A global cancer observatory analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.1726502306899819,"score_gpt":0.526731088053216,"score_spread":0.35408085736323414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79264176,0.0046163327,0.000080296595,0.19148585,0.0063013383,0.00011681566,0.000027820246,0.000031097792,0.0046987],"genre_scores_gemma":[0.93614006,0.0012517914,0.000114304115,0.048645213,0.013652245,0.000014205572,0.0000036096883,0.000014109375,0.0001644793],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541175,0.00022414449,0.0030336808,0.00032570082,0.000296789,0.0007079443],"domain_scores_gemma":[0.9970166,0.00079133915,0.0015088643,0.00017216816,0.00038665082,0.00012435872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007849111,0.00019071005,0.0018301165,0.0001756028,0.00006638679,0.0001042361,0.0004775363,0.0005134497,0.00058841787],"category_scores_gemma":[0.0030685985,0.00013880519,0.00074677885,0.0018355631,0.00018610233,0.0005708806,0.0002240865,0.0010330771,0.000095624506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028924222,0.000136162,0.60057455,0.00014366757,0.0010144315,0.00042868513,0.000090817804,0.010909616,0.0000010630907,0.004523763,0.31644893,0.06543909],"study_design_scores_gemma":[0.0006051413,0.000067636305,0.37056127,0.000054324886,0.00031299374,0.0000049553864,0.00025866213,0.010063802,1.660827e-8,0.0010131584,0.6169696,0.000088434725],"about_ca_topic_score_codex":0.024968276,"about_ca_topic_score_gemma":0.013774894,"teacher_disagreement_score":0.3005207,"about_ca_system_score_codex":0.00044187868,"about_ca_system_score_gemma":0.0014180418,"threshold_uncertainty_score":0.9815245},"labels":[],"label_agreement":null},{"id":"W4399305588","doi":"10.1200/jco.2024.42.16_suppl.12047","title":"Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Adverse effect; Immune system; Ipilimumab; Nivolumab; Melanoma; Immune checkpoint; Immunotherapy; Immunology; Oncology; Cancer research; Internal medicine","score_opus":0.02067868592833625,"score_gpt":0.35588459403834966,"score_spread":0.3352059081100134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449515,0.0019016295,0.00001544127,0.0014045247,0.00095457776,0.000461598,0.000004548258,0.000027187722,0.00073534495],"genre_scores_gemma":[0.9980721,0.0004750288,0.0006720601,0.00022965056,0.00015025989,0.000007785235,0.000018724539,0.000041394782,0.00033299244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953312,0.00028317544,0.0033691826,0.0002707221,0.00044323102,0.00030248714],"domain_scores_gemma":[0.9974475,0.0004758971,0.0013159576,0.00022911078,0.00032510285,0.00020643746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00197407,0.00024008779,0.0014380118,0.00029137617,0.00003139229,0.0000044401445,0.00014348849,0.0003990289,0.00019213559],"category_scores_gemma":[0.0002822838,0.00013802577,0.0005541592,0.00056503754,0.00021319126,0.000225209,0.00002971843,0.0012284017,0.000017707505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24276434,0.0041788835,0.57441014,0.000088711255,0.0037730907,0.0021322526,0.00032133993,0.00006979166,0.0020112018,0.000010181582,0.0001659025,0.17007418],"study_design_scores_gemma":[0.04714789,0.04594634,0.8980376,0.0013636487,0.0004560171,0.00024389222,0.00011829068,0.00006110498,0.0005521582,0.000021967455,0.0058676098,0.00018349355],"about_ca_topic_score_codex":0.00008482819,"about_ca_topic_score_gemma":0.000056233286,"teacher_disagreement_score":0.32362747,"about_ca_system_score_codex":0.0004598744,"about_ca_system_score_gemma":0.0013207678,"threshold_uncertainty_score":0.56285274},"labels":[],"label_agreement":null},{"id":"W4399305616","doi":"10.1200/jco.2024.42.16_suppl.12050","title":"Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Cancer-related fatigue; Randomized controlled trial; Placebo; Dexamethasone; Internal medicine; Oncology; Cancer; Physical therapy; Pathology; Alternative medicine","score_opus":0.10143095126127956,"score_gpt":0.48658915636677014,"score_spread":0.3851582051054906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630558,0.00666377,0.0019781103,0.019453498,0.0049271253,0.0031116675,0.000013562951,0.000038653136,0.00075781957],"genre_scores_gemma":[0.99385345,0.001507211,0.00027033995,0.0006969505,0.0026409826,0.00031949556,0.0000010793581,0.000026948184,0.0006835408],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99597365,0.0015260241,0.0016939904,0.00026740998,0.00031002922,0.00022889556],"domain_scores_gemma":[0.9594457,0.03867733,0.0010489913,0.00012762939,0.00036804943,0.00033227634],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0083190035,0.00018906438,0.004619699,0.00012405723,0.000038779446,0.00002326823,0.00008381658,0.0004494518,0.000065969165],"category_scores_gemma":[0.010348249,0.00011484675,0.0017342251,0.00012325,0.00028916998,0.00011395056,0.000022181699,0.0011460036,0.0000018925899],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8775156,0.0011900093,0.00006696423,0.00012647857,0.0030563346,0.00017516059,0.00038364978,0.00000857706,0.00009639639,0.00025449344,0.0013265704,0.11579976],"study_design_scores_gemma":[0.94560283,0.018230518,0.0004547665,0.00026210496,0.0060076555,0.000112495494,0.000068488596,0.017182287,0.00003579895,0.0008230033,0.011108727,0.00011133166],"about_ca_topic_score_codex":0.000059667087,"about_ca_topic_score_gemma":0.00005528852,"teacher_disagreement_score":0.11568843,"about_ca_system_score_codex":0.00014798694,"about_ca_system_score_gemma":0.00206153,"threshold_uncertainty_score":0.997988},"labels":[],"label_agreement":null},{"id":"W4399305683","doi":"10.1200/jco.2024.42.16_suppl.12090","title":"Novel screening approach for cancer cachexia using metagenomic gut microbiome profiling in patients with advanced non-small cell lung cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Metagenomics; Medicine; Microbiome; Cachexia; Cancer; Lung cancer; Gut microbiome; Profiling (computer programming); Cancer cachexia; Cancer research; Computational biology; Pathology; Bioinformatics; Internal medicine; Immunology; Biology; Gut flora; Gene","score_opus":0.17272676851635801,"score_gpt":0.49241343977649077,"score_spread":0.3196866712601327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466776,0.0035949924,0.046024464,0.0012648058,0.0012054711,0.001040872,0.000032967593,0.000012566074,0.00014624832],"genre_scores_gemma":[0.5825711,0.0003099588,0.41471252,0.0013310456,0.0009001776,0.000036675083,0.0000117693035,0.00004252995,0.000084222585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716806,0.00009031496,0.0018802044,0.00030072875,0.00018226389,0.00037842695],"domain_scores_gemma":[0.9977885,0.0005313623,0.00090643595,0.00010648068,0.0003915716,0.0002756364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019952224,0.00016925455,0.0012488666,0.0003077776,0.00006015397,0.000016779904,0.000120274926,0.0002618197,0.000021220123],"category_scores_gemma":[0.00015163393,0.00012512576,0.00025932744,0.00026418158,0.00007196068,0.00012604374,0.000032777614,0.0010948598,4.065166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015106631,0.0038307854,0.8373624,0.005846742,0.00091284356,0.00015281347,0.0005711722,0.010172233,0.041779067,0.00003266821,0.00060387916,0.083628744],"study_design_scores_gemma":[0.14145136,0.016769115,0.5070245,0.011543549,0.0045191417,0.00027072587,0.0010057683,0.2792774,0.003943102,0.000047889123,0.032951765,0.0011956668],"about_ca_topic_score_codex":0.00008241706,"about_ca_topic_score_gemma":0.000045478573,"teacher_disagreement_score":0.36868805,"about_ca_system_score_codex":0.0006076211,"about_ca_system_score_gemma":0.002621002,"threshold_uncertainty_score":0.51024806},"labels":[],"label_agreement":null},{"id":"W4399318770","doi":"10.1200/jco.2024.42.16_suppl.2023","title":"Clinical and molecular features and survival in thyroid cancer with brain metastases.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Thyroid cancer; Oncology; Brain metastasis; Brain cancer; Cancer; Thyroid; Internal medicine; Pathology; Cancer research; Metastasis","score_opus":0.06392357499739725,"score_gpt":0.4746806898744395,"score_spread":0.41075711487704225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399318770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89085054,0.055256374,0.000033021344,0.052366495,0.0007491533,0.00015645112,0.000008830306,0.0000076354945,0.00057149754],"genre_scores_gemma":[0.97392017,0.01969526,0.0015753713,0.004014598,0.000656597,0.0000094352245,0.0000013098346,0.000018472374,0.00010878608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975618,0.00046051308,0.0012853952,0.00027095515,0.00024449683,0.00017683714],"domain_scores_gemma":[0.9961213,0.0029937094,0.0003148032,0.000110793415,0.00010039667,0.00035903775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030398786,0.00014014634,0.0013332547,0.00011297134,0.000015088143,0.000022226244,0.00005424742,0.00023190236,0.00004032294],"category_scores_gemma":[0.0008268722,0.00008060127,0.00021741322,0.00013036666,0.00033281636,0.000075899174,0.000040702413,0.0009816103,0.0000014613563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037407367,0.0012329323,0.5962799,0.00009269376,0.0014656566,0.0113607645,0.00009375095,0.00000942402,0.00009151116,0.0013318493,0.015726551,0.3685742],"study_design_scores_gemma":[0.0118827,0.016002346,0.87911755,0.0004782801,0.0009499336,0.0010629122,0.00009895356,0.00002937901,0.0000617518,0.00047368548,0.089728154,0.000114354676],"about_ca_topic_score_codex":0.00009987087,"about_ca_topic_score_gemma":0.0005766832,"teacher_disagreement_score":0.36845982,"about_ca_system_score_codex":0.00006953023,"about_ca_system_score_gemma":0.0011304832,"threshold_uncertainty_score":0.4264663},"labels":[],"label_agreement":null},{"id":"W4399318772","doi":"10.1200/jco.23.02736","title":"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"Cilag; Genentech; Sirtex Medical; Daiichi Sankyo Europe; Servier; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Chugai Pharmaceutical; Seagen; Daiichi Sankyo Company; BeiGene; Halozyme; Mirati Therapeutics; Taiho Pharmaceutical; Array BioPharma; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Colorectal cancer; Lenvatinib; Oncology; Internal medicine; Open label; Randomized controlled trial; Cancer; Immunotherapy; Thyroid cancer","score_opus":0.19670539736259515,"score_gpt":0.5371934962452657,"score_spread":0.3404880988826705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399318772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843343,0.009293864,0.00012035559,0.0013355978,0.0016283318,0.0027456186,0.00021295277,0.000007023627,0.0003219939],"genre_scores_gemma":[0.9967122,0.0021306237,0.00047654356,0.00014090062,0.00020512249,0.00009981297,0.000012721557,0.000021182996,0.00020086684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941066,0.0011160721,0.0037490958,0.00026642415,0.0005340234,0.00022777764],"domain_scores_gemma":[0.9893932,0.006651673,0.0026122935,0.0002607792,0.0009450411,0.00013706088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056819627,0.00020833481,0.0050350926,0.0002895565,0.00007399489,0.000023981269,0.00045283203,0.00017302588,0.00025099007],"category_scores_gemma":[0.0024949997,0.00011428937,0.0017043719,0.0008420236,0.0005448619,0.00010349582,0.00008564073,0.0005328043,2.7418218e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86867243,0.0022117705,0.0007474287,0.0001921846,0.03196254,0.00009386642,0.0017756736,0.00006922037,0.000265685,0.000028210736,0.0009577854,0.09302319],"study_design_scores_gemma":[0.8390634,0.10083578,0.001373465,0.00038769876,0.047167875,0.000031050673,0.0019576887,0.0014625163,0.00051112886,0.000018976327,0.0070724986,0.00011794198],"about_ca_topic_score_codex":0.0004395726,"about_ca_topic_score_gemma":0.0024323987,"teacher_disagreement_score":0.098624006,"about_ca_system_score_codex":0.0005132034,"about_ca_system_score_gemma":0.005666661,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W4399318774","doi":"10.1200/jco.2024.42.16_suppl.e24149","title":"Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pathogenesis and Treatment of Hiccups","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Meta-analysis; Blockade; Immune system; Interleukin; Interleukin 2; Oncology; Intensive care medicine; Immunology; Internal medicine; Cytokine; Receptor","score_opus":0.24977981017709502,"score_gpt":0.531682777730936,"score_spread":0.2819029675538409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399318774","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002552668,0.99593514,0.000023543815,0.0010301966,0.00023901754,0.0025730203,0.00008630489,0.000006289132,0.00008096903],"genre_scores_gemma":[0.00015457417,0.9977618,0.00075668143,0.00024569928,0.00008516605,0.000055087992,0.000027787806,0.000037095677,0.0008761214],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98685217,0.001442828,0.010817464,0.00038077257,0.00031679583,0.00018999774],"domain_scores_gemma":[0.98450166,0.0058194697,0.008581559,0.00043012731,0.0003605852,0.000306615],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0086079305,0.00045672973,0.032719802,0.00043832502,0.000027105592,0.0000037828402,0.00020022465,0.0006930269,0.00007951666],"category_scores_gemma":[0.0057018707,0.00021858868,0.013297904,0.00041624918,0.00015590826,0.00004472293,0.00010763362,0.00090245524,0.000008508073],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002144739,0.0007054737,0.0000045754387,0.5259896,0.45984107,0.00023352368,0.000011078802,1.6654496e-7,7.6660186e-8,0.000044541615,0.000085489955,0.012869909],"study_design_scores_gemma":[0.0021693297,0.0033037772,0.000037260404,0.072106935,0.83060455,0.0011378791,0.0000072185635,0.0000030046972,5.7779495e-8,0.000023921293,0.09048751,0.00011854932],"about_ca_topic_score_codex":0.0000016412888,"about_ca_topic_score_gemma":0.0000022348286,"teacher_disagreement_score":0.45388266,"about_ca_system_score_codex":0.000115264775,"about_ca_system_score_gemma":0.0009609797,"threshold_uncertainty_score":0.9965837},"labels":[],"label_agreement":null},{"id":"W4399319907","doi":"10.1200/jco.2024.42.16_suppl.2085","title":"A 16 year-retrospective study of refractory meningiomas: Prognostic factors and systemic treatments.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Refractory (planetary science); Retrospective cohort study; Systemic therapy; Internal medicine; Oncology; Surgery; Cancer","score_opus":0.11188425767905621,"score_gpt":0.44475753425703013,"score_spread":0.33287327657797394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399319907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453294,0.0014377037,0.000043239208,0.00023608915,0.0010245944,0.0004986922,0.0000022010606,0.000017461796,0.0022071],"genre_scores_gemma":[0.9987825,0.00006671917,0.00023440066,0.000017168688,0.00032480966,0.0000061536734,0.0000011807793,0.00001729392,0.00054975017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971137,0.00033135826,0.0017730822,0.00022705247,0.00039912137,0.00015567086],"domain_scores_gemma":[0.997486,0.0011036785,0.0008180053,0.0001548975,0.00020905392,0.00022836677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017816917,0.00014697672,0.0013743322,0.00026413042,0.000025576155,0.000014512296,0.00008692777,0.00017009357,0.000065356544],"category_scores_gemma":[0.0014448795,0.00008870607,0.00027963024,0.00018200585,0.000096691045,0.000097104734,0.000057665922,0.00050329417,0.0000066934354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011181866,0.0030245557,0.9754734,0.00017413269,0.0028680677,0.005630091,0.0016295854,8.473424e-7,0.00021013916,0.00023285983,0.0009837277,0.008654429],"study_design_scores_gemma":[0.0056144996,0.057467524,0.926404,0.0004936481,0.0024198932,0.001026469,0.0045778374,0.000033544547,0.000019443378,0.00016795105,0.001685149,0.0000900274],"about_ca_topic_score_codex":0.000024075785,"about_ca_topic_score_gemma":0.0000058529095,"teacher_disagreement_score":0.05444297,"about_ca_system_score_codex":0.0002666281,"about_ca_system_score_gemma":0.00039907722,"threshold_uncertainty_score":0.36173284},"labels":[],"label_agreement":null},{"id":"W4399319932","doi":"10.1200/jco.2024.42.16_suppl.tps1137","title":"Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Regimen; Breast cancer; Oncology; Cancer; Internal medicine","score_opus":0.10424871972526778,"score_gpt":0.41614695405754826,"score_spread":0.3118982343322805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399319932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98109823,0.005631301,0.000030822383,0.0068028755,0.0030161208,0.00025473512,0.000062084095,0.000004489326,0.0030993663],"genre_scores_gemma":[0.9958394,0.0018033619,0.00014861599,0.00098327,0.0006810928,0.000009396854,2.3137775e-7,0.000020108479,0.0005145012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966106,0.00013358958,0.0026729403,0.00028542304,0.00006214392,0.00023530317],"domain_scores_gemma":[0.99646056,0.0010803377,0.002043472,0.00022185767,0.00008959912,0.00010419137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025334642,0.00014492303,0.0015687771,0.00016743154,0.000037349902,0.00003202008,0.00033741468,0.0001409638,0.00011334351],"category_scores_gemma":[0.0008838995,0.000113509785,0.00027899508,0.0002651191,0.00018029942,0.00043818008,0.00008978169,0.00071112614,0.0000143091365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013109007,0.0022072257,0.67664117,0.00010899526,0.0009322774,0.00010179849,0.0016352746,0.0008236868,0.000017922855,0.00998411,0.006001612,0.30023506],"study_design_scores_gemma":[0.0038341915,0.0018675275,0.93077207,0.00016008691,0.000093234645,0.000033377353,0.00030404856,0.00030078596,0.000004679083,0.009407593,0.05307417,0.00014824021],"about_ca_topic_score_codex":0.00061449234,"about_ca_topic_score_gemma":0.0014264357,"teacher_disagreement_score":0.30008683,"about_ca_system_score_codex":0.00019547244,"about_ca_system_score_gemma":0.00039951052,"threshold_uncertainty_score":0.46287948},"labels":[],"label_agreement":null},{"id":"W4399319966","doi":"10.1200/jco.2024.42.16_suppl.tps1127","title":"Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an <i>ESR1</i> mutation.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Open label; Randomized controlled trial; Cancer","score_opus":0.09312446749221592,"score_gpt":0.5052449030153938,"score_spread":0.4121204355231779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399319966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335856,0.0021452953,0.00702011,0.0030123307,0.0005595067,0.0037541438,0.00010016472,0.00001369269,0.00003618683],"genre_scores_gemma":[0.97034407,0.00058439333,0.0278647,0.0005791471,0.00029771877,0.000117970034,0.0000038277267,0.00005151045,0.00015664632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99504834,0.0009065743,0.0030431796,0.00033766532,0.0004230183,0.0002412232],"domain_scores_gemma":[0.98730356,0.008810398,0.0024642565,0.00028281446,0.00089312944,0.00024583688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035663764,0.00025163926,0.0029780199,0.00010735004,0.00007576405,0.000020400594,0.00033480205,0.00010256837,0.000063826476],"category_scores_gemma":[0.0021692154,0.0001222496,0.00020343882,0.0003148382,0.0005877096,0.0003666549,0.00009834825,0.000542061,2.484756e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61013144,0.0069831638,0.00023367708,0.00024004494,0.0020139795,0.00014808268,0.0009147819,0.0009500421,0.0005012355,0.00003241767,0.000012864946,0.37783825],"study_design_scores_gemma":[0.91822946,0.0610818,0.00238362,0.0019272771,0.0041933362,0.0009704955,0.0025550763,0.006958165,0.00027194998,0.00011175898,0.0011508012,0.00016623121],"about_ca_topic_score_codex":0.00007742294,"about_ca_topic_score_gemma":0.0004241325,"teacher_disagreement_score":0.37767202,"about_ca_system_score_codex":0.00017527153,"about_ca_system_score_gemma":0.0020608453,"threshold_uncertainty_score":0.49851942},"labels":[],"label_agreement":null},{"id":"W4399322455","doi":"10.1200/jco.2024.42.16_suppl.12131","title":"The influence of sarcopenia and myosteatosis on severe laboratory toxicity and overall mortality in older adults with cancer receiving chemotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Sarcopenia; Chemotherapy; Toxicity; Cancer; Internal medicine; Oncology; Gerontology","score_opus":0.055777734574181274,"score_gpt":0.45992868130785036,"score_spread":0.4041509467336691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399322455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803356,0.002563303,0.000001339807,0.0165968,0.00016408862,0.00016457187,0.000004241699,0.0000040013056,0.00016603715],"genre_scores_gemma":[0.98044527,0.013320946,0.0002722674,0.0057451604,0.00017688617,0.0000034122197,1.367852e-7,0.000007339403,0.000028592252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984584,0.00020877144,0.000907634,0.00012716567,0.00018190591,0.00011612569],"domain_scores_gemma":[0.99765027,0.0015558044,0.00037488702,0.0000819042,0.00018627124,0.00015086343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021633354,0.00007081741,0.0005570053,0.000055632347,0.000031652973,0.000009815598,0.000046561538,0.0001350479,0.00002441711],"category_scores_gemma":[0.00048522154,0.000039620852,0.000042246716,0.00011088041,0.00018622488,0.000080653386,0.000015727306,0.00073005323,3.399482e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048640394,0.0004306792,0.91669536,0.00053669687,0.00012468858,0.000150873,0.00067552313,0.000011348814,0.00017177533,0.00010503945,0.0008989969,0.07533497],"study_design_scores_gemma":[0.005010517,0.0020939233,0.9832814,0.002860374,0.00004478337,0.000058204783,0.00010883488,0.00006163061,0.00007347342,0.00010857511,0.0062557156,0.000042572712],"about_ca_topic_score_codex":0.000065945715,"about_ca_topic_score_gemma":0.0003609498,"teacher_disagreement_score":0.0752924,"about_ca_system_score_codex":0.00007642943,"about_ca_system_score_gemma":0.0007475579,"threshold_uncertainty_score":0.31717587},"labels":[],"label_agreement":null},{"id":"W4399322695","doi":"10.1200/jco.2024.42.16_suppl.596","title":"Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Oncology; Breast cancer; Chemotherapy; Internal medicine; Doxorubicin; Cancer","score_opus":0.036807645094533374,"score_gpt":0.4450239036082301,"score_spread":0.4082162585136967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399322695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999715,0.00061186973,0.000044740736,0.0068332097,0.0002683864,0.0020684607,0.000012051004,0.000015182604,0.00014896196],"genre_scores_gemma":[0.9985362,0.0004324607,0.00025371503,0.00038961536,0.00021847224,0.00006197702,0.000004569097,0.000047850084,0.00005509759],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948876,0.0013722574,0.0021149071,0.00041568207,0.00081289164,0.00039664205],"domain_scores_gemma":[0.99585295,0.0023902045,0.0006618546,0.00014831385,0.0006179418,0.0003287197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048650308,0.00025700152,0.002548275,0.0005438066,0.000054182565,0.00004269444,0.00014087906,0.00026331836,0.000105539686],"category_scores_gemma":[0.00055006536,0.00015557105,0.00016614523,0.00058255746,0.00037873813,0.0002514843,0.000046223187,0.0019885027,0.0000013309241],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45182538,0.010360571,0.30157307,0.000038947524,0.0007165151,0.0019520737,0.0042506093,0.000012319804,0.00002081956,0.000010850085,0.00002869034,0.22921018],"study_design_scores_gemma":[0.38958612,0.12052673,0.48691496,0.0010529283,0.00024065819,0.0001938904,0.0005023156,0.0007641009,0.000009648665,0.000020535392,0.00007792579,0.000110206354],"about_ca_topic_score_codex":0.0011487063,"about_ca_topic_score_gemma":0.00094748545,"teacher_disagreement_score":0.22909997,"about_ca_system_score_codex":0.0009876211,"about_ca_system_score_gemma":0.0028559843,"threshold_uncertainty_score":0.8639165},"labels":[],"label_agreement":null},{"id":"W4399323377","doi":"10.1200/jco.2024.42.16_suppl.e24023","title":"Cardio-Oncology Awareness: A multidisciplinary survey amongst health care trainees and practicing professionals at academic institutions.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multidisciplinary approach; Health professionals; Health care; Multidisciplinary team; Medical education; Nursing; Family medicine","score_opus":0.23549786557401955,"score_gpt":0.6265496903287999,"score_spread":0.3910518247547804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399323377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8574393,0.07777529,0.001449958,0.05164364,0.009491787,0.0005967026,0.00003923126,0.00005082261,0.0015132885],"genre_scores_gemma":[0.9542894,0.027418239,0.008419645,0.0055751964,0.0037110348,0.00001880623,0.00003093319,0.000034859553,0.00050193304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99408066,0.0022317015,0.0026061242,0.00038442537,0.00032915123,0.00036790918],"domain_scores_gemma":[0.9855592,0.011892118,0.0014172199,0.00018029576,0.00040304306,0.00054807804],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008610241,0.00021945882,0.0021950928,0.0002497078,0.00030120029,0.0000071136055,0.00016949778,0.0011065345,0.000057282494],"category_scores_gemma":[0.005670762,0.00014581093,0.0003698786,0.0002579728,0.00096048834,0.00029767377,0.00013578207,0.003152841,0.00001089023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010169467,0.0014757775,0.4596731,0.0006445861,0.0015661707,0.0047792587,0.009248153,0.0001343274,0.00024608267,0.0005964071,0.032587767,0.4788789],"study_design_scores_gemma":[0.0061929636,0.015314249,0.4239813,0.0008942868,0.0003490789,0.007296905,0.0042308476,0.00018797298,0.000018723427,0.0002054538,0.5411293,0.00019892855],"about_ca_topic_score_codex":0.000044201643,"about_ca_topic_score_gemma":0.0003924587,"teacher_disagreement_score":0.5085415,"about_ca_system_score_codex":0.0018248965,"about_ca_system_score_gemma":0.015085556,"threshold_uncertainty_score":0.99914694},"labels":[],"label_agreement":null},{"id":"W4399323727","doi":"10.1200/jco.2024.42.16_suppl.1055","title":"Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Human Epidermal Growth Factor Receptor 2; Cancer; Oncology; Hormone receptor; Internal medicine; Breast cancer; Receptor; Cancer research; Epidermal growth factor receptor; Metastatic breast cancer; Gynecology","score_opus":0.049924082980505526,"score_gpt":0.4670128968005136,"score_spread":0.41708881382000806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399323727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934382,0.00028966612,0.000011552271,0.003532835,0.0009815068,0.0009931267,0.00040545553,0.00003243474,0.0003152541],"genre_scores_gemma":[0.9938991,0.0017139401,0.002620895,0.00067143317,0.0006905657,0.00004038583,0.000023400722,0.00010134444,0.00023890425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99196076,0.00106137,0.004699021,0.0007393958,0.00084526977,0.00069417123],"domain_scores_gemma":[0.9906196,0.0048258826,0.0027899423,0.00034736295,0.0008431961,0.00057399384],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017071278,0.00057941175,0.0039964234,0.000617087,0.000056009823,0.000018014343,0.00029747694,0.00048956554,0.0005024944],"category_scores_gemma":[0.0014627627,0.0003625517,0.0010342507,0.0007875634,0.0007298567,0.00054987526,0.00007642387,0.0023425063,0.000014210783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035878018,0.0047746967,0.77035695,0.00005348728,0.0019056246,0.00018407629,0.00037528918,0.00003447064,0.00013545946,0.000027922244,0.00022401137,0.18605001],"study_design_scores_gemma":[0.032123897,0.026113147,0.9389545,0.0015788449,0.0002964665,0.000016939888,0.00009097455,0.000012381353,0.000087389424,0.00011439479,0.00029912012,0.00031194824],"about_ca_topic_score_codex":0.0008042983,"about_ca_topic_score_gemma":0.00068501575,"teacher_disagreement_score":0.18573807,"about_ca_system_score_codex":0.0025285839,"about_ca_system_score_gemma":0.0022600542,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W4399324232","doi":"10.1200/jco.2024.42.16_suppl.e13066","title":"Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Western University","funders":"","keywords":"Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Palbociclib; Cancer research; Metastatic breast cancer","score_opus":0.08438857424667509,"score_gpt":0.49997371258075923,"score_spread":0.41558513833408417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8604019,0.0030710963,0.0020170254,0.1297138,0.0024902395,0.0010657418,0.000041297444,0.000047199082,0.001151702],"genre_scores_gemma":[0.9839963,0.001301254,0.007262142,0.003961,0.0030827215,0.00013356624,0.0000021699643,0.000040988874,0.00021985844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969152,0.00018482273,0.001810748,0.00031399404,0.00041505467,0.000360182],"domain_scores_gemma":[0.99400115,0.0042187185,0.0009883062,0.00020508195,0.000410426,0.0001763022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020818366,0.00021215573,0.0011133458,0.00016334341,0.000071511386,0.000020275344,0.00025224735,0.00016644478,0.000066009525],"category_scores_gemma":[0.00064721407,0.00011495883,0.0003095268,0.0005244928,0.00036376482,0.00026305858,0.000032694807,0.0011772136,0.0000025284946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018525997,0.00079466903,0.1261166,0.0002348128,0.00041054713,0.001032002,0.005201259,0.0011113636,0.00019880578,0.00044790827,0.0010401318,0.8448859],"study_design_scores_gemma":[0.016150955,0.013617264,0.556943,0.0043331464,0.00044363816,0.0010438502,0.0051047564,0.0010491982,0.00031050254,0.0018173616,0.39880952,0.00037680037],"about_ca_topic_score_codex":0.000088585715,"about_ca_topic_score_gemma":0.0018500767,"teacher_disagreement_score":0.84450907,"about_ca_system_score_codex":0.0004912942,"about_ca_system_score_gemma":0.0015085251,"threshold_uncertainty_score":0.51144725},"labels":[],"label_agreement":null},{"id":"W4399324290","doi":"10.1200/jco.2024.42.16_suppl.1515","title":"Accuracy of a mobile sensor-based system for the detection of chemotherapy toxicity in older adults with cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Conquer Cancer Foundation","keywords":"Medicine; Toxicity; Chemotherapy; Oncology; Cancer; Internal medicine","score_opus":0.08504050993852287,"score_gpt":0.5091622472716965,"score_spread":0.4241217373331736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98366374,0.0009040258,0.008962742,0.0025836963,0.0028518946,0.00091366353,0.000016292708,0.000012695452,0.000091272814],"genre_scores_gemma":[0.9974241,0.0003190595,0.0009894137,0.00039247854,0.00074483507,0.00006950655,3.6059194e-7,0.000018522222,0.000041676325],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963899,0.00057371415,0.0024623252,0.000140175,0.00023156457,0.00020227463],"domain_scores_gemma":[0.9632885,0.03365106,0.0022477855,0.00014210238,0.0005981354,0.000072425064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004536365,0.00009924152,0.00096348487,0.00011867824,0.000060034337,0.0000023225139,0.00017019574,0.00031886657,0.000047865942],"category_scores_gemma":[0.0025509465,0.00005315519,0.00024405941,0.00022565023,0.00012941092,0.000055351316,0.00001603679,0.0009139058,0.0000020478951],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06977852,0.002589914,0.12192408,0.00961845,0.0011002693,0.00011726963,0.007968206,0.0051683495,0.004620212,0.00018159863,0.0019628622,0.7749703],"study_design_scores_gemma":[0.097901784,0.047648773,0.55615515,0.051127203,0.0015723461,0.0001335679,0.042331576,0.10589487,0.01971816,0.00015312704,0.07670207,0.0006613572],"about_ca_topic_score_codex":0.00029373594,"about_ca_topic_score_gemma":0.00060561445,"teacher_disagreement_score":0.7743089,"about_ca_system_score_codex":0.00016404185,"about_ca_system_score_gemma":0.0043106917,"threshold_uncertainty_score":0.76469815},"labels":[],"label_agreement":null},{"id":"W4399324547","doi":"10.1200/jco.2024.42.16_suppl.2005","title":"Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Glioblastoma; Pathology; Oncology; Internal medicine; Cancer research; Radiology","score_opus":0.26038789371947196,"score_gpt":0.5466973941276544,"score_spread":0.2863095004081824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898645,0.0021821947,0.0000786897,0.004843707,0.0017315221,0.0010459144,0.0000101829055,0.0000048611096,0.00023840506],"genre_scores_gemma":[0.9973865,0.0008309951,0.00064911396,0.00010557193,0.000937813,0.00006100414,0.0000071192044,0.000009514268,0.000012369747],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968245,0.000250866,0.0020994819,0.00017356752,0.0005249847,0.00012659686],"domain_scores_gemma":[0.99465996,0.0035998758,0.00091378525,0.00009971743,0.00056484964,0.00016178955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008690806,0.0001011733,0.0009007831,0.00023508162,0.000015334012,0.000012562362,0.000044077875,0.0002345977,0.000042520216],"category_scores_gemma":[0.008233136,0.00006347859,0.00033589164,0.0001506191,0.00007438331,0.00012372718,0.00001210312,0.00031158185,0.0000015174757],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07660635,0.006466493,0.00080085144,0.00007911921,0.00037816152,0.00027643057,0.00017831985,0.000021850048,0.000183656,0.00027799606,0.00435714,0.9103736],"study_design_scores_gemma":[0.7091144,0.20506428,0.021530675,0.0012172245,0.00463991,0.00023322288,0.00022167154,0.015353751,0.0009807053,0.006342533,0.035150733,0.00015091717],"about_ca_topic_score_codex":0.000009669568,"about_ca_topic_score_gemma":0.00019713165,"teacher_disagreement_score":0.9102227,"about_ca_system_score_codex":0.00023176419,"about_ca_system_score_gemma":0.0016950453,"threshold_uncertainty_score":0.98564273},"labels":[],"label_agreement":null},{"id":"W4399324685","doi":"10.1200/jco.2024.42.16_suppl.1571","title":"Outcomes of very young women and adolescent (VYWAA) with breast cancer (BC) in rural and urban Saskatchewan: A population-based cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; McGill University","funders":"","keywords":"Medicine; Breast cancer; Cohort; Demography; Population; Rural population; Cancer; Gerontology; Gynecology; Environmental health; Internal medicine","score_opus":0.033306360433740384,"score_gpt":0.4110191353775048,"score_spread":0.37771277494376443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638957,0.0005241651,0.0000068219983,0.0022762322,0.00047965787,0.0002727299,0.000010372467,0.000005121458,0.000035357327],"genre_scores_gemma":[0.9989089,0.00023173864,0.00006346934,0.00043279093,0.0002613958,0.000008265781,9.889318e-7,0.000012290272,0.00008015589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998197,0.00011609701,0.0011234442,0.00014364746,0.00027045596,0.00014931124],"domain_scores_gemma":[0.99870247,0.00048730167,0.00040856926,0.00008586276,0.00010813502,0.00020765133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011832992,0.00011151102,0.0011957844,0.00014431548,0.000013955533,0.000010413103,0.000041052568,0.00012635837,0.000051382798],"category_scores_gemma":[0.00011060465,0.00006734224,0.0000963377,0.00012117157,0.0001146951,0.000071480725,0.000019810841,0.00054386037,2.4416875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031737206,0.00070470164,0.9676824,0.000085628395,0.00033244173,0.00022212153,0.0006579566,0.000013084943,0.000005527742,0.000001775773,0.00019181984,0.026928786],"study_design_scores_gemma":[0.005170649,0.0038506722,0.9883415,0.0003399041,0.00025361715,0.00009940496,0.001434777,0.00012416959,8.686445e-7,0.000014586301,0.00030145716,0.00006841135],"about_ca_topic_score_codex":0.002297196,"about_ca_topic_score_gemma":0.004200424,"teacher_disagreement_score":0.026860375,"about_ca_system_score_codex":0.00029717418,"about_ca_system_score_gemma":0.001144551,"threshold_uncertainty_score":0.34726885},"labels":[],"label_agreement":null},{"id":"W4399324701","doi":"10.1200/jco.2024.42.16_suppl.2008","title":"Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Internal medicine; Metis","score_opus":0.07240373420940606,"score_gpt":0.5012010046874324,"score_spread":0.4287972704780264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878973,0.00031449716,0.00074088766,0.00930674,0.00067333947,0.00079239474,0.000010596241,0.0000071794066,0.00025708164],"genre_scores_gemma":[0.9935013,0.00025611953,0.0041514025,0.0015720677,0.00045536974,0.0000070780616,0.00001562683,0.000015040987,0.000025975074],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943414,0.0021416869,0.0026256265,0.00025429256,0.00049841346,0.000138592],"domain_scores_gemma":[0.9750279,0.02314705,0.0012198071,0.00018895057,0.00025890354,0.00015737569],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013745597,0.00013931036,0.0014597458,0.0001441398,0.00003973963,0.00003081662,0.00018710551,0.000096654876,0.00007378008],"category_scores_gemma":[0.024506269,0.00006846521,0.00020993309,0.000120157325,0.00022017583,0.00014304696,0.000048607166,0.0012978924,4.2265364e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37209103,0.0037265792,0.019060425,0.00000791474,0.0011611332,0.00025958335,0.0026669952,0.000108056636,0.00006107663,0.00001345944,0.00011999989,0.60072374],"study_design_scores_gemma":[0.81723887,0.033463877,0.092165366,0.0005726587,0.0008014301,0.000028739652,0.0008367938,0.05350147,0.000012682847,0.00006787494,0.001206701,0.00010351527],"about_ca_topic_score_codex":0.0003229633,"about_ca_topic_score_gemma":0.00004192555,"teacher_disagreement_score":0.6006202,"about_ca_system_score_codex":0.00004184322,"about_ca_system_score_gemma":0.00030563716,"threshold_uncertainty_score":0.9837107},"labels":[],"label_agreement":null},{"id":"W4399324721","doi":"10.1200/jco.2024.42.16_suppl.tps1136","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Fulvestrant; Medicine; Internal medicine; Hormone receptor; Oncology; Pharmacology; Cancer; Estrogen receptor; Breast cancer","score_opus":0.03719958490996564,"score_gpt":0.424430612596551,"score_spread":0.38723102768658535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135935,0.0014177228,0.00075788604,0.0029011385,0.0010596003,0.0020177183,0.00020471514,0.000056454657,0.00022541547],"genre_scores_gemma":[0.9919713,0.0017041469,0.004642085,0.00077674974,0.00046661965,0.00011022088,0.000024209281,0.00013661763,0.00016800777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9904431,0.0016282774,0.0049529443,0.0008614181,0.0013423086,0.0007719203],"domain_scores_gemma":[0.9901859,0.0037417659,0.00289668,0.00048048032,0.0019703573,0.0007248105],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023490305,0.0007242153,0.004214766,0.0005864342,0.00008144795,0.00004031844,0.0004933448,0.00042428824,0.00030887456],"category_scores_gemma":[0.0010122032,0.00047362715,0.0004767337,0.0015360344,0.00095537154,0.0008813967,0.00013503438,0.0027854263,0.000010692508],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3970987,0.036708485,0.015661325,0.00035421824,0.004419593,0.0069065294,0.005409337,0.0011587766,0.00078370207,0.00003120595,0.00057622435,0.5308919],"study_design_scores_gemma":[0.3272342,0.26293916,0.37657893,0.00629079,0.0035476137,0.0024470878,0.0105975885,0.0005639889,0.00066965335,0.00027930294,0.007689112,0.001162549],"about_ca_topic_score_codex":0.0006620032,"about_ca_topic_score_gemma":0.0012523611,"teacher_disagreement_score":0.52972937,"about_ca_system_score_codex":0.0012195734,"about_ca_system_score_gemma":0.0042740237,"threshold_uncertainty_score":0.99977154},"labels":[],"label_agreement":null},{"id":"W4399324723","doi":"10.1200/jco.2024.42.16_suppl.1523","title":"AI-assisted clinical summary and treatment planning for cancer care: A comparative study of human vs. AI-based approaches.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Western University; University of Toronto; Cancer Care Ontario; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Cancer treatment; Intensive care medicine; Oncology; Internal medicine","score_opus":0.48414117189728556,"score_gpt":0.5651371833581372,"score_spread":0.08099601146085167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92722976,0.0035252944,0.056107722,0.0065999557,0.0051202322,0.0010405811,0.000012667349,0.00005359833,0.000310176],"genre_scores_gemma":[0.9921589,0.000068524,0.00613369,0.0006223063,0.00091099,0.00005822703,0.000001189592,0.000012056892,0.000034115954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956906,0.000881698,0.0024965734,0.00043497645,0.00029511945,0.0002010469],"domain_scores_gemma":[0.99381965,0.004166677,0.0012080235,0.00025043177,0.00035262288,0.00020261323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002604801,0.00017788493,0.0015160016,0.0001728299,0.000095132425,0.000056390054,0.00039155805,0.00028528034,0.0000041718354],"category_scores_gemma":[0.00017439258,0.00012860069,0.00042164084,0.00022940205,0.00022490577,0.00024481482,0.000091607944,0.0007526898,6.152261e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036994878,0.0054816385,0.09588073,0.00014949603,0.0018240944,0.0002917897,0.0063670226,0.0024094165,0.00003788953,0.0005221261,0.007758423,0.87557787],"study_design_scores_gemma":[0.036172554,0.31161547,0.34460348,0.0008171831,0.0018182178,0.000114202594,0.003804912,0.15905914,0.00046742646,0.0014056909,0.13941501,0.000706712],"about_ca_topic_score_codex":0.000070181464,"about_ca_topic_score_gemma":0.0004685231,"teacher_disagreement_score":0.8748712,"about_ca_system_score_codex":0.0004154788,"about_ca_system_score_gemma":0.0019236517,"threshold_uncertainty_score":0.5244184},"labels":[],"label_agreement":null},{"id":"W4399324764","doi":"10.1200/jco.2024.42.16_suppl.1509","title":"Cost-utility of geriatric assessment (GA) in older adults with cancer: A model-based economic evaluation of four randomized controlled trials (RCTs).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Cancer; Gerontology; Economic evaluation; Physical therapy; Internal medicine; Pathology","score_opus":0.6357261923646556,"score_gpt":0.6164058463306313,"score_spread":0.019320346034024216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93214476,0.0100379605,0.023431573,0.022228401,0.0033325667,0.0063139824,0.00024405384,0.000011174569,0.0022555501],"genre_scores_gemma":[0.9910305,0.0013381137,0.0056039197,0.0009146846,0.0006030742,0.00044323163,0.0000070188025,0.000025296931,0.000034128905],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9447632,0.014172965,0.03966303,0.0005828757,0.00045311672,0.00036482722],"domain_scores_gemma":[0.91225946,0.056550264,0.029799616,0.00037083,0.0007792285,0.00024058347],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.43252507,0.00024601485,0.014737557,0.00089230976,0.000030283632,0.000029054963,0.00031497606,0.0004650022,0.0010801635],"category_scores_gemma":[0.059469994,0.00019367471,0.0017427014,0.00021266201,0.00023533418,0.00034823813,0.000027671495,0.00064730126,0.000018298442],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4355943,0.0046156393,0.07750349,0.002940836,0.00749987,0.000024017456,0.0023804803,0.37925184,0.000005430295,0.019500697,0.011740849,0.058942556],"study_design_scores_gemma":[0.2860787,0.0006744674,0.014791831,0.0004899518,0.0005420876,0.000003211445,0.00016099698,0.6910324,0.0000024960814,0.0057536317,0.00033691735,0.00013328367],"about_ca_topic_score_codex":0.0005716693,"about_ca_topic_score_gemma":0.000668234,"teacher_disagreement_score":0.3730551,"about_ca_system_score_codex":0.0013689402,"about_ca_system_score_gemma":0.013405268,"threshold_uncertainty_score":0.9998897},"labels":[],"label_agreement":null},{"id":"W4399324841","doi":"10.1200/jco.2024.42.16_suppl.1550","title":"The impact of admitting ward on resource utilization and outcomes among hospitalized cancer survivors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; Trillium Health Centre; Credit Valley Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Sinai Health System; University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of Toronto; Conquer Cancer Foundation","keywords":"Medicine; Cancer; Survivorship curve; Intensive care medicine; Emergency medicine; Internal medicine","score_opus":0.36633511512891703,"score_gpt":0.6125500895306555,"score_spread":0.24621497440173845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657733,0.007889401,0.000039733965,0.0032638616,0.0006106867,0.000089509245,0.000004639833,0.000006178189,0.0015186504],"genre_scores_gemma":[0.98741674,0.011615431,0.00016795273,0.00020583702,0.00038903343,0.0000012972121,9.573836e-7,0.000011016521,0.00019171303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978434,0.00031455795,0.0013740254,0.000102368096,0.00024284775,0.00012283317],"domain_scores_gemma":[0.99202293,0.0065644966,0.00088698266,0.00010354301,0.00028026305,0.00014177908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024447483,0.00009325525,0.0009949596,0.00008005684,0.000025966554,0.000007708897,0.00008248675,0.00017777465,0.000031601212],"category_scores_gemma":[0.0066456622,0.000045064477,0.00046506678,0.00012385954,0.0002494388,0.000054456654,0.000027435111,0.00046191987,8.7772e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009775058,0.00012742273,0.8958675,0.00004555145,0.00057730643,0.00005365475,0.00060241856,0.000018123788,0.000016888427,0.000060674025,0.0026602957,0.09899265],"study_design_scores_gemma":[0.0016494344,0.0050513544,0.94423246,0.0009478645,0.00024357258,0.000008589937,0.0004565256,0.0005015626,0.00009687051,0.00018648912,0.046579544,0.000045745874],"about_ca_topic_score_codex":0.00042550766,"about_ca_topic_score_gemma":0.00010458355,"teacher_disagreement_score":0.09894691,"about_ca_system_score_codex":0.00007814437,"about_ca_system_score_gemma":0.0005445869,"threshold_uncertainty_score":0.7955958},"labels":[],"label_agreement":null},{"id":"W4399324904","doi":"10.1200/jco.2024.42.16_suppl.2013","title":"A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Fondation Brain Canada","keywords":"Medicine; Durvalumab; Olaparib; Oncology; Internal medicine; Cancer research; Cancer; Genetics; Gene; Immunotherapy; Poly ADP ribose polymerase; Nivolumab","score_opus":0.11197130207715664,"score_gpt":0.5119855964718868,"score_spread":0.40001429439473013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934104,0.00064619735,0.00003897514,0.002978505,0.0018645342,0.00037211334,0.000010780401,0.000007975871,0.00067051227],"genre_scores_gemma":[0.99789214,0.000495473,0.0005859838,0.0003657283,0.0005944615,0.0000059515883,0.0000045274014,0.0000138659625,0.000041886797],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99676526,0.0003401262,0.0021869792,0.00016869797,0.0003923817,0.00014655002],"domain_scores_gemma":[0.9974658,0.000996983,0.0008853811,0.00011162999,0.00033061538,0.00020960256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00234323,0.000107666056,0.0011723333,0.0002618497,0.000017110011,0.0000059175077,0.00006676475,0.00023074461,0.00009898598],"category_scores_gemma":[0.0010724537,0.00007029875,0.00018636089,0.00028982083,0.00023660106,0.00010194273,0.000026058511,0.0008532279,0.000002339597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5280251,0.016396098,0.0062421104,0.00009322865,0.0004802218,0.0005526723,0.00035357184,0.0000032125208,0.00016148627,0.00009404032,0.0029244293,0.44467384],"study_design_scores_gemma":[0.6348906,0.2955498,0.021128694,0.001002211,0.00035033622,0.00013109644,0.000039880983,0.00014845912,0.00017019942,0.0004933603,0.045987636,0.000107714164],"about_ca_topic_score_codex":0.000006566968,"about_ca_topic_score_gemma":0.000012211947,"teacher_disagreement_score":0.44456613,"about_ca_system_score_codex":0.00015594624,"about_ca_system_score_gemma":0.0013907118,"threshold_uncertainty_score":0.3706898},"labels":[],"label_agreement":null},{"id":"W4399325041","doi":"10.1200/jco.2024.42.16_suppl.2079","title":"Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Pharma Medica Research (Canada)","funders":"","keywords":"Medicine; Propensity score matching; Internal medicine; Oncology; Overall survival; Surgery","score_opus":0.10895241217287241,"score_gpt":0.42766026033564924,"score_spread":0.31870784816277686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280035,0.003784596,0.00049424695,0.00016201449,0.0017604318,0.0008665817,0.000063921354,0.000014863777,0.000052967094],"genre_scores_gemma":[0.99926174,0.00020048335,0.00028767044,0.000063760875,0.000090605135,0.000009668531,0.000010339949,0.000021737773,0.00005400765],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.992976,0.0025536085,0.003467128,0.00044624784,0.0001883849,0.00036860906],"domain_scores_gemma":[0.995334,0.0018898346,0.0018840464,0.0003313602,0.0004436772,0.00011703499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00511065,0.00028397926,0.00321615,0.00022012217,0.000054186334,0.00002000069,0.00036158387,0.0004921603,0.00015405485],"category_scores_gemma":[0.00088784413,0.00019134677,0.00022710886,0.00018468073,0.00040121085,0.00021969812,0.00009460291,0.0016416032,0.0000037499528],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1011972,0.058246918,0.24163054,0.00022825411,0.0018170679,0.0008147308,0.0033378107,0.00013756982,0.53861797,0.00018639627,0.00022350819,0.053562038],"study_design_scores_gemma":[0.18056911,0.4927164,0.26724258,0.0014391282,0.001113533,0.0007220544,0.0054539167,0.0014096588,0.043860886,0.0009565045,0.0036166313,0.000899589],"about_ca_topic_score_codex":0.0003926684,"about_ca_topic_score_gemma":0.0011910625,"teacher_disagreement_score":0.4947571,"about_ca_system_score_codex":0.00008125911,"about_ca_system_score_gemma":0.00081613247,"threshold_uncertainty_score":0.7802895},"labels":[],"label_agreement":null},{"id":"W4399325131","doi":"10.1200/jco.2024.42.16_suppl.2567","title":"Proteogenomic profiling of clonal hematopoiesis in the solid tumor microenvironment.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Solid tumor; Tumor microenvironment; Profiling (computer programming); Cancer research; Haematopoiesis; Computational biology; Pathology; Tumor cells; Cancer; Biology; Stem cell; Internal medicine; Cell biology","score_opus":0.06547520236209697,"score_gpt":0.43998390383999003,"score_spread":0.37450870147789306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901734,0.0007425017,0.0032441607,0.003078925,0.00009534694,0.0002015017,0.00001236879,0.000011013852,0.002440765],"genre_scores_gemma":[0.9328442,0.00036010979,0.06597246,0.00028727134,0.00041000824,0.000044927383,0.0000015938756,0.000014328769,0.000065109176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977287,0.000080398655,0.0017569541,0.00013950844,0.00015507049,0.00013937785],"domain_scores_gemma":[0.99789214,0.0010114972,0.0008258508,0.00017956743,0.000038517555,0.00005244138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018727884,0.00008799365,0.00052546867,0.0000471154,0.000023983264,0.000009493513,0.0003726497,0.00015205727,0.00013488116],"category_scores_gemma":[0.00031356,0.000056981622,0.00028862176,0.0000828294,0.00017028934,0.000058489542,0.000058721856,0.0009089195,0.000007320347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008707405,0.002370902,0.011287029,0.00060322764,0.0002774056,0.00064519903,0.00042315316,0.0002578941,0.91688085,0.012920874,0.001972098,0.051490616],"study_design_scores_gemma":[0.002080667,0.0017060924,0.0022526903,0.00064231845,0.00023303418,0.00141707,0.0008178086,0.0010173554,0.7522682,0.06366634,0.17356789,0.0003305111],"about_ca_topic_score_codex":0.0000028096563,"about_ca_topic_score_gemma":0.0000021775477,"teacher_disagreement_score":0.1715958,"about_ca_system_score_codex":0.00008613376,"about_ca_system_score_gemma":0.00035869528,"threshold_uncertainty_score":0.39488536},"labels":[],"label_agreement":null},{"id":"W4399325142","doi":"10.1200/jco.2024.42.16_suppl.2564","title":"Circulating metabolic profiling as a biomarker for immune checkpoint blockade efficacy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; National Research Council Canada; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Biomarker; Profiling (computer programming); Immune system; Oncology; Cancer research; Immunology; Internal medicine; Receptor; Biology; Genetics","score_opus":0.14986171696981546,"score_gpt":0.4940249751471281,"score_spread":0.34416325817731264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551138,0.023855494,0.0008893013,0.012947188,0.0042039375,0.00055067684,0.000004366041,0.00004072834,0.0023944783],"genre_scores_gemma":[0.98569643,0.00127685,0.008807643,0.001126857,0.002508897,0.000013671877,0.0000044385065,0.000040169034,0.0005250245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957672,0.00020841426,0.0031866184,0.00024200554,0.00030219997,0.0002935666],"domain_scores_gemma":[0.9959605,0.0023123804,0.0010025753,0.00019067021,0.00030262917,0.00023126566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068387757,0.00016613788,0.0014175753,0.00021058267,0.000056332516,0.000030107863,0.00015024217,0.00039425713,0.000231047],"category_scores_gemma":[0.004173114,0.000112520465,0.0017667577,0.0002855997,0.00017781311,0.00009613246,0.000034745408,0.0008028696,0.000019323808],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015154481,0.0010241698,0.0009998078,0.0002276882,0.0034080755,0.0010384618,0.0001988343,0.0000052112778,0.20468345,0.0002488202,0.0009444876,0.77206653],"study_design_scores_gemma":[0.02834827,0.014848904,0.11517008,0.0013024511,0.002676654,0.006944019,0.00036256335,0.004161592,0.027886927,0.0011470328,0.7967789,0.00037259265],"about_ca_topic_score_codex":0.000017746584,"about_ca_topic_score_gemma":0.0000022928855,"teacher_disagreement_score":0.7958344,"about_ca_system_score_codex":0.00012662327,"about_ca_system_score_gemma":0.002238333,"threshold_uncertainty_score":0.49959087},"labels":[],"label_agreement":null},{"id":"W4399325164","doi":"10.1200/jco.2024.42.16_suppl.2022","title":"Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Melanoma; Immunotherapy; Brain metastasis; Dual (grammatical number); Oncology; Ipilimumab; Internal medicine; Metastatic melanoma; Cancer; Metastasis; Cancer research","score_opus":0.1229504389751034,"score_gpt":0.5100953196459392,"score_spread":0.38714488067083586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325164","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40289855,0.00041193143,0.5921346,0.00235226,0.0016044418,0.00022614321,0.00003663589,0.00001053872,0.00032491013],"genre_scores_gemma":[0.7485133,0.00021631666,0.25030592,0.00038790383,0.00023169655,0.000009234608,0.00001552322,0.000013758736,0.00030637463],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943161,0.0015843345,0.0032060975,0.00025213364,0.00048925227,0.00015208946],"domain_scores_gemma":[0.98329026,0.01339919,0.002285939,0.00027385264,0.00064938853,0.00010139818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008954735,0.00011960825,0.0013967003,0.000844035,0.000021980526,0.00002753791,0.00051232876,0.00010892723,0.000046349345],"category_scores_gemma":[0.0018207405,0.00009246763,0.001617447,0.0013405471,0.00010199816,0.00035818008,0.00011512463,0.0002624978,0.0000013582256],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010220672,0.0026143203,0.00535418,0.00009798014,0.008254864,0.00003684749,0.0005621205,0.017706322,0.0002479976,0.044586733,0.0041585676,0.915358],"study_design_scores_gemma":[0.0070978315,0.022273151,0.5010159,0.0002701235,0.0037079833,0.000018508075,0.00006897738,0.2782687,0.00085798197,0.08387888,0.10216572,0.00037625516],"about_ca_topic_score_codex":0.000031002088,"about_ca_topic_score_gemma":0.000071126145,"teacher_disagreement_score":0.9149817,"about_ca_system_score_codex":0.00011335363,"about_ca_system_score_gemma":0.0010402248,"threshold_uncertainty_score":0.37707204},"labels":[],"label_agreement":null},{"id":"W4399325178","doi":"10.1200/jco.2024.42.16_suppl.2088","title":"Marrow-ablative consolidation chemotherapy (HDCT) to decrease the development of choroid plexus carcinoma (CPC) specific relapse in high-risk TP53-mutated (germline or somatic) young children with newly diagnosed CPC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Medicine; Ablative case; Germline mutation; Germline; Chemotherapy; Somatic cell; Etoposide; Oncology; Internal medicine; Surgery; Radiation therapy; Mutation","score_opus":0.052456443736363705,"score_gpt":0.37641812927417606,"score_spread":0.32396168553781235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991608,0.0007606984,0.00022559709,0.005780903,0.00042542338,0.0010353422,0.000017182852,0.000016863489,0.00012994211],"genre_scores_gemma":[0.9841559,0.000692121,0.013922025,0.0006533902,0.00041348243,0.00004727671,0.00002783118,0.000040345316,0.00004765789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954524,0.00052993285,0.002852671,0.00034693812,0.0005098078,0.0003082709],"domain_scores_gemma":[0.9939604,0.0035289868,0.0012868338,0.0002944957,0.00037586995,0.00055340707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024623738,0.00027759306,0.0015000296,0.00033587802,0.0000675372,0.00002943772,0.0001974569,0.0002543999,0.00039085044],"category_scores_gemma":[0.0023359333,0.00014309594,0.00025161466,0.00059698056,0.00016770654,0.00011714254,0.00004532586,0.00075910776,0.000025113151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012546026,0.0048367647,0.8176331,0.000045590146,0.001996288,0.0026107288,0.0032989772,0.00017969742,0.00053412485,0.00008943966,0.0035103422,0.15271892],"study_design_scores_gemma":[0.020706011,0.007785367,0.96347874,0.00051425723,0.00055748434,0.00043520436,0.00041164202,0.00021818993,0.0030662818,0.000122539,0.0025433362,0.00016096202],"about_ca_topic_score_codex":0.00018323623,"about_ca_topic_score_gemma":0.001152182,"teacher_disagreement_score":0.15255795,"about_ca_system_score_codex":0.00044757302,"about_ca_system_score_gemma":0.0029836113,"threshold_uncertainty_score":0.5835283},"labels":[],"label_agreement":null},{"id":"W4399325258","doi":"10.1200/jco.2024.42.16_suppl.e14584","title":"Hyaluronic acid hydrogel to modulate tumor cell clustering and programmed death ligand 1 signaling in cancer stem cells.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institutes of Health","keywords":"Medicine; Stem cell; Cancer stem cell; Hyaluronic acid; Cancer research; Cancer; Cancer cell; Programmed cell death; Ligand (biochemistry); Cell biology; Apoptosis; Biochemistry; Receptor; Internal medicine; Biology; Anatomy","score_opus":0.0785926069865469,"score_gpt":0.4218848719742602,"score_spread":0.3432922649877133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988473,0.007448667,0.0007336162,0.00089335325,0.0005938651,0.00028801538,0.000008151836,0.000005633343,0.00014394704],"genre_scores_gemma":[0.99553037,0.0013830262,0.0015795649,0.00044935898,0.0006725974,0.000026815898,0.000001220397,0.000028703309,0.00032832043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976021,0.00019945078,0.0011769797,0.00037593592,0.00022587072,0.0004196871],"domain_scores_gemma":[0.9989429,0.00014292657,0.00023788038,0.00015840796,0.00012768227,0.000390197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021947639,0.00016762628,0.00060965127,0.00015298183,0.00003636423,0.00005263387,0.0002638507,0.0002790904,0.000011305411],"category_scores_gemma":[0.00012215861,0.00013212864,0.00019987632,0.00016342917,0.00010035118,0.000011843508,0.00022046336,0.00070970005,0.000005163913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014722553,0.0003810406,0.0056990846,0.00019396734,0.00015941005,0.0010370614,0.00013143774,0.0018084372,0.72957635,0.000010479469,0.00040022228,0.25913024],"study_design_scores_gemma":[0.0054450966,0.018612893,0.0031828834,0.0005440395,0.00013912814,0.00038608137,0.00018939788,0.011357263,0.78980035,0.0002286009,0.16954453,0.0005697515],"about_ca_topic_score_codex":0.00007221451,"about_ca_topic_score_gemma":0.00031340608,"teacher_disagreement_score":0.2585605,"about_ca_system_score_codex":0.00008901782,"about_ca_system_score_gemma":0.0011515672,"threshold_uncertainty_score":0.53880495},"labels":[],"label_agreement":null},{"id":"W4399325282","doi":"10.1200/jco.2024.42.16_suppl.e14625","title":"Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Pancreatic cancer; Internal medicine; Oncology; Cancer","score_opus":0.04679747478830996,"score_gpt":0.436894867980122,"score_spread":0.390097393191812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99482715,0.0009314022,0.000012691808,0.0028630283,0.00024859863,0.00021721785,0.0000049616697,0.000007058974,0.00088787585],"genre_scores_gemma":[0.9967688,0.0013593648,0.0009306822,0.0003381802,0.00030283845,0.0000045231736,0.000002749264,0.00001865562,0.00027425663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976724,0.00035622143,0.00107892,0.00020384182,0.00048723747,0.0002013846],"domain_scores_gemma":[0.99772745,0.0011765081,0.00029036365,0.000119713986,0.00034145216,0.0003445217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014193662,0.00010232223,0.0008545539,0.00019535277,0.00001886288,0.000014580137,0.00008372946,0.00023439094,0.00019414116],"category_scores_gemma":[0.0007526642,0.000063143685,0.00011862817,0.00020381877,0.00018382803,0.00007754222,0.00006269765,0.0010634091,0.000010201637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044259634,0.0013420434,0.7666413,0.000089351735,0.00018972982,0.0023616417,0.00009114121,0.000006925659,0.00031875685,0.00002599606,0.0006073877,0.22389977],"study_design_scores_gemma":[0.008520588,0.014744384,0.96995723,0.00065525377,0.00031469276,0.00039852317,0.000047750153,0.00034863013,0.000047524944,0.000041662643,0.004857237,0.000066506946],"about_ca_topic_score_codex":0.000029064722,"about_ca_topic_score_gemma":0.000058551384,"teacher_disagreement_score":0.22383326,"about_ca_system_score_codex":0.00012577682,"about_ca_system_score_gemma":0.0014044611,"threshold_uncertainty_score":0.46200427},"labels":[],"label_agreement":null},{"id":"W4399325374","doi":"10.1200/jco.2024.42.16_suppl.e14698","title":"Using exponential decay to model survival curves in immunotherapy trials.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Windsor; Western University","funders":"","keywords":"Medicine; Immunotherapy; Survival analysis; Proportional hazards model; Oncology; Internal medicine; Cancer","score_opus":0.9316817566096776,"score_gpt":0.754980948632271,"score_spread":0.1767008079774065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325374","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12233277,0.0020246934,0.8488499,0.0077395486,0.016207436,0.0006912743,0.000036175952,0.000044076147,0.0020741594],"genre_scores_gemma":[0.050533954,0.002032239,0.94218063,0.001682565,0.003359158,0.000008977298,2.5713862e-7,0.00006334577,0.00013889528],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9760672,0.010953845,0.01134125,0.00039975328,0.0008018787,0.00043610355],"domain_scores_gemma":[0.64929914,0.3466757,0.0025960691,0.00042231148,0.0004415749,0.00056520465],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11638846,0.00024072133,0.0047089728,0.00031093069,0.000030308476,0.00004726283,0.000557174,0.0006659485,0.00044844337],"category_scores_gemma":[0.38563925,0.00016916268,0.0013126847,0.0004213851,0.00019691665,0.00015859776,0.0001284065,0.0018144494,0.000025007665],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01618171,0.0050620465,0.00094407506,0.00074958213,0.0020734936,0.0020888222,0.0005123511,0.0018510141,0.0043960745,0.14440875,0.030605555,0.79112655],"study_design_scores_gemma":[0.00596662,0.0032229866,0.0005201465,0.0017642189,0.0005280917,0.00007175457,0.000050581955,0.015159913,0.0002347131,0.963614,0.008549662,0.00031731703],"about_ca_topic_score_codex":0.000011912699,"about_ca_topic_score_gemma":0.000021736794,"teacher_disagreement_score":0.8192052,"about_ca_system_score_codex":0.00021132555,"about_ca_system_score_gemma":0.0019420675,"threshold_uncertainty_score":0.909864},"labels":[],"label_agreement":null},{"id":"W4399325908","doi":"10.1200/jco.2024.42.16_suppl.e15030","title":"Circulating tumor cells enumeration and characterization in patients with lung cancer treated with immunotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"Academic Medical Organization of Southwestern Ontario","keywords":"Medicine; Lung cancer; Immunotherapy; Enumeration; Cancer immunotherapy; Cancer research; Cancer; Tumor cells; Oncology; Internal medicine","score_opus":0.04006512856295487,"score_gpt":0.4478770831718037,"score_spread":0.40781195460884884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399325908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969829,0.00072733546,0.00008320018,0.0016297033,0.00018075436,0.00027836597,0.0000057788843,0.000007166111,0.00010483749],"genre_scores_gemma":[0.99834406,0.00067394023,0.0002512097,0.00034649955,0.00028743542,0.0000096402,0.000006555319,0.000014841895,0.000065806846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863887,0.00014210012,0.0007059078,0.0001288204,0.00025841902,0.00012588235],"domain_scores_gemma":[0.9988777,0.00035882564,0.00035008692,0.00005471364,0.00027685854,0.000081817954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007044595,0.000080752616,0.00055288785,0.00011934057,0.000024590874,0.000018232091,0.000029947238,0.00006636486,0.000036013447],"category_scores_gemma":[0.00013904282,0.000045315635,0.00004262129,0.00017551752,0.00008598845,0.00016175435,0.00001132334,0.0004597989,5.741927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003704395,0.0002797158,0.93040717,0.00010519132,0.0003947029,0.0003390651,0.00029168744,0.000016819167,0.0019001812,0.0000048183983,0.00005988152,0.062496364],"study_design_scores_gemma":[0.0059728655,0.0056123696,0.98474306,0.0007006725,0.00013136092,0.000031660464,0.000021201986,0.000883733,0.00012205355,0.00000305286,0.0017245848,0.000053371623],"about_ca_topic_score_codex":0.000035608882,"about_ca_topic_score_gemma":0.00003880999,"teacher_disagreement_score":0.062442992,"about_ca_system_score_codex":0.00024151067,"about_ca_system_score_gemma":0.0007302766,"threshold_uncertainty_score":0.1997623},"labels":[],"label_agreement":null},{"id":"W4399328009","doi":"10.1200/jco.2024.42.16_suppl.3521","title":"Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; St. Paul's Hospital; Vancouver General Hospital; Ottawa Hospital; Providence Health Care; Princess Margaret Cancer Centre; University Health Network; Pancreas Centre (Canada); University of British Columbia","funders":"","keywords":"Medicine; Indeterminate; Adverse effect; Solid tumor; Oncology; Haematopoiesis; Internal medicine; Cancer research; Cancer; Stem cell; Genetics; Biology","score_opus":0.03944379255092406,"score_gpt":0.43019023690970976,"score_spread":0.3907464443587857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399328009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684346,0.00008879292,0.000038997103,0.002164937,0.000405204,0.00021043714,0.000006396513,0.0000054358493,0.00023634935],"genre_scores_gemma":[0.99761266,0.00008404777,0.0015452268,0.00036208858,0.00019117155,0.0000021272954,0.000002527923,0.00001937554,0.00018076347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966013,0.00029491828,0.0020486047,0.00019384138,0.00061344064,0.00024791821],"domain_scores_gemma":[0.997444,0.0011210609,0.00069071935,0.0001369455,0.00031313274,0.0002941454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022796527,0.00013720691,0.0015456124,0.00035538492,0.000016522143,0.000002869051,0.00014543216,0.0002697691,0.00008175809],"category_scores_gemma":[0.0015339825,0.00008388095,0.00027102936,0.0001849356,0.0002763197,0.00015423383,0.0001173397,0.0012678641,0.000008194307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060631316,0.0010256536,0.96892726,0.00016587912,0.0003989121,0.001975344,0.0001000411,0.000008640771,0.000035445773,0.000028533792,0.00028056616,0.020990606],"study_design_scores_gemma":[0.011318534,0.008136406,0.97854763,0.0004151679,0.00019385769,0.00029418396,0.00007193102,0.0002542395,0.000046744073,0.00023293777,0.00041424658,0.00007412951],"about_ca_topic_score_codex":0.000016237316,"about_ca_topic_score_gemma":0.000014494909,"teacher_disagreement_score":0.020916477,"about_ca_system_score_codex":0.0001943089,"about_ca_system_score_gemma":0.0018584488,"threshold_uncertainty_score":0.5508309},"labels":[],"label_agreement":null},{"id":"W4399328153","doi":"10.1200/jco.2024.42.16_suppl.e15189","title":"Evaluation of lipopolymer as therapeutic siRNA delivery agents in non-malignant and malignant primary cells.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Malignant cells; Cancer research; Primary (astronomy); Oncology; Cancer; Pharmacology; Internal medicine","score_opus":0.10143778808508215,"score_gpt":0.4323602046676994,"score_spread":0.3309224165826173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399328153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98471045,0.012376011,0.000076277334,0.00033011087,0.0011631763,0.00012131129,0.0000038162234,0.0000013811347,0.0012174699],"genre_scores_gemma":[0.9904955,0.007940898,0.00013039431,0.00084782334,0.00039557376,0.000003509248,0.000003909467,0.000012070493,0.0001703195],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744195,0.00050117966,0.0013011801,0.00023044599,0.00036726243,0.00015795552],"domain_scores_gemma":[0.9987016,0.00020933455,0.00045187044,0.00014738337,0.00038847356,0.00010138669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046584844,0.000118766744,0.0005163453,0.00011530419,0.000014316553,0.000012751498,0.00017507403,0.00034038353,0.000061475934],"category_scores_gemma":[0.00027343852,0.00008768211,0.00024354743,0.00007876631,0.00013169988,0.00001373201,0.00008400776,0.00028476468,0.000010655805],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008826539,0.0005357638,0.0044913376,0.000054033964,0.0004985852,0.00015820343,0.00012722351,0.00011347381,0.48756295,0.00001784157,0.0019089851,0.50364894],"study_design_scores_gemma":[0.013028294,0.04528422,0.25873438,0.0014873246,0.0027811178,0.00083064445,0.00087717304,0.007833334,0.60430336,0.0041178614,0.05977029,0.0009519875],"about_ca_topic_score_codex":0.00003833288,"about_ca_topic_score_gemma":0.00004225513,"teacher_disagreement_score":0.50269693,"about_ca_system_score_codex":0.000046977126,"about_ca_system_score_gemma":0.0013273105,"threshold_uncertainty_score":0.35755727},"labels":[],"label_agreement":null},{"id":"W4399328377","doi":"10.1200/jco.2024.42.16_suppl.e15625","title":"Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; St. Paul's Hospital; Providence Health Care; BC Cancer Agency; Genome British Columbia; Pancreas Centre (Canada); University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Cancer research; Oncology; Circulating tumor DNA; Internal medicine; Cancer","score_opus":0.04986565173663397,"score_gpt":0.40639304521050995,"score_spread":0.35652739347387596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399328377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762625,0.0003162532,0.00012356021,0.0008595178,0.00032110998,0.0003686108,0.000017856943,0.0000029920466,0.0003638577],"genre_scores_gemma":[0.9982324,0.00020404976,0.00026542266,0.00059446535,0.0006406938,0.000023129684,0.000010129863,0.000021963468,0.000007726021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997585,0.0006928592,0.0009775681,0.00030248074,0.00021697297,0.00022512717],"domain_scores_gemma":[0.99790895,0.0010725005,0.0004765034,0.00013137751,0.00029478408,0.000115861265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001608985,0.0001768902,0.00059489656,0.000087161105,0.0000269838,0.00003995587,0.00019279367,0.00015802347,0.0000071586915],"category_scores_gemma":[0.0007866089,0.00010172728,0.0001028227,0.00024713622,0.0001727519,0.000011800809,0.00003710357,0.00067008304,6.5574164e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023426626,0.010129347,0.8209851,0.000046282934,0.0015768851,0.018895306,0.006637213,0.007577919,0.07109987,0.00019260371,0.0007673135,0.038665548],"study_design_scores_gemma":[0.00988059,0.12313569,0.8354088,0.00035078693,0.00046602107,0.0012098717,0.0134272175,0.001683052,0.007989606,0.00009642275,0.0058341334,0.0005177895],"about_ca_topic_score_codex":0.00024620834,"about_ca_topic_score_gemma":0.014857426,"teacher_disagreement_score":0.113006346,"about_ca_system_score_codex":0.00015798803,"about_ca_system_score_gemma":0.0010992413,"threshold_uncertainty_score":0.8290793},"labels":[],"label_agreement":null},{"id":"W4399343072","doi":"10.1200/jco.2024.42.16_suppl.12138","title":"Comparing the characteristics and outcomes of hospitalizations between cancer and non-cancer survivors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; Trillium Health Centre; Credit Valley Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Sinai Health System; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of Toronto; Conquer Cancer Foundation","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.11551913808429674,"score_gpt":0.46986701894278304,"score_spread":0.3543478808584863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399343072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98069036,0.0045176214,0.0001911345,0.011919084,0.0021576749,0.00009318036,0.000022552776,0.0000049868486,0.00040338316],"genre_scores_gemma":[0.99080676,0.0073141525,0.000054012577,0.000588152,0.0010339525,0.000004051758,0.0000015226234,0.000011103105,0.00018631903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984313,0.00009139829,0.0010857158,0.000107824315,0.00017918726,0.00010455166],"domain_scores_gemma":[0.99736,0.0017069284,0.0004772881,0.00009103095,0.00022034127,0.00014443407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011739967,0.000085637206,0.001066853,0.000061839666,0.000032269054,0.000015928616,0.00007461321,0.00014313999,0.000044138545],"category_scores_gemma":[0.0004215331,0.000048575024,0.00016215636,0.000112862275,0.0002500436,0.000061059625,0.000053352574,0.00049286714,6.347411e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090413174,0.000050518865,0.93262094,0.0001093295,0.0004048325,0.00002087797,0.0005214618,0.0000010350329,0.000009267959,0.00011142178,0.00043920244,0.06562072],"study_design_scores_gemma":[0.0007161468,0.00065610005,0.965847,0.00023539802,0.00067696243,0.00001491194,0.00019441033,0.00015396207,0.000009800413,0.00009898288,0.031347424,0.00004888058],"about_ca_topic_score_codex":0.0007335557,"about_ca_topic_score_gemma":0.0018649021,"teacher_disagreement_score":0.06557184,"about_ca_system_score_codex":0.000041946176,"about_ca_system_score_gemma":0.0005218347,"threshold_uncertainty_score":0.21412899},"labels":[],"label_agreement":null},{"id":"W4399346745","doi":"10.1200/jco.2024.42.16_suppl.e24004","title":"Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cardiotoxicity; Incidence (geometry); Cumulative incidence; Oncology; Soft tissue sarcoma; Internal medicine; Meta-analysis; Soft tissue; Chemotherapy; Surgery; Cohort","score_opus":0.12321356692949491,"score_gpt":0.5005243226464209,"score_spread":0.37731075571692596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399346745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004404642,0.99248695,0.000007906964,0.00034821022,0.00009806814,0.0025410885,0.000096460055,0.000003032116,0.000013634422],"genre_scores_gemma":[0.049327977,0.94850725,0.0015264718,0.0003381298,0.000048932405,0.00019100147,0.00001249765,0.000028435812,0.000019327983],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9887455,0.0017843645,0.008187056,0.00041070103,0.00068339636,0.0001889766],"domain_scores_gemma":[0.98421776,0.005624625,0.008229208,0.0004986398,0.001204104,0.00022566822],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0028439043,0.00046895206,0.031206233,0.00049437565,0.000009723606,0.0000052504656,0.00020002358,0.0004316886,0.00004949312],"category_scores_gemma":[0.005416879,0.00021398236,0.0039013294,0.0008107429,0.00026744945,0.00010049234,0.0001073253,0.00089055666,0.000003474293],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055342016,0.0041535445,0.0069399774,0.6983565,0.23977932,0.0013315736,0.000053306605,0.000004170589,2.0863153e-8,0.000016505806,0.000039907438,0.048771776],"study_design_scores_gemma":[0.0018771794,0.004922045,0.0063704206,0.12874274,0.85614854,0.000097417396,0.000009403094,0.000001562614,3.9822058e-7,0.000022135351,0.0016590274,0.00014912104],"about_ca_topic_score_codex":0.00004301085,"about_ca_topic_score_gemma":0.000116707866,"teacher_disagreement_score":0.61636925,"about_ca_system_score_codex":0.00016146197,"about_ca_system_score_gemma":0.0007939235,"threshold_uncertainty_score":0.9831765},"labels":[],"label_agreement":null},{"id":"W4399347814","doi":"10.1200/jco.2024.42.16_suppl.1518","title":"Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Fertility; Prospective cohort study; Pregnancy; Gynecology; Obstetrics; Cohort; Cancer; Cohort study; Fertility preservation; Population; Internal medicine; Environmental health","score_opus":0.07060583304467119,"score_gpt":0.46368794343616304,"score_spread":0.3930821103914919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399347814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956865,0.0019969363,0.000045411973,0.002012707,0.0042412565,0.00090177235,0.000017989001,0.000042504773,0.0011727426],"genre_scores_gemma":[0.99727404,0.0006097446,0.00012118944,0.00016796334,0.0011376536,0.0000257414,0.0000010119102,0.000030201973,0.0006324506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961256,0.00039249103,0.00222707,0.00039777684,0.0005441545,0.00031295032],"domain_scores_gemma":[0.99684286,0.001061182,0.0008528138,0.00022808631,0.00050085643,0.00051419734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030456653,0.0001947774,0.0015422875,0.000122027675,0.00006605858,0.00003512156,0.00014960713,0.0002910702,0.00049391005],"category_scores_gemma":[0.001271801,0.00012998482,0.00058085885,0.00026956768,0.00021689547,0.0002101101,0.00007183338,0.0015981141,0.000012066756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015838938,0.0016496615,0.9383386,0.00010477965,0.0010465552,0.0012365263,0.00094180845,0.0000107433425,0.0000113129745,0.0000040707487,0.00054361805,0.05452844],"study_design_scores_gemma":[0.003457284,0.0022189096,0.98913133,0.0007558328,0.0009965068,0.00016283944,0.0008164543,0.0003786465,0.0000030792473,0.000028274972,0.0019301595,0.000120662226],"about_ca_topic_score_codex":0.0044610626,"about_ca_topic_score_gemma":0.01359153,"teacher_disagreement_score":0.05440778,"about_ca_system_score_codex":0.0006834754,"about_ca_system_score_gemma":0.0019637083,"threshold_uncertainty_score":0.75843924},"labels":[],"label_agreement":null},{"id":"W4399348782","doi":"10.1200/jco.2024.42.16_suppl.e24143","title":"Recommendations for the assessment of glomerular filtration rate in patients with cancer: A position statement and systematic review on behalf of the American Society of Onco-Nephrology (ASON).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Renal function; Position statement; Nephrology; Internal medicine; Urology; Oncology; Family medicine; Intensive care medicine","score_opus":0.06310013139695561,"score_gpt":0.4752462881743732,"score_spread":0.4121461567774176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399348782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92387754,0.006805917,0.00027343203,0.06687007,0.00025243757,0.001784932,0.00010611829,0.000002029558,0.000027519727],"genre_scores_gemma":[0.9810855,0.013204157,0.0007293108,0.0048421137,0.00005505611,0.00005546317,0.000013519951,0.000006510654,0.000008364244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975492,0.0004676791,0.0016236798,0.000086066364,0.00019544495,0.0000779674],"domain_scores_gemma":[0.9950099,0.0025604162,0.0019517161,0.00012708503,0.00029616157,0.00005473945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024920113,0.000067628476,0.0009955522,0.000035815716,0.000018432409,0.0000023877046,0.00006545741,0.000043590146,0.000021211767],"category_scores_gemma":[0.00048721128,0.000031212126,0.00025646112,0.00015336703,0.0001807638,0.000041290823,0.000015831562,0.00021314836,7.3684795e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006377118,0.013222021,0.46593145,0.32613242,0.010900209,0.000013177471,0.0010715865,0.00036862266,0.0011047275,0.001855718,0.09016122,0.08286173],"study_design_scores_gemma":[0.008485553,0.029264702,0.8711442,0.07666008,0.0072788494,0.0000055499,0.00041804576,0.0025143537,0.00012776404,0.00022715204,0.00378011,0.00009369163],"about_ca_topic_score_codex":0.000025400277,"about_ca_topic_score_gemma":0.000025724577,"teacher_disagreement_score":0.4052127,"about_ca_system_score_codex":0.00016493768,"about_ca_system_score_gemma":0.0014447095,"threshold_uncertainty_score":0.25628525},"labels":[],"label_agreement":null},{"id":"W4399374116","doi":"10.1200/jco.2024.42.17_suppl.lba5","title":"ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Oncology; Internal medicine; Stage (stratigraphy); Lung cancer; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.13536777185527651,"score_gpt":0.522701672356838,"score_spread":0.38733390050156147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399374116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97031164,0.004535393,0.0003559676,0.015881512,0.0021525195,0.0015722675,0.000060463633,0.00003405117,0.005096162],"genre_scores_gemma":[0.9750426,0.008731205,0.0032891927,0.0013874515,0.0022257164,0.00018272677,0.000021941341,0.000057904585,0.009061283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969888,0.00027531091,0.0015542057,0.0003057732,0.00050912524,0.00036678993],"domain_scores_gemma":[0.993855,0.0037277378,0.0007943726,0.00019354916,0.0010398071,0.00038951353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014055992,0.00020742601,0.0012540291,0.00018244036,0.00007666477,0.000032634995,0.00012964447,0.00023849381,0.00025675388],"category_scores_gemma":[0.0022947686,0.00012142913,0.0004298954,0.00017565442,0.00018382855,0.00012618357,0.000048568883,0.0006007661,0.000022540793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040239133,0.011425479,0.42263183,0.002278068,0.010610644,0.0020468165,0.002243946,0.000166069,0.0002172224,0.0005796896,0.08319858,0.4243625],"study_design_scores_gemma":[0.049097028,0.12255969,0.07281111,0.0013257286,0.004484434,0.00009474827,0.0004624756,0.0029838688,0.00060889416,0.00012420848,0.7451223,0.00032551136],"about_ca_topic_score_codex":0.000110544825,"about_ca_topic_score_gemma":0.00025198315,"teacher_disagreement_score":0.6619237,"about_ca_system_score_codex":0.0013677836,"about_ca_system_score_gemma":0.0053497306,"threshold_uncertainty_score":0.9490192},"labels":[],"label_agreement":null},{"id":"W4399380501","doi":"10.1200/jco.2024.42.16_suppl.5531","title":"Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Cervical cancer; Oncology; Internal medicine; Cancer","score_opus":0.4478745283013557,"score_gpt":0.5603032952923483,"score_spread":0.11242876699099263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.916253,0.039738465,0.00013454721,0.032705314,0.009158529,0.0006620334,0.0003030499,0.000045043933,0.0010000602],"genre_scores_gemma":[0.94661033,0.04003825,0.0031982756,0.0047399094,0.004828104,0.00003661485,0.000131703,0.0000597502,0.00035708945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99354726,0.00083285634,0.003706468,0.0006269881,0.0008150817,0.0004713627],"domain_scores_gemma":[0.9917924,0.0058230814,0.00091994,0.0005974354,0.00029653864,0.00057060557],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003621919,0.00031890263,0.0025020877,0.00035672172,0.000035490088,0.00004345072,0.0006605833,0.00033636377,0.003940276],"category_scores_gemma":[0.003149687,0.00018556225,0.00047658314,0.0010332229,0.00018319715,0.00024368525,0.00021055891,0.0021221025,0.00012008904],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021318747,0.004088201,0.018335572,0.0001132211,0.0019872752,0.006358487,0.00014930191,0.0000045473807,0.00012639537,0.00010193486,0.010629785,0.93678653],"study_design_scores_gemma":[0.041223966,0.025256118,0.28528905,0.0013280049,0.0015293628,0.00042693713,0.0001742571,0.0009588185,0.00020650818,0.0022455007,0.6409735,0.0003879587],"about_ca_topic_score_codex":0.0008218105,"about_ca_topic_score_gemma":0.0011679335,"teacher_disagreement_score":0.93639857,"about_ca_system_score_codex":0.00070580695,"about_ca_system_score_gemma":0.004321018,"threshold_uncertainty_score":0.99697024},"labels":[],"label_agreement":null},{"id":"W4399380508","doi":"10.1200/jco.2024.42.16_suppl.5607","title":"Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Chemotherapy; Adverse effect; Gynecologic cancer; Cancer; Oncology; Internal medicine; Ovarian cancer","score_opus":0.07858355072254367,"score_gpt":0.4615143637051832,"score_spread":0.38293081298263953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724127,0.0033777733,0.000007443109,0.0055957306,0.0015448135,0.0014433728,0.000032233587,0.000012865815,0.00074448535],"genre_scores_gemma":[0.9879409,0.008311983,0.0004173906,0.0012898694,0.0015323367,0.0000828122,0.000014958603,0.00003489372,0.00037487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994614,0.0011437396,0.0028234723,0.00034047218,0.00071825576,0.00036008313],"domain_scores_gemma":[0.98976797,0.0083918655,0.001156883,0.0002470276,0.00020969403,0.00022657412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004323393,0.0002803767,0.002537365,0.000503373,0.000020241445,0.0000035889568,0.000300395,0.00038779984,0.00059250026],"category_scores_gemma":[0.0022269145,0.00013180793,0.00057618495,0.0016064976,0.00019935073,0.00016046478,0.000035796646,0.001379806,0.000011229932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6501287,0.0063027046,0.009836981,0.0001176491,0.00094698044,0.0013572127,0.0005175278,0.000056428693,0.00011672768,0.0000075286966,0.0003414313,0.3302701],"study_design_scores_gemma":[0.6999119,0.10236156,0.16217992,0.0017309799,0.0013079026,0.0002507432,0.00052000285,0.00015768918,0.0002131513,0.00012707374,0.030956727,0.00028233646],"about_ca_topic_score_codex":0.00011279946,"about_ca_topic_score_gemma":0.00022923664,"teacher_disagreement_score":0.32998776,"about_ca_system_score_codex":0.0010690175,"about_ca_system_score_gemma":0.00407978,"threshold_uncertainty_score":0.72373545},"labels":[],"label_agreement":null},{"id":"W4399380532","doi":"10.1200/jco.2024.42.16_suppl.5599","title":"Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Tolerability; Paclitaxel; Olaparib; Carboplatin; Endometrial cancer; Oncology; Internal medicine; Gynecology; Atezolizumab; Cancer; Urology; Chemotherapy; Cisplatin; Adverse effect; Immunotherapy; Nivolumab","score_opus":0.0789982247170708,"score_gpt":0.45499178659023803,"score_spread":0.37599356187316724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596853,0.0030922485,0.00007070095,0.005030522,0.003381384,0.0019245913,0.00011406309,0.000012467911,0.00040552134],"genre_scores_gemma":[0.9936316,0.0040412694,0.0007004073,0.0007522601,0.00071234634,0.00006568351,0.000013662949,0.00003245557,0.000050293882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99113435,0.002242037,0.0047588954,0.00048397598,0.0009873825,0.0003933596],"domain_scores_gemma":[0.9804773,0.016521702,0.0019064335,0.0003780205,0.00043894892,0.0002775925],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009086075,0.00030033945,0.002742306,0.00034819925,0.00004696889,0.00002275502,0.0002677565,0.0004633901,0.00025366817],"category_scores_gemma":[0.010855,0.000171879,0.00041813913,0.00095492153,0.0004187139,0.00025752248,0.00004122891,0.0019766632,0.000001651558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67519087,0.0057608443,0.10509248,0.00016778582,0.00048372374,0.00029128394,0.0012690772,0.00008706625,0.00007783556,0.000081221275,0.0030720425,0.2084258],"study_design_scores_gemma":[0.5916226,0.061745245,0.30614772,0.0014910741,0.0004953975,0.000041953725,0.000361542,0.00015420234,0.00005779266,0.0004946937,0.037074044,0.0003137487],"about_ca_topic_score_codex":0.00021487691,"about_ca_topic_score_gemma":0.0011987359,"teacher_disagreement_score":0.20811205,"about_ca_system_score_codex":0.00078579836,"about_ca_system_score_gemma":0.0033437766,"threshold_uncertainty_score":0.997477},"labels":[],"label_agreement":null},{"id":"W4399380599","doi":"10.1200/jco.2024.42.16_suppl.5554","title":"Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Placebo; Ovarian cancer; Double blind; Randomized controlled trial; Oncology; Internal medicine; Surgery; Cancer; Alternative medicine","score_opus":0.16616123566817184,"score_gpt":0.5008747153787974,"score_spread":0.3347134797106255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698541,0.0017321857,0.0012541189,0.0147209875,0.004152358,0.0066634174,0.0001657192,0.00004510387,0.0014119734],"genre_scores_gemma":[0.97800124,0.0054504387,0.0055010323,0.0027655936,0.0062302537,0.001086868,0.000086396976,0.00010368338,0.00077451265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98841786,0.0024472051,0.0066859713,0.0007715829,0.0010839413,0.0005934235],"domain_scores_gemma":[0.97635996,0.018291522,0.0035540408,0.0004929203,0.00070508313,0.0005964501],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010581246,0.0005385587,0.005331063,0.00038266936,0.000099844736,0.000070977934,0.00029137815,0.00064218894,0.0006760843],"category_scores_gemma":[0.0044080545,0.00032457945,0.0014029451,0.00040656,0.00040495227,0.00027684987,0.000028879427,0.001655151,0.000033571854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83645624,0.005359791,0.0006780923,0.000012024437,0.0028101394,0.0008529339,0.0011342879,0.00064033654,0.000020744905,0.00010831596,0.000864363,0.15106271],"study_design_scores_gemma":[0.9205303,0.05765567,0.0007609845,0.0011103123,0.0014982027,0.000037821726,0.00010463092,0.0032149132,0.000036063015,0.000714828,0.014044398,0.0002918479],"about_ca_topic_score_codex":0.0014027338,"about_ca_topic_score_gemma":0.0005102349,"teacher_disagreement_score":0.15077087,"about_ca_system_score_codex":0.0019790742,"about_ca_system_score_gemma":0.00804801,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W4399380628","doi":"10.1200/jco.2024.42.16_suppl.5575","title":"Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Antibody; Cancer; Internal medicine; Class (philosophy); Pharmacology; Immunology; Artificial intelligence","score_opus":0.08142662190240947,"score_gpt":0.47689624892163535,"score_spread":0.3954696270192259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926142,0.0012329752,0.00014250296,0.0036994964,0.0009177758,0.0008151223,0.00050183054,0.000009474852,0.00006660435],"genre_scores_gemma":[0.98502374,0.0073549086,0.0065533873,0.00043291724,0.00023790196,0.000006468121,0.00012019491,0.00003472148,0.00023578297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945259,0.00049422483,0.003291247,0.00050715875,0.00073255046,0.0004489284],"domain_scores_gemma":[0.99373865,0.0042423764,0.00095866754,0.0002395081,0.00039336304,0.00042744516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022530595,0.00028794882,0.002246963,0.00039760838,0.00004479693,0.00001853217,0.00020933518,0.00028066387,0.00011701295],"category_scores_gemma":[0.0023563427,0.00016949115,0.0002145692,0.00045708183,0.00040553923,0.00021390086,0.0001289989,0.0014423366,0.0000060779016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17703262,0.01873695,0.7111065,0.00035243246,0.00099647,0.004412975,0.0004959813,0.00018089009,0.0004482041,0.000010363405,0.00045472608,0.08577187],"study_design_scores_gemma":[0.13979211,0.012090306,0.8238184,0.0026194206,0.00029831188,0.00006256297,0.00008109022,0.0061193644,0.000046321893,0.000009566146,0.014887055,0.00017551314],"about_ca_topic_score_codex":0.0011384008,"about_ca_topic_score_gemma":0.0021407623,"teacher_disagreement_score":0.11271187,"about_ca_system_score_codex":0.0001869372,"about_ca_system_score_gemma":0.001477023,"threshold_uncertainty_score":0.69116485},"labels":[],"label_agreement":null},{"id":"W4399380633","doi":"10.1200/jco.2024.42.16_suppl.5564","title":"Systematic review of frailty assessment in ovarian cancer studies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Cancer; Oncology; Internal medicine; Gynecology; Gerontology","score_opus":0.24850568810008422,"score_gpt":0.5898849890637008,"score_spread":0.34137930096361657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380633","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035661217,0.78915125,0.00028834792,0.1570873,0.009042513,0.0017946056,0.00001019933,0.000021292895,0.006943298],"genre_scores_gemma":[0.54151094,0.4354103,0.005862466,0.013745028,0.0016120991,0.0000619992,0.0000018637262,0.000037293616,0.001758],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9932749,0.00074782607,0.005141957,0.00016049153,0.00050998776,0.00016481554],"domain_scores_gemma":[0.9924881,0.0048536994,0.0016047201,0.0002395316,0.0006313957,0.00018259464],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009027261,0.00012273109,0.003580292,0.00015495482,0.000008254418,0.0000039117763,0.00016836674,0.00021746103,0.00023726869],"category_scores_gemma":[0.0146129085,0.00007445423,0.0005558018,0.00030363022,0.0001415976,0.00007971636,0.000055786335,0.0013437211,0.0000130147355],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002755891,0.0013719323,0.006476285,0.91541684,0.0036905047,0.0033849196,0.00040631735,0.000007630076,0.00007917474,0.0005825136,0.050789405,0.017518912],"study_design_scores_gemma":[0.004045628,0.0056005702,0.02833843,0.94384825,0.003320742,0.00064659084,0.00035144793,0.0001685332,0.000019945159,0.0005317296,0.013011262,0.000116851996],"about_ca_topic_score_codex":0.000027409793,"about_ca_topic_score_gemma":0.00006456091,"teacher_disagreement_score":0.5058497,"about_ca_system_score_codex":0.0004995695,"about_ca_system_score_gemma":0.00328953,"threshold_uncertainty_score":0.99368745},"labels":[],"label_agreement":null},{"id":"W4399380733","doi":"10.1200/jco.2024.42.16_suppl.5523","title":"Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gynecologic oncology; Precision oncology; Gynecologic cancer; Internal medicine; Oncology; Cancer; Ovarian cancer","score_opus":0.0735403117581049,"score_gpt":0.4580394458673659,"score_spread":0.384499134109261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96402395,0.0047588297,0.00078665,0.021940062,0.002065381,0.0009082082,0.000029887009,0.00004285329,0.0054441537],"genre_scores_gemma":[0.9351885,0.006499314,0.05352765,0.0022981262,0.0014450852,0.00012674833,0.000013057041,0.00005114628,0.00085038674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967968,0.00035507654,0.0019493247,0.00037823681,0.00022726708,0.0002932811],"domain_scores_gemma":[0.99109983,0.0072563575,0.0007936865,0.00018282718,0.00029447392,0.0003728301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002434073,0.00023460167,0.0018603569,0.00015636657,0.000061792365,0.000035154964,0.00009835985,0.00038054326,0.00021888572],"category_scores_gemma":[0.0019195863,0.00013886989,0.0007087418,0.00011589369,0.00014049087,0.000093763956,0.000049726754,0.00041908503,0.00002109482],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033756527,0.0031787844,0.003970511,0.00017007443,0.0016367468,0.009795956,0.0005307888,0.000019791742,0.0026060059,0.001767061,0.010196461,0.96275216],"study_design_scores_gemma":[0.024116911,0.21801694,0.038075995,0.0016595426,0.004367675,0.0042122686,0.0009112071,0.0013233804,0.0015308678,0.009929983,0.6954587,0.0003965166],"about_ca_topic_score_codex":0.000045265788,"about_ca_topic_score_gemma":0.000032526917,"teacher_disagreement_score":0.9623557,"about_ca_system_score_codex":0.0010279414,"about_ca_system_score_gemma":0.0028105353,"threshold_uncertainty_score":0.56629497},"labels":[],"label_agreement":null},{"id":"W4399380843","doi":"10.1200/jco.2024.42.16_suppl.5506","title":"Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Olaparib; Serous ovarian cancer; Ovarian cancer; Oncology; Internal medicine; Serous fluid; Randomized controlled trial; Cancer","score_opus":0.06979818042501257,"score_gpt":0.43066278141934455,"score_spread":0.360864600994332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815609,0.00046474548,0.000033059594,0.012540487,0.0025100326,0.0027928187,0.000026272639,0.000010422135,0.00006128839],"genre_scores_gemma":[0.99755555,0.00040150937,0.00064422126,0.0005676349,0.00063262216,0.000048890095,0.0000074007016,0.000027218282,0.000114961134],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942926,0.0015994667,0.0029954526,0.00031807704,0.000538509,0.00025588824],"domain_scores_gemma":[0.9923996,0.0050158277,0.0016816829,0.00025598664,0.00041921955,0.00022772176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034375128,0.0002349836,0.0030647635,0.0001559804,0.000060506583,0.00001482193,0.00012522713,0.00024131929,0.00008220831],"category_scores_gemma":[0.0013751476,0.00011315758,0.00047736708,0.0002811862,0.00020916136,0.000089021654,0.000054213455,0.0011118486,0.000002900849],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8113051,0.07200379,0.02500624,0.000027701277,0.0038420928,0.0019527565,0.0030687847,0.00012413667,0.0000028334068,0.000074694784,0.0008600282,0.08173183],"study_design_scores_gemma":[0.8715869,0.06699456,0.05571113,0.0004982719,0.0028511991,0.000022406832,0.00062528154,0.00034375046,0.000016165355,0.000031807504,0.0012202441,0.00009827443],"about_ca_topic_score_codex":0.00078341505,"about_ca_topic_score_gemma":0.0007718022,"teacher_disagreement_score":0.08163356,"about_ca_system_score_codex":0.00033763255,"about_ca_system_score_gemma":0.0015673491,"threshold_uncertainty_score":0.4830491},"labels":[],"label_agreement":null},{"id":"W4399380898","doi":"10.1200/jco.2024.42.16_suppl.5055","title":"Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [<sup>177</sup>Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Endocyte; Australian Nuclear Science and Technology Organisation","keywords":"Cabazitaxel; Medicine; Prostate cancer; Oncology; Prostate; Fraction (chemistry); Internal medicine; Urology; Cancer research; Cancer; Androgen deprivation therapy","score_opus":0.14565426119267283,"score_gpt":0.5184293515209151,"score_spread":0.37277509032824224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758584,0.0068101627,0.000018955689,0.0017661063,0.00070639467,0.0028779004,0.000047808764,0.00001309625,0.00017370356],"genre_scores_gemma":[0.9953777,0.0025411125,0.00085268175,0.00003682974,0.00064614834,0.00034786641,0.000020181646,0.000038845195,0.00013863418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99264354,0.0015291912,0.0042412267,0.00040563018,0.0007371145,0.00044333073],"domain_scores_gemma":[0.9921125,0.0050996076,0.0018386275,0.00020341326,0.000446375,0.00029947702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004691878,0.00031840196,0.0032627073,0.0006418681,0.00003886768,0.000038612627,0.000116013485,0.0002621104,0.0001684787],"category_scores_gemma":[0.0030793825,0.00020382678,0.0009231673,0.00056686276,0.00043885893,0.000305405,0.00002922706,0.0009168163,0.0000026680073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8619763,0.007883595,0.0015904907,0.00036002288,0.0022098827,0.0038381494,0.0025514285,0.00042865312,0.0035122123,0.000012985779,0.000025070101,0.1156112],"study_design_scores_gemma":[0.9442705,0.036400314,0.005170263,0.0022577096,0.0020891433,0.00011267775,0.0011998101,0.006660881,0.0009873813,0.0001941864,0.0004802857,0.00017686842],"about_ca_topic_score_codex":0.0004696974,"about_ca_topic_score_gemma":0.00026687726,"teacher_disagreement_score":0.11543433,"about_ca_system_score_codex":0.0012819576,"about_ca_system_score_gemma":0.0070425565,"threshold_uncertainty_score":0.9985866},"labels":[],"label_agreement":null},{"id":"W4399380900","doi":"10.1200/jco.2024.42.16_suppl.e17105","title":"Addition of MRI or DRE to clinical data and risk prediction for clinically significant prostate cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University; University of Calgary; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Oncology; Magnetic resonance imaging; Internal medicine; Radiology","score_opus":0.14141515787709968,"score_gpt":0.5425953067782464,"score_spread":0.4011801489011467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.894004,0.0014269353,0.03507828,0.05789197,0.009257224,0.0012007431,0.00082864705,0.000050170518,0.00026205656],"genre_scores_gemma":[0.81631476,0.06123965,0.10337422,0.0046727443,0.013357471,0.00003435163,0.00012070693,0.0000800115,0.0008060777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936696,0.0005808009,0.004695106,0.0004510299,0.00037286463,0.00023059767],"domain_scores_gemma":[0.9855377,0.011252657,0.0016903296,0.0003477203,0.0004935089,0.00067806774],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017874615,0.00014203406,0.0015657203,0.0001458599,0.00004852943,0.00002414733,0.00028328347,0.00038538326,0.00010237344],"category_scores_gemma":[0.04209702,0.000088772285,0.0003634383,0.0001783249,0.0003894064,0.00015650396,0.00014735507,0.0018932885,0.000004128073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008921135,0.0005888046,0.16127662,0.00020430006,0.00065232767,0.00018383384,0.00009992965,0.000050999523,0.00004885879,0.00003236589,0.09969413,0.7282467],"study_design_scores_gemma":[0.007862085,0.03623561,0.21389045,0.0013246661,0.0021814813,0.00021931894,0.00016247183,0.06315228,0.000009114066,0.00059508445,0.67422986,0.00013755697],"about_ca_topic_score_codex":0.000032524782,"about_ca_topic_score_gemma":0.000020991989,"teacher_disagreement_score":0.7281091,"about_ca_system_score_codex":0.000058235142,"about_ca_system_score_gemma":0.002588393,"threshold_uncertainty_score":0.9659718},"labels":[],"label_agreement":null},{"id":"W4399381307","doi":"10.1200/jco.2024.42.16_suppl.tps4616","title":"Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Internal medicine; Urothelial cancer; Urothelial carcinoma; Cancer research; Cancer; Immunotherapy; Bladder cancer","score_opus":0.05838603961958719,"score_gpt":0.41928429454730964,"score_spread":0.36089825492772243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399381307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675083,0.0005000691,0.00008587778,0.00050957635,0.00030800625,0.0015943117,0.000022951319,0.000020169617,0.00020820735],"genre_scores_gemma":[0.9980196,0.00019043392,0.00088728534,0.00040469907,0.00018638874,0.00003857465,0.000009595766,0.00006552772,0.00019789794],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962832,0.00046541914,0.0018241964,0.00038908367,0.00069680816,0.00034129174],"domain_scores_gemma":[0.99709725,0.00096330274,0.0009269596,0.00030164781,0.00039809494,0.00031275974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006463114,0.00032721861,0.0021527298,0.00022862262,0.000028840816,0.000022809963,0.00020039664,0.00014736198,0.00028640922],"category_scores_gemma":[0.0002448864,0.0001680739,0.00019520069,0.00035251086,0.0001912594,0.0002617738,0.000028271863,0.00068379974,0.00000517943],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39889354,0.052752525,0.4119465,0.00027256893,0.0023862363,0.0041865627,0.0017462394,0.00006642269,0.000030905103,0.0000033375936,0.00021905218,0.12749611],"study_design_scores_gemma":[0.2770494,0.36467943,0.35258967,0.0008455548,0.0018687268,0.0001989404,0.000904849,0.00006314111,0.00027679827,0.000018718947,0.001300501,0.00020428249],"about_ca_topic_score_codex":0.00015897727,"about_ca_topic_score_gemma":0.00034925374,"teacher_disagreement_score":0.3119269,"about_ca_system_score_codex":0.0002252886,"about_ca_system_score_gemma":0.0026002284,"threshold_uncertainty_score":0.6853854},"labels":[],"label_agreement":null},{"id":"W4399381359","doi":"10.1200/jco.2024.42.16_suppl.4514","title":"Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Oncology; Intensive care medicine","score_opus":0.14865811750976207,"score_gpt":0.42472553632350035,"score_spread":0.2760674188137383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399381359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97627676,0.015671952,0.00008325002,0.0035916115,0.0018670905,0.0004662797,0.00008741189,0.000015780635,0.0019398916],"genre_scores_gemma":[0.9851874,0.009416682,0.0024169257,0.00048106944,0.00084236,0.000020635316,0.000029652057,0.00003086641,0.0015743747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945172,0.0012429764,0.0026752024,0.00050830765,0.000710469,0.00034585755],"domain_scores_gemma":[0.98615175,0.011543912,0.001237259,0.0004279917,0.00023585936,0.0004032238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046346756,0.00029036787,0.0014976963,0.00029992766,0.000067202134,0.000078845886,0.0003528953,0.00016552096,0.00021937188],"category_scores_gemma":[0.0018535735,0.00017063634,0.00042952443,0.0003090339,0.0002613181,0.0003938128,0.00016748204,0.0014704587,0.00006714967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00564654,0.0013741445,0.94179523,0.00016528057,0.0014302426,0.016140696,0.0004712447,0.00010180643,0.0028703914,0.000046292535,0.0120577635,0.01790035],"study_design_scores_gemma":[0.015587683,0.009467956,0.94409394,0.003536208,0.0057868147,0.0021594951,0.0010420005,0.003899002,0.0022961455,0.00058078096,0.011202208,0.00034777715],"about_ca_topic_score_codex":0.0038544117,"about_ca_topic_score_gemma":0.0012111134,"teacher_disagreement_score":0.017552573,"about_ca_system_score_codex":0.00091654126,"about_ca_system_score_gemma":0.0026560957,"threshold_uncertainty_score":0.6958348},"labels":[],"label_agreement":null},{"id":"W4399381371","doi":"10.1200/jco.2024.42.16_suppl.4504","title":"Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Biomarker; Renal cell carcinoma; Internal medicine; Oncology","score_opus":0.18237941356264004,"score_gpt":0.4859540055649664,"score_spread":0.30357459200232634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399381371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991314,0.0025764192,0.00003294271,0.0026169922,0.0011160574,0.00050412933,0.000015278576,0.0000098459595,0.0018143187],"genre_scores_gemma":[0.99683344,0.00011584147,0.0013893258,0.00071259047,0.000751969,0.0000074686513,0.000021392312,0.000028571782,0.00013941045],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99599296,0.0007195761,0.0021501337,0.00030632154,0.00057416083,0.00025687256],"domain_scores_gemma":[0.99453056,0.00374785,0.0008290397,0.0003160904,0.0002641217,0.00031232432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014736924,0.00020354467,0.001348591,0.00017982523,0.000037059017,0.000022614373,0.00019765094,0.00024281167,0.00023416379],"category_scores_gemma":[0.0008616111,0.000096290605,0.0005801042,0.0003404984,0.00022517344,0.00012980486,0.000048520775,0.0010515606,0.00003320931],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5467648,0.009831218,0.14552984,0.000036534213,0.0010163261,0.0061394526,0.00023731562,0.000028041912,0.0007987127,0.000008166683,0.0065852082,0.2830244],"study_design_scores_gemma":[0.18258259,0.06571906,0.7334426,0.00017048436,0.0011835548,0.000033243843,0.00012449885,0.00011344296,0.00039511835,0.000067520814,0.016057236,0.00011066755],"about_ca_topic_score_codex":0.00007225873,"about_ca_topic_score_gemma":0.000036950678,"teacher_disagreement_score":0.58791274,"about_ca_system_score_codex":0.0002762916,"about_ca_system_score_gemma":0.0012393086,"threshold_uncertainty_score":0.4568566},"labels":[],"label_agreement":null},{"id":"W4399393998","doi":"10.1200/jco.2024.42.16_suppl.4505","title":"Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Axitinib; Sunitinib; Renal cell carcinoma; Pembrolizumab; Biomarker; Oncology; Internal medicine; Kidney cancer; Cancer; Immunotherapy","score_opus":0.20354513893132523,"score_gpt":0.4965729459471428,"score_spread":0.29302780701581754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399393998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227834,0.0012913211,0.00015450403,0.0010169926,0.0018960225,0.0009380955,0.00007255502,0.000010402303,0.0023417936],"genre_scores_gemma":[0.99814296,0.000083647275,0.000805591,0.00012438247,0.00042035844,0.000022443539,0.000017450793,0.000036439822,0.00034671577],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99387157,0.0007730332,0.00384714,0.0003846152,0.0007872199,0.00033639814],"domain_scores_gemma":[0.9887141,0.0069883903,0.0024174133,0.0005863904,0.0009521849,0.00034153377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002721349,0.00027912023,0.0028708535,0.00061990845,0.000057113506,0.000010790497,0.0003882167,0.00033153375,0.00018929593],"category_scores_gemma":[0.0020433709,0.00016745701,0.0024238664,0.0010507709,0.00031984973,0.00009303164,0.00011613434,0.00077304995,0.0000030289548],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50232,0.050461385,0.051747285,0.0012655599,0.04471979,0.00555782,0.0037925572,0.0018171011,0.027870221,0.0002871828,0.0074715056,0.30268958],"study_design_scores_gemma":[0.2440427,0.2361463,0.4029381,0.00033135046,0.069876954,0.00026815396,0.004242375,0.006616275,0.014450893,0.000104912746,0.020546451,0.00043554322],"about_ca_topic_score_codex":0.000047255246,"about_ca_topic_score_gemma":0.000101482954,"teacher_disagreement_score":0.3511908,"about_ca_system_score_codex":0.00037137355,"about_ca_system_score_gemma":0.0023701272,"threshold_uncertainty_score":0.68286985},"labels":[],"label_agreement":null},{"id":"W4399394081","doi":"10.1200/jco.2024.42.16_suppl.e16566","title":"Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Observational study; Urothelial carcinoma; Oncology; Internal medicine; Cancer; Bladder cancer","score_opus":0.594388247313195,"score_gpt":0.5451450472887684,"score_spread":0.0492432000244265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877721,0.00091250415,0.00004905376,0.006475572,0.0020948597,0.001959844,0.00005044834,0.00001733615,0.00066826533],"genre_scores_gemma":[0.9954706,0.00007686151,0.0023373098,0.00067643693,0.00071440876,0.00017460111,0.000007457996,0.000032452197,0.00050991296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951835,0.00063325,0.0029240435,0.00037058865,0.00043396675,0.00045461633],"domain_scores_gemma":[0.994216,0.0040770443,0.0005517543,0.0002080343,0.0003609993,0.0005861305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036981155,0.00021079832,0.001542658,0.0007937082,0.000039875144,0.000044152577,0.00022521801,0.00016997544,0.000102276346],"category_scores_gemma":[0.0040841633,0.00016053584,0.00039668145,0.0005987966,0.000074591655,0.00027843873,0.00002397095,0.0007996439,0.000014071174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005034964,0.0023010634,0.9737516,0.0002564611,0.00048640405,0.004665963,0.000703801,0.000035612353,0.000012906445,0.00044265657,0.0011409357,0.011167632],"study_design_scores_gemma":[0.02123003,0.0072498047,0.95993316,0.0008671712,0.0006605458,0.00017692058,0.0012884275,0.003381518,0.000012173262,0.00009117713,0.0049711773,0.00013789377],"about_ca_topic_score_codex":0.19322914,"about_ca_topic_score_gemma":0.7344382,"teacher_disagreement_score":0.54120904,"about_ca_system_score_codex":0.0022583713,"about_ca_system_score_gemma":0.022895306,"threshold_uncertainty_score":0.98264396},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4399394132","doi":"10.1200/jco.2024.42.16_suppl.4502","title":"Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma US","keywords":"Medicine; Internal medicine; Gemcitabine; Progression-free survival; Brief Pain Inventory; Quality of life (healthcare); Cancer; Carboplatin; Hazard ratio; Chemotherapy; Gastroenterology; Randomized controlled trial; Cisplatin; Oncology; Urology; Confidence interval; Physical therapy; Chronic pain","score_opus":0.09391004980722414,"score_gpt":0.47658217233799316,"score_spread":0.382672122530769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98846185,0.0016736476,0.0005594056,0.001902887,0.0034530843,0.0031337242,0.000118156444,0.00004408671,0.00065314973],"genre_scores_gemma":[0.9944336,0.0014456848,0.0021379837,0.0008523663,0.0005472594,0.00028796936,0.00002547263,0.00007613538,0.00019353675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99148124,0.0012380658,0.005568841,0.00047522888,0.0008113334,0.00042526913],"domain_scores_gemma":[0.98389465,0.012324096,0.0026303004,0.00034340424,0.00040889616,0.0003986416],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023290785,0.00044724345,0.005143073,0.0003443613,0.000031008236,0.000026484933,0.00020149846,0.0004224664,0.0011681974],"category_scores_gemma":[0.0069281324,0.00026901645,0.0013911105,0.00040076385,0.0003985025,0.00016756986,0.000025523655,0.0010565193,0.000008757247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7670813,0.0039716293,0.0007817007,0.00009622849,0.0038967454,0.0026912282,0.00048438346,0.00019787137,0.00010190684,0.000012785313,0.0001893101,0.22049487],"study_design_scores_gemma":[0.9479489,0.038498204,0.0007232493,0.00074936886,0.0039913286,0.00007300542,0.00010040463,0.0025714242,0.0008144197,0.00017129889,0.0041336245,0.00022480421],"about_ca_topic_score_codex":0.00080411276,"about_ca_topic_score_gemma":0.00050945673,"teacher_disagreement_score":0.22027007,"about_ca_system_score_codex":0.00063889497,"about_ca_system_score_gemma":0.014752995,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W4399394190","doi":"10.1200/jco.2024.42.16_suppl.4508","title":"Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Medicine; Axitinib; Renal cell carcinoma; Sunitinib; Javelin; Internal medicine; Oncology; Avelumab; Urology; Cancer; Immunotherapy; Nivolumab","score_opus":0.10584516674255887,"score_gpt":0.41340355821170205,"score_spread":0.3075583914691432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055713,0.0007819042,0.00020038856,0.0033502567,0.0013333212,0.0008262394,0.00011560316,0.000021763359,0.0028133977],"genre_scores_gemma":[0.99383,0.0002173992,0.002182072,0.0009352284,0.0020727096,0.000025337553,0.00020390992,0.00005694781,0.00047635107],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9912881,0.0018305241,0.0042072027,0.00070198043,0.001350242,0.00062192883],"domain_scores_gemma":[0.9889402,0.007255447,0.0018455117,0.00061868463,0.0006868312,0.00065336993],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004205124,0.00047908424,0.0030712187,0.0005300908,0.00008985809,0.00006512265,0.00046447635,0.00050334894,0.0010363165],"category_scores_gemma":[0.0016683986,0.0002752387,0.001548148,0.00091631856,0.00034520816,0.0002291016,0.00011829602,0.0025512886,0.00005633343],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6661796,0.016211083,0.18072663,0.00007415791,0.0045711976,0.013458992,0.0006766603,0.00041033333,0.00026298175,0.000068107234,0.0052918266,0.11206845],"study_design_scores_gemma":[0.30514273,0.08212438,0.58266073,0.00029321926,0.0065260096,0.00009374529,0.00020561508,0.0006769684,0.00037528586,0.00015698631,0.021391008,0.0003533042],"about_ca_topic_score_codex":0.0002795167,"about_ca_topic_score_gemma":0.00047694964,"teacher_disagreement_score":0.40193412,"about_ca_system_score_codex":0.0006519879,"about_ca_system_score_gemma":0.0031023596,"threshold_uncertainty_score":0.99996996},"labels":[],"label_agreement":null},{"id":"W4399394205","doi":"10.1200/jco.2024.42.16_suppl.e16555","title":"Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Urothelial carcinoma; Oncology; Urothelial cancer; Internal medicine; Solid tumor; Bladder cancer; Cancer","score_opus":0.061673013247210036,"score_gpt":0.40888773095158637,"score_spread":0.34721471770437634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020064,0.00036813656,0.000020488003,0.0072303344,0.00043907078,0.0011467017,0.000026479544,0.000011052277,0.0005570942],"genre_scores_gemma":[0.9962755,0.00044424637,0.0004035093,0.0022734022,0.00045218293,0.000039041468,0.000020128004,0.00003095166,0.00006103857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651384,0.0006739293,0.0015782099,0.00031534678,0.0006719758,0.00024670898],"domain_scores_gemma":[0.9962342,0.002427175,0.00065880443,0.00031451604,0.00025733263,0.000107983156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019507933,0.00021258269,0.0010429773,0.00010543937,0.000051069717,0.00003339327,0.00024317195,0.00018206179,0.000028452],"category_scores_gemma":[0.00051638455,0.00007864459,0.00014312645,0.00034092186,0.00020049285,0.00019054282,0.000023295572,0.0011036693,0.0000061419605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11610721,0.0033199717,0.8032315,0.000009982268,0.00025215323,0.00087479554,0.0021930854,0.000033638975,0.000017383054,0.000015425669,0.00026433915,0.07368054],"study_design_scores_gemma":[0.05559227,0.04312542,0.8981054,0.000555273,0.00019849338,0.00006788095,0.00043668682,0.00012465012,0.00004179261,0.00014297907,0.0015112666,0.00009791428],"about_ca_topic_score_codex":0.00035014906,"about_ca_topic_score_gemma":0.0006671235,"teacher_disagreement_score":0.094873905,"about_ca_system_score_codex":0.0002218686,"about_ca_system_score_gemma":0.0019673542,"threshold_uncertainty_score":0.47949556},"labels":[],"label_agreement":null},{"id":"W4399394226","doi":"10.1200/jco.2024.42.16_suppl.tps4619","title":"A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Urinary and Genital Oncology Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Urothelial cancer; Medicine; Cancer; Conjugate; Toxin; Cancer research; Internal medicine; Oncology; Bladder cancer; Microbiology; Biology","score_opus":0.07983621505020365,"score_gpt":0.48293748890758076,"score_spread":0.4031012738573771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995065,0.00072191464,0.000059668673,0.0019374632,0.0010018114,0.0007272129,0.000010853866,0.00001252631,0.0004636017],"genre_scores_gemma":[0.9971452,0.00020168246,0.0014995304,0.00051763735,0.0003108455,0.00003560247,0.000001206655,0.00002570423,0.00026259074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956791,0.00075767754,0.0026063723,0.0002827046,0.00039086334,0.00028329305],"domain_scores_gemma":[0.9938283,0.0043173213,0.001057299,0.00012687792,0.00045988426,0.0002103412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024649657,0.00020966707,0.0019545157,0.00023971485,0.000044301523,0.000007857389,0.00014009215,0.000160448,0.00014084303],"category_scores_gemma":[0.003517765,0.00012140624,0.00021533296,0.00039810204,0.00029418347,0.0001740677,0.00007315059,0.0011051031,0.0000056801446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19305338,0.06303131,0.42976165,0.0003631158,0.0042864806,0.012218279,0.003420719,0.00033678344,0.00036678513,0.000028811723,0.0011328578,0.29199985],"study_design_scores_gemma":[0.12464261,0.37973866,0.47395605,0.0008236271,0.0023808149,0.00027080727,0.004529964,0.0002857747,0.00019473885,0.00013570707,0.012731793,0.00030943827],"about_ca_topic_score_codex":0.00003414416,"about_ca_topic_score_gemma":0.00029764368,"teacher_disagreement_score":0.31670734,"about_ca_system_score_codex":0.00014097923,"about_ca_system_score_gemma":0.0019694131,"threshold_uncertainty_score":0.4950803},"labels":[],"label_agreement":null},{"id":"W4399394238","doi":"10.1200/jco.2024.42.16_suppl.e16588","title":"Retrospective analysis of outcomes of patients with bladder cancer when neoadjuvant chemotherapy is delayed.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatchewan Health; University of Saskatchewan","funders":"","keywords":"Medicine; Chemotherapy; Bladder cancer; Oncology; Retrospective cohort study; Neoadjuvant therapy; Internal medicine; Urothelial cancer; Cancer; Breast cancer","score_opus":0.0503117136924127,"score_gpt":0.4411368286301796,"score_spread":0.3908251149377669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181587,0.0011239211,0.00020190745,0.004791531,0.00060949754,0.00019253786,0.00013060152,0.000006635074,0.0011275306],"genre_scores_gemma":[0.9950302,0.0009911715,0.0012525894,0.0020263453,0.00021507911,0.000003901575,0.000004784206,0.000020782434,0.00045510172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731565,0.00010019609,0.0016987787,0.00020096137,0.00052992464,0.00015447065],"domain_scores_gemma":[0.9972797,0.00043499234,0.001116958,0.00019521844,0.0007976085,0.00017551062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058377744,0.0001506875,0.0022399926,0.00029777316,0.000013097602,0.000004459967,0.000113650574,0.00021730826,0.0015078149],"category_scores_gemma":[0.00018158166,0.000083523526,0.00087340316,0.0004264755,0.00018975421,0.00008170378,0.000018371355,0.00044090988,0.0000023712448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038445112,0.0014513211,0.9125495,0.00002407677,0.030030182,0.000059495942,0.00064224843,0.000011207176,0.00001562164,0.000025204201,0.002963168,0.04838349],"study_design_scores_gemma":[0.0069780657,0.012227948,0.9633999,0.000089614,0.010851208,0.000004236591,0.000051055635,0.00008126326,0.00015008691,0.00019508171,0.005899827,0.00007169663],"about_ca_topic_score_codex":0.00021183312,"about_ca_topic_score_gemma":0.00013551317,"teacher_disagreement_score":0.050850444,"about_ca_system_score_codex":0.00020042657,"about_ca_system_score_gemma":0.0012184577,"threshold_uncertainty_score":0.99940497},"labels":[],"label_agreement":null},{"id":"W4399394263","doi":"10.1200/jco.2024.42.16_suppl.e16608","title":"Bladder preservation in muscle invasive bladder cancer (MIBC): A population based analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bladder cancer; Medicine; Urology; Population; Cystectomy; Oncology; Cancer; Internal medicine","score_opus":0.1381305796862013,"score_gpt":0.4917405913472761,"score_spread":0.3536100116610748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023754,0.0019295169,0.00052196585,0.013966592,0.0013199548,0.0002900127,0.000013139736,0.000019555193,0.0017017187],"genre_scores_gemma":[0.99367,0.0005827413,0.0009594116,0.0032156135,0.0010835036,0.00001909003,0.000021543849,0.000018575693,0.00042950478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970991,0.0003295775,0.0017449866,0.00024426114,0.0003887587,0.00019331591],"domain_scores_gemma":[0.9974865,0.0013146902,0.0005437416,0.00016535676,0.0002799121,0.00020983229],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001452094,0.00013430353,0.0011186744,0.00049575215,0.000021898737,0.00002011914,0.000096497984,0.0003276491,0.0010330015],"category_scores_gemma":[0.0011644413,0.00009554533,0.000619547,0.0008103222,0.00004937406,0.00026779468,0.000019935338,0.0006821073,0.000014595341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017778067,0.0014078802,0.8642235,0.000084672545,0.0039437246,0.0009075847,0.00024034224,0.0019609686,0.00017042083,0.000087347486,0.0047474876,0.120448284],"study_design_scores_gemma":[0.004255695,0.0025002668,0.9687278,0.00015858722,0.0032939045,0.000014438645,0.000041820353,0.004113483,0.0000514227,0.0005042263,0.016251326,0.000087022694],"about_ca_topic_score_codex":0.0010079984,"about_ca_topic_score_gemma":0.003465012,"teacher_disagreement_score":0.12036126,"about_ca_system_score_codex":0.00037371818,"about_ca_system_score_gemma":0.0026530465,"threshold_uncertainty_score":0.9998802},"labels":[],"label_agreement":null},{"id":"W4399394383","doi":"10.1200/jco.2024.42.16_suppl.e16594","title":"Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; University of Toronto; Dalhousie University; University Health Network; Juravinski Cancer Centre; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; University of Calgary","funders":"Janssen Biotech","keywords":"Medicine; Bladder cancer; Clinical Practice; Urothelial cancer; Oncology; Cancer; Internal medicine; Urology; Family medicine","score_opus":0.08410808203693014,"score_gpt":0.47728455489016003,"score_spread":0.3931764728532299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8708755,0.0029457107,0.00005607972,0.08168261,0.005988542,0.00066738547,0.00015310821,0.000016902723,0.037614167],"genre_scores_gemma":[0.96972257,0.019221855,0.0014842212,0.0067163375,0.0019552694,0.000017752915,0.000005024599,0.000038652775,0.0008383006],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99591756,0.0006941953,0.0022482052,0.00030318787,0.00046609505,0.00037077095],"domain_scores_gemma":[0.9896127,0.0072058984,0.001513023,0.00025850872,0.0007397414,0.0006701541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002931699,0.0001956531,0.0013752559,0.00047940906,0.000035348625,0.000020248037,0.00017945838,0.0003665844,0.00076873123],"category_scores_gemma":[0.0069464096,0.00014590038,0.00036450554,0.00041115624,0.00011321045,0.0004519396,0.000039920375,0.0017875214,0.00004084949],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00741835,0.0041065374,0.42301184,0.000307776,0.005855487,0.022203982,0.0021974149,0.00014095324,0.0001060422,0.0005224848,0.03792919,0.49619994],"study_design_scores_gemma":[0.006754984,0.008755736,0.663514,0.0007808163,0.0032377308,0.00034058635,0.00090988976,0.00003642428,0.00014031357,0.00030849074,0.31506106,0.00015995305],"about_ca_topic_score_codex":0.48575655,"about_ca_topic_score_gemma":0.6101228,"teacher_disagreement_score":0.49604,"about_ca_system_score_codex":0.00085634517,"about_ca_system_score_gemma":0.015292389,"threshold_uncertainty_score":0.99029},"labels":[],"label_agreement":null},{"id":"W4399394385","doi":"10.1200/jco.2024.42.16_suppl.e16596","title":"Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; University of Toronto; Dalhousie University; University Health Network; Juravinski Cancer Centre; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; University of Calgary","funders":"Janssen Biotech","keywords":"Medicine; Bladder cancer; Oncology; Cancer; Internal medicine","score_opus":0.08483007707924406,"score_gpt":0.4404339630763551,"score_spread":0.355603885997111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98070824,0.00045750538,2.7356964e-7,0.00932362,0.00078980933,0.00042230875,0.00001734468,0.0000058084465,0.00827506],"genre_scores_gemma":[0.994251,0.0018178872,0.00012779648,0.0010760998,0.00043436402,0.000032164095,0.000009987569,0.000028201352,0.0022225124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730295,0.000292535,0.0014618465,0.00028897074,0.0003648039,0.00028891562],"domain_scores_gemma":[0.996029,0.0023725287,0.00094017526,0.00015677698,0.00020559989,0.00029589902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004372045,0.00020497908,0.0012060262,0.00025442915,0.00001903418,0.000013678152,0.00009027024,0.00017659996,0.00035291587],"category_scores_gemma":[0.0006253838,0.00012132798,0.00015039906,0.00042798874,0.00007495123,0.0001822228,0.000016226444,0.0006079974,0.000006887193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047320933,0.0023591155,0.92426145,0.00003010749,0.00081371405,0.0025297434,0.00024663148,0.000029381854,0.0000030303304,0.0000131839215,0.0024499772,0.06253155],"study_design_scores_gemma":[0.013912218,0.010589268,0.9221917,0.00035719803,0.00069778675,0.000018277766,0.0000778208,0.000020777818,0.0000439314,0.000025230776,0.051958837,0.00010697234],"about_ca_topic_score_codex":0.85539675,"about_ca_topic_score_gemma":0.9929741,"teacher_disagreement_score":0.13757735,"about_ca_system_score_codex":0.0021839761,"about_ca_system_score_gemma":0.013103319,"threshold_uncertainty_score":0.9924915},"labels":[],"label_agreement":null},{"id":"W4399394450","doi":"10.1200/jco.2024.42.16_suppl.5030","title":"Impact of mental health illness (MHI) prior to prostate cancer (PC) diagnosis (Dx) on treatment (Tx) received and PC outcomes.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Resilience and Mental Health","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Oncology; Gynecology; Internal medicine","score_opus":0.15798816359916326,"score_gpt":0.6219350570706516,"score_spread":0.4639468934714883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651759,0.002546869,0.000004080858,0.026449569,0.0041797035,0.0007317716,0.00010084225,0.000011304754,0.00079991086],"genre_scores_gemma":[0.9820638,0.012635195,0.0001540963,0.0033727114,0.00039354025,0.000066580295,0.0000029412738,0.000024337734,0.001286838],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960859,0.0006555282,0.0021681613,0.00035681506,0.00028373284,0.0004498754],"domain_scores_gemma":[0.99614406,0.0018402839,0.0009844858,0.00020239573,0.000088478046,0.00074031326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019025428,0.00022507171,0.0015421396,0.00021695747,0.0000847963,0.00001560042,0.00016920498,0.00022526235,0.0004895076],"category_scores_gemma":[0.00022960702,0.0001301945,0.0005169574,0.00019177982,0.0001600213,0.00010135467,0.000040277788,0.0005043232,0.00005115218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00330597,0.0021373508,0.27700028,0.000035438203,0.00046848733,0.00013491476,0.004408813,0.000017908726,0.000014596005,0.000060622566,0.012338796,0.7000768],"study_design_scores_gemma":[0.004676271,0.0664716,0.8677623,0.00033370283,0.00008508777,0.000101475394,0.0007408824,0.000010795834,0.000036831036,0.000086487395,0.05955433,0.00014021088],"about_ca_topic_score_codex":0.0019402124,"about_ca_topic_score_gemma":0.000642764,"teacher_disagreement_score":0.6999366,"about_ca_system_score_codex":0.0012603252,"about_ca_system_score_gemma":0.00207616,"threshold_uncertainty_score":0.5359765},"labels":[],"label_agreement":null},{"id":"W4399394481","doi":"10.1200/jco.2024.42.16_suppl.5023","title":"Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Oncology; Internal medicine; Cancer; Pathology; Prostate cancer; Alternative medicine","score_opus":0.11996644588690984,"score_gpt":0.46293829670586434,"score_spread":0.3429718508189545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453914,0.0005075285,0.000055512744,0.0007122238,0.00039500633,0.0036791516,0.000054378455,0.0000091065995,0.00004795398],"genre_scores_gemma":[0.99855447,0.0002327385,0.00070042606,0.000095026124,0.000089720575,0.00023692872,0.000030198149,0.00003330766,0.000027158385],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99559826,0.00044035472,0.0028445052,0.0003726248,0.0004970136,0.00024723657],"domain_scores_gemma":[0.99431753,0.0029915576,0.0018777382,0.00015285425,0.0004648393,0.00019548844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017314536,0.00025035333,0.0014207117,0.00040985912,0.000041376763,0.000015975169,0.000072956085,0.00011558133,0.000035485537],"category_scores_gemma":[0.0010132934,0.00018230586,0.00017046841,0.0003920274,0.00019456964,0.00031521177,0.000020113028,0.00034789453,0.0000011595254],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35452607,0.081709996,0.44313633,0.0033974885,0.0030266563,0.0029592249,0.017353173,0.009473737,0.014716329,0.000063587955,0.00015707269,0.069480315],"study_design_scores_gemma":[0.41161653,0.40549463,0.1413197,0.005744624,0.0030052294,0.00016770612,0.008343201,0.009048276,0.013045202,0.00034737805,0.0013071921,0.0005603267],"about_ca_topic_score_codex":0.00032432622,"about_ca_topic_score_gemma":0.0007656235,"teacher_disagreement_score":0.32378465,"about_ca_system_score_codex":0.00063161616,"about_ca_system_score_gemma":0.0019138802,"threshold_uncertainty_score":0.7434217},"labels":[],"label_agreement":null},{"id":"W4399394511","doi":"10.1200/jco.2024.42.16_suppl.5003","title":"Health-related quality of life and pain in a phase 3 study of [<sup>177</sup>Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Internal medicine; Oncology; Prostate; Cancer; Gynecology; Breast cancer","score_opus":0.1751515806080398,"score_gpt":0.5319333964631774,"score_spread":0.3567818158551376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349344,0.0010632852,0.000020687288,0.0044296705,0.00004952525,0.0008304184,0.000057089663,0.0000051094457,0.000050774324],"genre_scores_gemma":[0.9988712,0.00023698555,0.00045935359,0.00029070082,0.000058477613,0.00003494416,0.000010148864,0.000012867064,0.0000253424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939799,0.0009586736,0.0042170514,0.0002464355,0.0003874314,0.00021051828],"domain_scores_gemma":[0.9951284,0.0024850392,0.0015819715,0.00015115553,0.00028026922,0.0003731669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058463775,0.00014766671,0.0017051413,0.00013748577,0.000022505672,0.0000068281774,0.000092259914,0.00013224264,0.00004780231],"category_scores_gemma":[0.0024344847,0.00010209116,0.0001155759,0.00044602863,0.00024549707,0.00009084046,0.000021124422,0.0009805525,4.0823167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039195567,0.0386575,0.7248849,0.0026270899,0.0015418403,0.0006320885,0.0058866413,0.0017220427,0.0013656336,0.00016141984,0.0005165529,0.18280871],"study_design_scores_gemma":[0.09822967,0.05501598,0.8255272,0.0015951358,0.0008033752,0.000058437854,0.009044578,0.007395991,0.00021583543,0.0005199708,0.001261111,0.00033270236],"about_ca_topic_score_codex":0.000479236,"about_ca_topic_score_gemma":0.00054901926,"teacher_disagreement_score":0.18247601,"about_ca_system_score_codex":0.0001518052,"about_ca_system_score_gemma":0.0020281537,"threshold_uncertainty_score":0.42600673},"labels":[],"label_agreement":null},{"id":"W4399394528","doi":"10.1200/jco.2024.42.16_suppl.5101","title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostatectomy; Enzalutamide; Prostate cancer; Salvage therapy; Radiation therapy; Internal medicine; Biochemical recurrence; Urology; Oncology; Surgery; Cancer; Chemotherapy","score_opus":0.029562522535720417,"score_gpt":0.3630893649449603,"score_spread":0.3335268424092399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429464,0.00053451565,0.00021694663,0.0029021385,0.0009042917,0.00035705496,0.000021629554,0.00002393303,0.0007448498],"genre_scores_gemma":[0.9941653,0.00029766993,0.0041778684,0.00042202423,0.00079559686,0.000005046442,0.00006465493,0.000032776257,0.00003907529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950348,0.0007323854,0.002849818,0.00037647263,0.00074672105,0.00025980923],"domain_scores_gemma":[0.98471296,0.013121524,0.0011838718,0.00024868155,0.000402283,0.00033067862],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028767723,0.00021277955,0.002062413,0.0002658353,0.000029718021,0.000020607376,0.00012707816,0.00047504567,0.000018706147],"category_scores_gemma":[0.0128198415,0.0001313817,0.0006197539,0.00041629435,0.00029299047,0.00020069674,0.000031653235,0.0014832189,0.000007679994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065675065,0.0020185574,0.8657467,0.0001231676,0.0018451902,0.005925611,0.0009251745,0.00009707453,0.00029413062,0.0006135268,0.0007952062,0.055940617],"study_design_scores_gemma":[0.03940388,0.008592259,0.9342834,0.0014315214,0.0012914244,0.00012450626,0.0002462697,0.00014102375,0.0005802343,0.00018152317,0.0134993745,0.00022459167],"about_ca_topic_score_codex":0.00009738716,"about_ca_topic_score_gemma":0.000037885762,"teacher_disagreement_score":0.06853671,"about_ca_system_score_codex":0.0002461214,"about_ca_system_score_gemma":0.0016111569,"threshold_uncertainty_score":0.9954956},"labels":[],"label_agreement":null},{"id":"W4399394556","doi":"10.1200/jco.2024.42.16_suppl.5089","title":"A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Castration; Internal medicine; Oncology; Androgen; Clinical trial; Androgen receptor; Urology; Cancer; Gynecology; Hormone","score_opus":0.12210646872439937,"score_gpt":0.4901304543807966,"score_spread":0.36802398565639727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931404,0.0010538992,0.00043654608,0.0024304036,0.0002821001,0.0021091423,0.000033613265,0.000015487774,0.000498392],"genre_scores_gemma":[0.99204504,0.0014531662,0.00424749,0.00016739356,0.0014812687,0.00013899666,0.00006417589,0.000038888586,0.0003635669],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973059,0.00026568066,0.0013122299,0.00033697695,0.0005000277,0.00027914805],"domain_scores_gemma":[0.99730617,0.00059399306,0.00081441196,0.00016773104,0.000800534,0.000317151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020936413,0.00019306508,0.0010396761,0.00020393323,0.000097004166,0.00002858804,0.00008824709,0.0002259684,0.00002354834],"category_scores_gemma":[0.0002657689,0.00010809244,0.00021541573,0.00027492928,0.00030184252,0.0003212892,0.00002128798,0.00063404825,4.6474085e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6900534,0.010836851,0.003082399,0.00019301541,0.0027698365,0.0007699959,0.003553513,0.0001662054,0.0057926113,0.000120329416,0.0012368767,0.28142497],"study_design_scores_gemma":[0.540026,0.3826308,0.002630726,0.0009925582,0.0016944852,0.00091701024,0.0022446238,0.0033859708,0.058132686,0.0003853545,0.006591785,0.00036800053],"about_ca_topic_score_codex":0.00013307045,"about_ca_topic_score_gemma":0.00004195538,"teacher_disagreement_score":0.37179396,"about_ca_system_score_codex":0.00023516302,"about_ca_system_score_gemma":0.0047334423,"threshold_uncertainty_score":0.83969235},"labels":[],"label_agreement":null},{"id":"W4399394560","doi":"10.1200/jco.2024.42.16_suppl.5084","title":"EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adolescent Sexual and Reproductive Health","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Sexually active; Post-hoc analysis; Post hoc; Oncology; Gynecology; Internal medicine; Family medicine","score_opus":0.22235359516834036,"score_gpt":0.5566811562651846,"score_spread":0.3343275610968442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089706,0.00009562176,0.00005245666,0.004474532,0.0031753168,0.00094787026,0.00012495989,0.00002462237,0.00020754755],"genre_scores_gemma":[0.9957396,0.00012577376,0.00015467149,0.0016098458,0.00041248082,0.000015305814,0.000040483093,0.000038935843,0.0018629455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9856515,0.0054879915,0.0066561126,0.00076607487,0.0007579756,0.0006803717],"domain_scores_gemma":[0.98486626,0.008589563,0.004506754,0.0004906064,0.00108588,0.0004609379],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0077997735,0.00035779795,0.003615317,0.0012855781,0.00013449279,0.000006912535,0.0003262751,0.0009460802,0.0005276703],"category_scores_gemma":[0.011331451,0.00022598015,0.0004087509,0.0015159324,0.0002570776,0.00036844378,0.00039903095,0.0038029419,0.000024921923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021208445,0.0061269538,0.8422825,0.00035186522,0.0017688393,0.0003929636,0.004171026,0.00007631275,0.00011324473,0.000009469814,0.0011632151,0.12233522],"study_design_scores_gemma":[0.0058743944,0.013584565,0.9715968,0.0003786745,0.00071071606,0.0000069120697,0.004048442,0.0006025803,0.000013995962,0.000028124286,0.0029393195,0.00021547188],"about_ca_topic_score_codex":0.0003942411,"about_ca_topic_score_gemma":0.008773707,"teacher_disagreement_score":0.12931436,"about_ca_system_score_codex":0.0012978164,"about_ca_system_score_gemma":0.0038038152,"threshold_uncertainty_score":0.99849534},"labels":[],"label_agreement":null},{"id":"W4399394602","doi":"10.1200/jco.2024.42.16_suppl.e17087","title":"Prevalence of mutations associated with NCCN criteria for hereditary prostate cancer testing in an Indian population.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Genetic testing; Prostate; Population; Hereditary Cancer; Internal medicine; Gynecology; Breast cancer; Environmental health","score_opus":0.635903706185758,"score_gpt":0.5993551690462108,"score_spread":0.0365485371395472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98489445,0.0015040506,0.0002796809,0.010937392,0.0014024246,0.0004527999,0.00037966206,0.000010920392,0.00013862191],"genre_scores_gemma":[0.98939246,0.000087439636,0.008371952,0.0012657668,0.00069854164,0.000046685793,0.000016663764,0.000020688174,0.00009979387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99136233,0.0005880373,0.007504022,0.00025093858,0.000085150175,0.0002095183],"domain_scores_gemma":[0.98484313,0.009342719,0.0051999562,0.00012749893,0.00032553423,0.00016117259],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028086089,0.00009853509,0.0012727769,0.00033225524,0.000046781726,0.000026680884,0.00017390978,0.00022263787,0.000094988405],"category_scores_gemma":[0.025691418,0.000097283104,0.00012954937,0.00025137368,0.00008872344,0.0006726492,0.000014526312,0.0003741947,0.000006996237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014398892,0.0003658155,0.98792523,0.0006616809,0.00013320998,0.000022406413,0.0015093772,0.0015018858,0.0000017420957,0.0014404443,0.0014907129,0.0048034843],"study_design_scores_gemma":[0.0014969608,0.0024246266,0.9676154,0.0007480251,0.000036949037,0.000014714329,0.00036104076,0.013219964,7.148846e-7,0.012977339,0.0009827678,0.000121475176],"about_ca_topic_score_codex":0.0005817797,"about_ca_topic_score_gemma":0.0015724845,"teacher_disagreement_score":0.02030983,"about_ca_system_score_codex":0.00047648695,"about_ca_system_score_gemma":0.0013196664,"threshold_uncertainty_score":0.9825156},"labels":[],"label_agreement":null},{"id":"W4399394714","doi":"10.1200/jco.2024.42.16_suppl.5005","title":"EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Post-hoc analysis; Post hoc; Quality of life (healthcare); Health related quality of life; Gerontology; Internal medicine; Disease; Nursing","score_opus":0.6938739689974401,"score_gpt":0.6320979693535392,"score_spread":0.0617759996439009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708193,0.005640318,0.00011835429,0.020615922,0.0011693623,0.00029460154,0.00041137703,0.000007759907,0.00092302565],"genre_scores_gemma":[0.995438,0.0019547201,0.0006142017,0.0015902059,0.00025299366,0.0000027558826,0.000022598206,0.000019461224,0.000105086874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97116745,0.002530922,0.025447033,0.000370919,0.00019537605,0.0002883339],"domain_scores_gemma":[0.9602496,0.01579674,0.022562362,0.0004803534,0.0004405104,0.000470441],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.058710497,0.00020367435,0.0071026995,0.001269483,0.00004003458,0.000011181845,0.00027943976,0.00045891647,0.00095034007],"category_scores_gemma":[0.020128375,0.00017399945,0.0025166976,0.0007243811,0.0002060833,0.00019811795,0.000037208487,0.00047596684,0.000088752364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013179019,0.011774548,0.7188572,0.0021060016,0.04830907,0.000040778406,0.008012354,0.03037653,0.00011852345,0.0848803,0.040398587,0.04194706],"study_design_scores_gemma":[0.0044943173,0.037426725,0.94065195,0.00028103637,0.00046764524,0.00000861767,0.00062554434,0.006762347,0.000006137805,0.004113966,0.0049395147,0.00022220176],"about_ca_topic_score_codex":0.005039106,"about_ca_topic_score_gemma":0.00097426015,"teacher_disagreement_score":0.22179471,"about_ca_system_score_codex":0.0015643608,"about_ca_system_score_gemma":0.00430998,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W4399394761","doi":"10.1200/jco.2024.42.16_suppl.tps5123","title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Placebo; Homologous recombination; Oncology; Hormonal therapy; Internal medicine; Cancer; Hormone; Cohort; Prostate; Urology; Pathology; Gene","score_opus":0.0818484846970013,"score_gpt":0.4552824990079004,"score_spread":0.3734340143108991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042493,0.0003658354,0.00014650973,0.0008350737,0.00017753635,0.007907335,0.000009080617,0.000015300624,0.000118399454],"genre_scores_gemma":[0.99792725,0.0004015763,0.0009361816,0.00005155733,0.000048848466,0.00030527153,0.00006339201,0.000030242833,0.00023567936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995194,0.00093338307,0.002340639,0.00041389992,0.00083109376,0.00028693778],"domain_scores_gemma":[0.9957301,0.0013619125,0.0015249674,0.000130357,0.0010133781,0.00023926554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043429085,0.00027047005,0.0025394289,0.0006708835,0.00004544658,0.00003571547,0.00006201248,0.0001413803,0.000021399746],"category_scores_gemma":[0.00035199893,0.00014908945,0.00013664647,0.0005531492,0.0003299369,0.00044454174,0.000020896883,0.0008529926,6.0431074e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7181968,0.007962873,0.25726205,0.00007668062,0.0022600722,0.0009985219,0.0020694877,0.00035800936,0.000004879353,0.000018215987,0.000037831956,0.010754582],"study_design_scores_gemma":[0.7691241,0.058231212,0.16723973,0.0005161633,0.0017137495,0.00010660513,0.00090794265,0.001889826,0.000040645857,0.00009655505,0.0000065648096,0.00012694321],"about_ca_topic_score_codex":0.0009138781,"about_ca_topic_score_gemma":0.0018981004,"teacher_disagreement_score":0.09002234,"about_ca_system_score_codex":0.0004619447,"about_ca_system_score_gemma":0.0029251943,"threshold_uncertainty_score":0.60796916},"labels":[],"label_agreement":null},{"id":"W4399394762","doi":"10.1200/jco.2024.42.16_suppl.5079","title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"Cancer Council Australia","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.1389513501519841,"score_gpt":0.49574053834411713,"score_spread":0.356789188192133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919725,0.0050899494,0.00005698237,0.004296081,0.00007583437,0.00061511464,0.0002419279,0.0000081148855,0.00041875461],"genre_scores_gemma":[0.9947999,0.0035483527,0.0008242326,0.000099379584,0.00007029718,0.000043240405,0.00003072629,0.000019583418,0.0005642714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965977,0.00043698776,0.0020157795,0.00026504064,0.00040893958,0.00027555175],"domain_scores_gemma":[0.9942798,0.0034414078,0.0010061093,0.00020552507,0.00082026544,0.000246916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018720119,0.00016672707,0.0020672076,0.00076000526,0.000024392053,0.000007534722,0.00010801995,0.00015219193,0.00009493352],"category_scores_gemma":[0.0010136749,0.00009601929,0.00047822317,0.0015487795,0.0003927917,0.000103361155,0.00004512193,0.0005761412,0.000002726084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015452125,0.0019200062,0.9119206,0.00023540627,0.015223253,0.0016523696,0.0010548652,0.0005288356,0.0048019006,0.00007082145,0.00067481847,0.046464983],"study_design_scores_gemma":[0.005859652,0.007518799,0.97318184,0.0003856372,0.009212207,0.00008570766,0.0002339445,0.00093126186,0.0015577404,0.000119020064,0.0008185473,0.00009566117],"about_ca_topic_score_codex":0.00031554388,"about_ca_topic_score_gemma":0.0010069056,"teacher_disagreement_score":0.061261207,"about_ca_system_score_codex":0.00043276936,"about_ca_system_score_gemma":0.0024104216,"threshold_uncertainty_score":0.42759845},"labels":[],"label_agreement":null},{"id":"W4399394822","doi":"10.1200/jco.2024.42.16_suppl.5046","title":"Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Oncology; Internal medicine; Prostate; Cancer","score_opus":0.09275739901400289,"score_gpt":0.5132912379548935,"score_spread":0.42053383894089064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742646,0.0027498102,0.0000015034592,0.008091557,0.0005680114,0.00075408764,0.00009985223,0.0000024188384,0.0003063152],"genre_scores_gemma":[0.99484754,0.0044737705,0.000040075607,0.000052163956,0.00008997718,0.00003323719,0.000004105256,0.000009884092,0.00044925124],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99519545,0.0021408845,0.001892117,0.00019094911,0.00040500038,0.00017557846],"domain_scores_gemma":[0.986981,0.011645182,0.00080672605,0.0002140387,0.00016335427,0.00018970916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0082001295,0.00013714982,0.0018714252,0.00044103013,0.000027374721,0.000007296956,0.000100117,0.00011430399,0.000070662674],"category_scores_gemma":[0.0015759346,0.000062409395,0.00054853683,0.00073917944,0.00043822522,0.000039201375,0.000026157637,0.00055369077,7.300503e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78032684,0.0021219286,0.0853696,0.00037699455,0.011735701,0.0017363603,0.0011160458,0.00009946539,0.0031672483,0.00005610185,0.00030633813,0.1135874],"study_design_scores_gemma":[0.11214992,0.14221093,0.72518283,0.0010472027,0.011265777,0.00003743805,0.00036624682,0.0007922725,0.0036627953,0.000093609306,0.0030886088,0.0001023825],"about_ca_topic_score_codex":0.00017154646,"about_ca_topic_score_gemma":0.0007419944,"teacher_disagreement_score":0.6681769,"about_ca_system_score_codex":0.0004062207,"about_ca_system_score_gemma":0.004086704,"threshold_uncertainty_score":0.7249637},"labels":[],"label_agreement":null},{"id":"W4399394859","doi":"10.1200/jco.2024.42.16_suppl.5083","title":"Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Post-hoc analysis; Oncology; Prostate cancer; Internal medicine; Placebo; Cancer; Pathology","score_opus":0.07924704356902992,"score_gpt":0.4753456979310896,"score_spread":0.3960986543620597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992754,0.0024214238,0.00002240963,0.0031914304,0.00044768036,0.0005973324,0.0003874268,0.000009610788,0.00016871523],"genre_scores_gemma":[0.9923416,0.0053727683,0.0011374804,0.00020715497,0.00015031513,0.000011026201,0.000097630786,0.000031451058,0.00065060356],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99552274,0.00072883535,0.0021427567,0.00031141753,0.00095881335,0.00033545602],"domain_scores_gemma":[0.9918365,0.003184325,0.0015946758,0.00021500967,0.0027907211,0.0003787812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022367612,0.00022104903,0.0025859904,0.00064171973,0.00003399298,0.000012864357,0.00012864174,0.0001884358,0.00015641263],"category_scores_gemma":[0.0016954712,0.00011254453,0.0006267791,0.000990729,0.00055705593,0.00016506515,0.00006291951,0.0008140546,0.000003956114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5451511,0.004155667,0.18076529,0.00058013515,0.033206433,0.004616871,0.0025051814,0.0002809382,0.0021552935,0.000013824724,0.0011860321,0.22538324],"study_design_scores_gemma":[0.024328118,0.07519064,0.8801348,0.0011719605,0.01388177,0.000039061113,0.0011827017,0.0010646473,0.0009602234,0.000028466633,0.001818178,0.00019938374],"about_ca_topic_score_codex":0.00008551536,"about_ca_topic_score_gemma":0.00024832672,"teacher_disagreement_score":0.69936955,"about_ca_system_score_codex":0.00026564984,"about_ca_system_score_gemma":0.0036821533,"threshold_uncertainty_score":0.6531982},"labels":[],"label_agreement":null},{"id":"W4399394861","doi":"10.1200/jco.2024.42.16_suppl.5063","title":"Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Enzalutamide; Eribulin; Abiraterone; Olaparib; Prostate cancer; Prednisone; CYP17A1; Internal medicine; Bicalutamide; Oncology; Prednisolone; Urology; Androgen receptor; Cancer; Metastatic breast cancer; Poly ADP ribose polymerase; Breast cancer","score_opus":0.1287155339789746,"score_gpt":0.4297501000838353,"score_spread":0.3010345661048607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909282,0.003020563,0.0007641161,0.0021888064,0.0011147115,0.0016549386,0.00023167153,0.000046205794,0.000050832805],"genre_scores_gemma":[0.990746,0.00198956,0.00651366,0.00020827807,0.00015159567,0.00016788633,0.000100130856,0.000052803753,0.00007005765],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956362,0.0004502603,0.0026529306,0.00045846385,0.00045784822,0.00034429075],"domain_scores_gemma":[0.9940523,0.0030783575,0.0016927557,0.00021117851,0.0007114917,0.00025394655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020367089,0.00030916536,0.0018026554,0.00041871358,0.00012011256,0.00004117532,0.00009876709,0.00029779918,0.000035466357],"category_scores_gemma":[0.00053363177,0.00024060595,0.0002232912,0.00039146957,0.0004956081,0.0003384739,0.000034421308,0.00082865794,9.2138595e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5053562,0.013807483,0.2451418,0.0037995477,0.012717742,0.0013743993,0.02618224,0.022298811,0.004212267,0.0016494134,0.0038924608,0.15956767],"study_design_scores_gemma":[0.20399608,0.08738004,0.6826563,0.0023899488,0.0023007377,0.00029102986,0.0016749571,0.011048179,0.0013571596,0.0029061968,0.003283154,0.0007162125],"about_ca_topic_score_codex":0.00025533847,"about_ca_topic_score_gemma":0.001976484,"teacher_disagreement_score":0.4375145,"about_ca_system_score_codex":0.00072873826,"about_ca_system_score_gemma":0.0021067536,"threshold_uncertainty_score":0.9811626},"labels":[],"label_agreement":null},{"id":"W4399394886","doi":"10.1200/jco.2024.42.16_suppl.5008","title":"Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with <sup>177</sup>Lu-PSMA-617 versus change of ARPI in PSMAfore.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Medicine; Oncology; Internal medicine; Baseline (sea); Cancer; Breast cancer","score_opus":0.24683755409119756,"score_gpt":0.5178091961761405,"score_spread":0.27097164208494295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490726,0.00069172186,0.000011114221,0.0033601995,0.000077941244,0.00046203172,0.000059012546,0.000008330023,0.00042237018],"genre_scores_gemma":[0.9978737,0.0007720292,0.0007518666,0.00017476954,0.0001611788,0.000020506006,0.000047730253,0.00002200523,0.00017618563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741226,0.0003440491,0.0011951794,0.00024522637,0.0005149623,0.00028829862],"domain_scores_gemma":[0.995924,0.0025904335,0.0006404543,0.00013676158,0.00046887939,0.00023946301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012863305,0.000187948,0.0014790595,0.0005151076,0.000026453486,0.000013256712,0.00008672922,0.00022174066,0.000044864853],"category_scores_gemma":[0.00095922936,0.000093305556,0.00013056681,0.0006272347,0.00028708586,0.00019240592,0.000029914292,0.0008175238,0.0000018809687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017250579,0.0018134193,0.96297944,0.000059276572,0.0012000449,0.0012365824,0.0004755436,0.000060016788,0.000004635843,0.000010017887,0.00013282968,0.014777639],"study_design_scores_gemma":[0.033584423,0.02803482,0.9354502,0.0005167678,0.00072588935,0.000019256087,0.00062753086,0.00042782593,0.00003335528,0.000017124354,0.00045753786,0.000105277984],"about_ca_topic_score_codex":0.0003741997,"about_ca_topic_score_gemma":0.0017080703,"teacher_disagreement_score":0.027529225,"about_ca_system_score_codex":0.00034287255,"about_ca_system_score_gemma":0.0010602851,"threshold_uncertainty_score":0.38048902},"labels":[],"label_agreement":null},{"id":"W4399394934","doi":"10.1200/jco.2024.42.16_suppl.5020","title":"Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Oncology; Internal medicine; Cancer; Alternative medicine; Prostate cancer; Pathology; Androgen receptor","score_opus":0.14268424787588121,"score_gpt":0.5026659190322387,"score_spread":0.3599816711563575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914181,0.0007506459,0.000035221507,0.0017750455,0.0005355974,0.005191912,0.00016562895,0.000013433822,0.0001143721],"genre_scores_gemma":[0.99818844,0.00024247015,0.0006167642,0.00012530833,0.00016203547,0.00047809308,0.000026530295,0.00004458399,0.00011578224],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99340206,0.0006931215,0.0042695976,0.000506274,0.0007383557,0.00039058318],"domain_scores_gemma":[0.9921927,0.0044547683,0.0020257735,0.00030770185,0.00072351395,0.00029552783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026713873,0.00035005496,0.0023404195,0.0004892307,0.000037506103,0.000016407153,0.00016037385,0.00020482992,0.00018919619],"category_scores_gemma":[0.002656129,0.00023960127,0.000373301,0.0006150501,0.00033243926,0.00018197211,0.000032622487,0.00057606364,0.0000032010041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40896907,0.096273355,0.32543245,0.0012300886,0.003993557,0.0023186128,0.007321156,0.0011457305,0.0015346771,0.00003808496,0.0003510346,0.15139218],"study_design_scores_gemma":[0.28060156,0.275912,0.42451134,0.003252101,0.0025232425,0.00013885011,0.0015702574,0.0032519752,0.00179882,0.00036431913,0.005690816,0.000384755],"about_ca_topic_score_codex":0.000978796,"about_ca_topic_score_gemma":0.0034917102,"teacher_disagreement_score":0.17963862,"about_ca_system_score_codex":0.0006518489,"about_ca_system_score_gemma":0.004296744,"threshold_uncertainty_score":0.9770656},"labels":[],"label_agreement":null},{"id":"W4399394935","doi":"10.1200/jco.2024.42.16_suppl.tps5122","title":"Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Oncology; Internal medicine; Randomized controlled trial; Double blind; Cancer; Urology; Pathology; Alternative medicine","score_opus":0.0748434723450314,"score_gpt":0.45902999504555264,"score_spread":0.3841865227005212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888148,0.0043500857,0.000030445723,0.0012561214,0.00062146224,0.004837514,0.000022569671,0.000011326265,0.000055684715],"genre_scores_gemma":[0.9912562,0.007812044,0.00021067467,0.0000647246,0.0002983195,0.0002396849,0.000015896954,0.00002332547,0.00007912297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99495584,0.0009673178,0.0027211325,0.00033399384,0.00073073397,0.00029100364],"domain_scores_gemma":[0.99469316,0.002707834,0.0014364955,0.00019585917,0.00071309815,0.00025356858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057208315,0.00021676223,0.0029678743,0.00037558848,0.000031774132,0.000020077901,0.00016425466,0.00023318116,0.000059303882],"category_scores_gemma":[0.001126081,0.00011346741,0.0003895686,0.00045454444,0.0003678513,0.00015966974,0.00004028036,0.001205012,0.0000029660016],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7596215,0.0061644707,0.16879384,0.000043392636,0.0019575637,0.0002415477,0.00049042533,0.00003895297,0.000029139685,0.000006936496,0.000144803,0.062467437],"study_design_scores_gemma":[0.95001197,0.035071407,0.012298397,0.00041739165,0.0008699742,0.000011094136,0.00012200174,0.00038887528,0.00039314883,0.00010703707,0.00020345647,0.00010527656],"about_ca_topic_score_codex":0.0001664232,"about_ca_topic_score_gemma":0.000047394253,"teacher_disagreement_score":0.19039044,"about_ca_system_score_codex":0.00036611303,"about_ca_system_score_gemma":0.0032547533,"threshold_uncertainty_score":0.5773793},"labels":[],"label_agreement":null},{"id":"W4399394956","doi":"10.1200/jco.2024.42.16_suppl.5022","title":"Association between prostate-specific antigen (PSA) level &lt;0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Internal medicine; Oncology; Urology; Castration; Gynecology; Prostate; Cancer; Hormone","score_opus":0.12286845051297596,"score_gpt":0.45675678728374486,"score_spread":0.3338883367707689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948308,0.0028253582,0.000045488396,0.000983158,0.0002352941,0.0007246296,0.00029161648,0.0000065870113,0.000057067256],"genre_scores_gemma":[0.9874858,0.010704304,0.0013438227,0.000017798102,0.00012385423,0.000020693702,0.00007251221,0.000016771812,0.00021440248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995444,0.00071792473,0.0023518365,0.00033144662,0.0008371342,0.00031763013],"domain_scores_gemma":[0.9948479,0.0019227884,0.0020581954,0.00014710544,0.00078014296,0.00024384806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003691533,0.00019129961,0.0019757862,0.0005444157,0.000044942757,0.000020958796,0.000103798324,0.00029892477,0.000050473773],"category_scores_gemma":[0.0009959892,0.00010922787,0.0003539113,0.000932807,0.00029439526,0.00016232552,0.00003871992,0.00082317257,0.0000010378354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115382075,0.00088610966,0.88292176,0.00014679827,0.0058564176,0.00016601307,0.000607275,0.000075388954,0.0003648088,0.000006407355,0.00029768748,0.09713312],"study_design_scores_gemma":[0.010689053,0.015889334,0.9673399,0.00051350973,0.0037365134,0.0000030979115,0.00013959859,0.0002891228,0.00024996072,0.000069930305,0.0009783327,0.00010167388],"about_ca_topic_score_codex":0.00010162221,"about_ca_topic_score_gemma":0.0002994945,"teacher_disagreement_score":0.09703145,"about_ca_system_score_codex":0.0005180922,"about_ca_system_score_gemma":0.0013456658,"threshold_uncertainty_score":0.44541833},"labels":[],"label_agreement":null},{"id":"W4399394976","doi":"10.1200/jco.2024.42.16_suppl.5021","title":"Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Non-negative matrix factorization; Homologous recombination; Internal medicine; Matrix decomposition; Genetics; Cancer; Gene; Biology","score_opus":0.11696609909049363,"score_gpt":0.4567513490374288,"score_spread":0.33978524994693515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349695,0.0002812295,0.002238684,0.00083763653,0.00040863123,0.002583941,0.00012212177,0.00000894656,0.0000218813],"genre_scores_gemma":[0.9982889,0.0003968252,0.0008306105,0.000057300655,0.0000605126,0.00024803448,0.000055136818,0.000029887211,0.000032767326],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9953572,0.00044872102,0.0029240155,0.00040224916,0.0006371571,0.00023064046],"domain_scores_gemma":[0.99555737,0.0013973583,0.0021081918,0.00017585265,0.0006360136,0.00012521079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001490087,0.00027784894,0.0013983167,0.0006252758,0.00004123281,0.000027882941,0.000084074134,0.0001632033,0.000018483046],"category_scores_gemma":[0.00077357015,0.00020089776,0.00014422869,0.00069137826,0.00022337088,0.00063349894,0.000018100436,0.00045153187,5.628133e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22423306,0.13443233,0.49705148,0.0016540337,0.0015506195,0.00146576,0.02477452,0.053266216,0.016312456,0.00029444887,0.00004284459,0.04492224],"study_design_scores_gemma":[0.29856178,0.34332564,0.31072503,0.0041511767,0.0015881512,0.00009420439,0.0045758826,0.018077869,0.0172467,0.0010048925,0.00006825013,0.0005804232],"about_ca_topic_score_codex":0.0008164968,"about_ca_topic_score_gemma":0.003727007,"teacher_disagreement_score":0.2088933,"about_ca_system_score_codex":0.0013195681,"about_ca_system_score_gemma":0.0028517882,"threshold_uncertainty_score":0.8192373},"labels":[],"label_agreement":null},{"id":"W4399395001","doi":"10.1200/jco.2024.42.16_suppl.5502","title":"Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Cohort; Cancer; Oncology; Internal medicine; Immunotherapy","score_opus":0.09292514267589502,"score_gpt":0.4732235307505875,"score_spread":0.38029838807469246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861614,0.0027568878,0.00008819811,0.0019562072,0.0047866586,0.0033786385,0.00028818758,0.00006604264,0.00051778613],"genre_scores_gemma":[0.99486613,0.0010204368,0.0021300262,0.00029608147,0.0011279446,0.00010838429,0.000024489955,0.00007054382,0.0003559578],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99242437,0.0006557746,0.004628658,0.00067443145,0.0010965646,0.00052018213],"domain_scores_gemma":[0.98876935,0.006377681,0.0026082052,0.0006927217,0.001143177,0.00040884753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037286745,0.00039087175,0.002876768,0.00030245935,0.000093062736,0.000022102162,0.00045837453,0.0005031357,0.00014728191],"category_scores_gemma":[0.008083526,0.00021810076,0.0012063269,0.00095026876,0.0003832005,0.00010017423,0.00011634518,0.0013256053,0.0000037138927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6722021,0.014399202,0.10818154,0.0003559148,0.009003711,0.0010994328,0.0018752659,0.001606308,0.0053341887,0.000027681872,0.009065648,0.17684898],"study_design_scores_gemma":[0.40113917,0.247029,0.1781905,0.002809564,0.01510972,0.0007981033,0.0009337488,0.0077756154,0.009601981,0.00022719472,0.13556369,0.00082171673],"about_ca_topic_score_codex":0.00033035068,"about_ca_topic_score_gemma":0.00064999645,"teacher_disagreement_score":0.27106297,"about_ca_system_score_codex":0.00085018674,"about_ca_system_score_gemma":0.004978635,"threshold_uncertainty_score":0.9677319},"labels":[],"label_agreement":null},{"id":"W4399395081","doi":"10.1200/jco.2024.42.16_suppl.5520","title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Chemotherapy; Ovarian cancer; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Surgery; Cancer","score_opus":0.13313307254854903,"score_gpt":0.4930474423542216,"score_spread":0.3599143698056726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97044516,0.002388833,0.0002939642,0.018954497,0.0052766353,0.0016829714,0.00011672468,0.000013109163,0.00082810107],"genre_scores_gemma":[0.9841288,0.009711037,0.0028316793,0.001565039,0.0011630615,0.000097660915,0.000059495615,0.000045509238,0.0003977152],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994171,0.0011150319,0.0034646671,0.0004721953,0.0004814625,0.00029562553],"domain_scores_gemma":[0.9919295,0.005260039,0.0019204018,0.0002567615,0.0003515936,0.00028173535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00528415,0.00029401586,0.0047185593,0.00046449914,0.000035385583,0.000043176886,0.00019732752,0.00045610624,0.0009484211],"category_scores_gemma":[0.0011118765,0.00021518,0.0011814984,0.0007019751,0.00025787443,0.00023731364,0.000037785936,0.0010074846,0.0000031330849],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8539941,0.013479962,0.0005740667,0.00003357933,0.021373047,0.0005986249,0.0005269148,0.00002186913,0.0006530909,0.00007226146,0.0067208586,0.10195163],"study_design_scores_gemma":[0.95635855,0.0176364,0.0027630345,0.00031916588,0.0077449717,0.000018382649,0.00011527246,0.002841832,0.0005232904,0.000054460033,0.011448463,0.00017619136],"about_ca_topic_score_codex":0.0008826939,"about_ca_topic_score_gemma":0.00039454433,"teacher_disagreement_score":0.102364436,"about_ca_system_score_codex":0.00076105504,"about_ca_system_score_gemma":0.0025695325,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W4399395142","doi":"10.1200/jco.2024.42.16_suppl.5606","title":"Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Progression-free survival; Oncology; Chemotherapy; Ovarian cancer; Internal medicine; Cancer; Post-hoc analysis; Overall survival; Survival analysis; Cancer research","score_opus":0.03904731457116198,"score_gpt":0.3911665192181815,"score_spread":0.3521192046470195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945729,0.00083146675,0.000019630135,0.002204329,0.0005217906,0.0016422882,0.00009567485,0.0000098746505,0.000102045924],"genre_scores_gemma":[0.99795264,0.00048888504,0.0010264455,0.00017957271,0.00021600834,0.00005053083,0.000013534107,0.00003243283,0.000039955263],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9944113,0.0011216955,0.002525058,0.0003895064,0.0012495439,0.00030292248],"domain_scores_gemma":[0.9941083,0.003204505,0.001556683,0.00037391853,0.00058750866,0.00016904633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050359173,0.00026735655,0.0026901197,0.0006124614,0.00001963856,0.000014034719,0.0003144466,0.00041242756,0.00013976003],"category_scores_gemma":[0.001851738,0.0001383018,0.00042899663,0.0014273705,0.00035885905,0.00008790847,0.000061369836,0.0009566497,2.0036937e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62802505,0.0039476203,0.3475083,0.00018373142,0.004078185,0.00029332456,0.0007758444,0.000046235833,0.0004994314,0.00005107779,0.00022838352,0.014362786],"study_design_scores_gemma":[0.3568678,0.1560788,0.47914356,0.001158845,0.0033355677,0.000022469594,0.00039295902,0.00045871266,0.0010250389,0.00017969905,0.0009993637,0.00033719515],"about_ca_topic_score_codex":0.000597804,"about_ca_topic_score_gemma":0.0016036356,"teacher_disagreement_score":0.2711573,"about_ca_system_score_codex":0.00034245697,"about_ca_system_score_gemma":0.0019365774,"threshold_uncertainty_score":0.5639783},"labels":[],"label_agreement":null},{"id":"W4399395191","doi":"10.1200/jco.2024.42.16_suppl.5537","title":"Molecular characterization of cervical cancer histological subtypes: The VENUS study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cervical cancer; Cancer; Pathology; Internal medicine","score_opus":0.17238754096072753,"score_gpt":0.5301715556115609,"score_spread":0.3577840146508334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746176,0.0025735213,0.00014930102,0.018561095,0.0013340377,0.0002349629,0.000004440652,0.000008535913,0.0025165228],"genre_scores_gemma":[0.9965271,0.00081016356,0.000035670884,0.0012739109,0.0011628362,0.000008414289,0.0000017574471,0.000011477475,0.00016871259],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972492,0.0004897453,0.0014098618,0.00015533084,0.00053266267,0.00016322098],"domain_scores_gemma":[0.9975878,0.0011642426,0.00038147205,0.00016313803,0.00049938273,0.00020397699],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025842623,0.00008424822,0.00088071695,0.00008503678,0.000025001676,0.000010397529,0.00020310377,0.00023065611,0.0017084267],"category_scores_gemma":[0.0015081618,0.00004375291,0.00039658247,0.0002558275,0.0002473481,0.000045456425,0.000067546884,0.0012181554,0.000016137503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068711075,0.003267897,0.08506026,0.00023693411,0.0009320233,0.0029699183,0.00041928852,0.000008645979,0.0057099387,0.000825621,0.0015183374,0.89218],"study_design_scores_gemma":[0.0019826503,0.009971115,0.8974854,0.00005119975,0.00047733885,0.00013855514,0.00008919676,0.00026510732,0.0002270018,0.00021913089,0.089041606,0.000051716106],"about_ca_topic_score_codex":0.000033307526,"about_ca_topic_score_gemma":0.000027024253,"teacher_disagreement_score":0.8921283,"about_ca_system_score_codex":0.00014341362,"about_ca_system_score_gemma":0.0014182539,"threshold_uncertainty_score":0.99920416},"labels":[],"label_agreement":null},{"id":"W4399395212","doi":"10.1200/jco.24.00720","title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Hôpital Charles-Le Moyne","funders":"Aptitude Health","keywords":"Medicine; Internal medicine; Oncology; Clinical endpoint; Population; Lung cancer; Phases of clinical research; non-small cell lung cancer (NSCLC); Chemotherapy; Gastroenterology; Clinical trial","score_opus":0.033745585985306394,"score_gpt":0.44297073263212905,"score_spread":0.40922514664682264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256575,0.00199096,0.0000642675,0.0012807089,0.00058982096,0.002589173,0.000018899002,0.000012897766,0.00088752276],"genre_scores_gemma":[0.99666446,0.00034585258,0.0013613648,0.0007348515,0.00048655333,0.00013809,0.00001177266,0.000030755153,0.0002262994],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705267,0.0004047277,0.0015989288,0.00029753213,0.0003409581,0.00030521266],"domain_scores_gemma":[0.9980318,0.0006335204,0.0007667051,0.0002116709,0.0001968816,0.00015943573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011384037,0.00021420464,0.0010650335,0.00018096858,0.00007158919,0.000029997986,0.00017677477,0.00024067136,0.00005755156],"category_scores_gemma":[0.00019549383,0.00011746287,0.00024971415,0.00036025807,0.00009525743,0.00018454879,0.000024162786,0.0010113552,0.000001973699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27806288,0.02915448,0.20687482,0.00027887122,0.0008191992,0.0018569808,0.004239378,0.00057140214,0.0006150464,0.000011204567,0.0012565983,0.47625914],"study_design_scores_gemma":[0.7172253,0.13985035,0.11065747,0.002976482,0.002224663,0.000044924236,0.00033070528,0.0010290239,0.00057577476,0.00005503544,0.024621578,0.00040868745],"about_ca_topic_score_codex":0.00022344202,"about_ca_topic_score_gemma":0.0003132065,"teacher_disagreement_score":0.47585046,"about_ca_system_score_codex":0.00065099704,"about_ca_system_score_gemma":0.0027846473,"threshold_uncertainty_score":0.4939845},"labels":[],"label_agreement":null},{"id":"W4399395213","doi":"10.1200/jco.2024.42.16_suppl.5595","title":"Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by <i>BRCA1</i>/<i>BRCA2</i> mutation (BRCAm) status.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Paclitaxel; Carboplatin; Olaparib; Endometrial cancer; Oncology; Gynecology; Cancer; Internal medicine; Urology; Chemotherapy; Cisplatin; Immunotherapy; Nivolumab","score_opus":0.12658107772163069,"score_gpt":0.4967792795174652,"score_spread":0.3701982017958345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9175386,0.028779183,0.0010749141,0.028986774,0.015842244,0.003898749,0.0027399838,0.000120523146,0.0010190596],"genre_scores_gemma":[0.9346081,0.050219174,0.003982505,0.00321964,0.003864127,0.00091740437,0.00060501485,0.00016962156,0.0024144077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900684,0.0009141674,0.0061671627,0.00093060057,0.0010299409,0.0008897782],"domain_scores_gemma":[0.9749347,0.020334926,0.002687621,0.00044286193,0.00072235224,0.00087752705],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004310841,0.0005866847,0.0031435455,0.00054062204,0.00012446802,0.00006534462,0.0002694303,0.00083722454,0.00040399985],"category_scores_gemma":[0.017480452,0.00043247658,0.001180897,0.001003557,0.00027996863,0.0004056857,0.000044507055,0.0014185188,0.000025504069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2356489,0.0069632237,0.0013885794,0.00025190684,0.0019735089,0.0019397553,0.0012700673,0.00078228366,0.0021193528,0.000087205364,0.22299503,0.5245802],"study_design_scores_gemma":[0.22908996,0.07342731,0.0010457843,0.0012730683,0.0010123178,0.00021806406,0.00023257452,0.0011203523,0.0020734551,0.0009326239,0.6890871,0.0004873807],"about_ca_topic_score_codex":0.00067228917,"about_ca_topic_score_gemma":0.0024094959,"teacher_disagreement_score":0.5240928,"about_ca_system_score_codex":0.0038043372,"about_ca_system_score_gemma":0.006584851,"threshold_uncertainty_score":0.9998127},"labels":[],"label_agreement":null},{"id":"W4399402430","doi":"10.1200/jco.2024.42.16_suppl.e17603","title":"Recurrent vulvar squamous cell carcinoma: Outcomes across the treatment spectrum—Are we making progress?","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Vulvar cancer; Vulvar Carcinoma; Basal cell; Oncology; Dermatology; Internal medicine; Vulva","score_opus":0.22230983192164053,"score_gpt":0.5557882348194153,"score_spread":0.33347840289777475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399402430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8001166,0.041160055,0.00003818661,0.14527206,0.004576838,0.00059474964,0.000018735027,0.000034850607,0.008187894],"genre_scores_gemma":[0.99199134,0.0025030856,0.00019883575,0.0009324852,0.0032339662,0.000015521617,0.0000012496508,0.000026285115,0.0010972028],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965769,0.00038721893,0.0016539226,0.00027448346,0.000633231,0.00047424366],"domain_scores_gemma":[0.9953984,0.0031723862,0.00052420003,0.0002862803,0.0002494513,0.0003692831],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024120952,0.00019181603,0.0013009919,0.000085351625,0.000104231214,0.00006255066,0.00026660162,0.00028012323,0.0010558426],"category_scores_gemma":[0.0006096373,0.000089799185,0.0009824489,0.00022707418,0.00035039475,0.000065205415,0.00009347969,0.0016150628,0.000079223166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030106122,0.0026247802,0.24640003,0.00022661184,0.00022925419,0.004143737,0.00079490116,0.0000027818928,0.0000019582549,0.000111469184,0.0070828395,0.73537105],"study_design_scores_gemma":[0.0048964904,0.020889096,0.5457295,0.00005817649,0.00037761425,0.00033188186,0.00042604806,0.00018996146,0.000041219977,0.00038880654,0.42658058,0.00009061272],"about_ca_topic_score_codex":0.000018532972,"about_ca_topic_score_gemma":0.00021491238,"teacher_disagreement_score":0.7352804,"about_ca_system_score_codex":0.00063302036,"about_ca_system_score_gemma":0.0014870551,"threshold_uncertainty_score":0.9998573},"labels":[],"label_agreement":null},{"id":"W4399409854","doi":"10.1200/jco.2024.42.16_suppl.e17574","title":"Chemoresistance in high grade serous ovarian cancer molecular subtypes and the role of NRF2.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Serous ovarian cancer; Ovarian cancer; Serous fluid; Oncology; Internal medicine; Cancer; Cancer research","score_opus":0.022116854447416186,"score_gpt":0.3661993796436319,"score_spread":0.34408252519621574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399409854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97394586,0.02214887,0.00012980601,0.0027505334,0.00040431268,0.00008772576,0.000009745904,0.000001564223,0.0005215941],"genre_scores_gemma":[0.9940384,0.004194518,0.0007417021,0.00044351403,0.0005018838,0.0000051708034,0.0000027533656,0.000012017058,0.000060038834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998344,0.0002592085,0.00094625907,0.00019369114,0.000111771435,0.00014509294],"domain_scores_gemma":[0.9988937,0.00031193622,0.00043738593,0.00014941322,0.0001259244,0.0000816727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012377806,0.00010404099,0.0005831597,0.000037938287,0.0000146004995,0.0000105161225,0.00022192231,0.00024733314,0.00001120626],"category_scores_gemma":[0.0006279452,0.0000683212,0.00020034886,0.00007294404,0.00042225615,0.0000050429435,0.000080482605,0.00038245507,6.7397974e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075542983,0.0007181437,0.050391566,0.0001602896,0.0010867576,0.0002231236,0.00041029966,0.00023632977,0.8416418,0.011179647,0.0016374944,0.08476026],"study_design_scores_gemma":[0.014071376,0.0029214527,0.14042936,0.0003040131,0.0004282823,0.00015719119,0.00048599928,0.00032385712,0.65198267,0.057020623,0.13141344,0.00046172287],"about_ca_topic_score_codex":0.00007538571,"about_ca_topic_score_gemma":0.00016269024,"teacher_disagreement_score":0.1896591,"about_ca_system_score_codex":0.000020784082,"about_ca_system_score_gemma":0.00040713503,"threshold_uncertainty_score":0.27860576},"labels":[],"label_agreement":null},{"id":"W4399451380","doi":"10.1200/jco.2024.42.17_suppl.lba8505","title":"Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Lung cancer; Pharmacokinetics; Osimertinib; Urology; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Epidermal growth factor receptor; Erlotinib","score_opus":0.03199664137692556,"score_gpt":0.42768336129724355,"score_spread":0.395686719920318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399451380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697098,0.0069617545,0.00046727934,0.011819164,0.003021962,0.0038321153,0.00014783134,0.000035453468,0.004004647],"genre_scores_gemma":[0.9869083,0.009222846,0.0007636634,0.0017439171,0.0008604988,0.00015724644,0.00007317731,0.000047744375,0.00022259426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9918704,0.0018898845,0.004614167,0.00052452734,0.00062696007,0.0004740704],"domain_scores_gemma":[0.98065704,0.016052986,0.0023804575,0.00029954326,0.00033639575,0.00027355694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00525837,0.00039327773,0.004351421,0.00020815578,0.00008222216,0.00006014691,0.00027069266,0.0004061201,0.000047628],"category_scores_gemma":[0.0024086456,0.00020526572,0.00070131314,0.00037992626,0.00025681916,0.00023713494,0.000061865045,0.0013610645,0.0000038626185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94869405,0.0052935057,0.003002015,0.00007514579,0.0017809718,0.006484754,0.0008183377,0.00018759842,0.00040489124,0.000052017116,0.000657414,0.03254927],"study_design_scores_gemma":[0.96961594,0.013210777,0.006667303,0.0017828515,0.0027995491,0.00014559021,0.0002468482,0.0011576477,0.000032202282,0.0003162488,0.0037868146,0.00023823975],"about_ca_topic_score_codex":0.0008842259,"about_ca_topic_score_gemma":0.0013587225,"teacher_disagreement_score":0.03231103,"about_ca_system_score_codex":0.0022821033,"about_ca_system_score_gemma":0.0057464154,"threshold_uncertainty_score":0.9998901},"labels":[],"label_agreement":null},{"id":"W4399451413","doi":"10.1200/jco.2024.42.17_suppl.lba8010","title":"Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Clinical endpoint; Oncology; Interim analysis; Neoadjuvant therapy; Perioperative; Surgery; Randomized controlled trial; Cancer; Immunotherapy; Breast cancer","score_opus":0.03621996565292106,"score_gpt":0.40401146391662923,"score_spread":0.36779149826370816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399451413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97729284,0.0014047425,0.00002245041,0.016428174,0.001416029,0.00036130717,0.000017206035,0.000027166314,0.0030300876],"genre_scores_gemma":[0.98915267,0.003312035,0.0024927133,0.0033312622,0.0011734146,0.000014915574,0.000021859847,0.00005712325,0.0004440245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965697,0.00018587292,0.001869702,0.00042572035,0.0005555046,0.00039349296],"domain_scores_gemma":[0.9974013,0.0008718783,0.0007127603,0.00033159362,0.00030635524,0.00037613083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013477404,0.00025250818,0.0017465524,0.00017246636,0.00003175791,0.000037852624,0.00020225409,0.00039655354,0.0008261389],"category_scores_gemma":[0.00039182266,0.00016033546,0.00040638514,0.000290629,0.00014445925,0.00019642134,0.00005344609,0.0011427447,0.00012258955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022229493,0.0059590926,0.7240289,0.00011507775,0.0016166543,0.0019980078,0.00029147428,0.0000134064685,0.00004855927,0.00007693805,0.04054351,0.2030789],"study_design_scores_gemma":[0.048310082,0.01985599,0.75005686,0.001819938,0.00064923597,0.00007270263,0.00007198653,0.00018099562,0.00090100785,0.0004749164,0.17735456,0.00025171557],"about_ca_topic_score_codex":0.0002814634,"about_ca_topic_score_gemma":0.00023680483,"teacher_disagreement_score":0.20282717,"about_ca_system_score_codex":0.0010828046,"about_ca_system_score_gemma":0.0015696771,"threshold_uncertainty_score":0.9045642},"labels":[],"label_agreement":null},{"id":"W4399451898","doi":"10.1200/jco.2024.42.17_suppl.lba12007","title":"Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; University of Alberta","funders":"Rising Tide Foundation for Clinical Cancer Research; Alberta Cancer Foundation","keywords":"Medicine; Cachexia; Weight loss; Randomized controlled trial; Cancer; Physical therapy; Pancreatic cancer; Clinical endpoint; Internal medicine; Multimodal therapy; Lung cancer; Obesity","score_opus":0.07689530159567613,"score_gpt":0.4743457700470857,"score_spread":0.3974504684514096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399451898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985689,0.004082896,0.00027026728,0.00580599,0.001733306,0.0021461076,0.00019072014,0.000012632605,0.00006911723],"genre_scores_gemma":[0.98455834,0.005894534,0.008557472,0.0003297616,0.00048835896,0.000063680556,0.00007499743,0.000025055062,0.000007801813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99628824,0.00030566825,0.0023914033,0.00030381008,0.0005206741,0.00019021105],"domain_scores_gemma":[0.9962933,0.0013058387,0.0010768211,0.00015005075,0.0008663963,0.0003075648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016653744,0.00015261014,0.0015519664,0.00023929539,0.000046207584,0.000024699773,0.00012865847,0.00023852744,0.000030468063],"category_scores_gemma":[0.0011258735,0.00011879773,0.00013230645,0.00018706998,0.00011214934,0.00021128706,0.000050988987,0.00064765965,9.597873e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7704125,0.00061477243,0.0032977941,0.00056586106,0.00017081563,0.00006587756,0.0016301561,0.00001753553,0.000022438604,0.000004409684,0.0003715797,0.22282627],"study_design_scores_gemma":[0.9309118,0.022054438,0.028492335,0.009489817,0.00029301038,0.0000027956253,0.0017402832,0.00008839462,0.00011247792,0.00003920931,0.006650239,0.00012523627],"about_ca_topic_score_codex":0.00014180277,"about_ca_topic_score_gemma":0.00094970455,"teacher_disagreement_score":0.22270103,"about_ca_system_score_codex":0.0008815377,"about_ca_system_score_gemma":0.0021829663,"threshold_uncertainty_score":0.48444307},"labels":[],"label_agreement":null},{"id":"W4399452280","doi":"10.1200/jco.2024.42.17_suppl.lba8503","title":"Lorlatinib vs crizotinib in treatment-naïve patients with advanced <i>ALK</i>+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; Progression-free survival; Overall survival; Cancer research","score_opus":0.033117509232032535,"score_gpt":0.4386722818950109,"score_spread":0.40555477266297835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874476,0.0024222273,0.000026725045,0.0051238067,0.0014035522,0.0012873752,0.00008739306,0.000014061459,0.0021872658],"genre_scores_gemma":[0.995019,0.0014619424,0.0021090147,0.00037739618,0.0006779043,0.000058349444,0.000018482695,0.000032776647,0.00024509963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973896,0.000304164,0.0013651716,0.00032898408,0.0003687408,0.00024330152],"domain_scores_gemma":[0.9959579,0.0026535646,0.0006148287,0.00027675502,0.0002498052,0.000247151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075290026,0.00021628644,0.0010811081,0.00007529894,0.000082478226,0.000031562453,0.00015932224,0.00016147287,0.00009406885],"category_scores_gemma":[0.00035397738,0.000103631966,0.00018409881,0.0001994018,0.00013857646,0.00013109673,0.00006732276,0.0006268998,0.000003282123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008097011,0.0032857193,0.8423119,0.000028678327,0.00080885267,0.00041270518,0.0014678114,0.000029044322,0.000003960461,0.000008879079,0.0007357975,0.14280964],"study_design_scores_gemma":[0.038098663,0.021277701,0.91912085,0.0005302947,0.0017152794,0.00000773788,0.0010771555,0.00008742122,0.000009039787,0.000040613788,0.017923571,0.00011167826],"about_ca_topic_score_codex":0.00031808685,"about_ca_topic_score_gemma":0.0015024157,"teacher_disagreement_score":0.14269796,"about_ca_system_score_codex":0.0003632913,"about_ca_system_score_gemma":0.0019957728,"threshold_uncertainty_score":0.4225989},"labels":[],"label_agreement":null},{"id":"W4399452320","doi":"10.1200/jco.2024.42.17_suppl.lba105","title":"Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Bortezomib; Multiple myeloma; Interim analysis; Refractory (planetary science); Randomized controlled trial; Oncology; Gastroenterology","score_opus":0.11373483014546089,"score_gpt":0.45582014480989064,"score_spread":0.34208531466442976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475945,0.007331258,0.000074548465,0.004182009,0.00078128563,0.0023684306,0.00014124226,0.000029100367,0.00033267774],"genre_scores_gemma":[0.990634,0.0040245648,0.0037055772,0.00040202247,0.00082309375,0.000050605177,0.00003315015,0.00006350077,0.00026345687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98703784,0.005020711,0.005458715,0.00080101896,0.0010424836,0.0006392483],"domain_scores_gemma":[0.9283427,0.067724034,0.0020401892,0.0006211759,0.00041197066,0.0008599406],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01584676,0.0004855344,0.005021927,0.0004959754,0.00011223192,0.00006805893,0.00037058746,0.0006423584,0.000094692994],"category_scores_gemma":[0.043648828,0.00028893937,0.00066058943,0.0004504235,0.0010214234,0.00022934872,0.00030286284,0.0025879156,0.00001138623],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80217046,0.0065137143,0.058753144,0.000091626,0.003584513,0.009148266,0.0034059393,0.000020753057,0.00094047084,0.000021284122,0.0009686872,0.11438114],"study_design_scores_gemma":[0.7716349,0.019440204,0.1946801,0.0006796718,0.0019046841,0.00072055496,0.0023706316,0.0058926074,0.00024306463,0.0002584519,0.0019267745,0.00024837485],"about_ca_topic_score_codex":0.0031088358,"about_ca_topic_score_gemma":0.002343222,"teacher_disagreement_score":0.13592695,"about_ca_system_score_codex":0.00041773,"about_ca_system_score_gemma":0.002192859,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W4399452333","doi":"10.1200/jco.2024.42.17_suppl.lba5002","title":"A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Manitoba; St. Joseph’s Healthcare Hamilton; McMaster University; Queen's University; McGill University Health Centre; Health Sciences Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; University of Toronto; Western University; Hôpital Fleurimont; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Dalhousie University","funders":"","keywords":"Medicine; Metformin; Prostate cancer; Tolerability; Prostatectomy; Clinical endpoint; Prostate; Internal medicine; Placebo; Prostate-specific antigen; Randomized controlled trial; Cancer; Oncology; Urology; Gynecology; Adverse effect; Pathology; Insulin","score_opus":0.051335503293386535,"score_gpt":0.4349183717614382,"score_spread":0.3835828684680517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593772,0.02498483,0.00006527263,0.00014870327,0.0030395358,0.011768066,0.00001773701,0.0000047309322,0.00059389847],"genre_scores_gemma":[0.9348179,0.05914948,0.00024264133,0.000051717325,0.0020359643,0.0033624393,0.000006336994,0.00003216273,0.0003013495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993376,0.0019661526,0.0034507366,0.00043153696,0.00043180375,0.00034374523],"domain_scores_gemma":[0.99380964,0.0026463964,0.0028779423,0.00029970738,0.00024502483,0.000121272446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020354824,0.00025754713,0.0024855006,0.00018094972,0.00006618651,0.000033433345,0.00036869684,0.00030378628,0.00001706684],"category_scores_gemma":[0.002417178,0.00013781623,0.0010451054,0.00019346099,0.00022352685,0.000020603518,0.00009800775,0.00059621735,6.074399e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70505893,0.001246479,0.000054981712,0.000042523978,0.00146548,0.00002201,0.0003174519,0.00017933377,0.00004321883,0.000028531686,0.00021538734,0.29132566],"study_design_scores_gemma":[0.9709892,0.013780984,0.000045594938,0.00020324218,0.0006652196,0.0000025899667,0.0008974247,0.00034227222,0.001587351,0.00015552474,0.011178851,0.00015171108],"about_ca_topic_score_codex":0.000048604452,"about_ca_topic_score_gemma":0.00020916882,"teacher_disagreement_score":0.29117396,"about_ca_system_score_codex":0.000101146325,"about_ca_system_score_gemma":0.00084718026,"threshold_uncertainty_score":0.7054617},"labels":[],"label_agreement":null},{"id":"W4399452369","doi":"10.1200/jco.2024.42.17_suppl.lba7005","title":"Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Brentuximab vedotin; Rituximab; Population; Oncology; Refractory (planetary science); Clinical endpoint; Placebo; Phases of clinical research; Diffuse large B-cell lymphoma; Interim analysis; Gastroenterology; Surgery; Lymphoma; CD30; Chemotherapy; Randomized controlled trial; Multiple myeloma; Pathology","score_opus":0.05589310246874222,"score_gpt":0.41747220317367334,"score_spread":0.3615791007049311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944838,0.00062365335,0.00001900444,0.0032660668,0.00035597733,0.00077130203,0.000026867197,0.00001062154,0.00044269336],"genre_scores_gemma":[0.99839675,0.00035699864,0.00019105048,0.00045618764,0.00026123162,0.000009260664,0.00002209482,0.00003441741,0.00027200126],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953617,0.0012443737,0.0019337584,0.00037356833,0.0007684888,0.00031814902],"domain_scores_gemma":[0.99220467,0.0063139214,0.0006638521,0.00030010543,0.00029413428,0.0002233446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058795474,0.00019367614,0.0011969595,0.00027044155,0.000040798863,0.000041223295,0.00020209236,0.0002605969,0.000059651607],"category_scores_gemma":[0.0017355402,0.000104281724,0.00012286425,0.00039506957,0.0002198444,0.00019879123,0.00008209081,0.0016765014,0.000009440501],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17584723,0.2534467,0.39236888,0.000041354542,0.00041434253,0.0033837364,0.0024818354,0.0000018906519,0.000096339514,0.000012464354,0.0011489035,0.17075634],"study_design_scores_gemma":[0.49620098,0.034504604,0.45576248,0.00031073284,0.00016810799,0.000028435104,0.0006200421,0.00023248108,0.000022348264,0.00006715838,0.011983775,0.000098847384],"about_ca_topic_score_codex":0.00019295675,"about_ca_topic_score_gemma":0.00090614223,"teacher_disagreement_score":0.32035375,"about_ca_system_score_codex":0.0004080739,"about_ca_system_score_gemma":0.0012922133,"threshold_uncertainty_score":0.7283657},"labels":[],"label_agreement":null},{"id":"W4399452407","doi":"10.1200/jco.2024.42.17_suppl.lba8007","title":"Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Perioperative; Nivolumab; Adjuvant; Oncology; Stock options; Cancer; Surgery; Immunotherapy","score_opus":0.0700768060127514,"score_gpt":0.4588425139649711,"score_spread":0.3887657079522197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091214,0.0007478841,0.00007560279,0.0037109896,0.0016309551,0.00095919456,0.00028274936,0.000032345244,0.0016481606],"genre_scores_gemma":[0.9918552,0.0007551467,0.0004994314,0.0019193171,0.00079314294,0.000015657562,0.000048453647,0.00005266209,0.0040610093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928155,0.0012911678,0.0038686632,0.00057881186,0.00094814826,0.000497723],"domain_scores_gemma":[0.99099004,0.00563864,0.0017214026,0.0005129656,0.0006627155,0.0004742167],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005623192,0.0003452574,0.0020802026,0.00009182425,0.00017345481,0.00010693276,0.00035004673,0.0003747828,0.0003253341],"category_scores_gemma":[0.0020061182,0.0001574856,0.0005797513,0.00034040838,0.00096541806,0.0003332661,0.00008659991,0.0023359107,0.000016098254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23433739,0.008595224,0.6574806,0.000014842758,0.004848337,0.0012858235,0.002336421,0.000005140948,0.00004488257,0.0000034907857,0.016120072,0.07492776],"study_design_scores_gemma":[0.12856022,0.08370527,0.6256258,0.0003590049,0.0008767541,0.000026575502,0.0033321707,0.00011154498,0.000020211135,0.0000035033304,0.15715961,0.00021934639],"about_ca_topic_score_codex":0.0017828228,"about_ca_topic_score_gemma":0.002242338,"teacher_disagreement_score":0.14103954,"about_ca_system_score_codex":0.00033124976,"about_ca_system_score_gemma":0.0028655482,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W4399452560","doi":"10.1200/jco.2024.42.17_suppl.lba4004","title":"Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Stand Up To Cancer; Lustgarten Foundation","keywords":"Medicine; Adenocarcinoma; Oncology; Pancreatic cancer; Risk stratification; Internal medicine; Stratification (seeds); Pancreatic ductal adenocarcinoma; Cancer","score_opus":0.21401058393839906,"score_gpt":0.5104732330727061,"score_spread":0.29646264913430703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96846527,0.002528094,0.00023650879,0.02121111,0.0017664037,0.0014635301,0.00003672549,0.0000136119315,0.0042787623],"genre_scores_gemma":[0.9907237,0.000823964,0.0022274063,0.0002613057,0.0020358076,0.000041266194,0.000008385796,0.000020321628,0.0038578007],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995464,0.0007787594,0.0028183404,0.0002478852,0.00043276392,0.0002581971],"domain_scores_gemma":[0.98731947,0.010361112,0.0012542716,0.00036991376,0.00044738004,0.00024786996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004539262,0.00015453415,0.0018308866,0.00013591413,0.00006019869,0.000016256501,0.00024125403,0.0006474999,0.00006562444],"category_scores_gemma":[0.007993387,0.00007850085,0.00093149405,0.00024667493,0.000362467,0.00008510947,0.00002688407,0.0007147528,0.000010771907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.542522,0.008287495,0.13535048,0.00065606367,0.006998936,0.00083298364,0.0018758794,0.00001096162,0.0038956415,0.0047768964,0.062120546,0.23267208],"study_design_scores_gemma":[0.13728924,0.111560255,0.6713037,0.0005776582,0.0052217976,0.0003271865,0.0003415154,0.00094473455,0.00044936995,0.0043091713,0.0675243,0.00015106074],"about_ca_topic_score_codex":0.000042762174,"about_ca_topic_score_gemma":0.00003396071,"teacher_disagreement_score":0.5359532,"about_ca_system_score_codex":0.00025369623,"about_ca_system_score_gemma":0.0045237923,"threshold_uncertainty_score":0.9569408},"labels":[],"label_agreement":null},{"id":"W4399452580","doi":"10.1200/jco.2024.42.17_suppl.lba6500","title":"ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Dasatinib; Imatinib; Cancer research; Pharmacology; Cancer; Receptor","score_opus":0.045553177307305306,"score_gpt":0.38039245244959036,"score_spread":0.33483927514228506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283904,0.00148208,0.00000801901,0.002053877,0.0013750201,0.0016076732,0.000060809052,0.000054652668,0.00051884877],"genre_scores_gemma":[0.9954653,0.0006921201,0.0011765363,0.0010507744,0.0011829359,0.00004640389,0.00007588406,0.00009960601,0.00021048608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99013174,0.00092965533,0.005940531,0.00086406677,0.0014296125,0.0007044271],"domain_scores_gemma":[0.99096334,0.0037367821,0.0025804543,0.00066231313,0.0009282519,0.0011288507],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028969354,0.0005797841,0.0032897808,0.00077862915,0.00006704239,0.000034720375,0.00041217566,0.0007402073,0.00009966651],"category_scores_gemma":[0.007692506,0.0004139291,0.0005105378,0.0016529133,0.00058607594,0.0004081416,0.0001807067,0.0027610648,0.000031833508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07644065,0.05611768,0.50770175,0.00095887866,0.0039966223,0.02350245,0.004480691,0.0003200828,0.0014917422,0.000014667254,0.054545492,0.27042925],"study_design_scores_gemma":[0.26399773,0.20600832,0.50474083,0.0026647965,0.0019538742,0.00038153786,0.00029782823,0.0006508759,0.001024468,0.00003853964,0.017757615,0.00048356983],"about_ca_topic_score_codex":0.00069552485,"about_ca_topic_score_gemma":0.0009031325,"teacher_disagreement_score":0.26994568,"about_ca_system_score_codex":0.007879442,"about_ca_system_score_gemma":0.028364107,"threshold_uncertainty_score":0.99983126},"labels":[],"label_agreement":null},{"id":"W4399452667","doi":"10.1200/jco.2024.42.17_suppl.lba8500","title":"Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Lung cancer; Adverse effect; Neutropenia; Chemotherapy; Phases of clinical research; Toxicity; Progression-free survival; Oncology; Gastroenterology; Randomized controlled trial","score_opus":0.032692144126641835,"score_gpt":0.40939710860556705,"score_spread":0.3767049644789252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924216,0.0013861763,0.00012772955,0.0031101245,0.00032943225,0.0019461972,0.0001484306,0.00002371185,0.0005065998],"genre_scores_gemma":[0.9949681,0.00034758155,0.0021760012,0.0016093118,0.00043238685,0.00007555562,0.000066903835,0.00006185032,0.0002622903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621546,0.00038780214,0.001972884,0.00052329985,0.0005394637,0.0003610982],"domain_scores_gemma":[0.9955429,0.002270304,0.0012020558,0.0003310945,0.000315263,0.00033839268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011679704,0.00036717797,0.001624505,0.00017039587,0.000084902334,0.00005852711,0.0001693419,0.00017286143,0.00006475775],"category_scores_gemma":[0.00021388134,0.00018384116,0.00021059607,0.0004216528,0.00021188913,0.00016695153,0.00002734642,0.0009835081,0.0000023911377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07031552,0.015222062,0.81682104,0.00025436337,0.0039348733,0.0019317371,0.0045854817,0.00029523173,0.00010437436,0.0000013810229,0.0038295467,0.0827044],"study_design_scores_gemma":[0.21394718,0.046732467,0.72337157,0.0017762937,0.0065617342,0.000047345195,0.00070374506,0.00126591,0.0002052617,0.0000147424535,0.0050346837,0.00033909248],"about_ca_topic_score_codex":0.0012107592,"about_ca_topic_score_gemma":0.0013346152,"teacher_disagreement_score":0.14363165,"about_ca_system_score_codex":0.0009382554,"about_ca_system_score_gemma":0.0038660627,"threshold_uncertainty_score":0.7496825},"labels":[],"label_agreement":null},{"id":"W4399452838","doi":"10.1200/jco.2024.42.17_suppl.lba9516","title":"Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Adverse effect; Melanoma; Refractory (planetary science); Oncology; Randomized controlled trial; Surgery; Immunotherapy; Gastroenterology; Confidence interval; Cancer; Cancer research","score_opus":0.06765289190333494,"score_gpt":0.45780414285497767,"score_spread":0.3901512509516427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284524,0.00097391655,0.000063135616,0.0011504575,0.0023822354,0.001729709,0.000003032765,0.000016274687,0.0008359922],"genre_scores_gemma":[0.997847,0.00045078548,0.0010101079,0.00023731621,0.00027674492,0.00004994846,0.000016459322,0.00003179554,0.000079823185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943486,0.0011619511,0.0031636304,0.00031958907,0.00071000535,0.00029626084],"domain_scores_gemma":[0.99297374,0.004738277,0.001530516,0.00019679828,0.00039835833,0.0001622818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007885243,0.00022715334,0.0024388544,0.00043903996,0.000032919404,0.00001874681,0.00013598237,0.0003267537,0.00012818525],"category_scores_gemma":[0.0022653635,0.00013977448,0.00038115197,0.00043918204,0.00034800055,0.0003093771,0.00002272896,0.0012483066,0.0000037374662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7239008,0.005375352,0.00047868106,0.00003481782,0.00051025295,0.00033666223,0.00027492805,0.000011658873,0.0000660846,0.000009488628,0.000050601604,0.2689507],"study_design_scores_gemma":[0.82889205,0.15989126,0.007335715,0.0006227647,0.0004610395,0.000025559075,0.00014919351,0.0008847591,0.000025282756,0.000048838614,0.0015245941,0.0001389527],"about_ca_topic_score_codex":0.000038429294,"about_ca_topic_score_gemma":0.00013953961,"teacher_disagreement_score":0.26881173,"about_ca_system_score_codex":0.0007181987,"about_ca_system_score_gemma":0.0021822408,"threshold_uncertainty_score":0.5699838},"labels":[],"label_agreement":null},{"id":"W4399480368","doi":"10.1200/jco.24.01001","title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Ono Pharmaceutical; Chugai Pharmaceutical; Seagen; MacroGenics; Astex Pharmaceuticals; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Chemotherapy; Biology","score_opus":0.049807727072665654,"score_gpt":0.43392178263423586,"score_spread":0.3841140555615702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886831,0.0012885984,0.000052691536,0.0058983937,0.0019512802,0.0010023236,0.000119660705,0.000021133663,0.00098282],"genre_scores_gemma":[0.99681556,0.0014874729,0.00028909778,0.00053101033,0.0005971023,0.000028605227,0.00005366707,0.00003419923,0.00016328091],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99597037,0.0006323373,0.002337443,0.00037314667,0.0003805854,0.000306108],"domain_scores_gemma":[0.99210256,0.006255532,0.0009880915,0.00020760932,0.00023534897,0.00021083112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012689692,0.00022351692,0.0011652128,0.00019002019,0.000052099007,0.00002630334,0.00018411977,0.0002492488,0.00007083625],"category_scores_gemma":[0.00070749375,0.00012376739,0.00016935023,0.00032673808,0.0001271613,0.00015656781,0.00003667355,0.0012589361,0.0000057206357],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24942696,0.03614108,0.2411817,0.0001646232,0.003567251,0.03635366,0.022141429,0.000120042954,0.0016137512,0.000021982292,0.0040293797,0.40523815],"study_design_scores_gemma":[0.2643289,0.07871974,0.64192927,0.0013312855,0.0023537516,0.0002036815,0.0028603172,0.00056904525,0.00017795489,0.00006956042,0.007092542,0.00036398513],"about_ca_topic_score_codex":0.0015536502,"about_ca_topic_score_gemma":0.0024591186,"teacher_disagreement_score":0.40487418,"about_ca_system_score_codex":0.0012861221,"about_ca_system_score_gemma":0.0035633205,"threshold_uncertainty_score":0.63211775},"labels":[],"label_agreement":null},{"id":"W4399480487","doi":"10.1200/jco.2024.42.16_suppl.8045","title":"Neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer (NSCLC): A systematic review and extracted individual patient data meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Perioperative; Meta-analysis; Oncology; Lung cancer; Immunotherapy; Atezolizumab; Neoadjuvant therapy; Internal medicine; Cancer; Surgery; Pembrolizumab","score_opus":0.2979514897103825,"score_gpt":0.5404648519953893,"score_spread":0.2425133622850068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480487","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010270468,0.99417305,0.0000036018432,0.0015984828,0.0003140524,0.003388471,0.00026998314,0.0000046554856,0.00014501836],"genre_scores_gemma":[0.00015639272,0.99676704,0.00052016124,0.0015491144,0.00018407876,0.000457175,0.00007568425,0.000047917245,0.00024241096],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9902999,0.0019315217,0.006287157,0.00071722374,0.0004675368,0.00029668555],"domain_scores_gemma":[0.99136496,0.0029253208,0.00424668,0.00080852583,0.0003134504,0.00034109512],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.006094736,0.0005493697,0.02176569,0.0004527938,0.00003926999,0.000068651156,0.0003970003,0.0005635474,0.00021231917],"category_scores_gemma":[0.00083777116,0.0002686713,0.0023800656,0.0006335881,0.00011755473,0.00013150022,0.00030159217,0.001926912,0.000004204654],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011198065,0.0013240185,0.00021275805,0.57395345,0.355879,0.0014369021,0.00028351395,7.245919e-7,5.970459e-8,0.0000039438423,0.0029365034,0.063857116],"study_design_scores_gemma":[0.001483463,0.0022306198,0.0001242324,0.1307973,0.74969405,0.0002560538,0.000035007175,0.000020680607,6.8036925e-8,0.0000012429597,0.115176335,0.00018094845],"about_ca_topic_score_codex":0.00016945768,"about_ca_topic_score_gemma":0.0004478016,"teacher_disagreement_score":0.44315615,"about_ca_system_score_codex":0.00046058508,"about_ca_system_score_gemma":0.0039329794,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W4399480640","doi":"10.1200/jco.2024.42.16_suppl.7510","title":"Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Internal medicine; Venetoclax; Multiple myeloma; Refractory (planetary science); Oncology; Subgroup analysis; Lenalidomide; Leukemia; Meta-analysis","score_opus":0.09263894720094318,"score_gpt":0.45702555486786345,"score_spread":0.36438660766692027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946558,0.0009373179,0.00027450407,0.0006244797,0.0008965288,0.0020763953,0.000112867536,0.000040491203,0.00038162855],"genre_scores_gemma":[0.9959259,0.00019561472,0.0026997454,0.00018112348,0.00042438947,0.000046919256,0.000110222114,0.00010101049,0.00031509664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98823416,0.002873164,0.0049683307,0.0010277006,0.0019332612,0.0009633712],"domain_scores_gemma":[0.9817894,0.01235655,0.0023474537,0.00084062293,0.0014658588,0.0012001148],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071057254,0.0006480201,0.0046838024,0.0020618774,0.00009502899,0.00005204715,0.0005278807,0.0007555827,0.00036598937],"category_scores_gemma":[0.01006902,0.00044808374,0.001417157,0.0027171767,0.00067245547,0.00041517243,0.00021707594,0.0022117519,0.000035794666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063120805,0.03330049,0.77584714,0.00010159713,0.011490466,0.007800741,0.0005841346,0.00008326853,0.0003957744,0.000012727037,0.0004548823,0.106807984],"study_design_scores_gemma":[0.113173984,0.050696034,0.8269398,0.000460949,0.0043453765,0.00010104331,0.00035576927,0.0013076095,0.00025077167,0.000018163826,0.0020254725,0.00032502777],"about_ca_topic_score_codex":0.0014255715,"about_ca_topic_score_gemma":0.0038905647,"teacher_disagreement_score":0.10648295,"about_ca_system_score_codex":0.0015318018,"about_ca_system_score_gemma":0.0037410362,"threshold_uncertainty_score":0.9997971},"labels":[],"label_agreement":null},{"id":"W4399480665","doi":"10.1200/jco.2024.42.16_suppl.7561","title":"Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Regeneron Pharmaceuticals","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.13113638108570327,"score_gpt":0.46271516226638715,"score_spread":0.33157878118068385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612594,0.0006172811,0.000011803397,0.00029060655,0.0005221002,0.0013939897,0.00010870331,0.0000110548945,0.0009185293],"genre_scores_gemma":[0.99774003,0.0013519094,0.00048351218,0.00004411246,0.00011120711,0.000045436656,0.00015946725,0.000028094355,0.000036216577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993088,0.0030808705,0.002228238,0.0003421853,0.00086918066,0.00039154597],"domain_scores_gemma":[0.9765097,0.021013005,0.0009992038,0.0003156969,0.00088855065,0.00027388157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026433382,0.00030415584,0.0024247842,0.00082725787,0.00004069046,0.000014645716,0.00024196098,0.00027592128,0.00003431491],"category_scores_gemma":[0.001808551,0.0001648728,0.00042048073,0.0009770327,0.0004300994,0.00014439385,0.000046994097,0.0011236451,0.0000052199703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3134641,0.008380882,0.632693,0.00043659314,0.0017455432,0.002161555,0.0041747047,0.00026048138,0.00009583484,0.00005678464,0.00014677772,0.03638377],"study_design_scores_gemma":[0.09924277,0.12994425,0.75785196,0.0013687868,0.00039490947,0.000012206603,0.00236688,0.00069601485,0.001102412,0.000037150137,0.006852258,0.00013039073],"about_ca_topic_score_codex":0.0007550226,"about_ca_topic_score_gemma":0.0069922414,"teacher_disagreement_score":0.21422133,"about_ca_system_score_codex":0.0015513565,"about_ca_system_score_gemma":0.0023830722,"threshold_uncertainty_score":0.6723318},"labels":[],"label_agreement":null},{"id":"W4399480666","doi":"10.1200/jco.2024.42.16_suppl.7539","title":"Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Dexamethasone; Pharmacokinetics; Multiple myeloma; Refractory (planetary science); Internal medicine; Oncology; Pharmacology","score_opus":0.1267504707767002,"score_gpt":0.5154475091146857,"score_spread":0.3886970383379855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954051,0.0009127018,0.00006983246,0.0018924365,0.0006030125,0.0005756407,0.000025070522,0.000017318695,0.00049890304],"genre_scores_gemma":[0.99300045,0.0022110068,0.0035512832,0.00033564505,0.0005787604,0.000008661306,0.0000061877818,0.000043274118,0.0002647105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99370307,0.0010779683,0.0034585036,0.0004345147,0.00082343176,0.00050249],"domain_scores_gemma":[0.9829674,0.014269499,0.0010996967,0.0003155554,0.0003407216,0.0010071743],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005131432,0.00032581773,0.0026441677,0.00047848778,0.000031318108,0.000018863166,0.00019730227,0.00048435363,0.00016753926],"category_scores_gemma":[0.006324714,0.00018054705,0.0010239843,0.00028471067,0.0005468399,0.000115527575,0.00010137884,0.00248566,0.000019877407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043933917,0.0052131903,0.7690523,0.00007727486,0.003152112,0.007943518,0.000108904074,0.0001220875,0.00014460292,0.000008509811,0.0009571094,0.16928646],"study_design_scores_gemma":[0.04900552,0.071211725,0.87227,0.00052562536,0.00062403764,0.00059690484,0.000044319182,0.0032465216,0.00007150253,0.000047798592,0.0022151321,0.00014094835],"about_ca_topic_score_codex":0.00013941406,"about_ca_topic_score_gemma":0.00018361422,"teacher_disagreement_score":0.16914551,"about_ca_system_score_codex":0.0007813532,"about_ca_system_score_gemma":0.0044769812,"threshold_uncertainty_score":0.99981564},"labels":[],"label_agreement":null},{"id":"W4399480781","doi":"10.1200/jco.2024.42.16_suppl.tps7089","title":"BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Rituximab; Refractory (planetary science); Lymphoma; Bendamustine; Internal medicine; Oncology; Leukemia","score_opus":0.09580237776698809,"score_gpt":0.43501506333247886,"score_spread":0.3392126855654908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870283,0.005926623,0.000038800306,0.00006319497,0.0023201427,0.0030462556,0.000022130236,0.000097844044,0.0014567239],"genre_scores_gemma":[0.99519247,0.0019791385,0.00034309644,0.00019131567,0.0013603809,0.000113894115,0.00004262659,0.0002160995,0.00056100363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9864604,0.0017395605,0.0067129354,0.0013031419,0.002193327,0.0015906517],"domain_scores_gemma":[0.9864452,0.00691954,0.002739203,0.0013246876,0.0012078406,0.0013635221],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004944325,0.0009081737,0.005215826,0.0012542884,0.00012761139,0.00007558704,0.0010568323,0.0013315188,0.0002519913],"category_scores_gemma":[0.004396232,0.00069150876,0.0009881656,0.001733658,0.00093582185,0.0004124247,0.00042072753,0.0020691054,0.00016154833],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4493575,0.016102124,0.004047394,0.00371979,0.008781951,0.06705624,0.007008471,0.045287598,0.00031806823,0.00007870672,0.003248329,0.3949938],"study_design_scores_gemma":[0.6429993,0.18329921,0.0033384545,0.0027086271,0.0026631234,0.0015923554,0.00077937654,0.15020359,0.00017665877,0.000032622287,0.011555693,0.0006510222],"about_ca_topic_score_codex":0.0056271,"about_ca_topic_score_gemma":0.0021632158,"teacher_disagreement_score":0.3943428,"about_ca_system_score_codex":0.5232563,"about_ca_system_score_gemma":0.46187165,"threshold_uncertainty_score":0.99996495},"labels":[],"label_agreement":null},{"id":"W4399480809","doi":"10.1200/jco.2024.42.16_suppl.7543","title":"Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Oncology; Internal medicine; Refractory (planetary science)","score_opus":0.07123496320944629,"score_gpt":0.4203326377822693,"score_spread":0.34909767457282304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922084,0.0024657205,0.00007327607,0.0012401153,0.0007481786,0.0030222218,0.00004558746,0.000041751628,0.00015475639],"genre_scores_gemma":[0.99593437,0.0006488502,0.0024860676,0.00040826068,0.00026054907,0.00007217691,0.000058512767,0.000071169095,0.00006005158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906409,0.0025988559,0.0041120118,0.00080234394,0.0011993706,0.0006465286],"domain_scores_gemma":[0.9744759,0.021699328,0.0018783563,0.00058134476,0.0005158425,0.00084920635],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060090814,0.00054298266,0.004504709,0.00038957328,0.00018295443,0.0001193309,0.00024670686,0.00042791804,0.00007263185],"category_scores_gemma":[0.0116838515,0.0002913569,0.00047548802,0.00039063668,0.00078962825,0.00038907691,0.0002572721,0.0025560253,0.000008313301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21973291,0.007864022,0.6727525,0.000031815383,0.003439778,0.0027979293,0.00084845634,0.0000020470216,0.000016721264,0.0000034206084,0.00020459536,0.092305824],"study_design_scores_gemma":[0.3644601,0.013845827,0.61758965,0.00028026657,0.0013282355,0.00010945186,0.0005682628,0.0009239017,0.000012340301,0.00004129671,0.0006603783,0.0001802802],"about_ca_topic_score_codex":0.0009366515,"about_ca_topic_score_gemma":0.0010397554,"teacher_disagreement_score":0.14472719,"about_ca_system_score_codex":0.00025939563,"about_ca_system_score_gemma":0.00096403016,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4399480854","doi":"10.1200/jco.2024.42.16_suppl.7503","title":"DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","score_opus":0.1691857205432594,"score_gpt":0.5092422431011188,"score_spread":0.34005652255785934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845105,0.0108908,0.00021335013,0.0019014312,0.0010297701,0.0009205645,0.00017271625,0.000031833213,0.00032902733],"genre_scores_gemma":[0.9806215,0.00776106,0.009844337,0.00028924027,0.0011035871,0.000024883166,0.000094090516,0.000067920846,0.00019338573],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99151003,0.0017246299,0.0042893975,0.00081751903,0.0009672471,0.00069116213],"domain_scores_gemma":[0.98310536,0.013271521,0.0015939443,0.0005074933,0.00037696867,0.0011446985],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005366312,0.00049295014,0.003771832,0.0008700588,0.00007845908,0.0000665723,0.00029610883,0.0009551209,0.00035294224],"category_scores_gemma":[0.009993125,0.00036407643,0.0006931391,0.0006159278,0.0008122119,0.00035763264,0.00022296318,0.0026282393,0.00001957095],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37296587,0.011471316,0.14926246,0.00022826192,0.0038251826,0.011937746,0.0004503911,0.0000030816036,0.0071890964,0.000050586303,0.0025172571,0.44009876],"study_design_scores_gemma":[0.4894261,0.056137186,0.41937762,0.0010302888,0.0027220894,0.0010283426,0.00049759983,0.0047621126,0.0024387245,0.00057975017,0.021483436,0.00051673775],"about_ca_topic_score_codex":0.0009785894,"about_ca_topic_score_gemma":0.0010847118,"teacher_disagreement_score":0.43958202,"about_ca_system_score_codex":0.00029575243,"about_ca_system_score_gemma":0.0018985779,"threshold_uncertainty_score":0.99988115},"labels":[],"label_agreement":null},{"id":"W4399480874","doi":"10.1200/jco.2024.42.16_suppl.7547","title":"Patterns and predictors of electronically measured oral anticancer medication (OAM) adherence among patients with multiple myeloma (MM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research","keywords":"Medicine; Multiple myeloma; Medication adherence; Internal medicine; Oncology","score_opus":0.07575453923038708,"score_gpt":0.4108652265446498,"score_spread":0.33511068731426275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427295,0.0005193823,0.0018753958,0.0019663386,0.00067997276,0.0002484524,0.0000054613247,0.000015288737,0.00041677814],"genre_scores_gemma":[0.9972075,0.0006881058,0.0010521116,0.00049325,0.0003591541,0.000008801333,0.000006721468,0.000013279975,0.00017107162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970118,0.00022160336,0.0016484552,0.00022768228,0.0006961218,0.00019434534],"domain_scores_gemma":[0.9967014,0.00105964,0.0010405573,0.00018457613,0.00063275936,0.00038103032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017281248,0.000121857236,0.0008809916,0.00009480533,0.000022458511,0.000008852717,0.00016160846,0.00023655372,0.00030756934],"category_scores_gemma":[0.002475524,0.00007697306,0.00013885892,0.0001683702,0.0003605046,0.00015357231,0.00002822569,0.0007882436,0.000013473609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010887296,0.00049055065,0.9009861,0.000097346514,0.00028855712,0.00003600218,0.000061455066,9.277686e-7,0.000080312675,0.000039204686,0.001839119,0.094991736],"study_design_scores_gemma":[0.0040611094,0.009401087,0.97684205,0.0007581717,0.00032675389,0.000032984903,0.000040385068,0.0004043849,0.00009135512,0.00007779095,0.007891301,0.00007260726],"about_ca_topic_score_codex":0.000023000144,"about_ca_topic_score_gemma":0.00006485135,"teacher_disagreement_score":0.09491913,"about_ca_system_score_codex":0.000073016636,"about_ca_system_score_gemma":0.0017596872,"threshold_uncertainty_score":0.34245703},"labels":[],"label_agreement":null},{"id":"W4399480892","doi":"10.1200/jco.2024.42.16_suppl.7565","title":"Automated myeloma cell selection using machine learning and artificial intelligence.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Imaging for Blood Diseases","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Jewish General Hospital; Ontario Genomics","funders":"","keywords":"Medicine; Artificial intelligence; Selection (genetic algorithm); Multiple myeloma; Machine learning; Computer science; Internal medicine","score_opus":0.11022760263243482,"score_gpt":0.45161020193917045,"score_spread":0.34138259930673565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7928223,0.003381296,0.19335346,0.0029897534,0.0042352783,0.0001016977,0.0000019288207,0.0005024648,0.0026118436],"genre_scores_gemma":[0.9541598,0.000089118425,0.04507251,0.00018886589,0.00040992693,3.2397898e-7,3.6374325e-7,0.000009775135,0.00006932013],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979242,0.00026605802,0.0012028367,0.00020844454,0.00022037675,0.00017805009],"domain_scores_gemma":[0.9979376,0.0011393178,0.0004738468,0.000066016895,0.00016484212,0.00021835364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016208724,0.00009904409,0.00042146153,0.00019243288,0.000059885126,0.0002762332,0.00025401468,0.00011702777,0.000014998731],"category_scores_gemma":[0.0010852956,0.0000790673,0.00018484586,0.00035199377,0.00011213664,0.00075821904,0.00013913556,0.00061641174,0.000021696618],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010444881,0.00059916964,0.005136986,0.00004440855,0.00010892589,0.0007110562,0.00012116485,0.0013652301,0.0011567003,0.004915732,0.00047121913,0.98526496],"study_design_scores_gemma":[0.00014551278,0.0018921796,0.0011761852,0.000060327253,0.00007406279,0.0005991903,0.000023438022,0.97264427,0.0010640738,0.008846397,0.013367101,0.00010724142],"about_ca_topic_score_codex":0.000010643904,"about_ca_topic_score_gemma":0.000005609415,"teacher_disagreement_score":0.9851577,"about_ca_system_score_codex":0.000058947866,"about_ca_system_score_gemma":0.00073714956,"threshold_uncertainty_score":0.3224271},"labels":[],"label_agreement":null},{"id":"W4399480918","doi":"10.1200/jco.2024.42.16_suppl.tps7577","title":"MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. Everett Chalmers Regional Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine","score_opus":0.1305628271357605,"score_gpt":0.48819228077042975,"score_spread":0.35762945363466925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966803,0.00015074038,0.000016196549,0.00071347447,0.00022227026,0.0017985973,0.0000121446965,0.000007996108,0.00039823275],"genre_scores_gemma":[0.9972396,0.00010425091,0.0021136506,0.00013345762,0.00006886051,0.00003790104,0.000016285596,0.000032707365,0.00025331826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954138,0.0008428753,0.0022844402,0.00034675476,0.00079063367,0.00032149692],"domain_scores_gemma":[0.99496645,0.00305409,0.0008628389,0.00027914133,0.0004924588,0.00034500417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025330745,0.00020189524,0.001626071,0.0005374909,0.00002878093,0.00002573231,0.00028438785,0.00023742601,0.0001635013],"category_scores_gemma":[0.0029094936,0.00011388027,0.00007346065,0.0005589233,0.00017207224,0.0003586289,0.000105492756,0.0013031694,0.000012335642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15100618,0.13308398,0.49303237,0.00008530091,0.0005380453,0.008358173,0.00042371984,0.000003837679,0.000022169757,0.000008103332,0.00027792918,0.2131602],"study_design_scores_gemma":[0.3117968,0.1649495,0.520891,0.00046951976,0.00015017971,0.000040742376,0.00028333254,0.00051577884,0.000009161712,0.00001885453,0.0007999494,0.0000751615],"about_ca_topic_score_codex":0.0003042035,"about_ca_topic_score_gemma":0.0024918178,"teacher_disagreement_score":0.21308504,"about_ca_system_score_codex":0.00039690323,"about_ca_system_score_gemma":0.0021101928,"threshold_uncertainty_score":0.5661695},"labels":[],"label_agreement":null},{"id":"W4399480972","doi":"10.1200/jco.2024.42.16_suppl.7566","title":"Genome-wide 5-hydroxymethylation mapping and epigenetic pathways in multiple myeloma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Epigenetics; Medicine; Genome; Multiple myeloma; Computational biology; DNA methylation; Genetics; Epigenomics; Epigenome; Cancer research; Gene; Biology; Gene expression; Immunology","score_opus":0.08896850637574123,"score_gpt":0.38027928225028823,"score_spread":0.291310775874547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97244614,0.017188901,0.008217865,0.00059780036,0.0007597176,0.00010424962,0.0000027066494,0.0000041895923,0.00067840883],"genre_scores_gemma":[0.988731,0.006592015,0.0036205738,0.00016839827,0.00078791485,0.000002839982,0.000009740209,0.000017169215,0.00007034682],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976825,0.00036225215,0.0013939751,0.00024420375,0.00014119835,0.00017587835],"domain_scores_gemma":[0.99843276,0.0007713823,0.00040539925,0.00012810399,0.000114991184,0.00014734044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030586005,0.00011374567,0.0004434977,0.00015702346,0.000029658837,0.000024059947,0.00011624615,0.0003911619,0.000012071302],"category_scores_gemma":[0.0023136162,0.0000970526,0.00017931295,0.00012758085,0.000097692115,0.000009365438,0.00007238671,0.00038177625,0.000005478297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002928437,0.0002475166,0.23281653,0.00006439112,0.00015845695,0.00017185751,0.00025703874,0.001014539,0.41441765,0.00006321948,0.000083252446,0.3504127],"study_design_scores_gemma":[0.0015527043,0.0025774196,0.8179611,0.000061740204,0.00004032971,0.000025366759,0.000089360205,0.0016953922,0.011024122,0.0024080027,0.16238682,0.00017765693],"about_ca_topic_score_codex":0.0000055568853,"about_ca_topic_score_gemma":0.000057642734,"teacher_disagreement_score":0.5851446,"about_ca_system_score_codex":0.00003280034,"about_ca_system_score_gemma":0.00040805165,"threshold_uncertainty_score":0.39576903},"labels":[],"label_agreement":null},{"id":"W4399480981","doi":"10.1200/jco.2024.42.16_suppl.e19083","title":"CSF proteomics for predicting response to treatment in patients with primary and secondary central nervous system lymphoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Proteomics; Central nervous system; Primary central nervous system lymphoma; Lymphoma; Primary (astronomy); Oncology; Internal medicine; Biology","score_opus":0.035420541381216315,"score_gpt":0.3686283542189377,"score_spread":0.3332078128377214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941986,0.0005185587,0.00006962042,0.002982532,0.0006534363,0.0013408273,0.000034168606,0.00001656393,0.00018568033],"genre_scores_gemma":[0.99245095,0.000078250996,0.0063372185,0.00051623135,0.00042924364,0.0000786004,0.000008060761,0.000025480003,0.00007597562],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99774134,0.00022680547,0.0013301627,0.00024354445,0.00019964273,0.0002584741],"domain_scores_gemma":[0.9963798,0.0025882688,0.00035593632,0.00012144807,0.00015716038,0.00039736548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013477895,0.00015604068,0.0010769911,0.00017426159,0.000032224718,0.000023913055,0.00004911152,0.0001892432,0.000005145488],"category_scores_gemma":[0.0006592711,0.00009299835,0.00021852463,0.00010593394,0.00005151933,0.00008573943,0.00002800533,0.00015612936,0.0000022900351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045135323,0.002403777,0.38547218,0.00016993927,0.00045920163,0.0011946552,0.0002659139,0.0000125465185,0.000016919716,0.000023497187,0.00027973918,0.5645663],"study_design_scores_gemma":[0.021633873,0.04707794,0.9096828,0.0007041469,0.0004298804,0.00031705073,0.00011245439,0.00015412224,0.000036728394,0.0000072422968,0.019769033,0.000074736585],"about_ca_topic_score_codex":0.000024604335,"about_ca_topic_score_gemma":0.00003190563,"teacher_disagreement_score":0.56449157,"about_ca_system_score_codex":0.0017797294,"about_ca_system_score_gemma":0.0027661556,"threshold_uncertainty_score":0.49070415},"labels":[],"label_agreement":null},{"id":"W4399481113","doi":"10.1200/jco.2024.42.16_suppl.7061","title":"Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Roche (Canada)","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; CHOP; Pathology; Cancer research; Oncology; Internal medicine","score_opus":0.06469420735463101,"score_gpt":0.41847921984842756,"score_spread":0.35378501249379657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971609,0.0016013104,0.000008964848,0.00032976302,0.000200711,0.0005577969,0.00003360335,0.0000029879236,0.00010392203],"genre_scores_gemma":[0.9988342,0.00050462264,0.00035676622,0.00017401893,0.00008543065,0.0000139662125,0.00001347281,0.000011385452,0.0000061481733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996311,0.00059176906,0.0021200418,0.0002587374,0.0004897171,0.00022872018],"domain_scores_gemma":[0.9956393,0.0030418765,0.0007986972,0.00021274929,0.00016569601,0.00014164462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031370893,0.00017596295,0.0015379762,0.00056376227,0.00002122975,0.000013798823,0.00015097865,0.00017831213,0.00001848739],"category_scores_gemma":[0.00042181328,0.00009718891,0.00036717285,0.00065977505,0.00011791196,0.00009674166,0.00005851617,0.00033209962,9.641365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009529179,0.10582783,0.86798954,0.000080288824,0.0020174736,0.00086799276,0.0021784,0.0000070541464,0.00016357156,0.00005802321,0.000014563957,0.011266069],"study_design_scores_gemma":[0.12939283,0.027627792,0.83614355,0.000093914896,0.003701035,0.000008680014,0.0019569376,0.0005950899,0.000078534686,0.000010040662,0.00031988235,0.00007171249],"about_ca_topic_score_codex":0.00020344746,"about_ca_topic_score_gemma":0.0014404539,"teacher_disagreement_score":0.11986365,"about_ca_system_score_codex":0.00033396605,"about_ca_system_score_gemma":0.0006985153,"threshold_uncertainty_score":0.39632487},"labels":[],"label_agreement":null},{"id":"W4399481117","doi":"10.1200/jco.2024.42.16_suppl.7051","title":"A single-cell multiomics analysis of IRF4 in mediating treatment resistance in ibrutinib-treated chronic lymphocytic leukemia (CLL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Alberta; Simon Fraser University; Spinal Cord Injury BC","funders":"Michael Smith Health Research BC","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Venetoclax; Cancer research; Leukemia; Oncology; Immunology; Internal medicine","score_opus":0.1185399246747633,"score_gpt":0.45946295791884434,"score_spread":0.340923033244081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894736,0.006506953,0.00003522132,0.00051955384,0.00042682682,0.00032757092,0.000011251273,0.000017786733,0.0026812828],"genre_scores_gemma":[0.99385077,0.0030717691,0.0017466594,0.00011452468,0.00048311567,0.000011017232,0.000015092907,0.000035416975,0.00067166146],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99303776,0.00069844513,0.004588803,0.00044790894,0.0006774875,0.00054961897],"domain_scores_gemma":[0.98918486,0.008504581,0.0012506024,0.00039861485,0.0002962924,0.00036507097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004283539,0.00025705804,0.00297196,0.001636163,0.000019612122,0.000017209086,0.00026645197,0.0006272825,0.00011763101],"category_scores_gemma":[0.004149294,0.0001918477,0.00095729856,0.002480975,0.00032797214,0.0001279272,0.00007797155,0.0009398743,0.000017368611],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04467607,0.014027643,0.29037896,0.0045306836,0.022223426,0.0957057,0.009404872,0.0673376,0.041916333,0.00055393716,0.0023387754,0.406906],"study_design_scores_gemma":[0.16903308,0.0245443,0.06435113,0.0027327326,0.0078082844,0.0004576138,0.000673313,0.7069267,0.0077958787,0.00023080321,0.014883146,0.0005630185],"about_ca_topic_score_codex":0.0014831832,"about_ca_topic_score_gemma":0.006616617,"teacher_disagreement_score":0.6395891,"about_ca_system_score_codex":0.17271322,"about_ca_system_score_gemma":0.09212259,"threshold_uncertainty_score":0.91302425},"labels":[],"label_agreement":null},{"id":"W4399481122","doi":"10.1200/jco.2024.42.16_suppl.tps6592","title":"VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Polycythemia vera; Medicine; Hepcidin; Internal medicine; Gastroenterology; Oncology; Anemia","score_opus":0.04344162385569494,"score_gpt":0.4286534419399107,"score_spread":0.38521181808421573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134225,0.0007518679,0.000014618138,0.0038331167,0.00093904434,0.002558531,0.0000043237765,0.0000063842467,0.0005498793],"genre_scores_gemma":[0.9985033,0.00017940394,0.0002217551,0.00062436867,0.00023984739,0.00008758829,0.000001407816,0.000020225165,0.00012206179],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938577,0.0017466989,0.0033316354,0.00023348123,0.00062122865,0.00020927646],"domain_scores_gemma":[0.989414,0.008488558,0.0012860498,0.0002460477,0.00035825997,0.00020707835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040342933,0.00021907133,0.00450781,0.00018690257,0.00003312851,0.000014561959,0.00014886247,0.00018892772,0.00017146197],"category_scores_gemma":[0.0050111967,0.00009168141,0.0008733756,0.0002519397,0.0002148886,0.00006939558,0.00004427334,0.000890737,0.000007200905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6463149,0.02260033,0.31757993,0.000029251227,0.0032705276,0.00054367294,0.0005885609,0.000013818298,0.000017905364,0.00007570099,0.0004239967,0.008541406],"study_design_scores_gemma":[0.7802082,0.03549036,0.17987373,0.00043352137,0.0025362608,0.000034181547,0.00014443381,0.00022139886,0.00010657601,0.000075959746,0.00079794443,0.00007746531],"about_ca_topic_score_codex":0.000037494185,"about_ca_topic_score_gemma":0.00006004985,"teacher_disagreement_score":0.1377062,"about_ca_system_score_codex":0.00018756131,"about_ca_system_score_gemma":0.0012919578,"threshold_uncertainty_score":0.59992325},"labels":[],"label_agreement":null},{"id":"W4399481144","doi":"10.1200/jco.2024.42.16_suppl.7068","title":"Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Follicular lymphoma; Oncology; Internal medicine; Lymphoma","score_opus":0.07392619698520736,"score_gpt":0.44311054637387054,"score_spread":0.3691843493886632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486107,0.0020101583,0.000007452564,0.0013534654,0.0004918471,0.00043341375,0.000011635513,0.000011523136,0.00081945874],"genre_scores_gemma":[0.9952448,0.0032866534,0.00035153684,0.00045577702,0.00045768573,0.000016364904,0.000010005099,0.000031504595,0.00014568267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969161,0.0002870552,0.0017742342,0.00028228603,0.00044860024,0.00029172288],"domain_scores_gemma":[0.9972263,0.0012121531,0.0007736019,0.0002536515,0.00021351049,0.00032076248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007923886,0.00026822355,0.0017386349,0.00028968416,0.000023789327,0.00001710554,0.00010610763,0.00026902062,0.00009786852],"category_scores_gemma":[0.00022876944,0.00013623986,0.0010344185,0.00023233975,0.00009251313,0.00009876423,0.000019332781,0.00022499601,0.000019724397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007324594,0.013490297,0.60867524,0.000015418333,0.0016124882,0.0022190947,0.000112949856,0.000063079715,0.000025191188,0.000029385552,0.0006775827,0.3657547],"study_design_scores_gemma":[0.03608106,0.10455911,0.8515389,0.00042062206,0.0003604468,0.00012813127,0.000017840031,0.000103199636,0.0003841802,0.00002864607,0.00627603,0.00010181564],"about_ca_topic_score_codex":0.00026681897,"about_ca_topic_score_gemma":0.000034165638,"teacher_disagreement_score":0.3656529,"about_ca_system_score_codex":0.0015555213,"about_ca_system_score_gemma":0.0022171976,"threshold_uncertainty_score":0.55557},"labels":[],"label_agreement":null},{"id":"W4399481193","doi":"10.1200/jco.2024.42.16_suppl.7020","title":"Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoma; Internal medicine; Oncology; Hodgkin lymphoma; Phases of clinical research; Chemotherapy","score_opus":0.057857997307203125,"score_gpt":0.43845667029719165,"score_spread":0.3805986729899885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938809,0.00071244326,0.0000067021942,0.0025365634,0.0009315745,0.0013270596,0.000108918386,0.000038940227,0.00045689504],"genre_scores_gemma":[0.9959351,0.0007563212,0.0014207535,0.0007245896,0.00053772377,0.000052101597,0.00007257456,0.000054720404,0.0004461522],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99417496,0.000588425,0.0034843609,0.0006395407,0.0007334835,0.00037925658],"domain_scores_gemma":[0.9943089,0.0030529557,0.0012759531,0.00051505317,0.00034514422,0.0005019973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015570258,0.00039667438,0.0022643257,0.00031579786,0.00006874614,0.000034250235,0.00018642438,0.00047783117,0.00014211617],"category_scores_gemma":[0.0008920511,0.00021105137,0.00044794913,0.0004460338,0.0001291077,0.00021498861,0.00005821399,0.0005331731,0.000029684561],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.184366,0.08866411,0.32857946,0.000012056466,0.0023861425,0.011777925,0.0010303367,0.000005004085,0.000011308277,0.0000018837163,0.0033934305,0.37977234],"study_design_scores_gemma":[0.17533952,0.21635677,0.59333175,0.0005525276,0.00083098724,0.0000434369,0.00012816416,0.00007756002,0.00005047067,0.000017541617,0.013134195,0.00013706708],"about_ca_topic_score_codex":0.000691251,"about_ca_topic_score_gemma":0.00038740758,"teacher_disagreement_score":0.37963527,"about_ca_system_score_codex":0.0016498324,"about_ca_system_score_gemma":0.0025609976,"threshold_uncertainty_score":0.8606425},"labels":[],"label_agreement":null},{"id":"W4399481218","doi":"10.1200/jco.2024.42.16_suppl.7046","title":"Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Randomized controlled trial; Oncology; Internal medicine; Clinical endpoint; Lymphoma; Surrogate endpoint; Leukemia","score_opus":0.47920550893122277,"score_gpt":0.5875569842723763,"score_spread":0.10835147534115358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9066088,0.074878074,0.002379644,0.0029349953,0.0022573003,0.008915568,0.00006820927,0.000075250195,0.0018821446],"genre_scores_gemma":[0.9836617,0.005351099,0.005147956,0.0011834146,0.0016817469,0.00085187715,0.000029687824,0.00012264398,0.0019698618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9553266,0.015331495,0.024435727,0.0011056752,0.0025509428,0.0012495583],"domain_scores_gemma":[0.77098614,0.21507494,0.009542849,0.0010057013,0.00242779,0.00096258847],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.1920114,0.0007743436,0.046813004,0.0030829564,0.00007768744,0.000106490654,0.00080144685,0.001258792,0.0015940148],"category_scores_gemma":[0.24346793,0.00045374405,0.033427957,0.0021008898,0.0009724134,0.00022956876,0.0002376942,0.0010140118,0.00005510517],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.54331917,0.0004946003,0.000008130748,0.0008476734,0.40808073,0.0024530161,0.00038921603,0.02129697,0.00074926903,0.0011528588,0.00036149463,0.020846866],"study_design_scores_gemma":[0.3999338,0.005128853,0.000019579544,0.00019680032,0.2568693,0.00039320783,0.00008092022,0.33522153,0.00025153323,0.0010121568,0.000723525,0.0001688376],"about_ca_topic_score_codex":0.0018202227,"about_ca_topic_score_gemma":0.00056820485,"teacher_disagreement_score":0.31392455,"about_ca_system_score_codex":0.15436183,"about_ca_system_score_gemma":0.3846455,"threshold_uncertainty_score":0.99979144},"labels":[],"label_agreement":null},{"id":"W4399481260","doi":"10.1200/jco.2024.42.16_suppl.7021","title":"Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Internal medicine; Lymphoma; Subgroup analysis; B-cell lymphoma","score_opus":0.06794785047623743,"score_gpt":0.41044518608994285,"score_spread":0.34249733561370543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914012,0.002542432,0.000021617312,0.00094350794,0.00064536865,0.00036411572,0.000011096522,0.000029785595,0.004040904],"genre_scores_gemma":[0.9946319,0.0007988772,0.0018745268,0.0014155217,0.0004866242,0.00001387145,0.000022288617,0.000055503344,0.00070091296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564064,0.00041720277,0.002245128,0.00044982668,0.00078786805,0.0004593531],"domain_scores_gemma":[0.99543285,0.0022293222,0.001105789,0.00034763906,0.0003824546,0.0005019368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010639849,0.00032821845,0.0020131283,0.0003833683,0.00005105523,0.000040423078,0.00019197281,0.0004701181,0.00012368678],"category_scores_gemma":[0.00046397094,0.00016778933,0.0004297156,0.0005393935,0.00017761358,0.0003116355,0.000061350045,0.00076446694,0.000055065106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047416586,0.037454013,0.7982725,0.00020022917,0.0016902133,0.018574702,0.00043235923,0.000009663702,0.000029471239,0.000056310255,0.004089446,0.09177454],"study_design_scores_gemma":[0.07027134,0.06883621,0.8208739,0.00069308624,0.0011268049,0.00031561355,0.00011381437,0.000046300953,0.00004604113,0.000019310519,0.037468936,0.00018863949],"about_ca_topic_score_codex":0.00011261758,"about_ca_topic_score_gemma":0.00020720175,"teacher_disagreement_score":0.0915859,"about_ca_system_score_codex":0.0015100854,"about_ca_system_score_gemma":0.005021257,"threshold_uncertainty_score":0.8907494},"labels":[],"label_agreement":null},{"id":"W4399481268","doi":"10.1200/jco.2024.42.16_suppl.7055","title":"A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; Jewish General Hospital; CancerCare Manitoba","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Classical Hodgkin lymphoma; Oncology; Lymphoma; Internal medicine; Cancer research; Immunotherapy; Hodgkin lymphoma; Cancer","score_opus":0.10065436574981813,"score_gpt":0.4814330227714067,"score_spread":0.3807786570215886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960918,0.0002325115,0.00021339773,0.0019836957,0.000420018,0.000849138,0.000019453417,0.000019459643,0.00017052481],"genre_scores_gemma":[0.9979548,0.00017064216,0.0011078271,0.00030291325,0.00024310104,0.000037901056,0.000058865047,0.000028081915,0.00009590621],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952435,0.00071273476,0.0028376132,0.0004099174,0.00053202576,0.00026421473],"domain_scores_gemma":[0.9948871,0.0025211757,0.0013429549,0.0003044196,0.0006089498,0.0003353882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022735477,0.00023045306,0.0026117878,0.0007529549,0.000037540194,0.000022862001,0.0001626841,0.00038283868,0.00008707744],"category_scores_gemma":[0.00089952076,0.00013337616,0.0005512422,0.0009149009,0.00016476637,0.00023476858,0.000032041222,0.00041017757,0.0000034376471],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13116337,0.2995635,0.18392003,0.00011452212,0.012324333,0.01145695,0.0014480335,0.00009184428,0.00019276285,0.00040952358,0.002999331,0.35631582],"study_design_scores_gemma":[0.1792412,0.28491294,0.51325333,0.00017045315,0.008065432,0.0002985368,0.0010098268,0.005883385,0.00009961582,0.000092226284,0.0068188366,0.00015423102],"about_ca_topic_score_codex":0.000069186004,"about_ca_topic_score_gemma":0.00041186606,"teacher_disagreement_score":0.3561616,"about_ca_system_score_codex":0.00058683736,"about_ca_system_score_gemma":0.0025730082,"threshold_uncertainty_score":0.5438922},"labels":[],"label_agreement":null},{"id":"W4399481328","doi":"10.1200/jco.2024.42.16_suppl.e19002","title":"Real-world barriers to CAR-T access: A Canadian referral center perspective.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Referral; Perspective (graphical); Family medicine; Medical emergency","score_opus":0.16079550675472445,"score_gpt":0.5149049176788891,"score_spread":0.3541094109241647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481328","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16518968,0.0045767617,0.0003777974,0.35587904,0.041070662,0.00063717674,0.00019435145,0.00010790378,0.43196663],"genre_scores_gemma":[0.9709922,0.00078782183,0.0018268533,0.017364744,0.0011763796,0.000003703706,0.0000029235032,0.000027601509,0.007817746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644935,0.0010341849,0.0015866854,0.00033726796,0.00007693037,0.0005155691],"domain_scores_gemma":[0.9967659,0.0015178494,0.00030420808,0.00020529088,0.00038621266,0.0008205521],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036213214,0.00018253506,0.0010994896,0.00052293786,0.00010231778,0.000053416767,0.00057446625,0.00069999404,0.004114294],"category_scores_gemma":[0.0043364502,0.00012382296,0.0006144414,0.00044300072,0.00033732146,0.0001612246,0.00011983446,0.0017992208,0.00019993108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002463521,0.0004483338,0.034915563,0.000035031986,0.002260829,0.0019305857,0.0006957025,0.0000052340056,0.0019576955,0.024427518,0.77623063,0.15462935],"study_design_scores_gemma":[0.0010172841,0.0023027977,0.022288924,0.000085399704,0.00020852216,0.0002060907,0.00036622703,0.000006806702,0.0002522417,0.0018146663,0.97129166,0.00015939955],"about_ca_topic_score_codex":0.014635004,"about_ca_topic_score_gemma":0.08335967,"teacher_disagreement_score":0.8058025,"about_ca_system_score_codex":0.00061632495,"about_ca_system_score_gemma":0.0044662454,"threshold_uncertainty_score":0.9967961},"labels":[],"label_agreement":null},{"id":"W4399481588","doi":"10.1200/jco.2024.42.16_suppl.e19003","title":"Neurocognitive testing to predict ICANS post-CAR T.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.20436132135508994,"score_gpt":0.5313948194509309,"score_spread":0.327033498095841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65687233,0.000263026,0.017465785,0.29629925,0.001655319,0.0006434616,0.000018749894,0.00021497959,0.02656711],"genre_scores_gemma":[0.89448917,0.00010405986,0.07974785,0.02240826,0.0027195504,0.000014779945,0.0000023896314,0.000023267901,0.0004906724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977405,0.00013474858,0.0014540979,0.00018815161,0.00030018628,0.00018228832],"domain_scores_gemma":[0.99417704,0.0039605643,0.0003123397,0.00014640651,0.00070530485,0.0006983364],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021937087,0.00009181836,0.00068777835,0.00013632154,0.000028799153,0.0000152178545,0.00015030452,0.00017798759,0.00013388136],"category_scores_gemma":[0.017617183,0.0000620617,0.00028282116,0.00031437888,0.0001463955,0.000058890433,0.00006431404,0.001266675,0.00007923786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004943806,0.00094774365,0.00735811,0.00007912673,0.00021923216,0.0026195531,0.00011156162,0.000002242565,0.00745115,0.00084776036,0.15828201,0.82158715],"study_design_scores_gemma":[0.0013401234,0.017446041,0.05864288,0.0008352678,0.00061599276,0.0023152172,0.00008766939,0.001941455,0.00032745025,0.0013249303,0.915004,0.00011898025],"about_ca_topic_score_codex":0.000011167175,"about_ca_topic_score_gemma":0.0000016821333,"teacher_disagreement_score":0.8214682,"about_ca_system_score_codex":0.000058782778,"about_ca_system_score_gemma":0.0015016885,"threshold_uncertainty_score":0.99065787},"labels":[],"label_agreement":null},{"id":"W4399481598","doi":"10.1200/jco.2024.42.16_suppl.7053","title":"Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; ABVD; Stage (stratigraphy); Lymphoma; Dacarbazine; Overall survival; Oncology; Nuclear medicine; Chemotherapy; Surgery; Internal medicine; Vincristine","score_opus":0.07000405330839714,"score_gpt":0.4136482641684603,"score_spread":0.34364421086006314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972412,0.00026712587,0.000015390198,0.000555311,0.0008551159,0.00047959006,0.000037079142,0.000015899162,0.00053325994],"genre_scores_gemma":[0.99874264,0.00021405879,0.000380372,0.00010176317,0.00029457593,0.000009407406,0.00003754977,0.000025923968,0.0001936986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950582,0.0007908912,0.002578635,0.00043761716,0.0008259613,0.00030868952],"domain_scores_gemma":[0.9940113,0.0038269015,0.0010762429,0.00035562954,0.00036749576,0.0003624502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014695893,0.00026587394,0.0027248843,0.0004189793,0.000023970693,0.000028539482,0.00018711599,0.00037414223,0.00019368043],"category_scores_gemma":[0.00072235835,0.00016508857,0.0006448625,0.0006996067,0.00012750398,0.00016324066,0.000078504294,0.00046903244,0.000013899737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03257533,0.02031311,0.9079681,0.000020505395,0.01073622,0.0024771984,0.0005831686,0.00009606917,0.0000018028435,0.000044141045,0.00031469093,0.024869645],"study_design_scores_gemma":[0.08283528,0.039261293,0.8693434,0.00015500833,0.0062249885,0.000003554667,0.00044580802,0.0002041515,0.0000096206195,0.000018712328,0.0013716498,0.00012651506],"about_ca_topic_score_codex":0.0008978543,"about_ca_topic_score_gemma":0.0019742937,"teacher_disagreement_score":0.050259944,"about_ca_system_score_codex":0.00074146956,"about_ca_system_score_gemma":0.001483801,"threshold_uncertainty_score":0.67321163},"labels":[],"label_agreement":null},{"id":"W4399481603","doi":"10.1200/jco.2024.42.16_suppl.7056","title":"A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Classical Hodgkin lymphoma; Oncology; Lymphoma; Internal medicine; Brentuximab vedotin; Cancer research; Hodgkin lymphoma; Cancer; Immunotherapy","score_opus":0.08561850792821196,"score_gpt":0.4751666784907593,"score_spread":0.3895481705625473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996623,0.00032957585,0.00015414324,0.0014535292,0.00032257623,0.0008637505,0.000022873088,0.00002293305,0.0002076531],"genre_scores_gemma":[0.9986762,0.00012096184,0.00060013455,0.00021533633,0.00019515325,0.000035042343,0.00008357385,0.000027559028,0.000046053778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547464,0.000665033,0.0026757545,0.00040207867,0.0005133859,0.00026910278],"domain_scores_gemma":[0.9960149,0.001613751,0.0011270528,0.00029068082,0.0006089722,0.0003446545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018897665,0.00023586137,0.002553408,0.0007791983,0.000033968798,0.000025512461,0.00014882995,0.00036036686,0.00006792417],"category_scores_gemma":[0.00046973472,0.00014832953,0.0005625226,0.0009497798,0.0001520819,0.00023187131,0.00002750307,0.00035882817,0.0000028596596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048739582,0.26487303,0.40276805,0.00008762704,0.010416803,0.0052315076,0.00081219646,0.000106096246,0.00020106655,0.00025189744,0.0013098834,0.26520225],"study_design_scores_gemma":[0.12729432,0.20307298,0.6516269,0.00013246112,0.0070165107,0.00020124858,0.00044081008,0.006811714,0.00014961418,0.00006881149,0.0030536603,0.00013100082],"about_ca_topic_score_codex":0.00010584104,"about_ca_topic_score_gemma":0.00033920925,"teacher_disagreement_score":0.26507124,"about_ca_system_score_codex":0.0005447311,"about_ca_system_score_gemma":0.0018736403,"threshold_uncertainty_score":0.6048703},"labels":[],"label_agreement":null},{"id":"W4399487111","doi":"10.1200/jco.2024.42.16_suppl.e18504","title":"Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Complete remission; Internal medicine; Oncology; Surgery; Pediatrics; Chemotherapy","score_opus":0.06613484762689062,"score_gpt":0.424071032342389,"score_spread":0.3579361847154984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399487111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9363393,0.00005540059,0.00030665763,0.06019848,0.00037515906,0.0006103208,0.000017481341,0.000020637683,0.0020765488],"genre_scores_gemma":[0.9850486,0.00025547226,0.007370632,0.005325029,0.0005203526,0.0000086472355,0.000009592269,0.00005451053,0.001407183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960142,0.00039487449,0.00207038,0.00034869177,0.0007457194,0.00042614856],"domain_scores_gemma":[0.9934777,0.0041754693,0.000542772,0.00032187867,0.00074426865,0.0007379079],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024741401,0.00023284047,0.0018736458,0.0002962669,0.00006066684,0.000022968947,0.00031524542,0.00034729776,0.00011232509],"category_scores_gemma":[0.004191463,0.000112666974,0.00025858125,0.00044775679,0.00021016932,0.0001494356,0.0001354489,0.0023486323,0.000058176833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03676416,0.0014149788,0.8410172,0.0001285405,0.00055864936,0.0017770735,0.00055178074,0.000043167583,0.000040031864,0.00007663467,0.010316305,0.10731152],"study_design_scores_gemma":[0.014009294,0.02041069,0.7957814,0.00118937,0.00011641607,0.0001378647,0.00011153343,0.00033511556,0.000012426382,0.000025390835,0.16774169,0.0001288157],"about_ca_topic_score_codex":0.000034994577,"about_ca_topic_score_gemma":0.00039307508,"teacher_disagreement_score":0.15742539,"about_ca_system_score_codex":0.0008405473,"about_ca_system_score_gemma":0.002554424,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W4399488349","doi":"10.1200/jco.2024.42.16_suppl.6021","title":"BMI correlation with outcomes in patients with head and neck cancer undergoing immunotherapy: A comprehensive review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Head and neck cancer; Oncology; Internal medicine; Immunotherapy; Head and neck; Cancer; Surgery","score_opus":0.26796995922938077,"score_gpt":0.5351989506339818,"score_spread":0.26722899140460105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399488349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012114254,0.9942351,0.0000065543204,0.0034949998,0.00015442578,0.0007798987,0.000015370513,0.00000507678,0.00009713309],"genre_scores_gemma":[0.00021316724,0.9957228,0.0005427646,0.0031583929,0.00007143638,0.000034955898,0.000006181554,0.000030083838,0.00022023235],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959488,0.00052692706,0.002694496,0.00032490853,0.00032595734,0.00017890867],"domain_scores_gemma":[0.9948587,0.002150909,0.0022699628,0.00017457418,0.00037931767,0.00016654219],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0009787192,0.0003594675,0.016383013,0.000292423,0.000030879663,0.0000118047055,0.000070125745,0.00029707045,0.000056300367],"category_scores_gemma":[0.0002866111,0.00015522267,0.0012554171,0.00047691225,0.00018226547,0.000072597,0.000046884154,0.0013590681,0.0000018571117],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010186457,0.0006409723,0.082493015,0.030173741,0.41345775,0.0002577102,0.00008060717,0.000003207704,2.0969275e-9,0.000011306731,0.0010743804,0.4707887],"study_design_scores_gemma":[0.0028685697,0.005955542,0.047921296,0.00788101,0.5208612,0.00004682919,0.000008564614,9.703932e-7,6.9078365e-10,0.0000051048246,0.4143251,0.00012582967],"about_ca_topic_score_codex":0.000041131625,"about_ca_topic_score_gemma":0.0006298884,"teacher_disagreement_score":0.47066283,"about_ca_system_score_codex":0.00017700606,"about_ca_system_score_gemma":0.0016302785,"threshold_uncertainty_score":0.9982198},"labels":[],"label_agreement":null},{"id":"W4399519585","doi":"10.1200/jco.2024.42.16_suppl.tps8116","title":"The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Immunotherapy; Pathology","score_opus":0.13317905615974068,"score_gpt":0.4799944488978683,"score_spread":0.3468153927381276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567841,0.023906395,0.0032788345,0.004548409,0.0056215106,0.0048800255,0.00006737678,0.000083568055,0.00082973833],"genre_scores_gemma":[0.96695054,0.020939633,0.0009838324,0.0020180906,0.0030733831,0.00041264968,0.000009857427,0.00015786465,0.0054541538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913767,0.0018063792,0.0042708633,0.00070564175,0.0009380312,0.0009023573],"domain_scores_gemma":[0.987822,0.008136028,0.0020817837,0.00059918896,0.00080646144,0.00055451825],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009519619,0.00057878654,0.0026036121,0.00040252178,0.00039516453,0.00024232123,0.00097448274,0.00075107184,0.0006395228],"category_scores_gemma":[0.0012684561,0.00035283118,0.0016238443,0.0005652435,0.00049182225,0.00023791204,0.00015530441,0.0023839972,0.000019022304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7199179,0.0040016305,0.002915206,0.00025744893,0.0078118225,0.0020519865,0.006979298,0.00007316454,0.0032398698,0.000017197704,0.043219376,0.20951514],"study_design_scores_gemma":[0.43343723,0.122795545,0.020518292,0.0012747247,0.0033287979,0.0006085139,0.0027372374,0.013424057,0.00194049,0.00010934426,0.39893755,0.0008882009],"about_ca_topic_score_codex":0.00035574194,"about_ca_topic_score_gemma":0.00040113463,"teacher_disagreement_score":0.35571817,"about_ca_system_score_codex":0.0012913459,"about_ca_system_score_gemma":0.010460326,"threshold_uncertainty_score":0.99991757},"labels":[],"label_agreement":null},{"id":"W4399519592","doi":"10.1200/jco.2024.42.16_suppl.e20013","title":"Assessment of carcinoembryonic antigen-related cell adhesion molecule 5 expression by immunohistochemistry in real-world clinical samples of non-small cell lung cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carcinoembryonic antigen; Medicine; Immunohistochemistry; Lung cancer; Cell adhesion molecule; Antigen; Pathology; Cell; Cancer research; Oncology; Cancer; Internal medicine; Immunology; Biology","score_opus":0.08364373435868101,"score_gpt":0.5055882309269709,"score_spread":0.4219444965682899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767561,0.011690668,0.00006307481,0.0009644935,0.00091124186,0.00027874985,0.000034419696,0.0000072789653,0.009293996],"genre_scores_gemma":[0.967572,0.026723465,0.0024631969,0.00012140909,0.0003556169,0.000006189153,0.000020623715,0.000028457302,0.0027090611],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9932049,0.00064219924,0.00475934,0.00036803595,0.0006621021,0.0003634374],"domain_scores_gemma":[0.9935771,0.0036155116,0.0016938548,0.00028846637,0.0004384514,0.0003865693],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0040971166,0.00022064653,0.0021243612,0.00025787047,0.00003218384,0.000007362634,0.0003629994,0.0005859851,0.00038619773],"category_scores_gemma":[0.00041740618,0.00015820276,0.00092433643,0.00037121988,0.00036970223,0.000064785796,0.00018966687,0.0024558757,0.0000032521277],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015879493,0.0020305256,0.49039328,0.0010309365,0.00017415108,0.0004615736,0.00006382253,0.000026127036,0.49081165,0.000013153773,0.009128359,0.004278473],"study_design_scores_gemma":[0.005806283,0.0063029765,0.85136753,0.0024349648,0.00033648146,0.00003940714,0.00011577837,0.0024915533,0.12507813,0.000043560674,0.0057859677,0.00019736441],"about_ca_topic_score_codex":0.0007727691,"about_ca_topic_score_gemma":0.00003584661,"teacher_disagreement_score":0.3657335,"about_ca_system_score_codex":0.00026346653,"about_ca_system_score_gemma":0.0039487476,"threshold_uncertainty_score":0.9998455},"labels":[],"label_agreement":null},{"id":"W4399519774","doi":"10.1200/jco.2024.42.16_suppl.6509","title":"Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Oncology; INT; Clinical trial; Bone marrow","score_opus":0.05662040660429468,"score_gpt":0.420154701999125,"score_spread":0.36353429539483034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922853,0.0005631068,0.00008712379,0.004764616,0.0010824192,0.0008337045,0.00018404088,0.000014471634,0.00018518552],"genre_scores_gemma":[0.9952431,0.0027869018,0.0008203564,0.00024281838,0.00067024725,0.0000058110872,0.000052332216,0.000037813406,0.00014061843],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99327874,0.0014023277,0.0036874705,0.00044436898,0.0007868912,0.0004001972],"domain_scores_gemma":[0.9768726,0.02037244,0.0015311973,0.00037707906,0.00039824896,0.00044841808],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062363683,0.00026425824,0.0020365599,0.00028329305,0.00004773798,0.000025238676,0.00034352503,0.00042977984,0.00009174305],"category_scores_gemma":[0.018476872,0.00014285176,0.00033644066,0.0003981428,0.0007815935,0.00018807987,0.0001957285,0.0027993273,0.000019370365],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67323375,0.0039743804,0.014652222,0.00007432503,0.0008687358,0.002419049,0.00040632812,0.000039127062,0.000023713492,0.0000073896317,0.00551888,0.2987821],"study_design_scores_gemma":[0.35025775,0.12559947,0.51073456,0.0016584807,0.0010547881,0.00018789821,0.00016866637,0.0020682372,0.00004320149,0.000077767334,0.007992567,0.00015662958],"about_ca_topic_score_codex":0.00014929668,"about_ca_topic_score_gemma":0.0000859641,"teacher_disagreement_score":0.4960823,"about_ca_system_score_codex":0.00036143305,"about_ca_system_score_gemma":0.0022259087,"threshold_uncertainty_score":0.9995012},"labels":[],"label_agreement":null},{"id":"W4399519785","doi":"10.1200/jco.2024.42.16_suppl.6516","title":"Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Stem cell; Hematopoietic stem cell transplantation; Transplantation; Hematopoietic cell; Haematopoiesis; Leukemia; Oncology; Internal medicine; CD34; CD33","score_opus":0.040178814174143006,"score_gpt":0.38641022431902566,"score_spread":0.3462314101448827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271065,0.0001981281,0.00049803354,0.00484986,0.00037328593,0.0005264124,0.000009588894,0.000018773811,0.00081528036],"genre_scores_gemma":[0.99323034,0.0008521413,0.0041361763,0.0009076712,0.00021923895,0.0000073316464,0.0000049197724,0.000039999333,0.00060218794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965125,0.00020618556,0.001982987,0.00034532376,0.00057329296,0.00037975522],"domain_scores_gemma":[0.9967504,0.0019177945,0.00040403084,0.00013773437,0.0003137753,0.00047626306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00250248,0.00020991526,0.001419036,0.0004576543,0.000044331537,0.000031647323,0.00018938315,0.00030117107,0.000038585986],"category_scores_gemma":[0.0002598352,0.00013651216,0.00018182881,0.0004012289,0.00011957734,0.0002167243,0.00006413233,0.0015143713,0.000021284897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0088574905,0.00047027724,0.90975744,0.00046582313,0.00065478875,0.0026344492,0.0017627969,0.00007809545,0.0004702831,0.000056934892,0.0007395925,0.074052006],"study_design_scores_gemma":[0.012522887,0.009221348,0.97282594,0.0007768574,0.0006056058,0.0005887357,0.00043389888,0.00015899491,0.00025294404,0.00005993621,0.0023577588,0.00019506851],"about_ca_topic_score_codex":0.000015750531,"about_ca_topic_score_gemma":0.000025689467,"teacher_disagreement_score":0.07385694,"about_ca_system_score_codex":0.0011475757,"about_ca_system_score_gemma":0.0030453538,"threshold_uncertainty_score":0.65792733},"labels":[],"label_agreement":null},{"id":"W4399519807","doi":"10.1200/jco.2024.42.16_suppl.6506","title":"Frailty risk assessment and impact on acute myeloid leukemia outcomes (FRAIL-AML): A population-based study from Ontario, Canada.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Population; Leukemia; Gerontology; Intensive care medicine; Oncology; Internal medicine; Environmental health","score_opus":0.07380174558020768,"score_gpt":0.46879218715893656,"score_spread":0.39499044157872887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985317,0.00012757737,0.00008924908,0.010607616,0.0028120559,0.00043601412,0.000099474346,0.000024300958,0.00048671901],"genre_scores_gemma":[0.9930657,0.00004098495,0.0024016646,0.0030443857,0.000734799,0.0000065376817,0.000028681341,0.000032665408,0.0006445893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99535,0.00059763197,0.0024446286,0.00039539236,0.000904364,0.00030798517],"domain_scores_gemma":[0.9895547,0.008085876,0.0010674135,0.00036338854,0.00025789774,0.00067069713],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002081157,0.00030197782,0.0020079769,0.00018142955,0.000075462354,0.00005016058,0.00019443301,0.0003600877,0.00077897665],"category_scores_gemma":[0.001927921,0.00018814257,0.00051476544,0.00014598416,0.00006525963,0.00013221549,0.00005505606,0.0027773874,0.000009438799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017129463,0.00090798276,0.936399,0.000010785339,0.002477794,0.0026727498,0.00017628893,0.00024695424,0.0000066542657,0.0000051393354,0.014756585,0.040627126],"study_design_scores_gemma":[0.0086132595,0.014335719,0.96409756,0.00016995393,0.001707374,0.00006320272,0.00011767229,0.0010141684,0.0000022687452,0.00022553983,0.009491368,0.00016188495],"about_ca_topic_score_codex":0.8157212,"about_ca_topic_score_gemma":0.92430353,"teacher_disagreement_score":0.108582325,"about_ca_system_score_codex":0.005430682,"about_ca_system_score_gemma":0.024888333,"threshold_uncertainty_score":0.9995232},"labels":[],"label_agreement":null},{"id":"W4399519869","doi":"10.1200/jco.2024.42.16_suppl.6501","title":"Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Ponatinib; Mutation; Cancer research; Dasatinib; Imatinib; Gene; Genetics","score_opus":0.03931583916447061,"score_gpt":0.3960597151784573,"score_spread":0.35674387601398666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869629,0.0028031413,0.000056066845,0.006260993,0.0011375056,0.0007378818,0.000051628667,0.000027431417,0.0019624082],"genre_scores_gemma":[0.99388945,0.0013242548,0.0019162948,0.000494105,0.0018652258,0.000017373954,0.00008096604,0.000048479884,0.0003638755],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947372,0.00067328324,0.0029592873,0.00050965877,0.0007126497,0.00040792336],"domain_scores_gemma":[0.9915708,0.006079782,0.0012880006,0.00039004043,0.0003090505,0.00036233832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003413736,0.00030512665,0.0015967329,0.00022619507,0.00006513422,0.000048401424,0.00023737474,0.00048239392,0.00017246044],"category_scores_gemma":[0.0035756102,0.00017203229,0.0003181972,0.00032594043,0.0006025375,0.00028321522,0.00009727559,0.0019284507,0.00007142948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11295954,0.0033927,0.014509381,0.00024100245,0.0028570462,0.009022276,0.0017808917,0.00059121853,0.00010102571,0.0009802579,0.005873517,0.8476911],"study_design_scores_gemma":[0.56178373,0.0752695,0.26961163,0.0027526356,0.0025350791,0.001129646,0.00035383157,0.013629022,0.00018282964,0.0011436841,0.07108177,0.0005266626],"about_ca_topic_score_codex":0.00031791028,"about_ca_topic_score_gemma":0.0005364578,"teacher_disagreement_score":0.84716445,"about_ca_system_score_codex":0.0055670626,"about_ca_system_score_gemma":0.010047538,"threshold_uncertainty_score":0.99825037},"labels":[],"label_agreement":null},{"id":"W4399519890","doi":"10.1200/jco.2024.42.16_suppl.e20083","title":"Multimodal risk stratification of non-metastatic lung adenocarcinoma using AI on histology and immunohistochemistry slides.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Immunohistochemistry; Histology; Risk stratification; Adenocarcinoma; Pathology; Lung; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.05037953881576407,"score_gpt":0.47601615692893307,"score_spread":0.425636618113169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973675,0.0038240866,0.010146294,0.0045103217,0.0011329256,0.000115459065,0.0000028745426,0.000008233867,0.0005230805],"genre_scores_gemma":[0.9812759,0.00046345475,0.017102968,0.00056817004,0.00049028837,0.0000010912057,0.0000028228376,0.000017844317,0.000077434794],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973149,0.00025998498,0.0018153572,0.00020650076,0.00024782828,0.00015545748],"domain_scores_gemma":[0.99620575,0.0021222362,0.0010840769,0.00016225815,0.00019803032,0.00022765757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028718677,0.00012169506,0.0010470811,0.00016179713,0.0000408159,0.000011174966,0.00010557557,0.00022170154,0.000058141955],"category_scores_gemma":[0.004529864,0.00009121337,0.00027349452,0.00010238577,0.00039691228,0.0000676698,0.00002700781,0.0019426782,0.0000023445466],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041875136,0.0020319966,0.19229542,0.00142069,0.0019473874,0.00332516,0.0009711094,0.0010976546,0.100022644,0.0006772908,0.00685074,0.6851724],"study_design_scores_gemma":[0.008652906,0.009255333,0.29680422,0.0013704286,0.0029578176,0.004593602,0.00024932643,0.66858727,0.000984199,0.0014908331,0.0047847256,0.00026932947],"about_ca_topic_score_codex":0.000051287665,"about_ca_topic_score_gemma":6.764881e-7,"teacher_disagreement_score":0.6849031,"about_ca_system_score_codex":0.00017503893,"about_ca_system_score_gemma":0.001163595,"threshold_uncertainty_score":0.8440078},"labels":[],"label_agreement":null},{"id":"W4399519892","doi":"10.1200/jco.2024.42.16_suppl.6525","title":"Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Innovate UK","keywords":"Medicine; Myeloid leukemia; Drug; Algorithm; Myeloid; Oncology; Leukemia; Internal medicine; Pharmacology","score_opus":0.1403031564000324,"score_gpt":0.48609650401249865,"score_spread":0.3457933476124663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95188254,0.0021459754,0.0026508165,0.036750164,0.003925637,0.0012925004,0.000086552,0.000078232544,0.0011875803],"genre_scores_gemma":[0.75356734,0.033007096,0.16770351,0.010682864,0.011991643,0.00018055613,0.0000902576,0.00030181272,0.02247492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931827,0.00059696264,0.003853686,0.0006401541,0.00091256946,0.00081389415],"domain_scores_gemma":[0.9911239,0.0056840894,0.00069170963,0.0004658076,0.00057866774,0.0014558097],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044441796,0.00040756052,0.0024685266,0.0008281942,0.00007116237,0.00005988203,0.0005886471,0.0007939228,0.00034269367],"category_scores_gemma":[0.0056330618,0.0002896155,0.00079381483,0.0009640418,0.00025909208,0.0003652779,0.00027656666,0.003434585,0.0007327082],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00548919,0.0033404576,0.015341603,0.00011112126,0.0021757507,0.06002156,0.00067788025,0.00033918102,0.00057847967,0.000008447578,0.06464273,0.8472736],"study_design_scores_gemma":[0.077660315,0.04830137,0.1980344,0.0023351382,0.002729814,0.004926813,0.0006815569,0.04485072,0.0008718108,0.00020519883,0.6186552,0.0007476333],"about_ca_topic_score_codex":0.00038963836,"about_ca_topic_score_gemma":0.0005263061,"teacher_disagreement_score":0.84652597,"about_ca_system_score_codex":0.0036232444,"about_ca_system_score_gemma":0.009277957,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W4399519905","doi":"10.1200/jco.2024.42.16_suppl.e20077","title":"Neoadjuvant immuno-chemotherapy in resectable non-small cell lung cancer: A retrospective cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Chemotherapy; Retrospective cohort study; Oncology; Internal medicine; Lung cancer; Cancer; Cohort","score_opus":0.04049636534563364,"score_gpt":0.45262603696174164,"score_spread":0.41212967161610803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729112,0.010190453,0.000019364816,0.007655484,0.0026187915,0.0009501855,0.000004319487,0.000014259199,0.0056359703],"genre_scores_gemma":[0.98175544,0.014531525,0.00041339212,0.0009471614,0.0012919342,0.000078244295,0.0000011360837,0.000032834385,0.00094830996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678475,0.0002579989,0.0019037437,0.00035624468,0.00039722334,0.00030003846],"domain_scores_gemma":[0.9975464,0.0010780417,0.00059074274,0.000249627,0.00030105625,0.00023415468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034348778,0.00018222563,0.0018368148,0.00020204579,0.00003100776,0.000025264799,0.00015378166,0.0002683235,0.00037300968],"category_scores_gemma":[0.00028989458,0.00012138013,0.00046797743,0.00032367336,0.00007149939,0.00008935513,0.000044505156,0.0013470474,0.000014005169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002137703,0.0048466907,0.9569602,0.00008236616,0.0012704021,0.003549605,0.0005956665,0.000021336227,0.000055907032,0.000013095894,0.0120575875,0.018409448],"study_design_scores_gemma":[0.0124534145,0.016022807,0.9550145,0.00065704854,0.00083524117,0.0000862671,0.00021483394,0.00035790046,0.00013423838,0.00008113979,0.014036557,0.00010603905],"about_ca_topic_score_codex":0.0010189796,"about_ca_topic_score_gemma":0.00095396646,"teacher_disagreement_score":0.01830341,"about_ca_system_score_codex":0.0023843343,"about_ca_system_score_gemma":0.002973463,"threshold_uncertainty_score":0.62349516},"labels":[],"label_agreement":null},{"id":"W4399519971","doi":"10.1200/jco.2024.42.16_suppl.6502","title":"Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Surgery; Bone marrow","score_opus":0.11759710885495724,"score_gpt":0.45585084155277766,"score_spread":0.33825373269782044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390554,0.00030319873,0.00003735308,0.0034762556,0.00022739192,0.0017008398,0.00026244464,0.000006678023,0.000080292455],"genre_scores_gemma":[0.9978517,0.000286923,0.001004573,0.00020170315,0.0002678582,0.000025048937,0.00030883393,0.000020805644,0.00003254114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725366,0.00038942823,0.0015447511,0.0003340988,0.00031983762,0.0001582093],"domain_scores_gemma":[0.99283004,0.0056066634,0.00075682584,0.00030403538,0.00034587597,0.00015656138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009997074,0.00018746076,0.0011931113,0.00009219015,0.000050994564,0.000021947984,0.00013077872,0.0001326934,0.00003955276],"category_scores_gemma":[0.00061750796,0.000085618216,0.00008448885,0.00015688634,0.00013801524,0.00016092957,0.000052941272,0.0003181867,0.0000018660328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056461908,0.048936322,0.75299186,0.000033088956,0.0021293354,0.0003509622,0.0010764509,0.000007927966,0.000010203873,0.00013010752,0.0013906637,0.1364812],"study_design_scores_gemma":[0.10168175,0.12524395,0.761454,0.0003638704,0.0014686146,0.00002369156,0.00051539566,0.00023740201,0.00004066906,0.000034480076,0.008859866,0.00007632912],"about_ca_topic_score_codex":0.000099865465,"about_ca_topic_score_gemma":0.000608657,"teacher_disagreement_score":0.13640487,"about_ca_system_score_codex":0.00013921614,"about_ca_system_score_gemma":0.0006474849,"threshold_uncertainty_score":0.34914094},"labels":[],"label_agreement":null},{"id":"W4399565437","doi":"10.1200/jco.2024.42.16_suppl.11116","title":"A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Practices and Rehabilitation","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck; Descriptive statistics; Head and neck cancer; Patient-reported outcome; Physical therapy; Intensive care medicine; Quality of life (healthcare); Surgery; Internal medicine; Cancer; Nursing","score_opus":0.28218820161226377,"score_gpt":0.5955073087513552,"score_spread":0.3133191071390914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399565437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598695,0.00054063235,0.0021857445,0.033151083,0.002661584,0.00034004173,0.000008445712,0.000011674929,0.0012312727],"genre_scores_gemma":[0.99359864,0.0002705769,0.0030163673,0.0023729275,0.0003403287,0.0000047265403,0.0000018500062,0.000011670008,0.00038291002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934737,0.0016235189,0.0039341496,0.00023905314,0.00048085378,0.00024868886],"domain_scores_gemma":[0.9763707,0.020318775,0.0020431909,0.00017252145,0.00058770366,0.00050712517],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0059416676,0.000121362515,0.0015847712,0.00042723614,0.000107355736,0.000009877018,0.00011403568,0.00047983133,0.0004040733],"category_scores_gemma":[0.019822076,0.00007436389,0.00048798995,0.00064390944,0.00019393145,0.00019333173,0.000089162946,0.0014193542,0.000016220883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00512541,0.0013172871,0.7296847,0.0005449558,0.010690042,0.00047651544,0.044592656,0.000272764,0.00016925072,0.0031996653,0.015947942,0.1879788],"study_design_scores_gemma":[0.003803842,0.0122149065,0.8583996,0.00068598386,0.004729229,0.000015000387,0.03011315,0.002525743,0.000001272875,0.0039913235,0.083350584,0.00016932176],"about_ca_topic_score_codex":0.0002489495,"about_ca_topic_score_gemma":0.00033937467,"teacher_disagreement_score":0.18780948,"about_ca_system_score_codex":0.00021530234,"about_ca_system_score_gemma":0.0016161102,"threshold_uncertainty_score":0.9884344},"labels":[],"label_agreement":null},{"id":"W4399570650","doi":"10.1200/jco.2024.42.16_suppl.tps9602","title":"A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Human leukocyte antigen; Surgery; Immunotherapy; Cancer research; Immunology; Cancer; Antigen","score_opus":0.07968899237102706,"score_gpt":0.47349714728562897,"score_spread":0.3938081549146019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399570650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893338,0.0014158011,0.00009695216,0.0021774082,0.0024455427,0.0017928514,0.00003201657,0.000037751695,0.0026678443],"genre_scores_gemma":[0.9932457,0.0015167857,0.0019802244,0.00018260721,0.0010299353,0.000028605615,0.000025623598,0.00009386504,0.0018966517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99212795,0.0011483729,0.0038851926,0.0005698072,0.0015650279,0.0007036566],"domain_scores_gemma":[0.9916588,0.0044787335,0.0016864785,0.00059239374,0.0008995321,0.000684072],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004319316,0.00036850123,0.0033001632,0.0006101919,0.00004633727,0.00003477876,0.00040160998,0.00070175616,0.0012075334],"category_scores_gemma":[0.004361266,0.00026437666,0.0008078686,0.00079466356,0.0005273584,0.00026886145,0.000112033376,0.0025640705,0.000027374874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.713407,0.005045418,0.0018226742,0.0001111904,0.0012473505,0.0023717657,0.00046382606,0.000019172436,0.00029152664,0.00002655912,0.0027123517,0.2724812],"study_design_scores_gemma":[0.60790783,0.30353215,0.0021470056,0.00077082106,0.00077028415,0.00012996048,0.0002491962,0.00032623849,0.000272128,0.00009083355,0.08356299,0.00024055014],"about_ca_topic_score_codex":0.0000849197,"about_ca_topic_score_gemma":0.00025384498,"teacher_disagreement_score":0.29848674,"about_ca_system_score_codex":0.0016322319,"about_ca_system_score_gemma":0.006845065,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W4399570686","doi":"10.1200/jco.2024.42.16_suppl.tps8651","title":"Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated <i>KRAS G12C+</i>advanced non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Pemetrexed; Medicine; Pembrolizumab; Chemotherapy; Lung cancer; Oncology; KRAS; Lung; Internal medicine; non-small cell lung cancer (NSCLC); Phases of clinical research; Cancer; Cancer research; Cisplatin; Colorectal cancer; Immunotherapy","score_opus":0.04445174887146803,"score_gpt":0.48963043435992293,"score_spread":0.4451786854884549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399570686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889397,0.00523501,0.0001547716,0.0025065728,0.00085390935,0.001186204,0.00003489464,0.000022574888,0.0010663369],"genre_scores_gemma":[0.99591255,0.0013683895,0.0010921379,0.00069307606,0.00036241318,0.000052361276,0.0000103091,0.00004660684,0.00046217072],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99638593,0.00025497147,0.0022743747,0.00039618375,0.00036540598,0.00032313238],"domain_scores_gemma":[0.9966476,0.0014144917,0.0010151255,0.00023599948,0.0003456147,0.00034118755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008798539,0.000290673,0.0018261906,0.000390571,0.000060386195,0.000016108655,0.00014382404,0.0002731347,0.0002061864],"category_scores_gemma":[0.00029946954,0.00020440647,0.00033838107,0.00050553307,0.00012264345,0.00012703202,0.000038572143,0.000829578,0.0000013010549],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030435089,0.040013637,0.5690543,0.0009020128,0.0041723005,0.0040616095,0.0074038706,0.000827032,0.005806672,0.000019913754,0.00384326,0.33346027],"study_design_scores_gemma":[0.42802498,0.09649748,0.42610654,0.0026454676,0.008441161,0.00021696294,0.0019673735,0.02039724,0.0030183818,0.00007435181,0.011966985,0.0006430664],"about_ca_topic_score_codex":0.0002906007,"about_ca_topic_score_gemma":0.00034314988,"teacher_disagreement_score":0.3975899,"about_ca_system_score_codex":0.0004723713,"about_ca_system_score_gemma":0.0031765578,"threshold_uncertainty_score":0.8335454},"labels":[],"label_agreement":null},{"id":"W4399571391","doi":"10.1200/jco.2024.42.16_suppl.tps8668","title":"FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Exon; Oncology; Chemotherapy; Internal medicine; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.1094437706771043,"score_gpt":0.5412324112596139,"score_spread":0.43178864058250954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399571391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662364,0.0013335537,0.0030369961,0.024932241,0.0015216407,0.0015835697,0.00005509462,0.00002754544,0.0012729757],"genre_scores_gemma":[0.989196,0.001683717,0.0056461655,0.0006425073,0.00134462,0.00013924656,0.00008151954,0.00003700066,0.001229242],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99727815,0.00010950686,0.0019099489,0.00023543295,0.00027371405,0.00019322635],"domain_scores_gemma":[0.9965158,0.0015777056,0.0010414683,0.0001737571,0.00043730764,0.0002539239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007105225,0.00018389017,0.0011824892,0.00017055665,0.000063024454,0.000012430902,0.00007155292,0.00021445274,0.00014234385],"category_scores_gemma":[0.00057349534,0.000111291505,0.000641434,0.0002028191,0.00012817231,0.00015012099,0.0000066530874,0.0002518017,0.000008323197],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3823233,0.013385524,0.0002852282,0.000103778075,0.002545971,0.00028414515,0.0007379581,0.0003122973,0.0005277154,0.00022558674,0.000831956,0.59843653],"study_design_scores_gemma":[0.45308873,0.28952295,0.0017877895,0.0004984185,0.0034019423,0.00023099202,0.00024363062,0.00066138204,0.0014158307,0.0009091011,0.24808899,0.00015024673],"about_ca_topic_score_codex":0.00002657888,"about_ca_topic_score_gemma":0.00011311019,"teacher_disagreement_score":0.5982863,"about_ca_system_score_codex":0.0004186064,"about_ca_system_score_gemma":0.0024220715,"threshold_uncertainty_score":0.45383358},"labels":[],"label_agreement":null},{"id":"W4399571397","doi":"10.1200/jco.2024.42.16_suppl.tps8654","title":"Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring <i>HER2</i> tyrosine kinase domain (TKD) mutations.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Oncology; Standard of care; Lung cancer; Lung; Internal medicine; Clinical endpoint; Randomized controlled trial; A549 cell","score_opus":0.018421592337278008,"score_gpt":0.41105150654300915,"score_spread":0.3926299142057311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399571397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807824,0.005544805,0.0042766174,0.00051125884,0.0026729968,0.0053842533,0.00012012838,0.000012691042,0.0006948688],"genre_scores_gemma":[0.9925665,0.00072417257,0.005806343,0.00011807163,0.00033413744,0.00030146792,0.000045412788,0.000048030557,0.00005584276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936223,0.00057465263,0.0044347006,0.000342878,0.0006967564,0.00032871292],"domain_scores_gemma":[0.9896579,0.0056629935,0.0028128708,0.00023374261,0.0013339019,0.00029860952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002265327,0.0003219456,0.0048785005,0.0003955498,0.0000494434,0.00001717709,0.00014532053,0.00021897799,0.00006994162],"category_scores_gemma":[0.0016667149,0.00020637621,0.0009706031,0.00041707206,0.0002997941,0.00018167097,0.000032235203,0.0007119068,7.757591e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9703918,0.0046562073,0.0018045167,0.00060565205,0.0020626413,0.00040399117,0.0019449805,0.00083865447,0.00008868754,0.000028658704,0.00012117232,0.017053034],"study_design_scores_gemma":[0.94855917,0.038998354,0.00083210785,0.0018074343,0.007642903,0.0000041844423,0.0006371888,0.00091545074,0.00018327143,0.00003199554,0.0002200016,0.00016797087],"about_ca_topic_score_codex":0.00009698048,"about_ca_topic_score_gemma":0.00022081152,"teacher_disagreement_score":0.034342147,"about_ca_system_score_codex":0.00073718233,"about_ca_system_score_gemma":0.005477289,"threshold_uncertainty_score":0.9716476},"labels":[],"label_agreement":null},{"id":"W4399579773","doi":"10.1200/jco.2024.42.16_suppl.tps8669","title":"A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Queen's University; University Health Network; Ottawa Hospital","funders":"Mark Foundation For Cancer Research","keywords":"Medicine; Biomarker; Lung cancer; Chemotherapy; Oncology; Cancer; Internal medicine; Cancer research; Genetics; Biology","score_opus":0.03271430972047082,"score_gpt":0.39596648918321165,"score_spread":0.3632521794627408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399579773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995612,0.002242192,0.00062975043,0.000203703,0.00070968777,0.00049086806,0.000043274373,0.0000037419873,0.000064775035],"genre_scores_gemma":[0.9971563,0.0008555132,0.0013870805,0.00033939374,0.00013974974,0.000017055396,0.000008391238,0.000034385877,0.00006209631],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997415,0.00040018486,0.0014416957,0.0003250009,0.00018630293,0.00023179829],"domain_scores_gemma":[0.9980519,0.00038506996,0.000780982,0.0002494354,0.00038537232,0.00014727605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013244862,0.00019838511,0.0007641012,0.00015037316,0.000028881579,0.000012854292,0.00026413836,0.00028467132,0.000018070663],"category_scores_gemma":[0.00029460498,0.00015462059,0.0002489155,0.00018056323,0.00010622698,0.000007256243,0.00012027856,0.00041416995,4.8806305e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35569406,0.10618302,0.26855597,0.00012039091,0.004302857,0.001383671,0.002608325,0.0009813728,0.12538686,0.0000046701225,0.005781575,0.12899724],"study_design_scores_gemma":[0.31112567,0.26584432,0.36429283,0.0006861676,0.0009583929,0.000038088594,0.0010774863,0.0045877583,0.020179592,0.000016308666,0.030217905,0.00097550615],"about_ca_topic_score_codex":0.00011386959,"about_ca_topic_score_gemma":0.00027530667,"teacher_disagreement_score":0.1596613,"about_ca_system_score_codex":0.000113410635,"about_ca_system_score_gemma":0.0013987378,"threshold_uncertainty_score":0.63052446},"labels":[],"label_agreement":null},{"id":"W4399604378","doi":"10.1200/jco.2024.42.16_suppl.12076","title":"Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intestinal and Peritoneal Adhesions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Ambulatory; Multidisciplinary approach; Prospective cohort study; Multidisciplinary team; Colorectal cancer; General surgery; Cancer; Oncology; Internal medicine","score_opus":0.0577146274990909,"score_gpt":0.439840604139948,"score_spread":0.3821259766408571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399604378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995758,0.00029008617,0.000024231567,0.00049941486,0.0008327179,0.0012338645,0.000004730816,0.000028670205,0.0013283029],"genre_scores_gemma":[0.98704875,0.0003382781,0.011976516,0.000046300658,0.00026120042,0.00015240448,8.0630645e-7,0.0000150292835,0.0001607472],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99684846,0.00031310096,0.0018681415,0.00031303818,0.00037600938,0.00028124062],"domain_scores_gemma":[0.99774075,0.0007310931,0.00084784365,0.00014648479,0.00029840876,0.00023539487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018877368,0.00017071508,0.0011224044,0.00015475467,0.00004626449,0.0000089932,0.0001194408,0.00019705103,0.000105269864],"category_scores_gemma":[0.00035199523,0.00009953319,0.00018547612,0.00033656,0.00027871932,0.00011259586,0.000067916,0.0012336089,0.000004827753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030343687,0.0100281825,0.44028977,0.0003635078,0.001177362,0.012959381,0.0022045898,0.00039359857,0.00015292257,0.00018869562,0.00007645411,0.5018219],"study_design_scores_gemma":[0.0050722514,0.08482392,0.900354,0.0005197697,0.00032086266,0.00026885365,0.0071130125,0.00035348968,0.000030472707,0.00061553245,0.00042782968,0.00010000704],"about_ca_topic_score_codex":0.000033884877,"about_ca_topic_score_gemma":0.00010561204,"teacher_disagreement_score":0.50172186,"about_ca_system_score_codex":0.0007313283,"about_ca_system_score_gemma":0.0009814923,"threshold_uncertainty_score":0.5359486},"labels":[],"label_agreement":null},{"id":"W4399605265","doi":"10.1200/jco.2024.42.16_suppl.11500","title":"Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Range of motion; Oncology; Internal medicine; Physical therapy; Radiology; Surgery","score_opus":0.048358300477566604,"score_gpt":0.3948116689080352,"score_spread":0.3464533684304686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399605265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427515,0.00020399102,0.000018909606,0.0028489158,0.0011425932,0.00070006336,0.00009230334,0.000007850815,0.0007101944],"genre_scores_gemma":[0.99874574,0.00012294669,0.00034365267,0.00038459557,0.00029703978,0.00000248682,0.000038282975,0.000015616119,0.000049637732],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9953604,0.0003815488,0.0033614228,0.00023582714,0.000475138,0.00018571375],"domain_scores_gemma":[0.99415094,0.003508481,0.0017101867,0.00020877692,0.00022012176,0.00020149004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014225056,0.0001691702,0.0013375228,0.0000941214,0.000032570395,0.000012437586,0.00009068106,0.0001750007,0.000051779778],"category_scores_gemma":[0.0023059414,0.000080147,0.00033560436,0.00015437472,0.00019217466,0.00010262165,0.000054812783,0.00061296363,0.0000033990764],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4085514,0.013708171,0.22538151,0.00004081986,0.0011055318,0.0011114002,0.00047678762,0.00000904469,0.000017176008,0.000028890972,0.00047964972,0.34908962],"study_design_scores_gemma":[0.2373651,0.03235908,0.72147286,0.00018884499,0.00057456194,0.000020444091,0.000085158914,0.00003530845,0.000022565831,0.00005649375,0.007747259,0.00007230369],"about_ca_topic_score_codex":0.0003056832,"about_ca_topic_score_gemma":0.000055729633,"teacher_disagreement_score":0.49609137,"about_ca_system_score_codex":0.00008648684,"about_ca_system_score_gemma":0.00050755066,"threshold_uncertainty_score":0.32682997},"labels":[],"label_agreement":null},{"id":"W4399618865","doi":"10.1200/jco.2024.42.16_suppl.12019","title":"Patient reported symptoms after cancer diagnosis and the risk of short- and long-term severe mental health events among adolescents and young adults (AYA): A population-based study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Medicine; Cancer; Young adult; Mental health; Pediatrics; Population; Psychiatry; Gerontology; Environmental health; Internal medicine","score_opus":0.04351762600426679,"score_gpt":0.42981600327758657,"score_spread":0.3862983772733198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399618865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467195,0.008186498,0.0000072929383,0.004853293,0.0012200348,0.0010068121,0.000041932537,0.000009039686,0.0000031264146],"genre_scores_gemma":[0.99414325,0.0038385594,0.000048219477,0.0015468836,0.00033119123,0.00006016949,0.000004707004,0.000019861276,0.0000071904874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950944,0.0011268103,0.0027047505,0.00031685195,0.0005708389,0.00018630117],"domain_scores_gemma":[0.99659187,0.0011306321,0.001553579,0.00018838255,0.00016764717,0.0003678864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034588114,0.00017699636,0.0013525552,0.00010943513,0.00007079285,0.000016955524,0.00006169152,0.00016360168,0.000036384383],"category_scores_gemma":[0.0010446009,0.00011007548,0.00023632706,0.00011388108,0.00023656205,0.00010662559,0.00008224665,0.00073741254,1.740834e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065166596,0.0011130653,0.9221903,0.00033465333,0.00078664586,0.00013588268,0.0024707534,0.00000219718,1.0196049e-7,5.29819e-7,0.00017726368,0.06627193],"study_design_scores_gemma":[0.010358697,0.005559267,0.9792436,0.0032641292,0.00078104855,0.0001250049,0.00033461698,0.00014901975,6.372858e-7,0.000018247356,0.00007064359,0.00009510138],"about_ca_topic_score_codex":0.0017602065,"about_ca_topic_score_gemma":0.005915353,"teacher_disagreement_score":0.06617683,"about_ca_system_score_codex":0.00016596768,"about_ca_system_score_gemma":0.00056641345,"threshold_uncertainty_score":0.4488748},"labels":[],"label_agreement":null},{"id":"W4399619426","doi":"10.1200/jco.2024.42.16_suppl.12017","title":"Technology-enhanced palliative care for patients with advanced cancer undergoing phase I therapies: A pilot randomized clinical trial (RCT).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Wireless Body Area Networks","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Andrew Sabin Family Foundation; American Cancer Society","keywords":"Medicine; Randomized controlled trial; Palliative care; Cancer; Oncology; Surgery; Internal medicine; Nursing","score_opus":0.06486916390329149,"score_gpt":0.446936336509569,"score_spread":0.3820671726062775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399619426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91772026,0.00864839,0.058459092,0.0010045432,0.011092383,0.0023092271,0.00003333382,0.00024886982,0.00048387508],"genre_scores_gemma":[0.9812263,0.006400222,0.009356494,0.0001803392,0.0024216408,0.00028736066,0.000008740222,0.00008898377,0.00002992166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99453276,0.00060903124,0.003731613,0.00036584676,0.00032739568,0.00043335932],"domain_scores_gemma":[0.9781653,0.019505534,0.001136276,0.00022912836,0.0007319802,0.00023177528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032571014,0.00032326463,0.0029862393,0.00023423387,0.00007501197,0.000037779013,0.00037488187,0.0006558732,0.000045809295],"category_scores_gemma":[0.0047755297,0.00021504314,0.0008605591,0.00035081097,0.0004670434,0.0002457755,0.00004203759,0.0017619295,0.000005292367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5415794,0.00090904883,0.0003595078,0.00012400371,0.0020295277,0.000036453017,0.00034078863,0.0035722598,0.00001258724,0.00017338964,0.00065186294,0.45021114],"study_design_scores_gemma":[0.93605536,0.036625862,0.00022241459,0.0009625019,0.0007637102,0.0000021145586,0.0003950759,0.0069170385,0.000040628023,0.0014500794,0.016226267,0.00033895214],"about_ca_topic_score_codex":0.0000014310071,"about_ca_topic_score_gemma":0.00008489575,"teacher_disagreement_score":0.44987217,"about_ca_system_score_codex":0.00032752907,"about_ca_system_score_gemma":0.0012757501,"threshold_uncertainty_score":0.87692046},"labels":[],"label_agreement":null},{"id":"W4399627762","doi":"10.1200/jco.2024.42.16_suppl.12031","title":"Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Christie (Canada); McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Myocarditis; Immune system; Immune checkpoint; Translational research; Internal medicine; Cancer research; Immunology; Oncology; Immunotherapy; Pathology","score_opus":0.03469830852134992,"score_gpt":0.3690755164760821,"score_spread":0.3343772079547322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399627762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002606,0.0028409672,0.0033537722,0.0020398214,0.0010927059,0.0004599464,0.00001279056,0.000012477822,0.00016143973],"genre_scores_gemma":[0.9987519,0.00014396317,0.00049166224,0.00026695133,0.00030362402,0.0000062122317,8.9647494e-7,0.000020123312,0.000014664146],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968867,0.00031143267,0.002104764,0.00018050623,0.00037991974,0.00013671088],"domain_scores_gemma":[0.99788624,0.00093420653,0.00066766137,0.0001204537,0.00022908027,0.00016236871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032779877,0.0001380694,0.0011309859,0.0001474231,0.000025766047,0.000010957966,0.000059254064,0.00025878867,0.000077415716],"category_scores_gemma":[0.00022581797,0.000088595756,0.0004784359,0.00016471837,0.00015807373,0.000086480744,0.000009197574,0.00074550667,8.2742264e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13598406,0.00797135,0.06011771,0.000500317,0.033221398,0.11849134,0.0039076777,0.0001313515,0.15161093,0.00081586634,0.00036158046,0.4868864],"study_design_scores_gemma":[0.087775946,0.19971518,0.6336209,0.0016049986,0.0077297706,0.05423491,0.0031413333,0.0018131146,0.007050742,0.0014072831,0.0014916604,0.00041416488],"about_ca_topic_score_codex":0.000027939983,"about_ca_topic_score_gemma":0.000018649967,"teacher_disagreement_score":0.5735032,"about_ca_system_score_codex":0.00005881399,"about_ca_system_score_gemma":0.0010217868,"threshold_uncertainty_score":0.361283},"labels":[],"label_agreement":null},{"id":"W4399629256","doi":"10.1200/jco.2024.42.16_suppl.11537","title":"Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"University Health Network","keywords":"Medicine; Circulating tumor DNA; Soft tissue sarcoma; Minimal residual disease; Soft tissue; Sarcoma; Bespoke; Cancer research; DNA; Pathology; Oncology; Internal medicine; Cancer; Bone marrow; Biology; Genetics","score_opus":0.10209476772999095,"score_gpt":0.4663569677371095,"score_spread":0.36426220000711856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399629256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923375,0.0027277875,0.0007196811,0.0023344944,0.0011398687,0.0006240709,0.0000034793104,0.000025950178,0.00008713681],"genre_scores_gemma":[0.9967083,0.000049023205,0.001508458,0.0008734887,0.00078723877,0.000017164683,0.0000019816378,0.000041946907,0.000012447695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953721,0.0010209426,0.0023431543,0.00037853897,0.00055532914,0.00032993924],"domain_scores_gemma":[0.9961631,0.002236811,0.00065818266,0.00023718574,0.00020521689,0.0004995293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002844494,0.00022398724,0.0013209451,0.00034359473,0.00005214349,0.000040594423,0.00011704287,0.00019656422,0.000078075296],"category_scores_gemma":[0.0036708955,0.00016891042,0.00047690276,0.0002879311,0.00010307105,0.00013873557,0.00008001479,0.00096645363,0.000020052796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055908835,0.0117299715,0.6649499,0.00013268818,0.00094468746,0.115555294,0.00031267747,0.0004814655,0.0035946625,0.000026718157,0.00006812444,0.19661294],"study_design_scores_gemma":[0.022811595,0.0101932725,0.93311816,0.0011378324,0.0027516177,0.0010495286,0.0006343059,0.021749025,0.001226976,0.00034611562,0.004698366,0.0002832199],"about_ca_topic_score_codex":0.000102479615,"about_ca_topic_score_gemma":0.00013329876,"teacher_disagreement_score":0.26816824,"about_ca_system_score_codex":0.0005315718,"about_ca_system_score_gemma":0.0010308307,"threshold_uncertainty_score":0.68879676},"labels":[],"label_agreement":null},{"id":"W4399629289","doi":"10.1200/jco.2024.42.16_suppl.11531","title":"Anti-angiogenic TKIs in patients with advanced Ewing sarcoma: A systematic review and single-arm meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Eosinophilic Disorders and Syndromes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcoma; Meta-analysis; Ewing's sarcoma; Oncology; Internal medicine; Pathology","score_opus":0.23459404558153668,"score_gpt":0.48771100762822084,"score_spread":0.25311696204668416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399629289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021738115,0.9964916,0.0000053756303,0.0010918214,0.00021256623,0.0017528019,0.000012830907,0.000008079755,0.00020754151],"genre_scores_gemma":[0.0008606845,0.99694943,0.00062921195,0.0011400888,0.00007226004,0.00003889108,0.000017637529,0.000050595223,0.00024119853],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9896091,0.0014675631,0.007549564,0.00047131482,0.0006024885,0.0002999655],"domain_scores_gemma":[0.9913905,0.0022843794,0.0051338365,0.00048551118,0.00037119878,0.00033454943],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005376252,0.00050446595,0.03440067,0.0007757698,0.000022240329,0.000023385242,0.00027570094,0.00055223826,0.000103339364],"category_scores_gemma":[0.0032439134,0.00023866862,0.0074766777,0.0012019854,0.00014798617,0.00010204874,0.00009924476,0.0015441636,0.000017139833],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059209047,0.0026801452,0.00027637632,0.67758715,0.26023716,0.00090455724,0.000018513143,4.045357e-7,4.74215e-9,0.000011528778,0.00037974832,0.05784521],"study_design_scores_gemma":[0.001367828,0.006220419,0.00020185062,0.11915723,0.8087,0.00038731477,0.000008896737,7.3500996e-7,2.1326454e-9,0.000020280675,0.063747674,0.00018773178],"about_ca_topic_score_codex":0.0000028903055,"about_ca_topic_score_gemma":0.000015033532,"teacher_disagreement_score":0.5584299,"about_ca_system_score_codex":0.00016964729,"about_ca_system_score_gemma":0.0009881966,"threshold_uncertainty_score":0.97993463},"labels":[],"label_agreement":null},{"id":"W4399629901","doi":"10.1200/jco.2024.42.16_suppl.11504","title":"SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University Health Centre","funders":"Stand Up To Cancer","keywords":"Medicine; Pembrolizumab; Soft tissue sarcoma; Randomized controlled trial; Sarcoma; Soft tissue; Oncology; Internal medicine; Surgery; Cancer; Pathology; Immunotherapy","score_opus":0.130835704615947,"score_gpt":0.47691597547419234,"score_spread":0.34608027085824533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399629901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97617453,0.0069820057,0.00071916083,0.012635937,0.0014582936,0.0016846468,0.000009609815,0.000017783666,0.0003180563],"genre_scores_gemma":[0.9893295,0.002870503,0.005205383,0.00061979145,0.0014758082,0.000079285455,0.00000437246,0.000033386037,0.00038194584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958255,0.0004965331,0.002814861,0.00024990577,0.00036937444,0.00024378128],"domain_scores_gemma":[0.96780044,0.030182999,0.001162731,0.00017441835,0.0003490554,0.0003303442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054468247,0.0002000787,0.0045314664,0.00022325684,0.000030429286,0.00001881248,0.00007810629,0.0002894087,0.000110589375],"category_scores_gemma":[0.006000375,0.00009681653,0.00088225293,0.00013139876,0.00041250486,0.000085136344,0.000027643719,0.0004432463,0.0000029957396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.778422,0.002273751,0.0066821203,0.00013711289,0.0014882591,0.0013919285,0.000076452736,8.0285446e-7,0.000017642897,0.00011835686,0.0040915357,0.20530006],"study_design_scores_gemma":[0.89575315,0.033496987,0.0027581286,0.00074958557,0.003391092,0.0021728734,0.000059991846,0.0003001295,0.00015660159,0.00048627635,0.06055439,0.00012080666],"about_ca_topic_score_codex":0.000030525338,"about_ca_topic_score_gemma":0.000041131098,"teacher_disagreement_score":0.20517926,"about_ca_system_score_codex":0.00007387077,"about_ca_system_score_gemma":0.0025561666,"threshold_uncertainty_score":0.7183443},"labels":[],"label_agreement":null},{"id":"W4399661459","doi":"10.1200/jco.2024.42.16_suppl.2628","title":"Endogenous retrotransposable elements as a novel predictive biomarker of response to immunotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Biomarker; Internal medicine; Population; Cohort; Immunotherapy; Proportional hazards model; Immune checkpoint; Cancer; Immunology; Biology","score_opus":0.07545086072555161,"score_gpt":0.41830124685354886,"score_spread":0.34285038612799723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399661459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883355,0.0032133705,0.003304563,0.0014345816,0.0016323867,0.00019208103,0.000098027645,0.0000033600884,0.0017861477],"genre_scores_gemma":[0.9922569,0.0020713396,0.003701543,0.0010839155,0.0005737758,0.0000061144415,0.0000057517036,0.000023376908,0.0002772804],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977573,0.0001937261,0.0014686205,0.00020652337,0.0001860058,0.00018782853],"domain_scores_gemma":[0.9980962,0.00075361016,0.00046185643,0.00020583518,0.00029842334,0.00018405885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00292728,0.00011376677,0.00051888305,0.00010294532,0.000022012066,0.000012427753,0.00025093104,0.00028441334,0.00006504235],"category_scores_gemma":[0.0021414435,0.00009426799,0.00038879397,0.00012517875,0.00010453435,0.0000048005163,0.00006168177,0.0002461524,0.000010413321],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028432328,0.0006468027,0.0013698828,0.000018362003,0.0007955574,0.00012665964,0.00011801833,0.00012737446,0.92557335,0.00007134687,0.004271407,0.038448922],"study_design_scores_gemma":[0.0043269047,0.03698908,0.0109261945,0.00010756513,0.00016258637,0.00029687432,0.00008482774,0.000099023775,0.05882058,0.0003013686,0.8877115,0.00017344145],"about_ca_topic_score_codex":0.000021104766,"about_ca_topic_score_gemma":0.000016060003,"teacher_disagreement_score":0.88344014,"about_ca_system_score_codex":0.00006252418,"about_ca_system_score_gemma":0.0019288528,"threshold_uncertainty_score":0.38441372},"labels":[],"label_agreement":null},{"id":"W4399662535","doi":"10.1200/jco.2024.42.16_suppl.2614","title":"Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono","keywords":"Medicine; Pharmacokinetics; Avelumab; Pharmacodynamics; Pharmacology; Solid tumor; Oncology; Internal medicine; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.03838526387735447,"score_gpt":0.4547933671809966,"score_spread":0.41640810330364214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399662535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962891,0.0009867504,0.0000646849,0.0005742687,0.0013164447,0.0006649503,0.000030688687,0.000014058859,0.000059068785],"genre_scores_gemma":[0.9979456,0.0005689682,0.00046061695,0.00042337738,0.0004946618,0.000010015116,0.0000066742605,0.000040733135,0.00004936569],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964407,0.00024352894,0.0021879836,0.0003501211,0.0004872819,0.00029036318],"domain_scores_gemma":[0.9976662,0.0008445597,0.00076855015,0.00015157499,0.00026083906,0.0003082748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011161991,0.00022244046,0.0017903299,0.00030037714,0.00003016806,0.000016416392,0.00014688622,0.00015479987,0.00027030532],"category_scores_gemma":[0.00025568984,0.0001561362,0.00018312295,0.00033414658,0.000112396636,0.00020886723,0.00006235877,0.0010907068,0.000003017647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1431776,0.0667746,0.27795425,0.00041809105,0.00323888,0.006262133,0.0038857956,0.00022017125,0.05791389,0.000028004826,0.0011116425,0.43901494],"study_design_scores_gemma":[0.34109035,0.17381833,0.46387157,0.0021759085,0.0018153919,0.00015812993,0.00096507225,0.004356585,0.0055451873,0.00034032387,0.005367857,0.0004952832],"about_ca_topic_score_codex":0.00008529334,"about_ca_topic_score_gemma":0.00008892248,"teacher_disagreement_score":0.43851966,"about_ca_system_score_codex":0.0001667558,"about_ca_system_score_gemma":0.0007352361,"threshold_uncertainty_score":0.636705},"labels":[],"label_agreement":null},{"id":"W4399662556","doi":"10.1200/jco.2024.42.16_suppl.2645","title":"Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Cancer; Transcriptome; Immune checkpoint; Genome; Solid tumor; Oncology; Cancer therapy; Internal medicine; Immunotherapy; Gene; Genetics; Biology; Gene expression","score_opus":0.038149946340332565,"score_gpt":0.3825682155830793,"score_spread":0.3444182692427467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399662556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697767,0.027091999,0.000006832101,0.0018482415,0.0002795548,0.000877109,0.000101086946,0.000004243766,0.000014245099],"genre_scores_gemma":[0.9901245,0.008663393,0.00007298239,0.0007938681,0.00026382186,0.00003164135,0.000015595986,0.000019368057,0.000014809914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965164,0.00065736845,0.0019068685,0.00024860087,0.0004595429,0.0002112068],"domain_scores_gemma":[0.9967602,0.0012890955,0.0012273486,0.0002491612,0.00040495457,0.00006927468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011760263,0.0002061835,0.0018740036,0.0001330394,0.00004092556,0.000015592886,0.0001856573,0.00010491528,0.00010518607],"category_scores_gemma":[0.000036317684,0.00008616425,0.0003769357,0.00079717033,0.00041294994,0.00008634346,0.000018182602,0.00058048,1.5490855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07894097,0.0023578438,0.8427448,0.00003427077,0.011857842,0.00015829227,0.0038225285,0.0006210748,0.007088363,3.911618e-7,0.000099267556,0.052274354],"study_design_scores_gemma":[0.014331669,0.016515225,0.9588532,0.0004158716,0.0028878134,0.0000057280913,0.001688126,0.00007833261,0.00015596938,0.000004161091,0.0049660685,0.000097824755],"about_ca_topic_score_codex":0.000979661,"about_ca_topic_score_gemma":0.0018269185,"teacher_disagreement_score":0.11610841,"about_ca_system_score_codex":0.00010208503,"about_ca_system_score_gemma":0.00052063074,"threshold_uncertainty_score":0.3513676},"labels":[],"label_agreement":null},{"id":"W4399662669","doi":"10.1200/jco.2024.42.16_suppl.2612","title":"Pharmacodynamic (PD) and immunophenotyping analyses of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib in a phase Ib study in patients with advanced unresectable solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacodynamics; Immunophenotyping; Solid tumor; Pharmacokinetics; Cancer research; Internal medicine; Cancer; Immunology; Flow cytometry","score_opus":0.059781844456659135,"score_gpt":0.4524935369166164,"score_spread":0.3927116924599573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399662669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940647,0.008143935,0.00002716282,0.00016815355,0.0016951916,0.00048901193,0.000011227077,0.000013043146,0.000045830402],"genre_scores_gemma":[0.9993176,0.00030049976,0.000120095116,0.00004693363,0.00011186603,0.000010814735,0.000015763822,0.00002734056,0.00004908646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945626,0.0011400441,0.0033977672,0.00036242383,0.00014154457,0.00039557627],"domain_scores_gemma":[0.99636173,0.0017605509,0.0013212102,0.00020051481,0.0002871045,0.00006891054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024989953,0.00026013554,0.0019058245,0.00053608976,0.00005694218,0.00001958426,0.00023837572,0.00033351593,0.000070587244],"category_scores_gemma":[0.0010718904,0.00018741464,0.00022819554,0.0005786431,0.00025350146,0.0005533076,0.00012940145,0.0012175624,0.000008511951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036857374,0.017594578,0.45008427,0.0001604384,0.0017332982,0.00028013124,0.0014080276,0.0006680401,0.35128716,0.000022058346,0.00027334082,0.1396313],"study_design_scores_gemma":[0.06805168,0.038272448,0.86955106,0.001134821,0.0005324878,0.00004880795,0.0007341817,0.00066598307,0.019004717,0.00009045327,0.0015126498,0.00040069784],"about_ca_topic_score_codex":0.00009738587,"about_ca_topic_score_gemma":0.00017135296,"teacher_disagreement_score":0.41946682,"about_ca_system_score_codex":0.0001924892,"about_ca_system_score_gemma":0.0006814516,"threshold_uncertainty_score":0.7642547},"labels":[],"label_agreement":null},{"id":"W4399667054","doi":"10.1200/jco.2024.42.16_suppl.3105","title":"Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada); Bayer (Canada)","funders":"","keywords":"Trk receptor; Medicine; Cancer; Internal medicine; Oncology; Receptor; Neurotrophin","score_opus":0.12851684016314988,"score_gpt":0.46101490159885217,"score_spread":0.33249806143570226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399667054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395674,0.0008974193,0.0000056033514,0.0024104973,0.0017229256,0.0004579225,0.000058141948,0.0000123174905,0.00047841208],"genre_scores_gemma":[0.99741536,0.00046083704,0.0006589983,0.00026419185,0.001061948,0.000009085471,0.000017751488,0.000025293795,0.00008651044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969511,0.00024818096,0.0016971542,0.00034275863,0.00056682876,0.00019399988],"domain_scores_gemma":[0.99634224,0.0018140702,0.00093732256,0.00040344815,0.0003540197,0.00014890604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009593316,0.00020070834,0.0021377173,0.00021757558,0.00003166462,0.000014488461,0.00026720695,0.00009808585,0.00006361208],"category_scores_gemma":[0.00023904588,0.00010737818,0.00014543084,0.0003894423,0.00019874185,0.00015869425,0.00014777157,0.0008084475,0.0000025689412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013476328,0.0025247019,0.96240455,0.00003599733,0.0020209558,0.00027347708,0.0017558147,0.0000045367296,0.000011033201,0.0000018689201,0.003831758,0.0136589855],"study_design_scores_gemma":[0.01582524,0.012974333,0.9621431,0.0005500002,0.0007728094,0.00000288636,0.0010050577,0.000024214756,0.000009046415,0.0000145557015,0.006567609,0.000111153044],"about_ca_topic_score_codex":0.0021546136,"about_ca_topic_score_gemma":0.031495307,"teacher_disagreement_score":0.029340692,"about_ca_system_score_codex":0.00016471521,"about_ca_system_score_gemma":0.0010096116,"threshold_uncertainty_score":0.9861774},"labels":[],"label_agreement":null},{"id":"W4399667123","doi":"10.1200/jco.2024.42.16_suppl.3104","title":"Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"Jewish General Hospital; Pfizer; Conquer Cancer Foundation","keywords":"Medicine; Internal medicine; Oncology; Mutation; Clinical trial; Solid tumor; Cancer research; Cancer; Genetics; Gene","score_opus":0.12547345969595325,"score_gpt":0.44443399536287137,"score_spread":0.3189605356669181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399667123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955815,0.00071204914,0.00028336194,0.0018128227,0.00073798996,0.0005273625,0.000121337456,0.0000022917923,0.00022127593],"genre_scores_gemma":[0.9968648,0.00058538787,0.0014496853,0.00021738614,0.0005307478,0.000025527923,0.000018359446,0.000013169385,0.0002949519],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99786496,0.00023736348,0.0014273925,0.00019184854,0.0001390291,0.00013942891],"domain_scores_gemma":[0.9968045,0.0014864387,0.0010939062,0.00021529336,0.00026021965,0.0001396901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011401916,0.00013071978,0.0006135533,0.00004423691,0.00007991043,0.000007228814,0.00017657402,0.00018915541,0.0000046606374],"category_scores_gemma":[0.0019922233,0.00006235533,0.00034408632,0.00010914697,0.00046201525,0.000007648063,0.000039035538,0.00017242889,3.2121622e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35246304,0.012876735,0.0013443762,0.00021958235,0.004015544,0.00020630643,0.002150819,0.000913082,0.2898245,0.0006066756,0.01618106,0.3191983],"study_design_scores_gemma":[0.1854769,0.3133271,0.0036868968,0.0002637638,0.001320983,0.00024130297,0.00047537655,0.00075436983,0.19894578,0.0007080847,0.29454458,0.00025489123],"about_ca_topic_score_codex":0.0000074931822,"about_ca_topic_score_gemma":0.0000262485,"teacher_disagreement_score":0.31894344,"about_ca_system_score_codex":0.000015013878,"about_ca_system_score_gemma":0.0017384428,"threshold_uncertainty_score":0.3083923},"labels":[],"label_agreement":null},{"id":"W4399667405","doi":"10.1200/jco.2024.42.16_suppl.3052","title":"Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Cancer; Endocrine system; Hormone","score_opus":0.04237718569485227,"score_gpt":0.4209714391097517,"score_spread":0.37859425341489944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399667405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963691,0.00056246814,0.00040433838,0.0020385925,0.0002744853,0.00032463935,0.000016220985,0.000007920954,0.0000022079466],"genre_scores_gemma":[0.99514896,0.0003864434,0.0040068957,0.000290992,0.00013178444,0.0000049466885,0.0000028778295,0.000023873628,0.000003257709],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751604,0.00069276075,0.0011230872,0.0001814036,0.00031697328,0.00016972511],"domain_scores_gemma":[0.99733603,0.0011774686,0.00092666043,0.00008735249,0.0003261142,0.00014639103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020097967,0.00014575527,0.0009345732,0.00022802317,0.000020885864,0.000012244539,0.00003039629,0.00007628658,0.000013546621],"category_scores_gemma":[0.0006704526,0.00009401136,0.000070780865,0.00023203273,0.00023179584,0.00029753437,0.000031158575,0.00046792653,1.08708036e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05212504,0.00057914783,0.33096692,0.000170113,0.00032001964,0.00080842304,0.00032940885,0.000026780983,0.09352714,0.000007821553,0.0000014090091,0.5211378],"study_design_scores_gemma":[0.008317716,0.0042694113,0.98015904,0.0020143448,0.00014140047,0.00068049156,0.000051049086,0.00032757764,0.0036588737,0.000037585556,0.00024880082,0.0000937312],"about_ca_topic_score_codex":0.000035252244,"about_ca_topic_score_gemma":0.000021911703,"teacher_disagreement_score":0.6491921,"about_ca_system_score_codex":0.00019460937,"about_ca_system_score_gemma":0.001004041,"threshold_uncertainty_score":0.3833672},"labels":[],"label_agreement":null},{"id":"W4399670437","doi":"10.1200/jco.2024.42.16_suppl.e20123","title":"Treatment of relapsed small cell lung cancer in the real-world: A comparison of platinum-etoposide rechallenge and cyclophosphamide-doxorubicin-vincristine (CAV) chemotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Etoposide; Vincristine; Doxorubicin; Cyclophosphamide; Chemotherapy; Oncology; Internal medicine","score_opus":0.13541354670541178,"score_gpt":0.5286251097895158,"score_spread":0.39321156308410404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399670437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92946905,0.043339733,0.000016642487,0.020028658,0.0005212542,0.00057788496,0.00001160564,0.000008255741,0.006026888],"genre_scores_gemma":[0.9275086,0.07009994,0.0011073578,0.00019274678,0.0004920792,0.000019292225,0.000001076131,0.000020651165,0.0005582476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611455,0.0005147078,0.0024618865,0.0002310243,0.00042405553,0.0002537796],"domain_scores_gemma":[0.9922259,0.006069279,0.0010615562,0.00022558036,0.00026921724,0.0001484536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002472346,0.00018011154,0.0020168794,0.00023524906,0.00002797879,0.000006621206,0.00016482505,0.00019460444,0.00006873719],"category_scores_gemma":[0.0007041272,0.00009976103,0.00032434778,0.0003427185,0.00033231513,0.000042035335,0.000045827175,0.0008300116,7.7359323e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010638864,0.0040034316,0.7586802,0.0012312758,0.0015115214,0.0010881597,0.008757553,0.00005478854,0.0021178967,0.00024597667,0.0058428776,0.20582743],"study_design_scores_gemma":[0.028301097,0.047852274,0.845815,0.0024743788,0.0018624294,0.00013364358,0.0027011784,0.0022058277,0.0054516494,0.00059111393,0.06235707,0.0002543484],"about_ca_topic_score_codex":0.0010782538,"about_ca_topic_score_gemma":0.0028098768,"teacher_disagreement_score":0.20557308,"about_ca_system_score_codex":0.0004945602,"about_ca_system_score_gemma":0.0015222445,"threshold_uncertainty_score":0.40681368},"labels":[],"label_agreement":null},{"id":"W4399670554","doi":"10.1200/jco.2024.42.16_suppl.e20111","title":"Real world outcomes in extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation (cTRT) and chemoimmunotherapy (CIT): A population level study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Chemoimmunotherapy; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Radiation therapy; Population; Internal medicine; Radiology; Chemotherapy; Surgery; Cyclophosphamide","score_opus":0.16477889486802624,"score_gpt":0.5439998163855461,"score_spread":0.37922092151751985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399670554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014443,0.002808415,0.00003522495,0.0053169834,0.000281899,0.0009436486,0.000018712726,0.000018049772,0.00043261773],"genre_scores_gemma":[0.99139094,0.0050029694,0.0005539189,0.00036274912,0.00036694144,0.000039980398,0.0000050922245,0.00002943017,0.0022479824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970456,0.0005938049,0.0014168263,0.00029465236,0.0003890152,0.0002601263],"domain_scores_gemma":[0.9961516,0.0023887055,0.00072159857,0.00014192503,0.00042768035,0.00016846345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021149663,0.00019458197,0.0014987803,0.00041693807,0.000048196,0.000030226305,0.00008447352,0.00014343178,0.000055951285],"category_scores_gemma":[0.0006484842,0.000119628916,0.0001471016,0.00040390997,0.00016732122,0.00017062438,0.00004108911,0.0010529277,0.0000012207722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073818653,0.0008370694,0.9417608,0.0001324325,0.0011892639,0.0011244257,0.0017259571,0.00004695264,0.00016935956,0.000013711529,0.0003880191,0.04523015],"study_design_scores_gemma":[0.008708724,0.0068433904,0.98032576,0.00036668347,0.00046462435,0.000023134859,0.00097257044,0.0006294927,0.00008611018,0.000021296626,0.001440983,0.00011723488],"about_ca_topic_score_codex":0.0023095428,"about_ca_topic_score_gemma":0.004268954,"teacher_disagreement_score":0.045112915,"about_ca_system_score_codex":0.00086243526,"about_ca_system_score_gemma":0.0014020603,"threshold_uncertainty_score":0.48783255},"labels":[],"label_agreement":null},{"id":"W4399671887","doi":"10.1200/jco.2024.42.16_suppl.2035","title":"Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nomogram; Oncology; Lung cancer; Internal medicine; Cancer; Baseline (sea); Brain metastasis; Metastasis","score_opus":0.048872803382011,"score_gpt":0.41134480947348634,"score_spread":0.36247200609147534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399671887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951568,0.0012659527,0.001017035,0.0012158498,0.0005765561,0.00056248874,0.000095904754,0.000005287797,0.00010411143],"genre_scores_gemma":[0.9244885,0.00062244054,0.07400162,0.00052818464,0.00015405263,0.000015756068,0.00001781132,0.000023972376,0.00014769293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946778,0.00049148535,0.003830158,0.0003124754,0.00044002302,0.00024807168],"domain_scores_gemma":[0.9935108,0.003768535,0.001670669,0.0001964969,0.00040298735,0.00045055794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006817313,0.00020163404,0.001840904,0.00024021693,0.000027954597,0.00000816386,0.00014502823,0.00019779206,0.00011451656],"category_scores_gemma":[0.0018743386,0.000121468074,0.00032705333,0.00031879725,0.0001302079,0.00007269125,0.00013991942,0.0005675604,0.0000018011227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008897231,0.0025380633,0.7988012,0.0003211842,0.0011362757,0.00018432533,0.00027304536,0.00006550297,0.00003214737,0.0000023014402,0.0017143661,0.1860344],"study_design_scores_gemma":[0.026668303,0.024257658,0.92659676,0.0014519801,0.0023868396,0.000020375757,0.000119039774,0.00042141913,0.00042767808,0.000013242379,0.01747657,0.00016014818],"about_ca_topic_score_codex":0.00008096204,"about_ca_topic_score_gemma":0.0006685911,"teacher_disagreement_score":0.18587424,"about_ca_system_score_codex":0.00017183421,"about_ca_system_score_gemma":0.002180923,"threshold_uncertainty_score":0.49533242},"labels":[],"label_agreement":null},{"id":"W4399672006","doi":"10.1200/jco.2024.42.16_suppl.2055","title":"Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; University of Alberta; Hospital for Sick Children","funders":"","keywords":"Trametinib; Medicine; Dabrafenib; Glioma; Mutant; Oncology; Internal medicine; Cancer research; Cancer; Genetics; Gene; MAPK/ERK pathway; Biology; Phosphorylation; Vemurafenib; Metastatic melanoma","score_opus":0.20529667890765502,"score_gpt":0.5428811047524997,"score_spread":0.3375844258448447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436486,0.0012037224,0.00023417213,0.0009202266,0.001477963,0.0014903183,0.0000056838026,0.000015905649,0.00028713007],"genre_scores_gemma":[0.9978143,0.00046489525,0.0002428188,0.0000954265,0.0012179583,0.000018294088,0.0000026470464,0.000037027843,0.000106659674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99315315,0.0023689761,0.0030358604,0.00033982977,0.00076059415,0.0003415667],"domain_scores_gemma":[0.9843299,0.013906863,0.0007571358,0.00024805157,0.00044427058,0.00031378705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0144151505,0.00018624286,0.0020342642,0.00084799604,0.000022002845,0.000021779613,0.0002443532,0.00046151076,0.00035499065],"category_scores_gemma":[0.004372146,0.00013746937,0.00065284764,0.0011437995,0.00018693822,0.00013657253,0.00007839875,0.0019352144,0.000017305914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07109161,0.027020771,0.51476955,0.0019281631,0.0015111368,0.018219132,0.002222371,0.0017747431,0.1504918,0.00014279986,0.00053436577,0.21029352],"study_design_scores_gemma":[0.056853164,0.042396795,0.88098705,0.00075213553,0.0010231464,0.00094193046,0.0006546509,0.0041308496,0.005407752,0.00064968655,0.005919444,0.00028339168],"about_ca_topic_score_codex":0.000045550547,"about_ca_topic_score_gemma":0.000046761757,"teacher_disagreement_score":0.36621746,"about_ca_system_score_codex":0.0006002798,"about_ca_system_score_gemma":0.0031493974,"threshold_uncertainty_score":0.8407651},"labels":[],"label_agreement":null},{"id":"W4399672190","doi":"10.1200/jco.2024.42.16_suppl.2579","title":"Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pharmacokinetics; Biomarker; Cancer research; Oncology; Internal medicine; Chemistry","score_opus":0.14415824151901102,"score_gpt":0.5316970850717138,"score_spread":0.38753884355270274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968941,0.0006727766,0.000020271278,0.0007611357,0.0003397693,0.0007832198,0.000021343329,0.0000038405165,0.00050351006],"genre_scores_gemma":[0.998232,0.0004691429,0.0004914649,0.00036092382,0.00013350141,0.000005375506,0.0000042588845,0.00002385956,0.00027947393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956698,0.001152325,0.002022318,0.00029935353,0.0006309005,0.00022533462],"domain_scores_gemma":[0.99586827,0.0023761627,0.00081541104,0.000308369,0.00038981327,0.00024197568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033650887,0.00015827421,0.001777235,0.00035171,0.00003389837,0.000028713665,0.0003667828,0.00014213008,0.00054293155],"category_scores_gemma":[0.0007644899,0.000086912274,0.00019006332,0.0011240372,0.0002296954,0.00011821505,0.0002306516,0.0014071594,0.0000019271874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02420149,0.04528431,0.66132027,0.000046908903,0.0043073795,0.00094618974,0.0007883058,0.000059429407,0.013642307,0.0000010041937,0.00063253276,0.24876988],"study_design_scores_gemma":[0.12642269,0.03434741,0.82568955,0.00020098296,0.0032479397,0.000014877328,0.00049316656,0.0022478213,0.0008572958,0.000024304029,0.0063135824,0.00014035606],"about_ca_topic_score_codex":0.000062306906,"about_ca_topic_score_gemma":0.000084366045,"teacher_disagreement_score":0.24862953,"about_ca_system_score_codex":0.000092694725,"about_ca_system_score_gemma":0.00073838903,"threshold_uncertainty_score":0.6113485},"labels":[],"label_agreement":null},{"id":"W4399672803","doi":"10.1200/jco.2024.42.16_suppl.2500","title":"Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Synovial sarcoma; Myxoid liposarcoma; Interim; Interim analysis; Liposarcoma; Soft tissue sarcoma; Sarcoma; Pathology; Clinical trial","score_opus":0.0903309056363936,"score_gpt":0.42823852354457925,"score_spread":0.3379076179081857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383324,0.00073307956,0.0000126382165,0.0025661795,0.0015978871,0.0005093651,0.000024402714,0.000008350568,0.0007148557],"genre_scores_gemma":[0.99818254,0.00012635424,0.00039375495,0.00062397186,0.00045149954,0.00001137362,0.000009696145,0.000023221815,0.00017756803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954679,0.00061601907,0.0027343766,0.00029111322,0.00061868463,0.00027187742],"domain_scores_gemma":[0.9940216,0.0039253193,0.0012331591,0.0003358348,0.00025450974,0.00022958388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016934243,0.00022113373,0.0022258773,0.000486192,0.0000333285,0.00002334763,0.00027489392,0.0003139176,0.00020886284],"category_scores_gemma":[0.000896319,0.000103216065,0.0011072279,0.0009072553,0.00024721853,0.00010150648,0.00009969843,0.00093735085,0.000009139115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14883332,0.043321446,0.77088976,0.00006225193,0.005010743,0.0017932795,0.00021087444,0.00002742833,0.000023169809,0.0000413378,0.0017394084,0.02804698],"study_design_scores_gemma":[0.0832193,0.10319479,0.8010522,0.00029042354,0.0063943053,0.0000459888,0.00014831491,0.00019160505,0.00006206623,0.000033063763,0.005241783,0.00012613887],"about_ca_topic_score_codex":0.00006273367,"about_ca_topic_score_gemma":0.0004357224,"teacher_disagreement_score":0.06561403,"about_ca_system_score_codex":0.00027924925,"about_ca_system_score_gemma":0.0013028453,"threshold_uncertainty_score":0.4209029},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4399736336","doi":"10.1200/jco.2024.42.16_suppl.4131","title":"Safety and time to response of [<sup>177</sup>Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Neuroendocrine tumors; Internal medicine; Nuclear medicine","score_opus":0.0248250290612056,"score_gpt":0.38877248250506385,"score_spread":0.36394745344385826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399736336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935455,0.00025007952,0.000042703025,0.0042162305,0.000082648614,0.0018015633,0.00004235636,0.000011510908,0.0000074204354],"genre_scores_gemma":[0.9987529,0.00032489185,0.0003375862,0.00037548065,0.000043012977,0.00002195099,0.0000075682515,0.0000366267,0.000100019955],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9903393,0.0044021457,0.0035087853,0.00046879114,0.00083077536,0.00045024575],"domain_scores_gemma":[0.9860445,0.011405319,0.0013374019,0.0003995714,0.0003249778,0.00048822968],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023360723,0.00031605212,0.0041009383,0.0009101296,0.000037123824,0.000021259943,0.0002851842,0.000017895483,0.0000637521],"category_scores_gemma":[0.009946998,0.00017834707,0.0005279928,0.0011191235,0.00061157125,0.0001918301,0.00020797747,0.0010111537,0.0000019625904],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7897824,0.0067877257,0.182867,0.00014761371,0.003322988,0.00991386,0.00025300132,0.0016925355,0.0011322749,0.0000034381703,0.00019099902,0.003906159],"study_design_scores_gemma":[0.37703776,0.04004695,0.5712329,0.0005867731,0.0050482857,0.000462024,0.0002657859,0.0046033505,0.00034354845,0.00004082914,0.00018609685,0.00014563889],"about_ca_topic_score_codex":0.000034467586,"about_ca_topic_score_gemma":0.00005036562,"teacher_disagreement_score":0.4127446,"about_ca_system_score_codex":0.000084094056,"about_ca_system_score_gemma":0.0003220761,"threshold_uncertainty_score":0.99839264},"labels":[],"label_agreement":null},{"id":"W4399736408","doi":"10.1200/jco.2024.42.16_suppl.4090","title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Biliary tract cancer; Trastuzumab; Pancreatic cancer; Biliary tract; Internal medicine; Cancer; Oncology; Gemcitabine; Hepatocellular cancer; Gastroenterology; Breast cancer","score_opus":0.0882904112290206,"score_gpt":0.4252072724073897,"score_spread":0.3369168611783691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399736408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774527,0.014512216,0.000026321854,0.006019174,0.0012725194,0.0002863768,0.000042533058,0.00002307468,0.00036507956],"genre_scores_gemma":[0.99298686,0.003540219,0.0010042139,0.0013597872,0.0009182369,0.000029542645,0.0000047968197,0.00004283415,0.00011349381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669707,0.00027729725,0.0017771987,0.00041598885,0.00046053118,0.000371927],"domain_scores_gemma":[0.99621284,0.0023660343,0.0006562961,0.00018213365,0.00023192736,0.00035078367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008486222,0.00029144154,0.0020220063,0.00020334481,0.00006215028,0.000039275554,0.00013854026,0.0002572056,0.0001898208],"category_scores_gemma":[0.00070264185,0.0001803148,0.0002927447,0.0002240887,0.0003089485,0.00021840664,0.00006197884,0.0012639257,0.000003922319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017885576,0.00077072927,0.8111103,0.000107321335,0.00066516007,0.00080096675,0.0007195926,0.000009622243,0.000051237006,0.0000021759295,0.0013449269,0.18262936],"study_design_scores_gemma":[0.008472123,0.0045189466,0.9794192,0.0016563502,0.001138453,0.000071088936,0.00032319452,0.000101020334,0.00003985281,0.000107833235,0.0039558453,0.00019612185],"about_ca_topic_score_codex":0.0022045851,"about_ca_topic_score_gemma":0.0023469953,"teacher_disagreement_score":0.18243325,"about_ca_system_score_codex":0.00047815635,"about_ca_system_score_gemma":0.0018623037,"threshold_uncertainty_score":0.73530245},"labels":[],"label_agreement":null},{"id":"W4399736505","doi":"10.1200/jco.2024.42.16_suppl.4059","title":"A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: Efficacy and safety analysis (BOLD-100-001).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; FOLFOX; Chemotherapy; Cancer; Internal medicine; Oncology; Phases of clinical research; Surgery; Oxaliplatin; Colorectal cancer","score_opus":0.03741997769386642,"score_gpt":0.4346442823677094,"score_spread":0.397224304673843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399736505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681157,0.00039094326,0.00012353268,0.0016681121,0.00018729447,0.00068399485,0.0000036192723,0.000007084186,0.00012387385],"genre_scores_gemma":[0.9982741,0.00083625456,0.0004148697,0.0002904103,0.000079423226,0.000009707087,0.0000068009795,0.000015056621,0.00007337503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725425,0.00019400689,0.0016664284,0.00025231214,0.00044278402,0.00019022058],"domain_scores_gemma":[0.99791354,0.0007397447,0.0008532377,0.00014616645,0.00021324221,0.00013409609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012648691,0.000154472,0.0015780693,0.0008871668,0.000015552494,0.0000101679525,0.00010013389,0.00010129157,0.00007232684],"category_scores_gemma":[0.00016683002,0.00009858277,0.00012502236,0.0015849812,0.00008488232,0.00014301817,0.00002709513,0.00055438356,3.717812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02105247,0.017272975,0.6916622,0.000044744076,0.0012049914,0.00018830178,0.00028212738,0.00027910215,0.0000021951394,0.000008432344,0.00008524714,0.26791722],"study_design_scores_gemma":[0.113841124,0.07207266,0.81046844,0.00016957195,0.0014262446,0.0000045948423,0.00026019532,0.00030643688,0.000001683299,0.000008494898,0.0013681735,0.000072356146],"about_ca_topic_score_codex":0.00015228521,"about_ca_topic_score_gemma":0.00080278935,"teacher_disagreement_score":0.26784486,"about_ca_system_score_codex":0.00025515488,"about_ca_system_score_gemma":0.0003985883,"threshold_uncertainty_score":0.4020089},"labels":[],"label_agreement":null},{"id":"W4399736654","doi":"10.1200/jco.2024.42.16_suppl.4098","title":"Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre; Dalhousie University; University of Toronto; University Health Network; University of British Columbia; University of Calgary; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Immunotherapy; Tyrosine kinase; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Cancer research; Cancer; Receptor","score_opus":0.11536403050260323,"score_gpt":0.36797682557097877,"score_spread":0.25261279506837553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399736654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98192614,0.015657885,0.00007810749,0.0009510495,0.00042912585,0.00078080344,0.000056178684,0.000021589696,0.000099109646],"genre_scores_gemma":[0.9971828,0.0017198256,0.0002827712,0.000177865,0.00039971215,0.000023365124,0.00007343989,0.00004669009,0.00009352237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952267,0.0008592038,0.0026901173,0.00044976443,0.0004692816,0.00030496417],"domain_scores_gemma":[0.9950742,0.003088121,0.0008218478,0.00037400817,0.0002953491,0.0003464642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016720012,0.00036080484,0.002560226,0.00038020636,0.000046465302,0.00003529388,0.00019189679,0.00039965328,0.00012804252],"category_scores_gemma":[0.00034757107,0.00018768139,0.0007656991,0.000657475,0.00042054214,0.00019643408,0.000059582035,0.00088010094,0.00000187299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018411424,0.0014895877,0.9511431,0.000076687764,0.0053600324,0.01092615,0.00043452875,0.0000015453721,0.0011858442,0.000004444086,0.000044299308,0.010922399],"study_design_scores_gemma":[0.011749636,0.009103613,0.97074944,0.00056800945,0.004351869,0.000084858446,0.00013711076,0.001074598,0.0014021882,0.000005133864,0.0005936275,0.00017988923],"about_ca_topic_score_codex":0.00031816217,"about_ca_topic_score_gemma":0.00042884503,"teacher_disagreement_score":0.019606408,"about_ca_system_score_codex":0.00015796977,"about_ca_system_score_gemma":0.0010404899,"threshold_uncertainty_score":0.76534253},"labels":[],"label_agreement":null},{"id":"W4399736681","doi":"10.1200/jco.2024.42.16_suppl.tps3646","title":"The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Providence Health Care; University of Calgary; University of Ottawa; St. Paul's Hospital; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Chemoradiotherapy; Oncology; Chemotherapy; Internal medicine; Cancer; Randomized controlled trial","score_opus":0.22668190501593508,"score_gpt":0.5635484162285652,"score_spread":0.3368665112126301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399736681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713624,0.0060412763,0.0002513776,0.011368542,0.00774502,0.0028723662,0.000013187134,0.000018098259,0.0003277344],"genre_scores_gemma":[0.96027565,0.02984576,0.0022148476,0.00059311226,0.0060241413,0.0002900124,0.0000075267894,0.000059524074,0.0006894071],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99563754,0.00064073445,0.002758125,0.00026421697,0.0004697302,0.00022967273],"domain_scores_gemma":[0.976789,0.020938803,0.0014672303,0.00017806617,0.00038612468,0.00024077004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069562746,0.0001981375,0.0027262697,0.00009870309,0.00006631748,0.000036096968,0.00014426248,0.00036628818,0.00007218325],"category_scores_gemma":[0.0054798527,0.000107263986,0.0011966042,0.00020623482,0.00040470148,0.00012278899,0.000017623031,0.000557241,0.000001115106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6347713,0.0009629027,0.000050385002,0.000022904012,0.00100032,0.00004403479,0.000113980146,7.4460297e-7,0.00016460518,0.00003904336,0.0010052167,0.36182457],"study_design_scores_gemma":[0.8359093,0.075596675,0.00040825183,0.00015167415,0.0007242085,0.00003210753,0.000022452756,0.00077190984,0.00024506892,0.00044889055,0.085609704,0.000079724996],"about_ca_topic_score_codex":0.000056749224,"about_ca_topic_score_gemma":0.000020382513,"teacher_disagreement_score":0.36174485,"about_ca_system_score_codex":0.00029429834,"about_ca_system_score_gemma":0.0016585363,"threshold_uncertainty_score":0.65602916},"labels":[],"label_agreement":null},{"id":"W4399736861","doi":"10.1200/jco.2024.42.16_suppl.4015","title":"Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canceropôle PACA; Institut National de la Santé et de la Recherche Médicale","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Oncology; Adjuvant chemotherapy; Chemotherapy; Internal medicine; Adenocarcinoma; Adjuvant; Pancreatic cancer; Stage (stratigraphy); Cancer; Breast cancer","score_opus":0.07580817805584554,"score_gpt":0.4290092152161581,"score_spread":0.35320103716031254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399736861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334794,0.0019368558,0.00014848693,0.0035921002,0.0001838795,0.00041080418,0.0000029592577,0.0000061739756,0.0003707863],"genre_scores_gemma":[0.98902696,0.00019444052,0.009755427,0.0006456415,0.00013882408,0.000009034221,0.000005553,0.000017459784,0.00020664056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997281,0.00029654964,0.001493584,0.00021769489,0.00047872495,0.00023241155],"domain_scores_gemma":[0.997959,0.0010186309,0.00029341373,0.00010378148,0.00034379825,0.00028135214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022912174,0.000132098,0.00142557,0.00032626817,0.000025135645,0.00001027119,0.00009740206,0.00027555038,0.0001296566],"category_scores_gemma":[0.00071574317,0.00008419409,0.00011627712,0.00027607847,0.00016796551,0.00009692145,0.000019475821,0.0008333787,0.0000039321403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013409081,0.0011631323,0.95929337,0.00021445617,0.00065452995,0.00034170094,0.0016781187,0.0000033040492,0.0006692968,0.00005803727,0.0007719864,0.021742996],"study_design_scores_gemma":[0.00956974,0.010003983,0.9753805,0.000588769,0.00032904657,0.00009592534,0.00023445109,0.00009223227,0.00031819352,0.00005701682,0.0032477132,0.0000824761],"about_ca_topic_score_codex":0.000024230067,"about_ca_topic_score_gemma":0.000039765797,"teacher_disagreement_score":0.02166052,"about_ca_system_score_codex":0.00023058853,"about_ca_system_score_gemma":0.0027013381,"threshold_uncertainty_score":0.4792058},"labels":[],"label_agreement":null},{"id":"W4399737203","doi":"10.1200/jco.2024.42.16_suppl.tps3160","title":"An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Open label; Solid tumor; Internal medicine; Oncology; Cancer; Clinical trial","score_opus":0.07791344822614635,"score_gpt":0.4905662790886736,"score_spread":0.41265283086252724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958762,0.00034523456,0.00020279412,0.0015792119,0.0007539393,0.0006718567,0.000009467294,0.00000998913,0.0005513264],"genre_scores_gemma":[0.9921189,0.0001554786,0.0044790423,0.00223793,0.0007104108,0.000027498909,0.000018084134,0.000030654937,0.00022200431],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99662644,0.000579671,0.0017817166,0.00046998667,0.00026052337,0.0002816576],"domain_scores_gemma":[0.9981828,0.00013137066,0.0005682698,0.00032427558,0.00026538468,0.00052791345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026909425,0.00019915607,0.0008043148,0.0001549486,0.000042804673,0.000067285786,0.0006897554,0.00020776823,0.00003456457],"category_scores_gemma":[0.0011316154,0.00014410104,0.000070519935,0.00028105007,0.00014837515,0.00005673683,0.00018181276,0.00066586107,0.00001890146],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045928497,0.051079493,0.013443486,0.0001046949,0.00067527377,0.0038236629,0.001346643,0.0006830524,0.13341126,0.00028840607,0.020577775,0.72863775],"study_design_scores_gemma":[0.10367124,0.6088051,0.015084359,0.0014217435,0.00022890119,0.0005607624,0.003200303,0.0015911764,0.037177935,0.0006649086,0.22628167,0.0013118688],"about_ca_topic_score_codex":0.000027177168,"about_ca_topic_score_gemma":0.00028910823,"teacher_disagreement_score":0.72732586,"about_ca_system_score_codex":0.00005475151,"about_ca_system_score_gemma":0.0013926729,"threshold_uncertainty_score":0.587627},"labels":[],"label_agreement":null},{"id":"W4399737375","doi":"10.1200/jco.2024.42.16_suppl.tps3180","title":"A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Ottawa Hospital; McGill University; Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Tolerability; Pharmacokinetics; Maximum tolerated dose; Pharmacology; Open label; Oncology; Adverse effect","score_opus":0.09363379947207903,"score_gpt":0.45930803875461584,"score_spread":0.36567423928253684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997326,0.0006386333,0.00008146814,0.00091043604,0.00014587659,0.0008640088,0.0000052749247,0.0000022184993,0.000026052045],"genre_scores_gemma":[0.99894404,0.00047266655,0.00030685752,0.00016311946,0.000065898115,0.000015960988,0.0000026685568,0.000013745406,0.000015039884],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978119,0.0006051739,0.00084957073,0.00035171592,0.00020133247,0.00018026764],"domain_scores_gemma":[0.9989776,0.0002786482,0.00031442003,0.0001359941,0.00012334171,0.00016997023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025399856,0.00014911829,0.00062844827,0.000088906956,0.000035977973,0.00004254815,0.000093671784,0.000100228106,0.0000044250532],"category_scores_gemma":[0.0003819312,0.00009630907,0.00002188409,0.0001317985,0.0002046869,0.000047700163,0.00022357918,0.0002941049,2.3260243e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036916517,0.018797886,0.10894487,0.00015186005,0.00027744443,0.00047455035,0.0028767711,0.00017833276,0.4580703,0.000026586687,0.00010112128,0.37318376],"study_design_scores_gemma":[0.062067676,0.10082635,0.7972531,0.0005867993,0.000331751,0.00024892547,0.00090011593,0.0015704388,0.03495415,0.0002483476,0.0006696793,0.00034267607],"about_ca_topic_score_codex":0.00005730047,"about_ca_topic_score_gemma":0.00069281243,"teacher_disagreement_score":0.68830824,"about_ca_system_score_codex":0.00003304579,"about_ca_system_score_gemma":0.00030373884,"threshold_uncertainty_score":0.392737},"labels":[],"label_agreement":null},{"id":"W4399737405","doi":"10.1200/jco.2024.42.16_suppl.tps3174","title":"First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Olaparib; Medicine; Poly ADP ribose polymerase; Cancer research; Synthetic lethality; Polymerase; Homologous recombination; DNA repair; PARP1; Pharmacology; DNA; Biology; Genetics","score_opus":0.07941985966849405,"score_gpt":0.45097663381761144,"score_spread":0.37155677414911736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787915,0.00169588,0.000041385916,0.01645983,0.0010160644,0.001664414,0.000051240713,0.000051089566,0.00022862999],"genre_scores_gemma":[0.994068,0.00022451716,0.00032853722,0.0023400385,0.0025679134,0.000083801155,0.00002028341,0.00011380503,0.0002530554],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9904132,0.0015410753,0.005236336,0.0007788932,0.0012758162,0.0007547072],"domain_scores_gemma":[0.99290335,0.0026217198,0.0024060358,0.00082251884,0.00049497955,0.0007514206],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043356204,0.0006098261,0.0036497288,0.0007959333,0.00014978339,0.000053581953,0.0005655215,0.00047057276,0.0004211968],"category_scores_gemma":[0.00054958015,0.00032634343,0.00039099515,0.0012944046,0.0010870814,0.0005386709,0.00010303631,0.0027780018,0.000008905868],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6733917,0.12441416,0.06012056,0.00076974917,0.0033645288,0.04025568,0.017117392,0.0003093133,0.004802208,0.00024403166,0.012916943,0.062293734],"study_design_scores_gemma":[0.34429565,0.55798906,0.037868496,0.0082175,0.001778945,0.0033253087,0.014211709,0.001542659,0.018154759,0.0001822569,0.011200497,0.0012331989],"about_ca_topic_score_codex":0.00062760036,"about_ca_topic_score_gemma":0.009060413,"teacher_disagreement_score":0.4335749,"about_ca_system_score_codex":0.00042258293,"about_ca_system_score_gemma":0.0033935704,"threshold_uncertainty_score":0.9999189},"labels":[],"label_agreement":null},{"id":"W4399737488","doi":"10.1200/jco.2024.42.16_suppl.3091","title":"Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Somatostatin; Neuroendocrine tumors; Phase (matter); Internal medicine; Somatostatin Analogue; Phases of clinical research; Lanreotide; Oncology; Clinical trial; Cancer research; Pharmacology; Octreotide; Growth hormone; Hormone; Chemistry","score_opus":0.08718980111899502,"score_gpt":0.487025124728985,"score_spread":0.39983532360998997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925685,0.000786212,0.000040898103,0.005006104,0.00047722406,0.0010145924,0.000023351775,0.000015624126,0.00006749467],"genre_scores_gemma":[0.9966239,0.0018661536,0.00052002876,0.0002776406,0.00056926836,0.000018299825,0.000006451366,0.000038718343,0.00007956656],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934254,0.0012397249,0.0037376396,0.00036183407,0.0007646504,0.00047074724],"domain_scores_gemma":[0.9950434,0.0025039958,0.0015524128,0.00029918613,0.00025468197,0.00034634402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017337736,0.0002591418,0.0018166297,0.00043876376,0.000047556085,0.000028284225,0.00023791585,0.000040517396,0.00010315952],"category_scores_gemma":[0.0053338157,0.00016258495,0.0005427301,0.00048167838,0.00067620527,0.00031500263,0.00011102939,0.0015795635,0.0000018955028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5672003,0.020198783,0.078735754,0.0007344324,0.00062807486,0.02452134,0.00035119712,0.00016387513,0.0062510073,0.000033665267,0.0007791323,0.30040246],"study_design_scores_gemma":[0.61824775,0.1899136,0.13669081,0.004254101,0.001016546,0.018159661,0.0009659099,0.0052875504,0.0095927,0.0003306226,0.015162339,0.00037843036],"about_ca_topic_score_codex":0.000015055373,"about_ca_topic_score_gemma":0.000021428654,"teacher_disagreement_score":0.30002403,"about_ca_system_score_codex":0.00012525184,"about_ca_system_score_gemma":0.0010112124,"threshold_uncertainty_score":0.68625057},"labels":[],"label_agreement":null},{"id":"W4399737492","doi":"10.1200/jco.2024.42.16_suppl.3024","title":"Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"SymBio Pharmaceuticals Limited; Chugai Pharmaceutical; Eisai Canada; Japan Agency for Medical Research and Development; Daiichi-Sankyo; Otsuka Pharmaceutical; Boehringer Ingelheim Japan; Ono Pharmaceutical; Takeda Pharmaceutical Company","keywords":"Medicine; Precision oncology; Oncology; Clinical Oncology; Internal medicine; Key (lock); Cancer; Biology","score_opus":0.11061136036580115,"score_gpt":0.43423667021881224,"score_spread":0.3236253098530111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978929,0.0050976533,0.0026477678,0.0041481834,0.0069561205,0.00031374203,0.00019577585,0.0000043650707,0.0017073902],"genre_scores_gemma":[0.9855583,0.0031777078,0.005006455,0.0010496344,0.004819834,0.000010279047,0.00009750778,0.000022316284,0.0002580208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968757,0.00038091026,0.0021016179,0.00030418564,0.00017074103,0.00016683087],"domain_scores_gemma":[0.9952656,0.0025582465,0.0013002044,0.00033167517,0.00035733634,0.00018691567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015554988,0.00013816325,0.0007656699,0.00004733984,0.00005767936,0.000024897645,0.0004088642,0.0006870764,0.000050988787],"category_scores_gemma":[0.0041777655,0.00009015886,0.00069596147,0.00008219598,0.00026973485,0.000012074437,0.00016055928,0.0005141657,0.000003884783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059465147,0.0006834089,0.21792056,0.0000442426,0.0011226672,0.0001666769,0.00039518508,0.0007149752,0.00075161445,0.0008171566,0.29091194,0.48052505],"study_design_scores_gemma":[0.002963731,0.006904651,0.1230371,0.00012165927,0.0003735975,0.000022100809,0.00048498387,0.0005291285,0.00013237364,0.0026230766,0.86266977,0.00013785133],"about_ca_topic_score_codex":0.00012365068,"about_ca_topic_score_gemma":0.0024590779,"teacher_disagreement_score":0.5717578,"about_ca_system_score_codex":0.00009724799,"about_ca_system_score_gemma":0.002270582,"threshold_uncertainty_score":0.52993625},"labels":[],"label_agreement":null},{"id":"W4399737536","doi":"10.1200/jco.2024.42.16_suppl.3007","title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with <i>KRAS</i> G12C-mutant advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Mutant; Cancer research; Internal medicine; Cancer; Biochemistry; Biology","score_opus":0.02937231653991051,"score_gpt":0.35936293798304547,"score_spread":0.32999062144313496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969338,0.0006512963,0.00064990064,0.0003936744,0.0007903197,0.0003213114,0.000029459841,0.000007873973,0.00022235274],"genre_scores_gemma":[0.9972179,0.000099655175,0.0012293585,0.00042823795,0.00089119835,0.000011003583,0.000029711766,0.000029600458,0.000063340296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99671674,0.0004784008,0.001816451,0.0003720195,0.00034536255,0.00027104735],"domain_scores_gemma":[0.99767435,0.00018815919,0.0013161711,0.00022557453,0.000405232,0.00019051996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017224238,0.00023036062,0.0010091669,0.0001477447,0.000039387323,0.000021311878,0.00018225753,0.0003478763,0.000060456205],"category_scores_gemma":[0.00080372614,0.00017128108,0.00032705872,0.00021349512,0.0001808541,0.000041197403,0.000080231985,0.0006062998,0.000004332926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068100276,0.0020043296,0.015628697,0.00015229106,0.00031212656,0.00028645198,0.000076607765,0.0005264217,0.88888866,0.00008549185,0.0009928801,0.084235996],"study_design_scores_gemma":[0.012035981,0.023562161,0.108745724,0.0005903612,0.00017979777,0.00012996257,0.000056676563,0.0007277733,0.8083562,0.00018045618,0.044869117,0.0005657544],"about_ca_topic_score_codex":0.000006057756,"about_ca_topic_score_gemma":0.00018295755,"teacher_disagreement_score":0.09311703,"about_ca_system_score_codex":0.00007016638,"about_ca_system_score_gemma":0.0013191118,"threshold_uncertainty_score":0.698464},"labels":[],"label_agreement":null},{"id":"W4399737564","doi":"10.1200/jco.2024.42.16_suppl.3009","title":"Performance characteristics of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Head and neck; Head and neck cancer; Genome; DNA methylation; Computational biology; Cancer research; Cancer; Genetics; Gene; Internal medicine; Biology; Surgery; Gene expression","score_opus":0.05289677624190807,"score_gpt":0.4013535245114316,"score_spread":0.3484567482695235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835525,0.0072617945,0.0070938133,0.00064435875,0.0010010344,0.00017745793,0.000021036778,0.000002607424,0.00024535213],"genre_scores_gemma":[0.9829363,0.009268843,0.0064478507,0.00021884996,0.0008139787,0.0000069803623,0.000018453811,0.000017015092,0.000271713],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978099,0.00016773345,0.0014953405,0.00020141924,0.00014941665,0.00017622788],"domain_scores_gemma":[0.99760896,0.0010821996,0.000699055,0.00013885098,0.00032280126,0.00014811661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002919826,0.0001208242,0.00063228793,0.00007146293,0.000030301784,0.000014721965,0.00013518776,0.0003119324,0.000012062148],"category_scores_gemma":[0.002701286,0.00009608197,0.00019590734,0.000065827495,0.00011732542,0.000007587412,0.000068014946,0.00021548547,0.0000021383346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013057761,0.0005879312,0.08747006,0.00051470025,0.00055138185,0.000055111534,0.00013375696,0.0001147242,0.46418184,0.00014246543,0.0007853839,0.4441569],"study_design_scores_gemma":[0.0016883864,0.016888833,0.4186387,0.000119511074,0.00026401677,0.00003184154,0.00001825216,0.00043213216,0.043415528,0.00039531355,0.51791537,0.00019211271],"about_ca_topic_score_codex":0.000001998328,"about_ca_topic_score_gemma":0.0000035132061,"teacher_disagreement_score":0.51713,"about_ca_system_score_codex":0.000024442712,"about_ca_system_score_gemma":0.00047741443,"threshold_uncertainty_score":0.39181086},"labels":[],"label_agreement":null},{"id":"W4399737587","doi":"10.1200/jco.2024.42.16_suppl.3136","title":"Cold-inducible RNA-binding protein as a context-specific functional mediator of breast cancer metastasis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Arctic and Antarctic ice dynamics","field":"Earth and Planetary Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"Fondation du cancer du sein du Québec","keywords":"Medicine; Mediator; Breast cancer; Context (archaeology); Metastasis; Cancer; Cancer research; RNA; Oncology; Internal medicine; Gene; Biology; Genetics","score_opus":0.09540999043689241,"score_gpt":0.37321377037694337,"score_spread":0.27780377994005095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98319316,0.0017443737,0.00025733784,0.008120816,0.0043588467,0.00014236115,0.00014659604,0.000011873293,0.0020246585],"genre_scores_gemma":[0.99536777,0.0010179158,0.0009649084,0.00045891837,0.0015497133,0.0000012571036,0.000006951123,0.0000063966927,0.00062615064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706566,0.00030649116,0.0016519683,0.00021238493,0.00051225006,0.0002512348],"domain_scores_gemma":[0.9963834,0.0020534291,0.0008670453,0.00010299539,0.00028758447,0.00030549974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003261524,0.00013351427,0.0008309542,0.00014713997,0.00007612391,0.000028746308,0.00023222713,0.00023286423,0.007171499],"category_scores_gemma":[0.0004975533,0.00009036764,0.00040557803,0.00024763844,0.00028569115,0.00030667326,0.00001946457,0.0008788336,0.0001528719],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026101372,0.00045367575,0.119384475,0.00014206846,0.0011704754,0.0008909229,0.00027220085,0.00037345014,0.0011457811,0.0058973436,0.013639101,0.85402036],"study_design_scores_gemma":[0.0054122917,0.0083884215,0.30003512,0.0009812264,0.0008703254,0.0021562316,0.0030577842,0.004213664,0.0008472415,0.005266786,0.6681266,0.0006443319],"about_ca_topic_score_codex":0.000317205,"about_ca_topic_score_gemma":0.00033247008,"teacher_disagreement_score":0.85337603,"about_ca_system_score_codex":0.00003423146,"about_ca_system_score_gemma":0.0026855855,"threshold_uncertainty_score":0.9937361},"labels":[],"label_agreement":null},{"id":"W4399737838","doi":"10.1200/jco.2024.42.16_suppl.3092","title":"Ipatasertib in patients with <i>AKT1/2/3</i> mutation-positive (<i>AKT</i>mut) tumors: TAPISTRY study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; AKT1; Protein kinase B; Mutation; Cancer research; Oncology; Internal medicine; Pathology; Genetics; Phosphorylation; Gene; Biology","score_opus":0.027466343453686697,"score_gpt":0.3987068319265859,"score_spread":0.3712404884728992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640393,0.00094916625,0.00023552803,0.00044169166,0.0012281627,0.00027043562,0.000054796354,0.0000077388795,0.00040857427],"genre_scores_gemma":[0.9971316,0.000035438596,0.0005952557,0.000989888,0.0010458848,0.000012295738,0.000047101992,0.000034979967,0.000107569664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966802,0.00052324036,0.0017105717,0.00040400008,0.00039818938,0.00028378362],"domain_scores_gemma":[0.99786264,0.0005189236,0.000736138,0.00024954288,0.0004227716,0.00021001397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018811633,0.00020981998,0.0007334187,0.000109278146,0.00003673717,0.000034703142,0.00033550535,0.0003383842,0.00005442907],"category_scores_gemma":[0.00094230287,0.00015696886,0.0002351316,0.00021218225,0.00018483216,0.000023228746,0.0000942949,0.00084050244,0.000016244205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01245922,0.0078054117,0.89000547,0.00009710602,0.0016370442,0.0037869725,0.00059432455,0.0010716575,0.0027493015,0.000050700568,0.019610789,0.060132],"study_design_scores_gemma":[0.023061352,0.096686825,0.79725575,0.00079507305,0.00058128283,0.00025736837,0.00066092896,0.00009799826,0.0078107133,0.00039286006,0.071493424,0.0009063932],"about_ca_topic_score_codex":0.000027605984,"about_ca_topic_score_gemma":0.00014095491,"teacher_disagreement_score":0.09274969,"about_ca_system_score_codex":0.00012338726,"about_ca_system_score_gemma":0.0015662415,"threshold_uncertainty_score":0.6401004},"labels":[],"label_agreement":null},{"id":"W4399737887","doi":"10.1200/jco.2024.42.16_suppl.2515","title":"Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Final analysis of a multi-institutional reproducibility study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University","funders":"Society for Immunotherapy of Cancer","keywords":"Medicine; Reproducibility; Harmonization; Medical physics; Oncology; Internal medicine; Nuclear medicine; Statistics","score_opus":0.38368616817211587,"score_gpt":0.5908749837485884,"score_spread":0.2071888155764725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8638016,0.00046882062,0.12992015,0.0038671424,0.0010453924,0.00075687544,0.00012014184,0.000008516807,0.0000113776405],"genre_scores_gemma":[0.93244815,0.00023308181,0.066785,0.00015028495,0.0002536946,0.000011481013,0.00007333757,0.000009221355,0.00003576036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98932326,0.0041164868,0.0052010487,0.0006326056,0.0005706923,0.00015588489],"domain_scores_gemma":[0.9838703,0.011853237,0.0025828525,0.000781798,0.00077276805,0.00013901693],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.12893851,0.00013075708,0.0030327747,0.00071037695,0.0000443724,0.000014413794,0.00025606318,0.00016167863,0.000047473182],"category_scores_gemma":[0.19267814,0.000084323874,0.00062225113,0.0009684815,0.00026103237,0.00014216117,0.0001170086,0.0009045223,2.3057466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.113618344,0.01823754,0.5043597,0.00043453235,0.007505776,0.0029689255,0.00085500703,0.0051814304,0.011796338,0.00013300241,0.0036077672,0.33130163],"study_design_scores_gemma":[0.0154951215,0.010231009,0.70556587,0.00021938892,0.005095201,0.00011648279,0.00025430715,0.25924525,0.0000674273,0.0001053581,0.003527028,0.0000775385],"about_ca_topic_score_codex":0.00005791283,"about_ca_topic_score_gemma":0.000049233786,"teacher_disagreement_score":0.3312241,"about_ca_system_score_codex":0.00031018766,"about_ca_system_score_gemma":0.005009826,"threshold_uncertainty_score":0.8969411},"labels":[],"label_agreement":null},{"id":"W4399738014","doi":"10.1200/jco.2024.42.16_suppl.2516","title":"HLA associations with immunotherapy related endocrine toxicity.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; Toxicity; Human leukocyte antigen; Endocrine system; Immunology; Oncology; Internal medicine; Immune system; Hormone; Antigen","score_opus":0.050263295627410734,"score_gpt":0.4068455039456193,"score_spread":0.3565822083182086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399738014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92578405,0.051205497,0.00032359583,0.008538301,0.0069652563,0.00019574151,0.000017245728,0.00008876395,0.0068815704],"genre_scores_gemma":[0.98039556,0.005168218,0.0004156973,0.0010175376,0.00023212438,0.0000049818736,0.000013313818,0.0000372755,0.012715324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551004,0.0014858592,0.0023579043,0.00020500715,0.00009443095,0.00034675436],"domain_scores_gemma":[0.9934415,0.0049023703,0.0010989722,0.00022778282,0.00028665256,0.000042712025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034989538,0.00019551911,0.0011898521,0.00024682336,0.00013040999,0.0000308736,0.0003528958,0.0005999015,0.0019149482],"category_scores_gemma":[0.0011920496,0.00012582158,0.00060508196,0.00030886545,0.00041375018,0.00025732876,0.000034824403,0.001873644,0.00036911565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015174692,0.003841922,0.0075535914,0.00003300975,0.013505369,0.0013520238,0.0014938719,0.000055942062,0.2171825,0.0073707583,0.0362947,0.6961416],"study_design_scores_gemma":[0.0064771753,0.011474777,0.03679262,0.00014581639,0.00021565061,0.002277119,0.00016230813,0.000008017871,0.0082608955,0.0007624428,0.9332157,0.00020752123],"about_ca_topic_score_codex":0.000021363901,"about_ca_topic_score_gemma":0.000010576518,"teacher_disagreement_score":0.896921,"about_ca_system_score_codex":0.00013923702,"about_ca_system_score_gemma":0.0015106986,"threshold_uncertainty_score":0.99899745},"labels":[],"label_agreement":null},{"id":"W4399738268","doi":"10.1200/jco.2024.42.16_suppl.2659","title":"A multi-centre, single arm, phase 2 trial of pembrolizumab in treatment-naïve patients with carcinoma of unknown primary site.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Surgery; Cancer; Immunotherapy","score_opus":0.11717576926089053,"score_gpt":0.45178575037755075,"score_spread":0.33460998111666024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399738268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537706,0.0014583535,0.0000087836115,0.0010645401,0.0008397015,0.0006002545,0.000036565292,0.000004705014,0.0006100561],"genre_scores_gemma":[0.9975021,0.0005838674,0.0011962102,0.00014978151,0.00040379344,0.00000912131,0.000019044115,0.00001935285,0.00011675115],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99679095,0.00022405648,0.002229503,0.00021728597,0.0003451064,0.00019311476],"domain_scores_gemma":[0.9966871,0.0015038174,0.0010979368,0.00017898917,0.00030768837,0.00022443813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005177171,0.00016996561,0.0018552463,0.00023336631,0.000009724644,0.000005093932,0.00006804095,0.00020493758,0.00010386195],"category_scores_gemma":[0.00039365544,0.00010116674,0.00055379723,0.00020342655,0.00016003249,0.00007786972,0.000023865168,0.0003221189,0.000003756326],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24397683,0.15573628,0.3186017,0.00016310814,0.0011182991,0.0016729273,0.00042381737,0.000010889434,0.00011351308,0.000019663232,0.00071200513,0.27745095],"study_design_scores_gemma":[0.507183,0.20243,0.27217636,0.0005616773,0.0014026109,0.000048775815,0.000040210445,0.00008362755,0.00038646333,0.000012992522,0.015584144,0.00009014951],"about_ca_topic_score_codex":0.000108887194,"about_ca_topic_score_gemma":0.00022500263,"teacher_disagreement_score":0.2773608,"about_ca_system_score_codex":0.00069424236,"about_ca_system_score_gemma":0.0019545706,"threshold_uncertainty_score":0.412546},"labels":[],"label_agreement":null},{"id":"W4399763539","doi":"10.1200/jco.2024.42.16_suppl.2649","title":"Development of a novel risk stratification model for immune-related adverse events for patients with advanced melanoma and non-small cell lung cancer treated with immune checkpoint inhibitors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Melanoma; Lung cancer; Immune system; Adverse effect; Risk stratification; Oncology; Ipilimumab; Nivolumab; Immune checkpoint; Cancer research; Programmed cell death 1; Internal medicine; Immunotherapy; Immunology; PD-L1","score_opus":0.034133324472548104,"score_gpt":0.36361954555162995,"score_spread":0.3294862210790819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399763539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344547,0.0010899054,0.013518898,0.00023443412,0.00030326858,0.0013212316,0.000047900125,0.000008392028,0.000030509016],"genre_scores_gemma":[0.94278586,0.00051227474,0.0563128,0.00003375674,0.00006106209,0.00008853559,0.000029794159,0.000030671257,0.00014524946],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969257,0.000038909326,0.0024232129,0.00023184974,0.00019611041,0.00018418318],"domain_scores_gemma":[0.99681467,0.00041561745,0.0019541613,0.00012399036,0.00057436916,0.000117176416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012926923,0.0001793554,0.000909324,0.00012000716,0.000056991263,0.000004270122,0.000079177655,0.00024051,0.000007702543],"category_scores_gemma":[0.000115938434,0.0001104511,0.00029657574,0.00014330972,0.00010026326,0.000109655106,0.000014376059,0.00033014742,1.3378374e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2815483,0.01073516,0.154804,0.0021343036,0.008639318,0.000022154942,0.004512499,0.0024730081,0.094908305,0.00001979465,0.00013886644,0.44006428],"study_design_scores_gemma":[0.15725711,0.04230765,0.6516148,0.0043037166,0.0039790943,0.00003735023,0.00061763846,0.10553511,0.03165843,0.00003883325,0.0020861086,0.00056416047],"about_ca_topic_score_codex":0.000021880795,"about_ca_topic_score_gemma":0.000069128386,"teacher_disagreement_score":0.4968108,"about_ca_system_score_codex":0.00024372042,"about_ca_system_score_gemma":0.0022044799,"threshold_uncertainty_score":0.45040652},"labels":[],"label_agreement":null},{"id":"W4399765099","doi":"10.1200/jco.23.01680","title":"Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in <i>PIK3CA</i>-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Cancer Institute; National Institutes of Health; Ipsen; Parker Institute for Cancer Immunotherapy; Astellas Pharma; Eisai; Genentech; AstraZeneca; Celgene; FibroGen; Alliance for Clinical Trials in Oncology Foundation; Chugai Pharmaceutical; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Colorectal cancer; Clinical endpoint; Cancer; Celecoxib; Proportional hazards model; Randomized controlled trial; Confidence interval","score_opus":0.055886668383837976,"score_gpt":0.42079570343895284,"score_spread":0.36490903505511485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399765099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975116,0.0016193058,0.00014942935,0.003497913,0.003760276,0.0005092966,0.000016252945,0.00004050852,0.00065584795],"genre_scores_gemma":[0.9937491,0.0020250054,0.0003411118,0.0011315373,0.0022435696,0.00002661394,0.000009889008,0.00004667106,0.0004265215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592817,0.0005679145,0.002239537,0.00034417582,0.00048150905,0.0004386839],"domain_scores_gemma":[0.9963082,0.0016050363,0.0009845035,0.0001954251,0.0003611849,0.000545651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004004319,0.00025853317,0.0018976536,0.00019668922,0.00004237126,0.00002104547,0.00009386943,0.00056887604,0.00023566064],"category_scores_gemma":[0.0010108419,0.0001707397,0.00034073327,0.000416246,0.00022780636,0.00024073296,0.00003947028,0.0021217929,0.000016819697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11356955,0.0062725167,0.0848438,0.0023289435,0.0024251775,0.11095332,0.0016462842,0.0005953411,0.28949186,0.00049075007,0.016914897,0.37046754],"study_design_scores_gemma":[0.11173443,0.0908834,0.28999734,0.009100835,0.0022555946,0.0022837466,0.0014382214,0.010999117,0.08672102,0.0002427167,0.39271,0.0016335896],"about_ca_topic_score_codex":0.00029966058,"about_ca_topic_score_gemma":0.0014160881,"teacher_disagreement_score":0.3757951,"about_ca_system_score_codex":0.0005499643,"about_ca_system_score_gemma":0.0038514805,"threshold_uncertainty_score":0.92182523},"labels":[],"label_agreement":null},{"id":"W4399879795","doi":"10.1200/jco.2024.42.16_suppl.3587","title":"Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Juravinski Cancer Centre; Cancer Care Nova Scotia; Jewish General Hospital; Hôpital Charles-Le Moyne; St. John’s Health Sciences Centre; Hôtel-Dieu de Québec; Genome British Columbia; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; Queen's University; Moncton Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Immune checkpoint; Cancer research; Immunotherapy","score_opus":0.16106508784645318,"score_gpt":0.49620621256832026,"score_spread":0.3351411247218671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399879795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716436,0.014724953,0.0000088956,0.00887418,0.0034707687,0.00087916024,0.00007622452,0.000006241889,0.00031592834],"genre_scores_gemma":[0.99466616,0.0037128099,0.00009662746,0.00062629476,0.00063962064,0.00004028155,0.000003664398,0.000022156786,0.0001923879],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927663,0.0016272134,0.00464981,0.00025835732,0.00041714628,0.00028112758],"domain_scores_gemma":[0.99072737,0.0063404744,0.002253425,0.00016404505,0.00022130187,0.0002933588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01305837,0.00019822593,0.0032877955,0.0006655123,0.00005910823,0.000023358676,0.0001693219,0.00034809153,0.00064014463],"category_scores_gemma":[0.004607397,0.00011328346,0.0016145234,0.0012861332,0.00064102304,0.000087754495,0.00002932318,0.0011796785,0.0000018595375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47904038,0.003947308,0.05607304,0.00030521696,0.05659293,0.0010904623,0.0052747917,0.00028380973,0.024721382,0.00019583676,0.007001662,0.36547318],"study_design_scores_gemma":[0.12649058,0.012278321,0.79884756,0.0016188116,0.017631777,0.000110374975,0.0008505875,0.0018190318,0.002147936,0.00013672764,0.03777535,0.00029295],"about_ca_topic_score_codex":0.045020897,"about_ca_topic_score_gemma":0.3526789,"teacher_disagreement_score":0.7427745,"about_ca_system_score_codex":0.0010301259,"about_ca_system_score_gemma":0.007290591,"threshold_uncertainty_score":0.99833715},"labels":[],"label_agreement":null},{"id":"W4399880212","doi":"10.1200/jco.2024.42.16_suppl.e15609","title":"Patient factors related to the real-world adoption of 3 months of adjuvant chemotherapy (ACT) in patients with stage III colorectal cancer (CRC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Adjuvant chemotherapy; Stage (stratigraphy); Oncology; Cancer; Chemotherapy; Adjuvant; Internal medicine; Surgery; Breast cancer","score_opus":0.03911281260686708,"score_gpt":0.4081365594611901,"score_spread":0.36902374685432304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399880212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945688,0.0006711449,0.0000022178406,0.0017587711,0.0008344192,0.00054238294,0.000027381871,0.000005666612,0.0015892166],"genre_scores_gemma":[0.99798226,0.0014433984,0.00010365421,0.00017622318,0.00007193739,0.000010541118,0.000004211838,0.00001545395,0.00019234396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974567,0.00014559746,0.0016905704,0.00016159075,0.00038568475,0.00015983579],"domain_scores_gemma":[0.9977467,0.0007548448,0.0008990652,0.000105122796,0.00037336466,0.000120880446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058873766,0.00013987916,0.0012090626,0.00017634801,0.000019898796,0.00000331501,0.00007690599,0.00012599608,0.00011815215],"category_scores_gemma":[0.00021289154,0.000067304434,0.0002496493,0.00038138987,0.00014134991,0.00006646252,0.000033485987,0.0004832257,0.0000013540312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016165482,0.0014782939,0.88716096,0.000039528153,0.00086682563,0.000055270175,0.0023682553,0.00014607869,0.000033284203,0.000032115928,0.00054759195,0.091106325],"study_design_scores_gemma":[0.0058349282,0.02699261,0.95832646,0.00038115671,0.00023489515,0.0000015111249,0.00043538806,0.000041385676,0.00018273827,0.00001210997,0.0074951793,0.00006166379],"about_ca_topic_score_codex":0.0006207963,"about_ca_topic_score_gemma":0.0033510202,"teacher_disagreement_score":0.09104466,"about_ca_system_score_codex":0.00041883838,"about_ca_system_score_gemma":0.00078334194,"threshold_uncertainty_score":0.2744595},"labels":[],"label_agreement":null},{"id":"W4399881049","doi":"10.1200/jco.2024.42.16_suppl.4111","title":"Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; McMaster University; Juravinski Cancer Centre; BC Cancer Agency; University of Manitoba; Princess Margaret Cancer Centre; Dalhousie University; University of Toronto; University Health Network; University of British Columbia; University of Calgary","funders":"","keywords":"Lenvatinib; Medicine; Atezolizumab; Hepatocellular carcinoma; Bevacizumab; Oncology; Systemic therapy; Hepatocellular cancer; Internal medicine; Population; Regorafenib; Cancer; Colorectal cancer; Sorafenib; Chemotherapy; Pembrolizumab","score_opus":0.34399998184812175,"score_gpt":0.456259977843159,"score_spread":0.11225999599503728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97861016,0.010211598,0.000052900657,0.0073842853,0.0018639407,0.001405224,0.000107955035,0.000021424663,0.00034249216],"genre_scores_gemma":[0.9902754,0.0068770456,0.0007422717,0.00019931911,0.0013436909,0.00009545729,0.0002010762,0.000043691296,0.00022204852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99545264,0.00047900697,0.002972588,0.00037170705,0.0004227826,0.0003012676],"domain_scores_gemma":[0.98933446,0.008712896,0.0010230375,0.00046591868,0.00024045093,0.00022320279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015842268,0.00030974866,0.0022931872,0.00024112817,0.000064864595,0.00002161951,0.00021987672,0.0003156191,0.00019824799],"category_scores_gemma":[0.00077601086,0.00017202728,0.0011740888,0.0003308783,0.00011120722,0.00012721053,0.000034254346,0.00035201386,0.000016355605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015783295,0.0014682538,0.8982358,0.000099278535,0.0012616869,0.0013026542,0.0003502798,0.0000052221944,0.000037866812,0.0002717087,0.00031673038,0.080867246],"study_design_scores_gemma":[0.0639163,0.04724703,0.82575655,0.0010407701,0.0025129262,0.00019158976,0.0002469543,0.0070123626,0.0006042019,0.0006857123,0.05047793,0.00030767886],"about_ca_topic_score_codex":0.0030638021,"about_ca_topic_score_gemma":0.0013053656,"teacher_disagreement_score":0.08055957,"about_ca_system_score_codex":0.0006101009,"about_ca_system_score_gemma":0.001181921,"threshold_uncertainty_score":0.7015069},"labels":[],"label_agreement":null},{"id":"W4399881054","doi":"10.1200/jco.2024.42.16_suppl.4109","title":"Association between beta-catenin (<i>CTNNB1</i>) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pembrolizumab; Hepatocellular carcinoma; Hazard ratio; Logistic regression; Concordance; Wnt signaling pathway; Population; Proportional hazards model; Placebo; Cancer; Confidence interval; Immunotherapy; Gene; Pathology; Genetics","score_opus":0.10658505120204027,"score_gpt":0.4427904849517239,"score_spread":0.33620543374968365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279743,0.0038283002,0.0005804114,0.0014331235,0.001030536,0.00011568163,0.00011434735,0.000003896001,0.000096298805],"genre_scores_gemma":[0.9933941,0.0034700711,0.0017023749,0.0003751978,0.00091419904,0.0000044624185,0.00005926798,0.000021492047,0.000058882415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610084,0.0005120848,0.0026465848,0.00032017578,0.00022351938,0.00019681937],"domain_scores_gemma":[0.9944126,0.0036196439,0.0012842163,0.000186833,0.00029208753,0.00020461758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021754822,0.0001616944,0.0012235866,0.00012939364,0.000026247099,0.00002146248,0.00020032255,0.0005830228,0.0000155906],"category_scores_gemma":[0.0037300768,0.0001383004,0.0005750658,0.00013183354,0.00015097752,0.000018983146,0.000113642294,0.00058441656,0.000003923059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039524856,0.00025666069,0.98033255,0.000013566305,0.0008571882,0.000078369594,0.0000576042,0.00007820374,0.0032527652,0.000017054535,0.0010617574,0.013599053],"study_design_scores_gemma":[0.0039309883,0.0027352213,0.97284555,0.000039340408,0.0008694318,0.000005308642,0.00018159732,0.00025825406,0.0037624806,0.0008131498,0.014385673,0.00017297428],"about_ca_topic_score_codex":0.0001206845,"about_ca_topic_score_gemma":0.00027866542,"teacher_disagreement_score":0.013426079,"about_ca_system_score_codex":0.00010058537,"about_ca_system_score_gemma":0.001108747,"threshold_uncertainty_score":0.56397265},"labels":[],"label_agreement":null},{"id":"W4399881081","doi":"10.1200/jco.2024.42.16_suppl.4150","title":"GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute; Pancreatic Cancer Canada Foundation; Princess Margaret Hospital Foundation","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Biomarker; Cancer; Compass; Pancreatic cancer; Oncology; Internal medicine; Cartography","score_opus":0.12715936534964867,"score_gpt":0.46298076074901384,"score_spread":0.3358213953993652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602457,0.009256489,0.000010772591,0.026928073,0.0006238925,0.0014545458,0.000021185628,0.0000048760016,0.0014544104],"genre_scores_gemma":[0.9915163,0.0062310006,0.00026849422,0.0013985478,0.00040660953,0.00004028773,0.000007839281,0.000013469158,0.00011748068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955034,0.0018897726,0.0014846721,0.00030900992,0.00040292856,0.00041017553],"domain_scores_gemma":[0.98688376,0.011819055,0.0004410013,0.00018696627,0.00024598886,0.000423228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035111469,0.00018524559,0.00151367,0.00036031826,0.0001303787,0.0000331935,0.00022569229,0.00036658754,0.00007779845],"category_scores_gemma":[0.0033075665,0.000098562945,0.00018488648,0.00032807296,0.001276842,0.00013802669,0.00010506847,0.0017534207,0.00000529541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10409057,0.00072781165,0.87474066,0.00010479036,0.0005406734,0.004633994,0.0032096012,0.0000064563596,0.0000324993,0.0003047061,0.0025148813,0.009093368],"study_design_scores_gemma":[0.080289796,0.006520088,0.8977757,0.000741373,0.0006539073,0.0010564609,0.0026652445,0.0022395044,0.0000010132093,0.0006266271,0.0073402827,0.00009000832],"about_ca_topic_score_codex":0.018456178,"about_ca_topic_score_gemma":0.05177365,"teacher_disagreement_score":0.03331747,"about_ca_system_score_codex":0.00042112032,"about_ca_system_score_gemma":0.004673543,"threshold_uncertainty_score":0.98808},"labels":[],"label_agreement":null},{"id":"W4399881164","doi":"10.1200/jco.2024.42.16_suppl.4129","title":"Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cohort; Antibody; Oncology; Internal medicine; Immunology","score_opus":0.04618754680713361,"score_gpt":0.4433493690343295,"score_spread":0.39716182222719587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961272,0.00041712858,0.00003247746,0.0014769238,0.00083397294,0.00081807945,0.00022887088,0.000013013187,0.00005232459],"genre_scores_gemma":[0.99468714,0.0032840988,0.0014434541,0.00027364405,0.00013760236,0.0000047140816,0.00007869784,0.000037077727,0.00005356442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954812,0.0003915198,0.0025478036,0.00052994885,0.00059942796,0.00045011836],"domain_scores_gemma":[0.99572194,0.0024491411,0.0008129377,0.00028264965,0.00027494234,0.00045840314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007327667,0.00026635334,0.0017201825,0.0003961861,0.00003073285,0.000015412012,0.0001570101,0.0001483557,0.000025156274],"category_scores_gemma":[0.0023961798,0.00017822262,0.00017684748,0.00037403693,0.00029456505,0.00024170779,0.0001116428,0.0012617013,0.000005970693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11673284,0.025884014,0.79156643,0.00013860257,0.00057946536,0.016345968,0.00013902204,0.00017549258,0.00065805065,0.0000013865165,0.0003967376,0.047382005],"study_design_scores_gemma":[0.20491178,0.02100444,0.7658658,0.0014388507,0.00016517112,0.00009624085,0.0000259803,0.0022446795,0.00012300047,0.0000025822078,0.0040115966,0.00010987321],"about_ca_topic_score_codex":0.0003611473,"about_ca_topic_score_gemma":0.0009806388,"teacher_disagreement_score":0.08817894,"about_ca_system_score_codex":0.00029249332,"about_ca_system_score_gemma":0.001034452,"threshold_uncertainty_score":0.72677076},"labels":[],"label_agreement":null},{"id":"W4399881223","doi":"10.1200/jco.2024.42.16_suppl.4105","title":"Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada)","funders":"China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Medicine; Internal medicine; Hepatocellular carcinoma; Oncolytic virus; Gastroenterology; Adverse effect; Refractory (planetary science); Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Phases of clinical research; Clinical trial","score_opus":0.16664190966635062,"score_gpt":0.4833662554161306,"score_spread":0.31672434574978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945402,0.0018107712,0.00012414185,0.0004084889,0.0021332968,0.000855732,0.00008803923,0.0000066508974,0.000032676173],"genre_scores_gemma":[0.99386364,0.0017701689,0.0014369446,0.00043637588,0.002339924,0.000024086665,0.000027062144,0.00006787672,0.00003390214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98877084,0.0018142688,0.0074976846,0.0006808511,0.0008176863,0.0004186798],"domain_scores_gemma":[0.9924085,0.0031189157,0.0027015596,0.0006335594,0.0007237672,0.00041367547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010213981,0.00036983966,0.0027445,0.00029083024,0.00003035089,0.000020348205,0.0006124611,0.0011803632,0.000086855274],"category_scores_gemma":[0.0045653465,0.00025379387,0.0016340186,0.00028563384,0.0007908913,0.000032305543,0.0002650286,0.0017709475,0.00000439857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41154483,0.016374933,0.4606086,0.000033785134,0.0010238924,0.00015937524,0.00009243882,0.000008361023,0.009649865,9.552956e-7,0.00015383429,0.10034912],"study_design_scores_gemma":[0.3257592,0.29788494,0.3444638,0.00042173354,0.00036781482,0.000008916801,0.00007127407,0.00050957594,0.014333355,0.000051733336,0.015593704,0.0005339523],"about_ca_topic_score_codex":0.0000754091,"about_ca_topic_score_gemma":0.00024033249,"teacher_disagreement_score":0.28151,"about_ca_system_score_codex":0.000106508596,"about_ca_system_score_gemma":0.0036459868,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W4399881235","doi":"10.1200/jco.2024.42.16_suppl.4100","title":"Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Pembrolizumab; Cohort; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.08591963113597074,"score_gpt":0.37127027236374854,"score_spread":0.2853506412277778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993863,0.0017814867,0.00000692706,0.0008427369,0.00040290575,0.0025096983,0.00010672041,0.000019047959,0.000467504],"genre_scores_gemma":[0.99776256,0.00045621477,0.0002461893,0.0003141465,0.00036693897,0.00043256598,0.00017993331,0.000049655577,0.00019179434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948129,0.0011025482,0.002244556,0.00062230753,0.0007513422,0.00046631717],"domain_scores_gemma":[0.996583,0.0018404184,0.00054488244,0.00035089947,0.00031493744,0.0003658935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001803214,0.00044964597,0.0019755287,0.00044832777,0.00006331528,0.00004583312,0.00017417004,0.00035663816,0.0005613947],"category_scores_gemma":[0.00042024298,0.0002526429,0.00055325945,0.00049071066,0.0002199705,0.0002591419,0.000048779362,0.0009827167,0.000026547386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021431062,0.01049112,0.9023477,0.000029777888,0.0010598465,0.0176435,0.0007188444,0.0000013753072,0.0000046791965,0.000007660165,0.0004646608,0.0457998],"study_design_scores_gemma":[0.059526082,0.053748414,0.8770517,0.0002807864,0.0018222363,0.0002871997,0.0002507046,0.000635249,0.000024368424,0.000036130878,0.006117107,0.00021999139],"about_ca_topic_score_codex":0.00018048295,"about_ca_topic_score_gemma":0.00026795163,"teacher_disagreement_score":0.04557981,"about_ca_system_score_codex":0.0006651629,"about_ca_system_score_gemma":0.0011452596,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W4399881422","doi":"10.1200/jco.2024.42.16_suppl.4040","title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Internal medicine; Cancer; Esophageal cancer; Gastric adenocarcinoma; Esophageal adenocarcinoma; Chemotherapy; Adenocarcinoma; Gastroenterology; Oncology; Immunotherapy","score_opus":0.06582602180490636,"score_gpt":0.4236906571408252,"score_spread":0.35786463533591883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95854896,0.020550257,0.00066797575,0.01127726,0.007354833,0.0011464811,0.00009910532,0.0000643746,0.000290775],"genre_scores_gemma":[0.96026075,0.026803946,0.002905475,0.00154819,0.0041670976,0.00014083882,0.000029464927,0.00011199583,0.004032223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99466413,0.00017111964,0.0032782827,0.00061621884,0.0006188973,0.00065137853],"domain_scores_gemma":[0.9955438,0.0009924691,0.0019514449,0.00039565194,0.00065577275,0.0004608602],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016686738,0.00050123694,0.0026413754,0.00035508044,0.00011560074,0.000029791225,0.00031417806,0.0006479074,0.00095695304],"category_scores_gemma":[0.00039277435,0.00037818408,0.0019278674,0.00057079195,0.00034390925,0.00024473658,0.000040360883,0.00082726375,0.000013689665],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17714034,0.0023623726,0.027256409,0.0005872036,0.004624123,0.0005450647,0.0005062303,0.0001460816,0.008687113,0.000041671286,0.010150689,0.7679527],"study_design_scores_gemma":[0.25429985,0.18191986,0.20829001,0.0028659555,0.0061573316,0.0019099566,0.0006019492,0.0028767404,0.050839104,0.00057157234,0.28864062,0.001027069],"about_ca_topic_score_codex":0.0005716289,"about_ca_topic_score_gemma":0.00040714783,"teacher_disagreement_score":0.76692563,"about_ca_system_score_codex":0.001979813,"about_ca_system_score_gemma":0.0041899253,"threshold_uncertainty_score":0.9999563},"labels":[],"label_agreement":null},{"id":"W4399881498","doi":"10.1200/jco.2024.42.16_suppl.4115","title":"A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Jewish General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Biliary tract cancer; FOLFOX; Chemotherapy; Biliary tract; Cancer; Internal medicine; Oncology; Phases of clinical research; Gemcitabine; Gastroenterology; Colorectal cancer; Oxaliplatin","score_opus":0.04113835159290097,"score_gpt":0.42799671578682047,"score_spread":0.3868583641939195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399881498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589896,0.0017447817,0.00001540233,0.0013430914,0.0001461429,0.0007129442,0.000011382299,0.000008745316,0.00011852542],"genre_scores_gemma":[0.99843097,0.0010797427,0.00015221655,0.00018932787,0.000073158015,0.000014917721,0.000010105134,0.00001860084,0.000030966414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723864,0.00026192408,0.0016288012,0.00030275292,0.00038284267,0.00018501472],"domain_scores_gemma":[0.9976949,0.0009931008,0.0007089682,0.0001589021,0.00030629899,0.0001377979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00100205,0.00018202803,0.0018080682,0.00056247663,0.000021817967,0.000008241399,0.0000820522,0.00014413396,0.00003734784],"category_scores_gemma":[0.00018700537,0.00011164161,0.0001454275,0.001090542,0.00013435427,0.00014877768,0.000020523063,0.0006562498,2.4354046e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032639623,0.031145176,0.79077065,0.000054508077,0.0020810084,0.00035189954,0.0013558327,0.000082360944,0.000012517591,0.0000017801088,0.000060457176,0.14144422],"study_design_scores_gemma":[0.09969957,0.079506174,0.8177768,0.00028536553,0.0016252117,0.000010570283,0.00040058547,0.00018106787,0.000012913322,0.000005595289,0.00040379554,0.0000923655],"about_ca_topic_score_codex":0.000277969,"about_ca_topic_score_gemma":0.001489874,"teacher_disagreement_score":0.14135185,"about_ca_system_score_codex":0.0002451174,"about_ca_system_score_gemma":0.00053710473,"threshold_uncertainty_score":0.45526126},"labels":[],"label_agreement":null},{"id":"W4400036507","doi":"10.1200/jco.2024.42.16_suppl.9002","title":"Depicting oncologists' perceptions and knowledge of global disparities in conflicts of interest reporting: The ONCOTRUST-1 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Climate Change Communication and Perception","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Perception; Family medicine; Epistemology","score_opus":0.8442099762250084,"score_gpt":0.6665327792079623,"score_spread":0.1776771970170461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97407573,0.00089070515,0.000018125875,0.008088714,0.00094828295,0.00016040225,0.000003709029,0.000007904092,0.015806401],"genre_scores_gemma":[0.9951922,0.004122453,0.00014266424,0.00010078145,0.00034529655,0.0000033645802,5.52323e-7,0.0000036927163,0.00008895968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99485177,0.0017781578,0.0029924037,0.000107386666,0.00014160133,0.00012866045],"domain_scores_gemma":[0.99231786,0.0048635234,0.002244461,0.00014769017,0.00033230142,0.000094192794],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013773751,0.00006664394,0.0006518361,0.00006703724,0.00010367422,0.000026305082,0.00029544966,0.00021059782,0.00011989168],"category_scores_gemma":[0.013080862,0.000045013214,0.00018868873,0.0002766628,0.00093473145,0.00012368904,0.00014622055,0.00060026813,0.0000024822398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014703236,0.0011315715,0.79571813,0.000041281466,0.00006252744,0.00002301312,0.042511433,0.00000360335,0.000030195686,0.006534817,0.00039572714,0.15340063],"study_design_scores_gemma":[0.0005625467,0.0014791617,0.88740635,0.00017107493,0.00007755062,0.000024593966,0.07989593,0.000079127734,5.9644196e-7,0.0011731078,0.029081492,0.000048493628],"about_ca_topic_score_codex":0.0018910654,"about_ca_topic_score_gemma":0.09124952,"teacher_disagreement_score":0.15335214,"about_ca_system_score_codex":0.00021351394,"about_ca_system_score_gemma":0.0008873406,"threshold_uncertainty_score":0.9952324},"labels":[],"label_agreement":null},{"id":"W4400036601","doi":"10.1200/jco.2024.42.16_suppl.8578","title":"Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; Internal medicine; Chemotherapy; Clinical trial; Cancer; Immunotherapy","score_opus":0.05323586654378033,"score_gpt":0.43941106518965284,"score_spread":0.3861751986458725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933747,0.0012076641,0.000100903875,0.0030903297,0.0007629933,0.0011868356,0.000012603614,0.000004754106,0.00025923338],"genre_scores_gemma":[0.9959388,0.0009909396,0.0008668415,0.0017919642,0.00024280432,0.000022578533,0.000003383416,0.000026515698,0.0001162146],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99399716,0.001058504,0.003747232,0.0002396081,0.0006978837,0.00025961807],"domain_scores_gemma":[0.9898271,0.00651439,0.0029519428,0.00021213439,0.00039704965,0.000097361604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008050024,0.00021088061,0.002284052,0.00029292284,0.000019000447,0.000012599205,0.0002431109,0.0003575348,0.000087262786],"category_scores_gemma":[0.0011661485,0.000105727166,0.00064120116,0.0004817129,0.00018145393,0.00010268773,0.000014571473,0.0014259559,3.943746e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48819724,0.006632529,0.46330458,0.00020329742,0.0023860333,0.00023434142,0.0010675716,0.00011027059,0.00023538138,0.0000036408612,0.000788021,0.036837105],"study_design_scores_gemma":[0.41872606,0.037742436,0.53963864,0.00071649166,0.0013278059,0.000009091203,0.0003108144,0.00040549765,0.00017805847,0.00002178094,0.0007769763,0.00014634395],"about_ca_topic_score_codex":0.00021151324,"about_ca_topic_score_gemma":0.0005644103,"teacher_disagreement_score":0.076334074,"about_ca_system_score_codex":0.0005233297,"about_ca_system_score_gemma":0.0037455158,"threshold_uncertainty_score":0.6644384},"labels":[],"label_agreement":null},{"id":"W4400036644","doi":"10.1200/jco.2024.42.16_suppl.8577","title":"A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alethia Biotherapeutics (Canada); McGill University; Institute for Research in Immunology and Cancer; Institut universitaire de cardiologie et de pneumologie de Québec; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Chemoimmunotherapy; Oncology; Cancer; Internal medicine; Clinical trial; Phases of clinical research; Lung cancer; Chemotherapy; Immunotherapy","score_opus":0.03577434989442194,"score_gpt":0.43372774922604534,"score_spread":0.3979533993316234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872445,0.00057039096,0.00028762003,0.008303762,0.0011651753,0.0021427325,0.000025471645,0.000007913078,0.00025242448],"genre_scores_gemma":[0.9923628,0.000054962216,0.005108482,0.001514934,0.00040983656,0.00011198078,0.000008206111,0.000039616694,0.00038918733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969395,0.00025599,0.0016821194,0.00026427623,0.0005831616,0.0002749521],"domain_scores_gemma":[0.9976594,0.00089820346,0.0005773826,0.00022419028,0.00039572967,0.00024513583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017242327,0.00022176206,0.001508137,0.0002221094,0.00006476219,0.000019919798,0.00016997408,0.00011770644,0.000058359004],"category_scores_gemma":[0.00026022954,0.000107614986,0.00037624937,0.00047731362,0.00007920349,0.000117096126,0.00004788733,0.000648266,0.0000031762738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71586245,0.03985434,0.042443044,0.0006117029,0.011546331,0.001391602,0.011523393,0.0010474226,0.0036791628,0.00002675022,0.0050228927,0.16699089],"study_design_scores_gemma":[0.68449026,0.25466123,0.03788732,0.002167303,0.00775717,0.00002665447,0.000436361,0.00032963385,0.00077587296,0.000034436744,0.011126081,0.0003076991],"about_ca_topic_score_codex":0.00006975919,"about_ca_topic_score_gemma":0.00012060808,"teacher_disagreement_score":0.21480688,"about_ca_system_score_codex":0.00046852094,"about_ca_system_score_gemma":0.0049135713,"threshold_uncertainty_score":0.8716464},"labels":[],"label_agreement":null},{"id":"W4400036770","doi":"10.1200/jco.2024.42.16_suppl.8013","title":"Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Durvalumab; Tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Internal medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Anaplastic lymphoma kinase; Pathology; Cancer; Nivolumab; Receptor; Immunotherapy","score_opus":0.05820676860958907,"score_gpt":0.45930521840007354,"score_spread":0.4010984497904845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915464,0.001286308,0.0009911774,0.0030499038,0.0024336397,0.0014576283,0.000021484448,0.000028195478,0.0015770148],"genre_scores_gemma":[0.9951315,0.0002677704,0.0021190476,0.00087452895,0.0010003551,0.00014302341,0.000018053835,0.00003046273,0.0004152914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965188,0.00024718407,0.0020107473,0.00043924098,0.00045539506,0.00032865079],"domain_scores_gemma":[0.9976579,0.0004180286,0.0007113811,0.0002044444,0.000670824,0.00033742998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014138542,0.00023837929,0.0012120804,0.0002354189,0.00006132706,0.00005764309,0.00012030814,0.00025162118,0.00011771461],"category_scores_gemma":[0.0009328991,0.00018129418,0.00021547428,0.00087151973,0.000057660083,0.0003844572,0.00006192162,0.0006141655,0.000013514859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007944162,0.002905991,0.95249444,0.00014786085,0.00045138827,0.0010129727,0.0010107793,0.0031682176,0.0003138195,0.000029191395,0.0018437714,0.02867739],"study_design_scores_gemma":[0.017062511,0.0077087795,0.96336544,0.00083466736,0.0010105054,0.000037716985,0.0006356536,0.0059018363,0.00023547048,0.000068618596,0.0029418434,0.00019695965],"about_ca_topic_score_codex":0.00058930024,"about_ca_topic_score_gemma":0.004650475,"teacher_disagreement_score":0.028480431,"about_ca_system_score_codex":0.00329694,"about_ca_system_score_gemma":0.0034052057,"threshold_uncertainty_score":0.8621383},"labels":[],"label_agreement":null},{"id":"W4400036782","doi":"10.1200/jco.2024.42.16_suppl.8012","title":"Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Perioperative; Stage (stratigraphy); Quality of life (healthcare); non-small cell lung cancer (NSCLC); Oncology; Lung cancer; Internal medicine; Phases of clinical research; Randomized controlled trial; Cancer; Clinical trial; Surgery; Immunotherapy","score_opus":0.20068654264195598,"score_gpt":0.5358747334227361,"score_spread":0.3351881907807801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96482503,0.010470888,0.00020001379,0.018150363,0.0020371226,0.003845053,0.00013224361,0.000009972898,0.00032929608],"genre_scores_gemma":[0.99463993,0.0025878334,0.00032379493,0.001114058,0.0006080103,0.00022699499,0.000009686855,0.000034150627,0.0004555341],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9914718,0.001489818,0.0058564157,0.0003686467,0.0005283236,0.00028499129],"domain_scores_gemma":[0.97959036,0.015562136,0.0033923602,0.0003614715,0.0007132988,0.00038038497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069696303,0.0002791448,0.0052017216,0.000114488284,0.00008382695,0.00002372445,0.00025674922,0.00030909403,0.0002943759],"category_scores_gemma":[0.0016127188,0.00014262235,0.0015056386,0.00018929219,0.00028647186,0.000096761425,0.00006863557,0.00095113873,0.0000025824247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7479741,0.01490367,0.20596534,0.00045310636,0.011413046,0.00010359199,0.009753968,0.000137507,0.000021682083,0.0001516841,0.0014561402,0.007666183],"study_design_scores_gemma":[0.874273,0.01968197,0.09810984,0.00056928507,0.0038734847,0.000004908593,0.0016641989,0.0005805044,0.00008798142,0.000029441988,0.000988552,0.00013681714],"about_ca_topic_score_codex":0.007973976,"about_ca_topic_score_gemma":0.00199491,"teacher_disagreement_score":0.12629893,"about_ca_system_score_codex":0.00044515455,"about_ca_system_score_gemma":0.005389088,"threshold_uncertainty_score":0.998632},"labels":[],"label_agreement":null},{"id":"W4400036793","doi":"10.1200/jco.2024.42.16_suppl.8631","title":"Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Open label; Oncology; Internal medicine; Immunotherapy; Clinical trial; Cancer","score_opus":0.3515000415546273,"score_gpt":0.5714537571958971,"score_spread":0.2199537156412698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96471137,0.0001624798,0.00043823067,0.031679325,0.00054238207,0.0016539434,0.000028432602,0.000012897207,0.0007709375],"genre_scores_gemma":[0.99047583,0.00016814255,0.0051952167,0.0028753746,0.00083793077,0.00003377419,0.00004536049,0.000022058406,0.0003463274],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9942133,0.0014469293,0.0025438825,0.00034818138,0.0009866861,0.0004610594],"domain_scores_gemma":[0.9815,0.013302242,0.0009954948,0.00025871617,0.00091040676,0.0030331085],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011249158,0.00016091019,0.001316278,0.00023592751,0.00004944247,0.00006459277,0.0002546191,0.00029301833,0.0002350141],"category_scores_gemma":[0.06588734,0.00009497945,0.00006496275,0.0003250721,0.0002677525,0.0003676485,0.000075706805,0.0016379063,0.000028126326],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70991737,0.042388245,0.004816791,0.00009390055,0.0006790493,0.02311828,0.002040961,0.0000048216966,0.00035293362,0.00004731341,0.025523325,0.19101702],"study_design_scores_gemma":[0.2632371,0.630507,0.07892545,0.001711018,0.00045369816,0.00049100776,0.0010365626,0.0014231309,0.00003462476,0.00019431292,0.021822564,0.00016354237],"about_ca_topic_score_codex":0.00029439814,"about_ca_topic_score_gemma":0.0005564402,"teacher_disagreement_score":0.58811873,"about_ca_system_score_codex":0.00038110142,"about_ca_system_score_gemma":0.038311984,"threshold_uncertainty_score":0.9671399},"labels":[],"label_agreement":null},{"id":"W4400036823","doi":"10.1200/jco.2024.42.16_suppl.9046","title":"Bioethics of over- and undertreatment in older adults with cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bioethics; Cancer; Gerontology; Family medicine; Oncology; Internal medicine; Genetics","score_opus":0.3972359408244413,"score_gpt":0.6149744348189912,"score_spread":0.21773849399454986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734297,0.016902678,0.000046193327,0.008259523,0.00037055125,0.00008572259,0.00000469053,0.0000025010906,0.00089845085],"genre_scores_gemma":[0.97179353,0.025638094,0.0017734077,0.00046513893,0.00023480611,0.0000014546082,7.04408e-7,0.0000065825034,0.000086296386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985615,0.00010753606,0.00096622057,0.00009658471,0.0001830165,0.00008511511],"domain_scores_gemma":[0.99701387,0.0022159084,0.0004119925,0.0000613175,0.00018785524,0.00010907882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007857949,0.00006859051,0.00084243534,0.00009532579,0.000004524689,0.0000017875285,0.00003677802,0.0001990786,0.000053235475],"category_scores_gemma":[0.0006498661,0.000039371633,0.00011594841,0.00011550273,0.00029910795,0.000038814287,0.000015471634,0.00047769133,5.646692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00585205,0.0011506208,0.81501806,0.00057358906,0.0007415723,0.0013092617,0.0027453385,0.0000119059,0.00005264361,0.00058755226,0.0014086924,0.17054869],"study_design_scores_gemma":[0.019240284,0.031516213,0.8830189,0.016051782,0.00088149164,0.00017223845,0.0031208505,0.00030302515,0.0009437591,0.00062961405,0.043994475,0.00012737786],"about_ca_topic_score_codex":0.00030837063,"about_ca_topic_score_gemma":0.00068063306,"teacher_disagreement_score":0.17042132,"about_ca_system_score_codex":0.00008381988,"about_ca_system_score_gemma":0.0011056446,"threshold_uncertainty_score":0.20753577},"labels":[],"label_agreement":null},{"id":"W4400036852","doi":"10.1200/jco.2024.42.16_suppl.9022","title":"Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Innovations in Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Community practice; Community of practice; Clinical Practice; Family medicine; Medical practice; Medical education; Pedagogy","score_opus":0.19912619856951982,"score_gpt":0.624513239022326,"score_spread":0.4253870404528062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9232162,0.001041977,0.0004317505,0.06706778,0.003530207,0.00029672543,7.71733e-7,0.000004545761,0.004410047],"genre_scores_gemma":[0.9923098,0.00044380297,0.0032687422,0.0032797402,0.0006356653,0.000006313646,0.0000068436984,0.000006551996,0.000042507334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936786,0.0024303158,0.0023912468,0.00006750728,0.0013552525,0.00007705653],"domain_scores_gemma":[0.98898804,0.004485906,0.002182528,0.0002734265,0.003951355,0.00011873677],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.034208357,0.0000633075,0.0005088083,0.00015529021,0.000050327486,0.0000057779766,0.0001624606,0.0003370509,0.00019266589],"category_scores_gemma":[0.14708973,0.000039147628,0.00013674794,0.0003847807,0.00040097279,0.00028237808,0.000049676615,0.0016116532,0.000002752552],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040848262,0.0023310662,0.0019504837,0.00026247496,0.00017438487,0.0000018693518,0.0013665518,0.000004781885,0.00018354513,0.0021508182,0.043128863,0.9480367],"study_design_scores_gemma":[0.0124452235,0.010478423,0.5466944,0.0052366825,0.0061158272,0.0032780427,0.014744953,0.03214783,0.001372092,0.013369137,0.35390145,0.00021596832],"about_ca_topic_score_codex":0.000037841935,"about_ca_topic_score_gemma":0.000013885344,"teacher_disagreement_score":0.9478207,"about_ca_system_score_codex":0.00021420993,"about_ca_system_score_gemma":0.011502714,"threshold_uncertainty_score":0.99448574},"labels":[],"label_agreement":null},{"id":"W4400037110","doi":"10.1200/jco.2024.42.16_suppl.9053","title":"Development of equity, diversity, and inclusion competencies in residents and faculty in oncology through formal and informal learning.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Innovations in Medical Education","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Inclusion (mineral); Equity (law); Diversity (politics); Oncology; Medical education; Internal medicine; Family medicine; Psychology","score_opus":0.1976271450390399,"score_gpt":0.5281757754276408,"score_spread":0.33054863038860094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400037110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933073,0.00046694942,0.00013130772,0.0043825954,0.0004129079,0.00010598679,4.1338865e-7,0.0000035899968,0.0011889298],"genre_scores_gemma":[0.9768858,0.00085544505,0.021321857,0.0007832626,0.00010736608,0.0000010468523,0.0000033737233,0.0000035901744,0.0000382359],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975869,0.00012726084,0.001668637,0.000108870794,0.00035052924,0.00015780595],"domain_scores_gemma":[0.9985051,0.0007123719,0.0004822646,0.000038934024,0.0001824279,0.00007890832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060575916,0.00007482319,0.0006618877,0.00028200558,0.00021123403,0.0000055002743,0.00008674051,0.0003058369,0.000014711165],"category_scores_gemma":[0.0033821051,0.000056626766,0.000033420994,0.00022308958,0.00033562107,0.0003275381,0.0044427384,0.0011118012,5.701975e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064866414,0.00032497648,0.3529248,0.00019483682,0.00004486824,0.00013729863,0.025074063,0.0000031339248,0.00006554277,0.00069745455,0.0001971596,0.6196872],"study_design_scores_gemma":[0.0035814813,0.002886042,0.95343846,0.00041237075,0.000046438203,0.00028889484,0.0028989278,0.0004652136,0.000021453574,0.0011304561,0.034775257,0.000055020933],"about_ca_topic_score_codex":0.00006380453,"about_ca_topic_score_gemma":0.00025383983,"teacher_disagreement_score":0.6196322,"about_ca_system_score_codex":0.00019788201,"about_ca_system_score_gemma":0.0012718973,"threshold_uncertainty_score":0.5537556},"labels":[],"label_agreement":null},{"id":"W4400037124","doi":"10.1200/jco.2024.42.16_suppl.9055","title":"AI in oncology: Resident perspectives by gender and tech literacy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Literacy; Family medicine","score_opus":0.3900465139440941,"score_gpt":0.6530394560080152,"score_spread":0.26299294206392104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400037124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8753933,0.017669545,0.00020908497,0.10150639,0.0021086694,0.000155984,0.000001011596,0.000011662087,0.0029443845],"genre_scores_gemma":[0.9864234,0.0053552096,0.0010007346,0.0050493446,0.0015981047,0.00000398165,9.914655e-7,0.0000099425015,0.0005583419],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737513,0.00033976935,0.0017475822,0.00018881992,0.00017659756,0.0001721274],"domain_scores_gemma":[0.99611944,0.0028569463,0.00031196116,0.00009118638,0.0003650737,0.00025537665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036508886,0.00007929063,0.0006625052,0.00021120986,0.00002606107,0.000020181638,0.00006485643,0.00039846476,0.00018431267],"category_scores_gemma":[0.0032124375,0.000057428075,0.00014181528,0.00017769368,0.0001819186,0.00017302725,0.000023610412,0.0014411687,0.000025673055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014281302,0.001133354,0.043747034,0.0001091562,0.00012826614,0.0010682688,0.016823208,0.0000016396391,0.00046147965,0.00093376875,0.06897505,0.8651906],"study_design_scores_gemma":[0.000595554,0.01391112,0.10471381,0.0004385847,0.00021016134,0.001394407,0.020640172,0.00053741626,0.00037519287,0.016968498,0.8400733,0.00014181471],"about_ca_topic_score_codex":0.000105290244,"about_ca_topic_score_gemma":0.00004397285,"teacher_disagreement_score":0.8650488,"about_ca_system_score_codex":0.0004910088,"about_ca_system_score_gemma":0.003638575,"threshold_uncertainty_score":0.64546764},"labels":[],"label_agreement":null},{"id":"W4400037535","doi":"10.1200/jco.2024.42.16_suppl.8522","title":"Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced <i>ROS1</i> fusion-positive (<i>ROS1+)</i> NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; ROS1; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Clinical trial; Oncology; Cancer research; Cancer; Adenocarcinoma; Receptor","score_opus":0.056210437963042224,"score_gpt":0.45260694539413787,"score_spread":0.39639650743109567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400037535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816293,0.0058168094,0.000015426851,0.0069053713,0.0022617541,0.0028112135,0.00003389199,0.000027743343,0.0004984825],"genre_scores_gemma":[0.9872324,0.0077021546,0.0016923611,0.0017865264,0.0012320542,0.00013886894,0.00006132124,0.00006052253,0.00009379437],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912823,0.0018901972,0.004686609,0.0007670767,0.0008438851,0.00052995584],"domain_scores_gemma":[0.9915227,0.005309405,0.0018803419,0.00047087955,0.0003377432,0.00047889494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005298555,0.00048087887,0.002444195,0.00033584767,0.00008413844,0.00006528479,0.00022378266,0.00058215443,0.000053990425],"category_scores_gemma":[0.0022126187,0.00024702563,0.0005786179,0.00063074403,0.0004923812,0.00033613772,0.00008489953,0.0018631157,0.000012190699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1840239,0.023281276,0.04081586,0.0000458637,0.00051677425,0.008813829,0.0008115178,0.000004038224,0.00013259794,0.000056176188,0.001098805,0.74039936],"study_design_scores_gemma":[0.6646278,0.21687302,0.064704314,0.0026334776,0.001360588,0.0011325092,0.00064589735,0.00016219025,0.00078782026,0.00038001125,0.046240225,0.00045216252],"about_ca_topic_score_codex":0.000053415977,"about_ca_topic_score_gemma":0.00027874712,"teacher_disagreement_score":0.7399472,"about_ca_system_score_codex":0.0017757661,"about_ca_system_score_gemma":0.003335933,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4400038185","doi":"10.1200/jco.2024.42.16_suppl.9038","title":"Medical students' views on oncology specialty: A cross-sectional study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Specialty; Cross-sectional study; Internal medicine; Oncology; Clinical Oncology; Family medicine; Cancer; Pathology","score_opus":0.16563740340809877,"score_gpt":0.6373339391018986,"score_spread":0.4716965356937999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400038185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9230445,0.0026470737,0.00088342966,0.01669945,0.03258445,0.00057528657,0.000004222393,0.000055364442,0.023506215],"genre_scores_gemma":[0.9199815,0.005105222,0.0030529068,0.026988298,0.039774567,0.000023174849,0.0000037640216,0.00006005382,0.0050105476],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919444,0.001332678,0.004106747,0.00044821072,0.001811741,0.00035626328],"domain_scores_gemma":[0.9875482,0.009965178,0.0010842943,0.00027428285,0.00037164264,0.00075643696],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.017316433,0.00023484702,0.0022262244,0.00030423678,0.00010633865,0.000037383503,0.0006465923,0.0013333018,0.003938863],"category_scores_gemma":[0.0074353567,0.00014917008,0.0008796814,0.0002765552,0.00084403827,0.0001470477,0.00011644122,0.0041926927,0.00033450147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01013318,0.012770379,0.63524026,0.000029609584,0.0014673612,0.019424045,0.00024289914,0.000014570155,0.000008243601,0.00079945417,0.026541432,0.29332855],"study_design_scores_gemma":[0.006808483,0.044743028,0.40446213,0.000071780334,0.00014659336,0.0028073045,0.000068594934,0.000031248408,0.0000019122604,0.000566828,0.5402144,0.00007769365],"about_ca_topic_score_codex":0.0000037850493,"about_ca_topic_score_gemma":0.00008460446,"teacher_disagreement_score":0.51367295,"about_ca_system_score_codex":0.0008871585,"about_ca_system_score_gemma":0.00616044,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W4400038187","doi":"10.1200/jco.2024.42.16_suppl.8642","title":"Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral <i>EGFR</i> mutations: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Meta-analysis; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.13364122823626895,"score_gpt":0.5163258210502982,"score_spread":0.3826845928140293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400038187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000164906,0.9968498,0.000006144387,0.00088842044,0.000058738227,0.0018356211,0.00005217892,0.0000031201416,0.00014109035],"genre_scores_gemma":[0.0014228486,0.9972865,0.00051051745,0.0005427132,0.00003161412,0.000039794686,0.00003667378,0.000021397858,0.00010794107],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9937046,0.0008748493,0.0047346395,0.0002762267,0.0002845395,0.00012511782],"domain_scores_gemma":[0.99297804,0.0026373267,0.0036553196,0.00021848266,0.00028477973,0.00022607988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002263011,0.00028684572,0.014580443,0.00034834284,0.000021794389,0.00001211232,0.000076008495,0.00022428641,0.000022114307],"category_scores_gemma":[0.0014203353,0.00013322242,0.0012617352,0.0005367713,0.00019132323,0.0000687306,0.000048763264,0.0006848191,0.0000013646123],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046324654,0.001488669,0.0013690665,0.6266003,0.3099972,0.00023426421,0.00011302872,0.0000012349133,2.2393167e-9,0.00006146339,0.00015977849,0.05951169],"study_design_scores_gemma":[0.0033050773,0.0032481337,0.0021706752,0.049634162,0.9264764,0.0001291039,0.000014867019,0.0000015444831,3.347431e-9,0.000014584126,0.014905003,0.000100444144],"about_ca_topic_score_codex":0.000014625029,"about_ca_topic_score_gemma":0.00003018895,"teacher_disagreement_score":0.61647916,"about_ca_system_score_codex":0.00011375052,"about_ca_system_score_gemma":0.00097157405,"threshold_uncertainty_score":0.99668986},"labels":[],"label_agreement":null},{"id":"W4400062171","doi":"10.1200/jco.2024.42.16_suppl.9019","title":"Global interest in podcasts designed for medical oncology trainees.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical Oncology; Oncology; Medical physics; Radiation oncology; Internal medicine; Family medicine; Cancer; Radiation therapy","score_opus":0.5377607932089655,"score_gpt":0.6494096096139399,"score_spread":0.11164881640497437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400062171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68196565,0.0015812535,0.001754737,0.24104264,0.065316774,0.000954441,0.0000060276884,0.00003734635,0.007341109],"genre_scores_gemma":[0.97812814,0.0011002856,0.004348289,0.002713645,0.013572272,0.000084954525,0.0000013245302,0.000011885676,0.000039211474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941321,0.0021876378,0.002607668,0.00020405033,0.0004397346,0.00042880626],"domain_scores_gemma":[0.94976145,0.048174456,0.00078003627,0.0000809554,0.0003859481,0.0008171581],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0233938,0.000096341944,0.0009389601,0.00015204339,0.000080533355,0.000025663992,0.00045602606,0.001159939,0.00036429576],"category_scores_gemma":[0.13074473,0.00008158361,0.00034096037,0.00050025823,0.0006347708,0.00018554552,0.000029891458,0.00090666465,0.000023228939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004907473,0.000702348,0.009782822,0.000034433127,0.00005010324,0.00029149526,0.0054093944,0.0000014135703,0.0000015546058,0.023933282,0.0141750425,0.94512737],"study_design_scores_gemma":[0.001924332,0.004354647,0.034740172,0.00017297395,0.000055053988,0.000053148546,0.0032977595,0.00011321195,8.25556e-7,0.018598298,0.9365936,0.00009595933],"about_ca_topic_score_codex":0.00060648384,"about_ca_topic_score_gemma":0.02299803,"teacher_disagreement_score":0.9450314,"about_ca_system_score_codex":0.0017228364,"about_ca_system_score_gemma":0.025870316,"threshold_uncertainty_score":0.9948297},"labels":[],"label_agreement":null},{"id":"W4400108728","doi":"10.1200/jco.2024.42.16_suppl.8559","title":"Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with <i>KRAS</i>G12C mutation: A phase 1b study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Panitumumab; KRAS; Mutation; Lung cancer; Internal medicine; Oncology; Cancer; Cancer research; Colorectal cancer; Genetics; Biology; Gene","score_opus":0.07031068528454834,"score_gpt":0.5278725660293183,"score_spread":0.45756188074477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98507476,0.0025431109,0.0036224457,0.0033208542,0.0016491791,0.002011533,0.000045993824,0.000037102684,0.0016950362],"genre_scores_gemma":[0.9911286,0.0002777738,0.0029787184,0.0008153324,0.0016570833,0.00023232956,0.000018830733,0.000043821143,0.002847477],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975514,0.00013121426,0.0014837917,0.00029558048,0.0002856532,0.00025240207],"domain_scores_gemma":[0.9968717,0.0012404042,0.00072536425,0.0001649778,0.00065515534,0.0003423878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082135975,0.00020513144,0.001170406,0.00014339128,0.0000806965,0.000038379196,0.00011032818,0.0002014775,0.00012023363],"category_scores_gemma":[0.0002021652,0.00012245605,0.00037497506,0.00023195955,0.00008591566,0.0001432958,0.000018870127,0.0005447214,0.0000066294383],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07045387,0.07597279,0.23256116,0.0025026628,0.02528944,0.028336378,0.01726121,0.0012191079,0.00069476105,0.00012652106,0.0768698,0.4687123],"study_design_scores_gemma":[0.3529087,0.25014597,0.10130533,0.002303255,0.04439506,0.0016888045,0.0047188173,0.014298868,0.00085641595,0.00019970624,0.22638024,0.0007988276],"about_ca_topic_score_codex":0.00013701722,"about_ca_topic_score_gemma":0.00028732297,"teacher_disagreement_score":0.46791348,"about_ca_system_score_codex":0.0005939128,"about_ca_system_score_gemma":0.0060811834,"threshold_uncertainty_score":0.99955344},"labels":[],"label_agreement":null},{"id":"W4400108744","doi":"10.1200/jco.2024.42.16_suppl.8549","title":"Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Lung cancer; Cancer; Internal medicine; Cancer research","score_opus":0.10922058810761197,"score_gpt":0.48642766543260335,"score_spread":0.37720707732499137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987218,0.0051054335,0.00004445419,0.0049760207,0.0017809605,0.0005539746,0.000018390287,0.00000748825,0.00029526796],"genre_scores_gemma":[0.9953776,0.0017293642,0.0020221479,0.0003634527,0.0002987799,0.0000137331135,0.0000030887516,0.000023066994,0.00016874544],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99712515,0.0003896215,0.001885709,0.0002312328,0.00017324906,0.00019503295],"domain_scores_gemma":[0.9945389,0.00428773,0.00055720925,0.00013022403,0.00016705139,0.00031889646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021711567,0.00014730205,0.0010105566,0.00030387533,0.000019982475,0.0000129442005,0.00006482512,0.00014800087,0.00006905807],"category_scores_gemma":[0.0010993324,0.000102032696,0.0002685626,0.0002849552,0.00011086318,0.00004996056,0.00003268209,0.0003641732,0.000005279412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31358,0.009298576,0.025162859,0.0003891877,0.007307124,0.005225782,0.0051815705,0.000396277,0.08075975,0.000010889391,0.00308561,0.5496023],"study_design_scores_gemma":[0.19145022,0.17590886,0.54101986,0.0027837497,0.007467354,0.0002740677,0.0018924469,0.001599512,0.0158221,0.000050536757,0.061171137,0.00056016754],"about_ca_topic_score_codex":0.0001220867,"about_ca_topic_score_gemma":0.00010288591,"teacher_disagreement_score":0.54904217,"about_ca_system_score_codex":0.00049986853,"about_ca_system_score_gemma":0.002783,"threshold_uncertainty_score":0.49369228},"labels":[],"label_agreement":null},{"id":"W4400108894","doi":"10.1200/jco.2024.42.16_suppl.4529","title":"First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Systemic therapy; Immunotherapy; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Center (category theory); Cancer","score_opus":0.1452255188867837,"score_gpt":0.45703598364372494,"score_spread":0.31181046475694124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861705,0.0063073044,0.00020613529,0.0014990179,0.0046058097,0.0006501132,0.00000487504,0.000023678449,0.00053260097],"genre_scores_gemma":[0.99412197,0.001854903,0.0014902625,0.0005752908,0.0015134957,0.00002024394,0.000008886332,0.00005244047,0.00036253824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948491,0.00070024526,0.0030882456,0.00041650125,0.0006333335,0.00031257948],"domain_scores_gemma":[0.99730915,0.0010094842,0.0007685942,0.0003453156,0.0002478218,0.000319637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003624704,0.00027775503,0.0016246533,0.00042952655,0.000036705485,0.000040914183,0.0003680881,0.0003192747,0.00014024628],"category_scores_gemma":[0.00026223026,0.00018338223,0.0009550755,0.00019830976,0.00006746979,0.00027892858,0.00005525387,0.0012728627,0.00003485569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008751938,0.020887524,0.8004879,0.000066863664,0.0011872551,0.026975837,0.0015860045,0.00013484931,0.0023967186,0.000007682084,0.00020477109,0.13731268],"study_design_scores_gemma":[0.056642614,0.043702044,0.8815725,0.0006179673,0.00026754997,0.0018276458,0.0005940909,0.0021741756,0.00033079533,0.000029017903,0.012013096,0.0002285457],"about_ca_topic_score_codex":0.00008487886,"about_ca_topic_score_gemma":0.00011041149,"teacher_disagreement_score":0.13708413,"about_ca_system_score_codex":0.00070048246,"about_ca_system_score_gemma":0.0010114918,"threshold_uncertainty_score":0.747811},"labels":[],"label_agreement":null},{"id":"W4400108991","doi":"10.1200/jco.2024.42.16_suppl.6571","title":"Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anemia; Ruxolitinib; Internal medicine; Gastroenterology; Crossover study; Proportional hazards model; Myelofibrosis; Surgery; Placebo; Bone marrow; Pathology","score_opus":0.10952433892141154,"score_gpt":0.4284397066555723,"score_spread":0.31891536773416074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99142176,0.00028843794,0.00002665005,0.0044981767,0.0005919336,0.0026829904,0.000033458236,0.000014752919,0.00044182845],"genre_scores_gemma":[0.9973557,0.0004921088,0.00035984252,0.00050103816,0.00053358555,0.0003446632,0.00005273138,0.000046318262,0.00031403586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956006,0.0006236477,0.0022457386,0.00046540576,0.00061208045,0.0004525354],"domain_scores_gemma":[0.99396676,0.004302266,0.0008161189,0.00029021868,0.00035227308,0.00027238688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015039496,0.0003823871,0.0022057493,0.00029744438,0.00006124561,0.00006485456,0.00017422918,0.00032833955,0.0000695846],"category_scores_gemma":[0.0005090038,0.00017352712,0.00045787735,0.0004739663,0.0001867387,0.0001675975,0.000024038614,0.0005090254,0.000008419974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18719412,0.01234815,0.76565194,0.000067661575,0.0010577955,0.001402072,0.00033511498,0.000033378776,0.0000030448318,0.00009320329,0.0002835675,0.03152995],"study_design_scores_gemma":[0.1859646,0.118309386,0.69150186,0.00048336602,0.0008876579,0.00006096087,0.0001002841,0.000088286615,0.00008182866,0.000011544509,0.0023736274,0.00013659718],"about_ca_topic_score_codex":0.00007786136,"about_ca_topic_score_gemma":0.0013767147,"teacher_disagreement_score":0.10596124,"about_ca_system_score_codex":0.0008069697,"about_ca_system_score_gemma":0.0012393881,"threshold_uncertainty_score":0.70762306},"labels":[],"label_agreement":null},{"id":"W4400109015","doi":"10.1200/jco.2024.42.16_suppl.6578","title":"Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Anemia; Ruxolitinib; Internal medicine; Population; Randomized controlled trial; Gastroenterology; Surgery; Bone marrow","score_opus":0.05868376799624149,"score_gpt":0.422944571031209,"score_spread":0.36426080303496755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351674,0.0006823132,0.0000099810695,0.0033536155,0.0002085781,0.0003082921,0.000009103377,0.0000046438627,0.0019067312],"genre_scores_gemma":[0.9963657,0.00088974467,0.0018615123,0.00053237577,0.00022991444,0.0000048528836,0.000003914844,0.000016394935,0.00009557763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752533,0.00021697831,0.0015568553,0.00021218818,0.00031670943,0.00017191774],"domain_scores_gemma":[0.9962363,0.0026851348,0.0004860329,0.00012130936,0.00023208582,0.0002390886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009854021,0.0001444316,0.001576647,0.00014471804,0.000018204026,0.000013554971,0.000061485545,0.00022184453,0.000107933854],"category_scores_gemma":[0.0009333632,0.00008401574,0.00018728006,0.00012458506,0.00021404616,0.00010577024,0.000035802783,0.0005799666,0.0000042448137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046736905,0.0024742845,0.89914304,0.00009858979,0.0002895136,0.00045832797,0.00023894424,0.0000022764832,0.000012942511,0.00020177582,0.0015682954,0.09083832],"study_design_scores_gemma":[0.015408722,0.024149334,0.952669,0.0009719607,0.000359202,0.00006561043,0.00006157155,0.00002163797,0.00017108608,0.00006877441,0.0059797936,0.00007327673],"about_ca_topic_score_codex":0.00001316889,"about_ca_topic_score_gemma":0.000033569988,"teacher_disagreement_score":0.090765044,"about_ca_system_score_codex":0.000093310104,"about_ca_system_score_gemma":0.0006546862,"threshold_uncertainty_score":0.34260622},"labels":[],"label_agreement":null},{"id":"W4400109132","doi":"10.1200/jco.2024.42.16_suppl.8052","title":"Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Stage (stratigraphy); Oncology; Internal medicine; Hazard ratio; Adenocarcinoma; ROS1; Cohort; Chemotherapy; Lung cancer; Proportional hazards model; Cancer; Confidence interval; Colorectal cancer","score_opus":0.04536788095441011,"score_gpt":0.46609689625186485,"score_spread":0.4207290152974547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218243,0.0015138079,0.00048430727,0.002106762,0.0004440128,0.00025128416,0.000040888295,0.00000820058,0.0029683055],"genre_scores_gemma":[0.9924673,0.00044181081,0.0026995465,0.0003038001,0.00012920394,0.000015767888,0.000014784762,0.000015954574,0.003911863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978135,0.00013817589,0.0014228761,0.00018475417,0.00026492338,0.00017574178],"domain_scores_gemma":[0.99748737,0.0011149856,0.00065065315,0.00014656757,0.00042520955,0.0001752191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006623458,0.00011726744,0.0013494404,0.0005845004,0.00002359037,0.000012052242,0.00009121908,0.00017625852,0.00044177432],"category_scores_gemma":[0.00024808038,0.00007116639,0.0004520111,0.00092198414,0.00009621932,0.00012582155,0.000019228382,0.0005493107,0.000003157082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073728536,0.00091334234,0.9835679,0.00010145063,0.006184614,0.0010629215,0.0010395373,0.0023128185,0.00009332022,0.00002388101,0.00049676344,0.0034661745],"study_design_scores_gemma":[0.0053703687,0.0023938064,0.9745674,0.00022131833,0.009925585,0.000008230449,0.0002837773,0.0028002542,0.000102742204,0.000014116337,0.0042368528,0.000075516175],"about_ca_topic_score_codex":0.0007522993,"about_ca_topic_score_gemma":0.0014824799,"teacher_disagreement_score":0.00900046,"about_ca_system_score_codex":0.00027879816,"about_ca_system_score_gemma":0.0028808669,"threshold_uncertainty_score":0.5110534},"labels":[],"label_agreement":null},{"id":"W4400109243","doi":"10.1200/jco.2024.42.16_suppl.7007","title":"Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and <i>TP53</i> mutations in the SYMPATICO study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Ven; Venetoclax; Ibrutinib; Mantle cell lymphoma; Internal medicine; Hazard ratio; Population; Phases of clinical research; Bendamustine; Neutropenia; Gastroenterology; Oncology; Rituximab; Toxicity; Lymphoma; Confidence interval; Leukemia; Chronic lymphocytic leukemia","score_opus":0.04951817572860148,"score_gpt":0.41891423260579713,"score_spread":0.3693960568771957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658036,0.00087895885,0.000009608366,0.00080155965,0.00014533012,0.00067383924,0.0000033049284,0.0000029401465,0.000904106],"genre_scores_gemma":[0.99915814,0.00025503826,0.00021528594,0.00022057533,0.0000906868,0.000005775743,0.0000021285493,0.000012729387,0.000039624167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707204,0.0005490341,0.0015218302,0.00018550799,0.00047417908,0.00019739024],"domain_scores_gemma":[0.9934097,0.005806589,0.0003538608,0.00016932336,0.00013737268,0.0001231699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031172363,0.00010537289,0.000843549,0.00018723337,0.000022596996,0.000014144138,0.00013411668,0.00015529523,0.000016046552],"category_scores_gemma":[0.0011666124,0.000058767513,0.000068818765,0.00031086267,0.00030624343,0.00007260517,0.00007219536,0.00054141553,0.0000027732178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044055205,0.014014692,0.6094974,0.00081850507,0.0006616743,0.005454222,0.012372017,0.0006474827,0.000030339126,0.00022322222,0.00082354585,0.3114017],"study_design_scores_gemma":[0.11745843,0.018121732,0.85802126,0.0003885233,0.00024355484,0.00020966704,0.00090998673,0.0023441133,0.000009024277,0.00010122041,0.0021228557,0.00006963853],"about_ca_topic_score_codex":0.00010756579,"about_ca_topic_score_gemma":0.00012778852,"teacher_disagreement_score":0.31133205,"about_ca_system_score_codex":0.0020519358,"about_ca_system_score_gemma":0.010047965,"threshold_uncertainty_score":0.99556416},"labels":[],"label_agreement":null},{"id":"W4400109246","doi":"10.1200/jco.2024.42.16_suppl.7008","title":"Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Mantle cell lymphoma; Neutropenia; Urology; Tolerability; Progression-free survival; Surgery; Oncology; Nuclear medicine; Adverse effect; Toxicity; Lymphoma; Chemotherapy","score_opus":0.05460563674213853,"score_gpt":0.44120849765124337,"score_spread":0.38660286090910484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955536,0.0010415071,0.000057220823,0.0009160959,0.0005151005,0.0007119048,0.000039230308,0.000033802517,0.0011315311],"genre_scores_gemma":[0.99643743,0.00039196308,0.0004553349,0.0005064748,0.00033645442,0.000010640342,0.000070271504,0.000059686492,0.0017317223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943291,0.0010839619,0.0026638247,0.0005256743,0.0009844822,0.00041297812],"domain_scores_gemma":[0.9960606,0.0016505658,0.0008248846,0.0005000993,0.00053106353,0.0004327872],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002658688,0.0002869671,0.0023257819,0.000976757,0.000051973762,0.000037802984,0.00030517526,0.0004815803,0.0038648632],"category_scores_gemma":[0.0003267767,0.00019045261,0.00069209666,0.0016680944,0.00018147226,0.00020420547,0.00007267381,0.0013898743,0.000040346567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092221975,0.058342952,0.49154854,0.000020012054,0.0076582097,0.0038247912,0.0008984155,0.000030730374,0.0008634816,0.0000014082049,0.0020366528,0.34255284],"study_design_scores_gemma":[0.1341123,0.13578558,0.673567,0.00013484292,0.003022869,0.000019598698,0.0003389868,0.0011185205,0.0002310624,0.000041823492,0.051378727,0.0002486665],"about_ca_topic_score_codex":0.0003222715,"about_ca_topic_score_gemma":0.00022004737,"teacher_disagreement_score":0.34230417,"about_ca_system_score_codex":0.00068975,"about_ca_system_score_gemma":0.001776295,"threshold_uncertainty_score":0.99704576},"labels":[],"label_agreement":null},{"id":"W4400109279","doi":"10.1200/jco.2024.42.16_suppl.8018","title":"ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Toronto East General Hospital; Princess Margaret Cancer Centre; St Joseph's Health Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Internal medicine; Oncology; Circulating tumor DNA; Prospective cohort study; Lung; Gastroenterology; Cancer; Surgery","score_opus":0.04309600928695204,"score_gpt":0.39325434174916957,"score_spread":0.3501583324622175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98406965,0.0050905365,0.0023758141,0.001293221,0.0044863797,0.0004159583,0.00016230754,0.000009962544,0.0020961824],"genre_scores_gemma":[0.9827901,0.004535626,0.0029264162,0.0014118237,0.0026100236,0.000031411542,0.000026462842,0.0000649036,0.005603241],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972337,0.00013413432,0.001614374,0.00040666218,0.00019219214,0.00041896006],"domain_scores_gemma":[0.9968209,0.0014191641,0.00076546107,0.00031822087,0.00031291306,0.00036329048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014924166,0.00023311323,0.00088621245,0.00009901163,0.000079707606,0.000048927,0.00039762602,0.00063749246,0.00006094351],"category_scores_gemma":[0.0015680237,0.00019063627,0.00083118153,0.000082691935,0.00013630955,0.000008691705,0.00020217522,0.0005542777,0.000008786804],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014837146,0.0012299706,0.23138961,0.00092924276,0.0040409546,0.0013280947,0.0006515367,0.0035821684,0.13690634,0.0002575347,0.52827907,0.07656834],"study_design_scores_gemma":[0.0065987627,0.0108883465,0.058621798,0.00008364446,0.0005444088,0.00003691325,0.00007213187,0.0016506353,0.01663846,0.00017780348,0.9042319,0.00045518382],"about_ca_topic_score_codex":0.00017124003,"about_ca_topic_score_gemma":0.0016290173,"teacher_disagreement_score":0.37595287,"about_ca_system_score_codex":0.0003507539,"about_ca_system_score_gemma":0.002450913,"threshold_uncertainty_score":0.77739215},"labels":[],"label_agreement":null},{"id":"W4400109832","doi":"10.1200/jco.23.02276","title":"Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Ductal carcinoma; Breast-conserving surgery; In situ; Carcinoma in situ; Breast cancer; Oncology; Carcinoma; Mastectomy; Internal medicine; Cancer","score_opus":0.034421276990235644,"score_gpt":0.3478598945953646,"score_spread":0.3134386176051289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853528,0.005324528,0.0064022983,0.0016901575,0.0009850976,0.00014710013,0.000049244318,0.0000021089813,0.000046678833],"genre_scores_gemma":[0.9984771,0.00059553963,0.00024276883,0.0002186989,0.0004156337,0.000028450437,0.000006780626,0.000011360907,0.0000036683361],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982675,0.00026885455,0.00094681105,0.00023255535,0.00012641001,0.00015787805],"domain_scores_gemma":[0.9977923,0.0014245838,0.00038240012,0.00012633987,0.00019802482,0.00007636651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011768057,0.00012046407,0.0004935661,0.00005792392,0.000024141731,0.000008287224,0.00009998959,0.00025578597,0.000002795292],"category_scores_gemma":[0.000659542,0.00007779843,0.00027026873,0.00006580906,0.00037350136,0.000013159255,0.000121050594,0.00027649195,2.979725e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014493482,0.0011245218,0.40468696,0.00054183224,0.0010451564,0.0009953728,0.00048321675,0.0001579528,0.1612016,0.00009628581,0.004862119,0.4103115],"study_design_scores_gemma":[0.0032866916,0.003906215,0.8904209,0.0006423915,0.0003733189,0.0012456103,0.00092008937,0.0004186466,0.09559738,0.0007032058,0.0022773668,0.00020818032],"about_ca_topic_score_codex":0.000021237935,"about_ca_topic_score_gemma":0.00008253898,"teacher_disagreement_score":0.48573396,"about_ca_system_score_codex":0.00005318042,"about_ca_system_score_gemma":0.0007863804,"threshold_uncertainty_score":0.31725278},"labels":[],"label_agreement":null},{"id":"W4400186989","doi":"10.1200/jco.2024.42.16_suppl.4538","title":"Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University","funders":"","keywords":"Lenvatinib; Medicine; Internal medicine; Cabozantinib; Renal cell carcinoma; Oncology; Pembrolizumab; Cohort; Sunitinib; Sorafenib; Discontinuation; Cancer; Hepatocellular carcinoma; Immunotherapy","score_opus":0.056500831292173245,"score_gpt":0.3979426933400041,"score_spread":0.34144186204783084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400186989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926012,0.00095591124,0.0000098756855,0.0008550615,0.00057033804,0.00050057797,0.000011800854,0.000009867364,0.004485365],"genre_scores_gemma":[0.9953885,0.00012901533,0.0035205656,0.000263389,0.00027449912,0.0000070689543,0.00002124165,0.000036199126,0.00035949322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958183,0.00034231957,0.0026042918,0.0003236747,0.0006035945,0.00030779332],"domain_scores_gemma":[0.9957721,0.0019248057,0.0011320494,0.00028022716,0.00051132735,0.00037947277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000967928,0.00024613817,0.0016996621,0.00034595648,0.000017793629,0.000007413277,0.00015860506,0.00028917688,0.00012064668],"category_scores_gemma":[0.000700909,0.00014850275,0.0005354154,0.00031190514,0.00018279742,0.00013714023,0.000047134432,0.0008643093,0.00002811102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03472701,0.011258818,0.68117344,0.00019207643,0.00060558383,0.0051471554,0.0003790597,0.00006106757,0.0012133432,0.000023016413,0.00055846194,0.26466098],"study_design_scores_gemma":[0.033381402,0.08690068,0.87339824,0.0003693564,0.00070554356,0.00014409421,0.00006333404,0.00002451246,0.0023027728,0.00002322715,0.0025786753,0.00010814793],"about_ca_topic_score_codex":0.000034072917,"about_ca_topic_score_gemma":0.000019067094,"teacher_disagreement_score":0.26455283,"about_ca_system_score_codex":0.00047306248,"about_ca_system_score_gemma":0.0017912508,"threshold_uncertainty_score":0.6055766},"labels":[],"label_agreement":null},{"id":"W4400187099","doi":"10.1200/jco.2024.42.16_suppl.4574","title":"A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial carcinoma; Oncology; Internal medicine; Cancer; Cancer research; Bladder cancer; Immunotherapy","score_opus":0.12785480290398576,"score_gpt":0.46836267043816465,"score_spread":0.3405078675341789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400187099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925286,0.0026142437,0.000019194893,0.0011526918,0.0012624151,0.0004323423,0.0000071136724,0.000007971029,0.001975408],"genre_scores_gemma":[0.9978387,0.00051511335,0.00043829388,0.00035590475,0.00055994425,0.000008845556,6.024137e-7,0.000021475993,0.0002611187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705607,0.00032702557,0.00188287,0.00022580722,0.00031883057,0.00018938443],"domain_scores_gemma":[0.9978809,0.0011241556,0.00043873853,0.0001509139,0.00017268638,0.00023264083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012106679,0.000142818,0.0013583396,0.00024063465,0.000015991482,0.000007859745,0.00009664326,0.00009812683,0.000113655835],"category_scores_gemma":[0.0007825302,0.00009772272,0.00016832446,0.00020287267,0.00012568546,0.00010492981,0.00004634276,0.0007393707,0.0000063099988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04639094,0.014676552,0.58056015,0.00022437645,0.00090233085,0.005969286,0.0016659856,0.00001335018,0.0013789103,0.00010976904,0.00095334416,0.347155],"study_design_scores_gemma":[0.03807833,0.21656737,0.7339051,0.00023117286,0.00064746925,0.0005917787,0.0006933897,0.0000672558,0.00010735273,0.0003633269,0.008650238,0.00009725265],"about_ca_topic_score_codex":0.00022285948,"about_ca_topic_score_gemma":0.00035584008,"teacher_disagreement_score":0.34705776,"about_ca_system_score_codex":0.00012387955,"about_ca_system_score_gemma":0.0015628631,"threshold_uncertainty_score":0.39850166},"labels":[],"label_agreement":null},{"id":"W4400264619","doi":"10.1200/jco.2024.42.16_suppl.e19026","title":"Therapeutic utilization in chronic lymphocytic leukemia: A cross-sectional analysis of the Lymphoma Coalition’s 2022 Global Patient Survey.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pharmacyclics","keywords":"Medicine; Chronic lymphocytic leukemia; Cross-sectional study; Lymphoma; Internal medicine; Oncology; Leukemia; Pathology","score_opus":0.18705913266333404,"score_gpt":0.5106715889936395,"score_spread":0.32361245633030544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400264619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175143,0.0047118478,0.0003456559,0.00033372315,0.0018190804,0.00028465944,0.000056883724,0.000012697667,0.0006840118],"genre_scores_gemma":[0.997721,0.0009565159,0.000046847457,0.00060177717,0.00041930517,0.000008875394,0.000024787529,0.00001702734,0.000203853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930918,0.0015364147,0.0034110423,0.00035395724,0.0012425663,0.00036419247],"domain_scores_gemma":[0.99346334,0.004042051,0.0010610125,0.0004004045,0.00080096244,0.00023222476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006946774,0.00017820323,0.0014160227,0.0004221142,0.0000537671,0.00003720997,0.0003529775,0.0005682927,0.0004398391],"category_scores_gemma":[0.0037904712,0.000113772985,0.0011701118,0.0028209595,0.00056702935,0.00013861089,0.0001503605,0.0006311393,0.000015539166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0059154825,0.00083829736,0.8593321,0.00028610916,0.0061780894,0.00092682714,0.00016771337,0.027337093,0.00013053729,0.0010449616,0.0018035534,0.096039236],"study_design_scores_gemma":[0.011676993,0.0026178826,0.8239588,0.00012869202,0.0008484672,0.00041636708,0.000030891453,0.15659901,0.00004764815,0.0004418172,0.003152158,0.00008126767],"about_ca_topic_score_codex":0.0014744108,"about_ca_topic_score_gemma":0.0022531452,"teacher_disagreement_score":0.12926191,"about_ca_system_score_codex":0.15326989,"about_ca_system_score_gemma":0.16703174,"threshold_uncertainty_score":0.84998053},"labels":[],"label_agreement":null},{"id":"W4400264732","doi":"10.1200/jco.2024.42.16_suppl.e16038","title":"Population based assessment of HER-2 and PD-L1 positivity in gastric and gastroesophageal junction adenocarcinomas in a Canadian population.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Capital District Health Authority; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Gastroesophageal Junction; Population; Internal medicine; Adenocarcinoma; Gastroenterology; Cancer; Oncology; Environmental health","score_opus":0.05759177430560499,"score_gpt":0.4360038526696444,"score_spread":0.37841207836403945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400264732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404967,0.00045622443,0.00017457412,0.0043410934,0.00045309623,0.00017059669,0.0000019844767,0.000003326017,0.00034943916],"genre_scores_gemma":[0.99734735,0.00009085276,0.001953938,0.00034862905,0.00020124586,0.0000017993005,0.000007861223,0.0000066301877,0.000041678806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817985,0.00021861242,0.0011080395,0.00014173823,0.00018617745,0.00016559861],"domain_scores_gemma":[0.99888265,0.00047928185,0.00031728108,0.00005945448,0.00004699154,0.00021433637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021564593,0.000080815524,0.0006624966,0.00085819315,0.000013855417,0.000011503452,0.00002996267,0.00013229766,0.00003153754],"category_scores_gemma":[0.0003690936,0.00006685397,0.0000931496,0.0003474441,0.00003321345,0.0001267993,0.000015855698,0.00046738263,2.1358504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002912808,0.00011187375,0.93504703,0.00008011421,0.000029607265,0.00041832638,0.000015154737,0.00009133167,0.000005483927,0.00011648967,0.00007826974,0.06371505],"study_design_scores_gemma":[0.0029032978,0.0021046516,0.9885102,0.00014954316,0.00012898933,0.000083767976,0.000029074938,0.0056438483,4.6191215e-7,0.00012388495,0.0002868855,0.000035419052],"about_ca_topic_score_codex":0.04627543,"about_ca_topic_score_gemma":0.101327255,"teacher_disagreement_score":0.06367963,"about_ca_system_score_codex":0.0005220216,"about_ca_system_score_gemma":0.0007902985,"threshold_uncertainty_score":0.9600755},"labels":[],"label_agreement":null},{"id":"W4400265274","doi":"10.1200/jco.2024.42.16_suppl.tps2689","title":"A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tolerability; Medicine; Open label; Open label study; Maximum tolerated dose; Oncology; Internal medicine; Adverse effect","score_opus":0.15761621244561821,"score_gpt":0.5822574384733649,"score_spread":0.4246412260277467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400265274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851962,0.00033921638,0.00004425581,0.010968313,0.00039610028,0.00071965536,0.000007076975,0.0000037307723,0.0023254824],"genre_scores_gemma":[0.9986445,0.00017289667,0.00035639518,0.0005615218,0.00014100617,0.000009945619,0.0000016041456,0.0000068097766,0.0001053514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99752617,0.00036597598,0.0016842699,0.00015562773,0.00017437754,0.00009359826],"domain_scores_gemma":[0.9968831,0.0022116455,0.000505645,0.0001457325,0.00014633704,0.00010752866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002897111,0.0000792073,0.0008863581,0.00007144976,0.000030368019,0.00001253613,0.00009203891,0.00008137327,0.000055182096],"category_scores_gemma":[0.0015454027,0.000041920026,0.00007422688,0.00016179883,0.000106715,0.00012038796,0.00004467513,0.00048748447,0.000002204956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025328796,0.05022072,0.073230356,0.000072368915,0.00082911266,0.00090079015,0.0027647654,0.00008394407,0.0003979319,0.0009913596,0.0005775384,0.8446023],"study_design_scores_gemma":[0.06578619,0.10423784,0.8127251,0.0005501018,0.00077457674,0.00010813547,0.0016339126,0.0010896358,0.00005952708,0.0015857898,0.01135861,0.000090552036],"about_ca_topic_score_codex":0.000021171456,"about_ca_topic_score_gemma":0.000055176908,"teacher_disagreement_score":0.84451175,"about_ca_system_score_codex":0.00016150632,"about_ca_system_score_gemma":0.0009812581,"threshold_uncertainty_score":0.21179046},"labels":[],"label_agreement":null},{"id":"W4400270477","doi":"10.1200/jco.2024.42.16_suppl.e20530","title":"What is a bad ALK? A scoping review of molecular markers of poor prognosis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; University Health Network; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Crizotinib; Internal medicine; Oncology; Lung cancer","score_opus":0.16078240076422504,"score_gpt":0.5981349064903068,"score_spread":0.43735250572608175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400270477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011966017,0.9897918,0.000009714473,0.0052444106,0.0018075667,0.0015718634,0.000020905856,0.0000045507636,0.0015372062],"genre_scores_gemma":[0.000011705243,0.99458164,0.0017924077,0.0028936288,0.00036504783,0.000048969043,0.000012902261,0.000040279803,0.00025340696],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99262613,0.0005557174,0.005903068,0.00026196984,0.00047252164,0.00018058799],"domain_scores_gemma":[0.9920668,0.0012637902,0.0054917824,0.00025102485,0.00065877265,0.00026780608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002764451,0.0002724538,0.0076314183,0.00023637795,0.000011254578,0.0000092871815,0.00020674498,0.0005220973,0.00024355069],"category_scores_gemma":[0.0018788526,0.00015904331,0.0033601315,0.00036311685,0.0001833871,0.00010217778,0.000073749776,0.00094964524,0.000017642504],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000905786,0.0005330167,0.000010182319,0.2624512,0.0035344963,0.0004892277,0.000016525806,2.692825e-8,2.4190987e-7,0.000015454068,0.006956243,0.7259028],"study_design_scores_gemma":[0.0007295083,0.003445351,0.000004813211,0.50798726,0.024778573,0.0003052122,0.000012514691,2.9323311e-7,0.0000012898596,0.00001947697,0.46265733,0.000058356094],"about_ca_topic_score_codex":0.0000056246695,"about_ca_topic_score_gemma":0.0000020542868,"teacher_disagreement_score":0.72584444,"about_ca_system_score_codex":0.00021785586,"about_ca_system_score_gemma":0.01081694,"threshold_uncertainty_score":0.9947908},"labels":[],"label_agreement":null},{"id":"W4400271911","doi":"10.1200/jco.2024.42.16_suppl.e24125","title":"Screening for ocular toxicities of immunotherapy in a real-world population.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Immunotherapy; Population; Oncology; Intensive care medicine; Internal medicine; Cancer; Environmental health","score_opus":0.11511386859471376,"score_gpt":0.4577912602627124,"score_spread":0.3426773916679986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400271911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93275154,0.058206134,0.0023659868,0.0015638741,0.003947196,0.00029909183,0.000016356247,0.000022853566,0.0008269716],"genre_scores_gemma":[0.98849434,0.0063667414,0.0023624923,0.0003487396,0.0002016613,0.000009397618,0.000010779302,0.000025807649,0.0021800634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959181,0.00088025973,0.0027386886,0.00015474808,0.000058932317,0.00024925784],"domain_scores_gemma":[0.99328244,0.0054452056,0.0009349612,0.0001650074,0.00015277466,0.000019592633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046141264,0.00014167473,0.0012533343,0.00050216034,0.000048614686,0.000011222964,0.000268523,0.00043183714,0.00028912406],"category_scores_gemma":[0.0008803688,0.00010791616,0.00070445874,0.00024276189,0.00024548918,0.00018268936,0.00002715054,0.000728458,0.0000082113065],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02405784,0.00096795405,0.02178308,0.00009604488,0.0021555366,0.000082490435,0.00085085124,0.000111530564,0.093618296,0.007847624,0.0033769107,0.8450518],"study_design_scores_gemma":[0.011244279,0.010030672,0.23544657,0.0009133193,0.00013059146,0.0002064645,0.0004910081,0.00007870907,0.013240806,0.0039713522,0.7239574,0.0002887854],"about_ca_topic_score_codex":0.00023804461,"about_ca_topic_score_gemma":0.000101981626,"teacher_disagreement_score":0.84476304,"about_ca_system_score_codex":0.000072241135,"about_ca_system_score_gemma":0.00052908185,"threshold_uncertainty_score":0.44006932},"labels":[],"label_agreement":null},{"id":"W4400272135","doi":"10.1200/jco.2024.42.16_suppl.9554","title":"Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Basal cell; Dermatology; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.09897449490993147,"score_gpt":0.47161280875271777,"score_spread":0.3726383138427863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691195,0.0038009163,0.00043106618,0.0025093388,0.004094318,0.0013932367,0.000075232696,0.000018486671,0.0007654301],"genre_scores_gemma":[0.9958477,0.0005513544,0.0008267345,0.00057398085,0.0007012115,0.000020116935,0.0000060180314,0.0000452573,0.0014276183],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.993977,0.00082168856,0.003894761,0.0003797949,0.0005722383,0.00035450718],"domain_scores_gemma":[0.9889197,0.007932099,0.0019234414,0.00045090544,0.0005106832,0.0002632113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033501673,0.0002724593,0.0016870296,0.00018060373,0.00006958832,0.000024596462,0.00043436445,0.0002808972,0.000112177106],"category_scores_gemma":[0.003519552,0.00014889475,0.0012297736,0.00036377137,0.00039964207,0.0000980867,0.000074086194,0.0011133587,0.000004639889],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39895722,0.008847238,0.0021014411,0.00061827333,0.0006114543,0.003982794,0.0005695745,0.000016239184,0.0022173428,0.0000063065895,0.0046792296,0.5773929],"study_design_scores_gemma":[0.3617483,0.41206524,0.08030622,0.0017275218,0.005732208,0.0110171735,0.0012107763,0.0012947593,0.003820036,0.00018432608,0.1202486,0.00064483733],"about_ca_topic_score_codex":0.000015452633,"about_ca_topic_score_gemma":0.00012953597,"teacher_disagreement_score":0.5767481,"about_ca_system_score_codex":0.00027483495,"about_ca_system_score_gemma":0.0042104702,"threshold_uncertainty_score":0.74691933},"labels":[],"label_agreement":null},{"id":"W4400272169","doi":"10.1200/jco.2024.42.16_suppl.9559","title":"Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Melanoma; Internal medicine; Phases of clinical research; Clinical trial; Dermatology; Immunotherapy; Cancer; Cancer research","score_opus":0.07907522718799255,"score_gpt":0.43508881363543866,"score_spread":0.35601358644744613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933909,0.0022292612,0.0000067574692,0.0014956379,0.0017002083,0.00090675335,0.00002375105,0.000013758434,0.00023298412],"genre_scores_gemma":[0.9973052,0.00085194735,0.00014821003,0.0011778129,0.0003663172,0.000013406485,0.00000965523,0.000036192145,0.0000912595],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99645245,0.00055436156,0.0017411166,0.00029987947,0.0007050779,0.00024709318],"domain_scores_gemma":[0.99586695,0.0023794256,0.0011198968,0.00033774128,0.00017679362,0.000119216944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018556566,0.00021007204,0.0013877007,0.00014921607,0.000030395116,0.00002002971,0.00028025097,0.00024654926,0.00025329093],"category_scores_gemma":[0.0004188306,0.00011432851,0.00044973055,0.0003135584,0.0002589745,0.00015629015,0.000034560322,0.0009906224,0.000004863298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21427904,0.005722803,0.26525503,0.000019968571,0.0014273426,0.00042565516,0.0011193962,0.000007845361,0.00019492596,0.0000072796965,0.000976633,0.5105641],"study_design_scores_gemma":[0.12626988,0.05698656,0.79265785,0.0005195203,0.00020629767,0.000011219342,0.00036065603,0.000027555065,0.00011738296,0.000029291514,0.022700882,0.00011290057],"about_ca_topic_score_codex":0.0000903538,"about_ca_topic_score_gemma":0.00012831237,"teacher_disagreement_score":0.5274028,"about_ca_system_score_codex":0.0002044947,"about_ca_system_score_gemma":0.0013574614,"threshold_uncertainty_score":0.46621814},"labels":[],"label_agreement":null},{"id":"W4400272188","doi":"10.1200/jco.2024.42.16_suppl.9567","title":"Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Biosensing Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Cancer Institute","keywords":"Medicine; Oncology; Internal medicine; Biomarker; Correlation; Clinical trial; Stage (stratigraphy); Melanoma; Overall survival; Stratification (seeds); Cancer research","score_opus":0.2893820105112829,"score_gpt":0.552311864606561,"score_spread":0.2629298540952781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71808636,0.00063555496,0.27770546,0.0019102063,0.0006148812,0.0008158488,0.00011594425,0.0000075256858,0.000108177956],"genre_scores_gemma":[0.9311877,0.0017369295,0.0663798,0.00010656608,0.00036961172,0.000024493667,0.00004928153,0.000014789172,0.00013084963],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695486,0.00046024277,0.002111318,0.00026258308,0.00009844193,0.000112546826],"domain_scores_gemma":[0.9939125,0.0041915756,0.0012433105,0.00020932953,0.00035236956,0.00009092206],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008322966,0.0000994481,0.0006682984,0.00005984262,0.000025338873,0.00001758448,0.00013072953,0.00042800425,0.0000028772636],"category_scores_gemma":[0.010321524,0.000071436814,0.00024729132,0.00008437964,0.00020663913,0.000017409595,0.000035055193,0.00024635202,2.0266891e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021872293,0.0016827873,0.033649314,0.00021231337,0.0006113094,0.000021484379,0.00006411716,0.00006337793,0.05357597,0.019147707,0.014066182,0.85503316],"study_design_scores_gemma":[0.018979201,0.051959172,0.17130426,0.00063676544,0.0008263675,0.00014184974,0.00028089996,0.013932493,0.017076202,0.03465767,0.68948644,0.00071867346],"about_ca_topic_score_codex":0.0000063763496,"about_ca_topic_score_gemma":0.000088327244,"teacher_disagreement_score":0.85431445,"about_ca_system_score_codex":0.000015345975,"about_ca_system_score_gemma":0.00053564337,"threshold_uncertainty_score":0.998015},"labels":[],"label_agreement":null},{"id":"W4400272209","doi":"10.1200/jco.2024.42.16_suppl.e21016","title":"Descriptive and content analysis of breast cancer vlogs on YouTube.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.5957970645644348,"score_gpt":0.6170393805164288,"score_spread":0.021242315951993995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94467247,0.001212217,0.000021654647,0.04093251,0.011845035,0.00015790184,0.000014445675,0.000006414517,0.0011373411],"genre_scores_gemma":[0.9926033,0.004084046,0.00018428305,0.00072631234,0.0023281607,0.000012553908,3.959599e-7,0.000004671593,0.000056274188],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971729,0.0009080154,0.0012854637,0.00012401927,0.00035166982,0.00015794592],"domain_scores_gemma":[0.98677915,0.011512612,0.00081673486,0.00005632681,0.0005556093,0.0002795766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005319264,0.0000574347,0.00079124287,0.00025588035,0.000068584224,0.000015092628,0.00012776635,0.00026397913,0.00021996125],"category_scores_gemma":[0.009598501,0.00004294849,0.00029332933,0.0006128222,0.00052087015,0.00011996965,0.000013946577,0.00049318455,0.0000034589264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046480316,0.00042748995,0.3582146,0.000022261547,0.0014273995,0.000026168856,0.023652581,0.000012673126,0.000017711214,0.008046009,0.0016715348,0.60601676],"study_design_scores_gemma":[0.0003474965,0.0009944492,0.95263886,0.000091726026,0.0011839351,0.0000025732359,0.00882215,0.00006769474,0.0000026050404,0.0005077046,0.035291117,0.0000496836],"about_ca_topic_score_codex":0.0045765955,"about_ca_topic_score_gemma":0.0040681157,"teacher_disagreement_score":0.6059671,"about_ca_system_score_codex":0.00038226563,"about_ca_system_score_gemma":0.0030687745,"threshold_uncertainty_score":0.9987441},"labels":[],"label_agreement":null},{"id":"W4400272226","doi":"10.1200/jco.2024.42.16_suppl.e21533","title":"Prospective real-world evidence for the use of immune-checkpoint inhibitors and BRAF-targeted therapy in advanced melanoma from a large Canadian cohort.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Credit Valley Hospital; Niagara Health System; University of Alberta; Princess Margaret Cancer Centre; University of Calgary; Health Sciences Centre; Ottawa Hospital; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario","funders":"","keywords":"Medicine; Melanoma; Oncology; Targeted therapy; Immune checkpoint; Cohort; Ipilimumab; Prospective cohort study; Internal medicine; Immunotherapy; Cancer; Cancer research","score_opus":0.10461052156559818,"score_gpt":0.4095387828409206,"score_spread":0.3049282612753224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98799163,0.008782653,0.00017972574,0.0014116255,0.0010035885,0.00048032732,0.000056041114,0.0000025739657,0.00009181811],"genre_scores_gemma":[0.9911353,0.0064763064,0.0013027865,0.0003394039,0.00057049847,0.000024405097,0.000009748414,0.000015991243,0.00012556193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978132,0.00024868007,0.0013655103,0.0002460024,0.00010881582,0.00021774274],"domain_scores_gemma":[0.9969027,0.0019938932,0.0005460667,0.00019464675,0.00020356088,0.00015914727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00208098,0.00012308267,0.0005761362,0.00009960544,0.0000393449,0.000018732639,0.00017328461,0.00026053394,0.000018075452],"category_scores_gemma":[0.0024727855,0.00007918152,0.00030558335,0.000116071205,0.00012822491,0.00002017606,0.00004978771,0.00036666478,7.0563084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005061288,0.00031947828,0.80516195,0.000035712157,0.00084264396,0.00017004514,0.00035709143,0.000040827992,0.10810994,0.00043648158,0.0028012567,0.07666326],"study_design_scores_gemma":[0.0026463477,0.00569961,0.8526084,0.00017767459,0.00008649732,0.00002073959,0.00008538968,0.00024706096,0.01983367,0.00053004525,0.11793476,0.00012980911],"about_ca_topic_score_codex":0.012381201,"about_ca_topic_score_gemma":0.11627762,"teacher_disagreement_score":0.1151335,"about_ca_system_score_codex":0.000068039975,"about_ca_system_score_gemma":0.0015160766,"threshold_uncertainty_score":0.99419546},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4400272421","doi":"10.1200/jco.2024.42.16_suppl.9529","title":"Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Melanoma; Metastatic melanoma; Response Evaluation Criteria in Solid Tumors; Disease; Oncology; Internal medicine; Progressive disease; Cancer research","score_opus":0.18720516385571145,"score_gpt":0.5442839817790549,"score_spread":0.35707881792334345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257153,0.0008751004,0.00015672918,0.00466494,0.0011093008,0.0005070155,0.000028905355,0.0000059247836,0.000080541104],"genre_scores_gemma":[0.9937738,0.00010997525,0.0054892474,0.000158771,0.00020272256,0.000013523838,0.0000071819018,0.000015829777,0.00022893517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99445724,0.0012376629,0.0035933668,0.00024646145,0.00027306436,0.0001921781],"domain_scores_gemma":[0.98913646,0.008499662,0.0015854543,0.0001662258,0.00026054753,0.00035165506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064092544,0.00014390801,0.0026817168,0.00019097664,0.000022465118,0.0000053756044,0.000077840275,0.00019111428,0.00005043746],"category_scores_gemma":[0.006443329,0.00009104977,0.0004500113,0.0001361126,0.00058931386,0.00010032845,0.000027511758,0.00062570284,0.0000019297108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12723985,0.004835272,0.8418187,0.0001669309,0.0014130875,0.001199688,0.000121241865,0.000013478078,0.00006444748,0.0001411298,0.00062325597,0.022362912],"study_design_scores_gemma":[0.02051475,0.04088156,0.919766,0.000299736,0.002705113,0.0002626076,0.0003880571,0.00053604523,0.00019947016,0.00035650455,0.014005336,0.00008483879],"about_ca_topic_score_codex":0.000028199416,"about_ca_topic_score_gemma":0.00006353573,"teacher_disagreement_score":0.106725104,"about_ca_system_score_codex":0.00007957618,"about_ca_system_score_gemma":0.0026612808,"threshold_uncertainty_score":0.7713732},"labels":[],"label_agreement":null},{"id":"W4400272471","doi":"10.1200/jco.2024.42.16_suppl.e20618","title":"Sex influence on cancer immunotherapy efficacy and safety in advanced non-small cell lung cancer (NSCLC): A Canadian institution real-world experience.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Immunotherapy; Cancer immunotherapy; non-small cell lung cancer (NSCLC); Cancer","score_opus":0.04161408321969619,"score_gpt":0.43972808171603295,"score_spread":0.3981139984963368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793346,0.009015558,0.000018878987,0.0059582237,0.002277374,0.00044766042,0.000009677457,0.000017951412,0.0029200655],"genre_scores_gemma":[0.9444608,0.049517483,0.00023909482,0.004574294,0.00055346574,0.00003563411,0.0000011805862,0.000028592298,0.00058946444],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971986,0.00017118864,0.0017250997,0.00031578646,0.00023504678,0.00035427487],"domain_scores_gemma":[0.99804157,0.0007781632,0.0004810051,0.00018205782,0.0001413706,0.00037585694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014987454,0.0001996778,0.00096821494,0.00043758043,0.00006187836,0.000025592177,0.00016096,0.000297853,0.0001656429],"category_scores_gemma":[0.00017020818,0.00014967124,0.00022681971,0.00047566925,0.000264912,0.00017760533,0.000017808143,0.0010859991,0.0000021300161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025980853,0.0005172152,0.23881282,0.00016017974,0.00039716336,0.0011218786,0.002981046,0.000696096,0.008071099,0.00006552195,0.0011489815,0.7200472],"study_design_scores_gemma":[0.013154397,0.0030230286,0.78609157,0.0021198548,0.00010234998,0.000055702803,0.00019881997,0.00040508082,0.00062251923,0.000014693361,0.1940079,0.0002040716],"about_ca_topic_score_codex":0.059345204,"about_ca_topic_score_gemma":0.15175606,"teacher_disagreement_score":0.7198431,"about_ca_system_score_codex":0.001630083,"about_ca_system_score_gemma":0.0075698975,"threshold_uncertainty_score":0.99805623},"labels":[],"label_agreement":null},{"id":"W4400272633","doi":"10.1200/jco.2024.42.16_suppl.tps6127","title":"CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Oncology; Cancer research; Internal medicine; Squamous cell cancer; Head and neck cancer; Radiation therapy; Surgery","score_opus":0.042853724914328005,"score_gpt":0.4120093089269505,"score_spread":0.3691555840126225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950576,0.0021971248,0.00058990845,0.0006112764,0.0009897895,0.00044935534,0.000033497643,0.0000038092205,0.000067636116],"genre_scores_gemma":[0.9972554,0.00005084784,0.0010440485,0.00038892214,0.0011303427,0.00001945826,0.000007566744,0.000025405861,0.000078024226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795866,0.00021035469,0.001150765,0.000284875,0.00021135386,0.00018398417],"domain_scores_gemma":[0.9980801,0.00043451894,0.0007918025,0.00024003151,0.0003151021,0.0001384894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010284575,0.0001506097,0.0005710085,0.000043977467,0.000045402423,0.000015459696,0.00022795584,0.00025761517,0.0000057396073],"category_scores_gemma":[0.0006737567,0.00009505465,0.00020557464,0.00010898462,0.00015058344,0.000012392997,0.00007165857,0.00036567022,5.7128017e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06279213,0.026028646,0.056707058,0.000830704,0.001052699,0.00039539163,0.0013003298,0.0026152954,0.5638491,0.000044336437,0.02171452,0.2626698],"study_design_scores_gemma":[0.13684505,0.33299404,0.0213415,0.00033963172,0.0015548575,0.00033670483,0.001158014,0.0023346543,0.33728254,0.00023051561,0.16480884,0.0007736296],"about_ca_topic_score_codex":0.000012703901,"about_ca_topic_score_gemma":0.00010721263,"teacher_disagreement_score":0.3069654,"about_ca_system_score_codex":0.00004913688,"about_ca_system_score_gemma":0.0011287485,"threshold_uncertainty_score":0.3876216},"labels":[],"label_agreement":null},{"id":"W4400272676","doi":"10.1200/jco.2024.42.16_suppl.e17002","title":"Somatic tissue testing in prostate cancer using the Oncomine V3 panel: A single-institution retrospective analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Somatic cell; Internal medicine; Biology; Genetics","score_opus":0.7642061129486669,"score_gpt":0.6074532998897746,"score_spread":0.15675281305889233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945541,0.004723049,0.0042844173,0.04093462,0.0028547363,0.00041115275,0.00003949995,0.000026382542,0.0011850982],"genre_scores_gemma":[0.9896389,0.00024831618,0.005739661,0.002770256,0.0014558173,0.0000146525335,0.0000014553887,0.000022373219,0.00010854284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98834217,0.0009869793,0.009892453,0.0003408029,0.00013808924,0.00029949212],"domain_scores_gemma":[0.9860032,0.007196613,0.006196256,0.00023404839,0.00020953095,0.00016031635],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.045426317,0.00014496117,0.0023495003,0.00059416046,0.000100696576,0.00008325189,0.00025645082,0.00021982768,0.00009622584],"category_scores_gemma":[0.025577232,0.00012036443,0.0003360513,0.0010183073,0.00017590319,0.00047273934,0.00004761218,0.0008520919,0.000080480175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115924755,0.0006219559,0.94967633,0.00029618916,0.0014394508,0.0001629228,0.0026798425,0.021290649,0.00004055822,0.009766564,0.0015162706,0.012393309],"study_design_scores_gemma":[0.0022195526,0.001893569,0.69179016,0.0007449412,0.0005260771,0.00012972754,0.0010710736,0.23718466,0.000009377533,0.026710227,0.03735771,0.00036289252],"about_ca_topic_score_codex":0.0012269652,"about_ca_topic_score_gemma":0.001639794,"teacher_disagreement_score":0.25788617,"about_ca_system_score_codex":0.002151298,"about_ca_system_score_gemma":0.0015551952,"threshold_uncertainty_score":0.9829345},"labels":[],"label_agreement":null},{"id":"W4400272727","doi":"10.1200/jco.2024.42.16_suppl.tps5637","title":"Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Ovarian cancer; Internal medicine; Oncology; Alpha (finance); Gynecology; Cancer; Surgery","score_opus":0.06098242071726315,"score_gpt":0.42940563252334285,"score_spread":0.36842321180607973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853594,0.0045662806,0.000021978143,0.008348874,0.0005643707,0.0010260284,0.000050882743,0.000007214506,0.000055026983],"genre_scores_gemma":[0.99486196,0.0025403388,0.0014680314,0.0006339537,0.00040725732,0.000029637351,0.0000059080458,0.000034540026,0.000018400488],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99593234,0.00048903405,0.002442674,0.00039208884,0.0004954368,0.00024843588],"domain_scores_gemma":[0.9947143,0.0028521938,0.0015331948,0.000265746,0.00025960314,0.00037496802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021000255,0.000263429,0.0016878123,0.0001520715,0.000055152137,0.000024722185,0.00014230641,0.00024455393,0.00010810409],"category_scores_gemma":[0.0012808681,0.00014836104,0.00013234251,0.00029004598,0.00035978036,0.00013155329,0.000061342886,0.000921913,5.6947516e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056063578,0.010343651,0.26177034,0.00032224253,0.0020052206,0.00012123217,0.0027043358,0.000014030778,0.00033670955,0.000061106184,0.001570104,0.66468745],"study_design_scores_gemma":[0.08064845,0.04843829,0.8223691,0.0029750646,0.0010321571,0.000011437706,0.00022281462,0.00013055347,0.00018558232,0.000059760838,0.04374736,0.00017941106],"about_ca_topic_score_codex":0.00016817007,"about_ca_topic_score_gemma":0.00012358866,"teacher_disagreement_score":0.66450804,"about_ca_system_score_codex":0.00025311124,"about_ca_system_score_gemma":0.0014684054,"threshold_uncertainty_score":0.60499877},"labels":[],"label_agreement":null},{"id":"W4400272774","doi":"10.1200/jco.2024.42.16_suppl.tps4200","title":"REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Medicine; Regorafenib; Pembrolizumab; Oncology; Internal medicine; Radiology; Nuclear medicine; Colorectal cancer; Cancer; Immunotherapy","score_opus":0.22623714318770607,"score_gpt":0.45050288184038906,"score_spread":0.22426573865268298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699693,0.0012816188,0.011925527,0.0063304747,0.0013186303,0.009055262,0.00008615488,0.000010649719,0.000022409273],"genre_scores_gemma":[0.9951213,0.002198314,0.0007714784,0.00022837048,0.0011973593,0.00026012154,0.000067631074,0.000051805506,0.00010364604],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955965,0.0007417924,0.002455528,0.00045411167,0.00047816877,0.00027385217],"domain_scores_gemma":[0.9924474,0.0056132847,0.0007939735,0.0003293129,0.0005024452,0.0003135886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034305728,0.00038077205,0.002918835,0.00017928591,0.00014105364,0.00007441286,0.00023429471,0.000259177,0.00011101321],"category_scores_gemma":[0.0005563779,0.00016564001,0.00037078897,0.0003044288,0.0005611696,0.0001596983,0.000026600976,0.0002197402,4.1405394e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94088596,0.0024115907,0.00052254257,0.000115369505,0.00225251,0.00016359349,0.004118243,0.000022653272,0.00041332393,0.00006902354,0.0001455864,0.048879627],"study_design_scores_gemma":[0.82580256,0.14197636,0.0003855554,0.00019976574,0.0036139593,0.00014768481,0.00018540704,0.018023426,0.001400013,0.000018350105,0.008082178,0.00016471566],"about_ca_topic_score_codex":0.000046751236,"about_ca_topic_score_gemma":0.00008960228,"teacher_disagreement_score":0.13956477,"about_ca_system_score_codex":0.00012950957,"about_ca_system_score_gemma":0.0014684299,"threshold_uncertainty_score":0.67546034},"labels":[],"label_agreement":null},{"id":"W4400272792","doi":"10.1200/jco.2024.42.16_suppl.4563","title":"Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Pembrolizumab; Oncology; Cisplatin; Chemotherapy; Internal medicine; Urothelial carcinoma; Urothelial cancer; Cancer research; Cancer; Immunotherapy; Bladder cancer","score_opus":0.07223645194329825,"score_gpt":0.4361281868087091,"score_spread":0.3638917348654108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949237,0.0008944407,0.0005011029,0.0014093055,0.00069272454,0.00065866025,0.000051712777,0.000021334185,0.0008469838],"genre_scores_gemma":[0.99619037,0.0005387242,0.002187972,0.00043888527,0.00029797052,0.000025218314,0.000029234643,0.00005004011,0.00024156828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99541444,0.0005945369,0.0025827684,0.00040286517,0.00067385286,0.0003315496],"domain_scores_gemma":[0.9946419,0.0031317263,0.0012784811,0.00040745636,0.00030135558,0.00023909834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011579109,0.00032095186,0.002338046,0.00042083344,0.000040740455,0.000025541098,0.00027414216,0.00030906286,0.0005192439],"category_scores_gemma":[0.0011103626,0.00017239548,0.00081518665,0.0013071775,0.00019875896,0.00017123795,0.000028594335,0.0008765982,0.0000059691765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3065037,0.0031631705,0.38814014,0.0002309834,0.014827865,0.0020638441,0.0012660907,0.0036113267,0.00078978145,0.00013770263,0.00037067357,0.27889472],"study_design_scores_gemma":[0.07676368,0.022021292,0.8708969,0.00080354465,0.016982883,0.00019801606,0.00023698874,0.0075270464,0.0016048701,0.00034704982,0.002288312,0.00032942244],"about_ca_topic_score_codex":0.0016959892,"about_ca_topic_score_gemma":0.0027434693,"teacher_disagreement_score":0.48275676,"about_ca_system_score_codex":0.00050504657,"about_ca_system_score_gemma":0.0037226225,"threshold_uncertainty_score":0.70300835},"labels":[],"label_agreement":null},{"id":"W4400272804","doi":"10.1200/jco.2024.42.16_suppl.tps4199","title":"A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Biliary tract cancer; Biliary tract; Adjuvant chemotherapy; Chemotherapy; Cancer; Adjuvant; Internal medicine; Oncology; Gemcitabine; Gastroenterology; Breast cancer","score_opus":0.1268796463503963,"score_gpt":0.5067927268434355,"score_spread":0.3799130804930392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968132,0.01923384,0.000020369816,0.00875691,0.0019908375,0.0010358703,0.0000081105545,0.000019927598,0.0008021091],"genre_scores_gemma":[0.9901818,0.0073912865,0.00014402646,0.0007736464,0.0012463381,0.00004398108,0.0000017349437,0.000029383958,0.00018779954],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938238,0.0010346208,0.004019459,0.0003328732,0.00051445724,0.0002747354],"domain_scores_gemma":[0.9920899,0.005900869,0.0011262338,0.00025957538,0.00037494407,0.00024843987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006555246,0.00022490349,0.004381885,0.00042408786,0.000024694044,0.000010100186,0.00018748298,0.00029262304,0.00018963002],"category_scores_gemma":[0.0028622882,0.00014243815,0.0009671873,0.00048102246,0.00032560877,0.00012013188,0.000047140027,0.0014686296,0.00000412798],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59189135,0.024068058,0.07408245,0.00030842077,0.003899836,0.0067818374,0.007935639,0.000029595474,0.0010427348,0.000020184429,0.01313107,0.2768088],"study_design_scores_gemma":[0.8022498,0.034421504,0.14522237,0.0008677665,0.0018774999,0.00039667066,0.002230625,0.001147999,0.00018452093,0.00025736293,0.010946851,0.00019702282],"about_ca_topic_score_codex":0.00041532956,"about_ca_topic_score_gemma":0.0006444642,"teacher_disagreement_score":0.27661178,"about_ca_system_score_codex":0.00036057676,"about_ca_system_score_gemma":0.0028001196,"threshold_uncertainty_score":0.6380546},"labels":[],"label_agreement":null},{"id":"W4400272886","doi":"10.1200/jco.2024.42.16_suppl.tps4205","title":"Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for <i>BRCA1/2</i> or <i>PALB2</i> mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Nab-paclitaxel; Internal medicine; Paclitaxel; Pancreatic ductal adenocarcinoma; Pancreatic cancer; Platinum; Cancer research; Chemotherapy; Cancer","score_opus":0.19931363417768966,"score_gpt":0.5159172287940399,"score_spread":0.31660359461635024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771089,0.005904461,0.0007380758,0.0083162,0.002348032,0.0029018063,0.0001619332,0.000041038424,0.0024795712],"genre_scores_gemma":[0.96285224,0.004469478,0.014206113,0.0014724213,0.003456466,0.0002256295,0.000048347538,0.00008696576,0.013182341],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9905572,0.00092993194,0.00606443,0.0006845918,0.00092787034,0.0008359817],"domain_scores_gemma":[0.980575,0.014767285,0.0022198486,0.000578919,0.00089486584,0.0009640528],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007045562,0.0005358447,0.005940514,0.00035419318,0.00015944071,0.0000375171,0.0004172424,0.0006380052,0.0022775591],"category_scores_gemma":[0.009639759,0.0003326269,0.0016835589,0.0005402397,0.0008119078,0.00030252888,0.00012352758,0.0013239514,0.000046847803],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8546969,0.024556763,0.0020038555,0.0012118847,0.011117834,0.0150007075,0.0011597134,0.000007962552,0.0033097367,0.0011294239,0.015355727,0.07044949],"study_design_scores_gemma":[0.38134137,0.48608992,0.0008778984,0.0008697586,0.00965617,0.0055382606,0.0007784783,0.0023203287,0.0010344086,0.0022329642,0.10888749,0.00037296893],"about_ca_topic_score_codex":0.000046542158,"about_ca_topic_score_gemma":0.00009017169,"teacher_disagreement_score":0.47335553,"about_ca_system_score_codex":0.0006046909,"about_ca_system_score_gemma":0.010137289,"threshold_uncertainty_score":0.99991256},"labels":[],"label_agreement":null},{"id":"W4400272924","doi":"10.1200/jco.2024.42.16_suppl.tps4203","title":"Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; FOLFIRINOX; Atezolizumab; Pancreatic ductal adenocarcinoma; Oncology; Internal medicine; Open label; Stage (stratigraphy); Pancreatic cancer; Randomized controlled trial; Oxaliplatin; Cancer; Nivolumab; Colorectal cancer; Immunotherapy","score_opus":0.08772171573927955,"score_gpt":0.46363118832346023,"score_spread":0.37590947258418067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658585,0.0009984123,0.0001355642,0.00010303907,0.00019260602,0.001746878,0.00003385923,0.0000034047887,0.0002004046],"genre_scores_gemma":[0.998726,0.00020127371,0.00069965003,0.000059106358,0.0000734309,0.0000632012,0.000040702285,0.000031794018,0.000104805156],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99588317,0.0011945491,0.0017616535,0.00039550255,0.00045486554,0.0003102852],"domain_scores_gemma":[0.99749243,0.000680957,0.00089950033,0.0003119958,0.00035637734,0.00025870756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001804991,0.00023825555,0.0017424842,0.00015936987,0.000034673572,0.000046481033,0.00040914453,0.00010738778,0.000028103233],"category_scores_gemma":[0.00068861176,0.00014171828,0.00016347934,0.00019994394,0.0002768825,0.000034992987,0.00019033198,0.00046652422,0.0000023409423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8103674,0.044129983,0.1320319,0.000089258305,0.004926981,0.0021094105,0.00020912415,0.00018744823,0.00014229768,0.000035591616,0.00012025858,0.0056503485],"study_design_scores_gemma":[0.82841146,0.15279086,0.015940554,0.00014587029,0.0010055549,0.000024876192,0.0003291818,0.00077424874,0.00023032168,0.000045635006,0.00012645025,0.00017497536],"about_ca_topic_score_codex":0.00042846298,"about_ca_topic_score_gemma":0.0013450466,"teacher_disagreement_score":0.11609135,"about_ca_system_score_codex":0.00009320163,"about_ca_system_score_gemma":0.000990866,"threshold_uncertainty_score":0.5779104},"labels":[],"label_agreement":null},{"id":"W4400272940","doi":"10.1200/jco.2024.42.16_suppl.tps4192","title":"A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iterion Therapeutics","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Cancer research; Oncology","score_opus":0.0453222427616434,"score_gpt":0.37286588261366665,"score_spread":0.3275436398520233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844587,0.00023063035,0.00008345088,0.00021031771,0.0003128454,0.00048414798,0.0000067918795,0.000003500478,0.00022243195],"genre_scores_gemma":[0.9989187,0.000018681389,0.00065040437,0.000100709774,0.0002261463,0.000019719138,0.0000054704683,0.00002235667,0.00003781144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755347,0.00049722975,0.0012165415,0.00025406136,0.0002950744,0.00018363172],"domain_scores_gemma":[0.9982529,0.00025550023,0.0008687943,0.00020597396,0.00031209254,0.00010471618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011483794,0.00015282904,0.00054692157,0.000080251055,0.000043747863,0.000013213358,0.00023812115,0.00018807856,0.000009927827],"category_scores_gemma":[0.0006228531,0.00008460936,0.00014776037,0.00025370225,0.00015028218,0.00001626572,0.0000883049,0.00062274537,8.293121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009733386,0.0136606665,0.7858897,0.000096343225,0.00048127794,0.00030671468,0.0014546473,0.00038905276,0.044282585,0.00002662864,0.00013797326,0.14354104],"study_design_scores_gemma":[0.079559416,0.30862603,0.3377922,0.000977058,0.00048593117,0.00021323797,0.004925671,0.001171532,0.25154832,0.00017748355,0.0137854,0.0007377448],"about_ca_topic_score_codex":0.000022675644,"about_ca_topic_score_gemma":0.0000874891,"teacher_disagreement_score":0.4480975,"about_ca_system_score_codex":0.000050481878,"about_ca_system_score_gemma":0.00086865557,"threshold_uncertainty_score":0.34502697},"labels":[],"label_agreement":null},{"id":"W4400272952","doi":"10.1200/jco.2024.42.16_suppl.4566","title":"Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Metastatic Urothelial Carcinoma; Avelumab; Internal medicine; Clinical endpoint; Randomization; Oncology; Bladder cancer; Urology; Surgery; Randomized controlled trial; Urothelial carcinoma; Immunotherapy; Nivolumab; Cancer","score_opus":0.060258553354855554,"score_gpt":0.402080230916988,"score_spread":0.34182167756213244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400272952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871299,0.00077318423,0.00096283626,0.0067680744,0.0028176352,0.0010482235,0.00015643623,0.000026355436,0.00031733437],"genre_scores_gemma":[0.9915815,0.00027423762,0.002846309,0.0023234088,0.0019306146,0.000058589438,0.000032737025,0.00007809308,0.0008744987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582815,0.00015994266,0.0024626276,0.00051851623,0.000529235,0.00050155213],"domain_scores_gemma":[0.9959287,0.0019936848,0.00082527054,0.0003186098,0.0005118451,0.0004218779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080253545,0.0003642417,0.002067799,0.00021661435,0.000051647137,0.000028648032,0.00026460996,0.00032867643,0.00039242295],"category_scores_gemma":[0.0012578819,0.00022766126,0.0006567085,0.00019549484,0.00020750597,0.00020554438,0.00005666563,0.0010054819,0.000048725786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029984292,0.0031788694,0.7904103,0.00018089505,0.001122002,0.002873294,0.0003000108,0.000072894305,0.000028330618,0.000019894502,0.0016889636,0.17014027],"study_design_scores_gemma":[0.059201837,0.027122675,0.9016194,0.0009580346,0.0008551907,0.0001088422,0.000055414715,0.00027118518,0.00012710744,0.0002994435,0.009108675,0.00027220257],"about_ca_topic_score_codex":0.00012460585,"about_ca_topic_score_gemma":0.00045498993,"teacher_disagreement_score":0.16986807,"about_ca_system_score_codex":0.0005011728,"about_ca_system_score_gemma":0.002055192,"threshold_uncertainty_score":0.9283757},"labels":[],"label_agreement":null},{"id":"W4400273021","doi":"10.1200/jco.2024.42.16_suppl.e16291","title":"Quality of life (QoL) benefits following <sup>177</sup>Lu-DOTATATE therapy in patients (pts) with <sup>68</sup>Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; Toronto General Hospital; University of Toronto; St Joseph's Health Care; University Health Network","funders":"","keywords":"Medicine; Neuroendocrine tumors; Nuclear medicine; Internal medicine; Oncology","score_opus":0.061476307246018144,"score_gpt":0.4199029954271659,"score_spread":0.35842668818114776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903,0.002263271,0.000015338372,0.0049295295,0.00038375246,0.001154945,0.00012658258,0.000053564036,0.0007730237],"genre_scores_gemma":[0.9903989,0.003948249,0.001453758,0.003289599,0.00046518887,0.00002715479,0.000061493796,0.00012707479,0.00022861948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988216,0.002412317,0.0053870566,0.0008926168,0.0019591185,0.0011329205],"domain_scores_gemma":[0.9833196,0.012202282,0.0018662079,0.0005283261,0.00090363476,0.0011799939],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028952311,0.00060478784,0.0038306057,0.0007553991,0.00008624715,0.000057544494,0.0006033011,0.000031761254,0.00010438327],"category_scores_gemma":[0.012059692,0.00043331418,0.0010232822,0.0009609551,0.0005704775,0.0008000069,0.00029581046,0.0032296164,0.000052272673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054477204,0.008365929,0.65644604,0.00093994156,0.0018520855,0.18629435,0.00048783497,0.012745088,0.00029208942,0.00010306959,0.003358622,0.07463774],"study_design_scores_gemma":[0.043432094,0.08315795,0.8511002,0.002414617,0.0005030418,0.006944529,0.00049909536,0.0023389477,0.00025833226,0.00036463418,0.008296369,0.00069020735],"about_ca_topic_score_codex":0.00019899114,"about_ca_topic_score_gemma":0.00008321298,"teacher_disagreement_score":0.19465414,"about_ca_system_score_codex":0.00036551643,"about_ca_system_score_gemma":0.0028570064,"threshold_uncertainty_score":0.9998119},"labels":[],"label_agreement":null},{"id":"W4400273251","doi":"10.1200/jco.2024.42.16_suppl.tps1644","title":"Serial testing to assess cognitive function in patients with cancer being treated with immunotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Cognition; Cancer; Oncology; Cancer immunotherapy; Internal medicine","score_opus":0.10297818664077556,"score_gpt":0.44831797976065024,"score_spread":0.34533979311987467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946833,0.00025066972,0.00028599752,0.0014274184,0.0010557646,0.00050043955,0.0000068688837,0.000023817673,0.001765685],"genre_scores_gemma":[0.9968462,0.00009399808,0.0005243666,0.0014011217,0.00093558856,0.000026805277,0.0000034508985,0.000031043408,0.00013745548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979173,0.00020276992,0.00108486,0.00022261713,0.00034352273,0.00022890713],"domain_scores_gemma":[0.9960684,0.0021376563,0.00048701887,0.000055554196,0.0010930621,0.00015828111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009382631,0.00015874566,0.00093447755,0.00023747749,0.00004090438,0.000017570248,0.000044386987,0.0001645118,0.000096154974],"category_scores_gemma":[0.0013881262,0.0000960535,0.00010103408,0.0005694465,0.00011378075,0.00015965386,0.000021862965,0.0008919664,0.000007732217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038464427,0.00079040695,0.7260859,0.000027090911,0.0011932064,0.00032160094,0.00015723471,0.00004605537,0.000052391646,0.0000026152275,0.00022001058,0.23263904],"study_design_scores_gemma":[0.017027294,0.049426805,0.9274551,0.0026886272,0.0009102809,0.000035141213,0.00018676133,0.000036139496,0.00003327692,0.00001923697,0.0020681224,0.00011319022],"about_ca_topic_score_codex":0.000092635724,"about_ca_topic_score_gemma":0.00020172428,"teacher_disagreement_score":0.23252586,"about_ca_system_score_codex":0.00037792628,"about_ca_system_score_gemma":0.0012752991,"threshold_uncertainty_score":0.39169484},"labels":[],"label_agreement":null},{"id":"W4400273273","doi":"10.1200/jco.2024.42.16_suppl.e14003","title":"Impact of gadopiclenol on decision making in patients with brain metastases: A post-hoc study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Post-hoc analysis; Brain metastasis; Oncology; Internal medicine; Cancer; Metastasis","score_opus":0.055775450346456625,"score_gpt":0.48826077022124764,"score_spread":0.432485319874791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740356,0.0007885579,0.000027511134,0.00084132893,0.00044826278,0.00034328137,0.000006810182,0.0000061963588,0.00013449027],"genre_scores_gemma":[0.99848264,0.00012724912,0.00050199556,0.00047405835,0.00035672492,0.000002240328,0.0000012773543,0.000020369023,0.000033418757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99661493,0.0006272403,0.0018738075,0.0001897831,0.00049818045,0.00019608354],"domain_scores_gemma":[0.9929052,0.005654159,0.00074184843,0.00021876443,0.00033595224,0.00014407207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028271626,0.00014641132,0.0013760302,0.00042177236,0.000016357577,0.000012337678,0.00013640901,0.00016030423,0.00014809686],"category_scores_gemma":[0.0037212481,0.000082628954,0.00051574054,0.00028511166,0.00010840241,0.000110979214,0.000030654763,0.0007928117,0.000008960443],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123977885,0.005526998,0.36280152,0.00003329049,0.0005292385,0.001326513,0.0004289863,0.000053576237,0.000014441209,0.000005760381,0.0012939946,0.5040078],"study_design_scores_gemma":[0.01197305,0.15286607,0.82997864,0.0010615595,0.00022701675,0.00012777661,0.00026420457,0.000031128675,0.000002864386,0.000025484194,0.0033771042,0.00006508905],"about_ca_topic_score_codex":0.00004001146,"about_ca_topic_score_gemma":0.00006528078,"teacher_disagreement_score":0.5039427,"about_ca_system_score_codex":0.00027826618,"about_ca_system_score_gemma":0.0018838107,"threshold_uncertainty_score":0.44549504},"labels":[],"label_agreement":null},{"id":"W4400273307","doi":"10.1200/jco.2024.42.16_suppl.e14040","title":"Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Glioblastoma; Venous thromboembolism; Incidence (geometry); Retrospective cohort study; Chart; Risk factor; Pediatrics; Surgery; Oncology; Internal medicine; Thrombosis","score_opus":0.04710225349877382,"score_gpt":0.41702469418878063,"score_spread":0.3699224406900068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98275113,0.012061909,0.000021081194,0.002861093,0.0011118107,0.00054573326,0.000017053242,0.000019672843,0.00061049126],"genre_scores_gemma":[0.90206826,0.096214354,0.0002745718,0.0010301851,0.00035163827,0.000008206366,0.000002224184,0.00002246411,0.000028112576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957208,0.00049200235,0.0026965248,0.00030012112,0.0004941749,0.00029635872],"domain_scores_gemma":[0.99468523,0.0027108195,0.0017415178,0.00020260483,0.00038263612,0.0002772156],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050548045,0.00020360205,0.003422205,0.00028758656,0.00003372651,0.000013796947,0.00016585883,0.0003562088,0.000116533],"category_scores_gemma":[0.013103556,0.00014487449,0.00049478514,0.00042684365,0.00022972234,0.00020372384,0.00010838488,0.0013280896,0.000011289806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011167774,0.0147149805,0.7915167,0.0021404398,0.0031129285,0.0050610295,0.0038624103,0.000025779478,0.0003277168,0.00078343856,0.035427723,0.14191008],"study_design_scores_gemma":[0.0031561225,0.015114532,0.9677397,0.0053066947,0.0011265685,0.000068517424,0.00023069241,0.00017590969,0.000047863625,0.00070008443,0.0062100254,0.00012329876],"about_ca_topic_score_codex":0.0002988937,"about_ca_topic_score_gemma":0.0004312314,"teacher_disagreement_score":0.176223,"about_ca_system_score_codex":0.0003415049,"about_ca_system_score_gemma":0.00075071864,"threshold_uncertainty_score":0.9952095},"labels":[],"label_agreement":null},{"id":"W4400273366","doi":"10.1200/jco.2024.42.16_suppl.e14039","title":"Health state utility assessment for low-grade glioma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Glioma; Oncology; Cancer research","score_opus":0.720867298389494,"score_gpt":0.6574702956072632,"score_spread":0.06339700278223082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273366","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26892862,0.01103185,0.13352485,0.56463075,0.016563896,0.0012273893,0.0005045333,0.000059105078,0.0035290173],"genre_scores_gemma":[0.9092783,0.0015062062,0.050370626,0.034036305,0.0039901505,0.000044502198,0.000015932477,0.000055065993,0.0007029513],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9815333,0.0011922484,0.016262352,0.00042898278,0.00014137394,0.00044178125],"domain_scores_gemma":[0.9783948,0.012569762,0.008007485,0.00029757016,0.00018653575,0.00054383435],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1159083,0.00015799562,0.0030529364,0.00034211855,0.00010641399,0.0000726854,0.0003352113,0.00027810578,0.00025925483],"category_scores_gemma":[0.0120901475,0.00015827928,0.0007330339,0.0001784094,0.00013010844,0.00041690512,0.0000460402,0.00078822346,0.00027837322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005010502,0.0027337295,0.04561066,0.0024946483,0.001303772,0.000083867504,0.0013978886,0.0003275682,0.0000029836813,0.15505256,0.6344157,0.15607558],"study_design_scores_gemma":[0.0022832698,0.0030828821,0.06420562,0.00017487262,0.000018567342,0.000050431896,0.00019556661,0.012678678,0.0000011523064,0.09061754,0.826514,0.00017743613],"about_ca_topic_score_codex":0.00016158861,"about_ca_topic_score_gemma":0.00013973133,"teacher_disagreement_score":0.6403496,"about_ca_system_score_codex":0.0010158037,"about_ca_system_score_gemma":0.0044273566,"threshold_uncertainty_score":0.99623144},"labels":[],"label_agreement":null},{"id":"W4400273385","doi":"10.1200/jco.2024.42.16_suppl.e13793","title":"Mapping models of care for children, adolescent and young adult cancer survivors: A scoping review.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Childhood cancer; Gerontology; Internal medicine","score_opus":0.13007214684554844,"score_gpt":0.49458702854070047,"score_spread":0.364514881695152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58315027,0.37393826,0.0041546538,0.018073661,0.013783029,0.0023164547,0.00007028322,0.000043022454,0.0044703684],"genre_scores_gemma":[0.8121162,0.18240744,0.0017363933,0.0018152973,0.0018134072,0.000020904594,0.0000017289693,0.000017976934,0.0000706382],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968439,0.00047646146,0.001893038,0.00019164497,0.00036019404,0.0002347715],"domain_scores_gemma":[0.99635303,0.0015807492,0.00095216196,0.00009243413,0.0008309727,0.00019068169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045971926,0.00009763679,0.0010796575,0.00008908912,0.000103183535,0.000021913358,0.0002433009,0.00025365388,0.000028624569],"category_scores_gemma":[0.0029495426,0.00007778529,0.00036954455,0.00019618809,0.0003155656,0.00024996392,0.000053181335,0.00044877914,8.4531933e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000518785,0.0004827909,0.23481661,0.019870412,0.00062883424,0.000101255624,0.025774304,0.00016485137,0.000017817674,0.0075830068,0.020586483,0.68945485],"study_design_scores_gemma":[0.009794806,0.008029033,0.15061752,0.66792256,0.0024187907,0.0002666082,0.054831944,0.0023799837,0.000075424396,0.015216484,0.08662467,0.0018221617],"about_ca_topic_score_codex":0.0019033798,"about_ca_topic_score_gemma":0.014593096,"teacher_disagreement_score":0.6876327,"about_ca_system_score_codex":0.00014694399,"about_ca_system_score_gemma":0.0028538639,"threshold_uncertainty_score":0.814329},"labels":[],"label_agreement":null},{"id":"W4400273489","doi":"10.1200/jco.2024.42.16_suppl.e13807","title":"Rural palliative care in cancer: Using telemedicine to bridge the gap.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Telemedicine; Palliative care; Bridge (graph theory); Cancer; Family medicine; Medical emergency; Nursing; Health care; Surgery; Internal medicine; Economic growth","score_opus":0.2653989784771531,"score_gpt":0.48105901144650687,"score_spread":0.21566003296935377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400273489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9356485,0.030083584,0.0007850008,0.01904539,0.0057979943,0.0001806533,0.000051726063,0.0000060995567,0.0084010735],"genre_scores_gemma":[0.98863906,0.0039561163,0.0003828716,0.0040657655,0.0027546699,0.000005306025,6.337702e-7,0.00001696547,0.0001786266],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970135,0.000056664416,0.0024367976,0.00018030316,0.000045276265,0.00026743367],"domain_scores_gemma":[0.9978967,0.0007466193,0.0009323481,0.0001344263,0.000106980566,0.00018296883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025344559,0.00011714717,0.0011013412,0.00027992038,0.000038629136,0.000035192093,0.00030433084,0.00020129637,0.0002467039],"category_scores_gemma":[0.0013546215,0.000085850195,0.00029680005,0.00031982936,0.000121725025,0.00021026161,0.00005631293,0.00079367775,0.00008338668],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078266935,0.00019635305,0.5288878,0.00006718522,0.00030306893,0.00024918854,0.0043109288,0.0015794757,0.000010514159,0.04665236,0.016523687,0.40043676],"study_design_scores_gemma":[0.0011652528,0.001588974,0.4681518,0.00018165707,0.000026624373,0.0000122204165,0.00038961106,0.0007133748,0.0000042015313,0.008277682,0.51936114,0.00012744254],"about_ca_topic_score_codex":0.0008499398,"about_ca_topic_score_gemma":0.0009254093,"teacher_disagreement_score":0.5028375,"about_ca_system_score_codex":0.00065695524,"about_ca_system_score_gemma":0.00082050904,"threshold_uncertainty_score":0.35008693},"labels":[],"label_agreement":null},{"id":"W4400274003","doi":"10.1200/jco.2024.42.16_suppl.3082","title":"Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Refractory (planetary science); Maximum tolerated dose; Solid tumor; Clinical trial; Cancer research; Pharmacology; Oncology; Internal medicine; Cancer","score_opus":0.030012029105320415,"score_gpt":0.3647388429982193,"score_spread":0.3347268138928989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400274003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984643,0.000529766,0.00017998168,0.00012240148,0.00023256583,0.00032083094,0.000026334674,0.0000025064076,0.00012133253],"genre_scores_gemma":[0.9987535,0.0001832138,0.00076423836,0.000031664862,0.00019480035,0.000004848584,0.00003488407,0.000014990963,0.000017860046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99676365,0.00032319914,0.0022519473,0.00025599662,0.00024478545,0.00016043305],"domain_scores_gemma":[0.99840486,0.00022802442,0.0009051361,0.00013962951,0.00019854677,0.00012379624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001706136,0.00014413678,0.00074695545,0.00019479527,0.000021446092,0.000006961501,0.0000972373,0.00029146986,0.000005467662],"category_scores_gemma":[0.0006172969,0.00011491017,0.00017787522,0.00015353512,0.00019389892,0.000026542019,0.00002943136,0.00034701792,1.997378e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76979965,0.016309222,0.018098062,0.00039752186,0.00016523902,0.00042138368,0.0005052096,0.0013110056,0.078754455,0.000057541474,0.00029872605,0.113882],"study_design_scores_gemma":[0.72858214,0.15770441,0.051297177,0.0011915562,0.00019767003,0.000029899096,0.00013153243,0.00092454185,0.049333565,0.00030236662,0.009853257,0.0004518755],"about_ca_topic_score_codex":0.000016220074,"about_ca_topic_score_gemma":0.00013706619,"teacher_disagreement_score":0.1413952,"about_ca_system_score_codex":0.000044602075,"about_ca_system_score_gemma":0.0006783653,"threshold_uncertainty_score":0.46859008},"labels":[],"label_agreement":null},{"id":"W4400274087","doi":"10.1200/jco.2024.42.16_suppl.3081","title":"Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Conjugate; Drug; Peptide; Solid tumor; Cancer research; Pharmacology; Term (time); Safety profile; Oncology; Internal medicine; Cancer; Adverse effect; Biochemistry; Biology","score_opus":0.1771831390670611,"score_gpt":0.5125324242608817,"score_spread":0.3353492851938207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400274087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359954,0.005211508,0.00017815712,0.007682047,0.00165604,0.00035027394,0.00005046878,0.000019967516,0.0012519698],"genre_scores_gemma":[0.9905445,0.004713748,0.0014509443,0.0009245255,0.00182329,0.0000028228383,0.000035854227,0.000034529945,0.00046975928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948209,0.00032455754,0.0037071388,0.00044868016,0.00031669918,0.0003820317],"domain_scores_gemma":[0.9939756,0.0037941781,0.0013408485,0.0003211873,0.00019179923,0.00037639218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046351105,0.00023813125,0.0021977096,0.00029022052,0.000035612476,0.000017072132,0.0003326796,0.00029584154,0.00033945157],"category_scores_gemma":[0.0019452745,0.00017533496,0.0003521511,0.00026710398,0.0003624352,0.00025270152,0.00028634825,0.0015356165,0.000015146125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023318915,0.009579583,0.71409595,0.0009158802,0.003072944,0.012225205,0.0010192211,0.00006685618,0.012441129,0.00017963669,0.017092992,0.2059917],"study_design_scores_gemma":[0.025442531,0.008937378,0.93183815,0.0015017401,0.0019370422,0.0020561742,0.00012813606,0.0014453791,0.00070855016,0.00012498641,0.025602078,0.00027785246],"about_ca_topic_score_codex":0.00009104381,"about_ca_topic_score_gemma":0.00032110699,"teacher_disagreement_score":0.2177422,"about_ca_system_score_codex":0.00015842885,"about_ca_system_score_gemma":0.002060229,"threshold_uncertainty_score":0.71499527},"labels":[],"label_agreement":null},{"id":"W4400408056","doi":"10.1200/jco.2024.42.16_suppl.tps6122","title":"Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Oncology; Basal cell; Internal medicine; Head and neck; Minimal residual disease; Head and neck cancer; Cancer research; Radiation therapy; Surgery; Leukemia","score_opus":0.04711227416459132,"score_gpt":0.4684984377249661,"score_spread":0.4213861635603747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743,0.0028220373,0.00006577564,0.0071771606,0.00054702855,0.00035342723,0.000005648764,0.000009788608,0.0015891587],"genre_scores_gemma":[0.997765,0.00019982795,0.0006689986,0.0007786052,0.00033240474,0.000014225778,0.0000062695954,0.000018434524,0.00021620933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802446,0.00029907568,0.0010783355,0.00022298982,0.00022637645,0.00014873994],"domain_scores_gemma":[0.99844944,0.00066697586,0.00026446613,0.00012078247,0.0001223408,0.00037597684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006918319,0.00012042495,0.0006095369,0.00017893569,0.00002200268,0.000017324954,0.000063937965,0.00012157729,0.000042285115],"category_scores_gemma":[0.0004736552,0.00008738236,0.00019066977,0.00012680165,0.00011060934,0.00011372638,0.00003284667,0.00056149083,0.0000081496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01343861,0.00960734,0.6520515,0.00029377075,0.00040222114,0.04341616,0.002689852,0.00025697958,0.0007090415,0.00033229036,0.0025742503,0.27422798],"study_design_scores_gemma":[0.013795906,0.0136799775,0.95581836,0.00016850086,0.0007794201,0.0001974076,0.0007146386,0.00013965795,0.00001409897,0.00036583937,0.014234965,0.00009120682],"about_ca_topic_score_codex":0.00003976544,"about_ca_topic_score_gemma":0.00012722249,"teacher_disagreement_score":0.30376688,"about_ca_system_score_codex":0.00020969922,"about_ca_system_score_gemma":0.0016804357,"threshold_uncertainty_score":0.3563349},"labels":[],"label_agreement":null},{"id":"W4400408721","doi":"10.1200/jco.2024.42.16_suppl.e21517","title":"Spatially mapping the single-cell immune landscapes of melanoma brain metastases using imaging mass cytometry.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Montreal Neurological Institute and Hospital; University of Toronto; Université de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Mass cytometry; Medicine; Immune system; Flow cytometry; Melanoma; Cytometry; Brain metastasis; Cancer research; Pathology; Cancer; Metastasis; Internal medicine; Immunology; Phenotype; Biology","score_opus":0.09145264252515513,"score_gpt":0.3660288630872997,"score_spread":0.2745762205621446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.942153,0.0107091945,0.04154627,0.00225907,0.0021002125,0.00010872379,0.00001827725,0.000007685683,0.0010975688],"genre_scores_gemma":[0.9902613,0.0003863505,0.007446304,0.0005311427,0.0012125515,8.5745484e-7,0.000008607098,0.000029055118,0.00012380794],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968499,0.00056293077,0.0018733728,0.00022831878,0.00024207511,0.00024340213],"domain_scores_gemma":[0.997441,0.0010608833,0.0009168195,0.00022274326,0.00024585752,0.0001126755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034001418,0.00017440353,0.0007651283,0.0001465722,0.00005833956,0.000042442964,0.00039584187,0.00023889444,0.000040125862],"category_scores_gemma":[0.0010792135,0.0001147455,0.000685389,0.00020535811,0.00020086316,0.000015014582,0.00008049166,0.00051149644,0.0000025359323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004289736,0.0003613283,0.0049641673,0.000068195004,0.00036176623,0.00013638157,0.00008892385,0.00027247006,0.9502574,0.000030494455,0.000615082,0.04241477],"study_design_scores_gemma":[0.008196827,0.011421288,0.009198367,0.00060303597,0.0010733852,0.0012007288,0.0011736674,0.010762631,0.5100381,0.0009686659,0.44452015,0.0008431485],"about_ca_topic_score_codex":0.000033028828,"about_ca_topic_score_gemma":0.000022527565,"teacher_disagreement_score":0.4439051,"about_ca_system_score_codex":0.0000353281,"about_ca_system_score_gemma":0.0006768151,"threshold_uncertainty_score":0.46791855},"labels":[],"label_agreement":null},{"id":"W4400408746","doi":"10.1200/jco.2024.42.16_suppl.e21508","title":"Target trial emulation with real-world data to determine the population-level cost-effectiveness of multi-gene panel sequencing in advanced melanoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Terry Fox Research Institute; Genome British Columbia; Genome Canada","keywords":"Medicine; Real world data; Emulation; Population; Oncology; Computational biology; Data science; Computer science; Biology; Environmental health","score_opus":0.8583240151390256,"score_gpt":0.6126971765397031,"score_spread":0.24562683859932244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97371036,0.00037536517,0.015522426,0.006532716,0.0020575775,0.0013801403,0.00024978403,0.00000932925,0.00016229748],"genre_scores_gemma":[0.96898496,0.00009686207,0.029055621,0.00095017743,0.00074652804,0.000037669906,0.000050213246,0.000023533928,0.000054455635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892034,0.0016282478,0.008379972,0.00041307716,0.00014187944,0.00023345374],"domain_scores_gemma":[0.97840875,0.015957464,0.0048134476,0.0004985242,0.00015633827,0.00016549912],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0655921,0.00014085777,0.002080724,0.0004509881,0.000050625633,0.000028986948,0.0004833946,0.00015710504,0.00003613938],"category_scores_gemma":[0.016278997,0.00011294949,0.00015151594,0.00041188952,0.00008173972,0.00054473785,0.00008878229,0.0004972207,0.00004281586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03559861,0.0011673769,0.79088235,0.0008499746,0.0008256911,0.00011901787,0.001478146,0.109643474,0.00007335439,0.015140147,0.0012158831,0.043005984],"study_design_scores_gemma":[0.017723422,0.0027078441,0.903748,0.00040713325,0.000040784853,0.000021219339,0.00017969043,0.06444692,0.000009764227,0.0024966602,0.008016414,0.00020215136],"about_ca_topic_score_codex":0.0017458289,"about_ca_topic_score_gemma":0.0060752574,"teacher_disagreement_score":0.11286566,"about_ca_system_score_codex":0.001105363,"about_ca_system_score_gemma":0.0013331064,"threshold_uncertainty_score":0.9920073},"labels":[],"label_agreement":null},{"id":"W4400408753","doi":"10.1200/jco.2024.42.16_suppl.e21518","title":"Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Oncology; Ipilimumab; Pembrolizumab; Melanoma; Internal medicine; Nivolumab; PD-L1; Immune checkpoint; Immunotherapy; Cancer; Cancer research","score_opus":0.0408201708393422,"score_gpt":0.3967738527287622,"score_spread":0.35595368188942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433595,0.0021659324,0.000041654737,0.0014234663,0.00065680314,0.0002538372,0.0000066358352,0.0000149321,0.0011008014],"genre_scores_gemma":[0.9976324,0.00045902556,0.0009262813,0.00022659615,0.00022757635,0.000003938576,0.000006959658,0.000027057184,0.00049016887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969757,0.00012687466,0.0021042384,0.00018013114,0.00040528283,0.00020776017],"domain_scores_gemma":[0.99739367,0.0007127565,0.00114148,0.00019358785,0.00039554338,0.00016296674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011635592,0.00016857691,0.0014478011,0.00016460559,0.000024062818,0.000010778881,0.000117604526,0.00021534231,0.0002414261],"category_scores_gemma":[0.00028992654,0.000084706924,0.00046313953,0.0002593449,0.00028571076,0.00016423118,0.00002536883,0.00062102015,0.000003899701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037817296,0.0012779234,0.80752695,0.00010098572,0.0016923812,0.00048681523,0.0000660974,0.0000021496437,0.00074965204,0.0000040128616,0.000203178,0.15007254],"study_design_scores_gemma":[0.016186763,0.034927852,0.9398645,0.0007102557,0.00046828267,0.00012819827,0.000050148632,0.000005320352,0.0022113337,0.0000073236897,0.0053387336,0.00010130047],"about_ca_topic_score_codex":0.00003489851,"about_ca_topic_score_gemma":0.00004523433,"teacher_disagreement_score":0.14997125,"about_ca_system_score_codex":0.00014050824,"about_ca_system_score_gemma":0.0009998316,"threshold_uncertainty_score":0.34542483},"labels":[],"label_agreement":null},{"id":"W4400412464","doi":"10.1200/jco.2024.42.16_suppl.e17030","title":"Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Olaparib; Abiraterone; Internal medicine; Adverse effect; Oncology; Abiraterone acetate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.15646342875329372,"score_gpt":0.48990033029688707,"score_spread":0.33343690154359334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400412464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824967,0.00067311246,0.00008884807,0.013494248,0.0006684114,0.0022837194,0.00021914486,0.000004619374,0.00007122096],"genre_scores_gemma":[0.9938999,0.0028731117,0.0008055229,0.00011749382,0.0005675943,0.0001784068,0.00005827258,0.000020698028,0.001479032],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618924,0.0005017144,0.00226228,0.00019466317,0.0006050218,0.0002470956],"domain_scores_gemma":[0.99470633,0.0026119337,0.0016258435,0.00014901384,0.0007787107,0.00012817135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004124954,0.0001681676,0.0013411654,0.00015678865,0.000036740214,0.000008228864,0.00010990433,0.00015098418,0.000049485174],"category_scores_gemma":[0.0016823072,0.00008152361,0.00031623332,0.00024136626,0.00010975404,0.00012108116,0.000014111526,0.00041938917,0.0000026532462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8573639,0.012882654,0.029032512,0.001436909,0.005624396,0.0014023859,0.0030525194,0.00045850186,0.0013227975,0.00011299858,0.0011978258,0.08611264],"study_design_scores_gemma":[0.564394,0.29431987,0.07556093,0.0030044706,0.008722782,0.00014755646,0.0016014742,0.005048035,0.0023925765,0.0006059401,0.043831825,0.0003705508],"about_ca_topic_score_codex":0.00016881945,"about_ca_topic_score_gemma":0.0008898518,"teacher_disagreement_score":0.29296988,"about_ca_system_score_codex":0.0009146884,"about_ca_system_score_gemma":0.004771332,"threshold_uncertainty_score":0.8464138},"labels":[],"label_agreement":null},{"id":"W4400414398","doi":"10.1200/jco.2024.42.16_suppl.e16197","title":"Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Lymphocyte; Neutrophil to lymphocyte ratio; Subgroup analysis; Internal medicine; Platelet; Gastroenterology; Oncology; Immunology; Confidence interval","score_opus":0.034490979723350614,"score_gpt":0.34894019939529186,"score_spread":0.3144492196719412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400414398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505764,0.0022495002,0.000029450486,0.000467314,0.00032400148,0.0015503317,0.00004896985,0.000011766473,0.00026103767],"genre_scores_gemma":[0.99853474,0.00026736353,0.00037893234,0.00041981498,0.00023503088,0.00006638834,0.00003185102,0.00004205229,0.0000238093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928702,0.0013726089,0.003888994,0.0005195662,0.0009036246,0.0004449677],"domain_scores_gemma":[0.9949438,0.0021608928,0.001232609,0.00050384225,0.00071660517,0.00044223756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035139457,0.00035323316,0.0027176342,0.0016015888,0.000051137715,0.000038666774,0.00041862397,0.0004775965,0.00006987615],"category_scores_gemma":[0.0013384367,0.00023095132,0.0006160495,0.0025955462,0.00028072207,0.00018868019,0.00010793414,0.00069718336,0.000004256503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15065648,0.002018465,0.8321304,0.00020763025,0.0016246787,0.0016866495,0.0014079446,0.00048896123,0.0016363072,0.00005880888,0.00022128002,0.007862454],"study_design_scores_gemma":[0.08061665,0.023453088,0.87062895,0.00040317452,0.0042284178,0.00007311891,0.0006940747,0.014790673,0.0031114924,0.000047182806,0.0016297322,0.00032345176],"about_ca_topic_score_codex":0.00080483267,"about_ca_topic_score_gemma":0.0010316906,"teacher_disagreement_score":0.070039816,"about_ca_system_score_codex":0.0007115918,"about_ca_system_score_gemma":0.0026234984,"threshold_uncertainty_score":0.9417922},"labels":[],"label_agreement":null},{"id":"W4400522267","doi":"10.1200/jco.2024.42.16_suppl.tps2098","title":"A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Glioblastoma; Blood–brain barrier; Multicenter trial; Biopsy; Focused ultrasound; Multicenter study; Prospective cohort study; Ultrasound; Low-intensity pulsed ultrasound; Radiology; Pathology; Surgery; Oncology; Internal medicine; Central nervous system; Randomized controlled trial; Cancer research; Therapeutic ultrasound","score_opus":0.06519310511741004,"score_gpt":0.450099092787613,"score_spread":0.38490598767020295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400522267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975429,0.0002750486,0.0011506055,0.016179876,0.0045112013,0.0022625707,0.00006298379,0.000018982513,0.000109745306],"genre_scores_gemma":[0.9882156,0.000358894,0.006317366,0.0012501825,0.0034007034,0.00018220027,0.0000043362966,0.000047407488,0.00022328108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99564093,0.00026170115,0.0030600599,0.0003741309,0.00033003258,0.0003331121],"domain_scores_gemma":[0.9847411,0.012665645,0.0011125949,0.00021819786,0.0009616073,0.00030088273],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004867923,0.0002028377,0.0018760402,0.00030828422,0.000029148916,0.000019337289,0.00015877528,0.000553736,0.00008981929],"category_scores_gemma":[0.013135058,0.0001521211,0.0010747929,0.0002575856,0.0002582371,0.00017630684,0.00003421212,0.0008058043,0.0000045616966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.922839,0.007767596,0.022845317,0.0009014639,0.0015195608,0.00047425125,0.0006615888,0.000022973425,0.013582393,0.00030768072,0.017716622,0.011361592],"study_design_scores_gemma":[0.53894734,0.30278012,0.042088844,0.0034872757,0.0034112856,0.0008155823,0.00037335683,0.0017859128,0.031072393,0.0032178438,0.07146776,0.0005522516],"about_ca_topic_score_codex":0.000012293287,"about_ca_topic_score_gemma":0.00013271834,"teacher_disagreement_score":0.38389158,"about_ca_system_score_codex":0.00030520864,"about_ca_system_score_gemma":0.0014296713,"threshold_uncertainty_score":0.99517775},"labels":[],"label_agreement":null},{"id":"W4400523166","doi":"10.1200/jco.2024.42.16_suppl.610","title":"Circulating tumor DNA detection after neoadjuvant chemotherapy and prediction of distant relapse free survival, local recurrence, and distant recurrence in triple-negative breast cancer in the TRICIA study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; London Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Chemotherapy; Oncology; Internal medicine; Distant metastasis; Triple negative; Neoadjuvant therapy; Complete response; Cancer; Radiology; Metastasis","score_opus":0.030262241097451077,"score_gpt":0.3630463872870487,"score_spread":0.3327841461895976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400523166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935233,0.003595349,0.0007103759,0.00060205767,0.0011514405,0.0002761754,0.000106283616,0.000001367505,0.000033630306],"genre_scores_gemma":[0.9941122,0.005344066,0.000058965878,0.000102976606,0.00034809785,0.000020083593,0.0000016340989,0.000009290961,0.0000027029187],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978378,0.00040086018,0.0011965982,0.00025832004,0.00016698042,0.00013944227],"domain_scores_gemma":[0.99842954,0.0007717099,0.00047192466,0.00014234826,0.00011541134,0.00006907877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024590949,0.00011901896,0.00047695386,0.000085592495,0.000024049466,0.000021243563,0.00012715734,0.00014909457,0.0000052478795],"category_scores_gemma":[0.001022743,0.00008206347,0.000093469964,0.00020609722,0.00021117089,0.000013551766,0.00006141578,0.00047232595,7.554093e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009683773,0.0015502097,0.22152507,0.00011440843,0.00022297684,0.0004782357,0.0023659377,0.0001664766,0.0047117686,0.00006357652,0.00025727393,0.7588603],"study_design_scores_gemma":[0.00554308,0.0061766156,0.98026997,0.00030693924,0.00010542765,0.00020129161,0.0019670995,0.002072093,0.00037829138,0.0012229304,0.0016123708,0.00014390935],"about_ca_topic_score_codex":0.00021315683,"about_ca_topic_score_gemma":0.0035544964,"teacher_disagreement_score":0.7587449,"about_ca_system_score_codex":0.00008151347,"about_ca_system_score_gemma":0.0004340289,"threshold_uncertainty_score":0.33464512},"labels":[],"label_agreement":null},{"id":"W4400874984","doi":"10.1200/jco.23.01488","title":"Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Royal College of Physicians and Surgeons of Canada; Damon Runyon Cancer Research Foundation; LUNGevity Foundation; Parker Institute for Cancer Immunotherapy; Canadian Institutes of Health Research; Cancer Research Society; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Oncology; Internal medicine; Escherichia coli; Cohort; Lung cancer; H&E stain; Cancer; Cancer research; Immunotherapy; Immunohistochemistry; Biology; Confidence interval","score_opus":0.035084792224519386,"score_gpt":0.36301542237589723,"score_spread":0.32793063015137786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400874984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250954,0.00080068817,0.00019271506,0.0040576095,0.001498763,0.0005810516,0.000011140649,0.000016257021,0.00033221018],"genre_scores_gemma":[0.99604094,0.0001991946,0.0013071715,0.0018576772,0.00029682775,0.000018835737,0.0000103675475,0.000038719863,0.00023027784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969721,0.00020021228,0.0018666468,0.00028159647,0.00035856222,0.0003209122],"domain_scores_gemma":[0.99789244,0.00034989163,0.0009196668,0.00014634678,0.0004480713,0.00024361117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017585497,0.00021213524,0.0011762984,0.00016666761,0.000028465854,0.000026642065,0.000083539024,0.0002705838,0.00012575062],"category_scores_gemma":[0.00028784265,0.00013522209,0.00027532212,0.00053134956,0.0001002946,0.00013791231,0.000033055177,0.0010502758,0.0000025304282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20171638,0.012092439,0.42503205,0.00040934602,0.0035155346,0.0021221284,0.002148719,0.0001688526,0.1292449,0.0000037476225,0.0017081549,0.22183776],"study_design_scores_gemma":[0.036744256,0.048603512,0.9005551,0.0023347905,0.0005888914,0.000026387412,0.00020769566,0.00048647434,0.0070615243,0.0000068848685,0.0030787284,0.00030581106],"about_ca_topic_score_codex":0.000107248205,"about_ca_topic_score_gemma":0.00052541855,"teacher_disagreement_score":0.475523,"about_ca_system_score_codex":0.00094148243,"about_ca_system_score_gemma":0.0018597668,"threshold_uncertainty_score":0.5514197},"labels":[],"label_agreement":null},{"id":"W4400875117","doi":"10.1200/jco.23.02625","title":"Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Carboplatin; Pembrolizumab; Oncology; Paclitaxel; Head and neck; Internal medicine; Basal cell; Head and neck squamous-cell carcinoma; Phases of clinical research; Head and neck cancer; Chemotherapy; Radiation therapy; Surgery; Cancer; Immunotherapy; Cisplatin","score_opus":0.20172649813565985,"score_gpt":0.48994215371807975,"score_spread":0.2882156555824199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400875117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94635135,0.04029714,0.00011426879,0.0085399365,0.002669929,0.0009747815,0.000031329517,0.00001936261,0.001001918],"genre_scores_gemma":[0.98861223,0.0058097173,0.001313166,0.0012606019,0.0026298922,0.00003336371,0.000005449858,0.00003808176,0.00029752142],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964358,0.00028193,0.0022145994,0.00038133518,0.0003145872,0.00037173508],"domain_scores_gemma":[0.9922608,0.0061156056,0.00068026833,0.0001594251,0.00027012892,0.0005137306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019557492,0.00027012217,0.0022454427,0.000178721,0.00010587924,0.00003702546,0.00008951921,0.0002741102,0.00005766666],"category_scores_gemma":[0.0029386564,0.00018458712,0.00048585437,0.00015099964,0.00027249163,0.00010366499,0.00005000876,0.0009044422,0.000003920076],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47358078,0.0073434943,0.0005502929,0.0006567219,0.00040021003,0.0014997339,0.0016219701,0.00000261643,0.0002602386,0.00008466768,0.00795381,0.50604546],"study_design_scores_gemma":[0.42254928,0.40273905,0.002833706,0.0003446278,0.0009508009,0.000804419,0.00025915136,0.0019013581,0.00011069854,0.0008493037,0.16642103,0.00023658504],"about_ca_topic_score_codex":0.00003969871,"about_ca_topic_score_gemma":0.00009753102,"teacher_disagreement_score":0.5058089,"about_ca_system_score_codex":0.00019198353,"about_ca_system_score_gemma":0.0017017708,"threshold_uncertainty_score":0.7527244},"labels":[],"label_agreement":null},{"id":"W4400875450","doi":"10.1200/jco.24.00152","title":"Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Prospective cohort study; Prostate biopsy; Biopsy; Internal medicine; Clinical endpoint; Prostate; Relative risk; Cancer; Prostate-specific antigen; Cohort; Oncology; Gynecology; Clinical trial; Urology; Confidence interval","score_opus":0.11880770155656026,"score_gpt":0.5099998589795198,"score_spread":0.39119215742295954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400875450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821708,0.004088285,0.0002330384,0.004434032,0.0052062436,0.0036905017,0.000024538274,0.000020252237,0.00013231837],"genre_scores_gemma":[0.99205315,0.0037648075,0.0009454596,0.0004479648,0.0016172231,0.0008553703,0.00000316969,0.000026742959,0.00028610276],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99711037,0.00019476231,0.0019025177,0.0003009874,0.00023674601,0.0002546351],"domain_scores_gemma":[0.9970229,0.0016217667,0.0006548993,0.000111316425,0.0003675768,0.00022151695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002391382,0.00015019647,0.0012116292,0.00017497202,0.000026618902,0.000017733268,0.000064034415,0.00026369584,0.00004130467],"category_scores_gemma":[0.0016450397,0.000101536745,0.00060150935,0.00018798516,0.00009637004,0.00012695135,0.000021728254,0.0007577819,0.0000057705975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21932732,0.004429894,0.18707635,0.00019021526,0.0014535353,0.0007409455,0.00069780863,0.000045397253,0.00024465055,0.000016008105,0.0013802464,0.5843976],"study_design_scores_gemma":[0.30237266,0.08171344,0.5298297,0.0012301289,0.0018365708,0.00014124857,0.00022593266,0.0032579212,0.0011238427,0.0005628712,0.07748917,0.00021657691],"about_ca_topic_score_codex":0.00009884463,"about_ca_topic_score_gemma":0.0008093234,"teacher_disagreement_score":0.5841811,"about_ca_system_score_codex":0.0011228789,"about_ca_system_score_gemma":0.001836183,"threshold_uncertainty_score":0.41405484},"labels":[],"label_agreement":null},{"id":"W4400942592","doi":"10.1200/jco.23.01995","title":"Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Letrozole; Oncology; Internal medicine; Breast cancer; Cancer; Aromatase","score_opus":0.11256497217519879,"score_gpt":0.4348746515300794,"score_spread":0.32230967935488064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400942592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694825,0.0027968877,0.0005032633,0.0059139444,0.0026805939,0.000484669,0.00022627176,0.0000027586436,0.000443363],"genre_scores_gemma":[0.9958606,0.0014640179,0.00062463805,0.0004025086,0.0015614261,0.000033420652,0.000013912935,0.00001090537,0.000028609986],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969615,0.0007478375,0.0016616278,0.00023697733,0.0002302275,0.00016184404],"domain_scores_gemma":[0.9966713,0.0017533562,0.0009713325,0.00030992617,0.0002481848,0.000045900073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036279156,0.00013544959,0.00076637673,0.000040162584,0.0000381664,0.0000057692255,0.00039696466,0.0004132976,0.000027810367],"category_scores_gemma":[0.0011227451,0.0000710158,0.00071679096,0.00010421778,0.00032452896,0.0000068462928,0.000094634925,0.00040405837,6.0855655e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19302996,0.008189272,0.075510785,0.000059238817,0.0032949075,0.000038210324,0.00071661954,0.00008830269,0.041343257,0.00050979963,0.010237009,0.66698265],"study_design_scores_gemma":[0.04332992,0.015784325,0.81599253,0.000066973415,0.0003944779,0.000033466753,0.0003189856,0.0000925253,0.025173688,0.004100021,0.09460955,0.00010352323],"about_ca_topic_score_codex":0.00006265432,"about_ca_topic_score_gemma":0.0002567478,"teacher_disagreement_score":0.74048173,"about_ca_system_score_codex":0.000056729405,"about_ca_system_score_gemma":0.0008816263,"threshold_uncertainty_score":0.31877294},"labels":[],"label_agreement":null},{"id":"W4400942639","doi":"10.1200/jco-24-01244","title":"Reply to C.T. Matava et al","year":2024,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities","keywords":"Medicine","score_opus":0.29193754933375493,"score_gpt":0.5361154011062932,"score_spread":0.24417785177253826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400942639","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027245276,0.00036386005,0.00014987949,0.94946754,0.012836679,0.0005611921,0.00002917088,0.000026612788,0.009319805],"genre_scores_gemma":[0.001977447,0.0030054573,0.0012460372,0.9496231,0.008238254,0.000012347882,0.0000018459821,0.00011706418,0.035778448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98217237,0.0074502025,0.0060409396,0.0011377931,0.0020895735,0.0011091188],"domain_scores_gemma":[0.9694654,0.025396807,0.0026193934,0.0007596352,0.00052120053,0.001237594],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.014151165,0.0005353805,0.0034140293,0.0006385467,0.00012247481,0.00022178829,0.0022316573,0.0016715091,0.0013987701],"category_scores_gemma":[0.03291362,0.00041036066,0.00199664,0.00072044437,0.001077137,0.0003206662,0.000699506,0.018006492,0.0080707045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014400572,0.00079516094,0.00046412248,0.000114369264,0.00010303014,0.08708645,0.00009859474,0.000011777241,0.001377635,0.0006577061,0.8883117,0.019539405],"study_design_scores_gemma":[0.0010501418,0.021574702,0.0014884213,0.0004963313,0.0001872038,0.010854149,0.000016452943,0.00005875694,0.00071066536,0.0007245702,0.9624936,0.00034499596],"about_ca_topic_score_codex":0.000036147638,"about_ca_topic_score_gemma":0.0000098551345,"teacher_disagreement_score":0.0762323,"about_ca_system_score_codex":0.0003051201,"about_ca_system_score_gemma":0.005656859,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W4400942675","doi":"10.1200/jco.24.01054","title":"On the Strength of a Recommendation","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.6499986715414644,"score_gpt":0.640319478060416,"score_spread":0.009679193481048398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400942675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49415877,0.0019789902,0.00026921323,0.42923507,0.016013572,0.00081967603,0.000030506337,0.00004326596,0.05745094],"genre_scores_gemma":[0.9912043,0.00067246903,0.001019485,0.0061198017,0.00068678014,0.000016089265,0.000003339097,0.000011828905,0.0002658662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913039,0.004875266,0.0033277734,0.00010161228,0.00022517002,0.00016624403],"domain_scores_gemma":[0.9471,0.04978218,0.0021387795,0.0003109171,0.000542485,0.00012566829],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005299836,0.000071451774,0.00055969105,0.00011284851,0.0001521614,0.0000032765254,0.00037978558,0.00032546817,0.0012719388],"category_scores_gemma":[0.015475128,0.000039807135,0.00023298987,0.00018921665,0.00011592152,0.0000929398,0.000101946694,0.0026935851,0.00013332917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014429657,0.00090682047,0.017192403,0.0003445854,0.0002980206,0.00001877816,0.0056760274,0.000010339998,0.00002441338,0.10869928,0.29703337,0.568353],"study_design_scores_gemma":[0.001533723,0.00556942,0.019761557,0.0010044017,0.00007885825,0.000007759269,0.005481543,0.0010417979,0.000013300931,0.023731926,0.9417,0.00007575487],"about_ca_topic_score_codex":0.000038412185,"about_ca_topic_score_gemma":0.000060585753,"teacher_disagreement_score":0.6446666,"about_ca_system_score_codex":0.00018839979,"about_ca_system_score_gemma":0.0026459973,"threshold_uncertainty_score":0.99964106},"labels":[],"label_agreement":null},{"id":"W4400972548","doi":"10.1200/jco.24.00447","title":"15-Gene Expression Profile and <i>PRAME</i> as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"National Cancer Institute; National Eye Institute","keywords":"Medicine; Melanoma; Oncology; Internal medicine; Ocular Melanoma; Test (biology); Exact test; Cancer research","score_opus":0.05502320099022526,"score_gpt":0.44427693956915465,"score_spread":0.3892537385789294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400972548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866923,0.0023418255,0.00021075667,0.003437077,0.0025449623,0.002485928,0.00005256998,0.00003279065,0.0022017602],"genre_scores_gemma":[0.9812171,0.00035112925,0.016297435,0.00035719795,0.0008219096,0.00013837617,0.000053764325,0.000039469873,0.000723617],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9951462,0.0006971301,0.0029942729,0.0004939873,0.00036099588,0.00030742076],"domain_scores_gemma":[0.98662776,0.009210247,0.0018946488,0.00026954708,0.0015922809,0.0004055085],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004085763,0.00028061046,0.002332969,0.000205448,0.0001038982,0.000016048187,0.00015128762,0.0008421678,0.00010598475],"category_scores_gemma":[0.01873364,0.00018253534,0.00040004766,0.00034764007,0.00045852212,0.00015974803,0.00008543516,0.0010802394,0.000028607214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016810492,0.03532997,0.81385034,0.00049091957,0.0045574317,0.05881699,0.001092339,0.0000042325823,0.0045067226,0.00009796003,0.020336837,0.04410574],"study_design_scores_gemma":[0.033827834,0.46858558,0.11726596,0.0009994442,0.0057531656,0.010789811,0.00193371,0.00023400494,0.0028979701,0.00063500926,0.35672185,0.00035564916],"about_ca_topic_score_codex":0.000022091688,"about_ca_topic_score_gemma":0.00009395938,"teacher_disagreement_score":0.6965844,"about_ca_system_score_codex":0.00026784083,"about_ca_system_score_gemma":0.0040648957,"threshold_uncertainty_score":0.989532},"labels":[],"label_agreement":null},{"id":"W4401013748","doi":"10.1200/jco.24.00038","title":"Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Hodgkin lymphoma; Quality of life (healthcare); Pediatric oncology; Oncology; Internal medicine; Lymphoma; Pediatrics; Cancer; Nursing","score_opus":0.0910704380946099,"score_gpt":0.43044366127784334,"score_spread":0.33937322318323343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401013748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828688,0.0009023019,0.00004121035,0.012343436,0.0020854871,0.0013904237,0.000053721287,0.000060284798,0.00025432836],"genre_scores_gemma":[0.99514794,0.000556056,0.00030725624,0.0020237826,0.0018166774,0.00001576964,0.000022355545,0.00006340602,0.000046759775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98150593,0.008274207,0.007523963,0.00065137097,0.0015118151,0.00053273846],"domain_scores_gemma":[0.97571427,0.015014847,0.0070599825,0.0006569407,0.0006953365,0.0008586182],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019332465,0.00043272122,0.0042194948,0.0004366148,0.0001616277,0.000025735986,0.00049407023,0.00065302366,0.00017385527],"category_scores_gemma":[0.009379828,0.0002473123,0.0008352624,0.00094083644,0.000582,0.00017144615,0.00013201649,0.0024529994,0.00002964123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012562002,0.015631013,0.93349004,0.00009550106,0.002744098,0.0001865034,0.00093232736,0.00002469615,2.624399e-7,0.00017829485,0.003667723,0.03048756],"study_design_scores_gemma":[0.02175239,0.09595783,0.8795846,0.00019659981,0.0013114916,0.00004663287,0.00043345077,0.000012888786,0.0000011575133,0.00014723405,0.00035821434,0.00019747784],"about_ca_topic_score_codex":0.004721029,"about_ca_topic_score_gemma":0.0017423664,"teacher_disagreement_score":0.08032682,"about_ca_system_score_codex":0.00067628676,"about_ca_system_score_gemma":0.004728487,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W4401323801","doi":"10.1200/jco.2024.42.16_suppl.12020","title":"A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Cancer; Palliative care; Randomized controlled trial; Cannabis; Intensive care medicine; Internal medicine; Alternative medicine; Psychiatry; Nursing; Pathology","score_opus":0.07409683340405589,"score_gpt":0.48199737457340963,"score_spread":0.40790054116935376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401323801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95952564,0.0024817022,0.0001990611,0.02415361,0.0024755946,0.009255481,0.000012783235,0.000008265128,0.0018878732],"genre_scores_gemma":[0.99222773,0.0018773738,0.0007908734,0.0004358479,0.0010885897,0.0011999105,0.000007902699,0.00003690982,0.0023348718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99476236,0.0005357735,0.0031197185,0.00030662178,0.0009144015,0.00036110647],"domain_scores_gemma":[0.99534744,0.0014951379,0.0013398345,0.00016726521,0.0013333661,0.0003169543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062416233,0.00020532655,0.0036218492,0.00044969638,0.00003196236,0.000015334263,0.00017794319,0.00027194407,0.000113226655],"category_scores_gemma":[0.0021926728,0.000117149255,0.00085753144,0.00031867536,0.00034833295,0.00009459543,0.000047451522,0.0009398776,8.5986073e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91293997,0.0011811802,0.002042055,0.00042026484,0.002006396,0.00014716419,0.00051800546,0.00009878335,0.0000017881632,0.00018251427,0.005012587,0.07544929],"study_design_scores_gemma":[0.9386101,0.027317425,0.0067627192,0.0010850406,0.0014342426,0.0000037715656,0.00041509996,0.00021485676,0.0000104319715,0.00006104618,0.02397698,0.00010833719],"about_ca_topic_score_codex":0.00008265923,"about_ca_topic_score_gemma":0.00024698296,"teacher_disagreement_score":0.07534095,"about_ca_system_score_codex":0.0005493296,"about_ca_system_score_gemma":0.0032398063,"threshold_uncertainty_score":0.5747277},"labels":[],"label_agreement":null},{"id":"W4401323850","doi":"10.1200/jco.2024.42.16_suppl.6095","title":"Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Trk receptor; Thyroid carcinoma; Oncology; Internal medicine; Cancer research; Thyroid","score_opus":0.04796734938854738,"score_gpt":0.4037839699374507,"score_spread":0.3558166205489033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401323850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912545,0.0046524033,0.000009806725,0.002408578,0.00064151204,0.00033713024,0.000005589184,0.000006741259,0.0006837193],"genre_scores_gemma":[0.9962415,0.0027402092,0.00028608338,0.0002892149,0.0003590532,0.000004832287,0.0000043630207,0.000017725484,0.000057010566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745816,0.00021974767,0.0016042363,0.0002261705,0.00031138878,0.0001803141],"domain_scores_gemma":[0.9972309,0.0015754222,0.00061238505,0.00015057457,0.0001850279,0.00024569168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010724426,0.0001444613,0.0012076631,0.00016565713,0.000020321504,0.000007975243,0.00007579093,0.00022575726,0.00007200054],"category_scores_gemma":[0.00043490872,0.00008651742,0.00021341894,0.00017596086,0.00013967058,0.00008030197,0.00004609138,0.0006578683,0.000004752699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009259918,0.0030461503,0.7923422,0.00007781725,0.00024678424,0.0008527813,0.00015936441,0.0000034313189,0.00002860793,0.00002482081,0.00047780655,0.19348034],"study_design_scores_gemma":[0.024718614,0.03643694,0.93431216,0.0007133217,0.00044006188,0.0001421265,0.000024844467,0.000008381942,0.000111106325,0.000019180903,0.003001654,0.00007162311],"about_ca_topic_score_codex":0.000026615297,"about_ca_topic_score_gemma":0.00011283189,"teacher_disagreement_score":0.19340871,"about_ca_system_score_codex":0.00019982341,"about_ca_system_score_gemma":0.00071621983,"threshold_uncertainty_score":0.3528078},"labels":[],"label_agreement":null},{"id":"W4401324171","doi":"10.1200/jco.23.01448","title":"Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"EMD Serono; Genentech; Seagen; Ono Pharmaceutical; Apollomics; BeiGene; Five Prime Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AtriCure; GlaxoSmithKline; Astellas Pharma; Celldex Therapeutics; Relay Therapeutics; Amgen; Pfizer","keywords":"Medicine; Ipilimumab; Nivolumab; Adjuvant; Systemic therapy; Internal medicine; Oncology; Melanoma; Adjuvant therapy; Overall survival; Progression-free survival; Surgery; Chemotherapy; Immunotherapy; Cancer; Cancer research","score_opus":0.13032674529911756,"score_gpt":0.4726604284343066,"score_spread":0.3423336831351891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401324171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786798,0.011956316,0.000061464765,0.0059689586,0.0024938432,0.00064569,0.00000911433,0.000021533757,0.00016332149],"genre_scores_gemma":[0.99415636,0.0034565744,0.0009786168,0.00046296095,0.00060414744,0.00003739133,0.000004757177,0.000026218195,0.0002729684],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996893,0.00021590201,0.0021215002,0.00024216638,0.0002640552,0.00026339258],"domain_scores_gemma":[0.9972021,0.0016627731,0.0006491997,0.00016438955,0.00015772427,0.00016383443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023455694,0.00019577803,0.0015730471,0.00021072208,0.00002722739,0.000021299496,0.00011216056,0.00027027496,0.000031660413],"category_scores_gemma":[0.00047268998,0.00010222853,0.00091250445,0.00022500737,0.00008853843,0.00010322808,0.000011607299,0.00044776118,0.0000041236563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07138339,0.0018385076,0.12842889,0.0001973323,0.003329159,0.002920891,0.000845656,0.000005075566,0.013195362,0.000023755012,0.0006569008,0.77717507],"study_design_scores_gemma":[0.1102002,0.16290744,0.60743475,0.007754704,0.0010717871,0.0024306446,0.0012499694,0.00049137126,0.007737965,0.00018166905,0.09799635,0.00054316333],"about_ca_topic_score_codex":0.00005574526,"about_ca_topic_score_gemma":0.000115528106,"teacher_disagreement_score":0.7766319,"about_ca_system_score_codex":0.00056587247,"about_ca_system_score_gemma":0.0020824913,"threshold_uncertainty_score":0.41687584},"labels":[],"label_agreement":null},{"id":"W4401325730","doi":"10.1200/jco.2024.42.16_suppl.2609","title":"Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Cetuximab; Immunotherapy; Oncology; Internal medicine; Overall survival; Pancreatic cancer; Cancer; Antibiotics","score_opus":0.11345662085365917,"score_gpt":0.5116327631711042,"score_spread":0.398176142317445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401325730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892166,0.008332753,0.000011356357,0.00091262895,0.0006307141,0.0001907919,0.000014179046,0.000004006414,0.0006869294],"genre_scores_gemma":[0.98892546,0.010608172,0.00019280714,0.00006738019,0.00015511729,0.0000013187976,8.3334737e-7,0.0000117876325,0.000037124813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982923,0.00018058706,0.001034809,0.00013227288,0.00021606567,0.00014391252],"domain_scores_gemma":[0.9973163,0.0019374911,0.00042700107,0.00005862073,0.00014895565,0.000111620684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008498267,0.0001303908,0.0014965945,0.00012598804,0.000014061072,0.0000069195753,0.000041749154,0.00007519055,0.000059408085],"category_scores_gemma":[0.0002915098,0.00006655724,0.00026072003,0.00016939326,0.00023802154,0.00004017372,0.000013865056,0.000445739,7.59013e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01358469,0.0018255697,0.7412676,0.00010964871,0.003553699,0.0010595946,0.00041302864,0.000038458304,0.00020107772,0.00013442348,0.00018328546,0.2376289],"study_design_scores_gemma":[0.0068960614,0.07373643,0.91687495,0.00058937585,0.00054230896,0.00016709234,0.00012763076,0.00018950553,0.00005838516,0.000052279956,0.0007032627,0.000062754996],"about_ca_topic_score_codex":0.00020450723,"about_ca_topic_score_gemma":0.00034355855,"teacher_disagreement_score":0.23756616,"about_ca_system_score_codex":0.0002674777,"about_ca_system_score_gemma":0.0014976606,"threshold_uncertainty_score":0.27141252},"labels":[],"label_agreement":null},{"id":"W4401326757","doi":"10.1200/jco.2024.42.16_suppl.12011","title":"Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Center (category theory); Oncology; Internal medicine; Gerontology","score_opus":0.08790707796223605,"score_gpt":0.46857746659039334,"score_spread":0.3806703886281573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401326757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990006,0.0006706431,0.00021490433,0.008192236,0.00027555678,0.0002764331,0.00017484873,0.0000044722456,0.00018490534],"genre_scores_gemma":[0.99513793,0.00024501997,0.0022400639,0.002059931,0.00019262319,0.0000028541053,0.00005066844,0.000015435622,0.000055473043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99332917,0.002369471,0.0031914269,0.00025683176,0.00063915184,0.00021393587],"domain_scores_gemma":[0.9926898,0.004176392,0.0018396731,0.00041042143,0.00056802254,0.000315695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007359254,0.00017402091,0.002487212,0.00040137392,0.000024511339,0.000010266897,0.0002065201,0.00017224047,0.00021893594],"category_scores_gemma":[0.0041950527,0.000085365245,0.0008681782,0.00078411255,0.0003855232,0.00013357296,0.00006617075,0.0006746562,0.0000018933241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072134407,0.0072226943,0.9476765,0.000091745576,0.009503737,0.00026148243,0.00033065994,0.00016337192,0.000021243666,0.00065440335,0.0011580762,0.02570268],"study_design_scores_gemma":[0.008666745,0.013336115,0.96573454,0.00013836821,0.004117265,0.00001012055,0.0004152106,0.00015971364,0.000014939028,0.00006282688,0.007265104,0.00007903946],"about_ca_topic_score_codex":0.00021642791,"about_ca_topic_score_gemma":0.0011190178,"teacher_disagreement_score":0.02562364,"about_ca_system_score_codex":0.000110294306,"about_ca_system_score_gemma":0.0011599476,"threshold_uncertainty_score":0.5022173},"labels":[],"label_agreement":null},{"id":"W4401327236","doi":"10.1200/jco.2024.42.16_suppl.12100","title":"The adherence and response of a combined approach of online self-help cognitive behavioral therapy and phone-based psychological guidance among French patients with cancer with insomnia.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Cognitive behavioral therapy for insomnia; Insomnia; Psychological intervention; Cognitive behavioral therapy; Descriptive statistics; Post-hoc analysis; Physical therapy; Clinical psychology; Intervention (counseling); Repeated measures design; Cognition; Psychiatry; Internal medicine","score_opus":0.1296517163634581,"score_gpt":0.4687236466737551,"score_spread":0.33907193031029703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401327236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973872,0.00086528744,0.00005013771,0.00072662387,0.0003763911,0.00036348208,0.000040659597,0.000010420085,0.0001798566],"genre_scores_gemma":[0.9964928,0.00082240143,0.0023282655,0.00020238518,0.00009056867,0.000016679738,0.0000018001674,0.000010814342,0.000034270375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632066,0.0015520083,0.0011369382,0.00023753807,0.00054356444,0.00020928276],"domain_scores_gemma":[0.99208146,0.005660688,0.0011809753,0.00011157835,0.0007859374,0.0001793787],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0040576262,0.00013518278,0.0007372342,0.00006947165,0.00012169501,0.000026477435,0.00025854996,0.0002683272,0.000023088562],"category_scores_gemma":[0.0009809394,0.000069240974,0.000091476766,0.0003290886,0.002791415,0.00015115563,0.00003319149,0.00063188927,1.8425823e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017333228,0.003674239,0.92525977,0.000018999042,0.00015575973,0.000047697282,0.0027923665,0.000004216604,0.000015883797,0.000059531914,0.00027814409,0.05036016],"study_design_scores_gemma":[0.0058440566,0.018935734,0.9717486,0.0002285466,0.000120814206,0.0000039843826,0.0018776403,0.00005912591,0.00001495979,0.000084882486,0.0009801191,0.000101568636],"about_ca_topic_score_codex":0.00045892104,"about_ca_topic_score_gemma":0.00097200763,"teacher_disagreement_score":0.050258595,"about_ca_system_score_codex":0.000055750363,"about_ca_system_score_gemma":0.001679394,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4401327466","doi":"10.1200/jco.2024.42.16_suppl.7540","title":"Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Biotech","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology","score_opus":0.09953379128334754,"score_gpt":0.45577106812228896,"score_spread":0.3562372768389414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401327466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467546,0.00084962766,0.000047344947,0.001418279,0.0018228051,0.00083150563,0.00005255365,0.000011160206,0.00029125073],"genre_scores_gemma":[0.9977676,0.0003300343,0.00049740344,0.00021200013,0.0008976225,0.000013362968,0.000034783505,0.000028918921,0.00021825854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995622,0.0006627658,0.002296542,0.00027643424,0.00082763477,0.0003146363],"domain_scores_gemma":[0.99056506,0.0074177403,0.00091471814,0.00035888408,0.0003702144,0.0003733872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002044789,0.00019227217,0.0014081864,0.00018796399,0.000035887315,0.000019747436,0.00026596314,0.00035231348,0.00019548272],"category_scores_gemma":[0.0058575096,0.00009702878,0.00051135314,0.00025495727,0.00031154836,0.0001706397,0.00007067474,0.0015167276,0.00002612371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26898852,0.0067045945,0.50101066,0.000029386334,0.00075450033,0.0016281389,0.00009756653,6.1772437e-7,0.000035467983,0.000004141637,0.0006273751,0.22011906],"study_design_scores_gemma":[0.31747782,0.0359708,0.64201546,0.0004438693,0.00032548435,0.000016776947,0.000031749634,0.000041705254,0.000039373033,0.00003581602,0.0035364297,0.00006473728],"about_ca_topic_score_codex":0.000085684944,"about_ca_topic_score_gemma":0.0003167716,"teacher_disagreement_score":0.22005431,"about_ca_system_score_codex":0.00023428773,"about_ca_system_score_gemma":0.0018233821,"threshold_uncertainty_score":0.7012409},"labels":[],"label_agreement":null},{"id":"W4401331613","doi":"10.1200/jco.2024.42.16_suppl.e12531","title":"An open-label randomized trial comparing addition of olanzapine 5 mg versus olanzapine 10 mg as anti-emetic to standard anti-emetic regime for doxorubicin or epirubicin and cyclophosphamide in breast cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epirubicin; Olanzapine; Medicine; Cyclophosphamide; Doxorubicin; Breast cancer; Oncology; Randomized controlled trial; Pharmacology; Chemotherapy; Cancer; Internal medicine; Schizophrenia (object-oriented programming)","score_opus":0.16105938270377215,"score_gpt":0.5196871084898951,"score_spread":0.3586277257861229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401331613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708499,0.0028935184,0.00038236982,0.018006884,0.0035998062,0.0035878364,0.00019129679,0.000028442533,0.00045999573],"genre_scores_gemma":[0.98774064,0.006877951,0.0020975883,0.0011283495,0.0016687363,0.00015131677,0.000025253945,0.000056650937,0.00025352227],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934585,0.00091527146,0.0040169433,0.0005507328,0.0005738833,0.0004846422],"domain_scores_gemma":[0.98829556,0.008388966,0.0015827637,0.00025151268,0.0009832333,0.00049796974],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008148031,0.00036595933,0.005342205,0.0005511888,0.000083795756,0.000052390846,0.0003021463,0.0003678039,0.0005819742],"category_scores_gemma":[0.008965481,0.00025520386,0.00035170838,0.0006387742,0.0004942702,0.00031019727,0.00018073949,0.0009793801,0.000008870993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94088304,0.001859236,0.0010712272,0.00026100854,0.0016209269,0.00038847662,0.00019427348,0.00006763539,0.0012399894,0.000095297546,0.008030435,0.04428848],"study_design_scores_gemma":[0.90897965,0.05810223,0.0143933045,0.0029865964,0.0026620356,0.00029089878,0.000251596,0.001559946,0.0002854549,0.000303815,0.009904372,0.0002801004],"about_ca_topic_score_codex":0.00032432977,"about_ca_topic_score_gemma":0.00045740436,"teacher_disagreement_score":0.056242995,"about_ca_system_score_codex":0.0005396649,"about_ca_system_score_gemma":0.0023613132,"threshold_uncertainty_score":0.99999005},"labels":[],"label_agreement":null},{"id":"W4401379890","doi":"10.1200/jco.2024.42.4_suppl.18","title":"CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Medicine; Docetaxel; Clinical endpoint; Internal medicine; Prostate cancer; Oncology; Hormonal therapy; Metastatic breast cancer; Enzalutamide; Androgen deprivation therapy; Taxane; Urology; Cancer; Randomized controlled trial; Breast cancer; Androgen receptor","score_opus":0.15264072572719684,"score_gpt":0.5031225171413383,"score_spread":0.35048179141414143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401379890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945292,0.0020018634,0.000009700291,0.0012225749,0.00052277563,0.0012902898,0.00009592806,0.000007684656,0.00031999094],"genre_scores_gemma":[0.9977053,0.0010787466,0.0002740832,0.00019871337,0.00017735685,0.000048318983,0.000015224959,0.000029317895,0.00047297907],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99603397,0.0003045783,0.00225536,0.00030704628,0.00075793755,0.00034110906],"domain_scores_gemma":[0.9969071,0.0009841918,0.0009208896,0.0001700578,0.0007185067,0.00029923263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600656,0.00021967177,0.0016017295,0.00030515878,0.000040424893,0.000027274975,0.00014625848,0.00013445305,0.00032738154],"category_scores_gemma":[0.00022191675,0.00012568774,0.00021804837,0.00036488182,0.00018462565,0.00022121487,0.000029506351,0.0009951693,0.0000035600049],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4442075,0.05987224,0.25477985,0.0005744766,0.0073675616,0.008842922,0.008247887,0.00015306174,0.00429293,0.00010251958,0.0020568494,0.20950224],"study_design_scores_gemma":[0.21681333,0.20989886,0.55888426,0.0005766005,0.0006385199,0.00010101762,0.001678881,0.00038775854,0.0004954746,0.000038743754,0.010279222,0.00020731692],"about_ca_topic_score_codex":0.00027572236,"about_ca_topic_score_gemma":0.0011511861,"teacher_disagreement_score":0.30410442,"about_ca_system_score_codex":0.00042724982,"about_ca_system_score_gemma":0.005881177,"threshold_uncertainty_score":0.99975455},"labels":[],"label_agreement":null},{"id":"W4401379896","doi":"10.1200/jco.2024.42.3_suppl.tps241","title":"NSABP C-14/Exact Sciences 16-002: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"NSABP Foundation","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Circulating tumor DNA; Minimal residual disease; Stage (stratigraphy); Cancer; Microsatellite instability; Primary tumor; Surgical oncology; Metastasis; Microsatellite; Leukemia","score_opus":0.10293927281648856,"score_gpt":0.46202137929495424,"score_spread":0.35908210647846567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401379896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893005,0.00094096956,0.0011978563,0.00091468595,0.0067247213,0.000568466,0.00009802006,0.000011157116,0.00024363835],"genre_scores_gemma":[0.991633,0.0001760966,0.0022753817,0.0011214496,0.004686119,0.000021914928,0.0000066515104,0.00003142534,0.000047955848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947769,0.0009609583,0.0025565957,0.0007664499,0.00049199624,0.00044711822],"domain_scores_gemma":[0.9953076,0.0023140009,0.0009129854,0.00023574644,0.00044982103,0.00077980186],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008224625,0.00026007975,0.000929393,0.00018442833,0.00022185457,0.00014154836,0.0005159394,0.00024335692,0.00010871151],"category_scores_gemma":[0.014356985,0.00022330975,0.00044832562,0.0003770876,0.00025989785,0.000026915555,0.0004311155,0.0006871667,0.000009324608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013993306,0.00389662,0.509981,0.00014005258,0.001545223,0.0013997835,0.000886709,0.010551905,0.05239691,0.000052754327,0.056628074,0.3485277],"study_design_scores_gemma":[0.009182491,0.16185889,0.6690096,0.0013179386,0.002304946,0.00062266627,0.0017542513,0.0051938994,0.019987756,0.00059042615,0.12616622,0.002010865],"about_ca_topic_score_codex":0.000052633484,"about_ca_topic_score_gemma":0.0006601266,"teacher_disagreement_score":0.34651685,"about_ca_system_score_codex":0.00026148913,"about_ca_system_score_gemma":0.005502392,"threshold_uncertainty_score":0.9939455},"labels":[],"label_agreement":null},{"id":"W4401383859","doi":"10.1200/jco.24.00709","title":"Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; McGill University; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Oncology; Pharmacology; Internal medicine; Family medicine","score_opus":0.35329635205176785,"score_gpt":0.575118782852302,"score_spread":0.22182243080053415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401383859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8677103,0.0039810785,0.000058656973,0.12588437,0.0010149616,0.00026609027,0.000005585397,0.0000027730832,0.0010761805],"genre_scores_gemma":[0.99415755,0.0022369747,0.000996109,0.0022729773,0.00030322222,0.0000052697305,0.0000011930965,0.0000049218092,0.000021769489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966678,0.000756431,0.0022271906,0.0000877417,0.00015497535,0.00010584878],"domain_scores_gemma":[0.9677971,0.030924715,0.00093953754,0.00008019838,0.00015982361,0.0000986117],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0074576936,0.00007160714,0.0014905604,0.00014096279,0.000024199326,0.000008124925,0.00006099611,0.0001917718,0.000045550838],"category_scores_gemma":[0.011218952,0.000036382145,0.0002832877,0.00013271633,0.00016143122,0.00004258947,0.00003434945,0.0004101862,0.000002743024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032348456,0.0028807279,0.29107425,0.00008583957,0.0025760662,0.0014731877,0.0007382949,0.000021643647,0.00039354624,0.007824303,0.028213084,0.66148424],"study_design_scores_gemma":[0.015822632,0.0070441626,0.47659826,0.00044295695,0.0010434608,0.00022857758,0.0003910223,0.00014413877,0.00016184911,0.0022660939,0.49580348,0.000053366864],"about_ca_topic_score_codex":0.000023087949,"about_ca_topic_score_gemma":0.00007303263,"teacher_disagreement_score":0.66143084,"about_ca_system_score_codex":0.00018822301,"about_ca_system_score_gemma":0.0012423942,"threshold_uncertainty_score":0.99710995},"labels":[],"label_agreement":null},{"id":"W4401450637","doi":"10.1200/jco.23.02238","title":"Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Moonshot Research and Development Program; School of Medicine, University of North Carolina at Chapel Hill; National Cancer Institute; National Institutes of Health; Broad Institute; American Lebanese Syrian Associated Charities; St. Baldrick's Foundation; Children's Hospital of Philadelphia; Nationwide Children's Hospital; Cancer Moonshot; Seattle Children's Research Institute","keywords":"Medicine; Lymphoblastic Leukemia; Leukemia; Oncology; Internal medicine","score_opus":0.10384709368955303,"score_gpt":0.4783862440527168,"score_spread":0.37453915036316376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401450637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944225,0.0006329937,0.00025924083,0.0012065086,0.0018362525,0.000178678,0.000006457217,0.000011667834,0.0014457286],"genre_scores_gemma":[0.9942953,0.00070179073,0.0027676434,0.00061077985,0.0007878333,0.00000298614,8.9464646e-7,0.000033881937,0.00079888484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397945,0.00033108678,0.0044578547,0.00025555262,0.00058348506,0.0003925701],"domain_scores_gemma":[0.99269724,0.0053889877,0.0009336785,0.00025762696,0.00029432116,0.0004281186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044734525,0.00017190712,0.0022154232,0.00053392374,0.000014251914,0.00001129794,0.00034132265,0.00055273576,0.00018488693],"category_scores_gemma":[0.0054292823,0.00011789828,0.0006361546,0.0003745212,0.00037127518,0.00012635408,0.00015190388,0.001279324,0.0001225924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071133254,0.0008660085,0.74531865,0.00047762567,0.00083823764,0.032593384,0.00022285503,0.000079717574,0.0030296727,0.00015351716,0.0044276225,0.20487942],"study_design_scores_gemma":[0.016394133,0.013930584,0.924292,0.0009185164,0.0009631282,0.0076043676,0.00009543862,0.016634358,0.00050378864,0.0005874428,0.017884443,0.00019175603],"about_ca_topic_score_codex":0.000049635368,"about_ca_topic_score_gemma":0.000038866103,"teacher_disagreement_score":0.20468765,"about_ca_system_score_codex":0.002507215,"about_ca_system_score_gemma":0.012230951,"threshold_uncertainty_score":0.9933688},"labels":[],"label_agreement":null},{"id":"W4401514025","doi":"10.1200/jco.2024.42.23_suppl.174","title":"Autologous bone marrow transplant in standard-risk newly diagnosed multiple myeloma: A systematic review.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Bone marrow transplant; Oncology; Internal medicine; Bone marrow transplantation; Surgery","score_opus":0.07149453237243764,"score_gpt":0.4441682284034876,"score_spread":0.37267369603104994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401514025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81391865,0.1619698,0.000566374,0.017312875,0.0018885066,0.0030318405,0.00011678294,0.00007438926,0.0011207534],"genre_scores_gemma":[0.93946,0.056838725,0.0021590076,0.0008491576,0.00035698697,0.0000510222,0.000009845398,0.000029180484,0.00024611258],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99294245,0.0016063806,0.0039648125,0.0003006546,0.0007471163,0.00043860116],"domain_scores_gemma":[0.98866105,0.00914486,0.0009706584,0.00030245096,0.00028128715,0.0006397178],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00769986,0.00022510026,0.0036283778,0.00032381393,0.00003724078,0.000020678825,0.00019092833,0.00036738967,0.00015625033],"category_scores_gemma":[0.01942521,0.0001352688,0.000896849,0.00033614205,0.00015854137,0.00012384301,0.000032907268,0.0017747544,0.000106551284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023701593,0.005551257,0.25058475,0.2153566,0.004608183,0.31298155,0.00065020245,0.00001921592,0.00014396606,0.00013102719,0.017508991,0.16876267],"study_design_scores_gemma":[0.072172455,0.04703226,0.47906882,0.34962824,0.009229518,0.0160699,0.0002960572,0.005768196,0.00012349749,0.000610921,0.019377489,0.00062267063],"about_ca_topic_score_codex":0.00006813952,"about_ca_topic_score_gemma":0.00032785136,"teacher_disagreement_score":0.29691163,"about_ca_system_score_codex":0.0004021227,"about_ca_system_score_gemma":0.0021431283,"threshold_uncertainty_score":0.98883456},"labels":[],"label_agreement":null},{"id":"W4401514437","doi":"10.1200/jco.2024.42.23_suppl.18","title":"Descriptive and content analysis of breast cancer vlogs on YouTube.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University","funders":"","keywords":"Medicine; Breast cancer; Content analysis; Cancer; Internal medicine; Oncology","score_opus":0.5957970645644348,"score_gpt":0.6170393805164288,"score_spread":0.021242315951993995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401514437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94467247,0.001212217,0.000021654647,0.04093251,0.011845035,0.00015790184,0.000014445675,0.000006414517,0.0011373411],"genre_scores_gemma":[0.9926033,0.004084046,0.00018428305,0.00072631234,0.0023281607,0.000012553908,3.959599e-7,0.000004671593,0.000056274188],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971729,0.0009080154,0.0012854637,0.00012401927,0.00035166982,0.00015794592],"domain_scores_gemma":[0.98677915,0.011512612,0.00081673486,0.00005632681,0.0005556093,0.0002795766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005319264,0.0000574347,0.00079124287,0.00025588035,0.000068584224,0.000015092628,0.00012776635,0.00026397913,0.00021996125],"category_scores_gemma":[0.009598501,0.00004294849,0.00029332933,0.0006128222,0.00052087015,0.00011996965,0.000013946577,0.00049318455,0.0000034589264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046480316,0.00042748995,0.3582146,0.000022261547,0.0014273995,0.000026168856,0.023652581,0.000012673126,0.000017711214,0.008046009,0.0016715348,0.60601676],"study_design_scores_gemma":[0.0003474965,0.0009944492,0.95263886,0.000091726026,0.0011839351,0.0000025732359,0.00882215,0.00006769474,0.0000026050404,0.0005077046,0.035291117,0.0000496836],"about_ca_topic_score_codex":0.0045765955,"about_ca_topic_score_gemma":0.0040681157,"teacher_disagreement_score":0.6059671,"about_ca_system_score_codex":0.00038226563,"about_ca_system_score_gemma":0.0030687745,"threshold_uncertainty_score":0.9987441},"labels":[],"label_agreement":null},{"id":"W4401514512","doi":"10.1200/jco.2024.42.23_suppl.tps180","title":"Stronger together: Implementing patient-reported symptom tool in routine cancer care in diverse Asia—A multi-national pilot feasibility study (PROMiSE-Pilot).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Family medicine; Internal medicine","score_opus":0.4019948435049603,"score_gpt":0.5584096673742601,"score_spread":0.15641482386929983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401514512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948448,0.0011398424,0.000025538397,0.0012871857,0.0011159544,0.00079695997,0.000017218395,0.000017090393,0.00075541774],"genre_scores_gemma":[0.9976089,0.00007981149,0.0010590624,0.0005418632,0.0006032967,0.000026134336,0.000005756742,0.000016658418,0.00005849396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945172,0.00056669954,0.0032786771,0.0003998805,0.00084748154,0.00039002477],"domain_scores_gemma":[0.9971428,0.0008127055,0.000928806,0.00017339186,0.0007677606,0.00017453011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058327653,0.00018295992,0.0011164342,0.00023717973,0.000043557036,0.000025450412,0.00016455224,0.00015514775,0.0003708265],"category_scores_gemma":[0.0032134021,0.00014184676,0.00025910724,0.00035641063,0.0000811974,0.00024725267,0.00013308157,0.0013133846,0.0000065712193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047664247,0.0026170644,0.9346147,0.00004255203,0.00025886908,0.0019197084,0.0012031721,0.00017673303,0.00008890424,0.000018654408,0.00049588387,0.053797293],"study_design_scores_gemma":[0.013962816,0.018132387,0.9571473,0.00038899248,0.00024617356,0.0000783797,0.006671663,0.00047804668,0.000013571345,0.000054116037,0.0026945886,0.00013198091],"about_ca_topic_score_codex":0.0012700021,"about_ca_topic_score_gemma":0.009818114,"teacher_disagreement_score":0.053665314,"about_ca_system_score_codex":0.00161004,"about_ca_system_score_gemma":0.0033858966,"threshold_uncertainty_score":0.6006435},"labels":[],"label_agreement":null},{"id":"W4401514694","doi":"10.1200/jco.2024.42.23_suppl.108","title":"Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Metastatic Urothelial Carcinoma; Randomized controlled trial; Immunotherapy; Urothelial carcinoma; Bladder cancer","score_opus":0.09391004980722414,"score_gpt":0.47658217233799316,"score_spread":0.382672122530769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401514694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98846185,0.0016736476,0.0005594056,0.001902887,0.0034530843,0.0031337242,0.000118156444,0.00004408671,0.00065314973],"genre_scores_gemma":[0.9944336,0.0014456848,0.0021379837,0.0008523663,0.0005472594,0.00028796936,0.00002547263,0.00007613538,0.00019353675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99148124,0.0012380658,0.005568841,0.00047522888,0.0008113334,0.00042526913],"domain_scores_gemma":[0.98389465,0.012324096,0.0026303004,0.00034340424,0.00040889616,0.0003986416],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023290785,0.00044724345,0.005143073,0.0003443613,0.000031008236,0.000026484933,0.00020149846,0.0004224664,0.0011681974],"category_scores_gemma":[0.0069281324,0.00026901645,0.0013911105,0.00040076385,0.0003985025,0.00016756986,0.000025523655,0.0010565193,0.000008757247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7670813,0.0039716293,0.0007817007,0.00009622849,0.0038967454,0.0026912282,0.00048438346,0.00019787137,0.00010190684,0.000012785313,0.0001893101,0.22049487],"study_design_scores_gemma":[0.9479489,0.038498204,0.0007232493,0.00074936886,0.0039913286,0.00007300542,0.00010040463,0.0025714242,0.0008144197,0.00017129889,0.0041336245,0.00022480421],"about_ca_topic_score_codex":0.00080411276,"about_ca_topic_score_gemma":0.00050945673,"teacher_disagreement_score":0.22027007,"about_ca_system_score_codex":0.00063889497,"about_ca_system_score_gemma":0.014752995,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W4401527030","doi":"10.1200/jco.2024.42.23_suppl.215","title":"Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Richard Tam Foundation","keywords":"Medicine; Lung cancer; Oncology; Precision medicine; Crizotinib; Internal medicine; Cancer research; Pathology","score_opus":0.0898393799532811,"score_gpt":0.5290685278054648,"score_spread":0.43922914785218364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401527030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465582,0.0026062748,0.00012935848,0.025376905,0.0010425831,0.00061847916,0.000013207208,0.000010179029,0.02364481],"genre_scores_gemma":[0.9900756,0.0024278273,0.0024342153,0.0020645624,0.0010794486,0.00002207654,0.000003335674,0.000022752212,0.0018701949],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998154,0.000093181494,0.0012592468,0.000141431,0.00022678796,0.0001253427],"domain_scores_gemma":[0.99710673,0.002133208,0.00032848853,0.00013197657,0.00011338424,0.00018619357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008880339,0.000101161146,0.0007687809,0.00015434812,0.000021921638,0.0000049373334,0.000066873945,0.00013149325,0.00015085509],"category_scores_gemma":[0.0003662268,0.000047403722,0.00016799386,0.00015846713,0.00013992049,0.00004000051,0.000009765067,0.00017956004,0.0000055216756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055421875,0.0013979978,0.07067122,0.00007201468,0.0014340853,0.000808455,0.0052600913,0.0008099732,0.0006052364,0.00030328706,0.032771025,0.8803244],"study_design_scores_gemma":[0.019870447,0.051283043,0.14114076,0.0017356353,0.002244576,0.00015223224,0.0006996721,0.0046561253,0.00013591153,0.00038669433,0.7775685,0.00012640656],"about_ca_topic_score_codex":0.0007047576,"about_ca_topic_score_gemma":0.00047354572,"teacher_disagreement_score":0.880198,"about_ca_system_score_codex":0.00083033164,"about_ca_system_score_gemma":0.0020459623,"threshold_uncertainty_score":0.3629449},"labels":[],"label_agreement":null},{"id":"W4401688491","doi":"10.1200/jco-24-01373","title":"Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Radiation therapy; Lymphoma; Radiology; Oncology; Internal medicine","score_opus":0.10203807123778129,"score_gpt":0.46138059044866436,"score_spread":0.35934251921088306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401688491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730279,0.006196938,0.000029635834,0.008509531,0.0030995437,0.00029605982,0.0000062100407,0.000009199597,0.008824975],"genre_scores_gemma":[0.9858367,0.0058831526,0.004481287,0.00084861566,0.0025323564,0.0000056306944,0.000005238117,0.000017107519,0.0003899224],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955425,0.0003876275,0.003239612,0.00021241243,0.00043150326,0.00018634816],"domain_scores_gemma":[0.9934181,0.0049648965,0.0010104572,0.0001644105,0.00014477162,0.00029734877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037910745,0.00013740413,0.0016096246,0.00023468253,0.000012133344,0.0000075456583,0.00011862522,0.00038419472,0.0000740769],"category_scores_gemma":[0.0017502179,0.00008402024,0.00063563086,0.00019535932,0.0001301852,0.00007849818,0.000026890133,0.00036919123,0.000009916864],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26680583,0.017059462,0.009291489,0.00013073457,0.00037054814,0.006146706,0.00024656777,0.000007062281,0.00050220435,0.00006727128,0.018823953,0.6805482],"study_design_scores_gemma":[0.5324138,0.05566458,0.21637037,0.000888916,0.0005024185,0.0007393095,0.0000550529,0.00019567717,0.00071204704,0.00020805906,0.19212665,0.00012311868],"about_ca_topic_score_codex":0.000023107868,"about_ca_topic_score_gemma":0.0000056294543,"teacher_disagreement_score":0.68042505,"about_ca_system_score_codex":0.00052620715,"about_ca_system_score_gemma":0.003925583,"threshold_uncertainty_score":0.6963815},"labels":[],"label_agreement":null},{"id":"W4401729326","doi":"10.1200/jco.24.00438","title":"Cannabis for Refractory Chemotherapy-Induced Nausea and Vomiting","year":2024,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Nausea; Chemotherapy-induced nausea and vomiting; Vomiting; Refractory (planetary science); Chemotherapy; Antiemetic; Cannabis; Internal medicine; Oncology; Surgery; Psychiatry","score_opus":0.11286138890884574,"score_gpt":0.5058977686094226,"score_spread":0.39303637970057687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401729326","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029870063,0.0015332488,0.00006132076,0.017531347,0.947238,0.00058961584,0.000026545522,0.000033156884,0.0031166626],"genre_scores_gemma":[0.007126885,0.0021026768,0.0021666575,0.001701024,0.97993714,0.000014657425,0.000018760724,0.00010176873,0.006830455],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99537313,0.00022835848,0.0030037921,0.00040061303,0.00065171625,0.00034236317],"domain_scores_gemma":[0.98835826,0.0072402684,0.0027110728,0.00025043252,0.0009852138,0.00045475116],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007470604,0.00029084177,0.0026782246,0.0002781982,0.000052002513,0.00004114862,0.00021010241,0.0020275754,0.00003916629],"category_scores_gemma":[0.02207928,0.0002137522,0.00086232426,0.000097543256,0.0001273297,0.00006917965,0.000099397024,0.0035556732,0.000010590641],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029877375,0.0003782476,0.00012589626,0.0006749288,0.0011483773,0.00044283614,0.000048574777,1.0013301e-7,0.00003693606,0.000024343899,0.8856775,0.10845452],"study_design_scores_gemma":[0.008970528,0.014213933,0.0006332991,0.00080418185,0.001700307,0.00004878686,0.00005372674,0.000021788566,0.000023114071,0.00039190645,0.9729613,0.0001771306],"about_ca_topic_score_codex":0.000019796948,"about_ca_topic_score_gemma":0.000026319369,"teacher_disagreement_score":0.10827739,"about_ca_system_score_codex":0.0003377746,"about_ca_system_score_gemma":0.0038050576,"threshold_uncertainty_score":0.999268},"labels":[],"label_agreement":null},{"id":"W4402167552","doi":"10.1200/jco.24.00326","title":"Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Foghorn Therapeutics; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Mallinckrodt Pharmaceuticals; Massachusetts General Hospital; Eli Lilly and Company","keywords":"Medicine; Myocarditis; Pneumonitis; Internal medicine; Adverse effect","score_opus":0.07668197061795526,"score_gpt":0.46318749518581037,"score_spread":0.38650552456785514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402167552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662596,0.0018760164,0.00044873127,0.00035219363,0.00036944164,0.000122236,0.000016291624,0.000002453035,0.00018667136],"genre_scores_gemma":[0.9986616,0.0007667111,0.00045966898,0.000043597724,0.000027325408,0.0000020858138,0.000009296245,0.0000036869676,0.000026021518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704313,0.0003166785,0.002253926,0.00012216011,0.00018748421,0.00007663221],"domain_scores_gemma":[0.99747705,0.0012142183,0.0010148627,0.00007802533,0.00015760692,0.000058249338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025190779,0.000065511325,0.00076208054,0.00052033307,0.000007882508,0.0000017021329,0.000060533366,0.00012236346,0.00006328388],"category_scores_gemma":[0.00071611407,0.00004959267,0.00030703328,0.00045682144,0.000053982454,0.00013512652,0.000027188122,0.0003649677,2.3561067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07390465,0.004388165,0.46300527,0.00028291836,0.007220445,0.0003585474,0.019122606,0.005834799,0.03813341,0.0001690247,0.000043586315,0.38753656],"study_design_scores_gemma":[0.005000862,0.0018828767,0.88926953,0.0012193089,0.00066382124,0.000014880665,0.0042830184,0.09678687,0.00045909462,0.0002324962,0.00012188339,0.00006536467],"about_ca_topic_score_codex":0.00006800156,"about_ca_topic_score_gemma":0.0005629641,"teacher_disagreement_score":0.42626423,"about_ca_system_score_codex":0.00018405159,"about_ca_system_score_gemma":0.00034351708,"threshold_uncertainty_score":0.20223303},"labels":[],"label_agreement":null},{"id":"W4402183327","doi":"10.1200/jco.23.02510","title":"Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Cystectomy; Bladder cancer; Urology; Radiation therapy; Metastasis; Neutropenia; Surgery; Incidence (geometry); Oncology; Internal medicine; Chemotherapy; Cancer","score_opus":0.24440074460822267,"score_gpt":0.5543201257197373,"score_spread":0.3099193811115146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402183327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69925135,0.0034600291,0.0015917306,0.16566214,0.015083055,0.09712221,0.0043411893,0.00033715361,0.013151129],"genre_scores_gemma":[0.9348406,0.0016364374,0.009974559,0.004723202,0.01740156,0.02633994,0.00016615381,0.00015661943,0.0047609312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930154,0.0007201131,0.004263371,0.00078642083,0.0005917938,0.0006229159],"domain_scores_gemma":[0.99115527,0.005163011,0.0017076273,0.0005665916,0.0005615023,0.0008459789],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026877155,0.0004765228,0.0028903019,0.00021044422,0.00019541966,0.000045341985,0.00037663683,0.00097079185,0.00092636206],"category_scores_gemma":[0.0020403082,0.00031111043,0.0013299969,0.00026717145,0.0002948032,0.0002588597,0.00012688151,0.0012053405,0.000029422637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09256429,0.02271246,0.0012379427,0.00013567731,0.008508727,0.002428251,0.0011319608,0.000031149466,0.0011628382,0.00023472458,0.089590825,0.78026116],"study_design_scores_gemma":[0.12560831,0.10949359,0.004343527,0.00039689877,0.003657428,0.00013141338,0.00015619698,0.0005171287,0.002498477,0.004370332,0.7485486,0.0002780682],"about_ca_topic_score_codex":0.001995207,"about_ca_topic_score_gemma":0.0007500482,"teacher_disagreement_score":0.7799831,"about_ca_system_score_codex":0.0016665688,"about_ca_system_score_gemma":0.01019864,"threshold_uncertainty_score":0.99998695},"labels":[],"label_agreement":null},{"id":"W4402216730","doi":"10.1200/jco.24.00238","title":"Hypofractionated Preoperative Radiation Should Not Yet Be Used as Standard of Care for Extremity and Truncal Soft Tissue Sarcoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Soft tissue; Soft tissue sarcoma; Standard of care; Sarcoma; Radiation therapy; Radiology; Surgery; Pathology","score_opus":0.1536614935969474,"score_gpt":0.49915993415544696,"score_spread":0.34549844055849954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402216730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96370727,0.0061347834,0.00027254,0.027908338,0.0010528823,0.00049909676,0.0000878031,0.00001265645,0.00032464185],"genre_scores_gemma":[0.99476445,0.0010175252,0.0023697708,0.001206951,0.00049664214,0.00001528668,0.000019927065,0.000015415244,0.00009402527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788296,0.00020655082,0.001251075,0.00018724756,0.00034614583,0.0001260037],"domain_scores_gemma":[0.9922433,0.006473923,0.00047710884,0.00009439275,0.0005057065,0.00020558239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011448037,0.0001189289,0.0011272432,0.00010639415,0.000040462975,0.000014366016,0.000048542137,0.0003142689,0.00012778133],"category_scores_gemma":[0.0034546359,0.0000802024,0.00029354292,0.00008473828,0.00012338578,0.00013973337,0.00001934516,0.00044493252,0.0000025962825],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013501945,0.0021715038,0.103744365,0.00023223276,0.0011967969,0.00073060254,0.0010682765,0.00001578321,0.00054947863,0.0014971251,0.00843998,0.8668519],"study_design_scores_gemma":[0.01841296,0.060209535,0.35068253,0.00040618927,0.002094974,0.00061456545,0.0008958766,0.00048291252,0.009342687,0.0009915152,0.55569893,0.00016731484],"about_ca_topic_score_codex":0.000022449623,"about_ca_topic_score_gemma":0.000057775167,"teacher_disagreement_score":0.8666846,"about_ca_system_score_codex":0.00023348346,"about_ca_system_score_gemma":0.0012927841,"threshold_uncertainty_score":0.41357714},"labels":[],"label_agreement":null},{"id":"W4402259280","doi":"10.1200/jco.24.00110","title":"Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Medicine; Palbociclib; Tolerability; Internal medicine; Letrozole; Fulvestrant; Oncology; Adverse effect; Metastatic breast cancer; Breast cancer; Cancer; Tamoxifen","score_opus":0.11422356113720195,"score_gpt":0.4995596041199905,"score_spread":0.38533604298278856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402259280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709053,0.008563452,0.0016972465,0.013268533,0.0024279007,0.0021487304,0.0008613866,0.00004840988,0.00007901316],"genre_scores_gemma":[0.96766007,0.0120251505,0.015162979,0.0015003603,0.0029284246,0.00017787784,0.000031271396,0.000111017194,0.00040285927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99443,0.0006583909,0.0033650626,0.0005124278,0.0005227006,0.000511438],"domain_scores_gemma":[0.9893695,0.006472346,0.002221039,0.00021582175,0.0011949484,0.0005263125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015532112,0.00043364664,0.0031503905,0.0002753265,0.00009927866,0.00002517621,0.00022961822,0.00025439786,0.00047514675],"category_scores_gemma":[0.0018431733,0.00028199426,0.00075443956,0.0003875135,0.0007597042,0.00054620346,0.0000610605,0.0011629671,0.0000029823943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5114439,0.0033058336,0.00009960768,0.00019942228,0.002358499,0.00024330216,0.00068837905,0.0000127423955,0.021500474,0.00016045298,0.001166221,0.45882112],"study_design_scores_gemma":[0.76418346,0.15935107,0.0032929801,0.0011980734,0.001477531,0.0013903996,0.0009212791,0.0002302073,0.01637024,0.0016607139,0.049303327,0.00062069483],"about_ca_topic_score_codex":0.000069815294,"about_ca_topic_score_gemma":0.000030190482,"teacher_disagreement_score":0.45820042,"about_ca_system_score_codex":0.0004522088,"about_ca_system_score_gemma":0.00239171,"threshold_uncertainty_score":0.9999632},"labels":[],"label_agreement":null},{"id":"W4402389020","doi":"10.1200/jco.24.00767","title":"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Cabozantinib; Sunitinib; Medicine; Crizotinib; Clinical endpoint; Internal medicine; Hazard ratio; Papillary renal cell carcinomas; Oncology; Renal cell carcinoma; Axitinib; Pazopanib; Clinical trial; Urology; Confidence interval; Lung cancer","score_opus":0.1291674654152644,"score_gpt":0.43763600479905596,"score_spread":0.3084685393837916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402389020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150354,0.0027849989,0.0000761079,0.0006017657,0.00042780067,0.0009088373,0.000016182626,0.000015647183,0.0036651227],"genre_scores_gemma":[0.9972872,0.0004126339,0.0015065203,0.0001439704,0.0003524688,0.00001801887,0.000019865269,0.000037335925,0.00022198782],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919391,0.0018034332,0.0044831918,0.0005353535,0.0007967848,0.0004421054],"domain_scores_gemma":[0.989969,0.0068736905,0.0017724091,0.0003526526,0.00052549154,0.0005067332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007047998,0.0003834745,0.0060996274,0.0010695746,0.000061200706,0.000024849174,0.00019417981,0.00026567417,0.00012464999],"category_scores_gemma":[0.0013498568,0.0002503022,0.0010960032,0.00085242244,0.00047389342,0.00017650063,0.00014231144,0.0014318279,0.0000018093663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44056338,0.015900979,0.49165422,0.00031971975,0.007258094,0.018717753,0.0022070718,0.00048059516,0.0007645614,0.00019133589,0.00011679336,0.021825511],"study_design_scores_gemma":[0.45989302,0.0716662,0.44634804,0.00037702755,0.015066142,0.0005160533,0.0015702952,0.0030736113,0.0003201507,0.000057143425,0.0008308991,0.00028142618],"about_ca_topic_score_codex":0.0002494999,"about_ca_topic_score_gemma":0.00038133922,"teacher_disagreement_score":0.055765223,"about_ca_system_score_codex":0.00015671,"about_ca_system_score_gemma":0.001585034,"threshold_uncertainty_score":0.99999493},"labels":[],"label_agreement":null},{"id":"W4402401036","doi":"10.1200/jco.24.00791","title":"Just Humor Me","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Humor Studies and Applications","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital","funders":"","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.3627140347450541,"score_gpt":0.624017792063235,"score_spread":0.26130375731818095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402401036","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35538843,0.0068937642,0.0009593238,0.06923115,0.019136408,0.00018186371,0.000011823344,0.000064209125,0.548133],"genre_scores_gemma":[0.98485327,0.000393937,0.0010180189,0.0019243137,0.0043047504,0.000009532847,5.86988e-7,0.000015278523,0.007480325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976057,0.00023741821,0.0016508906,0.00016830406,0.00014257421,0.00019515304],"domain_scores_gemma":[0.99664205,0.0024265363,0.00047548243,0.00017230357,0.00009945988,0.00018413928],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024103601,0.00008368967,0.00066894374,0.00007419324,0.000052200372,0.000015343805,0.00024181751,0.00022038596,0.0027861786],"category_scores_gemma":[0.0005625973,0.000057485093,0.0004458802,0.00015634963,0.00017677614,0.000029806208,0.000049294304,0.000894595,0.0013498998],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020698732,0.00090522063,0.0018250042,0.000013365121,0.00072138745,0.0009672781,0.0014654816,0.0000024839298,0.00004426283,0.16420119,0.52159464,0.30805272],"study_design_scores_gemma":[0.0006680857,0.0017073244,0.02755682,0.000018618393,0.0001439949,0.00025183833,0.0014958937,0.000017284257,0.000002219527,0.0021278348,0.965948,0.00006212717],"about_ca_topic_score_codex":0.00000966397,"about_ca_topic_score_gemma":0.00001309845,"teacher_disagreement_score":0.6294648,"about_ca_system_score_codex":0.000044590197,"about_ca_system_score_gemma":0.00032301416,"threshold_uncertainty_score":0.9994277},"labels":[],"label_agreement":null},{"id":"W4402472398","doi":"10.1200/jco.24.00920","title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Medicine; Vinorelbine; Internal medicine; Metastatic breast cancer; Oncology; Chemotherapy; Eribulin; Gemcitabine; Breast cancer; Cancer","score_opus":0.12024444603652502,"score_gpt":0.47170743713032226,"score_spread":0.35146299109379725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402472398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580866,0.0027376846,0.000034544624,0.033591185,0.0017933449,0.0010117751,0.0010722422,0.000056831013,0.0016157945],"genre_scores_gemma":[0.97790223,0.013087373,0.0032631068,0.0016175053,0.0032238264,0.000059678834,0.00017977838,0.000117876945,0.0005486258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99109715,0.0022355427,0.004030524,0.0008222608,0.0010209652,0.0007935424],"domain_scores_gemma":[0.988343,0.008120082,0.0012588381,0.00041635282,0.0009679166,0.00089378934],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034472437,0.00045892905,0.0027792782,0.0004907799,0.000099508405,0.00007055651,0.0004898338,0.000576355,0.0017262304],"category_scores_gemma":[0.0035460535,0.00034380407,0.00060126797,0.00083456544,0.0006010535,0.0004156925,0.000118613185,0.003489507,0.00008605754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14872885,0.0045263246,0.025373753,0.00027608342,0.004194617,0.003241979,0.0035742295,0.000015170639,0.011976893,0.00005870188,0.047080897,0.7509525],"study_design_scores_gemma":[0.08217158,0.032093674,0.84937286,0.0027829066,0.0008426876,0.00046156874,0.0006690708,0.0002183022,0.003230744,0.00037116878,0.027063828,0.00072160806],"about_ca_topic_score_codex":0.0045723184,"about_ca_topic_score_gemma":0.0006976965,"teacher_disagreement_score":0.8239991,"about_ca_system_score_codex":0.0032753805,"about_ca_system_score_gemma":0.0065956106,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W4402555565","doi":"10.1200/jco-24-01798","title":"Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Chemotherapy; Enzalutamide; Cancer; Androgen receptor","score_opus":0.09170646046613255,"score_gpt":0.46258325047132764,"score_spread":0.3708767900051951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402555565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894312,0.0015504945,0.00006165429,0.0072756694,0.0002905862,0.0013165849,0.000020570249,0.0000056871754,0.00004752511],"genre_scores_gemma":[0.99623185,0.0027485804,0.00020425621,0.00047269842,0.00020567607,0.000039056944,0.00003410448,0.000016104903,0.00004765056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976447,0.00047871683,0.0010428235,0.00018968085,0.00045984596,0.00018423701],"domain_scores_gemma":[0.99753726,0.0014910444,0.00046084754,0.00010381052,0.0003086827,0.00009836668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016999283,0.000120361416,0.000774662,0.00015229074,0.00002751689,0.000020627938,0.00007076997,0.00009454267,0.000019011466],"category_scores_gemma":[0.0002711034,0.000053966432,0.00009518802,0.00035276622,0.00017721935,0.00018607915,0.000013469964,0.000807124,0.0000018504029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6427826,0.0039629256,0.10208215,0.000009387315,0.0007697291,0.000919291,0.0012732912,0.000038373237,0.00006809295,0.000016823686,0.00020448725,0.2478728],"study_design_scores_gemma":[0.4812862,0.05257807,0.4627832,0.0003306838,0.00023287904,0.000009553088,0.00019900294,0.00045600068,0.00015301131,0.00036406668,0.001527312,0.00008005435],"about_ca_topic_score_codex":0.0002330472,"about_ca_topic_score_gemma":0.00033571207,"teacher_disagreement_score":0.36070102,"about_ca_system_score_codex":0.0003236257,"about_ca_system_score_gemma":0.0017894366,"threshold_uncertainty_score":0.3506597},"labels":[],"label_agreement":null},{"id":"W4402580401","doi":"10.1200/jco-24-01661","title":"Caring for the Family Caregiver in Oncology","year":2024,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Family caregivers; Oncology; Internal medicine; Family medicine; Nursing","score_opus":0.3988157026831793,"score_gpt":0.6098169922287394,"score_spread":0.21100128954556013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402580401","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004117314,0.03277485,0.00013162494,0.0058362,0.9502446,0.00039499503,0.000053237563,0.000008266998,0.00643891],"genre_scores_gemma":[0.003843688,0.03610443,0.0019652825,0.00092523114,0.9555375,0.000021459091,0.00002032035,0.000055127683,0.0015269504],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99487704,0.0004345719,0.0034501962,0.00028949013,0.00063728314,0.00031142918],"domain_scores_gemma":[0.939021,0.05650171,0.0024909151,0.0002800356,0.0014836352,0.00022274061],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0059882845,0.000244935,0.0035022108,0.00027165122,0.000025212054,0.000008678759,0.0004337944,0.002531025,0.000023402115],"category_scores_gemma":[0.032517467,0.00014255835,0.0013206493,0.00017802494,0.0003656787,0.00004836579,0.00012573117,0.0044392655,0.000013212874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034315672,0.00033328022,0.0009507751,0.00028549688,0.0009711636,0.0009865182,0.0007986309,0.000011325227,0.00001173033,0.000045349094,0.92140245,0.07077169],"study_design_scores_gemma":[0.00607858,0.010958981,0.0007949203,0.0018299898,0.0016653291,0.000026063368,0.0011645213,0.000039521332,0.0000076094384,0.00037223607,0.976947,0.000115250084],"about_ca_topic_score_codex":0.00021641751,"about_ca_topic_score_gemma":0.00038621,"teacher_disagreement_score":0.07065643,"about_ca_system_score_codex":0.0006900693,"about_ca_system_score_gemma":0.009636863,"threshold_uncertainty_score":0.9987639},"labels":[],"label_agreement":null},{"id":"W4402638771","doi":"10.1200/jco.23.02018","title":"Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"National Center for Advancing Translational Sciences; Sanofi Pasteur; Pharmacyclics; Genentech; MorphoSys; Swedish Orphan Biovitrum; Ministry of Minority Affairs; Astellas Pharma; MacroGenics; Cardinal Health; Syndax Pharmaceuticals; Seagen; CTI Biopharma; BeiGene; Astex Pharmaceuticals; Therakos; TG Therapeutics; Ipsen; Jazz Pharmaceuticals; Y-mAbs Therapeutics; Fred Hutchinson Cancer Research Center; Ironwood Pharmaceuticals, Incorporated; Taiho Pharmaceutical; Case Western Reserve University; MEI Pharma; Karyopharm Therapeutics; Celgene; Regeneron Pharmaceuticals; CSL Behring; Abbott Laboratories; Actinium Pharmaceuticals; National Cancer Institute; Servier; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Spectrum Pharmaceuticals; Amgen; Moderna; Incyte; Pfizer; Sanofi","keywords":"Medicine; Transplantation; Hazard ratio; Internal medicine; Regimen; Surgery; Population; Refractory (planetary science); Clinical endpoint; Salvage therapy; Hematopoietic stem cell transplantation; Chemotherapy regimen; Gastroenterology; Chemotherapy; Randomized controlled trial; Confidence interval","score_opus":0.07114274363281915,"score_gpt":0.42597447653009834,"score_spread":0.3548317328972792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402638771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711797,0.0023309449,0.015454623,0.0013310121,0.0047147297,0.002419083,0.00011983925,0.000037551934,0.0024124675],"genre_scores_gemma":[0.99226,0.0015755697,0.003865253,0.0001506401,0.0014638677,0.00006682987,0.0002360643,0.000050247916,0.00033154315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993033,0.0008116946,0.0047622076,0.00035375313,0.0007312953,0.00030807027],"domain_scores_gemma":[0.9871242,0.009940969,0.001633609,0.00021564851,0.0007238974,0.00036167185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048777843,0.0002758707,0.002937779,0.0003006708,0.000058616406,0.000016965203,0.00019066603,0.0007337996,0.0003390939],"category_scores_gemma":[0.001305532,0.0002101381,0.0021095464,0.00017888297,0.00039640203,0.00015571364,0.000010013547,0.00086334714,0.000015535872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9753422,0.0023324005,0.000050245504,0.0030009267,0.0011815558,0.0006385936,0.003424333,0.0000896895,0.0006458709,0.0007796828,0.0006106646,0.0119038],"study_design_scores_gemma":[0.9541334,0.025824105,0.000067864545,0.00078821194,0.0058790706,0.00041599583,0.0011833137,0.0008385759,0.0012716322,0.00047029046,0.008959797,0.00016777773],"about_ca_topic_score_codex":0.0000072537155,"about_ca_topic_score_gemma":0.0000098496375,"teacher_disagreement_score":0.023491705,"about_ca_system_score_codex":0.00020251817,"about_ca_system_score_gemma":0.0027076188,"threshold_uncertainty_score":0.85691833},"labels":[],"label_agreement":null},{"id":"W4402670562","doi":"10.1200/jco.24.00119","title":"Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Ottawa; Dalhousie University; University Health Network; University of Toronto; McGill University; University of British Columbia; Western University","funders":"","keywords":"Medicine; Transoral robotic surgery; Swallowing; Dysphagia; Quality of life (healthcare); Clinical endpoint; Internal medicine; Radiation therapy; Neck dissection; Neutropenia; Head and neck squamous-cell carcinoma; Head and neck cancer; Randomized controlled trial; Surgery; Oncology; Chemotherapy; Cancer","score_opus":0.19295360341211756,"score_gpt":0.45936327305607355,"score_spread":0.26640966964395596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402670562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9361953,0.010694368,0.00035142462,0.02795001,0.022798972,0.0011481731,0.000024213596,0.000012453731,0.0008251],"genre_scores_gemma":[0.99280953,0.0009994307,0.00089608866,0.00054039725,0.004209084,0.000019506004,0.0000017328499,0.000022730645,0.00050148385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99492264,0.0009553677,0.0033038985,0.00020453303,0.00036114786,0.00025239817],"domain_scores_gemma":[0.96792674,0.030304566,0.0010547689,0.00017938045,0.000336627,0.000197894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007318263,0.00016381676,0.003944036,0.000111399975,0.0000509948,0.0000086749005,0.00015318781,0.0003020074,0.00004187722],"category_scores_gemma":[0.007375069,0.00008540594,0.0024302865,0.00019177143,0.0004161149,0.000058964113,0.000015562331,0.00074832194,0.0000015755991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9505775,0.0009086391,0.00012547338,0.00018729859,0.00037501476,0.00019879953,0.00022537465,0.00002210078,0.00010931518,0.000036391473,0.029906299,0.017327804],"study_design_scores_gemma":[0.9336277,0.024657331,0.0009533574,0.000110275534,0.001508685,0.00005135078,0.000047534155,0.0005175304,0.00022001,0.0000738036,0.038143665,0.000088715096],"about_ca_topic_score_codex":0.000021038188,"about_ca_topic_score_gemma":0.000023008208,"teacher_disagreement_score":0.05661426,"about_ca_system_score_codex":0.00014382758,"about_ca_system_score_gemma":0.004208281,"threshold_uncertainty_score":0.88291794},"labels":[],"label_agreement":null},{"id":"W4403020119","doi":"10.1200/jco.24.00440","title":"Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Queen's University; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Hysterectomy; Sexual function; Cervical cancer; Distress; Sexual dysfunction; Randomized controlled trial; Radical Hysterectomy; Gynecology; Orgasm; Clinical trial; Obstetrics; Cancer; Internal medicine; Surgery; Clinical psychology","score_opus":0.21431961175703904,"score_gpt":0.48419042734909995,"score_spread":0.26987081559206094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403020119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942206,0.0013765565,0.000016185697,0.0016301505,0.001844735,0.00051396096,0.0002217692,0.000015171046,0.00016087014],"genre_scores_gemma":[0.99695176,0.0005637326,0.000397347,0.0004931871,0.0015033415,0.0000068826544,0.000042324526,0.000022043045,0.00001936848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929353,0.0012918588,0.0041937768,0.00043485037,0.00079346605,0.0003507253],"domain_scores_gemma":[0.98819375,0.008437301,0.0019355754,0.00021968498,0.00021087774,0.0010028373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003186292,0.00022304166,0.0029464068,0.00020049197,0.000040595765,0.000020472986,0.00016151954,0.00035220158,0.00013833729],"category_scores_gemma":[0.005561159,0.0001441079,0.00027803896,0.00039943279,0.00027000264,0.00013257272,0.00009346124,0.001499629,0.000004314931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42789727,0.001731328,0.5133847,0.00011922087,0.00062108255,0.000058019334,0.0002074495,0.0000092558475,9.137046e-7,0.000013338165,0.00012204286,0.055835374],"study_design_scores_gemma":[0.28424004,0.036717914,0.6765079,0.0002448745,0.0002171651,9.749022e-7,0.00011344978,0.00015678322,0.0000024254446,0.00003339153,0.0016681748,0.000096922835],"about_ca_topic_score_codex":0.0092356,"about_ca_topic_score_gemma":0.003067229,"teacher_disagreement_score":0.16312319,"about_ca_system_score_codex":0.00040376547,"about_ca_system_score_gemma":0.0027177355,"threshold_uncertainty_score":0.99736196},"labels":[],"label_agreement":null},{"id":"W4403053424","doi":"10.1200/jco.24.00176","title":"Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; McGill University; Sunnybrook Health Science Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Public Health Ontario; Women's College Hospital; University Health Network; University of Toronto","funders":"National Cancer Institute; NRG Oncology; GlaxoSmithKline; Clovis Oncology; AstraZeneca","keywords":"Medicine; Hazard ratio; Breast cancer; Gynecology; Proportional hazards model; BRCA mutation; Germline mutation; Internal medicine; Hormonal contraception; Oncology; Population; Obstetrics; Cancer; Mutation; Family planning; Confidence interval; Genetics; Biology","score_opus":0.03334406080700069,"score_gpt":0.4160275961698577,"score_spread":0.382683535362857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403053424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98127574,0.011490013,0.0027858354,0.0032176941,0.0007583356,0.00015417328,0.00024453187,0.000002083145,0.000071603754],"genre_scores_gemma":[0.98797256,0.0077608335,0.0031359403,0.0002974465,0.00075294997,0.000016859723,0.000009716541,0.000012427072,0.000041283736],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984895,0.00014275868,0.0009822448,0.00018214216,0.00008927211,0.000114086535],"domain_scores_gemma":[0.99860543,0.00049057725,0.00048582145,0.0000717563,0.00024732988,0.00009910071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014373033,0.000083695166,0.00039479358,0.00007542972,0.000026190752,0.000010386047,0.00006817263,0.00026089643,0.000013711079],"category_scores_gemma":[0.00055023044,0.00007015049,0.00013809933,0.00007847304,0.00027931575,0.000011568791,0.000029255654,0.000272342,1.8721452e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031316497,0.00037651666,0.08833714,0.00015771925,0.0009668511,0.000032334225,0.00046522965,0.0016178078,0.04982862,0.00031963078,0.011671824,0.8430947],"study_design_scores_gemma":[0.0145694055,0.008748666,0.6746943,0.00028269165,0.0011666254,0.00091808697,0.0010160131,0.005361201,0.0051821447,0.0051900987,0.2823867,0.00048410083],"about_ca_topic_score_codex":0.00003086778,"about_ca_topic_score_gemma":0.00029419464,"teacher_disagreement_score":0.8426106,"about_ca_system_score_codex":0.0000471838,"about_ca_system_score_gemma":0.0010792551,"threshold_uncertainty_score":0.2860654},"labels":[],"label_agreement":null},{"id":"W4403053730","doi":"10.1200/jco.2022.40.16_suppl.6006","title":"Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; McGill University; University of Calgary","funders":"National Institutes of Health","keywords":"Medicine; Oncology; Cancer research; DNA; Internal medicine; Virology; Pathology; Genetics; Biology","score_opus":0.04006275547846992,"score_gpt":0.3712870080761294,"score_spread":0.3312242525976595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403053730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970898,0.00038795403,0.00028357198,0.0013336532,0.00032645767,0.000097958386,0.00019417632,0.0000014946696,0.00028491495],"genre_scores_gemma":[0.9968885,0.00021625652,0.0016639839,0.00035254084,0.0005073947,0.0000061314518,0.000079267505,0.0000108351605,0.00027509825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980936,0.0002319571,0.0011048943,0.00019618214,0.00024304911,0.00013032023],"domain_scores_gemma":[0.99749196,0.00062317046,0.0013771459,0.00012814041,0.00025924988,0.00012033027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073549914,0.00011330081,0.0007609604,0.00008185311,0.00005514992,0.0000091936645,0.00012352069,0.00011163926,0.00013029913],"category_scores_gemma":[0.0005604101,0.00009147585,0.00022494698,0.00015220017,0.00006152281,0.000004763468,0.00004926221,0.00021157297,7.487137e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017356418,0.0025318877,0.85918295,0.000016922453,0.01027181,0.00031167362,0.00036234048,0.039092906,0.025579257,0.00021602769,0.0034064318,0.04167139],"study_design_scores_gemma":[0.027305389,0.05186618,0.56539166,0.000010915239,0.0075876587,0.00013981371,0.00040469514,0.0047922567,0.009102838,0.00073771697,0.33207005,0.00059079693],"about_ca_topic_score_codex":0.00014376057,"about_ca_topic_score_gemma":0.00046738915,"teacher_disagreement_score":0.32866362,"about_ca_system_score_codex":0.00011304023,"about_ca_system_score_gemma":0.00075992243,"threshold_uncertainty_score":0.37302768},"labels":[],"label_agreement":null},{"id":"W4403089337","doi":"10.1200/jco.23.02718","title":"Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Université de Sherbrooke; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; Queen's University; McMaster University; University of British Columbia; McGill University Health Centre; University of Ottawa; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Pelvis; Radiation therapy; Radiology; Cancer; Internal medicine","score_opus":0.07479623176472212,"score_gpt":0.42429282721793193,"score_spread":0.3494965954532098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956612,0.0005004945,0.00017797254,0.0019582747,0.0005743755,0.00074172893,0.00020195551,0.000012822973,0.00017116033],"genre_scores_gemma":[0.9946375,0.00072666636,0.0033452727,0.00035451603,0.0006157441,0.000050705552,0.00007783587,0.000021555077,0.0001701861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754256,0.0001612407,0.0014872525,0.0002968448,0.00032476088,0.00018734376],"domain_scores_gemma":[0.99676436,0.0010070466,0.0008805141,0.00022318892,0.0007988983,0.00032598493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005823257,0.00017767187,0.0014629198,0.00024460652,0.00003381419,0.000010610983,0.00008500492,0.00024062618,0.000179195],"category_scores_gemma":[0.00028018042,0.00010443202,0.00073976,0.00040676017,0.00013431894,0.00018090369,0.00001036515,0.00022019476,0.0000025839395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060819164,0.005653726,0.56853485,0.00010395458,0.010815308,0.0000570618,0.00052334554,0.00017735375,0.000031385473,0.000040290397,0.00051238964,0.40746844],"study_design_scores_gemma":[0.018893639,0.06948196,0.8669255,0.00013003225,0.020828148,0.0000070006417,0.00009489454,0.0010035129,0.00024184652,0.00073012954,0.021519996,0.00014334869],"about_ca_topic_score_codex":0.00024391864,"about_ca_topic_score_gemma":0.001367543,"teacher_disagreement_score":0.4073251,"about_ca_system_score_codex":0.0005763422,"about_ca_system_score_gemma":0.002409529,"threshold_uncertainty_score":0.4274401},"labels":[],"label_agreement":null},{"id":"W4403089488","doi":"10.1200/jco.24.00683","title":"Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Olaparib; Medicine; Ovarian cancer; Refractory (planetary science); Oncology; Platinum; Internal medicine; Chemotherapy; Cancer; Poly ADP ribose polymerase","score_opus":0.10801391311127237,"score_gpt":0.4447158440343639,"score_spread":0.33670193092309153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96631116,0.002910007,0.0005576972,0.023629528,0.002651112,0.0011513211,0.000071352624,0.00010330417,0.00261452],"genre_scores_gemma":[0.97481984,0.006049335,0.006722253,0.008342573,0.0020688209,0.000056978697,0.000024469682,0.00010959332,0.0018061252],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377686,0.00060511584,0.0036458038,0.0005670746,0.00090456725,0.0005006027],"domain_scores_gemma":[0.99157417,0.0053740046,0.0017279505,0.0003179916,0.00046891242,0.00053695374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003481626,0.0004246396,0.0027520754,0.00044344086,0.00009597611,0.00006628799,0.00025840264,0.00070017605,0.0015763681],"category_scores_gemma":[0.00095913786,0.00024738288,0.00023473088,0.000697107,0.0005177295,0.00044764217,0.000045672088,0.002162632,0.000010543963],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6268571,0.007878601,0.041090976,0.0016976793,0.0031920534,0.012908715,0.0036425567,0.00012814724,0.012481604,0.0006942223,0.051410474,0.23801789],"study_design_scores_gemma":[0.14858878,0.048831765,0.36909348,0.005477154,0.0008853069,0.0030820465,0.0006751547,0.0018114506,0.0007102893,0.0005682579,0.4194514,0.0008249354],"about_ca_topic_score_codex":0.00015679127,"about_ca_topic_score_gemma":0.0017175571,"teacher_disagreement_score":0.4782683,"about_ca_system_score_codex":0.0012132596,"about_ca_system_score_gemma":0.0076184855,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W4403089783","doi":"10.1200/jco.2022.40.16_suppl.6015","title":"Refining nodal category in TNM staging with extent of extranodal extension for oral cavity squamous cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Sinai Health System; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; NODAL; Basal cell; Stage (stratigraphy); Oral cavity; Oncology; Staging system; Extension (predicate logic); Internal medicine; Radiology; Cancer; Pathology; Dentistry","score_opus":0.14419955691296935,"score_gpt":0.4419114038058317,"score_spread":0.29771184689286234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348956,0.0011413434,0.00017631995,0.0031533595,0.0008366598,0.00019095573,0.000008290878,0.000005241673,0.0009982766],"genre_scores_gemma":[0.9949675,0.000053520067,0.003441612,0.0009841018,0.00030101786,0.000015171594,0.0000024324443,0.000020562473,0.00021404296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967242,0.00039747517,0.0019141478,0.00023106756,0.00042913872,0.000303971],"domain_scores_gemma":[0.99640614,0.0016675857,0.0012060297,0.00016145335,0.00035991258,0.00019889903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004268198,0.0001363057,0.0017558777,0.00017227768,0.00009365398,0.0000024016642,0.00012828136,0.00012075596,0.000060567676],"category_scores_gemma":[0.0007845875,0.00009815783,0.00031280538,0.0001663034,0.00015779465,0.000059812002,0.000096672804,0.0011345468,5.035319e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04640737,0.005446694,0.8306681,0.00035420238,0.00012516131,0.0031075464,0.0016870904,0.0007974836,0.0057532648,0.00008522211,0.0036976181,0.101870276],"study_design_scores_gemma":[0.030326152,0.066547275,0.87335753,0.00009241369,0.00041399023,0.0005022572,0.0026313306,0.0005226443,0.00051588455,0.00009253799,0.024808101,0.00018990716],"about_ca_topic_score_codex":0.00029013332,"about_ca_topic_score_gemma":0.00030603798,"teacher_disagreement_score":0.10168037,"about_ca_system_score_codex":0.000301545,"about_ca_system_score_gemma":0.0019961626,"threshold_uncertainty_score":0.49291044},"labels":[],"label_agreement":null},{"id":"W4403089790","doi":"10.1200/jco.2022.40.16_suppl.6021","title":"Predicting emergency department use and unplanned hospitalization in patients with head and neck cancer: Development and validation of a machine learning algorithm.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Emergency department; Head and neck cancer; Head and neck; Cancer; Emergency medicine; Surgery; Internal medicine","score_opus":0.061835478800233115,"score_gpt":0.3947275142253781,"score_spread":0.332892035425145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986223,0.0004982504,0.00008796763,0.00035836943,0.00014479748,0.00024100457,0.0000065331833,0.0000036755532,0.0000371214],"genre_scores_gemma":[0.99729526,0.0007034858,0.0018438211,0.000052300027,0.000036054415,0.00000849677,0.000030439798,0.00000690559,0.000023236289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848545,0.00016484392,0.0008951375,0.000119971526,0.00024428556,0.000090311296],"domain_scores_gemma":[0.99882346,0.00014603994,0.00079744065,0.000037161804,0.000103751896,0.000092123766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007480148,0.00007041862,0.00040851627,0.00010025715,0.00005208021,0.000005941064,0.00002519922,0.000035983187,0.000037230417],"category_scores_gemma":[0.0002999348,0.000055863147,0.000021516837,0.00009311472,0.000041082814,0.00012945708,0.000078775854,0.00023682474,3.2019823e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001207028,0.00053844857,0.9483954,0.000060781807,0.0001404294,0.000027961889,0.00026739633,0.00035350432,8.113789e-7,0.00001057636,0.00003532378,0.04896236],"study_design_scores_gemma":[0.008139424,0.006584247,0.9807523,0.0000882746,0.00015605018,0.0000075730736,0.0002313897,0.0019213491,0.0000041560675,0.000021069654,0.0020445876,0.000049615654],"about_ca_topic_score_codex":0.000053607815,"about_ca_topic_score_gemma":0.00007246014,"teacher_disagreement_score":0.048912745,"about_ca_system_score_codex":0.00011607956,"about_ca_system_score_gemma":0.00029796376,"threshold_uncertainty_score":0.2278033},"labels":[],"label_agreement":null},{"id":"W4403089916","doi":"10.1200/jco-24-01520","title":"Reply to E. Topkan et al","year":2024,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.31307629796322445,"score_gpt":0.6303998569418306,"score_spread":0.3173235589786062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089916","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028087609,0.06493486,0.00028150255,0.8157514,0.07806657,0.00030882313,0.000017490698,0.00002093659,0.012530821],"genre_scores_gemma":[0.13212721,0.028463477,0.02494879,0.7653992,0.021589227,0.000011546496,0.0000023449693,0.00007140202,0.027386775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99287546,0.001146526,0.004354383,0.00037927926,0.0005902333,0.0006540947],"domain_scores_gemma":[0.9897343,0.006719974,0.0008747272,0.00032734353,0.00041207246,0.0019315706],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.012640904,0.00022005549,0.0019464793,0.00020866614,0.000034874316,0.000027574466,0.000214311,0.00048730287,0.0018369822],"category_scores_gemma":[0.005413226,0.00016332942,0.0007872338,0.0003371382,0.00023068246,0.00017390946,0.00009842796,0.0027145448,0.001686651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016445478,0.0010002702,0.0031514186,0.00015761971,0.0003867826,0.007827486,0.0001857475,0.000017145427,0.0000056804643,0.0014843264,0.5060663,0.47807264],"study_design_scores_gemma":[0.0030462074,0.05274038,0.020331,0.0023798372,0.0006489701,0.0019423104,0.00011409129,0.00013748396,0.00002178101,0.00093805254,0.9175861,0.000113805305],"about_ca_topic_score_codex":0.00022619811,"about_ca_topic_score_gemma":0.000084800304,"teacher_disagreement_score":0.47795883,"about_ca_system_score_codex":0.0019477619,"about_ca_system_score_gemma":0.0134676555,"threshold_uncertainty_score":0.9995862},"labels":[],"label_agreement":null},{"id":"W4403089919","doi":"10.1200/jco-24-01689","title":"Reply to H.O. Al-Shamsi et al","year":2024,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.12282141675795488,"score_gpt":0.5830338120229609,"score_spread":0.460212395265006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021205634,0.041060362,0.0010314635,0.86159605,0.041379403,0.0002487599,0.000036305224,0.000019589428,0.03342241],"genre_scores_gemma":[0.13363415,0.017017089,0.012325305,0.7582551,0.008746349,0.000012138336,0.000008192992,0.00006495342,0.06993668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580127,0.00052934815,0.0025896293,0.00030357647,0.00040708008,0.0003690715],"domain_scores_gemma":[0.99413985,0.0036902258,0.0005991966,0.00022792535,0.00041655163,0.0009262488],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004474815,0.0001772552,0.0012283302,0.00018269262,0.000040730836,0.000040748302,0.00015551248,0.00027953667,0.0017121293],"category_scores_gemma":[0.004066569,0.00012716555,0.0007561072,0.0002744315,0.00017714806,0.00021462857,0.00006417598,0.0015224313,0.0010933069],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057981175,0.0010253364,0.0019665463,0.000050639544,0.0012595523,0.00519473,0.00040452628,0.0000399329,0.000025788346,0.0021853615,0.6237963,0.3634715],"study_design_scores_gemma":[0.003324931,0.018213274,0.019129673,0.0011242877,0.0018921355,0.0013581956,0.00018989659,0.00015123117,0.000011771685,0.00074378686,0.9537548,0.00010601438],"about_ca_topic_score_codex":0.00012468042,"about_ca_topic_score_gemma":0.000035136218,"teacher_disagreement_score":0.3633655,"about_ca_system_score_codex":0.000670871,"about_ca_system_score_gemma":0.0077173477,"threshold_uncertainty_score":0.99968445},"labels":[],"label_agreement":null},{"id":"W4403089975","doi":"10.1200/jco.2022.40.16_suppl.6005","title":"ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Northeast Cancer Centre; Health Sciences North; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Mucositis; Medicine; Head and neck cancer; Chemoradiotherapy; Head and neck; Internal medicine; Cancer; Oncology; Surgery; Radiation therapy","score_opus":0.12766086586097725,"score_gpt":0.5254101535742833,"score_spread":0.3977492877133061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883064,0.0014403576,0.00021889545,0.005025783,0.0021465956,0.0026703994,0.00015492279,0.0000059418326,0.000030685504],"genre_scores_gemma":[0.96507496,0.0012352708,0.029164111,0.0030830703,0.0007727826,0.00042575557,0.000027345037,0.000052070394,0.00016462381],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956843,0.00038772542,0.0027928418,0.00030996313,0.00042354697,0.0004015865],"domain_scores_gemma":[0.9948817,0.002085973,0.002139637,0.0001862087,0.00034139995,0.00036508308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026032068,0.00020135142,0.0022403176,0.00016524523,0.00008297425,0.000004826052,0.0001465769,0.00016880037,0.00013372838],"category_scores_gemma":[0.0010722168,0.00016746267,0.00039034596,0.00017906654,0.00011655911,0.00011578437,0.000045734803,0.0006110788,3.4337725e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36636338,0.0076207956,0.05157052,0.00035227867,0.0002850732,0.000104093735,0.00018623724,0.00017920979,0.00002546379,0.000005852688,0.0017442972,0.57156277],"study_design_scores_gemma":[0.6437899,0.22879714,0.07489341,0.0003785938,0.00046918617,0.00010930945,0.0001419266,0.00094176125,0.000064503816,0.00027066076,0.049953148,0.00019045362],"about_ca_topic_score_codex":0.000094765586,"about_ca_topic_score_gemma":0.00040341448,"teacher_disagreement_score":0.57137233,"about_ca_system_score_codex":0.0012119488,"about_ca_system_score_gemma":0.0023973763,"threshold_uncertainty_score":0.6828929},"labels":[],"label_agreement":null},{"id":"W4403089980","doi":"10.1200/jco.2022.40.16_suppl.6032","title":"Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck: The IT-MATTERS study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Immunotherapy; Head and neck; Oncology; Internal medicine; Basal cell; Head and neck cancer; Radiation therapy; Surgery; Cancer","score_opus":0.04655279495941174,"score_gpt":0.3901283528487175,"score_spread":0.34357555788930577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866834,0.0021232835,0.000010500843,0.008116172,0.001647392,0.00059286586,0.000007058183,0.000004887,0.00081440446],"genre_scores_gemma":[0.9937201,0.0012851376,0.00006145034,0.0043007103,0.00026000518,0.000030286079,9.3872416e-7,0.000021731961,0.00031960328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540496,0.001746529,0.0019048542,0.00025128727,0.00043358808,0.00025879007],"domain_scores_gemma":[0.99567854,0.0022862244,0.0014873359,0.00029820018,0.00014807463,0.00010163116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025443672,0.00020453244,0.0015701466,0.00011680531,0.00017677547,0.0000068999566,0.00024536086,0.000110170855,0.00006126895],"category_scores_gemma":[0.0003313913,0.000110863686,0.0004257547,0.00020770617,0.0002742851,0.000079361795,0.00017794048,0.0012501294,8.48263e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03217443,0.0071660103,0.7848045,0.00004683126,0.00042397963,0.0003802705,0.0072550117,0.00080797717,0.0010013229,0.000005670838,0.0015743241,0.16435966],"study_design_scores_gemma":[0.029717717,0.061462007,0.89293283,0.0000576085,0.0002101456,0.00015549552,0.0045736567,0.000088557375,0.000085937434,0.000039426974,0.010578051,0.00009858203],"about_ca_topic_score_codex":0.0006167625,"about_ca_topic_score_gemma":0.0012225416,"teacher_disagreement_score":0.16426107,"about_ca_system_score_codex":0.00082538667,"about_ca_system_score_gemma":0.0012555411,"threshold_uncertainty_score":0.543126},"labels":[],"label_agreement":null},{"id":"W4403089994","doi":"10.1200/jco.2022.40.16_suppl.6031","title":"Complications and severity of COVID-19 in patients with head and neck cancer (HNC): A COVID-19 and Cancer Consortium (CCC19) registry analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Head and neck cancer; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cancer; Head and neck; Internal medicine; Oncology; Surgery; Virology; Outbreak; Disease; Infectious disease (medical specialty)","score_opus":0.20844036905705035,"score_gpt":0.55276160317072,"score_spread":0.34432123411366966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91726416,0.0017680175,0.000092609924,0.08014967,0.00012943237,0.0003490373,0.00017157855,0.000005581512,0.00006989365],"genre_scores_gemma":[0.9545632,0.0022277024,0.00034991646,0.042695213,0.00008123922,0.000021621992,0.000009786791,0.000009275001,0.000042028463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969689,0.000544819,0.0015862726,0.0002961739,0.00037631887,0.00022746666],"domain_scores_gemma":[0.9940794,0.0024121965,0.0016912826,0.00021829603,0.0002985569,0.0013002466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019838423,0.00013620059,0.0015307765,0.00031080586,0.00014335901,0.0000075517723,0.00010085522,0.00017652393,0.00013380595],"category_scores_gemma":[0.004004077,0.000106352745,0.000119448465,0.00048505657,0.0005336978,0.00007238379,0.0001183736,0.00094766443,1.01596534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005619624,0.00080854935,0.9806122,0.00028249004,0.00045940268,0.00009131088,0.00051640556,0.00023638555,0.000003671505,0.000042190437,0.002100832,0.009226936],"study_design_scores_gemma":[0.011673247,0.0043456596,0.90141463,0.000044984794,0.00072199485,0.000080287224,0.00024282227,0.00014230098,3.8767595e-7,0.00013778139,0.08110669,0.00008923418],"about_ca_topic_score_codex":0.009240934,"about_ca_topic_score_gemma":0.015871458,"teacher_disagreement_score":0.0791976,"about_ca_system_score_codex":0.0008237742,"about_ca_system_score_gemma":0.0102429725,"threshold_uncertainty_score":0.9973566},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4403090002","doi":"10.1200/jco.2022.40.16_suppl.6046","title":"Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch <sup>mut</sup> ).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Juravinski Cancer Centre; Western University","funders":"","keywords":"Medicine; Notch signaling pathway; Adenoid cystic carcinoma; Gamma secretase; Pathology; Internal medicine; Cancer research; Oncology; Carcinoma; Receptor; Biology; Genetics","score_opus":0.07298259955231844,"score_gpt":0.42926732370340953,"score_spread":0.3562847241510911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403090002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975983,0.00034053464,0.00019202082,0.00033588227,0.00038791407,0.0007610535,0.00016290194,0.0000043770287,0.00021700244],"genre_scores_gemma":[0.99700916,0.000055312667,0.0020243446,0.000052990355,0.00062906905,0.0000701495,0.00008309845,0.000040887808,0.000034983106],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991606,0.0028227367,0.0036960088,0.0005107209,0.000890296,0.00047425425],"domain_scores_gemma":[0.99207544,0.0027330394,0.0035788168,0.00039417794,0.00092367973,0.0002948269],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006139101,0.00026747116,0.0014342364,0.00046064745,0.00012354601,0.000012379148,0.00047316012,0.00025085552,0.00003488185],"category_scores_gemma":[0.02168903,0.00024033144,0.0004337773,0.0007976111,0.00037775983,0.000035956306,0.0002688842,0.0017729794,0.0000011808884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5664196,0.013953754,0.0018392244,0.00024335155,0.0007591719,0.0014192061,0.0030319407,0.007837109,0.36451536,0.000014800209,0.0023988225,0.03756762],"study_design_scores_gemma":[0.4184749,0.19661543,0.0033180923,0.0004428949,0.00060277514,0.0008660915,0.0059315804,0.0044451063,0.35962248,0.000120682125,0.008703998,0.00085596426],"about_ca_topic_score_codex":0.00015284668,"about_ca_topic_score_gemma":0.0001443825,"teacher_disagreement_score":0.18266167,"about_ca_system_score_codex":0.00032824805,"about_ca_system_score_gemma":0.0060419734,"threshold_uncertainty_score":0.99959284},"labels":[],"label_agreement":null},{"id":"W4403090786","doi":"10.1200/jco.2022.40.16_suppl.6037","title":"Individualized prediction of distant metastases risk in oral cavity carcinoma: A validated predictive-score model.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Kingston General Hospital; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Predictive value; Internal medicine; Oncology; Risk model; Framingham Risk Score; Predictive value of tests; Disease","score_opus":0.197449490671877,"score_gpt":0.4567937536395189,"score_spread":0.2593442629676419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403090786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530476,0.0008322218,0.00043841873,0.0010153911,0.00087721436,0.0002842155,0.00054787094,0.000010255096,0.0006896249],"genre_scores_gemma":[0.9969807,0.00061158946,0.0018350192,0.0002800864,0.00019342848,0.000020835003,0.000021178934,0.000013628309,0.000043521784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948389,0.0014177996,0.0026584505,0.00021648011,0.00063703116,0.00023136652],"domain_scores_gemma":[0.99618757,0.0011229008,0.0019558547,0.00018186339,0.00032870597,0.0002230951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061623272,0.00013919451,0.002143675,0.00022865065,0.000085520245,0.000002625453,0.00015568286,0.00015279849,0.00012671444],"category_scores_gemma":[0.0031151834,0.00010377219,0.00043906108,0.00034313335,0.00022745262,0.00009613489,0.00017500474,0.0015275228,4.2079856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021664131,0.0048643677,0.94271713,0.000066575434,0.0008272589,0.00066963583,0.001342184,0.0030140209,0.000352167,0.000063104475,0.0067914417,0.017627984],"study_design_scores_gemma":[0.028750146,0.038279448,0.9008449,0.00009482362,0.0017570747,0.00024384393,0.0012748865,0.012709348,0.00020927493,0.00090437214,0.014808877,0.00012305206],"about_ca_topic_score_codex":0.00020178525,"about_ca_topic_score_gemma":0.0001074701,"teacher_disagreement_score":0.041872278,"about_ca_system_score_codex":0.00035959174,"about_ca_system_score_gemma":0.0020490934,"threshold_uncertainty_score":0.66364115},"labels":[],"label_agreement":null},{"id":"W4403090837","doi":"10.1200/jco.2022.40.16_suppl.6010","title":"Effectiveness of adjuvant chemoradiotherapy for oral cavity squamous cell carcinoma with minor and major extranodal extension: A multi-institutional consortium study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Chemoradiotherapy; Basal cell; Adjuvant; Oncology; Squamous cell cancer; Internal medicine; Cancer","score_opus":0.09901170150085199,"score_gpt":0.4314409073178716,"score_spread":0.3324292058170196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403090837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950593,0.0021553922,0.00044301018,0.0007022907,0.00068537885,0.0008576023,0.000024790681,0.000004843699,0.00006737419],"genre_scores_gemma":[0.99552155,0.000040812087,0.003731407,0.00034758786,0.00022137332,0.00004916797,0.0000018852362,0.000014171994,0.00007205794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746764,0.00060783443,0.0011497984,0.00024287667,0.00034185624,0.00018999261],"domain_scores_gemma":[0.99602175,0.002418777,0.00075769436,0.00012897934,0.00046498602,0.0002077917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003426991,0.00015231741,0.0021663073,0.00008396415,0.00014910393,0.000002668469,0.00008909431,0.00009733317,0.000041619347],"category_scores_gemma":[0.00055618834,0.00009658517,0.00026600753,0.000101257814,0.00039089704,0.00004477452,0.000051530133,0.0005425729,2.0504514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09626371,0.014640307,0.85350835,0.0005805915,0.00047606783,0.0020549502,0.0007756835,0.000065985536,0.007323387,0.000027293234,0.00045868914,0.02382498],"study_design_scores_gemma":[0.05691923,0.0752375,0.8616711,0.000039342634,0.00056194374,0.00094378385,0.00057159615,0.00015790685,0.00067108666,0.000010697605,0.003113423,0.000102411854],"about_ca_topic_score_codex":0.00009028663,"about_ca_topic_score_gemma":0.0000878098,"teacher_disagreement_score":0.060597192,"about_ca_system_score_codex":0.00016499277,"about_ca_system_score_gemma":0.0018183445,"threshold_uncertainty_score":0.3938629},"labels":[],"label_agreement":null},{"id":"W4403119976","doi":"10.1200/jco.24.00055","title":"INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University Health Centre","funders":"","keywords":"Regorafenib; Medicine; Placebo; Internal medicine; Hazard ratio; Clinical endpoint; Cohort; Refractory (planetary science); Progression-free survival; Oncology; Quality of life (healthcare); Gastroenterology; Cancer; Surgery; Confidence interval; Overall survival; Clinical trial; Colorectal cancer; Pathology","score_opus":0.15417439950255993,"score_gpt":0.541799323162396,"score_spread":0.38762492365983603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403119976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604854,0.0051702023,0.0034867632,0.01723079,0.010401248,0.0011170377,0.000010473898,0.000053247706,0.002044818],"genre_scores_gemma":[0.9837376,0.0022770548,0.0024103003,0.0016126266,0.003378236,0.000041025316,0.000003472285,0.000030143432,0.0065095443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968015,0.00015324794,0.0021761588,0.00026376694,0.000333728,0.0002716204],"domain_scores_gemma":[0.99650866,0.0016872166,0.0009336429,0.00018837114,0.0003868528,0.0002952647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028490624,0.0001671429,0.0015048377,0.00031044203,0.00003961628,0.00002209384,0.00018320611,0.00017379632,0.000330655],"category_scores_gemma":[0.0016285247,0.00010965376,0.00067683455,0.00035168868,0.00008850583,0.0001811243,0.000050696097,0.0009855125,0.000011065208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012347417,0.002427615,0.008256036,0.00009420765,0.0011209991,0.0010439698,0.00016614134,0.000016553719,0.000100047735,0.00008477067,0.065111734,0.90923053],"study_design_scores_gemma":[0.040380687,0.043394357,0.019356564,0.00023531482,0.0020660306,0.000090919275,0.00084271264,0.00042211052,0.000012987559,0.00024005884,0.8928357,0.0001225979],"about_ca_topic_score_codex":0.000023232225,"about_ca_topic_score_gemma":0.000077642595,"teacher_disagreement_score":0.9091079,"about_ca_system_score_codex":0.00033254025,"about_ca_system_score_gemma":0.0016206712,"threshold_uncertainty_score":0.44715506},"labels":[],"label_agreement":null},{"id":"W4403121878","doi":"10.1200/jco.24.00022","title":"Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; NRG Oncology; ECOG-ACRIN Cancer Research Group; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Medicine; Nuclear medicine; Radiation therapy; Clinical endpoint; Confidence interval; Positron emission tomography; Population; Fluorodeoxyglucose; Stage (stratigraphy); Randomized controlled trial; Radiology; Surgery; Internal medicine","score_opus":0.06373585214348818,"score_gpt":0.4365389895125007,"score_spread":0.3728031373690125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403121878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974504,0.018522484,0.0006873932,0.0011541137,0.0011368877,0.003240526,0.00017907628,0.000023517545,0.000552014],"genre_scores_gemma":[0.96677554,0.009455728,0.022090107,0.0003664242,0.0009399475,0.00012826966,0.000046181765,0.0000661129,0.00013170861],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99086905,0.0015090246,0.0057012048,0.0006449457,0.00078428554,0.00049146725],"domain_scores_gemma":[0.991214,0.0041651344,0.0032320786,0.0004194343,0.0004796733,0.0004896879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005289493,0.0005122459,0.005385986,0.0009993273,0.00006457182,0.000020433665,0.00027334713,0.0006301385,0.00014741122],"category_scores_gemma":[0.00032555056,0.0003490999,0.0025071402,0.00086063915,0.00036202584,0.00017102194,0.00011147037,0.0010197001,2.892692e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90041226,0.026136521,0.0045001293,0.0005502969,0.006617721,0.0009658306,0.0025187347,0.00069924357,0.0030024683,0.000011895257,0.0014749842,0.053109944],"study_design_scores_gemma":[0.9250631,0.04359548,0.0021427101,0.0033145833,0.00501748,0.000045602806,0.00015287312,0.011438013,0.0071133557,0.000048337,0.0017823635,0.000286137],"about_ca_topic_score_codex":0.0008054993,"about_ca_topic_score_gemma":0.0000525772,"teacher_disagreement_score":0.052823804,"about_ca_system_score_codex":0.0011919305,"about_ca_system_score_gemma":0.0034510973,"threshold_uncertainty_score":0.9998961},"labels":[],"label_agreement":null},{"id":"W4403129728","doi":"10.1200/jco.2024.42.16_suppl.4597","title":"Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Bladder cancer; Bacillus (shape); Post-hoc analysis; Oncology; Post hoc; Internal medicine; Cancer; Immunotherapy; Microbiology","score_opus":0.03588075244463282,"score_gpt":0.40457235748121484,"score_spread":0.36869160503658205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403129728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991775,0.0005764036,0.0002275193,0.0053118216,0.0008210392,0.0006764021,0.00038985081,0.000015506628,0.0002065046],"genre_scores_gemma":[0.9946131,0.0006583829,0.001299966,0.0026936752,0.00027794193,0.000030561456,0.000017845334,0.000048100137,0.00036042294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943311,0.0010490357,0.0028037103,0.00052214536,0.00081734476,0.00047664365],"domain_scores_gemma":[0.9911377,0.0050920853,0.0012475457,0.00038493462,0.0014648681,0.0006728692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017203853,0.0003896166,0.0033118566,0.0011850742,0.000046289813,0.000022984324,0.00026214603,0.00048403675,0.0004418662],"category_scores_gemma":[0.0033795787,0.0002462753,0.0009160274,0.0015513869,0.00027506222,0.00017787909,0.000080449194,0.0012679799,0.00002637776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0866749,0.0022446082,0.830999,0.000059821286,0.010841027,0.0025932272,0.00074728054,0.0006246169,0.00008593707,0.000009804223,0.0008908817,0.064228855],"study_design_scores_gemma":[0.019613849,0.03511133,0.9358932,0.0002989835,0.006679105,0.000029226832,0.00019857989,0.00007604737,0.0001065495,0.000027910544,0.0017452786,0.00021995045],"about_ca_topic_score_codex":0.0014954199,"about_ca_topic_score_gemma":0.005315382,"teacher_disagreement_score":0.10489415,"about_ca_system_score_codex":0.00055656815,"about_ca_system_score_gemma":0.0063556847,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W4403147307","doi":"10.1200/jco.23.02470","title":"Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Mantle cell lymphoma; Internal medicine; Gastroenterology; Refractory (planetary science); Dosing; Neutropenia; Rash; Tolerability; Surgery; Adverse effect; Lymphoma; Toxicity","score_opus":0.10317170409455788,"score_gpt":0.4670318790647525,"score_spread":0.3638601749701946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403147307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817311,0.0034770044,0.0000032682724,0.005330698,0.0025605934,0.00033119344,0.00004279659,0.000020164905,0.0065031555],"genre_scores_gemma":[0.9956506,0.0008477162,0.0006316592,0.0007873622,0.0013420703,0.000009792737,0.000011640384,0.000022614075,0.00069654937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953959,0.00045675426,0.003091969,0.0003717985,0.00043112083,0.00025247716],"domain_scores_gemma":[0.99408287,0.0043039634,0.00078661693,0.00030236327,0.00014512791,0.00037904206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027020476,0.00019095585,0.0015168918,0.00022410614,0.00003825591,0.000019057003,0.0001576499,0.0003691534,0.00016502],"category_scores_gemma":[0.0016849021,0.00012527543,0.00052558153,0.00022023273,0.00008639912,0.000102415404,0.000089110166,0.0005878786,0.0001400765],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023993688,0.17095488,0.04175361,0.000030908894,0.0010505642,0.064070396,0.0016740101,0.000005499887,0.00013824251,0.000033834913,0.03495072,0.66134363],"study_design_scores_gemma":[0.22170395,0.1281735,0.3541813,0.00042073216,0.0013400036,0.00031549993,0.0010491146,0.00020313733,0.00018242777,0.00032297298,0.2919226,0.00018478067],"about_ca_topic_score_codex":0.00024219853,"about_ca_topic_score_gemma":0.00013606093,"teacher_disagreement_score":0.66115886,"about_ca_system_score_codex":0.0006292542,"about_ca_system_score_gemma":0.0021648044,"threshold_uncertainty_score":0.51085836},"labels":[],"label_agreement":null},{"id":"W4403173283","doi":"10.1200/jco.23.02768","title":"Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Immunohistochemistry; Oncology; Internal medicine; Lapatinib; Human Epidermal Growth Factor Receptor 2; Cohort; Stage (stratigraphy); Proportional hazards model; Cancer; Endometrial cancer; Breast cancer; Pathology; Biology","score_opus":0.30072103029406194,"score_gpt":0.566065639248905,"score_spread":0.265344608954843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403173283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98009586,0.003213138,0.00031919978,0.0087241065,0.0067241723,0.00048426367,0.0002957017,0.000017210275,0.00012634209],"genre_scores_gemma":[0.96719813,0.023851626,0.0036157437,0.0012840417,0.0037151163,0.000014460071,0.000008266745,0.000056485056,0.00025610116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99101686,0.002264851,0.0047654673,0.00047503444,0.0010260171,0.0004517523],"domain_scores_gemma":[0.9839879,0.0119130695,0.0021426324,0.0003026968,0.0007872051,0.0008664423],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008979123,0.00026802608,0.0032901347,0.00044843706,0.000054117903,0.00003792241,0.00032726035,0.00053083635,0.0032962107],"category_scores_gemma":[0.026409721,0.00017497249,0.00090978533,0.00044892353,0.00086999685,0.0001503402,0.00016577604,0.0033728797,0.000027709335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010558908,0.0016602107,0.21648492,0.0009437702,0.0029449267,0.0022420567,0.00019098129,2.3485757e-7,0.0006811133,0.00019963722,0.023014309,0.7410789],"study_design_scores_gemma":[0.032697175,0.0731896,0.65751266,0.0027353424,0.0048891497,0.0006405283,0.00015260933,0.00023750892,0.004424662,0.0015900503,0.22132088,0.0006098097],"about_ca_topic_score_codex":0.00018548251,"about_ca_topic_score_gemma":0.000039164956,"teacher_disagreement_score":0.7404691,"about_ca_system_score_codex":0.00020907148,"about_ca_system_score_gemma":0.0038386178,"threshold_uncertainty_score":0.9989264},"labels":[],"label_agreement":null},{"id":"W4403208177","doi":"10.1200/jco.24.00600","title":"OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Sunnybrook Health Science Centre; Université de Montréal; Centre hospitalier universitaire de Québec; Cégep de Lévis; University of Toronto; Western University; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; BC Cancer Agency; McMaster University; Université Laval; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cosmesis; Lumpectomy; Breast cancer; Ductal carcinoma; Randomized controlled trial; Adverse effect; Cancer; Nuclear medicine; Surgery; Urology; Mastectomy; Internal medicine","score_opus":0.049772902138728786,"score_gpt":0.4472107745239704,"score_spread":0.39743787238524164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403208177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259395,0.0019441061,0.0009704737,0.009925298,0.0035288564,0.0006070288,0.00021962402,0.000004953876,0.00020568326],"genre_scores_gemma":[0.9945008,0.0015073984,0.0005235861,0.00018946786,0.0030511757,0.000117016745,0.000009975585,0.000014383252,0.000086196764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99740493,0.000427992,0.0016256582,0.00021722724,0.00015182773,0.00017234344],"domain_scores_gemma":[0.997182,0.0014232341,0.00089799066,0.00011112061,0.00029308995,0.00009256828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019314712,0.00012614168,0.0010973869,0.00008560613,0.000030406769,0.0000116639,0.00012341686,0.0002834249,0.000025674295],"category_scores_gemma":[0.0009633608,0.00009354637,0.00065934396,0.00010350987,0.00020919868,0.000017856068,0.00003695832,0.00027925833,0.0000017171881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9205186,0.0010190884,0.005169846,0.000025703237,0.0013055353,0.00002194846,0.00017579642,0.00026839125,0.00051071256,0.000132208,0.0025410024,0.06831119],"study_design_scores_gemma":[0.8718514,0.0043592933,0.108116984,0.00017585873,0.00089561386,0.00019864946,0.000117571515,0.0004638212,0.00024460463,0.0006155135,0.012776225,0.00018448498],"about_ca_topic_score_codex":0.00031420754,"about_ca_topic_score_gemma":0.0002642593,"teacher_disagreement_score":0.10294714,"about_ca_system_score_codex":0.00009519374,"about_ca_system_score_gemma":0.0012673824,"threshold_uncertainty_score":0.381471},"labels":[],"label_agreement":null},{"id":"W4403471502","doi":"10.1200/jco-24-01887","title":"Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Hazard ratio; Oncology; Placebo; Endometrial cancer; Carboplatin; Interim analysis; Population; Surgery; Cancer; Chemotherapy; Clinical trial; Confidence interval; Immunotherapy; Cisplatin; Pathology","score_opus":0.08462971324505696,"score_gpt":0.44592718299427064,"score_spread":0.3612974697492137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403471502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782691,0.0047548646,0.001329857,0.0075571747,0.0056189084,0.0021214888,0.00008915742,0.00007452887,0.000184906],"genre_scores_gemma":[0.950555,0.01341388,0.02789741,0.0019328772,0.0044679674,0.00019313226,0.0000055896026,0.000120485514,0.0014136108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935288,0.0005856196,0.0037837743,0.00067123625,0.0008247448,0.0006058223],"domain_scores_gemma":[0.9838974,0.012957355,0.00177859,0.00040268103,0.0004498282,0.00051418017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053459797,0.00039799747,0.0032736857,0.0005324356,0.000059045367,0.000036628986,0.00032837506,0.0005991536,0.00038941286],"category_scores_gemma":[0.00822596,0.0002166901,0.00071662467,0.00081629655,0.00034571489,0.00010158394,0.000036168076,0.0016661164,0.0000047339227],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7102443,0.0012610193,0.021186924,0.00022919996,0.0012758113,0.0030299712,0.0012186948,0.0020948604,0.00013827684,0.000015710852,0.02152668,0.23777854],"study_design_scores_gemma":[0.38660893,0.19824608,0.048340708,0.0024091136,0.0013901464,0.0024400684,0.00069763034,0.011742676,0.00066829013,0.00014333456,0.34661344,0.00069957925],"about_ca_topic_score_codex":0.00068808714,"about_ca_topic_score_gemma":0.00293717,"teacher_disagreement_score":0.32508677,"about_ca_system_score_codex":0.0018890321,"about_ca_system_score_gemma":0.012177473,"threshold_uncertainty_score":0.99342257},"labels":[],"label_agreement":null},{"id":"W4403665847","doi":"10.1200/jco.24.00529","title":"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Medac","keywords":"Medicine; Metastatic breast cancer; Trastuzumab; Internal medicine; Trastuzumab emtansine; Oncology; Hazard ratio; Breast cancer; Clinical endpoint; Pertuzumab; Lapatinib; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Confidence interval","score_opus":0.2651344660519626,"score_gpt":0.5945402876781979,"score_spread":0.3294058216262353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403665847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742411,0.0016719068,0.00019510697,0.014583174,0.0033874244,0.004470543,0.00026498042,0.000048332575,0.0011374587],"genre_scores_gemma":[0.98823965,0.0038818025,0.0025858057,0.0012192695,0.0028204315,0.00028960343,0.000045789653,0.00010025285,0.0008173858],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9870741,0.0048989793,0.0056367465,0.0006828966,0.0009821609,0.0007251158],"domain_scores_gemma":[0.9869318,0.00912204,0.0015096763,0.00032970755,0.0009687425,0.0011380435],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011075283,0.0004206729,0.005584887,0.0005599049,0.00010240447,0.000110119276,0.0007197357,0.00045045605,0.0048146453],"category_scores_gemma":[0.007234652,0.00026553895,0.00051877263,0.0008339033,0.000733742,0.0008153813,0.00017907962,0.0031204624,0.00003407447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74774563,0.008920825,0.00014648345,0.00014305962,0.0014975939,0.004217531,0.00041155334,0.000005123169,0.0016446577,0.00008396988,0.00312562,0.23205794],"study_design_scores_gemma":[0.92104375,0.06854355,0.0009264947,0.001004869,0.0011071755,0.00096846797,0.00018756505,0.0008712982,0.00045599736,0.00020707527,0.0044078035,0.00027594453],"about_ca_topic_score_codex":0.0005870114,"about_ca_topic_score_gemma":0.0005547061,"teacher_disagreement_score":0.231782,"about_ca_system_score_codex":0.00147727,"about_ca_system_score_gemma":0.009231953,"threshold_uncertainty_score":0.9999797},"labels":[],"label_agreement":null},{"id":"W4403935320","doi":"10.1200/jco.24.01071","title":"Advances in Vulvar Cancer Biology and Management","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Immunotherapy; Targeted therapy; Cancer; Oncology; Endometrial cancer; Malignancy; Cancer research; Bioinformatics; Immunology; Internal medicine; Biology","score_opus":0.25362540816128576,"score_gpt":0.6114485950564893,"score_spread":0.35782318689520354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403935320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030767897,0.9886466,0.0000040561927,0.00080787967,0.0030566622,0.00039674065,0.000011047492,0.0000056666177,0.00704055],"genre_scores_gemma":[0.000047402882,0.9966374,0.0005445715,0.000505569,0.0018054965,0.00004036265,0.000004615507,0.000022768469,0.0003917824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959446,0.00039831625,0.0029697146,0.00029676995,0.00017250238,0.00021805042],"domain_scores_gemma":[0.99674547,0.0014612983,0.0013166784,0.00012506347,0.00007659839,0.00027491373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015734511,0.00024508234,0.0052182167,0.00046101277,0.000010708973,0.0000061625265,0.00014084873,0.00063951587,0.00014300365],"category_scores_gemma":[0.00053055986,0.00012927849,0.0008217726,0.000432474,0.00015156798,0.000052315245,0.00011079986,0.0013491208,0.000030544412],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040642853,0.00039025856,0.00060115504,0.009297802,0.0008650147,0.0016194666,0.000004429788,7.515327e-8,9.793093e-9,0.00038260632,0.00044660972,0.9859862],"study_design_scores_gemma":[0.0034868675,0.004275963,0.00041426488,0.012085913,0.006185769,0.0002681482,0.0000072646267,3.6305946e-7,2.0396946e-8,0.0009234841,0.97225416,0.000097778124],"about_ca_topic_score_codex":0.000015475718,"about_ca_topic_score_gemma":0.000060436614,"teacher_disagreement_score":0.98588836,"about_ca_system_score_codex":0.00033086108,"about_ca_system_score_gemma":0.00096423755,"threshold_uncertainty_score":0.5861333},"labels":[],"label_agreement":null},{"id":"W4404125740","doi":"10.1200/jco.24.01052","title":"Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; NODAL; Chemotherapy; Oncology; Neoadjuvant therapy; Internal medicine; Cancer; Breast cancer","score_opus":0.020755498745657557,"score_gpt":0.3672310666361383,"score_spread":0.34647556789048073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404125740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913527,0.0008910969,0.000007553689,0.0065698414,0.0007084933,0.00036660107,0.000016093998,0.000005832945,0.00008182253],"genre_scores_gemma":[0.99732023,0.00025618137,0.000269856,0.0013524668,0.0006502509,0.000021284133,0.0000029759651,0.00002265613,0.00010407507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769497,0.00043252954,0.0010608975,0.00032992565,0.00023756245,0.00024410797],"domain_scores_gemma":[0.99851793,0.000584385,0.00042114055,0.00020578848,0.00016676539,0.00010399077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001044612,0.00021717398,0.00084142754,0.00006372051,0.000045366778,0.000028181063,0.0002136742,0.00019774877,0.000020435013],"category_scores_gemma":[0.00022254439,0.000108536275,0.00015340827,0.00010272281,0.00026036272,0.000011262458,0.00014159484,0.00050850015,0.0000040522755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010105942,0.0018811426,0.9486013,0.000011182713,0.0012579063,0.00061068987,0.0005468181,0.000023327886,0.00012892045,0.0000024786436,0.0015273382,0.03530293],"study_design_scores_gemma":[0.0089133205,0.020075453,0.9586433,0.000035453482,0.00021315385,0.00003962736,0.00040626957,0.00000750948,0.000069394264,0.000034672514,0.0114228465,0.00013897175],"about_ca_topic_score_codex":0.00004341869,"about_ca_topic_score_gemma":0.00023117125,"teacher_disagreement_score":0.035163958,"about_ca_system_score_codex":0.00007017212,"about_ca_system_score_gemma":0.00040788212,"threshold_uncertainty_score":0.44259807},"labels":[],"label_agreement":null},{"id":"W4404258995","doi":"10.1200/jco-24-02133","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Stage (stratigraphy); Oncology; Cancer; Lung cancer; Internal medicine; Gynecology; Pathology","score_opus":0.06257167324106218,"score_gpt":0.5001184062087508,"score_spread":0.43754673296768865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404258995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8956547,0.016089743,0.03177612,0.037797164,0.0075654113,0.0016897393,0.000086274194,0.000042613116,0.009298263],"genre_scores_gemma":[0.8646019,0.011944838,0.05918992,0.009434631,0.0060752975,0.00012714848,0.000032404812,0.000087476496,0.048506375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982605,0.0000770285,0.0011219006,0.00018714897,0.00018865448,0.00016477013],"domain_scores_gemma":[0.9973213,0.0013838945,0.00045794077,0.000116575226,0.00052836724,0.00019188876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092106767,0.00011925546,0.0005929141,0.00011181813,0.000079969584,0.000027729206,0.00007596854,0.00016031128,0.00074703066],"category_scores_gemma":[0.00021824904,0.00007057546,0.00030404952,0.000137205,0.000050052815,0.00014073953,0.000015255787,0.00040806856,0.000008897684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058497055,0.0034825872,0.13037428,0.0004973137,0.004820985,0.0011802518,0.0023649798,0.0023783052,0.0010617025,0.00023986258,0.590022,0.257728],"study_design_scores_gemma":[0.009086162,0.011508877,0.020318445,0.0007626927,0.0016865467,0.000053492215,0.00031394928,0.007963251,0.00012730855,0.0000372481,0.9480162,0.00012580582],"about_ca_topic_score_codex":0.000051526476,"about_ca_topic_score_gemma":0.00008234428,"teacher_disagreement_score":0.3579942,"about_ca_system_score_codex":0.00028187843,"about_ca_system_score_gemma":0.0035079254,"threshold_uncertainty_score":0.8179462},"labels":[],"label_agreement":null},{"id":"W4404736942","doi":"10.1200/jco-24-01326","title":"First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Genentech; LEO Pharma; PharmaMar; Astellas Pharma; Novo Nordisk; Eisai; Seagen; Ipsen; BeiGene; Clovis Oncology; Fujirebio US; Regeneron Pharmaceuticals; National Cancer Institute; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Lenvatinib; Internal medicine; Pembrolizumab; Oncology; Carboplatin; Population; Chemotherapy; Cancer; Cisplatin; Confidence interval","score_opus":0.24586835090118422,"score_gpt":0.5513984472239566,"score_spread":0.3055300963227724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404736942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81141293,0.03136854,0.0061476463,0.0575505,0.07129426,0.014603215,0.0002184098,0.00012540759,0.0072790957],"genre_scores_gemma":[0.9146205,0.037490748,0.010823714,0.0041889017,0.028925255,0.0010785268,0.000046311616,0.00013052479,0.002695517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933034,0.0005239623,0.0045494786,0.00050165306,0.0006472807,0.0004742257],"domain_scores_gemma":[0.9674592,0.029030388,0.001955289,0.0002808912,0.0006142187,0.00066003966],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064715887,0.00035431125,0.005583846,0.0004102239,0.000105120234,0.000076191965,0.00048318406,0.0005494173,0.0010878573],"category_scores_gemma":[0.018301863,0.00022421694,0.0015571095,0.00078580406,0.00029789063,0.00029660165,0.0001015201,0.0010569452,0.000015898535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6298562,0.0038111052,0.000002636686,0.00007295578,0.0026154665,0.00021702805,0.000048355632,0.00001695875,0.000029790213,0.00028728927,0.0024968893,0.36054528],"study_design_scores_gemma":[0.7070197,0.08451184,0.0000037621528,0.00022801847,0.0020923084,0.00004716701,0.000018800807,0.00067037647,0.00010391409,0.00079636736,0.20436011,0.00014766016],"about_ca_topic_score_codex":0.00010074033,"about_ca_topic_score_gemma":0.000071789866,"teacher_disagreement_score":0.36039764,"about_ca_system_score_codex":0.00081143825,"about_ca_system_score_gemma":0.0049332674,"threshold_uncertainty_score":0.9998253},"labels":[],"label_agreement":null},{"id":"W4405276065","doi":"10.1200/jco-24-01278","title":"Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Dacarbazine; Medicine; Vinblastine; Nivolumab; Hodgkin lymphoma; Brentuximab vedotin; Oncology; Lymphoma; Doxorubicin; Bleomycin; Internal medicine; Chemotherapy; Cancer; Immunotherapy","score_opus":0.054305279392703645,"score_gpt":0.43882162680534387,"score_spread":0.38451634741264024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405276065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851882,0.0039464533,0.000038255308,0.00687729,0.0016056125,0.00075180095,0.000010776325,0.000017639004,0.001563989],"genre_scores_gemma":[0.99202263,0.003485375,0.001207844,0.001009866,0.0018632475,0.00002664464,0.000011401174,0.0000341552,0.00033882653],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99549586,0.00031317418,0.0029805407,0.00034175414,0.00057208637,0.00029658386],"domain_scores_gemma":[0.9957872,0.0020721778,0.0011383747,0.0002682821,0.00038114592,0.00035283528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017859758,0.00026051688,0.0023171545,0.00030489525,0.000029515479,0.000011269651,0.00016653314,0.00041386666,0.0003659459],"category_scores_gemma":[0.0010509922,0.00014949421,0.00059632823,0.00032952506,0.00021247017,0.00012423264,0.00004965547,0.00046371907,0.000017308792],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39667448,0.039148252,0.0037669835,0.00005348727,0.0009429597,0.005632947,0.00043774187,0.000010258733,0.00008754527,0.00008033823,0.0051228194,0.5480422],"study_design_scores_gemma":[0.648594,0.27869388,0.03650437,0.0012457843,0.00050921954,0.0007904771,0.0001350464,0.0005298911,0.00057501503,0.000069328824,0.032214805,0.00013814241],"about_ca_topic_score_codex":0.00020314346,"about_ca_topic_score_gemma":0.00013752733,"teacher_disagreement_score":0.547904,"about_ca_system_score_codex":0.0004404881,"about_ca_system_score_gemma":0.0039113117,"threshold_uncertainty_score":0.69384986},"labels":[],"label_agreement":null},{"id":"W4405430958","doi":"10.1200/jco.24.00857","title":"Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Liver transplantation; Cornerstone; Economic shortage; Transplantation; Intensive care medicine; Population; Oncology; Milan criteria; Liver disease; Cancer; Internal medicine; Immunotherapy; Disease","score_opus":0.26112553391665194,"score_gpt":0.4677838769604904,"score_spread":0.20665834304383845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405430958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11256872,0.8853978,0.0000547707,0.0001178668,0.0005131791,0.001198264,0.000049495167,0.0000031446323,0.00009678154],"genre_scores_gemma":[0.25514713,0.74349207,0.00071525504,0.000050980336,0.00042999256,0.00003670694,0.00008359668,0.00003229894,0.000011945576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946133,0.0010097695,0.0036310463,0.00022743581,0.0003304273,0.00018800283],"domain_scores_gemma":[0.99455065,0.0024550883,0.0023095761,0.00025801788,0.00031795484,0.00010871954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032717783,0.00027518507,0.00434214,0.00028007093,0.000022260469,0.000006802257,0.00027711428,0.00074993,0.00002710174],"category_scores_gemma":[0.00019812085,0.0001507775,0.0023447105,0.00025899988,0.00015883736,0.00006783424,0.000011727649,0.0012281665,0.000002125828],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023844242,0.00097634003,0.016025305,0.023392748,0.00078206166,0.0023343372,0.0025364817,1.4326743e-7,0.0000069628413,0.000060810144,0.000078530175,0.95142186],"study_design_scores_gemma":[0.019922309,0.09600496,0.005123171,0.04609866,0.04913781,0.003438304,0.0021360666,0.000333821,0.0001392582,0.0001652238,0.77689534,0.0006050589],"about_ca_topic_score_codex":0.000045146375,"about_ca_topic_score_gemma":0.000026176425,"teacher_disagreement_score":0.9508168,"about_ca_system_score_codex":0.00016367271,"about_ca_system_score_gemma":0.0020501288,"threshold_uncertainty_score":0.6148528},"labels":[],"label_agreement":null},{"id":"W4406119963","doi":"10.1200/jco.24.00994","title":"Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Fulvestrant; Anastrozole; Medicine; Hazard ratio; Internal medicine; Oncology; Breast cancer; Gynecology; Cancer; Tamoxifen; Confidence interval","score_opus":0.08268262787253476,"score_gpt":0.4658087781659373,"score_spread":0.3831261502934025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406119963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978991,0.0013414031,0.00015624105,0.016509628,0.0014999287,0.00079760776,0.00003504007,0.000009696137,0.00065949594],"genre_scores_gemma":[0.9929465,0.0031162659,0.00075548305,0.0018785461,0.0010948867,0.000090548056,0.000005797216,0.000020495796,0.000091452705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99579746,0.0007801879,0.0020678965,0.0003239473,0.0004886742,0.00054184604],"domain_scores_gemma":[0.9956764,0.0023887842,0.0011525092,0.00025699893,0.00031905816,0.00020624741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022700555,0.0002781506,0.0018861458,0.00024990295,0.000047159272,0.000013649537,0.0003268468,0.00017616285,0.00012553077],"category_scores_gemma":[0.00034498455,0.00016897665,0.00023527317,0.00047996262,0.00036816738,0.00024734702,0.00003585274,0.0017468994,0.0000014851593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62574834,0.0028355848,0.0016990016,0.0000069699286,0.00039605083,0.00056458963,0.0004396322,0.00015222326,0.00067880633,0.00008374909,0.0000799466,0.36731508],"study_design_scores_gemma":[0.7459311,0.055997487,0.17283808,0.00029091063,0.0001297111,0.00025180378,0.0024364681,0.000027741959,0.000112722424,0.00022538935,0.021566845,0.00019175545],"about_ca_topic_score_codex":0.00017510151,"about_ca_topic_score_gemma":0.0004166941,"teacher_disagreement_score":0.36712334,"about_ca_system_score_codex":0.0008818881,"about_ca_system_score_gemma":0.002648023,"threshold_uncertainty_score":0.7589506},"labels":[],"label_agreement":null},{"id":"W4406119971","doi":"10.1200/jco-24-02242","title":"Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Seagen; Pfizer","keywords":"Medicine; Placebo; Internal medicine; Hazard ratio; Lenalidomide; Diffuse large B-cell lymphoma; Clinical endpoint; Gastroenterology; Brentuximab vedotin; Rituximab; Surgery; Oncology; Confidence interval; Lymphoma; Clinical trial; Multiple myeloma; Pathology; CD30","score_opus":0.062473665567266086,"score_gpt":0.4445531832436627,"score_spread":0.38207951767639664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406119971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96814996,0.00088747055,0.00071062014,0.017971138,0.0026199438,0.00044145322,0.000008608251,0.000013959093,0.009196868],"genre_scores_gemma":[0.9902319,0.0005515416,0.0021909825,0.004724304,0.0003659564,0.000019417736,0.000011091288,0.000010960183,0.001893882],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974301,0.00019781374,0.0017766167,0.00016920049,0.00020773211,0.00021857207],"domain_scores_gemma":[0.9950046,0.0030884605,0.0010601681,0.0001747535,0.00046713324,0.00020491387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018270906,0.00012165707,0.001165217,0.0001428991,0.000059549693,0.0000106379985,0.000115945266,0.00033946737,0.000031085016],"category_scores_gemma":[0.0025363695,0.00008503222,0.00067722506,0.0001225794,0.000064426175,0.00006309868,0.00003953676,0.00019217536,0.000018530842],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010955479,0.19998656,0.17933436,0.00017267236,0.0011006019,0.00058493594,0.00010052015,0.0000011326174,0.00013553786,0.009851209,0.119702265,0.47807473],"study_design_scores_gemma":[0.2467901,0.013718449,0.33944827,0.00015061628,0.0010039898,0.00006789897,0.00007422838,0.0002442455,0.00064137735,0.001844853,0.39593598,0.00007999503],"about_ca_topic_score_codex":0.0000056003355,"about_ca_topic_score_gemma":0.000009094696,"teacher_disagreement_score":0.47799474,"about_ca_system_score_codex":0.0003582573,"about_ca_system_score_gemma":0.0015865333,"threshold_uncertainty_score":0.34675133},"labels":[],"label_agreement":null},{"id":"W4406120005","doi":"10.1200/jco-24-02089","title":"Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Context (archaeology); Clinical Oncology; Presentation (obstetrics); Biliary tract; General surgery; Medical physics; Oncology; Internal medicine; Radiology; Cancer","score_opus":0.24136564284997986,"score_gpt":0.5356603773867346,"score_spread":0.2942947345367547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406120005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012097238,0.98113036,0.00005525229,0.009933475,0.0049558138,0.0016310192,0.000049323175,0.000012866266,0.002110909],"genre_scores_gemma":[0.0002630114,0.9897309,0.0005042527,0.0027482684,0.004774453,0.0001743848,0.000019976877,0.000039909664,0.0017448756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942338,0.000523045,0.004099642,0.00038930296,0.00035244314,0.00040179686],"domain_scores_gemma":[0.9772407,0.017931875,0.0037192104,0.00042303966,0.0004425832,0.00024259693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003774077,0.00043388433,0.0069421693,0.00022425613,0.00018408065,0.000015479493,0.00048637707,0.0007761939,0.000102174425],"category_scores_gemma":[0.004544416,0.00020827516,0.004027338,0.00034369604,0.00027278363,0.000070600254,0.00006859042,0.0020758552,0.0000046586138],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016595162,0.00044771875,0.00019235339,0.0028631655,0.0018697435,0.00019725326,0.00005458974,0.0000029708012,5.8594154e-8,0.000035579335,0.04451331,0.94816375],"study_design_scores_gemma":[0.0076450305,0.007419837,0.00079391233,0.007332251,0.0041231024,0.00026360966,0.00003448509,0.0000034852658,5.414096e-7,0.00014596427,0.97205305,0.00018471615],"about_ca_topic_score_codex":0.000008796512,"about_ca_topic_score_gemma":0.00010774208,"teacher_disagreement_score":0.94797903,"about_ca_system_score_codex":0.00060379686,"about_ca_system_score_gemma":0.008197192,"threshold_uncertainty_score":0.99742544},"labels":[],"label_agreement":null},{"id":"W4406158635","doi":"10.1200/jco-24-02425","title":"Treatment of Pleural Mesothelioma: ASCO Guideline Update","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Alberta","funders":"","keywords":"Medicine; Guideline; Systematic review; Family medicine; Observational study; Psychological intervention; MEDLINE; Evidence-based medicine; Medical physics; Alternative medicine; Pathology; Nursing","score_opus":0.08484792370879728,"score_gpt":0.4961509547487606,"score_spread":0.4113030310399633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406158635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734554,0.0015338724,0.00012379044,0.018190712,0.0007280561,0.00010854618,0.000013997385,0.000004565495,0.005841046],"genre_scores_gemma":[0.99036044,0.0012503604,0.004081236,0.0025682563,0.00040275164,0.0000015137599,0.000011001751,0.0000053917875,0.0013190749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762475,0.00011063713,0.0018822643,0.0000924126,0.00019502219,0.00009488409],"domain_scores_gemma":[0.9983267,0.0005328829,0.000735267,0.000116716765,0.00012812506,0.00016027443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043777656,0.00008269239,0.00087990676,0.000075365904,0.000015853673,0.000001568776,0.00006983734,0.0001247538,0.0003621068],"category_scores_gemma":[0.00057886087,0.000050569324,0.0004849587,0.00008285046,0.00015058808,0.000040028754,0.000022808566,0.00012105429,0.00002148431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011869089,0.008964232,0.6660068,0.000038058304,0.0011459993,0.00048045794,0.00002140494,0.00006897099,0.0006961969,0.00086172303,0.02978019,0.2800669],"study_design_scores_gemma":[0.007465978,0.009938912,0.68385375,0.00004086214,0.00065975246,0.000084340536,0.00003367441,0.00009501101,0.00038942127,0.000867886,0.2965319,0.000038544495],"about_ca_topic_score_codex":0.000011933118,"about_ca_topic_score_gemma":0.0000042549805,"teacher_disagreement_score":0.28002834,"about_ca_system_score_codex":0.00012846178,"about_ca_system_score_gemma":0.00066471694,"threshold_uncertainty_score":0.39648157},"labels":[],"label_agreement":null},{"id":"W4406158653","doi":"10.1200/jco-24-02239","title":"Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Lung cancer; Chemotherapy; Oncology; Cancer; Surgery; Immunotherapy","score_opus":0.08983224065365615,"score_gpt":0.5073074975597608,"score_spread":0.41747525690610465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406158653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93530065,0.012944723,0.000091369075,0.02976457,0.0065306267,0.0003114338,0.000002456043,0.000012587106,0.01504161],"genre_scores_gemma":[0.96959925,0.015626436,0.0008565042,0.007866669,0.0012009903,0.000012659637,0.0000013340152,0.000020861293,0.0048152967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687564,0.00025152942,0.0021060347,0.00019968908,0.00027413518,0.00029298026],"domain_scores_gemma":[0.99719197,0.001344807,0.0008313184,0.00021831928,0.00026784505,0.00014572684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027045952,0.00013658569,0.0013799676,0.0002517204,0.00003643794,0.000009852499,0.0002104281,0.0004219743,0.0006275794],"category_scores_gemma":[0.0009979511,0.000102483114,0.00049677555,0.000420282,0.00017740807,0.00009372609,0.00003490554,0.0010599635,0.0000031504796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3318319,0.0013375807,0.04893854,0.000096974625,0.0014446316,0.0004879193,0.00023331644,0.000057872094,0.0013168807,0.00008928798,0.0508724,0.5632927],"study_design_scores_gemma":[0.17982075,0.011580329,0.26443213,0.00093976856,0.00039815728,0.00007969334,0.00037871563,0.001228879,0.0005513282,0.00016465648,0.5402332,0.00019239368],"about_ca_topic_score_codex":0.0004064173,"about_ca_topic_score_gemma":0.00095848885,"teacher_disagreement_score":0.5631003,"about_ca_system_score_codex":0.001149051,"about_ca_system_score_gemma":0.005615494,"threshold_uncertainty_score":0.99616456},"labels":[],"label_agreement":null},{"id":"W4406316580","doi":"10.1200/jco-24-02081","title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Tumor microenvironment; Colorectal cancer; T cell; Cancer; Cancer research; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.14160946337063576,"score_gpt":0.5378796703098482,"score_spread":0.39627020693921244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406316580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009726501,0.9842085,0.0000070811907,0.00061787816,0.003427048,0.0009913447,0.000012260402,0.0000102477015,0.0009991281],"genre_scores_gemma":[0.0001106329,0.99410295,0.00066911214,0.00036245622,0.0024993273,0.000032987093,0.000007414571,0.00006838887,0.0021467158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919584,0.0014216074,0.0051137474,0.00040725205,0.00052907725,0.0005699318],"domain_scores_gemma":[0.9923397,0.004287543,0.002501848,0.00028242098,0.00019954014,0.00038896408],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047997115,0.000405576,0.007973881,0.0010508331,0.00002452112,0.000018568051,0.00058649963,0.0009627629,0.0018068054],"category_scores_gemma":[0.0017453429,0.0003155492,0.0016114109,0.0010183706,0.00018248234,0.000075661526,0.000120603494,0.0046380023,0.0000407824],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017611268,0.0007517484,0.0011309882,0.0019266765,0.00058767584,0.0009505505,0.000092793176,0.00000881567,0.0006151362,0.000001851373,0.0028856106,0.989287],"study_design_scores_gemma":[0.0050036777,0.003293334,0.002354728,0.019417858,0.00022375208,0.0002120185,0.000020864121,0.0000075488874,0.00006568212,0.000023370163,0.9691566,0.00022054212],"about_ca_topic_score_codex":0.00028081983,"about_ca_topic_score_gemma":0.00021370177,"teacher_disagreement_score":0.9890665,"about_ca_system_score_codex":0.0013368452,"about_ca_system_score_gemma":0.017710997,"threshold_uncertainty_score":0.99992967},"labels":[],"label_agreement":null},{"id":"W4406351953","doi":"10.1200/jco-24-01534","title":"Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Snowball sampling; Medicine; Clinical trial; Scope (computer science); Drug development; Timeline; Government (linguistics); Clinical Oncology; Regulatory science; Oncology; Cancer; Internal medicine; Pharmacology; Drug; Pathology; Computer science","score_opus":0.8233383892293199,"score_gpt":0.7297194711303056,"score_spread":0.09361891809901435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406351953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058974596,0.967634,0.0016826326,0.0030505196,0.011033582,0.005716731,0.00021389482,0.000014012823,0.0047571333],"genre_scores_gemma":[0.0008259465,0.84111136,0.1540184,0.0005804853,0.0032610856,0.000093207884,0.0000034982068,0.000050257993,0.00005574043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.70571697,0.21701282,0.07319752,0.0010442167,0.002115954,0.0009125053],"domain_scores_gemma":[0.14162786,0.80461955,0.050461162,0.0012940982,0.0017334162,0.00026389337],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.33309528,0.00070160563,0.02385664,0.00040727935,0.0001413579,0.000026555683,0.0042205695,0.0038428153,0.00025106728],"category_scores_gemma":[0.60737836,0.0002977904,0.005395179,0.000997833,0.0024641433,0.00010276968,0.0008342525,0.008495801,0.000006947238],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033385577,0.00588417,0.00012336095,0.001945199,0.0019069846,0.00008204168,0.0006229779,0.0000010836154,0.0000015859583,0.009446716,0.0034151261,0.9732322],"study_design_scores_gemma":[0.008494185,0.009572606,0.00017770336,0.0065413527,0.006469852,0.00009713981,0.0011379882,0.000014799865,0.000013878721,0.105480134,0.86174357,0.00025681395],"about_ca_topic_score_codex":0.000016796357,"about_ca_topic_score_gemma":0.00010893596,"teacher_disagreement_score":0.9729754,"about_ca_system_score_codex":0.0002978945,"about_ca_system_score_gemma":0.019485842,"threshold_uncertainty_score":0.9999474},"labels":[],"label_agreement":null},{"id":"W4406501654","doi":"10.1200/jco-24-02314","title":"Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial","year":2025,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North; Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Oncology; Cancer; Prostate; Internal medicine; Surgery","score_opus":0.27865766790268487,"score_gpt":0.5766301250686224,"score_spread":0.29797245716593757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406501654","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016220508,0.0075366525,0.000011351808,0.96393454,0.008284973,0.0028842313,0.000069140515,0.000008172597,0.001050401],"genre_scores_gemma":[0.011955259,0.026793908,0.00013257461,0.89783245,0.045549393,0.00035432857,0.000033065957,0.00005299019,0.017296003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9874534,0.004638401,0.006131685,0.00034506072,0.00086607074,0.0005653669],"domain_scores_gemma":[0.9745771,0.020058814,0.004077708,0.00037127367,0.0007154088,0.00019963698],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.018518347,0.00033140706,0.0058799353,0.00041275393,0.000050349056,0.000035171997,0.00044117926,0.0016850102,0.00034189355],"category_scores_gemma":[0.017912896,0.00015206136,0.0017989984,0.00030082164,0.00048719716,0.000072803836,0.0000637898,0.0101519255,0.000014474697],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24377799,0.0005879878,0.0032301494,0.00012346824,0.0017141431,0.0058987197,0.000076901204,0.0000053064086,0.0000047532267,0.0000022670015,0.6509099,0.09366839],"study_design_scores_gemma":[0.23335919,0.009824116,0.002757381,0.0006302667,0.0014561312,0.00005704475,0.00002440761,0.000014790161,0.0000073895344,0.00030568452,0.75145924,0.000104379],"about_ca_topic_score_codex":0.00011761515,"about_ca_topic_score_gemma":0.000088690074,"teacher_disagreement_score":0.100549296,"about_ca_system_score_codex":0.00068244745,"about_ca_system_score_gemma":0.018537683,"threshold_uncertainty_score":0.999611},"labels":[],"label_agreement":null},{"id":"W4406690958","doi":"10.1200/jco-24-01829","title":"Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; NRG Oncology; Eli Lilly and Company","keywords":"Medicine; Cetuximab; Head and neck cancer; Internal medicine; Hazard ratio; Radiation therapy; Oncology; Cancer; Head and neck squamous-cell carcinoma; Toxicity; Exact test; Larynx; Surgery; Confidence interval; Colorectal cancer","score_opus":0.09291352606650967,"score_gpt":0.519990389511475,"score_spread":0.42707686344496537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406690958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93864065,0.012262693,0.00045417994,0.044544175,0.002325763,0.00026646588,0.000011059253,0.000006045646,0.0014889437],"genre_scores_gemma":[0.92633075,0.042718332,0.0064376453,0.021470614,0.0016695198,0.000026360765,8.2507717e-7,0.000014076216,0.0013319075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982294,0.0001621637,0.0011919105,0.00014722037,0.00010126754,0.000168044],"domain_scores_gemma":[0.99687505,0.0019204844,0.00055161916,0.000082317354,0.0004060601,0.00016447483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012489097,0.000103529506,0.0015248173,0.00008761464,0.00006287195,0.000006240533,0.00006935804,0.00020485773,0.000042428273],"category_scores_gemma":[0.0022236526,0.0000662668,0.0002715189,0.00008053538,0.00022053793,0.000053406948,0.000026224556,0.0005848206,7.4018027e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010638383,0.00065551774,0.18505064,0.000055594483,0.0010089217,0.000053532352,0.00049140386,0.0000022287018,0.00015423475,0.00016480713,0.04429254,0.7574322],"study_design_scores_gemma":[0.024057986,0.034543946,0.42689145,0.0003610896,0.00039021473,0.000041017473,0.00020233566,0.00016837678,0.00010156685,0.00036076058,0.5128044,0.000076875665],"about_ca_topic_score_codex":0.000037553564,"about_ca_topic_score_gemma":0.00021669392,"teacher_disagreement_score":0.75735533,"about_ca_system_score_codex":0.00014663431,"about_ca_system_score_gemma":0.0016024286,"threshold_uncertainty_score":0.28426394},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4406854676","doi":"10.1200/jco.24.00848","title":"Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Loxo Oncology; Bayer HealthCare; Jazz Pharmaceuticals; Eisai; Genentech; Y-mAbs Therapeutics; Royal Marsden NHS Foundation Trust; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; National Institute for Health and Care Research; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Medicine; Discontinuation; Trk receptor; Sarcoma; Internal medicine; Adverse effect; Surgery; Oncology; Pathology; Receptor; Neurotrophin","score_opus":0.030277760700745275,"score_gpt":0.39712309903873777,"score_spread":0.3668453383379925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406854676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950655,0.0007513021,0.0000065403674,0.0018196421,0.0002325627,0.00028099306,0.0000010653958,0.000002781456,0.0018396281],"genre_scores_gemma":[0.9987863,0.00041704712,0.00050899416,0.00013043174,0.00007105018,0.00000438801,0.0000026260414,0.0000055427986,0.00007364385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977477,0.00030561254,0.0014868879,0.00013958427,0.00020392396,0.00011624779],"domain_scores_gemma":[0.9967055,0.0017327296,0.0010796504,0.00007938026,0.0003087971,0.00009397728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010925452,0.000090555455,0.0009545408,0.00027374073,0.000018617355,0.0000027265773,0.000042986718,0.00017329826,0.000019247282],"category_scores_gemma":[0.0019784267,0.000055497654,0.0001347026,0.00033943847,0.000075386226,0.00006704558,0.000026824982,0.0004542413,8.011202e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002662784,0.004376734,0.91447604,0.000013850217,0.0001317214,0.00013162948,0.000100190766,0.0000027017572,0.000006942642,0.00009100909,0.0001227445,0.07788364],"study_design_scores_gemma":[0.01544792,0.009943309,0.9733719,0.00016722307,0.00041782876,0.000022021766,0.000074023716,0.000024731939,0.000053372005,0.000295629,0.00014082613,0.000041215833],"about_ca_topic_score_codex":0.00002412971,"about_ca_topic_score_gemma":0.00007829234,"teacher_disagreement_score":0.07784242,"about_ca_system_score_codex":0.00009715208,"about_ca_system_score_gemma":0.00057724456,"threshold_uncertainty_score":0.23685046},"labels":[],"label_agreement":null},{"id":"W4406868895","doi":"10.1200/jco.2025.43.4_suppl.661","title":"Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup> Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Neuroendocrine tumors; Somatostatin; Lanreotide; Internal medicine; Phases of clinical research; Oncology; Phase (matter); Clinical trial; Cancer research; Hormone; Chemistry","score_opus":0.0731165879375968,"score_gpt":0.48466065145493487,"score_spread":0.4115440635173381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406868895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924546,0.00036614834,0.000054147,0.005503447,0.0003610976,0.0011128399,0.00001557556,0.0000095363,0.00012264906],"genre_scores_gemma":[0.9971036,0.0013449996,0.0005954185,0.0005054463,0.00029354752,0.000019058243,0.0000053654235,0.000023739323,0.000108851294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932682,0.0013915165,0.003907188,0.00033033872,0.00064394326,0.0004588208],"domain_scores_gemma":[0.9944257,0.0023813292,0.0022274393,0.00033930913,0.00034529317,0.0002809338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016091925,0.0002494022,0.0019905455,0.0004629623,0.000059400278,0.000017069175,0.00027216674,0.000041804997,0.000052927477],"category_scores_gemma":[0.0077942703,0.00016233827,0.00048694218,0.0005127003,0.00071267603,0.00023827606,0.00013224424,0.0013863232,7.807669e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6004171,0.04286394,0.1560726,0.00039375783,0.00047448208,0.006729242,0.0001604272,0.00009706414,0.003132463,0.00003026258,0.0006066229,0.18902208],"study_design_scores_gemma":[0.72963184,0.084626675,0.16614985,0.0018212791,0.0005398424,0.0033010934,0.0005852812,0.0012649717,0.0063175657,0.00020430416,0.0053752433,0.00018207122],"about_ca_topic_score_codex":0.000017581106,"about_ca_topic_score_gemma":0.000029204073,"teacher_disagreement_score":0.18884002,"about_ca_system_score_codex":0.00012463414,"about_ca_system_score_gemma":0.0011034709,"threshold_uncertainty_score":0.93310326},"labels":[],"label_agreement":null},{"id":"W4406869106","doi":"10.1200/jco.2025.43.4_suppl.602","title":"Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Stereotactic radiotherapy; Oncology; Hepatocellular carcinoma; Radiosurgery; Radiation therapy; Internal medicine; Nuclear medicine; Radiology; Cancer; Immunotherapy","score_opus":0.051706459951020634,"score_gpt":0.46676355530399066,"score_spread":0.41505709535297003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893925,0.0022138671,0.000056007208,0.0064015863,0.00061075715,0.00057664636,7.4017606e-7,0.000008235839,0.00073961914],"genre_scores_gemma":[0.9941061,0.001622809,0.0007959792,0.0029304237,0.0001418781,0.000008653396,5.038908e-7,0.00001279934,0.00038081052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972582,0.00043302524,0.0016815263,0.0002063776,0.00022053748,0.00020032238],"domain_scores_gemma":[0.9974852,0.0011598563,0.00084555196,0.00019333669,0.00016333841,0.0001526903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020790962,0.0001513816,0.0015238909,0.00026702296,0.000050122017,0.00001016272,0.00011452451,0.0001795136,0.000059683818],"category_scores_gemma":[0.00049240777,0.00009862694,0.00017458762,0.00031722712,0.0001980921,0.00011228673,0.000026686248,0.00075510464,3.4563487e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3731815,0.015147972,0.14147748,0.000046881767,0.0013839462,0.0013743101,0.0007042458,0.0000025978138,0.0011703258,0.000023226195,0.00046987578,0.46501765],"study_design_scores_gemma":[0.2687643,0.23509291,0.47415033,0.00030745796,0.000338709,0.00043010782,0.00071817567,0.000071086615,0.00006419437,0.000070698574,0.019872649,0.000119410935],"about_ca_topic_score_codex":0.000030958556,"about_ca_topic_score_gemma":0.0001851167,"teacher_disagreement_score":0.46489823,"about_ca_system_score_codex":0.00021374242,"about_ca_system_score_gemma":0.0015007171,"threshold_uncertainty_score":0.40218896},"labels":[],"label_agreement":null},{"id":"W4406869152","doi":"10.1200/jco.2025.43.4_suppl.lba14","title":"Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"Natera; Alliance for Clinical Trials in Oncology Foundation","keywords":"Medicine; Oncology; Colorectal cancer; Internal medicine; Circulating tumor DNA; Cancer; Celecoxib; Stage (stratigraphy); Cancer research; Biology","score_opus":0.028503662511421626,"score_gpt":0.38060270591184675,"score_spread":0.35209904340042514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997171,0.0009610192,0.000032513573,0.0004788021,0.000318094,0.0005199012,0.000019072502,0.000008627659,0.0004910066],"genre_scores_gemma":[0.99857515,0.00023728561,0.00037732735,0.00039347977,0.0002798457,0.000022673417,0.000004330741,0.000015526404,0.00009438694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726397,0.00032134415,0.0016424807,0.0002383571,0.00027357473,0.00026024724],"domain_scores_gemma":[0.9953655,0.0027640061,0.0011942307,0.00011984667,0.00032492133,0.00023151792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014777131,0.00016800882,0.0016333666,0.00015391344,0.000034908913,0.000006252749,0.000098118086,0.0003072226,0.000057275636],"category_scores_gemma":[0.002362743,0.0001185314,0.00013892348,0.00026165866,0.0002493114,0.00009432055,0.000038120063,0.0009193207,8.7337287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008241271,0.0005513104,0.97524315,0.00012530357,0.00035662155,0.0010071377,0.00036796174,0.0000691459,0.0059866807,0.000026061745,0.00014765529,0.007877682],"study_design_scores_gemma":[0.013214547,0.007459656,0.97023994,0.001454691,0.00057041436,0.0000349063,0.00034238296,0.001968095,0.003491387,0.000085845444,0.0010363691,0.00010175329],"about_ca_topic_score_codex":0.00024157784,"about_ca_topic_score_gemma":0.00040418073,"teacher_disagreement_score":0.007775929,"about_ca_system_score_codex":0.00023096157,"about_ca_system_score_gemma":0.0018239113,"threshold_uncertainty_score":0.48335704},"labels":[],"label_agreement":null},{"id":"W4406869258","doi":"10.1200/jco.2025.43.4_suppl.tps847","title":"A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antibody-drug conjugate; Antibody; Conjugate; Cancer research; Monoclonal antibody; Internal medicine; Immunology","score_opus":0.07766651630289706,"score_gpt":0.5127989989166067,"score_spread":0.4351324826137097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474174,0.00014861819,0.00022762603,0.0017011362,0.00044785926,0.0023451052,0.000014689734,0.000021098795,0.00035214814],"genre_scores_gemma":[0.99353987,0.00005516205,0.00549463,0.00041151384,0.00025413043,0.000054988104,0.000015970207,0.000039087805,0.00013463985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99179107,0.0014305135,0.004396589,0.00054573745,0.0011773595,0.000658725],"domain_scores_gemma":[0.9928527,0.0015980231,0.0027684935,0.00044684936,0.0018378579,0.0004960769],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004974535,0.00033644232,0.002699789,0.0006815025,0.00010144045,0.000015952033,0.00042683296,0.00022845974,0.00011985806],"category_scores_gemma":[0.008105027,0.00025086667,0.00026549274,0.0009777154,0.00048087115,0.00025520942,0.00024743553,0.002353172,0.0000041953494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057774305,0.020478701,0.8752242,0.00025577605,0.00032422296,0.0016993635,0.00049746805,0.00044857533,0.0065752026,0.000015049617,0.0006584929,0.036048695],"study_design_scores_gemma":[0.109288156,0.11726509,0.763734,0.0049614473,0.00028094935,0.00011223031,0.0011387233,0.0010692251,0.0010019958,0.00015583861,0.0007243195,0.00026806278],"about_ca_topic_score_codex":0.00042318122,"about_ca_topic_score_gemma":0.0006728272,"teacher_disagreement_score":0.11149018,"about_ca_system_score_codex":0.0011110491,"about_ca_system_score_gemma":0.006100522,"threshold_uncertainty_score":0.99999434},"labels":[],"label_agreement":null},{"id":"W4406869295","doi":"10.1200/jco.2025.43.4_suppl.6","title":"GOBLET platform study: Preliminary safety and tumor response results for the relapsed anal carcinoma cohort in patients treated with pelareorep and atezolizumab.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Cohort; Oncology; Internal medicine; Carcinoma; Surgery; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.04289859851674939,"score_gpt":0.3750636194387777,"score_spread":0.3321650209220283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367446,0.00025998763,0.000006414951,0.004194954,0.00015885886,0.001067887,0.000017008524,0.0000054074326,0.000615034],"genre_scores_gemma":[0.9986974,0.000078696605,0.000114823226,0.0005856373,0.000102513884,0.000011098293,0.0000053604717,0.000009681137,0.00039477824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971166,0.00038727414,0.0017788799,0.00026905557,0.00023714046,0.00021102342],"domain_scores_gemma":[0.99240476,0.006128916,0.00072713627,0.00017443819,0.00037570536,0.00018905094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045321174,0.00015772624,0.001150547,0.00019143632,0.00010061876,0.000011421172,0.00010527059,0.00016637887,0.0000040578793],"category_scores_gemma":[0.0042292154,0.00008368894,0.00014344872,0.00024014451,0.00027512494,0.000077544755,0.000086444146,0.0007122555,3.1563388e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37987122,0.00086458836,0.60773844,0.000016979144,0.00018782968,0.00048888824,0.00017846686,0.00000259698,0.000003123105,0.000012329174,0.00037441208,0.010261117],"study_design_scores_gemma":[0.038708266,0.103377216,0.8537337,0.000117624564,0.000655805,0.00018049686,0.0006470756,0.00032812392,0.000005714063,0.000039671075,0.0021340167,0.0000722506],"about_ca_topic_score_codex":0.00007590943,"about_ca_topic_score_gemma":0.00022585632,"teacher_disagreement_score":0.34116298,"about_ca_system_score_codex":0.0001579172,"about_ca_system_score_gemma":0.0008225571,"threshold_uncertainty_score":0.5063071},"labels":[],"label_agreement":null},{"id":"W4406869302","doi":"10.1200/jco.2025.43.4_suppl.4","title":"Preliminary phase 1/1b dose expansion results of the bifunctional EGFR/TGFβ inhibitor ficerafusp alfa (BCA101) with pembrolizumab in patients with squamous cell carcinoma of the anal canal.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Basal cell; Oncology; Internal medicine; Anal canal; Bifunctional; Cancer research; Cancer; Immunotherapy; Rectum","score_opus":0.027988246278866424,"score_gpt":0.3403073014110149,"score_spread":0.31231905513214847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302053,0.00017986224,0.0000058709647,0.0033969297,0.0007183362,0.00041599324,0.000030590138,0.0000026523758,0.0022292251],"genre_scores_gemma":[0.99838483,0.000010016972,0.000109457025,0.00068379624,0.00027623374,0.0000042302386,0.0000064661517,0.00001214572,0.0005128148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996092,0.00051274494,0.002136429,0.00024876677,0.00078009296,0.00022994728],"domain_scores_gemma":[0.99536026,0.0013526053,0.0019473846,0.00033198766,0.00083902356,0.0001687401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011419674,0.0001894992,0.0010918657,0.00020738138,0.00006776745,0.0000041105977,0.00028404093,0.00027052165,0.000029674145],"category_scores_gemma":[0.001139705,0.000085825704,0.00041973853,0.0006230908,0.0004504684,0.00008083773,0.00013664713,0.0011978894,5.218546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22553585,0.011822046,0.74738526,0.00015086024,0.00013008557,0.00018228256,0.00027147273,0.00032131857,0.00033695175,0.00002545219,0.0042562513,0.009582188],"study_design_scores_gemma":[0.06254384,0.044619676,0.88933045,0.00032570882,0.0004630322,0.000059075006,0.00021881577,0.000182917,0.00079675857,0.000029671588,0.0013493513,0.000080728234],"about_ca_topic_score_codex":0.00042726533,"about_ca_topic_score_gemma":0.0010518959,"teacher_disagreement_score":0.16299202,"about_ca_system_score_codex":0.00022340332,"about_ca_system_score_gemma":0.003590915,"threshold_uncertainty_score":0.6370129},"labels":[],"label_agreement":null},{"id":"W4406869312","doi":"10.1200/jco.2025.43.4_suppl.448","title":"Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Pembrolizumab; Medicine; Trastuzumab; Metastatic melanoma; Cancer research; Gemcitabine; Nivolumab; Internal medicine; Oncology; Cancer; Immunotherapy; Melanoma","score_opus":0.0508744364437234,"score_gpt":0.3738558524944282,"score_spread":0.3229814160507048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98243403,0.002945381,0.0018225403,0.010148427,0.0009924085,0.0012344435,0.00011911563,0.000029284774,0.00027439182],"genre_scores_gemma":[0.99075574,0.0015245891,0.0051827105,0.0012729379,0.0004940641,0.000041995812,0.000111917376,0.000045300734,0.0005707378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931179,0.00081601826,0.0039243614,0.0006927155,0.00082250114,0.00062647654],"domain_scores_gemma":[0.99161834,0.0037518071,0.0030181427,0.00044868697,0.0008054236,0.00035757973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023206768,0.00051771244,0.0025244092,0.0006955593,0.00016214284,0.000041497155,0.00042995292,0.00031030277,0.00015212025],"category_scores_gemma":[0.0026185089,0.00033097714,0.00036461517,0.0015971297,0.00046659794,0.00033812854,0.00016099609,0.0016105059,0.0000034548777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.109211646,0.0027650401,0.73941827,0.000188775,0.0014326323,0.0020497101,0.0004931301,0.0013950444,0.0000610481,0.000060012782,0.005734584,0.13719013],"study_design_scores_gemma":[0.06293907,0.019745255,0.91069245,0.0006302384,0.0022188574,0.00033069754,0.000636631,0.0016528709,0.00011564597,0.00024509156,0.00060356315,0.0001896364],"about_ca_topic_score_codex":0.0012178675,"about_ca_topic_score_gemma":0.002696636,"teacher_disagreement_score":0.1712742,"about_ca_system_score_codex":0.00086296006,"about_ca_system_score_gemma":0.0022681665,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W4406869333","doi":"10.1200/jco.2025.43.4_suppl.562","title":"A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Low and middle income countries; High income countries; Environmental health; Oncology; Developing country; Internal medicine; Economic growth","score_opus":0.0887043784128009,"score_gpt":0.49923762308673525,"score_spread":0.41053324467393437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98505783,0.0037469552,0.000037634007,0.008415048,0.0007101159,0.0007336604,0.0000050526655,0.0000031288744,0.0012905627],"genre_scores_gemma":[0.9926923,0.004324263,0.0009169486,0.001842499,0.00016017257,0.000012342584,5.030647e-7,0.000004649521,0.000046345733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963392,0.0010593345,0.0018532862,0.0002354401,0.00031814005,0.00019458552],"domain_scores_gemma":[0.9918077,0.0058919624,0.0018363644,0.00020363911,0.00018392727,0.00007640595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049052304,0.00016875555,0.0015955011,0.00017114646,0.000059717444,0.000012255835,0.00022294208,0.00027485305,0.0000103800985],"category_scores_gemma":[0.0005371791,0.000104345294,0.00008536559,0.00027742007,0.0008379126,0.00013247924,0.000073470896,0.0008396151,9.2707336e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01133044,0.001903597,0.9751566,0.0003399549,0.0005131574,0.0021302844,0.001216542,0.0000326572,4.312773e-7,0.006766912,0.000045294844,0.0005641527],"study_design_scores_gemma":[0.014208706,0.012195599,0.96018374,0.00093692547,0.00033639156,0.0001518154,0.0051201447,0.00020476952,0.0000034532861,0.0023498868,0.0042295894,0.00007896004],"about_ca_topic_score_codex":0.000047628986,"about_ca_topic_score_gemma":0.00030745086,"teacher_disagreement_score":0.014972818,"about_ca_system_score_codex":0.00023957457,"about_ca_system_score_gemma":0.00054868945,"threshold_uncertainty_score":0.42550775},"labels":[],"label_agreement":null},{"id":"W4406869349","doi":"10.1200/jco.2025.43.4_suppl.83","title":"Annual incidence of colorectal cancer among patients with average risk in the United States between 2017 and 2023.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Exact Sciences Corporation","keywords":"Medicine; Colorectal cancer; Incidence (geometry); Cancer; Internal medicine; Oncology; Demography","score_opus":0.03909041785181567,"score_gpt":0.4091120522269175,"score_spread":0.3700216343751018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807376,0.00018687692,0.0001318218,0.00081735273,0.00025553477,0.00018081846,0.000036063706,0.0000030041676,0.00031476494],"genre_scores_gemma":[0.9986915,0.0006159597,0.00019088911,0.00032324434,0.00012880335,0.0000044880153,0.000004167687,0.0000038106225,0.000037127596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806553,0.0004704883,0.0009766978,0.000116474585,0.00025160515,0.00011922189],"domain_scores_gemma":[0.99558634,0.0027177064,0.0010488983,0.00008172872,0.00047929038,0.00008604039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021191083,0.00008164261,0.0006969601,0.0002045269,0.00003898982,0.0000043988616,0.00010713957,0.0001761288,0.000010150052],"category_scores_gemma":[0.0019109148,0.000046036334,0.00008523734,0.0004010839,0.00029000125,0.00008432784,0.000038483806,0.0009090372,2.6086153e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011114406,0.00021215805,0.95839405,0.000016624197,0.00014580613,0.000040187708,0.00042445216,0.00018159009,0.0000013364083,0.0000017758966,0.0007508279,0.028716777],"study_design_scores_gemma":[0.004899552,0.017408518,0.97462934,0.00020683541,0.00024609765,0.000011331421,0.00027552078,0.0002802272,0.00002350588,0.00008315595,0.0018935998,0.0000423031],"about_ca_topic_score_codex":0.0020419818,"about_ca_topic_score_gemma":0.0019322085,"teacher_disagreement_score":0.028674474,"about_ca_system_score_codex":0.00008185011,"about_ca_system_score_gemma":0.0005415936,"threshold_uncertainty_score":0.39493647},"labels":[],"label_agreement":null},{"id":"W4406869384","doi":"10.1200/jco.2025.43.4_suppl.828","title":"A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Claudin; Internal medicine; Oncology; Cancer research; Intensive care medicine; Tight junction; Genetics","score_opus":0.12147040642942414,"score_gpt":0.550833310599996,"score_spread":0.4293629041705718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393815,0.00037697374,0.0001393684,0.0028864073,0.00019731035,0.00089989754,0.0000011737316,0.000004860443,0.001555835],"genre_scores_gemma":[0.9967265,0.00026864847,0.0019861285,0.00056058227,0.00009511846,0.000005861714,5.000204e-7,0.000012159871,0.00034446185],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944778,0.0016740724,0.0027299048,0.00025464356,0.0005828603,0.00028069242],"domain_scores_gemma":[0.98793733,0.009678212,0.0013574992,0.00029556797,0.00052839273,0.00020302061],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0088492595,0.0001407483,0.0017721951,0.00026358172,0.00005375014,0.0000072001744,0.00023765797,0.00017302638,0.00007034732],"category_scores_gemma":[0.011348094,0.000078063305,0.00017222154,0.00048173638,0.00040810276,0.000043744465,0.00015230081,0.0016040647,0.0000024306491],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14109357,0.024205297,0.07700201,0.00015606462,0.00066658773,0.0036353841,0.00090192864,0.00076028926,0.0350948,0.000037992555,0.0005575628,0.7158885],"study_design_scores_gemma":[0.13029179,0.21944144,0.6376555,0.0007069018,0.0006183574,0.0003408668,0.0020688884,0.0037937164,0.0030324082,0.00013447543,0.0017687683,0.0001468913],"about_ca_topic_score_codex":0.000018079796,"about_ca_topic_score_gemma":0.00006903469,"teacher_disagreement_score":0.71574163,"about_ca_system_score_codex":0.00013796295,"about_ca_system_score_gemma":0.0029028566,"threshold_uncertainty_score":0.9969797},"labels":[],"label_agreement":null},{"id":"W4406869526","doi":"10.1200/jco.2025.43.4_suppl.275","title":"Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; St. Paul's Hospital; Providence Health Care; BC Cancer Agency; Genome British Columbia; Pancreas Centre (Canada); University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Interim; Cancer; Oncology; Internal medicine; Disease; Interim analysis; Minimal residual disease; Clinical trial","score_opus":0.15195065182303563,"score_gpt":0.500567202377146,"score_spread":0.3486165505541104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90087533,0.00013713041,0.09372326,0.00293748,0.0019863017,0.0002417622,0.000016696174,0.00000789603,0.00007416996],"genre_scores_gemma":[0.9895933,0.000021751857,0.009552429,0.00040260836,0.0004138328,0.0000041532226,0.0000014297651,0.000007574482,0.0000029085102],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99008423,0.00661687,0.002153139,0.00037850023,0.00055536925,0.00021189263],"domain_scores_gemma":[0.9814,0.016105551,0.0014534002,0.00028512685,0.00062078296,0.00013512372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00977871,0.00015365603,0.0006936511,0.00015339997,0.00012381049,0.00009098508,0.000901359,0.00014274848,0.0000035485996],"category_scores_gemma":[0.006905007,0.0000977593,0.00028393598,0.0005228377,0.00023072638,0.00045115352,0.00029243767,0.0010362734,5.1503986e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031902622,0.005886744,0.017324314,0.000022879958,0.0014979047,0.0045951055,0.01414337,0.52844316,0.032982126,0.0013233286,0.00008026376,0.36179817],"study_design_scores_gemma":[0.0062379357,0.0029619662,0.67534393,0.0002908523,0.00033284817,0.000078047095,0.0027112658,0.30046192,0.008477774,0.0027074146,0.00016447088,0.00023155547],"about_ca_topic_score_codex":0.0006080039,"about_ca_topic_score_gemma":0.00057185034,"teacher_disagreement_score":0.6580196,"about_ca_system_score_codex":0.00026426557,"about_ca_system_score_gemma":0.0019072935,"threshold_uncertainty_score":0.82664376},"labels":[],"label_agreement":null},{"id":"W4406869575","doi":"10.1200/jco.2025.43.4_suppl.304","title":"Impact of synchronous vs metachronous primary tumor resection on prognosis of BRAF-V600E mutant metastatic colorectal cancer (mCRC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Primary tumor; Resection; Mutant; Internal medicine; Cancer; Cancer research; Metastasis; Surgery; Gene","score_opus":0.07063328580657878,"score_gpt":0.4766317012106454,"score_spread":0.4059984154040666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906236,0.0027397743,0.000026676329,0.001424079,0.0010481563,0.00055996055,0.00003448484,0.000008359895,0.0035349068],"genre_scores_gemma":[0.9968303,0.0017055643,0.0006796009,0.0003611147,0.000267343,0.000036963585,0.0000027364151,0.000015614902,0.00010078798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961443,0.0004117195,0.0025180078,0.00024231435,0.00041870988,0.0002649262],"domain_scores_gemma":[0.9943495,0.0022334736,0.002270894,0.0001582583,0.00080907287,0.00017880577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014755299,0.00022232709,0.0028837174,0.00031053985,0.000053770676,0.0000049788237,0.00014210443,0.00015415884,0.00017922236],"category_scores_gemma":[0.0018770617,0.00013680833,0.0011565483,0.00038857412,0.00036938715,0.00007741796,0.000069695394,0.0006449128,0.0000019158665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12009858,0.017692951,0.54570353,0.000734515,0.020060686,0.0010372252,0.00043813203,0.00033788788,0.0070098047,0.00007733601,0.004232431,0.28257692],"study_design_scores_gemma":[0.00954243,0.1074133,0.8740827,0.0004980247,0.0029477368,0.00017450198,0.00010316777,0.000083869585,0.0039370293,0.000103771024,0.0010166863,0.00009678604],"about_ca_topic_score_codex":0.00047685986,"about_ca_topic_score_gemma":0.00036667212,"teacher_disagreement_score":0.32837918,"about_ca_system_score_codex":0.0012419585,"about_ca_system_score_gemma":0.0051265066,"threshold_uncertainty_score":0.9094202},"labels":[],"label_agreement":null},{"id":"W4406869603","doi":"10.1200/jco.2025.43.4_suppl.559","title":"Germline pathogenic variants in a cohort of individuals with biliary tract cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Medicine; Biliary tract cancer; Germline; Cohort; Biliary tract; Cancer; Internal medicine; Oncology; Genetics; Gene; Biology","score_opus":0.07241952556546814,"score_gpt":0.4479410488344308,"score_spread":0.37552152326896265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814802,0.0048759244,0.00003634206,0.009484846,0.0006333731,0.00023446986,0.0000120145605,0.0000039999204,0.0032388538],"genre_scores_gemma":[0.9935094,0.0028361764,0.0011594675,0.0018819761,0.0003657559,0.000009662213,0.0000014350649,0.000008580775,0.00022752743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970104,0.00023741036,0.0020990015,0.00017845603,0.0002869521,0.00018774455],"domain_scores_gemma":[0.99699646,0.0012324986,0.0011175764,0.0001726079,0.0003497149,0.00013112271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025933462,0.00012122894,0.0018262949,0.0002450517,0.000017294942,0.000002840799,0.0001392597,0.00024201864,0.00007797408],"category_scores_gemma":[0.0010624464,0.00007744176,0.00031111014,0.00036637252,0.00024782063,0.00006303268,0.00004862828,0.0008031948,0.0000010913428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023151443,0.0014859546,0.94897574,0.00006554996,0.0008801668,0.00068235694,0.00012879235,0.000008184571,0.00013844337,0.000037184614,0.002401961,0.042880528],"study_design_scores_gemma":[0.008986391,0.004587833,0.97744304,0.00043472036,0.00084540667,0.00017081892,0.00011662645,0.000012196656,0.00005030354,0.00015909948,0.007130657,0.00006288308],"about_ca_topic_score_codex":0.000096385214,"about_ca_topic_score_gemma":0.00029317001,"teacher_disagreement_score":0.042817645,"about_ca_system_score_codex":0.00013291089,"about_ca_system_score_gemma":0.0032150222,"threshold_uncertainty_score":0.57033116},"labels":[],"label_agreement":null},{"id":"W4406869644","doi":"10.1200/jco.2025.43.4_suppl.765","title":"Clinical and genomic features of the morphological subtypes in advanced pancreatic cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Medicine; Pancreatic cancer; Cancer; Internal medicine; Oncology; Pathology; Cancer research","score_opus":0.03474538900310452,"score_gpt":0.4194348479592539,"score_spread":0.38468945895614937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875905,0.0076896786,0.000036702728,0.0023868044,0.0012903422,0.000112953414,0.000008314233,7.736737e-7,0.000883938],"genre_scores_gemma":[0.97924066,0.01724968,0.00096938445,0.001978342,0.00036726505,0.0000035630635,9.2078096e-7,0.000005607979,0.00018459544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977771,0.00034558252,0.0014769154,0.00018681558,0.00007787145,0.00013572282],"domain_scores_gemma":[0.99782455,0.0009531854,0.0008028698,0.00019797502,0.00014194663,0.00007948913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015945717,0.000093326904,0.00073293503,0.000038307768,0.000023231389,0.000004968517,0.00028197747,0.0003781301,0.000008660088],"category_scores_gemma":[0.0039539337,0.000059485064,0.0002813348,0.00008539615,0.0004346961,0.000002605263,0.00020008533,0.00047579833,2.8423068e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002013155,0.00036888933,0.8717982,0.00001804848,0.0001513349,0.000024911395,0.000011448139,0.00020126058,0.009906322,0.00036382425,0.003381125,0.11176148],"study_design_scores_gemma":[0.0026261283,0.0017251071,0.95676935,0.000054529333,0.000092079266,0.000027338181,0.000037271486,0.000011084111,0.0010916693,0.0009273976,0.036576286,0.000061784245],"about_ca_topic_score_codex":0.00004194195,"about_ca_topic_score_gemma":0.00046496454,"teacher_disagreement_score":0.11169969,"about_ca_system_score_codex":0.000025142315,"about_ca_system_score_gemma":0.0011000506,"threshold_uncertainty_score":0.4733514},"labels":[],"label_agreement":null},{"id":"W4406869652","doi":"10.1200/jco.2025.43.4_suppl.296","title":"Effect of changes in body composition and sociodemographic factors on colon cancer survival.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Cancer survival; Internal medicine; Oncology","score_opus":0.15819367934431947,"score_gpt":0.5602103403032592,"score_spread":0.40201666095893973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97345656,0.0006650399,0.0000071660224,0.023964431,0.0010864001,0.00017594927,0.0000023621012,0.0000034745838,0.0006386358],"genre_scores_gemma":[0.9936713,0.0036319306,0.00006602299,0.0023944315,0.00019919407,0.0000033162805,0.0000013011866,0.0000037666985,0.000028726337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998052,0.0006862304,0.0009257099,0.00008712999,0.00014027065,0.00010865099],"domain_scores_gemma":[0.9952492,0.0038753855,0.0005938078,0.000050886018,0.00011885882,0.00011184264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032115155,0.00006746583,0.001051776,0.0002812678,0.000023722127,0.0000018438179,0.000039257964,0.00024023351,0.000027700222],"category_scores_gemma":[0.0005862266,0.000046828925,0.00012551344,0.00014868256,0.00013091383,0.000019379851,0.000013311081,0.0006778031,3.1860793e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005619378,0.0006335343,0.959708,0.00041137065,0.00009160935,0.00004021258,0.00005207406,0.0000015655646,0.0012723969,0.00018920195,0.00078261155,0.031198082],"study_design_scores_gemma":[0.010048336,0.01568474,0.9655666,0.0010420734,0.00017085228,0.0000082241,0.00004735429,0.000044668268,0.001849923,0.00017571622,0.005323617,0.00003793091],"about_ca_topic_score_codex":0.000027900467,"about_ca_topic_score_gemma":0.00012334451,"teacher_disagreement_score":0.031160152,"about_ca_system_score_codex":0.00008817712,"about_ca_system_score_gemma":0.00026888857,"threshold_uncertainty_score":0.2944755},"labels":[],"label_agreement":null},{"id":"W4406869677","doi":"10.1200/jco.2025.43.4_suppl.708","title":"Disease-free survival as a surrogate endpoint for overall survival in adults with early-stage pancreatic cancer: A trial-level surrogacy analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Dr. Georges-L.-Dumont University Hospital Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Surrogate endpoint; Stage (stratigraphy); Disease; Clinical endpoint; Oncology; Overall survival; Internal medicine; Cancer; Survival analysis; Randomized controlled trial","score_opus":0.14948804628873166,"score_gpt":0.49471243520440245,"score_spread":0.34522438891567075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795195,0.0006313285,0.0010378662,0.012193381,0.0010363907,0.0016654214,0.00011464884,0.000016372811,0.0037851096],"genre_scores_gemma":[0.98626256,0.002345988,0.0028404035,0.0010993266,0.0008266996,0.00017746561,0.000024969379,0.00003168804,0.0063909115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926738,0.0016318429,0.0035635845,0.0005319855,0.0008878237,0.00071093324],"domain_scores_gemma":[0.98194385,0.013678271,0.0017157567,0.000667845,0.0011194719,0.0008748371],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009964676,0.0003257101,0.0050833565,0.000798765,0.000085053434,0.000025574125,0.0005325662,0.00050191017,0.00035296055],"category_scores_gemma":[0.01899965,0.00022370208,0.0012274047,0.0009333789,0.00046405388,0.00015623048,0.00015134973,0.0013805409,0.0000074533596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35792166,0.0022778532,0.6296982,0.00019033047,0.0040260744,0.0010793629,0.000111333626,0.000043682216,0.0000027360554,0.0012061881,0.0005219454,0.0029205927],"study_design_scores_gemma":[0.18226443,0.014275833,0.7890404,0.00045978435,0.0057965983,0.00000934,0.00023671036,0.0009850892,0.0000028784182,0.0012682818,0.005493994,0.00016669488],"about_ca_topic_score_codex":0.002195538,"about_ca_topic_score_gemma":0.008612061,"teacher_disagreement_score":0.17565723,"about_ca_system_score_codex":0.0005502559,"about_ca_system_score_gemma":0.011505594,"threshold_uncertainty_score":0.99409825},"labels":[],"label_agreement":null},{"id":"W4406869684","doi":"10.1200/jco.2025.43.4_suppl.106","title":"Frequency of surveillance CT scan ordering in patients with stage II/III colorectal cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Stage (stratigraphy); Colorectal cancer; Cancer; Radiology; Computed tomography; Oncology; Internal medicine","score_opus":0.024111992701773076,"score_gpt":0.41852142187774644,"score_spread":0.3944094291759734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913108,0.00027078137,0.00017036663,0.0036409125,0.0008725428,0.00014561077,0.0000025439292,0.0000051274965,0.0035813153],"genre_scores_gemma":[0.99634886,0.0002903325,0.002234184,0.0007712382,0.00016445933,0.0000021311012,0.0000017827665,0.000009658549,0.00017737657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974733,0.00021899318,0.0016728186,0.00014820187,0.00028802405,0.00019864312],"domain_scores_gemma":[0.9973259,0.00092640385,0.0011353764,0.00010617151,0.00034225677,0.00016390435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002347587,0.00010234135,0.0012749454,0.00017606985,0.000031811505,0.0000035328,0.00015515092,0.000105429644,0.000084560976],"category_scores_gemma":[0.003532506,0.00006972486,0.00014727545,0.0002827305,0.00024798652,0.00006605493,0.000053214873,0.0012210852,3.4650046e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014915614,0.00075746916,0.931172,0.000043950273,0.00016512832,0.00013943367,0.00004378103,0.00017200442,0.0001059189,0.00008114632,0.00029797727,0.065529615],"study_design_scores_gemma":[0.012256563,0.003847253,0.97892666,0.0003802203,0.000060246428,0.000012264508,0.00003365649,0.0004602007,0.000037766247,0.000058996702,0.003865443,0.00006074413],"about_ca_topic_score_codex":0.00038870322,"about_ca_topic_score_gemma":0.00036332593,"teacher_disagreement_score":0.06546887,"about_ca_system_score_codex":0.00017896952,"about_ca_system_score_gemma":0.0018892699,"threshold_uncertainty_score":0.53050756},"labels":[],"label_agreement":null},{"id":"W4406869712","doi":"10.1200/jco.2025.43.4_suppl.493","title":"The immunogenomic landscape of primary and metastatic gastroesophageal adenocarcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Toronto General Hospital; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Physicians' Services Incorporated Foundation","keywords":"Medicine; Metastatic adenocarcinoma; Adenocarcinoma; Internal medicine; Oncology; Pathology; Cancer","score_opus":0.0894408982728937,"score_gpt":0.4215081549053511,"score_spread":0.3320672566324574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342442,0.055255424,0.000082680075,0.0043314565,0.00066847535,0.0001378246,0.0000036117378,0.0000023649532,0.005273955],"genre_scores_gemma":[0.9913958,0.004997127,0.0019558263,0.0009942828,0.00022785213,0.000002098284,8.2420235e-7,0.0000060998427,0.00042014656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708956,0.0004182889,0.0020007412,0.00011552866,0.00020930059,0.00016659718],"domain_scores_gemma":[0.99540275,0.0028801083,0.0010910764,0.00018463939,0.00032264803,0.00011880179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004198773,0.00010265883,0.0014618102,0.000095458425,0.00007613603,0.0000073687297,0.00012586974,0.000078190824,0.000028876313],"category_scores_gemma":[0.0017526208,0.00005445168,0.00039791808,0.00011032921,0.0003912452,0.00003501406,0.000105901956,0.0005132337,0.0000018864973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008686822,0.00094914675,0.56585914,0.00025950265,0.0035212396,0.0009429047,0.00014484893,0.0000019877434,0.00089248014,0.0021024968,0.016877607,0.39976186],"study_design_scores_gemma":[0.0052863397,0.0046988456,0.9667507,0.00006771484,0.0012954936,0.0005272951,0.00046549094,0.000019956893,0.000077779216,0.00036705929,0.020407233,0.000036083562],"about_ca_topic_score_codex":0.0000040415443,"about_ca_topic_score_gemma":0.0000055767205,"teacher_disagreement_score":0.4008916,"about_ca_system_score_codex":0.00004129051,"about_ca_system_score_gemma":0.0011106852,"threshold_uncertainty_score":0.22297736},"labels":[],"label_agreement":null},{"id":"W4406869723","doi":"10.1200/jco.2025.43.4_suppl.lba248","title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Merck","keywords":"Medicine; Pembrolizumab; Colorectal cancer; Oncology; Internal medicine; Standard of care; Cancer; Immunotherapy","score_opus":0.06375081820030999,"score_gpt":0.49278144716634126,"score_spread":0.4290306289660313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835267,0.007880615,0.000045635286,0.0018100968,0.0013566293,0.0027029617,0.000052546802,0.0000118601065,0.0026129773],"genre_scores_gemma":[0.99408746,0.0048366343,0.00013478554,0.0005692991,0.00015892106,0.00007055526,0.000013603903,0.000018946643,0.00010977225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930937,0.0018554602,0.0039050106,0.00025440313,0.0005372554,0.00035414443],"domain_scores_gemma":[0.98951364,0.007148196,0.0022064978,0.00022977775,0.00074406894,0.00015782488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005933662,0.00027195088,0.003969336,0.00032353456,0.00008786789,0.000016537015,0.00029443458,0.00027716655,0.00018804148],"category_scores_gemma":[0.0025720298,0.00015296953,0.0011679741,0.0005468669,0.00065122393,0.000110316556,0.000040624403,0.001099453,0.0000018146889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86564523,0.0021494878,0.0024476266,0.00007066214,0.0048956685,0.00044577205,0.0019199529,0.00003882053,0.0001425565,0.000025969148,0.00041884097,0.12179944],"study_design_scores_gemma":[0.8946962,0.078624904,0.012569436,0.00051250693,0.0039808415,0.00008541623,0.0037661914,0.00029064005,0.0011682973,0.000037308502,0.0041240784,0.00014419087],"about_ca_topic_score_codex":0.00042400265,"about_ca_topic_score_gemma":0.0012800957,"teacher_disagreement_score":0.12165525,"about_ca_system_score_codex":0.0013008405,"about_ca_system_score_gemma":0.0051540835,"threshold_uncertainty_score":0.91431224},"labels":[],"label_agreement":null},{"id":"W4406869831","doi":"10.1200/jco.2025.43.4_suppl.lba143","title":"First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Microsatellite instability; Colorectal cancer; Internal medicine; Oncology; Cancer; Immunotherapy; Microsatellite","score_opus":0.07950483723928436,"score_gpt":0.43114497227115217,"score_spread":0.3516401350318678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97998714,0.004268559,0.0008771033,0.006353196,0.0058721746,0.0014986343,0.00042729836,0.000052179686,0.00066370744],"genre_scores_gemma":[0.9658333,0.0030253937,0.027556067,0.0018559996,0.00067765586,0.00009083533,0.000032228698,0.000067178495,0.00086135766],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99106085,0.00067784626,0.0060385843,0.00081238156,0.0007456417,0.00066471176],"domain_scores_gemma":[0.9866675,0.0070525045,0.0035209425,0.0006984535,0.0016260601,0.00043450168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046691843,0.00048154127,0.0038713627,0.00033272765,0.00013756762,0.000024281271,0.00057668425,0.00076649507,0.00030517625],"category_scores_gemma":[0.0053887935,0.00038539374,0.001585786,0.0005558812,0.00080439553,0.000121043035,0.00017049824,0.0013124626,0.000008033972],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66960156,0.01467776,0.082387865,0.0025055315,0.011595996,0.0005398232,0.0057766857,0.0066351225,0.042612284,0.0004038052,0.042478345,0.120785214],"study_design_scores_gemma":[0.1655144,0.058968212,0.3213464,0.0032574106,0.0053030327,0.00016430153,0.0013336,0.007817913,0.058974236,0.0054605533,0.37069425,0.0011657089],"about_ca_topic_score_codex":0.0014590127,"about_ca_topic_score_gemma":0.0030454388,"teacher_disagreement_score":0.50408715,"about_ca_system_score_codex":0.0016207491,"about_ca_system_score_gemma":0.0063247834,"threshold_uncertainty_score":0.9998598},"labels":[],"label_agreement":null},{"id":"W4406869837","doi":"10.1200/jco.2025.43.4_suppl.11","title":"Personalized oncogenomic analysis of metastatic squamous cell carcinoma of the anus: Utilizing whole-genome sequencing to guide clinical decision-making.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Basal cell; Oncology; Anus; DNA sequencing; Genome; Internal medicine; Personalized medicine; Pathology; Bioinformatics; Gene; Surgery; Genetics; Biology","score_opus":0.11298974737087061,"score_gpt":0.46029283284042005,"score_spread":0.34730308546954947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959297,0.0014023335,0.0010808674,0.0021718128,0.0009134492,0.000313179,0.00003196356,0.0000053542585,0.0044880533],"genre_scores_gemma":[0.9888076,0.00006522534,0.0072757374,0.0030455203,0.00028134286,0.000002560139,0.0000025016768,0.000016408643,0.0005030608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911542,0.0010790857,0.0064093303,0.00037923627,0.000652913,0.000325243],"domain_scores_gemma":[0.98305005,0.011653008,0.003302612,0.00051888125,0.0011131149,0.000362341],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008037423,0.00023375437,0.003826846,0.0007624525,0.00007721268,0.000009068433,0.0006189728,0.00030798747,0.00017066978],"category_scores_gemma":[0.014599618,0.00014712899,0.0033875012,0.0016774685,0.0005122491,0.00007126771,0.00031349028,0.0010777689,0.000005912137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020809589,0.0041370736,0.8161455,0.00040839674,0.0060666497,0.0013658318,0.0015754688,0.0018674361,0.025729582,0.00042571756,0.0026126974,0.11885611],"study_design_scores_gemma":[0.008026257,0.011038264,0.9359315,0.00037978886,0.016610201,0.00014428941,0.0027402341,0.0022298028,0.00039700503,0.00061889255,0.021672811,0.00021095705],"about_ca_topic_score_codex":0.00008153405,"about_ca_topic_score_gemma":0.00022265388,"teacher_disagreement_score":0.11978605,"about_ca_system_score_codex":0.00046272745,"about_ca_system_score_gemma":0.0048384345,"threshold_uncertainty_score":0.9937008},"labels":[],"label_agreement":null},{"id":"W4406869847","doi":"10.1200/jco.2025.43.4_suppl.614","title":"Evaluating the safety of immune checkpoint inhibitors prior to liver transplant.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Immune system; Oncology; Cancer research; Intensive care medicine; Immunology","score_opus":0.15400404904907802,"score_gpt":0.516895985665552,"score_spread":0.3628919366164739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799376,0.000603793,0.00080711016,0.013475822,0.0010903765,0.00034956273,0.000005767272,0.0000042923816,0.003725684],"genre_scores_gemma":[0.9909832,0.0010767018,0.0054991925,0.0014954198,0.00020947793,0.000002619012,0.0000018440654,0.000006136963,0.0007253962],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99629474,0.00033200558,0.002824061,0.00010651963,0.00031541337,0.00012727822],"domain_scores_gemma":[0.9958238,0.0026232724,0.00095712655,0.00014727036,0.00031688437,0.00013166745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037964876,0.00009493403,0.0009863557,0.00010097503,0.000046082587,0.0000034529778,0.00013226827,0.00015728625,0.00010067362],"category_scores_gemma":[0.0012108369,0.000049324175,0.0006657209,0.00017785253,0.00009456722,0.000037782243,0.000016912403,0.00048562014,0.000010368675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044022284,0.0031752177,0.2419958,0.0005167039,0.0033619434,0.0008031159,0.0016330045,0.00036911078,0.007954816,0.00085748377,0.00031210962,0.69499844],"study_design_scores_gemma":[0.013405002,0.012317307,0.96032315,0.0015155743,0.0015626554,0.0002404249,0.00013558849,0.00017251258,0.0038042082,0.0001565152,0.0063016913,0.00006535899],"about_ca_topic_score_codex":0.000026049509,"about_ca_topic_score_gemma":0.000012782281,"teacher_disagreement_score":0.71832734,"about_ca_system_score_codex":0.00007142956,"about_ca_system_score_gemma":0.0008942681,"threshold_uncertainty_score":0.21098049},"labels":[],"label_agreement":null},{"id":"W4406869928","doi":"10.1200/jco.2025.43.4_suppl.20","title":"Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen's University; St. Paul's Hospital; Providence Health Care","funders":"","keywords":"Medicine; Colorectal cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Surgery","score_opus":0.12272753292542722,"score_gpt":0.5052444617822754,"score_spread":0.38251692885684824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97802943,0.000104587576,0.00056190597,0.01842973,0.001034669,0.0013128513,0.0000041315916,0.000009519894,0.00051318173],"genre_scores_gemma":[0.9927658,0.0006500342,0.0015714692,0.0042867893,0.00050091045,0.00007460474,0.0000036076876,0.000015227611,0.00013154351],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99592,0.0006306561,0.0023186207,0.00033758243,0.00054764136,0.00024547626],"domain_scores_gemma":[0.9920338,0.0062697968,0.0009135216,0.0002478503,0.00037712793,0.00015795032],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004263435,0.00018964242,0.0011093995,0.0003420517,0.00009083596,0.000026975411,0.00023851212,0.00035013692,0.00013345972],"category_scores_gemma":[0.018758789,0.00012633526,0.00020468836,0.0008517014,0.00008458846,0.00031616923,0.00010660983,0.0008683441,0.0000029229593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2917987,0.0030091417,0.035428792,0.000020740472,0.00012998472,0.00033966036,0.00096746674,0.0000808659,0.0014476805,0.00002798447,0.0013798879,0.6653691],"study_design_scores_gemma":[0.25774902,0.066334054,0.655574,0.0006312467,0.00019785142,0.000117576725,0.0004164432,0.0008622776,0.0016907866,0.005275155,0.010978107,0.00017344215],"about_ca_topic_score_codex":0.00035206435,"about_ca_topic_score_gemma":0.004082102,"teacher_disagreement_score":0.66519564,"about_ca_system_score_codex":0.0008597977,"about_ca_system_score_gemma":0.0020142577,"threshold_uncertainty_score":0.9895066},"labels":[],"label_agreement":null},{"id":"W4406869966","doi":"10.1200/jco.2025.43.4_suppl.730","title":"GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; FOLFIRINOX; Pancreatic ductal adenocarcinoma; Atezolizumab; Oncology; Internal medicine; Adenocarcinoma; Pancreatic cancer; Oxaliplatin; Cancer; Colorectal cancer; Immunotherapy","score_opus":0.11230884895115457,"score_gpt":0.44906849036059304,"score_spread":0.3367596414094385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98820347,0.00025596927,0.0002436437,0.0055564493,0.00034033958,0.002359815,0.00004821846,0.000007712584,0.0029844018],"genre_scores_gemma":[0.9963907,0.00024632452,0.0015679871,0.00040380305,0.00014942138,0.00005520566,0.000014956617,0.000022351947,0.0011492469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929124,0.0012147638,0.0043889103,0.00038119926,0.0006413095,0.0004614112],"domain_scores_gemma":[0.98757976,0.008248937,0.002147379,0.0005264807,0.0012365849,0.00026084267],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005093195,0.000265108,0.0032718764,0.00032751093,0.00011441117,0.00000774971,0.00043582113,0.00031724822,0.000031416108],"category_scores_gemma":[0.011902458,0.00014379201,0.0005285653,0.0006273652,0.0005305324,0.00008394712,0.00013539927,0.0010499842,0.0000026752664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07398245,0.0076944255,0.9096887,0.000165131,0.0018079927,0.0003406251,0.00030149537,0.00009173832,0.000006410484,0.00013307077,0.00097372156,0.004814224],"study_design_scores_gemma":[0.0706878,0.04289477,0.88004524,0.0004302784,0.0028971548,0.00008465492,0.00036512886,0.0010795709,0.000021451617,0.00048234695,0.00090691785,0.00010468481],"about_ca_topic_score_codex":0.0002500593,"about_ca_topic_score_gemma":0.00087585737,"teacher_disagreement_score":0.035200343,"about_ca_system_score_codex":0.00040476114,"about_ca_system_score_gemma":0.0030118881,"threshold_uncertainty_score":0.9964207},"labels":[],"label_agreement":null},{"id":"W4406869988","doi":"10.1200/jco.2025.43.4_suppl.253","title":"Real-world analysis of the impact of timing of biomarker testing on first-line treatment choice in patients with metastatic colorectal cancer in British Columbia.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Biomarker; Cancer; Internal medicine","score_opus":0.4639699047459582,"score_gpt":0.5545634519175991,"score_spread":0.09059354717164098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973116,0.00014744113,0.000014400931,0.0010850927,0.00022267025,0.00037081755,0.00022073294,0.0000011235672,0.00062613847],"genre_scores_gemma":[0.99899524,0.000119521064,0.0005816843,0.00019595958,0.00003074649,0.000012213013,0.0000031220256,0.000007530483,0.00005397735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903797,0.0007163766,0.008420299,0.00020331856,0.00010291866,0.00017737647],"domain_scores_gemma":[0.97801566,0.011546476,0.009926147,0.00018114825,0.00025935777,0.0000712189],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011275885,0.00009132197,0.0029027064,0.0006200434,0.00003198645,0.000010378601,0.00020238073,0.000108626125,0.00013043848],"category_scores_gemma":[0.012678895,0.00009035323,0.00043599043,0.0013716624,0.00013612716,0.000101265636,0.000030708532,0.00022922135,7.074996e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026703984,0.0016253047,0.97408205,0.000062006206,0.0014104603,0.0000017798045,0.000088752386,0.016391356,4.624927e-7,0.000018212133,0.00019082295,0.0058617466],"study_design_scores_gemma":[0.004596911,0.0024494373,0.9819718,0.00038202523,0.00019923723,3.4408794e-7,0.000044052187,0.010056395,9.0346487e-7,0.00016862211,0.00006817928,0.00006208875],"about_ca_topic_score_codex":0.16887753,"about_ca_topic_score_gemma":0.62948936,"teacher_disagreement_score":0.46061185,"about_ca_system_score_codex":0.0013243998,"about_ca_system_score_gemma":0.0010449731,"threshold_uncertainty_score":0.9956377},"labels":[],"label_agreement":null},{"id":"W4406870016","doi":"10.1200/jco.2025.43.4_suppl.135","title":"Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Standard of care; Renal cell carcinoma; Phases of clinical research; Chemotherapy","score_opus":0.04286997239890329,"score_gpt":0.4337288784768514,"score_spread":0.3908589060779481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804665,0.009065645,0.000038365255,0.0006792064,0.000342807,0.0015527736,0.00014066929,0.000005233611,0.00012862675],"genre_scores_gemma":[0.99517536,0.0030504146,0.0012616406,0.00016372536,0.000041107513,0.00023070835,0.000006573129,0.000027776165,0.000042683052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99525535,0.0006959082,0.0024353187,0.00041648248,0.00081043027,0.0003864985],"domain_scores_gemma":[0.99521255,0.0011432677,0.0020686905,0.00016851186,0.0012385877,0.00016841276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010401197,0.000374777,0.0033019993,0.00050806336,0.00006417919,0.00001325794,0.0001576757,0.000076047334,0.000118708034],"category_scores_gemma":[0.0002462586,0.00023197383,0.00018119908,0.00072153175,0.0004917459,0.00019398454,0.000068370064,0.0007089313,1.4652827e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087364644,0.015890686,0.7980828,0.00050706445,0.003721635,0.00044135549,0.006825304,0.0003994582,0.000058101286,0.000014685575,0.00009938267,0.08659488],"study_design_scores_gemma":[0.14212753,0.1412467,0.7011655,0.0012078782,0.004194341,0.000011593957,0.008954207,0.00011440631,0.00053631316,0.00006566135,0.00017920186,0.00019664348],"about_ca_topic_score_codex":0.0018604962,"about_ca_topic_score_gemma":0.02895545,"teacher_disagreement_score":0.12535603,"about_ca_system_score_codex":0.0011068078,"about_ca_system_score_gemma":0.0032389278,"threshold_uncertainty_score":0.9887636},"labels":[],"label_agreement":null},{"id":"W4406870062","doi":"10.1200/jco.2025.43.4_suppl.590","title":"Neoadjuvant immune checkpoint blockade in resectable hepatocellular carcinoma: A systematic review and meta-analyisis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Hepatocellular carcinoma; Oncology; Internal medicine; Neoadjuvant therapy; Meta-analysis; Cancer; Receptor","score_opus":0.33889319501302945,"score_gpt":0.4642910081575773,"score_spread":0.12539781314454784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019997459,0.99203986,0.000005880622,0.0024187418,0.000300423,0.004351479,0.00001805644,0.000011108255,0.00065445976],"genre_scores_gemma":[0.0018604056,0.9942696,0.0006404547,0.0006860638,0.00023315642,0.00031587316,0.000027574175,0.000055044373,0.0019118477],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.980096,0.0045932895,0.013533841,0.00062697777,0.000631875,0.00051801983],"domain_scores_gemma":[0.9849146,0.00556308,0.0074982955,0.0008885367,0.00054990966,0.0005855767],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.016198268,0.0007879952,0.03784049,0.00080657797,0.00005110133,0.000026263398,0.00048739597,0.0013622725,0.00027838777],"category_scores_gemma":[0.011338125,0.00044221204,0.008299659,0.0008890379,0.00017631894,0.00009828175,0.00024455774,0.0029641464,0.00003187865],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013204318,0.0011321782,0.002162155,0.9470795,0.018245574,0.00826368,0.000019000661,2.1388189e-8,3.1150222e-7,0.000012269039,0.0004129022,0.022540407],"study_design_scores_gemma":[0.0026120502,0.0030820577,0.00008841597,0.21388422,0.59129757,0.0023360238,0.000014914356,0.000021836266,0.0000025560942,0.00003408148,0.18630342,0.00032282632],"about_ca_topic_score_codex":0.000082309554,"about_ca_topic_score_gemma":0.000017196358,"teacher_disagreement_score":0.73319525,"about_ca_system_score_codex":0.00047149177,"about_ca_system_score_gemma":0.005094588,"threshold_uncertainty_score":0.9999342},"labels":[],"label_agreement":null},{"id":"W4406870066","doi":"10.1200/jco.2025.43.4_suppl.534","title":"Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mathematical Biology Tumor Growth","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Tremelimumab; Medicine; Durvalumab; Hepatocellular carcinoma; Internal medicine; Database; Oncology; Cancer; Immunotherapy; Nivolumab","score_opus":0.27109671353581916,"score_gpt":0.45645563576225806,"score_spread":0.1853589222264389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666847,0.00009741409,0.010050684,0.0015431639,0.0006940542,0.00076082983,0.00007267065,0.000009415975,0.000103326114],"genre_scores_gemma":[0.98955536,0.0003893209,0.009248994,0.00013910962,0.00030739864,0.000013590832,0.000021265994,0.000032909105,0.0002920325],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923257,0.001129384,0.005298836,0.00031264385,0.000518611,0.00041482653],"domain_scores_gemma":[0.98194736,0.011331921,0.0050799665,0.00069718546,0.00077185524,0.00017170787],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040820315,0.0002798191,0.002769276,0.00028033054,0.0000702565,0.000007829322,0.0005727572,0.00031071674,0.00013453848],"category_scores_gemma":[0.01589952,0.0001810844,0.00096205034,0.0004842856,0.0005470825,0.00015770362,0.00020883778,0.0004274096,4.816487e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038878042,0.056756444,0.48109752,0.0054117027,0.0066398922,0.00033660454,0.0008400309,0.00007929156,0.24301064,0.103824176,0.0020510124,0.061074648],"study_design_scores_gemma":[0.08452476,0.07475548,0.046673547,0.008234911,0.011182526,0.00044085272,0.0002503956,0.09876362,0.4916118,0.12689266,0.05526693,0.0014025042],"about_ca_topic_score_codex":0.00027192567,"about_ca_topic_score_gemma":0.0011052544,"teacher_disagreement_score":0.43442398,"about_ca_system_score_codex":0.00053460174,"about_ca_system_score_gemma":0.0023971666,"threshold_uncertainty_score":0.99239},"labels":[],"label_agreement":null},{"id":"W4406870176","doi":"10.1200/jco.2025.43.4_suppl.371","title":"Comparison of long-term outcomes for neoadjuvant chemoradiation (NA-CRT) followed by surgery versus (V) definitive chemoradiation (D-CRT) in localized gastroesophageal cancer (GEC): A single-center analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Single Center; Chemoradiotherapy; Neoadjuvant therapy; Cancer; Internal medicine; Oncology; Radiology; Breast cancer","score_opus":0.1742127725781704,"score_gpt":0.49663027970459966,"score_spread":0.32241750712642925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861919,0.0008985848,0.0039671813,0.00554406,0.0024391925,0.00057327555,0.000026317935,0.00001166112,0.00034778746],"genre_scores_gemma":[0.9970135,0.00026858822,0.00082778704,0.0012710706,0.00025638661,0.000030805826,0.00009930044,0.000015602931,0.00021692658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99514043,0.00026655037,0.003531518,0.000295417,0.00041743834,0.00034865155],"domain_scores_gemma":[0.99132216,0.004940182,0.0029084971,0.00020250167,0.00044540004,0.00018123105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020769832,0.00023023805,0.0036330086,0.0007965163,0.000033563178,0.000016461978,0.00017288893,0.0003042042,0.00008567175],"category_scores_gemma":[0.0028410875,0.00019041846,0.0014096389,0.00083007576,0.00013477077,0.00014596568,0.000050138497,0.00048045994,0.0000013102862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012670389,0.0023510433,0.9077716,0.00011389612,0.002575323,0.0000555938,0.000062058134,0.00016702189,0.000042654257,0.00002155496,0.006873838,0.067295045],"study_design_scores_gemma":[0.033966545,0.0024471583,0.95705736,0.00012706843,0.0037432476,0.0000023878442,0.00010392624,0.0011284992,0.00027481865,0.000017619677,0.0010189138,0.00011244156],"about_ca_topic_score_codex":0.00008026086,"about_ca_topic_score_gemma":0.000556753,"teacher_disagreement_score":0.0671826,"about_ca_system_score_codex":0.0007639045,"about_ca_system_score_gemma":0.00109574,"threshold_uncertainty_score":0.776504},"labels":[],"label_agreement":null},{"id":"W4406870189","doi":"10.1200/jco.2025.43.4_suppl.tps507","title":"CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Gastroesophageal Junction; Conjugate; Drug; Gemcitabine; Internal medicine; Pharmacology; Adenocarcinoma","score_opus":0.0657563796571697,"score_gpt":0.47181508817811013,"score_spread":0.40605870852094045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98850244,0.0009564154,0.0011884804,0.0029207352,0.0035516312,0.0023877816,0.000019093326,0.000035701636,0.0004377463],"genre_scores_gemma":[0.9875903,0.0022473186,0.0024468375,0.0020171301,0.0007945326,0.0000787231,0.000019889789,0.000036636782,0.0047685937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990079,0.0016226053,0.006358311,0.00057542557,0.00070700794,0.00065766147],"domain_scores_gemma":[0.99074656,0.0038234494,0.0038750498,0.00042401432,0.0007347217,0.00039618596],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064367587,0.00046805613,0.005720153,0.0014520038,0.000079371865,0.000025772879,0.0004062202,0.0004013847,0.0016227666],"category_scores_gemma":[0.0050236294,0.0002996156,0.00089437695,0.0019771962,0.00031751627,0.00031648003,0.00017853317,0.0020600967,0.00000595133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72114813,0.014092664,0.16951488,0.00034600086,0.0025023099,0.0027539833,0.00031296627,0.00043145893,0.00052080664,0.000015650528,0.0060654692,0.08229566],"study_design_scores_gemma":[0.75662994,0.029319167,0.19976828,0.00054802356,0.003141837,0.0001802088,0.0013123124,0.0011757255,0.000087808345,0.00009585839,0.00750257,0.0002382512],"about_ca_topic_score_codex":0.00023399787,"about_ca_topic_score_gemma":0.0020310946,"teacher_disagreement_score":0.08205741,"about_ca_system_score_codex":0.0005337598,"about_ca_system_score_gemma":0.0029997604,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W4406870271","doi":"10.1200/jco.2025.43.4_suppl.197","title":"Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Biotech","keywords":"Medicine; Colorectal cancer; Chemotherapy; Oncology; Cancer; Open label; Internal medicine; Clinical trial","score_opus":0.15915931674812303,"score_gpt":0.5423272323178473,"score_spread":0.3831679155697243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883414,0.00035665324,0.000017176018,0.006257218,0.0008000454,0.0014389253,0.00006547255,0.000018050614,0.002212298],"genre_scores_gemma":[0.9920211,0.0009132427,0.0034650133,0.002304811,0.0002939764,0.000064541244,0.00002404392,0.000025985886,0.0008872809],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99521965,0.0007356664,0.002809423,0.00050730334,0.00039793196,0.00033001896],"domain_scores_gemma":[0.99532425,0.0020029817,0.0015569249,0.00029081933,0.0005260149,0.00029900458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020377727,0.00030765028,0.0032437807,0.0002163846,0.000097943965,0.00004097261,0.00039950767,0.00018387989,0.00027039318],"category_scores_gemma":[0.0011162875,0.00016479788,0.000105462954,0.0005765218,0.00025735554,0.00025081597,0.00011397261,0.00088797393,0.00000294318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61393285,0.080656,0.10887534,0.00001528389,0.00636663,0.0056797364,0.001587753,0.000007916442,0.00037534948,0.000019667266,0.004835994,0.17764749],"study_design_scores_gemma":[0.50284404,0.22046955,0.24736667,0.00049769355,0.0025501554,0.00011459813,0.002477881,0.00056671776,0.00049747917,0.00023862298,0.022085227,0.00029134104],"about_ca_topic_score_codex":0.0023150367,"about_ca_topic_score_gemma":0.034211036,"teacher_disagreement_score":0.17735614,"about_ca_system_score_codex":0.00057477626,"about_ca_system_score_gemma":0.004212579,"threshold_uncertainty_score":0.9834121},"labels":[],"label_agreement":null},{"id":"W4406870347","doi":"10.1200/jco.2025.43.4_suppl.557","title":"Efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) vs percutaneous transhepatic biliary drainage (PTBD) for cholangiocarcinoma biliary obstruction: An updated systematic review and meta analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gallbladder and Bile Duct Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Endoscopic retrograde cholangiopancreatography; Biliary drainage; Percutaneous; Biliary tract; Radiology; General surgery; Surgery; Pancreatitis","score_opus":0.04973866625542372,"score_gpt":0.38965452999474887,"score_spread":0.33991586373932514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8593786,0.1264527,0.00056246115,0.00924723,0.0003623072,0.0035194033,0.000049631966,0.00003306148,0.00039463755],"genre_scores_gemma":[0.98553836,0.009007955,0.002830075,0.002402426,0.00006627039,0.000024192123,0.000039976683,0.000017148863,0.00007359298],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950457,0.0009418194,0.0031369964,0.00037089625,0.00026146203,0.00024312122],"domain_scores_gemma":[0.99589753,0.0017618403,0.0011892107,0.000430235,0.0004040922,0.0003171104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030600566,0.00026072856,0.0058231717,0.00054836867,0.00007159022,0.000015108281,0.0001952807,0.00032992903,0.000065582055],"category_scores_gemma":[0.0015779354,0.00016955804,0.0017134123,0.00086007715,0.00036021156,0.00013376796,0.000030122734,0.0005753339,2.8063252e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01839279,0.008174666,0.20978607,0.28751215,0.46266285,0.0012079102,0.00095985713,0.000018385985,0.00104366,0.0012284605,0.0021628414,0.0068503823],"study_design_scores_gemma":[0.0077990233,0.010357178,0.22292913,0.002131494,0.75393754,0.0011650174,0.000360291,0.00011778963,0.000017879238,0.00057959126,0.00039816534,0.00020689075],"about_ca_topic_score_codex":0.000024536235,"about_ca_topic_score_gemma":0.00003246105,"teacher_disagreement_score":0.2912747,"about_ca_system_score_codex":0.000034968572,"about_ca_system_score_gemma":0.00034226035,"threshold_uncertainty_score":0.6914376},"labels":[],"label_agreement":null},{"id":"W4406870903","doi":"10.1200/jco.2025.43.4_suppl.575","title":"Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Bevacizumab; Oncology; Internal medicine; Embolization; Durvalumab; Refractory (planetary science); Subgroup analysis; Radiology; Cancer; Chemotherapy; Immunotherapy; Meta-analysis; Nivolumab","score_opus":0.08693050606015161,"score_gpt":0.3746808627175119,"score_spread":0.28775035665736026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406870903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852415,0.00092141476,0.0054219547,0.0069550783,0.00019720585,0.0008989796,0.000065936125,0.000042171876,0.00025579004],"genre_scores_gemma":[0.9960532,0.0003421038,0.0013641675,0.001202858,0.00019511094,0.000042705615,0.00027694105,0.000043341184,0.00047957955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99464333,0.0009379986,0.0025543899,0.00065499917,0.0006648122,0.00054446294],"domain_scores_gemma":[0.99581647,0.0010011975,0.0013944857,0.0004663165,0.000692241,0.00062930724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015398394,0.0004917942,0.0035111953,0.00037488365,0.00016746945,0.00006710183,0.00020733892,0.0006365971,0.00025461297],"category_scores_gemma":[0.0004347747,0.00032678753,0.00057223975,0.0009946655,0.00031817198,0.0002883207,0.00003999556,0.0006363551,0.0000060606244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012152219,0.002002725,0.9749346,0.00006461013,0.006148512,0.00058205205,0.00038113177,0.00004600683,0.00046243533,0.000035315334,0.0008593828,0.0023310382],"study_design_scores_gemma":[0.039336998,0.0074336785,0.9054854,0.00014145751,0.01947935,0.000050342907,0.00019145127,0.019878669,0.004374191,0.00012579435,0.0030801212,0.00042256986],"about_ca_topic_score_codex":0.0009431005,"about_ca_topic_score_gemma":0.00044110065,"teacher_disagreement_score":0.069449194,"about_ca_system_score_codex":0.00025845715,"about_ca_system_score_gemma":0.001225129,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W4406875656","doi":"10.1200/jco.2025.43.4_suppl.751","title":"Beyond Khorana score 2: Molecular correlates of venous thromboembolism in pancreatic cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University Health Centre; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Venous thromboembolism; Internal medicine; Pancreatic cancer; Cancer; Gastroenterology; Oncology; Thrombosis","score_opus":0.05292476758751585,"score_gpt":0.4317497915218422,"score_spread":0.3788250239343263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406875656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97093046,0.006013557,0.00011210044,0.006332039,0.0017974715,0.00035286407,0.0000026534667,0.000006757705,0.014452106],"genre_scores_gemma":[0.9887604,0.0066714417,0.00077350653,0.0034083596,0.00022700778,0.000010069957,0.0000015858154,0.000014858831,0.00013278221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634176,0.00027870177,0.0025987858,0.00019915387,0.000316493,0.00026507632],"domain_scores_gemma":[0.9968648,0.0010459793,0.001314422,0.000250908,0.0003485202,0.00017535289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020853882,0.00015473091,0.0031339477,0.00033424958,0.000024278603,0.000005650255,0.000229954,0.00034732206,0.00015519281],"category_scores_gemma":[0.0017187881,0.000120046,0.00047664973,0.00037980845,0.00023691563,0.00006432046,0.000088237284,0.0008050863,0.000005598087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023633186,0.016660606,0.6316742,0.00077721867,0.0036912092,0.0026933958,0.00062539615,0.0008769416,0.0014004629,0.019193951,0.015538619,0.3045047],"study_design_scores_gemma":[0.0060213185,0.006448711,0.96960115,0.0012363072,0.0018125973,0.000035562065,0.0002350695,0.000120564255,0.0003750403,0.00802311,0.005984211,0.000106369735],"about_ca_topic_score_codex":0.00023718472,"about_ca_topic_score_gemma":0.00014068499,"teacher_disagreement_score":0.33792695,"about_ca_system_score_codex":0.00017792392,"about_ca_system_score_gemma":0.0016475638,"threshold_uncertainty_score":0.4895334},"labels":[],"label_agreement":null},{"id":"W4406875658","doi":"10.1200/jco.2025.43.4_suppl.398","title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Cancer; Chemotherapy; Internal medicine; Esophageal adenocarcinoma; Adenocarcinoma; Oncology; Esophageal cancer; Gastroenterology; Immunotherapy","score_opus":0.060370747793238394,"score_gpt":0.41646542137251774,"score_spread":0.3560946735792794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406875658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572986,0.008009459,0.0007252255,0.023709493,0.007917384,0.0013745807,0.00025963518,0.0000671107,0.0006385325],"genre_scores_gemma":[0.95328885,0.022966977,0.0048202337,0.005556891,0.004530226,0.00018361316,0.00011023557,0.000091375834,0.008451619],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936306,0.0002468938,0.0039575864,0.00082883204,0.00057496055,0.0007611148],"domain_scores_gemma":[0.99352926,0.0016586144,0.0029208947,0.00058873935,0.00080759224,0.0004949243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001685661,0.00058831146,0.0029045774,0.00035133454,0.00022413656,0.000038162856,0.00042662089,0.00084021897,0.0005084886],"category_scores_gemma":[0.0010616663,0.00046327763,0.0017008398,0.00060546806,0.0003182119,0.00022856239,0.000059310398,0.00096275366,0.000014182765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40510342,0.0024226916,0.03260641,0.00010222222,0.0035232257,0.00029717878,0.00030674625,0.00014052619,0.0032213593,0.000014507027,0.017703943,0.53455776],"study_design_scores_gemma":[0.35552478,0.057383183,0.34219965,0.0011929586,0.0033639478,0.00020377323,0.00036676714,0.00092588126,0.018866228,0.00048827264,0.21886265,0.00062190276],"about_ca_topic_score_codex":0.0022350452,"about_ca_topic_score_gemma":0.0014758576,"teacher_disagreement_score":0.5339359,"about_ca_system_score_codex":0.002764399,"about_ca_system_score_gemma":0.0047428575,"threshold_uncertainty_score":0.9997819},"labels":[],"label_agreement":null},{"id":"W4407678056","doi":"10.1200/jco.2025.43.5_suppl.tps279","title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Placebo; Oncology; Internal medicine; Hormone receptor; Cohort; Cancer; Androgen; Enzalutamide; Receptor; Prostate; Cancer research; Hormone; Breast cancer; Pathology","score_opus":0.03859430156463788,"score_gpt":0.4102411276178701,"score_spread":0.37164682605323224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882454,0.00043514222,0.00005360777,0.0007128614,0.00016859299,0.010200386,0.000010937532,0.000013692958,0.00015933244],"genre_scores_gemma":[0.9976771,0.0005641163,0.00083100906,0.000069029265,0.000026430476,0.000588419,0.000052728356,0.000025642852,0.00016554398],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99433404,0.0015568364,0.0026707442,0.00043190407,0.0006888511,0.000317622],"domain_scores_gemma":[0.9941788,0.0014998093,0.0024011761,0.00017244738,0.0015646486,0.0001831168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057608797,0.00029452614,0.00330403,0.00081581034,0.00006191587,0.000019495865,0.00007433304,0.00018409864,0.000007987036],"category_scores_gemma":[0.0006654156,0.0001634109,0.00014627802,0.00071026036,0.00047251297,0.00032716777,0.000034449695,0.0008494048,3.1206488e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6668038,0.012003064,0.30784065,0.000057925,0.0019253201,0.00031165482,0.0013521458,0.00011787932,0.000016468079,0.000010929047,0.000024024399,0.00953616],"study_design_scores_gemma":[0.86002386,0.0653148,0.06987834,0.00053639093,0.0013987477,0.000029275649,0.00189562,0.00036826805,0.00032762263,0.00006552916,0.000013646695,0.00014790214],"about_ca_topic_score_codex":0.00047617353,"about_ca_topic_score_gemma":0.00094342174,"teacher_disagreement_score":0.2379623,"about_ca_system_score_codex":0.00052405125,"about_ca_system_score_gemma":0.002155073,"threshold_uncertainty_score":0.66637033},"labels":[],"label_agreement":null},{"id":"W4407678084","doi":"10.1200/jco.2025.43.5_suppl.477","title":"Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Sunnybrook Hospital; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Immunotherapy; Oncology; Internal medicine; Second line; Cancer research; First line; Cancer","score_opus":0.11760310345271452,"score_gpt":0.41627909486239073,"score_spread":0.2986759914096762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806195,0.0017191472,0.0001869973,0.009889446,0.003530834,0.00079018454,0.00058877165,0.000013827192,0.0026613057],"genre_scores_gemma":[0.99093187,0.002655916,0.0038935256,0.00087150163,0.0003865643,0.000021128559,0.0004500655,0.000048131522,0.00074127543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895392,0.0019085172,0.00632173,0.00068968063,0.0010788947,0.00046196333],"domain_scores_gemma":[0.97338474,0.0189689,0.0053180777,0.0013095504,0.0007850488,0.00023366006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006932816,0.00049509073,0.0028175935,0.0006467482,0.00010236453,0.000042007847,0.001350154,0.00025618434,0.00020715466],"category_scores_gemma":[0.0036979832,0.00032282772,0.0008308434,0.00052828796,0.00057744,0.00028724418,0.00036520665,0.0018740506,0.000014729927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14068593,0.013421958,0.7860361,0.0001205056,0.005351679,0.0027671286,0.0014586941,0.00031205584,0.0036628777,0.0001332982,0.014539687,0.031510107],"study_design_scores_gemma":[0.09730445,0.009513644,0.87532544,0.0001560526,0.0018988368,0.000033566084,0.0005425743,0.001636075,0.004582702,0.00050558633,0.008256028,0.0002450485],"about_ca_topic_score_codex":0.003768784,"about_ca_topic_score_gemma":0.003584291,"teacher_disagreement_score":0.08928936,"about_ca_system_score_codex":0.0007875434,"about_ca_system_score_gemma":0.0024315864,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4407678310","doi":"10.1200/jco.2025.43.5_suppl.440","title":"KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Clear cell renal cell carcinoma; Oncology; Internal medicine; Cancer research; Cancer; Immunotherapy","score_opus":0.07810510800763588,"score_gpt":0.4207072258296449,"score_spread":0.34260211782200906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777435,0.0055245985,0.0003245868,0.004394372,0.0010529788,0.0010341138,0.000010114369,0.00002004455,0.009895672],"genre_scores_gemma":[0.9882039,0.0010115977,0.0058610784,0.0013766157,0.0003050404,0.00003803538,0.000012056631,0.000036237987,0.003155471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995965,0.0005000998,0.0023895134,0.00039971623,0.00036135656,0.00038432537],"domain_scores_gemma":[0.99373895,0.003204142,0.0013495877,0.00036013487,0.00089784106,0.00044935042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016856381,0.00029150955,0.0018025028,0.00029965385,0.00015124508,0.000020302485,0.000222658,0.00044455956,0.00006124644],"category_scores_gemma":[0.00088430406,0.0002161425,0.0007272791,0.00025784754,0.00024612184,0.000115947216,0.00007034397,0.00094398356,0.000009125962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18993577,0.057620127,0.33255914,0.0010182038,0.003141452,0.0034126623,0.0017838723,0.00030568533,0.07857989,0.0023805355,0.06645625,0.26280642],"study_design_scores_gemma":[0.11363378,0.0708942,0.7305525,0.00009767733,0.0011953216,0.00022327952,0.00043881807,0.00029081537,0.015897926,0.0018446586,0.06463708,0.00029393923],"about_ca_topic_score_codex":0.000016921747,"about_ca_topic_score_gemma":0.000018801087,"teacher_disagreement_score":0.39799336,"about_ca_system_score_codex":0.00028872944,"about_ca_system_score_gemma":0.0017662876,"threshold_uncertainty_score":0.88140357},"labels":[],"label_agreement":null},{"id":"W4407678360","doi":"10.1200/jco.2025.43.5_suppl.687","title":"Detection of early-stage urothelial cancers using methylation patterns in urine cell-free DNA.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Grail","keywords":"Medicine; Stage (stratigraphy); Urine; DNA methylation; Urothelial cancer; Cell-free fetal DNA; DNA; Cancer research; Methylation; Bladder cancer; Cancer; Pathology; Internal medicine; Gene; Biology; Genetics; Gene expression","score_opus":0.09353962825535082,"score_gpt":0.4518999914947042,"score_spread":0.3583603632393534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993058,0.00023821743,0.0025362687,0.00068064674,0.0014130365,0.00020805387,0.0000103519005,0.0000043665077,0.0018510169],"genre_scores_gemma":[0.9975977,0.00033470723,0.000829581,0.0004463938,0.00045355567,0.0000027303033,6.7286635e-7,0.000010397727,0.00032424397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975809,0.0002760943,0.0016297854,0.00013675625,0.00022856976,0.00014788615],"domain_scores_gemma":[0.9980486,0.00048789446,0.0009632918,0.00017601716,0.0002168895,0.00010728422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011515552,0.00010200017,0.0009042454,0.0002564667,0.000019622412,0.0000035306352,0.0001150119,0.0002580483,0.0000810461],"category_scores_gemma":[0.0006750823,0.00008056997,0.0002797898,0.00020651115,0.00007019581,0.00008351125,0.000038554997,0.00053298427,0.0000012198302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014340484,0.0018334892,0.79858255,0.00026409756,0.0005548445,0.0003387444,0.0002876535,0.0004849916,0.042627186,0.00003401071,0.000103305065,0.14054866],"study_design_scores_gemma":[0.025222247,0.010447615,0.91097414,0.00032372764,0.0006887915,0.000031028216,0.000153002,0.000476433,0.046593,0.0004493869,0.0045382017,0.00010243039],"about_ca_topic_score_codex":0.0015422672,"about_ca_topic_score_gemma":0.00082795473,"teacher_disagreement_score":0.14044625,"about_ca_system_score_codex":0.00047225758,"about_ca_system_score_gemma":0.0018887764,"threshold_uncertainty_score":0.33506083},"labels":[],"label_agreement":null},{"id":"W4407678390","doi":"10.1200/jco.2025.43.5_suppl.479","title":"Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; McMaster University; University of Calgary","funders":"","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Urology; Database","score_opus":0.09868426204672401,"score_gpt":0.41827685727317526,"score_spread":0.3195925952264512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771378,0.0009350373,0.00019866598,0.007884856,0.0013318178,0.00090017467,0.00041635704,0.00000772821,0.011187566],"genre_scores_gemma":[0.9923934,0.00012244066,0.003936603,0.0019389284,0.000595679,0.000027654864,0.00017050933,0.000029406476,0.0007854135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98828757,0.0044346154,0.0052169464,0.0005876178,0.0010056628,0.0004675879],"domain_scores_gemma":[0.96020937,0.03426908,0.0036904933,0.0008349498,0.0007543321,0.00024178282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014459549,0.0004049093,0.002388131,0.00044216798,0.00009871199,0.000033916065,0.00094741455,0.00017672712,0.00018581792],"category_scores_gemma":[0.004386711,0.0002249004,0.00085124274,0.0006784514,0.0004356256,0.0001743268,0.00027294582,0.0021138191,0.000011330952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07908481,0.0144590745,0.7891068,0.0011651447,0.003198393,0.018438092,0.002993004,0.0008140618,0.043324325,0.0006720442,0.033868246,0.012876],"study_design_scores_gemma":[0.034005735,0.0048935255,0.91082877,0.00043604212,0.0026792998,0.0002606483,0.0011232895,0.0006485241,0.036071908,0.0004161096,0.008422055,0.00021409756],"about_ca_topic_score_codex":0.0016740732,"about_ca_topic_score_gemma":0.002989986,"teacher_disagreement_score":0.12172196,"about_ca_system_score_codex":0.00035996272,"about_ca_system_score_gemma":0.0032317014,"threshold_uncertainty_score":0.918361},"labels":[],"label_agreement":null},{"id":"W4407678516","doi":"10.1200/jco.2025.43.5_suppl.471","title":"Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; London Health Sciences Centre; McGill University Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Ottawa Hospital; CancerCare Manitoba; University of Manitoba; Hôtel-Dieu de Québec; BC Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre; Western University; University of Toronto; Dalhousie University; University of Calgary; Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Papillary renal cell carcinomas; Internal medicine","score_opus":0.17689721804712585,"score_gpt":0.5136408992373269,"score_spread":0.33674368119020104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757521,0.0006822805,0.00008973061,0.0041652457,0.0010693524,0.00062385993,0.000013407064,0.000006129789,0.017597862],"genre_scores_gemma":[0.98063254,0.0028089539,0.013881648,0.00040824804,0.00025383988,0.000014518288,0.000009918969,0.00002230949,0.0019680376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9878873,0.0014327089,0.009295652,0.0003885462,0.0006476999,0.00034808472],"domain_scores_gemma":[0.9831877,0.010710556,0.0044930154,0.000584919,0.00061194773,0.00041189825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00587989,0.00033403994,0.0057128463,0.00064842013,0.000026236314,0.0000042534225,0.000270765,0.00035049714,0.00015636845],"category_scores_gemma":[0.0019342949,0.00021150072,0.001980976,0.00047903927,0.00037809616,0.00007234265,0.00011452214,0.0010008719,0.0000034647637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034739529,0.013300853,0.954119,0.00021395361,0.0013785881,0.0020188338,0.00005026292,0.0001385852,0.000111140616,0.00016714392,0.0006745296,0.02435311],"study_design_scores_gemma":[0.022717152,0.031589597,0.93642616,0.00021398843,0.0023960085,0.000039799637,0.000096651835,0.000258389,0.0009666376,0.00032028958,0.004862786,0.00011254025],"about_ca_topic_score_codex":0.0006742522,"about_ca_topic_score_gemma":0.001381791,"teacher_disagreement_score":0.02424057,"about_ca_system_score_codex":0.00068946084,"about_ca_system_score_gemma":0.005139568,"threshold_uncertainty_score":0.91173726},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4407678522","doi":"10.1200/jco.2025.43.5_suppl.tps305","title":"OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Clinical Oncology Group; Memorial University of Newfoundland; McGill University; University of Ottawa; Hôpital Maisonneuve-Rosemont; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Recurrent prostate cancer; Internal medicine; Cancer; Randomized controlled trial; Gynecology; Prostatectomy","score_opus":0.13796103542284305,"score_gpt":0.5154813904007078,"score_spread":0.3775203549778648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884702,0.0026208449,0.0001622632,0.0042186156,0.00072364125,0.003591785,0.0000373816,0.000014914768,0.00016036205],"genre_scores_gemma":[0.9583639,0.03661343,0.0034415012,0.00035356803,0.0003618633,0.00026993355,0.000040357667,0.000023778042,0.0005316956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99413645,0.0017785055,0.0028263873,0.00032958636,0.00059479463,0.00033426177],"domain_scores_gemma":[0.99344105,0.0028183435,0.002015927,0.00017849752,0.0013240156,0.00022215825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047701993,0.00027072927,0.0029786972,0.00044620395,0.00007331824,0.000016184431,0.00013116859,0.0002018505,0.00011826126],"category_scores_gemma":[0.0016949984,0.0001438401,0.00042610097,0.00067140476,0.00060487876,0.00016680661,0.000027556553,0.0009126235,8.737434e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8032774,0.0065386794,0.0024660253,0.00003923547,0.0018152117,0.00036444666,0.0008025146,0.000055281027,0.00035563155,0.00002455157,0.00027205888,0.18398902],"study_design_scores_gemma":[0.9378153,0.050748903,0.0037307008,0.00073480315,0.00040050974,0.00009522462,0.00018361384,0.0018229492,0.0024536047,0.00015484753,0.0017193834,0.000140126],"about_ca_topic_score_codex":0.00008453375,"about_ca_topic_score_gemma":0.00012017061,"teacher_disagreement_score":0.18384889,"about_ca_system_score_codex":0.0003143847,"about_ca_system_score_gemma":0.008755161,"threshold_uncertainty_score":0.99686426},"labels":[],"label_agreement":null},{"id":"W4407698114","doi":"10.1200/jco.2025.43.5_suppl.699","title":"Patterns of split-dose gemcitabine and cisplatin (GC) use in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a 10-country physician survey.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Gemcitabine; Urothelial carcinoma; Cisplatin; Urothelial cancer; Oncology; Internal medicine; Chemotherapy; Cancer; Bladder cancer","score_opus":0.06019323005253112,"score_gpt":0.40073797644489895,"score_spread":0.3405447463923678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821484,0.00008818628,0.00009319835,0.00028786456,0.00020702592,0.00047780023,0.00026624714,0.0000028722986,0.00036194612],"genre_scores_gemma":[0.99726266,0.00010434083,0.0017433736,0.0005426071,0.0000658767,0.0000073681554,0.000017966322,0.000018146042,0.00023769028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960213,0.0007037215,0.002437161,0.00024386395,0.00038434227,0.00020962494],"domain_scores_gemma":[0.9932984,0.0041300855,0.0015726672,0.0002381329,0.0005977296,0.00016296937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016462693,0.00019429805,0.0018504816,0.00020270722,0.000016057229,0.0000062466793,0.00012358603,0.00016783767,0.000030118474],"category_scores_gemma":[0.0035726116,0.00012045242,0.00015147241,0.00028769142,0.00019738254,0.00014766362,0.000051634048,0.00046885203,6.5332557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12898934,0.003300011,0.8101337,0.00015556323,0.00047007136,0.0001988124,0.00008555303,0.000018158922,0.000031620606,0.000021817594,0.00014580958,0.05644955],"study_design_scores_gemma":[0.061841607,0.018787995,0.9172464,0.0005458023,0.00053729216,0.000011558114,0.000057389578,0.000038842933,0.000118153956,0.000040547293,0.0006906329,0.00008378534],"about_ca_topic_score_codex":0.00060359744,"about_ca_topic_score_gemma":0.0017763753,"teacher_disagreement_score":0.1071127,"about_ca_system_score_codex":0.00009226794,"about_ca_system_score_gemma":0.0019232753,"threshold_uncertainty_score":0.49119073},"labels":[],"label_agreement":null},{"id":"W4407698562","doi":"10.1200/jco.2025.43.5_suppl.213","title":"Radiographic progression without PSA progression in advanced prostate cancer patients.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Oncology; Tumor progression; Internal medicine","score_opus":0.04472835794088329,"score_gpt":0.49550158249344156,"score_spread":0.45077322455255825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97879463,0.0071987994,0.0000061670125,0.010257359,0.0017021999,0.00097428076,0.0000045123215,0.000012598758,0.0010494518],"genre_scores_gemma":[0.98233324,0.013355945,0.0023709629,0.0014224078,0.00020462042,0.0001391794,0.000006477331,0.000014506751,0.00015263443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677324,0.00027249785,0.002057226,0.00026471863,0.00034651844,0.00028578992],"domain_scores_gemma":[0.9972144,0.00044298326,0.0014054785,0.00016308168,0.000516925,0.0002571338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012979605,0.0001683575,0.0013404246,0.00031973663,0.000039985604,0.000009211595,0.0001134404,0.00026979076,0.000032389777],"category_scores_gemma":[0.0008548787,0.000102522485,0.0003441597,0.00044291766,0.00017514522,0.00013793302,0.000053486066,0.00078736624,0.000002199466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042590452,0.0030486844,0.55279654,0.00005257471,0.00012504017,0.00013082146,0.000044607146,0.0000068132695,0.00002212691,0.00001669036,0.001034015,0.43846306],"study_design_scores_gemma":[0.021941967,0.014119655,0.8991908,0.0027407573,0.0002682656,0.0000103689235,0.00003451953,0.000033196447,0.00040412054,0.00027954543,0.06088881,0.00008804234],"about_ca_topic_score_codex":0.000012030067,"about_ca_topic_score_gemma":0.000050377963,"teacher_disagreement_score":0.43837503,"about_ca_system_score_codex":0.00036091753,"about_ca_system_score_gemma":0.0017215764,"threshold_uncertainty_score":0.41807455},"labels":[],"label_agreement":null},{"id":"W4407698650","doi":"10.1200/jco.2025.43.5_suppl.451","title":"Systemic therapy clinical trial participation in patients with bladder and kidney cancers.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diet and metabolism studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Systemic therapy; Clinical trial; Internal medicine; Oncology; Kidney cancer; Bladder cancer; Urothelial cancer; Cancer; Breast cancer","score_opus":0.13313402783097852,"score_gpt":0.5140107838532971,"score_spread":0.38087675602231863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901907,0.00088628405,0.000020972035,0.0036274805,0.0032035888,0.0004222529,0.000001115823,0.000004263218,0.0016433803],"genre_scores_gemma":[0.98993903,0.0039467257,0.0004142078,0.0046175863,0.0008873409,0.000009655236,0.0000011663028,0.000006369436,0.00017790742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670386,0.00047836936,0.0022940345,0.00015343874,0.0002117057,0.0001585933],"domain_scores_gemma":[0.9970111,0.0012798576,0.0009666643,0.00010997593,0.0003928031,0.00023955049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003245878,0.00009746136,0.001495895,0.00011208401,0.000022890048,0.0000057877382,0.000061344675,0.00024904739,0.000020402635],"category_scores_gemma":[0.0053424737,0.000056603236,0.0001759131,0.00013899629,0.0002059416,0.00006792628,0.000026129852,0.0006105713,0.0000014845111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12302809,0.0015455355,0.7385335,0.000016059268,0.00047000445,0.000021577134,0.00008360412,9.243148e-7,0.0000014061177,0.000057501726,0.0050146626,0.13122714],"study_design_scores_gemma":[0.15959653,0.013061989,0.78274196,0.00016456858,0.0002987011,0.0000016047549,0.000050487717,0.0000071661457,0.0000010587261,0.000048684033,0.043984912,0.000042295967],"about_ca_topic_score_codex":0.000016321785,"about_ca_topic_score_gemma":0.000028595123,"teacher_disagreement_score":0.13118483,"about_ca_system_score_codex":0.00006765164,"about_ca_system_score_gemma":0.0022259287,"threshold_uncertainty_score":0.6395826},"labels":[],"label_agreement":null},{"id":"W4407698678","doi":"10.1200/jco.2025.43.5_suppl.374","title":"GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University; University of Ottawa; Hamilton Health Sciences","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Incidence (geometry); Oncology; Cancer; Prostate; Internal medicine; Gynecology","score_opus":0.16486634966942956,"score_gpt":0.5224860290458619,"score_spread":0.35761967937643235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013604018,0.998406,0.000013225849,0.00021115332,0.00028698906,0.00088282174,0.000099827856,0.0000021729725,0.00008420224],"genre_scores_gemma":[0.000008563426,0.9945606,0.00019871317,0.0037973805,0.00034259586,0.00017635607,0.000026362984,0.00001819015,0.0008712454],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99224854,0.0023652308,0.0044044377,0.00048374123,0.00025458878,0.00024345718],"domain_scores_gemma":[0.99259096,0.00089441467,0.0052879266,0.00043225958,0.0005130098,0.00028145526],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0061388523,0.0004078571,0.016769674,0.00020068468,0.0000426489,0.00002899641,0.00039503392,0.00075467926,0.00007134478],"category_scores_gemma":[0.004004602,0.00023164393,0.0036759267,0.00036713865,0.00023172463,0.000009112956,0.00021241803,0.0007079352,0.0000016988876],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027847338,0.00009812214,0.000018542372,0.5423267,0.19050926,0.000029358203,0.000008209949,5.492163e-7,1.3586933e-7,0.000016462303,0.0044559753,0.26250884],"study_design_scores_gemma":[0.00016387935,0.00031254214,0.00000470544,0.008628856,0.48942617,0.000029933588,0.0000035111095,2.087639e-7,2.1918295e-7,0.00002051756,0.5012841,0.00012532072],"about_ca_topic_score_codex":0.000013740057,"about_ca_topic_score_gemma":0.00011453263,"teacher_disagreement_score":0.53369784,"about_ca_system_score_codex":0.000032289947,"about_ca_system_score_gemma":0.0022449517,"threshold_uncertainty_score":0.9978274},"labels":[],"label_agreement":null},{"id":"W4407698713","doi":"10.1200/jco.2025.43.5_suppl.121","title":"Efficacy of <sup>177</sup> Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nuclear medicine; Internal medicine; Oncology","score_opus":0.12215498754365973,"score_gpt":0.5367878985441408,"score_spread":0.41463291100048105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813068,0.00082654285,0.0034015176,0.011526724,0.000085772714,0.0005700969,0.00001886791,0.000006287442,0.0022574128],"genre_scores_gemma":[0.99236673,0.001043992,0.004264415,0.0006149053,0.00038384038,0.000020901112,0.0000064296823,0.000008676047,0.0012901218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742347,0.00012159389,0.0018941906,0.00018647451,0.00021717095,0.00015708858],"domain_scores_gemma":[0.9906217,0.007261273,0.001168865,0.00033875843,0.0004093275,0.00020006343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001093506,0.00013762782,0.0017732163,0.00010311077,0.000055929293,0.0000044719654,0.00019579034,0.00023157476,0.00019645141],"category_scores_gemma":[0.0008979821,0.000063856176,0.0008297086,0.00045477468,0.00043499103,0.00003480621,0.00001753847,0.00040692807,9.600152e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10744127,0.025434973,0.10218018,0.0004962441,0.02377526,0.00012233775,0.00056776515,0.003085104,0.004405477,0.00046194613,0.0070032836,0.72502613],"study_design_scores_gemma":[0.0785213,0.05789446,0.18962222,0.00041149856,0.044269323,0.00022406827,0.0011096605,0.023518126,0.024633301,0.00038883765,0.57913345,0.00027374836],"about_ca_topic_score_codex":0.0000060228654,"about_ca_topic_score_gemma":0.000008771104,"teacher_disagreement_score":0.7247524,"about_ca_system_score_codex":0.0000842802,"about_ca_system_score_gemma":0.0012755159,"threshold_uncertainty_score":0.26039794},"labels":[],"label_agreement":null},{"id":"W4407698783","doi":"10.1200/jco.2025.43.5_suppl.tps898","title":"A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Urothelial cancer; Medicine; Conjugate; Cancer; Cancer research; Oncology; Internal medicine; Bladder cancer","score_opus":0.05430610272365684,"score_gpt":0.4685326335031526,"score_spread":0.4142265307794958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682474,0.000047301637,0.00039019185,0.0016073922,0.000179589,0.00050935196,0.000009173777,0.00000869174,0.000423587],"genre_scores_gemma":[0.99608696,0.000049810762,0.0019880573,0.0014415628,0.00012674881,0.0000219591,0.000002626976,0.000017611052,0.00026464168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495745,0.00096993113,0.0030900282,0.00026987036,0.00045298052,0.00025974505],"domain_scores_gemma":[0.9941477,0.002678125,0.0019809594,0.00016789127,0.00079597783,0.00022934018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025339404,0.00019368822,0.0019884543,0.00042064697,0.000043526838,0.000009409321,0.00014467693,0.00013682635,0.00028396325],"category_scores_gemma":[0.0069933664,0.00012268672,0.00028417062,0.000660604,0.0001572926,0.00012037202,0.000048386475,0.00089643156,0.0000027319265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11145536,0.0679925,0.61271054,0.00023328325,0.0028071392,0.0016940361,0.00079604867,0.001415177,0.0033148644,0.000028712499,0.0009912137,0.19656113],"study_design_scores_gemma":[0.32840428,0.10668939,0.5421293,0.0034854102,0.0031152656,0.00006212413,0.006035542,0.001458405,0.0046260506,0.00016033073,0.0033528844,0.00048101903],"about_ca_topic_score_codex":0.00011618935,"about_ca_topic_score_gemma":0.0007990933,"teacher_disagreement_score":0.21694893,"about_ca_system_score_codex":0.00016813174,"about_ca_system_score_gemma":0.0024262979,"threshold_uncertainty_score":0.8372218},"labels":[],"label_agreement":null},{"id":"W4407698792","doi":"10.1200/jco.2025.43.5_suppl.147","title":"Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Biotech","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Internal medicine; Prostate; Castration; Oncology; Urology; Hormone; Cancer","score_opus":0.1759869625840245,"score_gpt":0.49849487037549023,"score_spread":0.32250790779146576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939276,0.0017347651,0.000039669412,0.001274831,0.0006109574,0.0023185075,0.000013326716,0.000007667765,0.00007267891],"genre_scores_gemma":[0.9947139,0.004511451,0.00023234093,0.00016951669,0.00011062075,0.00011716686,0.000014640181,0.000021937689,0.0001084412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448687,0.0009679648,0.0031560913,0.0003764108,0.0005322912,0.0004803969],"domain_scores_gemma":[0.9956715,0.0016562958,0.0014348108,0.00023303235,0.000757699,0.00024663567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028569077,0.00024134593,0.0019111865,0.0005427054,0.00004417855,0.000025312813,0.00017507645,0.00018192151,0.00002927259],"category_scores_gemma":[0.0010590678,0.00017543,0.00021076204,0.0006705605,0.0003075507,0.0002406654,0.00007795898,0.00089389086,0.0000021968679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09082454,0.008300132,0.681863,0.000040771058,0.0011063841,0.0023900524,0.0053268573,0.00029605132,0.0008099026,0.000008422296,0.000046220484,0.20898764],"study_design_scores_gemma":[0.11299023,0.027845128,0.8512971,0.00040500783,0.00026904905,0.000012808683,0.0036280164,0.0012800146,0.0018135281,0.00010822122,0.00021894758,0.00013197737],"about_ca_topic_score_codex":0.0009423099,"about_ca_topic_score_gemma":0.0067166383,"teacher_disagreement_score":0.20885566,"about_ca_system_score_codex":0.00057726545,"about_ca_system_score_gemma":0.0021200485,"threshold_uncertainty_score":0.7153828},"labels":[],"label_agreement":null},{"id":"W4407698914","doi":"10.1200/jco.2025.43.5_suppl.384","title":"Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Oncology; Internal medicine; Biomarker; Cancer","score_opus":0.07285131951477221,"score_gpt":0.5049981116449364,"score_spread":0.43214679213016416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829679,0.012021892,0.000025841831,0.0035173942,0.00023327828,0.00069725804,0.00007865875,0.0000021273156,0.0004556535],"genre_scores_gemma":[0.980998,0.018306237,0.00030226124,0.0001928029,0.00005136656,0.000027745122,0.000012672492,0.000006571353,0.000102382015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960263,0.0011954844,0.001840092,0.00018784199,0.0005909979,0.00015927899],"domain_scores_gemma":[0.9940277,0.002396316,0.0014802848,0.00013202176,0.0018312563,0.00013246661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008016424,0.00010417136,0.0014820021,0.00081883604,0.000020409847,0.0000039831652,0.000081458624,0.00021917687,0.00020031862],"category_scores_gemma":[0.00500374,0.000068715155,0.00029848318,0.00089095463,0.0003625851,0.00007748224,0.000030533894,0.0005442979,2.3025277e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015240969,0.001112425,0.67721444,0.00006906648,0.008141039,0.00005319673,0.00039022564,0.00013776882,0.00054561003,0.000009190391,0.00016862425,0.29691744],"study_design_scores_gemma":[0.020488197,0.010153284,0.9516227,0.00028319188,0.009737058,0.000010171597,0.0002147429,0.0062866746,0.0001906411,0.00061586616,0.00035312888,0.000044330587],"about_ca_topic_score_codex":0.0004734856,"about_ca_topic_score_gemma":0.000498716,"teacher_disagreement_score":0.29687312,"about_ca_system_score_codex":0.00036772282,"about_ca_system_score_gemma":0.0064546145,"threshold_uncertainty_score":0.9991779},"labels":[],"label_agreement":null},{"id":"W4407698997","doi":"10.1200/jco.2025.43.5_suppl.263","title":"Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Prostate cancer; Overall survival; Cancer","score_opus":0.1222603444521029,"score_gpt":0.48371376017259965,"score_spread":0.3614534157204967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867642,0.0046534855,0.00018525333,0.0043887882,0.00030383252,0.0012071306,0.00003468331,0.000005213947,0.0024574096],"genre_scores_gemma":[0.9626271,0.031034222,0.0038724612,0.0008880862,0.00016075827,0.00011236883,0.000014954323,0.000016005368,0.0012740522],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965272,0.0006839599,0.0018074381,0.00034177452,0.0002718371,0.00036780344],"domain_scores_gemma":[0.99655473,0.0013859123,0.0008437336,0.00016025627,0.00065152877,0.00040381137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090779783,0.00022061991,0.0024028174,0.00028448366,0.000045717363,0.000008293951,0.000103478764,0.00017919828,0.0000120812365],"category_scores_gemma":[0.0007281326,0.00013915748,0.00023669632,0.0006346454,0.0006849549,0.0001062843,0.000064213804,0.000579638,0.0000030722501],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05017288,0.013774123,0.34574303,0.00018778678,0.0041263406,0.0032989464,0.013795189,0.0007399124,0.00061459007,0.000102915,0.0023396814,0.5651046],"study_design_scores_gemma":[0.030334044,0.05901354,0.86345774,0.0002301065,0.00103113,0.00009371353,0.004791623,0.0007186643,0.0005167618,0.00008149868,0.03953624,0.00019495992],"about_ca_topic_score_codex":0.00043205806,"about_ca_topic_score_gemma":0.0013217217,"teacher_disagreement_score":0.56490964,"about_ca_system_score_codex":0.00089776685,"about_ca_system_score_gemma":0.0031715964,"threshold_uncertainty_score":0.56746775},"labels":[],"label_agreement":null},{"id":"W4407699006","doi":"10.1200/jco.2025.43.5_suppl.tps282","title":"ACCEL: [Ac-225]-PSMA-62 phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Tolerability; Prostate cancer; Oncology; Internal medicine; Dosimetry; Clinical trial; Cancer; Adverse effect; Nuclear medicine","score_opus":0.19159128697433736,"score_gpt":0.5557792121033651,"score_spread":0.36418792512902776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97011346,0.0016362745,0.000045136232,0.024716722,0.0009940608,0.0021585594,0.000083437335,0.000011983672,0.00024037436],"genre_scores_gemma":[0.9875852,0.007641867,0.0017587006,0.0019637651,0.0005010452,0.000048994432,0.00001860309,0.000023507922,0.0004583138],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9923035,0.0014856715,0.0046175416,0.0005791014,0.00050977926,0.000504412],"domain_scores_gemma":[0.9909633,0.006200586,0.0012140558,0.00027844284,0.0005229308,0.00082069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008171661,0.00030817612,0.0029915413,0.0004912352,0.00013633652,0.000052190455,0.00016528726,0.0002978332,0.000045105604],"category_scores_gemma":[0.006820872,0.00021638347,0.00037975376,0.0006021677,0.00062654034,0.00021227158,0.00024363183,0.0015043762,0.000003539431],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5589342,0.010206255,0.013752763,0.00018593366,0.0014924338,0.0020474852,0.00067301415,0.0000061742367,0.003049699,0.000078272176,0.0010048545,0.40856892],"study_design_scores_gemma":[0.3415942,0.0682941,0.5788187,0.00050836266,0.0013589765,0.00013261737,0.00042069197,0.00018650829,0.0004504994,0.00032477416,0.007650305,0.00026025774],"about_ca_topic_score_codex":0.00014401201,"about_ca_topic_score_gemma":0.0002514422,"teacher_disagreement_score":0.5650659,"about_ca_system_score_codex":0.0003582375,"about_ca_system_score_gemma":0.003750364,"threshold_uncertainty_score":0.8823862},"labels":[],"label_agreement":null},{"id":"W4407699241","doi":"10.1200/jco.2025.43.5_suppl.192","title":"Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Nadir; Medicine; Titan (rocket family); TEC; Latitude; Geodesy; Astrobiology; Satellite; Geology; Astronomy; Ionosphere","score_opus":0.2882905299093267,"score_gpt":0.49273831183867045,"score_spread":0.20444778192934376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703443,0.00072086,0.00039983352,0.0013579829,0.00008309895,0.00012308761,0.00009539359,0.0000010203886,0.00018429811],"genre_scores_gemma":[0.9912532,0.0011832387,0.007193258,0.00030573466,0.00002579851,0.0000018597008,0.000028236234,0.0000030452252,0.000005660742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802035,0.0000899752,0.001471477,0.00015065123,0.00018194337,0.000085598],"domain_scores_gemma":[0.9976441,0.0010094654,0.0009290141,0.00016057427,0.0001615313,0.000095317126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012912999,0.00006881176,0.0011246215,0.0003194383,0.000009972661,0.0000042839415,0.000072266004,0.00012772328,0.000005838054],"category_scores_gemma":[0.00090138556,0.00005128671,0.00009897563,0.0002731365,0.00011185029,0.00008877646,0.00007780933,0.00022437263,2.9608985e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010273259,0.0023100302,0.85246146,0.00005537674,0.0035809558,0.00005530551,0.0012204283,0.0015158796,0.000114792616,0.0003076786,0.00021451007,0.13713624],"study_design_scores_gemma":[0.008338768,0.0058276225,0.96323776,0.00031030507,0.0046567596,0.000010892536,0.0003140765,0.016371367,0.00014190843,0.00022012129,0.00051351206,0.00005691989],"about_ca_topic_score_codex":0.000050877436,"about_ca_topic_score_gemma":0.00013392924,"teacher_disagreement_score":0.13707931,"about_ca_system_score_codex":0.000046497295,"about_ca_system_score_gemma":0.00066319155,"threshold_uncertainty_score":0.20914112},"labels":[],"label_agreement":null},{"id":"W4407699263","doi":"10.1200/jco.2025.43.5_suppl.490","title":"Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): A contemporary national real-world analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Calgary; London Health Sciences Centre; BC Cancer Agency; Hôtel-Dieu de Québec; University of Ottawa; Sunnybrook Health Science Centre; Ottawa Hospital; CancerCare Manitoba; St. Joseph’s Healthcare Hamilton; University of Manitoba; University of Alberta; Queen Elizabeth II Health Sciences Centre; Université Laval; Western University; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Bone metastasis; Kidney cancer; Cancer research; Pathology; Metastasis; Cancer","score_opus":0.2551577889609626,"score_gpt":0.5015933947943251,"score_spread":0.2464356058333625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805076,0.0015038982,0.0012904024,0.0055310344,0.000315826,0.0013070155,0.00017189997,0.0000071805703,0.0018219807],"genre_scores_gemma":[0.98001367,0.00015034988,0.016561713,0.0018240871,0.00008544593,0.000039101884,0.00003290336,0.0000107290325,0.0012820201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556154,0.0006356932,0.0029426517,0.00025108454,0.00039472815,0.00021429466],"domain_scores_gemma":[0.991139,0.0047554816,0.0025015192,0.00015039535,0.0010866185,0.00036698117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032589557,0.00016572069,0.0025520588,0.0008141998,0.00006025133,0.0000079309575,0.000056300254,0.00015466828,0.000028636354],"category_scores_gemma":[0.0036594453,0.00011939213,0.0007346709,0.0005652599,0.00021926609,0.00014341388,0.00004212797,0.00047687264,9.757965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06357304,0.016475005,0.81064045,0.001241431,0.020953787,0.0027529579,0.00022490293,0.000084370244,0.00043794958,0.0017289431,0.048662897,0.03322427],"study_design_scores_gemma":[0.026794981,0.012303124,0.92175776,0.00013651533,0.009267042,0.000100453675,0.00006942919,0.0006223569,0.00047252557,0.0018502063,0.026508454,0.000117164374],"about_ca_topic_score_codex":0.00043778584,"about_ca_topic_score_gemma":0.0004871608,"teacher_disagreement_score":0.1111173,"about_ca_system_score_codex":0.00016958016,"about_ca_system_score_gemma":0.0038236177,"threshold_uncertainty_score":0.67829335},"labels":[],"label_agreement":null},{"id":"W4407699397","doi":"10.1200/jco.2025.43.5_suppl.189","title":"Prostate cancer liver metastases: Genomic profiling and clinical outcomes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Kelowna General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Profiling (computer programming); Metastasis; Cancer","score_opus":0.17432640506470304,"score_gpt":0.5542742172715622,"score_spread":0.3799478122068592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720025,0.009792996,0.0000401979,0.014212626,0.0016480831,0.00051979005,0.000013688505,0.000010619031,0.0017594739],"genre_scores_gemma":[0.9226687,0.05609595,0.0067538614,0.0062420736,0.00096380664,0.000021902972,0.00000597891,0.000024171453,0.0072235614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962513,0.0005195904,0.0024151085,0.00026014293,0.00026513383,0.00028871105],"domain_scores_gemma":[0.995448,0.0026037754,0.00087018416,0.00017674435,0.0004927692,0.00040854176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00485831,0.00014775082,0.0017206012,0.00017794674,0.000058793128,0.000016145888,0.0001359953,0.00030731273,0.00010708091],"category_scores_gemma":[0.002648199,0.0000871567,0.00057163177,0.00015580731,0.00045865728,0.000096471886,0.00012966679,0.0012964595,0.0000113341475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004597138,0.00091091904,0.7653046,0.000072027215,0.0016101131,0.0007342155,0.00003154084,0.000001635094,0.00004313333,0.00011976775,0.0033401607,0.2232347],"study_design_scores_gemma":[0.016747417,0.005357777,0.89129025,0.00017091645,0.0013527569,0.000076392105,0.000118513606,0.000103191574,0.000097748285,0.000382802,0.0842131,0.000089143105],"about_ca_topic_score_codex":0.000049741502,"about_ca_topic_score_gemma":0.000042893553,"teacher_disagreement_score":0.22314556,"about_ca_system_score_codex":0.00021545198,"about_ca_system_score_gemma":0.0043115993,"threshold_uncertainty_score":0.7648592},"labels":[],"label_agreement":null},{"id":"W4407699401","doi":"10.1200/jco.2025.43.5_suppl.80","title":"Frailty and adverse clinical outcomes in prostate cancer patients: An analysis from the RADICAL-PC cohort.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Niagara Health System; Population Health Research Institute; Université Laval; Hamilton Health Sciences; Impact; Université de Sherbrooke; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Adverse effect; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.07865535880672371,"score_gpt":0.48749893269899947,"score_spread":0.40884357389227577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96471095,0.00035510692,0.000044949375,0.03248534,0.0015759864,0.0004086381,0.000036630798,0.0000094718025,0.00037290202],"genre_scores_gemma":[0.98036027,0.0022766308,0.0011758042,0.015153662,0.00046520773,0.000011397588,0.000016688316,0.000011820899,0.0005285328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934149,0.001368536,0.0041240687,0.00037672734,0.00044803377,0.0002677805],"domain_scores_gemma":[0.98713255,0.0099756345,0.0015613434,0.0004152993,0.00048183382,0.00043333945],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048531857,0.00018463537,0.002537413,0.00021061908,0.000049663875,0.0000125644865,0.00030784786,0.0004698939,0.00023624103],"category_scores_gemma":[0.01622714,0.00010490613,0.0007504398,0.00048373677,0.000695962,0.00016015276,0.00012314883,0.0019292758,0.000005773367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021122734,0.0023433254,0.9086004,0.000007114335,0.002683542,0.00014921362,0.00014245462,0.000030434123,9.437489e-7,0.000016670896,0.0035614176,0.08035221],"study_design_scores_gemma":[0.013081447,0.002817697,0.9511323,0.00010680112,0.0032367462,0.000003508447,0.00016647208,0.00041528072,0.0000014385038,0.00033447446,0.028613143,0.00009071052],"about_ca_topic_score_codex":0.0010805024,"about_ca_topic_score_gemma":0.005150684,"teacher_disagreement_score":0.0802615,"about_ca_system_score_codex":0.00018458636,"about_ca_system_score_gemma":0.0013837971,"threshold_uncertainty_score":0.9920596},"labels":[],"label_agreement":null},{"id":"W4407699408","doi":"10.1200/jco.2025.43.5_suppl.tps890","title":"NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Bladder cancer; Oncology; Neoadjuvant therapy; Cancer; Urothelial cancer; Internal medicine; Surgery; Breast cancer","score_opus":0.09079120429685564,"score_gpt":0.4945529439766049,"score_spread":0.40376173967974927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.895052,0.013495048,0.0010922605,0.066855386,0.0075827325,0.0020338278,0.00028562086,0.00004253388,0.013560581],"genre_scores_gemma":[0.95698,0.017471338,0.0012666942,0.011991357,0.0017433825,0.00013924863,0.000018184488,0.000040430743,0.010349382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974702,0.00025110366,0.0014568616,0.00028386392,0.00021849861,0.0003194438],"domain_scores_gemma":[0.99611306,0.0020000015,0.00091398583,0.00020956779,0.0004886912,0.00027469912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006854636,0.00023299002,0.0018412836,0.000098713754,0.000071402006,0.000011076249,0.00014813006,0.00037863394,0.00027900923],"category_scores_gemma":[0.00056139147,0.00014648709,0.0008486089,0.00015984497,0.0001459631,0.000081072256,0.000017711964,0.0003876646,0.000005637283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05052296,0.004057064,0.085819796,0.000018091241,0.004695335,0.00011834905,0.00014045724,0.000006494458,0.00089052983,0.000047648326,0.11945151,0.73423177],"study_design_scores_gemma":[0.049296364,0.03361465,0.110198915,0.00008031568,0.00064771535,0.00003526779,0.00008057423,0.00003340753,0.0023911186,0.0003114277,0.8031761,0.00013414756],"about_ca_topic_score_codex":0.00017027391,"about_ca_topic_score_gemma":0.00019828185,"teacher_disagreement_score":0.7340976,"about_ca_system_score_codex":0.00046790208,"about_ca_system_score_gemma":0.003510493,"threshold_uncertainty_score":0.6227464},"labels":[],"label_agreement":null},{"id":"W4407699434","doi":"10.1200/jco.2025.43.5_suppl.137","title":"Association of statin use with overall survival and cardiac adverse events in patients with advanced prostate cancer treated with apalutamide: A pooled analysis of TITAN and SPARTAN.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto; University Health Network; Mount Sinai Hospital; Ottawa Hospital; BC Cancer Agency; University of British Columbia; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Adverse effect; Prostate; Overall survival; Cancer","score_opus":0.013151519289924736,"score_gpt":0.3380862972590667,"score_spread":0.32493477796914194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893403,0.00031795434,0.000030155008,0.00010223874,0.0003083311,0.00019331957,0.00007817876,8.669792e-7,0.00003493819],"genre_scores_gemma":[0.9973499,0.0016404275,0.0005533707,0.00006209075,0.00011593226,0.000005600346,0.000021260337,0.000007550486,0.00024382328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998422,0.00028385568,0.0007870419,0.00018042224,0.00019551143,0.00013113445],"domain_scores_gemma":[0.9977677,0.00021333732,0.0013104811,0.0001040351,0.0005278636,0.00007657773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065974565,0.0001106817,0.0010079629,0.00013295094,0.000013001631,0.0000021759522,0.000049181763,0.0001442067,0.0000026345022],"category_scores_gemma":[0.00034144655,0.00007325362,0.00009462701,0.0002450002,0.00009203815,0.000018177354,0.000024264364,0.00015445743,1.5910974e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012042655,0.0002983611,0.9789091,0.000020278601,0.003137708,4.780504e-7,0.00005296413,0.0007947076,0.000727375,0.000007707381,0.00008305319,0.003925641],"study_design_scores_gemma":[0.010130526,0.0035377694,0.9808606,0.000071336646,0.002143552,2.0602299e-7,0.000079913225,0.000023496255,0.00014805216,0.000005022711,0.002920809,0.00007870145],"about_ca_topic_score_codex":0.00024416472,"about_ca_topic_score_gemma":0.003109037,"teacher_disagreement_score":0.0038469397,"about_ca_system_score_codex":0.00005535871,"about_ca_system_score_gemma":0.000505065,"threshold_uncertainty_score":0.29871958},"labels":[],"label_agreement":null},{"id":"W4407699446","doi":"10.1200/jco.2025.43.5_suppl.130","title":"Impact of adherence to a remote exercise program on health-related quality of life in prostate cancer patients undergoing treatment: A prospective study in Brazil.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare during COVID-19 Pandemic","field":"Computer Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Cancer; Prospective cohort study; Physical therapy; Prostate; Oncology; Gerontology; Internal medicine; Nursing","score_opus":0.16086069298439062,"score_gpt":0.5685248527231737,"score_spread":0.407664159738783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450755,0.00019427328,0.00008283572,0.002224607,0.00045498082,0.0024651226,0.000004957136,0.000015011612,0.000050660015],"genre_scores_gemma":[0.99742895,0.00029546669,0.0018294896,0.00036807603,0.000017910508,0.00003665251,2.648709e-7,0.0000073372084,0.000015869033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99143827,0.002175328,0.0051760864,0.00041952502,0.0004042004,0.0003865688],"domain_scores_gemma":[0.99223703,0.0032250604,0.0033169445,0.00035636855,0.0005261776,0.00033844466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005568513,0.00018347768,0.0021990007,0.0005573784,0.000029795783,0.000012013305,0.0005480886,0.00018771518,0.0000024098795],"category_scores_gemma":[0.006711394,0.00013677312,0.00027844004,0.0013745058,0.00007861874,0.00017560285,0.00015001776,0.0007497244,0.0000013061891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003092002,0.007720471,0.6795038,0.00007521019,0.00008935947,0.000022331942,0.0026719214,0.000622837,0.0000019300858,0.000026438876,0.000016564445,0.3061571],"study_design_scores_gemma":[0.011713929,0.07073979,0.9149542,0.0010646059,0.000011262224,7.9765357e-7,0.00009429219,0.00048523207,0.0000055735204,0.0008398166,0.000009457826,0.00008105702],"about_ca_topic_score_codex":0.014455575,"about_ca_topic_score_gemma":0.01729788,"teacher_disagreement_score":0.30607605,"about_ca_system_score_codex":0.0023710001,"about_ca_system_score_gemma":0.0145594245,"threshold_uncertainty_score":0.9921073},"labels":[],"label_agreement":null},{"id":"W4407699454","doi":"10.1200/jco.2025.43.5_suppl.765","title":"Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bladder cancer; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.09811926584908452,"score_gpt":0.47016135365676626,"score_spread":0.3720420878076817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672228,0.0025369984,0.00030189627,0.020919297,0.002946609,0.0009436155,0.000084542124,0.00001281624,0.00503143],"genre_scores_gemma":[0.97809136,0.006042737,0.0005298911,0.012156467,0.0016607459,0.00016102944,0.0000051642846,0.000020565214,0.0013320262],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997739,0.0002225274,0.0013727726,0.00021196213,0.00019442721,0.00025930433],"domain_scores_gemma":[0.99582523,0.0025699916,0.00069351605,0.00024147105,0.0004542036,0.00021561577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048266497,0.00019135303,0.001014793,0.00009383504,0.0001393064,0.000013977792,0.00013209807,0.0002834066,0.00045803317],"category_scores_gemma":[0.0006606657,0.00009246119,0.00091043307,0.00013449742,0.00020954596,0.00006074409,0.000034639437,0.00042541084,0.000009412795],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033015085,0.0037219452,0.076562054,0.000032386437,0.0034440549,0.00007434425,0.0014849962,0.000046537945,0.00023198049,0.00021412369,0.04477531,0.86611074],"study_design_scores_gemma":[0.010839023,0.012387237,0.54236984,0.0001627638,0.0015346258,0.000036300884,0.00092203234,0.000025081026,0.00019631765,0.00052380626,0.43092352,0.00007945277],"about_ca_topic_score_codex":0.0001076178,"about_ca_topic_score_gemma":0.00087523257,"teacher_disagreement_score":0.8660313,"about_ca_system_score_codex":0.0005165849,"about_ca_system_score_gemma":0.0034956997,"threshold_uncertainty_score":0.62012213},"labels":[],"label_agreement":null},{"id":"W4407699506","doi":"10.1200/jco.2025.43.5_suppl.22","title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Nova Scotia Cancer Centre; Dalhousie University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McMaster University; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Trillium Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Université Laval; Credit Valley Hospital; Ottawa Regional Cancer Foundation; CancerCare Manitoba; University Health Network; Hôpital Charles-Le Moyne; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Systemic therapy; Randomized controlled trial; Oncology; Internal medicine; Castration; Cancer; Breast cancer; Hormone","score_opus":0.11886466220176782,"score_gpt":0.5201430815661987,"score_spread":0.40127841936443087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839934,0.0066049425,0.00006615329,0.00906263,0.0010525133,0.0044478388,0.0001071255,0.000017964396,0.00024151168],"genre_scores_gemma":[0.96679956,0.030066319,0.0009241771,0.0008916799,0.0003521842,0.0004975433,0.000043273914,0.000019445988,0.00040584613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919421,0.0030823478,0.0036930104,0.000314575,0.00058605353,0.00038189234],"domain_scores_gemma":[0.99426293,0.0033490013,0.0012075998,0.00019818281,0.00071485055,0.00026744168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010611332,0.00022814119,0.0031567733,0.00090238196,0.00006464767,0.000025802537,0.00014474752,0.00023506388,0.00017996739],"category_scores_gemma":[0.003786452,0.00014214711,0.00049661956,0.0009951903,0.00018353647,0.0001543752,0.000027318742,0.0009008169,0.0000020555772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7755605,0.003446306,0.00035325193,0.00004934569,0.00071106624,0.0007017681,0.00043448183,0.000039822233,0.001875491,0.000033088032,0.0016333616,0.21516155],"study_design_scores_gemma":[0.9245691,0.06278589,0.001384256,0.0009637483,0.00023992459,0.000033598433,0.000272162,0.00012100988,0.00095124793,0.00049989764,0.008062903,0.000116304465],"about_ca_topic_score_codex":0.00024719533,"about_ca_topic_score_gemma":0.00051059463,"teacher_disagreement_score":0.21504524,"about_ca_system_score_codex":0.0009940757,"about_ca_system_score_gemma":0.006286275,"threshold_uncertainty_score":0.99934715},"labels":[],"label_agreement":null},{"id":"W4407699539","doi":"10.1200/jco.2025.43.5_suppl.662","title":"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with <i>FGFR3</i> alterations: Initial results from FORAGER-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Gene isoform; Cancer research; Internal medicine; Pathology; Oncology; Biochemistry; Gene; Biology","score_opus":0.04495718704566696,"score_gpt":0.4567314972121554,"score_spread":0.4117743101664884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967901,0.00012423236,0.00030836978,0.0008609749,0.0003352481,0.0007834811,0.000070295195,0.000005251848,0.00072202523],"genre_scores_gemma":[0.9981003,0.00007840123,0.00087786006,0.0002849615,0.00046169752,0.00004276622,0.000044131997,0.000026305888,0.00008361045],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99419224,0.00085583393,0.0034865101,0.0005642747,0.00043910395,0.0004620298],"domain_scores_gemma":[0.9960914,0.001029983,0.0016056555,0.0004066183,0.0006583178,0.00020798288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019946285,0.00027683895,0.0014030486,0.00044204912,0.00008566501,0.000023881825,0.0004934481,0.0004425702,0.000009954762],"category_scores_gemma":[0.0033518665,0.0002254608,0.00025164735,0.00049513986,0.0002635824,0.00004788117,0.00023031908,0.0011815056,0.0000016945128],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32278106,0.08569128,0.13860928,0.0002817571,0.0029917106,0.004300825,0.0043038605,0.013321732,0.3769608,0.00020502777,0.010173556,0.040379114],"study_design_scores_gemma":[0.26856598,0.3078034,0.23415947,0.0017661569,0.00038267835,0.00012235549,0.0036729332,0.0011344667,0.16925605,0.0021083318,0.009838081,0.0011901103],"about_ca_topic_score_codex":0.0002526313,"about_ca_topic_score_gemma":0.005556593,"teacher_disagreement_score":0.22211212,"about_ca_system_score_codex":0.000174302,"about_ca_system_score_gemma":0.0017678186,"threshold_uncertainty_score":0.9194025},"labels":[],"label_agreement":null},{"id":"W4407699651","doi":"10.1200/jco.2025.43.5_suppl.308","title":"Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Gene signature; Prostate cancer; Prostate; Oncology; Signature (topology); Radiation dose; Internal medicine; Gene; Nuclear medicine; Cancer; Gene expression; Genetics; Biology","score_opus":0.05485380253128928,"score_gpt":0.48956686195233035,"score_spread":0.43471305942104105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93959695,0.00021938811,0.057219353,0.0017115573,0.0005053332,0.00049572345,0.000037966132,0.000005404935,0.00020832164],"genre_scores_gemma":[0.9789672,0.00008236674,0.020259695,0.00018769727,0.00034125574,0.00001206076,0.000005214657,0.00000789858,0.00013661648],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952342,0.0010746202,0.0032931634,0.000120223376,0.00016828289,0.000109532004],"domain_scores_gemma":[0.99367267,0.0028541316,0.0029391164,0.00014246993,0.00030348724,0.000088096494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068194764,0.000094863004,0.0013846433,0.00025005598,0.000012087066,0.0000034739514,0.00017714407,0.0001742565,0.00012592749],"category_scores_gemma":[0.0016314815,0.00007410577,0.00031447312,0.00027422668,0.00006749476,0.00011824846,0.000023248636,0.0004333361,1.8740133e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08771195,0.005242228,0.06052037,0.000033202927,0.0008320797,0.00003272743,0.0006881678,0.0029578148,0.1279267,0.001404833,0.004871454,0.70777845],"study_design_scores_gemma":[0.118883185,0.03638611,0.089949824,0.000585301,0.00064211636,0.000009112573,0.0003014794,0.0008193151,0.58710843,0.02411265,0.1407157,0.00048678403],"about_ca_topic_score_codex":0.000008571008,"about_ca_topic_score_gemma":7.0432276e-7,"teacher_disagreement_score":0.70729166,"about_ca_system_score_codex":0.00006635468,"about_ca_system_score_gemma":0.0011031165,"threshold_uncertainty_score":0.30219454},"labels":[],"label_agreement":null},{"id":"W4407699679","doi":"10.1200/jco.2025.43.5_suppl.152","title":"Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Université de Montréal; Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Concomitant; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.06289102622858335,"score_gpt":0.44303662251213805,"score_spread":0.3801455962835547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737966,0.00034797133,0.000011891385,0.00081022974,0.000056382323,0.001347494,0.000021068745,0.0000027726876,0.000022548746],"genre_scores_gemma":[0.99837357,0.0006480445,0.0006759738,0.00022129758,0.000014149933,0.000020912143,0.000011425588,0.000012389626,0.000022266857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966311,0.0009109646,0.0015679332,0.00025573044,0.00036477868,0.00026949903],"domain_scores_gemma":[0.9966316,0.0016706139,0.00080859114,0.00012625194,0.0005886354,0.0001743051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002327608,0.0001629469,0.001469145,0.00056471577,0.000020331514,0.000011765223,0.000060360395,0.00009791411,0.0000025078057],"category_scores_gemma":[0.00074914086,0.00010245134,0.00005096067,0.0004725463,0.00030396052,0.00025702344,0.00003911154,0.0008286059,1.7031083e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13897173,0.013607465,0.8094664,0.000040162613,0.00041765696,0.0037112567,0.0018409946,0.0002126847,0.00006883428,0.000009890919,0.000009494428,0.031643413],"study_design_scores_gemma":[0.14944175,0.048937857,0.7976471,0.00052661356,0.00026089966,0.000017327839,0.0023960867,0.00060264126,0.00003235825,0.000044047407,0.000016183862,0.000077146215],"about_ca_topic_score_codex":0.00049051427,"about_ca_topic_score_gemma":0.0031469534,"teacher_disagreement_score":0.035330392,"about_ca_system_score_codex":0.0004841599,"about_ca_system_score_gemma":0.001785629,"threshold_uncertainty_score":0.41778442},"labels":[],"label_agreement":null},{"id":"W4407699688","doi":"10.1200/jco.2025.43.5_suppl.505","title":"Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Database; Oncology; Internal medicine; Urology","score_opus":0.2089176474603002,"score_gpt":0.44566881026029537,"score_spread":0.23675116279999517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665516,0.002591235,0.00061020383,0.011393467,0.008496558,0.00046306092,0.00080974604,0.000016550459,0.009067549],"genre_scores_gemma":[0.9890768,0.0009006904,0.0029068242,0.0039764224,0.0018888593,0.000008290009,0.00054166786,0.000026988626,0.000673477],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9935405,0.0013143206,0.0034353267,0.00057624176,0.0008015166,0.00033204883],"domain_scores_gemma":[0.98064846,0.014095236,0.0028770973,0.0013536549,0.00055867195,0.00046691016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047078906,0.00031623698,0.001721086,0.00018148698,0.00009074155,0.000045237313,0.0015015826,0.00024732325,0.00055968633],"category_scores_gemma":[0.008229922,0.0001922892,0.0006295797,0.00018245737,0.00055686897,0.0003103973,0.00080286205,0.0019820638,0.00012617986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072748624,0.0073815654,0.2866751,0.00012599067,0.0065096477,0.018643802,0.00021661504,0.000032625983,0.0016790272,0.000085048465,0.56475407,0.04114792],"study_design_scores_gemma":[0.096640915,0.015218807,0.63197786,0.00078874873,0.007773147,0.00037479,0.001320681,0.0036650237,0.0058011212,0.0005164704,0.23542652,0.0004959108],"about_ca_topic_score_codex":0.00035018133,"about_ca_topic_score_gemma":0.00023699613,"teacher_disagreement_score":0.3453028,"about_ca_system_score_codex":0.00033111652,"about_ca_system_score_gemma":0.005308945,"threshold_uncertainty_score":0.9852579},"labels":[],"label_agreement":null},{"id":"W4407699726","doi":"10.1200/jco.2025.43.5_suppl.399","title":"Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McMaster University; McGill University Health Centre; Centre hospitalier universitaire de Québec","funders":"National Institutes of Health","keywords":"Medicine; Prostatectomy; DECIPHER; Oncology; Internal medicine; Radiation therapy; Randomized controlled trial; Prostate cancer; Cancer; Bioinformatics","score_opus":0.06896096030624796,"score_gpt":0.505670688163185,"score_spread":0.43670972785693696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9003344,0.0006508283,0.0022991423,0.0920716,0.0014306669,0.0022094809,0.0000033478257,0.000011937311,0.0009886014],"genre_scores_gemma":[0.9707023,0.0014916585,0.0052104383,0.021013618,0.0007158949,0.000093443174,0.000007532374,0.000023044606,0.0007420868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99030924,0.0044474322,0.0042111995,0.00029411484,0.0004511351,0.00028689505],"domain_scores_gemma":[0.978791,0.017650492,0.002129803,0.0004099183,0.0006800608,0.00033872275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024708722,0.00021745823,0.0033061574,0.0004934546,0.00004923881,0.00001528816,0.00033357722,0.00039232062,0.0001398263],"category_scores_gemma":[0.04829718,0.00011816786,0.0008610106,0.00042908793,0.00054200814,0.00006505784,0.000034268738,0.0012838343,0.000004598848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7858779,0.004507106,0.0014471492,0.000014667061,0.0006157376,0.00064676563,0.0015625594,0.000024583209,0.0026522172,0.00010781418,0.0024562955,0.20008722],"study_design_scores_gemma":[0.82646716,0.041766666,0.011265266,0.0002851459,0.0007246014,0.00018692638,0.0006627632,0.0009919988,0.00010091421,0.000338595,0.11712004,0.00008990707],"about_ca_topic_score_codex":0.00012273958,"about_ca_topic_score_gemma":0.000022500699,"teacher_disagreement_score":0.19999732,"about_ca_system_score_codex":0.000547061,"about_ca_system_score_gemma":0.0047113667,"threshold_uncertainty_score":0.9597194},"labels":[],"label_agreement":null},{"id":"W4407699740","doi":"10.1200/jco.2025.43.5_suppl.252","title":"Circulating tumor DNA levels and related kinetics as prognostic biomarkers for clinical outcomes in mCRPC: A post hoc analysis of CM 7DX.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Post-hoc analysis; Post hoc; Oncology; Internal medicine; Cancer research; Pathology","score_opus":0.06865620278592825,"score_gpt":0.45596976085556834,"score_spread":0.3873135580696401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526525,0.0011370283,0.00033564572,0.0017422776,0.0008087308,0.00026410495,0.000052604213,0.0000019681177,0.00039237784],"genre_scores_gemma":[0.9948677,0.0007878129,0.0028667047,0.0012490697,0.00013165649,0.000005938475,0.000018606981,0.00001299765,0.00005955439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578786,0.00031158476,0.0032439919,0.00030901018,0.0001263541,0.00022121656],"domain_scores_gemma":[0.99269706,0.0046962593,0.001711082,0.00023049625,0.0005030257,0.00016207334],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003030131,0.00015462117,0.0014762915,0.00029520207,0.00002721166,0.000012913396,0.00022936003,0.00047572493,0.00001159757],"category_scores_gemma":[0.024792688,0.00013192206,0.00084157294,0.00034119634,0.00028002713,0.000005140864,0.00014490506,0.00032024697,4.304038e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029396066,0.0015098208,0.93997693,0.000054964872,0.0059718215,0.00012293232,0.000043872788,0.0002832579,0.00843448,0.00030273217,0.0005914635,0.039768104],"study_design_scores_gemma":[0.0060028154,0.009416842,0.9744774,0.00006436712,0.0022002517,0.00003587545,0.00012429248,0.0006522249,0.00037771172,0.0007649629,0.00571901,0.00016425706],"about_ca_topic_score_codex":0.000022571021,"about_ca_topic_score_gemma":0.00022772708,"teacher_disagreement_score":0.039603848,"about_ca_system_score_codex":0.00004039994,"about_ca_system_score_gemma":0.0011163447,"threshold_uncertainty_score":0.9834219},"labels":[],"label_agreement":null},{"id":"W4407699835","doi":"10.1200/jco.2025.43.5_suppl.219","title":"Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Prostate cancer; Abiraterone; Germline; Somatic cell; Germline mutation; PARP inhibitor; Oncology; Enzalutamide; Internal medicine; Placebo; Cancer; Mutation; Androgen receptor; Poly ADP ribose polymerase; Pathology; Genetics","score_opus":0.13235641196189069,"score_gpt":0.47395915832958185,"score_spread":0.34160274636769117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071574,0.00017979454,0.0001839143,0.0049416553,0.0006067041,0.0030202311,0.000015710766,0.000007879576,0.0003283795],"genre_scores_gemma":[0.9962131,0.00014803621,0.002219566,0.0008056465,0.0001765774,0.00021791377,0.000013384629,0.000023856419,0.00018192564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940999,0.0011821125,0.003368344,0.00029363026,0.0007478923,0.0003081296],"domain_scores_gemma":[0.99254066,0.0037232444,0.0026566198,0.000286095,0.0006622381,0.00013112118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034532428,0.0002451595,0.0017583007,0.00034651998,0.00004761463,0.000022371876,0.00021818974,0.00017877547,0.00007844421],"category_scores_gemma":[0.0019785461,0.00012688748,0.00015292651,0.0007539962,0.00035320592,0.00020720174,0.000020134401,0.0009839743,0.0000024445194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9670758,0.004249311,0.004685185,0.0003034426,0.0006896625,0.0005617508,0.0020130635,0.0051163873,0.00014310761,0.00006012959,0.00029389627,0.014808245],"study_design_scores_gemma":[0.7865324,0.06318759,0.14353982,0.0021250497,0.0009728353,0.000059874736,0.0011545699,0.0010127897,0.00020272387,0.000106329746,0.0009064043,0.0001995883],"about_ca_topic_score_codex":0.00019606772,"about_ca_topic_score_gemma":0.0032682915,"teacher_disagreement_score":0.1805434,"about_ca_system_score_codex":0.001022311,"about_ca_system_score_gemma":0.008282797,"threshold_uncertainty_score":0.9973393},"labels":[],"label_agreement":null},{"id":"W4407699857","doi":"10.1200/jco.2025.43.5_suppl.tps891","title":"ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Chemotherapy; Immunotherapy; Oncology; Open label; Internal medicine; Randomized controlled trial; Pharmacology; Cancer","score_opus":0.17611272513261214,"score_gpt":0.5627920855961613,"score_spread":0.3866793604635492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846995,0.0016882645,0.0001814131,0.00893836,0.00046522988,0.0029900875,0.0000024852002,0.0000041210983,0.0010305624],"genre_scores_gemma":[0.99085224,0.004713312,0.0011516083,0.0020221986,0.00012667412,0.000041503383,0.000005258242,0.000014365664,0.0010728333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949242,0.0018033958,0.002524041,0.00021077588,0.00038709556,0.00015047888],"domain_scores_gemma":[0.9924452,0.005046551,0.0016417189,0.00015957606,0.000609576,0.00009742266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011880603,0.00015999976,0.0026344713,0.0002413841,0.000040492625,0.000011398182,0.00016831752,0.00020572935,0.00078415504],"category_scores_gemma":[0.001699907,0.00008882547,0.00010299066,0.0003849445,0.00024768515,0.0001242205,0.00003686483,0.00046647456,7.68775e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66400045,0.031296145,0.002769317,0.000020885263,0.0016204775,0.00012934157,0.0003869618,0.00001698884,0.00028051503,0.000024570067,0.0004603419,0.298994],"study_design_scores_gemma":[0.8962673,0.062433638,0.0331458,0.00017929613,0.001812399,0.00010396161,0.00018608541,0.00082576677,0.0001802423,0.00013525189,0.0046513933,0.00007889321],"about_ca_topic_score_codex":0.00009362495,"about_ca_topic_score_gemma":0.00025429708,"teacher_disagreement_score":0.29891512,"about_ca_system_score_codex":0.00029117748,"about_ca_system_score_gemma":0.0031591002,"threshold_uncertainty_score":0.8585948},"labels":[],"label_agreement":null},{"id":"W4407699871","doi":"10.1200/jco.2025.43.5_suppl.819","title":"Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary; University Health Network; Lakeridge Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bladder cancer; Chemotherapy; Oncology; Neoadjuvant therapy; Urology; Internal medicine; Cystectomy; Chemoradiotherapy; Cancer; Breast cancer","score_opus":0.057723729309533844,"score_gpt":0.4357738761988746,"score_spread":0.37805014688934074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958194,0.0007659076,0.0012457622,0.0052988706,0.0014763548,0.0011412407,0.000047421603,0.000013798584,0.0004287302],"genre_scores_gemma":[0.9845825,0.0014421135,0.005970483,0.006505016,0.0005679584,0.00006359423,0.000014166861,0.00006215011,0.00079201313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964365,0.00012964748,0.0022288074,0.00034641393,0.0004661701,0.00039245805],"domain_scores_gemma":[0.9952184,0.0013441662,0.0019143319,0.00034026158,0.00089188473,0.00029097567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006668189,0.0003356565,0.002776889,0.00021811301,0.00006402166,0.000012780837,0.0002624562,0.00032460125,0.0002636709],"category_scores_gemma":[0.00053898,0.00020939861,0.00075787876,0.0002192091,0.00029884087,0.00013814856,0.00003179971,0.0005367637,0.0000019523166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006386957,0.0033484916,0.75279653,0.00016472908,0.0048597315,0.000053900836,0.00027287533,0.0000143598645,0.000059642818,0.000019033247,0.000944786,0.23107894],"study_design_scores_gemma":[0.04527806,0.018327922,0.93066955,0.00043021975,0.0018392124,0.000014298329,0.00006390279,0.000019124536,0.00066145346,0.00019975405,0.0023385403,0.00015794463],"about_ca_topic_score_codex":0.00006291596,"about_ca_topic_score_gemma":0.00032083996,"teacher_disagreement_score":0.230921,"about_ca_system_score_codex":0.00032217082,"about_ca_system_score_gemma":0.0028339701,"threshold_uncertainty_score":0.85390276},"labels":[],"label_agreement":null},{"id":"W4407699982","doi":"10.1200/jco.2025.43.5_suppl.115","title":"Relationship between androgen deprivation therapy and kidney function in patients with prostate cancer: An analysis of the RADICAL-PC study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; Impact; University of British Columbia; Population Health Research Institute; London Health Sciences Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Cancer; Oncology; Internal medicine; Prostate; Urology; Kidney cancer; Androgen; Kidney; Gynecology; Hormone","score_opus":0.12963725065966775,"score_gpt":0.4753265225913741,"score_spread":0.34568927193170634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955047,0.00034574635,0.000020931708,0.003451815,0.000103519764,0.0005158943,0.0000065599993,0.0000020415569,0.000048835453],"genre_scores_gemma":[0.99900323,0.00040184136,0.00006264064,0.000378553,0.000055254954,0.000008824677,0.00001134295,0.000004164439,0.00007417258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980487,0.00051952136,0.00092481764,0.00012740085,0.00028431963,0.00009523692],"domain_scores_gemma":[0.99806195,0.00074979867,0.000602464,0.00013777781,0.00031808254,0.00012993217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016201772,0.00006580139,0.00067249703,0.00029921878,0.000045013534,0.000005276815,0.00007189418,0.000118510216,0.0000135560995],"category_scores_gemma":[0.0007904365,0.00003264448,0.00010520878,0.00080270506,0.00015583729,0.00009082066,0.000021854825,0.00043199593,8.05247e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009911771,0.0013281474,0.94463444,0.000010202103,0.0012932409,0.0000038146302,0.0001946502,0.000031478477,0.0000018974007,0.000011148673,0.00006805863,0.042511176],"study_design_scores_gemma":[0.014796215,0.008003147,0.9746405,0.000051738876,0.0015154665,2.582991e-7,0.00008647229,0.00004879552,0.0000102330205,0.00013271482,0.0006868405,0.000027658867],"about_ca_topic_score_codex":0.00008645717,"about_ca_topic_score_gemma":0.0001322666,"teacher_disagreement_score":0.042483516,"about_ca_system_score_codex":0.00013354921,"about_ca_system_score_gemma":0.0011667135,"threshold_uncertainty_score":0.20696998},"labels":[],"label_agreement":null},{"id":"W4407699987","doi":"10.1200/jco.2025.43.5_suppl.459","title":"Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Immune checkpoint; PD-L1; Ipilimumab; Immunotherapy; Cancer","score_opus":0.053857476111527094,"score_gpt":0.3980470898107144,"score_spread":0.3441896136991873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363434,0.00019737313,0.00003991781,0.0012243803,0.0013300492,0.002900951,0.000021643707,0.000012188163,0.0006391258],"genre_scores_gemma":[0.9975888,0.000007934511,0.0012495695,0.00042679562,0.00017666335,0.00005153939,0.000014035247,0.000049467828,0.000435178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913884,0.00089128717,0.0058552492,0.0005593944,0.0008427527,0.00046292585],"domain_scores_gemma":[0.99184525,0.0016530743,0.0044631995,0.0008092783,0.0009528096,0.00027639803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032239112,0.0004186001,0.0028108985,0.000370458,0.00010228835,0.000015668586,0.00035742595,0.0003919579,0.00001409146],"category_scores_gemma":[0.0019822333,0.00024116795,0.0012350108,0.00048096527,0.00023728963,0.00018681592,0.00011460133,0.0010422764,0.0000012039724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10820893,0.0325415,0.83608264,0.00006020457,0.0009829671,0.00046955593,0.0013842931,0.000021619433,0.0018617027,0.0000037368231,0.00027430442,0.01810854],"study_design_scores_gemma":[0.15124898,0.09116299,0.7449035,0.00023374244,0.0009033184,0.000013499143,0.0008257773,0.000043380365,0.009888113,0.000036061567,0.0005736294,0.00016701844],"about_ca_topic_score_codex":0.00025201566,"about_ca_topic_score_gemma":0.00020268801,"teacher_disagreement_score":0.09117915,"about_ca_system_score_codex":0.0005834357,"about_ca_system_score_gemma":0.0020672854,"threshold_uncertainty_score":0.98345435},"labels":[],"label_agreement":null},{"id":"W4407699991","doi":"10.1200/jco.2025.43.5_suppl.509","title":"Comorbidity burden and effectiveness of immunotherapy in patients with metastatic renal cell carcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Immunotherapy; Comorbidity; Oncology; Internal medicine; Kidney cancer; Intensive care medicine; Cancer","score_opus":0.051562645329693714,"score_gpt":0.35076503558368977,"score_spread":0.29920239025399603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102294,0.0019585502,0.00061174756,0.00029701678,0.0004587521,0.0001435922,0.000017705246,0.0000010309795,0.005488646],"genre_scores_gemma":[0.99869716,0.00041118936,0.0006313135,0.00014035292,0.00006728321,0.0000020614261,9.3698515e-7,0.0000070991637,0.00004257389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775326,0.00014791242,0.0017825576,0.00014949958,0.000028999191,0.00013779177],"domain_scores_gemma":[0.99689513,0.0010983505,0.0017185909,0.00012338941,0.000099513905,0.000065004904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032508806,0.00009385554,0.0013816712,0.00020868976,0.000017214008,0.000008014159,0.00015514507,0.00013024877,0.000033422293],"category_scores_gemma":[0.00045398856,0.00008009683,0.0001356802,0.00011837025,0.00016485725,0.00016652017,0.00003029109,0.00035325956,0.0000028761688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029647532,0.00040419382,0.9718648,0.000055893026,0.00010147708,0.000007648661,0.00005364454,0.000107082684,0.0000039425995,0.005129454,0.00007437143,0.019232748],"study_design_scores_gemma":[0.009868577,0.0030232752,0.9708119,0.00006388589,0.000019153518,9.869294e-7,0.000013839672,0.000039576957,0.00003798543,0.009152954,0.006892677,0.000075212],"about_ca_topic_score_codex":0.00019101701,"about_ca_topic_score_gemma":0.00003589118,"teacher_disagreement_score":0.019157536,"about_ca_system_score_codex":0.00012083217,"about_ca_system_score_gemma":0.00031649446,"threshold_uncertainty_score":0.32662538},"labels":[],"label_agreement":null},{"id":"W4407700018","doi":"10.1200/jco.2025.43.5_suppl.353","title":"Management strategies and patient outcomes among LPC patients with persistently positive PSA after RP.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; London Health Sciences Centre; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; McGill University; University of Alberta; University Health Network; Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.02631968173882065,"score_gpt":0.3821304734666605,"score_spread":0.35581079172783986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881573,0.0007448689,0.000028054266,0.004982106,0.00043520474,0.00037185833,0.000006703331,0.0000044132994,0.0052694967],"genre_scores_gemma":[0.9946244,0.00056151114,0.0012021005,0.0033727784,0.000035014884,0.000021690003,0.000002914356,0.000007022625,0.00017257062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839425,0.00010491879,0.000938372,0.00017294272,0.00023262479,0.00015691659],"domain_scores_gemma":[0.99847233,0.00039119963,0.00055353437,0.00011389104,0.00028585596,0.00018317378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025383173,0.00013174424,0.0008284974,0.00010104103,0.000032587857,0.000023342738,0.000047600424,0.00010972139,0.000030981108],"category_scores_gemma":[0.00007383396,0.00007464509,0.00021534816,0.00006494987,0.00019078494,0.00014851637,0.000054991116,0.0002809177,0.0000018636209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029733244,0.0019209496,0.83824396,0.00003165375,0.0014472256,0.00073484145,0.00012162984,0.0000033507358,9.3079535e-8,0.00014621606,0.0005766256,0.15380014],"study_design_scores_gemma":[0.008914777,0.013799814,0.9686398,0.00034860658,0.0009700891,0.0000075624835,0.0009008037,0.0000026689202,0.000004648796,0.0001824508,0.0061645787,0.00006421609],"about_ca_topic_score_codex":0.000011142673,"about_ca_topic_score_gemma":0.000028086231,"teacher_disagreement_score":0.15373594,"about_ca_system_score_codex":0.00017721296,"about_ca_system_score_gemma":0.00031299854,"threshold_uncertainty_score":0.30439383},"labels":[],"label_agreement":null},{"id":"W4407700106","doi":"10.1200/jco.2025.43.5_suppl.tps283","title":"Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib/abiraterone acetate plus prednisone (KNIGHTS) trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Oncology; Abiraterone; Internal medicine; Randomized controlled trial; Cancer; Prostate; Gynecology; Androgen deprivation therapy","score_opus":0.07797300144794202,"score_gpt":0.4487236016629508,"score_spread":0.3707506002150088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868163,0.0053198943,0.00025477455,0.0014085688,0.00029392156,0.0056825145,0.00012612199,0.000041181676,0.000056741927],"genre_scores_gemma":[0.9747788,0.020083461,0.0034129499,0.00010297547,0.00013366561,0.00047832364,0.00003492999,0.000045802833,0.00092912035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99131644,0.0037712876,0.0032177393,0.0005231555,0.000720258,0.0004511304],"domain_scores_gemma":[0.9895309,0.0044797077,0.003751876,0.00038954103,0.0014361258,0.00041182945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048575276,0.00043921993,0.0055785566,0.0006357925,0.00019315763,0.000041920823,0.00019278048,0.00020814841,0.00009244149],"category_scores_gemma":[0.001136937,0.00021416547,0.00035739806,0.00096100173,0.0010584117,0.00022575932,0.00004699246,0.0011367499,0.0000014314235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8673355,0.017111976,0.007924596,0.00007972018,0.025584815,0.0005635667,0.0012504653,0.00043980769,0.00009458843,0.000015503152,0.00012618746,0.07947329],"study_design_scores_gemma":[0.8483088,0.12016765,0.013223815,0.00019900821,0.015121441,0.000042990854,0.0007430559,0.0003512082,0.0011792119,0.00024711143,0.00023756035,0.00017812937],"about_ca_topic_score_codex":0.0033472327,"about_ca_topic_score_gemma":0.0012122776,"teacher_disagreement_score":0.10305567,"about_ca_system_score_codex":0.00028503945,"about_ca_system_score_gemma":0.003673399,"threshold_uncertainty_score":0.87334144},"labels":[],"label_agreement":null},{"id":"W4407700137","doi":"10.1200/jco.2025.43.5_suppl.538","title":"Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Everolimus; Internal medicine; Baseline (sea); Oncology; Disease","score_opus":0.20794132234252433,"score_gpt":0.574952022184666,"score_spread":0.3670106998421417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97755754,0.0024092768,0.00008937342,0.015911758,0.002844693,0.0006100618,0.00009482654,0.0000110009205,0.00047146887],"genre_scores_gemma":[0.9879955,0.0022624067,0.00011671909,0.00852484,0.0008584471,0.000020541618,0.000015104073,0.00001749164,0.00018894681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929638,0.0037320002,0.002200648,0.00033499213,0.00033773688,0.00043083774],"domain_scores_gemma":[0.9857293,0.012100175,0.0011218181,0.0002681034,0.0002234097,0.0005571941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0090258485,0.00029977586,0.0013691245,0.0001979607,0.00015855886,0.000035068868,0.00062427676,0.0003286543,0.00013837614],"category_scores_gemma":[0.0034860396,0.00018321413,0.00023670272,0.00032480934,0.00042265953,0.000105921,0.00013654045,0.0022910286,0.000007761831],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072121,0.020315666,0.4197777,0.000033164913,0.0016243244,0.0017243839,0.0010870678,0.000104607614,0.0002816454,0.00021892418,0.01112566,0.47158587],"study_design_scores_gemma":[0.08003467,0.0049462277,0.3976722,0.000026124968,0.0023339095,0.000021689943,0.00045410133,0.0012075973,0.00003809861,0.00013330813,0.5128834,0.00024862302],"about_ca_topic_score_codex":0.000013187641,"about_ca_topic_score_gemma":0.000028073193,"teacher_disagreement_score":0.5017578,"about_ca_system_score_codex":0.0000547946,"about_ca_system_score_gemma":0.0007772834,"threshold_uncertainty_score":0.9953507},"labels":[],"label_agreement":null},{"id":"W4407700158","doi":"10.1200/jco.2025.43.5_suppl.460","title":"Adherence to clinical surveillance guidelines in von Hippel-Lindau (vHL) disease: Evaluating the impact of a coordinated care centre implementation in Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Von Hippel–Lindau disease; Disease; Family medicine; Intensive care medicine; Gynecology; Internal medicine","score_opus":0.10126811656892848,"score_gpt":0.5464620504947622,"score_spread":0.4451939339258337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123544,0.0040297657,0.000060811482,0.002168724,0.0020930844,0.00029054715,0.00004900797,9.567543e-7,0.00007164693],"genre_scores_gemma":[0.996587,0.0013188515,0.00027007688,0.00083347736,0.00089659786,0.0000058250553,0.00001822829,0.0000075931603,0.00006239782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952491,0.0011234874,0.0029112182,0.00024569704,0.00021739677,0.0002531246],"domain_scores_gemma":[0.9968188,0.00064983574,0.0011365497,0.0002323213,0.0009774144,0.00018511913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041711177,0.00013167856,0.0008179037,0.00007514528,0.00002371991,0.0000066549464,0.00033038226,0.00017256428,0.000029587329],"category_scores_gemma":[0.008101287,0.00009054404,0.0003255855,0.00027233595,0.00007021017,0.000006088625,0.00011305681,0.00039405178,4.3018437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023452088,0.00011058571,0.7030402,0.000014315132,0.00008845682,0.0000084782,0.00005111572,0.0014232823,0.0009200515,0.0000056924764,0.009323591,0.28266907],"study_design_scores_gemma":[0.004381977,0.0022004815,0.9748154,0.000088806344,0.000047466692,0.0000029957853,0.00081030256,0.0003080272,0.00015259709,0.000052218147,0.017040545,0.00009917583],"about_ca_topic_score_codex":0.14235221,"about_ca_topic_score_gemma":0.7847015,"teacher_disagreement_score":0.6423493,"about_ca_system_score_codex":0.00025271645,"about_ca_system_score_gemma":0.016218513,"threshold_uncertainty_score":0.9893586},"labels":[],"label_agreement":null},{"id":"W4407700199","doi":"10.1200/jco.2025.43.5_suppl.267","title":"Population-adjusted network meta-analyses (NMA) to evaluate the efficacy of treatment alternatives for metastatic hormone-sensitive prostate cancer (mHSPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Prostate cancer; Population; Internal medicine; Cancer; Gynecology; Environmental health","score_opus":0.5225097753658603,"score_gpt":0.6219806102795193,"score_spread":0.09947083491365905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94713736,0.014440265,0.00097597647,0.033548724,0.00087687955,0.0025604446,0.00007192333,0.00000833055,0.0003801236],"genre_scores_gemma":[0.9876561,0.003962878,0.004347911,0.0012644192,0.00052996364,0.00016410522,0.000016987879,0.00001746926,0.002040139],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959774,0.0010130139,0.0020626537,0.00024281822,0.00039579096,0.00030830532],"domain_scores_gemma":[0.9891911,0.0079608755,0.0010989133,0.0002357246,0.0012929607,0.00022042397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033723535,0.00020408301,0.0025938402,0.00018499377,0.000083984065,0.000012281138,0.00015346268,0.00009543782,0.000046133377],"category_scores_gemma":[0.003166927,0.00009088608,0.0013283072,0.00041627875,0.00019663661,0.00006383295,0.00004799319,0.00031269397,0.0000026113237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15568918,0.0064496994,0.037730202,0.00023277041,0.23675732,0.0004458217,0.0028307545,0.042229995,0.0021722633,0.00077934057,0.01795788,0.49672475],"study_design_scores_gemma":[0.060251158,0.064531915,0.6873582,0.00038745147,0.13151476,0.00005280306,0.00094505027,0.0034409438,0.005238715,0.005015122,0.040939648,0.000324207],"about_ca_topic_score_codex":0.00031174585,"about_ca_topic_score_gemma":0.00019280794,"teacher_disagreement_score":0.64962804,"about_ca_system_score_codex":0.00045532305,"about_ca_system_score_gemma":0.002116383,"threshold_uncertainty_score":0.37913364},"labels":[],"label_agreement":null},{"id":"W4407700214","doi":"10.1200/jco.2025.43.5_suppl.254","title":"The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université Laval; Cancer Care Ontario; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Prostatectomy; Radiation therapy; Prostate cancer; Prostate-specific antigen; Oncology; Prostate; Internal medicine; Randomized controlled trial; Urology; Cancer","score_opus":0.14978938558090527,"score_gpt":0.5113925272481094,"score_spread":0.3616031416672041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97399396,0.01864899,0.00008285825,0.0032597326,0.0008677551,0.0024050465,0.00060424587,0.000008010436,0.0001294042],"genre_scores_gemma":[0.9735608,0.02306883,0.0022007744,0.0005868139,0.00022572205,0.000104835504,0.00020259475,0.000023105205,0.000026510867],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9864681,0.005107608,0.0069247354,0.00047098554,0.0006220114,0.00040657306],"domain_scores_gemma":[0.9673247,0.023423588,0.006497917,0.0009858946,0.0013874468,0.0003804833],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019143706,0.00031682698,0.0073130415,0.00057229743,0.00008301213,0.000025766054,0.00055132125,0.0003510465,0.00022821332],"category_scores_gemma":[0.009974822,0.00015650388,0.0024674034,0.0007716998,0.00094863016,0.00017662822,0.00025393494,0.0006695936,0.0000013692268],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39386627,0.0044486043,0.3563176,0.000027786611,0.031208592,0.00028211038,0.0007343324,0.00019471151,0.0002048933,0.000028613187,0.0013950343,0.21129143],"study_design_scores_gemma":[0.22330476,0.043578897,0.6996882,0.00019633399,0.018090256,0.000027177237,0.00023656625,0.0006720197,0.00027787033,0.00021067321,0.013561621,0.00015562416],"about_ca_topic_score_codex":0.0002219748,"about_ca_topic_score_gemma":0.00034248352,"teacher_disagreement_score":0.3433706,"about_ca_system_score_codex":0.000688934,"about_ca_system_score_gemma":0.0043173395,"threshold_uncertainty_score":0.99836457},"labels":[],"label_agreement":null},{"id":"W4407700218","doi":"10.1200/jco.2025.43.5_suppl.309","title":"Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Randomized controlled trial; Radiation therapy; Urology; Prostate; Oncology; Internal medicine; Cancer","score_opus":0.1475887690056317,"score_gpt":0.50980444491162,"score_spread":0.36221567590598835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574222,0.021964934,0.000823296,0.008798513,0.0033296554,0.0069553354,0.00055687834,0.000035424306,0.00011376245],"genre_scores_gemma":[0.94664973,0.040795997,0.008991758,0.0016395454,0.0009293676,0.00045823885,0.0004459907,0.000052579275,0.000036763562],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.977445,0.009994529,0.010199581,0.0008244951,0.00093681825,0.0005995479],"domain_scores_gemma":[0.9391044,0.050213013,0.008690412,0.0008149123,0.00055044057,0.0006268201],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.02423641,0.0005655297,0.0146339685,0.00044651044,0.000101679114,0.000067891764,0.00053216354,0.0005099025,0.00039002651],"category_scores_gemma":[0.019514663,0.00031831217,0.0011161062,0.0005296398,0.0010982035,0.00026481214,0.0001741518,0.0020653342,0.0000035907315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7179086,0.0053643333,0.013289552,0.000027700347,0.012373591,0.000664853,0.0006118753,0.00043251243,0.000013652183,0.000052898322,0.0033411116,0.24591932],"study_design_scores_gemma":[0.95268196,0.012750634,0.0024219833,0.00095818477,0.010306038,0.000016437587,0.00017275743,0.0037117063,0.0003019309,0.00051482004,0.015879532,0.00028402192],"about_ca_topic_score_codex":0.002791992,"about_ca_topic_score_gemma":0.0007034765,"teacher_disagreement_score":0.2456353,"about_ca_system_score_codex":0.0007921405,"about_ca_system_score_gemma":0.0053867083,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W4407700221","doi":"10.1200/jco.2025.43.5_suppl.20","title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council","keywords":"Medicine; Androgen receptor; Prostate cancer; Oncology; Internal medicine; Enzalutamide; Meta-analysis; Hormone; Cancer","score_opus":0.3820226163641716,"score_gpt":0.5198747717027395,"score_spread":0.13785215533856793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813815,0.009137588,0.000022436945,0.0063551837,0.00044762387,0.00071766396,0.0018274278,0.0000085401425,0.000102055106],"genre_scores_gemma":[0.99295604,0.0021760284,0.0030551907,0.0007162091,0.00024874645,0.00003646239,0.0004632496,0.00002816408,0.0003199354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944667,0.0007140159,0.0027631859,0.00049246394,0.0011334537,0.00043014952],"domain_scores_gemma":[0.9924284,0.0023154502,0.0022436318,0.0005906043,0.0019815003,0.00044037274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030206323,0.00029826045,0.0032885026,0.00027650353,0.000063367355,0.00002340362,0.00042820224,0.00022661024,0.00016862154],"category_scores_gemma":[0.002388444,0.0001591568,0.0004897699,0.00057680946,0.00043262827,0.00029206078,0.00031532368,0.00096103945,0.0000053777767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.100075126,0.015734132,0.3381312,0.00035631744,0.3265705,0.0013272825,0.0048423386,0.00045168758,0.003185197,0.000049938295,0.025765594,0.18351069],"study_design_scores_gemma":[0.05237122,0.02684071,0.7257124,0.00072257186,0.15085654,0.000023199345,0.0027274857,0.00021429881,0.019958334,0.0005005872,0.019536061,0.000536581],"about_ca_topic_score_codex":0.00038640224,"about_ca_topic_score_gemma":0.00039904276,"teacher_disagreement_score":0.38758123,"about_ca_system_score_codex":0.00014177935,"about_ca_system_score_gemma":0.0039351783,"threshold_uncertainty_score":0.6980837},"labels":[],"label_agreement":null},{"id":"W4407700377","doi":"10.1200/jco.2025.43.5_suppl.552","title":"KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunotherapy; Internal medicine; Oncology; Cancer research; Cancer","score_opus":0.09398857896513756,"score_gpt":0.43031866390823253,"score_spread":0.33633008494309496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98033816,0.003820934,0.0012228593,0.0022927828,0.0013693278,0.000976347,0.00001178321,0.000016630198,0.009951202],"genre_scores_gemma":[0.98085153,0.00076129334,0.010252541,0.002019814,0.0004826664,0.000028593377,0.0000067644337,0.000049420505,0.0055473936],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99548215,0.00031476872,0.0028382712,0.00047553438,0.00042009135,0.00046921018],"domain_scores_gemma":[0.9943952,0.0024168077,0.0016413534,0.00044323143,0.00064080243,0.0004626106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001909832,0.00035120102,0.002152518,0.0002765819,0.00012593083,0.000022650227,0.00028212852,0.0005140936,0.00007344663],"category_scores_gemma":[0.0006497719,0.0002636805,0.00090929953,0.00021024022,0.00024036052,0.000120015626,0.00009822968,0.0010160416,0.000011953065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26240507,0.035715688,0.25333965,0.0013014124,0.0032717844,0.0032373553,0.001227203,0.00023007349,0.1723397,0.0008759899,0.03516426,0.23089181],"study_design_scores_gemma":[0.11267113,0.051020946,0.6850721,0.00017037253,0.0014732003,0.0004250007,0.00035379213,0.00025622768,0.012950895,0.00052177964,0.1347507,0.0003338023],"about_ca_topic_score_codex":0.000024186815,"about_ca_topic_score_gemma":0.000017309696,"teacher_disagreement_score":0.43173248,"about_ca_system_score_codex":0.000383446,"about_ca_system_score_gemma":0.0016826304,"threshold_uncertainty_score":0.9999815},"labels":[],"label_agreement":null},{"id":"W4407700392","doi":"10.1200/jco.2025.43.5_suppl.101","title":"Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Observational study; Oncology; Internal medicine; Overall survival; Systematic review; Cancer; Cabazitaxel; Gynecology; Androgen deprivation therapy; MEDLINE","score_opus":0.24188029539468642,"score_gpt":0.5410807467225567,"score_spread":0.29920045132787026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700392","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6530565,0.31033403,0.000007712415,0.03163684,0.0003770588,0.0028183986,0.00007589988,0.000006382219,0.0016871486],"genre_scores_gemma":[0.34546334,0.64964527,0.0006700883,0.0006027098,0.00010548848,0.00015858434,0.000018687047,0.000010855024,0.0033250023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639875,0.00065547857,0.0022132096,0.00017833195,0.00038541493,0.00016881732],"domain_scores_gemma":[0.99558955,0.0021102873,0.0011752655,0.00014258901,0.00085301074,0.00012928835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021680207,0.00015601366,0.0022871294,0.00021090494,0.00002707427,0.000009401078,0.0000658361,0.00006420943,0.00001657334],"category_scores_gemma":[0.0008030102,0.00007820096,0.0001681546,0.00044670442,0.00014119953,0.000090586356,0.000024131465,0.0003399016,2.3829118e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014820133,0.0028780315,0.70978206,0.24626036,0.007678828,0.0041107466,0.0013616744,0.000016583343,0.000095310395,0.00081430393,0.0015421073,0.010639851],"study_design_scores_gemma":[0.022204652,0.012325926,0.63504833,0.3246117,0.0031022571,0.00011153658,0.0010000526,0.0000678296,0.000067713576,0.00023085682,0.0010978166,0.00013133865],"about_ca_topic_score_codex":0.00015101145,"about_ca_topic_score_gemma":0.001951484,"teacher_disagreement_score":0.3393112,"about_ca_system_score_codex":0.00054622674,"about_ca_system_score_gemma":0.0027473285,"threshold_uncertainty_score":0.48736426},"labels":[],"label_agreement":null},{"id":"W4407700420","doi":"10.1200/jco.2025.43.5_suppl.tps294","title":"Long-term safety outcomes of <sup>177</sup> Lu-PSMA-617 in patients with prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Term (time); Oncology; Prostate; Cancer; Internal medicine; Nuclear medicine; Urology","score_opus":0.06344107666936774,"score_gpt":0.47919631107960914,"score_spread":0.4157552344102414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829377,0.0007834255,0.00001117469,0.008416566,0.00036831008,0.0005483924,0.000018156394,0.0000052384457,0.001554953],"genre_scores_gemma":[0.994221,0.0021975061,0.0003269199,0.0008096569,0.00013230227,0.00001176066,0.0000102184995,0.000013913418,0.0022767296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663484,0.00027568417,0.0020890795,0.00020563634,0.0004736068,0.0003211815],"domain_scores_gemma":[0.99681735,0.0010914438,0.000954317,0.00021139186,0.000687168,0.00023835832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014350453,0.00015999957,0.0017397656,0.00027003218,0.00003251996,0.000006132678,0.00018691827,0.00025525177,0.000121423],"category_scores_gemma":[0.0009055634,0.00008987127,0.00028362646,0.0003152705,0.00034226748,0.000110169814,0.00007785258,0.000942461,0.0000033494596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029448817,0.002409487,0.8589601,0.00011890409,0.0007241881,0.0002817452,0.00015022611,0.000056251127,0.000003032381,0.000018141785,0.00056278077,0.10726632],"study_design_scores_gemma":[0.033748034,0.008804408,0.9544007,0.00053306826,0.00028670943,0.000005893103,0.00007587213,0.000020060505,0.000045226865,0.00007317438,0.0019359327,0.00007089708],"about_ca_topic_score_codex":0.000058586233,"about_ca_topic_score_gemma":0.00014095705,"teacher_disagreement_score":0.10719543,"about_ca_system_score_codex":0.0004147039,"about_ca_system_score_gemma":0.0032064808,"threshold_uncertainty_score":0.56881595},"labels":[],"label_agreement":null},{"id":"W4407700443","doi":"10.1200/jco.2025.43.5_suppl.51","title":"Role of liquid biopsy in the detection of homologous recombination repair gene mutations (HRRm) in metastatic prostate cancer (mPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Homologous recombination; Liquid biopsy; Prostate cancer; Cancer research; Gene; Biopsy; Prostate; Homologous chromosome; Cancer; Oncology; Internal medicine; Genetics; Biology","score_opus":0.07826902302054868,"score_gpt":0.4817508069233256,"score_spread":0.40348178390277695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088216,0.0032536217,0.000033634333,0.0046345405,0.00029087393,0.0004295868,0.0000056089684,0.000003384048,0.0004665711],"genre_scores_gemma":[0.9960727,0.0027595994,0.00075158186,0.00015581142,0.000046771012,0.00003752871,0.0000035613994,0.0000050058334,0.00016742515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970826,0.0007130007,0.0017201495,0.000115251474,0.00022738897,0.00014160073],"domain_scores_gemma":[0.99709284,0.0014309728,0.00086188223,0.00012355698,0.00044344677,0.000047310627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035740796,0.0000716433,0.00073154236,0.00042140085,0.000019725789,0.0000021585092,0.00010169905,0.00013197438,0.000020368532],"category_scores_gemma":[0.0017823746,0.000043514712,0.00021897328,0.0006001163,0.00020006526,0.00006721972,0.000021909811,0.0005614664,6.848258e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043108836,0.012405589,0.32973674,0.00055171683,0.0015108825,0.001056753,0.0045600636,0.0005969941,0.08471675,0.00043285705,0.000276337,0.52104646],"study_design_scores_gemma":[0.017415253,0.020280983,0.9177452,0.00046236554,0.0005702456,0.0001785561,0.0023859027,0.00070745713,0.03250883,0.005999203,0.0016633739,0.0000826695],"about_ca_topic_score_codex":0.00031590517,"about_ca_topic_score_gemma":0.0005457464,"teacher_disagreement_score":0.5880084,"about_ca_system_score_codex":0.00023746748,"about_ca_system_score_gemma":0.0017048778,"threshold_uncertainty_score":0.30243802},"labels":[],"label_agreement":null},{"id":"W4407700563","doi":"10.1200/jco.2025.43.5_suppl.385","title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Meta-analysis; Randomized controlled trial; Oncology; Lernaean Hydra; Prostate; Cancer; Internal medicine","score_opus":0.4749503162080772,"score_gpt":0.5801124235860613,"score_spread":0.1051621073779841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7847263,0.06207521,0.0008308621,0.14165974,0.0017811906,0.007081833,0.0015905884,0.00000934554,0.00024493114],"genre_scores_gemma":[0.96023136,0.020301258,0.0045419047,0.013835019,0.0002425097,0.0005538629,0.00020241988,0.000013059548,0.00007859744],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9882212,0.005118063,0.005808383,0.0002720107,0.00040997565,0.00017034104],"domain_scores_gemma":[0.95423895,0.03938708,0.00513586,0.00049889577,0.0006230233,0.0001161736],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03692797,0.00015455116,0.008797848,0.0004256597,0.000031924425,0.000016328837,0.00033051913,0.00019112961,0.00029496188],"category_scores_gemma":[0.015243194,0.00007196714,0.0029482816,0.0005066098,0.0002564177,0.00016434932,0.00003793919,0.0004113506,1.65536e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23176165,0.006585121,0.012779758,0.000042131654,0.5785622,0.00007620665,0.00053604617,0.00063950015,0.000028699029,0.00029723893,0.011161358,0.15753007],"study_design_scores_gemma":[0.22932263,0.0071520875,0.033909272,0.00003830634,0.6578575,0.000010444453,0.0003420327,0.0013353385,0.00012711417,0.0007488973,0.069060415,0.00009599644],"about_ca_topic_score_codex":0.00023399119,"about_ca_topic_score_gemma":0.0003005403,"teacher_disagreement_score":0.17550506,"about_ca_system_score_codex":0.00012559402,"about_ca_system_score_gemma":0.0020310543,"threshold_uncertainty_score":0.9930518},"labels":[],"label_agreement":null},{"id":"W4407700582","doi":"10.1200/jco.2025.43.5_suppl.375","title":"PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; McGill University Health Centre; Centre hospitalier universitaire de Québec; University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Adverse effect; Oncology; Internal medicine; Prostate; Radiation dose; Nuclear medicine; Cancer","score_opus":0.014357950683784202,"score_gpt":0.3856326352784119,"score_spread":0.3712746845946277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994941,0.00046186868,0.0029588654,0.00033821852,0.0005761112,0.00045273136,0.00005027673,0.0000100620155,0.00021088203],"genre_scores_gemma":[0.9916431,0.0013082,0.006408927,0.0002568095,0.00024720907,0.000017377057,0.0000066436087,0.00001904668,0.00009273838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964456,0.00053384295,0.0023735974,0.00019939886,0.000245909,0.00020166543],"domain_scores_gemma":[0.9956184,0.0008573559,0.0028657285,0.00022410053,0.00032639506,0.00010801456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014235269,0.00017726554,0.0011506113,0.00022361333,0.000017483455,0.000001670778,0.0002441709,0.00033472967,0.00022425783],"category_scores_gemma":[0.0002797366,0.00013627853,0.00048686663,0.0002931275,0.0001368995,0.00019012064,0.00003527914,0.000984131,8.2519443e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013751152,0.0024621277,0.83305657,0.000014508282,0.0006366285,0.00004038745,0.0002318895,0.00042615263,0.001990051,0.00013823395,0.00027892384,0.14697337],"study_design_scores_gemma":[0.012187429,0.005763201,0.9596951,0.00017795483,0.00012760147,0.0000031018244,0.000031961663,0.00026616183,0.00464108,0.009491614,0.0074660634,0.00014872965],"about_ca_topic_score_codex":0.00005339886,"about_ca_topic_score_gemma":0.0000062626177,"teacher_disagreement_score":0.14682463,"about_ca_system_score_codex":0.00008984033,"about_ca_system_score_gemma":0.00082514266,"threshold_uncertainty_score":0.55572766},"labels":[],"label_agreement":null},{"id":"W4407700595","doi":"10.1200/jco.2025.43.5_suppl.717","title":"Global real-world patients characteristics, treatment patterns, and impact of BCG shortage in patients with high-risk non-muscle invasive bladder cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Bladder cancer; Economic shortage; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.029333133924035762,"score_gpt":0.40970377722594165,"score_spread":0.3803706433019059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758446,0.000067430694,0.000008650885,0.00025673292,0.000586804,0.0005228361,0.00041726028,0.000003816256,0.00055198726],"genre_scores_gemma":[0.9965505,0.0026265618,0.00015620382,0.0003236509,0.00019762707,0.000012695398,0.000033300454,0.000014077953,0.000085371335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726653,0.00021325781,0.0017162318,0.00025834396,0.00028949778,0.00025614866],"domain_scores_gemma":[0.99707305,0.00049586955,0.0014588065,0.00020438404,0.00048749897,0.0002803966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003250847,0.000237851,0.0017188647,0.0001707418,0.000029707819,0.000008028299,0.00009993591,0.00020656269,0.00009788842],"category_scores_gemma":[0.00031830708,0.00014374973,0.00028049797,0.00022728022,0.00014060193,0.00009555492,0.000044478275,0.00032535498,0.00000112856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007128219,0.0042304667,0.84687877,0.000033098608,0.0013675513,0.000084216124,0.0000666227,0.0000063472125,0.0000010151679,0.0000034806753,0.00030810773,0.13989212],"study_design_scores_gemma":[0.027314734,0.033481825,0.937414,0.0003566526,0.0010958626,0.0000014487298,0.000023660232,0.0000047239796,0.000014468519,0.000041949505,0.00015554484,0.00009516674],"about_ca_topic_score_codex":0.011058713,"about_ca_topic_score_gemma":0.009489752,"teacher_disagreement_score":0.13979694,"about_ca_system_score_codex":0.0010450684,"about_ca_system_score_gemma":0.0023681174,"threshold_uncertainty_score":0.99552673},"labels":[],"label_agreement":null},{"id":"W4407700602","doi":"10.1200/jco.2025.43.5_suppl.155","title":"Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Androgen deprivation therapy; Cabazitaxel; Overall survival; Internal medicine; Abiraterone; Castration; Androgen receptor; Urology; Cancer; Hormone","score_opus":0.20432873725121756,"score_gpt":0.4870427981683177,"score_spread":0.28271406091710016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729476,0.0065287054,0.00013480581,0.01653768,0.0017696276,0.0014618144,0.00018717586,0.000010887827,0.00042170426],"genre_scores_gemma":[0.96066797,0.017725125,0.0038673438,0.0025561089,0.0022845708,0.00017916481,0.000088291905,0.000038086186,0.012593321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964426,0.0004515406,0.002042959,0.000324037,0.00038210896,0.0003567227],"domain_scores_gemma":[0.9961185,0.0017534695,0.0008888611,0.00015857759,0.0007663016,0.00031432626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028471667,0.00022394261,0.0014408189,0.00018733046,0.00016109983,0.000051321756,0.000110942376,0.00024271235,0.00032011772],"category_scores_gemma":[0.00089231867,0.00013570799,0.0003452393,0.00018134332,0.00022502427,0.00020683713,0.000032673986,0.0006016876,0.0000016544618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40660226,0.0055045066,0.031308275,0.00082964444,0.005314569,0.0013710934,0.0007643061,0.000074739895,0.044629335,0.0012828544,0.038683992,0.46363443],"study_design_scores_gemma":[0.17517608,0.05830398,0.10990625,0.00063957955,0.0013825427,0.00028676985,0.00044394145,0.0008765911,0.018695036,0.002207751,0.6315703,0.00051120063],"about_ca_topic_score_codex":0.000044129007,"about_ca_topic_score_gemma":0.00090093986,"teacher_disagreement_score":0.59288627,"about_ca_system_score_codex":0.0002991129,"about_ca_system_score_gemma":0.0068177464,"threshold_uncertainty_score":0.9988127},"labels":[],"label_agreement":null},{"id":"W4407700626","doi":"10.1200/jco.2025.43.5_suppl.310","title":"Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Oncology; Internal medicine; Prostate; Androgen; Overall survival; Cancer; Urology; Gynecology; Hormone","score_opus":0.11674083890217178,"score_gpt":0.4892841191672233,"score_spread":0.3725432802650515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996407,0.00087296363,0.000015844025,0.00069892564,0.00058564096,0.0010078707,0.00037352555,0.0000036532456,0.000034581288],"genre_scores_gemma":[0.99140865,0.007620555,0.00013929808,0.00021465468,0.00028166585,0.00001986457,0.00021118131,0.0000141661485,0.00008997805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694127,0.0004890978,0.0016629805,0.0002822533,0.00040682158,0.0002175842],"domain_scores_gemma":[0.996124,0.0015917054,0.0013604299,0.00041384864,0.00035148414,0.00015852244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015015359,0.00015803639,0.0013162453,0.00021428808,0.00002012702,0.000011161514,0.00021171726,0.00020850167,0.0001494968],"category_scores_gemma":[0.00082851126,0.000087779765,0.00018456524,0.00019114304,0.00012187042,0.00020834107,0.000076515025,0.00068006176,0.0000014499478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39719424,0.00485842,0.4827259,0.0000073026677,0.00079452456,0.00008509455,0.000027101616,0.000008050143,0.000014888352,2.0788828e-7,0.00017963685,0.11410464],"study_design_scores_gemma":[0.2912686,0.055219103,0.6527797,0.00027105887,0.00018050264,6.1778746e-7,0.000002388994,0.000009420713,0.00005186591,0.000059481725,0.00010804258,0.00004922751],"about_ca_topic_score_codex":0.00080276676,"about_ca_topic_score_gemma":0.00038822924,"teacher_disagreement_score":0.17005382,"about_ca_system_score_codex":0.00040569002,"about_ca_system_score_gemma":0.0025537254,"threshold_uncertainty_score":0.45301992},"labels":[],"label_agreement":null},{"id":"W4407700629","doi":"10.1200/jco.2025.43.5_suppl.159","title":"Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Post-hoc analysis; Internal medicine; Post hoc; Cancer; Gynecology; Androgen receptor","score_opus":0.03541493979559037,"score_gpt":0.41242726676455077,"score_spread":0.3770123269689604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907725,0.0024116274,0.0000148697045,0.0045468267,0.00021713717,0.001234215,0.0003191479,0.000019569927,0.00046412766],"genre_scores_gemma":[0.99065804,0.005961902,0.00082025304,0.0011201673,0.0000792443,0.00012786458,0.00020521418,0.000035994846,0.0009913202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951621,0.00065048673,0.0023067668,0.0006065357,0.0006493317,0.0006247472],"domain_scores_gemma":[0.9947142,0.001508304,0.001713091,0.000346407,0.0011936886,0.000524293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089488097,0.00046211516,0.0031421017,0.00067945744,0.00010054438,0.000030121782,0.00022156052,0.00039355241,0.00010555212],"category_scores_gemma":[0.0005939793,0.00024352923,0.00056578795,0.0010149573,0.00065150607,0.00015297632,0.00007046098,0.0013676779,0.0000060348452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08149604,0.0048544807,0.7833293,0.00004407757,0.008374255,0.00050413946,0.00022428102,0.00004098343,0.000039035156,0.000008161306,0.00070926035,0.120376],"study_design_scores_gemma":[0.07842653,0.052420508,0.8598349,0.0003787751,0.005271155,0.0000110613155,0.00021248385,0.000030657968,0.00088235125,0.000042591808,0.0022483899,0.00024058603],"about_ca_topic_score_codex":0.0008930006,"about_ca_topic_score_gemma":0.0018238433,"teacher_disagreement_score":0.12013541,"about_ca_system_score_codex":0.0025267333,"about_ca_system_score_gemma":0.0063784337,"threshold_uncertainty_score":0.99925447},"labels":[],"label_agreement":null},{"id":"W4407700779","doi":"10.1200/jco.2025.43.5_suppl.151","title":"Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Université de Montréal","funders":"Bayer","keywords":"Medicine; Prostate cancer; Oncology; Subgroup analysis; Internal medicine; Docetaxel; Disease; Cancer; Confidence interval","score_opus":0.051571423801224495,"score_gpt":0.4635281773739748,"score_spread":0.4119567535727503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908742,0.0015829264,0.00005739451,0.005771553,0.0003436305,0.0010742889,0.00019039735,0.0000031798913,0.00010248375],"genre_scores_gemma":[0.9964902,0.0011937057,0.00010764625,0.00077786803,0.000062528125,0.00003061763,0.000032326287,0.000011515211,0.0012936309],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99626285,0.00075627666,0.0018459808,0.00023995028,0.0006062448,0.00028870476],"domain_scores_gemma":[0.99629956,0.0010617482,0.0013634352,0.0002622657,0.0007134532,0.00029952795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016695076,0.00016228158,0.0019037671,0.0003818867,0.00004029989,0.0000088007855,0.00017321434,0.00010463459,0.00003652855],"category_scores_gemma":[0.0017009282,0.00008356202,0.00057609146,0.0012368764,0.00045612938,0.00010198761,0.000060580915,0.0007485401,9.990332e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5720307,0.0062390184,0.37556013,0.00005540971,0.006886071,0.00030637588,0.0002455181,0.00024125112,0.00004281504,0.000006832766,0.0028950728,0.035490744],"study_design_scores_gemma":[0.23453896,0.010644208,0.74193835,0.00018143404,0.008546369,8.40381e-7,0.0000998911,0.0011305215,0.000048526075,0.000054717064,0.002735146,0.00008106344],"about_ca_topic_score_codex":0.00015790483,"about_ca_topic_score_gemma":0.00018119121,"teacher_disagreement_score":0.3663782,"about_ca_system_score_codex":0.00051616353,"about_ca_system_score_gemma":0.004144049,"threshold_uncertainty_score":0.73513645},"labels":[],"label_agreement":null},{"id":"W4407700784","doi":"10.1200/jco.2025.43.5_suppl.567","title":"Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; McMaster University; McGill University Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Calgary; Ottawa Hospital; University of Alberta; Queen Elizabeth II Health Sciences Centre; Université Laval","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Adjuvant therapy; Kidney cancer; Overall survival; Adjuvant; Selection (genetic algorithm); Surgery","score_opus":0.04856286732297333,"score_gpt":0.37355196233724103,"score_spread":0.3249890950142677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908454,0.0047659837,0.0001331228,0.0024737387,0.0012315382,0.00044094565,0.0000441075,0.0000042054626,0.000060998602],"genre_scores_gemma":[0.9950272,0.0026963735,0.0010947592,0.00051103224,0.00054355466,0.00003588712,0.000009158221,0.000016286376,0.00006579163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966985,0.00061817653,0.0018382035,0.00026742884,0.00028617168,0.00029151613],"domain_scores_gemma":[0.9953168,0.0027704022,0.0010886687,0.00009033953,0.0005110733,0.00022274067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027365445,0.000187573,0.0014155123,0.00031193008,0.000048140137,0.000023864504,0.000046520698,0.00027206185,0.000040357765],"category_scores_gemma":[0.0003511791,0.00014482836,0.00028182997,0.0001861856,0.00008466581,0.00013003856,0.00003201897,0.00046224502,5.320712e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010224098,0.0006331331,0.9312432,0.00009197834,0.0005903366,0.0003034349,0.00009757917,0.0000047323247,0.0015656325,0.0000010599201,0.0049262634,0.050318558],"study_design_scores_gemma":[0.0103204455,0.004287543,0.97707874,0.000087656554,0.00046139373,0.000020957921,0.00006277919,0.00007592841,0.0010576753,0.00005525892,0.006381385,0.000110264016],"about_ca_topic_score_codex":0.00009984249,"about_ca_topic_score_gemma":0.000058688933,"teacher_disagreement_score":0.050208293,"about_ca_system_score_codex":0.00059073756,"about_ca_system_score_gemma":0.0013058952,"threshold_uncertainty_score":0.5905929},"labels":[],"label_agreement":null},{"id":"W4407700797","doi":"10.1200/jco.2025.43.5_suppl.2","title":"Prevention, diagnosis, and management of penile cancer in the LGBTQ+ community: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Penile cancer; Meta-analysis; Cancer; Oncology; Gynecology; Intensive care medicine; Internal medicine","score_opus":0.4651354933266937,"score_gpt":0.6272987953658619,"score_spread":0.16216330203916818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700797","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015572796,0.9936111,0.0000027338704,0.0031998926,0.00006162034,0.002670487,0.000028396444,0.0000011539545,0.00040903527],"genre_scores_gemma":[0.00046610096,0.99499273,0.00012913026,0.0035001081,0.000031460346,0.00044545846,0.0000070271685,0.000005949708,0.00042201468],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98816353,0.006148262,0.0051356666,0.0001355693,0.0002854249,0.00013154755],"domain_scores_gemma":[0.98872405,0.0064194035,0.003979405,0.00041839565,0.00022678821,0.00023198093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012556391,0.00019389162,0.013749918,0.0002476759,0.000036689322,0.000006130236,0.00026179483,0.00023165041,0.00011588014],"category_scores_gemma":[0.002363776,0.00009029382,0.002676581,0.00054703164,0.00010768956,0.000030434088,0.00010723484,0.0011213758,0.0000010796974],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033398646,0.0008240794,0.00010766406,0.93022525,0.034517873,0.00009523142,0.000016835069,8.547482e-8,6.1050554e-11,0.000041544434,0.0010908626,0.03304715],"study_design_scores_gemma":[0.000601797,0.00092983013,0.0006897467,0.07119439,0.870183,0.00006503271,0.000069748814,2.620775e-7,7.222339e-10,0.00008757019,0.056126505,0.00005211014],"about_ca_topic_score_codex":0.00004445877,"about_ca_topic_score_gemma":0.00018178635,"teacher_disagreement_score":0.8590309,"about_ca_system_score_codex":0.000056581885,"about_ca_system_score_gemma":0.001225617,"threshold_uncertainty_score":0.9399169},"labels":[],"label_agreement":null},{"id":"W4407700892","doi":"10.1200/jco.2025.43.5_suppl.583","title":"Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Chromophobe cell; Cancer research; Pathology; Clear cell; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology; Biology","score_opus":0.09890868938394103,"score_gpt":0.4084470096549643,"score_spread":0.30953832027102324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898393,0.0016094242,0.00003877191,0.0062734606,0.00042889584,0.00013101575,0.0000013514896,0.0000029766386,0.0016747686],"genre_scores_gemma":[0.9945929,0.0006922881,0.0028916718,0.0014415747,0.00029175825,0.000003778269,9.586523e-7,0.00000773429,0.00007735931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707556,0.00030371678,0.0020923147,0.0001632394,0.00021691257,0.00014825612],"domain_scores_gemma":[0.9974176,0.00089008,0.0010561876,0.00013066593,0.00031765885,0.00018775287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022355954,0.000102720674,0.001163177,0.00024831475,0.000020463935,0.000005181767,0.000118088035,0.00031020923,0.00006449257],"category_scores_gemma":[0.0011972317,0.00007885693,0.000237629,0.0002732777,0.00021599961,0.00008653293,0.00006575115,0.00065177144,0.0000010478501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018184605,0.00045252225,0.9155036,0.00022594498,0.00009409177,0.00007891986,0.00019300634,0.0000119198885,0.054377303,0.00006822735,0.0020944218,0.025081567],"study_design_scores_gemma":[0.008200256,0.007844634,0.90935653,0.0005181927,0.0004096034,0.00003564131,0.000266856,0.00017877857,0.06916907,0.00042883828,0.003502317,0.000089249144],"about_ca_topic_score_codex":0.000061877516,"about_ca_topic_score_gemma":0.000026658301,"teacher_disagreement_score":0.024992317,"about_ca_system_score_codex":0.000119706434,"about_ca_system_score_gemma":0.0014879777,"threshold_uncertainty_score":0.32156923},"labels":[],"label_agreement":null},{"id":"W4407700904","doi":"10.1200/jco.2025.43.5_suppl.393","title":"Defining subgroups of patients with intermediate risk prostate cancer for whom active surveillance is safe.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Sunnybrook Research Institute","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Watchful waiting; Oncology; Internal medicine; Gynecology; Intensive care medicine","score_opus":0.0459386927962106,"score_gpt":0.46108047085959025,"score_spread":0.41514177806337965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335164,0.0011663109,0.000120751516,0.0033401235,0.0007501094,0.00054126536,0.00020235471,0.000003918527,0.00052355666],"genre_scores_gemma":[0.9936875,0.0036507621,0.0010454553,0.0006977841,0.00017314735,0.000028003295,0.000015756328,0.000013676888,0.00068793376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765486,0.00022400891,0.0014027546,0.00018406722,0.00028198358,0.0002523202],"domain_scores_gemma":[0.9937584,0.0028811062,0.0017014722,0.00013377196,0.001356003,0.00016926153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015012558,0.00012243481,0.0012148008,0.00014495979,0.000057155972,0.000007149141,0.00012266384,0.00018303015,0.00005426177],"category_scores_gemma":[0.0022771978,0.00007125327,0.00027918536,0.00018908661,0.00036884443,0.00008271118,0.000046717818,0.0006454968,0.0000017129387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041325334,0.00073948415,0.76413596,0.00009320476,0.0009068289,0.000019632382,0.0002637343,0.0000047103904,0.0000059366907,0.000017695833,0.0029410294,0.18954645],"study_design_scores_gemma":[0.023054084,0.013027825,0.938042,0.00033509053,0.00032192966,0.0000018146818,0.00012366232,0.000037534173,0.0003764029,0.00029789598,0.024318272,0.00006348771],"about_ca_topic_score_codex":0.00004915989,"about_ca_topic_score_gemma":0.000147187,"teacher_disagreement_score":0.18948296,"about_ca_system_score_codex":0.00022639024,"about_ca_system_score_gemma":0.0032049667,"threshold_uncertainty_score":0.5685473},"labels":[],"label_agreement":null},{"id":"W4407700909","doi":"10.1200/jco.2025.43.5_suppl.461","title":"Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cancer; Oncology; Cancer research; Internal medicine","score_opus":0.10260600336450022,"score_gpt":0.40745424897975674,"score_spread":0.30484824561525653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744931,0.014796788,0.0038368106,0.003555251,0.0009047314,0.00026425728,0.0002954056,0.00000230311,0.0018513395],"genre_scores_gemma":[0.98076296,0.016923692,0.0005970317,0.00035865363,0.00016887521,0.0000100730895,0.0000022646027,0.000008472835,0.0011680026],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964462,0.00012094201,0.003034362,0.00019788224,0.00003129047,0.00016932611],"domain_scores_gemma":[0.9904437,0.0058467453,0.0031377026,0.00021691486,0.00026377276,0.000091155496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031926194,0.00013176353,0.0020097853,0.0003672507,0.000050369563,0.0000098047285,0.0002205357,0.00026968616,0.00014566732],"category_scores_gemma":[0.001813123,0.00009164861,0.0007309711,0.00037346457,0.00026763658,0.00008516683,0.000022500442,0.00021185266,0.000001301578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08914822,0.005031734,0.27075335,0.00006819723,0.017312873,0.000013909088,0.0017813738,0.004729327,0.0003368632,0.018000627,0.0058476524,0.5869759],"study_design_scores_gemma":[0.007671337,0.008289011,0.5851264,0.00003156924,0.0012177349,9.427541e-7,0.00013390521,0.0010506784,0.00024665656,0.0013001206,0.39483166,0.00009997221],"about_ca_topic_score_codex":0.0002389043,"about_ca_topic_score_gemma":0.00028665605,"teacher_disagreement_score":0.5868759,"about_ca_system_score_codex":0.00023499095,"about_ca_system_score_gemma":0.0007097236,"threshold_uncertainty_score":0.37373218},"labels":[],"label_agreement":null},{"id":"W4407700917","doi":"10.1200/jco.2025.43.5_suppl.669","title":"Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self-reported social determinants of health (SDOH).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Diversity (politics); Internal medicine; Oncology; Anthropology; Sociology","score_opus":0.21774744144758554,"score_gpt":0.4700278986500869,"score_spread":0.25228045720250136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961351,0.00041108145,0.0001954893,0.0016353631,0.0005997597,0.00029571494,0.00002079968,0.000007721576,0.0006989436],"genre_scores_gemma":[0.9939018,0.0043733404,0.0006536859,0.00077171385,0.00019881126,0.0000028876577,0.0000018030198,0.000011467615,0.00008450139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563986,0.00077864144,0.0028781744,0.000246928,0.00021120459,0.0002452064],"domain_scores_gemma":[0.9957217,0.002051776,0.0017581152,0.000108002256,0.00014018932,0.00022023518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034557434,0.00016073155,0.0021596206,0.00023491986,0.00015777323,0.000009028211,0.00009279522,0.00019752908,0.000011583859],"category_scores_gemma":[0.00090143475,0.00013010454,0.00021435879,0.00013893214,0.0004157247,0.000082132254,0.00021659156,0.0006426138,3.015247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042932937,0.0011248714,0.95888484,0.00022476312,0.00042218188,0.0004917623,0.00029315328,2.707436e-7,0.000003064405,0.00018330266,0.0001850958,0.03389342],"study_design_scores_gemma":[0.013495955,0.003669856,0.97994745,0.00023087046,0.00069934723,0.000101597005,0.0002525294,0.00010577248,0.0000027051756,0.001038516,0.00037207713,0.000083311024],"about_ca_topic_score_codex":0.00030051568,"about_ca_topic_score_gemma":0.0007187095,"teacher_disagreement_score":0.03381011,"about_ca_system_score_codex":0.00026950167,"about_ca_system_score_gemma":0.0025034402,"threshold_uncertainty_score":0.5305509},"labels":[],"label_agreement":null},{"id":"W4407701126","doi":"10.1200/jco.2025.43.5_suppl.16","title":"Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of <sup>177</sup> Lu-PSMA-617.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Nuclear medicine","score_opus":0.08324424851418714,"score_gpt":0.49096912256259706,"score_spread":0.4077248740484099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933605,0.000057906927,0.000007007607,0.005332533,0.00010403752,0.00082099857,0.000006293417,0.0000019393788,0.00030875547],"genre_scores_gemma":[0.998621,0.00040968257,0.00019107388,0.000415693,0.000089023386,0.0000135271675,0.000006361255,0.000007221213,0.00024641128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597,0.001109542,0.0019982357,0.00018723652,0.00056400074,0.00017098246],"domain_scores_gemma":[0.99186915,0.006084243,0.0013218748,0.00018451028,0.00045171255,0.00008850203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044826353,0.0001355785,0.0014981405,0.00024536473,0.000024614534,0.00000493659,0.00009578061,0.00023158021,0.000013837594],"category_scores_gemma":[0.0022302044,0.000058885336,0.00014838784,0.00028015784,0.00012971285,0.00007190279,0.000023936054,0.00078567275,6.124757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021377433,0.021299744,0.9166416,0.000021837248,0.0009242649,0.0000926481,0.00041776375,0.00007454561,2.887031e-7,0.000005869457,0.0002352421,0.038908787],"study_design_scores_gemma":[0.046850096,0.06828989,0.88191444,0.00016435,0.0004579727,0.0000022190945,0.0016557658,0.00007235854,0.000005650879,0.000045329547,0.0005026959,0.00003925365],"about_ca_topic_score_codex":0.00013374447,"about_ca_topic_score_gemma":0.00074477075,"teacher_disagreement_score":0.04699015,"about_ca_system_score_codex":0.0004088328,"about_ca_system_score_gemma":0.0008592137,"threshold_uncertainty_score":0.34134007},"labels":[],"label_agreement":null},{"id":"W4407701171","doi":"10.1200/jco.2025.43.5_suppl.tps432","title":"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Internal medicine; Oncology; Biochemical recurrence; breakpoint cluster region; Androgen; Randomized controlled trial; Cancer; Urology; Prostatectomy; Hormone; Pathology; Receptor","score_opus":0.06419575208520342,"score_gpt":0.4573852924826808,"score_spread":0.39318954039747733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901695,0.0019660012,0.00004032721,0.0014425021,0.0004906546,0.0057474156,0.000017164028,0.000007732984,0.0001186931],"genre_scores_gemma":[0.9932337,0.005750204,0.00026973287,0.00014869358,0.0001555828,0.00028132353,0.000015364038,0.000015722158,0.00012968158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943694,0.0012042449,0.0031081152,0.0003381988,0.00066078245,0.0003192766],"domain_scores_gemma":[0.99329776,0.0027938983,0.0023634445,0.00025503372,0.0010655775,0.0002243032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055565154,0.00023484902,0.0035509986,0.00043835424,0.00004747102,0.000013106866,0.00021622425,0.00027144217,0.000039728042],"category_scores_gemma":[0.0018256296,0.00012986828,0.00037969011,0.0005379968,0.00043363025,0.00012987021,0.000057331206,0.0011448622,0.0000013529841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62818617,0.00795315,0.32058227,0.000025999623,0.0016338805,0.00006626561,0.00022375652,0.0000357109,0.000021122256,0.000007731818,0.00013715164,0.041126795],"study_design_scores_gemma":[0.93695855,0.021795565,0.038718212,0.000336148,0.00088904484,0.000003584595,0.00014708933,0.00018459716,0.0005651827,0.0001373455,0.00016296493,0.000101709964],"about_ca_topic_score_codex":0.00022930591,"about_ca_topic_score_gemma":0.00007862695,"teacher_disagreement_score":0.3087724,"about_ca_system_score_codex":0.00041921673,"about_ca_system_score_gemma":0.0038892527,"threshold_uncertainty_score":0.68993676},"labels":[],"label_agreement":null},{"id":"W4407701227","doi":"10.1200/jco.2025.43.5_suppl.409","title":"Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Veracyte","keywords":"Medicine; Prostate cancer; Androgen receptor; Biopsy; Oncology; Prostate; Internal medicine; Correlation; Androgen; Cancer; Pathology; Hormone","score_opus":0.11370550760166957,"score_gpt":0.49731712329695016,"score_spread":0.3836116156952806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558956,0.0012530396,0.0000019259344,0.012386637,0.00019141576,0.00035866283,0.000018778002,0.0000022114773,0.00019774656],"genre_scores_gemma":[0.9891582,0.009294777,0.000285175,0.00010927936,0.000057871886,0.000025748479,0.0000017546273,0.0000057151783,0.0010614516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986093,0.00030437947,0.0006642836,0.00014218978,0.00014921177,0.0001306337],"domain_scores_gemma":[0.99690616,0.0022925502,0.00044998035,0.0000735932,0.00014500268,0.00013272377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009747968,0.00009624691,0.00087474566,0.0001769991,0.000028524195,0.000004030429,0.000026005504,0.00014948822,0.000043430096],"category_scores_gemma":[0.00050521933,0.00005358417,0.00007903064,0.00013503227,0.00028004675,0.000065443535,0.000034716813,0.00024102205,5.444219e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06877069,0.0008403972,0.8401656,0.000022838161,0.00038192893,0.0002021451,0.00019444866,0.000002801708,0.00029993174,0.0000057747848,0.00014059222,0.088972814],"study_design_scores_gemma":[0.019054206,0.012018139,0.9610562,0.00020104447,0.00022940272,0.000038085345,0.00008026774,0.000018579141,0.0024512624,0.000030283709,0.004779476,0.00004307785],"about_ca_topic_score_codex":0.00009679676,"about_ca_topic_score_gemma":0.00036856293,"teacher_disagreement_score":0.12089054,"about_ca_system_score_codex":0.00043018415,"about_ca_system_score_gemma":0.0011519141,"threshold_uncertainty_score":0.21850988},"labels":[],"label_agreement":null},{"id":"W4407701348","doi":"10.1200/jco.2025.43.5_suppl.629","title":"Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Stage (stratigraphy); Seminoma; Oncology; Internal medicine; Surgery","score_opus":0.28525857297149787,"score_gpt":0.4899905572861886,"score_spread":0.20473198431469075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9530044,0.00627708,0.00006610958,0.038315866,0.00019166271,0.00085588364,0.000010478163,0.000014166302,0.0012643164],"genre_scores_gemma":[0.95256054,0.025890559,0.005578798,0.014450152,0.0002768401,0.00004017333,0.0000076258907,0.000030236386,0.001165056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957338,0.0007780082,0.0025242763,0.0003499374,0.00036908357,0.0002448707],"domain_scores_gemma":[0.99025,0.007086669,0.0016401679,0.0004511837,0.0003138562,0.0002581364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019237465,0.00031543177,0.0027972127,0.00014026389,0.00007015449,0.0000148506,0.00017088557,0.00045846382,0.00008494375],"category_scores_gemma":[0.00038860465,0.00013873535,0.0008540206,0.00017538393,0.0008678951,0.000056278837,0.000021493432,0.000561457,4.3064563e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011445956,0.008921292,0.7796195,0.000012059279,0.0062082508,0.0001674406,0.00017274942,0.0000040450705,0.000018761504,0.00022153191,0.0028917394,0.19031669],"study_design_scores_gemma":[0.04294516,0.019338265,0.8448442,0.0000686232,0.00077050115,0.00020796935,0.00027637856,0.000065320906,0.00011725865,0.000076243625,0.091188245,0.000101815815],"about_ca_topic_score_codex":0.000080058286,"about_ca_topic_score_gemma":0.000035593774,"teacher_disagreement_score":0.19021487,"about_ca_system_score_codex":0.00018211716,"about_ca_system_score_gemma":0.0013897555,"threshold_uncertainty_score":0.56574637},"labels":[],"label_agreement":null},{"id":"W4407701365","doi":"10.1200/jco.2025.43.5_suppl.65","title":"Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of British Columbia","funders":"Movember Foundation; Amgen; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Prostate; Gynecology","score_opus":0.08952338661902576,"score_gpt":0.4735618148242244,"score_spread":0.3840384282051986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96754795,0.000852131,0.00015113637,0.028707959,0.00017824346,0.0021244697,0.00017676264,0.0000053016024,0.00025604968],"genre_scores_gemma":[0.99189997,0.0008612119,0.002928579,0.0005164001,0.00010257708,0.00039067154,0.000032312866,0.000019059162,0.0032492059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981489,0.00012619501,0.000926862,0.00023476522,0.00028875383,0.00027449374],"domain_scores_gemma":[0.9939791,0.004241648,0.00082272524,0.00012666566,0.00069454825,0.00013530326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012001913,0.00015166435,0.00086557755,0.00014027467,0.00009153589,0.000021212167,0.00012527076,0.000097185606,0.0000033919337],"category_scores_gemma":[0.0013771026,0.00007583808,0.000108330205,0.00017428068,0.0002821515,0.00016263609,0.000036127916,0.00052768434,1.9973659e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029783059,0.00029782995,0.93634754,0.00009237864,0.00086662517,0.00002491347,0.0003346495,0.000091622824,0.000007816952,0.00006020825,0.0009741082,0.03111924],"study_design_scores_gemma":[0.03225727,0.007140692,0.9505783,0.0002756795,0.0006108168,0.000004625758,0.0005994851,0.00011066609,0.000052722073,0.0009392351,0.007341934,0.00008861675],"about_ca_topic_score_codex":0.00009360643,"about_ca_topic_score_gemma":0.0005380212,"teacher_disagreement_score":0.031030623,"about_ca_system_score_codex":0.0004764477,"about_ca_system_score_gemma":0.0020477301,"threshold_uncertainty_score":0.36325854},"labels":[],"label_agreement":null},{"id":"W4407701397","doi":"10.1200/jco.2025.43.5_suppl.35","title":"A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Thunder Bay Regional Health Sciences Centre; London Health Sciences Centre; Cancer Care Ontario; McMaster University; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Western University","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Prostate; Cancer registry; Gynecology","score_opus":0.11371556228174574,"score_gpt":0.5345541847092006,"score_spread":0.42083862242745484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90145993,0.0047931983,0.00027715886,0.06611981,0.004208624,0.00817047,0.00090803887,0.00002484905,0.0140379],"genre_scores_gemma":[0.9684523,0.003920351,0.007073581,0.0005712841,0.0020743897,0.00064502977,0.000036925576,0.000030495907,0.017195662],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966094,0.00016262189,0.0022881993,0.00030422313,0.000310259,0.00032529444],"domain_scores_gemma":[0.9936779,0.0022220074,0.001835055,0.00022160143,0.0018263442,0.00021708262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031752193,0.00015093533,0.0014221575,0.00015192159,0.00006623981,0.000009159962,0.00018630133,0.000108811786,0.000011526258],"category_scores_gemma":[0.008236322,0.00009725922,0.0006229727,0.00018184171,0.00030125078,0.00007472918,0.000057934296,0.00061995036,6.9246687e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42205322,0.0050965413,0.054583903,0.0013789035,0.0023923763,0.000545645,0.0003429063,0.000011658842,0.0004363901,0.00092500023,0.2394304,0.27280304],"study_design_scores_gemma":[0.17475484,0.12768804,0.13400497,0.0027554813,0.002617172,0.00041895226,0.0008847894,0.0006541787,0.009940898,0.01232801,0.53360003,0.00035261345],"about_ca_topic_score_codex":0.00004728597,"about_ca_topic_score_gemma":0.00014555072,"teacher_disagreement_score":0.29416966,"about_ca_system_score_codex":0.00056399597,"about_ca_system_score_gemma":0.008575943,"threshold_uncertainty_score":0.9970445},"labels":[],"label_agreement":null},{"id":"W4407701490","doi":"10.1200/jco.2025.43.5_suppl.346","title":"Prostate Cancer Supportive Care (PCSC) program: An alternative to consolidated framework for implementation research (CFIR) model.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Implementation research; Oncology; Cancer; Internal medicine; Psychological intervention; Nursing","score_opus":0.8182993056589571,"score_gpt":0.7448222630662885,"score_spread":0.07347704259266863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8456924,0.0010423274,0.023815267,0.11995131,0.0031583547,0.0040524676,0.00083184073,0.00002681957,0.0014292265],"genre_scores_gemma":[0.89383346,0.00050886296,0.08436265,0.01866939,0.0013454172,0.0008302494,0.000043278378,0.0000348099,0.00037190923],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9884447,0.001308317,0.00903739,0.0004960478,0.00017836184,0.0005352135],"domain_scores_gemma":[0.98614085,0.005805624,0.0054359934,0.00029907713,0.0018734275,0.00044500706],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04041331,0.00015335325,0.0018724598,0.00058144046,0.00019484608,0.00007435131,0.00045860314,0.00037547835,0.0001930577],"category_scores_gemma":[0.015354117,0.00016277708,0.0002702785,0.00034648264,0.0001689106,0.0004391742,0.000087436034,0.0008622102,0.00005013489],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004663427,0.0023315349,0.17148624,0.00079605856,0.0015380165,0.00002190747,0.037075303,0.004738267,0.000007241608,0.41327035,0.14645231,0.21761933],"study_design_scores_gemma":[0.009514483,0.017525816,0.057823274,0.0005005661,0.00011110445,0.0000056178587,0.037678335,0.017166829,0.00007949998,0.48667055,0.37237132,0.0005526046],"about_ca_topic_score_codex":0.0006345726,"about_ca_topic_score_gemma":0.0011289825,"teacher_disagreement_score":0.22591901,"about_ca_system_score_codex":0.0013807241,"about_ca_system_score_gemma":0.0039793523,"threshold_uncertainty_score":0.99293995},"labels":[],"label_agreement":null},{"id":"W4407701510","doi":"10.1200/jco.2025.43.5_suppl.403","title":"Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver Coastal Health; University Health Network; University of British Columbia","funders":"Johnson and Johnson; Terry Fox Research Institute","keywords":"Medicine; Prostate cancer; Genome instability; Cancer; Prostate; Oncology; Cancer research; Pathology; Internal medicine; Genetics; Biology; DNA damage; DNA","score_opus":0.10337828107118216,"score_gpt":0.4887862410277097,"score_spread":0.38540795995652755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868341,0.0021990852,0.000007022951,0.0055033984,0.0003444674,0.0049896287,0.000020546275,0.0000032156745,0.00009853522],"genre_scores_gemma":[0.9939769,0.004384791,0.00014713944,0.00042008067,0.00010129566,0.00041698397,8.284211e-7,0.000010152201,0.0005418405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953955,0.0019133613,0.0020432784,0.0002326985,0.00016975781,0.0002454376],"domain_scores_gemma":[0.99658155,0.0019344061,0.00092292385,0.0002384879,0.00021675325,0.00010589294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004350675,0.00014549952,0.001257791,0.00028996854,0.00006113336,0.000010906348,0.00019908632,0.00019468114,0.000029335908],"category_scores_gemma":[0.0013153484,0.0000732418,0.00018172183,0.00033210038,0.00036983285,0.0000451384,0.0001501911,0.0010916984,0.0000010886691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017314987,0.0020882403,0.9313444,0.000042789325,0.00018817284,0.00037280456,0.0010253824,0.00014028816,0.0019675405,0.00001963965,0.0001202609,0.045375507],"study_design_scores_gemma":[0.024179272,0.0068725,0.9642288,0.0002475939,0.00012499365,0.000034090128,0.00086131186,0.00013672921,0.0003358648,0.00094058487,0.0019785408,0.000059733084],"about_ca_topic_score_codex":0.00064052857,"about_ca_topic_score_gemma":0.002146821,"teacher_disagreement_score":0.045315772,"about_ca_system_score_codex":0.00037367668,"about_ca_system_score_gemma":0.0034863995,"threshold_uncertainty_score":0.6184723},"labels":[],"label_agreement":null},{"id":"W4407701519","doi":"10.1200/jco.2025.43.5_suppl.417","title":"Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Disease; Prostate; Cancer; Oncology; Internal medicine","score_opus":0.06518662178121039,"score_gpt":0.4491162345683003,"score_spread":0.3839296127870899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697002,0.010914349,0.000014763475,0.016804464,0.0012583844,0.0011456838,0.00003295978,0.0000061451374,0.00012306018],"genre_scores_gemma":[0.98267496,0.014997258,0.00014828586,0.0010755967,0.0006841447,0.000059511298,0.000013455555,0.000015079474,0.0003317157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956051,0.0012849555,0.0022114739,0.00031326263,0.00029285633,0.00029234035],"domain_scores_gemma":[0.9963975,0.0021722722,0.00068358803,0.000285119,0.0001879741,0.00027355467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015451649,0.00017363997,0.0012353554,0.0002441461,0.00008898643,0.000026550679,0.00028078633,0.00016292355,0.000068003275],"category_scores_gemma":[0.00093324174,0.00009845324,0.00022864215,0.0003560012,0.0002569756,0.0000832052,0.000117304175,0.0015629957,0.000011903996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016870163,0.0032799398,0.9171788,0.000014380493,0.00054184033,0.0015953695,0.0012247217,0.0004910266,0.00020507908,0.00007093985,0.00088437146,0.057643358],"study_design_scores_gemma":[0.026349094,0.0029465775,0.9591716,0.00020812606,0.00041383674,0.000005491111,0.00075599493,0.0005668064,0.000018887613,0.0026050818,0.0068737795,0.0000847037],"about_ca_topic_score_codex":0.0032615466,"about_ca_topic_score_gemma":0.008680604,"teacher_disagreement_score":0.057558656,"about_ca_system_score_codex":0.00081328175,"about_ca_system_score_gemma":0.005464026,"threshold_uncertainty_score":0.9692947},"labels":[],"label_agreement":null},{"id":"W4407701538","doi":"10.1200/jco.2025.43.5_suppl.647","title":"Machine learning model integrating CT radiomics and circulating microRNAs to predict residual disease histology in metastatic non-seminoma testicular cancer (mNSTC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Seminoma; Radiomics; Testicular cancer; Histology; Disease; Cancer; Oncology; Nomogram; Pathology; Internal medicine; Radiology; Chemotherapy","score_opus":0.04860227002937559,"score_gpt":0.4369785461505426,"score_spread":0.388376276121167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95877504,0.0031298003,0.019083451,0.017546322,0.00064814626,0.00027282684,0.0000038390313,0.000014474989,0.00052609557],"genre_scores_gemma":[0.9425304,0.0006754159,0.051458325,0.004727638,0.00032900405,0.00001039945,0.000005145405,0.000026641621,0.00023702339],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99604404,0.0005264336,0.002427882,0.0003573967,0.0002753665,0.00036889614],"domain_scores_gemma":[0.99508435,0.0028590476,0.0010160649,0.00016946194,0.00022411079,0.0006469892],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044918023,0.0002193813,0.0016934691,0.00046937334,0.00009265524,0.000020112404,0.0001957076,0.00013059839,0.000018199402],"category_scores_gemma":[0.028118957,0.00017261924,0.0002395998,0.00029368864,0.00026309333,0.000084345156,0.00013685248,0.0027312364,0.0000011063595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012930909,0.00043299407,0.734511,0.00017637359,0.0003046843,0.002764302,0.00027333072,0.02912017,0.0015461382,0.00015503823,0.00084748596,0.22857538],"study_design_scores_gemma":[0.0071897064,0.0013540381,0.19609605,0.0011500504,0.00086347584,0.00071611436,0.00015154583,0.7868795,0.000021975782,0.0010567674,0.004341906,0.00017887712],"about_ca_topic_score_codex":0.00020559729,"about_ca_topic_score_gemma":0.00005704809,"teacher_disagreement_score":0.75775933,"about_ca_system_score_codex":0.00035923804,"about_ca_system_score_gemma":0.0023784323,"threshold_uncertainty_score":0.9995695},"labels":[],"label_agreement":null},{"id":"W4407701540","doi":"10.1200/jco.2025.43.5_suppl.tps889","title":"A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gemcitabine; Urothelial carcinoma; Multicenter study; Oncology; Carcinoma; Urology; Internal medicine; Chemotherapy; Bladder cancer; Cancer; Randomized controlled trial","score_opus":0.1555843798926918,"score_gpt":0.521490643124918,"score_spread":0.3659062632322262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933103,0.0004344313,0.0009739799,0.0025532555,0.0010291775,0.0012736372,0.000016659546,0.00000308019,0.0004054871],"genre_scores_gemma":[0.9926281,0.00016355104,0.005487492,0.0004679318,0.000903244,0.000004374766,0.0000067009637,0.000011675671,0.00032691998],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966375,0.0002904023,0.0024902984,0.00017533917,0.0002592763,0.00014713446],"domain_scores_gemma":[0.99388146,0.0035915503,0.001607554,0.00013476907,0.0006087685,0.00017589278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019307719,0.00012672588,0.0014592771,0.00015115365,0.000030959913,0.0000033312426,0.000070479306,0.00024582827,0.00006575694],"category_scores_gemma":[0.006495418,0.000089176174,0.0005123209,0.000098595294,0.00011306107,0.00007474536,0.000026161553,0.0003080653,5.134249e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67894745,0.006795394,0.016717453,0.00010372763,0.000559838,0.000023469505,0.00041049585,0.000009062384,0.004611614,0.00005744084,0.00064770295,0.29111633],"study_design_scores_gemma":[0.72360516,0.10160298,0.16055225,0.0003553593,0.0028372218,0.00003707513,0.00014421696,0.0010396788,0.0034244992,0.00027832968,0.006040299,0.00008295968],"about_ca_topic_score_codex":0.00006563388,"about_ca_topic_score_gemma":0.000007361242,"teacher_disagreement_score":0.2910334,"about_ca_system_score_codex":0.00010070565,"about_ca_system_score_gemma":0.0024150917,"threshold_uncertainty_score":0.7776091},"labels":[],"label_agreement":null},{"id":"W4407701628","doi":"10.1200/jco.2025.43.5_suppl.62","title":"Reflexive paired somatic and germline testing at time of medical oncology referral in mCSPC: Impact on timely treatment.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Germline; Referral; Somatic cell; Germline mutation; Oncology; Internal medicine; Family medicine; Mutation; Genetics","score_opus":0.11416889098344211,"score_gpt":0.494162449419967,"score_spread":0.3799935584365249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920657,0.0010299875,0.000022028364,0.0031860461,0.00034656798,0.000121587516,0.000014034502,0.000002167388,0.0032118484],"genre_scores_gemma":[0.994693,0.001973133,0.0012356617,0.0012452034,0.00046877406,0.0000037743996,0.000012220783,0.000011889273,0.00035637402],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972498,0.000402514,0.0017265842,0.00022372307,0.00018191815,0.00021545224],"domain_scores_gemma":[0.9956135,0.00278103,0.0010184083,0.0001875876,0.00017300979,0.00022644678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021271445,0.00015751562,0.0010976517,0.00012083949,0.000028325156,0.00000513994,0.00020465303,0.00066977827,0.00006935069],"category_scores_gemma":[0.0067776158,0.000111989975,0.00026361848,0.00011031291,0.00023730406,0.0000037227728,0.0001612901,0.00033431253,0.0000051145416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019373093,0.0064401063,0.2063097,0.0000880882,0.0015473344,0.0010043506,0.00022303265,0.0007654887,0.038291797,0.00023980043,0.016026229,0.709691],"study_design_scores_gemma":[0.041720632,0.16583017,0.64099437,0.0007430632,0.0007330204,0.00075967965,0.0001638012,0.005331911,0.009592667,0.0026385672,0.13087484,0.00061728776],"about_ca_topic_score_codex":0.000068888854,"about_ca_topic_score_gemma":0.0002494386,"teacher_disagreement_score":0.70907366,"about_ca_system_score_codex":0.00029746696,"about_ca_system_score_gemma":0.0026754695,"threshold_uncertainty_score":0.81139284},"labels":[],"label_agreement":null},{"id":"W4407701760","doi":"10.1200/jco.2025.43.5_suppl.143","title":"Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Subgroup analysis; Cancer; Meta-analysis","score_opus":0.046635863680190286,"score_gpt":0.4207439660642051,"score_spread":0.3741081023840148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517554,0.0029680403,0.00003039926,0.0010608898,0.00005381058,0.00060632196,0.000025501364,0.0000025519694,0.00007691509],"genre_scores_gemma":[0.9868885,0.012441812,0.0004204938,0.00014392375,0.000012433865,0.000005163765,0.000021702435,0.000008261344,0.000057707402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728227,0.00038084626,0.0016466298,0.00020382045,0.0003116891,0.00017477704],"domain_scores_gemma":[0.9966695,0.0013389008,0.0011713783,0.00012464865,0.0005594251,0.0001361977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014213072,0.00013339907,0.0017869534,0.0005596064,0.000023034274,0.000004959901,0.000051560448,0.00013257506,0.000008938767],"category_scores_gemma":[0.00054813543,0.00008152399,0.00015728481,0.00085716305,0.000502496,0.00008575036,0.000034501954,0.00044283966,1.1953067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09292237,0.0017389331,0.81118,0.00007344817,0.009112167,0.00026348382,0.0011250908,0.00031651097,0.00044413575,0.000037212387,0.000028132543,0.08275853],"study_design_scores_gemma":[0.05017279,0.007092824,0.9391834,0.00020688647,0.002245108,0.000005390706,0.00014882917,0.0004527937,0.00023235945,0.0000941355,0.00010445392,0.00006101953],"about_ca_topic_score_codex":0.00012519331,"about_ca_topic_score_gemma":0.00011713109,"teacher_disagreement_score":0.12800342,"about_ca_system_score_codex":0.00016436359,"about_ca_system_score_gemma":0.0009282788,"threshold_uncertainty_score":0.3324452},"labels":[],"label_agreement":null},{"id":"W4407701764","doi":"10.1200/jco.2025.43.5_suppl.808","title":"ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Urothelial cancer; Oncology; Internal medicine; Cancer research; Cancer; Bladder cancer","score_opus":0.07342563517190712,"score_gpt":0.44259894561825625,"score_spread":0.36917331044634916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912556,0.00025409018,0.0022764793,0.002520471,0.0011046267,0.0016421195,0.00004570177,0.000010812508,0.00089013006],"genre_scores_gemma":[0.98529744,0.00005430599,0.012829556,0.0007299465,0.0006915695,0.000096159376,0.000011692441,0.000030897674,0.0002584023],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963506,0.00030852627,0.0023694094,0.00028516146,0.00039681222,0.00028948166],"domain_scores_gemma":[0.9951073,0.002624161,0.0013496439,0.00021707709,0.00040029746,0.0003014989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011899814,0.000256378,0.0019636871,0.0002171089,0.000105860534,0.000020234414,0.00012062119,0.00018899569,0.000045101624],"category_scores_gemma":[0.0013085334,0.00016383578,0.00046725452,0.0002083661,0.00025501903,0.00011442291,0.000025028285,0.0004990046,8.429019e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8089148,0.010388097,0.04701981,0.00036938084,0.005783174,0.0012248157,0.0007766304,0.00007817174,0.0010003073,0.00044368283,0.0022249187,0.12177621],"study_design_scores_gemma":[0.731679,0.22920112,0.018123122,0.00066383986,0.008437281,0.00035847045,0.00046247197,0.0004933287,0.0033087241,0.0007025322,0.0062858406,0.0002842473],"about_ca_topic_score_codex":0.00005173896,"about_ca_topic_score_gemma":0.00011251761,"teacher_disagreement_score":0.21881302,"about_ca_system_score_codex":0.00010102804,"about_ca_system_score_gemma":0.004750973,"threshold_uncertainty_score":0.8428022},"labels":[],"label_agreement":null},{"id":"W4407701961","doi":"10.1200/jco.2025.43.5_suppl.633","title":"Outcomes of patients with stage I testicular cancer following orchidectomy with borderline retroperitoneal lymph node enlargement at diagnosis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retroperitoneal lymph node dissection; Testicular cancer; Stage (stratigraphy); Lymph node; Retroperitoneal space; Orchiectomy; Radiology; Urology; Cancer; Surgery; Internal medicine","score_opus":0.036013341452943506,"score_gpt":0.4252094943479492,"score_spread":0.3891961528950057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948971,0.0014980612,0.00017036013,0.002346542,0.00045528144,0.00035874394,0.000029505336,0.000009786986,0.00023456599],"genre_scores_gemma":[0.9913909,0.00024014016,0.006297592,0.0015951315,0.00009150814,0.0000285789,0.000013844074,0.000021064463,0.0003212493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973091,0.00016487026,0.0014858929,0.00023348126,0.00056126335,0.00024541822],"domain_scores_gemma":[0.9965122,0.001088716,0.0012778421,0.00025905273,0.00054452836,0.0003176912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004701471,0.00020265744,0.0016406197,0.00011722009,0.000054674532,0.0000062534973,0.00012302566,0.00014338337,0.00011159684],"category_scores_gemma":[0.0019648792,0.000107602784,0.00044577732,0.00020231234,0.00014345036,0.00006876563,0.000077246244,0.0002760466,0.0000024742299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004567865,0.0053924955,0.97327363,0.00009094419,0.0034360937,0.0011201904,0.000014823793,0.000115181305,0.0000042076276,0.000015348724,0.00026340663,0.0117058195],"study_design_scores_gemma":[0.027893126,0.0062363637,0.955287,0.0005115785,0.0032376382,0.000006806034,0.000025725825,0.00003608827,0.000035967965,0.0000095051655,0.006623249,0.000096982585],"about_ca_topic_score_codex":0.00010708342,"about_ca_topic_score_gemma":0.00007616088,"teacher_disagreement_score":0.023325263,"about_ca_system_score_codex":0.00035020785,"about_ca_system_score_gemma":0.0016547303,"threshold_uncertainty_score":0.43879142},"labels":[],"label_agreement":null},{"id":"W4407702292","doi":"10.1200/jco.2025.43.5_suppl.15","title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Randomized controlled trial; Oncology; Patient data; Internal medicine; Cancer; Medical physics; Database","score_opus":0.45323613473234275,"score_gpt":0.562627143051762,"score_spread":0.10939100831941923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88040036,0.034403905,0.0031640616,0.07414288,0.0014366822,0.002301533,0.0037903714,0.000024935032,0.00033526664],"genre_scores_gemma":[0.96952623,0.005115089,0.013739168,0.007924434,0.0007174194,0.00015581744,0.0017978766,0.000023331157,0.001000621],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9812421,0.010382584,0.0061248946,0.00066579296,0.0012099814,0.00037460358],"domain_scores_gemma":[0.94211215,0.050047282,0.0047484203,0.0012855561,0.0013520886,0.00045450477],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.026506303,0.00033125616,0.011309561,0.0011086504,0.0001715341,0.00017295271,0.0008640367,0.00020356094,0.0025854784],"category_scores_gemma":[0.020528907,0.00015863548,0.0040562307,0.0039743464,0.00043046146,0.00040146874,0.0003393752,0.001070122,0.0000057257525],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09251478,0.0012119716,0.065759376,0.000009639461,0.799962,0.00022851855,0.0010184663,0.0018931725,0.000016745202,0.000023822238,0.008318413,0.029043127],"study_design_scores_gemma":[0.095361434,0.00090302166,0.039782498,0.000025120398,0.8383937,0.000001038013,0.0012122716,0.003007401,0.00007914891,0.0012233075,0.01985706,0.0001540236],"about_ca_topic_score_codex":0.0025393984,"about_ca_topic_score_gemma":0.0073952735,"teacher_disagreement_score":0.08912588,"about_ca_system_score_codex":0.00028791785,"about_ca_system_score_gemma":0.0042896206,"threshold_uncertainty_score":0.9983263},"labels":[],"label_agreement":null},{"id":"W4407702330","doi":"10.1200/jco.2025.43.5_suppl.826","title":"Mechanism of action and translation to the clinic of detalimogene voraplasmid (EG-70): A novel, investigational, non-viral immunotherapy for non-muscle-invasive bladder cancer (NMIBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Bladder cancer; Cancer; Mechanism (biology); Investigational Drugs; Cancer immunotherapy; Mechanism of action; Oncology; Internal medicine; Clinical trial","score_opus":0.13907920804179502,"score_gpt":0.4697884836353675,"score_spread":0.3307092755935725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96054935,0.0008947202,0.016921751,0.018435309,0.0016742412,0.0010669497,0.00007209309,0.000004071237,0.0003814998],"genre_scores_gemma":[0.9843506,0.0024328642,0.008174589,0.00417438,0.00053161377,0.00005358686,0.0000050073895,0.000017339227,0.00025996863],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974503,0.00012610108,0.0018302504,0.00018577989,0.0002594791,0.00014809844],"domain_scores_gemma":[0.9959632,0.0018954225,0.0012307949,0.0001619828,0.00061885966,0.0001297235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014299109,0.00014330966,0.0010294924,0.00015598879,0.00005339422,0.000005324191,0.00012768923,0.00029038987,0.00007537689],"category_scores_gemma":[0.00054978154,0.00009443856,0.00041330408,0.0001867797,0.00018423672,0.000092627124,0.000017904025,0.0003137651,0.0000011724695],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03402518,0.0043083457,0.024086127,0.0005782502,0.0077743516,0.000015691776,0.0020798708,0.0002699605,0.2984038,0.0007984643,0.0077878865,0.6198721],"study_design_scores_gemma":[0.08715339,0.0708077,0.5597694,0.0017690535,0.006417321,0.000102160455,0.0010659503,0.0017466492,0.20625712,0.013936907,0.050472107,0.0005022573],"about_ca_topic_score_codex":0.000092547605,"about_ca_topic_score_gemma":0.0002526891,"teacher_disagreement_score":0.6193698,"about_ca_system_score_codex":0.00008247285,"about_ca_system_score_gemma":0.00276024,"threshold_uncertainty_score":0.48965475},"labels":[],"label_agreement":null},{"id":"W4407702418","doi":"10.1200/jco.2025.43.5_suppl.165","title":"Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Johnson and Johnson","keywords":"Medicine; Prostate cancer; Post-hoc analysis; Oncology; Post hoc; Internal medicine; Prostate; Cancer; Gynecology","score_opus":0.05926860180952538,"score_gpt":0.4207456123460205,"score_spread":0.3614770105364951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952528,0.0033897317,0.000011878068,0.00016464187,0.00013230926,0.0009508246,0.00005743501,0.0000010613467,0.000039347076],"genre_scores_gemma":[0.9973662,0.0022605478,0.00018428889,0.000028353286,0.000014782166,0.0000064978267,0.000003702346,0.00000610673,0.00012954995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677867,0.00091665325,0.0015493723,0.0001590563,0.00047256425,0.00012370144],"domain_scores_gemma":[0.99590546,0.0013597806,0.00142921,0.00019411897,0.0010310714,0.000080336824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019536389,0.00011163133,0.0020840487,0.00038637567,0.000017962358,0.0000015059787,0.00007575139,0.00007482695,0.000012604935],"category_scores_gemma":[0.0013779339,0.00005203226,0.00045435035,0.00064028037,0.0003463693,0.00005829362,0.00004030338,0.00039994397,3.9656655e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04893163,0.0032710154,0.8804041,0.00009303022,0.02921615,0.000060564973,0.0035683976,0.0006891108,0.00005900686,0.000004229943,0.000010392382,0.033692356],"study_design_scores_gemma":[0.018947791,0.010530916,0.95063853,0.00017028816,0.018075751,0.0000017679691,0.0010864814,0.0000758778,0.00009155492,0.0000042793476,0.00033753397,0.00003921551],"about_ca_topic_score_codex":0.001172983,"about_ca_topic_score_gemma":0.0018258373,"teacher_disagreement_score":0.070234425,"about_ca_system_score_codex":0.00035346672,"about_ca_system_score_gemma":0.003021617,"threshold_uncertainty_score":0.5360219},"labels":[],"label_agreement":null},{"id":"W4407702530","doi":"10.1200/jco.2025.43.5_suppl.853","title":"DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Urothelial cancer; Biomarker; Chemotherapy; DNA damage; Oncology; Cancer; Cancer research; DNA; Bladder cancer; Internal medicine; Pathology; Genetics; Biology","score_opus":0.10767130414792704,"score_gpt":0.5015680105756978,"score_spread":0.39389670642777075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93618864,0.00079688267,0.0077212825,0.040914055,0.002898147,0.0020300725,0.00013499285,0.000043332017,0.009272616],"genre_scores_gemma":[0.97327656,0.00026656163,0.00949247,0.014817731,0.00063969335,0.00014229905,0.0000106862735,0.000025329995,0.0013286726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735606,0.00029332846,0.0017197577,0.0002160373,0.00020739804,0.00020741875],"domain_scores_gemma":[0.9965266,0.002141091,0.0006701059,0.00017083672,0.00032148464,0.00016987676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001456823,0.00014896641,0.0011348036,0.00022405732,0.000047554688,0.000008456977,0.00010767698,0.00019819112,0.0002580594],"category_scores_gemma":[0.0017811195,0.00010871317,0.0005722217,0.00023098598,0.00014306356,0.000082239654,0.000012673073,0.00041481122,0.0000035678559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19208291,0.017170409,0.3706488,0.0004784645,0.009104567,0.0012100752,0.0008214454,0.0006859768,0.0038216205,0.0012454161,0.068568595,0.33416173],"study_design_scores_gemma":[0.12171779,0.042008165,0.6296994,0.00086152996,0.0026493003,0.000067353045,0.0002632363,0.010780902,0.0031143487,0.004808358,0.18375808,0.0002715099],"about_ca_topic_score_codex":0.000104298546,"about_ca_topic_score_gemma":0.000219104,"teacher_disagreement_score":0.3338902,"about_ca_system_score_codex":0.0003070727,"about_ca_system_score_gemma":0.0053608455,"threshold_uncertainty_score":0.950991},"labels":[],"label_agreement":null},{"id":"W4407702698","doi":"10.1200/jco.2025.43.5_suppl.349","title":"Population-based assessment of treatment patterns for high-risk localized prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; London Health Sciences Centre; University of Toronto; Western University; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; Jewish General Hospital; McGill University; University of Ottawa; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Population; Risk assessment; Internal medicine; Prostate; Gynecology; Environmental health","score_opus":0.11352595895436436,"score_gpt":0.5506829936409051,"score_spread":0.43715703468654077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848311,0.0005631852,0.002195708,0.010180718,0.0010084049,0.00089844456,0.00010882227,0.0000069383154,0.00020666582],"genre_scores_gemma":[0.9903389,0.0028804236,0.0048902715,0.00047875653,0.0002945335,0.00008174028,0.0000379459,0.0000113922115,0.0009860242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732715,0.00030019222,0.0017636225,0.00016784023,0.00023550894,0.00020566508],"domain_scores_gemma":[0.9954644,0.0022242658,0.0013447392,0.00016511892,0.0006204807,0.00018103415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014189283,0.00012462374,0.0014161936,0.00017343709,0.000051111438,0.0000057203424,0.00008889294,0.00019780449,0.00009256971],"category_scores_gemma":[0.00063205406,0.00007435071,0.00048211246,0.00013524554,0.00008694954,0.000037615446,0.000016588745,0.0003161545,4.601179e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072250618,0.0016257156,0.8049132,0.00013406046,0.0009109392,0.000037444337,0.00001957924,0.00031182403,0.00003362879,0.0001394956,0.00045239658,0.18419664],"study_design_scores_gemma":[0.03779634,0.028254142,0.9187665,0.0003233455,0.0011519335,0.0000028327886,0.000052067313,0.0015756225,0.0005356991,0.0007757854,0.010703719,0.00006202253],"about_ca_topic_score_codex":0.0013563009,"about_ca_topic_score_gemma":0.00033336025,"teacher_disagreement_score":0.18413462,"about_ca_system_score_codex":0.0010126773,"about_ca_system_score_gemma":0.0066369055,"threshold_uncertainty_score":0.9989945},"labels":[],"label_agreement":null},{"id":"W4407702707","doi":"10.1200/jco.2025.43.5_suppl.96","title":"Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Receipt; Internal medicine; Prostate; Gynecology","score_opus":0.17608452862159077,"score_gpt":0.5137218026286796,"score_spread":0.3376372740070889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756752,0.0014996778,0.0003822869,0.021011995,0.0003734483,0.0007126006,0.000054070417,0.0000046395035,0.00028602837],"genre_scores_gemma":[0.985404,0.010147785,0.0016224146,0.00028843782,0.00020043245,0.000024290466,0.000023798,0.000008828957,0.002280018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979916,0.0003052639,0.0012074066,0.00013766682,0.00018603189,0.00017198478],"domain_scores_gemma":[0.9947881,0.002476707,0.0012250191,0.00006333601,0.0013226429,0.00012416765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019314052,0.00010034156,0.001199214,0.00018696966,0.00004325194,0.000006699563,0.000033658613,0.00017431952,0.000008270445],"category_scores_gemma":[0.0014584762,0.0000658793,0.00026967947,0.00019640202,0.00014458747,0.000059998885,0.000013517901,0.00024503714,3.1288127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010340773,0.000753391,0.7623349,0.00022323166,0.0059481366,0.00006383681,0.00043228673,0.000009185413,0.00044088933,0.0001421194,0.0024301966,0.21688108],"study_design_scores_gemma":[0.035223506,0.029463068,0.90124834,0.00061815506,0.007136121,0.00002351843,0.0010790388,0.000328062,0.0043931697,0.0033074548,0.017051362,0.00012821823],"about_ca_topic_score_codex":0.00005990499,"about_ca_topic_score_gemma":0.00006699826,"teacher_disagreement_score":0.21675286,"about_ca_system_score_codex":0.00048222038,"about_ca_system_score_gemma":0.0018457242,"threshold_uncertainty_score":0.32742354},"labels":[],"label_agreement":null},{"id":"W4407702756","doi":"10.1200/jco.2025.43.5_suppl.tps886","title":"A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bladder cancer; Urothelial cancer; Oncology; Urology; Internal medicine; Cancer","score_opus":0.04831964550911251,"score_gpt":0.4395237639829985,"score_spread":0.39120411847388603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951756,0.0002263393,0.00066490186,0.0011364726,0.0010905361,0.001458279,0.00007835866,0.0000068580302,0.00016265603],"genre_scores_gemma":[0.99500865,0.00076509203,0.0019068572,0.001485624,0.0005750884,0.00008212854,0.000006481951,0.000029964014,0.00014013099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966656,0.0002781303,0.0020672432,0.00030685196,0.00040975673,0.00027243828],"domain_scores_gemma":[0.9949166,0.0017426829,0.0017154736,0.0002687262,0.0010712977,0.00028522444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007800996,0.00023604711,0.0018985649,0.00019151549,0.00006401287,0.000008188744,0.00019589489,0.00029040067,0.00011494478],"category_scores_gemma":[0.0007620545,0.00014919361,0.00037519165,0.00024632565,0.00019547541,0.00009653645,0.000034355257,0.0005656075,0.0000019510212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06343824,0.061616138,0.52802813,0.00007575571,0.0073246793,0.000114486036,0.0006511323,0.00005282797,0.00026317083,0.000016757745,0.0031225746,0.3352961],"study_design_scores_gemma":[0.17709798,0.21812381,0.59470356,0.00019390827,0.0039066556,0.0000067091105,0.0003594007,0.00004563281,0.0017021237,0.00030406466,0.0033956699,0.00016048354],"about_ca_topic_score_codex":0.00028604598,"about_ca_topic_score_gemma":0.0004544947,"teacher_disagreement_score":0.3351356,"about_ca_system_score_codex":0.00017253344,"about_ca_system_score_gemma":0.002861804,"threshold_uncertainty_score":0.6083939},"labels":[],"label_agreement":null},{"id":"W4407721050","doi":"10.1200/jco.2025.43.5_suppl.494","title":"Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Oncology; Internal medicine; Carcinoma","score_opus":0.06005095628383615,"score_gpt":0.35232714463549947,"score_spread":0.2922761883516633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407721050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98944074,0.0004249973,0.00044885784,0.004582482,0.0004986234,0.0010457647,0.00080676016,0.000016425402,0.0027353482],"genre_scores_gemma":[0.9858907,0.00014899521,0.009829452,0.0016704585,0.00018132053,0.000020494652,0.0007101493,0.000062591105,0.0014858331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920458,0.0009299962,0.004472923,0.0007134068,0.001319853,0.00051803066],"domain_scores_gemma":[0.98493904,0.0074170474,0.0045128665,0.0009959968,0.0016563131,0.0004787089],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020632364,0.000617593,0.0028718533,0.00037778527,0.00013122358,0.000038337996,0.0007953391,0.00022564066,0.00032749053],"category_scores_gemma":[0.0009698789,0.00031538194,0.00069281185,0.0005046892,0.0006462185,0.00022931294,0.00020406014,0.001357679,0.000021396307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09675896,0.01094232,0.86889005,0.00015927434,0.003759261,0.0027984942,0.0006086254,0.0003682556,0.0013151391,0.000008387437,0.012962695,0.0014285521],"study_design_scores_gemma":[0.07864321,0.02624361,0.8677334,0.00024573022,0.0062651103,0.000045183053,0.0005945763,0.00044938468,0.014107829,0.000032015494,0.005314338,0.00032557573],"about_ca_topic_score_codex":0.0008565583,"about_ca_topic_score_gemma":0.0004952231,"teacher_disagreement_score":0.018115751,"about_ca_system_score_codex":0.00038271656,"about_ca_system_score_gemma":0.0026613232,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W4407873120","doi":"10.1200/jco-24-01334","title":"Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Hazard ratio; Internal medicine; Oncology; Cancer; Surgical oncology; Proportional hazards model; Gynecology; Confidence interval","score_opus":0.03476084730471595,"score_gpt":0.4464492810006259,"score_spread":0.41168843369590996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407873120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918592,0.0037039202,0.0002294271,0.0008306472,0.0026396047,0.00020289843,0.00020296541,0.0000020038765,0.00032931438],"genre_scores_gemma":[0.9879787,0.009795505,0.0011495706,0.0004093837,0.00054491893,0.000020367224,0.000008960756,0.000015798965,0.00007677766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954406,0.00053209416,0.0032449896,0.0003163236,0.00021113394,0.00025483113],"domain_scores_gemma":[0.99592876,0.0010800423,0.0017655242,0.0002898438,0.0007415406,0.00019426543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024264564,0.00016034991,0.0012108397,0.0001380806,0.000024723176,0.000005187492,0.00029225973,0.0006315024,0.000029000634],"category_scores_gemma":[0.002723787,0.00014119754,0.0003390814,0.00022903523,0.0007192345,0.000011723501,0.00017110257,0.00057435775,2.3781253e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013621519,0.0008368303,0.9282319,0.00005817625,0.00026487248,0.000024892532,0.000042288266,0.00029981325,0.0053947684,0.000023240427,0.0016938492,0.06176722],"study_design_scores_gemma":[0.005365137,0.0019445688,0.9817045,0.00015932627,0.00041002387,0.00006392317,0.00015959311,0.000048443606,0.0033349746,0.00009769239,0.0065820822,0.00012974783],"about_ca_topic_score_codex":0.00021750273,"about_ca_topic_score_gemma":0.0015446683,"teacher_disagreement_score":0.061637472,"about_ca_system_score_codex":0.000107941305,"about_ca_system_score_gemma":0.0053426744,"threshold_uncertainty_score":0.94776756},"labels":[],"label_agreement":null},{"id":"W4408014791","doi":"10.1200/jco-24-02786","title":"Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Lung cancer; Clinical Practice; Family medicine; Clinical Oncology; Medical physics; Cancer; Oncology; Pathology; Internal medicine","score_opus":0.06068914633941983,"score_gpt":0.5161611105901931,"score_spread":0.45547196425077324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408014791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8880065,0.0070239417,0.034987632,0.040011637,0.008898166,0.0019245024,0.00005584371,0.000024870898,0.019066906],"genre_scores_gemma":[0.80429137,0.010531954,0.062339164,0.024351198,0.0034519928,0.00013855739,0.00002705986,0.000050425624,0.09481827],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787176,0.00011500388,0.0015025123,0.00018010744,0.00015603878,0.00017457081],"domain_scores_gemma":[0.9967517,0.0013118772,0.000831295,0.00015217144,0.00079019764,0.00016272494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010924515,0.00012178251,0.0007672414,0.00013591316,0.000116974814,0.000015905498,0.00010654242,0.00021233156,0.000500592],"category_scores_gemma":[0.00066209125,0.00008351452,0.00038717536,0.0001399432,0.000052787043,0.000104320054,0.000027302383,0.00038401465,0.000004739671],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003483023,0.0029488977,0.46986756,0.00016524162,0.0021377641,0.00009347569,0.0006337386,0.0008288147,0.0007306793,0.00015267248,0.38122365,0.13773447],"study_design_scores_gemma":[0.017350782,0.0049057323,0.09776105,0.0004977024,0.001633835,0.000009472075,0.00029986037,0.0045052357,0.00021482035,0.00008487898,0.8726202,0.00011641562],"about_ca_topic_score_codex":0.00006746773,"about_ca_topic_score_gemma":0.00009059136,"teacher_disagreement_score":0.49139658,"about_ca_system_score_codex":0.00032518012,"about_ca_system_score_gemma":0.003772428,"threshold_uncertainty_score":0.6692125},"labels":[],"label_agreement":null},{"id":"W4408128144","doi":"10.1200/jco-24-02407","title":"Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Neuroblastoma; Oncology; Internal medicine; Clinical Oncology; Pediatric oncology; Cancer research; Cancer; Genetics; Biology","score_opus":0.04854455155999149,"score_gpt":0.44613800111633595,"score_spread":0.39759344955634446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408128144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516046,0.00031319997,0.000016321917,0.003022444,0.00048442744,0.00078644865,0.000024885607,0.0000073279975,0.00018448339],"genre_scores_gemma":[0.9948023,0.0027627249,0.0015098868,0.0005802775,0.00022799116,0.000033557004,0.0000041319213,0.000014531139,0.000064625645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935342,0.0022340417,0.0030531865,0.0004483123,0.0004106717,0.00031956963],"domain_scores_gemma":[0.9868489,0.0106844315,0.0014463768,0.00020876911,0.0003154263,0.0004961023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030130239,0.00020028166,0.0019056438,0.00038532246,0.00007802873,0.000008528994,0.00017079408,0.00036543573,0.00006070507],"category_scores_gemma":[0.0059488546,0.00015246245,0.00030615772,0.00032310627,0.0009699493,0.00011733473,0.00020960525,0.0016508271,0.0000046768173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005090158,0.012325051,0.92573625,0.000021928894,0.0008441571,0.0023468668,0.00006374801,0.0000033038427,0.000083992025,0.00013683274,0.00047530228,0.052872382],"study_design_scores_gemma":[0.024016494,0.05523903,0.91828996,0.00008823866,0.00072044326,0.00030238758,0.00007831425,0.00002818026,0.000027030379,0.0007827012,0.0003487171,0.00007849796],"about_ca_topic_score_codex":0.00022870186,"about_ca_topic_score_gemma":0.0016435195,"teacher_disagreement_score":0.052793883,"about_ca_system_score_codex":0.00019002835,"about_ca_system_score_gemma":0.0014154137,"threshold_uncertainty_score":0.7172114},"labels":[],"label_agreement":null},{"id":"W4408167066","doi":"10.1200/jco-24-01283","title":"Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Pembrolizumab; Oncology; Double blind; Internal medicine; Randomized controlled trial; Prostate; Urology; Chemotherapy; Cancer; Placebo; Pathology; Immunotherapy","score_opus":0.2509900570005083,"score_gpt":0.551990400322006,"score_spread":0.30100034332149767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408167066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9377541,0.011222439,0.00042809735,0.030918138,0.004516872,0.012229673,0.00007265011,0.000031377785,0.0028266322],"genre_scores_gemma":[0.9759859,0.010657796,0.00077715213,0.0007717454,0.0017318893,0.0013524544,0.000059854447,0.000039538798,0.008623692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99311507,0.0011151383,0.004063819,0.00041030656,0.0006765139,0.0006191827],"domain_scores_gemma":[0.98631054,0.009105715,0.0023554803,0.0003860869,0.0014004316,0.0004417668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007632824,0.00035083687,0.0036775116,0.00029466162,0.00026510633,0.00007844035,0.0003679494,0.00031875816,0.00014460742],"category_scores_gemma":[0.0038122577,0.0001803926,0.0016349803,0.0004654413,0.0007820894,0.00019148653,0.00006339366,0.0011857089,0.000006091728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9503826,0.0026948862,0.00003563565,0.00015642686,0.0054747486,0.0003629493,0.00027725307,0.00007954029,0.00008291646,0.0005728866,0.0048501086,0.035030086],"study_design_scores_gemma":[0.94200057,0.023200314,0.00004630575,0.00022625971,0.006997623,0.00005043595,0.0002467312,0.00066504744,0.00031626926,0.00052717497,0.02557813,0.000145163],"about_ca_topic_score_codex":0.0002718216,"about_ca_topic_score_gemma":0.00033817205,"teacher_disagreement_score":0.038231757,"about_ca_system_score_codex":0.0007908628,"about_ca_system_score_gemma":0.012201781,"threshold_uncertainty_score":0.99339813},"labels":[],"label_agreement":null},{"id":"W4408179056","doi":"10.1200/jco.24.00727","title":"Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada); University of Alberta; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Ipilimumab; Medicine; Refractory (planetary science); Internal medicine; Melanoma; Oncology; Open label; Randomized controlled trial; Cancer; Cancer research; Immunotherapy","score_opus":0.062457962405469206,"score_gpt":0.44722081190433793,"score_spread":0.38476284949886874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408179056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943108,0.0003422253,0.00002658818,0.0007146553,0.0007460694,0.002279545,0.0000025391982,0.00000501377,0.0015725874],"genre_scores_gemma":[0.99865574,0.00033777652,0.00048890855,0.0003089164,0.000031486426,0.000045246194,0.000007519178,0.000017285442,0.00010710391],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99477535,0.001032317,0.0031940981,0.00029002587,0.0004708536,0.00023733925],"domain_scores_gemma":[0.9940516,0.0026231639,0.0023157503,0.00029391583,0.00060059055,0.000115018265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041937637,0.00021036144,0.0029759381,0.0004717492,0.000033735723,0.000010089982,0.000314034,0.00025784352,0.00005165614],"category_scores_gemma":[0.0011672182,0.00013491261,0.0001314855,0.0005825666,0.00036746153,0.00028401785,0.00007418906,0.00087266014,7.198737e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81566554,0.04662152,0.027349096,0.000032328342,0.0008826369,0.00017856849,0.00040103085,0.000009787861,0.000049818467,0.000014948303,0.00007549452,0.10871923],"study_design_scores_gemma":[0.7504681,0.12128948,0.1256725,0.00039163732,0.00039134687,0.000005923063,0.00085211295,0.000051615785,0.000034271965,0.000026405436,0.0007147002,0.00010192298],"about_ca_topic_score_codex":0.00019129952,"about_ca_topic_score_gemma":0.0010072455,"teacher_disagreement_score":0.10861731,"about_ca_system_score_codex":0.00047722345,"about_ca_system_score_gemma":0.0015153579,"threshold_uncertainty_score":0.55015767},"labels":[],"label_agreement":null},{"id":"W4409129984","doi":"10.1200/jco-25-00275","title":"Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Dysgeusia; Adverse effect; Clinical endpoint; Population; Clinical trial; Lung cancer; ROS1; Gastroenterology; Phases of clinical research; Surgery; Cancer; Adenocarcinoma","score_opus":0.04814570984505929,"score_gpt":0.49935750184501054,"score_spread":0.45121179199995126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409129984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88967586,0.0029428906,0.0001807018,0.014225226,0.0030812242,0.00030819472,0.0000051315574,0.000007604003,0.08957319],"genre_scores_gemma":[0.98006696,0.0023361365,0.0022010962,0.0063312505,0.0007240861,0.00001785609,0.0000021784638,0.000011376534,0.008309088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978418,0.000121644924,0.0015607021,0.00015400839,0.00013283701,0.00018902349],"domain_scores_gemma":[0.9978814,0.00086345576,0.0007084535,0.0001308479,0.00023472286,0.00018108843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009295019,0.00010354168,0.0010008228,0.00018475878,0.00003068271,0.000006927673,0.00010805971,0.00025117517,0.0001454771],"category_scores_gemma":[0.00057952205,0.00007415335,0.00031951276,0.00026965633,0.000072592295,0.00005429531,0.000029188463,0.0007529323,0.0000059571244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012326905,0.0021824585,0.83436066,0.00009283154,0.0004167541,0.0006372142,0.00020534734,0.00006800406,0.00013372065,0.000058893052,0.022853468,0.13775797],"study_design_scores_gemma":[0.02342643,0.0038102756,0.6471534,0.0004619027,0.001654403,0.00007068658,0.0003251829,0.00028803793,0.00035352336,0.00017202935,0.3221772,0.0001069565],"about_ca_topic_score_codex":0.00017114387,"about_ca_topic_score_gemma":0.0003523764,"teacher_disagreement_score":0.29932374,"about_ca_system_score_codex":0.0004152771,"about_ca_system_score_gemma":0.0042522615,"threshold_uncertainty_score":0.75433296},"labels":[],"label_agreement":null},{"id":"W4409318033","doi":"10.1200/jco-25-00099","title":"Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Systematic review; Sentinel lymph node; Breast cancer; MEDLINE; Psychological intervention; Family medicine; Clinical trial; Medical physics; Gynecology; Cancer; Pathology; Internal medicine; Nursing","score_opus":0.07024487964926483,"score_gpt":0.4749308110014868,"score_spread":0.404685931352222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409318033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011248508,0.9926584,0.00005187613,0.0025542546,0.0021128014,0.00021219101,0.00040353983,0.000006117519,0.00087600946],"genre_scores_gemma":[0.00020749407,0.9940322,0.00089267135,0.0011328277,0.0028801137,0.00003813816,0.000096305375,0.00004599877,0.00067426456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99311477,0.00077237404,0.004840341,0.00057298056,0.00026384927,0.00043568164],"domain_scores_gemma":[0.9945284,0.000478375,0.0038079869,0.00046786646,0.0004930063,0.00022435095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020215146,0.0005190396,0.004490524,0.00020225327,0.00005248693,0.000016892152,0.0006652063,0.0012875928,0.00006658654],"category_scores_gemma":[0.00089184096,0.00037820308,0.0016862475,0.00029869005,0.0002528067,0.000007825607,0.00043889452,0.00087153685,0.000017698849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064972404,0.0008802229,0.024886519,0.0015517344,0.0021284139,0.0004450746,0.0000048163165,0.000013226742,0.0000019110676,0.000018883213,0.008459174,0.9609603],"study_design_scores_gemma":[0.0030585767,0.00013944847,0.024206525,0.003462062,0.0013789361,0.00042748125,0.000008952261,0.0000013909051,0.0000011473094,0.000012800327,0.9670032,0.00029943892],"about_ca_topic_score_codex":0.00024522492,"about_ca_topic_score_gemma":0.00006565972,"teacher_disagreement_score":0.9606609,"about_ca_system_score_codex":0.00028520304,"about_ca_system_score_gemma":0.0054555777,"threshold_uncertainty_score":0.99986696},"labels":[],"label_agreement":null},{"id":"W4409531921","doi":"10.1200/jco-24-01351","title":"Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Melanoma; Internal medicine; Oncology; Cohort; Retrospective cohort study; Proportional hazards model; Survival analysis; Cancer research","score_opus":0.04418691623730867,"score_gpt":0.4179571370387645,"score_spread":0.37377022080145583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409531921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891438,0.0001351263,0.00029008658,0.009025015,0.00034369677,0.0008581974,0.000015071655,0.000003696957,0.00018530329],"genre_scores_gemma":[0.99108034,0.000043727214,0.008022838,0.0007264568,0.00005968279,0.000015999341,0.00001834015,0.000009539382,0.000023091554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965166,0.0011886783,0.0016164691,0.00020787316,0.00029763012,0.0001727445],"domain_scores_gemma":[0.99553573,0.0024176259,0.0012564361,0.00024731865,0.00038033785,0.00016255716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031452186,0.00014220033,0.0010815092,0.00012963393,0.000034249595,0.0000099493645,0.00013989935,0.00014187057,0.000016032698],"category_scores_gemma":[0.0027664579,0.000072989096,0.00016416324,0.0002529141,0.00023346677,0.00009874647,0.00006357293,0.0004963529,2.818101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019325785,0.004609643,0.9273677,0.000053441287,0.0005533256,0.00005338655,0.000031514064,0.000003343818,0.00003463517,0.0014011506,0.00007905045,0.06388023],"study_design_scores_gemma":[0.014565886,0.015766438,0.96651286,0.00016643835,0.00095524895,0.000024609531,0.00013297131,0.0001574782,0.000059397058,0.0005014933,0.0010971456,0.00006004392],"about_ca_topic_score_codex":0.000032673648,"about_ca_topic_score_gemma":0.00018425699,"teacher_disagreement_score":0.06382018,"about_ca_system_score_codex":0.000091200855,"about_ca_system_score_gemma":0.0013100934,"threshold_uncertainty_score":0.33119082},"labels":[],"label_agreement":null},{"id":"W4409631228","doi":"10.1200/jco-24-02821","title":"What I Wish I Had Known: A Pediatric Oncologist's Transition to Survivorship Care","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Survivorship curve; Medicine; Cancer survivorship; Pediatric oncology; Wish; Oncology; Family medicine; Gerontology; Cancer; Internal medicine","score_opus":0.12279862139470132,"score_gpt":0.4927269889932779,"score_spread":0.36992836759857656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409631228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83582366,0.0044102343,0.0011780274,0.13872781,0.01269373,0.00055229675,0.000005167026,0.00004571697,0.006563343],"genre_scores_gemma":[0.9400361,0.0032921287,0.0034355128,0.046421435,0.0061146766,0.000012458747,0.000007889688,0.000026660418,0.0006531326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931786,0.0014916108,0.0038225793,0.0004032532,0.00069386745,0.0004100541],"domain_scores_gemma":[0.9912562,0.0049052467,0.0014070264,0.0004068302,0.0012707432,0.00075397163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070727523,0.0002483334,0.0024289573,0.00045941185,0.00008192254,0.000049806677,0.00038166888,0.0008076971,0.00017725489],"category_scores_gemma":[0.008076445,0.00020734366,0.0009872727,0.00070968166,0.0001850576,0.00035048573,0.00008555968,0.0017509146,0.00007905143],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020244345,0.006619626,0.14706497,0.0013104411,0.0011831129,0.0017786428,0.011855464,0.00017933956,0.00006138178,0.00071305636,0.113257974,0.69573164],"study_design_scores_gemma":[0.016286593,0.030184522,0.48476768,0.0010900052,0.0021240138,0.00027224963,0.012830213,0.000021826938,0.000087594555,0.0012658334,0.4506512,0.00041829346],"about_ca_topic_score_codex":0.00017761388,"about_ca_topic_score_gemma":0.0019016383,"teacher_disagreement_score":0.69531333,"about_ca_system_score_codex":0.0005592433,"about_ca_system_score_gemma":0.005072731,"threshold_uncertainty_score":0.9668843},"labels":[],"label_agreement":null},{"id":"W4409676766","doi":"10.1200/jco-24-01606","title":"ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Regimen; Tolerability; Nausea; Neutropenia; Discontinuation; Clinical endpoint; Adverse effect; Anemia; Oncology; Chemotherapy regimen; Gastroenterology; Progression-free survival; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","score_opus":0.3371098409690602,"score_gpt":0.5681743691901731,"score_spread":0.23106452822111284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409676766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868882,0.0015401645,0.00006060216,0.007044466,0.0013392546,0.0022880065,0.000016908743,0.00000576386,0.0008166356],"genre_scores_gemma":[0.9953425,0.0005518249,0.0016513568,0.0011857747,0.00038895308,0.000044985605,0.0000048349993,0.000015565478,0.0008142162],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99614054,0.0005897876,0.0023989456,0.00031616382,0.00029222172,0.0002623695],"domain_scores_gemma":[0.99215376,0.005485421,0.001286038,0.00027958932,0.0004902629,0.00030494382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017062105,0.0002341051,0.0019137886,0.00012899854,0.00012792318,0.000040255232,0.0002699562,0.00016425406,0.00010512119],"category_scores_gemma":[0.0030668068,0.000114158436,0.00037640787,0.00025669654,0.00016921775,0.00011549628,0.00018697135,0.00036460767,0.000001226674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18933785,0.1010107,0.018235464,0.00010496331,0.0028970775,0.00038559525,0.00044632173,0.0000030151157,0.00022070641,0.000015104849,0.000280314,0.68706286],"study_design_scores_gemma":[0.36367318,0.48670337,0.0812216,0.00047807634,0.0051508546,0.00015271887,0.0020736111,0.00023644287,0.00026416066,0.00004200945,0.0598543,0.0001496748],"about_ca_topic_score_codex":0.00011781538,"about_ca_topic_score_gemma":0.00013429944,"teacher_disagreement_score":0.6869132,"about_ca_system_score_codex":0.00050377374,"about_ca_system_score_gemma":0.0013001206,"threshold_uncertainty_score":0.4655246},"labels":[],"label_agreement":null},{"id":"W4410002553","doi":"10.1200/jco-25-00690","title":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Juno Therapeutics; Swedish Orphan Biovitrum; Karyopharm Therapeutics; Gilead Sciences; BeiGene; Sanofi; Pharmacyclics; Genentech; Galápagos; Cilag; TG Therapeutics; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Bendamustine; Medicine; Mantle cell lymphoma; Rituximab; Oncology; Lymphoma; Internal medicine; Cancer research","score_opus":0.07492511335142048,"score_gpt":0.4563691692280959,"score_spread":0.3814440558766754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410002553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430899,0.0013317578,0.000021816373,0.012177782,0.001218709,0.0002250949,0.0000042385377,0.000012820517,0.04191789],"genre_scores_gemma":[0.99132437,0.0010989357,0.0015843798,0.0036697323,0.00037391987,0.000007090317,0.000005162875,0.000011622826,0.0019247637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964943,0.00028192438,0.0024398668,0.00023253953,0.0002543349,0.00029702586],"domain_scores_gemma":[0.9961668,0.0021721632,0.00087881525,0.0002216465,0.00027941764,0.00028110444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014727442,0.0001737653,0.0018174996,0.0002798583,0.000032334476,0.000010251718,0.00016245,0.00047932114,0.00019401211],"category_scores_gemma":[0.0015844539,0.00011931858,0.0004859147,0.00033438348,0.00013510376,0.000064146974,0.00007416056,0.0004060741,0.00008169311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008717207,0.03356099,0.48104703,0.00010541624,0.00058484427,0.00940608,0.00010242519,0.000022458413,0.00007152908,0.00068162335,0.03135806,0.43434232],"study_design_scores_gemma":[0.11399055,0.005441071,0.72677135,0.00030253423,0.00062817754,0.00030091387,0.00013404168,0.00021369988,0.00070517004,0.0003183139,0.1510893,0.00010486617],"about_ca_topic_score_codex":0.00009984477,"about_ca_topic_score_gemma":0.000077912126,"teacher_disagreement_score":0.43423745,"about_ca_system_score_codex":0.0007028277,"about_ca_system_score_gemma":0.0034655964,"threshold_uncertainty_score":0.6147819},"labels":[],"label_agreement":null},{"id":"W4410025632","doi":"10.1200/jco-25-00007","title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Medicine; Cabazitaxel; Enzalutamide; Guideline; Prostate cancer; Docetaxel; Androgen deprivation therapy; Oncology; Abiraterone; Internal medicine; Family medicine; Intensive care medicine; Gynecology; Cancer; Androgen receptor; Pathology","score_opus":0.16469826149718228,"score_gpt":0.542130665441387,"score_spread":0.37743240394420474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410025632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032757442,0.99212265,0.0000054204156,0.0012260714,0.00075831177,0.0022558472,0.00011675904,0.000007126437,0.00023205155],"genre_scores_gemma":[0.00040685115,0.99702114,0.000805649,0.0003434494,0.00037182306,0.00010615359,0.00013563091,0.00003812443,0.00077119825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99195486,0.0010862246,0.00553164,0.00035691168,0.0006914176,0.00037894718],"domain_scores_gemma":[0.9929482,0.0014277956,0.003719236,0.0003042648,0.0012823341,0.0003181682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032919103,0.00038429696,0.005975981,0.00041311843,0.000042733904,0.000020300526,0.00026834547,0.00039607548,0.00008960555],"category_scores_gemma":[0.0008099358,0.0001933247,0.00076220883,0.00053440983,0.00018408048,0.000100084835,0.000045026452,0.0016918184,0.000008884646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008268208,0.0015135623,0.004278563,0.005952633,0.002067494,0.0010106007,0.000020388674,0.0000055794562,1.179557e-7,0.000009118349,0.0028489344,0.9740248],"study_design_scores_gemma":[0.02159569,0.014857403,0.0026584978,0.033385903,0.0025629667,0.00009042011,0.00002442642,0.000002246851,3.7550635e-7,0.00002381054,0.92460805,0.00019020142],"about_ca_topic_score_codex":0.00006578488,"about_ca_topic_score_gemma":0.000088748246,"teacher_disagreement_score":0.9738346,"about_ca_system_score_codex":0.0009341533,"about_ca_system_score_gemma":0.02003934,"threshold_uncertainty_score":0.98551613},"labels":[],"label_agreement":null},{"id":"W4410085625","doi":"10.1200/jco-24-01861","title":"Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; BC Children's Hospital; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute on Deafness and Other Communication Disorders; National Cancer Institute","keywords":"Medicine; Ototoxicity; Cisplatin; Cohort; Internal medicine; Oncology; Area under the curve; Chemotherapy","score_opus":0.27758571544908045,"score_gpt":0.4759176810034321,"score_spread":0.19833196555435167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410085625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8087943,0.000018542803,0.18936758,0.0010002352,0.00045342007,0.00014201943,0.0000067038504,0.0000055618443,0.00021163937],"genre_scores_gemma":[0.8668039,0.00011094662,0.13179645,0.0009912342,0.00015290965,0.0000032728055,7.37747e-7,0.000008403218,0.00013215846],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976156,0.00010021291,0.0017478463,0.00019557221,0.00020425064,0.00013656546],"domain_scores_gemma":[0.99651897,0.0020977648,0.0009950552,0.000107014836,0.00018932788,0.00009186696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018553893,0.00008295367,0.0005259844,0.00010215838,0.000052720643,0.000012795316,0.00015045033,0.0002292606,0.0000051747593],"category_scores_gemma":[0.00425968,0.00007404488,0.00010086265,0.00010262379,0.00010747407,0.00008476278,0.000060728104,0.00031725905,5.149079e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048002806,0.0030183182,0.0495542,0.00013532443,0.00021036889,0.000013219906,0.0025802294,0.020161806,0.47830716,0.0018890059,0.0009872764,0.4383428],"study_design_scores_gemma":[0.01563137,0.002169031,0.11131022,0.00028232738,0.00013857457,0.00003262666,0.000096851625,0.4934441,0.345846,0.0044220025,0.026418863,0.00020806066],"about_ca_topic_score_codex":0.0000042834135,"about_ca_topic_score_gemma":0.000006737432,"teacher_disagreement_score":0.47328228,"about_ca_system_score_codex":0.00007438439,"about_ca_system_score_gemma":0.0010574267,"threshold_uncertainty_score":0.5099543},"labels":[],"label_agreement":null},{"id":"W4410141161","doi":"10.1200/jco-25-00131","title":"Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"SABR volatility model; Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Internal medicine; Ablative case; Randomized controlled trial; Oncology; Bone metastasis; Urology; Surgery; Cancer","score_opus":0.12960100049302373,"score_gpt":0.5239413866762818,"score_spread":0.39434038618325806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410141161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586881,0.009179397,0.001304592,0.021440236,0.002949576,0.0058607035,0.000048572478,0.000011015717,0.00051782286],"genre_scores_gemma":[0.96565294,0.022462819,0.0048991246,0.0019083989,0.0007341166,0.00027990452,0.000009944915,0.000051405746,0.0040013636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943078,0.0017285438,0.0027951887,0.00030871006,0.00045295633,0.00040680234],"domain_scores_gemma":[0.96951073,0.026743863,0.0025113407,0.00028361866,0.00068201346,0.00026843278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064258785,0.00030105407,0.0039387858,0.00033105232,0.00017326853,0.000027310407,0.00021870673,0.00023794668,0.000097521865],"category_scores_gemma":[0.0053610583,0.00015437635,0.001019638,0.0003241528,0.001196737,0.00019344885,0.000041060983,0.0008490687,4.3536747e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92856216,0.0024451283,0.0010113295,0.00009059315,0.017994797,0.000073789524,0.002248281,0.000010272657,0.00010702314,0.00021117003,0.00073569623,0.046509784],"study_design_scores_gemma":[0.92367554,0.057673786,0.0014842062,0.00014786747,0.0024944087,0.000028248744,0.0005522992,0.0007647554,0.00017188929,0.0007942726,0.012088358,0.00012440002],"about_ca_topic_score_codex":0.00006379818,"about_ca_topic_score_gemma":0.000024733952,"teacher_disagreement_score":0.055228658,"about_ca_system_score_codex":0.00067505566,"about_ca_system_score_gemma":0.0037405218,"threshold_uncertainty_score":0.6635525},"labels":[],"label_agreement":null},{"id":"W4410632440","doi":"10.1200/jco-24-02818","title":"Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Sunitinib; Clinical endpoint; Internal medicine; GiST; Population; Progression-free survival; Oncology; Intention-to-treat analysis; Surgery; Adverse effect; Gastroenterology; Overall survival; Randomized controlled trial; Stromal cell; Cancer","score_opus":0.07340256349398314,"score_gpt":0.41426400402446817,"score_spread":0.34086144053048506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410632440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959268,0.000059432696,0.00017592909,0.0016433842,0.0003074741,0.00035764687,0.00006793147,0.000011635786,0.0014497654],"genre_scores_gemma":[0.9966487,0.00006413038,0.0025593932,0.00019376464,0.00020398883,0.000003897082,0.00018752669,0.000018196368,0.00012038425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553,0.0008871609,0.0018602249,0.00042797576,0.00078559935,0.00050903205],"domain_scores_gemma":[0.9940402,0.0032820462,0.0010267437,0.00030004256,0.0007332753,0.00061772397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016150433,0.00030306086,0.00222369,0.00046677748,0.000062558625,0.000033988286,0.00021227585,0.00015802124,0.00030313307],"category_scores_gemma":[0.0017572654,0.00019407186,0.00031931087,0.0005102364,0.00038501876,0.00015596363,0.00012169733,0.0015064614,0.0000044766125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15063003,0.0027640003,0.83579856,0.000017485405,0.002927591,0.0038401084,0.000015089372,0.000046298166,0.000003150082,0.000096020405,0.00006727071,0.0037944142],"study_design_scores_gemma":[0.071046576,0.032585338,0.89357793,0.00024707787,0.0019851513,0.000046123718,0.000047303696,0.00007279928,0.0000051560523,0.000050950635,0.00020411414,0.00013146996],"about_ca_topic_score_codex":0.00032823923,"about_ca_topic_score_gemma":0.0021092535,"teacher_disagreement_score":0.07958345,"about_ca_system_score_codex":0.0003424263,"about_ca_system_score_gemma":0.0016265867,"threshold_uncertainty_score":0.7914021},"labels":[],"label_agreement":null},{"id":"W4410795426","doi":"10.1200/jco.2025.43.16_suppl.4116","title":"Whole-genome sequencing of biliary tract cancer: Uncovering the genomic origins of evolutionary trajectories.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Princess Margaret Cancer Foundation","keywords":"Biliary tract cancer; Genome; Medicine; Cancer; Genomics; Biliary tract; DNA sequencing; Genome instability; Computational biology; Genetics; Biology; Gene; DNA; Internal medicine","score_opus":0.09284901319337888,"score_gpt":0.4220951109219646,"score_spread":0.3292460977285857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97389114,0.015353955,0.00006137859,0.006531081,0.0018661892,0.0001647457,0.000030284347,0.000005050245,0.0020961708],"genre_scores_gemma":[0.99455583,0.0030828982,0.00048888364,0.0007783143,0.000900213,0.000004100568,0.0000016588173,0.000009169801,0.00017891351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971665,0.00018422649,0.0020617617,0.00014601836,0.00026404203,0.0001774395],"domain_scores_gemma":[0.99618155,0.0017064597,0.0013324212,0.00021313781,0.0004722788,0.00009418062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014332648,0.00012211895,0.0013731319,0.0001394786,0.000051898238,0.000002509092,0.00021891245,0.0001837145,0.00004389243],"category_scores_gemma":[0.00095304527,0.00007595622,0.00059295923,0.0002752213,0.0003830578,0.00007280167,0.000070989816,0.0007342807,0.0000010321901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033614214,0.00088069856,0.9193286,0.0003660278,0.0022695046,0.00021801228,0.001148904,0.0007356502,0.03214425,0.00052076223,0.004251997,0.034774233],"study_design_scores_gemma":[0.0027643826,0.0021321943,0.89227754,0.00021240393,0.0007143586,0.000095168194,0.00069894065,0.00003089123,0.00027526598,0.00031713018,0.1004221,0.000059633392],"about_ca_topic_score_codex":0.00046407865,"about_ca_topic_score_gemma":0.00013310713,"teacher_disagreement_score":0.096170105,"about_ca_system_score_codex":0.00096793944,"about_ca_system_score_gemma":0.0054845684,"threshold_uncertainty_score":0.97293884},"labels":[],"label_agreement":null},{"id":"W4410795431","doi":"10.1200/jco.2025.43.16_suppl.12037","title":"Systematic review of prognostic models for cardiomyopathy and heart failure applicable to survivors of adolescent and young adult cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; McMaster University; McGill University; Impact","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Heart failure; Cardiomyopathy; Cancer; Internal medicine; Cardiology; Oncology; Intensive care medicine","score_opus":0.04621573881291929,"score_gpt":0.4141509322489725,"score_spread":0.3679351934360532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92844355,0.0417399,0.009873565,0.015010989,0.00049238745,0.004145476,0.000021902575,0.0000070649676,0.00026518924],"genre_scores_gemma":[0.9787536,0.014634926,0.002981782,0.0033747114,0.00014763113,0.00006155946,0.0000010182878,0.000008479355,0.000036262456],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9975575,0.00020566359,0.0018060486,0.00013358965,0.00019023624,0.00010697032],"domain_scores_gemma":[0.9971402,0.00087691884,0.0008545329,0.00013367583,0.00084620435,0.00014844244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002586892,0.00009166162,0.0023000033,0.00007918555,0.000017024324,0.0000028671927,0.000058996444,0.00017607887,0.0000015092346],"category_scores_gemma":[0.002765136,0.00006678406,0.00032648788,0.00014027892,0.00008098902,0.000042396816,0.000024230523,0.00023589873,9.1723244e-8],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023530212,0.0010070698,0.04264203,0.91734684,0.0020135755,0.000014996554,0.0003250936,0.00008625802,0.013680606,0.001062798,0.006917477,0.012550208],"study_design_scores_gemma":[0.01844202,0.015226982,0.042864893,0.88467467,0.011839613,0.00077178446,0.0012061748,0.0015287588,0.01781197,0.002176097,0.0030440402,0.00041301613],"about_ca_topic_score_codex":0.000051576102,"about_ca_topic_score_gemma":0.00006571778,"teacher_disagreement_score":0.050310105,"about_ca_system_score_codex":0.00005864709,"about_ca_system_score_gemma":0.00054911367,"threshold_uncertainty_score":0.33103257},"labels":[],"label_agreement":null},{"id":"W4410795441","doi":"10.1200/jco.2025.43.16_suppl.12060","title":"Baseline circulating growth differentiation factor-15 and the cancer phenotype in the PROACC-1 phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"GDF15 and Related Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cancer; Cancer cachexia; Cachexia; Oncology; Internal medicine; Phenotype; Cancer research; Gene; Biology; Genetics","score_opus":0.04522568423028268,"score_gpt":0.4182877188079926,"score_spread":0.3730620345777099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940267,0.0005074992,0.000010187177,0.0043868395,0.00020817561,0.00078660354,0.0000042378083,8.891414e-7,0.00006886679],"genre_scores_gemma":[0.9993206,0.0002725445,0.000018150551,0.0003232769,0.000047299218,0.0000057633288,8.1080793e-7,0.0000043571217,0.000007154347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711424,0.0011357183,0.0012878813,0.00011597986,0.00025016104,0.000096013515],"domain_scores_gemma":[0.9962154,0.0023950255,0.0010141821,0.00012185692,0.0002178888,0.000035615172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022532796,0.000087714354,0.00070060993,0.000078836834,0.000037801845,0.0000034240056,0.00011653415,0.00013700342,0.000009103679],"category_scores_gemma":[0.0017692897,0.00003193887,0.000071307004,0.00028219805,0.00024572617,0.000031544616,0.000043265052,0.00063730165,1.6009773e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017398342,0.003600181,0.9478743,0.00004211964,0.00040267798,0.0000057062284,0.0016266181,0.000025166986,0.000052249514,0.000015710983,0.000023862438,0.028933082],"study_design_scores_gemma":[0.06454519,0.0023102416,0.931254,0.00030111233,0.0005038276,0.0000027645635,0.0006889384,0.0003078746,0.000009396812,0.000027577149,0.000019094356,0.000029956449],"about_ca_topic_score_codex":0.00042723035,"about_ca_topic_score_gemma":0.0006007601,"teacher_disagreement_score":0.047146853,"about_ca_system_score_codex":0.000058315654,"about_ca_system_score_gemma":0.00045881563,"threshold_uncertainty_score":0.2768794},"labels":[],"label_agreement":null},{"id":"W4410795467","doi":"10.1200/jco.2025.43.16_suppl.e23549","title":"Do all patients with primary retroperitoneal sarcoma benefit from resection?","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Sarcoma; Resection; Surgical resection; Surgery; Radiology; Pathology","score_opus":0.06753533112718299,"score_gpt":0.42395285319433906,"score_spread":0.35641752206715605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816652,0.0012538319,0.000015400987,0.008517716,0.0011185465,0.00019381376,0.0000081844855,0.000008547458,0.0072187497],"genre_scores_gemma":[0.9887106,0.0005376704,0.0038792135,0.0059198337,0.00067068264,0.0000061035007,0.00001680424,0.000012690225,0.00024644315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757314,0.00018185998,0.0014767318,0.0002097692,0.00038011835,0.0001783752],"domain_scores_gemma":[0.9965413,0.0016902535,0.00076251663,0.00024373927,0.0005155051,0.0002466571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070477347,0.00012838072,0.0011843175,0.00012423433,0.000040715404,0.000012849267,0.00012552616,0.00027922733,0.00016939481],"category_scores_gemma":[0.00073040137,0.00007577236,0.000325575,0.00013709189,0.000114783266,0.00007717742,0.000057916564,0.0007023359,0.000016833994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008605304,0.0054448335,0.83525217,0.000009180513,0.0009805094,0.00046800548,0.000019325547,0.0000019496326,0.000008712294,0.00008749866,0.008000229,0.14112228],"study_design_scores_gemma":[0.014700333,0.012181382,0.87997204,0.00018859796,0.00064845785,0.000027658121,0.000023171575,0.000002488879,0.000036196427,0.0004326771,0.091730244,0.000056746645],"about_ca_topic_score_codex":0.00006637975,"about_ca_topic_score_gemma":0.00006202746,"teacher_disagreement_score":0.14106554,"about_ca_system_score_codex":0.00032380418,"about_ca_system_score_gemma":0.0007352288,"threshold_uncertainty_score":0.30899072},"labels":[],"label_agreement":null},{"id":"W4410795530","doi":"10.1200/jco.2025.43.16_suppl.e13848","title":"Knowledge and practice of geriatric oncology among cancer care providers in Africa: A CROSS-sectional survey.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Queen's University","funders":"","keywords":"Medicine; Cross-sectional study; Geriatric oncology; Family medicine; Cancer; Clinical Oncology; Oncology; Internal medicine; Nursing; Pathology","score_opus":0.15151490958368102,"score_gpt":0.5315817783848429,"score_spread":0.38006686880116186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624344,0.0073241876,0.000046157315,0.0044706725,0.0028635042,0.00038018942,0.000012194553,0.0000067360643,0.022461941],"genre_scores_gemma":[0.9946962,0.001589759,0.0015772353,0.0005261365,0.00050626637,0.000013654353,0.0000025526224,0.000011760605,0.001076409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946445,0.0017324941,0.0028452766,0.00026545275,0.0002567978,0.00025546414],"domain_scores_gemma":[0.9765739,0.019161576,0.0018798738,0.00016051816,0.0020027733,0.00022136944],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0072460473,0.00013874675,0.001500811,0.00040202914,0.000033700027,0.000011258398,0.00016706517,0.0007166555,0.00006842861],"category_scores_gemma":[0.046230253,0.00011151253,0.00023688092,0.0005390335,0.0006134052,0.00024253482,0.0001118915,0.0014360173,0.000002922335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073882784,0.0014910542,0.9343436,0.00019321508,0.00031568288,0.00023974286,0.0007907098,0.000037983835,0.000042680596,0.000030610267,0.0051062386,0.05002023],"study_design_scores_gemma":[0.009529215,0.0049589947,0.8879766,0.00013655568,0.0001970843,0.00018671982,0.00047959157,0.00004309536,0.000013460227,0.000068789595,0.096340306,0.00006958423],"about_ca_topic_score_codex":0.0005920561,"about_ca_topic_score_gemma":0.0039216415,"teacher_disagreement_score":0.091234066,"about_ca_system_score_codex":0.0006872157,"about_ca_system_score_gemma":0.0072762007,"threshold_uncertainty_score":0.99835163},"labels":[],"label_agreement":null},{"id":"W4410795542","doi":"10.1200/jco.2025.43.16_suppl.11019","title":"Adherence of published randomized phase 3 cancer trials to principles proposed by common-sense oncology.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Kingston General Hospital; University Health Network; Queen's University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Randomized controlled trial; Cancer; Clinical Oncology","score_opus":0.7110368432121387,"score_gpt":0.6508170726244076,"score_spread":0.06021977058773109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6608818,0.005836701,0.008877075,0.29146346,0.009609715,0.003310862,0.00042533208,0.000024665038,0.01957035],"genre_scores_gemma":[0.91992855,0.0030608256,0.014812645,0.05664769,0.0017579311,0.00020607984,0.000017589948,0.00003980135,0.0035288646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9521654,0.009584487,0.037092112,0.0005197322,0.00020846447,0.00042979818],"domain_scores_gemma":[0.90010893,0.061818715,0.03607323,0.000568268,0.0008373389,0.0005935163],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2520167,0.00023161282,0.011781327,0.00059121323,0.000085474385,0.000048415084,0.00062781025,0.00070591044,0.0010200331],"category_scores_gemma":[0.25573707,0.00020476873,0.0011664984,0.00037476787,0.00042009784,0.0003961697,0.00012416279,0.0008750905,0.00010099898],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11950031,0.006958432,0.014981499,0.0005201391,0.0032360714,0.000033154964,0.0013896236,0.00037028865,0.000103970226,0.10428103,0.70215076,0.04647469],"study_design_scores_gemma":[0.2662441,0.005878316,0.0018352946,0.00034885402,0.0002542069,0.00001161961,0.00044572627,0.0012687698,0.000113578,0.026699727,0.69660246,0.0002973551],"about_ca_topic_score_codex":0.000652333,"about_ca_topic_score_gemma":0.00038096996,"teacher_disagreement_score":0.25904673,"about_ca_system_score_codex":0.00086800026,"about_ca_system_score_gemma":0.004930197,"threshold_uncertainty_score":0.9998932},"labels":[],"label_agreement":null},{"id":"W4410795548","doi":"10.1200/jco.2025.43.16_suppl.tps6118","title":"A phase III randomized controlled trial comparing palliative stereotactic body radiotherapy vs. palliative standard radiotherapy in patients with advanced head and neck cancer (NCT06641791).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre; Nova Scotia Cancer Centre; Queen's University; London Health Sciences Centre; University of Alberta; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Radiation therapy; Head and neck cancer; Head and neck; Radiosurgery; Randomized controlled trial; Palliative treatment; Palliative care; Radiology; Nuclear medicine; Surgery","score_opus":0.054169511473996484,"score_gpt":0.48025120693505424,"score_spread":0.4260816954610578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97936934,0.007876131,0.0005106721,0.0059786984,0.0014655784,0.0042396965,0.000006284468,0.000011422598,0.0005421594],"genre_scores_gemma":[0.9751842,0.01875602,0.0017965124,0.003371367,0.00051286403,0.00021145082,0.0000018651277,0.000023817935,0.00014189503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938484,0.0013383446,0.003628694,0.0003438237,0.00047961276,0.0003611602],"domain_scores_gemma":[0.99001354,0.0062671076,0.0025877284,0.00016528273,0.0006938807,0.0002724754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003418297,0.0003270821,0.010114159,0.00027416568,0.000081823084,0.000019909012,0.000121812474,0.00025258624,0.00006881984],"category_scores_gemma":[0.0023175231,0.00018924652,0.00059622654,0.0002587271,0.00044927257,0.00015070756,0.000025486863,0.0010910645,2.1755602e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82554406,0.003624054,0.14033788,0.00004067088,0.0044744853,0.000069812646,0.00075649377,0.000016833368,0.000010987335,0.00004013966,0.0002734489,0.024811098],"study_design_scores_gemma":[0.8538079,0.055217706,0.08428914,0.000952692,0.000789715,0.000001672603,0.00008625616,0.00046288545,0.0000073310866,0.000052230767,0.0041839303,0.00014854084],"about_ca_topic_score_codex":0.00005818375,"about_ca_topic_score_gemma":0.00027201322,"teacher_disagreement_score":0.056048747,"about_ca_system_score_codex":0.0007155607,"about_ca_system_score_gemma":0.0022767866,"threshold_uncertainty_score":0.77172494},"labels":[],"label_agreement":null},{"id":"W4410795567","doi":"10.1200/jco.2025.43.16_suppl.7516","title":"Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Johnson and Johnson","keywords":"Lenalidomide; Medicine; Daratumumab; Bortezomib; Multiple myeloma; Dexamethasone; Subgroup analysis; Oncology; Internal medicine; Confidence interval","score_opus":0.05493743037109683,"score_gpt":0.432347701128864,"score_spread":0.3774102707577672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973591,0.00023003406,0.00011061051,0.00061160274,0.00015514357,0.0012836849,0.000055920875,0.000004295452,0.00018963181],"genre_scores_gemma":[0.9982558,0.00035334393,0.0006527396,0.00056142564,0.00004699036,0.000029786626,0.00006376745,0.0000138861315,0.000022245342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99423975,0.0013476871,0.002795211,0.00037365893,0.00082459615,0.00041907927],"domain_scores_gemma":[0.9914871,0.006202956,0.0010999396,0.00036929143,0.0005488661,0.00029184282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003066099,0.0002586112,0.0025447642,0.0011064293,0.00005630367,0.0000183713,0.00030656176,0.00022898972,0.000029582234],"category_scores_gemma":[0.0035811907,0.00014803886,0.00036516527,0.0015274741,0.0002561314,0.00016117161,0.000057464214,0.0009960681,0.0000010941841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062412694,0.023271853,0.86250114,0.000040994106,0.0026360073,0.0009437215,0.0007860351,0.0000700116,0.000004177486,0.0000038246485,0.00016391865,0.04716559],"study_design_scores_gemma":[0.17176147,0.018006958,0.80670863,0.00013694499,0.0018968207,0.000003864847,0.00041147176,0.00065022527,0.000012401878,0.00001250583,0.00030733552,0.00009133844],"about_ca_topic_score_codex":0.0011496528,"about_ca_topic_score_gemma":0.007180542,"teacher_disagreement_score":0.109348774,"about_ca_system_score_codex":0.00024076519,"about_ca_system_score_gemma":0.0008479057,"threshold_uncertainty_score":0.60368496},"labels":[],"label_agreement":null},{"id":"W4410795580","doi":"10.1200/jco.2025.43.16_suppl.7515","title":"Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Oncology; Bortezomib; Multiple myeloma; Internal medicine; Lenalidomide; Refractory (planetary science)","score_opus":0.061370792376647235,"score_gpt":0.39533056254890103,"score_spread":0.3339597701722538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322,0.0007576331,0.000083817715,0.0037001332,0.00013483687,0.00177057,0.00015380325,0.000023109238,0.00015614445],"genre_scores_gemma":[0.9912167,0.0007529371,0.006297298,0.0007674202,0.00030304817,0.00006118324,0.00010023263,0.000046129706,0.00045502227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99140733,0.0032726303,0.0027507886,0.00086858275,0.0010054418,0.00069520215],"domain_scores_gemma":[0.9725695,0.02298172,0.0019750835,0.000690419,0.00062704907,0.0011561848],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037685644,0.00054371497,0.0035787506,0.0006706948,0.00020408718,0.00007772632,0.00031894236,0.00053097226,0.00010191615],"category_scores_gemma":[0.017108008,0.0002827989,0.00040940213,0.0012405257,0.0010025253,0.00030852674,0.00020907426,0.0017260464,0.0000032448559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43590084,0.002804661,0.5323374,0.000026765389,0.0034011672,0.0021210269,0.00009516499,0.000009547165,0.000021461741,0.00000301306,0.00024828335,0.023030628],"study_design_scores_gemma":[0.26733506,0.021600768,0.70457464,0.00030683493,0.0046588355,0.000033739663,0.00024111824,0.000494696,0.00006095724,0.000027281645,0.00046416273,0.00020186052],"about_ca_topic_score_codex":0.0020356635,"about_ca_topic_score_gemma":0.007945062,"teacher_disagreement_score":0.17223725,"about_ca_system_score_codex":0.00049639534,"about_ca_system_score_gemma":0.0031762235,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W4410795585","doi":"10.1200/jco.2025.43.16_suppl.e13849","title":"Exploring treatment adherence and unmet needs of older breast cancer survival in Nigeria.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Gerontology; Family medicine; Internal medicine","score_opus":0.4580086275411551,"score_gpt":0.5306795370408784,"score_spread":0.07267090949972332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913509,0.0012197496,0.000054707758,0.004457181,0.001079592,0.0000958821,0.0000039378283,0.0000026366044,0.0017354485],"genre_scores_gemma":[0.99326426,0.0052500614,0.0003935926,0.00058343186,0.00033515348,0.0000070854185,2.8231455e-7,0.0000041178123,0.00016204097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979952,0.0001751509,0.0013965631,0.000096903845,0.00018003811,0.00015616378],"domain_scores_gemma":[0.9981306,0.00081952725,0.00056901784,0.00009895664,0.0002318246,0.00015004553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013628729,0.00009189911,0.0011524357,0.00017864854,0.000014550528,0.0000039401502,0.000080147576,0.0001381662,0.000076765515],"category_scores_gemma":[0.0004981589,0.0000641187,0.0001737743,0.0002766401,0.00012435409,0.00012788361,0.000035233537,0.00034132547,7.6172813e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025685795,0.00034368708,0.7411148,0.000026676707,0.0001561326,0.00012797685,0.00031993768,0.000020047573,0.00016812858,0.000103269944,0.00016671636,0.25488403],"study_design_scores_gemma":[0.0064201267,0.004237849,0.9826872,0.0006816179,0.00017109506,0.000100327044,0.001999102,0.000018634555,0.00017208581,0.00010840277,0.0033498593,0.00005372382],"about_ca_topic_score_codex":0.0005508143,"about_ca_topic_score_gemma":0.0007203785,"teacher_disagreement_score":0.2548303,"about_ca_system_score_codex":0.00021512648,"about_ca_system_score_gemma":0.0013705806,"threshold_uncertainty_score":0.26146847},"labels":[],"label_agreement":null},{"id":"W4410795615","doi":"10.1200/jco.2025.43.16_suppl.e12512","title":"Impact of immigration status on survival amongst early-stage (1&amp;2) HER2 positive and triple-negative breast cancer patients in Ontario, Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto; Public Health Ontario","funders":"","keywords":"Medicine; Breast cancer; Triple-negative breast cancer; Immigration; Stage (stratigraphy); Oncology; Internal medicine; Triple negative; Cancer; Gynecology; Demography","score_opus":0.0848157080073079,"score_gpt":0.45590146511826574,"score_spread":0.3710857571109578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621755,0.000059437632,0.000012770257,0.001075684,0.00066970586,0.00020362204,0.00009411994,0.0000014275391,0.0016657015],"genre_scores_gemma":[0.99855554,0.0002007406,0.00011303006,0.00063240837,0.0000939548,0.0000022301435,0.000006853509,0.0000054005936,0.00038983568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974404,0.00031892705,0.0014439289,0.00016375363,0.00039535857,0.00023764788],"domain_scores_gemma":[0.9966916,0.0011391486,0.0010944969,0.00008946462,0.00073213386,0.00025318278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009236596,0.00013031135,0.0010897437,0.00013825562,0.00002741205,0.000006539219,0.00007472494,0.00019465302,0.00012802861],"category_scores_gemma":[0.0011706448,0.00009372734,0.00019313616,0.00020109935,0.0001194394,0.00012604622,0.000029946024,0.00089788885,3.6014765e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012729007,0.00047898656,0.9684483,0.000008208593,0.0002800383,0.00007925248,0.0003382673,0.00006632577,0.000013361425,0.00002097935,0.0014675568,0.016069712],"study_design_scores_gemma":[0.006749202,0.006344288,0.9853629,0.0003556674,0.00011891839,0.0000072577923,0.00023630304,0.000017119512,0.000017097173,0.00003976381,0.00068475696,0.00006674149],"about_ca_topic_score_codex":0.9857844,"about_ca_topic_score_gemma":0.9965384,"teacher_disagreement_score":0.01691458,"about_ca_system_score_codex":0.0022969702,"about_ca_system_score_gemma":0.011440829,"threshold_uncertainty_score":0.9941634},"labels":[],"label_agreement":null},{"id":"W4410795636","doi":"10.1200/jco.2025.43.16_suppl.11015","title":"Overall survival and quality of life superiority in modern phase III oncology trials.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Andrew Sabin Family Foundation","keywords":"Medicine; Oncology; Quality of life (healthcare); Internal medicine; Overall survival; Quality (philosophy); Clinical trial; Nursing","score_opus":0.8043864073400054,"score_gpt":0.6552058195651821,"score_spread":0.14918058777482335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93635297,0.0035496708,0.0030541166,0.047172874,0.0032521747,0.00039382352,0.00007181237,0.000005881082,0.0061466666],"genre_scores_gemma":[0.9865122,0.0018598406,0.0024436833,0.008233246,0.00074951124,0.00000942925,0.000003242839,0.000011120761,0.00017771241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95976996,0.0077833403,0.031541582,0.00042031545,0.00014522059,0.00033959033],"domain_scores_gemma":[0.93669873,0.042305604,0.019812029,0.0003924599,0.00032886004,0.0004622913],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.22641602,0.00017084599,0.008195147,0.0004995319,0.00005219858,0.000018286963,0.00034466453,0.00076980004,0.00018969586],"category_scores_gemma":[0.14324665,0.00017742053,0.0005707847,0.00017533914,0.00030177284,0.0003336514,0.000107273256,0.000968884,0.000016810889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009819661,0.006210403,0.6885178,0.00061073917,0.0009877137,0.000025309197,0.0018910577,0.00021805879,0.00003701737,0.24439031,0.008475354,0.03881656],"study_design_scores_gemma":[0.07964875,0.0054574967,0.6546392,0.00017856485,0.000091019785,0.000012200678,0.002283066,0.0042930264,0.0000048382262,0.12585667,0.12712559,0.00040963068],"about_ca_topic_score_codex":0.0012337331,"about_ca_topic_score_gemma":0.0011750164,"teacher_disagreement_score":0.118650235,"about_ca_system_score_codex":0.0005978162,"about_ca_system_score_gemma":0.0035959135,"threshold_uncertainty_score":0.86397016},"labels":[],"label_agreement":null},{"id":"W4410795637","doi":"10.1200/jco.2025.43.16_suppl.2636","title":"Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Lung cancer; Immune system; Precision medicine; Cancer; Oncology; Internal medicine; Cancer research; Immunology; Pathology","score_opus":0.08986989931342658,"score_gpt":0.4881347278346573,"score_spread":0.3982648285212307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942169,0.0026940464,0.000049070877,0.0013098222,0.0010555371,0.00040821466,0.000003116111,0.0000018375955,0.0002614423],"genre_scores_gemma":[0.99536896,0.0037693768,0.00016069648,0.00044867172,0.00013441594,0.000004173761,8.675533e-7,0.000005025382,0.000107836866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945416,0.0008646017,0.003935354,0.00019551095,0.00030907438,0.0001538791],"domain_scores_gemma":[0.9946608,0.0019482453,0.002587956,0.00035515692,0.00036413572,0.000083693194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068963147,0.00012713468,0.0023477485,0.0005015845,0.00003176078,0.0000016312025,0.0004044199,0.00034024895,0.00014847907],"category_scores_gemma":[0.0013513874,0.00006220528,0.0007085456,0.0011807694,0.00034247962,0.00003785026,0.00013304506,0.00057087495,1.00377996e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012973191,0.0027977128,0.8498607,0.000040731975,0.0007298248,0.000041918967,0.00044947662,0.0000480545,0.011679012,7.654991e-7,0.000082104605,0.1212965],"study_design_scores_gemma":[0.010921385,0.012174994,0.97038597,0.0005551708,0.0021235147,0.000006240422,0.00072179164,0.0013058685,0.0012758068,0.000017984532,0.00046083963,0.000050428],"about_ca_topic_score_codex":0.0010023866,"about_ca_topic_score_gemma":0.0018012432,"teacher_disagreement_score":0.12124607,"about_ca_system_score_codex":0.00016184794,"about_ca_system_score_gemma":0.0008176712,"threshold_uncertainty_score":0.26243114},"labels":[],"label_agreement":null},{"id":"W4410795654","doi":"10.1200/jco.2025.43.16_suppl.e23213","title":"First accounting of comprehensive radiotherapy life cycle assessment components in Africa.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton University","funders":"","keywords":"Medicine; Radiation therapy; Accounting; Internal medicine","score_opus":0.11594931613140393,"score_gpt":0.5228755302657303,"score_spread":0.4069262141343264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613474,0.0052150427,0.006118575,0.016424475,0.003464322,0.00028967386,0.0000019427657,0.000009094995,0.0071294922],"genre_scores_gemma":[0.94464236,0.00586786,0.04227913,0.0062252153,0.0007942772,0.0000037208576,0.0000010388934,0.00001267401,0.0001737023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624246,0.00043079458,0.0026718685,0.00017115912,0.00025329433,0.00023039471],"domain_scores_gemma":[0.9916723,0.005814363,0.0018007312,0.00019176377,0.00036545933,0.00015539429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021901636,0.00013331983,0.0020401177,0.00027698863,0.000044303095,0.0000031644338,0.00023250654,0.0004423218,0.00013937219],"category_scores_gemma":[0.0011406103,0.00009942321,0.00037624588,0.0002880526,0.0004228604,0.00010010075,0.00003996353,0.0011922105,0.0000016911325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01191852,0.008489019,0.83618,0.00024494142,0.0019249823,0.0007594001,0.00040752627,0.0045957444,0.0015352747,0.0018068394,0.008553629,0.12358417],"study_design_scores_gemma":[0.014484813,0.0041684937,0.71167195,0.0003130591,0.00011335048,0.00007181207,0.00022238355,0.0025560681,0.000012908112,0.0008219763,0.26548928,0.000073910014],"about_ca_topic_score_codex":0.0000103344855,"about_ca_topic_score_gemma":0.000015920074,"teacher_disagreement_score":0.25693563,"about_ca_system_score_codex":0.0003357375,"about_ca_system_score_gemma":0.001695812,"threshold_uncertainty_score":0.51796275},"labels":[],"label_agreement":null},{"id":"W4410795688","doi":"10.1200/jco.2025.43.16_suppl.e13862","title":"Expanding access to care through sustainable replicable model of care delivery.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intergenerational Family Dynamics and Caregiving","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nursing","score_opus":0.09961903748766915,"score_gpt":0.5072527462816495,"score_spread":0.40763370879398036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8196715,0.00084066176,0.012590312,0.0047934223,0.0017471736,0.00022926865,0.0000059491504,0.0000084147805,0.16011326],"genre_scores_gemma":[0.9908972,0.00047262767,0.0037182777,0.002082025,0.0004377947,0.000004911531,0.0000012087713,0.0000059234167,0.0023800388],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977146,0.00030254424,0.0012283501,0.0001625394,0.00033677346,0.0002551999],"domain_scores_gemma":[0.99574524,0.00082121184,0.00067093846,0.00013977489,0.0024997075,0.00012312409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782859,0.00007711089,0.00062831223,0.00011615301,0.0002739584,0.00005086434,0.00056708854,0.00025474146,0.000028783737],"category_scores_gemma":[0.002891168,0.00006767655,0.0003222422,0.00027871825,0.00013172113,0.00036500677,0.00019859597,0.00032962445,0.0000011473736],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016559814,0.0005421394,0.040505562,0.00037580275,0.00039402622,0.00013774431,0.060548425,0.16146864,0.00041450353,0.6481047,0.039887708,0.04596476],"study_design_scores_gemma":[0.0034068795,0.004045036,0.0057289833,0.00071093545,0.00037647624,0.000003520581,0.42787486,0.003970451,0.00074430846,0.040358853,0.51229566,0.00048401396],"about_ca_topic_score_codex":0.00081329246,"about_ca_topic_score_gemma":0.00196023,"teacher_disagreement_score":0.6077459,"about_ca_system_score_codex":0.00054920954,"about_ca_system_score_gemma":0.004331982,"threshold_uncertainty_score":0.76847506},"labels":[],"label_agreement":null},{"id":"W4410795692","doi":"10.1200/jco.2025.43.16_suppl.e12511","title":"Appropriate treatment for stage 1 and 2 HER 2 positive and triple-negative breast cancer by immigration status in Ontario, Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Immigration; Triple-negative breast cancer; Stage (stratigraphy); Breast cancer; Triple negative; Cancer; Oncology; Internal medicine; Gynecology","score_opus":0.024958798579930292,"score_gpt":0.37719483965276934,"score_spread":0.35223604107283907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921125,0.0018390794,0.00010038024,0.004816888,0.00035649256,0.00026522586,0.0002984296,7.44388e-7,0.00021023682],"genre_scores_gemma":[0.99451804,0.002712641,0.0005576619,0.0008024203,0.000094525916,0.000041304465,0.000022636319,0.0000065010718,0.0012442733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886084,0.00012783922,0.0005943539,0.00019356627,0.000062404026,0.00016099463],"domain_scores_gemma":[0.9989773,0.00030531964,0.00040378157,0.000056415516,0.00016565522,0.00009152186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025637465,0.00011998842,0.0005202077,0.000030309553,0.000041541145,0.000006661457,0.00003663447,0.00014565318,0.000009045697],"category_scores_gemma":[0.00013289812,0.00008746825,0.00006747687,0.000034676257,0.00009733722,0.000006504133,0.000030256784,0.00012769086,2.7378858e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013094847,0.0008657003,0.75326884,0.000018710602,0.0017529308,0.000028910488,0.00048611037,0.000025559599,0.0011327608,0.000053626492,0.008474453,0.22079757],"study_design_scores_gemma":[0.011084467,0.0022333758,0.93972766,0.00003326851,0.0001730491,0.000012971886,0.00042137076,0.00001661422,0.0009745826,0.000102842176,0.045124482,0.00009528289],"about_ca_topic_score_codex":0.7392129,"about_ca_topic_score_gemma":0.98769444,"teacher_disagreement_score":0.24848156,"about_ca_system_score_codex":0.0005664314,"about_ca_system_score_gemma":0.0033830402,"threshold_uncertainty_score":0.6001368},"labels":[],"label_agreement":null},{"id":"W4410795858","doi":"10.1200/jco.2025.43.16_suppl.11500","title":"Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Surgery; Physical therapy; Physical medicine and rehabilitation","score_opus":0.050130702658025626,"score_gpt":0.4363098681365479,"score_spread":0.38617916547852227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928742,0.00021647387,0.000012716864,0.0019861772,0.00095516304,0.00062059914,0.000006603306,0.000005888504,0.0033221566],"genre_scores_gemma":[0.9978622,0.00012309702,0.00039686877,0.0011509823,0.00009505269,0.0000029308324,0.0000022960883,0.0000108753475,0.00035569965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948599,0.0003762147,0.0039645443,0.00022929459,0.00033186836,0.00023820356],"domain_scores_gemma":[0.99572414,0.0016104464,0.001960072,0.0002178551,0.00024187562,0.00024562227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014094961,0.00018789271,0.0021786673,0.00022864532,0.00003397714,0.0000053406666,0.00010995285,0.000192461,0.00009612749],"category_scores_gemma":[0.0018632874,0.0001217184,0.00043548754,0.0001911216,0.00018670366,0.000071707116,0.00011236913,0.000639762,0.0000027564145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014761637,0.031406973,0.8112091,0.000099793,0.00095556566,0.0030157813,0.00025239476,0.000004937945,0.00013633246,0.0000502617,0.0003291005,0.13777816],"study_design_scores_gemma":[0.058556914,0.023811832,0.9071011,0.000115497714,0.0007127829,0.000114979506,0.00051878,0.000020410951,0.00010757221,0.000056745732,0.008796081,0.0000873117],"about_ca_topic_score_codex":0.00023501723,"about_ca_topic_score_gemma":0.000095342315,"teacher_disagreement_score":0.13769086,"about_ca_system_score_codex":0.00010874369,"about_ca_system_score_gemma":0.0008263457,"threshold_uncertainty_score":0.49635324},"labels":[],"label_agreement":null},{"id":"W4410795910","doi":"10.1200/jco.2025.43.16_suppl.tps11582","title":"Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Servier","keywords":"Medicine; Regimen; Placebo; Oncology; Systemic therapy; Internal medicine; Phases of clinical research; Chemotherapy; Cancer; Pathology; Breast cancer","score_opus":0.08625413762460546,"score_gpt":0.46227686335887747,"score_spread":0.376022725734272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491096,0.0007732057,0.000038497736,0.0009278077,0.00023969346,0.002860019,0.000019257619,0.000018603043,0.00021195771],"genre_scores_gemma":[0.99596,0.0009161866,0.0010009741,0.0002115514,0.000060341514,0.00018142074,0.000016322292,0.000030441814,0.0016227603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935536,0.0011102315,0.004044759,0.0004306459,0.0004900645,0.00037071176],"domain_scores_gemma":[0.9928613,0.0032655424,0.0025583538,0.0003783182,0.0005838435,0.0003526806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013268596,0.00037944457,0.003713941,0.0004368223,0.000047275415,0.000012618409,0.00018428735,0.00019443418,0.00020798325],"category_scores_gemma":[0.0011570303,0.00019385834,0.00036739002,0.0006382883,0.000196752,0.0001357615,0.00003787914,0.00049461465,0.0000085462925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40565088,0.13127543,0.3801261,0.00028051806,0.0076420885,0.031429246,0.00039465484,0.00015807096,0.0006117141,0.00004348812,0.00040389647,0.041983902],"study_design_scores_gemma":[0.48936483,0.42043695,0.07059412,0.0037597269,0.007322836,0.0036721302,0.001899103,0.00024578706,0.001180036,0.000035879493,0.001234039,0.00025454623],"about_ca_topic_score_codex":0.0002542767,"about_ca_topic_score_gemma":0.001473934,"teacher_disagreement_score":0.309532,"about_ca_system_score_codex":0.0008749967,"about_ca_system_score_gemma":0.00397979,"threshold_uncertainty_score":0.7905314},"labels":[],"label_agreement":null},{"id":"W4410795933","doi":"10.1200/jco.2025.43.16_suppl.11539","title":"Circulating free DNA derived from active chromatin as a predictive biomarker for clinical benefit to checkpoint inhibitor-based therapies in metastatic leiomyosarcoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Biomarker; Cancer research; Oncology; Chromatin; DNA; Internal medicine; Biology; Genetics","score_opus":0.1562331478541949,"score_gpt":0.48349034136230595,"score_spread":0.32725719350811106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97054213,0.0011460119,0.0014653871,0.02407755,0.0010451934,0.0012293798,0.000058537902,0.000017802164,0.00041799177],"genre_scores_gemma":[0.963544,0.00014558091,0.029956492,0.005648848,0.0004964728,0.00014331574,0.000017451846,0.000027622327,0.000020184543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397975,0.00074177526,0.004070484,0.00046542933,0.00038784102,0.00035471594],"domain_scores_gemma":[0.9783943,0.018534845,0.0016855428,0.00040009423,0.0005800095,0.000405194],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035394588,0.0002810163,0.0025697139,0.0003777969,0.00006467482,0.000020803827,0.00027241308,0.00040725243,0.0001044074],"category_scores_gemma":[0.015977992,0.00020410088,0.0011591362,0.00034486377,0.00021266105,0.00010480177,0.00011450781,0.00073243276,0.000009746721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030272076,0.014076054,0.4858399,0.000077058976,0.005341303,0.0016209472,0.0005603202,0.00005866529,0.0030660457,0.00015264402,0.0021965085,0.45673847],"study_design_scores_gemma":[0.03191907,0.0127377305,0.94045764,0.00091460266,0.0011747065,0.000037139638,0.00071981404,0.0008784035,0.0024799376,0.005544395,0.0029819212,0.00015462717],"about_ca_topic_score_codex":0.0001551441,"about_ca_topic_score_gemma":0.00029099858,"teacher_disagreement_score":0.45658386,"about_ca_system_score_codex":0.00047167012,"about_ca_system_score_gemma":0.0021703076,"threshold_uncertainty_score":0.9923108},"labels":[],"label_agreement":null},{"id":"W4410799985","doi":"10.1200/jco.2025.43.16_suppl.tps11588","title":"A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Vinblastine; Cisplatin; Chemotherapy; Systemic therapy; Oncology; Internal medicine; Standard of care; Randomized controlled trial; Multicenter study; Cancer","score_opus":0.05346789549982866,"score_gpt":0.45319341214620446,"score_spread":0.3997255166463758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989041,0.002328865,0.0013539515,0.002587591,0.00019728392,0.0043450464,0.000035356712,0.0000071425347,0.000103809885],"genre_scores_gemma":[0.9929035,0.00094491476,0.005088786,0.00089569745,0.00006058457,0.00007085016,0.0000052398295,0.000020417436,0.00001005796],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99375397,0.0015822563,0.003443863,0.00035964564,0.00058348424,0.0002767908],"domain_scores_gemma":[0.9899463,0.0064805103,0.0018867499,0.00033777187,0.001084406,0.00026425373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028888648,0.00034128377,0.004224286,0.00020854364,0.00004774094,0.00002047993,0.00026767878,0.00011225666,0.00003723943],"category_scores_gemma":[0.0020511376,0.00016134932,0.00019552035,0.00061776506,0.0004008581,0.00008295324,0.00006144316,0.00057817664,6.3213776e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75436383,0.012570532,0.1450158,0.00032629084,0.0020121506,0.0006904045,0.0030460292,0.00026770352,0.00001415699,0.000041692332,0.00011281734,0.08153855],"study_design_scores_gemma":[0.7975089,0.115252,0.06648083,0.0066745863,0.0017172657,0.00036396176,0.0105239265,0.0005227381,0.0001793586,0.000013562401,0.00058462325,0.00017823516],"about_ca_topic_score_codex":0.00024812843,"about_ca_topic_score_gemma":0.0022695155,"teacher_disagreement_score":0.10268147,"about_ca_system_score_codex":0.00041742786,"about_ca_system_score_gemma":0.0023851895,"threshold_uncertainty_score":0.65796345},"labels":[],"label_agreement":null},{"id":"W4410800326","doi":"10.1200/jco.2025.43.16_suppl.tps11587","title":"Integrating early palliative care in advanced sarcoma patients for enhanced quality of life: The SARQUALITY study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palliative care; Quality of life (healthcare); Sarcoma; Intensive care medicine; Oncology; Internal medicine; Nursing; Pathology","score_opus":0.37838257272851816,"score_gpt":0.6297020084694332,"score_spread":0.2513194357409151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943253,0.0011217021,0.0007963037,0.00094655075,0.00065951596,0.00071249634,0.000016388882,0.0000032627029,0.0014184861],"genre_scores_gemma":[0.99432266,0.00024924267,0.00452169,0.00070237456,0.00014091132,0.000015907757,0.0000034416748,0.000006783832,0.000036978843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944769,0.0010427803,0.0037922037,0.00017864293,0.00033849178,0.00017095396],"domain_scores_gemma":[0.98173887,0.012988984,0.0028958034,0.000220428,0.0020509814,0.00010491394],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00411142,0.0001319515,0.0019861707,0.000108309534,0.000031739582,0.0000030327708,0.00023716374,0.00021175978,0.0000073937276],"category_scores_gemma":[0.045547932,0.000078820885,0.00047825603,0.00026419468,0.00020643203,0.0000690142,0.000065271815,0.00072655175,4.3605527e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010270743,0.0020084563,0.8967074,0.00017211628,0.0003399261,0.0000026857863,0.007925989,0.000006921865,0.00021885808,0.0002293472,0.00011158421,0.08200595],"study_design_scores_gemma":[0.015393708,0.014221681,0.94286567,0.00075353874,0.0001565311,6.437972e-8,0.023129022,0.000007083139,0.0009365662,0.0005894089,0.0018843414,0.00006240641],"about_ca_topic_score_codex":0.00013791453,"about_ca_topic_score_gemma":0.0007252461,"teacher_disagreement_score":0.08194354,"about_ca_system_score_codex":0.00016952728,"about_ca_system_score_gemma":0.0012361605,"threshold_uncertainty_score":0.9624918},"labels":[],"label_agreement":null},{"id":"W4410800338","doi":"10.1200/jco.2025.43.16_suppl.11511","title":"Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Soft tissue sarcoma; Soft tissue; Sarcoma; Internal medicine; Oncology; Pathology","score_opus":0.1484102500903572,"score_gpt":0.4994158845123245,"score_spread":0.3510056344219673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932713,0.0014733957,0.0015321082,0.005127096,0.0016073721,0.00036427006,0.0000028394152,0.000008660335,0.0005571497],"genre_scores_gemma":[0.9731772,0.000106564694,0.023670016,0.002540106,0.00041380798,0.000005998334,0.0000010573837,0.000013201228,0.00007203713],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99633694,0.0005064269,0.0022321893,0.0002776063,0.0003036667,0.0003431718],"domain_scores_gemma":[0.99543136,0.0028851174,0.0008414434,0.00018813851,0.00031486043,0.00033906024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002196473,0.00018424571,0.0016757242,0.00032206188,0.000064855034,0.000017527545,0.00017904036,0.00031402725,0.00016500325],"category_scores_gemma":[0.006821997,0.000134914,0.00034995616,0.00042975906,0.00012385633,0.00009140661,0.00009139835,0.00080617465,0.0000094526295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038788624,0.0008472515,0.33486181,0.00003403394,0.0002655031,0.0018068956,0.00018766648,0.000056104553,0.00037908656,0.00013750265,0.0003433281,0.65720195],"study_design_scores_gemma":[0.033296943,0.008499363,0.9100869,0.0016101241,0.0008622354,0.0017368158,0.0005260923,0.0048043686,0.0006375092,0.0019841783,0.035676986,0.00027844412],"about_ca_topic_score_codex":0.00012789085,"about_ca_topic_score_gemma":0.00017481629,"teacher_disagreement_score":0.65692353,"about_ca_system_score_codex":0.00046302742,"about_ca_system_score_gemma":0.0013486327,"threshold_uncertainty_score":0.81670606},"labels":[],"label_agreement":null},{"id":"W4410802690","doi":"10.1200/jco.2025.43.16_suppl.8550","title":"Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; DNA methylation; Lung cancer; Cell-free fetal DNA; DNA; Genome; Cancer research; Cancer; Cell; Computational biology; Gene; Oncology; Biology; Internal medicine; Genetics; Gene expression","score_opus":0.028669029865681313,"score_gpt":0.37488519396396064,"score_spread":0.3462161640982793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97339356,0.0056969975,0.018268403,0.0008616741,0.0010748893,0.0004129452,0.00004950748,0.000001756817,0.00024026062],"genre_scores_gemma":[0.98474824,0.009415211,0.004566056,0.00048699626,0.00043147488,0.000024492381,0.0000101722635,0.000024292662,0.0002930861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967851,0.00022445625,0.0022185703,0.00032961066,0.00016741292,0.0002748601],"domain_scores_gemma":[0.99634945,0.00095989363,0.0017677913,0.0004448638,0.00035341005,0.0001246129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015770206,0.00021617842,0.00090965664,0.00019104003,0.000042164007,0.000022222936,0.0004580713,0.0004532407,0.000019986868],"category_scores_gemma":[0.0007728249,0.00019377877,0.0003554003,0.00018961272,0.00010010512,0.000008726908,0.00013455156,0.00030172348,0.0000010674688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008324634,0.0018840553,0.038529452,0.00005240689,0.00035949444,0.000023982262,0.00015893055,0.004931864,0.9454967,0.000022391037,0.00044257753,0.007265727],"study_design_scores_gemma":[0.02988222,0.011093364,0.25704393,0.0003030059,0.0012294482,0.000020423726,0.00027864153,0.00092880346,0.61725044,0.00045246343,0.08081092,0.00070635974],"about_ca_topic_score_codex":0.00033074475,"about_ca_topic_score_gemma":0.00050776155,"teacher_disagreement_score":0.32824624,"about_ca_system_score_codex":0.00037876444,"about_ca_system_score_gemma":0.0020284678,"threshold_uncertainty_score":0.7902069},"labels":[],"label_agreement":null},{"id":"W4410802702","doi":"10.1200/jco.2025.43.16_suppl.e13155","title":"Association of MRI biomarkers on survival in TNBC patients: A retrospective, multi-center cohort study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Retrospective cohort study; Cohort; Oncology; Center (category theory); Internal medicine","score_opus":0.03379967206470782,"score_gpt":0.4460606835638494,"score_spread":0.4122610114991416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841203,0.000022779404,0.0002627268,0.008460771,0.0024533842,0.0003316082,0.000001798692,0.0000048207216,0.0043418263],"genre_scores_gemma":[0.9967691,0.0001520622,0.0011251549,0.0013331688,0.0001911714,0.0000025395814,0.0000023731811,0.00000866814,0.00041580095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961813,0.0008455933,0.002111387,0.00018193413,0.00050908944,0.00017068388],"domain_scores_gemma":[0.9956603,0.0019310856,0.0016160511,0.00013624801,0.0005270516,0.00012926928],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00845128,0.00009806893,0.0013521382,0.00028543948,0.00002002086,0.0000050262533,0.00012947022,0.00023859732,0.00003360495],"category_scores_gemma":[0.024510702,0.00007237106,0.00028443243,0.00025653746,0.00008346955,0.000046264297,0.000044014614,0.0013614454,0.0000028263462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017730701,0.011249552,0.96544975,0.000014979878,0.00082126376,0.00009643124,0.00005911236,0.000010837575,0.000009081034,0.00002142246,0.004481268,0.016013203],"study_design_scores_gemma":[0.02541101,0.0054004597,0.96261376,0.00017030782,0.00022268257,0.000002218678,0.00009324256,0.0006465988,0.0000023676516,0.0000418271,0.005349662,0.000045846915],"about_ca_topic_score_codex":0.000052161286,"about_ca_topic_score_gemma":0.00006241548,"teacher_disagreement_score":0.02363794,"about_ca_system_score_codex":0.0006050981,"about_ca_system_score_gemma":0.0004602428,"threshold_uncertainty_score":0.98370624},"labels":[],"label_agreement":null},{"id":"W4410802704","doi":"10.1200/jco.2025.43.16_suppl.e14654","title":"Informing the gravid void: A population-based study of live birth rates after oncologic immunotherapy in reproductive age women.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Population; Live birth; Immunotherapy; Gynecology; Demography; Obstetrics; Pregnancy; Internal medicine; Cancer; Environmental health","score_opus":0.0710839953759015,"score_gpt":0.47623031944982475,"score_spread":0.40514632407392326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949466,0.00044166623,0.000016106027,0.003086449,0.0007947087,0.000526214,0.0000017987137,0.0000044687404,0.00018197802],"genre_scores_gemma":[0.9969717,0.00018129054,0.0001970992,0.002175029,0.00028364224,0.000031625335,7.758775e-7,0.0000075376993,0.00015128283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666464,0.0004654327,0.0022801103,0.00017259647,0.00023780926,0.000179425],"domain_scores_gemma":[0.9955703,0.0023621353,0.001440856,0.00027467907,0.00028026773,0.00007177209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038562168,0.00011867079,0.0012855718,0.00025333973,0.000033789995,0.000007302835,0.00015887788,0.00018919841,0.00011826052],"category_scores_gemma":[0.0025778334,0.00006590938,0.0002509659,0.00035781285,0.00012595902,0.00007112491,0.000035725127,0.0009102028,0.0000012349678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014327929,0.0027892545,0.9132045,0.000020739364,0.00028190672,0.00021346942,0.0032155411,0.00016466931,0.00003687448,0.00001100064,0.00009393548,0.06564021],"study_design_scores_gemma":[0.008762848,0.01541519,0.96222883,0.00009721118,0.00008527848,0.000008052556,0.0070951255,0.000029681572,0.000016341219,0.00041973905,0.0057861027,0.000055565717],"about_ca_topic_score_codex":0.0009021361,"about_ca_topic_score_gemma":0.0015003649,"teacher_disagreement_score":0.065584645,"about_ca_system_score_codex":0.00043170774,"about_ca_system_score_gemma":0.0012734425,"threshold_uncertainty_score":0.39544287},"labels":[],"label_agreement":null},{"id":"W4410802745","doi":"10.1200/jco.2025.43.16_suppl.8641","title":"Dermatologic prophylaxis and impact on patient-reported outcomes in first-line <i>EGFR</i> -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; Dermatology","score_opus":0.05556107731935047,"score_gpt":0.4735049464103127,"score_spread":0.41794386909096226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980275,0.00037796015,0.000025315338,0.016520845,0.0004133767,0.0012676811,0.00005704968,0.000015858885,0.0010469548],"genre_scores_gemma":[0.9960922,0.0004317425,0.00038099076,0.002830226,0.000096392876,0.000029928298,0.00003061175,0.000012690288,0.00009519138],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962987,0.00034988896,0.002569308,0.00028695393,0.00026996524,0.00022519332],"domain_scores_gemma":[0.992229,0.0051306756,0.0018307053,0.00029218948,0.00032689548,0.00019057121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007150551,0.00022412394,0.0016515454,0.00013074632,0.00007735521,0.000015241325,0.0001035134,0.00024459968,0.000013591809],"category_scores_gemma":[0.004852337,0.00009526499,0.00025014376,0.00033391253,0.00018195935,0.00008219812,0.000028915716,0.0007032904,0.0000017085908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64614415,0.0084048435,0.13470949,0.000016462871,0.0020810931,0.0032400442,0.00042450542,0.0002518183,0.0000569001,0.000012196124,0.0008213542,0.20383716],"study_design_scores_gemma":[0.60831743,0.09592484,0.28268215,0.000648164,0.0015795631,0.00019392274,0.00038572977,0.00019854185,0.00026095728,0.00015725622,0.00949954,0.00015191603],"about_ca_topic_score_codex":0.0002629104,"about_ca_topic_score_gemma":0.00028224615,"teacher_disagreement_score":0.20368524,"about_ca_system_score_codex":0.00037565472,"about_ca_system_score_gemma":0.001861959,"threshold_uncertainty_score":0.5809051},"labels":[],"label_agreement":null},{"id":"W4410802748","doi":"10.1200/jco.2025.43.16_suppl.8541","title":"Biomarker testing of lung cancer in North America versus globally.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Biomarker; Oncology; Cancer; Internal medicine","score_opus":0.1102041036443382,"score_gpt":0.5515508042231393,"score_spread":0.4413467005788011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95900536,0.0019285879,0.00010528116,0.0073378473,0.002004619,0.00016016507,0.000010056677,0.000004659467,0.02944342],"genre_scores_gemma":[0.9944745,0.0005573339,0.0034977805,0.0010501835,0.0001802643,0.000004423204,0.0000014838872,0.00000458221,0.00022947264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982283,0.00009911577,0.0013083414,0.00009479923,0.00014897539,0.000120433564],"domain_scores_gemma":[0.9969955,0.0016335828,0.00082550716,0.00008974183,0.0003552201,0.00010042148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004419666,0.00006592025,0.00075064297,0.00012179247,0.000015242848,0.0000023717052,0.000084108004,0.00010661435,0.00007533114],"category_scores_gemma":[0.002749096,0.00004593829,0.0001724585,0.00046581426,0.000108456195,0.00004211595,0.000028063258,0.00028139312,0.0000011500435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021809647,0.0006184302,0.6525065,0.000029886738,0.0005960358,0.000140896,0.000043809487,0.000097728676,0.000022837265,0.000021692498,0.002084623,0.34165666],"study_design_scores_gemma":[0.010724297,0.002309865,0.944828,0.00020867598,0.0008445427,0.000009546906,0.00008411875,0.0004794296,0.0000064745254,0.00002869688,0.040441133,0.000035242378],"about_ca_topic_score_codex":0.00025964077,"about_ca_topic_score_gemma":0.0006164961,"teacher_disagreement_score":0.3416214,"about_ca_system_score_codex":0.00032107506,"about_ca_system_score_gemma":0.0033248772,"threshold_uncertainty_score":0.58981895},"labels":[],"label_agreement":null},{"id":"W4410802805","doi":"10.1200/jco.2025.43.16_suppl.8643","title":"Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; ROS1; Cancer; Lung cancer; Oncology; Internal medicine; Adenocarcinoma","score_opus":0.1026324238354544,"score_gpt":0.5523450391033218,"score_spread":0.4497126152678674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667229,0.025172343,0.00025076477,0.0062052864,0.00045647108,0.0005146951,0.000024140401,0.000004281364,0.0006490991],"genre_scores_gemma":[0.98253757,0.010196896,0.004653558,0.00040532186,0.00024080556,0.000017370012,0.000002141996,0.000008180637,0.001938171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983973,0.00007500513,0.0011092739,0.00017723562,0.000080791135,0.00016037436],"domain_scores_gemma":[0.99444485,0.0041902815,0.00080890075,0.00007999291,0.00033087132,0.00014509488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007784903,0.00011440308,0.0013158489,0.000080256934,0.00011398149,0.000007773362,0.00004386645,0.00010546458,0.0000028718634],"category_scores_gemma":[0.0006272805,0.000078804296,0.000111785295,0.0001193023,0.00033126798,0.00006975888,0.000055614393,0.00028155724,6.480558e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064423964,0.00067486987,0.7930266,0.0007852024,0.0025673136,0.00002967756,0.0013927502,0.000047244186,0.00017755677,0.00009579925,0.0032616116,0.19149897],"study_design_scores_gemma":[0.039210215,0.005210014,0.9044306,0.001147284,0.0032297228,0.000026338852,0.0016525453,0.000068503745,0.00036870042,0.00033535672,0.044204563,0.00011610502],"about_ca_topic_score_codex":0.0000300086,"about_ca_topic_score_gemma":0.00031575595,"teacher_disagreement_score":0.19138286,"about_ca_system_score_codex":0.00008643948,"about_ca_system_score_gemma":0.0005505843,"threshold_uncertainty_score":0.32135457},"labels":[],"label_agreement":null},{"id":"W4410802810","doi":"10.1200/jco.2025.43.16_suppl.10001","title":"A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Chemoimmunotherapy; Cog; Eflornithine; Neuroblastoma; Refractory (planetary science); Oncology; Internal medicine; Lomustine; Randomized controlled trial; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.07020402218120037,"score_gpt":0.4922415114919991,"score_spread":0.4220374893107987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344236,0.00028018263,0.00008415447,0.0020433823,0.00053574884,0.0024714305,0.0000025675222,0.00001985699,0.0011203001],"genre_scores_gemma":[0.9960392,0.00048057458,0.0013166092,0.0010321349,0.00022002794,0.00008300303,0.000004023666,0.000039642542,0.0007847848],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908089,0.0026235539,0.0049616285,0.00047487853,0.0007027246,0.00042831822],"domain_scores_gemma":[0.9884318,0.0064164717,0.0036155856,0.00054165407,0.0006166873,0.00037777587],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006178054,0.00033337963,0.00532876,0.0007509047,0.000051375322,0.0000101080395,0.00031194545,0.0004156113,0.00013203312],"category_scores_gemma":[0.007985171,0.00018631853,0.00058738794,0.0006402051,0.000640327,0.00011837359,0.000100281344,0.0023430705,0.0000046721584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77255654,0.08698293,0.06790727,0.000040395702,0.0031390726,0.023581035,0.000286463,0.0000075583257,0.00055723917,0.0000075034154,0.00032646314,0.04460752],"study_design_scores_gemma":[0.6978505,0.2080863,0.08628049,0.0002708091,0.0011215421,0.0040674717,0.00019786593,0.00006506138,0.00010948854,0.00005203289,0.0017871668,0.00011128006],"about_ca_topic_score_codex":0.00015595723,"about_ca_topic_score_gemma":0.0007075087,"teacher_disagreement_score":0.121103376,"about_ca_system_score_codex":0.00028915188,"about_ca_system_score_gemma":0.003989903,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W4410802815","doi":"10.1200/jco.2025.43.16_suppl.e13102","title":"Association of rapid progression on CDK4/6 inhibitor (CDKi) for metastatic HR+HER2- breast cancer (mHRBC) with genomic, proteomic, and immune microenvironment alterations.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Collins Medical Trust; Conquer Cancer Foundation","keywords":"Medicine; Metastatic breast cancer; Immune system; Tumor microenvironment; Cancer; Breast cancer; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.03602998094487765,"score_gpt":0.4237871358077679,"score_spread":0.38775715486289025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9575008,0.0019510784,0.0020912357,0.03633559,0.0005875567,0.0013668414,0.00004773659,0.000007358772,0.00011176395],"genre_scores_gemma":[0.95624614,0.0014186652,0.038815953,0.0018968461,0.00074321654,0.00015372348,0.0000071050245,0.000033155025,0.000685181],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751747,0.00024147169,0.0016014418,0.00019922407,0.0002513343,0.00018907251],"domain_scores_gemma":[0.9961601,0.00090651534,0.0023429058,0.00014185268,0.00033348045,0.00011517699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015819517,0.00015156371,0.0011671039,0.00012613833,0.000057873047,0.000008255874,0.000080014026,0.00015624992,0.00007048099],"category_scores_gemma":[0.0003677432,0.00010049394,0.00020017482,0.000081894825,0.00017093909,0.00009791274,0.000030385601,0.00044025917,0.0000010201609],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051026423,0.0033103677,0.06089735,0.0004138687,0.0028487758,0.00003077882,0.0002543124,0.00021598567,0.08535412,0.000129138,0.0012312115,0.7942877],"study_design_scores_gemma":[0.049462177,0.0317024,0.8111848,0.0025079646,0.0021345816,0.0002797965,0.00026430513,0.00023418387,0.034195766,0.0009161165,0.06683552,0.0002823738],"about_ca_topic_score_codex":0.0000076682045,"about_ca_topic_score_gemma":0.000014352965,"teacher_disagreement_score":0.7940053,"about_ca_system_score_codex":0.0005957677,"about_ca_system_score_gemma":0.0009031646,"threshold_uncertainty_score":0.40980238},"labels":[],"label_agreement":null},{"id":"W4410802840","doi":"10.1200/jco.2025.43.16_suppl.8519","title":"Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with <i>KRAS</i> G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Eli Lilly and Company","keywords":"Medicine; KRAS; Immunotherapy; Oncology; Internal medicine; Mutant; Clinical trial; Cancer; Genetics","score_opus":0.03074186538294071,"score_gpt":0.4333939144166533,"score_spread":0.4026520490337126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98862535,0.0021934712,0.00013544086,0.0070166085,0.00053971366,0.0009122251,0.00006595306,0.0000032822077,0.0005079733],"genre_scores_gemma":[0.98737407,0.010314651,0.0012225391,0.00082121824,0.00013587647,0.000010454662,0.000026307083,0.0000117198315,0.00008315447],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971891,0.00023261097,0.0020554264,0.00017199373,0.00020831607,0.0001425442],"domain_scores_gemma":[0.99489194,0.0030386685,0.0014547923,0.0002439144,0.00028078048,0.000089931746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005186909,0.0001549102,0.0015136058,0.00008278568,0.000037654496,0.0000035279904,0.000104117484,0.0001550857,0.000062081395],"category_scores_gemma":[0.0004922135,0.00007568724,0.0002405514,0.0002024017,0.00022747675,0.000059925696,0.000017787723,0.00023339126,7.533611e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32376358,0.012372859,0.21738662,0.000015671778,0.0020327677,0.00005401361,0.00046704223,0.00011668609,0.00005387316,0.00006264354,0.00012489497,0.44354934],"study_design_scores_gemma":[0.30922285,0.028436186,0.6109791,0.00029340264,0.00093907135,0.0000035356666,0.00009315717,0.000011571157,0.00013594888,0.00015037363,0.049676374,0.000058440364],"about_ca_topic_score_codex":0.00013376944,"about_ca_topic_score_gemma":0.00024989844,"teacher_disagreement_score":0.4434909,"about_ca_system_score_codex":0.00023271171,"about_ca_system_score_gemma":0.0011190713,"threshold_uncertainty_score":0.3086436},"labels":[],"label_agreement":null},{"id":"W4410802861","doi":"10.1200/jco.2025.43.16_suppl.e14570","title":"Dual-omic analysis to reveal gene regulatory network of immune landscape in childhood solid tumors and implications for immunotherapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Université Laval","funders":"","keywords":"Immunotherapy; Medicine; Immune system; Gene; Computational biology; Omics; Cancer research; Bioinformatics; Immunology; Genetics; Biology","score_opus":0.018699971415385912,"score_gpt":0.3855029032266825,"score_spread":0.3668029318112966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891491,0.0044168676,0.0027246312,0.0030701791,0.00027395922,0.00017466486,0.000026971235,9.205277e-7,0.00016269395],"genre_scores_gemma":[0.99110526,0.002471371,0.0045590387,0.001313979,0.00045191526,0.000010955884,0.000016483165,0.000008006415,0.00006300597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980194,0.00008457881,0.0015365608,0.0001675243,0.000043366184,0.00014857271],"domain_scores_gemma":[0.99827236,0.0004477728,0.00074955344,0.00022843556,0.0002211563,0.00008073099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015334787,0.000083746745,0.00077035406,0.00011555336,0.000030432078,0.0000060379493,0.00014547382,0.00020706128,0.000003656734],"category_scores_gemma":[0.00083758327,0.000076368415,0.00035441402,0.00023707516,0.00006448309,0.000002509621,0.000075331096,0.00014131292,1.5718777e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005842376,0.0019335218,0.43509766,0.00003692519,0.005391837,0.000010467919,0.00015969161,0.02093251,0.1761942,0.0018323193,0.022702912,0.32986557],"study_design_scores_gemma":[0.0023398374,0.0018190559,0.9827892,0.000020928726,0.00027862776,0.000009677692,0.000019808745,0.000040290193,0.0022693903,0.0013508297,0.0089845965,0.000077767916],"about_ca_topic_score_codex":0.000011156492,"about_ca_topic_score_gemma":0.00011740922,"teacher_disagreement_score":0.5476915,"about_ca_system_score_codex":0.00002616433,"about_ca_system_score_gemma":0.00068090763,"threshold_uncertainty_score":0.31142136},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4410802869","doi":"10.1200/jco.2025.43.16_suppl.8513","title":"Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Placebo; Internal medicine; Pathology; Alternative medicine","score_opus":0.08479915726876193,"score_gpt":0.49022092613509843,"score_spread":0.4054217688663365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863714,0.00034434686,0.00014622361,0.006702792,0.0006488923,0.0015015292,0.00002696262,0.000009139108,0.004248692],"genre_scores_gemma":[0.99806,0.00010888973,0.00055941916,0.00069254515,0.00016668651,0.00001706412,0.000015701205,0.000010434251,0.0003692444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956538,0.0010837413,0.0025406664,0.00022758498,0.0003343544,0.00015982709],"domain_scores_gemma":[0.9881056,0.008877637,0.0020987743,0.00027433917,0.0004720161,0.00017161378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00263363,0.00015700223,0.0020772102,0.00012051392,0.000092919734,0.000014331776,0.00014875575,0.000147764,0.000021127353],"category_scores_gemma":[0.006221377,0.00008274124,0.0002843397,0.00019989023,0.00040486167,0.00007585683,0.000060056944,0.0005965327,0.0000013163993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85645163,0.018896483,0.08313708,0.000035430883,0.0053506424,0.00012445298,0.002628587,0.000065868444,0.0001091002,0.00034799596,0.002999901,0.029852804],"study_design_scores_gemma":[0.74383765,0.008458584,0.23764338,0.0003773772,0.0046969866,0.000022717888,0.0008974693,0.0003413733,0.00009924358,0.0003127472,0.003242895,0.00006953971],"about_ca_topic_score_codex":0.00019617878,"about_ca_topic_score_gemma":0.00016382539,"teacher_disagreement_score":0.1545063,"about_ca_system_score_codex":0.000117683776,"about_ca_system_score_gemma":0.0013884308,"threshold_uncertainty_score":0.7448019},"labels":[],"label_agreement":null},{"id":"W4410802873","doi":"10.1200/jco.2025.43.16_suppl.e14574","title":"Spatial profiling of solid tumor microenvironment using imaging mass cytometry with high-plex panels.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cell Image Analysis Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Medicine; Mass cytometry; Tumor microenvironment; Profiling (computer programming); Pathology; Cancer research; Tumor cells; Phenotype; Biology; Genetics","score_opus":0.02755781380322431,"score_gpt":0.3960471773335422,"score_spread":0.3684893635303179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8496795,0.0004284155,0.14893033,0.00028175156,0.00013197378,0.00011028361,0.0000034098894,0.0000039114225,0.00043039155],"genre_scores_gemma":[0.93235314,0.00026471153,0.06604865,0.00089294463,0.0003521747,0.0000016959932,0.000005618056,0.000015003814,0.000066051965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99742013,0.00027933132,0.001649393,0.00024997638,0.00019645279,0.000204685],"domain_scores_gemma":[0.99754244,0.00016203563,0.0016629027,0.00028141346,0.0002557456,0.00009544191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016058482,0.00014685976,0.0008850264,0.00017130836,0.000033473116,0.000008408848,0.0002889142,0.00017259698,0.000023057994],"category_scores_gemma":[0.0006356057,0.00011403579,0.00033491518,0.00013786838,0.0002886388,0.000008841925,0.00014727714,0.0003921792,7.578294e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008360491,0.00039233637,0.056754027,0.000026966742,0.00037892064,0.00012863675,0.000004428158,0.00013353385,0.9306932,0.000007760713,0.0003339558,0.010310154],"study_design_scores_gemma":[0.001899998,0.0020561172,0.014941612,0.00008660232,0.00046421925,0.00010082672,0.000081157996,0.00047425233,0.9732913,0.00012646755,0.006335922,0.0001415674],"about_ca_topic_score_codex":0.00003678117,"about_ca_topic_score_gemma":0.00001021126,"teacher_disagreement_score":0.08288167,"about_ca_system_score_codex":0.000068747366,"about_ca_system_score_gemma":0.0006421358,"threshold_uncertainty_score":0.46502447},"labels":[],"label_agreement":null},{"id":"W4410802876","doi":"10.1200/jco.2025.43.16_suppl.2551","title":"Plasma extracellular vesicles as biomarkers of primary versus acquired resistance to immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Medicine; Extracellular vesicles; Cancer research; Immune system; Immune checkpoint; Oncology; Internal medicine; Immunology; Immunotherapy; Cell biology; Biology","score_opus":0.024680055466339335,"score_gpt":0.3469325074952845,"score_spread":0.32225245202894515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360603,0.0019082264,0.00012784984,0.0007399521,0.0008468976,0.00030670757,0.0000081484595,0.0000043693926,0.0024517921],"genre_scores_gemma":[0.99519217,0.00015574292,0.003790094,0.00023188397,0.0001908706,0.00000750428,0.000015533018,0.0000259607,0.00039021802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954297,0.00047912126,0.0030155738,0.0003812289,0.0003644736,0.0003299168],"domain_scores_gemma":[0.9966793,0.00039957656,0.0017694656,0.00044852716,0.00042991768,0.0002731906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022631087,0.00022808417,0.0011066138,0.0002069274,0.000037438014,0.000011049333,0.0005278,0.000413931,0.000014974832],"category_scores_gemma":[0.0032043247,0.00019541585,0.00040421847,0.00031517426,0.00038728895,0.000017142424,0.0002285859,0.0003219095,0.0000055577684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1316942,0.0060680793,0.08557125,0.00022762157,0.0012312552,0.00045214227,0.00012616912,0.00033627404,0.7238783,0.0001481955,0.003574052,0.04669241],"study_design_scores_gemma":[0.03671519,0.02167709,0.36254194,0.0008867254,0.00035823128,0.00001265132,0.00038215157,0.000025384887,0.5439197,0.00034315756,0.03256594,0.00057184463],"about_ca_topic_score_codex":0.00001058828,"about_ca_topic_score_gemma":0.00006573703,"teacher_disagreement_score":0.27697068,"about_ca_system_score_codex":0.00016656776,"about_ca_system_score_gemma":0.001687068,"threshold_uncertainty_score":0.7968827},"labels":[],"label_agreement":null},{"id":"W4410802882","doi":"10.1200/jco.2025.43.16_suppl.2545","title":"Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; DNA methylation; Genome; Oncology; Computational biology; Internal medicine; Bioinformatics; Cancer; Genetics; Gene; Biology; Immunotherapy; Gene expression","score_opus":0.05140425094792985,"score_gpt":0.43893779500628,"score_spread":0.38753354405835017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468535,0.00009813456,0.00060439087,0.002531148,0.00077806314,0.0006959434,0.000008365554,0.00000919645,0.0005893781],"genre_scores_gemma":[0.9910562,0.00029333966,0.0058008926,0.0023407824,0.00014616647,0.000011839887,0.000018225594,0.000015215153,0.00031734107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934473,0.0013282561,0.0042662746,0.0002734088,0.0004528507,0.00023193409],"domain_scores_gemma":[0.9917999,0.005315305,0.0016935964,0.00030275213,0.00058631797,0.0003021204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006176122,0.00018311797,0.002249524,0.0004081237,0.000023036084,0.000008204368,0.00022652365,0.00039028408,0.00011185791],"category_scores_gemma":[0.0070108357,0.000117574265,0.00039837373,0.00041384835,0.00017432406,0.000107621476,0.000046278856,0.0006267888,0.0000034114057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073171325,0.0049780826,0.86945724,0.000025882213,0.0010067823,0.00008838725,0.000059198912,0.0002454147,0.00012894356,0.0000029037394,0.0003171624,0.050518658],"study_design_scores_gemma":[0.04376357,0.040658012,0.9100452,0.00016753889,0.0005840178,0.000008269035,0.00003443755,0.000034848403,0.00039153107,0.000026230104,0.0041918387,0.00009452196],"about_ca_topic_score_codex":0.000074799456,"about_ca_topic_score_gemma":0.00002477793,"teacher_disagreement_score":0.050424136,"about_ca_system_score_codex":0.00030198082,"about_ca_system_score_gemma":0.001233666,"threshold_uncertainty_score":0.8393132},"labels":[],"label_agreement":null},{"id":"W4410802901","doi":"10.1200/jco.2025.43.16_suppl.10013","title":"CCDI-COG molecular characterization initiative: The expanding data on childhood cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; CancerCare Manitoba","funders":"","keywords":"Medicine; Cog; Childhood cancer; Cancer; Family medicine; Gerontology; Oncology; Internal medicine","score_opus":0.13516708324912505,"score_gpt":0.5607126190603696,"score_spread":0.42554553581124455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83052605,0.0012191148,0.0029463952,0.14163688,0.0036472857,0.00050890876,0.000067353256,0.000015468297,0.019432548],"genre_scores_gemma":[0.98109704,0.0011736245,0.0003269708,0.016377706,0.00068232446,0.000008364151,0.00004910184,0.000007947712,0.00027691823],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984507,0.00020834232,0.0009120135,0.00014298697,0.00017771804,0.00010826545],"domain_scores_gemma":[0.9979378,0.00075450994,0.0007456277,0.00027728587,0.00019627066,0.000088494824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087882846,0.00007972118,0.0005189325,0.0000769291,0.00007239091,0.000011811832,0.00020606205,0.00012301723,0.0000722347],"category_scores_gemma":[0.0015155271,0.00004414902,0.00013254226,0.00016149456,0.00007772822,0.000107948836,0.000060906663,0.000483056,0.0000055235587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018400615,0.0037335663,0.05057323,0.00003735425,0.0036844395,0.00046543952,0.00061958266,0.000037733356,0.0015871633,0.0023795883,0.009945861,0.925096],"study_design_scores_gemma":[0.0073990813,0.0031604108,0.79894775,0.0003929772,0.0019036329,0.000047404294,0.00018786063,0.00012879565,0.0003886896,0.0004529574,0.1869244,0.00006603692],"about_ca_topic_score_codex":0.000007874372,"about_ca_topic_score_gemma":0.000006213151,"teacher_disagreement_score":0.92502993,"about_ca_system_score_codex":0.00012824674,"about_ca_system_score_gemma":0.0021544946,"threshold_uncertainty_score":0.3821981},"labels":[],"label_agreement":null},{"id":"W4410802947","doi":"10.1200/jco.2025.43.16_suppl.e14579","title":"Immunotherapy toxicity in the curative setting.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Toxicity; Immunotherapy; Oncology; Internal medicine; Cancer; Pharmacology","score_opus":0.05645164603574376,"score_gpt":0.4398737796779199,"score_spread":0.38342213364217614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93847036,0.019603843,0.00043647172,0.026915839,0.0041931756,0.0002557056,0.000003807963,0.000009696854,0.010111122],"genre_scores_gemma":[0.9825504,0.0023616583,0.000203764,0.012252614,0.00009217192,0.000006923841,0.0000018715157,0.000007219688,0.0025233822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928032,0.0044138497,0.0023019006,0.00014420765,0.00006074879,0.00027610047],"domain_scores_gemma":[0.98944825,0.008857743,0.0012113918,0.00027115995,0.00019909361,0.000012341532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008757505,0.00014775831,0.0010038465,0.00020570359,0.00012245559,0.000013889826,0.00072610436,0.0005590835,0.00028775347],"category_scores_gemma":[0.0030865958,0.0000844624,0.00048016792,0.00029651393,0.0004959363,0.00013571266,0.00004607756,0.0017764033,0.000052587347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02190741,0.0037267061,0.017630206,0.000011748585,0.0015033529,0.00014135355,0.0030227767,0.00001271629,0.06843845,0.0052927188,0.061868813,0.81644374],"study_design_scores_gemma":[0.0072734104,0.0035291242,0.1700668,0.00007490962,0.000042447387,0.00018389733,0.0013410321,0.0000017953547,0.005382,0.0019106569,0.8100942,0.00009974846],"about_ca_topic_score_codex":0.000031916425,"about_ca_topic_score_gemma":0.00003233248,"teacher_disagreement_score":0.816344,"about_ca_system_score_codex":0.00007437104,"about_ca_system_score_gemma":0.0011961479,"threshold_uncertainty_score":0.7717687},"labels":[],"label_agreement":null},{"id":"W4410802952","doi":"10.1200/jco.2025.43.16_suppl.e14575","title":"Integrated immune profiling approach for immuno-oncology: Unveiling biomarkers and therapeutic targets with mass cytometry.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Biosensing Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Mass cytometry; Medicine; Profiling (computer programming); Immune system; Flow cytometry; Oncology; Cancer research; Immunology; Internal medicine; Phenotype; Biology","score_opus":0.04890210515015619,"score_gpt":0.42399463229974144,"score_spread":0.37509252714958524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802952","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1411805,0.0041758204,0.8507224,0.0016064167,0.00026699845,0.00059141684,0.000010379537,0.000018875582,0.0014272311],"genre_scores_gemma":[0.600086,0.00069226325,0.39838728,0.00054205273,0.00013615433,0.000019964415,0.000026495549,0.000013795522,0.00009600546],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817806,0.00017628119,0.0010928366,0.0002688704,0.000076653734,0.00020727316],"domain_scores_gemma":[0.99801147,0.00037353803,0.0008726767,0.00020966654,0.0004478727,0.00008480511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018758352,0.00015284138,0.00065993675,0.000107298016,0.00009866326,0.000012991338,0.00021229757,0.00047170013,0.0000012604556],"category_scores_gemma":[0.0006238706,0.00010537686,0.00020529346,0.0002014698,0.00033402434,0.0000055688643,0.00006398253,0.00036313385,1.1750669e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004443858,0.00060315646,0.0023800505,0.00003798505,0.00093925925,0.000008232634,0.000013146822,0.00006053364,0.74975085,0.0006699066,0.00046277596,0.24063025],"study_design_scores_gemma":[0.0132922325,0.024628144,0.0039980263,0.0001695538,0.00086299045,0.00035865323,0.0015604018,0.00540292,0.36382478,0.0061863614,0.57901084,0.000705081],"about_ca_topic_score_codex":0.0000021907513,"about_ca_topic_score_gemma":0.0000023867067,"teacher_disagreement_score":0.5785481,"about_ca_system_score_codex":0.000054562162,"about_ca_system_score_gemma":0.00079400314,"threshold_uncertainty_score":0.42971435},"labels":[],"label_agreement":null},{"id":"W4410802961","doi":"10.1200/jco.2025.43.16_suppl.11558","title":"Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Term (time); Range of motion; Clinical trial; Outcome (game theory); Physical therapy; Oncology; Internal medicine; Physical medicine and rehabilitation; Surgery","score_opus":0.08538107930543326,"score_gpt":0.46954908112358956,"score_spread":0.3841680018181563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335164,0.000030904197,0.000115062845,0.0018395204,0.0011901913,0.0012304991,0.00008036822,0.000014476582,0.0021473668],"genre_scores_gemma":[0.9960592,0.000061452236,0.0010096367,0.0014494461,0.0008107269,0.000012170504,0.00011204204,0.000025076064,0.00046024527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99258304,0.0011656306,0.0047919024,0.00043859452,0.0006491303,0.00037168202],"domain_scores_gemma":[0.99232817,0.0035179986,0.0028511493,0.00044565526,0.00050381164,0.00035319902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003263314,0.00030212488,0.002152261,0.00013852115,0.000079449914,0.000029429402,0.0002820967,0.0003752208,0.00009713476],"category_scores_gemma":[0.001958703,0.00014385482,0.00053992914,0.00031733693,0.0003075433,0.00016996071,0.00007920314,0.0014319497,0.000016988202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28513947,0.014805799,0.6659465,0.000015928108,0.0005695187,0.0006028188,0.000014388758,0.0000022552683,0.0000010919122,0.000007770348,0.00026310814,0.03263138],"study_design_scores_gemma":[0.3180898,0.04100457,0.63894594,0.00019884759,0.0007681138,0.000006471463,0.000034296078,0.000012498937,0.0000060464254,0.00001471828,0.0008272532,0.000091428636],"about_ca_topic_score_codex":0.0002596486,"about_ca_topic_score_gemma":0.00021514764,"teacher_disagreement_score":0.032950345,"about_ca_system_score_codex":0.0002502309,"about_ca_system_score_gemma":0.00118005,"threshold_uncertainty_score":0.62211883},"labels":[],"label_agreement":null},{"id":"W4410803003","doi":"10.1200/jco.2025.43.16_suppl.8646","title":"Rechallenge with first-generation RET inhibitors in <i>RET</i> -rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Proto-Oncogene Proteins c-ret; Oncology; Cancer research; Internal medicine; Receptor","score_opus":0.09299969860512383,"score_gpt":0.4516467348935483,"score_spread":0.3586470362884244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8348046,0.00066847785,0.000065959495,0.15390638,0.0007171426,0.000978668,0.00008683835,0.000028894898,0.008743046],"genre_scores_gemma":[0.9844244,0.0010693087,0.0061459676,0.0030348345,0.0013096931,0.000049750142,0.00016777076,0.00002758558,0.0037706492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653363,0.0005560511,0.0019590396,0.00035841748,0.0003658778,0.00022696321],"domain_scores_gemma":[0.9941414,0.0032081113,0.0015282511,0.00044228998,0.00050353695,0.00017641122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019433658,0.0002067434,0.0010267089,0.00009433661,0.00011104521,0.000025046611,0.00017933555,0.00040377508,0.00004891251],"category_scores_gemma":[0.0033744639,0.00009616737,0.00014777575,0.00035995888,0.00021640028,0.0001292868,0.000029140127,0.0009820658,0.0000048349875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16299288,0.0060707293,0.30753595,0.00013868177,0.003765525,0.0034120742,0.006332589,0.00034365244,0.00025268673,0.000119928176,0.41531476,0.09372055],"study_design_scores_gemma":[0.07152057,0.030289037,0.35056475,0.004129843,0.0028040588,0.00032495172,0.0021556937,0.00020076944,0.00043962713,0.00014483357,0.5370976,0.00032829065],"about_ca_topic_score_codex":0.00055097515,"about_ca_topic_score_gemma":0.011862212,"teacher_disagreement_score":0.15087155,"about_ca_system_score_codex":0.0003340543,"about_ca_system_score_gemma":0.0035484398,"threshold_uncertainty_score":0.66193926},"labels":[],"label_agreement":null},{"id":"W4410803018","doi":"10.1200/jco.2025.43.16_suppl.tps7097","title":"A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Cancer research; Internal medicine","score_opus":0.07507945975374432,"score_gpt":0.4758546823248268,"score_spread":0.4007752225710825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97019327,0.0017883204,0.000007868199,0.005486853,0.002525079,0.00033810604,0.00000485723,0.0000051086913,0.019650517],"genre_scores_gemma":[0.99406916,0.0014758911,0.00097594265,0.0018772914,0.00078686024,0.000008718016,0.00000273227,0.000009350095,0.0007940414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959958,0.00040780308,0.0029246863,0.0001812279,0.00029462535,0.0001958181],"domain_scores_gemma":[0.99479055,0.0028732563,0.0016219366,0.00024333573,0.00025042816,0.00022050992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021880898,0.000142959,0.0018992082,0.00027416254,0.000016591412,0.0000043212945,0.00014879189,0.00060543313,0.00012409643],"category_scores_gemma":[0.002472148,0.00009547845,0.0007036093,0.00023676519,0.00013979599,0.0000491751,0.000045197197,0.00061415357,0.000011105152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39011618,0.12818056,0.060661405,0.00015541789,0.00079981907,0.0041652936,0.00017607052,0.000006772982,0.0005548106,0.00043461623,0.04182775,0.3729213],"study_design_scores_gemma":[0.66718274,0.05521249,0.07418281,0.00034700677,0.0007659821,0.00009322171,0.0001145331,0.000023020768,0.0011849899,0.0005629561,0.20024517,0.0000850907],"about_ca_topic_score_codex":0.000021163409,"about_ca_topic_score_gemma":0.000021925805,"teacher_disagreement_score":0.3728362,"about_ca_system_score_codex":0.00037959852,"about_ca_system_score_gemma":0.003467324,"threshold_uncertainty_score":0.61508834},"labels":[],"label_agreement":null},{"id":"W4410803025","doi":"10.1200/jco.2025.43.16_suppl.10019","title":"Second malignant neoplasm risk after mediastinal radiotherapy for pediatric Hodgkin lymphoma on Children’s Oncology Group AHOD1331.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; University Health Network; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Radiation therapy; Pediatric oncology; Hodgkin lymphoma; Lymphoma; Oncology; Internal medicine; Cancer","score_opus":0.030939594430976953,"score_gpt":0.4525656285661679,"score_spread":0.42162603413519095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772964,0.0033033686,0.002666827,0.00833626,0.004692543,0.00083395344,0.00010442561,0.000019038685,0.0027471646],"genre_scores_gemma":[0.9586229,0.0040481105,0.018738985,0.011320345,0.0055928202,0.000108580636,0.000023620109,0.00003975821,0.0015049088],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965187,0.0004506854,0.0020949221,0.00032761763,0.00025691022,0.0003512106],"domain_scores_gemma":[0.9928994,0.0045793345,0.0016003057,0.00022926663,0.0003229621,0.00036873415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018304625,0.00022840081,0.00165355,0.00035210935,0.00009056008,0.000012884891,0.0001753844,0.00055145996,0.0003546276],"category_scores_gemma":[0.0015100301,0.00015446769,0.00077911763,0.0001994498,0.00014986629,0.0000785401,0.000028092256,0.0005986125,0.000011957996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017111309,0.005085169,0.23358007,0.000053784046,0.002505031,0.0006104736,0.0003932937,0.000020989954,0.000017125376,0.00041592127,0.036868665,0.70333815],"study_design_scores_gemma":[0.030245144,0.03025627,0.71508074,0.00007049058,0.0024425115,0.0004025229,0.00006125566,0.000048922087,0.000024840592,0.0005833828,0.22066122,0.0001226846],"about_ca_topic_score_codex":0.000019224874,"about_ca_topic_score_gemma":0.00008020764,"teacher_disagreement_score":0.7032155,"about_ca_system_score_codex":0.00077443774,"about_ca_system_score_gemma":0.003610323,"threshold_uncertainty_score":0.6404558},"labels":[],"label_agreement":null},{"id":"W4410803029","doi":"10.1200/jco.2025.43.16_suppl.8622","title":"Novel potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Targeted therapy; Cancer research; Erlotinib; Gefitinib; Oncology; Pharmacology; Epidermal growth factor receptor; Internal medicine; Cancer","score_opus":0.09480371908270102,"score_gpt":0.49798839209019147,"score_spread":0.40318467300749045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88752156,0.004285575,0.044698507,0.053050164,0.004258968,0.0010346917,0.0000100498155,0.000015196237,0.0051253107],"genre_scores_gemma":[0.9718233,0.0006918278,0.022016805,0.0033575278,0.0015657531,0.000013132809,0.000005931913,0.000007773536,0.000517975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987316,0.00006379135,0.0008925366,0.00011459675,0.00009463536,0.00010281038],"domain_scores_gemma":[0.99810064,0.00074519904,0.000524146,0.000046276273,0.00048308712,0.00010065907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009547565,0.00007045819,0.0005011286,0.00008034116,0.000069747715,0.000008593615,0.000028593688,0.00015765397,0.000006142414],"category_scores_gemma":[0.0013019625,0.000046683577,0.00019321172,0.00008054586,0.000043953412,0.00006221718,0.000010465917,0.00024457512,4.5268993e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023972583,0.0017204082,0.016907327,0.00002254977,0.0013534585,0.000025545938,0.00032828058,0.0000713795,0.0069672777,0.0005464988,0.02478628,0.94487375],"study_design_scores_gemma":[0.091054045,0.04483283,0.23621744,0.00041367728,0.0032934558,0.00035878594,0.0011864314,0.0041708993,0.008294332,0.0027036627,0.6071479,0.00032657367],"about_ca_topic_score_codex":0.000014440178,"about_ca_topic_score_gemma":0.000014668449,"teacher_disagreement_score":0.9445472,"about_ca_system_score_codex":0.00015665505,"about_ca_system_score_gemma":0.0012960648,"threshold_uncertainty_score":0.22991633},"labels":[],"label_agreement":null},{"id":"W4410803040","doi":"10.1200/jco.2025.43.16_suppl.10025","title":"Integrated molecular characterization of pediatric soft tissue sarcomas: A report from the COG and CCDI molecular characterization initiative.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"St. Baldrick's Foundation","keywords":"Medicine; Soft tissue; Cog; Characterization (materials science); Pathology; Nanotechnology","score_opus":0.060691702847618975,"score_gpt":0.41216565485896256,"score_spread":0.35147395201134357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98110825,0.0012301656,0.0059450236,0.010631952,0.0005293207,0.0003227993,0.000023773455,0.000007961722,0.0002007274],"genre_scores_gemma":[0.99350065,0.0017188874,0.00082268816,0.0034294417,0.00031164286,0.000010116039,0.00016025908,0.0000129506425,0.00003336514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969412,0.00049429305,0.0019889604,0.00019754587,0.00025420132,0.00012378208],"domain_scores_gemma":[0.9957142,0.0013574281,0.001971422,0.00021416681,0.0006221913,0.00012059024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001091442,0.00014248842,0.0010247696,0.00013102968,0.00003355009,0.000013268276,0.00010674283,0.00027051155,0.000048711507],"category_scores_gemma":[0.0032944311,0.00008924557,0.00020644558,0.00030095095,0.00012373079,0.00008767422,0.00005492987,0.0004342009,0.0000024872954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015618764,0.002956326,0.6619361,0.00004256738,0.0011936862,0.004453996,0.00017609423,7.6224063e-7,0.11953056,0.00026324153,0.00028047824,0.20760432],"study_design_scores_gemma":[0.003929238,0.0016876069,0.964623,0.00014586233,0.0016289937,0.00019849141,0.00004902417,0.00006375306,0.01194413,0.00032207952,0.015334495,0.000073376505],"about_ca_topic_score_codex":0.000020597487,"about_ca_topic_score_gemma":0.0000033878455,"teacher_disagreement_score":0.30268684,"about_ca_system_score_codex":0.00005822865,"about_ca_system_score_gemma":0.00090421323,"threshold_uncertainty_score":0.39439797},"labels":[],"label_agreement":null},{"id":"W4410803047","doi":"10.1200/jco.2025.43.16_suppl.10020","title":"Mortality in survivors of childhood cancer diagnosed with subsequent thyroid cancer: A report from the Childhood Cancer Survivor Study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Institutes of Health","keywords":"Medicine; Cancer; Childhood cancer; Thyroid cancer; Cancer survivorship; Oncology; Pediatrics; Internal medicine; Survivorship curve","score_opus":0.08971972004286169,"score_gpt":0.47034962706042766,"score_spread":0.38062990701756594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560058,0.010024694,0.000031047657,0.027615825,0.0038437517,0.0016643539,0.00014701353,0.00002797022,0.00063955673],"genre_scores_gemma":[0.9834414,0.0074971677,0.00018982452,0.0064144116,0.002065979,0.0001931546,0.000012173802,0.0000551655,0.00013068177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98738045,0.0025748399,0.006955732,0.0008306887,0.0016253212,0.0006329701],"domain_scores_gemma":[0.98456043,0.00698805,0.0056478884,0.0011785232,0.0011462768,0.00047885094],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011050706,0.00051928207,0.004516367,0.00027166828,0.00011152597,0.000026155338,0.00087591715,0.0005447577,0.00034401717],"category_scores_gemma":[0.0055385763,0.00032441027,0.0008588275,0.0011322601,0.0006450335,0.00020377473,0.00022835839,0.0027542063,0.00000204839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030209036,0.009795687,0.95836234,0.00007320412,0.0040768506,0.001474045,0.0043591345,0.00026387724,0.000025737529,0.000021958738,0.0024462193,0.016080044],"study_design_scores_gemma":[0.017010435,0.0039321445,0.9662944,0.0015463263,0.0019876529,0.00006718794,0.0034031754,0.000011721862,0.0001006444,0.00021269564,0.005141026,0.0002925655],"about_ca_topic_score_codex":0.22764352,"about_ca_topic_score_gemma":0.6027311,"teacher_disagreement_score":0.3750876,"about_ca_system_score_codex":0.0007473017,"about_ca_system_score_gemma":0.014744423,"threshold_uncertainty_score":0.9999208},"labels":[],"label_agreement":null},{"id":"W4410803063","doi":"10.1200/jco.2025.43.16_suppl.10016","title":"Cognitive outcomes following proton vs. photon radiotherapy for CNS non-germinomatous germ cell tumors: A Children’s Oncology Group study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Germ cell tumors; Radiation oncology; Radiation therapy; Oncology; Cognition; Internal medicine; Proton therapy; Pediatric oncology; Cancer; Chemotherapy; Psychiatry","score_opus":0.05441765458377516,"score_gpt":0.46184904108643704,"score_spread":0.40743138650266186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98646826,0.0005465414,0.00023953117,0.0043538795,0.0016491311,0.0054861456,0.0000113630995,0.000022268505,0.0012228903],"genre_scores_gemma":[0.99111456,0.00018652488,0.00223869,0.005127703,0.0005028545,0.00063382124,0.000009252458,0.0000388493,0.00014774507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99501497,0.0005688531,0.0031422162,0.00044761415,0.00036736205,0.00045900355],"domain_scores_gemma":[0.9896481,0.0072046104,0.0021179053,0.00025939062,0.00039103127,0.000378946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032574574,0.000346889,0.003635477,0.0003869472,0.0001244002,0.000023721008,0.00023812463,0.0005129319,0.00006080639],"category_scores_gemma":[0.002210689,0.00023495071,0.0018041737,0.00022239408,0.00014389804,0.00011542103,0.00006534691,0.0008387083,0.00000748006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054977476,0.027970038,0.8918238,0.00006021901,0.003528188,0.0020416484,0.00034893694,0.0000012458942,0.00015991674,0.00001518569,0.0013302506,0.06722282],"study_design_scores_gemma":[0.06676851,0.06484822,0.8567791,0.0002735701,0.002495137,0.00015547918,0.0004901303,0.00004051029,0.00090716744,0.00011676553,0.00694951,0.00017588491],"about_ca_topic_score_codex":0.000060923234,"about_ca_topic_score_gemma":0.000051034676,"teacher_disagreement_score":0.06704693,"about_ca_system_score_codex":0.0005745599,"about_ca_system_score_gemma":0.002072672,"threshold_uncertainty_score":0.95810115},"labels":[],"label_agreement":null},{"id":"W4410803096","doi":"10.1200/jco.2025.43.16_suppl.10021","title":"Social determinants of health (SDOH) and late mortality among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Childhood cancer; Cancer; Social determinants of health; Survivorship curve; Cancer survivorship; Cancer survivor; Gerontology; Demography; Public health; Internal medicine","score_opus":0.13817613266993814,"score_gpt":0.5234792970106092,"score_spread":0.38530316434067113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722523,0.0069715125,0.00001661584,0.016877722,0.002457189,0.0010554931,0.000111126974,0.000016053327,0.00024198348],"genre_scores_gemma":[0.99093574,0.0036387548,0.00009977223,0.00387743,0.0012851997,0.000022111395,0.000005464633,0.000033556105,0.00010198788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9868105,0.0030798498,0.008007788,0.00055951066,0.0010893431,0.0004529857],"domain_scores_gemma":[0.9849135,0.003920355,0.009377444,0.0006364073,0.00080511114,0.00034712587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015506922,0.0003516681,0.0048465393,0.00016774706,0.00018761303,0.0000144175665,0.00051415147,0.0004622325,0.00009644892],"category_scores_gemma":[0.0045943474,0.00024494567,0.0008114353,0.00049175357,0.00086753495,0.00016744673,0.0002728503,0.0015762064,5.1692393e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088596623,0.004699942,0.93590844,0.0001400796,0.0023623072,0.00013803534,0.005734446,0.000007234222,0.0000052815262,0.000007962214,0.0019347407,0.048175562],"study_design_scores_gemma":[0.0082520805,0.0033303157,0.98157614,0.0007896359,0.0013355397,0.00003492365,0.0022362438,0.000014245195,0.000037662536,0.00033408537,0.0018898275,0.00016929723],"about_ca_topic_score_codex":0.0831752,"about_ca_topic_score_gemma":0.13271838,"teacher_disagreement_score":0.049543183,"about_ca_system_score_codex":0.00021265568,"about_ca_system_score_gemma":0.0076500108,"threshold_uncertainty_score":0.99885947},"labels":[],"label_agreement":null},{"id":"W4410803160","doi":"10.1200/jco.2025.43.16_suppl.10029","title":"Growth recovery in patients with <i>BRAF</i> altered pediatric low-grade gliomas (LGG) after discontinuation of tovorafenib.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Discontinuation; Glioma; Oncology; Internal medicine; Pediatrics; Cancer research","score_opus":0.025355997626448894,"score_gpt":0.366807481308581,"score_spread":0.3414514836821321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951447,0.00041877542,0.000029923616,0.0026828009,0.00088969787,0.00030703162,0.000005988254,0.000003625827,0.00051740644],"genre_scores_gemma":[0.9975511,0.00028867763,0.0009311535,0.0007867434,0.00037779586,0.00001206113,0.0000062482663,0.000010420207,0.000035840247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996986,0.00027046681,0.0020617137,0.00018224797,0.00031844183,0.000181133],"domain_scores_gemma":[0.99670565,0.001216819,0.0013314455,0.00016366795,0.00043447202,0.00014792258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009645386,0.0001367362,0.0012209621,0.0004318417,0.000012452541,0.0000066899593,0.00009520558,0.00023180088,0.0000309861],"category_scores_gemma":[0.001333657,0.000086792235,0.00032267792,0.00044529102,0.000078346464,0.00014097222,0.000037854457,0.0003946432,0.000003522418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006667589,0.00894794,0.9676673,0.00005357599,0.00024602082,0.00024544125,0.000032251428,0.0000084782705,0.000013802552,0.000030971016,0.001319555,0.014767094],"study_design_scores_gemma":[0.022263413,0.010851217,0.9649762,0.00023002502,0.0006016406,0.0000083352215,0.000013843188,0.0000055462156,0.00022796723,0.00036509542,0.0003899604,0.000066765504],"about_ca_topic_score_codex":0.000014478952,"about_ca_topic_score_gemma":0.000045823854,"teacher_disagreement_score":0.015595825,"about_ca_system_score_codex":0.00014915604,"about_ca_system_score_gemma":0.00071635284,"threshold_uncertainty_score":0.35392848},"labels":[],"label_agreement":null},{"id":"W4410803166","doi":"10.1200/jco.2025.43.16_suppl.tps10074","title":"A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children &lt; 12 years of age with <i>CBFA2T3::GLIS2</i> acute myeloid leukemia.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacokinetics; Open label; Oncology; Internal medicine; Adverse effect","score_opus":0.11076064407259632,"score_gpt":0.5383015413904161,"score_spread":0.42754089731781975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953318,0.00071253884,0.000014588075,0.0019073993,0.00013917933,0.0014229433,0.0000132230025,0.0000035545993,0.00045472843],"genre_scores_gemma":[0.9938397,0.0030383011,0.002178172,0.00063725264,0.00012367293,0.000008025147,0.0000017164667,0.000017316705,0.00015586939],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954267,0.0010248784,0.0023892866,0.00027925766,0.00059655635,0.00028331365],"domain_scores_gemma":[0.99305457,0.0047079767,0.0014273273,0.00027051524,0.00032151517,0.00021807411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044944244,0.00016730533,0.001739972,0.00022940928,0.000038824874,0.000017225288,0.00046333935,0.000044503144,0.000014081299],"category_scores_gemma":[0.005599004,0.00010604229,0.000072849645,0.00039472297,0.00063439057,0.00013493244,0.00054126856,0.001312195,3.7526914e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11408063,0.021539006,0.16371654,0.00012418246,0.0020029629,0.0068308655,0.0005903429,0.000111990186,0.008366315,0.00003727207,0.0008276532,0.68177223],"study_design_scores_gemma":[0.26354167,0.11988425,0.60830754,0.0006273716,0.0015528509,0.0014580654,0.00033827565,0.000538524,0.0007915891,0.000120697965,0.0026819583,0.00015719172],"about_ca_topic_score_codex":0.00005767308,"about_ca_topic_score_gemma":0.00012924607,"teacher_disagreement_score":0.68161505,"about_ca_system_score_codex":0.00007726219,"about_ca_system_score_gemma":0.0017142516,"threshold_uncertainty_score":0.6702935},"labels":[],"label_agreement":null},{"id":"W4410803189","doi":"10.1200/jco.2025.43.16_suppl.10023","title":"Does early phase study enrollment for pediatric oncology patients have an impact on symptom burden and quality of life (QOL)? A national Canadian study report.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"IWK Foundation; Montreal Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; London Health Sciences Centre; McMaster Children's Hospital; McMaster University; CancerCare Manitoba; Hospital for Sick Children; Stollery Children's Hospital; Alberta Children's Hospital; Children's Hospital of Eastern Ontario; University of Calgary; BC Children's Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Pediatric oncology; Cancer; Gerontology; Family medicine; Internal medicine; Nursing","score_opus":0.17339627223391552,"score_gpt":0.5680542759126007,"score_spread":0.3946580036786852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757166,0.00006400698,0.000019048728,0.007953712,0.0017514001,0.0020688316,0.000089858804,0.000008502776,0.00047296233],"genre_scores_gemma":[0.99493915,0.000028256773,0.00026935927,0.0022993842,0.0022619772,0.000034606623,0.000014828398,0.000018733715,0.00013369005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902855,0.0022641888,0.0055911113,0.00047411636,0.0010357505,0.00034928916],"domain_scores_gemma":[0.98489803,0.0074724234,0.0039972635,0.00037641116,0.00208123,0.0011746631],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016924815,0.00025609287,0.0027801723,0.0006117713,0.00010627758,0.00001862265,0.00026201457,0.00038758668,0.0000434666],"category_scores_gemma":[0.023778992,0.00016019623,0.0005043911,0.00021986978,0.00014633464,0.00011769559,0.00007072292,0.00087634387,0.0000010081843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015568175,0.024353826,0.9406585,0.000060725506,0.0014447431,0.00015227725,0.0028476855,0.000015550764,0.0000017411454,0.00002428036,0.0011181507,0.013754308],"study_design_scores_gemma":[0.04267495,0.11880059,0.8320716,0.00003250683,0.00068662927,0.000009771549,0.0030359512,0.000017570788,0.000001241517,0.00022459385,0.0023223937,0.00012219117],"about_ca_topic_score_codex":0.03429493,"about_ca_topic_score_gemma":0.07677348,"teacher_disagreement_score":0.10858692,"about_ca_system_score_codex":0.0009822423,"about_ca_system_score_gemma":0.013178887,"threshold_uncertainty_score":0.9924155},"labels":[],"label_agreement":null},{"id":"W4410803209","doi":"10.1200/jco.2025.43.16_suppl.8611","title":"Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Oncology; Internal medicine; Interim; Lung cancer","score_opus":0.07753471214883798,"score_gpt":0.4760811882307938,"score_spread":0.3985464760819558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924624,0.00029447585,0.00007016704,0.004197032,0.0010840666,0.00051126356,0.0000073762976,0.000004368947,0.0013688633],"genre_scores_gemma":[0.996251,0.00008694323,0.0012611058,0.0020903037,0.00020123484,0.0000063368902,0.000008099989,0.000010672397,0.00008429472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944529,0.00061303517,0.0041924324,0.00020802938,0.0003037589,0.00022985772],"domain_scores_gemma":[0.9948939,0.002228126,0.0022168872,0.00019041698,0.0003549817,0.0001156688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005506293,0.00014299189,0.001608278,0.00043972908,0.000014523402,0.0000051731467,0.00017812895,0.00030945384,0.000064307715],"category_scores_gemma":[0.005941436,0.00009737024,0.0003605471,0.0004987696,0.000221907,0.00006466174,0.000029465149,0.0009012028,0.0000010870073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80742145,0.00865796,0.058010504,0.000050652114,0.00021007315,0.00014246626,0.0001119947,0.000016079746,0.0002700965,0.0000027052822,0.0023105894,0.12279541],"study_design_scores_gemma":[0.6691703,0.059641507,0.24612054,0.0016966829,0.00014979915,0.00000422703,0.0001379222,0.00013952762,0.00037934192,0.000027560773,0.022427548,0.00010501296],"about_ca_topic_score_codex":0.00010915191,"about_ca_topic_score_gemma":0.00020159999,"teacher_disagreement_score":0.18811004,"about_ca_system_score_codex":0.00027043768,"about_ca_system_score_gemma":0.0027006795,"threshold_uncertainty_score":0.7112883},"labels":[],"label_agreement":null},{"id":"W4410803211","doi":"10.1200/jco.2025.43.16_suppl.tps7091","title":"TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Open label; Refractory (planetary science); CD8; Oncology; Multicenter study; Internal medicine; Cancer research; Clinical trial; Immunology; Antigen; Materials science; Metallurgy; Randomized controlled trial","score_opus":0.15544688119133895,"score_gpt":0.4794816699232975,"score_spread":0.32403478873195857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892247,0.00025358726,0.000014183197,0.0006818753,0.00086893246,0.0023200656,0.000015484358,0.00001083474,0.0066103716],"genre_scores_gemma":[0.99384457,0.0006648285,0.0012831353,0.0008013791,0.00017960973,0.000024795567,0.000007773698,0.000044926914,0.0031490014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99105,0.0022595085,0.004418959,0.0006314442,0.0010201787,0.00061992486],"domain_scores_gemma":[0.99237883,0.0034142307,0.0018492184,0.0007589636,0.0010927927,0.00050593837],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0058755605,0.00035595757,0.0027504377,0.00046431326,0.00006770981,0.00003816032,0.00092711515,0.0005884351,0.00086208346],"category_scores_gemma":[0.0018395355,0.00024763873,0.00018474126,0.0009780143,0.00028835257,0.00027004638,0.00027746477,0.0024583421,0.000017522289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4136163,0.2901079,0.21671645,0.00019937426,0.00046970038,0.013471045,0.00086020044,0.000033286862,0.0061804126,0.000010610949,0.008815539,0.04951916],"study_design_scores_gemma":[0.48168644,0.37392834,0.07245705,0.0006241063,0.00041479076,0.0001686551,0.002436066,0.00024553848,0.00051938643,0.000024878054,0.0671174,0.00037736417],"about_ca_topic_score_codex":0.00018601278,"about_ca_topic_score_gemma":0.0017416838,"teacher_disagreement_score":0.14425941,"about_ca_system_score_codex":0.0013809564,"about_ca_system_score_gemma":0.0027782484,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W4410803224","doi":"10.1200/jco.2025.43.16_suppl.8612","title":"Exploring decisional needs of patients considering first line treatment of advanced EGFR+ lung cancer: An interpretive descriptive study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Descriptive research; Oncology; Descriptive statistics; Internal medicine","score_opus":0.184280585907974,"score_gpt":0.5239373958316611,"score_spread":0.3396568099236871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954507,0.00085408473,0.0003492728,0.0006427215,0.0015611432,0.0005219902,0.000025929898,0.0000047813583,0.0005893806],"genre_scores_gemma":[0.9957275,0.0017599395,0.0020769802,0.00012840492,0.00015896739,0.000045250163,0.0000034769826,0.000010429875,0.00008905455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972911,0.00016177127,0.0020220438,0.00014117113,0.00024487075,0.00013903399],"domain_scores_gemma":[0.995528,0.0018246725,0.001302264,0.00016393705,0.0010046138,0.0001765533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039250756,0.00014223362,0.0013966799,0.00028659758,0.000042052052,0.0000032717783,0.00009161499,0.00009516368,0.000057747493],"category_scores_gemma":[0.0013034927,0.00009683305,0.00032000066,0.00023048175,0.00013323656,0.00020463247,0.000040550836,0.0002065532,3.44119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008989002,0.012906991,0.6786745,0.000040711588,0.002735366,0.00007001262,0.012027451,0.0007583756,0.00005027831,0.000056675446,0.000065201064,0.28362542],"study_design_scores_gemma":[0.028713426,0.070119664,0.8750269,0.001228509,0.003171739,0.000008554126,0.01678312,0.0002021252,0.00062247977,0.00012341236,0.0038920601,0.00010801725],"about_ca_topic_score_codex":0.0001494286,"about_ca_topic_score_gemma":0.00021707534,"teacher_disagreement_score":0.2835174,"about_ca_system_score_codex":0.0010596996,"about_ca_system_score_gemma":0.0021094412,"threshold_uncertainty_score":0.3948737},"labels":[],"label_agreement":null},{"id":"W4410803264","doi":"10.1200/jco.2025.43.16_suppl.e24048","title":"Preliminary effectiveness and acceptability of single-session acupuncture with infusion therapy at an academic cancer center.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acupuncture Treatment Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acupuncture; Session (web analytics); Center (category theory); Cancer; Physical therapy; Cancer therapy; Family medicine; Medical physics; Alternative medicine; Internal medicine; Pathology","score_opus":0.11501023962971628,"score_gpt":0.5287875520423431,"score_spread":0.4137773124126268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063855,0.0036939755,0.00006026755,0.0041931393,0.00031921905,0.0005920604,0.000004500009,0.000007899918,0.00049036863],"genre_scores_gemma":[0.9910793,0.0073217433,0.00064453925,0.0006006544,0.00022018186,0.000013657859,0.000002597139,0.0000095598725,0.00010777638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972427,0.0009099946,0.0010446947,0.00024182185,0.00036932388,0.00019146215],"domain_scores_gemma":[0.99417084,0.004058456,0.00082430284,0.0001941699,0.00053896254,0.00021325109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002062902,0.00022602803,0.0017875076,0.00012008853,0.00006901525,0.0000032313023,0.000129708,0.00043971214,0.000115197516],"category_scores_gemma":[0.0018123592,0.000082479666,0.00023675624,0.00016119723,0.0005401616,0.00013671743,0.00017627925,0.0009766413,3.164336e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047295388,0.0015068854,0.69688576,0.00015859892,0.0004520982,0.00006996109,0.00013727135,0.0000048678194,0.00484787,0.0000039053125,0.00037798216,0.24825938],"study_design_scores_gemma":[0.010787804,0.031176116,0.94404656,0.0004643302,0.0003508691,0.000091728056,0.00009856976,0.000008521193,0.0043405076,0.00009843901,0.008479815,0.000056732188],"about_ca_topic_score_codex":0.000020289517,"about_ca_topic_score_gemma":0.00004637386,"teacher_disagreement_score":0.24820264,"about_ca_system_score_codex":0.0003599674,"about_ca_system_score_gemma":0.0008025676,"threshold_uncertainty_score":0.4243075},"labels":[],"label_agreement":null},{"id":"W4410803274","doi":"10.1200/jco.2025.43.16_suppl.e24049","title":"Bridging the language gap in palliative oncology: A translation and validation of the Urdu version of EORTC’s QLQ-C15-PAL.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bridging (networking); Urdu; Oncology; Medical physics; Linguistics","score_opus":0.299340338883564,"score_gpt":0.5622682803986184,"score_spread":0.26292794151505444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98206925,0.002309998,0.0003783548,0.011289595,0.00041781645,0.00018908405,0.0000045110855,0.0000017492592,0.0033396292],"genre_scores_gemma":[0.9963803,0.0018545947,0.0009884236,0.00055649015,0.00014772498,0.0000012866388,0.0000019331414,0.0000037968919,0.00006543559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975101,0.0006670597,0.0014254205,0.00009178657,0.00021591078,0.00008972998],"domain_scores_gemma":[0.9941417,0.0040026386,0.0014053127,0.00011896673,0.00028949638,0.00004187737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027320478,0.0000727534,0.000833266,0.0001166036,0.000020912925,0.0000015271314,0.00012006958,0.00021922654,0.000019995388],"category_scores_gemma":[0.003647896,0.000040185107,0.0002320737,0.00023693593,0.00029835736,0.000055258544,0.00003487318,0.0005138126,4.0887562e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003430224,0.0006877934,0.77136284,0.00017070406,0.00032994512,0.000035863373,0.0073946696,0.0000993381,0.0046956846,0.00025100727,0.000914732,0.21062717],"study_design_scores_gemma":[0.011570099,0.004388898,0.93652254,0.0022774027,0.00078879413,0.000015017378,0.0063098483,0.0009970963,0.014650707,0.0008108148,0.02159137,0.00007741878],"about_ca_topic_score_codex":0.00007437647,"about_ca_topic_score_gemma":0.00010484595,"teacher_disagreement_score":0.21054976,"about_ca_system_score_codex":0.000088264474,"about_ca_system_score_gemma":0.0007108329,"threshold_uncertainty_score":0.43671358},"labels":[],"label_agreement":null},{"id":"W4410803316","doi":"10.1200/jco.2025.43.16_suppl.2521","title":"Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Biomarker; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.09818264285640337,"score_gpt":0.5118084556203576,"score_spread":0.4136258127639542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633425,0.0001234949,0.000004836003,0.0009630128,0.00014147168,0.0012870186,0.0000031866884,0.0000029596617,0.0011397768],"genre_scores_gemma":[0.99884325,0.00010103298,0.00014472358,0.0004002779,0.000035714886,0.000006984429,0.0000046178375,0.000015370735,0.00044800967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947621,0.0015007709,0.0026249762,0.00032444843,0.0004952266,0.00029245694],"domain_scores_gemma":[0.99573386,0.0019145383,0.0012435531,0.0004555029,0.00046798046,0.00018456428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048806285,0.00017582813,0.0022940997,0.0006445592,0.00007040522,0.000018631303,0.000498994,0.00019387297,0.0002626878],"category_scores_gemma":[0.0014008667,0.0001033374,0.00014467319,0.0017470832,0.0002840316,0.00011811966,0.00028120106,0.0014292774,8.2916154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024749689,0.07532785,0.8669836,0.000030828793,0.0014280634,0.0002744384,0.0002851305,0.00010589882,0.0025390368,0.0000031437187,0.0003739971,0.027898345],"study_design_scores_gemma":[0.16130349,0.028290126,0.8073136,0.0001605898,0.0006699503,0.0000035775192,0.00025836608,0.00015528538,0.00021075756,0.000011406579,0.0015425925,0.00008024408],"about_ca_topic_score_codex":0.000074540134,"about_ca_topic_score_gemma":0.00059573463,"teacher_disagreement_score":0.1365538,"about_ca_system_score_codex":0.00015427404,"about_ca_system_score_gemma":0.0007311084,"threshold_uncertainty_score":0.62095785},"labels":[],"label_agreement":null},{"id":"W4410803321","doi":"10.1200/jco.2025.43.16_suppl.11567","title":"Impact of time to relapse (TTR) and metastasectomy (MTS) on survival in leiomyosarcoma (LMS): A CanSaRCC study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Mount Sinai Hospital; University Health Network; University of Toronto; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastasectomy; Leiomyosarcoma; Oncology; Overall survival; Internal medicine; Surgery; Metastasis; Cancer","score_opus":0.09240302603704258,"score_gpt":0.49669780794724366,"score_spread":0.4042947819102011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915128,0.00048866065,0.0000059757854,0.0051272674,0.00026420483,0.00047720026,0.000010336898,0.0000039623133,0.0021096398],"genre_scores_gemma":[0.99828386,0.00013481895,0.00045727886,0.00074677565,0.00012326545,0.000009640777,0.0000013290987,0.000010865529,0.00023217348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653065,0.0007398451,0.0019751834,0.00022509915,0.0003114247,0.00021778022],"domain_scores_gemma":[0.99430686,0.0042599565,0.00062981556,0.00023994602,0.00022825644,0.00033514723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003261009,0.00016640393,0.002061159,0.00047614553,0.000019653653,0.0000064179912,0.00012361813,0.00017605728,0.00023707075],"category_scores_gemma":[0.002816197,0.0001053235,0.000471629,0.0003623072,0.000090575646,0.00004297587,0.00007072053,0.0006001255,0.000022833905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075958967,0.014868204,0.87753034,0.000012902137,0.0012935464,0.0020297968,0.00010757663,0.000025511064,0.00007201348,0.00003913986,0.0033916966,0.093033366],"study_design_scores_gemma":[0.016303077,0.038624525,0.9404498,0.00016997968,0.00054575474,0.0000813695,0.00010137997,0.000020692825,0.0000340941,0.000087916436,0.0035158086,0.00006564115],"about_ca_topic_score_codex":0.00040998013,"about_ca_topic_score_gemma":0.00033756546,"teacher_disagreement_score":0.09296773,"about_ca_system_score_codex":0.0002824419,"about_ca_system_score_gemma":0.001265502,"threshold_uncertainty_score":0.4294968},"labels":[],"label_agreement":null},{"id":"W4410803346","doi":"10.1200/jco.2025.43.16_suppl.tps7092","title":"waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; CHOP; Lymphoma; Diffuse large B-cell lymphoma; Internal medicine; Oncology; Nuclear medicine","score_opus":0.07439077906988986,"score_gpt":0.4476976849947862,"score_spread":0.37330690592489635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643211,0.0014192822,0.000031872576,0.008256332,0.0030390595,0.0003031313,0.000010340332,0.000018790495,0.022600127],"genre_scores_gemma":[0.99076504,0.0021248288,0.0008703426,0.0038493795,0.0005796295,0.00001010245,0.000010814154,0.00002074867,0.0017691253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99549085,0.00042744292,0.0028967133,0.0003367608,0.00038009018,0.00046813017],"domain_scores_gemma":[0.99346316,0.0042976597,0.0011079089,0.00035200478,0.00035841294,0.0004208608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017827816,0.00026845394,0.0021236497,0.0003395729,0.00004918232,0.000016981743,0.00022613454,0.00064788305,0.00015787846],"category_scores_gemma":[0.0036625126,0.00018950082,0.0007153404,0.00040563874,0.00012220831,0.00009488923,0.00011301538,0.0005660573,0.00010438645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08595608,0.14096299,0.42757735,0.00017313012,0.002477305,0.017165687,0.00034970406,0.00003860882,0.00017462394,0.002103406,0.048614867,0.27440625],"study_design_scores_gemma":[0.36010227,0.009030381,0.48001447,0.000294814,0.0010196199,0.00011182236,0.00022243409,0.0005852897,0.00036137868,0.00016732642,0.14791726,0.00017293476],"about_ca_topic_score_codex":0.00014716982,"about_ca_topic_score_gemma":0.0003174397,"teacher_disagreement_score":0.2742333,"about_ca_system_score_codex":0.0012792383,"about_ca_system_score_gemma":0.0039607817,"threshold_uncertainty_score":0.7727619},"labels":[],"label_agreement":null},{"id":"W4410803373","doi":"10.1200/jco.2025.43.16_suppl.10036","title":"Neurocognitive outcomes following 30.6-Gy whole-ventricular radiotherapy with 54-Gy total dose focal tumor bed boost for CNS non-germinomatous germ cell tumors: A Children’s Oncology Group study (ACNS1123).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Radiation therapy; Germ cell tumors; Neurocognitive; Germinoma; Germ cell; Radiation oncology; Nuclear medicine; Oncology; Internal medicine; Radiology; Chemotherapy","score_opus":0.030502848126993647,"score_gpt":0.4011230493815645,"score_spread":0.37062020125457085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884968,0.0007533081,0.0004214096,0.004783404,0.0015166106,0.0035768256,0.000026987347,0.000034961424,0.00038969342],"genre_scores_gemma":[0.99127907,0.00005067363,0.0023405924,0.005064754,0.0007476893,0.0003118138,0.000018814912,0.00007295788,0.00011360903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934961,0.00085820426,0.003530347,0.00073699787,0.00061429996,0.00076401257],"domain_scores_gemma":[0.9896037,0.00635144,0.0024248592,0.00042213823,0.00052335754,0.0006744841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002310662,0.0005862047,0.004450718,0.00052468793,0.0002003202,0.000049522187,0.00034751376,0.00044503566,0.00007138421],"category_scores_gemma":[0.0015978685,0.0003830428,0.0019147166,0.00039514014,0.00024011362,0.00018117717,0.00012083315,0.0012152574,0.000015661126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007081808,0.040759645,0.8750129,0.000054876233,0.0053288015,0.029422428,0.00046107033,0.000024627188,0.0003027071,0.000026732998,0.001765258,0.03975914],"study_design_scores_gemma":[0.08391905,0.081930324,0.82416403,0.00022378094,0.0037491205,0.0014711133,0.00077938597,0.00010612563,0.0002534918,0.000046804606,0.0030489438,0.00030785552],"about_ca_topic_score_codex":0.00007361375,"about_ca_topic_score_gemma":0.000068067384,"teacher_disagreement_score":0.076837234,"about_ca_system_score_codex":0.00065752637,"about_ca_system_score_gemma":0.0023840242,"threshold_uncertainty_score":0.99986213},"labels":[],"label_agreement":null},{"id":"W4410803408","doi":"10.1200/jco.2025.43.16_suppl.10035","title":"Survival and prognostic factors of patients with Ewing sarcoma at first recurrence following modern era multimodal therapy: A report from the Children’s Oncology Group (COG).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cog; Oncology; Internal medicine; Overall survival; Sarcoma; Ewing's sarcoma; Chemotherapy; Pathology","score_opus":0.06766401592635707,"score_gpt":0.3923971972346582,"score_spread":0.32473318130830114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223584,0.0026771652,0.000084940046,0.0031593384,0.00097566337,0.0006725501,0.000016186856,0.000008231699,0.00017011343],"genre_scores_gemma":[0.9971294,0.000590215,0.001572366,0.00044313236,0.00019288404,0.000016897711,0.000029180386,0.000016058397,0.000009896831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965892,0.0004918547,0.0019241306,0.00032800206,0.00042270985,0.00024410941],"domain_scores_gemma":[0.98664874,0.01095265,0.0016433548,0.00028380964,0.00027411658,0.00019731508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012862505,0.00021908348,0.0017013793,0.00008274495,0.00012713799,0.000010842374,0.0001810732,0.00030112002,0.00002577929],"category_scores_gemma":[0.0033142657,0.0001126742,0.00047443362,0.00014514748,0.00025586638,0.00008542828,0.00012126203,0.0007176572,7.1739976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029455654,0.003994507,0.8643169,0.000007078096,0.0016821104,0.00048024385,0.00023358357,0.000003857323,0.000005697996,0.000007923614,0.00016499951,0.12615757],"study_design_scores_gemma":[0.014740453,0.0075884536,0.9738735,0.00030316392,0.0010030421,0.00006302908,0.000079941885,0.000055837278,0.00002230708,0.00013448423,0.002043991,0.00009180909],"about_ca_topic_score_codex":0.00025182657,"about_ca_topic_score_gemma":0.0004798197,"teacher_disagreement_score":0.12606575,"about_ca_system_score_codex":0.00021292709,"about_ca_system_score_gemma":0.0007040763,"threshold_uncertainty_score":0.45947203},"labels":[],"label_agreement":null},{"id":"W4410803412","doi":"10.1200/jco.2025.43.16_suppl.e13696","title":"Dynamic prediction of cancer-associated thrombosis to guide prophylactic anticoagulation.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Thrombosis; Cancer; Intensive care medicine; Venous thromboembolism; Internal medicine; Oncology","score_opus":0.08602432913641311,"score_gpt":0.49113965493810313,"score_spread":0.40511532580169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710302,0.00030615286,0.00072684186,0.020350235,0.0022655395,0.00042726554,0.0000071016566,0.000012913397,0.004873758],"genre_scores_gemma":[0.99326056,0.0010632992,0.0020823544,0.0027947968,0.00016743831,0.000009557534,0.0000023906239,0.000009468625,0.0006101135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686205,0.00020239841,0.0023031344,0.00015317404,0.00031506576,0.00016419597],"domain_scores_gemma":[0.9968699,0.0006515421,0.0013883355,0.00017107358,0.0007605095,0.00015863862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020362213,0.00009787911,0.0015185444,0.00025000004,0.0000369356,0.0000057844973,0.00012872908,0.00023396459,0.00010853589],"category_scores_gemma":[0.003931878,0.00007465873,0.0003369512,0.0003573333,0.00008097011,0.0000700165,0.00006056402,0.00036036674,0.0000053934245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001494816,0.014350237,0.66280395,0.00043489563,0.004512118,0.00008202477,0.00031902624,0.0013104798,0.005235747,0.0011355461,0.07652677,0.23179437],"study_design_scores_gemma":[0.0029706284,0.0062911958,0.96629107,0.00038003604,0.0015247494,0.0000030865606,0.0000880265,0.0006428069,0.00016120159,0.00033653292,0.021265157,0.00004553102],"about_ca_topic_score_codex":0.00016723391,"about_ca_topic_score_gemma":0.00016562473,"teacher_disagreement_score":0.3034871,"about_ca_system_score_codex":0.0004152812,"about_ca_system_score_gemma":0.0013812823,"threshold_uncertainty_score":0.47071096},"labels":[],"label_agreement":null},{"id":"W4410803435","doi":"10.1200/jco.2025.43.16_suppl.tps3644","title":"Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natera","keywords":"Medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Oncology; Disease; Internal medicine; Colorectal cancer; Cancer; Breast cancer","score_opus":0.12887000329180764,"score_gpt":0.4832084056807142,"score_spread":0.35433840238890657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782379,0.0004639151,0.00009399012,0.016521178,0.0006437519,0.00029534486,0.000006572255,0.000007458326,0.00372988],"genre_scores_gemma":[0.99213964,0.00014025252,0.00026468787,0.0067361854,0.0004868675,0.000005079812,0.000010677308,0.000009712014,0.00020690696],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963997,0.00073148974,0.0017333154,0.00019460653,0.0007750312,0.00016582725],"domain_scores_gemma":[0.9956876,0.0015736382,0.001225285,0.00021408442,0.0009838081,0.0003155625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031578331,0.00013014622,0.0012093522,0.00021185279,0.000033268076,0.000004060383,0.00013565503,0.00017722102,0.00024411725],"category_scores_gemma":[0.005081401,0.00009180229,0.0005523623,0.00030446152,0.00024060349,0.000040177572,0.000023259618,0.00060996006,0.0000066020934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040844075,0.004917094,0.39183018,0.00010453138,0.0003954597,0.0003661949,0.00006218832,0.0019459468,0.0003881801,0.00007280068,0.00848165,0.5505917],"study_design_scores_gemma":[0.011606263,0.011881234,0.946332,0.00019555443,0.0010090182,0.000008804536,0.00004420033,0.010871454,0.0001093688,0.000437275,0.017428871,0.000075948956],"about_ca_topic_score_codex":0.000012432882,"about_ca_topic_score_gemma":0.00003404629,"teacher_disagreement_score":0.55450183,"about_ca_system_score_codex":0.00021776251,"about_ca_system_score_gemma":0.0044002794,"threshold_uncertainty_score":0.78059065},"labels":[],"label_agreement":null},{"id":"W4410803473","doi":"10.1200/jco.2025.43.16_suppl.e14628","title":"Comparative analysis of immunohistochemistry and imaging mass cytometry technologies for detection of clinical biomarkers in cancer tissues.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Medicine; Immunohistochemistry; Mass cytometry; Pathology; Cancer; Flow cytometry; Cancer research; Oncology; Internal medicine; Immunology; Biology; Phenotype","score_opus":0.10825918076697433,"score_gpt":0.5528176457700616,"score_spread":0.4445584650030873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798337,0.012737169,0.004114218,0.0018001223,0.0006398837,0.00019479441,0.000018482413,0.0000058661394,0.00065574504],"genre_scores_gemma":[0.990611,0.004155034,0.005005595,0.000100194295,0.00006460645,0.000007511673,0.0000015113278,0.0000035735875,0.00005095778],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965248,0.00013534025,0.002897975,0.00017749684,0.00014264425,0.00012175964],"domain_scores_gemma":[0.9947377,0.0025009352,0.0020780636,0.00015431806,0.0004690315,0.00005993972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031988728,0.00009339682,0.002530102,0.0006423717,0.000014544339,0.0000023674124,0.00010825422,0.00027965274,0.000017190212],"category_scores_gemma":[0.0028635564,0.00007308531,0.00062836887,0.00087723223,0.0005331885,0.000040459487,0.000042677784,0.0005009134,6.216352e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007493385,0.0006955083,0.36628464,0.00021771937,0.0062051155,0.000022164928,0.00005088404,0.000022542823,0.08346618,0.000012353948,0.00037006734,0.53515947],"study_design_scores_gemma":[0.020115012,0.005203152,0.7810665,0.00074002636,0.015324625,0.000025994455,0.0038203392,0.0026075924,0.14163437,0.0004421455,0.028808245,0.00021204211],"about_ca_topic_score_codex":0.000119568016,"about_ca_topic_score_gemma":0.000088957575,"teacher_disagreement_score":0.5349474,"about_ca_system_score_codex":0.00013604871,"about_ca_system_score_gemma":0.0007998441,"threshold_uncertainty_score":0.34281513},"labels":[],"label_agreement":null},{"id":"W4410803499","doi":"10.1200/jco.2025.43.16_suppl.e24056","title":"A post discharge palliative care pilot clinic for cancer patients.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Palliative care; Intensive care medicine; Internal medicine; Nursing","score_opus":0.36243274048489116,"score_gpt":0.6058018098403645,"score_spread":0.2433690693554733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684467,0.007561846,0.00034313457,0.010637911,0.003979154,0.0005757279,0.00013763079,0.000009197322,0.00830871],"genre_scores_gemma":[0.978172,0.0062012626,0.0047901757,0.0071527665,0.001206157,0.000026048101,0.000025035784,0.000018387758,0.0024081587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968148,0.00021175153,0.00234621,0.00018098748,0.00023590398,0.00021038036],"domain_scores_gemma":[0.99053323,0.004719933,0.0017124555,0.00013859547,0.0026927302,0.00020307252],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009810391,0.00013795569,0.0016720515,0.00013611114,0.000036778376,0.0000036027964,0.00016962846,0.00026193538,0.00015131496],"category_scores_gemma":[0.01114847,0.00009384851,0.00068156316,0.0001454665,0.00018689994,0.00006555935,0.0000484581,0.00059183204,0.000008094103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009754336,0.0019480886,0.9019025,0.00027246348,0.00087518163,0.000018358805,0.00085382536,0.000001332112,0.00007575866,0.0002943666,0.010342826,0.07366098],"study_design_scores_gemma":[0.015194433,0.029706111,0.47634715,0.0012907728,0.000867489,7.6082046e-7,0.0013490791,0.0000100158795,0.0003227742,0.00029298407,0.47452092,0.00009751102],"about_ca_topic_score_codex":0.000069352405,"about_ca_topic_score_gemma":0.00021468362,"teacher_disagreement_score":0.46417812,"about_ca_system_score_codex":0.00019652596,"about_ca_system_score_gemma":0.002242636,"threshold_uncertainty_score":0.99718106},"labels":[],"label_agreement":null},{"id":"W4410803503","doi":"10.1200/jco.2025.43.16_suppl.1037","title":"Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Immune system; Tumor microenvironment; Phenotype; Cancer; Cancer research; Oncology; Internal medicine; Immunology; Biology; Genetics; Gene","score_opus":0.07010473532947813,"score_gpt":0.4910602070998903,"score_spread":0.42095547177041215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810934,0.0007439127,0.0001371465,0.016948141,0.0006912334,0.00029475393,0.000023628187,0.0000016318087,0.000066123306],"genre_scores_gemma":[0.9945053,0.0038154223,0.0003218846,0.0007598373,0.00016173838,0.000008814734,0.0000012100933,0.000008718876,0.0004171039],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974819,0.00041065033,0.001530846,0.00013459231,0.00025630472,0.00018573151],"domain_scores_gemma":[0.9980101,0.000740384,0.0008508209,0.0001629291,0.00014920025,0.00008657306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019321365,0.000087145534,0.0009131583,0.000060022685,0.00003042592,0.0000054538946,0.00016130964,0.000118734315,0.00016929318],"category_scores_gemma":[0.001040655,0.000049426093,0.00013321097,0.00018943525,0.0003382013,0.000056566547,0.00011381384,0.000631097,0.0000012350131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009922213,0.0009149579,0.3157915,0.00019197431,0.00021147693,0.000067644265,0.00022730815,0.000023699728,0.045202944,0.000013913095,0.00004411003,0.62738824],"study_design_scores_gemma":[0.0049644047,0.0015803159,0.980448,0.0004788651,0.00010750683,0.00007147379,0.00012915766,0.00009646344,0.0043365727,0.0000493482,0.007697986,0.000039897626],"about_ca_topic_score_codex":0.0003094455,"about_ca_topic_score_gemma":0.0011280713,"teacher_disagreement_score":0.6646565,"about_ca_system_score_codex":0.00022372327,"about_ca_system_score_gemma":0.0014569183,"threshold_uncertainty_score":0.27418375},"labels":[],"label_agreement":null},{"id":"W4410803506","doi":"10.1200/jco.2025.43.16_suppl.11572","title":"Moving beyond the traditional two-step approach for prognosis prediction: The BayeSarc model.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Artificial intelligence; Computer science","score_opus":0.15999101279492334,"score_gpt":0.41896592669256294,"score_spread":0.2589749138976396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803506","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015448837,0.00019163385,0.94154376,0.045067515,0.0033020861,0.00035179153,0.0000053400604,0.000022445452,0.007970565],"genre_scores_gemma":[0.671088,0.00011037575,0.31485412,0.0104052555,0.003007043,0.00015481847,0.00000129079,0.000010434604,0.00036867146],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972756,0.0004671005,0.0014396423,0.0002370249,0.00038358758,0.00019702893],"domain_scores_gemma":[0.9935718,0.004660805,0.00096631615,0.00029700747,0.0004221933,0.00008186889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061580683,0.00010380393,0.00043180477,0.00007741632,0.0003092261,0.00007088694,0.0012242843,0.00019022072,0.0000059456875],"category_scores_gemma":[0.00095216464,0.000055595934,0.0004480212,0.0003040284,0.00025144493,0.0003531798,0.0001399106,0.0009095019,7.989533e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055312144,0.00095529424,0.0017240153,0.000028693868,0.0004722928,0.000005963013,0.0002595176,0.05502083,0.000028478098,0.14401716,0.119878314,0.6770563],"study_design_scores_gemma":[0.0015596625,0.0013731597,0.0033544467,0.000013264214,0.00010166217,0.000081698534,0.00005335095,0.8999659,0.000030028832,0.0605586,0.03285266,0.00005556749],"about_ca_topic_score_codex":0.0000026149273,"about_ca_topic_score_gemma":0.0000061100836,"teacher_disagreement_score":0.8449451,"about_ca_system_score_codex":0.00018262536,"about_ca_system_score_gemma":0.001573518,"threshold_uncertainty_score":0.39513838},"labels":[],"label_agreement":null},{"id":"W4410803602","doi":"10.1200/jco.2025.43.16_suppl.e24076","title":"Association of body mass index change and insulin resistance with survival during induction therapy in newly diagnosed multiple myeloma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Insulin resistance; Body mass index; Oncology; Internal medicine; Insulin","score_opus":0.0738720512615275,"score_gpt":0.3926911345884578,"score_spread":0.31881908332693026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991517,0.0012548186,0.000008442526,0.006302641,0.00036082458,0.00029068944,0.000003744091,0.000003807236,0.00025800572],"genre_scores_gemma":[0.9920026,0.006962995,0.00030549022,0.00031506186,0.00028175427,0.000018059327,0.0000020488226,0.0000064821047,0.000105481864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819475,0.00032049516,0.0009854133,0.00013607352,0.0002404515,0.00012281624],"domain_scores_gemma":[0.9968028,0.0016914324,0.0010341323,0.00009014153,0.00027595562,0.000105507985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011614523,0.00008902002,0.00081366237,0.00015893101,0.000022201244,0.000005079697,0.000046929534,0.00022770888,0.000011155543],"category_scores_gemma":[0.0013224311,0.0000617026,0.00011283616,0.00018993566,0.000053401993,0.00010887665,0.000014514065,0.0003706995,4.4389932e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009760968,0.0018586684,0.959704,0.000042445008,0.00048775808,0.00022203653,0.000110631765,0.0000031227992,0.0001251624,0.00002177569,0.000089439905,0.027574005],"study_design_scores_gemma":[0.025624447,0.0023454654,0.9697866,0.00029484488,0.0001703986,0.0000029028197,0.00014822511,0.000015515852,0.00026752768,0.00009533778,0.0012033042,0.00004542984],"about_ca_topic_score_codex":0.00007889135,"about_ca_topic_score_gemma":0.00058697123,"teacher_disagreement_score":0.027528575,"about_ca_system_score_codex":0.00026255564,"about_ca_system_score_gemma":0.0004153873,"threshold_uncertainty_score":0.25161588},"labels":[],"label_agreement":null},{"id":"W4410803628","doi":"10.1200/jco.2025.43.16_suppl.e24085","title":"Incidence and risk factors for venous thromboembolism after CAR T-cell therapy: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Venous thromboembolism; Meta-analysis; Incidence (geometry); Oncology; Surgery; Internal medicine; Thrombosis","score_opus":0.2845261523703347,"score_gpt":0.5438197238772523,"score_spread":0.2592935715069176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023635161,0.99445975,0.000041602492,0.00040370808,0.00019535815,0.004449645,0.00007843355,0.000006384015,0.00012879586],"genre_scores_gemma":[0.00007808042,0.99582523,0.00038967718,0.0013051094,0.00023267981,0.0002613112,0.000008112713,0.00004262178,0.0018572041],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98875266,0.003983581,0.005822081,0.0005167595,0.0005775566,0.00034734726],"domain_scores_gemma":[0.97003406,0.022454364,0.005598521,0.00066588185,0.0007451733,0.0005019832],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.012942517,0.00052670564,0.037323188,0.0005429691,0.000059163354,0.000033171724,0.0003781553,0.0009495306,0.0004966043],"category_scores_gemma":[0.009345386,0.00026758327,0.008743152,0.00056423893,0.00028643623,0.00007048293,0.00013587877,0.0021979883,0.0000034809302],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023614951,0.00062721566,0.00008128225,0.6577323,0.287965,0.0001763523,0.00006742465,9.871277e-8,1.5503707e-7,0.0000031945167,0.00037382264,0.05273697],"study_design_scores_gemma":[0.00093744847,0.003824979,0.0000817466,0.018755944,0.77909166,0.0001835402,0.0000152367975,0.0000011224454,1.432098e-7,0.00003685222,0.19690965,0.00016165123],"about_ca_topic_score_codex":0.000029523211,"about_ca_topic_score_gemma":0.000024758117,"teacher_disagreement_score":0.6389764,"about_ca_system_score_codex":0.00016697186,"about_ca_system_score_gemma":0.0027279495,"threshold_uncertainty_score":0.99997765},"labels":[],"label_agreement":null},{"id":"W4410803634","doi":"10.1200/jco.2025.43.16_suppl.tps7088","title":"Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Refractory (planetary science); Cohort; Internal medicine; Oncology; Lymphoma; Leukemia","score_opus":0.07794495170972114,"score_gpt":0.45810909371942043,"score_spread":0.3801641420096993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914145,0.0025034149,0.000030071194,0.00046306127,0.001175827,0.0017818075,0.00000735344,0.0000130460585,0.0026109454],"genre_scores_gemma":[0.9948391,0.0026211385,0.00030664468,0.0005189674,0.00038145742,0.000015761827,0.0000022071576,0.000041184412,0.0012735941],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9892978,0.0018540992,0.0065632937,0.00057016476,0.0010595765,0.0006550385],"domain_scores_gemma":[0.9825104,0.01214306,0.003147734,0.0010562724,0.0007041225,0.0004384115],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009704998,0.0003835996,0.0037593846,0.0005543922,0.00009337351,0.000011215281,0.00081895926,0.0008246819,0.00012466822],"category_scores_gemma":[0.018419541,0.000236447,0.0006492839,0.0012273645,0.0014222527,0.00009315532,0.00055384496,0.0011588454,0.000005755898],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.32295147,0.024440171,0.10014903,0.0028628327,0.006939384,0.0070736976,0.001981008,0.0025127132,0.003697421,0.00049969583,0.0042523304,0.5226402],"study_design_scores_gemma":[0.65317935,0.043290604,0.27055162,0.0025364927,0.00238131,0.0015312799,0.0007988302,0.012506042,0.0012668695,0.00015918794,0.011467867,0.0003305516],"about_ca_topic_score_codex":0.0009874288,"about_ca_topic_score_gemma":0.00059196714,"teacher_disagreement_score":0.5223097,"about_ca_system_score_codex":0.08897145,"about_ca_system_score_gemma":0.27978614,"threshold_uncertainty_score":0.98984873},"labels":[],"label_agreement":null},{"id":"W4410803696","doi":"10.1200/jco.2025.43.16_suppl.e18134","title":"Assessing mortality trends among patients with lip and oral cavity cancer due to tobacco consumption: A systematic analysis of the Global Burden of Disease-2021.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oral cavity; Tobacco use; Cancer; Disease; Environmental health; Consumption (sociology); Burden of disease; Internal medicine; Oncology; Dentistry; Population","score_opus":0.10548290366803363,"score_gpt":0.5002844309395109,"score_spread":0.39480152727147727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996322,0.00050956523,0.00004366126,0.0021730238,0.00042313483,0.00018441923,0.000029979345,0.0000017588023,0.00031245584],"genre_scores_gemma":[0.9993049,0.00008479871,0.00013749096,0.00033431032,0.00008553761,0.0000064370506,8.991245e-7,0.0000026815424,0.000042953096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727666,0.00047307933,0.0016218051,0.00014322872,0.0003673517,0.00011789405],"domain_scores_gemma":[0.9968281,0.00080423284,0.0013621637,0.00020603566,0.00059391576,0.00020560069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013218239,0.00009998454,0.0023141184,0.00012038252,0.000042583644,0.000007982071,0.00010393162,0.00010071524,0.000036317077],"category_scores_gemma":[0.0017159319,0.000052244475,0.00036187144,0.00071125483,0.0003066324,0.000073387295,0.00008036215,0.00022619683,1.15556446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009671696,0.0003945453,0.9839084,0.0008947621,0.0037301667,0.000022672917,0.000079650985,0.00007896329,0.0000012336833,0.000021156406,0.00012150155,0.009779737],"study_design_scores_gemma":[0.002255027,0.0009052451,0.9824007,0.0028761565,0.011203442,0.0000015631813,0.00012484532,0.00012628,0.0000014915586,0.000015122172,0.000047214915,0.000042921314],"about_ca_topic_score_codex":0.00047026345,"about_ca_topic_score_gemma":0.0024114263,"teacher_disagreement_score":0.009736816,"about_ca_system_score_codex":0.00019383694,"about_ca_system_score_gemma":0.0008951095,"threshold_uncertainty_score":0.21304679},"labels":[],"label_agreement":null},{"id":"W4410803724","doi":"10.1200/jco.2025.43.16_suppl.1062","title":"Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech","keywords":"Medicine; Pharmacokinetics; Paclitaxel; Pharmacology; Internal medicine; Oncology; Chemotherapy","score_opus":0.08265775153649609,"score_gpt":0.5225800354404776,"score_spread":0.4399222839039815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319285,0.0005037717,0.00026631993,0.002627488,0.00036767407,0.0014245546,0.00001591738,0.00000934082,0.0015920781],"genre_scores_gemma":[0.99626493,0.0011587174,0.0017028442,0.00041442554,0.00013317398,0.000024961682,0.0000024584817,0.000034141678,0.0002643672],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933777,0.0015996973,0.0032002826,0.0004213145,0.0009188299,0.00048218627],"domain_scores_gemma":[0.9922868,0.0041164923,0.0017766797,0.00036416846,0.0010175571,0.0004382878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004629866,0.0002837725,0.002605881,0.0005840418,0.000057905843,0.00001776695,0.0003485095,0.00020264072,0.00004454132],"category_scores_gemma":[0.004649551,0.00021109938,0.00017526207,0.00070817256,0.0005996572,0.00028099134,0.00026638518,0.002215228,0.0000026918672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12291964,0.07181705,0.31642884,0.00093544775,0.0007719015,0.003892792,0.000635145,0.00029120815,0.0004087698,0.00002633016,0.0015896845,0.4802832],"study_design_scores_gemma":[0.14481193,0.2739815,0.56793946,0.0026288184,0.000788459,0.00024368535,0.001373604,0.0011117378,0.0004824604,0.00022922968,0.006157469,0.00025161033],"about_ca_topic_score_codex":0.00007347711,"about_ca_topic_score_gemma":0.00008312596,"teacher_disagreement_score":0.48003158,"about_ca_system_score_codex":0.0003588865,"about_ca_system_score_gemma":0.003381808,"threshold_uncertainty_score":0.96241874},"labels":[],"label_agreement":null},{"id":"W4410803745","doi":"10.1200/jco.2025.43.16_suppl.8605","title":"MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Cancer; Cancer research; Internal medicine; Oncology; Pathology; Colorectal cancer","score_opus":0.08510264118710671,"score_gpt":0.5179413332001931,"score_spread":0.4328386920130864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9258007,0.006563811,0.004646112,0.036340397,0.0065728673,0.0018320588,0.0006219058,0.00003853118,0.017583657],"genre_scores_gemma":[0.9484977,0.0026530265,0.025521627,0.0081344545,0.0019355824,0.00011900897,0.00024082772,0.000049117174,0.012848649],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596006,0.00024057881,0.0028750813,0.00034099963,0.00025171821,0.00033158078],"domain_scores_gemma":[0.9921338,0.004680052,0.0016671123,0.00027386378,0.00087497116,0.00037019944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015565282,0.00022295972,0.0017170211,0.00018589757,0.0000970124,0.000021021155,0.0001963235,0.00029326678,0.00024134715],"category_scores_gemma":[0.002313131,0.00015218562,0.00062787917,0.00023729843,0.00012308075,0.000093733826,0.00004442125,0.0006863008,0.000015988668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0525203,0.01741162,0.054989446,0.0007974554,0.023561597,0.0022450825,0.002243189,0.001053323,0.0020325312,0.0004148771,0.39669102,0.44603953],"study_design_scores_gemma":[0.18563025,0.012121409,0.10073109,0.0014395093,0.030062169,0.00008131844,0.0008356487,0.004270948,0.0012735246,0.0027639095,0.6603111,0.00047914826],"about_ca_topic_score_codex":0.0005723424,"about_ca_topic_score_gemma":0.00037735442,"teacher_disagreement_score":0.4455604,"about_ca_system_score_codex":0.00048576834,"about_ca_system_score_gemma":0.005370809,"threshold_uncertainty_score":0.95275843},"labels":[],"label_agreement":null},{"id":"W4410803799","doi":"10.1200/jco.2025.43.16_suppl.e18132","title":"Real-world treatment outcomes and clinicopathologic determinants of response for patients with advanced thyroid cancer treated with first-line lenvatinib.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Lenvatinib; Medicine; Oncology; Thyroid cancer; Internal medicine; Cancer","score_opus":0.07360382656837233,"score_gpt":0.46957727163346,"score_spread":0.3959734450650877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417496,0.00059895037,0.000016793181,0.0037873217,0.00024291393,0.0009598702,0.000060033984,0.000010076414,0.00014907206],"genre_scores_gemma":[0.9867238,0.0072429655,0.004541384,0.00058308634,0.00007996104,0.0001440505,0.00000551256,0.00002101523,0.00065827277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969524,0.00026036546,0.0020210957,0.00031221917,0.00021086146,0.00024307017],"domain_scores_gemma":[0.99028987,0.0065636057,0.002050962,0.0002582382,0.00062904356,0.00020827352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009781218,0.0002577492,0.0023937589,0.0002078115,0.000059945825,0.000005447364,0.00008951807,0.00018463914,0.000015848485],"category_scores_gemma":[0.0012259099,0.00012819239,0.00030645783,0.00020295917,0.00026205293,0.00007314057,0.000025924024,0.00020994544,3.997025e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093202524,0.00451039,0.7913532,0.000055052868,0.00059583987,0.00013352967,0.00003624051,0.000023419201,0.000008712448,0.000009827743,0.00017007258,0.10990117],"study_design_scores_gemma":[0.051370677,0.11677912,0.8251876,0.0005414439,0.0014471852,0.00001084152,0.000029692479,0.000011053968,0.00030206103,0.000033021486,0.004193069,0.00009422877],"about_ca_topic_score_codex":0.00011039485,"about_ca_topic_score_gemma":0.0025192583,"teacher_disagreement_score":0.11226873,"about_ca_system_score_codex":0.00035042517,"about_ca_system_score_gemma":0.0015702138,"threshold_uncertainty_score":0.52275336},"labels":[],"label_agreement":null},{"id":"W4410803859","doi":"10.1200/jco.2025.43.16_suppl.e24092","title":"Outcomes of patients treated with dabrafenib and trametinib who developed pyrexia syndrome and severe/complicated pyrexia syndrome.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dabrafenib; Trametinib; Internal medicine; Cancer; Metastatic melanoma; Vemurafenib; MAPK/ERK pathway; Kinase","score_opus":0.02970780126378084,"score_gpt":0.35829007945581237,"score_spread":0.3285822781920315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997292,0.00060055667,0.0002176722,0.00043747222,0.00013410482,0.00018767893,0.000011064931,0.0000053794247,0.0011140666],"genre_scores_gemma":[0.99610174,0.0007901918,0.001918564,0.0005020017,0.00002611538,0.0000049705873,0.00001805089,0.000017942424,0.00062043476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740374,0.00027974334,0.0015674084,0.0003368231,0.00019003346,0.00022225194],"domain_scores_gemma":[0.99753904,0.00043723363,0.0011270902,0.00022317293,0.0004892569,0.0001841808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008861816,0.00022336586,0.0012711723,0.00010972857,0.00005571232,0.000015576872,0.00026780352,0.00051376194,0.000014094743],"category_scores_gemma":[0.0011547463,0.00015260845,0.00015457867,0.00018423496,0.0004922213,0.000013668321,0.00014052694,0.0003887249,8.236474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001750988,0.00066736154,0.9795918,0.00011793133,0.0008863104,0.000114591545,0.000022108365,0.0000063720254,0.0014191784,0.00006772417,0.0005952057,0.014760437],"study_design_scores_gemma":[0.00648752,0.006592991,0.9748415,0.00010725983,0.00027217413,0.00047979556,0.000046925277,0.000010789421,0.0025468755,0.00019826545,0.008222453,0.0001935047],"about_ca_topic_score_codex":0.000009233141,"about_ca_topic_score_gemma":0.000008447574,"teacher_disagreement_score":0.014566933,"about_ca_system_score_codex":0.000024709692,"about_ca_system_score_gemma":0.0007036082,"threshold_uncertainty_score":0.62231916},"labels":[],"label_agreement":null},{"id":"W4410803893","doi":"10.1200/jco.2025.43.16_suppl.e19504","title":"Tocilizumab prophylaxis for outpatient administration of teclistamab in relapsed/refractory multiple myeloma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Tocilizumab; Multiple myeloma; Refractory (planetary science); Internal medicine; Oncology; Rheumatoid arthritis","score_opus":0.11591799416245513,"score_gpt":0.4818491829674907,"score_spread":0.36593118880503556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938344,0.00039115053,0.00032739106,0.0019962713,0.000625673,0.00091596204,0.000016676746,0.0000051525035,0.0018873352],"genre_scores_gemma":[0.99303955,0.00012464973,0.005830792,0.00019213083,0.0001742729,0.00003442924,0.000010117602,0.000009193754,0.00058487064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99637365,0.0003228213,0.0025350123,0.00018883025,0.00034750273,0.0002321976],"domain_scores_gemma":[0.9939123,0.0037905958,0.0011378721,0.00020601036,0.0007343025,0.00021892699],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021079143,0.000118905664,0.0011967241,0.00030115116,0.000028106107,0.0000047292356,0.00013524292,0.00041693228,0.000034576482],"category_scores_gemma":[0.018227614,0.00008516095,0.00044522726,0.00020110719,0.00016974795,0.00006390751,0.000037187,0.00073099,0.0000034860216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07527791,0.010481208,0.33517146,0.00031502705,0.00046510925,0.0004947909,0.00011175941,0.000010406504,0.0007321002,0.00021168597,0.0014082394,0.5753203],"study_design_scores_gemma":[0.049219824,0.081519514,0.837229,0.00036264415,0.00016946689,0.000045794717,0.00023289646,0.0005315699,0.0017172426,0.0006387132,0.028245702,0.000087613276],"about_ca_topic_score_codex":0.000032729477,"about_ca_topic_score_gemma":0.00027473917,"teacher_disagreement_score":0.5752327,"about_ca_system_score_codex":0.00034413967,"about_ca_system_score_gemma":0.0035723646,"threshold_uncertainty_score":0.99004227},"labels":[],"label_agreement":null},{"id":"W4410803897","doi":"10.1200/jco.2025.43.16_suppl.3612","title":"Multicentric evaluation of an artificial intelligence model to stratify stage II colon cancer patients from whole slide images.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Colorectal cancer; Cancer; Internal medicine; Oncology; Artificial intelligence; Pathology","score_opus":0.16159546099774189,"score_gpt":0.5412015697004228,"score_spread":0.37960610870268086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749006,0.00015910673,0.014829333,0.007999832,0.0012680984,0.00032146528,0.000019288163,0.0000054451752,0.0004968177],"genre_scores_gemma":[0.9799302,0.00009116111,0.016979868,0.0024367184,0.0003985285,0.0000055920445,0.000010312731,0.000009474772,0.00013814351],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99626976,0.0005093474,0.0021510632,0.00020871001,0.0006837099,0.00017740339],"domain_scores_gemma":[0.99610066,0.0009257541,0.0011555344,0.00017077615,0.0013241546,0.00032314035],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004896709,0.000106355474,0.0008891348,0.00018620005,0.000054176504,0.000010655102,0.0002013756,0.00021501645,0.00014046035],"category_scores_gemma":[0.012987626,0.000083210805,0.00018448349,0.00021366322,0.00012397068,0.0001124593,0.00007031785,0.00095443765,0.0000032860305],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021317792,0.0029638072,0.01580873,0.00002441777,0.00019251667,0.000025913485,0.00038060127,0.05406406,0.004786718,0.00010968134,0.0013845033,0.91812724],"study_design_scores_gemma":[0.0039996696,0.0052204193,0.086921066,0.00027454682,0.0010113163,0.0000017773596,0.0002397942,0.8940463,0.0022672226,0.0029182187,0.002992511,0.00010713018],"about_ca_topic_score_codex":0.00018909649,"about_ca_topic_score_gemma":0.00008563019,"teacher_disagreement_score":0.9180201,"about_ca_system_score_codex":0.0002474554,"about_ca_system_score_gemma":0.002493229,"threshold_uncertainty_score":0.9953264},"labels":[],"label_agreement":null},{"id":"W4410803978","doi":"10.1200/jco.2025.43.16_suppl.3606","title":"Analysis of early onset colorectal cancer: Implications for research and clinical practice.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Clinical Practice; Cancer; Oncology; Internal medicine; Family medicine","score_opus":0.302031911276797,"score_gpt":0.6302146740275277,"score_spread":0.3281827627507307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97070366,0.0008772253,0.0013841031,0.023881448,0.00072933565,0.0003109115,0.000022184098,0.000007047019,0.002084057],"genre_scores_gemma":[0.9919574,0.001910031,0.004756574,0.0006585845,0.0004622586,0.000024095243,0.0000027433516,0.0000063888306,0.0002218693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629897,0.0006356979,0.0023961314,0.00023091155,0.00024933284,0.00018894458],"domain_scores_gemma":[0.9738209,0.021572003,0.0013114775,0.00017014332,0.0028838154,0.00024163412],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011393451,0.000076371995,0.0014409592,0.0006051225,0.00008510505,0.000011157399,0.0001273689,0.00040525786,0.000017069136],"category_scores_gemma":[0.025520338,0.000059926246,0.00063883106,0.001178161,0.00047269615,0.000086468695,0.000064098895,0.0010844122,5.24606e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042441256,0.0010797741,0.6538401,0.000021135122,0.003755539,0.000008366643,0.000039582155,0.0000071274676,0.000054533142,0.0002831492,0.003640956,0.29482847],"study_design_scores_gemma":[0.0032862446,0.041787058,0.91794133,0.00005513148,0.004280928,0.000037218248,0.00011726574,0.00034482218,0.00004726953,0.0006964072,0.031365305,0.000041033505],"about_ca_topic_score_codex":0.00024262203,"about_ca_topic_score_gemma":0.0006165838,"teacher_disagreement_score":0.29478744,"about_ca_system_score_codex":0.00015843613,"about_ca_system_score_gemma":0.0029382885,"threshold_uncertainty_score":0.9826881},"labels":[],"label_agreement":null},{"id":"W4410804010","doi":"10.1200/jco.2025.43.16_suppl.6033","title":"Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.0502117729583029,"score_gpt":0.4221898160640512,"score_spread":0.37197804310574833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962839,0.0003273678,0.00022856022,0.002062953,0.00031886212,0.00048389807,0.0000047436606,0.000003611889,0.000286143],"genre_scores_gemma":[0.9968398,0.00018582036,0.0021212962,0.0007608239,0.00004711012,0.0000042837555,0.000010322221,0.000010568355,0.000019952748],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99646974,0.0005790119,0.002256353,0.0001816501,0.000324266,0.00018900313],"domain_scores_gemma":[0.99544036,0.0025896993,0.0014090723,0.00011082231,0.00035198795,0.00009807057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025266358,0.00014305998,0.0012677009,0.0003534517,0.000024103676,0.000005843238,0.00009366679,0.00014559984,0.0000549713],"category_scores_gemma":[0.002003633,0.00008579186,0.00012558208,0.00045133106,0.00025990102,0.00007638851,0.000021027312,0.00067181396,3.016891e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5047111,0.005520203,0.29449776,0.0001756994,0.00033012478,0.00014267201,0.00016843005,0.0000664816,0.00002328902,0.000023203313,0.00013406623,0.19420695],"study_design_scores_gemma":[0.13520941,0.03298365,0.82772297,0.0012978633,0.00024151089,0.000014570324,0.00010908651,0.00026694723,0.00005130769,0.000025882617,0.0019913728,0.0000854299],"about_ca_topic_score_codex":0.00005276922,"about_ca_topic_score_gemma":0.00032111243,"teacher_disagreement_score":0.5332252,"about_ca_system_score_codex":0.00024035246,"about_ca_system_score_gemma":0.0023411566,"threshold_uncertainty_score":0.4153111},"labels":[],"label_agreement":null},{"id":"W4410804033","doi":"10.1200/jco.2025.43.16_suppl.6020","title":"Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Agonist; Oncology; Internal medicine; Basal cell; Cancer; Immunotherapy; Receptor","score_opus":0.0827834370328013,"score_gpt":0.40874124727580385,"score_spread":0.3259578102430025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956072,0.0014791758,0.000013567504,0.0005234398,0.0015066167,0.0005957835,0.00007720157,0.0000029538733,0.00019405155],"genre_scores_gemma":[0.99946386,0.000059376656,0.00006390403,0.0001858231,0.000026388214,0.0000037090663,0.000017479271,0.000011378215,0.00016810434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947552,0.0021762308,0.0023902452,0.00030479784,0.0001319736,0.00024152087],"domain_scores_gemma":[0.9929129,0.003769588,0.002239169,0.00073034223,0.00031219725,0.000035793633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014934358,0.00020508544,0.0012813004,0.0001338096,0.00015099639,0.000008768761,0.00094938354,0.00022634614,0.00006457561],"category_scores_gemma":[0.004135688,0.00010773843,0.00015963017,0.00024287817,0.0005509139,0.00010152515,0.0007985885,0.00119175,0.0000028864758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19297792,0.041072566,0.6970432,0.00018672863,0.0007790226,0.00009621962,0.0035091836,0.00013842604,0.004060999,0.000032290365,0.0019754055,0.058128063],"study_design_scores_gemma":[0.083047725,0.04086116,0.86962605,0.0004608086,0.00059130247,0.000035584893,0.0017618375,0.000118332755,0.0013708366,0.00005800162,0.0019343664,0.00013401797],"about_ca_topic_score_codex":0.0006874188,"about_ca_topic_score_gemma":0.0012336496,"teacher_disagreement_score":0.17258286,"about_ca_system_score_codex":0.00008375003,"about_ca_system_score_gemma":0.0012187043,"threshold_uncertainty_score":0.5177627},"labels":[],"label_agreement":null},{"id":"W4410804167","doi":"10.1200/jco.2025.43.16_suppl.e15728","title":"A gene-panel blood test for the detection of colorectal adenomas and cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Winnipeg","funders":"Research Manitoba","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Blood test; Cancer; Cancer research","score_opus":0.10771692740169021,"score_gpt":0.4490413259281752,"score_spread":0.341324398526485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847391,0.0064670094,0.0005081883,0.0053139953,0.0021695301,0.00039915988,0.0000085846195,0.0000043518307,0.00039008184],"genre_scores_gemma":[0.99387866,0.002437832,0.0020405238,0.0008026806,0.0005942924,0.000026190264,2.3094658e-7,0.000008731157,0.00021084951],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99815464,0.00010113763,0.0013018537,0.0001333764,0.00016721526,0.00014175291],"domain_scores_gemma":[0.9904436,0.007904622,0.0009171662,0.00011190686,0.00051280373,0.00010989856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015159601,0.00009229061,0.00082763267,0.000080692684,0.000049358485,0.0000044268895,0.00012718896,0.00029241043,0.000027240294],"category_scores_gemma":[0.0073455316,0.000056239784,0.0002776393,0.00014566025,0.00032498193,0.00002263063,0.000046409223,0.0005036081,3.2525307e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010547761,0.0013089535,0.27275646,0.00017851942,0.0014444583,0.000041280844,0.00016056994,0.00004067768,0.11548286,0.00003415655,0.0012408309,0.5967635],"study_design_scores_gemma":[0.010929865,0.029653927,0.85768694,0.00014348756,0.0025928246,0.00038555212,0.00016573523,0.00055866496,0.06579609,0.00049195584,0.031508375,0.000086567874],"about_ca_topic_score_codex":0.00003642956,"about_ca_topic_score_gemma":0.00018304928,"teacher_disagreement_score":0.5966769,"about_ca_system_score_codex":0.00009206593,"about_ca_system_score_gemma":0.0016946322,"threshold_uncertainty_score":0.8793818},"labels":[],"label_agreement":null},{"id":"W4410804207","doi":"10.1200/jco.2025.43.16_suppl.e18040","title":"Real-world effectiveness and healthcare utilization of nivolumab for recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC): A real-world population-based study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Head and neck; Basal cell; Oncology; Head and neck cancer; Head and neck squamous-cell carcinoma; Population; Metastatic melanoma; Internal medicine; Surgery; Cancer; Environmental health; Immunotherapy","score_opus":0.15899343172648467,"score_gpt":0.5083761069509866,"score_spread":0.3493826752245019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445224,0.0018594208,0.0001014794,0.001881578,0.0004039969,0.0010877254,0.000017536073,0.0000050170916,0.00019100336],"genre_scores_gemma":[0.997441,0.000721064,0.001437172,0.00020049379,0.00008908195,0.000023780729,0.0000042676334,0.000011991343,0.00007116689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967712,0.00068068656,0.0019403462,0.00023738015,0.00020523371,0.00016515602],"domain_scores_gemma":[0.9921289,0.0057673897,0.0011945459,0.00013658447,0.0005986371,0.0001739209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002359356,0.00014748338,0.002096408,0.00034193913,0.00007472948,0.0000041224225,0.000051901203,0.0000969589,0.00000442985],"category_scores_gemma":[0.0016236871,0.00010565207,0.00014915189,0.00032482774,0.00014375665,0.000047688696,0.000041614192,0.0002972493,3.993413e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017850496,0.0017618161,0.9068666,0.0025390899,0.00012733218,0.000024928991,0.00019278034,0.0000059954054,0.000024451696,0.00017580304,0.00013690078,0.070293814],"study_design_scores_gemma":[0.018310754,0.038931943,0.93990487,0.00066154415,0.00071473065,0.0000056004137,0.00027461583,0.0004364407,0.00010129023,0.00023301042,0.0003564051,0.00006882371],"about_ca_topic_score_codex":0.0014661839,"about_ca_topic_score_gemma":0.014676117,"teacher_disagreement_score":0.07022499,"about_ca_system_score_codex":0.00014982896,"about_ca_system_score_gemma":0.0012303982,"threshold_uncertainty_score":0.8189618},"labels":[],"label_agreement":null},{"id":"W4410804220","doi":"10.1200/jco.2025.43.16_suppl.6013","title":"Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Chemoradiotherapy; Head and neck; Oncology; Internal medicine; Head and neck squamous-cell carcinoma; Head and neck cancer; Surgery; Overall survival; Radiation therapy; Cancer; Pathology; Immunotherapy; Alternative medicine","score_opus":0.07645688324040456,"score_gpt":0.46729021821600475,"score_spread":0.3908333349756002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824718,0.005140612,0.0007934255,0.004538685,0.002685204,0.0026450774,0.0000469605,0.0000084259145,0.0016698107],"genre_scores_gemma":[0.9938538,0.0029181524,0.000730399,0.00079614756,0.0007431076,0.000055167777,0.0000037333757,0.000024106352,0.00087539677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993383,0.0011489192,0.004358286,0.00033702148,0.00042931782,0.00034346868],"domain_scores_gemma":[0.97832656,0.017242804,0.0029719004,0.00035389935,0.00084614364,0.00025870692],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004241504,0.00028962275,0.0049888287,0.00016238062,0.00007784875,0.000008381805,0.00030824848,0.00045556336,0.000023218972],"category_scores_gemma":[0.012558146,0.00015980907,0.0011151785,0.000246714,0.0010285303,0.00006562352,0.00009503648,0.0008913974,2.9306418e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9189345,0.003102696,0.0007253745,0.00057096744,0.0004294355,0.00009330754,0.00031736385,0.000018895511,0.00061600044,0.00004430379,0.0030406527,0.07210649],"study_design_scores_gemma":[0.94033283,0.043149505,0.0039567584,0.00058035186,0.00102073,0.00010255268,0.00007902081,0.00039091753,0.0022922545,0.000051658506,0.007913116,0.0001302996],"about_ca_topic_score_codex":0.00002940466,"about_ca_topic_score_gemma":0.0001397793,"teacher_disagreement_score":0.071976185,"about_ca_system_score_codex":0.00022226972,"about_ca_system_score_gemma":0.0051784245,"threshold_uncertainty_score":0.9957595},"labels":[],"label_agreement":null},{"id":"W4410804423","doi":"10.1200/jco.2025.43.16_suppl.e13125","title":"Sociodemographic and clinical determinants of survival in metastatic breast cancer: A population-based analysis from a Latin American developing country.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Juravinski Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Latin Americans; Breast cancer; Cancer; Oncology; Population; Metastatic breast cancer; Developing country; Internal medicine; Demography; Gynecology; Environmental health; Economic growth","score_opus":0.09807038458978948,"score_gpt":0.4293783468328729,"score_spread":0.33130796224308345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936538,0.0010393815,0.0018327195,0.0020943317,0.00080856466,0.00009034747,0.00024034984,0.0000031108991,0.00023742177],"genre_scores_gemma":[0.99235827,0.0023695973,0.003954497,0.0011283032,0.00015442622,0.0000032811424,0.000004626775,0.000009095426,0.000017920118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99412584,0.00021893562,0.0050859246,0.00029387156,0.000055300978,0.00022014255],"domain_scores_gemma":[0.9913251,0.003077233,0.005155216,0.00016433177,0.00014686125,0.00013125232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042521083,0.00014308677,0.0032513868,0.00065253983,0.000035594257,0.00001862397,0.0002330168,0.00021380017,0.00006418874],"category_scores_gemma":[0.0019216512,0.00014067143,0.00054581504,0.00083601655,0.00032811114,0.00015269472,0.000043002652,0.0004908542,0.00000162876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045397234,0.00023587003,0.93857616,0.000014487079,0.00077209633,0.000009886836,0.000028866692,0.00020179269,1.2135126e-7,0.0016412359,0.000030116733,0.058035422],"study_design_scores_gemma":[0.0026359772,0.00032141924,0.9829655,0.000067107394,0.00033945715,6.494716e-7,0.000056439934,0.005243396,3.8617347e-7,0.007222948,0.0010174691,0.00012922708],"about_ca_topic_score_codex":0.011524471,"about_ca_topic_score_gemma":0.022503879,"teacher_disagreement_score":0.057906196,"about_ca_system_score_codex":0.00020372524,"about_ca_system_score_gemma":0.0010283635,"threshold_uncertainty_score":0.9953329},"labels":[],"label_agreement":null},{"id":"W4410804527","doi":"10.1200/jco.2025.43.16_suppl.e13135","title":"Phase 1 study of the anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) + paclitaxel for previously untreated advanced triple negative breast cancer (TNBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Monoclonal antibody; Pembrolizumab; Triple-negative breast cancer; Antibody; Trastuzumab; Paclitaxel; Breast cancer; Cancer research; Virology; Cancer; Immunology; Immunotherapy; Immune system; Internal medicine","score_opus":0.11285010697904874,"score_gpt":0.5465878771365084,"score_spread":0.4337377701574596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778116,0.0023681964,0.0003272116,0.011001653,0.003637154,0.0035756016,0.00034769214,0.000022913346,0.00090798683],"genre_scores_gemma":[0.99280715,0.0021412482,0.00094567944,0.0014590124,0.00066601933,0.0001309328,0.000009831114,0.000052567495,0.0017875519],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9915359,0.0016604788,0.0044700126,0.00057188567,0.0010174909,0.0007442589],"domain_scores_gemma":[0.9904087,0.003541967,0.0023839776,0.0007349285,0.002478486,0.00045195056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043109,0.00040497934,0.0033005264,0.00031706624,0.00019854141,0.000020545256,0.0009068742,0.0005493451,0.0003572793],"category_scores_gemma":[0.0039595854,0.00026015256,0.0012602025,0.0009717855,0.00068469887,0.00020048526,0.00014798883,0.002096998,0.0000039140587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22005707,0.06229709,0.1359467,0.001035988,0.008004537,0.0007099472,0.0026214998,0.0004051068,0.01647335,0.00017390848,0.025115307,0.5271595],"study_design_scores_gemma":[0.32473752,0.08648759,0.5109277,0.0021531505,0.004118688,0.0005158619,0.0034793771,0.0011968294,0.00226933,0.0006229551,0.06298537,0.0005056264],"about_ca_topic_score_codex":0.00044700663,"about_ca_topic_score_gemma":0.00041269412,"teacher_disagreement_score":0.5266539,"about_ca_system_score_codex":0.0007336415,"about_ca_system_score_gemma":0.008742864,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W4410804591","doi":"10.1200/jco.2025.43.16_suppl.e14519","title":"A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Claudin; Cancer research; Internal medicine; Oncology; Tight junction","score_opus":0.12147040642942414,"score_gpt":0.550833310599996,"score_spread":0.4293629041705718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393815,0.00037697374,0.0001393684,0.0028864073,0.00019731035,0.00089989754,0.0000011737316,0.000004860443,0.001555835],"genre_scores_gemma":[0.9967265,0.00026864847,0.0019861285,0.00056058227,0.00009511846,0.000005861714,5.000204e-7,0.000012159871,0.00034446185],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944778,0.0016740724,0.0027299048,0.00025464356,0.0005828603,0.00028069242],"domain_scores_gemma":[0.98793733,0.009678212,0.0013574992,0.00029556797,0.00052839273,0.00020302061],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0088492595,0.0001407483,0.0017721951,0.00026358172,0.00005375014,0.0000072001744,0.00023765797,0.00017302638,0.00007034732],"category_scores_gemma":[0.011348094,0.000078063305,0.00017222154,0.00048173638,0.00040810276,0.000043744465,0.00015230081,0.0016040647,0.0000024306491],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14109357,0.024205297,0.07700201,0.00015606462,0.00066658773,0.0036353841,0.00090192864,0.00076028926,0.0350948,0.000037992555,0.0005575628,0.7158885],"study_design_scores_gemma":[0.13029179,0.21944144,0.6376555,0.0007069018,0.0006183574,0.0003408668,0.0020688884,0.0037937164,0.0030324082,0.00013447543,0.0017687683,0.0001468913],"about_ca_topic_score_codex":0.000018079796,"about_ca_topic_score_gemma":0.00006903469,"teacher_disagreement_score":0.71574163,"about_ca_system_score_codex":0.00013796295,"about_ca_system_score_gemma":0.0029028566,"threshold_uncertainty_score":0.9969797},"labels":[],"label_agreement":null},{"id":"W4410804686","doi":"10.1200/jco.2025.43.16_suppl.tps8669","title":"A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sault Area Hospital; Kingston Health Sciences Centre; Essar Steel Algoma (Canada); Juravinski Cancer Centre; Health Sciences North; University Health Network; Hamilton Health Sciences; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"Mark Foundation For Cancer Research","keywords":"Medicine; Lung cancer; Biomarker; Chemotherapy; Oncology; Cancer; Cancer research; Internal medicine; Biology; Genetics","score_opus":0.027331633166166054,"score_gpt":0.39182649926689445,"score_spread":0.3644948661007284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966935,0.0009934041,0.0007400453,0.00024245997,0.00056842354,0.0005894617,0.000028983208,0.0000024000938,0.00014133139],"genre_scores_gemma":[0.9967469,0.0006144085,0.0015864053,0.0008031008,0.000075342316,0.00002152657,0.0000072999037,0.000022558523,0.00012247289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971977,0.00048026888,0.0015880119,0.00031978326,0.00016860953,0.00024564398],"domain_scores_gemma":[0.99734527,0.00038954723,0.0012463864,0.00030967974,0.0005857395,0.00012336239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012292826,0.00020798102,0.0008980017,0.00017633535,0.000039423005,0.000008209924,0.00031896305,0.0003256183,0.000015067435],"category_scores_gemma":[0.0004691209,0.00016838317,0.00022724453,0.00020350721,0.00012170558,0.0000061146716,0.00016030994,0.00039040123,2.5249778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34305125,0.08511672,0.45464855,0.000044034037,0.0023757317,0.00022108089,0.00075247796,0.000594749,0.06565701,0.000002809336,0.003460758,0.044074826],"study_design_scores_gemma":[0.28017384,0.08817461,0.6034021,0.0002774399,0.00052454235,0.000005487963,0.0006144007,0.000813154,0.014577351,0.000011020879,0.010952042,0.00047403],"about_ca_topic_score_codex":0.0001505132,"about_ca_topic_score_gemma":0.00041942485,"teacher_disagreement_score":0.14875354,"about_ca_system_score_codex":0.0001239943,"about_ca_system_score_gemma":0.0015859115,"threshold_uncertainty_score":0.68664664},"labels":[],"label_agreement":null},{"id":"W4410804753","doi":"10.1200/jco.2025.43.16_suppl.tps8666","title":"Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Alectinib; Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Crizotinib; Cancer research; Lung cancer; Kinase; Lymphoma; Cancer; Oncology; Pathology; Internal medicine; Biology","score_opus":0.024372276477032263,"score_gpt":0.4274987139296226,"score_spread":0.4031264374525903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921969,0.00059517083,0.00026438807,0.0024673685,0.00090859504,0.0025707132,0.00007579357,0.000008311029,0.0009127147],"genre_scores_gemma":[0.9975056,0.00027342685,0.00082464766,0.00066476176,0.0002517234,0.00018643377,0.000018578725,0.000022989509,0.00025183617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967793,0.0003183069,0.0018812069,0.000365885,0.00032996244,0.00032532986],"domain_scores_gemma":[0.99502105,0.0022023257,0.0012573167,0.00024723698,0.0009749515,0.00029714432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038261688,0.00029372753,0.0017106759,0.00029978142,0.00012737734,0.000010435068,0.00015693669,0.00015299699,0.000017261154],"category_scores_gemma":[0.0003639259,0.00017012197,0.0002677761,0.000723465,0.00012035653,0.00008758427,0.000042087624,0.00027767415,0.0000013009317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06636005,0.06578793,0.72630936,0.00007769882,0.0032950332,0.0007020747,0.006243766,0.00425413,0.00006139427,0.0000062377835,0.0011318097,0.1257705],"study_design_scores_gemma":[0.14373758,0.110899426,0.7325449,0.00055511185,0.003528235,0.000010239944,0.0012422963,0.00047137815,0.0007662838,0.000014903654,0.0060572354,0.00017241885],"about_ca_topic_score_codex":0.0006358136,"about_ca_topic_score_gemma":0.0063926782,"teacher_disagreement_score":0.12559809,"about_ca_system_score_codex":0.0017121838,"about_ca_system_score_gemma":0.003672307,"threshold_uncertainty_score":0.69373727},"labels":[],"label_agreement":null},{"id":"W4410804757","doi":"10.1200/jco.2025.43.16_suppl.10047","title":"Multi-omics evaluation of relapsed pediatric cancers: What information do these sequential analyses yield?","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université Laval; Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Omics; Oncology; Bioinformatics; Internal medicine; Computational biology; Biology","score_opus":0.42670339760843057,"score_gpt":0.6043935415897919,"score_spread":0.1776901439813613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789185,0.0022601471,0.0018121632,0.0029028135,0.0015880199,0.00040152433,0.000002951563,0.0000051539014,0.0031353934],"genre_scores_gemma":[0.9824059,0.010152066,0.0057603936,0.0009284115,0.0005850079,0.000008740657,0.0000060196676,0.000004784818,0.00014866081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99524945,0.00090125005,0.0028105187,0.000110011264,0.0007424699,0.00018630638],"domain_scores_gemma":[0.9916176,0.0034328883,0.0020276143,0.0002140581,0.0025267038,0.00018111076],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011906656,0.00010206545,0.0013951948,0.00047982132,0.000034388937,0.000018767365,0.00017721359,0.00050624466,0.0002675989],"category_scores_gemma":[0.02181105,0.000071747374,0.00040088868,0.00038792525,0.00020517118,0.0005418246,0.000055314627,0.0008436206,0.000013320281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009587473,0.001948611,0.6075,0.00027256185,0.0021395076,0.000064898726,0.0010441552,0.00086398894,0.00074661465,0.00017693978,0.0063441857,0.36931103],"study_design_scores_gemma":[0.03730664,0.011220439,0.8884188,0.00056696194,0.012643991,0.000114752715,0.0038137976,0.035151552,0.00039551256,0.0013326715,0.008853461,0.00018143951],"about_ca_topic_score_codex":0.00008442575,"about_ca_topic_score_gemma":0.00004602693,"teacher_disagreement_score":0.3691296,"about_ca_system_score_codex":0.0005411716,"about_ca_system_score_gemma":0.012092553,"threshold_uncertainty_score":0.993508},"labels":[],"label_agreement":null},{"id":"W4410804792","doi":"10.1200/jco.2025.43.16_suppl.10037","title":"Post hoc analysis of rashes reported in patients (pts) with <i>BRAF</i> -altered relapsed/refractory (r/r) pediatric low-grade glioma (pLGG) treated with the type II RAF inhibitor tovorafenib in FIREFLY-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Post-hoc analysis; Refractory (planetary science); Post hoc; Glioma; Internal medicine; Oncology; Cancer research","score_opus":0.023774918182884755,"score_gpt":0.3318645945096321,"score_spread":0.3080896763267474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980214,0.00045025238,0.000013223601,0.0005473554,0.0003370489,0.00023051607,0.0000131076295,0.0000037153825,0.00038338252],"genre_scores_gemma":[0.99858266,0.00031231222,0.00019584347,0.00042464782,0.00025742454,0.000005624699,0.000053758107,0.000015057378,0.00015266474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964968,0.00058472925,0.002040915,0.00034210694,0.00027652134,0.0002589125],"domain_scores_gemma":[0.99647206,0.0004348923,0.0019853287,0.00040139805,0.0005829175,0.00012341922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014502616,0.00021184242,0.0011948306,0.00047164314,0.000046838013,0.000008636448,0.00031328664,0.000483358,0.000016204038],"category_scores_gemma":[0.0010734878,0.00012309117,0.00030182605,0.001333393,0.00017546244,0.000015218727,0.000107559004,0.0005742992,7.8602096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020171115,0.0036917008,0.9548792,0.00003367244,0.0013587055,0.00031589327,0.00009679523,0.00021647247,0.013122611,0.0000077698205,0.0017370303,0.004369024],"study_design_scores_gemma":[0.014342241,0.033485312,0.94042057,0.00006887497,0.0014335845,0.00002296673,0.000107919135,0.00003130395,0.00400085,0.000009884077,0.0058637634,0.00021270683],"about_ca_topic_score_codex":0.000053965596,"about_ca_topic_score_gemma":0.0008912179,"teacher_disagreement_score":0.02979361,"about_ca_system_score_codex":0.00006283154,"about_ca_system_score_gemma":0.0011116046,"threshold_uncertainty_score":0.5019512},"labels":[],"label_agreement":null},{"id":"W4410804811","doi":"10.1200/jco.2025.43.16_suppl.tps8667","title":"A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a <i>SMARCA4</i> mutation.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Solid tumor; Cancer research; Immunotherapy; Cancer","score_opus":0.024259020673460294,"score_gpt":0.4131760571855009,"score_spread":0.38891703651204057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889255,0.00015027115,0.00040187014,0.00012528454,0.000042018564,0.0003334627,0.0000024490992,9.31486e-7,0.000051169718],"genre_scores_gemma":[0.99859643,0.00012746338,0.0011153332,0.00011734481,0.000011418543,0.000005048807,0.000004534567,0.0000059141757,0.00001653086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99832475,0.0002480894,0.0010531427,0.00015873583,0.00012294031,0.000092322174],"domain_scores_gemma":[0.9987223,0.0002742031,0.00066623895,0.00008419301,0.00020167019,0.00005135022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006921843,0.00008756661,0.00059685943,0.00009244852,0.000016797045,0.000004413591,0.00006219725,0.00006739677,0.0000016284764],"category_scores_gemma":[0.0005929615,0.000055947432,0.000027249016,0.00013472697,0.0000953109,0.000011179564,0.000030717576,0.00019146189,2.7780299e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22161204,0.041089263,0.2537946,0.00022168075,0.0006837031,0.00020447717,0.0011631458,0.0068193907,0.0008920349,0.00003787698,0.00004918768,0.4734326],"study_design_scores_gemma":[0.25299525,0.13573943,0.6074104,0.0003847622,0.00022129076,0.00004493064,0.0010964326,0.0012118998,0.0003219836,0.000106394786,0.0002977722,0.00016947811],"about_ca_topic_score_codex":0.000013546132,"about_ca_topic_score_gemma":0.00034451194,"teacher_disagreement_score":0.47326314,"about_ca_system_score_codex":0.000027463044,"about_ca_system_score_gemma":0.0005154493,"threshold_uncertainty_score":0.22814701},"labels":[],"label_agreement":null},{"id":"W4410804815","doi":"10.1200/jco.2025.43.16_suppl.2515","title":"An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Monoclonal antibody; Solid tumor; Cancer research; Antibody; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.0392421339156431,"score_gpt":0.4236416349096234,"score_spread":0.38439950099398035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574167,0.00031477277,0.000040845785,0.0021959583,0.0009267591,0.00067895086,0.0000064188966,0.0000021638753,0.00009248751],"genre_scores_gemma":[0.99939376,0.000088371286,0.00014188749,0.00027293083,0.000035454043,0.000008827567,0.000016372043,0.0000075250546,0.000034859506],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967694,0.0011998508,0.0015709922,0.00018441588,0.00008931932,0.00018601125],"domain_scores_gemma":[0.99683046,0.0010035443,0.0016581351,0.00021583422,0.00026735858,0.00002469066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021920279,0.00013304158,0.0010205432,0.000136895,0.00009062199,0.000014412191,0.0004261695,0.0002578755,0.000009948869],"category_scores_gemma":[0.00055530266,0.00006574132,0.000051882926,0.00028467688,0.00048257553,0.0003251434,0.00012995584,0.00071684766,5.8182763e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5810025,0.04097002,0.1609917,0.000027601282,0.0005026839,0.00001555877,0.00035172622,0.00014732103,0.057703547,0.0005548848,0.00054762274,0.15718485],"study_design_scores_gemma":[0.32178393,0.035515446,0.6375901,0.00020867161,0.0000881974,0.000008719786,0.00010385232,0.000055616656,0.0030440774,0.00019951539,0.001313046,0.0000888401],"about_ca_topic_score_codex":0.00002665563,"about_ca_topic_score_gemma":0.00014461638,"teacher_disagreement_score":0.47659838,"about_ca_system_score_codex":0.00006808792,"about_ca_system_score_gemma":0.000693148,"threshold_uncertainty_score":0.31143862},"labels":[],"label_agreement":null},{"id":"W4410804826","doi":"10.1200/jco.2025.43.16_suppl.1003","title":"INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Oncology; Internal medicine; Pharmacology; Gynecology; Cancer; Estrogen receptor; Metastatic breast cancer; Breast cancer; Pathology","score_opus":0.03850210338684483,"score_gpt":0.4100375686141059,"score_spread":0.37153546522726105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882278,0.00083851744,0.0008806533,0.005634335,0.0013595783,0.0017785153,0.00059051317,0.000032757387,0.0006573532],"genre_scores_gemma":[0.9933153,0.0021447132,0.0023745222,0.0008843008,0.00068882946,0.000108778164,0.00010238208,0.00007257259,0.00030861268],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98966813,0.0013062455,0.0058563007,0.0009216512,0.0013133931,0.00093428546],"domain_scores_gemma":[0.9868767,0.0042774347,0.0051400354,0.0006139542,0.0024670037,0.00062483916],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022468697,0.00077910075,0.0059358855,0.0010834296,0.0001460086,0.000027339294,0.00057235785,0.00058169145,0.00040347624],"category_scores_gemma":[0.0017014344,0.00059297227,0.0012534563,0.002414412,0.001047031,0.00055570225,0.0001629992,0.002387712,0.0000033364388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8505651,0.013503165,0.045055825,0.00010546305,0.008109291,0.00070519425,0.0006033184,0.0032053143,0.00044730998,0.00009518014,0.0003140072,0.07729088],"study_design_scores_gemma":[0.6486465,0.048143037,0.2878221,0.0014531557,0.006207226,0.00007549316,0.0007583991,0.00055824977,0.00058036775,0.00026506346,0.004835531,0.0006549372],"about_ca_topic_score_codex":0.0014222749,"about_ca_topic_score_gemma":0.004208294,"teacher_disagreement_score":0.24276626,"about_ca_system_score_codex":0.0015720673,"about_ca_system_score_gemma":0.0030183296,"threshold_uncertainty_score":0.9999138},"labels":[],"label_agreement":null},{"id":"W4410804831","doi":"10.1200/jco.2025.43.16_suppl.tps1138","title":"Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology; Family medicine","score_opus":0.0740530162583808,"score_gpt":0.5179718007567261,"score_spread":0.4439187844983453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97305816,0.0009205182,0.00049603666,0.018973334,0.004253125,0.00076856784,0.0000592253,0.000016309375,0.0014547443],"genre_scores_gemma":[0.98540497,0.0007118237,0.002013215,0.009258879,0.0020431099,0.000035968904,0.0000052322544,0.000034247274,0.00049257587],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944287,0.00061397697,0.0036460778,0.0003654953,0.00053652533,0.0004092167],"domain_scores_gemma":[0.99307513,0.0028323994,0.0028882741,0.000363811,0.000568472,0.0002719213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020733427,0.000286515,0.0032011997,0.00035752772,0.000039635506,0.0000073708657,0.0003194275,0.00024913053,0.0002459098],"category_scores_gemma":[0.0017399542,0.00022119223,0.00068192265,0.0005231378,0.0003804796,0.0002602668,0.0000660888,0.0014568288,0.0000097477905],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41748935,0.0065232757,0.0012155871,0.00006872417,0.0008615269,0.00022520551,0.00005204184,0.00034601268,0.0013876864,0.00025191956,0.0008502748,0.5707284],"study_design_scores_gemma":[0.7952765,0.03056102,0.065033756,0.0017062754,0.0015481652,0.00019384087,0.00023046027,0.0002582404,0.0012873139,0.002871267,0.100677505,0.0003556114],"about_ca_topic_score_codex":0.00008443749,"about_ca_topic_score_gemma":0.00019053879,"teacher_disagreement_score":0.57037276,"about_ca_system_score_codex":0.00048821978,"about_ca_system_score_gemma":0.0027142284,"threshold_uncertainty_score":0.9019957},"labels":[],"label_agreement":null},{"id":"W4410804862","doi":"10.1200/jco.2025.43.16_suppl.e19560","title":"Preliminary results of 3D telomeres profiling for myeloma MRD and evaluation of concordance between blood and marrow.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Ontario Genomics; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Concordance; Multiple myeloma; Bone marrow; Oncology; Profiling (computer programming); Internal medicine; Pathology","score_opus":0.14257185217609525,"score_gpt":0.4788414863940381,"score_spread":0.33626963421794287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926089,0.0032526131,0.00012987784,0.0022684066,0.00037055236,0.0005631698,0.000026461987,0.000004786735,0.0007752558],"genre_scores_gemma":[0.98382443,0.0009949177,0.014469837,0.00020381704,0.00036780888,0.000006302496,0.0000056438876,0.000008957054,0.00011825652],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959745,0.00042418938,0.0028045303,0.00023119677,0.00039713437,0.00016844201],"domain_scores_gemma":[0.990457,0.005791801,0.002059373,0.00018261056,0.0013476745,0.00016151502],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007270181,0.00012735404,0.001515756,0.00020555317,0.000036123343,0.0000039833417,0.00011354126,0.00031412422,0.000005749384],"category_scores_gemma":[0.012865572,0.00009810302,0.00016938384,0.00016603273,0.00045129418,0.00009073503,0.00005955237,0.00040686261,1.7031437e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018181996,0.0007382913,0.43547153,0.00066314236,0.0006249816,0.000027568489,0.0001979163,0.000008295227,0.006452953,0.0001452825,0.00071922387,0.5367688],"study_design_scores_gemma":[0.024589593,0.02284513,0.92922467,0.0009190258,0.0028894031,0.00009618516,0.00034563433,0.0005746127,0.014561998,0.0012342955,0.0026108008,0.00010864089],"about_ca_topic_score_codex":0.000012709252,"about_ca_topic_score_gemma":0.00001254919,"teacher_disagreement_score":0.53666013,"about_ca_system_score_codex":0.000033007203,"about_ca_system_score_gemma":0.0015185347,"threshold_uncertainty_score":0.9954495},"labels":[],"label_agreement":null},{"id":"W4410804934","doi":"10.1200/jco.2025.43.16_suppl.3624","title":"Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"Pfizer","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Adverse effect; Cancer","score_opus":0.06191960050570112,"score_gpt":0.4269090754478631,"score_spread":0.364989474942162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424475,0.0005278772,0.000016906506,0.0034076385,0.00046506236,0.00029864514,0.0000039839792,0.0000040366203,0.001031099],"genre_scores_gemma":[0.9949368,0.0030274414,0.0002648318,0.001213908,0.000117430114,0.000015350137,0.0000015551435,0.0000057147004,0.00041697265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984615,0.00013442685,0.0008798784,0.00016449495,0.00020853872,0.00015120552],"domain_scores_gemma":[0.9985725,0.0004461812,0.00058123405,0.000066990586,0.00022462777,0.000108449225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043244803,0.00011987273,0.0011346824,0.000073321666,0.00004135637,0.0000024716517,0.000059561004,0.00014881171,0.00005944487],"category_scores_gemma":[0.00020999413,0.00007197015,0.000103477665,0.00013523166,0.00020442344,0.00006342875,0.000028082652,0.00037653017,5.8278795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062741097,0.0011515967,0.92281866,0.000024813951,0.00038294678,0.000031328167,0.00012578604,0.0000021717008,0.0000030639028,0.000008920526,0.00036990875,0.06880671],"study_design_scores_gemma":[0.015910968,0.0071934545,0.97249025,0.00032614282,0.00018101613,0.0000025849274,0.00010808741,0.000045138448,0.0000061509186,0.00010373816,0.0035722998,0.0000601604],"about_ca_topic_score_codex":0.00016001271,"about_ca_topic_score_gemma":0.0013468356,"teacher_disagreement_score":0.06874655,"about_ca_system_score_codex":0.00024388784,"about_ca_system_score_gemma":0.0004174674,"threshold_uncertainty_score":0.29348573},"labels":[],"label_agreement":null},{"id":"W4410804953","doi":"10.1200/jco.2025.43.16_suppl.tps9604","title":"TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Agonist; TLR7; TLR9; Toll-like receptor; Cancer research; Receptor; Toll-Like Receptor 9; Oncology; Internal medicine; Immunotherapy; Cancer; Gene; Innate immune system; Genetics","score_opus":0.04008054253250323,"score_gpt":0.4177264549160286,"score_spread":0.3776459123835254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997228,0.00013344162,0.000052987052,0.00069508044,0.0004258666,0.0008672319,0.0000047366634,0.000005286399,0.00058736367],"genre_scores_gemma":[0.99823266,0.00007252915,0.0010310046,0.00047243419,0.00005158233,0.000016196514,0.000007703977,0.000013636105,0.000102231796],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99648595,0.0005621671,0.002120991,0.00024188838,0.00039145758,0.00019753638],"domain_scores_gemma":[0.9970674,0.0006212955,0.0014793179,0.00021387934,0.00049793924,0.00012019183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015559235,0.0001646929,0.0014036425,0.00039821645,0.000026168298,0.0000056762005,0.00016181532,0.0002031327,0.000044446668],"category_scores_gemma":[0.00028617255,0.0001084055,0.00011718526,0.0005105332,0.00018865292,0.00020125542,0.000023973824,0.00068964914,5.743134e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39872244,0.03515841,0.394383,0.000023846069,0.000436922,0.00015561754,0.00052240735,0.00002938484,0.00007832665,0.000017349328,0.00017301863,0.17029928],"study_design_scores_gemma":[0.17447142,0.18479341,0.636981,0.0003214342,0.00015517343,0.000012210964,0.0013153452,0.00004312502,0.00005349066,0.000025506482,0.0017397819,0.00008808813],"about_ca_topic_score_codex":0.0001134992,"about_ca_topic_score_gemma":0.0013152554,"teacher_disagreement_score":0.24259798,"about_ca_system_score_codex":0.00039200974,"about_ca_system_score_gemma":0.001529301,"threshold_uncertainty_score":0.4420648},"labels":[],"label_agreement":null},{"id":"W4410804962","doi":"10.1200/jco.2025.43.16_suppl.e18109","title":"Comparison of survival outcomes of transoral surgery with or without adjuvant chemoradiotherapy vs chemoradiotherapy alone for oropharyngeal cancer: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemoradiotherapy; Oncology; Meta-analysis; Adjuvant; Internal medicine; Head and neck cancer; Surgery; Cancer; Overall survival","score_opus":0.42385987848991047,"score_gpt":0.593154952517222,"score_spread":0.16929507402731148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011548475,0.9934709,0.00017786174,0.0027553178,0.00031774986,0.0029667474,0.00015753035,0.0000066383973,0.000031764357],"genre_scores_gemma":[0.00039249173,0.9950542,0.0021558919,0.0013590526,0.00018342696,0.0002644072,0.00001168185,0.00005237195,0.0005265022],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98703635,0.0014520193,0.010071379,0.00044637482,0.00066624425,0.00032762386],"domain_scores_gemma":[0.9737109,0.013483261,0.01097642,0.0005004267,0.0010279986,0.0003010023],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0068868343,0.0006607678,0.1454023,0.000474954,0.00003834709,0.0000062923204,0.00031950927,0.0005522956,0.00014850032],"category_scores_gemma":[0.0017264235,0.00029928313,0.0089282505,0.0008291622,0.00042201826,0.00005993032,0.00002270017,0.0008602926,1.7531858e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026513445,0.001031787,0.003527432,0.6828186,0.28244528,0.00003345059,0.00007655737,4.764558e-7,1.7626513e-7,0.0000025978059,0.0007703819,0.026641939],"study_design_scores_gemma":[0.004408018,0.0077974405,0.00027074228,0.06440979,0.89525056,0.00008533047,0.00003994163,0.000006983246,0.000002616132,0.0000012304092,0.027464435,0.00026289042],"about_ca_topic_score_codex":0.00005914213,"about_ca_topic_score_gemma":0.0003044259,"teacher_disagreement_score":0.6184088,"about_ca_system_score_codex":0.00017314364,"about_ca_system_score_gemma":0.005528711,"threshold_uncertainty_score":0.99994594},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["metaepi_broad"],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4410804997","doi":"10.1200/jco.2025.43.16_suppl.10004","title":"Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Open label; Solid tumor; Crizotinib; ALK inhibitor; Oncology; Internal medicine; Clinical trial; Cancer","score_opus":0.15231239893266446,"score_gpt":0.5570303500313922,"score_spread":0.40471795109872777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045086,0.00057080336,0.000111871705,0.0067995037,0.0005022586,0.001344139,0.00008315104,0.00000875084,0.00012866159],"genre_scores_gemma":[0.9918982,0.00088376075,0.0031034097,0.0035151124,0.00033081477,0.000019922198,0.000036896978,0.000018547751,0.00019333795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971333,0.000405427,0.0015901048,0.0004010617,0.00022434873,0.00024576308],"domain_scores_gemma":[0.9975332,0.00071025884,0.0008719463,0.0004954767,0.0001816211,0.0002075132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015270922,0.00018385192,0.0011203092,0.00012093457,0.00019340031,0.000049403392,0.00058888266,0.00012184766,0.000043942757],"category_scores_gemma":[0.0016448232,0.000093596216,0.000055806362,0.00030279663,0.00013954222,0.00026993113,0.000648303,0.0009375312,0.0000031212294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012604701,0.0395457,0.87957436,0.00000988433,0.0015609991,0.0005919108,0.00047127405,0.000002453889,0.000020172914,0.0000033437773,0.0038337235,0.061781455],"study_design_scores_gemma":[0.1914591,0.0141549315,0.78343374,0.0011301221,0.0016716985,0.00023224577,0.00060173037,0.0002213758,0.0000065072895,0.000020472527,0.006956571,0.00011148582],"about_ca_topic_score_codex":0.00047512556,"about_ca_topic_score_gemma":0.0019729468,"teacher_disagreement_score":0.1788544,"about_ca_system_score_codex":0.00013007535,"about_ca_system_score_gemma":0.0021987928,"threshold_uncertainty_score":0.40731585},"labels":[],"label_agreement":null},{"id":"W4410805015","doi":"10.1200/jco.2025.43.16_suppl.e20555","title":"Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung; Oncology; Immune system; Cancer research; Basal cell; Lung cancer; Carcinoma; Pathology; Internal medicine; Immunology","score_opus":0.0405326169658677,"score_gpt":0.409315266569293,"score_spread":0.3687826496034253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203795,0.00092087005,0.0015574958,0.0031964926,0.0012382683,0.00088660355,0.000008198607,0.0000069757225,0.00014714006],"genre_scores_gemma":[0.9949894,0.000035475343,0.0029389418,0.0016983104,0.0001398387,0.000013505832,0.0000033086553,0.000024534542,0.00015670138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99532706,0.0007612647,0.0028563295,0.0002546254,0.00052279315,0.0002779447],"domain_scores_gemma":[0.9962246,0.0011408889,0.0012875099,0.0003228375,0.00074918236,0.00027499915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028337378,0.00020753087,0.0015076395,0.00039652298,0.000040684212,0.00001278822,0.00024486578,0.00019130357,0.00007884201],"category_scores_gemma":[0.001498148,0.000138368,0.0006275652,0.00042945895,0.00013335707,0.000059483245,0.0000855249,0.0005885537,0.0000031378554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3468289,0.0039752233,0.06242119,0.00017186311,0.0007164105,0.00028492368,0.00041044253,0.000034589833,0.5646119,0.0000055641867,0.000424526,0.020114457],"study_design_scores_gemma":[0.031486522,0.031322982,0.7484748,0.00028115298,0.0005325114,0.000018966683,0.00022739601,0.00002578776,0.1855894,0.000017727853,0.0018694354,0.00015335163],"about_ca_topic_score_codex":0.000039037222,"about_ca_topic_score_gemma":0.0000071171125,"teacher_disagreement_score":0.6860536,"about_ca_system_score_codex":0.00024339852,"about_ca_system_score_gemma":0.0016003492,"threshold_uncertainty_score":0.5642484},"labels":[],"label_agreement":null},{"id":"W4410805112","doi":"10.1200/jco.2025.43.16_suppl.10052","title":"Factors associated with survival following relapse of high-risk neuroblastoma: A study from the International Neuroblastoma Risk Group (INRG) Data Commons.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Garron Family Cancer Centre","keywords":"Medicine; Neuroblastoma; Oncology; Internal medicine","score_opus":0.16945939319481182,"score_gpt":0.4476892196454386,"score_spread":0.27822982645062677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320394,0.00005595123,0.00010538538,0.0027906664,0.0027913598,0.0005087707,0.00024073278,0.000022518328,0.00028069367],"genre_scores_gemma":[0.99888384,0.00012066059,0.00016867903,0.00035630117,0.00028873907,0.000004429192,0.00005203417,0.000030963212,0.00009432631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925739,0.0030802134,0.0023248328,0.0004788597,0.0012067339,0.00033546926],"domain_scores_gemma":[0.9744799,0.021166129,0.0027021319,0.00089270505,0.00043661954,0.00032250007],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004245961,0.00027785546,0.0018147236,0.00020965502,0.00015775263,0.00003541376,0.0012942201,0.0002252754,0.00004440101],"category_scores_gemma":[0.023987507,0.0001506737,0.00050948723,0.00046053674,0.00030265606,0.00024055582,0.0007241036,0.0025310332,0.000004762332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007852281,0.00893177,0.96421355,0.000003852394,0.0067813997,0.0014971305,0.000099589975,0.000025531142,0.000071604525,0.00001413967,0.0031363494,0.007372805],"study_design_scores_gemma":[0.021695431,0.022119602,0.9514458,0.00016242883,0.0023495737,0.000010794782,0.00039311877,0.0001967174,0.000039667255,0.00017137475,0.0013267355,0.00008874459],"about_ca_topic_score_codex":0.00087875867,"about_ca_topic_score_gemma":0.005094578,"teacher_disagreement_score":0.019741546,"about_ca_system_score_codex":0.00015168882,"about_ca_system_score_gemma":0.001125031,"threshold_uncertainty_score":0.99977016},"labels":[],"label_agreement":null},{"id":"W4410805121","doi":"10.1200/jco.2025.43.16_suppl.3503","title":"ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia","funders":"National Health and Medical Research Council; National Institutes of Health; Marcus Foundation","keywords":"Medicine; Oncology; Internal medicine; Colorectal cancer; Cohort; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Randomized controlled trial; Cancer; Breast cancer","score_opus":0.02145202439219167,"score_gpt":0.3953650284881216,"score_spread":0.3739130040959299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944691,0.0014337108,0.00042880722,0.0014271196,0.0008540197,0.0010952873,0.000069856906,0.0000010292646,0.00022107408],"genre_scores_gemma":[0.9928964,0.005527609,0.000096668315,0.0011235849,0.00019014203,0.000026461157,0.000023751125,0.000009109101,0.000106272615],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995751,0.0010939607,0.0025247168,0.0002703231,0.00022091769,0.00013903464],"domain_scores_gemma":[0.9939078,0.002981808,0.0023672278,0.00032476123,0.00036013793,0.00005824405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034411764,0.00015650116,0.0020159637,0.00010806695,0.000043844826,0.000012467913,0.0003513117,0.00029436697,0.000018165549],"category_scores_gemma":[0.0016234998,0.000094387105,0.0006414871,0.00029154698,0.0003708406,0.0000065660493,0.00018031156,0.00036436433,4.8385086e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67358917,0.0039643166,0.2640105,0.000017103228,0.013010592,0.000015122452,0.0009709923,0.002495085,0.0131631335,0.00006861432,0.0012748803,0.027420511],"study_design_scores_gemma":[0.4111202,0.0032879738,0.57795525,0.000067903035,0.0034332995,0.0000012226573,0.0004632524,0.0014045547,0.0011584209,0.00015399163,0.00083501014,0.00011890672],"about_ca_topic_score_codex":0.0017973792,"about_ca_topic_score_gemma":0.008223872,"teacher_disagreement_score":0.31394476,"about_ca_system_score_codex":0.00011995789,"about_ca_system_score_gemma":0.0009020353,"threshold_uncertainty_score":0.45891136},"labels":[],"label_agreement":null},{"id":"W4410805160","doi":"10.1200/jco.2025.43.16_suppl.e20514","title":"Utility of plasma cell-free DNA and tissue next generation sequencing (NGS) in detecting genetic mutations in non-small cell lung cancer (NSCLC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; DNA sequencing; Lung cancer; DNA; Cell-free fetal DNA; Cancer; Cell; Cancer research; Lung; Mutation; Pathology; Computational biology; Gene; Biology; Genetics; Internal medicine","score_opus":0.059080187174485745,"score_gpt":0.3823349708846274,"score_spread":0.32325478371014166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993876,0.0025774161,0.0017141588,0.00028243804,0.00062194717,0.00016710024,0.00000863583,8.153538e-7,0.00075153465],"genre_scores_gemma":[0.9920205,0.0026245925,0.0046900194,0.00026729572,0.0003377855,0.0000070814845,0.000003060154,0.000008297332,0.00004138431],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801695,0.00017602336,0.0013659969,0.0002084288,0.00007165889,0.0001609602],"domain_scores_gemma":[0.99841577,0.00048556065,0.00067685713,0.00016743067,0.0001759308,0.000078457146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095986255,0.00010106865,0.00046609927,0.000115274095,0.000027980235,0.000011819869,0.0001710069,0.00031370408,0.000009197012],"category_scores_gemma":[0.0012165812,0.000100753496,0.00008962839,0.00012204689,0.00008099828,0.00000652025,0.00011934142,0.00032908728,1.7992986e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037818556,0.00033259625,0.16165194,0.00012622241,0.00004996007,0.00005214028,0.00025884638,0.005650785,0.7456603,0.000008505723,0.00061663816,0.085213885],"study_design_scores_gemma":[0.010813072,0.0025680582,0.22577247,0.00021030195,0.00024623668,0.000029299197,0.0006111222,0.04275313,0.7118119,0.00038830735,0.0044842195,0.00031186914],"about_ca_topic_score_codex":0.00037104238,"about_ca_topic_score_gemma":0.008363287,"teacher_disagreement_score":0.08490202,"about_ca_system_score_codex":0.00008566847,"about_ca_system_score_gemma":0.0018501895,"threshold_uncertainty_score":0.46669108},"labels":[],"label_agreement":null},{"id":"W4410805169","doi":"10.1200/jco.2025.43.16_suppl.3508","title":"The KRAS G12C inhibitor MK-1084 for <i>KRAS</i> G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"KRAS; Medicine; Colorectal cancer; Cancer; Cancer research; Internal medicine","score_opus":0.06568988154422638,"score_gpt":0.47082916960670346,"score_spread":0.40513928806247707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9255457,0.009682544,0.000048223883,0.04666916,0.008747181,0.0010663315,0.00029224667,0.00003429921,0.007914317],"genre_scores_gemma":[0.9774111,0.010222822,0.0011682353,0.0041684913,0.00290156,0.00014198544,0.00004325532,0.000030412393,0.003912121],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954127,0.00032243363,0.0030066557,0.00041099158,0.0003857569,0.00046142578],"domain_scores_gemma":[0.9860628,0.01054705,0.0016990902,0.00024096994,0.0011538715,0.0002961807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019541588,0.00030036573,0.0020340213,0.00009292901,0.0003246927,0.000030053114,0.00026293524,0.0004165443,0.00006436865],"category_scores_gemma":[0.0070757065,0.00016608521,0.0007712173,0.00027178146,0.00044156305,0.00010198176,0.00011995119,0.0009483208,0.000009872761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14953727,0.002691531,0.016212707,0.00004761628,0.004499543,0.00030884097,0.00043349536,0.00004367188,0.0012690792,0.00015997932,0.17575304,0.6490432],"study_design_scores_gemma":[0.045536295,0.015509484,0.10034835,0.00034831604,0.0015132655,0.000027656257,0.0004683197,0.00011386219,0.0013276408,0.0012588617,0.8333577,0.00019025072],"about_ca_topic_score_codex":0.000289301,"about_ca_topic_score_gemma":0.002517908,"teacher_disagreement_score":0.65760463,"about_ca_system_score_codex":0.000596208,"about_ca_system_score_gemma":0.0024653529,"threshold_uncertainty_score":0.8470793},"labels":[],"label_agreement":null},{"id":"W4410805181","doi":"10.1200/jco.2025.43.16_suppl.tps1121","title":"IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Queen's University; University Health Network; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Kingston Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Oncology; Biopsy; Cancer; Internal medicine; Clinical trial; Gynecology","score_opus":0.20410881735378156,"score_gpt":0.5357717868143332,"score_spread":0.3316629694605517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563384,0.0012658342,0.00015429755,0.032988977,0.004915352,0.0024876224,0.0001118514,0.000018636782,0.0017189978],"genre_scores_gemma":[0.9774991,0.000838713,0.007859341,0.008845035,0.0033175438,0.0003835981,0.0000149236585,0.000055320474,0.0011863812],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99130577,0.0009833917,0.005979748,0.00038981435,0.0006173035,0.00072399],"domain_scores_gemma":[0.9904537,0.0050601168,0.0022979076,0.00037940245,0.0006015721,0.0012072844],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009419998,0.00038363345,0.0042874166,0.0010157393,0.00007929989,0.000025867721,0.0002929624,0.00045642545,0.00056907284],"category_scores_gemma":[0.009553965,0.00025880983,0.0009110048,0.00071549235,0.00019646782,0.00023717535,0.000052621213,0.00094215554,0.000019513447],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5895557,0.0016214153,0.0012471371,0.00006295146,0.0018339056,0.0010524997,0.0005148136,0.000092679846,0.0005044716,0.00024735287,0.0011995102,0.40206757],"study_design_scores_gemma":[0.40487635,0.07099414,0.055032004,0.0017149362,0.0024705299,0.00060912577,0.0011353752,0.00005192878,0.0003566326,0.0018423982,0.4604362,0.00048038177],"about_ca_topic_score_codex":0.01639823,"about_ca_topic_score_gemma":0.22639017,"teacher_disagreement_score":0.45923668,"about_ca_system_score_codex":0.005754888,"about_ca_system_score_gemma":0.026657702,"threshold_uncertainty_score":0.9999864},"labels":[],"label_agreement":null},{"id":"W4410805183","doi":"10.1200/jco.2025.43.16_suppl.3501","title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Colorectal cancer; Microsatellite instability; Internal medicine; Oncology; Chemotherapy; Cancer; Immunotherapy","score_opus":0.16382688165087683,"score_gpt":0.5057890840191294,"score_spread":0.34196220236825253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798348,0.0051903133,0.002635324,0.005367957,0.004615216,0.0017478687,0.00014111416,0.00010066867,0.00036672078],"genre_scores_gemma":[0.9407083,0.005293183,0.04317765,0.0072531505,0.0010855169,0.00018707542,0.00003625162,0.000116803945,0.0021420927],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9914988,0.000805304,0.005022057,0.0010072789,0.00081954856,0.0008469991],"domain_scores_gemma":[0.9892883,0.005181297,0.0027634776,0.00074854784,0.0014614837,0.00055692915],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034738304,0.00066649646,0.0045900205,0.0004102607,0.00018622223,0.000058416317,0.0006527394,0.0008804904,0.0014206419],"category_scores_gemma":[0.0028226692,0.00048102735,0.0019511137,0.000785456,0.00074440957,0.00016897192,0.00013260507,0.0014371672,0.000011318038],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47757456,0.010988335,0.065023765,0.0010835002,0.015493718,0.000551512,0.0032765588,0.0013709231,0.16424194,0.00008998901,0.027576732,0.23272847],"study_design_scores_gemma":[0.18828079,0.057552524,0.24561171,0.0022353742,0.008385939,0.00036873724,0.0024219553,0.007991947,0.24879074,0.0051093926,0.23130052,0.0019503665],"about_ca_topic_score_codex":0.0009276358,"about_ca_topic_score_gemma":0.0016497136,"teacher_disagreement_score":0.2892938,"about_ca_system_score_codex":0.0021891643,"about_ca_system_score_gemma":0.008502038,"threshold_uncertainty_score":0.99976414},"labels":[],"label_agreement":null},{"id":"W4410805186","doi":"10.1200/jco.2025.43.16_suppl.1004","title":"Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Roche (Canada)","funders":"","keywords":"Palbociclib; Medicine; Oncology; Metastatic breast cancer; Internal medicine; Endocrine system; Hormone receptor; Hormone; Cancer; Breast cancer","score_opus":0.020809135491573573,"score_gpt":0.39416071469548014,"score_spread":0.37335157920390655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960058,0.0011025805,0.00017409827,0.0011232977,0.00010198119,0.0013242933,0.000069459915,0.000007699936,0.00009080094],"genre_scores_gemma":[0.994792,0.0024770254,0.002232972,0.0003117186,0.000029867604,0.00007489803,0.000019096497,0.000036407622,0.000026020947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99412704,0.00122441,0.003079953,0.00049470545,0.00067877746,0.00039512542],"domain_scores_gemma":[0.9934455,0.002358609,0.0024485167,0.0002943601,0.001251801,0.0002011996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013721243,0.00038054187,0.003385013,0.0011850377,0.000027576885,0.000009043097,0.00022589181,0.00019142666,0.00002981858],"category_scores_gemma":[0.0005477302,0.00027382394,0.00016911692,0.002734101,0.000673908,0.00038288784,0.00006970946,0.0011875666,2.1135257e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14444429,0.035084426,0.66829664,0.0000796342,0.0024050432,0.0003060143,0.0017607007,0.0031660588,0.00036980654,0.0000074665036,0.000009867814,0.14407006],"study_design_scores_gemma":[0.18206356,0.045857236,0.766918,0.0010648024,0.00096995523,0.00003121211,0.0019923283,0.0004226421,0.00034897673,0.00009556067,0.000049630693,0.00018608171],"about_ca_topic_score_codex":0.0009434153,"about_ca_topic_score_gemma":0.004932507,"teacher_disagreement_score":0.14388397,"about_ca_system_score_codex":0.00057233905,"about_ca_system_score_gemma":0.0010818959,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W4410805216","doi":"10.1200/jco.2025.43.16_suppl.2567","title":"Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Immune system; Oncology; Internal medicine; Cancer; Cancer research; Immune checkpoint; Immunotherapy; Immunology","score_opus":0.024593712096844095,"score_gpt":0.36848697034536054,"score_spread":0.34389325824851646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857384,0.0051901075,0.0001366643,0.0013073945,0.0066999863,0.00018840843,0.000016395117,0.0000032895648,0.000719344],"genre_scores_gemma":[0.9894959,0.00542667,0.0004030324,0.0013704462,0.002408623,0.000014416735,0.000010578483,0.000017157034,0.0008531969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975901,0.00023512369,0.0015078546,0.00026586352,0.00013134803,0.0002696964],"domain_scores_gemma":[0.9981587,0.00030459033,0.0009873029,0.00017824693,0.00023180238,0.00013933872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011940586,0.00018901125,0.0011596846,0.000094135314,0.00003889545,0.000011608362,0.00019843824,0.00039614792,0.000009268379],"category_scores_gemma":[0.00048189855,0.00014046502,0.00027963863,0.000098310215,0.00015290696,0.000010205896,0.00012567794,0.0006085886,2.8458294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021851077,0.0010771366,0.9130844,0.000068715286,0.00053827337,0.000008889624,0.00012043538,0.000113248076,0.061488472,0.000003376931,0.0028559794,0.018455952],"study_design_scores_gemma":[0.011333344,0.002163104,0.9458073,0.00026719508,0.0002287796,0.000008003299,0.00020477286,0.00005514465,0.00420147,0.00002032386,0.035513632,0.00019692646],"about_ca_topic_score_codex":0.00013458298,"about_ca_topic_score_gemma":0.0021035257,"teacher_disagreement_score":0.057287,"about_ca_system_score_codex":0.000079076606,"about_ca_system_score_gemma":0.001122262,"threshold_uncertainty_score":0.57279974},"labels":[],"label_agreement":null},{"id":"W4410805231","doi":"10.1200/jco.2025.43.16_suppl.2571","title":"Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"FOLFIRINOX; Medicine; Pancreatic cancer; Oncology; Stage (stratigraphy); Internal medicine; Progression-free survival; Overall survival; Cancer; Oxaliplatin; Colorectal cancer","score_opus":0.048281268821453276,"score_gpt":0.4600465504407603,"score_spread":0.41176528161930703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976622,0.0008896041,0.000017108108,0.00078837207,0.00006150662,0.0001999501,0.000008543861,7.2366174e-7,0.0003719911],"genre_scores_gemma":[0.9972736,0.0020565079,0.0003562861,0.00015962987,0.000022576374,0.000014696615,0.00000284013,0.0000051298885,0.000108720546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836296,0.00034261573,0.00078168156,0.00015773943,0.00020447002,0.0001505466],"domain_scores_gemma":[0.9986789,0.00045773608,0.00048276878,0.00014740347,0.00015027694,0.0000828641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010708142,0.00008775422,0.00054435595,0.0001151366,0.00001260767,0.000005329463,0.0001486495,0.000092032205,0.000004567092],"category_scores_gemma":[0.0011842661,0.000060864484,0.0000578971,0.00012054705,0.00014561665,0.000008866152,0.00007388549,0.00026283463,1.9022012e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009161217,0.001612289,0.96065724,0.00008429345,0.0002567231,0.00021590143,0.000024515131,0.0011316574,0.0019072784,0.00023645359,0.00012014026,0.024592271],"study_design_scores_gemma":[0.014090166,0.011474249,0.97002405,0.00032663762,0.000046611694,0.00000782089,0.000034731056,0.00006378673,0.001990957,0.0008339035,0.0010408367,0.00006627499],"about_ca_topic_score_codex":0.00041364643,"about_ca_topic_score_gemma":0.0033892216,"teacher_disagreement_score":0.024525996,"about_ca_system_score_codex":0.00006918201,"about_ca_system_score_gemma":0.00092762493,"threshold_uncertainty_score":0.24819817},"labels":[],"label_agreement":null},{"id":"W4410805241","doi":"10.1200/jco.2025.43.16_suppl.e19521","title":"Concordance between blinded independent central review committee and physician-assessed responses: Analyses based on a real-world external control arm in relapsed/refractory multiple myeloma using International Myeloma Working Group data.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Regeneron Pharmaceuticals","keywords":"Medicine; Multiple myeloma; Concordance; Internal medicine; Oncology","score_opus":0.6840623360066128,"score_gpt":0.6438534735256439,"score_spread":0.04020886248096889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6720893,0.001926188,0.3049367,0.0067909975,0.008184741,0.0022670352,0.00034866418,0.00007577238,0.0033806101],"genre_scores_gemma":[0.72921985,0.0010814542,0.26372728,0.004514583,0.0013830961,0.000009911372,0.0000044195594,0.000032617332,0.000026778884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98063743,0.009536961,0.007487709,0.0007461355,0.0010478479,0.0005439449],"domain_scores_gemma":[0.76387084,0.22998364,0.004712346,0.00073927676,0.00037222827,0.00032167175],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.026232462,0.00040233252,0.0040957388,0.00054679497,0.00009512972,0.00006976484,0.0013926666,0.0005228708,0.00008323786],"category_scores_gemma":[0.20279089,0.00032905932,0.0005490225,0.0006171529,0.00049180526,0.00021255705,0.00034854884,0.0028637738,0.0000023758969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02674631,0.006620312,0.5088454,0.00063012895,0.0016141515,0.0014798007,0.000044124765,0.0001471749,0.00046780484,0.0055280593,0.0013178173,0.44655892],"study_design_scores_gemma":[0.044079337,0.0033735998,0.79284596,0.01745523,0.0024047168,0.000022697406,0.00008339878,0.022907501,0.000075684286,0.10940685,0.0067058397,0.00063916517],"about_ca_topic_score_codex":0.000066110726,"about_ca_topic_score_gemma":0.00026191768,"teacher_disagreement_score":0.44591975,"about_ca_system_score_codex":0.00057316566,"about_ca_system_score_gemma":0.0015205396,"threshold_uncertainty_score":0.99991614},"labels":[],"label_agreement":null},{"id":"W4410805263","doi":"10.1200/jco.2025.43.16_suppl.10068","title":"Financial hardship and non-adherence to lifestyle and surveillance recommendations in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adolescent and Pediatric Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cancer; Childhood cancer; Cancer survivor; Gerontology; Family medicine; Internal medicine","score_opus":0.10881163768571005,"score_gpt":0.5330963359437233,"score_spread":0.42428469825801324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414923,0.0017549245,0.000030093928,0.051534638,0.00376636,0.0010975049,0.00013718165,0.000006566889,0.00018039983],"genre_scores_gemma":[0.9815342,0.009261033,0.00019106732,0.0071018604,0.0016558286,0.0000716839,0.0000048957786,0.000012564181,0.00016689775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923881,0.0029346808,0.0036876274,0.0003508983,0.00027010884,0.0003685567],"domain_scores_gemma":[0.987159,0.009261512,0.00228133,0.00027601572,0.0007645038,0.0002576264],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0074599804,0.00017589917,0.0014176135,0.00013587456,0.00026817643,0.000007273909,0.00030353488,0.0004343174,0.00009943821],"category_scores_gemma":[0.012541707,0.00012194074,0.000115604664,0.0004971063,0.00010333164,0.000101383004,0.00021537898,0.002085169,0.0000024971287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045533225,0.0007652875,0.9310075,0.00004554947,0.00006523749,0.000032398704,0.0037270358,0.0000041877056,5.8713374e-7,0.000012980561,0.015846934,0.04803696],"study_design_scores_gemma":[0.0037507126,0.0012100871,0.974325,0.0004938439,0.000061810664,0.0000029833689,0.0024332781,0.000009822032,3.374224e-7,0.00013881938,0.017470518,0.000102763785],"about_ca_topic_score_codex":0.03185005,"about_ca_topic_score_gemma":0.3361094,"teacher_disagreement_score":0.30425933,"about_ca_system_score_codex":0.00013149231,"about_ca_system_score_gemma":0.0066838157,"threshold_uncertainty_score":0.9989474},"labels":[],"label_agreement":null},{"id":"W4410805272","doi":"10.1200/jco.2025.43.16_suppl.10007","title":"ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Irinotecan; Temozolomide; Refractory (planetary science); Solid tumor; Oncology; Internal medicine; Phases of clinical research; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.03372924563251851,"score_gpt":0.4115084532335546,"score_spread":0.3777792076010361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984884,0.00047464628,0.00010817894,0.00015978036,0.00025238647,0.00040444435,0.000010172277,0.0000022625816,0.0000997069],"genre_scores_gemma":[0.9979989,0.0008701556,0.00051189796,0.0002590416,0.00019475115,0.000011372158,0.0000044223284,0.00001483096,0.00013463649],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99777013,0.0002413841,0.0013186336,0.0002876492,0.00017349988,0.00020871434],"domain_scores_gemma":[0.9982261,0.00011341745,0.0010829887,0.0002156271,0.00022704789,0.00013481533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081965554,0.00017083387,0.0009254045,0.000117322284,0.00003310152,0.000009230894,0.00020902113,0.00022119973,0.000009515187],"category_scores_gemma":[0.00022194897,0.00009857924,0.00008101867,0.00014823908,0.00016166577,0.000008118553,0.00009315976,0.00046152234,1.4881701e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32626277,0.028254807,0.13810048,0.00008997705,0.0023508805,0.0006943774,0.000896151,0.00005237526,0.022650175,0.000048668306,0.000284484,0.48031488],"study_design_scores_gemma":[0.10946742,0.58204544,0.27736953,0.00082833826,0.00078130973,0.0014525948,0.0027411687,0.00007093651,0.017889211,0.000062684405,0.006755951,0.0005354465],"about_ca_topic_score_codex":0.0000798658,"about_ca_topic_score_gemma":0.003485336,"teacher_disagreement_score":0.5537906,"about_ca_system_score_codex":0.00004418691,"about_ca_system_score_gemma":0.0016458244,"threshold_uncertainty_score":0.4019945},"labels":[],"label_agreement":null},{"id":"W4410805300","doi":"10.1200/jco.2025.43.16_suppl.tps9600","title":"A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Open label; Cohort; Oncology; Internal medicine; Adverse effect","score_opus":0.07668714375346083,"score_gpt":0.4439034854278719,"score_spread":0.3672163416744111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893595,0.0005893831,0.000042013256,0.0041382182,0.000539242,0.0009059794,0.000005565002,0.0000020773139,0.004841547],"genre_scores_gemma":[0.99799186,0.0001411785,0.0011527465,0.0005198954,0.00004974911,0.000015093712,0.0000013083949,0.000010647854,0.00011751913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953464,0.00076122954,0.003015292,0.00026803405,0.00039543054,0.00021358945],"domain_scores_gemma":[0.99363005,0.0030241834,0.0023459315,0.00040264014,0.0005088535,0.00008832416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030916312,0.00016031026,0.0021276907,0.00019839309,0.00002907633,0.000004313025,0.00041347978,0.00029140443,0.000030421932],"category_scores_gemma":[0.0027627363,0.00010020789,0.00014827524,0.00051366555,0.0004576409,0.0000874689,0.00026127067,0.0009888519,5.5822477e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02075345,0.020124411,0.93574756,0.00019097496,0.0000763275,0.00048779452,0.00034478048,0.000066922585,0.000740232,0.00006559704,0.00046635824,0.020935612],"study_design_scores_gemma":[0.065351054,0.02418136,0.90574676,0.00036268975,0.00029164067,0.00018074426,0.00031128616,0.00028040019,0.0022238295,0.00046721936,0.0005141632,0.00008884123],"about_ca_topic_score_codex":0.00037046795,"about_ca_topic_score_gemma":0.0010397142,"teacher_disagreement_score":0.044597607,"about_ca_system_score_codex":0.00046428232,"about_ca_system_score_gemma":0.0024300052,"threshold_uncertainty_score":0.4310725},"labels":[],"label_agreement":null},{"id":"W4410805321","doi":"10.1200/jco.2025.43.16_suppl.6045","title":"Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immune checkpoint; Blockade; Squamous cell cancer; Oncology; Head and neck; Cancer; Transcriptome; Immune system; Head and neck squamous-cell carcinoma; Head and neck cancer; Internal medicine; Cancer research; Immunology; Receptor; Gene expression; Biology; Gene; Surgery","score_opus":0.06671949807138279,"score_gpt":0.4877176401056447,"score_spread":0.42099814203426195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604526,0.0016390296,0.0013911126,0.03456929,0.0009954998,0.00059903495,0.000039632054,0.0000073692772,0.00030642466],"genre_scores_gemma":[0.9907099,0.0005811578,0.004968101,0.0023847518,0.00019710255,0.00004641729,0.000004364635,0.0000130028875,0.0010951746],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996267,0.00049233454,0.002428317,0.00028271668,0.0002614428,0.00026816592],"domain_scores_gemma":[0.9969967,0.001491435,0.00054774515,0.00020812865,0.00027722318,0.00047879698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021312656,0.00017526915,0.0017022317,0.0006942585,0.000042471955,0.000014223792,0.00012944957,0.0001624087,0.00014896433],"category_scores_gemma":[0.0021611832,0.00011895551,0.0004549606,0.0008611858,0.00006704187,0.000052215168,0.000042001957,0.0005839655,0.0000035055546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32613763,0.013243386,0.21019322,0.0003150077,0.009586865,0.0025217037,0.0058070216,0.0035075713,0.007985239,0.000016609787,0.002846799,0.41783896],"study_design_scores_gemma":[0.03008998,0.026041405,0.8657232,0.00032719687,0.012430065,0.000052394647,0.0004881199,0.0010023849,0.00078705244,0.00006471382,0.0628137,0.00017976925],"about_ca_topic_score_codex":0.00083832536,"about_ca_topic_score_gemma":0.0052029984,"teacher_disagreement_score":0.65553,"about_ca_system_score_codex":0.0006176482,"about_ca_system_score_gemma":0.0033948715,"threshold_uncertainty_score":0.6022356},"labels":[],"label_agreement":null},{"id":"W4410805329","doi":"10.1200/jco.2025.43.16_suppl.1118","title":"Opioid use disorder among females with breast cancer: A comprehensive analysis of prevalence in the United States and associated factors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Breast cancer; Cancer; Opioid; Opioid use disorder; Oncology; Demography; Internal medicine; Psychiatry","score_opus":0.06885905540328753,"score_gpt":0.4176565762557469,"score_spread":0.3487975208524594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512285,0.0017058955,0.000016958196,0.002846954,0.00008428916,0.0001721627,0.000030941577,0.0000032262963,0.00001669662],"genre_scores_gemma":[0.98113364,0.017920945,0.000036746314,0.0007335123,0.00004249849,0.0000037793395,0.000011556338,0.0000056009408,0.00011172807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973644,0.0008775424,0.0012291068,0.00013468442,0.00024139181,0.00015289229],"domain_scores_gemma":[0.9912707,0.0067084823,0.0011798979,0.000158442,0.00060353987,0.00007892865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009725297,0.00012103951,0.0014225102,0.00046484955,0.00003537835,0.000013236116,0.0001401294,0.00017481994,0.000028630287],"category_scores_gemma":[0.0012758282,0.00006477753,0.00025864653,0.0010535535,0.0005634465,0.00009339416,0.000026372576,0.0005594236,6.8519284e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005926921,0.0008142186,0.9853776,0.000070169124,0.0021334835,0.00007158018,0.00083061005,0.00046445354,0.000011226731,0.0000063668112,0.00020384825,0.0040894994],"study_design_scores_gemma":[0.003635587,0.0019187541,0.98507863,0.00046619438,0.0030806563,0.00002774661,0.0020487658,0.0007291181,0.0000045954557,0.00000877173,0.0029423744,0.000058795267],"about_ca_topic_score_codex":0.0033540556,"about_ca_topic_score_gemma":0.00404209,"teacher_disagreement_score":0.01621505,"about_ca_system_score_codex":0.0000862497,"about_ca_system_score_gemma":0.0007771885,"threshold_uncertainty_score":0.5070351},"labels":[],"label_agreement":null},{"id":"W4410805340","doi":"10.1200/jco.2025.43.16_suppl.10057","title":"Longitudinal associations between chronic health condition burden and financial hardship among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor study (CCSS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Childhood cancer; Cancer; Survivorship curve; Cancer survivor; Longitudinal study; Gerontology; Internal medicine; Pathology","score_opus":0.08218977071209134,"score_gpt":0.4713996641012789,"score_spread":0.3892098933891876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91749805,0.007293763,0.00009161777,0.07059368,0.0026446173,0.0012061659,0.0004952718,0.000026020496,0.00015081961],"genre_scores_gemma":[0.98450136,0.0037289662,0.00012401537,0.0038421496,0.007544873,0.00004531855,0.00006978244,0.000033226446,0.000110318935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98961353,0.0023165033,0.0058505777,0.0006095333,0.0011093675,0.00050048245],"domain_scores_gemma":[0.98419875,0.0065031815,0.006974417,0.0005673901,0.001281797,0.00047447105],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009716944,0.0003560896,0.0036448159,0.00021398907,0.00029776123,0.00003241085,0.0004460465,0.0005399309,0.00013949981],"category_scores_gemma":[0.012109098,0.0002672215,0.0006981523,0.0005825957,0.00051517354,0.00024214826,0.00018491369,0.002237986,0.0000019910374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003980047,0.0016358357,0.9521795,0.00006334493,0.002178715,0.000085547596,0.0029325832,0.000030279683,0.0000018904367,0.000032370303,0.008892501,0.031569466],"study_design_scores_gemma":[0.009665009,0.0048717586,0.97557265,0.0009985425,0.0016609755,0.000027944598,0.0010272999,0.000009145134,0.000011540189,0.0003343792,0.005626767,0.00019396751],"about_ca_topic_score_codex":0.071989,"about_ca_topic_score_gemma":0.14930163,"teacher_disagreement_score":0.077312626,"about_ca_system_score_codex":0.00089373416,"about_ca_system_score_gemma":0.014340694,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W4410805349","doi":"10.1200/jco.2025.43.16_suppl.8590","title":"Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Adverse effect; Phase (matter); Event (particle physics); Internal medicine; Intensive care medicine","score_opus":0.14913641320519486,"score_gpt":0.6175495238850138,"score_spread":0.46841311067981894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859594,0.000057505396,0.00005690564,0.007646262,0.00036850508,0.00048517744,0.000009279199,0.0000023346815,0.0054146308],"genre_scores_gemma":[0.9983486,0.00004998157,0.00019705763,0.0008643548,0.00009128157,0.00001348579,0.0000020152966,0.000003798954,0.00042944754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764216,0.0003300291,0.0016249226,0.000097681266,0.00020632191,0.000098860364],"domain_scores_gemma":[0.99653494,0.0021176918,0.0008190321,0.00023076644,0.00021500446,0.000082537874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014925647,0.00008170827,0.000774677,0.00017384443,0.000030348921,0.000002785155,0.00012753077,0.0000897469,0.00007449958],"category_scores_gemma":[0.0019794544,0.00003915703,0.0005103498,0.00020911677,0.00007966964,0.000043133827,0.0000134109205,0.0004304087,0.0000048351308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052942988,0.05560545,0.8424527,0.000011103933,0.001910123,0.00025490022,0.0015725511,0.00061360345,0.000028020688,0.00043388098,0.0033810632,0.08844228],"study_design_scores_gemma":[0.022376323,0.020852413,0.95245343,0.000047243193,0.00073704123,0.00001101571,0.0009530643,0.00005660027,0.000002553628,0.00020824614,0.0022753614,0.000026677295],"about_ca_topic_score_codex":0.000078437384,"about_ca_topic_score_gemma":0.000058773625,"teacher_disagreement_score":0.11000073,"about_ca_system_score_codex":0.00022011957,"about_ca_system_score_gemma":0.0019485472,"threshold_uncertainty_score":0.3456639},"labels":[],"label_agreement":null},{"id":"W4410805371","doi":"10.1200/jco.2025.43.16_suppl.10062","title":"Retinoblastoma patient outcomes in the contemporary era: The RIVERBOAT Consortium.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Retinoblastoma; Oncology; Family medicine; Internal medicine; Genetics","score_opus":0.08983255364387971,"score_gpt":0.45932300922307673,"score_spread":0.369490455579197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8613626,0.00078564574,0.000014447564,0.10865645,0.0012841295,0.000338132,0.0000014966679,0.0000043687,0.027552739],"genre_scores_gemma":[0.96880335,0.00014381668,0.00027733907,0.030201977,0.00012294474,0.00000827917,9.129956e-7,0.000004510746,0.00043686942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962417,0.0014276897,0.0018005276,0.00012925813,0.00024240134,0.00015843855],"domain_scores_gemma":[0.991666,0.006834273,0.00097248063,0.00025354914,0.00019268939,0.00008099668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031682062,0.00011433704,0.0010841673,0.00009066883,0.00006859847,0.0000058990095,0.0002273161,0.00031146262,0.000041928328],"category_scores_gemma":[0.0039153346,0.000047531175,0.00047067457,0.00016136952,0.00045154948,0.000050252587,0.000055952332,0.0013588576,0.000021999806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002738784,0.0028092056,0.9286793,0.0000070021483,0.00068114954,0.002458703,0.00028679438,0.0000018705787,0.000004982659,0.00086398824,0.019961234,0.041506972],"study_design_scores_gemma":[0.007438406,0.007339312,0.8219822,0.000060592734,0.00027108847,0.00020272631,0.000573513,0.00000792492,0.000020888092,0.0010952833,0.16097224,0.000035818055],"about_ca_topic_score_codex":0.000017576811,"about_ca_topic_score_gemma":0.000047827063,"teacher_disagreement_score":0.141011,"about_ca_system_score_codex":0.00009948518,"about_ca_system_score_gemma":0.0017450656,"threshold_uncertainty_score":0.59036356},"labels":[],"label_agreement":null},{"id":"W4410805428","doi":"10.1200/jco.2025.43.16_suppl.2581","title":"Utilizing targeted intra-tumoral hyperthermia as an immunotherapy in immunogenically ‘cold’ tumor models.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Immunotherapy; Hyperthermia; Cancer research; Oncology; Internal medicine; Cancer","score_opus":0.08776387447650649,"score_gpt":0.4427767026546553,"score_spread":0.35501282817814883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97911376,0.0017142055,0.0001539119,0.0044783405,0.0014899893,0.00024231095,0.0000010045425,0.000020365336,0.012786135],"genre_scores_gemma":[0.9754249,0.00052029896,0.0022305725,0.02077853,0.00048465584,0.0000039252027,0.0000017410656,0.000021421634,0.0005339491],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99525833,0.00081249146,0.0030888251,0.0002340178,0.0003177711,0.00028856844],"domain_scores_gemma":[0.9971574,0.0007672171,0.0009931495,0.0002891338,0.00054074085,0.00025236094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036910337,0.00017654106,0.0014802922,0.00035473282,0.000057074492,0.000016327025,0.00028185197,0.00043003744,0.00027293415],"category_scores_gemma":[0.0012694689,0.00013066203,0.0005230027,0.0003268717,0.00022598037,0.00025524947,0.000043244898,0.0015500687,0.000024392435],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071295284,0.016705025,0.06843497,0.00015198563,0.0020558701,0.0111538125,0.0011358471,0.0019641975,0.11158517,0.013804728,0.005272726,0.6964404],"study_design_scores_gemma":[0.12011899,0.05192379,0.36328205,0.0017459027,0.0009943026,0.0028898853,0.0030943453,0.03390669,0.010607393,0.01123541,0.39886883,0.0013324181],"about_ca_topic_score_codex":0.00002879282,"about_ca_topic_score_gemma":0.000029703886,"teacher_disagreement_score":0.695108,"about_ca_system_score_codex":0.00022610654,"about_ca_system_score_gemma":0.0036631932,"threshold_uncertainty_score":0.67343634},"labels":[],"label_agreement":null},{"id":"W4410805437","doi":"10.1200/jco.2025.43.16_suppl.10055","title":"Association of neurocognitive impairment and financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"American Lebanese Syrian Associated Charities","keywords":"Childhood cancer; Neurocognitive; Medicine; Cancer; Cancer survivor; Gerontology; Association (psychology); Psychiatry; Clinical psychology; Internal medicine; Psychology; Cognition; Psychotherapist","score_opus":0.04702765907266782,"score_gpt":0.4330091009311132,"score_spread":0.3859814418584454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621577,0.0021943897,0.000013078776,0.03162901,0.0024365836,0.0011495437,0.00012779397,0.00000897339,0.0002828772],"genre_scores_gemma":[0.98838043,0.0035188491,0.000106549465,0.0066711307,0.001136258,0.00004377825,0.00000627182,0.000021531563,0.000115190036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905376,0.0023261583,0.0053291447,0.0004501963,0.00101849,0.00033844952],"domain_scores_gemma":[0.98384553,0.008135604,0.0059278826,0.0003705091,0.0015053987,0.00021504455],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009487199,0.00027068987,0.002867908,0.00021956532,0.00006108736,0.00001093815,0.00031542234,0.00045019158,0.00008254678],"category_scores_gemma":[0.024228495,0.00019608294,0.00054369704,0.0005683488,0.00021845291,0.00013971854,0.00016794693,0.0016477372,6.8074934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026896335,0.0074768,0.9587265,0.00006351937,0.0012819627,0.00016438274,0.0051344316,0.000016613776,0.000014868826,0.000010954324,0.0037704606,0.02064987],"study_design_scores_gemma":[0.014786693,0.0051201344,0.972645,0.0009227814,0.0012324611,0.000025499705,0.0023470547,0.000010135079,0.00008990083,0.0002246419,0.0024592325,0.00013648455],"about_ca_topic_score_codex":0.02318663,"about_ca_topic_score_gemma":0.087485455,"teacher_disagreement_score":0.06429882,"about_ca_system_score_codex":0.0003810575,"about_ca_system_score_gemma":0.005803635,"threshold_uncertainty_score":0.9998325},"labels":[],"label_agreement":null},{"id":"W4410805449","doi":"10.1200/jco.2025.43.16_suppl.10058","title":"Treatment and lifestyle profiles of healthy aging survivors: A report from the Childhood Cancer Survivor Study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Childhood cancer; Cancer; Cancer survivor; Gerontology; Cancer survivorship; Survivorship curve; Pediatrics; Internal medicine","score_opus":0.10576316828980592,"score_gpt":0.4973979458084826,"score_spread":0.3916347775186767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91479856,0.005560864,0.000045530534,0.07604496,0.002181599,0.00077548076,0.000023707935,0.000012672676,0.00055660575],"genre_scores_gemma":[0.9893101,0.0028007505,0.0006399984,0.004882376,0.0020505378,0.000025379752,0.000004659656,0.000020249421,0.0002659411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992873,0.0017854405,0.0041860486,0.00038149382,0.00050313264,0.0002708527],"domain_scores_gemma":[0.9863042,0.009173308,0.003151797,0.00053747033,0.00051441556,0.00031878747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068347757,0.00023286029,0.0025132687,0.00012402273,0.00009901984,0.000014580788,0.00024173241,0.00025797155,0.00005820085],"category_scores_gemma":[0.0055256016,0.00013763375,0.00047622877,0.00027612288,0.0003119074,0.0000849762,0.00012297374,0.0008487046,0.000001622117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019320791,0.0053270115,0.94464034,0.00005187539,0.0018833536,0.00033743144,0.0027751762,0.0000037792474,0.000016652746,0.00002918831,0.0019926785,0.041010458],"study_design_scores_gemma":[0.0098927,0.010065625,0.9453936,0.00039399866,0.0010421961,0.00018487548,0.0033768625,0.000009054927,0.00006137462,0.00021540563,0.029263599,0.000100694146],"about_ca_topic_score_codex":0.017505398,"about_ca_topic_score_gemma":0.01764872,"teacher_disagreement_score":0.074511535,"about_ca_system_score_codex":0.00021404294,"about_ca_system_score_gemma":0.005243131,"threshold_uncertainty_score":0.9890371},"labels":[],"label_agreement":null},{"id":"W4410805450","doi":"10.1200/jco.2025.43.16_suppl.10050","title":"Updated efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring <i>ROS1</i> fusions.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Central nervous system; Oncology; Cancer research; Cancer; Internal medicine; Adenocarcinoma","score_opus":0.03351364821035009,"score_gpt":0.40006504088110245,"score_spread":0.3665513926707524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969024,0.00014956531,0.000037798953,0.00096866663,0.00028946743,0.00053395296,0.000008408101,0.0000129175405,0.0010967887],"genre_scores_gemma":[0.997785,0.00040856603,0.0011112243,0.00029779237,0.00022696564,0.0000028770976,0.000004866355,0.000014233207,0.00014849962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966524,0.0004577987,0.0019329858,0.00023490918,0.00035043817,0.0003714246],"domain_scores_gemma":[0.99712586,0.0012817931,0.00081823644,0.00016720853,0.00019865361,0.00040821804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010841996,0.00016057664,0.001520448,0.00023847724,0.00004804057,0.000008867788,0.00013915617,0.00018911733,0.00003374837],"category_scores_gemma":[0.0009970932,0.00009649988,0.00016212063,0.0003225867,0.00021012039,0.000083928484,0.00008944463,0.0009793418,0.00000202313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09147337,0.0046588765,0.7602673,0.00016318086,0.0011079726,0.00523328,0.00006438917,0.000049818107,0.001300803,0.000051572908,0.0004538208,0.1351756],"study_design_scores_gemma":[0.030306775,0.01060069,0.9550051,0.0007714197,0.0003082969,0.0018124394,0.000051869643,0.00003961808,0.00031367454,0.000004473853,0.0007194976,0.00006610749],"about_ca_topic_score_codex":0.000041428302,"about_ca_topic_score_gemma":0.000053893014,"teacher_disagreement_score":0.19473782,"about_ca_system_score_codex":0.00021111725,"about_ca_system_score_gemma":0.0023654988,"threshold_uncertainty_score":0.42548072},"labels":[],"label_agreement":null},{"id":"W4410805477","doi":"10.1200/jco.2025.43.16_suppl.10070","title":"Predicting valvular heart disease in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort (SJLIFE).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Childhood cancer; Cohort; Cancer; Disease; Cohort study; Pediatrics; Internal medicine; Gerontology; Oncology","score_opus":0.0273005439734989,"score_gpt":0.402011513877811,"score_spread":0.3747109699043121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831595,0.0023102541,0.0000194005,0.012022294,0.0012222907,0.0010374768,0.000053302658,0.00001636055,0.00015914904],"genre_scores_gemma":[0.9921257,0.0023020399,0.00013541747,0.0039851083,0.001328626,0.000038346247,0.00000859063,0.000021055163,0.000055134034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511665,0.0009288774,0.0027556112,0.00037909305,0.000576471,0.00024328243],"domain_scores_gemma":[0.9948517,0.0024790054,0.0014469195,0.0003797335,0.00052115857,0.00032149925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047330833,0.00020250026,0.0018117343,0.00012755717,0.00007443194,0.000012037494,0.00017874636,0.00030103128,0.000043385888],"category_scores_gemma":[0.0061426368,0.0001413234,0.00049789983,0.00033126262,0.0002024516,0.00010409285,0.00008400459,0.0012881424,4.6525648e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013990377,0.0028030407,0.98481125,0.000036023135,0.0014961741,0.00026388437,0.00075310766,0.00008982045,0.00020772727,0.0000059893337,0.0007051509,0.0074288226],"study_design_scores_gemma":[0.008075366,0.0013697098,0.986163,0.0007575927,0.0011976364,0.000045760575,0.00065313774,0.000101175276,0.00022884057,0.0001804377,0.0011210112,0.00010630773],"about_ca_topic_score_codex":0.008521346,"about_ca_topic_score_gemma":0.00772704,"teacher_disagreement_score":0.008966211,"about_ca_system_score_codex":0.00017352356,"about_ca_system_score_gemma":0.00324956,"threshold_uncertainty_score":0.99808097},"labels":[],"label_agreement":null},{"id":"W4410805568","doi":"10.1200/jco.2025.43.16_suppl.e20585","title":"PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; PD-L1; Internal medicine; Programmed cell death 1; Meta-analysis; Cancer; Cancer research; Immunotherapy","score_opus":0.11961093292082893,"score_gpt":0.4749252272377434,"score_spread":0.35531429431691447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97193986,0.0063591576,0.00008601566,0.010166405,0.005707324,0.0005765462,0.000037376,0.000011517924,0.0051158047],"genre_scores_gemma":[0.9917,0.0029122776,0.001252375,0.0023521022,0.0003804082,0.000031519176,0.0000064651676,0.000026993042,0.001337887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923236,0.0008509924,0.005280047,0.00045847768,0.00064347615,0.00044344383],"domain_scores_gemma":[0.9882528,0.0066805235,0.003613297,0.00042572513,0.0007403908,0.0002872302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005160872,0.00037529884,0.006460983,0.001110733,0.000051923085,0.000012261742,0.00038070456,0.0006565897,0.00044864143],"category_scores_gemma":[0.0023431578,0.00026298867,0.0050286874,0.0019776989,0.00039907312,0.00014764826,0.0001182745,0.0014944822,0.0000024288345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119481154,0.004939424,0.535896,0.0003151914,0.284145,0.0005302461,0.0012295016,0.00139678,0.002690115,0.00003871365,0.007841776,0.041496105],"study_design_scores_gemma":[0.06827001,0.009575272,0.64607126,0.00027103606,0.23471853,0.0000074988284,0.0019485293,0.00048678202,0.004926145,0.00007789518,0.033103656,0.0005434092],"about_ca_topic_score_codex":0.0010689878,"about_ca_topic_score_gemma":0.004232257,"teacher_disagreement_score":0.110175245,"about_ca_system_score_codex":0.00078452955,"about_ca_system_score_gemma":0.0031694311,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W4410807220","doi":"10.1200/jco.2025.43.16_suppl.e23064","title":"Outcomes of temozolomide and capecitabine chemotherapy used in neuroendocrine and endocrine tumours: A real-world comparison of treatment evidence in Alberta, Canada, from 2011-2021.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services; Occupational Cancer Research Centre","funders":"","keywords":"Capecitabine; Temozolomide; Medicine; Chemotherapy; Oncology; Internal medicine; Neuroendocrine tumors; Endocrine system; Cancer; Hormone","score_opus":0.10330653711409622,"score_gpt":0.48036012408073003,"score_spread":0.3770535869666338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95825326,0.0014584458,0.0000012957533,0.039357815,0.00023596386,0.0004020133,0.000008660336,0.0000018867614,0.00028065027],"genre_scores_gemma":[0.99107575,0.006839207,0.00067575637,0.000524082,0.000082309656,0.000008253237,0.0000016266748,0.000013681568,0.00077933614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953951,0.0005465539,0.0030564063,0.00031123235,0.0003540204,0.00033665315],"domain_scores_gemma":[0.98525894,0.012799589,0.0012197978,0.00026552044,0.00018642165,0.00026972417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049155514,0.00021631602,0.0030654178,0.0004817431,0.000013494904,0.000004420924,0.00018109291,0.000021336862,0.000087811],"category_scores_gemma":[0.004513791,0.00015645844,0.00015360632,0.00028847042,0.0003188173,0.0001210441,0.00009338519,0.00068464456,3.8712204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050378228,0.0013418923,0.970941,0.00006946135,0.0001614151,0.0028668374,0.000047310885,0.000023204842,0.0011938161,0.000037528207,0.00073923304,0.017540468],"study_design_scores_gemma":[0.01512854,0.007153718,0.967877,0.00037807075,0.00012705446,0.00014388553,0.00016676114,0.00020904987,0.004382474,0.00015539314,0.004199395,0.00007869949],"about_ca_topic_score_codex":0.510335,"about_ca_topic_score_gemma":0.8890939,"teacher_disagreement_score":0.37875885,"about_ca_system_score_codex":0.00036938104,"about_ca_system_score_gemma":0.002564917,"threshold_uncertainty_score":0.63801897},"labels":[],"label_agreement":null},{"id":"W4410807268","doi":"10.1200/jco.2025.43.16_suppl.e23048","title":"Access to initial and subsequent indications of new oncology drugs: A US-Canada comparison.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical Oncology; Family medicine; Cancer","score_opus":0.19195813090809982,"score_gpt":0.4713735858601977,"score_spread":0.27941545495209785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89111435,0.002391261,0.0035411417,0.033558466,0.003435445,0.00021164605,0.00005185123,0.000003855093,0.06569196],"genre_scores_gemma":[0.9870667,0.00076841057,0.0017284097,0.009538656,0.0005078827,0.000003649451,0.0000012689454,0.000007944695,0.00037709431],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99581397,0.00006709667,0.0036453346,0.00020891667,0.000045991088,0.0002186655],"domain_scores_gemma":[0.9950597,0.001088023,0.003144384,0.00017752424,0.0001645162,0.00036580488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019458985,0.00011348893,0.0017635846,0.00029525568,0.000044319542,0.000025765989,0.00047902076,0.00029960292,0.00018354344],"category_scores_gemma":[0.0028916362,0.00011636258,0.00018217493,0.00022383091,0.00016258772,0.00024511557,0.00015227924,0.0005268202,0.000012470519],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009810327,0.0006920546,0.50637335,0.000031506752,0.00043006055,0.000026577913,0.00042245365,0.00020867729,0.0000035839478,0.0749942,0.16841474,0.24742174],"study_design_scores_gemma":[0.001744801,0.001055142,0.3990403,0.000024711733,0.000030459458,0.0000064343963,0.000074852884,0.00004428445,0.000018420695,0.0142755415,0.5836021,0.00008296124],"about_ca_topic_score_codex":0.031162845,"about_ca_topic_score_gemma":0.06423083,"teacher_disagreement_score":0.41518733,"about_ca_system_score_codex":0.00046707905,"about_ca_system_score_gemma":0.006154939,"threshold_uncertainty_score":0.99947923},"labels":[],"label_agreement":null},{"id":"W4410807344","doi":"10.1200/jco.2025.43.16_suppl.e23059","title":"The STAMPEDE2 trial: A site survey of current patterns of care, access to imaging, and treatment of metastatic prostrate cancer in Nigeria.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer; Cancer imaging; Oncology; Internal medicine","score_opus":0.10693139834892043,"score_gpt":0.5019518940525001,"score_spread":0.39502049570357967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886197,0.009544854,0.00014231891,0.00036150368,0.00076584914,0.0003215752,0.00020722677,2.572825e-7,0.000036704514],"genre_scores_gemma":[0.9793621,0.020368177,0.0000634236,0.00008226682,0.00008523152,0.000013491152,0.0000068717077,0.0000050384315,0.000013409902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997879,0.00033788176,0.0014572158,0.000128843,0.000085923144,0.00011110798],"domain_scores_gemma":[0.99731976,0.00093126466,0.0010868058,0.00015178148,0.00044194362,0.00006842478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001131431,0.00008621427,0.0007142863,0.00005951127,0.000012491205,0.000008553502,0.00016411312,0.000060992086,0.0000032872852],"category_scores_gemma":[0.0012373195,0.000056551955,0.00014273521,0.00008458468,0.00009834491,0.000003453698,0.000088359535,0.00008783929,4.0063785e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021191435,0.00077517354,0.7775878,0.00006664236,0.00022766153,0.000005413224,0.00014539223,0.00018790088,0.002645662,0.00001926632,0.00025999136,0.19688766],"study_design_scores_gemma":[0.021713989,0.010668505,0.93960226,0.00013123972,0.00016713468,0.000001879028,0.00015978556,0.000018435192,0.010138232,0.00008984495,0.01722412,0.00008459798],"about_ca_topic_score_codex":0.00083154626,"about_ca_topic_score_gemma":0.021433601,"teacher_disagreement_score":0.19680306,"about_ca_system_score_codex":0.000042309566,"about_ca_system_score_gemma":0.0015530353,"threshold_uncertainty_score":0.9964227},"labels":[],"label_agreement":null},{"id":"W4410807366","doi":"10.1200/jco.2025.43.16_suppl.e23023","title":"Partnering with patients to deliver window-of-opportunity clinical trials in immuno-oncology.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Window of opportunity; Clinical Oncology; Oncology; Clinical trial; Internal medicine; Medical physics; Cancer","score_opus":0.7126013148872049,"score_gpt":0.7015030280972834,"score_spread":0.01109828678992153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95334214,0.00018528751,0.0003638966,0.03731004,0.001517561,0.0007823959,0.0000040026425,0.000005743195,0.006488959],"genre_scores_gemma":[0.9614733,0.0016909597,0.003239889,0.032575443,0.0007209528,0.000010021303,0.0000031318596,0.000012834817,0.00027350808],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9818796,0.0066130958,0.009607332,0.00026626702,0.0008576596,0.0007760465],"domain_scores_gemma":[0.74076134,0.19879535,0.015397488,0.0017611344,0.007869109,0.035415594],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.100049056,0.00016071221,0.0045553884,0.00047286847,0.00003370705,0.0000052936193,0.00028731395,0.00081005215,0.00020111557],"category_scores_gemma":[0.66180724,0.00009736102,0.0006021145,0.000494464,0.0004343947,0.000100069235,0.00013188989,0.0027180393,0.000013405355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0253182,0.00394246,0.3360671,0.00008802375,0.00025058794,0.0005980759,0.000061606894,0.0000032711864,0.000038900194,0.000030059058,0.01979692,0.61380476],"study_design_scores_gemma":[0.023324853,0.04161763,0.63735294,0.00075395056,0.00020587776,0.000028392968,0.00011803049,0.00002391544,0.000038965813,0.000094380164,0.2963745,0.00006653703],"about_ca_topic_score_codex":0.000060393217,"about_ca_topic_score_gemma":0.00011745866,"teacher_disagreement_score":0.61373824,"about_ca_system_score_codex":0.00046253862,"about_ca_system_score_gemma":0.038696654,"threshold_uncertainty_score":0.9995827},"labels":[],"label_agreement":null},{"id":"W4410807393","doi":"10.1200/jco.2025.43.16_suppl.5100","title":"Assessment of the impact of delays to radiotherapy on prostate cancer mortality in localized prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Cancer; Prostate; Oncology; Internal medicine; Gynecology","score_opus":0.09115845439961211,"score_gpt":0.5579404797126093,"score_spread":0.4667820253129972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837787,0.0019017841,0.000025426492,0.011722117,0.00083094335,0.0010364356,0.00007037507,0.0000027702588,0.00063142384],"genre_scores_gemma":[0.98477966,0.012378806,0.00046636304,0.0020096991,0.0001285517,0.0000925476,0.0000011756135,0.00001237181,0.00013081559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963844,0.00043420683,0.0023692015,0.00021037855,0.00035943638,0.00024241146],"domain_scores_gemma":[0.9965321,0.0008104224,0.0016877679,0.0002986178,0.0004722636,0.00019882986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019811678,0.00017014594,0.0018211677,0.00015300271,0.00002100351,0.000004502135,0.0001829071,0.00016695305,0.00010650681],"category_scores_gemma":[0.00043670912,0.00008882124,0.0006571687,0.00043206778,0.00018842581,0.000044605054,0.000045101784,0.0005970072,2.554117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052202684,0.002958567,0.9070434,0.00008397501,0.0013325613,0.00006266605,0.00019335261,0.0063877953,0.0004862388,0.000085075466,0.002131893,0.07401424],"study_design_scores_gemma":[0.01210744,0.013156403,0.9684465,0.0011345167,0.0002995591,0.0000048371016,0.00004086449,0.00029991008,0.001097154,0.00021622573,0.0031320069,0.00006459678],"about_ca_topic_score_codex":0.0024366756,"about_ca_topic_score_gemma":0.0008426131,"teacher_disagreement_score":0.07394964,"about_ca_system_score_codex":0.0015625404,"about_ca_system_score_gemma":0.0073883473,"threshold_uncertainty_score":0.99823886},"labels":[],"label_agreement":null},{"id":"W4410807859","doi":"10.1200/jco.2025.43.16_suppl.12110","title":"Systematic screening of perception of curability among patients with advanced cancer: A longitudinal analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Digital Imaging in Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine","score_opus":0.055170213582113874,"score_gpt":0.4691533022362662,"score_spread":0.41398308865415234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925488,0.00025062417,0.0047919946,0.0007312936,0.0003109505,0.0003527958,0.000003667319,0.0000052509636,0.0010045702],"genre_scores_gemma":[0.9939889,0.000069488524,0.005596509,0.00018015779,0.000070974624,0.0000046835476,0.0000034394177,0.000006706034,0.00007914252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533045,0.00031998215,0.00346917,0.00017527229,0.00056264194,0.0001424764],"domain_scores_gemma":[0.99230903,0.001842718,0.003579021,0.00027462887,0.0018340432,0.00016052873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030309847,0.00012029245,0.003076262,0.00037278142,0.000015095018,0.0000033005665,0.0001559121,0.0001376399,0.000045342233],"category_scores_gemma":[0.007753092,0.00007339703,0.0005378987,0.0007029554,0.0005445916,0.0001816806,0.00003935681,0.0005190391,3.6829522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026263641,0.0013137152,0.9708026,0.0029611394,0.0026775508,0.000020037081,0.000060869217,0.0003816733,0.000029635687,0.0000105813215,0.00008835737,0.019027464],"study_design_scores_gemma":[0.0058513107,0.0055153435,0.97352916,0.007464602,0.0066107903,0.000006024822,0.00026793056,0.000634083,0.000014222978,0.00003249047,0.000025956098,0.00004810978],"about_ca_topic_score_codex":0.00005401454,"about_ca_topic_score_gemma":0.000043653337,"teacher_disagreement_score":0.018979354,"about_ca_system_score_codex":0.0001405971,"about_ca_system_score_gemma":0.00062565046,"threshold_uncertainty_score":0.9281735},"labels":[],"label_agreement":null},{"id":"W4410807931","doi":"10.1200/jco.2025.43.16_suppl.e18549","title":"Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: A meta-analysis of randomized controlled trials.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Mesenchymal stem cell; Graft-versus-host disease; Transplantation; Meta-analysis; Hematopoietic stem cell transplantation; Randomized controlled trial; Stem cell; Surgery; Haematopoiesis; Stromal cell; Disease; Clinical trial; Oncology; Internal medicine; Pathology; Biology","score_opus":0.21935017258165326,"score_gpt":0.4922804377489798,"score_spread":0.27293026516732655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9079033,0.03674131,0.017823087,0.017729478,0.0027774132,0.013785049,0.00029386298,0.000013809698,0.0029326759],"genre_scores_gemma":[0.994613,0.0014843444,0.0011382591,0.00022527213,0.00022087671,0.0003073651,0.000004280388,0.000014807879,0.0019918317],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9808382,0.0073518143,0.009927461,0.0003090197,0.0012550652,0.00031846133],"domain_scores_gemma":[0.8600093,0.1312443,0.0059383875,0.00047991483,0.0018955837,0.0004324819],"candidate_categories":["metaresearch","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.049836747,0.00027598962,0.020119859,0.00067978655,0.00005032607,0.000016688136,0.0004065987,0.00036905322,0.0010293619],"category_scores_gemma":[0.014901508,0.00012298646,0.020678194,0.0007430467,0.0006837794,0.00006782003,0.000048596634,0.00077441864,0.0000022981276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7886188,0.001430488,0.0004410156,0.0005960416,0.20666581,0.00016199838,0.00015060733,0.00015140788,0.00058457884,0.00024598974,0.00020667927,0.0007465736],"study_design_scores_gemma":[0.38318378,0.00516278,0.0020333736,0.000047962654,0.6062219,0.000004579142,0.00022597909,0.0012122192,0.0012973031,0.000103925915,0.00042181896,0.00008438268],"about_ca_topic_score_codex":0.000018243996,"about_ca_topic_score_gemma":0.000024234352,"teacher_disagreement_score":0.40543503,"about_ca_system_score_codex":0.00006572168,"about_ca_system_score_gemma":0.0027190903,"threshold_uncertainty_score":0.99988383},"labels":[],"label_agreement":null},{"id":"W4410807939","doi":"10.1200/jco.2025.43.16_suppl.1608","title":"Implementation of a clinical trial navigation program for cancer patients: Barriers and facilitators identified through stakeholder perspectives.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Windsor; University of Ottawa; Western University; University of Manitoba; University of Toronto","funders":"","keywords":"Medicine; Cancer; Stakeholder; Clinical trial; Family medicine; Internal medicine; Public relations","score_opus":0.6367294660333643,"score_gpt":0.7238857118357259,"score_spread":0.08715624580236159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849578,0.0004110036,0.00054431334,0.008248829,0.0031793073,0.0021520082,0.000040126928,0.000009712002,0.000456878],"genre_scores_gemma":[0.9896834,0.0017108171,0.006388455,0.00083631004,0.00084337586,0.00012929206,0.000009985308,0.000014816442,0.00038355336],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99143976,0.00097194756,0.0060830708,0.0004022243,0.0008245674,0.00027841213],"domain_scores_gemma":[0.96465605,0.027907576,0.0026936464,0.00023295936,0.0041271495,0.00038258586],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.020662282,0.00013930045,0.0017455082,0.00012704871,0.00007510998,0.000018715284,0.00020243533,0.0008983616,0.0001813565],"category_scores_gemma":[0.093753725,0.00010566834,0.0007607904,0.0002524916,0.001047298,0.00020167361,0.00009383506,0.0023022608,9.012741e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10205356,0.0038160107,0.39888465,0.00037802503,0.0016503875,0.000013195182,0.0014368859,0.0000014980905,0.000012505504,0.007826389,0.0044746003,0.4794523],"study_design_scores_gemma":[0.25800166,0.082304984,0.5745113,0.0006360304,0.0013878347,0.000003238556,0.019669533,0.00004025325,0.0001255085,0.02819119,0.034947116,0.00018135736],"about_ca_topic_score_codex":0.00014044977,"about_ca_topic_score_gemma":0.00024260678,"teacher_disagreement_score":0.47927094,"about_ca_system_score_codex":0.0002084588,"about_ca_system_score_gemma":0.0068230773,"threshold_uncertainty_score":0.99999946},"labels":[],"label_agreement":null},{"id":"W4410807952","doi":"10.1200/jco.2025.43.16_suppl.1625","title":"National cancer system characteristics and global pan-cancer outcomes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute; Prostate Cancer Foundation","keywords":"Medicine; Cancer; Oncology; Internal medicine","score_opus":0.24218519664557245,"score_gpt":0.5607742756040172,"score_spread":0.3185890789584447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493689,0.0030002429,0.0003634855,0.02739205,0.0048318924,0.00015207524,0.00004145825,0.000014772651,0.014835127],"genre_scores_gemma":[0.98563343,0.0012295768,0.0008693229,0.010599714,0.0012069984,0.000006496699,0.0000010072482,0.0000041939616,0.00044926026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749076,0.00012580019,0.0016333655,0.00014947477,0.0004299805,0.00017062086],"domain_scores_gemma":[0.9971598,0.0006394486,0.0009851424,0.000079276484,0.00093170867,0.00020463482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017889902,0.00010684732,0.0011911254,0.00005949925,0.000043820342,0.000013249926,0.000116787916,0.0002753487,0.0000622711],"category_scores_gemma":[0.0021964943,0.00007446433,0.00025139027,0.00015790635,0.00013745454,0.00008776286,0.000055718665,0.00051315146,0.0000048191196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010833334,0.000121289144,0.82687914,0.000068971785,0.00038731034,0.00015844333,0.000009203197,0.000004212701,0.000009473769,0.00232891,0.009932801,0.15901689],"study_design_scores_gemma":[0.0029942112,0.0007118972,0.92279434,0.00048393148,0.00037451985,0.00014167062,0.000085973596,0.00016297834,0.0000032406938,0.00024173767,0.07194874,0.000056755423],"about_ca_topic_score_codex":0.00013354018,"about_ca_topic_score_gemma":0.00010059416,"teacher_disagreement_score":0.15896013,"about_ca_system_score_codex":0.00069666014,"about_ca_system_score_gemma":0.003861225,"threshold_uncertainty_score":0.6849648},"labels":[],"label_agreement":null},{"id":"W4410807970","doi":"10.1200/jco.2025.43.16_suppl.e18522","title":"Who benefits from gilteritinib combination therapy amongst FLT3 <sup>mut</sup> R/R AML? Genomic insights.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cancer research; Oncology; Internal medicine","score_opus":0.0985192387814318,"score_gpt":0.43735206471058363,"score_spread":0.3388328259291518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635898,0.0024765912,0.00025991717,0.023355918,0.0009383355,0.00041383936,0.000010183269,0.00002156157,0.00893389],"genre_scores_gemma":[0.97455364,0.009695536,0.0017761225,0.009454649,0.0019934983,0.00001099236,0.000027823773,0.000038049588,0.0024497085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948057,0.0008925189,0.002954055,0.00037062328,0.0005809209,0.00039618803],"domain_scores_gemma":[0.9927335,0.004356282,0.0012019394,0.00043347775,0.0008005658,0.00047427052],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027638786,0.00023965212,0.0020171104,0.00042262056,0.00010319197,0.00003649288,0.0005369014,0.00084981904,0.00035616074],"category_scores_gemma":[0.0036242157,0.00017725509,0.0006246643,0.00036965753,0.00041317992,0.00020966628,0.00017389205,0.002423507,0.00009633194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017846195,0.0043085753,0.08853292,0.000049332775,0.0022143882,0.0013931936,0.00072985457,0.00015621807,0.002895289,0.004368759,0.059898715,0.81760657],"study_design_scores_gemma":[0.025090668,0.008222417,0.58211434,0.00026062256,0.00023876157,0.000103696286,0.0002571216,0.0017330829,0.00072112615,0.0029228798,0.37816828,0.00016702278],"about_ca_topic_score_codex":0.000102315804,"about_ca_topic_score_gemma":0.000034472032,"teacher_disagreement_score":0.81743956,"about_ca_system_score_codex":0.0007278814,"about_ca_system_score_gemma":0.0036133786,"threshold_uncertainty_score":0.9998779},"labels":[],"label_agreement":null},{"id":"W4410808236","doi":"10.1200/jco.2025.43.16_suppl.e17127","title":"Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Post-hoc analysis; Oncology; Internal medicine; Cancer; Prostate; Gynecology; Urology; Androgen receptor","score_opus":0.03541493979559037,"score_gpt":0.41242726676455077,"score_spread":0.3770123269689604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907725,0.0024116274,0.0000148697045,0.0045468267,0.00021713717,0.001234215,0.0003191479,0.000019569927,0.00046412766],"genre_scores_gemma":[0.99065804,0.005961902,0.00082025304,0.0011201673,0.0000792443,0.00012786458,0.00020521418,0.000035994846,0.0009913202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951621,0.00065048673,0.0023067668,0.0006065357,0.0006493317,0.0006247472],"domain_scores_gemma":[0.9947142,0.001508304,0.001713091,0.000346407,0.0011936886,0.000524293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089488097,0.00046211516,0.0031421017,0.00067945744,0.00010054438,0.000030121782,0.00022156052,0.00039355241,0.00010555212],"category_scores_gemma":[0.0005939793,0.00024352923,0.00056578795,0.0010149573,0.00065150607,0.00015297632,0.00007046098,0.0013676779,0.0000060348452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08149604,0.0048544807,0.7833293,0.00004407757,0.008374255,0.00050413946,0.00022428102,0.00004098343,0.000039035156,0.000008161306,0.00070926035,0.120376],"study_design_scores_gemma":[0.07842653,0.052420508,0.8598349,0.0003787751,0.005271155,0.0000110613155,0.00021248385,0.000030657968,0.00088235125,0.000042591808,0.0022483899,0.00024058603],"about_ca_topic_score_codex":0.0008930006,"about_ca_topic_score_gemma":0.0018238433,"teacher_disagreement_score":0.12013541,"about_ca_system_score_codex":0.0025267333,"about_ca_system_score_gemma":0.0063784337,"threshold_uncertainty_score":0.99925447},"labels":[],"label_agreement":null},{"id":"W4410808328","doi":"10.1200/jco.2025.43.16_suppl.e17144","title":"Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto; Western University; Université de Montréal; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Calgary; St. Joseph’s Healthcare Hamilton; University Health Network; Ottawa Hospital; Dalhousie University; McMaster University","funders":"","keywords":"Medicine; Cancer; Prostate; Prostate cancer; Peri; Gynecology; General surgery; Oncology; Internal medicine","score_opus":0.2731722979580551,"score_gpt":0.5644041773535432,"score_spread":0.2912318793954881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93309325,0.00017559605,0.010398484,0.052428823,0.0014279848,0.00171468,0.000047137968,0.000012301632,0.00070175173],"genre_scores_gemma":[0.96104926,0.000385479,0.024822015,0.013036435,0.000545315,0.000091744994,0.000013246628,0.00001533577,0.000041199244],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99285465,0.0010821841,0.0050304215,0.0002404884,0.0005384336,0.0002538445],"domain_scores_gemma":[0.9860528,0.0076992046,0.0033384813,0.00030917983,0.0022818572,0.0003184891],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007222265,0.00017774984,0.0015246785,0.00021321408,0.00015214726,0.000021060932,0.00024201047,0.00023233592,0.00012843062],"category_scores_gemma":[0.045026448,0.00011120422,0.0003796073,0.00054622965,0.00016670748,0.00014966482,0.00012130329,0.0014709615,0.00002414979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03855881,0.0012825135,0.4356508,0.00014618073,0.0008853679,0.000049379472,0.00234583,0.010052367,0.00012922415,0.00055297127,0.008406832,0.5019397],"study_design_scores_gemma":[0.029665941,0.026832884,0.781506,0.00073431607,0.0027673512,0.000021490023,0.005802798,0.002165356,0.0007191359,0.001286497,0.14825588,0.00024231143],"about_ca_topic_score_codex":0.0025934104,"about_ca_topic_score_gemma":0.0046247654,"teacher_disagreement_score":0.5016974,"about_ca_system_score_codex":0.00044561375,"about_ca_system_score_gemma":0.0037690236,"threshold_uncertainty_score":0.9630177},"labels":[],"label_agreement":null},{"id":"W4410808423","doi":"10.1200/jco.2025.43.16_suppl.1587","title":"Breast cancer optimal care timeframes for culturally and linguistically diverse populations and First Nations People: A regional centre experience in Australia.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Breast cancer; Family medicine; Internal medicine","score_opus":0.24579488007051375,"score_gpt":0.5396728090248177,"score_spread":0.293877928954304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97842103,0.00070073886,0.000188058,0.01977479,0.0004049604,0.00019629153,0.000026439922,0.000004106731,0.0002835863],"genre_scores_gemma":[0.9888727,0.0005175684,0.009235748,0.00074309023,0.00033972,0.000007762391,0.0000037769955,0.0000029055907,0.0002767077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874955,0.000044538436,0.0007699801,0.00014730726,0.00014582225,0.00014278968],"domain_scores_gemma":[0.9980448,0.0008194954,0.00028849623,0.000053619446,0.0006230487,0.00017053337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002811664,0.00007885922,0.0004918388,0.00009444105,0.00010327271,0.000014603095,0.000066775705,0.0001757608,0.00004679707],"category_scores_gemma":[0.0025115479,0.0000598164,0.00010410372,0.00015053633,0.00015793656,0.00008819453,0.00003898232,0.00031202257,3.6846924e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017958309,0.0001314904,0.9778009,0.00007527371,0.00006485728,0.00007963969,0.0021802508,0.00020046326,0.0000063180346,0.0022723633,0.0032240555,0.012168572],"study_design_scores_gemma":[0.0030645826,0.00060396525,0.97537905,0.00050895615,0.00018873601,0.00020376699,0.004339012,0.00041091244,0.0000010832433,0.00017299132,0.015062467,0.0000644967],"about_ca_topic_score_codex":0.000458375,"about_ca_topic_score_gemma":0.010185041,"teacher_disagreement_score":0.0190317,"about_ca_system_score_codex":0.0001367689,"about_ca_system_score_gemma":0.0005600082,"threshold_uncertainty_score":0.56834924},"labels":[],"label_agreement":null},{"id":"W4410808437","doi":"10.1200/jco.2025.43.16_suppl.1586","title":"Intervention adherence, engagement and tool utilization in the breast cancer weight loss (BWEL) trial by race and ethnicity (Alliance A011401).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Mount Sinai Hospital","funders":"","keywords":"Medicine; Ethnic group; Race (biology); Breast cancer; Alliance; Intervention (counseling); Randomized controlled trial; Weight loss; Oncology; Cancer; Internal medicine; Gerontology; Family medicine; Obesity; Nursing; Gender studies","score_opus":0.08407151172223234,"score_gpt":0.455114776313794,"score_spread":0.3710432645915617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870633,0.007748911,0.0007553152,0.0034169902,0.0006471746,0.00022072268,0.000022330049,0.0000012114403,0.0001240292],"genre_scores_gemma":[0.97325104,0.024566934,0.0001535271,0.0013471219,0.00048041219,0.00001547746,0.0000092319315,0.0000038470976,0.00017241697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99797326,0.00077979395,0.0008599548,0.0001751223,0.000105922074,0.00010591385],"domain_scores_gemma":[0.999128,0.00020066237,0.0003470563,0.000104871506,0.00015631231,0.00006310173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00213613,0.000083031344,0.000299161,0.000028006843,0.00004521772,0.000016171298,0.00013379898,0.00021002404,0.000026566493],"category_scores_gemma":[0.00060839986,0.000059915343,0.00011414487,0.00006547633,0.00016769316,0.00000725952,0.000060475602,0.00026141462,2.9301242e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07895729,0.0055828574,0.313088,0.00021336087,0.00038591848,0.000046044603,0.00020854054,0.00002329204,0.0053020683,0.0004287374,0.08785275,0.50791115],"study_design_scores_gemma":[0.083268695,0.006980801,0.6301134,0.00023617252,0.00031483395,0.000048378737,0.00034482,0.00013419201,0.001525539,0.002632927,0.27415404,0.00024614824],"about_ca_topic_score_codex":0.000018337969,"about_ca_topic_score_gemma":0.00014537523,"teacher_disagreement_score":0.507665,"about_ca_system_score_codex":0.000019804102,"about_ca_system_score_gemma":0.00025112473,"threshold_uncertainty_score":0.24432768},"labels":[],"label_agreement":null},{"id":"W4410808583","doi":"10.1200/jco.2025.43.16_suppl.e13558","title":"Modernizing clinical trial accessibility: Integrating the AI-powered LookUpTrials app into the CTN program.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Toronto; University of Manitoba; University of Ottawa; University of Windsor; Western University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.6096147068049095,"score_gpt":0.6910640350243265,"score_spread":0.08144932821941697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80898726,0.0011169795,0.0025296456,0.16695099,0.015274051,0.0017155153,4.3657184e-7,0.000033017746,0.003392123],"genre_scores_gemma":[0.9707622,0.00084447244,0.0030491708,0.016242482,0.008724539,0.000049062113,0.00000183567,0.000013336133,0.00031292965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98833597,0.0030408527,0.0075068786,0.00032668424,0.00045627472,0.00033336668],"domain_scores_gemma":[0.96517324,0.028349455,0.0036745418,0.00072480884,0.0017199619,0.00035798858],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03357873,0.00017305241,0.0016148383,0.00010999827,0.00030152782,0.00008272849,0.00061652006,0.0007101325,0.00011097666],"category_scores_gemma":[0.08272697,0.00007955916,0.0010023067,0.00040286715,0.000758799,0.00016710996,0.00013267466,0.0033272835,0.000023057857],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041956592,0.0018406908,0.019296193,0.000027490129,0.00026000498,0.000019010195,0.0008996772,0.0000040895225,0.000012170641,0.00077681773,0.005383779,0.92952347],"study_design_scores_gemma":[0.027966138,0.06451423,0.035111476,0.0011403497,0.0025576213,0.00013053913,0.017087542,0.0054900507,0.00045317976,0.11903836,0.72611636,0.000394154],"about_ca_topic_score_codex":0.00023271237,"about_ca_topic_score_gemma":0.00035148603,"teacher_disagreement_score":0.9291293,"about_ca_system_score_codex":0.000211634,"about_ca_system_score_gemma":0.0072773825,"threshold_uncertainty_score":0.99897206},"labels":[],"label_agreement":null},{"id":"W4410808631","doi":"10.1200/jco.2025.43.16_suppl.526","title":"Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Medicine; Adjuvant; Neutropenia; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer; Metastatic breast cancer","score_opus":0.08376305800752132,"score_gpt":0.4768709556258369,"score_spread":0.3931078976183156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523752,0.0009442445,0.000064109365,0.040535387,0.0030057258,0.0011613617,0.00001188802,0.000014259975,0.0018878566],"genre_scores_gemma":[0.99035984,0.00043604363,0.0008005174,0.005072827,0.00095968344,0.00004818131,0.0000022585778,0.000027399046,0.0022932636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925438,0.0023804693,0.0038198116,0.00033182846,0.00052904023,0.00039501066],"domain_scores_gemma":[0.9886496,0.008398791,0.0016589048,0.0005272331,0.00043381203,0.00033167188],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004819557,0.00027384126,0.0024959694,0.00037815204,0.000047940837,0.0000114859895,0.0004722619,0.00053647417,0.00021510465],"category_scores_gemma":[0.008958574,0.0001586886,0.00075721345,0.0006137121,0.00035403814,0.00009498972,0.00008597124,0.0011924108,0.000033670105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8191609,0.003531198,0.014147364,0.000022285838,0.00092842325,0.0013682646,0.0012272244,0.00008471947,0.001724904,0.00019028936,0.0014276206,0.15618685],"study_design_scores_gemma":[0.4510752,0.07649139,0.2590991,0.00043114586,0.00091059395,0.00050411036,0.0008831719,0.000030977586,0.000246983,0.0017585837,0.2084016,0.00016714235],"about_ca_topic_score_codex":0.00004984402,"about_ca_topic_score_gemma":0.00020818878,"teacher_disagreement_score":0.36808565,"about_ca_system_score_codex":0.0004925836,"about_ca_system_score_gemma":0.004343558,"threshold_uncertainty_score":0.9993894},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4410808660","doi":"10.1200/jco.2025.43.16_suppl.e13647","title":"Cox models vs. machine learning for survival prediction: Do traditional approaches still hold their ground?","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Proportional hazards model; Artificial intelligence; Machine learning; Oncology; Internal medicine; Computer science","score_opus":0.23888608714313792,"score_gpt":0.4226417471523241,"score_spread":0.1837556600091862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48708686,0.0034491792,0.3520968,0.11595931,0.010737583,0.0009666174,0.000073502975,0.00011801572,0.029512143],"genre_scores_gemma":[0.9816864,0.00072594924,0.010091308,0.003236023,0.0030710762,0.000013380013,0.00004553779,0.000027459566,0.0011028751],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9964586,0.000515459,0.002058638,0.00027850101,0.00040308002,0.0002857496],"domain_scores_gemma":[0.99296784,0.005159028,0.0009970586,0.0001579808,0.00035787665,0.0003601922],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006963933,0.00018721787,0.0014835045,0.0002074892,0.00012563988,0.00003085719,0.00023099863,0.0003949188,0.00007275694],"category_scores_gemma":[0.005877389,0.00013117955,0.00072422664,0.00016935387,0.00033572887,0.00015643395,0.000049865022,0.0025625534,0.0000021256296],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01693351,0.0057832813,0.13418458,0.00047140726,0.0033020268,0.0003636422,0.00053679146,0.026729733,0.00015112456,0.04681489,0.032170787,0.73255825],"study_design_scores_gemma":[0.015560426,0.008026714,0.06516176,0.00032682464,0.00073846866,0.0005376097,0.00025289107,0.5386678,0.000009543333,0.025583105,0.34496084,0.00017401786],"about_ca_topic_score_codex":0.000009421186,"about_ca_topic_score_gemma":0.0000027110636,"teacher_disagreement_score":0.7323842,"about_ca_system_score_codex":0.00014927232,"about_ca_system_score_gemma":0.0012423872,"threshold_uncertainty_score":0.9997386},"labels":[],"label_agreement":null},{"id":"W4410808825","doi":"10.1200/jco.2025.43.16_suppl.1557","title":"Computational pathology to predict docetaxel benefit for high-risk localized prostate cancer in NRG/RTOG 0521 (NCT00288080).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"DOD Prostate Cancer Research Program; National Institute of Biomedical Imaging and Bioengineering; DOD Peer Reviewed Cancer Research Program; National Heart, Lung, and Blood Institute; California Breast Cancer Research Program","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.031499245250890436,"score_gpt":0.4508992075127031,"score_spread":0.4193999622618127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.898325,0.00086534675,0.027438411,0.0693682,0.0028498273,0.0006357182,0.000030504296,0.00001664341,0.0004703185],"genre_scores_gemma":[0.93557805,0.0012715246,0.044975664,0.016211068,0.0011038516,0.000049218204,0.000012517836,0.00002589913,0.00077221735],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960917,0.00035820744,0.0025748855,0.0003094022,0.00031121314,0.00035455212],"domain_scores_gemma":[0.9940756,0.0037044785,0.0010981889,0.00015316675,0.0005814379,0.0003871411],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049559567,0.00016646531,0.0016769537,0.0003641603,0.000064271066,0.000012509182,0.0002177576,0.00034685468,0.0000929796],"category_scores_gemma":[0.010719131,0.00012492173,0.00034124515,0.00029595906,0.00021958014,0.000062194624,0.000079184785,0.0015908051,0.000005674031],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071795867,0.0009911363,0.4329474,0.0001131636,0.00036753362,0.0004508268,0.00017396644,0.024168078,0.000049681257,0.0014485792,0.010429027,0.521681],"study_design_scores_gemma":[0.03625933,0.00794831,0.7634633,0.00059966487,0.0006473779,0.00019144446,0.000092338334,0.040420394,0.000017818937,0.020366047,0.1298096,0.00018432563],"about_ca_topic_score_codex":0.00017791038,"about_ca_topic_score_gemma":0.00009515307,"teacher_disagreement_score":0.5214967,"about_ca_system_score_codex":0.00023400577,"about_ca_system_score_gemma":0.002014115,"threshold_uncertainty_score":0.997614},"labels":[],"label_agreement":null},{"id":"W4410808834","doi":"10.1200/jco.2025.43.16_suppl.1552","title":"Evaluation of longitudinal image-derived AI prognostication as a predictor of overall survival (OS) in a phase 3 advanced non-small cell lung cancer (aNSCLC) trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cancer; Internal medicine","score_opus":0.06920299580114199,"score_gpt":0.5114228554236663,"score_spread":0.4422198596225243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982166,0.000931353,0.006349366,0.0060873637,0.0016147294,0.0010108969,0.000003998578,0.0000053415506,0.0018309287],"genre_scores_gemma":[0.9935036,0.0009763067,0.0044231806,0.00047527257,0.00047943136,0.000033963646,0.000005581321,0.000014147422,0.00008855174],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947531,0.0010012861,0.003010945,0.00023778336,0.00078888395,0.00020799029],"domain_scores_gemma":[0.9931126,0.0023225807,0.0023148744,0.00019590165,0.0018596178,0.00019438312],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011824088,0.00014124071,0.0015606943,0.0002829545,0.000020828638,0.0000066269363,0.00019071452,0.0002561906,0.00014375045],"category_scores_gemma":[0.020389896,0.00011228009,0.0003551392,0.00025237523,0.00022611902,0.00011814799,0.000038196464,0.0011611583,8.193081e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1462015,0.018415751,0.3090714,0.0010781025,0.0014299371,0.00020894871,0.0007725927,0.0026769997,0.058545,0.00019604713,0.0022396683,0.45916405],"study_design_scores_gemma":[0.4241916,0.016798045,0.39450458,0.002086779,0.004641398,0.000027410675,0.00013954008,0.15185544,0.0027482158,0.0013503113,0.0014706778,0.00018600603],"about_ca_topic_score_codex":0.0001021046,"about_ca_topic_score_gemma":0.000033141867,"teacher_disagreement_score":0.45897806,"about_ca_system_score_codex":0.0002491129,"about_ca_system_score_gemma":0.0059080566,"threshold_uncertainty_score":0.99972755},"labels":[],"label_agreement":null},{"id":"W4410808847","doi":"10.1200/jco.2025.43.16_suppl.1547","title":"Automated conversational artificial intelligence (AI) for outpatient malignant bowel obstruction (MBO) symptom monitoring.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Innovations in Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Artificial intelligence; Internal medicine; Computer science","score_opus":0.12144213271334077,"score_gpt":0.5116983841409816,"score_spread":0.3902562514276408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.871912,0.000103454244,0.057608683,0.043936737,0.025310427,0.00053488585,0.000004241592,0.00006171365,0.0005278691],"genre_scores_gemma":[0.9649207,0.000056044755,0.029089179,0.0031592688,0.0024940558,0.000021922098,0.000015210273,0.000010485764,0.00023312792],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99617016,0.0001512789,0.002906394,0.0001856948,0.00039606474,0.00019041786],"domain_scores_gemma":[0.99494195,0.0013377178,0.0013080707,0.0001620922,0.0021322977,0.00011785155],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031576036,0.0001103713,0.0006839915,0.00030351573,0.00008370915,0.000013619354,0.00014355873,0.00045963246,0.00008277762],"category_scores_gemma":[0.015762355,0.00008867973,0.00026695253,0.00035297844,0.00023266235,0.000113296854,0.000027037859,0.0007962654,0.0000132365985],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036383476,0.002808144,0.043531176,0.00015289818,0.0005441602,0.000031637068,0.00034525085,0.00028511466,0.00038061064,0.024965083,0.036624294,0.8866933],"study_design_scores_gemma":[0.0074962317,0.018094536,0.61219144,0.0013966531,0.0017061763,0.00033124213,0.0040660445,0.10830603,0.0064708116,0.04405602,0.19543454,0.0004502387],"about_ca_topic_score_codex":0.0000050495714,"about_ca_topic_score_gemma":0.0000010962366,"teacher_disagreement_score":0.88624305,"about_ca_system_score_codex":0.00047164623,"about_ca_system_score_gemma":0.0027110807,"threshold_uncertainty_score":0.9925283},"labels":[],"label_agreement":null},{"id":"W4410808848","doi":"10.1200/jco.2025.43.16_suppl.12106","title":"The association between emotional distress prior to receiving immune checkpoint inhibitors and overall survival among patients with cancer: A population-based study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"University of Toronto; Conquer Cancer Foundation","keywords":"Medicine; Cancer; Population; Oncology; Distress; Internal medicine; Immune system; Clinical psychology; Immunology; Environmental health","score_opus":0.030321566814302824,"score_gpt":0.38707002757927794,"score_spread":0.35674846076497513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896946,0.000089903144,0.000054708675,0.007627123,0.0019820072,0.0003795939,0.000013116922,0.000006365713,0.00015257184],"genre_scores_gemma":[0.99868363,0.00002908205,0.00005789355,0.0003022087,0.0006591318,0.000010388432,0.000010224395,0.000008873055,0.0002385934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997234,0.00045546814,0.0014575634,0.00015852148,0.00053038617,0.0001640511],"domain_scores_gemma":[0.9948355,0.0029587795,0.0012487043,0.00011967925,0.00066834263,0.00016897636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002831591,0.0001066504,0.00077466713,0.0000797522,0.00013546376,0.000028396877,0.00009469763,0.00017050636,0.00001366906],"category_scores_gemma":[0.002933045,0.00006517705,0.00017639993,0.00017845705,0.000039770854,0.00006761876,0.00004538965,0.00059791916,4.0508155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001558082,0.00039694313,0.94709605,0.000016306481,0.00037263628,0.0000049237337,0.00012500273,0.00003371471,0.0000011063142,0.000006314535,0.00012990226,0.050259028],"study_design_scores_gemma":[0.0057458337,0.0025878684,0.98889476,0.00028696223,0.00036498887,2.1850282e-7,0.00017396343,0.000012234728,0.0000041337407,0.000030005858,0.0018350538,0.00006397317],"about_ca_topic_score_codex":0.0013614382,"about_ca_topic_score_gemma":0.009617718,"teacher_disagreement_score":0.050195057,"about_ca_system_score_codex":0.0006590155,"about_ca_system_score_gemma":0.00073929736,"threshold_uncertainty_score":0.53669125},"labels":[],"label_agreement":null},{"id":"W4410808885","doi":"10.1200/jco.2025.43.16_suppl.e13577","title":"Analysis of ASCO clinical guidelines authorship and institutional representation using HemOnc.org.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine","score_opus":0.7873314762986097,"score_gpt":0.728789412660439,"score_spread":0.058542063638170716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668643,0.00060691783,0.0010375303,0.018616004,0.010761947,0.00024700293,0.0000015162136,0.0000063837792,0.0018584233],"genre_scores_gemma":[0.9803386,0.0020733457,0.013260355,0.0012011442,0.0030527732,0.0000060785023,0.0000015547735,0.0000036642875,0.000062492036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918544,0.0028463185,0.004334795,0.00019170025,0.00059563987,0.00017709559],"domain_scores_gemma":[0.9700808,0.023846038,0.0030946909,0.00013524725,0.0025299625,0.00031325305],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02634818,0.00007142676,0.0012123564,0.0003482976,0.0002064729,0.000013284393,0.00021912619,0.00059403933,0.000066353066],"category_scores_gemma":[0.2224759,0.00006399938,0.00045523627,0.0013030029,0.001070904,0.00020955656,0.000046802736,0.00059987087,0.000001139812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002314543,0.0002734387,0.84959686,0.000013768791,0.0004068219,0.0000048311467,0.0013414347,0.0001152509,0.00000500061,0.0027767767,0.00039732136,0.144837],"study_design_scores_gemma":[0.0009016776,0.00033579796,0.9685299,0.00012733483,0.0013182601,0.0000014982647,0.001260314,0.0010017382,0.0000035862556,0.0028393005,0.02362274,0.000057872086],"about_ca_topic_score_codex":0.002003254,"about_ca_topic_score_gemma":0.0025364019,"teacher_disagreement_score":0.19612773,"about_ca_system_score_codex":0.00033720004,"about_ca_system_score_gemma":0.014619048,"threshold_uncertainty_score":0.99096715},"labels":[],"label_agreement":null},{"id":"W4410808887","doi":"10.1200/jco.2025.43.16_suppl.534","title":"Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Sunnybrook Health Science Centre; Western University","funders":"Canadian Cancer Society Research Institute; Apotex","keywords":"Medicine; Breast cancer; Cancer; Oncology; Cancer recurrence; Internal medicine","score_opus":0.060383098673676486,"score_gpt":0.4623018089985668,"score_spread":0.40191871032489035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914704,0.0018696378,0.00002257708,0.005599895,0.00070269965,0.000109923465,0.00004145348,7.3588694e-7,0.00018270046],"genre_scores_gemma":[0.9940077,0.004752615,0.000051889943,0.000756747,0.00035034798,0.000009794117,0.0000012064748,0.0000037493292,0.000065949556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983812,0.00033239476,0.00089418184,0.00014699505,0.00010198593,0.00014323898],"domain_scores_gemma":[0.9985587,0.00045678357,0.0006386514,0.00013521855,0.00017209387,0.000038579143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014309064,0.000089654044,0.0005266588,0.000027235008,0.000030721836,0.000007204257,0.00020833671,0.00018708645,0.0000065948616],"category_scores_gemma":[0.0004093166,0.0000544629,0.00014978678,0.00007743528,0.0001587498,0.0000053693475,0.00009556411,0.00026701568,3.5212673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021134363,0.0006350857,0.8446456,0.00002090234,0.00031220337,0.000021614682,0.00023925852,0.0000061086525,0.00024203435,0.000041603776,0.00048230056,0.1322189],"study_design_scores_gemma":[0.015836526,0.0016946362,0.97454643,0.00007512376,0.0000757958,0.000021859909,0.00013536532,0.0000010681804,0.0001500872,0.00014767867,0.0072667594,0.000048649636],"about_ca_topic_score_codex":0.00022996844,"about_ca_topic_score_gemma":0.00096079573,"teacher_disagreement_score":0.13217025,"about_ca_system_score_codex":0.000020366175,"about_ca_system_score_gemma":0.00038654695,"threshold_uncertainty_score":0.22209325},"labels":[],"label_agreement":null},{"id":"W4410808915","doi":"10.1200/jco.2025.43.16_suppl.561","title":"Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Overweight; Obesity; Pathological; Weight loss; Internal medicine; Cancer; Oncology","score_opus":0.029469904963398866,"score_gpt":0.3684554361108468,"score_spread":0.33898553114744795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672825,0.0001659473,0.0000033660665,0.011003421,0.0009193763,0.00026992674,0.0008647446,0.0000033181386,0.000041667852],"genre_scores_gemma":[0.99547696,0.0029971818,0.000032630567,0.00075286435,0.0006418642,0.0000038272697,0.000010042092,0.000008013986,0.000076632525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973199,0.0003242368,0.0016265125,0.00021500926,0.00033630343,0.00017803375],"domain_scores_gemma":[0.9947088,0.0026065134,0.0019712367,0.00012827812,0.0004285054,0.00015670086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013164133,0.00014777608,0.0013118272,0.00007195529,0.000040872208,0.000014292769,0.00009400733,0.0003926052,0.000045396293],"category_scores_gemma":[0.0011132123,0.000074482676,0.0001294557,0.0001510539,0.00020121594,0.00009587362,0.000058199475,0.0008334844,2.3840134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061736643,0.0009261155,0.91628796,0.000010633497,0.00029439564,0.000028562261,0.00020334362,2.6710163e-7,0.0000036450128,0.000008323698,0.0006964716,0.019803638],"study_design_scores_gemma":[0.05025313,0.0021463176,0.9444464,0.0002723247,0.00047607216,0.0000063998673,0.00003217059,0.0000051936563,0.0000029766068,0.000051995357,0.0022357865,0.00007124406],"about_ca_topic_score_codex":0.0019238731,"about_ca_topic_score_gemma":0.0010355259,"teacher_disagreement_score":0.028158428,"about_ca_system_score_codex":0.00027375208,"about_ca_system_score_gemma":0.0007830774,"threshold_uncertainty_score":0.36211213},"labels":[],"label_agreement":null},{"id":"W4410808919","doi":"10.1200/jco.2025.43.16_suppl.6574","title":"Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Incyte","keywords":"Medicine; Bromodomain; Myelofibrosis; Refractory (planetary science); Myeloid; Phases of clinical research; Internal medicine; Oncology; Cancer research; Clinical trial; Bone marrow; Epigenetics; Gene","score_opus":0.024315506004046687,"score_gpt":0.3728273287398614,"score_spread":0.3485118227358147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99845797,0.00043753325,0.00011044187,0.00021218414,0.00018861407,0.0003978706,0.000011682533,0.000002551712,0.00018113691],"genre_scores_gemma":[0.99698454,0.0004763125,0.0018697666,0.00039246192,0.00010737928,0.000005445931,0.0000040377417,0.000013966192,0.00014606921],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973716,0.00048516883,0.0015007838,0.00030965765,0.0001688323,0.0001639232],"domain_scores_gemma":[0.99806523,0.000502179,0.0009368659,0.00017155209,0.00016257669,0.00016161919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012264403,0.00017411142,0.00078684627,0.00013402877,0.000046541198,0.000011762804,0.00011523134,0.00031596102,0.000010172612],"category_scores_gemma":[0.0014608528,0.00012141469,0.00007290797,0.00012953191,0.00033457275,0.000023879076,0.00014621681,0.0003734342,2.0491264e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105520114,0.008449482,0.2782289,0.00009924131,0.00039226573,0.000081471,0.00034090702,0.0000066010566,0.03111927,0.000030777097,0.00052438205,0.5752066],"study_design_scores_gemma":[0.13885097,0.118126884,0.6731161,0.0005711829,0.0002824154,0.00009039945,0.0008432991,0.000039750917,0.008989037,0.000095114825,0.058546215,0.0004486661],"about_ca_topic_score_codex":0.000010367797,"about_ca_topic_score_gemma":0.000119966586,"teacher_disagreement_score":0.57475793,"about_ca_system_score_codex":0.0000349366,"about_ca_system_score_gemma":0.00044149623,"threshold_uncertainty_score":0.49511474},"labels":[],"label_agreement":null},{"id":"W4410808924","doi":"10.1200/jco.2025.43.16_suppl.557","title":"Assessment of ovarian function suppression (OFS)-containing adjuvant endocrine therapy in premenopausal women by Breast Cancer Index.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Endocrine system; Breast cancer; Oncology; Gynecology; Adjuvant; Internal medicine; Cancer; Hormone","score_opus":0.02847132488531553,"score_gpt":0.42397209652629453,"score_spread":0.395500771640979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438494,0.0017419714,0.00088091,0.0011153035,0.0010199104,0.00014455328,0.00003484348,0.00000216678,0.00067537086],"genre_scores_gemma":[0.9940349,0.0039988733,0.0002517353,0.0010278947,0.00051030325,0.000019537572,0.000017366996,0.000009319908,0.00013010194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764204,0.0004040774,0.0013506721,0.00021063855,0.00017666497,0.00021590847],"domain_scores_gemma":[0.9984425,0.00012859426,0.0007812429,0.00016519177,0.0003237373,0.00015878433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012064892,0.00012010159,0.0005950467,0.00009617623,0.000028480179,0.0000076153324,0.00017670069,0.0002432821,0.0001240171],"category_scores_gemma":[0.0002090313,0.00009815914,0.0001392017,0.000091459435,0.00009870196,0.00000957331,0.00006738993,0.00030684914,2.0185679e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013149373,0.0025724652,0.73353124,0.00003982505,0.0003353237,0.000020448957,0.000028008102,0.00016475371,0.15128568,0.000060177466,0.005315309,0.09349741],"study_design_scores_gemma":[0.011393859,0.0074309646,0.94681257,0.000082397375,0.000050088216,0.000012441901,0.0001643236,0.00006331033,0.0034589355,0.0005217374,0.029905656,0.0001037031],"about_ca_topic_score_codex":0.000051113933,"about_ca_topic_score_gemma":0.000056350695,"teacher_disagreement_score":0.21328136,"about_ca_system_score_codex":0.000095710166,"about_ca_system_score_gemma":0.0014596678,"threshold_uncertainty_score":0.40028134},"labels":[],"label_agreement":null},{"id":"W4410808952","doi":"10.1200/jco.2025.43.16_suppl.569","title":"Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"National Institutes of Health; Breast Cancer Research Foundation","keywords":"Medicine; Triple-negative breast cancer; Oncology; Triple negative; Internal medicine; Breast cancer; Cancer; Alliance; Cancer research","score_opus":0.15986993359986343,"score_gpt":0.5108996234774432,"score_spread":0.35102968987757976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218066,0.00048127517,0.000058526544,0.014563552,0.0013483051,0.00026080065,0.00005222945,0.0000064810115,0.0010481554],"genre_scores_gemma":[0.9919209,0.0034411002,0.0012553793,0.0024083627,0.00040756955,0.000006408135,0.000005317228,0.000013379042,0.00054159283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960386,0.00039501037,0.0028246576,0.00035459755,0.00014824062,0.00023890172],"domain_scores_gemma":[0.99405694,0.00429567,0.00101714,0.00024170415,0.00018781296,0.00020072541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030820759,0.00017569444,0.0017458509,0.00038372906,0.000036157744,0.000019426738,0.00020105309,0.00024824255,0.00014682818],"category_scores_gemma":[0.0024012066,0.00013257287,0.00016036564,0.0002711997,0.00022021186,0.00021173977,0.00019094381,0.0015741206,0.0000024604308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057894466,0.0009464387,0.9175196,0.00006598317,0.0002605862,0.0003241221,0.00019250164,0.000025113419,0.0017909398,0.00014064631,0.0013785316,0.07156605],"study_design_scores_gemma":[0.010471839,0.0018116586,0.9800525,0.0009087909,0.00023523737,0.00008712019,0.00029127096,0.0008178604,0.000120759556,0.0005162666,0.0045682285,0.000118476004],"about_ca_topic_score_codex":0.0017780248,"about_ca_topic_score_gemma":0.011723598,"teacher_disagreement_score":0.07144758,"about_ca_system_score_codex":0.00028581495,"about_ca_system_score_gemma":0.0013204592,"threshold_uncertainty_score":0.6838858},"labels":[],"label_agreement":null},{"id":"W4410809096","doi":"10.1200/jco.2025.43.16_suppl.e13560","title":"Connecting clinical trials with patients using patient navigation: A scoping review.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Empathy and Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Toronto; University of Windsor; University of Manitoba; Western University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.38566643192518174,"score_gpt":0.6420179525524746,"score_spread":0.2563515206272929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98112595,0.004349449,0.0010849398,0.0071684937,0.004258644,0.0008615203,7.8456355e-7,0.0000088295465,0.0011413699],"genre_scores_gemma":[0.9518492,0.0058843778,0.015294881,0.024711434,0.0021827365,0.000008064919,0.000010936617,0.000016742046,0.00004161498],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9896236,0.002594065,0.006954642,0.00021153403,0.00043106487,0.0001850627],"domain_scores_gemma":[0.97326744,0.01648885,0.0073904544,0.00028729494,0.001921984,0.0006439903],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023418143,0.00012402992,0.0027722232,0.000096084594,0.00006957277,0.000007805059,0.000101006095,0.00036876803,0.00010245169],"category_scores_gemma":[0.123430975,0.000076226956,0.00061578694,0.0002672882,0.00014107882,0.000110738736,0.000038789138,0.0012970924,0.000004704407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004472779,0.0040728482,0.087781385,0.0020934732,0.00057349226,0.00016788849,0.00074653444,0.000010736243,0.0000063869606,0.00004827491,0.0038007484,0.89622545],"study_design_scores_gemma":[0.06706007,0.07668127,0.13944124,0.6395775,0.0104631595,0.0009812736,0.007646028,0.0006527553,0.0002289081,0.00070278795,0.055949777,0.00061521435],"about_ca_topic_score_codex":0.000006271825,"about_ca_topic_score_gemma":0.0000048015886,"teacher_disagreement_score":0.8956102,"about_ca_system_score_codex":0.00013851574,"about_ca_system_score_gemma":0.0057242266,"threshold_uncertainty_score":0.9999124},"labels":[],"label_agreement":null},{"id":"W4410809147","doi":"10.1200/jco.2025.43.16_suppl.e17005","title":"Global burden of prostate cancer in 38 OECD countries and its trend from 1990-2021: An Insight from the Global Burden of Disease study 2021.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Burden of disease; Prostate cancer; Disease; Disease burden; Cancer; Global health; Environmental health; Internal medicine; Public health; Pathology","score_opus":0.2852694193636485,"score_gpt":0.5303423251006097,"score_spread":0.24507290573696122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9357133,0.01618028,0.00002012513,0.042456344,0.0014887938,0.00053033297,0.0029749782,0.0000025578913,0.000633312],"genre_scores_gemma":[0.9932642,0.0032812175,0.00016704809,0.002035848,0.0011502338,0.000017889071,0.000013399238,0.000008037931,0.0000621025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98857045,0.0016042646,0.008981587,0.00041627223,0.0001788823,0.00024851802],"domain_scores_gemma":[0.9875956,0.0049544787,0.006605018,0.0003624477,0.00019643205,0.0002859954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013590347,0.00018148207,0.0025598996,0.00012158244,0.000064711494,0.0000351251,0.0005016699,0.00025663862,0.00057188],"category_scores_gemma":[0.0058323853,0.00015813367,0.00021181804,0.0002279774,0.00023937595,0.00036121442,0.0001463666,0.0003560537,0.000022521539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015015984,0.0006718122,0.9823892,0.000053322958,0.0004826385,0.000016626778,0.0027196442,0.0009834834,3.3501104e-7,0.0037922945,0.0026470823,0.004741978],"study_design_scores_gemma":[0.0056227287,0.001182795,0.9191899,0.0001824821,0.00012913313,7.7635264e-7,0.003892302,0.0021182008,4.3294068e-7,0.019577071,0.047959786,0.00014440369],"about_ca_topic_score_codex":0.017053112,"about_ca_topic_score_gemma":0.014575826,"teacher_disagreement_score":0.0631993,"about_ca_system_score_codex":0.0006295244,"about_ca_system_score_gemma":0.0021130801,"threshold_uncertainty_score":0.9894924},"labels":[],"label_agreement":null},{"id":"W4410809204","doi":"10.1200/jco.2025.43.16_suppl.6569","title":"Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Refractory (planetary science); Erythropoiesis; Internal medicine; Anemia; Oncology; Bone marrow","score_opus":0.07245020380775764,"score_gpt":0.4544308113750213,"score_spread":0.38198060756726365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442846,0.0001441113,0.00018171234,0.0020018115,0.0010423595,0.0016062191,0.000023566754,0.000012544988,0.00055921986],"genre_scores_gemma":[0.9951691,0.003211902,0.0007527563,0.00020118836,0.00019685947,0.000025714397,0.0000033899398,0.000041600983,0.00039749764],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98858213,0.004981392,0.0041793464,0.0005442826,0.0011927249,0.00052009977],"domain_scores_gemma":[0.939065,0.056286752,0.0029830986,0.0006561577,0.00063145894,0.0003775312],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011083696,0.0004238435,0.003676639,0.00052659475,0.00010868546,0.000010781749,0.00042621462,0.0007214122,0.00021010073],"category_scores_gemma":[0.02308646,0.00020296469,0.0009450917,0.00060585944,0.00076866645,0.00012864433,0.0001367006,0.0028207737,0.0000124480275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.191166,0.014066163,0.37230372,0.0003830191,0.0023096139,0.0012729551,0.00022683627,0.0006393391,0.00059967465,0.0000117909585,0.00078543887,0.41623545],"study_design_scores_gemma":[0.07249042,0.33034956,0.5861063,0.0020232843,0.002307943,0.00009435271,0.00015445067,0.001427058,0.0029772187,0.000039314302,0.0017811096,0.00024900373],"about_ca_topic_score_codex":0.00024725526,"about_ca_topic_score_gemma":0.00023636005,"teacher_disagreement_score":0.41598645,"about_ca_system_score_codex":0.0013441375,"about_ca_system_score_gemma":0.005021354,"threshold_uncertainty_score":0.9994798},"labels":[],"label_agreement":null},{"id":"W4410809220","doi":"10.1200/jco.2025.43.16_suppl.585","title":"Bilateral mastectomy and breast cancer mortality for invasive lobular carcinoma: A SEER-based study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Cancer; Mastectomy; Oncology; Invasive lobular carcinoma; General surgery; Internal medicine; Gynecology; Invasive ductal carcinoma","score_opus":0.07444508330747077,"score_gpt":0.45168248919253245,"score_spread":0.3772374058850617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930019,0.00074217364,0.00112764,0.0034946047,0.0011133854,0.0003545832,0.000046785433,0.000002468212,0.000116485775],"genre_scores_gemma":[0.99550843,0.00007863023,0.001706531,0.0018218945,0.00067339046,0.00004628488,0.0000048880124,0.000011123928,0.00014883342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812996,0.00027171648,0.0010550099,0.0002611133,0.00011632781,0.00016588316],"domain_scores_gemma":[0.9981479,0.0003487035,0.0006198918,0.0002024658,0.00056919095,0.000111866444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013625794,0.00012329791,0.0005718573,0.000072819195,0.000054266548,0.000014147612,0.00019126746,0.00028333647,0.000020808106],"category_scores_gemma":[0.00070390286,0.00009864901,0.00023380031,0.0000924467,0.00014716446,0.000005947642,0.00008069469,0.00024891575,3.9666602e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019831983,0.0008345112,0.9705056,0.00005326191,0.0007308458,0.000040899897,0.000042159456,0.00038942427,0.0052591693,0.00001726976,0.003987773,0.016155904],"study_design_scores_gemma":[0.008520636,0.004040754,0.96641403,0.000029627887,0.00043994698,0.000037262264,0.00017756614,0.00012370171,0.0036394848,0.00024551703,0.016197458,0.00013400264],"about_ca_topic_score_codex":0.00004073736,"about_ca_topic_score_gemma":0.0004590558,"teacher_disagreement_score":0.016021902,"about_ca_system_score_codex":0.000105396306,"about_ca_system_score_gemma":0.0035446316,"threshold_uncertainty_score":0.6288024},"labels":[],"label_agreement":null},{"id":"W4410809228","doi":"10.1200/jco.2025.43.16_suppl.570","title":"MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Class (philosophy); Internal medicine","score_opus":0.1336709002924435,"score_gpt":0.5140138831179181,"score_spread":0.3803429828254746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8523353,0.0022223701,0.000002753451,0.1426092,0.0011133458,0.00041245008,0.000016114664,0.0000019256854,0.0012865765],"genre_scores_gemma":[0.96319425,0.023005577,0.00008092322,0.012800485,0.0004640445,0.0000105401205,0.0000015104223,0.0000059225745,0.00043673042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628216,0.0011349958,0.0020748423,0.00019403223,0.00016740551,0.00014655675],"domain_scores_gemma":[0.9909488,0.0077340677,0.0008357282,0.00037367732,0.000050822946,0.000056893572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011394425,0.00010291502,0.0011432626,0.00013886938,0.000040287305,0.000017557493,0.00036494053,0.00019850385,0.000051018058],"category_scores_gemma":[0.0011638214,0.000044611956,0.00015596539,0.00018861861,0.00048359123,0.00007873012,0.00015969796,0.0009690399,4.1875836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25540692,0.00064457866,0.54080236,0.000022775022,0.00018742384,0.00006744396,0.00020235394,0.0000011256402,0.000101644575,0.000086735316,0.006774311,0.19570237],"study_design_scores_gemma":[0.122521654,0.0007272344,0.8272706,0.00018660726,0.00015818629,0.00003505498,0.00029243194,0.000089055335,0.0000019550646,0.0003296843,0.04834543,0.00004206651],"about_ca_topic_score_codex":0.00051741104,"about_ca_topic_score_gemma":0.003580697,"teacher_disagreement_score":0.2864683,"about_ca_system_score_codex":0.00008833465,"about_ca_system_score_gemma":0.0010299634,"threshold_uncertainty_score":0.421005},"labels":[],"label_agreement":null},{"id":"W4410809230","doi":"10.1200/jco.2025.43.16_suppl.6546","title":"Matching-adjusted indirect comparison (MAIC) of olutasidenib (OLU) and ivosidenib (IVO) in isocitrate dehydrogenase 1 (IDH1)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Isocitrate dehydrogenase; Medicine; IDH1; Myeloid leukemia; Refractory (planetary science); Nuclear medicine; IDH2; Cancer research; Mutation; Enzyme; Gene; Biology; Genetics; Biochemistry","score_opus":0.04439825690302656,"score_gpt":0.38904592704680907,"score_spread":0.3446476701437825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445885,0.0025674007,0.00032067602,0.00083303935,0.0007401567,0.00022604602,0.000013203999,0.000008223274,0.00083241984],"genre_scores_gemma":[0.99488187,0.0021280176,0.0014160994,0.0009162249,0.0002443852,0.0000062208824,0.000024158244,0.000019901916,0.0003631294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953633,0.000855889,0.0028990654,0.00034267223,0.00024440093,0.00029468557],"domain_scores_gemma":[0.99666876,0.0005103329,0.0020311945,0.00025979863,0.00030886361,0.00022106554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00241208,0.00023159976,0.0013418329,0.00027098882,0.000057493275,0.000017336402,0.0003398095,0.0008568941,0.000024137651],"category_scores_gemma":[0.0014340284,0.0002033515,0.0003498358,0.000289782,0.00032386716,0.000028230981,0.00016467052,0.001038715,0.0000040247023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009762924,0.0021151656,0.09534119,0.00015723282,0.002023384,0.00042914838,0.0005023944,0.0008034006,0.8119559,0.00030611153,0.018352805,0.058250304],"study_design_scores_gemma":[0.0267369,0.013038381,0.15382667,0.00059797295,0.0008816051,0.0003347615,0.0009906271,0.00061168725,0.7450525,0.003426015,0.053660765,0.0008420701],"about_ca_topic_score_codex":0.00009449722,"about_ca_topic_score_gemma":0.00040290976,"teacher_disagreement_score":0.0669034,"about_ca_system_score_codex":0.00014622265,"about_ca_system_score_gemma":0.0019274567,"threshold_uncertainty_score":0.82924336},"labels":[],"label_agreement":null},{"id":"W4410809231","doi":"10.1200/jco.2025.43.16_suppl.6542","title":"Novel potent and selective inhibitors targeting FLT3 for AML therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lapatinib; Pharmacology; Cancer research; Cancer; Trastuzumab; Internal medicine; Breast cancer","score_opus":0.10600138975053246,"score_gpt":0.4911744738460747,"score_spread":0.38517308409554224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93378097,0.0019992236,0.0074396883,0.050597154,0.0015475287,0.0007107847,0.0000042390384,0.0000138120695,0.003906626],"genre_scores_gemma":[0.95956665,0.0018991163,0.029002093,0.0061477222,0.0022379246,0.000012043734,0.0000021214585,0.000019945619,0.0011123599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975729,0.00019600918,0.0015526795,0.00018769542,0.00022845538,0.00026226646],"domain_scores_gemma":[0.99357873,0.0044584526,0.00069889333,0.00009740837,0.00091093866,0.00025556984],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048367735,0.00010909076,0.0010560191,0.00019157582,0.00006779577,0.000010123108,0.000119416145,0.0003795115,0.000014602138],"category_scores_gemma":[0.010579803,0.000073209645,0.00034191468,0.00019330898,0.0001757767,0.00006898849,0.00006916105,0.0012431447,0.0000020238626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016405217,0.0018996423,0.041777346,0.00008405,0.0013253815,0.00016373117,0.00022430207,0.000013087194,0.017764537,0.00047453414,0.10857792,0.81129026],"study_design_scores_gemma":[0.05702231,0.034825746,0.2197578,0.0003233896,0.0004995299,0.0005744042,0.0008642005,0.0016622666,0.008417566,0.0026221063,0.67319334,0.00023736795],"about_ca_topic_score_codex":0.000015395195,"about_ca_topic_score_gemma":0.000005470375,"teacher_disagreement_score":0.81105286,"about_ca_system_score_codex":0.00031936137,"about_ca_system_score_gemma":0.0032586488,"threshold_uncertainty_score":0.9977545},"labels":[],"label_agreement":null},{"id":"W4410809237","doi":"10.1200/jco.2025.43.16_suppl.e17074","title":"Impact of BRCA alterations on androgen receptor pathway inhibition treatment outcome in advanced prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Cancer; Androgen; Prostate; Urothelial cancer; Hormone; Bladder cancer","score_opus":0.1388894687987531,"score_gpt":0.5490300485300793,"score_spread":0.4101405797313262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894576,0.0009309593,0.000005870475,0.0072459956,0.00046142587,0.00050900935,0.000044234555,0.0000045216575,0.0013403504],"genre_scores_gemma":[0.9936036,0.003996308,0.0003352383,0.00026786362,0.00017472485,0.000035180314,0.000016076572,0.000008215089,0.001562818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975028,0.00025144228,0.0016921499,0.00015458663,0.0002001028,0.00019890069],"domain_scores_gemma":[0.9979443,0.00071896095,0.0006961763,0.00013318137,0.0003346122,0.00017274938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083807553,0.00012167345,0.0010877026,0.00027779728,0.000028569726,0.000005024184,0.000050121394,0.00017259072,0.000121855985],"category_scores_gemma":[0.0006612207,0.00007054629,0.00044932985,0.0002611426,0.000108478256,0.00008437212,0.00001689557,0.00042171622,0.000004887775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016459981,0.0039005287,0.71379614,0.000038646376,0.00047008612,0.00022643957,0.0001783401,0.00026200069,0.0030726255,0.00006949164,0.0008520364,0.26067367],"study_design_scores_gemma":[0.04969182,0.08044767,0.8410634,0.00085102284,0.00024680403,0.000029322324,0.00013546484,0.00008172448,0.011628861,0.00047902914,0.0152202565,0.00012467605],"about_ca_topic_score_codex":0.0000860467,"about_ca_topic_score_gemma":0.00011508188,"teacher_disagreement_score":0.26054898,"about_ca_system_score_codex":0.0012985576,"about_ca_system_score_gemma":0.0037371463,"threshold_uncertainty_score":0.6629537},"labels":[],"label_agreement":null},{"id":"W4410809316","doi":"10.1200/jco.2025.43.16_suppl.e20695","title":"Clinical prognostic factors associated with progression-free survival in pts with metastatic EGFR-mutant non-small cell lung cancer treated with gefitinib first-line therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gefitinib; Medicine; Oncology; Lung cancer; Internal medicine; Mutant; Progression-free survival; Cancer research; Epidermal growth factor receptor; Cancer; Overall survival; Gene","score_opus":0.08928770459103813,"score_gpt":0.47621264863229523,"score_spread":0.3869249440412571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909772,0.0010042068,0.00027643764,0.0043271165,0.00048006725,0.0015260866,0.00003715121,0.000027641781,0.001344043],"genre_scores_gemma":[0.99525285,0.0011299856,0.0019718534,0.000753313,0.00020966462,0.00010329389,0.00003414436,0.000048423604,0.0004964806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953415,0.0006230694,0.0025380058,0.00044767358,0.0005794787,0.00047031877],"domain_scores_gemma":[0.98987794,0.0061616157,0.0022342247,0.0003393628,0.000960934,0.000425922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020026432,0.0003769783,0.0024569326,0.00024968397,0.000098669465,0.0000253716,0.0002628331,0.0003436271,0.000077763674],"category_scores_gemma":[0.0018682302,0.00018057287,0.00030382862,0.0007156668,0.00030967218,0.000121013865,0.000045049906,0.001322678,9.626424e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010936858,0.00832255,0.95736057,0.00008628968,0.0036925497,0.001677079,0.00023080199,0.00020278769,0.000007117405,0.000008402931,0.00030034047,0.01717465],"study_design_scores_gemma":[0.060640678,0.033780716,0.89648205,0.002646782,0.004079007,0.00003553143,0.0003010939,0.00034525376,0.000066166576,0.000029533556,0.0013805288,0.00021266051],"about_ca_topic_score_codex":0.00017447949,"about_ca_topic_score_gemma":0.0036996917,"teacher_disagreement_score":0.060878523,"about_ca_system_score_codex":0.0005202069,"about_ca_system_score_gemma":0.0065770764,"threshold_uncertainty_score":0.99905473},"labels":[],"label_agreement":null},{"id":"W4410809328","doi":"10.1200/jco.2025.43.16_suppl.tps5131","title":"Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Oncology; Internal medicine; Biochemical recurrence; Cancer; Urology; Prostatectomy; Pathology","score_opus":0.06389345534634007,"score_gpt":0.4574562585545091,"score_spread":0.39356280320816905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905271,0.0019033352,0.00004261045,0.0013067506,0.00042613858,0.0056604757,0.000016332595,0.000007119994,0.00011017331],"genre_scores_gemma":[0.9939547,0.0050528045,0.00028894102,0.00014083172,0.00014447776,0.00027816437,0.000015770756,0.000014733914,0.00010955741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99460506,0.0011683172,0.0029677998,0.0003231538,0.00062817615,0.00030749006],"domain_scores_gemma":[0.9935529,0.0027335035,0.0022460707,0.00024239229,0.0010081884,0.00021690215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053074164,0.0002237007,0.003399308,0.0004153849,0.00004544457,0.0000124609505,0.00021176635,0.00026059145,0.000035192403],"category_scores_gemma":[0.0017826268,0.00012344455,0.00035966234,0.0005094537,0.000398335,0.00012507047,0.000056367684,0.001061889,0.000001212523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5999651,0.0068579274,0.34909678,0.000023461267,0.0015801957,0.000060336795,0.00020699277,0.000036450194,0.000017613625,0.0000057374605,0.0001147885,0.042034622],"study_design_scores_gemma":[0.93365186,0.02010154,0.043744612,0.0003139776,0.00091692404,0.0000034625825,0.00013528927,0.00018831568,0.00057489745,0.00013249506,0.00013988416,0.00009675916],"about_ca_topic_score_codex":0.00024256161,"about_ca_topic_score_gemma":0.00009259941,"teacher_disagreement_score":0.33368674,"about_ca_system_score_codex":0.00040794403,"about_ca_system_score_gemma":0.0037599704,"threshold_uncertainty_score":0.6670026},"labels":[],"label_agreement":null},{"id":"W4410809329","doi":"10.1200/jco.2025.43.16_suppl.e17054","title":"Plasma ANGPTL3, Apo CIII, leptin, and lipid levels in patients with metastatic prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute; Université Laval","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Leptin; Internal medicine; Prostate; Cancer; Endocrinology; Oncology; Obesity","score_opus":0.036756677711051615,"score_gpt":0.39310669508814994,"score_spread":0.3563500173770983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911638,0.0013834239,0.00008651114,0.00120877,0.005258491,0.0001992367,0.000023338906,0.0000020392379,0.00067441433],"genre_scores_gemma":[0.98965555,0.0026132753,0.001531632,0.0018979611,0.0032372524,0.00001395605,0.000010648601,0.000016061114,0.0010236447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979885,0.00025522173,0.0011432224,0.00023629512,0.00015134849,0.00022538539],"domain_scores_gemma":[0.99849856,0.00018543759,0.0007186443,0.00014371908,0.00030509484,0.00014852872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010965802,0.00014108229,0.00080540625,0.00009811669,0.000031084684,0.000012544309,0.00015314312,0.00019649607,0.000030489487],"category_scores_gemma":[0.0007164581,0.0001015908,0.0001285731,0.00012240084,0.00019651471,0.000011529201,0.0000782715,0.0003855113,9.4387565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008134537,0.0012097693,0.61352056,0.000075590695,0.0006205672,0.000004161141,0.00013687808,0.00013842035,0.0022237278,0.00009502687,0.033871636,0.33996913],"study_design_scores_gemma":[0.0099791335,0.0028401779,0.49873844,0.000056422894,0.00012320055,0.0000067107503,0.00006701047,0.000008356861,0.00021339332,0.000057228994,0.48780522,0.000104709914],"about_ca_topic_score_codex":0.00004402549,"about_ca_topic_score_gemma":0.000691531,"teacher_disagreement_score":0.45393357,"about_ca_system_score_codex":0.000040024748,"about_ca_system_score_gemma":0.0012326657,"threshold_uncertainty_score":0.41427526},"labels":[],"label_agreement":null},{"id":"W4410809345","doi":"10.1200/jco.2025.43.16_suppl.6545","title":"A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Oncology; Internal medicine","score_opus":0.06511744294923902,"score_gpt":0.47775764935884624,"score_spread":0.4126402064096072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356085,0.00067572785,0.0000069653024,0.0020738246,0.0006787414,0.00083488406,0.000018255581,0.000009384813,0.0021413758],"genre_scores_gemma":[0.9937851,0.0012329571,0.0010037778,0.0005048252,0.000106860425,0.000020637937,0.0000054253883,0.000024561918,0.0033158618],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993151,0.0006969352,0.00493717,0.00035169584,0.0005349195,0.00032824918],"domain_scores_gemma":[0.9920804,0.0034924159,0.0032334654,0.00055288925,0.00036632823,0.00027451006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018037414,0.00030746657,0.0038710365,0.0003096051,0.000027710494,0.0000033737151,0.00026170496,0.00057620043,0.00015369305],"category_scores_gemma":[0.0021259785,0.00021013623,0.0007153965,0.00035182555,0.00024947658,0.00009309793,0.00009329126,0.0010373541,0.000012359164],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022072386,0.086342916,0.70699173,0.00008676691,0.008008614,0.003268714,0.0010921332,0.000020935937,0.0010962241,0.00003537046,0.009935264,0.16104893],"study_design_scores_gemma":[0.4308608,0.13406809,0.3899162,0.0005996774,0.0066619664,0.00048379033,0.0016768464,0.00006182505,0.0020044015,0.00022818008,0.03315618,0.00028203893],"about_ca_topic_score_codex":0.00046490706,"about_ca_topic_score_gemma":0.00019795785,"teacher_disagreement_score":0.4087884,"about_ca_system_score_codex":0.0039620693,"about_ca_system_score_gemma":0.0074204635,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W4410809346","doi":"10.1200/jco.2025.43.16_suppl.6527","title":"Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Venetoclax; Medicine; Myeloid leukemia; Myeloid; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.11610294035788578,"score_gpt":0.5120929912143497,"score_spread":0.39599005085646394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90813684,0.00016317081,0.00059083063,0.05917588,0.0016738279,0.0019957158,0.000007927397,0.000019034735,0.02823677],"genre_scores_gemma":[0.7861455,0.009366868,0.13127907,0.04615896,0.002048762,0.0003787428,0.00002181689,0.000100265985,0.024499984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947773,0.00071097596,0.0030098518,0.00040250807,0.000563425,0.00053591584],"domain_scores_gemma":[0.9872176,0.009169589,0.0020868126,0.00042414205,0.000571669,0.00053019176],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006454858,0.00019848478,0.0015736776,0.0011293525,0.000056666868,0.000023800085,0.0004440757,0.00036598698,0.000058546513],"category_scores_gemma":[0.011804365,0.00015663824,0.0004603532,0.0009245183,0.00013764879,0.00016490281,0.00025164048,0.0015255552,0.000028701503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07829081,0.0013882265,0.023987755,0.00024717083,0.0021531326,0.008408021,0.00040399,0.0006563486,0.00056442805,0.0019362664,0.3258351,0.55612874],"study_design_scores_gemma":[0.020887801,0.013616015,0.1661035,0.000449704,0.0006787163,0.00005848473,0.00079970347,0.0005285173,0.00023362717,0.00093090406,0.79555434,0.00015866797],"about_ca_topic_score_codex":0.00021666316,"about_ca_topic_score_gemma":0.00076501555,"teacher_disagreement_score":0.5559701,"about_ca_system_score_codex":0.005091729,"about_ca_system_score_gemma":0.009109074,"threshold_uncertainty_score":0.99872756},"labels":[],"label_agreement":null},{"id":"W4410809351","doi":"10.1200/jco.2025.43.16_suppl.tps5132","title":"Androgen suppression combined with elective nodal irradiation and dose escalated prostate treatment: A non-inferiority, phase III randomized controlled trial of stereotactic body radiation therapy versus brachytherapy boost in patients with unfavourable risk localized prostate cancer (ASCENDE-SBRT; CCTG PR24; NCT06235697).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McGill University; University of Ottawa; Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Queen's University; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Androgen suppression; Prostate cancer; Randomized controlled trial; Brachytherapy; Prostate; Radiation therapy; Nuclear medicine; Oncology; Radiosurgery; Androgen deprivation therapy; Urology; Internal medicine; Radiology; Cancer","score_opus":0.020098880292256545,"score_gpt":0.38831900745364945,"score_spread":0.3682201271613929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843256,0.0014518438,0.00001975113,0.001111733,0.0006677896,0.012279676,0.000049862847,0.0000121810035,0.0000815725],"genre_scores_gemma":[0.974389,0.02434047,0.00011073978,0.00014103757,0.00010167121,0.0007692746,0.000058864764,0.000030020194,0.0000588983],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944587,0.0015303072,0.0027999307,0.0004093398,0.00045191078,0.00034985965],"domain_scores_gemma":[0.9915275,0.003166557,0.00403638,0.0002195394,0.000787381,0.0002626711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002074062,0.0003967898,0.0047577713,0.00034834683,0.00009985241,0.00003259231,0.00007618242,0.00029293122,0.000030051466],"category_scores_gemma":[0.00065915025,0.00021242892,0.0004125952,0.00038561402,0.00027879296,0.0002921677,0.000016190039,0.000547155,3.7182755e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68628746,0.011331666,0.24509558,0.00002579658,0.004647445,0.00005839447,0.0005436308,0.00004746724,0.000026286429,0.000004551504,0.000019276893,0.051912416],"study_design_scores_gemma":[0.72773534,0.11828261,0.14991567,0.00030120506,0.0020958553,0.0000034751636,0.000033822747,0.00090894033,0.00033245838,0.000051334024,0.00020384933,0.00013545004],"about_ca_topic_score_codex":0.00043552078,"about_ca_topic_score_gemma":0.00020204585,"teacher_disagreement_score":0.106950946,"about_ca_system_score_codex":0.00083321735,"about_ca_system_score_gemma":0.0029514197,"threshold_uncertainty_score":0.86626},"labels":[],"label_agreement":null},{"id":"W4410809397","doi":"10.1200/jco.2025.43.16_suppl.tps5129","title":"TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Queen's University; University of British Columbia; Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Androgen receptor; Internal medicine; Clinical trial; Cancer","score_opus":0.0929500768874752,"score_gpt":0.48969468820828876,"score_spread":0.39674461132081357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379,0.0004456666,0.00028011904,0.008094979,0.0011935531,0.005985557,0.00017798945,0.0000048799866,0.000027248998],"genre_scores_gemma":[0.9954951,0.0009293315,0.001954704,0.0004537904,0.00046557,0.00031851386,0.000041751915,0.000018163233,0.00032311937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99319965,0.0023337898,0.0033829205,0.0003223408,0.00046083436,0.00030048622],"domain_scores_gemma":[0.9831065,0.0134884585,0.0017311104,0.00016821787,0.0012231692,0.00028257407],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013475521,0.00020455087,0.0025438985,0.00029987603,0.00007812606,0.00001855222,0.00009404124,0.00023088705,0.000033770062],"category_scores_gemma":[0.010422922,0.000107356645,0.0004799103,0.0003791064,0.00051678054,0.00014437415,0.000043325774,0.00073023763,7.9509374e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.897622,0.0032533768,0.0032941436,0.00004920969,0.0012688914,0.00007495132,0.0003541782,0.00001880134,0.00009701282,0.000015479,0.0013785204,0.092573434],"study_design_scores_gemma":[0.9310322,0.049469866,0.012592485,0.0004231642,0.0012922442,0.000009521591,0.00045756757,0.0002973341,0.00065594574,0.000072882365,0.0035920665,0.000104744955],"about_ca_topic_score_codex":0.0000465133,"about_ca_topic_score_gemma":0.00010328513,"teacher_disagreement_score":0.09246869,"about_ca_system_score_codex":0.0002321616,"about_ca_system_score_gemma":0.004150706,"threshold_uncertainty_score":0.9979127},"labels":[],"label_agreement":null},{"id":"W4410809399","doi":"10.1200/jco.2025.43.16_suppl.tps5118","title":"Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Amgen","keywords":"Cabazitaxel; Medicine; Taxane; Prostate cancer; Androgen receptor; Oncology; Androgen deprivation therapy; Internal medicine; Androgen; Cancer; Prostate; Gynecology; Breast cancer; Hormone","score_opus":0.17402627177558466,"score_gpt":0.5335429345411211,"score_spread":0.35951666276553645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775613,0.004271193,3.3897703e-7,0.004086204,0.0006562213,0.003057434,0.00009256841,0.000007605318,0.00007227701],"genre_scores_gemma":[0.99616975,0.0018951127,0.00061972893,0.00029428597,0.00019742508,0.00019109076,0.000016571214,0.000020790261,0.00059526594],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99345696,0.0014854429,0.0038072143,0.00031977965,0.0005834748,0.00034715777],"domain_scores_gemma":[0.99408054,0.0023754255,0.0019327835,0.00024325728,0.0010375824,0.00033038185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034899716,0.00022994101,0.0023773743,0.00060118205,0.0000320184,0.000011510842,0.00022943683,0.00022730324,0.00032889567],"category_scores_gemma":[0.0042912406,0.00014443793,0.00025141623,0.000877385,0.00043164726,0.00016398527,0.00004855432,0.00094110525,7.368619e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66563636,0.035462033,0.17983057,0.00040439566,0.002344777,0.0011789082,0.0023772856,0.000012889543,0.0062948894,0.00000850518,0.0014647841,0.104984626],"study_design_scores_gemma":[0.618127,0.15324491,0.21112789,0.00097525615,0.0006292175,0.000021238804,0.0026752013,0.00007487669,0.005475757,0.00009297674,0.0073392363,0.00021641405],"about_ca_topic_score_codex":0.0007137568,"about_ca_topic_score_gemma":0.008087004,"teacher_disagreement_score":0.11778288,"about_ca_system_score_codex":0.00037460343,"about_ca_system_score_gemma":0.011500556,"threshold_uncertainty_score":0.9941033},"labels":[],"label_agreement":null},{"id":"W4410809403","doi":"10.1200/jco.2025.43.16_suppl.tps5111","title":"Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Conjugate; Antibody-drug conjugate; Prostate cancer; Castration; Antibody; Orchiectomy; Prostate; Oncology; Cancer; Internal medicine; Monoclonal antibody; Immunology; Hormone","score_opus":0.11713708280343747,"score_gpt":0.5319695346725988,"score_spread":0.4148324518691613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949873,0.0003605081,0.0000046702667,0.0016191325,0.00027606147,0.0019626424,0.000032824377,0.0000031769707,0.0007536758],"genre_scores_gemma":[0.99797744,0.000285227,0.00068766973,0.00019599783,0.000048506172,0.000054350523,0.000019845198,0.000014003179,0.0007169669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958172,0.0005387489,0.0025718347,0.00028102117,0.0004699888,0.00032120082],"domain_scores_gemma":[0.996738,0.00092009146,0.0011910467,0.00021279728,0.00074042886,0.00019763212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027614622,0.00017466467,0.0017698039,0.00034331268,0.000067666646,0.000024836729,0.00022780368,0.00009626853,0.00008504121],"category_scores_gemma":[0.0005611253,0.000111317124,0.00006108652,0.00062615186,0.00017385081,0.00023389173,0.00010256067,0.00078710075,8.6106763e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07610871,0.09590287,0.81603277,0.00028610017,0.0013310434,0.0019754802,0.00090471556,0.00018721541,0.00043946333,0.0001224794,0.0010918174,0.00561733],"study_design_scores_gemma":[0.33353212,0.10464587,0.55631006,0.0012725448,0.0007180972,0.000009245229,0.001194299,0.00011157564,0.00013305039,0.0002804228,0.0016450429,0.0001476762],"about_ca_topic_score_codex":0.0014130562,"about_ca_topic_score_gemma":0.004050314,"teacher_disagreement_score":0.25972274,"about_ca_system_score_codex":0.00037113836,"about_ca_system_score_gemma":0.0039620893,"threshold_uncertainty_score":0.7028576},"labels":[],"label_agreement":null},{"id":"W4410809409","doi":"10.1200/jco.2025.43.16_suppl.6506","title":"Ziftomenib in relapsed/refractory (R/R) <i>NPM1</i> -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; NPM1; Refractory (planetary science); Oncology; Internal medicine; Mutant; Myeloid; Cancer research; Gene; Genetics; Biology","score_opus":0.08539747359179765,"score_gpt":0.4797452026748207,"score_spread":0.394347729083023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96592295,0.00051253894,0.00008110889,0.026713956,0.0022776127,0.0011655077,0.00012851215,0.000028676683,0.003169144],"genre_scores_gemma":[0.98428524,0.006386662,0.0008979358,0.005161646,0.002127533,0.000015400245,0.000019334833,0.000043438078,0.001062836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98511595,0.0049516344,0.0070933243,0.00093607046,0.0011201046,0.0007829157],"domain_scores_gemma":[0.9570051,0.037490524,0.0028671355,0.0010622063,0.00067336287,0.00090166955],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02590938,0.00045273273,0.0037860011,0.0004202295,0.00019803348,0.00004814415,0.0008769921,0.0012821048,0.00008594504],"category_scores_gemma":[0.026602661,0.0002842098,0.0007777119,0.0008822104,0.0012562028,0.0002783226,0.0007155868,0.00921205,0.00003952962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23954171,0.031725623,0.11579874,0.000030741292,0.0038104297,0.009897333,0.000571831,0.000008501959,0.0026442455,0.000046127698,0.039089013,0.5568357],"study_design_scores_gemma":[0.20330906,0.031316407,0.61678314,0.0002663254,0.0013558674,0.00030478876,0.0008159804,0.00053640414,0.00010624465,0.00029141124,0.14463504,0.00027933065],"about_ca_topic_score_codex":0.0005726656,"about_ca_topic_score_gemma":0.00071489403,"teacher_disagreement_score":0.5565564,"about_ca_system_score_codex":0.0019094222,"about_ca_system_score_gemma":0.010933488,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W4410809413","doi":"10.1200/jco.2025.43.16_suppl.e13512","title":"Enhancing patient understanding of pathology reports: Insights from a large database of patient inquiries.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiology practices and education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Pathology","score_opus":0.1491742363472082,"score_gpt":0.4760914503050082,"score_spread":0.32691721395780005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847368,0.0016673456,0.005553833,0.0025172126,0.0040798066,0.00015115575,0.0000061554165,0.000003605514,0.0012841132],"genre_scores_gemma":[0.9927858,0.0007442594,0.0045686746,0.0015980182,0.00026476238,0.0000020054272,0.000014480473,0.0000065990894,0.000015406134],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951202,0.0005987416,0.003712496,0.00019454371,0.00021735413,0.00015665566],"domain_scores_gemma":[0.99035823,0.0036452985,0.005091182,0.00030733884,0.00045482483,0.00014314464],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019124149,0.00010144161,0.0013665522,0.00023218885,0.000037921716,0.000002389264,0.00008076001,0.00036092123,0.00008686592],"category_scores_gemma":[0.01088664,0.000074523785,0.00026696592,0.00018222834,0.0003983616,0.00015413138,0.00008149166,0.00071580795,0.0000010420914],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021632107,0.020546798,0.7887926,0.0006440526,0.0040572057,0.010705745,0.017638529,0.000073995485,0.030820109,0.015101053,0.024529649,0.065458134],"study_design_scores_gemma":[0.03378658,0.10459195,0.27163938,0.006586517,0.008483968,0.0057668583,0.11461375,0.00043112814,0.040265504,0.09718871,0.31578672,0.00085893687],"about_ca_topic_score_codex":0.00003537931,"about_ca_topic_score_gemma":0.000044937267,"teacher_disagreement_score":0.5171532,"about_ca_system_score_codex":0.00020578213,"about_ca_system_score_gemma":0.0020249654,"threshold_uncertainty_score":0.9974451},"labels":[],"label_agreement":null},{"id":"W4410809414","doi":"10.1200/jco.2025.43.16_suppl.6508","title":"Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Transplantation; Stem cell; Term (time); Oncology; Internal medicine; Genetics","score_opus":0.058303014761857654,"score_gpt":0.4101907378529119,"score_spread":0.3518877230910542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352103,0.00017876271,0.001043176,0.0006992917,0.0015100677,0.00023519198,0.00001849709,0.0000072661137,0.0027866939],"genre_scores_gemma":[0.99660844,0.00061804365,0.0012694485,0.0009411069,0.000081316946,0.0000016927214,0.00001652928,0.000013105927,0.00045033672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623215,0.00037054686,0.0026606289,0.00015742682,0.00040432496,0.00017492792],"domain_scores_gemma":[0.9949264,0.0029011548,0.0012595005,0.00016403555,0.0005752977,0.00017361657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017202267,0.00012657304,0.0013273982,0.00023603145,0.00002061825,0.000004794936,0.00016763511,0.00033477988,0.000095610514],"category_scores_gemma":[0.0002653873,0.00009929262,0.00046661875,0.00015768783,0.00010812517,0.000080226986,0.000014453841,0.00045705962,0.0000112040725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013508007,0.0012366247,0.9622677,0.00044592336,0.00031175878,0.00029821575,0.000293516,0.000007778308,0.0005441951,0.00004306279,0.0000889799,0.033111453],"study_design_scores_gemma":[0.007816267,0.002313614,0.98711866,0.0002248051,0.00086848316,0.000042589334,0.00007443934,0.0000031458605,0.0012519652,0.000035389185,0.00018118863,0.00006946778],"about_ca_topic_score_codex":0.000007757412,"about_ca_topic_score_gemma":0.00003084284,"teacher_disagreement_score":0.033041984,"about_ca_system_score_codex":0.00006872783,"about_ca_system_score_gemma":0.00092665653,"threshold_uncertainty_score":0.40490356},"labels":[],"label_agreement":null},{"id":"W4410809556","doi":"10.1200/jco.2025.43.16_suppl.6500","title":"Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anagrelide; Essential thrombocythemia; Internal medicine; Oncology; Pediatrics; Polycythemia vera","score_opus":0.19727298350660116,"score_gpt":0.5520955850902599,"score_spread":0.35482260158365875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94202214,0.0011068883,0.0004242921,0.048528478,0.0043839714,0.0014980074,0.00006949736,0.0000040265927,0.0019626888],"genre_scores_gemma":[0.99216473,0.004683616,0.00090521894,0.0005496274,0.0008594566,0.000041504805,0.000008307634,0.000011098395,0.00077641406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996287,0.00043066958,0.002628634,0.00019831014,0.00028131795,0.00017406639],"domain_scores_gemma":[0.98443115,0.012339453,0.0021153053,0.00040074976,0.00060970924,0.00010365942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020640942,0.00017564483,0.0017177465,0.00007410286,0.000059557,0.0000066598936,0.00020794033,0.00023514168,0.000042501404],"category_scores_gemma":[0.0038830824,0.00007534818,0.0011450689,0.000151941,0.00028333,0.00003766681,0.000043734985,0.00031820862,0.0000011808529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77993995,0.029289287,0.0026908945,0.000058443584,0.0056966995,0.000069413305,0.00037406592,0.000101517864,0.0005571016,0.0013376409,0.021714948,0.15817004],"study_design_scores_gemma":[0.5937814,0.15843998,0.014366659,0.00029515574,0.0046642656,0.00002509046,0.0002602189,0.00026093345,0.021232339,0.000292024,0.20629093,0.000090961694],"about_ca_topic_score_codex":0.000056764206,"about_ca_topic_score_gemma":0.0002776775,"teacher_disagreement_score":0.18615852,"about_ca_system_score_codex":0.00021737997,"about_ca_system_score_gemma":0.0015511767,"threshold_uncertainty_score":0.46486926},"labels":[],"label_agreement":null},{"id":"W4410809590","doi":"10.1200/jco.2025.43.16_suppl.6511","title":"Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Stem cell; Transplantation; Haematopoiesis; Myeloid; Leukemia; Oncology; Immunology; Hematopoietic cell; Internal medicine; Genetics","score_opus":0.037513114537164584,"score_gpt":0.38099128050248665,"score_spread":0.34347816596532205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911342,0.0001999881,0.0002557128,0.0044562463,0.00059346575,0.00062375184,0.0000059088857,0.000022010498,0.0027086893],"genre_scores_gemma":[0.99126875,0.0013984665,0.00408013,0.0014660248,0.00016082377,0.000012749572,0.000017784047,0.000037765694,0.0015574812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99452597,0.00081811106,0.0031513236,0.0003863602,0.0006116863,0.00050657796],"domain_scores_gemma":[0.9948466,0.0023725585,0.0012998313,0.0003499997,0.00070005393,0.0004309844],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003075671,0.00026645474,0.0019484187,0.00055270677,0.0000614087,0.00001939433,0.0003887559,0.0007652074,0.00009788658],"category_scores_gemma":[0.00046100415,0.00018800327,0.00034303765,0.00078996393,0.00023206933,0.00018565585,0.000067932095,0.0025647879,0.00003284253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081480324,0.004593854,0.79704833,0.00071962125,0.002754465,0.007990664,0.001728154,0.0005248369,0.0061094584,0.000082873295,0.0058187526,0.09114866],"study_design_scores_gemma":[0.044938363,0.007354225,0.9417713,0.0007592761,0.0010816123,0.0003060297,0.00028308944,0.00010706547,0.0016133601,0.00011990776,0.0014484208,0.00021730793],"about_ca_topic_score_codex":0.000034529046,"about_ca_topic_score_gemma":0.00003814861,"teacher_disagreement_score":0.14472301,"about_ca_system_score_codex":0.0016225835,"about_ca_system_score_gemma":0.007991608,"threshold_uncertainty_score":0.9997363},"labels":[],"label_agreement":null},{"id":"W4410809597","doi":"10.1200/jco.2025.43.16_suppl.6517","title":"Age-related macular degeneration in individuals with clonal hematopoiesis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conquer Cancer Foundation","keywords":"Macular degeneration; Medicine; Gerontology; Oncology; Ophthalmology","score_opus":0.07644426328947711,"score_gpt":0.46658606663048063,"score_spread":0.3901418033410035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963545,0.00047138738,0.0003276848,0.026648663,0.0003504802,0.00024970926,0.0000011871208,0.000008461439,0.008397389],"genre_scores_gemma":[0.97993606,0.0003325517,0.013497103,0.0041436767,0.00034195604,0.000006819288,0.00000820391,0.000014416583,0.0017191812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961579,0.00064291834,0.0022848302,0.0001855183,0.0004751744,0.0002536686],"domain_scores_gemma":[0.9967797,0.0016609385,0.00075077766,0.00018212177,0.00039801537,0.00022849134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055909264,0.00011941713,0.0013231023,0.00043328383,0.000032383574,0.000012466959,0.00019208866,0.0005301195,0.00016288664],"category_scores_gemma":[0.0036349685,0.000078662626,0.000241801,0.00051764876,0.00028446587,0.000100085395,0.00006891475,0.0018451312,0.000020514004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005776197,0.0029560996,0.8593744,0.00012669602,0.0016009604,0.011017062,0.0002546808,0.00031407244,0.0020417897,0.007010603,0.044869263,0.06465819],"study_design_scores_gemma":[0.034595802,0.009314169,0.8283787,0.0005519289,0.00058030227,0.0015193056,0.00022032563,0.0004815593,0.00138791,0.003801149,0.11898855,0.00018034919],"about_ca_topic_score_codex":0.000015060978,"about_ca_topic_score_gemma":0.000063668034,"teacher_disagreement_score":0.074119285,"about_ca_system_score_codex":0.0004317771,"about_ca_system_score_gemma":0.0049673226,"threshold_uncertainty_score":0.8811817},"labels":[],"label_agreement":null},{"id":"W4410809598","doi":"10.1200/jco.2025.43.16_suppl.e13500","title":"Understanding access to novel high-cost therapies across Canada: A survey of pediatric oncology providers.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster Children's Hospital; University Health Network; Stollery Children's Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Family medicine","score_opus":0.6621936503966247,"score_gpt":0.611425232333352,"score_spread":0.0507684180632727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8179123,0.0014390586,0.003621989,0.1689048,0.004660569,0.00058193936,0.000053286785,0.000008061878,0.0028180284],"genre_scores_gemma":[0.97794724,0.0022667067,0.0007093625,0.018309258,0.00065680407,0.000005056707,0.0000016912702,0.000009719699,0.00009414118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612474,0.0006276433,0.0022811694,0.00020674773,0.00039168107,0.00036801325],"domain_scores_gemma":[0.9806775,0.016214317,0.0017551985,0.00014970926,0.0008083793,0.0003949178],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068871775,0.00014771082,0.0018390412,0.00008561487,0.00010442227,0.000020221725,0.00035473474,0.0003008437,0.00009175702],"category_scores_gemma":[0.01666149,0.00010227937,0.00019740875,0.000576705,0.00019152451,0.00017147478,0.00024542274,0.0011325942,0.0000019966324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020546375,0.0035921347,0.76262194,0.00020857397,0.0023725093,0.00049288594,0.00032418178,0.000069679605,0.000090076224,0.00040424953,0.11644586,0.092831515],"study_design_scores_gemma":[0.007288041,0.003522871,0.7244054,0.00004179029,0.0004899839,0.00004008653,0.0004990912,0.000022631539,0.000034822686,0.00013329637,0.26343504,0.00008695546],"about_ca_topic_score_codex":0.07441107,"about_ca_topic_score_gemma":0.43552023,"teacher_disagreement_score":0.36110917,"about_ca_system_score_codex":0.00091483723,"about_ca_system_score_gemma":0.007854879,"threshold_uncertainty_score":0.99776965},"labels":[],"label_agreement":null},{"id":"W4410809617","doi":"10.1200/jco.2025.43.16_suppl.tps5119","title":"A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Androgen; Cabazitaxel; Androgen deprivation therapy; Castration; Cancer; Hormone","score_opus":0.14199423844536826,"score_gpt":0.4844084449019102,"score_spread":0.34241420645654197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877843,0.000898885,0.0000012895598,0.008069195,0.0015554309,0.0013781812,0.000045645313,0.000008126998,0.00025892004],"genre_scores_gemma":[0.9966515,0.0009223003,0.00074354344,0.00051178475,0.00027553077,0.000075261596,0.000019366113,0.000020277012,0.0007804661],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99623245,0.0007325563,0.0019514121,0.0002283811,0.0005722258,0.00028297387],"domain_scores_gemma":[0.9955743,0.0017728145,0.0013532237,0.00022572633,0.00075890165,0.00031505837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016576577,0.00017371729,0.0012330035,0.00020367728,0.000060039376,0.000012043863,0.00019267536,0.00018767331,0.00005863638],"category_scores_gemma":[0.0040387437,0.00009170813,0.00025789137,0.0006827411,0.00038580626,0.00011610083,0.000040368297,0.0008961729,0.0000013952834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7813131,0.01097963,0.15541837,0.00016800052,0.0019651037,0.00009668404,0.00030578426,0.00001197959,0.0010906606,0.00003836795,0.0070399567,0.041572347],"study_design_scores_gemma":[0.810478,0.058266368,0.09657516,0.0010864442,0.0014240163,0.000003884883,0.00015424944,0.00004526689,0.0071601216,0.00011301332,0.024521548,0.00017197596],"about_ca_topic_score_codex":0.00020292852,"about_ca_topic_score_gemma":0.000634759,"teacher_disagreement_score":0.05884321,"about_ca_system_score_codex":0.00043860485,"about_ca_system_score_gemma":0.009132175,"threshold_uncertainty_score":0.9964851},"labels":[],"label_agreement":null},{"id":"W4410809619","doi":"10.1200/jco.2025.43.16_suppl.e13501","title":"STEP-1: A SickKids pilot providing upfront financial support for pediatric and adolescent patients travelling to access academic phase 1-2 studies in Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Adolescent and Pediatric Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"Garron Family Cancer Centre","keywords":"Medicine; Phase (matter); Family medicine","score_opus":0.4697377177802873,"score_gpt":0.6401953826001036,"score_spread":0.17045766481981628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777026,0.0012193487,0.0013405065,0.010841525,0.0069061066,0.0018573856,0.000041792508,0.0000069645303,0.00008375469],"genre_scores_gemma":[0.9772453,0.0038155522,0.00070411316,0.014692351,0.0032870558,0.0000520927,0.000003932526,0.00001589606,0.00018372432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349034,0.0009419615,0.0043137833,0.0002950084,0.00031295704,0.0006459777],"domain_scores_gemma":[0.99137765,0.005337269,0.0018173908,0.00010698372,0.0008496244,0.00051105325],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005252428,0.00018828857,0.0014993236,0.0003281667,0.0002466825,0.0000042323672,0.0003381233,0.00041093494,0.000012237461],"category_scores_gemma":[0.011622712,0.00015077234,0.000111552334,0.00035554412,0.000043853328,0.00014778528,0.00020257226,0.0025523994,0.0000019927868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038630094,0.0004934145,0.7978996,0.0010391407,0.000024325525,0.000030079367,0.00046856338,0.000009077899,5.742453e-7,0.000030126499,0.13499695,0.061145138],"study_design_scores_gemma":[0.022995232,0.007373069,0.85187113,0.0008486211,0.00027015602,0.0000016261034,0.0018764952,0.00016098832,0.000001645634,0.00035335193,0.11400252,0.00024514765],"about_ca_topic_score_codex":0.007203692,"about_ca_topic_score_gemma":0.16088471,"teacher_disagreement_score":0.15368101,"about_ca_system_score_codex":0.0015331376,"about_ca_system_score_gemma":0.03269159,"threshold_uncertainty_score":0.99974877},"labels":[],"label_agreement":null},{"id":"W4410809622","doi":"10.1200/jco.2025.43.16_suppl.tps5122","title":"A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Ottawa; McMaster University; Queen's University; Juravinski Cancer Centre; Ottawa Hospital; BC Cancer Agency; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Taxane; Medicine; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Prostate; Cancer research; Breast cancer","score_opus":0.10356424987557518,"score_gpt":0.48814089601623,"score_spread":0.38457664614065484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98598003,0.0006524321,0.00006749958,0.01048526,0.0002798097,0.002413123,0.00002012744,0.0000064428036,0.00009525095],"genre_scores_gemma":[0.9948116,0.0010694885,0.0026235394,0.00059566536,0.0001587699,0.00018475999,0.000028093513,0.000016501483,0.00051155884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942792,0.0020858971,0.0026717593,0.00028045088,0.00039634499,0.0002863701],"domain_scores_gemma":[0.99377877,0.004074064,0.0013353835,0.00014833448,0.00043786434,0.00022558794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066448743,0.00019717605,0.0017804331,0.0004886347,0.00008235739,0.00003796558,0.0000833083,0.00016592312,0.000037014728],"category_scores_gemma":[0.0041780807,0.00012519167,0.00016040377,0.00045825774,0.0004390739,0.00023117347,0.00002664512,0.000760582,6.025711e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95967025,0.0023185129,0.015246461,0.00006372915,0.00042263832,0.00028067388,0.00096930726,0.000078795885,0.0020704975,0.000044541674,0.00010197882,0.018732624],"study_design_scores_gemma":[0.9308872,0.009978034,0.055306427,0.0006393605,0.00030659605,0.000009068416,0.00036332343,0.0010863862,0.00041571414,0.00042987612,0.000467466,0.000110538116],"about_ca_topic_score_codex":0.0001745252,"about_ca_topic_score_gemma":0.0010118316,"teacher_disagreement_score":0.040059965,"about_ca_system_score_codex":0.00036791604,"about_ca_system_score_gemma":0.0040109735,"threshold_uncertainty_score":0.7115295},"labels":[],"label_agreement":null},{"id":"W4410809722","doi":"10.1200/jco.2025.43.16_suppl.e13547","title":"Regional disparities in cancer biomarker knowledge and access across Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Manitoba; Windsor Regional Hospital; University of Ottawa; University of Windsor; Western University","funders":"","keywords":"Medicine; Biomarker; Cancer; Oncology; Family medicine; Internal medicine; Genetics","score_opus":0.717210719648258,"score_gpt":0.7352992536834828,"score_spread":0.018088534035224813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8310383,0.005329699,0.000024628847,0.15530185,0.0018004058,0.00013046652,0.000006516179,0.0000030389763,0.006365062],"genre_scores_gemma":[0.969914,0.013908942,0.00025712073,0.011460958,0.00050460384,0.000007332273,7.778503e-7,0.0000087252565,0.003937494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607855,0.00048072482,0.0023675638,0.00022687158,0.00051952264,0.00032675895],"domain_scores_gemma":[0.94991285,0.047548562,0.0006558137,0.0002090374,0.0012359585,0.00043779233],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011918861,0.00010175881,0.0011975769,0.00008980061,0.00005313804,0.000020771635,0.0003496511,0.00071147934,0.00007802169],"category_scores_gemma":[0.046308573,0.00007346722,0.00016547555,0.000310363,0.0008060933,0.00009945176,0.00033426943,0.0036720366,0.0000010165098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026013418,0.00071554084,0.8242618,0.00020745478,0.00021008884,0.0004188035,0.000042136824,0.000002093912,0.0000095056175,0.001777533,0.040659957,0.12909374],"study_design_scores_gemma":[0.0039803633,0.0005968912,0.83295405,0.00058791204,0.000049189042,0.000036471494,0.00007906507,0.00007822715,0.000010179974,0.006807971,0.15476687,0.000052805284],"about_ca_topic_score_codex":0.088364765,"about_ca_topic_score_gemma":0.88143617,"teacher_disagreement_score":0.7930714,"about_ca_system_score_codex":0.00046479926,"about_ca_system_score_gemma":0.02144765,"threshold_uncertainty_score":0.99862653},"labels":[],"label_agreement":null},{"id":"W4410809731","doi":"10.1200/jco.2025.43.16_suppl.e12592","title":"Survival outcomes following upfront surgery vs neoadjuvant chemotherapy for triple-negative and HER2-positive T1c and T2 breast cancer: A retrospective, population-based cohort study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Retrospective cohort study; Triple-negative breast cancer; Chemotherapy; Neoadjuvant therapy; Internal medicine; Cancer; Cohort; Population; Overall survival; Triple negative; Surgery","score_opus":0.02646522579562946,"score_gpt":0.4053589326575465,"score_spread":0.37889370686191703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899612,0.00067789154,0.00036242735,0.0069442075,0.0012945248,0.0006025019,0.00008739212,0.000005136762,0.00006473644],"genre_scores_gemma":[0.9974463,0.00041760976,0.0005951286,0.001058113,0.00028875083,0.00006302621,0.000012360468,0.000017241922,0.000101450954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778533,0.00036313123,0.0010886283,0.00037656384,0.00017518253,0.0002111439],"domain_scores_gemma":[0.9968131,0.0017642751,0.0008123639,0.00013634312,0.00035997733,0.000113906586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016449029,0.00021749185,0.0015754021,0.000083325904,0.00013372382,0.000017742455,0.000089652836,0.00022722532,0.0000037376517],"category_scores_gemma":[0.0011867846,0.00016494542,0.00043742982,0.00008779817,0.00013299914,0.000011878066,0.000054846674,0.00020902614,1.5298843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004057663,0.0007191943,0.9764041,0.000010663602,0.002606051,0.00001587547,0.000043392447,0.000008453941,0.000029375222,0.000010868705,0.00053055363,0.015563846],"study_design_scores_gemma":[0.009422886,0.0017575531,0.98736984,0.00005680393,0.0005046762,0.0000075725493,0.00020450648,0.000021410053,0.000063566746,0.00017041339,0.00027849223,0.00014226888],"about_ca_topic_score_codex":0.00067782705,"about_ca_topic_score_gemma":0.0012620697,"teacher_disagreement_score":0.015421577,"about_ca_system_score_codex":0.0001805834,"about_ca_system_score_gemma":0.0006717738,"threshold_uncertainty_score":0.6726279},"labels":[],"label_agreement":null},{"id":"W4410809758","doi":"10.1200/jco.2025.43.16_suppl.7532","title":"Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology","score_opus":0.10576998602998161,"score_gpt":0.44522419343433833,"score_spread":0.3394542074043567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723227,0.0015040693,0.00009084178,0.021600889,0.001021964,0.0011739264,0.00014113366,0.000020987443,0.0021234793],"genre_scores_gemma":[0.9870145,0.0052591544,0.00308315,0.0027371647,0.00085423765,0.00002959486,0.00013646432,0.000025745861,0.00085998815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99281895,0.001664528,0.0038434106,0.00050672924,0.00058275566,0.00058363157],"domain_scores_gemma":[0.96983206,0.027461326,0.0012100923,0.0004673304,0.00039282648,0.00063635106],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005794081,0.0003102572,0.0022925704,0.00030806972,0.000108646906,0.000041097406,0.00037388652,0.0006615951,0.00008750536],"category_scores_gemma":[0.01813648,0.00018604069,0.00047402922,0.0005025229,0.0003900294,0.00016562367,0.00010747924,0.0018840223,0.000027566077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5048602,0.015137386,0.17876767,0.00002748697,0.0016322996,0.00564099,0.0002658583,0.000007995601,0.00018017822,0.00002905321,0.023250768,0.2702001],"study_design_scores_gemma":[0.5426465,0.004834322,0.41044274,0.00029244018,0.00048488198,0.00007447872,0.00012285406,0.0007254308,0.00016775254,0.00036450263,0.039718434,0.00012562424],"about_ca_topic_score_codex":0.0022115035,"about_ca_topic_score_gemma":0.004006943,"teacher_disagreement_score":0.2700745,"about_ca_system_score_codex":0.00020733752,"about_ca_system_score_gemma":0.0019286883,"threshold_uncertainty_score":0.9901342},"labels":[],"label_agreement":null},{"id":"W4410809842","doi":"10.1200/jco.2025.43.16_suppl.2664","title":"Association of intestinal exfoliome and Prevotellaceae with toxicity and clinical outcome during immune-checkpoint blockade.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Toxicity; Blockade; Immune checkpoint; Internal medicine; Receptor","score_opus":0.05647838485524735,"score_gpt":0.4325353031947334,"score_spread":0.376056918339486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98864245,0.0005304397,0.00004814899,0.008832812,0.00043762897,0.00015567236,0.0000016326725,0.000007926563,0.0013432748],"genre_scores_gemma":[0.9946222,0.0007743468,0.002704104,0.00044355518,0.00039403673,0.0000010205739,4.1518294e-7,0.000007462389,0.0010528963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958308,0.00033526804,0.003184836,0.00018205898,0.00026715783,0.00019990343],"domain_scores_gemma":[0.9942556,0.002803699,0.002176391,0.00011405687,0.00043704198,0.00021322494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004365036,0.00013245973,0.0016853628,0.00014439668,0.000048132373,0.000009612739,0.000090612346,0.00038485622,0.000027915985],"category_scores_gemma":[0.006306922,0.00008647914,0.00027960635,0.00016365654,0.00036309552,0.00007776683,0.00009933689,0.0010890883,0.0000011967797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004377423,0.0010849632,0.9801978,0.00021785595,0.0005380573,0.00022297216,0.00005900449,0.0000010439786,0.0033668505,0.000101940284,0.00007702711,0.009755092],"study_design_scores_gemma":[0.0077334535,0.008780767,0.9774974,0.0004974567,0.00072382414,0.00051427685,0.00016351997,0.000043846452,0.0020630094,0.00022682428,0.0016769702,0.000078647405],"about_ca_topic_score_codex":0.000023436281,"about_ca_topic_score_gemma":0.000031805044,"teacher_disagreement_score":0.009676444,"about_ca_system_score_codex":0.000097941054,"about_ca_system_score_gemma":0.0005132436,"threshold_uncertainty_score":0.755043},"labels":[],"label_agreement":null},{"id":"W4410809863","doi":"10.1200/jco.2025.43.16_suppl.e16058","title":"Sex-based differences in outcomes following minimally invasive gastrectomy for gastric cancer: A nationwide study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Cancer; Gastrectomy; General surgery; Internal medicine; Oncology; Surgery","score_opus":0.11457623543000484,"score_gpt":0.4714860655421708,"score_spread":0.356909830112166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97632694,0.00020405136,0.00047175627,0.019642182,0.0017801832,0.00083528244,0.0000025022628,0.000010419388,0.0007266736],"genre_scores_gemma":[0.99148107,0.00007834433,0.0033202202,0.0036175097,0.00022790671,0.00006952664,0.0000013810015,0.000009223058,0.001194845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967603,0.00025562444,0.0021549559,0.00022529745,0.00034139032,0.0002624326],"domain_scores_gemma":[0.9917373,0.006712593,0.00102135,0.00013571153,0.00025711372,0.00013592922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024585484,0.00016211432,0.0018994566,0.0006286945,0.000041714928,0.00001694557,0.00022912398,0.00014783385,0.000045109115],"category_scores_gemma":[0.0066938587,0.000114900045,0.00071075384,0.00045602993,0.000056442856,0.000084931205,0.000049264094,0.00048748203,0.0000010475501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013476078,0.001556072,0.9436835,0.000056557117,0.0007283292,0.00021307405,0.000074705415,0.000024377618,0.000010234637,0.000015724674,0.0012690205,0.051020786],"study_design_scores_gemma":[0.022538397,0.006541437,0.96661425,0.00017866207,0.0008221611,0.0000023360517,0.0008395868,0.000097902,0.000014307699,0.00017549761,0.002101274,0.00007419844],"about_ca_topic_score_codex":0.0000913529,"about_ca_topic_score_gemma":0.0015334629,"teacher_disagreement_score":0.05094659,"about_ca_system_score_codex":0.00026265872,"about_ca_system_score_gemma":0.0029744713,"threshold_uncertainty_score":0.80136573},"labels":[],"label_agreement":null},{"id":"W4410809877","doi":"10.1200/jco.2025.43.16_suppl.7529","title":"Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Johnson and Johnson","keywords":"Medicine; Lenalidomide; Daratumumab; Bortezomib; Multiple myeloma; Dexamethasone; Oncology; Internal medicine","score_opus":0.10313142747771947,"score_gpt":0.46795437639282544,"score_spread":0.36482294891510597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98926383,0.0029052028,0.0017983452,0.0029262132,0.00088585005,0.0012957215,0.00010609797,0.000027311433,0.00079141965],"genre_scores_gemma":[0.9880449,0.0068872403,0.0030097899,0.0010369907,0.0005859886,0.000054414093,0.000100377125,0.000035110344,0.00024518275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99151593,0.0015812713,0.004490997,0.0007199755,0.0008077018,0.00088408997],"domain_scores_gemma":[0.98781663,0.008943037,0.0012164753,0.0005186345,0.00040907785,0.0010961667],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043341443,0.00048517264,0.0043358007,0.0014253941,0.00012854871,0.00005455532,0.00040545786,0.0007395522,0.0001550958],"category_scores_gemma":[0.0046979114,0.00036867824,0.0012985736,0.0013026064,0.000429461,0.00020482167,0.00006789174,0.0017662339,0.000012582269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45702335,0.008240245,0.43280593,0.00012535577,0.005120351,0.009561783,0.00021681724,0.000060136696,0.0009131385,0.000021106247,0.00077234703,0.085139446],"study_design_scores_gemma":[0.5269048,0.019140324,0.43663287,0.00036406887,0.005206477,0.00030386014,0.0001157694,0.002579545,0.0007742299,0.0001575576,0.007514096,0.00030638615],"about_ca_topic_score_codex":0.00052652886,"about_ca_topic_score_gemma":0.0027889623,"teacher_disagreement_score":0.084833056,"about_ca_system_score_codex":0.00029385617,"about_ca_system_score_gemma":0.0021465104,"threshold_uncertainty_score":0.9998765},"labels":[],"label_agreement":null},{"id":"W4410809889","doi":"10.1200/jco.2025.43.16_suppl.11024","title":"Predictors of withdrawal for FDA accelerated approvals of anticancer drugs, 1992-2022.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Queen's University","funders":"","keywords":"Medicine; Pharmacology; Drug approval; Drug","score_opus":0.10100660155870456,"score_gpt":0.4045961998650246,"score_spread":0.30358959830632004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438975,0.0036889308,0.00532632,0.0030424485,0.004895056,0.00038148687,0.0002114467,0.000006893002,0.03854994],"genre_scores_gemma":[0.9942207,0.0013982668,0.0020913812,0.00082009175,0.000654034,0.000007595517,0.0000028662964,0.000015384028,0.0007897279],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947532,0.00005346785,0.004659993,0.00022995571,0.000055611657,0.00024781562],"domain_scores_gemma":[0.992564,0.0013702133,0.0053449366,0.00022076673,0.0003672718,0.00013276713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004117074,0.00013937037,0.0023094253,0.00029454194,0.000032083804,0.000010794007,0.00040997582,0.00041397408,0.00013865784],"category_scores_gemma":[0.0033741717,0.00013114764,0.0006372889,0.00024459814,0.0003352258,0.00024614748,0.00005927177,0.00040652062,0.000005022512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005865477,0.002150604,0.635342,0.00035505142,0.0022940778,0.000008246906,0.0004800511,0.00033902487,0.00015656812,0.20018011,0.055540193,0.097288616],"study_design_scores_gemma":[0.012080869,0.006907563,0.30212814,0.0001955148,0.00022825807,0.000005752364,0.00019300033,0.00081167126,0.0011160421,0.06407959,0.6119345,0.00031912082],"about_ca_topic_score_codex":0.00009805296,"about_ca_topic_score_gemma":0.00003694197,"teacher_disagreement_score":0.5563943,"about_ca_system_score_codex":0.00013868141,"about_ca_system_score_gemma":0.0011719707,"threshold_uncertainty_score":0.5348045},"labels":[],"label_agreement":null},{"id":"W4410809997","doi":"10.1200/jco.2025.43.16_suppl.e23281","title":"Head and neck cancers in Southeast Asia: 2022 incidence and mortality estimates for 2022 and projections for 2050.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Head and neck; Incidence (geometry); Head and neck cancer; Oncology; Demography; Internal medicine; Southeast asia; Cancer; Surgery; Ancient history","score_opus":0.13380113904729052,"score_gpt":0.530591728210776,"score_spread":0.39679058916348553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769233,0.006244566,0.0002072837,0.014584668,0.00064180605,0.0005623499,0.000021123293,0.000004481101,0.0008104362],"genre_scores_gemma":[0.98908705,0.004314142,0.0050504734,0.00085729425,0.0003587601,0.000082996135,0.0000018576519,0.000007722574,0.00023972915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855167,0.00006719318,0.0009453952,0.00018315203,0.00008568266,0.00016692147],"domain_scores_gemma":[0.9971478,0.0021299082,0.0003279202,0.00006540552,0.00019483695,0.00013412695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018359531,0.00009094778,0.0010473802,0.00010292051,0.000091935464,0.0000075752077,0.000037195357,0.00015509134,0.000005008034],"category_scores_gemma":[0.0038779364,0.00006763089,0.000094594645,0.00010913767,0.00025997093,0.00006621734,0.00004807346,0.0003795879,6.996939e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037357174,0.0003202814,0.8943384,0.00035489028,0.00035659154,0.000036974976,0.00026015932,0.000004185996,0.00010464071,0.000636532,0.0066364286,0.09321517],"study_design_scores_gemma":[0.008558969,0.007559241,0.9514622,0.00036460708,0.0003774897,0.00009863159,0.0012805809,0.00088191737,0.000013378863,0.0023914857,0.026942201,0.000069286754],"about_ca_topic_score_codex":0.0002333482,"about_ca_topic_score_gemma":0.0037872342,"teacher_disagreement_score":0.09314588,"about_ca_system_score_codex":0.0001100361,"about_ca_system_score_gemma":0.0010290523,"threshold_uncertainty_score":0.46425322},"labels":[],"label_agreement":null},{"id":"W4410809998","doi":"10.1200/jco.2025.43.16_suppl.7546","title":"DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Subgroup analysis; Oncology; Refractory (planetary science); Confidence interval","score_opus":0.036353756517859694,"score_gpt":0.38051493281884136,"score_spread":0.34416117630098164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554837,0.0019721386,0.000067622015,0.00036669703,0.00022201838,0.0016221436,0.000047245045,0.000012977033,0.00014079029],"genre_scores_gemma":[0.99377555,0.0017828596,0.003898715,0.00018072505,0.00010479369,0.000041617375,0.000034667133,0.000044053424,0.00013704548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914981,0.0022798516,0.0035630125,0.0008750723,0.0010488709,0.0007350997],"domain_scores_gemma":[0.9894195,0.00631729,0.0022703118,0.00065698486,0.000599961,0.00073591986],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0040643634,0.0005211301,0.0044846176,0.0018760022,0.0001125461,0.00003350752,0.0003438334,0.00074333424,0.000036964204],"category_scores_gemma":[0.005666169,0.00037826307,0.0003694568,0.0017370794,0.0005501574,0.00017489551,0.00029504354,0.0025667895,0.0000019554009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06274589,0.009832769,0.8519999,0.000094958814,0.004247834,0.0017320284,0.0006963502,0.0001967057,0.000039808376,0.0000048343795,0.000096600015,0.068312354],"study_design_scores_gemma":[0.13179353,0.0330212,0.8295118,0.0002691753,0.0030576654,0.00006225154,0.000981145,0.00087184925,0.00005432992,0.000032747448,0.00011498576,0.00022929335],"about_ca_topic_score_codex":0.00478175,"about_ca_topic_score_gemma":0.030440861,"teacher_disagreement_score":0.06904764,"about_ca_system_score_codex":0.00079693075,"about_ca_system_score_gemma":0.001749705,"threshold_uncertainty_score":0.9998669},"labels":[],"label_agreement":null},{"id":"W4410810019","doi":"10.1200/jco.2025.43.16_suppl.7527","title":"Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Oncology; Refractory (planetary science); Antigen; Internal medicine; Cancer research; Immunology","score_opus":0.0469796783495657,"score_gpt":0.4166866793760618,"score_spread":0.3697070010264961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970774,0.00044551358,0.000103211816,0.0005181365,0.0003422779,0.0006599442,0.000009870312,0.0000062660556,0.0008373973],"genre_scores_gemma":[0.9966113,0.0015125162,0.0013938727,0.0001429736,0.00010962749,0.000002627055,0.00004106264,0.000014940604,0.00017110464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966238,0.0004409587,0.0019414091,0.00025954563,0.00045736824,0.00027688534],"domain_scores_gemma":[0.9958365,0.0020357359,0.0011187735,0.00023982243,0.00048322996,0.00028596973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011504642,0.00017324592,0.0012804763,0.0003863181,0.000045923505,0.000010331566,0.00013506295,0.00033165776,0.000045686513],"category_scores_gemma":[0.001631473,0.00011474724,0.00018283767,0.00027252737,0.00026566224,0.00015807798,0.000071623836,0.00087194436,0.000005990271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04692067,0.006185464,0.85982937,0.00010045029,0.000326318,0.00038788514,0.00005484615,0.0000026829143,0.0006484648,0.0000059446993,0.00012573988,0.08541217],"study_design_scores_gemma":[0.06272291,0.011740258,0.9235076,0.0004712615,0.00013729931,0.000018389464,0.000032285057,0.000049946728,0.00019559887,0.0000075946255,0.0010387856,0.0000780994],"about_ca_topic_score_codex":0.00002111815,"about_ca_topic_score_gemma":0.00007877563,"teacher_disagreement_score":0.08533406,"about_ca_system_score_codex":0.00017108985,"about_ca_system_score_gemma":0.0008660182,"threshold_uncertainty_score":0.46792567},"labels":[],"label_agreement":null},{"id":"W4410810024","doi":"10.1200/jco.2025.43.16_suppl.7533","title":"DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Bortezomib; Oncology; Internal medicine; Lenalidomide; Multiple myeloma; Subgroup analysis; Refractory (planetary science); Meta-analysis","score_opus":0.03328689332769362,"score_gpt":0.37548436703091237,"score_spread":0.34219747370321874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613625,0.001484651,0.00005691131,0.00040748855,0.00017828263,0.0015979202,0.000039610324,0.0000112193475,0.000087685716],"genre_scores_gemma":[0.99315494,0.0010191534,0.005311622,0.0001969239,0.000095306495,0.000035456633,0.000023942368,0.00003978614,0.00012285417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99161386,0.0025112238,0.0034880256,0.0007689686,0.0009431481,0.0006747948],"domain_scores_gemma":[0.9876579,0.008325924,0.0022118287,0.00057106244,0.0005520457,0.0006812065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044946275,0.00047068886,0.0044142464,0.001873284,0.00008590858,0.000028637594,0.00030071728,0.0006523481,0.000037102614],"category_scores_gemma":[0.007935167,0.0003382562,0.00036412614,0.0015236887,0.0004937584,0.00015325604,0.0002699194,0.0020670916,0.000001528376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09316261,0.007733576,0.8580487,0.00008435565,0.003972064,0.0017906599,0.00051732373,0.00022218884,0.00006129667,0.0000054446523,0.000045698285,0.03435612],"study_design_scores_gemma":[0.15294373,0.024424477,0.81785583,0.00024984832,0.0029300088,0.000052292096,0.0007206454,0.00045252885,0.00008101324,0.00004232414,0.00004527487,0.00020203294],"about_ca_topic_score_codex":0.004626268,"about_ca_topic_score_gemma":0.020929076,"teacher_disagreement_score":0.059781127,"about_ca_system_score_codex":0.0006969197,"about_ca_system_score_gemma":0.0015078173,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W4410810027","doi":"10.1200/jco.2025.43.16_suppl.tps2687","title":"Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; T-cell receptor; Bifunctional; Antibody; Receptor; Cancer research; Immunology; Pharmacology; Molecular biology; Internal medicine; T cell; Biochemistry; Biology; Immune system","score_opus":0.03909459737228007,"score_gpt":0.4344524656994455,"score_spread":0.39535786832716546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956447,0.00025876833,0.00008547329,0.0009826986,0.00037797407,0.0020942949,0.000022067936,0.000009229642,0.00052479026],"genre_scores_gemma":[0.9971644,0.0006353133,0.0011971516,0.0005393789,0.00013912468,0.000021572767,0.00003205163,0.00004673067,0.0002242474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99219716,0.0013382098,0.003973214,0.0006046156,0.0013594967,0.0005273304],"domain_scores_gemma":[0.9935611,0.0018585214,0.0019613288,0.00041731956,0.0018048711,0.00039689304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044356296,0.0003513318,0.002567609,0.0014618321,0.00007221387,0.000011632577,0.00034322514,0.0003733433,0.00065181474],"category_scores_gemma":[0.002175425,0.00026605566,0.00029139718,0.0019121242,0.00023444646,0.00015676791,0.00012286555,0.0015086522,0.000005339804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26184356,0.11449828,0.43730736,0.00013295717,0.0005250666,0.0005322141,0.0015343672,0.00031999926,0.16737553,0.0000057021357,0.00247452,0.013450429],"study_design_scores_gemma":[0.2516508,0.28490025,0.4297187,0.0010712766,0.00020768827,0.000009784081,0.0017935403,0.0003544446,0.02205796,0.000051084204,0.007829262,0.0003552036],"about_ca_topic_score_codex":0.00045124444,"about_ca_topic_score_gemma":0.00039957825,"teacher_disagreement_score":0.17040196,"about_ca_system_score_codex":0.000551926,"about_ca_system_score_gemma":0.0030416732,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W4410810149","doi":"10.1200/jco.2025.43.16_suppl.tps2671","title":"ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer research; Solid tumor; Oncology; Internal medicine; Cancer","score_opus":0.1303790071812936,"score_gpt":0.4964741971718948,"score_spread":0.3660951899906012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561995,0.000118307,0.000035374782,0.0007093856,0.00031643145,0.0010878647,0.0000017562775,0.0000051534353,0.002105792],"genre_scores_gemma":[0.9978672,0.0001094911,0.00053063734,0.0004638868,0.00029891453,0.00002110269,0.000006158235,0.000022682962,0.0006799146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944258,0.0010572225,0.003198651,0.00031508645,0.0006541336,0.0003491602],"domain_scores_gemma":[0.9959714,0.0016179683,0.0012767315,0.000348651,0.0005479081,0.00023737721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039049122,0.00018825753,0.0019261682,0.0006428391,0.000050997238,0.000011708882,0.00024782092,0.0002391609,0.00041116404],"category_scores_gemma":[0.0015764867,0.00013942616,0.00022303447,0.000516507,0.00016651399,0.0001553499,0.000082407365,0.0019564677,0.000003100731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044745974,0.07731796,0.7019031,0.00015487403,0.0003861157,0.0012430195,0.001931268,0.000607368,0.019722559,0.000016218793,0.00086965103,0.15110187],"study_design_scores_gemma":[0.16735621,0.1141224,0.7081074,0.00045328762,0.00022483521,0.000015711776,0.001201719,0.00079080166,0.00185333,0.00008506445,0.00559001,0.00019920111],"about_ca_topic_score_codex":0.00006492272,"about_ca_topic_score_gemma":0.0009831717,"teacher_disagreement_score":0.15090267,"about_ca_system_score_codex":0.0003460765,"about_ca_system_score_gemma":0.0012215173,"threshold_uncertainty_score":0.8499988},"labels":[],"label_agreement":null},{"id":"W4410810218","doi":"10.1200/jco.2025.43.16_suppl.e12598","title":"A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Hormone receptor; Internal medicine; Cancer; Hormone therapy; Neoadjuvant therapy; Cancer research","score_opus":0.060797614044561125,"score_gpt":0.497628338165247,"score_spread":0.43683072412068585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98501796,0.005203504,0.00003556692,0.008544019,0.0003815434,0.0005415287,0.000019565863,0.0000051119678,0.0002511809],"genre_scores_gemma":[0.98974,0.0073883524,0.00072249933,0.001724763,0.00030636732,0.000015542822,6.3440757e-7,0.000013021603,0.00008879994],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99713373,0.0004959028,0.0017129134,0.00024191657,0.00022539592,0.00019011523],"domain_scores_gemma":[0.99618185,0.0018114372,0.0011949819,0.00013130091,0.00047543086,0.0002049775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012813574,0.00016978926,0.0017518079,0.00020697467,0.00003310256,0.0000060124266,0.00009655878,0.00020388355,0.000052469248],"category_scores_gemma":[0.0005750348,0.00012078592,0.00011950978,0.00028277704,0.0004246575,0.00014484623,0.000053689673,0.00080722134,5.293617e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06940435,0.009203378,0.0680658,0.000018406063,0.0009753554,0.00022028295,0.0024804063,0.00000531309,0.0025706994,0.00004746838,0.00017667779,0.84683186],"study_design_scores_gemma":[0.1009122,0.068703115,0.820272,0.00041974342,0.00024814214,0.0003463874,0.0049689407,0.000030185016,0.00052633655,0.00084385806,0.002608138,0.000120929944],"about_ca_topic_score_codex":0.00053790334,"about_ca_topic_score_gemma":0.00020148605,"teacher_disagreement_score":0.8467109,"about_ca_system_score_codex":0.0001515724,"about_ca_system_score_gemma":0.00088955206,"threshold_uncertainty_score":0.49255067},"labels":[],"label_agreement":null},{"id":"W4410810222","doi":"10.1200/jco.2025.43.16_suppl.e23236","title":"Implementing standardized documentation for goals of care among advanced stage cancer patients.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Roche (Canada); William Osler Health System","funders":"","keywords":"Medicine; Documentation; Stage (stratigraphy); Cancer; Family medicine; Oncology; Medical physics; Intensive care medicine; Internal medicine","score_opus":0.1864510780084846,"score_gpt":0.6193602383149966,"score_spread":0.43290916030651205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283266,0.0019576692,0.0014127562,0.00056750875,0.0008850646,0.00037064136,0.00008114347,0.0000031669053,0.0018893885],"genre_scores_gemma":[0.98636585,0.0022303006,0.0104469,0.00041445735,0.00019962218,0.000012789047,0.000017421266,0.0000080221525,0.00030464728],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972327,0.00014582113,0.0021135502,0.00010570793,0.00023833643,0.0001639202],"domain_scores_gemma":[0.99393,0.0019134514,0.0022192704,0.00008173878,0.0017723914,0.00008315314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013193147,0.00008091494,0.0012159933,0.00010786802,0.000027496491,0.0000027720373,0.00008089896,0.00013067755,0.00009755266],"category_scores_gemma":[0.0039393986,0.000060848542,0.0004017466,0.00010712709,0.00010047405,0.000109345005,0.00003535307,0.00021178303,1.6798147e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051259277,0.00025041844,0.78991807,0.00036141006,0.0004659833,0.0000051929114,0.00065398565,0.000020452191,0.0005306077,0.00013009833,0.0012579741,0.20127991],"study_design_scores_gemma":[0.041169584,0.013725671,0.4437604,0.0021874884,0.0011480263,3.8381054e-7,0.0070387055,0.000027891536,0.021198587,0.00029828376,0.4693314,0.00011355974],"about_ca_topic_score_codex":0.000046688838,"about_ca_topic_score_gemma":0.00017079408,"teacher_disagreement_score":0.46807346,"about_ca_system_score_codex":0.00018469297,"about_ca_system_score_gemma":0.0009621081,"threshold_uncertainty_score":0.47161126},"labels":[],"label_agreement":null},{"id":"W4410810680","doi":"10.1200/jco.2025.43.16_suppl.2643","title":"JAK inhibitor for the treatment of steroid refractory and life-threatening immune-related adverse events secondary to immune checkpoint inhibitors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Adverse effect; Immune system; Refractory (planetary science); Immune checkpoint; Oncology; Pharmacology; Internal medicine; Immunology; Immunotherapy","score_opus":0.07114671738270015,"score_gpt":0.4380272972597141,"score_spread":0.36688057987701395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830961,0.0072067087,0.000079825724,0.0067337756,0.0013271158,0.0010843936,0.000015728454,0.000007675166,0.00044865493],"genre_scores_gemma":[0.9932297,0.0032743798,0.0015528514,0.0002741034,0.0003956993,0.00003959576,0.0000073826604,0.000018512737,0.0012077936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995741,0.00030406777,0.0031385857,0.00022775255,0.00028584016,0.00030277064],"domain_scores_gemma":[0.99431235,0.0032494916,0.0012603396,0.00028840892,0.00045593944,0.00043348465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021960954,0.00019912564,0.001560703,0.00023532202,0.00010130229,0.0000048187367,0.00013961946,0.00032169354,0.00006732609],"category_scores_gemma":[0.0032126154,0.00011232518,0.00083330984,0.00016904189,0.0002012054,0.00008884645,0.00008237758,0.00054984767,0.0000073852893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042445492,0.008305828,0.09496179,0.00020515319,0.006811367,0.00037102838,0.0008244486,0.000024765855,0.012558047,0.000027602211,0.00082744996,0.832637],"study_design_scores_gemma":[0.05640624,0.054682165,0.8065917,0.00065063016,0.0012615595,0.000097998134,0.00072044926,0.0001677697,0.0075969365,0.00019011802,0.07149317,0.00014128927],"about_ca_topic_score_codex":0.00006251622,"about_ca_topic_score_gemma":0.000020644706,"teacher_disagreement_score":0.83249575,"about_ca_system_score_codex":0.00031382107,"about_ca_system_score_gemma":0.0016998273,"threshold_uncertainty_score":0.4580488},"labels":[],"label_agreement":null},{"id":"W4410810693","doi":"10.1200/jco.2025.43.16_suppl.11002","title":"Improving care of older adults with cancer: A randomized trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Cancer; Gerontology; Internal medicine","score_opus":0.14437518739765787,"score_gpt":0.5454267044619568,"score_spread":0.401051517064299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747235,0.0143719185,0.00072601397,0.0029300433,0.0015147263,0.0006488007,0.0000049740456,0.0000050563704,0.0050749746],"genre_scores_gemma":[0.9871283,0.0055259448,0.005413672,0.0009062914,0.00068688835,0.00001416621,0.0000015358642,0.000008534359,0.00031465394],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664944,0.00046254005,0.0023836256,0.00012352446,0.000253285,0.00012759269],"domain_scores_gemma":[0.990558,0.0054839747,0.002377591,0.00013764194,0.0013168604,0.00012588227],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020751487,0.00010354929,0.003015073,0.00013777193,0.000013299165,0.0000018380714,0.00011704379,0.00025273877,0.00006731242],"category_scores_gemma":[0.009511383,0.00005907954,0.0006445712,0.00015545484,0.00029647237,0.000042101306,0.000028377597,0.0005201744,5.3805223e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8314059,0.0004803321,0.012461202,0.0002965277,0.00077524554,0.000076138895,0.0010064279,0.0000048206734,0.000034045854,0.000056080986,0.0008705443,0.15253276],"study_design_scores_gemma":[0.96778625,0.0085451575,0.003065373,0.003921712,0.0015254596,0.000009034054,0.001949695,0.00004456168,0.00072352774,0.000042799496,0.012328424,0.00005798002],"about_ca_topic_score_codex":0.00023453176,"about_ca_topic_score_gemma":0.00010326913,"teacher_disagreement_score":0.15247478,"about_ca_system_score_codex":0.000085012725,"about_ca_system_score_gemma":0.0027650676,"threshold_uncertainty_score":0.9988319},"labels":[],"label_agreement":null},{"id":"W4410810709","doi":"10.1200/jco.2025.43.16_suppl.11003","title":"Randomized trial of a supportive oncology care at home intervention for patients with cancer receiving curative treatment.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Intervention (counseling); Cancer; Oncology; Internal medicine; Nursing","score_opus":0.09781154932039794,"score_gpt":0.5161677225829147,"score_spread":0.41835617326251673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827355,0.0007160472,0.000521088,0.008465641,0.0036115684,0.0026224044,0.000052741114,0.000008335396,0.0012666713],"genre_scores_gemma":[0.99452424,0.0007807536,0.0019339522,0.0010327018,0.0007827644,0.00017328543,0.000033982506,0.000019009238,0.0007193006],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99325037,0.0018663902,0.0040529915,0.00026326504,0.0003433191,0.0002236741],"domain_scores_gemma":[0.9815048,0.011005226,0.0053195516,0.00018426683,0.0017847234,0.00020141284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037276186,0.00019963678,0.0042474424,0.00020790013,0.00005160697,0.000004524957,0.00013036515,0.00039769843,0.00014691729],"category_scores_gemma":[0.008287217,0.00012503333,0.001477873,0.00016095878,0.00042098176,0.000105847525,0.000051774317,0.0004242593,0.0000011047463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8710522,0.004446233,0.026216999,0.00014985586,0.0027897153,0.000017776814,0.0024337885,0.0000042058605,0.0000031856737,0.000048477297,0.0014875055,0.09135005],"study_design_scores_gemma":[0.87220764,0.08356242,0.023011463,0.0007334793,0.0024373282,0.0000063110665,0.0012042945,0.0000099774925,0.00008507732,0.0002450672,0.016403444,0.00009348635],"about_ca_topic_score_codex":0.00023610392,"about_ca_topic_score_gemma":0.0017086023,"teacher_disagreement_score":0.09125657,"about_ca_system_score_codex":0.0014778733,"about_ca_system_score_gemma":0.0037519585,"threshold_uncertainty_score":0.99211705},"labels":[],"label_agreement":null},{"id":"W4410810717","doi":"10.1200/jco.2025.43.16_suppl.2632","title":"Validation of ENLIGHT, an AI predictor of immune checkpoint blockade (ICB) response and resistance, across the treatment span.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Oncology; Internal medicine; Receptor","score_opus":0.06131153850967042,"score_gpt":0.4603479341100242,"score_spread":0.3990363956003538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97873276,0.0027418442,0.00005761184,0.017266454,0.0005942551,0.00022528715,0.000014595817,0.0000036022764,0.00036360315],"genre_scores_gemma":[0.99430424,0.003258203,0.00056858937,0.000511113,0.00023226693,0.000003965342,0.0000019555816,0.0000066622983,0.0011130193],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964359,0.0006916255,0.002409331,0.00012716945,0.0002052868,0.00013072249],"domain_scores_gemma":[0.9957403,0.001979467,0.0015798389,0.0002742279,0.00034026915,0.00008589219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005540929,0.000102305385,0.0009861531,0.00007894106,0.000047027384,0.000005796525,0.00012865583,0.00023468096,0.00003811581],"category_scores_gemma":[0.0011867993,0.000056273944,0.00041880563,0.00016762222,0.0004924862,0.00006191282,0.000023686825,0.00030172314,2.8298098e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60299265,0.0066396478,0.065103754,0.00017486796,0.0032396705,0.00011988898,0.003211055,0.000011327033,0.21581496,0.00018012675,0.0016413698,0.10087069],"study_design_scores_gemma":[0.018277306,0.024138149,0.7733887,0.00030395394,0.00055424444,0.000055980956,0.0006156764,0.00002404965,0.07549528,0.00055724615,0.10652761,0.00006184637],"about_ca_topic_score_codex":0.000033500306,"about_ca_topic_score_gemma":0.00005411307,"teacher_disagreement_score":0.7082849,"about_ca_system_score_codex":0.00014388049,"about_ca_system_score_gemma":0.0011937824,"threshold_uncertainty_score":0.22947848},"labels":[],"label_agreement":null},{"id":"W4410810739","doi":"10.1200/jco.2025.43.16_suppl.11006","title":"Association of Medicaid expansion with five-year survival after cancer diagnosis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Medicaid; Cancer; Oncology; Cancer survival; Internal medicine; Demography; Health care","score_opus":0.062171945319653144,"score_gpt":0.3832580300486251,"score_spread":0.32108608472897193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513198,0.003475367,0.0006250504,0.015153041,0.004053295,0.00010752565,0.00007456802,0.0000048137013,0.025186514],"genre_scores_gemma":[0.9865551,0.007904239,0.000585683,0.0018057791,0.00070656784,0.000031794538,7.969181e-7,0.000010856254,0.0023991994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969931,0.0000805206,0.0024743616,0.00017790847,0.000072511335,0.00020159902],"domain_scores_gemma":[0.99457735,0.0012482044,0.003623963,0.00014302986,0.0002806467,0.00012679763],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035555954,0.00010462878,0.0014608565,0.000174962,0.000024750021,0.000011231218,0.00021356493,0.0003857365,0.000953351],"category_scores_gemma":[0.002953445,0.00008894497,0.00029771615,0.00015475636,0.000116210744,0.00024090544,0.00004229994,0.0004923429,0.00002539822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010372591,0.00033139347,0.9477266,0.000018084766,0.00038568367,0.000011296701,0.00008851438,0.000039214046,5.7923774e-7,0.0059023225,0.020959107,0.023499938],"study_design_scores_gemma":[0.002972911,0.001070148,0.6632016,0.00008766516,0.00006589625,7.9730506e-7,0.00004406644,0.00001991043,0.000017161794,0.00550291,0.3269314,0.00008559341],"about_ca_topic_score_codex":0.0002526782,"about_ca_topic_score_gemma":0.00052734243,"teacher_disagreement_score":0.30597228,"about_ca_system_score_codex":0.0003567904,"about_ca_system_score_gemma":0.00076903426,"threshold_uncertainty_score":0.9999599},"labels":[],"label_agreement":null},{"id":"W4410810832","doi":"10.1200/jco.2025.43.16_suppl.11066","title":"Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Head and neck cancer; Cancer; Head and neck; Oncology; Internal medicine; Family medicine; Gerontology; Surgery","score_opus":0.8532642527287402,"score_gpt":0.7325159824883356,"score_spread":0.12074827024040458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761063,0.00050514605,0.000116117495,0.021340614,0.0013866667,0.00038996787,0.00001864333,0.0000025361942,0.00013403583],"genre_scores_gemma":[0.99170315,0.0017462091,0.0041961223,0.0016444286,0.00026393146,0.000028193372,0.0000010796293,0.000009342698,0.0004075561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936826,0.0008475063,0.004386952,0.00024206283,0.0005911918,0.00024967492],"domain_scores_gemma":[0.92161614,0.075426586,0.0015737434,0.000082866296,0.0011102274,0.00019045107],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025311667,0.000109771456,0.0021259675,0.00030198446,0.000058311845,0.000021469525,0.000104878614,0.00073906797,0.00001164774],"category_scores_gemma":[0.23846897,0.00008172797,0.00026937056,0.000143099,0.0004059944,0.00010437475,0.00013101225,0.002058024,2.0156403e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038022124,0.0007380957,0.9012229,0.00015684796,0.00017524438,0.00012295178,0.00012482132,8.6537415e-7,0.000027381247,0.0008209426,0.00015536351,0.09265238],"study_design_scores_gemma":[0.021322416,0.0011893474,0.9597511,0.00046817397,0.00009044171,0.00001176037,0.00022296055,0.00021119551,0.000015989639,0.016115963,0.00053788134,0.0000627409],"about_ca_topic_score_codex":0.00023168302,"about_ca_topic_score_gemma":0.01314577,"teacher_disagreement_score":0.21315731,"about_ca_system_score_codex":0.00021174212,"about_ca_system_score_gemma":0.0034895267,"threshold_uncertainty_score":0.89412045},"labels":[],"label_agreement":null},{"id":"W4410810898","doi":"10.1200/jco.2025.43.16_suppl.e13851","title":"A global scoping review of barriers and strategies to implementation of geriatric assessment in older adults with cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Toronto","funders":"","keywords":"Medicine; Cancer; Geriatric oncology; Gerontology; Internal medicine","score_opus":0.04736983146099821,"score_gpt":0.5446298067811151,"score_spread":0.49725997532011684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726877,0.010557057,0.00045375,0.014020633,0.00036404814,0.00090874516,0.000009609396,0.000002304519,0.0009961056],"genre_scores_gemma":[0.9696261,0.022571057,0.005656177,0.0020366875,0.000079261044,0.000014660724,0.0000011972354,0.0000038862872,0.000010946267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971396,0.00021761382,0.0021509666,0.00012634486,0.00024433344,0.00012114963],"domain_scores_gemma":[0.99754626,0.00050453685,0.0012372128,0.000098713455,0.000458607,0.00015468913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016289471,0.000081871214,0.0012164005,0.000114269555,0.000008752061,0.0000031390723,0.00007931678,0.00009515921,0.000120655175],"category_scores_gemma":[0.00086035504,0.000058258804,0.00009514804,0.0003882142,0.00008608626,0.000086828375,0.000036111618,0.0002432105,9.4095086e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022728143,0.00035380406,0.75215036,0.015858943,0.00028316907,0.00008077932,0.00026355207,0.00004068609,0.00002369308,0.00021359258,0.0023699836,0.22608864],"study_design_scores_gemma":[0.009859717,0.0062959315,0.8939629,0.08698958,0.00032697126,0.00003405411,0.0021986093,0.000009697789,0.000028176808,0.000055030174,0.00018996492,0.000049322338],"about_ca_topic_score_codex":0.00035874202,"about_ca_topic_score_gemma":0.0026207839,"teacher_disagreement_score":0.22603932,"about_ca_system_score_codex":0.00019158659,"about_ca_system_score_gemma":0.0073770965,"threshold_uncertainty_score":0.9982501},"labels":[],"label_agreement":null},{"id":"W4410811025","doi":"10.1200/jco.2025.43.16_suppl.e12562","title":"Impact of pregnancy history and recency of childbirth on long-term outcomes in young patients with early-stage breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Childbirth; Breast cancer; Pregnancy; Stage (stratigraphy); Obstetrics; Cancer; Gynecology; Term (time); Oncology; Internal medicine","score_opus":0.05851014773825174,"score_gpt":0.4485099320146371,"score_spread":0.3899997842763854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716944,0.0008080911,0.0000044634503,0.0003451028,0.00059689395,0.00020119373,0.000031746862,0.000001962938,0.0008411014],"genre_scores_gemma":[0.9975821,0.0019376575,0.00004516902,0.00009993231,0.000056320972,0.0000018029104,0.0000011369607,0.000008511264,0.00026741254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979757,0.00011096673,0.0014191053,0.0001329786,0.00022287708,0.0001383396],"domain_scores_gemma":[0.9976154,0.00039698146,0.0014426967,0.00014586122,0.00026112143,0.00013796132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003613611,0.000116583746,0.0013743563,0.00020592342,0.000008422522,0.0000013121972,0.00008676069,0.00017477409,0.00011344326],"category_scores_gemma":[0.00031117958,0.000069021065,0.00026114951,0.00010167201,0.00020072682,0.00006994012,0.000024619667,0.00056815404,1.9497584e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005820097,0.001959769,0.9416419,0.00007721149,0.00033844437,0.00003909528,0.00014172657,0.000005861119,0.0000055301375,0.00001283833,0.000107330416,0.04985016],"study_design_scores_gemma":[0.01020635,0.011635423,0.9764969,0.0013523631,0.00015954628,0.00000876765,0.000008309039,0.0000015310573,0.000003352374,0.000007418844,0.00006997525,0.000050091883],"about_ca_topic_score_codex":0.0009362852,"about_ca_topic_score_gemma":0.0009868038,"teacher_disagreement_score":0.049800064,"about_ca_system_score_codex":0.00051599764,"about_ca_system_score_gemma":0.0015948897,"threshold_uncertainty_score":0.2829266},"labels":[],"label_agreement":null},{"id":"W4410811026","doi":"10.1200/jco.2025.43.16_suppl.e23125","title":"Pivotal studies of pharmacotherapies approved by the United States Food and Drug Administration for the treatment of cancer: A systematic review.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Cancer; Drug; Cancer drugs; Alternative medicine; Pharmacology; Family medicine; Gerontology; Intensive care medicine; Internal medicine; Pathology","score_opus":0.3423608623781233,"score_gpt":0.610826261558783,"score_spread":0.26846539918065965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54622513,0.36817896,0.000084955245,0.083131954,0.00051932846,0.0017920395,0.000028102011,0.0000023948614,0.00003714959],"genre_scores_gemma":[0.60693794,0.38828996,0.00009571966,0.004340778,0.000072630384,0.00005533687,0.0000021893447,0.0000038840426,0.00020158495],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975386,0.00048431914,0.0016913678,0.000067116234,0.00014349312,0.00007509817],"domain_scores_gemma":[0.979595,0.01797942,0.0018893599,0.00009529574,0.00039174553,0.000049152157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020638988,0.00008481561,0.0012941596,0.00003410558,0.000041335647,0.000003147053,0.0000795485,0.00004256292,0.0000061152045],"category_scores_gemma":[0.002259401,0.00003293719,0.00026090455,0.000104600644,0.00024539095,0.000035413566,0.000010531544,0.00016113104,6.55904e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060686037,0.023560205,0.08076217,0.44330442,0.09323592,0.00003313716,0.010168964,0.000075940916,0.0015264783,0.0017476353,0.10557618,0.1793229],"study_design_scores_gemma":[0.06299576,0.13988394,0.0045556366,0.055401348,0.08597846,0.00011496736,0.018235382,0.0078042476,0.009527246,0.0014177075,0.6137338,0.00035148705],"about_ca_topic_score_codex":0.000016980955,"about_ca_topic_score_gemma":0.000027784785,"teacher_disagreement_score":0.5081576,"about_ca_system_score_codex":0.000041824325,"about_ca_system_score_gemma":0.00028125895,"threshold_uncertainty_score":0.2704877},"labels":[],"label_agreement":null},{"id":"W4410811046","doi":"10.1200/jco.2025.43.16_suppl.e23226","title":"Identifying barriers and effective strategies to improve biomarker testing rates in non-small cell lung cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biomarker; Lung cancer; Cancer; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.05129701276020442,"score_gpt":0.5035954622646207,"score_spread":0.4522984495044163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865897,0.0012943131,0.0007811695,0.002524897,0.0013267733,0.00050774036,0.0000032099965,0.0000050575213,0.0069670854],"genre_scores_gemma":[0.9944404,0.00019748283,0.0037550682,0.0010796362,0.0001815763,0.000036046997,4.898034e-7,0.000007720739,0.0003016159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849796,0.0001375591,0.0009387497,0.00017107076,0.0000860393,0.0001686172],"domain_scores_gemma":[0.9970117,0.0019801026,0.0004333865,0.00007306241,0.0002684021,0.00023334655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010788898,0.00010090344,0.0006994874,0.0001879822,0.00004852596,0.000025381105,0.00006080419,0.00015078577,0.00001711985],"category_scores_gemma":[0.001720483,0.00007284769,0.00010483715,0.00026440775,0.00006824542,0.00010464696,0.000042393774,0.00039898162,0.0000010392523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011118364,0.0002921739,0.7941611,0.00024460413,0.0005831354,0.00035737126,0.00073086465,0.00009701296,0.0056877127,0.000036212314,0.00089527474,0.19580272],"study_design_scores_gemma":[0.008060839,0.0027581132,0.982739,0.0006604729,0.00084427436,0.000015469173,0.002021924,0.00063057576,0.0005740727,0.00031865132,0.0012976646,0.00007896083],"about_ca_topic_score_codex":0.00027903877,"about_ca_topic_score_gemma":0.00018896653,"teacher_disagreement_score":0.19572376,"about_ca_system_score_codex":0.0002961041,"about_ca_system_score_gemma":0.002658654,"threshold_uncertainty_score":0.4716338},"labels":[],"label_agreement":null},{"id":"W4410811187","doi":"10.1200/jco.2025.43.16_suppl.11167","title":"Impact of AI medical scribes on physician productivity and satisfaction in medical oncology.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Productivity; Family medicine; Patient satisfaction; Clinical Oncology; Oncology; Internal medicine; Nursing; Cancer","score_opus":0.265708426573312,"score_gpt":0.6312018350010656,"score_spread":0.36549340842775363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9129837,0.00019519943,0.00009757228,0.0833284,0.0016811409,0.00016394477,6.842894e-7,0.000004158895,0.001545177],"genre_scores_gemma":[0.993064,0.0006934453,0.00014025588,0.004818979,0.0012435984,0.0000031352358,9.18601e-7,0.0000052177993,0.000030456222],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99611086,0.00070718874,0.002263995,0.0001865317,0.0005435835,0.00018782803],"domain_scores_gemma":[0.99419004,0.0039691846,0.00079930044,0.00014573871,0.00048579066,0.0004099405],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0064564385,0.000098798504,0.0011919745,0.00027257274,0.000029940653,0.0000030743397,0.00009430954,0.00072358316,0.00016753029],"category_scores_gemma":[0.025271814,0.000067482906,0.00024268725,0.000275887,0.00043408995,0.000098403594,0.00003186938,0.0019953528,0.0000051220086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015642622,0.0015335492,0.44060346,0.000030849373,0.00007244984,0.00007972618,0.00012072681,0.0000036206536,0.000036380527,0.00022577113,0.0019820742,0.5537471],"study_design_scores_gemma":[0.0007942756,0.012849464,0.97813594,0.00052656746,0.000077304365,0.00013013299,0.00025248886,0.00024947757,0.00025506594,0.003508718,0.0031725992,0.00004793334],"about_ca_topic_score_codex":0.00084835506,"about_ca_topic_score_gemma":0.0011651014,"teacher_disagreement_score":0.5536992,"about_ca_system_score_codex":0.00039623113,"about_ca_system_score_gemma":0.011720676,"threshold_uncertainty_score":0.99388194},"labels":[],"label_agreement":null},{"id":"W4410811254","doi":"10.1200/jco.2025.43.16_suppl.5084","title":"Transcriptional profiling to identify a program of enzalutamide extreme non-response in lethal prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Profiling (computer programming); Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.20976517362380884,"score_gpt":0.5743259524163564,"score_spread":0.36456077879254756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97691417,0.001464851,0.00008143475,0.019055296,0.0008026924,0.0010421464,0.000012086002,0.000007730418,0.00061962055],"genre_scores_gemma":[0.9918872,0.0007040682,0.0049905996,0.0006355215,0.00025111652,0.000097550444,0.000002882799,0.00001168232,0.001419376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963523,0.00050327455,0.0021600425,0.00021604709,0.00044905144,0.0003192853],"domain_scores_gemma":[0.99715364,0.0012496153,0.0005390218,0.00013706146,0.0006399327,0.0002807323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050855903,0.00012827077,0.0011919955,0.00047174105,0.000026515927,0.000009173255,0.00017379217,0.00025045496,0.00006663473],"category_scores_gemma":[0.002136129,0.000090623944,0.00037777892,0.000524315,0.0002214745,0.00009429187,0.000045190875,0.0009290051,0.0000041984736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19157627,0.0058947834,0.41768953,0.00034478842,0.0006621779,0.001699325,0.00065297855,0.00014523961,0.072153896,0.000102784004,0.0012505692,0.30782765],"study_design_scores_gemma":[0.016554195,0.01703529,0.9435449,0.0009836212,0.00020812548,0.000058329806,0.00029486822,0.00016416216,0.006028765,0.00035820468,0.014681148,0.0000883829],"about_ca_topic_score_codex":0.000053714764,"about_ca_topic_score_gemma":0.00006447299,"teacher_disagreement_score":0.52585536,"about_ca_system_score_codex":0.00040143033,"about_ca_system_score_gemma":0.0062820218,"threshold_uncertainty_score":0.99935144},"labels":[],"label_agreement":null},{"id":"W4410811460","doi":"10.1200/jco.2025.43.16_suppl.5066","title":"Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Western University; Centre Hospitalier de l’Université de Montréal; McGill University; Juravinski Cancer Centre; Jewish General Hospital; London Health Sciences Centre; McMaster University; University Health Network; Ottawa Hospital; BC Cancer Agency","funders":"F. Hoffmann-La Roche; Pfizer","keywords":"Prostate cancer; Medicine; Cancer; Biomarker; Oncology; Internal medicine; Genetics; Biology","score_opus":0.1594768418501787,"score_gpt":0.5089278038883972,"score_spread":0.34945096203821846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97535336,0.008634231,0.000056489866,0.011508524,0.0013954581,0.002263797,0.00006141428,0.00001817722,0.0007085524],"genre_scores_gemma":[0.9795541,0.015333431,0.00033474306,0.0012969756,0.0005032541,0.0003138158,0.000023198118,0.000028143324,0.0026123063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99472517,0.0011436447,0.0025147682,0.00047795515,0.0004689108,0.0006695406],"domain_scores_gemma":[0.99512553,0.0015295398,0.0010250293,0.00017676562,0.0012109561,0.0009321618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004096881,0.00035292533,0.0024812275,0.0006177846,0.0002713917,0.00006321478,0.00014518353,0.0004396536,0.00030643225],"category_scores_gemma":[0.0012824406,0.00021868237,0.00035184636,0.00094712793,0.0002059176,0.00019087337,0.000058258523,0.00089226663,0.0000043243135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020579256,0.005196779,0.5397879,0.000044281165,0.009981097,0.0013706121,0.0008708513,0.000013146839,0.0015579936,0.00009694006,0.005834256,0.4146669],"study_design_scores_gemma":[0.063896954,0.041045938,0.81788284,0.00032221802,0.0030502053,0.00011176273,0.0008813254,0.00022889992,0.0007127659,0.00016610698,0.07138471,0.0003163043],"about_ca_topic_score_codex":0.05020307,"about_ca_topic_score_gemma":0.24917018,"teacher_disagreement_score":0.4143506,"about_ca_system_score_codex":0.0040082484,"about_ca_system_score_gemma":0.012603574,"threshold_uncertainty_score":0.99981517},"labels":[],"label_agreement":null},{"id":"W4410811464","doi":"10.1200/jco.2025.43.16_suppl.5090","title":"8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"Cancer Council Australia","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Androgen; Hormone; Cancer; Gynecology; Androgen receptor","score_opus":0.13830183537800853,"score_gpt":0.5165302946858149,"score_spread":0.37822845930780635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268,0.0023606608,0.00029242362,0.010635459,0.0016925078,0.0010857353,0.00013774565,0.000010022458,0.0011054105],"genre_scores_gemma":[0.98654306,0.0043818047,0.0053420383,0.0011419228,0.00037609873,0.000053535645,0.000013398366,0.000031400974,0.0021167388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618757,0.00030932162,0.0022462832,0.0003039537,0.0004980807,0.00045481342],"domain_scores_gemma":[0.99271965,0.003970765,0.0013832314,0.00025064105,0.0013387522,0.00033695812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026130753,0.00023699604,0.0026162346,0.00032212248,0.00006670504,0.000013961543,0.00020154397,0.00026981527,0.00003722062],"category_scores_gemma":[0.0026378802,0.00015469581,0.0009178046,0.0002960277,0.00043885477,0.0001387001,0.00009634477,0.00074047723,0.000006211163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23644237,0.0075789406,0.48432553,0.0008285065,0.026306523,0.002037572,0.0016885764,0.0001331593,0.010190921,0.0005968777,0.03217484,0.19769618],"study_design_scores_gemma":[0.17575367,0.05390823,0.6697322,0.0006401849,0.0073026684,0.000081720405,0.0026142914,0.00046167473,0.022935636,0.0010581918,0.0650374,0.0004741402],"about_ca_topic_score_codex":0.00006585731,"about_ca_topic_score_gemma":0.000060563667,"teacher_disagreement_score":0.19722204,"about_ca_system_score_codex":0.00031932176,"about_ca_system_score_gemma":0.0040236395,"threshold_uncertainty_score":0.71377635},"labels":[],"label_agreement":null},{"id":"W4410811468","doi":"10.1200/jco.2025.43.16_suppl.e23191","title":"Prevalence of immune-related adverse events (irAEs) and association with symptom distress score by Edmonton Symptom Assessment System (ESAS) in solid cancer patients receiving immune checkpoint inhibitor (ICI) therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Immune system; Distress; Association (psychology); Internal medicine; Cancer; Oncology; Psychiatry; Clinical psychology; Psychotherapist; Immunology","score_opus":0.020463591133806563,"score_gpt":0.37736551081582076,"score_spread":0.3569019196820142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922916,0.0036819517,0.00002446931,0.0008614235,0.002036069,0.00050360104,0.000030613726,0.000010560126,0.0005596992],"genre_scores_gemma":[0.99501204,0.0042080325,0.00004477881,0.0001223028,0.00012672841,0.000025325306,0.000010399686,0.000017769771,0.00043262678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99489796,0.00064629025,0.003300991,0.00027060177,0.00061931665,0.00026484442],"domain_scores_gemma":[0.99439204,0.0008110418,0.003678448,0.00020143313,0.0007681221,0.00014894339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003139036,0.00020426609,0.0015288338,0.0001572824,0.00004452436,0.0000060675466,0.00016999144,0.00048064842,0.000027776616],"category_scores_gemma":[0.0006361798,0.00014941559,0.00032643732,0.00028379686,0.0000981676,0.00016430576,0.0000741269,0.0010024462,4.8503875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002683956,0.0012763587,0.9759511,0.000604284,0.0006396557,0.000021330403,0.00050530344,0.000033717974,0.0008934749,0.000009721437,0.00008909876,0.017292045],"study_design_scores_gemma":[0.012745211,0.0038257302,0.97478664,0.0064714886,0.0004085533,0.000007156377,0.00062946876,0.00014133735,0.00063417706,0.000010074608,0.00021798727,0.00012219531],"about_ca_topic_score_codex":0.00056861236,"about_ca_topic_score_gemma":0.0003893523,"teacher_disagreement_score":0.01716985,"about_ca_system_score_codex":0.0015614061,"about_ca_system_score_gemma":0.0011739042,"threshold_uncertainty_score":0.60929906},"labels":[],"label_agreement":null},{"id":"W4410811469","doi":"10.1200/jco.2025.43.16_suppl.5096","title":"Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by <i>PTEN</i> status.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"PTEN; Medicine; Prostate cancer; Oncology; Overall survival; Internal medicine; Hormone; Metastatic breast cancer; Cancer; Cancer research; Breast cancer; PI3K/AKT/mTOR pathway; Apoptosis; Biology","score_opus":0.06884012411802144,"score_gpt":0.4462633216473706,"score_spread":0.37742319752934916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98834425,0.0032905692,0.000010004667,0.0055251713,0.00083437917,0.00070939946,0.00017188145,0.0000086335385,0.0011057262],"genre_scores_gemma":[0.8960952,0.10015366,0.00017195992,0.0011489597,0.00017801052,0.000038019345,0.00005768791,0.000020053696,0.0021364023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962633,0.0005477535,0.0020059235,0.00033904306,0.00038129304,0.0004626359],"domain_scores_gemma":[0.99652725,0.001469374,0.0009469509,0.00017341848,0.0004228807,0.00046010126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077692425,0.00026103118,0.0019224344,0.0003103865,0.00004769954,0.000024085757,0.000071971495,0.00015285864,0.00003077315],"category_scores_gemma":[0.00035760264,0.00016489819,0.00023230727,0.00020941423,0.00023586974,0.00012940816,0.00007236252,0.0006033196,0.0000035326716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030680439,0.004514047,0.61059177,0.00014587914,0.0019860233,0.004256779,0.0017479263,0.0000042526563,0.0007386504,0.00013538761,0.0052220593,0.33997682],"study_design_scores_gemma":[0.026076507,0.012970019,0.8749614,0.00042866167,0.00066910184,0.000023676806,0.0005120119,0.00011773172,0.00065696094,0.00033182895,0.08306414,0.00018797307],"about_ca_topic_score_codex":0.0022828626,"about_ca_topic_score_gemma":0.002094437,"teacher_disagreement_score":0.33978882,"about_ca_system_score_codex":0.0011037468,"about_ca_system_score_gemma":0.002277028,"threshold_uncertainty_score":0.6724353},"labels":[],"label_agreement":null},{"id":"W4410811534","doi":"10.1200/jco.2025.43.16_suppl.5060","title":"Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Germline; Somatic cell; Oncology; Internal medicine; BRCA mutation; Germline mutation; Cancer; Gynecology; Mutation; Ovarian cancer; Gene; Genetics","score_opus":0.08630820527101687,"score_gpt":0.49527910357005644,"score_spread":0.40897089829903954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959861,0.00011371118,0.000017275795,0.0021071471,0.00021370169,0.0013925264,0.000049768507,0.000002261062,0.000117515636],"genre_scores_gemma":[0.9989906,0.00007755126,0.000164312,0.0006040285,0.00009786756,0.000035262867,0.0000066069124,0.000010971622,0.000012779415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948208,0.0012624998,0.0029014838,0.00015042588,0.00067898113,0.0001858485],"domain_scores_gemma":[0.9870271,0.0079308655,0.0037991244,0.00028847886,0.0008846073,0.00006983749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021672582,0.00015683283,0.0014295562,0.00019923532,0.00003548281,0.000006092915,0.00019158765,0.0000744381,0.000034113513],"category_scores_gemma":[0.0021154566,0.00007496475,0.00028196012,0.0005582709,0.00025265213,0.00008675226,0.0000132490495,0.0006222034,3.9512517e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10194347,0.040803466,0.81227314,0.00035250495,0.0030541548,0.000070876806,0.006088618,0.0068892515,0.0013111512,0.00012724852,0.0009363215,0.02614978],"study_design_scores_gemma":[0.030853514,0.045656398,0.9206762,0.0005704517,0.0006341975,0.0000024561516,0.00093535875,0.00010793755,0.00026962892,0.00016692565,0.000074644246,0.000052331357],"about_ca_topic_score_codex":0.0005477305,"about_ca_topic_score_gemma":0.0005677025,"teacher_disagreement_score":0.108403005,"about_ca_system_score_codex":0.0002832771,"about_ca_system_score_gemma":0.002505511,"threshold_uncertainty_score":0.4444669},"labels":[],"label_agreement":null},{"id":"W4410811541","doi":"10.1200/jco.2025.43.16_suppl.5056","title":"Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Dalhousie University; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; London Health Sciences Centre; McMaster University; University of Toronto; Western University; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Cancer; Internal medicine; Oncology; Biomarker; Biology","score_opus":0.06804452329736803,"score_gpt":0.4216911073498777,"score_spread":0.35364658405250965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896427,0.0033925166,9.851068e-7,0.0013506989,0.00056896935,0.0045265267,0.0004947958,0.0000072132075,0.000015639376],"genre_scores_gemma":[0.99775237,0.00091069465,0.00010463554,0.00015372176,0.00009337626,0.0007351982,0.000025000803,0.00003713943,0.0001878847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927637,0.0016166822,0.0035729022,0.00054330175,0.00086205796,0.0006413779],"domain_scores_gemma":[0.99443257,0.0007853106,0.0027737604,0.00024266062,0.0012934069,0.00047228867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029076058,0.0004272765,0.0024614253,0.0005265914,0.00027802394,0.00003139723,0.00016151681,0.00018557932,0.00010448706],"category_scores_gemma":[0.00069175375,0.0002441647,0.000260966,0.0012949667,0.00033561853,0.00018598788,0.00006931111,0.00065423525,2.4468594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03317835,0.011399686,0.8713715,0.00014934287,0.003822808,0.00016242154,0.0027281016,0.00006855181,0.0072648865,0.0000014276877,0.00025954383,0.069593355],"study_design_scores_gemma":[0.08671715,0.038807184,0.86183953,0.0009011587,0.0021067858,0.0000120824425,0.0011399675,0.00010444629,0.0069186813,0.000011038918,0.0011833176,0.00025867834],"about_ca_topic_score_codex":0.053233847,"about_ca_topic_score_gemma":0.41816294,"teacher_disagreement_score":0.3649291,"about_ca_system_score_codex":0.002898965,"about_ca_system_score_gemma":0.011744479,"threshold_uncertainty_score":0.9956747},"labels":[],"label_agreement":null},{"id":"W4410811543","doi":"10.1200/jco.2025.43.16_suppl.5062","title":"PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Radium-223; Alkaline phosphatase; Oncology; Internal medicine; Cancer; Radium; Urology; Cancer research; Enzyme; Androgen receptor; Bone metastasis; Biochemistry; Radiochemistry; Biology; Chemistry","score_opus":0.22385904203999088,"score_gpt":0.5587866861940962,"score_spread":0.33492764415410536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818821,0.002072779,0.000010120004,0.015147974,0.000077172655,0.00066205405,0.00004329002,0.0000018284273,0.00010270605],"genre_scores_gemma":[0.9978111,0.0007341863,0.0005026243,0.00072544394,0.00012677208,0.000060268332,0.0000066070916,0.000004884025,0.00002815648],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99669087,0.0007238179,0.0019834996,0.00014625928,0.0003100675,0.00014551589],"domain_scores_gemma":[0.9935809,0.0046913717,0.0012726828,0.00015641775,0.00023230823,0.00006634359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072598495,0.00009944311,0.00073543395,0.00007425003,0.000046959318,0.000007021233,0.00013977462,0.00006857175,0.000050395498],"category_scores_gemma":[0.0034633284,0.00005623723,0.000090000096,0.00033442656,0.00025318784,0.000054123255,0.00002947068,0.0006523052,1.939174e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03067447,0.025035564,0.25810194,0.0019761797,0.0019913954,0.0007689583,0.013187356,0.0037271567,0.22570607,0.0016976433,0.0033230707,0.4338102],"study_design_scores_gemma":[0.037568506,0.016396035,0.856756,0.0017435495,0.0036930447,0.00010685643,0.03368674,0.01001497,0.031993132,0.0030837713,0.0046793334,0.00027810305],"about_ca_topic_score_codex":0.000121695986,"about_ca_topic_score_gemma":0.0007546215,"teacher_disagreement_score":0.59865403,"about_ca_system_score_codex":0.000063476,"about_ca_system_score_gemma":0.00069070683,"threshold_uncertainty_score":0.41461775},"labels":[],"label_agreement":null},{"id":"W4410811564","doi":"10.1200/jco.2025.43.16_suppl.5058","title":"Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)–directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Jewish General Hospital; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University; London Health Sciences Centre; McMaster University; Western University; Juravinski Cancer Centre; McGill University","funders":"","keywords":"Carboplatin; Medicine; Circulating tumor DNA; Oncology; Internal medicine; Cancer; Cancer research; Chemotherapy; Cisplatin","score_opus":0.07230359489327531,"score_gpt":0.4236817310986155,"score_spread":0.3513781362053402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693096,0.00069441635,0.0000029007017,0.00022415564,0.0005156475,0.0013888736,0.00015794208,0.0000018946189,0.00008318865],"genre_scores_gemma":[0.99925804,0.00018380956,0.00013750317,0.00018743218,0.000100076206,0.0000688504,0.000016236498,0.000019249443,0.000028815964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948811,0.0011027945,0.0031172088,0.0003031853,0.00030228845,0.00029342106],"domain_scores_gemma":[0.9947861,0.0006328175,0.0033056084,0.00029071118,0.0008038845,0.0001808828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026051498,0.00021809585,0.001519672,0.00017579469,0.00010800621,0.000014733393,0.00029424683,0.0001672883,0.000016459388],"category_scores_gemma":[0.0031505567,0.0001462526,0.0002368842,0.0004203049,0.00015605282,0.000010289171,0.000079819016,0.0003860514,6.3279174e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011502327,0.00938382,0.9160323,0.00010659674,0.0022927362,0.00009516992,0.0013762227,0.0031083173,0.020448968,0.000022930724,0.00040323476,0.03522737],"study_design_scores_gemma":[0.04227167,0.029143782,0.91864264,0.00039933712,0.0014954532,0.00000546165,0.0007177601,0.00016736423,0.005978332,0.00004906532,0.00086393335,0.0002652001],"about_ca_topic_score_codex":0.05708005,"about_ca_topic_score_gemma":0.7550381,"teacher_disagreement_score":0.69795805,"about_ca_system_score_codex":0.0003138169,"about_ca_system_score_gemma":0.005968565,"threshold_uncertainty_score":0.9996667},"labels":[],"label_agreement":null},{"id":"W4410811567","doi":"10.1200/jco.2025.43.16_suppl.e23110","title":"Assessment of OncoQuébec, an oncology clinical trials search engine, on clinical trial recruitment in Quebec.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical Text Mining and Ontologies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Quebec - Clinical Research Organization in Cancer","funders":"Innovative Medicines Canada; AbbVie; Pfizer","keywords":"Medicine; Clinical trial; Clinical Oncology; Oncology; Internal medicine; Family medicine; Cancer","score_opus":0.5833898828062747,"score_gpt":0.6698820581182794,"score_spread":0.0864921753120047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97205925,0.0007521202,0.001854958,0.008399529,0.009073768,0.0009807972,0.000013440936,0.000011733726,0.006854391],"genre_scores_gemma":[0.9528621,0.0069754217,0.028054733,0.0047767353,0.005664889,0.000056610483,0.00003317756,0.00003303769,0.001543291],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96521044,0.020107578,0.012875229,0.0007404959,0.00055792707,0.0005083034],"domain_scores_gemma":[0.9762959,0.017984277,0.00392447,0.000677803,0.0005462029,0.0005713553],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.091404304,0.0003030353,0.004579825,0.0003274561,0.00004636488,0.000018077279,0.0009214772,0.0028455863,0.00008324172],"category_scores_gemma":[0.055529803,0.000215411,0.0017634237,0.00027771108,0.0011268615,0.000012355639,0.00028415336,0.0029732506,0.000005744202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06750688,0.011089937,0.027728967,0.000021734013,0.00073159585,0.00014440817,0.000022404942,0.000051486833,0.0002814797,0.00042370052,0.012091467,0.87990594],"study_design_scores_gemma":[0.08517591,0.1334103,0.1323056,0.00013662764,0.00026363807,0.000014804302,0.00030324908,0.00018633142,0.00023048502,0.00031223494,0.6474454,0.00021543703],"about_ca_topic_score_codex":0.00036185287,"about_ca_topic_score_gemma":0.003729983,"teacher_disagreement_score":0.8796905,"about_ca_system_score_codex":0.00022983704,"about_ca_system_score_gemma":0.012785495,"threshold_uncertainty_score":0.99932694},"labels":[],"label_agreement":null},{"id":"W4410811576","doi":"10.1200/jco.2025.43.16_suppl.5059","title":"Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Chemotherapy; Etoposide; Docetaxel; Prostate cancer; Oncology; Cohort; Internal medicine; Cancer; Cisplatin; Immunotherapy","score_opus":0.11476497347675564,"score_gpt":0.5275964723278566,"score_spread":0.41283149885110093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534115,0.004953904,0.0003148971,0.037288044,0.0009860401,0.0019776514,0.0000518806,0.000025299456,0.0009907718],"genre_scores_gemma":[0.9479169,0.022843655,0.005166899,0.0074159373,0.00089036854,0.00022952445,0.000029577042,0.00006974391,0.01543736],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960069,0.00027802054,0.0022426003,0.00044971297,0.0004441755,0.0005785823],"domain_scores_gemma":[0.99490535,0.0025280328,0.0010582015,0.0002818208,0.0007063195,0.0005202695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015398273,0.00031931017,0.002514875,0.0002643448,0.000110948786,0.000031786534,0.00020075272,0.00016584244,0.0001460295],"category_scores_gemma":[0.0020401988,0.00020156542,0.00045865244,0.0003314144,0.00042573974,0.0001407498,0.000082275714,0.0010423505,0.000002573849],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28972644,0.0094874,0.02437888,0.0010931237,0.0050548175,0.00405215,0.0003382986,0.000027550048,0.0050845887,0.00010476469,0.021670194,0.6389818],"study_design_scores_gemma":[0.63226765,0.061387148,0.04453237,0.00094424194,0.0051806294,0.0022622058,0.00034588602,0.00532343,0.026826065,0.0019706292,0.21835688,0.00060289673],"about_ca_topic_score_codex":0.000118167794,"about_ca_topic_score_gemma":0.000102159625,"teacher_disagreement_score":0.6383789,"about_ca_system_score_codex":0.0005309149,"about_ca_system_score_gemma":0.005741767,"threshold_uncertainty_score":0.99989474},"labels":[],"label_agreement":null},{"id":"W4410811580","doi":"10.1200/jco.2025.43.16_suppl.5057","title":"Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Western University; McGill University; Jewish General Hospital; Ottawa Hospital; BC Cancer Agency; Queen's University; London Health Sciences Centre; McMaster University; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Durvalumab; Cancer; Prostate cancer; Oncology; Internal medicine; Urothelial cancer; Prostate; Bladder cancer; Immunotherapy","score_opus":0.11277655324953961,"score_gpt":0.4520381964419235,"score_spread":0.3392616431923839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696774,0.003954892,6.487174e-7,0.002266624,0.00036094507,0.0061191404,0.0002887854,0.000007968802,0.00003326967],"genre_scores_gemma":[0.995546,0.0031542226,0.000093535324,0.00010943378,0.00005388879,0.00063012994,0.000018893961,0.00003457791,0.0003593631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920974,0.0020721508,0.003756839,0.0006084292,0.00081881403,0.00064641534],"domain_scores_gemma":[0.99432874,0.00089916296,0.002301317,0.0002923721,0.0015696723,0.000608713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003592482,0.0004549464,0.002762312,0.0008625787,0.0003041814,0.000035277037,0.00016662499,0.00021684977,0.000048110647],"category_scores_gemma":[0.00094578916,0.0002514203,0.00022107229,0.0018674801,0.00034486238,0.00014477115,0.00007812369,0.00049498875,1.5850877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08665376,0.012911813,0.7357418,0.00017554479,0.0047211503,0.0001932896,0.003155163,0.00003685602,0.004349109,0.000003925049,0.00031861418,0.15173897],"study_design_scores_gemma":[0.086791806,0.064031,0.8416128,0.00095134636,0.0023305833,0.000008208371,0.00096782943,0.000049263563,0.0020442668,0.000013277409,0.00099385,0.00020575718],"about_ca_topic_score_codex":0.1349056,"about_ca_topic_score_gemma":0.7508906,"teacher_disagreement_score":0.615985,"about_ca_system_score_codex":0.0029160094,"about_ca_system_score_gemma":0.010394525,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W4410811592","doi":"10.1200/jco.2025.43.16_suppl.e23114","title":"Assessment of Onco+, a personalized navigation support, for oncology clinical trials in Quebec.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetics, Bioinformatics, and Biomedical Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Quebec Breast Cancer Foundation; Quebec - Clinical Research Organization in Cancer","funders":"AbbVie; Pfizer","keywords":"Medicine; Clinical trial; Oncology; Clinical Oncology; Personalized medicine; Internal medicine; Medical physics; Family medicine; Cancer; Bioinformatics","score_opus":0.2102071949288944,"score_gpt":0.5949364683362577,"score_spread":0.3847292734073633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9195027,0.00087483175,0.042343818,0.013144174,0.0063794507,0.0016185044,0.000085380736,0.0000065692648,0.016044613],"genre_scores_gemma":[0.94066066,0.0050361515,0.044940528,0.0029758592,0.0020828717,0.00004260908,0.00013693614,0.000021256335,0.004103139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9867181,0.0036744487,0.008533459,0.00028673073,0.00042525513,0.00036196702],"domain_scores_gemma":[0.98703194,0.0076627643,0.003724187,0.0002640786,0.0009868669,0.00033015313],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05598627,0.0001653963,0.002585052,0.00022471946,0.00003382162,0.000014869077,0.00049597584,0.0013165134,0.00006278994],"category_scores_gemma":[0.044328984,0.00012258734,0.0013281924,0.00017185471,0.00076983485,0.00001128785,0.00016684266,0.0008391852,0.0000022890517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073517053,0.004537828,0.039979137,0.00032452994,0.0010270168,0.00005125071,0.00009134319,0.000027605098,0.011330991,0.0016444969,0.047600646,0.8860335],"study_design_scores_gemma":[0.020644,0.02818713,0.07396974,0.00016366782,0.0002706993,0.000021942787,0.0006998705,0.00090141833,0.001487411,0.0013669366,0.87211865,0.00016855393],"about_ca_topic_score_codex":0.000093809824,"about_ca_topic_score_gemma":0.0008163035,"teacher_disagreement_score":0.8858649,"about_ca_system_score_codex":0.0001505609,"about_ca_system_score_gemma":0.010392985,"threshold_uncertainty_score":0.99998},"labels":[],"label_agreement":null},{"id":"W4410811627","doi":"10.1200/jco.2025.43.16_suppl.tps7563","title":"QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Lenalidomide; Oncology; Internal medicine; Phases of clinical research; Cancer research; Toxicity","score_opus":0.11608095900723578,"score_gpt":0.493371956361664,"score_spread":0.37729099735442817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617296,0.00027795782,0.000066369925,0.0010428973,0.00033908754,0.0019677677,0.0000106775715,0.000007957168,0.00011434913],"genre_scores_gemma":[0.9975474,0.00019556282,0.001632407,0.00025658507,0.000100501195,0.00002273212,0.000006546938,0.000020610445,0.00021766314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942335,0.0016909123,0.0027076586,0.00036254976,0.0006664956,0.0003389156],"domain_scores_gemma":[0.9879456,0.009246494,0.0014694949,0.0003412895,0.00066499156,0.0003321343],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042285346,0.0002355733,0.0016212965,0.00029155528,0.00010028213,0.000018009861,0.0001876945,0.00022361467,0.000046696652],"category_scores_gemma":[0.0155384205,0.00012205654,0.00016119292,0.0003007065,0.00041182624,0.00013314735,0.00014931339,0.0010522145,0.0000011999056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20938405,0.018781893,0.52289283,0.00007286015,0.0009294224,0.00040517034,0.0005897734,0.000005139394,0.0007581997,0.0000020233028,0.00008369364,0.24609494],"study_design_scores_gemma":[0.20822537,0.07195294,0.7153419,0.0003838375,0.0004965358,0.000017089831,0.0008849834,0.0021201866,0.000090152775,0.0000056404365,0.0004019515,0.00007939734],"about_ca_topic_score_codex":0.000092099224,"about_ca_topic_score_gemma":0.00043492985,"teacher_disagreement_score":0.24601553,"about_ca_system_score_codex":0.00018243676,"about_ca_system_score_gemma":0.0013536178,"threshold_uncertainty_score":0.9927541},"labels":[],"label_agreement":null},{"id":"W4410811633","doi":"10.1200/jco.2025.43.16_suppl.11120","title":"Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Cancer; Androgen receptor; Alternative medicine; Pathology","score_opus":0.19123378402062463,"score_gpt":0.5290824125384349,"score_spread":0.3378486285178103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785504,0.00044250308,0.00008509861,0.014780579,0.0014159392,0.0036928905,0.00037292397,0.000027933596,0.0006317667],"genre_scores_gemma":[0.99404484,0.0002910854,0.0013223672,0.0024896436,0.00046134696,0.0006301632,0.0001070182,0.000035803045,0.0006177365],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912339,0.0014046407,0.005625053,0.000575002,0.00067411875,0.00048732685],"domain_scores_gemma":[0.984272,0.010445504,0.003689805,0.00043632946,0.00088508154,0.00027126097],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037070166,0.0003960871,0.0022517133,0.00026613788,0.00018112201,0.00005161883,0.00022942074,0.00026083709,0.00012450943],"category_scores_gemma":[0.008603686,0.0002527153,0.00054254715,0.0004989778,0.0002514993,0.00020101224,0.0000427347,0.0009767348,0.00000370529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5906846,0.027630897,0.13096513,0.00007673627,0.008990842,0.004040884,0.009546409,0.0007637068,0.0056931153,0.00009844989,0.0110833645,0.21042585],"study_design_scores_gemma":[0.46097082,0.097689986,0.37649453,0.0012735493,0.0046406114,0.00022970348,0.005898887,0.0010775469,0.007189966,0.0026347945,0.041259624,0.0006399838],"about_ca_topic_score_codex":0.0014789907,"about_ca_topic_score_gemma":0.0035214236,"teacher_disagreement_score":0.24552941,"about_ca_system_score_codex":0.0012617565,"about_ca_system_score_gemma":0.0069893845,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W4410811646","doi":"10.1200/jco.2025.43.16_suppl.11123","title":"Quality of life in a phase III study of prospective radiation therapy (IMRT) +/- cetuximab for locally advanced resected head and neck cancer: NRG/RTOG 0920.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Head and neck cancer; Radiation therapy; Head and neck; Oncology; Quality of life (healthcare); Cancer; Prospective cohort study; Internal medicine; Surgery; Colorectal cancer","score_opus":0.15356052169919318,"score_gpt":0.5628685743264453,"score_spread":0.4093080526272521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886066,0.0052870233,0.00010984823,0.0038391536,0.00046329494,0.0013169898,0.000010489301,0.0000047444087,0.00036189036],"genre_scores_gemma":[0.9926747,0.0056669014,0.0004814258,0.00083731953,0.00022414039,0.000059270966,8.9554214e-7,0.000008224225,0.000047105917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995687,0.00047769115,0.0031821402,0.00021609891,0.00026069855,0.00017633593],"domain_scores_gemma":[0.9942304,0.0026937872,0.001814663,0.00014660871,0.0009774095,0.00013714048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030346243,0.00012508994,0.0027658555,0.00017693787,0.000035118348,0.0000022967442,0.00009419423,0.00019421265,0.000010301449],"category_scores_gemma":[0.0059098876,0.00009074056,0.00020338954,0.00032808786,0.00017947292,0.000077481134,0.000033557484,0.00050906086,6.616815e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15017708,0.0128929345,0.5066295,0.00017047979,0.0008636237,0.0000150178475,0.0017554252,0.000021616703,0.0011124233,0.00008089517,0.00070584496,0.3255751],"study_design_scores_gemma":[0.18767712,0.06326157,0.74491996,0.00028822693,0.00010870524,0.0000018300271,0.0011284365,0.00009365096,0.00025939394,0.00033009215,0.0018678387,0.000063190026],"about_ca_topic_score_codex":0.00038897226,"about_ca_topic_score_gemma":0.0025339404,"teacher_disagreement_score":0.32551193,"about_ca_system_score_codex":0.00020116995,"about_ca_system_score_gemma":0.0026462153,"threshold_uncertainty_score":0.7075114},"labels":[],"label_agreement":null},{"id":"W4410811666","doi":"10.1200/jco.2025.43.16_suppl.e23198","title":"Barriers and facilitators to implementing the clinical trial navigator program: A qualitative analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Windsor Regional Hospital; University of Manitoba; Western University; University of Ottawa; University of Windsor","funders":"","keywords":"Medicine; Qualitative research; Medical physics; Medical education","score_opus":0.516923100697544,"score_gpt":0.7389827530083973,"score_spread":0.22205965231085334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8434,0.0002521403,0.0004901516,0.15267603,0.00091981335,0.0011177843,0.0000068320237,0.000010059841,0.0011271875],"genre_scores_gemma":[0.9429439,0.00048428655,0.0053037666,0.049405597,0.0013214311,0.0000438658,0.0000024096614,0.000008752359,0.00048603828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98910356,0.004309819,0.004683184,0.00028123692,0.0008070123,0.00081518857],"domain_scores_gemma":[0.94643044,0.037452586,0.001688339,0.00042136028,0.00123444,0.012772802],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07755854,0.00013428046,0.0021504103,0.0002952324,0.00013866989,0.000024001416,0.00023537985,0.00037572748,0.00013754785],"category_scores_gemma":[0.5203512,0.000071105256,0.00088275096,0.0009801894,0.00067182415,0.000065193024,0.00014638952,0.0022253348,0.000008321461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06677724,0.0007578909,0.05207708,0.00006172992,0.0029068883,0.00017596091,0.0013505209,4.578279e-7,0.0000034891837,0.00031464786,0.056054443,0.81951964],"study_design_scores_gemma":[0.053902145,0.03994373,0.052492667,0.000111403046,0.001597277,0.000015018754,0.0069455835,0.00006984122,0.0000028910692,0.0004842321,0.84436166,0.00007357855],"about_ca_topic_score_codex":0.000052610932,"about_ca_topic_score_gemma":0.0000785435,"teacher_disagreement_score":0.8194461,"about_ca_system_score_codex":0.00016087868,"about_ca_system_score_gemma":0.021876203,"threshold_uncertainty_score":0.98366886},"labels":[],"label_agreement":null},{"id":"W4410811714","doi":"10.1200/jco.2025.43.16_suppl.e23143","title":"Examining factors affecting clinical trial enrolment in the Clinical Trials Navigator program.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor; University of Ottawa; University of Toronto; University of Manitoba; Western University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.9765253141224026,"score_gpt":0.7877459110341802,"score_spread":0.1887794030882224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688348,0.0006219614,0.0013977315,0.0055730254,0.01495454,0.0026199468,0.0000026551616,0.000005644958,0.005989693],"genre_scores_gemma":[0.9848666,0.0002761009,0.006713415,0.0032926868,0.004018969,0.000035475023,0.0000015321102,0.000012897094,0.0007823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.20407714,0.57538724,0.20868404,0.0020152659,0.008958321,0.0008780224],"domain_scores_gemma":[0.11973938,0.7852144,0.0884936,0.0034654434,0.002352236,0.0007349314],"candidate_categories":["metaresearch","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.9136653,0.00042855705,0.022956142,0.00054679735,0.00015739453,0.0006340846,0.0043469924,0.001185563,0.0011988875],"category_scores_gemma":[0.88637537,0.00015712726,0.014382292,0.0018009274,0.00048174785,0.00027794632,0.00033308775,0.0040087556,0.00021069865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004400096,0.0027714134,0.36353537,0.00001064382,0.00084057444,0.000085637424,0.00019042942,0.000008124381,6.3227435e-7,0.00023253665,0.04149264,0.5864319],"study_design_scores_gemma":[0.03943045,0.014444072,0.43579075,0.00018248432,0.0016622186,0.000025283249,0.0046760286,0.00039165549,0.0000011709973,0.0038843101,0.49930972,0.00020185923],"about_ca_topic_score_codex":0.0000075379903,"about_ca_topic_score_gemma":0.00005479804,"teacher_disagreement_score":0.58623004,"about_ca_system_score_codex":0.00009632674,"about_ca_system_score_gemma":0.0026521233,"threshold_uncertainty_score":0.99971414},"labels":[],"label_agreement":null},{"id":"W4410811788","doi":"10.1200/jco.2025.43.16_suppl.e18569","title":"Predictors of septic shock among BCR/ABL-positive chronic myeloid leukemia patients admitted for sepsis: A nationwide study and analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Septic shock; Sepsis; Internal medicine; Myeloid; Oncology; Immunology","score_opus":0.03273359574235987,"score_gpt":0.40261378956548566,"score_spread":0.36988019382312576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961201,0.0004344822,0.00034925822,0.00047542725,0.00068270264,0.0012700026,0.00002744245,0.000012688065,0.00062791957],"genre_scores_gemma":[0.99755794,0.00021239008,0.00081441575,0.00041339252,0.00031664618,0.000036514248,0.000030951705,0.000018884508,0.00059889344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951318,0.00050348317,0.0032060891,0.00037177542,0.0004909698,0.00029587795],"domain_scores_gemma":[0.992001,0.0038412677,0.0023220186,0.00029484543,0.0012134986,0.00032739603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020914003,0.0002406616,0.002523786,0.0006450646,0.00006987639,0.000010344833,0.00019297117,0.00042022613,0.000060289083],"category_scores_gemma":[0.005316726,0.00018300443,0.0008076929,0.00072773255,0.00027634695,0.00015163312,0.00010456666,0.00069305196,0.0000017612244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026296715,0.0029176245,0.9638269,0.000090177346,0.014335003,0.00005952137,0.0002843308,0.0001229807,0.00003117104,0.000011636828,0.0009764896,0.014714501],"study_design_scores_gemma":[0.030389184,0.021389697,0.93064547,0.0002149389,0.0139866015,0.0000076138685,0.00027998292,0.0019910736,0.00007667961,0.0000634101,0.00085290935,0.000102421116],"about_ca_topic_score_codex":0.000066454435,"about_ca_topic_score_gemma":0.0002769547,"teacher_disagreement_score":0.033181407,"about_ca_system_score_codex":0.0024445704,"about_ca_system_score_gemma":0.005831801,"threshold_uncertainty_score":0.9998042},"labels":[],"label_agreement":null},{"id":"W4410811842","doi":"10.1200/jco.2025.43.16_suppl.5002","title":"Prognostic significance of PSA&gt;0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of British Columbia; Ottawa Hospital","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Androgen deprivation therapy; Internal medicine; Cancer","score_opus":0.07017764310688307,"score_gpt":0.432330976317524,"score_spread":0.3621533332106409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878794,0.0020177998,0.00009583431,0.006695256,0.00043916385,0.0018489211,0.000769834,0.000006019987,0.0002477728],"genre_scores_gemma":[0.99159425,0.0018588719,0.0014403382,0.00025509764,0.0001374535,0.00028519286,0.000073454496,0.000018560848,0.004336751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961382,0.000457127,0.002262536,0.0003251076,0.00050620415,0.00031080926],"domain_scores_gemma":[0.99308324,0.0028103164,0.002184955,0.0002773959,0.0014354007,0.00020866735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014375609,0.00023115425,0.001999248,0.00038781116,0.000053978234,0.000008345184,0.00015930746,0.00015847654,0.000032990156],"category_scores_gemma":[0.0018479497,0.0001306871,0.0010793247,0.00078509864,0.0006328745,0.000072164934,0.00005658044,0.00038307076,6.21285e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112809174,0.013706996,0.63956946,0.0005551731,0.04313697,0.00037394604,0.0028240918,0.000492689,0.02713017,0.00019103842,0.014902224,0.14430806],"study_design_scores_gemma":[0.034787763,0.019414263,0.8328959,0.0009089489,0.019811695,0.000015587173,0.0013037898,0.002063423,0.04931607,0.00025548058,0.0388937,0.00033339427],"about_ca_topic_score_codex":0.00034574885,"about_ca_topic_score_gemma":0.0009697632,"teacher_disagreement_score":0.19332641,"about_ca_system_score_codex":0.00064483704,"about_ca_system_score_gemma":0.003082992,"threshold_uncertainty_score":0.5469095},"labels":[],"label_agreement":null},{"id":"W4410811860","doi":"10.1200/jco.2025.43.16_suppl.5093","title":"Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta","funders":"Cancer Council Australia","keywords":"Medicine; Immune system; Internal medicine; Oncology; Immunology","score_opus":0.032577548249444414,"score_gpt":0.4120416514686518,"score_spread":0.37946410321920737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937707,0.0008268318,0.000053742664,0.0031821858,0.00059903914,0.00016836869,0.000003039888,0.0000011233817,0.0013949298],"genre_scores_gemma":[0.99660134,0.0010740664,0.0005271667,0.001360908,0.00020514513,0.0000036129738,0.0000031899385,0.0000059726312,0.00021861843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614793,0.0012864042,0.0020491895,0.00015119392,0.00019541848,0.00016986387],"domain_scores_gemma":[0.995081,0.0024382286,0.0020955752,0.00014483953,0.00019248808,0.000047878926],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009911169,0.00009893383,0.0010045031,0.000060027935,0.000029630857,0.000012648229,0.00021564399,0.00042661306,0.0000057083084],"category_scores_gemma":[0.01024832,0.00005955227,0.00041245393,0.0001335756,0.00012825926,0.0000074842915,0.000056745914,0.00050604116,2.9329573e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006726377,0.0008933693,0.9461948,0.00000697318,0.0011371055,0.000006509452,0.000024652185,0.000017090246,0.00021248544,0.00008610809,0.0011345504,0.04355995],"study_design_scores_gemma":[0.036240116,0.0040600556,0.9380449,0.000027149159,0.00035646808,0.0000024870335,0.00033740597,0.000021549462,0.000049015645,0.00030006346,0.020483129,0.00007766616],"about_ca_topic_score_codex":0.000019080344,"about_ca_topic_score_gemma":0.000080055645,"teacher_disagreement_score":0.043482285,"about_ca_system_score_codex":0.000017032427,"about_ca_system_score_gemma":0.0005191548,"threshold_uncertainty_score":0.9980888},"labels":[],"label_agreement":null},{"id":"W4410811898","doi":"10.1200/jco.2025.43.16_suppl.e17611","title":"High grade serous ovarian cancer differentiation and invasion post chemotherapy: Role of NRF2.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Serous ovarian cancer; Medicine; Ovarian cancer; Chemotherapy; Serous fluid; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.027357229742034802,"score_gpt":0.36933847712588447,"score_spread":0.34198124738384966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948032,0.00153586,0.0003659839,0.0024389313,0.00051713956,0.00008438908,0.000013956924,0.0000014872396,0.00023908207],"genre_scores_gemma":[0.99387604,0.0029762944,0.0013459136,0.0011801204,0.0004811267,0.0000023343182,0.000013063402,0.000008035854,0.00011708663],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985177,0.00016956883,0.0009354541,0.00017255364,0.00008721795,0.00011750838],"domain_scores_gemma":[0.9984624,0.00014680428,0.00086591335,0.0001349057,0.00030153312,0.00008843737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004962324,0.00010153702,0.00055093993,0.00005104037,0.000026833044,0.000006416363,0.00016291653,0.00033458302,0.000020568807],"category_scores_gemma":[0.0005093064,0.000081704326,0.00016923304,0.000047873807,0.00014304751,0.0000054483053,0.000079412916,0.00023444643,3.5802947e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014259258,0.00052088767,0.050502073,0.000029752606,0.00034798917,0.000003638604,0.00005582942,0.000015758658,0.8744141,0.0002868001,0.00085375545,0.071543485],"study_design_scores_gemma":[0.0054837936,0.002480239,0.4813071,0.00007359636,0.00015868872,0.00001971383,0.00014643105,0.00002880031,0.4788439,0.0041202516,0.027193423,0.00014408828],"about_ca_topic_score_codex":0.00006380896,"about_ca_topic_score_gemma":0.000096131735,"teacher_disagreement_score":0.430805,"about_ca_system_score_codex":0.00002211863,"about_ca_system_score_gemma":0.00038110712,"threshold_uncertainty_score":0.33318058},"labels":[],"label_agreement":null},{"id":"W4410812091","doi":"10.1200/jco.2025.43.16_suppl.e18578","title":"Efficacy and safety of azacitidine in the treatment of elderly patients with higher-risk myelodysplastic syndromes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Barrie Urology Group; McMaster University","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Oncology; Internal medicine; Intensive care medicine; Bone marrow","score_opus":0.05468031437085299,"score_gpt":0.4206413806788454,"score_spread":0.3659610663079924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943088,0.00041820735,0.00005079124,0.0034140553,0.00019213048,0.0004272607,0.000008657428,0.0000018755106,0.0011782172],"genre_scores_gemma":[0.9960923,0.0025325406,0.00089520775,0.00018497305,0.00009624785,0.0000036268787,0.0000027742537,0.0000075879,0.00018473374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968185,0.00060919084,0.0018623846,0.00014510234,0.00038225861,0.00018257015],"domain_scores_gemma":[0.98999226,0.008191631,0.0010810421,0.00021736408,0.0003890704,0.00012864004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017492077,0.0001212484,0.0014359931,0.00022346337,0.000023457076,0.0000028629925,0.00015954953,0.0002198903,0.000042573956],"category_scores_gemma":[0.0019285867,0.00005893212,0.00016705612,0.0003226789,0.0004313956,0.000041534746,0.000027973167,0.00064487586,0.0000012404238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033199232,0.0073283482,0.695928,0.00009166624,0.00092257326,0.000359813,0.00027179913,0.000027856198,0.000027959959,0.00017806015,0.0006714263,0.26099327],"study_design_scores_gemma":[0.03728669,0.063184045,0.8855175,0.00023783052,0.00051785226,0.000044681165,0.00007272511,0.00002324026,0.000025764624,0.00008734926,0.01296385,0.000038486098],"about_ca_topic_score_codex":0.000045520515,"about_ca_topic_score_gemma":0.000031032603,"teacher_disagreement_score":0.2609548,"about_ca_system_score_codex":0.00023881154,"about_ca_system_score_gemma":0.0013447796,"threshold_uncertainty_score":0.28017005},"labels":[],"label_agreement":null},{"id":"W4410812202","doi":"10.1200/jco.2025.43.16_suppl.11109","title":"Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Follicular lymphoma; Oncology; Lymphoma; Internal medicine","score_opus":0.052886751790550156,"score_gpt":0.43958523803503885,"score_spread":0.3866984862444887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452436,0.0016899914,0.0000040485834,0.001291852,0.0004252204,0.00054022885,0.000012034626,0.0000036747178,0.0015085834],"genre_scores_gemma":[0.9985004,0.00088597345,0.0002674227,0.00016321335,0.00009993106,0.00002201055,0.0000035466128,0.0000043379005,0.00005317616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975462,0.0003231725,0.001453624,0.00023017678,0.0002763099,0.00017050405],"domain_scores_gemma":[0.99779516,0.0008777856,0.000809047,0.00017586682,0.00019917017,0.0001429683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031845263,0.00016772824,0.0014868726,0.0000854661,0.000027062728,0.000007225931,0.000095264266,0.00015758841,0.000012069007],"category_scores_gemma":[0.0004142297,0.00010551192,0.00032554968,0.00016283481,0.00013378552,0.00006347584,0.00006118537,0.000082959305,9.766762e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016905755,0.018634893,0.7786749,0.000014516788,0.00086108665,0.0002366786,0.00056123425,0.0000038211733,0.00000369145,0.00008682387,0.00024790826,0.19898383],"study_design_scores_gemma":[0.03511358,0.030019954,0.9248652,0.00015482705,0.000803662,0.000008114773,0.0024131467,0.00001198401,0.000101975114,0.00009101863,0.006351608,0.00006495518],"about_ca_topic_score_codex":0.00078169286,"about_ca_topic_score_gemma":0.0005642479,"teacher_disagreement_score":0.19891888,"about_ca_system_score_codex":0.0008071043,"about_ca_system_score_gemma":0.0008769664,"threshold_uncertainty_score":0.43026513},"labels":[],"label_agreement":null},{"id":"W4410812206","doi":"10.1200/jco.2025.43.16_suppl.5541","title":"Evolving global burden and trend of cervical cancer in G20 countries: Age, sex, regional disparities from 1990-2021.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cervical cancer; Cancer; Demography; Internal medicine","score_opus":0.13535059328932475,"score_gpt":0.4858377414696965,"score_spread":0.35048714818037174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598668,0.010217646,0.000085119456,0.024353288,0.00078717154,0.000091889924,0.00004280415,0.0000041229955,0.0045511215],"genre_scores_gemma":[0.99086297,0.0031104002,0.0010687563,0.0034309546,0.0012902519,0.0000026919374,0.0000035454084,0.000004664558,0.00022577505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970749,0.00021959702,0.001876709,0.00020101016,0.000408442,0.00021932654],"domain_scores_gemma":[0.99645936,0.0022457833,0.0007389637,0.00012708499,0.0002215546,0.00020724538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013146953,0.00012562801,0.0014462821,0.00009695168,0.000029600473,0.0000136453955,0.00016741532,0.00036871448,0.00024697205],"category_scores_gemma":[0.0017263151,0.000098154014,0.00023044081,0.00022234613,0.0004113623,0.0001292039,0.000091536334,0.0006840212,0.0000010189689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032109811,0.00012903889,0.94076884,0.000057709713,0.00023619326,0.00062271825,0.00014364766,0.000038746854,0.0000156062,0.0008398907,0.008893424,0.04504322],"study_design_scores_gemma":[0.0049142353,0.0013372215,0.933093,0.0010006172,0.00029094363,0.000061326646,0.0006511847,0.00024587466,0.000007204136,0.0034705806,0.054849982,0.00007780011],"about_ca_topic_score_codex":0.005414638,"about_ca_topic_score_gemma":0.0076014595,"teacher_disagreement_score":0.04595656,"about_ca_system_score_codex":0.00032709457,"about_ca_system_score_gemma":0.0017922547,"threshold_uncertainty_score":0.8185349},"labels":[],"label_agreement":null},{"id":"W4410812294","doi":"10.1200/jco.2025.43.16_suppl.505","title":"15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Exemestane; Tamoxifen; Breast cancer; Oncology; Internal medicine; Adjuvant; Gynecology; Hormone receptor; Estrogen receptor; Cancer","score_opus":0.04243620349608154,"score_gpt":0.3947413364333427,"score_spread":0.3523051329372612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99345124,0.0015767551,0.0005998224,0.0029762746,0.0006596448,0.0005122337,0.00006291245,0.000004140328,0.0001569542],"genre_scores_gemma":[0.9959604,0.0013677261,0.001024785,0.0007244783,0.00061038457,0.000049506965,0.000023258011,0.000018931887,0.00022049336],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99679357,0.0010766921,0.0013324486,0.00030893445,0.00020372115,0.00028464996],"domain_scores_gemma":[0.9963428,0.0020168552,0.0010800773,0.00016951142,0.00025054437,0.00014020871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037893753,0.00020289609,0.0010892489,0.00007506756,0.000101280675,0.00005541652,0.00020490611,0.00060128234,0.000027030868],"category_scores_gemma":[0.0012396176,0.000102646765,0.00014864952,0.00012148668,0.00014110065,0.000032437987,0.000071832714,0.00057160394,8.9538867e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15553045,0.002065291,0.15462247,0.000059788246,0.0035414544,0.00011239479,0.0007157619,0.00016236817,0.13876891,0.00013063867,0.007895289,0.5363952],"study_design_scores_gemma":[0.013662305,0.01388865,0.96333927,0.00022791608,0.00048820622,0.000035793324,0.00053272716,0.000030007468,0.001420163,0.00022681018,0.005963279,0.00018485062],"about_ca_topic_score_codex":0.00009553794,"about_ca_topic_score_gemma":0.0000983245,"teacher_disagreement_score":0.80871683,"about_ca_system_score_codex":0.000073411335,"about_ca_system_score_gemma":0.0008436565,"threshold_uncertainty_score":0.463764},"labels":[],"label_agreement":null},{"id":"W4410812321","doi":"10.1200/jco.2025.43.16_suppl.5035","title":"Predicting teratoma histology in postchemotherapy residual lesions of non-seminoma testicular cancer (NSTC) patients using integrated CT radiomics and circulating MicroRNAs modelling.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Seminoma; Medicine; Testicular cancer; Radiomics; Histology; Mature teratoma; Teratoma; Pathology; Cancer; Radiology; Oncology; Internal medicine; Chemotherapy","score_opus":0.07592566729025683,"score_gpt":0.4363338089910599,"score_spread":0.36040814170080304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429584,0.0033256758,0.001213731,0.0004405425,0.00041222686,0.0002496571,0.0000119352935,0.0000054990132,0.000044886194],"genre_scores_gemma":[0.9829943,0.00037514712,0.016112803,0.00037957096,0.00010297289,0.0000024383548,0.000005742557,0.00001582199,0.000011176417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972235,0.0002107186,0.0019759985,0.00022151094,0.00016193515,0.00020633647],"domain_scores_gemma":[0.9967071,0.0011351705,0.0013783008,0.00013938305,0.00045509977,0.00018495401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062531215,0.00016017882,0.00124513,0.00026275052,0.000046932273,0.0000062047097,0.000086981076,0.00021774665,0.000008580872],"category_scores_gemma":[0.0017676016,0.00012436335,0.0002140023,0.00023243735,0.00018805765,0.00006052008,0.00004148453,0.00053847674,1.7041852e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010911414,0.0015058718,0.94654775,0.00007123249,0.0004326722,0.00055030605,0.000091364614,0.0014377035,0.0012291624,0.000007237387,0.000033274562,0.047002267],"study_design_scores_gemma":[0.014205322,0.0023722483,0.90565217,0.0013871901,0.0009914029,0.00033058977,0.00011448629,0.07420989,0.00034604047,0.00015063465,0.00013341686,0.000106604304],"about_ca_topic_score_codex":0.00048691905,"about_ca_topic_score_gemma":0.00004455749,"teacher_disagreement_score":0.07277219,"about_ca_system_score_codex":0.00033703985,"about_ca_system_score_gemma":0.0019935218,"threshold_uncertainty_score":0.50713897},"labels":[],"label_agreement":null},{"id":"W4410812490","doi":"10.1200/jco.2025.43.16_suppl.e17540","title":"The socioeconomic burden of ovarian cancer in 11 countries.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ovarian Cancer Canada","funders":"ImmunoGen; Novocure","keywords":"Medicine; Socioeconomic status; Ovarian cancer; Cancer; Oncology; Gynecology; Demography; Internal medicine; Environmental health; Population","score_opus":0.027971550925343546,"score_gpt":0.41508436775993557,"score_spread":0.38711281683459203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799131,0.006684835,0.00008717991,0.010555138,0.0013564007,0.00008155459,0.0000142781055,8.2045966e-7,0.001306661],"genre_scores_gemma":[0.9848518,0.0123996325,0.00015578725,0.0011920119,0.000913436,0.0000040063346,0.0000018795831,0.0000049237196,0.0004765724],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982673,0.000215756,0.0012098806,0.000110779714,0.000067146495,0.00012914579],"domain_scores_gemma":[0.9985434,0.00033919644,0.00064866745,0.00015124887,0.0002383175,0.00007918035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014240269,0.000065528366,0.00038948195,0.00003896403,0.000035791312,0.0000069781995,0.00024546692,0.00025057848,0.00004438558],"category_scores_gemma":[0.0006798581,0.000047945392,0.00022441005,0.00003269032,0.00028221498,0.0000027014617,0.000055283428,0.0001745689,0.0000016052056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009897136,0.0014972944,0.730662,0.00012943229,0.0010098758,0.00005693281,0.00018415738,0.0012772288,0.010566335,0.004349771,0.11069163,0.1296782],"study_design_scores_gemma":[0.0058390596,0.0011449179,0.17310874,0.00004322126,0.000106987216,0.000005809225,0.0002673021,0.00004802943,0.0021125397,0.0037588333,0.8134735,0.00009106302],"about_ca_topic_score_codex":0.00006985199,"about_ca_topic_score_gemma":0.00061001553,"teacher_disagreement_score":0.70278186,"about_ca_system_score_codex":0.000039958722,"about_ca_system_score_gemma":0.0020366267,"threshold_uncertainty_score":0.36128885},"labels":[],"label_agreement":null},{"id":"W4410812540","doi":"10.1200/jco.2025.43.16_suppl.tps9047","title":"Evaluating the use of educational videos in a medical oncology sarcoma clinic to improve patient knowledge and satisfaction.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Education and Validation","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcoma; Oncology; Family medicine; Internal medicine; Medical physics; Pathology","score_opus":0.4488943274034308,"score_gpt":0.661956603631434,"score_spread":0.21306227622800322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8085346,0.00019044922,0.00006155498,0.18427245,0.0039996277,0.0003324453,0.0000012005462,0.0000019390714,0.0026056946],"genre_scores_gemma":[0.985378,0.0006169936,0.003441485,0.009186874,0.00077424524,0.000024654397,5.9999377e-7,0.000003899226,0.000573245],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99222666,0.0043530194,0.002664901,0.00015559456,0.00041138954,0.00018845592],"domain_scores_gemma":[0.9623335,0.035110205,0.0013521456,0.00011443609,0.00074867177,0.00034104154],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016434934,0.00006475074,0.00055622985,0.00019798453,0.0001478707,0.000015250358,0.00018162171,0.00036612398,0.00075151847],"category_scores_gemma":[0.09145933,0.000046215388,0.000113811555,0.00039068275,0.00034752957,0.00014681643,0.00006547631,0.00071547774,0.00001971594],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003231226,0.00078353926,0.11397583,0.000012692636,0.000027483868,0.0000011314861,0.0047753435,0.000007648035,0.000011004192,0.0035190638,0.009732168,0.86683095],"study_design_scores_gemma":[0.0011739299,0.0028351583,0.5617949,0.00008968438,0.000032329444,0.0000042667443,0.0017699691,0.00018812623,0.0000022703373,0.0017202265,0.43034562,0.000043553093],"about_ca_topic_score_codex":0.0010403283,"about_ca_topic_score_gemma":0.006836312,"teacher_disagreement_score":0.86678743,"about_ca_system_score_codex":0.00041414073,"about_ca_system_score_gemma":0.022084605,"threshold_uncertainty_score":0.9834593},"labels":[],"label_agreement":null},{"id":"W4410812629","doi":"10.1200/jco.2025.43.16_suppl.5563","title":"Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Chemotherapy; Monoclonal antibody; Antibody; Cancer research; Oncology; Internal medicine; Cancer; Immunology; Immunotherapy","score_opus":0.04754943468315769,"score_gpt":0.39742471670995433,"score_spread":0.34987528202679663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941898,0.002099704,0.0008293088,0.0011578819,0.00094871834,0.0002986366,0.000031786003,0.000009209346,0.00043495419],"genre_scores_gemma":[0.9931539,0.0024826683,0.0022076287,0.0011422597,0.00082080025,0.000022084303,0.00001684026,0.00004826628,0.000105507715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645215,0.00025333877,0.0018532025,0.00053321937,0.00028738836,0.0006206737],"domain_scores_gemma":[0.997478,0.00032260385,0.001142485,0.00038093774,0.00040602707,0.00026993683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011315846,0.0003565575,0.001368519,0.0001490383,0.00009542621,0.000039484275,0.00040901257,0.00041198236,0.000027107624],"category_scores_gemma":[0.00034820286,0.00027566354,0.00030470314,0.00032291727,0.0002465519,0.000021460311,0.0000638276,0.00073290657,0.000001414186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012997572,0.0013934342,0.7633374,0.00005958543,0.001085434,0.00087923644,0.0001293754,0.003713971,0.18502139,0.000028364655,0.00034461255,0.031009685],"study_design_scores_gemma":[0.03163812,0.007133119,0.89740723,0.0006864293,0.00050381134,0.00035044554,0.00026336152,0.00076133455,0.040309783,0.00006926535,0.020281032,0.00059608486],"about_ca_topic_score_codex":0.0004209549,"about_ca_topic_score_gemma":0.0005225832,"teacher_disagreement_score":0.1447116,"about_ca_system_score_codex":0.00022136226,"about_ca_system_score_gemma":0.0028053382,"threshold_uncertainty_score":0.99996954},"labels":[],"label_agreement":null},{"id":"W4410812638","doi":"10.1200/jco.2025.43.16_suppl.e15024","title":"Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Antibody-drug conjugate; Pharmacology; Drug; Conjugate; Antibody; Monoclonal antibody; Immunology","score_opus":0.11965148810061271,"score_gpt":0.5611931399788107,"score_spread":0.441541651878198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921567,0.0046482454,0.000020598463,0.0016877885,0.000616184,0.0006611607,0.000013084782,0.000005347833,0.00019093452],"genre_scores_gemma":[0.98689467,0.011992219,0.0003428769,0.00058442913,0.0001299805,0.0000023853631,0.0000021957103,0.000016267933,0.000034972833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553126,0.0009072525,0.0024626527,0.00023938275,0.000544765,0.0003146858],"domain_scores_gemma":[0.9896566,0.0070934338,0.0018599605,0.00012611567,0.0010624294,0.00020145997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005129643,0.00021518933,0.0021522604,0.0006364793,0.00005424749,0.0000073140577,0.00022436566,0.00012030351,0.000029942152],"category_scores_gemma":[0.0025557494,0.00012156591,0.00014451623,0.0009843083,0.0010975152,0.000093560746,0.00020222664,0.0014828877,1.9034101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072945934,0.0016162118,0.94909996,0.00069184485,0.0012370801,0.00013659301,0.0004883011,0.00010287708,0.0047221715,0.0000070679193,0.0005507722,0.034052514],"study_design_scores_gemma":[0.035786737,0.008293837,0.94286805,0.0006979719,0.0013032824,0.000039984225,0.0010314267,0.0012063541,0.0076032067,0.000050834173,0.0009774204,0.00014088846],"about_ca_topic_score_codex":0.000024624693,"about_ca_topic_score_gemma":0.000009421279,"teacher_disagreement_score":0.033911623,"about_ca_system_score_codex":0.00014676509,"about_ca_system_score_gemma":0.00086396426,"threshold_uncertainty_score":0.64424914},"labels":[],"label_agreement":null},{"id":"W4410812782","doi":"10.1200/jco.2025.43.16_suppl.5048","title":"Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Cancer; Oncology; Internal medicine; Prospective cohort study; Prostate","score_opus":0.09264886655805368,"score_gpt":0.4995175675732317,"score_spread":0.406868701015178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838864,0.0009494702,0.00008409313,0.012045002,0.00048878975,0.0009039438,0.000105427265,0.000006531398,0.001530326],"genre_scores_gemma":[0.9976954,0.0004786122,0.0004420818,0.00065513735,0.00034142687,0.000042115247,0.0000073274446,0.000007673659,0.0003302116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649864,0.00039946326,0.0022877906,0.00025238827,0.000342586,0.00021913547],"domain_scores_gemma":[0.9961374,0.0020296907,0.000992611,0.0002513538,0.0003893003,0.00019965979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019245453,0.00015473156,0.0011669251,0.00003220816,0.00006634047,0.0000118895205,0.00025897633,0.00015378637,0.00015173301],"category_scores_gemma":[0.0017716375,0.000098098266,0.00030798608,0.00042597105,0.00029277778,0.00007180353,0.000052772502,0.00093575084,0.0000039794695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01312062,0.0052005337,0.9663513,0.000057108977,0.0011056828,0.00028893142,0.0002088671,0.000033014116,0.0012943614,0.00045330223,0.0008073042,0.011079006],"study_design_scores_gemma":[0.021951938,0.0014593337,0.97114134,0.0001913076,0.0010975689,0.000021525322,0.00045550178,0.00003168576,0.000636347,0.0008185256,0.0021169449,0.00007796613],"about_ca_topic_score_codex":0.00019580091,"about_ca_topic_score_gemma":0.0011508969,"teacher_disagreement_score":0.013808997,"about_ca_system_score_codex":0.00038829804,"about_ca_system_score_gemma":0.0021152657,"threshold_uncertainty_score":0.4065424},"labels":[],"label_agreement":null},{"id":"W4410812800","doi":"10.1200/jco.2025.43.16_suppl.e12572","title":"Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto; Public Health Ontario","funders":"","keywords":"Medicine; Immigration; Breast cancer; Mammography; Cancer; Breast cancer screening; Gynecology; Family medicine; Demography; Gerontology; Oncology; Internal medicine","score_opus":0.10080836656673883,"score_gpt":0.4517325421047266,"score_spread":0.3509241755379877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911804,0.0013379268,0.000028897657,0.008604717,0.00024127302,0.00018508559,0.0000036092908,0.000004507484,0.00047592146],"genre_scores_gemma":[0.9934561,0.0011452446,0.0005925595,0.004051122,0.0001813381,0.000014080571,6.3958225e-7,0.0000071722784,0.00055171695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977342,0.00016586449,0.0013535134,0.00023252484,0.0002657338,0.00024817095],"domain_scores_gemma":[0.9980613,0.00076324795,0.00046434542,0.00011124235,0.00021086434,0.00038897822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018867897,0.00012716535,0.001068011,0.0003356418,0.000042875894,0.000021390251,0.000120337696,0.0002643375,0.00026240604],"category_scores_gemma":[0.0007067735,0.0001012241,0.00016151901,0.00027405337,0.00017330714,0.0001734137,0.00011080513,0.0008729483,0.0000031596799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025412957,0.00012715452,0.8709786,0.000019470956,0.00014877025,0.00072524726,0.00006906445,0.0000046071036,0.000013729382,0.0000031636152,0.001927412,0.1234415],"study_design_scores_gemma":[0.0041257325,0.0014094441,0.9910248,0.0018906143,0.0002561944,0.00023387726,0.0000423284,0.00001322392,0.000006245667,0.00005805961,0.00085790793,0.0000815635],"about_ca_topic_score_codex":0.033322033,"about_ca_topic_score_gemma":0.22490396,"teacher_disagreement_score":0.19158192,"about_ca_system_score_codex":0.00017185815,"about_ca_system_score_gemma":0.00078140455,"threshold_uncertainty_score":0.97311515},"labels":[],"label_agreement":null},{"id":"W4410812803","doi":"10.1200/jco.2025.43.16_suppl.tps7568","title":"MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Lenalidomide; Oncology; Internal medicine; Metallurgy","score_opus":0.0720768217424995,"score_gpt":0.4572068126716047,"score_spread":0.38512999092910516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951718,0.00054934266,0.000016267375,0.00080805965,0.00031490743,0.002915748,0.000015028748,0.000016530248,0.00019235194],"genre_scores_gemma":[0.99512804,0.0016379637,0.0021676326,0.00035433503,0.00009524703,0.000045921417,0.00001013257,0.000026347887,0.00053436804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930637,0.002302309,0.0031644222,0.00038782833,0.00069749705,0.00038426247],"domain_scores_gemma":[0.9863914,0.010350618,0.001664605,0.00036143247,0.0008154477,0.00041646542],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003527222,0.0002858185,0.0038071852,0.00057462294,0.00006455153,0.000013776824,0.00021633106,0.00036167816,0.00025835808],"category_scores_gemma":[0.015760262,0.0001443641,0.00028497647,0.000522118,0.00036677133,0.00015537863,0.00008395717,0.0011046454,0.0000028299862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5238009,0.023315234,0.27850464,0.00004280126,0.0011966748,0.0012717522,0.0001962976,7.8641665e-7,0.000039351136,7.1206193e-7,0.00018840378,0.17144242],"study_design_scores_gemma":[0.47916746,0.06289148,0.4558275,0.00020340252,0.00030844653,0.000021304617,0.00015263881,0.00015114757,0.000030491663,0.0000062466543,0.0011691046,0.00007074632],"about_ca_topic_score_codex":0.00014898131,"about_ca_topic_score_gemma":0.00059029774,"teacher_disagreement_score":0.17732286,"about_ca_system_score_codex":0.00015145654,"about_ca_system_score_gemma":0.0021219759,"threshold_uncertainty_score":0.9925304},"labels":[],"label_agreement":null},{"id":"W4410812807","doi":"10.1200/jco.2025.43.16_suppl.tps12141","title":"A randomized phase III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for participants with painful non-spine bone metastases (NCT06391242).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of Toronto; Health Sciences Centre; Ottawa Hospital; University Health Network; Centre Hospitalier de l’Université de Montréal; Université Laval; University of British Columbia; University of Ottawa; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; London Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Radiosurgery; Radiology; Stereotactic radiotherapy; Randomized controlled trial; Surgery","score_opus":0.18289499880305873,"score_gpt":0.5238997755186191,"score_spread":0.3410047767155604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8719011,0.0019939635,0.1136143,0.0053746616,0.0016710497,0.004926752,0.000015199999,0.000028849401,0.00047411534],"genre_scores_gemma":[0.97535896,0.00062749523,0.01946906,0.0028985855,0.00055021467,0.00025701933,0.00002394746,0.000042683576,0.0007720113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919259,0.0020127662,0.0043091364,0.00045642196,0.00077752245,0.00051825296],"domain_scores_gemma":[0.9853037,0.009365107,0.0035128186,0.0004192995,0.00082346465,0.00057562493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01249339,0.00039211588,0.0054090302,0.0004199597,0.0001177252,0.000046407422,0.000269921,0.00014558017,0.00038735566],"category_scores_gemma":[0.005361298,0.00026286466,0.0011826964,0.000347834,0.00048108195,0.00019457625,0.000046604397,0.0006930349,0.0000030102713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9226295,0.024583157,0.012745373,0.00020518155,0.024836898,0.00096539775,0.00033927834,0.00006261728,0.00007210449,0.00040188944,0.004141787,0.009016828],"study_design_scores_gemma":[0.90814376,0.037984684,0.020440394,0.00027686142,0.010504122,0.000020227533,0.000918638,0.008817265,0.00002046936,0.00013497252,0.0125091765,0.00022941203],"about_ca_topic_score_codex":0.000017108734,"about_ca_topic_score_gemma":0.000029895353,"teacher_disagreement_score":0.103457876,"about_ca_system_score_codex":0.0003565851,"about_ca_system_score_gemma":0.0018785553,"threshold_uncertainty_score":0.99998236},"labels":[],"label_agreement":null},{"id":"W4410812818","doi":"10.1200/jco.2025.43.16_suppl.tps7567","title":"Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Daratumumab; Multiple myeloma; Internal medicine; Oncology; Phases of clinical research; Toxicity","score_opus":0.11298973716068444,"score_gpt":0.4503265996954301,"score_spread":0.33733686253474565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858464,0.0026183247,0.0022518106,0.0034897686,0.00047279597,0.0022242314,0.000042156138,0.000017437946,0.0002988491],"genre_scores_gemma":[0.9889196,0.0029232416,0.006663598,0.0006165545,0.00024978144,0.000055999335,0.000009575396,0.000042374344,0.00051927735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907565,0.0032515954,0.003721471,0.0006514469,0.0008713685,0.0007476342],"domain_scores_gemma":[0.97829294,0.018334515,0.0015914699,0.00056421146,0.0005077753,0.00070910994],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071733035,0.0004911536,0.0035902807,0.00065017043,0.00016872498,0.00004387109,0.0004980301,0.0005957781,0.00010132254],"category_scores_gemma":[0.011569635,0.00031856738,0.00047036304,0.0007113614,0.0007902058,0.00021336829,0.00023637855,0.0019360378,0.000005861351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2270916,0.010361214,0.62770784,0.00032010177,0.0027315908,0.0061713434,0.001288418,0.00033686176,0.0027888026,0.000030313295,0.0017408615,0.11943105],"study_design_scores_gemma":[0.36018503,0.021503843,0.6002108,0.0012859748,0.001967942,0.0009971443,0.0011511437,0.0070388853,0.0032546583,0.00025636298,0.0017716319,0.00037657432],"about_ca_topic_score_codex":0.001085155,"about_ca_topic_score_gemma":0.0020709166,"teacher_disagreement_score":0.13309343,"about_ca_system_score_codex":0.00043515355,"about_ca_system_score_gemma":0.0031963459,"threshold_uncertainty_score":0.9999266},"labels":[],"label_agreement":null},{"id":"W4410812834","doi":"10.1200/jco.2025.43.16_suppl.11121","title":"Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Homologous recombination; Oncology; Internal medicine; PARP inhibitor; Gene; Cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics; Pathology; Biology; Polymerase","score_opus":0.1057754304687696,"score_gpt":0.4559922376212079,"score_spread":0.3502168071524383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884341,0.00031447763,0.000063182284,0.00802631,0.0002824205,0.0022954822,0.00001619599,0.000018635144,0.0005492158],"genre_scores_gemma":[0.99530953,0.00033505735,0.0023168344,0.0011260989,0.00009203129,0.0005725137,0.000013805576,0.00001995244,0.00021416992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946671,0.0013632765,0.0027451478,0.00040778177,0.00051458227,0.00030212317],"domain_scores_gemma":[0.99522585,0.0021508196,0.0017627749,0.0002808137,0.00045016574,0.0001295862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030019418,0.0002802972,0.0013811933,0.00038829487,0.00012970109,0.000042496224,0.00010427401,0.00014496897,0.000034488872],"category_scores_gemma":[0.00079171633,0.0001619801,0.00015145776,0.0005015158,0.00025689165,0.0002493762,0.000024438761,0.00077077514,5.6734143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04097622,0.007966248,0.90614706,0.000060019906,0.0015739038,0.004783975,0.0058383425,0.0009162847,0.0004830338,0.000072175986,0.00032434595,0.030858373],"study_design_scores_gemma":[0.05556567,0.0463106,0.8897462,0.00046571856,0.0009539864,0.0008720683,0.003914055,0.0004371851,0.0004369676,0.0003501777,0.0007325893,0.00021481645],"about_ca_topic_score_codex":0.00051796,"about_ca_topic_score_gemma":0.008359156,"teacher_disagreement_score":0.038344353,"about_ca_system_score_codex":0.0008645222,"about_ca_system_score_gemma":0.0030769797,"threshold_uncertainty_score":0.6605357},"labels":[],"label_agreement":null},{"id":"W4410812837","doi":"10.1200/jco.2025.43.16_suppl.9036","title":"The value of observerships abroad: Lessons from UA-MED supporting Ukrainian cancer care during the war.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Value (mathematics); Ukrainian; Cancer; Family medicine; Oncology; Internal medicine","score_opus":0.09936946699222855,"score_gpt":0.5680455736620311,"score_spread":0.4686761066698026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88719404,0.012615162,0.00009836587,0.0921864,0.0053790235,0.00022004294,0.000011204423,0.00000913932,0.0022866135],"genre_scores_gemma":[0.9786767,0.011119945,0.0018744888,0.00448966,0.0025496616,0.000009065012,0.0000016237482,0.000014940819,0.0012639259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611473,0.00082594965,0.0022980277,0.00018432904,0.00027698564,0.0002999487],"domain_scores_gemma":[0.985693,0.011078601,0.0022921,0.0003468213,0.0004423584,0.00014714165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003068247,0.00013932213,0.0012141974,0.000056451074,0.00027574666,0.0000051451116,0.000488128,0.00045838676,0.00014039686],"category_scores_gemma":[0.0057977834,0.0000684112,0.0005647048,0.00017978976,0.00084356876,0.0000652911,0.00007642306,0.0017219449,0.0000018639709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011464527,0.00079935463,0.5213277,0.00015361042,0.0031627868,0.0005829593,0.007819045,0.0004548978,0.0012262927,0.0014306925,0.006450341,0.44512784],"study_design_scores_gemma":[0.0061532417,0.001589412,0.5264513,0.00028931405,0.0005191901,0.00005688352,0.004406603,0.00006778114,0.00039679473,0.0011163575,0.4588764,0.00007675181],"about_ca_topic_score_codex":0.00007763372,"about_ca_topic_score_gemma":0.0005015367,"teacher_disagreement_score":0.45242608,"about_ca_system_score_codex":0.00032085815,"about_ca_system_score_gemma":0.0028104098,"threshold_uncertainty_score":0.7481089},"labels":[],"label_agreement":null},{"id":"W4410812928","doi":"10.1200/jco.2025.43.16_suppl.5503","title":"Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council","keywords":"Medicine; Cervical cancer; Cancer; Oncology; Surgery; Internal medicine","score_opus":0.09301320035008535,"score_gpt":0.4689902677863553,"score_spread":0.3759770674362699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550433,0.0034396697,0.00004513205,0.030975375,0.005344888,0.00079971534,0.000006680337,0.000012738285,0.004332477],"genre_scores_gemma":[0.9786069,0.0012440457,0.00056865945,0.0181526,0.0008345774,0.000047757916,0.000004934692,0.000014560381,0.00052598515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99427265,0.0006332908,0.0039522587,0.00031556297,0.0005510177,0.00027520861],"domain_scores_gemma":[0.9902741,0.006893775,0.0017096604,0.00034659173,0.00047250793,0.00030337615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010122358,0.00021877365,0.0022865417,0.00016414002,0.000049200866,0.000014059742,0.00026437626,0.0004770665,0.0004116852],"category_scores_gemma":[0.00819826,0.000109786124,0.00075012963,0.00062198524,0.00017751512,0.00010586301,0.000112012756,0.001342125,0.000015578706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16226622,0.004296072,0.38783365,0.000017453343,0.0014279725,0.00075626996,0.00012348671,0.000028437496,0.0000396902,0.00015557004,0.002011423,0.44104373],"study_design_scores_gemma":[0.19744183,0.007985062,0.71631175,0.00026663777,0.0007193689,0.000008542379,0.00017088675,0.000019453384,0.00006687048,0.0025669646,0.07433858,0.000104067054],"about_ca_topic_score_codex":0.00055501144,"about_ca_topic_score_gemma":0.001450939,"teacher_disagreement_score":0.44093966,"about_ca_system_score_codex":0.00040814476,"about_ca_system_score_gemma":0.0025324486,"threshold_uncertainty_score":0.9814676},"labels":[],"label_agreement":null},{"id":"W4410812941","doi":"10.1200/jco.2025.43.16_suppl.3044","title":"Impact of stereotactic ablative radiotherapy (SABR) on detection of ctDNA in patients with early-stage lung cancer: Interim findings from the prospective SABR-DETECT trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"SABR volatility model; Medicine; Ablative case; Radiation therapy; Interim analysis; Stage (stratigraphy); Interim; Lung cancer; Radiology; Nuclear medicine; Oncology; Surgery; Randomized controlled trial","score_opus":0.04029952567926402,"score_gpt":0.4606618013673675,"score_spread":0.42036227568810347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970741,0.00036044867,0.000048556092,0.0006274034,0.00065838,0.0010399603,0.00002505031,0.0000030186036,0.0001630728],"genre_scores_gemma":[0.998824,0.0006239266,0.00009834697,0.00020719608,0.00016447721,0.000029343315,9.836476e-7,0.000012707504,0.000038992555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974996,0.00040556272,0.0014645074,0.00019401894,0.00028786715,0.00014844768],"domain_scores_gemma":[0.99469936,0.0029868756,0.0016971364,0.00019427459,0.0003410693,0.00008125993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085023127,0.0001558422,0.0013877811,0.00015376591,0.00002427835,0.0000064898873,0.00011795035,0.00018417137,0.000094895],"category_scores_gemma":[0.00077534316,0.00007851866,0.00042966084,0.0002573261,0.00015469937,0.00008713129,0.000019297315,0.0006714963,3.1075496e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18449384,0.0024418298,0.7897215,0.000017496195,0.0029049453,0.000014925243,0.0004796498,0.000032571857,0.000060526563,0.000004337469,0.00008597943,0.01974243],"study_design_scores_gemma":[0.0864968,0.0671781,0.8439488,0.0007257277,0.0005199092,8.4287217e-7,0.000043172025,0.000025061,0.00089282973,0.000033906275,0.00008493732,0.00004993236],"about_ca_topic_score_codex":0.0015086705,"about_ca_topic_score_gemma":0.00051384163,"teacher_disagreement_score":0.09799703,"about_ca_system_score_codex":0.0018641925,"about_ca_system_score_gemma":0.0011036757,"threshold_uncertainty_score":0.48747987},"labels":[],"label_agreement":null},{"id":"W4410812945","doi":"10.1200/jco.2025.43.16_suppl.e16353","title":"Racial and ethnic disparities in US neuroendocrine tumor clinical trial enrollment over the past quarter century","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ethnic group; Quarter (Canadian coin); Clinical trial; Demography; Gerontology; Internal medicine; History","score_opus":0.11467639620390971,"score_gpt":0.5216945820431427,"score_spread":0.407018185839233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9461291,0.0013683527,0.0000061984483,0.04652829,0.0041854694,0.0007210858,0.0000029817763,0.000009793999,0.0010487708],"genre_scores_gemma":[0.9791774,0.0049356367,0.00016759968,0.012269972,0.0030200086,0.000021256174,9.721842e-7,0.00001611077,0.0003910387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922745,0.002256502,0.004005445,0.0003518973,0.0005882141,0.00052342203],"domain_scores_gemma":[0.9882996,0.0096404115,0.0011143652,0.00032559966,0.00021045448,0.00040955874],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0036486697,0.00020681423,0.0018787351,0.00025315298,0.0000617216,0.000027896305,0.00033265346,0.000042606225,0.00009108868],"category_scores_gemma":[0.013205054,0.000121782716,0.0005977887,0.00029279053,0.00081048487,0.00015854347,0.0002534037,0.0033145733,0.0000071849317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2143275,0.0047152927,0.6504621,0.000094740666,0.0002955689,0.025746705,0.00002775351,0.0000060906746,0.000025951513,0.00043260783,0.023330385,0.08053533],"study_design_scores_gemma":[0.09061208,0.02068062,0.719783,0.00009029225,0.00017053974,0.0012422273,0.00009517186,0.000043435964,0.000007960798,0.00057313987,0.16662152,0.000080011516],"about_ca_topic_score_codex":0.000031841355,"about_ca_topic_score_gemma":0.00020847327,"teacher_disagreement_score":0.14329115,"about_ca_system_score_codex":0.00009607745,"about_ca_system_score_gemma":0.0012099067,"threshold_uncertainty_score":0.9989848},"labels":[],"label_agreement":null},{"id":"W4410812977","doi":"10.1200/jco.2025.43.16_suppl.5535","title":"Global cervical cancer outcomes and national cancer system characteristics.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Cervical cancer; Oncology; Internal medicine; Gynecology","score_opus":0.1505278774669117,"score_gpt":0.5701181386647972,"score_spread":0.4195902611978855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77898276,0.005176848,0.00027757318,0.109676346,0.0067693465,0.00040688866,0.00012575014,0.00003079775,0.098553695],"genre_scores_gemma":[0.9884657,0.0014549042,0.00022594554,0.0074058888,0.0016500388,0.000013218584,0.0000016144356,0.0000061368773,0.000776536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972108,0.00019720918,0.0016068561,0.00018194487,0.0005825958,0.00022060736],"domain_scores_gemma":[0.99641067,0.0011887108,0.0005115875,0.00009256827,0.0014029532,0.0003935234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018572789,0.000112096444,0.0013588385,0.000096249365,0.00004948272,0.000017035964,0.00014247905,0.00032551918,0.00093471666],"category_scores_gemma":[0.0023191525,0.00007435159,0.00030004905,0.00020970491,0.00021104651,0.000057147045,0.00010029855,0.00070223236,0.0000064012997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021600123,0.0003026346,0.7127633,0.00020389339,0.0004224644,0.000103636245,0.000007790089,0.0000015886317,0.000003015826,0.0028830082,0.006991881,0.2741568],"study_design_scores_gemma":[0.0048229294,0.0007832453,0.9157789,0.00010676075,0.00025789862,0.00006176672,0.000038037702,0.00022125468,0.000002444181,0.0003325325,0.07753979,0.00005444497],"about_ca_topic_score_codex":0.00022561163,"about_ca_topic_score_gemma":0.00032576633,"teacher_disagreement_score":0.27410236,"about_ca_system_score_codex":0.0008346441,"about_ca_system_score_gemma":0.005130935,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W4410813020","doi":"10.1200/jco.2025.43.16_suppl.5561","title":"Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Clinical trial; Poly ADP ribose polymerase; Cancer; Cancer research; Gynecology; Genetics; DNA; Biology; Polymerase","score_opus":0.10424352434215015,"score_gpt":0.5265013115800238,"score_spread":0.42225778723787366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700925,0.00033648207,0.00021076846,0.022893732,0.0009944728,0.0015812812,0.000020658112,0.000020386517,0.003849721],"genre_scores_gemma":[0.9570955,0.00073555746,0.037152685,0.002177546,0.0017312178,0.00019735517,0.0000051252105,0.000042177682,0.00086285704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99258554,0.0010394469,0.00478639,0.0005059573,0.00059998693,0.00048269704],"domain_scores_gemma":[0.9926836,0.0021377061,0.0031156633,0.0004396164,0.0010644302,0.00055897847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00546706,0.0003074545,0.0031060288,0.00044207228,0.00009035192,0.000022132414,0.00021967817,0.00044196993,0.0003875667],"category_scores_gemma":[0.0009199801,0.00020198856,0.0003234244,0.0005855383,0.00038264767,0.00015377857,0.00006315433,0.0010009407,0.0000017550916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8439324,0.013413033,0.022340944,0.0000776904,0.0018864374,0.00090953964,0.00068703893,0.000101164085,0.0037339714,0.00004235723,0.0046344106,0.108241044],"study_design_scores_gemma":[0.55122334,0.26699826,0.13594352,0.003979663,0.00088105665,0.000040799685,0.00072898885,0.00021271368,0.00033383677,0.000119334116,0.039210793,0.000327706],"about_ca_topic_score_codex":0.000096287484,"about_ca_topic_score_gemma":0.00062711566,"teacher_disagreement_score":0.29270905,"about_ca_system_score_codex":0.0029833626,"about_ca_system_score_gemma":0.014969336,"threshold_uncertainty_score":0.9906149},"labels":[],"label_agreement":null},{"id":"W4410813257","doi":"10.1200/jco.2025.43.16_suppl.e16339","title":"Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Concordance; Octreotide; Nuclear medicine; Scintigraphy; Internal medicine; Oncology; Somatostatin","score_opus":0.1152835785183448,"score_gpt":0.5230982329277083,"score_spread":0.4078146544093635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765936,0.0008793793,0.00014771304,0.013811984,0.00060377386,0.00017888135,0.0000027953718,0.0000067413325,0.0077751204],"genre_scores_gemma":[0.99495,0.0016338477,0.0018067331,0.0012506106,0.00021434289,0.0000041701724,0.0000010514154,0.000004887707,0.00013435989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803346,0.00014480778,0.0014103111,0.0001637009,0.00012711466,0.00012062785],"domain_scores_gemma":[0.99560475,0.0029035609,0.0009038984,0.00019744657,0.00023486318,0.00015548886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009449263,0.00009270461,0.00085172337,0.00022197548,0.00004366618,0.000007125325,0.00007994146,0.000063582185,0.000017752409],"category_scores_gemma":[0.002296785,0.00006599361,0.0002792629,0.00020422014,0.00026154466,0.000072951734,0.000017535685,0.00030272309,0.0000022705126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060161287,0.0012881067,0.70083266,0.00003568882,0.0006429913,0.00006421809,0.00008679863,0.000044716286,0.00059933297,0.0021722817,0.0040117083,0.28420535],"study_design_scores_gemma":[0.010331994,0.010455986,0.94466275,0.00020321787,0.0004009486,0.000065422166,0.00010001289,0.00015702551,0.0008744581,0.00069052365,0.032004204,0.00005347035],"about_ca_topic_score_codex":0.000022116923,"about_ca_topic_score_gemma":0.00002300413,"teacher_disagreement_score":0.28415188,"about_ca_system_score_codex":0.00010458627,"about_ca_system_score_gemma":0.0010143071,"threshold_uncertainty_score":0.27496317},"labels":[],"label_agreement":null},{"id":"W4410813304","doi":"10.1200/jco.2025.43.16_suppl.e16347","title":"Real world outcome analysis of the two McGill University–associated hospitals with Lu-177 PRRT for metastatic NET.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Family medicine","score_opus":0.08389965211670095,"score_gpt":0.47540397315529637,"score_spread":0.39150432103859545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761687,0.00008186454,0.00008162829,0.018399155,0.00052876206,0.00043990643,0.000086430744,0.0000058150404,0.0042077214],"genre_scores_gemma":[0.9931532,0.00022036256,0.0014992007,0.0014026092,0.000054654458,0.0000027795566,0.0000042647343,0.000006570541,0.003656338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979007,0.00029106284,0.0012790157,0.00014593016,0.00023174084,0.00015150782],"domain_scores_gemma":[0.9941345,0.0033198523,0.0017108306,0.00019978595,0.0005139212,0.00012112312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015187499,0.00010266538,0.0017546266,0.00027620015,0.00005292071,0.0000023141063,0.00016006402,0.00008164032,0.000030723375],"category_scores_gemma":[0.0009847473,0.000054478725,0.0010113581,0.0009175383,0.00012122477,0.00004272901,0.00003978876,0.0002952377,4.844869e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025744156,0.0020825216,0.96308,0.00003334182,0.019722246,0.00008961124,0.000026612632,0.00019742214,0.0000036558229,0.0009071634,0.0052111577,0.006071867],"study_design_scores_gemma":[0.012528086,0.0050699776,0.92704123,0.00014206517,0.0330447,0.0000029953833,0.00012146372,0.00015594326,0.00002936399,0.00014768243,0.02166484,0.000051651416],"about_ca_topic_score_codex":0.00021033622,"about_ca_topic_score_gemma":0.005136667,"teacher_disagreement_score":0.036038753,"about_ca_system_score_codex":0.00076242705,"about_ca_system_score_gemma":0.0008473967,"threshold_uncertainty_score":0.28663805},"labels":[],"label_agreement":null},{"id":"W4410813462","doi":"10.1200/jco.2025.43.16_suppl.e13716","title":"Bridging the digital literacy gap: Empowering patients and care partners through the Digital Sherpa program.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Technology Use by Older Adults","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Exelixis; Regeneron Pharmaceuticals; Pfizer","keywords":"Bridging (networking); Medicine; Literacy; Digital literacy; World Wide Web; Pedagogy; Sociology; Computer science; Computer security","score_opus":0.0628009458011795,"score_gpt":0.4843367245371645,"score_spread":0.42153577873598497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9193877,0.00071470905,0.00010538215,0.033168975,0.0016972919,0.00041331165,0.000006152395,0.00006236119,0.044444136],"genre_scores_gemma":[0.99757,0.00022288163,0.00024647577,0.0011524801,0.00049990066,0.000008262037,0.0000013555698,0.0000084075555,0.00029024205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975864,0.00030589759,0.0012043762,0.0002013991,0.00035745933,0.000344416],"domain_scores_gemma":[0.9958406,0.0026428034,0.00082954025,0.0001934179,0.0003855736,0.00010807154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011727157,0.00012780834,0.0005059982,0.000051612325,0.00043888378,0.00036901495,0.0006782123,0.00031063874,0.0000064514],"category_scores_gemma":[0.007502801,0.00007031774,0.00026468813,0.00030003613,0.0015198768,0.000712221,0.00025558352,0.0010107814,0.0000053553135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009187766,0.00023405545,0.16317415,0.000005549148,0.00009025126,0.000023263985,0.009224182,0.0000019393672,1.2926122e-7,0.0012760599,0.0030712332,0.8228073],"study_design_scores_gemma":[0.0014973839,0.0010404433,0.099150814,0.00009055729,0.0000666664,0.000008545575,0.012158728,0.000015751457,0.000001967324,0.0030133135,0.88285387,0.000101953774],"about_ca_topic_score_codex":0.00004205513,"about_ca_topic_score_gemma":0.00014658172,"teacher_disagreement_score":0.8797826,"about_ca_system_score_codex":0.00012071356,"about_ca_system_score_gemma":0.00077453174,"threshold_uncertainty_score":0.8982095},"labels":[],"label_agreement":null},{"id":"W4410813553","doi":"10.1200/jco.2025.43.16_suppl.tps12139","title":"Randomized trial of a clinical nurse specialist–led enhanced survivorship and early palliative care intervention for patients with metastatic cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Survivorship curve; Intervention (counseling); Cancer survivorship; Palliative care; Randomized controlled trial; Cancer; Clinical trial; Nursing; Family medicine; Internal medicine","score_opus":0.28121692589710967,"score_gpt":0.5960000694632817,"score_spread":0.314783143566172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897085,0.0015045394,0.0034503131,0.00080620137,0.002387522,0.001463449,0.000028989767,0.0000037348793,0.000646781],"genre_scores_gemma":[0.99190617,0.0016727298,0.005348828,0.00018178803,0.0006525326,0.000044388886,0.000009674361,0.000011576325,0.00017232748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99294144,0.0017617451,0.0045927432,0.00021373486,0.00033069638,0.00015964975],"domain_scores_gemma":[0.97629404,0.016718837,0.004452151,0.00013628213,0.0022238398,0.00017482674],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051854374,0.00016081578,0.004378567,0.00015244097,0.000022643499,0.0000054084153,0.00012197227,0.00025780193,0.00002979743],"category_scores_gemma":[0.030134406,0.00010046758,0.0011951964,0.00015825429,0.0005653822,0.000076455755,0.000023855668,0.0004993373,3.136913e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8037894,0.0018752688,0.1326746,0.00029092433,0.0019760712,0.000008607529,0.00087826804,0.000001250659,0.0000037701855,0.00020019777,0.0001527637,0.058148906],"study_design_scores_gemma":[0.8514802,0.028208008,0.11182256,0.002202637,0.0028506718,2.8421445e-7,0.00085452065,0.000015037377,0.00013654541,0.000536644,0.0018140075,0.000078923935],"about_ca_topic_score_codex":0.0001660335,"about_ca_topic_score_gemma":0.00041465575,"teacher_disagreement_score":0.05806998,"about_ca_system_score_codex":0.00007880942,"about_ca_system_score_gemma":0.0010863772,"threshold_uncertainty_score":0.9780352},"labels":[],"label_agreement":null},{"id":"W4410813735","doi":"10.1200/jco.2025.43.16_suppl.3066","title":"Larotrectinib resistance in TRK fusion cancers: Analysis of a tumor-agnostic, global clinical trial dataset.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Trk receptor; Clinical trial; Oncology; Internal medicine; Cancer research; Receptor","score_opus":0.15198102947478676,"score_gpt":0.5249001518930358,"score_spread":0.3729191224182491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978089,0.0047372347,0.00007501023,0.006976338,0.003166683,0.0003811874,0.00017209108,0.000006683395,0.006395774],"genre_scores_gemma":[0.991812,0.0020408512,0.0015230303,0.003377698,0.0010617127,0.000008438949,0.0000311471,0.000006559095,0.00013858253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930282,0.0008614793,0.0050545856,0.00035610408,0.00043327734,0.00026635255],"domain_scores_gemma":[0.991005,0.005641416,0.0022700895,0.00039571978,0.00045213013,0.0002356463],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058317976,0.00017084501,0.0035871256,0.00037357118,0.00003637945,0.0000073014953,0.00028786185,0.00034313393,0.00010151085],"category_scores_gemma":[0.016113972,0.0001288679,0.0012110289,0.001494594,0.00036416162,0.00007703371,0.00014036862,0.0010269525,0.0000027600136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16276507,0.0021790788,0.7442616,0.000055344688,0.003961743,0.0008480701,0.00006273148,0.000019790688,0.000005504679,0.00013424343,0.060940344,0.024766466],"study_design_scores_gemma":[0.06917181,0.00596521,0.83208704,0.00027055392,0.0053669554,0.000012645127,0.00016051487,0.000042226475,0.000005498635,0.00024674763,0.086582825,0.000087972505],"about_ca_topic_score_codex":0.0003491428,"about_ca_topic_score_gemma":0.011853999,"teacher_disagreement_score":0.09359327,"about_ca_system_score_codex":0.00045208898,"about_ca_system_score_gemma":0.0039137355,"threshold_uncertainty_score":0.99217373},"labels":[],"label_agreement":null},{"id":"W4410813784","doi":"10.1200/jco.2025.43.16_suppl.9038","title":"The evolving landscape of academic and industry partnerships in gynecologic oncology clinical trials.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecologic oncology; Clinical Oncology; Clinical trial; Internal medicine; Oncology; Cancer","score_opus":0.7412502962268003,"score_gpt":0.6924123898093999,"score_spread":0.04883790641740038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76565,0.0053254482,0.0000274813,0.21708949,0.0018466323,0.0004341424,0.0000012424382,0.0000051933894,0.009620367],"genre_scores_gemma":[0.9595572,0.020957641,0.00041202208,0.01745814,0.0012445025,0.000007177787,6.5333205e-7,0.000007081963,0.00035560864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9766798,0.011889171,0.009667468,0.0002669024,0.0006311325,0.00086554856],"domain_scores_gemma":[0.45794958,0.51866937,0.009985667,0.0007706655,0.0015037645,0.011120946],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.16990055,0.00013164566,0.0032035778,0.0002760634,0.000063784784,0.000007147402,0.00031558346,0.0030968597,0.00011113533],"category_scores_gemma":[0.83551407,0.00006894859,0.00044084087,0.00039550225,0.0010358754,0.00007981061,0.0001505047,0.0116359005,0.00000382692],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059361006,0.0007047531,0.4021201,0.00007191011,0.00015143829,0.00032458265,0.000036328616,5.930786e-7,0.000028913397,0.00040304565,0.046510037,0.5437122],"study_design_scores_gemma":[0.015347231,0.015657177,0.598063,0.00042329528,0.00021792842,0.00011817886,0.00064112415,0.000236912,0.000015873053,0.0018831417,0.3673404,0.000055776083],"about_ca_topic_score_codex":0.000009554133,"about_ca_topic_score_gemma":0.00006587529,"teacher_disagreement_score":0.66561353,"about_ca_system_score_codex":0.00019571571,"about_ca_system_score_gemma":0.036861148,"threshold_uncertainty_score":0.9981973},"labels":[],"label_agreement":null},{"id":"W4410813910","doi":"10.1200/jco.2025.43.16_suppl.5516","title":"A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Ovary; Cisplatin","score_opus":0.024846257108481203,"score_gpt":0.39380533045977456,"score_spread":0.36895907335129335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967115,0.00010948936,0.000024498142,0.0017052712,0.00020083805,0.0011607019,0.00005953077,0.0000015839031,0.000026596967],"genre_scores_gemma":[0.99878085,0.00056741555,0.00043611522,0.00012318895,0.00004290148,0.000017102335,0.000019518835,0.000008906707,0.000003982393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661255,0.00050543656,0.0021797458,0.00024018547,0.0003409417,0.00012112865],"domain_scores_gemma":[0.9955693,0.0017983407,0.0019435828,0.00020904734,0.0004022082,0.000077529665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011188327,0.00015325863,0.001960837,0.00029927987,0.000026384925,0.000003697557,0.00008862821,0.00014853198,0.000025078774],"category_scores_gemma":[0.0004905983,0.00008885818,0.00011679941,0.00086290913,0.0001853418,0.00007001219,0.000031820582,0.00035264733,1.2142299e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1772445,0.033862747,0.65403897,0.000013390863,0.0020221192,0.000019306402,0.0008882568,0.00019361527,0.00006514172,0.00001764333,0.0000049764794,0.13162933],"study_design_scores_gemma":[0.34920463,0.037604112,0.6113087,0.0001792799,0.00108875,3.2883239e-7,0.00029157943,0.00013510621,0.00009078382,0.000015165606,0.000038235787,0.00004332191],"about_ca_topic_score_codex":0.003670489,"about_ca_topic_score_gemma":0.008208274,"teacher_disagreement_score":0.17196013,"about_ca_system_score_codex":0.00015542492,"about_ca_system_score_gemma":0.00080649497,"threshold_uncertainty_score":0.5548706},"labels":[],"label_agreement":null},{"id":"W4410814172","doi":"10.1200/jco.2025.43.16_suppl.e17565","title":"Healthcare resource use in the management of advanced epithelial ovarian cancer in Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Jewish General Hospital; ABB (Canada)","funders":"AbbVie Canada","keywords":"Medicine; Health care; Ovarian cancer; Epithelial ovarian cancer; Oncology; Cancer; Gynecology; Internal medicine; Cancer research; Economic growth","score_opus":0.08806862542293935,"score_gpt":0.46020819613853825,"score_spread":0.3721395707155989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84935606,0.0016949946,0.000008593204,0.14544438,0.00094213744,0.000408502,0.0000164694,0.000001207124,0.002127668],"genre_scores_gemma":[0.9869505,0.0032288576,0.0010166442,0.008495427,0.0001439927,0.000020342199,9.198973e-7,0.000005175674,0.00013814551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972705,0.00040696072,0.0017323772,0.00013963204,0.0002710039,0.00017951737],"domain_scores_gemma":[0.9975406,0.0013686924,0.00067887234,0.00020165082,0.000116169125,0.000093999435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016401077,0.00008595298,0.00090341584,0.00010948229,0.000014352388,0.0000031005075,0.00015727947,0.00010613191,0.000039242917],"category_scores_gemma":[0.00023907422,0.00005251525,0.00013975751,0.0002945954,0.00004829768,0.00003654478,0.000032862954,0.0005732647,3.3335044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029601832,0.0009992846,0.53785485,0.0001167633,0.00034155062,0.0019019472,0.00012317592,0.00033595998,0.0000023796006,0.0014012352,0.002665283,0.4512974],"study_design_scores_gemma":[0.008886947,0.0010334661,0.872261,0.00076772156,0.00016823727,0.000013055654,0.00068164006,0.000015108808,0.000012945308,0.00017585598,0.11595124,0.000032785367],"about_ca_topic_score_codex":0.27688086,"about_ca_topic_score_gemma":0.82284766,"teacher_disagreement_score":0.5459668,"about_ca_system_score_codex":0.0010774374,"about_ca_system_score_gemma":0.0056124195,"threshold_uncertainty_score":0.9956191},"labels":[],"label_agreement":null},{"id":"W4410814329","doi":"10.1200/jco.2025.43.16_suppl.5004","title":"Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Quality of life (healthcare); Health related quality of life; Oncology; Gerontology; Internal medicine; Physical therapy; Disease; Nursing","score_opus":0.185211030578615,"score_gpt":0.6027982367111153,"score_spread":0.41758720613250033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8894833,0.0007669874,0.00015622436,0.105013594,0.0006310412,0.00048654404,0.0000053988147,0.000003711702,0.003453221],"genre_scores_gemma":[0.98894113,0.00021639907,0.00072287145,0.009630205,0.00010635952,0.0000074184686,0.0000028701124,0.0000046918863,0.00036802993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951337,0.00098707,0.0033631248,0.00010903017,0.00026930083,0.0001378011],"domain_scores_gemma":[0.9934253,0.0039071576,0.0021205354,0.00019904926,0.00021050104,0.00013746085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053674174,0.000087414875,0.0017950061,0.00012459629,0.000032254906,0.0000036880726,0.00012559252,0.00015328887,0.000031711308],"category_scores_gemma":[0.004643598,0.000041314244,0.00032232943,0.00025238525,0.00016427634,0.000047928577,0.000012299296,0.00061948027,0.0000016584424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29415512,0.02377739,0.44562978,0.00017489599,0.0038098258,0.00033556722,0.0015383977,0.00008553124,0.000016230144,0.0030157103,0.006976253,0.22048531],"study_design_scores_gemma":[0.29442233,0.021418916,0.6673114,0.0001594053,0.0005599438,0.000026071928,0.00048480928,0.00001533177,0.0000027468027,0.00088755164,0.014666136,0.000045373716],"about_ca_topic_score_codex":0.0003354951,"about_ca_topic_score_gemma":0.00035758244,"teacher_disagreement_score":0.2216816,"about_ca_system_score_codex":0.0001479585,"about_ca_system_score_gemma":0.0055249142,"threshold_uncertainty_score":0.98009604},"labels":[],"label_agreement":null},{"id":"W4410814346","doi":"10.1200/jco.2025.43.16_suppl.e23308","title":"Real-world (rw) patient characteristics, treatment (tx) patterns, and clinical outcomes in advanced (adv) and recurrent (rec) endometrial cancer (EC) patients (pts) with known mismatch repair/microsatellite instability (MMR/MSI) status in Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; AstraZeneca (Canada); London Health Sciences Centre","funders":"AstraZeneca Canada","keywords":"Microsatellite instability; Medicine; Endometrial cancer; DNA mismatch repair; Cancer; Internal medicine; Gynecology; Oncology; Microsatellite; Gene; Genetics","score_opus":0.04775184118608195,"score_gpt":0.4143699050132975,"score_spread":0.36661806382721557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919257,0.00085303176,0.0000022877352,0.0016464365,0.0041634,0.0011106179,0.0001469506,0.000008978139,0.00014258992],"genre_scores_gemma":[0.9753279,0.021817219,0.0013199077,0.00122285,0.0001681499,0.00004388503,0.000011190927,0.000023130111,0.000065781045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926099,0.0009696556,0.0047477307,0.00064040034,0.00048371582,0.0005485585],"domain_scores_gemma":[0.99129975,0.0054411236,0.0018654254,0.0003345905,0.0004771434,0.0005819946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001650788,0.00037131738,0.0029730287,0.000365092,0.000038348615,0.000012768247,0.00012352815,0.00031193873,0.000064306456],"category_scores_gemma":[0.003319754,0.00025458788,0.0002645228,0.0003785292,0.00027757854,0.00008048143,0.00013086337,0.001208826,3.9774756e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014638285,0.0017316719,0.5913034,0.000064129796,0.00023038169,0.00011236154,0.00011719859,0.0000028475113,0.0000018025604,8.5110645e-7,0.00013845242,0.3916586],"study_design_scores_gemma":[0.025815548,0.018200815,0.9311791,0.00048246756,0.00027265467,0.00000645635,0.00017319343,0.000044552773,0.000028060447,0.000013508765,0.023589348,0.0001943104],"about_ca_topic_score_codex":0.1749427,"about_ca_topic_score_gemma":0.8846398,"teacher_disagreement_score":0.7096971,"about_ca_system_score_codex":0.0043648775,"about_ca_system_score_gemma":0.009072882,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W4410814439","doi":"10.1200/jco.2025.43.16_suppl.e23324","title":"Global practice patterns and outcomes for metastatic uveal melanoma treated regionally versus systemically.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Melanoma; Metastatic melanoma; Oncology; Internal medicine; Cancer research","score_opus":0.11358934617539429,"score_gpt":0.5123088645503527,"score_spread":0.39871951837495845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95002145,0.0008022396,0.0013318812,0.041291423,0.0021349902,0.0005332608,0.000019689902,0.000013876631,0.0038512037],"genre_scores_gemma":[0.9834958,0.00028565613,0.011241748,0.004194974,0.00023504112,0.000013257386,0.0000077340455,0.000007883383,0.0005179303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972298,0.0005613022,0.0016226392,0.00019925465,0.00019318005,0.00019378455],"domain_scores_gemma":[0.98848677,0.00940182,0.0011769319,0.0001486016,0.0005442836,0.00024160973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019055804,0.0001463485,0.0015455086,0.00008053926,0.00005197997,0.000008440915,0.00010117452,0.00033936847,0.000013455247],"category_scores_gemma":[0.01009228,0.00009507878,0.00044597007,0.00010201113,0.00014075957,0.00010222281,0.000040575018,0.00034558694,0.0000047202343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031210471,0.0026939202,0.9137308,0.0001322678,0.006834146,0.002418314,0.00001637476,0.0000016562791,0.0000030647207,0.0027105885,0.0029673858,0.037280995],"study_design_scores_gemma":[0.06061806,0.027288754,0.8427977,0.00023270825,0.008483885,0.0012526547,0.000288674,0.00005181429,0.000005465854,0.00094570324,0.05792909,0.00010551703],"about_ca_topic_score_codex":0.000028928625,"about_ca_topic_score_gemma":0.000089518675,"teacher_disagreement_score":0.07093315,"about_ca_system_score_codex":0.00025906562,"about_ca_system_score_gemma":0.0013007739,"threshold_uncertainty_score":0.99824613},"labels":[],"label_agreement":null},{"id":"W4410814758","doi":"10.1200/jco.2025.43.16_suppl.e16197","title":"Two decades of change: Tracking intrahepatic cholangiocarcinoma mortality in the United States from 1999 to 2020.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Intrahepatic Cholangiocarcinoma; Internal medicine; General surgery; Demography; Oncology","score_opus":0.24907932587153334,"score_gpt":0.5062484078776176,"score_spread":0.25716908200608424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745392,0.0033084697,0.00005689308,0.020412171,0.0006048245,0.00030201764,0.000011132253,0.000005091159,0.00076018233],"genre_scores_gemma":[0.9849481,0.0011270674,0.00061739655,0.012423141,0.0008378135,0.000012656539,0.00001040749,0.000007836123,0.000015582367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967811,0.00054993853,0.0019427078,0.00018392167,0.00032683794,0.00021546816],"domain_scores_gemma":[0.9953641,0.0032000372,0.0007111294,0.00025502942,0.00033459498,0.0001350737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028100708,0.00013783215,0.001319711,0.0002633176,0.000032543507,0.000010876979,0.00029547545,0.00016071413,0.000030593037],"category_scores_gemma":[0.0024005536,0.00008531194,0.0003516036,0.00070283836,0.00016442567,0.00007487915,0.00007937375,0.00084560167,0.0000028128813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011607949,0.00062683603,0.957684,0.000040274597,0.00048953434,0.0003769948,0.0022968529,0.000012524959,0.00007836796,0.00008863171,0.0036521447,0.033493083],"study_design_scores_gemma":[0.004146467,0.002005334,0.9791652,0.000286414,0.00055675936,0.000024757512,0.0023121615,0.000085988344,0.000109059125,0.00069527776,0.010545932,0.00006665388],"about_ca_topic_score_codex":0.0028697255,"about_ca_topic_score_gemma":0.0021868239,"teacher_disagreement_score":0.03342643,"about_ca_system_score_codex":0.00010404664,"about_ca_system_score_gemma":0.00041984647,"threshold_uncertainty_score":0.43381855},"labels":[],"label_agreement":null},{"id":"W4410814984","doi":"10.1200/jco.2025.43.16_suppl.tps4202","title":"Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with fluorouracil, leucovorin, and budigalimab in locally advanced/metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (a/m GEA).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AbbVie","keywords":"Medicine; Gastroesophageal Junction; Esophageal adenocarcinoma; Fluorouracil; Adenocarcinoma; Gastroenterology; Internal medicine; Metastatic adenocarcinoma; Stomach; Surgery; Chemotherapy; Cancer","score_opus":0.046927950906371224,"score_gpt":0.39246760355043697,"score_spread":0.3455396526440657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818822,0.0019091096,0.0036236837,0.009267981,0.0010642554,0.00086321763,0.0000028243164,0.000023446344,0.00136326],"genre_scores_gemma":[0.9849058,0.0008332845,0.010352166,0.001969788,0.00022858016,0.000023205723,0.0000060123393,0.000022457823,0.0016587223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550384,0.0003983467,0.0027175439,0.00040329847,0.00051640277,0.00046053863],"domain_scores_gemma":[0.9965951,0.0012763605,0.0011990658,0.00024074983,0.00041113148,0.00027759827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002557862,0.0002850902,0.0018864904,0.00095865875,0.000052231797,0.000030620155,0.0002124208,0.00020754355,0.0000776462],"category_scores_gemma":[0.0017988598,0.00020086227,0.00019883565,0.0009863332,0.00025351983,0.00036400807,0.00010200805,0.0012672098,0.0000045848446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016630707,0.0015278136,0.7574328,0.00022619654,0.00026908022,0.0044994373,0.00009985696,0.00019812334,0.000009895439,0.0002977647,0.0019321068,0.21687622],"study_design_scores_gemma":[0.041463118,0.017814552,0.93449837,0.00045563688,0.00044913095,0.0007241189,0.00058139017,0.00043530067,0.000013058515,0.00045118618,0.0029869024,0.00012720868],"about_ca_topic_score_codex":0.000083082996,"about_ca_topic_score_gemma":0.0006870919,"teacher_disagreement_score":0.21674901,"about_ca_system_score_codex":0.0006678928,"about_ca_system_score_gemma":0.0021190392,"threshold_uncertainty_score":0.8190926},"labels":[],"label_agreement":null},{"id":"W4410815036","doi":"10.1200/jco.2025.43.16_suppl.4013","title":"Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Chemotherapy; Internal medicine; Gastroesophageal Junction; Overall survival; Oncology; Metastatic adenocarcinoma; Adenocarcinoma; Cancer","score_opus":0.09468660590871203,"score_gpt":0.4711726015739391,"score_spread":0.37648599566522706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888986,0.0003983649,0.0015905912,0.00570081,0.0017697416,0.0013776511,0.000026809363,0.000007907221,0.0002295746],"genre_scores_gemma":[0.98837674,0.00066419714,0.0064252135,0.0021462166,0.00030673682,0.000025689858,0.000014040461,0.00002390552,0.0020172878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607193,0.00033450706,0.00262456,0.00030373884,0.00033307116,0.00033220497],"domain_scores_gemma":[0.99475366,0.003053875,0.0014882782,0.00023320972,0.00026742538,0.0002035615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025266425,0.00023916003,0.0027804212,0.0003388649,0.000029922645,0.00001522287,0.00022090203,0.00017443013,0.00015063507],"category_scores_gemma":[0.0025184315,0.00016527057,0.0006569575,0.0002309715,0.00017904228,0.00016682575,0.00007723604,0.0005162707,0.0000010473526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3935476,0.0036384535,0.5008827,0.000247701,0.0016559416,0.000598698,0.00012448578,0.000003073021,0.00003467985,0.00023716174,0.0012763633,0.097753204],"study_design_scores_gemma":[0.36791232,0.024364078,0.605469,0.0001537767,0.00084999297,0.00002165079,0.00016442277,0.000028132228,0.000036523335,0.00017623966,0.00074548787,0.00007839934],"about_ca_topic_score_codex":0.000021933662,"about_ca_topic_score_gemma":0.00015419252,"teacher_disagreement_score":0.10458631,"about_ca_system_score_codex":0.00016064732,"about_ca_system_score_gemma":0.0009390671,"threshold_uncertainty_score":0.67395383},"labels":[],"label_agreement":null},{"id":"W4410815108","doi":"10.1200/jco.2025.43.16_suppl.4182","title":"Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tumor microenvironment; Pancreatic cancer; Immune system; Cancer; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.0495109690181561,"score_gpt":0.45376450670097657,"score_spread":0.40425353768282046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98306894,0.01159727,0.0013225129,0.002982256,0.00016093289,0.0004090142,0.000012125074,0.0000019771505,0.00044494288],"genre_scores_gemma":[0.97578347,0.009899813,0.013364268,0.0005711984,0.000070008326,0.0000298629,0.0000052926953,0.000007491197,0.00026858906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970181,0.00032985836,0.0021276355,0.00017890464,0.0001376622,0.00020783077],"domain_scores_gemma":[0.9943931,0.0040182555,0.0011111886,0.00013969034,0.00022057042,0.000117184325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002711892,0.00012065602,0.002831515,0.0005174266,0.000028492534,0.0000029187509,0.000118341006,0.00018286081,0.00013521157],"category_scores_gemma":[0.002088848,0.00008023455,0.0004016047,0.00037449505,0.0002726887,0.00003363072,0.000044698223,0.0005347644,4.1943747e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009672147,0.0008537027,0.91420805,0.00009411149,0.006442432,0.00005647592,0.0004840002,0.00011788253,0.012699915,0.00019042952,0.00010007394,0.05508079],"study_design_scores_gemma":[0.009576817,0.0041307937,0.9746342,0.00024847942,0.0041454015,0.000010336696,0.0013685738,0.0036576956,0.00039020242,0.00053642044,0.0012413181,0.000059777976],"about_ca_topic_score_codex":0.00007996141,"about_ca_topic_score_gemma":0.00017552666,"teacher_disagreement_score":0.060426142,"about_ca_system_score_codex":0.00021981346,"about_ca_system_score_gemma":0.0013663889,"threshold_uncertainty_score":0.32718703},"labels":[],"label_agreement":null},{"id":"W4410815151","doi":"10.1200/jco.2025.43.16_suppl.4000","title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroesophageal Junction; Nivolumab; Adjuvant; Esophageal cancer; Oncology; Internal medicine; Chemoradiotherapy; Cancer; Neoadjuvant therapy; Adenocarcinoma; Immunotherapy; Breast cancer","score_opus":0.09071787476997857,"score_gpt":0.47284083428585577,"score_spread":0.3821229595158772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787646,0.009331782,0.000112333226,0.0065542613,0.0032946565,0.00064554706,0.00008299246,0.00002550304,0.001188352],"genre_scores_gemma":[0.9896555,0.004415466,0.0020485434,0.0007522823,0.0013139688,0.000029326671,0.00003027199,0.0000382845,0.0017163707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930476,0.00078049384,0.003997229,0.0005476782,0.00097037444,0.00065665273],"domain_scores_gemma":[0.9938635,0.0028336062,0.0017633952,0.0004632974,0.0005349093,0.00054126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035308467,0.00034859416,0.003273341,0.00045959177,0.00008326006,0.000022220494,0.00037297732,0.0005521461,0.0005227135],"category_scores_gemma":[0.0032370198,0.00024463594,0.0009126269,0.0006056018,0.00024106028,0.00022594618,0.00010749368,0.0017062048,0.000007556484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2650972,0.0071486756,0.5279951,0.00024796612,0.004009721,0.019949863,0.00058543915,0.0004687015,0.0008551521,0.000049598715,0.013362788,0.1602298],"study_design_scores_gemma":[0.09916363,0.020130213,0.8712512,0.00116672,0.00057627977,0.00006478122,0.00013245264,0.0007331004,0.001981663,0.000338996,0.0042833886,0.00017758041],"about_ca_topic_score_codex":0.0042420947,"about_ca_topic_score_gemma":0.006742028,"teacher_disagreement_score":0.34325612,"about_ca_system_score_codex":0.001423143,"about_ca_system_score_gemma":0.0053753206,"threshold_uncertainty_score":0.9975965},"labels":[],"label_agreement":null},{"id":"W4410815308","doi":"10.1200/jco.2025.43.16_suppl.4110","title":"Comparison of outcomes between open and minimally invasive hepatic resections for hepatocellular carcinoma: A retrospective analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Retrospective cohort study; Surgery; Hepatectomy; General surgery; Radiology; Oncology; Internal medicine; Resection","score_opus":0.2955645104915134,"score_gpt":0.5022063608111658,"score_spread":0.20664185031965238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912349,0.0007293402,0.0006395519,0.004788931,0.0002361947,0.0009446099,0.000024518644,0.000005145885,0.001396798],"genre_scores_gemma":[0.99241704,0.000104403865,0.006620272,0.000275131,0.00015515786,0.00003003084,0.00001759538,0.000011380229,0.00036897973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959967,0.00045940533,0.0028057282,0.00028025283,0.0002512065,0.00020669069],"domain_scores_gemma":[0.99110323,0.0056139375,0.0018335758,0.00025634398,0.00093256123,0.00026037433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028834918,0.0001749984,0.0039190347,0.00051256607,0.000088414956,0.000020459538,0.0002554105,0.00037063975,0.000031555144],"category_scores_gemma":[0.00541684,0.00012773946,0.0010832745,0.0006089944,0.00024078498,0.00010602729,0.00015599752,0.0005242787,0.000001091319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014296266,0.0012747148,0.98614854,0.000095597614,0.0067370613,0.000083347004,0.00018534373,6.173321e-7,0.00009395742,0.00022111635,0.000804467,0.0029256204],"study_design_scores_gemma":[0.007552272,0.011397859,0.96324193,0.000075523385,0.013179046,0.000007359145,0.00025810214,0.00082064915,0.0010825612,0.0009943894,0.001302833,0.00008748516],"about_ca_topic_score_codex":0.00015699996,"about_ca_topic_score_gemma":0.000254233,"teacher_disagreement_score":0.02290661,"about_ca_system_score_codex":0.00018092542,"about_ca_system_score_gemma":0.0016638541,"threshold_uncertainty_score":0.6484854},"labels":[],"label_agreement":null},{"id":"W4410815387","doi":"10.1200/jco.2025.43.16_suppl.12009","title":"A randomized controlled trial of cognitive behavioral therapy and bright light therapy for insomnia and fatigue during breast cancer treatment: SleepCaRe trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Insomnia; Randomized controlled trial; Breast cancer; Oncology; Cognition; Cognitive behavioral therapy for insomnia; Cancer; Cancer-related fatigue; Physical therapy; Internal medicine; Cognitive behavioral therapy; Psychiatry","score_opus":0.11402771398716073,"score_gpt":0.49114747094886146,"score_spread":0.37711975696170075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720823,0.007942056,0.000029845367,0.008174605,0.0016101196,0.009782783,0.00004919904,0.000009083273,0.00031999065],"genre_scores_gemma":[0.9527126,0.044303946,0.000061266204,0.00056057534,0.0010748496,0.0008785048,0.0000027946735,0.000017665272,0.0003877966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955171,0.0009444852,0.0028244227,0.00026429194,0.000226953,0.000222769],"domain_scores_gemma":[0.98737425,0.00905421,0.0022600507,0.00008826535,0.0010519121,0.00017134477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002211902,0.00026691888,0.0056065493,0.00025318778,0.00010075726,0.000013051758,0.000057816917,0.00035694512,0.000059026956],"category_scores_gemma":[0.0021165048,0.0001503533,0.0011718482,0.00012692962,0.0005284922,0.00008577704,0.000024900437,0.00039035972,1.3909839e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8582814,0.0047430685,0.0031105105,0.000021945163,0.0058498895,0.000032295895,0.0004276191,2.3852056e-7,0.000075364725,0.000013515598,0.00010287599,0.12734133],"study_design_scores_gemma":[0.9304202,0.041382484,0.022112578,0.0005153632,0.003983888,0.00004472069,0.00025193798,0.000012403965,0.00024377237,0.00012993821,0.00079379464,0.000108916625],"about_ca_topic_score_codex":0.00006277545,"about_ca_topic_score_gemma":0.00004405292,"teacher_disagreement_score":0.12723242,"about_ca_system_score_codex":0.00015567525,"about_ca_system_score_gemma":0.0011835207,"threshold_uncertainty_score":0.613123},"labels":[],"label_agreement":null},{"id":"W4410815489","doi":"10.1200/jco.2025.43.16_suppl.9025","title":"Leveraging the power of diagnostic metrics to competency based medical education (CBME) implementation in medical oncology (MO) across Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; University of Ottawa; University of Alberta; Juravinski Cancer Centre; Université de Sherbrooke; Royal College of Physicians and Surgeons of Canada; University of Toronto; Hôpital Maisonneuve-Rosemont; St. Michael's Hospital; University of British Columbia; Memorial University of Newfoundland; McMaster University; Queen's University","funders":"Royal College of Physicians and Surgeons of Canada","keywords":"Medicine; Precision oncology; Graduate medical education; Medical physics; Internal medicine; Medical education; Cancer; Accreditation","score_opus":0.044704366971183525,"score_gpt":0.5543558398192294,"score_spread":0.5096514728480459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6705376,0.001823652,0.008028266,0.3091959,0.008014723,0.00050513033,0.0000049328014,0.000005981549,0.0018838572],"genre_scores_gemma":[0.90940887,0.0010041874,0.0055243555,0.08334105,0.0006373578,0.000016029204,0.0000042781517,0.000009645797,0.000054214932],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943901,0.0011340484,0.0030453298,0.00020874581,0.0009005506,0.0003212314],"domain_scores_gemma":[0.9637325,0.033562105,0.0013359027,0.00021513968,0.00064756314,0.0005068217],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009109698,0.00013605699,0.0013597249,0.00019595928,0.0000723086,0.0000032170678,0.00045572233,0.00058781746,0.0007727734],"category_scores_gemma":[0.06660777,0.0000873731,0.00020202386,0.0007324397,0.00041297538,0.00005361638,0.00007650947,0.0016044929,0.000001676675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013876319,0.002157234,0.2616031,0.000032911128,0.00018590897,0.0004885487,0.00040329827,0.00006280412,0.0000089428,0.00095089216,0.021469729,0.711249],"study_design_scores_gemma":[0.011070775,0.0059212386,0.5666616,0.00037356882,0.00016165203,0.00035117008,0.002635781,0.00042064508,0.000048302314,0.0012332271,0.41101074,0.00011132941],"about_ca_topic_score_codex":0.0066801235,"about_ca_topic_score_gemma":0.16510144,"teacher_disagreement_score":0.7111377,"about_ca_system_score_codex":0.0011924831,"about_ca_system_score_gemma":0.07990669,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W4410815589","doi":"10.1200/jco.2025.43.16_suppl.5601","title":"Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Paclitaxel; Carboplatin; Internal medicine; Placebo; Endometrial cancer; Oncology; Chemotherapy; Gynecology; Urology; Cancer; Cisplatin; Pathology","score_opus":0.0932844738764972,"score_gpt":0.4219737349109923,"score_spread":0.32868926103449514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98103106,0.0018801544,0.00003821049,0.0055747824,0.0026224724,0.0049662236,0.000050468738,0.000030145948,0.0038064553],"genre_scores_gemma":[0.98746026,0.002759937,0.0022042391,0.0051105157,0.0013620056,0.0004389575,0.000047176884,0.000070670234,0.0005462692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898374,0.00247208,0.0043680104,0.00083481683,0.0015522353,0.0009354356],"domain_scores_gemma":[0.9819847,0.013511634,0.002505696,0.0006009262,0.0007980849,0.0005989995],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062529044,0.0006454502,0.004294356,0.0010942725,0.0001382591,0.000061421226,0.00069728104,0.00052240625,0.0003884405],"category_scores_gemma":[0.008665388,0.00034702112,0.0005004036,0.0030053498,0.00027318497,0.00030194208,0.00014974149,0.0024503046,0.000017158885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.69164646,0.004422713,0.025572298,0.00008460985,0.0008156914,0.0003745963,0.0010573715,0.0005845533,0.000054929227,0.0000056470176,0.00092812214,0.27445298],"study_design_scores_gemma":[0.655058,0.08982638,0.22252601,0.0026068822,0.0006725664,0.00005138942,0.0006271589,0.00007897993,0.00008086548,0.00004890269,0.02788865,0.00053419004],"about_ca_topic_score_codex":0.0006992954,"about_ca_topic_score_gemma":0.003371678,"teacher_disagreement_score":0.2739188,"about_ca_system_score_codex":0.0046030832,"about_ca_system_score_gemma":0.0065043024,"threshold_uncertainty_score":0.9998982},"labels":[],"label_agreement":null},{"id":"W4410815601","doi":"10.1200/jco.2025.43.16_suppl.e12629","title":"Comparative effectiveness and safety of neoadjuvant chemotherapy in combination with pembrolizumab for triple negative breast cancer: A real-world analysis from Alberta, Canada.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Triple negative; Immunotherapy","score_opus":0.02090193623467238,"score_gpt":0.3887212795047319,"score_spread":0.3678193432700595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513197,0.00037745165,0.000642631,0.0028801146,0.0001755518,0.00030913376,0.0001476112,7.2478e-7,0.00033481373],"genre_scores_gemma":[0.9982903,0.00082988106,0.00045335316,0.00024597195,0.000072253286,0.00002974806,0.000019564945,0.0000054617526,0.000053439293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983996,0.00034172708,0.0008252658,0.00021137742,0.00010168891,0.00012034772],"domain_scores_gemma":[0.9967054,0.0018354823,0.0008802419,0.00010159276,0.00041873072,0.00005851793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045602943,0.0001293217,0.0013237759,0.00011019506,0.000035002657,0.0000032380628,0.00009648808,0.0001119427,0.0000065054764],"category_scores_gemma":[0.00014465112,0.00009392955,0.00015427243,0.0003000347,0.00016449185,0.0000064153473,0.000028564338,0.00013914745,1.8003304e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069680996,0.0009075795,0.88580745,0.000032019027,0.008458697,0.0000071877002,0.00021427618,0.0006312513,0.00031575953,0.00013221492,0.00055853574,0.033254012],"study_design_scores_gemma":[0.021109624,0.0013297617,0.97327274,0.00008354627,0.0007804281,0.0000026744103,0.0001492226,0.0001442651,0.0018432604,0.00018276474,0.001021524,0.00008017964],"about_ca_topic_score_codex":0.3390757,"about_ca_topic_score_gemma":0.9268992,"teacher_disagreement_score":0.5878235,"about_ca_system_score_codex":0.00023546233,"about_ca_system_score_gemma":0.0020627552,"threshold_uncertainty_score":0.66532546},"labels":[],"label_agreement":null},{"id":"W4410815607","doi":"10.1200/jco.2025.43.16_suppl.e16418","title":"National trends in prevalence of pancreatic cancer in adults aged 70 and older: A global burden of disease analysis (1990–2021).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pancreatic cancer; Disease; Cancer; Gerontology; Demography; Environmental health; Internal medicine","score_opus":0.06283504543579546,"score_gpt":0.5052998090548824,"score_spread":0.44246476361908693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98941624,0.0027684537,0.00004142784,0.0051866933,0.000105570725,0.00015495275,0.000041143623,0.0000012681899,0.002284262],"genre_scores_gemma":[0.99331236,0.005225013,0.000611039,0.00017483786,0.00012577663,0.000011053548,0.0000030345523,0.0000030286337,0.0005338789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960826,0.0006880123,0.00236243,0.00020378928,0.00047212336,0.00019105512],"domain_scores_gemma":[0.9956019,0.0025762846,0.00096923567,0.00014170105,0.00048031207,0.00023055088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033976464,0.000103373735,0.0020302187,0.0007411526,0.000012712481,0.0000020191417,0.00015521364,0.00024844846,0.00045897719],"category_scores_gemma":[0.005367765,0.000078368,0.00033051538,0.0012748473,0.0004072631,0.000058010755,0.00006608602,0.0005134504,5.191513e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008882581,0.0012061337,0.9497872,0.00040190975,0.0010526377,0.0001670785,0.00016454076,0.00013285948,0.000015386357,0.00012560173,0.00032112483,0.03774293],"study_design_scores_gemma":[0.009615067,0.0016878451,0.9808355,0.0009600166,0.0022364254,0.0000072820267,0.000118424716,0.0038673575,0.000002406875,0.0005520162,0.00007055498,0.000047120906],"about_ca_topic_score_codex":0.0006210073,"about_ca_topic_score_gemma":0.001192958,"teacher_disagreement_score":0.03769581,"about_ca_system_score_codex":0.00029737505,"about_ca_system_score_gemma":0.0034900296,"threshold_uncertainty_score":0.64261043},"labels":[],"label_agreement":null},{"id":"W4410815619","doi":"10.1200/jco.2025.43.16_suppl.e16393","title":"Efficacy and safety of FOLFIRINOX versus gemcitabine-based regimens for treatment of metastatic pancreatic cancer: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Oncology; Pancreatic cancer; Internal medicine; Meta-analysis; Cancer; Irinotecan; Colorectal cancer","score_opus":0.44160762117004854,"score_gpt":0.5942882688305274,"score_spread":0.1526806476604789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815619","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007704222,0.9915628,0.00021086913,0.0014855146,0.000115121846,0.006165645,0.00019955784,0.0000037570421,0.0001797321],"genre_scores_gemma":[0.00008287395,0.9929279,0.0053688316,0.00022579062,0.000068817375,0.00051885913,0.000028152877,0.000023845127,0.0007548962],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98741376,0.0029401882,0.008457149,0.0004143672,0.00046578195,0.00030874345],"domain_scores_gemma":[0.9368833,0.052673057,0.008511814,0.0005982133,0.00093601225,0.00039766144],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.007054176,0.0004898023,0.050036397,0.0006320054,0.000042451924,0.0000050444532,0.00023310896,0.000493803,0.00012568475],"category_scores_gemma":[0.014033248,0.00025678414,0.006051842,0.0006449121,0.0005118595,0.000033003893,0.000053845008,0.00040861082,7.885568e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027180267,0.0012157406,0.00005297171,0.5924739,0.37903124,0.00006486873,0.00001530011,9.3190556e-7,4.6964693e-8,0.00006330471,0.00016943463,0.024194174],"study_design_scores_gemma":[0.012628818,0.01782172,0.000064711305,0.04645385,0.8932769,0.00007050617,0.0000142475155,0.000023936378,2.5616467e-7,0.000016841319,0.02949949,0.00012873727],"about_ca_topic_score_codex":0.00004852026,"about_ca_topic_score_gemma":0.00004672042,"teacher_disagreement_score":0.5460201,"about_ca_system_score_codex":0.00033139085,"about_ca_system_score_gemma":0.007167472,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W4410815665","doi":"10.1200/jco.2025.43.16_suppl.tps5618","title":"TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Open label; Surgery; Randomized controlled trial","score_opus":0.2634010053599993,"score_gpt":0.5589005241347339,"score_spread":0.2954995187747346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97652674,0.0030007293,0.0004390156,0.0054101725,0.0021262222,0.011419035,0.00014243796,0.000021963771,0.0009137159],"genre_scores_gemma":[0.98729074,0.003169213,0.0021776748,0.0023113668,0.0012270261,0.0017134118,0.000023917879,0.000055299406,0.0020313356],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99155533,0.0017298706,0.0049979985,0.00065267034,0.0005131965,0.0005509535],"domain_scores_gemma":[0.9814797,0.013342249,0.003411341,0.00046945948,0.00073301955,0.0005641988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019239219,0.0006323001,0.010285449,0.00040049115,0.00013605984,0.00004455602,0.00045449578,0.00025203294,0.00075549475],"category_scores_gemma":[0.0022077302,0.00034460626,0.0017048531,0.00047817008,0.00024421662,0.0001853201,0.00008311447,0.0004912208,0.000008860229],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5760512,0.07555751,0.0008144164,0.00007262421,0.014229627,0.00013007871,0.00031473412,0.000016492666,0.000099351026,0.000037359765,0.00013536561,0.3325413],"study_design_scores_gemma":[0.7642902,0.20260347,0.0012619864,0.00027084476,0.010522559,0.000013107832,0.0003561786,0.0014959292,0.0009378755,0.00019529815,0.017857216,0.00019530578],"about_ca_topic_score_codex":0.0009238458,"about_ca_topic_score_gemma":0.002798464,"teacher_disagreement_score":0.332346,"about_ca_system_score_codex":0.0021748259,"about_ca_system_score_gemma":0.0030737612,"threshold_uncertainty_score":0.9999006},"labels":[],"label_agreement":null},{"id":"W4410815755","doi":"10.1200/jco.2025.43.16_suppl.tps4232","title":"Adaptive organoid-based precision therapy study in pancreatic cancer (ADOPT): A phase II single-arm study to evaluate the efficacy of patient-derived organoid (PDO)-directed therapy in advanced pancreatic ductal adenocarcinoma (PDAC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Organoid; Medicine; Pancreatic ductal adenocarcinoma; Pancreatic cancer; Adenocarcinoma; Cancer; Oncology; Internal medicine; Biology; Neuroscience","score_opus":0.1307334483635377,"score_gpt":0.49423355905216265,"score_spread":0.363500110688625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866082,0.0026253439,0.000056724777,0.0028444438,0.00060533854,0.0070495633,0.0000070081483,0.000024604295,0.00017879222],"genre_scores_gemma":[0.9958317,0.0009790463,0.0014250649,0.001161349,0.00020069549,0.00027473643,0.0000031599286,0.000047754816,0.00007646583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872236,0.005517673,0.0047550118,0.0006727831,0.0011706515,0.00066025957],"domain_scores_gemma":[0.98391664,0.0118956,0.0015693736,0.00074536103,0.0014881882,0.00038482537],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071171876,0.00047185487,0.0042705247,0.0009150149,0.00015389339,0.00001578422,0.00064368115,0.0003594688,0.00038296118],"category_scores_gemma":[0.011291825,0.00028595398,0.00040765994,0.0020299524,0.00041620628,0.00012635157,0.00019806714,0.0017290544,0.00000558744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11202496,0.09694159,0.68425846,0.000020323272,0.0013717299,0.00066804636,0.0073879827,0.00017600377,0.009542707,0.0000021451774,0.00010932938,0.0874967],"study_design_scores_gemma":[0.090418465,0.21403575,0.68593824,0.00043283458,0.0006971468,0.000020684025,0.0062637865,0.00063173036,0.0012506038,0.00006375185,0.00007762132,0.00016936264],"about_ca_topic_score_codex":0.00051948905,"about_ca_topic_score_gemma":0.0010097563,"teacher_disagreement_score":0.11709416,"about_ca_system_score_codex":0.00089467823,"about_ca_system_score_gemma":0.0062774783,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W4410815810","doi":"10.1200/jco.2025.43.16_suppl.e15169","title":"Patient-derived xenografts (PDX) versus patient-derived organoids (PDO) as predictors of clinical response to anti-cancer therapies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; University of Windsor; McGill University","funders":"","keywords":"Medicine; Organoid; Cancer; Internal medicine; Oncology; Cancer research; Biology; Genetics","score_opus":0.09359356301173595,"score_gpt":0.4728419235203854,"score_spread":0.37924836050864946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693646,0.001613254,0.00012840852,0.01346279,0.013734159,0.000592564,0.00003732677,0.000023086914,0.0010438007],"genre_scores_gemma":[0.98324066,0.004729968,0.0037113868,0.0067036347,0.0013465794,0.000016289765,0.000004117657,0.000040948056,0.00020641944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99079823,0.0017246738,0.005766235,0.00047177804,0.00076052727,0.00047854072],"domain_scores_gemma":[0.9880223,0.006022246,0.0031617924,0.00054827635,0.0013670058,0.0008783415],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043166988,0.00031768045,0.003290605,0.00040183248,0.0000767488,0.000014636836,0.00033857828,0.0007269679,0.0008397316],"category_scores_gemma":[0.014466461,0.00023523028,0.0013563771,0.00062642613,0.000597959,0.00012047314,0.00022036083,0.0014449621,0.000026419932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23480733,0.005060627,0.06816004,0.00009476519,0.0040933406,0.00040670883,0.0011921339,0.00003073955,0.075907685,0.000045193196,0.024819123,0.58538234],"study_design_scores_gemma":[0.03569995,0.069909185,0.21146175,0.00049773726,0.0017816008,0.000038016886,0.0014677063,0.000006868217,0.03598194,0.00007682831,0.6427808,0.00029763678],"about_ca_topic_score_codex":0.00007735826,"about_ca_topic_score_gemma":0.000056349287,"teacher_disagreement_score":0.61796165,"about_ca_system_score_codex":0.00024345424,"about_ca_system_score_gemma":0.0058476278,"threshold_uncertainty_score":0.9997883},"labels":[],"label_agreement":null},{"id":"W4410815858","doi":"10.1200/jco.2025.43.16_suppl.tps8115","title":"KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Lung cancer; Stage (stratigraphy); Phases of clinical research; Oncology; non-small cell lung cancer (NSCLC); Cancer; Internal medicine; Surgery; Immunotherapy","score_opus":0.10847958062044266,"score_gpt":0.5293499109900792,"score_spread":0.42087033036963656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676145,0.0006227932,0.004670602,0.003368806,0.00038606435,0.0022923362,0.00003878787,0.000011842339,0.0018473448],"genre_scores_gemma":[0.97130924,0.0003788462,0.015414378,0.0019625642,0.00042144643,0.00017262954,0.000011705745,0.00004232466,0.010286867],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970255,0.00015210312,0.0017317879,0.00033663952,0.00044475184,0.0003092225],"domain_scores_gemma":[0.9957792,0.00088283204,0.0017288416,0.0002588493,0.0010346489,0.00031561495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010695076,0.00024671532,0.0016892677,0.00021193695,0.00015028166,0.000016828713,0.00018811214,0.00020325903,0.00018776333],"category_scores_gemma":[0.00029003626,0.00014155707,0.0002353739,0.00037713413,0.0002085036,0.00011391247,0.000034591518,0.00056055025,4.4935408e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29438132,0.031137703,0.6118727,0.0012780986,0.013812014,0.0007601009,0.0069372025,0.005434817,0.0007919698,0.00008068201,0.010061155,0.023452261],"study_design_scores_gemma":[0.6435116,0.2011716,0.06028955,0.0035065534,0.014183204,0.00019841535,0.005562705,0.0265873,0.00199132,0.00013653607,0.042248156,0.0006130778],"about_ca_topic_score_codex":0.0002136369,"about_ca_topic_score_gemma":0.000627303,"teacher_disagreement_score":0.5515831,"about_ca_system_score_codex":0.00049959007,"about_ca_system_score_gemma":0.014006177,"threshold_uncertainty_score":0.99158347},"labels":[],"label_agreement":null},{"id":"W4410815972","doi":"10.1200/jco.2025.43.16_suppl.tps4224","title":"Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Queen's University; Ottawa Hospital","funders":"Canadian Institutes of Health Research; Tour de Cure","keywords":"Radionuclide therapy; Peptide receptor; Somatostatin; Medicine; Somatostatin receptor; Internal medicine; Neuroendocrine tumors; Gastroenterology; Oncology; Receptor; Endocrinology","score_opus":0.0907963499686057,"score_gpt":0.4666050026430885,"score_spread":0.3758086526744828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270236,0.0007812503,0.000067417546,0.0040981052,0.00038649433,0.0018141133,0.0000092324035,0.000010011268,0.00013100875],"genre_scores_gemma":[0.9931682,0.0022993165,0.0037684059,0.0002649724,0.00024933112,0.000060946553,0.0000050547283,0.000023932987,0.00015983985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98534495,0.006901571,0.006293393,0.00036893328,0.0006852999,0.00040585038],"domain_scores_gemma":[0.9777766,0.017347053,0.0037584114,0.00028074434,0.00052655314,0.0003106547],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00758626,0.00028578402,0.0053908275,0.0008198385,0.000028324643,0.00001605568,0.00025445677,0.000039741833,0.00011657495],"category_scores_gemma":[0.036037844,0.0001955414,0.00058161636,0.0004578559,0.0006587283,0.00022686436,0.00008629366,0.0012015916,0.0000010344087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3710927,0.005092895,0.6016368,0.00019327084,0.0005320687,0.003622617,0.00022557021,0.000024196033,0.004031723,0.000035124012,0.00053751294,0.012975485],"study_design_scores_gemma":[0.3325612,0.030876813,0.6298337,0.0007610181,0.0006591595,0.0012380156,0.0016280992,0.00008551008,0.0011096346,0.0005735364,0.0005483491,0.000124992],"about_ca_topic_score_codex":0.00016999937,"about_ca_topic_score_gemma":0.00026105743,"teacher_disagreement_score":0.038531516,"about_ca_system_score_codex":0.000094027644,"about_ca_system_score_gemma":0.00071294716,"threshold_uncertainty_score":0.972082},"labels":[],"label_agreement":null},{"id":"W4410816026","doi":"10.1200/jco.2025.43.16_suppl.5600","title":"Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Quality of life (healthcare); Chemotherapy; Internal medicine; Oncology; Cancer; Gynecology; Nursing","score_opus":0.09580631164793793,"score_gpt":0.4561011069818735,"score_spread":0.3602947953339356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917861,0.00021767248,0.00003104485,0.0042031114,0.00051557616,0.0028451623,0.000027564858,0.000007410058,0.00036633297],"genre_scores_gemma":[0.9917325,0.0007749045,0.0010453982,0.005417879,0.0004865227,0.00020141627,0.000019437053,0.000022015023,0.00029996363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939854,0.0009817801,0.0035216487,0.0003675815,0.0008116221,0.00033193117],"domain_scores_gemma":[0.9927205,0.0040375325,0.002124317,0.00030048445,0.0005611103,0.0002560416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034194742,0.00027926918,0.0026532444,0.00049214065,0.00003419819,0.0000143741745,0.00027017604,0.00027023192,0.00031110054],"category_scores_gemma":[0.0048083807,0.00012535435,0.00026103656,0.0017089789,0.0001371764,0.00014132525,0.000046525445,0.0006995096,0.0000034865366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65295553,0.0055999802,0.024903312,0.00007379576,0.0004043504,0.000040562187,0.00017643145,0.000024799969,0.00012580618,0.0000017597478,0.00015568262,0.315538],"study_design_scores_gemma":[0.52588403,0.15670432,0.3112177,0.000484509,0.00035286933,0.0000028684542,0.00017138265,0.0000125812085,0.00019567733,0.000015414756,0.004799142,0.00015947738],"about_ca_topic_score_codex":0.0003651698,"about_ca_topic_score_gemma":0.0014864512,"teacher_disagreement_score":0.31537852,"about_ca_system_score_codex":0.0013706874,"about_ca_system_score_gemma":0.0041303616,"threshold_uncertainty_score":0.7327084},"labels":[],"label_agreement":null},{"id":"W4410816094","doi":"10.1200/jco.2025.43.16_suppl.12070","title":"Efficacy of Chinese medicine compound Fufang E’jiao Syrupfor symptom burden of cancer-related fatigue in patients with advanced cancer: A randomized clinical trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Healthcare and Venom Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer-related fatigue; Cancer; Randomized controlled trial; Traditional Chinese medicine; Internal medicine; Clinical trial; Alternative medicine; Pathology","score_opus":0.13472864820050143,"score_gpt":0.5850131761864459,"score_spread":0.4502845279859444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97669107,0.0027310776,0.000043256485,0.015525272,0.0018274192,0.002259901,0.00000852998,0.000008752888,0.0009047182],"genre_scores_gemma":[0.9917424,0.0061471243,0.0005531287,0.0005999501,0.0007305762,0.00003815934,0.000009330281,0.000020369012,0.00015901888],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98663443,0.0030633626,0.008763844,0.00032384356,0.0008319146,0.0003825952],"domain_scores_gemma":[0.96688044,0.0262509,0.00424051,0.00035209805,0.0018130861,0.00046295658],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015347494,0.000234899,0.006801231,0.0005236812,0.00003324884,0.0000028275745,0.0003478357,0.00063233904,0.00017148867],"category_scores_gemma":[0.028873136,0.00013168779,0.0007299905,0.0008261548,0.00096317835,0.00008528124,0.00007954847,0.0020200687,9.72379e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5776302,0.0031163455,0.29247698,0.00022998611,0.0012401785,0.00005978248,0.0002485068,0.000083544975,0.000008167924,0.000038054546,0.00023764439,0.12463056],"study_design_scores_gemma":[0.6470796,0.021174876,0.326879,0.0020259954,0.00057650974,0.0000033902588,0.00006581496,0.00027298531,0.000004207351,0.0001395464,0.0017049084,0.00007316783],"about_ca_topic_score_codex":0.00166678,"about_ca_topic_score_gemma":0.0004096445,"teacher_disagreement_score":0.1245574,"about_ca_system_score_codex":0.00030062944,"about_ca_system_score_gemma":0.0069524073,"threshold_uncertainty_score":0.99867725},"labels":[],"label_agreement":null},{"id":"W4410816202","doi":"10.1200/jco.2025.43.16_suppl.tps4214","title":"PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Atezolizumab; Placebo; Bevacizumab; Internal medicine; Peroxisome proliferator-activated receptor; Pharmacology; Receptor; Oncology; Urology; Cancer; Chemotherapy; Pathology; Immunotherapy","score_opus":0.03455723363610489,"score_gpt":0.3538965569478587,"score_spread":0.3193393233117538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500174,0.00053085136,0.00041227418,0.00015321802,0.00023765917,0.013581503,0.000034548837,0.000020534502,0.000027697277],"genre_scores_gemma":[0.9959771,0.0004367287,0.0009062118,0.00016610727,0.00012892504,0.002049409,0.00007336005,0.00009875703,0.00016339814],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9906061,0.0031667387,0.003978318,0.0008450141,0.0007505343,0.0006532829],"domain_scores_gemma":[0.99139863,0.0013456193,0.0040809284,0.0005203127,0.0023451361,0.0003093992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037853348,0.00070987997,0.0048335115,0.0005415428,0.0001356013,0.00006184896,0.00052154186,0.0005675481,0.000019900437],"category_scores_gemma":[0.002683455,0.00039331638,0.0004621204,0.00080682983,0.00035487217,0.00007498254,0.00008731701,0.000815037,9.2998425e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83936465,0.019787252,0.095381595,0.00024352904,0.0039016588,0.000082842715,0.00040614392,0.00013977806,0.037481323,0.000006509988,0.00009949466,0.0031052206],"study_design_scores_gemma":[0.7528565,0.13675605,0.00046629956,0.0006038599,0.0009010639,0.00007280797,0.0006666509,0.0006745195,0.106322296,0.0000068848376,0.00024544916,0.0004276177],"about_ca_topic_score_codex":0.000083657986,"about_ca_topic_score_gemma":0.00012221237,"teacher_disagreement_score":0.1169688,"about_ca_system_score_codex":0.00041633402,"about_ca_system_score_gemma":0.0037967288,"threshold_uncertainty_score":0.9998519},"labels":[],"label_agreement":null},{"id":"W4410816315","doi":"10.1200/jco.2025.43.16_suppl.e22000","title":"Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); BC Children's Hospital","funders":"Pfizer","keywords":"Medicine; Lymphoblastic Leukemia; Hematopoietic stem cell transplantation; Hematopoietic cell; Transplantation; Oncology; Acute lymphocytic leukemia; Leukemia; Internal medicine; Haematopoiesis; Stem cell","score_opus":0.013559502367016852,"score_gpt":0.31771968318982646,"score_spread":0.3041601808228096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979567,0.00014721333,0.00088296045,0.00016974552,0.00048748354,0.00014316154,0.000013556545,0.000002352393,0.00019680888],"genre_scores_gemma":[0.997648,0.00058479357,0.0007098749,0.0007501099,0.0000889755,0.0000037975426,0.000006362291,0.000013554341,0.00019455786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984934,0.00012440245,0.0008885397,0.00019991674,0.00013289989,0.00016084984],"domain_scores_gemma":[0.9990021,0.00012148304,0.0005533361,0.000111487396,0.00012564844,0.00008595246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034820486,0.0001366385,0.0005703554,0.00012268052,0.000030771807,0.000010276197,0.00012292105,0.0003107793,0.0000073418255],"category_scores_gemma":[0.000058032696,0.000101141806,0.00011833206,0.000105704254,0.00007142542,0.000008868669,0.000025858986,0.0002463355,7.932754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005315415,0.0007963858,0.97356147,0.00014777931,0.00049446407,0.00018874978,0.00024700738,0.00028943195,0.002062873,0.0001440592,0.00010452095,0.016647846],"study_design_scores_gemma":[0.012912598,0.007660981,0.97526306,0.000065083186,0.00047966937,0.00014649086,0.000059738166,0.000034764984,0.0010571922,0.0006609555,0.0014936513,0.00016581365],"about_ca_topic_score_codex":0.000012279358,"about_ca_topic_score_gemma":0.00015669805,"teacher_disagreement_score":0.016482033,"about_ca_system_score_codex":0.000105116356,"about_ca_system_score_gemma":0.0007719635,"threshold_uncertainty_score":0.41244432},"labels":[],"label_agreement":null},{"id":"W4410816340","doi":"10.1200/jco.2025.43.16_suppl.tps4619","title":"A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Urothelial cancer; Medicine; Conjugate; Cancer; Cancer research; Oncology; Internal medicine; Bladder cancer","score_opus":0.05154748193170067,"score_gpt":0.46630086190079534,"score_spread":0.41475337996909467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967976,0.00004549321,0.00037052744,0.0016847955,0.00017924243,0.0005048574,0.000009190941,0.000008584488,0.0003996801],"genre_scores_gemma":[0.99618065,0.000050793322,0.0019350225,0.0014008648,0.00012569371,0.00002220299,0.000002587168,0.000017387054,0.00026479916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949752,0.0009620336,0.0030905132,0.00026719004,0.00044806124,0.00025696508],"domain_scores_gemma":[0.99419576,0.0026359216,0.0019831073,0.00016586401,0.0007922078,0.00022714122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025044337,0.00019165546,0.0019730013,0.00041575724,0.00004360745,0.000009245569,0.0001416202,0.00013519752,0.0002810138],"category_scores_gemma":[0.0070814798,0.000121320445,0.00028143075,0.00065320526,0.00015573662,0.00011914652,0.00004787807,0.00088537607,0.0000027124045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11213341,0.06688946,0.6340653,0.00023141784,0.0027605095,0.0017788056,0.00078137417,0.0013497411,0.0034010683,0.000027919923,0.00095797144,0.17562306],"study_design_scores_gemma":[0.3144816,0.0995468,0.5647898,0.0032442727,0.002914328,0.00006178579,0.0056962254,0.0013038066,0.004442761,0.00014737433,0.0029204737,0.00045080646],"about_ca_topic_score_codex":0.00010892944,"about_ca_topic_score_gemma":0.0007825594,"teacher_disagreement_score":0.20234819,"about_ca_system_score_codex":0.00016514419,"about_ca_system_score_gemma":0.0023661668,"threshold_uncertainty_score":0.8477704},"labels":[],"label_agreement":null},{"id":"W4410816421","doi":"10.1200/jco.2025.43.16_suppl.4051","title":"Improving evidence-based treatment selection and patient-centered care in upper GI cancers: A Project ECHO initiative.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Echo (communications protocol); Selection (genetic algorithm); Oncology; Internal medicine","score_opus":0.22591726278325422,"score_gpt":0.524612045071617,"score_spread":0.29869478228836277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899239,0.0032878593,0.00015748393,0.00404193,0.00034682715,0.00061276846,0.000002486157,0.000006675923,0.0016200823],"genre_scores_gemma":[0.99263704,0.002064626,0.0031813297,0.0017958442,0.00019055192,0.000035176963,0.0000014630814,0.0000072493176,0.00008672056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971352,0.0007971669,0.0014057071,0.00021426831,0.00020592015,0.00024169161],"domain_scores_gemma":[0.9956622,0.0029266381,0.0006551118,0.00010215214,0.00050345843,0.0001504334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011681145,0.00012465673,0.0012620998,0.000384507,0.000049241655,0.0000096152935,0.000065879125,0.00032705304,0.000039499126],"category_scores_gemma":[0.004904524,0.00008431194,0.00019473919,0.00027303476,0.00015673225,0.00012295188,0.00003117782,0.0006715581,0.0000016206443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010002105,0.00067333365,0.6484457,0.0000888191,0.00020397636,0.00021152323,0.0006477221,0.000005339179,0.000118983226,0.000010576119,0.00028898026,0.33930293],"study_design_scores_gemma":[0.040423036,0.11995997,0.8013331,0.003072512,0.0012934195,0.00018525538,0.0060059386,0.0057685385,0.0008280866,0.00014047815,0.020789089,0.00020052008],"about_ca_topic_score_codex":0.00048110815,"about_ca_topic_score_gemma":0.0010491883,"teacher_disagreement_score":0.33910242,"about_ca_system_score_codex":0.0017951874,"about_ca_system_score_gemma":0.013543884,"threshold_uncertainty_score":0.9920484},"labels":[],"label_agreement":null},{"id":"W4410816426","doi":"10.1200/jco.2025.43.16_suppl.5608","title":"Post-hoc analysis evaluating selinexor maintenance therapy in patients with <i>TP53</i> wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Endometrial cancer; Oncology; Post-hoc analysis; Internal medicine; Overall survival; Post hoc; Progression-free survival; Cancer; Gynecology","score_opus":0.1492335963628104,"score_gpt":0.5535122013311622,"score_spread":0.4042786049683518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713523,0.0016221728,0.000015293206,0.007788005,0.001269621,0.0018686763,0.00004527664,0.0000092053215,0.00024653826],"genre_scores_gemma":[0.9944974,0.0029780683,0.00035475678,0.0013033202,0.0005390351,0.00007499227,0.000025995716,0.000020512312,0.00020589943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98889947,0.004395522,0.0039693634,0.00052825,0.0016214825,0.000585928],"domain_scores_gemma":[0.9825632,0.013373778,0.0018130431,0.0005734731,0.001382472,0.00029403792],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018975146,0.00030323796,0.0027491238,0.0007391613,0.000098204844,0.0000371506,0.00077606254,0.0003870375,0.00008576872],"category_scores_gemma":[0.013508029,0.00014036313,0.00073454436,0.0024231945,0.00037193878,0.0001512925,0.00014810568,0.0025022377,0.0000015035812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05556649,0.009549199,0.7673274,0.000010671596,0.0018948222,0.00017117472,0.00036333618,0.000018102304,0.000007911936,0.0000033404938,0.0011103322,0.16397722],"study_design_scores_gemma":[0.09068045,0.059035722,0.8444037,0.00016046302,0.00092233456,0.0000019336446,0.001310292,0.00006972047,0.000012395498,0.000035543453,0.003244008,0.00012346232],"about_ca_topic_score_codex":0.00031150595,"about_ca_topic_score_gemma":0.0012514696,"teacher_disagreement_score":0.16385375,"about_ca_system_score_codex":0.0004685091,"about_ca_system_score_gemma":0.0034208086,"threshold_uncertainty_score":0.999799},"labels":[],"label_agreement":null},{"id":"W4410816452","doi":"10.1200/jco.2025.43.16_suppl.4008","title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Cisplatin; Chemotherapy; Biliary tract; Resection; Surgery; Adjuvant chemotherapy; Adjuvant therapy; Biliary tract cancer; Adjuvant; Hepatectomy; Cancer; Oncology; Internal medicine","score_opus":0.09903066810933142,"score_gpt":0.42324589824964337,"score_spread":0.32421523014031195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.939699,0.017034639,0.0002215811,0.03648901,0.0044683497,0.0013704954,0.000072222116,0.00003079308,0.00061393005],"genre_scores_gemma":[0.9575075,0.034084447,0.00040090535,0.0035933724,0.0035690733,0.000076795186,0.0000612174,0.000045968707,0.0006607504],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99292713,0.0013001187,0.0033867217,0.00074955774,0.0010149593,0.00062150316],"domain_scores_gemma":[0.9888296,0.008069633,0.0017335364,0.00051337207,0.00043554182,0.00041827705],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004629144,0.000465726,0.0026716886,0.0002977887,0.00022398809,0.00003746881,0.00041987927,0.00080577424,0.00016708212],"category_scores_gemma":[0.0029789144,0.0002804542,0.0008387724,0.00073422655,0.00075832265,0.00022754952,0.00008320836,0.0029970675,0.0000057245047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7484167,0.0038097864,0.0070950924,0.000018193894,0.0015033098,0.0016608727,0.0008648662,0.00002635471,0.0007937817,0.000005346667,0.08030956,0.15549609],"study_design_scores_gemma":[0.7143324,0.055779155,0.15206937,0.000569461,0.00092431955,0.00011163368,0.00043734632,0.0014687756,0.00062909315,0.00005375575,0.073286735,0.00033797324],"about_ca_topic_score_codex":0.0030467103,"about_ca_topic_score_gemma":0.0032511721,"teacher_disagreement_score":0.15515812,"about_ca_system_score_codex":0.0010148161,"about_ca_system_score_gemma":0.0032112966,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W4410816674","doi":"10.1200/jco.2025.43.16_suppl.4181","title":"Multimodal machine learning predictions of treatment response and survival in advanced pancreatic cancer from the COMPASS trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research; Université de Montréal; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Pancreatic cancer; Compass; Oncology; Cancer; Internal medicine; Artificial intelligence; Cartography","score_opus":0.06053923847275409,"score_gpt":0.4690654250365223,"score_spread":0.4085261865637682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96849996,0.0019286176,0.0005861932,0.027308596,0.0011064274,0.0002514293,0.0000062686404,0.0000057828847,0.00030674034],"genre_scores_gemma":[0.99341345,0.0033719977,0.0018812692,0.0006370435,0.0003550144,0.000009950782,0.0000026359435,0.000007947542,0.00032071676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645454,0.0015428561,0.001557112,0.00014190473,0.0001688062,0.00013475637],"domain_scores_gemma":[0.985518,0.013298538,0.000804809,0.0001242345,0.000121033634,0.00013338149],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003915614,0.00010190474,0.0012531648,0.00010599165,0.00005185574,0.000005600915,0.0000983667,0.00014375811,0.00004407592],"category_scores_gemma":[0.012588865,0.000057714806,0.00021090271,0.00014458479,0.0002489774,0.000035899782,0.000036690228,0.0011418692,3.7559735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13763264,0.0009744664,0.6800801,0.000013472393,0.0005244491,0.00008745856,0.0002929388,0.0023631277,0.00047897684,0.000037357084,0.00017817669,0.17733683],"study_design_scores_gemma":[0.09313082,0.008901794,0.82005876,0.00034729455,0.00057701493,0.00001756095,0.0002771175,0.040661935,0.000013609238,0.0001328108,0.03583298,0.000048320147],"about_ca_topic_score_codex":0.0010966056,"about_ca_topic_score_gemma":0.00025955125,"teacher_disagreement_score":0.1772885,"about_ca_system_score_codex":0.00020354685,"about_ca_system_score_gemma":0.0012637216,"threshold_uncertainty_score":0.9957285},"labels":[],"label_agreement":null},{"id":"W4410816732","doi":"10.1200/jco.2025.43.16_suppl.9018","title":"Competencies for practicing medical oncology with common sense: A global curricula review.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Queen's University","funders":"","keywords":"Medicine; Curriculum; Medical education; Oncology; Internal medicine","score_opus":0.08394589813634093,"score_gpt":0.6006427471271603,"score_spread":0.5166968489908194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816732","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.110253096,0.07554746,0.07090897,0.6396097,0.012298114,0.0025329688,0.000017256689,0.00008534802,0.08874708],"genre_scores_gemma":[0.14940311,0.14029768,0.27482027,0.4249959,0.008160773,0.00008032348,0.00001892905,0.000056543216,0.002166456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99534565,0.00090694963,0.0027197108,0.00025011442,0.00044824064,0.00032934058],"domain_scores_gemma":[0.98351806,0.012513993,0.0024089022,0.00025127112,0.00088392023,0.00042382695],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066368654,0.00019213003,0.002960231,0.000082489416,0.00010397919,0.0000038978333,0.00023622645,0.00081779907,0.00014473332],"category_scores_gemma":[0.015381882,0.000113942195,0.0005269294,0.0003095952,0.0009715339,0.00011096226,0.00005439361,0.0016133558,0.000005112667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015579636,0.0038001132,0.06929122,0.00067295955,0.0014365038,0.0047315597,0.00004316044,0.000017592714,0.000016449458,0.005921204,0.16017342,0.7383162],"study_design_scores_gemma":[0.012903712,0.026230544,0.012106073,0.0028070472,0.0012044127,0.0105025405,0.0001518199,0.00021914695,0.0000065495233,0.0014581521,0.9322974,0.00011256836],"about_ca_topic_score_codex":0.0000060776847,"about_ca_topic_score_gemma":0.000108235334,"teacher_disagreement_score":0.772124,"about_ca_system_score_codex":0.0005875277,"about_ca_system_score_gemma":0.0074707256,"threshold_uncertainty_score":0.998156},"labels":[],"label_agreement":null},{"id":"W4410816765","doi":"10.1200/jco.2025.43.16_suppl.e16515","title":"Liquid-based kidney injury molecule-1 (KIM-1) as a diagnostic and prognostic indicator in renal cell carcinoma: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal cell carcinoma; Meta-analysis; Pathology; Kidney cancer; Oncology; Internal medicine; Kidney; Carcinoma; Acute kidney injury","score_opus":0.12507474088866435,"score_gpt":0.4597960338806852,"score_spread":0.3347212929920208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005953114,0.99129426,0.000013584672,0.002478153,0.0001214446,0.005073284,0.00006749117,0.000009645331,0.00034684574],"genre_scores_gemma":[0.0054542357,0.9856927,0.00058590877,0.0072329007,0.00011703887,0.0005638186,0.00005062452,0.00005173738,0.00025106358],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98325926,0.0054109446,0.009298021,0.0008210856,0.00075083185,0.00045985906],"domain_scores_gemma":[0.9682874,0.020881878,0.008176653,0.00080316473,0.00041734066,0.0014335326],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00770486,0.0008552573,0.032558423,0.0015707976,0.000042967094,0.000029265339,0.00040706538,0.0011426803,0.00015782773],"category_scores_gemma":[0.043892846,0.0004935075,0.0061485944,0.0012333908,0.0003163831,0.0000660697,0.00020721646,0.002483662,0.00002198895],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038206915,0.0018086048,0.0004568718,0.92526567,0.061602943,0.0072936206,0.000015196816,2.902826e-7,2.0662016e-7,0.000008720818,0.0013793408,0.0017864866],"study_design_scores_gemma":[0.0020116968,0.01193301,0.00031022183,0.06837645,0.9014801,0.00068682706,0.0000042048136,0.0000021453775,0.0000016890189,0.000009306142,0.0148804635,0.00030391014],"about_ca_topic_score_codex":0.000022055956,"about_ca_topic_score_gemma":0.00000776752,"teacher_disagreement_score":0.8568892,"about_ca_system_score_codex":0.00045120888,"about_ca_system_score_gemma":0.011080631,"threshold_uncertainty_score":0.99981767},"labels":[],"label_agreement":null},{"id":"W4410816859","doi":"10.1200/jco.2025.43.16_suppl.4006","title":"Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Paclitaxel; Nab-paclitaxel; Pancreatic ductal adenocarcinoma; Oncology; Internal medicine; Pancreatic cancer; Chemotherapy; Cancer","score_opus":0.08157372463904798,"score_gpt":0.4401021254919126,"score_spread":0.3585284008528646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057347,0.00087450194,0.00008248,0.0031331806,0.00034264853,0.0038279048,0.000028796549,0.000009379572,0.0011276464],"genre_scores_gemma":[0.99727994,0.00042155723,0.0015000041,0.0002380228,0.000119217926,0.00010996467,0.00007016838,0.000024535953,0.00023660927],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98815334,0.0051358365,0.0048400164,0.00047098618,0.00092071696,0.00047907824],"domain_scores_gemma":[0.96926236,0.026227213,0.0026576421,0.0005526313,0.0010347698,0.00026535403],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010624989,0.00033458884,0.0048598237,0.00045514174,0.00006919997,0.0000136750405,0.00037621058,0.00029520594,0.00007155642],"category_scores_gemma":[0.019943943,0.00017851432,0.00029561121,0.0008481441,0.00091217115,0.00017348038,0.00011428574,0.0015009203,0.0000052941364],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52222973,0.0154816415,0.4551961,0.000041833497,0.002034127,0.00090226304,0.0011620325,0.000018312405,0.0000018180294,0.00002649112,0.00033017353,0.0025754436],"study_design_scores_gemma":[0.4592815,0.07087337,0.46375856,0.00053091877,0.0033592838,0.00002305481,0.0013373038,0.000541033,0.0000031464745,0.00016164215,0.000044968714,0.00008522782],"about_ca_topic_score_codex":0.0011133748,"about_ca_topic_score_gemma":0.0010534283,"teacher_disagreement_score":0.06294826,"about_ca_system_score_codex":0.00042520405,"about_ca_system_score_gemma":0.0030613805,"threshold_uncertainty_score":0.98831147},"labels":[],"label_agreement":null},{"id":"W4410816902","doi":"10.1200/jco.2025.43.16_suppl.2045","title":"Association of plasma biomarkers with diagnostic molecular markers for potential diagnosis and prognosis of diffuse gliomas.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Glioma; Pathology; Oncology; Internal medicine; Cancer research","score_opus":0.027755848684536736,"score_gpt":0.3762756448780697,"score_spread":0.34851979619353296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983592,0.00084566924,0.00019410433,0.014070761,0.0003769194,0.0006727028,0.000020791042,0.000004416598,0.00022263902],"genre_scores_gemma":[0.99365246,0.0016010165,0.0042971624,0.00026290645,0.000075949254,0.000072665396,0.000004394091,0.000013252006,0.000020202233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972738,0.00023736132,0.0017725668,0.00018676203,0.00033834548,0.00019116855],"domain_scores_gemma":[0.9873948,0.009348044,0.0022031756,0.00012804844,0.0007422057,0.00018370352],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015925578,0.00014595993,0.0014207187,0.00029865952,0.000026954884,0.0000066455773,0.000087440276,0.00032612312,0.000017738214],"category_scores_gemma":[0.008398292,0.00010017977,0.00048925827,0.00026413958,0.0001742221,0.00005815235,0.00003869513,0.00020417784,2.6865155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058122957,0.0063279597,0.91979206,0.0002364692,0.0054110633,0.00028616565,0.000020915997,0.00001507036,0.0009211087,0.00014317197,0.005026351,0.056007363],"study_design_scores_gemma":[0.036636304,0.021325417,0.91199046,0.0008543368,0.007155531,0.000054530425,0.00012196335,0.00017949626,0.016776375,0.00026720017,0.0045234314,0.00011496084],"about_ca_topic_score_codex":0.0000201774,"about_ca_topic_score_gemma":0.000024746372,"teacher_disagreement_score":0.055892404,"about_ca_system_score_codex":0.00013284823,"about_ca_system_score_gemma":0.00054626534,"threshold_uncertainty_score":0.9999544},"labels":[],"label_agreement":null},{"id":"W4410816903","doi":"10.1200/jco.2025.43.16_suppl.4011","title":"NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Cancer Care Ontario; St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; FOLFIRINOX; Adenocarcinoma; Oncology; Internal medicine; Pancreatic ductal adenocarcinoma; Gemcitabine; Pancreatic cancer; Gastroenterology; Chemotherapy; Oxaliplatin; Cancer; Colorectal cancer","score_opus":0.10815440948929038,"score_gpt":0.516629167326244,"score_spread":0.4084747578369536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862192,0.0011259636,0.00013856628,0.003559519,0.00049012515,0.0018440705,0.000011211051,0.000010866418,0.0066004377],"genre_scores_gemma":[0.99161017,0.00034756964,0.00329948,0.0008495162,0.00035014504,0.00007806837,0.000003697823,0.00001994283,0.0034414397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933405,0.0011593613,0.0038040737,0.00045052485,0.0007098677,0.0005356765],"domain_scores_gemma":[0.9922804,0.00443654,0.0010854955,0.0004982621,0.0010251253,0.00067413814],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004373747,0.00026272726,0.003531126,0.00063116365,0.0001148085,0.000011063099,0.00042379068,0.0005217709,0.0003977145],"category_scores_gemma":[0.0135617405,0.00018809967,0.00036688632,0.0006129849,0.00027792004,0.00015509961,0.00035493847,0.0014920163,0.0000172199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06777629,0.025582789,0.8752308,0.00016850696,0.0010464882,0.0020735075,0.005070305,0.00008425227,0.0043445886,0.00019521212,0.002891741,0.015535555],"study_design_scores_gemma":[0.093184106,0.14224133,0.7478444,0.0016707394,0.0015234518,0.00017303367,0.0071060928,0.0023051724,0.0011143668,0.00071914383,0.0018988311,0.0002193392],"about_ca_topic_score_codex":0.0003800111,"about_ca_topic_score_gemma":0.0004207538,"teacher_disagreement_score":0.12738636,"about_ca_system_score_codex":0.0004159157,"about_ca_system_score_gemma":0.004455553,"threshold_uncertainty_score":0.99474746},"labels":[],"label_agreement":null},{"id":"W4410816943","doi":"10.1200/jco.2025.43.16_suppl.4610","title":"Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Urothelial cancer; Cancer; Bacillus (shape); Internal medicine; Oncology; Gynecology","score_opus":0.04503844893980579,"score_gpt":0.400640073618219,"score_spread":0.3556016246784132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869979,0.0006682278,0.000081018865,0.007919554,0.0017753394,0.0010406002,0.000061834464,0.000014921849,0.0014405816],"genre_scores_gemma":[0.9929302,0.0015494003,0.0010336826,0.0038506482,0.00024032862,0.000103664126,0.000027137708,0.00003823189,0.00022672446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936321,0.00082419073,0.0037428841,0.0006064061,0.0006621131,0.00053231133],"domain_scores_gemma":[0.99347717,0.0030490167,0.0022089414,0.00039431165,0.0005594352,0.00031111707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012965931,0.00040837622,0.0027218221,0.0007304672,0.000052549276,0.000020479072,0.00025354317,0.0006932494,0.00025426265],"category_scores_gemma":[0.0027557348,0.00029368736,0.0003643695,0.00078135484,0.0002698747,0.00025758264,0.0001055525,0.0020825737,0.000012315156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006528442,0.005129592,0.8916725,0.00003380124,0.0009598851,0.0033225338,0.00065353647,0.00020899341,0.00006368451,0.000026405025,0.00082857534,0.09057205],"study_design_scores_gemma":[0.0599442,0.00978685,0.924891,0.00074431644,0.0007573537,0.000027729315,0.0006582204,0.00010129539,0.00021653569,0.0012556079,0.001380606,0.00023629256],"about_ca_topic_score_codex":0.017262543,"about_ca_topic_score_gemma":0.033577356,"teacher_disagreement_score":0.090335764,"about_ca_system_score_codex":0.0013146261,"about_ca_system_score_gemma":0.004480404,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W4410816990","doi":"10.1200/jco.2025.43.16_suppl.tps4627","title":"Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Urothelial cancer; Cancer; Oncology; Urology; Internal medicine","score_opus":0.09020439217103945,"score_gpt":0.4854147767435448,"score_spread":0.39521038457250535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886693,0.00033734186,0.00014683694,0.007718985,0.001254182,0.0008376149,0.000014546968,0.000010711818,0.0010105309],"genre_scores_gemma":[0.9939563,0.0010838783,0.00012732482,0.0036413723,0.0008663431,0.00006208208,0.0000012711114,0.000022815553,0.00023859792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957695,0.00075663684,0.0022340007,0.00032527157,0.00044040685,0.00047416947],"domain_scores_gemma":[0.99557877,0.0022354766,0.0011212067,0.00036271178,0.00032311922,0.0003787077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021358812,0.00025283408,0.0017619662,0.00020362774,0.00008005728,0.000019684865,0.00033029806,0.00027446426,0.00018812662],"category_scores_gemma":[0.002005222,0.00013112724,0.0003218892,0.00039201137,0.000440045,0.00010360212,0.0000792075,0.0018333249,0.000012657608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023714924,0.013889514,0.55311626,0.00003466976,0.0029615501,0.002639538,0.002025367,0.000044511344,0.000087358494,0.000022537502,0.003696383,0.3977674],"study_design_scores_gemma":[0.058940925,0.047577072,0.8824336,0.0003378612,0.0026696587,0.00006237972,0.0023143333,0.00013175227,0.000250432,0.00025104464,0.0048878845,0.00014304277],"about_ca_topic_score_codex":0.000458205,"about_ca_topic_score_gemma":0.005140281,"teacher_disagreement_score":0.39762434,"about_ca_system_score_codex":0.00041230654,"about_ca_system_score_gemma":0.0058587766,"threshold_uncertainty_score":0.9997771},"labels":[],"label_agreement":null},{"id":"W4410817224","doi":"10.1200/jco.2025.43.16_suppl.4178","title":"Concurrent mutations in DNA damage repair genes <i>BRCA1</i> , <i>POLE</i> , <i>ATM</i> and <i>FANCA</i> to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada); Moncton Hospital; Centre Hospitalier de l’Université de Montréal; St. Michael's Hospital; Jewish General Hospital; Centre hospitalier universitaire de Québec; University Health Network; Ottawa Hospital; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Toronto; Pancreas Centre (Canada); London Health Sciences Centre; Queen's University; Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia","funders":"","keywords":"FANCA; Medicine; Cancer research; DNA damage; Gene; Mutation; DNA Damage Repair; DNA repair; DNA; Genetics; Fanconi anemia; Biology","score_opus":0.04657022406597526,"score_gpt":0.40439144148463446,"score_spread":0.3578212174186592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848105,0.00048226392,0.0003851581,0.007950452,0.00010222399,0.0060034664,0.000019297711,0.000012406239,0.00023427205],"genre_scores_gemma":[0.9937937,0.00061645854,0.0036265783,0.001127776,0.00008811844,0.0006336052,0.000045074652,0.000023675855,0.000044995104],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99431396,0.0020317289,0.002260793,0.00041057056,0.0006054053,0.00037752787],"domain_scores_gemma":[0.99051064,0.0075622927,0.0009790896,0.0002516218,0.00048064,0.00021574285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007118623,0.0002880685,0.0026636228,0.00039963954,0.00007588047,0.000028378267,0.00011345925,0.0002134192,0.0000055917544],"category_scores_gemma":[0.003183222,0.00015075174,0.00015621644,0.00054622913,0.0006969563,0.00018345346,0.00005015289,0.000736795,2.549655e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41771036,0.006106499,0.5711548,0.00017048894,0.00046459184,0.0004527841,0.0006928057,0.000010388396,0.00002727356,0.00019260783,0.000232477,0.0027849523],"study_design_scores_gemma":[0.57527536,0.033864733,0.38713244,0.0008252817,0.0008536602,0.00013664716,0.00049962715,0.0007584792,0.000029102375,0.00037483952,0.00012732002,0.00012252746],"about_ca_topic_score_codex":0.00010701016,"about_ca_topic_score_gemma":0.00083511445,"teacher_disagreement_score":0.18402232,"about_ca_system_score_codex":0.0002135443,"about_ca_system_score_gemma":0.0014100305,"threshold_uncertainty_score":0.61474776},"labels":[],"label_agreement":null},{"id":"W4410817399","doi":"10.1200/jco.2025.43.16_suppl.e15055","title":"Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Meta-analysis; Oncology; Minimal residual disease; Internal medicine; Disease; Residual; Circulating tumor DNA; Carcinoma; Radiology; Cancer","score_opus":0.13641509596955964,"score_gpt":0.47564502478877674,"score_spread":0.3392299288192171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023357691,0.9959464,0.000039222614,0.00025509697,0.00013360352,0.0010730226,0.00014316884,0.000001180733,0.00007252418],"genre_scores_gemma":[0.0072838045,0.9909314,0.0006330984,0.0007678965,0.00017765613,0.00010003108,0.000037456357,0.000017755678,0.00005089214],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.991913,0.002518939,0.004531836,0.0005663764,0.00023628835,0.00023351227],"domain_scores_gemma":[0.9910688,0.0027482444,0.005087079,0.00047146215,0.00024670974,0.00037774106],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0062057683,0.0003824264,0.010058642,0.00022504899,0.00004567651,0.000034882913,0.00032554197,0.0003797038,0.0000147702785],"category_scores_gemma":[0.011805032,0.00026700323,0.0024558115,0.00028884568,0.00014390858,0.000005747502,0.00031818636,0.00086456834,7.862597e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018726072,0.00086392084,0.0059408457,0.87724745,0.09451661,0.0026816204,0.000018714152,0.000009304952,8.922934e-7,0.0001485607,0.0009380672,0.017446753],"study_design_scores_gemma":[0.0007372068,0.0013670743,0.000756065,0.014064397,0.9494101,0.00024408386,0.000013898883,0.000032553246,1.9303138e-7,0.00010854116,0.03290352,0.000362384],"about_ca_topic_score_codex":0.000028727247,"about_ca_topic_score_gemma":0.000051052823,"teacher_disagreement_score":0.8631831,"about_ca_system_score_codex":0.000090341025,"about_ca_system_score_gemma":0.0047898525,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W4410817437","doi":"10.1200/jco.2025.43.16_suppl.2064","title":"Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital; Montreal Neurological Institute and Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Temozolomide; Medicine; Adjuvant; Concomitant; Oncology; Propensity score matching; Internal medicine; Glioblastoma; Radiation therapy; Phases of clinical research; Clinical trial; Cancer research","score_opus":0.10820838953347013,"score_gpt":0.483484045022182,"score_spread":0.3752756554887119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888832,0.0011277223,0.000010130942,0.0052331095,0.0012232922,0.0032928283,0.0000065626728,0.000016662105,0.00020646551],"genre_scores_gemma":[0.9931481,0.00063375384,0.0013805582,0.004274848,0.0003205975,0.00010192667,0.0000066344924,0.000025551539,0.00010801597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942321,0.0011614704,0.003349916,0.00045841586,0.00044549574,0.00035260766],"domain_scores_gemma":[0.99374354,0.002961469,0.001628106,0.00022822489,0.00082869444,0.0006099774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046415706,0.00032405244,0.0037450474,0.0005258173,0.0001420013,0.000041168987,0.00012769656,0.00035950134,0.000100063924],"category_scores_gemma":[0.0075023877,0.00021728357,0.00030122144,0.00037866112,0.00015684964,0.0003465763,0.00008610517,0.00078191335,0.0000037007671],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6157901,0.01803419,0.029026724,0.000017294047,0.0009792008,0.00074062234,0.00021055849,0.000011800832,0.0042328387,0.000041391857,0.00143679,0.3294785],"study_design_scores_gemma":[0.75797474,0.17784658,0.054024212,0.00025700187,0.00090412813,0.00018088246,0.00017250834,0.0016052276,0.0009996449,0.00018599675,0.005660371,0.00018872508],"about_ca_topic_score_codex":0.00006856221,"about_ca_topic_score_gemma":0.00018428694,"teacher_disagreement_score":0.32928976,"about_ca_system_score_codex":0.0003371211,"about_ca_system_score_gemma":0.0015202205,"threshold_uncertainty_score":0.8981601},"labels":[],"label_agreement":null},{"id":"W4410817483","doi":"10.1200/jco.2025.43.16_suppl.e15113","title":"Efficacy and safety data from Ph1b, dose optimization trial of two doses of TH1902 (sudocetaxel zendusortide), a novel SORT1-targeting peptide drug conjugate (PDC), administered weekly vs q3weekly in patients (pts) with advanced ovarian cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Conjugate; Pharmacology; Drug; Safety profile; Peptide; Clinical trial; Oncology; Internal medicine; Adverse effect","score_opus":0.10738001498988801,"score_gpt":0.46325764454127477,"score_spread":0.35587762955138674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876035,0.0004516105,0.0031321181,0.0044963616,0.001265423,0.0010369199,0.00028500278,0.000011679322,0.0005605436],"genre_scores_gemma":[0.9660584,0.0016689436,0.030560076,0.00096806244,0.00051013654,0.00001404976,0.00011397497,0.000030147352,0.00007624638],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934704,0.00057874736,0.0046420186,0.00048810174,0.00053551624,0.00028523576],"domain_scores_gemma":[0.99031764,0.0033759943,0.004825669,0.0005269744,0.0007117714,0.0002419733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002740118,0.00026441982,0.0024429373,0.00027328887,0.000050852253,0.000012211402,0.00039445382,0.00026727884,0.00012802517],"category_scores_gemma":[0.0038848731,0.00020676585,0.00018919245,0.000403075,0.00041604173,0.0003363357,0.00016653033,0.0009311051,6.122792e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79889107,0.007895642,0.13824025,0.00015711288,0.0012686291,0.00006863445,0.0003598615,0.004952722,0.0017014651,0.000055621636,0.0014287006,0.044980276],"study_design_scores_gemma":[0.6917114,0.019334262,0.2768591,0.0027303651,0.0010527993,0.000012811324,0.00023512072,0.0027011218,0.000848935,0.00014174292,0.0040886328,0.0002837091],"about_ca_topic_score_codex":0.00034300025,"about_ca_topic_score_gemma":0.00038980154,"teacher_disagreement_score":0.13861886,"about_ca_system_score_codex":0.0002144452,"about_ca_system_score_gemma":0.0029635334,"threshold_uncertainty_score":0.8431667},"labels":[],"label_agreement":null},{"id":"W4410817496","doi":"10.1200/jco.2025.43.16_suppl.e16397","title":"Impact of palliative care on the management and outcomes of elderly pancreatic cancer patients following admissions for acute pulmonary embolism.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Pulmonary embolism; Palliative care; Intensive care medicine; Pancreatic cancer; Cancer; Internal medicine; Nursing","score_opus":0.199851317724944,"score_gpt":0.5797925515340016,"score_spread":0.37994123380905753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938676,0.0018132166,0.00006199661,0.002137796,0.0004270315,0.00038254014,0.000042508575,0.0000017355451,0.0012655928],"genre_scores_gemma":[0.99407804,0.0037747708,0.0013324597,0.0005131727,0.00006246769,0.000011985942,0.000003583823,0.0000069996363,0.00021650348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980763,0.00014736329,0.0013170083,0.000109394256,0.00022279518,0.00012711965],"domain_scores_gemma":[0.9943338,0.0037812467,0.0011372194,0.0001290815,0.0004879376,0.00013068812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047760547,0.00011434314,0.00142132,0.000115651914,0.000030167705,0.000001705043,0.00012068074,0.00013732255,0.000021744248],"category_scores_gemma":[0.002281317,0.000058278707,0.0007526352,0.00011432438,0.00008802515,0.00003261099,0.000045504137,0.0002445511,1.4821838e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021458333,0.00067089306,0.937697,0.00014578139,0.005292335,0.00002688082,0.0008673247,0.000007829861,0.000036021447,0.00014692753,0.00076604047,0.052197147],"study_design_scores_gemma":[0.0042808014,0.008227426,0.97834504,0.0016702418,0.0026706741,3.415971e-7,0.0011824706,0.000018016328,0.0001093145,0.000375675,0.0030749182,0.00004507362],"about_ca_topic_score_codex":0.000039582887,"about_ca_topic_score_gemma":0.00000864116,"teacher_disagreement_score":0.052152075,"about_ca_system_score_codex":0.000105049025,"about_ca_system_score_gemma":0.0005802651,"threshold_uncertainty_score":0.27311143},"labels":[],"label_agreement":null},{"id":"W4410817865","doi":"10.1200/jco.2025.43.16_suppl.4102","title":"Concordance analysis between tumor tissue HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH) and a translational analysis of plasma ctDNA in patients (pts) with biliary tract cancer (BTC): An exploratory analysis from the phase 2 HERIZON-BTC-01 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Immunohistochemistry; In situ hybridization; Concordance; Biliary tract cancer; Cancer; Pathology; Oncology; Internal medicine; Gene expression; Biology; Gene; Gemcitabine","score_opus":0.04177207737698609,"score_gpt":0.4124343914044669,"score_spread":0.37066231402748084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436575,0.0037646394,0.00026188497,0.00091822556,0.00008050681,0.00029314877,0.00025860022,0.0000037709933,0.000053465814],"genre_scores_gemma":[0.9981558,0.00094432343,0.0002305554,0.00028406316,0.00011432316,0.000020746114,0.00022636075,0.0000092434675,0.000014600998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963063,0.0005248153,0.0021977539,0.00038585163,0.00038323321,0.0002020422],"domain_scores_gemma":[0.9958168,0.002069662,0.0013853501,0.00024134947,0.00031207243,0.00017472134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012836286,0.00020355338,0.002585277,0.0006145288,0.00005032172,0.000015726468,0.00013359511,0.00016717271,0.000048387716],"category_scores_gemma":[0.00047398356,0.00014276739,0.0003835155,0.0025485451,0.00033158943,0.00018494994,0.000029305782,0.0005688212,6.914918e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025095511,0.0016434412,0.9378293,0.000020884321,0.014313015,0.000039601364,0.00076743885,0.00023746167,0.0004328982,3.7570624e-7,0.000113904265,0.01950615],"study_design_scores_gemma":[0.045713313,0.0024796564,0.921315,0.00006003772,0.02852272,6.009465e-7,0.0005991304,0.0006270159,0.00020025665,0.000009886997,0.00035454467,0.00011782443],"about_ca_topic_score_codex":0.0010622797,"about_ca_topic_score_gemma":0.006758409,"teacher_disagreement_score":0.020617802,"about_ca_system_score_codex":0.00017647659,"about_ca_system_score_gemma":0.0008794402,"threshold_uncertainty_score":0.5821885},"labels":[],"label_agreement":null},{"id":"W4410817906","doi":"10.1200/jco.2025.43.16_suppl.10595","title":"Concordance of parent-of-origin predictions for hereditary cancer variants using proband-only analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Health Services Authority; BC Cancer Agency; Terry Fox Research Institute; Genome British Columbia; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; University of British Columbia; Canada Research Chairs","keywords":"Concordance; Proband; Medicine; Cancer; Genetics; Mutation; Internal medicine; Biology; Gene","score_opus":0.13374531332519185,"score_gpt":0.49598149969416894,"score_spread":0.3622361863689771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8853767,0.0018488576,0.109182924,0.00073825446,0.002072812,0.00017690197,0.00005342485,0.0000017609897,0.0005483601],"genre_scores_gemma":[0.99301225,0.0008228456,0.005069212,0.00024043524,0.00053174695,0.000010087815,0.000011236358,0.000005192233,0.00029702153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797887,0.0001779614,0.0014583967,0.00016492193,0.00011465477,0.00010518382],"domain_scores_gemma":[0.99733293,0.00018363462,0.0016013754,0.00017954178,0.00062800205,0.000074525735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009245189,0.00007696679,0.0006592166,0.0001204691,0.00002980239,0.000002662126,0.00019174116,0.00025150302,0.000024316976],"category_scores_gemma":[0.00064783776,0.00006200713,0.0004392169,0.00025821113,0.00013129879,0.0000061941228,0.000035498982,0.00014971435,7.746062e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064732567,0.0022817976,0.54040825,0.00022180074,0.0069606374,0.0000069301886,0.00007328785,0.017228572,0.29373965,0.0007183273,0.039704237,0.092183284],"study_design_scores_gemma":[0.010727056,0.006795754,0.619825,0.00036016313,0.0048880507,0.000026323522,0.00038099303,0.009037701,0.028034993,0.0009878544,0.31863582,0.00030028913],"about_ca_topic_score_codex":0.000022362341,"about_ca_topic_score_gemma":0.00007192239,"teacher_disagreement_score":0.2789316,"about_ca_system_score_codex":0.00003303253,"about_ca_system_score_gemma":0.0024232622,"threshold_uncertainty_score":0.4298763},"labels":[],"label_agreement":null},{"id":"W4410818215","doi":"10.1200/jco.2025.43.16_suppl.tps4630","title":"ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Immunotherapy; Open label; Chemotherapy; Internal medicine; Randomized controlled trial; Cancer","score_opus":0.17611272513261214,"score_gpt":0.5627920855961613,"score_spread":0.3866793604635492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846995,0.0016882645,0.0001814131,0.00893836,0.00046522988,0.0029900875,0.0000024852002,0.0000041210983,0.0010305624],"genre_scores_gemma":[0.99085224,0.004713312,0.0011516083,0.0020221986,0.00012667412,0.000041503383,0.000005258242,0.000014365664,0.0010728333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949242,0.0018033958,0.002524041,0.00021077588,0.00038709556,0.00015047888],"domain_scores_gemma":[0.9924452,0.005046551,0.0016417189,0.00015957606,0.000609576,0.00009742266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011880603,0.00015999976,0.0026344713,0.0002413841,0.000040492625,0.000011398182,0.00016831752,0.00020572935,0.00078415504],"category_scores_gemma":[0.001699907,0.00008882547,0.00010299066,0.0003849445,0.00024768515,0.0001242205,0.00003686483,0.00046647456,7.68775e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66400045,0.031296145,0.002769317,0.000020885263,0.0016204775,0.00012934157,0.0003869618,0.00001698884,0.00028051503,0.000024570067,0.0004603419,0.298994],"study_design_scores_gemma":[0.8962673,0.062433638,0.0331458,0.00017929613,0.001812399,0.00010396161,0.00018608541,0.00082576677,0.0001802423,0.00013525189,0.0046513933,0.00007889321],"about_ca_topic_score_codex":0.00009362495,"about_ca_topic_score_gemma":0.00025429708,"teacher_disagreement_score":0.29891512,"about_ca_system_score_codex":0.00029117748,"about_ca_system_score_gemma":0.0031591002,"threshold_uncertainty_score":0.8585948},"labels":[],"label_agreement":null},{"id":"W4410818233","doi":"10.1200/jco.2025.43.16_suppl.2002","title":"Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Medicine; Adjuvant; Glioma; Oncology; Internal medicine; Phases of clinical research; Glioblastoma; Clinical trial; Cancer research","score_opus":0.07698644840400602,"score_gpt":0.47986163615491084,"score_spread":0.4028751877509048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055487,0.0017941825,0.00028309593,0.005069272,0.0012320753,0.00084953697,0.000007239045,0.0000037221996,0.00020599959],"genre_scores_gemma":[0.997665,0.000996871,0.00016072387,0.0009523834,0.00016401129,0.000024773502,0.0000050055833,0.000008028226,0.000023225082],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99277866,0.001952545,0.0043817856,0.00033495156,0.00035616697,0.00019588739],"domain_scores_gemma":[0.9888137,0.008352317,0.0020570643,0.0002539897,0.00026805972,0.00025488783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059689176,0.00021539038,0.004466094,0.0005364582,0.000039477363,0.000010622095,0.00013921881,0.00035950448,0.000038084938],"category_scores_gemma":[0.0077606402,0.00011937191,0.0012849653,0.000540733,0.0009439259,0.000041339274,0.00009827036,0.0008477866,6.0389607e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8117037,0.008572541,0.12954533,0.000029679166,0.0061128847,0.00078672264,0.0000607407,0.000063263025,0.00007263841,0.00090482744,0.00054382393,0.041603863],"study_design_scores_gemma":[0.86025876,0.015572621,0.107167765,0.00048151953,0.012067039,0.000064314416,0.000055430395,0.0032115001,0.00012930937,0.00026658288,0.00063010055,0.00009506296],"about_ca_topic_score_codex":0.000032328335,"about_ca_topic_score_gemma":0.00017870378,"teacher_disagreement_score":0.04855506,"about_ca_system_score_codex":0.00008722034,"about_ca_system_score_gemma":0.00066378934,"threshold_uncertainty_score":0.92907715},"labels":[],"label_agreement":null},{"id":"W4410818285","doi":"10.1200/jco.2025.43.16_suppl.e16602","title":"Non-muscle invasive bladder cancer burden: The impact of BCG shortage and its interaction with epidemiological patient profile—A population cohort study in Brazil.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Bladder cancer; Epidemiology; Economic shortage; Cohort; Cancer; Population; Cohort study; Oncology; Internal medicine; Environmental health","score_opus":0.08393674413643219,"score_gpt":0.5021151829109328,"score_spread":0.4181784387745006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954475,0.00030523373,0.000008901906,0.0018844532,0.00034222752,0.0010961324,0.000004894569,0.000002788771,0.0009078689],"genre_scores_gemma":[0.9985921,0.00048667294,0.000060537277,0.0005406008,0.00021543555,0.000042599215,0.0000026640998,0.000007029027,0.00005238631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742323,0.0004964081,0.0015400548,0.00019044692,0.00020408105,0.00014577623],"domain_scores_gemma":[0.9968933,0.0015474154,0.0010217989,0.00012454632,0.000304208,0.000108773165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014898814,0.00013405332,0.0011936895,0.000112348374,0.000031393265,0.0000048461893,0.00007449144,0.00018429733,0.00012409162],"category_scores_gemma":[0.0014051178,0.000061834806,0.00019689926,0.00017659915,0.0000802566,0.000098180724,0.000040475865,0.00067075813,8.5454957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004526547,0.0014757446,0.95987135,0.000014448417,0.00090275303,0.00009894871,0.00030681508,0.0003020352,0.00007377709,0.0000043797845,0.0004824766,0.031940714],"study_design_scores_gemma":[0.004719973,0.02148549,0.97205013,0.00018394657,0.0004915031,0.00003545986,0.0005556559,0.00026284723,0.000038094408,0.000059995746,0.000067731715,0.000049191534],"about_ca_topic_score_codex":0.0018383138,"about_ca_topic_score_gemma":0.0009655732,"teacher_disagreement_score":0.03189152,"about_ca_system_score_codex":0.0002799384,"about_ca_system_score_gemma":0.0009602087,"threshold_uncertainty_score":0.29141477},"labels":[],"label_agreement":null},{"id":"W4410818307","doi":"10.1200/jco.2025.43.16_suppl.e22519","title":"Burden of tracheal, bronchus, and lung cancer in high-income North America: Trends from 1990 to 2021 and death projections to 2050.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Intensive care medicine; Lung; Internal medicine","score_opus":0.10518131961396607,"score_gpt":0.4955480386862715,"score_spread":0.39036671907230547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97610563,0.0020474866,0.00019927371,0.020274786,0.00047708815,0.00014864097,0.00002878804,0.0000028378217,0.0007154438],"genre_scores_gemma":[0.99075747,0.0012818322,0.004885114,0.0021489,0.00065157004,0.000009982471,0.0000028975776,0.0000056327526,0.00025662238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978686,0.00015427721,0.0013667757,0.00021468883,0.00020816387,0.00018751126],"domain_scores_gemma":[0.99816835,0.00073649595,0.00043954139,0.00012025382,0.00020518506,0.00033016235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006651484,0.00010647146,0.0011806664,0.00030510008,0.000029688554,0.000007720432,0.000100243386,0.00016925909,0.00010592505],"category_scores_gemma":[0.000977582,0.00008294548,0.00011052826,0.00052541675,0.000076400465,0.000078050776,0.00007384837,0.00057602435,8.1825704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018367837,0.00013377306,0.6305001,0.000019363892,0.00017133256,0.000117144686,0.00032521307,0.0002739889,0.00009283822,0.000018335137,0.00314069,0.36337042],"study_design_scores_gemma":[0.0027240084,0.0036685339,0.9620235,0.00036681557,0.00032580466,0.000024562185,0.0003376772,0.0002450325,0.000009375359,0.000048681297,0.03015788,0.00006812153],"about_ca_topic_score_codex":0.015082395,"about_ca_topic_score_gemma":0.010581182,"teacher_disagreement_score":0.36330232,"about_ca_system_score_codex":0.00020784744,"about_ca_system_score_gemma":0.0006352257,"threshold_uncertainty_score":0.99147624},"labels":[],"label_agreement":null},{"id":"W4410818503","doi":"10.1200/jco.2025.43.16_suppl.2075","title":"Correlative and spatial transcriptomic analysis of olaparib and durvalumab in patients with recurrent/refractory <i>IDH</i> -mutant gliomas.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Medicine; Refractory (planetary science); Durvalumab; Mutant; Cancer research; Glioma; Oncology; Internal medicine; Cancer; Biology; Genetics; Poly ADP ribose polymerase; Immunotherapy; Gene","score_opus":0.03232129771711527,"score_gpt":0.38340012696020903,"score_spread":0.35107882924309375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706,0.0008915914,0.00006499879,0.0010463761,0.00033225736,0.00021805966,0.000014377401,0.0000020784016,0.0003702455],"genre_scores_gemma":[0.9989014,0.000520112,0.00021513527,0.00030872042,0.000032417178,0.0000029655587,0.000006451313,0.0000055979576,0.0000071614927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975874,0.00028017577,0.0015761959,0.00018977506,0.00023234884,0.00013414671],"domain_scores_gemma":[0.9971565,0.0013032461,0.0009702773,0.000108559805,0.00029548543,0.00016591577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008597107,0.00012815707,0.0017416012,0.00057051127,0.0000201331,0.000004908254,0.00005170687,0.00021153026,0.000024558245],"category_scores_gemma":[0.0006115411,0.000082054765,0.0002315525,0.00048405965,0.00023060488,0.000067923196,0.000022478245,0.00046141332,2.8415033e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00724423,0.003906669,0.87838095,0.00002258476,0.0026716273,0.00011310574,0.00016627721,0.0000070789392,0.00005174738,0.00004419513,0.00007612508,0.10731538],"study_design_scores_gemma":[0.024582282,0.011019198,0.9574242,0.0001988198,0.0051550814,0.0000069401317,0.0000658523,0.00026895988,0.00005501598,0.0000533903,0.0011108462,0.00005936443],"about_ca_topic_score_codex":0.00011624073,"about_ca_topic_score_gemma":0.0008437303,"teacher_disagreement_score":0.10725601,"about_ca_system_score_codex":0.00012586705,"about_ca_system_score_gemma":0.0004739182,"threshold_uncertainty_score":0.33460963},"labels":[],"label_agreement":null},{"id":"W4410818605","doi":"10.1200/jco.2025.43.16_suppl.tps625","title":"NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Breast-conserving surgery; Stage (stratigraphy); Oncology; Breast surgery; Radiation therapy; Surgery; Internal medicine; Gynecology; Mastectomy; Cancer","score_opus":0.0902763062512939,"score_gpt":0.491627711294716,"score_spread":0.4013514050434221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228203,0.0013891159,0.000816919,0.0028888439,0.0019369336,0.00028640206,0.00012885164,0.0000062490617,0.00026466607],"genre_scores_gemma":[0.9970706,0.0006821186,0.0006345919,0.0003310066,0.0011385328,0.000020677628,0.000025376597,0.000020761785,0.00007633382],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99511117,0.0009714166,0.002904335,0.00032029673,0.00037665333,0.00031612164],"domain_scores_gemma":[0.99404335,0.0016503538,0.0032202932,0.00026507658,0.00066957425,0.00015135785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004792147,0.00022538673,0.0015548161,0.00018615669,0.000090877606,0.00001154257,0.00023921077,0.00044752442,0.00006936419],"category_scores_gemma":[0.0015990076,0.00020380861,0.0010105603,0.00027440977,0.00019187431,0.000030015992,0.00012563965,0.00033609912,4.7422523e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12813267,0.0026465296,0.22063316,0.0001259894,0.0029358726,0.000035190584,0.00012496412,0.00044345332,0.015113137,0.000030783387,0.0017931784,0.62798506],"study_design_scores_gemma":[0.15816844,0.00530643,0.82534456,0.0008650015,0.0021037192,0.00036461413,0.0005421361,0.0010396075,0.004417887,0.00024613962,0.0011936668,0.00040777953],"about_ca_topic_score_codex":0.00046454289,"about_ca_topic_score_gemma":0.00017556215,"teacher_disagreement_score":0.6275773,"about_ca_system_score_codex":0.00022759424,"about_ca_system_score_gemma":0.0039830077,"threshold_uncertainty_score":0.8311074},"labels":[],"label_agreement":null},{"id":"W4410818610","doi":"10.1200/jco.2025.43.16_suppl.tps628","title":"Radiation omission in patients with clinically node-negative breast cancer undergoing lumpectomy (ROSALIE).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Ontario Clinical Oncology Group; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lumpectomy; Breast cancer; Cancer; Radiation therapy; Oncology; Internal medicine; Mastectomy","score_opus":0.02001361952134324,"score_gpt":0.39812602109296413,"score_spread":0.3781124015716209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922258,0.00026249106,0.00026256358,0.0051845247,0.00086877943,0.0001629819,0.000017904775,0.0000036701695,0.001011243],"genre_scores_gemma":[0.99532366,0.0010836832,0.0013383612,0.0017056967,0.00043765985,0.000009601728,0.000008278626,0.000012130363,0.00008094734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757254,0.00035490477,0.0014360696,0.000261513,0.0001801983,0.00019478309],"domain_scores_gemma":[0.99739677,0.0007493939,0.0011630661,0.00015280515,0.00042880172,0.0001091627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008592074,0.00015104527,0.0007122231,0.00008826814,0.00004910271,0.000008301809,0.00016997609,0.00031189757,0.000023208244],"category_scores_gemma":[0.0012747075,0.00010524747,0.00018658298,0.00015623585,0.00016500682,0.000012738348,0.00008926257,0.00037475076,0.000001948275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009558804,0.0010096396,0.9208439,0.000011283931,0.0004243198,0.000009609864,0.000029332108,0.00013712165,0.00004457259,0.000020136651,0.0016797406,0.06623154],"study_design_scores_gemma":[0.014964886,0.00221716,0.9796378,0.00015728302,0.0001250889,0.0000037722523,0.00005393994,0.000009370419,0.00010150883,0.00015166853,0.0024743034,0.00010319841],"about_ca_topic_score_codex":0.000068039895,"about_ca_topic_score_gemma":0.0003426672,"teacher_disagreement_score":0.06612834,"about_ca_system_score_codex":0.00018061342,"about_ca_system_score_gemma":0.0017906461,"threshold_uncertainty_score":0.42918673},"labels":[],"label_agreement":null},{"id":"W4410818656","doi":"10.1200/jco.2025.43.16_suppl.9539","title":"Updated analyses from a global meta-analysis in metastatic uveal melanoma (mUM) to determine progression free and overall survival benchmarks by line of therapy: An international rare cancers initiative (IRCI) ocular melanoma study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melanoma; Oncology; Targeted therapy; Metastatic melanoma; Meta-analysis; Internal medicine; Overall survival; Dermatology; Cancer; Cancer research","score_opus":0.22434046841043975,"score_gpt":0.528509213333316,"score_spread":0.30416874492287627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286956,0.0022921497,0.00022478527,0.003050555,0.00035510646,0.0005434301,0.0002447573,0.000005068101,0.0004146098],"genre_scores_gemma":[0.9925135,0.00024904468,0.005622612,0.0012743897,0.00008875467,0.00002157004,0.00019249458,0.000008563268,0.000029085622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99443424,0.00193393,0.0024775458,0.00042320884,0.0005216271,0.00020943063],"domain_scores_gemma":[0.99591297,0.0013665761,0.001537572,0.00034607228,0.0005439836,0.00029284213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002213528,0.0002619248,0.0038104057,0.0004243715,0.00003404895,0.000014429502,0.00034588692,0.000281983,0.00050742505],"category_scores_gemma":[0.0014014468,0.00017058887,0.00088449405,0.0006373296,0.00017032967,0.00020039576,0.00014562339,0.0005047345,6.8422804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010621956,0.0054323133,0.7925386,0.0000059341146,0.17450713,0.0016412355,0.00022899521,0.00012405342,0.00009988166,0.000012820907,0.00030659098,0.01448048],"study_design_scores_gemma":[0.02256066,0.02314121,0.85484433,0.000030432715,0.09633452,0.0000233284,0.00053429883,0.00065786584,0.00021771975,0.0006090441,0.00089704193,0.00014957304],"about_ca_topic_score_codex":0.000963223,"about_ca_topic_score_gemma":0.00461864,"teacher_disagreement_score":0.07817261,"about_ca_system_score_codex":0.0003252977,"about_ca_system_score_gemma":0.0010893182,"threshold_uncertainty_score":0.6956413},"labels":[],"label_agreement":null},{"id":"W4410818934","doi":"10.1200/jco.2025.43.16_suppl.7015","title":"Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Gemcitabine; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Internal medicine; Lymphoma; Oncology; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.027591271327323627,"score_gpt":0.35002051646402144,"score_spread":0.3224292451366978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272245,0.0010204139,0.000022303877,0.0015167152,0.0009022023,0.00046035726,0.000032051117,0.0000100933585,0.0033134297],"genre_scores_gemma":[0.9950153,0.0012544226,0.0017145127,0.0011815677,0.00015421059,0.000010438731,0.000016702807,0.000025463081,0.00062736723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563557,0.0003834636,0.0026779466,0.00035825948,0.0005431333,0.00040163263],"domain_scores_gemma":[0.9950543,0.0019896966,0.0016939546,0.00035009885,0.00053215295,0.0003798013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015419547,0.00028741898,0.002229318,0.0003558746,0.000049502396,0.000012305618,0.00018015933,0.0005047172,0.000057760113],"category_scores_gemma":[0.0015461952,0.00019226741,0.00038461812,0.0003468986,0.00022436182,0.00016214671,0.00013418759,0.00047699563,0.000008431468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018727696,0.039108958,0.8932375,0.00011995107,0.0005616344,0.0005556353,0.00018907274,0.0000022933637,0.000017620017,0.00024352103,0.0040787663,0.0431574],"study_design_scores_gemma":[0.2591313,0.015505314,0.70316607,0.00037523214,0.0005714378,0.000023641902,0.0002037181,0.000036468806,0.00006997341,0.00010078551,0.020694552,0.00012150802],"about_ca_topic_score_codex":0.000087059365,"about_ca_topic_score_gemma":0.0001910796,"teacher_disagreement_score":0.24040362,"about_ca_system_score_codex":0.00068285473,"about_ca_system_score_gemma":0.001961359,"threshold_uncertainty_score":0.7840438},"labels":[],"label_agreement":null},{"id":"W4410818946","doi":"10.1200/jco.2025.43.16_suppl.tps4631","title":"LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Bladder cancer; Urology; Cancer; Urothelial cancer; Oncology; Internal medicine","score_opus":0.055545716074392626,"score_gpt":0.45342300534315355,"score_spread":0.3978772892687609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511683,0.00023282127,0.00080250064,0.00087587896,0.0012020787,0.0015075214,0.00011691141,0.000009547287,0.0001358845],"genre_scores_gemma":[0.9948119,0.00070613,0.0020310131,0.0014167961,0.00078627357,0.00008276335,0.0000120297345,0.00003815456,0.00011496488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962317,0.0003939138,0.0022162185,0.00037912314,0.00046262224,0.0003164242],"domain_scores_gemma":[0.9950481,0.001312349,0.0017907465,0.000339767,0.0011156513,0.00039340393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000897598,0.00027863745,0.002039925,0.00021933338,0.0000772029,0.000010531663,0.00023606035,0.00033188108,0.00012579122],"category_scores_gemma":[0.00039972927,0.00017873448,0.0003862533,0.00023989174,0.00020594886,0.0001502285,0.00003139635,0.0006162477,0.0000015984645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071615234,0.059529714,0.47410074,0.00007230417,0.0072087706,0.00015487922,0.0008624607,0.00010016901,0.0003078603,0.00002867026,0.0014085217,0.38461065],"study_design_scores_gemma":[0.14589837,0.24724956,0.59605193,0.00015686009,0.0044725523,0.000010399093,0.00054165017,0.00006978778,0.0021238937,0.00021961436,0.0030095724,0.0001958246],"about_ca_topic_score_codex":0.0003717994,"about_ca_topic_score_gemma":0.00085220835,"teacher_disagreement_score":0.38441485,"about_ca_system_score_codex":0.00018236629,"about_ca_system_score_gemma":0.003038533,"threshold_uncertainty_score":0.72885805},"labels":[],"label_agreement":null},{"id":"W4410818990","doi":"10.1200/jco.2025.43.16_suppl.2044","title":"Identification and validation of potential diagnostic plasma biomarkers for diffuse gliomas by multiplex immunoassays.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Multiplex; Identification (biology); Pathology; Oncology; Bioinformatics","score_opus":0.04569700200668756,"score_gpt":0.4126381434996756,"score_spread":0.366941141492988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410818990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958313,0.00097057916,0.0012442527,0.0066630607,0.0010202737,0.0004248129,0.000021627784,0.000004927117,0.000067356916],"genre_scores_gemma":[0.997727,0.00087402866,0.0010163635,0.0001563828,0.00012198112,0.000020828795,0.000021676498,0.000008229751,0.00005354246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747026,0.00018236526,0.0018879916,0.00015720958,0.00017976179,0.00012240071],"domain_scores_gemma":[0.99237424,0.005527241,0.0013912653,0.00013984903,0.00044173995,0.00012564358],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015206891,0.000100833146,0.0008123462,0.00020368685,0.000042251886,0.00001214614,0.00008011731,0.00024783888,0.000013402116],"category_scores_gemma":[0.00887469,0.0000754574,0.0003317303,0.00013579773,0.00015764582,0.00008169279,0.000029745292,0.00015957883,0.0000013719841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009186514,0.015907528,0.40245625,0.0002956429,0.004211873,0.00019336336,0.00010464659,0.00003259451,0.16572742,0.00043003025,0.04279912,0.35865504],"study_design_scores_gemma":[0.05868503,0.009013291,0.8172546,0.00037247536,0.0037675246,0.00018792815,0.00021936509,0.0016217879,0.09188227,0.001145993,0.015691914,0.00015778375],"about_ca_topic_score_codex":0.000015193382,"about_ca_topic_score_gemma":0.0000049794394,"teacher_disagreement_score":0.41479838,"about_ca_system_score_codex":0.000073456635,"about_ca_system_score_gemma":0.0002930136,"threshold_uncertainty_score":0.999474},"labels":[],"label_agreement":null},{"id":"W4410819067","doi":"10.1200/jco.2025.43.16_suppl.2030","title":"Evaluating the utility of DNA methylation signatures in tissue and biofluids for lung adenocarcinoma brain metastasis prediction and non-invasive detection.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adenocarcinoma; Brain metastasis; Metastasis; DNA methylation; Lung; Pathology; Methylation; Lung cancer; Cancer research; Oncology; Cancer; Internal medicine; DNA; Biology; Gene; Genetics; Gene expression","score_opus":0.10916274279965546,"score_gpt":0.5047946489785828,"score_spread":0.3956319061789274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823227,0.0059857857,0.0016768232,0.008902148,0.00040606203,0.0005765109,0.000009011706,0.0000021920002,0.00011878542],"genre_scores_gemma":[0.99671715,0.000825061,0.0017548554,0.00047169224,0.00017573262,0.000025123527,0.000001165031,0.000003984197,0.000025208088],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99815345,0.00038010083,0.001092116,0.00014582166,0.00014301798,0.00008547006],"domain_scores_gemma":[0.99186957,0.007122914,0.0005752206,0.000091234695,0.00028000333,0.00006108363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004179761,0.00007461784,0.0006434928,0.0001182743,0.00004536956,0.000005504414,0.00003776079,0.00018635484,0.000013814115],"category_scores_gemma":[0.00531269,0.000044759054,0.00012323841,0.00012918738,0.00012466105,0.000059305254,0.000025292047,0.00028703047,4.3707136e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003324486,0.0005681919,0.41224703,0.0002823292,0.00076288154,0.0000138670575,0.00026108974,0.000036981673,0.005395426,0.000044968536,0.0017089966,0.57535374],"study_design_scores_gemma":[0.006362494,0.009766267,0.9637594,0.00020075799,0.0011750018,0.000015836551,0.00016520232,0.005405686,0.011805973,0.0007421437,0.00057136646,0.000029857063],"about_ca_topic_score_codex":0.000036429818,"about_ca_topic_score_gemma":0.00016006142,"teacher_disagreement_score":0.5753239,"about_ca_system_score_codex":0.00011710867,"about_ca_system_score_gemma":0.00053674506,"threshold_uncertainty_score":0.63601696},"labels":[],"label_agreement":null},{"id":"W4410819406","doi":"10.1200/jco.2025.43.16_suppl.e15629","title":"Adjuvant chemotherapy outcomes among patients with stage II early-onset colon cancer in Alberta.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Stage (stratigraphy); Chemotherapy; Oncology; Colorectal cancer; Adjuvant; Adjuvant chemotherapy; Internal medicine; Cancer; Breast cancer","score_opus":0.03832194679568787,"score_gpt":0.4405069655601587,"score_spread":0.4021850187644709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859002,0.00030153836,0.0000026509194,0.009713414,0.0007540645,0.00032051673,0.000008973183,0.000004042871,0.0029945849],"genre_scores_gemma":[0.9911034,0.00068598276,0.00013781598,0.0028551903,0.000084792104,0.000018754037,0.000001345048,0.0000099969575,0.0051027234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980404,0.00012041186,0.0012311427,0.00016776046,0.00023419962,0.0002060783],"domain_scores_gemma":[0.9977142,0.0010189958,0.00073241245,0.00011810932,0.00028401526,0.0001322507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000504097,0.00014614801,0.0015355233,0.00012812809,0.000052550855,0.0000048252223,0.000091111084,0.00018522685,0.00014703217],"category_scores_gemma":[0.00060315395,0.000082096674,0.00022886298,0.00017919437,0.00018855781,0.00006772996,0.00004764995,0.00053039816,0.0000017133328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008805586,0.002060985,0.9312743,0.000014354067,0.00081811484,0.00010686169,0.0002790441,0.0000060564735,5.8990895e-7,0.000007848521,0.0014113485,0.05521492],"study_design_scores_gemma":[0.020425748,0.013004195,0.94236475,0.0001750958,0.00023317877,0.0000017668157,0.000060713202,0.000006874277,0.000007674074,0.000034085395,0.023617465,0.00006846137],"about_ca_topic_score_codex":0.0015612623,"about_ca_topic_score_gemma":0.016099112,"teacher_disagreement_score":0.055146456,"about_ca_system_score_codex":0.00035195824,"about_ca_system_score_gemma":0.0009926396,"threshold_uncertainty_score":0.8983683},"labels":[],"label_agreement":null},{"id":"W4410819566","doi":"10.1200/jco.2025.43.16_suppl.e14016","title":"Analysis of MFGE8 expression and regional localization in glioblastoma tumor samples at diagnosis and relapse.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Glioblastoma; Oncology; Cancer research; Internal medicine","score_opus":0.06249108403876588,"score_gpt":0.3940058893589839,"score_spread":0.33151480532021804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990934,0.0069207945,0.00038357888,0.0010708454,0.0005357073,0.00006784947,0.0000045917477,0.0000028783195,0.00007974371],"genre_scores_gemma":[0.99622077,0.0031735701,0.0001534779,0.00033608702,0.000024239438,0.0000035176777,0.0000074512604,0.000003644964,0.00007725285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735683,0.0006745449,0.0016373665,0.00016375245,0.000047071153,0.000120459095],"domain_scores_gemma":[0.9953705,0.00313406,0.0012006131,0.000106737876,0.00015778503,0.000030298686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015090145,0.000091253096,0.0010591883,0.0004929966,0.000055417437,0.0000037830662,0.000093311224,0.0003398019,0.00008288723],"category_scores_gemma":[0.001725868,0.00006956461,0.0001986318,0.00037050623,0.00033820118,0.00010410627,0.00010714422,0.0002852487,0.000001017513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032047138,0.0006847747,0.92381614,0.000027836344,0.0010074343,0.000010965643,0.00015632746,0.0002551872,0.023433538,0.00049954903,0.005999635,0.040903907],"study_design_scores_gemma":[0.0036634924,0.0016134372,0.9326215,0.00017903067,0.00074995396,0.000028783212,0.00012481552,0.0002826282,0.009016959,0.00033708193,0.051305972,0.000076382494],"about_ca_topic_score_codex":0.00003131823,"about_ca_topic_score_gemma":0.00018170854,"teacher_disagreement_score":0.045306336,"about_ca_system_score_codex":0.00006198831,"about_ca_system_score_gemma":0.00015275912,"threshold_uncertainty_score":0.28367627},"labels":[],"label_agreement":null},{"id":"W4410819570","doi":"10.1200/jco.2025.43.16_suppl.10583","title":"NuGenA (Nurse Led Genetic Counselling and Awareness): A proof-of-concept to implementation of genetic counseling for HBOC in LMICs.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"Conquer Cancer Foundation","keywords":"Medicine; Genetic counseling; Nursing; Family medicine; Genetics","score_opus":0.04382251279543794,"score_gpt":0.46489381988087214,"score_spread":0.4210713070854342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9001404,0.0040743398,0.09407351,0.0006223509,0.00064469903,0.00040535847,0.000015841053,0.0000010014106,0.000022521333],"genre_scores_gemma":[0.9680693,0.0012724769,0.029830663,0.00049592304,0.00025997657,0.00002765888,0.000005020618,0.00001272105,0.000026237032],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99731046,0.00018071526,0.001984488,0.0002281511,0.0001283041,0.00016790594],"domain_scores_gemma":[0.9977206,0.0004103171,0.0010200288,0.00016078439,0.00061225425,0.000076026314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013278797,0.00010998126,0.0006260563,0.00014483299,0.000026831047,0.0000059281747,0.00019003147,0.00024956054,0.000008155094],"category_scores_gemma":[0.00040976758,0.00010478846,0.00016171804,0.00015606455,0.00013686296,0.00000522844,0.000020178682,0.00014881471,1.1588797e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028526557,0.0006957635,0.08750956,0.00025197607,0.0005752622,0.000013087022,0.0014851312,0.027629273,0.061910253,0.00010582013,0.00213758,0.81483364],"study_design_scores_gemma":[0.034265853,0.030402273,0.19077118,0.000818356,0.0012881926,0.00012938867,0.005252796,0.0056332545,0.59958214,0.010229967,0.12072325,0.0009033927],"about_ca_topic_score_codex":0.000022362008,"about_ca_topic_score_gemma":0.0003472283,"teacher_disagreement_score":0.8139303,"about_ca_system_score_codex":0.000058274865,"about_ca_system_score_gemma":0.002027211,"threshold_uncertainty_score":0.42731494},"labels":[],"label_agreement":null},{"id":"W4410819589","doi":"10.1200/jco.2025.43.16_suppl.e13058","title":"Comparative analysis of <i>PIK3CA</i> mutation detection methods in the first-in-human phase 1/1b study of inavolisib.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Medicine; Mutation; Oncology; Internal medicine; Computational biology; Genetics; Gene; Biology","score_opus":0.2181846250729563,"score_gpt":0.6391249048324789,"score_spread":0.42094027975952253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995367,0.00016707502,0.0015980321,0.0006211143,0.00018996971,0.0004681821,0.0000010346864,0.0000017880975,0.001585816],"genre_scores_gemma":[0.9986336,0.00004867819,0.0009346261,0.0002649981,0.000078766585,0.000010156253,0.0000013770175,0.0000034470715,0.000024332543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99323267,0.002645902,0.0033203897,0.00017054405,0.00047090344,0.00015958482],"domain_scores_gemma":[0.987824,0.009677496,0.0016104862,0.00027445305,0.0005473696,0.00006618962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012865594,0.0000979189,0.002163927,0.0010774535,0.000028227054,0.0000044077533,0.0002568938,0.00021566689,0.00002606769],"category_scores_gemma":[0.0040710624,0.00006255972,0.00039827166,0.0021994703,0.00023195628,0.00007051064,0.000054819633,0.000923884,4.4152648e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06611631,0.18664539,0.25619492,0.0007205048,0.021282531,0.0035715937,0.048205826,0.017011294,0.008739945,0.0007434809,0.0014958358,0.38927236],"study_design_scores_gemma":[0.22320285,0.06231311,0.62401074,0.00026653268,0.006804491,0.00010059406,0.01899007,0.057486773,0.0039416156,0.0008464805,0.00190496,0.00013178728],"about_ca_topic_score_codex":0.0009229297,"about_ca_topic_score_gemma":0.0064519043,"teacher_disagreement_score":0.38914058,"about_ca_system_score_codex":0.0022500677,"about_ca_system_score_gemma":0.0037089135,"threshold_uncertainty_score":0.65794533},"labels":[],"label_agreement":null},{"id":"W4410819760","doi":"10.1200/jco.2025.43.16_suppl.2009","title":"Multicenter trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) with monthly adjuvant temozolomide for patients with high-grade gliomas.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Temozolomide; Adjuvant; Glioma; Focused ultrasound; Oncology; Glioblastoma; Clinical trial; Internal medicine; Ultrasound; Radiology; Cancer research","score_opus":0.021006777900404765,"score_gpt":0.3189271094583743,"score_spread":0.29792033155796954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848829,0.00010131287,0.012173001,0.00044535403,0.0008819992,0.0009083189,0.00007324779,0.00002870668,0.00050515635],"genre_scores_gemma":[0.98404485,0.00008530786,0.015241942,0.00014979589,0.0003400553,0.00004714388,0.000013748201,0.0000338516,0.000043311033],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99737394,0.00010865776,0.0018334776,0.00019443166,0.00021931407,0.0002701715],"domain_scores_gemma":[0.99561524,0.002930854,0.00069061096,0.00021328084,0.0004034676,0.0001465553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057220337,0.00020938032,0.0012728431,0.00014243569,0.000053846477,0.000015490994,0.0002991267,0.0003097496,0.000021633125],"category_scores_gemma":[0.00036776543,0.00013976509,0.0003308084,0.0002152653,0.00019187522,0.0001301064,0.000007789046,0.00047437404,0.0000017473149],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7082017,0.026257271,0.024952408,0.00066080806,0.008189903,0.000049419905,0.0013124832,0.016851684,0.08162836,0.0011209114,0.0058144075,0.12496063],"study_design_scores_gemma":[0.73666716,0.052499775,0.11987142,0.00056233496,0.0029807,0.000016878259,0.00024851025,0.0007228586,0.014855267,0.0010764665,0.06965142,0.00084719126],"about_ca_topic_score_codex":0.000014090473,"about_ca_topic_score_gemma":0.00017957893,"teacher_disagreement_score":0.12411344,"about_ca_system_score_codex":0.000082098544,"about_ca_system_score_gemma":0.0003598462,"threshold_uncertainty_score":0.5699455},"labels":[],"label_agreement":null},{"id":"W4410820120","doi":"10.1200/jco.2025.43.16_suppl.e14017","title":"Association of plasma biomarkers with recurrence in glioblastoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Glioblastoma; Oncology; Internal medicine; Cancer research","score_opus":0.04719081033600196,"score_gpt":0.42964062771576034,"score_spread":0.38244981737975836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816104,0.00017962989,0.000012944652,0.014244427,0.00048540774,0.000108493165,0.0000013505876,0.000002138838,0.0033551953],"genre_scores_gemma":[0.998189,0.00027396745,0.0010304991,0.00033443994,0.00007489527,0.000002772763,3.688422e-7,0.000003129682,0.00009092968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801654,0.00020210654,0.0013580173,0.00009229866,0.00021906134,0.00011199298],"domain_scores_gemma":[0.9955587,0.0025814069,0.0013584301,0.00008349533,0.00032928868,0.000088697685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019165546,0.000064836226,0.00087345095,0.00022937298,0.000008739266,0.0000023278938,0.00006323831,0.00021183456,0.000030869855],"category_scores_gemma":[0.0033782634,0.000041215073,0.00017810988,0.00031720375,0.00006159708,0.00004175933,0.000016091339,0.00033372355,0.0000026607406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00431071,0.00246557,0.8965082,0.000022320988,0.0007118543,0.00029028364,0.000021005037,0.00001100943,0.00009904589,0.00012474804,0.0055372803,0.08989792],"study_design_scores_gemma":[0.016328353,0.012397005,0.947908,0.00055194314,0.0004838638,0.000040660907,0.00007620151,0.00008155844,0.0016226186,0.00017735091,0.02029144,0.000041022042],"about_ca_topic_score_codex":0.000013441813,"about_ca_topic_score_gemma":0.00026108284,"teacher_disagreement_score":0.0898569,"about_ca_system_score_codex":0.000258799,"about_ca_system_score_gemma":0.0009541318,"threshold_uncertainty_score":0.40443408},"labels":[],"label_agreement":null},{"id":"W4410820157","doi":"10.1200/jco.2025.43.16_suppl.tps617","title":"Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Adjuvant; Breast cancer; Cancer; Clinical Practice; Population; Oncology; Clinical trial; Internal medicine; Adjuvant therapy; Endocrine system; Gynecology; Surgery; Family medicine; Hormone","score_opus":0.08150653700977262,"score_gpt":0.5433641036047657,"score_spread":0.4618575665949931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616377,0.0021865352,0.00020459495,0.03167271,0.0019339387,0.001759992,0.00004404662,0.000023090064,0.0005374395],"genre_scores_gemma":[0.97851944,0.005404249,0.006209035,0.008312237,0.0011509884,0.00011935444,0.000009271547,0.000053104828,0.00022231133],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99108803,0.0016225489,0.0054194774,0.00056974654,0.0008045612,0.0004956366],"domain_scores_gemma":[0.9886966,0.0050215623,0.004045788,0.0005376155,0.001162118,0.00053635874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002823477,0.00042507687,0.0034938618,0.00040900486,0.000052249477,0.000016711634,0.0002492277,0.00036523977,0.00019607131],"category_scores_gemma":[0.0032581545,0.00027432738,0.0007527808,0.0005744186,0.00028270078,0.00039645375,0.00006809538,0.0012809803,0.00000891894],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3919838,0.012279833,0.044031084,0.000017325974,0.001080825,0.0006876497,0.00039438842,0.00008133502,0.000119302276,0.00011373245,0.000112197034,0.5490985],"study_design_scores_gemma":[0.3674637,0.14085068,0.39643937,0.0009019651,0.00097094104,0.0007096788,0.00047665244,0.000038676888,0.00023305336,0.0009233732,0.09071412,0.00027780051],"about_ca_topic_score_codex":0.002023423,"about_ca_topic_score_gemma":0.00082848174,"teacher_disagreement_score":0.54882073,"about_ca_system_score_codex":0.0010138022,"about_ca_system_score_gemma":0.0041859206,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W4410820333","doi":"10.1200/jco.2025.43.16_suppl.8014","title":"Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Placebo; Chemoradiotherapy; Internal medicine; Oncology; Phases of clinical research; Clinical trial; Cancer; Pathology; Pembrolizumab; Immunotherapy; Alternative medicine","score_opus":0.06979469026144287,"score_gpt":0.5023767545804756,"score_spread":0.43258206431903273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98393273,0.008528806,0.00011536097,0.004567565,0.0011545424,0.0015679155,0.0000787656,0.0000060812404,0.000048253554],"genre_scores_gemma":[0.9851302,0.013094966,0.00062332966,0.000459458,0.00051511236,0.0000929213,0.000007332165,0.000021836498,0.00005484116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99357134,0.0016383086,0.0035631994,0.00035416236,0.00057625776,0.0002967289],"domain_scores_gemma":[0.98993933,0.0063205226,0.0025126066,0.00038364937,0.0005934167,0.0002504928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052035,0.000237503,0.0024597538,0.00016873033,0.000037901384,0.000023181723,0.0003075377,0.00039734197,0.0000551735],"category_scores_gemma":[0.006393504,0.00015192255,0.00032143298,0.00022714768,0.001262092,0.0000773868,0.00022243947,0.0012432738,2.3654599e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14525765,0.0028524098,0.7646694,0.00046371616,0.0008957631,0.00024621724,0.00040103216,5.051765e-7,0.00016417394,0.00001419044,0.00018411558,0.084850825],"study_design_scores_gemma":[0.19048099,0.013331036,0.7915974,0.0018513642,0.0009960518,0.0000074069817,0.0000796093,0.0004582838,0.00029981445,0.000026749218,0.0007361363,0.00013512843],"about_ca_topic_score_codex":0.000099014076,"about_ca_topic_score_gemma":0.00026136,"teacher_disagreement_score":0.084715694,"about_ca_system_score_codex":0.00013279062,"about_ca_system_score_gemma":0.0021450724,"threshold_uncertainty_score":0.76540834},"labels":[],"label_agreement":null},{"id":"W4410820377","doi":"10.1200/jco.2025.43.16_suppl.tps2089","title":"A multicenter, randomized, controlled, pivotal trial of microbubble-enhanced transcranial focused ultrasound for patients with NSCLC brain metastases (LIMITLESS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Focused ultrasound; Brain metastasis; Ultrasound; Transcranial Doppler; Oncology; Internal medicine; Radiology; Cancer; Metastasis","score_opus":0.022292219405481598,"score_gpt":0.34172033313832323,"score_spread":0.31942811373284163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9064929,0.00032501912,0.08673669,0.00070139323,0.001322865,0.0029854833,0.00008631655,0.000026393502,0.0013229743],"genre_scores_gemma":[0.9906025,0.0002004937,0.008326836,0.0002563806,0.0003364792,0.00015331742,0.000009979502,0.0000247998,0.00008919103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960342,0.00045283383,0.002926633,0.000156509,0.00020556936,0.0002242259],"domain_scores_gemma":[0.97627884,0.02198598,0.0010079591,0.00013773284,0.0004702797,0.00011918335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002537039,0.00020328574,0.0032017904,0.00014739188,0.000047490135,0.0000181417,0.00025266936,0.00025272983,0.000039855895],"category_scores_gemma":[0.0041839513,0.00013081495,0.0012588111,0.00013808337,0.00025970585,0.00010350498,0.0000073123247,0.00039674094,0.000001569645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97369397,0.0027733783,0.00008279824,0.00005380822,0.0024850285,0.0000016657925,0.00010188396,0.0004682865,0.0036129537,0.0003281298,0.0009386824,0.015459418],"study_design_scores_gemma":[0.9854654,0.0038822782,0.00028105074,0.00008711967,0.0015611738,0.0000025328507,0.000045137625,0.00032830716,0.00046334718,0.0002971861,0.0074550183,0.00013145237],"about_ca_topic_score_codex":0.0000048933525,"about_ca_topic_score_gemma":0.00004612231,"teacher_disagreement_score":0.08410966,"about_ca_system_score_codex":0.000047268688,"about_ca_system_score_gemma":0.00040156586,"threshold_uncertainty_score":0.53344786},"labels":[],"label_agreement":null},{"id":"W4410820396","doi":"10.1200/jco.2025.43.16_suppl.tps2100","title":"Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Glioblastoma; Oncology; Internal medicine; Medical physics; Cancer research","score_opus":0.12906400876150056,"score_gpt":0.49866603726667363,"score_spread":0.3696020285051731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745577,0.00051455246,0.000026858901,0.021121245,0.0019308319,0.0010503004,0.000020289315,0.0000095629575,0.00076867087],"genre_scores_gemma":[0.9931807,0.0007869749,0.0011208022,0.004345956,0.0004715089,0.000050616192,0.0000031542495,0.000010031023,0.000030285317],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964032,0.00036670818,0.0021783526,0.000343862,0.0003900076,0.00031782364],"domain_scores_gemma":[0.9945386,0.0034914787,0.00089559617,0.00023022835,0.00030496027,0.0005391501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002435304,0.00022211444,0.001689752,0.00030378278,0.000043289107,0.00001621728,0.00013044421,0.00031598748,0.000048766462],"category_scores_gemma":[0.007203991,0.0001409883,0.00036884827,0.00040355767,0.00010886463,0.0000819298,0.00008701922,0.00066601153,0.000026724485],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43341795,0.01699852,0.013484774,0.000014030949,0.0006161979,0.0030049274,0.00008416868,0.0000563887,0.00002697895,0.0004878509,0.025340203,0.506468],"study_design_scores_gemma":[0.62334645,0.18840559,0.093843386,0.0009083437,0.00094049686,0.00010188137,0.00020120427,0.0006951476,0.00021801305,0.00089235045,0.09025483,0.00019230013],"about_ca_topic_score_codex":0.000030574145,"about_ca_topic_score_gemma":0.000590691,"teacher_disagreement_score":0.5062757,"about_ca_system_score_codex":0.0005665685,"about_ca_system_score_gemma":0.0011696027,"threshold_uncertainty_score":0.86243707},"labels":[],"label_agreement":null},{"id":"W4410820423","doi":"10.1200/jco.2025.43.16_suppl.8046","title":"Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Chemotherapy; Adjuvant; Oncology; Adjuvant chemotherapy; Cisplatin; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Breast cancer; Nivolumab","score_opus":0.08332271275839634,"score_gpt":0.48218000100747865,"score_spread":0.3988572882490823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774581,0.002186632,0.000977813,0.0127824275,0.0020900483,0.00077187637,0.00006817466,0.000013394146,0.0036514986],"genre_scores_gemma":[0.97928226,0.0034712183,0.0044887546,0.009583608,0.00037426932,0.00003705177,0.000024721887,0.000037613157,0.002700503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643725,0.00012196054,0.0022221413,0.00043390054,0.0003625082,0.00042223276],"domain_scores_gemma":[0.9970483,0.00082431175,0.0011157276,0.0003002039,0.0003630261,0.000348399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009843196,0.0002898125,0.0019725487,0.00027763806,0.00007806301,0.000028178776,0.00023041607,0.000278363,0.0005087939],"category_scores_gemma":[0.00041651566,0.00020839491,0.00034313736,0.0003430589,0.00015324875,0.00015958183,0.00010515278,0.00089260464,0.0000046278296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002815815,0.0047591296,0.92423934,0.00006881011,0.002062998,0.00046465948,0.0004110168,0.00016166127,0.0011350136,0.000030324254,0.012058229,0.051793016],"study_design_scores_gemma":[0.053205293,0.0011332683,0.9074036,0.00062217214,0.0013020649,0.000030788262,0.00021319004,0.0028125169,0.0002443058,0.00006061188,0.032797463,0.00017472675],"about_ca_topic_score_codex":0.002585917,"about_ca_topic_score_gemma":0.0010527975,"teacher_disagreement_score":0.05161829,"about_ca_system_score_codex":0.00062246463,"about_ca_system_score_gemma":0.0034269565,"threshold_uncertainty_score":0.84980977},"labels":[],"label_agreement":null},{"id":"W4410820468","doi":"10.1200/jco.2025.43.16_suppl.10506","title":"Menopausal hormone therapy after a diagnosis of breast cancer in women with a <i>BRCA</i> pathogenic variant and risk of death.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital","funders":"Breast Cancer Society of Canada","keywords":"Medicine; Breast cancer; Hormone therapy; Oncology; Gynecology; Internal medicine; Menopause; Cancer","score_opus":0.015319431875238453,"score_gpt":0.3427823220634634,"score_spread":0.32746289018822494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98309255,0.01592991,0.0000755145,0.0004923411,0.00011094715,0.00011300203,0.00012440028,7.252583e-7,0.000060595325],"genre_scores_gemma":[0.9116966,0.08712132,0.00047662147,0.000484676,0.00016567545,0.00003330629,0.0000011572289,0.0000072950743,0.000013341745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825525,0.00032280703,0.0009913015,0.00016846102,0.00011033025,0.00015183463],"domain_scores_gemma":[0.9985404,0.00019306928,0.0007083618,0.00014706187,0.00027066734,0.00014042272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009446985,0.00010403239,0.00061082153,0.00007398726,0.00001277582,0.0000035183093,0.00011659623,0.0002174691,0.000022579015],"category_scores_gemma":[0.0001981533,0.000074861004,0.000090785295,0.00009015794,0.00019260841,0.0000047240123,0.00004820633,0.00017777675,9.0233215e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03749145,0.0024911268,0.8753448,0.000044022767,0.0007759823,0.000086203974,0.0001032376,0.000031610343,0.024553863,0.000012995397,0.00045057217,0.05861413],"study_design_scores_gemma":[0.008398473,0.008365537,0.97762376,0.000071520284,0.00017068583,0.000032723663,0.00007364102,0.000004002026,0.0015815914,0.00046483902,0.0031301794,0.00008306443],"about_ca_topic_score_codex":0.000053332828,"about_ca_topic_score_gemma":0.00013667316,"teacher_disagreement_score":0.10227893,"about_ca_system_score_codex":0.00002531366,"about_ca_system_score_gemma":0.000838647,"threshold_uncertainty_score":0.3052743},"labels":[],"label_agreement":null},{"id":"W4410820514","doi":"10.1200/jco.2025.43.16_suppl.7017","title":"Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had <i>TP53</i> mutations in the SYMPATICO study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Oncology; Internal medicine; Lymphoma; Cancer research; Chronic lymphocytic leukemia; Leukemia","score_opus":0.04735440968525347,"score_gpt":0.4183786760132616,"score_spread":0.37102426632800817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946967,0.0002759821,0.00004580158,0.002059093,0.00018180718,0.0012533639,0.0000051885477,0.0000033117483,0.0014787636],"genre_scores_gemma":[0.99836475,0.00026652994,0.0002895029,0.00070040417,0.000087078006,0.000014083222,0.000004314071,0.000014243865,0.00025911012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583757,0.0006087194,0.002422812,0.00024094075,0.0005942034,0.0002957495],"domain_scores_gemma":[0.99051505,0.007840236,0.0008359563,0.00033449434,0.00034002037,0.00013423877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003047304,0.0001605145,0.0014135841,0.00026032724,0.000050009985,0.000011091283,0.0002986283,0.0002550693,0.000051743085],"category_scores_gemma":[0.00278118,0.000087216504,0.000121467136,0.0005316951,0.00033327437,0.00007441197,0.0001233089,0.00068744563,0.0000029449586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08629555,0.023214146,0.77943516,0.00052824477,0.00056610757,0.0018555409,0.0039456347,0.0018079014,0.0000034228462,0.000076244316,0.0017945323,0.10047749],"study_design_scores_gemma":[0.21525897,0.015525783,0.76216877,0.0006294577,0.00026772093,0.000053886648,0.0007963766,0.0017279356,0.0000113943215,0.00005082347,0.0034314943,0.000077384095],"about_ca_topic_score_codex":0.00018888398,"about_ca_topic_score_gemma":0.0010083746,"teacher_disagreement_score":0.12896341,"about_ca_system_score_codex":0.003471646,"about_ca_system_score_gemma":0.015790634,"threshold_uncertainty_score":0.98978895},"labels":[],"label_agreement":null},{"id":"W4410820574","doi":"10.1200/jco.2025.43.16_suppl.e13040","title":"Breast cancer detection using a realtime breath analyzer: A pilot study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Chemical Sensor Technologies","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Cancer; Spectrum analyzer; Oncology; Internal medicine; Computer science","score_opus":0.08990460952187247,"score_gpt":0.44609209270816363,"score_spread":0.3561874831862912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300385,0.00035961947,0.004094765,0.00050142757,0.001125721,0.000119079275,0.0000039530473,0.00013765198,0.0006539538],"genre_scores_gemma":[0.9970668,0.00044722878,0.0019802554,0.00010323691,0.00034173913,0.000003929171,1.0064553e-7,0.000016429445,0.000040284398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978089,0.00010638278,0.001546869,0.00014975286,0.0001598359,0.00022831258],"domain_scores_gemma":[0.9982878,0.0007254754,0.00048763887,0.00018297251,0.00021317108,0.00010295485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005231767,0.00014197864,0.0009259167,0.00019467286,0.00003913273,0.000009513618,0.00025555413,0.0002276548,0.00002993866],"category_scores_gemma":[0.000630602,0.00011418958,0.0001668455,0.00040419435,0.000110400855,0.00012544826,0.00006023412,0.0010621448,0.0000028785428],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019265158,0.002006346,0.039340295,0.000052316227,0.0011996385,0.00028725312,0.0000365126,0.037786715,0.07030646,0.000033680368,0.00064778875,0.8463765],"study_design_scores_gemma":[0.029365048,0.033875193,0.72156346,0.0009289236,0.0036882216,0.0026218814,0.001771101,0.11594655,0.048143167,0.01250711,0.027855126,0.0017341921],"about_ca_topic_score_codex":0.00007438082,"about_ca_topic_score_gemma":0.00018224862,"teacher_disagreement_score":0.8446423,"about_ca_system_score_codex":0.00048527296,"about_ca_system_score_gemma":0.00010838478,"threshold_uncertainty_score":0.46565157},"labels":[],"label_agreement":null},{"id":"W4410820588","doi":"10.1200/jco.2025.43.16_suppl.tps2094","title":"A multicenter, pivotal trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) for plasma-based liquid biopsy in patients with glioblastoma (LIBERATE).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Glioblastoma; Liquid biopsy; Focused ultrasound; Ultrasound; Transcranial Doppler; Biopsy; Glioma; Multicenter trial; Oncology; Radiology; Multicenter study; Pathology; Internal medicine; Cancer research; Randomized controlled trial; Cancer","score_opus":0.019397157703484574,"score_gpt":0.32260565151843773,"score_spread":0.3032084938149532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879213,0.000026628171,0.009770783,0.00022686028,0.0009453875,0.000753465,0.000045215627,0.000022643517,0.00028774937],"genre_scores_gemma":[0.9932194,0.000022642238,0.0063252943,0.00011993886,0.00021174928,0.000044095395,0.00000719104,0.000027401766,0.00002232477],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99718946,0.0001291569,0.0020628427,0.00018166075,0.00017544956,0.0002614426],"domain_scores_gemma":[0.9958957,0.0029565059,0.00055185123,0.00016472385,0.0003107964,0.0001204236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070521183,0.00018961618,0.0010860933,0.00022137805,0.000035331574,0.0000136874805,0.00026331496,0.00035537995,0.000024532255],"category_scores_gemma":[0.00051201956,0.00015001274,0.00036927077,0.00028412274,0.00014760792,0.000105539846,0.0000067568126,0.000505317,0.0000020655766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87350684,0.013533198,0.0045482083,0.0002692201,0.0010857773,0.00001650182,0.000412731,0.00980562,0.06077714,0.0001544949,0.00056118635,0.03532907],"study_design_scores_gemma":[0.83876944,0.07650314,0.033258747,0.00060220406,0.0008815621,0.000012088963,0.0001272929,0.004730609,0.03080219,0.00019623058,0.013430823,0.00068569026],"about_ca_topic_score_codex":0.0000051420916,"about_ca_topic_score_gemma":0.00013861478,"teacher_disagreement_score":0.062969945,"about_ca_system_score_codex":0.00009831822,"about_ca_system_score_gemma":0.00052265776,"threshold_uncertainty_score":0.6117342},"labels":[],"label_agreement":null},{"id":"W4410820763","doi":"10.1200/jco.2025.43.16_suppl.tps5632","title":"Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenvatinib; Immunotherapy; Oncology; Internal medicine; Randomized controlled trial; Endometrial cancer; Gynecology; Carcinoma; Cancer; Sorafenib; Hepatocellular carcinoma","score_opus":0.11555544957277976,"score_gpt":0.4839434033552135,"score_spread":0.3683879537824338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894584,0.007173933,0.00003062701,0.00039195578,0.0007118892,0.0024358612,0.0000051110674,0.00000545561,0.0002993442],"genre_scores_gemma":[0.99355334,0.0045876447,0.0014923535,0.000065748114,0.00020237925,0.000031148527,0.0000035108064,0.000016251672,0.00004760467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99369526,0.0015641642,0.003813145,0.00028477263,0.0004009213,0.0002417567],"domain_scores_gemma":[0.98415816,0.012107794,0.002966597,0.00025840724,0.00043585792,0.00007317329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004551567,0.00025684916,0.0040579196,0.00039824133,0.00003694235,0.0000061165247,0.00014017757,0.0001875826,0.000030237215],"category_scores_gemma":[0.002792454,0.000160751,0.0006081362,0.0006413559,0.00044138767,0.000084313244,0.000025407171,0.00037938717,1.6156879e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5707983,0.0059449617,0.07177015,0.000035966725,0.0021908106,0.00003104733,0.00045677688,0.000059438775,0.00124727,0.0000024515482,0.000005258881,0.3474576],"study_design_scores_gemma":[0.5802949,0.09738566,0.3194635,0.00039434657,0.0010550665,0.00001001964,0.00031752288,0.000093044975,0.00044425108,0.0000016542123,0.00046304244,0.000076988166],"about_ca_topic_score_codex":0.0002394216,"about_ca_topic_score_gemma":0.00010202622,"teacher_disagreement_score":0.3473806,"about_ca_system_score_codex":0.00030567634,"about_ca_system_score_gemma":0.0013209688,"threshold_uncertainty_score":0.6555236},"labels":[],"label_agreement":null},{"id":"W4410820775","doi":"10.1200/jco.2025.43.16_suppl.tps2096","title":"A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Temozolomide; Medicine; Glioblastoma; Phases of clinical research; Oncology; Internal medicine; Open label; Clinical trial; Cancer research","score_opus":0.12599099487301693,"score_gpt":0.5039923030240893,"score_spread":0.37800130815107236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889107,0.00055011024,0.000078167344,0.0065817507,0.00032484398,0.0029166434,0.0000049791383,0.000009843551,0.00062297616],"genre_scores_gemma":[0.99655044,0.00072288397,0.0013828631,0.0011520311,0.00010790325,0.00005557541,0.0000016642247,0.00001526583,0.000011377186],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904352,0.003081045,0.0051581347,0.00044579146,0.00046136737,0.0004184687],"domain_scores_gemma":[0.97818196,0.01750194,0.0027279786,0.00044424654,0.00068321516,0.0004606363],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010607643,0.0003099314,0.005270348,0.00016781411,0.00008762434,0.00003713536,0.00041147144,0.00029975222,0.000018645836],"category_scores_gemma":[0.009254739,0.0001491958,0.00024879494,0.00077152613,0.0009990036,0.00012286291,0.00024029151,0.0009983578,0.000001985507],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44836992,0.04390265,0.4803918,0.000016821185,0.0027856654,0.0014143063,0.00012492211,0.00013162105,0.0000037017658,0.00018174358,0.0002579719,0.02241888],"study_design_scores_gemma":[0.6126517,0.04745319,0.3346346,0.00060611195,0.0029818981,0.00008928855,0.00053618354,0.0005709061,0.00002067167,0.00006798255,0.00029057887,0.00009689831],"about_ca_topic_score_codex":0.00031043886,"about_ca_topic_score_gemma":0.0035698626,"teacher_disagreement_score":0.16428177,"about_ca_system_score_codex":0.00016097807,"about_ca_system_score_gemma":0.0018041512,"threshold_uncertainty_score":0.99909073},"labels":[],"label_agreement":null},{"id":"W4410821065","doi":"10.1200/jco.2025.43.16_suppl.tps5637","title":"Stratification of vulvar squamous cell carcinoma (VSCC) by HPV and P53 status to guide excision: CCTG VU.2 STRIVE study (NCT06358469).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University; London Health Sciences Centre; Saskatchewan Health Authority; Centre Hospitalier de l’Université de Montréal; Sunnybrook Health Science Centre; BC Cancer Agency; Vancouver Coastal Health","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Déjà vu; Vulvar cancer; Vulvar Carcinoma; Basal cell; Oncology; Vulva; Internal medicine; Dermatology; Psychiatry","score_opus":0.11045196013397027,"score_gpt":0.5167713374099641,"score_spread":0.40631937727599376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628126,0.0016741271,0.0006127916,0.0051275035,0.0005305051,0.0006991702,0.000017546125,0.0000064295587,0.028519334],"genre_scores_gemma":[0.99559045,0.0003688176,0.00093633647,0.0010021386,0.00038123873,0.000008327855,0.0000040613877,0.000012035185,0.0016965911],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953614,0.000596056,0.0027352101,0.00031962516,0.0006680091,0.00031971183],"domain_scores_gemma":[0.99350756,0.003391245,0.00077406643,0.00034270357,0.001311293,0.0006731087],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003497455,0.00015272682,0.0014066343,0.0002501851,0.000055930042,0.000016818007,0.0002397908,0.00029815803,0.0009133726],"category_scores_gemma":[0.004548974,0.00011312737,0.00021838413,0.00038016407,0.00019068949,0.00007412563,0.00014358519,0.0010241382,0.000009427285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012441321,0.0073906714,0.32602587,0.00019467184,0.00018543257,0.0002936848,0.0006118656,0.000013646667,0.0013494454,0.00012502962,0.083760425,0.56760794],"study_design_scores_gemma":[0.012537369,0.03581779,0.8890075,0.000016892915,0.00033656828,0.000020571693,0.0019389669,0.000047243186,0.00092201994,0.00028249423,0.05897773,0.00009485624],"about_ca_topic_score_codex":0.00026932597,"about_ca_topic_score_gemma":0.00021746168,"teacher_disagreement_score":0.56751305,"about_ca_system_score_codex":0.00024418262,"about_ca_system_score_gemma":0.0027714926,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W4410821212","doi":"10.1200/jco.2025.43.16_suppl.7028","title":"Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Chimeric antigen receptor; Medicine; Safety profile; Adverse effect; Lymphoma; Adverse Event Reporting System; Postmarketing surveillance; Diffuse large B-cell lymphoma; Pharmacovigilance; Oncology; Antigen; Internal medicine; Cancer research; Immunology; Cancer; Immunotherapy","score_opus":0.06189013748469961,"score_gpt":0.43465728156570516,"score_spread":0.37276714408100553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439413,0.00096774846,0.000073709954,0.0011985528,0.0007624324,0.00065531774,0.000023725343,0.000017239488,0.011907136],"genre_scores_gemma":[0.99377847,0.0016491523,0.0020225386,0.00027692007,0.00040973618,0.000009369582,0.000026954114,0.000035404573,0.0017914657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97860026,0.0027309232,0.016655887,0.0004932577,0.0009797551,0.00053991046],"domain_scores_gemma":[0.9562536,0.009465198,0.032165382,0.0008410636,0.0010315048,0.00024326566],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03596587,0.0002819699,0.0041493005,0.00079214375,0.000108086984,0.0000108441955,0.00047475996,0.00040640493,0.00061466283],"category_scores_gemma":[0.01662991,0.00018923868,0.0020510368,0.0022018051,0.000266831,0.00009167166,0.00025276828,0.001208985,0.0000033903107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009179362,0.0071357936,0.88046396,0.00029013274,0.0035902108,0.00059424294,0.0011262079,0.000049474074,0.036013097,0.000014560969,0.00044058793,0.061102353],"study_design_scores_gemma":[0.01961262,0.001513823,0.95198935,0.0010793264,0.0021305429,0.00003184292,0.008569708,0.002386158,0.004789656,0.000011557127,0.0077098915,0.00017551311],"about_ca_topic_score_codex":0.0018540497,"about_ca_topic_score_gemma":0.0009158143,"teacher_disagreement_score":0.07152539,"about_ca_system_score_codex":0.0006443731,"about_ca_system_score_gemma":0.0027187672,"threshold_uncertainty_score":0.992676},"labels":[],"label_agreement":null},{"id":"W4410821434","doi":"10.1200/jco.2025.43.16_suppl.e15580","title":"The addition of monoclonal antibodies to chemotherapy in metastatic early-onset colorectal cancer: A comparative effectiveness study using real-world data.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Colorectal cancer; Monoclonal antibody; Oncology; Chemotherapy; Internal medicine; Cancer; Antibody; Immunology","score_opus":0.2578587939598505,"score_gpt":0.5733575565324137,"score_spread":0.3154987625725632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962208,0.00054271304,0.00002673755,0.0014070696,0.00055545877,0.00082782307,0.0000521654,0.0000032232856,0.00036399643],"genre_scores_gemma":[0.9979606,0.00089877617,0.0007807258,0.00017277265,0.000116079704,0.000030098008,0.0000031066934,0.000005953022,0.00003188709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707764,0.0009019795,0.0014051971,0.00020323593,0.00024431312,0.00016764567],"domain_scores_gemma":[0.9927542,0.005733979,0.00087366067,0.00016589649,0.00039245145,0.00007980461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027583076,0.00013448906,0.0018122329,0.00019492175,0.00008542742,0.000008969912,0.00018694602,0.000042237534,0.000011975655],"category_scores_gemma":[0.0007032646,0.00007847407,0.00016011164,0.00048669858,0.00029081752,0.00007254655,0.00011288838,0.0003836368,5.3822504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035876695,0.0027777085,0.9206601,0.000025076071,0.0024467916,0.00011347981,0.00089245854,0.000064569445,0.000089410496,0.000025957848,0.00068325055,0.03634453],"study_design_scores_gemma":[0.0073296083,0.012605534,0.97633165,0.00025892892,0.0005799338,0.000010069257,0.0013478955,0.00020334801,0.00019784077,0.0001642248,0.0009147983,0.00005615255],"about_ca_topic_score_codex":0.0020940478,"about_ca_topic_score_gemma":0.021454403,"teacher_disagreement_score":0.05567159,"about_ca_system_score_codex":0.0003835735,"about_ca_system_score_gemma":0.0013629051,"threshold_uncertainty_score":0.9964015},"labels":[],"label_agreement":null},{"id":"W4410821448","doi":"10.1200/jco.2025.43.16_suppl.4500","title":"Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Gemcitabine; Nivolumab; Ipilimumab; Carboplatin; Metastatic Urothelial Carcinoma; Cisplatin; Chemotherapy; Internal medicine; Oncology; Urology; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy","score_opus":0.14105371689962076,"score_gpt":0.4486486768325521,"score_spread":0.30759495993293134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97497237,0.0007472338,0.0012328121,0.009759227,0.0035999222,0.006443457,0.00075666595,0.00004556473,0.0024427378],"genre_scores_gemma":[0.9778513,0.00057044503,0.007291599,0.004597922,0.002609244,0.0005366712,0.00015819912,0.00009648382,0.0062881866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931092,0.00065979245,0.0042263204,0.0006562703,0.00060538057,0.0007429956],"domain_scores_gemma":[0.9843004,0.011014139,0.0024478969,0.000623833,0.0012400777,0.00037368137],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031306436,0.0005107882,0.0030713824,0.00020416548,0.00024480885,0.0000628504,0.0005515625,0.00050533836,0.00017895467],"category_scores_gemma":[0.009477652,0.00029891936,0.0012093397,0.00043499397,0.00023694882,0.0001711562,0.00008486118,0.0008211399,0.000009806012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90603477,0.0032447907,0.0099821165,0.00016775982,0.002660358,0.00008083225,0.00035970518,0.000056495806,0.000068891386,0.00005462135,0.03850714,0.038782537],"study_design_scores_gemma":[0.838654,0.05412582,0.037659217,0.0005268678,0.0049153734,0.00002850021,0.00015295057,0.002672545,0.0009304799,0.0014826667,0.05848235,0.00036922132],"about_ca_topic_score_codex":0.0005617962,"about_ca_topic_score_gemma":0.00039305325,"teacher_disagreement_score":0.06738074,"about_ca_system_score_codex":0.0006411681,"about_ca_system_score_gemma":0.0071484693,"threshold_uncertainty_score":0.9999463},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4410821487","doi":"10.1200/jco.2025.43.16_suppl.4505","title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Ipilimumab; Sunitinib; Nivolumab; Renal cell carcinoma; Internal medicine; Oncology; Phases of clinical research; Urology; Clinical trial; Cancer; Immunotherapy","score_opus":0.16938391920761428,"score_gpt":0.4654664655370909,"score_spread":0.2960825463294766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532444,0.0026425344,0.0011664382,0.006985036,0.0010682886,0.0013943374,0.00014474677,0.00001091529,0.001263246],"genre_scores_gemma":[0.9912294,0.0009862506,0.003840475,0.000557561,0.0012468074,0.000074561816,0.00011434427,0.000024305844,0.0019263048],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940251,0.0005973632,0.004101201,0.00042384438,0.0004609259,0.00039153255],"domain_scores_gemma":[0.9860746,0.009048961,0.0030219792,0.0006559987,0.00085798564,0.00034044907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018522412,0.00035214168,0.0037974552,0.00033015088,0.00012637214,0.000013945219,0.0003368468,0.00041652817,0.00021295367],"category_scores_gemma":[0.0017719191,0.00020599256,0.0028444221,0.000578885,0.00029891255,0.00007543938,0.000060385246,0.0005108378,0.000005532708],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7961435,0.0214426,0.009895711,0.00010921933,0.008176339,0.0009173082,0.00042965784,0.0011109259,0.00077559147,0.000058988742,0.0027693675,0.15817082],"study_design_scores_gemma":[0.6632989,0.16891024,0.056268144,0.00012906766,0.029156303,0.000044263666,0.0003784133,0.001901148,0.008368693,0.00042449252,0.07089283,0.0002275175],"about_ca_topic_score_codex":0.00020360852,"about_ca_topic_score_gemma":0.0003881161,"teacher_disagreement_score":0.15794331,"about_ca_system_score_codex":0.0008464261,"about_ca_system_score_gemma":0.0031768968,"threshold_uncertainty_score":0.84001327},"labels":[],"label_agreement":null},{"id":"W4410821527","doi":"10.1200/jco.2025.43.16_suppl.tps3164","title":"TUB-030, a novel ADC targeting 5T4: A phase I/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"ATP Synthase and ATPases Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Solid tumor; Center (category theory); Oncology; Cancer research; Internal medicine; Nuclear medicine; Cancer; Crystallography","score_opus":0.08850909577830092,"score_gpt":0.5084399677602239,"score_spread":0.419930871981923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967163,0.00022484992,0.0007051845,0.0007317386,0.00082644186,0.00058187306,0.000023133396,0.0000045991574,0.00018586303],"genre_scores_gemma":[0.9943433,0.0003724296,0.0035720859,0.0007238434,0.0007697939,0.000019000485,0.000051606978,0.000026631336,0.000121350626],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99380314,0.0007281606,0.004020899,0.0005363216,0.0003517719,0.0005597007],"domain_scores_gemma":[0.9967583,0.00079266995,0.0014281325,0.0003248563,0.0003701146,0.0003259235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042180903,0.0002554241,0.001559108,0.0002115865,0.000081765174,0.00001988617,0.00053227687,0.00059756223,0.00003533741],"category_scores_gemma":[0.006412874,0.00019692411,0.00052163546,0.00022141666,0.00032058268,0.00002386815,0.00027483975,0.001384198,0.000004027875],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3852055,0.09182715,0.44825602,0.000101665624,0.00074113044,0.0007472361,0.00006786961,0.0003752239,0.0061447895,0.000033833323,0.0035230718,0.06297653],"study_design_scores_gemma":[0.7281917,0.06646532,0.11762668,0.00051554927,0.00010449934,0.000007894005,0.00015469827,0.0008877264,0.0011272492,0.000035646295,0.084406905,0.00047617563],"about_ca_topic_score_codex":0.000025997851,"about_ca_topic_score_gemma":0.00038558565,"teacher_disagreement_score":0.34298617,"about_ca_system_score_codex":0.00009626485,"about_ca_system_score_gemma":0.0013244142,"threshold_uncertainty_score":0.80303323},"labels":[],"label_agreement":null},{"id":"W4410821606","doi":"10.1200/jco.2025.43.16_suppl.e13083","title":"Genomic risk stratification in breast cancer: A 10-year follow-up of a single-institution prospective cohort comparing Oncotype DX and MammaPrint.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Breast cancer; Risk stratification; Oncology; Cohort; Internal medicine; Prospective cohort study; Gynecology; Cancer","score_opus":0.03291391133037616,"score_gpt":0.3679770231418513,"score_spread":0.3350631118114752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564576,0.000692857,0.000544568,0.00043008628,0.0006499372,0.00017632979,0.000020596386,0.0000013812354,0.001838474],"genre_scores_gemma":[0.99516296,0.0037060995,0.00069064694,0.00008945025,0.00026937315,0.0000062455683,0.000005035166,0.0000056153553,0.000064557185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984222,0.00012908052,0.001064808,0.00019440074,0.00007796326,0.00011151298],"domain_scores_gemma":[0.9984152,0.00017159898,0.00091554906,0.00013371129,0.00029276535,0.00007117938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010419004,0.00008744745,0.0005310755,0.00007629434,0.000028358834,0.000010288069,0.00012227507,0.00023301895,0.000010661165],"category_scores_gemma":[0.00070785737,0.000080914666,0.0001226542,0.000087442844,0.00016500626,0.0000061191986,0.00007547969,0.000255785,8.3189644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028721693,0.00035799015,0.9517172,0.000017871846,0.00018891362,0.000004900616,0.000026787551,0.00044313716,0.023816459,0.00060647697,0.00043448978,0.019513577],"study_design_scores_gemma":[0.004135583,0.0012493585,0.9863996,0.000059856386,0.00014431145,0.000016577584,0.00006412846,0.00015759206,0.0024421678,0.000617763,0.0046344027,0.00007867547],"about_ca_topic_score_codex":0.00021675877,"about_ca_topic_score_gemma":0.0018061582,"teacher_disagreement_score":0.034682356,"about_ca_system_score_codex":0.00015046455,"about_ca_system_score_gemma":0.0012304644,"threshold_uncertainty_score":0.32996044},"labels":[],"label_agreement":null},{"id":"W4410821726","doi":"10.1200/jco.2025.43.16_suppl.4503","title":"Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Urothelial cancer; Bladder cancer; Perioperative; Cancer; Circulating tumor DNA; Urology; Internal medicine; Oncology; Surgery; Immunotherapy; Pembrolizumab","score_opus":0.02825702325365365,"score_gpt":0.372223055485248,"score_spread":0.34396603223159433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954555,0.00052499125,0.000048339774,0.0010336312,0.00068818766,0.00024598933,0.0000147330975,0.0000014770397,0.0019871322],"genre_scores_gemma":[0.99538934,0.0008939766,0.0005330701,0.002625065,0.00036613486,0.0000161946,0.00000891083,0.000016832073,0.00015047751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751675,0.00032648558,0.0014148181,0.00031444288,0.00016177239,0.00026573782],"domain_scores_gemma":[0.99787116,0.0005381907,0.00081656245,0.00018576217,0.000468356,0.000119963566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000920971,0.00016911651,0.0008186675,0.0001291941,0.000038772545,0.000018199498,0.00022483554,0.00028582022,0.00003060327],"category_scores_gemma":[0.0031106845,0.00013818055,0.00016690388,0.00018738904,0.00015903241,0.000011122311,0.0001040069,0.0005460214,0.000001249341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00379287,0.0014843052,0.92736286,0.00003575862,0.000383955,0.00028505982,0.0003296461,0.0043963175,0.0033321537,0.00008252913,0.0019040254,0.056610502],"study_design_scores_gemma":[0.011309945,0.0038762777,0.9632782,0.00022855522,0.00007644396,0.0000065823792,0.00021079973,0.00008095213,0.0008826473,0.00008439199,0.019762862,0.0002023852],"about_ca_topic_score_codex":0.00011563585,"about_ca_topic_score_gemma":0.0047485665,"teacher_disagreement_score":0.056408115,"about_ca_system_score_codex":0.00020042593,"about_ca_system_score_gemma":0.0029643888,"threshold_uncertainty_score":0.5634839},"labels":[],"label_agreement":null},{"id":"W4410821779","doi":"10.1200/jco.2025.43.16_suppl.4528","title":"Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Clinical endpoint; Oncology; Surrogate endpoint; Internal medicine; Immune checkpoint; Nivolumab; Cancer research; Immunotherapy; Urology; Cancer; Clinical trial","score_opus":0.06574010573805124,"score_gpt":0.43149644236610235,"score_spread":0.3657563366280511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699105,0.00020503518,0.00061708124,0.008933868,0.00047631172,0.0014171277,0.00008601669,0.000012391376,0.0012611204],"genre_scores_gemma":[0.96871716,0.000052161584,0.028044382,0.00088971155,0.00030411634,0.00006592754,0.000102874634,0.0000413747,0.0017823199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991835,0.0011333973,0.0049936464,0.00072599604,0.0007120795,0.00059988064],"domain_scores_gemma":[0.992019,0.0036844206,0.0019404514,0.0007333548,0.0007532051,0.00086956995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045153666,0.0004889275,0.0048224893,0.0012213788,0.000056884553,0.000026904476,0.00037182024,0.00038129126,0.0005157907],"category_scores_gemma":[0.0013721434,0.00036524018,0.002009415,0.000853344,0.00014322925,0.00014323197,0.00016952353,0.00075878535,0.000037671853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051930096,0.03005725,0.66138446,0.00035693473,0.019608205,0.006104312,0.0021568034,0.0042457115,0.21212274,0.00028390827,0.0032059643,0.008543623],"study_design_scores_gemma":[0.026133632,0.045811504,0.8844875,0.00022157819,0.0084147705,0.000035633955,0.00042973305,0.00080729305,0.027559904,0.00029709056,0.0055056517,0.00029567897],"about_ca_topic_score_codex":0.001006878,"about_ca_topic_score_gemma":0.0010472662,"teacher_disagreement_score":0.22310308,"about_ca_system_score_codex":0.0017040214,"about_ca_system_score_gemma":0.003373912,"threshold_uncertainty_score":0.99987996},"labels":[],"label_agreement":null},{"id":"W4410821794","doi":"10.1200/jco.2025.43.16_suppl.4517","title":"Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bladder cancer; Oncology; Stage (stratigraphy); Bacillus (shape); Disease; Internal medicine; Cancer; Microbiology","score_opus":0.08760939791952503,"score_gpt":0.44937335501430903,"score_spread":0.361763957094784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98410916,0.00046344328,0.00031821823,0.012154283,0.0011677102,0.001052277,0.00020916712,0.000010592799,0.00051517057],"genre_scores_gemma":[0.9949212,0.000527645,0.00019263875,0.0035686253,0.00046061815,0.000080180085,0.000026085012,0.000029937106,0.00019306938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942736,0.0019362489,0.0020691815,0.00050015573,0.00084601756,0.00037478408],"domain_scores_gemma":[0.9908114,0.0065486785,0.0012378927,0.0006607779,0.00040122538,0.00033998975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021676014,0.00033783965,0.0017644662,0.00036364814,0.00009332877,0.00002808217,0.00046871454,0.00026161646,0.00027841338],"category_scores_gemma":[0.0034960925,0.00020066647,0.00037511744,0.00069098896,0.0002465546,0.00014139105,0.000102670434,0.0015465068,0.000006486878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022392655,0.012094973,0.9410686,0.000026619557,0.0010387029,0.0020588618,0.00021023586,0.002357716,0.000020452624,0.000026698817,0.0009677941,0.017736727],"study_design_scores_gemma":[0.06192248,0.013780435,0.91956145,0.00041918035,0.0016454583,0.0000012893056,0.0008879522,0.000647982,0.000035699108,0.0003442624,0.0005907081,0.00016313007],"about_ca_topic_score_codex":0.013353916,"about_ca_topic_score_gemma":0.056448936,"teacher_disagreement_score":0.043095022,"about_ca_system_score_codex":0.000743712,"about_ca_system_score_gemma":0.0045835623,"threshold_uncertainty_score":0.9932162},"labels":[],"label_agreement":null},{"id":"W4410821849","doi":"10.1200/jco.2025.43.16_suppl.4571","title":"EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial cancer; Oncology; Chemotherapy; Internal medicine; Subgroup analysis; Phases of clinical research; Cancer; Immunotherapy; Bladder cancer; Meta-analysis","score_opus":0.04983913750394723,"score_gpt":0.44657523319513354,"score_spread":0.3967360956911863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956844,0.000402936,0.0005435218,0.0014393614,0.00018742247,0.001392286,0.000025443638,0.000009075909,0.0003155457],"genre_scores_gemma":[0.9982739,0.00027838498,0.0003709566,0.00082125765,0.00008218807,0.000051053514,0.000017565624,0.000018955578,0.00008574917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486774,0.001172524,0.0027644176,0.00036739756,0.0005257631,0.0003021264],"domain_scores_gemma":[0.9951613,0.0023807324,0.0015010718,0.00038319183,0.00040724158,0.00016644382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015757604,0.00029207303,0.0025542527,0.00029517745,0.000036026926,0.000017240403,0.00032785416,0.00021899598,0.00017955371],"category_scores_gemma":[0.00097106973,0.00016542834,0.00038412964,0.0013822886,0.00022299794,0.00012820652,0.000030470661,0.0006936811,0.0000014482202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11852607,0.017615305,0.77164286,0.00003892485,0.003229181,0.001243723,0.00061653473,0.00011804952,0.000034896046,0.000016571066,0.000030635736,0.08688727],"study_design_scores_gemma":[0.15037514,0.02929699,0.8145382,0.00021209684,0.0043334933,0.00005247346,0.00046677428,0.00029423376,0.0001543039,0.00010893086,0.000058277237,0.00010907448],"about_ca_topic_score_codex":0.0015088092,"about_ca_topic_score_gemma":0.014401941,"teacher_disagreement_score":0.0867782,"about_ca_system_score_codex":0.0006172094,"about_ca_system_score_gemma":0.0036008416,"threshold_uncertainty_score":0.80366206},"labels":[],"label_agreement":null},{"id":"W4410821876","doi":"10.1200/jco.2025.43.16_suppl.4532","title":"International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification and regression tree analysis to characterize objective response rates (ORR) in metastatic renal cell carcinoma (mRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Calgary; Dalhousie University; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Clear cell renal cell carcinoma; Internal medicine; Carcinoma; Cancer research","score_opus":0.1195791700164084,"score_gpt":0.43186613091434717,"score_spread":0.3122869608979388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862001,0.00062370434,0.0008750653,0.0089869555,0.00064828567,0.0006659956,0.000079960344,0.000010840567,0.0019091222],"genre_scores_gemma":[0.98648304,0.0002299282,0.010221034,0.0012964201,0.00020915638,0.00004436557,0.000111881374,0.00002695425,0.0013772261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913744,0.0029334198,0.0037782523,0.0007404675,0.000736589,0.0004369088],"domain_scores_gemma":[0.98954344,0.0059778797,0.0023996108,0.00056819787,0.00085080287,0.00066008326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006286289,0.0004157478,0.002520756,0.0019849164,0.00008319371,0.000047827456,0.00036426593,0.0002461417,0.0001822892],"category_scores_gemma":[0.004157051,0.00030376163,0.0007169821,0.0011672673,0.0002800549,0.00028934475,0.00021107942,0.0012024809,0.00001769769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10792433,0.006280701,0.63288677,0.00021247861,0.0028359927,0.008843266,0.0010494898,0.00008640859,0.21042928,0.00006586236,0.0038542436,0.025531195],"study_design_scores_gemma":[0.012326431,0.006564023,0.9520929,0.0001501113,0.004896896,0.00021063797,0.0007879993,0.001420909,0.01741468,0.00005883211,0.0038552205,0.00022135251],"about_ca_topic_score_codex":0.00014572035,"about_ca_topic_score_gemma":0.00018443416,"teacher_disagreement_score":0.31920615,"about_ca_system_score_codex":0.00084738777,"about_ca_system_score_gemma":0.002464476,"threshold_uncertainty_score":0.99994147},"labels":[],"label_agreement":null},{"id":"W4410821978","doi":"10.1200/jco.2025.43.16_suppl.e22620","title":"Real-world outcomes and toxicity with belzutifan in the treatment of Von Hippel–Lindau disease: A single centre Canadian experience.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Von Hippel–Lindau disease; Disease; Toxicity; Oncology; Internal medicine","score_opus":0.04312727718509779,"score_gpt":0.3972738773021404,"score_spread":0.35414660011704263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913601,0.0016977342,0.000008689297,0.0046387427,0.0006829921,0.00014227965,0.000012838841,8.2850437e-7,0.0014557518],"genre_scores_gemma":[0.9946174,0.0030225334,0.00018329841,0.0010376967,0.00045494895,0.000004344144,0.000004102273,0.0000049187665,0.0006707668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859965,0.0002317017,0.00071479904,0.0001598357,0.00010852009,0.00018552372],"domain_scores_gemma":[0.99892265,0.00020559297,0.00036600896,0.00018612959,0.00009921943,0.0002204238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047101875,0.000106503074,0.00055267004,0.0000922557,0.000036650174,0.000008287849,0.00015118739,0.00013030518,0.000011592288],"category_scores_gemma":[0.00028785606,0.00006082883,0.00016548665,0.00011099825,0.00021370969,0.0000047608373,0.00001717168,0.00012879209,1.9060066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022700296,0.001963161,0.8886235,0.000015715195,0.0002534622,0.000072645584,0.00087463454,0.000017526187,0.0021064242,0.00032438058,0.0019032698,0.10157526],"study_design_scores_gemma":[0.0026475145,0.0021816788,0.6031114,0.000025441414,0.000115478026,0.0000060079574,0.00043792708,0.000004307762,0.0009325054,0.00008482443,0.39038506,0.00006786672],"about_ca_topic_score_codex":0.0040895776,"about_ca_topic_score_gemma":0.25629905,"teacher_disagreement_score":0.3884818,"about_ca_system_score_codex":0.00007538527,"about_ca_system_score_gemma":0.0015408606,"threshold_uncertainty_score":0.7572716},"labels":[],"label_agreement":null},{"id":"W4410822172","doi":"10.1200/jco.2025.43.16_suppl.8082","title":"Test performance of a DNA methylation–based liquid biopsy biomarker for detection and classification of pleural mesothelioma (PM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Mesothelioma; Biomarker; Liquid biopsy; DNA methylation; Biopsy; Pathology; Methylation; Oncology; Cancer research; Internal medicine; DNA; Gene; Cancer; Biology; Gene expression; Genetics","score_opus":0.09012813910228751,"score_gpt":0.4324829928715626,"score_spread":0.3423548537692751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966304,0.00020277663,0.001003066,0.0015080909,0.00019274754,0.00016593895,0.000015489255,0.000002892316,0.00027862567],"genre_scores_gemma":[0.99754363,0.000085695014,0.0020130672,0.00020171906,0.00007934598,0.0000056380077,0.0000057555667,0.000004602416,0.00006056047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843496,0.000079020734,0.0011835274,0.000090756694,0.00014665627,0.00006510644],"domain_scores_gemma":[0.9967905,0.0018923703,0.0009606537,0.000077220466,0.0002027504,0.00007648621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090806995,0.00006258238,0.00047588596,0.00016074002,0.000024517936,0.0000014826355,0.000044958942,0.00014028786,0.000021290494],"category_scores_gemma":[0.001821701,0.000045936766,0.00019264726,0.00012731571,0.00020372284,0.0000656464,0.00001247946,0.000105480685,7.469975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022484109,0.0019936436,0.55266243,0.00031998008,0.00020890754,0.0000028102972,0.00001262677,0.000019457404,0.32749137,0.000055645763,0.00013770758,0.09461131],"study_design_scores_gemma":[0.003903709,0.008630784,0.9614005,0.00010787974,0.00034567143,0.000014138779,0.00002319524,0.0046647345,0.01939321,0.000088409215,0.0013933942,0.000034367516],"about_ca_topic_score_codex":0.0000022021766,"about_ca_topic_score_gemma":0.0000023403688,"teacher_disagreement_score":0.40873808,"about_ca_system_score_codex":0.000049751696,"about_ca_system_score_gemma":0.0003138804,"threshold_uncertainty_score":0.21808778},"labels":[],"label_agreement":null},{"id":"W4410822180","doi":"10.1200/jco.2025.43.16_suppl.3129","title":"Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab in the phase II INTEGRATE study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada's Michael Smith Genome Sciences Centre; Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"","keywords":"Atezolizumab; Medicine; Bevacizumab; Hepatocellular carcinoma; Cancer research; Immune checkpoint; Vascular endothelial growth factor; Oncology; Immune system; VEGF receptors; Immunotherapy; Internal medicine; Immunology; Nivolumab; Chemotherapy","score_opus":0.1036887650843341,"score_gpt":0.4531016664911236,"score_spread":0.3494129014067895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543613,0.0018983373,0.00011894436,0.0009473291,0.00061352743,0.0008200148,0.00000477643,0.0000037222303,0.0001572137],"genre_scores_gemma":[0.99829024,0.000199726,0.0007932015,0.0005013775,0.000120571385,0.000009048989,0.0000013946976,0.000013256169,0.000071198134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99535924,0.00053654116,0.0032895058,0.00025221435,0.000314427,0.00024806225],"domain_scores_gemma":[0.9972807,0.0008164655,0.0012614358,0.00027089857,0.00026946652,0.00010102192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047254246,0.00018721937,0.0014197615,0.0004141088,0.00006103881,0.000013792717,0.00025984045,0.0002404336,0.000014912845],"category_scores_gemma":[0.0012297272,0.00012014358,0.00033598067,0.00041713635,0.00014711676,0.00012844398,0.00013280506,0.0009013248,2.6596118e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05960339,0.003305787,0.024843458,0.00007763072,0.00007704064,0.0005794162,0.0051454348,0.00004611292,0.8781112,0.00000138039,0.000010865938,0.0281983],"study_design_scores_gemma":[0.14126134,0.07655283,0.25891235,0.0026180726,0.00051776116,0.00044870155,0.018892797,0.0013722214,0.4980871,0.00008812733,0.0009492261,0.00029947015],"about_ca_topic_score_codex":0.0006085114,"about_ca_topic_score_gemma":0.00017149273,"teacher_disagreement_score":0.38002408,"about_ca_system_score_codex":0.00065748964,"about_ca_system_score_gemma":0.0017540896,"threshold_uncertainty_score":0.48993132},"labels":[],"label_agreement":null},{"id":"W4410822217","doi":"10.1200/jco.2025.43.16_suppl.tps3174","title":"A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer research; Internal medicine; Oncology","score_opus":0.09521809611650829,"score_gpt":0.5079753282935783,"score_spread":0.41275723217707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99108267,0.0003239939,0.00010662688,0.005995743,0.0008642158,0.0011102464,0.000009357724,0.000009814463,0.00049731496],"genre_scores_gemma":[0.9960889,0.00015085752,0.0009800621,0.0022178125,0.00028044137,0.00003531586,0.000001929448,0.00001965708,0.00022497748],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99423265,0.001139353,0.0035377003,0.00027050145,0.00055689877,0.0002628917],"domain_scores_gemma":[0.9944787,0.0018428512,0.0026068753,0.0003906523,0.0004834069,0.00019750289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002516681,0.00021272556,0.001970974,0.00029747357,0.000053148276,0.000007845854,0.0002536032,0.00016300415,0.00012018666],"category_scores_gemma":[0.001861606,0.00011123865,0.00030549863,0.0007659319,0.0003314406,0.00017943725,0.000058577472,0.0010934584,0.0000020550835],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39021266,0.09392999,0.07156934,0.00030355802,0.0020245814,0.0017949851,0.003739452,0.0005319432,0.0063089593,0.00015858006,0.0026266496,0.42679933],"study_design_scores_gemma":[0.53119284,0.22194324,0.20997445,0.005348209,0.002039247,0.00064832356,0.0075378893,0.0012160321,0.012632667,0.0009821465,0.006030121,0.00045481598],"about_ca_topic_score_codex":0.00004235148,"about_ca_topic_score_gemma":0.0005500881,"teacher_disagreement_score":0.4263445,"about_ca_system_score_codex":0.0002305806,"about_ca_system_score_gemma":0.0029380529,"threshold_uncertainty_score":0.521198},"labels":[],"label_agreement":null},{"id":"W4410822229","doi":"10.1200/jco.2025.43.16_suppl.3114","title":"Development and validation of a biology-based novel therapeutic agent targeting the LIN28/ <i>let-7</i> pathway in cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Cancer; Cancer research; Computational biology; Oncology; Internal medicine; Biology","score_opus":0.08940132134343319,"score_gpt":0.39865502216794624,"score_spread":0.30925370082451303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829242,0.006786256,0.003996245,0.003504802,0.002357193,0.00019878552,0.000006626431,0.0000053133826,0.00022052765],"genre_scores_gemma":[0.9937464,0.00044245922,0.0033708399,0.0022563327,0.000050499442,0.0000119972,0.000004810458,0.0000062294803,0.00011041434],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705815,0.0005837356,0.0019558002,0.00015654565,0.00004049426,0.00020527218],"domain_scores_gemma":[0.99670583,0.0016953809,0.0012883357,0.00011972382,0.00016978187,0.000020925763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00419985,0.00012096871,0.00076234195,0.00013280826,0.00008303798,0.0000050806857,0.00025885526,0.00044932935,0.00006013001],"category_scores_gemma":[0.00077365356,0.0000739655,0.00015675965,0.00015099221,0.00026375338,0.000041267096,0.00007533231,0.0007660654,0.0000032601936],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011818841,0.0012755047,0.012302151,0.00003188651,0.0004827447,0.0000056519484,0.0005126357,0.000092855495,0.653359,0.0037303888,0.00029268896,0.32673258],"study_design_scores_gemma":[0.008825638,0.0021878262,0.031500787,0.00022080577,0.0001090816,0.000013644548,0.0006122745,0.000044468576,0.41657123,0.0008805351,0.5388729,0.00016079834],"about_ca_topic_score_codex":0.00003788847,"about_ca_topic_score_gemma":0.000049249928,"teacher_disagreement_score":0.53858024,"about_ca_system_score_codex":0.00007737185,"about_ca_system_score_gemma":0.0015661196,"threshold_uncertainty_score":0.34656397},"labels":[],"label_agreement":null},{"id":"W4410822468","doi":"10.1200/jco.2025.43.16_suppl.4549","title":"Clinical characteristics and determinants of primary refractory metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Refractory (planetary science); Oncology; Internal medicine; Cancer research","score_opus":0.16500516916579588,"score_gpt":0.47372204650189015,"score_spread":0.30871687733609426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951515,0.0004788598,0.00013756695,0.00043158344,0.0018892699,0.00055746513,0.000060784423,0.0000075724142,0.0012853489],"genre_scores_gemma":[0.9865726,0.00068785215,0.010763546,0.001095655,0.00042632248,0.0000082675615,0.00003379133,0.00002392604,0.00038804451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906627,0.0018925308,0.00604106,0.000464573,0.00065944635,0.0002796917],"domain_scores_gemma":[0.9891646,0.0049550235,0.003868514,0.0005645366,0.0008678926,0.0005794704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071223374,0.0002867276,0.0032081488,0.00037194966,0.000046533245,0.000018004266,0.00037206168,0.00019831602,0.000104282684],"category_scores_gemma":[0.0042068386,0.0002086001,0.0005245227,0.00015719495,0.0005502992,0.0002925494,0.00023600135,0.0012295655,0.000006027077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008337302,0.013570182,0.8748877,0.00022206476,0.00091021514,0.0059119505,0.00010665792,6.5184713e-7,0.0007340554,0.000015278274,0.0005140078,0.09478993],"study_design_scores_gemma":[0.015016692,0.027542517,0.9481085,0.00015822584,0.0034787138,0.0005012317,0.00033136772,0.00016135136,0.0003420802,0.00005092235,0.004171684,0.00013672668],"about_ca_topic_score_codex":0.00003836454,"about_ca_topic_score_gemma":0.000036542755,"teacher_disagreement_score":0.094653204,"about_ca_system_score_codex":0.0002173237,"about_ca_system_score_gemma":0.0030971467,"threshold_uncertainty_score":0.8506465},"labels":[],"label_agreement":null},{"id":"W4410822512","doi":"10.1200/jco.2025.43.16_suppl.tps3171","title":"A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Unum Therapeutics","keywords":"Medicine; Solid tumor; Intrahepatic Cholangiocarcinoma; Oncology; Internal medicine; Cancer research; Radiology; Cancer","score_opus":0.04407917643325134,"score_gpt":0.4446313771914444,"score_spread":0.4005522007581931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988587,0.00004476034,0.000075525524,0.000090023095,0.00014926065,0.00065210345,0.0000071134514,0.000002045796,0.000120447614],"genre_scores_gemma":[0.9991332,0.0000114600425,0.0005111521,0.00014381399,0.00008886011,0.000019874675,0.000004370108,0.0000206399,0.0000666155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964472,0.0005973876,0.0020623617,0.0003166777,0.00026646224,0.0003099172],"domain_scores_gemma":[0.99795455,0.00029297188,0.00095666613,0.00023319312,0.00043667128,0.00012594312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011736131,0.00017892991,0.001085636,0.00029547818,0.000028807544,0.000007543858,0.00031393574,0.00025406765,0.000015984568],"category_scores_gemma":[0.0017234517,0.00012377037,0.00014474931,0.00032125635,0.0001531742,0.000016632319,0.0001776662,0.00071808754,0.0000010058454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018714689,0.028606541,0.9457374,0.000047667287,0.00024990135,0.00009262384,0.0002539638,0.00009733099,0.0026257378,0.0000020485854,0.0001364409,0.0034356578],"study_design_scores_gemma":[0.078626916,0.06283224,0.8545447,0.00025480616,0.000037739595,0.0000049782243,0.00024323043,0.00007631284,0.0027072176,0.000015172716,0.00051786646,0.00013881848],"about_ca_topic_score_codex":0.000056680816,"about_ca_topic_score_gemma":0.0024890697,"teacher_disagreement_score":0.09119269,"about_ca_system_score_codex":0.00012372885,"about_ca_system_score_gemma":0.0007357272,"threshold_uncertainty_score":0.5047209},"labels":[],"label_agreement":null},{"id":"W4410822585","doi":"10.1200/jco.2025.43.16_suppl.e20031","title":"The HALP score as a prognostic biomarker in non-small cell lung cancer: A comprehensive meta-analysis of over 7,000 patients.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Meta-analysis; Biomarker; Oncology; Internal medicine; Cancer","score_opus":0.10909629497560241,"score_gpt":0.495622854527877,"score_spread":0.3865265595522746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837205,0.006459496,0.000047012552,0.004668683,0.0005590799,0.00058735564,0.00002487359,0.0000025219424,0.0039304947],"genre_scores_gemma":[0.99575907,0.0009851082,0.0003135538,0.0020221767,0.000045201337,0.00004234918,0.000007002311,0.0000076289357,0.00081788935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705595,0.00031527827,0.002018818,0.00017333512,0.00025802545,0.00017857799],"domain_scores_gemma":[0.9937172,0.0036490622,0.0014683316,0.00020635275,0.0008280768,0.00013099996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077608676,0.00013030018,0.0020766489,0.00032821638,0.00004594129,0.000008609628,0.00014830986,0.0001781166,0.00018419337],"category_scores_gemma":[0.0008465181,0.00006773122,0.0014686349,0.0007291649,0.00015749053,0.000041752908,0.000048567865,0.0004140778,0.0000013466142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013949148,0.002190654,0.85972995,0.00006192816,0.11862694,0.00011644186,0.00019806986,0.00018229787,0.000019406652,0.00005344335,0.002926168,0.0144998],"study_design_scores_gemma":[0.004770636,0.0014096391,0.77636564,0.000045409834,0.20683101,0.000002213325,0.0000939684,0.0004498899,0.000010475518,0.00005824399,0.009920484,0.000042382555],"about_ca_topic_score_codex":0.0005552924,"about_ca_topic_score_gemma":0.000832309,"teacher_disagreement_score":0.08820407,"about_ca_system_score_codex":0.0002203412,"about_ca_system_score_gemma":0.0018722313,"threshold_uncertainty_score":0.33212578},"labels":[],"label_agreement":null},{"id":"W4410822612","doi":"10.1200/jco.2025.43.16_suppl.3117","title":"Exploring the efficacy and mechanism of action of combined pan-Raf and MEK inhibition in halting the growth of non-V600 BRAF mutated tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University; University of Toronto; Jewish General Hospital","funders":"Conquer Cancer Foundation","keywords":"Medicine; Mechanism of action; Cancer research; Mechanism (biology); Trametinib; Pharmacology; MAPK/ERK pathway; Phosphorylation; In vitro; Cell biology; Biology; Genetics","score_opus":0.11044413258769474,"score_gpt":0.38591487342573005,"score_spread":0.2754707408380353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809533,0.00012297853,0.00044269493,0.00072868774,0.00026995092,0.00012638718,0.0000019043067,8.2756605e-7,0.00021121689],"genre_scores_gemma":[0.99888474,0.0006786753,0.00021665038,0.00011592299,0.00008425633,0.0000029695,0.0000018633827,0.00000442469,0.000010525163],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982189,0.00033316936,0.0011623745,0.00010677609,0.00009021648,0.00008859186],"domain_scores_gemma":[0.9978961,0.00077715504,0.0010137302,0.000101772246,0.00017746606,0.0000338155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002043959,0.000071848415,0.00048203784,0.00006421844,0.000028432181,0.000002975361,0.00008384678,0.0001327677,0.0000012175718],"category_scores_gemma":[0.0015116445,0.000043345703,0.000093564995,0.00009767441,0.00018324291,0.0000093188155,0.00008830771,0.00026111837,5.634482e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001986533,0.00042942772,0.0072972486,0.000108062864,0.00013830549,0.000016625263,0.0002703073,0.00001668988,0.9644217,0.0015759337,0.000056223747,0.023682958],"study_design_scores_gemma":[0.0057070027,0.005660974,0.22700948,0.00022695355,0.00011085922,0.00005432326,0.0006531214,0.00017635747,0.75808525,0.0021207903,0.0001277928,0.00006711868],"about_ca_topic_score_codex":0.000039478375,"about_ca_topic_score_gemma":0.000045995035,"teacher_disagreement_score":0.21971221,"about_ca_system_score_codex":0.000007609709,"about_ca_system_score_gemma":0.00021093896,"threshold_uncertainty_score":0.18096888},"labels":[],"label_agreement":null},{"id":"W4410822662","doi":"10.1200/jco.2025.43.16_suppl.4501","title":"Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Javelin; Avelumab; Medicine; Urothelial carcinoma; Interim analysis; Metastatic Urothelial Carcinoma; Interim; Internal medicine; Urology; Oncology; Bladder cancer; Clinical trial; Immunotherapy; Cancer; Nivolumab","score_opus":0.05185089913416787,"score_gpt":0.4237002166275673,"score_spread":0.37184931749339944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836771,0.00063088036,0.0013711149,0.009866742,0.0013728659,0.0018160419,0.00014942366,0.000020544725,0.0010953025],"genre_scores_gemma":[0.9898635,0.0015343853,0.0009988127,0.0055103796,0.0008396838,0.0001285256,0.000056035595,0.000050524915,0.0010181104],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938843,0.00075994234,0.003448835,0.0006890417,0.0006637189,0.0005541615],"domain_scores_gemma":[0.994126,0.0021958349,0.0019023253,0.00075599505,0.0006167109,0.00040311067],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011342759,0.00054416107,0.0033264211,0.0004231172,0.0001289327,0.00003776639,0.00047546125,0.000472614,0.00057691487],"category_scores_gemma":[0.00116514,0.0003017153,0.0012035092,0.0008863276,0.00036894204,0.00016526703,0.00006753332,0.0010231233,0.000022934648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5895854,0.01833761,0.10833174,0.000014270872,0.008996558,0.0006366495,0.0008517101,0.00017987439,0.000027077944,0.000035830813,0.000983323,0.27201992],"study_design_scores_gemma":[0.62340665,0.13176109,0.19378096,0.00031424308,0.00653899,0.000027492048,0.0003451409,0.0004630317,0.0003793385,0.0004838749,0.042141825,0.00035737018],"about_ca_topic_score_codex":0.0020034497,"about_ca_topic_score_gemma":0.0042571872,"teacher_disagreement_score":0.27166256,"about_ca_system_score_codex":0.0016367047,"about_ca_system_score_gemma":0.0036034023,"threshold_uncertainty_score":0.9999435},"labels":[],"label_agreement":null},{"id":"W4410822690","doi":"10.1200/jco.2025.43.16_suppl.e15561","title":"Deciphering colorectal cancer progression through integrative epigenomic analysis for precision therapeutics.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Epigenomics; Colorectal cancer; Cancer; Precision medicine; Oncology; Internal medicine; Bioinformatics; Pathology; DNA methylation; Genetics; Biology","score_opus":0.3445006426527239,"score_gpt":0.6433972210706295,"score_spread":0.29889657841790557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9468177,0.013178391,0.022660783,0.003841431,0.009222097,0.0006563605,0.000051785883,0.0000190833,0.0035523854],"genre_scores_gemma":[0.96847564,0.015590067,0.009182379,0.0050376826,0.0011864573,0.00007790191,0.000005804292,0.000020193605,0.00042388984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950422,0.0014689201,0.0025260523,0.00033800752,0.00021096152,0.00041382734],"domain_scores_gemma":[0.99059874,0.00625912,0.0019091695,0.00013978712,0.000847778,0.0002453892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053656506,0.00025846667,0.0017329507,0.00026286845,0.00020564768,0.000020399591,0.0005563516,0.00081338605,0.00036032594],"category_scores_gemma":[0.0010856284,0.00017935605,0.0011733569,0.00062489137,0.0003284811,0.00013831088,0.00013108872,0.0015825899,0.0000064355695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010214578,0.0017235162,0.0621071,0.000024823055,0.009196275,0.000031326676,0.00083243597,0.0037291674,0.018163567,0.0007241389,0.002748686,0.89050436],"study_design_scores_gemma":[0.0080809845,0.0019072945,0.040633556,0.00005333715,0.0077813687,0.000007420153,0.00018456703,0.008601593,0.036660604,0.004800303,0.8910525,0.00023650023],"about_ca_topic_score_codex":0.000012110998,"about_ca_topic_score_gemma":0.000077314726,"teacher_disagreement_score":0.8902679,"about_ca_system_score_codex":0.00019554107,"about_ca_system_score_gemma":0.0015781515,"threshold_uncertainty_score":0.73139274},"labels":[],"label_agreement":null},{"id":"W4410822789","doi":"10.1200/jco.2025.43.16_suppl.4555","title":"Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Manitoba; Occupational Cancer Research Centre; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Renal cell carcinoma; Refractory (planetary science); Oncology; Internal medicine; Second line; Metastatic Urothelial Carcinoma; First line; Cancer; Urothelial carcinoma","score_opus":0.1123336320096626,"score_gpt":0.4403739686444062,"score_spread":0.3280403366347436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417615,0.00034737407,0.00030896315,0.00079084956,0.0016330755,0.00087971723,0.00007719198,0.000013004612,0.0017736814],"genre_scores_gemma":[0.97874284,0.00016408766,0.01794184,0.0020602103,0.00025061012,0.00001432752,0.000088143956,0.000037127684,0.00070080906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98980916,0.002315668,0.0059566908,0.00054432603,0.001040224,0.00033394626],"domain_scores_gemma":[0.9853059,0.0075194226,0.004386571,0.00075864536,0.0015217587,0.00050771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006639603,0.0003777062,0.003454656,0.00045925195,0.000056555633,0.000018968647,0.00052793993,0.00018690364,0.00051825616],"category_scores_gemma":[0.0031336497,0.00023439371,0.0007679108,0.0002526328,0.0004666363,0.00042885213,0.00017864138,0.0015238121,0.000007156347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013340589,0.02543649,0.93347573,0.00013165078,0.0038779764,0.0011045462,0.00022531736,0.000010639552,0.00008266062,0.000013639228,0.0006007723,0.021699958],"study_design_scores_gemma":[0.028930958,0.040214688,0.92259383,0.00011903058,0.0031013924,0.000040786377,0.0006033393,0.000027117361,0.00008362341,0.000048850077,0.0040720785,0.00016432551],"about_ca_topic_score_codex":0.000038389233,"about_ca_topic_score_gemma":0.00012287716,"teacher_disagreement_score":0.021535633,"about_ca_system_score_codex":0.00034787468,"about_ca_system_score_gemma":0.003170674,"threshold_uncertainty_score":0.9558298},"labels":[],"label_agreement":null},{"id":"W4410822904","doi":"10.1200/jco.2025.43.16_suppl.e19057","title":"Sex-based differences in complications in patients with diffuse large B cell lymphoma receiving axicabtagene ciloleucel therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Oncology; Surgery","score_opus":0.10030424752009427,"score_gpt":0.4371271288490954,"score_spread":0.3368228813290011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907425,0.00020746599,0.00019536616,0.0042650364,0.0002131633,0.000423888,0.000004332325,0.000007483951,0.0039407555],"genre_scores_gemma":[0.9951581,0.0004000337,0.0007093628,0.0026375225,0.000099629,0.000015265883,0.0000051478123,0.000014892716,0.00096004095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653614,0.000753999,0.0017041565,0.00024230186,0.00043092598,0.000332472],"domain_scores_gemma":[0.99537086,0.0031599205,0.0006254663,0.00030223903,0.00033450627,0.00020702314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002508496,0.00014645555,0.0012452235,0.00046153355,0.000040214712,0.00001333805,0.00028447254,0.0002873416,0.00024297547],"category_scores_gemma":[0.00084327004,0.00009873153,0.00020327742,0.00050947216,0.00014775379,0.000059105332,0.000047194688,0.0008522607,0.00000565494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005565171,0.023025727,0.8695167,0.00002236323,0.00007553436,0.00006683704,0.00008646804,0.000004261178,0.00039890083,0.000015032325,0.00022253323,0.1010005],"study_design_scores_gemma":[0.0643984,0.0055717896,0.91994804,0.00017569667,0.000027507704,0.0000027455592,0.00007349258,0.0002549115,0.0002187417,0.000089274195,0.009159487,0.00007991358],"about_ca_topic_score_codex":0.000037094604,"about_ca_topic_score_gemma":0.0002043876,"teacher_disagreement_score":0.10092059,"about_ca_system_score_codex":0.00031593582,"about_ca_system_score_gemma":0.0018875209,"threshold_uncertainty_score":0.4026155},"labels":[],"label_agreement":null},{"id":"W4410822960","doi":"10.1200/jco.2025.43.16_suppl.4556","title":"Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Immunotherapy; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Risk stratification; Cancer; Urothelial carcinoma","score_opus":0.07046330052147087,"score_gpt":0.35372767028367874,"score_spread":0.28326436976220787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468905,0.00070629665,0.0005121232,0.0019931607,0.00081476383,0.00062036136,0.00017896897,0.000009933356,0.00047533822],"genre_scores_gemma":[0.9849458,0.0005405433,0.013205692,0.0006282675,0.0002138993,0.000054342836,0.0002018808,0.000045652654,0.00016392866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99235076,0.0011868038,0.0044801175,0.0005770458,0.0010186319,0.00038664514],"domain_scores_gemma":[0.98667145,0.0073580216,0.004231069,0.0006682255,0.0008179046,0.00025331878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042235055,0.0004059632,0.0019397532,0.0004690504,0.00010297093,0.00004370275,0.0006660899,0.00021486777,0.0002708434],"category_scores_gemma":[0.0028368703,0.00026919157,0.0004621973,0.00047301242,0.00041959106,0.00028237002,0.00016052945,0.0017358285,0.000012138032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012462173,0.0048598154,0.9692399,0.00011099161,0.000893802,0.0003059037,0.0009828265,0.00027428239,0.002321702,0.00002678996,0.0010670426,0.007454778],"study_design_scores_gemma":[0.025506953,0.011298448,0.9403694,0.0007170931,0.0017836036,0.000017228705,0.00061133865,0.00036038886,0.01851513,0.00013135794,0.00046830496,0.00022072408],"about_ca_topic_score_codex":0.0011378425,"about_ca_topic_score_gemma":0.0013456958,"teacher_disagreement_score":0.028870465,"about_ca_system_score_codex":0.00064296566,"about_ca_system_score_gemma":0.0018448316,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W4410822970","doi":"10.1200/jco.2025.43.16_suppl.e19049","title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Second line; Oncology; Lymphoma; First line","score_opus":0.14789144499785303,"score_gpt":0.4464841575960615,"score_spread":0.2985927125982085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849022,0.0065568904,0.00094039127,0.0024248136,0.0017823251,0.0019548351,0.00013782864,0.000035676923,0.0012650627],"genre_scores_gemma":[0.97084963,0.010209118,0.0103319585,0.00048272335,0.0005882757,0.000075994925,0.00006917258,0.00012845016,0.0072646555],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905957,0.0009989036,0.0054922076,0.0008167925,0.0012187182,0.00087769795],"domain_scores_gemma":[0.98728496,0.0056746188,0.0038571146,0.00097327295,0.001504397,0.00070566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035556094,0.000715817,0.0062186024,0.0008416666,0.00013663892,0.00003299587,0.0006587109,0.0011199685,0.0004813196],"category_scores_gemma":[0.0013428101,0.00050240086,0.0017055813,0.00083557056,0.00092417473,0.0002090121,0.00024401238,0.0007401602,0.00000691343],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39226028,0.022866108,0.026360953,0.0018367337,0.016354568,0.0015301144,0.0021415467,0.0003361373,0.084149,0.00021919233,0.0072214045,0.44472396],"study_design_scores_gemma":[0.3332532,0.21084903,0.059113093,0.0021708603,0.012920813,0.00060360215,0.0025608193,0.004185478,0.22780393,0.0006544005,0.14455652,0.001328246],"about_ca_topic_score_codex":0.0003877826,"about_ca_topic_score_gemma":0.0010973171,"teacher_disagreement_score":0.4433957,"about_ca_system_score_codex":0.00060230854,"about_ca_system_score_gemma":0.0032632342,"threshold_uncertainty_score":0.99974275},"labels":[],"label_agreement":null},{"id":"W4410823043","doi":"10.1200/jco.2025.43.16_suppl.4540","title":"Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Renal cell carcinoma; Metastatic melanoma; Oncology; Immune checkpoint; Internal medicine; Ipilimumab; Cancer research; Immunotherapy; Cancer","score_opus":0.05156941605445359,"score_gpt":0.36286318072101537,"score_spread":0.3112937646665618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939104,0.0003687476,0.000041673455,0.00027528495,0.00011740605,0.005047294,0.000056292072,0.000017612927,0.00016533275],"genre_scores_gemma":[0.9972895,0.00017209954,0.0015997726,0.000118757736,0.0001561768,0.00014543613,0.000072338575,0.00010007235,0.000345845],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9910506,0.0021850155,0.004136217,0.0007942555,0.0012374596,0.0005964802],"domain_scores_gemma":[0.9915101,0.0023067812,0.0036288665,0.0008134827,0.0013854074,0.00035538542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019335031,0.0008239975,0.0038633214,0.0008346337,0.000086067856,0.000030104053,0.000416445,0.00030857485,0.00019799072],"category_scores_gemma":[0.00048115643,0.00037727275,0.0004326366,0.0012763842,0.00061901694,0.00032467168,0.000049327715,0.0010582526,0.0000025302018],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5496733,0.14133202,0.2751686,0.00040160224,0.002598782,0.0030132474,0.0056413636,0.0000727492,0.0052666543,0.000008888547,0.000019457368,0.016803283],"study_design_scores_gemma":[0.25762898,0.43589622,0.2562304,0.0009372147,0.001847767,0.00012887697,0.0020530287,0.000055291577,0.044800278,0.000005744767,0.00012250463,0.00029368818],"about_ca_topic_score_codex":0.0010249341,"about_ca_topic_score_gemma":0.002790321,"teacher_disagreement_score":0.2945642,"about_ca_system_score_codex":0.0011902644,"about_ca_system_score_gemma":0.0037796944,"threshold_uncertainty_score":0.9998679},"labels":[],"label_agreement":null},{"id":"W4410823142","doi":"10.1200/jco.2025.43.16_suppl.e20126","title":"Survival outcomes for patients with extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation therapy (cTRT) and chemoimmunotherapy (CIT): A population level study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Chemoimmunotherapy; Oncology; Radiation therapy; Lung cancer; Stage (stratigraphy); Population; Internal medicine; Chemotherapy; Radiology; Cyclophosphamide","score_opus":0.13281562938069374,"score_gpt":0.516175931575943,"score_spread":0.38336030219524925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317753,0.0010237367,0.0003617235,0.0027162945,0.0002484254,0.0023164651,0.00004099362,0.000011171754,0.000103639046],"genre_scores_gemma":[0.99531245,0.0017659914,0.0010133515,0.0007847892,0.00016448794,0.00009605674,0.000014597574,0.000026363052,0.0008219148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748546,0.0004733939,0.0011182226,0.00028188174,0.00038613557,0.0002549277],"domain_scores_gemma":[0.9941925,0.0026099323,0.0012642035,0.00016972693,0.0016314812,0.00013217745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013767374,0.00021993532,0.0016023652,0.00019061149,0.00011402327,0.00002076837,0.000100654936,0.00015438747,0.000016456255],"category_scores_gemma":[0.0008131829,0.00012183662,0.00014752396,0.00021862854,0.00018320644,0.00012806494,0.000027821083,0.00050213037,1.8819192e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03653739,0.0019020876,0.9092886,0.00007192027,0.0024368586,0.00002771994,0.00058202335,0.000021082527,0.000026120733,0.000008197971,0.0002196207,0.048878387],"study_design_scores_gemma":[0.039208088,0.021085294,0.93676066,0.00014244484,0.00053072436,0.0000017421512,0.00065543415,0.00008644257,0.00007142385,0.000014346656,0.0013276975,0.00011568023],"about_ca_topic_score_codex":0.0003919654,"about_ca_topic_score_gemma":0.0003771521,"teacher_disagreement_score":0.04876271,"about_ca_system_score_codex":0.00041191885,"about_ca_system_score_gemma":0.0012632,"threshold_uncertainty_score":0.49683535},"labels":[],"label_agreement":null},{"id":"W4410823148","doi":"10.1200/jco.2025.43.16_suppl.4544","title":"Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Post-hoc analysis; Renal cell carcinoma; Oncology; Radiological weapon; Internal medicine; Surgery","score_opus":0.06575000979964242,"score_gpt":0.3984571933586429,"score_spread":0.3327071835590005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98479575,0.0023826563,0.0027895551,0.0069259084,0.00024055336,0.0025098915,0.000076226,0.000020010104,0.00025946798],"genre_scores_gemma":[0.9887177,0.0015320099,0.0069167395,0.0016779919,0.00074253173,0.00012702007,0.00011389088,0.000028592973,0.0001435445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9873181,0.005158635,0.005710834,0.00070118037,0.00061409513,0.00049715367],"domain_scores_gemma":[0.97566086,0.019328816,0.0029442487,0.000556067,0.0007450298,0.0007649651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009348519,0.00052552414,0.008172648,0.0010948934,0.00007731486,0.000029936986,0.00034098874,0.00037174672,0.0003921693],"category_scores_gemma":[0.00647177,0.00028682585,0.0022358447,0.0015271413,0.000341507,0.00009048308,0.000062200335,0.0015281914,0.000011131479],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95311147,0.007937701,0.009159074,0.000018280018,0.0066365977,0.009263194,0.00023098582,0.0006536195,0.00079708645,0.0000060461766,0.0003887354,0.0117972335],"study_design_scores_gemma":[0.8705031,0.083455384,0.024056705,0.00011129371,0.016967215,0.00011820268,0.0002222445,0.0025968042,0.0009249963,0.000124359,0.0006807411,0.00023894291],"about_ca_topic_score_codex":0.0011449511,"about_ca_topic_score_gemma":0.0011838125,"teacher_disagreement_score":0.082608335,"about_ca_system_score_codex":0.00045828585,"about_ca_system_score_gemma":0.0022270675,"threshold_uncertainty_score":0.9999584},"labels":[],"label_agreement":null},{"id":"W4410823208","doi":"10.1200/jco.2025.43.16_suppl.e20003","title":"Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive non-small cell lung cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Osimertinib; Adjuvant; Oncology; Lung cancer; Internal medicine; Adverse effect; Mutation; Cancer; Lung; Epidermal growth factor receptor; Gene; Erlotinib; Genetics; Biology","score_opus":0.039176949167436644,"score_gpt":0.4746904172840064,"score_spread":0.43551346811656977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806414,0.00031313638,0.00013388474,0.006475741,0.0008124216,0.00045906982,0.000012359487,0.0000067107794,0.011145277],"genre_scores_gemma":[0.99273664,0.0006851071,0.0020505174,0.0010435651,0.00014178522,0.00002205704,0.00000863635,0.000012917319,0.0032987983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977945,0.00025198015,0.0013460893,0.00020422775,0.0002043222,0.00019886399],"domain_scores_gemma":[0.99676263,0.0016847588,0.00082575943,0.00011685643,0.00040661567,0.00020337645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007730731,0.00014139446,0.0011406996,0.00026020402,0.000048138765,0.0000036828653,0.00007664967,0.0001474778,0.00004146699],"category_scores_gemma":[0.0004007579,0.00009137422,0.00015395123,0.00031896454,0.00009356702,0.000086662454,0.00003165721,0.0005618906,0.0000013944725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034255222,0.0010374563,0.98289275,0.00005923378,0.00079353136,0.00076257647,0.00036730262,0.00012754816,0.000035261975,0.00005055983,0.000394592,0.010053687],"study_design_scores_gemma":[0.02009744,0.0026748662,0.9738911,0.00048231313,0.0013111321,0.000016427482,0.00038328982,0.00024351595,0.00007880948,0.00006384285,0.00067901134,0.000078294885],"about_ca_topic_score_codex":0.0013175522,"about_ca_topic_score_gemma":0.0063535487,"teacher_disagreement_score":0.016671918,"about_ca_system_score_codex":0.00044264598,"about_ca_system_score_gemma":0.0031929298,"threshold_uncertainty_score":0.56641203},"labels":[],"label_agreement":null},{"id":"W4410823212","doi":"10.1200/jco.2025.43.16_suppl.tps3160","title":"Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Mesothelin; Medicine; Solid tumor; Cancer research; CD3; Bispecific antibody; Oncology; Nuclear medicine; Internal medicine; Cancer; Monoclonal antibody; Immune system; Immunology; Antibody","score_opus":0.24522242943177328,"score_gpt":0.5255013246005501,"score_spread":0.2802788951687768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950785,0.00051834865,0.00024585615,0.0008015205,0.0002453407,0.001947541,0.0000019726576,0.000005712827,0.0011551883],"genre_scores_gemma":[0.9930915,0.0004964107,0.005313513,0.00024053977,0.00013113156,0.00004664853,0.000001002566,0.000037949452,0.00064125797],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9906175,0.0026845904,0.0049943784,0.0004251999,0.00066520175,0.0006130873],"domain_scores_gemma":[0.989739,0.0065603363,0.0022515925,0.0004572362,0.00070143637,0.0002904007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014115176,0.00025167354,0.0031375205,0.0006306347,0.000057147154,0.000016127211,0.0006901761,0.0002752898,0.0004053059],"category_scores_gemma":[0.0041899784,0.00018364735,0.00017014262,0.0006874591,0.00030382772,0.00016182958,0.000262413,0.002111563,0.000003648026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12146554,0.12356453,0.51947325,0.0005419149,0.0011464466,0.0039768233,0.0068511297,0.0033482546,0.18637413,0.000021896542,0.0008502628,0.032385834],"study_design_scores_gemma":[0.5128251,0.21712615,0.1802159,0.006371977,0.001073617,0.00008376948,0.02594281,0.011218954,0.037621226,0.0003658799,0.0063739284,0.0007807372],"about_ca_topic_score_codex":0.00014501813,"about_ca_topic_score_gemma":0.00086461846,"teacher_disagreement_score":0.39135954,"about_ca_system_score_codex":0.00029755547,"about_ca_system_score_gemma":0.0016049622,"threshold_uncertainty_score":0.9173808},"labels":[],"label_agreement":null},{"id":"W4410823609","doi":"10.1200/jco.2025.43.16_suppl.4548","title":"Second-line outcomes in metastatic renal cell carcinoma: The role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Alberta; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Immunotherapy; Oncology; Internal medicine; Second line; Carcinoma; First line; Cancer research; Cancer","score_opus":0.06370025275547174,"score_gpt":0.3831138386709389,"score_spread":0.31941358591546715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870984,0.0052258,0.00023918584,0.0034590336,0.0011031808,0.0009070321,0.00014579248,0.000009278989,0.001812301],"genre_scores_gemma":[0.9940299,0.00029408408,0.0029569373,0.001110662,0.00021817334,0.000052062485,0.000059712474,0.000042022006,0.0012364398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922214,0.001064136,0.00490762,0.0004783432,0.0008268816,0.0005015804],"domain_scores_gemma":[0.98835063,0.007285771,0.002682498,0.0006536629,0.00070100377,0.00032645295],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031286546,0.0004826268,0.0027252391,0.0006233754,0.00006243944,0.000024934869,0.00062633,0.00022831539,0.000967766],"category_scores_gemma":[0.0019207554,0.00028499705,0.0011249584,0.00038967308,0.00047819916,0.00020566549,0.00021710378,0.0016027461,0.000014407411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008393501,0.0062659113,0.974253,0.00022862913,0.0009718151,0.0022904219,0.00044109832,0.00013592454,0.0034109831,0.000042869236,0.00047977004,0.0030860768],"study_design_scores_gemma":[0.019126842,0.008723281,0.93935955,0.0001705257,0.002023511,0.00021042919,0.0006059587,0.00046445697,0.019384224,0.0003845763,0.009306134,0.00024053291],"about_ca_topic_score_codex":0.00018292411,"about_ca_topic_score_gemma":0.00056761026,"teacher_disagreement_score":0.03489347,"about_ca_system_score_codex":0.00040863993,"about_ca_system_score_gemma":0.002347278,"threshold_uncertainty_score":0.99996024},"labels":[],"label_agreement":null},{"id":"W4410841109","doi":"10.1200/jco.2025.43.16_suppl.9007","title":"Board certification and billing practices of international medical graduate hematologists and oncologists.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Certification; Family medicine; Board certification; Medical education; Continuing medical education; Continuing education","score_opus":0.2446033873062142,"score_gpt":0.6021396420961331,"score_spread":0.3575362547899189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410841109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8444104,0.0050480566,0.005589363,0.1368069,0.003430062,0.0001619519,0.0000013328888,0.000010799566,0.004541134],"genre_scores_gemma":[0.9338769,0.038681388,0.02215288,0.0044621355,0.0005928436,0.0000028359611,0.0000014131193,0.00000558284,0.00022403568],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99724287,0.00035477735,0.0018164485,0.00017711833,0.0002977434,0.00011101832],"domain_scores_gemma":[0.9894182,0.0068405448,0.003022238,0.00011284406,0.00043345866,0.00017269333],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004315452,0.000090783615,0.0010515094,0.0001572422,0.00004146901,0.0000049389046,0.00015648069,0.00052760687,0.00004477337],"category_scores_gemma":[0.025451068,0.000059861988,0.00012872896,0.00010306189,0.001186312,0.00012601752,0.00005923963,0.0009025034,8.051999e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049234843,0.0012960613,0.45175397,0.000090105335,0.0006497064,0.00038070834,0.00011244238,0.0000050455637,0.00018711013,0.0037603609,0.0031098698,0.5337311],"study_design_scores_gemma":[0.010022309,0.007091417,0.53926253,0.00039675809,0.00047008475,0.002254559,0.0004268738,0.0011019785,0.00024366177,0.0066514187,0.4319645,0.00011389578],"about_ca_topic_score_codex":0.000012247133,"about_ca_topic_score_gemma":0.000017693044,"teacher_disagreement_score":0.53361726,"about_ca_system_score_codex":0.00007643722,"about_ca_system_score_gemma":0.0013241488,"threshold_uncertainty_score":0.982758},"labels":[],"label_agreement":null},{"id":"W4410841132","doi":"10.1200/jco.2025.43.16_suppl.9015","title":"Rethinking future workforce planning by developing novel metrics of complexity in cancer care.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biomedical and Engineering Education","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Workforce; Developing country; Nursing; Economic growth","score_opus":0.21222958099065065,"score_gpt":0.4659084144443096,"score_spread":0.25367883345365894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410841132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8813949,0.018038139,0.07931859,0.006189341,0.012652154,0.00009601234,0.000007663387,0.00003863158,0.0022645758],"genre_scores_gemma":[0.96912825,0.0011954518,0.028651923,0.00037124392,0.000615009,0.0000020614468,0.000002844531,0.000009406147,0.000023783647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983019,0.000042123665,0.0012752387,0.00007618707,0.00015435764,0.00015019755],"domain_scores_gemma":[0.99867624,0.000763907,0.00028405237,0.00006568007,0.0001359135,0.000074229625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001079499,0.00008355726,0.00060461473,0.00021824484,0.000015258942,0.0000048084066,0.00018637875,0.00035930963,0.0000078627],"category_scores_gemma":[0.00062725967,0.00007069325,0.00009729875,0.0005741797,0.00006134767,0.00006051038,0.000025982363,0.0009011204,2.837194e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003532652,0.00062021334,0.09438496,0.0020451574,0.0006015573,0.000039683742,0.004991322,0.04347187,0.0016140899,0.005631473,0.043022286,0.80322415],"study_design_scores_gemma":[0.0058169467,0.0007812214,0.37419304,0.0034229273,0.0001886451,0.000023913904,0.0018416009,0.023684043,0.0012947636,0.004418144,0.58382237,0.0005124018],"about_ca_topic_score_codex":0.000022242099,"about_ca_topic_score_gemma":0.0000283496,"teacher_disagreement_score":0.8027117,"about_ca_system_score_codex":0.00029017762,"about_ca_system_score_gemma":0.0004518483,"threshold_uncertainty_score":0.391497},"labels":[],"label_agreement":null},{"id":"W4410849200","doi":"10.1200/jco-24-02121","title":"Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; Hospital for Sick Children; University of Toronto; SickKids Foundation; Institute for Work & Health","funders":"","keywords":"Medicine; Cancer; Demography; Cohort; Population; Breast cancer; Retrospective cohort study; Cohort study; Internal medicine; Pediatrics","score_opus":0.039791132124045406,"score_gpt":0.44028993980978104,"score_spread":0.40049880768573565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410849200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926034,0.0010785752,0.00015448703,0.0028403443,0.0021528364,0.00096113334,0.0000060062066,0.000020856853,0.00018232856],"genre_scores_gemma":[0.9959361,0.0011605562,0.00022645539,0.0016026649,0.0008519461,0.000016968943,0.000002273735,0.000024719526,0.00017831913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995205,0.00052875734,0.0026873876,0.00046191557,0.0007117433,0.00040521382],"domain_scores_gemma":[0.9959383,0.0005800127,0.0019527994,0.0003440214,0.0006047901,0.0005800748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038007242,0.00028631376,0.0024573037,0.00023125883,0.0000898573,0.00002847468,0.0002467875,0.0003880158,0.000041424395],"category_scores_gemma":[0.0023812673,0.00020916764,0.00031739258,0.0003020513,0.00039440367,0.00020776874,0.00013332456,0.001665305,0.0000030921728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0139748175,0.0034670867,0.9559355,0.0003247841,0.00083309715,0.0014172358,0.000760492,0.0000029820105,0.0000031867705,0.000002276696,0.0004929112,0.022785628],"study_design_scores_gemma":[0.018745676,0.011440046,0.96425056,0.0031945547,0.0013896731,0.00033592997,0.0003609821,0.000025491283,0.0000029995538,0.000023611592,0.00005535386,0.00017514254],"about_ca_topic_score_codex":0.0010785419,"about_ca_topic_score_gemma":0.028964266,"teacher_disagreement_score":0.027885724,"about_ca_system_score_codex":0.00040046943,"about_ca_system_score_gemma":0.0034009952,"threshold_uncertainty_score":0.98875463},"labels":[],"label_agreement":null},{"id":"W4410998031","doi":"10.1200/jco-25-00744","title":"Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Pomalidomide; Adverse effect; Dexamethasone; Refractory (planetary science); Internal medicine; Clinical endpoint; Multiple myeloma; Gastroenterology; Randomized controlled trial; Lenalidomide","score_opus":0.08940169969264583,"score_gpt":0.4717100872894226,"score_spread":0.38230838759677677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410998031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921832,0.0015361508,0.00004065148,0.0016448915,0.0015924276,0.0012825117,0.000027968199,0.000025176105,0.0016670285],"genre_scores_gemma":[0.99656266,0.00063504453,0.000897312,0.0007462781,0.00041314086,0.000028573208,0.000013615508,0.000039270613,0.0006641019],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935336,0.0013745143,0.003026,0.00060586724,0.00075918576,0.00070083386],"domain_scores_gemma":[0.9845207,0.012669823,0.0011415259,0.00048014018,0.00038448922,0.0008033363],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032671492,0.00040327414,0.0029205903,0.0006172514,0.00011688091,0.00003239529,0.00032210536,0.0006435789,0.000111211186],"category_scores_gemma":[0.014504259,0.0003083621,0.0003956411,0.0004416684,0.00041947974,0.00011588416,0.00016503953,0.0026964021,0.000028103039],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45560154,0.063294806,0.08344736,0.00007848171,0.0028224674,0.02936272,0.0006558117,0.000011873323,0.0015617713,0.00003629867,0.004886474,0.3582404],"study_design_scores_gemma":[0.6055309,0.21193823,0.1620993,0.0003037691,0.0010470386,0.0007876914,0.0017782616,0.0011666801,0.00036659927,0.000092526716,0.014502641,0.0003863584],"about_ca_topic_score_codex":0.00039521971,"about_ca_topic_score_gemma":0.00046406075,"teacher_disagreement_score":0.35785404,"about_ca_system_score_codex":0.0011539615,"about_ca_system_score_gemma":0.0027193432,"threshold_uncertainty_score":0.9999368},"labels":[],"label_agreement":null},{"id":"W4411017103","doi":"10.1200/jco-24-02816","title":"Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bruyère; University of Ottawa; Health Sciences Centre; McMaster University; Queen's University; University of Toronto; University Health Network; Sunnybrook Health Science Centre; Sinai Health System; Princess Margaret Cancer Centre; Public Health Ontario","funders":"","keywords":"Medicine; Logistic regression; Receipt; Cancer; Odds; Chemotherapy; Odds ratio; Emergency medicine; Internal medicine","score_opus":0.2711100718947255,"score_gpt":0.558067687898541,"score_spread":0.2869576160038155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411017103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98201734,0.011252737,0.000035794303,0.005850384,0.00035740502,0.00020724411,0.000019057237,0.000002332847,0.00025771296],"genre_scores_gemma":[0.9746471,0.021482354,0.0006378443,0.0027139017,0.00019250286,0.000004162699,0.0000015248586,0.0000062707827,0.00031435883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980224,0.0001562509,0.0013486666,0.00012305591,0.00021894492,0.00013068109],"domain_scores_gemma":[0.9957805,0.0017712263,0.0017364144,0.00013462009,0.00040062243,0.00017658551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086784764,0.000098009106,0.0012909223,0.000062170526,0.000030279516,0.0000030535284,0.0000861104,0.00013093755,0.00002641872],"category_scores_gemma":[0.0003634215,0.000048103193,0.00013436336,0.0001185136,0.00034858257,0.00006735823,0.000041187486,0.00026190997,3.8873503e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004299232,0.00037533845,0.9782819,0.00051948405,0.0009831762,0.000019932922,0.0007825224,0.00001776908,0.000065994675,0.000021828997,0.00054752047,0.014085261],"study_design_scores_gemma":[0.009345293,0.00448391,0.9713315,0.007135101,0.0005273414,0.000031996056,0.0011316282,0.00006285704,0.00010545799,0.000006336033,0.0057988754,0.000039720417],"about_ca_topic_score_codex":0.00228644,"about_ca_topic_score_gemma":0.0035076623,"teacher_disagreement_score":0.014045541,"about_ca_system_score_codex":0.00016150268,"about_ca_system_score_gemma":0.0015537657,"threshold_uncertainty_score":0.34564286},"labels":[],"label_agreement":null},{"id":"W4411025709","doi":"10.1200/jco.2025.43.17_suppl.lba5506","title":"FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.14722634429479448,"score_gpt":0.5387418993511217,"score_spread":0.39151555505632724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411025709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92588806,0.0042003025,0.00013874941,0.06278236,0.0044160914,0.0010612934,0.00003584702,0.000012076132,0.001465218],"genre_scores_gemma":[0.96296865,0.028444193,0.0035215504,0.0031725045,0.001558443,0.00006197641,0.0000054132456,0.000024500494,0.00024275272],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99252665,0.0005242003,0.0056653,0.0004924259,0.0004033633,0.0003880467],"domain_scores_gemma":[0.9896538,0.0065163993,0.002457232,0.00041831064,0.00047792407,0.00047631943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004603331,0.0002872674,0.0034778109,0.00032929133,0.00006145539,0.000013358304,0.00022493715,0.0007218797,0.0002564498],"category_scores_gemma":[0.005974112,0.00021313001,0.0008089081,0.00042415707,0.00042438888,0.0001430286,0.00011811209,0.001420172,0.0000039687866],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2552202,0.022360882,0.15998185,0.00017847081,0.0014840282,0.00090348657,0.000119486926,0.000087077984,0.000014029452,0.0004772472,0.0044170762,0.55475616],"study_design_scores_gemma":[0.5100984,0.04830107,0.2222376,0.0010531176,0.0014204658,0.00004977587,0.00006630303,0.00026874756,0.000067116736,0.0008008714,0.21546428,0.00017222817],"about_ca_topic_score_codex":0.00023588882,"about_ca_topic_score_gemma":0.001913104,"teacher_disagreement_score":0.55458397,"about_ca_system_score_codex":0.00036264336,"about_ca_system_score_gemma":0.0033104613,"threshold_uncertainty_score":0.869119},"labels":[],"label_agreement":null},{"id":"W4411025723","doi":"10.1200/jco.2025.43.17_suppl.lba8010","title":"Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Perioperative; Internal medicine; Oncology; Placebo; Cisplatin; Biomarker; Surgery; Chemotherapy; Cancer; Immunotherapy; Pathology","score_opus":0.09496438120777968,"score_gpt":0.45888745761025634,"score_spread":0.3639230764024767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411025723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743045,0.00086911826,0.000064685366,0.0037329358,0.0008199367,0.0002863975,0.000013657901,0.000008767445,0.0067740525],"genre_scores_gemma":[0.9958846,0.00057514297,0.0009383378,0.0013653883,0.00014287721,0.0000046825976,0.000017020926,0.000015471956,0.0010564523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654806,0.00071647053,0.0018519358,0.0002943851,0.0003263085,0.00026285986],"domain_scores_gemma":[0.99719226,0.0010968585,0.0008527921,0.00020549279,0.00047667508,0.00017590077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020591936,0.00019491944,0.0015751146,0.00028762253,0.00007302636,0.000027902382,0.00015150734,0.0003626851,0.00034591166],"category_scores_gemma":[0.0009413853,0.00012635929,0.00022458204,0.00047661277,0.0004189705,0.00016918489,0.00006258493,0.000748318,0.0000035930568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29683754,0.0020077992,0.6192509,0.000029031,0.0024034095,0.00028955322,0.00022677642,0.0000062095123,0.0025706717,0.000023533605,0.004447606,0.07190701],"study_design_scores_gemma":[0.061947104,0.008505392,0.910935,0.00035592387,0.00038047408,0.000016592778,0.00049577403,0.00017282869,0.00038235332,0.000035999714,0.016637016,0.00013558687],"about_ca_topic_score_codex":0.00091194385,"about_ca_topic_score_gemma":0.0013111058,"teacher_disagreement_score":0.2916841,"about_ca_system_score_codex":0.0002702048,"about_ca_system_score_gemma":0.0014692172,"threshold_uncertainty_score":0.5152782},"labels":[],"label_agreement":null},{"id":"W4411025725","doi":"10.1200/jco.2025.43.17_suppl.lba5","title":"Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Oxaliplatin; Fluorouracil; Cancer; Chemotherapy; Internal medicine; Durvalumab; Gastroesophageal Junction; Oncology; Phases of clinical research; Adenocarcinoma; Colorectal cancer; Immunotherapy","score_opus":0.06781187243049028,"score_gpt":0.45831035925184216,"score_spread":0.3904984868213519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411025725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890558,0.00095476984,0.00061007007,0.0057448237,0.0016475631,0.0012350839,0.0000034010216,0.000008854513,0.00073959265],"genre_scores_gemma":[0.9951203,0.0016588127,0.0007129914,0.0008398706,0.0005119383,0.000048794096,0.0000021558676,0.000018420764,0.0010867355],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937246,0.0011835699,0.0037898142,0.00034499768,0.0005847281,0.00037230476],"domain_scores_gemma":[0.9953788,0.0021281212,0.0017077524,0.0003294724,0.0002853638,0.00017049102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008122861,0.00024838228,0.003390368,0.0007158305,0.00003506837,0.0000185045,0.00028059937,0.00023410734,0.00020423012],"category_scores_gemma":[0.0025662049,0.00019032611,0.00037328023,0.0006963956,0.00017624706,0.000196076,0.00015738679,0.0010970562,0.0000011822582],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29644048,0.0052799764,0.62177336,0.00014843511,0.00085131,0.00056211016,0.0004962804,0.00041063863,0.000055441305,0.00004364037,0.003814246,0.070124075],"study_design_scores_gemma":[0.5886291,0.0075977566,0.3996212,0.00024838166,0.00057756144,0.00003763356,0.0011667663,0.00089551264,0.000017432683,0.00025690228,0.0008555201,0.00009622418],"about_ca_topic_score_codex":0.0014773516,"about_ca_topic_score_gemma":0.0024721927,"teacher_disagreement_score":0.29218864,"about_ca_system_score_codex":0.0005131137,"about_ca_system_score_gemma":0.0011669921,"threshold_uncertainty_score":0.77612734},"labels":[],"label_agreement":null},{"id":"W4411026697","doi":"10.1200/jco.2025.43.17_suppl.lba1005","title":"A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Western University; Hôpital du Saint-Sacrement; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Royal Victoria Regional Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; HER2 negative; Metastatic breast cancer; Palbociclib; Placebo; Internal medicine; Double blind; Cyclin-dependent kinase; Breast cancer; Oncology; Estrogen; Cancer; Pathology; Cell cycle","score_opus":0.057816360904797394,"score_gpt":0.47860900126528566,"score_spread":0.42079264036048825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411026697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752631,0.0026445852,0.00010260786,0.009611108,0.0009805837,0.011129257,0.00022291853,0.000013113285,0.00003271627],"genre_scores_gemma":[0.9950883,0.0013178817,0.0011327869,0.00034452163,0.0009848318,0.00097272516,0.00002165425,0.000033330958,0.0001039749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949916,0.00092035066,0.0028565796,0.0004989058,0.00040801123,0.00032453102],"domain_scores_gemma":[0.9865751,0.010058335,0.0023650131,0.00023945804,0.0004167291,0.00034531605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032825551,0.00044161692,0.0042245784,0.00020016152,0.00022136407,0.000029491572,0.00011074455,0.00029019167,0.000019193782],"category_scores_gemma":[0.0017431804,0.00023127541,0.0006678665,0.00015776849,0.00063766364,0.00018795917,0.000067639834,0.000569266,3.2105865e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8485302,0.0071479245,0.00038567753,0.00004722828,0.0041482677,0.00010916968,0.0007370357,0.000021341588,0.000507522,0.000029322668,0.000045953155,0.13829038],"study_design_scores_gemma":[0.92984176,0.05985537,0.0003809944,0.0011369603,0.0039607235,0.000098956494,0.0011519411,0.00010593274,0.0022273362,0.00017258812,0.00089341565,0.00017399772],"about_ca_topic_score_codex":0.0001094984,"about_ca_topic_score_gemma":0.00015920572,"teacher_disagreement_score":0.13811637,"about_ca_system_score_codex":0.00024651972,"about_ca_system_score_gemma":0.0012717148,"threshold_uncertainty_score":0.94311374},"labels":[],"label_agreement":null},{"id":"W4411026879","doi":"10.1200/jco.2025.43.17_suppl.lba8000","title":"Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Chemotherapy; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.047331245279506856,"score_gpt":0.43827712917511064,"score_spread":0.3909458838956038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411026879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866452,0.00074459607,0.000030041145,0.0056453273,0.00021989048,0.0004811802,0.000002557821,0.0000067110486,0.0062244805],"genre_scores_gemma":[0.99593097,0.00044041566,0.0011537845,0.0013481084,0.00014944225,0.000011051378,0.000004402848,0.000019730895,0.00094206596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695706,0.0003380529,0.0014016237,0.00027770546,0.00058554835,0.00044002407],"domain_scores_gemma":[0.99776495,0.0007258709,0.0005731203,0.00024906438,0.00040297495,0.00028404998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020613954,0.0001780899,0.0015201286,0.0003018699,0.000025553389,0.000012388014,0.00017708883,0.00023948729,0.00013757644],"category_scores_gemma":[0.00063124567,0.00010684038,0.00015421952,0.00040267213,0.0001715561,0.00013647125,0.000042959193,0.0012625445,0.000005900131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061974857,0.0039649,0.88861513,0.00004755775,0.00030115288,0.0013622701,0.00005461884,0.000026349227,0.0000056336376,0.000059401893,0.00062736054,0.04296079],"study_design_scores_gemma":[0.075128764,0.022440186,0.89913386,0.0004996009,0.00005995003,0.000018769233,0.000036215788,0.000031721964,0.00009147166,0.00020504328,0.0022731493,0.00008125788],"about_ca_topic_score_codex":0.00038995163,"about_ca_topic_score_gemma":0.0014733314,"teacher_disagreement_score":0.042879533,"about_ca_system_score_codex":0.0007670261,"about_ca_system_score_gemma":0.003052306,"threshold_uncertainty_score":0.54851985},"labels":[],"label_agreement":null},{"id":"W4411026891","doi":"10.1200/jco.2025.43.17_suppl.lba5507","title":"ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Electron Spin Resonance Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Paclitaxel; Nab-paclitaxel; Ovarian cancer; Internal medicine; Oncology; Chemotherapy; Cancer","score_opus":0.03332340995140805,"score_gpt":0.4212310579593341,"score_spread":0.38790764800792604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411026891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671614,0.0012506337,0.00009044324,0.00057254743,0.00041332483,0.0006117912,0.000012312596,0.0000031511856,0.0003296564],"genre_scores_gemma":[0.9980819,0.00083058455,0.0006215226,0.00018692622,0.00011288456,0.000041455463,0.0000066461234,0.000020983962,0.0000970692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965324,0.0005500426,0.0018408749,0.0003819183,0.00036481026,0.00032994975],"domain_scores_gemma":[0.9971546,0.00045276998,0.001469166,0.00027791466,0.0005571354,0.00008839499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015152349,0.00023596478,0.0011602612,0.0002122435,0.00004682458,0.00000866484,0.00027484784,0.00031561079,0.0000073306574],"category_scores_gemma":[0.0008025726,0.00017014128,0.0001120138,0.00038442374,0.00019388026,0.00001612418,0.000070186776,0.0006620906,3.4380213e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12269051,0.014134236,0.83062494,0.000035857895,0.0010497428,0.00008101225,0.000572475,0.00024872937,0.0021789235,0.00014732435,0.0004849849,0.027751252],"study_design_scores_gemma":[0.11684581,0.10206318,0.77416486,0.00017924652,0.00013135026,0.0000015927367,0.0008509549,0.000025680938,0.0005959802,0.00008498312,0.004851139,0.00020521622],"about_ca_topic_score_codex":0.00027863428,"about_ca_topic_score_gemma":0.0062619373,"teacher_disagreement_score":0.08792894,"about_ca_system_score_codex":0.00021635562,"about_ca_system_score_gemma":0.0012005297,"threshold_uncertainty_score":0.693816},"labels":[],"label_agreement":null},{"id":"W4411026895","doi":"10.1200/jco.2025.43.17_suppl.lba3509","title":"Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Overall survival","score_opus":0.05392827788181261,"score_gpt":0.41294434529990365,"score_spread":0.35901606741809106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411026895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900009,0.00089696737,0.000025930169,0.0076180985,0.0010202354,0.0002586325,0.000030919033,0.000009029795,0.00013928414],"genre_scores_gemma":[0.99417406,0.0023027002,0.000103340135,0.0016570516,0.0010463673,0.000008054456,0.000018211795,0.00001712212,0.0006731015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643445,0.0006244519,0.001892369,0.00025963038,0.000490084,0.00029901415],"domain_scores_gemma":[0.9941845,0.003833962,0.0012614161,0.00015658936,0.00033996484,0.00022354923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020408223,0.00018364139,0.001742741,0.00014487584,0.000052755386,0.00001585369,0.00014657549,0.00055929524,0.00007291528],"category_scores_gemma":[0.0015474173,0.00013987118,0.00019706805,0.00017892562,0.00016823382,0.00014813103,0.00005984442,0.0012715686,0.0000033747422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010638107,0.0004782781,0.9155508,0.000043121283,0.0005699733,0.00012322588,0.00019978022,0.000004648634,0.000010416106,5.20456e-7,0.0030697878,0.06931133],"study_design_scores_gemma":[0.016657697,0.0037188388,0.9329612,0.0004182592,0.00048486772,0.0000015219723,0.000102925675,0.000026082964,0.000017167116,0.000017221515,0.0454773,0.00011687785],"about_ca_topic_score_codex":0.00054387946,"about_ca_topic_score_gemma":0.0014460452,"teacher_disagreement_score":0.06919445,"about_ca_system_score_codex":0.00073674455,"about_ca_system_score_gemma":0.0017557826,"threshold_uncertainty_score":0.57037807},"labels":[],"label_agreement":null},{"id":"W4411027220","doi":"10.1200/jco.2025.43.17_suppl.lba9500","title":"Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Adjuvant; Stage (stratigraphy); Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.09703807293845568,"score_gpt":0.39292538388310383,"score_spread":0.29588731094464815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411027220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770696,0.0051240753,0.004946839,0.0038006091,0.0020608217,0.0007663893,0.0004953061,0.000010781025,0.005725555],"genre_scores_gemma":[0.98624706,0.0020304814,0.0044269143,0.000555067,0.0010013615,0.00002392571,0.00020882202,0.00002737091,0.005479017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522346,0.00076822797,0.0029199203,0.0004595592,0.00027864228,0.0003502143],"domain_scores_gemma":[0.9920317,0.004216688,0.002377432,0.00069696706,0.0005023734,0.0001748389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022050822,0.00026774092,0.0017636935,0.00009763498,0.00015249813,0.000014595766,0.00051434606,0.0007485835,0.000023049352],"category_scores_gemma":[0.002927549,0.00017782442,0.00084225665,0.00014224477,0.0003725727,0.000012934524,0.0001757643,0.0004940651,0.0000037463985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32040933,0.010178112,0.0137411,0.00019147746,0.009446218,0.0007112582,0.001044057,0.00072567083,0.17213634,0.0019815925,0.12656619,0.34286866],"study_design_scores_gemma":[0.07369911,0.051177382,0.098477736,0.00013612029,0.0010747666,0.00006116694,0.0002814532,0.0008595002,0.012551186,0.0008999397,0.7604248,0.00035686867],"about_ca_topic_score_codex":0.00033386296,"about_ca_topic_score_gemma":0.00063441816,"teacher_disagreement_score":0.63385856,"about_ca_system_score_codex":0.00021814017,"about_ca_system_score_gemma":0.0023262273,"threshold_uncertainty_score":0.72514695},"labels":[],"label_agreement":null},{"id":"W4411027625","doi":"10.1200/jco.2025.43.17_suppl.lba3","title":"Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Protagonist Therapeutics","keywords":"Medicine; Polycythemia vera; Placebo; Double blind; Internal medicine; Pharmacology; Pathology; Alternative medicine","score_opus":0.21537154448924106,"score_gpt":0.5330535497673295,"score_spread":0.3176820052780885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411027625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884916,0.00063417706,0.00010821274,0.004733449,0.000955161,0.0029159146,0.000096042655,0.000006923165,0.0017009609],"genre_scores_gemma":[0.9957947,0.0006633118,0.0019204991,0.0003366991,0.00057038997,0.0001793264,0.000023330142,0.000016737133,0.0004950199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937341,0.00042622705,0.004874138,0.00034370786,0.0003788169,0.00024300018],"domain_scores_gemma":[0.9850428,0.010674645,0.0028737187,0.00039347238,0.0007404146,0.00027494197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017178549,0.00027501694,0.00434899,0.00025516734,0.00005060868,0.000007629466,0.00015941207,0.00035715743,0.00007436743],"category_scores_gemma":[0.0026886011,0.00016868605,0.0010735311,0.00016914097,0.00013124653,0.000058607173,0.000035062854,0.00026977286,0.0000032011499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85262066,0.06857661,0.022068342,0.00002665216,0.0077085,0.0002743592,0.0007493606,0.000037615624,0.00050769764,0.00011482053,0.0016495186,0.045665864],"study_design_scores_gemma":[0.80845207,0.1516121,0.015446204,0.00020837685,0.0048655677,0.000016589092,0.00058885413,0.00017588913,0.007059988,0.00016943594,0.0113051655,0.000099730874],"about_ca_topic_score_codex":0.00022360065,"about_ca_topic_score_gemma":0.00024024653,"teacher_disagreement_score":0.083035484,"about_ca_system_score_codex":0.00030061943,"about_ca_system_score_gemma":0.0020578385,"threshold_uncertainty_score":0.68788177},"labels":[],"label_agreement":null},{"id":"W4411027651","doi":"10.1200/jco.2025.43.17_suppl.lba1000","title":"Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; Human Epidermal Growth Factor Receptor 2; Internal medicine; Breast cancer; Oncology; Epidermal growth factor receptor; Cancer; Metastatic breast cancer; Cancer research","score_opus":0.031905329103192576,"score_gpt":0.4072173557020049,"score_spread":0.37531202659881235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411027651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886746,0.00056076463,0.00010954048,0.006716881,0.001255254,0.0017755793,0.00044897723,0.000006434011,0.00045201075],"genre_scores_gemma":[0.9971561,0.0008356159,0.0008576609,0.00048040436,0.00043374047,0.00008298053,0.000021473554,0.000016217466,0.000115799994],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928087,0.0026647397,0.0033671348,0.0004584982,0.00035662748,0.00034432154],"domain_scores_gemma":[0.99561745,0.0006818878,0.0024895964,0.00033487895,0.0006688295,0.00020736731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002640002,0.00030900494,0.0017073825,0.00009436643,0.0001031385,0.000018721448,0.0006142791,0.00046986635,0.00004630712],"category_scores_gemma":[0.004656729,0.00020795153,0.00078969233,0.00036534457,0.0006604051,0.000035568763,0.00014558104,0.00078724755,0.000001703578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70075667,0.01839165,0.082645155,0.00014803167,0.003018538,0.00008961002,0.00052332255,0.00007996866,0.0762407,0.00088643486,0.0069830576,0.11023685],"study_design_scores_gemma":[0.6531025,0.019541182,0.1553026,0.00080891553,0.0005717116,0.00008982037,0.0009124929,0.00003592456,0.15811536,0.0010059339,0.009830041,0.00068350375],"about_ca_topic_score_codex":0.00026034244,"about_ca_topic_score_gemma":0.00028573087,"teacher_disagreement_score":0.109553345,"about_ca_system_score_codex":0.00018311857,"about_ca_system_score_gemma":0.001856002,"threshold_uncertainty_score":0.8480017},"labels":[],"label_agreement":null},{"id":"W4411027965","doi":"10.1200/jco.2025.43.17_suppl.lba109","title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Chemotherapy; Cancer; Oncology; Internal medicine; Immunotherapy","score_opus":0.03209540618474122,"score_gpt":0.4260614781526635,"score_spread":0.39396607196792227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411027965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556617,0.0032462436,0.00014244801,0.031763006,0.002025554,0.0043822248,0.0003229972,0.00004415007,0.0024116442],"genre_scores_gemma":[0.9748184,0.009077577,0.00055406056,0.012937799,0.0009782027,0.0001379835,0.000058610025,0.00006248835,0.0013748606],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9876548,0.0038016303,0.0061657694,0.0008386762,0.0008333923,0.0007057039],"domain_scores_gemma":[0.9798602,0.013914084,0.0041737515,0.00073853513,0.0009509299,0.00036252599],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00747749,0.0006406613,0.005336875,0.00035588056,0.0001769743,0.000054962315,0.00069744955,0.00071146997,0.00035438768],"category_scores_gemma":[0.0047881,0.00039613538,0.0016295608,0.0010517648,0.0009976447,0.00028142091,0.00011755235,0.0023895963,0.0000068109516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7455861,0.0064753345,0.0033095784,0.000032719825,0.004094665,0.0004496476,0.0019233625,0.000020386482,0.0009704404,0.000006933592,0.0035143194,0.23361649],"study_design_scores_gemma":[0.72516847,0.008061945,0.25682265,0.001157753,0.0015631025,0.00010870039,0.0009819665,0.00021180186,0.00047663663,0.00017944038,0.0049581826,0.00030935078],"about_ca_topic_score_codex":0.0037635684,"about_ca_topic_score_gemma":0.0021421327,"teacher_disagreement_score":0.25351307,"about_ca_system_score_codex":0.0023460733,"about_ca_system_score_gemma":0.006185792,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W4411028002","doi":"10.1200/jco.2025.43.17_suppl.lba12000","title":"PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Dysphagia Assessment and Management","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario; Jewish General Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"Patient-Centered Outcomes Research Institute","keywords":"Medicine; Head and neck cancer; Radiation therapy; Head and neck; Randomized controlled trial; Cancer; Intervention (counseling); Surgery; Internal medicine; Nursing","score_opus":0.12816417857782417,"score_gpt":0.5862585280653704,"score_spread":0.45809434948754624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96403164,0.0002150889,0.018958097,0.0014651092,0.0035416682,0.011287138,0.000011946333,0.0000047144927,0.00048462988],"genre_scores_gemma":[0.99517655,0.00023569613,0.0031558708,0.00011295946,0.00022917612,0.0008983439,0.0000055243154,0.00001037797,0.00017550195],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99060225,0.0053998283,0.0034829234,0.00015683495,0.00017318224,0.00018498708],"domain_scores_gemma":[0.9564001,0.037634414,0.0050850753,0.00012479813,0.0007020977,0.00005351134],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022112483,0.00011436899,0.0020302737,0.000118346776,0.00012935068,0.0000057183775,0.00017453078,0.00017540915,0.0000064131646],"category_scores_gemma":[0.016315553,0.0000676626,0.00050350284,0.00011300544,0.00015022587,0.00012568082,0.00005552052,0.00043489493,7.237456e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9025985,0.0030344229,0.004923736,0.002214251,0.0011735104,3.755647e-7,0.00033170852,0.000020173049,0.000048130492,0.00055448565,0.0003888765,0.08471182],"study_design_scores_gemma":[0.9491969,0.016933378,0.023478782,0.001963295,0.000776153,1.4448317e-7,0.00019773515,0.0025708089,0.000027131604,0.001993868,0.002805406,0.000056395773],"about_ca_topic_score_codex":0.00006686166,"about_ca_topic_score_gemma":0.000099756595,"teacher_disagreement_score":0.08465542,"about_ca_system_score_codex":0.00020849552,"about_ca_system_score_gemma":0.00073514896,"threshold_uncertainty_score":0.9919704},"labels":[],"label_agreement":null},{"id":"W4411028189","doi":"10.1200/jco.2025.43.17_suppl.lba4","title":"Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Endocrine system; Disease; Oncology; First line treatment; Palbociclib; Internal medicine; Cancer; Hormone; Chemotherapy; Metastatic breast cancer; Breast cancer","score_opus":0.09887842059387833,"score_gpt":0.4985457819358709,"score_spread":0.39966736134199254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98146707,0.003271618,0.0004549769,0.010548888,0.00067539274,0.0034267176,0.00013409763,0.000010263394,0.00001096315],"genre_scores_gemma":[0.99211055,0.0052063116,0.001517151,0.00030442287,0.00034214035,0.00041331223,0.000023676817,0.00003421016,0.000048219765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961034,0.0002290181,0.0026069311,0.0003348822,0.00041731994,0.00030846067],"domain_scores_gemma":[0.99490404,0.0014979318,0.0021192292,0.0003050925,0.0008910399,0.0002826672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005942985,0.00030663647,0.001623337,0.0002354002,0.00009371643,0.000008536925,0.00014644998,0.00013134569,0.000040154126],"category_scores_gemma":[0.00022970997,0.0001701576,0.0004078301,0.00032560385,0.0003854398,0.00017272161,0.000020241407,0.0003309872,1.2437314e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71810263,0.01658782,0.037297305,0.00020335993,0.00069695764,0.00004454927,0.00018599376,0.0025706014,0.00048538204,0.000012937138,0.000015779007,0.22379665],"study_design_scores_gemma":[0.84014994,0.041149866,0.10655394,0.0018481683,0.0008895208,0.00001797335,0.00014613436,0.00032466304,0.00445207,0.00008467402,0.0042015268,0.00018153845],"about_ca_topic_score_codex":0.0000751981,"about_ca_topic_score_gemma":0.00037203555,"teacher_disagreement_score":0.22361512,"about_ca_system_score_codex":0.00035199852,"about_ca_system_score_gemma":0.002354269,"threshold_uncertainty_score":0.6938825},"labels":[],"label_agreement":null},{"id":"W4411028356","doi":"10.1200/jco.2025.43.17_suppl.lba5006","title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Oncology; Internal medicine; Homologous recombination; CYP17A1; Cancer research; Gene; Cancer; Endocrinology; Androgen deprivation therapy; Genetics; Biology","score_opus":0.11947778305563772,"score_gpt":0.49364550539346247,"score_spread":0.37416772233782475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895825,0.0009675229,0.00067437865,0.0051733996,0.00066098274,0.0027109284,0.000059241956,0.0000145367,0.00015653393],"genre_scores_gemma":[0.9900787,0.0022315278,0.0051190755,0.0005657919,0.00015732567,0.00031941858,0.00008035651,0.000020148098,0.0014276708],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99681574,0.00048960536,0.001806135,0.00032012077,0.00027026015,0.00029812235],"domain_scores_gemma":[0.9963341,0.0012337258,0.0009749145,0.00014538104,0.0011141239,0.00019780122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020356965,0.00018004437,0.001277109,0.00030474443,0.000101595186,0.000030601677,0.000066021006,0.00016482366,0.000012832115],"category_scores_gemma":[0.0009682876,0.00012232257,0.00018382895,0.00026874195,0.0002592683,0.00022069893,0.00002978246,0.00048915547,9.66991e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5551714,0.017772136,0.040217035,0.0004856495,0.0031074937,0.00081410044,0.0018155811,0.00035847555,0.0004784641,0.000289683,0.0026029793,0.37688702],"study_design_scores_gemma":[0.7836539,0.10649664,0.09533909,0.00069541397,0.0018756699,0.0000803479,0.00053872034,0.0027327319,0.0012042342,0.0012460651,0.0058700345,0.0002671323],"about_ca_topic_score_codex":0.00010421554,"about_ca_topic_score_gemma":0.0006447913,"teacher_disagreement_score":0.37661988,"about_ca_system_score_codex":0.0005647477,"about_ca_system_score_gemma":0.0030228542,"threshold_uncertainty_score":0.53624135},"labels":[],"label_agreement":null},{"id":"W4411028389","doi":"10.1200/jco.2025.43.17_suppl.lba3510","title":"A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Saskatchewan; University of Alberta; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; Alberta Health Services; Queen's University","funders":"National Health and Medical Research Council; Cancer Research UK","keywords":"Medicine; Randomized controlled trial; Stage (stratigraphy); Colorectal cancer; Internal medicine; Oncology; Distributed File System; Cancer; Disease; Overall survival; Surgery","score_opus":0.12316038342622392,"score_gpt":0.5205599701436624,"score_spread":0.39739958671743847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97946745,0.0022692746,0.0000073873584,0.004498536,0.0068846806,0.0048693083,0.0016686125,0.000010513706,0.00032420582],"genre_scores_gemma":[0.9860146,0.01163048,0.000045998167,0.00024464857,0.0012252722,0.0002830335,0.000014669423,0.000030506795,0.0005107607],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98765373,0.0052228807,0.0054498133,0.0003731584,0.0008001424,0.0005002725],"domain_scores_gemma":[0.9848205,0.0075669684,0.0054676756,0.0006911245,0.0006336552,0.0008200877],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013848646,0.00036190974,0.0071337433,0.0004928848,0.0000681773,0.00001621029,0.00062735204,0.00062245765,0.0007141811],"category_scores_gemma":[0.01786849,0.00019135993,0.0025371837,0.00062073854,0.00053015875,0.00007881367,0.00007885741,0.0016038286,2.9438888e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8795101,0.0038011875,0.0053282278,0.00018290251,0.0016965363,0.00023769669,0.00034885804,0.00017453183,0.000023344071,0.00012180571,0.0018717897,0.106703036],"study_design_scores_gemma":[0.94988024,0.018523945,0.020935398,0.0010593311,0.0027626692,0.0000018491049,0.0005364433,0.0001499774,0.00006801863,0.00041627663,0.0054866723,0.00017918638],"about_ca_topic_score_codex":0.30261716,"about_ca_topic_score_gemma":0.7401801,"teacher_disagreement_score":0.43756294,"about_ca_system_score_codex":0.0012320355,"about_ca_system_score_gemma":0.022767616,"threshold_uncertainty_score":0.9904044},"labels":[],"label_agreement":null},{"id":"W4411084855","doi":"10.1200/jco-25-00166","title":"Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bendamustine; Idelalisib; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Ofatumumab; Gastroenterology; Clinical endpoint; Hazard ratio; Venetoclax; Ibrutinib; Leukemia; Lymphoma; Oncology; Confidence interval; Randomized controlled trial","score_opus":0.12965460044835456,"score_gpt":0.4747918773236469,"score_spread":0.3451372768752924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411084855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293364,0.0040175663,0.00019408014,0.0010398901,0.006320514,0.002185841,0.000047506757,0.000081735016,0.0031792016],"genre_scores_gemma":[0.98947453,0.0038103457,0.0010879309,0.0008538134,0.002776886,0.00006927167,0.000057366953,0.00011906493,0.0017508024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9829709,0.0016149356,0.010699761,0.0011925291,0.0018909243,0.0016309364],"domain_scores_gemma":[0.98042095,0.011044334,0.004146958,0.0014123749,0.0017834663,0.0011919094],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0088204695,0.0009136497,0.0069404477,0.0017276146,0.00014794646,0.00005894282,0.0012125516,0.0019905781,0.0004852526],"category_scores_gemma":[0.021905527,0.00071776996,0.0017561963,0.002432831,0.00151836,0.0003476103,0.0006163743,0.0018530653,0.00008213791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8215061,0.018164916,0.00012381944,0.0010604626,0.0016036483,0.011320874,0.00017409294,0.0006896382,0.0017052803,0.0002545003,0.0059175105,0.13747916],"study_design_scores_gemma":[0.87368006,0.071547695,0.0002440545,0.0024211174,0.0018443905,0.0012845383,0.0002542214,0.02691108,0.0067781787,0.00011105614,0.014420223,0.00050337875],"about_ca_topic_score_codex":0.0026994604,"about_ca_topic_score_gemma":0.0011591777,"teacher_disagreement_score":0.1583436,"about_ca_system_score_codex":0.19804563,"about_ca_system_score_gemma":0.35638922,"threshold_uncertainty_score":0.99952734},"labels":[],"label_agreement":null},{"id":"W4411141147","doi":"10.1200/jco-24-01893","title":"International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Context (archaeology); Oncology; Internal medicine; Risk stratification; Clinical trial; Fluorescence in situ hybridization; Clinical Practice; Intensive care medicine; Family medicine; Gene; Genetics","score_opus":0.15608531305572798,"score_gpt":0.4504290073324454,"score_spread":0.2943436942767174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411141147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8897257,0.00009350798,0.0010606633,0.077173874,0.0046407734,0.00044290567,0.0000881713,0.000022570961,0.026751831],"genre_scores_gemma":[0.97200507,0.0013519735,0.022796324,0.0022952843,0.0010401749,0.000020307954,0.00007272179,0.000017788467,0.000400375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955817,0.00072193,0.0023530428,0.00028883418,0.0007627902,0.0002917256],"domain_scores_gemma":[0.984352,0.012211592,0.0019928594,0.00029642796,0.00092039676,0.0002267329],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032487717,0.0002017553,0.0009292981,0.00028320588,0.00017164186,0.00003035129,0.00044919358,0.00035373043,0.0005816977],"category_scores_gemma":[0.011127154,0.00013336325,0.0008769102,0.0002703995,0.00040058797,0.00008046382,0.00015630038,0.0013935495,0.000037070662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010241136,0.0041099936,0.2745163,0.000024940988,0.005179019,0.0003998569,0.00015584053,0.000026788732,0.00050332927,0.013132003,0.03633294,0.6553778],"study_design_scores_gemma":[0.02104641,0.0045188335,0.83682424,0.0005625498,0.00051308953,0.00030804623,0.00058548094,0.0021002488,0.00048574706,0.0065885102,0.1263048,0.00016202744],"about_ca_topic_score_codex":0.000059048332,"about_ca_topic_score_gemma":0.00006835454,"teacher_disagreement_score":0.6552158,"about_ca_system_score_codex":0.0003862687,"about_ca_system_score_gemma":0.0008201433,"threshold_uncertainty_score":0.9972025},"labels":[],"label_agreement":null},{"id":"W4411230443","doi":"10.1200/jco-24-02540","title":"Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Mindfulness and Compassion Interventions","field":"Psychology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Psychological intervention; Mood; Randomized controlled trial; Psychosocial; Mindfulness; Distress; Intervention (counseling); Preference; Physical therapy; Cancer; Comparative effectiveness research; Clinical psychology; Alternative medicine; Internal medicine; Psychiatry","score_opus":0.2638088622314628,"score_gpt":0.564215201853358,"score_spread":0.3004063396218952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411230443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9053774,0.0004540094,0.08321823,0.0019901535,0.0055750487,0.0028305629,0.00004906404,0.0000069161624,0.0004986083],"genre_scores_gemma":[0.9956867,0.0000025534907,0.00043706482,0.0005324764,0.00018815359,0.0027684902,0.0000028003576,0.000009335904,0.00037240793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895811,0.0059387274,0.0037341886,0.00029972702,0.00021834618,0.00022790926],"domain_scores_gemma":[0.97704524,0.018492954,0.0035495958,0.00021690097,0.0005311322,0.00016415385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009542495,0.00019934509,0.004796059,0.00025827513,0.0001049844,0.0000137388115,0.00028712023,0.00026293282,0.00043642597],"category_scores_gemma":[0.0013766253,0.00013013608,0.0010321706,0.00016533362,0.0003421873,0.00005897841,0.000063898166,0.000576263,0.0000013615274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8111562,0.010995033,0.01556727,0.00015686812,0.002909159,0.00000840581,0.00046522543,0.00003271611,7.062218e-7,0.006426724,0.0025996107,0.14968209],"study_design_scores_gemma":[0.77051324,0.012331412,0.20855534,0.0003486189,0.00065253297,0.0000026100186,0.00071254064,0.0001277063,0.00010466788,0.004185732,0.0023475804,0.00011804357],"about_ca_topic_score_codex":0.0003145526,"about_ca_topic_score_gemma":0.00035988967,"teacher_disagreement_score":0.19298807,"about_ca_system_score_codex":0.000104955405,"about_ca_system_score_gemma":0.0013667016,"threshold_uncertainty_score":0.5306795},"labels":[],"label_agreement":null},{"id":"W4411330578","doi":"10.1200/jco-25-00204","title":"Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Neutropenia; Febrile neutropenia; Nivolumab; Adverse effect; Lymphoma; Gastroenterology; Surgery; Cancer; Chemotherapy; Hodgkin lymphoma; Immunotherapy","score_opus":0.04522248505722954,"score_gpt":0.4201453365192767,"score_spread":0.3749228514620472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411330578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812539,0.00036795923,0.000019631716,0.0037624768,0.0023982527,0.00052869815,0.000007253613,0.000014762664,0.011647029],"genre_scores_gemma":[0.9950565,0.0004624463,0.0008391384,0.0024409944,0.00028203122,0.000026106063,0.000010032002,0.000023453342,0.000859265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960519,0.00047172065,0.002164449,0.00037771647,0.00053710974,0.00039712462],"domain_scores_gemma":[0.9944102,0.0032008898,0.0013352105,0.00034261824,0.00038399317,0.00032706687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010782154,0.00027812977,0.0019381895,0.00033734797,0.00005618262,0.000015470721,0.00020112295,0.00040678613,0.00015956309],"category_scores_gemma":[0.0017569875,0.00018080152,0.00048010368,0.00034948112,0.0001785925,0.00012308806,0.00006745482,0.0005390113,0.000043271328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036652006,0.016082488,0.5024099,0.000031784457,0.00062908116,0.0010608404,0.00005752014,0.00004430312,0.0000026276534,0.00024886566,0.0029774744,0.43980312],"study_design_scores_gemma":[0.17584226,0.027716786,0.7561102,0.0004500369,0.00035630146,0.000012084504,0.000095345225,0.00003607175,0.00004453855,0.000043701886,0.03917443,0.00011826475],"about_ca_topic_score_codex":0.000028808827,"about_ca_topic_score_gemma":0.000138798,"teacher_disagreement_score":0.43968487,"about_ca_system_score_codex":0.0011623669,"about_ca_system_score_gemma":0.0023669705,"threshold_uncertainty_score":0.7372872},"labels":[],"label_agreement":null},{"id":"W4411630452","doi":"10.1200/jco-25-00489","title":"Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Health Services Authority; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Call to action; Intensive care medicine; Clinical trial; Internal medicine; Cardiology","score_opus":0.34139931520120737,"score_gpt":0.5796324778397054,"score_spread":0.23823316263849803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411630452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98260295,0.00026478447,0.00010317211,0.01050479,0.0056320988,0.00062827533,0.0000018478381,0.000006500303,0.00025555707],"genre_scores_gemma":[0.9906336,0.0028556178,0.0012260703,0.003743309,0.0014567252,0.000013949668,0.0000012104566,0.000010085071,0.000059414342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9924828,0.00053911656,0.006253604,0.00028282183,0.00024786897,0.00019380805],"domain_scores_gemma":[0.9929904,0.0008631798,0.004970962,0.00020791702,0.0003909655,0.00057661266],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0076453406,0.00013265581,0.0025718007,0.00015483181,0.00005160043,0.000011317766,0.000086146465,0.000291259,0.00004457678],"category_scores_gemma":[0.014601418,0.000099291574,0.00030718342,0.00011413447,0.0001322442,0.00009867309,0.00012636335,0.00052164233,8.387441e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08567806,0.018973483,0.11000147,0.00039235607,0.0027347251,0.000516587,0.00045673197,0.000059143757,0.00077499135,0.00039650445,0.00975967,0.7702563],"study_design_scores_gemma":[0.040437125,0.035349887,0.9017723,0.00047958654,0.0017907595,0.000083025494,0.00039810236,0.00007159576,0.000046142915,0.00042804977,0.019035306,0.000108072825],"about_ca_topic_score_codex":0.00015153452,"about_ca_topic_score_gemma":0.00025259837,"teacher_disagreement_score":0.7917709,"about_ca_system_score_codex":0.00013060406,"about_ca_system_score_gemma":0.0017920869,"threshold_uncertainty_score":0.993699},"labels":[],"label_agreement":null},{"id":"W4411934388","doi":"10.1200/jco-25-00234","title":"Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Immune system; Clear cell; Renal cell carcinoma; Medicine; Chromophobe cell; Immune checkpoint; CD8; Cancer research; Clear cell renal cell carcinoma; Pathology; Immunotherapy; Immunology","score_opus":0.050407176237038394,"score_gpt":0.3793142436953793,"score_spread":0.3289070674583409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411934388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959375,0.0018938266,0.0000025819447,0.0003849066,0.00036471896,0.0002496562,0.000004324795,0.0000026138423,0.0011598193],"genre_scores_gemma":[0.9978104,0.00043465442,0.0011174448,0.00035576485,0.00011894092,0.0000023348746,0.0000014435446,0.000011216945,0.00014777879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963887,0.0004552663,0.0024850955,0.00020358861,0.0002245413,0.00024282183],"domain_scores_gemma":[0.9972373,0.0008772126,0.0013110114,0.0002474014,0.00009593606,0.00023112675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016973906,0.00017367596,0.0017720714,0.00027655868,0.000029057452,0.0000043755704,0.00015419339,0.00020148925,0.000048746562],"category_scores_gemma":[0.00050342537,0.00013067566,0.00036896582,0.00015910008,0.0003996973,0.00008201569,0.00014499652,0.0007792595,0.0000041894486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041840677,0.0025418662,0.93565434,0.00013927055,0.00007601358,0.0068430416,0.00007431385,0.0000011768982,0.022452837,0.0000038328685,0.00020554775,0.027823688],"study_design_scores_gemma":[0.011509544,0.010296635,0.9269996,0.00018712274,0.00030403535,0.0014921754,0.00014725118,0.000024487485,0.048385188,0.00004491149,0.00053394696,0.00007506016],"about_ca_topic_score_codex":0.00013917971,"about_ca_topic_score_gemma":0.00006329107,"teacher_disagreement_score":0.027748628,"about_ca_system_score_codex":0.00032095716,"about_ca_system_score_gemma":0.0011029943,"threshold_uncertainty_score":0.5328799},"labels":[],"label_agreement":null},{"id":"W4412125702","doi":"10.1200/jco-25-00040","title":"Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Jewish General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Genentech; National Institute for Health and Care Research","keywords":"Medicine; KRAS; Cancer; Term (time); Lung cancer; Oncology; Internal medicine; Colorectal cancer","score_opus":0.04610129798774334,"score_gpt":0.4679623443631901,"score_spread":0.4218610463754468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412125702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441004,0.000430069,0.00023452926,0.00075201015,0.0011476853,0.0011204036,0.00001863915,0.0000040603577,0.0018825766],"genre_scores_gemma":[0.9979837,0.000110075154,0.0003890048,0.00079031364,0.0001419477,0.000025563786,0.000008902178,0.000013847649,0.0005366628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972866,0.00022929632,0.0017588927,0.00022097069,0.00029482532,0.00020937315],"domain_scores_gemma":[0.9970625,0.0006421645,0.0012845377,0.00017848884,0.0006328223,0.00019948704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059054483,0.00016656911,0.0013608449,0.00020093673,0.0000361173,0.0000072015478,0.00013008522,0.00015528985,0.000042424927],"category_scores_gemma":[0.00023384916,0.000108499524,0.0002615491,0.00027197052,0.00009677963,0.00007839527,0.00004686154,0.00048996386,0.0000011095714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010419373,0.03234326,0.90662473,0.00007451094,0.0014235816,0.00045143883,0.00088028744,0.000018397655,0.000056948687,0.000002651157,0.00031996387,0.047384832],"study_design_scores_gemma":[0.09176245,0.035427306,0.86826044,0.000547393,0.003229745,0.000004582625,0.0002253703,0.000013169745,0.00021790856,0.000005689321,0.00022794007,0.00007801369],"about_ca_topic_score_codex":0.00012453785,"about_ca_topic_score_gemma":0.00047888153,"teacher_disagreement_score":0.081343085,"about_ca_system_score_codex":0.0005508109,"about_ca_system_score_gemma":0.002285906,"threshold_uncertainty_score":0.44244823},"labels":[],"label_agreement":null},{"id":"W4412125722","doi":"10.1200/jco-24-02697","title":"Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Hormone receptor; Breastfeeding; Oncology; Internal medicine; Cancer; Gynecology; Obstetrics; Pediatrics","score_opus":0.058556478783968524,"score_gpt":0.44529908858177114,"score_spread":0.3867426097978026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412125722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8385987,0.0017144252,0.00009204775,0.14951783,0.0053687226,0.00038357146,0.000592766,0.0000097073325,0.0037221643],"genre_scores_gemma":[0.9815885,0.0026442043,0.00024642693,0.007578241,0.007457146,0.000010382188,0.000012318913,0.000013177186,0.0004496199],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964142,0.0004482489,0.0022727484,0.00026092833,0.00035604177,0.0002478218],"domain_scores_gemma":[0.99239254,0.005088129,0.0014106297,0.00020758125,0.00063241506,0.00026868848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022819026,0.00016881696,0.0013380243,0.00008205623,0.00007610182,0.000022649747,0.00020387067,0.00041691333,0.00020013793],"category_scores_gemma":[0.0018542862,0.00009626327,0.00068425003,0.0002260718,0.0002987795,0.00011216757,0.00008686388,0.0015222345,0.000012414175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61080074,0.00084839016,0.014750646,0.0000027668818,0.0011521257,0.00019910258,0.0004073691,0.0000026105774,0.0001845673,0.000049175866,0.050875556,0.32072696],"study_design_scores_gemma":[0.09382127,0.0054152356,0.8607209,0.00039464387,0.00090686255,0.0000812838,0.00022765838,0.000014336113,0.000050261035,0.00021190947,0.038061153,0.00009447929],"about_ca_topic_score_codex":0.0016949483,"about_ca_topic_score_gemma":0.00027673715,"teacher_disagreement_score":0.8459703,"about_ca_system_score_codex":0.00042597303,"about_ca_system_score_gemma":0.0022602512,"threshold_uncertainty_score":0.66134363},"labels":[],"label_agreement":null},{"id":"W4412156955","doi":"10.1200/jco-25-01346","title":"RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Nivolumab; Melanoma; Metastatic melanoma; Oncology; Ipilimumab; Internal medicine; Cancer research; Immunotherapy; Cancer","score_opus":0.03912793746815623,"score_gpt":0.4373174219530394,"score_spread":0.39818948448488317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412156955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244606,0.0007839471,0.00024293401,0.0028551738,0.0004530644,0.00021393027,0.0000023109312,0.0000043161726,0.0029982503],"genre_scores_gemma":[0.99528635,0.0008437901,0.0011820815,0.001468392,0.00026317575,0.000008409691,0.0000061690375,0.000018264012,0.00092338905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969645,0.00074121327,0.0014300845,0.0002925089,0.00024350418,0.00032818646],"domain_scores_gemma":[0.99805754,0.000397685,0.0006554445,0.0003408742,0.00037322342,0.00017520803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026424709,0.0001597307,0.0009291787,0.0001732247,0.000040154897,0.000012232504,0.00047134797,0.00043464548,0.00005742348],"category_scores_gemma":[0.0011630418,0.0001201509,0.00024813914,0.00026108974,0.00023969745,0.000009190544,0.000111908856,0.00072773243,0.000008574677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23226549,0.004646897,0.3025344,0.00006712284,0.0013361453,0.0009286602,0.00006493443,0.0011066986,0.1821014,0.00018687472,0.009417379,0.265344],"study_design_scores_gemma":[0.070089325,0.28064147,0.34994256,0.000301814,0.00017705084,0.000121802994,0.00033735126,0.00024161396,0.13808632,0.0012468124,0.15814714,0.00066672295],"about_ca_topic_score_codex":0.000007746889,"about_ca_topic_score_gemma":0.00068003574,"teacher_disagreement_score":0.27599457,"about_ca_system_score_codex":0.00007061581,"about_ca_system_score_gemma":0.002127377,"threshold_uncertainty_score":0.48996115},"labels":[],"label_agreement":null},{"id":"W4412491393","doi":"10.1200/jco-25-01061","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Guideline; Medicine; Clinical Practice; Family medicine; Clinical Oncology; Schedule; Stage (stratigraphy); Cancer; Pathology; Internal medicine","score_opus":0.05752244483960633,"score_gpt":0.5041533275611548,"score_spread":0.4466308827215485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412491393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9073891,0.0049052965,0.03972351,0.02951052,0.0032494904,0.0016041175,0.00003821988,0.00001936508,0.01356039],"genre_scores_gemma":[0.83762497,0.009623974,0.08026374,0.025087625,0.0026748981,0.00014191378,0.000030447829,0.000047561378,0.044504847],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982315,0.0000911565,0.001199957,0.00016622686,0.0001512813,0.00015988138],"domain_scores_gemma":[0.9968205,0.0013344716,0.00075245625,0.00013939275,0.0008093885,0.00014375543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008433128,0.00011359449,0.00067261065,0.00011849231,0.00009332726,0.000013974377,0.00009321928,0.00016792085,0.00028582988],"category_scores_gemma":[0.0003684357,0.000070667484,0.00026314933,0.00012008851,0.00005507349,0.00009815896,0.000019463272,0.0003311033,0.0000028645936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00863152,0.0045737787,0.47982097,0.00022516976,0.0034913335,0.00022414624,0.00085906504,0.0020403948,0.0007473423,0.00023242843,0.34089732,0.1582565],"study_design_scores_gemma":[0.028087908,0.011844169,0.13205242,0.00082129636,0.0022385505,0.000014378639,0.0004749391,0.003627332,0.00032929605,0.00006611818,0.82029176,0.00015183902],"about_ca_topic_score_codex":0.0000751708,"about_ca_topic_score_gemma":0.00012374147,"teacher_disagreement_score":0.4793944,"about_ca_system_score_codex":0.00028425173,"about_ca_system_score_gemma":0.004223894,"threshold_uncertainty_score":0.74930066},"labels":[],"label_agreement":null},{"id":"W4412493872","doi":"10.1200/jco-25-00186","title":"Reading the Room: A Joint Perspective From a Scientist- and Patient-Partnered Working Group on the Importance of Patient-Centered Language in the Dissemination of Cancer Research","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Patient Safety Institute; McGill University; McGill University Health Centre; GRi Simulations (Canada); Acadia University","funders":"","keywords":"Perspective (graphical); Medicine; Reading (process); Medical education; Family medicine; Linguistics; Visual arts","score_opus":0.4171796200529895,"score_gpt":0.6105917855304738,"score_spread":0.1934121654774843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412493872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94535005,0.003983835,0.000006315926,0.046642393,0.00082243874,0.0009356833,0.0000183871,0.0000028263012,0.0022380515],"genre_scores_gemma":[0.9969799,0.0004717662,0.00021270596,0.002091404,0.00010502832,0.00010295768,0.0000020699722,0.000007530814,0.00002665632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98730165,0.008949745,0.002645689,0.00020479194,0.00061751925,0.0002806329],"domain_scores_gemma":[0.9612042,0.034181517,0.0029732294,0.000579808,0.0009983141,0.000062965344],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006778178,0.00009564959,0.00058692705,0.00020649064,0.0004326036,0.000009665937,0.00062969374,0.00020590266,0.00004506237],"category_scores_gemma":[0.020313505,0.000047051646,0.00013441572,0.0006473513,0.00045858612,0.000076857694,0.00025955282,0.0023953344,0.0000010160694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024450053,0.0011571355,0.7186378,0.00009577795,0.00016288858,0.000017804196,0.1972094,0.000010946534,0.00059625134,0.023729509,0.00706456,0.04887291],"study_design_scores_gemma":[0.001524121,0.0016891069,0.5772469,0.0035632506,0.000050927734,0.0000014174368,0.40607598,0.00024211158,0.00009572559,0.005955975,0.0034899672,0.00006448903],"about_ca_topic_score_codex":0.001622993,"about_ca_topic_score_gemma":0.0042090863,"teacher_disagreement_score":0.20886658,"about_ca_system_score_codex":0.00046357253,"about_ca_system_score_gemma":0.0009813837,"threshold_uncertainty_score":0.9999062},"labels":[],"label_agreement":null},{"id":"W4413107878","doi":"10.1200/jco-25-00385","title":"Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Population; Cancer; Relative risk; Standardized mortality ratio; Cumulative incidence; Late effect; Relative survival; Demography; Incidence (geometry); Pediatrics; Cancer registry; Internal medicine; Confidence interval; Cohort; Environmental health","score_opus":0.08883987638275372,"score_gpt":0.49862765803098186,"score_spread":0.40978778164822816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413107878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9015175,0.0057912935,0.00002068118,0.08547116,0.005210725,0.001162304,0.00008197368,0.000020975005,0.0007233505],"genre_scores_gemma":[0.97700274,0.0030033772,0.0005076628,0.017692722,0.0013655565,0.000038466926,0.000010578649,0.000042447984,0.0003364416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98717165,0.0027685708,0.007687097,0.0006033789,0.0012205875,0.0005486959],"domain_scores_gemma":[0.9853241,0.007532311,0.0053382367,0.00092915463,0.0004292033,0.00044699135],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014486841,0.00036695093,0.0049810302,0.00033742524,0.00008532541,0.000019986255,0.0007711126,0.00043798055,0.00018882738],"category_scores_gemma":[0.0075344862,0.00025303342,0.000998057,0.0007659033,0.0003795028,0.00013228769,0.00026021936,0.002488019,0.000003978434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010398879,0.007985894,0.9208003,0.00004638313,0.001979418,0.0007153043,0.0061165616,0.00003575802,0.0000031013942,0.00003136922,0.0064320397,0.054813925],"study_design_scores_gemma":[0.012110071,0.0033072643,0.96148115,0.0006778251,0.000544374,0.00005532921,0.0031327298,0.0000025979173,0.000005323937,0.0005736602,0.017930863,0.00017879673],"about_ca_topic_score_codex":0.11065204,"about_ca_topic_score_gemma":0.29854342,"teacher_disagreement_score":0.18789138,"about_ca_system_score_codex":0.0005729917,"about_ca_system_score_gemma":0.01097176,"threshold_uncertainty_score":0.9999922},"labels":[],"label_agreement":null},{"id":"W4413108138","doi":"10.1200/jco-25-00221","title":"Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Prophylactic cranial irradiation; Conventional PCI; Internal medicine; Hazard ratio; Lung cancer; Randomized controlled trial; Surgery; Oncology; Urology; Confidence interval; Myocardial infarction","score_opus":0.052532914754491816,"score_gpt":0.46942480112778784,"score_spread":0.416891886373296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413108138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849744,0.0012383268,0.0009032572,0.00499175,0.003050475,0.0041617416,0.000011739353,0.000014953121,0.00065337395],"genre_scores_gemma":[0.99209577,0.00089575787,0.0024073056,0.0006083306,0.0025583617,0.00030907776,0.000004646048,0.000022845312,0.0010978862],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955409,0.00072553125,0.0024846257,0.00030431643,0.0005363579,0.00040825538],"domain_scores_gemma":[0.9912108,0.004844015,0.002124181,0.00019214425,0.0013375191,0.00029132457],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040540574,0.00021274427,0.0026981006,0.00022573076,0.00021691057,0.000018254035,0.00019401274,0.0002679739,0.000052119187],"category_scores_gemma":[0.01048334,0.00013433743,0.00066204695,0.00023362483,0.00031831075,0.0001412749,0.00007333066,0.0010615434,8.412327e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96126425,0.0049327076,0.008108072,0.00043916746,0.0011856384,0.000053285356,0.00021859362,0.000029113058,0.000082518454,0.000015525107,0.0019088768,0.021762228],"study_design_scores_gemma":[0.9530619,0.031674348,0.008146823,0.0002952491,0.0020025559,0.0000046218515,0.00003813378,0.00037276544,0.00009207692,0.00012718879,0.0040594526,0.00012490069],"about_ca_topic_score_codex":0.00003982552,"about_ca_topic_score_gemma":0.000056223602,"teacher_disagreement_score":0.02674164,"about_ca_system_score_codex":0.0007468427,"about_ca_system_score_gemma":0.0049120365,"threshold_uncertainty_score":0.9978518},"labels":[],"label_agreement":null},{"id":"W4413115631","doi":"10.1200/jco-25-00356","title":"Brain Imaging Surveillance for Patients With Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Metastatic breast cancer; Clinical trial; Oncology; Cancer; Medical physics; Internal medicine","score_opus":0.08818671439036631,"score_gpt":0.5332197387365147,"score_spread":0.44503302434614844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413115631","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3147075,0.0011193613,0.024148459,0.6440571,0.006843487,0.007041116,0.0002275735,0.000029110493,0.001826298],"genre_scores_gemma":[0.5898989,0.0014051921,0.22056746,0.18170121,0.0036821535,0.00038559598,0.00003746776,0.00008447198,0.0022375237],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9901142,0.0035967808,0.005055036,0.00040178403,0.00048628586,0.00034591104],"domain_scores_gemma":[0.941179,0.052619636,0.003278396,0.00033824195,0.0020802626,0.0005044745],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027464781,0.0002317842,0.0039981226,0.00017099251,0.0000687038,0.000025533496,0.00019298715,0.00015215228,0.00008779925],"category_scores_gemma":[0.07215033,0.00013593839,0.0012719639,0.00027174462,0.00027675103,0.00015992601,0.00006173153,0.0005967253,0.0000059768995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68641406,0.004224088,0.01814082,0.00003030108,0.0028764058,0.00014798832,0.00003115866,0.000005010997,4.804449e-7,0.00009990794,0.05817995,0.22984985],"study_design_scores_gemma":[0.7089147,0.01222592,0.01487488,0.00019034017,0.0028360263,0.000089071706,0.00006830678,0.00012267953,0.0000011709444,0.00020547441,0.2603685,0.000102959966],"about_ca_topic_score_codex":0.000081755235,"about_ca_topic_score_gemma":0.000045512134,"teacher_disagreement_score":0.46235588,"about_ca_system_score_codex":0.00025866338,"about_ca_system_score_gemma":0.00388725,"threshold_uncertainty_score":0.95188},"labels":[],"label_agreement":null},{"id":"W4413964886","doi":"10.1200/jco-24-02644","title":"Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Pazopanib; Medicine; Placebo; Internal medicine; Clinical endpoint; Neuroendocrine tumors; Hazard ratio; Adverse effect; Gastroenterology; Oncology; Randomized controlled trial; Cancer; Pathology; Confidence interval; Sunitinib","score_opus":0.06837118256339604,"score_gpt":0.476552029058464,"score_spread":0.408180846495068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413964886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903621,0.00032554718,0.000033975743,0.0034591008,0.0014624269,0.0022688238,0.000004827987,0.000012437856,0.002070769],"genre_scores_gemma":[0.99561805,0.0010045512,0.0021283042,0.0004088714,0.00025126737,0.000051701052,0.0000040277328,0.000025137862,0.00050809584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927368,0.0015223888,0.004088094,0.00035484997,0.0008111583,0.00048671753],"domain_scores_gemma":[0.9861388,0.01008537,0.0023614198,0.0003707704,0.0006758213,0.00036782146],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020919114,0.00026010923,0.0041269376,0.00037961034,0.000042379517,0.0000066630505,0.00034840096,0.000034838824,0.00008808043],"category_scores_gemma":[0.032055456,0.00017340691,0.0005866324,0.0005885984,0.0006740377,0.00023234614,0.00011811617,0.0015055418,0.000002558445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9469681,0.010163565,0.0049393126,0.000099020945,0.00034532262,0.0037085693,0.000012502603,0.000062052415,0.000058463407,0.00011238382,0.0003167722,0.03321397],"study_design_scores_gemma":[0.88585484,0.10378785,0.004745767,0.0004383174,0.00039199158,0.00007892851,0.00004107516,0.00006557455,0.00030087717,0.0001520891,0.0040430366,0.0000996616],"about_ca_topic_score_codex":0.00000989191,"about_ca_topic_score_gemma":0.000028378408,"teacher_disagreement_score":0.09362429,"about_ca_system_score_codex":0.00014318814,"about_ca_system_score_gemma":0.001970341,"threshold_uncertainty_score":0.97609794},"labels":[],"label_agreement":null},{"id":"W4413964893","doi":"10.1200/jco-25-00272","title":"Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Chemoradiotherapy; Hazard ratio; Internal medicine; Adverse effect; Phases of clinical research; Head and neck squamous-cell carcinoma; Surgery; Urology; Head and neck cancer; Gastroenterology; Radiation therapy; Randomized controlled trial; Chemotherapy; Confidence interval; Pathology","score_opus":0.06312164681586484,"score_gpt":0.451714309524306,"score_spread":0.38859266270844117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413964893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869175,0.002765771,0.00015392003,0.0048285816,0.0007123887,0.0018737607,0.0000033386905,0.000006680038,0.00096379063],"genre_scores_gemma":[0.9961537,0.00038457738,0.000743716,0.002108199,0.00018186074,0.000035948924,4.7059413e-7,0.000014918299,0.00037661399],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99475026,0.0012031089,0.003154834,0.0002577872,0.00036007405,0.00027395628],"domain_scores_gemma":[0.98913336,0.008571451,0.0014550005,0.00027369853,0.00038334023,0.00018314132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040015304,0.00021745286,0.0043797647,0.00020692447,0.000060072336,0.0000057874695,0.00021278621,0.00025225893,0.000039608713],"category_scores_gemma":[0.005958589,0.0001137966,0.00044428796,0.0004616886,0.00046293196,0.0000463613,0.00006907819,0.0010206308,3.4294288e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91048014,0.007055411,0.040431004,0.000170373,0.00025534036,0.00056417816,0.0009127978,0.00012245795,0.00036652418,0.000007832067,0.000945754,0.038688198],"study_design_scores_gemma":[0.89950466,0.030282225,0.06418246,0.00041982962,0.00046018398,0.000044291093,0.00083780737,0.0018013366,0.0005661886,0.000024597335,0.0017699699,0.00010645475],"about_ca_topic_score_codex":0.00013059583,"about_ca_topic_score_gemma":0.0008284675,"teacher_disagreement_score":0.038581744,"about_ca_system_score_codex":0.00025735798,"about_ca_system_score_gemma":0.0047429106,"threshold_uncertainty_score":0.84137195},"labels":[],"label_agreement":null},{"id":"W4414082275","doi":"10.1200/jco-25-00788","title":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epidermal growth factor receptor; Lung cancer; Exon; Tyrosine kinase; Adverse effect; Mutation; Gefitinib; Tyrosine-kinase inhibitor; Kinase","score_opus":0.057831053484738014,"score_gpt":0.47379767761173325,"score_spread":0.41596662412699525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414082275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922672,0.0003776957,0.0002872639,0.0026518432,0.00068810116,0.0017572216,0.00002860551,0.000012243732,0.0019298184],"genre_scores_gemma":[0.99673307,0.00026482347,0.0014863003,0.00041085435,0.00018553062,0.0001171342,0.000023512792,0.000019450961,0.00075932365],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954337,0.0007175658,0.0030477622,0.00027145824,0.0002900382,0.00023950233],"domain_scores_gemma":[0.9942073,0.002549601,0.0020544145,0.00017996728,0.000792105,0.00021656723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012619005,0.00021641923,0.002253136,0.00040018148,0.00008354566,0.000008501705,0.00012615613,0.00026693815,0.00020933812],"category_scores_gemma":[0.0015825758,0.00013888697,0.00033774838,0.000499124,0.00016187181,0.00015441736,0.00003622922,0.00070123735,0.0000015803364],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26151314,0.0520737,0.64317304,0.00024181342,0.004012281,0.00045251494,0.007721468,0.0006047872,0.0021291175,0.000030340783,0.0013312199,0.026716558],"study_design_scores_gemma":[0.7463025,0.033416264,0.20986325,0.0006768558,0.004732898,0.000018650475,0.0018477066,0.0013129313,0.0011389941,0.000054381322,0.0004571337,0.00017847236],"about_ca_topic_score_codex":0.0008149643,"about_ca_topic_score_gemma":0.001377232,"teacher_disagreement_score":0.48478934,"about_ca_system_score_codex":0.0003791288,"about_ca_system_score_gemma":0.0030826293,"threshold_uncertainty_score":0.56636465},"labels":[],"label_agreement":null},{"id":"W4414108695","doi":"10.1200/jco-25-00436","title":"PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"FOLFIRINOX; Pancreatic cancer; Metastatic adenocarcinoma; Pancreatic ductal adenocarcinoma; Adenocarcinoma; Phases of clinical research; Overall survival; Chemotherapy","score_opus":0.16241778863201745,"score_gpt":0.538592460887957,"score_spread":0.37617467225593954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414108695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733711,0.0047736354,0.008583859,0.005649725,0.001154265,0.003148659,0.00002147013,0.000010708597,0.0032866115],"genre_scores_gemma":[0.986574,0.0043704,0.0066167437,0.0005042511,0.0002902239,0.00023906231,0.000009498014,0.000021320111,0.001374535],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99319357,0.0018887318,0.0038093473,0.00031068208,0.00039406464,0.00040357767],"domain_scores_gemma":[0.9712279,0.024928465,0.0022288451,0.00027325746,0.00094650005,0.00039503837],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008160601,0.00025445843,0.0058896253,0.00031911946,0.00009307375,0.0000081546295,0.00018892875,0.0004165489,0.00010127529],"category_scores_gemma":[0.03694582,0.00016851569,0.0010002588,0.00027528752,0.0010433161,0.00009168503,0.000088369954,0.0007593399,0.000001065941],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.946508,0.0045076096,0.001476805,0.00027402915,0.007758338,0.00016911246,0.00022730032,0.000018858751,0.0002608769,0.0024356719,0.0009769812,0.035386402],"study_design_scores_gemma":[0.91204953,0.06166121,0.0010354427,0.00039124474,0.013278088,0.000031581432,0.00016685668,0.0052711884,0.00009002769,0.004469582,0.0014369183,0.00011830438],"about_ca_topic_score_codex":0.00008987162,"about_ca_topic_score_gemma":0.000026592477,"teacher_disagreement_score":0.0571536,"about_ca_system_score_codex":0.00018218863,"about_ca_system_score_gemma":0.0040808786,"threshold_uncertainty_score":0.9711664},"labels":[],"label_agreement":null},{"id":"W4414119284","doi":"10.1200/jco-25-01608","title":"End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Bladder cancer; Perioperative; Clinical trial; Urothelial cancer; Cancer; MEDLINE; Cystectomy","score_opus":0.3125837297208131,"score_gpt":0.4929975713143874,"score_spread":0.18041384159357426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414119284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91155475,0.0031495844,0.01598284,0.0522421,0.008121239,0.0066916943,0.00019284917,0.000020890622,0.0020440714],"genre_scores_gemma":[0.9807884,0.0011673545,0.0050228466,0.0083487965,0.0032673336,0.0003760908,0.00002033093,0.000028591416,0.0009802423],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969426,0.00036939842,0.0019204713,0.00025316273,0.00026774567,0.0002466274],"domain_scores_gemma":[0.9891208,0.0077594733,0.0013394221,0.00018066599,0.0014388412,0.0001608392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025645576,0.00019234653,0.0015471014,0.00009021424,0.0001936804,0.000036915786,0.00014587541,0.00025866175,0.00016966536],"category_scores_gemma":[0.0071980916,0.00009665479,0.00059600774,0.000114876246,0.00016486969,0.0001605298,0.000026158605,0.0003823872,0.0000016046698],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04135427,0.0044333967,0.07247798,0.00014715541,0.01314268,0.000031061638,0.0011655161,0.00025088488,0.0011710743,0.00092455914,0.036431167,0.82847023],"study_design_scores_gemma":[0.14888173,0.06684588,0.42936584,0.00065712247,0.016715543,0.000024376963,0.0012518609,0.001303478,0.0043020574,0.00088479806,0.32929623,0.00047109436],"about_ca_topic_score_codex":0.000044791825,"about_ca_topic_score_gemma":0.00044648172,"teacher_disagreement_score":0.8279992,"about_ca_system_score_codex":0.00022791598,"about_ca_system_score_gemma":0.0036298756,"threshold_uncertainty_score":0.8617308},"labels":[],"label_agreement":null},{"id":"W4414309670","doi":"10.1200/jco-25-01235","title":"Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Missile; Conjugate; Pandemic; Key (lock); Cancer","score_opus":0.3070645395625706,"score_gpt":0.579066841590274,"score_spread":0.27200230202770337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414309670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.581355,0.003518569,0.00020684488,0.34012222,0.0022055318,0.00052058545,0.0000081276785,0.000010790172,0.07205237],"genre_scores_gemma":[0.9859052,0.0009893831,0.0010398448,0.009720004,0.00095780345,0.0000036718786,0.0000016718723,0.000012152515,0.0013703067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497205,0.0012903347,0.0026905148,0.00016885277,0.0005821938,0.00029604213],"domain_scores_gemma":[0.9884099,0.008854018,0.0013764297,0.0004888751,0.00065330794,0.00021746606],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0108772265,0.00012471984,0.0013752764,0.00010097053,0.00013139386,0.000016894373,0.0006368383,0.00021314855,0.00037669728],"category_scores_gemma":[0.009004471,0.000058806585,0.00053078035,0.00032657737,0.002173808,0.000056150766,0.00016618882,0.0018454082,0.000014992944],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064966646,0.0028702572,0.17862163,0.00053533964,0.0022507985,0.00067619886,0.0010691766,0.000101729194,0.0055119228,0.06371095,0.6290655,0.10908982],"study_design_scores_gemma":[0.0087143835,0.004710035,0.34909388,0.0007373597,0.00072355976,0.00054205855,0.00089455146,0.0010332259,0.0033512758,0.08715213,0.5429039,0.00014362184],"about_ca_topic_score_codex":0.0001248677,"about_ca_topic_score_gemma":0.00007155045,"teacher_disagreement_score":0.4045502,"about_ca_system_score_codex":0.000121411365,"about_ca_system_score_gemma":0.0037563683,"threshold_uncertainty_score":0.9993431},"labels":[],"label_agreement":null},{"id":"W4414498177","doi":"10.1200/jco-25-01694","title":"Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Hôpital Maisonneuve-Rosemont","funders":"Gilead Sciences","keywords":"Refractory (planetary science); Clinical trial; Safety profile; Overall survival; Cancer; Toxicity","score_opus":0.12806434935643887,"score_gpt":0.5223809701529823,"score_spread":0.3943166207965435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414498177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93820846,0.0004292959,0.00009726435,0.03326103,0.0015211622,0.00030179854,0.0000018672397,0.000018766608,0.026160356],"genre_scores_gemma":[0.967113,0.0017314714,0.0044924426,0.01304403,0.0008710593,0.000007280315,0.0000030201593,0.000025503938,0.012712187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994601,0.0009316854,0.003345658,0.00024897105,0.00046701755,0.0004056719],"domain_scores_gemma":[0.9912604,0.006338189,0.0010614888,0.00031909748,0.0005999359,0.00042087163],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0069387644,0.00015410305,0.0018782456,0.0005958832,0.000031918855,0.000008997756,0.00034419968,0.0007617739,0.0004382947],"category_scores_gemma":[0.019554427,0.000099803554,0.00039105292,0.00078923913,0.00032237815,0.000094788826,0.0001262818,0.0036274593,0.00007528975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08807817,0.0066774595,0.1171282,0.00019261734,0.0011526215,0.024911996,0.0002567918,0.000032887016,0.0048508677,0.0003892735,0.29801598,0.4583131],"study_design_scores_gemma":[0.042077716,0.018626543,0.20615691,0.00045692557,0.0002796705,0.0006900884,0.00034000634,0.00038627133,0.00040259073,0.0008020866,0.7296308,0.00015034512],"about_ca_topic_score_codex":0.000036283553,"about_ca_topic_score_gemma":0.000088527195,"teacher_disagreement_score":0.45816278,"about_ca_system_score_codex":0.0010695998,"about_ca_system_score_gemma":0.011523293,"threshold_uncertainty_score":0.99867123},"labels":[],"label_agreement":null},{"id":"W4414533110","doi":"10.1200/jco-25-00925","title":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Prednisone; International Prognostic Index; Tolerability; Lymphoma; Overall survival; Population; Diffuse large B-cell lymphoma; Progression-free survival; Cohort","score_opus":0.04100241325133839,"score_gpt":0.42187365049220954,"score_spread":0.38087123724087113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414533110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964049,0.000116188006,0.000008830367,0.0010293819,0.0003712597,0.0004765719,0.0000025762702,0.0000032751916,0.0015870155],"genre_scores_gemma":[0.9985887,0.000034287004,0.00014984439,0.00064745813,0.000063068226,0.000001888585,4.282614e-7,0.000011115287,0.0005032345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966834,0.00054408103,0.0017109358,0.00019089914,0.00058645837,0.00028420106],"domain_scores_gemma":[0.99605626,0.002261949,0.00081872375,0.00033865534,0.0003438688,0.00018054876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025239326,0.00013255994,0.0014916031,0.00019513106,0.000044122768,0.000009364232,0.00029901008,0.00020503091,0.000012923349],"category_scores_gemma":[0.0028898683,0.00007001592,0.00019701416,0.00029861578,0.0002528398,0.0000708175,0.00031762908,0.00071072695,0.0000021587693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040614586,0.018877095,0.9738326,0.000048498394,0.0002921254,0.00009198283,0.000265125,0.0000025134398,0.0000044214953,0.00006199028,0.0002769545,0.0021852471],"study_design_scores_gemma":[0.21010831,0.004731905,0.78342974,0.00011237785,0.00018704588,0.000008963985,0.00048093926,0.00018577457,0.000008349568,0.000027367083,0.00067340606,0.00004582217],"about_ca_topic_score_codex":0.0002807546,"about_ca_topic_score_gemma":0.0003735193,"teacher_disagreement_score":0.20604685,"about_ca_system_score_codex":0.0018539389,"about_ca_system_score_gemma":0.007221705,"threshold_uncertainty_score":0.9984064},"labels":[],"label_agreement":null},{"id":"W4414697096","doi":"10.1200/jco-25-00531","title":"Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; University of Alberta","funders":"National Cancer Institute","keywords":"Childhood cancer; Chemotherapy; Radiation therapy; Colorectal cancer; Radiation dose; Cancer","score_opus":0.047851783534136445,"score_gpt":0.4305104552912655,"score_spread":0.3826586717571291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414697096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846075,0.0032191712,0.00006166993,0.0062877247,0.0034442886,0.0019459415,0.00003632852,0.000021475134,0.0003758648],"genre_scores_gemma":[0.9797719,0.017212976,0.00020380404,0.000983539,0.0012494164,0.00035810022,0.0000054910024,0.000031436517,0.00018330764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566215,0.00055537897,0.0026438897,0.00046112222,0.00031809008,0.00035938274],"domain_scores_gemma":[0.9954282,0.0016612525,0.001886227,0.0002159374,0.0005610512,0.0002473202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003933955,0.00025754765,0.0018299447,0.00033577217,0.00013701439,0.0000312031,0.00015488494,0.00036997485,0.00011280756],"category_scores_gemma":[0.0012386048,0.00020196963,0.00042679123,0.0005301126,0.00019431904,0.00015429227,0.000044930533,0.0010143906,0.0000012580242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005085578,0.0049234494,0.8928816,0.000028876037,0.00083961553,0.00022737255,0.00088575337,0.000061352766,0.00027765168,0.000045572437,0.0015282016,0.093215],"study_design_scores_gemma":[0.019177457,0.0078222705,0.9383421,0.00016601458,0.000515838,0.00022373826,0.0005117966,0.000020432126,0.00029642787,0.00023008231,0.0325289,0.00016495025],"about_ca_topic_score_codex":0.002262463,"about_ca_topic_score_gemma":0.022115389,"teacher_disagreement_score":0.093050055,"about_ca_system_score_codex":0.0006200196,"about_ca_system_score_gemma":0.0033966587,"threshold_uncertainty_score":0.99572843},"labels":[],"label_agreement":null},{"id":"W4414761454","doi":"10.1200/jco-25-01957","title":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Phases of clinical research; Clinical trial; Adverse effect; Primary (astronomy); Clinical endpoint; Safety profile","score_opus":0.05260119380452237,"score_gpt":0.419853000832879,"score_spread":0.36725180702835664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414761454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97556037,0.0017975771,0.000020635041,0.0047617783,0.0026304622,0.0007399788,0.000047171143,0.000009664371,0.01443238],"genre_scores_gemma":[0.9944402,0.0018159227,0.00028336997,0.0017976826,0.0005246252,0.0000131557035,0.000019480012,0.000016240818,0.0010893496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99345016,0.00074858876,0.0045844684,0.0003169725,0.0005186893,0.00038113355],"domain_scores_gemma":[0.99307364,0.0036458934,0.0022976382,0.00046449213,0.0002741243,0.00024421778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031030118,0.00024469147,0.0024450263,0.00026856514,0.00006188961,0.000009006939,0.00035941566,0.00064175104,0.00003339851],"category_scores_gemma":[0.0016614617,0.00014583445,0.0009950453,0.00043724748,0.0001837241,0.00009405029,0.000080882106,0.0007036834,0.000006560688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81742924,0.0905357,0.013697501,0.0001726169,0.0009301499,0.0020131194,0.00062160747,0.00002736436,0.00057589804,0.00033499204,0.021591429,0.05207039],"study_design_scores_gemma":[0.8394177,0.015965344,0.056535877,0.00050226063,0.0009558005,0.00008923349,0.00010676851,0.000109006105,0.0010328825,0.00014713651,0.085021414,0.00011655199],"about_ca_topic_score_codex":0.00018150936,"about_ca_topic_score_gemma":0.00016533295,"teacher_disagreement_score":0.07457035,"about_ca_system_score_codex":0.001174799,"about_ca_system_score_gemma":0.00852244,"threshold_uncertainty_score":0.9970983},"labels":[],"label_agreement":null},{"id":"W4415110440","doi":"10.1200/jco-25-01630","title":"Beyond the Trials: Real-World Considerations for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Biopsy; Sentinel lymph node; Breast cancer; Sentinel node; Cancer; Lymph node","score_opus":0.11238063981957103,"score_gpt":0.4809503302426199,"score_spread":0.3685696904230489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415110440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8959672,0.0015339145,0.00025001576,0.09515711,0.002603149,0.00035593603,0.00009863884,0.0000049827145,0.004029052],"genre_scores_gemma":[0.9917563,0.0015272084,0.0010765276,0.003544733,0.0014429375,0.00005312504,0.000005143485,0.000010602534,0.00058338454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718565,0.0006013606,0.0017265172,0.00020222402,0.00010059747,0.00018367716],"domain_scores_gemma":[0.99557763,0.0027797916,0.0010277453,0.00017616288,0.00036386726,0.00007482518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029924372,0.00012868816,0.0008822566,0.000089315065,0.00010467488,0.000016318787,0.00014474193,0.0002259107,0.000023936564],"category_scores_gemma":[0.0029782616,0.00007696796,0.000432333,0.00012407478,0.00018119416,0.000006176236,0.000079170546,0.00021056924,0.0000010074476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070464145,0.0011482686,0.9065167,0.00002672285,0.0015183288,0.000036951522,0.00008690693,0.00015419148,0.0042900336,0.0018247202,0.03613179,0.041218992],"study_design_scores_gemma":[0.008349234,0.00015244723,0.97483087,0.00006315518,0.00033731363,0.000046692847,0.00007222481,0.000026233738,0.00044970034,0.0030685426,0.012515686,0.00008792442],"about_ca_topic_score_codex":0.00024680578,"about_ca_topic_score_gemma":0.0005108263,"teacher_disagreement_score":0.095789135,"about_ca_system_score_codex":0.000092374845,"about_ca_system_score_gemma":0.0015972891,"threshold_uncertainty_score":0.35654724},"labels":[],"label_agreement":null},{"id":"W4415177062","doi":"10.1200/jco-25-01376","title":"Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Dosimetry; Radiation therapy; Cancer; Clinical trial; MEDLINE","score_opus":0.49826251327171805,"score_gpt":0.5202481893919765,"score_spread":0.021985676120258424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415177062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89366734,0.038209133,0.04514848,0.019269977,0.00047848225,0.0017936061,0.000022366185,0.000009551748,0.0014010576],"genre_scores_gemma":[0.9947541,0.0013950948,0.0026215622,0.00080353714,0.00033883494,0.000037535137,0.0000027621395,0.0000061620794,0.000040436236],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976517,0.00055114605,0.0013566329,0.00016590477,0.00010915489,0.00016546655],"domain_scores_gemma":[0.9879931,0.010757816,0.0006199593,0.000101561454,0.00040055191,0.00012700069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034726865,0.000119491175,0.0015965699,0.00017102841,0.00007903563,0.000010941278,0.00006492284,0.00020769674,0.000009351776],"category_scores_gemma":[0.002202774,0.000069760354,0.00039632432,0.00014420229,0.00022461075,0.000056971883,0.000016342145,0.0003263306,2.7063854e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060041588,0.0025026998,0.2648005,0.0005169377,0.0055183694,0.010122837,0.0019092533,0.00010039658,0.0001425126,0.0068020234,0.0056299637,0.64191294],"study_design_scores_gemma":[0.29641965,0.07225655,0.2505566,0.0016690599,0.017123917,0.008180988,0.019786628,0.17847884,0.0031423834,0.003156781,0.14851724,0.0007113826],"about_ca_topic_score_codex":0.000010556665,"about_ca_topic_score_gemma":0.000103621554,"teacher_disagreement_score":0.64120156,"about_ca_system_score_codex":0.00010355229,"about_ca_system_score_gemma":0.0007369181,"threshold_uncertainty_score":0.2844745},"labels":[],"label_agreement":null},{"id":"W4415395806","doi":"10.1200/jco-25-00248","title":"Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Economic evaluation; Selection (genetic algorithm); Clinical trial; Cost–benefit analysis; MEDLINE; Quality-adjusted life year; Cost effectiveness","score_opus":0.11018379754136605,"score_gpt":0.5136461161663273,"score_spread":0.40346231862496124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415395806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823737,0.00043852342,0.0029286456,0.00871792,0.0005234294,0.001063065,0.000005059852,0.0000034324112,0.003946213],"genre_scores_gemma":[0.9881576,0.0010248375,0.009827081,0.0007932445,0.00008058824,0.00003828437,0.0000026942168,0.000005984797,0.00006972776],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997383,0.00030926755,0.0017171354,0.00019520978,0.0002619468,0.00013341763],"domain_scores_gemma":[0.99760246,0.00077008404,0.0010038288,0.00017849937,0.00033022702,0.0001148916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003773774,0.00009779105,0.00091883406,0.00023292078,0.000012753233,0.0000036981828,0.00009196086,0.00017154966,0.0001121933],"category_scores_gemma":[0.00026653786,0.000072769115,0.00011152282,0.00012014152,0.00012594827,0.00006367338,0.000034303575,0.0004368659,5.4246794e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006478137,0.0014948556,0.34955266,0.0003330137,0.00030730185,0.000046915557,0.00006920338,0.009708168,0.0000035196301,0.00006652307,0.002296837,0.6296429],"study_design_scores_gemma":[0.023808394,0.0016153333,0.72678345,0.00048723558,0.0005146182,0.000006558714,0.00008348878,0.24592009,0.000015678701,0.000168366,0.0005521201,0.00004463736],"about_ca_topic_score_codex":0.000068726855,"about_ca_topic_score_gemma":0.0005430038,"teacher_disagreement_score":0.62959826,"about_ca_system_score_codex":0.0005206601,"about_ca_system_score_gemma":0.0035558378,"threshold_uncertainty_score":0.63079035},"labels":[],"label_agreement":null},{"id":"W4415712355","doi":"10.1200/jco-25-01070","title":"Metformin Active Surveillance Trial in Low-Risk Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Sunnybrook Health Science Centre; University of Manitoba; St. Joseph’s Healthcare Hamilton; Centre Hospitalier de l’Université de Montréal; McMaster University; Queen's University; McGill University Health Centre; Health Sciences Centre; University Health Network; CancerCare Manitoba; Ottawa Hospital; Hôpital Fleurimont; Princess Margaret Cancer Centre; University of Toronto; Western University","funders":"","keywords":"Metformin; Prostate cancer; Adverse effect; Cancer; Prostatectomy; Diabetes mellitus; Prostate-specific antigen","score_opus":0.037531695843816625,"score_gpt":0.44403037266170237,"score_spread":0.40649867681788576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415712355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93178564,0.06279261,0.000061693914,0.0002829537,0.0036402054,0.00022535081,0.000022972217,0.0000019624472,0.0011866293],"genre_scores_gemma":[0.76679033,0.22883177,0.00031866328,0.0015086513,0.0019522153,0.000030717187,0.0000051340508,0.000012211904,0.00055029773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969178,0.00071874965,0.0017225294,0.00023534837,0.00015169084,0.00025389763],"domain_scores_gemma":[0.9975398,0.0004927613,0.001365094,0.00018443326,0.00029748076,0.00012038325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036008407,0.00012972903,0.00093556405,0.000088159795,0.000028095596,0.000008800521,0.00026014072,0.00041466198,0.00005255452],"category_scores_gemma":[0.0043932996,0.00009910465,0.0003485623,0.00015988544,0.00013983218,0.000008851202,0.00007447695,0.000614295,0.0000026293783],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04925902,0.0005434087,0.022226134,0.00001916404,0.00029733364,0.000019700317,0.000036110425,0.00011448962,0.00039087137,0.00003229226,0.0042302413,0.92283124],"study_design_scores_gemma":[0.054023538,0.0034420702,0.03571806,0.00006824881,0.00008765724,0.0000037316217,0.0000804403,0.000025923342,0.0048770336,0.00069668214,0.9008203,0.00015630774],"about_ca_topic_score_codex":0.0000582348,"about_ca_topic_score_gemma":0.00081663526,"teacher_disagreement_score":0.92267495,"about_ca_system_score_codex":0.00006353014,"about_ca_system_score_gemma":0.0022044457,"threshold_uncertainty_score":0.52595073},"labels":[],"label_agreement":null},{"id":"W4416153578","doi":"10.1200/jco-25-00532","title":"Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Wilms' tumor; Histology; Stage (stratigraphy); Tumor cells; Primary tumor; Lung","score_opus":0.029574906739316696,"score_gpt":0.41718738349597406,"score_spread":0.3876124767566574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416153578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161035,0.0024655326,0.00005758161,0.0020741962,0.0015549028,0.0003862739,0.00001522577,0.0000040781533,0.0018318712],"genre_scores_gemma":[0.9973417,0.000403801,0.00021353945,0.0011287164,0.000584315,0.000014291625,0.000021563968,0.00001669433,0.00027540664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994459,0.0012669528,0.0032559466,0.00043285117,0.0002355419,0.00034974873],"domain_scores_gemma":[0.995185,0.0011338418,0.0027313216,0.0005097107,0.00027350496,0.00016660466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030368539,0.00025316112,0.00182623,0.00014367812,0.00005827146,0.00000740462,0.0007246878,0.0005456535,0.000053380303],"category_scores_gemma":[0.0027895777,0.00014461283,0.00091128465,0.00025533693,0.00045001355,0.000011002913,0.00023994435,0.0012846638,0.0000031837892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037894193,0.0029489552,0.963037,0.0000062311665,0.0018742577,0.0031010157,0.00007503302,0.00041459702,0.0029048584,0.000009329797,0.0055764234,0.01626288],"study_design_scores_gemma":[0.0051680966,0.011232993,0.96824735,0.000058097758,0.00032796775,0.0011924137,0.00042291958,0.000031844,0.0000774746,0.00037131895,0.012713967,0.00015554871],"about_ca_topic_score_codex":0.0022576188,"about_ca_topic_score_gemma":0.00048155736,"teacher_disagreement_score":0.01610733,"about_ca_system_score_codex":0.00025891903,"about_ca_system_score_gemma":0.00325714,"threshold_uncertainty_score":0.58971405},"labels":[],"label_agreement":null},{"id":"W4416330185","doi":"10.1200/jco-25-00507","title":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University; Juravinski Hospital","funders":"","keywords":"Lymphoma; Lactate dehydrogenase; Refractory (planetary science); Cytokine release syndrome; Clinical trial; Survival analysis; Overall survival; Immunotherapy; Prospective cohort study","score_opus":0.048001974939657285,"score_gpt":0.42936079321755405,"score_spread":0.38135881827789675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416330185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962796,0.000100242534,0.000017689805,0.0008332676,0.00057491707,0.00037693785,0.000011465329,0.0000018845064,0.008455618],"genre_scores_gemma":[0.99551874,0.0002112757,0.00022139632,0.0005215699,0.000138817,0.0000022795998,0.0000032484293,0.000010998414,0.003371694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550796,0.00096633297,0.0024105094,0.00017195307,0.0007212239,0.00022205034],"domain_scores_gemma":[0.9943999,0.0026483326,0.0017552049,0.0004147415,0.0006476252,0.00013419446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004136093,0.00011178642,0.0018819331,0.0005226544,0.000021081156,0.000003115414,0.00033260533,0.00036352142,0.0005487493],"category_scores_gemma":[0.0026440101,0.00006473713,0.0008517683,0.0012080525,0.00026985555,0.000048688515,0.00010452058,0.0008008874,0.0000028099894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25281504,0.021714035,0.6869728,0.000050858896,0.0026337483,0.00004601045,0.00016516108,0.000029483783,0.0003131596,0.000041904597,0.002597739,0.03262006],"study_design_scores_gemma":[0.22828169,0.015105234,0.7361104,0.000085225205,0.0014437685,0.000001006087,0.000090273425,0.000058551126,0.00018652307,0.000038742906,0.018552601,0.00004600143],"about_ca_topic_score_codex":0.000035331213,"about_ca_topic_score_gemma":0.00012423571,"teacher_disagreement_score":0.049137574,"about_ca_system_score_codex":0.00020761223,"about_ca_system_score_gemma":0.0022994743,"threshold_uncertainty_score":0.600842},"labels":[],"label_agreement":null},{"id":"W4416887160","doi":"10.1200/jco-25-01204","title":"STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba","funders":"","keywords":"Lomustine; Eflornithine; Phases of clinical research; Chemotherapy; Radiation therapy","score_opus":0.12655478146775173,"score_gpt":0.4809994842584339,"score_spread":0.3544447027906822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416887160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932648,0.0005222788,0.000040551222,0.0015869794,0.0015193544,0.0024873735,0.00000903033,0.000006812119,0.00056281907],"genre_scores_gemma":[0.9975397,0.00017867037,0.0016721545,0.00027818978,0.00019876343,0.00004424829,0.000017409815,0.000018423521,0.000052412313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99356025,0.0008884311,0.0042805057,0.0003431777,0.0006236453,0.0003039802],"domain_scores_gemma":[0.99115825,0.0044775815,0.0028090593,0.000353222,0.00086725526,0.0003346124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036787535,0.0002891055,0.0047249463,0.0004270796,0.00004295342,0.000015832484,0.00034477396,0.00024079767,0.000076385884],"category_scores_gemma":[0.0038790074,0.00017557612,0.00026335422,0.0005471611,0.0002375044,0.000116656585,0.0002166082,0.00096501346,0.0000030079898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77713954,0.11370689,0.06011683,0.00004118653,0.0022144334,0.0011221098,0.00014417006,0.0000608585,0.000005379509,0.000019643152,0.001052659,0.044376295],"study_design_scores_gemma":[0.8466946,0.09429077,0.054551102,0.00045747275,0.0027115878,0.000020197336,0.0002562404,0.00018584817,0.000041551226,0.000019043073,0.0006704529,0.00010117082],"about_ca_topic_score_codex":0.00007016074,"about_ca_topic_score_gemma":0.0003120919,"teacher_disagreement_score":0.069555014,"about_ca_system_score_codex":0.00034134474,"about_ca_system_score_gemma":0.0012128524,"threshold_uncertainty_score":0.7159786},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4416928707","doi":"10.1200/jco-25-00892","title":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health; Cancerfonden; Mater Foundation","keywords":"Follicular lymphoma; Clinical trial; Lymphoma; Prognostic model; Proportional hazards model; Cause of death; Disease; Follicular phase","score_opus":0.10786766392590452,"score_gpt":0.4663264441712946,"score_spread":0.3584587802453901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416928707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97801703,0.0015398022,0.0049737296,0.010232283,0.002562597,0.0019465444,0.000009203554,0.000018612021,0.00070021895],"genre_scores_gemma":[0.97380584,0.002651708,0.015940787,0.0052514384,0.0016537256,0.00016814636,0.0000067685432,0.000021834412,0.0004997619],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99438184,0.00040198868,0.004043451,0.00043176964,0.00038491664,0.0003560326],"domain_scores_gemma":[0.9864329,0.010840966,0.001423707,0.00031375277,0.0005134976,0.00047514643],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004105727,0.00025356095,0.0025248704,0.00014927436,0.00008220311,0.000030071275,0.00017382995,0.0006670088,0.000011536046],"category_scores_gemma":[0.011957472,0.00017094048,0.0014089976,0.0001233332,0.00021046423,0.00009816723,0.000101444675,0.0003415004,0.0000047427025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10539012,0.01918629,0.16292648,0.000077627774,0.0025830765,0.00078168826,0.000058228325,0.00011639584,0.000008966056,0.0013912319,0.009979708,0.69750017],"study_design_scores_gemma":[0.5625829,0.045492638,0.30929422,0.00033024227,0.0055047907,0.00012469183,0.000049646827,0.023399608,0.00001552797,0.0065240795,0.046448417,0.00023319488],"about_ca_topic_score_codex":0.000007801316,"about_ca_topic_score_gemma":0.000015345395,"teacher_disagreement_score":0.697267,"about_ca_system_score_codex":0.0003118121,"about_ca_system_score_gemma":0.0039874716,"threshold_uncertainty_score":0.99636525},"labels":[],"label_agreement":null},{"id":"W4417198347","doi":"10.1200/jco-25-02600","title":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital","funders":"","keywords":"Pertuzumab; Trastuzumab; Metastatic breast cancer; Placebo; Maintenance therapy; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.1733979768876252,"score_gpt":0.5582290306535705,"score_spread":0.38483105376594534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417198347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741904,0.00070501585,0.00024630313,0.021847589,0.0006112632,0.0020094204,0.000018161989,0.0000058057535,0.00036604883],"genre_scores_gemma":[0.99556154,0.0022215284,0.0007443919,0.0007591804,0.00016876745,0.0001670008,0.0000024919134,0.00002324662,0.00035183484],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962677,0.0005177724,0.002100179,0.00029898167,0.00049866893,0.00031673885],"domain_scores_gemma":[0.99193853,0.0055021723,0.0011039012,0.00022122644,0.0010011296,0.00023302631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039267074,0.00018656018,0.0017687964,0.0003002374,0.000053385014,0.000011657329,0.00020723612,0.00016786248,0.000114222115],"category_scores_gemma":[0.0023017318,0.00012410045,0.0001715694,0.00041737498,0.00029704167,0.000100352176,0.000039298546,0.00091447035,6.234737e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4485508,0.034372807,0.028227353,0.0002970198,0.0016746846,0.00042566544,0.0017983819,0.000115248346,0.000054798635,0.00014555138,0.0029298917,0.4814078],"study_design_scores_gemma":[0.589039,0.27934954,0.1052106,0.0011727718,0.00073160714,0.00034057745,0.0062370677,0.0018789211,0.00007784405,0.00041919257,0.015343215,0.00019964209],"about_ca_topic_score_codex":0.00060001214,"about_ca_topic_score_gemma":0.003125145,"teacher_disagreement_score":0.48120815,"about_ca_system_score_codex":0.0006232319,"about_ca_system_score_gemma":0.0045107407,"threshold_uncertainty_score":0.80018604},"labels":[],"label_agreement":null},{"id":"W4417258216","doi":"10.1200/jco-25-02115","title":"Management of Cancer During Pregnancy: ASCO Guideline","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Guideline; Referral; Cancer; Psychosocial; Pregnancy; Gestation; Harm; Risk factor","score_opus":0.106879708400488,"score_gpt":0.5433394218813237,"score_spread":0.4364597134808357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417258216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95508647,0.00877129,0.00038606243,0.01485773,0.002978269,0.00021449453,0.0000041201483,0.000007468279,0.017694082],"genre_scores_gemma":[0.97684467,0.014586876,0.00346467,0.0008550161,0.00052195933,0.0000038073,6.122608e-7,0.00000820362,0.0037141903],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99707615,0.000066272776,0.0024007086,0.00011210096,0.00021206104,0.00013270912],"domain_scores_gemma":[0.9980206,0.00021118394,0.0011490271,0.00015762789,0.00033508247,0.00012650983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071945455,0.00007808152,0.0010139447,0.000111293826,0.00001693148,0.0000020895227,0.00011979462,0.00016575256,0.00030107735],"category_scores_gemma":[0.00025935585,0.000054392636,0.0003923645,0.0001510055,0.000091959606,0.000036733578,0.00006422416,0.0004404724,0.0000020776297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030757308,0.0010313703,0.23992775,0.00039476145,0.0016695079,0.0009130778,0.000041696556,0.00006578402,0.00022512717,0.00047617932,0.011580203,0.7405988],"study_design_scores_gemma":[0.008734794,0.0018332821,0.7521275,0.0022127207,0.00092487695,0.00003207784,0.00010647213,0.000033297358,0.00051473157,0.0003237322,0.23309802,0.00005847487],"about_ca_topic_score_codex":0.00007799765,"about_ca_topic_score_gemma":0.000057974103,"teacher_disagreement_score":0.7405403,"about_ca_system_score_codex":0.00014699764,"about_ca_system_score_gemma":0.00078654964,"threshold_uncertainty_score":0.32965857},"labels":[],"label_agreement":null},{"id":"W4417274379","doi":"10.1200/jco-25-00924","title":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Primary (astronomy); Clinical endpoint; Phase (matter); Phases of clinical research; Point (geometry)","score_opus":0.09756831229007881,"score_gpt":0.4690346421725317,"score_spread":0.3714663298824529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417274379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847846,0.0011257164,0.0000777572,0.003045213,0.002342031,0.0029531321,0.000043862554,0.000012612081,0.005615102],"genre_scores_gemma":[0.99570024,0.00051611743,0.0018323091,0.0004883935,0.00039847946,0.000054634842,0.000014704411,0.000029627292,0.00096547825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9868849,0.0054402403,0.0055086445,0.0005176721,0.0010831954,0.0005653449],"domain_scores_gemma":[0.9543906,0.039839696,0.003400337,0.0007851141,0.0011028474,0.0004814021],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014801703,0.00035856362,0.0046340963,0.0005625144,0.000098861376,0.000014385676,0.0005619433,0.0005889144,0.000051657382],"category_scores_gemma":[0.05965873,0.00021840484,0.0012139198,0.00084903836,0.00097432535,0.00016797027,0.00032328218,0.002321336,0.0000070864858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8493048,0.016063169,0.05885642,0.000051771818,0.0031091429,0.0018586088,0.00046786212,0.00004245406,0.00069501565,0.000038616694,0.0013081406,0.06820402],"study_design_scores_gemma":[0.75492656,0.015585951,0.2241701,0.0003917071,0.0011869264,0.000051844843,0.000513364,0.0002194707,0.00057934626,0.000086134656,0.002159379,0.00012919388],"about_ca_topic_score_codex":0.0013712341,"about_ca_topic_score_gemma":0.0016034183,"teacher_disagreement_score":0.16531369,"about_ca_system_score_codex":0.0013331077,"about_ca_system_score_gemma":0.0069428086,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W4417410238","doi":"10.1200/jco-25-02206","title":"Assessing the Benefit of Specialist Palliative Care in Oncology: Rethinking Clinical Trial Design","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Palliative care; Clinical trial; Research design; MEDLINE; Clinical study design; Patient care","score_opus":0.6775939605584578,"score_gpt":0.6669200894794847,"score_spread":0.010673871078973107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417410238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565109,0.004890523,0.0019333416,0.012137892,0.0055567883,0.00064282696,0.0000041385597,0.000007687276,0.018315872],"genre_scores_gemma":[0.9618689,0.005428214,0.026789278,0.0028134994,0.002948991,0.000005701892,0.0000030263648,0.000014964548,0.00012745577],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9902461,0.00279569,0.005978932,0.0002546528,0.00046995448,0.000254628],"domain_scores_gemma":[0.956014,0.037643928,0.004499533,0.00030057595,0.0013729774,0.000168985],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014388787,0.00017512213,0.0030959265,0.00023286816,0.00005282681,0.000012142493,0.000400403,0.00091888686,0.00005035726],"category_scores_gemma":[0.038724802,0.00010930914,0.0009441273,0.0004185528,0.00077391113,0.00012352636,0.00011535293,0.0023171403,0.0000021336862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11579442,0.002405075,0.43096864,0.00015089482,0.0011474966,0.0006748187,0.0042623063,0.000094754745,0.00007409245,0.0019253369,0.0037732336,0.43872893],"study_design_scores_gemma":[0.16607428,0.05868071,0.5051441,0.005487197,0.0020793267,0.000022937247,0.014692545,0.0002108705,0.00075439847,0.013615983,0.23297144,0.0002661643],"about_ca_topic_score_codex":0.000050349197,"about_ca_topic_score_gemma":0.00022134249,"teacher_disagreement_score":0.43846276,"about_ca_system_score_codex":0.00041499853,"about_ca_system_score_gemma":0.005839989,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W4417497465","doi":"10.1200/jco-25-00661","title":"Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Colorectal cancer screening; Colonoscopy; Incidence (geometry); Colorectal cancer; Childhood cancer; Guideline; Cancer; Cancer screening","score_opus":0.03775524283943827,"score_gpt":0.3818940470010564,"score_spread":0.34413880416161813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417497465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890792,0.007480933,0.0001907901,0.0016661327,0.00050507404,0.0003630237,0.000008031663,0.000017511118,0.00068934966],"genre_scores_gemma":[0.9928238,0.0053748568,0.00080266735,0.00024204895,0.0005471874,0.0000217927,0.0000026145876,0.000016233003,0.00016884632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975745,0.00024957478,0.0014366398,0.00023822603,0.00028796314,0.00021305835],"domain_scores_gemma":[0.996685,0.0009249458,0.001505718,0.000106168314,0.00054573925,0.0002323837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013657612,0.00016545474,0.0013348442,0.0002489947,0.00006335802,0.0000119105325,0.00009618212,0.0003307819,0.000055344874],"category_scores_gemma":[0.00082591985,0.00011725243,0.000224668,0.0004056294,0.00022817726,0.00013692281,0.00003783085,0.00072241423,3.027117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015518614,0.00017911666,0.52751666,0.000046376437,0.0006429632,0.000019490139,0.00020535156,0.001003885,0.0000967408,0.0000064809283,0.00018958742,0.45457473],"study_design_scores_gemma":[0.008649291,0.013546645,0.97133195,0.0008523793,0.0010847022,0.000077182674,0.00018158578,0.0010581213,0.0013400383,0.00001145929,0.0017601168,0.00010655086],"about_ca_topic_score_codex":0.0066063637,"about_ca_topic_score_gemma":0.0054984116,"teacher_disagreement_score":0.4544682,"about_ca_system_score_codex":0.00017898687,"about_ca_system_score_gemma":0.0013585272,"threshold_uncertainty_score":0.998689},"labels":[],"label_agreement":null},{"id":"W564668927","doi":"10.1200/jco.2009.27.15_suppl.5512","title":"Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Debulking; Internal medicine; Chemotherapy; Oncology; Stage (stratigraphy); Epithelial ovarian carcinoma; Epithelial ovarian cancer; Ovarian carcinoma; Multivariate analysis; Cancer; Surgery; Gastroenterology","score_opus":0.06119754401351552,"score_gpt":0.43756990917775684,"score_spread":0.37637236516424133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W564668927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701237,0.00042168927,0.0005188425,0.025425265,0.0025917424,0.00045748084,0.000004380589,0.000009204034,0.00044768403],"genre_scores_gemma":[0.9731068,0.00034427588,0.022186646,0.0019349342,0.0023227467,0.000012926433,0.0000038342932,0.000015694746,0.00007212783],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974385,0.000117858646,0.0017296929,0.0002237437,0.00023217947,0.00025803837],"domain_scores_gemma":[0.9980139,0.000577785,0.00083262223,0.00014934708,0.00015678344,0.00026952816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015805981,0.00014597579,0.0012847396,0.00013893054,0.000032627773,0.000007734396,0.000094670555,0.00029749295,0.000046776968],"category_scores_gemma":[0.00075938215,0.000107004096,0.0007433734,0.00011918937,0.000045036246,0.00013259213,0.0000074153886,0.0004495596,0.0000020860173],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014777586,0.0043155346,0.18175024,0.000013337201,0.00045797357,0.00080722634,0.0002856847,0.00023583502,0.0008289595,0.00024285814,0.0013867011,0.7948981],"study_design_scores_gemma":[0.040191635,0.033126287,0.88938016,0.00012776774,0.00036314916,0.00017119931,0.00010626486,0.00018322609,0.0007078475,0.00042994256,0.035110172,0.000102345024],"about_ca_topic_score_codex":0.000011012751,"about_ca_topic_score_gemma":0.000007444345,"teacher_disagreement_score":0.79479575,"about_ca_system_score_codex":0.0003902281,"about_ca_system_score_gemma":0.0011005739,"threshold_uncertainty_score":0.43635005},"labels":[],"label_agreement":null},{"id":"W565115277","doi":"10.1200/jco.2006.24.18_suppl.7228","title":"Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); McGill University Health Centre; McMaster University; University of Waterloo","funders":"","keywords":"Medicine; Zoledronic acid; Internal medicine; Placebo; Relative risk; Population; Cancer; Lung cancer; N-terminal telopeptide; Surgery; Gastroenterology; Alkaline phosphatase; Confidence interval; Pathology","score_opus":0.028593413507043575,"score_gpt":0.3828623579706785,"score_spread":0.35426894446363494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W565115277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925596,0.0034796195,0.00014297635,0.002487957,0.0005224317,0.0005906213,0.00014541646,0.000007540443,0.00006379651],"genre_scores_gemma":[0.9952316,0.00074509106,0.0018376501,0.001590264,0.00030161775,0.0000122622,0.00010458267,0.000028364488,0.00014851119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955496,0.00061602634,0.0026273811,0.00029741574,0.0005314547,0.00037810183],"domain_scores_gemma":[0.99467695,0.002601142,0.0016855147,0.00018428393,0.00039572688,0.0004563839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026728967,0.00025600038,0.0019390259,0.000151437,0.000037388625,0.0000049317628,0.00008205785,0.00032603313,0.00009291629],"category_scores_gemma":[0.0013640347,0.00016941079,0.00014124111,0.00020617725,0.00017158108,0.000108059176,0.000026714999,0.0008441066,0.0000031419052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042160638,0.016595548,0.81467855,0.0005201872,0.00053241133,0.0014541254,0.000025159887,0.00008358699,0.00022725393,0.00009235379,0.010521762,0.1131084],"study_design_scores_gemma":[0.067970686,0.01833144,0.90755653,0.00066760497,0.00066708395,0.00002340624,0.000007507279,0.00027145495,0.001784954,0.00004791436,0.002507256,0.00016413041],"about_ca_topic_score_codex":0.0010855539,"about_ca_topic_score_gemma":0.0012396562,"teacher_disagreement_score":0.11294427,"about_ca_system_score_codex":0.00023088443,"about_ca_system_score_gemma":0.0012999953,"threshold_uncertainty_score":0.69083714},"labels":[],"label_agreement":null},{"id":"W58191675","doi":"10.1200/jco.2005.23.16_suppl.5103","title":"A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Epirubicin; Irinotecan; Neutropenia; Internal medicine; Nedaplatin; Cervical cancer; Adverse effect; Phases of clinical research; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Oncology; Anemia; Chemotherapy; Cisplatin; Common Terminology Criteria for Adverse Events; Cancer; Surgery; Colorectal cancer; Cyclophosphamide","score_opus":0.049245210516349794,"score_gpt":0.40413494976524433,"score_spread":0.35488973924889455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W58191675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834627,0.0003480551,0.00035186423,0.00026359735,0.00021890177,0.00038454335,0.000012683741,0.0000014688702,0.00007258769],"genre_scores_gemma":[0.99637276,0.00012446677,0.0025991225,0.00065164815,0.0001702792,0.000006760404,0.000005696114,0.000019944537,0.000049299902],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972487,0.00031285346,0.0016363238,0.00027911167,0.00027811955,0.0002449099],"domain_scores_gemma":[0.9979364,0.0001848488,0.0011033369,0.00022766499,0.00032434732,0.00022336331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096626923,0.00017500848,0.0008702418,0.000098491066,0.000036271693,0.0000071050285,0.00021929678,0.00017888934,0.000020440255],"category_scores_gemma":[0.0002467321,0.00013309902,0.000117536256,0.000095854,0.000112369846,0.0000144576325,0.00014831826,0.00039054936,4.105081e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09007494,0.045378912,0.17816523,0.000074074014,0.00067529496,0.00015405337,0.00053121574,0.00038833194,0.01254335,0.000018958444,0.00010996305,0.67188567],"study_design_scores_gemma":[0.13470544,0.47195786,0.37349528,0.0001300978,0.0003757616,0.0000451776,0.0006785726,0.00046111643,0.004225531,0.000049969385,0.013508628,0.00036656894],"about_ca_topic_score_codex":0.00002357799,"about_ca_topic_score_gemma":0.0007513937,"teacher_disagreement_score":0.6715191,"about_ca_system_score_codex":0.000044987806,"about_ca_system_score_gemma":0.00046467193,"threshold_uncertainty_score":0.5427621},"labels":[],"label_agreement":null},{"id":"W593708258","doi":"10.1200/jco.2005.23.16_suppl.500","title":"Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; PTEN; Tissue microarray; Immunohistochemistry; Metastatic breast cancer; Hormonal therapy","score_opus":0.12459404427531262,"score_gpt":0.563880348099123,"score_spread":0.4392863038238104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W593708258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9378628,0.0006460128,0.00011778625,0.0602957,0.0004309889,0.0003750491,0.000015609945,0.000004750232,0.00025128282],"genre_scores_gemma":[0.9902487,0.0009101354,0.0048493217,0.0029837762,0.000790512,0.000010053881,4.0769848e-7,0.000024033256,0.00018310912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925089,0.0022434609,0.0039200797,0.00026858706,0.0006885827,0.0003704142],"domain_scores_gemma":[0.99234396,0.0049400046,0.00087811216,0.00024603587,0.0007064397,0.0008854657],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016505862,0.00014330148,0.0019693743,0.0003839212,0.000014681368,0.0000060217776,0.00022623068,0.00030333185,0.0002634978],"category_scores_gemma":[0.014015624,0.00010660832,0.00036165255,0.0003755605,0.0004991493,0.000082751154,0.000100642384,0.0014911204,0.0000062528766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0752704,0.0029704992,0.6124515,0.00011051407,0.000563282,0.0021913508,0.0003760918,0.00013709703,0.0012868594,0.000041550207,0.0059288503,0.29867202],"study_design_scores_gemma":[0.014279926,0.018475998,0.92003113,0.00031316507,0.00029238078,0.00058006146,0.00040767173,0.00020621522,0.00014682554,0.00008640734,0.045075655,0.00010456786],"about_ca_topic_score_codex":0.000063365565,"about_ca_topic_score_gemma":0.00017854091,"teacher_disagreement_score":0.30757964,"about_ca_system_score_codex":0.00039844704,"about_ca_system_score_gemma":0.006188361,"threshold_uncertainty_score":0.9994456},"labels":[],"label_agreement":null},{"id":"W596674826","doi":"10.1200/jco.2009.27.15_suppl.8504","title":"Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Lenalidomide; Internal medicine; Thalidomide; Bortezomib; Proteasome inhibitor; Phases of clinical research; Multiple myeloma; Gastroenterology; Surgery; Chemotherapy","score_opus":0.23576606908328196,"score_gpt":0.48849202840508077,"score_spread":0.2527259593217988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W596674826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975131,0.000113557224,0.0000020425139,0.00037220938,0.00014051651,0.0010818049,0.000043840224,0.0000039889255,0.0007289476],"genre_scores_gemma":[0.99685514,0.00011799233,0.0026156676,0.000117712705,0.00011932088,0.0000056093954,0.000023333572,0.000018418239,0.00012681469],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99365854,0.0010365159,0.0037350021,0.00037375174,0.00082405825,0.00037210545],"domain_scores_gemma":[0.99308264,0.0017484141,0.0031556499,0.00045028527,0.0009952704,0.00056773925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030801357,0.00023146052,0.0023646802,0.00033300745,0.000056429755,0.000007892653,0.00035413017,0.0003083807,0.000029825896],"category_scores_gemma":[0.0067929677,0.0001564783,0.000105487416,0.00031554225,0.0003284912,0.00032065457,0.00015832351,0.00088264944,7.619392e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24118166,0.25720984,0.22824082,0.00005193545,0.00057241105,0.0012539448,0.00081621466,0.000007872921,0.0015487672,0.0000047086082,0.00044744962,0.26866436],"study_design_scores_gemma":[0.19620213,0.38892224,0.41267988,0.0002223719,0.0001896272,0.000028359094,0.00033706153,0.00006721777,0.00044660526,0.000020918387,0.0008083248,0.00007525703],"about_ca_topic_score_codex":0.000267876,"about_ca_topic_score_gemma":0.00055785745,"teacher_disagreement_score":0.2685891,"about_ca_system_score_codex":0.00014975251,"about_ca_system_score_gemma":0.0009457582,"threshold_uncertainty_score":0.81323075},"labels":[],"label_agreement":null},{"id":"W596742190","doi":"10.1200/jco.2009.27.15_suppl.e20680","title":"Comorbidities, concominant medications, and clinical guidelines/algorithms in treating elderley patients with hormone receptor positive early breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Guideline; Hormonal therapy; Comorbidity; Breast cancer; Internal medicine; Cancer; Hormone therapy; Adjuvant; Pathology","score_opus":0.08677737473387369,"score_gpt":0.4920250777672494,"score_spread":0.4052477030333757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W596742190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96418613,0.0017281163,0.00003740136,0.03247888,0.00073456083,0.00035772068,0.000046198547,0.000008514775,0.00042250328],"genre_scores_gemma":[0.9768574,0.010146995,0.004895729,0.0058825784,0.0019721524,0.000008900904,0.000020781541,0.00001642486,0.00019898612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579275,0.00046698414,0.0028556783,0.00026316935,0.0003570999,0.00026435126],"domain_scores_gemma":[0.9950275,0.0017697922,0.0016706408,0.00012355682,0.000934888,0.00047361667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021048894,0.00018883885,0.0016089256,0.00013731586,0.00007250903,0.0000081825165,0.000119964054,0.00037103196,0.00013100849],"category_scores_gemma":[0.0006456167,0.00012216816,0.0002075583,0.00017434664,0.0003424708,0.00013915866,0.000046828434,0.0009995243,0.0000033323886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075582177,0.0026787731,0.6051964,0.00000386355,0.00033751474,0.00016908685,0.00013638148,9.328365e-7,0.000010117174,0.0000121399735,0.007046838,0.3768497],"study_design_scores_gemma":[0.02853539,0.03201198,0.9326311,0.00023035491,0.0007333344,0.00017836553,0.00008777397,0.000054849283,0.000004056306,0.000048305825,0.0053682853,0.00011625357],"about_ca_topic_score_codex":0.00042709138,"about_ca_topic_score_gemma":0.00020799486,"teacher_disagreement_score":0.37673345,"about_ca_system_score_codex":0.00028584595,"about_ca_system_score_gemma":0.0014780328,"threshold_uncertainty_score":0.4981873},"labels":[],"label_agreement":null},{"id":"W600131440","doi":"10.1200/jco.2004.22.90140.8150","title":"Prognostic significance of symptoms of advanced cancer patients","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Medical Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Vomiting; Dysphagia; Anorexia; Abdominal pain; Palliative care; Internal medicine; Univariate analysis; Depression (economics); Swallowing; Multivariate analysis; Surgery","score_opus":0.10032471490737374,"score_gpt":0.5171827842584265,"score_spread":0.41685806935105274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W600131440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609953,0.00055190234,0.000104141305,0.00142497,0.0004965641,0.00031347177,0.000008483753,0.000002456199,0.000998483],"genre_scores_gemma":[0.99637526,0.00078161573,0.002208346,0.00031255782,0.00021066496,0.000008031561,0.0000020861191,0.000008497412,0.000092934235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968449,0.00015653,0.001954598,0.00011958839,0.0007133975,0.00021098],"domain_scores_gemma":[0.99504465,0.0017403899,0.0015972223,0.00012495363,0.00095246854,0.00054034434],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010281398,0.00008640978,0.0012112648,0.00008663184,0.000011533436,9.434565e-7,0.00013874914,0.00018815677,0.000164786],"category_scores_gemma":[0.015155407,0.00005365399,0.0003088718,0.00015478814,0.00036060635,0.000056791672,0.000029927432,0.0005226079,0.0000063153093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005122877,0.0076557905,0.62635404,0.00014058063,0.00054898753,0.000236705,0.00005440875,0.00003740076,0.0005449001,0.00009133443,0.00023258507,0.3589804],"study_design_scores_gemma":[0.024393642,0.057465035,0.9107818,0.0007092257,0.00033637622,0.000016374246,0.000028463837,0.000005656121,0.001965296,0.00093256764,0.0033116576,0.000053904027],"about_ca_topic_score_codex":0.000035217472,"about_ca_topic_score_gemma":0.000014764022,"teacher_disagreement_score":0.35892648,"about_ca_system_score_codex":0.00014128625,"about_ca_system_score_gemma":0.0032795786,"threshold_uncertainty_score":0.99314034},"labels":[],"label_agreement":null},{"id":"W603820443","doi":"10.1200/jco.2004.22.90140.4519","title":"Long-term effects of conservation therapy for muscle invasive bladder carcinoma","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Radiation therapy; Bladder cancer; Cystoscopy; Surgery; Urology; Chemotherapy; Carcinoma; Survival rate; Cancer; Internal medicine; Urinary system","score_opus":0.10765998591047263,"score_gpt":0.44364298719860124,"score_spread":0.33598300128812864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W603820443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917737,0.001047072,0.0005785269,0.004716986,0.0010205568,0.0005776818,0.000003468194,0.0000046037067,0.00027736512],"genre_scores_gemma":[0.99250317,0.0009426225,0.0017170327,0.0039014684,0.0008348208,0.0000136791505,0.0000035343573,0.000015308395,0.000068373556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982215,0.000117091855,0.0012011669,0.00012233571,0.00019458606,0.00014330725],"domain_scores_gemma":[0.99611074,0.002032817,0.0010339639,0.0001308803,0.0005124373,0.00017916632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006087794,0.00010441843,0.0009417666,0.000071362054,0.000023928465,0.0000030243723,0.00008744269,0.00024625123,0.000038686507],"category_scores_gemma":[0.0014365822,0.00007094712,0.0004615614,0.00006856583,0.00014114045,0.00007325547,0.000011789802,0.00026448024,0.0000034568814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011732612,0.005386398,0.8027287,0.0002743173,0.0014175356,0.0006656045,0.00045675295,0.000007686623,0.006952574,0.0001741339,0.0017173383,0.16848633],"study_design_scores_gemma":[0.035612367,0.034794796,0.9144496,0.00013737842,0.00041784125,0.000096402146,0.00002145954,0.000001133052,0.012351515,0.00091675133,0.001145648,0.00005512795],"about_ca_topic_score_codex":0.00003940734,"about_ca_topic_score_gemma":0.00004582358,"teacher_disagreement_score":0.1684312,"about_ca_system_score_codex":0.00011039511,"about_ca_system_score_gemma":0.002416717,"threshold_uncertainty_score":0.42871523},"labels":[],"label_agreement":null},{"id":"W628106130","doi":"10.1200/jco.2009.27.15_suppl.e15070","title":"Predictors of adjuvant chemotherapy (AT) decision-making in referred patients (pts) with stage II and III colon cancer (CC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Sleep Society; University of British Columbia","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Cancer; Perineural invasion; Statistical significance; Lymphovascular invasion; Oncology; Surgery; Metastasis","score_opus":0.057577298516653656,"score_gpt":0.45142038251812777,"score_spread":0.3938430840014741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W628106130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960736,0.00063440553,0.0000104874525,0.0011019871,0.00043442467,0.0003477156,0.000008537372,0.000005874867,0.0013829927],"genre_scores_gemma":[0.99605685,0.0014728308,0.0010245905,0.0010868359,0.00018589364,0.0000048586267,0.0000014583374,0.000013561912,0.00015308603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970431,0.00015728176,0.0018491315,0.00023094482,0.0004948067,0.00022475516],"domain_scores_gemma":[0.9961385,0.0015784634,0.0015313602,0.0001484103,0.0003330927,0.0002701648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000957534,0.00016151952,0.0016763294,0.00015326981,0.000035555404,0.000003050616,0.00010716709,0.00029053312,0.00014521844],"category_scores_gemma":[0.0010647969,0.00010109943,0.00018114525,0.00022249416,0.00016818466,0.00009114858,0.00005288095,0.00053638994,7.5992824e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046476748,0.004875863,0.64922976,0.000011092181,0.0002023561,0.00032521167,0.0002643494,0.000016849892,0.00003120023,0.0000035980286,0.00040427322,0.29815874],"study_design_scores_gemma":[0.048762914,0.044407014,0.89449155,0.00055284245,0.00015104482,0.00004094404,0.000034817655,0.000049253635,0.000057465593,0.00007927204,0.011291269,0.000081609964],"about_ca_topic_score_codex":0.000031537344,"about_ca_topic_score_gemma":0.0003987637,"teacher_disagreement_score":0.2980771,"about_ca_system_score_codex":0.0006470664,"about_ca_system_score_gemma":0.0007362832,"threshold_uncertainty_score":0.4122715},"labels":[],"label_agreement":null},{"id":"W636666193","doi":"10.1200/jco.2005.23.16_suppl.8187","title":"Impact of intensive chemotherapy versus supportive care on quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Referral; Cancer; Myeloid leukemia; Intensive care; Internal medicine; Physical therapy; Pediatrics; Intensive care medicine; Population; Family medicine","score_opus":0.07599451779225107,"score_gpt":0.4753275861335163,"score_spread":0.3993330683412652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W636666193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398136,0.00027947588,0.00007322105,0.003730938,0.00029799185,0.00057697686,0.00005964627,0.000007844177,0.0009925213],"genre_scores_gemma":[0.99278057,0.0014466095,0.0030161967,0.0017676187,0.0008514557,0.0000050782046,0.000014856084,0.000043950786,0.000073676754],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99316025,0.0007474808,0.0042221034,0.00033817385,0.0010872227,0.00044477943],"domain_scores_gemma":[0.97900325,0.007064842,0.005552885,0.00053915434,0.007086532,0.0007533126],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024703294,0.00030858163,0.0036822925,0.00031533095,0.000023885908,0.0000034896818,0.00042018775,0.00067736517,0.0003634159],"category_scores_gemma":[0.013879402,0.00019387639,0.0012624557,0.00036163823,0.0009144649,0.00015192262,0.00008268651,0.0018857074,0.000008539862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57154745,0.0038890282,0.20426378,0.00036010033,0.00880526,0.00077051384,0.009094343,0.00037370002,0.0031463718,0.000040123537,0.017222324,0.18048704],"study_design_scores_gemma":[0.10121604,0.091601156,0.7955762,0.0006027322,0.0005678704,0.00008787266,0.0054084957,0.00007136128,0.0040371884,0.000008238785,0.00063814886,0.00018469992],"about_ca_topic_score_codex":0.0005005663,"about_ca_topic_score_gemma":0.00017515133,"teacher_disagreement_score":0.5913124,"about_ca_system_score_codex":0.0016700791,"about_ca_system_score_gemma":0.013676948,"threshold_uncertainty_score":0.9944271},"labels":[],"label_agreement":null},{"id":"W640291790","doi":"10.1200/jco.2006.24.18_suppl.10549","title":"The experience of a sample of Canadian men with breast cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Feeling; Cancer; Malignancy; Qualitative research; Family medicine; Gynecology; Internal medicine; Psychology; Social psychology","score_opus":0.0420187782709784,"score_gpt":0.4035069247498092,"score_spread":0.3614881464788308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W640291790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909925,0.0008795715,0.00021698319,0.0038263265,0.00031862533,0.0000680952,0.000050561517,5.604348e-7,0.0036468],"genre_scores_gemma":[0.9964254,0.0006704221,0.0020321934,0.00020910634,0.0004863294,0.000005526553,0.0000018817707,0.0000070395995,0.00016212372],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998632,0.00011919416,0.00088289345,0.00009269984,0.00013804605,0.0001351561],"domain_scores_gemma":[0.9979817,0.00029188505,0.00094687263,0.00016308007,0.00051985943,0.00009655766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007382143,0.00005972911,0.00030559595,0.000056710447,0.000038540307,0.0000033169013,0.00024709912,0.00014528118,0.000035896046],"category_scores_gemma":[0.00034783414,0.00003566741,0.00011514325,0.00013848279,0.00040341925,0.0000035969515,0.000024636944,0.00014179893,2.5083335e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050751977,0.00076870044,0.6966515,0.000030143892,0.00092575024,0.00004300156,0.000542983,0.0036924765,0.039022744,0.0012577816,0.09009117,0.16189852],"study_design_scores_gemma":[0.0024212785,0.0032329934,0.44654143,0.000036030127,0.00010311666,0.00018246623,0.00075044966,0.000046297333,0.019942768,0.0004152523,0.5261957,0.00013222777],"about_ca_topic_score_codex":0.036069755,"about_ca_topic_score_gemma":0.17542545,"teacher_disagreement_score":0.43610454,"about_ca_system_score_codex":0.00006417847,"about_ca_system_score_gemma":0.0036285091,"threshold_uncertainty_score":0.97034913},"labels":[],"label_agreement":null},{"id":"W644277546","doi":"10.1200/jco.2009.27.15_suppl.e22017","title":"Investigation of HDAC inhibition targeting of BRCA1 expression as a mechanism to enhance platinum sensitivity in breast and ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Cisplatin; Carboplatin; Ovarian cancer; Cancer research; Breast cancer; Flow cytometry; MTT assay; Histone deacetylase inhibitor; Medicine; Cell culture; Cancer; Molecular biology; Histone deacetylase; Biology; Internal medicine; Immunology; Chemotherapy; Histone; DNA; Biochemistry","score_opus":0.03583562840852877,"score_gpt":0.417113696360159,"score_spread":0.3812780679516302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W644277546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964288,0.00010890787,0.0007127183,0.0023588277,0.00013217956,0.00011891377,0.000008531258,0.0000011774385,0.00012996358],"genre_scores_gemma":[0.9955824,0.00015125098,0.0035638714,0.00038149912,0.00028804757,0.0000018707838,0.000004753874,0.0000065118625,0.000019798485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769264,0.00052762334,0.001221616,0.00018724764,0.00022719224,0.00014364648],"domain_scores_gemma":[0.99821913,0.00019867514,0.0009401506,0.00010154945,0.00037076022,0.00016973248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030180789,0.0000857885,0.0005089262,0.00010943703,0.000020745176,0.000003178393,0.00005956987,0.00032447776,0.000010170053],"category_scores_gemma":[0.0017147838,0.00007632355,0.00009608793,0.00011905516,0.000109635985,0.000013253683,0.000060709815,0.0003447819,6.86947e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001098244,0.00013270293,0.0026987002,0.000015626727,0.000012832183,0.000032629247,0.00015421248,0.000051095594,0.98397297,0.000036499798,0.00039606346,0.011398415],"study_design_scores_gemma":[0.0010457716,0.0028418587,0.03201593,0.0002154225,0.000010539287,0.00007332118,0.00006079312,0.000061516424,0.9628161,0.0005843565,0.0002028316,0.000071531394],"about_ca_topic_score_codex":0.00009381829,"about_ca_topic_score_gemma":0.00012548851,"teacher_disagreement_score":0.029317232,"about_ca_system_score_codex":0.000046038174,"about_ca_system_score_gemma":0.00058893464,"threshold_uncertainty_score":0.3112384},"labels":[],"label_agreement":null},{"id":"W648132389","doi":"10.1200/jco.2007.25.18_suppl.21047","title":"Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Gastroenterology; Histology; Esophageal cancer; Adenocarcinoma; Cancer; Single-nucleotide polymorphism; Carcinoma; Lung cancer; Genotype; Esophagus; Oncology; Biology; Gene","score_opus":0.12390230898249707,"score_gpt":0.501151456860917,"score_spread":0.3772491478784199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W648132389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97854906,0.0028746661,0.00008553814,0.017219217,0.0003091998,0.00017274452,0.000007483843,0.000004411252,0.000777696],"genre_scores_gemma":[0.99575585,0.00047117044,0.0006623856,0.001550169,0.0005520264,0.0000024520152,0.0000014192864,0.000008457125,0.0009960391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847555,0.00015837603,0.0009083461,0.00014466283,0.00015062609,0.00016244921],"domain_scores_gemma":[0.995083,0.00382395,0.00060933403,0.0000924138,0.00013082226,0.00026049043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018567353,0.00009407152,0.00059185916,0.000055975703,0.00009641087,0.000009523066,0.000048444348,0.00022050757,0.000021762531],"category_scores_gemma":[0.0012779812,0.000055179164,0.00006483893,0.00005095647,0.0004245761,0.00010670094,0.000038150618,0.0005942966,9.634721e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004551992,0.00009263351,0.96896756,0.00001711298,0.0001893256,0.00019680602,0.00034989108,0.000001026047,0.000017443506,0.0010490849,0.0001577557,0.028506143],"study_design_scores_gemma":[0.004482283,0.001913392,0.97765803,0.000034062024,0.00052635325,0.00022239033,0.00005785206,0.0000031771963,0.0000049920477,0.001102907,0.013946637,0.00004791103],"about_ca_topic_score_codex":0.00016068442,"about_ca_topic_score_gemma":0.00017158182,"teacher_disagreement_score":0.028458232,"about_ca_system_score_codex":0.0001032507,"about_ca_system_score_gemma":0.00054721604,"threshold_uncertainty_score":0.2581956},"labels":[],"label_agreement":null},{"id":"W650326983","doi":"10.1200/jco.2009.27.15_suppl.e15034","title":"Histological hepatic changes in patients undergoing liver resection for colorectal metastasis: A retrospective cohort study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Medicine; Hepatectomy; Surgery; Colorectal cancer; Chemotherapy; Regimen; Metastasis; Retrospective cohort study; Lymph node; Cancer; Internal medicine; Resection","score_opus":0.10254248248152109,"score_gpt":0.43723631252600537,"score_spread":0.3346938300444843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W650326983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946427,0.00038848686,0.000017799248,0.0018835036,0.0007666761,0.0012792763,0.000003127966,0.000009038686,0.0010094421],"genre_scores_gemma":[0.9978304,0.0004915898,0.0006465987,0.0005407376,0.0003741622,0.000042363496,0.0000022101744,0.000007772098,0.00006417115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975254,0.00036917796,0.0012687946,0.0002542355,0.0003572979,0.0002250869],"domain_scores_gemma":[0.99693245,0.0013262782,0.00094941625,0.000089861984,0.00056238135,0.00013963644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022327844,0.00014538881,0.0017172514,0.00017189514,0.00006955225,0.000006345412,0.000073553114,0.00019194477,0.000033917106],"category_scores_gemma":[0.0054344386,0.00009613363,0.0003043616,0.00018023598,0.00008418669,0.00006808989,0.000028304796,0.000505532,0.0000016306188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024907688,0.007913787,0.9262832,0.000010372442,0.0006604912,0.00022965748,0.0002852666,0.0000015895882,0.000003717652,0.000020232834,0.0005921318,0.039091893],"study_design_scores_gemma":[0.012319321,0.21774913,0.7682661,0.000040303254,0.00065696164,0.000023956343,0.00023625302,0.000025099791,0.0000076242045,0.00023252612,0.00037938505,0.00006335155],"about_ca_topic_score_codex":0.000029644349,"about_ca_topic_score_gemma":0.0028274863,"teacher_disagreement_score":0.20983535,"about_ca_system_score_codex":0.001170128,"about_ca_system_score_gemma":0.0004000094,"threshold_uncertainty_score":0.6505923},"labels":[],"label_agreement":null},{"id":"W652069878","doi":"10.1200/jco.2009.27.15_suppl.607","title":"Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Family history; Hazard ratio; Proportional hazards model; Internal medicine; Medical record; Medical history; Cohort; Cancer; Radiation therapy; Retrospective cohort study; Oncology; Gynecology; Confidence interval","score_opus":0.046542092035920926,"score_gpt":0.37004135290485923,"score_spread":0.3234992608689383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W652069878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137074,0.004640012,0.000064122,0.0034411885,0.0002394587,0.00014671111,0.000023167886,0.000001351052,0.00007322784],"genre_scores_gemma":[0.99657744,0.0016533694,0.00026319636,0.0009942901,0.00044899265,0.00002327108,0.0000018902688,0.000007136174,0.00003038674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99876845,0.00015975977,0.00066387706,0.00015545919,0.00008381563,0.00016864919],"domain_scores_gemma":[0.99859375,0.00014361762,0.00094409025,0.00011290085,0.00013626463,0.000069364934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006586569,0.00011206479,0.0006053745,0.000043538956,0.000021543448,0.0000031093268,0.00010541019,0.00015298493,0.0000060009233],"category_scores_gemma":[0.00009012663,0.00006404348,0.00010037211,0.000034187684,0.00019551229,0.000007817686,0.000020933747,0.00009888489,1.1461253e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01465133,0.0006886345,0.21841912,0.00002093852,0.0006726827,0.00003164939,0.00050181954,0.00013619005,0.0004899463,0.0000070756173,0.0015513485,0.76282924],"study_design_scores_gemma":[0.0069296765,0.0052462323,0.973844,0.000027942573,0.00015199804,0.00017808855,0.00012124511,0.000016615319,0.00014607073,0.000052442785,0.013207277,0.00007840661],"about_ca_topic_score_codex":0.000093229675,"about_ca_topic_score_gemma":0.00013771212,"teacher_disagreement_score":0.76275086,"about_ca_system_score_codex":0.00041874286,"about_ca_system_score_gemma":0.000771756,"threshold_uncertainty_score":0.26116174},"labels":[],"label_agreement":null},{"id":"W653311130","doi":"10.1200/jco.2006.24.18_suppl.6500","title":"Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Internal medicine; Pharmacokinetics; Anorexia; Oncology; Myelodysplastic syndromes; Pharmacodynamics; Leukemia; Vomiting; Mucositis; Gastroenterology; Adverse effect; Pharmacology; Phases of clinical research; Toxicity; Bone marrow","score_opus":0.043873317621000135,"score_gpt":0.42761684070166034,"score_spread":0.3837435230806602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W653311130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984687,0.00008666647,0.000033198812,0.00023900537,0.0004567797,0.0005251218,0.00004905847,0.0000019193249,0.00013954057],"genre_scores_gemma":[0.99891317,0.00007853906,0.00036735972,0.000036674082,0.0003345348,0.000004618606,0.0000058896485,0.000021315904,0.00023791443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938756,0.0017370734,0.0031322066,0.00039008397,0.0005891341,0.00027586406],"domain_scores_gemma":[0.99446374,0.0017010289,0.0026083405,0.00043849883,0.0005904476,0.00019792127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004717788,0.00020520517,0.0013913377,0.00013224699,0.00005240446,0.00000541337,0.0003583683,0.00048484906,0.000007752509],"category_scores_gemma":[0.006909797,0.00012137726,0.00029592612,0.00026279286,0.0009759927,0.00001757467,0.00024919558,0.0009813214,8.595318e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2900465,0.041968424,0.58031946,0.00013643665,0.0007580507,0.00041240934,0.00017297221,0.00029742174,0.022189276,0.0000084702,0.0063868524,0.05730373],"study_design_scores_gemma":[0.061148513,0.056383345,0.87115496,0.00014666044,0.000165092,0.00005160374,0.00007621837,0.000038992705,0.006907071,0.000006894362,0.0037420453,0.00017857506],"about_ca_topic_score_codex":0.00014150479,"about_ca_topic_score_gemma":0.0012600655,"teacher_disagreement_score":0.29083556,"about_ca_system_score_codex":0.00017576739,"about_ca_system_score_gemma":0.0025649741,"threshold_uncertainty_score":0.82721716},"labels":[],"label_agreement":null},{"id":"W654212481","doi":"10.1200/jco.2009.27.15_suppl.1040","title":"Gene expression differences between disseminated tumor cells and tumor cells from overt bone metastases in patients with metastatic breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Bone marrow; Medicine; Osteopontin; Cancer research; Breast cancer; Pathology; Circulating tumor cell; Gene expression profiling; Metastasis; Bone metastasis; Cancer; Gene; Gene expression; Biology; Immunology; Internal medicine","score_opus":0.047276211950007856,"score_gpt":0.3900520360823256,"score_spread":0.3427758241323177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W654212481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639595,0.0010347518,0.000008597957,0.0016146626,0.000239835,0.0002751517,0.00040716134,0.0000048354145,0.000019053266],"genre_scores_gemma":[0.995676,0.0007383209,0.0024038379,0.00084759423,0.00027874944,0.000008042378,0.000022023132,0.000012344696,0.000013103171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734855,0.00026900787,0.0014924143,0.00026925525,0.00039026042,0.00023052689],"domain_scores_gemma":[0.9965803,0.0014431274,0.0012518928,0.00014140934,0.00018724201,0.0003959992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004842885,0.00020495856,0.0018662834,0.000115833886,0.000029927489,0.0000145536915,0.000084039064,0.00007709782,0.00018681961],"category_scores_gemma":[0.00012555977,0.00011509562,0.00017161986,0.00012184729,0.00011394254,0.00011677366,0.000029285531,0.0004343538,0.0000022060574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004320844,0.004296567,0.926093,0.000016160562,0.0003451617,0.0008402635,0.00006302418,0.000005348873,0.001228174,6.195884e-7,0.0010903105,0.061700515],"study_design_scores_gemma":[0.013187881,0.009338035,0.96686316,0.00056528323,0.0011430932,0.000027171367,0.000046639292,0.0000064307296,0.008278621,0.00005885795,0.00036792923,0.00011689043],"about_ca_topic_score_codex":0.00025830074,"about_ca_topic_score_gemma":0.000099228564,"teacher_disagreement_score":0.061583623,"about_ca_system_score_codex":0.00015839886,"about_ca_system_score_gemma":0.00039731123,"threshold_uncertainty_score":0.46934634},"labels":[],"label_agreement":null},{"id":"W6726021","doi":"10.1200/jco.2009.27.15_suppl.7571","title":"Comparison of primary tumor maximal standardized uptake value (SUV<sub>max</sub>) on preoperative [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and histological subtype in patients with non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Standardized uptake value; Histology; Positron emission tomography; Nuclear medicine; Pathological; Carcinoma; Adenocarcinoma; Fluorodeoxyglucose; Radiology; Cancer; Pathology; Internal medicine","score_opus":0.019999461109965175,"score_gpt":0.3577746419173138,"score_spread":0.3377751808073486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6726021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446386,0.001636511,0.0005894117,0.0015899107,0.00044680212,0.0006165782,0.000007653446,0.000017197926,0.0006320478],"genre_scores_gemma":[0.98721915,0.00026103138,0.010304865,0.0019530763,0.00020908721,0.0000047013095,0.00001358859,0.000026008933,0.000008459703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953025,0.00066777685,0.0024479865,0.00045447168,0.00070405984,0.00042322034],"domain_scores_gemma":[0.9957046,0.0009795995,0.0020111105,0.00022013328,0.0005043696,0.0005802146],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021565198,0.00033594738,0.0026296459,0.00043651427,0.000080587495,0.000019688809,0.00023922714,0.00011438208,0.000016520036],"category_scores_gemma":[0.00074770476,0.00022188506,0.00041002737,0.000401771,0.0003535355,0.00011370717,0.000062975596,0.0024155728,3.8634454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020898866,0.0054480913,0.9177656,0.000116629555,0.00023110391,0.0011295166,0.000162965,0.0003996944,0.0029898966,0.000016698445,0.0011624572,0.049678486],"study_design_scores_gemma":[0.020789351,0.025306951,0.94592756,0.00091209705,0.00049764145,0.00015347394,0.000035702826,0.004102256,0.0015928332,0.000038270002,0.00042394997,0.00021993561],"about_ca_topic_score_codex":0.000023949035,"about_ca_topic_score_gemma":0.000007455625,"teacher_disagreement_score":0.04945855,"about_ca_system_score_codex":0.0002802901,"about_ca_system_score_gemma":0.0011346288,"threshold_uncertainty_score":0.9998859},"labels":[],"label_agreement":null},{"id":"W7116849844","doi":"10.1200/jco-24-02679","title":"Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Risk stratification; Lymph node; Risk factor; Risk assessment; Carcinoma; Stratification (seeds)","score_opus":0.07277834932568797,"score_gpt":0.4781544402871778,"score_spread":0.40537609096148985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116849844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864263,0.0014080731,0.00013808541,0.008010881,0.00085907034,0.00014968787,0.0000019703846,0.000017879203,0.002988043],"genre_scores_gemma":[0.99143076,0.0023187622,0.00482145,0.0010829704,0.0002348702,0.0000039980373,0.0000013416395,0.0000059725808,0.00009990154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974321,0.00036235625,0.0016790273,0.00018978544,0.00017823552,0.00015851032],"domain_scores_gemma":[0.99768907,0.0010847104,0.00068187085,0.00012572226,0.00027394283,0.00014470631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022778437,0.00010302287,0.0011845197,0.00014856555,0.000049178947,0.000007639127,0.00006179934,0.00023988751,0.0000134955],"category_scores_gemma":[0.001271561,0.00007242015,0.0001369508,0.00014509646,0.00014586473,0.000077209144,0.000035271307,0.0006126841,0.0000012243879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020809376,0.0010381445,0.7103835,0.00007644864,0.00014498958,0.0003219869,0.000095025935,0.000006122572,0.007106638,0.00013567931,0.0017663749,0.27684417],"study_design_scores_gemma":[0.00792419,0.0029900356,0.9810588,0.0001507573,0.0002235699,0.00006300889,0.00016998743,0.0054305214,0.00008474555,0.00023157497,0.00161868,0.000054128966],"about_ca_topic_score_codex":0.00008398169,"about_ca_topic_score_gemma":0.000062325766,"teacher_disagreement_score":0.27679005,"about_ca_system_score_codex":0.00019070934,"about_ca_system_score_gemma":0.0019188694,"threshold_uncertainty_score":0.3403992},"labels":[],"label_agreement":null},{"id":"W80307787","doi":"10.1200/jco.2013.31.26_suppl.118","title":"Social support as a determinant of health-related quality of life in breast cancer survivors in California.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Anxiety; Social support; Depression (economics); Affect (linguistics); Clinical psychology; Menopause; Internal medicine; Cancer; Psychiatry; Psychotherapist; Psychology","score_opus":0.14120753482382267,"score_gpt":0.49518424577174913,"score_spread":0.3539767109479265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W80307787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97384226,0.00043395386,0.0000038442868,0.024115046,0.0008088892,0.00022057614,0.000028261982,0.0000027802907,0.0005443989],"genre_scores_gemma":[0.9971554,0.0005244226,0.000035737037,0.0019357074,0.00025409274,0.000008286779,0.0000026622906,0.00001292941,0.000070757924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99141085,0.0013954269,0.006309245,0.00016148016,0.00043315202,0.00028983477],"domain_scores_gemma":[0.99388105,0.0012256225,0.003908726,0.00013348844,0.00054527476,0.00030585701],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007989351,0.000124568,0.0029092836,0.00021120915,0.000014511194,0.0000021715382,0.00015611449,0.00046432114,0.0009830224],"category_scores_gemma":[0.0016317359,0.000094664145,0.0004677515,0.00031826322,0.0002682017,0.000074950265,0.00004598492,0.0009788021,0.000010330132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028992738,0.0011683677,0.90612656,0.00019896867,0.00009135605,0.0000623986,0.0011361636,0.0000042450006,0.00006478914,0.00003303892,0.00084771885,0.0873671],"study_design_scores_gemma":[0.0059121037,0.002274317,0.98808056,0.00019456743,0.000040624433,0.000072676165,0.001112834,0.000018438037,0.000011947432,0.00032077878,0.0018826955,0.00007847314],"about_ca_topic_score_codex":0.10663728,"about_ca_topic_score_gemma":0.08819662,"teacher_disagreement_score":0.087288626,"about_ca_system_score_codex":0.00028401642,"about_ca_system_score_gemma":0.005649289,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W81857156","doi":"10.1200/jco.2007.25.18_suppl.5010","title":"Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Renal cell carcinoma; Population; Expanded access; Tyrosine-kinase inhibitor; Concomitant; Gastroenterology; Cancer; Surgery; Oncology; Urology","score_opus":0.23060746489563758,"score_gpt":0.5225273647036596,"score_spread":0.291919899808022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W81857156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969204,0.00009795768,0.0009326247,0.00023365233,0.00020785736,0.00061937043,0.000002646031,0.0000034504017,0.0009820557],"genre_scores_gemma":[0.9924411,0.0000272463,0.007026673,0.0001393099,0.00029400064,0.000008041916,0.000023459013,0.000015457463,0.000024709621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934832,0.0012737387,0.0039403304,0.00025878786,0.0007043045,0.00033966493],"domain_scores_gemma":[0.9936194,0.0025070335,0.0027781294,0.0002895382,0.0003897013,0.0004162048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008906723,0.00019663658,0.0024426663,0.0010948491,0.000018255892,0.0000098784185,0.00020861035,0.0002569898,0.00007307602],"category_scores_gemma":[0.00063404953,0.0001346945,0.00049368007,0.0009550076,0.0001319686,0.00033532677,0.000050642335,0.00089204445,3.7566699e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11867233,0.008512902,0.863558,0.000040591403,0.0003382869,0.0020973242,0.00016510766,0.00086900796,0.00039084902,0.000008960246,0.000010652559,0.0053360024],"study_design_scores_gemma":[0.06571853,0.05492178,0.8743245,0.00005058742,0.002052885,0.000091676666,0.00032040715,0.00065676874,0.0017152238,0.00003596388,0.00001332473,0.00009835041],"about_ca_topic_score_codex":0.00032291227,"about_ca_topic_score_gemma":0.0028845884,"teacher_disagreement_score":0.052953795,"about_ca_system_score_codex":0.00052943506,"about_ca_system_score_gemma":0.0014662023,"threshold_uncertainty_score":0.54926825},"labels":[],"label_agreement":null},{"id":"W86002999","doi":"10.1200/jco.2005.23.16_suppl.532","title":"Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Zoledronic acid; N-terminal telopeptide; Creatinine; Internal medicine; Multiple myeloma; Urinary system; Bone remodeling; Breast cancer; Bone resorption; Urology; Cancer; Gastroenterology; Endocrinology; Alkaline phosphatase; Osteocalcin","score_opus":0.08500177567517317,"score_gpt":0.4840565467770949,"score_spread":0.3990547711019218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W86002999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98677933,0.0014731637,0.00016702076,0.009569033,0.0006082708,0.00019472594,0.000004164598,0.0000055769833,0.0011986854],"genre_scores_gemma":[0.99147815,0.0008902078,0.004734094,0.0020204557,0.00031577772,0.0000012540415,0.000004610448,0.000012988912,0.0005424551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957704,0.00035239552,0.003199993,0.00016227129,0.00031612953,0.00019879827],"domain_scores_gemma":[0.9953066,0.00153865,0.0022467845,0.00014916166,0.00021422308,0.00054458773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002924414,0.00011823701,0.0014932862,0.00007100285,0.000027740383,0.000002730841,0.000048835023,0.00046044128,0.00012703349],"category_scores_gemma":[0.001569336,0.00007014418,0.00025058922,0.00006836716,0.00025020054,0.00012845814,0.000026606851,0.0010063375,0.000012025341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012765162,0.0017013041,0.8376807,0.000029682253,0.00019302523,0.000108986205,0.000016780334,0.000002983117,0.000028271443,0.000009383146,0.010434677,0.13702902],"study_design_scores_gemma":[0.021966264,0.017262628,0.89433265,0.00013338833,0.0005120767,0.0005665903,0.000020516825,0.00019113986,0.000029264032,0.000027216389,0.06489646,0.00006178494],"about_ca_topic_score_codex":0.000011583889,"about_ca_topic_score_gemma":0.000035341403,"teacher_disagreement_score":0.13696724,"about_ca_system_score_codex":0.00008799256,"about_ca_system_score_gemma":0.0007663336,"threshold_uncertainty_score":0.43720913},"labels":[],"label_agreement":null},{"id":"W93406142","doi":"10.1200/jco.2004.22.90140.6090","title":"Medicine and media: The role of journalism in public health education","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Journalism; Newspaper; The Internet; Medicine; Perception; News media; Health care; Public relations; Medical education; Psychology; Media studies; Political science; Sociology; World Wide Web","score_opus":0.4416553363373488,"score_gpt":0.6164134436529547,"score_spread":0.17475810731560587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W93406142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51393396,0.004638728,0.000010539898,0.47229463,0.00705848,0.00020936683,2.1783046e-7,0.0000020275202,0.0018520434],"genre_scores_gemma":[0.97866464,0.011325405,0.00080351287,0.0037800488,0.0054074945,0.000010453348,3.2945195e-7,0.000004552662,0.0000035704218],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949849,0.002050633,0.0021507957,0.00008349347,0.0004978742,0.0002322623],"domain_scores_gemma":[0.9826883,0.013331518,0.0028377555,0.00008537285,0.0005651163,0.00049192406],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023857664,0.00005416282,0.0006455214,0.00018114869,0.0001401752,0.000008028413,0.00026473356,0.00023242527,0.000048553084],"category_scores_gemma":[0.07533647,0.000035159814,0.000073899086,0.0003990742,0.0009324695,0.00018461385,0.00001752406,0.0007933683,0.0000014093481],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041200146,0.00058279326,0.074941576,0.000008512028,0.000014241417,0.0000016012604,0.07605496,0.000001326158,0.000002662082,0.05187024,0.0006240379,0.79585683],"study_design_scores_gemma":[0.0012225155,0.0011345308,0.42505172,0.00012238028,0.000015473805,0.00001642875,0.057704754,7.6618096e-7,0.0000010601524,0.09533618,0.41935694,0.000037277263],"about_ca_topic_score_codex":0.0066482215,"about_ca_topic_score_gemma":0.008374809,"teacher_disagreement_score":0.7958196,"about_ca_system_score_codex":0.0004914883,"about_ca_system_score_gemma":0.021135505,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W98243944","doi":"10.1200/jco.2006.24.18_suppl.6044","title":"The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Trastuzumab; Bevacizumab; Pharmacy; Metastatic breast cancer; Context (archaeology); Oncology; Internal medicine; Breast cancer; Monoclonal antibody; Health care; Cancer; Chemotherapy; Immunology; Family medicine; Antibody","score_opus":0.09339007286560588,"score_gpt":0.39925434027272616,"score_spread":0.30586426740712025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W98243944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96767277,0.0063714865,0.00017019971,0.01553071,0.00083787314,0.00018345864,0.000041827443,0.0000027714218,0.009188896],"genre_scores_gemma":[0.97960776,0.018334143,0.00030099985,0.0004479745,0.0009967225,0.000004023944,0.0000017514699,0.000015977463,0.00029065902],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956562,0.00007879808,0.003687371,0.00020427312,0.00005472522,0.00031862658],"domain_scores_gemma":[0.99526054,0.0011441835,0.0031805327,0.00016974272,0.00011346453,0.00013154706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032974249,0.00014870107,0.0015174387,0.00016571299,0.00006834496,0.000033422995,0.00033817478,0.00027121956,0.00006570543],"category_scores_gemma":[0.0007290065,0.000116352014,0.00029204568,0.00011631179,0.0003761586,0.00020496138,0.000044139633,0.0005790198,0.000010729174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044159046,0.0013406234,0.30629948,0.000030144649,0.0003464248,0.00013639769,0.0008532741,0.0010709501,0.000081558406,0.06678685,0.007044802,0.6115936],"study_design_scores_gemma":[0.008339848,0.006498176,0.48538724,0.000084134976,0.000017180078,0.00007584464,0.00038080305,0.0008773163,0.00006766383,0.09516585,0.4028234,0.0002825657],"about_ca_topic_score_codex":0.0008623978,"about_ca_topic_score_gemma":0.00085648836,"teacher_disagreement_score":0.611311,"about_ca_system_score_codex":0.00018445066,"about_ca_system_score_gemma":0.00054912607,"threshold_uncertainty_score":0.47446972},"labels":[],"label_agreement":null},{"id":"W998056773","doi":"10.1200/jco.2013.31.15_suppl.7510","title":"Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Surrogate endpoint; Hazard ratio; Clinical endpoint; Internal medicine; Progression-free survival; Oncology; Proportional hazards model; Lung cancer; Randomized controlled trial; Clinical trial; Confidence interval; Overall survival","score_opus":0.08920509898993889,"score_gpt":0.4516637083956656,"score_spread":0.3624586094057267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W998056773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940175,0.0020691291,0.00043863186,0.00046604915,0.0014577645,0.0012411322,0.000102421465,0.0000035663436,0.0002038022],"genre_scores_gemma":[0.99171966,0.0034776754,0.002936992,0.0002964659,0.0011980535,0.00010767672,0.00011320054,0.00003296438,0.000117316995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99500763,0.0012011315,0.0024343305,0.00046969173,0.00048598857,0.00040120818],"domain_scores_gemma":[0.99302715,0.0012286472,0.002536439,0.0004892317,0.0023913416,0.00032718843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068069943,0.00025439475,0.0015322539,0.00013885966,0.000041703603,0.000030150079,0.0004903667,0.00055551337,0.00020528396],"category_scores_gemma":[0.006922158,0.0002101681,0.00074999384,0.00019657561,0.00013417941,0.000022478585,0.00015509412,0.00036647954,0.000001762019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04734326,0.010909061,0.62225056,0.00040609617,0.0075074867,0.00016390582,0.00071987143,0.081085555,0.09211452,0.00042259714,0.0063906414,0.13068648],"study_design_scores_gemma":[0.11696207,0.029667376,0.69377357,0.00029177274,0.008879038,0.000014208352,0.000550781,0.10302358,0.022243854,0.0014231877,0.021811739,0.0013588499],"about_ca_topic_score_codex":0.0008468071,"about_ca_topic_score_gemma":0.008510724,"teacher_disagreement_score":0.12932763,"about_ca_system_score_codex":0.00017915461,"about_ca_system_score_gemma":0.0028012048,"threshold_uncertainty_score":0.85704064},"labels":[],"label_agreement":null}]}